Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
KIRP	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg05347473	chr6:146136440	FBXO30	-0.63	-9.13	-0.5	2.62e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg21864845	chr1:1208426	UBE2J2	0.51	6.34	0.37	1.1e-9	Asthma;
KIRP	cis	rs4302748	0.862	rs4723481	chr7:36180023	A/G	cg24442661	chr7:36192818	EEPD1	0.59	6.67	0.39	1.72e-10	Platelet count;
KIRP	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg27462398	chr1:86174642	ZNHIT6	0.45	5.92	0.35	1.08e-8	Urate levels in overweight individuals;
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.68e-8	Life satisfaction;
KIRP	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.71	10.27	0.55	8.29e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.87	0.3	1.98e-6	Lymphocyte counts;
KIRP	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg12560992	chr17:57184187	TRIM37	-0.91	-11.92	-0.61	3.66e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.71	10.43	0.55	2.49e-21	Retinal vascular caliber;
KIRP	cis	rs11605924	0.901	rs7105751	chr11:45856973	G/A	cg23097878	chr11:45879730	CRY2	0.33	6.74	0.39	1.11e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	1.09	17.81	0.75	3.82e-46	Cognitive function;
KIRP	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.93	15.21	0.7	2.77e-37	Adiposity;
KIRP	cis	rs9815354	1.000	rs28702390	chr3:41889920	C/A	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs367943	0.660	rs9632462	chr5:112697801	T/C	cg12552261	chr5:112820674	MCC	0.56	6.56	0.39	3.14e-10	Type 2 diabetes;
KIRP	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg24110177	chr3:50126178	RBM5	-0.54	-6.52	-0.38	3.92e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12360000	0.800	rs7096499	chr10:1918528	A/G	cg26364871	chr10:1889757	NA	0.53	6.42	0.38	6.89e-10	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs9381040	1.000	rs9394766	chr6:41159801	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.61	-6.47	-0.38	5.19e-10	Alzheimer's disease (late onset);
KIRP	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg02569458	chr12:86230093	RASSF9	-0.43	-6.39	-0.38	8.06e-10	Major depressive disorder;
KIRP	cis	rs7945718	0.591	rs12797960	chr11:12841771	T/C	cg25843174	chr11:12811716	TEAD1	-0.34	-6.27	-0.37	1.61e-9	Educational attainment (years of education);
KIRP	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg03929089	chr4:120376271	NA	0.99	7.2	0.42	7.32e-12	Myopia (pathological);
KIRP	cis	rs12580194	0.593	rs61957878	chr12:55716754	G/T	cg11794356	chr12:55725991	OR6C3	-0.6	-8.41	-0.47	3.31e-15	Cancer;
KIRP	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.21	-0.46	1.27e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	5.07	0.31	7.93e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.83	-0.35	1.69e-8	Bipolar disorder;
KIRP	cis	rs2296225	0.722	rs58464781	chr1:21051430	C/A	cg14666476	chr1:21112556	HP1BP3	0.69	6.38	0.38	8.58e-10	Eosinophilic esophagitis;
KIRP	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs963731	0.579	rs11692687	chr2:39265428	A/G	cg04010122	chr2:39346883	SOS1	-1.02	-6.82	-0.4	7.09e-11	Corticobasal degeneration;
KIRP	cis	rs7692976	0.868	rs2237053	chr4:110911080	T/C	cg06981781	chr4:110842888	EGF	-0.24	-5.21	-0.32	3.99e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.72	5.84	0.35	1.61e-8	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09728506	chr3:196439567	PIGX;C3orf34	0.53	6.47	0.38	5.29e-10	Parkinson's disease;
KIRP	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg11608241	chr8:8085544	FLJ10661	0.51	6.0	0.36	6.9e-9	Mood instability;
KIRP	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.54	-0.33	7.91e-8	Bipolar disorder;
KIRP	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg05083358	chr7:2394359	EIF3B	-0.73	-7.13	-0.41	1.09e-11	Multiple sclerosis;
KIRP	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.28	14.54	0.68	5.29e-35	Uric acid levels;
KIRP	cis	rs865483	0.929	rs853225	chr17:35791505	A/C	cg06716730	chr17:35851459	DUSP14	0.25	5.99	0.36	7.52e-9	Monocyte count;
KIRP	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.85	-0.3	2.17e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs4478037	0.558	rs59482503	chr3:33077163	G/A	cg19404215	chr3:33155277	CRTAP	0.87	5.55	0.33	7.32e-8	Major depressive disorder;
KIRP	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-35.99	-0.92	5.15e-100	Myeloid white cell count;
KIRP	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	cis	rs4363506	0.668	rs1970169	chr10:129275575	A/G	cg07804728	chr10:129284050	NA	0.4	5.46	0.33	1.17e-7	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg03714773	chr7:91764589	CYP51A1	-0.38	-5.35	-0.32	2.05e-7	Breast cancer;
KIRP	cis	rs12476592	0.516	rs6734648	chr2:63801525	A/G	cg17519650	chr2:63277830	OTX1	-0.46	-5.13	-0.31	5.95e-7	Childhood ear infection;
KIRP	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.54	7.56	0.43	7.79e-13	Systemic lupus erythematosus;
KIRP	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.28	-0.32	2.91e-7	Primary biliary cholangitis;
KIRP	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.18	-0.46	1.53e-14	Response to antipsychotic treatment;
KIRP	cis	rs885389	1.000	rs867411	chr12:131621789	T/G	cg07124762	chr12:131619285	GPR133	-0.38	-4.93	-0.3	1.5e-6	RR interval (heart rate);
KIRP	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.87	-0.45	1.13e-13	Bipolar disorder;
KIRP	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.45	0.33	1.2e-7	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.94	0.35	9.91e-9	Menopause (age at onset);
KIRP	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.61	-7.05	-0.41	1.85e-11	Menarche (age at onset);
KIRP	cis	rs6540556	0.517	rs1474655	chr1:209884730	G/C	cg23920097	chr1:209922102	NA	-0.48	-5.4	-0.33	1.54e-7	Red blood cell count;
KIRP	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg16989719	chr2:238392110	NA	-0.52	-6.92	-0.4	3.94e-11	Prostate cancer;
KIRP	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg18190219	chr22:46762943	CELSR1	-0.72	-6.17	-0.37	2.76e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.57	-0.43	7.48e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.25	-0.32	3.29e-7	Life satisfaction;
KIRP	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg02297831	chr4:17616191	MED28	0.54	6.84	0.4	6.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg12486944	chr17:80159399	CCDC57	0.38	5.11	0.31	6.56e-7	Life satisfaction;
KIRP	trans	rs2826891	0.590	rs1599229	chr21:22981633	T/C	cg14528756	chr2:176862893	KIAA1715	-0.42	-6.15	-0.37	3.11e-9	Longevity;
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.79	13.15	0.64	2.96e-30	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4006360	0.560	rs3861283	chr17:39243940	C/G	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	4.92	0.3	1.57e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15454043	chr8:16942004	EFHA2	0.46	6.26	0.37	1.66e-9	Interleukin-4 levels;
KIRP	cis	rs240764	0.817	rs6907240	chr6:101153782	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-5.23	-0.32	3.65e-7	Neuroticism;
KIRP	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.55	6.83	0.4	6.46e-11	Monocyte count;
KIRP	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.8	0.49	2.42e-16	Motion sickness;
KIRP	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.57	7.0	0.41	2.44e-11	Monocyte count;
KIRP	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	7.43	0.43	1.74e-12	Mean corpuscular hemoglobin;
KIRP	trans	rs972578	0.765	rs7074	chr22:43265827	G/T	cg15321293	chr3:36422198	STAC	-0.48	-6.24	-0.37	1.94e-9	Mean platelet volume;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg21698718	chr17:80085957	CCDC57	0.38	5.48	0.33	1.03e-7	Life satisfaction;
KIRP	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.61	7.33	0.42	3.36e-12	Schizophrenia;
KIRP	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg22437258	chr11:111473054	SIK2	0.6	7.05	0.41	1.85e-11	Primary sclerosing cholangitis;
KIRP	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.41	-0.33	1.51e-7	Platelet count;
KIRP	cis	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.72	-9.04	-0.5	4.71e-17	Aortic root size;
KIRP	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg10047753	chr17:41438598	NA	0.89	12.6	0.63	2.02e-28	Menopause (age at onset);
KIRP	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.46	-0.33	1.19e-7	Blood metabolite levels;
KIRP	cis	rs2120243	1.000	rs10936090	chr3:157142754	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.52	7.13	0.41	1.1e-11	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg09795085	chr6:101329169	ASCC3	0.5	6.1	0.36	4.02e-9	Neuroticism;
KIRP	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	7.81	0.45	1.63e-13	Neuroticism;
KIRP	trans	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	6.25	0.37	1.75e-9	Ulcerative colitis;
KIRP	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	9.44	0.52	2.95e-18	Smoking behavior;
KIRP	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.56	-8.47	-0.48	2.31e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs1891275	0.515	rs1418161	chr10:93484655	C/G	cg07889827	chr10:93443413	NA	-0.43	-7.33	-0.42	3.3e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-0.9	-12.04	-0.61	1.47e-26	Blood protein levels;
KIRP	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.03	-0.64	7.39e-30	Height;
KIRP	cis	rs926938	0.527	rs360667	chr1:115481451	C/G	cg12756093	chr1:115239321	AMPD1	-0.55	-7.31	-0.42	3.79e-12	Autism;
KIRP	cis	rs3794288	1.000	rs11062303	chr12:2778971	A/G	cg19945202	chr12:2788847	CACNA1C	0.88	5.41	0.33	1.46e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22168489	chr12:122356033	WDR66	0.65	9.58	0.52	1.1e-18	Mean corpuscular volume;
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg05231480	chr19:49170277	SEC1;NTN5	-0.32	-4.87	-0.3	1.96e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.59	7.47	0.43	1.36e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01696193	chr6:56819912	BEND6;DST	-0.49	-6.29	-0.37	1.46e-9	Myopia;
KIRP	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.81	0.49	2.28e-16	Bladder cancer;
KIRP	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7039377	0.554	rs7873962	chr9:38673606	T/G	cg13837857	chr9:38672315	NA	0.35	5.91	0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs6546886	0.956	rs35749047	chr2:74280369	G/T	cg14702570	chr2:74259524	NA	-0.3	-5.82	-0.35	1.83e-8	Dialysis-related mortality;
KIRP	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg02896835	chr1:92012615	NA	-0.58	-7.4	-0.43	2.14e-12	Breast cancer;
KIRP	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-14.86	-0.69	4.41e-36	Primary sclerosing cholangitis;
KIRP	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.56	-7.25	-0.42	5.25e-12	Eye color traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21216600	chr7:137139113	DGKI	0.43	6.11	0.36	3.86e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	12.81	0.63	3.95e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg11833968	chr6:79620685	NA	-0.38	-5.23	-0.32	3.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.84	6.95	0.4	3.35e-11	Initial pursuit acceleration;
KIRP	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15617883	chr1:200371248	NA	-0.42	-6.1	-0.36	4.04e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.86	14.12	0.67	1.51e-33	Coronary artery disease;
KIRP	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg03474202	chr17:45855739	NA	-0.47	-7.39	-0.43	2.3e-12	IgG glycosylation;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.63	8.52	0.48	1.61e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.77	8.51	0.48	1.71e-15	Cholesterol, total;
KIRP	cis	rs9826463	1.000	rs7638338	chr3:142334730	C/T	cg20824294	chr3:142316082	PLS1	-0.34	-5.81	-0.35	1.9e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7714584	1.000	rs11746807	chr5:150300419	G/A	cg22134413	chr5:150180641	NA	0.73	6.01	0.36	6.82e-9	Crohn's disease;
KIRP	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.36	-0.38	9.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	8.88	0.49	1.47e-16	Platelet count;
KIRP	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg15147215	chr3:52552868	STAB1	-0.29	-4.93	-0.3	1.51e-6	Electroencephalogram traits;
KIRP	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-7.02	-0.41	2.19e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3017493	0.786	rs12295625	chr11:70671860	A/G	cg10362475	chr11:70507825	SHANK2	-0.38	-5.64	-0.34	4.68e-8	Renal transplant outcome;
KIRP	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	10.34	0.55	4.81e-21	Cognitive test performance;
KIRP	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg15976283	chr2:238042351	NA	0.37	4.93	0.3	1.52e-6	Systemic lupus erythematosus;
KIRP	cis	rs698833	0.788	rs1142523	chr2:44545576	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.71	0.34	3.29e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.44	-5.22	-0.32	3.75e-7	Acne (severe);
KIRP	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.58	0.34	6.36e-8	Alzheimer's disease;
KIRP	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.53	6.67	0.39	1.68e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11603020	0.950	rs28362950	chr11:57371918	G/A	cg23127183	chr11:57508653	C11orf31	-0.47	-5.54	-0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-6.8	-0.4	7.77e-11	Mean corpuscular volume;
KIRP	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg15249062	chr17:2415618	METT10D	0.45	6.19	0.37	2.55e-9	Liver disease severity in Alagille syndrome;
KIRP	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.53	6.57	0.39	3.04e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs77372450	0.636	rs11746670	chr5:157027705	C/T	cg23851860	chr5:157002805	ADAM19	0.45	4.93	0.3	1.53e-6	Bipolar disorder (body mass index interaction);
KIRP	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.27e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4835473	0.932	rs10030428	chr4:144683852	C/T	cg08833778	chr4:144622313	FREM3	0.35	5.0	0.3	1.07e-6	Immature fraction of reticulocytes;
KIRP	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.55	-7.02	-0.41	2.12e-11	Testicular germ cell tumor;
KIRP	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg27490568	chr2:178487706	NA	0.63	8.54	0.48	1.46e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1359582	0.793	rs2057641	chr10:90400148	G/C	cg15661332	chr10:90342814	RNLS	0.56	5.94	0.35	9.84e-9	Depressive and manic episodes in bipolar disorder;
KIRP	trans	rs13170463	0.579	rs13165668	chr5:8035170	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.27	0.37	1.65e-9	Colorectal cancer;
KIRP	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg08501292	chr6:25962987	TRIM38	1.11	7.83	0.45	1.45e-13	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.12e-15	Menarche (age at onset);
KIRP	cis	rs3857067	0.806	rs4693374	chr4:95086164	A/C	cg00507259	chr4:95128692	SMARCAD1	0.39	4.9	0.3	1.75e-6	QT interval;
KIRP	cis	rs7737355	0.947	rs6864145	chr5:130637861	C/T	cg06307176	chr5:131281290	NA	0.53	5.77	0.35	2.36e-8	Life satisfaction;
KIRP	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs3741798	1.000	rs55865572	chr12:12497333	T/C	cg08615371	chr12:12503544	MANSC1	0.96	8.49	0.48	2.04e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg01097406	chr16:89675127	NA	-0.29	-4.9	-0.3	1.75e-6	Vitiligo;
KIRP	cis	rs1829883	0.835	rs2511961	chr5:98878673	A/G	cg08333243	chr5:99726346	NA	0.39	5.32	0.32	2.31e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.7	7.22	0.42	6.29e-12	Vitiligo;
KIRP	cis	rs501120	0.584	rs58129751	chr10:44706720	G/A	cg09554077	chr10:44749378	NA	0.66	6.84	0.4	6.13e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs526231	0.543	rs34804	chr5:102428239	G/A	cg23492399	chr5:102201601	PAM	-0.6	-6.43	-0.38	6.55e-10	Primary biliary cholangitis;
KIRP	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1018836	0.886	rs7817954	chr8:91535105	G/A	cg16814680	chr8:91681699	NA	-0.76	-9.52	-0.52	1.68e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7560272	0.501	rs12992607	chr2:73959960	G/T	cg20560298	chr2:73613845	ALMS1	0.44	5.22	0.32	3.81e-7	Schizophrenia;
KIRP	cis	rs8049040	0.564	rs310335	chr16:71573918	T/A	cg08717414	chr16:71523259	ZNF19	-0.56	-6.56	-0.39	3.15e-10	Blood protein levels;
KIRP	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.46	10.61	0.56	6.75e-22	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.89	0.57	8.22e-23	Bone mineral density;
KIRP	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.78	-0.44	2.05e-13	Blood protein levels;
KIRP	trans	rs4650994	0.816	rs2093770	chr1:178604633	C/A	cg05059571	chr16:84539110	KIAA1609	0.53	6.96	0.41	3.07e-11	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg08873628	chr1:175162347	KIAA0040	-0.41	-6.04	-0.36	5.63e-9	Alcohol dependence;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12831102	chr11:119205214	RNF26	-0.51	-6.41	-0.38	7.57e-10	Myopia;
KIRP	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.5	0.38	4.35e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4692589	0.965	rs6847470	chr4:170954468	T/C	cg19918862	chr4:170955249	NA	0.47	5.83	0.35	1.74e-8	Anxiety disorder;
KIRP	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg04310649	chr10:35416472	CREM	-0.59	-6.92	-0.4	3.99e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs918629	0.798	rs7705279	chr5:95324375	C/T	cg16656078	chr5:95278638	ELL2	-0.44	-6.51	-0.38	4.18e-10	IgG glycosylation;
KIRP	cis	rs4363385	0.693	rs10788849	chr1:152902240	C/A	cg07796016	chr1:152779584	LCE1C	-0.4	-4.87	-0.3	2.03e-6	Inflammatory skin disease;
KIRP	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.38e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.4	-0.43	2.12e-12	Response to antipsychotic treatment;
KIRP	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-9.94	-0.54	8.44e-20	Hypospadias;
KIRP	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs11606709	1	rs11606709	chr11:46730522	A/G	cg16389345	chr11:46697382	NA	0.43	5.24	0.32	3.42e-7	Total body bone mineral density;
KIRP	cis	rs259842	0.584	rs13388545	chr2:180709194	G/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.43	-0.33	1.34e-7	Blood protein levels;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg24874828	chr4:187887005	NA	-0.5	-7.56	-0.43	7.97e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg05072774	chr3:49840536	C3orf54	0.43	5.52	0.33	8.57e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.79	7.47	0.43	1.42e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	5.88	0.35	1.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.49	2.59e-16	Bladder cancer;
KIRP	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25517755	chr10:38738941	LOC399744	-0.52	-7.18	-0.42	8.31e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg13010199	chr12:38710504	ALG10B	-0.39	-5.04	-0.31	9.03e-7	Heart rate;
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg00080972	chr5:178986291	RUFY1	-0.39	-6.14	-0.36	3.32e-9	Lung cancer;
KIRP	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg22029157	chr1:209979665	IRF6	0.5	6.52	0.38	3.86e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.25	-6.54	-0.39	3.44e-10	Mean corpuscular volume;
KIRP	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.79	-0.35	2.16e-8	Bipolar disorder;
KIRP	trans	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg06521331	chr12:34319734	NA	-0.59	-7.1	-0.41	1.35e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	1.12	8.11	0.46	2.4e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.1	-0.31	6.95e-7	Pulmonary function;
KIRP	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.69	-9.15	-0.5	2.24e-17	Blood metabolite levels;
KIRP	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg23533419	chr12:54090519	NA	-0.33	-5.23	-0.32	3.56e-7	Height;
KIRP	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg09699651	chr6:150184138	LRP11	0.48	6.49	0.38	4.69e-10	Lung cancer;
KIRP	cis	rs228437	1.000	rs73775366	chr6:134963061	T/C	cg24504307	chr6:134963096	NA	0.52	7.72	0.44	2.88e-13	Melanoma;
KIRP	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.89	-10.09	-0.54	2.92e-20	White matter hyperintensity burden;
KIRP	cis	rs1200821	0.704	rs9888115	chr10:37658351	C/T	cg00409905	chr10:38381863	ZNF37A	0.48	6.2	0.37	2.36e-9	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg05347473	chr6:146136440	FBXO30	0.61	8.8	0.49	2.55e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg05973401	chr12:123451056	ABCB9	-0.57	-5.56	-0.33	7.16e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.9	12.53	0.62	3.6e-28	Cognitive function;
KIRP	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg18709589	chr6:96969512	KIAA0776	0.34	5.04	0.31	8.89e-7	Headache;
KIRP	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.03	0.41	2.05e-11	Height;
KIRP	cis	rs77861329	1.000	rs164638	chr3:52207886	T/G	cg08692210	chr3:52188851	WDR51A	0.93	7.21	0.42	6.69e-12	Macrophage inflammatory protein 1b levels;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17150246	chr1:161068070	KLHDC9	0.75	7.03	0.41	2.06e-11	Lung function (FEV1);
KIRP	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg02811702	chr13:24901961	NA	0.38	4.88	0.3	1.92e-6	Obesity-related traits;
KIRP	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg03060546	chr3:49711283	APEH	-0.6	-5.26	-0.32	3.13e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.27	0.32	2.91e-7	Lung cancer;
KIRP	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg27471124	chr11:109292789	C11orf87	0.48	5.47	0.33	1.09e-7	Schizophrenia;
KIRP	trans	rs12517041	0.935	rs6894054	chr5:23305356	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs1497828	0.956	rs2646820	chr1:217526479	A/T	cg04411442	chr1:217543379	NA	-0.43	-6.58	-0.39	2.73e-10	Dialysis-related mortality;
KIRP	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.94	-16.19	-0.72	1.29e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.19e-9	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04938255	chr1:94312360	MIR760	0.5	6.09	0.36	4.36e-9	Parkinson's disease;
KIRP	cis	rs6450176	1.000	rs7735253	chr5:53297611	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.33	-0.59	3.2e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2718812	0.766	rs11924101	chr3:133394478	T/G	cg11941060	chr3:133502564	NA	-0.38	-4.86	-0.3	2.11e-6	Iron status biomarkers;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg10546176	chr5:34929404	DNAJC21	0.42	6.07	0.36	4.81e-9	Bladder cancer;
KIRP	cis	rs11792861	0.532	rs10979659	chr9:111788975	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	7.41	0.43	1.98e-12	Menarche (age at onset);
KIRP	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	5.99	0.36	7.55e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.47	-6.94	-0.4	3.48e-11	Electroencephalogram traits;
KIRP	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.43	-6.28	-0.37	1.5e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.99	0.45	5.27e-14	Coffee consumption (cups per day);
KIRP	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	15.4	0.7	6.28e-38	Platelet count;
KIRP	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg20493526	chr2:3714936	ALLC	0.49	6.21	0.37	2.28e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6750047	0.515	rs13417487	chr2:38289162	G/T	cg07380506	chr2:38303506	CYP1B1	0.43	5.31	0.32	2.49e-7	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11955398	0.625	rs34395679	chr5:59954716	A/G	cg02684056	chr5:59996105	DEPDC1B	0.47	5.31	0.32	2.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-5.81	-0.35	1.92e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg14673194	chr17:80132900	CCDC57	0.76	8.56	0.48	1.21e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg00629928	chr5:358741	AHRR	0.52	5.22	0.32	3.84e-7	Breast cancer;
KIRP	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg03060546	chr3:49711283	APEH	-0.72	-5.46	-0.33	1.15e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs68170813	0.617	rs2283041	chr7:107190415	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-7.15	-0.41	9.88e-12	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611198	0.792	rs2092168	chr22:39947068	T/C	cg10455938	chr22:40058150	CACNA1I	0.47	6.54	0.38	3.54e-10	Schizophrenia;
KIRP	cis	rs597583	0.760	rs688968	chr11:117406739	C/G	cg27161313	chr11:117392002	DSCAML1	-0.64	-6.62	-0.39	2.23e-10	Putamen volume;
KIRP	cis	rs904092	0.678	rs1230020	chr4:100175407	G/A	cg12011299	chr4:100065546	ADH4	0.49	4.94	0.3	1.42e-6	Alcohol dependence;
KIRP	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg01879757	chr17:41196368	BRCA1	-0.79	-11.06	-0.58	2.32e-23	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.72	8.02	0.46	4.42e-14	Cholesterol, total;
KIRP	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	7.09	0.41	1.45e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00149659	chr3:10157352	C3orf10	0.84	9.19	0.51	1.69e-17	Alzheimer's disease;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.79	-0.35	2.19e-8	Life satisfaction;
KIRP	cis	rs12210905	1.000	rs4636015	chr6:27097316	C/T	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06173319	chr16:90148775	NA	0.55	5.02	0.3	9.91e-7	Skin colour saturation;
KIRP	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.84	-14.43	-0.68	1.31e-34	Post bronchodilator FEV1;
KIRP	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.4	5.06	0.31	8.17e-7	Lymphocyte counts;
KIRP	cis	rs2573652	0.722	rs12904962	chr15:100544113	A/G	cg09918751	chr15:100517450	ADAMTS17	0.54	7.72	0.44	2.95e-13	Height;
KIRP	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18576335	chr17:8110165	AURKB	-0.55	-7.29	-0.42	4.14e-12	Parkinson's disease;
KIRP	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-8.07	-0.46	3.05e-14	Homocysteine levels;
KIRP	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.3	-5.33	-0.32	2.27e-7	Monocyte percentage of white cells;
KIRP	trans	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.49	-0.43	1.21e-12	Myopia (pathological);
KIRP	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg15848620	chr12:58087721	OS9	-0.5	-5.86	-0.35	1.52e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg25486957	chr4:152246857	NA	-0.48	-5.39	-0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg11038491	chr20:34638489	LOC647979	-0.76	-8.12	-0.46	2.26e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg09990169	chr2:241835740	C2orf54	-0.44	-6.12	-0.36	3.64e-9	Urinary metabolites;
KIRP	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg24881330	chr22:46731750	TRMU	0.69	6.27	0.37	1.6e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.77	12.25	0.62	2.97e-27	Menarche (age at onset);
KIRP	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.68	-0.34	3.82e-8	Pulmonary function;
KIRP	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg22951263	chr5:87985283	NA	-0.48	-6.77	-0.4	9.32e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	1.21	9.24	0.51	1.25e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.46	0.33	1.14e-7	Schizophrenia;
KIRP	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg14416269	chr4:6271139	WFS1	0.33	4.95	0.3	1.35e-6	Cisplatin-induced ototoxicity;
KIRP	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg20243544	chr17:37824526	PNMT	0.48	6.61	0.39	2.36e-10	Asthma;
KIRP	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.78	-11.79	-0.6	1.01e-25	Hip circumference;
KIRP	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.71	10.0	0.54	5.71e-20	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.63	-0.48	7.69e-16	Joint mobility (Beighton score);
KIRP	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-5.24	-0.32	3.51e-7	Personality dimensions;
KIRP	cis	rs7084402	0.967	rs1649039	chr10:60330041	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.48	-0.56	1.72e-21	Refractive error;
KIRP	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.54	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-6.09	-0.36	4.35e-9	Obesity (extreme);
KIRP	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15556689	chr8:8085844	FLJ10661	0.73	8.56	0.48	1.26e-15	Red cell distribution width;
KIRP	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.66	0.48	6.17e-16	Electroencephalogram traits;
KIRP	cis	rs13185784	0.667	rs4441844	chr5:179645386	C/T	cg23248424	chr5:179741104	GFPT2	-0.49	-5.26	-0.32	3.18e-7	TRAIL levels;
KIRP	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.28e-8	Retinal vascular caliber;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05746407	chr16:85646856	KIAA0182	0.47	6.16	0.37	2.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs5753037	0.543	rs140119	chr22:30138149	A/T	cg01021169	chr22:30184971	ASCC2	-0.48	-6.47	-0.38	5.2e-10	Type 1 diabetes;
KIRP	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2594989	0.616	rs6442255	chr3:11474492	A/G	cg01796438	chr3:11312864	ATG7	-0.56	-7.12	-0.41	1.2e-11	Circulating chemerin levels;
KIRP	cis	rs300890	0.642	rs6537155	chr4:144293053	G/A	cg01719995	chr4:144104893	USP38	-0.42	-5.19	-0.31	4.37e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg07936489	chr17:37558343	FBXL20	-0.45	-5.58	-0.34	6.17e-8	Asthma;
KIRP	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg15605315	chr1:45957053	TESK2	0.39	5.04	0.31	8.92e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6546324	0.959	rs11126143	chr2:67865408	A/G	cg15745817	chr2:67799979	NA	0.4	5.52	0.33	8.69e-8	Endometriosis;
KIRP	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.54	-6.17	-0.37	2.81e-9	Breast cancer;
KIRP	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs7566780	0.725	rs4347841	chr2:16702165	C/T	cg09580478	chr2:16689509	NA	0.48	5.28	0.32	2.88e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs4794202	0.579	rs9904503	chr17:45884372	T/C	cg10638573	chr17:45915098	SCRN2	0.46	5.58	0.33	6.49e-8	Alzheimer's disease (cognitive decline);
KIRP	cis	rs7091068	0.671	rs517785	chr10:95403973	G/A	cg20715218	chr10:95462985	C10orf4	-0.48	-4.85	-0.3	2.18e-6	Urinary tract infection frequency;
KIRP	cis	rs4664293	1.000	rs13014418	chr2:160483685	T/G	cg08347373	chr2:160653686	CD302	-0.4	-6.18	-0.37	2.62e-9	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg08662619	chr6:150070041	PCMT1	0.36	5.79	0.35	2.08e-8	Lung cancer;
KIRP	cis	rs7715811	1.000	rs2896103	chr5:13764419	G/A	cg07548982	chr5:13769939	DNAH5	-0.53	-6.61	-0.39	2.42e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.61	0.34	5.47e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.73	9.32	0.51	6.81e-18	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.54	6.21	0.37	2.27e-9	Height;
KIRP	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.93	13.95	0.66	5.72e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.68	0.44	3.68e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9314323	0.737	rs7818293	chr8:26264116	C/A	cg11498726	chr8:26250323	BNIP3L	0.52	7.09	0.41	1.41e-11	Red cell distribution width;
KIRP	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.94	0.4	3.51e-11	Platelet count;
KIRP	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	cg04338863	chr8:33670619	NA	0.48	6.19	0.37	2.52e-9	Body mass index;
KIRP	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg27205649	chr11:78285834	NARS2	-0.68	-8.44	-0.47	2.75e-15	Alzheimer's disease (survival time);
KIRP	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.13	-0.31	5.94e-7	Bipolar disorder;
KIRP	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg16797656	chr11:68205561	LRP5	0.42	5.48	0.33	1.06e-7	Total body bone mineral density;
KIRP	cis	rs7927997	0.623	rs4494327	chr11:76294836	A/T	cg17647271	chr11:76299819	NA	-0.37	-5.08	-0.31	7.37e-7	Gut microbiota (functional units);Crohn's disease;
KIRP	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.97	-0.41	2.95e-11	Initial pursuit acceleration;
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.21	0.37	2.22e-9	Platelet count;
KIRP	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg17724175	chr1:150552817	MCL1	0.31	5.21	0.32	4.08e-7	Melanoma;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs806215	0.547	rs12667197	chr7:127369147	A/T	cg08586737	chr7:127225949	GCC1	-0.41	-5.07	-0.31	7.81e-7	Type 2 diabetes;
KIRP	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg12623918	chr2:306882	NA	0.51	6.4	0.38	7.65e-10	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs282587	0.560	rs375527	chr13:113417589	A/G	cg04656015	chr13:113407548	ATP11A	0.59	5.85	0.35	1.54e-8	Glycated hemoglobin levels;
KIRP	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.98	0.45	5.62e-14	Obesity-related traits;
KIRP	cis	rs6714016	0.744	rs2551347	chr2:23912401	C/T	cg08917208	chr2:24149416	ATAD2B	-0.46	-5.23	-0.32	3.65e-7	Plateletcrit;
KIRP	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.47	0.43	1.43e-12	Mean corpuscular volume;
KIRP	cis	rs7539542	0.529	rs9651059	chr1:202885934	C/G	cg19681188	chr1:202830198	LOC148709	-0.47	-5.11	-0.31	6.38e-7	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27539720	chr17:60023175	MED13	-0.42	-6.57	-0.39	2.94e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.7	8.41	0.47	3.42e-15	Schizophrenia;
KIRP	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.27	0.42	4.83e-12	Prudent dietary pattern;
KIRP	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.45e-21	Diabetic kidney disease;
KIRP	cis	rs6500395	0.588	rs2047601	chr16:48578101	C/T	cg04672837	chr16:48644449	N4BP1	-0.43	-6.02	-0.36	6.31e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg23594656	chr7:65796392	TPST1	0.38	5.47	0.33	1.13e-7	Aortic root size;
KIRP	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.9	-12.93	-0.64	1.61e-29	Lung cancer;
KIRP	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	1.01	14.34	0.67	2.56e-34	Homoarginine levels;
KIRP	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.78	11.36	0.59	2.6e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9840812	0.769	rs1279840	chr3:136006576	T/C	cg15507776	chr3:136538369	TMEM22	0.4	5.03	0.31	9.37e-7	Fibrinogen levels;
KIRP	cis	rs1318772	0.932	rs11746565	chr5:112934273	T/A	cg12552261	chr5:112820674	MCC	0.75	5.2	0.31	4.25e-7	F-cell distribution;
KIRP	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	7.58	0.44	7.03e-13	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08951903	chr10:44070173	ZNF239	0.49	6.25	0.37	1.76e-9	Parkinson's disease;
KIRP	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.74	7.35	0.42	2.95e-12	Lung function (FEV1/FVC);
KIRP	cis	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg21546286	chr11:48923668	NA	0.45	5.84	0.35	1.64e-8	HDL cholesterol;
KIRP	cis	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg00576331	chr11:65640516	EFEMP2	-0.43	-5.36	-0.32	1.96e-7	DNA methylation (variation);
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.05	0.69	9.57e-37	Platelet count;
KIRP	cis	rs516946	1.000	rs516946	chr8:41519248	C/T	cg19441908	chr8:41529140	ANK1	0.45	6.3	0.37	1.34e-9	Type 2 diabetes;
KIRP	cis	rs9381040	1.000	rs9394767	chr6:41159905	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.61	-6.47	-0.38	5.19e-10	Alzheimer's disease (late onset);
KIRP	cis	rs405956	0.769	rs221652	chr6:105546452	C/T	cg22580625	chr6:105627791	POPDC3	0.47	5.33	0.32	2.24e-7	QT interval;
KIRP	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.28	5.74	0.34	2.83e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.47	0.43	1.4e-12	Coronary artery disease;
KIRP	cis	rs9311474	0.713	rs352170	chr3:52236077	A/G	cg05315796	chr3:52349193	DNAH1	0.42	6.47	0.38	5.19e-10	Electroencephalogram traits;
KIRP	cis	rs2281603	0.521	rs3742608	chr14:64937033	G/C	cg01860774	chr14:64969374	ZBTB25	0.34	5.42	0.33	1.44e-7	Lymphocyte counts;
KIRP	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-1.01	-16.94	-0.73	3.55e-43	Height;
KIRP	cis	rs6142102	0.961	rs6059649	chr20:32643877	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	6.75	0.4	1.05e-10	Skin pigmentation;
KIRP	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	0.95	8.19	0.46	1.46e-14	Arsenic metabolism;
KIRP	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.88	0.3	1.88e-6	Breast cancer;
KIRP	cis	rs7075426	0.669	rs11202042	chr10:88237104	T/C	cg07322936	chr10:88137208	NA	0.51	5.51	0.33	9.2e-8	Migraine without aura;
KIRP	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg09184832	chr6:79620586	NA	-0.53	-7.57	-0.43	7.4e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg06212747	chr3:49208901	KLHDC8B	0.53	5.95	0.35	9.02e-9	Resting heart rate;
KIRP	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg11693508	chr17:37793320	STARD3	0.8	8.44	0.47	2.78e-15	Bipolar disorder;
KIRP	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.36	0.32	1.92e-7	Smoking behavior;
KIRP	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg08975724	chr8:8085496	FLJ10661	0.76	9.85	0.53	1.6e-19	Mood instability;
KIRP	cis	rs62413470	1.000	rs34910254	chr6:55963885	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs3008706	0.833	rs3008712	chr9:16017830	A/C	cg14451791	chr9:16040625	NA	-0.51	-5.4	-0.33	1.6e-7	Bilirubin levels;
KIRP	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.83	12.37	0.62	1.17e-27	Menopause (age at onset);
KIRP	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg06307176	chr5:131281290	NA	-0.51	-5.62	-0.34	5.26e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	8.99	0.5	6.86e-17	Neuroticism;
KIRP	cis	rs970548	0.730	rs61854093	chr10:45934881	C/A	cg15590007	chr10:45870220	ALOX5	0.52	5.91	0.35	1.16e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg05526886	chr2:227700861	RHBDD1	-0.62	-6.62	-0.39	2.23e-10	Coronary artery disease;
KIRP	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.54	-8.25	-0.47	9.63e-15	Itch intensity from mosquito bite;
KIRP	cis	rs4460629	0.742	rs6693477	chr1:155081940	A/G	cg02153340	chr1:155202674	NA	-0.36	-5.23	-0.32	3.71e-7	Serum magnesium levels;
KIRP	cis	rs4073416	0.542	rs7150094	chr14:65936361	A/G	cg03016385	chr14:66212404	NA	-0.57	-6.89	-0.4	4.57e-11	N-glycan levels;
KIRP	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.91	14.33	0.67	2.81e-34	Mean corpuscular volume;
KIRP	cis	rs7180079	0.620	rs11632928	chr15:65092537	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.05	-0.31	8.79e-7	Monocyte count;
KIRP	cis	rs4389656	1.000	rs35140683	chr5:6726544	G/A	cg10857441	chr5:6722123	POLS	0.46	5.81	0.35	1.95e-8	Coronary artery disease;
KIRP	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.71	-10.1	-0.54	2.8e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2275620	0.526	rs4466755	chr10:96632253	T/C	cg09036531	chr10:96991505	NA	-0.47	-5.69	-0.34	3.59e-8	Gout;
KIRP	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.72	10.24	0.55	1.02e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg21253087	chr9:139290292	SNAPC4	-0.51	-7.08	-0.41	1.52e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.55	6.86	0.4	5.44e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1440410	0.835	rs4323054	chr4:144052123	T/C	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03737475	chr4:123814785	FGF2;NUDT6	0.38	6.3	0.37	1.33e-9	C-reactive protein;
KIRP	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg02336718	chr17:17403227	NA	-0.34	-5.31	-0.32	2.41e-7	Total body bone mineral density;
KIRP	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg26408565	chr15:76604113	ETFA	-0.42	-5.63	-0.34	4.89e-8	Blood metabolite levels;
KIRP	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.53	8.1	0.46	2.52e-14	Itch intensity from mosquito bite;
KIRP	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.7	10.63	0.56	5.67e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1009647	0.656	rs10147254	chr14:55850315	C/A	cg04306507	chr14:55594613	LGALS3	0.4	5.93	0.35	1.03e-8	Testicular germ cell tumor;
KIRP	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg25039879	chr17:56429692	SUPT4H1	0.62	5.48	0.33	1.06e-7	Cognitive test performance;
KIRP	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg27490568	chr2:178487706	NA	0.41	5.59	0.34	5.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.81	6.52	0.38	4.06e-10	Initial pursuit acceleration;
KIRP	trans	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.58	0.44	6.91e-13	Retinal vascular caliber;
KIRP	cis	rs4262150	0.810	rs56047721	chr5:152082865	A/T	cg12297329	chr5:152029980	NA	-0.67	-8.14	-0.46	2.01e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg13256891	chr4:100009986	ADH5	0.6	7.28	0.42	4.39e-12	Alcohol dependence;
KIRP	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.92	-0.35	1.06e-8	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs7116495	1.000	rs58991229	chr11:71839878	G/A	cg11196788	chr11:71737549	NUMA1	-0.58	-5.13	-0.31	5.98e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05597232	chr5:149378456	TIGD6	0.51	6.21	0.37	2.25e-9	Interleukin-4 levels;
KIRP	cis	rs7688540	0.739	rs11729659	chr4:237284	G/C	cg17891759	chr4:299121	NA	-0.43	-4.9	-0.3	1.75e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg14683738	chr19:37701593	ZNF585B	0.48	4.91	0.3	1.69e-6	Coronary artery calcification;
KIRP	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-8.77	-0.49	3.03e-16	Colorectal cancer;
KIRP	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.52	-0.38	3.96e-10	Neuroticism;
KIRP	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.35	8.94	0.5	9.78e-17	Crohn's disease;
KIRP	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.68	-11.49	-0.59	9.85e-25	Obesity-related traits;
KIRP	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.97	10.23	0.55	1.08e-20	Blood protein levels;
KIRP	cis	rs13082711	0.954	rs67282221	chr3:27552752	T/A	cg02860705	chr3:27208620	NA	0.58	7.19	0.42	7.67e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2862064	1.000	rs7706978	chr5:156432566	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-7.42	-0.43	1.87e-12	Platelet count;
KIRP	cis	rs11603020	1.000	rs11603020	chr11:57374332	C/T	cg23127183	chr11:57508653	C11orf31	0.46	5.37	0.32	1.86e-7	Blood protein levels;
KIRP	cis	rs9815354	1.000	rs2128835	chr3:41862873	A/G	cg03022575	chr3:42003672	ULK4	0.6	6.9	0.4	4.36e-11	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-1.03	-17.39	-0.74	1.01e-44	Height;
KIRP	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.61	-0.39	2.37e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12292205	chr6:26970375	C6orf41	-0.64	-7.06	-0.41	1.72e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs889512	0.642	rs13337397	chr16:75295639	C/A	cg03315344	chr16:75512273	CHST6	-0.62	-4.92	-0.3	1.58e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9788721	0.805	rs67426328	chr15:78934318	C/G	cg18825076	chr15:78729989	IREB2	-0.44	-5.23	-0.32	3.7e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg22800045	chr5:56110881	MAP3K1	0.78	8.0	0.45	4.96e-14	Initial pursuit acceleration;
KIRP	cis	rs745080	0.603	rs17725312	chr14:53065714	C/T	cg23333723	chr14:53022898	GPR137C	-0.53	-6.74	-0.39	1.1e-10	Orofacial clefts;
KIRP	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg00277334	chr10:82204260	NA	-0.45	-5.17	-0.31	4.82e-7	Post bronchodilator FEV1;
KIRP	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.52	-6.99	-0.41	2.54e-11	Type 2 diabetes;
KIRP	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.64	9.06	0.5	4.16e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.84	12.0	0.61	1.99e-26	Itch intensity from mosquito bite;
KIRP	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.54	-5.31	-0.32	2.45e-7	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs6893300	0.826	rs7709723	chr5:179144263	C/T	cg14593053	chr5:179126677	CANX	-0.59	-7.03	-0.41	2.06e-11	Resting heart rate;
KIRP	cis	rs501120	0.657	rs583489	chr10:44738688	C/G	cg09554077	chr10:44749378	NA	0.77	11.91	0.6	3.91e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg21905437	chr5:178450457	ZNF879	-0.51	-5.97	-0.36	8.03e-9	Pubertal anthropometrics;
KIRP	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg20607798	chr8:58055168	NA	0.7	5.58	0.34	6.24e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg00262122	chr8:11665843	FDFT1	-0.45	-5.63	-0.34	5.02e-8	Triglycerides;
KIRP	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-6.77	-0.4	9.53e-11	Body mass index;
KIRP	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.52	6.54	0.39	3.44e-10	Coronary heart disease;
KIRP	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.68	-5.47	-0.33	1.1e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	5.8	0.35	1.98e-8	Educational attainment;
KIRP	cis	rs17065868	0.803	rs61948009	chr13:45186596	T/G	cg10246903	chr13:45222710	NA	0.55	5.89	0.35	1.25e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-1.03	-17.02	-0.74	1.8e-43	Coronary artery disease;
KIRP	trans	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.52	6.03	0.36	5.91e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg16524733	chr11:117070046	TAGLN	0.41	5.33	0.32	2.23e-7	Blood protein levels;
KIRP	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg05315796	chr3:52349193	DNAH1	0.39	6.35	0.38	1.02e-9	Bipolar disorder;
KIRP	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-7.01	-0.41	2.24e-11	Monocyte percentage of white cells;
KIRP	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.5	-6.38	-0.38	8.88e-10	Schizophrenia;
KIRP	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg08392591	chr16:89556376	ANKRD11	0.4	5.14	0.31	5.47e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	8.29	0.47	7.48e-15	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs2033732	0.596	rs1550212	chr8:85057433	C/T	cg05716166	chr8:85095498	RALYL	0.54	6.05	0.36	5.36e-9	Body mass index;
KIRP	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg03563238	chr19:33554763	RHPN2	-0.34	-6.3	-0.37	1.39e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-1.03	-18.61	-0.76	7.62e-49	Height;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.57	-7.77	-0.44	2.07e-13	Glycated hemoglobin levels;
KIRP	cis	rs4903214	0.895	rs7161419	chr14:74695757	A/G	cg08255017	chr14:74727001	VSX2	-0.38	-4.95	-0.3	1.39e-6	Inflammatory bowel disease;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.66	9.62	0.52	8.27e-19	Menarche (age at onset);
KIRP	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg20701182	chr2:24300061	SF3B14	0.51	5.33	0.32	2.26e-7	Asthma;
KIRP	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg17554472	chr22:41940697	POLR3H	-0.46	-5.12	-0.31	6.31e-7	Vitiligo;
KIRP	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg00507259	chr4:95128692	SMARCAD1	0.42	5.35	0.32	2.03e-7	QT interval;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg01765077	chr12:122356316	WDR66	-0.59	-8.3	-0.47	6.99e-15	Mean corpuscular volume;
KIRP	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.56	-0.56	9.77e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg21775007	chr8:11205619	TDH	0.45	5.91	0.35	1.11e-8	Neuroticism;
KIRP	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.54	6.78	0.4	9.03e-11	Coronary artery disease;
KIRP	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.56	0.39	3.18e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-6.76	-0.4	1.01e-10	Systemic lupus erythematosus;
KIRP	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg05347473	chr6:146136440	FBXO30	0.46	6.55	0.39	3.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg08131204	chr22:41487073	MIR1281	-0.44	-5.14	-0.31	5.62e-7	Neuroticism;
KIRP	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.37	-5.1	-0.31	6.81e-7	Coronary artery disease;
KIRP	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg21214613	chr1:16344536	HSPB7	-0.34	-5.22	-0.32	3.87e-7	Dilated cardiomyopathy;
KIRP	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg16077055	chr2:106428750	NCK2	0.3	6.16	0.37	2.98e-9	Addiction;
KIRP	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg19507638	chr5:93509721	C5orf36	-0.57	-5.01	-0.3	1.04e-6	Diabetic retinopathy;
KIRP	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-7.9	-0.45	9.42e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.88	9.91	0.53	1.1e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg09579323	chr1:150459698	TARS2	0.42	5.15	0.31	5.46e-7	Migraine;
KIRP	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.47	-6.68	-0.39	1.61e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg11965913	chr1:205819406	PM20D1	-0.57	-5.74	-0.34	2.72e-8	Menarche (age at onset);
KIRP	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.65	8.85	0.49	1.81e-16	Alcohol dependence;
KIRP	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.84	11.37	0.59	2.3e-24	Morning vs. evening chronotype;
KIRP	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg25922125	chr7:127225783	GCC1	0.45	4.89	0.3	1.83e-6	Type 2 diabetes;
KIRP	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-1.14	-11.23	-0.58	6.8e-24	Post bronchodilator FEV1;
KIRP	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg01988459	chr11:68622903	NA	-0.37	-5.4	-0.33	1.57e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19313758	chr11:64889193	FAU;MRPL49	0.48	6.16	0.37	2.97e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.82	-12.52	-0.62	3.89e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7011507	1.000	rs80153910	chr8:49183119	A/G	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg18473234	chr19:5097819	KDM4B	-0.6	-6.87	-0.4	5.28e-11	Monocyte percentage of white cells;
KIRP	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.09	-0.58	1.9e-23	Chronic sinus infection;
KIRP	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.5	6.35	0.38	1.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.69	9.9	0.53	1.19e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.46	6.72	0.39	1.24e-10	Urate levels in lean individuals;
KIRP	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.95	11.06	0.58	2.44e-23	Corneal astigmatism;
KIRP	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.05	-0.41	1.82e-11	Neuroticism;
KIRP	cis	rs240764	0.817	rs12207086	chr6:101150463	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.47	-0.33	1.11e-7	Neuroticism;
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg19923238	chr8:142232952	SLC45A4	-0.41	-4.84	-0.3	2.27e-6	Immature fraction of reticulocytes;
KIRP	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.76	9.06	0.5	4.1e-17	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7209700	0.745	rs8074348	chr17:45353413	G/C	cg08085267	chr17:45401833	C17orf57	0.44	5.49	0.33	9.97e-8	IgG glycosylation;
KIRP	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg06360820	chr2:242988706	NA	-0.81	-7.62	-0.44	5.38e-13	Obesity-related traits;
KIRP	cis	rs17065868	1.000	rs9316088	chr13:45104665	C/T	cg10246903	chr13:45222710	NA	0.65	7.09	0.41	1.46e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00629928	chr5:358741	AHRR	0.45	4.88	0.3	1.94e-6	Breast cancer;
KIRP	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg03999872	chr20:62272968	STMN3	-0.49	-5.06	-0.31	8.14e-7	Glioblastoma;
KIRP	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.8	0.4	7.89e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13161895	0.702	rs73810942	chr5:179499267	C/A	cg02702477	chr5:179499311	RNF130	1.07	7.46	0.43	1.51e-12	LDL cholesterol;
KIRP	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg00852783	chr1:26633632	UBXN11	-0.56	-5.78	-0.35	2.2e-8	Obesity-related traits;
KIRP	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg17385448	chr1:15911702	AGMAT	0.25	4.94	0.3	1.43e-6	Systolic blood pressure;
KIRP	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.7	-0.34	3.45e-8	Aortic root size;
KIRP	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg16141378	chr3:129829833	LOC729375	0.49	6.42	0.38	6.98e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9581857	0.547	rs9579086	chr13:28058537	T/A	cg22138327	chr13:27999177	GTF3A	0.87	6.36	0.38	9.88e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.77	11.13	0.58	1.38e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.76	12.98	0.64	1.09e-29	Blood metabolite levels;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.67	-8.31	-0.47	6.6e-15	Breast cancer;
KIRP	cis	rs2661868	0.788	rs2708631	chr1:8463510	C/T	cg25722041	chr1:8623473	RERE	0.4	4.84	0.3	2.26e-6	Life satisfaction;
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13939156	chr17:80058883	NA	0.5	7.54	0.43	9.21e-13	Life satisfaction;
KIRP	cis	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg09231725	chr11:64357281	SLC22A12	0.52	6.11	0.36	3.87e-9	Urate levels in obese individuals;
KIRP	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg16268157	chr7:99778414	STAG3	-0.55	-6.07	-0.36	4.93e-9	Lung function (FEV1/FVC);
KIRP	cis	rs3779635	1.000	rs725788	chr8:27265371	T/C	cg06815112	chr8:27182871	PTK2B	0.44	5.76	0.34	2.55e-8	Neuroticism;
KIRP	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	7.23	0.42	6.19e-12	Lung cancer;
KIRP	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.73	9.43	0.52	3.17e-18	Schizophrenia;
KIRP	trans	rs2898857	0.504	rs35822701	chr17:47422317	C/T	cg11430096	chr6:110968061	CDK19	-0.53	-6.52	-0.38	4.01e-10	Cancer;
KIRP	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg21475434	chr5:93447410	FAM172A	0.75	6.75	0.4	1.08e-10	Diabetic retinopathy;
KIRP	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17554472	chr22:41940697	POLR3H	0.7	7.17	0.42	9.01e-12	Vitiligo;
KIRP	cis	rs1461503	0.900	rs7119398	chr11:122832492	C/A	cg27398637	chr11:122830231	C11orf63	-0.7	-9.17	-0.5	1.92e-17	Menarche (age at onset);
KIRP	cis	rs12188164	0.554	rs72711364	chr5:415323	A/G	cg03877420	chr5:1004367	NA	-0.43	-5.03	-0.31	9.4e-7	Cystic fibrosis severity;
KIRP	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg00504896	chr12:9437009	LOC642846	-0.56	-7.48	-0.43	1.31e-12	Breast size;
KIRP	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg15352829	chr14:105391018	PLD4	0.48	9.96	0.54	7.58e-20	Rheumatoid arthritis;
KIRP	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.62	-8.02	-0.46	4.37e-14	QT interval;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.65	12.29	0.62	2.17e-27	Sjögren's syndrome;
KIRP	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg00319359	chr11:70116639	PPFIA1	0.8	6.92	0.4	4e-11	Coronary artery disease;
KIRP	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.5	6.97	0.41	2.92e-11	Dupuytren's disease;
KIRP	cis	rs1011018	0.955	rs1015122	chr7:139454843	A/G	cg03224163	chr7:139420300	HIPK2	-0.46	-4.91	-0.3	1.68e-6	Systolic blood pressure;
KIRP	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.41	0.38	7.53e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.71	7.79	0.44	1.85e-13	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01073178	chr12:117537710	TESC	0.49	6.68	0.39	1.55e-10	Parkinson's disease;
KIRP	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.59	-0.56	7.83e-22	Menopause (age at onset);
KIRP	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-5.41	-0.33	1.48e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg02696742	chr7:106810147	HBP1	-0.73	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.44	5.79	0.35	2.19e-8	Testicular germ cell tumor;
KIRP	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.61	-0.34	5.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14085500	chr9:119460334	TRIM32;ASTN2	0.51	6.31	0.37	1.31e-9	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19400545	chr4:124319236	SPRY1	0.47	6.48	0.38	5.09e-10	Parkinson's disease;
KIRP	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	1.04	10.59	0.56	7.84e-22	Blood protein levels;
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg05562828	chr17:3906858	NA	0.71	13.83	0.66	1.38e-32	Type 2 diabetes;
KIRP	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.58	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14275779	chr17:40830236	PLEKHH3	0.67	8.15	0.46	1.82e-14	Smoking initiation;
KIRP	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg02336718	chr17:17403227	NA	0.32	5.11	0.31	6.48e-7	Total body bone mineral density;
KIRP	cis	rs1023500	1.000	rs7293091	chr22:42341308	A/G	cg04733989	chr22:42467013	NAGA	-0.49	-5.5	-0.33	9.6e-8	Schizophrenia;
KIRP	cis	rs1620921	0.783	rs1740448	chr6:161230370	T/C	cg01280913	chr6:161186852	NA	-0.43	-6.22	-0.37	2.11e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs12786942	0.502	rs7108099	chr11:101301236	C/T	cg03942599	chr11:101341554	TRPC6	0.39	4.85	0.3	2.2e-6	Facial depth;
KIRP	trans	rs270421	0.555	rs407083	chr16:79242444	T/C	cg26284735	chr3:5065165	NA	0.24	6.14	0.36	3.21e-9	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	8.08	0.46	2.88e-14	Eosinophil percentage of white cells;
KIRP	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.84	-7.04	-0.41	1.96e-11	Obesity-related traits;
KIRP	trans	rs3857536	0.813	rs6903678	chr6:66931208	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.46	6.07	0.36	4.74e-9	Blood trace element (Cu levels);
KIRP	cis	rs4356932	1.000	rs10003240	chr4:76955330	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs6723226	0.679	rs116617324	chr2:32622709	C/T	cg02381751	chr2:32503542	YIPF4	-0.65	-8.51	-0.48	1.71e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05668926	chr7:39609343	C7orf36	-0.43	-6.49	-0.38	4.78e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17554472	chr22:41940697	POLR3H	0.56	6.22	0.37	2.13e-9	Vitiligo;
KIRP	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7084783	0.600	rs11191738	chr10:105345984	A/T	cg00126946	chr10:105363258	SH3PXD2A	-0.49	-6.74	-0.39	1.14e-10	Fear of pain;
KIRP	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.79	-9.52	-0.52	1.73e-18	Corneal astigmatism;
KIRP	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg09699651	chr6:150184138	LRP11	0.49	6.28	0.37	1.53e-9	Lung cancer;
KIRP	cis	rs9826463	0.582	rs73238143	chr3:142054935	A/G	cg20824294	chr3:142316082	PLS1	0.49	6.72	0.39	1.28e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.69	-0.63	1.02e-28	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02902865	chr1:12679132	DHRS3	0.61	6.04	0.36	5.69e-9	Lung function (FEV1);
KIRP	trans	rs6866721	0.904	rs13161202	chr5:116218493	T/C	cg12737536	chr10:5227162	AKR1CL1	0.44	6.15	0.37	3.05e-9	Body mass index;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.52	-5.74	-0.34	2.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.75	11.31	0.58	3.75e-24	Blood metabolite ratios;
KIRP	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	13.11	0.64	3.95e-30	Electrocardiographic conduction measures;
KIRP	cis	rs883565	0.502	rs9839582	chr3:38943120	G/A	cg01426195	chr3:39028469	NA	0.48	7.28	0.42	4.44e-12	Handedness;
KIRP	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-20.91	-0.8	1.7e-56	Height;
KIRP	cis	rs6753739	0.784	rs11690649	chr2:219947771	T/C	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.76	-0.63	5.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	cis	rs4775041	1.000	rs4775041	chr15:58674695	C/G	cg02781660	chr15:58358775	ALDH1A2	-0.4	-4.87	-0.3	2.03e-6	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg22150459	chr19:42388348	ARHGEF1	-0.46	-6.17	-0.37	2.85e-9	Morning vs. evening chronotype;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13445258	chr3:128369860	RPN1	0.51	6.73	0.39	1.21e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-4.99	-0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.81	-0.53	2.23e-19	Response to antipsychotic treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27188447	chr15:67358130	SMAD3	0.5	6.38	0.38	8.97e-10	Parkinson's disease;
KIRP	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-4.89	-0.3	1.85e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9400467	0.506	rs12191195	chr6:111712718	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27297192	chr10:134578999	INPP5A	0.62	7.65	0.44	4.66e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.77	0.73	1.33e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg24253500	chr15:84953950	NA	0.52	5.84	0.35	1.61e-8	Schizophrenia;
KIRP	cis	rs9638182	0.697	rs12539316	chr7:72977898	C/T	cg07452164	chr7:72993570	TBL2	-0.52	-6.01	-0.36	6.52e-9	Triglycerides;
KIRP	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg05552183	chr6:42928497	GNMT	0.45	5.15	0.31	5.43e-7	Blood protein levels;
KIRP	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.09	0.46	2.68e-14	Morning vs. evening chronotype;
KIRP	trans	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg17830980	chr10:43048298	ZNF37B	0.53	6.77	0.4	9.27e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.65	-0.44	4.58e-13	Height;
KIRP	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg04731861	chr2:219085781	ARPC2	-0.23	-5.64	-0.34	4.76e-8	Colorectal cancer;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg07265985	chr2:220432066	OBSL1	0.46	6.03	0.36	6.05e-9	Pancreatic cancer;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.49	6.68	0.39	1.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg27490568	chr2:178487706	NA	0.53	7.39	0.43	2.28e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg13147721	chr7:65941812	NA	-0.99	-6.89	-0.4	4.77e-11	Diabetic kidney disease;
KIRP	cis	rs10929159	0.928	rs6431418	chr2:236919559	C/T	cg20128773	chr2:236923534	AGAP1	0.3	5.23	0.32	3.61e-7	Parkinson's disease;
KIRP	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.47	5.37	0.32	1.83e-7	Schizophrenia;
KIRP	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.36	-0.32	1.91e-7	Pulmonary function;
KIRP	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.67	10.24	0.55	1.01e-20	Hip circumference;
KIRP	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.14e-7	Retinal vascular caliber;
KIRP	cis	rs11924390	0.749	rs822363	chr3:186452991	C/G	cg12454167	chr3:186435060	KNG1	0.5	8.49	0.48	2.03e-15	Adiponectin levels;
KIRP	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.56	8.62	0.48	8.36e-16	Sitting height ratio;
KIRP	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg16306078	chr6:126000798	NA	0.26	4.91	0.3	1.67e-6	Endometrial cancer;
KIRP	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg18404041	chr3:52824283	ITIH1	-0.53	-6.94	-0.4	3.4e-11	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07494646	chr22:37415349	MPST;TST	0.5	6.37	0.38	9.38e-10	Parkinson's disease;
KIRP	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg09165964	chr15:75287851	SCAMP5	-0.36	-4.84	-0.3	2.25e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs735860	0.687	rs2294852	chr6:53157214	C/G	cg10236188	chr6:53219634	NA	-0.4	-5.34	-0.32	2.15e-7	Glaucoma;
KIRP	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg26338869	chr17:61819248	STRADA	0.53	6.33	0.37	1.18e-9	Prudent dietary pattern;
KIRP	cis	rs2880765	0.546	rs11639291	chr15:86064130	G/A	cg10818794	chr15:86012489	AKAP13	-0.53	-6.92	-0.4	3.87e-11	Coronary artery disease;
KIRP	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.85	-0.57	1.18e-22	Chronic sinus infection;
KIRP	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg16497661	chr14:103986332	CKB	-0.51	-6.43	-0.38	6.42e-10	Coronary artery disease;
KIRP	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg12453748	chr11:64085041	PRDX5;TRMT112	0.47	5.07	0.31	7.79e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.58	-6.22	-0.37	2.11e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4262150	0.544	rs56028813	chr5:151915830	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.85	-0.49	1.73e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs3736594	0.802	rs9678824	chr2:27964328	G/C	cg27432699	chr2:27873401	GPN1	0.59	7.31	0.42	3.72e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg13010199	chr12:38710504	ALG10B	0.58	7.23	0.42	6.23e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg17595323	chr11:93583763	C11orf90	-0.3	-5.11	-0.31	6.49e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.94	9.92	0.53	1.01e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-5.54	-0.33	7.95e-8	Lung cancer;
KIRP	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg05785598	chr3:49045655	WDR6	0.32	5.88	0.35	1.36e-8	Parkinson's disease;
KIRP	cis	rs6540559	0.673	rs2357230	chr1:210019498	G/A	cg22029157	chr1:209979665	IRF6	0.46	5.0	0.3	1.11e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.33	-0.32	2.18e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03512643	chr14:74486160	C14orf45;ENTPD5	0.44	6.18	0.37	2.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.28	-0.37	1.5e-9	Arsenic metabolism;
KIRP	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.76	6.61	0.39	2.42e-10	Diabetic retinopathy;
KIRP	cis	rs9469913	0.808	rs2744971	chr6:34581636	T/G	cg17674042	chr6:34482479	PACSIN1	-0.49	-6.43	-0.38	6.68e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2057178	0.546	rs10835881	chr11:32322859	A/C	cg05837727	chr11:32355149	NA	0.45	5.22	0.32	3.73e-7	Tuberculosis;
KIRP	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg02336718	chr17:17403227	NA	0.35	5.52	0.33	8.66e-8	Total body bone mineral density;
KIRP	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg26513180	chr16:89883248	FANCA	0.87	5.5	0.33	9.35e-8	Skin colour saturation;
KIRP	cis	rs2860975	0.620	rs1891072	chr10:96804978	G/A	cg09036531	chr10:96991505	NA	-0.48	-5.81	-0.35	1.89e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs7119167	0.686	rs55771351	chr11:73051625	G/C	cg17517138	chr11:73019481	ARHGEF17	0.49	5.17	0.31	4.78e-7	Blood protein levels;
KIRP	cis	rs11209185	0.545	rs1926284	chr1:68446291	T/C	cg22082780	chr1:68452167	NA	0.34	5.04	0.31	9.22e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6723108	0.702	rs55920206	chr2:135432066	C/T	cg12500956	chr2:135428796	TMEM163	-0.42	-5.79	-0.35	2.17e-8	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.92	12.47	0.62	5.5e-28	Menopause (age at onset);
KIRP	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg06640241	chr16:89574553	SPG7	0.6	7.27	0.42	4.66e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18252515	chr7:66147081	NA	0.42	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg02023728	chr11:77925099	USP35	0.32	5.45	0.33	1.25e-7	Alzheimer's disease (survival time);
KIRP	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg23693289	chr8:27183097	PTK2B	0.49	6.4	0.38	7.95e-10	Neuroticism;
KIRP	cis	rs4704187	0.687	rs6453123	chr5:74519049	G/A	cg03227963	chr5:74354835	NA	0.4	5.82	0.35	1.84e-8	Response to amphetamines;
KIRP	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg24315340	chr6:146058215	EPM2A	0.4	4.98	0.3	1.19e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.72	10.61	0.56	6.55e-22	Colorectal cancer;
KIRP	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.35	-4.94	-0.3	1.42e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.61	7.64	0.44	4.83e-13	Resting heart rate;
KIRP	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.75	-9.0	-0.5	6.17e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg03605463	chr16:89740564	NA	0.62	7.93	0.45	7.53e-14	Vitiligo;
KIRP	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.03	-0.46	3.93e-14	Migraine;Coronary artery disease;
KIRP	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.05e-14	Aortic root size;
KIRP	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs13272623	0.502	rs268601	chr8:71518548	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.53	-6.95	-0.41	3.21e-11	IgG glycosylation;
KIRP	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-5.29	-0.32	2.7e-7	Body mass index;
KIRP	cis	rs1867631	0.585	rs6670827	chr1:67127006	C/T	cg02459107	chr1:67143332	SGIP1	0.42	6.46	0.38	5.55e-10	Menopause (age at onset);
KIRP	cis	rs4700695	0.841	rs417074	chr5:65314894	C/T	cg21114390	chr5:65439923	SFRS12	0.6	5.67	0.34	4.06e-8	Facial morphology (factor 19);
KIRP	cis	rs9972944	0.756	rs6504349	chr17:63764140	G/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.82	-0.45	1.56e-13	Total body bone mineral density;
KIRP	cis	rs754423	0.515	rs8005920	chr14:52560934	C/T	cg05884192	chr14:52515736	NID2	-0.49	-5.95	-0.35	8.95e-9	Craniofacial microsomia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22519738	chr19:4684891	DPP9	-0.48	-6.23	-0.37	1.99e-9	Parkinson's disease;
KIRP	cis	rs75920871	0.925	rs61903399	chr11:116942475	A/T	cg23684410	chr11:116897558	SIK3	0.55	5.71	0.34	3.16e-8	Subjective well-being;
KIRP	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.54	6.92	0.4	3.81e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24663090	chr5:53182145	ARL15	0.46	6.21	0.37	2.3e-9	Interleukin-4 levels;
KIRP	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg24110177	chr3:50126178	RBM5	0.65	8.35	0.47	4.95e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6142102	0.778	rs4911374	chr20:32516001	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	5.75	0.34	2.7e-8	Skin pigmentation;
KIRP	cis	rs2916247	0.954	rs1160821	chr8:93105771	C/G	cg10183463	chr8:93005414	RUNX1T1	-0.47	-5.71	-0.34	3.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.63	9.84	0.53	1.73e-19	Bone mineral density;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	0.97	16.79	0.73	1.16e-42	Menarche (age at onset);
KIRP	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.83	-0.35	1.7e-8	Triglycerides;
KIRP	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.51	-0.38	4.29e-10	Coronary artery disease;
KIRP	cis	rs2625529	0.761	rs11853268	chr15:72238973	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-6.18	-0.37	2.7e-9	Red blood cell count;
KIRP	cis	rs4953911	1.000	rs7587559	chr2:135069472	G/A	cg18482303	chr2:135041380	MGAT5	-0.27	-5.21	-0.31	4.09e-7	Multiple sclerosis (severity);
KIRP	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg00631329	chr6:26305371	NA	-0.61	-7.94	-0.45	7.36e-14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.65	8.89	0.49	1.34e-16	Retinal vascular caliber;
KIRP	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg07636037	chr3:49044803	WDR6	-0.78	-7.46	-0.43	1.49e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs804280	0.535	rs10435719	chr8:11776904	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.65	0.44	4.5e-13	Myopia (pathological);
KIRP	trans	rs9929218	0.677	rs12597188	chr16:68814826	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.61	-6.97	-0.41	2.84e-11	Colorectal cancer;
KIRP	cis	rs9905704	0.633	rs2021733	chr17:56489168	C/T	cg12560992	chr17:57184187	TRIM37	-0.54	-5.13	-0.31	5.79e-7	Testicular germ cell tumor;
KIRP	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.66	8.46	0.47	2.45e-15	Age-related hearing impairment;
KIRP	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-4.86	-0.3	2.1e-6	Neuroticism;
KIRP	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11696739	0.835	rs6074894	chr20:1597050	G/A	cg02198625	chr20:1600641	SIRPB1	0.38	5.01	0.3	1.03e-6	Mean platelet volume;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03743753	chr16:86575852	MTHFSD	0.51	6.5	0.38	4.46e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.5	-7.23	-0.42	6.09e-12	Neurofibrillary tangles;
KIRP	trans	rs7939886	0.920	rs12224086	chr11:55798259	G/T	cg15704280	chr7:45808275	SEPT13	0.82	6.03	0.36	5.87e-9	Myopia (pathological);
KIRP	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	5.04	0.31	8.96e-7	Breast cancer;
KIRP	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg02375832	chr11:62437615	C11orf48	0.52	6.38	0.38	8.61e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26314531	chr2:26401878	FAM59B	-0.48	-5.07	-0.31	7.87e-7	Gut microbiome composition (summer);
KIRP	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.36	-5.46	-0.33	1.14e-7	Body mass index;
KIRP	cis	rs9912468	0.803	rs4423457	chr17:64284000	G/A	cg19474267	chr17:64306194	PRKCA	0.54	7.42	0.43	1.93e-12	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs9815354	1.000	rs114960066	chr3:41882323	A/G	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs11710845	1.000	rs4681610	chr3:150064115	A/G	cg21175685	chr3:99378032	COL8A1;MIR548G	0.38	6.23	0.37	1.96e-9	Intraocular pressure;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg23698023	chr8:27181813	PTK2B	0.35	5.3	0.32	2.53e-7	Neuroticism;
KIRP	cis	rs10214930	0.697	rs6958747	chr7:27691863	C/T	cg22168087	chr7:27702803	HIBADH	-0.47	-5.03	-0.31	9.43e-7	Hypospadias;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17218435	chr17:19913408	NA	-0.46	-6.09	-0.36	4.21e-9	Interleukin-4 levels;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.6	-6.96	-0.41	2.99e-11	Menopause (age at onset);
KIRP	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg18904891	chr8:8559673	CLDN23	0.58	6.51	0.38	4.2e-10	Obesity-related traits;
KIRP	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	9.63	0.52	7.97e-19	Gut microbiome composition (summer);
KIRP	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.05	-0.31	8.7e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19158325	chr17:8339163	NDEL1	0.5	6.44	0.38	6.07e-10	Parkinson's disease;
KIRP	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.9	10.51	0.56	1.44e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.38	-0.62	1.13e-27	Exhaled nitric oxide output;
KIRP	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.48	5.3	0.32	2.58e-7	Total body bone mineral density;
KIRP	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.59	-0.56	7.52e-22	Height;
KIRP	cis	rs9890032	0.570	rs8068504	chr17:29112070	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.44	-5.6	-0.34	5.6e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.89	0.45	1.02e-13	Coffee consumption (cups per day);
KIRP	cis	rs4654899	1.000	rs4654902	chr1:21435056	T/G	cg05370193	chr1:21551575	ECE1	0.43	5.81	0.35	1.88e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg11645453	chr3:52864694	ITIH4	-0.35	-5.43	-0.33	1.33e-7	Body mass index;
KIRP	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg16482183	chr6:26056742	HIST1H1C	0.44	5.61	0.34	5.52e-8	Schizophrenia;
KIRP	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26450747	chr19:55628998	PPP1R12C	0.56	7.47	0.43	1.37e-12	Parkinson's disease;
KIRP	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-5.47	-0.33	1.08e-7	Endometrial cancer;
KIRP	cis	rs11625487	0.915	rs11845826	chr14:77966145	C/A	cg20045696	chr14:77926864	AHSA1	0.51	5.25	0.32	3.28e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg01304814	chr3:48885189	PRKAR2A	0.81	5.88	0.35	1.34e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg03511173	chr18:77590860	NA	-0.49	-5.66	-0.34	4.11e-8	Opioid sensitivity;
KIRP	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.75	-10.84	-0.57	1.25e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4523957	0.553	rs2172593	chr17:2025544	G/C	cg16513277	chr17:2031491	SMG6	-0.84	-12.62	-0.63	1.8e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.49	0.52	2.13e-18	Monocyte percentage of white cells;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg18045575	chr2:27341901	CGREF1	-0.41	-6.11	-0.36	3.84e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-0.96	-6.96	-0.41	3.09e-11	Mitochondrial DNA levels;
KIRP	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	8.94	0.5	9.42e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.69	0.66	4.36e-32	Smoking behavior;
KIRP	trans	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg24644049	chr4:85504048	CDS1	1.03	6.78	0.4	8.61e-11	Skin colour saturation;
KIRP	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	0.82	12.11	0.61	8.91e-27	Body mass index;
KIRP	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	7.01	0.41	2.31e-11	Monocyte count;
KIRP	cis	rs3782455	1.000	rs73401073	chr12:114395959	T/C	cg02019088	chr12:114368640	RBM19	0.71	5.11	0.31	6.38e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs3784262	0.669	rs12905608	chr15:58314139	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.87	-0.3	2.04e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05505450	chr2:58273643	VRK2	0.53	6.23	0.37	2.01e-9	Smoking initiation;
KIRP	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-8.04	-0.46	3.78e-14	Glomerular filtration rate;
KIRP	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.48	-0.52	2.25e-18	Brugada syndrome;
KIRP	trans	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg03735916	chr2:200715285	NA	-0.46	-6.21	-0.37	2.19e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	0.84	7.49	0.43	1.21e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs13343954	0.825	rs7259371	chr19:33534641	G/A	cg27124370	chr19:33622961	WDR88	0.62	6.86	0.4	5.4e-11	Colorectal cancer;
KIRP	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.61	7.7	0.44	3.33e-13	Height;
KIRP	cis	rs1620921	0.774	rs783153	chr6:161229578	G/T	cg01280913	chr6:161186852	NA	0.41	6.01	0.36	6.52e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11987759	chr7:65425863	GUSB	-0.47	-5.63	-0.34	4.89e-8	Aortic root size;
KIRP	cis	rs6977660	0.714	rs6970798	chr7:19816741	G/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg22138327	chr13:27999177	GTF3A	0.8	7.22	0.42	6.33e-12	Weight;
KIRP	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg06640241	chr16:89574553	SPG7	0.64	7.81	0.45	1.67e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs11974702	1	rs11974702	chr7:99163951	A/G	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite levels;
KIRP	cis	rs1981331	0.867	rs76188425	chr21:48002207	C/T	cg23283320	chr21:48055893	PRMT2	1.34	8.48	0.48	2.18e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.86	13.82	0.66	1.54e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.72	0.39	1.27e-10	Bladder cancer;
KIRP	cis	rs2411233	0.967	rs7161833	chr15:39285635	C/A	cg02291532	chr15:39874776	THBS1	0.38	5.12	0.31	6.24e-7	Platelet count;
KIRP	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg07741184	chr6:167504864	NA	0.24	6.43	0.38	6.44e-10	Crohn's disease;
KIRP	cis	rs2806561	1.000	rs2776819	chr1:23470116	A/T	cg19743168	chr1:23544995	NA	0.59	8.32	0.47	5.91e-15	Height;
KIRP	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg00103785	chr1:155043322	NA	0.3	5.39	0.32	1.65e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.39	5.53	0.33	8.32e-8	Coronary artery disease;
KIRP	cis	rs189798	0.807	rs9949	chr8:8994512	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	4.91	0.3	1.67e-6	Myopia (pathological);
KIRP	cis	rs259282	0.605	rs60968670	chr19:33108982	T/C	cg02997394	chr19:33096574	ANKRD27	-0.52	-6.16	-0.37	2.97e-9	Schizophrenia;
KIRP	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.17	-0.42	8.97e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.4	-0.47	3.52e-15	Retinal vascular caliber;
KIRP	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	9.02	0.5	5.34e-17	Nonalcoholic fatty liver disease;
KIRP	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.06e-10	Obesity-related traits;
KIRP	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg06654118	chr4:1303317	MAEA	0.3	5.4	0.33	1.6e-7	Obesity-related traits;
KIRP	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.09	-7.98	-0.45	5.75e-14	Mitochondrial DNA levels;
KIRP	cis	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg05873124	chr14:61966719	PRKCH	-0.41	-5.46	-0.33	1.17e-7	Select biomarker traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05307257	chr19:58298065	NA	-0.48	-6.61	-0.39	2.42e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg23335576	chr14:104009727	NA	0.4	5.53	0.33	8.17e-8	Body mass index;
KIRP	trans	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.59	-8.3	-0.47	6.72e-15	Prostate cancer;
KIRP	cis	rs6684514	1.000	rs59468948	chr1:156288058	A/T	cg16558208	chr1:156270281	VHLL	-0.45	-5.95	-0.35	9.29e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	trans	rs6601327	0.670	rs4128198	chr8:9433499	T/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.02	0.41	2.17e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg13147721	chr7:65941812	NA	-1.01	-6.86	-0.4	5.39e-11	Diabetic kidney disease;
KIRP	trans	rs12517041	1.000	rs12520032	chr5:23285074	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.3	-0.47	7.14e-15	Calcium levels;
KIRP	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg05272587	chr13:111038400	COL4A2	-0.35	-5.19	-0.31	4.41e-7	Coronary artery disease;
KIRP	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.42	5.8	0.35	2.08e-8	Total body bone mineral density;
KIRP	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.51	6.65	0.39	1.91e-10	IgG glycosylation;
KIRP	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.75	-10.87	-0.57	9.78e-23	Morning vs. evening chronotype;
KIRP	cis	rs7216169	1	rs7216169	chr17:5219511	C/T	cg21654974	chr17:5389607	DERL2;MIS12	0.67	5.58	0.34	6.44e-8	Red blood cell density in sickle cell anemia;
KIRP	cis	rs7246657	0.722	rs10412510	chr19:38075944	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23020857	chr14:54980058	CGRRF1	0.5	6.14	0.36	3.37e-9	Interleukin-4 levels;
KIRP	cis	rs4805272	1.000	rs7256538	chr19:29323188	G/T	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4494114	0.967	rs9438976	chr1:39353386	C/T	cg25970120	chr1:39325951	RRAGC	-0.41	-5.11	-0.31	6.4e-7	Blood protein levels;
KIRP	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	10.22	0.55	1.19e-20	Calcium levels;
KIRP	trans	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.06	-0.41	1.65e-11	Bladder cancer;
KIRP	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12893428	chr3:195717962	SDHAP1	0.47	6.26	0.37	1.67e-9	Pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.76	0.53	3.18e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg12437481	chr16:420112	MRPL28	0.55	7.08	0.41	1.51e-11	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg14132834	chr19:41945861	ATP5SL	0.58	7.54	0.43	9.26e-13	Height;
KIRP	cis	rs7714670	0.764	rs11957938	chr5:73073615	T/C	cg04480106	chr5:72934606	RGNEF	-0.4	-5.24	-0.32	3.5e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg02696742	chr7:106810147	HBP1	-0.69	-7.13	-0.41	1.09e-11	Coronary artery disease;
KIRP	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.44	0.38	6.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.5	6.42	0.38	7.15e-10	Total body bone mineral density;
KIRP	cis	rs2033732	1.000	rs1465809	chr8:85080457	G/A	cg05716166	chr8:85095498	RALYL	0.63	6.75	0.4	1.05e-10	Body mass index;
KIRP	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.8	0.35	2.01e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.76	-0.34	2.54e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg11569703	chr11:65557185	OVOL1	0.55	9.16	0.5	2.09e-17	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.37	-0.32	1.81e-7	Aortic root size;
KIRP	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.14	16.36	0.72	3.37e-41	Breast cancer;
KIRP	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.43	8.4	0.47	3.6e-15	Economic and political preferences (immigration/crime);
KIRP	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg16506815	chr2:162101123	NA	0.47	5.61	0.34	5.32e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg12549451	chr6:135224345	NA	0.42	5.16	0.31	5.15e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.53	0.33	8.36e-8	Retinal vascular caliber;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg14221460	chr8:27183342	PTK2B	0.5	6.57	0.39	3.03e-10	Neuroticism;
KIRP	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-10.21	-0.55	1.2e-20	Height;
KIRP	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.67	7.66	0.44	4.34e-13	Alcohol dependence;
KIRP	cis	rs830124	0.714	rs1177589	chr12:122403933	A/G	cg22618164	chr12:122356400	WDR66	0.5	5.06	0.31	8.11e-7	Urinary metabolites;
KIRP	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.69	9.64	0.52	7.5e-19	Blood protein levels;
KIRP	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg08975724	chr8:8085496	FLJ10661	-0.59	-8.11	-0.46	2.35e-14	Neuroticism;
KIRP	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	7.93	0.45	7.8500000000000006e-14	Breast cancer;
KIRP	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.75	-8.75	-0.49	3.4e-16	Longevity;
KIRP	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg03340356	chr1:67600835	NA	0.42	5.15	0.31	5.35e-7	Psoriasis;
KIRP	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg02725872	chr8:58115012	NA	-0.55	-6.35	-0.38	1.05e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06481639	chr22:41940642	POLR3H	0.45	5.29	0.32	2.76e-7	Vitiligo;
KIRP	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.55	0.59	5.92e-25	Menarche (age at onset);
KIRP	cis	rs997295	1.000	rs8032675	chr15:67959464	A/G	cg24579218	chr15:68104479	NA	0.36	5.38	0.32	1.76e-7	Motion sickness;
KIRP	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs6707387	0.662	rs2113472	chr2:214456185	G/A	cg08319019	chr2:214017104	IKZF2	0.46	5.35	0.32	2.02e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg12861170	chr19:19639553	YJEFN3	-0.49	-5.07	-0.31	8e-7	Bipolar disorder;
KIRP	cis	rs2071403	0.933	rs10183226	chr2:1404756	T/G	cg07083862	chr2:1417248	TPO	0.36	5.81	0.35	1.9e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg20387954	chr3:183756860	HTR3D	0.64	9.46	0.52	2.61e-18	Anterior chamber depth;
KIRP	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.85	-10.53	-0.56	1.16e-21	Bipolar disorder and schizophrenia;
KIRP	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.52	-6.58	-0.39	2.84e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg06917634	chr15:78832804	PSMA4	-0.63	-7.11	-0.41	1.25e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs7939886	0.920	rs77344682	chr11:55999358	A/G	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs28489187	0.706	rs233095	chr1:85824816	T/C	cg16011679	chr1:85725395	C1orf52	0.55	6.65	0.39	1.91e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.15	-0.31	5.43e-7	Post bronchodilator FEV1;
KIRP	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-10.19	-0.54	1.4e-20	Schizophrenia;
KIRP	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg10047753	chr17:41438598	NA	1.13	18.22	0.76	1.53e-47	Menopause (age at onset);
KIRP	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.03	-0.31	9.69e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.48	-0.52	2.32e-18	Gut microbiome composition (summer);
KIRP	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg21466736	chr12:48725269	NA	0.54	6.7	0.39	1.42e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.53	-0.33	8.22e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg16497661	chr14:103986332	CKB	-0.82	-13.74	-0.66	2.82e-32	Body mass index;
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg09695851	chr17:3907499	NA	-0.64	-9.28	-0.51	9.21e-18	Type 2 diabetes;
KIRP	cis	rs7923609	0.905	rs7088799	chr10:65016174	T/G	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.09	-0.31	7.24e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12367572	0.601	rs10880730	chr12:45422443	G/A	cg04608330	chr12:45269318	NELL2	-0.43	-5.75	-0.34	2.61e-8	Gut microbiome composition (summer);
KIRP	cis	rs1010254	0.510	rs72806396	chr5:151708325	G/A	cg12297329	chr5:152029980	NA	-0.65	-6.6	-0.39	2.56e-10	Optic nerve measurement (cup area);
KIRP	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.4	7.82	0.45	1.53e-13	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.51	5.48	0.33	1.05e-7	Red blood cell count;
KIRP	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.51	6.5	0.38	4.53e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg03289416	chr15:75166202	SCAMP2	0.58	8.25	0.47	9.6e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg09658497	chr7:2847517	GNA12	-0.35	-4.96	-0.3	1.33e-6	Height;
KIRP	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.43	4.91	0.3	1.65e-6	Mean platelet volume;
KIRP	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	7.04	0.41	1.87e-11	Prudent dietary pattern;
KIRP	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.94	-0.4	3.39e-11	Monocyte percentage of white cells;
KIRP	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.71	-0.34	3.19e-8	Mood instability;
KIRP	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg18165381	chr3:44552316	NA	-0.39	-4.85	-0.3	2.24e-6	Depressive symptoms;
KIRP	cis	rs3736485	0.966	rs8040538	chr15:51904584	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.19	-0.31	4.43e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs829661	0.739	rs1447186	chr2:30868928	A/G	cg10949345	chr2:30726833	LCLAT1	1.08	13.31	0.65	8.61e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg21923884	chr14:100626084	DEGS2	-0.47	-6.43	-0.38	6.41e-10	Myopia;
KIRP	trans	rs863345	0.526	rs857724	chr1:158607372	C/T	cg10848522	chr2:75937996	C2orf3	0.46	6.07	0.36	4.79e-9	Pneumococcal bacteremia;
KIRP	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.78	-7.81	-0.45	1.6e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.81e-10	Bipolar disorder;
KIRP	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg25838818	chr2:108905173	SULT1C2	-0.43	-6.86	-0.4	5.6e-11	Blood pressure;
KIRP	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.38	5.06	0.31	8.39e-7	Mean platelet volume;
KIRP	cis	rs4149577	1.000	rs4149577	chr12:6447522	C/T	cg00556515	chr12:6442607	TNFRSF1A	0.31	5.42	0.33	1.43e-7	Monocyte count;
KIRP	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.67	-7.65	-0.44	4.65e-13	Gut microbiome composition (summer);
KIRP	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg10189774	chr4:17578691	LAP3	0.41	5.02	0.3	9.83e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg08805041	chr16:621841	PIGQ	-0.38	-5.18	-0.31	4.68e-7	Height;
KIRP	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg04310649	chr10:35416472	CREM	-0.5	-5.87	-0.35	1.43e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14829155	chr15:31115871	NA	0.72	9.94	0.54	8.9e-20	Huntington's disease progression;
KIRP	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.43	0.33	1.37e-7	Coronary artery disease;
KIRP	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.74	-7.65	-0.44	4.61e-13	Body mass index;
KIRP	cis	rs6959887	0.788	rs57639115	chr7:35275921	T/C	cg06685737	chr7:35301730	NA	0.44	6.36	0.38	9.63e-10	Birth weight;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15124968	chr5:140855469	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGC3;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.51	6.1	0.36	4.05e-9	Smoking initiation;
KIRP	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs258892	0.895	rs13177678	chr5:72045646	G/T	cg21869765	chr5:72125136	TNPO1	-0.5	-5.64	-0.34	4.56e-8	Small cell lung carcinoma;
KIRP	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.86	-12.8	-0.63	4.2e-29	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25585364	chr2:118846169	INSIG2	0.46	6.69	0.39	1.5e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg18306943	chr3:40428807	ENTPD3	0.44	5.67	0.34	3.92e-8	Renal cell carcinoma;
KIRP	cis	rs9584850	0.834	rs3783005	chr13:99111337	A/T	cg20750642	chr13:99100586	FARP1	0.53	6.56	0.39	3.12e-10	Neuroticism;
KIRP	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.99	17.24	0.74	3.29e-44	Breast cancer;
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	trans	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	6.44	0.38	6.19e-10	Ulcerative colitis;
KIRP	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg22654517	chr2:96458247	NA	0.33	5.01	0.3	1.04e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg18944383	chr4:111397179	ENPEP	0.58	10.68	0.56	3.96e-22	Height;
KIRP	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg02297831	chr4:17616191	MED28	0.52	6.44	0.38	6.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6450176	0.857	rs1541680	chr5:53304725	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.4	-0.59	1.95e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07570687	chr10:102243282	WNT8B	0.49	6.07	0.36	4.7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.83	-0.53	1.96e-19	Aortic root size;
KIRP	cis	rs8077577	0.689	rs62072515	chr17:18213435	T/G	cg18869244	chr17:18121946	NA	0.45	5.11	0.31	6.32e-7	Obesity-related traits;
KIRP	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg07701084	chr6:150067640	NUP43	0.54	6.85	0.4	5.8200000000000003e-11	Testicular germ cell tumor;
KIRP	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg25801113	chr15:45476975	SHF	-0.45	-8.19	-0.46	1.41e-14	Uric acid levels;
KIRP	cis	rs6735179	0.958	rs7577768	chr2:1772552	T/C	cg08166568	chr2:1746647	PXDN	-0.4	-4.89	-0.3	1.83e-6	Response to antipsychotic treatment;
KIRP	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg17822266	chr1:2720087	NA	-0.46	-6.3	-0.37	1.33e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.64	-8.06	-0.46	3.42e-14	Prudent dietary pattern;
KIRP	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.78	-10.98	-0.57	4.32e-23	Morning vs. evening chronotype;
KIRP	cis	rs17123764	1.000	rs73305012	chr12:49962637	A/C	cg02054252	chr12:50078554	FMNL3	0.42	5.1	0.31	6.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg04824913	chr4:887549	GAK	0.58	5.8	0.35	1.99e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.86	11.84	0.6	6.77e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-5.86	-0.35	1.45e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.22	14.11	0.67	1.61e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg08461772	chr7:95026248	PON3	-0.4	-5.87	-0.35	1.41e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20273697	chr2:8977583	KIDINS220	0.5	6.16	0.37	2.91e-9	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.73	0.49	4.08e-16	Prudent dietary pattern;
KIRP	cis	rs6840360	0.573	rs10024721	chr4:152265331	G/A	cg25486957	chr4:152246857	NA	-0.44	-5.57	-0.33	6.67e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs11809524	0.759	rs78536757	chr1:103521216	C/T	cg15143788	chr5:92909434	FLJ42709	-0.51	-6.12	-0.36	3.57e-9	Bone mineral density;
KIRP	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg15247329	chr7:2764246	NA	-0.38	-5.41	-0.33	1.48e-7	Height;
KIRP	cis	rs9840812	0.591	rs1291921	chr3:136036226	A/G	cg15507776	chr3:136538369	TMEM22	0.42	5.58	0.34	6.28e-8	Fibrinogen levels;
KIRP	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.38	-0.43	2.46e-12	Height;
KIRP	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.57	-6.42	-0.38	6.83e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.69	-7.95	-0.45	6.93e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.91	-0.3	1.68e-6	Longevity;
KIRP	cis	rs9815354	1.000	rs9825741	chr3:41761828	A/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.46	-0.33	1.16e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	7.01	0.41	2.32e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06634786	chr22:41940651	POLR3H	-0.54	-6.22	-0.37	2.14e-9	Vitiligo;
KIRP	cis	rs60311166	1.000	rs6762788	chr3:52792311	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.97	6.57	0.39	3.01e-10	CTACK levels;
KIRP	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs78545713	0.649	rs77362785	chr6:26232351	G/A	cg01420254	chr6:26195488	NA	1.21	7.6	0.44	6.07e-13	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.59	-7.11	-0.41	1.22e-11	Schizophrenia;
KIRP	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	8.03	0.46	3.96e-14	Myopia (pathological);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10263684	chr2:46520913	NA	0.57	6.45	0.38	6.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	1.04	18.94	0.77	5.69e-50	Heart rate;
KIRP	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.88	-0.3	1.91e-6	Pulmonary function;
KIRP	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.29	-0.32	2.74e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7010267	0.773	rs13277230	chr8:119922993	C/T	cg01975934	chr8:119970761	NA	0.4	5.0	0.3	1.09e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs258892	0.947	rs34955	chr5:72203628	T/C	cg21869765	chr5:72125136	TNPO1	0.61	6.99	0.41	2.5e-11	Small cell lung carcinoma;
KIRP	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs2882877	0.610	rs13008848	chr2:190445284	C/G	cg10752008	chr2:190445175	SLC40A1	0.54	5.92	0.35	1.08e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.65	-0.44	4.45e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.36	-5.21	-0.32	4.01e-7	Lymphocyte counts;
KIRP	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg24881330	chr22:46731750	TRMU	0.78	5.33	0.32	2.27e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg19507638	chr5:93509721	C5orf36	-0.58	-5.05	-0.31	8.67e-7	Diabetic retinopathy;
KIRP	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	cg04338863	chr8:33670619	NA	0.5	6.62	0.39	2.3e-10	Body mass index;
KIRP	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg11498726	chr8:26250323	BNIP3L	0.45	7.0	0.41	2.46e-11	Height;
KIRP	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.28	-0.51	8.98e-18	Triglycerides;
KIRP	cis	rs2219968	0.798	rs57034374	chr8:78911919	T/C	cg00738934	chr8:78996279	NA	-0.38	-5.17	-0.31	4.76e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs5760842	0.538	rs1076047	chr22:25495049	T/C	cg16733866	chr21:42792609	MX1	0.69	8.91	0.49	1.15e-16	Recurrent major depressive disorder;
KIRP	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg11569703	chr11:65557185	OVOL1	-0.74	-14.31	-0.67	3.41e-34	Acne (severe);
KIRP	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.76	-0.34	2.52e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.26	0.37	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg24098013	chr12:12878779	APOLD1	0.64	6.48	0.38	5e-10	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22977876	chr2:172950067	DLX1	0.49	6.75	0.4	1.08e-10	Parkinson's disease;
KIRP	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg07148914	chr20:33460835	GGT7	-0.41	-5.09	-0.31	7.26e-7	Height;
KIRP	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.84	11.0	0.57	3.85e-23	Mean platelet volume;
KIRP	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg06212747	chr3:49208901	KLHDC8B	0.75	10.2	0.55	1.37e-20	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg11204139	chr17:3907470	NA	-0.81	-14.84	-0.69	5.35e-36	Type 2 diabetes;
KIRP	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg06060754	chr5:176797920	RGS14	0.46	6.99	0.41	2.63e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19882132	chr14:106167949	NA	-0.41	-5.07	-0.31	7.7e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.66	-10.9	-0.57	7.71e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs262150	0.788	rs2657389	chr7:158763795	G/A	cg27247782	chr7:158767135	NA	-0.43	-5.2	-0.31	4.12e-7	Facial morphology (factor 20);
KIRP	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.4	-5.86	-0.35	1.44e-8	Colorectal cancer;
KIRP	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg09873164	chr1:152488093	CRCT1	0.57	7.6	0.44	6.4e-13	Hair morphology;
KIRP	trans	rs6589563	0.609	rs12285095	chr11:116658031	T/G	cg05354432	chr4:109089890	LEF1;LOC641518	-0.86	-6.04	-0.36	5.73e-9	Eosinophil counts;
KIRP	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.49	-0.48	2.01e-15	Lung cancer;
KIRP	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.86	-0.35	1.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.68	-0.34	3.87e-8	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg09264619	chr17:80180166	NA	0.37	5.4	0.33	1.55e-7	Life satisfaction;
KIRP	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg09137382	chr11:130731461	NA	0.59	8.58	0.48	1.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs974417	0.559	rs7776330	chr6:97388314	C/G	cg00261665	chr3:131101138	NUDT16	-0.49	-6.28	-0.37	1.5e-9	Body mass index;
KIRP	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.55	-7.19	-0.42	7.54e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.56	0.39	3.09e-10	Platelet count;
KIRP	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg10047753	chr17:41438598	NA	1.13	18.21	0.76	1.64e-47	Menopause (age at onset);
KIRP	cis	rs7638995	0.628	rs4855550	chr3:69185740	C/A	cg26574240	chr3:69171822	LMOD3	-0.75	-8.79	-0.49	2.63e-16	Alzheimer's disease (late onset);
KIRP	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.46	0.62	5.97e-28	Smoking behavior;
KIRP	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs35771425	1.000	rs34221813	chr1:211595896	C/T	cg10512769	chr1:211675356	NA	-0.51	-5.1	-0.31	6.66e-7	Educational attainment (years of education);
KIRP	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg00310523	chr12:86230176	RASSF9	0.39	6.07	0.36	4.88e-9	Major depressive disorder;
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg07511668	chr11:68622177	NA	0.43	5.74	0.34	2.8e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg13147721	chr7:65941812	NA	-0.73	-6.03	-0.36	5.88e-9	Diabetic kidney disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21683783	chr13:50624746	MIR15A;DLEU2	0.42	6.03	0.36	5.9e-9	Survival in pancreatic cancer;
KIRP	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19623624	chr10:135278901	LOC619207	-0.53	-5.88	-0.35	1.3e-8	Systemic lupus erythematosus;
KIRP	cis	rs11148252	0.535	rs11616459	chr13:53076400	A/T	cg02158880	chr13:53174818	NA	0.38	5.04	0.31	9.01e-7	Lewy body disease;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg01763666	chr17:80159506	CCDC57	-0.36	-4.91	-0.3	1.67e-6	Life satisfaction;
KIRP	cis	rs11574514	0.661	rs8058310	chr16:67893839	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.38	-0.32	1.77e-7	Crohn's disease;
KIRP	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.17	-0.46	1.62e-14	Mean corpuscular volume;
KIRP	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg16141378	chr3:129829833	LOC729375	0.46	6.07	0.36	4.8e-9	Systolic blood pressure;
KIRP	cis	rs4713118	0.824	rs9468225	chr6:27745719	T/G	cg20933634	chr6:27740509	NA	0.39	5.15	0.31	5.44e-7	Parkinson's disease;
KIRP	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	21.71	0.81	4.2e-59	Chronic sinus infection;
KIRP	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	0.7	6.56	0.39	3.09e-10	Obesity-related traits;
KIRP	cis	rs6032067	0.777	rs13044826	chr20:43801865	C/T	cg10761708	chr20:43804764	PI3	0.53	5.41	0.33	1.47e-7	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19866325	chr1:47078752	MOBKL2C	-0.48	-6.67	-0.39	1.67e-10	Survival in pancreatic cancer;
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg11945507	chr8:142233382	SLC45A4	0.91	15.7	0.71	6.09e-39	Immature fraction of reticulocytes;
KIRP	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg03788504	chr6:150331562	NA	-0.28	-5.28	-0.32	2.81e-7	Alopecia areata;
KIRP	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg09323728	chr8:95962352	TP53INP1	-0.24	-5.01	-0.3	1.06e-6	Type 2 diabetes;
KIRP	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	12.19	0.61	4.87e-27	Blood protein levels;
KIRP	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.5	5.89	0.35	1.25e-8	Metabolite levels;
KIRP	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg01631408	chr1:248437212	OR2T33	-0.67	-8.98	-0.5	7.24e-17	Common traits (Other);
KIRP	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.11e-8	Life satisfaction;
KIRP	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg04310649	chr10:35416472	CREM	-0.59	-7.14	-0.41	1.06e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg05335186	chr13:53173507	NA	0.34	5.15	0.31	5.28e-7	Lewy body disease;
KIRP	cis	rs9303542	0.527	rs62066689	chr17:46609092	T/C	cg04904318	chr17:46607828	HOXB1	-0.63	-6.73	-0.39	1.18e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs2230307	0.706	rs564562	chr1:100471566	T/C	cg24955406	chr1:100503596	HIAT1	0.56	5.57	0.33	6.57e-8	Carotid intima media thickness;
KIRP	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg04306507	chr14:55594613	LGALS3	0.47	7.35	0.42	2.85e-12	Protein biomarker;
KIRP	cis	rs7615316	0.779	rs13061823	chr3:142120786	C/T	cg20824294	chr3:142316082	PLS1	0.24	5.58	0.34	6.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg08648136	chr8:956695	NA	-0.42	-5.79	-0.35	2.16e-8	Schizophrenia;
KIRP	cis	rs2274273	0.905	rs28429419	chr14:55574793	T/C	cg04306507	chr14:55594613	LGALS3	0.53	8.45	0.47	2.56e-15	Protein biomarker;
KIRP	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.1	-0.36	4.15e-9	Response to antipsychotic treatment;
KIRP	cis	rs6132905	0.590	rs7270022	chr20:2615108	T/C	cg24848351	chr20:2622020	TMC2	-0.58	-5.22	-0.32	3.83e-7	Mumps;
KIRP	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.79	9.6	0.52	9.93e-19	Corneal astigmatism;
KIRP	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	0.82	9.05	0.5	4.52e-17	Gut microbiome composition (summer);
KIRP	cis	rs9900062	0.586	rs2676307	chr17:62690713	C/G	cg02097616	chr17:62675921	NA	0.53	6.36	0.38	9.67e-10	QT interval;
KIRP	cis	rs7534824	0.543	rs72734254	chr1:101382039	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	7.35	0.42	2.97e-12	Refractive astigmatism;
KIRP	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg09904177	chr6:26538194	HMGN4	-0.47	-5.88	-0.35	1.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs2573652	1.000	rs2581345	chr15:100514291	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.68	-10.22	-0.55	1.11e-20	Height;
KIRP	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	1.04	19.9	0.79	3.56e-53	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.87	13.3	0.65	8.96e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg12573674	chr2:1569213	NA	-0.52	-4.98	-0.3	1.21e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg18016565	chr1:150552671	MCL1	0.41	6.27	0.37	1.6e-9	Melanoma;
KIRP	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.52	-6.32	-0.37	1.22e-9	P wave terminal force;
KIRP	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg11189052	chr15:85197271	WDR73	-0.43	-5.18	-0.31	4.64e-7	P wave terminal force;
KIRP	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.58e-7	Body mass index;
KIRP	cis	rs17221829	0.733	rs10501708	chr11:89394435	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.25e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg25182066	chr10:30743637	MAP3K8	-0.59	-7.32	-0.42	3.54e-12	Inflammatory bowel disease;
KIRP	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.83	12.96	0.64	1.23e-29	Monocyte percentage of white cells;
KIRP	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.77	-11.59	-0.59	4.43e-25	Endometriosis;
KIRP	trans	rs6919346	0.572	rs9347411	chr6:160936320	T/C	cg01413548	chr6:11656844	NA	-0.38	-6.18	-0.37	2.64e-9	Lp (a) levels;
KIRP	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg01988459	chr11:68622903	NA	-0.35	-4.87	-0.3	1.97e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.17	-0.42	8.85e-12	Glomerular filtration rate;
KIRP	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.82	-12.41	-0.62	8.56e-28	Asthma;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg07648498	chr16:89883185	FANCA	0.39	5.23	0.32	3.54e-7	Vitiligo;
KIRP	cis	rs7688540	0.771	rs11729365	chr4:272524	G/A	cg10134910	chr4:1076041	RNF212	-0.24	-4.95	-0.3	1.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg01689657	chr7:91764605	CYP51A1	0.38	5.65	0.34	4.52e-8	Breast cancer;
KIRP	cis	rs12692119	0.568	rs4527162	chr2:127617310	G/A	cg25501666	chr2:127640322	NA	-0.43	-4.95	-0.3	1.36e-6	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.44	9.25	0.51	1.16e-17	Mean corpuscular volume;
KIRP	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg21546286	chr11:48923668	NA	-0.47	-5.96	-0.36	8.5e-9	HDL cholesterol;
KIRP	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.28	-0.32	2.77e-7	Total body bone mineral density;
KIRP	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg01270228	chr10:1369114	ADARB2	0.44	5.57	0.33	6.53e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.51	-11.61	-0.59	3.95e-25	Diabetic kidney disease;
KIRP	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-1.07	-19.63	-0.78	2.88e-52	Bone mineral density;
KIRP	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg00677455	chr12:58241039	CTDSP2	0.55	6.97	0.41	2.97e-11	Multiple sclerosis;
KIRP	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.27	-0.32	2.94e-7	Educational attainment (years of education);
KIRP	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.39	-5.3	-0.32	2.57e-7	Bipolar disorder;
KIRP	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.72	8.6	0.48	9.19e-16	Vitiligo;
KIRP	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.84	11.39	0.59	2.1e-24	Morning vs. evening chronotype;
KIRP	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg00360474	chr6:37504404	NA	-0.47	-6.68	-0.39	1.58e-10	Cognitive performance;
KIRP	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	1.03	18.36	0.76	5.17e-48	Leprosy;
KIRP	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg08741688	chr4:3415352	RGS12	-0.47	-5.52	-0.33	8.56e-8	Serum sulfate level;
KIRP	cis	rs1620921	0.505	rs4708886	chr6:161206350	G/T	cg01280913	chr6:161186852	NA	-0.69	-9.38	-0.51	4.41e-18	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs174601	0.582	rs108499	chr11:61547237	C/T	cg19610905	chr11:61596333	FADS2	-0.54	-7.98	-0.45	5.42e-14	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.42	-0.33	1.42e-7	Colorectal cancer;
KIRP	cis	rs7534824	0.625	rs6699653	chr1:101499162	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	5.79	0.35	2.18e-8	Refractive astigmatism;
KIRP	cis	rs9309473	1.000	rs6546837	chr2:73677898	G/C	cg20560298	chr2:73613845	ALMS1	-0.47	-5.52	-0.33	8.5e-8	Metabolite levels;
KIRP	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg02975922	chr3:195473998	MUC4	-0.56	-6.56	-0.39	3.14e-10	Pancreatic cancer;
KIRP	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.54	-7.67	-0.44	3.88e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.73	7.3	0.42	4.06e-12	Menarche (age at onset);
KIRP	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg13880726	chr7:1868755	MAD1L1	0.48	5.87	0.35	1.41e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15776560	chr3:25916362	NA	0.57	7.38	0.43	2.37e-12	Interleukin-4 levels;
KIRP	cis	rs2224391	0.628	rs9504365	chr6:5256116	A/G	cg13962347	chr6:5174647	LYRM4	-0.73	-10.27	-0.55	8e-21	Height;
KIRP	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs963731	0.649	rs297151	chr2:39326511	A/C	cg04010122	chr2:39346883	SOS1	-0.67	-5.08	-0.31	7.53e-7	Corticobasal degeneration;
KIRP	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.91	0.49	1.19e-16	Motion sickness;
KIRP	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.76	-0.34	2.52e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.79	0.35	2.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-5.65	-0.34	4.51e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs73200209	0.553	rs17426844	chr12:116632928	C/T	cg01776926	chr12:116560359	MED13L	-0.5	-5.14	-0.31	5.69e-7	Total body bone mineral density;
KIRP	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.48	5.75	0.34	2.58e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.21	0.37	2.2e-9	Breast cancer;
KIRP	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.47	-5.78	-0.35	2.22e-8	Diastolic blood pressure;
KIRP	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg16342193	chr10:102329863	NA	-0.38	-4.97	-0.3	1.28e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.67	-8.86	-0.49	1.61e-16	Male sexual orientation;
KIRP	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12826209	chr6:26865740	GUSBL1	0.71	8.35	0.47	4.86e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg25251562	chr2:3704773	ALLC	-0.49	-5.52	-0.33	8.58e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs17057718	1.000	rs78345417	chr3:57143942	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-5.07	-0.31	7.65e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07820310	chr20:44035078	DBNDD2;SYS1-DBNDD2	0.46	6.02	0.36	6.33e-9	Parkinson's disease;
KIRP	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	6.97	0.41	2.96e-11	Height;
KIRP	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg17385448	chr1:15911702	AGMAT	0.26	5.02	0.31	9.74e-7	Systolic blood pressure;
KIRP	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg04865290	chr3:52927548	TMEM110	-0.68	-7.17	-0.42	8.88e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.84	-12.73	-0.63	7.63e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4148087	1.000	rs9975154	chr21:43639741	C/G	cg08841829	chr21:43638893	ABCG1	-0.58	-4.92	-0.3	1.58e-6	Eating disorder in bipolar disorder;
KIRP	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.77	7.91	0.45	8.5e-14	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.26	-0.37	1.67e-9	Lung cancer;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4262150	0.883	rs55826179	chr5:152162776	G/A	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19402405	chr10:64576514	EGR2	0.5	6.64	0.39	1.97e-10	Survival in pancreatic cancer;
KIRP	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.05	-13.26	-0.65	1.24e-30	Exhaled nitric oxide output;
KIRP	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.47	-5.65	-0.34	4.32e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg23950597	chr19:37808831	NA	-0.63	-6.42	-0.38	6.86e-10	Coronary artery calcification;
KIRP	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-1.03	-17.56	-0.75	2.72e-45	Height;
KIRP	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg16396542	chr1:89473148	GBP3	0.4	5.51	0.33	9.18e-8	Carotid intima media thickness;
KIRP	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg07862535	chr7:139043722	LUC7L2	0.48	5.41	0.33	1.46e-7	Diisocyanate-induced asthma;
KIRP	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.69	5.82	0.35	1.82e-8	Diabetic retinopathy;
KIRP	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg19761014	chr17:28927070	LRRC37B2	0.68	5.04	0.31	9.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19717773	chr7:2847554	GNA12	0.41	6.08	0.36	4.6e-9	Height;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg02164492	chr11:46414469	NA	0.72	6.56	0.39	3.09e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.93	-14.55	-0.68	4.89e-35	Body mass index;
KIRP	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.59	-0.44	6.8e-13	Electroencephalogram traits;
KIRP	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-6.98	-0.41	2.69e-11	Retinal vascular caliber;
KIRP	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.6	0.52	9.84e-19	Prudent dietary pattern;
KIRP	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs6732160	0.564	rs1430346	chr2:73367245	T/C	cg01422370	chr2:73384389	NA	0.5	6.48	0.38	5.05e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	0.812	rs73073358	chr3:41842527	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02359409	chr6:42947317	PEX6	-0.5	-6.86	-0.4	5.49e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.99	14.91	0.69	2.91e-36	Menopause (age at onset);
KIRP	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.62	-8.08	-0.46	2.98e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg08501292	chr6:25962987	TRIM38	0.81	5.5	0.33	9.64e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.6	-9.14	-0.5	2.39e-17	Coronary artery disease;
KIRP	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	10.8	0.57	1.68e-22	Electrocardiographic conduction measures;
KIRP	cis	rs13102973	0.899	rs7438900	chr4:135909921	T/A	cg14419869	chr4:135874104	NA	0.47	7.26	0.42	5.14e-12	Subjective well-being;
KIRP	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.51	-0.56	1.4e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg00255919	chr5:131827918	IRF1	-0.3	-6.51	-0.38	4.09e-10	Asthma (sex interaction);
KIRP	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.36	-0.62	1.24e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs66561647	0.597	rs34390452	chr8:128940141	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	4.98	0.3	1.19e-6	Hemoglobin concentration;
KIRP	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.67	-12.57	-0.63	2.5e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.06	-0.41	1.66e-11	Diabetic kidney disease;
KIRP	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.62	8.92	0.49	1.09e-16	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs12282928	1.000	rs6485817	chr11:48250764	T/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.04	-0.36	5.6e-9	Migraine - clinic-based;
KIRP	cis	rs16958440	1.000	rs4609941	chr18:44645491	T/C	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg21858823	chr1:15850916	CASP9	0.54	5.77	0.35	2.37e-8	Systolic blood pressure;
KIRP	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.63	-8.33	-0.47	5.67e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs2625529	0.617	rs8025939	chr15:72460339	T/A	cg16672083	chr15:72433130	SENP8	0.45	6.19	0.37	2.52e-9	Red blood cell count;
KIRP	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.58	-6.09	-0.36	4.26e-9	Obesity-related traits;
KIRP	cis	rs758324	0.947	rs1604080	chr5:131176644	A/G	cg25547332	chr5:131281432	NA	-0.47	-5.3	-0.32	2.58e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.44	0.38	6.06e-10	Personality dimensions;
KIRP	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg07741184	chr6:167504864	NA	0.24	6.43	0.38	6.44e-10	Crohn's disease;
KIRP	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08439880	chr3:133502540	NA	-0.44	-5.26	-0.32	3.2e-7	Iron status biomarkers;
KIRP	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.64	-9.07	-0.5	4.03e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs9650657	0.737	rs2409669	chr8:10623969	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.2	-0.37	2.41e-9	Neuroticism;
KIRP	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.22	0.37	2.18e-9	Breast cancer;
KIRP	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg05941025	chr16:89927596	SPIRE2	0.32	4.87	0.3	2.03e-6	Vitiligo;
KIRP	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.43	-5.19	-0.31	4.36e-7	P wave terminal force;
KIRP	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg02297831	chr4:17616191	MED28	0.63	7.83	0.45	1.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.97	-14.59	-0.68	3.63e-35	Coronary artery disease;
KIRP	cis	rs988913	0.706	rs9475130	chr6:54925466	C/T	cg03513858	chr6:54763001	FAM83B	-0.35	-4.87	-0.3	2e-6	Menarche (age at onset);
KIRP	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8133932	0.654	rs379493	chr21:47360778	G/C	cg11214348	chr21:47283868	PCBP3	-0.39	-5.02	-0.3	9.95e-7	Schizophrenia;
KIRP	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.66	8.7	0.49	4.69e-16	Coronary artery disease;
KIRP	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg12549451	chr6:135224345	NA	0.42	5.12	0.31	6.11e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.44	-0.33	1.3e-7	Depression;
KIRP	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.15	0.36	3.18e-9	Total body bone mineral density;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg05627522	chr15:75251581	NA	0.32	4.98	0.3	1.19e-6	Breast cancer;
KIRP	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	5.38	0.32	1.71e-7	Breast cancer;
KIRP	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg00343986	chr7:65444356	GUSB	0.39	4.86	0.3	2.12e-6	Aortic root size;
KIRP	cis	rs7147624	1.000	rs7147624	chr14:65865625	G/T	cg03016385	chr14:66212404	NA	0.97	10.32	0.55	5.62e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4523957	0.583	rs2641444	chr17:2037402	T/C	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2859741	0.608	rs480411	chr1:37476077	T/C	cg09363841	chr1:37513479	NA	-0.55	-8.6	-0.48	9.2e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg05477027	chr19:46295590	DMWD	0.67	6.19	0.37	2.56e-9	Lung function (FEV1);
KIRP	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.79	-0.4	8.55e-11	Monocyte percentage of white cells;
KIRP	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg02344993	chr17:57696989	CLTC	0.57	5.46	0.33	1.15e-7	Hemoglobin concentration;
KIRP	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.79	11.6	0.59	4.23e-25	Heart rate;
KIRP	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.51	-6.78	-0.4	8.68e-11	Hip circumference;Waist circumference;
KIRP	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.39	-0.51	4.2e-18	Hemoglobin concentration;
KIRP	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.61	8.82	0.49	2.15e-16	Blood protein levels;
KIRP	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg16141378	chr3:129829833	LOC729375	0.49	6.14	0.36	3.21e-9	Triglycerides;
KIRP	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg05315796	chr3:52349193	DNAH1	0.38	5.95	0.35	9.01e-9	Bipolar disorder;
KIRP	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.92	0.3	1.6e-6	Menopause (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22111009	chr5:173416274	C5orf47	0.44	6.1	0.36	4.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	15.24	0.7	2.24e-37	Platelet count;
KIRP	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.05	12.74	0.63	6.87e-29	Smoking behavior;
KIRP	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg22777020	chr22:31556080	RNF185	-0.5	-5.29	-0.32	2.74e-7	Colorectal cancer;
KIRP	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg19045956	chr2:200819837	C2orf60;C2orf47	0.46	5.66	0.34	4.14e-8	Osteoporosis;
KIRP	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg07157834	chr1:205819609	PM20D1	0.49	5.28	0.32	2.82e-7	Parkinson's disease;
KIRP	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13198984	chr17:80129470	CCDC57	-0.52	-7.97	-0.45	5.83e-14	Life satisfaction;
KIRP	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.31	17.35	0.74	1.41e-44	Corneal structure;
KIRP	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs6977660	0.714	rs12334001	chr7:19814399	T/C	cg05791153	chr7:19748676	TWISTNB	0.6	5.79	0.35	2.09e-8	Thyroid stimulating hormone;
KIRP	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.98e-11	Hypertriglyceridemia;
KIRP	cis	rs911119	0.913	rs67483168	chr20:23581312	T/C	cg16589663	chr20:23618590	CST3	0.66	6.18	0.37	2.6e-9	Chronic kidney disease;
KIRP	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	6.9	0.4	4.27e-11	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg04310649	chr10:35416472	CREM	-0.57	-7.04	-0.41	1.91e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg19274270	chr17:78178856	CARD14	-0.34	-6.2	-0.37	2.41e-9	Morning vs. evening chronotype;
KIRP	trans	rs6601327	0.603	rs10104807	chr8:9669775	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.95	-0.41	3.29e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.61	8.16	0.46	1.77e-14	Bladder cancer;
KIRP	cis	rs77372450	0.636	rs11746670	chr5:157027705	C/T	cg05585991	chr5:157099197	C5orf52	0.44	5.12	0.31	6.16e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg24826892	chr11:71159390	DHCR7	0.44	4.89	0.3	1.81e-6	Vitamin D levels;
KIRP	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs2562456	0.754	rs62109228	chr19:21536931	G/C	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.5	-14.92	-0.69	2.69e-36	Plateletcrit;
KIRP	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06481639	chr22:41940642	POLR3H	0.68	6.08	0.36	4.63e-9	Vitiligo;
KIRP	cis	rs2191566	1.000	rs7256908	chr19:44528898	C/T	cg18700516	chr19:44507157	ZNF230	-0.47	-5.54	-0.33	7.66e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.29	-0.78	4.04e-51	Schizophrenia;
KIRP	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.61	7.76	0.44	2.27e-13	Longevity;Endometriosis;
KIRP	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg13385521	chr17:29058706	SUZ12P	1.04	7.63	0.44	5.15e-13	Body mass index;
KIRP	cis	rs7555523	0.832	rs7524755	chr1:165694897	A/G	cg24409356	chr1:165738333	TMCO1	0.55	5.23	0.32	3.6e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.41	-7.47	-0.43	1.39e-12	Refractive error;
KIRP	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.83	11.46	0.59	1.2e-24	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg00405596	chr8:11794950	NA	-0.47	-6.28	-0.37	1.51e-9	Joint mobility (Beighton score);
KIRP	cis	rs12620999	0.774	rs13402764	chr2:237951984	C/T	cg15976283	chr2:238042351	NA	0.36	5.15	0.31	5.32e-7	Systemic lupus erythematosus;
KIRP	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	1.18	11.52	0.59	7.86e-25	Red blood cell traits;
KIRP	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-1.02	-10.52	-0.56	1.28e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg22974920	chr21:40686053	BRWD1	0.51	5.89	0.35	1.24e-8	Cognitive function;
KIRP	cis	rs6142102	0.625	rs4911138	chr20:32547699	G/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	trans	rs7999699	0.902	rs9526394	chr13:48320373	C/G	cg23237801	chr1:16476620	EPHA2	0.51	6.33	0.37	1.15e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.51	7.06	0.41	1.7e-11	Coronary artery disease;
KIRP	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	ch.11.340609R	chr11:12831013	TEAD1	-0.42	-5.2	-0.31	4.23e-7	Educational attainment (years of education);
KIRP	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.89	-10.49	-0.56	1.65e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.38	-0.38	8.92e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11731606	0.667	rs3805301	chr4:95412692	G/A	cg20625393	chr4:95128694	SMARCAD1	0.49	5.04	0.31	8.83e-7	Mean platelet volume;
KIRP	cis	rs3755132	0.929	rs4668454	chr2:15740128	A/C	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs6484504	0.512	rs2774402	chr11:31312897	G/C	cg26647111	chr11:31128758	NA	0.44	5.22	0.32	3.74e-7	Red blood cell count;
KIRP	cis	rs2213920	0.619	rs7042718	chr9:118202187	C/T	cg13918206	chr9:118159781	DEC1	0.98	10.17	0.54	1.66e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs16857609	0.748	rs2618146	chr2:218302013	A/G	cg15335768	chr2:218268053	DIRC3	-0.37	-5.43	-0.33	1.35e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-4.87	-0.3	1.99e-6	Tonsillectomy;
KIRP	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg01843034	chr6:37503916	NA	-0.85	-12.05	-0.61	1.34e-26	Cognitive performance;
KIRP	cis	rs7077164	1.000	rs1227775	chr10:71580862	C/G	cg20696214	chr10:71583771	COL13A1	-0.47	-6.61	-0.39	2.37e-10	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12930096	0.938	rs8048558	chr16:11678332	G/A	cg07439791	chr16:11680400	LITAF	0.71	5.92	0.35	1.05e-8	QT interval;
KIRP	cis	rs7827545	0.545	rs1867062	chr8:135559079	G/A	cg17885191	chr8:135476712	NA	0.7	6.42	0.38	7.06e-10	Hypertension (SNP x SNP interaction);
KIRP	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.63	8.3	0.47	7.16e-15	Mood instability;
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03704899	chr6:112231927	NA	0.4	6.28	0.37	1.55e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs7919006	0.793	rs7924211	chr10:76767208	A/G	cg01390419	chr10:76803856	DUPD1	0.5	5.83	0.35	1.75e-8	Weight;
KIRP	cis	rs4478858	0.735	rs7523438	chr1:31788313	C/T	cg00250761	chr1:31883323	NA	0.3	5.34	0.32	2.17e-7	Alcohol dependence;
KIRP	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.87	9.24	0.51	1.2e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.03	-0.36	6.1e-9	Obesity-related traits;
KIRP	cis	rs7113874	0.802	rs11042030	chr11:8690718	T/C	cg08015107	chr11:8618950	NA	-0.44	-5.76	-0.34	2.44e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09699651	chr6:150184138	LRP11	0.59	8.0	0.45	5.01e-14	Testicular germ cell tumor;
KIRP	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg03571507	chr19:53239146	ZNF611	0.21	5.17	0.31	4.77e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs7709377	0.620	rs11742938	chr5:115474074	T/G	cg23108291	chr5:115420582	COMMD10	0.42	5.02	0.3	9.92e-7	Metabolite levels  (X-11787);
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.35	-6.24	-0.37	1.94e-9	Renal cell carcinoma;
KIRP	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-5.02	-0.3	9.82e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.6	-8.74	-0.49	3.74e-16	Menopause (age at onset);
KIRP	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg02389323	chr16:88786976	FAM38A	0.78	4.97	0.3	1.24e-6	Hair color;
KIRP	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg22974920	chr21:40686053	BRWD1	0.51	6.21	0.37	2.29e-9	Cognitive function;
KIRP	cis	rs12900413	0.687	rs8034777	chr15:90313057	C/T	cg24650279	chr15:90327240	NA	0.4	5.16	0.31	5.06e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg03128060	chr6:142623767	GPR126	0.37	5.35	0.32	2.06e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.8	-12.76	-0.63	5.83e-29	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs13395090	1.000	rs11687349	chr2:3717496	A/C	cg20493526	chr2:3714936	ALLC	0.65	8.85	0.49	1.74e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.3	-0.32	2.59e-7	Life satisfaction;
KIRP	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg03006477	chr6:74432658	CD109	0.25	5.36	0.32	1.9e-7	Blood protein levels;Calcium levels;
KIRP	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.24	-0.37	1.88e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg01864069	chr14:103024347	NA	-0.86	-10.11	-0.54	2.48e-20	Platelet count;
KIRP	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.87	-0.45	1.11e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14092259	chr1:41220011	MIR30E;NFYC	0.49	6.18	0.37	2.66e-9	Interleukin-4 levels;
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.65	0.39	1.91e-10	Electroencephalogram traits;
KIRP	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg14683738	chr19:37701593	ZNF585B	0.47	4.86	0.3	2.08e-6	Coronary artery calcification;
KIRP	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.7	-0.39	1.4e-10	Obesity-related traits;
KIRP	cis	rs6681460	0.625	rs6680364	chr1:67104834	G/A	cg13052034	chr1:66999238	SGIP1	0.35	4.97	0.3	1.23e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.95	-0.3	1.4e-6	Life satisfaction;
KIRP	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg17108064	chr15:78857060	CHRNA5	0.35	5.0	0.3	1.09e-6	Sudden cardiac arrest;
KIRP	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.92	-0.4	3.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.46	5.9	0.35	1.21e-8	Response to temozolomide;
KIRP	cis	rs6499755	0.712	rs76667757	chr16:55362378	T/G	cg05099576	chr16:55362342	IRX6	0.3	6.24	0.37	1.88e-9	Hypospadias;
KIRP	cis	rs9815354	0.951	rs1619558	chr3:41914213	C/G	cg03022575	chr3:42003672	ULK4	0.48	5.48	0.33	1.05e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs494562	0.892	rs640093	chr6:86115866	C/T	cg21730993	chr6:86159210	NT5E	0.55	5.08	0.31	7.63e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg04691961	chr3:161091175	C3orf57	-0.57	-9.15	-0.5	2.21e-17	Morning vs. evening chronotype;
KIRP	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg00106254	chr7:1943704	MAD1L1	0.42	4.86	0.3	2.08e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.51	7.28	0.42	4.62e-12	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg26384229	chr12:38710491	ALG10B	0.72	9.57	0.52	1.18e-18	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs7771547	0.855	rs9366911	chr6:36589340	C/G	cg04289385	chr6:36355825	ETV7	-0.39	-5.47	-0.33	1.12e-7	Platelet distribution width;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.96	0.54	7.75e-20	Lung cancer;
KIRP	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg04490037	chr7:50633773	DDC	0.36	4.92	0.3	1.62e-6	Body mass index;
KIRP	cis	rs6991838	0.584	rs66486920	chr8:66486693	C/T	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg02811702	chr13:24901961	NA	0.41	5.39	0.33	1.63e-7	Obesity-related traits;
KIRP	cis	rs9815354	0.857	rs7634985	chr3:42019565	C/T	cg03022575	chr3:42003672	ULK4	-0.54	-6.09	-0.36	4.39e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.71	-10.28	-0.55	7.25e-21	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs17384381	1.000	rs12132677	chr1:85879613	A/C	cg16011679	chr1:85725395	C1orf52	0.81	8.15	0.46	1.83e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs911119	1.000	rs71334202	chr20:23618652	A/C	cg16589663	chr20:23618590	CST3	0.64	6.56	0.39	3.11e-10	Chronic kidney disease;
KIRP	trans	rs1916521	1.000	rs2244956	chr10:57414479	G/C	cg10367743	chr4:15003669	NA	-0.48	-6.03	-0.36	6.04e-9	Cardiac hypertrophy;
KIRP	cis	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.44	5.2	0.31	4.2e-7	Aortic root size;
KIRP	cis	rs253959	0.523	rs785367	chr5:115644056	C/G	cg23108291	chr5:115420582	COMMD10	-0.46	-5.26	-0.32	3.09e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.21	5.33	0.32	2.23e-7	Primary biliary cholangitis;
KIRP	cis	rs7359257	1.000	rs7359257	chr15:67702907	A/C	cg24579218	chr15:68104479	NA	0.36	5.43	0.33	1.38e-7	Menarche (age at onset);
KIRP	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.55	-7.53	-0.43	9.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg07936489	chr17:37558343	FBXL20	0.56	7.54	0.43	9.29e-13	Asthma;
KIRP	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.07	0.31	7.68e-7	Asthma;
KIRP	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg19468946	chr17:37922297	IKZF3	-0.46	-6.63	-0.39	2.06e-10	Asthma;
KIRP	cis	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg04691961	chr3:161091175	C3orf57	-0.48	-7.16	-0.42	9.3e-12	Morning vs. evening chronotype;
KIRP	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg07645718	chr20:61493192	TCFL5	0.78	6.14	0.36	3.36e-9	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21664614	chr13:111277611	CARKD	0.48	6.31	0.37	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg09455208	chr3:40491958	NA	0.29	4.9	0.3	1.7e-6	Renal cell carcinoma;
KIRP	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.47	-6.58	-0.39	2.83e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs867371	0.656	rs2665103	chr15:82432715	A/G	cg06066596	chr15:83166174	LOC80154	0.38	5.1	0.31	6.74e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12463550	chr7:65579703	CRCP	0.76	4.87	0.3	2.03e-6	Diabetic kidney disease;
KIRP	cis	rs427941	0.703	rs201454	chr7:101740056	A/G	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.27e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg15445000	chr17:37608096	MED1	0.47	5.5	0.33	9.28e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.82	-0.45	1.6e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs11644362	0.932	rs34290494	chr16:12987705	A/C	cg06890432	chr16:12997467	SHISA9	-0.39	-6.01	-0.36	6.78e-9	Positive affect;Subjective well-being;
KIRP	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg11584989	chr19:19387371	SF4	0.41	5.28	0.32	2.81e-7	Tonsillectomy;
KIRP	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.4	-0.59	1.88e-24	Diabetic kidney disease;
KIRP	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.72	8.31	0.47	6.6e-15	Obesity-related traits;
KIRP	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.89	9.83	0.53	1.89e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg08283408	chr3:49949060	MON1A	0.44	5.85	0.35	1.52e-8	Body mass index;
KIRP	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	11.24	0.58	6.07e-24	Birth weight;
KIRP	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.63	-8.1	-0.46	2.58e-14	Bipolar disorder;
KIRP	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.95	15.56	0.7	1.77e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17286411	0.806	rs12600163	chr16:71877201	G/C	cg04254540	chr16:71951199	KIAA0174	-0.39	-5.21	-0.32	3.97e-7	Blood protein levels;
KIRP	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7737355	1.000	rs27421	chr5:130743771	C/T	cg06307176	chr5:131281290	NA	-0.55	-5.89	-0.35	1.27e-8	Life satisfaction;
KIRP	cis	rs11586313	0.506	rs6671493	chr1:152870341	A/G	cg13444842	chr1:152974279	SPRR3	-0.38	-5.02	-0.3	1.01e-6	Vitamin D levels;
KIRP	cis	rs1712790	0.702	rs2040324	chr11:114630049	C/T	cg19465033	chr11:114479364	NA	0.39	5.17	0.31	4.82e-7	Urinary albumin excretion;
KIRP	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.5	-0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs17125944	0.686	rs7145440	chr14:53333717	A/G	cg00686598	chr14:53173677	PSMC6	-0.73	-7.2	-0.42	7.14e-12	Alzheimer's disease (late onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18309286	chr11:77123047	PAK1	-0.52	-6.19	-0.37	2.44e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-10.94	-0.57	5.92e-23	Bone mineral density;
KIRP	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	8.0	0.45	4.77e-14	Iron status biomarkers;
KIRP	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg24375607	chr4:120327624	NA	0.58	6.73	0.39	1.15e-10	Corneal astigmatism;
KIRP	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.43	0.38	6.59e-10	Electroencephalogram traits;
KIRP	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.85	12.68	0.63	1.13e-28	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.41	5.1	0.31	6.69e-7	IgG glycosylation;
KIRP	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg18806716	chr10:30721971	MAP3K8	-0.35	-5.21	-0.32	3.97e-7	Inflammatory bowel disease;
KIRP	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.36	-0.38	9.64e-10	Aortic root size;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg23288298	chr2:43451559	ZFP36L2	0.53	6.16	0.37	3.03e-9	DNA methylation (variation);
KIRP	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.55	8.76	0.49	3.23e-16	Blood metabolite levels;
KIRP	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg01283332	chr5:1856932	NA	-0.5	-6.39	-0.38	8.25e-10	Cardiovascular disease risk factors;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.53	-6.75	-0.4	1.04e-10	Longevity;Endometriosis;
KIRP	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.34	7.23	0.42	5.9e-12	Breast cancer;
KIRP	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.05e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg04398451	chr17:18023971	MYO15A	0.75	10.82	0.57	1.4e-22	Total body bone mineral density;
KIRP	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.76	8.85	0.49	1.71e-16	Adiposity;
KIRP	trans	rs763014	0.931	rs2071980	chr16:626346	A/C	cg00950418	chr7:105029125	SRPK2	-0.5	-6.23	-0.37	2.06e-9	Height;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.82	11.49	0.59	9.64e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg24881330	chr22:46731750	TRMU	0.59	6.08	0.36	4.6e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.75	-9.74	-0.53	3.52e-19	QT interval;
KIRP	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.79	-11.36	-0.59	2.52e-24	Blood metabolite levels;
KIRP	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	1.02	14.32	0.67	2.97e-34	Platelet distribution width;
KIRP	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.53	-0.43	9.4e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1961637	0.960	rs10460429	chr2:223905578	A/C	cg02552189	chr2:223891284	NA	-0.39	-5.19	-0.31	4.48e-7	Oropharynx cancer;
KIRP	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg20578329	chr17:80767326	TBCD	-0.95	-8.94	-0.5	9.52e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg00792783	chr2:198669748	PLCL1	0.48	5.34	0.32	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs11955175	1.000	rs113120818	chr5:40642896	T/A	cg04002187	chr5:40835754	RPL37	0.65	5.26	0.32	3.09e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.68	10.3	0.55	6.49e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs2904967	0.778	rs620427	chr11:65094583	C/A	cg12562828	chr11:65076843	NA	0.89	12.01	0.61	1.88e-26	Mean corpuscular volume;
KIRP	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.51	6.51	0.38	4.2e-10	Corneal structure;
KIRP	cis	rs7215564	0.908	rs2873059	chr17:78663874	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg05676341	chr10:135206831	MTG1	1.4	11.85	0.6	6.45e-26	Lifespan;
KIRP	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	6.01	0.36	6.79e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Parkinson's disease;
KIRP	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg21466736	chr12:48725269	NA	-0.53	-6.62	-0.39	2.28e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.79	-0.4	8.15e-11	Immature fraction of reticulocytes;
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg16898833	chr6:26189333	HIST1H4D	0.66	5.01	0.3	1.05e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg24868830	chr4:140374821	RAB33B	-1.11	-6.08	-0.36	4.51e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg21775007	chr8:11205619	TDH	-0.4	-5.37	-0.32	1.79e-7	Monocyte count;
KIRP	cis	rs4845459	0.933	rs6700181	chr1:152593087	A/G	cg07796016	chr1:152779584	LCE1C	-0.49	-5.95	-0.35	9.1e-9	Psoriasis;
KIRP	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.61	-7.88	-0.45	1.05e-13	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.37	-4.88	-0.3	1.9e-6	Lewy body disease;
KIRP	cis	rs7221595	0.756	rs35852805	chr17:3892563	C/T	cg09695851	chr17:3907499	NA	0.6	5.91	0.35	1.13e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg13010199	chr12:38710504	ALG10B	0.58	7.47	0.43	1.42e-12	Morning vs. evening chronotype;
KIRP	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	6.2	0.37	2.33e-9	Longevity;
KIRP	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg07810366	chr2:100720526	AFF3	-0.32	-4.99	-0.3	1.14e-6	Educational attainment;
KIRP	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.32	-0.37	1.19e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10266483	0.739	rs682662	chr7:63766485	C/T	cg04636841	chr7:63768139	NA	-0.39	-5.24	-0.32	3.5e-7	Response to statin therapy;
KIRP	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg10950524	chr7:2139216	MAD1L1	0.31	4.91	0.3	1.63e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs7215564	0.908	rs4889783	chr17:78667160	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.22	0.32	3.83e-7	Myopia (pathological);
KIRP	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.93	14.87	0.69	4.2e-36	Menopause (age at onset);
KIRP	cis	rs6442310	0.512	rs1175542	chr3:12466214	G/A	cg02700894	chr3:12045449	SYN2	-0.41	-5.63	-0.34	4.84e-8	Hematocrit;
KIRP	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg15934090	chr1:100435551	SLC35A3	0.52	6.42	0.38	7.01e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7188697	0.922	rs37053	chr16:58558707	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.13	0.31	5.89e-7	QT interval;
KIRP	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg10189774	chr4:17578691	LAP3	0.52	6.43	0.38	6.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs2712184	0.756	rs2712163	chr2:217660346	G/A	cg05032264	chr2:217675019	NA	-0.49	-7.15	-0.42	9.61e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg09165964	chr15:75287851	SCAMP5	0.51	6.71	0.39	1.36e-10	Breast cancer;
KIRP	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.64	0.39	2.04e-10	Major depressive disorder;
KIRP	cis	rs7940866	0.738	rs10791114	chr11:130889850	G/A	cg12179176	chr11:130786555	SNX19	0.72	8.37	0.47	4.44e-15	Schizophrenia;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg21224049	chr4:668623	ATP5I	0.8	6.79	0.4	8.48e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg08975724	chr8:8085496	FLJ10661	0.67	8.56	0.48	1.21e-15	Neuroticism;
KIRP	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-12.72	-0.63	8.22e-29	Platelet distribution width;
KIRP	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg20701182	chr2:24300061	SF3B14	0.57	5.15	0.31	5.41e-7	Lymphocyte counts;
KIRP	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg18154014	chr19:37997991	ZNF793	0.91	9.33	0.51	6.56e-18	Coronary artery calcification;
KIRP	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg13180566	chr4:1052158	NA	-0.51	-5.22	-0.32	3.8e-7	Recombination rate (females);
KIRP	cis	rs14403	0.954	rs9803993	chr1:243672125	G/A	cg21452805	chr1:244014465	NA	0.53	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	8.94	0.5	9.58e-17	Coffee consumption (cups per day);
KIRP	cis	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg21546286	chr11:48923668	NA	0.42	5.17	0.31	4.91e-7	HDL cholesterol;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16340023	chr20:60544932	NA	0.43	6.14	0.36	3.31e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg23093090	chr10:104574429	C10orf26	0.37	6.1	0.36	4.1e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26207909	chr14:103986467	CKB	0.73	10.31	0.55	6e-21	Body mass index;
KIRP	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-10.41	-0.55	2.86e-21	Prostate cancer;
KIRP	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-0.67	-7.72	-0.44	3e-13	Initial pursuit acceleration;
KIRP	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4006360	0.574	rs6503592	chr17:39253010	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.66	-0.52	6.47e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs9921338	0.961	rs17605444	chr16:11413589	A/C	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.86	-0.35	1.45e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.45	-6.15	-0.36	3.16e-9	Height;
KIRP	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	7.02	0.41	2.21e-11	Lymphocyte counts;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg27121462	chr16:89883253	FANCA	0.63	9.31	0.51	7.54e-18	Vitiligo;
KIRP	cis	rs17023223	0.537	rs2765531	chr1:119585497	A/G	cg18261050	chr1:119551319	NA	0.52	6.98	0.41	2.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.59	6.56	0.39	3.09e-10	Aortic root size;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14597492	chr8:125487571	RNF139	-0.54	-6.3	-0.37	1.34e-9	Menopause (age at onset);
KIRP	cis	rs7129556	0.737	rs4344516	chr11:77438059	A/G	cg12586386	chr11:77299805	AQP11	0.44	5.77	0.35	2.36e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg15893493	chr8:124194847	FAM83A	0.94	8.2	0.46	1.3e-14	Urinary uromodulin levels;
KIRP	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19717773	chr7:2847554	GNA12	-0.39	-5.71	-0.34	3.22e-8	Height;
KIRP	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.59	8.07	0.46	3.11e-14	Morning vs. evening chronotype;
KIRP	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23281280	chr6:28129359	ZNF389	0.45	4.93	0.3	1.53e-6	Parkinson's disease;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg08132940	chr7:1081526	C7orf50	-0.41	-5.08	-0.31	7.59e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.63	-8.04	-0.46	3.78e-14	Glomerular filtration rate;
KIRP	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17554472	chr22:41940697	POLR3H	0.68	7.02	0.41	2.16e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg04369109	chr6:150039330	LATS1	-0.6	-7.65	-0.44	4.45e-13	Lung cancer;
KIRP	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg14703610	chr5:56206110	C5orf35	0.48	6.65	0.39	1.92e-10	Coronary artery disease;
KIRP	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.72	9.07	0.5	3.8e-17	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs16828019	0.777	rs12023079	chr1:41470111	G/A	cg18742814	chr1:41828276	NA	0.67	5.69	0.34	3.62e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	cg21523751	chr1:182988639	NA	0.35	4.94	0.3	1.46e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg12501888	chr15:85177176	SCAND2	-0.43	-5.54	-0.33	7.66e-8	P wave terminal force;
KIRP	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.65	9.09	0.5	3.3e-17	Prostate cancer;
KIRP	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg03808351	chr9:123631620	PHF19	0.41	5.68	0.34	3.78e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs5753037	0.803	rs131262	chr22:30133044	G/T	cg27665648	chr22:30112403	NA	0.43	6.22	0.37	2.15e-9	Type 1 diabetes;
KIRP	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg20701182	chr2:24300061	SF3B14	0.63	5.37	0.32	1.82e-7	Lymphocyte counts;
KIRP	trans	rs12043259	0.730	rs10458590	chr1:204792166	C/T	cg11485465	chr5:54518469	NA	0.35	6.28	0.37	1.55e-9	Addiction;
KIRP	trans	rs587242	1.000	rs2011693	chr1:96884287	G/A	cg10631902	chr5:14652156	NA	0.53	6.11	0.36	3.91e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.72	-0.39	1.28e-10	Joint mobility (Beighton score);
KIRP	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.06	-0.31	8.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.56	-6.86	-0.4	5.55e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs9309473	0.500	rs2421664	chr2:73858881	C/T	cg20560298	chr2:73613845	ALMS1	0.48	5.84	0.35	1.64e-8	Metabolite levels;
KIRP	cis	rs16937	0.662	rs10900456	chr1:205145005	C/T	cg21643547	chr1:205240462	TMCC2	-0.46	-6.06	-0.36	5.07e-9	Schizophrenia;
KIRP	cis	rs17428704	0.571	rs62344983	chr5:14360722	A/G	cg26595256	chr5:14380529	TRIO	-0.82	-6.11	-0.36	3.96e-9	Electroencephalogram traits;
KIRP	cis	rs1062753	0.731	rs11090065	chr22:42384171	T/C	cg22189786	chr22:42395067	WBP2NL	0.45	5.49	0.33	9.98e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.93	15.94	0.71	8.82e-40	Metabolic syndrome;
KIRP	cis	rs4742903	0.935	rs1507513	chr9:106973857	A/G	cg14250997	chr9:106856677	SMC2	0.38	4.94	0.3	1.47e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg20636351	chr8:55087400	NA	-0.65	-8.0	-0.45	5.03e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg17133734	chr15:86042851	AKAP13	-0.45	-5.7	-0.34	3.36e-8	Coronary artery disease;
KIRP	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg17108064	chr15:78857060	CHRNA5	0.38	5.45	0.33	1.2e-7	Sudden cardiac arrest;
KIRP	cis	rs4262150	0.883	rs72799183	chr5:152173815	G/A	cg12297329	chr5:152029980	NA	-0.65	-7.95	-0.45	6.84e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9761603	0.812	rs9307773	chr4:138415539	A/G	cg12033966	chr4:138453416	PCDH18	0.44	5.87	0.35	1.43e-8	Diastolic blood pressure;
KIRP	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.78	-0.44	1.95e-13	Retinal vascular caliber;
KIRP	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs10875746	0.903	rs11168386	chr12:48467977	C/T	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs3096299	0.646	rs918722	chr16:89415081	C/G	cg08392591	chr16:89556376	ANKRD11	0.45	5.73	0.34	2.97e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs6850606	0.577	rs12503906	chr4:42851978	G/T	cg24533989	chr4:42659536	ATP8A1	0.44	4.91	0.3	1.64e-6	Interferon alpha levels in systemic lupus erythematosus;
KIRP	cis	rs8177876	0.822	rs8177940	chr16:81117394	G/A	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg27490568	chr2:178487706	NA	0.6	8.1	0.46	2.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.67	7.78	0.44	2.05e-13	Corneal astigmatism;
KIRP	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg19507638	chr5:93509721	C5orf36	-0.53	-5.01	-0.3	1.02e-6	Diabetic retinopathy;
KIRP	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg23067535	chr8:124195133	FAM83A	-0.78	-7.63	-0.44	5.05e-13	Urinary uromodulin levels;
KIRP	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg16141378	chr3:129829833	LOC729375	-0.57	-7.41	-0.43	2.04e-12	Mood instability;
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.77	11.89	0.6	4.57e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg00405596	chr8:11794950	NA	-0.46	-5.7	-0.34	3.5e-8	Neuroticism;
KIRP	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs1387259	0.619	rs7134565	chr12:48630024	C/T	cg26205652	chr12:48591994	NA	0.36	4.87	0.3	2e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.35	-0.42	2.84e-12	Joint mobility (Beighton score);
KIRP	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg04317338	chr11:64019027	PLCB3	0.79	7.09	0.41	1.4e-11	Mean platelet volume;
KIRP	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg09904177	chr6:26538194	HMGN4	0.44	5.94	0.35	9.86e-9	Schizophrenia;
KIRP	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05025164	chr4:1340916	KIAA1530	0.4	5.1	0.31	6.94e-7	Obesity-related traits;
KIRP	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.64	7.47	0.43	1.41e-12	Height;
KIRP	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg08761264	chr16:28874980	SH2B1	-0.52	-6.0	-0.36	6.93e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg14664628	chr15:75095509	CSK	0.51	6.12	0.36	3.62e-9	Systemic lupus erythematosus;
KIRP	cis	rs12210905	1.000	rs12192446	chr6:26995638	C/A	cg11502198	chr6:26597334	ABT1	-0.78	-4.93	-0.3	1.54e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg16524733	chr11:117070046	TAGLN	0.38	4.95	0.3	1.35e-6	Blood protein levels;
KIRP	cis	rs4851254	0.618	rs7596359	chr2:100665274	T/G	cg22139774	chr2:100720529	AFF3	-0.41	-5.18	-0.31	4.57e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg00310523	chr12:86230176	RASSF9	0.42	6.45	0.38	5.83e-10	Major depressive disorder;
KIRP	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg22138327	chr13:27999177	GTF3A	0.89	6.6	0.39	2.47e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7923609	0.967	rs3999089	chr10:65203808	C/T	cg08743896	chr10:65200160	JMJD1C	0.36	5.33	0.32	2.19e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	5.25	0.32	3.25e-7	Leprosy;
KIRP	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg22676075	chr6:135203613	NA	-0.61	-8.15	-0.46	1.86e-14	High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg02815282	chr11:67141135	LOC100130987;CLCF1	-0.49	-6.6	-0.39	2.57e-10	Platelet-derived growth factor BB levels;
KIRP	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	14.4	0.68	1.68e-34	Gut microbiome composition (summer);
KIRP	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.15	-0.36	3.16e-9	Obesity-related traits;
KIRP	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	7.48	0.43	1.31e-12	Total body bone mineral density;
KIRP	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.8	-11.51	-0.59	8.22e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs2072732	0.861	rs72629498	chr1:2954203	C/T	cg11731671	chr1:2995604	PRDM16	-0.56	-6.59	-0.39	2.66e-10	Plateletcrit;
KIRP	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	0.8	6.54	0.39	3.45e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.26	0.32	3.18e-7	Breast cancer;
KIRP	cis	rs17221829	0.645	rs4753227	chr11:89369102	C/T	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.2	-0.31	4.21e-7	Anxiety in major depressive disorder;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg19410738	chr19:39226868	CAPN12	-0.53	-6.1	-0.36	4e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg06647332	chr5:131281008	NA	0.47	5.36	0.32	1.88e-7	Life satisfaction;
KIRP	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg02221750	chr19:17393354	ANKLE1	-0.67	-6.36	-0.38	9.91e-10	Systemic lupus erythematosus;
KIRP	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.8	11.0	0.57	3.88e-23	Aortic root size;
KIRP	cis	rs7116495	0.737	rs7102192	chr11:71648169	G/A	cg11196788	chr11:71737549	NUMA1	0.55	4.87	0.3	2.04e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.72	-0.39	1.25e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10073892	0.701	rs10067136	chr5:101722320	C/T	cg19774478	chr5:101632501	SLCO4C1	0.66	6.86	0.4	5.5e-11	Cognitive decline (age-related);
KIRP	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.56	6.25	0.37	1.82e-9	Diisocyanate-induced asthma;
KIRP	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs10107145	0.509	rs4310166	chr8:10763736	A/G	cg21625330	chr8:9911636	MSRA	0.43	5.03	0.31	9.37e-7	Systolic blood pressure;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	6.86	0.4	5.57e-11	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15834993	chr8:49826049	NA	0.4	6.11	0.36	3.92e-9	Interleukin-4 levels;
KIRP	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg23442198	chr4:187126114	CYP4V2	-0.78	-7.14	-0.41	1.03e-11	Blood protein levels;
KIRP	cis	rs405956	0.769	rs7453071	chr6:105558795	A/C	cg22580625	chr6:105627791	POPDC3	-0.48	-5.31	-0.32	2.42e-7	QT interval;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-1.01	-15.41	-0.7	5.79e-38	Coronary artery disease;
KIRP	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.68	-7.03	-0.41	1.98e-11	Coronary artery calcification;
KIRP	cis	rs9513627	0.588	rs9585073	chr13:100128516	A/G	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.37	4.9	0.3	1.74e-6	Social autistic-like traits;
KIRP	cis	rs6585424	0.500	rs12777382	chr10:81920710	G/A	cg27417294	chr10:81904244	PLAC9	0.86	5.79	0.35	2.11e-8	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.62	-6.38	-0.38	8.94e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05564831	chr3:52568323	NT5DC2	0.44	7.0	0.41	2.48e-11	Electroencephalogram traits;
KIRP	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9434723	0.841	rs9435152	chr1:9308249	C/T	cg04199779	chr1:9294473	H6PD	0.6	6.56	0.39	3.24e-10	Height;
KIRP	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.6	7.69	0.44	3.5e-13	Total body bone mineral density;
KIRP	cis	rs12318506	1.000	rs12318506	chr12:75718423	G/T	cg04728562	chr12:75699417	CAPS2	-1.02	-7.4	-0.43	2.18e-12	Coronary artery calcification;
KIRP	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg24579218	chr15:68104479	NA	0.43	6.47	0.38	5.14e-10	Motion sickness;
KIRP	cis	rs593254	0.523	rs206008	chr6:164429226	T/C	cg00040411	chr6:164393165	NA	0.48	5.02	0.3	9.88e-7	Gestational age at birth in labor-initiated deliveries (maternal effect);
KIRP	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg26384229	chr12:38710491	ALG10B	0.65	8.68	0.48	5.53e-16	Morning vs. evening chronotype;
KIRP	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.75	10.85	0.57	1.15e-22	Psoriasis;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg21584983	chr19:11640070	ECSIT	0.51	6.07	0.36	4.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.12	-0.74	8.52e-44	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs8060686	0.623	rs2418736	chr16:68154862	A/G	cg26727032	chr16:67993705	SLC12A4	0.75	9.19	0.51	1.72e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.87	-11.18	-0.58	1.01e-23	Parkinson's disease;
KIRP	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	5.55	0.33	7.2e-8	Schizophrenia;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg12486944	chr17:80159399	CCDC57	0.38	5.08	0.31	7.47e-7	Life satisfaction;
KIRP	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	13.98	0.67	4.52e-33	Cognitive ability;
KIRP	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-7.5	-0.43	1.19e-12	Eye color traits;
KIRP	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.61	-0.59	3.87e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs2387326	0.818	rs2782862	chr10:129919825	A/G	cg16087940	chr10:129947807	NA	-0.41	-5.31	-0.32	2.4e-7	Select biomarker traits;
KIRP	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.83	6.97	0.41	2.92e-11	Fat distribution (HIV);
KIRP	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23281280	chr6:28129359	ZNF389	0.45	4.92	0.3	1.59e-6	Depression;
KIRP	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg17554472	chr22:41940697	POLR3H	0.57	6.6	0.39	2.56e-10	Vitiligo;
KIRP	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.44	-6.05	-0.36	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16318349	chr1:154917307	PBXIP1	-0.34	-5.32	-0.32	2.38e-7	Prostate cancer;
KIRP	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.55	8.1	0.46	2.58e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.17	-0.54	1.66e-20	Alzheimer's disease (late onset);
KIRP	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg23625390	chr15:77176239	SCAPER	0.51	6.51	0.38	4.17e-10	Blood metabolite levels;
KIRP	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.34	0.37	1.1e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6568686	0.786	rs9481155	chr6:111829239	A/G	cg15721981	chr6:111408429	SLC16A10	-0.68	-6.04	-0.36	5.72e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs41005	0.967	rs193928	chr2:8107899	T/C	cg03155496	chr2:8117019	LOC339788	0.56	9.31	0.51	7.17e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-7.54	-0.43	9.09e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.17	0.46	1.59e-14	Neuroticism;
KIRP	cis	rs11997175	0.603	rs67661085	chr8:33731976	A/G	ch.8.33884649F	chr8:33765107	NA	0.57	6.27	0.37	1.64e-9	Body mass index;
KIRP	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00194886	chr1:226494497	LIN9	0.39	6.14	0.36	3.37e-9	C-reactive protein;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13435832	chr9:103065209	TEX10	0.43	6.17	0.37	2.86e-9	Survival in pancreatic cancer;
KIRP	cis	rs72730918	0.648	rs10519317	chr15:51977593	A/G	cg14296394	chr15:51910925	DMXL2	-0.81	-7.03	-0.41	2.03e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13409248	chr3:40428643	ENTPD3	0.38	5.1	0.31	6.9e-7	Renal cell carcinoma;
KIRP	trans	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.84	-0.4	6.07e-11	Heart rate;
KIRP	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs2278796	0.639	rs4951152	chr1:204970495	G/T	cg17947172	chr1:204966197	NFASC	0.66	8.92	0.49	1.08e-16	Mean platelet volume;
KIRP	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.63	12.35	0.62	1.42e-27	Bone mineral density;
KIRP	cis	rs3736485	0.966	rs4775958	chr15:51891562	G/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.11	-0.31	6.39e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.09	-0.31	7.28e-7	Rheumatoid arthritis;
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg12705353	chr12:122356852	WDR66	0.41	5.53	0.33	8.28e-8	Mean corpuscular volume;
KIRP	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.64	8.96	0.5	8.21e-17	Schizophrenia;
KIRP	trans	rs270421	0.555	rs450829	chr16:79242770	A/G	cg26284735	chr3:5065165	NA	0.24	6.14	0.36	3.21e-9	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg17207736	chr8:142237307	SLC45A4	0.54	6.9	0.4	4.45e-11	Immature fraction of reticulocytes;
KIRP	cis	rs10073892	0.620	rs13168111	chr5:101951568	A/T	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs6956675	0.915	rs4717497	chr7:62645096	A/G	cg08930214	chr7:62859557	LOC100287834	0.43	5.26	0.32	3.2e-7	Obesity-related traits;
KIRP	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg01426195	chr3:39028469	NA	0.54	7.92	0.45	8.32e-14	Handedness;
KIRP	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg05025164	chr4:1340916	KIAA1530	0.45	5.52	0.33	8.72e-8	Obesity-related traits;
KIRP	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.46	-5.59	-0.34	5.93e-8	Testicular germ cell tumor;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg07404485	chr7:94953653	PON1	0.59	8.56	0.48	1.23e-15	Paraoxonase activity;
KIRP	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg12856521	chr11:46389249	DGKZ	0.43	6.1	0.36	4.15e-9	Leprosy;
KIRP	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.81	-0.4	7.62e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.31	5.68	0.34	3.73e-8	Calcium levels;
KIRP	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.33	0.37	1.13e-9	Morning vs. evening chronotype;
KIRP	cis	rs2273669	0.504	rs79498470	chr6:109499259	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.02	-0.3	9.93e-7	Prostate cancer;
KIRP	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-7.98	-0.45	5.69e-14	Alzheimer's disease;
KIRP	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.2	21.98	0.81	5.81e-60	Cognitive function;
KIRP	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg17425144	chr1:10567563	PEX14	-0.31	-5.41	-0.33	1.49e-7	Hepatocellular carcinoma;
KIRP	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-4.99	-0.3	1.15e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6977660	0.714	rs6945297	chr7:19814029	A/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.28	0.32	2.86e-7	Thyroid stimulating hormone;
KIRP	cis	rs11955175	1.000	rs2228058	chr5:40681254	C/T	cg04002187	chr5:40835754	RPL37	0.71	5.54	0.33	7.82e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.78	-13.2	-0.64	1.96e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs7180079	0.544	rs8038016	chr15:64995737	C/T	cg15337035	chr15:64978493	NA	-0.5	-5.47	-0.33	1.11e-7	Monocyte count;
KIRP	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg02733842	chr7:1102375	C7orf50	0.41	4.91	0.3	1.69e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg04238871	chr10:126431886	FAM53B	0.72	7.49	0.43	1.24e-12	Lung function (FEV1);
KIRP	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26207909	chr14:103986467	CKB	0.76	11.48	0.59	1.06e-24	Body mass index;
KIRP	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08158076	chr1:90287038	LRRC8D	0.47	6.1	0.36	4.05e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.69	0.53	4.95e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg15038512	chr6:170123185	PHF10	0.46	5.15	0.31	5.44e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	0.45	6.13	0.36	3.47e-9	Renal function-related traits (BUN);
KIRP	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13198984	chr17:80129470	CCDC57	0.57	8.63	0.48	8e-16	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg08662619	chr6:150070041	PCMT1	0.36	5.96	0.36	8.48e-9	Lung cancer;
KIRP	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.42	-5.95	-0.35	9.32e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg15790184	chr11:494944	RNH1	0.42	5.2	0.31	4.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg11031976	chr2:198649780	BOLL	-0.52	-4.99	-0.3	1.15e-6	Ulcerative colitis;
KIRP	cis	rs151997	0.671	rs395557	chr5:50215832	G/T	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.73	-9.95	-0.54	7.87e-20	Hypospadias;
KIRP	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg24296786	chr1:45957014	TESK2	-0.42	-5.27	-0.32	2.93e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.7	9.39	0.51	4.14e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.22	-0.32	3.89e-7	Parkinson's disease;
KIRP	cis	rs2839619	0.901	rs1571741	chr21:44433681	A/G	cg20154816	chr21:44412511	PKNOX1	-0.29	-4.94	-0.3	1.46e-6	Biochemical measures;
KIRP	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.69	-8.3	-0.47	7.16e-15	Gut microbiome composition (summer);
KIRP	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.68	-5.87	-0.35	1.42e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs494562	0.892	rs547963	chr6:86118743	T/C	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-33.76	-0.91	2.58e-94	Myeloid white cell count;
KIRP	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.23	-0.42	5.9e-12	Type 2 diabetes;
KIRP	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg06742321	chr12:123595122	PITPNM2	0.41	5.02	0.3	9.97e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.81	-11.91	-0.6	3.99e-26	Urate levels in lean individuals;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11997175	0.902	rs7462140	chr8:33717880	A/G	ch.8.33884649F	chr8:33765107	NA	0.44	5.29	0.32	2.67e-7	Body mass index;
KIRP	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.29	0.42	4.13e-12	Retinal vascular caliber;
KIRP	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11169552	0.510	rs10876073	chr12:51025910	T/A	cg12884762	chr12:50931848	DIP2B	-0.41	-4.9	-0.3	1.73e-6	Colorectal cancer;
KIRP	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg03060546	chr3:49711283	APEH	0.46	5.89	0.35	1.24e-8	Parkinson's disease;
KIRP	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	0.94	15.52	0.7	2.46e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.79	9.94	0.54	8.37e-20	Corneal astigmatism;
KIRP	cis	rs988913	1.000	rs960834	chr6:54823431	C/T	cg03513858	chr6:54763001	FAM83B	-0.39	-5.37	-0.32	1.81e-7	Menarche (age at onset);
KIRP	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.79	-11.57	-0.59	5.34e-25	Caffeine consumption;
KIRP	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-10.36	-0.55	4.12e-21	Coffee consumption (cups per day);
KIRP	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.8	13.07	0.64	5.47e-30	Brugada syndrome;
KIRP	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg00405596	chr8:11794950	NA	0.47	5.95	0.35	9e-9	Retinal vascular caliber;
KIRP	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg01941274	chr14:50234650	KLHDC2	0.4	4.99	0.3	1.12e-6	Carotid intima media thickness;
KIRP	cis	rs4774899	0.966	rs1814585	chr15:57509058	A/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.04	-0.31	8.88e-7	Urinary tract infection frequency;
KIRP	cis	rs9815354	0.812	rs73075234	chr3:42051801	G/A	cg03022575	chr3:42003672	ULK4	0.73	7.59	0.44	6.65e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.54	-6.94	-0.4	3.48e-11	Eye color traits;
KIRP	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00166722	chr3:10149974	C3orf24	0.48	4.88	0.3	1.92e-6	Alzheimer's disease;
KIRP	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg24315340	chr6:146058215	EPM2A	-0.39	-4.98	-0.3	1.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.11e-7	Breast cancer;
KIRP	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg21433313	chr16:3507492	NAT15	0.57	7.93	0.45	7.51e-14	Tuberculosis;
KIRP	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06634786	chr22:41940651	POLR3H	-0.45	-5.44	-0.33	1.28e-7	Vitiligo;
KIRP	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg04306507	chr14:55594613	LGALS3	0.52	8.31	0.47	6.47e-15	Protein biomarker;
KIRP	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg24315340	chr6:146058215	EPM2A	-0.37	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2299587	0.560	rs12718385	chr8:17781257	T/C	cg01800426	chr8:17659068	MTUS1	-0.63	-7.56	-0.43	7.93e-13	Economic and political preferences;
KIRP	cis	rs909341	0.818	rs67468102	chr20:62344883	G/C	cg11503966	chr20:62272292	STMN3	-0.43	-6.1	-0.36	4.03e-9	Atopic dermatitis;
KIRP	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg23649088	chr2:200775458	C2orf69	-0.57	-4.96	-0.3	1.31e-6	Schizophrenia;
KIRP	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg20749741	chr2:264178	ACP1;SH3YL1	0.47	5.11	0.31	6.6e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.93	-0.4	3.56e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg20701182	chr2:24300061	SF3B14	0.53	5.25	0.32	3.25e-7	Lymphocyte counts;
KIRP	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg21252483	chr19:49399788	TULP2	-0.48	-6.23	-0.37	2.02e-9	Red cell distribution width;
KIRP	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.95	0.35	9.03e-9	Total cholesterol levels;
KIRP	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg10223061	chr2:219282414	VIL1	0.42	6.74	0.4	1.09e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg10645314	chr2:3704589	ALLC	0.58	6.41	0.38	7.38e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg02569458	chr12:86230093	RASSF9	0.34	4.87	0.3	1.97e-6	Major depressive disorder;
KIRP	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg11344533	chr11:111475393	SIK2	-0.29	-4.9	-0.3	1.74e-6	Primary sclerosing cholangitis;
KIRP	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.41	-5.12	-0.31	6.18e-7	Pubertal anthropometrics;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg24209194	chr3:40518798	ZNF619	0.41	5.31	0.32	2.45e-7	Renal cell carcinoma;
KIRP	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg02820901	chr13:113351484	ATP11A	0.72	6.43	0.38	6.47e-10	Glycated hemoglobin levels;
KIRP	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.83	13.39	0.65	4.57e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.41	-6.25	-0.37	1.79e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.68	-6.31	-0.37	1.29e-9	Menarche (age at onset);
KIRP	cis	rs9400467	0.506	rs78051065	chr6:111600406	A/G	cg15721981	chr6:111408429	SLC16A10	0.75	6.87	0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.5	6.97	0.41	2.92e-11	Dupuytren's disease;
KIRP	cis	rs4663866	1.000	rs4663300	chr2:239181491	T/C	cg17283117	chr2:239148619	HES6	0.68	4.96	0.3	1.3e-6	Irritable bowel syndrome;
KIRP	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	13.99	0.67	4.16e-33	Smoking behavior;
KIRP	cis	rs7932354	0.655	rs6485690	chr11:46798631	A/G	cg16389345	chr11:46697382	NA	0.41	5.15	0.31	5.24e-7	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs11593576	0.861	rs11002892	chr10:81011589	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.35	-5.1	-0.31	6.69e-7	Vitiligo;
KIRP	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg18225595	chr11:63971243	STIP1	0.67	6.08	0.36	4.47e-9	Mean platelet volume;
KIRP	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.37	-0.43	2.63e-12	Neuroticism;
KIRP	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg10402321	chr1:26617780	UBXN11	-0.41	-5.21	-0.32	4.07e-7	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.6	7.51	0.43	1.1e-12	Coronary artery disease;
KIRP	cis	rs16857609	0.564	rs12232972	chr2:218257272	C/T	cg15335768	chr2:218268053	DIRC3	-0.52	-6.68	-0.39	1.61e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.9	16.33	0.72	4.29e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02467765	chr4:78978708	FRAS1	0.58	6.96	0.41	3.12e-11	Smoking initiation;
KIRP	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg07541023	chr7:19748670	TWISTNB	0.63	6.29	0.37	1.43e-9	Thyroid stimulating hormone;
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg07701084	chr6:150067640	NUP43	0.73	10.08	0.54	3.17e-20	Lung cancer;
KIRP	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs7246657	0.765	rs4803262	chr19:38066760	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07840538	chr7:99097998	ZNF394	0.54	6.36	0.38	9.71e-10	Smoking initiation;
KIRP	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.3	1e-6	Initial pursuit acceleration;
KIRP	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg01631408	chr1:248437212	OR2T33	-0.37	-5.14	-0.31	5.6e-7	Common traits (Other);
KIRP	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.5	-7.42	-0.43	1.91e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg12647257	chr2:47043387	NA	0.37	5.11	0.31	6.58e-7	Height;
KIRP	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.48	-11.34	-0.59	2.93e-24	Diabetic kidney disease;
KIRP	cis	rs28489187	0.597	rs10489513	chr1:85855622	C/T	cg16011679	chr1:85725395	C1orf52	-0.44	-5.48	-0.33	1.06e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.44	-6.47	-0.38	5.19e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.7	9.3	0.51	8.09e-18	Eye color traits;
KIRP	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.74	10.56	0.56	9.35e-22	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs76793172	1.000	rs77461667	chr19:46341177	G/A	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.26	-0.37	1.69e-9	Eosinophil counts;
KIRP	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.19	0.51	1.71e-17	Multiple sclerosis;
KIRP	cis	rs6142102	0.961	rs6088360	chr20:32557189	A/G	cg08999081	chr20:33150536	PIGU	0.5	5.95	0.35	9.03e-9	Skin pigmentation;
KIRP	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg07777115	chr5:623756	CEP72	0.57	5.93	0.35	1e-8	Obesity-related traits;
KIRP	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.86	-11.47	-0.59	1.09e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2273669	0.667	rs12206423	chr6:109353216	C/T	cg05315195	chr6:109294784	ARMC2	-0.67	-6.55	-0.39	3.27e-10	Prostate cancer;
KIRP	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	20.42	0.79	6.87e-55	Prudent dietary pattern;
KIRP	cis	rs4073221	0.654	rs67595197	chr3:18296884	A/G	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	trans	rs488628	0.518	rs16828183	chr3:118003640	G/T	cg20873327	chr2:241371545	NA	0.42	6.34	0.37	1.07e-9	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg03060546	chr3:49711283	APEH	0.44	5.67	0.34	3.89e-8	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.41	-0.51	3.79e-18	Body mass index;
KIRP	cis	rs60311166	1.000	rs72960212	chr3:52720489	T/A	cg13174197	chr3:52720522	GNL3;PBRM1	1.0	7.06	0.41	1.65e-11	CTACK levels;
KIRP	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg04935436	chr20:30431758	NA	0.56	6.86	0.4	5.47e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg08885800	chr1:201084119	NA	0.36	4.99	0.3	1.13e-6	Permanent tooth development;
KIRP	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg06307176	chr5:131281290	NA	0.53	5.79	0.35	2.14e-8	Life satisfaction;
KIRP	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.66	-9.52	-0.52	1.73e-18	Retinal vascular caliber;
KIRP	cis	rs61823972	0.510	rs11240351	chr1:205044339	C/T	cg00857998	chr1:205179979	DSTYK	0.51	6.72	0.39	1.23e-10	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
KIRP	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg10495392	chr1:46806563	NSUN4	0.45	4.96	0.3	1.34e-6	Menopause (age at onset);
KIRP	cis	rs732716	0.785	rs11085073	chr19:4375162	A/G	cg19820705	chr19:4455316	UBXN6	-0.62	-7.37	-0.43	2.66e-12	Mean corpuscular volume;
KIRP	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.38	-4.87	-0.3	1.99e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg08648136	chr8:956695	NA	0.41	5.58	0.34	6.37e-8	Schizophrenia;
KIRP	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.73	9.32	0.51	7.11e-18	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg03929089	chr4:120376271	NA	0.7	6.28	0.37	1.5e-9	Axial length;
KIRP	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg05347473	chr6:146136440	FBXO30	0.41	5.66	0.34	4.2e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.28	0.37	1.56e-9	Rheumatoid arthritis;
KIRP	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.67	-9.7	-0.53	4.75e-19	Schizophrenia;
KIRP	cis	rs258892	0.846	rs266441	chr5:72197677	A/G	cg21869765	chr5:72125136	TNPO1	0.57	6.25	0.37	1.78e-9	Small cell lung carcinoma;
KIRP	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.36	-6.27	-0.37	1.57e-9	Cystic fibrosis severity;
KIRP	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.66	9.63	0.52	7.87e-19	Dupuytren's disease;
KIRP	cis	rs3126085	0.515	rs12032854	chr1:152347361	G/A	cg26876637	chr1:152193138	HRNR	-0.59	-7.18	-0.42	8.12e-12	Atopic dermatitis;
KIRP	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg05692746	chr2:100937584	LONRF2	-0.46	-5.41	-0.33	1.51e-7	Educational attainment;
KIRP	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.25	-0.47	9.42e-15	Lung cancer;
KIRP	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg14580859	chr9:123691850	NA	0.35	4.96	0.3	1.29e-6	Rheumatoid arthritis;
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-8.76	-0.49	3.33e-16	Lymphocyte counts;
KIRP	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg23594656	chr7:65796392	TPST1	0.45	7.12	0.41	1.18e-11	Aortic root size;
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	12.42	0.62	8.13e-28	Platelet count;
KIRP	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.59	8.22	0.46	1.19e-14	Lewy body disease;
KIRP	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08822215	chr16:89438651	ANKRD11	-0.43	-5.89	-0.35	1.28e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	8.45	0.47	2.64e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg13010199	chr12:38710504	ALG10B	0.61	7.6	0.44	6.08e-13	Morning vs. evening chronotype;
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.28	-0.32	2.9e-7	Obesity-related traits;
KIRP	cis	rs698833	0.852	rs698823	chr2:44720947	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	4.96	0.3	1.3e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs6601327	0.635	rs7844461	chr8:9653055	T/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.4	0.43	2.11e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	11.15	0.58	1.2e-23	Lung cancer in ever smokers;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08642814	chr1:3734907	KIAA0562	0.57	6.38	0.38	8.86e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6496667	0.779	rs16944518	chr15:91035084	A/C	cg10434728	chr15:90938212	IQGAP1	0.38	5.18	0.31	4.59e-7	Rheumatoid arthritis;
KIRP	cis	rs7582720	1.000	rs115400054	chr2:203676105	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	9.63	0.52	7.63e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg03315344	chr16:75512273	CHST6	0.54	5.21	0.31	4.08e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs33912345	0.750	rs1254331	chr14:60916237	A/G	cg27398547	chr14:60952738	C14orf39	-0.38	-5.01	-0.3	1.06e-6	Glaucoma (high intraocular pressure);
KIRP	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg21605333	chr4:119757512	SEC24D	1.56	10.58	0.56	8.15e-22	Cannabis dependence symptom count;
KIRP	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg03465714	chr1:152285911	FLG	-0.41	-4.91	-0.3	1.65e-6	Atopic dermatitis;
KIRP	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.51	6.23	0.37	1.98e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.81	8.15	0.46	1.8e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.46	-10.39	-0.55	3.23e-21	Alzheimer's disease (late onset);
KIRP	cis	rs6723108	0.678	rs638382	chr2:135288740	T/C	cg12500956	chr2:135428796	TMEM163	0.43	5.35	0.32	2.01e-7	Type 2 diabetes;
KIRP	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.8	-0.4	7.92e-11	Coronary artery disease;
KIRP	cis	rs909341	0.868	rs1291206	chr20:62329169	G/A	cg03999872	chr20:62272968	STMN3	-0.56	-6.52	-0.38	3.89e-10	Atopic dermatitis;
KIRP	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	cis	rs240764	0.782	rs239235	chr6:101100528	A/G	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg04132472	chr17:19861366	AKAP10	-0.4	-5.17	-0.31	4.81e-7	Schizophrenia;
KIRP	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg13482628	chr17:19912719	NA	0.61	8.69	0.48	5.18e-16	Schizophrenia;
KIRP	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg16497661	chr14:103986332	CKB	-0.65	-7.24	-0.42	5.6e-12	Bone mineral density;
KIRP	cis	rs11583043	0.708	rs3861735	chr1:101530191	C/A	cg17443007	chr1:101659419	NA	0.37	5.08	0.31	7.45e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17453880	0.853	rs10476785	chr5:151973924	A/G	cg12297329	chr5:152029980	NA	-0.68	-10.17	-0.54	1.71e-20	Subjective well-being;
KIRP	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg00806126	chr19:22604979	ZNF98	-0.67	-7.11	-0.41	1.24e-11	Pain;
KIRP	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.96	-13.78	-0.66	2.04e-32	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg00204512	chr16:28754710	NA	0.49	6.5	0.38	4.54e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg02931644	chr1:25747376	RHCE	-0.37	-6.72	-0.39	1.24e-10	Erythrocyte sedimentation rate;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09372778	chr14:24702290	GMPR2;NEDD8	0.69	6.66	0.39	1.79e-10	Lung function (FEV1);
KIRP	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg00631329	chr6:26305371	NA	-0.7	-8.79	-0.49	2.67e-16	Educational attainment;
KIRP	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.18	-19.05	-0.77	2.48e-50	Ulcerative colitis;
KIRP	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.65	-9.09	-0.5	3.37e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg04287289	chr16:89883240	FANCA	-0.42	-5.39	-0.33	1.62e-7	Vitiligo;
KIRP	cis	rs2742417	1.000	rs2673036	chr3:45752471	C/T	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg25173405	chr17:45401733	C17orf57	-0.5	-6.38	-0.38	8.83e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	0.72	6.84	0.4	6.42e-11	Methadone dose in opioid dependence;
KIRP	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.43	0.47	2.86e-15	Motion sickness;
KIRP	cis	rs11785693	0.862	rs10503292	chr8:4992275	A/G	cg26367366	chr8:4980734	NA	0.67	7.33	0.42	3.25e-12	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs7707921	0.752	rs2897554	chr5:81276241	C/T	cg15871215	chr5:81402204	ATG10	0.45	5.69	0.34	3.56e-8	Breast cancer;
KIRP	cis	rs7113874	0.959	rs11042017	chr11:8649691	C/G	cg08015107	chr11:8618950	NA	0.35	4.96	0.3	1.29e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg09676129	chr20:60540388	NA	-0.34	-4.91	-0.3	1.63e-6	Body mass index;
KIRP	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg00579200	chr11:133705235	NA	-0.42	-5.6	-0.34	5.59e-8	Childhood ear infection;
KIRP	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg13165212	chr22:42675999	NA	0.39	6.46	0.38	5.5e-10	Cognitive function;
KIRP	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg00149659	chr3:10157352	C3orf10	0.77	6.28	0.37	1.56e-9	Alzheimer's disease;
KIRP	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.17	-16.12	-0.72	2.23e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs975752	0.717	rs7916126	chr10:102007373	T/C	cg13817732	chr10:102046368	BLOC1S2	0.71	5.98	0.36	7.85e-9	Schizophrenia;
KIRP	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.56	6.99	0.41	2.64e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg13010199	chr12:38710504	ALG10B	-0.56	-7.07	-0.41	1.6e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg26149184	chr10:133730230	NA	0.43	5.1	0.31	6.89e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg18016565	chr1:150552671	MCL1	0.38	5.49	0.33	9.79e-8	Melanoma;
KIRP	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00321850	chr1:175162397	KIAA0040	0.36	6.49	0.38	4.66e-10	Alcohol dependence;
KIRP	cis	rs7727544	0.564	rs3852206	chr5:131415436	G/A	cg07395648	chr5:131743802	NA	-0.39	-5.24	-0.32	3.48e-7	Blood metabolite levels;
KIRP	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.33	-4.95	-0.3	1.39e-6	Monocyte count;
KIRP	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg27490568	chr2:178487706	NA	0.61	8.39	0.47	3.75e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.66	-8.26	-0.47	8.75e-15	Type 1 diabetes;
KIRP	trans	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg06521331	chr12:34319734	NA	-0.55	-6.76	-0.4	9.96e-11	Heart rate;
KIRP	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg21573476	chr21:45109991	RRP1B	0.56	7.51	0.43	1.07e-12	Mean corpuscular volume;
KIRP	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.54	5.95	0.35	9.27e-9	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02214595	chr16:67143798	C16orf70	0.42	6.09	0.36	4.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg19000871	chr14:103996768	TRMT61A	0.43	5.15	0.31	5.46e-7	Reticulocyte count;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg23664318	chr19:36630914	CAPNS1	-0.46	-6.25	-0.37	1.76e-9	Morning vs. evening chronotype;
KIRP	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04509940	chr21:45079326	HSF2BP;RRP1B	0.56	7.16	0.42	9.16e-12	Parkinson's disease;
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg11814155	chr7:99998594	ZCWPW1	0.56	5.35	0.32	1.98e-7	Platelet count;
KIRP	cis	rs963731	0.649	rs12620071	chr2:39345873	G/A	cg04010122	chr2:39346883	SOS1	0.93	6.39	0.38	8.09e-10	Corticobasal degeneration;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09028215	chr2:67624308	ETAA1	0.47	6.34	0.37	1.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs13170463	0.579	rs17268677	chr5:8034540	A/G	cg03862380	chr20:43029895	HNF4A	-0.41	-6.61	-0.39	2.34e-10	Colorectal cancer;
KIRP	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.83	-10.22	-0.55	1.15e-20	Blood protein levels;
KIRP	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg03808351	chr9:123631620	PHF19	0.43	5.98	0.36	7.62e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.64	-8.46	-0.47	2.36e-15	Metabolic syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26299089	chr14:65171029	PLEKHG3	0.48	6.2	0.37	2.39e-9	Parkinson's disease;
KIRP	cis	rs9549260	0.712	rs1334241	chr13:41223110	C/T	cg21288729	chr13:41239152	FOXO1	0.49	4.94	0.3	1.45e-6	Red blood cell count;
KIRP	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg16497661	chr14:103986332	CKB	0.38	4.91	0.3	1.69e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.83	11.75	0.6	1.32e-25	Total body bone mineral density;
KIRP	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg12131826	chr15:77904385	NA	-0.5	-6.28	-0.37	1.55e-9	Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	9.88	0.53	1.32e-19	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12631766	chr1:184025029	TSEN15	-0.45	-7.25	-0.42	5.49e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.42	0.38	6.82e-10	Retinal vascular caliber;
KIRP	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.54	6.09	0.36	4.21e-9	Blood metabolite levels;
KIRP	cis	rs7180079	0.620	rs6494493	chr15:65041622	C/A	cg15337035	chr15:64978493	NA	-0.47	-5.09	-0.31	7.19e-7	Monocyte count;
KIRP	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.61	-7.61	-0.44	5.69e-13	Neuroticism;
KIRP	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.88	0.35	1.32e-8	Motion sickness;
KIRP	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg26248373	chr2:1572462	NA	-0.62	-5.83	-0.35	1.73e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg12856521	chr11:46389249	DGKZ	0.56	7.35	0.42	3e-12	Crohn's disease;
KIRP	cis	rs9473924	0.505	rs9473921	chr6:50828072	C/T	cg14470998	chr6:50812995	TFAP2B	0.82	7.51	0.43	1.11e-12	Body mass index;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg00738919	chr7:1100172	C7orf50	0.43	5.06	0.31	8.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.3	6.1	0.36	4.07e-9	Schizophrenia;
KIRP	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg15507776	chr3:136538369	TMEM22	0.39	5.29	0.32	2.69e-7	Neuroticism;
KIRP	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.78	-11.29	-0.58	4.2e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg02807482	chr3:125708958	NA	-0.53	-4.98	-0.3	1.19e-6	Blood pressure (smoking interaction);
KIRP	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg13010199	chr12:38710504	ALG10B	0.54	7.41	0.43	1.99e-12	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00920043	chr1:11333412	UBIAD1	0.69	6.34	0.37	1.08e-9	Lung function (FEV1);
KIRP	cis	rs920590	0.560	rs10090638	chr8:19673750	T/G	cg03894339	chr8:19674705	INTS10	-0.42	-4.87	-0.3	2.01e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9467160	0.532	rs2744565	chr6:24458461	G/T	cg20631270	chr6:24437470	GPLD1	-0.43	-5.26	-0.32	3.07e-7	Liver enzyme levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10661629	chr19:2900748	ZNF57	0.46	6.19	0.37	2.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2074977	0.530	rs10401784	chr19:3445721	A/C	cg08380311	chr19:3435252	NFIC	0.45	5.44	0.33	1.31e-7	Height;
KIRP	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.48	-6.18	-0.37	2.64e-9	Schizophrenia;
KIRP	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs11634397	0.513	rs12440875	chr15:80370872	T/C	cg08257866	chr15:80351198	ZFAND6	0.52	5.48	0.33	1.06e-7	Type 2 diabetes;
KIRP	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.76	8.38	0.47	4.05e-15	Diastolic blood pressure;
KIRP	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg02404636	chr22:31891804	SFI1	-0.5	-5.19	-0.31	4.33e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg07701084	chr6:150067640	NUP43	0.61	6.51	0.38	4.09e-10	Lung cancer;
KIRP	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg14580859	chr9:123691850	NA	0.35	4.9	0.3	1.74e-6	Rheumatoid arthritis;
KIRP	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.02	0.64	7.74e-30	Bladder cancer;
KIRP	cis	rs2742417	1.000	rs2742431	chr3:45737121	C/G	cg04037228	chr3:45636386	LIMD1	-0.35	-5.13	-0.31	5.94e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.67	-10.24	-0.55	1.02e-20	Urate levels in overweight individuals;
KIRP	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-7.67	-0.44	4.09e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2594989	1.000	rs2594993	chr3:11360744	C/T	cg01796438	chr3:11312864	ATG7	-0.69	-7.86	-0.45	1.18e-13	Circulating chemerin levels;
KIRP	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	1.04	15.17	0.7	3.95e-37	Height;
KIRP	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg16141378	chr3:129829833	LOC729375	0.51	6.4	0.38	7.91e-10	Joint mobility (Beighton score);
KIRP	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.65	9.63	0.52	7.86e-19	Schizophrenia;
KIRP	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	5.08	0.31	7.57e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs5753037	0.835	rs737908	chr22:30388302	G/A	cg01021169	chr22:30184971	ASCC2	-0.39	-5.11	-0.31	6.51e-7	Type 1 diabetes;
KIRP	cis	rs6577655	0.517	rs4909295	chr8:135588042	G/A	cg17885191	chr8:135476712	NA	0.66	6.46	0.38	5.5e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg10189261	chr14:101176105	NA	-0.47	-6.67	-0.39	1.7e-10	Platelet count;
KIRP	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.48	-0.43	1.33e-12	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg13385521	chr17:29058706	SUZ12P	-0.52	-5.03	-0.31	9.44e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg06627628	chr2:24431161	ITSN2	0.46	5.61	0.34	5.31e-8	Asthma;
KIRP	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.67e-19	Prudent dietary pattern;
KIRP	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-16.2	-0.72	1.17e-40	Height;
KIRP	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.06	23.77	0.83	1.16e-65	Multiple myeloma;
KIRP	cis	rs7011049	1.000	rs72643576	chr8:53845016	A/T	cg26025543	chr8:53854495	NA	0.75	7.67	0.44	4.02e-13	Systolic blood pressure;
KIRP	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.06	22.02	0.81	4.34e-60	Myeloid white cell count;
KIRP	cis	rs2929278	0.589	rs2411284	chr15:44038899	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-6.88	-0.4	4.9e-11	Schizophrenia;
KIRP	cis	rs17453880	0.929	rs7715495	chr5:152048107	T/G	cg12297329	chr5:152029980	NA	-0.71	-10.54	-0.56	1.11e-21	Subjective well-being;
KIRP	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg03171003	chr2:111875934	NA	0.44	6.23	0.37	1.97e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg24011408	chr12:48396354	COL2A1	0.43	6.12	0.36	3.62e-9	Plateletcrit;
KIRP	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.89	13.16	0.64	2.69e-30	Coronary artery disease;
KIRP	cis	rs914615	0.552	rs12752585	chr1:155135406	G/A	cg02153340	chr1:155202674	NA	-0.47	-7.04	-0.41	1.95e-11	Urinary albumin-to-creatinine ratio;
KIRP	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	1.03	11.64	0.6	3.03e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	5.69	0.34	3.66e-8	Mean platelet volume;
KIRP	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg15234197	chr11:68924956	NA	0.34	4.92	0.3	1.59e-6	Blond vs. brown hair color;
KIRP	cis	rs4466137	0.868	rs6866067	chr5:83022369	A/G	cg15083037	chr5:83017644	HAPLN1	-0.58	-8.53	-0.48	1.47e-15	Prostate cancer;
KIRP	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.19	-0.31	4.36e-7	Metabolite levels;
KIRP	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-6.21	-0.37	2.25e-9	Breast cancer;
KIRP	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs2278796	0.639	rs6697344	chr1:204971485	G/T	cg17947172	chr1:204966197	NFASC	0.62	8.28	0.47	7.85e-15	Mean platelet volume;
KIRP	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.26	0.51	1.03e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8177876	0.822	rs16954582	chr16:81114157	C/T	cg08591886	chr16:81111003	C16orf46	-0.53	-5.3	-0.32	2.58e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg18877969	chr2:232395326	NMUR1	-0.37	-5.37	-0.32	1.79e-7	Height;
KIRP	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-0.81	-8.88	-0.49	1.39e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg02297831	chr4:17616191	MED28	-0.47	-5.85	-0.35	1.57e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.82	9.9	0.53	1.11e-19	Corneal astigmatism;
KIRP	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.33	-0.37	1.12e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg26022315	chr17:47021804	SNF8	0.42	5.41	0.33	1.47e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.52	-6.89	-0.4	4.73e-11	Aortic root size;
KIRP	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11622362	chr11:34938112	PDHX;APIP	0.43	5.23	0.32	3.6e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	ch.1.3259774R	chr1:166827647	TADA1	-0.42	-4.98	-0.3	1.19e-6	Refractive astigmatism;
KIRP	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.61	-6.32	-0.37	1.21e-9	DNA methylation (variation);
KIRP	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.57	-7.09	-0.41	1.42e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6681460	0.966	rs9659879	chr1:67121434	T/C	cg02459107	chr1:67143332	SGIP1	0.49	6.99	0.41	2.64e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6662572	0.737	rs9429093	chr1:46555252	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.49	0.33	9.8e-8	Blood protein levels;
KIRP	trans	rs909341	0.909	rs2253823	chr20:62372956	C/T	cg01311341	chr22:25575246	KIAA1671	-0.59	-6.73	-0.39	1.15e-10	Atopic dermatitis;
KIRP	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg01304814	chr3:48885189	PRKAR2A	0.76	5.72	0.34	3.09e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.25e-11	Diabetic kidney disease;
KIRP	cis	rs7870753	0.783	rs1885427	chr9:99188248	A/G	cg25260653	chr9:99212216	HABP4	0.53	5.87	0.35	1.39e-8	Height;
KIRP	cis	rs10267417	0.603	rs10258214	chr7:19911906	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.73	8.3	0.47	6.84e-15	Gestational age at birth (maternal effect);
KIRP	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.72	-9.96	-0.54	7.61e-20	Late-onset Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18559136	chr18:33767393	MOCOS	0.53	7.11	0.41	1.29e-11	Parkinson's disease;
KIRP	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg26065057	chr18:74961000	GALR1	-0.63	-6.79	-0.4	8.58e-11	Obesity-related traits;
KIRP	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg19404215	chr3:33155277	CRTAP	0.68	5.1	0.31	6.87e-7	Major depressive disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01753966	chr4:3531945	LRPAP1	-0.43	-6.1	-0.36	4.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg02023728	chr11:77925099	USP35	0.33	5.33	0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs35883536	0.967	rs1981134	chr1:101111205	G/T	cg06223162	chr1:101003688	GPR88	-0.34	-6.87	-0.4	5.08e-11	Monocyte count;
KIRP	cis	rs2274273	0.624	rs11158034	chr14:55753560	C/T	cg04306507	chr14:55594613	LGALS3	0.39	5.41	0.33	1.49e-7	Protein biomarker;
KIRP	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.49	-5.47	-0.33	1.1e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.56	6.54	0.38	3.62e-10	Height;
KIRP	cis	rs71277158	0.688	rs7631178	chr3:169766424	G/T	cg04067573	chr3:169899625	PHC3	-0.58	-5.43	-0.33	1.37e-7	Prostate cancer;
KIRP	cis	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg02795151	chr17:7402630	POLR2A	0.78	8.03	0.46	4.11e-14	Androgen levels;
KIRP	cis	rs2281603	0.951	rs10133411	chr14:64988924	T/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	10.63	0.56	5.98e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	9.72	0.53	4.27e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6450176	0.909	rs1541681	chr5:53304620	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.24	-0.58	6.06e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.71	-0.34	3.22e-8	IgG glycosylation;
KIRP	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06481639	chr22:41940642	POLR3H	-0.49	-5.4	-0.33	1.55e-7	Vitiligo;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03647317	chr4:187891568	NA	-0.78	-13.63	-0.66	6.68e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.79	-12.86	-0.63	2.76e-29	Heart rate;
KIRP	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	6.92	0.4	3.9e-11	Coronary artery disease;
KIRP	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.6	-6.69	-0.39	1.48e-10	Recalcitrant atopic dermatitis;
KIRP	cis	rs4345220	0.585	rs4861125	chr4:41642969	T/G	cg15232654	chr4:41643107	LIMCH1	0.44	5.77	0.35	2.35e-8	Migraine with aura;
KIRP	cis	rs1076160	0.846	rs4962218	chr9:135707843	G/A	cg04648087	chr9:135819397	TSC1	-0.39	-4.85	-0.3	2.21e-6	Psoriasis;
KIRP	cis	rs16828019	0.850	rs12027691	chr1:41462032	C/T	cg24596898	chr1:41849189	NA	0.64	4.93	0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	cg21523751	chr1:182988639	NA	0.41	6.32	0.37	1.22e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg21926883	chr2:100939477	LONRF2	0.54	7.14	0.41	1.03e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg04989706	chr14:50066350	PPIL5	-0.5	-6.17	-0.37	2.75e-9	Carotid intima media thickness;
KIRP	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg04310649	chr10:35416472	CREM	-0.59	-6.97	-0.41	2.95e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg02794779	chr13:100150711	NA	0.42	4.86	0.3	2.08e-6	Obesity-related traits;
KIRP	trans	rs353116	0.697	rs353121	chr2:166129323	A/G	cg23361659	chr2:28914775	NA	0.33	6.39	0.38	8.43e-10	Parkinson's disease;
KIRP	cis	rs6142102	0.625	rs1883706	chr20:32552877	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs73058052	0.569	rs10417980	chr19:50101713	T/C	cg13432900	chr19:49999314	RPS11	0.39	4.88	0.3	1.89e-6	Fibrinogen levels;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg16214573	chr11:120081755	OAF	0.53	6.13	0.36	3.56e-9	Plasma plasminogen activator levels;
KIRP	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg21523564	chr15:75251491	NA	-0.35	-6.02	-0.36	6.16e-9	Caffeine consumption;
KIRP	cis	rs1629083	0.738	rs619250	chr11:118064582	A/T	cg18857871	chr11:118064634	AMICA1	0.74	10.5	0.56	1.55e-21	Lung cancer;
KIRP	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.97	14.61	0.68	3.07e-35	Sudden cardiac arrest;
KIRP	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg04132472	chr17:19861366	AKAP10	0.42	5.68	0.34	3.72e-8	Schizophrenia;
KIRP	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12311346	chr5:56204834	C5orf35	-0.37	-4.9	-0.3	1.71e-6	Coronary artery disease;
KIRP	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-5.44	-0.33	1.3e-7	Aortic root size;
KIRP	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.59	5.96	0.36	8.8e-9	Vitiligo;
KIRP	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg03171003	chr2:111875934	NA	0.4	5.73	0.34	2.85e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs78545713	0.502	rs57145038	chr6:26311510	A/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.66	-5.69	-0.34	3.61e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00300879	chr1:26503847	CNKSR1	0.46	6.46	0.38	5.57e-10	Height;
KIRP	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs16828019	0.852	rs10489520	chr1:41511755	C/A	cg03387723	chr1:41708464	SCMH1	-0.78	-6.48	-0.38	5.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7712401	0.601	rs415534	chr5:122325301	C/T	cg19412675	chr5:122181750	SNX24	-0.51	-5.59	-0.34	6.07e-8	Mean platelet volume;
KIRP	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.52	6.29	0.37	1.48e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	cg21523751	chr1:182988639	NA	0.42	6.43	0.38	6.44e-10	Colorectal cancer;
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.46	0.7	4.07e-38	Platelet count;
KIRP	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg05315796	chr3:52349193	DNAH1	0.4	5.83	0.35	1.72e-8	Bipolar disorder;
KIRP	cis	rs629922	1.000	rs499878	chr11:114067550	A/G	cg25009965	chr11:114031120	ZBTB16	0.41	5.45	0.33	1.25e-7	Paneth cell defects in Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13544758	chr6:35889047	SRPK1	0.52	7.02	0.41	2.13e-11	Parkinson's disease;
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.62	8.3	0.47	6.86e-15	Longevity;Endometriosis;
KIRP	cis	rs6142102	0.961	rs4911392	chr20:32570518	G/C	cg08999081	chr20:33150536	PIGU	0.49	6.37	0.38	8.99e-10	Skin pigmentation;
KIRP	cis	rs6738485	0.588	rs12712247	chr2:106849382	C/T	cg16099169	chr2:106886729	NA	-0.43	-6.46	-0.38	5.41e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg11038491	chr20:34638489	LOC647979	-0.7	-7.59	-0.44	6.48e-13	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs77688320	0.553	rs2540432	chr2:202364894	T/C	cg06431681	chr2:202330990	STRADB	-0.44	-5.17	-0.31	4.84e-7	Breast cancer;
KIRP	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.93	-11.0	-0.57	3.65e-23	White matter hyperintensity burden;
KIRP	cis	rs9815354	0.812	rs12186050	chr3:41836879	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4774899	1.000	rs12911518	chr15:57501494	T/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.26	-0.32	3.09e-7	Urinary tract infection frequency;
KIRP	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg02725872	chr8:58115012	NA	-0.61	-6.3	-0.37	1.4e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	0.99	12.15	0.61	6.24e-27	Corneal structure;
KIRP	trans	rs2531992	1.000	rs2531992	chr16:4021734	A/G	cg09155362	chr15:33487289	NA	-0.59	-7.28	-0.42	4.42e-12	Waist circumference;
KIRP	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg00990874	chr7:1149470	C7orf50	-0.61	-6.27	-0.37	1.57e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.41	-5.11	-0.31	6.55e-7	Multiple sclerosis;
KIRP	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.39	-0.32	1.69e-7	Metabolite levels;
KIRP	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18252515	chr7:66147081	NA	0.47	5.51	0.33	8.92e-8	Aortic root size;
KIRP	cis	rs6496667	0.908	rs8024857	chr15:90854719	T/G	cg10434728	chr15:90938212	IQGAP1	0.38	5.23	0.32	3.67e-7	Rheumatoid arthritis;
KIRP	cis	rs11671005	0.569	rs73068335	chr19:59089308	C/G	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.56	-6.46	-0.38	5.48e-10	Mean platelet volume;
KIRP	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg24542667	chr1:43209606	NA	-0.5	-6.64	-0.39	2e-10	Inflammatory biomarkers;
KIRP	cis	rs10426930	0.607	rs877287	chr19:5041989	G/A	cg18473234	chr19:5097819	KDM4B	0.44	4.99	0.3	1.15e-6	Monocyte percentage of white cells;
KIRP	cis	rs745080	0.698	rs2249925	chr14:52906179	C/T	cg23333723	chr14:53022898	GPR137C	-0.37	-5.17	-0.31	4.86e-7	Orofacial clefts;
KIRP	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21643547	chr1:205240462	TMCC2	-0.72	-11.02	-0.57	3.28e-23	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg02023728	chr11:77925099	USP35	-0.31	-5.52	-0.33	8.62e-8	Alzheimer's disease (survival time);
KIRP	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.38	-0.47	3.97e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg05315796	chr3:52349193	DNAH1	0.44	6.81	0.4	7.64e-11	Bipolar disorder;
KIRP	cis	rs526231	0.511	rs1011453	chr5:102368027	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.2	-0.31	4.26e-7	Primary biliary cholangitis;
KIRP	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-6.76	-0.4	9.94e-11	Body mass index;
KIRP	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg09571762	chr12:39539558	NA	0.37	4.97	0.3	1.26e-6	Heart rate;
KIRP	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	0.78	9.12	0.5	2.78e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.41	5.12	0.31	6.32e-7	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04550367	chr14:101453070	SNORD114-27;SNORD114-26	-0.44	-6.67	-0.39	1.67e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.75	-0.4	1.04e-10	Neuroticism;
KIRP	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg25019033	chr10:957182	NA	-0.71	-9.32	-0.51	6.92e-18	Eosinophil percentage of granulocytes;
KIRP	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.28	-0.32	2.91e-7	Primary biliary cholangitis;
KIRP	trans	rs4305714	0.645	rs6923088	chr6:22933279	A/T	cg16403932	chr12:57881247	MARS	0.5	6.1	0.36	4.17e-9	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer;
KIRP	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg05562828	chr17:3906858	NA	0.53	5.59	0.34	5.87e-8	Type 2 diabetes;
KIRP	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26002218	chr14:103986227	CKB	0.26	4.96	0.3	1.33e-6	Body mass index;
KIRP	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg18657303	chr4:1051139	NA	0.55	5.19	0.31	4.45e-7	Recombination rate (females);
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00933542	chr6:150070202	PCMT1	0.27	5.38	0.32	1.75e-7	Lung cancer;
KIRP	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.42	-0.33	1.41e-7	Red blood cell count;
KIRP	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.96	-0.3	1.32e-6	Obesity-related traits;
KIRP	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.83	11.4	0.59	1.83e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12379764	chr21:47803548	PCNT	-0.41	-5.03	-0.31	9.62e-7	Testicular germ cell tumor;
KIRP	cis	rs12210905	1.000	rs12196084	chr6:27198204	A/C	cg11502198	chr6:26597334	ABT1	-0.84	-5.16	-0.31	5e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.75	-11.07	-0.58	2.3e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg09699651	chr6:150184138	LRP11	0.46	6.07	0.36	4.88e-9	Lung cancer;
KIRP	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.59	-9.44	-0.52	2.96e-18	Lung cancer;
KIRP	cis	rs16857609	0.628	rs1382440	chr2:218338968	C/T	cg15335768	chr2:218268053	DIRC3	-0.37	-5.49	-0.33	1.02e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-6.04	-0.36	5.63e-9	Blood metabolite levels;
KIRP	cis	rs6568686	0.679	rs6913489	chr6:111845573	A/C	cg15721981	chr6:111408429	SLC16A10	-0.69	-6.27	-0.37	1.57e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.68	10.83	0.57	1.36e-22	Cancer;
KIRP	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	6.02	0.36	6.14e-9	Glycated hemoglobin levels;
KIRP	trans	rs6446298	0.738	rs6446296	chr3:49838052	G/A	cg21659725	chr3:3221576	CRBN	0.63	6.55	0.39	3.43e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs17401966	0.838	rs35257796	chr1:10267390	T/A	cg19773385	chr1:10388646	KIF1B	-0.71	-10.53	-0.56	1.17e-21	Hepatocellular carcinoma;
KIRP	cis	rs7870753	0.529	rs10760999	chr9:99174951	G/A	cg25260653	chr9:99212216	HABP4	0.56	5.72	0.34	3.06e-8	Height;
KIRP	cis	rs2625529	0.627	rs11858015	chr15:72552492	G/A	cg16672083	chr15:72433130	SENP8	-0.45	-5.4	-0.33	1.57e-7	Red blood cell count;
KIRP	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.61	-6.47	-0.38	5.12e-10	Vitiligo;
KIRP	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.52	0.38	3.98e-10	Diabetic retinopathy;
KIRP	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.53	6.77	0.4	9.29e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg12692727	chr7:1102344	C7orf50	0.48	5.18	0.31	4.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs925255	0.591	rs7559046	chr2:28644670	G/C	cg01273330	chr2:28605224	NA	-0.39	-6.92	-0.4	3.98e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.57	7.55	0.43	8.28e-13	Prudent dietary pattern;
KIRP	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg00784671	chr22:46762841	CELSR1	-0.61	-6.11	-0.36	3.96e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-7.76	-0.44	2.32e-13	Morning vs. evening chronotype;
KIRP	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.49	-5.88	-0.35	1.31e-8	Coronary artery disease;
KIRP	cis	rs580438	0.890	rs12632827	chr3:13340058	C/T	cg10657019	chr3:13328039	NA	0.83	10.97	0.57	4.61e-23	Myringotomy;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.82	11.82	0.6	7.84e-26	Obesity-related traits;
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg11945507	chr8:142233382	SLC45A4	-0.9	-15.66	-0.71	8.31e-39	Immature fraction of reticulocytes;
KIRP	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15541040	chr2:3486749	NA	-0.45	-5.42	-0.33	1.44e-7	Neurofibrillary tangles;
KIRP	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg27205649	chr11:78285834	NARS2	-0.5	-5.09	-0.31	7.22e-7	Testicular germ cell tumor;
KIRP	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.22	0.61	3.66e-27	Bone mineral density;
KIRP	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.14	0.41	1.06e-11	Height;
KIRP	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.23	-0.32	3.67e-7	Alcohol dependence;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg14530476	chr8:117778582	UTP23	0.44	6.36	0.38	9.93e-10	Coronary artery disease;
KIRP	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.43	9.22	0.51	1.36e-17	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.8	0.49	2.47e-16	Motion sickness;
KIRP	cis	rs9513593	1.000	rs1927731	chr13:99925872	G/A	cg21788972	chr13:99853209	UBAC2	0.51	5.25	0.32	3.27e-7	Psoriasis;
KIRP	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26850624	chr5:429559	AHRR	0.32	5.84	0.35	1.65e-8	Cystic fibrosis severity;
KIRP	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg10047753	chr17:41438598	NA	0.85	12.13	0.61	7.2e-27	Menopause (age at onset);
KIRP	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.65	-0.44	4.58e-13	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16320208	chr1:98036695	DPYD	-0.44	-6.12	-0.36	3.63e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs918629	0.563	rs3777188	chr5:95254502	A/G	cg16656078	chr5:95278638	ELL2	-0.38	-5.66	-0.34	4.19e-8	IgG glycosylation;
KIRP	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg27411982	chr8:10470053	RP1L1	0.42	5.51	0.33	9.15e-8	Retinal vascular caliber;
KIRP	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg05669848	chr5:237993	SDHA	-0.47	-4.96	-0.3	1.31e-6	Breast cancer;
KIRP	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.87	-0.45	1.09e-13	Sudden cardiac arrest;
KIRP	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg06121193	chr1:90282411	NA	-0.48	-6.94	-0.4	3.55e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg26061582	chr7:22766209	IL6	0.44	5.0	0.3	1.1e-6	Lung cancer;
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13198984	chr17:80129470	CCDC57	-0.57	-8.51	-0.48	1.75e-15	Life satisfaction;
KIRP	cis	rs2862064	0.929	rs2862062	chr5:156445677	C/T	cg12943317	chr5:156479607	HAVCR1	-0.82	-7.48	-0.43	1.28e-12	Platelet count;
KIRP	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.54	0.38	3.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg24633833	chr3:10029261	TMEM111	0.53	5.57	0.33	6.72e-8	Alzheimer's disease;
KIRP	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.33	-0.32	2.22e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17407555	0.657	rs4698001	chr4:10279413	A/T	cg11266682	chr4:10021025	SLC2A9	0.33	5.04	0.31	9e-7	Schizophrenia (age at onset);
KIRP	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg21747090	chr2:27597821	SNX17	-0.39	-5.27	-0.32	2.96e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs7113850	0.541	rs76344090	chr11:24223375	C/G	ch.11.24196551F	chr11:24239977	NA	0.94	7.7	0.44	3.28e-13	Bone fracture in osteoporosis;
KIRP	cis	rs2230307	0.656	rs11166389	chr1:100466279	G/A	cg24955406	chr1:100503596	HIAT1	0.56	5.57	0.33	6.57e-8	Carotid intima media thickness;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02084834	chr2:201983708	CFLAR	0.65	6.22	0.37	2.14e-9	Lung function (FEV1);
KIRP	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg05347473	chr6:146136440	FBXO30	0.56	8.0	0.45	5.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2072732	0.904	rs9660819	chr1:2952823	C/T	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs11676676	0.593	rs6752599	chr2:109773689	T/C	cg01741688	chr2:109781768	SH3RF3	-0.49	-4.98	-0.3	1.2e-6	Pediatric bone mineral density (spine);
KIRP	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.72	11.16	0.58	1.15e-23	Dupuytren's disease;
KIRP	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg07828340	chr4:882639	GAK	1.04	8.2	0.46	1.3e-14	Parkinson's disease;
KIRP	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.88	-0.35	1.3e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs41307935	0.722	rs12724052	chr1:27234682	G/A	cg12203394	chr1:27248618	NUDC	0.62	5.31	0.32	2.48e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.71	-10.17	-0.54	1.67e-20	Morning vs. evening chronotype;
KIRP	cis	rs1408799	0.750	rs7037315	chr9:12657911	A/T	cg05274944	chr9:12693694	TYRP1	0.36	5.04	0.31	8.96e-7	Eye color;Blue vs. green eyes;
KIRP	trans	rs7618501	0.699	rs1062633	chr3:49924940	T/C	cg21659725	chr3:3221576	CRBN	0.66	8.9	0.49	1.27e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.46	-6.87	-0.4	5.16e-11	Lymphocyte counts;
KIRP	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.88	-11.72	-0.6	1.7e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs8018808	0.875	rs176781	chr14:77887681	C/T	cg20045696	chr14:77926864	AHSA1	0.45	5.43	0.33	1.33e-7	Myeloid white cell count;
KIRP	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.89	-8.88	-0.49	1.47e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg25866889	chr13:114914595	NA	-0.38	-5.26	-0.32	3.16e-7	Schizophrenia;
KIRP	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06544989	chr22:39130855	UNC84B	0.47	7.93	0.45	7.71e-14	Menopause (age at onset);
KIRP	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg04289385	chr6:36355825	ETV7	0.43	6.85	0.4	5.85e-11	Platelet distribution width;
KIRP	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.61	-0.34	5.47e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.38	4.96	0.3	1.34e-6	Vitiligo;
KIRP	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.75	-9.74	-0.53	3.58e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.73	9.28	0.51	8.99e-18	Coronary artery disease;
KIRP	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg05315796	chr3:52349193	DNAH1	0.36	5.46	0.33	1.18e-7	Bipolar disorder;
KIRP	cis	rs1823913	0.637	rs17348013	chr2:192168452	A/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg04025307	chr7:1156635	C7orf50	0.71	7.74	0.44	2.53e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2282032	1.000	rs74485471	chr14:90746112	G/A	cg04374321	chr14:90722782	PSMC1	0.59	5.64	0.34	4.55e-8	Longevity;
KIRP	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg10046767	chr12:53297693	KRT8	0.51	6.37	0.38	9.07e-10	Cancer (pleiotropy);
KIRP	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg05340658	chr4:99064831	C4orf37	0.54	6.46	0.38	5.46e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg23788917	chr6:8435910	SLC35B3	-0.62	-8.01	-0.45	4.48e-14	Motion sickness;
KIRP	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg18833306	chr6:118973337	C6orf204	-0.47	-4.97	-0.3	1.23e-6	Diastolic blood pressure;
KIRP	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.44	5.46	0.33	1.17e-7	Aortic root size;
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.69	11.87	0.6	5.32e-26	Cardiovascular disease risk factors;
KIRP	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg25173405	chr17:45401733	C17orf57	-0.41	-5.32	-0.32	2.32e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6700559	0.740	rs4387211	chr1:200645938	A/T	cg07804481	chr1:200639085	DDX59	-0.5	-6.6	-0.39	2.52e-10	Coronary artery disease;
KIRP	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.38	-5.16	-0.31	5.05e-7	Neuroticism;
KIRP	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.1	0.46	2.55e-14	Menopause (age at onset);
KIRP	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.56	0.43	7.89e-13	Menarche (age at onset);
KIRP	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-9.11	-0.5	3.03e-17	Triglycerides;
KIRP	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.93	13.86	0.66	1.15e-32	Mean platelet volume;
KIRP	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg16586182	chr3:47516702	SCAP	0.68	9.25	0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs9400467	0.506	rs10457238	chr6:111762593	C/G	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg08742575	chr21:47604166	C21orf56	-0.38	-4.96	-0.3	1.29e-6	Testicular germ cell tumor;
KIRP	cis	rs174775	0.513	rs3788411	chr22:29728783	T/C	cg07256473	chr22:29710276	RASL10A	-0.44	-6.91	-0.4	4.19e-11	Immature fraction of reticulocytes;
KIRP	cis	rs2718058	0.540	rs2722331	chr7:37816055	G/T	cg15028436	chr7:37888078	TXNDC3	0.46	5.61	0.34	5.44e-8	Alzheimer's disease (late onset);
KIRP	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg14078157	chr9:128172775	NA	-0.52	-6.27	-0.37	1.59e-9	Mean arterial pressure;
KIRP	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.63	-0.44	5.25e-13	Recombination measurement;
KIRP	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.56	4.87	0.3	2.01e-6	Bipolar disorder;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg21186296	chr8:27182909	PTK2B	0.51	6.54	0.38	3.49e-10	Neuroticism;
KIRP	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.78	7.69	0.44	3.42e-13	Lung function (FEV1/FVC);
KIRP	cis	rs17428704	0.522	rs60123555	chr5:14416830	T/C	cg26595256	chr5:14380529	TRIO	-0.7	-5.52	-0.33	8.5e-8	Electroencephalogram traits;
KIRP	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.75	-0.34	2.61e-8	Menarche (age at onset);
KIRP	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.99	18.86	0.77	1.1e-49	Parkinson's disease;
KIRP	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.45	-5.61	-0.34	5.51e-8	Asthma;
KIRP	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg21184320	chr1:21044207	KIF17	-0.37	-5.59	-0.34	5.92e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14685339	chr14:77787351	POMT2;GSTZ1	0.54	6.23	0.37	2.05e-9	Smoking initiation;
KIRP	cis	rs6009824	0.891	rs6009820	chr22:50085456	C/T	cg18178197	chr22:50098317	NA	0.6	6.58	0.39	2.87e-10	Natriuretic peptide levels;
KIRP	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.15	12.63	0.63	1.57e-28	Uric acid levels;
KIRP	cis	rs4950322	0.518	rs72692970	chr1:146804618	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.63	-9.53	-0.52	1.64e-18	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9398803	0.865	rs9375442	chr6:126803137	A/C	cg19875578	chr6:126661172	C6orf173	0.45	5.86	0.35	1.46e-8	Male-pattern baldness;
KIRP	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2737618	0.674	rs2737684	chr1:200092951	C/T	cg21825944	chr1:200113062	NR5A2	-0.53	-7.35	-0.42	2.99e-12	Uric acid levels;
KIRP	cis	rs1800469	1.000	rs2241715	chr19:41856886	A/C	cg08477640	chr19:41863820	B9D2	0.58	6.76	0.4	1e-10	Colorectal cancer;
KIRP	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.86	0.35	1.52e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg27124370	chr19:33622961	WDR88	0.55	6.86	0.4	5.7e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12591125	chr7:1885375	MAD1L1	0.5	4.99	0.3	1.16e-6	Bipolar disorder;
KIRP	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-7.46	-0.43	1.47e-12	Systemic lupus erythematosus;
KIRP	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.09	-0.41	1.39e-11	Menopause (age at onset);
KIRP	cis	rs7119	0.636	rs11635606	chr15:77819591	A/G	cg12131826	chr15:77904385	NA	0.47	5.43	0.33	1.33e-7	Type 2 diabetes;
KIRP	trans	rs12517041	0.572	rs3919638	chr5:23303287	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.14	-0.36	3.33e-9	Type 2 diabetes;
KIRP	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg22681709	chr2:178499509	PDE11A	-0.62	-9.11	-0.5	2.98e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	11.59	0.59	4.49e-25	Platelet count;
KIRP	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.16	-0.42	9.23e-12	Gut microbiome composition (summer);
KIRP	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg19468946	chr17:37922297	IKZF3	-0.49	-6.81	-0.4	7.36e-11	Self-reported allergy;
KIRP	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-12.99	-0.64	9.92e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.84	9.48	0.52	2.28e-18	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.94	0.45	7.07e-14	Lung cancer in ever smokers;
KIRP	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	6.12	0.36	3.7e-9	Schizophrenia;
KIRP	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.59	8.0	0.45	4.77e-14	HDL cholesterol;
KIRP	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg05370193	chr1:21551575	ECE1	0.42	5.95	0.35	9.18e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22162821	chr4:123301256	ADAD1	0.43	6.41	0.38	7.28e-10	Interleukin-4 levels;
KIRP	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.57	6.62	0.39	2.25e-10	Blood protein levels;
KIRP	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05718146	chr15:80544652	NA	0.56	7.92	0.45	8.23e-14	Parkinson's disease;
KIRP	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.54	6.82	0.4	7.16e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg26174226	chr8:58114915	NA	-0.58	-6.6	-0.39	2.5e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.47	6.99	0.41	2.64e-11	Bone mineral density;
KIRP	cis	rs6601327	0.665	rs12543369	chr8:9655915	C/A	cg27411982	chr8:10470053	RP1L1	-0.39	-4.9	-0.3	1.71e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs988913	0.624	rs1580892	chr6:54859213	C/G	cg03513858	chr6:54763001	FAM83B	-0.34	-4.9	-0.3	1.76e-6	Menarche (age at onset);
KIRP	cis	rs17095355	1.000	rs17126890	chr10:111699169	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.52	-0.38	3.98e-10	Biliary atresia;
KIRP	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg22029157	chr1:209979665	IRF6	0.55	6.52	0.38	4.05e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs3779635	0.967	rs750538	chr8:27275726	G/T	cg23736307	chr8:27182930	PTK2B	0.45	5.7	0.34	3.35e-8	Neuroticism;
KIRP	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg08017634	chr8:144659831	NAPRT1	0.81	5.14	0.31	5.48e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs4262150	0.726	rs10515675	chr5:152013789	G/C	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.18e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs8014252	0.803	rs7157618	chr14:71010166	C/T	cg19730268	chr14:71022823	NA	-0.57	-5.48	-0.33	1.04e-7	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg00405596	chr8:11794950	NA	-0.43	-5.25	-0.32	3.31e-7	Neuroticism;
KIRP	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg02487422	chr3:49467188	NICN1	0.44	5.65	0.34	4.32e-8	Resting heart rate;
KIRP	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-7.13	-0.41	1.1e-11	Neuroticism;
KIRP	cis	rs3789045	0.774	rs898388	chr1:204500257	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.63	-6.3	-0.37	1.35e-9	Educational attainment (college completion);
KIRP	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.12	17.62	0.75	1.64e-45	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13939156	chr17:80058883	NA	0.48	7.21	0.42	6.99e-12	Life satisfaction;
KIRP	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg02297831	chr4:17616191	MED28	0.56	6.92	0.4	3.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.47	6.88	0.4	4.97e-11	Coronary artery disease;
KIRP	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg15655495	chr12:38532458	NA	-0.28	-5.15	-0.31	5.32e-7	Heart rate;
KIRP	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-6.63	-0.39	2.15e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9535307	0.719	rs10492591	chr13:50385256	C/T	cg04663916	chr13:50265991	EBPL	-0.64	-6.74	-0.39	1.12e-10	Obesity-related traits;
KIRP	cis	rs1209950	0.536	rs13047489	chr21:40200095	A/G	cg02119577	chr21:40195074	ETS2	0.4	5.43	0.33	1.34e-7	Non-small cell lung cancer (survival);
KIRP	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg17507749	chr15:85114479	UBE2QP1	0.87	9.92	0.53	1e-19	Schizophrenia;
KIRP	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg08885076	chr2:99613938	TSGA10	-0.53	-8.91	-0.49	1.19e-16	Chronic sinus infection;
KIRP	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg02367723	chr1:46378857	MAST2	0.42	4.92	0.3	1.56e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg08600765	chr20:34638493	LOC647979	-0.89	-9.06	-0.5	4.18e-17	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.6	7.36	0.42	2.8e-12	Height;
KIRP	cis	rs3744061	0.557	rs2098091	chr17:74646817	A/G	cg27546012	chr17:74684504	MXRA7	-0.43	-5.13	-0.31	5.83e-7	Retinal arteriolar caliber;
KIRP	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.53	-7.58	-0.44	7.11e-13	Bipolar disorder;
KIRP	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.57	-7.1	-0.41	1.32e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs698833	0.886	rs8886	chr2:44547909	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.5	-5.97	-0.36	8.11e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.92	-14.06	-0.67	2.41e-33	Height;
KIRP	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg27205649	chr11:78285834	NARS2	0.63	8.24	0.47	1.03e-14	Alzheimer's disease (survival time);
KIRP	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.74	-7.98	-0.45	5.49e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.44	6.44	0.38	6.29e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.9	-15.31	-0.7	1.25e-37	Oral cavity cancer;
KIRP	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-0.99	-16.4	-0.72	2.39e-41	Height;
KIRP	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.82	-12.46	-0.62	5.73e-28	Breast cancer;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.59	-8.08	-0.46	2.87e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.52e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.91	0.3	1.69e-6	Cognitive test performance;
KIRP	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	cg21523751	chr1:182988639	NA	-0.44	-6.85	-0.4	6.04e-11	Colorectal cancer;
KIRP	cis	rs7527798	0.592	rs10746386	chr1:207855095	C/T	cg09232269	chr1:207846808	CR1L	-0.36	-5.27	-0.32	2.93e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.47	0.38	5.11e-10	Hemoglobin concentration;
KIRP	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg02336718	chr17:17403227	NA	-0.35	-5.39	-0.32	1.66e-7	Total body bone mineral density;
KIRP	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg03289416	chr15:75166202	SCAMP2	0.47	6.15	0.37	3.12e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	1.06	18.76	0.77	2.46e-49	Bone mineral density;
KIRP	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg05347473	chr6:146136440	FBXO30	0.5	7.0	0.41	2.38e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	1.19	14.4	0.68	1.69e-34	Type 2 diabetes nephropathy;
KIRP	cis	rs2013441	0.579	rs34370440	chr17:20003430	A/G	cg13482628	chr17:19912719	NA	0.46	6.05	0.36	5.42e-9	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg08888203	chr3:10149979	C3orf24	0.48	5.07	0.31	7.95e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.65e-7	Life satisfaction;
KIRP	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg08885076	chr2:99613938	TSGA10	0.52	8.88	0.49	1.43e-16	Chronic sinus infection;
KIRP	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg14292368	chr19:18793705	CRTC1	0.49	6.04	0.36	5.73e-9	Menarche (age at onset);
KIRP	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	5.04	0.31	9.13e-7	Height;
KIRP	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg01631408	chr1:248437212	OR2T33	-0.37	-4.98	-0.3	1.19e-6	Common traits (Other);
KIRP	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.46	-5.39	-0.32	1.68e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9513627	1.000	rs2147625	chr13:100140645	G/T	cg25919922	chr13:100150906	NA	0.7	5.51	0.33	9.06e-8	Obesity-related traits;
KIRP	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.78	7.24	0.42	5.81e-12	Mean platelet volume;
KIRP	cis	rs8060686	0.920	rs73591968	chr16:67803063	G/A	cg04539111	chr16:67997858	SLC12A4	-0.61	-6.01	-0.36	6.64e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.76	10.4	0.55	3.19e-21	Monocyte count;
KIRP	cis	rs10982256	0.774	rs1535960	chr9:117251352	C/T	cg13636371	chr9:117264095	DFNB31	0.59	8.31	0.47	6.48e-15	Bipolar disorder;
KIRP	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.56	0.43	7.84e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.51	-7.89	-0.45	1.02e-13	Sudden cardiac arrest;
KIRP	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.85	-13.46	-0.65	2.54e-31	Systemic lupus erythematosus;
KIRP	cis	rs2073499	1.000	rs2073498	chr3:50369546	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.62	4.86	0.3	2.07e-6	Schizophrenia;
KIRP	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg06212747	chr3:49208901	KLHDC8B	0.44	5.05	0.31	8.75e-7	Resting heart rate;
KIRP	cis	rs10463316	0.817	rs730526	chr5:150789232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.18	-0.37	2.6e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6466055	0.720	rs12334245	chr7:104995627	T/C	cg04380332	chr7:105027541	SRPK2	-0.63	-9.41	-0.51	3.58e-18	Schizophrenia;
KIRP	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-6.46	-0.38	5.63e-10	Type 2 diabetes;
KIRP	cis	rs9815354	0.812	rs17217536	chr3:41923300	A/C	cg03022575	chr3:42003672	ULK4	0.8	8.18	0.46	1.54e-14	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg16141378	chr3:129829833	LOC729375	-0.49	-6.68	-0.39	1.61e-10	Neuroticism;
KIRP	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.85	12.21	0.61	4.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg02297831	chr4:17616191	MED28	0.62	7.7	0.44	3.39e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg10223061	chr2:219282414	VIL1	0.41	6.64	0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg01988459	chr11:68622903	NA	-0.43	-5.93	-0.35	1.03e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.93	11.46	0.59	1.19e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6558530	0.666	rs11136422	chr8:1695909	T/C	cg08198773	chr8:1697536	NA	0.49	6.08	0.36	4.59e-9	Systolic blood pressure;
KIRP	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.19	-0.37	2.45e-9	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.48	-0.43	1.32e-12	Mood instability;
KIRP	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs970548	0.688	rs2082110	chr10:45931070	A/G	cg15590007	chr10:45870220	ALOX5	0.54	5.71	0.34	3.22e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs6120849	0.901	rs6088733	chr20:33744904	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.07	0.36	4.72e-9	Protein C levels;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg16590910	chr6:42928470	GNMT	0.47	6.7	0.39	1.42e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-9.36	-0.51	5.12e-18	Platelet count;
KIRP	cis	rs2880765	0.546	rs35316253	chr15:86065560	T/C	cg15340431	chr15:86040528	AKAP13	-0.46	-5.71	-0.34	3.29e-8	Coronary artery disease;
KIRP	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg12940439	chr1:67600707	NA	0.38	5.71	0.34	3.32e-8	Psoriasis;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.73	11.42	0.59	1.6e-24	Menarche (age at onset);
KIRP	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.63	-9.37	-0.51	4.93e-18	Total body bone mineral density;
KIRP	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg27205649	chr11:78285834	NARS2	-0.55	-4.87	-0.3	2.01e-6	Testicular germ cell tumor;
KIRP	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg10755058	chr3:40428713	ENTPD3	0.44	6.06	0.36	4.99e-9	Renal cell carcinoma;
KIRP	cis	rs11650494	0.710	rs11651666	chr17:47474571	C/T	cg08112188	chr17:47440006	ZNF652	1.34	8.25	0.47	9.93e-15	Prostate cancer;
KIRP	cis	rs370915	0.928	rs433477	chr4:187814866	C/G	cg19519643	chr4:187840862	NA	0.36	4.93	0.3	1.49e-6	Gout;
KIRP	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.85	12.66	0.63	1.27e-28	Longevity;
KIRP	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg06064525	chr11:970664	AP2A2	-0.37	-7.4	-0.43	2.15e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	0.95	8.42	0.47	3.09e-15	Type 2 diabetes nephropathy;
KIRP	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg19507638	chr5:93509721	C5orf36	-0.63	-5.41	-0.33	1.47e-7	Diabetic retinopathy;
KIRP	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg11271282	chr2:238384023	NA	0.51	5.8	0.35	2.05e-8	Prostate cancer;
KIRP	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg13147721	chr7:65941812	NA	-1.01	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs2387326	0.717	rs10829343	chr10:129944496	T/C	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	20.84	0.8	2.85e-56	Prudent dietary pattern;
KIRP	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg17507749	chr15:85114479	UBE2QP1	0.81	8.4	0.47	3.6e-15	Schizophrenia;
KIRP	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg25547332	chr5:131281432	NA	-0.47	-5.31	-0.32	2.5e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18863666	chr10:529214	DIP2C	0.54	6.68	0.39	1.57e-10	Interleukin-4 levels;
KIRP	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.81	-9.71	-0.53	4.35e-19	Body mass index;
KIRP	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	1.02	19.46	0.78	1.06e-51	Breast cancer;
KIRP	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.37	-0.32	1.81e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs735539	0.521	rs693489	chr13:21423005	A/G	cg04906043	chr13:21280425	IL17D	-0.42	-4.94	-0.3	1.45e-6	Dental caries;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.43	-8.35	-0.47	4.99e-15	Urinary metabolites;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg21224049	chr4:668623	ATP5I	-0.51	-6.29	-0.37	1.47e-9	Neuroticism;
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.7	-11.23	-0.58	6.62e-24	Paraoxonase activity;
KIRP	cis	rs6988636	0.818	rs59428574	chr8:124166061	G/A	cg15893493	chr8:124194847	FAM83A	0.92	6.53	0.38	3.78e-10	Urinary uromodulin levels;
KIRP	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.11	-0.61	9.02e-27	Alzheimer's disease;
KIRP	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.56	-8.57	-0.48	1.16e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg16898833	chr6:26189333	HIST1H4D	0.72	5.13	0.31	5.76e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01128800	chr10:69644938	SIRT1	0.54	7.01	0.41	2.27e-11	Myopia (pathological);
KIRP	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg24732563	chr1:204349887	NA	-0.46	-6.36	-0.38	9.67e-10	Inflammatory biomarkers;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23098811	chr1:215450695	NA	-0.43	-6.08	-0.36	4.68e-9	Inflammatory biomarkers;
KIRP	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.31	-0.37	1.29e-9	Monocyte count;
KIRP	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.59	0.56	7.86e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1620921	0.967	rs1652502	chr6:161194542	C/T	cg01280913	chr6:161186852	NA	-0.39	-5.62	-0.34	5.1e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs6693295	0.816	rs12404559	chr1:246313321	G/A	cg11798871	chr1:246315928	SMYD3	-0.56	-6.36	-0.38	9.54e-10	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.41	-6.91	-0.4	4.02e-11	Huntington's disease progression;
KIRP	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.73	-10.38	-0.55	3.59e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6973256	0.897	rs17659708	chr7:133355098	A/G	cg10665199	chr7:133106180	EXOC4	-0.48	-5.93	-0.35	9.94e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7635838	1.000	rs7635838	chr3:11412604	A/G	cg00170343	chr3:11313890	ATG7	0.41	5.12	0.31	6.11e-7	HDL cholesterol;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.67	-6.22	-0.37	2.09e-9	Menarche (age at onset);
KIRP	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg05621596	chr22:47072043	GRAMD4	-0.55	-6.32	-0.37	1.25e-9	Urate levels in obese individuals;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg02733842	chr7:1102375	C7orf50	0.56	5.76	0.34	2.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.72e-11	Aortic root size;
KIRP	cis	rs6690583	0.524	rs6680422	chr1:85451945	C/T	cg22153463	chr1:85462885	MCOLN2	0.59	5.37	0.32	1.84e-7	Serum sulfate level;
KIRP	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg18944383	chr4:111397179	ENPEP	0.57	9.5	0.52	1.93e-18	Coronary artery disease;
KIRP	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg04226714	chr8:49833948	SNAI2	-0.51	-6.79	-0.4	8.51e-11	Life satisfaction;
KIRP	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg01879757	chr17:41196368	BRCA1	-0.54	-7.27	-0.42	4.64e-12	Menopause (age at onset);
KIRP	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.27	-0.42	4.89e-12	Aortic root size;
KIRP	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs981844	0.712	rs10009854	chr4:154741785	C/T	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg06223162	chr1:101003688	GPR88	-0.4	-7.94	-0.45	7.42e-14	Monocyte count;
KIRP	cis	rs4262150	0.544	rs72795340	chr5:151905013	G/C	cg12297329	chr5:152029980	NA	-0.72	-8.89	-0.49	1.31e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.9	-12.41	-0.62	9.06e-28	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2274273	0.686	rs28631821	chr14:55845987	T/C	cg04306507	chr14:55594613	LGALS3	0.52	8.25	0.47	9.93e-15	Protein biomarker;
KIRP	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9616064	0.638	rs738244	chr22:46946127	C/T	cg05621596	chr22:47072043	GRAMD4	-0.48	-4.95	-0.3	1.35e-6	Urate levels in obese individuals;
KIRP	trans	rs62056376	0.736	rs885691	chr17:32641225	C/T	cg13554086	chr5:76507100	PDE8B	-0.5	-6.13	-0.36	3.46e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.13	-0.41	1.15e-11	Bone mineral density;
KIRP	cis	rs73198271	1.000	rs73198279	chr8:8608504	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.8	-0.35	2.01e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg10096100	chr1:26503862	CNKSR1	0.46	6.27	0.37	1.61e-9	Height;
KIRP	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.8	13.64	0.66	6.41e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg20307385	chr11:47447363	PSMC3	0.5	5.57	0.33	6.79e-8	Subjective well-being;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08280861	chr8:58055591	NA	-0.74	-6.34	-0.37	1.11e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg18357526	chr6:26021779	HIST1H4A	0.42	4.86	0.3	2.13e-6	Blood metabolite levels;
KIRP	cis	rs4776059	1.000	rs4776059	chr15:52886962	C/T	cg22715398	chr15:52968154	KIAA1370	-0.66	-7.95	-0.45	6.55e-14	Schizophrenia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23784313	chr12:15942613	EPS8	-0.5	-6.64	-0.39	1.94e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.82	10.08	0.54	3.22e-20	Pulse pressure;
KIRP	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.46	0.43	1.44e-12	Myopia (pathological);
KIRP	cis	rs7274811	0.625	rs169797	chr20:31926490	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.43	5.05	0.31	8.69e-7	Height;
KIRP	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.69	7.26	0.42	5.19e-12	Bipolar disorder;
KIRP	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-7.64	-0.44	4.79e-13	Neuroticism;
KIRP	cis	rs7212590	0.529	rs60283440	chr17:57994248	T/C	cg10252138	chr17:58120427	NA	-0.7	-5.83	-0.35	1.7e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.94	-0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.77	9.89	0.53	1.28e-19	Corneal astigmatism;
KIRP	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.75	-6.91	-0.4	4.19e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.68	8.41	0.47	3.28e-15	Cognitive function;
KIRP	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg19847130	chr8:10466454	RP1L1	0.35	5.12	0.31	6.31e-7	Triglycerides;
KIRP	cis	rs2120243	0.539	rs6441128	chr3:157121258	A/C	cg24825693	chr3:157122686	VEPH1	-0.6	-9.05	-0.5	4.59e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.37	-0.32	1.83e-7	Chronic sinus infection;
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.72	9.74	0.53	3.61e-19	Lung cancer;
KIRP	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg02527881	chr3:46936655	PTH1R	-0.41	-5.95	-0.35	9.26e-9	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14507002	chr2:73089775	NA	0.49	6.15	0.37	3.05e-9	Parkinson's disease;
KIRP	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.46	7.02	0.41	2.15e-11	Major depressive disorder;
KIRP	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	1.1	15.61	0.71	1.17e-38	Multiple sclerosis;
KIRP	cis	rs10924970	1.000	rs12095653	chr1:235327138	T/C	cg26050004	chr1:235667680	B3GALNT2	0.43	5.2	0.31	4.28e-7	Asthma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14738643	chr19:52531952	ZNF614	0.51	6.11	0.36	3.84e-9	Smoking initiation;
KIRP	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.83	-0.4	6.8e-11	Aortic root size;
KIRP	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.56	0.33	7.05e-8	Putamen volume;
KIRP	cis	rs4481887	0.741	rs11485458	chr1:248569050	A/G	cg01631408	chr1:248437212	OR2T33	-0.46	-6.07	-0.36	4.82e-9	Common traits (Other);
KIRP	cis	rs2882667	0.690	rs288029	chr5:138217305	A/G	cg04439458	chr5:138467593	SIL1	-0.35	-4.9	-0.3	1.76e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21984481	chr17:79567631	NPLOC4	-0.48	-7.87	-0.45	1.14e-13	Eye color traits;
KIRP	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.62	-9.31	-0.51	7.61e-18	Body mass index;
KIRP	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.48	-6.03	-0.36	6.05e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.78	6.43	0.38	6.45e-10	Bipolar disorder;
KIRP	cis	rs4638749	0.501	rs1486194	chr2:108755891	C/T	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.14	-0.31	5.57e-7	Blood pressure;
KIRP	cis	rs13382811	1.000	rs13382811	chr2:145223620	C/T	cg04873637	chr2:145231644	ZEB2	-0.53	-5.14	-0.31	5.58e-7	Myopia (severe);
KIRP	cis	rs12282928	1.000	rs11039675	chr11:48336301	A/G	cg26585981	chr11:48327164	OR4S1	0.51	6.16	0.37	2.93e-9	Migraine - clinic-based;
KIRP	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg03474202	chr17:45855739	NA	0.41	5.84	0.35	1.67e-8	IgG glycosylation;
KIRP	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.8	11.28	0.58	4.49e-24	Extrinsic epigenetic age acceleration;
KIRP	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.41	-0.47	3.34e-15	Colorectal cancer;
KIRP	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.83	-0.4	6.67e-11	Neuroticism;
KIRP	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.33	0.62	1.63e-27	Bipolar disorder;
KIRP	cis	rs9905704	0.671	rs2531737	chr17:56554357	A/G	cg12560992	chr17:57184187	TRIM37	-0.54	-5.07	-0.31	7.76e-7	Testicular germ cell tumor;
KIRP	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.33	-6.07	-0.36	4.84e-9	Renal cell carcinoma;
KIRP	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg06627628	chr2:24431161	ITSN2	-0.52	-4.85	-0.3	2.24e-6	Lymphocyte counts;
KIRP	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-7.48	-0.43	1.28e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10214930	0.697	rs12700822	chr7:27645426	G/T	cg22168087	chr7:27702803	HIBADH	0.47	5.07	0.31	7.74e-7	Hypospadias;
KIRP	cis	rs731174	0.797	rs686083	chr1:38149193	C/T	cg14170840	chr1:38155120	C1orf109	-0.41	-5.2	-0.31	4.2e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs16948098	1	rs16948098	chr15:44219607	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	5.75	0.34	2.66e-8	Serum albumin level;
KIRP	trans	rs7819412	0.502	rs34440473	chr8:10906841	A/T	cg08975724	chr8:8085496	FLJ10661	0.5	6.07	0.36	4.79e-9	Triglycerides;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg07701084	chr6:150067640	NUP43	0.71	9.54	0.52	1.44e-18	Lung cancer;
KIRP	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.7	-6.4	-0.38	7.59e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	cg12689670	chr1:183009347	LAMC1	0.58	7.96	0.45	6.34e-14	Fuchs's corneal dystrophy;
KIRP	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.99	-0.41	2.55e-11	Triglycerides;
KIRP	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.18	-0.77	9.19e-51	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.34	0.47	5.5e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4764487	0.687	rs10744702	chr12:6349127	G/A	cg08284733	chr12:6341482	CD9	0.61	10.43	0.55	2.54e-21	Mean platelet volume;
KIRP	cis	rs4356932	0.967	rs28681694	chr4:76972594	A/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.27	-0.32	3.03e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22112476	chr4:1714772	SLBP	0.48	6.17	0.37	2.86e-9	Parkinson's disease;
KIRP	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	9.06	0.5	4.26e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs71636778	0.631	rs71636787	chr1:27185115	T/A	cg12203394	chr1:27248618	NUDC	0.71	5.7	0.34	3.34e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.85e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.71	-8.9	-0.49	1.27e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg19268477	chr7:157951471	PTPRN2	0.52	8.33	0.47	5.78e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-0.98	-6.93	-0.4	3.65e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs5752326	0.510	rs5752333	chr22:26878967	T/C	cg20819150	chr22:26891497	TFIP11	0.54	5.03	0.31	9.51e-7	Ischemic stroke;
KIRP	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.72	10.81	0.57	1.59e-22	Colorectal cancer;
KIRP	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg23067535	chr8:124195133	FAM83A	-0.83	-8.08	-0.46	2.88e-14	Urinary uromodulin levels;
KIRP	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg17366294	chr4:99064904	C4orf37	0.46	5.8	0.35	2.04e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg02336718	chr17:17403227	NA	-0.32	-5.07	-0.31	7.88e-7	Total body bone mineral density;
KIRP	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg24579218	chr15:68104479	NA	-0.57	-9.33	-0.51	6.25e-18	Restless legs syndrome;
KIRP	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.55	6.07	0.36	4.79e-9	Coronary artery disease;
KIRP	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.49	7.68	0.44	3.66e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.1	-0.36	4.12e-9	Myopia (pathological);
KIRP	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-11.95	-0.61	2.94e-26	Neuroticism;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg14221460	chr8:27183342	PTK2B	0.52	6.84	0.4	6.3e-11	Neuroticism;
KIRP	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.53	0.38	3.67e-10	Mean corpuscular volume;
KIRP	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.75	-9.69	-0.53	5.2e-19	Total body bone mineral density;
KIRP	cis	rs2150410	0.915	rs2183574	chr21:40593947	T/C	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.18	0.31	4.7e-7	Bipolar disorder;
KIRP	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.49	7.44	0.43	1.67e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg06307176	chr5:131281290	NA	0.55	5.96	0.36	8.67e-9	Life satisfaction;
KIRP	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.5	-7.86	-0.45	1.21e-13	Huntington's disease progression;
KIRP	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-1.06	-13.18	-0.64	2.33e-30	Exhaled nitric oxide output;
KIRP	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg23484912	chr5:273055	PDCD6	0.6	7.48	0.43	1.31e-12	Pancreatic cancer;
KIRP	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.69	8.91	0.49	1.18e-16	Resting heart rate;
KIRP	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg11752832	chr7:134001865	SLC35B4	0.43	5.03	0.31	9.31e-7	Mean platelet volume;
KIRP	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg11845111	chr2:191398756	TMEM194B	-0.94	-10.3	-0.55	6.68e-21	Diastolic blood pressure;
KIRP	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	6.62	0.39	2.24e-10	Initial pursuit acceleration;
KIRP	cis	rs78487399	0.614	rs7600657	chr2:43710444	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-5.3	-0.32	2.54e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.1	0.46	2.65e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	8.03	0.46	3.96e-14	Joint mobility (Beighton score);
KIRP	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg25650185	chr19:21324782	ZNF431	-0.48	-5.13	-0.31	5.95e-7	Pain;
KIRP	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.54	-6.98	-0.41	2.73e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg13628971	chr7:2884303	GNA12	0.65	7.45	0.43	1.56e-12	Height;
KIRP	cis	rs4789452	0.902	rs4789454	chr17:75375199	C/T	cg12985929	chr17:75370611	SEPT9	-0.39	-5.46	-0.33	1.16e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6496667	0.738	rs56337344	chr15:90988371	A/T	cg10434728	chr15:90938212	IQGAP1	0.36	4.84	0.3	2.27e-6	Rheumatoid arthritis;
KIRP	trans	rs800292	0.593	rs10922082	chr1:196513694	C/T	cg05672026	chr3:64016453	NA	-0.48	-6.07	-0.36	4.89e-9	Matrix metalloproteinase-8 levels;Neovascular age-related macular degeneration;Circulating myeloperoxidase levels (serum);
KIRP	cis	rs6142102	0.923	rs4911394	chr20:32577327	C/T	cg08999081	chr20:33150536	PIGU	0.49	5.83	0.35	1.7e-8	Skin pigmentation;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg12427896	chr2:111880694	BCL2L11	0.55	6.27	0.37	1.61e-9	Sleep duration;
KIRP	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg05527609	chr1:210001259	C1orf107	-0.49	-5.21	-0.32	4.07e-7	Red blood cell count;
KIRP	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.61	-8.66	-0.48	6.21e-16	Bipolar disorder;
KIRP	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg10130564	chr11:117069849	TAGLN	0.43	5.4	0.33	1.6e-7	Blood protein levels;
KIRP	cis	rs7923609	0.756	rs7080386	chr10:65048306	C/A	cg01631684	chr10:65280961	REEP3	-0.47	-5.4	-0.33	1.56e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg23845249	chr11:68861649	NA	0.57	8.22	0.46	1.18e-14	Blond vs. brown hair color;
KIRP	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.5	-6.02	-0.36	6.41e-9	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs1961637	0.960	rs11890421	chr2:223914850	A/C	cg02552189	chr2:223891284	NA	0.36	4.94	0.3	1.41e-6	Oropharynx cancer;
KIRP	cis	rs11191270	0.868	rs77389536	chr10:104168125	T/C	cg15320455	chr10:103880129	LDB1	0.59	5.2	0.31	4.21e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg26769984	chr7:1090371	C7orf50	0.73	6.03	0.36	5.93e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg17330251	chr7:94953956	PON1	0.72	10.84	0.57	1.27e-22	Paraoxonase activity;
KIRP	cis	rs4664304	0.620	rs2048436	chr2:160712119	A/G	cg03641300	chr2:160917029	PLA2R1	0.37	5.55	0.33	7.44e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4141404	0.816	rs5749227	chr22:31581166	A/G	cg02404636	chr22:31891804	SFI1	-0.5	-5.2	-0.31	4.16e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs7221595	0.778	rs12946045	chr17:3904307	G/C	cg21851534	chr17:3907994	ZZEF1	0.58	6.31	0.37	1.27e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.71	-8.05	-0.46	3.45e-14	Body mass index;
KIRP	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.64	-10.76	-0.57	2.29e-22	White blood cell count (basophil);
KIRP	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.76	9.62	0.52	8.58e-19	Aortic root size;
KIRP	cis	rs7084402	0.967	rs1365741	chr10:60277489	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg04998671	chr14:104000505	TRMT61A	-0.54	-6.23	-0.37	2.04e-9	Coronary artery disease;
KIRP	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg04398451	chr17:18023971	MYO15A	-0.61	-8.34	-0.47	5.29e-15	Total body bone mineral density;
KIRP	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg13736514	chr6:26305472	NA	0.5	6.3	0.37	1.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.75	9.31	0.51	7.17e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg13565492	chr6:43139072	SRF	-0.83	-7.77	-0.44	2.18e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20865740	chr3:119063744	CDGAP	0.55	6.25	0.37	1.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06481639	chr22:41940642	POLR3H	0.47	5.46	0.33	1.16e-7	Vitiligo;
KIRP	cis	rs35934224	0.831	rs1044732	chr22:19863142	T/C	cg11182965	chr22:19864308	TXNRD2	-0.47	-5.78	-0.35	2.21e-8	Glaucoma (primary open-angle);
KIRP	cis	rs6450176	0.638	rs16881969	chr5:53300748	A/G	ch.5.1024479R	chr5:53302184	ARL15	1.18	14.07	0.67	2.23e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.79	-7.71	-0.44	3.03e-13	Systemic lupus erythematosus;
KIRP	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.93	-14.31	-0.67	3.41e-34	Ulcerative colitis;
KIRP	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg26248373	chr2:1572462	NA	-0.63	-6.1	-0.36	4.12e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7106204	0.748	rs7101572	chr11:24213982	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	9.58	0.52	1.13e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs12643440	0.960	rs34891733	chr4:17204557	G/T	cg22650099	chr4:17144496	NA	-0.51	-6.14	-0.36	3.33e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg09754948	chr16:28834200	ATXN2L	0.44	4.96	0.3	1.34e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg09597638	chr17:3907349	NA	0.51	5.15	0.31	5.4e-7	Type 2 diabetes;
KIRP	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.96	11.52	0.59	7.81e-25	Corneal astigmatism;
KIRP	cis	rs57994353	0.508	rs7874956	chr9:139336813	T/G	cg14169450	chr9:139327907	INPP5E	0.53	7.86	0.45	1.19e-13	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg05991184	chr2:219186017	PNKD	0.36	5.02	0.3	9.84e-7	Colorectal cancer;
KIRP	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.5	-6.41	-0.38	7.27e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4073416	0.542	rs8017880	chr14:65942924	G/C	cg03016385	chr14:66212404	NA	-0.55	-6.74	-0.39	1.11e-10	N-glycan levels;
KIRP	cis	rs11673344	0.566	rs8109103	chr19:37994111	C/T	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.21	-0.32	3.91e-7	Obesity-related traits;
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-1.05	-20.55	-0.79	2.53e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.75	9.5	0.52	1.94e-18	Prostate cancer;
KIRP	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg14683738	chr19:37701593	ZNF585B	0.47	4.87	0.3	1.96e-6	Coronary artery calcification;
KIRP	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs72653721	0.730	rs12664138	chr6:11039799	T/C	cg13562911	chr6:11044106	ELOVL2	0.55	5.3	0.32	2.57e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.1	-0.41	1.37e-11	Aortic root size;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13460439	chr1:200522459	KIF14	0.39	6.42	0.38	6.93e-10	C-reactive protein;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg18845289	chr12:121124611	MLEC	0.55	6.79	0.4	8.18e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg16141378	chr3:129829833	LOC729375	-0.52	-6.33	-0.37	1.15e-9	Retinal vascular caliber;
KIRP	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg11635098	chr7:100497156	NA	-0.69	-7.38	-0.43	2.4e-12	Resting heart rate;
KIRP	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.51	0.56	1.39e-21	Exhaled nitric oxide output;
KIRP	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg25482853	chr8:67687455	SGK3	0.93	8.26	0.47	9.01e-15	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg02297831	chr4:17616191	MED28	0.58	7.36	0.42	2.75e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.96	0.36	8.66e-9	Renal cell carcinoma;
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.12	0.36	3.76e-9	Lung cancer;
KIRP	cis	rs12595433	1.000	rs4238369	chr15:63293082	T/C	cg03196360	chr15:63270641	NA	-0.29	-5.38	-0.32	1.71e-7	Obesity-related traits;
KIRP	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	1.05	7.48	0.43	1.32e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs642803	0.527	rs1647570	chr11:65568256	A/T	cg08755490	chr11:65554678	OVOL1	-0.52	-5.67	-0.34	4.02e-8	Urate levels;
KIRP	cis	rs4664293	0.867	rs10194483	chr2:160596394	G/A	cg08347373	chr2:160653686	CD302	-0.42	-6.42	-0.38	7.06e-10	Monocyte percentage of white cells;
KIRP	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.29	5.86	0.35	1.51e-8	Schizophrenia;
KIRP	cis	rs6466055	0.720	rs1121194	chr7:104981133	T/C	cg04380332	chr7:105027541	SRPK2	0.54	8.06	0.46	3.23e-14	Schizophrenia;
KIRP	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	trans	rs7863100	0.636	rs13286493	chr9:18650109	A/G	cg13196806	chr10:133996309	JAKMIP3	0.6	6.11	0.36	3.93e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.61	-6.51	-0.38	4.07e-10	Carotid intima media thickness;
KIRP	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.68	9.38	0.51	4.68e-18	Obesity-related traits;
KIRP	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg07382826	chr16:28625726	SULT1A1	0.45	5.02	0.3	1.01e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg27432699	chr2:27873401	GPN1	-0.46	-5.89	-0.35	1.27e-8	Total body bone mineral density;
KIRP	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg11833968	chr6:79620685	NA	-0.45	-7.0	-0.41	2.43e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.6	8.53	0.48	1.55e-15	Menarche (age at onset);
KIRP	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-5.35	-0.32	2e-7	Height;
KIRP	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	7.52	0.43	1.02e-12	Neuroticism;
KIRP	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.91	-13.25	-0.65	1.27e-30	Bladder cancer;
KIRP	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg19773385	chr1:10388646	KIF1B	-0.35	-4.91	-0.3	1.64e-6	Asthma;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03399598	chr4:174091002	GALNT7	0.53	7.06	0.41	1.72e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs73200209	0.744	rs61562746	chr12:116456445	A/C	cg01776926	chr12:116560359	MED13L	-0.55	-5.99	-0.36	7.51e-9	Total body bone mineral density;
KIRP	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.14	-0.41	1.04e-11	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06152496	chr10:95462325	C10orf4	0.49	6.06	0.36	4.95e-9	Parkinson's disease;
KIRP	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.57	-9.31	-0.51	7.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06634786	chr22:41940651	POLR3H	-0.47	-5.21	-0.32	4.03e-7	Vitiligo;
KIRP	cis	rs2278796	0.639	rs11240331	chr1:204968339	C/T	cg17947172	chr1:204966197	NFASC	0.65	8.66	0.48	6.41e-16	Mean platelet volume;
KIRP	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg10645314	chr2:3704589	ALLC	0.67	7.62	0.44	5.59e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg24253500	chr15:84953950	NA	0.59	6.87	0.4	5.21e-11	Schizophrenia;
KIRP	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.74	10.4	0.55	3.22e-21	Red blood cell count;
KIRP	cis	rs6120849	0.901	rs6058193	chr20:33734464	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	6.77	0.4	9.42e-11	Protein C levels;
KIRP	cis	rs7794364	0.658	rs35895632	chr7:117506470	C/G	cg21880328	chr7:117514017	CTTNBP2	-0.36	-5.34	-0.32	2.16e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.92	-14.8	-0.69	6.87e-36	Testicular germ cell tumor;
KIRP	cis	rs12936587	0.633	rs12937187	chr17:17513295	T/C	cg01246520	chr17:17644344	RAI1	-0.37	-5.63	-0.34	4.85e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs9886651	0.935	rs4733759	chr8:128804840	C/T	cg24514600	chr8:128805414	PVT1	-0.74	-12.64	-0.63	1.54e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg04132472	chr17:19861366	AKAP10	0.42	5.84	0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs2400749	0.830	rs11160527	chr14:100032999	C/T	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.44	-0.33	1.32e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.08	-0.31	7.49e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.46	-6.25	-0.37	1.83e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.57	-5.71	-0.34	3.19e-8	Platelet distribution width;
KIRP	cis	rs2219968	0.923	rs35703732	chr8:78953269	C/T	cg00738934	chr8:78996279	NA	0.4	5.0	0.3	1.09e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	1.02	10.21	0.55	1.22e-20	Psoriasis;
KIRP	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.76	-0.34	2.55e-8	Breast cancer;
KIRP	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs7707921	0.767	rs6880209	chr5:81574182	C/T	cg07807695	chr5:81608485	ATP6AP1L	0.42	5.39	0.32	1.67e-7	Breast cancer;
KIRP	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.71	-0.53	4.37e-19	Aortic root size;
KIRP	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.2	0.51	1.55e-17	Menopause (age at onset);
KIRP	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.52	-7.71	-0.44	3.1400000000000003e-13	IgG glycosylation;
KIRP	trans	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs7546094	0.967	rs910697	chr1:113063125	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.59	0.39	2.71e-10	Platelet distribution width;
KIRP	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg02023728	chr11:77925099	USP35	0.29	5.05	0.31	8.73e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.23	-0.42	6.22e-12	Glomerular filtration rate;
KIRP	cis	rs2154427	0.752	rs78511491	chr21:34124249	T/C	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.62	-5.0	-0.3	1.08e-6	Bilirubin levels;
KIRP	cis	rs13102973	0.666	rs2042650	chr4:135897082	T/C	cg14419869	chr4:135874104	NA	-0.43	-6.3	-0.37	1.36e-9	Subjective well-being;
KIRP	cis	rs8067287	0.554	rs56035746	chr17:16841433	C/T	cg26910001	chr17:16838321	NA	-0.63	-6.02	-0.36	6.26e-9	Diabetic kidney disease;
KIRP	trans	rs7012814	1	rs7012814	chr8:9173358	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	6.14	0.36	3.22e-9	Fibrinogen levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02620307	chr1:161283965	SDHC;LOC642502	0.46	6.13	0.36	3.43e-9	Parkinson's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07737236	chr3:161089327	C3orf57	-0.45	-6.08	-0.36	4.54e-9	Myopia;
KIRP	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11987759	chr7:65425863	GUSB	-0.61	-8.13	-0.46	2.08e-14	Aortic root size;
KIRP	cis	rs16858210	0.874	rs34113436	chr3:183573836	G/A	cg25686905	chr3:183603175	PARL	-0.43	-5.07	-0.31	7.67e-7	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24000444	chr18:3771452	DLGAP1	0.5	6.48	0.38	4.96e-10	Parkinson's disease;
KIRP	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.57	8.05	0.46	3.59e-14	Multiple system atrophy;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24862246	chr1:48764354	SPATA6	0.41	6.31	0.37	1.3e-9	Migraine with aura;
KIRP	cis	rs3736485	0.903	rs7165887	chr15:51750846	G/A	cg14296394	chr15:51910925	DMXL2	-0.36	-5.34	-0.32	2.15e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.24	13.65	0.66	5.98e-32	Uric acid levels;
KIRP	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.81	11.44	0.59	1.4e-24	Body mass index;
KIRP	cis	rs74181299	0.533	rs12713533	chr2:65364702	G/T	cg05010058	chr2:65284262	CEP68	-0.41	-5.27	-0.32	2.98e-7	Pulse pressure;
KIRP	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.97	12.57	0.63	2.59e-28	Homoarginine levels;
KIRP	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.87	0.35	1.41e-8	Menopause (age at onset);
KIRP	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-5.81	-0.35	1.89e-8	Colorectal cancer;
KIRP	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	8.18	0.46	1.55e-14	Neuroticism;
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg25347419	chr2:177043501	NA	0.43	5.98	0.36	7.64e-9	IgG glycosylation;
KIRP	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg15557168	chr22:42548783	NA	-0.39	-5.46	-0.33	1.18e-7	Cognitive function;
KIRP	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.42	6.59	0.39	2.6e-10	Inflammatory bowel disease;
KIRP	cis	rs4704187	0.687	rs6858969	chr5:74379281	T/C	cg03227963	chr5:74354835	NA	0.42	6.13	0.36	3.38e-9	Response to amphetamines;
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg14338887	chr6:42928500	GNMT	0.47	6.86	0.4	5.56e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.91	-0.4	4.2e-11	Mood instability;
KIRP	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07570687	chr10:102243282	WNT8B	0.48	6.21	0.37	2.29e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg08992911	chr2:238395768	MLPH	0.46	5.74	0.34	2.84e-8	Prostate cancer;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg03171003	chr2:111875934	NA	0.45	6.43	0.38	6.53e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	8.78	0.49	2.73e-16	Personality dimensions;
KIRP	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg06818126	chr11:68850279	TPCN2	-0.49	-5.62	-0.34	5.08e-8	Hair color;
KIRP	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg12062639	chr20:23401060	NAPB	0.81	6.96	0.41	3.09e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7017914	0.967	rs7825446	chr8:71664174	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs9398803	0.687	rs853962	chr6:127027650	G/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.44	-0.33	1.26e-7	Male-pattern baldness;
KIRP	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.8	8.3	0.47	6.76e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg13271783	chr10:134563150	INPP5A	-0.62	-8.0	-0.45	4.8e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.41	-5.36	-0.32	1.94e-7	Renal cell carcinoma;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10002088	chr19:9271911	ZNF317	-0.47	-6.03	-0.36	6.11e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs12476592	0.602	rs6732791	chr2:63788901	C/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06128612	chr12:123868427	SETD8	0.48	6.3	0.37	1.37e-9	Parkinson's disease;
KIRP	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22654626	chr19:18699620	C19orf60	-0.49	-6.93	-0.4	3.71e-11	Myopia;
KIRP	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.36e-11	Arsenic metabolism;
KIRP	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.41	-11.29	-0.58	4.41e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.1	-0.31	6.92e-7	Retinal vascular caliber;
KIRP	cis	rs6788895	1.000	rs74950732	chr3:150482621	C/T	cg09723797	chr3:150481914	SIAH2	0.76	4.95	0.3	1.37e-6	Breast cancer;
KIRP	cis	rs12022452	0.506	rs6673386	chr1:41011879	C/G	cg25568243	chr1:40974465	DEM1	0.57	6.16	0.37	3.02e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg18016565	chr1:150552671	MCL1	0.37	5.88	0.35	1.33e-8	Melanoma;
KIRP	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg23280166	chr11:118938394	VPS11	-0.59	-7.18	-0.42	8.1e-12	Coronary artery disease;
KIRP	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg20302533	chr7:39170763	POU6F2	-0.24	-4.9	-0.3	1.72e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs966423	0.550	rs2618147	chr2:218302138	C/A	cg15335768	chr2:218268053	DIRC3	-0.39	-5.64	-0.34	4.75e-8	Thyroid cancer;
KIRP	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg21775007	chr8:11205619	TDH	-0.52	-6.97	-0.41	2.86e-11	Neuroticism;
KIRP	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.66e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.42	-5.44	-0.33	1.27e-7	Body mass index;
KIRP	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02187348	chr16:89574699	SPG7	0.46	5.79	0.35	2.09e-8	Multiple myeloma (IgH translocation);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10775733	chr6:110498910	WASF1	0.42	6.07	0.36	4.93e-9	Migraine with aura;
KIRP	cis	rs76793172	0.920	rs77588767	chr19:46326472	G/C	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.12	-0.36	3.67e-9	Eosinophil counts;
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.67	-8.99	-0.5	6.78e-17	Breast cancer;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.61	6.07	0.36	4.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs28680850	0.541	rs28501642	chr8:1379528	G/A	cg06035437	chr8:1398411	NA	-0.84	-8.57	-0.48	1.16e-15	Triglycerides;
KIRP	cis	rs78545713	0.649	rs77727979	chr6:26222026	T/A	cg23601095	chr6:26197514	HIST1H3D	0.88	5.22	0.32	3.83e-7	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg18944383	chr4:111397179	ENPEP	0.54	9.48	0.52	2.24e-18	Height;
KIRP	cis	rs1440410	0.835	rs7687417	chr4:144080001	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg06627628	chr2:24431161	ITSN2	0.48	5.77	0.35	2.4e-8	Asthma;
KIRP	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	13.13	0.64	3.33e-30	Intelligence (multi-trait analysis);
KIRP	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.77	-11.72	-0.6	1.73e-25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.16	0.42	9.24e-12	Lung cancer;
KIRP	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg08975724	chr8:8085496	FLJ10661	0.69	9.21	0.51	1.49e-17	Mood instability;
KIRP	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.11	0.31	6.48e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.67	7.11	0.41	1.23e-11	Lymphocyte counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02659803	chr13:23409813	NA	-0.41	-6.65	-0.39	1.89e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg11641102	chr8:27183873	PTK2B	0.42	5.48	0.33	1.03e-7	Neuroticism;
KIRP	cis	rs12541635	0.966	rs10955409	chr8:107022586	A/C	cg10147462	chr8:107024639	NA	0.34	4.96	0.3	1.29e-6	Age of smoking initiation;
KIRP	cis	rs3744061	0.557	rs2098092	chr17:74646757	T/C	cg27546012	chr17:74684504	MXRA7	-0.43	-5.13	-0.31	5.83e-7	Retinal arteriolar caliber;
KIRP	cis	rs9815354	0.767	rs17280980	chr3:41810949	A/T	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.48	1.32e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg17724175	chr1:150552817	MCL1	0.32	5.38	0.32	1.76e-7	Melanoma;
KIRP	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg14092988	chr3:52407081	DNAH1	0.32	5.79	0.35	2.19e-8	Bipolar disorder;
KIRP	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.87	10.88	0.57	9.14e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs888194	0.690	rs3782894	chr12:110026024	G/T	cg05360138	chr12:110035743	NA	0.43	5.19	0.31	4.31e-7	Neuroticism;
KIRP	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg02336718	chr17:17403227	NA	-0.36	-5.42	-0.33	1.4e-7	Total body bone mineral density;
KIRP	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-6.64	-0.39	2.01e-10	Self-reported allergy;
KIRP	cis	rs56873913	0.904	rs3760708	chr19:50084596	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.56	6.7	0.39	1.41e-10	Schizophrenia;
KIRP	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.48	-0.43	1.31e-12	Neuroticism;
KIRP	cis	rs4460629	0.905	rs4971077	chr1:155128717	T/C	cg02153340	chr1:155202674	NA	-0.48	-7.31	-0.42	3.85e-12	Serum magnesium levels;
KIRP	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg18306943	chr3:40428807	ENTPD3	0.37	4.92	0.3	1.61e-6	Renal cell carcinoma;
KIRP	cis	rs73200209	0.744	rs61936954	chr12:116473408	T/A	cg01776926	chr12:116560359	MED13L	-0.54	-5.74	-0.34	2.76e-8	Total body bone mineral density;
KIRP	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg05714579	chr10:131428358	MGMT	0.52	6.79	0.4	8.33e-11	Response to temozolomide;
KIRP	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg13444842	chr1:152974279	SPRR3	0.48	6.94	0.4	3.43e-11	Inflammatory skin disease;
KIRP	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg06637938	chr14:75390232	RPS6KL1	0.69	9.27	0.51	1.01e-17	Height;
KIRP	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg13482628	chr17:19912719	NA	0.53	6.85	0.4	5.99e-11	Schizophrenia;
KIRP	cis	rs11710088	0.726	rs4314111	chr3:149198676	A/C	cg08667024	chr3:149219783	TM4SF4	-0.47	-6.76	-0.4	9.72e-11	QRS duration;
KIRP	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg17376030	chr22:41985996	PMM1	0.58	6.6	0.39	2.44e-10	Vitiligo;
KIRP	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg25039879	chr17:56429692	SUPT4H1	0.57	5.19	0.31	4.38e-7	Cognitive test performance;
KIRP	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg07972983	chr1:205091412	RBBP5	0.42	4.99	0.3	1.12e-6	Red blood cell count;
KIRP	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.47	0.43	1.35e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00149659	chr3:10157352	C3orf10	0.84	9.19	0.51	1.66e-17	Alzheimer's disease;
KIRP	cis	rs6001982	0.748	rs6001949	chr22:40904486	G/A	cg07138101	chr22:40742427	ADSL	0.66	5.23	0.32	3.64e-7	Breast cancer;
KIRP	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.62	7.29	0.42	4.17e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg02487422	chr3:49467188	NICN1	0.42	5.68	0.34	3.73e-8	Parkinson's disease;
KIRP	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.48e-10	Coronary artery disease;
KIRP	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.53	7.02	0.41	2.15e-11	HDL cholesterol;
KIRP	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.53	7.16	0.42	9.43e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs357618	1.000	rs357627	chr5:150850260	A/G	cg22672639	chr5:150884813	FAT2	0.35	5.35	0.32	1.98e-7	Basophil percentage of white cells;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg18234130	chr8:27182889	PTK2B	0.56	7.09	0.41	1.44e-11	Neuroticism;
KIRP	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg18944383	chr4:111397179	ENPEP	0.51	8.22	0.46	1.2e-14	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.51	0.33	9.19e-8	Platelet count;
KIRP	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.81	-12.93	-0.64	1.58e-29	Monocyte percentage of white cells;
KIRP	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.69	9.85	0.53	1.6e-19	Schizophrenia;
KIRP	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.19	21.28	0.8	1.05e-57	Cognitive function;
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg17650747	chr5:1873721	NA	0.42	5.13	0.31	5.94e-7	Cardiovascular disease risk factors;
KIRP	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg06654118	chr4:1303317	MAEA	0.29	5.29	0.32	2.65e-7	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	trans	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg16141378	chr3:129829833	LOC729375	-0.55	-7.62	-0.44	5.38e-13	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15615436	chr19:50354304	PTOV1	0.48	6.1	0.36	4.16e-9	Parkinson's disease;
KIRP	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg09904177	chr6:26538194	HMGN4	0.55	6.45	0.38	5.91e-10	Small cell lung carcinoma;
KIRP	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.6	8.07	0.46	3.22e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12130219	1.000	rs1552994	chr1:152171461	A/G	cg17718321	chr1:152188247	HRNR	0.44	5.35	0.32	2.03e-7	Inflammatory skin disease;
KIRP	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.87	-11.4	-0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.44	-5.19	-0.31	4.5e-7	Dialysis-related mortality;
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg21698718	chr17:80085957	CCDC57	0.34	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	10.25	0.55	9.56e-21	Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg13939156	chr17:80058883	NA	0.47	7.17	0.42	8.55e-12	Life satisfaction;
KIRP	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.84	-10.39	-0.55	3.26e-21	Menarche (age at onset);
KIRP	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	1.03	13.32	0.65	7.8e-31	Exhaled nitric oxide output;
KIRP	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-7.45	-0.43	1.57e-12	Coffee consumption (cups per day);
KIRP	cis	rs56146971	0.763	rs28624795	chr14:91859055	C/T	cg16433844	chr14:91963127	SMEK1	-0.59	-5.35	-0.32	2.03e-7	Alzheimer disease and age of onset;
KIRP	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.92	12.65	0.63	1.38e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg15192750	chr16:69999425	NA	-0.4	-5.07	-0.31	8e-7	Sjögren's syndrome;
KIRP	cis	rs4959270	0.869	rs962518	chr6:461906	G/A	cg13299325	chr6:447777	NA	0.25	5.2	0.31	4.27e-7	Limited cutaneous systemic scleroderma;
KIRP	cis	rs7572644	0.699	rs7426295	chr2:28078994	G/A	cg27432699	chr2:27873401	GPN1	0.45	5.39	0.33	1.61e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	5.99	0.36	7.42e-9	Total body bone mineral density;
KIRP	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg12940923	chr8:10282607	MSRA	-0.37	-4.9	-0.3	1.77e-6	Retinal vascular caliber;
KIRP	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	6.79	0.4	8.3e-11	Monocyte count;
KIRP	cis	rs10767971	0.527	rs7944652	chr11:32862393	G/T	cg14042352	chr11:32815968	CCDC73	-0.47	-5.44	-0.33	1.28e-7	Parkinson's disease (age of onset);
KIRP	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg23920097	chr1:209922102	NA	-0.47	-5.62	-0.34	5.2100000000000003e-08	Red blood cell count;
KIRP	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	cis	rs17453880	0.929	rs6859908	chr5:152049109	G/A	cg12297329	chr5:152029980	NA	-0.71	-10.54	-0.56	1.11e-21	Subjective well-being;
KIRP	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg24009623	chr19:33667908	NA	0.49	6.48	0.38	4.83e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.45	-0.33	1.24e-7	Colorectal cancer;
KIRP	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs2213920	0.679	rs4979536	chr9:118213738	C/T	cg13918206	chr9:118159781	DEC1	0.98	10.14	0.54	2.11e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs6987853	0.814	rs1349471	chr8:42454011	C/T	cg09913449	chr8:42400586	C8orf40	0.4	5.23	0.32	3.69e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14840081	chr7:152551660	ACTR3B	0.5	6.03	0.36	5.98e-9	Interleukin-4 levels;
KIRP	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg20701182	chr2:24300061	SF3B14	0.51	4.99	0.3	1.15e-6	Lymphocyte counts;
KIRP	cis	rs252716	1	rs252716	chr5:110425063	G/C	cg04022379	chr5:110408740	TSLP	-0.45	-6.36	-0.38	9.82e-10	Eosinophilic esophagitis;
KIRP	cis	rs1629083	0.934	rs1573559	chr11:118104627	G/A	cg18857871	chr11:118064634	AMICA1	0.62	8.17	0.46	1.62e-14	Lung cancer;
KIRP	cis	rs2733310	0.742	rs2615227	chr15:57546066	C/G	cg13626582	chr15:57592083	LOC283663	0.28	6.41	0.38	7.51e-10	Mean platelet volume;
KIRP	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06634786	chr22:41940651	POLR3H	0.42	4.94	0.3	1.45e-6	Vitiligo;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06166242	chr6:148663498	SASH1	-0.43	-6.07	-0.36	4.92e-9	Survival in pancreatic cancer;
KIRP	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg13736514	chr6:26305472	NA	-0.44	-5.0	-0.3	1.1e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13095912	0.925	rs11922634	chr3:185349190	G/A	cg11274856	chr3:185301563	NA	0.55	6.98	0.41	2.78e-11	Systolic blood pressure;
KIRP	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.47	-0.33	1.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg14675211	chr2:100938903	LONRF2	0.54	7.22	0.42	6.28e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4904167	0.841	rs1031787	chr14:84694489	C/G	cg06310157	chr7:140218138	NA	0.47	6.35	0.38	1.05e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs198389	0.589	rs535107	chr1:11889468	C/T	cg24844545	chr1:11908347	NPPA	0.39	5.58	0.34	6.36e-8	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
KIRP	trans	rs7246760	1.000	rs10421336	chr19:9939831	A/G	cg02900749	chr2:68251473	NA	-0.89	-8.07	-0.46	3.03e-14	Pursuit maintenance gain;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07047347	chr8:96281113	C8orf37	-0.47	-6.31	-0.37	1.32e-9	Myopia;
KIRP	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.11	0.31	6.41e-7	Cognitive test performance;
KIRP	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.89	12.52	0.62	3.89e-28	Menopause (age at onset);
KIRP	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	10.41	0.55	2.97e-21	Hip circumference;
KIRP	cis	rs2976388	0.578	rs4736324	chr8:143830462	G/A	cg06565975	chr8:143823917	SLURP1	-0.52	-7.54	-0.43	9.27e-13	Urinary tract infection frequency;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03218198	chr16:588562	SOLH	0.47	6.1	0.36	4.18e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1562975	0.681	rs62317082	chr4:109467764	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.43	5.1	0.31	6.91e-7	Height;
KIRP	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.43	5.62	0.34	5.09e-8	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg02487422	chr3:49467188	NICN1	0.35	5.0	0.3	1.08e-6	Parkinson's disease;
KIRP	cis	rs16857609	0.586	rs6754393	chr2:218356936	A/G	cg15335768	chr2:218268053	DIRC3	-0.34	-4.97	-0.3	1.24e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg15038512	chr6:170123185	PHF10	0.49	5.55	0.33	7.45e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg00310523	chr12:86230176	RASSF9	0.41	6.32	0.37	1.23e-9	Major depressive disorder;
KIRP	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg15226275	chr6:116381976	FRK	0.21	5.98	0.36	7.62e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs259842	0.612	rs10195952	chr2:180714995	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.41	-5.61	-0.34	5.33e-8	Blood protein levels;
KIRP	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg13319975	chr6:146136371	FBXO30	0.47	6.35	0.38	1.05e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.37	-0.43	2.63e-12	Morning vs. evening chronotype;
KIRP	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg18154014	chr19:37997991	ZNF793	0.62	6.72	0.39	1.28e-10	Coronary artery calcification;
KIRP	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.41	5.84	0.35	1.62e-8	Body mass index;
KIRP	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs240764	0.817	rs240113	chr6:101058886	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.57	0.33	6.7e-8	Neuroticism;
KIRP	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	12.28	0.62	2.38e-27	Smoking behavior;
KIRP	cis	rs1014246	0.807	rs12784789	chr10:118473593	A/T	cg14919929	chr10:118506882	NA	0.62	7.4	0.43	2.1e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg07001201	chr5:642380	CEP72	0.7	6.47	0.38	5.25e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01906442	chr15:69706823	KIF23	0.47	6.27	0.37	1.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.53	0.52	1.61e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg15557168	chr22:42548783	NA	-0.37	-5.34	-0.32	2.1e-7	Cognitive function;
KIRP	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.23	0.42	6.23e-12	Bipolar disorder;
KIRP	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg26876637	chr1:152193138	HRNR	0.71	9.66	0.52	6.38e-19	Atopic dermatitis;
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg21523564	chr15:75251491	NA	0.43	6.69	0.39	1.46e-10	Caffeine consumption;
KIRP	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-9.07	-0.5	3.77e-17	Blood trace element (Zn levels);
KIRP	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.67	0.48	6.04e-16	Morning vs. evening chronotype;
KIRP	cis	rs11671005	0.656	rs55652736	chr19:59007566	G/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.58	-5.73	-0.34	2.96e-8	Mean platelet volume;
KIRP	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg25019033	chr10:957182	NA	-0.54	-5.8	-0.35	2.06e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7560272	0.682	rs2421546	chr2:73641077	A/C	cg20560298	chr2:73613845	ALMS1	0.49	6.07	0.36	4.81e-9	Schizophrenia;
KIRP	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-6.72	-0.39	1.29e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs78487399	0.808	rs7581586	chr2:43668176	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.53	7.32	0.42	3.43e-12	Glioblastoma;Glioma;
KIRP	cis	rs7737355	0.812	rs251015	chr5:131029683	A/G	cg06307176	chr5:131281290	NA	0.4	4.87	0.3	2.03e-6	Life satisfaction;
KIRP	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg12131826	chr15:77904385	NA	0.45	6.14	0.36	3.36e-9	Type 2 diabetes;
KIRP	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg04166393	chr7:2884313	GNA12	0.48	6.66	0.39	1.82e-10	Height;
KIRP	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.07	-0.36	4.77e-9	Morning vs. evening chronotype;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00748821	chr4:83932227	LIN54	0.55	7.09	0.41	1.4e-11	Smoking initiation;
KIRP	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg06521331	chr12:34319734	NA	-0.48	-5.99	-0.36	7.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg01616529	chr11:638424	DRD4	-0.38	-5.21	-0.32	3.91e-7	Systemic lupus erythematosus;
KIRP	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	0.98	6.89	0.4	4.64e-11	Type 2 diabetes nephropathy;
KIRP	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.58	-0.52	1.1e-18	Neuroticism;
KIRP	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-9.81	-0.53	2.13e-19	Height;
KIRP	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.5e-13	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13672462	chr22:36424369	RBM9	-0.58	-6.27	-0.37	1.63e-9	Menopause (age at onset);
KIRP	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.98	0.45	5.7e-14	Height;
KIRP	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-8.85	-0.49	1.71e-16	Coronary artery disease;
KIRP	cis	rs17065868	0.764	rs17210696	chr13:45046432	T/C	cg10246903	chr13:45222710	NA	0.59	4.95	0.3	1.36e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2224391	0.628	rs2773304	chr6:5242602	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-6.04	-0.36	5.65e-9	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20284440	chr14:52118688	FRMD6	0.53	6.17	0.37	2.82e-9	Smoking initiation;
KIRP	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	10.26	0.55	8.41e-21	Mean platelet volume;
KIRP	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg00094735	chr5:1949198	NA	0.46	5.49	0.33	1.02e-7	Gut microbiome composition (winter);
KIRP	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg11833968	chr6:79620685	NA	0.44	6.63	0.39	2.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg03171003	chr2:111875934	NA	0.45	6.34	0.37	1.12e-9	Chronic lymphocytic leukemia;
KIRP	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.74	-0.49	3.61e-16	Joint mobility (Beighton score);
KIRP	cis	rs7870753	0.735	rs6477495	chr9:99255608	G/A	cg25260653	chr9:99212216	HABP4	0.55	5.83	0.35	1.74e-8	Height;
KIRP	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg27170947	chr2:26402098	FAM59B	-0.62	-6.91	-0.4	4.18e-11	Gut microbiome composition (summer);
KIRP	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.82	11.33	0.59	3.17e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg08662619	chr6:150070041	PCMT1	0.37	6.18	0.37	2.71e-9	Lung cancer;
KIRP	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-5.19	-0.31	4.31e-7	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10720867	chr6:155537595	TIAM2	0.47	6.03	0.36	6e-9	Interleukin-4 levels;
KIRP	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.66	-10.47	-0.56	1.92e-21	Calcium levels;
KIRP	cis	rs3767633	0.925	rs4233380	chr1:161892483	A/C	cg09175582	chr1:161736000	ATF6	0.73	5.67	0.34	4.04e-8	IgG glycosylation;
KIRP	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.77	-10.69	-0.56	3.85e-22	Inflammatory bowel disease;
KIRP	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.84	6.94	0.4	3.37e-11	Initial pursuit acceleration;
KIRP	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.53	6.64	0.39	2.01e-10	HDL cholesterol;
KIRP	cis	rs787274	1.000	rs787274	chr9:115550363	A/C	cg13803584	chr9:115635662	SNX30	-0.73	-7.97	-0.45	5.88e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6496044	0.963	rs7165300	chr15:86070069	G/C	cg10818794	chr15:86012489	AKAP13	-0.38	-4.89	-0.3	1.78e-6	Interstitial lung disease;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg07701084	chr6:150067640	NUP43	0.71	10.3	0.55	6.43e-21	Lung cancer;
KIRP	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.18	0.46	1.53e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.57	7.73	0.44	2.8e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	9.67	0.52	5.74e-19	Mood instability;
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.64	9.92	0.53	1.02e-19	Immature fraction of reticulocytes;
KIRP	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg19847130	chr8:10466454	RP1L1	0.33	4.87	0.3	1.99e-6	Triglycerides;
KIRP	cis	rs2048523	0.529	rs1434513	chr18:44828677	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.5	0.33	9.31e-8	Menarche (age at onset);
KIRP	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg09307838	chr4:120376055	NA	0.63	6.85	0.4	6.04e-11	Educational attainment;
KIRP	cis	rs13073817	0.582	rs13084808	chr3:18692093	A/G	cg21454600	chr3:18772063	NA	0.35	4.97	0.3	1.28e-6	Crohn's disease;
KIRP	cis	rs10875746	0.669	rs11168487	chr12:48640709	G/A	cg26205652	chr12:48591994	NA	0.81	10.25	0.55	9.37e-21	Longevity (90 years and older);
KIRP	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.86	-11.79	-0.6	1.01e-25	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.16	-0.31	5.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.17	0.37	2.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs3126085	0.515	rs1923506	chr1:152359700	A/T	cg26876637	chr1:152193138	HRNR	-0.54	-6.93	-0.4	3.6e-11	Atopic dermatitis;
KIRP	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.53	-0.48	1.5e-15	Mean corpuscular volume;
KIRP	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg10402321	chr1:26617780	UBXN11	-0.4	-5.18	-0.31	4.52e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3087591	0.683	rs17826544	chr17:29640225	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	9.29	0.51	8.76e-18	Hip circumference;
KIRP	cis	rs731174	0.759	rs497705	chr1:38162760	C/G	cg14170840	chr1:38155120	C1orf109	-0.4	-5.12	-0.31	6.28e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.61	-8.4	-0.47	3.57e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs490234	0.627	rs4838276	chr9:128364901	A/G	cg14078157	chr9:128172775	NA	0.57	6.68	0.39	1.55e-10	Mean arterial pressure;
KIRP	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19856749	chr10:124316636	NA	-0.54	-7.7	-0.44	3.42e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.71	-0.44	3.18e-13	Body mass index;
KIRP	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.44	-0.76	2.76e-48	Schizophrenia;
KIRP	cis	rs4006360	0.546	rs1848812	chr17:39235917	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.66	-0.48	6.38e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg04166393	chr7:2884313	GNA12	-0.41	-5.55	-0.33	7.36e-8	Height;
KIRP	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg08501292	chr6:25962987	TRIM38	1.06	8.25	0.47	9.69e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6732426	0.550	rs6544647	chr2:43578419	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.37	-4.94	-0.3	1.46e-6	Hair morphology;
KIRP	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg23479056	chr15:41276147	INO80	-0.41	-6.08	-0.36	4.64e-9	Menopause (age at onset);
KIRP	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.64	8.43	0.47	2.92e-15	Alcohol dependence;
KIRP	cis	rs6580649	0.941	rs3742074	chr12:48457385	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.87	8.81	0.49	2.32e-16	Hip geometry;
KIRP	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	0.96	16.16	0.72	1.62e-40	Ulcerative colitis;
KIRP	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.52	-7.08	-0.41	1.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9473924	0.580	rs68118663	chr6:50815367	C/T	cg14470998	chr6:50812995	TFAP2B	0.99	8.81	0.49	2.34e-16	Body mass index;
KIRP	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg17145862	chr1:211918768	LPGAT1	-0.91	-13.37	-0.65	5.21e-31	Leprosy;
KIRP	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg13256891	chr4:100009986	ADH5	0.46	5.58	0.34	6.4e-8	Alcohol dependence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25423755	chr2:220306636	SPEG	0.47	6.09	0.36	4.22e-9	Parkinson's disease;
KIRP	cis	rs10489202	0.954	rs3820399	chr1:168062053	C/T	cg24449463	chr1:168025552	DCAF6	-0.45	-5.22	-0.32	3.78e-7	Schizophrenia;
KIRP	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.7e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg13819577	chr1:248512075	OR14C36	-0.37	-5.17	-0.31	4.93e-7	Common traits (Other);
KIRP	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg17366294	chr4:99064904	C4orf37	0.38	4.86	0.3	2.14e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs141759085	1	rs141759085	chr16:530967	A/G	cg00676925	chr16:540266	RAB11FIP3	-0.69	-6.2	-0.37	2.33e-9	Platelet count;
KIRP	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs4786125	0.581	rs7193000	chr16:6918270	G/C	cg03623568	chr16:6915990	A2BP1	-0.41	-5.04	-0.31	9.11e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg09597638	chr17:3907349	NA	0.63	10.74	0.56	2.6e-22	Type 2 diabetes;
KIRP	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-8.08	-0.46	2.84e-14	Fibrinogen levels;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.65	-8.22	-0.46	1.16e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-7.64	-0.44	4.98e-13	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.62	9.21	0.51	1.53e-17	Lung cancer;
KIRP	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.26	-0.37	1.67e-9	Alcohol dependence;
KIRP	trans	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg06521331	chr12:34319734	NA	-0.55	-6.89	-0.4	4.72e-11	Morning vs. evening chronotype;
KIRP	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg10402321	chr1:26617780	UBXN11	-0.43	-5.57	-0.33	6.52e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.31	0.47	6.47e-15	Bipolar disorder;
KIRP	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.49	5.12	0.31	6.29e-7	Recombination rate (females);
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-7.19	-0.42	7.69e-12	Longevity;Endometriosis;
KIRP	cis	rs17123764	0.892	rs60415769	chr12:49989105	A/T	cg02054252	chr12:50078554	FMNL3	0.5	5.0	0.3	1.1e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.6	-0.39	2.55e-10	Coronary artery calcification;
KIRP	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.25	0.42	5.37e-12	Bipolar disorder;
KIRP	cis	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg21775007	chr8:11205619	TDH	-0.38	-4.96	-0.3	1.33e-6	Triglycerides;
KIRP	cis	rs4481887	0.830	rs1538703	chr1:248519821	T/G	cg01631408	chr1:248437212	OR2T33	-0.43	-6.09	-0.36	4.4e-9	Common traits (Other);
KIRP	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.78	0.44	2.06e-13	Neuroticism;
KIRP	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg21360079	chr12:107162445	NA	-0.66	-9.3	-0.51	8.16e-18	Heart rate;
KIRP	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	10.71	0.56	3.11e-22	Coffee consumption (cups per day);
KIRP	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-6.74	-0.4	1.09e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03762994	chr17:6899332	ALOX12	0.29	4.97	0.3	1.23e-6	Tonsillectomy;
KIRP	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg05991184	chr2:219186017	PNKD	0.35	4.86	0.3	2.07e-6	Colorectal cancer;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg19876724	chr3:129159024	IFT122;MBD4	0.52	6.24	0.37	1.91e-9	DNA methylation (variation);
KIRP	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.9	-12.62	-0.63	1.72e-28	Coronary artery disease;
KIRP	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg17554472	chr22:41940697	POLR3H	0.65	6.64	0.39	2.01e-10	Vitiligo;
KIRP	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.71	0.39	1.33e-10	Aortic root size;
KIRP	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg03351412	chr1:154909251	PMVK	0.64	8.62	0.48	8.4e-16	Prostate cancer;
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.61	-5.27	-0.32	2.91e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7116495	0.881	rs7930142	chr11:71737016	C/T	cg26138937	chr11:71823887	C11orf51	-0.7	-5.65	-0.34	4.46e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1829883	0.931	rs7713876	chr5:98878187	C/G	cg08333243	chr5:99726346	NA	-0.38	-5.22	-0.32	3.8e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg19761014	chr17:28927070	LRRC37B2	0.54	5.16	0.31	5.04e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25123564	chr7:156917471	NA	0.5	6.55	0.39	3.42e-10	Interleukin-4 levels;
KIRP	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg09699651	chr6:150184138	LRP11	0.55	7.33	0.42	3.37e-12	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.53	7.38	0.43	2.49e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-8.57	-0.48	1.15e-15	Platelet count;
KIRP	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-11.16	-0.58	1.15e-23	Colorectal cancer;
KIRP	cis	rs7202877	0.656	rs4888370	chr16:75308230	T/C	cg03315344	chr16:75512273	CHST6	0.61	5.97	0.36	8.39e-9	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg12131826	chr15:77904385	NA	0.44	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	trans	rs1106684	1.000	rs11762266	chr7:131457689	A/G	cg13607082	chr12:122652224	LRRC43	-0.67	-6.81	-0.4	7.24e-11	Body mass index;
KIRP	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	7.69	0.44	3.54e-13	Iron status biomarkers;
KIRP	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.47	6.23	0.37	2.06e-9	Breast cancer;
KIRP	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.63	-5.22	-0.32	3.85e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-0.78	-10.38	-0.55	3.59e-21	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19863459	chr19:4639366	TNFAIP8L1	0.47	6.29	0.37	1.41e-9	Parkinson's disease;
KIRP	cis	rs580438	0.510	rs6806012	chr3:13390629	C/T	cg10657019	chr3:13328039	NA	0.58	7.69	0.44	3.52e-13	Myringotomy;
KIRP	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg22437258	chr11:111473054	SIK2	0.59	7.15	0.42	9.62e-12	Primary sclerosing cholangitis;
KIRP	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.45	5.75	0.34	2.64e-8	Initial pursuit acceleration;
KIRP	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.41	5.15	0.31	5.44e-7	High light scatter reticulocyte count;
KIRP	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg09264619	chr17:80180166	NA	0.45	5.2	0.31	4.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8135828	1.000	rs458196	chr22:29978026	A/T	cg23204276	chr22:29729285	AP1B1;SNORD125	0.44	4.96	0.3	1.34e-6	Lipid traits;
KIRP	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.87	8.81	0.49	2.31e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg03511173	chr18:77590860	NA	-0.46	-5.04	-0.31	9.21e-7	Opioid sensitivity;
KIRP	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs9914988	0.613	rs66701171	chr17:27276421	G/T	cg10538030	chr17:27276405	PHF12	-0.61	-5.18	-0.31	4.52e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.54	6.81	0.4	7.59e-11	Total body bone mineral density;
KIRP	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs2721195	0.810	rs2721142	chr8:145752467	A/T	cg11211951	chr8:145729740	GPT	0.45	7.51	0.43	1.12e-12	Age at first birth;
KIRP	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg25486957	chr4:152246857	NA	-0.49	-5.58	-0.34	6.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6547631	0.844	rs13012309	chr2:85907924	G/A	cg07313956	chr2:85895360	SFTPB	0.34	5.0	0.3	1.08e-6	Blood protein levels;
KIRP	cis	rs1413885	0.549	rs4593866	chr1:65850968	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.56	6.18	0.37	2.69e-9	Anticoagulant levels;
KIRP	cis	rs7923609	0.778	rs7075195	chr10:65050659	A/G	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.05	-0.31	8.8e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg00689492	chr4:1303491	MAEA	0.28	5.31	0.32	2.4e-7	Longevity;
KIRP	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.75	-11.05	-0.58	2.6e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs7267005	1.000	rs79242605	chr20:34492016	T/C	cg17201900	chr20:34330562	RBM39	0.87	4.9	0.3	1.71e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg02462569	chr6:150064036	NUP43	-0.32	-4.86	-0.3	2.09e-6	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16213072	chr14:78082735	SPTLC2	0.51	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg04310649	chr10:35416472	CREM	-0.5	-5.9	-0.35	1.18e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.68	-7.15	-0.41	9.99e-12	Bipolar disorder;
KIRP	cis	rs1043099	0.536	rs9620979	chr22:30808752	T/C	cg03868770	chr22:30783737	RNF215	-0.49	-5.26	-0.32	3.12e-7	Rheumatoid arthritis;
KIRP	cis	rs829661	0.947	rs829574	chr2:30682360	G/A	cg10949345	chr2:30726833	LCLAT1	0.72	10.09	0.54	3.04e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12313068	0.709	rs10849698	chr12:110504798	C/G	cg12870014	chr12:110450643	ANKRD13A	0.57	7.54	0.43	8.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg07308232	chr7:1071921	C7orf50	-0.78	-9.57	-0.52	1.21e-18	Longevity;Endometriosis;
KIRP	cis	rs1978968	0.913	rs34272636	chr22:18433603	A/C	cg03078520	chr22:18463400	MICAL3	-0.74	-8.21	-0.46	1.22e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.38	0.38	8.65e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs16828019	0.777	rs67460888	chr1:41469337	T/C	cg03387723	chr1:41708464	SCMH1	-0.75	-6.06	-0.36	4.97e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg24009623	chr19:33667908	NA	0.47	5.73	0.34	2.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg21573476	chr21:45109991	RRP1B	-0.81	-10.79	-0.57	1.75e-22	Mean corpuscular volume;
KIRP	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.89	-0.4	4.56e-11	Type 2 diabetes;
KIRP	cis	rs7975161	0.515	rs7299866	chr12:104576197	C/T	cg25273343	chr12:104657179	TXNRD1	-0.58	-4.85	-0.3	2.22e-6	Toenail selenium levels;
KIRP	cis	rs17381785	0.586	rs1874205	chr4:14971155	T/C	cg12377275	chr4:15005593	CPEB2	0.73	10.21	0.55	1.23e-20	Urate levels in overweight individuals;
KIRP	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.48	6.15	0.37	3.12e-9	Multiple sclerosis;
KIRP	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.59	-6.47	-0.38	5.23e-10	Alcohol dependence;
KIRP	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-0.52	-7.3	-0.42	3.92e-12	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	12.67	0.63	1.15e-28	Platelet count;
KIRP	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	5.54	0.33	7.94e-8	Mean platelet volume;
KIRP	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg24296786	chr1:45957014	TESK2	0.51	6.18	0.37	2.57e-9	Homocysteine levels;
KIRP	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	6.28	0.37	1.51e-9	Breast cancer;
KIRP	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg14851346	chr12:38532713	NA	-0.41	-5.12	-0.31	6.2e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7851660	0.809	rs10115216	chr9:100657119	G/T	cg13688889	chr9:100608707	NA	0.72	9.15	0.5	2.3e-17	Strep throat;
KIRP	cis	rs8010715	0.816	rs762093	chr14:24591918	G/C	cg23112188	chr14:24563095	PCK2	-0.35	-5.15	-0.31	5.29e-7	IgG glycosylation;
KIRP	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg00647317	chr7:50633725	DDC	0.39	5.74	0.34	2.83e-8	Systemic sclerosis;
KIRP	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs1832871	0.683	rs62437360	chr6:158720162	G/A	cg07215822	chr6:158701037	NA	-0.64	-7.36	-0.42	2.8e-12	Height;
KIRP	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg07511934	chr16:89386912	ANKRD11	0.46	5.73	0.34	2.96e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.5	-0.38	4.37e-10	Joint mobility (Beighton score);
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg14221460	chr8:27183342	PTK2B	0.52	6.74	0.39	1.11e-10	Neuroticism;
KIRP	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg15436174	chr10:43711423	RASGEF1A	0.55	6.65	0.39	1.87e-10	Hirschsprung disease;
KIRP	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg27398547	chr14:60952738	C14orf39	0.55	5.26	0.32	3.07e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg25730555	chr22:47059586	GRAMD4	0.52	6.09	0.36	4.26e-9	Urate levels in obese individuals;
KIRP	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.91	14.28	0.67	4.07e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.89	13.21	0.64	1.87e-30	Bladder cancer;
KIRP	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.62	-6.84	-0.4	6.26e-11	Urate levels in lean individuals;
KIRP	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.4	-0.33	1.6e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg22676075	chr6:135203613	NA	0.49	7.17	0.42	8.81e-12	Red blood cell count;
KIRP	cis	rs2742417	1.000	rs9821974	chr3:45784963	T/C	cg04037228	chr3:45636386	LIMD1	0.36	5.17	0.31	4.94e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.47	6.27	0.37	1.65e-9	Breast cancer;
KIRP	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.46	5.96	0.36	8.86e-9	Initial pursuit acceleration;
KIRP	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.96	12.69	0.63	1.01e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-9.19	-0.51	1.69e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg09936142	chr19:10668400	KRI1	-0.42	-4.9	-0.3	1.71e-6	Inflammatory skin disease;
KIRP	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.78	0.35	2.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg22138327	chr13:27999177	GTF3A	0.86	6.88	0.4	5.01e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.34	-0.32	2.09e-7	Life satisfaction;
KIRP	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.96	-0.3	1.29e-6	Pulmonary function;
KIRP	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg10523679	chr1:76189770	ACADM	-0.5	-6.96	-0.41	3.06e-11	Daytime sleep phenotypes;
KIRP	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg09549813	chr16:4587862	C16orf5	-0.33	-4.98	-0.3	1.22e-6	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11014373	chr2:105479054	NA	0.44	6.3	0.37	1.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.22	-0.37	2.13e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg25036284	chr2:26402008	FAM59B	0.61	6.07	0.36	4.82e-9	Gut microbiome composition (summer);
KIRP	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.96e-7	Aortic root size;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.17	0.37	2.84e-9	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09319194	chr6:122793185	PKIB;SERINC1	-0.45	-6.32	-0.37	1.23e-9	Interleukin-4 levels;
KIRP	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.72	10.52	0.56	1.29e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg09699651	chr6:150184138	LRP11	0.5	6.74	0.39	1.13e-10	Lung cancer;
KIRP	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.44	-6.41	-0.38	7.45e-10	Airway imaging phenotypes;
KIRP	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.4	6.61	0.39	2.37e-10	Testicular germ cell tumor;
KIRP	cis	rs1847505	0.609	rs7327571	chr13:61487601	C/G	cg25164009	chr13:61490935	NA	-0.53	-5.52	-0.33	8.68e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.36	-0.42	2.81e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6959887	0.962	rs2024345	chr7:35297240	T/G	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs7534824	0.625	rs61780285	chr1:101357627	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.1	0.41	1.3e-11	Refractive astigmatism;
KIRP	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07570687	chr10:102243282	WNT8B	0.47	4.86	0.3	2.08e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg26376749	chr17:30677620	ZNF207	0.68	6.3	0.37	1.38e-9	Lung function (FEV1);
KIRP	cis	rs7714584	1.000	rs76433514	chr5:150306532	C/G	cg22134413	chr5:150180641	NA	0.8	5.87	0.35	1.43e-8	Crohn's disease;
KIRP	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.38	-5.0	-0.3	1.11e-6	Coronary artery disease;
KIRP	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-6.16	-0.37	2.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs986417	0.901	rs713449	chr14:61029084	C/G	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.7	-10.82	-0.57	1.46e-22	Monocyte percentage of white cells;
KIRP	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.61	-0.39	2.33e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10073892	0.917	rs10479204	chr5:101680060	A/C	cg19774478	chr5:101632501	SLCO4C1	0.65	7.14	0.41	1.04e-11	Cognitive decline (age-related);
KIRP	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg13289132	chr10:30722225	MAP3K8	-0.4	-5.05	-0.31	8.52e-7	Inflammatory bowel disease;
KIRP	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg13271783	chr10:134563150	INPP5A	-0.62	-7.92	-0.45	8.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg23950597	chr19:37808831	NA	-0.57	-6.17	-0.37	2.77e-9	Coronary artery calcification;
KIRP	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.73	8.78	0.49	2.78e-16	Corneal astigmatism;
KIRP	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg24879335	chr3:133465180	TF	0.5	8.02	0.46	4.22e-14	Iron status biomarkers;
KIRP	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg20673091	chr1:2541236	MMEL1	-0.68	-10.63	-0.56	5.94e-22	Ulcerative colitis;
KIRP	cis	rs6545883	0.929	rs10190332	chr2:61619267	T/G	cg15711740	chr2:61764176	XPO1	0.61	8.11	0.46	2.34e-14	Tuberculosis;
KIRP	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg06012730	chr15:75315579	PPCDC	-0.4	-4.99	-0.3	1.13e-6	Blood trace element (Zn levels);
KIRP	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg26531700	chr6:26746687	NA	0.47	6.83	0.4	6.62e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	1.000	rs17161966	chr11:71815308	T/C	cg26138937	chr11:71823887	C11orf51	0.69	5.51	0.33	9.2e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs287982	1.000	rs287980	chr2:9971366	G/A	cg18436444	chr2:10917754	ATP6V1C2	0.34	5.01	0.3	1.05e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.55e-23	Primary sclerosing cholangitis;
KIRP	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26207909	chr14:103986467	CKB	0.75	11.54	0.59	6.48e-25	Body mass index;
KIRP	trans	rs1559777	0.646	rs1343912	chr15:58087100	G/A	cg11764937	chr2:234116266	INPP5D	0.58	6.03	0.36	5.97e-9	Myopia (pathological);
KIRP	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.4	-5.0	-0.3	1.09e-6	Schizophrenia;
KIRP	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.85	-11.28	-0.58	4.58e-24	Type 2 diabetes;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg08018356	chr19:36706053	ZNF146;ZNF565	-0.49	-6.77	-0.4	9.32e-11	Morning vs. evening chronotype;
KIRP	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6504622	0.818	rs9910899	chr17:45034342	G/C	cg24703533	chr17:45055318	NA	0.38	5.05	0.31	8.72e-7	Orofacial clefts;
KIRP	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.73	-8.35	-0.47	4.98e-15	Adiposity;
KIRP	trans	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg10756647	chr7:56101905	PSPH	1.06	8.15	0.46	1.91e-14	Diabetic kidney disease;
KIRP	trans	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.67	8.93	0.49	1.02e-16	Morning vs. evening chronotype;
KIRP	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg00129232	chr17:37814104	STARD3	-0.52	-6.54	-0.38	3.61e-10	Self-reported allergy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18139254	chr14:100751903	NA	0.45	6.06	0.36	5.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.59	0.52	1.05e-18	Body mass index;
KIRP	cis	rs2733310	0.947	rs1115019	chr15:57141231	A/G	cg13626582	chr15:57592083	LOC283663	-0.23	-5.52	-0.33	8.61e-8	Mean platelet volume;
KIRP	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg09137382	chr11:130731461	NA	0.52	7.59	0.44	6.67e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4006360	1.000	rs4006360	chr17:39250639	A/G	cg25341923	chr17:39239918	KRTAP4-7	0.63	9.94	0.54	8.72e-20	Bipolar disorder and schizophrenia;
KIRP	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg11861562	chr11:117069780	TAGLN	-0.39	-5.13	-0.31	5.96e-7	Blood protein levels;
KIRP	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23161317	chr6:28129485	ZNF389	0.43	5.06	0.31	8.25e-7	Depression;
KIRP	cis	rs7188697	0.775	rs8056620	chr16:58604387	T/A	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.35	0.32	1.98e-7	Cognitive test performance;
KIRP	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26207909	chr14:103986467	CKB	0.74	10.53	0.56	1.19e-21	Body mass index;
KIRP	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg06027949	chr8:82754900	SNX16	-0.62	-6.75	-0.4	1.05e-10	Diastolic blood pressure;
KIRP	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.6	-0.34	5.81e-8	Metabolite levels;
KIRP	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.72	-9.17	-0.5	1.98e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7027203	0.514	rs2265806	chr9:96506903	G/T	cg14598338	chr9:96623480	NA	-0.44	-6.47	-0.38	5.18e-10	DNA methylation (variation);
KIRP	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg16989719	chr2:238392110	NA	-0.56	-6.29	-0.37	1.45e-9	Prostate cancer;
KIRP	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.73	0.49	4.02e-16	Electroencephalogram traits;
KIRP	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg01620082	chr3:125678407	NA	-1.33	-8.35	-0.47	5.13e-15	Depression;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11987759	chr7:65425863	GUSB	-0.46	-5.46	-0.33	1.14e-7	Aortic root size;
KIRP	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.64	8.11	0.46	2.42e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	11.08	0.58	2.14e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6442310	0.534	rs2921190	chr3:12419475	T/C	cg22839075	chr3:12045461	SYN2	0.36	5.2	0.31	4.15e-7	Hematocrit;
KIRP	cis	rs6088813	0.767	rs4911179	chr20:33972899	A/C	cg14752227	chr20:34000481	UQCC	-0.52	-6.86	-0.4	5.42e-11	Height;
KIRP	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.79	10.83	0.57	1.33e-22	Systemic lupus erythematosus;
KIRP	cis	rs7975161	0.640	rs10735394	chr12:104687142	C/A	cg25273343	chr12:104657179	TXNRD1	-0.6	-5.51	-0.33	8.83e-8	Toenail selenium levels;
KIRP	cis	rs9596863	0.950	rs1379827	chr13:54395414	A/C	ch.13.53330881F	chr13:54432880	NA	0.62	6.25	0.37	1.82e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg00012203	chr2:219082015	ARPC2	0.66	8.66	0.48	6.27e-16	Colorectal cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15828085	chr19:30302476	CCNE1	-0.46	-6.02	-0.36	6.16e-9	Metabolic traits;
KIRP	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26850624	chr5:429559	AHRR	-0.32	-5.67	-0.34	3.96e-8	Cystic fibrosis severity;
KIRP	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg02887458	chr19:19495540	GATAD2A	-0.5	-5.8	-0.35	2.05e-8	Bipolar disorder;
KIRP	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg00277334	chr10:82204260	NA	-0.44	-4.9	-0.3	1.76e-6	Post bronchodilator FEV1;
KIRP	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg09455208	chr3:40491958	NA	0.35	6.04	0.36	5.57e-9	Renal cell carcinoma;
KIRP	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg15103426	chr22:29168792	CCDC117	0.55	7.06	0.41	1.69e-11	Lymphocyte counts;
KIRP	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.72	-0.49	4.29e-16	Neuroticism;
KIRP	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg02375832	chr11:62437615	C11orf48	-0.4	-4.88	-0.3	1.95e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg10645314	chr2:3704589	ALLC	-0.64	-7.1	-0.41	1.32e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg08885076	chr2:99613938	TSGA10	0.59	10.21	0.55	1.25e-20	Chronic sinus infection;
KIRP	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.48	6.05	0.36	5.5e-9	Coronary heart disease;
KIRP	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.67	-9.65	-0.52	6.87e-19	Metabolite levels;
KIRP	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg03254818	chr6:169586852	NA	-0.47	-7.12	-0.41	1.16e-11	Pulse pressure;
KIRP	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.51	0.43	1.07e-12	Body mass index;
KIRP	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.62	-0.34	5.24e-8	Coronary artery disease;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg12692727	chr7:1102344	C7orf50	0.48	5.13	0.31	5.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.58	0.39	2.79e-10	Skin colour saturation;
KIRP	trans	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-6.49	-0.38	4.58e-10	Obesity-related traits;
KIRP	trans	rs4683505	1.000	rs507760	chr3:140189400	G/C	cg09131339	chr1:109914235	SORT1	-0.7	-6.07	-0.36	4.92e-9	Myopia (pathological);
KIRP	cis	rs9329221	0.539	rs35060302	chr8:10264771	C/G	cg27411982	chr8:10470053	RP1L1	0.41	5.07	0.31	7.77e-7	Neuroticism;
KIRP	cis	rs7301016	1.000	rs10877856	chr12:62870536	C/G	cg01804193	chr12:63026212	NA	0.53	5.36	0.32	1.91e-7	IgG glycosylation;
KIRP	cis	rs12135191	0.771	rs61835531	chr1:236499757	A/C	cg21399712	chr1:236511386	NA	-0.48	-6.19	-0.37	2.54e-9	Urate levels (BMI interaction);
KIRP	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg23173402	chr1:227635558	NA	0.84	6.3	0.37	1.33e-9	Major depressive disorder;
KIRP	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg14558114	chr2:88469736	THNSL2	0.65	5.32	0.32	2.38e-7	Plasma clusterin levels;
KIRP	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.68	6.5	0.38	4.41e-10	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg24874828	chr4:187887005	NA	-0.48	-7.11	-0.41	1.26e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg18132916	chr6:79620363	NA	-0.41	-5.75	-0.34	2.57e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs73200209	0.744	rs1136427	chr12:116608487	C/T	cg01776926	chr12:116560359	MED13L	-0.51	-5.42	-0.33	1.43e-7	Total body bone mineral density;
KIRP	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg13880726	chr7:1868755	MAD1L1	0.51	5.99	0.36	7.46e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg15469184	chr8:337539	NA	0.59	6.05	0.36	5.39e-9	Obesity-related traits;
KIRP	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg10253484	chr15:75165896	SCAMP2	0.62	6.74	0.39	1.11e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.68	7.92	0.45	7.93e-14	Blood metabolite levels;
KIRP	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.63	0.39	2.11e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.69	8.04	0.46	3.89e-14	Height;
KIRP	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.78	11.52	0.59	7.45e-25	Heart rate;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08894960	chr1:237061516	MTR	0.58	7.35	0.42	2.91e-12	Interleukin-4 levels;
KIRP	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg10167378	chr1:228756711	NA	0.88	7.37	0.43	2.63e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs687432	0.885	rs7930102	chr11:57814759	G/A	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.41	4.95	0.3	1.38e-6	Glycated hemoglobin levels;
KIRP	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1030268	0.651	rs13222377	chr7:133466346	C/T	cg10665199	chr7:133106180	EXOC4	0.5	4.99	0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg21775007	chr8:11205619	TDH	-0.42	-5.33	-0.32	2.22e-7	Triglycerides;
KIRP	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.69	-6.8	-0.4	7.99e-11	Breast cancer;
KIRP	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.25e-11	Diabetic kidney disease;
KIRP	cis	rs7209395	0.700	rs17690171	chr17:64202857	C/T	cg19474267	chr17:64306194	PRKCA	-0.43	-4.92	-0.3	1.57e-6	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
KIRP	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg16989719	chr2:238392110	NA	-0.53	-5.39	-0.33	1.61e-7	Prostate cancer;
KIRP	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg11503966	chr20:62272292	STMN3	0.37	5.47	0.33	1.11e-7	Prostate cancer;
KIRP	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.44	0.38	6.29e-10	Retinal vascular caliber;
KIRP	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.55	6.37	0.38	9.42e-10	Aortic root size;
KIRP	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.12e-11	Blood metabolite levels;
KIRP	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.76	7.7	0.44	3.42e-13	Migraine;Coronary artery disease;
KIRP	cis	rs2904967	0.866	rs506280	chr11:65069534	A/C	cg12562828	chr11:65076843	NA	0.48	7.3	0.42	4.04e-12	Mean corpuscular volume;
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg13906792	chr15:75199810	C15orf17	-0.39	-5.64	-0.34	4.74e-8	Breast cancer;
KIRP	cis	rs77861329	1.000	rs9841469	chr3:52166596	C/A	cg08692210	chr3:52188851	WDR51A	0.95	7.63	0.44	5.21e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs8028182	0.636	rs4243034	chr15:75750969	G/A	cg20655648	chr15:75932815	IMP3	0.55	6.89	0.4	4.57e-11	Sudden cardiac arrest;
KIRP	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg17554472	chr22:41940697	POLR3H	-0.61	-6.53	-0.38	3.74e-10	Vitiligo;
KIRP	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15557168	chr22:42548783	NA	-0.47	-6.17	-0.37	2.73e-9	Cognitive function;
KIRP	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4262150	0.810	rs72797262	chr5:152018288	C/A	cg12297329	chr5:152029980	NA	-0.68	-8.33	-0.47	5.86e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14286274	chr1:211555998	C1orf97	0.54	7.55	0.43	8.53e-13	Survival in pancreatic cancer;
KIRP	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg22117172	chr7:91764530	CYP51A1	0.42	5.94	0.35	9.56e-9	Breast cancer;
KIRP	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05220968	chr6:146057943	EPM2A	0.39	5.01	0.3	1.03e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4764487	0.760	rs2268009	chr12:6340388	A/G	cg08284733	chr12:6341482	CD9	0.58	9.59	0.52	1.05e-18	Mean platelet volume;
KIRP	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	cis	rs17221829	0.733	rs11018715	chr11:89394462	A/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg18016565	chr1:150552671	MCL1	0.39	5.87	0.35	1.41e-8	Tonsillectomy;
KIRP	cis	rs7909791	0.743	rs12776760	chr10:105627575	C/A	cg11005552	chr10:105648138	OBFC1	0.42	4.86	0.3	2.11e-6	White matter hyperintensity burden;
KIRP	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.63	5.84	0.35	1.68e-8	Lung function (FEV1/FVC);
KIRP	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.72	9.63	0.52	7.91e-19	Parkinson's disease;
KIRP	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg13034073	chr7:2769681	GNA12	0.29	5.12	0.31	6.23e-7	Height;
KIRP	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.31	5.68	0.34	3.7e-8	Renal cell carcinoma;
KIRP	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg11189052	chr15:85197271	WDR73	-0.47	-5.73	-0.34	2.89e-8	P wave terminal force;
KIRP	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.13	15.49	0.7	3.03e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7572644	0.699	rs6738887	chr2:28268467	C/T	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs16857609	1.000	rs16857609	chr2:218296508	C/T	cg15335768	chr2:218268053	DIRC3	-0.46	-6.58	-0.39	2.83e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg26512142	chr11:2554198	KCNQ1	0.72	6.06	0.36	5.15e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.28	-0.32	2.84e-7	Recombination measurement;
KIRP	cis	rs397969	0.596	rs35925051	chr17:19877369	G/A	cg04132472	chr17:19861366	AKAP10	0.47	5.39	0.33	1.61e-7	Platelet count;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg03087334	chr18:33077969	INO80C	0.46	6.39	0.38	8.17e-10	Ischemic stroke;
KIRP	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg17554472	chr22:41940697	POLR3H	0.43	5.15	0.31	5.23e-7	Vitiligo;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03001457	chr8:57906166	IMPAD1	-0.44	-6.12	-0.36	3.65e-9	Metabolic traits;
KIRP	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	8.61	0.48	8.75e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1359582	0.793	rs10736361	chr10:90403797	C/T	cg15661332	chr10:90342814	RNLS	-0.61	-6.88	-0.4	4.97e-11	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	6.03	0.36	5.93e-9	Height;
KIRP	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.9	0.64	2.05e-29	Exhaled nitric oxide output;
KIRP	cis	rs4786125	0.636	rs8062299	chr16:6902722	T/C	cg03623568	chr16:6915990	A2BP1	-0.43	-5.25	-0.32	3.23e-7	Heart rate variability traits (SDNN);
KIRP	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.55	-6.76	-0.4	9.92e-11	Platelet distribution width;
KIRP	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg00677455	chr12:58241039	CTDSP2	-0.59	-7.04	-0.41	1.9e-11	Multiple sclerosis;
KIRP	cis	rs7119167	0.686	rs7123298	chr11:73038820	C/T	cg17517138	chr11:73019481	ARHGEF17	0.46	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-6.31	-0.37	1.32e-9	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.64	-9.52	-0.52	1.65e-18	Lung cancer;
KIRP	cis	rs2594989	0.943	rs7646500	chr3:11478000	A/G	cg01796438	chr3:11312864	ATG7	-0.58	-7.32	-0.42	3.58e-12	Circulating chemerin levels;
KIRP	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg01028140	chr2:1542097	TPO	-0.78	-6.92	-0.4	3.9e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg06636001	chr8:8085503	FLJ10661	0.92	12.93	0.64	1.62e-29	Mood instability;
KIRP	cis	rs6504950	0.830	rs72831295	chr17:53043804	T/C	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg02248941	chr16:2239361	CASKIN1	0.38	5.31	0.32	2.44e-7	Height;
KIRP	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg20243544	chr17:37824526	PNMT	-0.4	-4.96	-0.3	1.3e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg15112475	chr7:1198522	ZFAND2A	-0.55	-5.01	-0.3	1.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6001930	0.581	rs73167046	chr22:40843365	G/C	cg07138101	chr22:40742427	ADSL	0.71	4.94	0.3	1.47e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12963246	chr6:28129442	ZNF389	0.41	4.87	0.3	2.04e-6	Parkinson's disease;
KIRP	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.71	7.46	0.43	1.52e-12	Diastolic blood pressure;
KIRP	cis	rs7709377	0.620	rs10051302	chr5:115488698	G/C	cg23108291	chr5:115420582	COMMD10	0.43	5.26	0.32	3.2e-7	Metabolite levels  (X-11787);
KIRP	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.85	-9.63	-0.52	7.62e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg13198984	chr17:80129470	CCDC57	0.59	8.88	0.49	1.41e-16	Life satisfaction;
KIRP	cis	rs7809615	0.901	rs10261661	chr7:99189722	A/T	cg12290671	chr7:99195819	NA	-0.7	-6.71	-0.39	1.3100000000000001e-10	Blood metabolite ratios;
KIRP	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.7	5.61	0.34	5.56e-8	Diabetic retinopathy;
KIRP	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg06223162	chr1:101003688	GPR88	-0.51	-10.71	-0.56	3.27e-22	Breast cancer;
KIRP	cis	rs9896052	0.572	rs4078474	chr17:73489567	C/G	cg25649188	chr17:73499917	CASKIN2	0.46	6.03	0.36	6.06e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg01403660	chr11:68851641	TPCN2	0.68	6.64	0.39	2.02e-10	Blond vs. brown hair color;
KIRP	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-8.0	-0.45	4.83e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2299587	0.689	rs2299588	chr8:17801725	A/G	cg01800426	chr8:17659068	MTUS1	-0.53	-6.09	-0.36	4.3e-9	Economic and political preferences;
KIRP	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.32	-5.12	-0.31	6.13e-7	Parkinson's disease;
KIRP	cis	rs9687846	0.877	rs3936510	chr5:55860866	G/T	cg15001016	chr5:55860904	NA	-0.29	-5.13	-0.31	5.78e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs963731	0.649	rs2278914	chr2:39218552	G/A	cg04010122	chr2:39346883	SOS1	-0.86	-5.73	-0.34	2.99e-8	Corticobasal degeneration;
KIRP	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.29e-11	Type 2 diabetes;
KIRP	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg04289385	chr6:36355825	ETV7	0.39	5.03	0.31	9.59e-7	Platelet distribution width;
KIRP	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg23920097	chr1:209922102	NA	-0.47	-5.56	-0.33	7.01e-8	Red blood cell count;
KIRP	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg25547332	chr5:131281432	NA	-0.47	-5.28	-0.32	2.91e-7	Life satisfaction;
KIRP	cis	rs2224391	0.534	rs2773308	chr6:5246833	C/T	cg13962347	chr6:5174647	LYRM4	-0.71	-9.9	-0.53	1.19e-19	Height;
KIRP	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg16524733	chr11:117070046	TAGLN	-0.41	-5.46	-0.33	1.15e-7	Blood protein levels;
KIRP	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.49	-8.25	-0.47	9.35e-15	Pneumonia;
KIRP	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.85	0.35	1.52e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.77	9.78	0.53	2.66e-19	Corneal astigmatism;
KIRP	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg11382394	chr1:2564504	MMEL1	-0.39	-4.84	-0.3	2.26e-6	Ulcerative colitis;
KIRP	trans	rs909341	0.868	rs1291206	chr20:62329169	G/A	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.42	-0.43	1.91e-12	Atopic dermatitis;
KIRP	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg18586891	chr4:952366	TMEM175	0.59	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4862307	0.836	rs13107384	chr4:185004073	C/T	cg06737308	chr4:185021514	ENPP6	-0.59	-7.67	-0.44	3.94e-13	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs6893300	1.000	rs62406176	chr5:179164143	T/G	cg14593053	chr5:179126677	CANX	-0.54	-6.02	-0.36	6.15e-9	Resting heart rate;
KIRP	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg23791538	chr6:167370224	RNASET2	-0.47	-5.69	-0.34	3.65e-8	Crohn's disease;
KIRP	cis	rs675026	0.927	rs619089	chr6:154424488	G/A	cg07813322	chr6:154414604	OPRM1	-0.49	-6.45	-0.38	5.73e-10	Hypertension;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.76	-11.03	-0.58	3.04e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg08885076	chr2:99613938	TSGA10	-0.42	-6.26	-0.37	1.68e-9	Bipolar disorder;
KIRP	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	5.21	0.32	4.01e-7	Cardiovascular disease risk factors;
KIRP	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg22907277	chr7:1156413	C7orf50	0.56	7.44	0.43	1.67e-12	Longevity;Endometriosis;
KIRP	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.73	-10.38	-0.55	3.7e-21	Height;
KIRP	cis	rs960902	0.643	rs72793797	chr2:37725697	A/T	cg25341268	chr2:37734390	NA	-0.57	-7.34	-0.42	3.19e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs6142102	0.961	rs4911408	chr20:32700566	G/A	cg08999081	chr20:33150536	PIGU	0.52	6.23	0.37	2.06e-9	Skin pigmentation;
KIRP	cis	rs883565	0.528	rs11716902	chr3:38958010	G/T	cg01426195	chr3:39028469	NA	0.56	8.86	0.49	1.6e-16	Handedness;
KIRP	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.82	9.25	0.51	1.16e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.11	-0.31	6.56e-7	Schizophrenia;
KIRP	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	13.09	0.64	4.44e-30	Platelet count;
KIRP	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-5.59	-0.34	6.04e-8	Height;
KIRP	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.04	-0.36	5.81e-9	IgG glycosylation;
KIRP	cis	rs4356932	0.656	rs11931349	chr4:76860040	G/A	cg00809888	chr4:76862425	NAAA	-0.51	-7.24	-0.42	5.57e-12	Blood protein levels;
KIRP	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.55	7.3	0.42	3.96e-12	Subjective well-being;Cardiovascular disease risk factors;
KIRP	cis	rs751728	0.643	rs12173787	chr6:33735471	G/C	cg25922239	chr6:33757077	LEMD2	0.45	5.33	0.32	2.26e-7	Crohn's disease;
KIRP	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg01849789	chr22:41697279	ZC3H7B	-0.42	-5.22	-0.32	3.9e-7	Neuroticism;
KIRP	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.83	11.13	0.58	1.41e-23	Longevity;
KIRP	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg08923054	chr8:41654455	ANK1	0.72	8.46	0.47	2.45e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg08807892	chr2:162101083	NA	0.65	9.02	0.5	5.55e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs6546886	0.912	rs6741544	chr2:74294221	T/C	cg14702570	chr2:74259524	NA	-0.27	-5.35	-0.32	2e-7	Dialysis-related mortality;
KIRP	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg23479056	chr15:41276147	INO80	0.39	5.77	0.35	2.36e-8	Menopause (age at onset);
KIRP	cis	rs4414128	0.778	rs7922326	chr10:5677237	A/G	cg12223502	chr10:5658492	NA	0.53	5.85	0.35	1.58e-8	Breast cancer;
KIRP	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.87	-9.05	-0.5	4.4e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.94	-0.61	3.15e-26	Eye color traits;
KIRP	cis	rs2391754	0.596	rs6949379	chr7:29338213	C/G	cg00901138	chr7:29329370	CHN2	-0.42	-5.24	-0.32	3.52e-7	CSF tryptophan concentration in tuberculous meningitis;
KIRP	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg27205649	chr11:78285834	NARS2	-0.52	-5.81	-0.35	1.9e-8	Testicular germ cell tumor;
KIRP	cis	rs2862064	1.000	rs1948759	chr5:156442657	C/T	cg12943317	chr5:156479607	HAVCR1	0.72	6.95	0.41	3.23e-11	Platelet count;
KIRP	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.51	-0.43	1.06e-12	Neuroticism;
KIRP	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.35	-0.38	1.05e-9	Schizophrenia;
KIRP	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.9e-16	Immature fraction of reticulocytes;
KIRP	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg00977110	chr5:151150581	G3BP1	0.59	5.9	0.35	1.23e-8	Preschool internalizing problems;
KIRP	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.06	-0.36	4.98e-9	Colorectal cancer;
KIRP	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg23601095	chr6:26197514	HIST1H3D	1.07	7.97	0.45	5.87e-14	Gout;Renal underexcretion gout;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.93	-13.24	-0.65	1.41e-30	Menopause (age at onset);
KIRP	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg00405596	chr8:11794950	NA	-0.41	-5.19	-0.31	4.45e-7	Systolic blood pressure;
KIRP	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.84	-11.05	-0.58	2.66e-23	Coronary artery disease;
KIRP	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg06634786	chr22:41940651	POLR3H	-0.44	-4.85	-0.3	2.21e-6	Neuroticism;
KIRP	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.66	-10.73	-0.56	2.75e-22	Morning vs. evening chronotype;
KIRP	cis	rs7534824	0.583	rs6577225	chr1:101506126	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	5.81	0.35	1.9e-8	Refractive astigmatism;
KIRP	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg17724175	chr1:150552817	MCL1	-0.34	-5.92	-0.35	1.08e-8	Tonsillectomy;
KIRP	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-6.87	-0.4	5.36e-11	Morning vs. evening chronotype;
KIRP	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-7.73	-0.44	2.71e-13	Morning vs. evening chronotype;
KIRP	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23598886	chr18:12777645	NA	-0.71	-5.21	-0.32	4.02e-7	Inflammatory skin disease;
KIRP	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.63	-8.12	-0.46	2.19e-14	Inflammatory bowel disease;
KIRP	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	8.47	0.48	2.22e-15	Morning vs. evening chronotype;
KIRP	cis	rs6921919	0.609	rs9468357	chr6:28342053	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.42	-6.03	-0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.54	7.24	0.42	5.87e-12	Mean corpuscular volume;
KIRP	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg07930552	chr6:133119739	C6orf192	0.89	9.4	0.51	3.9e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg23172400	chr8:95962367	TP53INP1	0.31	6.17	0.37	2.74e-9	Type 2 diabetes;
KIRP	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg06483076	chr3:194406458	FAM43A	0.45	6.71	0.39	1.3100000000000001e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg26207909	chr14:103986467	CKB	-0.44	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13198984	chr17:80129470	CCDC57	0.53	7.91	0.45	8.7e-14	Life satisfaction;
KIRP	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-8.62	-0.48	8.04e-16	Platelet count;
KIRP	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg18932078	chr1:2524107	MMEL1	0.39	5.21	0.32	4.03e-7	Ulcerative colitis;
KIRP	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.78	8.91	0.49	1.16e-16	Corneal astigmatism;
KIRP	cis	rs7709377	0.595	rs7730551	chr5:115419186	G/T	cg23108291	chr5:115420582	COMMD10	0.41	5.0	0.3	1.1e-6	Metabolite levels  (X-11787);
KIRP	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg18016565	chr1:150552671	MCL1	0.37	5.63	0.34	4.91e-8	Melanoma;
KIRP	cis	rs7851660	0.874	rs1955144	chr9:100634589	A/G	cg13688889	chr9:100608707	NA	-0.67	-8.74	-0.49	3.63e-16	Strep throat;
KIRP	cis	rs12365397	0.634	rs7124481	chr11:43293940	A/G	cg07515919	chr11:43391688	TTC17	0.37	4.99	0.3	1.12e-6	Migraine;
KIRP	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	6.17	0.37	2.75e-9	Thyroid stimulating hormone;
KIRP	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.66	-0.34	4.23e-8	Pulmonary function;
KIRP	cis	rs7572644	0.723	rs13023003	chr2:28032137	G/C	cg27432699	chr2:27873401	GPN1	0.46	5.1	0.31	6.73e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.52	-6.72	-0.39	1.26e-10	Body mass index;
KIRP	cis	rs9549260	0.564	rs4943805	chr13:41270080	A/G	cg21288729	chr13:41239152	FOXO1	0.57	7.54	0.43	9.02e-13	Red blood cell count;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.03	-0.41	2.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs2284378	0.515	rs6059579	chr20:32527865	C/G	cg24642439	chr20:33292090	TP53INP2	0.42	4.85	0.3	2.15e-6	Breast cancer;
KIRP	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg08761264	chr16:28874980	SH2B1	-0.51	-5.89	-0.35	1.29e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-8.08	-0.46	2.9e-14	Gut microbiome composition (summer);
KIRP	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.83	12.58	0.63	2.36e-28	Ulcerative colitis;
KIRP	trans	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.09	-0.36	4.26e-9	Neuroticism;
KIRP	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg06307176	chr5:131281290	NA	-0.51	-5.6	-0.34	5.69e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4740619	0.590	rs4247294	chr9:16030960	C/T	cg14451791	chr9:16040625	NA	-0.41	-5.35	-0.32	2.05e-7	Body mass index;
KIRP	cis	rs9815354	1.000	rs1716660	chr3:41929960	G/A	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.11e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00373665	chr1:234735703	NA	0.56	6.73	0.39	1.18e-10	Smoking initiation;
KIRP	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.72	-11.24	-0.58	6.35e-24	Hepatocellular carcinoma;
KIRP	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.27	5.52	0.33	8.61e-8	Height;
KIRP	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.04	0.31	8.9e-7	Educational attainment;
KIRP	cis	rs2000999	0.573	rs34139543	chr16:72158477	C/T	cg04254540	chr16:71951199	KIAA0174	-0.81	-5.77	-0.35	2.4e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs6446298	0.738	rs6446296	chr3:49838052	G/A	cg03060546	chr3:49711283	APEH	-0.54	-5.65	-0.34	4.37e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg12661088	chr5:43120934	ZNF131	-0.48	-6.03	-0.36	5.98e-9	Neuroticism;
KIRP	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg01475377	chr6:109611718	NA	-0.42	-5.89	-0.35	1.26e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.74	0.44	2.56e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.68	-8.88	-0.49	1.39e-16	Height;
KIRP	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.91	-0.66	7.57e-33	Primary sclerosing cholangitis;
KIRP	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.67	-7.28	-0.42	4.41e-12	DNA methylation (variation);
KIRP	cis	rs11671005	0.779	rs55875034	chr19:58983558	T/G	cg13877915	chr19:58951672	ZNF132	0.54	4.86	0.3	2.13e-6	Mean platelet volume;
KIRP	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg05220968	chr6:146057943	EPM2A	0.4	5.06	0.31	8.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	0.48	6.83	0.4	6.45e-11	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.18	0.7	3.63e-37	Platelet count;
KIRP	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.67	8.85	0.49	1.71e-16	Coronary artery disease;
KIRP	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg22906224	chr7:99728672	NA	-0.42	-4.91	-0.3	1.63e-6	Alzheimer's disease (late onset);
KIRP	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg10755058	chr3:40428713	ENTPD3	0.47	6.59	0.39	2.7e-10	Renal cell carcinoma;
KIRP	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.37	-0.32	1.78e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.29	-0.37	1.4e-9	Arsenic metabolism;
KIRP	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18252515	chr7:66147081	NA	0.46	5.63	0.34	4.8e-8	Aortic root size;
KIRP	cis	rs6838801	0.857	rs17002148	chr4:77580240	A/G	cg17476223	chr4:77663285	SHROOM3	-0.51	-7.45	-0.43	1.6e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.68	7.29	0.42	4.34e-12	Lymphocyte counts;
KIRP	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	cg04338863	chr8:33670619	NA	0.48	6.26	0.37	1.69e-9	Body mass index;
KIRP	cis	rs16867321	0.507	rs2013577	chr2:181370505	C/T	cg23363182	chr2:181467187	NA	-0.4	-5.72	-0.34	3.14e-8	Obesity;
KIRP	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg08975724	chr8:8085496	FLJ10661	0.56	7.42	0.43	1.85e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg05991184	chr2:219186017	PNKD	0.36	5.02	0.3	9.84e-7	Colorectal cancer;
KIRP	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01616529	chr11:638424	DRD4	-0.42	-5.67	-0.34	4.02e-8	Systemic lupus erythematosus;
KIRP	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg19507638	chr5:93509721	C5orf36	-0.61	-5.62	-0.34	5.27e-8	Diabetic retinopathy;
KIRP	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.81	8.18	0.46	1.52e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	cg21523751	chr1:182988639	NA	0.45	7.13	0.41	1.09e-11	Hypertriglyceridemia;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.84	7.89	0.45	9.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.3	-6.07	-0.36	4.79e-9	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.9e-11	Retinal vascular caliber;
KIRP	cis	rs6782228	0.675	rs4443194	chr3:128383446	T/A	cg18648031	chr3:128330563	NA	0.26	5.26	0.32	3.1e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.82	11.05	0.58	2.67e-23	Height;
KIRP	cis	rs795484	0.926	rs1726390	chr12:118645384	A/G	cg16572268	chr12:118583242	PEBP1	-0.37	-4.87	-0.3	2.04e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
KIRP	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.62	0.44	5.57e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg23920097	chr1:209922102	NA	0.43	5.67	0.34	3.93e-8	Red blood cell count;
KIRP	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.38	5.01	0.3	1.03e-6	Dupuytren's disease;
KIRP	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	7.49	0.43	1.23e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.57	-5.85	-0.35	1.58e-8	Platelet distribution width;
KIRP	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12016809	chr21:47604291	C21orf56	0.4	5.5	0.33	9.34e-8	Testicular germ cell tumor;
KIRP	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg14593290	chr7:50529359	DDC	0.81	9.25	0.51	1.13e-17	Malaria;
KIRP	cis	rs4595586	0.679	rs1356264	chr12:39393754	A/T	cg26384229	chr12:38710491	ALG10B	0.48	6.14	0.36	3.21e-9	Morning vs. evening chronotype;
KIRP	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg07382826	chr16:28625726	SULT1A1	0.42	4.94	0.3	1.43e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2061333	0.500	rs8113750	chr19:44608789	C/T	cg21636353	chr19:44617292	ZNF225	-0.52	-5.06	-0.31	8.34e-7	Alzheimer's disease;
KIRP	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.82	6.64	0.39	1.96e-10	Initial pursuit acceleration;
KIRP	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg24650279	chr15:90327240	NA	-0.44	-5.47	-0.33	1.11e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg03929089	chr4:120376271	NA	0.67	6.04	0.36	5.75e-9	Axial length;
KIRP	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	5.35	0.32	1.99e-7	Height;
KIRP	cis	rs4919044	0.866	rs55853605	chr10:94825097	G/A	cg05127821	chr10:94822908	CYP26C1	-0.95	-7.11	-0.41	1.28e-11	Coronary artery disease;
KIRP	cis	rs2213920	0.749	rs7467654	chr9:118253677	C/T	cg13918206	chr9:118159781	DEC1	1.01	10.01	0.54	5.11e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	cis	rs975752	0.867	rs7924284	chr10:102018089	A/G	cg13817732	chr10:102046368	BLOC1S2	-0.7	-5.87	-0.35	1.42e-8	Schizophrenia;
KIRP	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.81	-11.29	-0.58	4.22e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-8.14	-0.46	1.95e-14	Systemic lupus erythematosus;
KIRP	cis	rs2562456	0.793	rs11672341	chr19:21507304	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-5.04	-0.31	8.96e-7	Pain;
KIRP	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.55	-7.3	-0.42	3.99e-12	HDL cholesterol;
KIRP	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg26876637	chr1:152193138	HRNR	-0.76	-9.07	-0.5	3.87e-17	Atopic dermatitis;
KIRP	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg08761264	chr16:28874980	SH2B1	-0.45	-5.21	-0.32	3.92e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.4	-5.1	-0.31	6.87e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.52	7.3	0.42	3.93e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs6546324	0.625	rs1430791	chr2:67864800	A/C	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs151997	0.925	rs27260	chr5:50166696	C/T	cg06027927	chr5:50259733	NA	0.6	7.52	0.43	1.02e-12	Callous-unemotional behaviour;
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07256732	chr16:621771	PIGQ	-0.43	-5.97	-0.36	8.26e-9	Height;
KIRP	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg22676075	chr6:135203613	NA	0.5	7.16	0.42	9.16e-12	Red blood cell count;
KIRP	cis	rs9473924	0.632	rs4715212	chr6:50901054	C/A	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	5.23	0.32	3.62e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg18595228	chr15:67193261	NA	0.62	4.94	0.3	1.45e-6	Lung cancer (smoking interaction);
KIRP	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg27490568	chr2:178487706	NA	0.48	6.45	0.38	5.97e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-1.05	-14.17	-0.67	1e-33	Blood pressure (smoking interaction);
KIRP	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-0.79	-7.7	-0.44	3.32e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg10326726	chr10:51549505	MSMB	-0.58	-8.18	-0.46	1.53e-14	Prostate-specific antigen levels;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg04898765	chr4:139484268	NA	-0.42	-6.15	-0.37	3.1e-9	Select biomarker traits;
KIRP	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg01251548	chr11:17372745	DKFZp686O24166	-0.38	-5.12	-0.31	6.22e-7	Type 2 diabetes;
KIRP	cis	rs7017914	0.902	rs10504481	chr8:71699517	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.93	-0.49	1.03e-16	Resting heart rate;
KIRP	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.65	-0.34	4.47e-8	Pulmonary function;
KIRP	cis	rs1215050	0.791	rs165242	chr4:98686482	A/C	cg05340658	chr4:99064831	C4orf37	-0.43	-4.9	-0.3	1.76e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.66	-8.05	-0.46	3.56e-14	IgG glycosylation;
KIRP	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.24	15.34	0.7	1.02e-37	Corneal structure;
KIRP	cis	rs4332428	0.892	rs35288270	chr10:4961278	T/C	cg19648686	chr10:5044992	AKR1C2	-0.68	-5.72	-0.34	3.1e-8	Height;
KIRP	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.84	12.06	0.61	1.24e-26	Coronary artery disease;
KIRP	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.15	-0.46	1.87e-14	Total cholesterol levels;
KIRP	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.62	-6.84	-0.4	6.09e-11	Neuroticism;
KIRP	trans	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.78	-0.4	9.07e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9896052	0.614	rs34042490	chr17:73452956	T/C	cg25649188	chr17:73499917	CASKIN2	0.5	6.46	0.38	5.43e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.92	-0.35	1.07e-8	Coronary artery disease;
KIRP	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg19468946	chr17:37922297	IKZF3	-0.45	-6.35	-0.38	1.05e-9	Self-reported allergy;
KIRP	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg05775895	chr3:12838266	CAND2	0.46	7.59	0.44	6.73e-13	QRS complex (12-leadsum);
KIRP	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.33	0.37	1.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg00343986	chr7:65444356	GUSB	0.49	5.92	0.35	1.07e-8	Calcium levels;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.9	-0.3	1.75e-6	Life satisfaction;
KIRP	trans	rs909341	0.909	rs2872881	chr20:62342801	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.91	-0.4	4.04e-11	Atopic dermatitis;
KIRP	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.44	5.14	0.31	5.56e-7	Lung function (FEV1);
KIRP	cis	rs758324	0.540	rs31481	chr5:131397202	A/G	cg06307176	chr5:131281290	NA	0.52	5.24	0.32	3.51e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.08	-0.46	2.94e-14	Coffee consumption (cups per day);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12445461	chr9:6681608	NA	0.59	6.89	0.4	4.63e-11	Smoking initiation;
KIRP	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	0.99	7.71	0.44	3.02e-13	Arsenic metabolism;
KIRP	cis	rs4805272	1.000	rs888826	chr19:29325419	C/A	cg15000279	chr19:29285009	NA	-0.37	-5.27	-0.32	2.96e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17183009	chr3:120277827	NA	0.56	6.38	0.38	8.81e-10	Corneal astigmatism;
KIRP	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg10756647	chr7:56101905	PSPH	0.9	7.06	0.41	1.65e-11	Diabetic kidney disease;
KIRP	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.63	-0.34	5e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.98	14.22	0.67	6.75e-34	Cognitive function;
KIRP	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-6.02	-0.36	6.37e-9	Fear of minor pain;
KIRP	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.58	-6.06	-0.36	5.02e-9	Ulcerative colitis;
KIRP	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.72	5.67	0.34	4.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	5.34	0.32	2.1e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.98	11.98	0.61	2.29e-26	Migraine;
KIRP	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.51	-5.93	-0.35	1.03e-8	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg01391022	chr12:122360665	WDR66	-0.36	-5.32	-0.32	2.32e-7	Mean corpuscular volume;
KIRP	cis	rs17023223	0.537	rs10802075	chr1:119627227	C/T	cg05756136	chr1:119680316	WARS2	-0.57	-7.55	-0.43	8.71e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.1	0.5	3.22e-17	Lung cancer in ever smokers;
KIRP	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.72	-8.55	-0.48	1.31e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.77	-10.89	-0.57	8.41e-23	Asthma;
KIRP	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.65	8.59	0.48	1.02e-15	Total body bone mineral density;
KIRP	cis	rs2708977	0.730	rs674920	chr2:97070156	C/G	cg01950434	chr2:97203154	ARID5A	-0.42	-5.41	-0.33	1.52e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	cg21523751	chr1:182988639	NA	0.45	7.2	0.42	7.19e-12	Colorectal cancer;
KIRP	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.18	-0.37	2.7e-9	Obesity-related traits;
KIRP	cis	rs7027203	0.514	rs2265807	chr9:96506756	A/T	cg14598338	chr9:96623480	NA	-0.43	-6.4	-0.38	7.98e-10	DNA methylation (variation);
KIRP	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.58	8.92	0.49	1.1e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.67	0.44	4.13e-13	White blood cell count;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg15181151	chr6:150070149	PCMT1	0.29	4.89	0.3	1.8e-6	Lung cancer;
KIRP	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.47	-6.21	-0.37	2.27e-9	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs501120	1.000	rs694425	chr10:44761804	C/G	cg09554077	chr10:44749378	NA	0.66	9.49	0.52	2.12e-18	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.98	-12.35	-0.62	1.39e-27	Response to antineoplastic agents;
KIRP	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg10760299	chr15:45669010	GATM	0.34	5.05	0.31	8.42e-7	Homoarginine levels;
KIRP	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg25486957	chr4:152246857	NA	-0.51	-5.68	-0.34	3.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg17376030	chr22:41985996	PMM1	-0.83	-8.83	-0.49	1.98e-16	Vitiligo;
KIRP	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.96	17.68	0.75	1.04e-45	Colorectal adenoma (advanced);
KIRP	cis	rs501120	0.584	rs7097076	chr10:44701352	C/A	cg09554077	chr10:44749378	NA	0.51	5.54	0.33	7.93e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.47	-5.69	-0.34	3.68e-8	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs405956	0.769	rs1190278	chr6:105598184	C/T	cg22580625	chr6:105627791	POPDC3	0.49	5.45	0.33	1.2e-7	QT interval;
KIRP	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.07	0.46	3.2e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.51	5.22	0.32	3.72e-7	Alzheimer's disease;
KIRP	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	12.48	0.62	5.05e-28	Body mass index (adult);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02196458	chr15:90809250	NGRN	0.54	6.22	0.37	2.11e-9	Smoking initiation;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg03188948	chr7:1209495	NA	0.71	6.61	0.39	2.31e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg18944383	chr4:111397179	ENPEP	0.52	9.14	0.5	2.35e-17	Height;
KIRP	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.76	11.35	0.59	2.81e-24	Blood metabolite ratios;
KIRP	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	4.97	0.3	1.26e-6	Psychosis and Alzheimer's disease;
KIRP	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.78	10.47	0.56	1.84e-21	Resting heart rate;
KIRP	cis	rs807029	0.758	rs807027	chr10:102764607	T/A	cg04662943	chr10:102668895	NA	0.53	6.05	0.36	5.49e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.38	-0.38	8.8e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9826463	0.582	rs11714244	chr3:142138294	C/T	cg20824294	chr3:142316082	PLS1	0.48	6.68	0.39	1.55e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg17252645	chr8:143867129	LY6D	-0.31	-4.98	-0.3	1.21e-6	Urinary tract infection frequency;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.46	-5.57	-0.33	6.75e-8	Longevity;Endometriosis;
KIRP	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs7225151	0.901	rs61481506	chr17:5158714	T/C	cg24500398	chr17:5266808	RABEP1	-0.54	-5.23	-0.32	3.56e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg11168104	chr5:1857477	NA	-0.38	-4.94	-0.3	1.47e-6	Cardiovascular disease risk factors;
KIRP	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.39	7.76	0.44	2.2e-13	Multiple system atrophy;
KIRP	cis	rs10214930	0.671	rs7799957	chr7:27882260	A/G	cg22168087	chr7:27702803	HIBADH	0.49	5.01	0.3	1.05e-6	Hypospadias;
KIRP	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.41	-0.33	1.49e-7	Life satisfaction;
KIRP	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.81	0.49	2.28e-16	Bladder cancer;
KIRP	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.95	16.25	0.72	7.82e-41	Breast cancer;
KIRP	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-14.47	-0.68	9.6e-35	Gut microbiome composition (summer);
KIRP	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.85	-0.35	1.54e-8	Parkinson's disease;
KIRP	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.12e-6	Atopic dermatitis;
KIRP	cis	rs6991838	0.584	rs1053088	chr8:66515783	A/G	cg13398993	chr8:66546079	ARMC1	0.46	5.32	0.32	2.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.3	13.48	0.65	2.19e-31	Diabetic retinopathy;
KIRP	cis	rs7103648	0.966	rs11500477	chr11:47409051	T/A	cg20307385	chr11:47447363	PSMC3	0.9	12.66	0.63	1.23e-28	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs6901004	0.803	rs1322214	chr6:111480045	T/A	cg15721981	chr6:111408429	SLC16A10	-0.51	-7.0	-0.41	2.44e-11	Blood metabolite levels;
KIRP	cis	rs6545883	1.000	rs6742276	chr2:61768745	G/A	cg15711740	chr2:61764176	XPO1	-0.59	-8.01	-0.45	4.67e-14	Tuberculosis;
KIRP	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.7e-10	Red blood cell count;
KIRP	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.55	7.57	0.43	7.46e-13	Tuberculosis;
KIRP	cis	rs74181299	0.964	rs2540951	chr2:65276736	A/G	cg05010058	chr2:65284262	CEP68	0.46	6.6	0.39	2.54e-10	Pulse pressure;
KIRP	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	cis	rs9400467	0.537	rs73530951	chr6:111484814	G/A	cg15721981	chr6:111408429	SLC16A10	0.77	7.13	0.41	1.1e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6568686	0.627	rs17539951	chr6:111664969	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.33	0.42	3.23e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.75e-8	Neuroticism;
KIRP	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.73	8.25	0.47	9.6e-15	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4702	0.611	rs1894401	chr15:91429042	C/T	cg05469396	chr15:91419421	FURIN	0.36	4.88	0.3	1.88e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.54	-0.33	7.58e-8	Neutrophil percentage of white cells;
KIRP	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.73	-5.97	-0.36	8.06e-9	IgG glycosylation;
KIRP	cis	rs7651039	0.641	rs2455827	chr3:15662906	C/G	cg16303742	chr3:15540471	COLQ	0.58	7.77	0.44	2.09e-13	Coronary heart disease;
KIRP	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.5	-6.39	-0.38	8.15e-10	Post bronchodilator FEV1;
KIRP	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-6.83	-0.4	6.64e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.45	7.89	0.45	9.65e-14	Systemic lupus erythematosus;
KIRP	cis	rs6681460	0.966	rs4655650	chr1:67142286	A/G	cg02459107	chr1:67143332	SGIP1	0.51	7.19	0.42	7.8e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7106204	0.544	rs16912364	chr11:24291549	A/G	ch.11.24196551F	chr11:24239977	NA	0.63	5.18	0.31	4.54e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7520050	1.000	rs7540699	chr1:46338585	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg00814883	chr7:100076585	TSC22D4	-0.53	-5.02	-0.3	1.01e-6	Lung function (FEV1/FVC);
KIRP	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.74	-9.46	-0.52	2.54e-18	Childhood ear infection;
KIRP	trans	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg19274270	chr17:78178856	CARD14	-0.34	-6.2	-0.37	2.41e-9	Morning vs. evening chronotype;
KIRP	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.95	15.0	0.69	1.5e-36	Menarche (age at onset);
KIRP	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg24505687	chr6:33548425	BAK1	0.26	5.31	0.32	2.49e-7	Platelet count;
KIRP	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-6.97	-0.41	2.98e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	1.02	13.93	0.66	6.7e-33	Menopause (age at onset);
KIRP	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg14983838	chr19:29218262	NA	0.73	7.06	0.41	1.66e-11	Methadone dose in opioid dependence;
KIRP	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22117172	chr7:91764530	CYP51A1	0.51	7.19	0.42	7.87e-12	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00498163	chr2:242821619	NA	-0.41	-6.2	-0.37	2.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.39	0.51	4.38e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2882667	0.858	rs13170388	chr5:138436865	A/G	cg04439458	chr5:138467593	SIL1	-0.52	-7.64	-0.44	4.85e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7083	0.653	rs573442	chr11:117177920	T/C	cg11523350	chr11:117171073	BACE1	-0.32	-5.82	-0.35	1.85e-8	Blood protein levels;
KIRP	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.51	-6.52	-0.38	3.93e-10	Subjective well-being;
KIRP	trans	rs1973993	0.580	rs80145696	chr1:96989052	C/T	cg10631902	chr5:14652156	NA	-0.53	-6.35	-0.38	1.04e-9	Weight;
KIRP	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.43	6.45	0.38	5.87e-10	Major depressive disorder;
KIRP	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg08761264	chr16:28874980	SH2B1	-0.45	-4.94	-0.3	1.43e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs2273669	0.667	rs75671532	chr6:109341298	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.71	-8.58	-0.48	1.11e-15	Cognitive function;
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.4	-0.33	1.54e-7	Electroencephalogram traits;
KIRP	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-5.51	-0.33	8.87e-8	Triglycerides;
KIRP	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.71	5.64	0.34	4.73e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg20607798	chr8:58055168	NA	0.62	5.46	0.33	1.19e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg20742981	chr22:31644190	LIMK2	0.35	4.86	0.3	2.11e-6	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04900915	chr14:73393158	DCAF4	0.56	7.02	0.41	2.13e-11	Parkinson's disease;
KIRP	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.19	0.51	1.65e-17	Colorectal cancer;
KIRP	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.64	8.51	0.48	1.71e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg08224773	chr8:11311868	FAM167A	0.28	5.03	0.31	9.49e-7	Rheumatoid arthritis;
KIRP	cis	rs75920871	1.000	rs7130531	chr11:116863833	C/T	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.78	9.55	0.52	1.42e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4006360	0.575	rs404154	chr17:39315341	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.4	-5.71	-0.34	3.21e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg08975724	chr8:8085496	FLJ10661	0.59	8.04	0.46	3.77e-14	Acne (severe);
KIRP	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.82	11.69	0.6	2.15e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs2910162	1.000	rs2961919	chr5:159903134	G/A	cg03306240	chr5:159912455	MIR146A	-0.41	-6.16	-0.37	2.88e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.76	-5.6	-0.34	5.67e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.44	5.66	0.34	4.23e-8	Height;
KIRP	cis	rs3850699	0.926	rs12570611	chr10:104421679	G/C	cg04362960	chr10:104952993	NT5C2	0.53	6.15	0.37	3.08e-9	Prostate cancer;
KIRP	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.32	-0.32	2.37e-7	Neuroticism;
KIRP	cis	rs737693	1.000	rs72983513	chr11:102728985	T/C	cg19620758	chr11:102826565	MMP13	0.71	5.65	0.34	4.42e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.28	-0.42	4.4e-12	Neuroticism;
KIRP	cis	rs75884327	0.584	rs2836901	chr21:40499194	A/G	cg11890956	chr21:40555474	PSMG1	0.67	5.7	0.34	3.36e-8	Daytime sleep phenotypes;
KIRP	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg11519256	chr10:5708881	ASB13	0.55	7.71	0.44	3.11e-13	Childhood ear infection;
KIRP	cis	rs7870753	0.838	rs34447339	chr9:99247274	C/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.57	0.48	1.19e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.66	9.11	0.5	2.88e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg06775570	chr1:201857621	SHISA4	0.38	7.06	0.41	1.68e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg23587288	chr2:27483067	SLC30A3	0.56	7.17	0.42	8.9e-12	Blood metabolite levels;
KIRP	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.5	-6.16	-0.37	2.99e-9	Subjective well-being;
KIRP	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.43	-5.1	-0.31	6.88e-7	Height;
KIRP	cis	rs8028182	0.636	rs28623700	chr15:75849714	T/A	cg20655648	chr15:75932815	IMP3	0.55	7.06	0.41	1.7e-11	Sudden cardiac arrest;
KIRP	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.69	-8.72	-0.49	4.23e-16	Triglycerides;
KIRP	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.73	5.19	0.31	4.46e-7	Schizophrenia;
KIRP	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg07541023	chr7:19748670	TWISTNB	0.5	5.23	0.32	3.64e-7	Thyroid stimulating hormone;
KIRP	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.56	-6.23	-0.37	1.96e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.75	7.52	0.43	1.02e-12	Vitiligo;
KIRP	trans	rs12690897	0.609	rs4466324	chr7:85275522	C/T	cg25658385	chr6:35265341	DEF6	-0.33	-6.11	-0.36	3.91e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs6832769	1.000	rs17085889	chr4:56402115	G/A	cg09317128	chr4:56265301	TMEM165	-0.55	-7.35	-0.42	2.89e-12	Personality dimensions;
KIRP	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg00262122	chr8:11665843	FDFT1	0.43	5.41	0.33	1.52e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs740698	0.521	rs9891713	chr17:60789405	C/T	cg13195520	chr17:60813227	MARCH10	0.54	8.0	0.45	4.77e-14	Pulse pressure;
KIRP	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.56	14.85	0.69	4.79e-36	Airflow obstruction;
KIRP	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.15	14.79	0.69	7.6e-36	Type 2 diabetes nephropathy;
KIRP	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg01304814	chr3:48885189	PRKAR2A	0.7	5.45	0.33	1.2e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs6601327	0.665	rs4841218	chr8:9653902	T/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.43	-0.38	6.7e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg17654217	chr7:100282651	GIGYF1	0.52	5.04	0.31	9.2e-7	Other erythrocyte phenotypes;
KIRP	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg26875233	chr11:93583750	C11orf90	-0.39	-7.43	-0.43	1.83e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6973256	0.604	rs6975134	chr7:133531432	T/C	cg10665199	chr7:133106180	EXOC4	0.41	4.99	0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2980439	0.729	rs2955585	chr8:8093511	A/G	cg06636001	chr8:8085503	FLJ10661	0.92	13.72	0.66	3.33e-32	Neuroticism;
KIRP	cis	rs7395581	0.918	rs10742799	chr11:47293702	T/C	cg26139080	chr11:47293733	MADD	-0.44	-5.51	-0.33	9.24e-8	HDL cholesterol;
KIRP	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg07317062	chr7:27170388	HOXA4	-0.4	-5.08	-0.31	7.48e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Body mass index;
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.58	7.48	0.43	1.32e-12	Testicular germ cell tumor;
KIRP	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.84	14.37	0.68	2.1e-34	Menarche (age at onset);
KIRP	cis	rs16854884	1.000	rs62269906	chr3:143808812	A/G	cg06585982	chr3:143692056	C3orf58	0.53	5.33	0.32	2.22e-7	Economic and political preferences (feminism/equality);
KIRP	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.68	-10.25	-0.55	9.29e-21	Sum eosinophil basophil counts;
KIRP	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg01304814	chr3:48885189	PRKAR2A	0.48	4.91	0.3	1.68e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.27e-10	Hepatitis;
KIRP	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg12962167	chr3:53033115	SFMBT1	0.71	5.28	0.32	2.8e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.48	7.26	0.42	5.04e-12	Resting heart rate;
KIRP	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.72	9.75	0.53	3.45e-19	Breast cancer;
KIRP	cis	rs11710088	0.740	rs13076896	chr3:149192281	G/A	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.42	-0.33	1.39e-7	QRS duration;
KIRP	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	8.74	0.49	3.67e-16	Cognitive test performance;
KIRP	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg01181863	chr3:195395398	SDHAP2	0.43	4.85	0.3	2.16e-6	Mean corpuscular volume;
KIRP	cis	rs12643440	0.538	rs16894428	chr4:17142974	A/G	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2548003	0.518	rs2554904	chr5:28726189	T/A	cg11015470	chr5:28928158	NA	0.52	5.71	0.34	3.23e-8	Hip geometry;
KIRP	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-4.95	-0.3	1.38e-6	Menarche (age at onset);
KIRP	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs7714584	1.000	rs931058	chr5:150333698	A/T	cg22134413	chr5:150180641	NA	0.68	5.1	0.31	6.82e-7	Crohn's disease;
KIRP	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg25922239	chr6:33757077	LEMD2	0.54	6.62	0.39	2.22e-10	Crohn's disease;
KIRP	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.33	-7.36	-0.43	2.68e-12	Cutaneous nevi;
KIRP	cis	rs11577318	0.579	rs10794532	chr1:26694260	T/C	cg00852783	chr1:26633632	UBXN11	-0.46	-5.24	-0.32	3.42e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.42	-4.87	-0.3	1.99e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.37	0.47	4.38e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg14132834	chr19:41945861	ATP5SL	0.58	7.43	0.43	1.84e-12	Height;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07308232	chr7:1071921	C7orf50	-0.7	-8.72	-0.49	4.11e-16	Longevity;Endometriosis;
KIRP	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-0.72	-7.13	-0.41	1.1e-11	Alzheimer's disease (late onset);
KIRP	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg16586182	chr3:47516702	SCAP	-0.68	-9.07	-0.5	3.93e-17	Colorectal cancer;
KIRP	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15320075	chr8:145703422	NA	0.72	9.81	0.53	2.26e-19	Age at first birth;
KIRP	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg14664628	chr15:75095509	CSK	0.47	5.87	0.35	1.42e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs11153147	0.655	rs117298489	chr6:109432996	T/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.14	-0.31	5.53e-7	Mean corpuscular volume;
KIRP	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.85e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-1.07	-19.69	-0.78	1.82e-52	Height;
KIRP	trans	rs199950	0.911	rs199940	chr1:181596440	C/T	cg04237608	chr1:18659049	IGSF21	0.39	6.58	0.39	2.79e-10	Body mass index (change over time);
KIRP	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.93	-0.4	3.59e-11	Coronary artery disease;
KIRP	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.43	-5.57	-0.33	6.76e-8	Refractive error;
KIRP	cis	rs745080	0.698	rs2249922	chr14:52906081	G/T	cg23333723	chr14:53022898	GPR137C	0.37	5.07	0.31	7.78e-7	Orofacial clefts;
KIRP	cis	rs2274273	0.624	rs7159824	chr14:55772536	C/T	cg04306507	chr14:55594613	LGALS3	0.39	5.37	0.32	1.8e-7	Protein biomarker;
KIRP	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.15	0.58	1.21e-23	Primary sclerosing cholangitis;
KIRP	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.68	6.64	0.39	2.02e-10	Axial length;
KIRP	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.33	5.11	0.31	6.47e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.46	4.86	0.3	2.09e-6	Breast cancer;
KIRP	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.81	-9.83	-0.53	1.89e-19	Vitamin D levels;
KIRP	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg11833968	chr6:79620685	NA	-0.46	-6.87	-0.4	5.21e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00338735	chr4:53728038	RASL11B	0.43	5.49	0.33	1.01e-7	Optic nerve measurement (cup area);
KIRP	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs2574975	0.531	rs1210066	chr10:52210157	T/C	cg10034176	chr10:52120283	SGMS1	0.39	5.55	0.33	7.2e-8	Response to amphetamines;
KIRP	cis	rs7395581	0.959	rs7120118	chr11:47286290	T/C	cg26139080	chr11:47293733	MADD	-0.4	-5.04	-0.31	9.12e-7	HDL cholesterol;
KIRP	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-10.0	-0.54	5.76e-20	Height;
KIRP	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg16497661	chr14:103986332	CKB	0.43	5.67	0.34	3.94e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.07	0.41	1.63e-11	Electroencephalogram traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06798572	chr14:100842754	WARS;WDR25	-0.52	-7.22	-0.42	6.32e-12	Metabolic traits;
KIRP	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.35	0.38	1.04e-9	Bipolar disorder;
KIRP	trans	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg24644049	chr4:85504048	CDS1	1.1	7.25	0.42	5.49e-12	Skin colour saturation;
KIRP	cis	rs4563143	0.647	rs61378972	chr19:29218742	C/T	cg12667521	chr19:29218732	NA	1.05	10.67	0.56	4.26e-22	Methadone dose in opioid dependence;
KIRP	cis	rs7590368	0.961	rs2357815	chr2:10959769	C/T	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11987759	chr7:65425863	GUSB	-0.7	-9.95	-0.54	8.12e-20	Calcium levels;
KIRP	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.76	11.03	0.58	2.99e-23	Hip circumference;
KIRP	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg21014159	chr11:117668035	DSCAML1	0.41	6.16	0.37	3.01e-9	Myopia;
KIRP	trans	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.34	0.37	1.1e-9	Retinal vascular caliber;
KIRP	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg00204512	chr16:28754710	NA	0.38	4.95	0.3	1.35e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8113308	0.810	rs56029016	chr19:52452462	T/A	cg25782003	chr19:52490127	ZNF350	0.55	5.11	0.31	6.34e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg08885076	chr2:99613938	TSGA10	0.53	9.29	0.51	8.68e-18	Chronic sinus infection;
KIRP	cis	rs787274	0.557	rs912662	chr9:115669880	A/C	cg13803584	chr9:115635662	SNX30	-0.63	-4.89	-0.3	1.82e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.57	7.42	0.43	1.95e-12	Coronary artery disease;
KIRP	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg00405596	chr8:11794950	NA	0.48	6.09	0.36	4.25e-9	Retinal vascular caliber;
KIRP	trans	rs78049276	0.688	rs80157433	chr4:148370548	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.69	-7.17	-0.42	8.9e-12	Pulse pressure;
KIRP	cis	rs2307121	0.512	rs2047066	chr5:64734172	T/C	cg00944502	chr5:64858997	PPWD1;CENPK	0.43	5.48	0.33	1.04e-7	Corneal structure;
KIRP	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg19920283	chr7:105172520	RINT1	0.54	6.33	0.37	1.13e-9	Bipolar disorder (body mass index interaction);
KIRP	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.57	-0.52	1.23e-18	Retinal vascular caliber;
KIRP	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.62	-7.5	-0.43	1.14e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg10189774	chr4:17578691	LAP3	0.58	7.23	0.42	6.04e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.81	8.73	0.49	3.85e-16	Prostate cancer;
KIRP	cis	rs7635838	0.892	rs7644968	chr3:11489493	C/T	cg00170343	chr3:11313890	ATG7	0.46	6.09	0.36	4.24e-9	HDL cholesterol;
KIRP	cis	rs4740619	0.511	rs3008731	chr9:16003441	G/A	cg14451791	chr9:16040625	NA	-0.4	-5.48	-0.33	1.07e-7	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17765480	chr2:220094470	ANKZF1;ATG9A	0.5	6.11	0.36	3.8e-9	Parkinson's disease;
KIRP	cis	rs6901004	0.803	rs9387000	chr6:111459941	A/C	cg15721981	chr6:111408429	SLC16A10	-0.56	-7.62	-0.44	5.31e-13	Blood metabolite levels;
KIRP	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	10.55	0.56	1.03e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.98e-7	Body mass index;
KIRP	cis	rs6484504	0.532	rs1475558	chr11:31263428	A/G	cg26647111	chr11:31128758	NA	-0.47	-5.49	-0.33	1.02e-7	Red blood cell count;
KIRP	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg24253500	chr15:84953950	NA	-0.61	-6.43	-0.38	6.6e-10	Schizophrenia;
KIRP	cis	rs2275906	0.748	rs11964886	chr6:25878379	C/T	cg21844956	chr6:25963442	TRIM38	0.52	5.02	0.3	1.01e-6	Urate levels in lean individuals;
KIRP	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.17	0.54	1.65e-20	Coffee consumption (cups per day);
KIRP	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.3	-0.72	5.51e-41	Height;
KIRP	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg26531700	chr6:26746687	NA	0.39	5.19	0.31	4.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg27124370	chr19:33622961	WDR88	0.61	7.43	0.43	1.76e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.75	0.49	3.44e-16	Bipolar disorder;
KIRP	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.51	-6.96	-0.41	3.07e-11	Schizophrenia;
KIRP	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.72	-6.29	-0.37	1.46e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs35771425	0.626	rs6677230	chr1:211652902	A/C	cg10512769	chr1:211675356	NA	-0.69	-8.31	-0.47	6.6e-15	Educational attainment (years of education);
KIRP	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24549020	chr5:56110836	MAP3K1	0.49	5.03	0.31	9.41e-7	Initial pursuit acceleration;
KIRP	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg21360079	chr12:107162445	NA	-0.71	-10.21	-0.55	1.21e-20	Heart rate;
KIRP	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.34	-0.42	3.07e-12	Aortic root size;
KIRP	cis	rs2904967	0.852	rs1858783	chr11:65042941	A/G	cg09225861	chr11:65069680	NA	0.43	5.62	0.34	5.1e-8	Mean corpuscular volume;
KIRP	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	11.27	0.58	5.18e-24	Smoking behavior;
KIRP	cis	rs9513627	0.920	rs6491510	chr13:100171447	C/T	cg25919922	chr13:100150906	NA	0.66	5.18	0.31	4.56e-7	Obesity-related traits;
KIRP	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.91	-0.66	7.57e-33	Primary sclerosing cholangitis;
KIRP	cis	rs7572644	0.665	rs12478766	chr2:28041200	T/C	cg27432699	chr2:27873401	GPN1	0.48	5.49	0.33	1.01e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg17554472	chr22:41940697	POLR3H	-0.44	-5.08	-0.31	7.58e-7	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14989522	chr19:58874386	ZNF497	0.47	6.11	0.36	3.78e-9	Parkinson's disease;
KIRP	cis	rs838147	0.733	rs8106205	chr19:49250197	T/C	cg21064579	chr19:49206444	FUT2	-0.37	-4.89	-0.3	1.81e-6	Dietary macronutrient intake;
KIRP	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg17554472	chr22:41940697	POLR3H	0.5	5.87	0.35	1.42e-8	Vitiligo;
KIRP	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	cis	rs17095355	1.000	rs731793	chr10:111716667	C/G	cg00817464	chr10:111662876	XPNPEP1	0.44	6.51	0.38	4.15e-10	Biliary atresia;
KIRP	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.35	1.14e-8	Retinal vascular caliber;
KIRP	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg10760299	chr15:45669010	GATM	0.36	5.3	0.32	2.63e-7	Homoarginine levels;
KIRP	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg16482183	chr6:26056742	HIST1H1C	-0.39	-5.1	-0.31	6.66e-7	Schizophrenia;
KIRP	trans	rs1864585	0.552	rs17776497	chr8:10675162	C/A	cg26278703	chr11:58910052	FAM111A	0.65	6.34	0.37	1.07e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.6	0.34	5.61e-8	Personality dimensions;
KIRP	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg21174375	chr14:64681225	SYNE2	-0.53	-6.3	-0.37	1.34e-9	Atrial fibrillation;
KIRP	cis	rs12476592	0.602	rs262506	chr2:63863022	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg26531700	chr6:26746687	NA	-0.38	-5.13	-0.31	5.93e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-20.03	-0.79	1.4e-53	Height;
KIRP	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11987759	chr7:65425863	GUSB	0.44	5.34	0.32	2.12e-7	Aortic root size;
KIRP	cis	rs17125944	0.615	rs2357945	chr14:53318434	A/G	cg00686598	chr14:53173677	PSMC6	-0.71	-6.7	-0.39	1.38e-10	Alzheimer's disease (late onset);
KIRP	cis	rs1847505	0.562	rs75643704	chr13:61431974	G/T	cg25164009	chr13:61490935	NA	0.48	5.1	0.31	6.65e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.71	10.96	0.57	5.1e-23	Height;
KIRP	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	5.39	0.33	1.63e-7	Body mass index;
KIRP	cis	rs13102973	0.867	rs4429776	chr4:135883394	G/T	cg14419869	chr4:135874104	NA	0.46	6.87	0.4	5.16e-11	Subjective well-being;
KIRP	cis	rs1461503	0.900	rs7107502	chr11:122830214	G/A	cg27398637	chr11:122830231	C11orf63	-0.81	-11.77	-0.6	1.18e-25	Menarche (age at onset);
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.86	-9.08	-0.5	3.71e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs9462846	0.652	rs77807794	chr6:42906242	C/T	cg05552183	chr6:42928497	GNMT	0.61	6.98	0.41	2.71e-11	Blood protein levels;
KIRP	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06634786	chr22:41940651	POLR3H	-0.44	-5.35	-0.32	2.06e-7	Vitiligo;
KIRP	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg23442198	chr4:187126114	CYP4V2	-0.56	-5.4	-0.33	1.59e-7	Blood protein levels;
KIRP	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg14972814	chr11:95582409	MTMR2	0.35	5.76	0.34	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12210905	1.000	rs72843640	chr6:27202093	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.4	-0.38	7.77e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs1635	0.655	rs2159275	chr6:28308446	G/A	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg00800038	chr16:89945340	TCF25	-0.76	-5.28	-0.32	2.78e-7	Skin colour saturation;
KIRP	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg21427119	chr20:30132790	HM13	-0.62	-6.67	-0.39	1.7e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21385522	chr1:16154831	NA	0.5	6.36	0.38	9.95e-10	Dilated cardiomyopathy;
KIRP	cis	rs2273669	0.667	rs117412830	chr6:109336617	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg23587288	chr2:27483067	SLC30A3	-0.77	-8.02	-0.46	4.34e-14	Blood metabolite levels;
KIRP	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12027358	chr15:65133575	PLEKHO2	0.49	6.18	0.37	2.71e-9	Parkinson's disease;
KIRP	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg08992911	chr2:238395768	MLPH	0.52	5.53	0.33	8.25e-8	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs12282928	0.743	rs2202249	chr11:48200586	C/T	cg04607699	chr11:48328132	OR4S1	-0.39	-5.49	-0.33	1.01e-7	Migraine - clinic-based;
KIRP	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12292205	chr6:26970375	C6orf41	-0.68	-7.3	-0.42	4.05e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6547631	0.635	rs12714149	chr2:85898898	C/A	cg07313956	chr2:85895360	SFTPB	0.42	6.05	0.36	5.3300000000000004e-09	Blood protein levels;
KIRP	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.88	11.18	0.58	9.82e-24	Platelet distribution width;
KIRP	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.68	9.13	0.5	2.64e-17	Personality dimensions;
KIRP	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.77	-0.4	9.6e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2997447	0.706	rs61776574	chr1:26429492	C/T	cg19633962	chr1:26362018	EXTL1	-0.69	-5.85	-0.35	1.54e-8	QRS complex (12-leadsum);
KIRP	trans	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg10756647	chr7:56101905	PSPH	1.01	7.54	0.43	9.29e-13	Diabetic kidney disease;
KIRP	cis	rs35892873	0.703	rs7615776	chr3:126060617	G/A	cg15490784	chr3:126061950	KLF15	0.43	5.41	0.33	1.53e-7	Male-pattern baldness;
KIRP	cis	rs4950322	0.542	rs3766520	chr1:146686228	C/T	cg22381352	chr1:146742008	CHD1L	-0.42	-4.98	-0.3	1.2e-6	Protein quantitative trait loci;
KIRP	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.77	-5.56	-0.33	7.06e-8	Body mass index;
KIRP	cis	rs714515	0.934	rs9425589	chr1:172355276	G/A	cg01573306	chr1:172330400	DNM3	0.45	5.83	0.35	1.69e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg10818794	chr15:86012489	AKAP13	-0.5	-7.15	-0.41	9.9e-12	Coronary artery disease;
KIRP	cis	rs988913	1.000	rs6941796	chr6:54837621	A/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.57	-0.33	6.75e-8	Menarche (age at onset);
KIRP	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.74	9.31	0.51	7.52e-18	Menopause (age at onset);
KIRP	cis	rs6545883	0.895	rs7588814	chr2:61695589	A/T	cg15711740	chr2:61764176	XPO1	-0.6	-7.89	-0.45	9.7e-14	Tuberculosis;
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg12140854	chr5:148520817	ABLIM3	0.54	6.25	0.37	1.77e-9	Breast cancer;
KIRP	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg26576206	chr19:1064938	ABCA7	0.37	5.19	0.31	4.5e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.67	-9.09	-0.5	3.4e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.68	-0.44	3.69e-13	Response to antipsychotic treatment;
KIRP	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg01988459	chr11:68622903	NA	-0.43	-5.97	-0.36	8.05e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.1	0.46	2.55e-14	Menopause (age at onset);
KIRP	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg12173498	chr6:36355764	ETV7	0.31	4.96	0.3	1.34e-6	Platelet distribution width;
KIRP	cis	rs11955175	1.000	rs45480797	chr5:40680964	C/G	cg17351974	chr5:40835760	RPL37	0.63	5.5	0.33	9.62e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	6.13	0.36	3.46e-9	Menarche (age at onset);
KIRP	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.98	10.03	0.54	4.49e-20	Eosinophilic esophagitis;
KIRP	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg11757124	chr7:157526947	PTPRN2	-0.5	-5.9	-0.35	1.23e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs934734	0.544	rs4671127	chr2:65562970	C/G	cg08085232	chr2:65598271	SPRED2	-0.54	-6.77	-0.4	9.57e-11	Rheumatoid arthritis;
KIRP	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg23625390	chr15:77176239	SCAPER	0.53	6.93	0.4	3.71e-11	Blood metabolite levels;
KIRP	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.94	-0.3	1.43e-6	Schizophrenia;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.54	-0.43	8.8e-13	Life satisfaction;
KIRP	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.83	-9.18	-0.51	1.81e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs981844	0.712	rs1563461	chr4:154751913	C/T	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.57	7.15	0.41	1.01e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg27490568	chr2:178487706	NA	0.41	5.46	0.33	1.17e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	12.11	0.61	8.45e-27	Menarche (age at onset);
KIRP	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg07827796	chr19:33622959	WDR88	0.43	5.05	0.31	8.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.65	0.66	5.7e-32	Bladder cancer;
KIRP	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	5.5	0.33	9.28e-8	Resting heart rate;
KIRP	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.04	0.36	5.53e-9	Neuroticism;
KIRP	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs12476592	0.543	rs262480	chr2:63873032	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs1697938	0.640	rs13156109	chr5:40906076	A/G	cg01087697	chr5:40835557	RPL37	-0.48	-5.51	-0.33	9.2e-8	Multiple system atrophy;
KIRP	cis	rs654384	0.898	rs13242365	chr7:4175025	G/T	cg21882563	chr7:4172065	SDK1	0.43	5.6	0.34	5.72e-8	Positive affect;
KIRP	cis	rs4132509	0.603	rs12408951	chr1:243679364	A/G	cg25706552	chr1:244017396	NA	0.44	5.02	0.3	9.94e-7	RR interval (heart rate);
KIRP	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.33	-12.18	-0.61	5.09e-27	Diabetic retinopathy;
KIRP	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.85	8.21	0.46	1.29e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg17595323	chr11:93583763	C11orf90	-0.3	-5.15	-0.31	5.31e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.08	0.36	4.66e-9	Neuroticism;
KIRP	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg18657303	chr4:1051139	NA	0.55	5.1	0.31	6.64e-7	Recombination rate (females);
KIRP	cis	rs7590368	0.673	rs17455708	chr2:10926767	A/G	cg15705551	chr2:10952987	PDIA6	0.65	6.16	0.37	2.87e-9	Educational attainment (years of education);
KIRP	trans	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.24	0.42	5.76e-12	Retinal vascular caliber;
KIRP	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	8.53	0.48	1.56e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs73411413	0.608	rs7126170	chr11:1539387	C/A	cg04803994	chr11:1592587	HCCA2;LOC338651;DUSP8	-0.54	-6.65	-0.39	1.87e-10	Myringotomy;
KIRP	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.96	-8.0	-0.45	4.86e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17016394	chr21:34442360	OLIG1	0.45	6.07	0.36	4.83e-9	Parkinson's disease;
KIRP	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg11584989	chr19:19387371	SF4	0.62	6.65	0.39	1.85e-10	Bipolar disorder;
KIRP	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg12962167	chr3:53033115	SFMBT1	-0.61	-4.84	-0.3	2.24e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.66	-8.02	-0.46	4.43e-14	Iron status biomarkers;
KIRP	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg01403660	chr11:68851641	TPCN2	0.65	6.09	0.36	4.23e-9	Blond vs. brown hair color;
KIRP	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg05528293	chr18:74961138	GALR1	0.53	5.52	0.33	8.72e-8	Obesity-related traits;
KIRP	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.71	7.55	0.43	8.61e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.63	-10.6	-0.56	7.05e-22	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.76	7.87	0.45	1.15e-13	Resting heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15971888	chr8:67089599	CRH	0.52	7.17	0.42	8.67e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg03060546	chr3:49711283	APEH	-0.72	-5.46	-0.33	1.15e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs8093481	1.000	rs7234687	chr18:10694410	T/C	cg21165219	chr18:10698044	FAM38B	-0.44	-5.43	-0.33	1.38e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs412050	0.547	rs17821500	chr22:22152480	T/C	cg17089214	chr22:22089827	YPEL1	0.64	5.85	0.35	1.55e-8	Attention deficit hyperactivity disorder;
KIRP	trans	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.59	6.7	0.39	1.43e-10	Cystic fibrosis severity;
KIRP	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.67	9.21	0.51	1.5e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4478037	0.558	rs72854778	chr3:33071945	G/T	cg19404215	chr3:33155277	CRTAP	0.88	5.48	0.33	1.03e-7	Major depressive disorder;
KIRP	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg24315340	chr6:146058215	EPM2A	0.39	4.95	0.3	1.4e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.82	9.84	0.53	1.75e-19	Corneal astigmatism;
KIRP	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.41	6.94	0.4	3.51e-11	Heart rate;
KIRP	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.74	0.71	4.26e-39	Bipolar disorder;
KIRP	cis	rs3789045	0.774	rs12041243	chr1:204490470	A/G	cg18185008	chr1:204589407	LRRN2	-0.6	-6.54	-0.38	3.53e-10	Educational attainment (college completion);
KIRP	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.59	-0.39	2.65e-10	QT interval;
KIRP	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.41	-0.43	1.99e-12	Hemoglobin concentration;
KIRP	trans	rs2048656	0.605	rs13248108	chr8:9651273	G/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.97	0.41	2.88e-11	Schizophrenia;
KIRP	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg05370193	chr1:21551575	ECE1	0.47	6.26	0.37	1.71e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg15252951	chr6:33757062	LEMD2	0.47	5.27	0.32	2.96e-7	Crohn's disease;
KIRP	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg08499158	chr17:42289980	UBTF	0.49	6.14	0.36	3.3e-9	Total body bone mineral density;
KIRP	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	1.02	13.36	0.65	5.52e-31	Exhaled nitric oxide output;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.85	13.68	0.66	4.68e-32	Menarche (age at onset);
KIRP	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg00933542	chr6:150070202	PCMT1	0.29	5.64	0.34	4.58e-8	Lung cancer;
KIRP	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.72	-9.09	-0.5	3.38e-17	Coronary artery disease;
KIRP	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.79	-9.17	-0.5	1.96e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg10353785	chr11:16759993	C11orf58	-0.42	-6.11	-0.36	3.92e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-0.89	-6.76	-0.4	9.83e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	7.11	0.41	1.26e-11	Eye color traits;
KIRP	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.72e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.64	8.31	0.47	6.34e-15	Pulse pressure;
KIRP	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.61	-8.96	-0.5	8.5e-17	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs12043259	1.000	rs61173840	chr1:204827645	A/G	cg11485465	chr5:54518469	NA	0.37	6.02	0.36	6.46e-9	Addiction;
KIRP	cis	rs2346160	0.899	rs384974	chr6:167688418	C/T	cg27333441	chr6:167680455	NA	-0.41	-5.55	-0.33	7.53e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs1620921	0.655	rs59754710	chr6:161187850	C/A	cg01280913	chr6:161186852	NA	-0.38	-4.95	-0.3	1.37e-6	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.84	0.3	2.25e-6	Menarche (age at onset);
KIRP	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg13736514	chr6:26305472	NA	-0.65	-8.43	-0.47	2.98e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg26134248	chr17:3907702	NA	0.39	5.06	0.31	8.4e-7	Type 2 diabetes;
KIRP	cis	rs2635047	0.569	rs9958817	chr18:44786481	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.02	0.36	6.24e-9	Educational attainment;
KIRP	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg21361702	chr7:150065534	REPIN1	0.58	6.3	0.37	1.38e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg12940439	chr1:67600707	NA	0.43	6.29	0.37	1.41e-9	Psoriasis;
KIRP	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.48	7.23	0.42	6.03e-12	Total body bone mineral density;
KIRP	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23016472	chr19:49217901	MAMSTR	0.52	6.57	0.39	2.89e-10	Parkinson's disease;
KIRP	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.54	-7.38	-0.43	2.46e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg14541582	chr5:601475	NA	-0.47	-5.48	-0.33	1.04e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	6.73	0.39	1.15e-10	Height;
KIRP	cis	rs7523273	0.564	rs1977265	chr1:207880683	G/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-5.35	-0.32	1.97e-7	Schizophrenia;
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.6	8.25	0.47	9.42e-15	Menarche (age at onset);
KIRP	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg24060327	chr5:131705240	SLC22A5	0.55	6.88	0.4	4.98e-11	Acylcarnitine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06109664	chr4:99850540	EIF4E	-0.52	-6.84	-0.4	6.2e-11	Interleukin-4 levels;
KIRP	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg14847009	chr1:175162515	KIAA0040	0.25	5.39	0.32	1.68e-7	Alcohol dependence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23204296	chr5:9544782	SEMA5A	0.46	6.33	0.37	1.16e-9	Parkinson's disease;
KIRP	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg02536541	chr18:77568900	NA	-0.75	-11.0	-0.57	3.69e-23	Schizophrenia;
KIRP	cis	rs28595532	0.545	rs72677057	chr4:119264162	A/T	cg21605333	chr4:119757512	SEC24D	0.69	5.84	0.35	1.67e-8	Cannabis dependence symptom count;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-1.07	-21.15	-0.8	2.73e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10073892	0.744	rs10053827	chr5:101786525	C/T	cg19774478	chr5:101632501	SLCO4C1	0.67	6.49	0.38	4.62e-10	Cognitive decline (age-related);
KIRP	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs6001982	0.748	rs5995867	chr22:40888136	T/G	cg07138101	chr22:40742427	ADSL	0.73	5.98	0.36	8.02e-9	Breast cancer;
KIRP	cis	rs7113874	0.802	rs10769938	chr11:8671547	C/T	cg08015107	chr11:8618950	NA	-0.41	-5.45	-0.33	1.22e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14530259	chr9:133455155	LOC100272217;FUBP3	0.53	6.76	0.4	9.86e-11	Parkinson's disease;
KIRP	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg15068132	chr12:102092402	CHPT1	-0.4	-5.15	-0.31	5.26e-7	Blood protein levels;
KIRP	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg23100626	chr2:96804247	ASTL	0.47	6.03	0.36	6.08e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.76	0.81	2.97e-59	Prudent dietary pattern;
KIRP	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg05914723	chr15:78953907	NA	0.45	5.41	0.33	1.51e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg05692746	chr2:100937584	LONRF2	-0.39	-4.99	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.85	-0.4	5.9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg00579200	chr11:133705235	NA	-0.39	-4.95	-0.3	1.41e-6	Childhood ear infection;
KIRP	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.45	-7.34	-0.42	3.13e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg01391022	chr12:122360665	WDR66	0.37	5.01	0.3	1.02e-6	Mean corpuscular volume;
KIRP	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.57	-7.01	-0.41	2.32e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.65	-6.32	-0.37	1.23e-9	Bronchopulmonary dysplasia;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg23030676	chr10:131648308	EBF3	0.34	6.39	0.38	8.2e-10	Serum protein levels (sST2);
KIRP	cis	rs9488822	0.585	rs390255	chr6:116237680	A/G	cg15226275	chr6:116381976	FRK	0.23	5.89	0.35	1.27e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.43	-6.45	-0.38	5.84e-10	Refractive error;
KIRP	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.7	10.03	0.54	4.39e-20	Retinal vascular caliber;
KIRP	cis	rs7011507	1.000	rs75634849	chr8:49178535	C/T	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg12940923	chr8:10282607	MSRA	-0.38	-4.85	-0.3	2.23e-6	Triglycerides;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24782169	chr11:62554862	TMEM179B	-0.46	-6.2	-0.37	2.38e-9	Metabolic traits;
KIRP	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg09165964	chr15:75287851	SCAMP5	-0.37	-4.99	-0.3	1.12e-6	Caffeine consumption;
KIRP	cis	rs3026101	0.671	rs12603639	chr17:5320808	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.89	0.35	1.27e-8	Body mass index;
KIRP	cis	rs1903068	1.000	rs73236109	chr4:56007425	C/T	cg01777861	chr4:56023843	NA	0.38	4.89	0.3	1.84e-6	Endometriosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26474270	chr16:73092823	ZFHX3	0.46	6.4	0.38	7.8e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4936894	0.500	rs4936916	chr11:124157440	G/A	cg27160556	chr11:124181099	OR8D1	-0.46	-6.6	-0.39	2.55e-10	Aging (time to death);
KIRP	cis	rs7709377	0.597	rs7733128	chr5:115474841	G/T	cg23108291	chr5:115420582	COMMD10	0.42	5.02	0.3	9.97e-7	Metabolite levels  (X-11787);
KIRP	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.58	7.16	0.42	9.1e-12	QRS duration;
KIRP	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg00405596	chr8:11794950	NA	0.55	7.65	0.44	4.56e-13	Myopia (pathological);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19753373	chr11:64597090	CDC42BPG	-0.52	-6.88	-0.4	4.93e-11	Parkinson's disease;
KIRP	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.64	8.53	0.48	1.54e-15	Pulse pressure;
KIRP	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.73e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.77	7.27	0.42	4.84e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg01879757	chr17:41196368	BRCA1	-0.78	-10.64	-0.56	5.55e-22	Menopause (age at onset);
KIRP	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	10.32	0.55	5.58e-21	Electrocardiographic conduction measures;
KIRP	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.27	-22.23	-0.82	8.87e-61	Breast cancer;
KIRP	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.88	-0.45	1.04e-13	Breast cancer;
KIRP	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.38	-0.32	1.74e-7	Coronary artery disease;
KIRP	cis	rs9810890	1.000	rs73198820	chr3:128476794	G/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs7582180	0.934	rs2309817	chr2:100897674	T/A	cg14675211	chr2:100938903	LONRF2	0.54	6.3	0.37	1.35e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7084402	0.967	rs11817440	chr10:60272369	T/C	cg05938607	chr10:60274200	BICC1	0.43	10.31	0.55	5.85e-21	Refractive error;
KIRP	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.69	-8.82	-0.49	2.17e-16	Blood metabolite levels;
KIRP	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg07068956	chr7:100330872	ZAN	0.41	5.44	0.33	1.28e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg04287289	chr16:89883240	FANCA	0.56	7.49	0.43	1.22e-12	Vitiligo;
KIRP	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.47	5.98	0.36	7.97e-9	Recombination rate (males);
KIRP	cis	rs7923609	0.869	rs10733792	chr10:65232539	A/G	cg01631684	chr10:65280961	REEP3	-0.51	-6.0	-0.36	7.17e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs41005	1.000	rs41008	chr2:8108588	G/T	cg03155496	chr2:8117019	LOC339788	0.59	10.0	0.54	5.69e-20	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs193541	0.632	rs154504	chr5:122204086	A/T	cg19412675	chr5:122181750	SNX24	0.58	6.28	0.37	1.48e-9	Glucose homeostasis traits;
KIRP	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.44	-0.33	1.3e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.51	5.74	0.34	2.75e-8	Cannabis dependence symptom count;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.48	4.85	0.3	2.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.76	-0.34	2.52e-8	IgG glycosylation;
KIRP	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg06917634	chr15:78832804	PSMA4	-0.49	-4.94	-0.3	1.45e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg25547332	chr5:131281432	NA	0.45	5.12	0.31	6.04e-7	Life satisfaction;
KIRP	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg23950597	chr19:37808831	NA	-0.68	-7.16	-0.42	9.28e-12	Coronary artery calcification;
KIRP	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs6732160	0.613	rs59979991	chr2:73384422	G/A	cg01422370	chr2:73384389	NA	0.52	7.05	0.41	1.82e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg02725872	chr8:58115012	NA	-0.57	-6.23	-0.37	1.96e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	0.83	10.68	0.56	4.03e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.86	-11.06	-0.58	2.35e-23	Breast cancer;
KIRP	cis	rs4950322	0.570	rs17356492	chr1:146767770	T/C	cg22381352	chr1:146742008	CHD1L	-0.44	-5.28	-0.32	2.88e-7	Protein quantitative trait loci;
KIRP	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg04369109	chr6:150039330	LATS1	-0.67	-8.76	-0.49	3.26e-16	Lung cancer;
KIRP	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg03808351	chr9:123631620	PHF19	0.47	6.59	0.39	2.67e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs787274	1.000	rs72768411	chr9:115502670	C/A	cg13803584	chr9:115635662	SNX30	0.73	7.75	0.44	2.4e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg16497661	chr14:103986332	CKB	0.75	11.17	0.58	1.07e-23	Body mass index;
KIRP	cis	rs494562	0.667	rs9450263	chr6:86097702	G/A	cg21730993	chr6:86159210	NT5E	0.58	5.75	0.34	2.68e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg22437258	chr11:111473054	SIK2	-0.58	-6.57	-0.39	2.94e-10	Primary sclerosing cholangitis;
KIRP	cis	rs6973256	0.897	rs12333918	chr7:133330374	T/G	cg10665199	chr7:133106180	EXOC4	-0.51	-6.37	-0.38	9.2e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3857747	0.578	rs6965764	chr7:40409406	A/C	cg00420559	chr7:40367873	C7orf10	-0.42	-6.04	-0.36	5.72e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.58	-0.63	2.44e-28	Exhaled nitric oxide output;
KIRP	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.9	-12.25	-0.62	2.88e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.25	-5.23	-0.32	3.64e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs9323205	0.798	rs2999391	chr14:51655109	A/G	cg23942311	chr14:51606299	NA	0.61	7.84	0.45	1.38e-13	Cancer;
KIRP	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17376030	chr22:41985996	PMM1	0.6	6.44	0.38	6.13e-10	Vitiligo;
KIRP	cis	rs684232	0.800	rs2002015	chr17:534525	G/T	cg15660573	chr17:549704	VPS53	0.5	6.52	0.38	3.96e-10	Prostate cancer;
KIRP	cis	rs3026101	0.671	rs8067917	chr17:5278307	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.68	0.34	3.75e-8	Body mass index;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg01988459	chr11:68622903	NA	-0.42	-5.74	-0.34	2.78e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9815354	0.953	rs1629462	chr3:41927452	G/C	cg03022575	chr3:42003672	ULK4	-0.46	-5.25	-0.32	3.36e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.43	-0.38	6.65e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13198984	chr17:80129470	CCDC57	-0.58	-8.78	-0.49	2.83e-16	Life satisfaction;
KIRP	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.5	-7.27	-0.42	4.69e-12	Birth weight;
KIRP	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg09788416	chr12:39539408	NA	0.4	5.37	0.32	1.85e-7	Morning vs. evening chronotype;
KIRP	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.84	0.4	6.21e-11	Colorectal cancer;
KIRP	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.33	5.09	0.31	6.98e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.9	-11.52	-0.59	7.85e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.88	-11.75	-0.6	1.36e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg05802129	chr4:122689817	NA	-0.64	-8.14	-0.46	1.97e-14	Type 2 diabetes;
KIRP	cis	rs10824796	1.000	rs2384044	chr10:54536083	C/G	cg27418851	chr10:54531653	MBL2	-0.45	-5.2	-0.31	4.23e-7	Blood protein levels;
KIRP	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.55	7.3	0.42	4.04e-12	Red blood cell count;
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21016266	chr12:122356598	WDR66	0.48	6.26	0.37	1.72e-9	Mean corpuscular volume;
KIRP	cis	rs4776059	1.000	rs11858743	chr15:52936330	G/A	cg22715398	chr15:52968154	KIAA1370	-0.59	-7.14	-0.41	1.02e-11	Schizophrenia;
KIRP	cis	rs4560672	0.938	rs866662	chr6:158545673	G/A	cg14029994	chr6:158589857	SERAC1;GTF2H5	0.55	5.05	0.31	8.5e-7	Smoking quantity;
KIRP	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.73	-7.58	-0.44	7.04e-13	Vitiligo;
KIRP	cis	rs9400467	0.528	rs9689727	chr6:111796563	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.52	-0.33	8.44e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs4805834	0.640	rs11671862	chr19:33304298	C/T	cg07201929	chr19:33182834	NUDT19	-0.59	-4.95	-0.3	1.39e-6	Creatinine levels;
KIRP	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.77	9.91	0.53	1.08e-19	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23104823	chr14:45553408	PRPF39	0.69	6.39	0.38	8.15e-10	Lung function (FEV1);
KIRP	cis	rs787274	0.867	rs1711746	chr9:115452656	A/G	cg13803584	chr9:115635662	SNX30	0.67	6.29	0.37	1.48e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg22676075	chr6:135203613	NA	0.47	6.62	0.39	2.27e-10	Red blood cell count;
KIRP	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.45	6.65	0.39	1.92e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.76	9.22	0.51	1.38e-17	Response to antipsychotic treatment;
KIRP	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg10259518	chr2:233765616	NGEF	0.34	5.05	0.31	8.79e-7	Coronary artery disease;
KIRP	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs6545883	0.759	rs777585	chr2:61412559	A/G	cg15711740	chr2:61764176	XPO1	0.51	6.68	0.39	1.54e-10	Tuberculosis;
KIRP	cis	rs687432	0.847	rs11601223	chr11:57752003	C/T	cg19752551	chr11:57585705	CTNND1	-0.56	-7.57	-0.43	7.29e-13	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00330888	chr2:46524148	EPAS1	0.56	7.07	0.41	1.57e-11	Parkinson's disease;
KIRP	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg12962167	chr3:53033115	SFMBT1	0.71	5.28	0.32	2.8e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg11130432	chr3:121712080	ILDR1	0.46	5.71	0.34	3.16e-8	Multiple sclerosis;
KIRP	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs732716	0.785	rs55660045	chr19:4425305	T/G	cg03719555	chr19:4455413	UBXN6	0.48	7.35	0.42	2.84e-12	Mean corpuscular volume;
KIRP	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-8.62	-0.48	8.21e-16	Platelet count;
KIRP	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.43	-5.27	-0.32	2.96e-7	Aortic root size;
KIRP	cis	rs16936870	0.543	rs1014160	chr8:71253575	C/T	cg14232793	chr8:71155543	NCOA2	0.54	6.24	0.37	1.95e-9	QT interval;
KIRP	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	5.63	0.34	4.91e-8	Personality dimensions;
KIRP	cis	rs7534824	0.543	rs12569174	chr1:101386179	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.74	6.84	0.4	6.4e-11	Refractive astigmatism;
KIRP	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg25037394	chr1:24152592	HMGCL	0.38	5.0	0.3	1.08e-6	Immature fraction of reticulocytes;
KIRP	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-6.6	-0.39	2.55e-10	Lung cancer;
KIRP	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.48	-0.52	2.32e-18	Joint mobility (Beighton score);
KIRP	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.56	12.27	0.62	2.62e-27	Diabetic kidney disease;
KIRP	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.12e-6	Atopic dermatitis;
KIRP	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg17646820	chr3:66848679	NA	0.74	8.66	0.48	6.36e-16	Type 2 diabetes;
KIRP	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.58	-7.3	-0.42	3.93e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.25e-10	Protein C levels;
KIRP	cis	rs7011049	1.000	rs78200075	chr8:53845907	G/A	cg26025543	chr8:53854495	NA	0.75	7.67	0.44	4.02e-13	Systolic blood pressure;
KIRP	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.61	4.87	0.3	1.99e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26314531	chr2:26401878	FAM59B	0.47	4.9	0.3	1.75e-6	Gut microbiome composition (summer);
KIRP	cis	rs4148660	1.000	rs2176394	chr12:22078571	T/A	cg14669847	chr12:22099120	NA	0.33	5.62	0.34	5.07e-8	Gout;
KIRP	cis	rs490234	0.756	rs6478705	chr9:128216326	G/T	cg14078157	chr9:128172775	NA	-0.4	-5.03	-0.31	9.61e-7	Mean arterial pressure;
KIRP	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.71	6.81	0.4	7.65e-11	Gut microbiome composition (summer);
KIRP	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg18357526	chr6:26021779	HIST1H4A	0.49	5.91	0.35	1.13e-8	Blood metabolite levels;
KIRP	cis	rs17001868	1.000	rs17001868	chr22:40778231	A/C	cg07138101	chr22:40742427	ADSL	0.71	5.85	0.35	1.58e-8	Mammographic density (dense area);
KIRP	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.76	11.12	0.58	1.57e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.6e-6	Total body bone mineral density;
KIRP	cis	rs4774830	0.744	rs60931351	chr15:56305541	A/T	cg24530489	chr15:56299380	NA	-0.82	-5.37	-0.32	1.8e-7	Delta-5 desaturase activity;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	10.65	0.56	4.85e-22	Lymphocyte counts;
KIRP	trans	rs10851411	0.908	rs10454039	chr15:42832534	C/T	cg24009656	chr6:146759324	NA	0.48	6.18	0.37	2.59e-9	Glucose homeostasis traits;
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.51	6.87	0.4	5.11e-11	Testicular germ cell tumor;
KIRP	cis	rs4671400	0.543	rs62152274	chr2:61499588	C/A	cg15711740	chr2:61764176	XPO1	0.62	6.7	0.39	1.38e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.71	-0.39	1.32e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg08131204	chr22:41487073	MIR1281	-0.42	-4.85	-0.3	2.19e-6	Neuroticism;
KIRP	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg18306943	chr3:40428807	ENTPD3	-0.38	-5.24	-0.32	3.48e-7	Renal cell carcinoma;
KIRP	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg18944383	chr4:111397179	ENPEP	-0.41	-6.78	-0.4	8.79e-11	Height;
KIRP	cis	rs2502731	0.539	rs3003614	chr9:130994736	G/A	cg09976142	chr9:130955436	CIZ1	0.38	5.69	0.34	3.58e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.76	10.98	0.57	4.51e-23	Heart rate;
KIRP	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-1.03	-9.41	-0.51	3.6e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.46	5.91	0.35	1.15e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.58	7.97	0.45	5.76e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.85	-11.37	-0.59	2.35e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.43	-6.97	-0.41	2.92e-11	Refractive error;
KIRP	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg17425144	chr1:10567563	PEX14	0.52	10.36	0.55	4.13e-21	Breast size;
KIRP	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	13.26	0.65	1.2e-30	Schizophrenia;
KIRP	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.74	-8.02	-0.46	4.42e-14	Vitiligo;
KIRP	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.67	8.17	0.46	1.59e-14	Blood metabolite levels;
KIRP	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.55	7.28	0.42	4.37e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	cg04338863	chr8:33670619	NA	0.41	5.33	0.32	2.18e-7	Body mass index;
KIRP	cis	rs6495367	0.872	rs7183818	chr15:79372413	A/G	cg17916960	chr15:79447300	NA	0.37	6.28	0.37	1.55e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.57	7.05	0.41	1.85e-11	Iron status biomarkers;
KIRP	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg07636037	chr3:49044803	WDR6	0.47	5.26	0.32	3.12e-7	Prion diseases;
KIRP	cis	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg07460842	chr6:66804631	NA	0.9	7.6	0.44	6.23e-13	Exhaled nitric oxide output;
KIRP	cis	rs2278796	0.789	rs12136572	chr1:204962660	G/A	cg17449235	chr1:204966235	NFASC	0.63	8.41	0.47	3.32e-15	Mean platelet volume;
KIRP	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg10047753	chr17:41438598	NA	1.14	18.88	0.77	9.76e-50	Menopause (age at onset);
KIRP	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg04865290	chr3:52927548	TMEM110	-0.64	-6.76	-0.4	1.01e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs16912285	0.748	rs7104694	chr11:24280281	A/C	ch.11.24196551F	chr11:24239977	NA	0.8	9.56	0.52	1.32e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00290607	chr11:67383545	NA	0.35	4.89	0.3	1.82e-6	Mean corpuscular volume;
KIRP	cis	rs400736	0.729	rs2493216	chr1:8008366	C/A	cg25007680	chr1:8021821	PARK7	-0.55	-7.2	-0.42	7.26e-12	Response to antidepressants and depression;
KIRP	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.98	-17.47	-0.74	5.67e-45	Breast cancer;
KIRP	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.44	5.12	0.31	6.07e-7	Aortic root size;
KIRP	cis	rs4700695	0.841	rs251614	chr5:65228251	C/G	cg21114390	chr5:65439923	SFRS12	-0.51	-6.02	-0.36	6.26e-9	Facial morphology (factor 19);
KIRP	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg08501292	chr6:25962987	TRIM38	0.71	4.93	0.3	1.48e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-10.99	-0.57	4.2e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.93	0.64	1.57e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.65	6.97	0.41	2.9e-11	Response to diuretic therapy;
KIRP	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.43	0.52	3.15e-18	Height;
KIRP	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.7	-7.88	-0.45	1.06e-13	Menarche (age at onset);
KIRP	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg17470723	chr8:74884337	TCEB1	0.62	7.94	0.45	7.11e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.01	0.36	6.75e-9	Height;
KIRP	cis	rs9972944	0.756	rs11870607	chr17:63773122	A/G	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.54	-0.43	9.02e-13	Bipolar disorder;
KIRP	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.7	-0.34	3.41e-8	Type 2 diabetes;
KIRP	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.11	23.09	0.83	1.64e-63	Testicular germ cell tumor;
KIRP	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.68	-9.64	-0.52	7.28e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.68	-6.52	-0.38	4.03e-10	Diabetic retinopathy;
KIRP	cis	rs9826463	1.000	rs13316756	chr3:142340879	A/G	cg20824294	chr3:142316082	PLS1	0.34	5.81	0.35	1.9e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg13409248	chr3:40428643	ENTPD3	0.38	5.17	0.31	4.77e-7	Renal cell carcinoma;
KIRP	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.34	7.62	0.44	5.47e-13	Cutaneous nevi;
KIRP	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg01990225	chr2:97406019	LMAN2L	-1.1	-7.34	-0.42	3.1e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.06	0.41	1.66e-11	Retinal vascular caliber;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16888603	chr8:144696651	TSTA3	0.5	6.47	0.38	5.26e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03648734	chr8:104411856	SLC25A32	-0.42	-6.59	-0.39	2.61e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2997447	0.846	rs61775416	chr1:26393329	C/T	cg19633962	chr1:26362018	EXTL1	-0.75	-6.29	-0.37	1.41e-9	QRS complex (12-leadsum);
KIRP	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08822215	chr16:89438651	ANKRD11	-0.46	-6.11	-0.36	3.95e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.29	-0.32	2.74e-7	Neuroticism;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.26	0.47	9.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.95	13.2	0.64	1.92e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.77	-0.44	2.09e-13	Resting heart rate;
KIRP	cis	rs7916697	0.842	rs4746749	chr10:70009389	C/T	cg18338521	chr10:69995036	NA	0.39	4.89	0.3	1.86e-6	Optic disc area;
KIRP	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg11833968	chr6:79620685	NA	-0.46	-6.99	-0.41	2.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs71636778	0.524	rs78614739	chr1:27174180	C/T	cg12203394	chr1:27248618	NUDC	0.71	5.73	0.34	2.89e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10170310	0.608	rs10928657	chr2:139291769	G/A	cg10095539	chr2:139258744	SPOPL	0.38	5.93	0.35	1.04e-8	Response to antipsychotic treatment;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02056921	chr1:901892	PLEKHN1	0.49	6.63	0.39	2.14e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	Neuroticism;
KIRP	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.39	-4.91	-0.3	1.63e-6	Height;
KIRP	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg11995313	chr8:8860691	ERI1	0.38	5.06	0.31	8.02e-7	Joint mobility (Beighton score);
KIRP	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.63	-6.57	-0.39	3.02e-10	Gut microbiome composition (summer);
KIRP	cis	rs4523957	0.928	rs4790072	chr17:2173497	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.46	-0.47	2.45e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	10.22	0.55	1.14e-20	Mood instability;
KIRP	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.67	9.0	0.5	6.46e-17	Breast cancer;
KIRP	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.39	-0.43	2.3e-12	Joint mobility (Beighton score);
KIRP	cis	rs6032067	0.850	rs34274189	chr20:43864298	G/T	cg10761708	chr20:43804764	PI3	0.51	4.92	0.3	1.56e-6	Blood protein levels;
KIRP	cis	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07570687	chr10:102243282	WNT8B	0.49	6.1	0.36	4.1e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs7534824	0.507	rs61780294	chr1:101398011	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.88	0.45	1.02e-13	Refractive astigmatism;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg04102784	chr5:81152212	NA	-0.45	-6.1	-0.36	4.06e-9	Select biomarker traits;
KIRP	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.97	-0.36	8.07e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg08501292	chr6:25962987	TRIM38	0.83	5.59	0.34	5.98e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-7.37	-0.43	2.52e-12	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg00857998	chr1:205179979	DSTYK	0.64	7.59	0.44	6.77e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8077577	0.747	rs7405677	chr17:18131236	C/T	cg18869244	chr17:18121946	NA	-0.49	-5.46	-0.33	1.18e-7	Obesity-related traits;
KIRP	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg24296786	chr1:45957014	TESK2	0.63	8.39	0.47	3.79e-15	High light scatter reticulocyte count;
KIRP	cis	rs1011108	0.518	rs935172	chr2:26804247	A/G	cg02095504	chr2:26804199	CIB4	-0.33	-4.9	-0.3	1.74e-6	Periodontal microbiota;
KIRP	cis	rs12220238	0.543	rs12358427	chr10:76377587	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.66	5.31	0.32	2.42e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06677660	chr19:49140777	SEC1;DBP	-0.5	-5.84	-0.35	1.67e-8	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg01765077	chr12:122356316	WDR66	0.59	7.99	0.45	5.09e-14	Mean corpuscular volume;
KIRP	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.72	-9.84	-0.53	1.78e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs860295	0.639	rs10908469	chr1:155468732	A/C	cg02153340	chr1:155202674	NA	-0.52	-7.18	-0.42	8.24e-12	Body mass index;
KIRP	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.47	-0.33	1.09e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4363385	0.510	rs55959888	chr1:152913490	A/G	cg25856811	chr1:152973957	SPRR3	-0.39	-5.47	-0.33	1.09e-7	Inflammatory skin disease;
KIRP	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg08741688	chr4:3415352	RGS12	-0.46	-5.35	-0.32	2.01e-7	Serum sulfate level;
KIRP	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.51	-0.43	1.08e-12	Neuroticism;
KIRP	cis	rs11650175	0.727	rs1421026	chr17:63751535	C/T	cg18091269	chr17:63822838	CCDC46	0.32	5.04	0.31	8.99e-7	Chin dimples;
KIRP	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.67	8.6	0.48	9.36e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg05562828	chr17:3906858	NA	-0.72	-14.32	-0.67	3.19e-34	Type 2 diabetes;
KIRP	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.72	7.46	0.43	1.48e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.51	-0.33	8.91e-8	IgG glycosylation;
KIRP	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg17554472	chr22:41940697	POLR3H	-0.67	-7.22	-0.42	6.46e-12	Vitiligo;
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.25	-0.58	5.78e-24	Body mass index;
KIRP	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.51	-0.48	1.68e-15	Triglycerides;
KIRP	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.77	13.46	0.65	2.49e-31	Weight;
KIRP	cis	rs6545883	0.894	rs2694649	chr2:61573826	G/A	cg15711740	chr2:61764176	XPO1	0.61	7.98	0.45	5.73e-14	Tuberculosis;
KIRP	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	cg12689670	chr1:183009347	LAMC1	0.44	6.46	0.38	5.61e-10	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03375703	chr2:160176473	BAZ2B	-0.41	-6.46	-0.38	5.59e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.05	-0.36	5.43e-9	Alcohol dependence;
KIRP	cis	rs10484761	1.000	rs4443506	chr6:40808595	G/A	cg02680909	chr6:39899321	MOCS1	-0.23	-4.93	-0.3	1.48e-6	Esophageal cancer;
KIRP	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.67	9.86	0.53	1.56e-19	Lymphocyte counts;
KIRP	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.15e-51	Height;
KIRP	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg08807101	chr21:30365312	RNF160	-0.54	-5.4	-0.33	1.57e-7	Cognitive test performance;
KIRP	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg26207909	chr14:103986467	CKB	0.56	7.62	0.44	5.43e-13	Body mass index;
KIRP	cis	rs2574975	0.679	rs2842106	chr10:52131237	A/G	cg10034176	chr10:52120283	SGMS1	-0.53	-7.23	-0.42	5.95e-12	Response to amphetamines;
KIRP	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.65	-9.82	-0.53	2.08e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04371633	chr14:65381025	CHURC1	0.52	6.34	0.37	1.08e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.45	6.38	0.38	8.5e-10	Testicular germ cell tumor;
KIRP	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg04374321	chr14:90722782	PSMC1	-0.86	-12.82	-0.63	3.84e-29	Mortality in heart failure;
KIRP	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg06671706	chr8:8559999	CLDN23	0.52	6.13	0.36	3.4e-9	Obesity-related traits;
KIRP	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-6.44	-0.38	6.05e-10	Chronic sinus infection;
KIRP	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.97	0.36	8.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-6.06	-0.36	5.09e-9	Inflammatory skin disease;
KIRP	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.85	12.47	0.62	5.69e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.24	0.42	5.86e-12	Height;
KIRP	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.43	-6.25	-0.37	1.84e-9	Height;
KIRP	cis	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg27487796	chr7:28973253	NA	-0.22	-5.08	-0.31	7.31e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07516702	chr19:5240224	PTPRS	-0.46	-6.16	-0.37	2.99e-9	Parkinson's disease;
KIRP	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg21361702	chr7:150065534	REPIN1	0.59	5.77	0.35	2.41e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15784913	chr19:2900708	ZNF57	0.53	6.78	0.4	9.05e-11	Parkinson's disease;
KIRP	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.62	-7.12	-0.41	1.17e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.96	12.93	0.64	1.62e-29	Vitamin D levels;
KIRP	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.01	0.57	3.54e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg11645453	chr3:52864694	ITIH4	-0.34	-5.16	-0.31	5.17e-7	Body mass index;
KIRP	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.58	-7.93	-0.45	7.79e-14	Schizophrenia;
KIRP	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg05361325	chr10:32636312	EPC1	-0.65	-6.14	-0.36	3.26e-9	Sexual dysfunction (female);
KIRP	cis	rs7084402	0.967	rs1658427	chr10:60331504	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.71	0.34	3.18e-8	Renal cell carcinoma;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09820084	chr6:18387507	RNF144B	-0.47	-6.07	-0.36	4.76e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg18461458	chr19:21324796	ZNF431	0.47	4.88	0.3	1.94e-6	Pain;
KIRP	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	12.37	0.62	1.17e-27	Primary sclerosing cholangitis;
KIRP	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.41	6.04	0.36	5.63e-9	Lipoprotein (a) levels;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg18234130	chr8:27182889	PTK2B	0.53	6.89	0.4	4.53e-11	Neuroticism;
KIRP	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.73	-0.78	1.35e-52	Height;
KIRP	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08439880	chr3:133502540	NA	-0.49	-6.24	-0.37	1.92e-9	Iron status biomarkers;
KIRP	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg00262122	chr8:11665843	FDFT1	0.39	4.92	0.3	1.56e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg03188948	chr7:1209495	NA	0.45	5.09	0.31	7.07e-7	Longevity;Endometriosis;
KIRP	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.98	13.0	0.64	9.55e-30	Vitamin D levels;
KIRP	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.23	-0.51	1.26e-17	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs6462411	0.938	rs10243770	chr7:3915753	A/G	cg27451672	chr7:99156362	ZNF655	0.48	6.06	0.36	5.05e-9	Quantitative traits;
KIRP	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18867708	chr6:26865862	GUSBL1	0.47	5.98	0.36	7.61e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.9	0.35	1.21e-8	Breast cancer;
KIRP	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg20493526	chr2:3714936	ALLC	-0.4	-4.99	-0.3	1.13e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg04657146	chr19:12876947	HOOK2	-0.45	-5.06	-0.31	8.09e-7	Mean corpuscular volume;
KIRP	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg04691961	chr3:161091175	C3orf57	-0.66	-11.18	-0.58	9.56e-24	Morning vs. evening chronotype;
KIRP	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.73	8.96	0.5	8.52e-17	Mammographic density (dense area);
KIRP	trans	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg11693508	chr17:37793320	STARD3	0.58	7.14	0.41	1.03e-11	Neuroticism;
KIRP	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg08719095	chr7:1135190	C7orf50	-0.4	-4.84	-0.3	2.27e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg12623918	chr2:306882	NA	-0.5	-6.79	-0.4	8.34e-11	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-19.3	-0.78	3.69e-51	Height;
KIRP	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg25801113	chr15:45476975	SHF	-0.45	-8.19	-0.46	1.41e-14	Uric acid levels;
KIRP	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg09323728	chr8:95962352	TP53INP1	-0.24	-5.19	-0.31	4.39e-7	Type 2 diabetes;
KIRP	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-5.38	-0.32	1.77e-7	Menarche (age at onset);
KIRP	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-7.32	-0.42	3.6e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.65	6.16	0.37	2.94e-9	Plateletcrit;
KIRP	cis	rs4400599	0.758	rs60633748	chr1:154121510	T/C	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.29	-4.92	-0.3	1.55e-6	Platelet distribution width;
KIRP	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.57	0.43	7.66e-13	Coffee consumption (cups per day);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17053845	chr2:74375133	BOLA3	-0.47	-6.3	-0.37	1.37e-9	Metabolic traits;
KIRP	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg23163573	chr2:108905468	SULT1C2	-0.32	-5.99	-0.36	7.54e-9	Lobe size;
KIRP	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg27205649	chr11:78285834	NARS2	0.68	9.02	0.5	5.33e-17	Alzheimer's disease (survival time);
KIRP	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg03563238	chr19:33554763	RHPN2	-0.33	-5.65	-0.34	4.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2224391	0.590	rs72815603	chr6:5278701	A/C	cg13962347	chr6:5174647	LYRM4	-0.79	-7.88	-0.45	1.09e-13	Height;
KIRP	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.12	0.36	3.6e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.59	0.39	2.61e-10	Retinal vascular caliber;
KIRP	cis	rs76693355	0.512	rs11217875	chr11:120325559	C/A	cg24566217	chr11:120254723	ARHGEF12	-0.44	-5.64	-0.34	4.73e-8	Intraocular pressure;
KIRP	cis	rs11664298	0.606	rs11081564	chr18:77551586	A/G	cg24058013	chr18:77568902	NA	-0.5	-6.2	-0.37	2.4e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.49	5.58	0.34	6.4e-8	Height;
KIRP	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26314531	chr2:26401878	FAM59B	0.47	4.9	0.3	1.75e-6	Gut microbiome composition (summer);
KIRP	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.02	-9.21	-0.51	1.52e-17	Body mass index;
KIRP	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg08126542	chr6:37504118	NA	-0.57	-6.55	-0.39	3.31e-10	Cognitive performance;
KIRP	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.05	0.69	1.03e-36	Gut microbiome composition (summer);
KIRP	cis	rs7221595	0.825	rs12939802	chr17:3933904	C/T	cg09695851	chr17:3907499	NA	0.51	5.06	0.31	8.06e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg06917634	chr15:78832804	PSMA4	-0.68	-6.85	-0.4	6e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.44	5.36	0.32	1.93e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.44	0.47	2.73e-15	Prudent dietary pattern;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19434433	chr17:44849214	WNT3	0.5	6.86	0.4	5.57e-11	Myopia (pathological);
KIRP	cis	rs10484885	0.571	rs56019056	chr6:90630623	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.56	-4.85	-0.3	2.18e-6	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.72	8.83	0.49	1.96e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-1.05	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08949862	chr2:63277672	OTX1	-0.42	-6.45	-0.38	5.78e-10	Metabolic traits;
KIRP	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg09788416	chr12:39539408	NA	0.37	5.11	0.31	6.52e-7	Morning vs. evening chronotype;
KIRP	cis	rs7919006	0.793	rs7924170	chr10:76767134	A/G	cg01390419	chr10:76803856	DUPD1	0.5	5.83	0.35	1.75e-8	Weight;
KIRP	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg27490568	chr2:178487706	NA	0.72	9.61	0.52	9.21e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1147199	0.585	rs17087472	chr9:87246051	A/G	cg22402007	chr9:87282823	NTRK2	0.41	4.96	0.3	1.29e-6	Body mass index;
KIRP	cis	rs3218477	1.000	rs3218397	chr7:152370193	T/A	cg06618968	chr7:152373420	XRCC2	-0.83	-5.38	-0.32	1.69e-7	Mean platelet volume;
KIRP	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg05527609	chr1:210001259	C1orf107	0.43	5.28	0.32	2.85e-7	Red blood cell count;
KIRP	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-8.75	-0.49	3.54e-16	Response to antipsychotic treatment;
KIRP	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.59	-8.21	-0.46	1.24e-14	Calcium levels;
KIRP	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.71	8.89	0.49	1.34e-16	Height;
KIRP	cis	rs77972916	0.561	rs13411629	chr2:43566990	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-6.79	-0.4	8.55e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2997447	0.846	rs61775425	chr1:26405634	A/T	cg19633962	chr1:26362018	EXTL1	-0.56	-4.93	-0.3	1.49e-6	QRS complex (12-leadsum);
KIRP	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg27490568	chr2:178487706	NA	-0.63	-8.23	-0.46	1.12e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg00012203	chr2:219082015	ARPC2	0.81	11.66	0.6	2.75e-25	Colorectal cancer;
KIRP	cis	rs76533333	1.000	rs76533333	chr13:113352916	A/G	cg04656015	chr13:113407548	ATP11A	0.63	5.28	0.32	2.82e-7	Red cell distribution width;
KIRP	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg15556689	chr8:8085844	FLJ10661	0.76	11.06	0.58	2.47e-23	Retinal vascular caliber;
KIRP	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Bladder cancer;
KIRP	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg15443732	chr18:74961078	GALR1	0.58	5.45	0.33	1.2e-7	Obesity-related traits;
KIRP	cis	rs2400749	0.598	rs60796394	chr14:100019308	A/G	cg19965031	chr14:100038389	CCDC85C	-0.43	-5.21	-0.32	4.06e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.45	5.8	0.35	2.07e-8	Age at first birth;
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs1009170	0.718	rs7140188	chr14:92591978	C/G	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.49	4.86	0.3	2.13e-6	Dialysis-related mortality;
KIRP	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-7.21	-0.42	7.02e-12	Total cholesterol levels;
KIRP	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.98	0.71	6.44e-40	Bipolar disorder;
KIRP	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg22875332	chr1:76189707	ACADM	-0.34	-4.85	-0.3	2.24e-6	Daytime sleep phenotypes;
KIRP	cis	rs7017914	0.967	rs7000647	chr8:71688408	C/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.5	6.89	0.4	4.52e-11	Birth weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14318237	chr3:113666425	ZDHHC23	0.51	6.51	0.38	4.17e-10	Parkinson's disease;
KIRP	cis	rs1978968	0.833	rs5992941	chr22:18463747	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.77	-10.54	-0.56	1.13e-21	Presence of antiphospholipid antibodies;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03097111	chr10:99078896	FRAT1	-0.57	-6.19	-0.37	2.49e-9	Menopause (age at onset);
KIRP	cis	rs529866	0.519	rs4451969	chr16:11383519	A/G	cg00044050	chr16:11439710	C16orf75	-0.46	-5.5	-0.33	9.71e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg25356066	chr3:128598488	ACAD9	0.47	5.43	0.33	1.34e-7	IgG glycosylation;
KIRP	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg04398451	chr17:18023971	MYO15A	0.74	10.59	0.56	7.79e-22	Total body bone mineral density;
KIRP	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.8	-9.07	-0.5	4e-17	Diastolic blood pressure;
KIRP	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.34	-5.34	-0.32	2.16e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg04865290	chr3:52927548	TMEM110	-0.66	-7.01	-0.41	2.22e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg21734707	chr17:3908241	ZZEF1	-0.6	-8.86	-0.49	1.61e-16	Type 2 diabetes;
KIRP	cis	rs4356932	0.935	rs7677924	chr4:76977023	C/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg01324343	chr3:183735012	ABCC5	0.4	5.32	0.32	2.33e-7	Menopause (age at onset);
KIRP	cis	rs865483	1.000	rs865483	chr17:35851177	A/C	cg06716730	chr17:35851459	DUSP14	0.25	5.95	0.35	9.25e-9	Monocyte count;
KIRP	cis	rs7709377	0.595	rs810742	chr5:115616638	G/A	cg23108291	chr5:115420582	COMMD10	-0.43	-5.33	-0.32	2.18e-7	Metabolite levels  (X-11787);
KIRP	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	1.01	14.37	0.68	2.09e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.38	-5.16	-0.31	5.01e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09976282	chr15:31357238	TRPM1;MIR211	0.5	6.23	0.37	2.06e-9	Interleukin-4 levels;
KIRP	cis	rs7941600	0.708	rs4627080	chr11:9336349	G/T	cg19415743	chr11:9336845	TMEM41B	-0.71	-6.3	-0.37	1.34e-9	Coronary artery disease;
KIRP	cis	rs2219968	0.961	rs35174414	chr8:78977693	C/T	cg00738934	chr8:78996279	NA	0.39	4.87	0.3	2.03e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1408799	0.550	rs1063380	chr9:12710090	T/C	cg05274944	chr9:12693694	TYRP1	0.4	5.87	0.35	1.43e-8	Eye color;Blue vs. green eyes;
KIRP	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	11.39	0.59	2.04e-24	Platelet count;
KIRP	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg20701182	chr2:24300061	SF3B14	0.5	5.75	0.34	2.62e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs2481665	0.777	rs17379217	chr1:62545085	C/T	cg18591186	chr1:62594603	INADL	-0.66	-9.45	-0.52	2.73e-18	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg08660285	chr1:67390436	MIER1;WDR78	1.11	10.7	0.56	3.35e-22	Neutrophil percentage of white cells;
KIRP	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg25173405	chr17:45401733	C17orf57	0.51	7.13	0.41	1.14e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7116495	0.881	rs598835	chr11:71797727	C/T	cg26138937	chr11:71823887	C11orf51	-0.65	-5.06	-0.31	8.15e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.52e-15	Skin colour saturation;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20540327	chr15:72668275	HEXA;C15orf34	0.65	6.03	0.36	5.91e-9	Lung function (FEV1);
KIRP	trans	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	6.63	0.39	2.1e-10	Ulcerative colitis;
KIRP	trans	rs1421898	1.000	rs1421898	chr5:158111073	C/T	cg04237997	chr11:124629752	ESAM	-0.8	-6.83	-0.4	6.51e-11	Inflammatory skin disease;
KIRP	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg02023728	chr11:77925099	USP35	-0.31	-5.38	-0.32	1.75e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.64	-8.65	-0.48	6.95e-16	Cognitive test performance;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20964589	chr5:118788780	HSD17B4	0.46	6.05	0.36	5.37e-9	Inflammatory biomarkers;
KIRP	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.47	6.27	0.37	1.62e-9	Breast cancer;
KIRP	cis	rs35955747	0.539	rs738685	chr22:32032278	T/A	cg02404636	chr22:31891804	SFI1	-0.46	-5.99	-0.36	7.36e-9	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.68	5.04	0.31	9.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.88	13.65	0.66	5.73e-32	Ulcerative colitis;
KIRP	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg01200585	chr1:228362443	C1orf69	0.45	5.45	0.33	1.23e-7	Diastolic blood pressure;
KIRP	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg14541582	chr5:601475	NA	-0.58	-6.59	-0.39	2.73e-10	Obesity-related traits;
KIRP	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-19.6	-0.78	3.67e-52	Schizophrenia;
KIRP	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.79	-10.73	-0.56	2.83e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs35176054	1.000	rs35176054	chr10:105480387	T/A	cg00730670	chr10:105510713	SH3PXD2A	-0.47	-5.06	-0.31	8.06e-7	Atrial fibrillation;
KIRP	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg01879757	chr17:41196368	BRCA1	-0.78	-10.64	-0.56	5.55e-22	Menopause (age at onset);
KIRP	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg13798912	chr7:905769	UNC84A	0.55	5.56	0.33	6.91e-8	Cerebrospinal P-tau181p levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08951903	chr10:44070173	ZNF239	0.46	6.35	0.38	1.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	0.92	12.02	0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.64	8.57	0.48	1.15e-15	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.27	14.15	0.67	1.13e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg10189261	chr14:101176105	NA	-0.5	-5.14	-0.31	5.71e-7	Plateletcrit;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg21800906	chr11:32914818	QSER1	0.66	6.08	0.36	4.61e-9	Lung function (FEV1);
KIRP	cis	rs11203032	0.831	rs61853069	chr10:90935641	C/G	cg16672925	chr10:90967113	CH25H	0.41	5.0	0.3	1.11e-6	Heart failure;
KIRP	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg16989719	chr2:238392110	NA	-0.54	-7.08	-0.41	1.54e-11	Prostate cancer;
KIRP	cis	rs1040	0.690	rs9393165	chr6:169620247	T/C	cg04662567	chr6:169592167	NA	-0.49	-6.1	-0.36	4.12e-9	Joint mobility (Beighton score);
KIRP	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg17279839	chr7:150038598	RARRES2	0.47	6.42	0.38	7.01e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24110177	chr3:50126178	RBM5	0.53	6.44	0.38	6.32e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6662572	0.737	rs6687316	chr1:46581449	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.75	0.34	2.69e-8	Blood protein levels;
KIRP	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.72	-0.34	3.1e-8	Cognitive function;
KIRP	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.73	-9.18	-0.51	1.78e-17	Aortic root size;
KIRP	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg05991184	chr2:219186017	PNKD	-0.38	-5.63	-0.34	4.93e-8	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16285701	chr14:100626089	DEGS2	0.51	6.83	0.4	6.79e-11	Parkinson's disease;
KIRP	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.6	6.61	0.39	2.42e-10	Coronary artery disease;
KIRP	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg21869046	chr19:41225005	ITPKC	0.46	5.48	0.33	1.04e-7	Kawasaki disease;
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.1	0.36	3.99e-9	Lung cancer;
KIRP	cis	rs4638749	0.501	rs4322804	chr2:108744939	G/T	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.01	-0.3	1.03e-6	Blood pressure;
KIRP	cis	rs9653442	0.545	rs4851257	chr2:100775297	C/T	cg17356467	chr2:100759845	AFF3	0.46	6.16	0.37	2.88e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs8062405	0.540	rs151226	chr16:28549823	A/C	cg00931491	chr16:28608288	SULT1A2	-0.23	-5.09	-0.31	7.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.45	-0.55	2.24e-21	Chronic sinus infection;
KIRP	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.44	-0.68	1.2e-34	Alzheimer's disease;
KIRP	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.53	7.15	0.41	9.75e-12	Schizophrenia;
KIRP	cis	rs12760731	0.777	rs6701080	chr1:178382261	A/C	cg00404053	chr1:178313656	RASAL2	0.65	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.96	14.39	0.68	1.74e-34	Coronary artery disease;
KIRP	cis	rs4956211	0.524	rs1840063	chr4:109711994	T/C	cg07086381	chr4:109682776	AGXT2L1	-0.43	-5.77	-0.35	2.38e-8	Systemic lupus erythematosus;
KIRP	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.45	-7.35	-0.42	2.99e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.22	-0.37	2.18e-9	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11816841	chr3:46734995	ALS2CL	0.54	6.85	0.4	5.94e-11	Parkinson's disease;
KIRP	cis	rs2839627	0.561	rs1107830	chr21:44275097	G/A	cg03543861	chr21:44258195	NA	0.58	6.61	0.39	2.36e-10	Information processing speed;
KIRP	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg03959625	chr15:84868606	LOC388152	0.53	6.18	0.37	2.7e-9	Schizophrenia;
KIRP	cis	rs6430538	0.671	rs10928518	chr2:135567253	T/C	cg25422880	chr2:135218333	TMEM163	-0.44	-6.19	-0.37	2.54e-9	Parkinson's disease;
KIRP	cis	rs12148477	0.623	rs4775942	chr15:51663597	A/G	cg00184732	chr15:51633821	GLDN	-0.27	-5.0	-0.3	1.07e-6	Follicule stimulating hormone;
KIRP	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg06917634	chr15:78832804	PSMA4	-0.54	-5.73	-0.34	2.9e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.54	5.96	0.36	8.51e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.18	0.7	3.63e-37	Platelet count;
KIRP	trans	rs12517041	1.000	rs1428625	chr5:23290664	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.92	-0.49	1.11e-16	Calcium levels;
KIRP	cis	rs96067	0.772	rs6664471	chr1:36606757	A/G	cg24686825	chr1:36642396	MAP7D1	-0.47	-5.48	-0.33	1.04e-7	Corneal structure;
KIRP	cis	rs714027	0.525	rs6006274	chr22:30232843	C/T	cg27665648	chr22:30112403	NA	0.47	6.28	0.37	1.49e-9	Lymphocyte counts;
KIRP	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.62	-7.84	-0.45	1.38e-13	Longevity;
KIRP	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11987759	chr7:65425863	GUSB	-0.69	-9.7	-0.53	4.87e-19	Aortic root size;
KIRP	cis	rs9810890	1.000	rs76610941	chr3:128524526	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.86	13.35	0.65	5.84e-31	Height;
KIRP	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05347473	chr6:146136440	FBXO30	0.49	7.05	0.41	1.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.82	11.33	0.59	3.13e-24	Morning vs. evening chronotype;
KIRP	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.26	0.32	3.16e-7	Parkinson's disease;
KIRP	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg20243544	chr17:37824526	PNMT	-0.44	-4.99	-0.3	1.15e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.19	21.37	0.81	5.31e-58	Cognitive function;
KIRP	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7849270	1.000	rs1360172	chr9:131907980	A/G	cg13538475	chr9:131942899	NA	-0.37	-6.0	-0.36	7.06e-9	Blood metabolite ratios;
KIRP	cis	rs61863818	0.842	rs11189214	chr10:99181008	A/G	cg20016023	chr10:99160130	RRP12	0.42	5.17	0.31	4.78e-7	Monocyte percentage of white cells;
KIRP	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-5.22	-0.32	3.76e-7	Cognitive function;
KIRP	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg03571507	chr19:53239146	ZNF611	0.22	5.54	0.33	7.79e-8	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7849270	0.959	rs10760591	chr9:131915028	A/G	cg13538475	chr9:131942899	NA	-0.35	-5.7	-0.34	3.43e-8	Blood metabolite ratios;
KIRP	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.11	-0.31	6.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.57	0.33	6.58e-8	Putamen volume;
KIRP	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.59	-8.37	-0.47	4.42e-15	Type 2 diabetes;
KIRP	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.91	11.31	0.58	3.74e-24	Homoarginine levels;
KIRP	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg20140201	chr2:241835670	C2orf54	-0.35	-5.32	-0.32	2.31e-7	Urinary metabolites;
KIRP	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg02751453	chr18:77725136	HSBP1L1	-0.48	-5.66	-0.34	4.28e-8	Opioid sensitivity;
KIRP	cis	rs12311304	1.000	rs12310061	chr12:15390019	A/T	cg08258403	chr12:15378311	NA	0.39	5.76	0.34	2.44e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs68149176	0.772	rs997762	chr16:87879562	C/A	cg03553613	chr16:87879502	SLC7A5	-0.42	-4.87	-0.3	1.96e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.79	-11.13	-0.58	1.39e-23	Coronary artery disease;
KIRP	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.63	-7.24	-0.42	5.85e-12	Menarche (age at onset);
KIRP	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.35	0.7	9.06e-38	Chronic sinus infection;
KIRP	cis	rs4959799	0.557	rs9501975	chr6:3272807	A/G	cg10513992	chr6:3293720	SLC22A23	0.66	4.84	0.3	2.25e-6	Survival in rectal cancer;
KIRP	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.34	-4.84	-0.3	2.26e-6	Coronary artery disease;
KIRP	cis	rs1620921	0.711	rs1782632	chr6:161249412	A/G	cg01280913	chr6:161186852	NA	-0.37	-5.03	-0.31	9.48e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs11997175	1.000	rs6468201	chr8:33746854	G/C	cg04338863	chr8:33670619	NA	0.44	5.7	0.34	3.39e-8	Body mass index;
KIRP	cis	rs16857609	0.628	rs2568158	chr2:218334534	C/T	cg15335768	chr2:218268053	DIRC3	-0.37	-5.52	-0.33	8.54e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg24253500	chr15:84953950	NA	0.68	7.87	0.45	1.12e-13	Schizophrenia;
KIRP	cis	rs2463822	0.583	rs7104825	chr11:62026833	C/T	cg06239285	chr11:62104954	ASRGL1	-0.81	-6.54	-0.38	3.55e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	1.0	10.15	0.54	1.95e-20	Systemic lupus erythematosus;
KIRP	cis	rs6991838	0.584	rs7459944	chr8:66478275	T/C	cg13398993	chr8:66546079	ARMC1	-0.47	-5.35	-0.32	2.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg15358701	chr1:161410459	NA	-0.58	-5.34	-0.32	2.11e-7	Rheumatoid arthritis;
KIRP	cis	rs6831352	0.505	rs11722561	chr4:100088737	T/A	cg12011299	chr4:100065546	ADH4	0.5	6.63	0.39	2.06e-10	Alcohol dependence;
KIRP	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg16586182	chr3:47516702	SCAP	0.82	11.64	0.6	3.07e-25	Colorectal cancer;
KIRP	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg01420254	chr6:26195488	NA	1.13	9.92	0.53	9.66e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg04034577	chr2:241836375	C2orf54	-0.29	-5.46	-0.33	1.14e-7	Urinary metabolites;
KIRP	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	0.68	7.73	0.44	2.75e-13	Dental caries;
KIRP	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.63	-0.44	5.19e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2290402	0.536	rs56307842	chr4:854232	T/C	cg00846425	chr4:957561	DGKQ	-0.5	-5.4	-0.33	1.54e-7	Type 2 diabetes;
KIRP	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.65	7.91	0.45	8.83e-14	Height;
KIRP	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg23335576	chr14:104009727	NA	0.4	5.49	0.33	1.02e-7	Body mass index;
KIRP	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.78	8.94	0.5	9.48e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg09231725	chr11:64357281	SLC22A12	-0.63	-8.37	-0.47	4.27e-15	Urate levels in obese individuals;
KIRP	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg25358565	chr5:93447407	FAM172A	-0.57	-6.44	-0.38	6.24e-10	Diabetic retinopathy;
KIRP	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15554466	chr19:39936040	SUPT5H	0.55	7.29	0.42	4.34e-12	Parkinson's disease;
KIRP	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.81	-12.44	-0.62	7.01e-28	Blood metabolite levels;
KIRP	cis	rs6442310	0.534	rs1822825	chr3:12449963	G/A	cg02700894	chr3:12045449	SYN2	-0.42	-5.76	-0.34	2.45e-8	Hematocrit;
KIRP	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	11.27	0.58	5.18e-24	Smoking behavior;
KIRP	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg02951883	chr7:2050386	MAD1L1	-0.44	-4.87	-0.3	2.02e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.53	-6.58	-0.39	2.83e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.44	-0.62	6.77e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	8.42	0.47	3.18e-15	Neuroticism;
KIRP	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg09526685	chr4:187126073	CYP4V2	0.74	5.72	0.34	3.06e-8	Blood protein levels;
KIRP	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg08017634	chr8:144659831	NAPRT1	0.81	5.14	0.31	5.48e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg15733309	chr7:157513707	PTPRN2	0.42	6.39	0.38	8.39e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10996143	chr20:1373995	FKBP1A	0.59	6.81	0.4	7.3e-11	Smoking initiation;
KIRP	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-13.99	-0.67	3.97e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs785830	0.717	rs600951	chr9:224742	A/G	cg14500300	chr9:211689	NA	0.54	7.47	0.43	1.37e-12	Platelet distribution width;
KIRP	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06998765	chr14:75389618	RPS6KL1	0.24	4.89	0.3	1.8e-6	Caffeine consumption;
KIRP	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.67	9.01	0.5	5.99e-17	Eye color traits;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg21851534	chr17:3907994	ZZEF1	0.65	10.36	0.55	4.09e-21	Type 2 diabetes;
KIRP	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.82	-9.07	-0.5	3.81e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs870825	0.858	rs2014964	chr4:185588836	G/A	cg04058563	chr4:185651563	MLF1IP	1.09	10.25	0.55	9.55e-21	Blood protein levels;
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.73	10.65	0.56	4.86e-22	Menarche (age at onset);
KIRP	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg01620082	chr3:125678407	NA	-0.85	-6.24	-0.37	1.88e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg03714773	chr7:91764589	CYP51A1	-0.34	-4.92	-0.3	1.59e-6	Breast cancer;
KIRP	cis	rs11969893	0.655	rs67724651	chr6:101417004	T/G	cg12253828	chr6:101329408	ASCC3	1.29	7.34	0.42	3.11e-12	Economic and political preferences (immigration/crime);
KIRP	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg12386194	chr3:101231763	SENP7	0.45	5.32	0.32	2.32e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.14	-23.4	-0.83	1.71e-64	Testicular germ cell tumor;
KIRP	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg23307798	chr14:103986281	CKB	-0.51	-6.92	-0.4	3.82e-11	Coronary artery disease;
KIRP	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs2282032	1.000	rs17799244	chr14:90760040	C/T	cg04374321	chr14:90722782	PSMC1	0.53	5.21	0.32	3.95e-7	Longevity;
KIRP	cis	rs4262150	0.726	rs6895969	chr5:152015208	G/A	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.18e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg00579200	chr11:133705235	NA	-0.42	-5.37	-0.32	1.86e-7	Childhood ear infection;
KIRP	cis	rs1050631	0.527	rs592261	chr18:33752244	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.49	0.33	1.01e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.49	-5.76	-0.34	2.5e-8	Glomerular filtration rate;
KIRP	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.45	-5.51	-0.33	9.16e-8	IgG glycosylation;
KIRP	cis	rs6457821	1.000	rs114672225	chr6:35440288	G/A	cg06087101	chr6:35551932	FKBP5	0.48	5.05	0.31	8.73e-7	Height;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-13.29	-0.65	9.56e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg09408571	chr1:101003634	GPR88	0.24	5.47	0.33	1.08e-7	Monocyte count;
KIRP	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.46	-6.22	-0.37	2.12e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16228688	chr11:66247121	DPP3	0.47	6.15	0.37	3.1e-9	Parkinson's disease;
KIRP	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.96	15.39	0.7	7.03e-38	Uric acid clearance;
KIRP	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05025164	chr4:1340916	KIAA1530	0.41	5.09	0.31	7.1e-7	Obesity-related traits;
KIRP	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg11569703	chr11:65557185	OVOL1	0.5	7.56	0.43	7.9e-13	Breast cancer;
KIRP	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg25019033	chr10:957182	NA	-0.6	-6.27	-0.37	1.59e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg08755490	chr11:65554678	OVOL1	0.37	5.15	0.31	5.29e-7	Acne (severe);
KIRP	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.42	9.09	0.5	3.47e-17	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.62	7.81	0.45	1.66e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11209002	0.614	rs7544189	chr1:67568351	C/T	cg02640540	chr1:67518911	SLC35D1	0.6	6.78	0.4	8.92e-11	Crohn's disease;
KIRP	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-6.05	-0.36	5.27e-9	Systemic lupus erythematosus;
KIRP	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg13798912	chr7:905769	UNC84A	-0.54	-5.53	-0.33	8.05e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05220968	chr6:146057943	EPM2A	0.43	5.72	0.34	3.09e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg03433033	chr1:76189801	ACADM	-0.42	-6.15	-0.36	3.19e-9	Daytime sleep phenotypes;
KIRP	cis	rs73242632	1.000	rs2276896	chr4:57845091	C/T	cg20415529	chr4:57845134	POLR2B;C4orf14	0.71	4.92	0.3	1.56e-6	Congenital heart disease (maternal effect);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01934787	chr3:37152029	LRRFIP2	-0.41	-6.15	-0.37	3.17e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	1.1	20.25	0.79	2.5e-54	Bone mineral density;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	6.95e-7	Life satisfaction;
KIRP	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg07636037	chr3:49044803	WDR6	0.56	5.3	0.32	2.59e-7	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.47	6.83	0.4	6.78e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg26681399	chr22:41777847	TEF	0.46	4.96	0.3	1.33e-6	Vitiligo;
KIRP	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg00800569	chr2:239229395	TRAF3IP1	0.41	4.85	0.3	2.2e-6	Multiple system atrophy;
KIRP	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg18404041	chr3:52824283	ITIH1	0.36	5.02	0.3	1.01e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg02297831	chr4:17616191	MED28	-0.49	-5.95	-0.35	8.97e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6832769	1.000	rs59804446	chr4:56429541	A/C	cg05960024	chr4:56376020	CLOCK	-0.69	-8.57	-0.48	1.17e-15	Personality dimensions;
KIRP	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg09904177	chr6:26538194	HMGN4	0.57	6.63	0.39	2.15e-10	Small cell lung carcinoma;
KIRP	cis	rs9921338	0.887	rs7189044	chr16:11442196	G/C	cg00044050	chr16:11439710	C16orf75	-0.54	-5.82	-0.35	1.83e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.74	9.84	0.53	1.82e-19	Total body bone mineral density;
KIRP	cis	rs6738627	1.000	rs12692737	chr2:165554309	C/A	cg03182029	chr2:165697222	COBLL1	0.42	5.43	0.33	1.32e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg09264619	chr17:80180166	NA	-0.39	-5.54	-0.33	7.92e-8	Life satisfaction;
KIRP	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg23587288	chr2:27483067	SLC30A3	-0.56	-7.06	-0.41	1.7e-11	Blood metabolite levels;
KIRP	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.6	7.76	0.44	2.33e-13	Coronary artery disease;
KIRP	cis	rs6988636	0.584	rs75096144	chr8:124131225	C/T	cg23067535	chr8:124195133	FAM83A	-0.67	-5.51	-0.33	8.9e-8	Urinary uromodulin levels;
KIRP	trans	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg06521331	chr12:34319734	NA	-0.53	-6.59	-0.39	2.72e-10	Heart rate;
KIRP	cis	rs6459788	0.934	rs10807646	chr7:157260294	C/T	cg06271696	chr7:157225062	NA	-0.42	-5.17	-0.31	4.88e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs57994353	0.793	rs33982662	chr9:139324737	C/A	cg14169450	chr9:139327907	INPP5E	0.6	7.57	0.43	7.42e-13	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg07460842	chr6:66804631	NA	-0.49	-6.11	-0.36	3.88e-9	Blood trace element (Cu levels);
KIRP	cis	rs6546324	0.625	rs2861640	chr2:67794589	G/C	cg15745817	chr2:67799979	NA	-0.63	-6.66	-0.39	1.79e-10	Endometriosis;
KIRP	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.84	-8.88	-0.49	1.46e-16	Hirschsprung disease;
KIRP	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.82	-10.78	-0.57	1.9e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05472934	chr7:22766657	IL6	0.81	10.34	0.55	4.95e-21	Lung cancer;
KIRP	cis	rs4006360	0.524	rs6503601	chr17:39280487	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.35	-0.42	2.89e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg17376030	chr22:41985996	PMM1	0.62	6.66	0.39	1.75e-10	Vitiligo;
KIRP	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.35	5.13	0.31	5.95e-7	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08582346	chr17:26727727	SLC46A1;SARM1	0.47	6.16	0.37	2.93e-9	Survival in pancreatic cancer;
KIRP	trans	rs6535028	0.803	rs4565134	chr4:135456548	C/T	cg02011446	chr19:13213716	LYL1	0.7	6.03	0.36	6.03e-9	Response to radiotherapy in prostate cancer (overall toxicity);
KIRP	cis	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg21775007	chr8:11205619	TDH	-0.4	-5.18	-0.31	4.64e-7	Morning vs. evening chronotype;
KIRP	cis	rs4262150	0.842	rs55752615	chr5:152138718	C/T	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7213347	0.707	rs216181	chr17:2172753	A/T	cg15816464	chr17:2026533	SMG6	-0.4	-5.69	-0.34	3.55e-8	Total body bone mineral density;
KIRP	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.74	-9.3	-0.51	7.85e-18	Aortic root size;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.78	-13.15	-0.64	2.76e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.04	0.31	8.84e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6855629	0.711	rs13109676	chr4:106108032	G/C	cg08924430	chr4:106067052	TET2	0.36	5.18	0.31	4.57e-7	Height;
KIRP	trans	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg04702396	chr17:15466718	FAM18B2	0.52	6.58	0.39	2.83e-10	Educational attainment (years of education);
KIRP	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg03235661	chr20:60525775	NA	-0.37	-5.64	-0.34	4.68e-8	Body mass index;
KIRP	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg02336718	chr17:17403227	NA	0.33	5.21	0.32	3.96e-7	Total body bone mineral density;
KIRP	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.67	4.97	0.3	1.23e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.79	12.88	0.63	2.28e-29	Menarche (age at onset);
KIRP	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg13753209	chr17:57696993	CLTC	0.52	5.11	0.31	6.36e-7	Hemoglobin concentration;
KIRP	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg20673841	chr7:107026890	COG5	-0.38	-4.86	-0.3	2.05e-6	Coronary artery disease;
KIRP	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-6.72	-0.39	1.24e-10	Vitiligo;
KIRP	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg21699342	chr2:239360505	ASB1	0.49	6.33	0.37	1.16e-9	Multiple system atrophy;
KIRP	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.58	7.75	0.44	2.39e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10073892	0.660	rs2400833	chr5:101983542	A/C	cg19774478	chr5:101632501	SLCO4C1	0.55	5.61	0.34	5.52e-8	Cognitive decline (age-related);
KIRP	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.57	5.66	0.34	4.27e-8	White matter hyperintensity burden;
KIRP	cis	rs11264213	0.901	rs644095	chr1:36363172	C/T	cg27506609	chr1:36549197	TEKT2	0.91	9.26	0.51	1.06e-17	Schizophrenia;
KIRP	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.81	-0.4	7.3e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.79	-9.71	-0.53	4.38e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg16917193	chr12:54089295	NA	0.85	16.34	0.72	3.89e-41	Height;
KIRP	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-0.96	-11.62	-0.6	3.64e-25	Vitiligo;
KIRP	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	trans	rs9545047	0.604	rs7336581	chr13:79959874	C/T	cg16315928	chr6:109776240	MICAL1	0.4	6.09	0.36	4.28e-9	Schizophrenia;
KIRP	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg05585630	chr7:157510462	PTPRN2	-0.5	-6.63	-0.39	2.12e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg23682824	chr7:23144976	KLHL7	0.55	6.7	0.39	1.37e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg00405596	chr8:11794950	NA	0.58	8.03	0.46	4.09e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.43	4.99	0.3	1.17e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2274273	0.905	rs4652	chr14:55605036	A/C	cg04306507	chr14:55594613	LGALS3	0.53	8.51	0.48	1.68e-15	Protein biomarker;
KIRP	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg02023728	chr11:77925099	USP35	0.35	5.38	0.32	1.71e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7312774	0.881	rs79048355	chr12:107311169	G/T	cg16260113	chr12:107380972	MTERFD3	0.72	6.53	0.38	3.7e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg04132472	chr17:19861366	AKAP10	0.42	5.84	0.35	1.62e-8	Schizophrenia;
KIRP	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg09137382	chr11:130731461	NA	0.54	7.91	0.45	9e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg15252951	chr6:33757062	LEMD2	0.41	4.94	0.3	1.47e-6	Crohn's disease;
KIRP	cis	rs8028182	0.549	rs56395816	chr15:75664571	A/T	cg20655648	chr15:75932815	IMP3	-0.51	-6.53	-0.38	3.78e-10	Sudden cardiac arrest;
KIRP	trans	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg23484912	chr5:273055	PDCD6	0.65	7.89	0.45	9.79e-14	Pancreatic cancer;
KIRP	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg11833968	chr6:79620685	NA	-0.41	-5.93	-0.35	1.04e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-10.42	-0.55	2.66e-21	Hepatocellular carcinoma;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.63	9.75	0.53	3.32e-19	Lung cancer;
KIRP	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg06636001	chr8:8085503	FLJ10661	0.62	8.22	0.46	1.17e-14	Neuroticism;
KIRP	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04004882	chr2:215674386	BARD1	-0.82	-8.97	-0.5	7.77e-17	Neuroblastoma;
KIRP	cis	rs4566357	1.000	rs4296417	chr2:227921941	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.04	-0.31	9.03e-7	Coronary artery disease;
KIRP	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.35	12.29	0.62	2.19e-27	Diabetic retinopathy;
KIRP	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.8	0.53	2.29e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg16558253	chr16:72132732	DHX38	-0.41	-4.99	-0.3	1.16e-6	Blood protein levels;
KIRP	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg10845886	chr2:3471009	TTC15	-0.47	-6.35	-0.38	1.01e-9	Neurofibrillary tangles;
KIRP	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.51	5.36	0.32	1.91e-7	Schizophrenia;
KIRP	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.73	-0.34	2.92e-8	Breast cancer;
KIRP	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg24315340	chr6:146058215	EPM2A	0.38	4.96	0.3	1.35e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg18944383	chr4:111397179	ENPEP	0.5	8.33	0.47	5.78e-15	Coronary artery disease;
KIRP	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg13119609	chr19:45449297	APOC2	0.52	7.36	0.42	2.69e-12	Blood protein levels;
KIRP	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	1.2	11.39	0.59	2.07e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs75920871	0.920	rs11216178	chr11:116766390	G/T	cg23684410	chr11:116897558	SIK3	0.53	5.78	0.35	2.28e-8	Subjective well-being;
KIRP	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg21775007	chr8:11205619	TDH	0.46	6.11	0.36	3.9e-9	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02386183	chr20:13619553	TASP1	0.5	6.76	0.4	9.89e-11	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg08662619	chr6:150070041	PCMT1	0.38	6.17	0.37	2.76e-9	Lung cancer;
KIRP	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.58	-0.48	1.06e-15	Neuroticism;
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-13.19	-0.64	2.14e-30	Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00753739	chr10:11653489	USP6NL	0.56	6.5	0.38	4.32e-10	Smoking initiation;
KIRP	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.55	5.01	0.3	1.04e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.91	-0.3	1.69e-6	Life satisfaction;
KIRP	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg12935359	chr14:103987150	CKB	-0.32	-4.9	-0.3	1.73e-6	Body mass index;
KIRP	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.88	10.23	0.55	1.04e-20	Pulmonary function decline;
KIRP	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg07777115	chr5:623756	CEP72	-0.57	-5.82	-0.35	1.85e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4132509	0.779	rs4515770	chr1:243686913	A/G	cg25706552	chr1:244017396	NA	0.48	6.88	0.4	4.86e-11	RR interval (heart rate);
KIRP	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Colorectal cancer;
KIRP	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg24488311	chr11:68621650	NA	-0.48	-6.04	-0.36	5.72e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	5.03	0.31	9.48e-7	Height;
KIRP	cis	rs273218	1.000	rs156438	chr5:53374120	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.62	6.87	0.4	5.22e-11	Migraine;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05533119	chr20:23343103	NA	0.56	6.1	0.36	3.99e-9	Lung cancer in ever smokers;
KIRP	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.93	13.61	0.66	8.14e-32	Bladder cancer;
KIRP	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-8.47	-0.47	2.32e-15	Morning vs. evening chronotype;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.64	9.34	0.51	5.91e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.24	-0.32	3.44e-7	Renal cell carcinoma;
KIRP	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg01422370	chr2:73384389	NA	0.49	6.63	0.39	2.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg07777115	chr5:623756	CEP72	-0.57	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6684514	1.000	rs12130361	chr1:156260301	C/T	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.48e-6	Life satisfaction;
KIRP	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg03115019	chr17:80708279	FN3K	0.42	4.9	0.3	1.71e-6	Glycated hemoglobin levels;
KIRP	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg25482853	chr8:67687455	SGK3	0.79	6.92	0.4	3.96e-11	Obesity-related traits;
KIRP	cis	rs4851254	0.618	rs35840153	chr2:100669829	A/G	cg22139774	chr2:100720529	AFF3	-0.4	-4.99	-0.3	1.16e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	1.06	11.92	0.61	3.75e-26	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs10214930	0.651	rs4722728	chr7:27694288	C/T	cg22168087	chr7:27702803	HIBADH	-0.43	-4.97	-0.3	1.23e-6	Hypospadias;
KIRP	cis	rs754423	0.703	rs1874569	chr14:52519555	T/C	cg10149976	chr14:52535953	NID2	-0.41	-5.51	-0.33	8.87e-8	Craniofacial microsomia;
KIRP	cis	rs6733011	0.628	rs4850888	chr2:99456946	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.26	-0.32	3.06e-7	Bipolar disorder;
KIRP	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg10755058	chr3:40428713	ENTPD3	-0.37	-5.4	-0.33	1.59e-7	Renal cell carcinoma;
KIRP	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.92	-0.35	1.05e-8	Breast cancer;
KIRP	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.94	-0.45	7.32e-14	Coffee consumption (cups per day);
KIRP	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.02	0.5	5.5e-17	Bipolar disorder;
KIRP	trans	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	6.44	0.38	6.37e-10	Ulcerative colitis;
KIRP	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.57	-7.09	-0.41	1.45e-11	Aortic root size;
KIRP	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.94	-0.61	3.24e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.52	5.16	0.31	5.02e-7	Diastolic blood pressure;
KIRP	trans	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg06521331	chr12:34319734	NA	0.54	6.78	0.4	9.06e-11	Heart rate;
KIRP	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg09571762	chr12:39539558	NA	0.36	5.06	0.31	8.21e-7	Morning vs. evening chronotype;
KIRP	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.38	-0.43	2.44e-12	Body mass index;
KIRP	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-10.06	-0.54	3.58e-20	Coffee consumption (cups per day);
KIRP	cis	rs3755132	0.929	rs55668395	chr2:15748423	T/C	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg08738300	chr3:44038990	NA	0.7	9.83	0.53	1.92e-19	Coronary artery disease;
KIRP	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg24631222	chr15:78858424	CHRNA5	0.76	9.06	0.5	4.17e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs1440410	0.798	rs10010367	chr4:144164822	C/A	cg01719995	chr4:144104893	USP38	0.42	5.72	0.34	3.12e-8	Ischemic stroke;
KIRP	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg02951883	chr7:2050386	MAD1L1	-0.42	-4.86	-0.3	2.13e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg00792783	chr2:198669748	PLCL1	0.47	5.13	0.31	5.8e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.7	7.85	0.45	1.25e-13	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.02e-8	Motion sickness;
KIRP	cis	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg04691961	chr3:161091175	C3orf57	0.44	6.47	0.38	5.28e-10	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.86	-0.35	1.44e-8	Colorectal cancer;
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg06815112	chr8:27182871	PTK2B	0.52	6.63	0.39	2.07e-10	Neuroticism;
KIRP	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.16	-0.5	2.13e-17	Platelet count;
KIRP	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg03788504	chr6:150331562	NA	-0.33	-6.28	-0.37	1.52e-9	Alopecia areata;
KIRP	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.71	-8.84	-0.49	1.92e-16	Hypospadias;
KIRP	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.84	-0.49	1.93e-16	Mood instability;
KIRP	cis	rs10267417	0.603	rs1557774	chr7:19908777	A/G	cg05791153	chr7:19748676	TWISTNB	0.56	5.49	0.33	9.93e-8	Night sleep phenotypes;
KIRP	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg10755058	chr3:40428713	ENTPD3	0.45	6.33	0.37	1.14e-9	Renal cell carcinoma;
KIRP	cis	rs4903214	0.848	rs62006811	chr14:74717699	C/A	cg08255017	chr14:74727001	VSX2	-0.4	-5.09	-0.31	7.27e-7	Inflammatory bowel disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg04918831	chr1:241795170	CHML;OPN3	0.44	6.14	0.36	3.36e-9	Migraine with aura;
KIRP	cis	rs1497828	0.956	rs2815232	chr1:217538336	A/G	cg04411442	chr1:217543379	NA	-0.43	-6.63	-0.39	2.06e-10	Dialysis-related mortality;
KIRP	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg06871246	chr4:1363661	KIAA1530	0.44	5.47	0.33	1.09e-7	Obesity-related traits;
KIRP	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.45	6.12	0.36	3.74e-9	Hypertriglyceridemia;
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.66	-8.14	-0.46	1.95e-14	Obesity-related traits;
KIRP	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-4.94	-0.3	1.42e-6	Coronary artery disease;
KIRP	trans	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.37	1.58e-9	Triglycerides;
KIRP	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg00507259	chr4:95128692	SMARCAD1	0.4	5.12	0.31	6.06e-7	QT interval;
KIRP	cis	rs35740288	0.770	rs1871285	chr15:86152487	C/T	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg24130564	chr14:104152367	KLC1	-0.53	-7.14	-0.41	1.03e-11	Body mass index;
KIRP	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.4	-6.2	-0.37	2.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23620236	chr14:45368282	C14orf28	0.45	7.27	0.42	4.87e-12	C-reactive protein;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15865771	chr17:12920709	ELAC2	0.56	6.99	0.41	2.54e-11	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27013765	chr3:197402007	MIR922;KIAA0226	0.49	6.46	0.38	5.71e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.83	12.0	0.61	2.06e-26	Bladder cancer;
KIRP	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg02678768	chr17:74002944	EVPL	0.42	5.54	0.33	7.84e-8	White matter hyperintensity burden;
KIRP	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.87	9.04	0.5	4.85e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg18944383	chr4:111397179	ENPEP	0.61	11.26	0.58	5.39e-24	Height;
KIRP	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg25650185	chr19:21324782	ZNF431	0.49	5.18	0.31	4.54e-7	Pain;
KIRP	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.42	5.27	0.32	2.96e-7	Educational attainment (years of education);
KIRP	trans	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg08400319	chr2:242004533	SNED1	0.44	6.08	0.36	4.45e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg01864069	chr14:103024347	NA	-0.97	-13.06	-0.64	5.98e-30	Platelet count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05940240	chr22:41762302	TEF	0.41	6.39	0.38	8.31e-10	Survival in pancreatic cancer;
KIRP	cis	rs7646881	1.000	rs73015651	chr3:158450922	C/T	cg19483011	chr3:158453295	NA	-0.58	-6.31	-0.37	1.27e-9	Tetralogy of Fallot;
KIRP	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-6.98	-0.41	2.72e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs9325144	0.881	rs56344858	chr12:39180935	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-6.83	-0.4	6.49e-11	Morning vs. evening chronotype;
KIRP	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.53	5.65	0.34	4.39e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6882046	0.513	rs651666	chr5:88048767	A/G	cg24804195	chr5:87968844	LOC645323	-0.47	-6.18	-0.37	2.59e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs35000415	0.688	rs12537284	chr7:128717906	G/A	cg19972273	chr7:128594194	NA	0.61	5.04	0.31	9.2e-7	Systemic lupus erythematosus;
KIRP	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.18	-0.31	4.63e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	1.08	20.42	0.79	6.8e-55	Bone mineral density;
KIRP	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg00864860	chr1:7907996	UTS2	-0.52	-6.17	-0.37	2.81e-9	Crohn's disease;
KIRP	cis	rs7539542	0.556	rs3820152	chr1:202878492	A/T	cg08940984	chr1:202857613	RABIF	-0.45	-5.7	-0.34	3.39e-8	Mean platelet volume;
KIRP	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.99	14.8	0.69	6.92e-36	Monocyte count;
KIRP	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg17279839	chr7:150038598	RARRES2	-0.45	-5.8	-0.35	2.03e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.72	0.49	4.37e-16	Bipolar disorder;
KIRP	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg16898833	chr6:26189333	HIST1H4D	0.75	5.16	0.31	5.1e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs1978968	1.000	rs1076539	chr22:18439598	A/G	cg02610425	chr22:18483192	MICAL3	0.36	5.0	0.3	1.1e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs2294369	0.593	rs136832	chr22:40046538	A/G	cg10455938	chr22:40058150	CACNA1I	-0.49	-5.8	-0.35	2.01e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.57	-6.79	-0.4	8.58e-11	Obesity-related traits;
KIRP	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg22676075	chr6:135203613	NA	0.47	6.7	0.39	1.43e-10	Red blood cell count;
KIRP	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.81	-9.5	-0.52	1.9e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.84e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	trans	rs12517041	1.000	rs1428627	chr5:23309212	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg06598544	chr20:61472147	COL9A3	-0.74	-6.4	-0.38	7.73e-10	Obesity-related traits;
KIRP	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	10.79	0.57	1.74e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs858239	0.601	rs28673077	chr7:23250854	C/T	cg23682824	chr7:23144976	KLHL7	0.44	4.89	0.3	1.82e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs3755132	0.929	rs59734551	chr2:15754125	G/A	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.47	-5.87	-0.35	1.38e-8	Testicular germ cell tumor;
KIRP	trans	rs262150	0.788	rs2657389	chr7:158763795	G/A	cg21167628	chr1:45308625	PTCH2	-0.42	-6.14	-0.36	3.35e-9	Facial morphology (factor 20);
KIRP	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.2	0.55	1.36e-20	Dupuytren's disease;
KIRP	cis	rs17123764	0.579	rs55637397	chr12:50014181	G/A	cg02054252	chr12:50078554	FMNL3	0.5	5.06	0.31	8.35e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14156121	chr10:33948478	NA	0.49	6.25	0.37	1.81e-9	Interleukin-4 levels;
KIRP	cis	rs6594713	0.570	rs35933960	chr5:112841469	T/C	cg12552261	chr5:112820674	MCC	0.55	4.94	0.3	1.48e-6	Brain cytoarchitecture;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23197559	chr2:232573080	PTMA	0.48	6.19	0.37	2.5e-9	Myopia (pathological);
KIRP	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg16524733	chr11:117070046	TAGLN	0.38	4.95	0.3	1.4e-6	Blood protein levels;
KIRP	cis	rs57590327	0.503	rs4856350	chr3:81503374	G/A	cg07356753	chr3:81810745	GBE1	0.5	6.26	0.37	1.66e-9	Extraversion;
KIRP	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg17145862	chr1:211918768	LPGAT1	0.61	6.63	0.39	2.07e-10	Crohn's disease;
KIRP	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg24375607	chr4:120327624	NA	0.54	5.48	0.33	1.06e-7	Corneal astigmatism;
KIRP	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.45	-11.3	-0.58	4.1e-24	Diabetic kidney disease;
KIRP	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg22800045	chr5:56110881	MAP3K1	0.61	7.03	0.41	2.06e-11	Initial pursuit acceleration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19161053	chr7:99036702	CPSF4;PTCD1	0.59	6.8	0.4	8.09e-11	Smoking initiation;
KIRP	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.6	-6.53	-0.38	3.74e-10	DNA methylation (variation);
KIRP	cis	rs742614	0.533	rs2747536	chr20:32404128	C/G	cg06304546	chr20:32448765	NA	-0.88	-13.62	-0.66	7.15e-32	Stearic acid (18:0) levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18045575	chr2:27341901	CGREF1	0.49	6.82	0.4	7.21e-11	Parkinson's disease;
KIRP	cis	rs3857747	0.578	rs4452702	chr7:40371871	G/A	cg00420559	chr7:40367873	C7orf10	-0.45	-6.49	-0.38	4.58e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6466055	0.589	rs66482905	chr7:104974206	T/G	cg04380332	chr7:105027541	SRPK2	0.35	4.95	0.3	1.4e-6	Schizophrenia;
KIRP	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.69	-0.34	3.67e-8	Height;
KIRP	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg02297831	chr4:17616191	MED28	0.55	6.89	0.4	4.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg17757837	chr7:157058334	UBE3C	0.77	10.51	0.56	1.37e-21	Body mass index;
KIRP	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	1.19	8.43	0.47	3e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.9	9.11	0.5	2.98e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs9325144	1.000	rs10506124	chr12:39019236	C/A	cg26384229	chr12:38710491	ALG10B	-0.53	-6.35	-0.38	1.03e-9	Morning vs. evening chronotype;
KIRP	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg02367723	chr1:46378857	MAST2	0.44	5.06	0.31	8.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9653442	0.564	rs10185510	chr2:100790581	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.11	-0.31	6.55e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.76	7.75	0.44	2.41e-13	Iron status biomarkers;
KIRP	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg17691542	chr6:26056736	HIST1H1C	0.67	7.94	0.45	6.98e-14	Iron status biomarkers;
KIRP	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	8.38	0.47	4.06e-15	Joint mobility (Beighton score);
KIRP	cis	rs4356975	0.563	rs5013211	chr4:69972777	G/A	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs2871865	0.544	rs1319868	chr15:99186979	A/C	cg03437748	chr15:99193247	IGF1R	-0.59	-5.03	-0.31	9.3e-7	Height;
KIRP	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs9381040	1.000	rs9394766	chr6:41159801	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.6	-6.45	-0.38	5.89e-10	Alzheimer's disease (late onset);
KIRP	cis	rs6547631	0.635	rs934774	chr2:85898143	G/T	cg24620635	chr2:85921963	GNLY	0.36	5.29	0.32	2.66e-7	Blood protein levels;
KIRP	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg04310649	chr10:35416472	CREM	-0.53	-5.97	-0.36	8.41e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.75	9.74	0.53	3.69e-19	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00938859	chr5:1591904	SDHAP3	0.63	8.43	0.47	3e-15	Breast cancer;
KIRP	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.86e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.52	-7.27	-0.42	4.83e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs17407555	0.683	rs6852641	chr4:10275746	G/C	cg11266682	chr4:10021025	SLC2A9	0.33	4.97	0.3	1.23e-6	Schizophrenia (age at onset);
KIRP	cis	rs10193935	0.681	rs13396880	chr2:42374700	G/T	cg27598129	chr2:42591480	NA	-0.75	-6.57	-0.39	3.03e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg21775007	chr8:11205619	TDH	0.44	5.44	0.33	1.31e-7	Monocyte count;
KIRP	cis	rs4740619	0.619	rs943787	chr9:16031796	T/C	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17794905	chr4:108827503	SGMS2	-0.47	-6.92	-0.4	3.88e-11	Inflammatory biomarkers;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01280098	chr15:69116504	MIR548H4	0.41	6.14	0.36	3.25e-9	C-reactive protein;
KIRP	cis	rs7119167	0.901	rs55751428	chr11:73173902	A/T	cg17517138	chr11:73019481	ARHGEF17	0.47	4.91	0.3	1.68e-6	Blood protein levels;
KIRP	cis	rs9297145	0.673	rs62473003	chr7:98725660	A/G	cg05967295	chr7:98741636	SMURF1	0.81	8.62	0.48	8.54e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11715095	chr19:19737444	LPAR2	0.48	6.48	0.38	5.1e-10	Pancreatic cancer;
KIRP	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.57	-7.38	-0.43	2.48e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.54	7.5	0.43	1.18e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg20737812	chr15:86336631	KLHL25	-0.54	-6.88	-0.4	5.01e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg18209359	chr17:80159595	CCDC57	0.42	5.57	0.33	6.58e-8	Life satisfaction;
KIRP	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.17	-0.42	8.64e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.52	6.57	0.39	3.05e-10	Tonsillectomy;
KIRP	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg00677455	chr12:58241039	CTDSP2	0.47	5.34	0.32	2.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7267005	0.661	rs75333313	chr20:34406615	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.88	10.43	0.55	2.47e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.8	11.77	0.6	1.12e-25	Heart rate;
KIRP	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.86	11.89	0.6	4.77e-26	Platelet distribution width;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg17441377	chr17:3906640	NA	-0.53	-7.98	-0.45	5.48e-14	Type 2 diabetes;
KIRP	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg21014159	chr11:117668035	DSCAML1	0.42	6.31	0.37	1.32e-9	Myopia;
KIRP	cis	rs4699052	1.000	rs4699055	chr4:104154500	T/C	cg16532752	chr4:104119610	CENPE	-0.39	-4.93	-0.3	1.52e-6	Testicular germ cell tumor;
KIRP	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg14664628	chr15:75095509	CSK	0.64	6.95	0.4	3.32e-11	Systemic lupus erythematosus;
KIRP	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.46	0.38	5.56e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs554111	0.660	rs1985278	chr1:21091861	G/T	cg08890418	chr1:21044141	KIF17	-0.56	-8.37	-0.47	4.31e-15	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Intracranial aneurysm;
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg09033563	chr22:24373618	LOC391322	-0.4	-5.33	-0.32	2.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg00465337	chr10:15145341	RPP38	-0.45	-6.06	-0.36	5.11e-9	Select biomarker traits;
KIRP	cis	rs7179456	0.567	rs72745027	chr15:59094329	A/G	cg05156742	chr15:59063176	FAM63B	-0.73	-9.86	-0.53	1.59e-19	Asperger disorder;
KIRP	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.71	-0.56	3.17e-22	Gut microbiome composition (summer);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15356195	chr7:5569741	ACTB	0.5	7.26	0.42	5.03e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg19847866	chr10:1019161	NA	-0.63	-5.78	-0.35	2.28e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.54	-5.29	-0.32	2.66e-7	Pubertal anthropometrics;
KIRP	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg21573476	chr21:45109991	RRP1B	-0.61	-8.16	-0.46	1.74e-14	Mean corpuscular volume;
KIRP	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.49	7.49	0.43	1.24e-12	Testicular germ cell tumor;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg04025307	chr7:1156635	C7orf50	0.68	7.42	0.43	1.85e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.96	0.3	1.29e-6	Personality dimensions;
KIRP	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.82	-0.4	7.02e-11	Electroencephalogram traits;
KIRP	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.42	-0.55	2.73e-21	Hypospadias;
KIRP	cis	rs9308433	0.643	rs4655330	chr1:214466068	A/G	cg06198575	chr1:214491504	SMYD2	-0.49	-6.3	-0.37	1.37e-9	IgG glycosylation;
KIRP	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg00042356	chr1:8021962	PARK7	0.79	6.39	0.38	8.15e-10	Inflammatory bowel disease;
KIRP	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.69	-6.8	-0.4	7.99e-11	Breast cancer;
KIRP	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg19715936	chr7:50634035	DDC	0.4	5.16	0.31	5.06e-7	Malaria;
KIRP	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.3	0.67	3.61e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg23594656	chr7:65796392	TPST1	0.39	6.01	0.36	6.66e-9	Aortic root size;
KIRP	cis	rs539514	0.690	rs480929	chr13:76312773	G/A	cg04757411	chr13:76259545	LMO7	-0.35	-4.93	-0.3	1.53e-6	Type 1 diabetes;
KIRP	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.44	6.64	0.39	2.04e-10	Major depressive disorder;
KIRP	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg24633833	chr3:10029261	TMEM111	0.57	5.5	0.33	9.43e-8	Alzheimer's disease;
KIRP	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg04865290	chr3:52927548	TMEM110	-0.63	-6.42	-0.38	6.99e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10073892	0.581	rs1027660	chr5:101933831	A/G	cg19774478	chr5:101632501	SLCO4C1	0.48	5.08	0.31	7.51e-7	Cognitive decline (age-related);
KIRP	cis	rs1659258	0.568	rs1258443	chr2:88597243	A/C	cg00685853	chr2:88648947	NA	-0.54	-6.47	-0.38	5.29e-10	Visceral fat;
KIRP	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.1e-9	Cognitive function;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22046318	chr13:35212111	NA	0.48	6.66	0.39	1.77e-10	Interleukin-4 levels;
KIRP	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-10.87	-0.57	9.85e-23	Exhaled nitric oxide output;
KIRP	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4363385	0.530	rs11205181	chr1:153045728	C/T	cg07796016	chr1:152779584	LCE1C	-0.48	-6.1	-0.36	4.01e-9	Inflammatory skin disease;
KIRP	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-0.79	-6.98	-0.41	2.76e-11	Obesity-related traits;
KIRP	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg22689280	chr22:47017522	NA	0.43	4.86	0.3	2.11e-6	Urate levels in obese individuals;
KIRP	cis	rs593254	0.735	rs735859	chr6:164392968	A/G	cg00040411	chr6:164393165	NA	0.46	5.45	0.33	1.23e-7	Gestational age at birth in labor-initiated deliveries (maternal effect);
KIRP	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg26554054	chr8:600488	NA	0.68	4.89	0.3	1.83e-6	IgG glycosylation;
KIRP	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.51	-0.38	4.09e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg12951224	chr8:38126910	PPAPDC1B	0.56	6.38	0.38	8.88e-10	Sleep duration;
KIRP	cis	rs926938	0.557	rs6667218	chr1:115238982	G/A	cg12756093	chr1:115239321	AMPD1	-0.82	-12.53	-0.62	3.5e-28	Autism;
KIRP	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg13206674	chr6:150067644	NUP43	0.5	6.9	0.4	4.43e-11	Lung cancer;
KIRP	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	1.02	15.96	0.71	7.81e-40	Menopause (age at onset);
KIRP	cis	rs45544231	0.544	rs9931232	chr16:52572832	A/G	cg09051775	chr16:52580266	TOX3	0.37	5.18	0.31	4.52e-7	Restless legs syndrome;
KIRP	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.91	13.92	0.66	7.36e-33	Mean corpuscular hemoglobin;
KIRP	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg10017260	chr10:834428	NA	-0.39	-6.02	-0.36	6.47e-9	Survival in rectal cancer;
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.44	0.33	1.28e-7	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.49	-0.33	9.92e-8	Total body bone mineral density;
KIRP	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg18306943	chr3:40428807	ENTPD3	0.46	5.87	0.35	1.37e-8	Renal cell carcinoma;
KIRP	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg26354017	chr1:205819088	PM20D1	0.5	5.56	0.33	6.98e-8	Parkinson's disease;
KIRP	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg11608241	chr8:8085544	FLJ10661	-0.46	-6.09	-0.36	4.31e-9	Triglycerides;
KIRP	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.15	-0.36	3.16e-9	Obesity-related traits;
KIRP	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	cis	rs76917914	0.820	rs7041811	chr9:100821028	C/T	cg03040243	chr9:100819229	NANS	0.64	6.79	0.4	8.18e-11	Immature fraction of reticulocytes;
KIRP	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg26335602	chr6:28129616	ZNF389	0.45	5.03	0.31	9.26e-7	Depression;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	7.99	0.45	5.12e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg20542592	chr8:11973495	FAM66D	0.39	4.87	0.3	1.99e-6	Triglycerides;
KIRP	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.12	0.31	6.03e-7	Tonsillectomy;
KIRP	cis	rs807029	0.577	rs3740489	chr10:102754238	A/G	cg04662943	chr10:102668895	NA	0.47	5.12	0.31	6.21e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8060686	0.920	rs4474673	chr16:67758778	C/T	cg04539111	chr16:67997858	SLC12A4	-0.6	-5.84	-0.35	1.68e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6973256	0.897	rs2066924	chr7:133338462	C/A	cg10665199	chr7:133106180	EXOC4	-0.51	-6.38	-0.38	8.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.67	-9.69	-0.53	4.98e-19	Brugada syndrome;
KIRP	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.25	0.47	9.75e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11578119	0.933	rs3923079	chr1:170462467	A/G	cg09767346	chr1:170501363	GORAB	-0.37	-5.11	-0.31	6.41e-7	Male-pattern baldness;
KIRP	cis	rs7572644	0.680	rs12623170	chr2:28020157	C/T	cg27432699	chr2:27873401	GPN1	0.47	5.41	0.33	1.51e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.45e-24	Cognitive test performance;
KIRP	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg23442198	chr4:187126114	CYP4V2	0.52	4.98	0.3	1.23e-6	Blood protein levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04591808	chr17:17942662	ATPAF2;C17orf39	0.51	6.23	0.37	2.06e-9	Myopia (pathological);
KIRP	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-6.57	-0.39	3.02e-10	Gut microbiome composition (summer);
KIRP	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg02487422	chr3:49467188	NICN1	0.38	4.96	0.3	1.34e-6	Resting heart rate;
KIRP	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg27205649	chr11:78285834	NARS2	-0.52	-4.9	-0.3	1.76e-6	Testicular germ cell tumor;
KIRP	cis	rs9323205	0.798	rs4465517	chr14:51673715	C/A	cg23942311	chr14:51606299	NA	0.58	7.24	0.42	5.88e-12	Cancer;
KIRP	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06050784	chr16:88016603	BANP	0.44	5.3	0.32	2.54e-7	Menopause (age at onset);
KIRP	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg07701084	chr6:150067640	NUP43	0.56	7.26	0.42	4.92e-12	Testicular germ cell tumor;
KIRP	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.59	6.43	0.38	6.62e-10	Aortic root size;
KIRP	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.65	-7.22	-0.42	6.56e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg12042659	chr19:58951599	ZNF132	0.5	6.14	0.36	3.36e-9	Uric acid clearance;
KIRP	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	5.09	0.31	7.26e-7	Personality dimensions;
KIRP	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.31	0.58	3.64e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs8014252	0.803	rs17108246	chr14:71054992	G/A	cg19730268	chr14:71022823	NA	-0.72	-6.4	-0.38	7.9e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs10073892	0.701	rs28625937	chr5:101652229	G/A	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17176517	chr3:125239027	SNX4	0.5	6.16	0.37	2.99e-9	Parkinson's disease;
KIRP	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg00262122	chr8:11665843	FDFT1	-0.4	-4.92	-0.3	1.59e-6	Morning vs. evening chronotype;
KIRP	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg05754148	chr16:3507555	NAT15	0.54	5.32	0.32	2.28e-7	Tuberculosis;
KIRP	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.78	0.44	2e-13	Calcium levels;
KIRP	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-5.13	-0.31	5.96e-7	Schizophrenia;
KIRP	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.97	11.63	0.6	3.41e-25	Exhaled nitric oxide levels;
KIRP	trans	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg06521331	chr12:34319734	NA	-0.53	-6.47	-0.38	5.4e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7106204	1.000	rs12798139	chr11:24220907	A/G	ch.11.24196551F	chr11:24239977	NA	0.82	8.76	0.49	3.27e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg23505145	chr19:12996616	KLF1	0.55	8.09	0.46	2.71e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg20821713	chr7:1055600	C7orf50	0.35	5.5	0.33	9.68e-8	Longevity;Endometriosis;
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.65	-7.99	-0.45	5.12e-14	Aortic root size;
KIRP	trans	rs1864585	0.520	rs73208781	chr8:10677498	A/C	cg26278703	chr11:58910052	FAM111A	0.64	6.24	0.37	1.92e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs58785573	0.771	rs4832783	chr4:38648406	G/C	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.43	-4.9	-0.3	1.78e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs2412208	0.527	rs4436414	chr1:7120915	G/A	cg20434152	chr1:7120926	CAMTA1	-0.46	-6.71	-0.39	1.33e-10	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.51	0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	cis	rs6466055	0.720	rs4730082	chr7:105027509	A/G	cg04380332	chr7:105027541	SRPK2	-0.62	-9.32	-0.51	7.08e-18	Schizophrenia;
KIRP	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.68	7.16	0.42	9.23e-12	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18252515	chr7:66147081	NA	0.43	5.09	0.31	6.97e-7	Aortic root size;
KIRP	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.31	-0.32	2.5e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs13424612	0.839	rs1530144	chr2:240923050	C/T	cg19172429	chr2:240878313	NA	0.3	5.05	0.31	8.79e-7	Odorant perception (isobutyraldehyde);
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4950322	0.542	rs115179956	chr1:146644199	C/A	cg22381352	chr1:146742008	CHD1L	-0.37	-5.13	-0.31	5.88e-7	Protein quantitative trait loci;
KIRP	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg07166546	chr14:35805898	NA	-0.28	-6.3	-0.37	1.4e-9	Psoriasis;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.67	-8.32	-0.47	6.02e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg11814155	chr7:99998594	ZCWPW1	0.64	5.79	0.35	2.12e-8	Platelet count;
KIRP	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.75	11.31	0.58	3.75e-24	Blood metabolite ratios;
KIRP	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.23e-13	Corneal astigmatism;
KIRP	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg05527609	chr1:210001259	C1orf107	-0.49	-5.45	-0.33	1.22e-7	Red blood cell count;
KIRP	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.8e-7	Major depressive disorder;
KIRP	cis	rs2865126	0.818	rs7227167	chr18:10763007	A/G	cg21165219	chr18:10698044	FAM38B	-0.55	-5.36	-0.32	1.88e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
KIRP	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg00319359	chr11:70116639	PPFIA1	0.82	7.16	0.42	9.09e-12	Coronary artery disease;
KIRP	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg21775007	chr8:11205619	TDH	-0.43	-5.26	-0.32	3.08e-7	Triglycerides;
KIRP	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg27426351	chr10:43362370	NA	0.46	6.33	0.37	1.17e-9	Blood protein levels;
KIRP	cis	rs12580194	0.593	rs12581916	chr12:55764409	A/C	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	9.95	0.54	7.83e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.63	9.46	0.52	2.52e-18	Lung cancer;
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13012494	chr21:47604986	C21orf56	0.39	4.95	0.3	1.37e-6	Testicular germ cell tumor;
KIRP	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.61	-0.39	2.42e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.89	-0.3	1.84e-6	Pulmonary function;
KIRP	cis	rs259842	0.612	rs55869281	chr2:180684788	G/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.42	-5.58	-0.34	6.34e-8	Blood protein levels;
KIRP	cis	rs7744392	1.000	rs6900530	chr6:35280971	C/T	cg03063928	chr6:35490164	NA	-0.61	-4.94	-0.3	1.46e-6	Cataracts in type 2 diabetes;
KIRP	cis	rs11209002	0.592	rs6672126	chr1:67558063	C/G	cg02640540	chr1:67518911	SLC35D1	0.57	6.34	0.37	1.07e-9	Crohn's disease;
KIRP	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg21775007	chr8:11205619	TDH	0.44	6.05	0.36	5.28e-9	Neuroticism;
KIRP	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13198984	chr17:80129470	CCDC57	0.58	8.32	0.47	6.04e-15	Life satisfaction;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07308232	chr7:1071921	C7orf50	-0.65	-8.21	-0.46	1.25e-14	Longevity;Endometriosis;
KIRP	cis	rs7074356	0.569	rs7090863	chr10:82021393	C/A	cg27171509	chr10:82033454	MAT1A	-0.39	-5.3	-0.32	2.61e-7	Borderline personality disorder;
KIRP	cis	rs4908768	0.657	rs6693466	chr1:8817938	C/T	cg25722041	chr1:8623473	RERE	0.53	6.9	0.4	4.43e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg04166393	chr7:2884313	GNA12	0.4	5.26	0.32	3.21e-7	Height;
KIRP	cis	rs600806	0.850	rs11102976	chr1:109917540	G/C	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.91	-0.64	1.9e-29	Exhaled nitric oxide output;
KIRP	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg10047753	chr17:41438598	NA	1.14	18.88	0.77	9.76e-50	Menopause (age at onset);
KIRP	cis	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-5.53	-0.33	8.04e-8	Height;
KIRP	cis	rs8054556	1.000	rs11150577	chr16:29986525	C/T	cg06326092	chr16:30034487	C16orf92	0.35	5.0	0.3	1.11e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs526231	0.511	rs34823	chr5:102438291	C/T	cg23492399	chr5:102201601	PAM	0.49	5.36	0.32	1.88e-7	Primary biliary cholangitis;
KIRP	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg12131826	chr15:77904385	NA	0.41	5.52	0.33	8.67e-8	Type 2 diabetes;
KIRP	cis	rs57338032	0.891	rs78901746	chr15:78770917	G/A	cg06917634	chr15:78832804	PSMA4	0.55	4.86	0.3	2.1e-6	CTACK levels;
KIRP	cis	rs6466055	0.777	rs10953470	chr7:104871892	G/T	cg04380332	chr7:105027541	SRPK2	0.64	9.84	0.53	1.82e-19	Schizophrenia;
KIRP	cis	rs4908768	0.657	rs3938719	chr1:8804997	A/G	cg25722041	chr1:8623473	RERE	0.54	7.19	0.42	7.64e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-6.99	-0.41	2.52e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs1345301	0.518	rs56238602	chr2:102863095	G/T	cg12451869	chr2:102867685	NA	0.48	6.82	0.4	6.82e-11	Waist circumference;
KIRP	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.52	7.31	0.42	3.71e-12	Coronary artery disease;
KIRP	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.84	-12.4	-0.62	9.67e-28	Neurofibrillary tangles;
KIRP	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.84	-13.08	-0.64	4.93e-30	Breast cancer;
KIRP	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg13160058	chr8:26243215	BNIP3L	-0.52	-7.28	-0.42	4.52e-12	Red cell distribution width;
KIRP	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg16141378	chr3:129829833	LOC729375	-0.57	-7.51	-0.43	1.11e-12	Neuroticism;
KIRP	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg13482628	chr17:19912719	NA	0.61	8.7	0.48	4.9e-16	Schizophrenia;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19723775	chr5:179050963	HNRNPH1	0.55	6.45	0.38	5.76e-10	Lung cancer;
KIRP	trans	rs9547443	0.647	rs4396434	chr13:86587441	A/C	cg16620233	chr3:53781107	CACNA1D	0.45	6.46	0.38	5.72e-10	Male sexual orientation;
KIRP	cis	rs10181042	0.565	rs62150982	chr2:61280675	T/C	cg15711740	chr2:61764176	XPO1	0.38	4.99	0.3	1.13e-6	Crohn's disease;
KIRP	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.47	-0.43	1.42e-12	Bipolar disorder;
KIRP	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.87	7.41	0.43	2.03e-12	Fat distribution (HIV);
KIRP	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg17595323	chr11:93583763	C11orf90	-0.31	-5.23	-0.32	3.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.67	9.18	0.51	1.79e-17	Blood protein levels;
KIRP	cis	rs7756236	0.521	rs6907437	chr6:36625021	A/G	cg08179530	chr6:36648295	CDKN1A	0.44	5.73	0.34	2.99e-8	QRS duration;
KIRP	cis	rs2124969	0.506	rs10497210	chr2:160985549	G/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.32	-0.37	1.22e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.7	8.56	0.48	1.28e-15	Aortic root size;
KIRP	cis	rs4073416	0.569	rs2092914	chr14:66079115	C/T	cg03016385	chr14:66212404	NA	-0.43	-5.56	-0.33	7.12e-8	N-glycan levels;
KIRP	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.35	5.42	0.33	1.41e-7	Type 2 diabetes;
KIRP	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.0	0.71	5.83e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.59	-7.39	-0.43	2.34e-12	Fibrinogen levels;
KIRP	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg00405596	chr8:11794950	NA	0.54	7.24	0.42	5.65e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.92	0.49	1.08e-16	Colorectal cancer;
KIRP	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06212747	chr3:49208901	KLHDC8B	0.75	10.79	0.57	1.76e-22	Parkinson's disease;
KIRP	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg24498760	chr8:49746867	NA	0.4	4.88	0.3	1.94e-6	Blood metabolite ratios;
KIRP	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.61	7.74	0.44	2.62e-13	Coronary artery disease;
KIRP	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.41	-4.9	-0.3	1.72e-6	Resistin levels;
KIRP	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	0.94	12.37	0.62	1.17e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.6	7.27	0.42	4.71e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs2414059	0.518	rs56398519	chr15:50773432	A/G	cg08437265	chr15:50716283	USP8	-0.36	-4.91	-0.3	1.64e-6	QT interval;
KIRP	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.67	-10.14	-0.54	2.1e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg02527881	chr3:46936655	PTH1R	-0.37	-5.32	-0.32	2.36e-7	Colorectal cancer;
KIRP	trans	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	1.08	8.09	0.46	2.72e-14	Skin colour saturation;
KIRP	cis	rs614367	1.000	rs614367	chr11:69328764	A/G	cg15442037	chr11:69286293	NA	0.45	4.85	0.3	2.17e-6	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma (childhood onset);
KIRP	cis	rs4363385	0.510	rs11205187	chr1:153053323	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-6.32	-0.37	1.2e-9	Inflammatory skin disease;
KIRP	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.52	6.71	0.39	1.35e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.96	11.28	0.58	4.81e-24	Corneal astigmatism;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg02696790	chr15:75250997	RPP25	0.32	5.53	0.33	8.01e-8	Breast cancer;
KIRP	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg27205649	chr11:78285834	NARS2	-0.55	-5.19	-0.31	4.35e-7	Testicular germ cell tumor;
KIRP	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	6.69	0.39	1.53e-10	Type 2 diabetes;
KIRP	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-19.17	-0.77	9.84e-51	Schizophrenia;
KIRP	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.83	-13.02	-0.64	8.19e-30	Breast cancer;
KIRP	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.71	9.92	0.53	1e-19	Mean corpuscular volume;
KIRP	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs4805272	0.962	rs4387706	chr19:29325559	T/C	cg15000279	chr19:29285009	NA	-0.36	-5.06	-0.31	8.1e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg05665937	chr4:1216051	CTBP1	0.42	5.54	0.33	7.67e-8	Obesity-related traits;
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg10304824	chr2:177028804	HOXD3	0.25	5.12	0.31	6.19e-7	IgG glycosylation;
KIRP	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	6.92	0.4	3.87e-11	Educational attainment (years of education);
KIRP	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.76	-0.63	5.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs6956675	0.957	rs10236165	chr7:62596446	T/A	cg08930214	chr7:62859557	LOC100287834	0.51	5.84	0.35	1.67e-8	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg10591111	chr5:226296	SDHA	-0.47	-4.91	-0.3	1.65e-6	Breast cancer;
KIRP	cis	rs2820315	0.931	rs2644114	chr1:201864830	A/G	cg11586189	chr1:201857591	SHISA4	0.4	5.58	0.34	6.36e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7084402	0.967	rs2114564	chr10:60314729	T/C	cg05938607	chr10:60274200	BICC1	-0.4	-9.76	-0.53	3.04e-19	Refractive error;
KIRP	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg18316498	chr11:111250196	POU2AF1	0.42	6.77	0.4	9.46e-11	Primary biliary cholangitis;
KIRP	cis	rs258892	0.947	rs266448	chr5:72182229	G/A	cg21869765	chr5:72125136	TNPO1	0.58	6.4	0.38	7.9e-10	Small cell lung carcinoma;
KIRP	cis	rs4466137	0.868	rs1975801	chr5:83022127	A/G	cg15083037	chr5:83017644	HAPLN1	-0.59	-8.55	-0.48	1.3e-15	Prostate cancer;
KIRP	cis	rs2224391	0.628	rs2753233	chr6:5250982	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.57	-0.39	3.06e-10	Height;
KIRP	cis	rs4762326	0.934	rs12320196	chr12:95645385	A/G	cg07737802	chr12:95537812	FGD6	0.46	6.39	0.38	8.35e-10	Endometriosis;
KIRP	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.58	7.31	0.42	3.74e-12	Resting heart rate;
KIRP	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.47	5.21	0.32	3.91e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.41	8.16	0.46	1.75e-14	Multiple system atrophy;
KIRP	cis	rs7615316	0.902	rs6440091	chr3:142313515	C/T	cg20824294	chr3:142316082	PLS1	0.22	4.86	0.3	2.07e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs62056376	0.646	rs2857657	chr17:32583132	G/C	cg17635953	chr13:28535085	NA	0.59	6.09	0.36	4.35e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.18	-0.31	4.6e-7	Metabolite levels;
KIRP	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg23594656	chr7:65796392	TPST1	-0.49	-7.57	-0.43	7.38e-13	Aortic root size;
KIRP	cis	rs10918270	1.000	rs2341471	chr1:161924749	C/T	cg19735514	chr1:161762739	ATF6	-0.35	-4.95	-0.3	1.41e-6	Parkinson's disease (age of onset);
KIRP	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.55	-7.91	-0.45	8.45e-14	Huntington's disease progression;
KIRP	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg00784671	chr22:46762841	CELSR1	-0.66	-8.31	-0.47	6.64e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6001982	0.584	rs73167030	chr22:40819013	T/C	cg07138101	chr22:40742427	ADSL	0.65	5.06	0.31	8.13e-7	Breast cancer;
KIRP	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.39	5.35	0.32	1.97e-7	Endometrial cancer;
KIRP	trans	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg06521331	chr12:34319734	NA	-0.49	-6.22	-0.37	2.16e-9	Bladder cancer;
KIRP	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22364869	chr1:7740271	CAMTA1	-0.49	-6.92	-0.4	3.96e-11	Metabolic traits;
KIRP	cis	rs300890	0.642	rs1510880	chr4:144290998	A/T	cg01719995	chr4:144104893	USP38	-0.42	-5.31	-0.32	2.5e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.6	-6.17	-0.37	2.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs501120	0.810	rs683297	chr10:44746140	A/G	cg09554077	chr10:44749378	NA	0.75	12.45	0.62	6.35e-28	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.96	15.14	0.69	4.97e-37	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.3	-0.32	2.59e-7	Life satisfaction;
KIRP	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	5.28	0.32	2.77e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.53	-7.07	-0.41	1.61e-11	HDL cholesterol;
KIRP	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18876405	chr7:65276391	NA	0.41	5.05	0.31	8.81e-7	Aortic root size;
KIRP	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg14092571	chr14:90743983	NA	0.42	5.59	0.34	5.96e-8	Mortality in heart failure;
KIRP	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.41	-6.55	-0.39	3.34e-10	Refractive error;
KIRP	cis	rs259282	0.562	rs2021772	chr19:33107651	C/T	cg02997394	chr19:33096574	ANKRD27	-0.48	-5.58	-0.34	6.41e-8	Schizophrenia;
KIRP	cis	rs2635047	0.638	rs2289133	chr18:44602249	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	6.07	0.36	4.9e-9	Educational attainment;
KIRP	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg06636001	chr8:8085503	FLJ10661	0.68	8.81	0.49	2.27e-16	Platelet distribution width;
KIRP	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-13.1	-0.64	4.33e-30	Chronic sinus infection;
KIRP	cis	rs12431939	0.817	rs7153408	chr14:51671492	G/A	cg23942311	chr14:51606299	NA	0.47	5.55	0.33	7.27e-8	Cancer;
KIRP	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg24631222	chr15:78858424	CHRNA5	-0.8	-9.66	-0.52	6.29e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg07001201	chr5:642380	CEP72	0.65	6.54	0.38	3.59e-10	Obesity-related traits;
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg09263875	chr16:632152	PIGQ	0.74	12.53	0.62	3.4e-28	Height;
KIRP	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-5.67	-0.34	3.92e-8	Triglycerides;
KIRP	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.43	0.55	2.43e-21	Bone mineral density;
KIRP	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg02461776	chr11:598696	PHRF1	0.62	6.78	0.4	9.1e-11	Systemic lupus erythematosus;
KIRP	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.38	6.9	0.4	4.5e-11	Refractive error;
KIRP	cis	rs10767971	0.545	rs10767970	chr11:32892919	G/A	cg14042352	chr11:32815968	CCDC73	-0.44	-5.14	-0.31	5.52e-7	Parkinson's disease (age of onset);
KIRP	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg03060546	chr3:49711283	APEH	-0.64	-6.01	-0.36	6.78e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.4	0.33	1.61e-7	Heart rate;
KIRP	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.71	6.6	0.39	2.48e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs35740288	0.787	rs11637768	chr15:86223410	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-5.0	-0.3	1.1e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.86	-13.49	-0.65	2.06e-31	Prostate cancer;
KIRP	cis	rs4236601	1.000	rs12540035	chr7:116159526	G/A	cg05166801	chr7:116143459	CAV2	0.48	5.92	0.35	1.1e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs6832769	1.000	rs4864998	chr4:56332606	A/G	cg05960024	chr4:56376020	CLOCK	0.7	8.76	0.49	3.26e-16	Personality dimensions;
KIRP	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.68	-9.52	-0.52	1.72e-18	Lymphocyte counts;
KIRP	cis	rs9409565	1.000	rs9409567	chr9:97252505	A/G	cg04523069	chr9:97136363	HIATL1	-0.42	-5.58	-0.34	6.23e-8	Colorectal cancer (alcohol consumption interaction);
KIRP	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg22732515	chr19:44031385	ETHE1	-0.63	-9.21	-0.51	1.51e-17	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.63	7.78	0.44	2.03e-13	Multiple sclerosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18393905	chr5:39062214	RICTOR	-0.41	-6.56	-0.39	3.07e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.38	-5.71	-0.34	3.23e-8	Body mass index;
KIRP	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg00852783	chr1:26633632	UBXN11	0.54	7.77	0.44	2.18e-13	Obesity-related traits;
KIRP	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg06636001	chr8:8085503	FLJ10661	0.66	9.1	0.5	3.11e-17	Retinal vascular caliber;
KIRP	cis	rs3126085	0.515	rs10888484	chr1:152352514	C/T	cg26876637	chr1:152193138	HRNR	-0.47	-5.95	-0.35	9.28e-9	Atopic dermatitis;
KIRP	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.45	5.75	0.34	2.58e-8	Monocyte count;
KIRP	cis	rs4149577	0.630	rs4149570	chr12:6451590	A/C	cg11268190	chr12:6442526	TNFRSF1A	0.24	5.12	0.31	6.28e-7	Monocyte count;
KIRP	cis	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg07460842	chr6:66804631	NA	0.47	5.63	0.34	4.78e-8	Metabolite levels;
KIRP	cis	rs6662572	0.686	rs11805376	chr1:46559664	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.77	0.35	2.41e-8	Blood protein levels;
KIRP	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.86	9.42	0.51	3.48e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs7005380	0.581	rs13265734	chr8:120919948	C/A	cg21645572	chr8:120931649	DEPDC6	0.52	7.19	0.42	7.81e-12	Interstitial lung disease;
KIRP	cis	rs4936894	0.500	rs4936911	chr11:124076220	C/G	cg27160556	chr11:124181099	OR8D1	-0.4	-5.91	-0.35	1.16e-8	Aging (time to death);
KIRP	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg03714773	chr7:91764589	CYP51A1	0.4	5.75	0.34	2.6e-8	Breast cancer;
KIRP	cis	rs57590327	0.679	rs2121949	chr3:81671394	A/G	cg07356753	chr3:81810745	GBE1	-0.58	-6.27	-0.37	1.61e-9	Extraversion;
KIRP	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.96	8.05	0.46	3.49e-14	Body mass index;
KIRP	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.3	-0.37	1.37e-9	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.55	0.52	1.42e-18	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.3	5.86	0.35	1.45e-8	Lung cancer;
KIRP	cis	rs829661	0.947	rs829654	chr2:30714717	A/G	cg10949345	chr2:30726833	LCLAT1	0.69	9.66	0.52	6.38e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.65	10.64	0.56	5.2e-22	Pulse pressure;
KIRP	cis	rs7301016	0.846	rs17732182	chr12:63026131	C/T	cg01804193	chr12:63026212	NA	0.59	6.35	0.38	1.04e-9	IgG glycosylation;
KIRP	cis	rs9462846	0.959	rs9471958	chr6:42883669	C/T	cg05552183	chr6:42928497	GNMT	0.47	5.24	0.32	3.39e-7	Blood protein levels;
KIRP	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14598338	chr9:96623480	NA	-0.67	-11.46	-0.59	1.17e-24	DNA methylation (variation);
KIRP	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg00981070	chr1:2046702	PRKCZ	0.44	6.32	0.37	1.24e-9	Height;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26240185	chr11:13690157	FAR1	-0.5	-6.18	-0.37	2.71e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg07511934	chr16:89386912	ANKRD11	-0.43	-5.15	-0.31	5.46e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.53	-0.38	3.74e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.36	-0.32	1.93e-7	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18500826	chr12:68716789	MDM1	0.48	6.12	0.36	3.65e-9	Interleukin-4 levels;
KIRP	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.71	0.6	1.76e-25	Primary sclerosing cholangitis;
KIRP	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg18944383	chr4:111397179	ENPEP	0.52	9.05	0.5	4.5e-17	Height;
KIRP	cis	rs17095355	1.000	rs12246851	chr10:111726340	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.28	-0.32	2.9e-7	Biliary atresia;
KIRP	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	0.44	5.96	0.36	8.81e-9	Systemic lupus erythematosus;
KIRP	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg03468072	chr12:39539422	NA	0.39	5.69	0.34	3.58e-8	Morning vs. evening chronotype;
KIRP	cis	rs367943	0.672	rs6594712	chr5:112715211	T/G	cg12552261	chr5:112820674	MCC	0.56	6.61	0.39	2.32e-10	Type 2 diabetes;
KIRP	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.37	-0.43	2.67e-12	Aortic root size;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.53	5.2	0.31	4.25e-7	Alzheimer's disease;
KIRP	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg00717180	chr2:96193071	NA	-0.51	-6.21	-0.37	2.19e-9	HDL cholesterol;
KIRP	cis	rs2415984	0.622	rs8022305	chr14:46946545	C/T	cg14871534	chr14:47121158	RPL10L	-0.45	-5.37	-0.32	1.85e-7	Number of children ever born;
KIRP	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg21775007	chr8:11205619	TDH	-0.45	-5.77	-0.35	2.38e-8	Neuroticism;
KIRP	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.52	6.89	0.4	4.54e-11	Height;
KIRP	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	4.93e-23	Prudent dietary pattern;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.69	9.32	0.51	6.82e-18	Menarche (age at onset);
KIRP	cis	rs2280630	0.529	rs6599274	chr3:39013948	T/C	cg01426195	chr3:39028469	NA	-0.66	-10.68	-0.56	4.04e-22	Verbal declarative memory;
KIRP	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.32	-5.8	-0.35	2.08e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-1.17	-12.14	-0.61	6.88e-27	Breast cancer;
KIRP	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg23978390	chr7:1156363	C7orf50	0.43	5.8	0.35	2.01e-8	Longevity;Endometriosis;
KIRP	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.81	-11.11	-0.58	1.69e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11672447	chr18:72921434	TSHZ1;ZADH2	-0.46	-6.42	-0.38	6.78e-10	Metabolic traits;
KIRP	cis	rs1165472	0.951	rs1039296	chr1:56103659	A/T	cg11523071	chr1:56160889	NA	-0.39	-5.15	-0.31	5.34e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs909341	0.810	rs2427529	chr20:62359564	T/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.84	-0.35	1.65e-8	Atopic dermatitis;
KIRP	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg13877915	chr19:58951672	ZNF132	-0.61	-6.04	-0.36	5.74e-9	Mean platelet volume;
KIRP	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	1.02	7.41	0.43	2.04e-12	Skin colour saturation;
KIRP	cis	rs62355272	0.863	rs10050705	chr5:35831158	C/G	cg13894535	chr5:35919491	CAPSL	-0.4	-5.06	-0.31	8.05e-7	Lymphocyte counts;
KIRP	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg04731861	chr2:219085781	ARPC2	0.3	7.65	0.44	4.53e-13	Colorectal cancer;
KIRP	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg02297831	chr4:17616191	MED28	0.64	8.18	0.46	1.48e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.62	-8.72	-0.49	4.27e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9815354	0.638	rs113496706	chr3:42028574	G/T	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.64	-0.52	7.2e-19	Total body bone mineral density;
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg09699651	chr6:150184138	LRP11	0.42	5.03	0.31	9.52e-7	Lung cancer;
KIRP	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.32	-0.32	2.38e-7	Testicular germ cell tumor;
KIRP	trans	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.05	-0.46	3.58e-14	Retinal vascular caliber;
KIRP	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg05526886	chr2:227700861	RHBDD1	0.43	5.19	0.31	4.4e-7	Pulmonary function;
KIRP	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.24	13.65	0.66	5.98e-32	Uric acid levels;
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg05315796	chr3:52349193	DNAH1	0.46	7.04	0.41	1.86e-11	Electroencephalogram traits;
KIRP	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg18032046	chr6:28092343	ZSCAN16	0.5	5.41	0.33	1.46e-7	Depression;
KIRP	cis	rs151997	0.962	rs27714	chr5:50180396	G/C	cg06027927	chr5:50259733	NA	0.59	7.41	0.43	2.02e-12	Callous-unemotional behaviour;
KIRP	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg08992911	chr2:238395768	MLPH	0.53	5.45	0.33	1.25e-7	Prostate cancer;
KIRP	cis	rs10871290	0.650	rs12600126	chr16:74489732	A/T	cg01733217	chr16:74700730	RFWD3	-0.6	-8.15	-0.46	1.84e-14	Breast cancer;
KIRP	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18252515	chr7:66147081	NA	0.43	5.02	0.31	9.72e-7	Aortic root size;
KIRP	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8017423	0.529	rs12898020	chr14:90835752	A/G	cg04374321	chr14:90722782	PSMC1	-0.49	-5.69	-0.34	3.58e-8	Mortality in heart failure;
KIRP	cis	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg06521331	chr12:34319734	NA	-0.4	-4.86	-0.3	2.14e-6	Morning vs. evening chronotype;
KIRP	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01200585	chr1:228362443	C1orf69	0.43	5.33	0.32	2.25e-7	Diastolic blood pressure;
KIRP	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.52	-6.71	-0.39	1.37e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.3	-0.47	6.85e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24933247	chr19:19729558	PBX4	0.46	6.46	0.38	5.63e-10	Cancer;
KIRP	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg06742321	chr12:123595122	PITPNM2	0.42	5.22	0.32	3.86e-7	Platelet count;
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.73	6.47	0.38	5.27e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.56	-7.3	-0.42	4.07e-12	Hip circumference;
KIRP	cis	rs12949688	0.935	rs9893344	chr17:55826114	G/A	cg12582317	chr17:55822272	NA	0.6	9.33	0.51	6.64e-18	Schizophrenia;
KIRP	cis	rs7560272	0.564	rs4852939	chr2:73856769	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.56	-0.33	7.17e-8	Schizophrenia;
KIRP	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-5.83	-0.35	1.77e-8	Chronic sinus infection;
KIRP	trans	rs516805	0.596	rs1531186	chr6:122529365	T/A	cg26484001	chr10:33630103	NA	-0.45	-6.03	-0.36	5.85e-9	Lymphocyte counts;
KIRP	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg10223061	chr2:219282414	VIL1	0.28	4.89	0.3	1.85e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg13165212	chr22:42675999	NA	0.28	4.98	0.3	1.19e-6	Cognitive function;
KIRP	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.92	-11.97	-0.61	2.55e-26	Blood protein levels;
KIRP	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.77	8.55	0.48	1.34e-15	Corneal astigmatism;
KIRP	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg10840412	chr1:235813424	GNG4	0.69	6.16	0.37	2.99e-9	Bipolar disorder;
KIRP	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg06565975	chr8:143823917	SLURP1	-0.43	-6.54	-0.38	3.57e-10	Urinary tract infection frequency;
KIRP	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg19773385	chr1:10388646	KIF1B	-0.68	-8.85	-0.49	1.78e-16	Hepatocellular carcinoma;
KIRP	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg09596252	chr17:78655493	RPTOR	0.53	6.07	0.36	4.86e-9	Fractional excretion of uric acid;
KIRP	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.91	0.3	1.66e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.67	9.75	0.53	3.47e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2425143	1.000	rs733609	chr20:34393074	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.08	-0.31	7.38e-7	Blood protein levels;
KIRP	cis	rs6750047	0.585	rs4670234	chr2:38272477	C/T	cg07380506	chr2:38303506	CYP1B1	0.43	5.67	0.34	3.93e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22117172	chr7:91764530	CYP51A1	-0.42	-5.8	-0.35	2.01e-8	Breast cancer;
KIRP	cis	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.45	5.75	0.34	2.62e-8	Leprosy;
KIRP	cis	rs10875746	0.624	rs7297298	chr12:48672306	C/G	cg26205652	chr12:48591994	NA	0.84	10.87	0.57	9.95e-23	Longevity (90 years and older);
KIRP	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg20701182	chr2:24300061	SF3B14	0.53	5.22	0.32	3.72e-7	Lymphocyte counts;
KIRP	cis	rs2046867	0.862	rs62251656	chr3:72827393	T/C	cg25664220	chr3:72788482	NA	-0.48	-7.19	-0.42	7.89e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.53	0.43	9.35e-13	Coffee consumption (cups per day);
KIRP	cis	rs4908768	0.906	rs12403339	chr1:8558292	G/A	cg03610117	chr1:8450231	RERE	-0.49	-5.23	-0.32	3.56e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20135002	chr11:47629003	NA	-0.43	-4.93	-0.3	1.52e-6	Subjective well-being;
KIRP	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.62	8.72	0.49	4.32e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg11189052	chr15:85197271	WDR73	0.53	5.38	0.32	1.7e-7	Schizophrenia;
KIRP	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.57	-8.21	-0.46	1.24e-14	Vitiligo;
KIRP	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.86	-0.4	5.39e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.6	6.42	0.38	7.02e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.8	12.42	0.62	7.84e-28	Dental caries;
KIRP	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg24642439	chr20:33292090	TP53INP2	0.77	12.03	0.61	1.56e-26	Coronary artery disease;
KIRP	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg01320579	chr17:75405842	SEPT9	0.46	7.6	0.44	6.14e-13	Airflow obstruction;
KIRP	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.97	0.54	7.01e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg01559446	chr3:44596178	ZNF167	-0.35	-5.06	-0.31	8.33e-7	Depressive symptoms;
KIRP	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg19592336	chr6:28129416	ZNF389	0.48	5.56	0.33	6.88e-8	Depression;
KIRP	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.81	-12.43	-0.62	7.52e-28	Breast cancer;
KIRP	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-8.11	-0.46	2.34e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.51	7.48	0.43	1.3e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg11783602	chr8:55087084	NA	-0.47	-5.69	-0.34	3.64e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4702718	0.616	rs267984	chr5:10714364	T/A	cg14521931	chr5:10832172	NA	-0.44	-5.9	-0.35	1.17e-8	Obesity-related traits;
KIRP	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.55	-0.43	8.23e-13	Mean corpuscular volume;
KIRP	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.71	-9.24	-0.51	1.21e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7005380	0.581	rs10099088	chr8:120939658	C/T	cg21645572	chr8:120931649	DEPDC6	0.49	6.55	0.39	3.38e-10	Interstitial lung disease;
KIRP	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg21187068	chr8:144659627	NAPRT1	0.74	5.05	0.31	8.49e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg08501292	chr6:25962987	TRIM38	0.72	4.98	0.3	1.2e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.38	0.43	2.4e-12	IgG glycosylation;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.78	-13.2	-0.64	1.96e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9581857	0.547	rs77005033	chr13:28109793	A/G	cg22138327	chr13:27999177	GTF3A	0.71	5.71	0.34	3.21e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.44	5.89	0.35	1.24e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg13289132	chr10:30722225	MAP3K8	-0.41	-5.09	-0.31	7.26e-7	Inflammatory bowel disease;
KIRP	cis	rs9863706	0.520	rs4676873	chr3:72399598	C/G	cg05607079	chr3:72387937	NA	0.44	5.69	0.34	3.58e-8	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21796825	chr12:64173751	TMEM5	0.54	6.35	0.38	1.03e-9	Smoking initiation;
KIRP	cis	rs9381107	0.860	rs9380845	chr6:9442251	G/T	cg14735645	chr6:9486422	NA	-0.45	-5.36	-0.32	1.88e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04246357	chr6:158589294	SERAC1;GTF2H5	0.51	6.92	0.4	3.8e-11	Parkinson's disease;
KIRP	cis	rs6430538	0.646	rs6430539	chr2:135549730	A/G	cg12500956	chr2:135428796	TMEM163	0.41	5.2	0.31	4.17e-7	Parkinson's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09397319	chr2:64250606	NA	0.41	6.86	0.4	5.45e-11	C-reactive protein;
KIRP	cis	rs17286411	0.836	rs1035543	chr16:71983772	C/G	cg04254540	chr16:71951199	KIAA0174	0.37	4.87	0.3	2.01e-6	Blood protein levels;
KIRP	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg24498760	chr8:49746867	NA	0.39	4.86	0.3	2.09e-6	Blood metabolite ratios;
KIRP	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	1.05	14.56	0.68	4.55e-35	Menopause (age at onset);
KIRP	cis	rs8192282	0.739	rs4518898	chr1:154492432	T/C	cg07911225	chr1:154474108	TDRD10;SHE	-0.34	-4.97	-0.3	1.24e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs830124	0.673	rs529736	chr12:122384457	A/C	cg12705353	chr12:122356852	WDR66	0.47	4.85	0.3	2.2e-6	Urinary metabolites;
KIRP	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.87	0.3	1.99e-6	Tonsillectomy;
KIRP	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.17	-0.42	8.85e-12	Glomerular filtration rate;
KIRP	cis	rs2033908	0.620	rs1440271	chr11:12852068	A/G	cg25843174	chr11:12811716	TEAD1	-0.35	-6.58	-0.39	2.86e-10	Sitting height ratio;
KIRP	cis	rs889312	0.923	rs1862625	chr5:56032719	G/A	cg14703610	chr5:56206110	C5orf35	0.4	5.09	0.31	7.18e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg04906043	chr13:21280425	IL17D	0.56	7.63	0.44	5.04e-13	Dental caries;
KIRP	cis	rs8054556	0.633	rs12928610	chr16:30016022	C/T	cg06326092	chr16:30034487	C16orf92	0.45	6.86	0.4	5.62e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17125944	0.686	rs7145242	chr14:53349842	G/A	cg00686598	chr14:53173677	PSMC6	-0.67	-6.28	-0.37	1.56e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.56	-7.29	-0.42	4.19e-12	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.07	-0.36	4.72e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg06066596	chr15:83166174	LOC80154	-0.52	-6.05	-0.36	5.37e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.54	4.96	0.3	1.29e-6	Schizophrenia;
KIRP	cis	rs4561483	0.603	rs62038777	chr16:11934176	A/C	cg08843971	chr16:11963173	GSPT1	0.5	6.75	0.4	1.05e-10	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.73	-0.34	2.91e-8	Life satisfaction;
KIRP	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11987759	chr7:65425863	GUSB	-0.69	-9.8	-0.53	2.38e-19	Aortic root size;
KIRP	cis	rs6959887	0.962	rs988271	chr7:35300377	C/A	cg06685737	chr7:35301730	NA	0.44	6.45	0.38	5.98e-10	Birth weight;
KIRP	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg17133734	chr15:86042851	AKAP13	-0.42	-5.32	-0.32	2.34e-7	Interstitial lung disease;
KIRP	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg11693508	chr17:37793320	STARD3	0.75	8.36	0.47	4.69e-15	Bipolar disorder;
KIRP	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg03563238	chr19:33554763	RHPN2	-0.32	-5.64	-0.34	4.69e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05025164	chr4:1340916	KIAA1530	-0.5	-6.52	-0.38	3.92e-10	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs732505	1.000	rs732505	chr19:5582535	G/A	cg26242866	chr19:5711310	LONP1	0.71	5.35	0.32	1.97e-7	vWF and FVIII levels;
KIRP	cis	rs5753037	0.653	rs131282	chr22:30156608	A/C	cg01021169	chr22:30184971	ASCC2	-0.43	-5.9	-0.35	1.21e-8	Type 1 diabetes;
KIRP	cis	rs11671005	0.735	rs12981875	chr19:58935130	A/C	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17065868	1.000	rs55889128	chr13:45108341	G/A	cg10246903	chr13:45222710	NA	0.7	6.85	0.4	5.96e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6921919	0.583	rs9461456	chr6:28343816	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.11e-16	Bladder cancer;
KIRP	cis	rs2274273	0.870	rs4496026	chr14:55790512	A/G	cg04306507	chr14:55594613	LGALS3	0.43	6.61	0.39	2.43e-10	Protein biomarker;
KIRP	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.34e-17	Bladder cancer;
KIRP	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.58	-6.11	-0.36	3.85e-9	Obesity-related traits;
KIRP	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.36	0.62	1.28e-27	Smoking behavior;
KIRP	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg05938607	chr10:60274200	BICC1	0.43	10.52	0.56	1.32e-21	Refractive error;
KIRP	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	6.05	0.36	5.43e-9	Response to antipsychotic treatment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04235548	chr5:118580164	DMXL1	-0.47	-7.25	-0.42	5.29e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg01475377	chr6:109611718	NA	-0.37	-5.14	-0.31	5.56e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	7.04	0.41	1.94e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg08992911	chr2:238395768	MLPH	-0.42	-5.28	-0.32	2.88e-7	Prostate cancer;
KIRP	cis	rs73105738	0.590	rs16871164	chr5:73280953	T/C	cg26653990	chr5:72510846	NA	-0.49	-5.37	-0.32	1.86e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.76	-0.4	9.79e-11	Longevity;Endometriosis;
KIRP	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg08975724	chr8:8085496	FLJ10661	0.66	8.46	0.47	2.46e-15	Neuroticism;
KIRP	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg11845111	chr2:191398756	TMEM194B	-0.93	-10.11	-0.54	2.59e-20	Diastolic blood pressure;
KIRP	cis	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg19847130	chr8:10466454	RP1L1	-0.34	-5.41	-0.33	1.47e-7	Neuroticism;
KIRP	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.91	0.35	1.12e-8	Renal cell carcinoma;
KIRP	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg13319975	chr6:146136371	FBXO30	0.44	5.91	0.35	1.15e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.11	0.36	3.9e-9	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.57	7.23	0.42	5.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.18	18.93	0.77	6.55e-50	Cognitive function;
KIRP	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16538289	chr6:41703332	TFEB	-0.56	-6.2	-0.37	2.37e-9	Menopause (age at onset);
KIRP	cis	rs2916247	1.000	rs7820440	chr8:93036627	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.67	-9.28	-0.51	8.96e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4308124	1.000	rs4308124	chr2:112010486	T/C	cg04571233	chr2:111982156	NA	-0.42	-5.42	-0.33	1.39e-7	Vitiligo;
KIRP	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg04132472	chr17:19861366	AKAP10	-0.47	-6.81	-0.4	7.58e-11	Schizophrenia;
KIRP	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs300032	1.000	rs12600217	chr16:86680658	A/G	cg00440195	chr16:86652360	NA	-0.48	-4.99	-0.3	1.13e-6	IgG glycosylation;
KIRP	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.51	-5.37	-0.32	1.84e-7	Coronary artery disease;
KIRP	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg05729581	chr11:3078854	CARS	-0.5	-6.17	-0.37	2.87e-9	Longevity;
KIRP	cis	rs6540556	1.000	rs6540556	chr1:209936631	G/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.39	-0.33	1.62e-7	Red blood cell count;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03442322	chr10:33524393	NRP1	-0.47	-6.56	-0.39	3.11e-10	Select biomarker traits;
KIRP	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg26681399	chr22:41777847	TEF	-0.42	-4.89	-0.3	1.86e-6	Neuroticism;
KIRP	cis	rs2671245	0.565	rs61776400	chr1:56133431	T/G	cg11523071	chr1:56160889	NA	0.43	6.44	0.38	6.38e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.38	-0.38	8.92e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23008136	chr2:55743936	NA	-0.4	-6.32	-0.37	1.22e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4478037	1.000	rs61433006	chr3:33162363	T/A	cg19404215	chr3:33155277	CRTAP	0.7	6.49	0.38	4.64e-10	Major depressive disorder;
KIRP	cis	rs2061333	0.948	rs4803681	chr19:44609485	G/A	cg21636353	chr19:44617292	ZNF225	-0.47	-4.99	-0.3	1.12e-6	Alzheimer's disease;
KIRP	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	trans	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.5	-6.62	-0.39	2.23e-10	Mean corpuscular volume;
KIRP	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.16	-0.37	2.98e-9	Systolic blood pressure;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26475306	chr20:33999876	UQCC	0.46	6.52	0.38	3.86e-10	Survival in pancreatic cancer;
KIRP	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-0.67	-7.44	-0.43	1.66e-12	Gut microbiome composition (summer);
KIRP	cis	rs8077577	1.000	rs62073606	chr17:18069142	G/A	cg09161412	chr17:18057145	MYO15A	-0.4	-5.11	-0.31	6.46e-7	Obesity-related traits;
KIRP	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg18527119	chr7:66119851	NA	-0.46	-4.95	-0.3	1.38e-6	Aortic root size;
KIRP	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-9.53	-0.52	1.54e-18	Coffee consumption (cups per day);
KIRP	cis	rs876084	0.722	rs2875932	chr8:121043869	C/T	cg06265175	chr8:121136014	COL14A1	0.45	5.09	0.31	7.02e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs73200209	0.912	rs57465027	chr12:116627026	G/C	cg01776926	chr12:116560359	MED13L	-0.45	-5.48	-0.33	1.07e-7	Total body bone mineral density;
KIRP	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16858146	chr10:7864607	TAF3	0.48	6.09	0.36	4.36e-9	Interleukin-4 levels;
KIRP	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20135002	chr11:47629003	NA	-0.47	-5.27	-0.32	3.05e-7	Subjective well-being;
KIRP	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.21	0.61	3.9e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.57	-7.48	-0.43	1.32e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs867371	1.000	rs1174543	chr15:82448073	C/T	cg06066596	chr15:83166174	LOC80154	0.46	5.41	0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.57	-8.53	-0.48	1.49e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.57	-7.01	-0.41	2.23e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs11731606	0.508	rs17376943	chr4:95277117	G/A	cg00507259	chr4:95128692	SMARCAD1	0.68	5.96	0.36	8.52e-9	Mean platelet volume;
KIRP	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	1.05	15.16	0.7	4.08e-37	Menopause (age at onset);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22389730	chr1:161697241	FCRLB	-0.45	-6.13	-0.36	3.49e-9	Myopia;
KIRP	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-7.8	-0.45	1.74e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg24499839	chr1:231762238	TSNAX-DISC1;DISC1	0.36	5.06	0.31	8.21e-7	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs2950163	0.898	rs2693935	chr2:6189216	T/C	cg26659079	chr2:5836181	SOX11	0.38	4.96	0.3	1.33e-6	Response to metformin (IC50);
KIRP	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.95	-15.73	-0.71	4.65e-39	Metabolite levels;
KIRP	cis	rs752010	0.715	rs4083592	chr1:42099522	A/G	cg06885757	chr1:42089581	HIVEP3	0.88	14.68	0.68	1.85e-35	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs9815354	0.812	rs77732985	chr3:41945872	G/A	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg16584676	chr17:46985605	UBE2Z	0.49	6.05	0.36	5.4e-9	Type 2 diabetes;
KIRP	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg00042356	chr1:8021962	PARK7	0.66	5.18	0.31	4.56e-7	Inflammatory bowel disease;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.42	4.99	0.3	1.13e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-1.21	-14.09	-0.67	1.95e-33	Breast cancer;
KIRP	cis	rs61884328	0.866	rs61897307	chr11:46832158	C/A	cg23433285	chr11:47201945	PACSIN3	0.78	5.3	0.32	2.63e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs5762813	0.562	rs13053879	chr22:29259102	T/A	cg02153584	chr22:29168773	CCDC117	0.61	5.34	0.32	2.11e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2411233	1.000	rs11855642	chr15:39281968	C/T	cg02291532	chr15:39874776	THBS1	0.38	5.27	0.32	3.05e-7	Platelet count;
KIRP	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg19025524	chr12:109796872	NA	-0.43	-5.42	-0.33	1.44e-7	Neuroticism;
KIRP	cis	rs17331151	0.505	rs13066644	chr3:52565247	G/A	cg04865290	chr3:52927548	TMEM110	-0.55	-4.84	-0.3	2.27e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.13	-0.31	5.88e-7	Menarche (age at onset);
KIRP	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.5	6.62	0.39	2.22e-10	Total body bone mineral density;
KIRP	cis	rs1883415	0.750	rs2076317	chr6:24490147	A/G	cg20631270	chr6:24437470	GPLD1	0.42	5.18	0.31	4.67e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.57	-0.39	2.95e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1805008	0.568	rs118068966	chr16:90111516	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.91	-5.93	-0.35	1.04e-8	Skin colour saturation;
KIRP	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04338863	chr8:33670619	NA	-0.37	-4.9	-0.3	1.71e-6	Body mass index;
KIRP	cis	rs2652822	0.662	rs34367270	chr15:63410912	G/A	cg02713581	chr15:63449717	RPS27L	0.48	5.51	0.33	9.06e-8	Metabolic traits;
KIRP	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.6e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.94	-14.67	-0.68	1.97e-35	Sudden cardiac arrest;
KIRP	cis	rs7359257	1.000	rs55854539	chr15:67707832	G/C	cg24579218	chr15:68104479	NA	0.37	5.51	0.33	9.17e-8	Menarche (age at onset);
KIRP	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.6	-0.91	6.55e-94	Myeloid white cell count;
KIRP	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.81	0.49	2.32e-16	Resting heart rate;
KIRP	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7289126	1.000	rs7290309	chr22:38630287	C/T	cg25457927	chr22:38595422	NA	-0.32	-7.18	-0.42	8.02e-12	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg23307798	chr14:103986281	CKB	-0.5	-6.69	-0.39	1.51e-10	Coronary artery disease;
KIRP	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.52	-0.43	1.03e-12	Neuroticism;
KIRP	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.83	-0.49	1.97e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7635838	0.722	rs6773963	chr3:11511975	G/A	cg00170343	chr3:11313890	ATG7	0.49	6.37	0.38	9.35e-10	HDL cholesterol;
KIRP	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg04310649	chr10:35416472	CREM	-0.54	-5.99	-0.36	7.33e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.94	12.18	0.61	5e-27	Breast cancer;
KIRP	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.62	-6.76	-0.4	1.01e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6540559	0.673	rs17015309	chr1:210007218	C/T	cg22029157	chr1:209979665	IRF6	0.5	5.19	0.31	4.5e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs11718455	0.629	rs4082418	chr3:43908243	C/T	cg08738300	chr3:44038990	NA	-0.46	-6.32	-0.37	1.25e-9	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.54	-0.33	7.66e-8	Menarche (age at onset);
KIRP	cis	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg12315302	chr6:26189340	HIST1H4D	0.79	5.53	0.33	8.37e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01985106	chr4:155469629	PLRG1	0.4	6.12	0.36	3.66e-9	C-reactive protein;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg05315796	chr3:52349193	DNAH1	0.45	6.95	0.41	3.3e-11	Bipolar disorder;
KIRP	cis	rs8014252	0.708	rs8010473	chr14:70988993	G/C	cg11204974	chr14:71022665	NA	-0.61	-6.5	-0.38	4.31e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16524936	chr4:1340807	KIAA1530	-0.41	-5.2	-0.31	4.24e-7	Longevity;
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.57	7.74	0.44	2.63e-13	Menarche (age at onset);
KIRP	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg02367723	chr1:46378857	MAST2	0.42	4.9	0.3	1.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.61	7.68	0.44	3.76e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg01629716	chr15:45996671	NA	0.37	6.6	0.39	2.48e-10	Waist circumference;Weight;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04212229	chr3:148460131	AGTR1	-0.42	-6.2	-0.37	2.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9815354	0.812	rs17280952	chr3:41810834	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.48	1.32e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.41	-4.92	-0.3	1.6e-6	Coronary artery disease;
KIRP	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.62	-6.37	-0.38	9.05e-10	White matter integrity;
KIRP	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg13444842	chr1:152974279	SPRR3	-0.45	-6.17	-0.37	2.77e-9	Inflammatory skin disease;
KIRP	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.67	7.11	0.41	1.23e-11	Lymphocyte counts;
KIRP	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg20578329	chr17:80767326	TBCD	-0.91	-8.94	-0.5	9.32e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23308107	chr11:47429939	SLC39A13	0.52	6.56	0.39	3.13e-10	Parkinson's disease;
KIRP	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg06365898	chr1:16533907	ARHGEF19	0.51	7.17	0.42	8.7e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg17764715	chr19:33622953	WDR88	0.79	11.52	0.59	7.41e-25	Bone properties (heel);
KIRP	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs7751419	0.527	rs4714216	chr6:39106207	G/A	cg25014318	chr6:39016776	GLP1R	0.34	5.19	0.31	4.41e-7	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.77	-0.35	2.32e-8	Height;
KIRP	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	cis	rs11650494	0.710	rs73987294	chr17:47474730	T/C	cg08112188	chr17:47440006	ZNF652	1.11	7.26	0.42	5.04e-12	Prostate cancer;
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg02804510	chr19:49199965	FUT2	0.35	5.12	0.31	6.27e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs4774830	0.744	rs62046381	chr15:56300281	T/G	cg24530489	chr15:56299380	NA	-0.81	-5.48	-0.33	1.03e-7	Delta-5 desaturase activity;
KIRP	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg13939156	chr17:80058883	NA	-0.49	-5.73	-0.34	2.93e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2671245	0.933	rs1877717	chr1:56162495	C/G	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10949834	0.817	rs6460071	chr7:73497196	G/A	cg07137043	chr7:73588983	EIF4H	-0.6	-5.0	-0.3	1.08e-6	Verbal memory performance (residualized delayed recall change);
KIRP	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg17376030	chr22:41985996	PMM1	-0.77	-8.15	-0.46	1.81e-14	Vitiligo;
KIRP	cis	rs11834862	0.765	rs10794456	chr12:132685285	G/A	cg05229598	chr12:132699923	GALNT9	-0.56	-5.86	-0.35	1.5e-8	Anti-saccade response;
KIRP	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg23594656	chr7:65796392	TPST1	-0.37	-5.35	-0.32	2.05e-7	Aortic root size;
KIRP	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg19554555	chr3:13937349	NA	-0.46	-6.21	-0.37	2.23e-9	Ovarian reserve;
KIRP	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg05315796	chr3:52349193	DNAH1	0.41	6.45	0.38	5.96e-10	Electroencephalogram traits;
KIRP	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	6.2	0.37	2.41e-9	Putamen volume;
KIRP	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg13880726	chr7:1868755	MAD1L1	0.49	5.49	0.33	1.01e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4671458	0.846	rs12472865	chr2:63771769	C/T	cg17519650	chr2:63277830	OTX1	-0.51	-5.14	-0.31	5.6e-7	Subjective well-being;
KIRP	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg14952266	chr13:112191215	NA	0.37	4.95	0.3	1.36e-6	Hepatitis;
KIRP	cis	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg21546286	chr11:48923668	NA	-0.48	-6.11	-0.36	3.83e-9	HDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15199800	chr15:44069791	ELL3	-0.48	-6.28	-0.37	1.54e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg07884673	chr3:53033167	SFMBT1	0.81	6.38	0.38	8.86e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg08931102	chr16:67261071	TMEM208;LRRC29	-0.43	-6.06	-0.36	4.95e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs4073221	0.789	rs35171423	chr3:18217771	T/C	cg07694806	chr3:18168406	NA	-0.72	-6.29	-0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs2970992	0.764	rs4850949	chr2:101324382	A/T	cg01042948	chr2:101319752	NA	-0.47	-7.34	-0.42	3.18e-12	Educational attainment;
KIRP	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg10223061	chr2:219282414	VIL1	-0.4	-6.15	-0.37	3.03e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg00405596	chr8:11794950	NA	0.51	6.51	0.38	4.21e-10	Retinal vascular caliber;
KIRP	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg06115741	chr20:33292138	TP53INP2	-0.37	-5.0	-0.3	1.08e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs2019216	0.967	rs7214686	chr17:21955349	T/G	cg22648282	chr17:21454238	C17orf51	-0.36	-4.9	-0.3	1.77e-6	Pelvic organ prolapse;
KIRP	cis	rs4728302	0.630	rs7793739	chr7:133582973	G/T	cg10665199	chr7:133106180	EXOC4	0.43	5.0	0.3	1.1e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.67	8.28	0.47	7.88e-15	Blood metabolite levels;
KIRP	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.84	12.68	0.63	1.09e-28	Height;
KIRP	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	1.13	17.63	0.75	1.61e-45	Monocyte percentage of white cells;
KIRP	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg23411274	chr6:26421120	BTN2A3	-0.31	-4.88	-0.3	1.88e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4959799	0.557	rs6901656	chr6:3273988	T/C	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.26	-0.32	3.11e-7	Survival in rectal cancer;
KIRP	cis	rs9290877	0.667	rs9821679	chr3:188463443	T/C	cg17392043	chr3:188495102	LPP	-0.54	-6.95	-0.41	3.22e-11	IgE levels;
KIRP	cis	rs2712184	0.721	rs2541401	chr2:217641006	T/C	cg05032264	chr2:217675019	NA	-0.42	-5.86	-0.35	1.46e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.91	15.39	0.7	6.83e-38	Headache;
KIRP	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg06565975	chr8:143823917	SLURP1	0.47	7.4	0.43	2.1e-12	Urinary tract infection frequency;
KIRP	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg05304507	chr6:116381966	FRK	0.22	5.96	0.36	8.61e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8177876	0.822	rs56198248	chr16:81108474	G/A	cg08591886	chr16:81111003	C16orf46	-0.72	-5.34	-0.32	2.15e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4776059	1.000	rs12915981	chr15:52901433	C/T	cg25063058	chr15:52860530	ARPP19	0.6	6.56	0.39	3.15e-10	Schizophrenia;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg08805041	chr16:621841	PIGQ	-0.36	-4.99	-0.3	1.12e-6	Height;
KIRP	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	1.04	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.8	11.17	0.58	1.09e-23	Aortic root size;
KIRP	cis	rs4664293	0.934	rs1365800	chr2:160555623	A/C	cg08347373	chr2:160653686	CD302	-0.42	-6.07	-0.36	4.73e-9	Monocyte percentage of white cells;
KIRP	cis	rs8018808	0.935	rs4223	chr14:77893276	A/G	cg20045696	chr14:77926864	AHSA1	-0.45	-5.4	-0.33	1.55e-7	Myeloid white cell count;
KIRP	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Colorectal cancer;
KIRP	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.67	-10.17	-0.54	1.61e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs78487399	0.908	rs55855805	chr2:43808490	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.7	-0.34	3.42e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13152856	chr4:38691626	KLF3	0.45	6.06	0.36	4.96e-9	Interleukin-4 levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02112027	chr8:82373819	FABP9	-0.43	-6.47	-0.38	5.23e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.46	7.76	0.44	2.21e-13	Erythrocyte sedimentation rate;
KIRP	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.05	-18.0	-0.75	9.04e-47	Multiple system atrophy;
KIRP	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-9.28	-0.51	9.09e-18	Electrocardiographic conduction measures;
KIRP	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg23752985	chr2:85803571	VAMP8	0.56	8.12	0.46	2.27e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg22284058	chr8:142237359	SLC45A4	-0.42	-5.2	-0.31	4.22e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs7147624	0.683	rs8017258	chr14:66231017	C/G	cg03016385	chr14:66212404	NA	0.84	7.85	0.45	1.26e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.59	-8.01	-0.45	4.65e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg13319975	chr6:146136371	FBXO30	0.57	6.57	0.39	2.99e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7656342	0.636	rs10012880	chr4:9835480	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-4.88	-0.3	1.89e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.47	-5.36	-0.32	1.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg07116693	chr15:90310901	NA	-0.23	-5.03	-0.31	9.63e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs220519	0.745	rs120520	chr20:37273572	T/C	cg24308336	chr20:37270989	C20orf95	0.24	5.36	0.32	1.96e-7	Schizophrenia;
KIRP	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.03	-0.61	1.64e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4236601	0.720	rs28587043	chr7:116145696	G/A	cg05166801	chr7:116143459	CAV2	0.49	5.9	0.35	1.2e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03041700	chr1:1407645	ATAD3B	0.5	6.66	0.39	1.83e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs73198271	0.562	rs112717383	chr8:8663216	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.18	-0.31	4.53e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.81	7.83	0.45	1.41e-13	Eosinophil percentage of granulocytes;
KIRP	trans	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg00405596	chr8:11794950	NA	-0.47	-6.04	-0.36	5.66e-9	Mood instability;
KIRP	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.42	-5.2	-0.31	4.16e-7	IgG glycosylation;
KIRP	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg27494647	chr7:150038898	RARRES2	0.39	5.88	0.35	1.32e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7187994	0.848	rs34457873	chr16:84782871	T/G	cg07647771	chr16:84786436	USP10	-0.37	-5.22	-0.32	3.74e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.62	-0.48	8.21e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6752107	0.503	rs12997325	chr2:234237387	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	7.05	0.41	1.76e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.62	9.06	0.5	4.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg23950597	chr19:37808831	NA	0.55	5.92	0.35	1.08e-8	Coronary artery calcification;
KIRP	trans	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg02002194	chr4:3960332	NA	-0.45	-6.09	-0.36	4.33e-9	Parkinson's disease;
KIRP	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.83	-13.32	-0.65	7.72e-31	Blood metabolite levels;
KIRP	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	0.79	8.68	0.48	5.59e-16	Gut microbiome composition (summer);
KIRP	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg08738300	chr3:44038990	NA	0.67	9.32	0.51	6.95e-18	Coronary artery disease;
KIRP	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.47	5.9	0.35	1.21e-8	Radiation response;
KIRP	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.43	0.52	3.25e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2562456	0.833	rs2562416	chr19:21613411	A/G	cg00806126	chr19:22604979	ZNF98	-0.61	-5.67	-0.34	3.95e-8	Pain;
KIRP	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-4.86	-0.3	2.12e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg15534755	chr11:117069859	TAGLN	0.4	5.11	0.31	6.39e-7	Blood protein levels;
KIRP	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.52	-6.42	-0.38	6.87e-10	Coronary artery disease;
KIRP	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg27205649	chr11:78285834	NARS2	0.69	9.19	0.51	1.7e-17	Alzheimer's disease (survival time);
KIRP	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg15764593	chr10:829463	NA	-0.8	-8.39	-0.47	3.95e-15	Uric acid levels;
KIRP	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.95	0.45	6.67e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.8	-10.94	-0.57	5.88e-23	Calcium levels;
KIRP	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.95	0.3	1.4e-6	Bipolar disorder;
KIRP	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.57	0.39	2.99e-10	Lung cancer;
KIRP	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg03388025	chr16:89894329	SPIRE2	-0.31	-5.78	-0.35	2.24e-8	Vitiligo;
KIRP	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg15893493	chr8:124194847	FAM83A	0.87	7.64	0.44	4.81e-13	Urinary uromodulin levels;
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg21285383	chr16:89894308	SPIRE2	0.31	5.83	0.35	1.69e-8	Vitiligo;
KIRP	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg01879757	chr17:41196368	BRCA1	0.62	8.44	0.47	2.68e-15	Menopause (age at onset);
KIRP	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.72	-0.63	8.2e-29	Primary sclerosing cholangitis;
KIRP	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.8	10.16	0.54	1.76e-20	Breast cancer;
KIRP	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.38	-5.03	-0.31	9.26e-7	Electroencephalogram traits;
KIRP	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs6700559	0.565	rs2809341	chr1:200597688	A/G	cg07804481	chr1:200639085	DDX59	-0.46	-5.88	-0.35	1.31e-8	Coronary artery disease;
KIRP	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg13160058	chr8:26243215	BNIP3L	-0.47	-7.02	-0.41	2.15e-11	Red cell distribution width;
KIRP	cis	rs2380205	0.967	rs2203197	chr10:5904918	A/G	cg27141509	chr10:5886111	NA	0.37	5.37	0.32	1.81e-7	Breast cancer;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg25263898	chr1:36774223	C1orf113	0.46	7.27	0.42	4.87e-12	Serum protein levels (sST2);
KIRP	trans	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.1	-0.36	4e-9	Neuroticism;
KIRP	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.57	0.59	5.07e-25	Menarche (age at onset);
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.36	0.32	1.95e-7	Lung cancer;
KIRP	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg06988349	chr10:69991859	ATOH7	0.37	4.88	0.3	1.89e-6	Optic disc area;
KIRP	cis	rs7737355	1.000	rs248652	chr5:130654837	A/T	cg06647332	chr5:131281008	NA	-0.46	-5.11	-0.31	6.57e-7	Life satisfaction;
KIRP	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg07636037	chr3:49044803	WDR6	-0.74	-5.59	-0.34	6.11e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.66	9.07	0.5	3.86e-17	Mosquito bite size;
KIRP	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.81	12.22	0.61	3.65e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.31	-0.37	1.28e-9	Aortic root size;
KIRP	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.51	-6.09	-0.36	4.37e-9	Longevity;
KIRP	cis	rs10518128	1.000	rs10011647	chr4:75711216	A/G	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	trans	rs6601327	0.670	rs9987266	chr8:9659346	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.87	-0.4	5.12e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4006360	0.553	rs71383383	chr17:39318172	T/A	cg15015397	chr17:39261100	KRTAP4-9	0.36	5.06	0.31	8.03e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6545883	0.929	rs10173974	chr2:61748900	C/G	cg15711740	chr2:61764176	XPO1	-0.57	-7.78	-0.44	1.98e-13	Tuberculosis;
KIRP	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.47	-5.83	-0.35	1.7e-8	Asthma;
KIRP	cis	rs753955	0.592	rs7325382	chr13:24350093	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.45	-5.93	-0.35	1e-8	Lung cancer;
KIRP	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.34	-0.32	2.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.69	10.5	0.56	1.47e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg05628496	chr17:17991167	DRG2	0.65	6.12	0.36	3.6e-9	Lung function (FEV1);
KIRP	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.64	-9.37	-0.51	5.01e-18	Brugada syndrome;
KIRP	trans	rs2859741	0.647	rs548661	chr1:37479392	T/G	cg04172795	chr14:100578523	EVL	-0.45	-6.33	-0.37	1.17e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg20542592	chr8:11973495	FAM66D	-0.38	-4.95	-0.3	1.39e-6	Retinal vascular caliber;
KIRP	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.48	-5.65	-0.34	4.42e-8	Uric acid clearance;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg03585969	chr10:35415529	CREM	0.81	9.8	0.53	2.35e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.24	-0.32	3.44e-7	Fear of minor pain;
KIRP	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg14593290	chr7:50529359	DDC	0.44	5.63	0.34	4.79e-8	Malaria;
KIRP	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg23335576	chr14:104009727	NA	0.4	5.47	0.33	1.11e-7	Body mass index;
KIRP	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.08	-0.41	1.54e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg05669848	chr5:237993	SDHA	-0.5	-5.18	-0.31	4.64e-7	Breast cancer;
KIRP	trans	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.75	-0.4	1.03e-10	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03909902	chr12:108154529	PRDM4	-0.44	-6.15	-0.37	3.09e-9	Metabolic traits;
KIRP	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	13.93	0.66	6.56e-33	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12807537	chr10:80827367	ZMIZ1;LOC283050	0.49	6.09	0.36	4.42e-9	Parkinson's disease;
KIRP	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.58	5.34	0.32	2.08e-7	Alzheimer's disease;
KIRP	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.56	-7.68	-0.44	3.84e-13	Type 2 diabetes;
KIRP	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.55	-7.28	-0.42	4.45e-12	IgG glycosylation;
KIRP	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.45e-9	Type 2 diabetes;
KIRP	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.67	9.15	0.5	2.27e-17	Caffeine consumption;
KIRP	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg06636001	chr8:8085503	FLJ10661	0.53	5.64	0.34	4.56e-8	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.6	-5.48	-0.33	1.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg26850624	chr5:429559	AHRR	0.33	5.98	0.36	7.84e-9	Cystic fibrosis severity;
KIRP	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.82	-9.41	-0.51	3.79e-18	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23161317	chr6:28129485	ZNF389	0.48	5.57	0.33	6.55e-8	Depression;
KIRP	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg15764593	chr10:829463	NA	-0.83	-8.94	-0.5	9.56e-17	Uric acid levels;
KIRP	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-0.39	-4.88	-0.3	1.91e-6	Type 2 diabetes;
KIRP	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.46	6.9	0.4	4.35e-11	Tuberculosis;
KIRP	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.95	12.04	0.61	1.46e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.36	-4.96	-0.3	1.34e-6	Neuroticism;
KIRP	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg16898833	chr6:26189333	HIST1H4D	0.66	5.01	0.3	1.05e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.74	9.43	0.52	3.17e-18	Response to antipsychotic treatment;
KIRP	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg27144592	chr16:783916	NARFL	0.38	5.23	0.32	3.67e-7	Height;
KIRP	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg23188430	chr6:125850052	NA	0.34	5.51	0.33	9.25e-8	Brugada syndrome;
KIRP	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.59	-6.69	-0.39	1.49e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.85	5.08	0.31	7.48e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2415984	0.622	rs2123126	chr14:46926609	C/T	cg14871534	chr14:47121158	RPL10L	-0.44	-5.28	-0.32	2.79e-7	Number of children ever born;
KIRP	cis	rs9309473	0.519	rs4852950	chr2:73864670	C/T	cg20560298	chr2:73613845	ALMS1	0.48	5.94	0.35	9.81e-9	Metabolite levels;
KIRP	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14893161	chr1:205819251	PM20D1	-0.58	-5.68	-0.34	3.86e-8	Menarche (age at onset);
KIRP	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg16141378	chr3:129829833	LOC729375	-0.49	-6.67	-0.39	1.68e-10	Neuroticism;
KIRP	cis	rs31771	0.526	rs11134409	chr5:165514142	T/C	cg13976338	chr5:165423657	NA	0.45	4.92	0.3	1.57e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.58	-4.97	-0.3	1.25e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs4356932	0.967	rs10856873	chr4:76972924	T/G	cg19388996	chr4:76862389	NAAA	0.4	5.11	0.31	6.53e-7	Blood protein levels;
KIRP	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.53	-6.15	-0.37	3.03e-9	Aortic root size;
KIRP	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.61	5.25	0.32	3.22e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg19610905	chr11:61596333	FADS2	-0.56	-8.05	-0.46	3.55e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.68	9.46	0.52	2.6e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6504622	0.967	rs9889762	chr17:45026366	C/T	cg24703533	chr17:45055318	NA	0.36	5.07	0.31	7.88e-7	Orofacial clefts;
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.09	-0.31	7.28e-7	Lung cancer;
KIRP	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.82	-0.35	1.84e-8	Life satisfaction;
KIRP	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg23601095	chr6:26197514	HIST1H3D	0.84	5.54	0.33	7.75e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg08871354	chr16:85723489	GINS2	-0.45	-4.9	-0.3	1.77e-6	Platelet distribution width;
KIRP	trans	rs2221894	0.959	rs6558089	chr8:28894237	C/T	cg22714290	chr1:207992548	LOC148696	-0.49	-6.08	-0.36	4.52e-9	Obesity-related traits;
KIRP	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.68	-7.09	-0.41	1.45e-11	Gut microbiome composition (summer);
KIRP	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg01320579	chr17:75405842	SEPT9	0.46	7.3	0.42	3.92e-12	Airflow obstruction;
KIRP	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	1.18	10.27	0.55	7.75e-21	Skin colour saturation;
KIRP	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.88	0.35	1.3e-8	Total cholesterol levels;
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg00684032	chr4:1343700	KIAA1530	0.44	5.53	0.33	8.19e-8	Longevity;
KIRP	cis	rs9815354	1.000	rs76471037	chr3:41799414	T/C	cg03022575	chr3:42003672	ULK4	0.53	5.97	0.36	8.08e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10267417	0.535	rs10281472	chr7:19915443	A/G	cg05791153	chr7:19748676	TWISTNB	0.54	5.08	0.31	7.58e-7	Night sleep phenotypes;
KIRP	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.75	7.56	0.43	8.2e-13	Bipolar disorder;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg25571184	chr12:58166309	METTL1;FAM119B	0.51	6.33	0.37	1.13e-9	DNA methylation (variation);
KIRP	cis	rs6142102	0.625	rs6142062	chr20:32548512	C/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs2692947	0.759	rs2949885	chr2:96662415	A/G	cg23100626	chr2:96804247	ASTL	0.42	5.72	0.34	3.06e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.07	0.46	3.16e-14	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23847162	chr6:15663024	DTNBP1	0.51	6.19	0.37	2.43e-9	Parkinson's disease;
KIRP	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg04287289	chr16:89883240	FANCA	0.54	6.73	0.39	1.17e-10	Vitiligo;
KIRP	cis	rs9533799	1.000	rs9533799	chr13:44808174	C/A	cg19190762	chr13:44806055	NA	0.61	8.15	0.46	1.81e-14	Amyotrophic lateral sclerosis;
KIRP	cis	rs714515	0.586	rs10911792	chr1:172451378	G/C	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.66	-7.73	-0.44	2.7e-13	Menopause (age at onset);
KIRP	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.83	9.78	0.53	2.8e-19	Post bronchodilator FEV1;
KIRP	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.68	-9.2	-0.51	1.59e-17	Huntington's disease progression;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07435269	chr16:427561	TMEM8A	0.52	6.34	0.37	1.08e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1390897	0.589	rs1580454	chr16:77114499	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.45	-5.25	-0.32	3.25e-7	beta-nerve growth factor levels;
KIRP	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg05347473	chr6:146136440	FBXO30	0.46	6.69	0.39	1.47e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.59	-0.68	3.79e-35	Primary sclerosing cholangitis;
KIRP	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg08847533	chr14:75593920	NEK9	0.51	6.08	0.36	4.5e-9	IgG glycosylation;
KIRP	cis	rs2108622	0.527	rs67617968	chr19:15977565	A/G	cg00230586	chr19:16013833	NA	-0.4	-5.1	-0.31	6.89e-7	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
KIRP	cis	rs4233802	1.000	rs11895581	chr2:151125904	A/G	cg25300694	chr2:151184358	NA	0.87	6.83	0.4	6.59e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs904092	0.638	rs6830685	chr4:100143184	G/A	cg12011299	chr4:100065546	ADH4	-0.48	-5.19	-0.31	4.36e-7	Alcohol dependence;
KIRP	cis	rs13406665	1	rs13406665	chr2:30498653	G/A	cg05247661	chr2:30472410	LBH	0.66	5.39	0.32	1.67e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg25902810	chr10:99078978	FRAT1	0.58	7.14	0.41	1.07e-11	Monocyte count;
KIRP	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	20.05	0.79	1.15e-53	Prudent dietary pattern;
KIRP	cis	rs11671005	0.779	rs3794971	chr19:58985866	T/C	cg13877915	chr19:58951672	ZNF132	0.56	5.11	0.31	6.42e-7	Mean platelet volume;
KIRP	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg20302533	chr7:39170763	POU6F2	0.26	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.61	-7.14	-0.41	1.04e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.33	0.42	3.31e-12	IgG glycosylation;
KIRP	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.67	-8.25	-0.47	9.37e-15	Iron status biomarkers;
KIRP	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg17595323	chr11:93583763	C11orf90	-0.39	-6.52	-0.38	3.98e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg00310523	chr12:86230176	RASSF9	0.4	6.17	0.37	2.72e-9	Major depressive disorder;
KIRP	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg00405596	chr8:11794950	NA	0.45	5.62	0.34	5.03e-8	Retinal vascular caliber;
KIRP	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.4	-0.43	2.11e-12	Type 2 diabetes;
KIRP	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.33	5.42	0.33	1.45e-7	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.78	9.76	0.53	3.22e-19	Mean platelet volume;
KIRP	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.48	-0.33	1.04e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs34421088	0.560	rs11780851	chr8:11401116	G/A	cg16141378	chr3:129829833	LOC729375	0.65	8.28	0.47	8.04e-15	Neuroticism;
KIRP	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.75	10.63	0.56	5.96e-22	Colorectal cancer;
KIRP	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-16.66	-0.73	3.11e-42	Height;
KIRP	cis	rs240764	0.817	rs6922219	chr6:101153907	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-5.1	-0.31	6.94e-7	Neuroticism;
KIRP	cis	rs9308731	0.505	rs10169613	chr2:111934977	C/T	cg04202892	chr2:111875749	ACOXL	0.48	6.75	0.4	1.05e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.84	-12.84	-0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1864585	0.520	rs78050613	chr8:10657451	G/A	cg26278703	chr11:58910052	FAM111A	0.65	6.49	0.38	4.75e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04303024	chr17:73781011	UNK	0.48	6.1	0.36	4.1e-9	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05638359	chr1:190444387	FAM5C	0.44	6.32	0.37	1.19e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg21827317	chr3:136751795	NA	0.38	5.42	0.33	1.42e-7	Gestational age at birth (child effect);
KIRP	cis	rs17428704	0.571	rs60892841	chr5:14373899	G/A	cg26595256	chr5:14380529	TRIO	-0.85	-6.45	-0.38	5.78e-10	Electroencephalogram traits;
KIRP	cis	rs72772090	0.908	rs6864233	chr5:96044681	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.51	5.07	0.31	7.89e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg13072238	chr3:49761600	GMPPB	0.62	5.3	0.32	2.59e-7	Menarche (age at onset);
KIRP	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg02138098	chr1:2040968	PRKCZ	-0.44	-5.99	-0.36	7.23e-9	Height;
KIRP	cis	rs7799006	0.789	rs4719468	chr7:2285019	G/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-5.13	-0.31	5.78e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs258892	1.000	rs26576	chr5:72298256	A/C	cg21869765	chr5:72125136	TNPO1	-0.51	-6.22	-0.37	2.15e-9	Small cell lung carcinoma;
KIRP	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg11150807	chr10:43354902	NA	0.7	7.88	0.45	1.03e-13	Blood protein levels;
KIRP	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.88	0.49	1.46e-16	Bipolar disorder;
KIRP	cis	rs16912285	0.535	rs7109619	chr11:24251339	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	9.88	0.53	1.3e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg00800038	chr16:89945340	TCF25	-0.78	-5.25	-0.32	3.26e-7	Skin colour saturation;
KIRP	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.81	6.52	0.38	4.06e-10	Initial pursuit acceleration;
KIRP	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.76	-0.34	2.46e-8	Parkinson's disease;
KIRP	cis	rs2299587	0.521	rs3739406	chr8:17739538	T/C	cg01800426	chr8:17659068	MTUS1	-0.43	-5.3	-0.32	2.58e-7	Economic and political preferences;
KIRP	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg11752769	chr1:207818423	CR1L	-0.77	-5.0	-0.3	1.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs1832871	0.711	rs76962726	chr6:158674041	C/T	cg07215822	chr6:158701037	NA	-0.65	-7.63	-0.44	5.15e-13	Height;
KIRP	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg00147788	chr6:125855365	NA	-0.31	-4.87	-0.3	2.01e-6	Brugada syndrome;
KIRP	cis	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg07460842	chr6:66804631	NA	0.48	5.76	0.34	2.5e-8	Metabolite levels;
KIRP	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.46	-4.89	-0.3	1.8e-6	Platelet distribution width;
KIRP	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	7.43	0.43	1.74e-12	Schizophrenia;
KIRP	cis	rs6977660	0.714	rs6959039	chr7:19818182	T/C	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	trans	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg00938859	chr5:1591904	SDHAP3	-0.62	-8.44	-0.47	2.84e-15	Breast cancer;
KIRP	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.97	-14.12	-0.67	1.53e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg22117172	chr7:91764530	CYP51A1	-0.37	-5.07	-0.31	7.7e-7	Breast cancer;
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg21523564	chr15:75251491	NA	0.4	6.51	0.38	4.26e-10	Breast cancer;
KIRP	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg08499158	chr17:42289980	UBTF	-0.72	-10.06	-0.54	3.68e-20	Total body bone mineral density;
KIRP	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.67	5.54	0.33	7.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.32	-0.32	2.34e-7	Coronary artery disease;
KIRP	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.73	9.24	0.51	1.18e-17	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.21	0.37	2.22e-9	Aortic root size;
KIRP	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg26207909	chr14:103986467	CKB	-0.51	-6.55	-0.39	3.26e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	16.31	0.72	4.92e-41	Platelet count;
KIRP	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg12311346	chr5:56204834	C5orf35	-0.37	-4.99	-0.3	1.14e-6	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.69	-5.87	-0.35	1.38e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.83	0.4	6.49e-11	Electroencephalogram traits;
KIRP	cis	rs828999	0.583	rs10494090	chr1:108693336	A/G	cg06207961	chr1:108661230	NA	0.43	6.35	0.38	1e-9	Monocyte percentage of white cells;
KIRP	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.75	12.41	0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.43	5.66	0.34	4.11e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7560272	0.538	rs13014700	chr2:73920121	C/G	cg20560298	chr2:73613845	ALMS1	0.51	6.17	0.37	2.82e-9	Schizophrenia;
KIRP	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg15839431	chr19:19639596	YJEFN3	-0.5	-5.31	-0.32	2.47e-7	Bipolar disorder;
KIRP	cis	rs757081	0.671	rs214070	chr11:17305317	T/A	cg15432903	chr11:17409602	KCNJ11	-0.64	-7.46	-0.43	1.48e-12	Systolic blood pressure;
KIRP	trans	rs13019227	0.658	rs1432242	chr2:137769840	A/G	cg12599275	chr1:3011274	PRDM16	0.78	6.29	0.37	1.41e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg16899367	chr7:73097788	WBSCR22;DNAJC30	-1.21	-6.83	-0.4	6.67e-11	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	0.9	14.42	0.68	1.39e-34	Ewing sarcoma;
KIRP	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg14132834	chr19:41945861	ATP5SL	-0.56	-7.29	-0.42	4.32e-12	Height;
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.49	-0.52	2.13e-18	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26671687	chr1:54872113	SSBP3	0.49	6.2	0.37	2.39e-9	Parkinson's disease;
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.73	8.7	0.48	4.96e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs787274	0.867	rs786977	chr9:115459708	A/G	cg13803584	chr9:115635662	SNX30	0.6	6.19	0.37	2.51e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.63	6.7	0.39	1.4e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.19	-0.51	1.69e-17	Platelet count;
KIRP	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg11498726	chr8:26250323	BNIP3L	-0.57	-8.28	-0.47	7.76e-15	Red cell distribution width;
KIRP	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.5	6.45	0.38	5.9e-10	Age at first birth;
KIRP	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg17691542	chr6:26056736	HIST1H1C	0.41	5.6	0.34	5.73e-8	Schizophrenia;
KIRP	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19717773	chr7:2847554	GNA12	-0.43	-6.47	-0.38	5.16e-10	Height;
KIRP	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg00631329	chr6:26305371	NA	-0.69	-8.42	-0.47	3.05e-15	Educational attainment;
KIRP	cis	rs1823913	0.503	rs6706578	chr2:192211718	A/G	cg12404831	chr2:192114017	MYO1B	0.48	6.25	0.37	1.75e-9	Obesity-related traits;
KIRP	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.43	-0.52	3.3e-18	Coronary artery disease;
KIRP	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.7	-9.2	-0.51	1.58e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg08901578	chr4:187885870	NA	0.47	7.03	0.41	2.04e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg02534363	chr3:47050950	NBEAL2	-0.29	-5.0	-0.3	1.11e-6	Colorectal cancer;
KIRP	cis	rs712039	0.617	rs853201	chr17:35804187	C/A	cg16670864	chr17:35848621	DUSP14	0.44	5.14	0.31	5.69e-7	Tuberculosis;
KIRP	cis	rs11676348	0.772	rs10932745	chr2:218942976	T/C	cg00012203	chr2:219082015	ARPC2	-0.41	-5.07	-0.31	7.9e-7	Ulcerative colitis;
KIRP	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg11153868	chr12:69751374	NA	0.41	5.25	0.32	3.31e-7	Response to diuretic therapy;
KIRP	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	10.8	0.57	1.65e-22	Total body bone mineral density;
KIRP	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs10929159	0.928	rs2123513	chr2:236920638	T/C	cg20128773	chr2:236923534	AGAP1	0.3	5.15	0.31	5.25e-7	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22193146	chr19:45681580	BLOC1S3;TRAPPC6A	0.49	6.28	0.37	1.56e-9	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.28e-8	Pubertal anthropometrics;
KIRP	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.97	0.3	1.23e-6	Educational attainment;
KIRP	cis	rs8113308	0.810	rs55810059	chr19:52450728	G/A	cg24732339	chr19:52471368	ZNF350	-0.45	-5.02	-0.3	9.83e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.34	-0.42	3.07e-12	Aortic root size;
KIRP	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.78	10.02	0.54	4.85e-20	Platelet count;
KIRP	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.33	-0.37	1.13e-9	IgG glycosylation;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23182539	chr10:121355708	TIAL1	0.67	6.22	0.37	2.08e-9	Lung function (FEV1);
KIRP	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg16511985	chr3:153974050	SGEF	0.4	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg08873628	chr1:175162347	KIAA0040	-0.42	-6.08	-0.36	4.51e-9	Alcohol dependence;
KIRP	cis	rs7688540	0.771	rs1986557	chr4:283118	T/C	cg17891759	chr4:299121	NA	-0.44	-5.15	-0.31	5.38e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.7	-0.48	4.97e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg04154034	chr17:28927549	LRRC37B2	0.49	4.95	0.3	1.36e-6	Body mass index;
KIRP	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg12173498	chr6:36355764	ETV7	0.3	4.91	0.3	1.64e-6	Platelet distribution width;
KIRP	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.13e-25	Diabetic kidney disease;
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.49	-0.33	9.9e-8	Lung cancer;
KIRP	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	1.05	18.64	0.77	5.86e-49	Bone mineral density;
KIRP	trans	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg09872104	chr7:134855509	C7orf49	-0.82	-6.04	-0.36	5.59e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg02038168	chr22:39784481	NA	-0.44	-5.22	-0.32	3.73e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg06115741	chr20:33292138	TP53INP2	0.47	6.45	0.38	5.86e-10	Coronary artery disease;
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.52	-6.59	-0.39	2.6e-10	Paraoxonase activity;
KIRP	cis	rs61990749	0.597	rs10148373	chr14:78280199	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.84	7.59	0.44	6.66e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.54	-6.77	-0.4	9.63e-11	Type 2 diabetes;
KIRP	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05010179	chr15:75018495	CYP1A1	0.44	6.04	0.36	5.76e-9	Parkinson's disease;
KIRP	cis	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg19847130	chr8:10466454	RP1L1	-0.43	-6.35	-0.38	1.06e-9	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs2033732	0.673	rs1437510	chr8:85065019	A/G	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg22000725	chr19:8478147	MARCH2	0.6	6.88	0.4	5.06e-11	Electroencephalogram traits;
KIRP	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	8.8	0.49	2.5e-16	Colorectal cancer;
KIRP	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.47	5.98	0.36	7.97e-9	Recombination rate (males);
KIRP	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg23102388	chr7:1867652	MAD1L1	-0.46	-6.27	-0.37	1.64e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03850334	chr11:62341623	EEF1G	-0.56	-6.01	-0.36	6.5e-9	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16550656	chr5:61874017	LRRC70;IPO11	-0.39	-6.06	-0.36	5.12e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg13206674	chr6:150067644	NUP43	0.49	6.88	0.4	4.79e-11	Lung cancer;
KIRP	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.84	0.35	1.65e-8	Aortic root size;
KIRP	cis	rs662064	0.852	rs2056417	chr1:10581658	G/A	cg19773385	chr1:10388646	KIF1B	-0.42	-5.53	-0.33	8.13e-8	Asthma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11487977	chr19:9879695	ZNF846	0.56	6.79	0.4	8.37e-11	Smoking initiation;
KIRP	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg05785598	chr3:49045655	WDR6	0.29	5.26	0.32	3.21e-7	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs918629	0.567	rs1423268	chr5:95256974	T/C	cg16656078	chr5:95278638	ELL2	-0.35	-5.38	-0.32	1.76e-7	IgG glycosylation;
KIRP	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.84	0.4	6.2e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17123764	0.892	rs7967073	chr12:50122208	T/A	cg20471783	chr12:50157085	TMBIM6	0.44	6.04	0.36	5.53e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs785830	0.717	rs602742	chr9:224338	A/T	cg14500300	chr9:211689	NA	0.52	6.92	0.4	3.82e-11	Platelet distribution width;
KIRP	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg24110177	chr3:50126178	RBM5	0.44	5.67	0.34	4.02e-8	Blood protein levels;
KIRP	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.86	-12.1	-0.61	9.72e-27	Cocaine dependence;
KIRP	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.88e-16	Immature fraction of reticulocytes;
KIRP	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg26904215	chr21:47823096	PCNT	-0.83	-5.66	-0.34	4.15e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.38	0.43	2.5e-12	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06440553	chr19:41222923	ADCK4;ITPKC	0.48	6.18	0.37	2.67e-9	Parkinson's disease;
KIRP	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg00990874	chr7:1149470	C7orf50	-0.8	-6.6	-0.39	2.51e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.8	-0.45	1.77e-13	Gut microbiome composition (summer);
KIRP	cis	rs812925	0.515	rs1177308	chr2:61387254	C/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.13	-0.31	5.78e-7	Immature fraction of reticulocytes;
KIRP	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-7.78	-0.44	2.02e-13	Total body bone mineral density;
KIRP	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-0.76	-6.73	-0.39	1.21e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs41005	1.000	rs34505904	chr2:8115159	T/C	cg03155496	chr2:8117019	LOC339788	-0.58	-9.35	-0.51	5.79e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs4363506	0.635	rs11018148	chr10:129283956	C/T	cg07804728	chr10:129284050	NA	0.46	6.17	0.37	2.8e-9	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg14458575	chr2:238380390	NA	0.55	5.76	0.34	2.45e-8	Prostate cancer;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.16	-0.42	9.34e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72829446	0.530	rs12325773	chr17:7393871	G/A	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	5.03	0.31	9.31e-7	Androgen levels;
KIRP	cis	rs6594713	0.717	rs8180416	chr5:112868440	A/G	cg12552261	chr5:112820674	MCC	0.56	5.62	0.34	5.12e-8	Brain cytoarchitecture;
KIRP	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.87	11.65	0.6	2.83e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs263156	0.903	rs263130	chr6:142928295	A/G	cg01789478	chr2:182545485	NEUROD1	0.35	6.05	0.36	5.34e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02651945	chr19:14629212	DNAJB1	0.55	6.99	0.41	2.62e-11	Parkinson's disease;
KIRP	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	cg12689670	chr1:183009347	LAMC1	0.56	7.82	0.45	1.52e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.04	0.36	5.7e-9	Hemoglobin concentration;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-5.6	-0.34	5.71e-8	Lung cancer;
KIRP	trans	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.58	0.39	2.79e-10	Skin colour saturation;
KIRP	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.98	0.41	2.71e-11	Bipolar disorder;
KIRP	cis	rs61935443	0.666	rs73218073	chr12:95314346	A/G	cg21533806	chr12:95267307	NA	0.57	5.22	0.32	3.78e-7	Schizophrenia;
KIRP	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.76	9.78	0.53	2.77e-19	Aortic root size;
KIRP	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	5.44	0.33	1.26e-7	Homoarginine levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg12309176	chr10:88195736	WAPAL	0.41	6.29	0.37	1.43e-9	Migraine with aura;
KIRP	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.67	7.15	0.41	1.01e-11	Vitiligo;
KIRP	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg11846333	chr4:119757529	SEC24D	-0.75	-5.3	-0.32	2.64e-7	Cannabis dependence symptom count;
KIRP	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	-0.66	-8.19	-0.46	1.38e-14	Inflammatory bowel disease;
KIRP	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.99	11.98	0.61	2.4e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10073892	0.743	rs62372221	chr5:101651466	G/A	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg26138937	chr11:71823887	C11orf51	-1.16	-7.55	-0.43	8.52e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs2425143	1.000	rs7273174	chr20:34350306	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.86	-0.3	2.09e-6	Blood protein levels;
KIRP	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-5.45	-0.33	1.24e-7	Total body bone mineral density;
KIRP	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.82	-11.15	-0.58	1.26e-23	Selective IgA deficiency;
KIRP	trans	rs7939886	0.764	rs1552142	chr11:56087538	T/G	cg03929089	chr4:120376271	NA	0.93	6.37	0.38	9.43e-10	Myopia (pathological);
KIRP	cis	rs7215564	0.818	rs4890055	chr17:78587225	A/C	cg06153925	chr17:78755379	RPTOR	0.35	5.44	0.33	1.25e-7	Myopia (pathological);
KIRP	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.71	-13.21	-0.64	1.84e-30	Body mass index;
KIRP	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg00405596	chr8:11794950	NA	0.47	5.85	0.35	1.57e-8	Retinal vascular caliber;
KIRP	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.28	7.47	0.43	1.42e-12	Primary biliary cholangitis;
KIRP	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg22771759	chr13:24902376	NA	0.38	5.05	0.31	8.6e-7	Obesity-related traits;
KIRP	cis	rs7523273	0.565	rs1998538	chr1:207886487	C/T	cg22525895	chr1:207977042	MIR29B2	-0.45	-5.69	-0.34	3.6e-8	Schizophrenia;
KIRP	trans	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg08400319	chr2:242004533	SNED1	0.44	6.04	0.36	5.69e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.69	7.94	0.45	7.27e-14	Smoking initiation;
KIRP	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg08499158	chr17:42289980	UBTF	0.66	8.56	0.48	1.26e-15	Total body bone mineral density;
KIRP	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	0.83	8.89	0.49	1.36e-16	Gut microbiome composition (summer);
KIRP	cis	rs4713675	0.584	rs942643	chr6:33668370	A/G	cg15676125	chr6:33679581	C6orf125	0.41	5.4	0.33	1.57e-7	Plateletcrit;
KIRP	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg26116260	chr4:7069785	GRPEL1	-0.75	-5.34	-0.32	2.07e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6450176	1.000	rs60652351	chr5:53306140	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.26	-0.58	5.29e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.03	0.36	6.1e-9	Retinal vascular caliber;
KIRP	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg16497661	chr14:103986332	CKB	0.82	13.61	0.66	7.83e-32	Bone mineral density;
KIRP	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg08775375	chr8:10454154	NA	0.36	4.97	0.3	1.28e-6	Neuroticism;
KIRP	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg11645453	chr3:52864694	ITIH4	-0.33	-5.07	-0.31	7.79e-7	Body mass index;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09103073	chr17:39019724	KRT12	0.57	6.61	0.39	2.32e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2273669	0.667	rs111523655	chr6:109301664	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg08975724	chr8:8085496	FLJ10661	0.63	7.88	0.45	1.05e-13	Neuroticism;
KIRP	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg15744005	chr10:104629667	AS3MT	-0.38	-7.73	-0.44	2.82e-13	Arsenic metabolism;
KIRP	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg08499158	chr17:42289980	UBTF	-0.51	-6.5	-0.38	4.39e-10	Total body bone mineral density;
KIRP	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.76	-12.59	-0.63	2.24e-28	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06134546	chr15:64753130	NA	0.48	6.56	0.39	3.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17173891	chr6:87967392	ZNF292	0.46	6.42	0.38	6.79e-10	Interleukin-4 levels;
KIRP	trans	rs2997105	0.938	rs2645919	chr13:56416218	C/T	cg08528735	chr3:184428879	MAGEF1	-0.59	-6.03	-0.36	6.02e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg26516362	chr5:178986906	RUFY1	-0.34	-5.74	-0.34	2.74e-8	Lung cancer;
KIRP	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg06060754	chr5:176797920	RGS14	0.48	7.28	0.42	4.44e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg17554472	chr22:41940697	POLR3H	0.58	6.3	0.37	1.36e-9	Vitiligo;
KIRP	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg22089800	chr15:90895588	ZNF774	0.45	5.33	0.32	2.22e-7	Rheumatoid arthritis;
KIRP	cis	rs580438	0.510	rs4684131	chr3:13412657	A/G	cg10657019	chr3:13328039	NA	-0.59	-7.88	-0.45	1.04e-13	Myringotomy;
KIRP	cis	rs7624766	0.555	rs1829716	chr3:160477861	T/C	cg22637730	chr3:160473554	PPM1L	0.44	5.47	0.33	1.13e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.58	7.82	0.45	1.52e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg10189774	chr4:17578691	LAP3	0.51	6.18	0.37	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs113084984	0.718	rs4669744	chr2:11681568	T/C	cg07314298	chr2:11723111	GREB1	0.41	5.37	0.32	1.81e-7	Breast cancer;
KIRP	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg20965017	chr5:231967	SDHA	-0.54	-6.23	-0.37	1.96e-9	Breast cancer;
KIRP	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.37	7.05	0.41	1.81e-11	Alopecia areata;
KIRP	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.48	-6.36	-0.38	9.96e-10	Multiple sclerosis;
KIRP	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.36	-0.62	1.24e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.43	-0.43	1.81e-12	Vitiligo;
KIRP	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.25	0.51	1.1e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg08719095	chr7:1135190	C7orf50	-0.43	-4.95	-0.3	1.37e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs4356975	0.563	rs6600891	chr4:69971596	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-6.05	-0.36	5.38e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg01097406	chr16:89675127	NA	0.39	6.68	0.39	1.56e-10	Hemoglobin concentration;
KIRP	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.66	-9.81	-0.53	2.25e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg13332499	chr17:408570	NA	0.59	8.16	0.46	1.79e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg02733842	chr7:1102375	C7orf50	0.41	4.89	0.3	1.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4919087	0.748	rs701816	chr10:98977250	C/T	cg25902810	chr10:99078978	FRAT1	-0.46	-4.88	-0.3	1.87e-6	Monocyte count;
KIRP	cis	rs2882667	0.824	rs12173085	chr5:138480025	A/G	cg04439458	chr5:138467593	SIL1	-0.48	-7.32	-0.42	3.62e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8133932	0.654	rs7277632	chr21:47327542	A/G	cg11214348	chr21:47283868	PCBP3	0.44	5.11	0.31	6.44e-7	Schizophrenia;
KIRP	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.68	-6.19	-0.37	2.44e-9	Neutrophil percentage of white cells;
KIRP	trans	rs7999699	0.902	rs57427955	chr13:48300525	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	trans	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg13565492	chr6:43139072	SRF	-0.93	-8.53	-0.48	1.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg20243544	chr17:37824526	PNMT	0.49	6.71	0.39	1.37e-10	Asthma;
KIRP	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.17	-0.31	4.91e-7	Breast cancer;
KIRP	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.98	13.94	0.66	6.29e-33	Alcohol dependence;
KIRP	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg12173498	chr6:36355764	ETV7	0.3	4.96	0.3	1.33e-6	Platelet distribution width;
KIRP	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg18164611	chr1:46958628	NA	0.43	5.4	0.33	1.56e-7	Monobrow;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16087541	chr7:115862648	TES	0.41	6.18	0.37	2.68e-9	Survival in pancreatic cancer;
KIRP	cis	rs7937612	1.000	rs6589810	chr11:120233908	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.04	-0.41	1.85e-11	Intraocular pressure;
KIRP	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.21	-0.67	7.22e-34	Alzheimer's disease;
KIRP	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.02	-0.41	2.15e-11	Type 2 diabetes;
KIRP	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	0.63	6.86	0.4	5.47e-11	Crohn's disease;
KIRP	cis	rs10782582	0.668	rs7516477	chr1:76204502	C/G	cg10523679	chr1:76189770	ACADM	-0.47	-7.11	-0.41	1.26e-11	Daytime sleep phenotypes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22854591	chr10:65220901	JMJD1C	-0.41	-6.34	-0.37	1.07e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg01677386	chr11:118938358	VPS11	-0.55	-6.64	-0.39	2.02e-10	Coronary artery disease;
KIRP	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg11970804	chr8:8084126	NA	-0.37	-4.85	-0.3	2.22e-6	Mood instability;
KIRP	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.55	-7.11	-0.41	1.24e-11	Testicular germ cell tumor;
KIRP	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.19	12.35	0.62	1.35e-27	Alzheimer's disease;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.6	-6.17	-0.37	2.85e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg26207909	chr14:103986467	CKB	-0.44	-5.39	-0.32	1.65e-7	Coronary artery disease;
KIRP	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.83	10.43	0.55	2.53e-21	Gestational age at birth (maternal effect);
KIRP	cis	rs6882076	1.000	rs4704727	chr5:156380067	T/G	cg12943317	chr5:156479607	HAVCR1	-0.54	-6.34	-0.37	1.1e-9	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg16558253	chr16:72132732	DHX38	-0.41	-4.86	-0.3	2.1e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs71597109	0.681	rs17200433	chr4:102722913	A/G	cg14855874	chr4:102712397	BANK1	0.4	5.35	0.32	2e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs9608946	1.000	rs2189835	chr22:30878217	C/A	cg23383138	chr22:30885012	SEC14L4	0.4	4.88	0.3	1.92e-6	Red cell distribution width;
KIRP	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg02175308	chr1:109941060	SORT1	-0.3	-5.69	-0.34	3.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.29	-0.32	2.73e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg04935436	chr20:30431758	NA	0.53	6.52	0.38	4.05e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.85	-10.75	-0.57	2.31e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11874712	0.527	rs9807399	chr18:43640714	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-7.1	-0.41	1.29e-11	Migraine - clinic-based;
KIRP	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.97	11.63	0.6	3.41e-25	Exhaled nitric oxide levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27365485	chr11:64126452	RPS6KA4	0.49	6.18	0.37	2.62e-9	Parkinson's disease;
KIRP	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs6467136	0.782	rs10281944	chr7:127160364	T/C	cg08586737	chr7:127225949	GCC1	-0.39	-5.26	-0.32	3.19e-7	Type 2 diabetes;
KIRP	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.54	-8.59	-0.48	1.04e-15	Longevity;
KIRP	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.71	-7.2	-0.42	7.5e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25204764	chr1:24995933	SRRM1	-0.4	-6.12	-0.36	3.61e-9	Myopia;
KIRP	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.71	-0.39	1.36e-10	Renal cell carcinoma;
KIRP	cis	rs11718455	0.591	rs6765212	chr3:43931484	C/T	cg08738300	chr3:44038990	NA	0.51	6.79	0.4	8.53e-11	Coronary artery disease;
KIRP	trans	rs909341	0.818	rs6122154	chr20:62359345	C/T	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.91	-0.4	4.04e-11	Atopic dermatitis;
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	cis	rs2671245	0.933	rs2767513	chr1:56159043	G/A	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.79	-12.99	-0.64	9.9e-30	Vitiligo;
KIRP	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg06204229	chr3:52865917	ITIH4	0.55	7.66	0.44	4.4e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7523273	0.565	rs2488248	chr1:207899682	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-5.9	-0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.51	-5.04	-0.31	9.07e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg13147721	chr7:65941812	NA	-1.01	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs55692468	0.804	rs10169514	chr2:153327157	A/G	cg04681845	chr2:153283485	FMNL2	-0.47	-5.85	-0.35	1.57e-8	Intraocular pressure;
KIRP	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.44	5.99	0.36	7.25e-9	Optic nerve measurement (cup area);
KIRP	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.54	5.53	0.33	8.2e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.83	-13.42	-0.65	3.65e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs7215564	0.818	rs7214465	chr17:78566792	G/A	cg06153925	chr17:78755379	RPTOR	0.46	5.98	0.36	7.62e-9	Myopia (pathological);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg13038030	chr17:73267041	MIF4GD	-0.57	-7.25	-0.42	5.35e-12	Neuroticism;
KIRP	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.6	-6.58	-0.39	2.89e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.51e-19	Prudent dietary pattern;
KIRP	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.51	-0.33	9.2e-8	Ileal carcinoids;
KIRP	cis	rs6800768	0.633	rs826371	chr3:24163645	C/G	cg10674438	chr3:24145617	LOC152024	-0.47	-6.3	-0.37	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg21361702	chr7:150065534	REPIN1	0.67	6.66	0.39	1.79e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.96	-0.45	6.25e-14	Migraine;Coronary artery disease;
KIRP	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.1e-9	Morning vs. evening chronotype;
KIRP	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs8014252	0.803	rs77359887	chr14:70999238	A/C	cg11204974	chr14:71022665	NA	-0.77	-7.22	-0.42	6.34e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.33	-0.32	2.25e-7	Parkinson's disease;
KIRP	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.8	-11.46	-0.59	1.21e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4638749	0.501	rs2101357	chr2:108748974	G/A	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.07	-0.31	7.95e-7	Blood pressure;
KIRP	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.96	-0.45	6.53e-14	Coffee consumption (cups per day);
KIRP	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.58	-7.76	-0.44	2.21e-13	Total body bone mineral density;
KIRP	cis	rs1440410	0.830	rs985619	chr4:144174576	T/C	cg01719995	chr4:144104893	USP38	0.38	4.93	0.3	1.49e-6	Ischemic stroke;
KIRP	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg24253500	chr15:84953950	NA	0.62	6.56	0.39	3.13e-10	Schizophrenia;
KIRP	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.95	-0.3	1.41e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs6681460	0.966	rs7524851	chr1:67093018	T/C	cg02459107	chr1:67143332	SGIP1	0.49	6.95	0.41	3.21e-11	Presence of antiphospholipid antibodies;
KIRP	trans	rs74233809	0.901	rs4409766	chr10:104616663	A/G	cg26256223	chr8:145106582	OPLAH	-0.44	-6.24	-0.37	1.92e-9	Birth weight;
KIRP	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.41	6.94	0.4	3.42e-11	Heart rate;
KIRP	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg01522456	chr1:115632236	TSPAN2	-0.37	-5.0	-0.3	1.07e-6	Autism;
KIRP	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.47	4.95	0.3	1.36e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.58e-7	Body mass index;
KIRP	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg26134248	chr17:3907702	NA	0.56	8.34	0.47	5.22e-15	Type 2 diabetes;
KIRP	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.79	-9.88	-0.53	1.36e-19	Schizophrenia;
KIRP	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.89	-13.91	-0.66	7.58e-33	Breast cancer;
KIRP	cis	rs77669868	0.929	rs3782002	chr11:114070563	A/T	cg01914181	chr11:114070210	ZBTB16	0.56	6.16	0.37	2.87e-9	Monocyte percentage of white cells;
KIRP	cis	rs17023223	0.537	rs17023171	chr1:119593268	A/C	cg18261050	chr1:119551319	NA	0.54	7.12	0.41	1.19e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.68	10.27	0.55	8.28e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs16958440	0.708	rs62096462	chr18:44625179	C/G	cg17192377	chr18:44677553	HDHD2	0.45	4.92	0.3	1.62e-6	Sitting height ratio;
KIRP	cis	rs7851660	0.844	rs12342417	chr9:100639065	G/A	cg13688889	chr9:100608707	NA	-0.67	-8.74	-0.49	3.63e-16	Strep throat;
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.44	-5.42	-0.33	1.39e-7	Testicular germ cell tumor;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg16265552	chr3:113667068	ZDHHC23	0.68	6.19	0.37	2.53e-9	Lung function (FEV1);
KIRP	cis	rs6540559	0.673	rs11805830	chr1:209984969	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.9	0.35	1.21e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs13082711	0.911	rs74279676	chr3:27512944	G/A	cg02860705	chr3:27208620	NA	0.55	7.65	0.44	4.49e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.39	6.8	0.4	8.02e-11	Renal cell carcinoma;
KIRP	cis	rs6681460	1.000	rs7521123	chr1:67121663	T/C	cg02459107	chr1:67143332	SGIP1	0.49	7.04	0.41	1.94e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9535307	0.719	rs1201716	chr13:50378425	T/G	cg04663916	chr13:50265991	EBPL	-0.56	-6.05	-0.36	5.39e-9	Obesity-related traits;
KIRP	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.49	-6.14	-0.36	3.37e-9	Post bronchodilator FEV1;
KIRP	cis	rs710987	0.967	rs1697996	chr5:3530474	A/G	cg14530963	chr5:3489551	NA	0.41	5.01	0.3	1.05e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs12780845	0.540	rs11254424	chr10:17218554	T/C	cg01003015	chr10:17271136	VIM	-0.4	-4.87	-0.3	1.99e-6	Homocysteine levels;
KIRP	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-1.02	-19.22	-0.77	7.01e-51	Breast cancer;
KIRP	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-1.15	-9.61	-0.52	8.74e-19	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
KIRP	cis	rs7481584	1.000	rs4758623	chr11:3014953	T/C	cg25174290	chr11:3078921	CARS	-0.58	-6.3	-0.37	1.38e-9	Calcium levels;
KIRP	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.16	0.46	1.77e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg05991184	chr2:219186017	PNKD	0.34	4.99	0.3	1.14e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14064774	chr4:48540281	FRYL	-0.42	-6.55	-0.39	3.29e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg12536502	chr19:46142673	MIR330;EML2	0.44	6.02	0.36	6.2e-9	Colorectal cancer;
KIRP	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21545522	chr1:205238299	TMCC2	0.41	5.54	0.33	7.73e-8	Red blood cell count;
KIRP	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	10.12	0.54	2.43e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs240764	0.817	rs240115	chr6:101053069	T/C	cg09795085	chr6:101329169	ASCC3	0.47	5.57	0.33	6.79e-8	Neuroticism;
KIRP	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg13770153	chr20:60521292	NA	-0.42	-4.99	-0.3	1.15e-6	Body mass index;
KIRP	cis	rs12210905	0.688	rs9368509	chr6:27379422	A/G	cg23155468	chr6:27110703	HIST1H2BK	0.78	6.44	0.38	6.19e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg03146154	chr1:46216737	IPP	0.42	5.19	0.31	4.39e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.09	0.46	2.69e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7937612	1.000	rs6589813	chr11:120293490	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.5	-7.57	-0.43	7.35e-13	Intraocular pressure;
KIRP	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg02367723	chr1:46378857	MAST2	0.42	4.86	0.3	2.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.67	9.27	0.51	9.85e-18	Mean corpuscular volume;
KIRP	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.45	6.4	0.38	7.7e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg03209412	chr4:183728196	NA	0.48	6.24	0.37	1.93e-9	Pediatric autoimmune diseases;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg16104446	chr8:48873951	MCM4;PRKDC	0.76	6.54	0.38	3.44e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg18190219	chr22:46762943	CELSR1	-0.75	-7.08	-0.41	1.5e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.69	6.5	0.38	4.32e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.03	12.75	0.63	6.22e-29	IgG glycosylation;
KIRP	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg23752985	chr2:85803571	VAMP8	0.57	8.38	0.47	3.96e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg23387468	chr7:139079360	LUC7L2	-0.29	-5.06	-0.31	8.25e-7	Diisocyanate-induced asthma;
KIRP	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.59	-7.39	-0.43	2.22e-12	Extraversion;
KIRP	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg15691649	chr6:25882328	NA	0.57	6.2	0.37	2.31e-9	Blood metabolite levels;
KIRP	cis	rs4356932	1.000	rs10010920	chr4:76982733	C/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.55	-0.33	7.19e-8	Bronchopulmonary dysplasia;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg04691540	chr1:179198414	ABL2	-0.51	-6.5	-0.38	4.41e-10	Neuroticism;
KIRP	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg17554472	chr22:41940697	POLR3H	0.59	6.23	0.37	1.97e-9	Vitiligo;
KIRP	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	0.81	13.61	0.66	7.98e-32	Prudent dietary pattern;
KIRP	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg19610905	chr11:61596333	FADS2	0.52	7.88	0.45	1.04e-13	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10438487	chr15:99640813	NA	0.49	6.27	0.37	1.63e-9	Myopia (pathological);
KIRP	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2299587	0.585	rs2299590	chr8:17802192	A/C	cg01800426	chr8:17659068	MTUS1	-0.58	-6.89	-0.4	4.77e-11	Economic and political preferences;
KIRP	trans	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg13565492	chr6:43139072	SRF	-0.94	-8.58	-0.48	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.52e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs981844	0.601	rs1337	chr4:154631587	C/G	cg14289246	chr4:154710475	SFRP2	0.59	5.79	0.35	2.16e-8	Response to statins (LDL cholesterol change);
KIRP	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg21132104	chr15:45694354	SPATA5L1	0.75	9.53	0.52	1.62e-18	Homoarginine levels;
KIRP	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg08392591	chr16:89556376	ANKRD11	0.41	5.05	0.31	8.67e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.93	0.49	1.05e-16	Motion sickness;
KIRP	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg03808351	chr9:123631620	PHF19	0.35	4.96	0.3	1.3e-6	Rheumatoid arthritis;
KIRP	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg17366294	chr4:99064904	C4orf37	0.43	6.26	0.37	1.67e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1823913	0.599	rs17511410	chr2:192142769	T/C	cg12404831	chr2:192114017	MYO1B	0.53	7.38	0.43	2.42e-12	Obesity-related traits;
KIRP	cis	rs9393813	0.528	rs6903282	chr6:27466712	A/G	cg03332623	chr6:27441972	ZNF184	-0.35	-5.13	-0.31	5.97e-7	Bipolar disorder;
KIRP	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg15507776	chr3:136538369	TMEM22	0.39	5.18	0.31	4.69e-7	Neuroticism;
KIRP	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6969780	0.908	rs6461987	chr7:27166956	G/C	cg26364809	chr7:27145159	NA	-0.6	-5.27	-0.32	2.95e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg17425144	chr1:10567563	PEX14	-0.32	-5.57	-0.33	6.79e-8	Hepatocellular carcinoma;
KIRP	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg23307798	chr14:103986281	CKB	0.46	6.47	0.38	5.15e-10	Body mass index;
KIRP	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	5.28	0.32	2.88e-7	Renal cell carcinoma;
KIRP	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.79	-6.5	-0.38	4.48e-10	Blood pressure (smoking interaction);
KIRP	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.41e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.65	-8.39	-0.47	3.83e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg23594656	chr7:65796392	TPST1	-0.45	-7.09	-0.41	1.44e-11	Aortic root size;
KIRP	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg18032289	chr17:61959525	GH2	-0.38	-5.0	-0.3	1.08e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.84	-11.79	-0.6	9.73e-26	Systemic lupus erythematosus;
KIRP	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.43	0.55	2.57e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	1.1	8.14	0.46	1.92e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs13343954	0.825	rs11084698	chr19:33534174	A/G	cg17764715	chr19:33622953	WDR88	0.72	8.11	0.46	2.47e-14	Colorectal cancer;
KIRP	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg02002194	chr4:3960332	NA	0.45	6.5	0.38	4.41e-10	Neuroticism;
KIRP	cis	rs4845875	0.530	rs4846048	chr1:11846252	A/G	cg24844545	chr1:11908347	NPPA	-0.35	-4.92	-0.3	1.61e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg19752551	chr11:57585705	CTNND1	-0.82	-13.74	-0.66	2.87e-32	Schizophrenia;
KIRP	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.57	7.68	0.44	3.87e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg06102954	chr21:42741788	MX2	-0.55	-7.96	-0.45	6.15e-14	Melanoma;
KIRP	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.93	-0.4	3.74e-11	Bladder cancer;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.2	-0.31	4.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.39	5.98	0.36	7.91e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.84	7.75	0.44	2.38e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.61	-6.59	-0.39	2.71e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Bladder cancer;
KIRP	cis	rs1318772	1.000	rs11739509	chr5:112650751	T/C	cg12552261	chr5:112820674	MCC	0.82	5.09	0.31	6.97e-7	F-cell distribution;
KIRP	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg14541582	chr5:601475	NA	-0.58	-6.61	-0.39	2.32e-10	Obesity-related traits;
KIRP	cis	rs3087591	0.659	rs2525570	chr17:29681245	A/G	cg24425628	chr17:29625626	OMG;NF1	0.6	8.76	0.49	3.31e-16	Hip circumference;
KIRP	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-9.9	-0.53	1.19e-19	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg05973401	chr12:123451056	ABCB9	0.49	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs3741489	1.000	rs2062161	chr12:133428032	G/A	cg24132527	chr5:140019269	TMCO6	1.04	6.64	0.39	2.03e-10	Cognitive function;
KIRP	cis	rs735539	0.598	rs2149769	chr13:21266227	C/T	cg04906043	chr13:21280425	IL17D	0.49	6.17	0.37	2.81e-9	Dental caries;
KIRP	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg13482628	chr17:19912719	NA	-0.53	-6.91	-0.4	4.08e-11	Schizophrenia;
KIRP	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg13173536	chr2:3403300	TTC15	-0.36	-4.94	-0.3	1.43e-6	Obesity-related traits;
KIRP	trans	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg06521331	chr12:34319734	NA	-0.49	-6.12	-0.36	3.73e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9217	1.000	rs11658168	chr17:7406134	C/T	cg02795151	chr17:7402630	POLR2A	0.47	5.32	0.32	2.33e-7	Height;
KIRP	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.84	9.38	0.51	4.53e-18	Gut microbiome composition (summer);
KIRP	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg08499158	chr17:42289980	UBTF	0.7	9.27	0.51	9.68e-18	Total body bone mineral density;
KIRP	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-1.24	-8.36	-0.47	4.75e-15	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
KIRP	cis	rs7212590	0.655	rs8067568	chr17:57999215	A/G	cg10252138	chr17:58120427	NA	-0.69	-5.95	-0.35	9.26e-9	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.77	9.78	0.53	2.66e-19	Corneal astigmatism;
KIRP	cis	rs9815354	0.812	rs73071236	chr3:41992042	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.38	0.47	4.17e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17761864	0.579	rs12325821	chr17:2050166	G/T	cg16513277	chr17:2031491	SMG6	0.42	5.09	0.31	7.25e-7	Esophageal cancer (squamous cell);
KIRP	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.65	9.25	0.51	1.1e-17	Lymphocyte counts;
KIRP	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.13e-6	Bladder cancer;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg08662619	chr6:150070041	PCMT1	0.35	5.61	0.34	5.37e-8	Lung cancer;
KIRP	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg11686214	chr19:59084984	MZF1;LOC100131691	0.52	6.63	0.39	2.06e-10	Educational attainment;
KIRP	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.7	-9.74	-0.53	3.68e-19	Schizophrenia;
KIRP	trans	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.4	-0.38	7.66e-10	Neuroticism;
KIRP	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.67	7.27	0.42	4.82e-12	Vitiligo;
KIRP	cis	rs6959887	0.962	rs10280159	chr7:35296638	T/C	cg06685737	chr7:35301730	NA	0.45	6.61	0.39	2.39e-10	Birth weight;
KIRP	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06618957	chr4:52883909	LRRC66	0.37	6.07	0.36	4.69e-9	C-reactive protein;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16986746	chr3:48594219	PFKFB4	0.55	6.89	0.4	4.64e-11	Parkinson's disease;
KIRP	cis	rs7213347	0.581	rs4790881	chr17:2068932	C/A	cg15816464	chr17:2026533	SMG6	0.44	6.66	0.39	1.76e-10	Total body bone mineral density;
KIRP	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.69	-0.34	3.53e-8	Coronary artery disease;
KIRP	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg21017887	chr14:105400489	NA	-0.53	-8.61	-0.48	9.02e-16	Rheumatoid arthritis;
KIRP	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.79	9.92	0.53	1.02e-19	Sudden cardiac arrest;
KIRP	cis	rs4460629	0.521	rs4361977	chr1:155076079	C/T	cg02153340	chr1:155202674	NA	-0.37	-5.08	-0.31	7.55e-7	Serum magnesium levels;
KIRP	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg18016565	chr1:150552671	MCL1	0.39	6.06	0.36	5.03e-9	Melanoma;
KIRP	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg13319975	chr6:146136371	FBXO30	0.44	5.91	0.35	1.11e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-6.23	-0.37	2.03e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg24807547	chr6:37504484	NA	-0.55	-8.08	-0.46	2.84e-14	Cognitive performance;
KIRP	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.68	-0.44	3.72e-13	Triglycerides;
KIRP	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg06654118	chr4:1303317	MAEA	0.31	5.84	0.35	1.68e-8	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.16	-0.42	9.07e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2348418	0.715	rs12307709	chr12:28719700	G/A	cg13890972	chr12:28721907	NA	-0.33	-5.16	-0.31	5.04e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.72	10.85	0.57	1.15e-22	Oral cavity cancer;
KIRP	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.96	0.41	3.06e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs883565	0.611	rs4676588	chr3:38940741	C/T	cg01426195	chr3:39028469	NA	0.4	5.74	0.34	2.79e-8	Handedness;
KIRP	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.46	-5.71	-0.34	3.24e-8	IgG glycosylation;
KIRP	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg21184320	chr1:21044207	KIF17	0.36	5.34	0.32	2.15e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.77	12.51	0.62	4.07e-28	Calcium levels;
KIRP	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.94	-10.91	-0.57	7.2e-23	Neuroticism;
KIRP	trans	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg10756647	chr7:56101905	PSPH	1.02	7.52	0.43	1.02e-12	Diabetic kidney disease;
KIRP	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg21479132	chr6:26055353	NA	0.75	4.99	0.3	1.14e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2415984	0.622	rs10147795	chr14:46936528	C/T	cg14871534	chr14:47121158	RPL10L	-0.41	-4.99	-0.3	1.12e-6	Number of children ever born;
KIRP	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-1.07	-9.45	-0.52	2.85e-18	Blood protein levels;
KIRP	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.07	12.61	0.63	1.86e-28	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs3857536	0.730	rs6455092	chr6:66961914	T/C	cg07460842	chr6:66804631	NA	-0.46	-5.48	-0.33	1.07e-7	Blood trace element (Cu levels);
KIRP	cis	rs11255291	1.000	rs11255291	chr10:7736904	C/T	cg26051552	chr10:7670683	ITIH5	0.42	5.33	0.32	2.19e-7	Ovarian reserve;
KIRP	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg12560992	chr17:57184187	TRIM37	0.63	5.86	0.35	1.48e-8	Cognitive test performance;
KIRP	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs4950322	0.570	rs72692953	chr1:146793135	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.64e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs829661	0.947	rs829660	chr2:30726765	A/C	cg10949345	chr2:30726833	LCLAT1	1.08	14.32	0.67	3.07e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12311346	chr5:56204834	C5orf35	-0.49	-6.68	-0.39	1.57e-10	Coronary artery disease;
KIRP	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.81	7.34	0.42	3.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	7.22	0.42	6.49e-12	Neuroticism;
KIRP	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg20387954	chr3:183756860	HTR3D	0.63	8.99	0.5	6.98e-17	Anterior chamber depth;
KIRP	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.03	-0.46	4.02e-14	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.73	0.49	4.09e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.54	-8.74	-0.49	3.8e-16	Total body bone mineral density;
KIRP	cis	rs6024905	0.551	rs2425364	chr20:36969340	G/T	cg07053727	chr20:36965646	BPI	0.47	7.51	0.43	1.06e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg00784671	chr22:46762841	CELSR1	-0.82	-8.14	-0.46	2.02e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.69	-8.29	-0.47	7.61e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.67	-10.21	-0.55	1.22e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.75	9.75	0.53	3.31e-19	Aortic root size;
KIRP	cis	rs2013441	0.670	rs35317166	chr17:19959820	T/A	cg13482628	chr17:19912719	NA	0.47	5.3	0.32	2.56e-7	Obesity-related traits;
KIRP	trans	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.59	-6.4	-0.38	7.62e-10	Ulcerative colitis;
KIRP	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.86	11.98	0.61	2.41e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27297192	chr10:134578999	INPP5A	0.63	7.82	0.45	1.59e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.82	9.84	0.53	1.75e-19	Corneal astigmatism;
KIRP	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.7	8.22	0.46	1.19e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg16141378	chr3:129829833	LOC729375	-0.51	-6.46	-0.38	5.42e-10	Neuroticism;
KIRP	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs6506900	0.692	rs9947444	chr18:28901153	G/A	cg10906284	chr12:63544430	AVPR1A	0.37	6.04	0.36	5.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12220238	0.822	rs7919517	chr10:76111355	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.62	0.39	2.23e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.53	0.33	8.36e-8	Platelet count;
KIRP	cis	rs4704187	0.687	rs10051040	chr5:74501976	G/C	cg03227963	chr5:74354835	NA	0.4	5.8	0.35	2e-8	Response to amphetamines;
KIRP	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.92	-0.3	1.56e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg13198984	chr17:80129470	CCDC57	0.59	8.96	0.5	8.46e-17	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2820315	0.541	rs10753906	chr1:201887382	C/G	cg11586189	chr1:201857591	SHISA4	-0.4	-6.55	-0.39	3.38e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	6.75	0.4	1.07e-10	Body mass index;
KIRP	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05555928	chr11:63887634	MACROD1	0.43	6.17	0.37	2.85e-9	Platelet count;
KIRP	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs10864907	0.806	rs879711	chr2:113716254	G/T	cg03712744	chr2:113669835	IL1F7	0.32	5.02	0.3	1.01e-6	Pulmonary function;
KIRP	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.24	0.55	1.01e-20	Cognitive test performance;
KIRP	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg00310523	chr12:86230176	RASSF9	0.37	5.68	0.34	3.75e-8	Major depressive disorder;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4959270	0.901	rs2316794	chr6:456344	C/T	cg13299325	chr6:447777	NA	0.25	4.93	0.3	1.52e-6	Limited cutaneous systemic scleroderma;
KIRP	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.47	5.87	0.35	1.39e-8	Blood metabolite levels;
KIRP	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg26681399	chr22:41777847	TEF	0.5	5.45	0.33	1.23e-7	Vitiligo;
KIRP	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg23920097	chr1:209922102	NA	-0.41	-5.48	-0.33	1.04e-7	Red blood cell count;
KIRP	cis	rs2733310	0.895	rs4774895	chr15:57106245	T/C	cg13626582	chr15:57592083	LOC283663	-0.23	-5.12	-0.31	6.27e-7	Mean platelet volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12731353	chr1:33429760	RNF19B	-0.45	-6.07	-0.36	4.69e-9	Metabolic traits;
KIRP	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.24	0.42	5.78e-12	Morning vs. evening chronotype;
KIRP	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.82	-8.43	-0.47	2.99e-15	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.26	-0.37	1.71e-9	Type 2 diabetes;
KIRP	cis	rs7084402	0.565	rs6481407	chr10:60335090	C/T	cg05938607	chr10:60274200	BICC1	0.29	6.25	0.37	1.76e-9	Refractive error;
KIRP	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-8.17	-0.46	1.64e-14	Colorectal cancer;
KIRP	cis	rs687432	0.688	rs17152364	chr11:57880725	A/G	cg19752551	chr11:57585705	CTNND1	-0.57	-7.7	-0.44	3.26e-13	Parkinson's disease;
KIRP	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.43	-4.89	-0.3	1.8e-6	Schizophrenia;
KIRP	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-5.27	-0.32	3.05e-7	IgG glycosylation;
KIRP	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.18	21.34	0.81	6.98e-58	Cognitive function;
KIRP	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg01631408	chr1:248437212	OR2T33	-0.68	-8.75	-0.49	3.35e-16	Common traits (Other);
KIRP	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg20701182	chr2:24300061	SF3B14	0.47	4.94	0.3	1.47e-6	Asthma;
KIRP	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.46	6.73	0.39	1.16e-10	Schizophrenia;
KIRP	cis	rs2241685	0.680	rs11695699	chr2:1954444	G/A	cg22511877	chr2:1942942	MYT1L	-0.63	-5.82	-0.35	1.8e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	4.9	0.3	1.72e-6	Personality dimensions;
KIRP	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.63	-7.73	-0.44	2.82e-13	Extraversion;
KIRP	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.73	-8.86	-0.49	1.68e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.55	7.82	0.45	1.52e-13	Dupuytren's disease;
KIRP	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg00857998	chr1:205179979	DSTYK	0.62	7.38	0.43	2.41e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04843900	chr20:16710618	SNRPB2	0.52	6.41	0.38	7.42e-10	Parkinson's disease;
KIRP	cis	rs600806	0.778	rs2787015	chr1:110009434	A/C	cg02175308	chr1:109941060	SORT1	-0.27	-4.91	-0.3	1.68e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03938320	chr7:73153632	ABHD11	-0.47	-6.05	-0.36	5.27e-9	Myopia;
KIRP	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg18898632	chr2:242989856	NA	-0.51	-4.91	-0.3	1.65e-6	Obesity-related traits;
KIRP	cis	rs9547996	0.876	rs9547941	chr13:38130243	C/T	cg13634560	chr13:38173852	POSTN	-0.41	-5.74	-0.34	2.7e-8	Diastolic blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.4.3383604F	chr4:184607857	C4orf41	0.43	6.23	0.37	1.97e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28489187	0.706	rs2300637	chr1:85822772	T/C	cg16011679	chr1:85725395	C1orf52	0.54	6.5	0.38	4.35e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.24	-0.47	1.03e-14	Retinal vascular caliber;
KIRP	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg03609598	chr5:56110824	MAP3K1	-0.48	-5.55	-0.33	7.3e-8	Initial pursuit acceleration;
KIRP	trans	rs1620921	0.967	rs1084658	chr6:161180477	G/A	cg01090089	chr7:6570974	GRID2IP	0.38	6.07	0.36	4.71e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9403521	1.000	rs9390126	chr6:143980432	A/G	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.14	-0.31	5.49e-7	Obesity-related traits;
KIRP	cis	rs9392653	1.000	rs9378931	chr6:5070238	G/A	cg13207534	chr6:5087447	PPP1R3G	-0.42	-4.89	-0.3	1.81e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg05887092	chr17:76393375	PGS1	-0.49	-6.61	-0.39	2.35e-10	HDL cholesterol levels;
KIRP	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.91	-14.91	-0.69	2.98e-36	Urate levels in lean individuals;
KIRP	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-9.09	-0.5	3.33e-17	Rheumatoid arthritis;
KIRP	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg13119609	chr19:45449297	APOC2	0.52	7.36	0.42	2.69e-12	Blood protein levels;
KIRP	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg02023728	chr11:77925099	USP35	-0.3	-5.22	-0.32	3.83e-7	Alzheimer's disease (survival time);
KIRP	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-7.57	-0.43	7.7e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-5.84	-0.35	1.61e-8	Blood protein levels;
KIRP	cis	rs300890	0.507	rs11945731	chr4:144321254	T/C	cg01719995	chr4:144104893	USP38	-0.45	-5.51	-0.33	9.24e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg20578329	chr17:80767326	TBCD	0.47	6.19	0.37	2.49e-9	Breast cancer;
KIRP	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.87	13.55	0.65	1.26e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.14	0.5	2.44e-17	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05347473	chr6:146136440	FBXO30	-0.6	-8.82	-0.49	2.16e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs68092024	0.731	rs793479	chr3:99488232	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-4.94	-0.3	1.42e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg06740227	chr12:86229804	RASSF9	0.41	5.25	0.32	3.34e-7	Major depressive disorder;
KIRP	trans	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg10756647	chr7:56101905	PSPH	0.91	9.04	0.5	4.9e-17	Diabetic kidney disease;
KIRP	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.68	8.23	0.46	1.11e-14	Post bronchodilator FEV1;
KIRP	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg00852783	chr1:26633632	UBXN11	0.53	7.59	0.44	6.69e-13	Obesity-related traits;
KIRP	trans	rs4332037	0.576	rs62434668	chr7:1866901	G/A	cg11693508	chr17:37793320	STARD3	0.71	6.88	0.4	5e-11	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg10755058	chr3:40428713	ENTPD3	0.49	6.74	0.4	1.09e-10	Renal cell carcinoma;
KIRP	cis	rs4700695	0.614	rs153388	chr5:65422308	G/T	cg21114390	chr5:65439923	SFRS12	-0.69	-5.57	-0.33	6.5e-8	Facial morphology (factor 19);
KIRP	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.76	10.68	0.56	3.99e-22	Body mass index;
KIRP	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.48	-6.69	-0.39	1.47e-10	Colorectal cancer;
KIRP	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg19847130	chr8:10466454	RP1L1	0.38	5.74	0.34	2.71e-8	Retinal vascular caliber;
KIRP	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00361562	chr2:198649771	BOLL	-0.5	-5.33	-0.32	2.27e-7	Ulcerative colitis;
KIRP	cis	rs7011049	1.000	rs11993171	chr8:53832898	C/A	cg26025543	chr8:53854495	NA	0.71	7.56	0.43	7.93e-13	Systolic blood pressure;
KIRP	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.9	-13.97	-0.67	4.76e-33	Dental caries;
KIRP	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.82	0.71	2.34e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg10892158	chr8:24857894	NA	0.72	7.01	0.41	2.29e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg00343986	chr7:65444356	GUSB	0.43	5.12	0.31	6.21e-7	Aortic root size;
KIRP	trans	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.27	-0.42	4.86e-12	Bladder cancer;
KIRP	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.84	12.47	0.62	5.3e-28	Body mass index (adult);
KIRP	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.75	10.47	0.56	1.92e-21	Schizophrenia;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03822858	chr10:4066499	NA	-0.4	-6.18	-0.37	2.62e-9	Select biomarker traits;
KIRP	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.73	7.19	0.42	7.61e-12	Menarche (age at onset);
KIRP	cis	rs4849845	0.889	rs4848582	chr2:121018747	A/G	cg24070213	chr2:121070622	NA	0.38	5.21	0.32	3.92e-7	Mean platelet volume;
KIRP	cis	rs2071403	0.933	rs12329063	chr2:1400686	G/A	cg07083862	chr2:1417248	TPO	0.34	5.49	0.33	9.82e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	trans	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg21775007	chr8:11205619	TDH	0.51	6.36	0.38	9.61e-10	Mood instability;
KIRP	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg21204522	chr6:27730016	NA	-0.61	-5.32	-0.32	2.36e-7	Lung cancer in ever smokers;
KIRP	cis	rs554111	0.858	rs10916855	chr1:21056382	T/C	cg08890418	chr1:21044141	KIF17	0.58	9.11	0.5	2.93e-17	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.25	0.32	3.24e-7	Alzheimer's disease;
KIRP	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg04546413	chr19:29218101	NA	0.89	8.99	0.5	6.98e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.59	-9.71	-0.53	4.61e-19	Total body bone mineral density;
KIRP	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg05315796	chr3:52349193	DNAH1	0.44	6.65	0.39	1.85e-10	Bipolar disorder;
KIRP	cis	rs4073416	0.707	rs761830	chr14:66212986	G/A	cg03016385	chr14:66212404	NA	-0.41	-5.24	-0.32	3.38e-7	N-glycan levels;
KIRP	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg23307798	chr14:103986281	CKB	0.44	6.1	0.36	4.05e-9	Body mass index;
KIRP	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg19847130	chr8:10466454	RP1L1	0.38	5.74	0.34	2.71e-8	Retinal vascular caliber;
KIRP	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	8.69	0.48	5.3e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg21851534	chr17:3907994	ZZEF1	0.64	10.34	0.55	4.72e-21	Type 2 diabetes;
KIRP	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg21545522	chr1:205238299	TMCC2	0.41	5.48	0.33	1.05e-7	Red blood cell count;
KIRP	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.52	-7.08	-0.41	1.54e-11	Blood metabolite levels;
KIRP	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg02811702	chr13:24901961	NA	0.44	5.74	0.34	2.78e-8	Obesity-related traits;
KIRP	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg19196401	chr6:110721138	DDO	-0.45	-6.62	-0.39	2.28e-10	Platelet distribution width;
KIRP	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-6.28	-0.37	1.48e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.78	10.07	0.54	3.52e-20	Coronary artery disease;
KIRP	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg16497661	chr14:103986332	CKB	0.76	11.35	0.59	2.73e-24	Body mass index;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg03289416	chr15:75166202	SCAMP2	0.54	7.59	0.44	6.7e-13	Breast cancer;
KIRP	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg04202892	chr2:111875749	ACOXL	0.44	5.95	0.35	9.22e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26207909	chr14:103986467	CKB	0.73	10.03	0.54	4.62e-20	Body mass index;
KIRP	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg13147721	chr7:65941812	NA	-0.91	-6.45	-0.38	5.94e-10	Diabetic kidney disease;
KIRP	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.7	9.27	0.51	9.49e-18	Breast cancer;
KIRP	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg02487422	chr3:49467188	NICN1	0.36	5.04	0.31	9.01e-7	Parkinson's disease;
KIRP	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.7	-9.51	-0.52	1.86e-18	Waist circumference;Body mass index;
KIRP	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.27	-22.23	-0.82	8.87e-61	Breast cancer;
KIRP	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.65	-9.73	-0.53	3.75e-19	Coronary artery disease;
KIRP	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg27205649	chr11:78285834	NARS2	-0.62	-7.01	-0.41	2.24e-11	Testicular germ cell tumor;
KIRP	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18867708	chr6:26865862	GUSBL1	0.46	5.73	0.34	2.85e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs927821	0.715	rs12415921	chr10:104191769	G/T	cg06646780	chr6:130182053	C6orf191	-0.67	-6.31	-0.37	1.31e-9	Social autistic-like traits;
KIRP	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg13736514	chr6:26305472	NA	-0.66	-8.83	-0.49	2e-16	Educational attainment;
KIRP	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.56	6.99	0.41	2.59e-11	Asperger disorder;
KIRP	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.32	0.37	1.21e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg05627522	chr15:75251581	NA	0.34	5.08	0.31	7.39e-7	Caffeine consumption;
KIRP	cis	rs10929159	0.928	rs2317303	chr2:236921702	A/G	cg20128773	chr2:236923534	AGAP1	0.3	5.15	0.31	5.25e-7	Parkinson's disease;
KIRP	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg14440974	chr22:39074834	NA	0.44	5.17	0.31	4.77e-7	Menopause (age at onset);
KIRP	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	10.55	0.56	1e-21	Bone mineral density;
KIRP	cis	rs654950	0.775	rs28972757	chr1:41993013	T/C	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.47	-0.38	5.32e-10	Airway imaging phenotypes;
KIRP	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.45	-5.22	-0.32	3.79e-7	Schizophrenia;
KIRP	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.18	0.31	4.68e-7	Eosinophil percentage of white cells;
KIRP	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs42648	0.536	rs39270	chr7:89772626	A/T	cg25739043	chr7:89950458	NA	-0.39	-6.08	-0.36	4.54e-9	Homocysteine levels;
KIRP	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg01528321	chr10:82214614	TSPAN14	-1.18	-9.73	-0.53	3.9e-19	Post bronchodilator FEV1;
KIRP	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.47	3.84e-15	Motion sickness;
KIRP	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.54	-0.43	9.14e-13	Migraine;Coronary artery disease;
KIRP	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg05315796	chr3:52349193	DNAH1	0.45	6.94	0.4	3.39e-11	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09190696	chr6:91296794	MAP3K7	0.49	6.08	0.36	4.45e-9	Parkinson's disease;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg02733842	chr7:1102375	C7orf50	0.45	4.94	0.3	1.45e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.47	-0.33	1.11e-7	Bipolar disorder;
KIRP	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg12042659	chr19:58951599	ZNF132	0.51	6.21	0.37	2.27e-9	Uric acid clearance;
KIRP	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.46	6.72	0.39	1.24e-10	Urate levels in lean individuals;
KIRP	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg03388025	chr16:89894329	SPIRE2	-0.32	-5.9	-0.35	1.21e-8	Vitiligo;
KIRP	cis	rs1832871	0.711	rs9459829	chr6:158680799	C/T	cg07215822	chr6:158701037	NA	-0.61	-7.05	-0.41	1.75e-11	Height;
KIRP	cis	rs4863687	0.507	rs10005805	chr4:140665918	G/A	cg17540159	chr4:140657573	MAML3	-0.58	-5.57	-0.33	6.5e-8	Chronic mucus hypersecretion;
KIRP	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg24579218	chr15:68104479	NA	-0.57	-9.26	-0.51	1.07e-17	Restless legs syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12908608	chr2:198380725	MOBKL3	0.5	6.45	0.38	5.95e-10	Parkinson's disease;
KIRP	trans	rs34421088	0.531	rs2245232	chr8:11400944	G/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.3	-0.47	7.09e-15	Neuroticism;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg13453750	chr1:205783389	SLC41A1	-0.5	-7.57	-0.43	7.43e-13	Menarche (age at onset);
KIRP	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg23992470	chr4:843637	GAK	0.68	4.91	0.3	1.63e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.93	-14.73	-0.68	1.23e-35	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08078772	chr17:66244589	AMZ2	0.55	6.68	0.39	1.55e-10	Smoking initiation;
KIRP	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.55	7.64	0.44	4.81e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg23594656	chr7:65796392	TPST1	-0.37	-5.35	-0.32	1.97e-7	Aortic root size;
KIRP	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.23	0.42	6.17e-12	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18520856	chr22:36925425	EIF3D	0.51	6.49	0.38	4.64e-10	Parkinson's disease;
KIRP	cis	rs870825	0.585	rs2696039	chr4:185610899	T/C	cg04058563	chr4:185651563	MLF1IP	-0.79	-9.88	-0.53	1.29e-19	Blood protein levels;
KIRP	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg15655495	chr12:38532458	NA	-0.28	-5.0	-0.3	1.11e-6	Morning vs. evening chronotype;
KIRP	cis	rs4805272	1.000	rs1422213	chr19:29330134	G/A	cg04546413	chr19:29218101	NA	0.44	4.95	0.3	1.36e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.43	-5.43	-0.33	1.35e-7	Ulcerative colitis;
KIRP	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg04289385	chr6:36355825	ETV7	0.39	5.17	0.31	4.75e-7	Platelet distribution width;
KIRP	cis	rs775227	0.574	rs13064411	chr3:113046640	A/G	cg18753928	chr3:113234510	CCDC52	-0.63	-5.63	-0.34	4.84e-8	Dental caries;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.64	-8.42	-0.47	3.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	16.4	0.72	2.4e-41	Homoarginine levels;
KIRP	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.41	1.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.99	12.87	0.63	2.62e-29	Breast cancer;
KIRP	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.54	6.29	0.37	1.46e-9	Menarche (age at onset);
KIRP	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.53	-6.78	-0.4	8.7e-11	Immature fraction of reticulocytes;
KIRP	cis	rs1832871	0.672	rs56075516	chr6:158745752	G/A	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	trans	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.32	0.42	3.57e-12	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21734487	chr8:27695307	PBK	0.52	7.13	0.41	1.08e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.8	0.35	2.02e-8	Motion sickness;
KIRP	cis	rs7951870	0.945	rs10160701	chr11:46551918	C/T	cg16389345	chr11:46697382	NA	-0.48	-5.38	-0.32	1.75e-7	Schizophrenia;
KIRP	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.63	8.08	0.46	2.85e-14	Pulse pressure;
KIRP	cis	rs62012628	0.527	rs12437868	chr15:79088460	T/C	cg04896959	chr15:78267971	NA	-0.82	-10.92	-0.57	6.75e-23	Diastolic blood pressure;
KIRP	cis	rs897080	0.553	rs1067338	chr2:44624708	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.42	0.38	6.81e-10	Height;
KIRP	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.37	0.65	5.32e-31	Personality dimensions;
KIRP	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg06740227	chr12:86229804	RASSF9	0.47	6.24	0.37	1.94e-9	Major depressive disorder;
KIRP	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg13072238	chr3:49761600	GMPPB	-0.52	-4.86	-0.3	2.1e-6	Menarche (age at onset);
KIRP	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.46	5.44	0.33	1.28e-7	Alzheimer's disease (late onset);
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.82	11.8	0.6	9.15e-26	Obesity-related traits;
KIRP	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.66	-7.3	-0.42	3.89e-12	Chronic sinus infection;
KIRP	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg03887218	chr1:16534349	ARHGEF19	-0.64	-8.62	-0.48	8.41e-16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00585698	chr12:123750864	CDK2AP1	-0.5	-6.3	-0.37	1.33e-9	Neutrophil percentage of white cells;
KIRP	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg11569703	chr11:65557185	OVOL1	0.78	15.25	0.7	2.02e-37	Acne (severe);
KIRP	cis	rs10073892	0.703	rs9885011	chr5:101866862	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.31	0.37	1.29e-9	Cognitive decline (age-related);
KIRP	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.49	6.74	0.39	1.11e-10	Height;
KIRP	cis	rs1318772	1.000	rs10519354	chr5:112689650	C/G	cg12552261	chr5:112820674	MCC	-0.69	-5.83	-0.35	1.75e-8	F-cell distribution;
KIRP	cis	rs2299587	0.662	rs7816769	chr8:17768548	G/T	cg01800426	chr8:17659068	MTUS1	0.55	6.78	0.4	8.9e-11	Economic and political preferences;
KIRP	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg14593290	chr7:50529359	DDC	-0.43	-5.44	-0.33	1.31e-7	Malaria;
KIRP	cis	rs28489187	0.706	rs233115	chr1:85786977	G/A	cg16011679	chr1:85725395	C1orf52	0.5	6.11	0.36	3.9e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg19468946	chr17:37922297	IKZF3	-0.46	-6.4	-0.38	7.63e-10	Self-reported allergy;
KIRP	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg04006718	chr10:1068667	C10orf110;IDI2	-0.71	-4.97	-0.3	1.25e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4805272	1.000	rs7254988	chr19:29326157	C/T	cg15000279	chr19:29285009	NA	-0.37	-5.27	-0.32	2.96e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.53	-0.38	3.77e-10	Response to antipsychotic treatment;
KIRP	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg01849789	chr22:41697279	ZC3H7B	-0.4	-4.86	-0.3	2.08e-6	Neuroticism;
KIRP	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg26585981	chr11:48327164	OR4S1	-0.42	-5.25	-0.32	3.35e-7	Height;
KIRP	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.18	-0.64	2.35e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9381040	0.869	rs9357347	chr6:41150591	A/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.56	-5.67	-0.34	4.03e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg03115019	chr17:80708279	FN3K	0.41	4.91	0.3	1.65e-6	Glycated hemoglobin levels;
KIRP	cis	rs9426935	0.966	rs1127091	chr1:153779412	A/G	cg09895920	chr1:153941186	CREB3L4;SLC39A1	0.28	4.87	0.3	2.01e-6	Lentiform nucleus volume;
KIRP	cis	rs9400467	0.537	rs17606481	chr6:111542388	A/G	cg15721981	chr6:111408429	SLC16A10	0.81	7.37	0.43	2.63e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12936587	0.633	rs12951181	chr17:17502453	T/C	cg01246520	chr17:17644344	RAI1	-0.37	-5.43	-0.33	1.37e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19348733	chr22:26908517	TFIP11	-0.47	-6.14	-0.36	3.22e-9	Metabolic traits;
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg07701084	chr6:150067640	NUP43	0.75	10.21	0.55	1.25e-20	Lung cancer;
KIRP	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.52e-15	Skin colour saturation;
KIRP	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg22705602	chr4:152727874	NA	-0.55	-9.69	-0.53	5.24e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.46	-0.72	1.47e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg09184832	chr6:79620586	NA	-0.51	-7.37	-0.43	2.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.47	0.48	2.28e-15	Electroencephalogram traits;
KIRP	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-6.96	-0.41	3.01e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.64	7.77	0.44	2.14e-13	Coronary artery disease;
KIRP	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.88	13.29	0.65	9.69e-31	Eosinophil percentage of white cells;
KIRP	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08822215	chr16:89438651	ANKRD11	-0.44	-5.98	-0.36	7.77e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.72	0.49	4.36e-16	Bipolar disorder;
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.41	-0.33	1.47e-7	Obesity-related traits;
KIRP	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg01557791	chr16:72042693	DHODH	-0.69	-7.37	-0.43	2.61e-12	Blood protein levels;
KIRP	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11644362	0.966	rs11645507	chr16:12992570	C/A	cg06890432	chr16:12997467	SHISA9	-0.42	-6.59	-0.39	2.71e-10	Positive affect;Subjective well-being;
KIRP	cis	rs787274	0.718	rs1711745	chr9:115452909	C/A	cg13803584	chr9:115635662	SNX30	0.55	6.32	0.37	1.19e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg27490568	chr2:178487706	NA	0.52	7.02	0.41	2.2e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.38	0.51	4.48e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg25347419	chr2:177043501	NA	0.44	6.23	0.37	2.04e-9	IgG glycosylation;
KIRP	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.56	6.89	0.4	4.7e-11	Subjective well-being;
KIRP	cis	rs2290416	0.786	rs77951814	chr8:144657152	C/G	cg08017634	chr8:144659831	NAPRT1	0.78	5.01	0.3	1.03e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs75920871	0.528	rs10082609	chr11:116949074	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.33	-0.32	2.26e-7	Subjective well-being;
KIRP	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	13.45	0.65	2.8e-31	Platelet count;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10537699	chr11:60897371	NA	0.92	6.06	0.36	5.09e-9	P wave terminal force;
KIRP	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs1823913	0.599	rs1823912	chr2:192131114	C/T	cg12404831	chr2:192114017	MYO1B	0.48	6.69	0.39	1.54e-10	Obesity-related traits;
KIRP	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg05072774	chr3:49840536	C3orf54	0.43	5.52	0.33	8.57e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7178909	0.831	rs1910587	chr15:90440487	A/C	cg19708238	chr15:90437601	AP3S2	0.6	8.3	0.47	7.1e-15	Common traits (Other);
KIRP	cis	rs17123764	0.710	rs74089182	chr12:50063768	G/A	cg02054252	chr12:50078554	FMNL3	0.48	5.04	0.31	9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.75	-10.99	-0.57	4.08e-23	Waist circumference;Body mass index;
KIRP	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg06121193	chr1:90282411	NA	-0.52	-7.49	-0.43	1.22e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.84	-0.35	1.61e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.94	-0.45	7.19e-14	Coffee consumption (cups per day);
KIRP	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg09699651	chr6:150184138	LRP11	0.54	7.36	0.42	2.74e-12	Testicular germ cell tumor;
KIRP	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg23307798	chr14:103986281	CKB	0.36	4.91	0.3	1.63e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg11895451	chr1:16533891	ARHGEF19	0.46	5.96	0.36	8.6e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg24826892	chr11:71159390	DHCR7	0.45	5.01	0.3	1.06e-6	Vitamin D levels;
KIRP	cis	rs2224391	0.628	rs2753224	chr6:5244864	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-6.18	-0.37	2.63e-9	Height;
KIRP	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07582204	chr3:43275279	NA	0.43	6.06	0.36	4.94e-9	Interleukin-4 levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24792749	chr19:33166123	ANKRD27;RGS9BP	0.67	7.99	0.45	5.22e-14	Smoking initiation;
KIRP	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.65	-6.32	-0.37	1.23e-9	Bronchopulmonary dysplasia;
KIRP	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg16141378	chr3:129829833	LOC729375	-0.47	-6.26	-0.37	1.74e-9	Neuroticism;
KIRP	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.14	0.5	2.34e-17	Corneal astigmatism;
KIRP	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg12560992	chr17:57184187	TRIM37	0.43	4.91	0.3	1.67e-6	Cognitive test performance;
KIRP	cis	rs6968419	0.674	rs4730724	chr7:115905339	A/G	cg02561103	chr7:115862891	TES	-0.41	-5.68	-0.34	3.89e-8	Intraocular pressure;
KIRP	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.64	8.93	0.49	9.96e-17	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12923728	chr3:195709715	SDHAP1	0.57	6.66	0.39	1.76e-10	Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.57	5.55	0.33	7.27e-8	Alzheimer's disease;
KIRP	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7116495	0.609	rs2508860	chr11:71805052	C/T	cg07596299	chr11:71824057	C11orf51	0.88	5.51	0.33	9.14e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7119038	0.818	rs6589684	chr11:118610957	A/G	cg19308663	chr11:118741387	NA	-0.47	-7.58	-0.44	7.11e-13	Sjögren's syndrome;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg00729690	chr4:77227631	STBD1	-0.47	-6.29	-0.37	1.46e-9	Serum protein levels (sST2);
KIRP	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11987759	chr7:65425863	GUSB	0.46	5.76	0.34	2.52e-8	Aortic root size;
KIRP	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg10381502	chr11:71823885	C11orf51	1.16	8.09	0.46	2.77e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg19847130	chr8:10466454	RP1L1	-0.32	-4.86	-0.3	2.05e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14895029	chr7:2775587	GNA12	-0.44	-5.17	-0.31	4.89e-7	Height;
KIRP	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs7178909	0.902	rs2043882	chr15:90439753	G/A	cg19708238	chr15:90437601	AP3S2	0.6	8.27	0.47	8.64e-15	Common traits (Other);
KIRP	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.38	-0.68	1.98e-34	Alzheimer's disease;
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.8	-10.03	-0.54	4.46e-20	Longevity;Endometriosis;
KIRP	cis	rs75920871	0.748	rs12225230	chr11:116728630	G/C	cg23684410	chr11:116897558	SIK3	0.44	4.85	0.3	2.21e-6	Subjective well-being;
KIRP	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.26	17.69	0.75	9.67e-46	Atopic dermatitis;
KIRP	cis	rs7766436	0.848	rs66989470	chr6:22598707	G/C	cg13666174	chr6:22585274	NA	-0.48	-6.49	-0.38	4.78e-10	Coronary artery disease;
KIRP	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg24304309	chr1:154577895	ADAR	0.38	6.22	0.37	2.14e-9	Blood protein levels;
KIRP	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.77	9.6	0.52	9.88e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6545883	0.965	rs7591345	chr2:61729641	T/A	cg15711740	chr2:61764176	XPO1	-0.59	-7.97	-0.45	5.88e-14	Tuberculosis;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.8	13.16	0.64	2.69e-30	Vitiligo;
KIRP	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.96	-0.45	6.47e-14	Retinal vascular caliber;
KIRP	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.98	0.45	5.51e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs397969	0.646	rs203454	chr17:19821513	G/C	cg13482628	chr17:19912719	NA	0.52	6.37	0.38	9.2e-10	Platelet count;
KIRP	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg08501292	chr6:25962987	TRIM38	1.1	8.13	0.46	2.09e-14	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-7.14	-0.41	1.05e-11	Coronary artery disease;
KIRP	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-1.04	-19.57	-0.78	4.58e-52	Height;
KIRP	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	9.49	0.52	2.12e-18	Renal function-related traits (BUN);
KIRP	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg26207909	chr14:103986467	CKB	-0.42	-5.18	-0.31	4.56e-7	Coronary artery disease;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10012599	chr11:46744754	F2	1.07	6.28	0.37	1.56e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg24579218	chr15:68104479	NA	-0.38	-5.33	-0.32	2.22e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-0.82	-9.19	-0.51	1.69e-17	Gut microbiome composition (summer);
KIRP	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg02404636	chr22:31891804	SFI1	0.47	5.33	0.32	2.2e-7	Colorectal cancer;
KIRP	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.53	-6.29	-0.37	1.4e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.98e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.1	0.36	4.11e-9	Monocyte percentage of white cells;
KIRP	trans	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg07393940	chr7:158741817	NA	0.45	6.18	0.37	2.65e-9	Life satisfaction;
KIRP	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	1.08	15.22	0.7	2.55e-37	Pulmonary function decline;
KIRP	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	27.47	0.87	6.46e-77	Schizophrenia;
KIRP	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.52	8.91	0.49	1.2e-16	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7188697	0.922	rs2243463	chr16:58571189	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.11	0.31	6.47e-7	QT interval;
KIRP	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.3	-0.32	2.54e-7	Colorectal cancer;
KIRP	cis	rs860295	0.871	rs11582072	chr1:155477570	T/C	cg02153340	chr1:155202674	NA	0.39	5.26	0.32	3.08e-7	Body mass index;
KIRP	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08930741	chr1:59369549	NA	0.4	6.15	0.37	3.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.1	0.31	6.66e-7	Educational attainment;
KIRP	cis	rs1891498	0.516	rs12037169	chr1:147248057	A/G	cg27546670	chr1:147246839	GJA5	0.76	10.43	0.55	2.46e-21	Cognitive performance;
KIRP	cis	rs35300120	0.757	rs73101509	chr1:233655461	A/G	cg23054119	chr1:233659267	NA	-0.41	-5.75	-0.34	2.63e-8	Cognitive function;
KIRP	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg16584676	chr17:46985605	UBE2Z	-0.46	-5.7	-0.34	3.45e-8	Type 2 diabetes;
KIRP	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.84	0.35	1.61e-8	Personality dimensions;
KIRP	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg10189774	chr4:17578691	LAP3	0.58	7.23	0.42	6.04e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.1.2289685F	chr1:92578731	BTBD8	0.45	6.08	0.36	4.55e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg22563815	chr15:78856949	CHRNA5	-0.46	-7.15	-0.41	9.98e-12	Sudden cardiac arrest;
KIRP	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.27	-0.37	1.59e-9	Cardiac Troponin-T levels;
KIRP	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-12.93	-0.64	1.6e-29	Chronic sinus infection;
KIRP	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.75	6.24	0.37	1.95e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.69	-7.41	-0.43	2.03e-12	DNA methylation (variation);
KIRP	cis	rs10073892	0.789	rs10044449	chr5:101852441	T/A	cg19774478	chr5:101632501	SLCO4C1	0.65	6.49	0.38	4.73e-10	Cognitive decline (age-related);
KIRP	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6782228	0.651	rs9852825	chr3:128387357	C/G	cg18648031	chr3:128330563	NA	0.27	5.49	0.33	9.91e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs4786125	0.587	rs12709158	chr16:6925056	A/G	cg03623568	chr16:6915990	A2BP1	-0.44	-5.32	-0.32	2.31e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.05	-0.36	5.38e-9	Pulmonary function;
KIRP	cis	rs6009824	0.836	rs6009821	chr22:50085697	C/T	cg18178197	chr22:50098317	NA	0.63	7.42	0.43	1.94e-12	Natriuretic peptide levels;
KIRP	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	trans	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg24644049	chr4:85504048	CDS1	1.03	7.19	0.42	7.62e-12	Skin colour saturation;
KIRP	cis	rs6681460	0.901	rs1570815	chr1:67139667	C/T	cg13052034	chr1:66999238	SGIP1	0.46	6.33	0.37	1.16e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs71446622	0.506	rs36090150	chr13:113432388	T/C	cg04656015	chr13:113407548	ATP11A	0.69	5.12	0.31	6.16e-7	Mean corpuscular volume;
KIRP	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg07691761	chr5:131892711	RAD50	0.47	6.2	0.37	2.33e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.26	0.55	8.5e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.69	9.23	0.51	1.29e-17	Total body bone mineral density;
KIRP	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26604191	chr7:5372559	TNRC18	0.49	6.06	0.36	5.03e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs61990749	0.571	rs2364841	chr14:78284036	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.84	6.35	0.38	1.03e-9	Fibroblast growth factor basic levels;
KIRP	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.55	-0.33	7.44e-8	Parkinson's disease;
KIRP	cis	rs137887	1.000	rs137887	chr22:50464439	C/G	cg17558497	chr22:50464837	TTLL8	0.51	7.71	0.44	3.08e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.76e-7	Life satisfaction;
KIRP	cis	rs10875746	0.859	rs4760695	chr12:48591848	A/G	cg20731937	chr12:48336164	NA	0.42	5.4	0.33	1.57e-7	Longevity (90 years and older);
KIRP	cis	rs1843834	0.721	rs4674939	chr2:225613552	G/A	cg22509189	chr2:225307070	NA	-0.44	-5.35	-0.32	1.97e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Corneal astigmatism;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22831533	chr15:76031080	DNM1P35	-0.53	-6.57	-0.39	2.97e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	1.14	9.53	0.52	1.59e-18	Cognitive function;
KIRP	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2219968	0.828	rs13265358	chr8:78930198	T/C	cg00738934	chr8:78996279	NA	-0.37	-5.02	-0.3	9.8e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg02297831	chr4:17616191	MED28	-0.6	-7.01	-0.41	2.29e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.64	5.91	0.35	1.15e-8	Neutrophil percentage of white cells;
KIRP	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.56e-17	Retinal vascular caliber;
KIRP	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.83	-12.18	-0.61	4.91e-27	Schizophrenia;
KIRP	cis	rs10761482	0.861	rs1350633	chr10:62111910	T/C	cg01186212	chr10:62110162	ANK3	-0.29	-4.96	-0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs988913	0.706	rs34563989	chr6:54945469	G/A	cg03513858	chr6:54763001	FAM83B	-0.37	-5.12	-0.31	6.16e-7	Menarche (age at onset);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg01112249	chr10:28591961	NA	-1.09	-6.11	-0.36	3.97e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.41	-6.58	-0.39	2.75e-10	Inflammatory bowel disease;
KIRP	cis	rs6545883	0.894	rs2694639	chr2:61595291	G/A	cg15711740	chr2:61764176	XPO1	0.6	7.7	0.44	3.29e-13	Tuberculosis;
KIRP	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg08741688	chr4:3415352	RGS12	-0.44	-4.89	-0.3	1.83e-6	Serum sulfate level;
KIRP	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg23682824	chr7:23144976	KLHL7	0.47	5.54	0.33	7.85e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	15.56	0.7	1.76e-38	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.94	13.31	0.65	8.27e-31	Menopause (age at onset);
KIRP	cis	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg11503966	chr20:62272292	STMN3	-0.41	-5.87	-0.35	1.41e-8	Atopic dermatitis;
KIRP	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.77	10.4	0.55	3.11e-21	Adiposity;
KIRP	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.1	-0.36	4.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg12560992	chr17:57184187	TRIM37	0.61	5.52	0.33	8.6e-8	Cognitive test performance;
KIRP	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg19820705	chr19:4455316	UBXN6	0.42	5.71	0.34	3.19e-8	Mean corpuscular volume;
KIRP	cis	rs8014252	0.803	rs58777530	chr14:71001222	C/T	cg19730268	chr14:71022823	NA	-0.62	-5.88	-0.35	1.33e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.92	14.65	0.68	2.32e-35	Blood protein levels;
KIRP	trans	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg21659725	chr3:3221576	CRBN	0.68	6.99	0.41	2.61e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	9.07	0.5	4.01e-17	Resting heart rate;
KIRP	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.23	14.45	0.68	1.07e-34	Uric acid levels;
KIRP	cis	rs10102274	1.000	rs7013400	chr8:91775846	G/T	cg16814680	chr8:91681699	NA	-0.8	-4.9	-0.3	1.73e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.52	-0.56	1.33e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.44e-8	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07059167	chr19:50354224	PTOV1	0.51	6.59	0.39	2.61e-10	Parkinson's disease;
KIRP	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	15.92	0.71	1.09e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.39	-5.06	-0.31	8.24e-7	Leprosy;
KIRP	cis	rs73206853	0.543	rs7972256	chr12:110575444	G/A	cg12870014	chr12:110450643	ANKRD13A	0.56	5.66	0.34	4.11e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.47	-0.52	2.48e-18	Neuroticism;
KIRP	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.36e-11	Arsenic metabolism;
KIRP	cis	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.93	10.11	0.54	2.5e-20	Alzheimer's disease;
KIRP	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg18190219	chr22:46762943	CELSR1	-0.61	-6.39	-0.38	8.3e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-7.56	-0.43	8.21e-13	Lung cancer;
KIRP	cis	rs13424612	0.965	rs4149541	chr2:240957734	G/A	cg01812947	chr2:240904978	NDUFA10	0.5	6.51	0.38	4.1e-10	Odorant perception (isobutyraldehyde);
KIRP	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.75	9.13	0.5	2.59e-17	Selective IgA deficiency;
KIRP	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.58	-5.85	-0.35	1.54e-8	Platelet distribution width;
KIRP	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.93	-0.4	3.68e-11	Self-reported allergy;
KIRP	cis	rs7582720	1.000	rs72932753	chr2:203670122	T/C	cg08076091	chr2:203926405	NBEAL1	0.83	8.64	0.48	7.38e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg19847866	chr10:1019161	NA	0.51	5.86	0.35	1.51e-8	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs3858145	0.588	rs2305083	chr10:70044937	C/A	cg04882175	chr6:131122610	NA	-0.6	-6.96	-0.41	3e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs7577696	0.785	rs3769602	chr2:32381829	G/A	cg02381751	chr2:32503542	YIPF4	-0.44	-4.86	-0.3	2.07e-6	Inflammatory biomarkers;
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg10802521	chr3:52805072	NEK4	0.38	5.19	0.31	4.41e-7	Electroencephalogram traits;
KIRP	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.23	0.37	1.96e-9	Aortic root size;
KIRP	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.63	-0.39	2.14e-10	Renal cell carcinoma;
KIRP	cis	rs1629083	0.967	rs1715450	chr11:118128445	C/G	cg18857871	chr11:118064634	AMICA1	-0.68	-10.0	-0.54	5.64e-20	Lung cancer;
KIRP	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg22117172	chr7:91764530	CYP51A1	0.48	6.66	0.39	1.81e-10	Breast cancer;
KIRP	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	10.81	0.57	1.57e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.57	6.95	0.41	3.2e-11	Monobrow;
KIRP	cis	rs9634489	0.588	rs7331395	chr13:96936275	G/A	cg02571835	chr13:96230311	CLDN10	-0.34	-4.85	-0.3	2.15e-6	Body mass index;
KIRP	cis	rs12780845	0.540	rs10904904	chr10:17240640	G/C	cg01003015	chr10:17271136	VIM	-0.46	-5.78	-0.35	2.2e-8	Homocysteine levels;
KIRP	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg17724175	chr1:150552817	MCL1	0.37	5.97	0.36	8.21e-9	Melanoma;
KIRP	cis	rs17102423	0.661	rs4468529	chr14:65611968	C/T	cg11161011	chr14:65562177	MAX	-0.53	-5.65	-0.34	4.49e-8	Obesity-related traits;
KIRP	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg04691961	chr3:161091175	C3orf57	-0.52	-8.33	-0.47	5.71e-15	Morning vs. evening chronotype;
KIRP	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.72	8.44	0.47	2.83e-15	High light scatter reticulocyte count;
KIRP	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.72	-6.91	-0.4	4.08e-11	Menarche (age at onset);
KIRP	cis	rs68092024	0.704	rs793487	chr3:99495422	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-5.04	-0.31	8.83e-7	Cleft lip with or without cleft palate;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04710198	chr22:47189600	TBC1D22A	0.49	6.32	0.37	1.23e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg22117172	chr7:91764530	CYP51A1	0.4	5.56	0.33	7.11e-8	Breast cancer;
KIRP	cis	rs10849605	0.895	rs3748522	chr12:1058688	A/C	cg22243222	chr12:1059299	RAD52	-0.43	-5.96	-0.35	8.9e-9	Lung cancer;
KIRP	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg26874164	chr19:58962979	ZNF324B	0.47	5.49	0.33	1.02e-7	Uric acid clearance;
KIRP	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.68	8.26	0.47	8.76e-15	Aortic root size;
KIRP	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.64	9.11	0.5	3.01e-17	Resting heart rate;
KIRP	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.03e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.82	11.01	0.57	3.42e-23	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-1.05	-14.5	-0.68	7.42e-35	Monocyte percentage of white cells;
KIRP	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.99	-0.36	7.45e-9	Prudent dietary pattern;
KIRP	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-12.08	-0.61	1.08e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.38	-0.38	8.58e-10	Height;
KIRP	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.23	0.46	1.1e-14	Lung cancer;
KIRP	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg05347473	chr6:146136440	FBXO30	0.61	8.62	0.48	8.4e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.7	9.85	0.53	1.63e-19	Plateletcrit;Platelet count;
KIRP	cis	rs986417	0.901	rs1989477	chr14:61024867	T/C	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg20243544	chr17:37824526	PNMT	0.41	5.03	0.31	9.51e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-7.46	-0.43	1.51e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	11.09	0.58	1.97e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.27e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs10214930	0.723	rs6960834	chr7:27635986	G/C	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs1950626	0.796	rs7152870	chr14:101389987	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.59	-6.52	-0.38	3.91e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.76	-0.44	2.25e-13	Alcohol dependence;
KIRP	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.78	12.38	0.62	1.1e-27	Schizophrenia;
KIRP	cis	rs9394438	0.628	rs10947680	chr6:37543668	T/C	cg00985040	chr6:37553208	NA	-0.35	-4.86	-0.3	2.13e-6	IgG glycosylation;
KIRP	trans	rs2270927	0.510	rs6876070	chr5:75579237	T/A	cg13563193	chr19:33072644	PDCD5	0.91	6.65	0.39	1.87e-10	Mean corpuscular volume;
KIRP	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.41	-0.47	3.34e-15	Platelet count;
KIRP	cis	rs2117029	0.553	rs731350	chr12:49524587	G/C	cg24176009	chr12:49580217	TUBA1A	-0.38	-5.16	-0.31	5.21e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4901847	0.577	rs10782436	chr14:58574964	T/C	cg15908186	chr14:58618357	C14orf37	0.54	6.64	0.39	1.98e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.36	5.18	0.31	4.7e-7	Calcium levels;
KIRP	trans	rs61931739	0.555	rs1482982	chr12:33691601	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.12	-0.36	3.72e-9	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg01689657	chr7:91764605	CYP51A1	0.44	6.28	0.37	1.51e-9	Breast cancer;
KIRP	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Body mass index;
KIRP	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.67	-0.39	1.68e-10	Neuroticism;
KIRP	cis	rs2862064	0.613	rs2862060	chr5:156443895	A/C	cg12943317	chr5:156479607	HAVCR1	-0.74	-6.94	-0.4	3.37e-11	Platelet count;
KIRP	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Educational attainment;
KIRP	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg18944383	chr4:111397179	ENPEP	0.61	11.38	0.59	2.12e-24	Height;
KIRP	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg19743168	chr1:23544995	NA	0.56	7.76	0.44	2.24e-13	Height;
KIRP	cis	rs10875746	0.903	rs11168403	chr12:48484958	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs988913	0.723	rs75537920	chr6:54999717	T/C	cg03513858	chr6:54763001	FAM83B	0.37	5.37	0.32	1.79e-7	Menarche (age at onset);
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg05518842	chr16:1823291	MRPS34;EME2	-0.53	-6.62	-0.39	2.26e-10	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	10.46	0.55	2.04e-21	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01627046	chr12:125473657	DHX37	0.51	6.42	0.38	6.79e-10	Parkinson's disease;
KIRP	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg03714773	chr7:91764589	CYP51A1	0.42	6.36	0.38	9.66e-10	Breast cancer;
KIRP	cis	rs6988636	0.584	rs75096144	chr8:124131225	C/T	cg22384356	chr8:124195192	FAM83A	-0.57	-5.08	-0.31	7.62e-7	Urinary uromodulin levels;
KIRP	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg03605463	chr16:89740564	NA	-0.43	-5.21	-0.32	4e-7	Vitiligo;
KIRP	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.28	0.51	8.82e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.26	0.55	8.5e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.23	-0.46	1.11e-14	Retinal vascular caliber;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	ch.5.2763962F	chr5:147115232	JAKMIP2	-0.41	-6.06	-0.36	5e-9	Obesity-related traits;
KIRP	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	1.12	12.79	0.63	4.59e-29	Red blood cell traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01847620	chr20:60905922	LAMA5	0.51	6.62	0.39	2.19e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.74	-9.47	-0.52	2.37e-18	Aortic root size;
KIRP	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.79	6.86	0.4	5.44e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10463316	0.963	rs10463315	chr5:150745615	T/A	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.86	-0.35	1.48e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7116495	1.000	rs2250866	chr11:71804513	A/G	cg26138937	chr11:71823887	C11orf51	-0.68	-5.37	-0.32	1.86e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs785830	0.558	rs2479328	chr9:261855	C/T	cg14500300	chr9:211689	NA	0.41	5.37	0.32	1.82e-7	Platelet distribution width;
KIRP	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.2	0.37	2.33e-9	Educational attainment;
KIRP	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg12140854	chr5:148520817	ABLIM3	-0.42	-4.84	-0.3	2.25e-6	Breast cancer;
KIRP	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	1.04	15.74	0.71	4.35e-39	Menopause (age at onset);
KIRP	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg21605333	chr4:119757512	SEC24D	1.6	11.71	0.6	1.76e-25	Cannabis dependence symptom count;
KIRP	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7267005	1.000	rs17093212	chr20:34472450	A/G	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.24	-4.89	-0.3	1.8e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-7.58	-0.44	6.89e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7808935	0.593	rs72598569	chr7:28004953	A/C	cg22168087	chr7:27702803	HIBADH	0.49	4.87	0.3	1.97e-6	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	14.73	0.68	1.27e-35	Chronic sinus infection;
KIRP	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-0.87	-7.71	-0.44	3.16e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23396286	chr10:99258505	UBTD1;MMS19	0.67	8.13	0.46	2.06e-14	Smoking initiation;
KIRP	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.73	8.26	0.47	9.17e-15	Corneal astigmatism;
KIRP	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg16586182	chr3:47516702	SCAP	0.7	9.47	0.52	2.35e-18	Colorectal cancer;
KIRP	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.82	-14.07	-0.67	2.17e-33	Post bronchodilator FEV1;
KIRP	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg07148914	chr20:33460835	GGT7	-0.53	-7.15	-0.41	9.75e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15988010	chr4:166033722	TMEM192	0.51	6.59	0.39	2.69e-10	Parkinson's disease;
KIRP	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg10047753	chr17:41438598	NA	1.13	18.16	0.76	2.55e-47	Menopause (age at onset);
KIRP	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.67	-5.64	-0.34	4.59e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg03959625	chr15:84868606	LOC388152	0.65	7.3	0.42	3.93e-12	Schizophrenia;
KIRP	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg00684032	chr4:1343700	KIAA1530	0.46	6.17	0.37	2.78e-9	Obesity-related traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24933605	chr2:216177085	ATIC	-0.42	-6.03	-0.36	5.93e-9	Myopia;
KIRP	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg13736514	chr6:26305472	NA	0.66	8.89	0.49	1.32e-16	Educational attainment;
KIRP	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg03465714	chr1:152285911	FLG	0.41	4.91	0.3	1.65e-6	Atopic dermatitis;
KIRP	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg12560992	chr17:57184187	TRIM37	0.6	5.49	0.33	9.83e-8	Cognitive test performance;
KIRP	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.53	0.38	3.78e-10	Morning vs. evening chronotype;
KIRP	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.62	-8.45	-0.47	2.65e-15	Total body bone mineral density;
KIRP	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg13180566	chr4:1052158	NA	-0.52	-5.34	-0.32	2.13e-7	Recombination rate (females);
KIRP	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.86	0.3	2.14e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.67	9.56	0.52	1.3e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs520865	0.786	rs4704697	chr5:80348238	C/T	cg17330048	chr5:80257322	RASGRF2	-0.46	-6.65	-0.39	1.85e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.83	-0.4	6.61e-11	Daytime sleep phenotypes;
KIRP	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg08533674	chr1:46993347	NA	0.39	4.98	0.3	1.18e-6	Monobrow;
KIRP	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.61	0.44	5.99e-13	Obesity-related traits;
KIRP	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.86	10.37	0.55	3.75e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.71	8.55	0.48	1.31e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.55	7.53	0.43	9.33e-13	Colorectal cancer;
KIRP	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.82	11.31	0.58	3.82e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	26.67	0.86	1.49e-74	Schizophrenia;
KIRP	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06647332	chr5:131281008	NA	0.45	4.88	0.3	1.87e-6	Life satisfaction;
KIRP	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.68	9.4	0.51	4.07e-18	Obesity-related traits;
KIRP	cis	rs2625529	0.652	rs2957734	chr15:72261385	A/G	cg16672083	chr15:72433130	SENP8	0.46	6.42	0.38	6.93e-10	Red blood cell count;
KIRP	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.48	-0.43	1.27e-12	Aortic root size;
KIRP	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg05802129	chr4:122689817	NA	-0.67	-9.27	-0.51	1.01e-17	Type 2 diabetes;
KIRP	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.57	8.2	0.46	1.31e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.77	-10.41	-0.55	2.84e-21	Aortic root size;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10916865	chr7:158497561	NCAPG2	-0.49	-6.72	-0.39	1.27e-10	Metabolic traits;
KIRP	cis	rs7766436	0.553	rs72833230	chr6:22618417	T/A	cg13666174	chr6:22585274	NA	-0.44	-4.88	-0.3	1.93e-6	Coronary artery disease;
KIRP	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg02023728	chr11:77925099	USP35	-0.32	-5.1	-0.31	6.93e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	cis	rs4356932	1.000	rs4371639	chr4:76946569	G/T	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs73198271	0.710	rs3827808	chr8:8679357	A/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.52	-0.38	3.98e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg07862535	chr7:139043722	LUC7L2	0.48	5.34	0.32	2.09e-7	Diisocyanate-induced asthma;
KIRP	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.98	-15.97	-0.71	7.23e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.64	8.97	0.5	7.61e-17	Lymphocyte counts;
KIRP	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.88	-0.57	8.82e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg16141378	chr3:129829833	LOC729375	0.5	6.73	0.39	1.19e-10	Mood instability;
KIRP	cis	rs2745572	0.557	rs2745574	chr6:1549225	C/G	cg01806741	chr6:1527072	NA	0.33	4.96	0.3	1.31e-6	Glaucoma (high intraocular pressure);Glaucoma (primary open-angle);Intraocular pressure;
KIRP	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.67	5.54	0.33	7.92e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs514024	0.729	rs7852204	chr9:130373596	T/C	cg13643465	chr9:130375613	STXBP1	0.47	6.13	0.36	3.4e-9	Eating disorders (purging via substances);
KIRP	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg03146154	chr1:46216737	IPP	-0.59	-6.81	-0.4	7.28e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.51	0.48	1.77e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.76	-0.34	2.48e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg13686331	chr21:40557788	BRWD1	0.39	6.05	0.36	5.44e-9	Migraine with aura;
KIRP	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg15704280	chr7:45808275	SEPT13	-0.56	-6.44	-0.38	6.2e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.39	0.38	8.24e-10	Menarche (age at onset);
KIRP	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.57	7.18	0.42	8.18e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13198984	chr17:80129470	CCDC57	-0.54	-8.15	-0.46	1.81e-14	Life satisfaction;
KIRP	trans	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg06521331	chr12:34319734	NA	-0.6	-7.16	-0.42	9.46e-12	Bladder cancer;
KIRP	trans	rs972578	0.765	rs4820492	chr22:43276030	A/C	cg15321293	chr3:36422198	STAC	-0.47	-6.11	-0.36	3.8e-9	Mean platelet volume;
KIRP	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.63	7.82	0.45	1.5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7258465	0.563	rs10854166	chr19:18652844	A/G	cg10790698	chr19:18539756	SSBP4	0.27	5.08	0.31	7.39e-7	Breast cancer;
KIRP	cis	rs9400467	0.592	rs462493	chr6:111683740	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.92e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg05669848	chr5:237993	SDHA	-0.48	-5.04	-0.31	8.88e-7	Breast cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01507044	chr13:23949294	SACS	-0.48	-6.12	-0.36	3.57e-9	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27391396	chr19:13976740	NA	0.47	6.48	0.38	4.92e-10	Parkinson's disease;
KIRP	cis	rs8177876	0.731	rs57606521	chr16:81137042	T/C	cg08591886	chr16:81111003	C16orf46	-0.66	-4.87	-0.3	1.97e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1448094	0.836	rs6539935	chr12:86376809	T/C	cg02569458	chr12:86230093	RASSF9	0.35	5.1	0.31	6.71e-7	Major depressive disorder;
KIRP	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.52	0.33	8.54e-8	Renal cell carcinoma;
KIRP	cis	rs1413885	0.516	rs10789183	chr1:65856779	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	5.81	0.35	1.94e-8	Anticoagulant levels;
KIRP	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.73	-0.39	1.18e-10	Bipolar disorder;
KIRP	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	8.0	0.45	4.85e-14	Coronary artery disease;
KIRP	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg04080417	chr5:1859792	NA	-0.49	-5.18	-0.31	4.51e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.58	7.39	0.43	2.29e-12	Tonsillectomy;
KIRP	cis	rs10046574	0.561	rs9656458	chr7:135202300	G/A	cg27474649	chr7:135195673	CNOT4	0.56	5.26	0.32	3.17e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.38	-0.51	4.7e-18	Systolic blood pressure;
KIRP	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg06627628	chr2:24431161	ITSN2	0.46	5.6	0.34	5.69e-8	Asthma;
KIRP	cis	rs4400599	0.549	rs12044616	chr1:154189417	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.45	-6.88	-0.4	4.88e-11	Platelet distribution width;
KIRP	cis	rs9308731	0.863	rs616582	chr2:111941995	T/C	cg23466623	chr2:111982296	NA	-0.48	-6.27	-0.37	1.58e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.37	-5.39	-0.32	1.68e-7	Body mass index;
KIRP	cis	rs934734	0.563	rs1858037	chr2:65598300	T/A	cg08085232	chr2:65598271	SPRED2	-0.57	-7.22	-0.42	6.48e-12	Rheumatoid arthritis;
KIRP	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs9596863	0.898	rs9563174	chr13:54335298	G/A	ch.13.53330881F	chr13:54432880	NA	0.6	5.79	0.35	2.16e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.12	0.61	8.3e-27	Platelet count;
KIRP	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.84	-12.08	-0.61	1.05e-26	Ileal carcinoids;
KIRP	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg11382394	chr1:2564504	MMEL1	-0.4	-5.03	-0.31	9.32e-7	Ulcerative colitis;
KIRP	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.42	4.94	0.3	1.44e-6	Aortic root size;
KIRP	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.13	-0.31	5.84e-7	Body mass index;
KIRP	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.66	5.43	0.33	1.34e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7106204	1.000	rs4622259	chr11:24215789	A/G	ch.11.24196551F	chr11:24239977	NA	0.85	9.12	0.5	2.84e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7714584	1.000	rs75774363	chr5:150223722	C/T	cg22134413	chr5:150180641	NA	0.75	6.44	0.38	6.13e-10	Crohn's disease;
KIRP	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg09201719	chr10:104596890	CYP17A1	0.39	5.78	0.35	2.25e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.33	0.59	3.17e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7221595	0.825	rs7225453	chr17:3960620	T/C	cg11204139	chr17:3907470	NA	0.54	5.27	0.32	2.92e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6450176	0.830	rs7718193	chr5:53291591	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-10.96	-0.57	5.05e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.46	-5.73	-0.34	2.94e-8	IgG glycosylation;
KIRP	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.9	-14.81	-0.69	6.45e-36	Urate levels in lean individuals;
KIRP	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.6	-6.27	-0.37	1.6e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.99	-16.12	-0.72	2.1e-40	Monocyte count;
KIRP	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.53	-6.38	-0.38	8.84e-10	Renal function-related traits (BUN);
KIRP	trans	rs909341	0.680	rs2427534	chr20:62366478	A/G	cg01311341	chr22:25575246	KIAA1671	-0.59	-6.86	-0.4	5.45e-11	Atopic dermatitis;
KIRP	cis	rs10073892	0.588	rs2895839	chr5:101907424	A/G	cg19774478	chr5:101632501	SLCO4C1	0.52	4.92	0.3	1.59e-6	Cognitive decline (age-related);
KIRP	trans	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg06521331	chr12:34319734	NA	-0.55	-6.76	-0.4	1.02e-10	Heart rate;
KIRP	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.49	-6.36	-0.38	9.9e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg20542592	chr8:11973495	FAM66D	0.41	5.24	0.32	3.54e-7	Triglycerides;
KIRP	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.81	0.45	1.63e-13	Morning vs. evening chronotype;
KIRP	cis	rs7712401	0.601	rs28892	chr5:122283826	A/G	cg19412675	chr5:122181750	SNX24	-0.48	-5.39	-0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs2652822	0.525	rs2053633	chr15:63505649	G/A	cg02713581	chr15:63449717	RPS27L	0.47	5.37	0.32	1.82e-7	Metabolic traits;
KIRP	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.42	4.85	0.3	2.18e-6	Blood protein levels;
KIRP	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02034447	chr16:89574710	SPG7	0.38	4.89	0.3	1.84e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11987759	chr7:65425863	GUSB	0.49	6.49	0.38	4.74e-10	Aortic root size;
KIRP	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs10193935	0.748	rs11124879	chr2:42697576	C/A	cg27598129	chr2:42591480	NA	0.71	6.83	0.4	6.71e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.85	12.21	0.61	4.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs79724016	0.546	rs16828475	chr1:42076364	C/T	cg25935697	chr3:51853898	NA	0.84	6.54	0.38	3.45e-10	Breast cancer;
KIRP	cis	rs732716	0.785	rs62130979	chr19:4432444	T/C	cg19820705	chr19:4455316	UBXN6	0.68	8.2	0.46	1.33e-14	Mean corpuscular volume;
KIRP	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs7187994	0.848	rs8048680	chr16:84762708	A/G	cg07647771	chr16:84786436	USP10	-0.44	-5.62	-0.34	5.16e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.13	0.41	1.13e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg07395648	chr5:131743802	NA	0.55	7.34	0.42	3.11e-12	Blood metabolite levels;
KIRP	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs62413470	0.935	rs12196649	chr6:55950172	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs2414059	0.518	rs8026653	chr15:50736620	G/C	cg05456662	chr15:50716270	USP8	-0.43	-5.74	-0.34	2.83e-8	QT interval;
KIRP	cis	rs11169552	0.510	rs4768858	chr12:51039818	C/T	cg12884762	chr12:50931848	DIP2B	-0.43	-4.88	-0.3	1.94e-6	Colorectal cancer;
KIRP	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg01721255	chr8:58191610	C8orf71	0.5	4.89	0.3	1.85e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4363385	0.530	rs58298199	chr1:152908814	A/C	cg13444842	chr1:152974279	SPRR3	-0.36	-5.12	-0.31	6.11e-7	Inflammatory skin disease;
KIRP	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.88	14.07	0.67	2.22e-33	Mean corpuscular volume;
KIRP	cis	rs7666738	0.546	rs3911415	chr4:98692401	T/A	cg05340658	chr4:99064831	C4orf37	0.66	7.67	0.44	4.04e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.32	0.65	7.53e-31	Bladder cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07695826	chr18:51884330	C18orf54	-0.5	-6.29	-0.37	1.43e-9	Interleukin-4 levels;
KIRP	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg00405596	chr8:11794950	NA	-0.39	-4.88	-0.3	1.93e-6	Systolic blood pressure;
KIRP	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg03289416	chr15:75166202	SCAMP2	-0.4	-5.29	-0.32	2.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs7712401	0.623	rs7723798	chr5:122369717	C/G	cg19412675	chr5:122181750	SNX24	0.47	5.23	0.32	3.69e-7	Mean platelet volume;
KIRP	cis	rs11955398	0.585	rs10041431	chr5:60010917	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg17507749	chr15:85114479	UBE2QP1	0.85	8.88	0.49	1.45e-16	Bipolar disorder lithium response (categorical) or schizophrenia;
KIRP	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-5.86	-0.35	1.45e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.55	0.56	1.03e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.62	8.54	0.48	1.38e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg10047753	chr17:41438598	NA	1.15	18.6	0.76	8.47e-49	Menopause (age at onset);
KIRP	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.07	0.41	1.59e-11	Height;
KIRP	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg12480562	chr20:23434244	CST11	0.58	5.67	0.34	3.95e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg21830797	chr15:40226279	EIF2AK4	-0.66	-6.92	-0.4	3.83e-11	Response to haloperidol in psychosis;
KIRP	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	9.67	0.52	5.74e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.39	-0.32	1.68e-7	Leprosy;
KIRP	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00149659	chr3:10157352	C3orf10	0.95	10.34	0.55	4.66e-21	Alzheimer's disease;
KIRP	cis	rs7833787	1.000	rs17468166	chr8:18705047	C/T	cg17701159	chr8:18705777	PSD3	-0.38	-7.3	-0.42	3.92e-12	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs17539620	0.624	rs58469593	chr6:154850105	G/A	cg20019720	chr6:154832845	CNKSR3	0.44	5.83	0.35	1.73e-8	Lipoprotein (a) levels;
KIRP	cis	rs988913	1.000	rs1503134	chr6:54836224	G/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.67	-0.34	3.97e-8	Menarche (age at onset);
KIRP	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05665937	chr4:1216051	CTBP1	0.58	8.47	0.48	2.2e-15	Obesity-related traits;
KIRP	cis	rs8014252	0.803	rs17113651	chr14:71061836	T/C	cg19730268	chr14:71022823	NA	-0.61	-5.79	-0.35	2.18e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs397969	0.646	rs203454	chr17:19821513	G/C	cg04132472	chr17:19861366	AKAP10	0.64	8.5	0.48	1.82e-15	Platelet count;
KIRP	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.68	7.29	0.42	4.34e-12	Lymphocyte counts;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.74	-8.48	-0.48	2.1e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-1.16	-15.06	-0.69	8.96e-37	Platelet distribution width;
KIRP	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	6.71	0.39	1.36e-10	Educational attainment;
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.77	8.68	0.48	5.52e-16	Corneal astigmatism;
KIRP	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.59	-7.37	-0.43	2.57e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg02678768	chr17:74002944	EVPL	0.41	5.33	0.32	2.19e-7	White matter hyperintensity burden;
KIRP	cis	rs78487399	0.808	rs17030889	chr2:43702829	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.03	-0.31	9.63e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.05	-0.58	2.5e-23	Height;
KIRP	trans	rs17079247	0.841	rs9575845	chr13:85809115	G/T	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24511898	chr2:242576823	ATG4B;THAP4	0.66	6.1	0.36	4.18e-9	Lung function (FEV1);
KIRP	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg23602478	chr1:26503979	CNKSR1	0.44	6.35	0.38	1.02e-9	Height;
KIRP	cis	rs9314323	0.501	rs6557911	chr8:26189230	G/T	cg11498726	chr8:26250323	BNIP3L	-0.47	-6.79	-0.4	8.38e-11	Red cell distribution width;
KIRP	cis	rs7106204	0.764	rs58215218	chr11:24234720	G/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.37	0.47	4.29e-15	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg21452805	chr1:244014465	NA	0.72	6.7	0.39	1.44e-10	RR interval (heart rate);
KIRP	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.68	-8.64	-0.48	7.12e-16	Body mass index;
KIRP	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg13444842	chr1:152974279	SPRR3	-0.48	-6.93	-0.4	3.71e-11	Inflammatory skin disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg07414239	chr6:126278153	HINT3	-0.6	-6.7	-0.39	1.4e-10	Menopause (age at onset);
KIRP	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg06360820	chr2:242988706	NA	-0.74	-6.49	-0.38	4.59e-10	Obesity-related traits;
KIRP	cis	rs3925075	1.000	rs4506917	chr16:31347350	T/G	cg02846316	chr16:31340340	ITGAM	0.61	9.6	0.52	9.5e-19	IgA nephropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03939054	chr11:96076473	MAML2	0.5	6.6	0.39	2.55e-10	Parkinson's disease;
KIRP	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14829155	chr15:31115871	NA	-0.77	-9.53	-0.52	1.62e-18	Huntington's disease progression;
KIRP	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.63	-7.6	-0.44	6.18e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg20362242	chr5:692897	TPPP	0.58	5.0	0.3	1.08e-6	Obesity-related traits;
KIRP	cis	rs8033133	0.881	rs4344720	chr15:25324141	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.55	-6.64	-0.39	1.98e-10	Blood osmolality (transformed sodium);
KIRP	cis	rs1823913	0.599	rs35495506	chr2:192172277	G/A	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.65e-12	Obesity-related traits;
KIRP	cis	rs10875746	0.669	rs10875767	chr12:48599257	A/C	cg26205652	chr12:48591994	NA	0.66	8.86	0.49	1.69e-16	Longevity (90 years and older);
KIRP	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.77	-9.95	-0.54	7.94e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg12046867	chr14:103022105	NA	0.52	6.12	0.36	3.77e-9	Platelet count;
KIRP	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.94	10.9	0.57	8.01e-23	Neuroticism;
KIRP	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.9	14.74	0.68	1.13e-35	Dental caries;
KIRP	cis	rs7760535	1.000	rs7760535	chr6:111747083	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.42	5.49	0.33	1e-7	Metabolic traits;
KIRP	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs6516091	0.778	rs62199231	chr20:6050133	C/T	cg25325723	chr20:6104886	FERMT1	-0.64	-6.41	-0.38	7.27e-10	Abdominal aortic aneurysm;
KIRP	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.95	-0.4	3.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg14456004	chr13:21872349	NA	1.23	16.1	0.72	2.61e-40	White matter hyperintensity burden;
KIRP	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.81	9.8	0.53	2.39e-19	Corneal astigmatism;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg13939156	chr17:80058883	NA	-0.5	-7.48	-0.43	1.3e-12	Life satisfaction;
KIRP	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	0.89	9.03	0.5	5.29e-17	Methadone dose in opioid dependence;
KIRP	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg00094735	chr5:1949198	NA	0.45	5.42	0.33	1.42e-7	Gut microbiome composition (winter);
KIRP	cis	rs2916247	0.955	rs2976501	chr8:92976563	T/G	cg10183463	chr8:93005414	RUNX1T1	0.6	8.05	0.46	3.64e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.59	-7.8	-0.45	1.71e-13	Longevity;
KIRP	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21643547	chr1:205240462	TMCC2	-0.87	-14.84	-0.69	5.28e-36	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.94	-12.56	-0.63	2.69e-28	Schizophrenia;
KIRP	cis	rs4664304	0.781	rs3828323	chr2:160808075	C/T	cg23995753	chr2:160760732	LY75	-0.39	-4.99	-0.3	1.12e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.9	-0.6	4.4e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18369257	chr11:61520258	C11orf9	0.55	6.87	0.4	5.14e-11	Parkinson's disease;
KIRP	cis	rs4262150	0.774	rs6872796	chr5:151951125	A/C	cg12297329	chr5:152029980	NA	-0.65	-7.91	-0.45	8.95e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.9	-0.4	4.51e-11	Response to antipsychotic treatment;
KIRP	cis	rs6499755	0.712	rs31093	chr16:55366176	C/G	cg05099576	chr16:55362342	IRX6	0.29	6.04	0.36	5.72e-9	Hypospadias;
KIRP	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-8.91	-0.49	1.17e-16	Neuroticism;
KIRP	cis	rs9513593	1.000	rs723090	chr13:100017105	A/G	cg21788972	chr13:99853209	UBAC2	0.54	5.75	0.34	2.57e-8	Psoriasis;
KIRP	cis	rs1134634	0.520	rs7661102	chr4:15598537	A/G	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.7	-0.34	3.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg09597638	chr17:3907349	NA	0.76	14.58	0.68	4e-35	Type 2 diabetes;
KIRP	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.12	0.5	2.85e-17	Morning vs. evening chronotype;
KIRP	cis	rs1476670	0.710	rs751442	chr1:44509551	A/C	cg09470012	chr1:44509516	NA	0.38	6.03	0.36	6.02e-9	Eotaxin levels;
KIRP	cis	rs1863824	0.502	rs11202058	chr10:88282611	G/A	cg07322936	chr10:88137208	NA	-0.51	-4.84	-0.3	2.27e-6	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs17401966	0.577	rs1556915	chr1:10242654	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-7.25	-0.42	5.52e-12	Hepatocellular carcinoma;
KIRP	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.35	0.32	2e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs28595532	0.720	rs72670230	chr4:119312490	T/C	cg21605333	chr4:119757512	SEC24D	1.03	7.11	0.41	1.27e-11	Cannabis dependence symptom count;
KIRP	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg09873164	chr1:152488093	CRCT1	0.53	6.44	0.38	6.27e-10	Hair morphology;
KIRP	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg15880211	chr22:50250494	ZBED4	-0.65	-7.31	-0.42	3.72e-12	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20853569	chr17:79247697	SLC38A10	0.48	6.08	0.36	4.62e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg16262614	chr3:133464971	TF	0.38	5.58	0.34	6.18e-8	Iron status biomarkers (transferrin levels);
KIRP	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	6.71	0.39	1.35e-10	Iron status biomarkers;
KIRP	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg18586891	chr4:952366	TMEM175	0.63	5.11	0.31	6.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.74	0.71	4.26e-39	Bipolar disorder;
KIRP	cis	rs62355272	0.793	rs57804084	chr5:35820893	C/A	cg13894535	chr5:35919491	CAPSL	-0.5	-5.46	-0.33	1.18e-7	Lymphocyte counts;
KIRP	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs7792596	0.539	rs34680645	chr7:94005301	T/C	cg20814616	chr7:94014465	NA	-0.41	-5.2	-0.31	4.18e-7	Intelligence;
KIRP	cis	rs5167	0.566	rs2075620	chr19:45480037	C/T	cg13119609	chr19:45449297	APOC2	-0.4	-5.11	-0.31	6.53e-7	Blood protein levels;
KIRP	cis	rs2929278	0.617	rs11070410	chr15:44057045	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.48	-5.75	-0.34	2.67e-8	Schizophrenia;
KIRP	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg16006841	chr5:176797999	RGS14	0.69	8.13	0.46	2.05e-14	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.84	-12.93	-0.64	1.59e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00321850	chr1:175162397	KIAA0040	0.36	6.49	0.38	4.66e-10	Alcohol dependence;
KIRP	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.44	9.04	0.5	4.64e-17	Rheumatoid arthritis;
KIRP	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.58	-5.61	-0.34	5.52e-8	Blood trace element (Zn levels);
KIRP	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg13902645	chr11:5959945	NA	-0.6	-6.31	-0.37	1.26e-9	DNA methylation (variation);
KIRP	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.4	-7.22	-0.42	6.42e-12	Refractive error;
KIRP	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg01849466	chr14:104193079	ZFYVE21	0.42	5.17	0.31	4.82e-7	Schizophrenia;
KIRP	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.29	0.32	2.71e-7	Body mass index;
KIRP	cis	rs11877825	0.826	rs4121956	chr18:10569930	C/T	cg07277756	chr18:10589357	NA	0.49	6.19	0.37	2.52e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg23920097	chr1:209922102	NA	-0.42	-4.97	-0.3	1.26e-6	Red blood cell count;
KIRP	cis	rs3789045	0.837	rs57450685	chr1:204580832	A/T	cg18185008	chr1:204589407	LRRN2	-0.63	-7.22	-0.42	6.42e-12	Educational attainment (college completion);
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.44	0.43	1.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.77	-0.4	9.14e-11	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02738049	chr15:43663357	ZSCAN29;TUBGCP4	0.53	7.06	0.41	1.7e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs61332075	0.531	rs11885695	chr2:239338632	G/A	cg18131467	chr2:239335373	ASB1	-0.67	-7.12	-0.41	1.16e-11	Lung function (FEV1/FVC);
KIRP	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21747090	chr2:27597821	SNX17	-0.47	-6.48	-0.38	4.99e-10	Total body bone mineral density;
KIRP	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg22705602	chr4:152727874	NA	0.53	9.25	0.51	1.11e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-5.36	-0.32	1.88e-7	Neuroticism;
KIRP	cis	rs6009824	1.000	rs6009823	chr22:50086334	C/T	cg27029450	chr22:50098074	NA	0.53	5.54	0.33	7.6e-8	Natriuretic peptide levels;
KIRP	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.33	0.42	3.24e-12	Rheumatoid arthritis;
KIRP	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg21452805	chr1:244014465	NA	0.72	6.78	0.4	9.01e-11	RR interval (heart rate);
KIRP	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.38	-0.38	8.56e-10	Monocyte percentage of white cells;
KIRP	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.49	-0.43	1.2e-12	Body mass index;
KIRP	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg17757837	chr7:157058334	UBE3C	0.78	10.83	0.57	1.28e-22	Body mass index;
KIRP	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18255839	chr2:239335447	ASB1	0.4	4.85	0.3	2.19e-6	Multiple system atrophy;
KIRP	cis	rs12220238	0.841	rs11001001	chr10:76097678	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.61	0.39	2.34e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.67	-6.82	-0.4	6.95e-11	Axial length;
KIRP	cis	rs35740288	0.929	rs11630684	chr15:86306256	C/A	cg17133734	chr15:86042851	AKAP13	-0.49	-5.39	-0.33	1.65e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg24110177	chr3:50126178	RBM5	-0.66	-7.62	-0.44	5.39e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18357526	chr6:26021779	HIST1H4A	0.52	6.72	0.39	1.23e-10	Height;
KIRP	trans	rs7939886	0.841	rs79902631	chr11:55995241	A/C	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	1.05	10.98	0.57	4.26e-23	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.58	-8.05	-0.46	3.63e-14	Diastolic blood pressure;
KIRP	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	24.36	0.84	1.67e-67	Schizophrenia;
KIRP	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg18240062	chr17:79603768	NPLOC4	0.81	10.77	0.57	2.11e-22	Eye color traits;
KIRP	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg15764593	chr10:829463	NA	-0.83	-8.85	-0.49	1.7e-16	Uric acid levels;
KIRP	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg17145862	chr1:211918768	LPGAT1	-0.92	-13.37	-0.65	5.15e-31	Leprosy;
KIRP	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg21798802	chr22:38057573	PDXP	0.42	5.11	0.31	6.34e-7	Fat distribution (HIV);
KIRP	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg05775895	chr3:12838266	CAND2	0.34	5.49	0.33	9.87e-8	P wave duration;
KIRP	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.71e-25	Vitiligo;
KIRP	cis	rs8113308	0.810	rs16983256	chr19:52449481	G/A	cg24732339	chr19:52471368	ZNF350	-0.45	-5.02	-0.3	9.83e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg14458575	chr2:238380390	NA	0.57	7.52	0.43	1.02e-12	Prostate cancer;
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs2278796	0.639	rs4950976	chr1:204970243	C/T	cg17449235	chr1:204966235	NFASC	-0.56	-7.88	-0.45	1.08e-13	Mean platelet volume;
KIRP	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.69	-9.61	-0.52	8.94e-19	Plateletcrit;Platelet count;
KIRP	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg26441486	chr22:50317300	CRELD2	-0.4	-5.59	-0.34	5.96e-8	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg07309820	chr7:148901717	ZNF282	-0.4	-5.2	-0.31	4.18e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg22117172	chr7:91764530	CYP51A1	0.43	5.82	0.35	1.86e-8	Breast cancer;
KIRP	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg24631222	chr15:78858424	CHRNA5	0.76	9.08	0.5	3.7e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.38	-0.32	1.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8179	0.645	rs66939011	chr7:92265798	T/C	cg15732164	chr7:92237376	CDK6	-0.39	-5.18	-0.31	4.55e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg16339924	chr4:17578868	LAP3	0.58	7.79	0.44	1.88e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.21	-0.32	3.91e-7	Metabolite levels;
KIRP	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg16649577	chr8:11646810	NA	0.4	5.47	0.33	1.11e-7	Retinal vascular caliber;
KIRP	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg09137382	chr11:130731461	NA	0.57	7.86	0.45	1.18e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.0	13.89	0.66	8.76e-33	Response to antipsychotic treatment;
KIRP	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg08133631	chr1:26527909	CATSPER4	-0.47	-5.42	-0.33	1.44e-7	Obesity-related traits;
KIRP	cis	rs58649573	0.509	rs917783	chr9:126790607	A/C	cg14112217	chr9:126806003	NA	0.35	5.13	0.31	5.87e-7	Post-traumatic stress disorder;
KIRP	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.72	-7.94	-0.45	7.17e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg21479132	chr6:26055353	NA	0.82	5.76	0.34	2.52e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg27411982	chr8:10470053	RP1L1	-0.47	-5.94	-0.35	9.53e-9	Neuroticism;
KIRP	cis	rs7119167	0.686	rs12294659	chr11:73041007	G/A	cg17517138	chr11:73019481	ARHGEF17	0.46	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.76	-10.23	-0.55	1.08e-20	Menarche (age at onset);
KIRP	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg02336718	chr17:17403227	NA	0.33	5.23	0.32	3.57e-7	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06624832	chr17:72772340	TMEM104;NAT9	0.53	6.23	0.37	1.98e-9	Smoking initiation;
KIRP	cis	rs4664293	0.631	rs13024749	chr2:160656117	T/G	cg08347373	chr2:160653686	CD302	0.34	5.28	0.32	2.79e-7	Monocyte percentage of white cells;
KIRP	cis	rs77688320	0.553	rs2080320	chr2:202379173	C/T	cg06431681	chr2:202330990	STRADB	0.44	5.17	0.31	4.84e-7	Breast cancer;
KIRP	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg00405596	chr8:11794950	NA	-0.45	-5.52	-0.33	8.38e-8	Neuroticism;
KIRP	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03352830	chr11:487213	PTDSS2	0.76	6.11	0.36	3.81e-9	Body mass index;
KIRP	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.92	16.87	0.73	5.94e-43	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs72634030	0.536	rs61222806	chr17:5227195	G/A	cg20802942	chr17:5185005	RABEP1	0.52	4.99	0.3	1.17e-6	Rheumatoid arthritis;
KIRP	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.55	7.37	0.43	2.51e-12	Longevity;Endometriosis;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.44	-0.33	1.26e-7	Lung cancer;
KIRP	cis	rs2494663	0.585	rs11265076	chr1:154074299	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.93	-0.3	1.5e-6	Mean platelet volume;
KIRP	cis	rs1215050	0.791	rs7681599	chr4:98664109	C/T	cg05340658	chr4:99064831	C4orf37	-0.49	-6.02	-0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg23719950	chr11:63933701	MACROD1	-0.68	-6.61	-0.39	2.39e-10	Mean platelet volume;
KIRP	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-16.66	-0.73	3.11e-42	Height;
KIRP	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.8	7.69	0.44	3.62e-13	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27572240	chr22:41682267	RANGAP1	0.47	6.21	0.37	2.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs785830	0.636	rs601023	chr9:224693	A/G	cg14500300	chr9:211689	NA	0.51	6.83	0.4	6.7e-11	Platelet distribution width;
KIRP	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.53	-6.17	-0.37	2.72e-9	Monocyte count;
KIRP	trans	rs1973993	0.745	rs7512263	chr1:96941158	C/A	cg10631902	chr5:14652156	NA	-0.61	-8.61	-0.48	8.76e-16	Weight;
KIRP	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.72	-9.07	-0.5	3.9e-17	Coronary artery disease;
KIRP	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.63	-9.0	-0.5	6.16e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.81	7.74	0.44	2.64e-13	Methadone dose in opioid dependence;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19545348	chr1:211434133	RCOR3	0.52	6.11	0.36	3.86e-9	Smoking initiation;
KIRP	cis	rs61935443	0.614	rs11107787	chr12:95311669	C/T	cg21533806	chr12:95267307	NA	0.57	5.2	0.31	4.1e-7	Schizophrenia;
KIRP	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.76	-9.51	-0.52	1.84e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg13753209	chr17:57696993	CLTC	0.51	4.95	0.3	1.39e-6	Hemoglobin concentration;
KIRP	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.62	8.52	0.48	1.59e-15	Bladder cancer;
KIRP	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.57	-0.39	3.01e-10	Lung cancer;
KIRP	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg04362960	chr10:104952993	NT5C2	0.56	7.04	0.41	1.87e-11	Arsenic metabolism;
KIRP	cis	rs1341267	1.000	rs1341267	chr13:95284980	A/C	cg11945895	chr13:95253670	GPR180	-0.26	-4.94	-0.3	1.45e-6	Triglyceride levels;
KIRP	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg09231725	chr11:64357281	SLC22A12	0.6	8.03	0.46	4.09e-14	Urate levels in obese individuals;
KIRP	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.59	-8.24	-0.47	1.02e-14	Lung cancer;
KIRP	cis	rs6430538	0.646	rs11887093	chr2:135538418	G/C	cg12500956	chr2:135428796	TMEM163	0.42	5.35	0.32	1.97e-7	Parkinson's disease;
KIRP	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.44	0.43	1.63e-12	Lung cancer;
KIRP	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg10503236	chr1:231470652	EXOC8	-0.48	-6.64	-0.39	2.01e-10	Hemoglobin concentration;
KIRP	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	Neuroticism;
KIRP	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.28e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg23985595	chr17:80112537	CCDC57	-0.37	-5.59	-0.34	5.98e-8	Life satisfaction;
KIRP	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.51	5.99	0.36	7.46e-9	Mean platelet volume;
KIRP	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.71	-7.85	-0.45	1.25e-13	Body mass index;
KIRP	cis	rs2241685	0.646	rs7588882	chr2:1931058	A/G	cg22511877	chr2:1942942	MYT1L	-0.55	-5.82	-0.35	1.84e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.3	0.47	6.84e-15	Motion sickness;
KIRP	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs6593803	0.774	rs2353	chr1:147222372	A/G	cg27546670	chr1:147246839	GJA5	0.69	7.96	0.45	6.16e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.25	12.89	0.64	2.08e-29	Diabetic retinopathy;
KIRP	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg10664184	chr19:17420304	DDA1	-0.72	-8.5	-0.48	1.9e-15	Systemic lupus erythematosus;
KIRP	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.73	-10.02	-0.54	4.81e-20	Coronary artery disease;
KIRP	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg19610905	chr11:61596333	FADS2	-0.56	-8.46	-0.47	2.37e-15	Trans fatty acid levels;
KIRP	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12480562	chr20:23434244	CST11	0.66	5.11	0.31	6.53e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.8	11.18	0.58	1.01e-23	Aortic root size;
KIRP	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.15	0.31	5.27e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.7e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg01097406	chr16:89675127	NA	0.33	5.22	0.32	3.72e-7	Vitiligo;
KIRP	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.76	-10.04	-0.54	4.24e-20	Neuroblastoma (high-risk);
KIRP	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.79	-13.62	-0.66	7.61e-32	Itch intensity from mosquito bite;
KIRP	cis	rs11673344	0.864	rs11667146	chr19:37495395	G/A	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.3	-0.32	2.6e-7	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg10755058	chr3:40428713	ENTPD3	0.47	6.58	0.39	2.78e-10	Renal cell carcinoma;
KIRP	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.12	-0.36	3.68e-9	Aortic root size;
KIRP	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	ch.8.33884649F	chr8:33765107	NA	0.61	7.55	0.43	8.73e-13	Body mass index;
KIRP	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.55	5.32	0.32	2.33e-7	Gut microbiome composition (summer);
KIRP	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg01631408	chr1:248437212	OR2T33	-0.44	-5.74	-0.34	2.83e-8	Common traits (Other);
KIRP	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg00800038	chr16:89945340	TCF25	-0.89	-7.28	-0.42	4.62e-12	Skin colour saturation;
KIRP	cis	rs4478137	0.839	rs3967763	chr4:164239273	G/C	cg06758707	chr4:164254230	NPY1R	0.7	9.07	0.5	4e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg11693508	chr17:37793320	STARD3	0.74	8.14	0.46	1.98e-14	Bipolar disorder;
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.84	14.52	0.68	6.6e-35	Longevity;Endometriosis;
KIRP	cis	rs13315871	1.000	rs1131052	chr3:58411530	A/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15809806	chr10:33518295	NRP1	0.5	6.1	0.36	4.03e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-5.42	-0.33	1.43e-7	Skin colour saturation;
KIRP	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.59	-4.94	-0.3	1.45e-6	Putamen volume;
KIRP	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg19773385	chr1:10388646	KIF1B	-0.75	-12.0	-0.61	2.06e-26	Hepatocellular carcinoma;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.65	7.79	0.44	1.93e-13	Mean platelet volume;
KIRP	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.39	-5.46	-0.33	1.14e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs17125944	0.615	rs11629431	chr14:53320528	C/G	cg00686598	chr14:53173677	PSMC6	-0.72	-7.06	-0.41	1.73e-11	Alzheimer's disease (late onset);
KIRP	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg05714579	chr10:131428358	MGMT	0.48	6.3	0.37	1.34e-9	Response to temozolomide;
KIRP	cis	rs4589502	0.557	rs7495093	chr15:67155221	T/C	cg12317470	chr15:67143691	NA	0.45	4.85	0.3	2.2e-6	Lung cancer (smoking interaction);
KIRP	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-5.63	-0.34	4.97e-8	Personality dimensions;
KIRP	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.66	8.69	0.48	5.13e-16	Aortic root size;
KIRP	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Hypertriglyceridemia;
KIRP	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg18944383	chr4:111397179	ENPEP	0.42	6.84	0.4	6.39e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.53	7.34	0.42	3.02e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.42	-5.52	-0.33	8.57e-8	Body mass index;
KIRP	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	trans	rs2797160	0.547	rs4144549	chr6:125945251	C/G	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.2	0.37	2.31e-9	Endometrial cancer;
KIRP	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg24488311	chr11:68621650	NA	0.41	5.03	0.31	9.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.83e-16	Immature fraction of reticulocytes;
KIRP	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	11.52	0.59	7.53e-25	Platelet count;
KIRP	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.2	-0.37	2.42e-9	Personality dimensions;
KIRP	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.34	5.83	0.35	1.76e-8	Refractive error;
KIRP	cis	rs17095355	1.000	rs12263915	chr10:111744664	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.37	-5.2	-0.31	4.15e-7	Biliary atresia;
KIRP	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg13147721	chr7:65941812	NA	-0.9	-6.55	-0.39	3.33e-10	Diabetic kidney disease;
KIRP	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg03808351	chr9:123631620	PHF19	0.44	5.95	0.35	9.3e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg13939156	chr17:80058883	NA	-0.48	-5.57	-0.33	6.77e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18093693	chr15:72668265	HEXA;C15orf34	0.62	7.32	0.42	3.58e-12	Smoking initiation;
KIRP	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.63	-0.34	4.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg16482183	chr6:26056742	HIST1H1C	0.65	7.31	0.42	3.69e-12	Iron status biomarkers;
KIRP	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg16583315	chr14:65563665	MAX	0.34	5.23	0.32	3.71e-7	Obesity-related traits;
KIRP	cis	rs8038465	1.000	rs8041523	chr15:73982556	C/T	cg15420318	chr15:73925796	NPTN	0.55	7.03	0.41	1.98e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.59	6.15	0.37	3.11e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	ch.11.340609R	chr11:12831013	TEAD1	-0.39	-5.0	-0.3	1.09e-6	Educational attainment (years of education);
KIRP	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-0.78	-9.0	-0.5	6.39e-17	Diastolic blood pressure;
KIRP	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg21775007	chr8:11205619	TDH	0.45	6.32	0.37	1.2e-9	Neuroticism;
KIRP	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg26335602	chr6:28129616	ZNF389	0.45	5.04	0.31	9.07e-7	Depression;
KIRP	cis	rs699371	0.507	rs10149787	chr14:74925452	A/C	cg16374328	chr14:74960395	NPC2;ISCA2	-0.5	-6.24	-0.37	1.85e-9	Height;
KIRP	cis	rs6681460	1.000	rs6696927	chr1:67070381	A/G	cg02459107	chr1:67143332	SGIP1	0.45	6.49	0.38	4.79e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.65	8.61	0.48	8.92e-16	Colorectal cancer;
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13939156	chr17:80058883	NA	0.5	7.54	0.43	8.98e-13	Life satisfaction;
KIRP	cis	rs6882046	0.513	rs639725	chr5:88001969	A/G	cg22951263	chr5:87985283	NA	-0.47	-6.68	-0.39	1.62e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs10484761	0.956	rs6916263	chr6:40810611	G/C	cg02680909	chr6:39899321	MOCS1	-0.24	-5.06	-0.31	8.07e-7	Esophageal cancer;
KIRP	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg24631222	chr15:78858424	CHRNA5	0.82	9.4	0.51	4.09e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs336284	0.502	rs6976419	chr7:35326018	G/A	cg06685737	chr7:35301730	NA	0.46	5.55	0.33	7.49e-8	Suicide;Suicide behavior;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.16	-0.46	1.77e-14	Obesity-related traits;
KIRP	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg19847130	chr8:10466454	RP1L1	0.36	5.27	0.32	2.96e-7	Neuroticism;
KIRP	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.61	-6.67	-0.39	1.68e-10	DNA methylation (variation);
KIRP	cis	rs4262150	0.883	rs72799178	chr5:152157489	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.73	-0.66	3.2e-32	Primary sclerosing cholangitis;
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.77	10.12	0.54	2.33e-20	Aortic root size;
KIRP	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg23815491	chr16:72088622	HP	0.48	7.05	0.41	1.78e-11	Blood protein levels;
KIRP	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg14673194	chr17:80132900	CCDC57	0.77	8.69	0.48	5.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.69	-10.01	-0.54	5.42e-20	Airway imaging phenotypes;
KIRP	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg17757837	chr7:157058334	UBE3C	0.78	10.55	0.56	1.02e-21	Body mass index;
KIRP	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.5	5.83	0.35	1.73e-8	Uric acid levels;
KIRP	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg24130564	chr14:104152367	KLC1	-0.42	-4.94	-0.3	1.42e-6	Reticulocyte count;
KIRP	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.45	-0.52	2.85e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.13	-0.36	3.49e-9	Parkinson's disease;
KIRP	cis	rs754423	0.622	rs730531	chr14:52518683	A/G	cg05884192	chr14:52515736	NID2	-0.57	-5.99	-0.36	7.51e-9	Craniofacial microsomia;
KIRP	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg16434002	chr17:42200994	HDAC5	0.44	5.16	0.31	5.06e-7	Total body bone mineral density;
KIRP	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg07653901	chr22:50250238	ZBED4	-0.63	-6.91	-0.4	4.15e-11	Schizophrenia;
KIRP	cis	rs4805272	0.962	rs2870543	chr19:29324690	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.82	-0.4	7.01e-11	Aortic root size;
KIRP	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.15	0.61	6.54e-27	Ileal carcinoids;
KIRP	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg11204139	chr17:3907470	NA	0.55	5.14	0.31	5.48e-7	Type 2 diabetes;
KIRP	cis	rs35740288	0.597	rs12900830	chr15:86326154	T/C	cg20737812	chr15:86336631	KLHL25	-0.52	-6.23	-0.37	2.03e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg26116260	chr4:7069785	GRPEL1	-1.02	-6.4	-0.38	7.59e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.85	11.55	0.59	6.31e-25	Selective IgA deficiency;
KIRP	cis	rs17065868	0.764	rs9525957	chr13:45040940	C/T	cg10246903	chr13:45222710	NA	0.58	5.0	0.3	1.08e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.82	9.87	0.53	1.41e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg07796016	chr1:152779584	LCE1C	-0.45	-5.91	-0.35	1.13e-8	Inflammatory skin disease;
KIRP	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg01403660	chr11:68851641	TPCN2	0.62	7.15	0.41	9.62e-12	Blond vs. brown hair color;
KIRP	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg00852783	chr1:26633632	UBXN11	0.59	7.82	0.45	1.52e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.47	0.72	1.41e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.5	-5.97	-0.36	8.4e-9	Body mass index;
KIRP	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	6.82	0.4	6.89e-11	Height;
KIRP	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg23335576	chr14:104009727	NA	-0.36	-4.98	-0.3	1.2e-6	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15092420	chr4:17885244	LCORL	-0.41	-6.62	-0.39	2.24e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.57	-7.49	-0.43	1.26e-12	Longevity;
KIRP	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg08888203	chr3:10149979	C3orf24	0.49	5.19	0.31	4.5e-7	Alzheimer's disease;
KIRP	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.04	-0.58	2.75e-23	Height;
KIRP	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08045932	chr20:61659980	NA	0.55	7.02	0.41	2.14e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4132509	1.000	rs6659180	chr1:243995348	C/T	cg25706552	chr1:244017396	NA	0.61	7.58	0.44	6.87e-13	RR interval (heart rate);
KIRP	cis	rs6540556	0.643	rs2282739	chr1:209883001	C/T	cg23920097	chr1:209922102	NA	-0.44	-5.96	-0.35	8.91e-9	Red blood cell count;
KIRP	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.98	17.23	0.74	3.57e-44	Breast cancer;
KIRP	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.63	-6.34	-0.37	1.11e-9	Schizophrenia;
KIRP	cis	rs929596	0.793	rs2741045	chr2:234580140	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-6.01	-0.36	6.71e-9	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	8.21	0.46	1.29e-14	Educational attainment;
KIRP	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg13010199	chr12:38710504	ALG10B	0.62	7.72	0.44	2.96e-13	Morning vs. evening chronotype;
KIRP	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.57	6.93	0.4	3.59e-11	Type 2 diabetes;
KIRP	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.82	-12.06	-0.61	1.28e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.48	5.32	0.32	2.38e-7	Blood metabolite levels;
KIRP	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.47	-0.33	1.12e-7	Height;
KIRP	cis	rs6088813	1.000	rs6087705	chr20:34001250	C/T	cg14752227	chr20:34000481	UQCC	-0.49	-6.5	-0.38	4.45e-10	Height;
KIRP	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg09915433	chr19:53449742	NA	-0.45	-6.9	-0.4	4.47e-11	Psoriasis;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18432252	chr5:177558089	RMND5B	0.46	6.33	0.37	1.13e-9	Cancer;
KIRP	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-5.51	-0.33	8.95e-8	Morning vs. evening chronotype;
KIRP	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.04	-0.31	8.88e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.43	4.9	0.3	1.72e-6	Schizophrenia;
KIRP	cis	rs6733011	0.578	rs12712039	chr2:99497980	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-5.25	-0.32	3.31e-7	Bipolar disorder;
KIRP	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg08662619	chr6:150070041	PCMT1	0.37	6.05	0.36	5.47e-9	Lung cancer;
KIRP	cis	rs4356932	1.000	rs4859588	chr4:76943677	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.77	-11.12	-0.58	1.49e-23	Hip circumference;
KIRP	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	8.17	0.46	1.62e-14	Neuroticism;
KIRP	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08280861	chr8:58055591	NA	0.72	5.43	0.33	1.35e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.45	5.87	0.35	1.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.62	0.48	8.18e-16	Motion sickness;
KIRP	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg18586891	chr4:952366	TMEM175	0.63	5.65	0.34	4.44e-8	Parkinson's disease;
KIRP	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.54	6.7	0.39	1.38e-10	Resistin levels;
KIRP	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg08989290	chr16:615782	NHLRC4	0.43	6.27	0.37	1.64e-9	Height;
KIRP	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg09699651	chr6:150184138	LRP11	0.47	6.24	0.37	1.92e-9	Lung cancer;
KIRP	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg15655495	chr12:38532458	NA	0.27	5.34	0.32	2.11e-7	Bladder cancer;
KIRP	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.79	-0.35	2.09e-8	Parkinson's disease;
KIRP	cis	rs11901793	0.505	rs34446892	chr2:237495452	C/T	cg25295825	chr2:237489920	CXCR7	0.76	7.7	0.44	3.32e-13	Total mean fractional anisotropy measurement in first episode schizophrenia;
KIRP	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	7.97	0.45	5.92e-14	Personality dimensions;
KIRP	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg05791153	chr7:19748676	TWISTNB	0.66	6.05	0.36	5.43e-9	Thyroid stimulating hormone;
KIRP	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.81	7.86	0.45	1.17e-13	Lung function (FEV1/FVC);
KIRP	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.88e-18	Height;
KIRP	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg05973401	chr12:123451056	ABCB9	-0.49	-5.47	-0.33	1.12e-7	Neutrophil percentage of white cells;
KIRP	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.88	-0.4	5.05e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.32	-0.37	1.21e-9	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.75	-10.14	-0.54	2.02e-20	Height;
KIRP	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.99	0.45	5.09e-14	Height;
KIRP	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	1.07	15.78	0.71	3.12e-39	Menopause (age at onset);
KIRP	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg14851346	chr12:38532713	NA	-0.39	-4.85	-0.3	2.19e-6	Bladder cancer;
KIRP	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	24.3	0.84	2.53e-67	Chronic sinus infection;
KIRP	cis	rs7187994	0.848	rs7498187	chr16:84770570	G/A	cg07647771	chr16:84786436	USP10	-0.5	-6.04	-0.36	5.61e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18357526	chr6:26021779	HIST1H4A	0.52	6.72	0.39	1.23e-10	Height;
KIRP	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg07930552	chr6:133119739	C6orf192	0.84	8.46	0.47	2.35e-15	Type 2 diabetes nephropathy;
KIRP	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.46	5.79	0.35	2.11e-8	Facial morphology (factor 20);
KIRP	cis	rs698813	0.572	rs4953076	chr2:44480950	G/C	cg04920474	chr2:44395004	PPM1B	0.37	4.97	0.3	1.23e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	1.99e-12	Morning vs. evening chronotype;
KIRP	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.81	-10.58	-0.56	8.53e-22	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg00405596	chr8:11794950	NA	-0.44	-5.68	-0.34	3.72e-8	Monocyte count;
KIRP	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg23978390	chr7:1156363	C7orf50	0.41	5.41	0.33	1.51e-7	Longevity;Endometriosis;
KIRP	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg22906224	chr7:99728672	NA	0.52	6.26	0.37	1.68e-9	Coronary artery disease;
KIRP	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.93	-0.35	1e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg13736514	chr6:26305472	NA	-0.44	-4.92	-0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.69	-5.41	-0.33	1.48e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.46	-6.06	-0.36	5.19e-9	Blood protein levels;
KIRP	cis	rs231513	0.911	rs231517	chr17:41961789	C/T	cg26893861	chr17:41843967	DUSP3	-0.49	-5.13	-0.31	5.74e-7	Cognitive function;
KIRP	cis	rs3087591	0.879	rs12103564	chr17:29607243	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.6	-7.96	-0.45	6.46e-14	Hip circumference;
KIRP	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.84	-12.83	-0.63	3.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12496230	0.794	rs12635603	chr3:66858921	C/T	cg04995300	chr3:66848608	NA	0.45	6.95	0.41	3.26e-11	Type 2 diabetes;
KIRP	cis	rs55882075	0.936	rs34646062	chr5:179186318	A/G	cg14593053	chr5:179126677	CANX	-0.63	-8.45	-0.47	2.64e-15	Monocyte percentage of white cells;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20080590	chr4:24831413	CCDC149	0.46	6.34	0.37	1.1e-9	Survival in pancreatic cancer;
KIRP	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg11584989	chr19:19387371	SF4	0.62	6.65	0.39	1.85e-10	Bipolar disorder;
KIRP	cis	rs838721	0.574	rs11676156	chr2:234259001	G/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	4.91	0.3	1.64e-6	Total body bone mineral density;
KIRP	cis	rs2598107	0.601	rs35850626	chr7:37958467	C/A	cg25225232	chr7:37962694	EPDR1	-0.41	-4.89	-0.3	1.81e-6	Dupuytren's disease;
KIRP	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg14416269	chr4:6271139	WFS1	0.37	5.52	0.33	8.44e-8	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg00784671	chr22:46762841	CELSR1	0.52	7.01	0.41	2.24e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg08501292	chr6:25962987	TRIM38	0.79	5.44	0.33	1.31e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg25281562	chr12:121454272	C12orf43	0.5	5.58	0.34	6.25e-8	N-glycan levels;
KIRP	cis	rs17221829	0.703	rs10830347	chr11:89415165	C/T	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.36	-0.32	1.93e-7	Anxiety in major depressive disorder;
KIRP	cis	rs876084	0.545	rs10096311	chr8:121102031	A/G	cg06265175	chr8:121136014	COL14A1	0.5	6.2	0.37	2.34e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-1.08	-21.58	-0.81	1.11e-58	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.21	14.37	0.68	2.07e-34	Uric acid levels;
KIRP	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.74	0.49	3.7e-16	Lung cancer in ever smokers;
KIRP	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.8	-9.49	-0.52	2.13e-18	Corneal astigmatism;
KIRP	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.67	-8.77	-0.49	3e-16	Calcium levels;
KIRP	cis	rs9815354	0.951	rs9849393	chr3:41875369	G/C	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg26681399	chr22:41777847	TEF	-0.51	-4.87	-0.3	2.03e-6	Vitiligo;
KIRP	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs9810890	1.000	rs73198819	chr3:128475662	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs7190997	0.525	rs9673398	chr16:31347519	A/G	cg02846316	chr16:31340340	ITGAM	0.4	5.0	0.3	1.11e-6	IgA nephropathy;
KIRP	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg26597838	chr10:835615	NA	0.5	6.15	0.36	3.17e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg10756647	chr7:56101905	PSPH	-1.02	-6.76	-0.4	1.02e-10	Diabetic kidney disease;
KIRP	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	6.97	0.41	2.9e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.33	-0.37	1.18e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg16988262	chr1:15930761	NA	0.38	4.87	0.3	1.97e-6	Systolic blood pressure;
KIRP	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg08648136	chr8:956695	NA	0.47	7.15	0.41	9.67e-12	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.31	-0.37	1.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6142102	0.961	rs2284379	chr20:32594642	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.61	0.39	2.41e-10	Skin pigmentation;
KIRP	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.66	-11.61	-0.59	3.94e-25	White blood cell count (basophil);
KIRP	cis	rs2151522	0.762	rs62426328	chr6:127155481	G/A	cg21431617	chr6:127135037	NA	0.3	5.42	0.33	1.45e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg08648136	chr8:956695	NA	0.41	6.09	0.36	4.27e-9	Schizophrenia;
KIRP	cis	rs501120	0.564	rs2246891	chr10:44680591	A/G	cg09554077	chr10:44749378	NA	0.51	6.75	0.4	1.08e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg00343986	chr7:65444356	GUSB	-0.4	-5.01	-0.3	1.03e-6	Aortic root size;
KIRP	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	6.28	0.37	1.53e-9	Menopause (age at onset);
KIRP	cis	rs4664293	1.000	rs10432413	chr2:160495754	T/A	cg08347373	chr2:160653686	CD302	-0.44	-6.18	-0.37	2.71e-9	Monocyte percentage of white cells;
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-6.3	-0.37	1.37e-9	Longevity;Endometriosis;
KIRP	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg23594656	chr7:65796392	TPST1	0.39	5.69	0.34	3.6e-8	Aortic root size;
KIRP	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg07936489	chr17:37558343	FBXL20	-0.46	-5.64	-0.34	4.74e-8	Asthma;
KIRP	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg16586182	chr3:47516702	SCAP	-0.71	-10.05	-0.54	4.03e-20	Colorectal cancer;
KIRP	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.5	5.82	0.35	1.79e-8	Metabolite levels;
KIRP	cis	rs7106204	0.514	rs12789549	chr11:24254726	C/G	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-6.81	-0.4	7.24e-11	Chronic sinus infection;
KIRP	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg11846333	chr4:119757529	SEC24D	1.05	6.16	0.37	2.99e-9	Cannabis dependence symptom count;
KIRP	cis	rs4716602	0.596	rs4490714	chr7:156162510	C/A	cg16983916	chr7:156159713	NA	-0.44	-5.59	-0.34	6.05e-8	Anti-saccade response;
KIRP	cis	rs4791746	0.857	rs6503152	chr17:8631006	A/G	cg03115937	chr17:8649504	CCDC42	-0.52	-5.79	-0.35	2.12e-8	Heroin dependence;
KIRP	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.01	0.3	1.06e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg18404041	chr3:52824283	ITIH1	-0.46	-5.7	-0.34	3.34e-8	Schizophrenia;
KIRP	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	2.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.47	5.61	0.34	5.57e-8	Huntington's disease progression;
KIRP	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg17133734	chr15:86042851	AKAP13	-0.45	-5.7	-0.34	3.41e-8	Coronary artery disease;
KIRP	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.65	8.35	0.47	5.02e-15	Red blood cell count;
KIRP	cis	rs5753037	0.869	rs5763649	chr22:30361385	C/T	cg27665648	chr22:30112403	NA	0.38	5.29	0.32	2.66e-7	Type 1 diabetes;
KIRP	cis	rs1816752	0.819	rs7988388	chr13:24986813	C/A	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	cis	rs10493773	0.502	rs12066742	chr1:86081149	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-5.65	-0.34	4.53e-8	Urate levels in overweight individuals;
KIRP	cis	rs2916247	1.000	rs1443559	chr8:92997242	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.56	-7.32	-0.42	3.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-4.97	-0.3	1.24e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26836800	chr19:5997372	RFX2	0.49	6.16	0.37	2.97e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.74	10.89	0.57	8.46e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Bladder cancer;
KIRP	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg08134877	chr2:44394819	PPM1B	0.49	5.0	0.3	1.07e-6	Height;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13064049	chr1:38478702	UTP11L	0.47	6.26	0.37	1.74e-9	Inflammatory biomarkers;
KIRP	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	0.84	7.68	0.44	3.75e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07350703	chr13:38923610	UFM1	0.44	6.3	0.37	1.38e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg06204229	chr3:52865917	ITIH4	0.47	5.4	0.33	1.59e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg11725975	chr4:72052874	SLC4A4	-0.5	-6.07	-0.36	4.88e-9	Brain structure;
KIRP	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.92	-0.3	1.57e-6	Neutrophil percentage of white cells;
KIRP	cis	rs6959887	1.000	rs10235849	chr7:35295363	T/A	cg06685737	chr7:35301730	NA	0.45	6.46	0.38	5.51e-10	Birth weight;
KIRP	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg18882449	chr10:104885122	NT5C2	-0.51	-6.61	-0.39	2.43e-10	Arsenic metabolism;
KIRP	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.28	5.57	0.33	6.67e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg14673194	chr17:80132900	CCDC57	-0.73	-7.84	-0.45	1.35e-13	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00346434	chr17:37353248	CACNB1	-0.43	-6.07	-0.36	4.75e-9	Metabolic traits;
KIRP	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-9.52	-0.52	1.72e-18	Coronary artery disease;
KIRP	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.71	9.09	0.5	3.42e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg12861170	chr19:19639553	YJEFN3	0.48	4.9	0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.61	-7.2	-0.42	7.43e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.51	7.18	0.42	8.13e-12	Monocyte percentage of white cells;
KIRP	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18252515	chr7:66147081	NA	0.47	5.43	0.33	1.34e-7	Aortic root size;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23797839	chr10:60094994	UBE2D1	-0.5	-6.71	-0.39	1.3100000000000001e-10	Myopia;
KIRP	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.81	-0.78	7.56e-53	Schizophrenia;
KIRP	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg18461458	chr19:21324796	ZNF431	0.47	4.94	0.3	1.45e-6	Pain;
KIRP	cis	rs11955175	1.000	rs11953942	chr5:40674713	C/A	cg04002187	chr5:40835754	RPL37	0.67	5.41	0.33	1.5e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-6.99	-0.41	2.59e-11	Platelet count;
KIRP	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.61	8.01	0.45	4.59e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.05	0.36	5.29e-9	Depression;
KIRP	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg03733263	chr8:22462867	KIAA1967	-0.8	-11.68	-0.6	2.22e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.74	0.71	4.32e-39	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06070960	chr3:134514110	EPHB1	0.46	6.18	0.37	2.6e-9	Parkinson's disease;
KIRP	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg12826209	chr6:26865740	GUSBL1	0.64	4.86	0.3	2.05e-6	Breast cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08215575	chr2:96874731	STARD7	-0.62	-6.94	-0.4	3.5e-11	Menopause (age at onset);
KIRP	cis	rs7084402	0.935	rs12248958	chr10:60278255	G/A	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs7923609	0.869	rs10733792	chr10:65232539	A/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.86	-0.35	1.46e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4523957	0.890	rs11655813	chr17:2119101	C/T	cg16513277	chr17:2031491	SMG6	-0.67	-9.16	-0.5	2.17e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6466055	0.660	rs55712418	chr7:104846173	A/G	cg04380332	chr7:105027541	SRPK2	0.37	5.02	0.3	1e-6	Schizophrenia;
KIRP	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.36	5.55	0.33	7.25e-8	Lung cancer;
KIRP	cis	rs883565	0.528	rs35946914	chr3:38992107	A/G	cg01426195	chr3:39028469	NA	-0.49	-7.23	-0.42	6.25e-12	Handedness;
KIRP	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg25356066	chr3:128598488	ACAD9	0.45	5.26	0.32	3.12e-7	IgG glycosylation;
KIRP	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs12580194	0.593	rs11171430	chr12:55755254	A/G	cg19537932	chr12:55886519	OR6C68	-0.47	-6.22	-0.37	2.12e-9	Cancer;
KIRP	cis	rs77861329	0.748	rs352152	chr3:52210700	A/C	cg08692210	chr3:52188851	WDR51A	-0.57	-5.83	-0.35	1.71e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.94	9.14	0.5	2.41e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg18882449	chr10:104885122	NT5C2	-0.51	-6.51	-0.38	4.12e-10	Arsenic metabolism;
KIRP	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.49	-0.43	1.24e-12	Response to antipsychotic treatment;
KIRP	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg14458575	chr2:238380390	NA	0.62	8.27	0.47	8.59e-15	Prostate cancer;
KIRP	cis	rs5753037	0.809	rs5752964	chr22:30208608	C/T	cg27665648	chr22:30112403	NA	0.46	6.29	0.37	1.42e-9	Type 1 diabetes;
KIRP	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg26513180	chr16:89883248	FANCA	0.79	5.63	0.34	4.9e-8	Skin colour saturation;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24686911	chr14:31029063	G2E3	-0.44	-6.31	-0.37	1.29e-9	C-reactive protein;
KIRP	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-1.01	-14.55	-0.68	5.19e-35	Alcohol dependence;
KIRP	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.49	-5.89	-0.35	1.26e-8	Menarche (age at onset);
KIRP	cis	rs80282103	0.618	rs11250249	chr10:1116999	T/C	cg08668510	chr10:1095578	IDI1	0.95	6.08	0.36	4.54e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	1.0	17.32	0.74	1.8e-44	Breast cancer;
KIRP	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.69	-6.5	-0.38	4.56e-10	Body mass index;
KIRP	cis	rs798766	0.904	rs13142863	chr4:1755549	T/G	cg07775547	chr4:1625484	NA	-0.45	-5.27	-0.32	3.05e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs1434579	0.897	rs12610672	chr19:44945571	G/T	cg15540054	chr19:45004280	ZNF180	-0.47	-5.04	-0.31	8.99e-7	Tuberculosis;
KIRP	cis	rs860295	0.665	rs11264393	chr1:155574471	C/A	cg02153340	chr1:155202674	NA	-0.48	-6.62	-0.39	2.3e-10	Body mass index;
KIRP	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.55	-0.52	1.37e-18	Neuroticism;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.39	-0.32	1.68e-7	Life satisfaction;
KIRP	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg14664628	chr15:75095509	CSK	-1.17	-20.46	-0.79	5.14e-55	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg11707556	chr5:10655725	ANKRD33B	0.56	6.87	0.4	5.12e-11	Coronary artery disease;
KIRP	cis	rs7916697	0.947	rs7916410	chr10:69995667	T/C	cg06988349	chr10:69991859	ATOH7	-0.44	-5.64	-0.34	4.73e-8	Optic disc area;
KIRP	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg14664628	chr15:75095509	CSK	-0.48	-5.63	-0.34	4.93e-8	Systemic lupus erythematosus;
KIRP	cis	rs9398803	0.865	rs1361108	chr6:126767600	C/T	cg19875578	chr6:126661172	C6orf173	0.49	6.37	0.38	9.21e-10	Male-pattern baldness;
KIRP	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.85e-7	Diabetic retinopathy;
KIRP	cis	rs1978968	0.826	rs5992946	chr22:18466111	G/T	cg03078520	chr22:18463400	MICAL3	-0.75	-8.22	-0.46	1.14e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23422044	chr7:1970798	MAD1L1	-0.72	-7.38	-0.43	2.43e-12	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17984783	chr8:59465534	SDCBP	0.44	6.31	0.37	1.31e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8018808	1.000	rs4899652	chr14:77848972	A/G	cg20045696	chr14:77926864	AHSA1	-0.43	-5.37	-0.32	1.86e-7	Myeloid white cell count;
KIRP	cis	rs74181299	0.684	rs1228	chr2:65311555	C/T	cg05010058	chr2:65284262	CEP68	-0.39	-4.88	-0.3	1.9e-6	Pulse pressure;
KIRP	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.99	17.31	0.74	1.93e-44	Breast cancer;
KIRP	cis	rs13095912	1.000	rs6784948	chr3:185342787	C/T	cg11274856	chr3:185301563	NA	0.53	6.82	0.4	7.1e-11	Systolic blood pressure;
KIRP	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg09555818	chr19:45449301	APOC2	-0.54	-7.94	-0.45	7.31e-14	Blood protein levels;
KIRP	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	8.16	0.46	1.68e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.69	8.62	0.48	8.38e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.8	11.18	0.58	9.67e-24	Aortic root size;
KIRP	cis	rs7404928	0.794	rs56046165	chr16:23874366	T/G	cg21745164	chr16:23765304	CHP2	-0.54	-6.51	-0.38	4.1e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05315796	chr3:52349193	DNAH1	0.43	6.57	0.39	2.99e-10	Electroencephalogram traits;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04164538	chr19:48867262	TMEM143;SYNGR4	-0.57	-6.03	-0.36	6.09e-9	Menopause (age at onset);
KIRP	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.52	-6.46	-0.38	5.47e-10	Height;
KIRP	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg21926883	chr2:100939477	LONRF2	-0.54	-7.33	-0.42	3.21e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg08975724	chr8:8085496	FLJ10661	0.57	7.69	0.44	3.58e-13	Retinal vascular caliber;
KIRP	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.41	-0.38	7.53e-10	Type 2 diabetes;
KIRP	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg03585969	chr10:35415529	CREM	0.76	9.39	0.51	4.29e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg04995300	chr3:66848608	NA	0.76	9.13	0.5	2.62e-17	Type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09238520	chr4:143754306	INPP4B	-0.38	-6.4	-0.38	7.95e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs5753037	0.869	rs737939	chr22:30315416	G/T	cg27665648	chr22:30112403	NA	0.38	5.43	0.33	1.37e-7	Type 1 diabetes;
KIRP	cis	rs4671458	0.626	rs72806058	chr2:63842399	C/T	cg17519650	chr2:63277830	OTX1	-0.5	-5.14	-0.31	5.65e-7	Subjective well-being;
KIRP	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	1.16	14.34	0.67	2.67e-34	Type 2 diabetes nephropathy;
KIRP	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.52	6.48	0.38	5.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4233802	1.000	rs4577299	chr2:151138798	A/C	cg25300694	chr2:151184358	NA	-0.86	-7.07	-0.41	1.64e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs3935685	0.845	rs7175083	chr15:78006842	T/C	cg25212270	chr15:78015279	NA	0.6	8.14	0.46	2.01e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.14	12.2	0.61	4.26e-27	Mitochondrial DNA levels;
KIRP	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.26	-0.37	1.73e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1050631	0.564	rs1785905	chr18:33713287	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	trans	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19894588	chr14:64061835	NA	-0.67	-7.85	-0.45	1.25e-13	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-10.16	-0.54	1.82e-20	Mean corpuscular volume;
KIRP	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg26531700	chr6:26746687	NA	0.47	6.83	0.4	6.62e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3767633	0.925	rs2298019	chr1:161736035	A/G	cg09175582	chr1:161736000	ATF6	0.72	5.42	0.33	1.4e-7	IgG glycosylation;
KIRP	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs897080	0.515	rs1067409	chr2:44673057	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.81	0.35	1.9e-8	Height;
KIRP	cis	rs151997	0.962	rs27476	chr5:50178160	A/T	cg06027927	chr5:50259733	NA	-0.59	-7.41	-0.43	2.02e-12	Callous-unemotional behaviour;
KIRP	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.38	5.1	0.31	6.94e-7	Dupuytren's disease;
KIRP	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.26	-5.45	-0.33	1.22e-7	Menarche (age at onset);
KIRP	cis	rs4742903	0.527	rs2122576	chr9:106870187	G/T	cg14250997	chr9:106856677	SMC2	-0.43	-5.88	-0.35	1.34e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.62	-6.85	-0.4	5.77e-11	Response to antineoplastic agents;
KIRP	cis	rs539514	0.648	rs660942	chr13:76373924	G/A	cg04757411	chr13:76259545	LMO7	-0.36	-4.99	-0.3	1.14e-6	Type 1 diabetes;
KIRP	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7527798	0.545	rs6696228	chr1:207846830	G/A	cg09232269	chr1:207846808	CR1L	-0.39	-5.65	-0.34	4.47e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs1355223	0.573	rs1901830	chr11:34725028	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.13	-0.36	3.42e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.78	-11.73	-0.6	1.59e-25	Dental caries;
KIRP	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Parkinson's disease;
KIRP	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-5.55	-0.33	7.47e-8	Personality dimensions;
KIRP	cis	rs12447804	0.822	rs9926547	chr16:58081794	C/T	cg03859792	chr16:58121049	NA	0.48	6.43	0.38	6.54e-10	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg01689657	chr7:91764605	CYP51A1	0.44	6.41	0.38	7.32e-10	Breast cancer;
KIRP	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg09754948	chr16:28834200	ATXN2L	0.46	5.31	0.32	2.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21643547	chr1:205240462	TMCC2	-0.87	-13.89	-0.66	9.11e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.62	0.34	5.25e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-9.39	-0.51	4.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.62	-9.2	-0.51	1.61e-17	Immature fraction of reticulocytes;
KIRP	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg05340658	chr4:99064831	C4orf37	0.68	8.93	0.49	9.95e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18252515	chr7:66147081	NA	0.47	5.79	0.35	2.16e-8	Aortic root size;
KIRP	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg09695851	chr17:3907499	NA	0.51	5.76	0.34	2.49e-8	Type 2 diabetes;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg22325292	chr17:80708367	FN3K	0.38	5.1	0.31	6.83e-7	Glycated hemoglobin levels;
KIRP	cis	rs6142102	0.923	rs2268078	chr20:32596704	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	6.49	0.38	4.63e-10	Skin pigmentation;
KIRP	cis	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg06521331	chr12:34319734	NA	-0.59	-7.29	-0.42	4.16e-12	Morning vs. evening chronotype;
KIRP	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg10189774	chr4:17578691	LAP3	0.46	5.5	0.33	9.74e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg20813462	chr7:2646259	IQCE	0.65	6.22	0.37	2.08e-9	Urate levels in lean individuals;
KIRP	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg27170947	chr2:26402098	FAM59B	-0.59	-6.62	-0.39	2.24e-10	Gut microbiome composition (summer);
KIRP	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg06671706	chr8:8559999	CLDN23	0.56	6.37	0.38	9.35e-10	Obesity-related traits;
KIRP	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.2e-24	Cognitive test performance;
KIRP	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg13010199	chr12:38710504	ALG10B	0.62	7.59	0.44	6.47e-13	Morning vs. evening chronotype;
KIRP	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.75	10.28	0.55	7.46e-21	Coronary artery disease or large artery stroke;
KIRP	cis	rs8135828	1.000	rs2531849	chr22:30037900	C/G	cg23204276	chr22:29729285	AP1B1;SNORD125	0.45	4.94	0.3	1.46e-6	Lipid traits;
KIRP	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg16524733	chr11:117070046	TAGLN	0.38	4.95	0.3	1.35e-6	Blood protein levels;
KIRP	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-7.4	-0.43	2.2e-12	Schizophrenia;
KIRP	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.24e-10	Hypertriglyceridemia;
KIRP	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.43	-5.43	-0.33	1.35e-7	Ulcerative colitis;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg19923238	chr8:142232952	SLC45A4	-0.42	-5.03	-0.31	9.26e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg07274523	chr3:49395745	GPX1	0.69	8.6	0.48	9.33e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Body mass index;
KIRP	cis	rs1355223	0.902	rs286862	chr11:34718779	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.6	0.34	5.85e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.12	-0.61	7.96e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs2826891	0.603	rs2079133	chr21:23023413	C/A	cg18742814	chr1:41828276	NA	-0.4	-6.25	-0.37	1.77e-9	Longevity;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16716044	chr1:171071334	MIR1295;FMO3	-0.45	-7.47	-0.43	1.37e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4650994	0.593	rs6694406	chr1:178532010	C/T	cg12486710	chr1:178512616	C1orf220	-0.25	-5.27	-0.32	3.05e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	trans	rs6506900	0.692	rs8087410	chr18:28901574	C/A	cg10906284	chr12:63544430	AVPR1A	0.37	6.03	0.36	5.83e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg06585982	chr3:143692056	C3orf58	0.59	7.35	0.42	2.93e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs193541	0.632	rs26370	chr5:122235192	T/C	cg19412675	chr5:122181750	SNX24	0.61	6.31	0.37	1.32e-9	Glucose homeostasis traits;
KIRP	trans	rs5742915	0.523	rs876383	chr15:74333413	A/G	cg26551187	chr5:162932467	MAT2B	0.51	6.07	0.36	4.89e-9	Height;Paget's disease;
KIRP	cis	rs859767	0.501	rs10171371	chr2:135372159	C/T	cg25422880	chr2:135218333	TMEM163	0.36	5.25	0.32	3.3e-7	Neuroticism;
KIRP	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.82	-0.45	1.6e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs3784262	0.669	rs34226780	chr15:58280168	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.95	-0.3	1.37e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25517755	chr10:38738941	LOC399744	0.5	6.9	0.4	4.32e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg05370193	chr1:21551575	ECE1	0.48	6.96	0.41	3.14e-11	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2273669	0.667	rs12195848	chr6:109279105	A/C	cg05315195	chr6:109294784	ARMC2	-0.56	-5.85	-0.35	1.59e-8	Prostate cancer;
KIRP	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.77	-0.44	2.15e-13	Height;
KIRP	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg06742321	chr12:123595122	PITPNM2	0.42	5.13	0.31	5.86e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.97	-0.3	1.26e-6	Prostate cancer;
KIRP	cis	rs17121403	0.661	rs76334301	chr1:100498969	A/G	cg24955406	chr1:100503596	HIAT1	0.76	5.01	0.3	1.05e-6	Pulmonary function decline;
KIRP	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg04865290	chr3:52927548	TMEM110	-0.61	-6.77	-0.4	9.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg02462569	chr6:150064036	NUP43	-0.46	-6.59	-0.39	2.71e-10	Lung cancer;
KIRP	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg13409248	chr3:40428643	ENTPD3	-0.4	-5.66	-0.34	4.11e-8	Renal cell carcinoma;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg04767207	chr11:60929031	VPS37C	0.53	6.27	0.37	1.65e-9	Educational attainment;
KIRP	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.67	-8.32	-0.47	6.08e-15	Recalcitrant atopic dermatitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04369958	chr19:39935932	SUPT5H	0.47	6.32	0.37	1.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.69	10.41	0.55	2.95e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.36	-0.51	5.35e-18	Platelet count;
KIRP	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.89	-0.53	1.28e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.16	-0.31	5.12e-7	Neuroticism;
KIRP	cis	rs2806561	0.823	rs658508	chr1:23480362	T/C	cg19743168	chr1:23544995	NA	0.61	8.71	0.49	4.41e-16	Height;
KIRP	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04317338	chr11:64019027	PLCB3	0.56	6.48	0.38	4.89e-10	Platelet count;
KIRP	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.56	6.23	0.37	2.02e-9	Urinary tract infection frequency;
KIRP	cis	rs35883536	1.000	rs3861733	chr1:101111807	G/A	cg06223162	chr1:101003688	GPR88	0.33	6.63	0.39	2.15e-10	Monocyte count;
KIRP	cis	rs7172809	0.573	rs1446313	chr15:77475380	G/T	cg05673287	chr15:77411982	SGK269	0.42	4.87	0.3	2e-6	Glucose homeostasis traits;
KIRP	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.47	6.13	0.36	3.4e-9	Blood metabolite levels;
KIRP	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg13660082	chr14:53194042	PSMC6	-0.53	-5.04	-0.31	8.96e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg14593290	chr7:50529359	DDC	-0.8	-10.0	-0.54	5.52e-20	Malaria;
KIRP	trans	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg04373760	chr16:53404718	NA	0.63	6.71	0.39	1.34e-10	Hypertriglyceridemia;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs7688540	0.771	rs61794997	chr4:222103	C/T	cg17891759	chr4:299121	NA	-0.52	-5.36	-0.32	1.96e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.84	9.87	0.53	1.44e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.71	-9.77	-0.53	2.91e-19	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.08e-11	Blood metabolite levels;
KIRP	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg21643547	chr1:205240462	TMCC2	-0.72	-10.96	-0.57	5.23e-23	Red blood cell count;
KIRP	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg00074818	chr8:8560427	CLDN23	-0.29	-5.04	-0.31	9.22e-7	Neuroticism;
KIRP	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.75	9.43	0.52	3.31e-18	Response to antipsychotic treatment;
KIRP	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg11271282	chr2:238384023	NA	0.47	5.49	0.33	1.01e-7	Prostate cancer;
KIRP	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg13264159	chr8:625131	ERICH1	0.7	5.15	0.31	5.43e-7	IgG glycosylation;
KIRP	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.21	0.51	1.51e-17	Bladder cancer;
KIRP	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg14703610	chr5:56206110	C5orf35	0.47	6.51	0.38	4.09e-10	Coronary artery disease;
KIRP	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.82	9.94	0.54	8.95e-20	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2916247	0.954	rs1443558	chr8:92986385	G/A	cg10183463	chr8:93005414	RUNX1T1	0.59	7.83	0.45	1.48e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.623	rs7201591	chr16:68086105	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-7.68	-0.44	3.69e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2046867	0.908	rs11927126	chr3:72806622	A/G	cg25664220	chr3:72788482	NA	-0.43	-6.55	-0.39	3.3e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.43	-0.38	6.67e-10	Coronary artery disease;
KIRP	cis	rs830233	0.609	rs62383306	chr5:165444386	G/C	cg13976338	chr5:165423657	NA	-0.63	-6.1	-0.36	4.18e-9	QT interval (sulfonylurea treatment interaction);
KIRP	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.22	-0.42	6.41e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6545883	1.000	rs778762	chr2:61782921	G/T	cg15711740	chr2:61764176	XPO1	-0.61	-8.31	-0.47	6.43e-15	Tuberculosis;
KIRP	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-1.06	-10.16	-0.54	1.81e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.86	8.54	0.48	1.43e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs742614	0.533	rs2626547	chr20:32404921	G/A	cg06304546	chr20:32448765	NA	-0.78	-12.05	-0.61	1.39e-26	Stearic acid (18:0) levels;
KIRP	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.23	0.55	1.07e-20	Coffee consumption (cups per day);
KIRP	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.64	7.76	0.44	2.28e-13	Type 2 diabetes;
KIRP	cis	rs2594989	0.779	rs2437686	chr3:11588989	C/T	cg01796438	chr3:11312864	ATG7	-0.4	-5.31	-0.32	2.41e-7	Circulating chemerin levels;
KIRP	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs11710088	0.626	rs6803863	chr3:149225718	A/G	cg08667024	chr3:149219783	TM4SF4	0.37	4.98	0.3	1.21e-6	QRS duration;
KIRP	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	7.05	0.41	1.82e-11	Mean platelet volume;
KIRP	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.72	11.13	0.58	1.4e-23	Noise-induced hearing loss;
KIRP	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20295408	chr7:1910781	MAD1L1	-0.53	-5.36	-0.32	1.93e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-0.78	-9.08	-0.5	3.54e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.56	8.76	0.49	3.18e-16	Bone mineral density;
KIRP	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1981331	0.609	rs117296583	chr21:48053238	C/T	cg17243659	chr21:48055224	PRMT2	1.37	8.46	0.47	2.45e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs12210905	1.000	rs9379970	chr6:27255231	T/C	cg11502198	chr6:26597334	ABT1	-0.85	-4.85	-0.3	2.22e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs8010715	0.816	rs7153156	chr14:24598846	A/G	cg23112188	chr14:24563095	PCK2	-0.34	-5.04	-0.31	9.06e-7	IgG glycosylation;
KIRP	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.67	8.56	0.48	1.21e-15	Height;
KIRP	cis	rs929596	0.564	rs2741028	chr2:234518914	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.69	-0.34	3.62e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.25	-0.37	1.8e-9	Daytime sleep phenotypes;
KIRP	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.45	-10.18	-0.54	1.51e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22161983	chr8:103818636	NA	0.57	6.21	0.37	2.21e-9	Lung cancer in ever smokers;
KIRP	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.38	0.32	1.78e-7	Cognitive test performance;
KIRP	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg26513180	chr16:89883248	FANCA	-0.55	-6.72	-0.39	1.22e-10	Vitiligo;
KIRP	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg07653901	chr22:50250238	ZBED4	-0.44	-5.22	-0.32	3.77e-7	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12600053	0.687	rs11149686	chr16:84847247	A/G	cg09249803	chr16:84846936	NA	0.35	5.09	0.31	7.19e-7	Asthma (childhood onset);
KIRP	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.66	9.15	0.5	2.27e-17	Lymphocyte counts;
KIRP	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.59	-7.25	-0.42	5.43e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg17376030	chr22:41985996	PMM1	-0.54	-6.42	-0.38	6.88e-10	Vitiligo;
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.63	9.47	0.52	2.4e-18	Lung cancer;
KIRP	cis	rs1978968	0.731	rs9605463	chr22:18459889	C/T	cg02610425	chr22:18483192	MICAL3	0.38	5.68	0.34	3.78e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.39	-4.88	-0.3	1.94e-6	Renal function-related traits (BUN);
KIRP	cis	rs16858210	0.607	rs59321941	chr3:183571024	A/G	cg25686905	chr3:183603175	PARL	-0.49	-5.3	-0.32	2.56e-7	Menopause (age at onset);
KIRP	cis	rs4356932	1.000	rs3921	chr4:76942943	C/G	cg00809888	chr4:76862425	NAAA	0.45	6.27	0.37	1.64e-9	Blood protein levels;
KIRP	trans	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.98e-12	Bladder cancer;
KIRP	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-6.82	-0.4	7.01e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs2742417	1.000	rs767280	chr3:45771601	C/G	cg04037228	chr3:45636386	LIMD1	0.36	5.26	0.32	3.11e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6142102	0.961	rs4911411	chr20:32715842	C/T	cg08999081	chr20:33150536	PIGU	0.54	6.97	0.41	2.87e-11	Skin pigmentation;
KIRP	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.79	-9.48	-0.52	2.3e-18	Corneal astigmatism;
KIRP	cis	rs6832769	0.961	rs11735267	chr4:56347287	C/T	cg05960024	chr4:56376020	CLOCK	0.74	9.52	0.52	1.72e-18	Personality dimensions;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07189025	chr1:235671652	NA	-0.48	-7.12	-0.41	1.2e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02050903	chr11:44117243	EXT2	0.48	6.77	0.4	9.49e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.71	8.63	0.48	7.87e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg08994789	chr17:28903642	LRRC37B2	0.74	8.49	0.48	1.96e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.78	-10.37	-0.55	3.77e-21	Body mass index;
KIRP	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg04310649	chr10:35416472	CREM	-0.57	-6.7	-0.39	1.38e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.28	0.42	4.48e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs17101923	1.000	rs10878347	chr12:66321492	T/C	cg06712651	chr12:66351869	HMGA2	-0.57	-6.31	-0.37	1.25e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs3781264	0.724	rs12780491	chr10:96121022	A/G	cg07270175	chr10:96123049	NOC3L	0.42	4.92	0.3	1.56e-6	Esophageal cancer and gastric cancer;
KIRP	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.69	9.7	0.53	4.62e-19	Lymphocyte counts;
KIRP	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.56	-7.33	-0.42	3.35e-12	Aortic root size;
KIRP	cis	rs9652601	0.779	rs725613	chr16:11169683	T/G	cg04616529	chr16:11181986	CLEC16A	0.38	5.1	0.31	6.85e-7	Systemic lupus erythematosus;
KIRP	cis	rs2562456	0.558	rs62108173	chr19:21427188	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.84e-6	Pain;
KIRP	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg13198984	chr17:80129470	CCDC57	0.57	8.79	0.49	2.68e-16	Life satisfaction;
KIRP	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	10.07	0.54	3.31e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg26134248	chr17:3907702	NA	0.55	8.2	0.46	1.31e-14	Type 2 diabetes;
KIRP	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.54	6.2	0.37	2.31e-9	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs2302729	0.515	rs1894980	chr12:2767183	G/C	cg19945202	chr12:2788847	CACNA1C	-0.79	-11.54	-0.59	6.64e-25	Sleep quality;
KIRP	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg03714773	chr7:91764589	CYP51A1	0.37	5.38	0.32	1.72e-7	Breast cancer;
KIRP	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00149659	chr3:10157352	C3orf10	0.58	6.91	0.4	4.13e-11	Alzheimer's disease;
KIRP	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg21573476	chr21:45109991	RRP1B	-0.56	-7.33	-0.42	3.34e-12	Mean corpuscular volume;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18271581	chr22:34047559	LARGE	-0.43	-6.18	-0.37	2.69e-9	Inflammatory biomarkers;
KIRP	cis	rs4819052	0.851	rs11558445	chr21:46685175	A/G	cg06618935	chr21:46677482	NA	-0.36	-4.93	-0.3	1.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg10281770	chr17:80606947	WDR45L	0.73	9.93	0.53	9.26e-20	Breast cancer;
KIRP	cis	rs2242420	0.920	rs6658321	chr1:21968660	C/T	cg00421585	chr1:21930189	RAP1GAP	0.59	4.95	0.3	1.4e-6	Hematological and biochemical traits;
KIRP	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg17736920	chr1:242011382	EXO1	0.46	5.68	0.34	3.77e-8	Menopause (age at onset);
KIRP	cis	rs16976116	0.901	rs73409851	chr15:55502516	G/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2741335	0.876	rs2565056	chr8:27337227	G/A	cg00421144	chr8:27336675	CHRNA2	-0.34	-5.31	-0.32	2.49e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs7656342	0.665	rs6449090	chr4:9884536	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.53	-0.33	8.01e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.71	-0.34	3.23e-8	Body mass index;
KIRP	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.61	-0.52	9.15e-19	Body mass index;
KIRP	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11987759	chr7:65425863	GUSB	-0.69	-9.71	-0.53	4.37e-19	Aortic root size;
KIRP	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.6	7.47	0.43	1.36e-12	Corneal astigmatism;
KIRP	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.92	0.3	1.59e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2625529	0.607	rs2912231	chr15:72567957	G/T	cg16672083	chr15:72433130	SENP8	-0.45	-5.84	-0.35	1.68e-8	Red blood cell count;
KIRP	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs1147199	0.585	rs56300626	chr9:87246091	T/C	cg22402007	chr9:87282823	NTRK2	0.4	4.96	0.3	1.33e-6	Body mass index;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13412395	chr9:102583693	NR4A3	0.66	6.12	0.36	3.71e-9	Lung function (FEV1);
KIRP	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs2733310	0.895	rs4774894	chr15:57106243	G/C	cg13626582	chr15:57592083	LOC283663	-0.23	-5.12	-0.31	6.27e-7	Mean platelet volume;
KIRP	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg04398451	chr17:18023971	MYO15A	0.69	9.4	0.51	3.85e-18	Total body bone mineral density;
KIRP	cis	rs193541	0.632	rs400207	chr5:122318497	C/T	cg19412675	chr5:122181750	SNX24	-0.6	-6.45	-0.38	6.03e-10	Glucose homeostasis traits;
KIRP	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.4	-0.38	7.64e-10	Aortic root size;
KIRP	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.56	-5.98	-0.36	7.86e-9	Body mass index;
KIRP	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.64	8.83	0.49	2.04e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-0.7	-7.55	-0.43	8.41e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2839619	0.521	rs2839621	chr21:44440024	C/T	cg20154816	chr21:44412511	PKNOX1	-0.34	-5.37	-0.32	1.83e-7	Biochemical measures;
KIRP	cis	rs7584330	0.554	rs6729415	chr2:238429943	C/G	cg14458575	chr2:238380390	NA	0.49	5.87	0.35	1.43e-8	Prostate cancer;
KIRP	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg24579218	chr15:68104479	NA	-0.44	-7.1	-0.41	1.34e-11	Restless legs syndrome;
KIRP	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-7.53	-0.43	9.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.77e-7	Bladder cancer;
KIRP	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg01872077	chr2:219646372	CYP27A1	-0.38	-4.85	-0.3	2.2e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.09	0.36	4.29e-9	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg09695851	chr17:3907499	NA	-0.55	-6.61	-0.39	2.34e-10	Type 2 diabetes;
KIRP	cis	rs7215564	0.908	rs9900687	chr17:78739721	C/T	cg06153925	chr17:78755379	RPTOR	-0.33	-5.86	-0.35	1.45e-8	Myopia (pathological);
KIRP	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	8.66	0.48	6.24e-16	Mood instability;
KIRP	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.86	-0.35	1.44e-8	Colorectal cancer;
KIRP	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg19645103	chr12:69753606	YEATS4	-0.48	-5.0	-0.3	1.07e-6	Response to diuretic therapy;
KIRP	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg10189774	chr4:17578691	LAP3	0.53	6.41	0.38	7.57e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.46e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.76e-10	Hypertriglyceridemia;
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg05941025	chr16:89927596	SPIRE2	0.35	5.38	0.32	1.76e-7	Vitiligo;
KIRP	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.9	-0.45	9.37e-14	Aortic root size;
KIRP	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg05768032	chr16:30646687	NA	0.42	5.01	0.3	1.03e-6	Multiple myeloma;
KIRP	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.67	9.81	0.53	2.11e-19	Lymphocyte counts;
KIRP	trans	rs242364	0.530	rs2830965	chr21:28847771	C/T	cg01278232	chr17:17606846	RAI1	0.55	6.13	0.36	3.39e-9	Daytime sleep phenotypes;
KIRP	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg05623727	chr3:50126028	RBM5	0.35	5.3	0.32	2.61e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg23335576	chr14:104009727	NA	0.36	5.15	0.31	5.22e-7	Body mass index;
KIRP	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg10932868	chr11:921992	NA	0.55	6.96	0.41	3.13e-11	Alzheimer's disease (late onset);
KIRP	cis	rs710987	0.933	rs1604438	chr5:3501539	G/A	cg14530963	chr5:3489551	NA	-0.46	-5.82	-0.35	1.87e-8	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.08	0.31	7.49e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.3	13.35	0.65	6.19e-31	Diabetic retinopathy;
KIRP	cis	rs6743226	0.870	rs10933547	chr2:242230443	C/G	cg10021735	chr2:242295487	FARP2	-0.46	-5.74	-0.34	2.81e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg22974920	chr21:40686053	BRWD1	0.49	5.9	0.35	1.19e-8	Cognitive function;
KIRP	cis	rs662064	0.852	rs1411402	chr1:10579545	G/T	cg19773385	chr1:10388646	KIF1B	-0.42	-5.53	-0.33	8.14e-8	Asthma;
KIRP	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.18	-0.37	2.59e-9	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04233664	chr10:126848743	CTBP2	0.48	6.28	0.37	1.53e-9	Parkinson's disease;
KIRP	cis	rs4595586	0.679	rs1878228	chr12:39355595	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.33	0.37	1.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.49	5.28	0.32	2.79e-7	Alzheimer's disease;
KIRP	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.73	11.07	0.58	2.23e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.8	11.13	0.58	1.38e-23	Schizophrenia;
KIRP	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.67	-9.58	-0.52	1.13e-18	Retinal vascular caliber;
KIRP	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg23594656	chr7:65796392	TPST1	-0.38	-5.4	-0.33	1.58e-7	Aortic root size;
KIRP	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.55	-7.46	-0.43	1.48e-12	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg01877450	chr7:97915802	BRI3	-0.55	-7.09	-0.41	1.45e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-1.04	-17.61	-0.75	1.87e-45	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9912468	0.676	rs10048158	chr17:64236318	T/C	cg19474267	chr17:64306194	PRKCA	-0.47	-5.92	-0.35	1.09e-8	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs11264213	0.892	rs11263828	chr1:36298872	G/C	cg27506609	chr1:36549197	TEKT2	0.73	7.07	0.41	1.57e-11	Schizophrenia;
KIRP	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	10.57	0.56	8.69e-22	Total body bone mineral density;
KIRP	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25944668	chr8:16940339	EFHA2	-0.39	-6.14	-0.36	3.37e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	5.48	0.33	1.05e-7	Renal cell carcinoma;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03952484	chr1:149899818	SF3B4	-0.49	-6.33	-0.37	1.16e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg18833306	chr6:118973337	C6orf204	-0.47	-5.04	-0.31	9.1e-7	Diastolic blood pressure;
KIRP	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg01181863	chr3:195395398	SDHAP2	0.43	4.87	0.3	1.98e-6	Mean corpuscular volume;
KIRP	cis	rs10486003	1.000	rs17168782	chr7:97193585	C/A	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.64	-5.48	-0.33	1.05e-7	Response to platinum-based agents;
KIRP	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-9.36	-0.51	5.32e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg08741688	chr4:3415352	RGS12	-0.46	-5.04	-0.31	8.82e-7	Serum sulfate level;
KIRP	cis	rs7224685	0.569	rs10521129	chr17:4008820	C/T	cg11204139	chr17:3907470	NA	0.47	4.86	0.3	2.13e-6	Type 2 diabetes;
KIRP	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg26818010	chr10:134567672	INPP5A	-0.68	-7.64	-0.44	4.86e-13	Migraine;
KIRP	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg25797454	chr6:150327115	RAET1K	0.32	5.87	0.35	1.42e-8	Alopecia areata;
KIRP	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.91	14.28	0.67	4.16e-34	Blood protein levels;
KIRP	cis	rs929596	0.667	rs7567229	chr2:234612539	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-8.53	-0.48	1.5e-15	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.43	5.63	0.34	4.83e-8	Childhood ear infection;
KIRP	cis	rs7127900	0.821	rs10840603	chr11:2233797	A/G	cg25635251	chr11:2234043	NA	0.52	7.89	0.45	9.92e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg06212747	chr3:49208901	KLHDC8B	0.69	8.14	0.46	2e-14	Menarche (age at onset);
KIRP	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs73200209	0.744	rs17498893	chr12:116674831	G/C	cg01776926	chr12:116560359	MED13L	-0.57	-6.32	-0.37	1.22e-9	Total body bone mineral density;
KIRP	cis	rs7106204	0.534	rs113048476	chr11:24257588	T/C	ch.11.24196551F	chr11:24239977	NA	0.7	4.88	0.3	1.88e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.81	0.4	7.48e-11	Menarche (age at onset);
KIRP	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg19743168	chr1:23544995	NA	-0.48	-6.35	-0.38	1.01e-9	Height;
KIRP	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.19	-0.46	1.45e-14	Monocyte percentage of white cells;
KIRP	cis	rs7582180	0.967	rs7595580	chr2:100896964	A/G	cg14675211	chr2:100938903	LONRF2	0.5	5.78	0.35	2.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.59e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg19847130	chr8:10466454	RP1L1	-0.35	-5.03	-0.31	9.44e-7	Retinal vascular caliber;
KIRP	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg11189052	chr15:85197271	WDR73	0.54	5.75	0.34	2.61e-8	Schizophrenia;
KIRP	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.74	0.49	3.69e-16	Motion sickness;
KIRP	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.59	6.93	0.4	3.62e-11	Height;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25216538	chr4:6925470	TBC1D14	0.45	6.3	0.37	1.34e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11718455	0.585	rs11710802	chr3:43930155	T/G	cg21419209	chr3:44054225	NA	-0.63	-7.37	-0.43	2.66e-12	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19169976	chr17:48071254	DLX3	0.41	6.32	0.37	1.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.72	-10.57	-0.56	9.13e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg06204229	chr3:52865917	ITIH4	0.47	5.4	0.33	1.59e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg08847533	chr14:75593920	NEK9	-0.41	-4.98	-0.3	1.17e-6	Caffeine consumption;
KIRP	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.5	-0.48	1.8e-15	Platelet count;
KIRP	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.76	11.11	0.58	1.68e-23	Hip circumference;
KIRP	cis	rs6088813	1.000	rs6088823	chr20:33994265	G/T	cg14752227	chr20:34000481	UQCC	-0.53	-6.83	-0.4	6.58e-11	Height;
KIRP	cis	rs9790314	0.613	rs34297047	chr3:160631478	A/G	cg04691961	chr3:161091175	C3orf57	0.42	6.17	0.37	2.84e-9	Morning vs. evening chronotype;
KIRP	cis	rs988913	0.957	rs9475100	chr6:54840233	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.53	-0.33	8.11e-8	Menarche (age at onset);
KIRP	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.37	5.36	0.32	1.92e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs259842	0.794	rs259831	chr2:180704878	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.47	-0.33	1.12e-7	Blood protein levels;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg09699651	chr6:150184138	LRP11	0.51	6.63	0.39	2.08e-10	Lung cancer;
KIRP	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.56	-6.91	-0.4	4.03e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-7.17	-0.42	9.01e-12	Hemoglobin concentration;
KIRP	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-15.84	-0.71	2e-39	Electrocardiographic conduction measures;
KIRP	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.82	8.24	0.46	1.05e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-0.99	-16.35	-0.72	3.52e-41	Height;
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.48	6.4	0.38	7.61e-10	Breast cancer;
KIRP	cis	rs2274273	0.624	rs7150234	chr14:55802181	A/G	cg04306507	chr14:55594613	LGALS3	0.4	5.5	0.33	9.41e-8	Protein biomarker;
KIRP	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.96	9.87	0.53	1.44e-19	Methadone dose in opioid dependence;
KIRP	cis	rs1461503	0.934	rs11605693	chr11:122837037	T/C	cg27398637	chr11:122830231	C11orf63	-0.68	-8.93	-0.49	1e-16	Menarche (age at onset);
KIRP	cis	rs9400467	0.537	rs17606672	chr6:111546833	G/C	cg15721981	chr6:111408429	SLC16A10	0.81	7.37	0.43	2.63e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.89	-0.35	1.29e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6674970	0.777	rs12087892	chr1:151118500	T/C	cg03258749	chr1:151040405	MLLT11	0.56	6.45	0.38	5.94e-10	Childhood ear infection;
KIRP	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.38	0.38	8.67e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7945718	0.811	rs7104832	chr11:12786489	A/G	cg25843174	chr11:12811716	TEAD1	0.27	5.0	0.3	1.1e-6	Educational attainment (years of education);
KIRP	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg00042356	chr1:8021962	PARK7	0.77	6.27	0.37	1.62e-9	Inflammatory bowel disease;
KIRP	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.52	7.26	0.42	5.15e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14834257	chr1:153586504	S100A16	0.52	6.59	0.39	2.59e-10	Interleukin-4 levels;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg20607798	chr8:58055168	NA	-0.68	-5.79	-0.35	2.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg16141378	chr3:129829833	LOC729375	0.51	6.93	0.4	3.66e-11	Mood instability;
KIRP	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.63	10.14	0.54	2.06e-20	HDL cholesterol levels;
KIRP	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.47	-7.06	-0.41	1.66e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg02175503	chr12:58329896	NA	0.55	5.85	0.35	1.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg22535103	chr8:58192502	C8orf71	-0.86	-8.21	-0.46	1.25e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg19468946	chr17:37922297	IKZF3	-0.38	-5.4	-0.33	1.6e-7	Asthma;
KIRP	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-5.03	-0.31	9.42e-7	Schizophrenia;
KIRP	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.68e-11	Type 2 diabetes;
KIRP	cis	rs1355223	0.902	rs6484726	chr11:34697558	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-4.92	-0.3	1.55e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg00684032	chr4:1343700	KIAA1530	-0.56	-7.33	-0.42	3.37e-12	Obesity-related traits;
KIRP	cis	rs7927771	0.832	rs2071304	chr11:47372377	G/C	cg20307385	chr11:47447363	PSMC3	-0.56	-5.81	-0.35	1.93e-8	Subjective well-being;
KIRP	cis	rs4765905	0.610	rs4765670	chr12:2313126	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.6	-0.39	2.46e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	-0.49	-5.92	-0.35	1.08e-8	Prudent dietary pattern;
KIRP	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25517755	chr10:38738941	LOC399744	-0.39	-5.33	-0.32	2.17e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	1.11	13.21	0.64	1.79e-30	Type 2 diabetes nephropathy;
KIRP	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.54	5.96	0.36	8.57e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg26207909	chr14:103986467	CKB	0.56	7.61	0.44	6.01e-13	Body mass index;
KIRP	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg09165964	chr15:75287851	SCAMP5	0.43	5.47	0.33	1.09e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs3126085	0.515	rs6671146	chr1:152354472	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-6.58	-0.39	2.77e-10	Atopic dermatitis;
KIRP	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs10186029	0.509	rs7566029	chr2:213941189	A/G	cg08319019	chr2:214017104	IKZF2	-0.45	-5.34	-0.32	2.06e-7	Systemic sclerosis;
KIRP	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.6	7.26	0.42	5.1e-12	Height;
KIRP	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04374321	chr14:90722782	PSMC1	0.9	14.72	0.68	1.35e-35	Mortality in heart failure;
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	11.4	0.59	1.84e-24	Platelet count;
KIRP	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg01629716	chr15:45996671	NA	0.37	6.59	0.39	2.73e-10	Waist circumference;Weight;
KIRP	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg02367723	chr1:46378857	MAST2	0.42	4.9	0.3	1.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4363506	0.625	rs10830099	chr10:129284365	C/T	cg07804728	chr10:129284050	NA	0.41	5.68	0.34	3.83e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12756303	chr2:74692479	MOGS	0.45	6.05	0.36	5.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.01	-0.3	1.04e-6	Neuroticism;
KIRP	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg24499839	chr1:231762238	TSNAX-DISC1;DISC1	-0.34	-4.91	-0.3	1.64e-6	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg10792982	chr14:105748885	BRF1	0.87	13.47	0.65	2.36e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7221595	0.778	rs2290439	chr17:3924306	A/G	cg11204139	chr17:3907470	NA	0.57	6.48	0.38	5.08e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg19743168	chr1:23544995	NA	0.46	6.21	0.37	2.28e-9	Height;
KIRP	cis	rs2000999	0.691	rs11648003	chr16:72052348	A/G	cg16558253	chr16:72132732	DHX38	-0.49	-5.22	-0.32	3.72e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.49	-7.09	-0.41	1.39e-11	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg11859384	chr17:80120422	CCDC57	0.45	5.74	0.34	2.71e-8	Life satisfaction;
KIRP	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs2236918	1.000	rs2236919	chr1:242017731	A/G	cg17736920	chr1:242011382	EXO1	0.72	9.32	0.51	7.01e-18	Menopause (age at onset);
KIRP	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.61	-7.69	-0.44	3.5e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg21214613	chr1:16344536	HSPB7	0.34	5.26	0.32	3.17e-7	Dilated cardiomyopathy;
KIRP	cis	rs7116495	1.000	rs6592448	chr11:71670044	C/T	cg26138937	chr11:71823887	C11orf51	0.7	5.67	0.34	3.91e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg08501292	chr6:25962987	TRIM38	1.04	8.4	0.47	3.66e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg06223162	chr1:101003688	GPR88	-0.39	-7.7	-0.44	3.35e-13	Monocyte count;
KIRP	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.55	-7.51	-0.43	1.08e-12	Symmetrical dimethylarginine levels;
KIRP	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21643547	chr1:205240462	TMCC2	-0.87	-13.89	-0.66	9.11e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg16141378	chr3:129829833	LOC729375	-0.48	-6.46	-0.38	5.51e-10	Retinal vascular caliber;
KIRP	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg13453750	chr1:205783389	SLC41A1	-0.5	-7.34	-0.42	3.18e-12	Menarche (age at onset);
KIRP	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.31	0.37	1.31e-9	Subjective well-being;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg11204139	chr17:3907470	NA	0.87	16.9	0.73	4.88e-43	Type 2 diabetes;
KIRP	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg10354764	chr16:3285464	ZNF200	0.66	6.02	0.36	6.15e-9	Lung function (FEV1);
KIRP	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.47	-6.73	-0.39	1.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.78	-11.17	-0.58	1.04e-23	Morning vs. evening chronotype;
KIRP	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg17524265	chr8:144659883	NAPRT1	0.8	5.19	0.31	4.32e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Electroencephalogram traits;
KIRP	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg25173405	chr17:45401733	C17orf57	0.45	6.1	0.36	4.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg25039879	chr17:56429692	SUPT4H1	0.57	5.19	0.31	4.38e-7	Cognitive test performance;
KIRP	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.7	-10.11	-0.54	2.5e-20	Oral cavity cancer;
KIRP	cis	rs7113874	0.578	rs7924477	chr11:8538247	T/C	cg08015107	chr11:8618950	NA	-0.51	-6.77	-0.4	9.37e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.54	-6.33	-0.37	1.15e-9	Aortic root size;
KIRP	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg08999081	chr20:33150536	PIGU	0.47	6.43	0.38	6.71e-10	Height;
KIRP	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs829661	0.947	rs829646	chr2:30719326	T/C	cg10949345	chr2:30726833	LCLAT1	0.72	10.15	0.54	1.96e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg05187965	chr10:45406764	TMEM72	-0.29	-6.5	-0.38	4.48e-10	Mean corpuscular volume;
KIRP	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.85	-11.75	-0.6	1.36e-25	Prostate cancer;
KIRP	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg13409248	chr3:40428643	ENTPD3	0.36	5.04	0.31	9.07e-7	Renal cell carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18744802	chr19:9945810	PIN1	0.49	6.44	0.38	6.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05962139	chr1:228871311	RHOU	0.49	6.05	0.36	5.47e-9	Parkinson's disease;
KIRP	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.99	17.31	0.74	1.93e-44	Breast cancer;
KIRP	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg20818283	chr2:191399100	TMEM194B	0.54	6.79	0.4	8.43e-11	Pulse pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13552710	chr2:30144547	ALK	0.5	6.13	0.36	3.49e-9	Parkinson's disease;
KIRP	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21545522	chr1:205238299	TMCC2	0.39	5.1	0.31	6.8e-7	Red blood cell count;
KIRP	cis	rs9815354	0.812	rs73828505	chr3:42042714	C/T	cg03022575	chr3:42003672	ULK4	0.75	7.71	0.44	3.04e-13	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg21698718	chr17:80085957	CCDC57	0.35	5.11	0.31	6.52e-7	Life satisfaction;
KIRP	trans	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.68	-8.79	-0.49	2.59e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg01426831	chr19:12098817	NA	0.51	6.32	0.37	1.23e-9	Asthma;
KIRP	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.9	14.71	0.68	1.48e-35	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25059436	chr11:47574990	CUGBP1	-0.52	-6.76	-0.4	1.01e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg01708552	chr7:100815485	C7orf52	0.68	6.39	0.38	8.06e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.56	7.66	0.44	4.22e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg22800045	chr5:56110881	MAP3K1	-0.46	-5.17	-0.31	4.94e-7	Coronary artery disease;
KIRP	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg13165212	chr22:42675999	NA	0.4	6.87	0.4	5.16e-11	Cognitive function;
KIRP	cis	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg18131467	chr2:239335373	ASB1	-0.73	-6.11	-0.36	3.85e-9	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.42	-7.86	-0.45	1.17e-13	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg25019033	chr10:957182	NA	-0.6	-6.99	-0.41	2.52e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.94	12.28	0.62	2.32e-27	Menopause (age at onset);
KIRP	cis	rs4704187	0.663	rs17738989	chr5:74533730	C/T	cg03227963	chr5:74354835	NA	0.4	5.84	0.35	1.65e-8	Response to amphetamines;
KIRP	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.57	7.2	0.42	7.27e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs732505	0.850	rs10412919	chr19:5586749	T/C	cg26242866	chr19:5711310	LONP1	0.66	5.06	0.31	8.12e-7	vWF and FVIII levels;
KIRP	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-9.15	-0.5	2.31e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.62e-8	Motion sickness;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg01238044	chr22:24384105	GSTT1	0.56	7.47	0.43	1.43e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4716602	0.596	rs10270517	chr7:156160010	A/G	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16206743	chr13:37633760	FAM48A	0.47	6.15	0.37	3.04e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-13.56	-0.65	1.16e-31	Vitiligo;
KIRP	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.97	-15.04	-0.69	1.12e-36	Height;
KIRP	cis	rs1519814	1.000	rs4504680	chr8:121132175	T/C	cg22335954	chr8:121166405	COL14A1	-0.61	-6.19	-0.37	2.45e-9	Breast cancer;
KIRP	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.09	0.54	2.92e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.95	0.45	6.56e-14	Height;
KIRP	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg22117172	chr7:91764530	CYP51A1	0.48	6.84	0.4	6.33e-11	Breast cancer;
KIRP	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	1.0	8.13	0.46	2.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.58	7.75	0.44	2.44e-13	Vitiligo;
KIRP	cis	rs754133	0.964	rs894738	chr12:54417525	C/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.28	6.01	0.36	6.68e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
KIRP	cis	rs367943	0.712	rs6594709	chr5:112700714	T/C	cg12552261	chr5:112820674	MCC	0.57	6.59	0.39	2.64e-10	Type 2 diabetes;
KIRP	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg15507776	chr3:136538369	TMEM22	0.4	5.42	0.33	1.39e-7	Neuroticism;
KIRP	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.94	0.5	9.35e-17	Electroencephalogram traits;
KIRP	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.98	-13.96	-0.66	4.98e-33	Schizophrenia;
KIRP	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.38e-7	Ileal carcinoids;
KIRP	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.73	8.26	0.47	9.29e-15	Corneal astigmatism;
KIRP	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg14169450	chr9:139327907	INPP5E	0.33	4.85	0.3	2.18e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15731816	chr14:75230414	YLPM1	0.53	6.29	0.37	1.48e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7833787	1.000	rs6586778	chr8:18706170	G/C	cg17701159	chr8:18705777	PSD3	-0.4	-7.48	-0.43	1.34e-12	Obesity-related traits;
KIRP	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg11266682	chr4:10021025	SLC2A9	0.37	5.91	0.35	1.11e-8	Cardiovascular disease risk factors;
KIRP	cis	rs3829109	0.564	rs11145910	chr9:139300494	A/G	cg21253087	chr9:139290292	SNAPC4	0.51	5.64	0.34	4.66e-8	Peak insulin response;Acute insulin response;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20555785	chr7:99756458	C7orf43	0.46	6.19	0.37	2.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg02972257	chr16:68554789	NA	-0.68	-5.99	-0.36	7.22e-9	Ulcerative colitis;
KIRP	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.43	5.37	0.32	1.79e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg23693289	chr8:27183097	PTK2B	0.48	6.01	0.36	6.61e-9	Neuroticism;
KIRP	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11987759	chr7:65425863	GUSB	-0.46	-5.43	-0.33	1.34e-7	Aortic root size;
KIRP	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg16497661	chr14:103986332	CKB	0.49	6.7	0.39	1.42e-10	Body mass index;
KIRP	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg20673091	chr1:2541236	MMEL1	-0.65	-9.61	-0.52	9.01e-19	Ulcerative colitis;
KIRP	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.75	7.47	0.43	1.36e-12	Methadone dose in opioid dependence;
KIRP	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.29	-0.32	2.75e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2562456	0.520	rs279793	chr19:21455774	C/T	cg13978929	chr19:21580086	ZNF493	-0.55	-4.86	-0.3	2.09e-6	Pain;
KIRP	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.55	-0.43	8.54e-13	Alcohol dependence;
KIRP	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg22800045	chr5:56110881	MAP3K1	0.57	6.14	0.36	3.2e-9	Type 2 diabetes;
KIRP	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.44	5.4	0.33	1.59e-7	HDL cholesterol;
KIRP	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg09184832	chr6:79620586	NA	-0.39	-5.02	-0.3	9.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.14	19.99	0.79	1.82e-53	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs367943	0.799	rs13154055	chr5:112971516	A/T	cg12552261	chr5:112820674	MCC	0.57	6.18	0.37	2.58e-9	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05893876	chr8:120428507	NOV	0.43	6.22	0.37	2.07e-9	Parkinson's disease;
KIRP	cis	rs6723226	0.598	rs2710629	chr2:32765844	C/T	cg02381751	chr2:32503542	YIPF4	0.62	7.7	0.44	3.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.39	9.74	0.53	3.5e-19	Corneal astigmatism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04233747	chr5:145214971	PRELID2	0.47	6.23	0.37	1.95e-9	C-reactive protein;
KIRP	cis	rs7527798	0.592	rs11118345	chr1:207854827	A/T	cg09232269	chr1:207846808	CR1L	-0.37	-5.34	-0.32	2.11e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs10421328	0.784	rs11667828	chr19:19768474	G/T	cg03709012	chr19:19516395	GATAD2A	-0.48	-5.74	-0.34	2.8e-8	Parental longevity (combined parental age at death);
KIRP	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg12549451	chr6:135224345	NA	0.42	5.07	0.31	7.82e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7737355	0.812	rs257391	chr5:130740005	A/C	cg06307176	chr5:131281290	NA	0.45	5.49	0.33	1.01e-7	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.25	0.32	3.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.32	-6.14	-0.36	3.36e-9	Educational attainment (years of education);
KIRP	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.66	9.09	0.5	3.47e-17	Obesity-related traits;
KIRP	trans	rs12517041	1.000	rs10941982	chr5:23298902	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs9596863	1.000	rs9596859	chr13:54431200	T/A	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs71520386	0.607	rs11767419	chr7:22878983	T/G	cg15401507	chr7:22894281	NA	0.4	5.1	0.31	6.94e-7	Fibrinogen levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16177737	chr2:85581666	RETSAT;ELMOD3	0.49	6.18	0.37	2.66e-9	Parkinson's disease;
KIRP	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.38	-0.38	8.86e-10	Neuroticism;
KIRP	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	1.0	11.6	0.59	4.13e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.61	-6.11	-0.36	3.84e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9659323	1.000	rs10923714	chr1:119512913	C/T	cg18261050	chr1:119551319	NA	0.36	5.04	0.31	8.88e-7	Body mass index;
KIRP	cis	rs7590368	0.600	rs56195743	chr2:10914867	A/T	cg15705551	chr2:10952987	PDIA6	0.63	5.25	0.32	3.24e-7	Educational attainment (years of education);
KIRP	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.82	6.64	0.39	1.96e-10	Initial pursuit acceleration;
KIRP	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg08890418	chr1:21044141	KIF17	0.34	5.16	0.31	5.05e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg11693508	chr17:37793320	STARD3	0.69	7.25	0.42	5.4e-12	Bipolar disorder;
KIRP	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.42	-0.33	1.41e-7	Aortic root size;
KIRP	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3767633	0.925	rs2055539	chr1:161807866	T/C	cg09175582	chr1:161736000	ATF6	0.73	5.88	0.35	1.36e-8	IgG glycosylation;
KIRP	cis	rs7255374	0.566	rs7255904	chr19:41529020	C/T	cg27089200	chr19:41531976	NA	0.39	5.33	0.32	2.2e-7	DDT metabolite (p,p'-DDE levels);
KIRP	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.81	-0.35	1.97e-8	Yeast infection;
KIRP	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.22	-0.32	3.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.89	0.3	1.84e-6	Renal cell carcinoma;
KIRP	cis	rs7582720	0.731	rs10207567	chr2:203714973	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.68	7.13	0.41	1.08e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg12140854	chr5:148520817	ABLIM3	-0.52	-6.28	-0.37	1.52e-9	Breast cancer;
KIRP	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.52	-11.19	-0.58	9.31e-24	Refractive error;
KIRP	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-14.68	-0.68	1.77e-35	Primary sclerosing cholangitis;
KIRP	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.65	-9.09	-0.5	3.37e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09841758	chr17:72869237	FDXR	0.43	6.16	0.37	2.95e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs78487399	0.710	rs7567685	chr2:43668169	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-6.56	-0.39	3.19e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.96	-0.3	1.33e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12696666	chr3:156877901	CCNL1	0.59	7.33	0.42	3.3e-12	Parkinson's disease;
KIRP	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.32	-0.32	2.34e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg21775007	chr8:11205619	TDH	-0.46	-6.08	-0.36	4.56e-9	Neuroticism;
KIRP	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	6.97	0.41	2.81e-11	Eosinophil percentage of white cells;
KIRP	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.71	0.39	1.3100000000000001e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7721647	0.853	rs1822167	chr5:90864497	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.4	5.01	0.3	1.05e-6	Breast cancer;
KIRP	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg08847533	chr14:75593920	NEK9	-0.54	-6.37	-0.38	9.01e-10	IgG glycosylation;
KIRP	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg22563815	chr15:78856949	CHRNA5	-0.47	-7.38	-0.43	2.48e-12	Sudden cardiac arrest;
KIRP	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.88	12.9	0.64	1.94e-29	Coronary artery disease;
KIRP	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg13319975	chr6:146136371	FBXO30	0.47	6.62	0.39	2.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg04990556	chr1:26633338	UBXN11	0.65	6.11	0.36	3.91e-9	Obesity-related traits;
KIRP	cis	rs6540559	0.673	rs7550857	chr1:209956542	C/A	cg22029157	chr1:209979665	IRF6	0.51	5.7	0.34	3.33e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs3789045	1.000	rs3747631	chr1:204587569	G/C	cg18185008	chr1:204589407	LRRN2	-0.67	-7.47	-0.43	1.36e-12	Educational attainment (college completion);
KIRP	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.38	0.38	8.64e-10	Morning vs. evening chronotype;
KIRP	cis	rs2224391	0.590	rs2773312	chr6:5251798	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.47	-0.38	5.22e-10	Height;
KIRP	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.92	-15.73	-0.71	4.81e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4666002	0.636	rs2272406	chr2:27892023	A/T	cg05484376	chr2:27715224	FNDC4	-0.46	-5.69	-0.34	3.63e-8	Phospholipid levels (plasma);
KIRP	cis	rs7615316	0.844	rs13069307	chr3:142315074	G/A	cg20824294	chr3:142316082	PLS1	0.26	5.82	0.35	1.82e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.88	-15.01	-0.69	1.38e-36	Height;
KIRP	trans	rs17685	0.961	rs41301394	chr7:75612803	C/T	cg19862616	chr7:65841803	NCRNA00174	0.66	7.45	0.43	1.58e-12	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg07856975	chr6:36356162	ETV7	0.46	5.78	0.35	2.3e-8	Platelet distribution width;
KIRP	cis	rs1635	0.826	rs79567170	chr6:28280057	C/T	cg15743358	chr6:28303923	ZNF323	-0.76	-5.47	-0.33	1.13e-7	Schizophrenia;
KIRP	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.89	-0.3	1.85e-6	Lung cancer;
KIRP	cis	rs17301259	0.509	rs4352770	chr7:88407694	C/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-4.98	-0.3	1.21e-6	Heschl's gyrus morphology;
KIRP	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.98	13.57	0.65	1.12e-31	Menopause (age at onset);
KIRP	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg02569458	chr12:86230093	RASSF9	-0.52	-7.64	-0.44	4.79e-13	Major depressive disorder;
KIRP	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-0.84	-9.36	-0.51	5.22e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg00656387	chr3:40428638	ENTPD3	0.37	5.03	0.31	9.31e-7	Renal cell carcinoma;
KIRP	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg25019033	chr10:957182	NA	-0.59	-6.17	-0.37	2.81e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg08885076	chr2:99613938	TSGA10	0.48	8.21	0.46	1.27e-14	Chronic sinus infection;
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00933542	chr6:150070202	PCMT1	-0.27	-5.14	-0.31	5.57e-7	Lung cancer;
KIRP	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.73	9.2	0.51	1.59e-17	Gestational age at birth (maternal effect);
KIRP	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.65	-7.92	-0.45	8.05e-14	Corneal astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12090413	chr18:47807928	MBD1	0.56	7.86	0.45	1.22e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2150410	0.915	rs413078	chr21:40542695	T/C	cg11890956	chr21:40555474	PSMG1	-0.75	-5.53	-0.33	7.98e-8	Temperament (bipolar disorder);
KIRP	cis	rs12780845	1.000	rs12783490	chr10:17223716	T/A	cg01003015	chr10:17271136	VIM	0.47	5.02	0.3	9.9e-7	Homocysteine levels;
KIRP	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg09682330	chr6:28411287	ZSCAN23	0.4	5.04	0.31	8.83e-7	Pubertal anthropometrics;
KIRP	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-0.9	-8.91	-0.49	1.18e-16	Obesity-related traits;
KIRP	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	0.99	17.93	0.75	1.5e-46	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.88	11.91	0.6	4e-26	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs2273669	0.915	rs10872028	chr6:109313728	A/G	cg05315195	chr6:109294784	ARMC2	0.48	5.46	0.33	1.18e-7	Prostate cancer;
KIRP	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26002218	chr14:103986227	CKB	0.29	5.81	0.35	1.89e-8	Body mass index;
KIRP	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.53	7.13	0.41	1.13e-11	Blood metabolite levels;
KIRP	cis	rs2034088	1.000	rs3744731	chr17:420467	T/C	cg06217071	chr17:408420	NA	0.74	11.13	0.58	1.41e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.99	14.27	0.67	4.73e-34	Cognitive function;
KIRP	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.67	-7.92	-0.45	7.97e-14	Obesity-related traits;
KIRP	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.69	-7.76	-0.44	2.2e-13	Blood pressure (smoking interaction);
KIRP	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg17294928	chr15:75287854	SCAMP5	0.58	7.86	0.45	1.2e-13	Breast cancer;
KIRP	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.24	0.32	3.49e-7	Cognitive test performance;
KIRP	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	0.95	7.85	0.45	1.26e-13	Gut microbiota (bacterial taxa);
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg04369109	chr6:150039330	LATS1	-0.5	-6.35	-0.38	1.03e-9	Lung cancer;
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg09695851	chr17:3907499	NA	0.86	16.66	0.73	3.21e-42	Type 2 diabetes;
KIRP	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg23594656	chr7:65796392	TPST1	-0.45	-6.27	-0.37	1.62e-9	Aortic root size;
KIRP	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg05802129	chr4:122689817	NA	0.47	6.8	0.4	7.88e-11	Type 2 diabetes;
KIRP	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg00129232	chr17:37814104	STARD3	0.66	7.04	0.41	1.87e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.2	-0.31	4.25e-7	Ulcerative colitis;
KIRP	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs7075426	0.905	rs11202038	chr10:88204877	C/T	cg07322936	chr10:88137208	NA	0.43	4.9	0.3	1.74e-6	Migraine without aura;
KIRP	cis	rs7721647	0.853	rs2919809	chr5:90860165	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg11657440	chr19:46296263	DMWD	-0.74	-9.69	-0.53	5.01e-19	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	8.34	0.47	5.39e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	5.35	0.32	2.05e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg00343986	chr7:65444356	GUSB	0.49	5.91	0.35	1.13e-8	Calcium levels;
KIRP	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.37	4.91	0.3	1.7e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg26566898	chr11:117069891	TAGLN	0.4	5.23	0.32	3.64e-7	Blood protein levels;
KIRP	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11645453	chr3:52864694	ITIH4	0.33	4.87	0.3	2.01e-6	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05359465	chr18:13726739	C18orf19;RNMT	0.55	6.98	0.41	2.78e-11	Parkinson's disease;
KIRP	cis	rs62070183	0.882	rs17183295	chr17:31078272	C/T	cg05781649	chr17:31146240	MYO1D	-0.5	-4.98	-0.3	1.18e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7766436	0.648	rs2876643	chr6:22591525	C/A	cg13666174	chr6:22585274	NA	-0.37	-5.21	-0.31	4.08e-7	Coronary artery disease;
KIRP	cis	rs714027	0.566	rs1548389	chr22:30573552	T/C	cg01021169	chr22:30184971	ASCC2	-0.44	-5.61	-0.34	5.44e-8	Lymphocyte counts;
KIRP	cis	rs981844	1.000	rs2251639	chr4:154656410	T/C	cg14289246	chr4:154710475	SFRP2	0.64	6.85	0.4	5.88e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2120243	1.000	rs10936090	chr3:157142754	A/C	cg24825693	chr3:157122686	VEPH1	-0.35	-5.03	-0.31	9.62e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15861578	chr12:56511939	ZC3H10	0.55	6.42	0.38	7.13e-10	Smoking initiation;
KIRP	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.55	13.9	0.66	8.45e-33	Airflow obstruction;
KIRP	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-14.49	-0.68	8.33e-35	Alzheimer's disease;
KIRP	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.69	-8.91	-0.49	1.16e-16	Huntington's disease progression;
KIRP	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.12	0.46	2.23e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg16309518	chr5:176445507	NA	-0.79	-12.36	-0.62	1.31e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg08619932	chr19:49200058	FUT2	0.38	5.92	0.35	1.06e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.71	5.81	0.35	1.92e-8	Body mass index;
KIRP	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.0	-0.3	1.09e-6	Cervical cancer;
KIRP	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg18527119	chr7:66119851	NA	0.47	5.0	0.3	1.09e-6	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11013977	chr3:49131405	QRICH1	0.55	7.11	0.41	1.22e-11	Parkinson's disease;
KIRP	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.85	-0.3	2.22e-6	Monocyte percentage of white cells;
KIRP	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	8.26	0.47	8.98e-15	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg21360079	chr12:107162445	NA	-0.67	-9.59	-0.52	1.06e-18	Heart rate;
KIRP	cis	rs1143633	0.509	rs2068777	chr2:113696126	A/G	cg06156847	chr2:113672199	IL1F7	-0.42	-5.45	-0.33	1.2e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.3	0.32	2.54e-7	Educational attainment;
KIRP	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg11941060	chr3:133502564	NA	-0.48	-5.88	-0.35	1.32e-8	Iron status biomarkers;
KIRP	cis	rs8062405	0.508	rs9929088	chr16:29001460	A/C	cg07382826	chr16:28625726	SULT1A1	-0.48	-5.29	-0.32	2.64e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-11.2	-0.58	8.76e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.2	-0.8	1.87e-57	Ulcerative colitis;
KIRP	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-7.59	-0.44	6.74e-13	Vitiligo;
KIRP	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.66	-6.28	-0.37	1.52e-9	Diisocyanate-induced asthma;
KIRP	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.42	0.47	3.18e-15	Electroencephalogram traits;
KIRP	cis	rs12143943	0.866	rs12032618	chr1:204532659	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.41	-0.38	7.19e-10	Cognitive performance;
KIRP	cis	rs930036	0.602	rs6758331	chr2:171847269	T/C	cg12801329	chr2:171670795	NA	0.44	4.91	0.3	1.7e-6	Menopause (age at onset);
KIRP	cis	rs6753739	0.784	rs6730783	chr2:219922835	A/G	cg01749213	chr2:219906749	CCDC108	0.43	5.33	0.32	2.2e-7	Height;
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg26831259	chr4:1366826	KIAA1530	0.38	5.06	0.31	8.11e-7	Obesity-related traits;
KIRP	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg10223061	chr2:219282414	VIL1	0.4	6.42	0.38	7.15e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg13180566	chr4:1052158	NA	-0.56	-5.6	-0.34	5.77e-8	Recombination rate (females);
KIRP	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-4.92	-0.3	1.55e-6	Large artery stroke;
KIRP	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg18225595	chr11:63971243	STIP1	0.6	5.51	0.33	9.07e-8	Mean platelet volume;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.01	0.41	2.33e-11	Lymphocyte counts;
KIRP	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg16917193	chr12:54089295	NA	0.87	16.57	0.73	6.45e-42	Height;
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.36	-5.18	-0.31	4.64e-7	Lymphocyte counts;
KIRP	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.91	-0.4	4.21e-11	Coronary artery disease;
KIRP	cis	rs965513	1.000	rs7864322	chr9:100548934	C/T	cg13688889	chr9:100608707	NA	-0.6	-7.74	-0.44	2.61e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg14555127	chr7:35841578	SEPT7	0.9	6.21	0.37	2.28e-9	P wave terminal force;
KIRP	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.78	-5.44	-0.33	1.3e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.81	-0.45	1.61e-13	Retinal vascular caliber;
KIRP	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.55	-6.05	-0.36	5.5e-9	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg04369109	chr6:150039330	LATS1	-0.61	-7.32	-0.42	3.57e-12	Lung cancer;
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.36	-0.51	5.35e-18	Platelet count;
KIRP	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg05802129	chr4:122689817	NA	-0.46	-6.7	-0.39	1.39e-10	Type 2 diabetes;
KIRP	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg09117114	chr16:67998030	SLC12A4	-0.53	-5.56	-0.33	7.12e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.7	10.23	0.55	1.03e-20	Oral cavity cancer;
KIRP	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.5	-6.31	-0.37	1.26e-9	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs6462411	0.702	rs10485864	chr7:3923656	G/C	cg18022346	chr7:3920534	SDK1	-0.46	-5.11	-0.31	6.46e-7	Quantitative traits;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg21734707	chr17:3908241	ZZEF1	-0.62	-9.3	-0.51	8.19e-18	Type 2 diabetes;
KIRP	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg25753631	chr6:25732923	NA	-0.27	-5.01	-0.3	1.03e-6	Iron status biomarkers;
KIRP	cis	rs25422	0.938	rs62422193	chr6:118912285	G/A	cg21191810	chr6:118973309	C6orf204	-0.44	-4.86	-0.3	2.13e-6	Renal cell carcinoma;
KIRP	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.53	5.2	0.31	4.29e-7	Alzheimer's disease;
KIRP	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	1.18	10.28	0.55	7.32e-21	LDL cholesterol;
KIRP	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.46	6.85	0.4	5.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg07884673	chr3:53033167	SFMBT1	0.75	6.11	0.36	3.91e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.64	-0.44	4.92e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	1.01	16.05	0.72	3.65e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.5	-13.25	-0.65	1.37e-30	Hip circumference adjusted for BMI;
KIRP	cis	rs71597109	0.681	rs11929782	chr4:102724542	T/C	cg14855874	chr4:102712397	BANK1	0.4	5.35	0.32	2e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.78	-0.35	2.24e-8	Bipolar disorder;
KIRP	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.3	0.47	6.98e-15	Schizophrenia;
KIRP	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.61	-6.55	-0.39	3.31e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg19773385	chr1:10388646	KIF1B	-0.7	-9.9	-0.53	1.18e-19	Hepatocellular carcinoma;
KIRP	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.17	-0.61	5.48e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.74	-0.39	1.11e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11987759	chr7:65425863	GUSB	0.51	6.86	0.4	5.55e-11	Aortic root size;
KIRP	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg23067535	chr8:124195133	FAM83A	-0.81	-6.7	-0.39	1.43e-10	Urinary uromodulin levels;
KIRP	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg16296679	chr22:42394374	WBP2NL	0.37	5.07	0.31	7.96e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12311346	chr5:56204834	C5orf35	0.46	5.92	0.35	1.1e-8	Coronary artery disease;
KIRP	cis	rs7312774	0.881	rs1822737	chr12:107309175	A/G	cg16260113	chr12:107380972	MTERFD3	0.72	6.55	0.39	3.28e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	7.84	0.45	1.38e-13	Eosinophil percentage of white cells;
KIRP	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22117172	chr7:91764530	CYP51A1	0.48	6.68	0.39	1.57e-10	Breast cancer;
KIRP	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg03970086	chr16:88974840	CBFA2T3	0.47	6.12	0.36	3.65e-9	Social autistic-like traits;
KIRP	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.61	-0.6	3.83e-25	Body mass index;
KIRP	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg04226714	chr8:49833948	SNAI2	-0.46	-6.52	-0.38	4.03e-10	Life satisfaction;
KIRP	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg20636351	chr8:55087400	NA	-0.53	-6.43	-0.38	6.74e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg02725872	chr8:58115012	NA	-0.45	-5.09	-0.31	7.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.62	-8.44	-0.47	2.81e-15	Total body bone mineral density;
KIRP	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg01689657	chr7:91764605	CYP51A1	0.46	6.66	0.39	1.76e-10	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08427575	chr7:75988356	YWHAG	0.54	6.91	0.4	4.02e-11	Parkinson's disease;
KIRP	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.69	-0.53	5.05e-19	Neuroticism;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg23985595	chr17:80112537	CCDC57	-0.34	-5.14	-0.31	5.53e-7	Life satisfaction;
KIRP	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.11e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.66	9.59	0.52	1.03e-18	Dupuytren's disease;
KIRP	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.43	-4.92	-0.3	1.58e-6	Schizophrenia;
KIRP	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.46	6.89	0.4	4.79e-11	Bipolar disorder;
KIRP	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg05043794	chr9:111880884	C9orf5	0.22	5.31	0.32	2.42e-7	Menarche (age at onset);
KIRP	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg12826209	chr6:26865740	GUSBL1	0.65	4.89	0.3	1.81e-6	Depression;
KIRP	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.91	-0.64	1.86e-29	Exhaled nitric oxide output;
KIRP	cis	rs754466	0.706	rs7099526	chr10:79657705	C/G	cg17075019	chr10:79541650	NA	-0.89	-10.98	-0.57	4.34e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg18586891	chr4:952366	TMEM175	0.59	5.4	0.33	1.61e-7	Parkinson's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01808912	chr17:4458859	MYBBP1A	-0.46	-6.16	-0.37	3.01e-9	Myopia;
KIRP	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14168246	chr10:35689206	CCNY	0.44	6.56	0.39	3.21e-10	Migraine with aura;
KIRP	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.86	0.45	1.2e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11987759	chr7:65425863	GUSB	0.46	5.83	0.35	1.7e-8	Aortic root size;
KIRP	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.5	8.41	0.47	3.39e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.16	-0.31	5.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1620921	0.505	rs9458031	chr6:161210119	G/A	cg01280913	chr6:161186852	NA	-0.58	-7.69	-0.44	3.42e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17554472	chr22:41940697	POLR3H	0.69	7.1	0.41	1.35e-11	Vitiligo;
KIRP	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	1.15	8.09	0.46	2.69e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	14.2	0.67	7.8e-34	Smoking behavior;
KIRP	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.6	-0.66	8.93e-32	Ulcerative colitis;
KIRP	cis	rs4523957	0.620	rs9900587	chr17:2071097	G/A	cg16513277	chr17:2031491	SMG6	-0.85	-12.33	-0.62	1.67e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.85	0.57	1.17e-22	Cognitive test performance;
KIRP	cis	rs894344	0.650	rs11166598	chr8:135581352	T/C	cg09855544	chr8:135498122	ZFAT	0.4	5.18	0.31	4.73e-7	Systolic blood pressure;
KIRP	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg05692746	chr2:100937584	LONRF2	-0.38	-5.06	-0.31	8.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg16077055	chr2:106428750	NCK2	0.27	5.54	0.33	7.68e-8	Addiction;
KIRP	cis	rs7404095	0.695	rs12928465	chr16:23868137	C/T	cg21745164	chr16:23765304	CHP2	0.35	5.06	0.31	8.3e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13919506	chr9:131535850	NA	0.5	6.37	0.38	9.25e-10	Interleukin-4 levels;
KIRP	cis	rs1629083	0.846	rs1806	chr11:118076004	C/T	cg18857871	chr11:118064634	AMICA1	0.7	9.93	0.53	9.48e-20	Lung cancer;
KIRP	cis	rs8014252	0.518	rs58919501	chr14:71069022	G/A	cg11204974	chr14:71022665	NA	-0.52	-5.82	-0.35	1.87e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg23093090	chr10:104574429	C10orf26	0.37	6.07	0.36	4.87e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.56	0.33	7.15e-8	Putamen volume;
KIRP	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.73	-8.82	-0.49	2.22e-16	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg05347473	chr6:146136440	FBXO30	0.5	6.96	0.41	3.06e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs953387	1.000	rs2056297	chr2:136899116	G/T	cg05194412	chr2:137003533	NA	-0.4	-5.19	-0.31	4.51e-7	Arthritis (juvenile idiopathic);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25722198	chr1:226595776	PARP1	0.49	6.3	0.37	1.34e-9	Parkinson's disease;
KIRP	cis	rs963731	0.649	rs297130	chr2:39299314	C/T	cg04010122	chr2:39346883	SOS1	0.87	6.01	0.36	6.6e-9	Corticobasal degeneration;
KIRP	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg26022315	chr17:47021804	SNF8	0.42	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg12560992	chr17:57184187	TRIM37	-0.58	-6.44	-0.38	6.22e-10	Testicular germ cell tumor;
KIRP	trans	rs4613509	1	rs4613509	chr3:160728059	T/C	cg19274270	chr17:78178856	CARD14	-0.35	-6.29	-0.37	1.42e-9	Morning vs. evening chronotype;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg25703541	chr22:24373054	LOC391322	-0.55	-7.23	-0.42	6.23e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00968012	chr17:46048404	CDK5RAP3	-0.49	-6.64	-0.39	1.96e-10	Metabolic traits;
KIRP	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg00262122	chr8:11665843	FDFT1	0.44	5.51	0.33	8.96e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg24565620	chr2:194026	NA	-0.61	-6.43	-0.38	6.7e-10	Blood protein levels;
KIRP	cis	rs6669919	0.510	rs4951758	chr1:211690631	A/G	cg10512769	chr1:211675356	NA	-0.37	-5.37	-0.32	1.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7187994	0.848	rs12922556	chr16:84784290	C/T	cg07647771	chr16:84786436	USP10	0.37	5.26	0.32	3.12e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg10729496	chr3:10149963	C3orf24	-0.59	-4.98	-0.3	1.17e-6	Alzheimer's disease;
KIRP	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.1	-0.31	6.88e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-1.03	-12.71	-0.63	8.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs7236492	0.572	rs112024357	chr18:77175610	T/C	cg15644404	chr18:77186268	NFATC1	-0.95	-6.17	-0.37	2.77e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg23442198	chr4:187126114	CYP4V2	0.79	7.56	0.43	7.82e-13	Blood protein levels;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg24796471	chr19:6737389	GPR108	0.48	6.04	0.36	5.6e-9	Educational attainment;
KIRP	cis	rs654384	0.898	rs11766511	chr7:4173613	A/G	cg21882563	chr7:4172065	SDK1	0.42	5.54	0.33	7.62e-8	Positive affect;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26621805	chr8:110373460	PKHD1L1	0.44	6.04	0.36	5.65e-9	Myopia (pathological);
KIRP	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.68	-8.57	-0.48	1.14e-15	Iron status biomarkers;
KIRP	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Parkinson's disease;
KIRP	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.01e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.6	6.68	0.39	1.56e-10	Aortic root size;
KIRP	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.59	6.17	0.37	2.81e-9	Gut microbiome composition (summer);
KIRP	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg00677455	chr12:58241039	CTDSP2	0.99	12.95	0.64	1.38e-29	Multiple sclerosis;
KIRP	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg18643199	chr10:82363313	SH2D4B	0.46	5.01	0.3	1.05e-6	Post bronchodilator FEV1;
KIRP	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	1.01	10.17	0.54	1.61e-20	Psoriasis;
KIRP	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	9.23	0.51	1.31e-17	Bone mineral density;
KIRP	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.48	-0.48	2.08e-15	Blood trace element (Zn levels);
KIRP	cis	rs6102059	0.525	rs6129632	chr20:39194227	T/C	cg22477343	chr20:39312069	NA	0.45	5.77	0.35	2.34e-8	LDL cholesterol;
KIRP	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg05340658	chr4:99064831	C4orf37	0.54	6.52	0.38	3.9e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg12218747	chr21:37451666	NA	-0.41	-5.06	-0.31	8.35e-7	Mitral valve prolapse;
KIRP	cis	rs9653442	0.527	rs11123812	chr2:100761548	T/C	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6546886	0.912	rs4853009	chr2:74296411	G/A	cg14702570	chr2:74259524	NA	-0.26	-4.97	-0.3	1.25e-6	Dialysis-related mortality;
KIRP	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg16917193	chr12:54089295	NA	-0.53	-6.59	-0.39	2.72e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21545522	chr1:205238299	TMCC2	0.39	5.1	0.31	6.8e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg07274523	chr3:49395745	GPX1	0.71	8.79	0.49	2.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg24375607	chr4:120327624	NA	0.55	6.25	0.37	1.82e-9	Corneal astigmatism;
KIRP	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg01304814	chr3:48885189	PRKAR2A	0.58	5.1	0.31	6.92e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6909279	0.933	rs7761420	chr6:151872567	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.47	-6.19	-0.37	2.43e-9	Bone mineral density;
KIRP	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.61	-9.31	-0.51	7.56e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6453429	0.720	rs642934	chr5:78364844	C/A	cg06501366	chr5:78365687	BHMT2;DMGDH	-0.35	-5.77	-0.35	2.41e-8	Urinary metabolites;
KIRP	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg20026190	chr17:76395443	PGS1	-0.48	-6.07	-0.36	4.84e-9	HDL cholesterol levels;
KIRP	cis	rs735539	0.574	rs10870743	chr13:21258756	C/A	cg04906043	chr13:21280425	IL17D	-0.5	-5.71	-0.34	3.23e-8	Dental caries;
KIRP	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.59	-0.56	7.92e-22	Height;
KIRP	cis	rs8063160	0.935	rs73283869	chr16:90067184	G/A	cg07984980	chr16:89898383	SPIRE2	1.07	5.87	0.35	1.44e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs7011507	1.000	rs6981583	chr8:49157997	A/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.72	-9.16	-0.5	2.07e-17	Dilated cardiomyopathy;
KIRP	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg18132916	chr6:79620363	NA	-0.42	-5.74	-0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7246760	1.000	rs10419915	chr19:9890957	G/A	cg02900749	chr2:68251473	NA	-0.95	-8.79	-0.49	2.61e-16	Pursuit maintenance gain;
KIRP	cis	rs10489202	0.583	rs203777	chr1:167876616	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-7.68	-0.44	3.82e-13	Schizophrenia;
KIRP	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.76	-10.64	-0.56	5.3e-22	Blood metabolite levels;
KIRP	cis	rs9807841	0.500	rs1368459	chr19:10835338	C/G	cg17710535	chr19:10819994	QTRT1	0.42	5.11	0.31	6.57e-7	Inflammatory skin disease;
KIRP	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17376030	chr22:41985996	PMM1	0.7	7.44	0.43	1.65e-12	Vitiligo;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg20597820	chr11:68216546	LRP5	0.4	6.04	0.36	5.57e-9	Serum protein levels (sST2);
KIRP	trans	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg03929089	chr4:120376271	NA	0.9	6.54	0.38	3.48e-10	Intraocular pressure;
KIRP	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg16898833	chr6:26189333	HIST1H4D	0.7	4.89	0.3	1.81e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.83	-9.15	-0.5	2.18e-17	Bipolar disorder and schizophrenia;
KIRP	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.49	-0.48	1.97e-15	Colorectal cancer;
KIRP	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.91	-0.49	1.19e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg23845249	chr11:68861649	NA	0.54	7.84	0.45	1.36e-13	Blond vs. brown hair color;
KIRP	cis	rs3806843	0.900	rs3756334	chr5:140213796	G/A	cg19875535	chr5:140030758	IK	0.64	8.75	0.49	3.53e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg07701084	chr6:150067640	NUP43	0.7	9.88	0.53	1.33e-19	Lung cancer;
KIRP	cis	rs2671245	0.933	rs2671233	chr1:56163719	G/A	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8033133	0.881	rs3803328	chr15:25330550	T/A	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.47	-5.44	-0.33	1.3e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs7180079	0.620	rs1567985	chr15:64685207	G/A	cg15337035	chr15:64978493	NA	-0.49	-5.29	-0.32	2.7e-7	Monocyte count;
KIRP	cis	rs6681460	0.649	rs1415974	chr1:67005503	C/T	cg02459107	chr1:67143332	SGIP1	-0.38	-5.37	-0.32	1.83e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.74	-9.04	-0.5	4.92e-17	Migraine;Coronary artery disease;
KIRP	trans	rs1941687	0.769	rs1493911	chr18:31356019	A/G	cg04226714	chr8:49833948	SNAI2	-0.45	-6.04	-0.36	5.71e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7520050	0.966	rs6701614	chr1:46309420	G/C	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4233802	1.000	rs6761697	chr2:151141735	A/G	cg25300694	chr2:151184358	NA	0.72	5.85	0.35	1.56e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.52	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.55	7.46	0.43	1.52e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs4006360	0.503	rs1848808	chr17:39249321	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.52	0.33	8.68e-8	Major depressive disorder;
KIRP	cis	rs12580194	0.556	rs11171433	chr12:55757797	A/T	cg19537932	chr12:55886519	OR6C68	-0.5	-6.48	-0.38	5.02e-10	Cancer;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.4	-5.32	-0.32	2.34e-7	Renal function-related traits (BUN);
KIRP	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17344932	chr17:38183730	MED24;SNORD124	-0.32	-5.04	-0.31	8.94e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg16586182	chr3:47516702	SCAP	0.63	8.48	0.48	2.13e-15	Colorectal cancer;
KIRP	trans	rs8002861	0.658	rs9533635	chr13:44397921	C/A	cg17145862	chr1:211918768	LPGAT1	-0.56	-7.01	-0.41	2.29e-11	Leprosy;
KIRP	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-1.01	-10.41	-0.55	2.85e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.61	-6.58	-0.39	2.8e-10	DNA methylation (variation);
KIRP	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.41	-4.97	-0.3	1.24e-6	Testicular germ cell tumor;
KIRP	cis	rs259282	0.605	rs28615461	chr19:33110149	T/C	cg02997394	chr19:33096574	ANKRD27	-0.53	-6.3	-0.37	1.36e-9	Schizophrenia;
KIRP	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.59	7.61	0.44	5.96e-13	Height;
KIRP	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.58	7.17	0.42	8.89e-12	Arsenic metabolism;
KIRP	cis	rs6977660	0.943	rs10249996	chr7:19844935	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	5.39	0.33	1.65e-7	Thyroid stimulating hormone;
KIRP	trans	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.13	0.36	3.46e-9	Schizophrenia;
KIRP	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg07382826	chr16:28625726	SULT1A1	0.5	5.77	0.35	2.43e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.65	-6.8	-0.4	7.76e-11	Menarche (age at onset);
KIRP	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.43	5.37	0.32	1.8e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7188697	0.922	rs37061	chr16:58566671	A/G	cg21335942	chr16:58549945	SETD6	0.47	5.16	0.31	5e-7	QT interval;
KIRP	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	0.82	9.52	0.52	1.72e-18	Gut microbiome composition (summer);
KIRP	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.89	13.82	0.66	1.58e-32	Coronary artery disease;
KIRP	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.11	0.46	2.45e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.2e-8	Life satisfaction;
KIRP	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.37	5.03	0.31	9.61e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.29	15.62	0.71	1.1e-38	Eosinophil percentage of granulocytes;
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.8	13.4	0.65	4.18e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs4349753	0.870	rs378442	chr5:144181861	C/T	cg16033277	chr17:80885358	TBCD	0.4	6.25	0.37	1.84e-9	Photic sneeze reflex;
KIRP	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.17	0.31	4.76e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.84e-11	Colorectal cancer;
KIRP	cis	rs1425132	0.692	rs7801424	chr7:37570431	T/C	cg15028436	chr7:37888078	TXNDC3	-0.4	-5.12	-0.31	6.17e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
KIRP	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg05805236	chr11:65401703	PCNXL3	-0.43	-5.56	-0.33	7e-8	Urate levels;
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg23985595	chr17:80112537	CCDC57	-0.35	-5.17	-0.31	4.94e-7	Life satisfaction;
KIRP	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg21775007	chr8:11205619	TDH	-0.5	-6.6	-0.39	2.57e-10	Mood instability;
KIRP	cis	rs16936870	0.543	rs16936881	chr8:71200158	C/G	cg14232793	chr8:71155543	NCOA2	0.53	6.29	0.37	1.44e-9	QT interval;
KIRP	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.09	-0.58	1.9e-23	Chronic sinus infection;
KIRP	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.72	-9.83	-0.53	1.84e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.96	-0.36	8.67e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg00825309	chr19:58991885	ZNF446	-0.56	-6.94	-0.4	3.42e-11	Uric acid clearance;
KIRP	trans	rs6601327	0.635	rs28828176	chr8:9663453	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.8	-0.4	7.74e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	0.81	7.16	0.42	9.35e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs2625529	0.730	rs12912771	chr15:72162928	A/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.22	-0.37	2.18e-9	Red blood cell count;
KIRP	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.99	11.43	0.59	1.46e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg05025164	chr4:1340916	KIAA1530	0.53	6.98	0.41	2.8e-11	Longevity;
KIRP	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.35	0.42	2.93e-12	Height;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg15117754	chr3:10150083	C3orf24	0.56	5.31	0.32	2.47e-7	Alzheimer's disease;
KIRP	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.92	12.25	0.62	3.08e-27	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg15181151	chr6:150070149	PCMT1	0.3	5.17	0.31	4.78e-7	Lung cancer;
KIRP	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.61	-9.31	-0.51	7.56e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs17123764	0.710	rs12316284	chr12:50158866	G/A	cg20471783	chr12:50157085	TMBIM6	0.31	4.93	0.3	1.48e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg06740227	chr12:86229804	RASSF9	0.45	5.73	0.34	2.85e-8	Major depressive disorder;
KIRP	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.78	10.93	0.57	6.32e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.59	7.94	0.45	7.34e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs16828019	0.929	rs8179465	chr1:41701747	C/T	cg08144172	chr1:41849203	NA	0.61	5.0	0.3	1.1e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.51	7.23	0.42	5.94e-12	Systemic lupus erythematosus;
KIRP	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg25174290	chr11:3078921	CARS	-0.6	-6.35	-0.38	1.04e-9	Calcium levels;
KIRP	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg20673091	chr1:2541236	MMEL1	-0.78	-12.68	-0.63	1.08e-28	Ulcerative colitis;
KIRP	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.9	-12.28	-0.62	2.4e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg05370193	chr1:21551575	ECE1	0.45	6.18	0.37	2.61e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01748703	chr7:121738915	AASS	-0.44	-6.94	-0.4	3.49e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.04	7.94	0.45	6.99e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg23845249	chr11:68861649	NA	0.58	8.35	0.47	5.07e-15	Blond vs. brown hair color;
KIRP	cis	rs61884328	0.852	rs17790246	chr11:47071513	C/T	cg23433285	chr11:47201945	PACSIN3	0.77	6.26	0.37	1.67e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.46	5.21	0.32	4.03e-7	Schizophrenia;
KIRP	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.8	-0.53	2.28e-19	Aortic root size;
KIRP	cis	rs4908768	0.579	rs11121237	chr1:8876392	A/G	cg25722041	chr1:8623473	RERE	0.58	7.32	0.42	3.52e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1413885	0.549	rs1334877	chr1:65846406	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	5.76	0.34	2.47e-8	Anticoagulant levels;
KIRP	cis	rs9596863	0.898	rs34107297	chr13:54374962	A/T	ch.13.53330881F	chr13:54432880	NA	0.62	6.09	0.36	4.22e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.89	0.45	9.98e-14	Lung cancer in ever smokers;
KIRP	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11644478	chr21:40555479	PSMG1	-0.62	-6.9	-0.4	4.34e-11	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.15	0.41	1.01e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.63	10.06	0.54	3.61e-20	Neuroticism;
KIRP	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.53	7.11	0.41	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.94	0.4	3.36e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.52	-6.35	-0.38	1.01e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.64	9.87	0.53	1.45e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs10242455	0.702	rs76840929	chr7:98945858	T/C	cg18809830	chr7:99032528	PTCD1	-1.07	-5.97	-0.36	8.32e-9	Blood metabolite levels;
KIRP	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.23	-6.59	-0.39	2.65e-10	Type 2 diabetes;
KIRP	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg15488143	chr7:128924101	AHCYL2	0.63	6.75	0.4	1.08e-10	White matter hyperintensity burden;
KIRP	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg10189774	chr4:17578691	LAP3	-0.45	-5.51	-0.33	9.22e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10405744	0.744	rs7246986	chr19:20189967	A/T	cg15934607	chr13:114802548	RASA3	-0.5	-6.18	-0.37	2.61e-9	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);
KIRP	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13198984	chr17:80129470	CCDC57	-0.46	-7.01	-0.41	2.27e-11	Life satisfaction;
KIRP	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg24579218	chr15:68104479	NA	-0.44	-7.16	-0.42	9.33e-12	Restless legs syndrome;
KIRP	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.4	-0.33	1.6e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20135002	chr11:47629003	NA	-0.46	-5.45	-0.33	1.23e-7	Subjective well-being;
KIRP	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.58	0.8	2.02e-55	Prudent dietary pattern;
KIRP	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.73	-9.09	-0.5	3.37e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs490234	0.932	rs474489	chr9:128317881	C/G	cg14078157	chr9:128172775	NA	0.41	5.22	0.32	3.82e-7	Mean arterial pressure;
KIRP	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-9.46	-0.52	2.69e-18	Eye color traits;
KIRP	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6942756	0.876	rs822038	chr7:129065477	A/G	cg02491457	chr7:128862824	NA	-0.56	-6.46	-0.38	5.55e-10	White matter hyperintensity burden;
KIRP	cis	rs9513627	1.000	rs4294655	chr13:100216696	A/G	cg25919922	chr13:100150906	NA	0.66	5.07	0.31	7.78e-7	Obesity-related traits;
KIRP	cis	rs12580194	0.635	rs61957879	chr12:55716971	A/C	cg11794356	chr12:55725991	OR6C3	-0.6	-8.55	-0.48	1.29e-15	Cancer;
KIRP	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg04166393	chr7:2884313	GNA12	0.63	7.48	0.43	1.31e-12	Height;
KIRP	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs9311676	0.656	rs11714807	chr3:58405431	A/G	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg25547332	chr5:131281432	NA	-0.47	-5.07	-0.31	7.7e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg01877450	chr7:97915802	BRI3	-0.57	-7.46	-0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg14061069	chr19:46274453	DMPK	-0.38	-5.25	-0.32	3.28e-7	Coronary artery disease;
KIRP	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.94	0.61	3.15e-26	Ileal carcinoids;
KIRP	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.84	13.52	0.65	1.66e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.6	-0.39	2.46e-10	Neutrophil percentage of white cells;
KIRP	cis	rs12210905	1.000	rs72843629	chr6:27175215	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.08	-0.36	4.56e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg13180566	chr4:1052158	NA	-0.5	-5.16	-0.31	4.99e-7	Recombination rate (females);
KIRP	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	12.07	0.61	1.16e-26	Smoking behavior;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg02733842	chr7:1102375	C7orf50	0.49	5.3	0.32	2.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7712401	0.601	rs34126945	chr5:122329729	A/G	cg19412675	chr5:122181750	SNX24	-0.48	-5.28	-0.32	2.81e-7	Mean platelet volume;
KIRP	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-5.59	-0.34	5.93e-8	Chronic sinus infection;
KIRP	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	7.09	0.41	1.43e-11	Aortic root size;
KIRP	cis	rs2290416	0.786	rs77951814	chr8:144657152	C/G	cg17524265	chr8:144659883	NAPRT1	0.76	4.86	0.3	2.13e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs12282928	1.000	rs11039668	chr11:48326479	A/G	cg26585981	chr11:48327164	OR4S1	0.51	6.22	0.37	2.09e-9	Migraine - clinic-based;
KIRP	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg03146154	chr1:46216737	IPP	0.56	5.93	0.35	1.04e-8	Platelet count;
KIRP	cis	rs17065868	1.000	rs7319249	chr13:45128282	A/G	cg10246903	chr13:45222710	NA	0.63	6.75	0.4	1.09e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg09163369	chr1:210001066	C1orf107	0.53	5.73	0.34	2.87e-8	Orofacial clefts;
KIRP	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg16141378	chr3:129829833	LOC729375	-0.54	-6.69	-0.39	1.46e-10	Neuroticism;
KIRP	cis	rs9533799	0.966	rs7999368	chr13:44807184	G/A	cg19190762	chr13:44806055	NA	0.61	8.34	0.47	5.16e-15	Amyotrophic lateral sclerosis;
KIRP	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg03060546	chr3:49711283	APEH	-0.69	-5.36	-0.32	1.89e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg00784671	chr22:46762841	CELSR1	-0.61	-6.15	-0.36	3.14e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12949688	1.000	rs886926	chr17:55817413	A/G	cg12582317	chr17:55822272	NA	-0.61	-10.07	-0.54	3.45e-20	Schizophrenia;
KIRP	trans	rs7404843	0.778	rs72774864	chr16:15512322	A/G	cg02716450	chr16:28638775	NA	1.02	10.22	0.55	1.16e-20	Testicular germ cell tumor;
KIRP	trans	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg19274270	chr17:78178856	CARD14	-0.35	-6.34	-0.37	1.07e-9	Morning vs. evening chronotype;
KIRP	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg21775007	chr8:11205619	TDH	0.48	6.51	0.38	4.21e-10	Mood instability;
KIRP	cis	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.55	-0.39	3.38e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg11584989	chr19:19387371	SF4	-0.4	-5.06	-0.31	8.31e-7	Tonsillectomy;
KIRP	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.48	6.02	0.36	6.29e-9	Glycated hemoglobin levels;
KIRP	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg06307176	chr5:131281290	NA	0.55	5.97	0.36	8.16e-9	Life satisfaction;
KIRP	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.92	-0.35	1.06e-8	Morning vs. evening chronotype;
KIRP	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.41	-0.33	1.47e-7	Aortic root size;
KIRP	cis	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg07460842	chr6:66804631	NA	-0.57	-7.34	-0.42	3.12e-12	Blood trace element (Cu levels);
KIRP	cis	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg00852783	chr1:26633632	UBXN11	0.56	5.69	0.34	3.59e-8	Obesity-related traits;
KIRP	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06481639	chr22:41940642	POLR3H	-0.58	-6.8	-0.4	7.74e-11	Vitiligo;
KIRP	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg15976283	chr2:238042351	NA	0.39	5.39	0.32	1.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.41	-0.33	1.47e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.66	-4.89	-0.3	1.82e-6	Coronary artery disease;
KIRP	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg26384229	chr12:38710491	ALG10B	0.66	8.84	0.49	1.91e-16	Morning vs. evening chronotype;
KIRP	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.32	-0.32	2.39e-7	Coronary artery disease;
KIRP	cis	rs367943	0.698	rs2115208	chr5:112973994	A/G	cg12552261	chr5:112820674	MCC	0.45	5.0	0.3	1.08e-6	Type 2 diabetes;
KIRP	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15424120	chr19:58663300	ZNF329	0.46	6.14	0.36	3.33e-9	Interleukin-4 levels;
KIRP	cis	rs6669119	0.668	rs75088145	chr1:19092368	G/A	cg19637330	chr1:19110922	NA	0.62	5.4	0.33	1.55e-7	Percentage gas trapping;
KIRP	cis	rs4654899	0.865	rs6426658	chr1:21361176	G/A	cg05370193	chr1:21551575	ECE1	0.46	6.1	0.36	4.14e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg27205649	chr11:78285834	NARS2	-0.66	-7.57	-0.43	7.66e-13	Alzheimer's disease (survival time);
KIRP	cis	rs3829109	0.564	rs10781511	chr9:139280766	G/A	cg14169450	chr9:139327907	INPP5E	0.47	5.7	0.34	3.44e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg10932868	chr11:921992	NA	0.63	8.36	0.47	4.72e-15	Alzheimer's disease (late onset);
KIRP	trans	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg06521331	chr12:34319734	NA	-0.51	-6.16	-0.37	2.87e-9	Bladder cancer;
KIRP	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg23690444	chr14:81902736	NA	0.69	7.5	0.43	1.15e-12	Prudent dietary pattern;
KIRP	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.8	11.04	0.58	2.76e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1010254	0.510	rs17544525	chr5:151756719	A/C	cg12297329	chr5:152029980	NA	-0.7	-6.94	-0.4	3.4e-11	Optic nerve measurement (cup area);
KIRP	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.51	0.62	3.97e-28	Platelet count;
KIRP	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg04731861	chr2:219085781	ARPC2	0.26	6.66	0.39	1.82e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs10267417	0.603	rs10273885	chr7:19911992	T/C	cg05791153	chr7:19748676	TWISTNB	0.49	4.97	0.3	1.24e-6	Night sleep phenotypes;
KIRP	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg18350739	chr11:68623251	NA	-0.53	-8.22	-0.46	1.16e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.74	-8.93	-0.49	1.02e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg19592336	chr6:28129416	ZNF389	-0.47	-5.43	-0.33	1.36e-7	Depression;
KIRP	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg09699651	chr6:150184138	LRP11	0.52	6.82	0.4	7.21e-11	Lung cancer;
KIRP	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.81	11.4	0.59	1.89e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.97	16.01	0.71	5e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.93	-15.53	-0.7	2.32e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.42	-0.51	3.46e-18	Bipolar disorder and schizophrenia;
KIRP	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg23335576	chr14:104009727	NA	0.36	5.17	0.31	4.83e-7	Body mass index;
KIRP	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg00343986	chr7:65444356	GUSB	-0.45	-5.39	-0.32	1.68e-7	Aortic root size;
KIRP	cis	rs10883969	0.504	rs805701	chr10:105819956	G/A	cg13448625	chr10:105845238	COL17A1	-0.48	-5.91	-0.35	1.12e-8	Preeclampsia;
KIRP	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.91	0.3	1.65e-6	Childhood ear infection;
KIRP	cis	rs7760535	1.000	rs7760535	chr6:111747083	C/G	cg15721981	chr6:111408429	SLC16A10	0.4	4.84	0.3	2.27e-6	Metabolic traits;
KIRP	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05025164	chr4:1340916	KIAA1530	0.4	4.99	0.3	1.14e-6	Obesity-related traits;
KIRP	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.59	-7.14	-0.41	1.03e-11	Mosquito bite size;
KIRP	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.51	7.77	0.44	2.19e-13	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9972944	0.756	rs8077164	chr17:63764645	C/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.81	-0.45	1.65e-13	Total body bone mineral density;
KIRP	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.94	0.35	9.72e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.37	0.47	4.38e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.9	-12.15	-0.61	6.58e-27	Cognitive function;
KIRP	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg19077165	chr18:44547161	KATNAL2	0.46	5.8	0.35	2.06e-8	Personality dimensions;
KIRP	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg10018233	chr7:150070692	REPIN1	0.69	8.32	0.47	6.02e-15	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg03929089	chr4:120376271	NA	-0.56	-6.53	-0.38	3.69e-10	HDL cholesterol;
KIRP	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.34	0.42	3.09e-12	Rheumatoid arthritis;
KIRP	cis	rs7640424	0.649	rs1369555	chr3:107901184	A/G	cg09227934	chr3:107805635	CD47	0.36	6.01	0.36	6.48e-9	Body mass index;
KIRP	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg22508957	chr16:3507546	NAT15	0.58	7.13	0.41	1.13e-11	Tuberculosis;
KIRP	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.41	5.15	0.31	5.38e-7	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg05861140	chr6:150128134	PCMT1	-0.45	-6.29	-0.37	1.45e-9	Lung cancer;
KIRP	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.92	12.83	0.63	3.39e-29	Personality dimensions;
KIRP	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.75	7.57	0.43	7.5e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.6	-6.55	-0.39	3.24e-10	Colorectal adenoma (advanced);
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg11814155	chr7:99998594	ZCWPW1	0.54	5.39	0.33	1.61e-7	Platelet count;
KIRP	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.67	7.62	0.44	5.62e-13	Body mass index;
KIRP	cis	rs7945718	0.805	rs11022510	chr11:12833262	G/A	cg25843174	chr11:12811716	TEAD1	0.36	6.97	0.41	2.84e-11	Educational attainment (years of education);
KIRP	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg00405596	chr8:11794950	NA	-0.42	-5.13	-0.31	5.97e-7	Systolic blood pressure;
KIRP	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6539288	0.674	rs989560	chr12:107285751	T/C	cg15890332	chr12:107067104	RFX4	0.3	5.17	0.31	4.81e-7	Total body bone mineral density;
KIRP	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg12091567	chr17:66097778	LOC651250	0.78	9.35	0.51	5.78e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg26831259	chr4:1366826	KIAA1530	-0.38	-5.23	-0.32	3.7e-7	Obesity-related traits;
KIRP	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg11641102	chr8:27183873	PTK2B	0.38	4.9	0.3	1.76e-6	Neuroticism;
KIRP	cis	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg20368463	chr18:77673604	PQLC1	-0.46	-5.78	-0.35	2.26e-8	Schizophrenia;
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg23594656	chr7:65796392	TPST1	0.39	5.74	0.34	2.72e-8	Aortic root size;
KIRP	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.63	8.96	0.5	8.55e-17	Schizophrenia;
KIRP	cis	rs830233	0.779	rs62383301	chr5:165438680	T/C	cg13976338	chr5:165423657	NA	-0.72	-7.38	-0.43	2.39e-12	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.46	-5.45	-0.33	1.23e-7	Response to antidepressants in depression;
KIRP	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.81	-0.35	1.96e-8	Endometrial cancer;
KIRP	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg22089800	chr15:90895588	ZNF774	0.6	8.09	0.46	2.67e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg22903471	chr2:27725779	GCKR	0.39	5.48	0.33	1.03e-7	Oral cavity cancer;
KIRP	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg06636001	chr8:8085503	FLJ10661	0.69	8.77	0.49	3.05e-16	Neuroticism;
KIRP	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg02951883	chr7:2050386	MAD1L1	-0.52	-5.81	-0.35	1.88e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.61	5.49	0.33	1.02e-7	Major depressive disorder;
KIRP	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.46	-0.33	1.14e-7	Personality dimensions;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.62	8.37	0.47	4.29e-15	Menarche (age at onset);
KIRP	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg27205649	chr11:78285834	NARS2	0.66	8.7	0.48	4.94e-16	Alzheimer's disease (survival time);
KIRP	cis	rs9462846	0.841	rs66541797	chr6:42825942	C/T	cg05552183	chr6:42928497	GNMT	0.46	5.41	0.33	1.51e-7	Blood protein levels;
KIRP	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg16141378	chr3:129829833	LOC729375	0.53	7.07	0.41	1.64e-11	Retinal vascular caliber;
KIRP	cis	rs78579285	0.544	rs11549835	chr16:88781073	G/A	cg09054528	chr16:88821542	FAM38A	-0.59	-5.07	-0.31	7.68e-7	Joint mobility (Beighton score);
KIRP	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs17221829	0.703	rs75183199	chr11:89356987	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.99	-0.3	1.14e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg06212747	chr3:49208901	KLHDC8B	0.69	8.17	0.46	1.59e-14	Menarche (age at onset);
KIRP	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg24060327	chr5:131705240	SLC22A5	-0.48	-6.23	-0.37	1.97e-9	Blood metabolite levels;
KIRP	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.66	6.27	0.37	1.58e-9	Neutrophil percentage of white cells;
KIRP	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.42e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.48	-0.43	1.34e-12	Electroencephalogram traits;
KIRP	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.13	0.41	1.12e-11	Lung cancer;
KIRP	cis	rs2033732	0.706	rs4268126	chr8:85065958	T/G	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.97	-13.0	-0.64	9.03e-30	Menopause (age at onset);
KIRP	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10982256	1.000	rs10982256	chr9:117260834	A/G	cg13636371	chr9:117264095	DFNB31	-0.6	-8.18	-0.46	1.54e-14	Bipolar disorder;
KIRP	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.47	6.48	0.38	5.04e-10	Methadone dose in opioid dependence;
KIRP	cis	rs859767	0.540	rs13424016	chr2:135406395	A/G	cg12500956	chr2:135428796	TMEM163	-0.46	-6.05	-0.36	5.24e-9	Neuroticism;
KIRP	cis	rs6725041	0.547	rs17419211	chr2:213207921	C/T	cg16329650	chr2:213403929	ERBB4	-0.39	-4.93	-0.3	1.5e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg16691251	chr5:66510806	NA	0.43	5.64	0.34	4.64e-8	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19236395	chr7:44122272	POLM	0.56	7.21	0.42	6.8e-12	Parkinson's disease;
KIRP	cis	rs838147	0.537	rs485073	chr19:49207255	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.45	-5.8	-0.35	1.99e-8	Dietary macronutrient intake;
KIRP	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg17691542	chr6:26056736	HIST1H1C	0.5	6.48	0.38	5.06e-10	Height;
KIRP	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.61e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg00677455	chr12:58241039	CTDSP2	0.98	12.83	0.63	3.33e-29	Multiple sclerosis;
KIRP	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.72	-5.98	-0.36	7.97e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	trans	rs7819412	0.593	rs11778398	chr8:10974243	C/T	cg16141378	chr3:129829833	LOC729375	0.56	7.24	0.42	5.68e-12	Triglycerides;
KIRP	cis	rs17065868	0.803	rs11618063	chr13:45195442	T/G	cg10246903	chr13:45222710	NA	0.55	5.89	0.35	1.25e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1978968	0.731	rs9617648	chr22:18460059	G/T	cg03078520	chr22:18463400	MICAL3	-0.85	-12.25	-0.62	3.04e-27	Presence of antiphospholipid antibodies;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09251891	chr19:11374363	DOCK6	0.46	6.16	0.37	2.95e-9	Interleukin-4 levels;
KIRP	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.7	10.86	0.57	1.04e-22	Resting heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26837479	chr8:146228149	ZNF252;C8orf77	0.48	6.17	0.37	2.83e-9	Parkinson's disease;
KIRP	cis	rs965513	0.932	rs10818050	chr9:100538923	A/G	cg13688889	chr9:100608707	NA	-0.59	-7.68	-0.44	3.84e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.68	-6.82	-0.4	7.22e-11	Hair shape;
KIRP	cis	rs6910061	1.000	rs6910061	chr6:11101918	A/T	cg27233058	chr6:11094804	LOC221710	-0.56	-5.55	-0.33	7.44e-8	Diabetic kidney disease;
KIRP	cis	rs684232	0.568	rs2644714	chr17:633188	G/A	cg15660573	chr17:549704	VPS53	-0.83	-11.54	-0.59	6.35e-25	Prostate cancer;
KIRP	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg24009623	chr19:33667908	NA	0.48	5.82	0.35	1.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7096127	1.000	rs4747481	chr10:24502392	A/C	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.93	0.3	1.55e-6	Lobe attachment (rater scored);
KIRP	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-6.83	-0.4	6.73e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.51	6.97	0.41	2.97e-11	Coronary artery disease;
KIRP	cis	rs4132509	0.793	rs10927046	chr1:243801190	T/C	cg25706552	chr1:244017396	NA	0.62	6.67	0.39	1.69e-10	RR interval (heart rate);
KIRP	cis	rs9810890	1.000	rs73196978	chr3:128450228	C/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg07596299	chr11:71824057	C11orf51	-0.91	-6.11	-0.36	3.79e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg18441811	chr11:71824068	C11orf51	-0.77	-5.12	-0.31	6.29e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2224391	0.628	rs2753236	chr6:5252214	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.5	-0.38	4.34e-10	Height;
KIRP	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.43	-5.02	-0.3	9.95e-7	Crohn's disease;
KIRP	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.47	-0.38	5.12e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6832769	0.961	rs10026692	chr4:56452706	C/T	cg09317128	chr4:56265301	TMEM165	-0.51	-6.75	-0.4	1.07e-10	Personality dimensions;
KIRP	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.72	-7.93	-0.45	7.49e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg03808351	chr9:123631620	PHF19	0.44	6.13	0.36	3.41e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg18085866	chr17:45331354	ITGB3	-0.74	-6.28	-0.37	1.51e-9	Body mass index;
KIRP	cis	rs7937612	0.965	rs11217840	chr11:120238655	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.07	-0.41	1.61e-11	Intraocular pressure;
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg14324370	chr2:177042789	NA	0.74	9.6	0.52	9.36e-19	IgG glycosylation;
KIRP	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26002218	chr14:103986227	CKB	0.29	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.87	12.13	0.61	7.37e-27	Bone mineral density;
KIRP	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.18	0.42	8.38e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2016266	0.752	rs10783562	chr12:53657467	G/A	cg16917193	chr12:54089295	NA	0.4	4.92	0.3	1.56e-6	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.97	-16.65	-0.73	3.26e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.55	-7.36	-0.42	2.75e-12	Vitiligo;
KIRP	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg23024343	chr7:107201750	COG5	0.45	4.94	0.3	1.45e-6	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18876405	chr7:65276391	NA	-0.42	-5.37	-0.32	1.85e-7	Aortic root size;
KIRP	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.98	10.29	0.55	7.12e-21	Alzheimer's disease;
KIRP	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.91	-14.38	-0.68	1.96e-34	Height;
KIRP	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.3	-0.42	3.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg05562828	chr17:3906858	NA	-0.56	-8.88	-0.49	1.43e-16	Type 2 diabetes;
KIRP	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.58	7.99	0.45	5.14e-14	Height;
KIRP	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg05768032	chr16:30646687	NA	0.41	5.01	0.3	1.06e-6	Dementia with Lewy bodies;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15809806	chr10:33518295	NRP1	0.46	6.32	0.37	1.19e-9	Interleukin-4 levels;
KIRP	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-6.97	-0.41	2.86e-11	Height;
KIRP	cis	rs732765	0.734	rs12892937	chr14:75168927	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.4	-4.95	-0.3	1.4e-6	Non-small cell lung cancer;
KIRP	cis	rs7395662	0.606	rs11512384	chr11:48838187	A/G	cg21546286	chr11:48923668	NA	-0.43	-5.47	-0.33	1.12e-7	HDL cholesterol;
KIRP	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg01420254	chr6:26195488	NA	1.16	10.2	0.55	1.31e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.59	9.8	0.53	2.42e-19	Schizophrenia;
KIRP	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.47	-0.38	5.27e-10	Joint mobility (Beighton score);
KIRP	cis	rs10940138	0.501	rs6878860	chr5:67244515	A/G	ch.5.1281357F	chr5:67228439	NA	-0.48	-6.84	-0.4	6.27e-11	Menarche (age at onset);
KIRP	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg24315340	chr6:146058215	EPM2A	-0.4	-5.13	-0.31	5.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg00504896	chr12:9437009	LOC642846	-0.51	-6.33	-0.37	1.18e-9	Breast size;
KIRP	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-8.44	-0.47	2.75e-15	Response to antipsychotic treatment;
KIRP	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.27e-12	Prudent dietary pattern;
KIRP	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.65	-9.08	-0.5	3.6e-17	Mean platelet volume;
KIRP	cis	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg08501292	chr6:25962987	TRIM38	0.92	6.53	0.38	3.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs8179	0.645	rs11771637	chr7:92260161	G/A	cg15732164	chr7:92237376	CDK6	-0.48	-6.19	-0.37	2.49e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg23100626	chr2:96804247	ASTL	0.44	5.61	0.34	5.41e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.65	10.55	0.56	1.03e-21	Coronary artery disease;
KIRP	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg06521331	chr12:34319734	NA	-0.64	-7.66	-0.44	4.3e-13	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08756266	chr6:88106569	C6orf164	0.43	6.03	0.36	5.92e-9	Interleukin-4 levels;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-1.01	-11.86	-0.6	5.86e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12549025	0.516	rs13257250	chr8:23342959	G/A	cg08322043	chr8:23340750	NA	-0.53	-5.72	-0.34	3.07e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.78	-11.65	-0.6	2.85e-25	Total body bone mineral density;
KIRP	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg17644776	chr2:200775616	C2orf69	0.57	6.09	0.36	4.36e-9	Schizophrenia;
KIRP	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.63	-7.93	-0.45	7.58e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.28	-0.42	4.48e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	cis	rs6594713	0.642	rs6871934	chr5:112787828	T/C	cg12552261	chr5:112820674	MCC	0.61	5.42	0.33	1.45e-7	Brain cytoarchitecture;
KIRP	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.02	-12.94	-0.64	1.52e-29	Alzheimer's disease;
KIRP	cis	rs66569888	0.583	rs66529457	chr2:106727010	G/A	cg16099169	chr2:106886729	NA	-0.41	-5.33	-0.32	2.27e-7	Facial morphology (factor 23);
KIRP	cis	rs12580194	0.957	rs73118932	chr12:55706631	C/T	cg11794356	chr12:55725991	OR6C3	-0.44	-4.95	-0.3	1.37e-6	Cancer;
KIRP	cis	rs2371030	1.000	rs2193618	chr2:211573464	A/G	cg18417063	chr2:211583084	NA	-0.48	-7.08	-0.41	1.46e-11	Non-small cell lung cancer;
KIRP	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.51	-6.59	-0.39	2.68e-10	Body mass index;
KIRP	cis	rs4262150	0.617	rs4130911	chr5:152251661	A/G	cg12297329	chr5:152029980	NA	0.47	6.6	0.39	2.48e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.75	-11.0	-0.57	3.69e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4356975	0.563	rs12506962	chr4:69966024	G/A	cg27372994	chr4:70080453	UGT2B11	0.37	4.96	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.66	9.82	0.53	2.02e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg00800038	chr16:89945340	TCF25	-0.76	-5.28	-0.32	2.78e-7	Skin colour saturation;
KIRP	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-7.61	-0.44	5.71e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs35740288	0.770	rs11632750	chr15:86215614	A/C	cg10818794	chr15:86012489	AKAP13	-0.46	-5.56	-0.33	6.85e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10861342	1.000	rs11112359	chr12:105471661	C/A	cg23923672	chr12:105501055	KIAA1033	0.78	5.83	0.35	1.7e-8	IgG glycosylation;
KIRP	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.76	6.8	0.4	7.95e-11	Plateletcrit;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12183978	chr5:102203071	PAM	-0.43	-6.33	-0.37	1.18e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.62	-0.34	5.29e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.47	6.07	0.36	4.87e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25672142	chr3:100211485	TMEM45A	0.46	6.4	0.38	8e-10	Parkinson's disease;
KIRP	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.77	10.27	0.55	8.1e-21	Mosquito bite size;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14542196	chr14:102227915	PPP2R5C	-0.57	-6.21	-0.37	2.29e-9	Menopause (age at onset);
KIRP	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.58	-7.22	-0.42	6.46e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.05	-0.31	8.8e-7	Inflammatory skin disease;
KIRP	cis	rs62355272	0.563	rs59030624	chr5:35910951	C/G	cg13894535	chr5:35919491	CAPSL	-0.36	-4.84	-0.3	2.26e-6	Lymphocyte counts;
KIRP	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.46	5.91	0.35	1.15e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.21	14.22	0.67	6.91e-34	Corneal structure;
KIRP	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg24858140	chr15:80189322	MTHFS	-0.55	-6.03	-0.36	6.03e-9	Menopause (age at onset);
KIRP	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.96	11.29	0.58	4.45e-24	Corneal astigmatism;
KIRP	cis	rs6959887	0.609	rs4720169	chr7:35287301	G/A	cg06685737	chr7:35301730	NA	0.59	9.58	0.52	1.13e-18	Birth weight;
KIRP	cis	rs1978968	0.717	rs13057517	chr22:18402669	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.48	-5.9	-0.35	1.22e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.54	5.53	0.33	8.27e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.8	12.92	0.64	1.76e-29	Vitiligo;
KIRP	cis	rs8141529	0.600	rs739196	chr22:29311271	G/A	cg02153584	chr22:29168773	CCDC117	0.62	6.1	0.36	4e-9	Lymphocyte counts;
KIRP	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg02574844	chr11:5959923	NA	0.48	4.88	0.3	1.92e-6	DNA methylation (variation);
KIRP	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.34	-0.47	5.3e-15	Coronary artery disease;
KIRP	cis	rs62413470	1.000	rs12209192	chr6:55967702	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg06917634	chr15:78832804	PSMA4	-0.55	-5.78	-0.35	2.28e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	6e-19	Prudent dietary pattern;
KIRP	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.67	-8.04	-0.46	3.67e-14	Iron status biomarkers;
KIRP	cis	rs12906542	0.580	rs4509986	chr15:78267385	A/T	cg23683012	chr15:78369302	TBC1D2B	-0.36	-4.94	-0.3	1.44e-6	Breast cancer;
KIRP	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg00129232	chr17:37814104	STARD3	0.52	6.57	0.39	2.94e-10	Self-reported allergy;
KIRP	cis	rs5753037	0.809	rs5763512	chr22:30212366	C/T	cg27665648	chr22:30112403	NA	0.44	6.12	0.36	3.69e-9	Type 1 diabetes;
KIRP	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.31	-0.32	2.41e-7	Ovarian reserve;
KIRP	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg20917491	chr3:195578259	NA	0.43	5.91	0.35	1.14e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs9302690	0.557	rs223875	chr16:57506915	C/T	cg27017172	chr16:57497170	POLR2C	0.63	6.68	0.39	1.55e-10	Blood protein levels;
KIRP	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg03929089	chr4:120376271	NA	0.73	6.49	0.38	4.62e-10	Axial length;
KIRP	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.67	9.91	0.53	1.09e-19	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg08975724	chr8:8085496	FLJ10661	0.54	6.74	0.39	1.14e-10	Neuroticism;
KIRP	cis	rs17092148	0.945	rs6058115	chr20:33358397	T/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02875558	chr17:37309177	PLXDC1	-0.48	-6.32	-0.37	1.23e-9	Select biomarker traits;
KIRP	cis	rs7106204	0.609	rs35037636	chr11:24299533	C/G	ch.11.24196551F	chr11:24239977	NA	0.71	5.26	0.32	3.16e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg07661805	chr8:143867942	LY6D	-0.29	-5.08	-0.31	7.4e-7	Urinary tract infection frequency;
KIRP	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg04865290	chr3:52927548	TMEM110	-0.62	-6.92	-0.4	3.85e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.75	-9.25	-0.51	1.13e-17	Mammographic density (dense area);
KIRP	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2729354	0.729	rs2848634	chr11:57252328	G/A	cg24343310	chr11:57249947	NA	0.28	5.38	0.32	1.69e-7	Blood protein levels;
KIRP	cis	rs9937943	0.667	rs12934000	chr16:74623420	T/G	cg01733217	chr16:74700730	RFWD3	0.65	6.08	0.36	4.68e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.87	14.08	0.67	2e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-7.09	-0.41	1.44e-11	Vitiligo;
KIRP	cis	rs918629	0.798	rs7724599	chr5:95323378	T/C	cg16656078	chr5:95278638	ELL2	-0.47	-6.86	-0.4	5.39e-11	IgG glycosylation;
KIRP	cis	rs2562456	0.833	rs62109225	chr19:21536663	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs11225247	0.892	rs12277747	chr11:102281614	C/T	cg06323957	chr11:102217781	BIRC2	-0.84	-5.96	-0.36	8.51e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.23	-0.46	1.13e-14	Bone mineral density;
KIRP	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.93	10.91	0.57	7.49e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-13.58	-0.65	1.01e-31	Ulcerative colitis;
KIRP	cis	rs4650994	0.593	rs12096732	chr1:178523164	C/T	cg12486710	chr1:178512616	C1orf220	-0.23	-4.93	-0.3	1.49e-6	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg15507776	chr3:136538369	TMEM22	0.38	5.27	0.32	2.96e-7	Neuroticism;
KIRP	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg08885076	chr2:99613938	TSGA10	-0.37	-5.27	-0.32	3e-7	Fear of minor pain;
KIRP	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.35	0.47	4.94e-15	Motion sickness;
KIRP	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg20578329	chr17:80767326	TBCD	-0.47	-6.2	-0.37	2.42e-9	Breast cancer;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg03188948	chr7:1209495	NA	0.69	6.45	0.38	5.84e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg01620082	chr3:125678407	NA	-0.96	-6.16	-0.37	2.96e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg21639236	chr22:46664151	TTC38	-0.45	-6.23	-0.37	2.01e-9	Metabolite levels (MHPG);
KIRP	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-9.71	-0.53	4.49e-19	Total body bone mineral density;
KIRP	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.52e-13	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14524775	chr1:155920832	ARHGEF2	-0.5	-6.58	-0.39	2.8e-10	Parkinson's disease;
KIRP	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.51	5.89	0.35	1.23e-8	Mean platelet volume;
KIRP	cis	rs5167	0.645	rs1130742	chr19:45452812	C/T	cg13119609	chr19:45449297	APOC2	0.45	5.53	0.33	8.35e-8	Blood protein levels;
KIRP	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.59	-0.39	2.69e-10	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12317783	chr3:178789784	ZMAT3	0.58	7.21	0.42	6.78e-12	Parkinson's disease;
KIRP	cis	rs6088813	0.961	rs6060369	chr20:33907161	A/G	cg14752227	chr20:34000481	UQCC	0.46	5.81	0.35	1.88e-8	Height;
KIRP	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9531006	0.752	rs11840648	chr13:80555822	C/T	cg04645545	chr10:103534563	FGF8	-0.3	-6.08	-0.36	4.65e-9	Sleep duration;
KIRP	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.79	-9.71	-0.53	4.38e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1950626	0.827	rs35829821	chr14:101409763	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.83	0.4	6.72e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4356975	0.583	rs6600877	chr4:69957223	G/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.67	0.52	6.01e-19	Prudent dietary pattern;
KIRP	cis	rs10073892	0.743	rs10035407	chr5:101669220	C/G	cg19774478	chr5:101632501	SLCO4C1	-0.65	-6.79	-0.4	8.24e-11	Cognitive decline (age-related);
KIRP	cis	rs12220238	0.543	rs11001095	chr10:76412766	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.65	5.17	0.31	4.85e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.58	-9.44	-0.52	3.08e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.64	0.48	7.16e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg16691251	chr5:66510806	NA	-0.58	-7.62	-0.44	5.45e-13	Breast cancer;
KIRP	cis	rs1629083	0.875	rs4938490	chr11:118080977	G/A	cg18857871	chr11:118064634	AMICA1	0.64	8.52	0.48	1.57e-15	Lung cancer;
KIRP	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.01	17.48	0.74	4.9e-45	Schizophrenia;
KIRP	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg11569703	chr11:65557185	OVOL1	0.78	15.19	0.7	3.41e-37	Acne (severe);
KIRP	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg15247329	chr7:2764246	NA	-0.42	-6.03	-0.36	6.02e-9	Height;
KIRP	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	14.27	0.67	4.56e-34	Subjective well-being;
KIRP	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.6	-5.35	-0.32	2e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-0.76	-6.66	-0.39	1.81e-10	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg10755058	chr3:40428713	ENTPD3	0.49	6.67	0.39	1.63e-10	Renal cell carcinoma;
KIRP	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.48	6.36	0.38	9.5e-10	Cardiovascular disease risk factors;
KIRP	cis	rs12693043	0.601	rs9287977	chr2:175422852	T/A	cg11778734	chr2:175439522	WIPF1	0.43	5.09	0.31	7.11e-7	Urate levels (BMI interaction);
KIRP	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-9.04	-0.5	4.66e-17	Total cholesterol levels;
KIRP	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg08822215	chr16:89438651	ANKRD11	-0.5	-6.46	-0.38	5.67e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs11877825	0.865	rs34956381	chr18:10571021	G/A	cg07277756	chr18:10589357	NA	0.49	5.96	0.35	8.91e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.93	15.27	0.7	1.81e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7546668	1.000	rs4233534	chr1:15842329	C/T	cg21858823	chr1:15850916	CASP9	0.47	5.19	0.31	4.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.41	0.33	1.53e-7	Educational attainment;
KIRP	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.85	-12.83	-0.63	3.3e-29	Height;
KIRP	trans	rs9865818	0.647	rs13079741	chr3:188101861	C/G	cg09132250	chr2:131148721	NA	-0.33	-6.06	-0.36	5.08e-9	Allergic sensitization;
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.49	-0.33	9.91e-8	Aortic root size;
KIRP	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg17724175	chr1:150552817	MCL1	0.35	5.54	0.33	7.83e-8	Melanoma;
KIRP	cis	rs60311166	1.000	rs4532127	chr3:52727736	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.96	6.76	0.4	9.98e-11	CTACK levels;
KIRP	cis	rs6496044	0.568	rs3743321	chr15:86064968	A/G	cg17133734	chr15:86042851	AKAP13	-0.48	-6.02	-0.36	6.32e-9	Interstitial lung disease;
KIRP	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.18	-0.54	1.58e-20	Response to antipsychotic treatment;
KIRP	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-8.68	-0.48	5.44e-16	Morning vs. evening chronotype;
KIRP	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg10223061	chr2:219282414	VIL1	-0.34	-5.56	-0.33	7.03e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs57590327	0.679	rs35395999	chr3:81613013	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-6.1	-0.36	4e-9	Extraversion;
KIRP	cis	rs228437	0.802	rs228447	chr6:134902903	C/T	cg24504307	chr6:134963096	NA	-0.42	-6.02	-0.36	6.15e-9	Melanoma;
KIRP	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.39	-0.33	1.63e-7	HDL cholesterol;
KIRP	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.81	-10.03	-0.54	4.61e-20	Blood protein levels;
KIRP	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.79	-0.35	2.17e-8	Body mass index;
KIRP	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg25486957	chr4:152246857	NA	-0.46	-5.51	-0.33	9.2e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-1.09	-7.74	-0.44	2.51e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.79	-9.28	-0.51	8.86e-18	Gut microbiome composition (summer);
KIRP	cis	rs7809950	0.954	rs11977187	chr7:107210383	C/T	cg23024343	chr7:107201750	COG5	0.47	6.73	0.39	1.2e-10	Coronary artery disease;
KIRP	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.25	-0.32	3.3e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg12560992	chr17:57184187	TRIM37	0.48	5.73	0.34	2.91e-8	Cognitive test performance;
KIRP	cis	rs11997175	0.524	rs12164218	chr8:33669658	G/C	ch.8.33884649F	chr8:33765107	NA	0.55	6.15	0.37	3.12e-9	Body mass index;
KIRP	trans	rs1106684	1.000	rs11763164	chr7:131461953	C/T	cg13607082	chr12:122652224	LRRC43	-0.66	-6.72	-0.39	1.25e-10	Body mass index;
KIRP	trans	rs804280	0.535	rs10435719	chr8:11776904	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.31	0.37	1.31e-9	Myopia (pathological);
KIRP	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18876405	chr7:65276391	NA	0.41	5.0	0.3	1.09e-6	Aortic root size;
KIRP	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.3	-0.42	3.86e-12	Joint mobility (Beighton score);
KIRP	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg25486957	chr4:152246857	NA	-0.52	-5.69	-0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg02976359	chr3:347869	CHL1	-0.31	-6.02	-0.36	6.36e-9	Suicide attempts in major depressive disorder;
KIRP	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg22437258	chr11:111473054	SIK2	-0.59	-6.81	-0.4	7.53e-11	Primary sclerosing cholangitis;
KIRP	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg11189052	chr15:85197271	WDR73	0.49	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg00310523	chr12:86230176	RASSF9	0.4	6.13	0.36	3.55e-9	Major depressive disorder;
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22168489	chr12:122356033	WDR66	0.69	10.88	0.57	9.47e-23	Mean platelet volume;
KIRP	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.23	0.46	1.1e-14	Personality dimensions;
KIRP	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg05998816	chr21:47859926	PCNT	-0.53	-6.04	-0.36	5.8e-9	Lymphocyte counts;
KIRP	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.43	5.91	0.35	1.12e-8	Sitting height ratio;
KIRP	cis	rs3134353	0.713	rs71506350	chr8:101962901	A/G	cg07585502	chr8:101912084	NA	-0.4	-4.91	-0.3	1.63e-6	Body mass index;
KIRP	trans	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg00405596	chr8:11794950	NA	0.49	6.67	0.39	1.64e-10	Joint mobility (Beighton score);
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg01988459	chr11:68622903	NA	-0.43	-5.83	-0.35	1.75e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	9.16	0.5	2.14e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	1.05	7.48	0.43	1.32e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg13606994	chr1:44402422	ARTN	-0.28	-5.55	-0.33	7.21e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg08807101	chr21:30365312	RNF160	-0.55	-5.35	-0.32	2.05e-7	Cognitive test performance;
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg04369109	chr6:150039330	LATS1	-0.58	-7.43	-0.43	1.77e-12	Lung cancer;
KIRP	cis	rs4740619	0.619	rs1887667	chr9:16033109	T/G	cg14451791	chr9:16040625	NA	-0.42	-5.56	-0.33	6.91e-8	Body mass index;
KIRP	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg23173402	chr1:227635558	NA	0.67	5.44	0.33	1.27e-7	Major depressive disorder;
KIRP	cis	rs6691722	0.506	rs12030365	chr1:24739220	T/A	cg18323236	chr1:24743029	NIPAL3	0.55	8.23	0.46	1.13e-14	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.25	6.58	0.39	2.81e-10	Crohn's disease;
KIRP	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.45	5.8	0.35	2.06e-8	Renal cell carcinoma;
KIRP	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.68	10.12	0.54	2.33e-20	Dupuytren's disease;
KIRP	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg03929089	chr4:120376271	NA	-0.68	-6.82	-0.4	6.84e-11	Axial length;
KIRP	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.71	10.51	0.56	1.36e-21	Eosinophilic esophagitis;
KIRP	cis	rs9616064	0.520	rs875559	chr22:47034838	T/C	cg25730555	chr22:47059586	GRAMD4	0.51	6.02	0.36	6.15e-9	Urate levels in obese individuals;
KIRP	cis	rs9815354	0.761	rs73083326	chr3:41927150	G/T	cg03022575	chr3:42003672	ULK4	0.77	7.99	0.45	5.18e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7894407	0.760	rs1163072	chr10:105024378	C/T	cg05636881	chr10:105038444	INA	-0.41	-5.08	-0.31	7.59e-7	White matter hyperintensity burden;
KIRP	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.57	6.6	0.39	2.46e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg21252483	chr19:49399788	TULP2	-0.43	-8.19	-0.46	1.46e-14	Red cell distribution width;
KIRP	cis	rs2274273	0.600	rs10131730	chr14:55840092	C/T	cg04306507	chr14:55594613	LGALS3	0.38	5.3	0.32	2.54e-7	Protein biomarker;
KIRP	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg07843065	chr1:150265600	MRPS21	0.45	6.26	0.37	1.74e-9	Migraine;
KIRP	cis	rs12476592	0.602	rs7571325	chr2:63785914	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-6.18	-0.37	2.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg04369109	chr6:150039330	LATS1	-0.55	-6.96	-0.41	3.08e-11	Lung cancer;
KIRP	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.48	-0.52	2.32e-18	Response to antipsychotic treatment;
KIRP	cis	rs10189230	0.546	rs6727259	chr2:222358292	C/G	cg14652038	chr2:222343519	EPHA4	-0.39	-5.62	-0.34	5.06e-8	Urate levels in lean individuals;
KIRP	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.65	7.35	0.42	2.86e-12	Body mass index;
KIRP	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.62	8.07	0.46	3.18e-14	Systemic lupus erythematosus;
KIRP	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg22604316	chr1:46958801	NA	-0.34	-4.91	-0.3	1.67e-6	Monobrow;
KIRP	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.5	-6.13	-0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs427941	0.632	rs201502	chr7:101759561	C/T	cg06246474	chr7:101738831	CUX1	-0.55	-6.74	-0.39	1.1e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.64	8.13	0.46	2.12e-14	Prudent dietary pattern;
KIRP	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.67	-10.14	-0.54	2.1e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.45	-0.33	1.24e-7	Colorectal cancer;
KIRP	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg23163573	chr2:108905468	SULT1C2	-0.27	-4.89	-0.3	1.81e-6	Lobe size;
KIRP	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-8.07	-0.46	3.11e-14	Coffee consumption (cups per day);
KIRP	cis	rs7771547	0.642	rs629560	chr6:36511391	A/G	cg04289385	chr6:36355825	ETV7	0.45	6.86	0.4	5.59e-11	Platelet distribution width;
KIRP	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.28	0.37	1.53e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4774830	0.590	rs61732704	chr15:56243766	C/T	cg05129572	chr15:56138634	NEDD4	0.71	4.95	0.3	1.37e-6	Delta-5 desaturase activity;
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg01721255	chr8:58191610	C8orf71	0.62	5.33	0.32	2.2e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg04080417	chr5:1859792	NA	-0.56	-6.83	-0.4	6.46e-11	Cardiovascular disease risk factors;
KIRP	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg05362011	chr13:21860987	NA	-0.46	-4.93	-0.3	1.51e-6	White matter hyperintensity burden;
KIRP	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.76	-0.4	1e-10	Response to antipsychotic treatment;
KIRP	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.43	-0.52	3.3e-18	Coronary artery disease;
KIRP	cis	rs10924970	0.967	rs12027832	chr1:235385934	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.03	0.31	9.43e-7	Asthma;
KIRP	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.42	6.91	0.4	4.05e-11	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg17376030	chr22:41985996	PMM1	0.54	6.01	0.36	6.49e-9	Vitiligo;
KIRP	cis	rs11169552	0.510	rs10783383	chr12:51102869	A/G	cg12884762	chr12:50931848	DIP2B	-0.45	-5.37	-0.32	1.8e-7	Colorectal cancer;
KIRP	cis	rs77688320	0.535	rs34625194	chr2:202271538	A/C	cg06431681	chr2:202330990	STRADB	0.52	6.92	0.4	3.96e-11	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03239638	chr21:37529510	NA	0.47	6.44	0.38	6.31e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	0.88	7.39	0.43	2.3e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.6	0.56	7.41e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs6681460	0.576	rs1338200	chr1:66992197	C/A	cg13052034	chr1:66999238	SGIP1	0.43	5.66	0.34	4.13e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg09699651	chr6:150184138	LRP11	0.4	5.23	0.32	3.65e-7	Lung cancer;
KIRP	cis	rs559928	0.502	rs10897504	chr11:64190137	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.47	4.95	0.3	1.4e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.41	5.27	0.32	2.94e-7	High light scatter reticulocyte count;
KIRP	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.58	-7.79	-0.44	1.87e-13	Post bronchodilator FEV1;
KIRP	cis	rs12220238	0.722	rs10740440	chr10:76380366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.55	6.01	0.36	6.63e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg03465714	chr1:152285911	FLG	-0.41	-4.92	-0.3	1.57e-6	Atopic dermatitis;
KIRP	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.52	5.78	0.35	2.23e-8	Urinary metabolites;
KIRP	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.63	-7.92	-0.45	8.23e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7011049	0.778	rs73601272	chr8:53866659	T/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.29e-10	Systolic blood pressure;
KIRP	cis	rs73206853	0.764	rs73194012	chr12:111100627	T/C	cg12870014	chr12:110450643	ANKRD13A	0.51	4.97	0.3	1.23e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	0.8	6.4	0.38	7.98e-10	Psoriasis;
KIRP	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00700412	chr12:58011837	NA	0.37	6.69	0.39	1.46e-10	Multiple sclerosis;
KIRP	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg21204522	chr6:27730016	NA	-0.67	-5.31	-0.32	2.51e-7	Depression;
KIRP	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.37	5.75	0.34	2.61e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2574975	0.679	rs2255859	chr10:52131786	C/T	cg10034176	chr10:52120283	SGMS1	-0.53	-7.23	-0.42	5.95e-12	Response to amphetamines;
KIRP	cis	rs4148087	0.725	rs1378577	chr21:43619665	T/G	cg08841829	chr21:43638893	ABCG1	-0.44	-5.01	-0.3	1.05e-6	Eating disorder in bipolar disorder;
KIRP	cis	rs7941600	0.708	rs4537761	chr11:9323353	T/C	cg19415743	chr11:9336845	TMEM41B	0.7	6.4	0.38	7.64e-10	Coronary artery disease;
KIRP	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.66	-7.99	-0.45	5.24e-14	Iron status biomarkers;
KIRP	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg07274523	chr3:49395745	GPX1	0.72	8.71	0.49	4.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.92	14.05	0.67	2.64e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.58	8.44	0.47	2.69e-15	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.6	7.77	0.44	2.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.88	12.81	0.63	4.08e-29	Mean platelet volume;
KIRP	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-10.81	-0.57	1.55e-22	Total body bone mineral density;
KIRP	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg16797656	chr11:68205561	LRP5	-0.42	-5.94	-0.35	9.82e-9	Bone mineral density (spine);
KIRP	cis	rs12431939	1.000	rs67065973	chr14:51656225	T/C	cg23942311	chr14:51606299	NA	-0.6	-5.46	-0.33	1.18e-7	Cancer;
KIRP	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	11.38	0.59	2.19e-24	Platelet count;
KIRP	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.53	-6.43	-0.38	6.58e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg26354017	chr1:205819088	PM20D1	0.48	5.47	0.33	1.11e-7	Parkinson's disease;
KIRP	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg02153584	chr22:29168773	CCDC117	0.63	7.86	0.45	1.21e-13	Lymphocyte counts;
KIRP	cis	rs4650994	0.593	rs7540745	chr1:178529757	C/T	cg12486710	chr1:178512616	C1orf220	-0.23	-4.98	-0.3	1.21e-6	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.89	14.05	0.67	2.62e-33	Coronary artery disease;
KIRP	cis	rs2072732	0.904	rs2993481	chr1:2973433	A/T	cg11731671	chr1:2995604	PRDM16	-0.43	-5.41	-0.33	1.48e-7	Plateletcrit;
KIRP	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.14	-0.36	3.22e-9	Type 2 diabetes;
KIRP	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.78	8.68	0.48	5.59e-16	Pulmonary function decline;
KIRP	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.61	6.38	0.38	8.5e-10	Gastritis;
KIRP	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.91	15.75	0.71	3.95e-39	Headache;
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.69	11.73	0.6	1.54e-25	Cardiovascular disease risk factors;
KIRP	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg17133734	chr15:86042851	AKAP13	-0.47	-5.93	-0.35	1e-8	Coronary artery disease;
KIRP	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg07596299	chr11:71824057	C11orf51	-0.91	-6.11	-0.36	3.79e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs1417569	0.517	rs2934637	chr10:31193339	T/C	cg00428179	chr10:31322131	ZNF438	-0.37	-5.54	-0.33	7.83e-8	Tuberculosis;
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	4.91	0.3	1.64e-6	Longevity;
KIRP	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.86	-10.81	-0.57	1.55e-22	Dupuytren's disease;
KIRP	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg00241281	chr14:105779794	PACS2	-0.36	-4.98	-0.3	1.21e-6	Platelet count;
KIRP	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg17133734	chr15:86042851	AKAP13	-0.46	-5.88	-0.35	1.32e-8	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg04310649	chr10:35416472	CREM	-0.57	-6.51	-0.38	4.29e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12924262	chr12:102091054	CHPT1	0.5	6.57	0.39	2.96e-10	Blood protein levels;
KIRP	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg00495681	chr13:53174319	NA	0.42	5.88	0.35	1.34e-8	Lewy body disease;
KIRP	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.45	-0.38	5.78e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.56	-6.28	-0.37	1.53e-9	Menarche (age at onset);
KIRP	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.65	5.22	0.32	3.84e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs860295	0.812	rs6657670	chr1:155787867	C/T	cg02153340	chr1:155202674	NA	-0.41	-5.5	-0.33	9.54e-8	Body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg12188830	chr3:57741926	SLMAP	0.89	6.26	0.37	1.68e-9	P wave terminal force;
KIRP	cis	rs7560272	0.501	rs6755500	chr2:73942233	C/T	cg20560298	chr2:73613845	ALMS1	0.49	5.92	0.35	1.09e-8	Schizophrenia;
KIRP	trans	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.83	-0.4	6.5500000000000006e-11	Heart rate;
KIRP	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-10.4	-0.55	3.12e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.41	-0.47	3.34e-15	Colorectal cancer;
KIRP	cis	rs9567307	1	rs9567307	chr13:44471877	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	4.98	0.3	1.18e-6	Leprosy;
KIRP	cis	rs11078597	0.650	rs62090056	chr17:1645410	C/T	cg17514665	chr17:1657533	SERPINF2	0.46	5.69	0.34	3.64e-8	Serum albumin level;
KIRP	cis	rs78487399	0.808	rs13417883	chr2:43700154	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.98	-0.3	1.21e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg18241048	chr10:5855009	GDI2	0.51	6.35	0.38	1.05e-9	DNA methylation (variation);
KIRP	cis	rs1021993	0.545	rs60534728	chr1:209548171	G/A	cg24446417	chr1:209558027	NA	-0.51	-4.97	-0.3	1.24e-6	Gut microbiome composition (winter);
KIRP	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg07348845	chr1:227544540	NA	0.35	5.21	0.32	3.96e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.48	5.96	0.36	8.53e-9	Tonsillectomy;
KIRP	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.62	-7.97	-0.45	5.99e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.79	-0.35	2.11e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg07621104	chr11:117668040	DSCAML1	0.47	7.2	0.42	7.16e-12	Myopia;
KIRP	cis	rs4786125	0.636	rs11644404	chr16:6904030	C/A	cg03623568	chr16:6915990	A2BP1	-0.44	-5.39	-0.32	1.67e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.57	-6.46	-0.38	5.5e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.75	-8.12	-0.46	2.28e-14	Parkinson's disease;
KIRP	cis	rs4006360	0.505	rs9916287	chr17:39286884	T/G	cg25341923	chr17:39239918	KRTAP4-7	-0.6	-7.88	-0.45	1.06e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.5	-0.52	2.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.52	-9.54	-0.52	1.44e-18	Refractive error;
KIRP	cis	rs7246657	0.722	rs2291002	chr19:38033926	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.66	-0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs787274	0.850	rs4978510	chr9:115643795	C/G	cg13803584	chr9:115635662	SNX30	0.61	5.21	0.31	4.09e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7202877	0.706	rs40217	chr16:75480066	C/A	cg03315344	chr16:75512273	CHST6	-0.58	-5.43	-0.33	1.37e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs77861329	1.000	rs6781635	chr3:52125343	A/G	cg08692210	chr3:52188851	WDR51A	0.96	7.52	0.43	1.03e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-8.99	-0.5	6.64e-17	Menarche (age at onset);
KIRP	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg00405596	chr8:11794950	NA	0.49	6.53	0.38	3.65e-10	Mood instability;
KIRP	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.17	-0.31	4.89e-7	Obesity-related traits;
KIRP	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.37	-5.28	-0.32	2.85e-7	Blood metabolite levels;
KIRP	cis	rs6450176	0.909	rs255755	chr5:53307772	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-10.29	-0.55	6.8e-21	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs2151522	0.762	rs34178981	chr6:127163458	G/T	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25419628	chr10:115613987	NHLRC2;DCLRE1A	-0.44	-6.36	-0.38	9.91e-10	Migraine with aura;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg00024416	chr22:24240387	NA	-0.34	-4.88	-0.3	1.88e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.42	-5.26	-0.32	3.2e-7	Aortic root size;
KIRP	cis	rs10463316	0.928	rs4958267	chr5:150752643	A/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-7.03	-0.41	2.06e-11	Metabolite levels (Pyroglutamine);
KIRP	trans	rs12043259	0.730	rs1107714	chr1:204819063	A/G	cg11485465	chr5:54518469	NA	0.37	6.51	0.38	4.25e-10	Addiction;
KIRP	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg25182066	chr10:30743637	MAP3K8	-0.6	-7.39	-0.43	2.23e-12	Inflammatory bowel disease;
KIRP	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.78	-7.85	-0.45	1.31e-13	Bipolar disorder;
KIRP	cis	rs7601312	0.903	rs2194552	chr2:229314935	G/A	cg02542817	chr2:229291442	NA	-0.54	-8.08	-0.46	2.95e-14	Schizophrenia;
KIRP	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg14664628	chr15:75095509	CSK	0.51	5.66	0.34	4.23e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06889484	chr19:18304021	MPV17L2	0.5	6.06	0.36	5.17e-9	Parkinson's disease;
KIRP	cis	rs10875746	0.768	rs4760676	chr12:48421663	G/A	cg20731937	chr12:48336164	NA	0.49	6.16	0.37	3.02e-9	Longevity (90 years and older);
KIRP	cis	rs897080	0.552	rs1067405	chr2:44674861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.95	0.35	9.01e-9	Height;
KIRP	cis	rs4654899	0.865	rs12406144	chr1:21347228	A/C	cg05370193	chr1:21551575	ECE1	0.47	5.91	0.35	1.16e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg12181417	chr19:49337499	HSD17B14	-0.47	-5.01	-0.3	1.02e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6832769	0.961	rs7660808	chr4:56456672	G/A	cg05960024	chr4:56376020	CLOCK	-0.62	-8.06	-0.46	3.24e-14	Personality dimensions;
KIRP	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.46	6.78	0.4	9.07e-11	Coronary artery disease;
KIRP	cis	rs11605924	0.935	rs6485645	chr11:45862353	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.5	-5.99	-0.36	7.23e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg00857998	chr1:205179979	DSTYK	0.59	7.19	0.42	7.89e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg09631192	chr20:23583594	CST9	-0.52	-5.2	-0.31	4.27e-7	Chronic kidney disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21221695	chr4:72188145	SLC4A4	0.43	6.57	0.39	2.95e-10	Interleukin-4 levels;
KIRP	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.88	13.84	0.66	1.3e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.71	7.18	0.42	8.11e-12	Vitiligo;
KIRP	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.7	10.55	0.56	1.03e-21	Dupuytren's disease;
KIRP	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.41	-0.47	3.4e-15	Mean corpuscular volume;
KIRP	cis	rs9318086	0.534	rs1962469	chr13:24377544	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	5.3	0.32	2.52e-7	Myopia (pathological);
KIRP	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg10018233	chr7:150070692	REPIN1	0.58	7.2	0.42	7.26e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.23	0.37	2.05e-9	Diabetic retinopathy;
KIRP	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-6.35	-0.38	1.02e-9	Renal cell carcinoma;
KIRP	cis	rs4698790	0.635	rs3822272	chr4:110683550	C/T	cg07850274	chr4:110748770	RRH	0.35	5.19	0.31	4.38e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg01304814	chr3:48885189	PRKAR2A	0.79	5.84	0.35	1.65e-8	Cognitive function;
KIRP	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg26965718	chr17:79658957	HGS	-0.62	-4.9	-0.3	1.71e-6	Dental caries;
KIRP	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg06636001	chr8:8085503	FLJ10661	0.72	10.48	0.56	1.72e-21	Mood instability;
KIRP	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.45	5.83	0.35	1.75e-8	Crohn's disease;
KIRP	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg04315214	chr1:2043799	PRKCZ	0.35	5.61	0.34	5.45e-8	Height;
KIRP	cis	rs490234	0.902	rs10739663	chr9:128278739	A/G	cg14078157	chr9:128172775	NA	-0.41	-5.21	-0.32	3.99e-7	Mean arterial pressure;
KIRP	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg07701084	chr6:150067640	NUP43	0.69	9.54	0.52	1.51e-18	Lung cancer;
KIRP	cis	rs11203032	0.831	rs10887920	chr10:90924415	C/T	cg16672925	chr10:90967113	CH25H	0.73	7.26	0.42	5.11e-12	Heart failure;
KIRP	cis	rs11638352	1.000	rs12900880	chr15:44339598	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.72	-5.75	-0.34	2.58e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg02560085	chr5:140220810	PCDHA6;PCDHA2;PCDHA1;PCDHA8;PCDHA7;PCDHA5;PCDHA3;PCDHA4	-0.43	-4.95	-0.3	1.41e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg21926883	chr2:100939477	LONRF2	-0.54	-7.33	-0.42	3.21e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs981844	1.000	rs981843	chr4:154651985	C/T	cg14289246	chr4:154710475	SFRP2	0.67	7.18	0.42	8.01e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.81	-0.35	1.88e-8	Educational attainment;
KIRP	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.03	11.62	0.6	3.71e-25	Vitiligo;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg04025307	chr7:1156635	C7orf50	0.85	9.13	0.5	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg07884673	chr3:53033167	SFMBT1	0.98	7.6	0.44	6.35e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.15	0.36	3.16e-9	Colorectal cancer;
KIRP	cis	rs7011507	1.000	rs76393713	chr8:49167548	C/G	cg15325961	chr8:49183143	NA	0.6	5.05	0.31	8.57e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg02462569	chr6:150064036	NUP43	-0.37	-5.42	-0.33	1.41e-7	Lung cancer;
KIRP	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27297192	chr10:134578999	INPP5A	0.64	7.79	0.44	1.87e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg02461776	chr11:598696	PHRF1	0.57	6.3	0.37	1.4e-9	Systemic lupus erythematosus;
KIRP	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg23533926	chr12:111358616	MYL2	-0.48	-6.36	-0.38	9.99e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg07701084	chr6:150067640	NUP43	0.7	9.57	0.52	1.19e-18	Lung cancer;
KIRP	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.69	-9.18	-0.51	1.89e-17	Cognitive test performance;
KIRP	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.72	9.23	0.51	1.32e-17	Bladder cancer;
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg11814155	chr7:99998594	ZCWPW1	0.59	5.49	0.33	9.86e-8	Lung function (FEV1/FVC);
KIRP	cis	rs7760535	0.763	rs10457241	chr6:111849034	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.42	-5.49	-0.33	9.79e-8	Metabolic traits;
KIRP	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.11	8.21	0.46	1.24e-14	Mitochondrial DNA levels;
KIRP	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.71	0.39	1.32e-10	Menarche (age at onset);
KIRP	cis	rs526231	0.543	rs34791	chr5:102462104	C/A	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.67	0.39	1.63e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.72	0.53	4.15e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg03152288	chr2:177042942	NA	0.64	8.97	0.5	7.56e-17	IgG glycosylation;
KIRP	cis	rs501120	0.925	rs494045	chr10:44773498	C/T	cg09554077	chr10:44749378	NA	0.64	8.99	0.5	6.74e-17	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg07001201	chr5:642380	CEP72	0.68	6.4	0.38	7.71e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12134133	1.000	rs4844590	chr1:207496129	C/T	cg00797651	chr1:207494336	CD55	0.33	4.87	0.3	2.01e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
KIRP	cis	rs12976411	0.702	rs35465982	chr19:32819413	A/G	cg02282382	chr19:32836354	ZNF507	0.63	5.17	0.31	4.96e-7	Coronary artery disease;
KIRP	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.73	9.08	0.5	3.55e-17	Coronary artery disease;
KIRP	cis	rs4356932	0.729	rs6855257	chr4:76964788	T/C	cg00809888	chr4:76862425	NAAA	0.43	5.93	0.35	1.02e-8	Blood protein levels;
KIRP	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00321850	chr1:175162397	KIAA0040	-0.35	-6.33	-0.37	1.16e-9	Alcohol dependence;
KIRP	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.4	3.46e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs6691722	0.583	rs7537875	chr1:24695151	A/T	cg18323236	chr1:24743029	NIPAL3	0.38	5.43	0.33	1.35e-7	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.92	0.53	1.02e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10073892	0.667	rs10063351	chr5:101641361	A/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.87	10.47	0.56	1.81e-21	Breast cancer;
KIRP	cis	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg26585981	chr11:48327164	OR4S1	-0.42	-5.11	-0.31	6.35e-7	HDL cholesterol;
KIRP	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg27205649	chr11:78285834	NARS2	-0.52	-5.74	-0.34	2.84e-8	Testicular germ cell tumor;
KIRP	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.63	-0.56	5.91e-22	Height;
KIRP	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.62	-6.91	-0.4	4.12e-11	Platelet count;
KIRP	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	9.0	0.5	6.15e-17	Personality dimensions;
KIRP	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.71	10.83	0.57	1.32e-22	Type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21607141	chr4:119722917	SEC24D	-0.39	-6.06	-0.36	5.13e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.52	6.54	0.39	3.44e-10	Coronary heart disease;
KIRP	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.68	-8.47	-0.48	2.24e-15	Extraversion;
KIRP	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.57	0.52	1.22e-18	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg09873164	chr1:152488093	CRCT1	0.61	7.99	0.45	5.15e-14	Hair morphology;
KIRP	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs10463316	0.817	rs7708940	chr5:150789051	A/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.58	-0.39	2.82e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs13343954	0.575	rs10402158	chr19:33527784	G/C	cg27124370	chr19:33622961	WDR88	0.6	6.64	0.39	2e-10	Colorectal cancer;
KIRP	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.66	-7.53	-0.43	9.74e-13	IgG glycosylation;
KIRP	cis	rs524023	0.914	rs2360873	chr11:64391157	G/C	cg09231725	chr11:64357281	SLC22A12	0.59	7.89	0.45	9.83e-14	Urate levels in obese individuals;
KIRP	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg02073558	chr3:44770973	ZNF501	-0.73	-11.9	-0.6	4.38e-26	Depressive symptoms;
KIRP	trans	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg03060546	chr3:49711283	APEH	-0.65	-6.89	-0.4	4.58e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs4936894	0.500	rs10893168	chr11:124079739	A/C	cg27160556	chr11:124181099	OR8D1	-0.37	-5.25	-0.32	3.23e-7	Aging (time to death);
KIRP	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-5.25	-0.32	3.27e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9653442	0.564	rs7593261	chr2:100789907	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-4.9	-0.3	1.75e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4006360	0.646	rs9902561	chr17:39295384	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.53	-8.05	-0.46	3.65e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2820315	0.867	rs2820323	chr1:201883160	G/A	cg11586189	chr1:201857591	SHISA4	-0.39	-5.65	-0.34	4.34e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs10073892	1.000	rs10073892	chr5:101726770	T/C	cg19774478	chr5:101632501	SLCO4C1	0.68	6.99	0.41	2.56e-11	Cognitive decline (age-related);
KIRP	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg11650704	chr1:154556575	ADAR	0.41	5.11	0.31	6.41e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.3	-0.32	2.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.842	rs7731001	chr5:130781338	T/C	cg06307176	chr5:131281290	NA	-0.41	-4.89	-0.3	1.8e-6	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14270612	chr9:133738235	ABL1	0.49	6.2	0.37	2.31e-9	Interleukin-4 levels;
KIRP	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.47	6.56	0.39	3.23e-10	Red blood cell count;
KIRP	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg07884673	chr3:53033167	SFMBT1	0.63	4.88	0.3	1.94e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.23	0.51	1.33e-17	Body mass index;
KIRP	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.77	0.4	9.26e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4356932	1.000	rs4859588	chr4:76943677	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.62e-9	Blood protein levels;
KIRP	trans	rs9650657	0.746	rs4841441	chr8:10630898	C/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.3	-0.37	1.33e-9	Neuroticism;
KIRP	cis	rs7084402	0.565	rs10826200	chr10:60333847	T/C	cg05938607	chr10:60274200	BICC1	-0.29	-6.45	-0.38	6.01e-10	Refractive error;
KIRP	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.6	8.66	0.48	6.25e-16	Blood metabolite levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07035298	chr11:76168949	C11orf30	0.4	6.4	0.38	7.73e-10	C-reactive protein;
KIRP	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg17133734	chr15:86042851	AKAP13	-0.45	-5.7	-0.34	3.4e-8	Coronary artery disease;
KIRP	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26850624	chr5:429559	AHRR	0.32	5.84	0.35	1.6e-8	Cystic fibrosis severity;
KIRP	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.3	-7.12	-0.41	1.21e-11	Mean corpuscular volume;
KIRP	cis	rs7077164	0.960	rs1227777	chr10:71581131	A/G	cg20696214	chr10:71583771	COL13A1	0.46	6.55	0.39	3.32e-10	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs4750440	0.614	rs7921866	chr10:14030161	C/T	cg27542038	chr10:14027202	FRMD4A	-0.55	-7.39	-0.43	2.29e-12	Adiponectin levels;
KIRP	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.54	-6.71	-0.39	1.3e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg08700190	chr5:6636046	SRD5A1	-0.48	-5.99	-0.36	7.53e-9	Response to amphetamines;
KIRP	cis	rs1978968	0.763	rs34364976	chr22:18462027	C/T	cg03078520	chr22:18463400	MICAL3	-0.84	-12.08	-0.61	1.07e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs7656342	0.622	rs13141635	chr4:9845985	T/C	cg11266682	chr4:10021025	SLC2A9	0.33	5.06	0.31	8.2e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.88e-7	Life satisfaction;
KIRP	cis	rs16936870	0.543	rs6472517	chr8:71210331	A/G	cg14232793	chr8:71155543	NCOA2	0.59	7.26	0.42	5.04e-12	QT interval;
KIRP	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg07395648	chr5:131743802	NA	-0.39	-5.56	-0.33	6.89e-8	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	trans	rs526821	0.532	rs578067	chr11:55313690	T/G	cg15704280	chr7:45808275	SEPT13	-0.52	-6.3	-0.37	1.39e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.79	9.15	0.5	2.2e-17	Coronary artery disease;
KIRP	cis	rs42648	0.905	rs42622	chr7:89956824	A/G	cg25739043	chr7:89950458	NA	-0.47	-7.3	-0.42	3.87e-12	Homocysteine levels;
KIRP	cis	rs1413885	0.549	rs4593866	chr1:65850968	G/C	cg13202122	chr1:65886182	LEPROT;LEPR	0.45	5.33	0.32	2.17e-7	Anticoagulant levels;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg01314691	chr13:111367171	ING1	0.48	6.09	0.36	4.35e-9	Colorectal cancer;
KIRP	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg00784671	chr22:46762841	CELSR1	-0.69	-8.59	-0.48	9.9e-16	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.86	11.78	0.6	1.1e-25	Bipolar disorder and schizophrenia;
KIRP	cis	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg21546286	chr11:48923668	NA	-0.47	-6.01	-0.36	6.59e-9	HDL cholesterol;
KIRP	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg00405596	chr8:11794950	NA	-0.49	-6.57	-0.39	2.9e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.19	-0.61	4.63e-27	Ulcerative colitis;
KIRP	cis	rs4494114	1.000	rs7539067	chr1:39359694	A/G	cg25970120	chr1:39325951	RRAGC	-0.4	-5.06	-0.31	8.11e-7	Blood protein levels;
KIRP	cis	rs4849845	0.812	rs3931843	chr2:121039308	T/G	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.45	-0.33	1.24e-7	Colorectal cancer;
KIRP	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg10017260	chr10:834428	NA	-0.55	-5.41	-0.33	1.53e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.78	7.95	0.45	6.66e-14	Resting heart rate;
KIRP	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.67	0.34	4.02e-8	Coronary artery disease;
KIRP	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.79	-7.32	-0.42	3.58e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg12369402	chr1:90227771	NA	-0.37	-5.3	-0.32	2.54e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.55	-5.67	-0.34	3.98e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg12119029	chr16:89752879	CDK10	0.28	6.02	0.36	6.18e-9	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18080269	chr17:35849444	DUSP14	0.51	6.42	0.38	6.82e-10	Parkinson's disease;
KIRP	cis	rs986417	1.000	rs1269984	chr14:60898138	C/G	cg27398547	chr14:60952738	C14orf39	-0.67	-5.81	-0.35	1.91e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg18944383	chr4:111397179	ENPEP	0.49	7.99	0.45	5.27e-14	Coronary artery disease;
KIRP	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	5.76	0.34	2.5e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-9.66	-0.52	6.41e-19	Coffee consumption (cups per day);
KIRP	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	ch.1.3259774R	chr1:166827647	TADA1	0.42	5.03	0.31	9.4e-7	Refractive astigmatism;
KIRP	cis	rs4704187	0.687	rs6869345	chr5:74378742	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.0	-0.3	1.11e-6	Pulmonary function;
KIRP	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-6.86	-0.4	5.5e-11	Mood instability;
KIRP	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.85	9.51	0.52	1.87e-18	Obesity-related traits;
KIRP	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.61	-7.94	-0.45	7.31e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.47	0.43	1.36e-12	Major depressive disorder;
KIRP	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26002218	chr14:103986227	CKB	0.26	4.99	0.3	1.14e-6	Body mass index;
KIRP	trans	rs1864729	1.000	rs1835743	chr8:98282643	T/C	cg08679828	chr8:102218111	ZNF706	-0.75	-6.85	-0.4	5.74e-11	Estradiol plasma levels (breast cancer);
KIRP	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.39	0.51	4.38e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs16975963	0.644	rs11083430	chr19:38139488	A/G	cg18030218	chr19:38865513	PSMD8	0.53	4.86	0.3	2.06e-6	Longevity;
KIRP	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21643547	chr1:205240462	TMCC2	-0.86	-14.63	-0.68	2.76e-35	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.71	8.5	0.48	1.88e-15	Pancreatic cancer;
KIRP	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	5.77	0.35	2.33e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.86	11.37	0.59	2.43e-24	Gestational age at birth (maternal effect);
KIRP	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	1.08	19.64	0.78	2.71e-52	Monocyte count;
KIRP	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg13206674	chr6:150067644	NUP43	0.49	6.88	0.4	4.79e-11	Lung cancer;
KIRP	cis	rs72792276	1.000	rs17839658	chr5:127423013	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	7.0	0.41	2.41e-11	Red cell distribution width;
KIRP	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg02993010	chr8:124780839	FAM91A1	-0.57	-5.78	-0.35	2.25e-8	Pancreatic cancer;
KIRP	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg00147788	chr6:125855365	NA	-0.31	-4.97	-0.3	1.25e-6	Brugada syndrome;
KIRP	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.31	-6.07	-0.36	4.87e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs240764	0.567	rs12528607	chr6:101260131	A/G	cg09795085	chr6:101329169	ASCC3	0.46	5.35	0.32	1.97e-7	Neuroticism;
KIRP	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg03342759	chr3:160939853	NMD3	-0.42	-5.03	-0.31	9.6e-7	Morning vs. evening chronotype;
KIRP	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg22705602	chr4:152727874	NA	-0.55	-9.46	-0.52	2.64e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6681460	0.834	rs1280310	chr1:67216823	T/A	cg02459107	chr1:67143332	SGIP1	-0.42	-5.9	-0.35	1.22e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs494562	0.892	rs544403	chr6:86119116	G/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg06565975	chr8:143823917	SLURP1	-0.34	-5.02	-0.3	1.01e-6	Urinary tract infection frequency;
KIRP	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.84	-10.96	-0.57	5.1e-23	Blood protein levels;
KIRP	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.5	-6.36	-0.38	1e-9	White blood cell count;
KIRP	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.39	-5.63	-0.34	4.81e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs12282928	0.879	rs713324	chr11:48285064	T/C	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs11718455	0.548	rs9824340	chr3:43902170	A/G	cg08738300	chr3:44038990	NA	0.43	6.2	0.37	2.31e-9	Coronary artery disease;
KIRP	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg27205649	chr11:78285834	NARS2	-0.57	-6.56	-0.39	3.21e-10	Testicular germ cell tumor;
KIRP	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.29	5.86	0.35	1.51e-8	Schizophrenia;
KIRP	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22741823	chr4:108746275	SGMS2	0.54	6.69	0.39	1.47e-10	Parkinson's disease;
KIRP	cis	rs2290419	0.730	rs74342245	chr11:68938776	G/A	cg17042914	chr11:68898666	NA	-0.72	-5.17	-0.31	4.79e-7	Cutaneous malignant melanoma;
KIRP	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.26	0.32	3.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1867631	0.585	rs4655639	chr1:67089090	T/C	cg02459107	chr1:67143332	SGIP1	0.39	5.73	0.34	2.99e-8	Menopause (age at onset);
KIRP	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.79	7.23	0.42	6.16e-12	Mean platelet volume;
KIRP	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.95	11.52	0.59	7.59e-25	Diastolic blood pressure;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg08901578	chr4:187885870	NA	-0.51	-7.86	-0.45	1.19e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17866680	chr15:82338403	MEX3B	0.46	6.08	0.36	4.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg27205649	chr11:78285834	NARS2	-0.59	-6.81	-0.4	7.42e-11	Testicular germ cell tumor;
KIRP	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.39	-5.19	-0.31	4.48e-7	Blood protein levels;
KIRP	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.55	6.69	0.39	1.5e-10	Breast cancer;
KIRP	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg00310523	chr12:86230176	RASSF9	-0.47	-7.59	-0.44	6.77e-13	Major depressive disorder;
KIRP	trans	rs587242	0.956	rs12030748	chr1:96904404	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03217964	chr16:75182191	ZFP1	0.58	6.68	0.39	1.58e-10	Smoking initiation;
KIRP	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.34	0.32	2.16e-7	Lymphocyte counts;
KIRP	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg09557387	chr1:207818395	CR1L	1.08	6.51	0.38	4.2e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.39	0.38	8.39e-10	Menarche (age at onset);
KIRP	cis	rs7737355	1.000	rs257390	chr5:130740617	C/T	cg06307176	chr5:131281290	NA	-0.54	-5.85	-0.35	1.59e-8	Life satisfaction;
KIRP	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.0	-0.36	6.88e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.09	-0.36	4.4e-9	Bladder cancer;
KIRP	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg20936604	chr3:58311152	NA	-0.7	-5.96	-0.35	8.89e-9	Cholesterol, total;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10035591	chr13:77668698	MYCBP2	0.48	6.51	0.38	4.11e-10	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17558973	chr5:37249223	C5orf42	0.44	6.16	0.37	2.99e-9	Parkinson's disease;
KIRP	cis	rs1440410	0.866	rs4637346	chr4:144134043	A/T	cg01719995	chr4:144104893	USP38	0.45	6.24	0.37	1.92e-9	Ischemic stroke;
KIRP	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg02389323	chr16:88786976	FAM38A	0.96	5.98	0.36	7.9e-9	Plateletcrit;
KIRP	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg06963709	chr7:155150793	NA	0.54	6.52	0.38	4.01e-10	Stem cell growth factor beta levels;
KIRP	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs838721	0.574	rs34332006	chr2:234257452	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	5.11	0.31	6.47e-7	Total body bone mineral density;
KIRP	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg13798780	chr7:105162888	PUS7	0.41	4.96	0.3	1.32e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg03060546	chr3:49711283	APEH	0.43	5.42	0.33	1.41e-7	Parkinson's disease;
KIRP	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg26531700	chr6:26746687	NA	0.47	6.83	0.4	6.62e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07402062	chr16:89894098	SPIRE2	0.33	6.88	0.4	4.96e-11	Vitiligo;
KIRP	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg15117754	chr3:10150083	C3orf24	0.48	4.91	0.3	1.67e-6	Alzheimer's disease;
KIRP	cis	rs13033859	0.827	rs11127461	chr2:143541	C/T	cg10118717	chr2:203439	NA	-0.46	-7.24	-0.42	5.77e-12	Mitochondrial DNA levels;
KIRP	cis	rs77688320	0.553	rs6761777	chr2:202264602	A/T	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-5.55	-0.33	7.36e-8	Colorectal cancer;
KIRP	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.8	11.64	0.6	3.05e-25	N-glycan levels;
KIRP	cis	rs4132509	0.566	rs1578275	chr1:243680442	C/G	cg25706552	chr1:244017396	NA	-0.42	-4.93	-0.3	1.55e-6	RR interval (heart rate);
KIRP	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00950418	chr7:105029125	SRPK2	-0.54	-6.78	-0.4	8.7e-11	Height;
KIRP	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.68	-8.23	-0.46	1.1e-14	Blood protein levels;
KIRP	trans	rs1106684	1.000	rs6960129	chr7:131454649	C/T	cg13607082	chr12:122652224	LRRC43	-0.6	-6.19	-0.37	2.47e-9	Body mass index;
KIRP	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg24631222	chr15:78858424	CHRNA5	0.8	9.7	0.53	4.8e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs16857609	0.628	rs2568155	chr2:218335905	G/A	cg15335768	chr2:218268053	DIRC3	-0.37	-5.55	-0.33	7.21e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg20887711	chr4:1340912	KIAA1530	0.42	4.88	0.3	1.94e-6	Obesity-related traits;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg12692727	chr7:1102344	C7orf50	0.47	5.0	0.3	1.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4356932	1.000	rs4241580	chr4:76956188	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.68	-0.44	3.71e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.75	11.49	0.59	9.37e-25	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg06219351	chr7:158114137	PTPRN2	-0.56	-8.08	-0.46	2.98e-14	Calcium levels;
KIRP	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg06611532	chr13:114900021	NA	0.22	5.12	0.31	6.03e-7	Schizophrenia;
KIRP	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg06521331	chr12:34319734	NA	-0.65	-7.87	-0.45	1.16e-13	Morning vs. evening chronotype;
KIRP	cis	rs6969780	0.778	rs11564055	chr7:27145350	A/G	cg26364809	chr7:27145159	NA	-0.62	-5.71	-0.34	3.22e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.66	0.34	4.19e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs17834760	0.913	rs1076732	chr6:62043536	C/T	cg08476511	chr6:168435923	KIF25	0.52	6.08	0.36	4.65e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg18234130	chr8:27182889	PTK2B	0.52	6.85	0.4	5.98e-11	Neuroticism;
KIRP	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.7	-10.4	-0.55	3.06e-21	Prostate cancer;
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg05457628	chr5:178986728	RUFY1	-0.58	-9.34	-0.51	6.13e-18	Lung cancer;
KIRP	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.16	15.08	0.69	7.91e-37	Platelet count;
KIRP	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.58	-0.39	2.81e-10	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg16141378	chr3:129829833	LOC729375	0.49	6.55	0.39	3.4e-10	Mood instability;
KIRP	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.69	13.1	0.64	4.17e-30	White blood cell count (basophil);
KIRP	cis	rs7072216	0.922	rs7905265	chr10:100143193	C/G	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.01	-0.3	1.05e-6	Metabolite levels;
KIRP	cis	rs329674	0.556	rs73028354	chr11:133728578	G/A	cg06766960	chr11:133703094	NA	-0.7	-5.0	-0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.1	-0.36	4.19e-9	Schizophrenia;
KIRP	cis	rs6893807	1.000	rs1422192	chr5:87959023	G/A	cg24804195	chr5:87968844	LOC645323	0.58	6.2	0.37	2.3e-9	Body mass index;
KIRP	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg17764715	chr19:33622953	WDR88	0.66	8.29	0.47	7.25e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10888111	chr2:1637068	PXDN	0.44	6.3	0.37	1.38e-9	Pancreatic cancer;
KIRP	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg21360079	chr12:107162445	NA	-0.7	-9.89	-0.53	1.23e-19	Heart rate;
KIRP	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs798554	0.591	rs1636248	chr7:2882030	T/C	cg04166393	chr7:2884313	GNA12	0.5	6.7	0.39	1.41e-10	Height;
KIRP	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg00074818	chr8:8560427	CLDN23	0.4	6.22	0.37	2.13e-9	Obesity-related traits;
KIRP	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg11503966	chr20:62272292	STMN3	0.33	5.0	0.3	1.08e-6	Prostate cancer;
KIRP	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.63	7.75	0.44	2.4e-13	Type 2 diabetes;
KIRP	cis	rs7712401	0.623	rs30043	chr5:122272293	G/C	cg19412675	chr5:122181750	SNX24	0.47	5.2	0.31	4.22e-7	Mean platelet volume;
KIRP	cis	rs1359582	0.958	rs2576158	chr10:90297026	C/A	cg15661332	chr10:90342814	RNLS	0.52	5.11	0.31	6.38e-7	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.97	-0.3	1.23e-6	Coronary artery disease;
KIRP	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs6684428	0.706	rs11206673	chr1:56326340	C/T	cg11651538	chr1:56320950	NA	0.91	11.79	0.6	1.02e-25	Airflow obstruction;
KIRP	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.62	7.61	0.44	5.92e-13	Obesity-related traits;
KIRP	cis	rs28595532	0.748	rs72670248	chr4:119335536	A/C	cg21605333	chr4:119757512	SEC24D	1.1	8.22	0.46	1.15e-14	Cannabis dependence symptom count;
KIRP	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.35	8.34	0.47	5.51e-15	Asthma (sex interaction);
KIRP	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg24579218	chr15:68104479	NA	0.39	6.32	0.37	1.22e-9	Restless legs syndrome;
KIRP	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.84	0.35	1.65e-8	Aortic root size;
KIRP	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.63	-8.46	-0.47	2.49e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg09264619	chr17:80180166	NA	-0.51	-6.07	-0.36	4.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg24796726	chr7:884288	UNC84A	-0.59	-5.19	-0.31	4.49e-7	Initial pursuit acceleration;
KIRP	cis	rs735539	0.645	rs7326068	chr13:21209512	A/G	cg27499820	chr13:21296301	IL17D	-0.34	-4.95	-0.3	1.4e-6	Dental caries;
KIRP	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.1	-0.31	6.77e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.78	11.36	0.59	2.61e-24	Heart rate;
KIRP	cis	rs4664304	0.658	rs2667012	chr2:160867553	G/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.98	-0.45	5.53e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.01	-0.54	5.16e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg08975724	chr8:8085496	FLJ10661	0.56	6.62	0.39	2.28e-10	Nose size;
KIRP	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg05861140	chr6:150128134	PCMT1	-0.51	-7.12	-0.41	1.18e-11	Lung cancer;
KIRP	cis	rs9393813	0.528	rs13207497	chr6:27457380	C/A	cg03332623	chr6:27441972	ZNF184	-0.35	-5.18	-0.31	4.7e-7	Bipolar disorder;
KIRP	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.35	0.38	1.02e-9	Morning vs. evening chronotype;
KIRP	cis	rs1009181	0.585	rs72834696	chr6:26161399	G/A	cg13736514	chr6:26305472	NA	-0.53	-5.45	-0.33	1.23e-7	Childhood ear infection;
KIRP	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg00125455	chr20:44574271	PCIF1	-0.3	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.06	-0.36	5.01e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg14829360	chr17:73884958	NA	-0.59	-7.92	-0.45	8.17e-14	Psoriasis;
KIRP	cis	rs6987853	0.814	rs1947296	chr8:42452999	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.23	0.32	3.69e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9653442	0.564	rs12712071	chr2:100793876	G/A	cg17356467	chr2:100759845	AFF3	0.45	5.73	0.34	2.99e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg13072238	chr3:49761600	GMPPB	-0.59	-5.64	-0.34	4.58e-8	Menarche (age at onset);
KIRP	cis	rs4704187	0.663	rs965735	chr5:74459220	A/G	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.7	8.28	0.47	8.03e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.39	5.33	0.32	2.25e-7	Metabolite levels;
KIRP	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.79	-0.35	2.14e-8	IgG glycosylation;
KIRP	cis	rs62577244	0.645	rs12001733	chr9:138431675	G/T	cg14097499	chr9:138441348	OBP2A	0.51	6.72	0.39	1.23e-10	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
KIRP	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.2	0.31	4.1e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.45	0.55	2.19e-21	Hip circumference;
KIRP	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.49	-0.52	2.15e-18	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23130686	chr12:53689494	PFDN5	0.49	6.12	0.36	3.7e-9	Parkinson's disease;
KIRP	cis	rs6545883	0.507	rs12478192	chr2:61591175	A/G	cg15711740	chr2:61764176	XPO1	0.46	5.53	0.33	8.22e-8	Tuberculosis;
KIRP	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.49	4.9	0.3	1.72e-6	Alzheimer's disease;
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg10305451	chr2:177043427	NA	0.51	6.91	0.4	4.12e-11	IgG glycosylation;
KIRP	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.14e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg03585969	chr10:35415529	CREM	0.76	9.39	0.51	4.29e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.61e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg24699146	chr1:24152579	HMGCL	0.48	6.61	0.39	2.42e-10	Immature fraction of reticulocytes;
KIRP	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	1.24	11.24	0.58	6.13e-24	Mean corpuscular hemoglobin;
KIRP	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg06115741	chr20:33292138	TP53INP2	0.44	5.38	0.32	1.7e-7	Coronary artery disease;
KIRP	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.78	-10.99	-0.57	4.06e-23	Body mass index;
KIRP	cis	rs2034088	0.828	rs2289620	chr17:415667	T/C	cg06217071	chr17:408420	NA	0.68	10.69	0.56	3.81e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.56	7.28	0.42	4.4e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.7	9.08	0.5	3.75e-17	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.64	7.74	0.44	2.59e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg00383909	chr3:49044727	WDR6	0.46	5.06	0.31	8.09e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg08999081	chr20:33150536	PIGU	0.47	6.02	0.36	6.35e-9	Height;
KIRP	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-0.89	-9.76	-0.53	3.12e-19	Gut microbiome composition (summer);
KIRP	cis	rs1971256	0.500	rs17081284	chr6:151800796	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-6.15	-0.37	3.03e-9	Endometriosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07897452	chr16:11762209	SNN	0.56	7.4	0.43	2.2e-12	Parkinson's disease;
KIRP	cis	rs3779635	0.967	rs750538	chr8:27275726	G/T	cg18234130	chr8:27182889	PTK2B	0.44	5.55	0.33	7.32e-8	Neuroticism;
KIRP	cis	rs1185460	0.565	rs10892325	chr11:118912702	T/C	cg23280166	chr11:118938394	VPS11	-0.43	-5.03	-0.31	9.65e-7	Coronary artery disease;
KIRP	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg17457637	chr7:27170717	HOXA4	-0.35	-5.14	-0.31	5.61e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6088813	1.000	rs6142379	chr20:33999267	A/G	cg14752227	chr20:34000481	UQCC	-0.52	-6.72	-0.39	1.23e-10	Height;
KIRP	cis	rs7998202	0.667	rs7989810	chr13:113370627	C/T	cg04656015	chr13:113407548	ATP11A	-0.58	-6.36	-0.38	9.74e-10	Glycated hemoglobin levels;
KIRP	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01200585	chr1:228362443	C1orf69	0.43	5.33	0.32	2.25e-7	Diastolic blood pressure;
KIRP	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg00800038	chr16:89945340	TCF25	-0.7	-4.93	-0.3	1.51e-6	Skin colour saturation;
KIRP	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg24253500	chr15:84953950	NA	0.49	5.7	0.34	3.43e-8	Schizophrenia;
KIRP	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg09163369	chr1:210001066	C1orf107	-0.65	-6.77	-0.4	9.12e-11	Orofacial clefts;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.62e-9	Lung cancer;
KIRP	cis	rs9826463	0.702	rs2140436	chr3:142389669	G/T	cg20824294	chr3:142316082	PLS1	0.45	5.63	0.34	4.94e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-5.44	-0.33	1.32e-7	Colorectal cancer;
KIRP	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	Myopia (pathological);
KIRP	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-5.85	-0.35	1.53e-8	Blood metabolite levels;
KIRP	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.06	-0.31	8.17e-7	Red blood cell count;
KIRP	cis	rs9473924	0.632	rs871050	chr6:50915513	T/C	cg03432817	chr6:50765336	NA	0.35	5.4	0.33	1.59e-7	Body mass index;
KIRP	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	cg04338863	chr8:33670619	NA	0.44	5.44	0.33	1.28e-7	Body mass index;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg21186296	chr8:27182909	PTK2B	0.45	5.64	0.34	4.76e-8	Neuroticism;
KIRP	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg05507819	chr15:63340323	TPM1	0.45	5.04	0.31	8.82e-7	HDL cholesterol;
KIRP	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.87	8.47	0.48	2.3e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs4849845	0.653	rs3925970	chr2:121018153	C/A	cg24070213	chr2:121070622	NA	0.38	5.67	0.34	3.97e-8	Mean platelet volume;
KIRP	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.35	-0.32	2.01e-7	Aortic root size;
KIRP	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.36	-0.32	1.92e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3126085	0.515	rs2275264	chr1:152331533	T/G	cg26876637	chr1:152193138	HRNR	-0.55	-6.82	-0.4	7.03e-11	Atopic dermatitis;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.35	-0.32	2.02e-7	Life satisfaction;
KIRP	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg01631408	chr1:248437212	OR2T33	-0.67	-8.64	-0.48	7.12e-16	Common traits (Other);
KIRP	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11987759	chr7:65425863	GUSB	0.56	7.32	0.42	3.54e-12	Cotinine glucuronidation;
KIRP	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg22283653	chr8:49824208	NA	0.48	6.57	0.39	2.99e-10	Sudden cardiac arrest;
KIRP	cis	rs2408955	0.515	rs10875742	chr12:48493374	G/A	cg26205652	chr12:48591994	NA	0.47	6.37	0.38	9.18e-10	Glycated hemoglobin levels;
KIRP	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg16649577	chr8:11646810	NA	0.37	4.86	0.3	2.07e-6	Retinal vascular caliber;
KIRP	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.01	-0.3	1.06e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-9.43	-0.52	3.22e-18	Hip circumference;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07092213	chr7:1199455	ZFAND2A	0.43	5.19	0.31	4.37e-7	Longevity;Endometriosis;
KIRP	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.49	5.22	0.32	3.87e-7	Alzheimer's disease;
KIRP	cis	rs7538876	0.967	rs72637463	chr1:17719089	G/A	cg01904812	chr1:17746340	RCC2	0.3	5.06	0.31	8.16e-7	Basal cell carcinoma;
KIRP	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.82	12.96	0.64	1.22e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4006360	0.575	rs7502215	chr17:39306261	C/T	cg25341923	chr17:39239918	KRTAP4-7	0.44	5.84	0.35	1.64e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	1.1	13.9	0.66	8.48e-33	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-6.34	-0.37	1.12e-9	Initial pursuit acceleration;
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs10274279	0.660	rs9638055	chr7:157379914	A/G	cg09270525	chr7:157391030	PTPRN2	0.43	5.03	0.31	9.6e-7	Myopia (pathological);
KIRP	cis	rs17095355	0.579	rs72828224	chr10:111702047	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.48	-0.38	5.05e-10	Biliary atresia;
KIRP	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg06217071	chr17:408420	NA	0.72	11.65	0.6	2.88e-25	Hip circumference adjusted for BMI;
KIRP	cis	rs2377585	0.524	rs35146959	chr12:8847546	C/T	cg03761649	chr12:8850719	RIMKLB	0.5	4.98	0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.8	-12.56	-0.63	2.72e-28	Idiopathic membranous nephropathy;
KIRP	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg17385448	chr1:15911702	AGMAT	0.25	4.91	0.3	1.67e-6	Systolic blood pressure;
KIRP	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18255839	chr2:239335447	ASB1	0.44	5.26	0.32	3.07e-7	Multiple system atrophy;
KIRP	cis	rs2585417	0.742	rs6127138	chr20:52828384	A/G	cg14415559	chr20:52836060	PFDN4	-0.38	-5.97	-0.36	8.34e-9	Obesity-related traits;
KIRP	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg20578329	chr17:80767326	TBCD	-0.86	-8.68	-0.48	5.4e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs15676	0.947	rs2977999	chr9:131579807	G/A	cg00228799	chr9:131580591	ENDOG	0.57	6.55	0.39	3.4e-10	Blood metabolite levels;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.55	-0.56	1.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8756	0.818	rs7970350	chr12:66360164	C/T	cg06712651	chr12:66351869	HMGA2	-0.72	-12.28	-0.62	2.46e-27	Height;
KIRP	trans	rs994014	0.691	rs7699600	chr4:82271857	C/T	cg04076444	chr16:85646805	KIAA0182	0.54	6.6	0.39	2.56e-10	Height;
KIRP	cis	rs2072732	0.861	rs72630906	chr1:2961023	C/A	cg11731671	chr1:2995604	PRDM16	-0.55	-6.12	-0.36	3.71e-9	Plateletcrit;
KIRP	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg03929089	chr4:120376271	NA	0.69	6.09	0.36	4.43e-9	Axial length;
KIRP	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs7215564	0.908	rs2340772	chr17:78752017	C/A	cg06153925	chr17:78755379	RPTOR	-0.38	-6.32	-0.37	1.25e-9	Myopia (pathological);
KIRP	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.9	-13.33	-0.65	7.34e-31	Height;
KIRP	cis	rs755109	1.000	rs2417577	chr9:100701446	A/G	cg13688889	chr9:100608707	NA	-0.43	-5.0	-0.3	1.1e-6	Quantitative traits;
KIRP	cis	rs6669919	0.647	rs1578838	chr1:211671118	T/G	cg10512769	chr1:211675356	NA	-0.43	-6.06	-0.36	4.95e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12476592	0.602	rs174485	chr2:63857402	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.02	-0.3	1.01e-6	Childhood ear infection;
KIRP	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg19773385	chr1:10388646	KIF1B	-0.76	-11.58	-0.59	4.87e-25	Hepatocellular carcinoma;
KIRP	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2531992	1.000	rs710893	chr16:4014964	A/G	cg09155362	chr15:33487289	NA	-0.52	-6.3	-0.37	1.39e-9	Waist circumference;
KIRP	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.6	7.0	0.41	2.4e-11	Obesity-related traits;
KIRP	cis	rs7945718	0.621	rs10831894	chr11:12680733	G/A	cg25843174	chr11:12811716	TEAD1	0.31	5.58	0.34	6.41e-8	Educational attainment (years of education);
KIRP	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.68	-0.34	3.78e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg26441486	chr22:50317300	CRELD2	0.49	5.71	0.34	3.31e-8	Schizophrenia;
KIRP	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg02527881	chr3:46936655	PTH1R	0.37	4.99	0.3	1.14e-6	Colorectal cancer;
KIRP	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg00647317	chr7:50633725	DDC	0.46	6.65	0.39	1.86e-10	Systemic sclerosis;
KIRP	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.27	-0.51	9.8e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.39	-0.38	8.11e-10	Personality dimensions;
KIRP	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05220968	chr6:146057943	EPM2A	0.38	4.89	0.3	1.85e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg14228332	chr4:119757509	SEC24D	0.79	4.86	0.3	2.1e-6	Cannabis dependence symptom count;
KIRP	cis	rs7523273	1.000	rs1142469	chr1:207965427	G/A	cg22525895	chr1:207977042	MIR29B2	-0.68	-8.67	-0.48	5.96e-16	Schizophrenia;
KIRP	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg12173498	chr6:36355764	ETV7	-0.33	-5.32	-0.32	2.29e-7	Platelet distribution width;
KIRP	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg13611997	chr5:233750	SDHA	-0.43	-5.11	-0.31	6.44e-7	Breast cancer;
KIRP	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.98	-0.36	7.72e-9	Breast cancer;
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg05586540	chr6:43046201	PTK7	0.42	6.21	0.37	2.24e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg01879757	chr17:41196368	BRCA1	-0.62	-8.26	-0.47	9.01e-15	Menopause (age at onset);
KIRP	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.43	7.3	0.42	4.03e-12	Huntington's disease progression;
KIRP	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.52	-6.39	-0.38	8.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.05e-8	Skin colour saturation;
KIRP	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg25039879	chr17:56429692	SUPT4H1	0.57	5.19	0.31	4.38e-7	Cognitive test performance;
KIRP	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.31	0.32	2.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2398893	0.855	rs11791859	chr9:96788758	G/A	cg14459158	chr9:96720562	NA	0.3	5.32	0.32	2.37e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1421898	0.929	rs62386869	chr5:158133674	C/T	cg04237997	chr11:124629752	ESAM	-0.76	-6.3	-0.37	1.35e-9	Inflammatory skin disease;
KIRP	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.95	-0.45	6.69e-14	Monocyte percentage of white cells;
KIRP	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.37e-7	Putamen volume;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-8.6	-0.48	9.73e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.58	-6.88	-0.4	4.92e-11	Mosquito bite size;
KIRP	cis	rs10128264	1.000	rs2802364	chr10:80960486	G/C	cg20744163	chr10:80999841	ZMIZ1	-0.3	-5.18	-0.31	4.52e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.94	7.46	0.43	1.46e-12	Obesity-related traits;
KIRP	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-9.16	-0.5	2.16e-17	Coronary artery disease;
KIRP	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.34	-0.47	5.16e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.67	7.28	0.42	4.48e-12	Smoking initiation;
KIRP	cis	rs2224391	0.628	rs2773317	chr6:5254509	C/T	cg13962347	chr6:5174647	LYRM4	-0.73	-10.29	-0.55	6.7e-21	Height;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg22603710	chr3:134514098	EPHB1	-0.48	-6.47	-0.38	5.11e-10	Morning vs. evening chronotype;
KIRP	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.45	-8.55	-0.48	1.34e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-7.46	-0.43	1.52e-12	Diastolic blood pressure;
KIRP	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.44	9.92	0.53	9.72e-20	Alzheimer's disease (late onset);
KIRP	cis	rs151997	0.962	rs27475	chr5:50180439	A/C	cg06027927	chr5:50259733	NA	0.59	7.41	0.43	2.02e-12	Callous-unemotional behaviour;
KIRP	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg06565975	chr8:143823917	SLURP1	0.45	7.01	0.41	2.26e-11	Urinary tract infection frequency;
KIRP	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	trans	rs13170463	0.579	rs75868304	chr5:8041654	C/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.68	-9.13	-0.5	2.57e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9308731	1.000	rs6542334	chr2:111907214	G/A	cg23466623	chr2:111982296	NA	-0.44	-5.52	-0.33	8.41e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg20060108	chr2:102954350	IL1RL1	-0.64	-5.68	-0.34	3.76e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg25547332	chr5:131281432	NA	-0.47	-5.21	-0.32	3.93e-7	Life satisfaction;
KIRP	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.4	-6.28	-0.37	1.51e-9	Body mass index;
KIRP	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg18586891	chr4:952366	TMEM175	0.61	5.54	0.33	7.82e-8	Parkinson's disease;
KIRP	cis	rs58804349	1.000	rs58804349	chr10:43355640	G/A	cg11150807	chr10:43354902	NA	0.69	6.11	0.36	3.8e-9	Pediatric bone mineral content (radius);
KIRP	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg03909863	chr11:638404	DRD4	-0.4	-4.97	-0.3	1.24e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14012249	chr9:35748803	RGP1;GBA2	0.48	6.12	0.36	3.59e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05702448	chr1:167905194	DCAF6;BRP44	0.47	6.13	0.36	3.55e-9	Parkinson's disease;
KIRP	cis	rs12143943	0.934	rs12567161	chr1:204577832	G/A	cg20240347	chr1:204465584	NA	-0.36	-6.47	-0.38	5.15e-10	Cognitive performance;
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.74	-10.62	-0.56	6.23e-22	Paraoxonase activity;
KIRP	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.38	-0.38	8.61e-10	Response to antipsychotic treatment;
KIRP	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg14972814	chr11:95582409	MTMR2	0.34	5.44	0.33	1.28e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08439880	chr3:133502540	NA	-0.51	-6.34	-0.37	1.08e-9	Iron status biomarkers;
KIRP	cis	rs1010254	0.510	rs957211	chr5:151757858	T/A	cg12297329	chr5:152029980	NA	-0.71	-6.91	-0.4	4.15e-11	Optic nerve measurement (cup area);
KIRP	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.86	-9.99	-0.54	6.08e-20	Osteoarthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08448284	chr3:130652221	ATP2C1	-0.43	-6.02	-0.36	6.22e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4148660	0.927	rs59061211	chr12:22049588	A/G	cg14669847	chr12:22099120	NA	-0.36	-6.19	-0.37	2.52e-9	Gout;
KIRP	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg18806716	chr10:30721971	MAP3K8	-0.31	-5.05	-0.31	8.42e-7	Inflammatory bowel disease;
KIRP	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.49	6.42	0.38	6.78e-10	Menopause (age at onset);
KIRP	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00512023	chr15:34396328	PGBD4	-0.49	-7.23	-0.42	5.99e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.74	-10.83	-0.57	1.37e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs16828019	0.929	rs8179465	chr1:41701747	C/T	cg18742814	chr1:41828276	NA	0.6	5.42	0.33	1.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.92	11.51	0.59	8.41e-25	Obesity;Body mass index;
KIRP	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg02151108	chr14:50098012	C14orf104	-0.51	-7.1	-0.41	1.3e-11	Carotid intima media thickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19105459	chr4:83295282	HNRNPD	0.48	6.19	0.37	2.56e-9	Parkinson's disease;
KIRP	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg20701182	chr2:24300061	SF3B14	0.57	5.08	0.31	7.61e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs9815354	0.812	rs55788971	chr3:41843965	T/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.73	-0.34	2.87e-8	Aortic root size;
KIRP	cis	rs4765905	0.549	rs2239026	chr12:2312291	C/T	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.51e-11	Schizophrenia;
KIRP	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg17554472	chr22:41940697	POLR3H	-0.44	-5.05	-0.31	8.62e-7	Neuroticism;
KIRP	cis	rs6859018	1.000	rs3212227	chr5:158742950	T/G	cg26646896	chr5:158686746	NA	-0.34	-4.94	-0.3	1.47e-6	Serum sulfate level;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg04964845	chr14:60761524	PPM1A	0.43	6.55	0.39	3.28e-10	Migraine with aura;
KIRP	cis	rs62413470	0.872	rs75536377	chr6:55958364	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg16141378	chr3:129829833	LOC729375	0.54	7.33	0.42	3.31e-12	Morning vs. evening chronotype;
KIRP	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg03585969	chr10:35415529	CREM	0.8	9.71	0.53	4.34e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg08662619	chr6:150070041	PCMT1	-0.33	-5.35	-0.32	2.02e-7	Lung cancer;
KIRP	trans	rs301901	0.828	rs4308503	chr5:37454193	T/C	cg01568846	chr3:179281462	ACTL6A	0.49	6.01	0.36	6.51e-9	Height;
KIRP	cis	rs7084783	0.538	rs11191734	chr10:105338128	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.44	5.58	0.34	6.42e-8	Fear of pain;
KIRP	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2904967	1.000	rs636928	chr11:65093484	A/C	cg12562828	chr11:65076843	NA	0.62	9.12	0.5	2.73e-17	Mean corpuscular volume;
KIRP	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.66	0.34	4.29e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg27454946	chr8:145133526	EXOSC4	0.56	4.96	0.3	1.32e-6	Blood metabolite levels;
KIRP	cis	rs6142102	0.580	rs6142101	chr20:32697845	G/A	cg08999081	chr20:33150536	PIGU	0.38	4.91	0.3	1.69e-6	Skin pigmentation;
KIRP	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg09184832	chr6:79620586	NA	-0.45	-6.44	-0.38	6.23e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg12486944	chr17:80159399	CCDC57	0.4	5.34	0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg06060754	chr5:176797920	RGS14	-0.61	-7.03	-0.41	1.99e-11	Urate levels in lean individuals;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18632100	chr19:59028615	ZBTB45	0.53	6.86	0.4	5.64e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.61	8.25	0.47	9.77e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs2599510	0.703	rs58852184	chr2:32729763	A/T	cg02381751	chr2:32503542	YIPF4	0.44	5.09	0.31	7e-7	Interleukin-18 levels;
KIRP	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-7.42	-0.43	1.84e-12	Bone mineral density (spine);
KIRP	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.93	0.35	1.04e-8	Menopause (age at onset);
KIRP	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg02023728	chr11:77925099	USP35	-0.3	-5.31	-0.32	2.44e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6466055	0.932	rs2057883	chr7:104929837	C/G	cg04380332	chr7:105027541	SRPK2	0.51	7.77	0.44	2.07e-13	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.79	-8.9	-0.49	1.26e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.52	7.53	0.43	9.45e-13	Coronary artery disease;
KIRP	cis	rs1981331	1.000	rs118078026	chr21:48012129	T/C	cg17243659	chr21:48055224	PRMT2	1.05	6.23	0.37	2e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	8.02	0.46	4.25e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6500395	0.651	rs28432694	chr16:48666310	A/T	cg04672837	chr16:48644449	N4BP1	0.4	5.41	0.33	1.51e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.79	11.53	0.59	6.84e-25	Heart rate;
KIRP	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.02	-0.36	6.14e-9	Type 2 diabetes;
KIRP	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg21775007	chr8:11205619	TDH	-0.54	-6.93	-0.4	3.74e-11	Joint mobility (Beighton score);
KIRP	cis	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg25276700	chr6:44698697	NA	0.35	5.01	0.3	1.03e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.35	-5.13	-0.31	5.76e-7	Body mass index;
KIRP	cis	rs6977660	0.607	rs13239423	chr7:19816571	T/C	cg07541023	chr7:19748670	TWISTNB	0.57	5.39	0.32	1.69e-7	Thyroid stimulating hormone;
KIRP	trans	rs17079247	0.778	rs1038736	chr13:85805655	A/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs56161922	1.000	rs4562622	chr1:207876577	A/C	cg11752769	chr1:207818423	CR1L	0.79	5.22	0.32	3.79e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs3026101	0.697	rs2107152	chr17:5297350	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.52	-6.26	-0.37	1.72e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.55	14.0	0.67	3.85e-33	Airflow obstruction;
KIRP	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.65	5.21	0.32	3.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1106684	1.000	rs11770006	chr7:131462011	A/G	cg13607082	chr12:122652224	LRRC43	-0.66	-6.72	-0.39	1.25e-10	Body mass index;
KIRP	cis	rs4713118	0.662	rs149961	chr6:28015569	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-4.9	-0.3	1.7e-6	Parkinson's disease;
KIRP	cis	rs11825064	0.666	rs73596940	chr11:134495250	G/A	cg06603561	chr11:134479413	NA	-0.74	-6.12	-0.36	3.68e-9	Seasonality;
KIRP	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg11965913	chr1:205819406	PM20D1	0.48	5.35	0.32	2e-7	Parkinson's disease;
KIRP	cis	rs6593803	0.805	rs11590206	chr1:147199309	G/A	cg27546670	chr1:147246839	GJA5	-0.56	-5.98	-0.36	7.98e-9	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.46	6.42	0.38	6.87e-10	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15615829	chr17:12008797	MAP2K4	-0.42	-6.59	-0.39	2.67e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.73	7.95	0.45	6.7e-14	Corneal astigmatism;
KIRP	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	0.73	6.94	0.4	3.36e-11	Breast cancer;
KIRP	cis	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg21546286	chr11:48923668	NA	0.43	5.37	0.32	1.78e-7	HDL cholesterol;
KIRP	cis	rs6499755	0.965	rs9888978	chr16:55352984	T/G	cg05099576	chr16:55362342	IRX6	0.28	5.83	0.35	1.78e-8	Hypospadias;
KIRP	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.32	-0.42	3.55e-12	Triglycerides;
KIRP	cis	rs62380364	0.602	rs589544	chr5:88064462	T/C	cg24804195	chr5:87968844	LOC645323	-0.43	-5.56	-0.33	6.85e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg00484396	chr16:3507460	NAT15	0.52	5.23	0.32	3.68e-7	Tuberculosis;
KIRP	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.63	9.0	0.5	6.13e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-0.81	-12.56	-0.63	2.79e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg20526800	chr20:33880825	FAM83C	0.4	4.89	0.3	1.81e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg07843065	chr1:150265600	MRPS21	0.49	7.03	0.41	2e-11	Migraine;
KIRP	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.25	-0.51	1.16e-17	Morning vs. evening chronotype;
KIRP	cis	rs2281603	0.570	rs1980519	chr14:64959855	C/G	cg01860774	chr14:64969374	ZBTB25	0.33	5.37	0.32	1.8e-7	Lymphocyte counts;
KIRP	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.84	-9.5	-0.52	1.96e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg10523679	chr1:76189770	ACADM	0.6	6.92	0.4	3.96e-11	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.61	-0.39	2.31e-10	Glomerular filtration rate;
KIRP	cis	rs11673344	0.526	rs17305193	chr19:38089665	C/T	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.43	-0.33	1.34e-7	Obesity-related traits;
KIRP	cis	rs6893300	1.000	rs17617068	chr5:179168097	T/C	cg14593053	chr5:179126677	CANX	-0.57	-6.28	-0.37	1.5e-9	Resting heart rate;
KIRP	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.31	7.93	0.45	7.78e-14	Primary biliary cholangitis;
KIRP	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.92	10.5	0.56	1.46e-21	Triglycerides;
KIRP	trans	rs17121403	0.661	rs12132802	chr1:100565459	C/T	cg05735639	chr17:49021875	NA	-0.76	-6.58	-0.39	2.74e-10	Pulmonary function decline;
KIRP	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg21775007	chr8:11205619	TDH	0.67	9.54	0.52	1.52e-18	Retinal vascular caliber;
KIRP	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.78	-0.4	8.94e-11	Hemoglobin concentration;
KIRP	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03934478	chr11:495069	RNH1	0.88	6.84	0.4	6.4e-11	Body mass index;
KIRP	cis	rs6832769	0.961	rs11947476	chr4:56339751	T/C	cg05960024	chr4:56376020	CLOCK	0.63	8.17	0.46	1.65e-14	Personality dimensions;
KIRP	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg23533419	chr12:54090519	NA	-0.35	-5.28	-0.32	2.8e-7	Height;
KIRP	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21545522	chr1:205238299	TMCC2	0.43	5.88	0.35	1.3e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.37	-4.85	-0.3	2.16e-6	Mean platelet volume;
KIRP	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg27211696	chr2:191398769	TMEM194B	0.76	9.17	0.5	2.01e-17	Diastolic blood pressure;
KIRP	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg13393036	chr8:95962371	TP53INP1	-0.3	-5.52	-0.33	8.45e-8	Type 2 diabetes;
KIRP	trans	rs972578	0.765	rs5751397	chr22:43272792	C/T	cg15321293	chr3:36422198	STAC	-0.47	-6.11	-0.36	3.8e-9	Mean platelet volume;
KIRP	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.75	10.95	0.57	5.58e-23	Prudent dietary pattern;
KIRP	cis	rs4959799	0.655	rs9501974	chr6:3272775	T/C	cg03657281	chr6:3270030	SLC22A23	0.79	6.06	0.36	5.14e-9	Survival in rectal cancer;
KIRP	cis	rs4262150	0.544	rs4958554	chr5:151903294	T/G	cg12297329	chr5:152029980	NA	-0.71	-8.79	-0.49	2.7e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.4	-5.1	-0.31	6.76e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2562456	0.833	rs11667361	chr19:21539382	C/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs16828019	0.852	rs2268678	chr1:41511053	G/A	cg18742814	chr1:41828276	NA	0.69	5.91	0.35	1.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg07460842	chr6:66804631	NA	0.89	7.62	0.44	5.55e-13	Exhaled nitric oxide output;
KIRP	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg15247329	chr7:2764246	NA	-0.38	-5.51	-0.33	9.2e-8	Height;
KIRP	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg21573476	chr21:45109991	RRP1B	-0.57	-7.99	-0.45	5.16e-14	Mean corpuscular volume;
KIRP	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21747090	chr2:27597821	SNX17	-0.5	-6.87	-0.4	5.13e-11	Total body bone mineral density;
KIRP	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.73	10.89	0.57	8.8e-23	Oral cavity cancer;
KIRP	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.61e-11	Electroencephalogram traits;
KIRP	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg21775007	chr8:11205619	TDH	-0.52	-6.66	-0.39	1.81e-10	Neuroticism;
KIRP	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.85	-0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.23	-0.37	1.99e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6681460	0.966	rs10889643	chr1:67143368	G/C	cg13052034	chr1:66999238	SGIP1	0.45	6.18	0.37	2.64e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.74	10.94	0.57	5.95e-23	Hip circumference;
KIRP	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.8	9.9	0.53	1.15e-19	Phospholipid levels (plasma);
KIRP	cis	rs3105593	0.933	rs2003359	chr15:50833113	A/G	cg08437265	chr15:50716283	USP8	0.41	5.59	0.34	6.02e-8	QT interval;
KIRP	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	1.06	15.64	0.71	9.3e-39	Cognitive function;
KIRP	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.7	-0.39	1.44e-10	Alcohol dependence;
KIRP	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg13319975	chr6:146136371	FBXO30	0.46	6.3	0.37	1.39e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg23587288	chr2:27483067	SLC30A3	-0.55	-7.01	-0.41	2.33e-11	Blood metabolite levels;
KIRP	cis	rs2249694	0.960	rs7084384	chr10:135412322	A/G	cg20169779	chr10:135381914	SYCE1	-0.42	-4.98	-0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.92	-10.3	-0.55	6.47e-21	Exhaled nitric oxide output;
KIRP	cis	rs624899	0.655	rs73514607	chr19:11632207	G/A	cg08680689	chr19:11670216	ELOF1	-0.79	-5.27	-0.32	3.01e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg06636001	chr8:8085503	FLJ10661	0.63	8.88	0.49	1.42e-16	Neuroticism;
KIRP	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	1.08	10.44	0.55	2.4e-21	Thyroid stimulating hormone;
KIRP	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-9.59	-0.52	1.01e-18	Body mass index;
KIRP	cis	rs832187	1.000	rs832187	chr3:63833050	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.53	6.36	0.38	9.54e-10	Schizophrenia;
KIRP	cis	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg06521331	chr12:34319734	NA	-0.41	-5.21	-0.32	4e-7	Morning vs. evening chronotype;
KIRP	cis	rs6594499	0.872	rs10050834	chr5:110427328	C/T	cg04022379	chr5:110408740	TSLP	0.44	6.66	0.39	1.78e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.68	-13.03	-0.64	7.35e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	10.9	0.57	7.63e-23	Mean platelet volume;
KIRP	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.56	-7.09	-0.41	1.45e-11	Body mass index;
KIRP	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.09e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg08126542	chr6:37504118	NA	-0.71	-10.11	-0.54	2.61e-20	Cognitive performance;
KIRP	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17376030	chr22:41985996	PMM1	0.82	8.49	0.48	1.99e-15	Vitiligo;
KIRP	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-7.94	-0.45	7.12e-14	Body mass index;
KIRP	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.67	-6.72	-0.39	1.24e-10	Body mass index;
KIRP	trans	rs12517041	0.935	rs2099089	chr5:23287372	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.68	-0.48	5.57e-16	Calcium levels;
KIRP	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.68	11.06	0.58	2.45e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg03585969	chr10:35415529	CREM	0.84	10.09	0.54	2.9e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg20302533	chr7:39170763	POU6F2	0.27	5.61	0.34	5.37e-8	IgG glycosylation;
KIRP	cis	rs73206853	0.698	rs871922	chr12:111114942	T/C	cg12870014	chr12:110450643	ANKRD13A	0.51	4.94	0.3	1.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs17030434	0.784	rs72617459	chr4:154661686	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-6.81	-0.4	7.28e-11	Electrocardiographic conduction measures;
KIRP	cis	rs8077577	0.895	rs6502640	chr17:18122485	G/A	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs4805272	1.000	rs888832	chr19:29324563	T/C	cg04546413	chr19:29218101	NA	0.43	4.86	0.3	2.05e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg01689657	chr7:91764605	CYP51A1	0.48	7.09	0.41	1.41e-11	Breast cancer;
KIRP	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	trans	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg08400319	chr2:242004533	SNED1	0.44	6.02	0.36	6.43e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.06	-0.36	5.2e-9	Bladder cancer;
KIRP	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24564603	chr7:158456404	NCAPG2	-0.41	-4.95	-0.3	1.36e-6	Height;
KIRP	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg09596252	chr17:78655493	RPTOR	0.59	7.83	0.45	1.43e-13	Obesity;
KIRP	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg22903471	chr2:27725779	GCKR	0.38	5.24	0.32	3.41e-7	Oral cavity cancer;
KIRP	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.96	-0.45	6.25e-14	Migraine;Coronary artery disease;
KIRP	cis	rs2733310	0.843	rs8039176	chr15:57564142	T/A	cg13626582	chr15:57592083	LOC283663	0.27	6.11	0.36	3.84e-9	Mean platelet volume;
KIRP	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.43	-6.21	-0.37	2.29e-9	Vitamin D levels;
KIRP	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg08648136	chr8:956695	NA	0.36	5.06	0.31	8.24e-7	Schizophrenia;
KIRP	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-6.35	-0.38	1.01e-9	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-6.91	-0.4	4.15e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.09	-0.36	4.4e-9	Neuroticism;
KIRP	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg10189774	chr4:17578691	LAP3	0.49	5.99	0.36	7.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs698813	0.763	rs698764	chr2:44573658	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.19	0.37	2.46e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg12160578	chr15:63334699	TPM1	0.64	6.78	0.4	8.89e-11	Orofacial clefts;
KIRP	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	7.11	0.41	1.24e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8033133	0.602	rs12438531	chr15:25323876	A/C	cg14481604	chr15:25334117	SNORD116-22	-0.43	-5.35	-0.32	2.04e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.46	9.93	0.53	9.44e-20	Mean corpuscular volume;
KIRP	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg17133734	chr15:86042851	AKAP13	-0.45	-5.7	-0.34	3.4e-8	Coronary artery disease;
KIRP	trans	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg14791747	chr16:20752902	THUMPD1	0.63	6.94	0.4	3.42e-11	Cognitive test performance;
KIRP	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.53	6.68	0.39	1.56e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Systolic blood pressure;
KIRP	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-1.04	-14.65	-0.68	2.37e-35	Menopause (age at onset);
KIRP	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg10761708	chr20:43804764	PI3	0.51	5.23	0.32	3.63e-7	Blood protein levels;
KIRP	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.73e-8	Tonsillectomy;
KIRP	trans	rs1033962	1.000	rs4748991	chr10:25219544	A/G	cg04878152	chr3:148415960	AGTR1	0.39	6.03	0.36	6.09e-9	Post-traumatic stress disorder;
KIRP	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.4	-5.68	-0.34	3.76e-8	Coronary artery disease;
KIRP	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.86	0.35	1.49e-8	Educational attainment;
KIRP	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg07636037	chr3:49044803	WDR6	0.56	5.3	0.32	2.59e-7	Menarche (age at onset);
KIRP	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-6.96	-0.41	3.13e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4356975	0.563	rs4337789	chr4:69973044	A/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg02820040	chr2:241836501	C2orf54	-0.24	-5.52	-0.33	8.7e-8	Urinary metabolites;
KIRP	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05347473	chr6:146136440	FBXO30	0.58	8.31	0.47	6.67e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	9.48	0.52	2.2e-18	Mood instability;
KIRP	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26207909	chr14:103986467	CKB	0.74	10.66	0.56	4.51e-22	Body mass index;
KIRP	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	10.85	0.57	1.13e-22	Response to antipsychotic treatment;
KIRP	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg03474202	chr17:45855739	NA	-0.47	-6.47	-0.38	5.36e-10	IgG glycosylation;
KIRP	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.68	9.84	0.53	1.82e-19	Dupuytren's disease;
KIRP	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.48	0.62	4.97e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.96	12.69	0.63	1.04e-28	Cognitive function;
KIRP	cis	rs3026101	0.578	rs1806237	chr17:5295399	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs10465746	0.570	rs1886769	chr1:84471134	C/A	cg10977910	chr1:84465055	TTLL7	0.46	5.6	0.34	5.6e-8	Obesity-related traits;
KIRP	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg15488143	chr7:128924101	AHCYL2	0.6	6.51	0.38	4.14e-10	White matter hyperintensity burden;
KIRP	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.5	6.54	0.39	3.47e-10	Height;
KIRP	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.57	-7.61	-0.44	6e-13	Alcohol dependence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13609937	chr9:133588314	ABL1	0.48	6.17	0.37	2.76e-9	Parkinson's disease;
KIRP	cis	rs1978968	0.731	rs9605466	chr22:18461056	A/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.8	-11.35	-0.59	2.7e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.29	0.42	4.17e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg25554036	chr4:6271136	WFS1	0.4	5.68	0.34	3.74e-8	Cisplatin-induced ototoxicity;
KIRP	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg21253087	chr9:139290292	SNAPC4	0.38	4.96	0.3	1.29e-6	Monocyte percentage of white cells;
KIRP	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-5.04	-0.31	9e-7	Neuroticism;
KIRP	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg07777115	chr5:623756	CEP72	-0.59	-5.99	-0.36	7.57e-9	Obesity-related traits;
KIRP	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.32	0.47	6.05e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg10189774	chr4:17578691	LAP3	0.41	5.1	0.31	6.9e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.73	7.47	0.43	1.43e-12	Prostate cancer;
KIRP	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs745821	0.879	rs58000211	chr18:48138375	A/G	cg18923635	chr18:48083994	NA	0.43	5.03	0.31	9.47e-7	Diastolic blood pressure;
KIRP	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg16486109	chr11:613632	IRF7	0.44	5.21	0.32	3.99e-7	Systemic lupus erythematosus;
KIRP	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21643547	chr1:205240462	TMCC2	-0.7	-10.31	-0.55	5.81e-21	Red blood cell count;
KIRP	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	ch.8.33884649F	chr8:33765107	NA	0.55	7.1	0.41	1.37e-11	Body mass index;
KIRP	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg08822215	chr16:89438651	ANKRD11	-0.46	-5.63	-0.34	5.02e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-5.28	-0.32	2.85e-7	Asthma;
KIRP	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	12.03	0.61	1.6e-26	Menopause (age at onset);
KIRP	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg27205649	chr11:78285834	NARS2	0.67	7.26	0.42	5.14e-12	Alzheimer's disease (survival time);
KIRP	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg14345882	chr6:26364793	BTN3A2	0.55	4.97	0.3	1.26e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6450176	1.000	rs12521454	chr5:53297304	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.33	-0.59	3.2e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.68	-0.34	3.83e-8	Metabolite levels;
KIRP	cis	rs330048	0.525	rs10112237	chr8:9072729	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.5	-0.38	4.37e-10	Systemic lupus erythematosus;
KIRP	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07685180	chr8:600429	NA	0.66	4.86	0.3	2.06e-6	IgG glycosylation;
KIRP	cis	rs9828933	0.752	rs12633353	chr3:63970280	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.75	-5.34	-0.32	2.15e-7	Type 2 diabetes;
KIRP	cis	rs78487399	1.000	rs79611878	chr2:43844803	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.09	-0.31	7.23e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00414306	chr2:172779015	HAT1	0.53	6.9	0.4	4.43e-11	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12762517	chr3:51975968	PARP3;RRP9	0.45	6.03	0.36	5.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg26827852	chr1:89887630	LOC400759	-0.36	-4.84	-0.3	2.25e-6	Carotid intima media thickness;
KIRP	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg00277334	chr10:82204260	NA	0.44	5.03	0.31	9.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg21252483	chr19:49399788	TULP2	-0.47	-6.19	-0.37	2.5e-9	Red cell distribution width;
KIRP	cis	rs13401104	0.796	rs61160252	chr2:237119074	A/G	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7534824	0.625	rs17448356	chr1:101345093	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.71	0.34	3.31e-8	Refractive astigmatism;
KIRP	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs7246657	0.722	rs4802029	chr19:38055612	A/T	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.6	-0.44	6.2800000000000005e-13	Pulmonary function;
KIRP	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.64	-9.65	-0.52	6.91e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.73e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6142102	0.961	rs2377957	chr20:32554473	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	6.0	0.36	7.04e-9	Skin pigmentation;
KIRP	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg20701182	chr2:24300061	SF3B14	0.49	5.08	0.31	7.48e-7	Asthma;
KIRP	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.42	0.43	1.95e-12	Coronary artery disease;
KIRP	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05220968	chr6:146057943	EPM2A	-0.44	-5.71	-0.34	3.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg19849509	chr2:175204996	NA	-0.54	-6.33	-0.37	1.17e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4742903	0.509	rs12377116	chr9:106959243	A/G	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	2.04e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	8.12	0.46	2.22e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22455342	chr2:225449267	CUL3	0.5	5.73	0.34	2.85e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.01	0.36	6.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.83	-12.62	-0.63	1.72e-28	Height;
KIRP	cis	rs1832871	0.711	rs9459946	chr6:158707957	T/C	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs4919044	0.641	rs56112656	chr10:94678966	A/G	cg05127821	chr10:94822908	CYP26C1	-0.9	-7.0	-0.41	2.36e-11	Coronary artery disease;
KIRP	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg25174290	chr11:3078921	CARS	-0.69	-8.98	-0.5	7.09e-17	Calcium levels;
KIRP	cis	rs58785573	0.513	rs6531649	chr4:38592245	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.88	0.3	1.95e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs8060686	0.516	rs1971546	chr16:68280893	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-7.64	-0.44	4.92e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.51	-6.1	-0.36	4.05e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06544989	chr22:39130855	UNC84B	0.46	6.71	0.39	1.32e-10	Menopause (age at onset);
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg00772714	chr1:15479360	TMEM51;C1orf126	-0.41	-6.04	-0.36	5.69e-9	Metabolite levels (MHPG);
KIRP	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	10.11	0.54	2.51e-20	Coffee consumption (cups per day);
KIRP	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg00012203	chr2:219082015	ARPC2	0.82	11.66	0.6	2.68e-25	Colorectal cancer;
KIRP	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg01620082	chr3:125678407	NA	-1.02	-6.59	-0.39	2.65e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs42648	0.869	rs3810891	chr7:89908851	A/G	cg25739043	chr7:89950458	NA	-0.47	-7.48	-0.43	1.28e-12	Homocysteine levels;
KIRP	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg26898376	chr11:64110657	CCDC88B	0.58	4.92	0.3	1.59e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.5	-0.33	9.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg07395648	chr5:131743802	NA	-0.35	-4.88	-0.3	1.89e-6	Blood metabolite levels;
KIRP	cis	rs4889855	0.614	rs7209676	chr17:78500751	T/C	cg16591659	chr17:78472290	NA	-0.47	-6.97	-0.41	2.98e-11	Fractional excretion of uric acid;
KIRP	cis	rs60154123	0.772	rs628908	chr1:210428002	C/T	cg06375148	chr1:209958343	C1orf74	0.62	4.87	0.3	2e-6	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05863116	chr5:133562407	PPP2CA	0.46	6.48	0.38	4.86e-10	Survival in pancreatic cancer;
KIRP	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.42	5.42	0.33	1.4e-7	Gout;
KIRP	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.77	12.58	0.63	2.39e-28	Vitiligo;
KIRP	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg25173405	chr17:45401733	C17orf57	-0.4	-5.22	-0.32	3.86e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg03959625	chr15:84868606	LOC388152	0.59	6.69	0.39	1.49e-10	Schizophrenia;
KIRP	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg11031976	chr2:198649780	BOLL	-0.55	-5.41	-0.33	1.52e-7	Ulcerative colitis;
KIRP	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.5	-0.33	9.73e-8	Bipolar disorder;
KIRP	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.23	-0.42	6.24e-12	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg08313168	chr12:7315531	NA	0.69	6.29	0.37	1.48e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6450176	0.564	rs34360866	chr5:53332737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-8.71	-0.49	4.54e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.28	27.41	0.87	9.9e-77	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12871990	chr3:88199156	C3orf38	0.5	6.14	0.36	3.2e-9	Parkinson's disease;
KIRP	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg13409248	chr3:40428643	ENTPD3	0.4	5.3	0.32	2.57e-7	Renal cell carcinoma;
KIRP	cis	rs8113308	0.810	rs11881650	chr19:52450139	A/C	cg25782003	chr19:52490127	ZNF350	-0.54	-5.11	-0.31	6.44e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.73	6.46	0.38	5.44e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.61	-6.75	-0.4	1.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs42648	0.564	rs6465248	chr7:89824740	C/T	cg25739043	chr7:89950458	NA	-0.39	-6.05	-0.36	5.4e-9	Homocysteine levels;
KIRP	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.06	-7.76	-0.44	2.27e-13	Mitochondrial DNA levels;
KIRP	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07944736	chr1:28908226	SNHG12;SNORA44;SNORA16A	0.49	6.11	0.36	3.94e-9	Parkinson's disease;
KIRP	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg18225595	chr11:63971243	STIP1	0.66	5.61	0.34	5.54e-8	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18967534	chr4:2795345	SH3BP2	0.52	6.27	0.37	1.62e-9	Parkinson's disease;
KIRP	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg04998671	chr14:104000505	TRMT61A	-0.53	-6.0	-0.36	6.94e-9	Coronary artery disease;
KIRP	cis	rs631288	0.557	rs7546434	chr1:146676339	A/G	cg25205988	chr1:146714368	CHD1L	0.91	5.99	0.36	7.51e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg12131826	chr15:77904385	NA	-0.45	-5.69	-0.34	3.62e-8	Type 2 diabetes;
KIRP	trans	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.37	0.47	4.51e-15	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.45	5.8	0.35	2.06e-8	Hypertriglyceridemia;
KIRP	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg13180566	chr4:1052158	NA	-0.53	-5.38	-0.32	1.76e-7	Recombination rate (females);
KIRP	trans	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg04702396	chr17:15466718	FAM18B2	0.53	6.74	0.39	1.15e-10	Educational attainment (years of education);
KIRP	cis	rs7538876	0.903	rs6681150	chr1:17750685	G/A	cg07965774	chr1:17746286	RCC2	0.29	5.05	0.31	8.53e-7	Basal cell carcinoma;
KIRP	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg25039879	chr17:56429692	SUPT4H1	0.57	5.11	0.31	6.58e-7	Cognitive test performance;
KIRP	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.32	0.42	3.44e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1983891	0.742	rs9367109	chr6:41562530	A/G	cg20194872	chr6:41519635	FOXP4	0.43	5.48	0.33	1.05e-7	Prostate cancer;
KIRP	cis	rs737693	0.915	rs28381684	chr11:102737192	A/T	cg19620758	chr11:102826565	MMP13	0.69	5.53	0.33	8.08e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04773262	chr15:43210848	TTBK2	-0.43	-6.51	-0.38	4.12e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg01620082	chr3:125678407	NA	-1.15	-7.4	-0.43	2.14e-12	Depression;
KIRP	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.49	0.38	4.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.97	-14.96	-0.69	2.08e-36	Height;
KIRP	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg03887218	chr1:16534349	ARHGEF19	-0.6	-7.85	-0.45	1.31e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12195984	chr10:13203598	MCM10	0.49	6.16	0.37	2.9e-9	Parkinson's disease;
KIRP	cis	rs72925845	0.577	rs691061	chr17:76429847	C/T	cg03830375	chr17:76426088	DNAH17	0.5	5.14	0.31	5.61e-7	Triglycerides;
KIRP	cis	rs7312774	0.618	rs7304621	chr12:107325888	C/T	cg16260113	chr12:107380972	MTERFD3	0.77	6.81	0.4	7.58e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg05973401	chr12:123451056	ABCB9	0.59	6.94	0.4	3.44e-11	Neutrophil percentage of white cells;
KIRP	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.34	0.42	3.1e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4073221	0.725	rs35161320	chr3:18279526	C/A	cg07694806	chr3:18168406	NA	-0.65	-5.9	-0.35	1.2e-8	Parkinson's disease;
KIRP	cis	rs2591576	0.577	rs248546	chr5:165390149	A/T	cg13976338	chr5:165423657	NA	-0.76	-11.5	-0.59	8.98e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.76	-0.34	2.52e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6662572	0.737	rs6674105	chr1:46301379	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	5.57	0.33	6.73e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.44	5.69	0.34	3.69e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.64	5.55	0.33	7.55e-8	Initial pursuit acceleration;
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.43	5.75	0.34	2.63e-8	Testicular germ cell tumor;
KIRP	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.26	0.32	3.15e-7	Rheumatoid arthritis;
KIRP	cis	rs11955175	1.000	rs73080591	chr5:40634687	T/C	cg05478818	chr5:40835740	RPL37	0.69	5.42	0.33	1.41e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2671245	0.513	rs6667315	chr1:56138345	T/C	cg11523071	chr1:56160889	NA	0.41	6.32	0.37	1.2e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg09455208	chr3:40491958	NA	0.39	6.58	0.39	2.87e-10	Renal cell carcinoma;
KIRP	cis	rs220324	0.683	rs469114	chr21:43590243	G/A	cg08841829	chr21:43638893	ABCG1	0.46	5.39	0.32	1.67e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.77	8.69	0.48	5.16e-16	Corneal astigmatism;
KIRP	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.45	5.87	0.35	1.41e-8	Crohn's disease;
KIRP	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.47	7.17	0.42	8.79e-12	Total body bone mineral density;
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg09695851	chr17:3907499	NA	0.6	8.54	0.48	1.46e-15	Type 2 diabetes;
KIRP	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	0.83	7.58	0.44	7.14e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2808510	0.521	rs4427435	chr1:200421466	A/G	cg10889502	chr1:200398670	NA	-0.31	-4.87	-0.3	2e-6	Myopia;
KIRP	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.73	-8.76	-0.49	3.13e-16	Breast size;
KIRP	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg21573476	chr21:45109991	RRP1B	-0.64	-8.7	-0.48	4.98e-16	Mean corpuscular volume;
KIRP	trans	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.92	0.4	3.81e-11	Breast cancer;
KIRP	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg17724175	chr1:150552817	MCL1	0.32	5.33	0.32	2.25e-7	Melanoma;
KIRP	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-12.15	-0.61	6.48e-27	Vitiligo;
KIRP	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg08761264	chr16:28874980	SH2B1	0.46	5.04	0.31	9.07e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg26784012	chr10:32216390	ARHGAP12	0.3	4.85	0.3	2.18e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg15488143	chr7:128924101	AHCYL2	0.59	6.42	0.38	6.96e-10	White matter hyperintensity burden;
KIRP	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.5	-6.48	-0.38	5.1e-10	Menopause (age at onset);
KIRP	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.45	8.73	0.49	3.97e-16	Educational attainment (years of education);
KIRP	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg19507638	chr5:93509721	C5orf36	-0.54	-5.13	-0.31	5.8e-7	Diabetic retinopathy;
KIRP	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg15038512	chr6:170123185	PHF10	0.49	5.55	0.33	7.45e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg11569703	chr11:65557185	OVOL1	0.73	14.09	0.67	1.89e-33	Acne (severe);
KIRP	cis	rs9886651	0.935	rs4524749	chr8:128805447	G/A	cg24514600	chr8:128805414	PVT1	-0.74	-12.65	-0.63	1.41e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs6589219	1.000	rs6589219	chr11:111172911	G/C	cg25129781	chr11:111156908	C11orf53	-0.47	-5.97	-0.36	8.39e-9	Colorectal cancer;
KIRP	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	1.1	17.86	0.75	2.61e-46	Cognitive function;
KIRP	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.58	8.59	0.48	1.01e-15	Bone mineral density;
KIRP	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg03684893	chr10:554711	DIP2C	-0.35	-4.99	-0.3	1.17e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.16	-21.52	-0.81	1.77e-58	Exhaled nitric oxide output;
KIRP	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.54	-7.65	-0.44	4.44e-13	Prostate cancer;
KIRP	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.09	-17.87	-0.75	2.36e-46	Schizophrenia;
KIRP	trans	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg06521331	chr12:34319734	NA	0.5	6.48	0.38	5.02e-10	Morning vs. evening chronotype;
KIRP	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.77	9.29	0.51	8.52e-18	Response to antipsychotic treatment;
KIRP	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg27490568	chr2:178487706	NA	0.7	8.55	0.48	1.3e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg08999081	chr20:33150536	PIGU	-0.4	-5.18	-0.31	4.53e-7	Height;
KIRP	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.76	-0.44	2.29e-13	Total cholesterol levels;
KIRP	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.44	-0.33	1.31e-7	Breast cancer;
KIRP	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.72	0.34	3.11e-8	Personality dimensions;
KIRP	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.43	5.4	0.33	1.59e-7	Melanoma;
KIRP	cis	rs35740288	0.770	rs11630112	chr15:86120246	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.49	-0.33	9.86e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg13165212	chr22:42675999	NA	-0.37	-6.22	-0.37	2.15e-9	Cognitive function;
KIRP	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.87	12.12	0.61	8.36e-27	Breast cancer;
KIRP	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg18225595	chr11:63971243	STIP1	0.65	5.94	0.35	9.93e-9	Mean platelet volume;
KIRP	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg27129171	chr3:47204927	SETD2	-0.62	-7.68	-0.44	3.67e-13	Colorectal cancer;
KIRP	cis	rs2411233	1.000	rs2411235	chr15:39275321	A/G	cg02291532	chr15:39874776	THBS1	-0.36	-4.89	-0.3	1.8e-6	Platelet count;
KIRP	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-6.05	-0.36	5.28e-9	Educational attainment;
KIRP	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg09029085	chr17:47094198	IGF2BP1	0.24	5.6	0.34	5.63e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg11702503	chr19:6215254	MLLT1	-0.45	-6.17	-0.37	2.75e-9	Bladder cancer;
KIRP	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	cg12689670	chr1:183009347	LAMC1	0.56	7.9	0.45	9.42e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs4363385	0.510	rs61811886	chr1:153035743	G/A	cg07796016	chr1:152779584	LCE1C	-0.5	-6.27	-0.37	1.57e-9	Inflammatory skin disease;
KIRP	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	1.18	14.47	0.68	9.22e-35	Type 2 diabetes nephropathy;
KIRP	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg08917208	chr2:24149416	ATAD2B	-0.63	-5.37	-0.32	1.86e-7	Lymphocyte counts;
KIRP	cis	rs1345301	1.000	rs13431601	chr2:102873713	G/A	cg12451869	chr2:102867685	NA	0.39	5.75	0.34	2.7e-8	Waist circumference;
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg21851534	chr17:3907994	ZZEF1	0.7	11.54	0.59	6.79e-25	Type 2 diabetes;
KIRP	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg07148914	chr20:33460835	GGT7	-0.54	-7.48	-0.43	1.32e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs72960926	0.744	rs72967299	chr6:75034041	C/T	cg03266952	chr6:74778945	NA	-0.7	-5.22	-0.32	3.76e-7	Metabolite levels (MHPG);
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.83	9.21	0.51	1.44e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	trans	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg00800038	chr16:89945340	TCF25	-0.89	-7.26	-0.42	4.94e-12	Skin colour saturation;
KIRP	cis	rs4780401	0.588	rs8191298	chr16:11767055	C/A	cg01061890	chr16:11836724	TXNDC11	-0.42	-4.86	-0.3	2.05e-6	Rheumatoid arthritis;
KIRP	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	10.01	0.54	5.4e-20	Caffeine consumption;
KIRP	cis	rs2274273	0.624	rs11848575	chr14:55755788	A/G	cg04306507	chr14:55594613	LGALS3	0.38	5.25	0.32	3.29e-7	Protein biomarker;
KIRP	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg08847533	chr14:75593920	NEK9	-0.49	-5.79	-0.35	2.12e-8	IgG glycosylation;
KIRP	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.47	-0.48	2.24e-15	Colorectal cancer;
KIRP	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.27	-0.42	4.63e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13397067	chr3:13521642	HDAC11	0.51	6.39	0.38	8.38e-10	Parkinson's disease;
KIRP	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.46	-5.75	-0.34	2.57e-8	Iron status biomarkers;
KIRP	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.58	8.02	0.46	4.26e-14	Height;
KIRP	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg05991184	chr2:219186017	PNKD	0.36	5.06	0.31	8.39e-7	Colorectal cancer;
KIRP	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	7.2	0.42	7.35e-12	Mean platelet volume;
KIRP	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-13.23	-0.64	1.6e-30	Tonsillectomy;
KIRP	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.49	5.14	0.31	5.57e-7	Alzheimer's disease;
KIRP	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.52	-6.47	-0.38	5.18e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2279817	0.735	rs71644063	chr1:17987274	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.98	-0.45	5.71e-14	Neuroticism;
KIRP	cis	rs4704187	0.687	rs4235683	chr5:74415088	T/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.71	10.01	0.54	5.21e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10308265	chr17:42290028	UBTF	0.42	5.04	0.31	9.09e-7	Total body bone mineral density;
KIRP	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg04132472	chr17:19861366	AKAP10	0.39	5.0	0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs7129556	0.954	rs10899387	chr11:77276188	C/T	cg12586386	chr11:77299805	AQP11	0.47	6.24	0.37	1.92e-9	Weight loss (gastric bypass surgery);
KIRP	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-7.19	-0.42	7.6e-12	Coffee consumption (cups per day);
KIRP	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg19338460	chr6:170058176	WDR27	-0.72	-8.06	-0.46	3.33e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg01411142	chr8:19674711	INTS10	0.5	5.43	0.33	1.38e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.71	8.99	0.5	6.7e-17	Platelet count;
KIRP	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg16589663	chr20:23618590	CST3	0.73	6.92	0.4	3.79e-11	Chronic kidney disease;
KIRP	cis	rs939574	0.722	rs115402093	chr2:220096128	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.78	5.34	0.32	2.08e-7	Platelet distribution width;
KIRP	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.58e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs2554380	0.943	rs1477593	chr15:84363045	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-9.02	-0.5	5.41e-17	Height;
KIRP	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.06	-0.54	3.7799999999999997e-20	Hemoglobin concentration;
KIRP	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.98	10.01	0.54	5.1e-20	Eosinophilic esophagitis;
KIRP	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg12620499	chr2:216877984	MREG	0.65	8.18	0.46	1.56e-14	Alcohol dependence;
KIRP	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg07636037	chr3:49044803	WDR6	0.45	5.42	0.33	1.44e-7	Resting heart rate;
KIRP	cis	rs7770628	0.622	rs1965091	chr6:161120648	G/A	cg14663533	chr6:160955178	LPA	0.43	5.81	0.35	1.89e-8	Protein quantitative trait loci;Lipoprotein (a) levels;
KIRP	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg00852783	chr1:26633632	UBXN11	0.53	7.66	0.44	4.17e-13	Obesity-related traits;
KIRP	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.75	0.34	2.59e-8	Menopause (age at onset);
KIRP	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.8	12.11	0.61	8.84e-27	Retinal vascular caliber;
KIRP	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.87	12.98	0.64	1.11e-29	Coronary artery disease;
KIRP	cis	rs997295	0.713	rs12904982	chr15:68006279	T/C	cg24579218	chr15:68104479	NA	0.36	5.05	0.31	8.48e-7	Motion sickness;
KIRP	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.33	5.32	0.32	2.3e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18252515	chr7:66147081	NA	-0.42	-4.9	-0.3	1.76e-6	Calcium levels;
KIRP	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs13102973	0.965	rs28874134	chr4:135867088	C/A	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.5	0.43	1.17e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2708977	0.665	rs1081717	chr2:96978317	G/C	cg01950434	chr2:97203154	ARID5A	-0.54	-5.68	-0.34	3.74e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.71	9.02	0.5	5.63e-17	Longevity;
KIRP	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.71	-0.34	3.19e-8	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11079354	chr6:27740361	NA	0.55	6.95	0.41	3.21e-11	Smoking initiation;
KIRP	cis	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.76	8.77	0.49	3.04e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs7267005	0.661	rs78098129	chr20:34396239	T/A	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9398803	0.865	rs2184967	chr6:126773487	C/T	cg19875578	chr6:126661172	C6orf173	0.51	6.63	0.39	2.1e-10	Male-pattern baldness;
KIRP	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-6.41	-0.38	7.26e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-7.05	-0.41	1.85e-11	Aortic root size;
KIRP	cis	rs60154123	0.730	rs4844989	chr1:210460086	C/T	cg09074223	chr1:210466472	NA	0.58	5.74	0.34	2.75e-8	Coronary artery disease;
KIRP	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.5	-6.45	-0.38	5.75e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg25797454	chr6:150327115	RAET1K	0.37	6.9	0.4	4.5e-11	Alopecia areata;
KIRP	cis	rs9513593	1.000	rs7325957	chr13:99965155	C/T	cg21788972	chr13:99853209	UBAC2	-0.57	-6.06	-0.36	4.97e-9	Psoriasis;
KIRP	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.37	-5.46	-0.33	1.16e-7	Coronary artery disease;
KIRP	cis	rs9381107	1.000	rs9381107	chr6:9469238	G/A	cg14735645	chr6:9486422	NA	-0.47	-6.01	-0.36	6.58e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1524927	0.966	rs2140742	chr7:96364115	G/A	cg00227355	chr7:96336147	SHFM1	-0.32	-4.87	-0.3	2.01e-6	Total body bone mineral density;
KIRP	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	7.52	0.43	1.02e-12	Mood instability;
KIRP	cis	rs7646881	0.812	rs79303235	chr3:158444793	C/T	cg19483011	chr3:158453295	NA	-0.53	-5.43	-0.33	1.33e-7	Tetralogy of Fallot;
KIRP	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg09873164	chr1:152488093	CRCT1	0.57	7.16	0.42	9.32e-12	Hair morphology;
KIRP	cis	rs1050631	0.564	rs1785934	chr18:33718326	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.8	-6.57	-0.39	2.9e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.01	-0.45	4.59e-14	Neuroticism;
KIRP	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.51	0.59	8.52e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19294448	chr17:6900799	ALOX12	-0.36	-4.98	-0.3	1.17e-6	Tonsillectomy;
KIRP	cis	rs988913	1.000	rs9370342	chr6:54820670	C/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.56	-0.33	6.84e-8	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.27	-0.32	2.93e-7	Life satisfaction;
KIRP	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs13108043	0.605	rs13136465	chr4:87958822	G/T	cg11209507	chr4:87813803	C4orf36	0.47	4.97	0.3	1.27e-6	Red blood cell count;
KIRP	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg00204512	chr16:28754710	NA	0.49	6.36	0.38	9.92e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs981844	0.796	rs11099904	chr4:154681861	A/G	cg14289246	chr4:154710475	SFRP2	0.54	6.71	0.39	1.3e-10	Response to statins (LDL cholesterol change);
KIRP	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.78	10.8	0.57	1.61e-22	Prostate cancer;
KIRP	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	10.99	0.57	4.05e-23	Exhaled nitric oxide levels;
KIRP	cis	rs11955398	0.585	rs930864	chr5:60021688	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20364594	chr6:158981615	TMEM181	-0.45	-6.3	-0.37	1.39e-9	Myopia;
KIRP	cis	rs31771	0.692	rs31730	chr5:165467624	T/C	cg13976338	chr5:165423657	NA	-0.54	-5.4	-0.33	1.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg21605333	chr4:119757512	SEC24D	1.48	9.55	0.52	1.36e-18	Cannabis dependence symptom count;
KIRP	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg22426938	chr7:1423890	NA	-0.49	-5.19	-0.31	4.34e-7	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
KIRP	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg07001201	chr5:642380	CEP72	0.65	6.49	0.38	4.76e-10	Obesity-related traits;
KIRP	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.74	10.33	0.55	5.18e-21	Red blood cell count;
KIRP	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.78	-11.07	-0.58	2.23e-23	Height;
KIRP	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.5e-9	Schizophrenia;
KIRP	cis	rs6450176	0.564	rs391470	chr5:53332338	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-8.71	-0.49	4.54e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-7.31	-0.42	3.77e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6142102	0.961	rs4911146	chr20:32640047	C/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.64	0.39	1.99e-10	Skin pigmentation;
KIRP	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-16.0	-0.71	5.4e-40	Schizophrenia;
KIRP	cis	rs155346	0.625	rs2560714	chr5:139358307	A/G	cg24724630	chr5:139362307	NRG2	-0.38	-4.99	-0.3	1.15e-6	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs8113308	1.000	rs8104737	chr19:52441697	T/G	cg25782003	chr19:52490127	ZNF350	0.51	4.95	0.3	1.38e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs735539	0.598	rs2290144	chr13:21265658	C/G	cg27499820	chr13:21296301	IL17D	0.35	5.23	0.32	3.71e-7	Dental caries;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05333564	chr19:58898534	RPS5	0.49	6.13	0.36	3.39e-9	Parkinson's disease;
KIRP	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg20636351	chr8:55087400	NA	-0.65	-8.0	-0.45	5.03e-14	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12571005	chr2:202316370	STRADB;TRAK2	-0.49	-6.25	-0.37	1.78e-9	Myopia;
KIRP	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	1.07	14.93	0.69	2.49e-36	Alopecia areata;
KIRP	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg24579218	chr15:68104479	NA	-0.51	-7.39	-0.43	2.32e-12	Restless legs syndrome;
KIRP	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-9.39	-0.51	4.19e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17065868	1.000	rs9533893	chr13:45099865	A/C	cg10246903	chr13:45222710	NA	0.72	6.7	0.39	1.45e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg10360139	chr7:1886902	MAD1L1	-0.45	-5.05	-0.31	8.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7221595	0.825	rs9905748	chr17:3968639	C/T	cg11204139	chr17:3907470	NA	0.61	6.43	0.38	6.67e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.17	0.5	1.92e-17	Lymphocyte counts;
KIRP	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg05347473	chr6:146136440	FBXO30	0.5	7.18	0.42	8.29e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.09	0.69	7.04e-37	Lymphocyte percentage of white cells;
KIRP	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.26	26.19	0.86	4.3e-73	IgG glycosylation;
KIRP	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.73	9.15	0.5	2.25e-17	Aortic root size;
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.5	-0.48	1.79e-15	Life satisfaction;
KIRP	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.93	11.91	0.6	4.01e-26	Breast cancer;
KIRP	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.77	12.58	0.63	2.39e-28	Vitiligo;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21107223	chr15:75182455	MPI	0.49	7.09	0.41	1.42e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.63	10.01	0.54	5.38e-20	Lung function (FVC);
KIRP	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.3e-7	Bipolar disorder;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08018356	chr19:36706053	ZNF146;ZNF565	-0.45	-6.45	-0.38	5.76e-10	Metabolic traits;
KIRP	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7172677	0.737	rs6495158	chr15:75448813	A/G	cg14664628	chr15:75095509	CSK	-0.49	-5.36	-0.32	1.89e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11203032	0.831	rs10887924	chr10:90937247	C/T	cg16672925	chr10:90967113	CH25H	0.45	5.4	0.33	1.55e-7	Heart failure;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07682378	chr3:150128910	TSC22D2	0.67	6.39	0.38	8.23e-10	Lung function (FEV1);
KIRP	cis	rs57994353	0.568	rs3812581	chr9:139311471	C/T	cg21253087	chr9:139290292	SNAPC4	0.48	5.34	0.32	2.16e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg08662619	chr6:150070041	PCMT1	0.34	5.52	0.33	8.75e-8	Testicular germ cell tumor;
KIRP	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg02367723	chr1:46378857	MAST2	0.45	5.2	0.31	4.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05665937	chr4:1216051	CTBP1	0.55	7.64	0.44	4.86e-13	Obesity-related traits;
KIRP	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.6	-0.34	5.6e-8	Coronary artery disease;
KIRP	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg12573674	chr2:1569213	NA	-0.52	-5.03	-0.31	9.27e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg24110177	chr3:50126178	RBM5	-0.55	-6.59	-0.39	2.71e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg06647332	chr5:131281008	NA	0.48	5.24	0.32	3.48e-7	Life satisfaction;
KIRP	cis	rs72792276	1.000	rs72792276	chr5:127364126	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	5.58	0.34	6.32e-8	Red cell distribution width;
KIRP	trans	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.95	0.41	3.27e-11	Mean corpuscular volume;
KIRP	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.85	0.35	1.56e-8	Morning vs. evening chronotype;
KIRP	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg14092571	chr14:90743983	NA	0.4	4.86	0.3	2.09e-6	Mortality in heart failure;
KIRP	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.81	-8.54	-0.48	1.46e-15	Hair shape;
KIRP	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg19743168	chr1:23544995	NA	0.5	6.95	0.41	3.19e-11	Height;
KIRP	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.55	-7.24	-0.42	5.71e-12	Height;
KIRP	cis	rs6028335	0.674	rs57993460	chr20:37662068	C/A	cg16355469	chr20:37678765	NA	0.53	5.29	0.32	2.69e-7	Alcohol and nicotine co-dependence;
KIRP	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg17294928	chr15:75287854	SCAMP5	-0.64	-5.56	-0.33	7.09e-8	Lung cancer;
KIRP	cis	rs7534824	0.625	rs17610202	chr1:101429724	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.51	0.33	9.04e-8	Refractive astigmatism;
KIRP	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg06259664	chr16:537672	RAB11FIP3	-0.47	-5.14	-0.31	5.52e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.68	9.53	0.52	1.6e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs17065868	0.803	rs7320846	chr13:45196954	T/G	cg10246903	chr13:45222710	NA	0.55	5.89	0.35	1.25e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.7	9.19	0.51	1.71e-17	Huntington's disease progression;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg08600765	chr20:34638493	LOC647979	-0.72	-6.76	-0.4	9.97e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	1.09	8.1	0.46	2.61e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.24	13.65	0.66	5.98e-32	Uric acid levels;
KIRP	trans	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg15655154	chr3:113604241	GRAMD1C	-0.58	-8.05	-0.46	3.5e-14	Diastolic blood pressure;
KIRP	cis	rs2143950	0.831	rs80031420	chr14:35556121	G/A	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.0	-0.3	1.07e-6	Atopic dermatitis;
KIRP	cis	rs986417	0.551	rs1956553	chr14:60952298	T/A	cg27398547	chr14:60952738	C14orf39	0.73	7.28	0.42	4.38e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs17123764	0.748	rs55686423	chr12:49963534	A/T	cg02054252	chr12:50078554	FMNL3	0.49	5.16	0.31	5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1847505	0.609	rs1514541	chr13:61586096	C/G	cg25164009	chr13:61490935	NA	-0.8	-13.41	-0.65	3.83e-31	Polychlorinated biphenyl levels;
KIRP	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-5.61	-0.34	5.52e-8	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25857018	chr15:91260385	BLM	0.45	6.08	0.36	4.6e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg02462569	chr6:150064036	NUP43	-0.47	-6.9	-0.4	4.43e-11	Lung cancer;
KIRP	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg12940439	chr1:67600707	NA	0.43	6.45	0.38	5.88e-10	Psoriasis;
KIRP	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.54e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg22284058	chr8:142237359	SLC45A4	-0.47	-5.91	-0.35	1.14e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.71	8.37	0.47	4.42e-15	Coronary artery disease;
KIRP	cis	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07988820	chr12:82153109	PPFIA2	0.68	7.38	0.43	2.38e-12	Resting heart rate;
KIRP	cis	rs1847505	0.663	rs9539005	chr13:61587796	C/G	cg25164009	chr13:61490935	NA	-0.6	-7.22	-0.42	6.61e-12	Polychlorinated biphenyl levels;
KIRP	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg13798780	chr7:105162888	PUS7	0.65	5.89	0.35	1.26e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.51	-5.56	-0.33	6.98e-8	Blood pressure (smoking interaction);
KIRP	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.42	5.25	0.32	3.35e-7	Cardiac Troponin-T levels;
KIRP	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs8756	1.000	rs7968682	chr12:66371880	G/T	cg06712651	chr12:66351869	HMGA2	-0.76	-13.24	-0.65	1.44e-30	Height;
KIRP	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.95	12.42	0.62	8.31e-28	Menopause (age at onset);
KIRP	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg13206674	chr6:150067644	NUP43	0.59	8.24	0.46	1.04e-14	Lung cancer;
KIRP	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.72	9.17	0.5	1.9e-17	Coronary artery disease;
KIRP	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	1.22	9.78	0.53	2.68e-19	Prostate cancer;
KIRP	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg18306943	chr3:40428807	ENTPD3	0.42	5.82	0.35	1.86e-8	Renal cell carcinoma;
KIRP	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.59	7.35	0.42	2.99e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.88	-10.45	-0.55	2.19e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg13271783	chr10:134563150	INPP5A	-0.61	-7.81	-0.45	1.66e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.19	13.83	0.66	1.44e-32	Sexual dysfunction (female);
KIRP	cis	rs501120	0.657	rs114070077	chr10:44742911	A/G	cg09554077	chr10:44749378	NA	0.78	12.08	0.61	1.08e-26	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg16141378	chr3:129829833	LOC729375	-0.49	-6.9	-0.4	4.48e-11	Neuroticism;
KIRP	cis	rs4750440	0.706	rs11258770	chr10:14018910	G/T	cg27542038	chr10:14027202	FRMD4A	-0.54	-7.25	-0.42	5.39e-12	Adiponectin levels;
KIRP	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs4774830	0.590	rs62045214	chr15:56254537	C/T	cg05129572	chr15:56138634	NEDD4	0.67	4.93	0.3	1.49e-6	Delta-5 desaturase activity;
KIRP	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg17077180	chr1:38461687	NA	0.5	7.11	0.41	1.25e-11	Coronary artery disease;
KIRP	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-6.46	-0.38	5.52e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg05342945	chr12:48394962	COL2A1	0.48	4.93	0.3	1.52e-6	Lung cancer;
KIRP	cis	rs4409675	0.641	rs4908379	chr1:28273016	A/C	cg23691781	chr1:28212827	C1orf38	-0.26	-5.44	-0.33	1.29e-7	Corneal astigmatism;
KIRP	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	0.72	6.64	0.39	2e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9653442	0.545	rs11123813	chr2:100765692	C/T	cg17356467	chr2:100759845	AFF3	0.41	5.52	0.33	8.67e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4919044	0.808	rs10748590	chr10:94812426	A/T	cg05127821	chr10:94822908	CYP26C1	1.07	11.22	0.58	7.42e-24	Coronary artery disease;
KIRP	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg05865280	chr17:75406074	SEPT9	0.52	12.6	0.63	2.03e-28	Airflow obstruction;
KIRP	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg00852783	chr1:26633632	UBXN11	0.53	7.54	0.43	9.21e-13	Obesity-related traits;
KIRP	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.51	-0.33	9.2e-8	Ileal carcinoids;
KIRP	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.46	4.85	0.3	2.24e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg25039879	chr17:56429692	SUPT4H1	0.55	4.88	0.3	1.95e-6	Cognitive test performance;
KIRP	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg23594656	chr7:65796392	TPST1	-0.45	-7.48	-0.43	1.28e-12	Aortic root size;
KIRP	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg07701084	chr6:150067640	NUP43	0.51	5.46	0.33	1.17e-7	Lung cancer;
KIRP	cis	rs10128264	0.934	rs1250590	chr10:80983786	A/C	cg18737081	chr10:80999807	ZMIZ1	0.32	5.97	0.36	8.43e-9	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg15105011	chr4:940614	TMEM175	-0.33	-5.02	-0.3	9.82e-7	Systemic sclerosis;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg17518899	chr12:50017006	PRPF40B	0.51	6.23	0.37	2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7714584	1.000	rs13361189	chr5:150223387	A/G	cg22134413	chr5:150180641	NA	0.55	4.85	0.3	2.24e-6	Crohn's disease;
KIRP	cis	rs62413470	1.000	rs12190695	chr6:55943429	T/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg21434563	chr6:161413126	MAP3K4	0.52	6.6	0.39	2.52e-10	Colorectal cancer;
KIRP	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.86	-0.4	5.66e-11	Obesity-related traits;
KIRP	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.63	-8.32	-0.47	6.06e-15	Coronary artery disease;
KIRP	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg17356467	chr2:100759845	AFF3	0.54	5.48	0.33	1.07e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg02475777	chr4:1388615	CRIPAK	0.37	4.99	0.3	1.13e-6	Obesity-related traits;
KIRP	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.76	0.34	2.5e-8	Morning vs. evening chronotype;
KIRP	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.53	-0.38	3.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.13	-0.46	2.08e-14	Aortic root size;
KIRP	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.79	10.56	0.56	1e-21	Platelet count;
KIRP	cis	rs6058796	0.792	rs35938376	chr20:31270536	G/A	cg13636640	chr20:31349939	DNMT3B	0.59	5.12	0.31	6.29e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg16482183	chr6:26056742	HIST1H1C	0.65	7.21	0.42	6.99e-12	Iron status biomarkers;
KIRP	cis	rs8070740	0.838	rs57745425	chr17:5327528	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	6.33	0.37	1.17e-9	Menopause (age at onset);
KIRP	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs8018808	0.902	rs8006688	chr14:77926649	G/A	cg20045696	chr14:77926864	AHSA1	0.45	5.4	0.33	1.61e-7	Myeloid white cell count;
KIRP	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.47	-5.56	-0.33	6.93e-8	Glomerular filtration rate;
KIRP	cis	rs12130219	1.000	rs1552994	chr1:152171461	A/G	cg23107878	chr1:152161397	NA	-0.47	-5.19	-0.31	4.5e-7	Inflammatory skin disease;
KIRP	cis	rs7709377	0.547	rs1677415	chr5:115683658	T/G	cg23108291	chr5:115420582	COMMD10	-0.41	-4.84	-0.3	2.25e-6	Metabolite levels  (X-11787);
KIRP	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.58	-5.61	-0.34	5.31e-8	Narcolepsy;
KIRP	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.92	9.48	0.52	2.27e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg10792982	chr14:105748885	BRF1	0.92	13.56	0.65	1.21e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.82	-0.4	7.18e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.39	-8.14	-0.46	2e-14	Body mass index;
KIRP	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg03929089	chr4:120376271	NA	-0.69	-6.94	-0.4	3.54e-11	Axial length;
KIRP	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.66	8.39	0.47	3.88e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs4650994	0.593	rs12735140	chr1:178544218	C/A	cg12486710	chr1:178512616	C1orf220	-0.24	-5.13	-0.31	5.93e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2273669	0.504	rs78662936	chr6:109449690	G/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.14	-0.31	5.53e-7	Prostate cancer;
KIRP	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg19743168	chr1:23544995	NA	0.52	7.32	0.42	3.45e-12	Height;
KIRP	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.74	6.51	0.38	4.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08813099	chr3:138067623	MRAS	0.61	8.2	0.46	1.34e-14	Parkinson's disease;
KIRP	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.43	6.96	0.41	3.03e-11	Renal cell carcinoma;
KIRP	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.75	9.23	0.51	1.32e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1116547	0.714	rs4705821	chr5:112773784	A/G	cg12552261	chr5:112820674	MCC	-0.48	-5.28	-0.32	2.87e-7	Cerebral amyloid angiopathy;
KIRP	cis	rs8033133	1.000	rs8033133	chr15:25350474	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.46	-5.37	-0.32	1.84e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.76	6.4	0.38	7.84e-10	Diabetic retinopathy;
KIRP	cis	rs364477	0.661	rs279903	chr9:962184	C/T	cg13952963	chr9:998547	NA	-0.55	-5.95	-0.35	9.08e-9	Major depressive disorder;
KIRP	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg15744005	chr10:104629667	AS3MT	0.31	6.31	0.37	1.3e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7674212	0.570	rs2069274	chr4:104020781	C/G	cg16532752	chr4:104119610	CENPE	-0.43	-5.2	-0.31	4.27e-7	Type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13384867	chr19:39663807	PAK4	0.49	6.04	0.36	5.52e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.52	-11.26	-0.58	5.57e-24	Refractive error;
KIRP	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.6	-0.44	6.19e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg21605333	chr4:119757512	SEC24D	1.66	10.42	0.55	2.7e-21	Cannabis dependence symptom count;
KIRP	cis	rs258892	0.895	rs13166571	chr5:72039858	A/G	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg00310523	chr12:86230176	RASSF9	0.39	6.06	0.36	5.11e-9	Major depressive disorder;
KIRP	cis	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.47	6.22	0.37	2.12e-9	Leprosy;
KIRP	cis	rs1950626	0.623	rs34603287	chr14:101433831	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.54	6.1	0.36	4.03e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.83	-13.23	-0.64	1.58e-30	Blood metabolite levels;
KIRP	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg24972876	chr7:65420302	NA	-0.37	-5.22	-0.32	3.84e-7	Aortic root size;
KIRP	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.46	-0.38	5.68e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4654899	1.000	rs7521675	chr1:21424070	T/C	cg05370193	chr1:21551575	ECE1	0.43	5.93	0.35	1.01e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.72	0.44	2.96e-13	Rheumatoid arthritis;
KIRP	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg04310649	chr10:35416472	CREM	-0.57	-6.94	-0.4	3.38e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	cis	rs35740288	0.731	rs12913556	chr15:86102196	C/T	cg10818794	chr15:86012489	AKAP13	-0.47	-5.55	-0.33	7.54e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg06795125	chr2:108905320	SULT1C2	-0.59	-10.4	-0.55	3.02e-21	Lobe size;
KIRP	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.64	8.1	0.46	2.59e-14	Type 2 diabetes;
KIRP	cis	rs1878931	0.580	rs7204571	chr16:3402444	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.84	12.1	0.61	9.11e-27	Body mass index (adult);
KIRP	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg02503808	chr4:7069936	GRPEL1	0.94	12.67	0.63	1.19e-28	Monocyte percentage of white cells;
KIRP	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.92	-12.3	-0.62	1.97e-27	Platelet distribution width;
KIRP	trans	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg08989290	chr16:615782	NHLRC4	0.4	5.84	0.35	1.66e-8	Height;
KIRP	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.69	-7.95	-0.45	6.56e-14	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg16599007	chr12:121647205	P2RX4	-0.41	-4.94	-0.3	1.47e-6	Mean corpuscular volume;
KIRP	trans	rs17079247	0.722	rs9602699	chr13:85809598	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.43	-0.38	6.53e-10	Bipolar disorder (mania);
KIRP	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2880765	0.546	rs35316253	chr15:86065560	T/C	cg10818794	chr15:86012489	AKAP13	-0.53	-7.04	-0.41	1.9e-11	Coronary artery disease;
KIRP	trans	rs1106684	0.925	rs11764266	chr7:131463005	G/A	cg13607082	chr12:122652224	LRRC43	-0.65	-6.65	-0.39	1.85e-10	Body mass index;
KIRP	cis	rs7712401	0.715	rs6862366	chr5:122360158	G/C	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09897338	chr1:211849090	NEK2	0.53	6.7	0.39	1.43e-10	Parkinson's disease;
KIRP	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.53	-6.28	-0.37	1.53e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg08392591	chr16:89556376	ANKRD11	0.46	6.04	0.36	5.63e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs684232	0.623	rs117314378	chr17:521672	C/T	cg12384639	chr17:618140	VPS53	0.49	5.99	0.36	7.27e-9	Prostate cancer;
KIRP	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.09	-0.36	4.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.75	10.83	0.57	1.35e-22	Bladder cancer;
KIRP	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.73	-10.35	-0.55	4.39e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.36	5.19	0.31	4.33e-7	Calcium levels;
KIRP	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs2150410	0.915	rs718225	chr21:40652616	C/G	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.81	14.97	0.69	1.8e-36	Lymphocyte counts;
KIRP	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.61	-7.57	-0.43	7.44e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs17101923	0.951	rs1460123	chr12:66322322	C/A	cg06712651	chr12:66351869	HMGA2	-0.58	-6.6	-0.39	2.57e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg18209359	chr17:80159595	CCDC57	0.41	5.4	0.33	1.56e-7	Life satisfaction;
KIRP	cis	rs6681460	0.932	rs536410	chr1:67191084	C/T	cg13052034	chr1:66999238	SGIP1	0.38	5.39	0.32	1.67e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10521094	chr7:107262441	BCAP29	0.57	7.21	0.42	6.68e-12	Interleukin-4 levels;
KIRP	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg00405596	chr8:11794950	NA	0.47	5.73	0.34	2.94e-8	Monocyte count;
KIRP	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.77	9.17	0.5	1.95e-17	Adiposity;
KIRP	cis	rs35740288	0.721	rs11636347	chr15:86241233	A/G	cg17133734	chr15:86042851	AKAP13	-0.49	-5.34	-0.32	2.13e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	7.3	0.42	3.85e-12	Lung cancer;
KIRP	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.11	-0.46	2.44e-14	Idiopathic membranous nephropathy;
KIRP	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.47	-5.06	-0.31	8.08e-7	Subjective well-being;
KIRP	trans	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.28	-0.37	1.54e-9	Neuroticism;
KIRP	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg10434728	chr15:90938212	IQGAP1	0.44	7.58	0.44	7.13e-13	Rheumatoid arthritis;
KIRP	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.58	-0.52	1.09e-18	Response to antipsychotic treatment;
KIRP	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2685295	0.509	rs10925504	chr1:237904870	C/T	cg27157575	chr19:1164145	SBNO2	-0.49	-6.1	-0.36	4.05e-9	Bipolar disorder and eating disorder;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg09699651	chr6:150184138	LRP11	0.48	6.39	0.38	8.13e-10	Lung cancer;
KIRP	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06544989	chr22:39130855	UNC84B	0.46	7.79	0.44	1.83e-13	Menopause (age at onset);
KIRP	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.7	0.34	3.43e-8	Educational attainment;
KIRP	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1971762	0.527	rs7972401	chr12:53940046	T/C	cg16917193	chr12:54089295	NA	0.66	10.62	0.56	6.15e-22	Height;
KIRP	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg00405596	chr8:11794950	NA	-0.47	-5.96	-0.36	8.63e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs300890	1.000	rs300893	chr4:144257116	C/T	cg19876092	chr4:144208277	NA	0.44	7.24	0.42	5.76e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.56	0.39	3.18e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.57	0.43	7.41e-13	Aortic root size;
KIRP	cis	rs6450176	0.909	rs6898870	chr5:53293107	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-10.96	-0.57	5.05e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs4664293	0.967	rs13397722	chr2:160515651	G/A	cg08347373	chr2:160653686	CD302	-0.42	-6.07	-0.36	4.73e-9	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-5.49	-0.33	1.01e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.47	-0.38	5.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19171272	chr22:38449367	NA	-0.59	-8.8	-0.49	2.41e-16	Glioblastoma;Glioma;
KIRP	cis	rs2371030	0.833	rs13000743	chr2:211571015	G/A	cg18417063	chr2:211583084	NA	-0.48	-6.55	-0.39	3.26e-10	Non-small cell lung cancer;
KIRP	cis	rs4523957	0.583	rs7225168	chr17:2023089	T/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-8.19	-0.46	1.43e-14	Resting heart rate;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04554905	chr3:172428857	NCEH1	0.53	6.12	0.36	3.76e-9	Smoking initiation;
KIRP	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg17279839	chr7:150038598	RARRES2	0.52	6.5	0.38	4.47e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs13385	0.769	rs10477333	chr5:139617885	T/C	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs4262150	0.693	rs4304124	chr5:152260774	A/C	cg12297329	chr5:152029980	NA	0.45	6.3	0.37	1.37e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.54	0.7	2.16e-38	Headache;
KIRP	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.41	5.12	0.31	6.09e-7	Height;
KIRP	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.82	-0.49	2.13e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4704187	0.640	rs1600075	chr5:74418304	G/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs981844	0.961	rs56148270	chr4:154660874	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs12580194	0.593	rs55637917	chr12:55747565	T/C	cg11794356	chr12:55725991	OR6C3	-0.54	-7.16	-0.42	9.29e-12	Cancer;
KIRP	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.56	-0.56	9.73e-22	Height;
KIRP	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg11657440	chr19:46296263	DMWD	0.93	14.99	0.69	1.59e-36	Coronary artery disease;
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.44	6.16	0.37	2.87e-9	Lung cancer;
KIRP	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg21466736	chr12:48725269	NA	-0.44	-5.92	-0.35	1.1e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.92	9.87	0.53	1.4e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg21573476	chr21:45109991	RRP1B	0.58	8.02	0.46	4.23e-14	Mean corpuscular volume;
KIRP	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.89	0.45	9.61e-14	Lung cancer in ever smokers;
KIRP	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.14	0.41	1.06e-11	Height;
KIRP	cis	rs1461503	0.534	rs4293127	chr11:122804263	G/C	cg27398637	chr11:122830231	C11orf63	-0.56	-7.33	-0.42	3.3e-12	Menarche (age at onset);
KIRP	cis	rs76533333	0.646	rs71446627	chr13:113392773	G/A	cg04656015	chr13:113407548	ATP11A	0.66	5.85	0.35	1.59e-8	Red cell distribution width;
KIRP	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.48	5.87	0.35	1.42e-8	Common traits (Other);
KIRP	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.7	0.39	1.42e-10	Bipolar disorder;
KIRP	cis	rs4840086	1.000	rs9403051	chr6:100194846	A/G	cg08875094	chr6:100016130	CCNC	-0.42	-4.89	-0.3	1.82e-6	Menarche (age at onset);
KIRP	cis	rs7903847	0.667	rs3818787	chr10:99145179	T/C	cg20016023	chr10:99160130	RRP12	-0.4	-5.65	-0.34	4.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg17507749	chr15:85114479	UBE2QP1	0.82	9.21	0.51	1.51e-17	Schizophrenia;
KIRP	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.57	-6.04	-0.36	5.57e-9	DNA methylation (variation);
KIRP	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.75	6.74	0.4	1.09e-10	Cognitive function;
KIRP	cis	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg06360820	chr2:242988706	NA	-0.76	-6.66	-0.39	1.82e-10	Obesity-related traits;
KIRP	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.96	15.27	0.7	1.8e-37	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.95	16.33	0.72	4.11e-41	Menarche (age at onset);
KIRP	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.6	-9.42	-0.51	3.39e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.62	0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs9790314	0.582	rs11922752	chr3:160600599	G/C	cg19274270	chr17:78178856	CARD14	0.34	6.14	0.36	3.25e-9	Morning vs. evening chronotype;
KIRP	cis	rs74181299	0.890	rs2540950	chr2:65279223	C/T	cg05010058	chr2:65284262	CEP68	0.43	5.88	0.35	1.3e-8	Pulse pressure;
KIRP	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg08888203	chr3:10149979	C3orf24	0.5	5.3	0.32	2.55e-7	Alzheimer's disease;
KIRP	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.63	6.7	0.39	1.38e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.82	8.95	0.5	8.92e-17	Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05220968	chr6:146057943	EPM2A	-0.43	-5.44	-0.33	1.29e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg16751203	chr2:127950803	CYP27C1	0.38	4.95	0.3	1.37e-6	Protein C levels;
KIRP	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.47	-5.87	-0.35	1.42e-8	Blood metabolite levels;
KIRP	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.99	9.64	0.52	7.53e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.61	-7.14	-0.41	1.04e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs12724450	0.793	rs34609268	chr1:150477840	G/C	cg24207068	chr17:78865662	RPTOR	-0.77	-6.07	-0.36	4.7e-9	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.64e-11	Lung cancer;
KIRP	cis	rs17023223	0.537	rs7525871	chr1:119621894	T/C	cg05756136	chr1:119680316	WARS2	-0.55	-7.39	-0.43	2.22e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.54	7.23	0.42	5.99e-12	Response to temozolomide;
KIRP	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg10189261	chr14:101176105	NA	-0.49	-4.96	-0.3	1.34e-6	Plateletcrit;
KIRP	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.75	-10.47	-0.56	1.88e-21	Prostate cancer;
KIRP	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.6	7.42	0.43	1.94e-12	Obesity-related traits;
KIRP	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg18461458	chr19:21324796	ZNF431	0.48	4.99	0.3	1.16e-6	Pain;
KIRP	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.89	0.3	1.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6496044	0.963	rs11853972	chr15:86062440	A/G	cg17133734	chr15:86042851	AKAP13	-0.47	-5.51	-0.33	8.96e-8	Interstitial lung disease;
KIRP	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.24	6.39	0.38	8.08e-10	Crohn's disease;
KIRP	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg23166289	chr1:210001082	C1orf107	0.52	5.66	0.34	4.19e-8	Orofacial clefts;
KIRP	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1595825	1.000	rs74935794	chr2:198871195	T/G	cg00982548	chr2:198649783	BOLL	-0.5	-4.98	-0.3	1.18e-6	Ulcerative colitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27143049	chr11:14665558	PDE3B;PSMA1	-0.47	-6.98	-0.41	2.71e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs27434	0.583	rs34759	chr5:96153133	T/C	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.15e-8	Ankylosing spondylitis;
KIRP	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.0	-0.5	6.21e-17	Hemoglobin concentration;
KIRP	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.67	-7.49	-0.43	1.22e-12	Response to antineoplastic agents;
KIRP	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg00495681	chr13:53174319	NA	0.37	5.07	0.31	7.91e-7	Lewy body disease;
KIRP	cis	rs6662572	1.000	rs28433203	chr1:46196813	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	4.87	0.3	2e-6	Blood protein levels;
KIRP	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	1.05	15.28	0.7	1.65e-37	Cognitive function;
KIRP	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.64	-9.26	-0.51	1.04e-17	Educational attainment;
KIRP	cis	rs1318772	1.000	rs185336	chr5:112739836	T/C	cg12552261	chr5:112820674	MCC	0.77	4.97	0.3	1.24e-6	F-cell distribution;
KIRP	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg04691961	chr3:161091175	C3orf57	-0.61	-9.05	-0.5	4.38e-17	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.56	8.98	0.5	7e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs10940138	0.779	rs991123	chr5:67246171	G/A	ch.5.1281357F	chr5:67228439	NA	0.73	10.51	0.56	1.36e-21	Menarche (age at onset);
KIRP	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	7.83	0.45	1.42e-13	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07226193	chr11:9685651	SWAP70	0.48	6.09	0.36	4.25e-9	Parkinson's disease;
KIRP	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.79	10.36	0.55	4.03e-21	Eye color traits;
KIRP	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.44	-5.67	-0.34	4.05e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.81	-0.35	1.88e-8	IgG glycosylation;
KIRP	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.64	8.51	0.48	1.77e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.44	-5.36	-0.32	1.88e-7	Monocyte count;
KIRP	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg17764715	chr19:33622953	WDR88	0.78	11.41	0.59	1.7e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs4954585	0.708	rs10200263	chr2:137007429	C/T	cg05194412	chr2:137003533	NA	0.49	6.54	0.38	3.52e-10	Colorectal cancer;
KIRP	trans	rs7980799	0.935	rs10772076	chr12:33553574	A/C	cg26384229	chr12:38710491	ALG10B	-0.53	-6.64	-0.39	1.94e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.39	-4.86	-0.3	2.08e-6	Carotid intima media thickness;
KIRP	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg19847130	chr8:10466454	RP1L1	0.4	5.78	0.35	2.3e-8	Retinal vascular caliber;
KIRP	cis	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg06521331	chr12:34319734	NA	-0.62	-7.35	-0.42	2.94e-12	Morning vs. evening chronotype;
KIRP	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	6.45	0.38	5.84e-10	Iron status biomarkers;
KIRP	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg23307798	chr14:103986281	CKB	-0.51	-6.92	-0.4	3.86e-11	Coronary artery disease;
KIRP	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg06115741	chr20:33292138	TP53INP2	0.4	4.9	0.3	1.76e-6	Height;
KIRP	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg26668828	chr6:292823	DUSP22	-0.56	-6.61	-0.39	2.41e-10	Menopause (age at onset);
KIRP	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-8.32	-0.47	6.2e-15	Morning vs. evening chronotype;
KIRP	trans	rs62056376	0.736	rs885691	chr17:32641225	C/T	cg12726354	chr15:28342256	OCA2	-0.54	-6.36	-0.38	9.84e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9584850	0.874	rs9168	chr13:99101583	C/A	cg20750642	chr13:99100586	FARP1	-0.54	-6.4	-0.38	7.64e-10	Neuroticism;
KIRP	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg02175503	chr12:58329896	NA	-0.49	-5.52	-0.33	8.5e-8	Multiple sclerosis;
KIRP	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg02158880	chr13:53174818	NA	0.39	5.09	0.31	7.29e-7	Lewy body disease;
KIRP	cis	rs6102059	0.503	rs6513671	chr20:39176972	A/G	cg22477343	chr20:39312069	NA	0.4	5.13	0.31	5.84e-7	LDL cholesterol;
KIRP	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg25019722	chr6:37503610	NA	0.76	10.5	0.56	1.47e-21	Cognitive performance;
KIRP	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.3	0.37	1.4e-9	Red blood cell count;
KIRP	cis	rs7590368	0.926	rs12621237	chr2:10957538	T/C	cg15705551	chr2:10952987	PDIA6	0.49	5.47	0.33	1.09e-7	Educational attainment (years of education);
KIRP	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg05315796	chr3:52349193	DNAH1	0.42	6.45	0.38	5.77e-10	Bipolar disorder;
KIRP	cis	rs6800768	0.633	rs57903454	chr3:24092407	A/T	cg10674438	chr3:24145617	LOC152024	-0.44	-6.01	-0.36	6.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4523957	0.583	rs2760737	chr17:2024647	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-11.59	-0.59	4.65e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs2290159	0.948	rs73130305	chr3:12621075	C/T	cg23032965	chr3:12705835	RAF1	0.71	7.76	0.44	2.22e-13	Cholesterol, total;
KIRP	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.67	-0.44	4.09e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs524023	0.756	rs576076	chr11:64360623	G/A	cg09231725	chr11:64357281	SLC22A12	-0.62	-7.32	-0.42	3.55e-12	Urate levels in obese individuals;
KIRP	cis	rs4664293	0.867	rs2357529	chr2:160595433	C/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.31	0.42	3.78e-12	Height;
KIRP	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Colorectal cancer;
KIRP	cis	rs662064	0.852	rs616402	chr1:10566272	C/T	cg17425144	chr1:10567563	PEX14	-0.3	-4.92	-0.3	1.61e-6	Asthma;
KIRP	cis	rs2882667	0.931	rs1433009	chr5:138333784	G/A	cg04439458	chr5:138467593	SIL1	-0.44	-7.4	-0.43	2.12e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs654950	0.934	rs653369	chr1:42002376	A/T	cg06885757	chr1:42089581	HIVEP3	-0.65	-9.34	-0.51	6e-18	Airway imaging phenotypes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22252026	chr11:111167304	C11orf92	0.5	6.63	0.39	2.12e-10	Interleukin-4 levels;
KIRP	cis	rs6743226	0.901	rs7599888	chr2:242248033	C/G	cg10021735	chr2:242295487	FARP2	-0.46	-5.72	-0.34	3.05e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg19468946	chr17:37922297	IKZF3	-0.45	-6.58	-0.39	2.87e-10	Asthma;
KIRP	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.86	-11.63	-0.6	3.33e-25	Cognitive function;
KIRP	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.79	10.8	0.57	1.68e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12200782	0.872	rs41266837	chr6:26409729	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.52	-4.97	-0.3	1.23e-6	Small cell lung carcinoma;
KIRP	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg05044414	chr3:183734942	ABCC5	0.38	5.8	0.35	2.01e-8	Anterior chamber depth;
KIRP	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11673344	0.566	rs2385180	chr19:37922356	T/C	cg14683738	chr19:37701593	ZNF585B	0.45	5.2	0.31	4.29e-7	Obesity-related traits;
KIRP	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.54	7.1	0.41	1.37e-11	Response to temozolomide;
KIRP	cis	rs71636213	0.527	rs9293816	chr5:79664437	A/T	cg12576332	chr5:79646847	LOC441089	-0.39	-5.42	-0.33	1.41e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs13006833	0.668	rs906916	chr2:191166212	G/A	cg27211696	chr2:191398769	TMEM194B	0.37	5.28	0.32	2.82e-7	Urinary metabolites;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.52	-5.55	-0.33	7.25e-8	Neuroticism;
KIRP	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg18357526	chr6:26021779	HIST1H4A	0.39	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.73	8.2	0.46	1.31e-14	Smoking behavior;
KIRP	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg20731937	chr12:48336164	NA	0.41	5.3	0.32	2.58e-7	Longevity (90 years and older);
KIRP	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg07843065	chr1:150265600	MRPS21	0.47	6.44	0.38	6.07e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg15655495	chr12:38532458	NA	-0.3	-5.41	-0.33	1.47e-7	Bladder cancer;
KIRP	cis	rs13385	0.769	rs17286613	chr5:139581205	T/G	cg01860693	chr5:139557145	C5orf32	0.49	5.08	0.31	7.49e-7	Atrial fibrillation;
KIRP	cis	rs7106204	0.748	rs6484028	chr11:24222438	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	9.61	0.52	9.01e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg05072774	chr3:49840536	C3orf54	0.43	5.5	0.33	9.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs6593803	0.639	rs6593804	chr1:147205876	C/T	cg27546670	chr1:147246839	GJA5	0.6	6.89	0.4	4.74e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg01028140	chr2:1542097	TPO	-0.6	-6.01	-0.36	6.73e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02084834	chr2:201983708	CFLAR	0.57	6.91	0.4	4.07e-11	Smoking initiation;
KIRP	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.56	7.87	0.45	1.13e-13	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs662064	0.755	rs6667629	chr1:10524467	T/C	cg19773385	chr1:10388646	KIF1B	-0.45	-5.54	-0.33	7.87e-8	Asthma;
KIRP	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.67	10.4	0.55	3.04e-21	Pulse pressure;
KIRP	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.51	-0.38	4.1e-10	Type 2 diabetes;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14023874	chr1:168698975	DPT	-0.48	-6.34	-0.37	1.08e-9	Inflammatory biomarkers;
KIRP	cis	rs728616	0.681	rs36073865	chr10:81916055	C/T	cg27417294	chr10:81904244	PLAC9	0.56	5.02	0.3	1.01e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs10214930	0.697	rs13308974	chr7:27652338	G/A	cg22168087	chr7:27702803	HIBADH	0.47	5.07	0.31	7.74e-7	Hypospadias;
KIRP	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	1.1	15.58	0.7	1.59e-38	Breast cancer;
KIRP	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.5	-9.32	-0.51	6.7e-18	Cystic fibrosis severity;
KIRP	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.8	-0.49	2.5e-16	Blood metabolite levels;
KIRP	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.67	-9.11	-0.5	2.94e-17	Age at first birth;
KIRP	cis	rs6016377	1.000	rs6016377	chr20:39172728	A/G	cg22477343	chr20:39312069	NA	-0.44	-5.48	-0.33	1.03e-7	Birth weight;
KIRP	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg22903471	chr2:27725779	GCKR	-0.39	-5.51	-0.33	9.22e-8	Oral cavity cancer;
KIRP	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	10.99	0.57	4.07e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-4.99	-0.3	1.16e-6	Total cholesterol levels;
KIRP	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.82	0.6	7.9e-26	Ileal carcinoids;
KIRP	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg04935436	chr20:30431758	NA	0.47	6.11	0.36	3.9e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05901451	chr6:126070800	HEY2	-0.46	-6.3	-0.37	1.33e-9	High light scatter reticulocyte count;
KIRP	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg15234197	chr11:68924956	NA	0.35	4.99	0.3	1.12e-6	Blond vs. brown hair color;
KIRP	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg23985595	chr17:80112537	CCDC57	-0.35	-5.18	-0.31	4.59e-7	Life satisfaction;
KIRP	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.38	7.23	0.42	6.15e-12	Height;
KIRP	cis	rs12580194	1.000	rs7968881	chr12:55694434	A/C	cg11794356	chr12:55725991	OR6C3	-0.45	-6.26	-0.37	1.69e-9	Cancer;
KIRP	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.8	10.49	0.56	1.65e-21	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg18944383	chr4:111397179	ENPEP	-0.43	-6.84	-0.4	6.17e-11	Coronary artery disease;
KIRP	cis	rs7188697	0.922	rs1549607	chr16:58583975	A/G	cg21335942	chr16:58549945	SETD6	-0.46	-5.08	-0.31	7.6e-7	QT interval;
KIRP	cis	rs1864585	0.520	rs73208789	chr8:10679187	A/G	cg21775007	chr8:11205619	TDH	-0.5	-5.0	-0.3	1.11e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs1915919	0.794	rs4398451	chr3:20010886	T/C	cg05072819	chr3:20081367	KAT2B	0.42	5.1	0.31	6.88e-7	Post-traumatic stress disorder;
KIRP	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg06640241	chr16:89574553	SPG7	0.64	7.62	0.44	5.41e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs12913538	0.962	rs12437894	chr15:62896799	A/G	cg09983546	chr15:62884068	NA	0.59	8.5	0.48	1.9e-15	Sleep depth;
KIRP	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg00621247	chr5:1949277	NA	-0.49	-5.42	-0.33	1.39e-7	Gut microbiome composition (winter);
KIRP	cis	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg09559047	chr8:10916868	XKR6	-0.38	-5.51	-0.33	9.15e-8	Triglycerides;
KIRP	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.47	-7.83	-0.45	1.46e-13	Height;
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg23698023	chr8:27181813	PTK2B	0.35	5.16	0.31	5.2e-7	Neuroticism;
KIRP	cis	rs7851660	0.805	rs10759981	chr9:100635780	A/G	cg13688889	chr9:100608707	NA	-0.67	-8.74	-0.49	3.63e-16	Strep throat;
KIRP	cis	rs7116495	1.000	rs7124000	chr11:71754338	T/C	cg26138937	chr11:71823887	C11orf51	-0.64	-5.24	-0.32	3.5e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs631288	0.793	rs10900331	chr1:146733128	C/G	cg25205988	chr1:146714368	CHD1L	1.07	8.4	0.47	3.6e-15	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.46	-0.33	1.16e-7	Metabolite levels;
KIRP	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	1.07	10.94	0.57	6e-23	Sexual dysfunction (female);
KIRP	cis	rs501120	1.000	rs915083	chr10:44755406	T/G	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9549260	0.620	rs9532580	chr13:41244260	T/C	cg21288729	chr13:41239152	FOXO1	0.66	7.66	0.44	4.4e-13	Red blood cell count;
KIRP	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17507749	chr15:85114479	UBE2QP1	-0.64	-6.55	-0.39	3.25e-10	Schizophrenia;
KIRP	cis	rs9400467	0.506	rs10485124	chr6:111631907	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.92	0.3	1.57e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.66	0.34	4.14e-8	Menopause (age at onset);
KIRP	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07570687	chr10:102243282	WNT8B	0.52	6.84	0.4	6.22e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.81	0.63	3.94e-29	Morning vs. evening chronotype;
KIRP	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.48	-5.86	-0.35	1.47e-8	Asthma (sex interaction);
KIRP	cis	rs6495367	1.000	rs4778634	chr15:79380822	C/T	cg26321766	chr15:79852363	NA	0.35	5.0	0.3	1.08e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg05627522	chr15:75251581	NA	0.4	6.44	0.38	6.23e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	7.52	0.43	1.02e-12	Iron status biomarkers;
KIRP	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.53	5.5	0.33	9.45e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.25	-0.42	5.52e-12	Glomerular filtration rate;
KIRP	cis	rs9462846	0.919	rs9462844	chr6:42856502	T/G	cg02353165	chr6:42928485	GNMT	0.41	5.04	0.31	9.23e-7	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	7.14e-8	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01519350	chr3:137906342	ARMC8	0.66	6.07	0.36	4.78e-9	Lung function (FEV1);
KIRP	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.87	13.92	0.66	7.04e-33	Breast cancer;
KIRP	cis	rs4704187	0.687	rs4404660	chr5:74422210	T/C	cg03227963	chr5:74354835	NA	0.41	5.94	0.35	9.57e-9	Response to amphetamines;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04309227	chr1:26561027	CCDC21	-0.47	-6.19	-0.37	2.45e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.24	0.58	6.14e-24	Bladder cancer;
KIRP	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-12.62	-0.63	1.76e-28	Blood trace element (Zn levels);
KIRP	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg19770292	chr5:1868693	NA	0.48	5.56	0.33	7.18e-8	Cardiovascular disease risk factors;
KIRP	cis	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg19847130	chr8:10466454	RP1L1	-0.34	-5.36	-0.32	1.94e-7	Neuroticism;
KIRP	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	0.99	15.4	0.7	6.22e-38	Primary sclerosing cholangitis;
KIRP	cis	rs7737355	0.812	rs244735	chr5:130818061	C/T	cg25547332	chr5:131281432	NA	0.39	4.86	0.3	2.12e-6	Life satisfaction;
KIRP	trans	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg25042112	chr7:64838748	ZNF92	-0.6	-6.34	-0.37	1.1e-9	Pain;
KIRP	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.37	-0.32	1.81e-7	Aortic root size;
KIRP	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg19257562	chr1:2043853	PRKCZ	0.47	7.01	0.41	2.27e-11	Height;
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02359409	chr6:42947317	PEX6	-0.39	-5.12	-0.31	6.15e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7172677	1.000	rs4886659	chr15:75414760	A/G	cg14082893	chr15:75400931	NA	0.37	5.38	0.32	1.76e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs259282	0.562	rs28505804	chr19:33110047	T/C	cg02997394	chr19:33096574	ANKRD27	-0.53	-6.3	-0.37	1.36e-9	Schizophrenia;
KIRP	cis	rs4664308	0.618	rs66484345	chr2:160894930	C/T	cg03641300	chr2:160917029	PLA2R1	-0.66	-10.27	-0.55	7.82e-21	Idiopathic membranous nephropathy;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg26134248	chr17:3907702	NA	0.58	8.6	0.48	9.44e-16	Type 2 diabetes;
KIRP	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.48	-6.56	-0.39	3.07e-10	Asthma;
KIRP	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg00319359	chr11:70116639	PPFIA1	0.82	7.16	0.42	9.09e-12	Coronary artery disease;
KIRP	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.46	6.41	0.38	7.2e-10	Coronary artery disease;
KIRP	cis	rs6968419	0.755	rs2402057	chr7:115897096	C/T	cg02561103	chr7:115862891	TES	0.39	5.55	0.33	7.42e-8	Intraocular pressure;
KIRP	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	7.85e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.53	-5.04	-0.31	9.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.87	11.56	0.59	5.56e-25	Platelet distribution width;
KIRP	cis	rs3736594	0.918	rs12471347	chr2:27981655	G/C	cg27432699	chr2:27873401	GPN1	0.48	5.63	0.34	4.98e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg04132472	chr17:19861366	AKAP10	0.44	6.08	0.36	4.67e-9	Schizophrenia;
KIRP	cis	rs7923609	0.967	rs10740134	chr10:65315433	T/C	cg01631684	chr10:65280961	REEP3	-0.49	-5.73	-0.34	2.91e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11138902	0.627	rs11139236	chr9:72157008	A/G	cg14397918	chr9:72078829	APBA1	0.33	5.31	0.32	2.47e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg02073427	chr10:15252052	NA	-0.51	-7.05	-0.41	1.76e-11	Neuroticism;
KIRP	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18364779	chr6:26104403	HIST1H4C	0.38	5.1	0.31	6.88e-7	Schizophrenia;
KIRP	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.41	7.98	0.45	5.44e-14	Height;
KIRP	cis	rs714031	0.934	rs4820386	chr22:40068051	C/T	cg21377881	chr22:40064566	CACNA1I	-0.68	-10.54	-0.56	1.14e-21	Schizophrenia;
KIRP	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg09201719	chr10:104596890	CYP17A1	0.38	5.55	0.33	7.31e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	8.04	0.46	3.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.89e-44	Breast cancer;
KIRP	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.7	7.09	0.41	1.43e-11	Bipolar disorder;
KIRP	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.31	-0.55	6.17e-21	Triglycerides;
KIRP	cis	rs72802342	0.541	rs185052	chr16:75467063	C/T	cg03315344	chr16:75512273	CHST6	-0.58	-5.24	-0.32	3.43e-7	Advanced age-related macular degeneration;
KIRP	cis	rs4561483	0.583	rs1019813	chr16:11940829	C/T	cg08843971	chr16:11963173	GSPT1	0.49	6.77	0.4	9.43e-11	Testicular germ cell tumor;
KIRP	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.51	6.77	0.4	9.66e-11	Schizophrenia;
KIRP	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.65	-9.31	-0.51	7.25e-18	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02950886	chr11:417189	SIGIRR	0.59	7.82	0.45	1.5700000000000001e-13	Parkinson's disease;
KIRP	cis	rs2860975	1.000	rs7070074	chr10:96786886	T/C	cg09036531	chr10:96991505	NA	-0.52	-6.59	-0.39	2.65e-10	Immune response to smallpox vaccine (IL-6);
KIRP	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs2411233	0.934	rs1824492	chr15:39284513	A/C	cg02291532	chr15:39874776	THBS1	0.41	5.49	0.33	1.01e-7	Platelet count;
KIRP	cis	rs6142102	0.923	rs4911383	chr20:32555779	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	6.45	0.38	5.85e-10	Skin pigmentation;
KIRP	cis	rs17001868	0.892	rs73167027	chr22:40808676	A/T	cg07138101	chr22:40742427	ADSL	0.75	6.06	0.36	5.13e-9	Mammographic density (dense area);
KIRP	cis	rs9815354	1.000	rs7632387	chr3:41853161	C/T	cg03022575	chr3:42003672	ULK4	0.53	5.69	0.34	3.65e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.92	-0.35	1.1e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.69	-9.04	-0.5	4.78e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09524192	chr20:39657308	TOP1	-0.47	-6.32	-0.37	1.21e-9	Metabolic traits;
KIRP	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg04287289	chr16:89883240	FANCA	-0.39	-5.02	-0.3	9.83e-7	Vitiligo;
KIRP	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg16989719	chr2:238392110	NA	-0.42	-5.66	-0.34	4.19e-8	Prostate cancer;
KIRP	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	8.0	0.45	4.77e-14	Iron status biomarkers;
KIRP	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	7.12	0.41	1.15e-11	Protein C levels;
KIRP	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg07713946	chr22:31675144	LIMK2	0.3	4.89	0.3	1.86e-6	Colorectal cancer;
KIRP	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg00933542	chr6:150070202	PCMT1	0.27	5.34	0.32	2.13e-7	Lung cancer;
KIRP	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.49	-0.33	1e-7	Multiple sclerosis;
KIRP	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg12384639	chr17:618140	VPS53	0.49	5.96	0.36	8.84e-9	Prostate cancer;
KIRP	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-5.1	-0.31	6.88e-7	Ulcerative colitis;
KIRP	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.7	9.31	0.51	7.36e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.5	-5.92	-0.35	1.1e-8	Aortic root size;
KIRP	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.4	0.43	2.13e-12	Coffee consumption (cups per day);
KIRP	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg16797656	chr11:68205561	LRP5	0.37	4.87	0.3	2.01e-6	Total body bone mineral density;
KIRP	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg09904177	chr6:26538194	HMGN4	0.48	5.74	0.34	2.74e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.41	-4.91	-0.3	1.69e-6	P wave terminal force;
KIRP	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg08392591	chr16:89556376	ANKRD11	0.4	5.01	0.3	1.05e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.21	-0.42	6.82e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6450176	1.000	rs10805455	chr5:53302302	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-11.12	-0.58	1.49e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2371030	0.965	rs4673548	chr2:211571627	T/C	cg18417063	chr2:211583084	NA	-0.51	-7.55	-0.43	8.58e-13	Non-small cell lung cancer;
KIRP	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg18357526	chr6:26021779	HIST1H4A	0.4	5.07	0.31	7.79e-7	Schizophrenia;
KIRP	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.48	6.37	0.38	9.06e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1712517	0.771	rs2292807	chr10:105155645	T/C	cg05636881	chr10:105038444	INA	0.44	6.3	0.37	1.33e-9	Migraine;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg21655969	chr15:90792609	TTLL13	-0.37	-6.07	-0.36	4.84e-9	Metabolite levels (MHPG);
KIRP	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.46	5.89	0.35	1.27e-8	IgG glycosylation;
KIRP	cis	rs2904967	0.929	rs592050	chr11:65030189	C/G	cg12562828	chr11:65076843	NA	0.47	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg10189774	chr4:17578691	LAP3	0.58	7.23	0.42	6.04e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.58	-7.48	-0.43	1.31e-12	Morning vs. evening chronotype;
KIRP	cis	rs56116382	0.668	rs4688759	chr3:50008118	T/C	cg07636037	chr3:49044803	WDR6	-0.72	-5.76	-0.34	2.52e-8	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.59	0.39	2.72e-10	Breast cancer;
KIRP	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.6	7.14	0.41	1.08e-11	Mosquito bite size;
KIRP	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.54	6.7	0.39	1.42e-10	Monocyte count;
KIRP	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Colorectal cancer;
KIRP	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg16988262	chr1:15930761	NA	0.4	5.29	0.32	2.74e-7	Systolic blood pressure;
KIRP	cis	rs2860975	0.936	rs7904000	chr10:96767858	A/T	cg09036531	chr10:96991505	NA	-0.54	-6.83	-0.4	6.44e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.91	-0.49	1.18e-16	Blood metabolite levels;
KIRP	cis	rs10214930	0.671	rs12530626	chr7:27689808	A/T	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21270015	chr4:113567813	LARP7	-0.45	-6.93	-0.4	3.64e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg25783544	chr11:47291846	MADD	0.44	4.97	0.3	1.24e-6	HDL cholesterol;
KIRP	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.58	7.64	0.44	4.73e-13	Hip circumference;
KIRP	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg08603382	chr10:743973	NA	0.51	7.52	0.43	1.01e-12	Psychosis in Alzheimer's disease;
KIRP	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg07169764	chr2:136633963	MCM6	0.53	6.15	0.37	3.06e-9	Mosquito bite size;
KIRP	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.72	8.51	0.48	1.7e-15	Cocaine dependence;
KIRP	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.38	-5.48	-0.33	1.05e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg06223162	chr1:101003688	GPR88	0.41	8.16	0.46	1.69e-14	Monocyte count;
KIRP	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.8	9.04	0.5	4.85e-17	Corneal astigmatism;
KIRP	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	0.83	7.92	0.45	8.42e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	7.08	0.41	1.46e-11	Caffeine consumption;
KIRP	cis	rs71403859	0.570	rs78972826	chr16:71454264	A/G	cg08717414	chr16:71523259	ZNF19	-0.91	-8.69	-0.48	5.13e-16	Post bronchodilator FEV1;
KIRP	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg00405596	chr8:11794950	NA	-0.39	-4.9	-0.3	1.72e-6	Morning vs. evening chronotype;
KIRP	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg07384165	chr1:10488281	NA	-0.43	-5.42	-0.33	1.43e-7	Breast size;
KIRP	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.45	6.21	0.37	2.3e-9	Sitting height ratio;
KIRP	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.34	5.3	0.32	2.59e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	1.02	11.31	0.58	3.73e-24	Alzheimer's disease;
KIRP	cis	rs35740288	0.787	rs2008916	chr15:86221190	C/T	cg17133734	chr15:86042851	AKAP13	-0.48	-5.25	-0.32	3.36e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.46	-0.43	1.52e-12	Platelet count;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05463782	chr22:38142159	TRIOBP	-0.54	-5.87	-0.35	1.39e-8	Menopause (age at onset);
KIRP	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.84	-0.57	1.22e-22	Colorectal cancer;
KIRP	cis	rs16854884	1.000	rs7649614	chr3:143789028	G/A	cg06585982	chr3:143692056	C3orf58	0.51	5.52	0.33	8.76e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09287717	chr20:45035259	ELMO2	-0.45	-6.32	-0.37	1.19e-9	Metabolic traits;
KIRP	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-8.11	-0.46	2.34e-14	Homocysteine levels;
KIRP	cis	rs2274273	0.688	rs6573001	chr14:55556502	A/G	cg04306507	chr14:55594613	LGALS3	0.49	7.71	0.44	3.03e-13	Protein biomarker;
KIRP	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.48	-0.43	1.3e-12	Aortic root size;
KIRP	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg15893493	chr8:124194847	FAM83A	0.93	8.13	0.46	2.14e-14	Urinary uromodulin levels;
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg00738919	chr7:1100172	C7orf50	0.43	5.06	0.31	8.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Melanoma;
KIRP	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.44	-6.44	-0.38	6.13e-10	Mean corpuscular volume;
KIRP	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.77	-9.52	-0.52	1.73e-18	Huntington's disease progression;
KIRP	trans	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg25042112	chr7:64838748	ZNF92	0.58	6.25	0.37	1.75e-9	Pain;
KIRP	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs4474465	1.000	rs11237520	chr11:78201201	G/C	cg27205649	chr11:78285834	NARS2	-0.59	-6.87	-0.4	5.22e-11	Alzheimer's disease (survival time);
KIRP	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg24315340	chr6:146058215	EPM2A	-0.43	-5.42	-0.33	1.42e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg14829155	chr15:31115871	NA	-0.78	-9.45	-0.52	2.79e-18	Huntington's disease progression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18771195	chr17:182656	RPH3AL	0.48	6.43	0.38	6.59e-10	Interleukin-4 levels;
KIRP	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.49	-0.33	9.9e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.37	0.38	9.01e-10	Aortic root size;
KIRP	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg18764771	chr6:116381957	FRK	0.2	5.46	0.33	1.16e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2882667	0.898	rs3828600	chr5:138386859	G/T	cg04439458	chr5:138467593	SIL1	-0.43	-7.42	-0.43	1.85e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12580194	0.593	rs11171431	chr12:55757609	G/T	cg11794356	chr12:55725991	OR6C3	-0.55	-7.7	-0.44	3.25e-13	Cancer;
KIRP	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.92	-15.37	-0.7	7.88e-38	Breast cancer;
KIRP	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.74	9.96	0.54	7.27e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs742134	1.000	rs742134	chr22:43518275	C/T	cg26453588	chr22:43506021	BIK	-0.39	-5.5	-0.33	9.51e-8	Prostate cancer;
KIRP	cis	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg25547332	chr5:131281432	NA	0.48	5.39	0.33	1.63e-7	Life satisfaction;
KIRP	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg26384229	chr12:38710491	ALG10B	0.61	7.97	0.45	5.89e-14	Bladder cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01911352	chr22:38302090	MICALL1	-0.49	-6.69	-0.39	1.48e-10	Metabolic traits;
KIRP	cis	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26292547	chr6:111804695	REV3L	-0.38	-5.04	-0.31	9.16e-7	Metabolic traits;
KIRP	cis	rs35740288	0.571	rs11633790	chr15:86326370	G/A	cg20737812	chr15:86336631	KLHL25	-0.53	-6.75	-0.4	1.07e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg01620082	chr3:125678407	NA	-0.88	-6.44	-0.38	6.28e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15097336	chr1:115301970	CSDE1	-0.43	-6.13	-0.36	3.52e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg09699651	chr6:150184138	LRP11	0.45	5.94	0.35	9.55e-9	Lung cancer;
KIRP	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.4	-0.38	7.75e-10	Neuroticism;
KIRP	cis	rs7937612	0.965	rs4539328	chr11:120218243	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.55	-0.39	3.3e-10	Intraocular pressure;
KIRP	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.47	-4.96	-0.3	1.34e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs12431939	0.779	rs3007081	chr14:51645492	G/A	cg23942311	chr14:51606299	NA	0.46	5.33	0.32	2.23e-7	Cancer;
KIRP	trans	rs12367448	0.604	rs73137999	chr12:69565133	C/T	cg21546300	chr22:47050341	GRAMD4	0.73	6.18	0.37	2.58e-9	IgG glycosylation;
KIRP	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.68	-0.39	1.61e-10	Response to antipsychotic treatment;
KIRP	trans	rs2562456	0.833	rs2928211	chr19:21541297	A/G	cg25042112	chr7:64838748	ZNF92	0.59	6.23	0.37	1.98e-9	Pain;
KIRP	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.97	12.94	0.64	1.42e-29	Menopause (age at onset);
KIRP	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg12598211	chr12:123634384	NA	-0.44	-5.37	-0.32	1.8e-7	Neutrophil percentage of white cells;
KIRP	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.95	11.43	0.59	1.54e-24	Corneal astigmatism;
KIRP	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.5	-7.1	-0.41	1.32e-11	Motion sickness;
KIRP	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8177876	0.642	rs10514513	chr16:81114183	C/T	cg08591886	chr16:81111003	C16orf46	-0.61	-5.93	-0.35	1.04e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4774830	0.744	rs62046392	chr15:56312554	C/G	cg24530489	chr15:56299380	NA	-0.87	-5.32	-0.32	2.31e-7	Delta-5 desaturase activity;
KIRP	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg18306943	chr3:40428807	ENTPD3	0.45	5.88	0.35	1.33e-8	Renal cell carcinoma;
KIRP	cis	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg21546286	chr11:48923668	NA	-0.44	-5.59	-0.34	6e-8	HDL cholesterol;
KIRP	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg26695010	chr11:65641043	EFEMP2	-0.5	-4.99	-0.3	1.12e-6	Crohn's disease;
KIRP	cis	rs661054	0.554	rs1350069	chr11:114422804	C/G	cg19465033	chr11:114479364	NA	-0.42	-5.04	-0.31	9.11e-7	Ulcerative colitis;
KIRP	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.67	-7.94	-0.45	7.08e-14	Coronary artery disease;
KIRP	cis	rs7180079	0.620	rs12903003	chr15:64711986	A/G	cg15337035	chr15:64978493	NA	-0.48	-5.29	-0.32	2.76e-7	Monocyte count;
KIRP	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22878388	chr2:105853796	NA	-0.43	-6.88	-0.4	5.05e-11	Type 2 diabetes;
KIRP	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.54	-5.53	-0.33	8.35e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg08501292	chr6:25962987	TRIM38	0.79	5.3	0.32	2.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10861342	0.892	rs74971338	chr12:105499757	C/A	cg23923672	chr12:105501055	KIAA1033	0.91	7.42	0.43	1.87e-12	IgG glycosylation;
KIRP	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.59	7.5	0.43	1.19e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg20673091	chr1:2541236	MMEL1	0.66	10.03	0.54	4.47e-20	Ulcerative colitis;
KIRP	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-7.07	-0.41	1.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17401966	0.838	rs8019	chr1:10366487	T/G	cg19773385	chr1:10388646	KIF1B	-0.68	-10.6	-0.56	6.98e-22	Hepatocellular carcinoma;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg19694781	chr19:47549865	TMEM160	0.58	7.7	0.44	3.26e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	1.06	16.94	0.73	3.6e-43	Cognitive function;
KIRP	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg18441811	chr11:71824068	C11orf51	0.78	5.14	0.31	5.53e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs3925075	0.531	rs4261553	chr16:31349164	T/C	cg02846316	chr16:31340340	ITGAM	0.46	5.53	0.33	8.23e-8	IgA nephropathy;
KIRP	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.62	-6.68	-0.39	1.58e-10	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.63	-0.56	5.75e-22	Height;
KIRP	cis	rs364477	0.868	rs604973	chr9:971066	A/G	cg13952963	chr9:998547	NA	0.55	5.06	0.31	8.34e-7	Major depressive disorder;
KIRP	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs12545912	0.770	rs7003791	chr8:9545368	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.33	-0.37	1.16e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs526231	0.543	rs152137	chr5:102560063	C/T	cg23492399	chr5:102201601	PAM	-0.53	-5.56	-0.33	7.05e-8	Primary biliary cholangitis;
KIRP	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	12.08	0.61	1.07e-26	Mean platelet volume;
KIRP	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg10503236	chr1:231470652	EXOC8	0.47	6.4	0.38	7.73e-10	Hemoglobin concentration;
KIRP	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.52	-5.98	-0.36	7.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg21775007	chr8:11205619	TDH	-0.42	-5.2	-0.31	4.3e-7	Triglycerides;
KIRP	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.94	13.64	0.66	6.16e-32	Coronary artery disease;
KIRP	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.8	-7.1	-0.41	1.3e-11	Pulse pressure;
KIRP	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.24	0.42	5.6e-12	Aortic root size;
KIRP	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.59	7.09	0.41	1.45e-11	Obesity-related traits;
KIRP	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.4	5.17	0.31	4.85e-7	Aortic root size;
KIRP	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg19773385	chr1:10388646	KIF1B	-0.69	-9.1	-0.5	3.18e-17	Hepatocellular carcinoma;
KIRP	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05665937	chr4:1216051	CTBP1	0.57	7.91	0.45	8.6e-14	Obesity-related traits;
KIRP	cis	rs2594989	0.895	rs439738	chr3:11322577	G/C	cg01796438	chr3:11312864	ATG7	-0.76	-8.54	-0.48	1.4e-15	Circulating chemerin levels;
KIRP	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4400599	1.000	rs3001363	chr1:154125067	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.37	5.39	0.32	1.67e-7	Platelet distribution width;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03829241	chr11:2923504	SLC22A18AS;SLC22A18	-0.42	-6.13	-0.36	3.48e-9	Metabolic traits;
KIRP	cis	rs72820985	1.000	rs12444274	chr16:80843702	A/C	cg04448709	chr16:81349954	GAN	0.51	5.11	0.31	6.43e-7	Breast cancer;
KIRP	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg16141378	chr3:129829833	LOC729375	0.48	6.28	0.37	1.55e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg23533926	chr12:111358616	MYL2	-0.48	-6.32	-0.37	1.19e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs16858210	0.837	rs1879254	chr3:183609471	C/T	cg25686905	chr3:183603175	PARL	-0.48	-6.14	-0.36	3.35e-9	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10891473	chr12:55820093	OR6C76	-0.38	-6.62	-0.39	2.26e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6977660	0.619	rs71526305	chr7:19785374	G/C	cg07541023	chr7:19748670	TWISTNB	0.53	5.52	0.33	8.47e-8	Thyroid stimulating hormone;
KIRP	cis	rs2594989	1.000	rs2606747	chr3:11374955	T/C	cg01796438	chr3:11312864	ATG7	-0.68	-7.86	-0.45	1.18e-13	Circulating chemerin levels;
KIRP	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.56	-7.5	-0.43	1.16e-12	Vitiligo;
KIRP	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.77e-6	Bipolar disorder;
KIRP	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.57	7.4	0.43	2.11e-12	Height;
KIRP	cis	rs501120	0.925	rs1657345	chr10:44779078	A/G	cg09554077	chr10:44749378	NA	0.67	8.05	0.46	3.56e-14	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg25386820	chr18:21242428	ANKRD29	0.52	6.67	0.39	1.66e-10	Sleep duration;
KIRP	cis	rs7404928	0.718	rs11074582	chr16:23864825	G/A	cg21745164	chr16:23765304	CHP2	-0.6	-7.37	-0.43	2.52e-12	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	trans	rs7999699	0.902	rs4941603	chr13:48307960	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg12292205	chr6:26970375	C6orf41	0.33	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.51	-0.33	8.89e-8	Lung cancer;
KIRP	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-0.77	-6.88	-0.4	5.04e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg08392591	chr16:89556376	ANKRD11	0.41	5.27	0.32	3.05e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.5	7.39	0.43	2.31e-12	Schizophrenia;
KIRP	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg04995300	chr3:66848608	NA	0.76	9.22	0.51	1.39e-17	Type 2 diabetes;
KIRP	cis	rs2594989	0.779	rs62245949	chr3:11575969	C/G	cg01796438	chr3:11312864	ATG7	0.42	5.54	0.33	7.66e-8	Circulating chemerin levels;
KIRP	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.54	0.38	3.54e-10	Breast cancer;
KIRP	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg24315340	chr6:146058215	EPM2A	-0.39	-5.0	-0.3	1.11e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs963731	0.649	rs10166801	chr2:39250771	C/T	cg04010122	chr2:39346883	SOS1	-1.06	-7.14	-0.41	1.02e-11	Corticobasal degeneration;
KIRP	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.54	-0.52	1.47e-18	Colorectal cancer;
KIRP	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.8	12.09	0.61	1.04e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13198984	chr17:80129470	CCDC57	-0.59	-8.98	-0.5	7.39e-17	Life satisfaction;
KIRP	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.63	8.74	0.49	3.57e-16	Autism;
KIRP	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.57	-7.89	-0.45	9.71e-14	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7715811	0.912	rs1502049	chr5:13779935	T/C	cg07548982	chr5:13769939	DNAH5	-0.55	-6.87	-0.4	5.24e-11	Subclinical atherosclerosis traits (other);
KIRP	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6662572	0.737	rs7512448	chr1:46449291	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.18e-8	Blood protein levels;
KIRP	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.52	0.33	8.42e-8	Retinal vascular caliber;
KIRP	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.6	6.78	0.4	8.73e-11	Asthma;
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg10305451	chr2:177043427	NA	0.57	7.66	0.44	4.15e-13	IgG glycosylation;
KIRP	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg13753209	chr17:57696993	CLTC	0.56	5.48	0.33	1.04e-7	Hemoglobin concentration;
KIRP	cis	rs10073892	0.789	rs72778000	chr5:101664729	G/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.37	0.38	9.42e-10	Cognitive decline (age-related);
KIRP	cis	rs7116495	0.881	rs673478	chr11:71799104	G/A	cg07596299	chr11:71824057	C11orf51	-0.62	-4.93	-0.3	1.49e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.54	0.38	3.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg15147215	chr3:52552868	STAB1	-0.29	-5.04	-0.31	8.93e-7	Electroencephalogram traits;
KIRP	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg12046867	chr14:103022105	NA	-0.54	-6.97	-0.41	2.9100000000000002e-11	Platelet count;
KIRP	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.96	11.64	0.6	3.12e-25	Corneal astigmatism;
KIRP	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg12140854	chr5:148520817	ABLIM3	-0.52	-5.66	-0.34	4.13e-8	Breast cancer;
KIRP	cis	rs11677416	1.000	rs2856837	chr2:113541925	G/A	cg23974023	chr2:113544294	IL1A	-0.33	-5.1	-0.31	6.75e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs2273669	0.667	rs116189763	chr6:109302894	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.63	-8.79	-0.49	2.63e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg25922239	chr6:33757077	LEMD2	0.73	9.43	0.52	3.19e-18	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg07701084	chr6:150067640	NUP43	0.71	9.96	0.54	7.3e-20	Lung cancer;
KIRP	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.04	-0.41	1.89e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg11987759	chr7:65425863	GUSB	0.53	7.25	0.42	5.42e-12	Calcium levels;
KIRP	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.44	-6.04	-0.36	5.63e-9	Renal function-related traits (BUN);
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg05941025	chr16:89927596	SPIRE2	0.35	5.49	0.33	9.78e-8	Vitiligo;
KIRP	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.6	6.5	0.38	4.49e-10	Gut microbiome composition (summer);
KIRP	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg00982548	chr2:198649783	BOLL	-0.6	-5.93	-0.35	1e-8	Ulcerative colitis;
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.79	-0.4	8.53e-11	Menopause (age at onset);
KIRP	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.26	-0.37	1.7e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg19500275	chr17:80737654	TBCD	0.54	7.4	0.43	2.14e-12	Glycated hemoglobin levels;
KIRP	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.6	7.96	0.45	6.26e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.78e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-6.52	-0.38	4.05e-10	Uric acid levels;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.61	6.09	0.36	4.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg12962167	chr3:53033115	SFMBT1	0.71	5.28	0.32	2.8e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6504622	0.537	rs2920397	chr17:44997329	G/A	cg16759221	chr17:45003025	GOSR2	-0.39	-5.85	-0.35	1.54e-8	Orofacial clefts;
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg21237687	chr17:6899380	ALOX12	0.3	5.22	0.32	3.78e-7	Tonsillectomy;
KIRP	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00166722	chr3:10149974	C3orf24	0.48	4.9	0.3	1.7e-6	Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18092665	chr7:80732349	NA	-0.47	-7.43	-0.43	1.74e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3750082	0.754	rs35110377	chr7:32971770	C/G	cg08946731	chr7:32981826	RP9P	-0.32	-4.86	-0.3	2.12e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6545883	0.894	rs12622458	chr2:61523554	A/C	cg15711740	chr2:61764176	XPO1	0.56	7.23	0.42	6.16e-12	Tuberculosis;
KIRP	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.86	-0.45	1.18e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.52	-5.18	-0.31	4.72e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.2	-0.46	1.38e-14	Monocyte percentage of white cells;
KIRP	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs829661	0.793	rs2609943	chr2:30859548	A/G	cg10949345	chr2:30726833	LCLAT1	1.14	13.77	0.66	2.3e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-8.87	-0.49	1.52e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	1.1	17.9	0.75	1.83e-46	Cognitive function;
KIRP	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.44	4.95	0.3	1.4e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10102274	1.000	rs16905319	chr8:91781544	G/A	cg16814680	chr8:91681699	NA	-0.8	-4.9	-0.3	1.73e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs2120243	0.967	rs7648322	chr3:157143684	A/G	cg24825693	chr3:157122686	VEPH1	-0.36	-5.13	-0.31	5.81e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs6973256	0.897	rs9656424	chr7:133325031	A/T	cg10665199	chr7:133106180	EXOC4	-0.52	-6.6	-0.39	2.57e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.42	5.39	0.32	1.69e-7	Childhood ear infection;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.56	5.9	0.35	1.2e-8	Mean corpuscular volume;
KIRP	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.82	-0.35	1.81e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.37	-5.66	-0.34	4.18e-8	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.57	0.33	6.54e-8	Platelet count;
KIRP	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg17736920	chr1:242011382	EXO1	0.45	5.6	0.34	5.86e-8	Menopause (age at onset);
KIRP	cis	rs28595532	0.800	rs114321375	chr4:119341663	G/A	cg21605333	chr4:119757512	SEC24D	1.1	8.23	0.46	1.06e-14	Cannabis dependence symptom count;
KIRP	cis	rs7119167	0.851	rs3741148	chr11:73114723	A/G	cg17517138	chr11:73019481	ARHGEF17	0.47	4.94	0.3	1.42e-6	Blood protein levels;
KIRP	cis	rs7084402	0.764	rs2033149	chr10:60264741	A/T	cg05938607	chr10:60274200	BICC1	-0.4	-9.3	-0.51	7.9e-18	Refractive error;
KIRP	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg18306943	chr3:40428807	ENTPD3	-0.38	-5.17	-0.31	4.76e-7	Renal cell carcinoma;
KIRP	cis	rs77362122	0.681	rs72737677	chr9:87337539	G/A	cg22402007	chr9:87282823	NTRK2	0.55	4.97	0.3	1.28e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04353095	chr3:140770588	SPSB4	0.52	6.77	0.4	9.29e-11	Parkinson's disease;
KIRP	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.7	0.66	4.06e-32	Mean platelet volume;
KIRP	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg13147721	chr7:65941812	NA	-0.97	-6.86	-0.4	5.62e-11	Diabetic kidney disease;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg15181151	chr6:150070149	PCMT1	0.31	5.33	0.32	2.27e-7	Lung cancer;
KIRP	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.64	0.44	4.75e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg25281562	chr12:121454272	C12orf43	-0.47	-5.06	-0.31	8.19e-7	Metabolic traits;LDL cholesterol;
KIRP	cis	rs1318772	1.000	rs36613	chr5:112758471	G/A	cg12552261	chr5:112820674	MCC	0.77	4.96	0.3	1.29e-6	F-cell distribution;
KIRP	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.47	5.82	0.35	1.83e-8	Mean platelet volume;
KIRP	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-0.89	-6.23	-0.37	2.06e-9	Inflammatory biomarkers;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg25341789	chr19:3506185	FZR1	0.52	6.25	0.37	1.84e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-14.13	-0.67	1.37e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10924309	0.889	rs10802247	chr1:245858508	G/A	cg00036263	chr1:245852353	KIF26B	-0.5	-6.75	-0.4	1.04e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg11641102	chr8:27183873	PTK2B	-0.4	-5.03	-0.31	9.36e-7	Alzheimer's disease (late onset);
KIRP	cis	rs1629083	0.840	rs11602739	chr11:118076953	T/A	cg18857871	chr11:118064634	AMICA1	0.65	8.77	0.49	2.98e-16	Lung cancer;
KIRP	cis	rs11997175	0.583	rs7459675	chr8:33837097	G/A	cg04338863	chr8:33670619	NA	0.5	6.5	0.38	4.55e-10	Body mass index;
KIRP	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.27	-5.11	-0.31	6.5e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.01	-0.45	4.57e-14	Mean corpuscular volume;
KIRP	cis	rs17301259	0.624	rs10952930	chr7:88430455	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-5.34	-0.32	2.14e-7	Heschl's gyrus morphology;
KIRP	cis	rs2273669	0.667	rs4509156	chr6:109308952	A/C	cg05315195	chr6:109294784	ARMC2	0.61	6.22	0.37	2.14e-9	Prostate cancer;
KIRP	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.44	-6.1	-0.36	4.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg23307798	chr14:103986281	CKB	0.72	11.24	0.58	6.34e-24	Body mass index;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg21314302	chr13:44204106	ENOX1	0.39	6.15	0.37	3.05e-9	Migraine with aura;
KIRP	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.91	-0.4	4.23e-11	Systemic lupus erythematosus;
KIRP	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.53	5.98	0.36	7.9e-9	Diisocyanate-induced asthma;
KIRP	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg21466736	chr12:48725269	NA	0.42	5.24	0.32	3.38e-7	Glycated hemoglobin levels;
KIRP	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.78	0.4	8.91e-11	Coffee consumption (cups per day);
KIRP	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.44	-0.43	1.69e-12	Bipolar disorder;
KIRP	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg12598211	chr12:123634384	NA	-0.44	-5.45	-0.33	1.21e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.51	5.94	0.35	9.52e-9	Osteoporosis;
KIRP	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.84	13.52	0.65	1.57e-31	Blood metabolite levels;
KIRP	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg22705602	chr4:152727874	NA	-0.62	-9.51	-0.52	1.79e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.9	0.45	9.18e-14	Resting heart rate;
KIRP	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg18198730	chr1:247681584	NA	0.6	5.67	0.34	3.94e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1190552	0.894	rs2236349	chr14:102963640	G/A	cg18135206	chr14:102964638	TECPR2	0.45	4.92	0.3	1.6e-6	Blood protein levels;
KIRP	cis	rs714027	1.000	rs1003342	chr22:30570022	A/G	cg27665648	chr22:30112403	NA	0.4	5.85	0.35	1.55e-8	Lymphocyte counts;
KIRP	trans	rs6901152	0.525	rs4896651	chr6:143691393	A/G	cg23194024	chr17:38278610	MSL1	-0.48	-6.37	-0.38	9.18e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg12826209	chr6:26865740	GUSBL1	0.78	5.31	0.32	2.41e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg14972814	chr11:95582409	MTMR2	0.34	5.48	0.33	1.03e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.8	-0.45	1.72e-13	Cutaneous nevi;
KIRP	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.71	-11.0	-0.57	3.79e-23	Prostate cancer;
KIRP	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05220968	chr6:146057943	EPM2A	-0.42	-5.32	-0.32	2.36e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.47	0.33	1.1e-7	Lung cancer;
KIRP	cis	rs3736485	0.966	rs10220909	chr15:51762412	C/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.3	-0.32	2.63e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg01877450	chr7:97915802	BRI3	0.56	7.46	0.43	1.46e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.8	11.02	0.58	3.14e-23	Aortic root size;
KIRP	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.21	0.42	6.97e-12	Retinal vascular caliber;
KIRP	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg07395648	chr5:131743802	NA	0.55	7.8	0.45	1.8e-13	Acylcarnitine levels;
KIRP	trans	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg15655154	chr3:113604241	GRAMD1C	0.53	7.3	0.42	3.85e-12	Diastolic blood pressure;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg12486944	chr17:80159399	CCDC57	0.41	5.33	0.32	2.27e-7	Life satisfaction;
KIRP	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.56	7.87	0.45	1.12e-13	Huntington's disease progression;
KIRP	cis	rs6545883	0.868	rs2518933	chr2:61797030	C/A	cg15711740	chr2:61764176	XPO1	-0.61	-8.32	-0.47	6.15e-15	Tuberculosis;
KIRP	cis	rs10185178	1.000	rs10185178	chr2:171356274	A/G	cg21128415	chr2:171359116	MYO3B	-1.12	-8.86	-0.49	1.61e-16	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs4478858	0.602	rs6425723	chr1:31715204	T/C	cg00250761	chr1:31883323	NA	-0.32	-5.56	-0.33	6.93e-8	Alcohol dependence;
KIRP	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.95	-0.41	3.29e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg10223061	chr2:219282414	VIL1	0.29	4.92	0.3	1.58e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.97	13.94	0.66	6.19e-33	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22093035	chr18:76829138	ATP9B	0.52	6.48	0.38	5.02e-10	Parkinson's disease;
KIRP	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.31	-6.8	-0.4	7.9e-11	Cutaneous nevi;
KIRP	cis	rs5417	0.610	rs222843	chr17:7145981	T/C	cg25256661	chr17:7137939	DVL2	0.9	13.28	0.65	1.07e-30	Diastolic blood pressure;
KIRP	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg10645314	chr2:3704589	ALLC	-0.49	-5.56	-0.33	7.08e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.49	6.51	0.38	4.2e-10	Asthma (bronchodilator response);
KIRP	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.24e-6	Ulcerative colitis;
KIRP	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.38e-9	Neuroticism;
KIRP	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg16387850	chr1:46982889	NA	0.28	5.1	0.31	6.71e-7	Monobrow;
KIRP	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06481639	chr22:41940642	POLR3H	0.65	7.14	0.41	1.04e-11	Vitiligo;
KIRP	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg07827796	chr19:33622959	WDR88	0.45	5.57	0.33	6.55e-8	Colorectal cancer;
KIRP	cis	rs78487399	0.808	rs7601039	chr2:43828637	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.52	-0.33	8.45e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	0.74	6.85	0.4	5.81e-11	Breast cancer;
KIRP	cis	rs2718812	0.766	rs10935071	chr3:133394159	T/C	cg01448562	chr3:133502909	NA	-0.38	-4.99	-0.3	1.12e-6	Iron status biomarkers;
KIRP	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg22437258	chr11:111473054	SIK2	-0.49	-6.03	-0.36	5.94e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.15	-0.46	1.89e-14	Total cholesterol levels;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	10.15	0.54	1.94e-20	Multiple sclerosis;
KIRP	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.63	7.75	0.44	2.4e-13	Type 2 diabetes;
KIRP	cis	rs12210905	1.000	rs12192446	chr6:26995638	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.62	-0.39	2.24e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.95	11.17	0.58	1.02e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs9535307	0.929	rs2038608	chr13:50272027	A/C	cg04663916	chr13:50265991	EBPL	0.66	5.42	0.33	1.41e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9815354	0.597	rs17283481	chr3:41924015	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.58	0.44	6.89e-13	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs12043259	0.730	rs73075644	chr1:204798107	G/A	cg11485465	chr5:54518469	NA	0.36	6.42	0.38	7.15e-10	Addiction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00003202	chr1:151319512	RFX5	0.51	6.4	0.38	7.75e-10	Parkinson's disease;
KIRP	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.66	-0.39	1.74e-10	Mood instability;
KIRP	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12292205	chr6:26970375	C6orf41	0.61	6.93	0.4	3.67e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg20936604	chr3:58311152	NA	-0.68	-5.23	-0.32	3.64e-7	Cholesterol, total;
KIRP	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23544223	chr18:12777786	NA	0.76	6.42	0.38	6.9e-10	Inflammatory skin disease;
KIRP	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.39	-5.64	-0.34	4.67e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.68	8.93	0.49	1.01e-16	Cognitive function;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13169072	chr14:36350271	NA	0.44	6.39	0.38	8.47e-10	Interleukin-4 levels;
KIRP	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg25486957	chr4:152246857	NA	-0.41	-4.88	-0.3	1.9e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg22681709	chr2:178499509	PDE11A	-0.59	-6.98	-0.41	2.75e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2151522	0.563	rs1539556	chr6:127145721	A/C	cg21431617	chr6:127135037	NA	-0.32	-5.83	-0.35	1.76e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg15485101	chr11:133734466	NA	0.49	6.66	0.39	1.8e-10	Childhood ear infection;
KIRP	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.26	-0.32	3.11e-7	Total body bone mineral density;
KIRP	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.51	6.49	0.38	4.67e-10	Coronary heart disease;
KIRP	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.73	11.45	0.59	1.33e-24	Brugada syndrome;
KIRP	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs10073892	0.703	rs10045752	chr5:101638440	C/A	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs9815354	0.812	rs11129932	chr3:41838767	C/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg00806126	chr19:22604979	ZNF98	-0.64	-6.64	-0.39	1.99e-10	Pain;
KIRP	cis	rs7172677	0.691	rs12901092	chr15:75374145	C/A	cg21523564	chr15:75251491	NA	-0.35	-5.73	-0.34	2.93e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.54	-0.38	3.51e-10	Retinal vascular caliber;
KIRP	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.15	-0.31	5.43e-7	Post bronchodilator FEV1;
KIRP	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg05973401	chr12:123451056	ABCB9	0.51	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.72	0.44	2.87e-13	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.2e-8	Life satisfaction;
KIRP	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.47	5.78	0.35	2.24e-8	Tuberculosis;
KIRP	cis	rs2071403	1.000	rs4927604	chr2:1416435	A/G	cg07083862	chr2:1417248	TPO	0.32	5.11	0.31	6.38e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs7106204	0.534	rs1443050	chr11:24275162	C/T	ch.11.24196551F	chr11:24239977	NA	0.71	4.93	0.3	1.52e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11161853	chr3:67705044	SUCLG2	0.47	6.28	0.37	1.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4974559	0.790	rs10012582	chr4:1324481	G/A	cg02980000	chr4:1222292	CTBP1	0.81	9.23	0.51	1.3e-17	Systolic blood pressure;
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12406363	chr1:224475811	NVL	-0.41	-6.25	-0.37	1.83e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.8	7.71	0.44	3.09e-13	Diisocyanate-induced asthma;
KIRP	cis	rs4423214	0.559	rs11234042	chr11:71239086	C/A	cg05163923	chr11:71159392	DHCR7	-0.74	-7.12	-0.41	1.18e-11	Vitamin D levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09395572	chr15:96985428	NA	0.41	6.46	0.38	5.63e-10	Cancer;
KIRP	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.91	-0.3	1.67e-6	Pulmonary function;
KIRP	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.4	4.98	0.3	1.21e-6	Lung cancer;
KIRP	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.71	-9.67	-0.52	5.98e-19	Schizophrenia;
KIRP	cis	rs2415984	0.622	rs73245837	chr14:46947914	A/G	cg14871534	chr14:47121158	RPL10L	-0.43	-5.25	-0.32	3.22e-7	Number of children ever born;
KIRP	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.69	10.51	0.56	1.35e-21	Pulse pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14128259	chr12:27848523	REP15	-0.41	-6.09	-0.36	4.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.38	-0.32	1.75e-7	Height;
KIRP	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.89e-31	Eye color traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06026817	chr11:68518826	MTL5	-0.49	-6.6	-0.39	2.49e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7119167	0.686	rs11827650	chr11:73029246	G/C	cg17517138	chr11:73019481	ARHGEF17	0.47	4.98	0.3	1.2e-6	Blood protein levels;
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg17441377	chr17:3906640	NA	0.47	6.06	0.36	5.14e-9	Type 2 diabetes;
KIRP	cis	rs6466055	0.661	rs7776832	chr7:104886669	T/C	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	7.01e-7	Schizophrenia;
KIRP	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.62	8.26	0.47	8.85e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.03	0.31	9.54e-7	Lung cancer;
KIRP	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg17788362	chr6:86352627	SYNCRIP	0.49	6.45	0.38	6.01e-10	Smooth-surface caries;
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg19292749	chr17:79650816	ARL16;HGS	0.54	4.9	0.3	1.75e-6	Dental caries;
KIRP	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	trans	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg16141378	chr3:129829833	LOC729375	-0.56	-6.62	-0.39	2.29e-10	Neuroticism;
KIRP	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg26587870	chr6:27730563	NA	0.69	5.42	0.33	1.41e-7	Depression;
KIRP	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.84e-15	Prudent dietary pattern;
KIRP	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg04149295	chr10:70884716	VPS26A	0.45	5.01	0.3	1.02e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg15655495	chr12:38532458	NA	0.25	4.94	0.3	1.47e-6	Bladder cancer;
KIRP	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg21361702	chr7:150065534	REPIN1	0.57	6.07	0.36	4.9e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs1106684	1.000	rs35457641	chr7:131459479	C/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.56	6.92	0.4	3.81e-11	Aortic root size;
KIRP	cis	rs981844	0.816	rs62325148	chr4:154727993	A/G	cg14289246	chr4:154710475	SFRP2	0.65	7.55	0.43	8.59e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg00684032	chr4:1343700	KIAA1530	0.49	6.62	0.39	2.26e-10	Longevity;
KIRP	cis	rs9905704	0.918	rs11655808	chr17:56854517	T/C	cg12560992	chr17:57184187	TRIM37	0.59	5.86	0.35	1.48e-8	Testicular germ cell tumor;
KIRP	cis	rs9596863	0.950	rs9563183	chr13:54396931	A/C	ch.13.53330881F	chr13:54432880	NA	0.58	5.98	0.36	7.98e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg13289132	chr10:30722225	MAP3K8	0.37	4.94	0.3	1.44e-6	Inflammatory bowel disease;
KIRP	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-1.01	-13.09	-0.64	4.68e-30	Platelet distribution width;
KIRP	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	trans	rs12043259	0.730	rs7525016	chr1:204792995	C/T	cg11485465	chr5:54518469	NA	0.39	6.5	0.38	4.42e-10	Addiction;
KIRP	trans	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	6.05	0.36	5.23e-9	Metabolite levels;
KIRP	trans	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg21775007	chr8:11205619	TDH	-0.45	-6.21	-0.37	2.28e-9	Joint mobility (Beighton score);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17932484	chr13:24463526	MIPEP;PCOTH	0.51	7.18	0.42	8.07e-12	Survival in pancreatic cancer;
KIRP	cis	rs17121403	0.661	rs12119143	chr1:100508655	C/T	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg00405596	chr8:11794950	NA	0.46	5.62	0.34	5.08e-8	Retinal vascular caliber;
KIRP	cis	rs6545883	0.507	rs4411680	chr2:61584105	A/C	cg15711740	chr2:61764176	XPO1	0.42	5.05	0.31	8.48e-7	Tuberculosis;
KIRP	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg02811702	chr13:24901961	NA	0.42	5.46	0.33	1.15e-7	Obesity-related traits;
KIRP	cis	rs7561273	0.586	rs9309225	chr2:24292863	T/C	cg20701182	chr2:24300061	SF3B14	0.44	5.41	0.33	1.5e-7	Quantitative traits;
KIRP	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs6450176	1.000	rs1445887	chr5:53299376	A/T	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.1	-0.36	4.11e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09635681	chr16:19729622	C16orf88;IQCK	0.5	6.19	0.37	2.46e-9	Parkinson's disease;
KIRP	trans	rs61884328	0.866	rs61897307	chr11:46832158	C/A	cg10758369	chr1:48459236	NA	0.52	6.6	0.39	2.46e-10	Total body bone mineral density (age over 60);
KIRP	cis	rs1978968	1.000	rs5992917	chr22:18443699	G/T	cg02610425	chr22:18483192	MICAL3	0.37	5.12	0.31	6.04e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg05484376	chr2:27715224	FNDC4	0.34	5.56	0.33	7.1e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-16.62	-0.73	4.12e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.93	-10.88	-0.57	9.45e-23	Corneal astigmatism;
KIRP	cis	rs4356975	0.563	rs4356974	chr4:69972414	A/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg01304814	chr3:48885189	PRKAR2A	0.64	5.6	0.34	5.84e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg25902810	chr10:99078978	FRAT1	0.58	7.28	0.42	4.41e-12	Monocyte count;
KIRP	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6968419	0.674	rs17138528	chr7:115907289	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.84	-0.35	1.65e-8	Intraocular pressure;
KIRP	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	9.39	0.51	4.21e-18	Lung cancer in ever smokers;
KIRP	cis	rs11825064	0.774	rs2000861	chr11:134496258	A/G	cg06603561	chr11:134479413	NA	-0.6	-5.3	-0.32	2.61e-7	Seasonality;
KIRP	trans	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg08400319	chr2:242004533	SNED1	0.44	6.05	0.36	5.4e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs10214930	0.813	rs7806415	chr7:27673537	C/T	cg22168087	chr7:27702803	HIBADH	0.51	5.07	0.31	7.97e-7	Hypospadias;
KIRP	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-5.22	-0.32	3.78e-7	Lung cancer;
KIRP	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.76	10.41	0.55	2.85e-21	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs61990749	0.597	rs9788540	chr14:78132172	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.7	-6.9	-0.4	4.3e-11	Fibroblast growth factor basic levels;
KIRP	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg00310523	chr12:86230176	RASSF9	0.54	8.43	0.47	2.93e-15	Major depressive disorder;
KIRP	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.5	6.4	0.38	7.66e-10	HDL cholesterol levels;
KIRP	cis	rs10924970	1.000	rs2382567	chr1:235349803	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.08	0.31	7.56e-7	Asthma;
KIRP	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.87	12.44	0.62	6.79e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2274273	1.000	rs3825613	chr14:55593172	A/C	cg04306507	chr14:55594613	LGALS3	0.46	7.07	0.41	1.62e-11	Protein biomarker;
KIRP	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08439880	chr3:133502540	NA	-0.54	-6.51	-0.38	4.16e-10	Iron status biomarkers;
KIRP	cis	rs4561483	0.583	rs62038798	chr16:12001569	C/T	cg08843971	chr16:11963173	GSPT1	0.53	7.54	0.43	9.09e-13	Testicular germ cell tumor;
KIRP	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg15226275	chr6:116381976	FRK	-0.2	-5.29	-0.32	2.75e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.16	14.17	0.67	1.01e-33	Corneal structure;
KIRP	trans	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg14835575	chr10:16859367	RSU1	0.55	7.48	0.43	1.29e-12	Platelet distribution width;
KIRP	cis	rs1364705	0.955	rs1346014	chr8:120224949	G/C	cg09273054	chr8:120220131	MAL2	0.51	6.02	0.36	6.25e-9	Hippocampal atrophy;
KIRP	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg11518657	chr1:67396239	MIER1	0.61	6.01	0.36	6.5e-9	Lymphocyte percentage of white cells;
KIRP	cis	rs71403859	0.685	rs12927044	chr16:71930105	C/A	cg08717414	chr16:71523259	ZNF19	-0.93	-6.19	-0.37	2.56e-9	Post bronchodilator FEV1;
KIRP	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg00310523	chr12:86230176	RASSF9	0.39	5.96	0.36	8.8e-9	Major depressive disorder;
KIRP	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.71	0.44	3.18e-13	Educational attainment;
KIRP	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.78	-11.89	-0.6	4.65e-26	Electrocardiographic conduction measures;
KIRP	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg00908189	chr16:619842	PIGQ	0.84	11.6	0.59	4.13e-25	Height;
KIRP	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.23	-0.42	6.24e-12	Migraine;Coronary artery disease;
KIRP	cis	rs13095912	0.962	rs6785918	chr3:185330631	A/G	cg11274856	chr3:185301563	NA	0.55	7.16	0.42	9.3e-12	Systolic blood pressure;
KIRP	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg25358565	chr5:93447407	FAM172A	-0.55	-6.46	-0.38	5.6e-10	Diabetic retinopathy;
KIRP	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.41	7.98	0.45	5.44e-14	Height;
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.35	-4.91	-0.3	1.62e-6	Bipolar disorder;
KIRP	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.15	15.72	0.71	5.01e-39	Lymphocyte percentage of white cells;
KIRP	cis	rs17428704	0.571	rs16903460	chr5:14394556	G/A	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs4692589	0.540	rs1904823	chr4:170956772	C/T	cg19918862	chr4:170955249	NA	0.6	6.6	0.39	2.55e-10	Anxiety disorder;
KIRP	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg23978390	chr7:1156363	C7orf50	0.56	5.88	0.35	1.3e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs4523957	0.855	rs12603057	chr17:2112567	T/C	cg16513277	chr17:2031491	SMG6	-0.68	-9.49	-0.52	2.17e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1978968	0.826	rs34596632	chr22:18463254	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.72	-8.08	-0.46	2.84e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.91	15.75	0.71	3.99e-39	Headache;
KIRP	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.5	0.48	1.9e-15	Lung cancer in ever smokers;
KIRP	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.59	-4.86	-0.3	2.08e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.39	4.92	0.3	1.57e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.49	7.2	0.42	7.09e-12	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17528648	chr5:38846100	OSMR	0.46	6.74	0.39	1.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.13e-8	Common traits (Other);
KIRP	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-10.46	-0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg06131755	chr6:160182447	ACAT2	0.61	6.44	0.38	6.25e-10	Iron status biomarkers;
KIRP	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.5	7.3	0.42	3.92e-12	Schizophrenia;
KIRP	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg05868516	chr6:26286170	HIST1H4H	0.39	5.2	0.31	4.26e-7	Educational attainment;
KIRP	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.7	10.62	0.56	6.1e-22	Dupuytren's disease;
KIRP	cis	rs4073221	0.860	rs1849477	chr3:18245719	A/G	cg07694806	chr3:18168406	NA	-0.76	-6.51	-0.38	4.07e-10	Parkinson's disease;
KIRP	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg03563238	chr19:33554763	RHPN2	-0.34	-5.79	-0.35	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	5.69	0.34	3.51e-8	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.9	-8.97	-0.5	7.66e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.51	-0.38	4.07e-10	Systemic lupus erythematosus;
KIRP	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.77	-0.35	2.34e-8	Type 2 diabetes;
KIRP	cis	rs7084402	0.967	rs1649063	chr10:60309215	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.5	5.95	0.35	8.94e-9	Metabolite levels;
KIRP	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.56	-6.98	-0.41	2.76e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.76	-8.99	-0.5	6.72e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs34375054	0.573	rs12581813	chr12:125656402	A/G	cg25124228	chr12:125621409	AACS	-0.53	-5.21	-0.32	3.93e-7	Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00544901	chr19:49999417	RPS11	1.01	6.79	0.4	8.28e-11	P wave terminal force;
KIRP	cis	rs8077577	0.895	rs62073615	chr17:18080329	T/A	cg09161412	chr17:18057145	MYO15A	-0.41	-5.32	-0.32	2.29e-7	Obesity-related traits;
KIRP	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-7.82	-0.45	1.54e-13	Breast cancer;
KIRP	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.51	-0.38	4.21e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.79	-0.35	2.17e-8	Colorectal cancer;
KIRP	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.27e-11	Diabetic kidney disease;
KIRP	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00255919	chr5:131827918	IRF1	-0.3	-6.4	-0.38	7.79e-10	Asthma (sex interaction);
KIRP	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg06766960	chr11:133703094	NA	-0.58	-7.33	-0.42	3.4e-12	Childhood ear infection;
KIRP	trans	rs353116	0.697	rs353119	chr2:166130379	C/T	cg23361659	chr2:28914775	NA	0.34	6.66	0.39	1.73e-10	Parkinson's disease;
KIRP	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg22139774	chr2:100720529	AFF3	-0.32	-5.16	-0.31	5.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.31	0.51	7.33e-18	Lymphocyte counts;
KIRP	cis	rs7707921	0.752	rs2406909	chr5:81276087	T/C	cg15871215	chr5:81402204	ATG10	0.47	5.89	0.35	1.25e-8	Breast cancer;
KIRP	cis	rs7715806	0.500	rs34355	chr5:74959970	G/A	cg19683494	chr5:74908142	NA	-0.58	-5.4	-0.33	1.61e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg12940439	chr1:67600707	NA	0.41	6.19	0.37	2.51e-9	Psoriasis;
KIRP	trans	rs2048656	0.637	rs10107396	chr8:9673152	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.15	-0.41	1e-11	Schizophrenia;
KIRP	cis	rs3755132	0.929	rs61314003	chr2:15748524	A/G	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	0.94	16.11	0.72	2.37e-40	Ulcerative colitis;
KIRP	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg18709589	chr6:96969512	KIAA0776	0.33	5.01	0.3	1.05e-6	Headache;
KIRP	cis	rs2594989	0.887	rs9850117	chr3:11571991	C/T	cg01796438	chr3:11312864	ATG7	0.68	7.91	0.45	8.81e-14	Circulating chemerin levels;
KIRP	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.62	8.72	0.49	4.12e-16	Endometrial cancer;
KIRP	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg04935436	chr20:30431758	NA	-0.49	-6.54	-0.39	3.46e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9815354	0.638	rs75687617	chr3:42044664	C/T	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.56	6.78	0.4	9.08e-11	Longevity;Endometriosis;
KIRP	cis	rs6921919	0.583	rs4642462	chr6:28389251	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.56	7.73	0.44	2.66e-13	Longevity;Endometriosis;
KIRP	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.75	-0.49	3.55e-16	Triglycerides;
KIRP	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.68	-0.39	1.55e-10	Neuroticism;
KIRP	cis	rs911119	1.000	rs13039536	chr20:23612305	A/G	cg16589663	chr20:23618590	CST3	0.63	6.17	0.37	2.83e-9	Chronic kidney disease;
KIRP	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg06740227	chr12:86229804	RASSF9	-0.48	-5.88	-0.35	1.34e-8	Major depressive disorder;
KIRP	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.72	-10.44	-0.55	2.26e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	8.63	0.48	7.9e-16	Bipolar disorder;
KIRP	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	0.72	9.83	0.53	1.9e-19	Red blood cell count;
KIRP	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.55	7.67	0.44	3.97e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg11846333	chr4:119757529	SEC24D	0.96	5.72	0.34	3.04e-8	Cannabis dependence symptom count;
KIRP	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg12405258	chr13:114927641	NA	0.46	6.59	0.39	2.58e-10	Schizophrenia;
KIRP	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9972944	0.729	rs7222147	chr17:63774100	C/T	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg25319279	chr11:5960081	NA	-0.62	-6.37	-0.38	9.46e-10	DNA methylation (variation);
KIRP	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg07972983	chr1:205091412	RBBP5	0.43	5.22	0.32	3.85e-7	Red blood cell count;
KIRP	cis	rs6001982	0.665	rs5995856	chr22:40849062	C/T	cg07138101	chr22:40742427	ADSL	0.72	6.35	0.38	1.02e-9	Breast cancer;
KIRP	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00149659	chr3:10157352	C3orf10	0.81	8.9	0.49	1.21e-16	Alzheimer's disease;
KIRP	cis	rs882732	1.000	rs1005348	chr14:95033275	T/G	cg08495878	chr14:95027859	SERPINA4	-0.41	-5.09	-0.31	7.07e-7	Blood protein levels;
KIRP	cis	rs11203032	0.831	rs4078488	chr10:90966546	C/T	cg16672925	chr10:90967113	CH25H	0.82	7.52	0.43	1.05e-12	Heart failure;
KIRP	cis	rs11871801	0.517	rs60929812	chr17:40759448	G/A	cg14558262	chr17:40713999	COASY	0.47	5.06	0.31	8.02e-7	Crohn's disease;
KIRP	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg22906224	chr7:99728672	NA	-0.65	-7.91	-0.45	8.67e-14	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg26174226	chr8:58114915	NA	-0.61	-7.15	-0.41	1e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.41	8.35	0.47	4.91e-15	Mean corpuscular volume;
KIRP	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg21858823	chr1:15850916	CASP9	0.51	5.29	0.32	2.65e-7	Systolic blood pressure;
KIRP	cis	rs11731606	0.508	rs10000820	chr4:95313493	G/A	cg00507259	chr4:95128692	SMARCAD1	0.6	5.67	0.34	3.92e-8	Mean platelet volume;
KIRP	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.73	8.76	0.49	3.14e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs503734	0.502	rs348880	chr3:100981426	A/G	cg27318481	chr3:100970896	IMPG2	-0.59	-8.03	-0.46	3.92e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.32	5.25	0.32	3.27e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.95	-0.3	1.37e-6	Blood metabolite levels;
KIRP	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg17554472	chr22:41940697	POLR3H	-0.59	-6.62	-0.39	2.28e-10	Vitiligo;
KIRP	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.82	-12.36	-0.62	1.31e-27	Height;
KIRP	trans	rs6901152	0.525	rs4896651	chr6:143691393	A/G	ch.6.154106492R	chr6:154064799	NA	0.39	6.52	0.38	4.04e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2241685	0.850	rs7591787	chr2:1942841	C/T	cg22511877	chr2:1942942	MYT1L	-0.65	-6.12	-0.36	3.74e-9	Attention deficit hyperactivity disorder;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg11873147	chr2:119915139	C1QL2	-0.4	-6.67	-0.39	1.71e-10	Serum protein levels (sST2);
KIRP	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg01214346	chr17:406501	NA	-0.47	-6.01	-0.36	6.81e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg21051989	chr6:90121833	RRAGD	-0.54	-7.18	-0.42	8.04e-12	Blood metabolite levels;
KIRP	cis	rs9426935	0.966	rs6700115	chr1:153781888	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	0.28	4.87	0.3	2.01e-6	Lentiform nucleus volume;
KIRP	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.75	-0.34	2.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg12623918	chr2:306882	NA	0.51	6.28	0.37	1.56e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg17888390	chr10:101282816	NA	-0.27	-4.88	-0.3	1.88e-6	Dental caries;
KIRP	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.71	9.22	0.51	1.42e-17	Blood metabolite levels;
KIRP	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg26354017	chr1:205819088	PM20D1	-0.6	-5.91	-0.35	1.13e-8	Menarche (age at onset);
KIRP	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.67	-9.74	-0.53	3.48e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-5.74	-0.34	2.79e-8	Parkinson's disease;
KIRP	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.28	0.62	2.4e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7551222	0.721	rs1460036	chr1:204527379	A/G	cg20240347	chr1:204465584	NA	-0.44	-8.42	-0.47	3.07e-15	Schizophrenia;
KIRP	cis	rs9660180	0.967	rs66701417	chr1:1698092	A/G	cg16926213	chr1:1841314	NA	0.34	5.79	0.35	2.1e-8	Body mass index;
KIRP	cis	rs1021993	0.672	rs2495295	chr1:209489688	C/T	cg06155620	chr1:209527581	NA	0.35	4.87	0.3	1.97e-6	Gut microbiome composition (winter);
KIRP	cis	rs9311676	0.618	rs62258135	chr3:58403330	C/T	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg14829360	chr17:73884958	NA	-0.45	-5.89	-0.35	1.23e-8	White matter hyperintensity burden;
KIRP	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg01631408	chr1:248437212	OR2T33	-0.64	-8.5	-0.48	1.87e-15	Common traits (Other);
KIRP	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg17507749	chr15:85114479	UBE2QP1	0.83	9.27	0.51	1e-17	Schizophrenia;
KIRP	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.75	-0.44	2.47e-13	Response to antipsychotic treatment;
KIRP	cis	rs2905347	0.757	rs2961295	chr7:22696272	C/T	cg23521230	chr7:22704884	NA	-0.42	-5.44	-0.33	1.31e-7	Major depression and alcohol dependence;
KIRP	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.57	6.37	0.38	9.25e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg21479132	chr6:26055353	NA	-0.79	-5.07	-0.31	7.85e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.47	6.2	0.37	2.41e-9	Lymphocyte percentage of white cells;
KIRP	cis	rs6662572	0.686	rs72692639	chr1:46446096	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.19	0.31	4.37e-7	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.99	-17.18	-0.74	5.1e-44	Breast cancer;
KIRP	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	10.56	0.56	9.77e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	5.25	0.32	3.36e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.11e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg15841412	chr13:111365552	ING1	-0.49	-5.26	-0.32	3.06e-7	Coronary artery disease;
KIRP	cis	rs7709377	0.597	rs10079691	chr5:115472076	A/G	cg23108291	chr5:115420582	COMMD10	-0.41	-4.9	-0.3	1.76e-6	Metabolite levels  (X-11787);
KIRP	trans	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg25042112	chr7:64838748	ZNF92	-0.6	-6.34	-0.37	1.1e-9	Pain;
KIRP	cis	rs7224685	0.569	rs8066707	chr17:3996550	T/C	cg09695851	chr17:3907499	NA	0.54	5.2	0.31	4.29e-7	Type 2 diabetes;
KIRP	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.42	-5.21	-0.32	4.03e-7	Platelet count;
KIRP	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.6	-9.34	-0.51	6.1e-18	Coronary artery disease;
KIRP	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg17554472	chr22:41940697	POLR3H	0.41	4.96	0.3	1.29e-6	Vitiligo;
KIRP	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg27624424	chr6:160112604	SOD2	0.47	4.88	0.3	1.89e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg21475434	chr5:93447410	FAM172A	-0.65	-5.21	-0.32	3.91e-7	Diabetic retinopathy;
KIRP	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg23024343	chr7:107201750	COG5	0.41	4.92	0.3	1.57e-6	Coronary artery disease;
KIRP	trans	rs7939886	0.920	rs7933691	chr11:56046900	G/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.53	-5.74	-0.34	2.75e-8	Diisocyanate-induced asthma;
KIRP	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.45	7.31	0.42	3.78e-12	Testicular germ cell tumor;
KIRP	cis	rs13343954	0.778	rs10425324	chr19:33541302	C/T	cg17764715	chr19:33622953	WDR88	0.7	7.93	0.45	7.83e-14	Colorectal cancer;
KIRP	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.77	8.69	0.48	5.16e-16	Corneal astigmatism;
KIRP	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.72	7.52	0.43	1.04e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg22857025	chr5:266934	NA	-0.81	-6.23	-0.37	2.04e-9	Breast cancer;
KIRP	cis	rs1829883	0.701	rs6594575	chr5:98980037	C/G	cg08333243	chr5:99726346	NA	-0.43	-5.78	-0.35	2.23e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05776053	chr2:74358815	NA	0.52	5.38	0.32	1.74e-7	Gestational age at birth (maternal effect);
KIRP	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	trans	rs55728055	0.661	rs62237849	chr22:32029807	T/C	cg02791973	chr19:1132256	SBNO2	-0.59	-6.49	-0.38	4.65e-10	Age-related hearing impairment;
KIRP	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg17863274	chr19:49399704	TULP2	-0.41	-5.8	-0.35	2.08e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.4	-0.38	7.8e-10	Breast cancer;
KIRP	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.68	-8.12	-0.46	2.32e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.01	-7.57	-0.43	7.63e-13	Mitochondrial DNA levels;
KIRP	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg00101154	chr16:420108	MRPL28	-0.63	-7.34	-0.42	3.17e-12	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs7809615	0.901	rs6947941	chr7:99156446	G/T	cg24024660	chr7:99195788	NA	-0.57	-5.07	-0.31	7.78e-7	Blood metabolite ratios;
KIRP	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg07862535	chr7:139043722	LUC7L2	0.49	5.51	0.33	8.97e-8	Diisocyanate-induced asthma;
KIRP	cis	rs13132184	0.507	rs12649018	chr4:38060085	A/G	cg14409701	chr4:38048871	TBC1D1	-0.79	-7.4	-0.43	2.1e-12	Verbal declarative memory;
KIRP	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg07636037	chr3:49044803	WDR6	0.58	5.63	0.34	5.03e-8	Menarche (age at onset);
KIRP	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg06521331	chr12:34319734	NA	-0.61	-7.33	-0.42	3.25e-12	Morning vs. evening chronotype;
KIRP	cis	rs7937612	0.965	rs10892564	chr11:120224650	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.62	-0.39	2.19e-10	Intraocular pressure;
KIRP	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-5.05	-0.31	8.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	6.17	0.37	2.84e-9	Depressive symptoms;
KIRP	cis	rs2273669	0.667	rs77002235	chr6:109321497	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.99	-0.36	7.59e-9	Prostate cancer;
KIRP	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg19402173	chr7:128379420	CALU	-0.62	-8.05	-0.46	3.59e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6499755	0.712	rs31114	chr16:55380055	C/T	cg05099576	chr16:55362342	IRX6	0.29	5.81	0.35	1.95e-8	Hypospadias;
KIRP	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.57	-7.81	-0.45	1.68e-13	Lung cancer;
KIRP	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.62	-8.44	-0.47	2.81e-15	Total body bone mineral density;
KIRP	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.44	6.18	0.37	2.67e-9	Testicular germ cell tumor;
KIRP	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.7	0.56	3.42e-22	Cognitive test performance;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg01870619	chr5:32444265	ZFR	-0.46	-6.11	-0.36	3.83e-9	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06130950	chr11:123612538	ZNF202	0.5	7.34	0.42	3.14e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.5	12.99	0.64	1e-29	Cutaneous nevi;
KIRP	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.91	-0.4	4.03e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4148660	1.000	rs1421602	chr12:22061731	A/G	cg14669847	chr12:22099120	NA	0.35	5.98	0.36	7.7e-9	Gout;
KIRP	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg15556689	chr8:8085844	FLJ10661	0.78	10.32	0.55	5.4e-21	Mood instability;
KIRP	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06504518	chr5:133984392	SEC24A	0.53	6.78	0.4	8.74e-11	Parkinson's disease;
KIRP	cis	rs4805834	0.719	rs55977451	chr19:33298122	A/G	cg07201929	chr19:33182834	NUDT19	-0.62	-5.24	-0.32	3.45e-7	Creatinine levels;
KIRP	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.67	8.9	0.49	1.29e-16	Morning vs. evening chronotype;
KIRP	cis	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs4356975	0.583	rs62296935	chr4:69948596	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	4.95	0.3	1.4e-6	Obesity-related traits;
KIRP	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.44	-6.12	-0.36	3.73e-9	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg09699651	chr6:150184138	LRP11	0.59	7.88	0.45	1.03e-13	Lung cancer;
KIRP	cis	rs9815354	1.000	rs9847006	chr3:41755359	T/C	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.33e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1978968	0.833	rs5992941	chr22:18463747	T/C	cg03078520	chr22:18463400	MICAL3	-0.82	-11.23	-0.58	6.61e-24	Presence of antiphospholipid antibodies;
KIRP	trans	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg10756647	chr7:56101905	PSPH	0.98	7.0	0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg10047753	chr17:41438598	NA	1.14	17.91	0.75	1.73e-46	Menopause (age at onset);
KIRP	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.77	0.53	2.95e-19	Corneal astigmatism;
KIRP	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.37	5.61	0.34	5.56e-8	Coronary artery disease;
KIRP	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11987759	chr7:65425863	GUSB	-0.61	-8.13	-0.46	2.08e-14	Aortic root size;
KIRP	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.89	-0.49	1.36e-16	Hirschsprung disease;
KIRP	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.59	7.24	0.42	5.6e-12	Aortic root size;
KIRP	cis	rs4006360	0.628	rs439075	chr17:39239467	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.62	-9.64	-0.52	7.09e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg04398451	chr17:18023971	MYO15A	-0.47	-5.54	-0.33	7.78e-8	Total body bone mineral density;
KIRP	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg04733989	chr22:42467013	NAGA	0.61	8.26	0.47	9.19e-15	Cognitive function;
KIRP	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.87	-12.1	-0.61	9.26e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.8	-10.8	-0.57	1.71e-22	Systemic lupus erythematosus;
KIRP	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.67	10.14	0.54	2.05e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-12.94	-0.64	1.43e-29	Dental caries;
KIRP	cis	rs2274273	0.638	rs17672364	chr14:55705904	G/T	cg04306507	chr14:55594613	LGALS3	0.42	5.58	0.34	6.4e-8	Protein biomarker;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15604097	chr19:46390101	IRF2BP1	0.48	6.02	0.36	6.46e-9	Parkinson's disease;
KIRP	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.7	-0.44	3.39e-13	Mean platelet volume;
KIRP	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.32	-0.47	6.13e-15	Personality dimensions;
KIRP	cis	rs6670533	0.571	rs7540973	chr1:24864576	G/T	cg07475527	chr1:24864545	NA	-0.98	-8.46	-0.47	2.38e-15	Fasting blood insulin (BMI interaction);
KIRP	cis	rs2950163	0.898	rs2609101	chr2:6185634	A/C	cg26659079	chr2:5836181	SOX11	0.38	4.91	0.3	1.62e-6	Response to metformin (IC50);
KIRP	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.47	-0.48	2.21e-15	Retinal vascular caliber;
KIRP	cis	rs6568686	0.786	rs7450789	chr6:111816975	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.6	-5.42	-0.33	1.45e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.65	7.97	0.45	5.76e-14	Obesity-related traits;
KIRP	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	1.03	13.25	0.65	1.3e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4132509	1.000	rs2291410	chr1:243716654	A/C	cg21452805	chr1:244014465	NA	-0.47	-5.07	-0.31	7.69e-7	RR interval (heart rate);
KIRP	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg00806126	chr19:22604979	ZNF98	0.63	6.66	0.39	1.79e-10	Pain;
KIRP	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg02569458	chr12:86230093	RASSF9	0.35	5.15	0.31	5.44e-7	Major depressive disorder;
KIRP	cis	rs1823913	0.614	rs11693878	chr2:192164125	G/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.26	-0.37	1.67e-9	Obesity-related traits;
KIRP	cis	rs6987853	0.688	rs2923433	chr8:42418723	T/C	cg09913449	chr8:42400586	C8orf40	0.39	5.24	0.32	3.38e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.87e-10	Fibrinogen levels;
KIRP	trans	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg06521331	chr12:34319734	NA	-0.49	-6.21	-0.37	2.24e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.9	0.35	1.23e-8	Schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23766305	chr17:27507501	MYO18A	0.48	6.17	0.37	2.77e-9	Myopia (pathological);
KIRP	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13047869	chr3:10149882	C3orf24	0.6	5.46	0.33	1.18e-7	Alzheimer's disease;
KIRP	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.03	-0.36	6.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg27124370	chr19:33622961	WDR88	0.6	7.43	0.43	1.84e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg22875332	chr1:76189707	ACADM	-0.34	-4.91	-0.3	1.63e-6	Daytime sleep phenotypes;
KIRP	cis	rs1009181	0.585	rs9379830	chr6:26173767	T/C	cg00631329	chr6:26305371	NA	-0.57	-6.01	-0.36	6.49e-9	Childhood ear infection;
KIRP	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.6	8.03	0.46	3.94e-14	Lymphocyte counts;
KIRP	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg17724175	chr1:150552817	MCL1	-0.32	-5.37	-0.32	1.82e-7	Melanoma;
KIRP	trans	rs1424233	1.000	rs1364340	chr16:79676682	G/A	cg11120865	chr14:21853037	SUPT16H	0.37	6.03	0.36	5.91e-9	Obesity;
KIRP	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg18190219	chr22:46762943	CELSR1	-0.72	-7.58	-0.44	7.01e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.22	-0.32	3.9e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg08994789	chr17:28903642	LRRC37B2	0.66	5.48	0.33	1.07e-7	Body mass index;
KIRP	trans	rs2075423	1.000	rs2075423	chr1:214154719	A/C	cg14479377	chr9:138742730	CAMSAP1	0.35	6.07	0.36	4.87e-9	Type 2 diabetes;
KIRP	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg22906224	chr7:99728672	NA	-0.65	-7.91	-0.45	8.67e-14	Coronary artery disease;
KIRP	cis	rs1577917	0.545	rs1335443	chr6:86478737	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-7.6	-0.44	6.37e-13	Response to antipsychotic treatment;
KIRP	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg24807547	chr6:37504484	NA	-0.62	-10.06	-0.54	3.77e-20	Cognitive performance;
KIRP	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.52	6.05	0.36	5.41e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs16976116	0.951	rs13733	chr15:55489104	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.91	0.45	8.93e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9914544	0.628	rs9908821	chr17:18679404	A/G	cg26378065	chr17:18585709	ZNF286B	0.4	5.05	0.31	8.41e-7	Educational attainment (years of education);
KIRP	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.47	6.09	0.36	4.39e-9	Multiple sclerosis;
KIRP	cis	rs5995756	0.666	rs3788567	chr22:40006035	G/T	cg10455938	chr22:40058150	CACNA1I	0.4	5.4	0.33	1.55e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.8	14.89	0.69	3.54e-36	Lymphocyte counts;
KIRP	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg17376030	chr22:41985996	PMM1	-0.51	-6.28	-0.37	1.48e-9	Cannabis dependence symptom count;
KIRP	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.91	-0.4	4.06e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.56	-7.28	-0.42	4.4e-12	Aortic root size;
KIRP	cis	rs4774830	0.744	rs2288346	chr15:56139153	T/C	cg05129572	chr15:56138634	NEDD4	-0.65	-5.43	-0.33	1.37e-7	Delta-5 desaturase activity;
KIRP	cis	rs883565	0.582	rs7623343	chr3:39146792	A/C	cg01426195	chr3:39028469	NA	-0.64	-10.4	-0.55	3.09e-21	Handedness;
KIRP	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	0.76	6.23	0.37	2.06e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg07796016	chr1:152779584	LCE1C	-0.55	-6.92	-0.4	3.88e-11	Inflammatory skin disease;
KIRP	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.93	-0.57	6.29e-23	Height;
KIRP	cis	rs72627123	0.867	rs8019192	chr14:74471267	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.97	0.3	1.24e-6	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.88	14.21	0.67	7.17e-34	Breast cancer;
KIRP	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.94	14.88	0.69	3.67e-36	Metabolite levels;
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.57	7.74	0.44	2.63e-13	Menarche (age at onset);
KIRP	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-5.65	-0.34	4.51e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.77	8.39	0.47	3.8e-15	Corneal astigmatism;
KIRP	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg18709589	chr6:96969512	KIAA0776	0.38	5.07	0.31	7.95e-7	Migraine;Coronary artery disease;
KIRP	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.75	-10.81	-0.57	1.57e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.63	10.42	0.55	2.74e-21	Coronary artery disease;
KIRP	cis	rs787274	1.000	rs1891403	chr9:115527183	C/T	cg13803584	chr9:115635662	SNX30	-0.74	-8.38	-0.47	4.15e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6901250	0.759	rs9489040	chr6:117131740	G/A	cg05399210	chr6:117082661	FAM162B	-0.41	-5.6	-0.34	5.57e-8	C-reactive protein levels;
KIRP	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg01528321	chr10:82214614	TSPAN14	1.04	11.57	0.59	5.23e-25	Post bronchodilator FEV1;
KIRP	cis	rs7520050	0.966	rs4660317	chr1:46326226	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.05e-8	Lung cancer;
KIRP	cis	rs3126085	0.560	rs3120666	chr1:152316981	G/C	cg26876637	chr1:152193138	HRNR	-0.55	-6.51	-0.38	4.11e-10	Atopic dermatitis;
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg21734707	chr17:3908241	ZZEF1	-0.62	-9.08	-0.5	3.54e-17	Type 2 diabetes;
KIRP	cis	rs7534824	0.625	rs61780281	chr1:101324152	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.83	7.03	0.41	1.98e-11	Refractive astigmatism;
KIRP	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg21775007	chr8:11205619	TDH	-0.44	-5.77	-0.35	2.36e-8	Triglycerides;
KIRP	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	0.87	10.37	0.55	3.94e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs12210905	1.000	rs12196084	chr6:27198204	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.54	-0.38	3.59e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.59	9.75	0.53	3.41e-19	Schizophrenia;
KIRP	cis	rs4950322	0.580	rs72706441	chr1:146594183	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-5.07	-0.31	7.85e-7	Protein quantitative trait loci;
KIRP	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.18	-0.31	4.52e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2048656	0.578	rs7817784	chr8:9682553	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.8	-0.45	1.74e-13	Schizophrenia;
KIRP	cis	rs13385	0.769	rs13163983	chr5:139622572	A/C	cg01860693	chr5:139557145	C5orf32	0.46	5.11	0.31	6.6e-7	Atrial fibrillation;
KIRP	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.57	8.04	0.46	3.78e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.79	-10.5	-0.56	1.53e-21	Longevity;
KIRP	cis	rs714027	0.605	rs4820830	chr22:30531091	C/T	cg01021169	chr22:30184971	ASCC2	0.43	5.4	0.33	1.54e-7	Lymphocyte counts;
KIRP	trans	rs12517041	1.000	rs1428619	chr5:23282426	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs282587	0.569	rs282598	chr13:113384331	A/G	cg04656015	chr13:113407548	ATP11A	0.66	8.0	0.45	4.8e-14	Glycated hemoglobin levels;
KIRP	cis	rs1143633	1.000	rs1143633	chr2:113590467	A/G	cg12858261	chr2:113808755	IL1F8	0.43	5.05	0.31	8.68e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg18209359	chr17:80159595	CCDC57	0.42	5.51	0.33	9.25e-8	Life satisfaction;
KIRP	cis	rs2033732	0.673	rs2401050	chr8:85054711	C/T	cg05716166	chr8:85095498	RALYL	0.54	6.05	0.36	5.36e-9	Body mass index;
KIRP	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.74	9.48	0.52	2.2e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.99	0.61	2.09e-26	Monocyte percentage of white cells;
KIRP	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg02297831	chr4:17616191	MED28	0.58	7.38	0.43	2.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.79	6.38	0.38	8.54e-10	Fat distribution (HIV);
KIRP	cis	rs3767633	0.925	rs1394070	chr1:161814020	T/G	cg09175582	chr1:161736000	ATF6	0.74	5.97	0.36	8.39e-9	IgG glycosylation;
KIRP	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.63	-7.5	-0.43	1.17e-12	Systemic lupus erythematosus;
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21016266	chr12:122356598	WDR66	0.66	8.8	0.49	2.5e-16	Mean corpuscular volume;
KIRP	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg08501292	chr6:25962987	TRIM38	1.02	7.99	0.45	5.14e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.59	6.72	0.39	1.29e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.93	12.55	0.62	3.06e-28	Vitamin D levels;
KIRP	cis	rs1365505	0.600	rs4238381	chr15:50484714	A/T	cg26188685	chr15:50540269	HDC	0.35	5.92	0.35	1.09e-8	Blood metabolite ratios;
KIRP	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg24579218	chr15:68104479	NA	-0.45	-6.7	-0.39	1.4e-10	Obesity;
KIRP	cis	rs7688540	0.771	rs11724176	chr4:224901	C/T	cg17891759	chr4:299121	NA	-0.52	-5.39	-0.33	1.62e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.84	-0.35	1.68e-8	Educational attainment;
KIRP	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg06740227	chr12:86229804	RASSF9	-0.5	-6.43	-0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg14221460	chr8:27183342	PTK2B	0.5	6.55	0.39	3.24e-10	Neuroticism;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23024824	chr15:70349890	TLE3	0.48	6.19	0.37	2.54e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1816752	0.875	rs7993132	chr13:24987041	C/T	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	trans	rs35100037	0.730	rs10055331	chr5:128613294	A/T	cg23338408	chr14:31289523	NA	-0.61	-6.23	-0.37	2.02e-9	Ankle injury;
KIRP	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.22e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4783244	0.794	rs12596316	chr16:82646152	C/T	cg09415485	chr16:82663111	CDH13	0.27	4.92	0.3	1.57e-6	Adiponectin levels;
KIRP	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.77	11.18	0.58	9.56e-24	Total body bone mineral density;
KIRP	cis	rs2505998	0.833	rs2505535	chr10:43593043	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.75	-0.34	2.58e-8	Hirschsprung disease;
KIRP	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg14580859	chr9:123691850	NA	0.35	5.0	0.3	1.08e-6	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.32	-0.32	2.35e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.57	0.39	2.96e-10	Neuroticism;
KIRP	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs12900413	0.687	rs72754547	chr15:90308166	A/C	cg24650279	chr15:90327240	NA	-0.41	-5.27	-0.32	2.93e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-4.96	-0.3	1.29e-6	Large artery stroke;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17626178	chr2:205410273	PARD3B	0.54	6.6	0.39	2.47e-10	Parkinson's disease;
KIRP	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-5.47	-0.33	1.11e-7	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg05315796	chr3:52349193	DNAH1	0.44	6.78	0.4	9.07e-11	Bipolar disorder;
KIRP	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg16606324	chr3:10149918	C3orf24	-0.64	-6.21	-0.37	2.27e-9	Alzheimer's disease;
KIRP	cis	rs687432	0.679	rs3853676	chr11:57893967	A/C	cg19752551	chr11:57585705	CTNND1	-0.62	-8.29	-0.47	7.28e-15	Parkinson's disease;
KIRP	cis	rs7119038	0.509	rs10892257	chr11:118579327	G/A	cg19308663	chr11:118741387	NA	0.41	6.4	0.38	7.8e-10	Sjögren's syndrome;
KIRP	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.4	7.65	0.44	4.64e-13	Height;
KIRP	cis	rs17221829	0.703	rs10047486	chr11:89405190	A/G	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.13	-0.31	5.82e-7	Anxiety in major depressive disorder;
KIRP	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.56	7.5	0.43	1.12e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6466055	0.777	rs10238507	chr7:104807207	G/T	cg04380332	chr7:105027541	SRPK2	0.61	9.49	0.52	2.16e-18	Schizophrenia;
KIRP	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.26	17.69	0.75	9.67e-46	Atopic dermatitis;
KIRP	cis	rs7246865	0.510	rs7254154	chr19:17178119	A/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.53	6.69	0.39	1.49e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs7612445	1.000	rs7612445	chr3:179172979	G/T	cg01750654	chr3:179170617	GNB4	-0.58	-6.44	-0.38	6.12e-10	Resting heart rate;Heart rate;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17665931	chr19:38894173	FAM98C	-0.46	-6.16	-0.37	2.96e-9	Myopia;
KIRP	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.8	13.43	0.65	3.28e-31	Longevity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12990844	chr2:170655321	SSB	0.52	6.93	0.4	3.67e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg09579323	chr1:150459698	TARS2	0.41	4.86	0.3	2.1e-6	Migraine;
KIRP	cis	rs1359582	0.801	rs2576167	chr10:90345671	A/C	cg15661332	chr10:90342814	RNLS	0.59	5.96	0.36	8.81e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs4356932	1.000	rs3921	chr4:76942943	C/G	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.22e-6	Blood protein levels;
KIRP	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg13606994	chr1:44402422	ARTN	-0.28	-5.63	-0.34	4.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.79	-0.49	2.68e-16	Coronary artery disease;
KIRP	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.65	-9.38	-0.51	4.67e-18	Retinal vascular caliber;
KIRP	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.34	-0.37	1.12e-9	Coronary artery disease;
KIRP	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.81	8.19	0.46	1.46e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs4356975	0.522	rs7679184	chr4:69965930	C/G	cg27372994	chr4:70080453	UGT2B11	0.37	4.97	0.3	1.27e-6	Obesity-related traits;
KIRP	cis	rs4262150	0.883	rs72799190	chr5:152187123	T/G	cg12297329	chr5:152029980	NA	-0.66	-8.52	-0.48	1.67e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg13482628	chr17:19912719	NA	0.61	8.68	0.48	5.61e-16	Schizophrenia;
KIRP	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.47	5.23	0.32	3.67e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.97	-0.3	1.25e-6	Systemic lupus erythematosus;
KIRP	cis	rs2665103	0.610	rs1972460	chr15:82530630	A/G	cg00614314	chr15:82944287	LOC80154	0.38	4.99	0.3	1.15e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12956079	chr19:10764738	ILF3;LOC147727	0.49	6.43	0.38	6.59e-10	Parkinson's disease;
KIRP	cis	rs6662572	0.737	rs9429184	chr1:46524739	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.78	0.35	2.26e-8	Blood protein levels;
KIRP	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.6	-7.37	-0.43	2.52e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg11262906	chr1:85462892	MCOLN2	-0.56	-6.45	-0.38	5.78e-10	Serum sulfate level;
KIRP	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg13334819	chr7:99746414	C7orf59	0.52	5.99	0.36	7.47e-9	Coronary artery disease;
KIRP	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.73	9.28	0.51	8.88e-18	Corneal astigmatism;
KIRP	cis	rs1832871	0.599	rs661857	chr6:158658788	T/C	cg07215822	chr6:158701037	NA	-0.63	-9.21	-0.51	1.46e-17	Height;
KIRP	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.62	10.16	0.54	1.77e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs6142102	0.961	rs2300204	chr20:32588773	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	6.81	0.4	7.38e-11	Skin pigmentation;
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg18234130	chr8:27182889	PTK2B	0.57	7.43	0.43	1.84e-12	Neuroticism;
KIRP	cis	rs4671458	1.000	rs4671458	chr2:63374063	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-5.64	-0.34	4.73e-8	Subjective well-being;
KIRP	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.82	10.31	0.55	6.09e-21	Mean platelet volume;
KIRP	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.44	4.84	0.3	2.27e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	5.48	0.33	1.03e-7	Schizophrenia;
KIRP	cis	rs7909791	0.632	rs3752949	chr10:105670503	A/G	cg11005552	chr10:105648138	OBFC1	0.45	5.03	0.31	9.6e-7	White matter hyperintensity burden;
KIRP	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.6	7.87	0.45	1.14e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.82	11.33	0.59	3.17e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.7	8.1	0.46	2.54e-14	Smoking initiation;
KIRP	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.75	12.38	0.62	1.06e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23281280	chr6:28129359	ZNF389	-0.51	-5.71	-0.34	3.29e-8	Depression;
KIRP	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.65	-9.87	-0.53	1.43e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7590368	0.715	rs55863332	chr2:10958976	A/G	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.82	12.96	0.64	1.24e-29	Multiple myeloma (IgH translocation);
KIRP	cis	rs3790645	0.958	rs7543005	chr1:26879376	T/C	cg23229016	chr1:26872525	RPS6KA1	0.23	6.13	0.36	3.53e-9	Glucose homeostasis traits;
KIRP	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.6	0.48	9.41e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13401104	0.587	rs62190974	chr2:237145263	C/T	cg19324714	chr2:237145437	ASB18	0.57	6.68	0.39	1.59e-10	Educational attainment;
KIRP	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.98	16.23	0.72	8.91e-41	Menopause (age at onset);
KIRP	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg07382826	chr16:28625726	SULT1A1	0.47	5.47	0.33	1.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9308731	0.591	rs10199020	chr2:111946456	T/A	cg04780086	chr2:111875790	ACOXL	0.37	4.95	0.3	1.38e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg00931491	chr16:28608288	SULT1A2	-0.25	-4.97	-0.3	1.28e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.43	5.81	0.35	1.96e-8	Blood metabolite levels;
KIRP	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.36	-0.38	9.89e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	7.14e-8	Breast cancer;
KIRP	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.42	-0.33	1.39e-7	Coronary artery disease;
KIRP	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.66	0.39	1.75e-10	Educational attainment;
KIRP	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.18	-0.42	8.16e-12	Neuroticism;
KIRP	cis	rs3790645	1.000	rs3127013	chr1:26891360	T/G	cg23229016	chr1:26872525	RPS6KA1	0.23	6.13	0.36	3.41e-9	Glucose homeostasis traits;
KIRP	cis	rs3733418	0.860	rs13129396	chr4:165936346	G/A	cg10852876	chr4:165953100	TRIM60	-0.47	-5.1	-0.31	6.66e-7	Obesity-related traits;
KIRP	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	8.44	0.47	2.83e-15	Coffee consumption (cups per day);
KIRP	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg27147174	chr7:100797783	AP1S1	-0.67	-8.23	-0.46	1.08e-14	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg02462569	chr6:150064036	NUP43	-0.39	-6.07	-0.36	4.93e-9	Lung cancer;
KIRP	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06481639	chr22:41940642	POLR3H	0.51	5.77	0.35	2.38e-8	Vitiligo;
KIRP	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg20578329	chr17:80767326	TBCD	-0.39	-5.34	-0.32	2.13e-7	Breast cancer;
KIRP	cis	rs13315871	0.929	rs71311849	chr3:58230809	G/A	cg20936604	chr3:58311152	NA	-0.69	-5.88	-0.35	1.32e-8	Cholesterol, total;
KIRP	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.89	13.55	0.65	1.31e-31	Dental caries;
KIRP	cis	rs2425143	1.000	rs1056196	chr20:34327159	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.69	-0.44	3.57e-13	Myopia (pathological);
KIRP	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.5	-5.86	-0.35	1.46e-8	IgG glycosylation;
KIRP	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.82	-0.35	1.78e-8	Bipolar disorder;
KIRP	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.35	-6.12	-0.36	3.6e-9	Refractive error;
KIRP	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.79	0.35	2.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.07	8.81	0.49	2.35e-16	Mitochondrial DNA levels;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg24874828	chr4:187887005	NA	-0.47	-7.02	-0.41	2.21e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3218477	1.000	rs3218480	chr7:152356614	A/C	cg06618968	chr7:152373420	XRCC2	0.84	5.49	0.33	9.97e-8	Mean platelet volume;
KIRP	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.83	-13.14	-0.64	3.2e-30	Oral cavity cancer;
KIRP	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg04080417	chr5:1859792	NA	-0.56	-6.32	-0.37	1.2e-9	Cardiovascular disease risk factors;
KIRP	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.67	-9.25	-0.51	1.15e-17	Schizophrenia;
KIRP	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.04	-17.28	-0.74	2.49e-44	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs236907	0.859	rs12730717	chr1:171756515	C/T	cg01410279	chr1:171621941	MYOC	-0.49	-5.46	-0.33	1.13e-7	Mean platelet volume;
KIRP	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.0	-15.41	-0.7	5.92e-38	Primary sclerosing cholangitis;
KIRP	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.35	-4.89	-0.3	1.85e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.73	-9.52	-0.52	1.66e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21747090	chr2:27597821	SNX17	-0.49	-6.79	-0.4	8.54e-11	Total body bone mineral density;
KIRP	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg16141378	chr3:129829833	LOC729375	0.56	7.84	0.45	1.33e-13	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02490182	chr8:103563653	ODF1	-0.4	-6.22	-0.37	2.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.73	0.49	3.98e-16	Morning vs. evening chronotype;
KIRP	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg16482183	chr6:26056742	HIST1H1C	-0.52	-6.22	-0.37	2.09e-9	Iron status biomarkers;
KIRP	cis	rs12049351	0.774	rs12066463	chr1:229669287	C/T	cg11742688	chr1:229674241	ABCB10	-0.36	-5.36	-0.32	1.93e-7	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs7246760	0.867	rs12461215	chr19:9782461	G/A	cg02900749	chr2:68251473	NA	-1.16	-9.53	-0.52	1.56e-18	Pursuit maintenance gain;
KIRP	cis	rs1134634	0.520	rs10034328	chr4:15618387	C/T	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.79	-0.35	2.18e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.97	-15.04	-0.69	1.12e-36	Height;
KIRP	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.53	0.33	8.04e-8	Lung cancer;
KIRP	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg24812749	chr6:127587940	RNF146	0.49	6.29	0.37	1.46e-9	Breast cancer;
KIRP	cis	rs228437	0.657	rs6902569	chr6:134947804	G/C	cg24504307	chr6:134963096	NA	0.35	5.66	0.34	4.11e-8	Melanoma;
KIRP	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg27170947	chr2:26402098	FAM59B	0.65	6.9	0.4	4.28e-11	Gut microbiome composition (summer);
KIRP	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	8.31	0.47	6.5e-15	Lung cancer in ever smokers;
KIRP	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.61	-0.44	5.66e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs10875746	0.859	rs11168371	chr12:48437686	C/T	cg26205652	chr12:48591994	NA	0.81	10.53	0.56	1.23e-21	Longevity (90 years and older);
KIRP	trans	rs6601327	0.663	rs12543346	chr8:9655823	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.83	-0.4	6.54e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.75	-10.21	-0.55	1.26e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	16.53	0.73	8.71e-42	Height;
KIRP	cis	rs9905704	0.718	rs193391	chr17:56672944	T/C	cg12560992	chr17:57184187	TRIM37	0.53	4.92	0.3	1.61e-6	Testicular germ cell tumor;
KIRP	cis	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg16898833	chr6:26189333	HIST1H4D	1.15	6.63	0.39	2.16e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11203032	0.831	rs4933496	chr10:90952338	T/C	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg21401794	chr1:90099060	LRRC8C	0.53	7.25	0.42	5.26e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.72	10.32	0.55	5.59e-21	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	0.79	6.16	0.37	3e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6690583	0.623	rs1371141	chr1:85455372	C/A	cg22153463	chr1:85462885	MCOLN2	0.6	5.53	0.33	8.27e-8	Serum sulfate level;
KIRP	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg16497661	chr14:103986332	CKB	0.49	6.22	0.37	2.07e-9	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.94	9.25	0.51	1.12e-17	Lymphocyte counts;
KIRP	trans	rs2235682	0.822	rs2283982	chr22:36986227	C/T	cg03691822	chr16:47999378	NA	-0.49	-6.05	-0.36	5.35e-9	Airway responsiveness in chronic obstructive pulmonary disease;
KIRP	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-6.18	-0.37	2.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.75	-10.63	-0.56	5.8e-22	Prostate cancer;
KIRP	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.73	7.7	0.44	3.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg12131826	chr15:77904385	NA	0.38	4.91	0.3	1.68e-6	Type 2 diabetes;
KIRP	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.74	9.05	0.5	4.33e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.22	-0.37	2.07e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs2573652	0.722	rs11636084	chr15:100543394	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.23	-0.42	6.15e-12	Height;
KIRP	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.53	8.06	0.46	3.41e-14	Itch intensity from mosquito bite;
KIRP	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.77	10.62	0.56	6.25e-22	Blood protein levels;
KIRP	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	8.88	0.49	1.47e-16	Cognitive test performance;
KIRP	cis	rs6921919	0.583	rs6928773	chr6:28375210	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.48	-6.8	-0.4	7.75e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6450176	1.000	rs3776718	chr5:53298714	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-7.56	-0.43	7.84e-13	Mortality in heart failure;
KIRP	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.52	5.69	0.34	3.53e-8	Diastolic blood pressure;
KIRP	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.54	-0.62	3.12e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.75	10.83	0.57	1.34e-22	Lung cancer;
KIRP	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg16482183	chr6:26056742	HIST1H1C	0.44	5.49	0.33	1.01e-7	Height;
KIRP	cis	rs838721	0.574	rs13014016	chr2:234257454	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	5.02	0.31	9.74e-7	Total body bone mineral density;
KIRP	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	1.06	10.21	0.55	1.23e-20	Opioid sensitivity;
KIRP	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.63	6.88	0.4	5e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg21475434	chr5:93447410	FAM172A	-0.44	-5.17	-0.31	4.75e-7	Diabetic retinopathy;
KIRP	cis	rs10782582	1.000	rs11161853	chr1:76369494	T/C	cg10523679	chr1:76189770	ACADM	-0.38	-5.63	-0.34	5.01e-8	Daytime sleep phenotypes;
KIRP	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.44	5.17	0.31	4.74e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4494114	1.000	rs4589074	chr1:39354508	T/G	cg25970120	chr1:39325951	RRAGC	-0.41	-5.11	-0.31	6.4e-7	Blood protein levels;
KIRP	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.46	6.53	0.38	3.81e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg21605333	chr4:119757512	SEC24D	1.66	10.42	0.55	2.7e-21	Cannabis dependence symptom count;
KIRP	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.01	0.45	4.74e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.64	-5.92	-0.35	1.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.21	0.37	2.2e-9	Coronary artery disease;
KIRP	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg08999081	chr20:33150536	PIGU	-0.39	-5.04	-0.31	8.85e-7	Height;
KIRP	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.21	0.72	1.05e-40	Electrocardiographic conduction measures;
KIRP	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.57	-8.19	-0.46	1.46e-14	Testicular germ cell tumor;
KIRP	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg23625390	chr15:77176239	SCAPER	0.49	6.39	0.38	8.38e-10	Blood metabolite levels;
KIRP	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg02297831	chr4:17616191	MED28	0.54	6.79	0.4	8.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35000415	0.688	rs13229034	chr7:128714843	T/C	cg19972273	chr7:128594194	NA	0.61	5.01	0.3	1.05e-6	Systemic lupus erythematosus;
KIRP	cis	rs7173743	0.507	rs6495341	chr15:79133026	C/T	cg00079375	chr15:79125835	NA	0.39	5.58	0.34	6.32e-8	Coronary artery disease;
KIRP	cis	rs6977660	0.660	rs28663574	chr7:19816905	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs3815700	0.764	rs259234	chr19:33121729	A/C	cg02997394	chr19:33096574	ANKRD27	-1.31	-8.68	-0.48	5.61e-16	Eosinophilic esophagitis;
KIRP	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg21479132	chr6:26055353	NA	0.76	5.06	0.31	8.24e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg04607699	chr11:48328132	OR4S1	-0.35	-4.95	-0.3	1.37e-6	HDL cholesterol;
KIRP	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.55	-0.48	1.31e-15	Triglycerides;
KIRP	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.56	-7.81	-0.45	1.66e-13	Brugada syndrome;
KIRP	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.84	-12.58	-0.63	2.36e-28	Systemic lupus erythematosus;
KIRP	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	7.23	0.42	5.93e-12	Renal function-related traits (BUN);
KIRP	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs16976116	0.901	rs8028525	chr15:55492317	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.35	0.42	3.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26002218	chr14:103986227	CKB	0.26	5.19	0.31	4.37e-7	Body mass index;
KIRP	cis	rs7916697	0.520	rs10762201	chr10:70040111	A/G	cg18338521	chr10:69995036	NA	0.37	4.88	0.3	1.87e-6	Optic disc area;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg21285383	chr16:89894308	SPIRE2	0.34	6.5	0.38	4.48e-10	Vitiligo;
KIRP	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	0.82	12.57	0.63	2.48e-28	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg05861140	chr6:150128134	PCMT1	-0.47	-6.68	-0.39	1.56e-10	Lung cancer;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg00668182	chr20:30795591	POFUT1;PLAGL2	0.51	6.35	0.38	1.06e-9	DNA methylation (variation);
KIRP	cis	rs7084402	1.000	rs6481402	chr10:60268977	T/C	cg05938607	chr10:60274200	BICC1	0.41	9.98	0.54	6.68e-20	Refractive error;
KIRP	cis	rs9840812	0.769	rs534944	chr3:135961031	T/G	cg15507776	chr3:136538369	TMEM22	0.4	5.16	0.31	5.17e-7	Fibrinogen levels;
KIRP	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg12315302	chr6:26189340	HIST1H4D	0.78	5.35	0.32	1.97e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg17644776	chr2:200775616	C2orf69	0.57	5.23	0.32	3.56e-7	Schizophrenia;
KIRP	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	1.01	10.6	0.56	7.2e-22	Nonalcoholic fatty liver disease;
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg21734707	chr17:3908241	ZZEF1	0.66	10.26	0.55	8.65e-21	Type 2 diabetes;
KIRP	cis	rs9309473	0.500	rs12997018	chr2:73912899	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.64	0.34	4.75e-8	Metabolite levels;
KIRP	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.83	9.39	0.51	4.26e-18	High light scatter reticulocyte count;
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg21285383	chr16:89894308	SPIRE2	0.3	5.74	0.34	2.74e-8	Vitiligo;
KIRP	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.67	-0.39	1.65e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.22	-25.0	-0.85	1.77e-69	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77956314	1.000	rs113179672	chr12:117327241	G/A	cg02017074	chr12:117425053	FBXW8	-0.86	-4.92	-0.3	1.56e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.75	10.19	0.54	1.43e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg05973401	chr12:123451056	ABCB9	-0.56	-6.77	-0.4	9.65e-11	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg25019722	chr6:37503610	NA	0.68	9.25	0.51	1.1e-17	Cognitive performance;
KIRP	cis	rs6132905	0.590	rs76990741	chr20:2606746	A/G	cg24848351	chr20:2622020	TMC2	-0.57	-5.65	-0.34	4.37e-8	Mumps;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14082097	chr8:28573503	EXTL3	0.49	6.46	0.38	5.6e-10	Interleukin-4 levels;
KIRP	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.12	-0.36	3.64e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00332212	chr4:48908696	OCIAD2	-0.51	-6.45	-0.38	5.89e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.43	-0.33	1.36e-7	Height;
KIRP	cis	rs28785552	0.897	rs10424736	chr19:53239176	G/A	cg03571507	chr19:53239146	ZNF611	0.25	6.49	0.38	4.59e-10	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.64	-9.85	-0.53	1.7e-19	Hip circumference;
KIRP	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.26	-0.42	5.1e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs698833	0.757	rs9309116	chr2:44557919	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.66	0.34	4.31e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19828298	chr1:3713105	LRRC47	0.54	6.24	0.37	1.91e-9	Smoking initiation;
KIRP	cis	rs4901847	0.901	rs8019367	chr14:58553750	A/G	cg15908186	chr14:58618357	C14orf37	0.41	5.16	0.31	5.14e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2862064	0.799	rs4704835	chr5:156443251	G/A	cg12943317	chr5:156479607	HAVCR1	-0.65	-6.38	-0.38	8.7e-10	Platelet count;
KIRP	cis	rs6450176	1.000	rs3776716	chr5:53298923	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7317038	0.745	rs75590443	chr13:114015421	A/T	cg18412546	chr13:114005154	GRTP1	-0.37	-5.49	-0.33	1e-7	Mean platelet volume;
KIRP	cis	rs17030434	0.769	rs11727144	chr4:154645181	G/C	cg14289246	chr4:154710475	SFRP2	-0.78	-8.9	-0.49	1.27e-16	Electrocardiographic conduction measures;
KIRP	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	8.91	0.49	1.18e-16	Cognitive test performance;
KIRP	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg11693508	chr17:37793320	STARD3	0.77	8.36	0.47	4.59e-15	Bipolar disorder;
KIRP	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.42	-4.85	-0.3	2.15e-6	Monocyte count;
KIRP	cis	rs4936894	0.500	rs10893161	chr11:124075848	T/C	cg27160556	chr11:124181099	OR8D1	-0.4	-5.92	-0.35	1.09e-8	Aging (time to death);
KIRP	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg21775007	chr8:11205619	TDH	-0.49	-6.5	-0.38	4.44e-10	Retinal vascular caliber;
KIRP	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	10.44	0.55	2.26e-21	Blood protein levels;
KIRP	trans	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-8.3	-0.47	7.03e-15	Morning vs. evening chronotype;
KIRP	cis	rs193541	0.556	rs30024	chr5:122285160	A/G	cg19412675	chr5:122181750	SNX24	0.6	6.38	0.38	8.51e-10	Glucose homeostasis traits;
KIRP	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.13	0.46	2.08e-14	Personality dimensions;
KIRP	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08330117	chr8:90770456	RIPK2	-0.44	-6.06	-0.36	5.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.96	14.73	0.68	1.19e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.74	10.47	0.56	1.86e-21	Parkinson's disease;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02399570	chr3:156877196	CCNL1	0.96	6.72	0.39	1.22e-10	P wave terminal force;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs9308433	0.529	rs4655333	chr1:214493549	A/G	cg06198575	chr1:214491504	SMYD2	0.54	6.9	0.4	4.36e-11	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00104131	chr3:138327850	FAIM	0.5	6.15	0.37	3.14e-9	Parkinson's disease;
KIRP	cis	rs7267005	1.000	rs79232078	chr20:34470631	C/T	cg17201900	chr20:34330562	RBM39	0.97	5.58	0.34	6.43e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.65	-0.34	4.49e-8	Life satisfaction;
KIRP	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg10117171	chr1:25599238	RHD	-0.4	-5.34	-0.32	2.08e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg07460842	chr6:66804631	NA	-0.49	-6.08	-0.36	4.46e-9	Blood trace element (Cu levels);
KIRP	cis	rs6088813	0.635	rs6088792	chr20:33909784	A/G	cg14752227	chr20:34000481	UQCC	-0.44	-5.04	-0.31	8.96e-7	Height;
KIRP	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	5.91	0.35	1.11e-8	Coronary artery disease;
KIRP	cis	rs7714584	0.793	rs35707106	chr5:150225377	G/A	cg22134413	chr5:150180641	NA	0.57	5.08	0.31	7.4e-7	Crohn's disease;
KIRP	cis	rs2904967	0.852	rs667341	chr11:65050182	T/C	cg09225861	chr11:65069680	NA	0.41	4.91	0.3	1.67e-6	Mean corpuscular volume;
KIRP	cis	rs3925075	1.000	rs9673405	chr16:31347599	A/C	cg02846316	chr16:31340340	ITGAM	0.61	9.65	0.52	6.7e-19	IgA nephropathy;
KIRP	cis	rs35740288	0.770	rs11630286	chr15:86202529	T/C	cg10818794	chr15:86012489	AKAP13	-0.43	-5.29	-0.32	2.76e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4006360	0.628	rs34859541	chr17:39226322	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.52	-8.19	-0.46	1.45e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6746896	0.708	rs6727384	chr2:97400324	A/G	cg01990225	chr2:97406019	LMAN2L	-0.55	-7.03	-0.41	1.97e-11	Bipolar disorder;
KIRP	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-9.26	-0.51	1.05e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.2	0.37	2.3e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17376030	chr22:41985996	PMM1	-0.79	-7.97	-0.45	6.1e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2882667	0.858	rs11750382	chr5:138456994	A/G	cg04439458	chr5:138467593	SIL1	0.5	7.48	0.43	1.32e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17123764	0.710	rs12310510	chr12:50066244	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.93	0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7799006	0.782	rs2159044	chr7:2262941	C/A	cg02951883	chr7:2050386	MAD1L1	-0.43	-5.24	-0.32	3.49e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15128208	chr22:42549153	NA	0.45	5.68	0.34	3.69e-8	Cognitive function;
KIRP	cis	rs3784262	0.867	rs8036453	chr15:58371635	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.14	-0.31	5.59e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-6.77	-0.4	9.34e-11	Total body bone mineral density;
KIRP	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.53	-7.26	-0.42	4.97e-12	Type 2 diabetes;
KIRP	cis	rs33912345	0.695	rs1254271	chr14:60843401	C/T	cg27398547	chr14:60952738	C14orf39	-0.41	-5.55	-0.33	7.33e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.72	7.65	0.44	4.41e-13	Uric acid levels;
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg07701084	chr6:150067640	NUP43	0.61	7.93	0.45	7.92e-14	Lung cancer;
KIRP	cis	rs13424612	1.000	rs7590071	chr2:240900947	G/C	cg01812947	chr2:240904978	NDUFA10	0.42	5.43	0.33	1.34e-7	Odorant perception (isobutyraldehyde);
KIRP	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09253211	chr11:63438586	ATL3	0.44	6.27	0.37	1.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.82	9.85	0.53	1.63e-19	Gestational age at birth (maternal effect);
KIRP	cis	rs12210905	1.000	rs7756481	chr6:27115069	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.61	-8.98	-0.5	7.17e-17	Ovarian reserve;
KIRP	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.47	5.48	0.33	1.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs62355272	0.764	rs11950763	chr5:35830733	T/C	cg13894535	chr5:35919491	CAPSL	-0.49	-5.52	-0.33	8.68e-8	Lymphocyte counts;
KIRP	trans	rs4578769	0.918	rs6507457	chr18:20626436	C/T	cg00137585	chr16:3450828	ZNF174;ZNF434	-0.56	-6.28	-0.37	1.56e-9	Eosinophil percentage of white cells;
KIRP	cis	rs4664293	0.867	rs1126842	chr2:160627317	C/G	cg08347373	chr2:160653686	CD302	-0.42	-6.52	-0.38	4.05e-10	Monocyte percentage of white cells;
KIRP	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-9.94	-0.54	8.75e-20	Colorectal cancer;
KIRP	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.42	0.55	2.61e-21	Cognitive test performance;
KIRP	cis	rs4073416	0.504	rs1953418	chr14:65915226	G/A	cg03016385	chr14:66212404	NA	-0.57	-6.89	-0.4	4.6e-11	N-glycan levels;
KIRP	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg26384229	chr12:38710491	ALG10B	0.66	8.91	0.49	1.16e-16	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.54	-5.66	-0.34	4.29e-8	DNA methylation (variation);
KIRP	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07570687	chr10:102243282	WNT8B	0.44	5.15	0.31	5.27e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.51	6.95	0.41	3.18e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.52	-8.78	-0.49	2.85e-16	Refractive error;
KIRP	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	5.89	0.35	1.26e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg07424155	chr7:116503126	CAPZA2	-0.47	-6.47	-0.38	5.23e-10	Morning vs. evening chronotype;
KIRP	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.7	9.63	0.52	8.13e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.71	-11.0	-0.57	3.79e-23	Prostate cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03270376	chr2:219536588	RNF25;STK36	0.48	6.4	0.38	7.76e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22117172	chr7:91764530	CYP51A1	0.44	6.01	0.36	6.7e-9	Breast cancer;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg05861140	chr6:150128134	PCMT1	-0.45	-6.17	-0.37	2.83e-9	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16858463	chr3:48130806	MAP4	0.45	6.23	0.37	2.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	1.17	12.39	0.62	1e-27	Alzheimer's disease;
KIRP	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.94	12.24	0.62	3.33e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	0.84	12.48	0.62	5.11e-28	Body mass index;
KIRP	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.7	-10.97	-0.57	4.58e-23	Hepatocellular carcinoma;
KIRP	cis	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.08e-11	Morning vs. evening chronotype;
KIRP	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg02491457	chr7:128862824	NA	0.49	6.17	0.37	2.77e-9	White matter hyperintensity burden;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07376067	chr1:244011194	NA	-0.43	-6.76	-0.4	9.7e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00094256	chr4:25378438	ANAPC4	0.45	6.66	0.39	1.76e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.8	-0.6	9.04e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg15655495	chr12:38532458	NA	-0.29	-5.12	-0.31	6.17e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.06	19.67	0.78	2.1e-52	Testicular germ cell tumor;
KIRP	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.37	-0.32	1.8e-7	Red blood cell count;
KIRP	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.5	6.23	0.37	1.97e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg19847130	chr8:10466454	RP1L1	-0.35	-5.14	-0.31	5.58e-7	Retinal vascular caliber;
KIRP	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs77861329	1.000	rs59890038	chr3:52147850	A/G	cg08692210	chr3:52188851	WDR51A	0.94	7.59	0.44	6.69e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs4560672	1.000	rs13194997	chr6:158589608	C/T	cg14029994	chr6:158589857	SERAC1;GTF2H5	-0.56	-4.96	-0.3	1.33e-6	Smoking quantity;
KIRP	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.86	14.32	0.67	3.19e-34	Prostate cancer;
KIRP	trans	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg06521331	chr12:34319734	NA	-0.54	-6.74	-0.39	1.11e-10	Heart rate;
KIRP	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg03098644	chr7:100410630	EPHB4	-0.65	-8.7	-0.48	4.98e-16	Plasminogen activator inhibitor type 1 levels (PAI-1);
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.62	-9.27	-0.51	9.47e-18	Immature fraction of reticulocytes;
KIRP	trans	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg16141378	chr3:129829833	LOC729375	0.46	6.08	0.36	4.56e-9	Neuroticism;
KIRP	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg16111737	chr12:117408163	FBXW8	-0.52	-5.16	-0.31	5.12e-7	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg18404041	chr3:52824283	ITIH1	0.38	5.35	0.32	2.05e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.28	0.47	8.07e-15	Lung cancer in ever smokers;
KIRP	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	9.45	0.52	2.78e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.01	0.61	1.89e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.13	0.31	5.84e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.72	-0.34	3.04e-8	Life satisfaction;
KIRP	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg21033440	chr11:65409861	SIPA1	-0.47	-5.23	-0.32	3.67e-7	Blood pressure (age interaction);
KIRP	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg02975922	chr3:195473998	MUC4	-0.53	-6.22	-0.37	2.13e-9	Pancreatic cancer;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg10150615	chr22:24372951	LOC391322	0.52	6.34	0.37	1.11e-9	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg18306943	chr3:40428807	ENTPD3	0.45	5.67	0.34	3.92e-8	Renal cell carcinoma;
KIRP	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.72	-9.89	-0.53	1.22e-19	Body mass index;
KIRP	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg16141378	chr3:129829833	LOC729375	-0.55	-7.03	-0.41	2.05e-11	Retinal vascular caliber;
KIRP	cis	rs7976059	0.895	rs73109505	chr12:52244921	G/A	cg09126859	chr12:52244063	NA	0.47	8.05	0.46	3.56e-14	Urate levels;
KIRP	cis	rs7737355	0.812	rs31241	chr5:130808198	T/C	cg06307176	chr5:131281290	NA	0.41	5.0	0.3	1.1e-6	Life satisfaction;
KIRP	cis	rs960902	0.643	rs7584987	chr2:37730154	A/G	cg25341268	chr2:37734390	NA	0.52	6.73	0.39	1.16e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs12431939	0.762	rs60616710	chr14:51704361	A/T	cg23942311	chr14:51606299	NA	-0.59	-5.77	-0.35	2.37e-8	Cancer;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg20701182	chr2:24300061	SF3B14	-0.41	-5.22	-0.32	3.74e-7	Asthma;
KIRP	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.63	-5.38	-0.32	1.77e-7	Putamen volume;
KIRP	cis	rs1784581	0.722	rs1789993	chr6:162398976	T/C	cg17173639	chr6:162384350	PARK2	-0.57	-9.18	-0.51	1.81e-17	Itch intensity from mosquito bite;
KIRP	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17342709	chr2:235319934	NA	-0.46	-6.19	-0.37	2.5e-9	Inflammatory biomarkers;
KIRP	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.2	0.42	7.4e-12	Personality dimensions;
KIRP	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg26248373	chr2:1572462	NA	-0.78	-9.97	-0.54	6.93e-20	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg21523564	chr15:75251491	NA	-0.39	-6.32	-0.37	1.23e-9	Breast cancer;
KIRP	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.66	9.74	0.53	3.6e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.98	14.12	0.67	1.43e-33	Platelet distribution width;
KIRP	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.32	1.9e-7	Menopause (age at onset);
KIRP	cis	rs7173743	0.525	rs7166501	chr15:79133739	C/T	cg00079375	chr15:79125835	NA	0.44	6.27	0.37	1.57e-9	Coronary artery disease;
KIRP	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs77972916	0.561	rs17406174	chr2:43557484	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-6.4	-0.38	7.72e-10	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.18	14.7	0.68	1.62e-35	Uric acid levels;
KIRP	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg24807547	chr6:37504484	NA	-0.64	-9.98	-0.54	6.35e-20	Cognitive performance;
KIRP	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.74	-10.4	-0.55	3.04e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.52	-6.0	-0.36	6.99e-9	White matter hyperintensity burden;
KIRP	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.04	-0.41	1.91e-11	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.44e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg06935464	chr4:38784597	TLR10	0.5	5.17	0.31	4.74e-7	Breast cancer;
KIRP	cis	rs12365397	0.634	rs10838091	chr11:43300039	G/T	cg07515919	chr11:43391688	TTC17	0.37	4.95	0.3	1.36e-6	Migraine;
KIRP	cis	rs13279522	0.536	rs884839	chr8:67019988	A/C	cg04041976	chr8:67085823	TRIM55	-0.43	-5.34	-0.32	2.1e-7	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg21546286	chr11:48923668	NA	0.4	4.94	0.3	1.47e-6	HDL cholesterol;
KIRP	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.47	-6.42	-0.38	7.11e-10	Testicular germ cell tumor;
KIRP	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.99	13.36	0.65	5.8e-31	Cognitive function;
KIRP	cis	rs7084402	0.967	rs1649055	chr10:60320045	T/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.77	-0.57	2.01e-22	Refractive error;
KIRP	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg12131826	chr15:77904385	NA	-0.51	-6.45	-0.38	5.83e-10	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12802720	chr12:52467448	C12orf44	0.44	6.19	0.37	2.51e-9	Survival in pancreatic cancer;
KIRP	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg11189052	chr15:85197271	WDR73	-0.5	-5.96	-0.35	8.91e-9	P wave terminal force;
KIRP	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg11584989	chr19:19387371	SF4	0.42	5.36	0.32	1.91e-7	Tonsillectomy;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.54	-7.05	-0.41	1.83e-11	Longevity;Endometriosis;
KIRP	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.8	12.08	0.61	1.1e-26	Metabolic syndrome;
KIRP	cis	rs10073892	0.701	rs13358882	chr5:101652028	C/T	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs2120243	0.967	rs7648322	chr3:157143684	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.51	6.9	0.4	4.43e-11	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.26	0.55	8.41e-21	Coffee consumption (cups per day);
KIRP	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg09455208	chr3:40491958	NA	0.34	5.95	0.35	8.98e-9	Renal cell carcinoma;
KIRP	cis	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4073221	0.858	rs73034316	chr3:18268543	G/A	cg07694806	chr3:18168406	NA	-0.84	-7.13	-0.41	1.11e-11	Parkinson's disease;
KIRP	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.61	-0.39	2.4e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg00129232	chr17:37814104	STARD3	-0.52	-6.42	-0.38	7.15e-10	Self-reported allergy;
KIRP	cis	rs6011002	0.872	rs6010987	chr20:62277675	G/A	cg23957118	chr20:62200850	PRIC285	0.77	5.0	0.3	1.08e-6	Dental caries;
KIRP	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05776053	chr2:74358815	NA	0.53	5.5	0.33	9.61e-8	Gestational age at birth (maternal effect);
KIRP	cis	rs4786125	0.665	rs1565634	chr16:6919370	T/C	cg03623568	chr16:6915990	A2BP1	-0.44	-5.31	-0.32	2.48e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs889398	0.802	rs2937121	chr16:69870409	T/G	cg09409435	chr16:70099608	PDXDC2	-0.43	-5.15	-0.31	5.41e-7	Body mass index;
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg00933542	chr6:150070202	PCMT1	0.28	4.94	0.3	1.42e-6	Lung cancer;
KIRP	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.83	-12.77	-0.63	5.59e-29	Asthma;
KIRP	trans	rs225245	0.782	rs321618	chr17:33912404	A/G	cg19694781	chr19:47549865	TMEM160	-0.53	-6.49	-0.38	4.73e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs889398	0.774	rs6499263	chr16:69890149	T/C	cg09409435	chr16:70099608	PDXDC2	0.43	5.24	0.32	3.45e-7	Body mass index;
KIRP	cis	rs7827545	1.000	rs6578235	chr8:135568022	C/T	cg17885191	chr8:135476712	NA	0.51	5.88	0.35	1.35e-8	Hypertension (SNP x SNP interaction);
KIRP	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.62	-7.12	-0.41	1.15e-11	Multiple sclerosis;
KIRP	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.78	-11.08	-0.58	2.09e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7215564	0.908	rs7503757	chr17:78685599	A/G	cg06153925	chr17:78755379	RPTOR	0.43	5.88	0.35	1.35e-8	Myopia (pathological);
KIRP	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-7.51	-0.43	1.07e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg05484376	chr2:27715224	FNDC4	0.41	6.81	0.4	7.41e-11	Total body bone mineral density;
KIRP	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	0.83	6.16	0.37	2.88e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg00360474	chr6:37504404	NA	-0.5	-7.42	-0.43	1.87e-12	Cognitive performance;
KIRP	cis	rs7011049	0.778	rs111899960	chr8:53870132	A/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.75	8.31	0.47	6.59e-15	Uric acid levels;
KIRP	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03579738	chr19:2900714	ZNF57	0.49	6.25	0.37	1.8e-9	Parkinson's disease;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.8	-0.35	2e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.59	-0.48	9.9e-16	Joint mobility (Beighton score);
KIRP	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg02527881	chr3:46936655	PTH1R	-0.37	-5.32	-0.32	2.28e-7	Colorectal cancer;
KIRP	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.52	6.63	0.39	2.07e-10	Calcium levels;
KIRP	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg07810366	chr2:100720526	AFF3	0.32	5.55	0.33	7.24e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg22907277	chr7:1156413	C7orf50	0.56	6.87	0.4	5.19e-11	Longevity;Endometriosis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11229315	chr1:27877018	AHDC1	0.51	6.55	0.39	3.33e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.61	-8.22	-0.46	1.17e-14	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs568617	0.533	rs679147	chr11:65644363	A/G	cg26695010	chr11:65641043	EFEMP2	0.6	6.93	0.4	3.76e-11	Crohn's disease;
KIRP	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	0.9	13.58	0.65	9.82e-32	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs526231	0.511	rs27896	chr5:102488571	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.55	-0.33	7.46e-8	Primary biliary cholangitis;
KIRP	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg02712587	chr15:40268421	EIF2AK4	-0.51	-4.85	-0.3	2.15e-6	Corneal curvature;
KIRP	cis	rs6733011	0.560	rs7579189	chr2:99464718	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.38	-0.32	1.75e-7	Bipolar disorder;
KIRP	cis	rs889312	0.781	rs1121654	chr5:56036566	A/C	cg14703610	chr5:56206110	C5orf35	0.47	5.65	0.34	4.43e-8	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11987759	chr7:65425863	GUSB	0.6	7.94	0.45	7.3e-14	Aortic root size;
KIRP	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg13736514	chr6:26305472	NA	-0.65	-7.95	-0.45	6.76e-14	Educational attainment;
KIRP	cis	rs4658101	0.815	rs11164978	chr1:92043661	T/C	cg09075522	chr1:92031145	NA	0.47	5.5	0.33	9.32e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.68	8.77	0.49	3.01e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.7	7.28	0.42	4.37e-12	Vitiligo;
KIRP	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.38	-0.38	8.6e-10	Mood instability;
KIRP	cis	rs6466055	0.699	rs4496901	chr7:104898337	G/T	cg04380332	chr7:105027541	SRPK2	0.64	9.73	0.53	3.76e-19	Schizophrenia;
KIRP	cis	rs2839627	0.561	rs7281655	chr21:44269743	A/G	cg03543861	chr21:44258195	NA	0.53	6.01	0.36	6.65e-9	Information processing speed;
KIRP	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.37	-4.92	-0.3	1.6e-6	Cancer (pleiotropy);
KIRP	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	7.44	0.43	1.7e-12	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24684336	chr15:42565701	GANC;TMEM87A	-0.54	-6.55	-0.39	3.34e-10	Interleukin-4 levels;
KIRP	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg18190219	chr22:46762943	CELSR1	-0.85	-7.31	-0.42	3.8e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg21475434	chr5:93447410	FAM172A	0.76	6.92	0.4	3.94e-11	Diabetic retinopathy;
KIRP	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	7.55	0.43	8.31e-13	Eosinophil percentage of white cells;
KIRP	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.65	7.35	0.42	2.86e-12	Body mass index;
KIRP	cis	rs3774830	0.811	rs2526306	chr4:5432419	T/G	cg26943120	chr4:5472116	STK32B	-0.22	-5.57	-0.33	6.68e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs17094273	1.000	rs56127553	chr14:97095153	C/T	cg27186851	chr7:2566750	LFNG	0.6	6.15	0.37	3.03e-9	Tanning;
KIRP	cis	rs7721647	0.778	rs231383	chr5:90830204	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.42	-5.17	-0.31	4.95e-7	Breast cancer;
KIRP	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.02	-0.41	2.17e-11	Neuroticism;
KIRP	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.52	-5.86	-0.35	1.44e-8	Metabolite levels;
KIRP	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg01689657	chr7:91764605	CYP51A1	0.37	5.4	0.33	1.59e-7	Breast cancer;
KIRP	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.49	7.27	0.42	4.7e-12	Height;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg00798029	chr15:66161798	RAB11A	-0.47	-6.12	-0.36	3.62e-9	Hippocampal sclerosis of aging;
KIRP	cis	rs7336332	0.941	rs9579097	chr13:28084337	C/T	cg22138327	chr13:27999177	GTF3A	0.83	6.45	0.38	5.79e-10	Weight;
KIRP	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-10.6	-0.56	7.35e-22	Response to antipsychotic treatment;
KIRP	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg26531700	chr6:26746687	NA	0.38	5.19	0.31	4.46e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.35	-0.42	2.84e-12	Joint mobility (Beighton score);
KIRP	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.95e-8	Endometrial cancer;
KIRP	cis	rs4262150	0.767	rs4958317	chr5:151942880	G/A	cg12297329	chr5:152029980	NA	-0.61	-7.61	-0.44	5.77e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.66	-7.19	-0.42	7.72e-12	Vitiligo;
KIRP	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.45	4.93	0.3	1.54e-6	IFN-related cytopenia;
KIRP	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10858047	0.883	rs6537843	chr1:115210578	C/A	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg00684032	chr4:1343700	KIAA1530	0.46	5.73	0.34	2.94e-8	Longevity;
KIRP	cis	rs7615316	0.934	rs2227930	chr3:142277575	A/T	cg20824294	chr3:142316082	PLS1	0.22	4.99	0.3	1.15e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.82e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9513593	1.000	rs12861519	chr13:100029555	A/C	cg21788972	chr13:99853209	UBAC2	0.57	6.2	0.37	2.39e-9	Psoriasis;
KIRP	cis	rs4356932	0.967	rs7659236	chr4:76953611	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.7	-7.96	-0.45	6.26e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.46	5.65	0.34	4.47e-8	Glycated hemoglobin levels;
KIRP	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.38	-4.85	-0.3	2.23e-6	Carotid intima media thickness;
KIRP	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg02175503	chr12:58329896	NA	0.63	7.7	0.44	3.21e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.79	6.91	0.4	4.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.41	5.95	0.35	9.26e-9	Colorectal cancer;
KIRP	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg02336718	chr17:17403227	NA	-0.35	-5.49	-0.33	9.91e-8	Total body bone mineral density;
KIRP	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg02461776	chr11:598696	PHRF1	0.52	5.55	0.33	7.37e-8	Systemic lupus erythematosus;
KIRP	cis	rs73058052	0.597	rs11878568	chr19:50095961	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.56	6.82	0.4	7.17e-11	Fibrinogen levels;
KIRP	cis	rs6723108	0.713	rs6728095	chr2:135376072	T/A	cg25422880	chr2:135218333	TMEM163	0.38	5.72	0.34	3.06e-8	Type 2 diabetes;
KIRP	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.17	-0.31	4.89e-7	Life satisfaction;
KIRP	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-7.98	-0.45	5.68e-14	Neuroticism;
KIRP	cis	rs16976116	0.901	rs28433503	chr15:55499857	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg04833646	chr19:10679720	CDKN2D	0.97	12.54	0.62	3.32e-28	Red cell distribution width;
KIRP	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg26513180	chr16:89883248	FANCA	0.6	8.11	0.46	2.39e-14	Vitiligo;
KIRP	cis	rs11723261	0.582	rs3747693	chr4:124375	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.91	0.3	1.63e-6	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg23625390	chr15:77176239	SCAPER	0.53	6.93	0.4	3.72e-11	Blood metabolite levels;
KIRP	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg08131204	chr22:41487073	MIR1281	-0.44	-5.13	-0.31	6e-7	Neuroticism;
KIRP	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg18882449	chr10:104885122	NT5C2	-0.53	-6.86	-0.4	5.54e-11	Arsenic metabolism;
KIRP	cis	rs2150410	0.915	rs6517541	chr21:40679887	C/T	cg11890956	chr21:40555474	PSMG1	0.8	5.67	0.34	4.07e-8	Temperament (bipolar disorder);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13146426	chr11:122932858	HSPA8	0.46	6.14	0.36	3.34e-9	Survival in pancreatic cancer;
KIRP	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-4.89	-0.3	1.85e-6	Tonsillectomy;
KIRP	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.61	7.95	0.45	6.58e-14	Motion sickness;
KIRP	cis	rs8067545	0.720	rs9916675	chr17:19900168	A/G	cg13482628	chr17:19912719	NA	0.56	7.73	0.44	2.68e-13	Schizophrenia;
KIRP	cis	rs997295	0.504	rs12905397	chr15:68034150	T/C	cg24579218	chr15:68104479	NA	0.42	6.13	0.36	3.53e-9	Motion sickness;
KIRP	cis	rs4776059	1.000	rs4776058	chr15:52880263	A/G	cg22715398	chr15:52968154	KIAA1370	-0.64	-7.51	-0.43	1.06e-12	Schizophrenia;
KIRP	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg00409905	chr10:38381863	ZNF37A	0.53	5.85	0.35	1.58e-8	Obesity (extreme);
KIRP	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg26116260	chr4:7069785	GRPEL1	-0.74	-5.15	-0.31	5.44e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg24009623	chr19:33667908	NA	0.47	5.71	0.34	3.18e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg01620082	chr3:125678407	NA	-1.27	-8.04	-0.46	3.81e-14	Depression;
KIRP	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.5	-7.59	-0.44	6.56e-13	Immature fraction of reticulocytes;
KIRP	cis	rs9928842	0.824	rs12924999	chr16:75262425	T/G	cg09066997	chr16:75300724	BCAR1	0.62	5.25	0.32	3.37e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.62	5.15	0.31	5.41e-7	Bipolar disorder;
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.7	-0.44	3.35e-13	Platelet count;
KIRP	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.22	-0.58	7.52e-24	Chronic sinus infection;
KIRP	cis	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.44	-5.4	-0.33	1.58e-7	Mean platelet volume;
KIRP	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.61	-6.58	-0.39	2.8e-10	DNA methylation (variation);
KIRP	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg12560992	chr17:57184187	TRIM37	0.58	6.55	0.39	3.3e-10	Testicular germ cell tumor;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg12882476	chr5:114632168	CCDC112	-0.45	-6.07	-0.36	4.89e-9	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg04025307	chr7:1156635	C7orf50	0.81	8.69	0.48	5.07e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg21466736	chr12:48725269	NA	0.43	5.85	0.35	1.53e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.44	5.16	0.31	5.11e-7	Cardiac Troponin-T levels;
KIRP	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg18882449	chr10:104885122	NT5C2	-0.51	-6.63	-0.39	2.06e-10	Arsenic metabolism;
KIRP	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg15744005	chr10:104629667	AS3MT	-0.25	-4.87	-0.3	1.99e-6	Arsenic metabolism;
KIRP	cis	rs4902647	0.703	rs17835647	chr14:69274654	A/T	cg03189333	chr14:69283534	NA	-0.39	-4.91	-0.3	1.64e-6	Multiple sclerosis;
KIRP	cis	rs12049351	0.719	rs6587338	chr1:229632638	G/T	cg11742688	chr1:229674241	ABCB10	-0.39	-5.64	-0.34	4.68e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-11.46	-0.59	1.22e-24	Personality dimensions;
KIRP	cis	rs11138902	0.649	rs11139224	chr9:72155195	G/T	cg14123607	chr9:72164709	APBA1	-0.38	-4.89	-0.3	1.84e-6	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg24315340	chr6:146058215	EPM2A	-0.43	-5.48	-0.33	1.03e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26207909	chr14:103986467	CKB	0.54	7.36	0.42	2.81e-12	Body mass index;
KIRP	cis	rs9311676	0.656	rs11915190	chr3:58409700	G/A	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.75	-11.02	-0.58	3.13e-23	Hip circumference;
KIRP	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.23	-0.37	1.97e-9	Longevity;
KIRP	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.61	6.97	0.41	2.88e-11	Schizophrenia;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg09698166	chr20:21106763	PLK1S1	0.53	6.02	0.36	6.44e-9	Sleep duration;
KIRP	cis	rs17121403	0.661	rs1960059	chr1:100595154	C/T	cg24955406	chr1:100503596	HIAT1	0.78	5.08	0.31	7.35e-7	Pulmonary function decline;
KIRP	cis	rs981844	0.778	rs55895613	chr4:154638121	G/T	cg14289246	chr4:154710475	SFRP2	0.64	6.71	0.39	1.3e-10	Response to statins (LDL cholesterol change);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27109568	chr5:82876579	VCAN	0.45	6.98	0.41	2.72e-11	Migraine with aura;
KIRP	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.14	-0.41	1.03e-11	Aortic root size;
KIRP	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg26207909	chr14:103986467	CKB	0.49	6.37	0.38	9.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6601327	0.663	rs12543346	chr8:9655823	C/G	cg27411982	chr8:10470053	RP1L1	-0.39	-5.0	-0.3	1.09e-6	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg06636001	chr8:8085503	FLJ10661	0.69	8.95	0.5	9.06e-17	Retinal vascular caliber;
KIRP	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.05	-0.36	5.3e-9	Neuroticism;
KIRP	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.38	-5.39	-0.32	1.69e-7	Mean corpuscular volume;
KIRP	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg16388071	chr6:169726476	NA	-0.37	-5.03	-0.31	9.37e-7	Obesity-related traits;
KIRP	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg26022315	chr17:47021804	SNF8	-0.43	-5.44	-0.33	1.29e-7	Type 2 diabetes;
KIRP	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg13731523	chr4:3047190	NA	-0.31	-5.33	-0.32	2.2e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7737355	0.773	rs1422870	chr5:130942624	G/T	cg06307176	chr5:131281290	NA	0.42	5.12	0.31	6.1e-7	Life satisfaction;
KIRP	cis	rs6499755	0.730	rs31080	chr16:55359608	C/T	cg05099576	chr16:55362342	IRX6	0.3	6.02	0.36	6.15e-9	Hypospadias;
KIRP	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-5.63	-0.34	5.01e-8	Aortic root size;
KIRP	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.07	-0.41	1.61e-11	Eosinophil percentage of granulocytes;
KIRP	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.76	8.73	0.49	4.02e-16	Corneal astigmatism;
KIRP	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14895029	chr7:2775587	GNA12	-0.43	-5.01	-0.3	1.04e-6	Height;
KIRP	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.3	0.32	2.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.48	-0.52	2.32e-18	Personality dimensions;
KIRP	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	cis	rs580438	0.529	rs6810356	chr3:13415146	G/T	cg10657019	chr3:13328039	NA	-0.53	-6.85	-0.4	5.94e-11	Myringotomy;
KIRP	cis	rs6832769	1.000	rs11133399	chr4:56413831	A/G	cg05960024	chr4:56376020	CLOCK	-0.69	-8.53	-0.48	1.49e-15	Personality dimensions;
KIRP	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg06953865	chr19:18549723	ISYNA1	-0.4	-6.22	-0.37	2.18e-9	Breast cancer;
KIRP	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg17376030	chr22:41985996	PMM1	0.81	8.29	0.47	7.22e-15	Vitiligo;
KIRP	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg03808351	chr9:123631620	PHF19	0.38	5.07	0.31	7.86e-7	Rheumatoid arthritis;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.88	8.37	0.47	4.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.31	5.07	0.31	7.76e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.86	-0.4	5.63e-11	Aortic root size;
KIRP	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg10818794	chr15:86012489	AKAP13	-0.49	-6.82	-0.4	6.92e-11	Interstitial lung disease;
KIRP	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.48	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	cis	rs12282928	0.959	rs11039633	chr11:48297665	A/C	cg26585981	chr11:48327164	OR4S1	0.5	6.11	0.36	3.89e-9	Migraine - clinic-based;
KIRP	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.68	-0.39	1.6e-10	Axial length;
KIRP	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	7.89	0.45	9.64e-14	Height;
KIRP	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.12	-9.96	-0.54	7.44e-20	Plateletcrit;
KIRP	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg18441811	chr11:71824068	C11orf51	-0.81	-5.57	-0.33	6.52e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.94e-8	Life satisfaction;
KIRP	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg07167872	chr1:205819463	PM20D1	0.43	5.0	0.3	1.12e-6	White blood cell types;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2569991	0.636	rs361223	chr3:12922526	T/C	cg22481960	chr3:13008800	IQSEC1	-0.5	-4.94	-0.3	1.44e-6	Periodontitis (DPAL);
KIRP	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.93	0.53	9.3e-20	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs75920871	0.688	rs77320801	chr11:116836349	C/T	cg23684410	chr11:116897558	SIK3	0.57	4.91	0.3	1.64e-6	Subjective well-being;
KIRP	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.02	-0.36	6.38e-9	Mean corpuscular volume;
KIRP	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg06042504	chr8:55087323	NA	-0.54	-6.69	-0.39	1.5e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg00409905	chr10:38381863	ZNF37A	0.58	6.37	0.38	9.18e-10	Obesity (extreme);
KIRP	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Parkinson's disease;
KIRP	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg06935464	chr4:38784597	TLR10	0.52	5.0	0.3	1.11e-6	Breast cancer;
KIRP	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg07395648	chr5:131743802	NA	-0.57	-8.38	-0.47	4.17e-15	Blood metabolite levels;
KIRP	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	10.61	0.56	6.72e-22	Blood protein levels;
KIRP	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg13607699	chr17:42295918	UBTF	0.46	5.71	0.34	3.25e-8	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17956079	chr11:73358572	PLEKHB1	0.43	6.23	0.37	2e-9	Smoking initiation;
KIRP	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.41	-5.25	-0.32	3.37e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs1823913	0.637	rs1947456	chr2:192163485	G/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.57e-9	Obesity-related traits;
KIRP	cis	rs12042938	0.622	rs11122318	chr1:231806852	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	5.67	0.34	3.99e-8	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.71	8.26	0.47	8.93e-15	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.35	-10.28	-0.55	7.71e-21	Diabetic kidney disease;
KIRP	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.7	-7.14	-0.41	1.02e-11	Menarche (age at onset);
KIRP	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.68	8.69	0.48	5.13e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.94	12.72	0.63	8.32e-29	Homoarginine levels;
KIRP	cis	rs7945718	0.870	rs10765988	chr11:12731218	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.47	-5.8	-0.35	2.01e-8	Educational attainment (years of education);
KIRP	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.97	-12.51	-0.62	4.06e-28	Response to antineoplastic agents;
KIRP	cis	rs3755132	0.852	rs6431718	chr2:15747875	C/T	cg12888861	chr2:15731646	DDX1	0.4	5.19	0.31	4.42e-7	Wilms tumor;
KIRP	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg24579218	chr15:68104479	NA	-0.58	-9.25	-0.51	1.15e-17	Restless legs syndrome;
KIRP	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.54	7.39	0.43	2.26e-12	Mean corpuscular volume;
KIRP	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.85	10.7	0.56	3.53e-22	Coronary artery disease;
KIRP	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.19	0.31	4.46e-7	Educational attainment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04707703	chr2:230656907	TRIP12	0.56	6.87	0.4	5.08e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13409248	chr3:40428643	ENTPD3	0.37	5.03	0.31	9.36e-7	Renal cell carcinoma;
KIRP	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg00666640	chr1:248458726	OR2T12	0.45	5.41	0.33	1.47e-7	Common traits (Other);
KIRP	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Smoking initiation;
KIRP	cis	rs4849845	0.889	rs4849849	chr2:121046573	A/G	cg24070213	chr2:121070622	NA	0.41	5.66	0.34	4.22e-8	Mean platelet volume;
KIRP	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.73	-7.79	-0.44	1.85e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.74	-0.39	1.11e-10	Lung cancer;
KIRP	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.59	7.86	0.45	1.18e-13	Retinal vascular caliber;
KIRP	cis	rs2051773	0.538	rs4468326	chr11:17041034	A/G	cg15432903	chr11:17409602	KCNJ11	-0.48	-5.82	-0.35	1.82e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg23978390	chr7:1156363	C7orf50	0.51	4.9	0.3	1.72e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.36	-4.87	-0.3	1.97e-6	Metabolite levels;
KIRP	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg06386533	chr2:46925753	SOCS5	0.52	4.96	0.3	1.33e-6	Height;
KIRP	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-4.89	-0.3	1.85e-6	Diabetic retinopathy;
KIRP	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.58	-6.11	-0.36	3.85e-9	Obesity-related traits;
KIRP	cis	rs17123764	0.818	rs2005195	chr12:49983479	A/G	cg02054252	chr12:50078554	FMNL3	0.42	4.96	0.3	1.35e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22117172	chr7:91764530	CYP51A1	0.49	6.92	0.4	3.9e-11	Breast cancer;
KIRP	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3741489	1.000	rs2306545	chr12:133419296	G/A	cg24132527	chr5:140019269	TMCO6	1.04	6.64	0.39	2.03e-10	Cognitive function;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14317554	chr3:184870948	C3orf70	-0.44	-6.26	-0.37	1.73e-9	Myopia;
KIRP	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg06740227	chr12:86229804	RASSF9	0.49	6.22	0.37	2.14e-9	Major depressive disorder;
KIRP	trans	rs2421992	0.959	rs2422073	chr1:172230780	A/G	cg17305834	chr11:118868656	CCDC84	-0.51	-6.07	-0.36	4.93e-9	Height;
KIRP	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.46	7.13	0.41	1.12e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg07414643	chr4:187882934	NA	0.36	4.85	0.3	2.18e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg15676125	chr6:33679581	C6orf125	0.39	5.15	0.31	5.25e-7	Plateletcrit;
KIRP	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg27432699	chr2:27873401	GPN1	-0.46	-5.94	-0.35	9.52e-9	Total body bone mineral density;
KIRP	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.41	-0.47	3.36e-15	Inflammatory bowel disease;
KIRP	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg03465714	chr1:152285911	FLG	0.49	5.29	0.32	2.69e-7	Atopic dermatitis;
KIRP	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg01522456	chr1:115632236	TSPAN2	-0.43	-5.93	-0.35	1.04e-8	Autism;
KIRP	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.99	15.83	0.71	2.17e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.1	-0.41	1.31e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs838147	0.844	rs12611203	chr19:49248295	G/A	cg13540341	chr19:49222985	MAMSTR	0.35	5.63	0.34	4.86e-8	Dietary macronutrient intake;
KIRP	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18932078	chr1:2524107	MMEL1	0.45	6.22	0.37	2.13e-9	Ulcerative colitis;
KIRP	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.7	8.46	0.47	2.45e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg05315796	chr3:52349193	DNAH1	0.45	6.87	0.4	5.35e-11	Bipolar disorder;
KIRP	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.37	-0.43	2.65e-12	Colorectal cancer;
KIRP	cis	rs8028182	0.525	rs9920028	chr15:75927717	G/A	cg20655648	chr15:75932815	IMP3	0.59	7.41	0.43	2.08e-12	Sudden cardiac arrest;
KIRP	cis	rs72772090	0.539	rs72773981	chr5:96156059	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.8	-7.01	-0.41	2.31e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	15.88	0.71	1.4e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7818345	0.935	rs7016592	chr8:19277735	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.38	0.38	8.95e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7923609	0.875	rs10740118	chr10:65101207	C/G	cg08743896	chr10:65200160	JMJD1C	0.34	4.85	0.3	2.17e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.31	-0.37	1.31e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg10223061	chr2:219282414	VIL1	0.42	6.45	0.38	5.88e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12580194	0.593	rs12099808	chr12:55731178	T/A	cg11794356	chr12:55725991	OR6C3	-0.54	-7.21	-0.42	7.07e-12	Cancer;
KIRP	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.53	4.92	0.3	1.62e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.74	10.9	0.57	8.09e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.66	-8.63	-0.48	7.65e-16	Motion sickness;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.57	-8.95	-0.5	9.1e-17	Lymphocyte counts;
KIRP	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg16497661	chr14:103986332	CKB	0.76	11.26	0.58	5.58e-24	Body mass index;
KIRP	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.11	-0.31	6.34e-7	Aortic root size;
KIRP	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.64	-9.41	-0.51	3.62e-18	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.26e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg11062466	chr8:58055876	NA	0.6	5.58	0.34	6.44e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-5.08	-0.31	7.47e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.65	0.56	4.92e-22	Cognitive test performance;
KIRP	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.66	8.71	0.49	4.64e-16	Aortic root size;
KIRP	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.52	6.76	0.4	9.79e-11	Lung cancer;
KIRP	cis	rs4478858	0.684	rs10798837	chr1:31719340	C/T	cg00250761	chr1:31883323	NA	-0.31	-5.43	-0.33	1.34e-7	Alcohol dependence;
KIRP	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-1.0	-12.92	-0.64	1.65e-29	Platelet distribution width;
KIRP	cis	rs10492096	0.898	rs12426815	chr12:6580314	A/G	cg13857086	chr12:6580257	VAMP1	0.62	6.49	0.38	4.57e-10	Hip geometry;
KIRP	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.87	-11.44	-0.59	1.37e-24	Cognitive function;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09602541	chr3:174792068	NAALADL2	-0.46	-6.93	-0.4	3.71e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.51	6.78	0.4	8.9e-11	IgG glycosylation;
KIRP	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg24375607	chr4:120327624	NA	0.59	6.15	0.36	3.19e-9	Corneal astigmatism;
KIRP	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg17652424	chr22:38574118	PLA2G6	-0.23	-4.9	-0.3	1.71e-6	Cutaneous nevi;
KIRP	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.63	-7.27	-0.42	4.88e-12	Menarche (age at onset);
KIRP	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.64	0.48	7.4e-16	Motion sickness;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg01114163	chr5:1856713	NA	-0.43	-5.31	-0.32	2.41e-7	Cardiovascular disease risk factors;
KIRP	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.1	0.5	3.14e-17	Colorectal cancer;
KIRP	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.72	8.49	0.48	1.91e-15	Resting heart rate;
KIRP	cis	rs3764563	0.799	rs2017776	chr19:15698229	T/C	cg20725493	chr19:15740067	CYP4F8	0.88	6.23	0.37	2.01e-9	Inflammatory biomarkers;
KIRP	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.85	0.4	5.9e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg24060327	chr5:131705240	SLC22A5	0.58	7.31	0.42	3.82e-12	Acylcarnitine levels;
KIRP	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg20302533	chr7:39170763	POU6F2	0.28	5.96	0.36	8.66e-9	IgG glycosylation;
KIRP	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.85	-11.29	-0.58	4.2e-24	Type 2 diabetes;
KIRP	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.42	6.15	0.36	3.16e-9	Carotid intima media thickness;
KIRP	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.55	-8.4	-0.47	3.51e-15	Diastolic blood pressure;
KIRP	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg17509989	chr5:176798049	RGS14	0.74	7.67	0.44	3.98e-13	Urate levels in lean individuals;
KIRP	cis	rs9311474	0.713	rs352165	chr3:52242902	A/G	cg05315796	chr3:52349193	DNAH1	0.42	6.23	0.37	2.06e-9	Electroencephalogram traits;
KIRP	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	trans	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06481639	chr22:41940642	POLR3H	0.7	7.12	0.41	1.2e-11	Cannabis dependence symptom count;
KIRP	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	1.11	17.93	0.75	1.55e-46	Homoarginine levels;
KIRP	cis	rs16854884	0.770	rs7621079	chr3:143814500	G/C	cg06585982	chr3:143692056	C3orf58	0.4	4.85	0.3	2.24e-6	Economic and political preferences (feminism/equality);
KIRP	cis	rs740698	0.522	rs1024653	chr17:60791818	A/C	cg13195520	chr17:60813227	MARCH10	-0.5	-7.41	-0.43	2.07e-12	Pulse pressure;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs72730918	0.590	rs8025974	chr15:51985275	A/G	cg14296394	chr15:51910925	DMXL2	-0.7	-9.79	-0.53	2.52e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs16854884	1.000	rs11924473	chr3:143787075	C/G	cg06585982	chr3:143692056	C3orf58	0.51	5.74	0.34	2.77e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	0.77	5.85	0.35	1.52e-8	IgG glycosylation;
KIRP	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-15.38	-0.7	7.22e-38	Ulcerative colitis;
KIRP	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.1e-9	Cognitive function;
KIRP	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg25356066	chr3:128598488	ACAD9	0.56	6.43	0.38	6.48e-10	IgG glycosylation;
KIRP	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.56	6.08	0.36	4.59e-9	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.98	-15.68	-0.71	6.99e-39	Leprosy;
KIRP	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg13373371	chr19:49828787	SLC6A16	0.42	5.22	0.32	3.9e-7	Multiple sclerosis;
KIRP	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.7	9.39	0.51	4.24e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4006360	0.524	rs7219230	chr17:39286180	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.49	-7.19	-0.42	7.92e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.68	9.35	0.51	5.72e-18	Lymphocyte counts;
KIRP	cis	rs10875746	0.859	rs4760695	chr12:48591848	A/G	cg26205652	chr12:48591994	NA	0.81	11.07	0.58	2.18e-23	Longevity (90 years and older);
KIRP	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05347473	chr6:146136440	FBXO30	-0.46	-6.33	-0.37	1.13e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.73	9.42	0.51	3.47e-18	Coronary artery disease;
KIRP	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06505273	chr16:24850292	NA	0.39	5.16	0.31	5.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs654384	0.866	rs13224870	chr7:4172006	C/T	cg21882563	chr7:4172065	SDK1	0.43	5.6	0.34	5.71e-8	Positive affect;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03941577	chr4:26862456	STIM2	0.5	6.16	0.37	2.96e-9	Parkinson's disease;
KIRP	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.47	-11.7	-0.6	1.96e-25	Diabetic kidney disease;
KIRP	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg18944383	chr4:111397179	ENPEP	0.4	6.29	0.37	1.47e-9	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-1.05	-9.49	-0.52	2.04e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs17253792	0.598	rs71413578	chr14:56018651	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.12	0.31	6.31e-7	Putamen volume;
KIRP	cis	rs9309473	1.000	rs10189574	chr2:73698518	C/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.41	-0.33	1.47e-7	Metabolite levels;
KIRP	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	12.79	0.63	4.83e-29	Smoking behavior;
KIRP	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.46	5.61	0.34	5.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7215564	0.908	rs115148337	chr17:78688545	G/T	cg06153925	chr17:78755379	RPTOR	0.35	5.49	0.33	1.02e-7	Myopia (pathological);
KIRP	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg18190219	chr22:46762943	CELSR1	-0.87	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.64	-0.66	6.54e-32	Primary sclerosing cholangitis;
KIRP	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg20362242	chr5:692897	TPPP	0.62	5.22	0.32	3.81e-7	Obesity-related traits;
KIRP	cis	rs6462411	0.938	rs1962783	chr7:3920544	C/G	cg18022346	chr7:3920534	SDK1	-0.44	-5.13	-0.31	5.75e-7	Quantitative traits;
KIRP	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg03627880	chr6:151815985	C6orf97	-0.4	-4.86	-0.3	2.11e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs17221829	0.703	rs11018680	chr11:89364011	G/A	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.28	-0.32	2.81e-7	Anxiety in major depressive disorder;
KIRP	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-1.05	-13.0	-0.64	8.94e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs4733601	1.000	rs4733601	chr8:129269466	A/G	cg10554651	chr5:179233137	SQSTM1;MGAT4B	0.48	6.19	0.37	2.5e-9	Diffuse large B cell lymphoma;
KIRP	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.59	7.99	0.45	5.3e-14	Schizophrenia;
KIRP	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs72627123	0.656	rs77660260	chr14:74569573	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.91	0.3	1.7e-6	Morning vs. evening chronotype;
KIRP	trans	rs2043599	0.920	rs61750024	chr19:56467281	A/G	cg25841159	chr17:74137454	FOXJ1	-0.95	-6.08	-0.36	4.49e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.73	7.33	0.42	3.23e-12	Bipolar disorder;
KIRP	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg06647332	chr5:131281008	NA	-0.45	-4.95	-0.3	1.35e-6	Life satisfaction;
KIRP	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg10189774	chr4:17578691	LAP3	0.51	6.18	0.37	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg12310025	chr6:25882481	NA	-0.65	-7.77	-0.44	2.17e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.585	rs195525	chr6:116248273	C/T	cg05304507	chr6:116381966	FRK	0.2	5.07	0.31	7.87e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg10223061	chr2:219282414	VIL1	0.28	4.89	0.3	1.85e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4671458	0.625	rs4671522	chr2:63844917	G/T	cg17519650	chr2:63277830	OTX1	0.46	4.89	0.3	1.8e-6	Subjective well-being;
KIRP	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.11	-0.77	1.59e-50	Height;
KIRP	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg05315796	chr3:52349193	DNAH1	0.46	7.0	0.41	2.41e-11	Bipolar disorder;
KIRP	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.37	0.43	2.58e-12	Lung cancer;
KIRP	cis	rs55788414	0.932	rs9921748	chr16:81181783	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.29	-0.47	7.58e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7215564	0.908	rs79961397	chr17:78687146	T/A	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.4e-7	Myopia (pathological);
KIRP	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.74	11.09	0.58	1.96e-23	Oral cavity cancer;
KIRP	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.61	7.65	0.44	4.63e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4356932	1.000	rs11097219	chr4:76980163	G/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg08662619	chr6:150070041	PCMT1	0.36	5.98	0.36	7.89e-9	Lung cancer;
KIRP	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	6.39	0.38	8.14e-10	Menarche (age at onset);
KIRP	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg21361702	chr7:150065534	REPIN1	0.65	6.82	0.4	6.98e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs865483	0.895	rs2522972	chr17:35839021	C/T	cg06716730	chr17:35851459	DUSP14	0.26	6.25	0.37	1.81e-9	Monocyte count;
KIRP	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.58	-7.22	-0.42	6.46e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs258892	0.895	rs10039408	chr5:72069110	G/T	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13045813	chr2:196933518	DNAH7	0.51	6.53	0.38	3.65e-10	Parkinson's disease;
KIRP	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg06640241	chr16:89574553	SPG7	0.84	13.48	0.65	2.28e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs1656402	1.000	rs1190442	chr2:233422205	A/C	cg03852847	chr2:233439513	NA	0.68	11.13	0.58	1.41e-23	Non-small cell lung cancer (survival);
KIRP	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.58	-5.98	-0.36	7.79e-9	Total cholesterol levels;
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg00933542	chr6:150070202	PCMT1	0.27	5.22	0.32	3.81e-7	Lung cancer;
KIRP	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg04989706	chr14:50066350	PPIL5	0.49	6.02	0.36	6.44e-9	Carotid intima media thickness;
KIRP	cis	rs10858047	0.883	rs2137365	chr1:115078685	C/G	cg12756093	chr1:115239321	AMPD1	-0.54	-5.48	-0.33	1.03e-7	Autism;
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg09699651	chr6:150184138	LRP11	0.45	5.91	0.35	1.15e-8	Lung cancer;
KIRP	cis	rs4716602	0.596	rs12386632	chr7:156158221	G/A	cg16983916	chr7:156159713	NA	-0.43	-5.44	-0.33	1.26e-7	Anti-saccade response;
KIRP	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	6.26	0.37	1.71e-9	Monocyte count;
KIRP	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs258892	0.895	rs13157632	chr5:72036499	G/A	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-6.24	-0.37	1.95e-9	Breast cancer;
KIRP	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg06307176	chr5:131281290	NA	-0.55	-5.98	-0.36	7.7e-9	Life satisfaction;
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg16268157	chr7:99778414	STAG3	-0.51	-5.34	-0.32	2.16e-7	Lung function (FEV1/FVC);
KIRP	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg00507259	chr4:95128692	SMARCAD1	0.41	5.24	0.32	3.37e-7	QT interval;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11963430	chr19:19729565	PBX4	0.46	6.5	0.38	4.55e-10	Cancer;
KIRP	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.46	6.88	0.4	4.92e-11	Daytime sleep phenotypes;
KIRP	cis	rs1485395	1.000	rs7969819	chr12:54001221	G/T	cg16917193	chr12:54089295	NA	-0.61	-6.36	-0.38	9.64e-10	Migraine without aura;
KIRP	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg27572855	chr1:25598939	RHD	-0.48	-8.02	-0.46	4.24e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-9.21	-0.51	1.53e-17	Pancreatic cancer;
KIRP	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg24169773	chr3:122142474	KPNA1	-0.58	-6.45	-0.38	5.9e-10	LDL cholesterol levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05596319	chr10:124714047	C10orf88	0.46	6.39	0.38	8.27e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs575018	0.774	rs6595822	chr5:100593271	T/C	cg03848127	chr5:100126093	NA	-0.45	-5.42	-0.33	1.41e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg12549451	chr6:135224345	NA	0.42	5.09	0.31	7.25e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.73	8.12	0.46	2.21e-14	High light scatter reticulocyte count;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23269605	chr13:77675444	MYCBP2	0.43	6.54	0.38	3.59e-10	Migraine with aura;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14270612	chr9:133738235	ABL1	-0.44	-6.37	-0.38	9.13e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.11	0.64	4.03e-30	Exhaled nitric oxide output;
KIRP	trans	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs13209747	0.658	rs1105955	chr6:127147168	T/A	cg21431617	chr6:127135037	NA	0.33	5.96	0.35	8.92e-9	Diastolic blood pressure;Systolic blood pressure;Blood pressure;
KIRP	cis	rs2839627	0.638	rs7276320	chr21:44269588	A/G	cg03543861	chr21:44258195	NA	-0.57	-6.27	-0.37	1.65e-9	Information processing speed;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22683308	chr4:1340831	KIAA1530	0.4	4.96	0.3	1.29e-6	Longevity;
KIRP	cis	rs7818345	0.967	rs13255677	chr8:19288985	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.68	0.39	1.58e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.97e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs6545883	0.929	rs3732170	chr2:61749716	C/T	cg15711740	chr2:61764176	XPO1	-0.61	-8.29	-0.47	7.56e-15	Tuberculosis;
KIRP	cis	rs7520050	0.833	rs1085242	chr1:46544224	T/A	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg09324608	chr17:30823087	MYO1D	0.41	5.1	0.31	6.7e-7	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.63e-15	Initial pursuit acceleration;
KIRP	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg23250157	chr14:64679961	SYNE2	0.45	4.98	0.3	1.22e-6	Atrial fibrillation;
KIRP	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg26138937	chr11:71823887	C11orf51	1.04	7.1	0.41	1.3e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs13279522	0.536	rs7824630	chr8:67003194	C/G	cg04041976	chr8:67085823	TRIM55	-0.44	-5.52	-0.33	8.81e-8	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.75	-12.27	-0.62	2.56e-27	Calcium levels;
KIRP	cis	rs9488822	0.662	rs195531	chr6:116252551	A/T	cg18764771	chr6:116381957	FRK	0.19	5.18	0.31	4.6e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.75	-0.34	2.63e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs270421	0.658	rs383362	chr16:79245820	G/T	cg26284735	chr3:5065165	NA	0.25	6.76	0.4	9.78e-11	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs12022452	0.506	rs11208363	chr1:41010454	A/G	cg25568243	chr1:40974465	DEM1	0.57	6.25	0.37	1.75e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-16.95	-0.73	3.33e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35740288	0.571	rs11631009	chr15:86318653	G/A	cg20737812	chr15:86336631	KLHL25	-0.51	-6.02	-0.36	6.3e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7614311	0.555	rs3774715	chr3:63919876	T/C	cg22134162	chr3:63841271	THOC7	-0.48	-5.7	-0.34	3.41e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs4006360	0.578	rs9893220	chr17:39231963	C/A	cg15015397	chr17:39261100	KRTAP4-9	-0.51	-7.8	-0.45	1.72e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4148660	0.719	rs1517272	chr12:22097301	T/C	cg14669847	chr12:22099120	NA	-0.34	-5.72	-0.34	3.1e-8	Gout;
KIRP	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg04780086	chr2:111875790	ACOXL	0.41	5.7	0.34	3.37e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg18357645	chr12:58087776	OS9	0.66	8.15	0.46	1.9e-14	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs295140	0.605	rs1436164	chr2:201158411	C/T	cg23649088	chr2:200775458	C2orf69	-0.42	-5.28	-0.32	2.9e-7	QT interval;
KIRP	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.8	8.33	0.47	5.82e-15	Gastritis;
KIRP	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.53	7.83	0.45	1.46e-13	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.63	9.58	0.52	1.14e-18	Lung cancer;
KIRP	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg24154853	chr7:158122151	PTPRN2	0.39	5.56	0.33	7.17e-8	Calcium levels;
KIRP	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.14	12.37	0.62	1.14e-27	Nonalcoholic fatty liver disease;
KIRP	cis	rs4742903	0.509	rs10991159	chr9:106960542	C/A	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	2.01e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.08	-0.31	7.46e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs580438	0.510	rs13061844	chr3:13370963	C/G	cg10657019	chr3:13328039	NA	-0.58	-7.66	-0.44	4.3e-13	Myringotomy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26645494	chr7:44153500	AEBP1	-0.48	-7.11	-0.41	1.24e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg11972305	chr2:233791962	NGEF	-0.38	-5.25	-0.32	3.27e-7	Schizophrenia;
KIRP	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.92	15.68	0.71	7.03e-39	Metabolic syndrome;
KIRP	cis	rs1978968	0.956	rs35598889	chr22:18450794	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-7.34	-0.42	3.09e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg05147244	chr20:61493195	TCFL5	0.93	7.17	0.42	8.56e-12	Obesity-related traits;
KIRP	cis	rs2880765	0.546	rs11639291	chr15:86064130	G/A	cg17133734	chr15:86042851	AKAP13	-0.62	-7.46	-0.43	1.46e-12	Coronary artery disease;
KIRP	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.71	9.9	0.53	1.18e-19	Mean corpuscular volume;
KIRP	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-9.03	-0.5	5.17e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.54	-6.03	-0.36	6.12e-9	Menarche (age at onset);
KIRP	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg15655495	chr12:38532458	NA	-0.28	-4.98	-0.3	1.17e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.69	8.87	0.49	1.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-0.96	-8.95	-0.5	9.12e-17	Blood pressure (smoking interaction);
KIRP	cis	rs7553864	0.667	rs10873820	chr1:87605973	C/G	cg17420885	chr1:87600446	LOC339524	0.59	7.68	0.44	3.85e-13	Smoking behavior;
KIRP	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.55	-6.45	-0.38	5.75e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.61	-6.36	-0.38	9.52e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-1.06	-20.78	-0.8	4.58e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg14829360	chr17:73884958	NA	-0.59	-8.23	-0.46	1.08e-14	Psoriasis;
KIRP	cis	rs55962025	0.883	rs3755883	chr4:3223250	A/G	cg06533319	chr4:3265114	C4orf44	0.43	5.01	0.3	1.05e-6	Parental longevity (mother's age at death);
KIRP	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg01557791	chr16:72042693	DHODH	0.42	5.25	0.32	3.36e-7	Fibrinogen levels;
KIRP	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg25457927	chr22:38595422	NA	-0.28	-5.9	-0.35	1.18e-8	Cutaneous nevi;
KIRP	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.73	-9.56	-0.52	1.28e-18	Glaucoma (primary open-angle);
KIRP	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg17145862	chr1:211918768	LPGAT1	-0.92	-13.47	-0.65	2.36e-31	Leprosy;
KIRP	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg13206674	chr6:150067644	NUP43	0.52	7.29	0.42	4.28e-12	Lung cancer;
KIRP	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg07068956	chr7:100330872	ZAN	-0.51	-5.2	-0.31	4.16e-7	Other erythrocyte phenotypes;
KIRP	cis	rs96067	0.772	rs6700737	chr1:36598214	A/G	cg24686825	chr1:36642396	MAP7D1	-0.6	-6.47	-0.38	5.25e-10	Corneal structure;
KIRP	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg06611532	chr13:114900021	NA	0.22	4.91	0.3	1.68e-6	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.44	-6.06	-0.36	5.04e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg23594656	chr7:65796392	TPST1	-0.52	-8.18	-0.46	1.54e-14	Aortic root size;
KIRP	cis	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg21546286	chr11:48923668	NA	0.43	5.17	0.31	4.91e-7	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01382900	chr6:13615583	NOL7	0.52	6.67	0.39	1.72e-10	Parkinson's disease;
KIRP	cis	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg06521852	chr22:38141419	TRIOBP	0.38	5.3	0.32	2.57e-7	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13047869	chr3:10149882	C3orf24	-0.5	-4.9	-0.3	1.77e-6	Alzheimer's disease;
KIRP	cis	rs2688419	0.565	rs1094607	chr3:23062581	C/A	cg00327796	chr3:23032191	NA	-0.42	-5.92	-0.35	1.07e-8	Type 2 diabetes;
KIRP	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.68	-7.51	-0.43	1.07e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg18764771	chr6:116381957	FRK	0.19	5.06	0.31	8.08e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs6589219	0.826	rs36029541	chr11:111139942	C/T	cg25129781	chr11:111156908	C11orf53	-0.41	-5.24	-0.32	3.43e-7	Colorectal cancer;
KIRP	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.5	0.33	9.42e-8	Colorectal cancer;
KIRP	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.49	-0.33	1e-7	Height;
KIRP	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg25303436	chr1:84941094	NA	0.39	6.2	0.37	2.39e-9	C-reactive protein;
KIRP	cis	rs3087591	0.659	rs2214538	chr17:29636570	C/T	cg24425628	chr17:29625626	OMG;NF1	0.64	9.38	0.51	4.4e-18	Hip circumference;
KIRP	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg18225595	chr11:63971243	STIP1	0.57	4.93	0.3	1.54e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.18	12.61	0.63	1.83e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	0.77	7.31	0.42	3.74e-12	Arsenic metabolism;
KIRP	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	11.38	0.59	2.19e-24	Platelet count;
KIRP	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg03714773	chr7:91764589	CYP51A1	0.41	5.93	0.35	1.04e-8	Breast cancer;
KIRP	trans	rs7863100	0.711	rs74489584	chr9:18644138	C/A	cg13196806	chr10:133996309	JAKMIP3	0.61	6.13	0.36	3.5e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.71	-0.39	1.32e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.69	8.53	0.48	1.54e-15	Multiple sclerosis;
KIRP	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.98	16.38	0.72	2.84e-41	Breast cancer;
KIRP	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg03929089	chr4:120376271	NA	-0.62	-6.44	-0.38	6.19e-10	Axial length;
KIRP	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg12131826	chr15:77904385	NA	-0.42	-4.9	-0.3	1.74e-6	Type 2 diabetes;
KIRP	cis	rs7224685	0.722	rs12945048	chr17:4159244	C/A	cg05562828	chr17:3906858	NA	0.53	6.3	0.37	1.34e-9	Type 2 diabetes;
KIRP	cis	rs1829883	0.775	rs2845989	chr5:98901165	C/T	cg08333243	chr5:99726346	NA	-0.43	-5.52	-0.33	8.69e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-8.82	-0.49	2.16e-16	Mean corpuscular volume;
KIRP	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.59	-7.4	-0.43	2.1e-12	Extraversion;
KIRP	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.22	0.42	6.4e-12	Joint mobility (Beighton score);
KIRP	trans	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg04740258	chr3:138553760	NA	-0.42	-6.31	-0.37	1.28e-9	Breast cancer;
KIRP	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.06	0.5	4.07e-17	Menopause (age at onset);
KIRP	cis	rs2213920	0.679	rs10759786	chr9:118241188	A/G	cg13918206	chr9:118159781	DEC1	0.75	8.09	0.46	2.65e-14	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs9467160	0.871	rs9461015	chr6:24449020	C/G	cg20631270	chr6:24437470	GPLD1	-0.42	-4.85	-0.3	2.24e-6	Liver enzyme levels;
KIRP	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.97	13.13	0.64	3.25e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg04989706	chr14:50066350	PPIL5	-0.48	-5.94	-0.35	9.71e-9	Carotid intima media thickness;
KIRP	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	7.59	0.44	6.76e-13	Height;
KIRP	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25517755	chr10:38738941	LOC399744	0.39	5.13	0.31	5.89e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-6.86	-0.4	5.64e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.79	-12.72	-0.63	7.9e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg09596252	chr17:78655493	RPTOR	0.51	6.12	0.36	3.76e-9	Fractional excretion of uric acid;
KIRP	cis	rs12780845	0.505	rs10795459	chr10:17244124	C/T	cg01003015	chr10:17271136	VIM	-0.49	-6.27	-0.37	1.64e-9	Homocysteine levels;
KIRP	cis	rs11955398	0.625	rs286153	chr5:59928948	A/G	cg02684056	chr5:59996105	DEPDC1B	0.48	5.63	0.34	5.01e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg25204440	chr1:209979598	IRF6	0.48	4.97	0.3	1.23e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs3736485	0.934	rs8038203	chr15:51870683	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.16	-0.31	5.15e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg16989719	chr2:238392110	NA	-0.57	-5.74	-0.34	2.81e-8	Prostate cancer;
KIRP	cis	rs997154	0.655	rs2008345	chr14:23401442	T/A	cg25600027	chr14:23388339	RBM23	-0.44	-5.07	-0.31	7.68e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.5	-6.22	-0.37	2.12e-9	Iron status biomarkers;
KIRP	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23722778	chr6:46112967	ENPP4	-0.44	-6.68	-0.39	1.6e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg06565975	chr8:143823917	SLURP1	-0.43	-6.54	-0.38	3.57e-10	Urinary tract infection frequency;
KIRP	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.75	-12.34	-0.62	1.45e-27	Prostate cancer;
KIRP	trans	rs933360	0.585	rs11238311	chr7:50825368	A/C	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg00376283	chr12:123451042	ABCB9	-0.65	-6.68	-0.39	1.58e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	0.75	5.9	0.35	1.19e-8	Arsenic metabolism;
KIRP	cis	rs6102059	0.692	rs6029188	chr20:39200914	A/G	cg22477343	chr20:39312069	NA	0.45	5.87	0.35	1.37e-8	LDL cholesterol;
KIRP	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg04058563	chr4:185651563	MLF1IP	-0.5	-6.83	-0.4	6.61e-11	Kawasaki disease;
KIRP	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.49	4.77e-16	Retinal vascular caliber;
KIRP	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg18350739	chr11:68623251	NA	-0.52	-7.96	-0.45	6.38e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.51	-7.64	-0.44	4.85e-13	Longevity;
KIRP	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6561750	1.000	rs1319798	chr13:54439142	A/G	ch.13.53330881F	chr13:54432880	NA	-0.37	-4.96	-0.3	1.31e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg03609598	chr5:56110824	MAP3K1	0.44	5.12	0.31	6.07e-7	Initial pursuit acceleration;
KIRP	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.63	10.04	0.54	4.26e-20	Neuroticism;
KIRP	cis	rs12200782	0.722	rs12205731	chr6:26370660	G/A	cg11502198	chr6:26597334	ABT1	-0.89	-5.01	-0.3	1.03e-6	Small cell lung carcinoma;
KIRP	cis	rs16854884	0.837	rs6804060	chr3:143804040	C/T	cg06585982	chr3:143692056	C3orf58	0.49	5.72	0.34	3.06e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs4006360	0.579	rs2132841	chr17:39234970	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.61	-8.71	-0.49	4.62e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	22.77	0.82	1.71e-62	Schizophrenia;
KIRP	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs17092148	1.000	rs6088603	chr20:33370945	A/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.6	-0.34	5.78e-8	Neuroticism;
KIRP	cis	rs7572263	0.652	rs34575089	chr2:209047368	G/A	cg23998903	chr2:209048830	C2orf80	-0.34	-5.32	-0.32	2.32e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs986417	0.901	rs10483726	chr14:61039476	A/G	cg27398547	chr14:60952738	C14orf39	0.67	6.73	0.39	1.17e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-1.04	-7.89	-0.45	9.93e-14	Mitochondrial DNA levels;
KIRP	cis	rs57338032	0.891	rs16969883	chr15:78765189	C/T	cg06917634	chr15:78832804	PSMA4	0.56	4.95	0.3	1.41e-6	CTACK levels;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg08901578	chr4:187885870	NA	-0.47	-7.09	-0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21747090	chr2:27597821	SNX17	-0.49	-6.79	-0.4	8.12e-11	Total body bone mineral density;
KIRP	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg08847533	chr14:75593920	NEK9	0.94	15.26	0.7	1.93e-37	Height;
KIRP	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.41	-0.38	7.19e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4663866	0.908	rs2304670	chr2:239165636	C/T	cg16914508	chr2:239161102	PER2	0.7	5.08	0.31	7.47e-7	Irritable bowel syndrome;
KIRP	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg00629941	chr15:75287862	SCAMP5	-0.49	-5.18	-0.31	4.66e-7	Blood trace element (Zn levels);
KIRP	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.99	-0.45	5.21e-14	Retinal vascular caliber;
KIRP	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.67	8.39	0.47	3.92e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.32	-0.37	1.25e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7015630	0.648	rs6996564	chr8:90850765	A/G	cg18493113	chr8:90847772	NA	-0.53	-5.87	-0.35	1.4e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-7.3	-0.42	3.96e-12	Lung cancer;
KIRP	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.57	-7.75	-0.44	2.41e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7404843	0.789	rs222909	chr16:15499289	A/G	cg02716450	chr16:28638775	NA	0.96	10.64	0.56	5.36e-22	Testicular germ cell tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14992154	chr4:20701870	PACRGL	-0.49	-6.35	-0.38	1.05e-9	Interleukin-4 levels;
KIRP	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.4	-5.47	-0.33	1.13e-7	Endometrial cancer;
KIRP	cis	rs7577696	0.513	rs212685	chr2:32434701	A/G	cg02381751	chr2:32503542	YIPF4	0.54	5.42	0.33	1.4e-7	Inflammatory biomarkers;
KIRP	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.4	0.7	6.17e-38	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26527583	chr19:40931697	SERTAD1	0.53	6.52	0.38	3.98e-10	Parkinson's disease;
KIRP	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg08885076	chr2:99613938	TSGA10	-0.53	-9.01	-0.5	5.92e-17	Chronic sinus infection;
KIRP	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg18404041	chr3:52824283	ITIH1	0.33	4.85	0.3	2.21e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.7	0.39	1.38e-10	Menarche (age at onset);
KIRP	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg12560992	chr17:57184187	TRIM37	0.61	5.47	0.33	1.11e-7	Cognitive test performance;
KIRP	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.99	11.43	0.59	1.46e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.35	12.29	0.62	2.19e-27	Diabetic retinopathy;
KIRP	cis	rs10207060	0.500	rs72992168	chr2:240712932	G/A	cg20333904	chr2:240724165	NA	-0.41	-4.92	-0.3	1.59e-6	Obesity-related traits;
KIRP	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00149659	chr3:10157352	C3orf10	0.52	5.99	0.36	7.48e-9	Alzheimer's disease;
KIRP	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg18944383	chr4:111397179	ENPEP	0.71	13.3	0.65	9.3e-31	Coronary artery disease;
KIRP	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg03808351	chr9:123631620	PHF19	0.38	5.1	0.31	6.79e-7	Rheumatoid arthritis;
KIRP	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg11641102	chr8:27183873	PTK2B	0.38	4.9	0.3	1.76e-6	Neuroticism;
KIRP	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg23477460	chr3:66848765	NA	0.69	7.21	0.42	6.8e-12	Type 2 diabetes;
KIRP	cis	rs6001982	0.667	rs56215843	chr22:40837253	C/T	cg07138101	chr22:40742427	ADSL	0.71	4.94	0.3	1.47e-6	Breast cancer;
KIRP	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.32	4.92	0.3	1.59e-6	Migraine;
KIRP	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.65	-7.17	-0.42	8.6e-12	Vitiligo;
KIRP	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	10.76	0.57	2.19e-22	Electrocardiographic conduction measures;
KIRP	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	0.66	7.58	0.44	6.95e-13	Dental caries;
KIRP	cis	rs7998202	0.614	rs668967	chr13:113369948	G/A	cg02820901	chr13:113351484	ATP11A	0.52	4.88	0.3	1.89e-6	Glycated hemoglobin levels;
KIRP	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg07451762	chr16:28383216	NA	0.38	4.93	0.3	1.51e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg18441811	chr11:71824068	C11orf51	-0.77	-5.12	-0.31	6.29e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-18.87	-0.77	1e-49	Ulcerative colitis;
KIRP	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg09137382	chr11:130731461	NA	0.59	8.58	0.48	1.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs4234798	1.000	rs4689088	chr4:7222253	G/A	cg18431297	chr4:7219810	SORCS2	0.67	8.81	0.49	2.27e-16	Insulin-like growth factors;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10048212	chr10:90345860	LIPJ	-0.44	-6.8	-0.4	7.79e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg21775007	chr8:11205619	TDH	0.55	7.7	0.44	3.41e-13	Retinal vascular caliber;
KIRP	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-14.63	-0.68	2.76e-35	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs62355272	0.900	rs6872631	chr5:35831936	C/T	cg13894535	chr5:35919491	CAPSL	-0.41	-5.11	-0.31	6.42e-7	Lymphocyte counts;
KIRP	cis	rs2415984	0.579	rs61993338	chr14:46969142	T/C	cg14871534	chr14:47121158	RPL10L	-0.41	-4.9	-0.3	1.74e-6	Number of children ever born;
KIRP	cis	rs6545883	0.860	rs6545848	chr2:61461183	G/T	cg15711740	chr2:61764176	XPO1	0.58	7.59	0.44	6.71e-13	Tuberculosis;
KIRP	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg19847130	chr8:10466454	RP1L1	-0.34	-4.96	-0.3	1.31e-6	Retinal vascular caliber;
KIRP	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.38	4.97	0.3	1.28e-6	Birth weight;
KIRP	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.49	7.22	0.42	6.54e-12	Testicular germ cell tumor;
KIRP	cis	rs6752107	0.935	rs10929326	chr2:234151045	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.69	0.44	3.56e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4740619	0.619	rs1410453	chr9:16042191	T/A	cg14451791	chr9:16040625	NA	-0.43	-5.67	-0.34	3.92e-8	Body mass index;
KIRP	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.83	11.26	0.58	5.26e-24	Essential tremor;
KIRP	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg19731401	chr7:2775893	GNA12	0.62	6.65	0.39	1.86e-10	Childhood ear infection;
KIRP	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.22	12.26	0.62	2.77e-27	Corneal structure;
KIRP	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.94	15.09	0.69	7.36e-37	Metabolite levels;
KIRP	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.79	12.79	0.63	4.8e-29	Longevity;
KIRP	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.25	6.54	0.38	3.55e-10	Crohn's disease;
KIRP	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.77	5.98	0.36	7.94e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg11189052	chr15:85197271	WDR73	0.56	5.9	0.35	1.18e-8	Schizophrenia;
KIRP	trans	rs7999699	0.840	rs4942687	chr13:48312739	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Bipolar disorder;
KIRP	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg17644776	chr2:200775616	C2orf69	0.55	5.93	0.35	1.04e-8	Schizophrenia;
KIRP	cis	rs10411936	0.712	rs3810198	chr19:16601194	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.37	0.32	1.8e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs17772222	0.606	rs1955598	chr14:88823655	C/T	cg07029226	chr1:2104223	PRKCZ	-0.44	-6.02	-0.36	6.43e-9	Coronary artery calcification;
KIRP	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg16497661	chr14:103986332	CKB	-0.49	-6.29	-0.37	1.44e-9	Coronary artery disease;
KIRP	cis	rs10140922	0.966	rs10132397	chr14:35822447	G/T	cg07166546	chr14:35805898	NA	-0.28	-6.74	-0.39	1.13e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	trans	rs1864729	1.000	rs2439700	chr8:98277168	G/A	cg08679828	chr8:102218111	ZNF706	-0.68	-6.18	-0.37	2.7e-9	Estradiol plasma levels (breast cancer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03252527	chr11:798106	NA	0.52	6.52	0.38	4.06e-10	Parkinson's disease;
KIRP	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg23172400	chr8:95962367	TP53INP1	0.32	6.18	0.37	2.64e-9	Type 2 diabetes;
KIRP	cis	rs35740288	0.770	rs55740125	chr15:86155736	G/A	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4776059	0.798	rs4774634	chr15:52872488	G/C	cg22715398	chr15:52968154	KIAA1370	-0.48	-5.52	-0.33	8.47e-8	Schizophrenia;
KIRP	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.75	-11.48	-0.59	9.99e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.23	-0.32	3.64e-7	Mean platelet volume;
KIRP	cis	rs255758	0.813	rs255760	chr5:53322187	T/C	cg22592108	chr5:53304441	ARL15	0.45	5.87	0.35	1.44e-8	Rheumatoid arthritis;
KIRP	cis	rs35771425	0.956	rs12758491	chr1:211589572	C/T	cg10512769	chr1:211675356	NA	-0.51	-5.1	-0.31	6.66e-7	Educational attainment (years of education);
KIRP	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	0.89	5.73	0.34	3e-8	Obesity (early onset extreme);
KIRP	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg24203234	chr3:128598194	ACAD9	0.42	4.9	0.3	1.73e-6	IgG glycosylation;
KIRP	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.51	-11.28	-0.58	4.73e-24	Diabetic kidney disease;
KIRP	cis	rs2274273	0.624	rs72717738	chr14:55842761	C/G	cg04306507	chr14:55594613	LGALS3	0.37	5.04	0.31	9.04e-7	Protein biomarker;
KIRP	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	0.74	7.83	0.45	1.45e-13	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	1.07	20.24	0.79	2.83e-54	Height;
KIRP	cis	rs10267417	0.603	rs7779502	chr7:19945828	T/C	cg05791153	chr7:19748676	TWISTNB	0.52	5.24	0.32	3.43e-7	Night sleep phenotypes;
KIRP	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg16989719	chr2:238392110	NA	-0.5	-6.47	-0.38	5.21e-10	Prostate cancer;
KIRP	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg12826209	chr6:26865740	GUSBL1	-0.79	-5.41	-0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg19847130	chr8:10466454	RP1L1	0.36	5.45	0.33	1.25e-7	Triglycerides;
KIRP	cis	rs11874712	0.932	rs34907121	chr18:43677793	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.44	-6.09	-0.36	4.43e-9	Migraine - clinic-based;
KIRP	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.46	-5.41	-0.33	1.51e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg25019033	chr10:957182	NA	-0.54	-5.8	-0.35	2.06e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.67	7.81	0.45	1.62e-13	Breast cancer;
KIRP	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.56	-7.52	-0.43	1.05e-12	Response to temozolomide;
KIRP	cis	rs3105593	0.563	rs539383	chr15:50878478	C/T	cg05456662	chr15:50716270	USP8	0.38	4.87	0.3	1.97e-6	QT interval;
KIRP	trans	rs921874	0.585	rs2513239	chr11:86782728	T/G	cg20852851	chr2:240168848	HDAC4	0.46	6.26	0.37	1.68e-9	Total body bone mineral density;
KIRP	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg22437258	chr11:111473054	SIK2	-0.56	-6.59	-0.39	2.64e-10	Primary sclerosing cholangitis;
KIRP	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg02023728	chr11:77925099	USP35	0.32	5.4	0.33	1.54e-7	Alzheimer's disease (survival time);
KIRP	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg14092571	chr14:90743983	NA	0.42	5.13	0.31	5.97e-7	Mortality in heart failure;
KIRP	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.07	0.36	4.92e-9	Hypertriglyceridemia;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg20786246	chr2:72377174	NA	0.41	6.06	0.36	5.12e-9	Ischemic stroke;
KIRP	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	1.08	7.89	0.45	9.99e-14	Skin colour saturation;
KIRP	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.5	-6.06	-0.36	5.12e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.63	8.45	0.47	2.65e-15	Aortic root size;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.45	-5.19	-0.31	4.36e-7	Total body bone mineral density;
KIRP	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.96	-0.41	3.09e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.66	0.39	1.74e-10	Electroencephalogram traits;
KIRP	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.65	-0.52	6.93e-19	Response to antipsychotic treatment;
KIRP	cis	rs9815354	1.000	rs9869207	chr3:41878661	C/G	cg03022575	chr3:42003672	ULK4	0.52	6.05	0.36	5.38e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-9.18	-0.51	1.84e-17	Morning vs. evening chronotype;
KIRP	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg12856521	chr11:46389249	DGKZ	0.43	6.22	0.37	2.14e-9	Leprosy;
KIRP	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10536369	chr2:170335894	BBS5	0.96	6.69	0.39	1.45e-10	P wave terminal force;
KIRP	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg13271783	chr10:134563150	INPP5A	-0.49	-6.33	-0.37	1.14e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg01448562	chr3:133502909	NA	-0.48	-5.73	-0.34	2.9e-8	Iron status biomarkers;
KIRP	trans	rs12545912	0.770	rs4313162	chr8:9548592	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.59	-0.39	2.63e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg00376283	chr12:123451042	ABCB9	0.72	9.06	0.5	4.15e-17	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.49	0.52	2.07e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg13206674	chr6:150067644	NUP43	0.59	8.39	0.47	3.77e-15	Lung cancer;
KIRP	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg15880211	chr22:50250494	ZBED4	-0.66	-7.43	-0.43	1.74e-12	Schizophrenia;
KIRP	cis	rs870825	0.932	rs2696059	chr4:185575127	A/T	cg04058563	chr4:185651563	MLF1IP	-0.94	-10.45	-0.55	2.13e-21	Blood protein levels;
KIRP	cis	rs9653442	0.545	rs13415465	chr2:100764004	T/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7590368	0.706	rs56268818	chr2:10956011	C/T	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.51	-6.24	-0.37	1.91e-9	Longevity;Endometriosis;
KIRP	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.56	6.19	0.37	2.47e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.36	-0.47	4.71e-15	Coronary artery disease;
KIRP	cis	rs10129255	0.500	rs4774189	chr14:107176517	G/T	cg23076370	chr14:107095027	NA	-0.43	-5.22	-0.32	3.85e-7	Kawasaki disease;
KIRP	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg03315344	chr16:75512273	CHST6	0.53	5.1	0.31	6.63e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.64	8.65	0.48	6.91e-16	Longevity;Endometriosis;
KIRP	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg18964960	chr10:1102726	WDR37	-0.63	-7.13	-0.41	1.1e-11	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.76	-8.92	-0.49	1.05e-16	Adiposity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26304930	chr1:119571871	NA	-0.42	-6.38	-0.38	8.66e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg00784671	chr22:46762841	CELSR1	-0.74	-8.24	-0.47	1.01e-14	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg17145862	chr1:211918768	LPGAT1	0.6	6.13	0.36	3.55e-9	Crohn's disease;
KIRP	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.35	5.36	0.32	1.88e-7	Ulcerative colitis;
KIRP	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.8	10.92	0.57	6.81e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.38	-0.38	8.92e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25096440	chr11:9482398	ZNF143	0.64	7.64	0.44	4.74e-13	Smoking initiation;
KIRP	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.77	7.05	0.41	1.76e-11	Diabetic retinopathy;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02232875	chr1:32645332	TXLNA	-0.5	-6.08	-0.36	4.66e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	1.11	10.8	0.57	1.68e-22	Blood protein levels;
KIRP	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.61	8.38	0.47	4.15e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs12022452	0.556	rs11208298	chr1:40978878	A/G	cg25568243	chr1:40974465	DEM1	0.53	5.71	0.34	3.16e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02398342	chr17:80708632	TBCD;FN3K	0.46	5.74	0.34	2.83e-8	Glycated hemoglobin levels;
KIRP	cis	rs2275565	0.872	rs11802532	chr1:237056601	C/T	cg17297354	chr1:237056641	MTR	-0.4	-4.9	-0.3	1.73e-6	Homocysteine levels;
KIRP	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg17376030	chr22:41985996	PMM1	-0.52	-6.36	-0.38	9.5e-10	Vitiligo;
KIRP	cis	rs986417	1.000	rs1116854	chr14:60917496	C/A	cg27398547	chr14:60952738	C14orf39	-0.74	-7.44	-0.43	1.69e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs17221829	0.681	rs75322840	chr11:89390394	T/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.93	-0.3	1.49e-6	Anxiety in major depressive disorder;
KIRP	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.27	-0.32	2.98e-7	Life satisfaction;
KIRP	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.45	4.98	0.3	1.22e-6	Schizophrenia;
KIRP	cis	rs1570884	0.767	rs3751384	chr13:50123622	G/C	cg11801959	chr13:50123613	RCBTB1	-0.35	-4.98	-0.3	1.2e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg10578777	chr12:7781093	NA	0.56	5.64	0.34	4.76e-8	HDL cholesterol levels;
KIRP	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg18016565	chr1:150552671	MCL1	-0.46	-7.13	-0.41	1.08e-11	Tonsillectomy;
KIRP	trans	rs4908768	0.501	rs12756257	chr1:8616933	C/A	cg04109822	chr20:50158057	NFATC2	0.37	6.06	0.36	5.22e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg24579218	chr15:68104479	NA	0.38	6.25	0.37	1.82e-9	Restless legs syndrome;
KIRP	cis	rs7116495	0.529	rs575871	chr11:71778822	A/G	cg26138937	chr11:71823887	C11orf51	-0.78	-5.85	-0.35	1.57e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg17376030	chr22:41985996	PMM1	-0.82	-8.63	-0.48	7.61e-16	Cannabis dependence symptom count;
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg09597638	chr17:3907349	NA	0.54	8.04	0.46	3.82e-14	Type 2 diabetes;
KIRP	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.8	10.34	0.55	4.9e-21	Mean platelet volume;
KIRP	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg00319359	chr11:70116639	PPFIA1	0.8	6.92	0.4	4e-11	Coronary artery disease;
KIRP	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15128208	chr22:42549153	NA	-0.44	-5.55	-0.33	7.4e-8	Cognitive function;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg07650554	chr16:30457408	SEPHS2	0.46	6.03	0.36	5.99e-9	Ischemic stroke;
KIRP	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg20243544	chr17:37824526	PNMT	-0.43	-4.92	-0.3	1.58e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	15.2	0.7	3.17e-37	Electrocardiographic conduction measures;
KIRP	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.48	6.61	0.39	2.36e-10	Testicular germ cell tumor;
KIRP	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.74	8.61	0.48	8.82e-16	Obesity-related traits;
KIRP	cis	rs1978968	0.751	rs5992138	chr22:18458621	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.72	-9.16	-0.5	2.03e-17	Presence of antiphospholipid antibodies;
KIRP	cis	rs4363385	0.574	rs4845505	chr1:152960943	T/A	cg07796016	chr1:152779584	LCE1C	-0.41	-5.09	-0.31	7.22e-7	Inflammatory skin disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06517794	chr1:78180274	USP33	-0.43	-6.36	-0.38	9.8e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.37	6.8	0.4	7.71e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.92	-11.53	-0.59	6.84e-25	Corneal structure;
KIRP	cis	rs9473924	0.542	rs9473952	chr6:50921779	T/C	cg14470998	chr6:50812995	TFAP2B	0.81	7.66	0.44	4.23e-13	Body mass index;
KIRP	cis	rs9826463	0.757	rs73240309	chr3:142240223	A/G	cg20824294	chr3:142316082	PLS1	0.39	6.25	0.37	1.84e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg09365446	chr1:150670422	GOLPH3L	0.4	5.19	0.31	4.46e-7	Tonsillectomy;
KIRP	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg03959625	chr15:84868606	LOC388152	-0.55	-6.97	-0.41	2.86e-11	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg07216194	chr8:27182965	PTK2B	0.43	5.37	0.32	1.79e-7	Neuroticism;
KIRP	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.61	7.22	0.42	6.38e-12	Schizophrenia;
KIRP	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.68	10.01	0.54	5.3e-20	Dupuytren's disease;
KIRP	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.71	-6.12	-0.36	3.65e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.61	6.88	0.4	4.95e-11	Aortic root size;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg23628684	chr21:30446052	CCT8	0.59	7.47	0.43	1.35e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02475777	chr4:1388615	CRIPAK	0.36	4.85	0.3	2.15e-6	Longevity;
KIRP	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg02527881	chr3:46936655	PTH1R	-0.38	-5.39	-0.33	1.63e-7	Colorectal cancer;
KIRP	cis	rs9372498	0.732	rs17080124	chr6:118717814	A/G	cg18833306	chr6:118973337	C6orf204	-0.59	-5.22	-0.32	3.77e-7	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06694283	chr10:44144043	ZNF32	0.55	7.1	0.41	1.36e-11	Parkinson's disease;
KIRP	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg25174290	chr11:3078921	CARS	-0.69	-8.96	-0.5	8.26e-17	Calcium levels;
KIRP	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.74	-9.3	-0.51	7.74e-18	Facial morphology (factor 19);
KIRP	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.81	-11.26	-0.58	5.24e-24	Colorectal cancer;
KIRP	cis	rs239198	0.602	rs17672397	chr6:101288160	C/T	cg09795085	chr6:101329169	ASCC3	0.49	5.7	0.34	3.41e-8	Menarche (age at onset);
KIRP	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.99	17.31	0.74	1.93e-44	Breast cancer;
KIRP	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Recalcitrant atopic dermatitis;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.75	11.64	0.6	3.02e-25	Menarche (age at onset);
KIRP	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.52	-5.33	-0.32	2.17e-7	Gut microbiome composition (summer);
KIRP	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-5.76	-0.34	2.45e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4363385	0.574	rs6671520	chr1:152944156	C/T	cg13444842	chr1:152974279	SPRR3	-0.48	-6.97	-0.41	2.85e-11	Inflammatory skin disease;
KIRP	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg24253500	chr15:84953950	NA	0.54	5.54	0.33	7.92e-8	Schizophrenia;
KIRP	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg05478818	chr5:40835740	RPL37	0.69	4.93	0.3	1.52e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg04310649	chr10:35416472	CREM	0.59	7.15	0.41	9.69e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3744061	0.505	rs9907915	chr17:74651236	A/G	cg27546012	chr17:74684504	MXRA7	-0.45	-5.47	-0.33	1.12e-7	Retinal arteriolar caliber;
KIRP	cis	rs7923609	0.841	rs10761786	chr10:65336207	T/C	cg08743896	chr10:65200160	JMJD1C	-0.36	-5.41	-0.33	1.49e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg24203234	chr3:128598194	ACAD9	0.44	5.01	0.3	1.06e-6	IgG glycosylation;
KIRP	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg26174226	chr8:58114915	NA	-0.63	-7.47	-0.43	1.39e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9303542	0.625	rs17703636	chr17:46566890	C/T	cg04904318	chr17:46607828	HOXB1	0.5	5.45	0.33	1.24e-7	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	12.1	0.61	9.04e-27	Bipolar disorder;
KIRP	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg07972983	chr1:205091412	RBBP5	0.42	4.99	0.3	1.12e-6	Red blood cell count;
KIRP	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg13206674	chr6:150067644	NUP43	0.61	8.95	0.5	8.87e-17	Lung cancer;
KIRP	cis	rs1062746	0.771	rs9308348	chr16:87371941	G/A	cg02258303	chr16:87377426	FBXO31	-0.63	-9.09	-0.5	3.43e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.55	6.46	0.38	5.61e-10	Schizophrenia;
KIRP	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg01872077	chr2:219646372	CYP27A1	0.41	5.31	0.32	2.45e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.09	-0.31	7.05e-7	Longevity;
KIRP	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.47	-0.33	1.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs198389	0.617	rs503040	chr1:11890695	C/T	cg24844545	chr1:11908347	NPPA	-0.36	-5.2	-0.31	4.22e-7	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08184586	chr19:1940417	CSNK1G2	0.47	6.3	0.37	1.39e-9	Parkinson's disease;
KIRP	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg21184320	chr1:21044207	KIF17	-0.38	-5.72	-0.34	3.11e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.55	-7.21	-0.42	6.96e-12	Melanoma;
KIRP	cis	rs6738627	0.766	rs13389219	chr2:165528876	C/T	cg03182029	chr2:165697222	COBLL1	0.38	5.03	0.31	9.69e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs7680126	0.596	rs1978274	chr4:10245087	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.07	-0.31	7.75e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.78	8.62	0.48	8.19e-16	Corneal astigmatism;
KIRP	cis	rs687432	0.885	rs61903966	chr11:57801927	T/A	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs17023223	0.537	rs1325938	chr1:119582642	C/T	cg18261050	chr1:119551319	NA	0.52	6.97	0.41	2.84e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7084402	0.967	rs1593677	chr10:60291642	A/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs2072732	0.861	rs56398543	chr1:2950237	G/A	cg11731671	chr1:2995604	PRDM16	-0.44	-5.52	-0.33	8.56e-8	Plateletcrit;
KIRP	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg15890332	chr12:107067104	RFX4	0.4	6.68	0.39	1.63e-10	Heart rate;
KIRP	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-12.93	-0.64	1.6e-29	Chronic sinus infection;
KIRP	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg05784532	chr1:230284198	GALNT2	0.41	6.2	0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg13010199	chr12:38710504	ALG10B	0.61	8.01	0.45	4.72e-14	Bladder cancer;
KIRP	cis	rs3789045	0.913	rs55678522	chr1:204573481	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.53	-5.35	-0.32	1.99e-7	Educational attainment (college completion);
KIRP	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.77	9.45	0.52	2.79e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.78	7.92	0.45	8.3e-14	Behavioural disinhibition (generation interaction);
KIRP	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.36	0.42	2.68e-12	Morning vs. evening chronotype;
KIRP	cis	rs300890	1.000	rs300890	chr4:144249770	T/C	cg19876092	chr4:144208277	NA	0.44	7.22	0.42	6.59e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21545522	chr1:205238299	TMCC2	0.5	6.54	0.38	3.57e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.71	0.66	3.7e-32	Tonsillectomy;
KIRP	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.64	-8.37	-0.47	4.27e-15	Inflammatory bowel disease;
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs9346649	0.630	rs4708643	chr6:168491681	A/G	cg09211372	chr6:168490623	NA	-0.38	-6.56	-0.39	3.13e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg17457637	chr7:27170717	HOXA4	-0.39	-5.69	-0.34	3.65e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.39	-5.04	-0.31	9.09e-7	Renal cell carcinoma;
KIRP	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.45	5.44	0.33	1.27e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.67	6.88	0.4	5.01e-11	Corneal astigmatism;
KIRP	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.88	-0.53	1.34e-19	Hemoglobin concentration;
KIRP	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4740619	0.617	rs1328275	chr9:16027029	T/C	cg14451791	chr9:16040625	NA	-0.39	-5.35	-0.32	2.02e-7	Body mass index;
KIRP	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.44	2.78e-13	Myopia (pathological);
KIRP	cis	rs7106204	0.534	rs56157310	chr11:24260694	A/G	ch.11.24196551F	chr11:24239977	NA	0.67	5.23	0.32	3.67e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.85	10.27	0.55	8.16e-21	Cocaine dependence;
KIRP	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.91	-0.35	1.16e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg07622451	chr1:3079886	PRDM16	0.35	4.95	0.3	1.4e-6	Migraine;
KIRP	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg04731861	chr2:219085781	ARPC2	0.28	7.37	0.43	2.54e-12	Colorectal cancer;
KIRP	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.97	-16.69	-0.73	2.43e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg17133734	chr15:86042851	AKAP13	-0.45	-5.63	-0.34	4.81e-8	Interstitial lung disease;
KIRP	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg15436174	chr10:43711423	RASGEF1A	0.85	9.42	0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg21433313	chr16:3507492	NAT15	0.64	7.02	0.41	2.11e-11	Tuberculosis;
KIRP	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.49	6.0	0.36	7.17e-9	Common traits (Other);
KIRP	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00290607	chr11:67383545	NA	0.36	5.06	0.31	8.1e-7	Mean corpuscular volume;
KIRP	cis	rs7523273	0.565	rs2796232	chr1:207900368	T/A	cg22525895	chr1:207977042	MIR29B2	-0.49	-6.1	-0.36	4.09e-9	Schizophrenia;
KIRP	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg11498726	chr8:26250323	BNIP3L	-0.53	-8.0	-0.45	4.77e-14	Red cell distribution width;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.57	-8.01	-0.45	4.69e-14	Longevity;Endometriosis;
KIRP	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08035567	chr12:94853589	CCDC41;LOC144486	0.49	6.03	0.36	5.99e-9	Parkinson's disease;
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg01391022	chr12:122360665	WDR66	-0.38	-5.66	-0.34	4.13e-8	Mean corpuscular volume;
KIRP	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg18190219	chr22:46762943	CELSR1	-0.72	-6.06	-0.36	5.1e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.0	-0.36	6.86e-9	Metabolite levels;
KIRP	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.85	-0.35	1.56e-8	IgG glycosylation;
KIRP	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.52	0.33	8.59e-8	Menarche (age at onset);
KIRP	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.83	13.98	0.67	4.58e-33	Vitiligo;
KIRP	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.47	6.95	0.41	3.27e-11	Bone mineral density;
KIRP	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg06618935	chr21:46677482	NA	-0.39	-5.24	-0.32	3.46e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs933360	0.585	rs757773	chr7:50821425	T/A	cg20003124	chr12:4557277	NA	0.5	6.15	0.37	3.13e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.13	10.95	0.57	5.37e-23	Alzheimer's disease (late onset);
KIRP	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg06223162	chr1:101003688	GPR88	0.48	10.03	0.54	4.42e-20	Monocyte count;
KIRP	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.6	-7.97	-0.45	6.02e-14	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24429081	chr19:55741476	TMEM86B;SAPS1	-0.49	-6.47	-0.38	5.2e-10	Parkinson's disease;
KIRP	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.74	10.87	0.57	1e-22	Prostate cancer;
KIRP	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg20999797	chr1:1681921	NA	0.5	7.66	0.44	4.25e-13	Body mass index;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg23978390	chr7:1156363	C7orf50	0.59	7.04	0.41	1.92e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10214930	0.651	rs42085	chr7:27697939	C/A	cg22168087	chr7:27702803	HIBADH	-0.48	-5.12	-0.31	6.25e-7	Hypospadias;
KIRP	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg19847130	chr8:10466454	RP1L1	0.37	5.65	0.34	4.36e-8	Retinal vascular caliber;
KIRP	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	cis	rs6545883	0.931	rs9807965	chr2:61732159	T/C	cg15711740	chr2:61764176	XPO1	-0.59	-8.19	-0.46	1.44e-14	Tuberculosis;
KIRP	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg00074818	chr8:8560427	CLDN23	-0.29	-5.06	-0.31	8.27e-7	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07725658	chr4:71705655	GRSF1	0.52	6.36	0.38	9.94e-10	Parkinson's disease;
KIRP	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg15556689	chr8:8085844	FLJ10661	0.61	7.55	0.43	8.28e-13	Neuroticism;
KIRP	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.46	-0.33	1.18e-7	Breast cancer;
KIRP	cis	rs1978968	0.912	rs34156568	chr22:18444261	C/T	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.46	-0.43	1.5e-12	Retinal vascular caliber;
KIRP	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg02297831	chr4:17616191	MED28	0.58	7.38	0.43	2.4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.5	6.52	0.38	3.97e-10	High light scatter reticulocyte count;
KIRP	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.63	7.75	0.44	2.4e-13	Type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	cg21523751	chr1:182988639	NA	0.43	6.67	0.39	1.67e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9534288	0.699	rs2146885	chr13:46659853	A/G	cg15192986	chr13:46630673	CPB2	-0.78	-9.46	-0.52	2.66e-18	Blood protein levels;
KIRP	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.83	-0.53	1.96e-19	Aortic root size;
KIRP	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.65	-0.39	1.84e-10	Axial length;
KIRP	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-6.18	-0.37	2.69e-9	Schizophrenia;
KIRP	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.95	13.11	0.64	3.97e-30	Breast cancer;
KIRP	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.7	-0.44	3.23e-13	Mean platelet volume;
KIRP	cis	rs7688540	0.656	rs79657896	chr4:299261	G/A	cg10134910	chr4:1076041	RNF212	-0.25	-5.06	-0.31	8.28e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg07884673	chr3:53033167	SFMBT1	-0.74	-6.38	-0.38	8.88e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg15147215	chr3:52552868	STAB1	-0.3	-5.1	-0.31	6.75e-7	Electroencephalogram traits;
KIRP	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.52	-5.99	-0.36	7.33e-9	Urate levels in overweight individuals;
KIRP	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg13147721	chr7:65941812	NA	-0.89	-6.36	-0.38	9.62e-10	Diabetic kidney disease;
KIRP	cis	rs7656342	0.653	rs6831580	chr4:9852750	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.98	0.3	1.22e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs4148660	1.000	rs4148654	chr12:22063971	A/G	cg14669847	chr12:22099120	NA	0.35	5.98	0.36	7.7e-9	Gout;
KIRP	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg13165212	chr22:42675999	NA	0.28	5.05	0.31	8.78e-7	Cognitive function;
KIRP	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg07701084	chr6:150067640	NUP43	0.7	9.15	0.5	2.32e-17	Lung cancer;
KIRP	cis	rs79149102	0.579	rs74247779	chr15:75397131	G/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-6.35	-0.38	1.01e-9	Lung cancer;
KIRP	cis	rs7523050	0.643	rs17621922	chr1:109404454	C/T	cg08274380	chr1:109419600	GPSM2	1.05	9.16	0.5	2.13e-17	Fat distribution (HIV);
KIRP	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.58	8.18	0.46	1.53e-14	Multiple system atrophy;
KIRP	cis	rs2387326	0.717	rs10829341	chr10:129944226	G/A	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs669446	0.533	rs4660261	chr1:44229597	G/A	cg12599982	chr1:44399894	ARTN	0.42	5.13	0.31	5.76e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg08741688	chr4:3415352	RGS12	-0.45	-4.89	-0.3	1.81e-6	Serum sulfate level;
KIRP	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg16649577	chr8:11646810	NA	0.35	4.84	0.3	2.26e-6	Retinal vascular caliber;
KIRP	cis	rs6832769	0.925	rs6817267	chr4:56338541	G/A	cg05960024	chr4:56376020	CLOCK	0.63	8.17	0.46	1.65e-14	Personality dimensions;
KIRP	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg15247329	chr7:2764246	NA	-0.38	-5.49	-0.33	9.98e-8	Height;
KIRP	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.04	-0.5	4.65e-17	Retinal vascular caliber;
KIRP	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-1.09	-7.74	-0.44	2.51e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg06808227	chr14:105710500	BRF1	-0.77	-9.24	-0.51	1.17e-17	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9653442	0.527	rs10176782	chr2:100782827	C/A	cg07810366	chr2:100720526	AFF3	-0.32	-5.1	-0.31	6.76e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	1.02	8.93	0.49	9.91e-17	Pulse pressure;
KIRP	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.68	8.1	0.46	2.63e-14	Gestational age at birth (maternal effect);
KIRP	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.48	6.57	0.39	2.98e-10	Mean corpuscular volume;
KIRP	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.46	5.85	0.35	1.58e-8	Schizophrenia (inflammation and infection response interaction);
KIRP	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg05223392	chr7:2647927	IQCE	0.36	6.05	0.36	5.26e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg21475434	chr5:93447410	FAM172A	-0.43	-4.97	-0.3	1.24e-6	Diabetic retinopathy;
KIRP	trans	rs7939886	0.844	rs12421584	chr11:55937410	G/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.02	-0.46	4.34e-14	Personality dimensions;
KIRP	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg21132104	chr15:45694354	SPATA5L1	0.77	9.78	0.53	2.69e-19	Homoarginine levels;
KIRP	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg04727924	chr7:799746	HEATR2	-0.79	-8.91	-0.49	1.18e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.88	0.35	1.32e-8	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17105358	chr1:162531703	UAP1	0.45	6.15	0.37	3.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs6684428	0.764	rs61777585	chr1:56394683	G/A	cg11651538	chr1:56320950	NA	-0.85	-11.05	-0.58	2.65e-23	Airflow obstruction;
KIRP	cis	rs7582180	0.629	rs11895772	chr2:100938917	G/C	cg21926883	chr2:100939477	LONRF2	-0.62	-8.43	-0.47	3.02e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg02733842	chr7:1102375	C7orf50	0.43	5.06	0.31	8.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg17595323	chr11:93583763	C11orf90	-0.31	-5.12	-0.31	6.26e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2070433	1.000	rs11701310	chr21:47962836	G/C	cg05998816	chr21:47859926	PCNT	0.52	6.09	0.36	4.4e-9	Lymphocyte counts;
KIRP	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg18132916	chr6:79620363	NA	-0.4	-5.62	-0.34	5.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg08499158	chr17:42289980	UBTF	-0.63	-8.59	-0.48	1.02e-15	Total body bone mineral density;
KIRP	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-8.48	-0.48	2.14e-15	Common traits (Other);
KIRP	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.63	-8.58	-0.48	1.07e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.35	0.59	2.81e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg10523679	chr1:76189770	ACADM	-0.52	-7.42	-0.43	1.9e-12	Daytime sleep phenotypes;
KIRP	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.82	-11.28	-0.58	4.52e-24	Prudent dietary pattern;
KIRP	cis	rs4704187	0.687	rs10942729	chr5:74364300	C/T	cg03227963	chr5:74354835	NA	0.41	6.02	0.36	6.41e-9	Response to amphetamines;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	7.76	0.44	2.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2286379	1.000	rs10744552	chr12:1900735	C/G	cg05227549	chr12:1770782	NA	0.31	5.02	0.3	1e-6	Blood pressure (smoking interaction);
KIRP	cis	rs7601312	0.869	rs11884688	chr2:229283753	T/C	cg02542817	chr2:229291442	NA	-0.54	-8.28	-0.47	7.95e-15	Schizophrenia;
KIRP	cis	rs876084	0.505	rs6469899	chr8:121102762	C/T	cg06265175	chr8:121136014	COL14A1	0.51	6.39	0.38	8.38e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.78	-0.35	2.3e-8	Schizophrenia;
KIRP	cis	rs1420338	1.000	rs4723351	chr7:34155813	T/G	cg01275685	chr7:34179230	BMPER	-0.5	-7.37	-0.43	2.52e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.85	-0.57	1.16e-22	Breast cancer;
KIRP	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.87	0.35	1.43e-8	Menopause (age at onset);
KIRP	cis	rs10924970	1.000	rs7339903	chr1:235337733	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	4.91	0.3	1.68e-6	Asthma;
KIRP	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	7.45	0.43	1.54e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.33	-0.42	3.38e-12	Uric acid levels;
KIRP	trans	rs7084921	0.608	rs11596883	chr10:101861622	T/C	cg13808641	chr9:96006533	WNK2	-0.39	-6.05	-0.36	5.4e-9	Bone mineral density;
KIRP	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.09	-0.36	4.27e-9	Colorectal cancer;
KIRP	trans	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.32	0.47	5.91e-15	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg11784071	chr10:104629166	AS3MT	-0.39	-5.28	-0.32	2.91e-7	Arsenic metabolism;
KIRP	cis	rs7083	0.967	rs477269	chr11:117138291	G/T	cg11523350	chr11:117171073	BACE1	-0.28	-5.35	-0.32	2.02e-7	Blood protein levels;
KIRP	cis	rs6921919	0.583	rs7764737	chr6:28354615	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs918629	0.567	rs2348984	chr5:95236010	A/C	cg16656078	chr5:95278638	ELL2	-0.36	-5.56	-0.33	7.07e-8	IgG glycosylation;
KIRP	trans	rs2629046	0.817	rs1823823	chr2:225077669	C/T	cg06102602	chr12:96895446	NA	-0.44	-6.09	-0.36	4.41e-9	Height;
KIRP	trans	rs74233809	0.901	rs3824755	chr10:104595849	G/C	cg26199906	chr8:145106246	OPLAH	-0.42	-6.15	-0.37	3.1e-9	Birth weight;
KIRP	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.57	-7.98	-0.45	5.49e-14	Airway imaging phenotypes;
KIRP	cis	rs580438	0.510	rs7619194	chr3:13375431	A/C	cg10657019	chr3:13328039	NA	-0.58	-7.78	-0.44	1.96e-13	Myringotomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19729672	chr1:231004369	C1orf198	0.54	6.92	0.4	3.94e-11	Parkinson's disease;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02570171	chr17:39822195	NA	-0.47	-6.15	-0.37	3.12e-9	Warfarin maintenance dose;
KIRP	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15557168	chr22:42548783	NA	-0.42	-5.69	-0.34	3.66e-8	Cognitive function;
KIRP	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.5	7.4	0.43	2.1e-12	Testicular germ cell tumor;
KIRP	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.53	-8.14	-0.46	1.96e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg10818794	chr15:86012489	AKAP13	-0.49	-7.02	-0.41	2.13e-11	Coronary artery disease;
KIRP	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.47	-0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg12756093	chr1:115239321	AMPD1	0.47	5.61	0.34	5.32e-8	Autism;
KIRP	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23903597	chr17:61704154	MAP3K3	-0.63	-8.35	-0.47	4.88e-15	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg08847533	chr14:75593920	NEK9	0.46	5.58	0.34	6.26e-8	IgG glycosylation;
KIRP	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.49	0.38	4.66e-10	Prudent dietary pattern;
KIRP	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.32	5.28	0.32	2.84e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	1.07	18.94	0.77	6.11e-50	Schizophrenia;
KIRP	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.03e-9	Depression;
KIRP	cis	rs829661	0.947	rs829677	chr2:30709977	A/G	cg10949345	chr2:30726833	LCLAT1	0.69	9.71	0.53	4.45e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-5.0	-0.3	1.09e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.27e-12	Prudent dietary pattern;
KIRP	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-9.95	-0.54	7.8e-20	Colorectal cancer;
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11987759	chr7:65425863	GUSB	0.58	7.73	0.44	2.69e-13	Aortic root size;
KIRP	cis	rs4950322	0.570	rs72691102	chr1:146772888	A/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.38	-0.32	1.77e-7	Protein quantitative trait loci;
KIRP	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.55	-7.08	-0.41	1.46e-11	Total body bone mineral density;
KIRP	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg20673091	chr1:2541236	MMEL1	0.67	10.05	0.54	3.8e-20	Ulcerative colitis;
KIRP	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg10018233	chr7:150070692	REPIN1	0.69	8.32	0.47	6.02e-15	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-4.9	-0.3	1.72e-6	Triglycerides;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04022063	chr15:30114295	TJP1	0.43	6.05	0.36	5.3300000000000004e-09	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.26	-0.32	3.07e-7	Pulmonary function;
KIRP	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.36	6.35	0.38	1e-9	Migraine;
KIRP	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26526719	chr5:1949144	NA	-0.49	-5.59	-0.34	5.95e-8	Gut microbiome composition (winter);
KIRP	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	1.0	12.93	0.64	1.64e-29	Neutrophil percentage of white cells;
KIRP	cis	rs7737355	0.812	rs171523	chr5:130844946	A/G	cg06307176	chr5:131281290	NA	0.4	4.85	0.3	2.22e-6	Life satisfaction;
KIRP	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.99	17.08	0.74	1.15e-43	Menopause (age at onset);
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg08989290	chr16:615782	NHLRC4	0.4	5.86	0.35	1.45e-8	Height;
KIRP	cis	rs4700695	0.841	rs36301	chr5:65348940	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.03	0.36	6.01e-9	Facial morphology (factor 19);
KIRP	cis	rs9426935	0.570	rs1591902	chr1:154043693	C/T	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.28	-4.85	-0.3	2.16e-6	Lentiform nucleus volume;
KIRP	cis	rs6977660	0.619	rs12534026	chr7:19788687	T/C	cg07541023	chr7:19748670	TWISTNB	0.49	5.1	0.31	6.91e-7	Thyroid stimulating hormone;
KIRP	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.52	-7.98	-0.45	5.48e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs55788414	0.860	rs9929059	chr16:81182117	G/C	cg06400318	chr16:81190750	PKD1L2	-0.86	-8.24	-0.46	1.05e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.86	12.21	0.61	4.17e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.23	-0.32	3.54e-7	Blood metabolite levels;
KIRP	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg13611997	chr5:233750	SDHA	0.42	5.05	0.31	8.74e-7	Breast cancer;
KIRP	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg01872077	chr2:219646372	CYP27A1	0.38	5.01	0.3	1.03e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.47	6.3	0.37	1.38e-9	Hemoglobin concentration;
KIRP	cis	rs7640424	1.000	rs7640424	chr3:107820063	C/T	cg09227934	chr3:107805635	CD47	-0.43	-6.74	-0.39	1.15e-10	Body mass index;
KIRP	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg18016565	chr1:150552671	MCL1	0.38	5.88	0.35	1.3e-8	Tonsillectomy;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09255666	chr1:200378965	ZNF281	-0.54	-6.58	-0.39	2.81e-10	Brain structure;
KIRP	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg01763666	chr17:80159506	CCDC57	-0.35	-4.84	-0.3	2.27e-6	Life satisfaction;
KIRP	cis	rs7721647	0.853	rs1441391	chr5:90862309	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.41	5.04	0.31	8.88e-7	Breast cancer;
KIRP	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg17143192	chr8:8559678	CLDN23	0.73	8.41	0.47	3.31e-15	Obesity-related traits;
KIRP	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.96	0.41	3.1e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.5e-39	Headache;
KIRP	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-1.06	-12.15	-0.61	6.43e-27	Uric acid levels;
KIRP	cis	rs9398803	0.723	rs2793052	chr6:127064917	T/A	cg19875578	chr6:126661172	C6orf173	-0.37	-4.85	-0.3	2.15e-6	Male-pattern baldness;
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.61	-7.53	-0.43	9.8e-13	Breast cancer;
KIRP	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18867708	chr6:26865862	GUSBL1	-0.52	-6.37	-0.38	9.27e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.63	-7.5	-0.43	1.19e-12	Height;
KIRP	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14159747	chr11:113255604	NA	0.38	5.66	0.34	4.2e-8	Neuroticism;
KIRP	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg22356347	chr1:167427500	CD247	-0.47	-6.37	-0.38	9.23e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs9398803	0.965	rs6907898	chr6:126666416	C/T	cg19875578	chr6:126661172	C6orf173	0.49	6.49	0.38	4.73e-10	Male-pattern baldness;
KIRP	cis	rs4936894	0.500	rs4393330	chr11:124108956	A/T	cg27160556	chr11:124181099	OR8D1	-0.39	-5.85	-0.35	1.56e-8	Aging (time to death);
KIRP	cis	rs9815354	0.680	rs61646756	chr3:42029352	A/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4400599	0.572	rs7516809	chr1:154205501	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.99	-0.36	7.38e-9	Platelet distribution width;
KIRP	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.87	-9.63	-0.52	7.69e-19	Blood protein levels;
KIRP	cis	rs76533333	0.564	rs9604433	chr13:113420658	G/C	cg04656015	chr13:113407548	ATP11A	0.56	5.18	0.31	4.58e-7	Red cell distribution width;
KIRP	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg26695010	chr11:65641043	EFEMP2	0.43	5.17	0.31	4.96e-7	Eosinophil percentage of white cells;
KIRP	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.6	8.11	0.46	2.45e-14	Response to temozolomide;
KIRP	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	6.17	0.37	2.85e-9	Ulcerative colitis;
KIRP	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.5	-5.96	-0.36	8.63e-9	Lung cancer;
KIRP	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg16898833	chr6:26189333	HIST1H4D	0.74	5.31	0.32	2.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg01153342	chr14:74254319	C14orf43	0.45	6.26	0.37	1.74e-9	Ischemic stroke;
KIRP	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg21427119	chr20:30132790	HM13	-0.42	-4.98	-0.3	1.18e-6	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg18357526	chr6:26021779	HIST1H4A	0.39	5.11	0.31	6.38e-7	Height;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7614311	0.681	rs12631045	chr3:63856085	T/C	cg22134162	chr3:63841271	THOC7	-0.37	-5.22	-0.32	3.87e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.85	12.66	0.63	1.25e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.6	7.89	0.45	1.01e-13	Retinal vascular caliber;
KIRP	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg07741184	chr6:167504864	NA	-0.23	-6.27	-0.37	1.57e-9	Crohn's disease;
KIRP	cis	rs2377585	0.653	rs73053860	chr12:8844774	C/T	cg03761649	chr12:8850719	RIMKLB	0.52	5.14	0.31	5.63e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs17030434	0.654	rs28640133	chr4:154645926	T/A	cg14289246	chr4:154710475	SFRP2	-0.65	-7.68	-0.44	3.84e-13	Electrocardiographic conduction measures;
KIRP	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	6.88	0.4	4.89e-11	Iron status biomarkers;
KIRP	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg07843065	chr1:150265600	MRPS21	0.47	6.52	0.38	3.95e-10	Morning vs. evening chronotype;
KIRP	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.91	-0.35	1.12e-8	LDL cholesterol levels;
KIRP	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.85	8.21	0.46	1.29e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.45	5.23	0.32	3.7e-7	Schizophrenia;
KIRP	trans	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.24	-0.37	1.92e-9	Triglycerides;
KIRP	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.39	6.21	0.37	2.25e-9	QRS complex (12-leadsum);
KIRP	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg14593290	chr7:50529359	DDC	-0.77	-9.63	-0.52	7.83e-19	Malaria;
KIRP	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg22777020	chr22:31556080	RNF185	-0.5	-5.25	-0.32	3.27e-7	Colorectal cancer;
KIRP	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.74	6.02	0.36	6.17e-9	Diabetic retinopathy;
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg10729496	chr3:10149963	C3orf24	0.54	4.89	0.3	1.85e-6	Alzheimer's disease;
KIRP	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16318349	chr1:154917307	PBXIP1	-0.33	-5.19	-0.31	4.5e-7	Prostate cancer;
KIRP	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-9.38	-0.51	4.61e-18	Morning vs. evening chronotype;
KIRP	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.67	7.62	0.44	5.62e-13	Body mass index;
KIRP	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs11673344	0.502	rs17304703	chr19:38073547	G/A	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.52	-0.33	8.41e-8	Obesity-related traits;
KIRP	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.51	-0.65	1.76e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12292205	chr6:26970375	C6orf41	-0.69	-8.21	-0.46	1.22e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2904967	1.000	rs487989	chr11:65064690	G/A	cg09225861	chr11:65069680	NA	0.43	5.18	0.31	4.6e-7	Mean corpuscular volume;
KIRP	cis	rs2071403	0.933	rs10183226	chr2:1404756	T/G	cg06500727	chr2:1417164	TPO	0.49	7.79	0.44	1.86e-13	Thyroid peroxidase antibody positivity;
KIRP	cis	rs4400599	0.606	rs7542975	chr1:154204813	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.98	-0.36	7.67e-9	Platelet distribution width;
KIRP	cis	rs28489187	0.683	rs233093	chr1:85823120	C/T	cg16011679	chr1:85725395	C1orf52	0.52	6.41	0.38	7.19e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.79	-0.35	2.18e-8	Schizophrenia;
KIRP	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg23649088	chr2:200775458	C2orf69	0.68	5.91	0.35	1.15e-8	Schizophrenia;
KIRP	cis	rs17065868	1.000	rs9525985	chr13:45167390	C/G	cg10246903	chr13:45222710	NA	0.64	6.77	0.4	9.39e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9473924	0.505	rs9463664	chr6:50902570	T/A	cg14470998	chr6:50812995	TFAP2B	0.85	7.85	0.45	1.25e-13	Body mass index;
KIRP	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.57	-0.43	7.61e-13	Type 2 diabetes;
KIRP	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg19847130	chr8:10466454	RP1L1	0.36	5.51	0.33	9.05e-8	Retinal vascular caliber;
KIRP	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg09323728	chr8:95962352	TP53INP1	-0.24	-5.02	-0.3	9.88e-7	Type 2 diabetes;
KIRP	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	10.31	0.55	5.99e-21	Cognitive test performance;
KIRP	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.78	-0.49	2.87e-16	Total cholesterol levels;
KIRP	cis	rs151997	1.000	rs27284	chr5:50198086	A/G	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.7	7.41	0.43	2.03e-12	Bipolar disorder;
KIRP	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.69	-8.89	-0.49	1.31e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.47	10.7	0.56	3.58e-22	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg19468946	chr17:37922297	IKZF3	-0.46	-6.39	-0.38	8.04e-10	Self-reported allergy;
KIRP	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.77	-0.44	2.08e-13	Myopia (pathological);
KIRP	cis	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg08885076	chr2:99613938	TSGA10	-0.61	-10.98	-0.57	4.51e-23	Chronic sinus infection;
KIRP	cis	rs9581857	0.685	rs12584061	chr13:28024544	C/T	cg22138327	chr13:27999177	GTF3A	0.78	6.29	0.37	1.45e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg14092571	chr14:90743983	NA	0.43	5.37	0.32	1.79e-7	Mortality in heart failure;
KIRP	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg00343986	chr7:65444356	GUSB	-0.41	-4.9	-0.3	1.71e-6	Aortic root size;
KIRP	cis	rs42648	0.564	rs259134	chr7:89795852	G/A	cg25739043	chr7:89950458	NA	-0.36	-5.73	-0.34	2.91e-8	Homocysteine levels;
KIRP	trans	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.15e-10	Diabetic kidney disease;
KIRP	cis	rs3007168	1.000	rs3007168	chr14:51608293	G/A	cg23942311	chr14:51606299	NA	0.52	5.54	0.33	7.92e-8	Cancer;
KIRP	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg11584989	chr19:19387371	SF4	0.4	5.15	0.31	5.3e-7	Tonsillectomy;
KIRP	cis	rs7712401	0.601	rs390234	chr5:122331523	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.35	0.42	3e-12	Aortic root size;
KIRP	cis	rs2916247	1.000	rs11990286	chr8:93061406	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.81	0.45	1.7e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	0.93	11.14	0.58	1.32e-23	Corneal structure;
KIRP	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg05973401	chr12:123451056	ABCB9	0.48	5.15	0.31	5.33e-7	Allergy;
KIRP	cis	rs4356932	1.000	rs6820370	chr4:76952278	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11987759	chr7:65425863	GUSB	0.69	9.62	0.52	8.21e-19	Aortic root size;
KIRP	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-7.58	-0.43	7.17e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg14673194	chr17:80132900	CCDC57	0.77	8.69	0.48	5.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg27121462	chr16:89883253	FANCA	0.52	7.04	0.41	1.86e-11	Vitiligo;
KIRP	cis	rs6593803	0.553	rs11582163	chr1:147167854	G/T	cg27546670	chr1:147246839	GJA5	-0.56	-5.56	-0.33	6.91e-8	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	0.93	10.43	0.55	2.58e-21	Iron status biomarkers;
KIRP	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	trans	rs1864585	0.616	rs117478948	chr8:10664824	A/C	cg26278703	chr11:58910052	FAM111A	0.65	6.44	0.38	6.16e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.54	7.51	0.43	1.12e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg16558253	chr16:72132732	DHX38	-0.37	-5.1	-0.31	6.95e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs597583	0.806	rs11603366	chr11:117396505	G/T	cg27161313	chr11:117392002	DSCAML1	-0.53	-5.86	-0.35	1.46e-8	Putamen volume;
KIRP	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.64	-0.39	2.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg07936489	chr17:37558343	FBXL20	-0.46	-5.71	-0.34	3.29e-8	Asthma;
KIRP	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.33	0.32	2.22e-7	Personality dimensions;
KIRP	cis	rs6450176	1.000	rs4334836	chr5:53300835	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.51	5.57	0.33	6.8e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.97	0.54	6.75e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.47	6.42	0.38	7.11e-10	Testicular germ cell tumor;
KIRP	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	0.9	14.08	0.67	2e-33	Breast cancer;
KIRP	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	7.0	0.41	2.41e-11	Platelet count;
KIRP	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	7.45	0.43	1.54e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12210905	0.841	rs28410967	chr6:27265235	T/C	cg11502198	chr6:26597334	ABT1	-0.8	-4.94	-0.3	1.43e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.73	-0.56	2.72e-22	Height;
KIRP	cis	rs9603616	1.000	rs8002731	chr13:40362229	A/C	cg26701198	chr13:40229707	COG6	-0.48	-5.19	-0.31	4.44e-7	Rheumatoid arthritis;
KIRP	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg24807547	chr6:37504484	NA	-0.53	-7.84	-0.45	1.34e-13	Cognitive performance;
KIRP	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.65	8.27	0.47	8.2e-15	Iron status biomarkers;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg00738919	chr7:1100172	C7orf50	0.44	5.14	0.31	5.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2562456	0.833	rs2928211	chr19:21541297	A/G	cg00806126	chr19:22604979	ZNF98	0.66	6.81	0.4	7.55e-11	Pain;
KIRP	trans	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.48	-0.43	1.34e-12	Atopic dermatitis;
KIRP	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-9.22	-0.51	1.42e-17	Colorectal cancer;
KIRP	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.35	0.51	5.5e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg15976283	chr2:238042351	NA	0.39	5.59	0.34	6.05e-8	Systemic lupus erythematosus;
KIRP	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg24304309	chr1:154577895	ADAR	0.37	5.95	0.35	9.18e-9	Blood protein levels;
KIRP	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.37	-10.44	-0.55	2.37e-21	Diabetic kidney disease;
KIRP	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-7.67	-0.44	3.96e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.69	10.4	0.55	3.06e-21	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10208940	0.920	rs12713643	chr2:68724129	C/G	cg12452813	chr2:68675892	NA	0.47	5.07	0.31	7.97e-7	Urate levels in lean individuals;
KIRP	cis	rs986417	1.000	rs1474999	chr14:60905920	T/C	cg27398547	chr14:60952738	C14orf39	-0.74	-7.43	-0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs1903068	0.853	rs28838369	chr4:56007249	A/G	cg20092376	chr4:56023423	NA	0.42	5.05	0.31	8.61e-7	Endometriosis;
KIRP	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.75	-0.34	2.68e-8	Coronary artery disease;
KIRP	cis	rs6733011	0.628	rs981602	chr2:99464275	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.24	-0.32	3.37e-7	Bipolar disorder;
KIRP	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg24375607	chr4:120327624	NA	0.54	5.94	0.35	9.58e-9	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.76	10.12	0.54	2.34e-20	Morning vs. evening chronotype;
KIRP	cis	rs7929679	0.551	rs906902	chr11:34780278	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.44	-5.35	-0.32	1.99e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.76	11.0	0.57	3.62e-23	Prudent dietary pattern;
KIRP	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg15880211	chr22:50250494	ZBED4	0.46	5.54	0.33	7.83e-8	Schizophrenia;
KIRP	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.64	8.34	0.47	5.33e-15	Mood instability;
KIRP	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg06217071	chr17:408420	NA	0.66	10.73	0.56	2.71e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg20368463	chr18:77673604	PQLC1	-0.5	-5.09	-0.31	7.04e-7	Opioid sensitivity;
KIRP	cis	rs8113308	0.752	rs73068868	chr19:52491001	A/G	cg25782003	chr19:52490127	ZNF350	0.99	9.43	0.52	3.23e-18	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9914988	0.887	rs7213285	chr17:27206029	G/A	cg20469991	chr17:27169893	C17orf63	-0.74	-5.98	-0.36	7.74e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4262150	0.883	rs72804778	chr5:152309607	G/A	cg12297329	chr5:152029980	NA	-0.64	-8.3	-0.47	6.76e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.51	6.41	0.38	7.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg06154084	chr10:102792249	PDZD7;SFXN3	0.49	5.87	0.35	1.42e-8	Educational attainment;
KIRP	cis	rs11997175	1.000	rs7838577	chr8:33760802	A/G	ch.8.33884649F	chr8:33765107	NA	0.53	6.69	0.39	1.49e-10	Body mass index;
KIRP	cis	rs7224685	0.569	rs12950730	chr17:3994225	G/T	cg09597638	chr17:3907349	NA	0.47	4.89	0.3	1.86e-6	Type 2 diabetes;
KIRP	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs8077577	0.747	rs62072541	chr17:18226699	G/A	cg18869244	chr17:18121946	NA	0.44	4.99	0.3	1.15e-6	Obesity-related traits;
KIRP	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg23565292	chr14:50234668	KLHDC2	-0.49	-5.76	-0.34	2.5e-8	Carotid intima media thickness;
KIRP	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg22431228	chr1:16359049	CLCNKA	-0.53	-6.27	-0.37	1.59e-9	Dilated cardiomyopathy;
KIRP	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg27087555	chr16:88793112	FAM38A	-1.4	-14.24	-0.67	5.95e-34	Plateletcrit;
KIRP	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.5	-6.02	-0.36	6.41e-9	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-0.93	-8.32	-0.47	6.1e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg01988459	chr11:68622903	NA	-0.43	-5.97	-0.36	8.05e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-30.55	-0.89	1.07e-85	Myeloid white cell count;
KIRP	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.47	5.77	0.35	2.35e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs6952809	1.000	rs6952809	chr7:2448493	T/C	cg25507518	chr7:2405875	EIF3B	0.36	4.96	0.3	1.34e-6	Multiple sclerosis;
KIRP	cis	rs1505368	0.505	rs12694279	chr2:213253406	C/A	cg16329650	chr2:213403929	ERBB4	0.4	5.52	0.33	8.57e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg25173405	chr17:45401733	C17orf57	-0.56	-7.98	-0.45	5.6e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-13.96	-0.66	5.09e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg05861140	chr6:150128134	PCMT1	-0.52	-7.29	-0.42	4.17e-12	Lung cancer;
KIRP	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg05552183	chr6:42928497	GNMT	-0.43	-5.53	-0.33	7.97e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
KIRP	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg20813462	chr7:2646259	IQCE	0.65	6.21	0.37	2.26e-9	Urate levels in lean individuals;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01869067	chr22:46374411	WNT7B	0.52	6.72	0.39	1.24e-10	Smoking initiation;
KIRP	cis	rs2071426	0.959	rs11188155	chr10:96811556	T/G	cg09036531	chr10:96991505	NA	-0.65	-7.25	-0.42	5.48e-12	Blood metabolite levels;
KIRP	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg01843034	chr6:37503916	NA	-0.9	-12.69	-0.63	1.04e-28	Cognitive performance;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg05941025	chr16:89927596	SPIRE2	0.35	5.48	0.33	1.05e-7	Vitiligo;
KIRP	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg00629928	chr5:358741	AHRR	0.53	5.13	0.31	5.95e-7	Breast cancer;
KIRP	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.63	0.6	3.34e-25	Alzheimer's disease;
KIRP	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.6	-7.38	-0.43	2.37e-12	Non-response to antidepressants and depression;
KIRP	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs4804368	0.591	rs1035941	chr19:7199939	A/G	cg09377704	chr19:7936683	NA	0.44	4.91	0.3	1.67e-6	Renal cell carcinoma;
KIRP	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg23903597	chr17:61704154	MAP3K3	0.44	5.47	0.33	1.11e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9513627	1.000	rs73556170	chr13:100121612	T/A	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.43	4.95	0.3	1.36e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs735539	0.521	rs9315905	chr13:21404969	A/G	cg04906043	chr13:21280425	IL17D	0.45	5.51	0.33	8.97e-8	Dental caries;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22333733	chr11:31391482	DNAJC24;DCDC1	-0.44	-6.34	-0.37	1.09e-9	Survival in pancreatic cancer;
KIRP	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.77	9.8	0.53	2.31e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.52	-0.33	8.44e-8	Life satisfaction;
KIRP	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg05527609	chr1:210001259	C1orf107	0.52	5.94	0.35	9.75e-9	Red blood cell count;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg02475834	chr10:13628849	PRPF18	0.49	6.3	0.37	1.36e-9	Inflammatory biomarkers;
KIRP	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.89	12.18	0.61	5e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs4750440	0.702	rs4750445	chr10:14030314	C/T	cg27542038	chr10:14027202	FRMD4A	-0.47	-6.44	-0.38	6.38e-10	Adiponectin levels;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg21285383	chr16:89894308	SPIRE2	0.3	5.55	0.33	7.29e-8	Vitiligo;
KIRP	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs10140922	0.966	rs10083375	chr14:35823531	C/T	cg07166546	chr14:35805898	NA	-0.26	-6.4	-0.38	7.89e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Parkinson's disease;
KIRP	cis	rs965513	1.000	rs10818090	chr9:100561486	C/T	cg13688889	chr9:100608707	NA	-0.6	-7.45	-0.43	1.6e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17497419	chr2:24346215	PFN4;LOC375190	0.5	6.07	0.36	4.7e-9	Parkinson's disease;
KIRP	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.58	-6.06	-0.36	5.02e-9	Ulcerative colitis;
KIRP	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11987759	chr7:65425863	GUSB	-0.54	-7.14	-0.41	1.04e-11	Aortic root size;
KIRP	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg20295408	chr7:1910781	MAD1L1	0.52	5.96	0.36	8.53e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.9	10.47	0.56	1.88e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg09408571	chr1:101003634	GPR88	0.24	5.44	0.33	1.32e-7	Monocyte count;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-10.59	-0.56	7.76e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs7635838	0.859	rs6786166	chr3:11511424	T/C	cg00170343	chr3:11313890	ATG7	0.44	5.67	0.34	4.01e-8	HDL cholesterol;
KIRP	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.34	-4.93	-0.3	1.49e-6	Monocyte count;
KIRP	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg08975724	chr8:8085496	FLJ10661	0.55	6.27	0.37	1.58e-9	Neuroticism;
KIRP	cis	rs6929812	0.577	rs2294309	chr6:27483816	G/T	cg03332623	chr6:27441972	ZNF184	-0.33	-4.91	-0.3	1.66e-6	Neuroticism (multi-trait analysis);
KIRP	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs16958440	0.581	rs11873880	chr18:44692465	T/C	cg17192377	chr18:44677553	HDHD2	0.65	6.32	0.37	1.22e-9	Sitting height ratio;
KIRP	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-7.34	-0.42	3.12e-12	Electroencephalogram traits;
KIRP	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06481639	chr22:41940642	POLR3H	0.45	5.31	0.32	2.42e-7	Vitiligo;
KIRP	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.49	6.49	0.38	4.57e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg17441377	chr17:3906640	NA	-0.5	-7.27	-0.42	4.84e-12	Type 2 diabetes;
KIRP	cis	rs2980439	0.729	rs2955585	chr8:8093511	A/G	cg08975724	chr8:8085496	FLJ10661	0.8	10.98	0.57	4.32e-23	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05421799	chr2:172778343	HAT1	-0.42	-6.21	-0.37	2.26e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg04306507	chr14:55594613	LGALS3	0.52	8.11	0.46	2.39e-14	Protein biomarker;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13050318	chr14:58896613	KIAA0586	-0.44	-6.55	-0.39	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12292205	chr6:26970375	C6orf41	-0.61	-6.68	-0.39	1.57e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.79	-11.81	-0.6	8.31e-26	Hip circumference;
KIRP	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg08501292	chr6:25962987	TRIM38	-0.96	-5.81	-0.35	1.97e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.66	-8.52	-0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.47	0.52	2.5e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.76	8.69	0.48	5.19e-16	Coronary artery disease;
KIRP	cis	rs7633770	0.841	rs6774048	chr3:46702202	C/G	cg11219411	chr3:46661640	NA	0.61	8.35	0.47	4.91e-15	Coronary artery disease;
KIRP	cis	rs228437	0.770	rs376192	chr6:134904524	A/G	cg24504307	chr6:134963096	NA	0.39	6.12	0.36	3.72e-9	Melanoma;
KIRP	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.19	0.51	1.73e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.63	-5.85	-0.35	1.56e-8	Tuberculosis;
KIRP	cis	rs7116495	1.000	rs17161991	chr11:71839960	T/C	cg26138937	chr11:71823887	C11orf51	0.69	5.49	0.33	9.81e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg17747265	chr1:1875780	NA	-0.71	-13.29	-0.65	9.75e-31	Body mass index;
KIRP	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.44	-6.16	-0.37	2.98e-9	Coronary artery disease;
KIRP	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.67	8.07	0.46	3.14e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg24807547	chr6:37504484	NA	-0.54	-8.0	-0.45	4.85e-14	Cognitive performance;
KIRP	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg16497661	chr14:103986332	CKB	-0.55	-7.48	-0.43	1.28e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	1.0	9.22	0.51	1.34e-17	Systolic blood pressure;
KIRP	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.7	-8.12	-0.46	2.23e-14	Pancreatic cancer;
KIRP	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.39	6.7	0.39	1.44e-10	Heart rate;
KIRP	trans	rs921874	0.553	rs1968742	chr11:86781426	C/T	cg20852851	chr2:240168848	HDAC4	0.46	6.12	0.36	3.63e-9	Total body bone mineral density;
KIRP	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg10645314	chr2:3704589	ALLC	-0.52	-6.42	-0.38	6.9e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	0.92	7.98	0.45	5.55e-14	Arsenic metabolism;
KIRP	trans	rs6601327	0.665	rs4841218	chr8:9653902	T/C	cg16141378	chr3:129829833	LOC729375	0.46	6.1	0.36	4.13e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg03735888	chr19:58951602	ZNF132	-0.46	-5.48	-0.33	1.06e-7	Uric acid clearance;
KIRP	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg26784012	chr10:32216390	ARHGAP12	0.31	4.92	0.3	1.59e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	9.57	0.52	1.18e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.49	5.71	0.34	3.2e-8	Lung cancer;
KIRP	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg13206674	chr6:150067644	NUP43	0.56	8.08	0.46	2.91e-14	Lung cancer;
KIRP	cis	rs7737355	0.898	rs6864413	chr5:130637868	G/T	cg06647332	chr5:131281008	NA	0.45	5.0	0.3	1.08e-6	Life satisfaction;
KIRP	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04561822	chr19:3094117	GNA11	0.54	6.86	0.4	5.53e-11	Parkinson's disease;
KIRP	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs742071	0.585	rs58432030	chr1:18927823	C/T	cg22389438	chr1:18926496	NA	-0.37	-5.24	-0.32	3.42e-7	Nonsyndromic cleft lip with cleft palate;Orofacial clefts;
KIRP	cis	rs6772849	0.768	rs4521246	chr3:128421166	A/G	cg08795948	chr3:128337044	NA	-0.46	-5.16	-0.31	5.16e-7	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg10223061	chr2:219282414	VIL1	-0.33	-5.4	-0.33	1.54e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg02073558	chr3:44770973	ZNF501	0.6	8.48	0.48	2.07e-15	Depressive symptoms;
KIRP	cis	rs16857609	0.529	rs2373058	chr2:218250549	G/C	cg15335768	chr2:218268053	DIRC3	-0.54	-6.85	-0.4	5.9e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs13424612	0.839	rs4854065	chr2:240910158	A/G	cg19172429	chr2:240878313	NA	0.29	4.94	0.3	1.48e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs12681366	0.620	rs2930968	chr8:95462695	C/T	cg13257157	chr8:95487014	RAD54B	0.41	5.08	0.31	7.57e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1978968	0.956	rs4992882	chr22:18445021	T/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.94	-12.7	-0.63	9.48e-29	Cognitive function;
KIRP	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.54	7.2	0.42	7.43e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg00677901	chr16:88017247	BANP	0.41	4.86	0.3	2.05e-6	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15013526	chr3:170588137	RPL22L1	0.49	6.41	0.38	7.48e-10	Parkinson's disease;
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg27532560	chr4:187881888	NA	-0.72	-11.69	-0.6	2.07e-25	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg26043149	chr18:55253948	FECH	0.5	6.13	0.36	3.47e-9	Bone mineral density;
KIRP	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.9	0.3	1.78e-6	Renal cell carcinoma;
KIRP	cis	rs8114671	0.967	rs12481169	chr20:33794510	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.18	-0.31	4.57e-7	Height;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.52	0.48	1.62e-15	Resting heart rate;
KIRP	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg00204512	chr16:28754710	NA	0.49	6.52	0.38	3.94e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg19338460	chr6:170058176	WDR27	-1.22	-9.6	-0.52	9.75e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.81	-0.45	1.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00645628	chr1:101213654	NA	0.38	6.69	0.39	1.49e-10	C-reactive protein;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.51	-6.59	-0.39	2.6200000000000003e-10	Testicular germ cell tumor;
KIRP	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg19847130	chr8:10466454	RP1L1	0.35	5.08	0.31	7.38e-7	Retinal vascular caliber;
KIRP	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg14972814	chr11:95582409	MTMR2	0.29	5.04	0.31	9.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs1345705	chr5:74507007	C/A	cg03227963	chr5:74354835	NA	0.4	5.82	0.35	1.83e-8	Response to amphetamines;
KIRP	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.68	8.91	0.49	1.14e-16	Bladder cancer;
KIRP	cis	rs11779988	0.629	rs11780813	chr8:17856014	T/C	cg01800426	chr8:17659068	MTUS1	-0.63	-7.29	-0.42	4.25e-12	Breast cancer;
KIRP	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg27490568	chr2:178487706	NA	0.71	8.49	0.48	2.03e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.98	-0.3	1.2e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.79	11.59	0.59	4.64e-25	Heart rate;
KIRP	cis	rs9972944	0.756	rs6504350	chr17:63764336	G/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.82	-0.45	1.56e-13	Total body bone mineral density;
KIRP	cis	rs4938534	0.533	rs1806397	chr11:111264915	T/C	cg11362935	chr11:111250201	POU2AF1	0.38	6.08	0.36	4.65e-9	Primary biliary cholangitis;
KIRP	cis	rs11593576	0.550	rs1749845	chr10:80991900	C/T	cg18737081	chr10:80999807	ZMIZ1	-0.31	-5.58	-0.34	6.28e-8	Vitiligo;
KIRP	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.55	-7.67	-0.44	3.99e-13	Type 2 diabetes;
KIRP	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg14458575	chr2:238380390	NA	0.57	7.52	0.43	1.02e-12	Prostate cancer;
KIRP	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.6	-0.39	2.46e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.58	-0.34	6.29e-8	Life satisfaction;
KIRP	cis	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg21625330	chr8:9911636	MSRA	0.38	4.94	0.3	1.43e-6	Neuroticism;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg22336107	chr19:14606894	GIPC1	-0.55	-6.1	-0.36	4.14e-9	Menopause (age at onset);
KIRP	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.6	8.13	0.46	2.14e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg22800045	chr5:56110881	MAP3K1	0.81	8.73	0.49	4.07e-16	Initial pursuit acceleration;
KIRP	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.7	9.95	0.54	8.04e-20	Lymphocyte counts;
KIRP	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.53	-0.43	9.91e-13	Response to antipsychotic treatment;
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.53	6.32	0.37	1.24e-9	Menopause (age at onset);
KIRP	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg00977110	chr5:151150581	G3BP1	0.6	6.02	0.36	6.19e-9	Preschool internalizing problems;
KIRP	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg11344533	chr11:111475393	SIK2	0.29	5.11	0.31	6.32e-7	Primary sclerosing cholangitis;
KIRP	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg17595323	chr11:93583763	C11orf90	-0.35	-5.86	-0.35	1.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11987759	chr7:65425863	GUSB	0.68	9.57	0.52	1.21e-18	Aortic root size;
KIRP	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.47	-5.73	-0.34	2.87e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.89	14.53	0.68	5.72e-35	Prostate cancer;
KIRP	cis	rs7011049	0.778	rs118059348	chr8:53865777	C/T	cg26025543	chr8:53854495	NA	0.67	6.99	0.41	2.62e-11	Systolic blood pressure;
KIRP	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27297192	chr10:134578999	INPP5A	0.47	6.03	0.36	6.03e-9	Migraine;
KIRP	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01973587	chr1:228161476	NA	-0.4	-5.08	-0.31	7.64e-7	Diastolic blood pressure;
KIRP	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14169450	chr9:139327907	INPP5E	-0.44	-6.28	-0.37	1.49e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg20169779	chr10:135381914	SYCE1	-0.42	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs716316	0.532	rs410996	chr20:14905951	A/T	cg04470754	chr20:14904432	MACROD2	0.44	4.85	0.3	2.22e-6	Advanced glycation end-product levels;
KIRP	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg05347473	chr6:146136440	FBXO30	0.48	7.11	0.41	1.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.67	-7.12	-0.41	1.15e-11	Lymphocyte counts;
KIRP	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg17554472	chr22:41940697	POLR3H	-0.56	-6.46	-0.38	5.57e-10	Vitiligo;
KIRP	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.19	21.88	0.81	1.2e-59	Cognitive function;
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02475777	chr4:1388615	CRIPAK	0.7	8.83	0.49	2.06e-16	Longevity;
KIRP	trans	rs1973993	0.689	rs67544133	chr1:96971241	G/A	cg10631902	chr5:14652156	NA	-0.59	-8.52	-0.48	1.6e-15	Weight;
KIRP	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.95	15.04	0.69	1.09e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.46	7.72	0.44	2.88e-13	Testicular germ cell tumor;
KIRP	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg08000102	chr2:233561755	GIGYF2	-0.51	-6.41	-0.38	7.55e-10	Coronary artery disease;
KIRP	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg06027949	chr8:82754900	SNX16	-0.63	-6.95	-0.41	3.19e-11	Diastolic blood pressure;
KIRP	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg02807482	chr3:125708958	NA	-0.55	-5.06	-0.31	8.08e-7	Blood pressure (smoking interaction);
KIRP	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.61	-0.39	2.39e-10	Mean platelet volume;
KIRP	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.38	0.38	8.54e-10	Colorectal cancer;
KIRP	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.96	16.32	0.72	4.63e-41	Metabolic syndrome;
KIRP	cis	rs9810890	1.000	rs73198815	chr3:128473832	C/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.73	-9.8	-0.53	2.38e-19	Childhood ear infection;
KIRP	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.62	-0.52	8.27e-19	Coronary artery disease;
KIRP	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.4	-0.33	1.57e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg15358701	chr1:161410459	NA	-0.75	-6.83	-0.4	6.6e-11	Rheumatoid arthritis;
KIRP	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.54e-10	Fibrinogen levels;
KIRP	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg26893134	chr6:116381904	FRK	0.21	5.86	0.35	1.46e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.23	0.32	3.67e-7	Educational attainment;
KIRP	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.88	9.71	0.53	4.31e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg05315796	chr3:52349193	DNAH1	0.5	7.8	0.45	1.79e-13	Electroencephalogram traits;
KIRP	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.87	12.14	0.61	6.88e-27	Breast cancer;
KIRP	cis	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg06521331	chr12:34319734	NA	-0.5	-6.05	-0.36	5.43e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.46	-0.38	5.5e-10	Aortic root size;
KIRP	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg10818794	chr15:86012489	AKAP13	-0.49	-6.88	-0.4	4.82e-11	Interstitial lung disease;
KIRP	cis	rs7106204	0.590	rs28864378	chr11:24206582	C/A	ch.11.24196551F	chr11:24239977	NA	0.77	8.19	0.46	1.38e-14	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4356932	1.000	rs10000130	chr4:76939335	T/C	cg19388996	chr4:76862389	NAAA	0.39	4.91	0.3	1.63e-6	Blood protein levels;
KIRP	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07570687	chr10:102243282	WNT8B	-0.53	-7.19	-0.42	7.84e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.66	-7.44	-0.43	1.7e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7215564	0.818	rs112155856	chr17:78594573	A/T	cg06153925	chr17:78755379	RPTOR	0.42	5.59	0.34	6.11e-8	Myopia (pathological);
KIRP	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22455342	chr2:225449267	CUL3	0.57	6.28	0.37	1.48e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	cis	rs7011507	1.000	rs78756833	chr8:49141989	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg26876637	chr1:152193138	HRNR	0.77	10.13	0.54	2.27e-20	Atopic dermatitis;
KIRP	cis	rs71403859	0.730	rs17356206	chr16:71736359	G/C	cg08717414	chr16:71523259	ZNF19	-1.06	-8.59	-0.48	9.93e-16	Post bronchodilator FEV1;
KIRP	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.41	5.59	0.34	6.11e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.87	-9.95	-0.54	7.92e-20	Gut microbiome composition (summer);
KIRP	cis	rs78545713	0.541	rs111465843	chr6:26222823	G/A	cg23601095	chr6:26197514	HIST1H3D	0.88	5.22	0.32	3.83e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.74	10.76	0.57	2.29e-22	Dupuytren's disease;
KIRP	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26002218	chr14:103986227	CKB	0.26	5.02	0.31	9.69e-7	Body mass index;
KIRP	cis	rs654950	0.967	rs621727	chr1:41984612	C/T	cg06885757	chr1:42089581	HIVEP3	-0.5	-7.29	-0.42	4.16e-12	Airway imaging phenotypes;
KIRP	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.08e-6	Red blood cell count;Reticulocyte count;
KIRP	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.11	0.46	2.43e-14	Morning vs. evening chronotype;
KIRP	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg11621586	chr10:70884670	VPS26A	0.93	9.54	0.52	1.46e-18	Left atrial antero-posterior diameter;
KIRP	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.86	12.08	0.61	1.06e-26	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg18306943	chr3:40428807	ENTPD3	0.47	6.28	0.37	1.54e-9	Renal cell carcinoma;
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.48	6.39	0.38	8.29e-10	Breast cancer;
KIRP	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26002218	chr14:103986227	CKB	0.26	4.96	0.3	1.33e-6	Body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg01583365	chr2:172778734	HAT1	0.92	6.11	0.36	3.98e-9	P wave terminal force;
KIRP	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg23594656	chr7:65796392	TPST1	-0.44	-6.16	-0.37	2.93e-9	Aortic root size;
KIRP	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.05	0.75	6.05e-47	Chronic sinus infection;
KIRP	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.37	-0.32	1.8e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.62	0.34	5.12e-8	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.22e-15	Motion sickness;
KIRP	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	4.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18252515	chr7:66147081	NA	0.45	5.29	0.32	2.64e-7	Aortic root size;
KIRP	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg01428437	chr1:1852164	TMEM52	0.28	4.84	0.3	2.26e-6	Body mass index;
KIRP	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00791764	chr4:53727839	RASL11B	0.34	4.99	0.3	1.12e-6	Optic nerve measurement (cup area);
KIRP	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg00806126	chr19:22604979	ZNF98	0.63	6.7	0.39	1.43e-10	Pain;
KIRP	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	11.77	0.6	1.13e-25	Platelet count;
KIRP	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg18306943	chr3:40428807	ENTPD3	0.48	6.54	0.38	3.54e-10	Renal cell carcinoma;
KIRP	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.43	-0.76	2.97e-48	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15136568	chr1:154938439	SHC1	0.51	6.07	0.36	4.8e-9	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17981554	chr6:149969568	NA	0.5	6.3	0.37	1.37e-9	Parkinson's disease;
KIRP	cis	rs1864585	0.520	rs73208781	chr8:10677498	A/C	cg21775007	chr8:11205619	TDH	-0.49	-4.89	-0.3	1.79e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.71	10.9	0.57	7.97e-23	Coronary artery disease;
KIRP	cis	rs7078219	0.714	rs12414770	chr10:101288238	G/T	cg07044859	chr10:101282883	NA	-0.34	-5.03	-0.31	9.63e-7	Dental caries;
KIRP	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.93e-8	Coronary artery disease;
KIRP	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.53	-5.81	-0.35	1.95e-8	Corneal structure;
KIRP	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg22968622	chr17:43663579	NA	-0.66	-8.75	-0.49	3.41e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6973256	0.897	rs763644	chr7:133343349	G/C	cg10665199	chr7:133106180	EXOC4	-0.51	-6.46	-0.38	5.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg18234130	chr8:27182889	PTK2B	0.56	7.23	0.42	5.96e-12	Neuroticism;
KIRP	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.36	5.63	0.34	5.03e-8	Colorectal cancer;
KIRP	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.09	-0.36	4.39e-9	Obesity-related traits;
KIRP	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.56	-6.99	-0.41	2.58e-11	Schizophrenia;
KIRP	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-7.56	-0.43	7.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs471756	0.554	rs2484967	chr9:221874	C/T	cg14500300	chr9:211689	NA	0.4	5.47	0.33	1.08e-7	Mean platelet volume;
KIRP	cis	rs68170813	0.617	rs17481842	chr7:107121862	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-6.59	-0.39	2.68e-10	Coronary artery disease;
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.73	11.12	0.58	1.56e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.57	-6.34	-0.37	1.12e-9	DNA methylation (variation);
KIRP	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs926938	0.618	rs360587	chr1:115467553	A/G	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.24	-0.32	3.46e-7	Autism;
KIRP	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg27129171	chr3:47204927	SETD2	-0.65	-8.91	-0.49	1.16e-16	Colorectal cancer;
KIRP	cis	rs7612445	1.000	rs7634416	chr3:179173224	A/T	cg01750654	chr3:179170617	GNB4	-0.59	-6.71	-0.39	1.32e-10	Resting heart rate;Heart rate;
KIRP	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.15	0.58	1.2e-23	Alzheimer's disease;
KIRP	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg12661370	chr5:149340060	SLC26A2	-0.52	-5.39	-0.33	1.62e-7	HIV-1 control;
KIRP	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg01988459	chr11:68622903	NA	-0.35	-4.84	-0.3	2.26e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg17764715	chr19:33622953	WDR88	0.67	8.41	0.47	3.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs687432	0.924	rs7929515	chr11:57776956	T/C	cg19752551	chr11:57585705	CTNND1	-0.68	-8.82	-0.49	2.19e-16	Parkinson's disease;
KIRP	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg21854759	chr1:92012499	NA	0.49	6.06	0.36	5.18e-9	Breast cancer;
KIRP	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.92	11.73	0.6	1.59e-25	Menopause (age at onset);
KIRP	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.5	6.17	0.37	2.77e-9	Urinary tract infection frequency;
KIRP	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg13319975	chr6:146136371	FBXO30	0.47	6.35	0.38	1.05e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3735025	0.927	rs320707	chr7:137053273	A/C	cg13839563	chr7:136910420	NA	0.38	4.9	0.3	1.77e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12230513	0.732	rs4343668	chr12:55868936	G/T	cg19537932	chr12:55886519	OR6C68	-0.62	-7.46	-0.43	1.49e-12	Contrast sensitivity;
KIRP	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.25	-5.42	-0.33	1.45e-7	Menarche (age at onset);
KIRP	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-1.05	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	cis	rs748404	0.723	rs573169	chr15:43550581	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.35	0.42	2.92e-12	Lung cancer;
KIRP	cis	rs9921338	0.961	rs72773833	chr16:11413274	G/A	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7546094	1.000	rs12126277	chr1:113106369	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs57590327	0.679	rs35754586	chr3:81601765	T/C	cg07356753	chr3:81810745	GBE1	-0.59	-6.33	-0.37	1.17e-9	Extraversion;
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg12140854	chr5:148520817	ABLIM3	-0.6	-6.37	-0.38	9.48e-10	Breast cancer;
KIRP	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22633769	chr20:60982531	CABLES2	0.67	8.71	0.49	4.49e-16	Colorectal cancer;
KIRP	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs494562	0.892	rs9353309	chr6:86126145	C/T	cg27039625	chr6:86159096	NT5E	0.43	5.65	0.34	4.39e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.43	5.5	0.33	9.68e-8	Aortic root size;
KIRP	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg18441811	chr11:71824068	C11orf51	-0.81	-5.43	-0.33	1.33e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs397969	0.646	rs8079923	chr17:19869544	C/T	cg13482628	chr17:19912719	NA	0.47	5.28	0.32	2.79e-7	Platelet count;
KIRP	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10556349	chr10:835070	NA	0.58	4.91	0.3	1.67e-6	Eosinophil percentage of granulocytes;
KIRP	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-9.26	-0.51	1.04e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18867708	chr6:26865862	GUSBL1	0.53	6.54	0.38	3.56e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.63	0.56	5.81e-22	Cognitive test performance;
KIRP	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.5	7.13	0.41	1.1e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.08	13.01	0.64	8.38e-30	Platelet count;
KIRP	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg10047753	chr17:41438598	NA	1.12	17.54	0.75	3.22e-45	Menopause (age at onset);
KIRP	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg03060546	chr3:49711283	APEH	0.43	5.46	0.33	1.14e-7	Parkinson's disease;
KIRP	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg25706552	chr1:244017396	NA	0.51	5.42	0.33	1.4e-7	RR interval (heart rate);
KIRP	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.38	-4.88	-0.3	1.87e-6	Menarche (age at onset);
KIRP	cis	rs354225	0.584	rs13432302	chr2:54813938	A/C	cg01766943	chr2:54829624	SPTBN1	0.37	5.05	0.31	8.41e-7	Schizophrenia;
KIRP	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-0.96	-11.67	-0.6	2.43e-25	Vitiligo;
KIRP	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg08662619	chr6:150070041	PCMT1	0.33	5.34	0.32	2.08e-7	Testicular germ cell tumor;
KIRP	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.9	-10.94	-0.57	5.79e-23	Gut microbiome composition (summer);
KIRP	cis	rs554111	0.510	rs10916863	chr1:21120592	C/T	cg21184320	chr1:21044207	KIF17	0.4	5.9	0.35	1.22e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg18490616	chr2:88469792	THNSL2	0.66	5.33	0.32	2.22e-7	Plasma clusterin levels;
KIRP	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.72	7.9	0.45	9.2e-14	Gut microbiome composition (summer);
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	5.28	0.32	2.87e-7	Renal cell carcinoma;
KIRP	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg21573476	chr21:45109991	RRP1B	0.62	8.28	0.47	7.98e-15	Mean corpuscular volume;
KIRP	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg00745463	chr17:30367425	LRRC37B	-0.57	-5.71	-0.34	3.2e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs6450176	0.625	rs3776725	chr5:53290138	C/A	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-12.93	-0.64	1.55e-29	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg04373760	chr16:53404718	NA	0.62	6.86	0.4	5.65e-11	Hypertriglyceridemia;
KIRP	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.73	0.49	3.95e-16	Motion sickness;
KIRP	cis	rs7737355	0.773	rs9327616	chr5:130902196	C/T	cg06307176	chr5:131281290	NA	0.42	5.03	0.31	9.64e-7	Life satisfaction;
KIRP	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.96	12.93	0.64	1.62e-29	Vitamin D levels;
KIRP	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.75e-7	Skin colour saturation;
KIRP	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg03808351	chr9:123631620	PHF19	0.43	5.86	0.35	1.5e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg04306507	chr14:55594613	LGALS3	0.53	8.45	0.47	2.58e-15	Protein biomarker;
KIRP	cis	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	5.03	0.31	9.63e-7	Leprosy;
KIRP	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg12131826	chr15:77904385	NA	0.5	6.04	0.36	5.55e-9	Type 2 diabetes;
KIRP	cis	rs2275620	0.505	rs10128455	chr10:96851353	T/C	cg09036531	chr10:96991505	NA	-0.4	-5.07	-0.31	7.99e-7	Gout;
KIRP	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.34	0.47	5.51e-15	Asthma (sex interaction);
KIRP	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg07827796	chr19:33622959	WDR88	0.41	4.94	0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.63	7.95	0.45	6.71e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs74181299	0.554	rs6748462	chr2:65359282	T/G	cg05010058	chr2:65284262	CEP68	-0.5	-6.73	-0.39	1.22e-10	Pulse pressure;
KIRP	cis	rs79387448	0.655	rs79091585	chr2:102917243	C/T	cg09003973	chr2:102972529	NA	1.22	9.29	0.51	8.54e-18	Gut microbiota (bacterial taxa);
KIRP	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg00981070	chr1:2046702	PRKCZ	0.4	5.83	0.35	1.77e-8	Height;
KIRP	cis	rs7172677	0.737	rs7179426	chr15:75441488	A/G	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12145552	chr21:43374218	C2CD2	0.46	6.28	0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg06871246	chr4:1363661	KIAA1530	-0.51	-6.53	-0.38	3.66e-10	Longevity;
KIRP	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg21926883	chr2:100939477	LONRF2	-0.53	-7.33	-0.42	3.33e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg19507638	chr5:93509721	C5orf36	-0.61	-5.59	-0.34	6.09e-8	Diabetic retinopathy;
KIRP	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	5.44	0.33	1.3e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.44e-7	Menopause (age at onset);
KIRP	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10309340	chr10:102747329	C10orf2;MRPL43	0.45	6.59	0.39	2.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg24315340	chr6:146058215	EPM2A	-0.39	-4.95	-0.3	1.37e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.73	0.6	1.6e-25	Total body bone mineral density;
KIRP	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.75	6.54	0.38	3.53e-10	Inflammatory bowel disease;
KIRP	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18223153	chr7:540667	PDGFA	0.54	6.42	0.38	7.08e-10	Interleukin-4 levels;
KIRP	cis	rs427941	0.703	rs201443	chr7:101737688	A/T	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.24e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg12940923	chr8:10282607	MSRA	-0.41	-5.24	-0.32	3.51e-7	Neuroticism;
KIRP	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.7	8.44	0.47	2.81e-15	Aortic root size;
KIRP	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.78	10.13	0.54	2.18e-20	Body mass index;
KIRP	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg05791153	chr7:19748676	TWISTNB	0.68	6.17	0.37	2.74e-9	Thyroid stimulating hormone;
KIRP	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.47	6.05	0.36	5.31e-9	Menopause (age at onset);
KIRP	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.93	15.79	0.71	2.92e-39	Ulcerative colitis;
KIRP	cis	rs12362504	0.504	rs7929338	chr11:9895885	T/C	cg07197493	chr11:9884649	SBF2	-0.42	-5.79	-0.35	2.13e-8	Survival in pancreatic cancer;
KIRP	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.46	0.47	2.38e-15	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01684528	chr16:4233614	NA	0.49	6.27	0.37	1.64e-9	Parkinson's disease;
KIRP	cis	rs2120243	0.658	rs7626884	chr3:157144149	G/C	cg24825693	chr3:157122686	VEPH1	-0.38	-5.29	-0.32	2.74e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs3105593	0.555	rs3131560	chr15:50775562	T/C	cg08437265	chr15:50716283	USP8	0.34	4.88	0.3	1.9e-6	QT interval;
KIRP	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg05347473	chr6:146136440	FBXO30	0.61	8.74	0.49	3.82e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.75	10.99	0.57	3.91e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg21253087	chr9:139290292	SNAPC4	-0.39	-5.14	-0.31	5.54e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs45535039	0.506	rs4936467	chr11:119086629	A/T	cg16724696	chr11:118992527	HINFP	-0.64	-9.78	-0.53	2.68e-19	Plateletcrit;
KIRP	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.07e-7	Eye color traits;
KIRP	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg11234688	chr2:1609660	NA	0.57	5.27	0.32	3.06e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	1.22	11.23	0.58	6.87e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.21	-0.42	6.96e-12	Mood instability;
KIRP	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg26441486	chr22:50317300	CRELD2	-0.44	-7.09	-0.41	1.44e-11	Schizophrenia;
KIRP	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.36	-5.07	-0.31	7.9e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1355223	0.902	rs34875830	chr11:34722205	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-4.96	-0.3	1.29e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8177876	0.749	rs58144189	chr16:81098083	T/C	cg08591886	chr16:81111003	C16orf46	-0.74	-5.93	-0.35	1.03e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.3	0.42	4.07e-12	Lung cancer;
KIRP	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg04289385	chr6:36355825	ETV7	0.38	5.0	0.3	1.11e-6	Platelet distribution width;
KIRP	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.44	-0.65	3.06e-31	Height;
KIRP	cis	rs2425143	1.000	rs79035779	chr20:34343004	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.04	-0.31	9.05e-7	Blood protein levels;
KIRP	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg12591125	chr7:1885375	MAD1L1	-0.43	-4.97	-0.3	1.28e-6	Bipolar disorder;
KIRP	cis	rs4666002	0.789	rs6727388	chr2:27932587	A/G	cg05484376	chr2:27715224	FNDC4	-0.48	-5.84	-0.35	1.63e-8	Phospholipid levels (plasma);
KIRP	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.82	-11.67	-0.6	2.42e-25	Multiple sclerosis;
KIRP	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6684514	1.000	rs2273832	chr1:156233143	A/G	cg16558208	chr1:156270281	VHLL	-0.43	-5.46	-0.33	1.18e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg00738919	chr7:1100172	C7orf50	0.42	4.96	0.3	1.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15243630	chr3:32147959	GPD1L	0.46	6.1	0.36	4.11e-9	Parkinson's disease;
KIRP	cis	rs654950	0.841	rs2810549	chr1:41991761	C/T	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.45	-0.38	5.81e-10	Airway imaging phenotypes;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.5	-6.49	-0.38	4.82e-10	Testicular germ cell tumor;
KIRP	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.83	13.04	0.64	7.01e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9596863	1.000	rs35429587	chr13:54406523	T/A	ch.13.53330881F	chr13:54432880	NA	0.66	6.68	0.39	1.56e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.5	7.11	0.41	1.25e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.68	-10.28	-0.55	7.42e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4356932	1.000	rs6840980	chr4:76985331	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.98	-8.33	-0.47	5.78e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg20673091	chr1:2541236	MMEL1	0.36	4.96	0.3	1.32e-6	Ulcerative colitis;
KIRP	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg04804543	chr8:142233427	SLC45A4	-0.58	-7.15	-0.41	9.73e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.5	8.55	0.48	1.33e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11955398	0.665	rs11948543	chr5:59918937	T/C	cg02684056	chr5:59996105	DEPDC1B	0.43	5.17	0.31	4.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg23594656	chr7:65796392	TPST1	0.36	5.28	0.32	2.81e-7	Aortic root size;
KIRP	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.77	9.83	0.53	1.91e-19	Age at first birth;
KIRP	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.48	6.02	0.36	6.43e-9	Tonsillectomy;
KIRP	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg26875137	chr12:53738046	NA	-0.38	-5.29	-0.32	2.7e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs6504663	0.596	rs7208018	chr17:48557863	C/T	cg00901687	chr17:48585270	MYCBPAP	-0.41	-5.14	-0.31	5.66e-7	Visceral fat;
KIRP	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg07856975	chr6:36356162	ETV7	-0.41	-6.06	-0.36	5.17e-9	Platelet distribution width;
KIRP	cis	rs911119	1.000	rs1010117	chr20:23608421	G/C	cg16589663	chr20:23618590	CST3	0.63	6.14	0.36	3.25e-9	Chronic kidney disease;
KIRP	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg26784012	chr10:32216390	ARHGAP12	0.31	4.97	0.3	1.25e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg08132940	chr7:1081526	C7orf50	-0.7	-7.04	-0.41	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg09264619	chr17:80180166	NA	-0.51	-5.94	-0.35	9.7e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg11784071	chr10:104629166	AS3MT	-0.36	-4.98	-0.3	1.18e-6	Arsenic metabolism;
KIRP	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6750047	0.605	rs1374191	chr2:38265420	T/G	cg07380506	chr2:38303506	CYP1B1	-0.46	-6.03	-0.36	6.12e-9	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11987759	chr7:65425863	GUSB	0.45	5.32	0.32	2.34e-7	Aortic root size;
KIRP	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	9.51	0.52	1.88e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg09455208	chr3:40491958	NA	0.33	5.93	0.35	1.04e-8	Renal cell carcinoma;
KIRP	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs60154123	1.000	rs4844996	chr1:210476423	C/T	cg09074223	chr1:210466472	NA	0.54	5.07	0.31	7.77e-7	Coronary artery disease;
KIRP	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg11189052	chr15:85197271	WDR73	-0.47	-5.84	-0.35	1.65e-8	P wave terminal force;
KIRP	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.38	4.93	0.3	1.51e-6	Melanoma;
KIRP	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.65	9.74	0.53	3.69e-19	Heart rate;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03480535	chr4:87856849	AFF1	0.57	6.91	0.4	4.16e-11	Smoking initiation;
KIRP	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg26138937	chr11:71823887	C11orf51	1.16	8.02	0.46	4.37e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg13978929	chr19:21580086	ZNF493	-0.5	-4.89	-0.3	1.79e-6	Pain;
KIRP	cis	rs977145	1.000	rs6703162	chr1:71929968	A/C	cg24940889	chr1:71929976	NEGR1	0.35	4.86	0.3	2.13e-6	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks);
KIRP	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.46	5.34	0.32	2.09e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	6.81	0.4	7.38e-11	Menarche (age at onset);
KIRP	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.82	11.86	0.6	5.63e-26	Bladder cancer;
KIRP	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.48	-5.79	-0.35	2.18e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg08890418	chr1:21044141	KIF17	0.34	5.1	0.31	6.85e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg01025720	chr13:113346439	ATP11A	0.52	5.02	0.31	9.76e-7	Glycated hemoglobin levels;
KIRP	cis	rs2273669	0.667	rs12198182	chr6:109318704	T/G	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.82	12.19	0.61	4.8e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.51	-7.51	-0.43	1.11e-12	Refractive error;
KIRP	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.72	8.26	0.47	9.18e-15	Platelet count;
KIRP	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	ch.5.1024479R	chr5:53302184	ARL15	-1.18	-14.82	-0.69	6.27e-36	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.42	5.99	0.36	7.49e-9	Testicular germ cell tumor;
KIRP	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg26513180	chr16:89883248	FANCA	0.89	5.57	0.33	6.7e-8	Skin colour saturation;
KIRP	cis	rs1298062	0.763	rs2387112	chr19:50984853	A/G	cg11430371	chr19:50961752	MYBPC2	0.36	4.97	0.3	1.28e-6	Age of smoking initiation;
KIRP	cis	rs27434	0.583	rs151908	chr5:96156494	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1.01e-7	Ankylosing spondylitis;
KIRP	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg24399712	chr22:39784796	NA	-0.78	-12.69	-0.63	1e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg18306943	chr3:40428807	ENTPD3	0.45	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg15839431	chr19:19639596	YJEFN3	0.54	5.46	0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.59	-7.87	-0.45	1.16e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.36	-0.51	5.41e-18	Joint mobility (Beighton score);
KIRP	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg11846333	chr4:119757529	SEC24D	1.05	5.8	0.35	2e-8	Cannabis dependence symptom count;
KIRP	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg26149184	chr10:133730230	NA	-0.42	-5.03	-0.31	9.43e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg00405596	chr8:11794950	NA	0.62	8.71	0.49	4.42e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-8.11	-0.46	2.48e-14	Neuroticism;
KIRP	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg23920097	chr1:209922102	NA	-0.47	-5.62	-0.34	5.07e-8	Red blood cell count;
KIRP	cis	rs7843479	0.828	rs4357289	chr8:21777476	G/A	cg17168535	chr8:21777572	XPO7	0.71	9.65	0.52	6.71e-19	Mean corpuscular volume;
KIRP	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg13289132	chr10:30722225	MAP3K8	-0.42	-5.23	-0.32	3.61e-7	Inflammatory bowel disease;
KIRP	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.17	0.42	8.68e-12	Mean corpuscular volume;
KIRP	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg00405596	chr8:11794950	NA	0.59	8.41	0.47	3.31e-15	Neuroticism;
KIRP	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg15488143	chr7:128924101	AHCYL2	0.62	6.95	0.41	3.28e-11	White matter hyperintensity burden;
KIRP	cis	rs10918270	0.934	rs9783069	chr1:161936121	A/C	cg19735514	chr1:161762739	ATF6	-0.35	-4.94	-0.3	1.47e-6	Parkinson's disease (age of onset);
KIRP	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg14086599	chr2:241536098	CAPN10	-0.48	-5.29	-0.32	2.7e-7	Bipolar disorder;
KIRP	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg01872077	chr2:219646372	CYP27A1	-0.37	-4.93	-0.3	1.51e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7809615	0.901	rs1581492	chr7:99186826	C/T	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite ratios;
KIRP	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.56	6.89	0.4	4.71e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.61	-0.59	3.87e-25	Glomerular filtration rate (creatinine);
KIRP	trans	rs4143844	0.867	rs35764401	chr15:62149657	C/T	cg04814990	chr13:111957387	ARHGEF7	0.98	6.47	0.38	5.18e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6901004	0.803	rs11153272	chr6:111479539	C/T	cg15721981	chr6:111408429	SLC16A10	-0.57	-7.9	-0.45	9.29e-14	Blood metabolite levels;
KIRP	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.61	7.42	0.43	1.88e-12	Blood metabolite levels;
KIRP	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg06212747	chr3:49208901	KLHDC8B	0.69	8.14	0.46	2e-14	Menarche (age at onset);
KIRP	cis	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg21775007	chr8:11205619	TDH	0.41	5.08	0.31	7.61e-7	Neuroticism;
KIRP	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.33	0.32	2.25e-7	Menopause (age at onset);
KIRP	cis	rs6142102	0.778	rs6059555	chr20:32514324	G/C	cg24642439	chr20:33292090	TP53INP2	0.53	5.71	0.34	3.21e-8	Skin pigmentation;
KIRP	cis	rs8067287	0.688	rs11654431	chr17:16844863	C/A	cg26910001	chr17:16838321	NA	-0.47	-5.5	-0.33	9.29e-8	Diabetic kidney disease;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg00738919	chr7:1100172	C7orf50	0.42	4.96	0.3	1.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs4776970	0.632	rs12592101	chr15:68029570	A/G	cg24579218	chr15:68104479	NA	0.37	5.63	0.34	5.02e-8	Waist circumference;Body mass index;
KIRP	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg13256891	chr4:100009986	ADH5	-0.46	-6.06	-0.36	4.99e-9	Alcohol dependence;
KIRP	cis	rs829661	0.847	rs829622	chr2:30753445	T/C	cg10949345	chr2:30726833	LCLAT1	0.72	10.48	0.56	1.77e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12976411	0.867	rs35113780	chr19:32836430	G/A	cg02282382	chr19:32836354	ZNF507	0.64	5.52	0.33	8.77e-8	Coronary artery disease;
KIRP	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.62	-6.69	-0.39	1.46e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg08975724	chr8:8085496	FLJ10661	0.53	6.02	0.36	6.17e-9	Systolic blood pressure;
KIRP	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.76	10.12	0.54	2.43e-20	Resting heart rate;
KIRP	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.43	-5.62	-0.34	5.09e-8	Schizophrenia (inflammation and infection response interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12841375	chr6:52929709	FBXO9	0.52	6.1	0.36	4.01e-9	Smoking initiation;
KIRP	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.01	0.61	1.88e-26	Smoking behavior;
KIRP	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.06e-11	Bipolar disorder;
KIRP	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg10932868	chr11:921992	NA	0.52	6.49	0.38	4.74e-10	Alzheimer's disease (late onset);
KIRP	cis	rs2904967	0.929	rs655433	chr11:65069275	G/C	cg09225861	chr11:65069680	NA	0.42	5.05	0.31	8.64e-7	Mean corpuscular volume;
KIRP	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg16558253	chr16:72132732	DHX38	-0.6	-8.95	-0.5	8.84e-17	Fibrinogen levels;
KIRP	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.07	0.41	1.57e-11	Morning vs. evening chronotype;
KIRP	cis	rs7671900	0.932	rs6531978	chr4:88277927	G/A	cg23841344	chr4:88312519	HSD17B11	-0.5	-6.6	-0.39	2.51e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.593	rs4696103	chr4:152564611	A/G	cg22705602	chr4:152727874	NA	-0.56	-8.77	-0.49	3.05e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg24633833	chr3:10029261	TMEM111	-0.56	-4.93	-0.3	1.53e-6	Alzheimer's disease;
KIRP	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg23594656	chr7:65796392	TPST1	0.38	5.63	0.34	4.91e-8	Aortic root size;
KIRP	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.93	-0.35	1.03e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg21360079	chr12:107162445	NA	-0.71	-10.21	-0.55	1.21e-20	Heart rate;
KIRP	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.13	8.3	0.47	7e-15	Skin colour saturation;
KIRP	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg02996583	chr8:142237188	SLC45A4	-0.42	-4.95	-0.3	1.35e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.84	9.95	0.54	8.16e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg21734707	chr17:3908241	ZZEF1	0.51	7.23	0.42	5.91e-12	Type 2 diabetes;
KIRP	cis	rs4523957	0.855	rs9893573	chr17:2126003	A/G	cg16513277	chr17:2031491	SMG6	-0.67	-9.16	-0.5	2.07e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg06647332	chr5:131281008	NA	-0.44	-4.86	-0.3	2.11e-6	Life satisfaction;
KIRP	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.9	10.69	0.56	3.86e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.18	-18.9	-0.77	8.19e-50	Ulcerative colitis;
KIRP	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg18904891	chr8:8559673	CLDN23	0.71	7.82	0.45	1.55e-13	Obesity-related traits;
KIRP	cis	rs4926611	1.000	rs6685730	chr1:54116788	C/T	cg08927728	chr1:54059983	GLIS1	-0.27	-5.9	-0.35	1.2e-8	Hand grip strength;
KIRP	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg19116668	chr7:99932089	PMS2L1	-0.56	-6.39	-0.38	8.11e-10	Coronary artery disease;
KIRP	cis	rs4700695	0.841	rs706679	chr5:65317181	A/G	cg21114390	chr5:65439923	SFRS12	-0.56	-6.09	-0.36	4.29e-9	Facial morphology (factor 19);
KIRP	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.5	-15.25	-0.7	2.1e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs2797160	0.904	rs1777198	chr6:126007416	C/T	cg05901451	chr6:126070800	HEY2	0.41	5.6	0.34	5.66e-8	Endometrial cancer;
KIRP	cis	rs2071426	0.580	rs6583966	chr10:96759902	C/T	cg09036531	chr10:96991505	NA	-0.47	-4.89	-0.3	1.83e-6	Blood metabolite levels;
KIRP	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	1.06	8.47	0.48	2.25e-15	Parkinson's disease;
KIRP	cis	rs62355272	0.580	rs6873195	chr5:35919917	G/A	cg13894535	chr5:35919491	CAPSL	-0.37	-4.94	-0.3	1.42e-6	Lymphocyte counts;
KIRP	cis	rs1014246	0.807	rs10886003	chr10:118461226	G/A	cg14919929	chr10:118506882	NA	0.76	9.54	0.52	1.45e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs1021993	0.545	rs7548184	chr1:209531600	C/T	cg24446417	chr1:209558027	NA	-0.52	-5.25	-0.32	3.31e-7	Gut microbiome composition (winter);
KIRP	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	7.87	0.45	1.11e-13	Refractive astigmatism;
KIRP	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.76	9.66	0.52	6.25e-19	Aortic root size;
KIRP	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg08280861	chr8:58055591	NA	0.53	5.02	0.3	9.82e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13401104	0.796	rs10929168	chr2:237115373	C/T	cg19324714	chr2:237145437	ASB18	-0.49	-5.22	-0.32	3.88e-7	Educational attainment;
KIRP	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg06115741	chr20:33292138	TP53INP2	0.47	6.44	0.38	6.38e-10	Coronary artery disease;
KIRP	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg16586182	chr3:47516702	SCAP	-0.75	-10.78	-0.57	1.87e-22	Colorectal cancer;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg18350739	chr11:68623251	NA	-0.51	-7.96	-0.45	6.48e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.33	-6.2	-0.37	2.38e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg00784671	chr22:46762841	CELSR1	-0.55	-7.19	-0.42	7.91e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs57908212	1	rs57908212	chr19:2161321	T/C	cg09261902	chr19:2140048	AP3D1	0.65	9.92	0.53	1.03e-19	Red blood cell count;Hemoglobin concentration;Hematocrit;
KIRP	cis	rs7429990	0.932	rs2361684	chr3:48152618	G/C	cg11946769	chr3:48343235	NME6	-0.43	-5.17	-0.31	4.85e-7	Educational attainment (years of education);
KIRP	cis	rs10214930	0.767	rs42087	chr7:27700482	C/T	cg22168087	chr7:27702803	HIBADH	-0.52	-5.24	-0.32	3.49e-7	Hypospadias;
KIRP	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.66	0.48	6.51e-16	Motion sickness;
KIRP	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.39	5.1	0.31	6.75e-7	Schizophrenia;
KIRP	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg25919922	chr13:100150906	NA	0.69	6.65	0.39	1.87e-10	Obesity-related traits;
KIRP	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17554472	chr22:41940697	POLR3H	-0.66	-6.77	-0.4	9.43e-11	Vitiligo;
KIRP	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.84	10.08	0.54	3.21e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.58	-7.14	-0.41	1.04e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg01798813	chr17:3906674	NA	0.47	6.31	0.37	1.26e-9	Type 2 diabetes;
KIRP	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg03609598	chr5:56110824	MAP3K1	0.48	5.43	0.33	1.35e-7	Initial pursuit acceleration;
KIRP	cis	rs17401966	0.540	rs6541084	chr1:10285447	A/G	cg17425144	chr1:10567563	PEX14	-0.29	-5.06	-0.31	8.3e-7	Hepatocellular carcinoma;
KIRP	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.64	-7.74	-0.44	2.52e-13	Obesity-related traits;
KIRP	cis	rs72960926	0.744	rs1817735	chr6:74980974	T/C	cg03266952	chr6:74778945	NA	-0.7	-4.98	-0.3	1.23e-6	Metabolite levels (MHPG);
KIRP	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs1891275	0.515	rs2153653	chr10:93495926	T/A	cg07889827	chr10:93443413	NA	-0.43	-7.37	-0.43	2.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	0.956	rs35089989	chr22:18424298	T/C	cg03078520	chr22:18463400	MICAL3	-0.73	-8.33	-0.47	5.79e-15	Presence of antiphospholipid antibodies;
KIRP	cis	rs9653442	0.564	rs2309753	chr2:100775920	C/A	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg27490568	chr2:178487706	NA	0.46	6.17	0.37	2.8e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg03289416	chr15:75166202	SCAMP2	0.56	7.61	0.44	5.83e-13	Breast cancer;
KIRP	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.76	7.72	0.44	3e-13	Menarche (age at onset);
KIRP	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg23950597	chr19:37808831	NA	0.61	6.61	0.39	2.35e-10	Coronary artery calcification;
KIRP	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.4	-5.3	-0.32	2.62e-7	Coronary artery disease;
KIRP	cis	rs573521	1.000	rs602128	chr11:102713465	A/G	cg19620758	chr11:102826565	MMP13	0.36	4.9	0.3	1.73e-6	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;
KIRP	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.05	0.41	1.83e-11	Mean platelet volume;
KIRP	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.52	-7.16	-0.42	9.3e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03826430	chr10:135192749	PAOX	-0.53	-6.09	-0.36	4.36e-9	Menopause (age at onset);
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg21186296	chr8:27182909	PTK2B	0.51	6.5	0.38	4.42e-10	Neuroticism;
KIRP	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	1.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.43	5.49	0.33	1e-7	Gout;
KIRP	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.36	-5.59	-0.34	6.07e-8	Neuroticism;
KIRP	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg19906672	chr4:6918868	TBC1D14	0.47	5.03	0.31	9.64e-7	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06715928	chr10:112257500	DUSP5	-0.52	-7.1	-0.41	1.37e-11	Myopia;
KIRP	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.52e-6	Life satisfaction;
KIRP	cis	rs6005807	0.688	rs9625475	chr22:28841839	C/T	cg12565055	chr22:29076175	TTC28	-0.54	-5.06	-0.31	8.29e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg17376030	chr22:41985996	PMM1	-0.81	-8.5	-0.48	1.85e-15	Vitiligo;
KIRP	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.08	0.41	1.49e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg07274523	chr3:49395745	GPX1	0.56	5.28	0.32	2.89e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg22541963	chr20:60982533	CABLES2	0.4	4.94	0.3	1.43e-6	Colorectal cancer;
KIRP	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.09	0.46	2.65e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.75	-0.44	2.42e-13	Height;
KIRP	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg25547332	chr5:131281432	NA	-0.46	-5.14	-0.31	5.58e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.29	0.62	2.12e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg00405596	chr8:11794950	NA	-0.52	-7.03	-0.41	2.01e-11	Joint mobility (Beighton score);
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg02733842	chr7:1102375	C7orf50	0.53	5.55	0.33	7.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6593803	0.732	rs4950344	chr1:147227066	A/G	cg27546670	chr1:147246839	GJA5	0.68	8.01	0.45	4.48e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.81	0.45	1.69e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg06066596	chr15:83166174	LOC80154	0.52	5.91	0.35	1.12e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs56873913	0.597	rs7254831	chr19:50073237	C/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.47	4.91	0.3	1.64e-6	Schizophrenia;
KIRP	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.45	5.22	0.32	3.77e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.87	-12.92	-0.64	1.67e-29	Monocyte percentage of white cells;
KIRP	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg07689907	chr11:61582574	FADS1	0.4	5.26	0.32	3.17e-7	Trans fatty acid levels;
KIRP	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.67	9.28	0.51	8.87e-18	Blood protein levels;
KIRP	cis	rs2278796	0.789	rs12136572	chr1:204962660	G/A	cg17947172	chr1:204966197	NFASC	0.76	10.21	0.55	1.2e-20	Mean platelet volume;
KIRP	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.26	-0.32	3.08e-7	Breast cancer;
KIRP	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg23625390	chr15:77176239	SCAPER	0.53	6.93	0.4	3.71e-11	Blood metabolite levels;
KIRP	cis	rs675026	1.000	rs675026	chr6:154414563	A/G	cg07813322	chr6:154414604	OPRM1	-0.54	-6.79	-0.4	8.29e-11	Hypertension;
KIRP	cis	rs4765905	0.671	rs12424245	chr12:2322513	A/G	cg10668781	chr12:2307325	CACNA1C	-0.31	-5.71	-0.34	3.25e-8	Schizophrenia;
KIRP	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg26022315	chr17:47021804	SNF8	0.42	5.41	0.33	1.47e-7	Type 2 diabetes;
KIRP	cis	rs501120	0.584	rs11511571	chr10:44727167	T/C	cg09554077	chr10:44749378	NA	0.66	7.38	0.43	2.39e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-7.82	-0.45	1.52e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.67	-0.48	6.1e-16	Vitiligo;
KIRP	cis	rs6545883	0.929	rs1186707	chr2:61673520	C/A	cg15711740	chr2:61764176	XPO1	-0.61	-8.19	-0.46	1.44e-14	Tuberculosis;
KIRP	cis	rs2880765	0.527	rs1483578	chr15:86075417	A/G	cg17133734	chr15:86042851	AKAP13	-0.58	-7.13	-0.41	1.11e-11	Coronary artery disease;
KIRP	cis	rs10073892	0.917	rs10213787	chr5:101659154	G/C	cg19774478	chr5:101632501	SLCO4C1	0.65	7.14	0.41	1.04e-11	Cognitive decline (age-related);
KIRP	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg05692746	chr2:100937584	LONRF2	-0.46	-5.41	-0.33	1.51e-7	Educational attainment;
KIRP	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.6	7.67	0.44	3.98e-13	Platelet distribution width;
KIRP	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg26876637	chr1:152193138	HRNR	-0.77	-8.77	-0.49	3.09e-16	Atopic dermatitis;
KIRP	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg13679303	chr9:96623674	NA	-0.5	-7.05	-0.41	1.77e-11	DNA methylation (variation);
KIRP	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg11783602	chr8:55087084	NA	-0.59	-7.24	-0.42	5.82e-12	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.44	0.52	2.9e-18	Height;
KIRP	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg20387954	chr3:183756860	HTR3D	0.64	9.43	0.52	3.21e-18	Anterior chamber depth;
KIRP	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.55	7.54	0.43	8.79e-13	Schizophrenia;
KIRP	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.63	7.73	0.44	2.72e-13	Mean platelet volume;
KIRP	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg21395723	chr22:39101663	GTPBP1	0.41	5.15	0.31	5.47e-7	Menopause (age at onset);
KIRP	cis	rs17125944	0.686	rs8003683	chr14:53366605	G/T	cg00686598	chr14:53173677	PSMC6	0.75	6.92	0.4	3.91e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7712401	0.601	rs34348084	chr5:122335114	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.77	16.12	0.72	2.21e-40	Sjögren's syndrome;
KIRP	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-6.41	-0.38	7.21e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg22800045	chr5:56110881	MAP3K1	0.65	6.67	0.39	1.66e-10	Type 2 diabetes;
KIRP	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.46	-5.64	-0.34	4.68e-8	Urinary tract infection frequency;
KIRP	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.48	-6.42	-0.38	6.93e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg08999081	chr20:33150536	PIGU	0.47	6.28	0.37	1.52e-9	Height;
KIRP	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.1	-0.46	2.64e-14	Mood instability;
KIRP	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-8.5	-0.48	1.89e-15	Schizophrenia;
KIRP	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	7.31	0.42	3.75e-12	Educational attainment;
KIRP	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.98	13.63	0.66	6.91e-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.27	-15.36	-0.7	8.87e-38	Breast cancer;
KIRP	cis	rs77372450	0.636	rs6556105	chr5:157022864	C/T	cg23851860	chr5:157002805	ADAM19	0.45	5.12	0.31	6.11e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg18805032	chr6:3853096	NA	0.54	6.33	0.37	1.17e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.92	0.61	3.63e-26	Lung cancer in ever smokers;
KIRP	cis	rs12210905	1.000	rs9348758	chr6:27255238	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.8	-5.91	-0.35	1.12e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	6.01	0.36	6.63e-9	Height;
KIRP	trans	rs4650994	0.816	rs1074896	chr1:178591190	A/G	cg05059571	chr16:84539110	KIAA1609	0.53	7.08	0.41	1.46e-11	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.73	-0.53	3.74e-19	Total body bone mineral density;
KIRP	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.58	7.17	0.42	8.89e-12	Arsenic metabolism;
KIRP	cis	rs17123764	0.892	rs12313353	chr12:50138666	T/G	cg20471783	chr12:50157085	TMBIM6	0.42	5.99	0.36	7.49e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg00012203	chr2:219082015	ARPC2	-0.41	-5.03	-0.31	9.62e-7	Ulcerative colitis;
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-6.44	-0.38	6.15e-10	Lung cancer;
KIRP	cis	rs2278796	0.639	rs12145998	chr1:204969419	C/T	cg04862289	chr1:204966208	NFASC	0.65	9.18	0.51	1.81e-17	Mean platelet volume;
KIRP	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg16141378	chr3:129829833	LOC729375	0.55	7.59	0.44	6.8e-13	Neuroticism;
KIRP	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg01872077	chr2:219646372	CYP27A1	0.39	5.1	0.31	6.67e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.63	-9.52	-0.52	1.65e-18	Educational attainment;
KIRP	cis	rs9328573	1.000	rs9328573	chr15:100511004	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.46	-6.56	-0.39	3.11e-10	Urate levels in lean individuals;
KIRP	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg01689657	chr7:91764605	CYP51A1	-0.37	-5.38	-0.32	1.69e-7	Breast cancer;
KIRP	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.32	0.55	5.76e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs1832871	0.521	rs62437410	chr6:158822888	G/C	cg07215822	chr6:158701037	NA	-0.54	-6.33	-0.37	1.18e-9	Height;
KIRP	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.99	13.61	0.66	8.16e-32	Neutrophil percentage of white cells;
KIRP	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.41	-5.42	-0.33	1.41e-7	Body mass index;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg13198984	chr17:80129470	CCDC57	0.59	8.78	0.49	2.86e-16	Life satisfaction;
KIRP	cis	rs4973397	0.643	rs2034413	chr2:232288149	C/T	cg09339159	chr2:232260559	B3GNT7	0.4	5.21	0.32	3.93e-7	Anti-saccade response;
KIRP	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.83	-9.91	-0.53	1.04e-19	Body mass index;
KIRP	cis	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	6.51	0.38	4.29e-10	Hemoglobin concentration;
KIRP	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.84	12.28	0.62	2.43e-27	Colorectal cancer;
KIRP	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs2172802	0.924	rs10018746	chr4:62445246	T/C	cg02936451	chr4:62066211	NA	0.41	4.99	0.3	1.16e-6	Partial epilepsies;
KIRP	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.75	-6.88	-0.4	4.89e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06223186	chr7:1544111	INTS1	0.45	6.16	0.37	3.02e-9	Myopia (pathological);
KIRP	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg10104451	chr8:143696006	ARC	-0.68	-7.44	-0.43	1.71e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17465462	chr3:32148028	GPD1L	-0.49	-6.21	-0.37	2.26e-9	Myopia;
KIRP	cis	rs7119038	0.580	rs7123726	chr11:118694547	T/C	cg19308663	chr11:118741387	NA	0.56	9.33	0.51	6.35e-18	Sjögren's syndrome;
KIRP	cis	rs1629083	0.790	rs951657	chr11:118067621	A/G	cg18857871	chr11:118064634	AMICA1	0.74	10.69	0.56	3.62e-22	Lung cancer;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-4.94	-0.3	1.45e-6	Life satisfaction;
KIRP	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.77	0.4	9.2e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.38	-5.12	-0.31	6.04e-7	Vitiligo;
KIRP	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg10950524	chr7:2139216	MAD1L1	0.32	5.14	0.31	5.61e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.48	-4.91	-0.3	1.65e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.69	-9.06	-0.5	4.23e-17	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22903657	chr4:1355424	KIAA1530	-0.5	-7.03	-0.41	2.01e-11	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09606734	chr11:47511307	CUGBP1	0.45	6.35	0.38	1.06e-9	Survival in pancreatic cancer;
KIRP	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg03474202	chr17:45855739	NA	-0.48	-7.39	-0.43	2.26e-12	IgG glycosylation;
KIRP	cis	rs12580194	0.593	rs7960719	chr12:55722035	G/A	cg11794356	chr12:55725991	OR6C3	-0.58	-8.41	-0.47	3.4e-15	Cancer;
KIRP	trans	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg13565492	chr6:43139072	SRF	-0.93	-8.61	-0.48	8.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg07862535	chr7:139043722	LUC7L2	0.46	5.2	0.31	4.28e-7	Diisocyanate-induced asthma;
KIRP	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08109568	chr15:31115862	NA	-0.77	-8.49	-0.48	2.04e-15	Huntington's disease progression;
KIRP	cis	rs7084402	0.902	rs1649016	chr10:60288540	T/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.77e-23	Refractive error;
KIRP	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.93	-14.27	-0.67	4.4e-34	Body mass index;
KIRP	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs3752645	1.000	rs11767753	chr7:106723467	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-4.95	-0.3	1.36e-6	Bladder cancer (smoking interaction);
KIRP	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.65	7.05	0.41	1.82e-11	DNA methylation (variation);
KIRP	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg18154014	chr19:37997991	ZNF793	0.73	7.77	0.44	2.2e-13	Coronary artery calcification;
KIRP	cis	rs728478	1.000	rs728478	chr17:57466504	C/T	cg16535752	chr17:57448097	YPEL2	-0.23	-5.36	-0.32	1.89e-7	QT interval;
KIRP	cis	rs155346	0.625	rs264351	chr5:139364695	T/C	cg24724630	chr5:139362307	NRG2	-0.41	-5.49	-0.33	1.02e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.85	12.33	0.62	1.63e-27	Calcium levels;
KIRP	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.49	-6.43	-0.38	6.71e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.65	-0.39	1.92e-10	Urinary tract infection frequency;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg02733842	chr7:1102375	C7orf50	0.57	5.85	0.35	1.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7246760	1.000	rs67509260	chr19:9864321	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.09	-0.54	3.04e-20	Pursuit maintenance gain;
KIRP	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.5	-5.96	-0.36	8.68e-9	Bone mineral density;
KIRP	cis	rs259842	0.725	rs7588035	chr2:180669808	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.41	-5.94	-0.35	9.86e-9	Blood protein levels;
KIRP	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg22705602	chr4:152727874	NA	0.54	9.37	0.51	4.75e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	6.33	0.37	1.17e-9	Menopause (age at onset);
KIRP	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg16141378	chr3:129829833	LOC729375	0.65	8.92	0.49	1.12e-16	Neuroticism;
KIRP	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg06935464	chr4:38784597	TLR10	0.5	5.09	0.31	7.08e-7	Breast cancer;
KIRP	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg24009623	chr19:33667908	NA	0.5	6.19	0.37	2.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3134353	1.000	rs3134353	chr8:101947453	A/T	cg07585502	chr8:101912084	NA	-0.41	-5.18	-0.31	4.73e-7	Body mass index;
KIRP	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg09408571	chr1:101003634	GPR88	-0.24	-5.42	-0.33	1.44e-7	Monocyte count;
KIRP	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg13147721	chr7:65941812	NA	-1.04	-7.14	-0.41	1.06e-11	Diabetic kidney disease;
KIRP	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg07856975	chr6:36356162	ETV7	0.37	5.58	0.34	6.31e-8	Platelet distribution width;
KIRP	cis	rs2425143	1.000	rs2425149	chr20:34359587	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-5.97	-0.36	8.25e-9	Blood protein levels;
KIRP	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	5.95	0.35	9.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs953387	1.000	rs4954392	chr2:136901607	A/G	cg05194412	chr2:137003533	NA	-0.41	-5.28	-0.32	2.81e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3087591	0.615	rs12943365	chr17:29680526	C/G	cg24425628	chr17:29625626	OMG;NF1	0.47	6.32	0.37	1.24e-9	Hip circumference;
KIRP	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.63	-0.52	7.59e-19	Neuroticism;
KIRP	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.86	-0.49	1.63e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08692423	chr21:45148864	PDXK	0.52	6.74	0.39	1.14e-10	Smoking initiation;
KIRP	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.58	7.25	0.42	5.25e-12	Monobrow;
KIRP	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg05896524	chr21:47604654	C21orf56	0.4	5.06	0.31	8.12e-7	Testicular germ cell tumor;
KIRP	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.19	-0.31	4.36e-7	Metabolite levels;
KIRP	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.53e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg24110177	chr3:50126178	RBM5	-0.66	-7.52	-0.43	1.01e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.97	0.36	8.3e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg21226059	chr5:178986404	RUFY1	0.45	6.91	0.4	4.22e-11	Lung cancer;
KIRP	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg00852783	chr1:26633632	UBXN11	-0.58	-5.96	-0.36	8.73e-9	Obesity-related traits;
KIRP	cis	rs6466055	0.748	rs9640686	chr7:104867330	T/G	cg04380332	chr7:105027541	SRPK2	0.63	9.26	0.51	1.04e-17	Schizophrenia;
KIRP	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.15	0.37	3.13e-9	Mean corpuscular volume;
KIRP	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	8.41	0.47	3.27e-15	Lung cancer in ever smokers;
KIRP	cis	rs8141529	0.529	rs5762780	chr22:29151760	G/A	cg02153584	chr22:29168773	CCDC117	0.56	5.1	0.31	6.94e-7	Lymphocyte counts;
KIRP	cis	rs6577655	0.517	rs62525562	chr8:135587076	C/T	cg17885191	chr8:135476712	NA	0.66	6.54	0.38	3.58e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2860975	1.000	rs7899746	chr10:96787859	T/C	cg09036531	chr10:96991505	NA	-0.52	-6.66	-0.39	1.81e-10	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg08131204	chr22:41487073	MIR1281	-0.42	-4.92	-0.3	1.56e-6	Neuroticism;
KIRP	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg27411982	chr8:10470053	RP1L1	-0.42	-5.25	-0.32	3.32e-7	Triglycerides;
KIRP	cis	rs9436747	0.585	rs11581702	chr1:65987659	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.56	-5.92	-0.35	1.1e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs9400467	0.537	rs3218591	chr6:111696129	T/A	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg05938607	chr10:60274200	BICC1	0.41	10.01	0.54	5.21e-20	Refractive error;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24074884	chr19:17356310	NR2F6	0.51	7.07	0.41	1.6e-11	Survival in pancreatic cancer;
KIRP	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.82	-10.85	-0.57	1.13e-22	Parkinson's disease;
KIRP	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	4.03e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6832769	1.000	rs6812042	chr4:56396079	A/C	cg05960024	chr4:56376020	CLOCK	0.74	9.55	0.52	1.41e-18	Personality dimensions;
KIRP	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg19636519	chr7:99541626	NA	0.32	5.92	0.35	1.08e-8	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16106770	chr11:120206550	ARHGEF12	0.44	6.23	0.37	1.99e-9	Survival in pancreatic cancer;
KIRP	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	5.12	0.31	6.15e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.44	-0.43	1.68e-12	Bladder cancer;
KIRP	cis	rs2273156	0.570	rs11156875	chr14:35619816	A/G	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.2	-0.31	4.15e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.66	6.18	0.37	2.64e-9	Neutrophil percentage of white cells;
KIRP	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg23601095	chr6:26197514	HIST1H3D	0.98	8.28	0.47	8.02e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs16854884	1.000	rs1961542	chr3:143765503	G/A	cg06585982	chr3:143692056	C3orf58	0.54	6.11	0.36	3.82e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.11	0.61	8.89e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.67	-0.44	3.89e-13	Total cholesterol levels;
KIRP	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.7	-6.75	-0.4	1.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	0.83	9.89	0.53	1.22e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg26531700	chr6:26746687	NA	0.5	7.16	0.42	9.55e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4363506	0.646	rs10765111	chr10:129272971	C/T	cg07804728	chr10:129284050	NA	0.41	5.58	0.34	6.27e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg04025307	chr7:1156635	C7orf50	0.83	8.97	0.5	7.55e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.64	-9.13	-0.5	2.5e-17	Lung cancer;
KIRP	cis	rs9921338	0.961	rs4780357	chr16:11370971	G/A	cg00044050	chr16:11439710	C16orf75	-0.48	-4.96	-0.3	1.33e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.66	-6.99	-0.41	2.55e-11	Lymphocyte counts;
KIRP	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg10495392	chr1:46806563	NSUN4	0.48	5.48	0.33	1.04e-7	Menopause (age at onset);
KIRP	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	1.09	7.97	0.45	5.87e-14	Mitochondrial DNA levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09527123	chr13:114806955	RASA3	0.5	6.13	0.36	3.45e-9	Interleukin-4 levels;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg27144592	chr16:783916	NARFL	0.37	5.26	0.32	3.19e-7	Height;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.55	0.52	1.42e-18	Lung cancer;
KIRP	cis	rs7017914	1.000	rs13253842	chr8:71625503	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs2346160	0.831	rs1467391	chr6:167690062	A/G	cg27333441	chr6:167680455	NA	-0.44	-5.77	-0.35	2.41e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg27205649	chr11:78285834	NARS2	-0.53	-4.94	-0.3	1.46e-6	Testicular germ cell tumor;
KIRP	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.89	11.96	0.61	2.75e-26	Bipolar disorder;
KIRP	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.65	9.41	0.51	3.6e-18	Schizophrenia;
KIRP	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.67	-6.82	-0.4	6.95e-11	Axial length;
KIRP	cis	rs7538876	0.967	rs72637463	chr1:17719089	G/A	cg07394400	chr1:17752023	RCC2	-0.36	-5.13	-0.31	5.9e-7	Basal cell carcinoma;
KIRP	cis	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.23	0.32	3.59e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2273156	0.517	rs7159324	chr14:35626997	C/T	cg09327582	chr14:35236912	BAZ1A	0.5	5.2	0.31	4.1e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs3736485	0.966	rs6493498	chr15:51754451	T/C	cg14296394	chr15:51910925	DMXL2	-0.36	-5.4	-0.33	1.6e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.59	7.41	0.43	2e-12	Tonsillectomy;
KIRP	cis	rs8077577	0.945	rs62072496	chr17:18124743	G/A	cg18869244	chr17:18121946	NA	0.5	5.41	0.33	1.49e-7	Obesity-related traits;
KIRP	trans	rs4498364	0.541	rs1206154	chr6:97548919	G/A	cg01048931	chr7:55639931	VOPP1	0.48	6.06	0.36	5.05e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs4356932	1.000	rs4859595	chr4:76950062	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs71277158	0.688	rs7638400	chr3:169837787	A/G	cg04067573	chr3:169899625	PHC3	0.65	6.14	0.36	3.29e-9	Prostate cancer;
KIRP	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.01	-11.54	-0.59	6.79e-25	Colorectal cancer;
KIRP	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.7	10.18	0.54	1.52e-20	Lymphocyte counts;
KIRP	cis	rs10875746	0.669	rs17122812	chr12:48597053	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-5.26	-0.32	3.15e-7	Longevity (90 years and older);
KIRP	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg05156742	chr15:59063176	FAM63B	0.49	5.57	0.33	6.62e-8	Schizophrenia;
KIRP	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.76	8.75	0.49	3.5e-16	Corneal astigmatism;
KIRP	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.83	-0.4	6.63e-11	Systolic blood pressure;
KIRP	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.46	5.78	0.35	2.27e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.78	10.2	0.55	1.28e-20	Aortic root size;
KIRP	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.95	-0.35	9.4e-9	Glomerular filtration rate;
KIRP	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg21466736	chr12:48725269	NA	-0.48	-6.48	-0.38	4.92e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs7084402	0.967	rs1658478	chr10:60289551	C/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg15556689	chr8:8085844	FLJ10661	0.67	9.02	0.5	5.52e-17	Mood instability;
KIRP	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.69	-8.42	-0.47	3.22e-15	Cognitive function;
KIRP	cis	rs9608946	1.000	rs8137267	chr22:30889139	G/C	cg23383138	chr22:30885012	SEC14L4	0.4	4.93	0.3	1.52e-6	Red cell distribution width;
KIRP	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.64	8.49	0.48	1.91e-15	Aortic root size;
KIRP	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg17514665	chr17:1657533	SERPINF2	-0.44	-5.46	-0.33	1.17e-7	Serum albumin level;
KIRP	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg07898084	chr13:53029385	CKAP2	0.53	6.36	0.38	9.68e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2882667	0.690	rs10045605	chr5:138272147	T/C	cg04439458	chr5:138467593	SIL1	-0.36	-4.87	-0.3	2.04e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7688540	0.515	rs28415975	chr4:260166	A/T	cg17891759	chr4:299121	NA	-0.4	-4.95	-0.3	1.37e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	1.02	21.94	0.81	7.85e-60	Multiple myeloma;
KIRP	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.54	6.31	0.37	1.28e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg09355771	chr2:177043147	NA	0.46	6.09	0.36	4.38e-9	IgG glycosylation;
KIRP	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.42	-5.61	-0.34	5.39e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg00310523	chr12:86230176	RASSF9	-0.56	-8.67	-0.48	6.08e-16	Major depressive disorder;
KIRP	cis	rs930036	0.628	rs13026444	chr2:171933014	G/A	cg12801329	chr2:171670795	NA	0.43	4.89	0.3	1.85e-6	Menopause (age at onset);
KIRP	cis	rs6541297	0.645	rs4846920	chr1:230301574	A/G	cg05784532	chr1:230284198	GALNT2	0.35	4.92	0.3	1.59e-6	Coronary artery disease;
KIRP	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg19847130	chr8:10466454	RP1L1	0.4	6.18	0.37	2.7e-9	Neuroticism;
KIRP	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.7	7.6	0.44	6.03e-13	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02282317	chr17:35306345	AATF	0.5	6.11	0.36	3.97e-9	Parkinson's disease;
KIRP	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg17678928	chr4:25913177	NA	-0.4	-5.04	-0.31	8.82e-7	Obesity-related traits;
KIRP	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.47	-5.65	-0.34	4.43e-8	Initial pursuit acceleration;
KIRP	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.76	-11.02	-0.57	3.16e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg00204512	chr16:28754710	NA	0.41	5.34	0.32	2.16e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.53	-6.9	-0.4	4.35e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6500395	0.584	rs8059077	chr16:48742029	T/C	cg04672837	chr16:48644449	N4BP1	0.41	4.95	0.3	1.37e-6	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg24879335	chr3:133465180	TF	-0.43	-6.95	-0.41	3.25e-11	Iron status biomarkers;
KIRP	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.93e-9	Breast cancer;
KIRP	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg27347728	chr4:17578864	LAP3	-0.4	-4.89	-0.3	1.85e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg13565492	chr6:43139072	SRF	-0.96	-8.82	-0.49	2.08e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.48	5.61	0.34	5.46e-8	Diastolic blood pressure;
KIRP	cis	rs2625529	0.730	rs4777485	chr15:72389384	G/C	cg16672083	chr15:72433130	SENP8	-0.39	-5.0	-0.3	1.1e-6	Red blood cell count;
KIRP	cis	rs240764	0.817	rs12201852	chr6:101149576	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-5.23	-0.32	3.65e-7	Neuroticism;
KIRP	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.93	-0.4	3.58e-11	Bipolar disorder;
KIRP	cis	rs17065868	1.000	rs7322132	chr13:45074212	G/A	cg10246903	chr13:45222710	NA	0.6	6.1	0.36	4.2e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg17333051	chr19:2783644	SGTA	0.38	4.85	0.3	2.18e-6	Total cholesterol levels;
KIRP	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	7.73	0.44	2.78e-13	Personality dimensions;
KIRP	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg03468072	chr12:39539422	NA	0.39	5.7	0.34	3.47e-8	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.08	-11.83	-0.6	7.18e-26	Vitiligo;
KIRP	cis	rs9815354	0.767	rs17281609	chr3:41833432	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.42	0.47	3.11e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg12140854	chr5:148520817	ABLIM3	-0.63	-6.5	-0.38	4.35e-10	Breast cancer;
KIRP	trans	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg24644049	chr4:85504048	CDS1	1.1	7.25	0.42	5.49e-12	Skin colour saturation;
KIRP	cis	rs9596863	0.898	rs9563178	chr13:54373714	C/A	ch.13.53330881F	chr13:54432880	NA	0.61	6.0	0.36	7.1e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg10760299	chr15:45669010	GATM	0.35	5.13	0.31	5.78e-7	Homoarginine levels;
KIRP	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg00629941	chr15:75287862	SCAMP5	-0.49	-5.2	-0.31	4.22e-7	Blood trace element (Zn levels);
KIRP	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.97	-0.3	1.27e-6	Metabolite levels;
KIRP	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.51	7.17	0.42	8.53e-12	Mean corpuscular volume;
KIRP	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg23262073	chr20:60523788	NA	-0.56	-5.62	-0.34	5.16e-8	Body mass index;
KIRP	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.52	-8.65	-0.48	6.75e-16	Height;
KIRP	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg09137382	chr11:130731461	NA	0.53	7.9	0.45	9.33e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.78	9.62	0.52	8.61e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg24972876	chr7:65420302	NA	-0.42	-5.76	-0.34	2.53e-8	Calcium levels;
KIRP	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.55	-6.81	-0.4	7.23e-11	Uric acid clearance;
KIRP	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.6	-8.67	-0.48	5.87e-16	Schizophrenia;
KIRP	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs16858210	0.607	rs35205152	chr3:183563329	C/A	cg25686905	chr3:183603175	PARL	-0.49	-5.33	-0.32	2.21e-7	Menopause (age at onset);
KIRP	cis	rs930036	0.602	rs71415229	chr2:171771808	G/A	cg12801329	chr2:171670795	NA	0.48	5.3	0.32	2.59e-7	Menopause (age at onset);
KIRP	cis	rs1134634	0.520	rs56041141	chr4:15599845	C/T	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.7	-0.34	3.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.6	-9.13	-0.5	2.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.2	-0.37	2.35e-9	Daytime sleep phenotypes;
KIRP	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.87	13.59	0.65	9.63e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.52	-5.67	-0.34	4.01e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9309473	0.500	rs13022837	chr2:73912567	T/A	cg20560298	chr2:73613845	ALMS1	0.51	6.31	0.37	1.26e-9	Metabolite levels;
KIRP	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.62	-8.26	-0.47	8.97e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg10117171	chr1:25599238	RHD	0.39	5.26	0.32	3.21e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg01877450	chr7:97915802	BRI3	-0.53	-6.86	-0.4	5.44e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg01689657	chr7:91764605	CYP51A1	0.38	5.47	0.33	1.08e-7	Breast cancer;
KIRP	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs11644362	0.966	rs35678048	chr16:12989235	A/G	cg06890432	chr16:12997467	SHISA9	-0.42	-6.56	-0.39	3.12e-10	Positive affect;Subjective well-being;
KIRP	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.58e-6	Total body bone mineral density;
KIRP	trans	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.92e-11	Skin colour saturation;
KIRP	cis	rs7577696	0.597	rs2280968	chr2:32290040	G/T	cg02381751	chr2:32503542	YIPF4	-0.52	-5.26	-0.32	3.08e-7	Inflammatory biomarkers;
KIRP	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg26207909	chr14:103986467	CKB	-0.48	-6.2	-0.37	2.42e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11673344	0.642	rs55755939	chr19:37844625	T/C	cg14683738	chr19:37701593	ZNF585B	-0.43	-5.02	-0.31	9.71e-7	Obesity-related traits;
KIRP	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.41	-0.33	1.46e-7	Platelet count;
KIRP	cis	rs367943	0.712	rs26961	chr5:112736779	A/G	cg12552261	chr5:112820674	MCC	0.56	6.69	0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs17065868	1.000	rs17065995	chr13:45222314	C/T	cg10246903	chr13:45222710	NA	0.76	8.51	0.48	1.68e-15	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4936894	0.500	rs11219567	chr11:124166375	T/C	cg27160556	chr11:124181099	OR8D1	-0.45	-6.48	-0.38	4.84e-10	Aging (time to death);
KIRP	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.76	9.36	0.51	5.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg23950597	chr19:37808831	NA	-0.84	-8.61	-0.48	9.12e-16	Coronary artery calcification;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16650896	chr7:64838774	ZNF92	0.59	6.52	0.38	4.03e-10	Lung cancer in ever smokers;
KIRP	cis	rs908922	1.000	rs1199150	chr1:152455602	T/C	cg09873164	chr1:152488093	CRCT1	0.5	5.56	0.33	6.87e-8	Hair morphology;
KIRP	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.41	7.11	0.41	1.24e-11	Renal cell carcinoma;
KIRP	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg26248373	chr2:1572462	NA	-0.66	-7.79	-0.44	1.88e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs490234	0.702	rs4838275	chr9:128352785	C/T	cg14078157	chr9:128172775	NA	-0.61	-7.13	-0.41	1.11e-11	Mean arterial pressure;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10996143	chr20:1373995	FKBP1A	0.47	6.02	0.36	6.31e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.66	0.66	5.36e-32	Cognitive function;
KIRP	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.23	0.46	1.1e-14	Schizophrenia;
KIRP	cis	rs13361707	0.920	rs1345778	chr5:40712797	A/C	cg01087697	chr5:40835557	RPL37	-0.48	-5.37	-0.32	1.83e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg20312557	chr2:97357134	FER1L5	-0.79	-5.43	-0.33	1.34e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg13385521	chr17:29058706	SUZ12P	0.57	5.57	0.33	6.75e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15832574	chr1:63901727	ALG6	-0.42	-6.06	-0.36	5.07e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.4	-0.47	3.51e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg04731861	chr2:219085781	ARPC2	0.3	7.65	0.44	4.53e-13	Colorectal cancer;
KIRP	cis	rs13424612	0.839	rs4149548	chr2:240933241	A/G	cg01812947	chr2:240904978	NDUFA10	-0.41	-5.66	-0.34	4.14e-8	Odorant perception (isobutyraldehyde);
KIRP	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	5.84	0.35	1.64e-8	Red blood cell count;
KIRP	cis	rs137699	0.652	rs137707	chr22:39751401	T/C	cg24399712	chr22:39784796	NA	-0.62	-7.36	-0.42	2.77e-12	IgG glycosylation;
KIRP	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	cg04338863	chr8:33670619	NA	0.48	6.27	0.37	1.57e-9	Body mass index;
KIRP	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg17554472	chr22:41940697	POLR3H	-0.43	-5.12	-0.31	6.23e-7	Vitiligo;
KIRP	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6893807	0.620	rs34483452	chr5:87986314	C/A	cg24804195	chr5:87968844	LOC645323	0.6	5.66	0.34	4.21e-8	Body mass index;
KIRP	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg11211951	chr8:145729740	GPT	-0.34	-5.64	-0.34	4.7e-8	Age at first birth;
KIRP	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.25	-0.32	3.36e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4865875	0.579	rs57045622	chr5:54184721	A/T	cg08820104	chr5:54183619	NA	-0.73	-5.13	-0.31	5.79e-7	Sense of smell;
KIRP	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.28	0.32	2.9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.67	8.49	0.48	1.98e-15	Prudent dietary pattern;
KIRP	cis	rs684232	0.583	rs2543776	chr17:557149	G/A	cg12384639	chr17:618140	VPS53	0.48	6.07	0.36	4.82e-9	Prostate cancer;
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.91e-8	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14311108	chr9:139377450	C9orf163;SEC16A	0.49	6.96	0.41	3.09e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg10047753	chr17:41438598	NA	1.15	18.22	0.76	1.51e-47	Menopause (age at onset);
KIRP	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg18478394	chr8:109455254	TTC35	-0.47	-5.67	-0.34	3.95e-8	Dupuytren's disease;
KIRP	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.94	0.5	9.27e-17	IgG glycosylation;
KIRP	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.13	0.31	5.94e-7	Asthma;
KIRP	cis	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg11502198	chr6:26597334	ABT1	-0.84	-5.17	-0.31	4.89e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.63	-7.59	-0.44	6.63e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18932078	chr1:2524107	MMEL1	-0.43	-6.04	-0.36	5.62e-9	Ulcerative colitis;
KIRP	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg10547527	chr2:198650123	BOLL	-0.56	-5.06	-0.31	8.05e-7	Ulcerative colitis;
KIRP	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.83	0.4	6.73e-11	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4517514	0.509	rs11018894	chr11:89904238	C/A	cg06174606	chr11:89959870	NA	-0.57	-5.91	-0.35	1.11e-8	Trans fatty acid levels;
KIRP	cis	rs3027234	0.734	rs11650309	chr17:8129538	C/G	cg06726167	chr17:8076949	TMEM107	-0.55	-5.63	-0.34	5.01e-8	Telomere length;
KIRP	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.82	-12.8	-0.63	4.27e-29	Blood metabolite levels;
KIRP	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.2	0.42	7.27e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg23625390	chr15:77176239	SCAPER	0.48	6.42	0.38	7.01e-10	Blood metabolite levels;
KIRP	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.39	-6.31	-0.37	1.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg27490568	chr2:178487706	NA	-0.66	-8.32	-0.47	6.05e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-5.38	-0.32	1.74e-7	Educational attainment;
KIRP	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.38	4.91	0.3	1.69e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6479901	0.501	rs4414112	chr10:64875546	A/G	cg25356468	chr10:64875536	NA	-0.46	-5.37	-0.32	1.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.97	0.41	2.94e-11	Lymphocyte counts;
KIRP	cis	rs2535633	0.631	rs2257216	chr3:52968726	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-5.45	-0.33	1.25e-7	Body mass index;
KIRP	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.84	9.77	0.53	2.91e-19	Prostate-specific antigen levels;
KIRP	cis	rs503734	0.502	rs348864	chr3:100910127	T/G	cg27318481	chr3:100970896	IMPG2	-0.53	-7.16	-0.42	9.25e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1971256	0.500	rs17081325	chr6:151817992	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-6.35	-0.38	1.02e-9	Endometriosis;
KIRP	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg24112000	chr20:60950667	NA	0.6	9.1	0.5	3.26e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs17095355	1.000	rs12570230	chr10:111691614	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.92	-0.35	1.08e-8	Biliary atresia;
KIRP	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-4.99	-0.3	1.16e-6	Cognitive function;
KIRP	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.95	-15.65	-0.71	8.53e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.86	12.67	0.63	1.17e-28	Colorectal cancer;
KIRP	cis	rs9815354	0.812	rs17215498	chr3:41829679	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.74	-0.34	2.8e-8	Height;
KIRP	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg11846333	chr4:119757529	SEC24D	1.17	7.18	0.42	8.16e-12	Cannabis dependence symptom count;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.85	0.53	1.67e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.97	-14.99	-0.69	1.54e-36	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11302992	chr11:31789446	ELP4	-0.41	-6.69	-0.39	1.49e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	7.88	0.45	1.08e-13	Lung function (FEV1/FVC);
KIRP	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg24253500	chr15:84953950	NA	-0.41	-5.21	-0.32	3.99e-7	P wave terminal force;
KIRP	cis	rs9488822	0.662	rs195521	chr6:116244114	T/C	cg05304507	chr6:116381966	FRK	0.2	5.15	0.31	5.23e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.82	11.33	0.59	3.17e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg07701084	chr6:150067640	NUP43	0.69	9.42	0.51	3.44e-18	Lung cancer;
KIRP	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10988449	0.830	rs10988448	chr9:132368645	C/A	cg18327994	chr9:132372705	NA	-0.62	-5.77	-0.35	2.36e-8	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03520103	chr2:74757144	HTRA2;AUP1	-0.52	-6.65	-0.39	1.9e-10	Myopia;
KIRP	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.73	-8.45	-0.47	2.49e-15	Body mass index;
KIRP	trans	rs4131099	0.793	rs11076452	chr16:51374733	C/T	cg02207200	chr8:17353980	SLC7A2	0.56	6.29	0.37	1.46e-9	Personality dimensions;
KIRP	cis	rs6499755	0.712	rs31105	chr16:55375723	C/T	cg05099576	chr16:55362342	IRX6	0.28	5.74	0.34	2.84e-8	Hypospadias;
KIRP	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.78	-10.6	-0.56	7.47e-22	Aortic root size;
KIRP	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg25019033	chr10:957182	NA	-0.72	-9.16	-0.5	2.04e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs78487399	0.808	rs7578597	chr2:43732823	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.06	-0.31	8.28e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-5.16	-0.31	5.04e-7	Breast cancer;
KIRP	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.39	-0.51	4.2e-18	Hemoglobin concentration;
KIRP	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.51	-0.33	9.2e-8	Ileal carcinoids;
KIRP	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg21605333	chr4:119757512	SEC24D	1.47	9.89	0.53	1.26e-19	Cannabis dependence symptom count;
KIRP	cis	rs1978968	0.956	rs7291304	chr22:18421821	C/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-6.96	-0.41	3.07e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg24375607	chr4:120327624	NA	0.57	6.53	0.38	3.76e-10	Corneal astigmatism;
KIRP	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg20936604	chr3:58311152	NA	-0.67	-5.03	-0.31	9.56e-7	Cholesterol, total;
KIRP	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg23690444	chr14:81902736	NA	0.62	7.32	0.42	3.52e-12	Prudent dietary pattern;
KIRP	cis	rs988913	0.515	rs11756299	chr6:54951016	A/G	cg03513858	chr6:54763001	FAM83B	-0.36	-5.41	-0.33	1.5e-7	Menarche (age at onset);
KIRP	cis	rs687432	0.885	rs7121128	chr11:57743931	A/C	cg19752551	chr11:57585705	CTNND1	-0.69	-9.1	-0.5	3.23e-17	Parkinson's disease;
KIRP	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	9.8	0.53	2.27e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	4.91	0.3	1.63e-6	Personality dimensions;
KIRP	cis	rs9644630	0.901	rs13276417	chr8:19350199	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.25	-4.9	-0.3	1.73e-6	Oropharynx cancer;
KIRP	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14893161	chr1:205819251	PM20D1	0.45	5.03	0.31	9.37e-7	Parkinson's disease;
KIRP	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg02887458	chr19:19495540	GATAD2A	0.48	5.75	0.34	2.65e-8	Bipolar disorder;
KIRP	cis	rs220324	0.954	rs467479	chr21:43592910	G/C	cg15319517	chr21:43638949	ABCG1	0.44	5.19	0.31	4.34e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.88	9.07	0.5	3.78e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6723108	0.654	rs669759	chr2:135291135	C/T	cg25422880	chr2:135218333	TMEM163	-0.39	-5.27	-0.32	3.03e-7	Type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg04995300	chr3:66848608	NA	0.78	8.75	0.49	3.47e-16	Type 2 diabetes;
KIRP	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.77	10.95	0.57	5.61e-23	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13456812	chr6:167369504	RNASET2	0.6	6.99	0.41	2.56e-11	Smoking initiation;
KIRP	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg02297831	chr4:17616191	MED28	0.53	6.6	0.39	2.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	9.41	0.51	3.58e-18	Renal function-related traits (BUN);
KIRP	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg02297831	chr4:17616191	MED28	0.54	6.42	0.38	7.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	4.06e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg20701182	chr2:24300061	SF3B14	0.51	5.27	0.32	3.02e-7	Asthma;
KIRP	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-17.25	-0.74	3.09e-44	Chronic sinus infection;
KIRP	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05220968	chr6:146057943	EPM2A	-0.39	-4.98	-0.3	1.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg17724175	chr1:150552817	MCL1	0.32	5.36	0.32	1.95e-7	Tonsillectomy;
KIRP	cis	rs4356932	0.935	rs6532160	chr4:76978199	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.61	9.34	0.51	6.2e-18	C-reactive protein levels;
KIRP	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.93	11.35	0.59	2.69e-24	Migraine;
KIRP	cis	rs9547996	1.000	rs9547996	chr13:38220161	T/G	cg13634560	chr13:38173852	POSTN	-0.38	-5.06	-0.31	8.11e-7	Diastolic blood pressure;
KIRP	cis	rs1376877	0.519	rs4675332	chr2:204190907	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.53	5.26	0.32	3.1e-7	Subclinical atherosclerosis traits (other);
KIRP	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07570687	chr10:102243282	WNT8B	0.51	6.75	0.4	1.04e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs3812049	0.532	rs251390	chr5:127538346	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	8.56	0.48	1.22e-15	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.77	-10.29	-0.55	6.74e-21	Huntington's disease progression;
KIRP	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.36	0.38	9.86e-10	Subjective well-being;
KIRP	cis	rs1010254	0.559	rs72808320	chr5:151741858	G/C	cg12297329	chr5:152029980	NA	-0.66	-6.62	-0.39	2.28e-10	Optic nerve measurement (cup area);
KIRP	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg23335576	chr14:104009727	NA	0.4	5.47	0.33	1.11e-7	Body mass index;
KIRP	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.92	-11.06	-0.58	2.48e-23	Post bronchodilator FEV1;
KIRP	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg13180566	chr4:1052158	NA	-0.5	-5.04	-0.31	9.2e-7	Recombination rate (females);
KIRP	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg27205649	chr11:78285834	NARS2	-0.54	-5.05	-0.31	8.55e-7	Testicular germ cell tumor;
KIRP	cis	rs9534288	0.789	rs4942470	chr13:46636652	A/G	cg15192986	chr13:46630673	CPB2	-0.86	-10.71	-0.56	3.31e-22	Blood protein levels;
KIRP	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-8.29	-0.47	7.6e-15	Coronary artery disease;
KIRP	cis	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg06585982	chr3:143692056	C3orf58	0.59	7.39	0.43	2.28e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg04691961	chr3:161091175	C3orf57	0.59	9.51	0.52	1.77e-18	Morning vs. evening chronotype;
KIRP	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.46	0.52	2.52e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg12756093	chr1:115239321	AMPD1	0.55	7.49	0.43	1.21e-12	Autism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23092527	chr1:8703002	RERE	0.5	6.16	0.37	2.99e-9	Interleukin-4 levels;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg08901578	chr4:187885870	NA	-0.52	-8.19	-0.46	1.42e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.48	5.38	0.32	1.71e-7	Schizophrenia;
KIRP	trans	rs7980799	0.840	rs7315695	chr12:33551841	G/C	cg26384229	chr12:38710491	ALG10B	-0.54	-6.7	-0.39	1.43e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	6.04	0.36	5.79e-9	Motion sickness;
KIRP	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.5	7.6	0.44	6.29e-13	Testicular germ cell tumor;
KIRP	cis	rs11610422	1.000	rs12824814	chr12:31414473	G/T	cg14306366	chr12:31406441	NA	-0.58	-6.15	-0.37	3.04e-9	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03971828	chr1:25071582	CLIC4	0.47	6.18	0.37	2.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	5.7	0.34	3.38e-8	Ovarian reserve;
KIRP	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg04733989	chr22:42467013	NAGA	0.56	7.48	0.43	1.32e-12	Cognitive function;
KIRP	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.91	-15.83	-0.71	2.12e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1009181	0.585	rs9379830	chr6:26173767	T/C	cg13736514	chr6:26305472	NA	-0.55	-5.74	-0.34	2.73e-8	Childhood ear infection;
KIRP	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg04935436	chr20:30431758	NA	0.48	5.61	0.34	5.35e-8	Mean corpuscular hemoglobin;
KIRP	trans	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg06521331	chr12:34319734	NA	-0.53	-6.46	-0.38	5.62e-10	Bladder cancer;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg12486944	chr17:80159399	CCDC57	-0.41	-5.62	-0.34	5.15e-8	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.98	10.89	0.57	8.49e-23	HIV-1 control;
KIRP	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.85	-11.0	-0.57	3.83e-23	Cognitive function;
KIRP	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.62	0.52	8.2e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	14.65	0.68	2.27e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg27411982	chr8:10470053	RP1L1	0.4	4.9	0.3	1.76e-6	Neuroticism;
KIRP	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg18932078	chr1:2524107	MMEL1	0.44	5.83	0.35	1.73e-8	Ulcerative colitis;
KIRP	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Parkinson's disease;
KIRP	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg00241281	chr14:105779794	PACS2	-0.36	-4.9	-0.3	1.77e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2400749	0.830	rs9671899	chr14:100033629	A/G	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.44	-0.33	1.32e-7	Alzheimer's disease (survival time);
KIRP	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg21858823	chr1:15850916	CASP9	0.53	5.63	0.34	4.93e-8	Systolic blood pressure;
KIRP	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.21	-0.32	4.01e-7	Height;
KIRP	cis	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg11266682	chr4:10021025	SLC2A9	0.39	6.63	0.39	2.07e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs13065560	0.594	rs4364115	chr3:38895359	C/T	cg01426195	chr3:39028469	NA	-0.42	-6.79	-0.4	8.26e-11	Interleukin-18 levels;
KIRP	cis	rs1440410	0.835	rs13150694	chr4:144077053	G/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.22	0.37	2.16e-9	Resting heart rate;
KIRP	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg06121193	chr1:90282411	NA	-0.49	-7.02	-0.41	2.16e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2901656	0.677	rs1063412	chr1:172410967	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	6.11	0.36	3.8e-9	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.45	-5.82	-0.35	1.79e-8	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21593670	chr3:52489874	NISCH	0.45	6.14	0.36	3.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10515953	chr10:61666281	CCDC6	0.45	6.06	0.36	5.19e-9	Survival in pancreatic cancer;
KIRP	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.22	-0.37	2.14e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10203711	0.966	rs4293520	chr2:239567184	A/C	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9815354	1.000	rs1717009	chr3:41946308	T/C	cg03022575	chr3:42003672	ULK4	-0.48	-5.49	-0.33	9.89e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg07653901	chr22:50250238	ZBED4	0.43	5.07	0.31	7.68e-7	Schizophrenia;
KIRP	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.03	0.31	9.68e-7	Alzheimer's disease;
KIRP	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.73	0.53	3.95e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg04935436	chr20:30431758	NA	0.49	6.54	0.39	3.46e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.13	-0.41	1.12e-11	Morning vs. evening chronotype;
KIRP	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg08461457	chr11:2027003	NA	-0.38	-5.09	-0.31	6.99e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs7944584	0.504	rs11039138	chr11:47249223	G/A	cg20307385	chr11:47447363	PSMC3	0.6	7.11	0.41	1.25e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17127132	chr2:85788382	GGCX	0.53	6.07	0.36	4.72e-9	Smoking initiation;
KIRP	cis	rs1867631	0.585	rs12094526	chr1:67126114	A/G	cg13052034	chr1:66999238	SGIP1	0.45	6.92	0.4	3.84e-11	Menopause (age at onset);
KIRP	cis	rs303795	0.562	rs303765	chr12:52264525	A/G	cg27042523	chr12:52245356	NA	0.37	4.92	0.3	1.56e-6	LDL peak particle diameter (total fat intake interaction);
KIRP	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg11845111	chr2:191398756	TMEM194B	-0.66	-7.17	-0.42	8.88e-12	Diastolic blood pressure;
KIRP	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg27068330	chr11:65405492	SIPA1	0.36	4.92	0.3	1.59e-6	Acne (severe);
KIRP	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-6.6	-0.39	2.57e-10	Aortic root size;
KIRP	cis	rs2733310	0.895	rs1657935	chr15:57113106	G/A	cg13626582	chr15:57592083	LOC283663	-0.23	-5.03	-0.31	9.57e-7	Mean platelet volume;
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.7	-0.39	1.43e-10	Longevity;Endometriosis;
KIRP	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg27422857	chr2:105853526	NA	-0.44	-6.13	-0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg01214346	chr17:406501	NA	-0.47	-5.89	-0.35	1.29e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs1014246	0.826	rs11197802	chr10:118472000	T/A	cg14919929	chr10:118506882	NA	-0.57	-7.46	-0.43	1.47e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs870825	0.615	rs2696038	chr4:185610903	C/T	cg04058563	chr4:185651563	MLF1IP	-0.93	-11.67	-0.6	2.49e-25	Blood protein levels;
KIRP	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05472934	chr7:22766657	IL6	0.81	10.59	0.56	7.81e-22	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10070431	chr2:232322438	NCL;SNORD20	-0.53	-6.89	-0.4	4.52e-11	Inflammatory biomarkers;
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg06654118	chr4:1303317	MAEA	0.3	5.37	0.32	1.79e-7	Obesity-related traits;
KIRP	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg16497661	chr14:103986332	CKB	-0.51	-6.75	-0.4	1.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18932078	chr1:2524107	MMEL1	0.43	5.98	0.36	7.76e-9	Multiple sclerosis;
KIRP	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.55	6.89	0.4	4.62e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2120243	0.510	rs7623173	chr3:157119949	A/G	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12211364	chr7:33384022	BBS9	-0.4	-6.06	-0.36	5.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.7	7.74	0.44	2.5e-13	Asthma;
KIRP	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.42	-0.51	3.51e-18	Coronary artery disease;
KIRP	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.56	-8.71	-0.49	4.64e-16	Longevity;
KIRP	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.62	-10.22	-0.55	1.11e-20	Sense of smell;
KIRP	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg15436174	chr10:43711423	RASGEF1A	0.79	8.46	0.47	2.45e-15	Hirschsprung disease;
KIRP	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.07	8.84	0.49	1.91e-16	Mitochondrial DNA levels;
KIRP	cis	rs12595433	1.000	rs1489315	chr15:63292446	C/T	cg03196360	chr15:63270641	NA	-0.29	-5.39	-0.32	1.67e-7	Obesity-related traits;
KIRP	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.71	8.75	0.49	3.57e-16	Cognitive function;
KIRP	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-5.62	-0.34	5.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00554614	chr7:127225750	GCC1	-0.51	-6.23	-0.37	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	6.59	0.39	2.72e-10	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.98	-0.5	7.37e-17	Hirschsprung disease;
KIRP	cis	rs9653442	0.545	rs13032454	chr2:100756009	T/C	cg07810366	chr2:100720526	AFF3	-0.31	-5.1	-0.31	6.84e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.97	13.46	0.65	2.61e-31	Menopause (age at onset);
KIRP	cis	rs7172677	0.737	rs12442392	chr15:75437478	G/T	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6725041	0.717	rs1357138	chr2:213098546	A/T	cg16329650	chr2:213403929	ERBB4	-0.37	-5.24	-0.32	3.53e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs12580194	0.593	rs7313465	chr12:55736863	C/T	cg11794356	chr12:55725991	OR6C3	-0.61	-8.76	-0.49	3.28e-16	Cancer;
KIRP	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg23107878	chr1:152161397	NA	-0.48	-5.27	-0.32	3.01e-7	Inflammatory skin disease;
KIRP	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.42	-0.33	1.41e-7	Platelet count;
KIRP	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	0.83	12.49	0.62	4.86e-28	Body mass index;
KIRP	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg06671706	chr8:8559999	CLDN23	0.58	6.66	0.39	1.8e-10	Obesity-related traits;
KIRP	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20135002	chr11:47629003	NA	-0.47	-5.56	-0.33	6.9e-8	Subjective well-being;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08000278	chr4:109683819	AGXT2L1	-0.46	-6.61	-0.39	2.32e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.08	0.31	7.61e-7	Menopause (age at onset);
KIRP	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.63	-0.34	4.85e-8	Coronary artery disease;
KIRP	cis	rs4654899	0.965	rs4654907	chr1:21521094	C/T	cg05370193	chr1:21551575	ECE1	0.44	6.05	0.36	5.3e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.73	6.96	0.41	2.99e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23129613	chr7:150065255	REPIN1	0.59	6.96	0.41	3.1e-11	Smoking initiation;
KIRP	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg02461776	chr11:598696	PHRF1	0.49	5.22	0.32	3.89e-7	Systemic lupus erythematosus;
KIRP	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg02297831	chr4:17616191	MED28	0.5	6.36	0.38	9.8e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6738485	0.557	rs12988865	chr2:106854386	G/A	cg16099169	chr2:106886729	NA	-0.45	-6.61	-0.39	2.33e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs4073221	0.520	rs13072195	chr3:18199498	C/T	cg07694806	chr3:18168406	NA	-0.77	-6.5	-0.38	4.39e-10	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs78487399	0.808	rs77527404	chr2:43678387	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2562456	0.583	rs4809144	chr19:21772730	C/T	cg00806126	chr19:22604979	ZNF98	-0.67	-6.41	-0.38	7.32e-10	Pain;
KIRP	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.9	-13.03	-0.64	7.06e-30	Tonsillectomy;
KIRP	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.58	-6.52	-0.38	3.85e-10	LDL cholesterol levels;
KIRP	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.76	-11.02	-0.57	3.16e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.32	-0.32	2.33e-7	Educational attainment (years of education);
KIRP	cis	rs1832871	0.505	rs11757895	chr6:158812456	G/T	cg07215822	chr6:158701037	NA	-0.54	-5.74	-0.34	2.71e-8	Height;
KIRP	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg26876637	chr1:152193138	HRNR	0.78	8.9	0.49	1.24e-16	Atopic dermatitis;
KIRP	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg25019033	chr10:957182	NA	-0.61	-7.27	-0.42	4.86e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs9435732	0.778	rs6662202	chr1:17336253	C/T	cg02580006	chr1:16560116	C1orf89	0.42	5.33	0.32	2.17e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.54	7.21	0.42	6.74e-12	HDL cholesterol;
KIRP	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.71	7.35	0.42	2.96e-12	Vitiligo;
KIRP	cis	rs13418717	0.793	rs7425345	chr2:127640396	C/T	cg25501666	chr2:127640322	NA	1.04	10.82	0.57	1.4e-22	Heart failure;
KIRP	cis	rs12153243	0.714	rs17342167	chr5:142895830	A/G	cg13907255	chr5:142895549	NA	-0.39	-5.01	-0.3	1.02e-6	Migraine;
KIRP	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg19731401	chr7:2775893	GNA12	-0.5	-5.69	-0.34	3.58e-8	Childhood ear infection;
KIRP	cis	rs7241530	0.775	rs11081529	chr18:75902735	C/T	cg14642773	chr18:75888474	NA	-0.38	-5.29	-0.32	2.72e-7	Educational attainment (years of education);
KIRP	cis	rs2463822	0.513	rs72919445	chr11:62029078	A/C	cg06239285	chr11:62104954	ASRGL1	-0.79	-6.24	-0.37	1.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7923609	1.000	rs10822163	chr10:65124098	C/G	cg01631684	chr10:65280961	REEP3	-0.51	-5.94	-0.35	9.54e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.43	-6.15	-0.37	3.03e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.93	-15.26	-0.7	1.85e-37	Breast cancer;
KIRP	cis	rs1823913	0.637	rs4853573	chr2:192160592	A/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.18	-0.37	2.61e-9	Obesity-related traits;
KIRP	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.31	-0.47	6.53e-15	Total cholesterol levels;
KIRP	trans	rs877282	0.583	rs112372193	chr10:826602	A/G	cg22713356	chr15:30763199	NA	0.84	8.18	0.46	1.55e-14	Uric acid levels;
KIRP	cis	rs1629083	0.967	rs1715456	chr11:118123517	A/G	cg18857871	chr11:118064634	AMICA1	0.69	9.89	0.53	1.21e-19	Lung cancer;
KIRP	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.13	0.36	3.54e-9	Menopause (age at onset);
KIRP	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.99	-17.66	-0.75	1.2e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg19847130	chr8:10466454	RP1L1	0.33	4.9	0.3	1.71e-6	Retinal vascular caliber;
KIRP	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg23216685	chr1:86174607	ZNHIT6	0.53	7.28	0.42	4.55e-12	Urate levels in overweight individuals;
KIRP	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.52	17.12	0.74	8.3e-44	Opioid sensitivity;
KIRP	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg05043794	chr9:111880884	C9orf5	0.24	5.03	0.31	9.29e-7	Menarche (age at onset);
KIRP	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg18305652	chr10:134549665	INPP5A	0.5	7.84	0.45	1.39e-13	Migraine;
KIRP	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg08923054	chr8:41654455	ANK1	-0.6	-6.23	-0.37	2.04e-9	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13315871	1.000	rs36097398	chr3:58367330	G/A	cg12435725	chr3:58293450	RPP14	-0.5	-5.32	-0.32	2.35e-7	Cholesterol, total;
KIRP	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.82	-8.97	-0.5	7.99e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.47	0.33	1.12e-7	Cognitive test performance;
KIRP	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg01338139	chr15:38987640	C15orf53	-0.56	-6.31	-0.37	1.31e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.87	-0.45	1.12e-13	Heart rate;
KIRP	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg14593290	chr7:50529359	DDC	0.77	8.95	0.5	8.8e-17	Malaria;
KIRP	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg10047753	chr17:41438598	NA	1.06	16.72	0.73	1.94e-42	Menopause (age at onset);
KIRP	cis	rs2346160	0.899	rs206974	chr6:167690300	G/A	cg04673565	chr6:167680447	NA	-0.39	-5.02	-0.3	1.01e-6	Parental extreme longevity (95 years and older);
KIRP	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.04	0.31	9.12e-7	Parkinson's disease;
KIRP	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.79	-7.58	-0.44	7.12e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg00689492	chr4:1303491	MAEA	0.31	5.53	0.33	8.29e-8	Longevity;
KIRP	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-7.08	-0.41	1.49e-11	Coronary artery disease;
KIRP	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.54	-6.37	-0.38	9.13e-10	Type 2 diabetes;
KIRP	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.71	-7.69	-0.44	3.49e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.65	8.06	0.46	3.36e-14	Breast cancer;
KIRP	cis	rs6991838	0.584	rs7463649	chr8:66485995	C/T	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.2	16.58	0.73	5.97e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09038717	chr11:68675878	IGHMBP2	0.5	6.26	0.37	1.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.58	-0.39	2.74e-10	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.14	-0.31	5.74e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.88	13.89	0.66	8.75e-33	Longevity;Endometriosis;
KIRP	cis	rs7560272	0.723	rs1083919	chr2:73713863	C/G	cg20560298	chr2:73613845	ALMS1	0.47	5.89	0.35	1.23e-8	Schizophrenia;
KIRP	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.39	-0.38	8.2e-10	Neuroticism;
KIRP	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg07001201	chr5:642380	CEP72	0.65	6.0	0.36	7.07e-9	Obesity-related traits;
KIRP	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg13615516	chr5:77269221	NA	0.53	8.3	0.47	6.83e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.44	-5.51	-0.33	9.08e-8	P wave terminal force;
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg05861140	chr6:150128134	PCMT1	-0.54	-7.77	-0.44	2.12e-13	Lung cancer;
KIRP	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg25547332	chr5:131281432	NA	-0.51	-6.25	-0.37	1.8e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-7.39	-0.43	2.22e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs58688157	0.960	rs61877856	chr11:617378	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.66	-8.05	-0.46	3.64e-14	Systemic lupus erythematosus;
KIRP	cis	rs57590327	0.527	rs11917558	chr3:81610805	G/A	cg07356753	chr3:81810745	GBE1	-0.57	-7.39	-0.43	2.28e-12	Extraversion;
KIRP	cis	rs28595532	0.623	rs34284204	chr4:119227672	C/T	cg21605333	chr4:119757512	SEC24D	0.76	5.9	0.35	1.17e-8	Cannabis dependence symptom count;
KIRP	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg02254774	chr11:50257496	LOC441601	-0.48	-5.84	-0.35	1.68e-8	Height;
KIRP	cis	rs3096299	0.809	rs3096325	chr16:89421678	A/G	cg06640241	chr16:89574553	SPG7	0.55	7.05	0.41	1.78e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Colorectal cancer;
KIRP	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.78	0.44	2e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.3	1.44e-6	Cognitive test performance;
KIRP	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg22437258	chr11:111473054	SIK2	0.59	7.15	0.42	9.62e-12	Primary sclerosing cholangitis;
KIRP	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	1.11	18.24	0.76	1.3e-47	Cognitive function;
KIRP	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg05418105	chr22:50981406	NA	-0.57	-7.16	-0.42	9.45e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg01528321	chr10:82214614	TSPAN14	0.86	9.2	0.51	1.59e-17	Post bronchodilator FEV1;
KIRP	cis	rs2073300	1.000	rs6048813	chr20:23448221	G/A	cg12062639	chr20:23401060	NAPB	0.79	6.85	0.4	5.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4654899	0.580	rs1977296	chr1:21091543	G/T	cg05370193	chr1:21551575	ECE1	0.36	5.09	0.31	6.99e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.24	0.37	1.88e-9	Retinal vascular caliber;
KIRP	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg17554472	chr22:41940697	POLR3H	-0.66	-7.38	-0.43	2.46e-12	Vitiligo;
KIRP	cis	rs16854884	0.632	rs35629416	chr3:143748424	C/T	cg06585982	chr3:143692056	C3orf58	0.58	7.53	0.43	9.84e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg17207736	chr8:142237307	SLC45A4	-0.44	-5.48	-0.33	1.04e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg10756647	chr7:56101905	PSPH	-0.94	-6.9	-0.4	4.35e-11	Diabetic kidney disease;
KIRP	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.71	-0.49	4.53e-16	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg10224037	chr5:178157518	ZNF354A	0.85	10.27	0.55	8.18e-21	Neutrophil percentage of white cells;
KIRP	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg00852783	chr1:26633632	UBXN11	-0.55	-5.48	-0.33	1.08e-7	Obesity-related traits;
KIRP	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg21161173	chr5:140098174	VTRNA1-2	0.4	5.13	0.31	5.89e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.96	-0.57	5.1e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg15117754	chr3:10150083	C3orf24	0.48	4.94	0.3	1.42e-6	Alzheimer's disease;
KIRP	cis	rs3736485	0.934	rs17609666	chr15:51858038	G/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7224314	1.000	rs62084080	chr17:65387014	C/T	cg01507342	chr17:65387096	PITPNC1	-0.53	-7.77	-0.44	2.18e-13	Diisocyanate-induced asthma;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.16	-0.37	3e-9	Lung cancer;
KIRP	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.55	7.65	0.44	4.41e-13	Schizophrenia;
KIRP	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg15841412	chr13:111365552	ING1	-0.49	-5.72	-0.34	3.13e-8	Coronary artery disease;
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg00684032	chr4:1343700	KIAA1530	0.52	7.0	0.41	2.49e-11	Longevity;
KIRP	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg18882449	chr10:104885122	NT5C2	0.52	6.53	0.38	3.72e-10	Arsenic metabolism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07696690	chr16:20911578	DCUN1D3;LYRM1	0.45	6.31	0.37	1.31e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.26	11.5	0.59	8.79e-25	Diabetic retinopathy;
KIRP	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg15534755	chr11:117069859	TAGLN	0.4	4.96	0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.0	10.58	0.56	8.63e-22	HIV-1 control;
KIRP	cis	rs698833	0.926	rs786622	chr2:44606598	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.57	0.39	2.89e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs8177876	0.822	rs9925943	chr16:81111007	T/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.56	-5.99	-0.36	7.24e-9	Schizophrenia;
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.63	10.41	0.55	2.81e-21	Lung cancer;
KIRP	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg17691542	chr6:26056736	HIST1H1C	0.67	7.94	0.45	6.98e-14	Iron status biomarkers;
KIRP	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.9	10.65	0.56	5.17e-22	Exhaled nitric oxide levels;
KIRP	cis	rs9462846	0.919	rs9462844	chr6:42856502	T/G	cg05552183	chr6:42928497	GNMT	0.39	4.87	0.3	2e-6	Blood protein levels;
KIRP	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.76	-0.34	2.44e-8	Menarche (age at onset);
KIRP	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.7	9.73	0.53	3.88e-19	Mean corpuscular volume;
KIRP	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.59	-0.39	2.66e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.45	-0.38	5.83e-10	Neuroticism;
KIRP	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.53	6.63	0.39	2.15e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.46	-0.38	5.6e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg13819577	chr1:248512075	OR14C36	-0.35	-4.95	-0.3	1.35e-6	Common traits (Other);
KIRP	trans	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.18	0.37	2.66e-9	Retinal vascular caliber;
KIRP	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-8.03	-0.46	3.95e-14	Personality dimensions;
KIRP	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.67	-0.34	4.07e-8	Parkinson's disease;
KIRP	cis	rs17209837	1.000	rs17149641	chr7:87086090	T/C	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	trans	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg14715136	chr2:108537789	NA	-0.45	-6.12	-0.36	3.68e-9	Facial morphology (factor 23);
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.18	0.7	3.63e-37	Platelet count;
KIRP	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg24296786	chr1:45957014	TESK2	-0.4	-4.93	-0.3	1.55e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg01251548	chr11:17372745	DKFZp686O24166	-0.39	-5.19	-0.31	4.36e-7	Type 2 diabetes;
KIRP	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg03959625	chr15:84868606	LOC388152	0.59	6.52	0.38	3.94e-10	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.48	6.43	0.38	6.43e-10	Leprosy;
KIRP	cis	rs55986470	0.670	rs6704902	chr2:239417161	G/C	cg18131467	chr2:239335373	ASB1	-0.54	-5.15	-0.31	5.37e-7	Chronotype;
KIRP	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	11.49	0.59	9.69e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	7.67	0.44	4.05e-13	Total cholesterol levels;
KIRP	cis	rs745080	0.515	rs10132407	chr14:52969455	C/G	cg23333723	chr14:53022898	GPR137C	-0.4	-5.43	-0.33	1.34e-7	Orofacial clefts;
KIRP	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.31	0.51	7.33e-18	Lymphocyte counts;
KIRP	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg03959625	chr15:84868606	LOC388152	0.51	6.07	0.36	4.7e-9	Schizophrenia;
KIRP	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg13798912	chr7:905769	UNC84A	0.54	5.49	0.33	1.02e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7852872	0.812	rs2416560	chr9:119252207	A/C	cg13792444	chr9:119245443	ASTN2	0.47	7.23	0.42	6.07e-12	Hippocampal volume;
KIRP	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.67	-0.39	1.65e-10	Joint mobility (Beighton score);
KIRP	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.53	-5.25	-0.32	3.23e-7	DNA methylation (variation);
KIRP	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.13	-0.46	2.08e-14	Mean corpuscular volume;
KIRP	cis	rs2573652	0.928	rs2581348	chr15:100514063	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.66	-9.91	-0.53	1.08e-19	Height;
KIRP	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg16386425	chr10:429943	DIP2C	0.38	4.85	0.3	2.15e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.47	6.06	0.36	5.08e-9	Facial morphology (factor 20);
KIRP	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07560096	chr11:86383182	ME3	-0.45	-6.02	-0.36	6.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg01879757	chr17:41196368	BRCA1	-0.78	-10.93	-0.57	6.39e-23	Menopause (age at onset);
KIRP	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.62	-0.63	1.78e-28	Electrocardiographic conduction measures;
KIRP	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.47	6.83	0.4	6.78e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg07870213	chr5:140052090	DND1	-0.61	-7.46	-0.43	1.52e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.6	7.5	0.43	1.14e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs42648	0.869	rs12704518	chr7:89914388	G/T	cg25739043	chr7:89950458	NA	-0.47	-7.36	-0.42	2.7e-12	Homocysteine levels;
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg01391022	chr12:122360665	WDR66	-0.37	-5.35	-0.32	2.03e-7	Mean corpuscular volume;
KIRP	cis	rs829661	0.532	rs12621663	chr2:30784540	G/A	cg10949345	chr2:30726833	LCLAT1	0.43	6.15	0.37	3.11e-9	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15420615	chr5:161178796	NA	0.43	7.01	0.41	2.26e-11	Cancer;
KIRP	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.79	10.68	0.56	3.92e-22	Aortic root size;
KIRP	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	20.51	0.79	3.68e-55	Prudent dietary pattern;
KIRP	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg21475434	chr5:93447410	FAM172A	0.75	6.75	0.4	1.08e-10	Diabetic retinopathy;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg08894960	chr1:237061516	MTR	-0.49	-6.28	-0.37	1.52e-9	Inflammatory biomarkers;
KIRP	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.17	-20.49	-0.79	4.09e-55	Ulcerative colitis;
KIRP	cis	rs273218	1.000	rs156384	chr5:53371333	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.61	6.95	0.4	3.32e-11	Migraine;
KIRP	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.68	0.48	5.5e-16	Prudent dietary pattern;
KIRP	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.78	11.73	0.6	1.52e-25	Hip circumference;
KIRP	cis	rs9653442	0.564	rs10197987	chr2:100790783	A/T	cg17356467	chr2:100759845	AFF3	0.37	5.1	0.31	6.93e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9584850	0.834	rs7985565	chr13:99113471	C/G	cg20750642	chr13:99100586	FARP1	-0.48	-5.56	-0.33	6.95e-8	Neuroticism;
KIRP	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	cis	rs1403694	0.966	rs9869244	chr3:186437554	A/T	cg12454167	chr3:186435060	KNG1	0.51	8.83	0.49	1.95e-16	Blood protein levels;
KIRP	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg02524346	chr8:600233	NA	0.86	6.82	0.4	7.06e-11	IgG glycosylation;
KIRP	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg27398637	chr11:122830231	C11orf63	-0.77	-10.3	-0.55	6.37e-21	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25325159	chr1:19812210	CAPZB	0.49	6.31	0.37	1.32e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08026941	chr19:17336882	OCEL1	0.46	6.55	0.39	3.34e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.95	15.09	0.69	7.15e-37	Blood protein levels;
KIRP	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.62	0.34	5.04e-8	Menopause (age at onset);
KIRP	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.6	6.54	0.39	3.47e-10	Gut microbiome composition (summer);
KIRP	cis	rs2346160	0.899	rs206980	chr6:167691798	A/G	cg04673565	chr6:167680447	NA	0.38	4.85	0.3	2.22e-6	Parental extreme longevity (95 years and older);
KIRP	cis	rs2882667	0.518	rs10041986	chr5:138424437	A/G	cg26929925	chr5:138714136	SLC23A1	0.35	5.07	0.31	7.77e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs829661	0.532	rs829627	chr2:30756661	C/T	cg10949345	chr2:30726833	LCLAT1	0.49	7.2	0.42	7.48e-12	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg13271783	chr10:134563150	INPP5A	-0.61	-7.76	-0.44	2.23e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19717773	chr7:2847554	GNA12	-0.32	-5.17	-0.31	4.8e-7	Height;
KIRP	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.69	-0.44	3.54e-13	Breast cancer;
KIRP	cis	rs56079296	1.000	rs56079296	chr5:121276797	A/G	cg01191064	chr5:121408893	LOX	-0.46	-5.08	-0.31	7.3e-7	Coronary artery disease;
KIRP	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-0.77	-10.21	-0.55	1.26e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19623624	chr10:135278901	LOC619207	-0.53	-5.88	-0.35	1.3e-8	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg17376030	chr22:41985996	PMM1	-0.53	-6.69	-0.39	1.51e-10	Vitiligo;
KIRP	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg13444842	chr1:152974279	SPRR3	-0.37	-5.2	-0.31	4.29e-7	Inflammatory skin disease;
KIRP	cis	rs7221595	0.778	rs2727072	chr17:3918585	C/G	cg05562828	chr17:3906858	NA	0.64	8.81	0.49	2.29e-16	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.41	-4.96	-0.3	1.31e-6	P wave terminal force;
KIRP	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg25486957	chr4:152246857	NA	0.41	4.84	0.3	2.25e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg12181417	chr19:49337499	HSD17B14	0.42	5.37	0.32	1.82e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg00982548	chr2:198649783	BOLL	-0.6	-5.5	-0.33	9.46e-8	Ulcerative colitis;
KIRP	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.6	-7.3	-0.42	4.07e-12	Glomerular filtration rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26258273	chr3:138153439	ESYT3	0.44	6.25	0.37	1.75e-9	Parkinson's disease;
KIRP	cis	rs960902	0.747	rs13009200	chr2:37712496	C/A	cg25341268	chr2:37734390	NA	0.6	7.9	0.45	9.17e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg14558114	chr2:88469736	THNSL2	0.66	5.35	0.32	2.04e-7	Plasma clusterin levels;
KIRP	cis	rs1978968	0.731	rs9605463	chr22:18459889	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.8	-11.35	-0.59	2.7e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs2224391	0.628	rs2753223	chr6:5244317	C/A	cg13962347	chr6:5174647	LYRM4	-0.74	-10.23	-0.55	1.08e-20	Height;
KIRP	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg09075268	chr16:1270372	CACNA1H	0.53	6.77	0.4	9.25e-11	Blood protein levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12877462	chr4:100484858	RG9MTD2;MTTP	0.55	7.49	0.43	1.24e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs9912468	1.000	rs9893075	chr17:64311249	C/T	cg19474267	chr17:64306194	PRKCA	-0.66	-9.34	-0.51	5.98e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	1.07	11.81	0.6	8.61e-26	Eosinophil percentage of granulocytes;
KIRP	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.94	14.9	0.69	3.34e-36	Metabolite levels;
KIRP	cis	rs4654899	0.802	rs10916906	chr1:21255675	C/A	cg05370193	chr1:21551575	ECE1	0.46	5.86	0.35	1.48e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.3e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-9.61	-0.52	8.94e-19	Response to antipsychotic treatment;
KIRP	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	15.82	0.71	2.28e-39	Post bronchodilator FEV1;
KIRP	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg13880726	chr7:1868755	MAD1L1	0.53	6.25	0.37	1.83e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4794202	0.700	rs11079797	chr17:45912302	C/T	cg02219949	chr17:45927392	SP6	0.52	6.29	0.37	1.42e-9	Alzheimer's disease (cognitive decline);
KIRP	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg16898833	chr6:26189333	HIST1H4D	0.79	5.42	0.33	1.42e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.53	5.07	0.31	7.85e-7	Bipolar disorder;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10267855	chr11:67121112	POLD4;LOC100130987	-0.51	-6.51	-0.38	4.3e-10	Myopia;
KIRP	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.9	10.52	0.56	1.32e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg04132472	chr17:19861366	AKAP10	0.43	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs7106204	0.609	rs34102968	chr11:24304149	C/T	ch.11.24196551F	chr11:24239977	NA	0.71	5.26	0.32	3.16e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg24879335	chr3:133465180	TF	0.43	6.35	0.38	1.04e-9	Iron status biomarkers;
KIRP	cis	rs12936587	0.535	rs12936201	chr17:17511709	T/G	cg01246520	chr17:17644344	RAI1	-0.31	-5.25	-0.32	3.33e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.51	6.12	0.36	3.72e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.22e-7	Life satisfaction;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01600621	chr19:42681426	NA	0.43	6.19	0.37	2.53e-9	Survival in pancreatic cancer;
KIRP	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg22139774	chr2:100720529	AFF3	0.36	6.44	0.38	6.27e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg16341495	chr8:142228727	SLC45A4	-0.4	-5.0	-0.3	1.07e-6	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.65	-9.27	-0.51	9.75e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3799378	0.582	rs1796518	chr6:26388672	C/T	cg09904177	chr6:26538194	HMGN4	-0.54	-6.81	-0.4	7.46e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg24324837	chr19:49891574	CCDC155	0.66	8.48	0.48	2.11e-15	Multiple sclerosis;
KIRP	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.29e-9	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15830682	chr1:6298637	NA	0.53	6.97	0.41	2.87e-11	Interleukin-4 levels;
KIRP	cis	rs7116495	0.881	rs7128974	chr11:71677032	C/G	cg26138937	chr11:71823887	C11orf51	0.72	5.73	0.34	2.96e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.83	12.5	0.62	4.38e-28	Body mass index;
KIRP	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg13256891	chr4:100009986	ADH5	-0.46	-6.02	-0.36	6.34e-9	Alcohol dependence;
KIRP	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg22903471	chr2:27725779	GCKR	-0.6	-8.59	-0.48	1.04e-15	Total body bone mineral density;
KIRP	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg21775007	chr8:11205619	TDH	-0.39	-5.18	-0.31	4.65e-7	Neuroticism;
KIRP	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	cg21523751	chr1:182988639	NA	-0.45	-7.03	-0.41	2e-11	Colorectal cancer;
KIRP	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.61	9.09	0.5	3.37e-17	Itch intensity from mosquito bite;
KIRP	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.81	8.68	0.48	5.58e-16	Prostate cancer;
KIRP	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.5	6.9	0.4	4.28e-11	Red blood cell count;
KIRP	cis	rs15676	0.947	rs7854319	chr9:131567995	G/A	cg00228799	chr9:131580591	ENDOG	-0.52	-5.54	-0.33	7.58e-8	Blood metabolite levels;
KIRP	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.7	9.4	0.51	3.94e-18	Height;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg26985447	chr14:105343315	KIAA0284	-0.34	-6.95	-0.41	3.33e-11	Bladder cancer;
KIRP	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.68	7.16	0.42	9.13e-12	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs6993244	1	rs6993244	chr8:8863059	C/G	cg00405596	chr8:11794950	NA	0.47	6.27	0.37	1.58e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg25019033	chr10:957182	NA	-0.69	-8.82	-0.49	2.11e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18252515	chr7:66147081	NA	-0.44	-5.31	-0.32	2.44e-7	Aortic root size;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg23985595	chr17:80112537	CCDC57	-0.35	-5.16	-0.31	5.04e-7	Life satisfaction;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10471876	chr10:112679113	NCRNA00081;SHOC2	-0.54	-6.84	-0.4	6.17e-11	Migraine with aura;
KIRP	cis	rs8067354	0.645	rs2271304	chr17:57814641	A/G	cg02344993	chr17:57696989	CLTC	0.55	4.96	0.3	1.33e-6	Hemoglobin concentration;
KIRP	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.66	-12.13	-0.61	7.47e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg02023728	chr11:77925099	USP35	0.48	7.91	0.45	8.48e-14	Testicular germ cell tumor;
KIRP	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg07862535	chr7:139043722	LUC7L2	0.49	5.51	0.33	9.02e-8	Diisocyanate-induced asthma;
KIRP	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11987759	chr7:65425863	GUSB	-0.46	-5.43	-0.33	1.34e-7	Aortic root size;
KIRP	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg26138937	chr11:71823887	C11orf51	-1.04	-7.13	-0.41	1.12e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg10207240	chr12:122356781	WDR66	-0.5	-6.58	-0.39	2.74e-10	Mean corpuscular volume;
KIRP	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg08501292	chr6:25962987	TRIM38	0.82	5.29	0.32	2.71e-7	Lung cancer;Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg21698718	chr17:80085957	CCDC57	-0.37	-5.46	-0.33	1.15e-7	Life satisfaction;
KIRP	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg05507819	chr15:63340323	TPM1	0.45	5.04	0.31	8.82e-7	HDL cholesterol;
KIRP	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.86	-0.45	1.18e-13	Mood instability;
KIRP	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	8.86	0.49	1.63e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg04804543	chr8:142233427	SLC45A4	-0.45	-5.55	-0.33	7.41e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17376030	chr22:41985996	PMM1	-0.72	-7.86	-0.45	1.21e-13	Vitiligo;
KIRP	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg06742321	chr12:123595122	PITPNM2	0.46	5.37	0.32	1.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4908768	0.906	rs12405049	chr1:8626117	C/T	cg25722041	chr1:8623473	RERE	0.8	9.87	0.53	1.44e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.77	10.5	0.56	1.5e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.54	-7.11	-0.41	1.23e-11	Coronary artery disease;
KIRP	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg04267008	chr7:1944627	MAD1L1	0.46	4.93	0.3	1.5e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.35	5.15	0.31	5.36e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.93	0.61	3.38e-26	Ileal carcinoids;
KIRP	cis	rs1440410	0.798	rs13140643	chr4:144070374	C/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.5	0.38	4.38e-10	Height;
KIRP	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg02975922	chr3:195473998	MUC4	-0.57	-6.45	-0.38	5.99e-10	Pancreatic cancer;
KIRP	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-6.93	-0.4	3.65e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg15247329	chr7:2764246	NA	-0.34	-4.86	-0.3	2.06e-6	Height;
KIRP	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.5	0.33	9.29e-8	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04054907	chr8:17104065	CNOT7;VPS37A	0.42	6.2	0.37	2.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.41	1.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06634786	chr22:41940651	POLR3H	0.45	5.28	0.32	2.83e-7	Vitiligo;
KIRP	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.44	-0.38	6.22e-10	Daytime sleep phenotypes;
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.4	-0.33	1.55e-7	Life satisfaction;
KIRP	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg04315214	chr1:2043799	PRKCZ	-0.36	-5.65	-0.34	4.4e-8	Height;
KIRP	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-6.99	-0.41	2.52e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.46	-6.23	-0.37	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.36	-0.38	1e-9	Bipolar disorder;
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg05562828	chr17:3906858	NA	0.77	16.33	0.72	4.28e-41	Type 2 diabetes;
KIRP	cis	rs6449957	0.801	rs6449953	chr5:67456530	A/G	cg09038926	chr5:67483109	NA	-0.39	-5.24	-0.32	3.48e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg22532475	chr10:104410764	TRIM8	-0.32	-5.14	-0.31	5.59e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs7572644	0.723	rs7578052	chr2:28318879	G/A	cg27432699	chr2:27873401	GPN1	0.47	5.0	0.3	1.09e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg15140703	chr7:99775532	STAG3;GPC2	-0.36	-4.86	-0.3	2.09e-6	Coronary artery disease;
KIRP	cis	rs151997	0.671	rs27845	chr5:50197420	A/C	cg06027927	chr5:50259733	NA	0.56	7.75	0.44	2.4e-13	Callous-unemotional behaviour;
KIRP	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.63	-8.46	-0.47	2.34e-15	Colorectal cancer;
KIRP	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.75	11.72	0.6	1.71e-25	Resting heart rate;
KIRP	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg06740227	chr12:86229804	RASSF9	0.4	5.04	0.31	8.91e-7	Major depressive disorder;
KIRP	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	1.06	19.97	0.79	2.13e-53	Heart rate;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg11833968	chr6:79620685	NA	-0.45	-6.93	-0.4	3.73e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1967309	0.604	rs8061182	chr16:4070333	A/G	cg00061520	chr16:4070371	ADCY9	0.47	6.61	0.39	2.33e-10	Response to Dalcetrapib treatment in acute coronary syndrome;
KIRP	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.79	9.46	0.52	2.61e-18	Red cell distribution width;
KIRP	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.43	0.47	2.85e-15	Motion sickness;
KIRP	cis	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.01	-0.36	6.56e-9	Ulcerative colitis;
KIRP	cis	rs3821902	0.646	rs56359789	chr3:64016911	T/C	cg09006292	chr3:64049408	NA	-0.51	-5.16	-0.31	5e-7	Breast cancer;
KIRP	cis	rs7534016	0.512	rs949827	chr1:59841785	A/G	cg09869950	chr1:59783505	FGGY	-0.49	-5.91	-0.35	1.16e-8	Obesity-related traits;
KIRP	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg16989719	chr2:238392110	NA	-0.54	-7.58	-0.44	7.12e-13	Prostate cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19386159	chr12:109125243	CORO1C	-0.52	-6.87	-0.4	5.38e-11	Myopia;
KIRP	cis	rs397969	0.607	rs169413	chr17:19849745	G/A	cg04132472	chr17:19861366	AKAP10	0.55	6.64	0.39	2.03e-10	Platelet count;
KIRP	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg03894339	chr8:19674705	INTS10	0.63	7.41	0.43	1.97e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.85	7.98	0.45	5.68e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04276977	chr22:32340769	C22orf24;YWHAH	0.48	6.03	0.36	5.83e-9	Parkinson's disease;
KIRP	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-11.4	-0.59	1.83e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.5	0.33	9.57e-8	Height;
KIRP	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg20999797	chr1:1681921	NA	0.51	7.83	0.45	1.5e-13	Body mass index;
KIRP	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01784909	chr11:31269140	NA	-0.4	-6.1	-0.36	4.04e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg07972983	chr1:205091412	RBBP5	0.42	5.01	0.3	1.04e-6	Red blood cell count;
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg11204139	chr17:3907470	NA	0.89	17.47	0.74	5.47e-45	Type 2 diabetes;
KIRP	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.89	-13.23	-0.64	1.52e-30	Schizophrenia;
KIRP	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg12131826	chr15:77904385	NA	-0.46	-6.36	-0.38	9.9e-10	Type 2 diabetes;
KIRP	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.45	-0.38	5.9e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg27130769	chr7:5417105	TNRC18	0.46	6.34	0.37	1.08e-9	Morning vs. evening chronotype;
KIRP	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg20742981	chr22:31644190	LIMK2	0.33	4.85	0.3	2.15e-6	Paclitaxel-induced neuropathy;
KIRP	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.57	0.56	9.26e-22	Cognitive test performance;
KIRP	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-10.87	-0.57	9.85e-23	Exhaled nitric oxide output;
KIRP	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-5.57	-0.33	6.79e-8	Alzheimer's disease (late onset);
KIRP	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg20578329	chr17:80767326	TBCD	0.58	7.16	0.42	9.52e-12	Breast cancer;
KIRP	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.21	-0.32	4.02e-7	Bipolar disorder;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18263451	chr1:25573180	C1orf63	-0.52	-6.57	-0.39	2.98e-10	Pancreatic cancer;
KIRP	cis	rs6681460	0.932	rs2044400	chr1:67054081	T/A	cg13052034	chr1:66999238	SGIP1	0.4	5.56	0.33	7.01e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs5753037	0.838	rs28749829	chr22:30219326	C/T	cg27665648	chr22:30112403	NA	0.48	6.58	0.39	2.88e-10	Type 1 diabetes;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg18084215	chr5:125936716	PHAX	-0.48	-6.09	-0.36	4.42e-9	Blood metabolite levels;
KIRP	cis	rs3008706	0.920	rs3008737	chr9:15986650	G/C	cg14451791	chr9:16040625	NA	-0.51	-5.13	-0.31	5.92e-7	Bilirubin levels;
KIRP	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg01777586	chr17:80163174	CCDC57	-0.46	-4.9	-0.3	1.76e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.9	-0.49	1.21e-16	Urate levels in overweight individuals;
KIRP	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14829155	chr15:31115871	NA	-0.65	-8.72	-0.49	4.11e-16	Huntington's disease progression;
KIRP	cis	rs933360	0.535	rs11974751	chr7:50845090	A/G	cg14997413	chr7:51384937	COBL	0.31	4.87	0.3	1.95e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg11641102	chr8:27183873	PTK2B	0.4	5.11	0.31	6.44e-7	Neuroticism;
KIRP	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs258892	0.843	rs13190547	chr5:72035753	G/A	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.25	17.47	0.74	5.58e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg26876637	chr1:152193138	HRNR	-0.68	-9.03	-0.5	5e-17	Atopic dermatitis;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.41	4.88	0.3	1.92e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.53	7.9	0.45	9.23e-14	Itch intensity from mosquito bite;
KIRP	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01338834	chr21:40720919	HMGN1	-0.46	-7.03	-0.41	2.04e-11	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19019038	chr5:56469576	GPBP1	0.47	6.21	0.37	2.23e-9	Parkinson's disease;
KIRP	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.88	13.38	0.65	4.95e-31	Colorectal cancer;
KIRP	cis	rs10114408	0.959	rs12342427	chr9:96641701	A/C	cg14598338	chr9:96623480	NA	-0.34	-5.17	-0.31	4.92e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg27411982	chr8:10470053	RP1L1	0.46	6.02	0.36	6.42e-9	Neuroticism;
KIRP	cis	rs3789045	0.774	rs11801299	chr1:204529084	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.21	-0.37	2.22e-9	Educational attainment (college completion);
KIRP	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.99	-10.16	-0.54	1.73e-20	Systemic lupus erythematosus;
KIRP	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg26338869	chr17:61819248	STRADA	0.53	6.34	0.37	1.1e-9	Prudent dietary pattern;
KIRP	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.57	7.92	0.45	8.37e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs925228	0.504	rs6729231	chr2:24292597	A/T	cg01493198	chr2:24299560	SF3B14	0.78	5.59	0.34	6.12e-8	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.89	0.4	4.66e-11	Height;
KIRP	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg08280861	chr8:58055591	NA	0.51	4.98	0.3	1.18e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-7.31	-0.42	3.8e-12	Morning vs. evening chronotype;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09976282	chr15:31357238	TRPM1;MIR211	0.46	6.44	0.38	6.13e-10	Survival in pancreatic cancer;
KIRP	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.75	5.75	0.34	2.65e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10875746	0.729	rs11168355	chr12:48410978	A/G	cg20731937	chr12:48336164	NA	-0.49	-6.25	-0.37	1.77e-9	Longevity (90 years and older);
KIRP	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs13095912	0.597	rs112800013	chr3:185313807	A/G	cg11274856	chr3:185301563	NA	0.59	7.58	0.44	6.87e-13	Systolic blood pressure;
KIRP	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg05973401	chr12:123451056	ABCB9	-0.6	-5.65	-0.34	4.4e-8	Neutrophil percentage of white cells;
KIRP	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27297192	chr10:134578999	INPP5A	0.59	7.43	0.43	1.83e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.96	15.39	0.7	7.03e-38	Uric acid clearance;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24397552	chr15:40226086	EIF2AK4	-0.47	-6.19	-0.37	2.49e-9	Survival in pancreatic cancer;
KIRP	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.44	6.32	0.37	1.21e-9	Height;
KIRP	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.546	rs36058627	chr4:119233201	G/T	cg21605333	chr4:119757512	SEC24D	0.76	5.9	0.35	1.17e-8	Cannabis dependence symptom count;
KIRP	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg11970804	chr8:8084126	NA	-0.38	-4.89	-0.3	1.82e-6	Neuroticism;
KIRP	cis	rs75920871	0.843	rs4936363	chr11:116972935	A/G	cg23684410	chr11:116897558	SIK3	-0.53	-5.26	-0.32	3.06e-7	Subjective well-being;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.43	4.86	0.3	2.11e-6	Longevity;Endometriosis;
KIRP	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg12591125	chr7:1885375	MAD1L1	0.64	6.09	0.36	4.27e-9	Bipolar disorder;
KIRP	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg10755058	chr3:40428713	ENTPD3	0.4	5.53	0.33	8.23e-8	Renal cell carcinoma;
KIRP	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.23	14.56	0.68	4.58e-35	Eosinophil percentage of granulocytes;
KIRP	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.62	-8.2	-0.46	1.33e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg08632701	chr21:37451849	NA	-0.43	-5.41	-0.33	1.47e-7	Mitral valve prolapse;
KIRP	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.6	6.78	0.4	8.85e-11	Aortic root size;
KIRP	cis	rs795484	0.633	rs904662	chr12:118581833	C/T	cg16572268	chr12:118583242	PEBP1	0.38	5.53	0.33	8.34e-8	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19224886	chr12:72054629	ZFC3H1	-0.39	-6.06	-0.36	5.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7221595	0.825	rs8078629	chr17:3983964	A/C	cg09695851	chr17:3907499	NA	0.59	5.86	0.35	1.52e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04514249	chr4:144621385	FREM3	0.49	7.14	0.41	1.03e-11	Smoking initiation;
KIRP	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg26207909	chr14:103986467	CKB	-0.43	-5.27	-0.32	3.03e-7	Coronary artery disease;
KIRP	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg17507749	chr15:85114479	UBE2QP1	0.75	7.0	0.41	2.38e-11	Schizophrenia;
KIRP	cis	rs10875746	0.537	rs4760625	chr12:48673743	A/T	cg26205652	chr12:48591994	NA	0.81	10.54	0.56	1.12e-21	Longevity (90 years and older);
KIRP	cis	rs35740288	0.731	rs11634651	chr15:86093926	A/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.5	-0.33	9.71e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.61	-6.49	-0.38	4.6e-10	Height;
KIRP	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg16141378	chr3:129829833	LOC729375	0.57	7.62	0.44	5.34e-13	Neuroticism;
KIRP	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06544989	chr22:39130855	UNC84B	0.5	8.65	0.48	6.9e-16	Menopause (age at onset);
KIRP	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.23	-11.31	-0.59	3.62e-24	Diabetic retinopathy;
KIRP	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg15358701	chr1:161410459	NA	-0.63	-5.87	-0.35	1.43e-8	Rheumatoid arthritis;
KIRP	cis	rs73200209	0.625	rs11611787	chr12:116644886	G/T	cg01776926	chr12:116560359	MED13L	-0.56	-6.1	-0.36	4.01e-9	Total body bone mineral density;
KIRP	cis	rs56161922	1.000	rs55821028	chr1:207843000	G/A	cg09557387	chr1:207818395	CR1L	1.08	6.5	0.38	4.51e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.91	11.42	0.59	1.64e-24	Homoarginine levels;
KIRP	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	0.83	9.6	0.52	9.95e-19	Gut microbiome composition (summer);
KIRP	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg15556689	chr8:8085844	FLJ10661	0.58	7.09	0.41	1.39e-11	Neuroticism;
KIRP	trans	rs2048656	0.605	rs7814507	chr8:9646560	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	6.59	0.39	2.59e-10	Schizophrenia;
KIRP	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19671926	chr4:122722719	EXOSC9	0.47	5.64	0.34	4.6e-8	Type 2 diabetes;
KIRP	cis	rs1874124	0.577	rs2807853	chr1:221024353	A/T	cg22888665	chr1:221052729	HLX	-0.51	-5.06	-0.31	8.35e-7	Cholesterol, total;
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Parkinson's disease;
KIRP	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.52	7.31	0.42	3.64e-12	Systemic lupus erythematosus;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18462226	chr4:76598323	G3BP2	-0.48	-6.15	-0.37	3.12e-9	Myopia;
KIRP	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg22437258	chr11:111473054	SIK2	0.61	7.13	0.41	1.11e-11	Primary sclerosing cholangitis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17967970	chr15:63335016	TPM1	-0.44	-6.1	-0.36	4.05e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.59	7.04	0.41	1.89e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg10790698	chr19:18539756	SSBP4	-0.32	-6.79	-0.4	8.33e-11	Breast cancer;
KIRP	cis	rs9653442	0.545	rs12987209	chr2:100761148	C/T	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.52	0.52	1.65e-18	Monocyte percentage of white cells;
KIRP	cis	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg06521331	chr12:34319734	NA	-0.58	-7.03	-0.41	1.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	cg12689670	chr1:183009347	LAMC1	0.45	6.35	0.38	1.04e-9	Hypertriglyceridemia;
KIRP	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.82	-11.62	-0.6	3.54e-25	Calcium levels;
KIRP	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg26139080	chr11:47293733	MADD	-0.41	-5.0	-0.3	1.07e-6	HDL cholesterol;
KIRP	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg09455208	chr3:40491958	NA	0.35	6.12	0.36	3.58e-9	Renal cell carcinoma;
KIRP	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.3	-0.47	7.04e-15	Blood protein levels;
KIRP	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01786109	chr1:16056218	PLEKHM2	-0.45	-6.08	-0.36	4.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.05	-0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-6.53	-0.38	3.66e-10	Vitamin D levels;
KIRP	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg26681399	chr22:41777847	TEF	-0.46	-5.47	-0.33	1.11e-7	Vitiligo;
KIRP	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.94	-0.45	7.19e-14	Coffee consumption (cups per day);
KIRP	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.72	-0.39	1.26e-10	Response to antipsychotic treatment;
KIRP	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.83	6.86	0.4	5.56e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	1.08	16.87	0.73	6.15e-43	Homoarginine levels;
KIRP	cis	rs9653442	0.545	rs2009094	chr2:100765077	G/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs1298062	0.663	rs1274685	chr19:50997828	G/A	cg17071417	chr19:50962282	MYBPC2	0.41	4.84	0.3	2.25e-6	Age of smoking initiation;
KIRP	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg25039879	chr17:56429692	SUPT4H1	0.59	5.06	0.31	8.1e-7	Cognitive test performance;
KIRP	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.25	4.92	0.3	1.58e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg26139080	chr11:47293733	MADD	-0.43	-5.36	-0.32	1.89e-7	HDL cholesterol;
KIRP	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg27205649	chr11:78285834	NARS2	0.68	8.92	0.49	1.09e-16	Alzheimer's disease (survival time);
KIRP	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg00343986	chr7:65444356	GUSB	0.43	5.12	0.31	6.05e-7	Aortic root size;
KIRP	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	1.02	16.59	0.73	5.38e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg05887092	chr17:76393375	PGS1	0.53	7.21	0.42	6.72e-12	HDL cholesterol levels;
KIRP	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg10755058	chr3:40428713	ENTPD3	0.37	5.3	0.32	2.63e-7	Renal cell carcinoma;
KIRP	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	5.85	0.35	1.56e-8	Breast cancer;
KIRP	cis	rs72730918	0.564	rs17524750	chr15:51780722	C/T	cg14296394	chr15:51910925	DMXL2	0.78	10.66	0.56	4.67e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18173182	chr12:123001840	RSRC2	0.44	6.7	0.39	1.45e-10	Interleukin-4 levels;
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.44	0.33	1.3e-7	Lung cancer;
KIRP	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.61	-7.9	-0.45	9.53e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	0.89	11.89	0.6	4.63e-26	Monocyte percentage of white cells;
KIRP	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg06026331	chr20:60912101	LAMA5	0.54	5.91	0.35	1.15e-8	Colorectal cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27380774	chr11:1000560	AP2A2	0.51	6.72	0.39	1.24e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24622439	chr2:212246986	ERBB4	0.39	6.06	0.36	5e-9	Migraine with aura;
KIRP	cis	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg07460842	chr6:66804631	NA	-0.39	-4.99	-0.3	1.13e-6	Metabolite levels;
KIRP	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00585698	chr12:123750864	CDK2AP1	0.46	5.92	0.35	1.09e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.71	9.73	0.53	3.8e-19	Red blood cell count;
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg05562828	chr17:3906858	NA	-0.7	-13.58	-0.65	1.02e-31	Type 2 diabetes;
KIRP	cis	rs8028182	0.636	rs4886699	chr15:75692303	A/C	cg20655648	chr15:75932815	IMP3	0.54	7.06	0.41	1.73e-11	Sudden cardiac arrest;
KIRP	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg23594656	chr7:65796392	TPST1	0.38	5.51	0.33	9.12e-8	Aortic root size;
KIRP	cis	rs4460629	0.901	rs4745	chr1:155106227	A/T	cg02153340	chr1:155202674	NA	0.44	6.34	0.37	1.08e-9	Serum magnesium levels;
KIRP	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.53	-8.42	-0.47	3.13e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs41271473	0.750	rs17352829	chr1:228889664	A/G	cg10167378	chr1:228756711	NA	0.55	5.23	0.32	3.55e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg04691961	chr3:161091175	C3orf57	0.45	6.73	0.39	1.15e-10	Morning vs. evening chronotype;
KIRP	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg05479556	chr5:449004	EXOC3	0.4	4.93	0.3	1.54e-6	Fat distribution (HIV);
KIRP	cis	rs9311676	0.656	rs12495490	chr3:58373251	A/G	cg06643156	chr3:58380774	PXK	0.35	4.92	0.3	1.56e-6	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-0.98	-11.4	-0.59	1.9e-24	Vitiligo;
KIRP	cis	rs73198271	0.710	rs11779561	chr8:8679988	G/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.55	-0.43	8.72e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.36	-5.17	-0.31	4.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg21573476	chr21:45109991	RRP1B	-0.53	-7.17	-0.42	8.75e-12	Mean corpuscular volume;
KIRP	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.31	-0.37	1.28e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg27205649	chr11:78285834	NARS2	0.83	12.16	0.61	6.12e-27	Alzheimer's disease (survival time);
KIRP	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg02023728	chr11:77925099	USP35	-0.32	-5.6	-0.34	5.84e-8	Alzheimer's disease (survival time);
KIRP	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg21858823	chr1:15850916	CASP9	0.53	5.63	0.34	4.93e-8	Systolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16316507	chr7:144533041	TPK1	0.54	6.24	0.37	1.85e-9	Smoking initiation;
KIRP	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.62e-8	Aortic root size;
KIRP	trans	rs6601327	0.600	rs10103925	chr8:9652211	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.45	-0.38	5.91e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7633770	0.735	rs11719679	chr3:46687684	A/G	cg11219411	chr3:46661640	NA	-0.41	-5.46	-0.33	1.19e-7	Coronary artery disease;
KIRP	trans	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	1.03	20.4	0.79	8.35e-55	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23465989	chr20:37101470	RALGAPB	0.49	6.24	0.37	1.94e-9	Parkinson's disease;
KIRP	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.04	12.83	0.63	3.53e-29	Corneal structure;
KIRP	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.48	0.52	2.3e-18	Multiple sclerosis;
KIRP	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg23281280	chr6:28129359	ZNF389	0.48	5.3	0.32	2.61e-7	Depression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04351131	chr11:129729453	TMEM45B	0.49	6.17	0.37	2.75e-9	Interleukin-4 levels;
KIRP	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg27462398	chr1:86174642	ZNHIT6	-0.53	-7.12	-0.41	1.19e-11	Urate levels in overweight individuals;
KIRP	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.51	-6.5	-0.38	4.35e-10	Capecitabine sensitivity;
KIRP	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.43	6.35	0.38	1.02e-9	Sitting height ratio;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-0.59	-8.18	-0.46	1.52e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15320075	chr8:145703422	NA	0.66	8.81	0.49	2.28e-16	Age at first birth;
KIRP	cis	rs9653442	0.564	rs4851256	chr2:100775045	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-4.9	-0.3	1.77e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-1.05	-9.23	-0.51	1.32e-17	Obesity-related traits;
KIRP	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.53	-8.14	-0.46	1.96e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs42648	0.748	rs10226014	chr7:89902533	C/T	cg25739043	chr7:89950458	NA	0.43	6.88	0.4	4.91e-11	Homocysteine levels;
KIRP	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg03146154	chr1:46216737	IPP	0.47	4.85	0.3	2.18e-6	Platelet count;
KIRP	trans	rs28573326	0.629	rs1438119	chr4:166348346	T/C	cg13437084	chr2:26467494	HADHB;HADHA	-0.84	-9.88	-0.53	1.37e-19	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4663969	0.839	rs7572563	chr2:234617236	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-6.02	-0.36	6.46e-9	Total bilirubin levels in HIV-1 infection;
KIRP	trans	rs2472591	0.925	rs790943	chr13:50637787	G/T	cg04548715	chr7:99598775	NA	0.55	6.1	0.36	4.03e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.52	6.65	0.39	1.88e-10	Chronic sinus infection;
KIRP	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.09	-0.31	6.96e-7	Metabolite levels;
KIRP	cis	rs580438	0.529	rs7632138	chr3:13423656	T/C	cg10657019	chr3:13328039	NA	-0.5	-6.47	-0.38	5.26e-10	Myringotomy;
KIRP	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.6	-6.6	-0.39	2.44e-10	Prostate cancer;
KIRP	cis	rs960902	0.592	rs4503968	chr2:37734216	T/C	cg25341268	chr2:37734390	NA	-0.62	-8.73	-0.49	3.89e-16	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg04865290	chr3:52927548	TMEM110	-0.49	-5.19	-0.31	4.37e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs11386980	1	rs11386980	chr7:29005573	A/AT	cg19402173	chr7:128379420	CALU	-0.7	-7.76	-0.44	2.21e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.74	-8.8	-0.49	2.51e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg00376283	chr12:123451042	ABCB9	0.82	10.85	0.57	1.14e-22	Platelet count;
KIRP	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.56	-0.43	8.04e-13	Mood instability;
KIRP	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.83	-10.71	-0.56	3.27e-22	Cognitive function;
KIRP	cis	rs67756423	0.503	rs12549009	chr8:143323346	G/A	cg24996280	chr8:143481281	TSNARE1	0.42	5.72	0.34	3.1e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.55	0.56	1.03e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs4750440	0.614	rs4750446	chr10:14030319	T/G	cg27542038	chr10:14027202	FRMD4A	-0.58	-7.69	-0.44	3.47e-13	Adiponectin levels;
KIRP	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.49	-7.49	-0.43	1.22e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1420338	0.933	rs6462533	chr7:34168028	G/A	cg01275685	chr7:34179230	BMPER	-0.6	-9.09	-0.5	3.43e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	7.59	0.44	6.64e-13	Lung cancer;
KIRP	cis	rs6959887	0.962	rs10224889	chr7:35283529	A/G	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs597583	0.664	rs10892133	chr11:117383694	C/T	cg27161313	chr11:117392002	DSCAML1	-0.54	-5.34	-0.32	2.09e-7	Putamen volume;
KIRP	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-6.38	-0.38	8.73e-10	Depression;
KIRP	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg23649088	chr2:200775458	C2orf69	0.53	5.08	0.31	7.37e-7	Schizophrenia;
KIRP	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs7404928	1.000	rs3785398	chr16:23900568	G/C	cg21745164	chr16:23765304	CHP2	-0.43	-5.94	-0.35	9.84e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.19	21.62	0.81	8.42e-59	Cognitive function;
KIRP	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg16558253	chr16:72132732	DHX38	-0.54	-7.99	-0.45	5.32e-14	Fibrinogen levels;
KIRP	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg14541582	chr5:601475	NA	-0.54	-6.18	-0.37	2.65e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg25214090	chr10:38739885	LOC399744	0.48	6.1	0.36	4.19e-9	Diastolic blood pressure;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg00914777	chr14:93651123	MOAP1;C14orf109	0.49	6.19	0.37	2.49e-9	Myopia (pathological);
KIRP	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06634786	chr22:41940651	POLR3H	-0.52	-5.83	-0.35	1.73e-8	Vitiligo;
KIRP	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.55	7.53	0.43	9.33e-13	Colorectal cancer;
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg06815112	chr8:27182871	PTK2B	0.53	6.81	0.4	7.41e-11	Neuroticism;
KIRP	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg05370193	chr1:21551575	ECE1	-0.47	-6.44	-0.38	6.1e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs1669338	0.507	rs4685606	chr3:3177973	T/G	cg16797762	chr3:3221439	CRBN	-0.67	-6.49	-0.38	4.68e-10	White matter integrity;
KIRP	cis	rs7119038	0.509	rs10892259	chr11:118583002	G/A	cg19308663	chr11:118741387	NA	0.42	6.53	0.38	3.63e-10	Sjögren's syndrome;
KIRP	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg15103426	chr22:29168792	CCDC117	0.66	9.54	0.52	1.5e-18	Lymphocyte counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08346273	chr5:122734518	CEP120	-0.42	-6.6	-0.39	2.46e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.49	2.71e-16	Bladder cancer;
KIRP	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg01081584	chr15:40268610	EIF2AK4	0.52	6.36	0.38	9.52e-10	Corneal curvature;
KIRP	cis	rs7221595	0.825	rs12939802	chr17:3933904	C/T	cg09597638	chr17:3907349	NA	0.47	4.99	0.3	1.14e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-0.78	-5.25	-0.32	3.34e-7	Systolic blood pressure response to hydrochlorothiazide in hypertension;
KIRP	cis	rs4926611	0.762	rs11206175	chr1:54055318	T/C	cg08927728	chr1:54059983	GLIS1	0.3	6.29	0.37	1.46e-9	Hand grip strength;
KIRP	cis	rs4845875	0.626	rs12734761	chr1:11834182	G/A	cg24844545	chr1:11908347	NPPA	0.35	5.03	0.31	9.48e-7	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg20966754	chr17:47091339	IGF2BP1	-0.28	-5.68	-0.34	3.88e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs504918	0.588	rs11712619	chr3:124019802	C/T	cg05766129	chr3:123988013	KALRN	-0.44	-5.66	-0.34	4.25e-8	Schizophrenia;
KIRP	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.65	9.94	0.54	8.65e-20	Menopause (age at onset);
KIRP	cis	rs6545883	0.860	rs4671399	chr2:61458518	C/T	cg15711740	chr2:61764176	XPO1	0.57	7.41	0.43	2.02e-12	Tuberculosis;
KIRP	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.07	-0.36	4.7e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.79	-0.45	1.83e-13	Total cholesterol levels;
KIRP	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg13180566	chr4:1052158	NA	-0.53	-5.37	-0.32	1.87e-7	Recombination rate (females);
KIRP	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs11583043	0.708	rs3861735	chr1:101530191	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.13	0.31	5.99e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9398803	0.965	rs17754780	chr6:126664333	C/T	cg19875578	chr6:126661172	C6orf173	0.5	6.63	0.39	2.09e-10	Male-pattern baldness;
KIRP	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg15038512	chr6:170123185	PHF10	0.47	5.27	0.32	2.95e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg04398451	chr17:18023971	MYO15A	-0.66	-9.16	-0.5	2.05e-17	Total body bone mineral density;
KIRP	cis	rs4936894	0.519	rs10893194	chr11:124142531	T/C	cg27160556	chr11:124181099	OR8D1	-0.47	-6.68	-0.39	1.6e-10	Aging (time to death);
KIRP	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.24	11.64	0.6	3.02e-25	Diabetic retinopathy;
KIRP	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg07395648	chr5:131743802	NA	0.58	8.03	0.46	3.98e-14	Breast cancer;Mosquito bite size;
KIRP	cis	rs2591576	0.553	rs58189929	chr5:165424808	G/T	cg13976338	chr5:165423657	NA	-0.86	-13.85	-0.66	1.2e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg27205649	chr11:78285834	NARS2	-0.56	-6.31	-0.37	1.31e-9	Testicular germ cell tumor;
KIRP	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11645453	chr3:52864694	ITIH4	-0.34	-5.45	-0.33	1.25e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.53	-0.33	8.17e-8	Lung cancer;
KIRP	cis	rs7737355	0.812	rs9687376	chr5:130918037	A/C	cg25547332	chr5:131281432	NA	0.4	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17554472	chr22:41940697	POLR3H	-0.62	-6.7	-0.39	1.42e-10	Vitiligo;
KIRP	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.76	8.69	0.48	5.31e-16	Corneal astigmatism;
KIRP	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg00129232	chr17:37814104	STARD3	-0.67	-7.27	-0.42	4.69e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg16898833	chr6:26189333	HIST1H4D	0.71	5.4	0.33	1.58e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.74	-8.99	-0.5	6.54e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.44	5.85	0.35	1.53e-8	Menarche (age at onset);
KIRP	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.88	0.4	5.04e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4594175	0.926	rs10498421	chr14:51586412	A/G	cg23942311	chr14:51606299	NA	-0.49	-5.79	-0.35	2.15e-8	Cancer;
KIRP	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.71	10.81	0.57	1.52e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg25019033	chr10:957182	NA	-0.61	-6.73	-0.39	1.21e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.83	-8.95	-0.5	9.15e-17	Asthma;
KIRP	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg00383909	chr3:49044727	WDR6	0.53	5.1	0.31	6.9e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg14683738	chr19:37701593	ZNF585B	0.52	5.2	0.31	4.13e-7	Coronary artery calcification;
KIRP	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.79	-0.35	2.19e-8	Depression;
KIRP	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg14440974	chr22:39074834	NA	-0.38	-4.94	-0.3	1.44e-6	Menopause (age at onset);
KIRP	cis	rs6969780	1.000	rs73071548	chr7:27147430	A/G	cg26364809	chr7:27145159	NA	-0.63	-5.56	-0.33	6.84e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.19e-26	Eye color traits;
KIRP	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	0.7	9.5	0.52	1.96e-18	Prostate cancer;
KIRP	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.31	-11.89	-0.6	4.54e-26	Diabetic retinopathy;
KIRP	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg09788416	chr12:39539408	NA	0.4	5.21	0.32	4.02e-7	Morning vs. evening chronotype;
KIRP	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg09699651	chr6:150184138	LRP11	0.42	5.37	0.32	1.83e-7	Lung cancer;
KIRP	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg05156742	chr15:59063176	FAM63B	0.53	6.46	0.38	5.7e-10	Asperger disorder;
KIRP	cis	rs9826463	0.527	rs56088529	chr3:142146369	A/G	cg20824294	chr3:142316082	PLS1	0.41	6.06	0.36	4.95e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.65	5.78	0.35	2.26e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg24699146	chr1:24152579	HMGCL	-0.41	-5.14	-0.31	5.62e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9309473	0.904	rs78450880	chr2:73821381	T/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.28	-0.32	2.81e-7	Metabolite levels;
KIRP	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	7.5	0.43	1.14e-12	Bipolar disorder;
KIRP	cis	rs970821	0.667	rs10956146	chr8:124749704	T/G	cg00283535	chr8:124749564	ANXA13	-0.36	-6.14	-0.36	3.33e-9	Breast cancer;
KIRP	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.29	0.47	7.43e-15	Response to antipsychotic treatment;
KIRP	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	13.79	0.66	2.02e-32	Tonsillectomy;
KIRP	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.89	12.85	0.63	2.91e-29	Morning vs. evening chronotype;
KIRP	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.92	15.65	0.71	8.71e-39	Metabolic syndrome;
KIRP	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-6.68	-0.39	1.59e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	9.91	0.53	1.1e-19	Lymphocyte counts;
KIRP	cis	rs7771547	0.642	rs1003250	chr6:36437412	A/G	cg04289385	chr6:36355825	ETV7	-0.4	-6.36	-0.38	9.51e-10	Platelet distribution width;
KIRP	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	8.99	0.5	6.62e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-6.67	-0.39	1.72e-10	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs6442310	0.534	rs709148	chr3:12450166	C/A	cg02700894	chr3:12045449	SYN2	-0.42	-5.76	-0.34	2.45e-8	Hematocrit;
KIRP	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg06740227	chr12:86229804	RASSF9	0.51	6.7	0.39	1.44e-10	Major depressive disorder;
KIRP	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.43	5.77	0.35	2.43e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.44	-5.7	-0.34	3.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2224391	1.000	rs2773320	chr6:5261681	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.93	-0.4	3.7e-11	Height;
KIRP	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2223471	0.624	rs6928797	chr6:50735537	A/G	cg03432817	chr6:50765336	NA	-0.35	-5.1	-0.31	6.74e-7	Subcutaneous adipose tissue;
KIRP	cis	rs2635047	0.542	rs2668768	chr18:44783447	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.69	0.39	1.46e-10	Educational attainment;
KIRP	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg15997130	chr1:24165203	NA	-0.5	-5.96	-0.36	8.59e-9	Immature fraction of reticulocytes;
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg14338887	chr6:42928500	GNMT	0.47	7.0	0.41	2.37e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg14593290	chr7:50529359	DDC	0.66	7.86	0.45	1.22e-13	Malaria;
KIRP	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-0.89	-6.77	-0.4	9.54e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04152151	chr2:149215884	MBD5	-0.42	-6.77	-0.4	9.24e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.81	7.81	0.45	1.7e-13	Lung function (FEV1/FVC);
KIRP	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.55	-0.33	7.5e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.6	-7.92	-0.45	8.37e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.93	-14.39	-0.68	1.75e-34	Sudden cardiac arrest;
KIRP	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg02336718	chr17:17403227	NA	0.34	5.39	0.32	1.65e-7	Total body bone mineral density;
KIRP	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.39	8.29	0.47	7.54e-15	IgG glycosylation;
KIRP	cis	rs16957091	0.909	rs731984	chr15:43014477	G/A	cg24196017	chr15:43021976	CDAN1	-0.54	-7.17	-0.42	8.61e-12	MGMT methylation in smokers;
KIRP	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg07167872	chr1:205819463	PM20D1	-0.51	-4.96	-0.3	1.31e-6	Menarche (age at onset);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07031542	chr1:214567074	PTPN14	0.39	6.45	0.38	5.92e-10	C-reactive protein;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg11641102	chr8:27183873	PTK2B	0.45	5.97	0.36	8.25e-9	Neuroticism;
KIRP	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.56	-6.62	-0.39	2.18e-10	Aortic root size;
KIRP	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.94	-16.6	-0.73	5.08e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg05370193	chr1:21551575	ECE1	0.41	5.55	0.33	7.49e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg09455208	chr3:40491958	NA	-0.28	-5.0	-0.3	1.08e-6	Renal cell carcinoma;
KIRP	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.42	-5.01	-0.3	1.02e-6	Menarche (age at onset);
KIRP	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.12e-22	Coronary artery disease;
KIRP	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	9.43	0.52	3.18e-18	Post bronchodilator FEV1;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.73	6.46	0.38	5.44e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg08975724	chr8:8085496	FLJ10661	0.67	9.01	0.5	6e-17	Mood instability;
KIRP	cis	rs282587	0.530	rs380036	chr13:113418496	T/C	cg04656015	chr13:113407548	ATP11A	0.62	6.86	0.4	5.6e-11	Glycated hemoglobin levels;
KIRP	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.89	0.49	1.34e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg25011176	chr20:3776985	CDC25B	-0.42	-4.91	-0.3	1.65e-6	Bipolar disorder;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.47e-13	Bipolar disorder;
KIRP	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg14228332	chr4:119757509	SEC24D	0.84	4.99	0.3	1.15e-6	Cannabis dependence symptom count;
KIRP	cis	rs7536201	1.000	rs7528484	chr1:25292668	C/T	cg23273869	chr1:25296894	NA	-0.36	-4.98	-0.3	1.18e-6	Psoriasis vulgaris;
KIRP	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.58	-6.97	-0.41	2.9100000000000002e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.46	0.65	2.56e-31	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04287982	chr1:21766521	NBPF3	0.44	6.16	0.37	3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.11	-0.46	2.44e-14	Idiopathic membranous nephropathy;
KIRP	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg00405596	chr8:11794950	NA	0.53	7.12	0.41	1.15e-11	Retinal vascular caliber;
KIRP	cis	rs35160687	0.814	rs7563887	chr2:86516121	C/T	cg23811061	chr2:86423046	IMMT	0.39	5.44	0.33	1.26e-7	Night sleep phenotypes;
KIRP	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.41	-5.26	-0.32	3.14e-7	Abdominal aortic aneurysm;
KIRP	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.56	4.92	0.3	1.59e-6	Bipolar disorder;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.84	-12.02	-0.61	1.77e-26	Longevity;Endometriosis;
KIRP	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg06026331	chr20:60912101	LAMA5	-0.49	-6.33	-0.37	1.17e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.28	-5.42	-0.33	1.44e-7	Caffeine consumption;
KIRP	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-9.62	-0.52	8.2e-19	Response to antipsychotic treatment;
KIRP	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg11663144	chr21:46675770	NA	-0.58	-6.52	-0.38	4.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10875746	0.855	rs12310999	chr12:48447658	A/G	cg26205652	chr12:48591994	NA	0.77	10.29	0.55	6.69e-21	Longevity (90 years and older);
KIRP	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg05315796	chr3:52349193	DNAH1	0.4	6.43	0.38	6.59e-10	Electroencephalogram traits;
KIRP	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.99	-0.36	7.43e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.79	0.57	1.84e-22	Cognitive test performance;
KIRP	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.59	7.67	0.44	3.95e-13	Pulse pressure;
KIRP	cis	rs1345301	0.518	rs2110661	chr2:102863221	C/T	cg12451869	chr2:102867685	NA	0.48	6.85	0.4	5.87e-11	Waist circumference;
KIRP	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg10018233	chr7:150070692	REPIN1	0.62	7.13	0.41	1.14e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4780401	0.678	rs7189287	chr16:11764608	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.2	-0.31	4.23e-7	Rheumatoid arthritis;
KIRP	cis	rs9394841	0.692	rs9381095	chr6:41806708	T/A	cg08135965	chr6:41755394	TOMM6	0.52	5.55	0.33	7.51e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05119084	chr18:46477127	SMAD7	0.49	6.42	0.38	6.85e-10	Parkinson's disease;
KIRP	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg00310523	chr12:86230176	RASSF9	0.4	6.13	0.36	3.55e-9	Major depressive disorder;
KIRP	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.9	-0.49	1.27e-16	Resting heart rate;
KIRP	cis	rs9625935	0.833	rs140151	chr22:30186139	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-5.04	-0.31	9.1e-7	Tonsillectomy;
KIRP	cis	rs4302748	0.774	rs58840739	chr7:36181940	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.11	-0.61	8.39e-27	Ulcerative colitis;
KIRP	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.88	10.43	0.55	2.47e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.57	-6.59	-0.39	2.58e-10	Menarche (age at onset);
KIRP	trans	rs2048656	0.578	rs7817784	chr8:9682553	G/A	cg16141378	chr3:129829833	LOC729375	0.51	6.69	0.39	1.53e-10	Schizophrenia;
KIRP	cis	rs5756391	0.568	rs11705504	chr22:37317493	G/A	cg16356956	chr22:37317934	CSF2RB	0.38	5.18	0.31	4.52e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.76	9.62	0.52	8.5e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg06060754	chr5:176797920	RGS14	0.54	5.89	0.35	1.29e-8	Urate levels in lean individuals;
KIRP	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-9.51	-0.52	1.86e-18	Longevity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00500522	chr12:57504387	STAT6	0.51	6.52	0.38	3.88e-10	Parkinson's disease;
KIRP	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg24296786	chr1:45957014	TESK2	-0.48	-5.84	-0.35	1.65e-8	Homocysteine levels;
KIRP	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg02160872	chr5:212506	CCDC127	-0.47	-5.08	-0.31	7.51e-7	Breast cancer;
KIRP	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18252515	chr7:66147081	NA	0.42	4.91	0.3	1.63e-6	Aortic root size;
KIRP	cis	rs7677751	0.767	rs7676985	chr4:55064573	G/A	cg17187183	chr4:55093834	PDGFRA	0.78	9.33	0.51	6.58e-18	Corneal astigmatism;
KIRP	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	5.35	0.32	2.05e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.14	-0.31	5.47e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10137463	chr15:23085908	NIPA1	0.48	6.77	0.4	9.13e-11	Survival in pancreatic cancer;
KIRP	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg25039879	chr17:56429692	SUPT4H1	0.59	4.93	0.3	1.49e-6	Cognitive test performance;
KIRP	cis	rs9308433	0.643	rs955920	chr1:214464309	G/A	cg06198575	chr1:214491504	SMYD2	0.49	6.33	0.37	1.17e-9	IgG glycosylation;
KIRP	trans	rs12043259	0.892	rs35627019	chr1:204793461	T/C	cg11485465	chr5:54518469	NA	0.38	6.05	0.36	5.42e-9	Addiction;
KIRP	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21640587	chr11:117668038	DSCAML1	0.52	6.55	0.39	3.33e-10	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15405796	chr19:14682957	NDUFB7	0.55	6.92	0.4	3.81e-11	Parkinson's disease;
KIRP	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg07541023	chr7:19748670	TWISTNB	0.56	5.44	0.33	1.28e-7	Thyroid stimulating hormone;
KIRP	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.71	8.2	0.46	1.33e-14	Menarche (age at onset);
KIRP	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	0.86	12.61	0.63	1.84e-28	Essential tremor;
KIRP	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02725872	chr8:58115012	NA	-0.59	-7.23	-0.42	5.94e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg16341495	chr8:142228727	SLC45A4	-0.4	-4.92	-0.3	1.57e-6	Immature fraction of reticulocytes;
KIRP	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.79	10.82	0.57	1.44e-22	Aortic root size;
KIRP	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg15488143	chr7:128924101	AHCYL2	0.63	6.99	0.41	2.56e-11	White matter hyperintensity burden;
KIRP	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs28669119	0.778	rs770525	chr5:88123550	A/T	cg18498987	chr5:88179539	MEF2C	-0.53	-6.61	-0.39	2.37e-10	Schizophrenia;
KIRP	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.14	-0.36	3.21e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.53e-10	Aortic root size;
KIRP	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.62	-8.2	-0.46	1.35e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	11.36	0.59	2.64e-24	Personality dimensions;
KIRP	cis	rs13102973	0.646	rs4428339	chr4:135886187	C/T	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs9653442	0.545	rs13415465	chr2:100764004	T/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19524238	chr7:2802976	GNA12	-0.36	-4.94	-0.3	1.48e-6	Height;
KIRP	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.81	10.72	0.56	3.07e-22	Blood metabolite levels;
KIRP	cis	rs5753618	0.555	rs9609302	chr22:31895987	A/C	cg02404636	chr22:31891804	SFI1	0.54	5.92	0.35	1.06e-8	Colorectal cancer;
KIRP	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.67	9.15	0.5	2.19e-17	Red blood cell count;
KIRP	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	7.19	0.42	7.67e-12	Mean platelet volume;
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg21523564	chr15:75251491	NA	0.48	8.15	0.46	1.91e-14	Breast cancer;
KIRP	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.77	-0.35	2.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg01879757	chr17:41196368	BRCA1	-0.54	-7.3	-0.42	4.05e-12	Menopause (age at onset);
KIRP	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg16434002	chr17:42200994	HDAC5	-0.59	-7.53	-0.43	9.47e-13	Total body bone mineral density;
KIRP	cis	rs7113850	0.541	rs7131336	chr11:24219418	C/T	ch.11.24196551F	chr11:24239977	NA	0.82	8.18	0.46	1.54e-14	Bone fracture in osteoporosis;
KIRP	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg05938607	chr10:60274200	BICC1	0.42	10.22	0.55	1.11e-20	Refractive error;
KIRP	cis	rs16866061	0.816	rs115900205	chr2:225467840	G/C	cg12698349	chr2:225449008	CUL3	0.89	11.01	0.57	3.55e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.92	13.75	0.66	2.76e-32	Tonsillectomy;
KIRP	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.12	-0.31	6.27e-7	Rheumatoid arthritis;
KIRP	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.77	8.69	0.48	5.16e-16	Corneal astigmatism;
KIRP	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	6.8	0.4	7.97e-11	Colorectal cancer;
KIRP	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg26384229	chr12:38710491	ALG10B	0.56	7.11	0.41	1.23e-11	Resting heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03427120	chr20:47662890	CSE1L	0.54	6.84	0.4	6.34e-11	Parkinson's disease;
KIRP	cis	rs28834970	0.928	rs17057043	chr8:27220310	C/T	cg06815112	chr8:27182871	PTK2B	-0.43	-5.59	-0.34	6e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.65	8.4	0.47	3.69e-15	Menarche (age at onset);
KIRP	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.83	11.64	0.6	3.2e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.18	26.67	0.86	1.49e-74	Schizophrenia;
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg21523564	chr15:75251491	NA	0.42	6.68	0.39	1.58e-10	Caffeine consumption;
KIRP	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.15	9.83	0.53	1.88e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-7.95	-0.45	6.59e-14	Bone mineral density;
KIRP	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg16586182	chr3:47516702	SCAP	0.78	11.15	0.58	1.23e-23	Colorectal cancer;
KIRP	cis	rs9488822	0.585	rs569201	chr6:116265861	C/T	cg26893134	chr6:116381904	FRK	-0.2	-5.3	-0.32	2.55e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg25173405	chr17:45401733	C17orf57	0.42	5.39	0.32	1.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg15896084	chr13:114927664	NA	0.41	5.27	0.32	3.03e-7	Schizophrenia;
KIRP	cis	rs17030434	1.000	rs17030434	chr4:154703596	A/G	cg14289246	chr4:154710475	SFRP2	-0.82	-10.05	-0.54	3.97e-20	Electrocardiographic conduction measures;
KIRP	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	5.78	0.35	2.22e-8	HIV-1 control;
KIRP	cis	rs867371	1.000	rs6495643	chr15:82479254	C/G	cg06066596	chr15:83166174	LOC80154	-0.47	-5.53	-0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg02389323	chr16:88786976	FAM38A	0.83	6.64	0.39	1.94e-10	Plateletcrit;
KIRP	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg06360820	chr2:242988706	NA	-0.82	-7.24	-0.42	5.68e-12	Obesity-related traits;
KIRP	cis	rs2742417	1.000	rs9829631	chr3:45740558	T/C	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.57	7.5	0.43	1.14e-12	White matter hyperintensity burden;
KIRP	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.13	0.31	5.87e-7	Height;
KIRP	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.82	-12.08	-0.61	1.11e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.78	-8.53	-0.48	1.47e-15	Parkinson's disease;
KIRP	cis	rs6832769	0.961	rs7684810	chr4:56352794	C/T	cg05960024	chr4:56376020	CLOCK	0.7	8.67	0.48	6.06e-16	Personality dimensions;
KIRP	cis	rs1440410	0.835	rs28649839	chr4:144146200	A/T	cg01719995	chr4:144104893	USP38	0.43	5.99	0.36	7.24e-9	Ischemic stroke;
KIRP	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.48	6.43	0.38	6.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.67	-7.76	-0.44	2.3e-13	Primary sclerosing cholangitis;
KIRP	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.51	7.87	0.45	1.15e-13	Testicular germ cell tumor;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15776560	chr3:25916362	NA	0.57	6.37	0.38	9.39e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg01620082	chr3:125678407	NA	-1.18	-7.63	-0.44	5.19e-13	Depression;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.58	7.34	0.42	3.09e-12	Longevity;
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg23985595	chr17:80112537	CCDC57	0.37	5.44	0.33	1.28e-7	Life satisfaction;
KIRP	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg25233709	chr10:116636983	FAM160B1	0.36	5.6	0.34	5.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06850241	chr22:41845214	NA	-0.44	-5.06	-0.31	8.1e-7	Vitiligo;
KIRP	cis	rs7078219	0.965	rs11190134	chr10:101282200	C/T	cg23904955	chr10:101282759	NA	-0.33	-5.07	-0.31	8.01e-7	Dental caries;
KIRP	cis	rs1062746	0.557	rs35441225	chr16:87335498	C/A	cg02258303	chr16:87377426	FBXO31	-0.42	-5.71	-0.34	3.31e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.61	-5.85	-0.35	1.58e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg06995285	chr7:2418615	EIF3B	0.71	7.9	0.45	9.16e-14	Multiple sclerosis;
KIRP	cis	rs651907	0.640	rs1091664	chr3:101618690	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	5.23	0.32	3.54e-7	Colorectal cancer;
KIRP	cis	rs11608355	0.521	rs7976839	chr12:109830534	C/A	cg19025524	chr12:109796872	NA	-0.51	-7.05	-0.41	1.84e-11	Neuroticism;
KIRP	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.06	-0.58	2.4e-23	Height;
KIRP	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.58	7.23	0.42	5.98e-12	Coronary artery disease;
KIRP	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg09462578	chr12:12878428	APOLD1	-0.69	-7.22	-0.42	6.43e-12	Systemic lupus erythematosus;
KIRP	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14895029	chr7:2775587	GNA12	-0.42	-4.97	-0.3	1.27e-6	Height;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg05489143	chr3:40498640	RPL14	0.99	7.1	0.41	1.34e-11	P wave terminal force;
KIRP	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg13206674	chr6:150067644	NUP43	-0.6	-8.69	-0.48	5.18e-16	Lung cancer;
KIRP	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg10189774	chr4:17578691	LAP3	0.5	6.05	0.36	5.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg00405596	chr8:11794950	NA	0.41	5.09	0.31	7.04e-7	Retinal vascular caliber;
KIRP	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.94	-16.38	-0.72	2.77e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.85	-13.07	-0.64	5.29e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7078219	0.743	rs11190133	chr10:101278725	C/T	cg07044859	chr10:101282883	NA	-0.38	-5.97	-0.36	8.43e-9	Dental caries;
KIRP	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg15976283	chr2:238042351	NA	0.39	5.39	0.32	1.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg08477640	chr19:41863820	B9D2	0.63	7.39	0.43	2.3e-12	Colorectal cancer;
KIRP	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg13160058	chr8:26243215	BNIP3L	-0.45	-6.99	-0.41	2.62e-11	Red cell distribution width;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-0.83	-14.75	-0.69	1.01e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.91	-10.23	-0.55	1.1e-20	Exhaled nitric oxide output;
KIRP	cis	rs2051773	0.567	rs12288579	chr11:17039910	G/A	cg15432903	chr11:17409602	KCNJ11	-0.51	-6.03	-0.36	6.04e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	0.9	9.79	0.53	2.61e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4638749	0.501	rs6715622	chr2:108759372	A/C	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.14	-0.31	5.57e-7	Blood pressure;
KIRP	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-9.97	-0.54	7.04e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	7.9	0.45	9.36e-14	Type 2 diabetes;
KIRP	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.85	-12.12	-0.61	7.96e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7923609	0.905	rs10740129	chr10:65250808	G/A	cg01631684	chr10:65280961	REEP3	-0.52	-6.09	-0.36	4.39e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.67	-6.9	-0.4	4.32e-11	Axial length;
KIRP	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg24375607	chr4:120327624	NA	0.52	6.13	0.36	3.51e-9	Corneal astigmatism;
KIRP	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg11752832	chr7:134001865	SLC35B4	0.47	6.18	0.37	2.63e-9	Mean platelet volume;
KIRP	cis	rs1570884	0.740	rs12146924	chr13:50134358	T/C	cg08779649	chr13:50194554	NA	0.5	6.99	0.41	2.51e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	trans	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg16141378	chr3:129829833	LOC729375	0.51	6.83	0.4	6.45e-11	Mood instability;
KIRP	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.43	-0.33	1.34e-7	Headache;
KIRP	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg15655495	chr12:38532458	NA	0.25	4.86	0.3	2.07e-6	Bladder cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04770025	chr11:108172798	ATM	-0.41	-6.4	-0.38	7.77e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg00807237	chr7:934156	C7orf20	0.45	5.48	0.33	1.05e-7	Subjective well-being;
KIRP	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.75e-9	Breast cancer;
KIRP	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.53	-6.43	-0.38	6.58e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs1462872	0.736	rs327347	chr8:31796699	G/A	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs10513788	0.951	rs60965899	chr3:182073282	A/G	cg01449425	chr3:181957089	NA	-0.47	-6.33	-0.37	1.12e-9	Cognitive function;
KIRP	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-12.06	-0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.65	-9.4	-0.51	3.88e-18	Schizophrenia;
KIRP	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.24	-0.37	1.9e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	9.42	0.51	3.42e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs4765905	0.610	rs10848632	chr12:2315993	A/G	cg10668781	chr12:2307325	CACNA1C	0.32	6.57	0.39	2.9e-10	Schizophrenia;
KIRP	cis	rs3120667	0.720	rs6696556	chr1:152430842	A/C	cg26876637	chr1:152193138	HRNR	0.58	5.49	0.33	1.02e-7	Eating disorders;
KIRP	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.39	4.92	0.3	1.61e-6	IgG glycosylation;
KIRP	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg07636037	chr3:49044803	WDR6	0.79	6.41	0.38	7.41e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg21926883	chr2:100939477	LONRF2	-0.57	-7.88	-0.45	1.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg00147788	chr6:125855365	NA	-0.32	-5.02	-0.3	9.97e-7	Brugada syndrome;
KIRP	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg16553119	chr1:165599451	MGST3	-0.43	-4.99	-0.3	1.15e-6	Total ventricular volume;
KIRP	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4704187	0.687	rs922390	chr5:74401269	A/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07682378	chr3:150128910	TSC22D2	0.46	6.24	0.37	1.86e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.2	-0.42	7.16e-12	Aortic root size;
KIRP	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-0.95	-10.56	-0.56	9.64e-22	Blood protein levels;
KIRP	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.84	12.95	0.64	1.33e-29	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg09264619	chr17:80180166	NA	-0.39	-5.54	-0.33	7.78e-8	Life satisfaction;
KIRP	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg01879757	chr17:41196368	BRCA1	-0.73	-10.42	-0.55	2.74e-21	Menopause (age at onset);
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.43	-6.05	-0.36	5.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg01411142	chr8:19674711	INTS10	0.45	4.92	0.3	1.62e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.46	0.38	5.55e-10	Personality dimensions;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01906197	chr14:23067002	ABHD4	0.51	6.17	0.37	2.82e-9	Smoking initiation;
KIRP	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.8	-11.73	-0.6	1.61e-25	Obesity-related traits;
KIRP	cis	rs4363385	0.588	rs12079087	chr1:153023888	T/C	cg07796016	chr1:152779584	LCE1C	-0.44	-5.66	-0.34	4.24e-8	Inflammatory skin disease;
KIRP	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg07001201	chr5:642380	CEP72	0.69	6.36	0.38	9.55e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7712401	0.601	rs246308	chr5:122270090	G/T	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.52e-7	Mean platelet volume;
KIRP	cis	rs960902	0.592	rs7571760	chr2:37742758	A/G	cg25341268	chr2:37734390	NA	-0.63	-8.83	-0.49	1.97e-16	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.35	0.42	2.92e-12	Lung cancer;
KIRP	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.5	-6.78	-0.4	8.69e-11	Menarche (age at onset);
KIRP	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg08501292	chr6:25962987	TRIM38	1.1	8.13	0.46	2.09e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	0.717	rs1072405	chr22:18406068	A/C	cg03078520	chr22:18463400	MICAL3	-0.52	-6.25	-0.37	1.83e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs9914544	0.591	rs9900052	chr17:18699398	G/A	cg04702396	chr17:15466718	FAM18B2	0.7	10.47	0.56	1.85e-21	Educational attainment (years of education);
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg21285383	chr16:89894308	SPIRE2	-0.33	-6.27	-0.37	1.65e-9	Vitiligo;
KIRP	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.94	16.38	0.72	2.81e-41	Metabolic syndrome;
KIRP	cis	rs2067615	0.521	rs1216002	chr12:107213601	A/T	cg21360079	chr12:107162445	NA	-0.43	-5.23	-0.32	3.68e-7	Heart rate;
KIRP	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.68	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.59	-6.65	-0.39	1.93e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs427941	0.632	rs201503	chr7:101759595	C/G	cg06246474	chr7:101738831	CUX1	0.52	6.55	0.39	3.32e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs838147	0.844	rs12975033	chr19:49249443	A/T	cg13540341	chr19:49222985	MAMSTR	0.34	5.54	0.33	7.85e-8	Dietary macronutrient intake;
KIRP	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.31	0.37	1.3e-9	Bipolar disorder;
KIRP	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.68	-0.44	3.71e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.18	-18.96	-0.77	4.93e-50	Ulcerative colitis;
KIRP	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.61	-0.34	5.57e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7246657	0.598	rs10417545	chr19:37654263	C/G	cg18154014	chr19:37997991	ZNF793	0.7	5.99	0.36	7.41e-9	Coronary artery calcification;
KIRP	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.48	5.59	0.34	5.99e-8	Primary tooth development (time to first tooth eruption);
KIRP	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.76	-9.48	-0.52	2.3e-18	Coronary artery disease;
KIRP	cis	rs2573652	0.722	rs12898366	chr15:100543067	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.4	-0.43	2.16e-12	Height;
KIRP	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.72	-12.65	-0.63	1.36e-28	Obesity-related traits;
KIRP	cis	rs55788414	0.932	rs12103301	chr16:81181423	A/C	cg06400318	chr16:81190750	PKD1L2	-0.83	-7.55	-0.43	8.75e-13	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg27205649	chr11:78285834	NARS2	0.64	7.28	0.42	4.54e-12	Alzheimer's disease (survival time);
KIRP	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.38	7.44e-10	Height;
KIRP	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.48	-6.4	-0.38	7.75e-10	Mean corpuscular volume;
KIRP	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	29.07	0.88	1.54e-81	Chronic sinus infection;
KIRP	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg02775129	chr4:119771670	NA	-0.84	-5.18	-0.31	4.61e-7	Cannabis dependence symptom count;
KIRP	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	10.04	0.54	4.31e-20	Parkinson's disease;
KIRP	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg00982548	chr2:198649783	BOLL	-0.57	-5.62	-0.34	5.06e-8	Ulcerative colitis;
KIRP	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg14169450	chr9:139327907	INPP5E	0.6	7.33	0.42	3.33e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9581857	0.547	rs9579094	chr13:28081495	G/A	cg22138327	chr13:27999177	GTF3A	0.83	6.45	0.38	5.79e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14984162	chr13:114776704	RASA3	0.54	6.96	0.41	3.02e-11	Interleukin-4 levels;
KIRP	trans	rs656319	0.729	rs471480	chr8:9812462	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.77	-0.4	9.6e-11	Myopia (pathological);
KIRP	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg00579200	chr11:133705235	NA	-0.39	-4.85	-0.3	2.16e-6	Childhood ear infection;
KIRP	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.74	-8.51	-0.48	1.73e-15	Adiposity;
KIRP	cis	rs73086581	0.947	rs73084531	chr20:3878429	G/A	cg02187196	chr20:3869020	PANK2	0.51	4.9	0.3	1.77e-6	Response to antidepressants in depression;
KIRP	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.52	7.34	0.42	3.08e-12	Systemic lupus erythematosus;
KIRP	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg05973401	chr12:123451056	ABCB9	0.61	5.58	0.34	6.41e-8	Neutrophil percentage of white cells;
KIRP	cis	rs137699	0.652	rs137707	chr22:39751401	T/C	cg05872129	chr22:39784769	NA	-0.54	-6.2	-0.37	2.4e-9	IgG glycosylation;
KIRP	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.78	7.66	0.44	4.19e-13	Neuroblastoma;
KIRP	cis	rs1983891	0.955	rs6917029	chr6:41548540	C/G	cg20194872	chr6:41519635	FOXP4	0.56	7.21	0.42	7.04e-12	Prostate cancer;
KIRP	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg22916017	chr11:64110731	CCDC88B	0.51	5.63	0.34	4.99e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.75	-0.34	2.59e-8	Neutrophil percentage of white cells;
KIRP	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.36	-0.47	4.82e-15	Height;
KIRP	cis	rs2729354	0.768	rs2584856	chr11:57267312	C/A	cg24343310	chr11:57249947	NA	0.28	5.41	0.33	1.51e-7	Blood protein levels;
KIRP	cis	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg03146154	chr1:46216737	IPP	0.43	5.34	0.32	2.13e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	1.04	15.74	0.71	4.35e-39	Menopause (age at onset);
KIRP	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg17724175	chr1:150552817	MCL1	0.34	5.71	0.34	3.17e-8	Melanoma;
KIRP	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.71	-0.49	4.38e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.12	-0.31	6.17e-7	Testicular germ cell tumor;
KIRP	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.6	8.69	0.48	5.25e-16	Blood metabolite levels;
KIRP	cis	rs12282928	0.759	rs7395503	chr11:48344386	C/T	cg26585981	chr11:48327164	OR4S1	0.52	6.26	0.37	1.7e-9	Migraine - clinic-based;
KIRP	cis	rs6662572	0.737	rs11211214	chr1:46347328	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs66561647	0.853	rs66824612	chr8:128967819	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.55	7.5	0.43	1.14e-12	Hemoglobin concentration;
KIRP	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.06	-0.5	4.21e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg03235661	chr20:60525775	NA	-0.31	-5.2	-0.31	4.22e-7	Body mass index;
KIRP	cis	rs367943	0.712	rs9326889	chr5:112731438	A/G	cg12552261	chr5:112820674	MCC	0.58	6.88	0.4	4.98e-11	Type 2 diabetes;
KIRP	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg11663144	chr21:46675770	NA	-0.58	-8.32	-0.47	6.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.56	8.1	0.46	2.58e-14	Carotid intima media thickness;
KIRP	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.64	-8.1	-0.46	2.58e-14	Iron status biomarkers;
KIRP	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	8.83	0.49	1.97e-16	Resting heart rate;
KIRP	cis	rs6684514	1.000	rs2277870	chr1:156246792	C/T	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs4901847	0.933	rs11623561	chr14:58556776	G/T	cg15908186	chr14:58618357	C14orf37	-0.4	-5.15	-0.31	5.28e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	cis	rs2746347	0.722	rs10889007	chr1:57119753	T/A	cg09935045	chr1:57111199	PRKAA2	-0.51	-5.22	-0.32	3.83e-7	Lymphocyte counts;
KIRP	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg17747265	chr1:1875780	NA	-0.72	-13.18	-0.64	2.31e-30	Body mass index;
KIRP	cis	rs6001982	0.510	rs77426923	chr22:40889908	G/A	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg23594656	chr7:65796392	TPST1	-0.43	-5.95	-0.35	9e-9	Aortic root size;
KIRP	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Urinary tract infection frequency;
KIRP	cis	rs6102059	0.572	rs6129631	chr20:39190359	C/T	cg22477343	chr20:39312069	NA	0.47	5.98	0.36	7.97e-9	LDL cholesterol;
KIRP	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg00262122	chr8:11665843	FDFT1	-0.42	-5.12	-0.31	6.25e-7	Neuroticism;
KIRP	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg20744362	chr22:50050164	C22orf34	0.39	6.74	0.39	1.14e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	1.11	22.17	0.82	1.39e-60	Height;
KIRP	cis	rs4780401	0.526	rs12929396	chr16:11774625	C/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-4.87	-0.3	2.03e-6	Rheumatoid arthritis;
KIRP	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg09184832	chr6:79620586	NA	-0.53	-7.38	-0.43	2.39e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.69	-0.34	3.69e-8	Aortic root size;
KIRP	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg03563238	chr19:33554763	RHPN2	0.32	5.66	0.34	4.11e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7274811	0.625	rs293722	chr20:31927361	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.42	-4.94	-0.3	1.44e-6	Height;
KIRP	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg24747557	chr10:131355152	MGMT	0.37	4.95	0.3	1.38e-6	Response to temozolomide;
KIRP	cis	rs7998202	0.614	rs394369	chr13:113370228	A/G	cg04656015	chr13:113407548	ATP11A	-0.6	-6.44	-0.38	6.11e-10	Glycated hemoglobin levels;
KIRP	cis	rs4938330	0.723	rs7931398	chr11:116879676	T/C	cg04087571	chr11:116723030	SIK3	-0.26	-5.49	-0.33	9.82e-8	Blood protein levels;
KIRP	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg07777115	chr5:623756	CEP72	-0.53	-5.73	-0.34	2.91e-8	Obesity-related traits;
KIRP	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	7.75	0.44	2.35e-13	Cognitive test performance;
KIRP	cis	rs2273156	1.000	rs12880928	chr14:35475678	A/G	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.45	-0.33	1.25e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.76	-9.02	-0.5	5.39e-17	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-1.06	-10.16	-0.54	1.81e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.73	-0.34	2.99e-8	Breast cancer;
KIRP	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.44	5.96	0.36	8.51e-9	Red blood cell count;
KIRP	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.49	-6.49	-0.38	4.72e-10	Schizophrenia;
KIRP	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg06060754	chr5:176797920	RGS14	0.47	7.13	0.41	1.14e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs7267005	0.661	rs79491781	chr20:34376708	C/G	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4849845	0.889	rs6542579	chr2:121014370	C/T	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07513820	chr20:47894984	C20orf199;SNORD12C;ZNFX1	0.5	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs9815354	1.000	rs2272007	chr3:41996136	A/G	cg03022575	chr3:42003672	ULK4	-0.49	-5.69	-0.34	3.57e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7937612	1.000	rs10892578	chr11:120308290	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.89	-0.4	4.57e-11	Intraocular pressure;
KIRP	cis	rs1971762	0.545	rs10747675	chr12:54000031	A/G	cg23533419	chr12:54090519	NA	0.32	5.03	0.31	9.25e-7	Height;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	6.64	0.39	2.03e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07989796	chr19:41082579	SHKBP1	0.54	6.9	0.4	4.29e-11	Parkinson's disease;
KIRP	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg06636001	chr8:8085503	FLJ10661	0.62	8.6	0.48	9.64e-16	Neuroticism;
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg21523564	chr15:75251491	NA	0.39	6.37	0.38	9.48e-10	Breast cancer;
KIRP	cis	rs6743226	1.000	rs6743226	chr2:242236972	T/C	cg10021735	chr2:242295487	FARP2	0.47	5.78	0.35	2.31e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.07	0.31	7.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.78	6.79	0.4	8.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.65	6.74	0.39	1.1e-10	Axial length;
KIRP	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.56	-0.33	6.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.87	-0.45	1.09e-13	Sudden cardiac arrest;
KIRP	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.38e-10	Diabetic retinopathy;
KIRP	cis	rs7923609	0.967	rs10761758	chr10:65172747	A/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.45	6.71	0.39	1.32e-10	Major depressive disorder;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19613905	chr15:56757180	MNS1	0.52	6.29	0.37	1.44e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18500431	chr7:1709489	NA	0.66	6.05	0.36	5.36e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg19773385	chr1:10388646	KIF1B	-0.68	-9.23	-0.51	1.32e-17	Hepatocellular carcinoma;
KIRP	cis	rs494562	0.892	rs490079	chr6:86117599	T/C	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs4262150	0.883	rs72799172	chr5:152148371	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs62380364	0.558	rs34319	chr5:88023349	A/T	cg24804195	chr5:87968844	LOC645323	-0.45	-5.81	-0.35	1.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1440410	0.835	rs6818149	chr4:144125085	A/C	cg01719995	chr4:144104893	USP38	0.39	5.25	0.32	3.32e-7	Ischemic stroke;
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.97	16.13	0.72	1.94e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg15117754	chr3:10150083	C3orf24	0.52	5.02	0.3	9.87e-7	Alzheimer's disease;
KIRP	cis	rs780096	0.967	rs1260334	chr2:27748597	C/A	cg22903471	chr2:27725779	GCKR	-0.43	-6.33	-0.37	1.18e-9	Total body bone mineral density;
KIRP	cis	rs2299587	0.901	rs7836639	chr8:17809810	T/A	cg01800426	chr8:17659068	MTUS1	-0.44	-5.32	-0.32	2.33e-7	Economic and political preferences;
KIRP	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4389656	0.857	rs274719	chr5:6720916	A/G	cg10857441	chr5:6722123	POLS	-0.47	-6.58	-0.39	2.76e-10	Coronary artery disease;
KIRP	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.53	6.69	0.39	1.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.43	-5.06	-0.31	8.05e-7	Myopia;
KIRP	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.66	-6.94	-0.4	3.56e-11	Coronary artery calcification;
KIRP	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	4.89	0.3	1.84e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg06627628	chr2:24431161	ITSN2	-0.52	-4.85	-0.3	2.24e-6	Lymphocyte counts;
KIRP	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg17145862	chr1:211918768	LPGAT1	-0.92	-13.36	-0.65	5.54e-31	Leprosy;
KIRP	cis	rs2072732	0.861	rs12041583	chr1:2950886	A/G	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs6593803	0.843	rs11240118	chr1:147225584	G/A	cg27546670	chr1:147246839	GJA5	0.59	8.21	0.46	1.24e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.69	5.49	0.33	1.01e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7851660	0.844	rs10984103	chr9:100639275	G/T	cg13688889	chr9:100608707	NA	0.66	8.62	0.48	8.07e-16	Strep throat;
KIRP	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.65	0.34	4.41e-8	Breast cancer;
KIRP	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg00278547	chr2:177037212	HOXD3	-0.38	-4.98	-0.3	1.17e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.74	7.72	0.44	2.93e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg15556689	chr8:8085844	FLJ10661	0.8	10.6	0.56	7.24e-22	Systolic blood pressure;
KIRP	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-1.07	-19.5	-0.78	7.82e-52	Migraine;
KIRP	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg00262122	chr8:11665843	FDFT1	-0.44	-5.4	-0.33	1.6e-7	Retinal vascular caliber;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08887933	chr16:71601037	TAT	0.6	7.96	0.45	6.34e-14	Interleukin-4 levels;
KIRP	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg21775007	chr8:11205619	TDH	0.46	6.11	0.36	3.9e-9	Neuroticism;
KIRP	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg06917634	chr15:78832804	PSMA4	0.47	4.89	0.3	1.81e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg27487796	chr7:28973253	NA	-0.22	-4.97	-0.3	1.27e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-1.03	-14.05	-0.67	2.55e-33	Blood pressure (smoking interaction);
KIRP	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.85	-0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs6832769	0.961	rs6824955	chr4:56317136	A/C	cg05960024	chr4:56376020	CLOCK	0.7	8.87	0.49	1.53e-16	Personality dimensions;
KIRP	cis	rs10518128	1.000	rs28695767	chr4:75697131	C/T	cg20122727	chr4:75719957	BTC	0.56	5.68	0.34	3.84e-8	Electroencephalogram traits;
KIRP	cis	rs3105593	1.000	rs12442787	chr15:50918107	G/T	cg05456662	chr15:50716270	USP8	0.42	5.14	0.31	5.54e-7	QT interval;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10802291	chr19:56186542	EPN1	0.52	6.47	0.38	5.26e-10	Parkinson's disease;
KIRP	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg10503236	chr1:231470652	EXOC8	-0.55	-8.07	-0.46	3.11e-14	Hemoglobin concentration;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.81	0.35	1.88e-8	Lung cancer;
KIRP	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.07	-0.64	5.21e-30	Chronic sinus infection;
KIRP	cis	rs6866344	0.569	rs56070635	chr5:178150169	A/C	cg03877680	chr5:178157825	ZNF354A	1.03	13.17	0.64	2.44e-30	Neutrophil percentage of white cells;
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg13906792	chr15:75199810	C15orf17	-0.36	-5.45	-0.33	1.22e-7	Breast cancer;
KIRP	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.46	6.96	0.41	3.07e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.58	7.24	0.42	5.8e-12	Arsenic metabolism;
KIRP	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg08125733	chr17:73851984	WBP2	0.43	5.37	0.32	1.81e-7	White matter hyperintensity burden;
KIRP	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.41	-6.45	-0.38	5.75e-10	Refractive error;
KIRP	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg07148914	chr20:33460835	GGT7	-0.41	-5.07	-0.31	7.84e-7	Height;
KIRP	cis	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.47	6.28	0.37	1.51e-9	Leprosy;
KIRP	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg27205649	chr11:78285834	NARS2	0.69	7.56	0.43	8.18e-13	Alzheimer's disease (survival time);
KIRP	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.7	6.39	0.38	8.42e-10	Methadone dose in opioid dependence;
KIRP	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs612683	0.694	rs6688364	chr1:101000874	G/A	cg06223162	chr1:101003688	GPR88	0.52	10.54	0.56	1.13e-21	Breast cancer;
KIRP	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.7	10.4	0.55	3.12e-21	Dupuytren's disease;
KIRP	cis	rs4776059	1.000	rs11853917	chr15:52922054	T/C	cg25063058	chr15:52860530	ARPP19	0.53	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.9	12.35	0.62	1.4e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg27490568	chr2:178487706	NA	-0.47	-6.21	-0.37	2.22e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.67	-8.25	-0.47	9.95e-15	Obesity-related traits;
KIRP	trans	rs73191547	0.690	rs7011281	chr8:10036035	C/T	cg20582800	chr6:43612764	RSPH9	0.43	6.24	0.37	1.94e-9	Schizophrenia;
KIRP	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.42	7.09	0.41	1.45e-11	Heart rate;
KIRP	trans	rs9650657	0.812	rs6601522	chr8:10629061	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.18	-0.37	2.66e-9	Neuroticism;
KIRP	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.86	-11.15	-0.58	1.25e-23	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.52	0.52	1.72e-18	Coffee consumption (cups per day);
KIRP	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.2	0.37	2.36e-9	Retinal vascular caliber;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08946658	chr2:136719185	DARS	0.44	6.79	0.4	8.5e-11	Survival in pancreatic cancer;
KIRP	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg10977910	chr1:84465055	TTLL7	0.44	5.3	0.32	2.56e-7	Obesity-related traits;
KIRP	trans	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg25042112	chr7:64838748	ZNF92	-0.59	-6.28	-0.37	1.48e-9	Pain;
KIRP	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg10189774	chr4:17578691	LAP3	0.49	6.03	0.36	5.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.38	0.47	4.23e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg11234688	chr2:1609660	NA	0.53	5.01	0.3	1.05e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs986417	1.000	rs10136642	chr14:60946098	G/C	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs3087591	1.000	rs4795579	chr17:29458682	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	10.21	0.55	1.23e-20	Hip circumference;
KIRP	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.09	0.36	4.32e-9	Height;
KIRP	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg27624424	chr6:160112604	SOD2	-0.52	-6.26	-0.37	1.67e-9	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.63	-0.44	5.19e-13	Bipolar disorder;
KIRP	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg20744362	chr22:50050164	C22orf34	0.38	6.5	0.38	4.38e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg16497661	chr14:103986332	CKB	-0.54	-7.12	-0.41	1.19e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs231513	0.911	rs231527	chr17:41951228	T/C	cg26893861	chr17:41843967	DUSP3	-0.5	-5.16	-0.31	4.99e-7	Cognitive function;
KIRP	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.6	8.35	0.47	5.07e-15	Lewy body disease;
KIRP	cis	rs710987	0.967	rs1613757	chr5:3530475	A/C	cg14530963	chr5:3489551	NA	0.41	5.01	0.3	1.05e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	trans	rs13170463	0.649	rs34525917	chr5:8035555	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.77	-9.48	-0.52	2.3e-18	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.77	-10.29	-0.55	6.74e-21	Huntington's disease progression;
KIRP	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.44	6.0	0.36	6.92e-9	Total body bone mineral density;
KIRP	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	0.95	17.49	0.74	4.71e-45	Dental caries;
KIRP	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.47	-6.05	-0.36	5.38e-9	Schizophrenia;
KIRP	cis	rs3857067	1.000	rs2865332	chr4:95013858	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.85	-0.3	2.16e-6	QT interval;
KIRP	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.83	7.87	0.45	1.1e-13	Psoriasis vulgaris;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17335440	chr11:48161380	PTPRJ	0.5	6.08	0.36	4.52e-9	Interleukin-4 levels;
KIRP	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg04055107	chr11:65626734	MUS81;CFL1	0.4	4.9	0.3	1.71e-6	Eosinophil percentage of white cells;
KIRP	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg27205649	chr11:78285834	NARS2	-0.55	-5.37	-0.32	1.79e-7	Testicular germ cell tumor;
KIRP	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg22029157	chr1:209979665	IRF6	0.39	5.96	0.36	8.65e-9	Monobrow;
KIRP	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg12962167	chr3:53033115	SFMBT1	0.77	5.72	0.34	3.13e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg18016565	chr1:150552671	MCL1	0.37	5.82	0.35	1.81e-8	Melanoma;
KIRP	cis	rs710987	0.967	rs710991	chr5:3518510	G/T	cg14530963	chr5:3489551	NA	0.4	4.9	0.3	1.71e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.55	8.17	0.46	1.6e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.73	11.41	0.59	1.76e-24	Resting heart rate;
KIRP	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.12	0.36	3.65e-9	Menopause (age at onset);
KIRP	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg08975724	chr8:8085496	FLJ10661	0.58	7.68	0.44	3.86e-13	Neuroticism;
KIRP	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.52	0.48	1.59e-15	Morning vs. evening chronotype;
KIRP	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg23625390	chr15:77176239	SCAPER	0.52	6.76	0.4	1.01e-10	Blood metabolite levels;
KIRP	cis	rs112591243	0.570	rs2839340	chr21:47989804	C/T	cg26904215	chr21:47823096	PCNT	-0.76	-6.52	-0.38	3.9e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.7	9.08	0.5	3.63e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14014471	chr1:178694459	RALGPS2	0.47	6.35	0.38	1.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2963155	0.518	rs174048	chr5:142650404	T/C	cg17617527	chr5:142782415	NR3C1	0.7	6.63	0.39	2.1e-10	Breast cancer;
KIRP	cis	rs10073892	0.703	rs59934563	chr5:101634575	T/C	cg19774478	chr5:101632501	SLCO4C1	0.63	6.34	0.37	1.11e-9	Cognitive decline (age-related);
KIRP	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-1.2	-13.01	-0.64	8.39e-30	Monocyte percentage of white cells;
KIRP	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg17366294	chr4:99064904	C4orf37	0.43	5.96	0.36	8.66e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg16141378	chr3:129829833	LOC729375	0.54	7.25	0.42	5.25e-12	Triglycerides;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.78	6.83	0.4	6.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg19913688	chr11:428466	ANO9	-0.76	-6.1	-0.36	4.09e-9	Body mass index;
KIRP	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.43	-8.48	-0.48	2.16e-15	Urinary metabolites;
KIRP	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg17595323	chr11:93583763	C11orf90	-0.34	-5.75	-0.34	2.7e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs7618501	0.699	rs11713193	chr3:49924424	G/A	cg24110177	chr3:50126178	RBM5	-0.65	-8.93	-0.49	1.04e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs4356932	1.000	rs4484324	chr4:76984713	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs59197085	0.636	rs4731517	chr7:128458649	A/C	cg00734629	chr7:128471146	FLNC	-0.48	-5.78	-0.35	2.29e-8	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.64	-8.66	-0.48	6.3e-16	Motion sickness;
KIRP	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.45	-0.65	2.7e-31	Height;
KIRP	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg06640241	chr16:89574553	SPG7	0.65	8.69	0.48	5.03e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.47	-5.15	-0.31	5.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.18	0.37	2.63e-9	Hemoglobin concentration;
KIRP	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-5.41	-0.33	1.51e-7	Total body bone mineral density;
KIRP	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg02023728	chr11:77925099	USP35	0.29	4.91	0.3	1.69e-6	Alzheimer's disease (survival time);
KIRP	cis	rs9398803	0.835	rs4897182	chr6:126755642	A/C	cg19875578	chr6:126661172	C6orf173	0.5	6.44	0.38	6.27e-10	Male-pattern baldness;
KIRP	cis	rs4704187	0.687	rs1345704	chr5:74489998	G/A	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg03788504	chr6:150331562	NA	-0.35	-6.46	-0.38	5.64e-10	Alopecia areata;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11521979	chr1:67266410	INSL5	0.38	6.02	0.36	6.4e-9	Survival in pancreatic cancer;
KIRP	cis	rs1364705	1.000	rs12677951	chr8:120226900	C/G	cg09273054	chr8:120220131	MAL2	0.49	5.46	0.33	1.19e-7	Hippocampal atrophy;
KIRP	cis	rs4006360	0.646	rs3843966	chr17:39250840	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.5e-20	Coffee consumption (cups per day);
KIRP	cis	rs4692589	1.000	rs4692589	chr4:170935245	C/T	cg19918862	chr4:170955249	NA	-0.41	-5.01	-0.3	1.05e-6	Anxiety disorder;
KIRP	cis	rs10266483	0.741	rs10254313	chr7:63739313	C/T	cg04636841	chr7:63768139	NA	-0.41	-5.38	-0.32	1.77e-7	Response to statin therapy;
KIRP	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.87	0.49	1.53e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg06740227	chr12:86229804	RASSF9	0.42	5.32	0.32	2.37e-7	Major depressive disorder;
KIRP	cis	rs714027	0.585	rs5752978	chr22:30300586	C/G	cg01021169	chr22:30184971	ASCC2	-0.41	-5.08	-0.31	7.49e-7	Lymphocyte counts;
KIRP	cis	rs7017914	1.000	rs7007450	chr8:71640269	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs2281603	0.570	rs1980520	chr14:64959846	T/C	cg01860774	chr14:64969374	ZBTB25	0.33	5.37	0.32	1.8e-7	Lymphocyte counts;
KIRP	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-0.72	-6.8	-0.4	8.02e-11	Breast cancer;
KIRP	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08822215	chr16:89438651	ANKRD11	-0.42	-5.49	-0.33	9.95e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13443122	chr2:70142154	MXD1	0.51	6.38	0.38	8.76e-10	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg18032046	chr6:28092343	ZSCAN16	0.53	5.69	0.34	3.56e-8	Depression;
KIRP	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.96	15.03	0.69	1.13e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs9311676	0.656	rs55727087	chr3:58404547	G/A	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs16912285	0.688	rs7128427	chr11:24338598	C/T	ch.11.24196551F	chr11:24239977	NA	0.66	5.93	0.35	1.03e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs42648	0.596	rs194523	chr7:89860574	A/T	cg25739043	chr7:89950458	NA	-0.39	-6.19	-0.37	2.51e-9	Homocysteine levels;
KIRP	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-12.08	-0.61	1.08e-26	Vitiligo;
KIRP	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg00262122	chr8:11665843	FDFT1	-0.45	-5.48	-0.33	1.04e-7	Retinal vascular caliber;
KIRP	cis	rs62413470	1.000	rs12214519	chr6:55966884	T/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	11.84	0.6	6.74e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.63	0.39	2.12e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.82	-11.03	-0.58	3.06e-23	Mortality in heart failure;
KIRP	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg18944383	chr4:111397179	ENPEP	0.53	9.27	0.51	1.01e-17	Height;
KIRP	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg16235748	chr6:149772707	ZC3H12D	-0.3	-4.97	-0.3	1.23e-6	Dupuytren's disease;
KIRP	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg21573476	chr21:45109991	RRP1B	-0.7	-10.15	-0.54	1.88e-20	Mean corpuscular volume;
KIRP	cis	rs228437	0.565	rs11759614	chr6:134962916	A/G	cg24504307	chr6:134963096	NA	-0.31	-5.23	-0.32	3.63e-7	Melanoma;
KIRP	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.75	-10.39	-0.55	3.28e-21	Hypospadias;
KIRP	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.42	0.43	1.91e-12	Coronary artery disease;
KIRP	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	7.03	0.41	1.99e-11	Eotaxin levels;
KIRP	cis	rs1847505	0.957	rs2134869	chr13:61523637	A/G	cg25164009	chr13:61490935	NA	-0.58	-6.34	-0.37	1.12e-9	Polychlorinated biphenyl levels;
KIRP	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.61	7.42	0.43	1.88e-12	Blood metabolite levels;
KIRP	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.53	7.38	0.43	2.43e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs2548003	0.518	rs2014316	chr5:28723711	T/C	cg12623145	chr2:97778927	ANKRD36	0.65	6.52	0.38	3.97e-10	Hip geometry;
KIRP	cis	rs1620921	0.711	rs1652466	chr6:161249569	T/G	cg01280913	chr6:161186852	NA	-0.37	-5.03	-0.31	9.48e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs812925	0.519	rs1186706	chr2:61673394	G/T	cg15711740	chr2:61764176	XPO1	-0.46	-5.95	-0.35	9.12e-9	Immature fraction of reticulocytes;
KIRP	trans	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg10756647	chr7:56101905	PSPH	0.9	6.3	0.37	1.37e-9	Diabetic kidney disease;
KIRP	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg12962167	chr3:53033115	SFMBT1	0.83	5.94	0.35	9.54e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.89	0.49	1.3e-16	Morning vs. evening chronotype;
KIRP	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg00405596	chr8:11794950	NA	0.62	8.71	0.49	4.42e-16	Neuroticism;
KIRP	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	1.05	19.53	0.78	6.5e-52	Height;
KIRP	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.6	8.53	0.48	1.55e-15	Menarche (age at onset);
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg01114163	chr5:1856713	NA	-0.43	-5.22	-0.32	3.89e-7	Cardiovascular disease risk factors;
KIRP	cis	rs4356932	0.967	rs4859591	chr4:76948578	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg12559939	chr2:27858050	GPN1	0.4	5.01	0.3	1.06e-6	Oral cavity cancer;
KIRP	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	5.61	0.34	5.41e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.45	5.21	0.32	4.04e-7	Osteoporosis;
KIRP	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg11886554	chr3:170076028	SKIL	0.5	5.54	0.33	7.65e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg11031976	chr2:198649780	BOLL	-0.52	-5.07	-0.31	7.78e-7	Ulcerative colitis;
KIRP	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs17079247	0.841	rs9602698	chr13:85809536	A/G	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.6	0.56	7.45e-22	Cognitive test performance;
KIRP	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.02	-0.57	3.31e-23	Height;
KIRP	cis	rs888194	0.628	rs11609896	chr12:110038454	G/A	cg05360138	chr12:110035743	NA	0.46	5.7	0.34	3.37e-8	Neuroticism;
KIRP	cis	rs4716602	0.633	rs10249382	chr7:156159349	G/T	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg02273166	chr14:105487914	CDCA4	0.48	6.04	0.36	5.79e-9	Asthma;
KIRP	trans	rs11710845	0.961	rs4681609	chr3:150063820	A/G	cg21175685	chr3:99378032	COL8A1;MIR548G	0.38	6.16	0.37	2.88e-9	Intraocular pressure;
KIRP	cis	rs2985684	0.948	rs7143010	chr14:50081803	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.14	-0.31	5.65e-7	Carotid intima media thickness;
KIRP	trans	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg06521331	chr12:34319734	NA	-0.49	-6.23	-0.37	1.97e-9	Bladder cancer;
KIRP	cis	rs1659258	0.568	rs1258437	chr2:88608769	T/G	cg00685853	chr2:88648947	NA	-0.54	-6.47	-0.38	5.29e-10	Visceral fat;
KIRP	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.36	-5.1	-0.31	6.63e-7	Mean corpuscular volume;
KIRP	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.69	8.26	0.47	9.07e-15	Corneal astigmatism;
KIRP	cis	rs73200209	0.701	rs11609930	chr12:116644670	A/G	cg01776926	chr12:116560359	MED13L	-0.56	-6.24	-0.37	1.91e-9	Total body bone mineral density;
KIRP	cis	rs10073892	0.662	rs5012584	chr5:101643030	A/G	cg19774478	chr5:101632501	SLCO4C1	0.62	6.38	0.38	8.78e-10	Cognitive decline (age-related);
KIRP	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg10845886	chr2:3471009	TTC15	-0.49	-6.95	-0.41	3.26e-11	Neurofibrillary tangles;
KIRP	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg14768367	chr16:72042858	DHODH	-0.93	-10.35	-0.55	4.53e-21	Blood protein levels;
KIRP	cis	rs2979489	0.891	rs4537262	chr8:30306757	T/A	cg26383811	chr8:30366931	RBPMS	0.38	5.13	0.31	6e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.59	-8.21	-0.46	1.23e-14	Glaucoma (primary open-angle);
KIRP	cis	rs4664293	0.903	rs10185155	chr2:160553228	G/A	cg08347373	chr2:160653686	CD302	-0.43	-6.17	-0.37	2.75e-9	Monocyte percentage of white cells;
KIRP	cis	rs6504622	0.537	rs7342957	chr17:44997356	G/A	cg16759221	chr17:45003025	GOSR2	0.35	5.29	0.32	2.74e-7	Orofacial clefts;
KIRP	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg15841412	chr13:111365552	ING1	0.54	5.85	0.35	1.58e-8	Coronary artery disease;
KIRP	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.71	-10.5	-0.56	1.49e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg24747557	chr10:131355152	MGMT	-0.45	-6.15	-0.36	3.15e-9	Response to temozolomide;
KIRP	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	9.3	0.51	8.1e-18	Mood instability;
KIRP	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg12940439	chr1:67600707	NA	-0.41	-6.13	-0.36	3.54e-9	Psoriasis;
KIRP	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg05333889	chr7:157238977	NA	-0.4	-5.58	-0.34	6.3e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.7	6.39	0.38	8.46e-10	Lung function (FEV1/FVC);
KIRP	trans	rs4482537	0.566	rs4264602	chr2:49061815	G/C	cg24885526	chr20:10653480	JAG1	0.49	6.09	0.36	4.36e-9	Laterality in neovascular age-related macular degeneration;
KIRP	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg25173405	chr17:45401733	C17orf57	0.44	6.05	0.36	5.4e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.45	-0.43	1.57e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.38	6.19	0.37	2.49e-9	Birth weight;
KIRP	cis	rs9914544	0.545	rs4924945	chr17:18813160	A/G	cg26378065	chr17:18585709	ZNF286B	0.39	4.87	0.3	2.03e-6	Educational attainment (years of education);
KIRP	cis	rs6988636	0.710	rs73339626	chr8:124142757	A/G	cg15893493	chr8:124194847	FAM83A	0.89	6.61	0.39	2.34e-10	Urinary uromodulin levels;
KIRP	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg08975724	chr8:8085496	FLJ10661	0.72	8.38	0.47	4.23e-15	Red cell distribution width;
KIRP	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg16434002	chr17:42200994	HDAC5	0.58	7.2	0.42	7.51e-12	Total body bone mineral density;
KIRP	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05903289	chr2:130345205	NA	-0.42	-5.58	-0.34	6.2e-8	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.74	8.9	0.49	1.27e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.84	-0.35	1.66e-8	Multiple sclerosis;
KIRP	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg24375607	chr4:120327624	NA	0.6	6.57	0.39	2.92e-10	Corneal astigmatism;
KIRP	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg05315796	chr3:52349193	DNAH1	0.39	5.11	0.31	6.49e-7	Schizophrenia;
KIRP	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.78	11.36	0.59	2.61e-24	Heart rate;
KIRP	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg21775007	chr8:11205619	TDH	0.46	6.24	0.37	1.9e-9	Neuroticism;
KIRP	cis	rs2976388	1.000	rs2920283	chr8:143757037	T/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.53	-0.38	3.83e-10	Urinary tract infection frequency;
KIRP	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg12046867	chr14:103022105	NA	0.58	6.48	0.38	4.99e-10	Platelet count;
KIRP	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs4356975	0.563	rs4588522	chr4:69973667	C/G	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.39	5.91	0.35	1.11e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20664221	chr12:56522980	ESYT1	0.52	6.03	0.36	6.13e-9	Smoking initiation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13860548	chr1:15853252	DNAJC16	0.46	6.06	0.36	4.95e-9	Survival in pancreatic cancer;
KIRP	cis	rs9815354	0.638	rs56008529	chr3:42026755	A/T	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9905704	0.633	rs2680713	chr17:56523900	G/T	cg12560992	chr17:57184187	TRIM37	0.53	4.92	0.3	1.57e-6	Testicular germ cell tumor;
KIRP	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.06	-0.41	1.66e-11	Initial pursuit acceleration;
KIRP	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.46	-5.83	-0.35	1.76e-8	Blood metabolite levels;
KIRP	cis	rs9488822	0.585	rs7756746	chr6:116239881	C/T	cg26893134	chr6:116381904	FRK	-0.23	-5.47	-0.33	1.13e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.55e-23	Primary sclerosing cholangitis;
KIRP	cis	rs7106204	1.000	rs7110656	chr11:24216034	G/T	ch.11.24196551F	chr11:24239977	NA	0.85	9.12	0.5	2.84e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.23	-0.32	3.55e-7	Electroencephalogram traits;
KIRP	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.69	0.34	3.58e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg21605333	chr4:119757512	SEC24D	0.73	5.65	0.34	4.38e-8	Cannabis dependence symptom count;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18775587	chr5:154135052	LARP1	-0.49	-6.6	-0.39	2.5e-10	Myopia;
KIRP	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-7.57	-0.43	7.46e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.85	0.53	1.6e-19	Ileal carcinoids;
KIRP	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.45	-6.01	-0.36	6.6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3789045	0.729	rs16853822	chr1:204450341	C/G	cg18185008	chr1:204589407	LRRN2	-0.52	-5.64	-0.34	4.55e-8	Educational attainment (college completion);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24715339	chr11:66036115	RAB1B	-0.47	-6.28	-0.37	1.56e-9	Myopia;
KIRP	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.56	-0.33	6.91e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg26207909	chr14:103986467	CKB	0.52	6.98	0.41	2.71e-11	Body mass index;
KIRP	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg19773385	chr1:10388646	KIF1B	0.44	6.26	0.37	1.68e-9	Hepatocellular carcinoma;
KIRP	cis	rs5997397	0.720	rs132549	chr22:29318724	C/T	cg15103426	chr22:29168792	CCDC117	-0.48	-6.04	-0.36	5.57e-9	Red cell distribution width;
KIRP	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.48	6.09	0.36	4.42e-9	Height;
KIRP	cis	rs4148087	0.530	rs221953	chr21:43608656	A/G	cg15319517	chr21:43638949	ABCG1	0.41	5.04	0.31	9.05e-7	Eating disorder in bipolar disorder;
KIRP	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.19	0.58	9.2e-24	Cognitive test performance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21014972	chr2:241380248	GPC1	0.51	6.13	0.36	3.51e-9	Interleukin-4 levels;
KIRP	cis	rs4692589	0.965	rs6842442	chr4:170933203	C/T	cg19918862	chr4:170955249	NA	0.42	5.11	0.31	6.49e-7	Anxiety disorder;
KIRP	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08206623	chr11:2907334	CDKN1C	-0.44	-6.32	-0.37	1.19e-9	Myopia;
KIRP	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.04	0.31	8.95e-7	Parkinson's disease;
KIRP	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	10.38	0.55	3.58e-21	Bone mineral density;
KIRP	cis	rs2151522	0.585	rs9398817	chr6:127110444	C/T	cg21431617	chr6:127135037	NA	0.33	6.06	0.36	5.05e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-14.34	-0.67	2.61e-34	Blood trace element (Zn levels);
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.79	0.53	2.44e-19	Lung cancer;
KIRP	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	1.1	21.85	0.81	1.46e-59	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10284115	chr3:15841404	ANKRD28	0.42	6.08	0.36	4.53e-9	Interleukin-4 levels;
KIRP	cis	rs6540556	0.723	rs12086634	chr1:209880259	T/G	cg05527609	chr1:210001259	C1orf107	-0.49	-5.07	-0.31	7.94e-7	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00337957	chr19:8547807	HNRNPM	0.52	6.23	0.37	1.99e-9	Interleukin-4 levels;
KIRP	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg06289844	chr6:126071538	HEY2	0.36	5.26	0.32	3.16e-7	Brugada syndrome;
KIRP	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.57	-4.94	-0.3	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13401104	0.680	rs11680714	chr2:237142605	A/G	cg19324714	chr2:237145437	ASB18	0.54	5.5	0.33	9.37e-8	Educational attainment;
KIRP	cis	rs6580649	0.941	rs7971668	chr12:48469696	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-7.82	-0.45	1.58e-13	Plateletcrit;Platelet count;
KIRP	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg04201373	chr6:33551533	GGNBP1	0.47	5.82	0.35	1.78e-8	Testicular germ cell tumor;
KIRP	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg04132472	chr17:19861366	AKAP10	-0.44	-5.75	-0.34	2.63e-8	Schizophrenia;
KIRP	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	7.75	0.44	2.37e-13	Menarche (age at onset);
KIRP	cis	rs3781264	0.557	rs10882437	chr10:96121830	T/C	cg07270175	chr10:96123049	NOC3L	0.4	4.91	0.3	1.65e-6	Esophageal cancer and gastric cancer;
KIRP	cis	rs2860975	0.620	rs2275622	chr10:96827178	T/C	cg09036531	chr10:96991505	NA	-0.48	-5.76	-0.34	2.45e-8	Immune response to smallpox vaccine (IL-6);
KIRP	trans	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg19694781	chr19:47549865	TMEM160	-0.52	-6.34	-0.37	1.08e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs754423	0.511	rs1497084	chr14:52521322	A/T	cg05884192	chr14:52515736	NID2	-0.54	-6.71	-0.39	1.37e-10	Craniofacial microsomia;
KIRP	cis	rs7756236	0.538	rs6936598	chr6:36626096	T/C	cg08179530	chr6:36648295	CDKN1A	0.45	5.82	0.35	1.78e-8	QRS duration;
KIRP	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.69	9.97	0.54	6.77e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	trans	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg19274270	chr17:78178856	CARD14	-0.36	-6.48	-0.38	5.04e-10	Educational attainment (years of education);
KIRP	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.58	7.37	0.43	2.65e-12	Arsenic metabolism;
KIRP	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg23950597	chr19:37808831	NA	-0.67	-5.99	-0.36	7.32e-9	Coronary artery calcification;
KIRP	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg00631329	chr6:26305371	NA	-0.67	-8.25	-0.47	9.75e-15	Educational attainment;
KIRP	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00149659	chr3:10157352	C3orf10	0.58	6.91	0.4	4.13e-11	Alzheimer's disease;
KIRP	cis	rs4908768	0.906	rs12122851	chr1:8634290	A/G	cg25722041	chr1:8623473	RERE	-0.63	-8.04	-0.46	3.77e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg02975922	chr3:195473998	MUC4	-0.55	-6.44	-0.38	6.35e-10	Pancreatic cancer;
KIRP	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.38	-0.32	1.74e-7	Ovarian reserve;
KIRP	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.74	10.33	0.55	5.18e-21	Red blood cell count;
KIRP	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg16141378	chr3:129829833	LOC729375	-0.47	-6.19	-0.37	2.47e-9	Retinal vascular caliber;
KIRP	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg00579200	chr11:133705235	NA	-0.38	-4.9	-0.3	1.78e-6	Childhood ear infection;
KIRP	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.51	6.64	0.39	1.98e-10	Tuberculosis;
KIRP	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.78	-9.06	-0.5	4.14e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs72960926	0.744	rs55795936	chr6:75006841	A/G	cg03266952	chr6:74778945	NA	-0.67	-5.54	-0.33	7.92e-8	Metabolite levels (MHPG);
KIRP	cis	rs10073892	0.743	rs62372219	chr5:101651151	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27311414	chr1:161147232	B4GALT3	0.51	6.46	0.38	5.6e-10	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20905746	chr15:79165638	MORF4L1	0.46	6.21	0.37	2.26e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.56	-7.33	-0.42	3.35e-12	Aortic root size;
KIRP	cis	rs17209837	0.667	rs45605032	chr7:87090301	C/T	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.49e-16	Gallbladder cancer;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg18209359	chr17:80159595	CCDC57	-0.42	-5.61	-0.34	5.34e-8	Life satisfaction;
KIRP	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg14458575	chr2:238380390	NA	0.55	5.9	0.35	1.2e-8	Prostate cancer;
KIRP	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.86	-0.35	1.51e-8	Breast cancer;
KIRP	cis	rs5753037	0.653	rs131286	chr22:30158351	C/T	cg01021169	chr22:30184971	ASCC2	-0.42	-5.84	-0.35	1.66e-8	Type 1 diabetes;
KIRP	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg06636001	chr8:8085503	FLJ10661	0.66	8.74	0.49	3.81e-16	Retinal vascular caliber;
KIRP	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg21452805	chr1:244014465	NA	0.71	6.88	0.4	5.02e-11	RR interval (heart rate);
KIRP	cis	rs2213920	0.619	rs2188047	chr9:118256660	G/C	cg13918206	chr9:118159781	DEC1	1.01	10.01	0.54	5.11e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg12501888	chr15:85177176	SCAND2	-0.42	-5.2	-0.31	4.13e-7	P wave terminal force;
KIRP	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.47	-5.58	-0.34	6.37e-8	Body mass index;
KIRP	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00902147	chr17:76993394	CANT1	0.43	6.15	0.37	3.1e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9359856	0.518	rs11962279	chr6:90233695	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.47	-4.92	-0.3	1.56e-6	Bipolar disorder;
KIRP	cis	rs10046574	0.519	rs17403948	chr7:135215169	C/T	cg27474649	chr7:135195673	CNOT4	-0.56	-5.13	-0.31	5.9e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.75	9.02	0.5	5.69e-17	Lymphocyte percentage of white cells;
KIRP	cis	rs7078219	1.000	rs11190130	chr10:101275206	C/T	cg07044859	chr10:101282883	NA	-0.33	-5.62	-0.34	5.1e-8	Dental caries;
KIRP	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg06740227	chr12:86229804	RASSF9	0.43	5.46	0.33	1.17e-7	Major depressive disorder;
KIRP	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg26354017	chr1:205819088	PM20D1	0.47	5.22	0.32	3.72e-7	Prostate-specific antigen levels;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.88	-9.24	-0.51	1.23e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.49	-5.62	-0.34	5.08e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs28530674	1.000	rs28755825	chr1:19222140	A/G	cg26407146	chr1:19229049	ALDH4A1	1.02	7.42	0.43	1.85e-12	Eosinophilic esophagitis;
KIRP	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg26384229	chr12:38710491	ALG10B	-0.69	-9.45	-0.52	2.87e-18	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg05805236	chr11:65401703	PCNXL3	-0.56	-7.28	-0.42	4.58e-12	Acne (severe);
KIRP	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.3	-4.96	-0.3	1.31e-6	Height;
KIRP	cis	rs6681460	0.934	rs4655631	chr1:67054907	C/G	cg13052034	chr1:66999238	SGIP1	0.38	5.31	0.32	2.49e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg01422370	chr2:73384389	NA	0.4	5.19	0.31	4.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs5753037	0.702	rs140143	chr22:30173109	G/T	cg27665648	chr22:30112403	NA	0.45	6.33	0.37	1.14e-9	Type 1 diabetes;
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	6.08	0.36	4.44e-9	Obesity-related traits;
KIRP	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.71	9.01	0.5	5.71e-17	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12936587	0.633	rs12946063	chr17:17512768	T/C	cg01246520	chr17:17644344	RAI1	-0.37	-5.58	-0.34	6.3e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg15556689	chr8:8085844	FLJ10661	0.44	5.35	0.32	1.97e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	1.1	16.22	0.72	1.01e-40	Breast cancer;
KIRP	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.79	-0.35	2.09e-8	IgG glycosylation;
KIRP	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg17279839	chr7:150038598	RARRES2	0.42	5.82	0.35	1.85e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg00677455	chr12:58241039	CTDSP2	-0.53	-5.94	-0.35	9.58e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.35	0.38	1.01e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1823913	0.538	rs35311234	chr2:192181678	G/A	cg12404831	chr2:192114017	MYO1B	0.51	7.05	0.41	1.76e-11	Obesity-related traits;
KIRP	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17554472	chr22:41940697	POLR3H	0.72	7.2	0.42	7.39e-12	Vitiligo;
KIRP	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg11608241	chr8:8085544	FLJ10661	0.44	5.58	0.34	6.22e-8	Joint mobility (Beighton score);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04555837	chr1:173768981	CENPL	-0.46	-7.21	-0.42	6.96e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg17470723	chr8:74884337	TCEB1	0.63	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg04002187	chr5:40835754	RPL37	0.79	5.91	0.35	1.12e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg16898833	chr6:26189333	HIST1H4D	0.96	5.88	0.35	1.3e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg13514129	chr1:39547527	MACF1	0.53	7.97	0.45	5.93e-14	Fractional exhaled nitric oxide (childhood);
KIRP	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.24	-0.42	5.67e-12	Systemic lupus erythematosus;
KIRP	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg23422044	chr7:1970798	MAD1L1	-0.58	-5.84	-0.35	1.63e-8	Bipolar disorder;
KIRP	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg10255544	chr17:80519551	FOXK2	0.57	8.26	0.47	8.91e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	6.93e-8	Life satisfaction;
KIRP	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.59	7.73	0.44	2.83e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg27490568	chr2:178487706	NA	0.57	7.65	0.44	4.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg08885076	chr2:99613938	TSGA10	-0.48	-6.38	-0.38	8.52e-10	Chronic sinus infection;
KIRP	cis	rs9400467	0.506	rs12215189	chr6:111646002	G/C	cg15721981	chr6:111408429	SLC16A10	0.73	6.38	0.38	8.9e-10	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.74	-0.44	2.53e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443189	0.703	rs2748950	chr6:76442985	A/G	cg01950844	chr6:76311363	SENP6	-0.59	-6.39	-0.38	8.29e-10	Prostate cancer;
KIRP	cis	rs4253772	0.515	rs7287164	chr22:46781008	T/C	cg00784671	chr22:46762841	CELSR1	-0.67	-6.76	-0.4	9.73e-11	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.71	9.18	0.51	1.86e-17	Corneal astigmatism;
KIRP	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24110177	chr3:50126178	RBM5	-0.67	-9.08	-0.5	3.54e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	5.41	0.33	1.5e-7	Renal cell carcinoma;
KIRP	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.18	0.37	2.61e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	10.04	0.54	4.32e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs57994353	0.600	rs1130640	chr9:139317979	C/T	cg14169450	chr9:139327907	INPP5E	0.55	6.32	0.37	1.21e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.53	7.84	0.45	1.4e-13	Immature fraction of reticulocytes;
KIRP	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.41	5.21	0.32	3.92e-7	Multiple sclerosis;
KIRP	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.71	9.05	0.5	4.61e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg05785598	chr3:49045655	WDR6	0.32	5.86	0.35	1.48e-8	Parkinson's disease;
KIRP	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-5.78	-0.35	2.26e-8	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.59	-9.63	-0.52	7.77e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs12949688	1.000	rs7212186	chr17:55818454	C/A	cg12582317	chr17:55822272	NA	0.6	10.01	0.54	5.14e-20	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg01879757	chr17:41196368	BRCA1	-0.77	-10.88	-0.57	9.34e-23	Menopause (age at onset);
KIRP	cis	rs11603020	0.950	rs11229067	chr11:57374946	A/C	cg19752551	chr11:57585705	CTNND1	0.72	10.01	0.54	5.24e-20	Blood protein levels;
KIRP	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	8.91	0.49	1.14e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.38	-0.51	4.53e-18	Lung function (FEV1);
KIRP	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	1.01	12.37	0.62	1.23e-27	Post bronchodilator FEV1;
KIRP	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.9	14.25	0.67	5.4e-34	Coronary artery disease;
KIRP	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.58	-7.07	-0.41	1.63e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.12	-0.31	6.13e-7	Bladder cancer;
KIRP	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.71	0.44	3.07e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg15147215	chr3:52552868	STAB1	-0.34	-5.94	-0.35	9.71e-9	Electroencephalogram traits;
KIRP	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-1.12	-10.04	-0.54	4.16e-20	Body mass index;
KIRP	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg09473613	chr1:24152604	HMGCL	0.38	4.95	0.3	1.41e-6	Immature fraction of reticulocytes;
KIRP	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.12e-22	Morning vs. evening chronotype;
KIRP	cis	rs7113874	0.613	rs4326784	chr11:8533149	G/T	cg08015107	chr11:8618950	NA	-0.51	-6.75	-0.4	1.03e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg08313168	chr12:7315531	NA	0.7	6.28	0.37	1.56e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12780845	0.540	rs6602178	chr10:17180169	A/C	cg01003015	chr10:17271136	VIM	-0.49	-6.23	-0.37	2.02e-9	Homocysteine levels;
KIRP	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.42	4.99	0.3	1.12e-6	Lung cancer;
KIRP	cis	rs554111	0.686	rs519209	chr1:21043790	C/T	cg08890418	chr1:21044141	KIF17	-0.47	-6.88	-0.4	5.02e-11	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7246657	0.722	rs1291	chr19:38229378	G/A	cg14683738	chr19:37701593	ZNF585B	-0.45	-4.86	-0.3	2.12e-6	Coronary artery calcification;
KIRP	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg24315340	chr6:146058215	EPM2A	0.42	5.28	0.32	2.87e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs60752752	0.852	rs3006475	chr1:153344636	A/C	cg00420347	chr1:65362428	JAK1	0.63	6.31	0.37	1.26e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2072732	0.861	rs10909867	chr1:2961402	G/T	cg11731671	chr1:2995604	PRDM16	-0.42	-5.23	-0.32	3.59e-7	Plateletcrit;
KIRP	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.54	7.16	0.42	9.43e-12	Primary sclerosing cholangitis;
KIRP	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.71	9.07	0.5	4.01e-17	Prudent dietary pattern;
KIRP	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.91	0.3	1.69e-6	Childhood ear infection;
KIRP	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg07395648	chr5:131743802	NA	0.55	6.63	0.39	2.12e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg21475434	chr5:93447410	FAM172A	0.43	4.98	0.3	1.21e-6	Diabetic retinopathy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05238522	chr4:72323166	SLC4A4	-0.45	-7.02	-0.41	2.22e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	5.23	0.32	3.6e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.63	3.22e-29	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.86	-12.8	-0.63	4.2e-29	Height;
KIRP	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.74	-0.34	2.76e-8	Testicular germ cell tumor;
KIRP	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.28	0.42	4.6e-12	Lung cancer;
KIRP	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg02073558	chr3:44770973	ZNF501	0.58	8.23	0.46	1.12e-14	Depressive symptoms;
KIRP	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.64	-9.58	-0.52	1.12e-18	Endometriosis;
KIRP	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.05e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg07936489	chr17:37558343	FBXL20	-0.5	-6.27	-0.37	1.61e-9	Asthma;
KIRP	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.72	9.37	0.51	4.94e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs362272	0.525	rs2857849	chr4:3043638	A/T	cg13731523	chr4:3047190	NA	-0.38	-7.13	-0.41	1.13e-11	Serum sulfate level;
KIRP	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg03468072	chr12:39539422	NA	-0.42	-5.84	-0.35	1.62e-8	Heart rate;
KIRP	cis	rs7539542	0.556	rs1539357	chr1:202878454	T/A	cg08940984	chr1:202857613	RABIF	0.46	5.76	0.34	2.56e-8	Mean platelet volume;
KIRP	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg25287198	chr4:183728479	NA	0.56	4.97	0.3	1.23e-6	Pediatric autoimmune diseases;
KIRP	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.66	8.62	0.48	8.54e-16	Breast cancer;
KIRP	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg02297831	chr4:17616191	MED28	0.61	7.63	0.44	5.12e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.79	7.76	0.44	2.29e-13	Neuroblastoma;
KIRP	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg06565975	chr8:143823917	SLURP1	-0.43	-6.54	-0.38	3.57e-10	Urinary tract infection frequency;
KIRP	cis	rs2224391	0.737	rs36117780	chr6:5262233	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.72	-0.39	1.23e-10	Height;
KIRP	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-7.33	-0.42	3.36e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs6545883	0.801	rs778142	chr2:61681428	G/T	cg15711740	chr2:61764176	XPO1	-0.61	-7.95	-0.45	6.61e-14	Tuberculosis;
KIRP	cis	rs1593	0.531	rs4241821	chr4:187176834	C/T	cg09526685	chr4:187126073	CYP4V2	-0.59	-5.28	-0.32	2.89e-7	Activated partial thromboplastin time;
KIRP	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.98	12.74	0.63	6.73e-29	Menopause (age at onset);
KIRP	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg05784532	chr1:230284198	GALNT2	0.47	7.37	0.43	2.63e-12	Coronary artery disease;
KIRP	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.65	-8.02	-0.46	4.19e-14	Iron status biomarkers;
KIRP	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg10761708	chr20:43804764	PI3	0.52	5.47	0.33	1.09e-7	Blood protein levels;
KIRP	cis	rs7246657	0.722	rs954504	chr19:38045394	A/G	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.85	-9.74	-0.53	3.68e-19	Blood pressure;
KIRP	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.89	9.47	0.52	2.37e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs10789491	0.767	rs1816730	chr1:47207346	T/C	cg15501359	chr1:47185051	KIAA0494	1.1	12.08	0.61	1.13e-26	Response to hepatitis C treatment;
KIRP	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg08085267	chr17:45401833	C17orf57	-0.47	-5.9	-0.35	1.17e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.44	-0.43	1.69e-12	Bipolar disorder;
KIRP	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.53	-8.06	-0.46	3.27e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.88	-13.59	-0.65	9.23e-32	Height;
KIRP	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg04362960	chr10:104952993	NT5C2	0.42	5.05	0.31	8.68e-7	Colorectal cancer;
KIRP	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg06115741	chr20:33292138	TP53INP2	0.41	5.52	0.33	8.39e-8	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg01721255	chr8:58191610	C8orf71	0.7	5.68	0.34	3.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs2797685	0.606	rs72632043	chr1:7809383	C/T	cg06712362	chr1:7811235	CAMTA1	0.66	6.93	0.4	3.59e-11	Crohn's disease;
KIRP	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg22356347	chr1:167427500	CD247	-0.44	-5.87	-0.35	1.44e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	6.44	0.38	6.35e-10	Body mass index;
KIRP	cis	rs953387	1.000	rs4954564	chr2:136895508	A/G	cg05194412	chr2:137003533	NA	-0.41	-5.41	-0.33	1.52e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs244899	0.935	rs2432643	chr5:167925030	G/T	cg06604206	chr5:167912465	RARS	-0.52	-7.22	-0.42	6.52e-12	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.68	-6.2	-0.37	2.33e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg05163923	chr11:71159392	DHCR7	-0.66	-6.56	-0.39	3.2e-10	Vitamin D levels;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18918831	chr3:195489782	MUC4	0.78	6.96	0.41	3.05e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg26373071	chr5:1325741	CLPTM1L	0.56	7.28	0.42	4.43e-12	Lung cancer;
KIRP	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.48	6.8	0.4	7.77e-11	Sitting height ratio;
KIRP	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg10790698	chr19:18539756	SSBP4	-0.34	-7.34	-0.42	3.11e-12	Breast cancer;
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07256732	chr16:621771	PIGQ	-0.47	-6.55	-0.39	3.25e-10	Height;
KIRP	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg09264619	chr17:80180166	NA	0.49	5.87	0.35	1.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg07936489	chr17:37558343	FBXL20	-0.48	-5.99	-0.36	7.31e-9	Asthma;
KIRP	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg16586182	chr3:47516702	SCAP	-0.71	-9.97	-0.54	7.21e-20	Colorectal cancer;
KIRP	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.92	-14.29	-0.67	4.04e-34	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg04731861	chr2:219085781	ARPC2	-0.21	-5.33	-0.32	2.21e-7	Colorectal cancer;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13837895	chr19:50145301	SCAF1	-0.49	-6.17	-0.37	2.83e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg05973401	chr12:123451056	ABCB9	0.61	7.12	0.41	1.18e-11	Platelet count;
KIRP	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.85	11.5	0.59	8.59e-25	Morning vs. evening chronotype;
KIRP	cis	rs754466	0.958	rs58916802	chr10:79695870	G/A	cg17075019	chr10:79541650	NA	-0.87	-9.57	-0.52	1.16e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12230513	0.732	rs55797706	chr12:55836585	G/A	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.81	0.66	1.7e-32	Cognitive function;
KIRP	cis	rs330048	0.525	rs10112237	chr8:9072729	A/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.92	-0.35	1.06e-8	Systemic lupus erythematosus;
KIRP	cis	rs2224391	0.628	rs9392666	chr6:5249888	C/A	cg13962347	chr6:5174647	LYRM4	-0.69	-9.72	-0.53	4.17e-19	Height;
KIRP	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-10.34	-0.55	4.86e-21	Heart rate;
KIRP	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.95	12.34	0.62	1.5e-27	Menopause (age at onset);
KIRP	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs9810890	0.850	rs73196995	chr3:128458070	G/A	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs6466055	0.612	rs10247691	chr7:104692291	T/C	cg04380332	chr7:105027541	SRPK2	-0.4	-5.48	-0.33	1.03e-7	Schizophrenia;
KIRP	cis	rs829661	0.793	rs2602806	chr2:30824096	G/A	cg10949345	chr2:30726833	LCLAT1	1.06	13.1	0.64	4.33e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg20651018	chr11:3035856	CARS	-0.36	-4.99	-0.3	1.13e-6	Longevity;
KIRP	cis	rs6142102	0.961	rs761235	chr20:32534408	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	6.17	0.37	2.84e-9	Skin pigmentation;
KIRP	cis	rs1538970	0.924	rs12097497	chr1:45880669	C/T	cg05343316	chr1:45956843	TESK2	0.7	7.95	0.45	6.9e-14	Platelet count;
KIRP	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.7	-6.56	-0.39	3.13e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-5.77	-0.35	2.31e-8	Aortic root size;
KIRP	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.41	0.51	3.81e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03321231	chr17:157219	RPH3AL	0.46	6.7	0.39	1.43e-10	Cancer;
KIRP	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	1.0	14.42	0.68	1.43e-34	Height;
KIRP	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.53	6.83	0.4	6.58e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg03511173	chr18:77590860	NA	0.47	5.42	0.33	1.42e-7	Opioid sensitivity;
KIRP	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	5.24	0.32	3.52e-7	Menarche (age at onset);
KIRP	cis	rs11907546	1	rs11907546	chr20:32719797	C/T	cg08999081	chr20:33150536	PIGU	0.55	6.98	0.41	2.78e-11	Cancer;Cancer (pleiotropy);
KIRP	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.46	7.65	0.44	4.61e-13	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00040945	chr15:83680531	C15orf40	0.47	6.09	0.36	4.22e-9	Parkinson's disease;
KIRP	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.6	9.81	0.53	2.16e-19	Total body bone mineral density;
KIRP	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs17767294	0.541	rs72845050	chr6:27610070	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-5.85	-0.35	1.57e-8	Parkinson's disease;
KIRP	cis	rs231513	0.954	rs231508	chr17:41967583	G/A	cg26893861	chr17:41843967	DUSP3	-0.48	-5.02	-0.3	9.95e-7	Cognitive function;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.82	11.66	0.6	2.64e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg11635098	chr7:100497156	NA	-0.66	-7.16	-0.42	9.24e-12	Resting heart rate;
KIRP	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	trans	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.78	0.4	8.86e-11	Mean corpuscular volume;
KIRP	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg14703610	chr5:56206110	C5orf35	0.44	5.72	0.34	3.13e-8	Coronary artery disease;
KIRP	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.73	9.71	0.53	4.43e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.92	-0.4	3.8e-11	Total body bone mineral density;
KIRP	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.3	-0.81	9.07e-58	Ulcerative colitis;
KIRP	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg13607699	chr17:42295918	UBTF	0.48	6.28	0.37	1.51e-9	Total body bone mineral density;
KIRP	cis	rs12044355	0.927	rs61835384	chr1:231833422	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	5.83	0.35	1.72e-8	Alzheimer's disease;
KIRP	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.53	-5.7	-0.34	3.44e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.06	-0.41	1.71e-11	Eye color traits;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15877295	chr7:138915876	UBN2	0.48	6.57	0.39	2.94e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10435719	0.746	rs58007588	chr8:11794969	A/G	cg00405596	chr8:11794950	NA	0.6	8.43	0.47	2.92e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.43	-5.57	-0.33	6.81e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg00530740	chr6:53409368	GCLC	0.53	6.37	0.38	9.24e-10	Beard thickness;
KIRP	cis	rs9398803	0.865	rs4895808	chr6:126781434	C/T	cg19875578	chr6:126661172	C6orf173	0.51	6.63	0.39	2.1e-10	Male-pattern baldness;
KIRP	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-6.03	-0.36	6.01e-9	Longevity;
KIRP	cis	rs1440410	0.835	rs10016850	chr4:144056847	T/C	cg01719995	chr4:144104893	USP38	0.41	5.36	0.32	1.92e-7	Ischemic stroke;
KIRP	cis	rs9290877	0.743	rs9877192	chr3:188426256	A/G	cg17392043	chr3:188495102	LPP	-0.42	-5.32	-0.32	2.36e-7	IgE levels;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01765077	chr12:122356316	WDR66	0.45	6.17	0.37	2.86e-9	Mean corpuscular volume;
KIRP	cis	rs829661	0.948	rs829655	chr2:30729654	G/C	cg10949345	chr2:30726833	LCLAT1	0.69	9.68	0.53	5.44e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg08648136	chr8:956695	NA	0.48	7.13	0.41	1.09e-11	Schizophrenia;
KIRP	cis	rs7849270	0.692	rs4397510	chr9:131854950	G/A	cg13538475	chr9:131942899	NA	-0.36	-5.59	-0.34	6.16e-8	Blood metabolite ratios;
KIRP	cis	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg06521331	chr12:34319734	NA	-0.45	-5.17	-0.31	4.94e-7	Resting heart rate;
KIRP	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.4	-0.38	7.62e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3790645	0.958	rs2278979	chr1:26877708	G/A	cg23229016	chr1:26872525	RPS6KA1	0.25	6.25	0.37	1.78e-9	Glucose homeostasis traits;
KIRP	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.05	-0.31	8.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17681684	0.565	rs62066034	chr17:9758829	A/G	cg26853458	chr17:9805074	RCVRN	0.53	5.06	0.31	8.31e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.75	-9.0	-0.5	6.17e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg00080972	chr5:178986291	RUFY1	0.43	6.76	0.4	9.72e-11	Lung cancer;
KIRP	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05665937	chr4:1216051	CTBP1	0.57	8.05	0.46	3.66e-14	Obesity-related traits;
KIRP	cis	rs9443189	0.774	rs2647405	chr6:76450023	C/T	cg01950844	chr6:76311363	SENP6	-0.57	-6.21	-0.37	2.2e-9	Prostate cancer;
KIRP	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20007643	chr7:130791009	FLJ43663	-0.59	-6.8	-0.4	7.8e-11	Menopause (age at onset);
KIRP	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg21775007	chr8:11205619	TDH	0.43	5.91	0.35	1.11e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs7999699	0.902	rs59890896	chr13:48321393	A/G	cg23237801	chr1:16476620	EPHA2	0.52	6.48	0.38	5.07e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.54	-6.63	-0.39	2.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg26116260	chr4:7069785	GRPEL1	-0.81	-5.21	-0.32	3.99e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-8.52	-0.48	1.67e-15	Extrinsic epigenetic age acceleration;
KIRP	trans	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.43	-0.43	1.77e-12	Neuroticism;
KIRP	cis	rs1978968	0.956	rs35089989	chr22:18424298	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.67	-7.62	-0.44	5.57e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.42	-5.17	-0.31	4.75e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs10795061	0.576	rs10904074	chr10:3710962	G/A	cg22632523	chr10:3711048	NA	0.36	5.54	0.33	7.77e-8	Subjective well-being;
KIRP	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs10208940	0.920	rs11894861	chr2:68706723	C/G	cg12452813	chr2:68675892	NA	0.47	5.07	0.31	7.97e-7	Urate levels in lean individuals;
KIRP	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg10755058	chr3:40428713	ENTPD3	0.39	5.28	0.32	2.88e-7	Renal cell carcinoma;
KIRP	cis	rs4363385	0.510	rs11590369	chr1:152903603	G/C	cg07796016	chr1:152779584	LCE1C	-0.44	-5.5	-0.33	9.55e-8	Inflammatory skin disease;
KIRP	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg26207909	chr14:103986467	CKB	0.48	4.89	0.3	1.81e-6	Coronary artery disease;
KIRP	cis	rs10463316	0.817	rs906679	chr5:150779302	T/A	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.38	-0.38	8.86e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.33	-4.84	-0.3	2.26e-6	Monocyte count;
KIRP	cis	rs1978968	1.000	rs11704827	chr22:18450287	A/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.69	-0.39	1.46e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg19645103	chr12:69753606	YEATS4	-0.47	-5.31	-0.32	2.4e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg26876637	chr1:152193138	HRNR	-0.88	-8.79	-0.49	2.58e-16	Atopic dermatitis;
KIRP	cis	rs1975974	0.511	rs17052375	chr17:21743877	G/A	cg18423549	chr17:21743878	NA	-0.45	-4.89	-0.3	1.83e-6	Psoriasis;
KIRP	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	6.03	0.36	6.03e-9	Longevity;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05573182	chr20:39318437	MAFB	0.5	6.68	0.39	1.54e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18252515	chr7:66147081	NA	-0.44	-5.4	-0.33	1.57e-7	Aortic root size;
KIRP	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg21827317	chr3:136751795	NA	0.38	5.28	0.32	2.8e-7	Neuroticism;
KIRP	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05220968	chr6:146057943	EPM2A	-0.42	-5.35	-0.32	1.97e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg00360474	chr6:37504404	NA	-0.47	-6.51	-0.38	4.18e-10	Cognitive performance;
KIRP	cis	rs914615	0.552	rs4971089	chr1:155142927	A/G	cg02153340	chr1:155202674	NA	-0.48	-7.21	-0.42	6.92e-12	Urinary albumin-to-creatinine ratio;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22626041	chr1:175162049	KIAA0040	0.49	6.34	0.37	1.1e-9	Parkinson's disease;
KIRP	cis	rs16958440	0.708	rs62096477	chr18:44662310	G/A	cg17192377	chr18:44677553	HDHD2	0.5	5.21	0.32	3.91e-7	Sitting height ratio;
KIRP	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg05639522	chr1:247681581	NA	0.76	5.12	0.31	6.13e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12701220	1.000	rs12701220	chr7:1022728	T/C	cg26769984	chr7:1090371	C7orf50	0.79	7.82	0.45	1.58e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs2387326	0.723	rs67579537	chr10:129940527	G/A	cg16087940	chr10:129947807	NA	-0.36	-4.88	-0.3	1.87e-6	Select biomarker traits;
KIRP	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.23	0.37	1.98e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.82	10.72	0.56	3.05e-22	Response to diuretic therapy;
KIRP	cis	rs9367716	0.912	rs9382695	chr6:57110054	G/T	cg17346177	chr6:56820087	BEND6;DST	-0.44	-4.96	-0.3	1.33e-6	Coronary artery disease;
KIRP	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.85	12.42	0.62	8.26e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg25319279	chr11:5960081	NA	-0.57	-5.78	-0.35	2.25e-8	DNA methylation (variation);
KIRP	cis	rs7149242	0.796	rs12588718	chr14:101149605	G/C	cg10189261	chr14:101176105	NA	0.53	7.13	0.41	1.09e-11	Platelet count;
KIRP	cis	rs16976116	0.851	rs11855907	chr15:55494634	A/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.86	11.3	0.58	4.06e-24	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.52	-6.03	-0.36	5.85e-9	Inhibitory control;
KIRP	cis	rs61863818	0.533	rs954148	chr10:99123006	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-5.69	-0.34	3.54e-8	Monocyte percentage of white cells;
KIRP	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.54	-0.33	7.77e-8	Ovarian reserve;
KIRP	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg04935436	chr20:30431758	NA	0.47	5.85	0.35	1.56e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.61	6.82	0.4	6.82e-11	Schizophrenia;
KIRP	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.42	-0.33	1.41e-7	Pulmonary function;
KIRP	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg21919602	chr1:242011447	EXO1	-0.46	-5.93	-0.35	1.04e-8	Menopause (age at onset);
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg17441377	chr17:3906640	NA	0.55	8.32	0.47	5.96e-15	Type 2 diabetes;
KIRP	cis	rs8014252	0.803	rs10135356	chr14:71030355	T/C	cg11204974	chr14:71022665	NA	-0.61	-6.39	-0.38	8.25e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.54	0.38	3.62e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg01320130	chr1:67600311	NA	0.43	5.43	0.33	1.35e-7	Psoriasis;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg14862950	chr11:66112661	BRMS1	0.48	6.51	0.38	4.19e-10	Ischemic stroke;
KIRP	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg07636037	chr3:49044803	WDR6	0.46	5.56	0.33	6.86e-8	Resting heart rate;
KIRP	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg16497661	chr14:103986332	CKB	0.75	11.15	0.58	1.21e-23	Body mass index;
KIRP	cis	rs3120667	0.720	rs36061814	chr1:152416864	G/A	cg26876637	chr1:152193138	HRNR	-0.64	-5.96	-0.36	8.74e-9	Eating disorders;
KIRP	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.44	7.79	0.45	1.82e-13	Systemic lupus erythematosus;
KIRP	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg00677455	chr12:58241039	CTDSP2	-0.59	-7.06	-0.41	1.73e-11	Multiple sclerosis;
KIRP	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-5.99	-0.36	7.5e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs71636778	0.509	rs71636795	chr1:27241025	A/G	cg12203394	chr1:27248618	NUDC	0.61	5.22	0.32	3.78e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3741151	0.773	rs11235770	chr11:73184002	C/T	cg17517138	chr11:73019481	ARHGEF17	0.62	5.47	0.33	1.1e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.58	7.43	0.43	1.81e-12	Aortic root size;
KIRP	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-8.82	-0.49	2.09e-16	Mood instability;
KIRP	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-13.07	-0.64	5.47e-30	Exhaled nitric oxide output;
KIRP	cis	rs7246967	0.673	rs12985825	chr19:22953451	A/C	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	4.98e-9	Depression;
KIRP	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg04132472	chr17:19861366	AKAP10	0.39	5.02	0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.59	5.56	0.33	6.85e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.83	9.01	0.5	6.01e-17	Prostate cancer;
KIRP	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.67	-9.29	-0.51	8.25e-18	Height;
KIRP	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.32	-5.38	-0.32	1.75e-7	Height;
KIRP	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	trans	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg25042112	chr7:64838748	ZNF92	0.56	6.03	0.36	6.02e-9	Pain;
KIRP	cis	rs7187994	0.848	rs16974532	chr16:84783310	G/A	cg07647771	chr16:84786436	USP10	-0.37	-5.14	-0.31	5.7e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg03289416	chr15:75166202	SCAMP2	0.4	5.21	0.32	3.99e-7	Systemic lupus erythematosus;
KIRP	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.97	0.3	1.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs362272	0.505	rs2857854	chr4:3043184	G/T	cg13731523	chr4:3047190	NA	-0.38	-7.31	-0.42	3.67e-12	Serum sulfate level;
KIRP	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg14289246	chr4:154710475	SFRP2	-0.53	-6.89	-0.4	4.76e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.68	-0.39	1.59e-10	Blood pressure;
KIRP	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg24972876	chr7:65420302	NA	0.41	5.6	0.34	5.57e-8	Aortic root size;
KIRP	cis	rs7640424	0.680	rs68147515	chr3:107903216	T/A	cg09227934	chr3:107805635	CD47	-0.35	-5.91	-0.35	1.15e-8	Body mass index;
KIRP	cis	rs55962025	0.883	rs362275	chr4:3224602	C/T	cg13731523	chr4:3047190	NA	0.33	5.15	0.31	5.45e-7	Parental longevity (mother's age at death);
KIRP	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg04731861	chr2:219085781	ARPC2	0.3	7.56	0.43	7.99e-13	Colorectal cancer;
KIRP	cis	rs2441986	0.857	rs17553949	chr11:57953459	T/C	cg19752551	chr11:57585705	CTNND1	-0.44	-5.26	-0.32	3.18e-7	Systolic blood pressure;
KIRP	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg17554472	chr22:41940697	POLR3H	0.67	6.81	0.4	7.55e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7119038	0.629	rs11216994	chr11:118603520	C/T	cg19308663	chr11:118741387	NA	0.48	7.79	0.44	1.86e-13	Sjögren's syndrome;
KIRP	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg00376283	chr12:123451042	ABCB9	0.82	11.0	0.57	3.86e-23	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.38	0.38	8.88e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-4.89	-0.3	1.84e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.28	7.64	0.44	4.78e-13	Crohn's disease;
KIRP	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.48	-5.95	-0.35	9.33e-9	Crohn's disease;
KIRP	cis	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19171272	chr22:38449367	NA	0.5	6.4	0.38	7.72e-10	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	0.72	10.06	0.54	3.71e-20	Inflammatory bowel disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00954467	chr8:18769863	PSD3	0.43	6.13	0.36	3.44e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.55	-7.35	-0.42	2.97e-12	Ulcerative colitis;
KIRP	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.48	-4.87	-0.3	2.01e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs6102059	0.503	rs6102032	chr20:39183949	C/T	cg22477343	chr20:39312069	NA	0.48	6.21	0.37	2.24e-9	LDL cholesterol;
KIRP	cis	rs7714670	0.801	rs4597943	chr5:73088068	G/T	cg04480106	chr5:72934606	RGNEF	-0.37	-4.89	-0.3	1.81e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg07777115	chr5:623756	CEP72	-0.61	-6.17	-0.37	2.77e-9	Obesity-related traits;
KIRP	cis	rs17818399	0.815	rs17768138	chr2:46868217	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.49	0.33	1e-7	Height;
KIRP	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.75	0.34	2.59e-8	Menopause (age at onset);
KIRP	cis	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg02972257	chr16:68554789	NA	-0.72	-7.13	-0.41	1.11e-11	Ulcerative colitis;
KIRP	cis	rs4006360	0.579	rs2320223	chr17:39234769	G/T	cg25341923	chr17:39239918	KRTAP4-7	-0.61	-8.66	-0.48	6.33e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs804280	0.544	rs804276	chr8:11625008	G/A	cg00262122	chr8:11665843	FDFT1	0.52	6.41	0.38	7.22e-10	Myopia (pathological);
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	0.99	18.15	0.76	2.77e-47	Menarche (age at onset);
KIRP	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	10.22	0.55	1.17e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-4.87	-0.3	2.02e-6	Neuroticism;
KIRP	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.86	-12.01	-0.61	1.93e-26	Total body bone mineral density;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23708337	chr7:1209742	NA	0.41	4.95	0.3	1.4e-6	Longevity;Endometriosis;
KIRP	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg24488311	chr11:68621650	NA	0.47	5.42	0.33	1.41e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg18404041	chr3:52824283	ITIH1	-0.34	-4.86	-0.3	2.08e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7939886	0.920	rs11227507	chr11:55972274	G/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs1459104	0.778	rs67930054	chr11:55800592	C/G	cg07850316	chr11:56344833	OR5M10;OR8U8	0.69	5.4	0.33	1.55e-7	Body mass index;
KIRP	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg16524733	chr11:117070046	TAGLN	0.38	4.88	0.3	1.89e-6	Blood protein levels;
KIRP	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.66	7.27	0.42	4.81e-12	Gut microbiome composition (summer);
KIRP	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.7	9.82	0.53	1.97e-19	Obesity-related traits;
KIRP	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.7e-15	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22360028	chr1:192548288	RGS1	-0.42	-6.39	-0.38	8.26e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.53	8.08	0.46	2.84e-14	Red cell distribution width;
KIRP	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.59	7.32	0.42	3.49e-12	Arsenic metabolism;
KIRP	cis	rs117145500	0.536	rs9928588	chr16:52945166	C/T	cg06054593	chr16:53737861	RPGRIP1L;FTO	0.63	5.68	0.34	3.81e-8	Sex hormone levels;
KIRP	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	-0.65	-9.16	-0.5	2.13e-17	Inflammatory bowel disease;
KIRP	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06850241	chr22:41845214	NA	-0.42	-4.92	-0.3	1.57e-6	Vitiligo;
KIRP	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	6.04	0.36	5.74e-9	Personality dimensions;
KIRP	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.7	8.97	0.5	7.93e-17	Multiple myeloma;
KIRP	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.62	8.05	0.46	3.55e-14	Platelet distribution width;
KIRP	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.79	11.74	0.6	1.41e-25	Height;
KIRP	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg22029157	chr1:209979665	IRF6	-0.42	-6.68	-0.39	1.57e-10	Orofacial clefts;
KIRP	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg00106254	chr7:1943704	MAD1L1	-0.62	-6.73	-0.39	1.21e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15731152	chr12:6781789	ZNF384	0.58	6.7	0.39	1.4e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Melanoma;
KIRP	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg18192325	chr2:105854051	NA	-0.38	-5.06	-0.31	8.19e-7	Type 2 diabetes;
KIRP	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg26531700	chr6:26746687	NA	0.39	5.0	0.3	1.11e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-0.99	-12.53	-0.62	3.49e-28	Vitiligo;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.98e-14	Body mass index;
KIRP	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.26	0.37	1.69e-9	Coronary artery disease;
KIRP	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.65	-9.1	-0.5	3.15e-17	Hip circumference;
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg13206674	chr6:150067644	NUP43	0.52	7.45	0.43	1.56e-12	Lung cancer;
KIRP	cis	rs1403694	1.000	rs1656911	chr3:186439373	T/C	cg12454167	chr3:186435060	KNG1	0.5	8.73	0.49	3.88e-16	Blood protein levels;
KIRP	cis	rs10875746	0.551	rs1471997	chr12:48723595	G/A	cg26205652	chr12:48591994	NA	0.75	9.57	0.52	1.22e-18	Longevity (90 years and older);
KIRP	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.21	-0.32	3.96e-7	Blood metabolite levels;
KIRP	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs9943753	0.525	rs7957928	chr12:109835975	C/G	cg19025524	chr12:109796872	NA	-0.46	-6.3	-0.37	1.33e-9	HDL cholesterol;
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.63	-9.2	-0.51	1.58e-17	Lung cancer;
KIRP	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06634786	chr22:41940651	POLR3H	0.42	4.96	0.3	1.34e-6	Vitiligo;
KIRP	trans	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	6.05	0.36	5.41e-9	Metabolite levels;
KIRP	cis	rs17253792	0.822	rs10145687	chr14:56124384	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.75	5.94	0.35	9.62e-9	Putamen volume;
KIRP	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.56	0.43	8.03e-13	Lung cancer;
KIRP	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-6.75	-0.4	1.04e-10	Chronic sinus infection;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg20003494	chr4:90757398	SNCA	-0.37	-4.9	-0.3	1.75e-6	Neuroticism;
KIRP	cis	rs7923609	0.967	rs7076310	chr10:65135672	C/A	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.55	-0.33	7.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7289126	0.966	rs5995554	chr22:38630272	T/C	cg25457927	chr22:38595422	NA	-0.31	-6.91	-0.4	4.08e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.54	6.77	0.4	9.34e-11	Obesity-related traits;
KIRP	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.74	-0.44	2.5e-13	Neuroticism;
KIRP	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.93e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7756236	0.521	rs9462208	chr6:36627890	T/C	cg08179530	chr6:36648295	CDKN1A	0.45	5.89	0.35	1.24e-8	QRS duration;
KIRP	cis	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-5.0	-0.3	1.11e-6	Neuroticism;
KIRP	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.85	-0.35	1.56e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg00204512	chr16:28754710	NA	0.43	5.5	0.33	9.36e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6974574	1.000	rs1524067	chr7:38122969	C/A	cg10754659	chr7:38110151	NA	-0.37	-5.05	-0.31	8.42e-7	Height;
KIRP	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	0.75	7.23	0.42	6.13e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg03999872	chr20:62272968	STMN3	-0.55	-6.45	-0.38	6.01e-10	Atopic dermatitis;
KIRP	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	1.13	18.87	0.77	1.05e-49	Cognitive function;
KIRP	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs4523957	0.786	rs28524880	chr17:2125444	C/A	cg16513277	chr17:2031491	SMG6	-0.68	-9.53	-0.52	1.59e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1443512	0.755	rs1373160	chr12:54340383	A/G	cg17410650	chr12:54324560	NA	-0.44	-5.65	-0.34	4.41e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg18944383	chr4:111397179	ENPEP	0.49	8.14	0.46	1.98e-14	Coronary artery disease;
KIRP	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.64	0.48	7.35e-16	Menopause (age at onset);
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-5.79	-0.35	2.09e-8	Lung cancer;
KIRP	trans	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs2910162	0.865	rs6878034	chr5:159915121	T/C	cg03306240	chr5:159912455	MIR146A	0.45	6.68	0.39	1.61e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg15093079	chr3:96533290	EPHA6	-0.45	-6.28	-0.37	1.56e-9	Migraine with aura;
KIRP	cis	rs7546668	1.000	rs1129347	chr1:15817334	G/A	cg21858823	chr1:15850916	CASP9	0.47	5.22	0.32	3.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.56	-7.33	-0.42	3.35e-12	Aortic root size;
KIRP	cis	rs7572644	0.699	rs7577342	chr2:28205581	A/G	cg27432699	chr2:27873401	GPN1	0.43	5.17	0.31	4.77e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09658987	chr6:83903672	PGM3;RWDD2A	0.62	6.94	0.4	3.37e-11	Lung cancer in ever smokers;
KIRP	cis	rs12986413	0.624	rs12460763	chr19:2138507	A/G	cg09261902	chr19:2140048	AP3D1	0.71	11.72	0.6	1.69e-25	Height;
KIRP	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.61	-6.99	-0.41	2.51e-11	Menarche (age at onset);
KIRP	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg16988262	chr1:15930761	NA	0.38	4.93	0.3	1.5e-6	Systolic blood pressure;
KIRP	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg00277334	chr10:82204260	NA	-0.62	-6.44	-0.38	6.07e-10	Post bronchodilator FEV1;
KIRP	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12501888	chr15:85177176	SCAND2	0.46	5.86	0.35	1.48e-8	P wave terminal force;
KIRP	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.34e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7999699	0.902	rs9534799	chr13:48318545	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.34	0.37	1.1e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.6	-7.89	-0.45	9.85e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg07701084	chr6:150067640	NUP43	0.59	7.49	0.43	1.21e-12	Testicular germ cell tumor;
KIRP	trans	rs10078397	0.626	rs6861718	chr5:107853869	A/G	cg20207829	chr8:110132541	NA	-0.47	-6.05	-0.36	5.34e-9	Neuroticism;
KIRP	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16576597	chr16:28551801	NUPR1	0.34	5.0	0.3	1.08e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg19592336	chr6:28129416	ZNF389	0.48	5.56	0.33	6.98e-8	Depression;
KIRP	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.6	-8.51	-0.48	1.77e-15	Longevity;
KIRP	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.8	-10.29	-0.55	6.77e-21	Gut microbiome composition (winter);
KIRP	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-0.9	-6.75	-0.4	1.08e-10	Mitochondrial DNA levels;
KIRP	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-1.02	-12.19	-0.61	4.65e-27	Exhaled nitric oxide output;
KIRP	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg05709478	chr1:6581295	PLEKHG5	0.62	6.25	0.37	1.75e-9	Body mass index;
KIRP	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.5	5.34	0.32	2.07e-7	Breast cancer;
KIRP	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.74	-0.39	1.12e-10	Type 2 diabetes;
KIRP	cis	rs62380364	0.602	rs640177	chr5:88002084	T/A	cg22951263	chr5:87985283	NA	-0.47	-6.68	-0.39	1.62e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.9	14.34	0.67	2.66e-34	IgG glycosylation;
KIRP	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.74	-7.9	-0.45	9.3e-14	Blood pressure (smoking interaction);
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.33	-0.32	2.23e-7	Obesity-related traits;
KIRP	cis	rs6681460	0.674	rs7543607	chr1:67012592	G/T	cg13052034	chr1:66999238	SGIP1	0.45	6.34	0.38	1.06e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.48	6.21	0.37	2.22e-9	Blood metabolite levels;
KIRP	cis	rs6580649	0.941	rs4760683	chr12:48516296	T/C	cg26205652	chr12:48591994	NA	-0.43	-5.09	-0.31	7.02e-7	Lung cancer;
KIRP	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg26893134	chr6:116381904	FRK	0.19	5.18	0.31	4.7e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7819412	0.521	rs13256092	chr8:11000377	A/T	cg00405596	chr8:11794950	NA	-0.44	-5.18	-0.31	4.6e-7	Triglycerides;
KIRP	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.2	-0.31	4.28e-7	Alcohol dependence;
KIRP	cis	rs883565	0.655	rs4645092	chr3:39051718	G/A	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg08992911	chr2:238395768	MLPH	-0.47	-5.72	-0.34	3.04e-8	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg08885076	chr2:99613938	TSGA10	-0.44	-6.46	-0.38	5.48e-10	Bipolar disorder;
KIRP	cis	rs981844	0.603	rs13132437	chr4:154748006	T/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.96	-0.41	3.11e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.53	6.98	0.41	2.78e-11	Colorectal cancer;
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.8	14.29	0.67	4.04e-34	Height;
KIRP	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg23796481	chr11:64053134	BAD;GPR137	-0.56	-5.47	-0.33	1.09e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg21698718	chr17:80085957	CCDC57	0.34	5.03	0.31	9.28e-7	Life satisfaction;
KIRP	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg15979348	chr13:112237479	NA	0.39	4.99	0.3	1.12e-6	Menarche (age at onset);
KIRP	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	9.11	0.5	3.05e-17	Systemic lupus erythematosus;
KIRP	cis	rs7551222	0.716	rs6679311	chr1:204559676	T/C	cg20240347	chr1:204465584	NA	-0.36	-6.11	-0.36	3.87e-9	Schizophrenia;
KIRP	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg03714773	chr7:91764589	CYP51A1	0.36	5.16	0.31	5.16e-7	Breast cancer;
KIRP	trans	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg13565492	chr6:43139072	SRF	-1.01	-9.68	-0.53	5.53e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.91	14.33	0.67	2.95e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg23625390	chr15:77176239	SCAPER	-0.8	-10.98	-0.57	4.36e-23	Blood metabolite levels;
KIRP	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.61	6.92	0.4	3.96e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	6.88	0.4	4.81e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4728302	0.607	rs6955061	chr7:133589145	C/T	cg10665199	chr7:133106180	EXOC4	0.43	5.04	0.31	9.21e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15013279	chr4:128886282	MFSD8;C4orf29	0.45	6.2	0.37	2.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs722599	0.651	rs7159354	chr14:75253847	A/G	cg08847533	chr14:75593920	NEK9	0.51	6.2	0.37	2.36e-9	IgG glycosylation;
KIRP	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.58	7.69	0.44	3.63e-13	Airway imaging phenotypes;
KIRP	cis	rs4148660	0.927	rs1344569	chr12:22067208	T/C	cg14669847	chr12:22099120	NA	-0.34	-5.79	-0.35	2.1e-8	Gout;
KIRP	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-8.85	-0.49	1.73e-16	Chronic sinus infection;
KIRP	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg18944383	chr4:111397179	ENPEP	0.55	9.05	0.5	4.52e-17	Coronary artery disease;
KIRP	cis	rs4523957	0.928	rs394752	chr17:2199749	C/A	cg16513277	chr17:2031491	SMG6	0.61	8.32	0.47	5.92e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.67	0.44	4.09e-13	Calcium levels;
KIRP	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg19743168	chr1:23544995	NA	-0.52	-7.32	-0.42	3.45e-12	Height;
KIRP	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg02569458	chr12:86230093	RASSF9	0.54	7.92	0.45	8e-14	Major depressive disorder;
KIRP	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.58	-6.33	-0.37	1.17e-9	DNA methylation (variation);
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg12486944	chr17:80159399	CCDC57	0.38	5.1	0.31	6.65e-7	Life satisfaction;
KIRP	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg15655495	chr12:38532458	NA	-0.3	-5.2	-0.31	4.11e-7	Bladder cancer;
KIRP	cis	rs6838801	0.892	rs56248930	chr4:77534438	A/T	cg17476223	chr4:77663285	SHROOM3	0.51	7.09	0.41	1.43e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg13606994	chr1:44402422	ARTN	-0.27	-4.97	-0.3	1.28e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3105593	0.965	rs12442721	chr15:50910813	C/T	cg08437265	chr15:50716283	USP8	0.39	4.93	0.3	1.48e-6	QT interval;
KIRP	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	1.08	17.18	0.74	5.22e-44	Cognitive function;
KIRP	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.97	15.37	0.7	8.3e-38	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.41	-0.38	7.24e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-6.02	-0.36	6.38e-9	HDL cholesterol;
KIRP	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg01877450	chr7:97915802	BRI3	-0.54	-7.0	-0.41	2.42e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	11.97	0.61	2.48e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.38	5.03	0.31	9.36e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12292205	chr6:26970375	C6orf41	-0.64	-7.1	-0.41	1.36e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2929278	0.617	rs3087657	chr15:44063859	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	6.64	0.39	2.02e-10	Schizophrenia;
KIRP	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg14440974	chr22:39074834	NA	-0.38	-4.95	-0.3	1.4e-6	Menopause (age at onset);
KIRP	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.92	9.95	0.54	8.23e-20	Corneal astigmatism;
KIRP	cis	rs12210905	1.000	rs72843607	chr6:27110715	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.49	6.65	0.39	1.86e-10	Leprosy;
KIRP	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.61	-8.21	-0.46	1.24e-14	Colorectal cancer;
KIRP	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06634786	chr22:41940651	POLR3H	-0.5	-5.85	-0.35	1.56e-8	Neuroticism;
KIRP	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7916697	0.891	rs4746748	chr10:70009388	G/A	cg18338521	chr10:69995036	NA	0.39	4.89	0.3	1.86e-6	Optic disc area;
KIRP	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg19847130	chr8:10466454	RP1L1	-0.42	-6.15	-0.37	3.13e-9	Retinal vascular caliber;
KIRP	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.86	-0.45	1.21e-13	Triglycerides;
KIRP	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03352830	chr11:487213	PTDSS2	0.77	6.22	0.37	2.15e-9	Body mass index;
KIRP	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.87	13.17	0.64	2.45e-30	Birth weight;
KIRP	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.93	0.57	6.37e-23	Cognitive test performance;
KIRP	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.43	-5.54	-0.33	7.59e-8	Aortic root size;
KIRP	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-5.28	-0.32	2.81e-7	Vitiligo;
KIRP	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.79	9.64	0.52	7.29e-19	Monocyte percentage of white cells;
KIRP	cis	rs10121009	0.635	rs17361814	chr9:35313054	G/A	cg15271616	chr9:35490515	RUSC2	0.39	5.02	0.3	9.81e-7	Parkinson's disease;
KIRP	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18867708	chr6:26865862	GUSBL1	-0.5	-6.28	-0.37	1.55e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg14673194	chr17:80132900	CCDC57	0.77	8.69	0.48	5.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.65	10.09	0.54	3.04e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.76	-8.47	-0.48	2.22e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4356932	1.000	rs4333205	chr4:76984795	A/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs4663866	1.000	rs4663866	chr2:239150815	A/C	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.88	8.35	0.47	4.9e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.45	-0.33	1.25e-7	Neuroticism;
KIRP	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs4664304	0.900	rs17231993	chr2:160741415	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.69	-0.39	1.46e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14831990	chr22:21400167	LOC400891	0.42	6.05	0.36	5.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg26248373	chr2:1572462	NA	-0.65	-6.83	-0.4	6.53e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs12022452	0.591	rs6672398	chr1:41002177	A/T	cg25568243	chr1:40974465	DEM1	0.53	5.86	0.35	1.44e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.92	12.04	0.61	1.5e-26	Cognitive function;
KIRP	cis	rs2737618	0.651	rs2816976	chr1:200081021	A/T	cg21825944	chr1:200113062	NR5A2	-0.54	-7.65	-0.44	4.47e-13	Uric acid levels;
KIRP	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.41	6.13	0.36	3.53e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	12.74	0.63	6.77e-29	Smoking behavior;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23977821	chr2:24270452	C2orf44	0.45	6.2	0.37	2.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs597583	0.715	rs4938399	chr11:117398399	C/T	cg27161313	chr11:117392002	DSCAML1	-0.71	-7.12	-0.41	1.22e-11	Putamen volume;
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.62	-8.21	-0.46	1.29e-14	Aortic root size;
KIRP	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.89	14.3	0.67	3.57e-34	Morning vs. evening chronotype;
KIRP	cis	rs9937943	0.667	rs35253850	chr16:74599103	T/C	cg01733217	chr16:74700730	RFWD3	0.56	5.45	0.33	1.22e-7	Neutrophil percentage of white cells;
KIRP	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg10402321	chr1:26617780	UBXN11	-0.43	-5.56	-0.33	7.11e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.63	6.04	0.36	5.69e-9	Breast cancer;
KIRP	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-8.18	-0.46	1.52e-14	Personality dimensions;
KIRP	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg20243544	chr17:37824526	PNMT	0.48	6.15	0.37	3.06e-9	Primary biliary cholangitis;
KIRP	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg02297831	chr4:17616191	MED28	0.51	6.03	0.36	5.83e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	1.14	9.01	0.5	5.81e-17	Parkinson's disease;
KIRP	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg23978390	chr7:1156363	C7orf50	0.38	4.99	0.3	1.13e-6	Longevity;Endometriosis;
KIRP	cis	rs3857747	0.827	rs7803105	chr7:40477360	G/A	cg00420559	chr7:40367873	C7orf10	0.55	7.47	0.43	1.35e-12	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg04691961	chr3:161091175	C3orf57	0.44	6.31	0.37	1.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.0	-0.41	2.49e-11	Alzheimer's disease;
KIRP	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.65	7.68	0.44	3.76e-13	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13831459	chr10:101380774	SLC25A28	0.5	6.22	0.37	2.13e-9	Parkinson's disease;
KIRP	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-5.79	-0.35	2.09e-8	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	trans	rs2288327	0.557	rs7577862	chr2:179352857	G/A	cg14011486	chr1:26737247	LIN28	0.69	6.84	0.4	6.36e-11	Atrial fibrillation;
KIRP	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.84	6.98	0.41	2.81e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs12313068	0.600	rs7136207	chr12:110491487	T/C	cg12870014	chr12:110450643	ANKRD13A	0.52	6.82	0.4	6.89e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg08885076	chr2:99613938	TSGA10	0.42	6.22	0.37	2.11e-9	Bipolar disorder;
KIRP	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Body mass index;
KIRP	cis	rs34091987	0.622	rs2193052	chr17:70026137	G/A	cg09344028	chr17:70110421	NA	0.29	5.64	0.34	4.78e-8	Nose size;
KIRP	cis	rs3026101	0.671	rs72634032	chr17:5303437	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	trans	rs2902193	0.643	rs11151472	chr18:53643688	C/T	cg17815252	chr3:142838682	CHST2	-0.48	-6.04	-0.36	5.58e-9	Cancer;
KIRP	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-7.43	-0.43	1.77e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.89	-13.61	-0.66	7.78e-32	Height;
KIRP	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg19847130	chr8:10466454	RP1L1	0.35	5.32	0.32	2.31e-7	Triglycerides;
KIRP	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg13010199	chr12:38710504	ALG10B	0.63	7.79	0.44	1.88e-13	Morning vs. evening chronotype;
KIRP	cis	rs2554380	0.943	rs2585052	chr15:84355990	T/A	cg14598478	chr15:84363061	ADAMTSL3	-0.64	-8.95	-0.5	8.71e-17	Height;
KIRP	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.24	-0.32	3.47e-7	Pulmonary function;
KIRP	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	5.27	0.32	3.01e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg06969265	chr17:73775802	H3F3B	0.84	6.59	0.39	2.65e-10	Psoriasis;
KIRP	cis	rs72627123	0.867	rs79250763	chr14:74491121	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.87	5.68	0.34	3.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.44	5.75	0.34	2.68e-8	Body mass index;
KIRP	cis	rs9359856	0.564	rs56224741	chr6:90475231	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.87	-0.45	1.13e-13	Bipolar disorder;
KIRP	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg12454167	chr3:186435060	KNG1	0.52	8.92	0.49	1.08e-16	Blood protein levels;
KIRP	cis	rs8077577	0.747	rs2294913	chr17:18202996	C/T	cg18869244	chr17:18121946	NA	0.46	5.16	0.31	5.07e-7	Obesity-related traits;
KIRP	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.96	12.57	0.63	2.6e-28	Breast cancer;
KIRP	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	11.31	0.58	3.62e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg06740227	chr12:86229804	RASSF9	0.4	5.02	0.3	1.02e-6	Major depressive disorder;
KIRP	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06771106	chr2:113671356	IL1F7	0.44	5.17	0.31	4.93e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	9.34	0.51	5.98e-18	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg07596299	chr11:71824057	C11orf51	0.81	5.3	0.32	2.57e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg05775895	chr3:12838266	CAND2	0.36	6.15	0.37	3.08e-9	QRS complex (12-leadsum);
KIRP	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg12623918	chr2:306882	NA	0.4	5.05	0.31	8.71e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg08126542	chr6:37504118	NA	-0.83	-13.08	-0.64	4.92e-30	Cognitive performance;
KIRP	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.89	-0.35	1.29e-8	IgG glycosylation;
KIRP	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	1.02	20.11	0.79	7.44e-54	Parkinson's disease;
KIRP	trans	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg00405596	chr8:11794950	NA	-0.47	-6.25	-0.37	1.81e-9	Mood instability;
KIRP	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.46	-6.98	-0.41	2.67e-11	Coronary artery disease;
KIRP	cis	rs7923609	0.967	rs10761729	chr10:64995604	G/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.61	-0.34	5.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	6.56	0.39	3.15e-10	Schizophrenia;
KIRP	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg07621104	chr11:117668040	DSCAML1	0.48	5.96	0.36	8.83e-9	Myopia;
KIRP	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00857998	chr1:205179979	DSTYK	0.67	8.59	0.48	9.87e-16	Red blood cell count;
KIRP	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.21	-0.37	2.3e-9	Aortic root size;
KIRP	cis	rs7520050	0.966	rs12411269	chr1:46271052	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.5	-0.33	9.5e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs514406	0.928	rs1672917	chr1:53291550	A/G	cg16325326	chr1:53192061	ZYG11B	0.87	12.5	0.62	4.52e-28	Monocyte count;
KIRP	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.05	12.74	0.63	6.87e-29	Smoking behavior;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25518386	chr19:18315738	RAB3A	0.46	6.54	0.38	3.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.65	-8.68	-0.48	5.54e-16	Personality dimensions;
KIRP	cis	rs2072732	0.904	rs1138513	chr1:2976816	T/C	cg11731671	chr1:2995604	PRDM16	-0.42	-5.67	-0.34	3.97e-8	Plateletcrit;
KIRP	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-7.39	-0.43	2.22e-12	Vitiligo;
KIRP	cis	rs4656940	0.574	rs520316	chr1:160789551	A/G	cg17331569	chr1:160788135	LY9	0.41	4.86	0.3	2.06e-6	Crohn's disease;
KIRP	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg10792982	chr14:105748885	BRF1	0.88	13.55	0.65	1.28e-31	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.64	8.57	0.48	1.15e-15	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06481639	chr22:41940642	POLR3H	-0.47	-5.78	-0.35	2.27e-8	Vitiligo;
KIRP	cis	rs9290877	0.667	rs6766661	chr3:188456581	T/C	cg17392043	chr3:188495102	LPP	-0.49	-6.45	-0.38	5.99e-10	IgE levels;
KIRP	cis	rs17301259	0.548	rs2718405	chr7:88402192	C/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.3	-4.92	-0.3	1.57e-6	Heschl's gyrus morphology;
KIRP	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25833597	chr17:30823145	MYO1D	0.41	5.04	0.31	8.85e-7	Schizophrenia;
KIRP	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06481639	chr22:41940642	POLR3H	0.64	6.5	0.38	4.34e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg20026190	chr17:76395443	PGS1	0.5	6.41	0.38	7.3e-10	HDL cholesterol levels;
KIRP	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.16	0.58	1.18e-23	Bipolar disorder;
KIRP	cis	rs9972944	0.756	rs4594282	chr17:63762930	G/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.83	-0.45	1.44e-13	Total body bone mineral density;
KIRP	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg22689280	chr22:47017522	NA	0.45	5.0	0.3	1.1e-6	Urate levels in obese individuals;
KIRP	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.92	0.45	8.2e-14	Iron status biomarkers;
KIRP	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	0.86	7.52	0.43	1.01e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg11204139	chr17:3907470	NA	0.81	14.71	0.68	1.4e-35	Type 2 diabetes;
KIRP	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.36	-0.32	1.91e-7	IgG glycosylation;
KIRP	cis	rs3739821	1.000	rs3739821	chr9:130702477	A/G	cg17308606	chr9:130706144	FAM102A	0.37	6.17	0.37	2.74e-9	Glaucoma (primary angle closure);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09736950	chr15:62938334	MGC15885;TLN2	0.51	6.59	0.39	2.6e-10	Interleukin-4 levels;
KIRP	cis	rs7175404	1.000	rs7167271	chr15:94048332	A/C	cg23502883	chr15:93959149	NA	-0.48	-5.24	-0.32	3.44e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.48	-5.58	-0.34	6.39e-8	Osteoporosis;
KIRP	cis	rs4132509	0.515	rs76243949	chr1:243674094	G/A	cg21452805	chr1:244014465	NA	0.57	5.4	0.33	1.55e-7	RR interval (heart rate);
KIRP	cis	rs8049040	0.547	rs12934168	chr16:71436778	C/T	cg08717414	chr16:71523259	ZNF19	-0.57	-6.62	-0.39	2.22e-10	Blood protein levels;
KIRP	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.52	4.85	0.3	2.14e-6	Height;
KIRP	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.75	8.4	0.47	3.58e-15	Response to diuretic therapy;
KIRP	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.73	-0.39	1.18e-10	Obesity (extreme);
KIRP	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.58	5.42	0.33	1.45e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2278796	0.639	rs4950976	chr1:204970243	C/T	cg17947172	chr1:204966197	NFASC	-0.64	-8.69	-0.48	5.02e-16	Mean platelet volume;
KIRP	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg04865290	chr3:52927548	TMEM110	-0.65	-6.85	-0.4	6.05e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10214930	0.697	rs28429439	chr7:27633799	G/A	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.96e-7	Aortic root size;
KIRP	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg13628971	chr7:2884303	GNA12	0.4	4.97	0.3	1.25e-6	Height;
KIRP	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.26	-0.78	4.82e-51	Height;
KIRP	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.71	7.46	0.43	1.52e-12	Diastolic blood pressure;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01708552	chr7:100815485	C7orf52	0.46	6.66	0.39	1.79e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.88	0.45	1.05e-13	Retinal vascular caliber;
KIRP	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg06212747	chr3:49208901	KLHDC8B	0.65	7.2	0.42	7.08e-12	Menarche (age at onset);
KIRP	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	0.98	7.99	0.45	5.3e-14	Arsenic metabolism;
KIRP	cis	rs7172677	0.508	rs12917120	chr15:75329091	T/C	cg14664628	chr15:75095509	CSK	-0.54	-6.73	-0.39	1.2e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.45	5.93	0.35	1.04e-8	Breast cancer;
KIRP	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg02375832	chr11:62437615	C11orf48	-0.4	-5.0	-0.3	1.11e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.87	-0.49	1.54e-16	Alzheimer's disease;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22776125	chr6:167041314	RPS6KA2	-0.47	-6.03	-0.36	5.89e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg07137983	chr6:135709029	AHI1	-0.6	-6.39	-0.38	8.32e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.53	-5.69	-0.34	3.62e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9653442	0.510	rs13415583	chr2:100764087	T/G	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.71	-10.6	-0.56	7.37e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.93	-0.45	7.56e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9921338	0.961	rs7200667	chr16:11440404	C/A	cg00044050	chr16:11439710	C16orf75	-0.55	-5.87	-0.35	1.43e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25118511	chr3:53926156	SELK	0.46	6.14	0.36	3.27e-9	Parkinson's disease;
KIRP	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg18944383	chr4:111397179	ENPEP	-0.54	-6.33	-0.37	1.18e-9	Axial length;
KIRP	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg26727032	chr16:67993705	SLC12A4	-0.64	-5.67	-0.34	3.96e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.82	-0.35	1.81e-8	Pulmonary function;
KIRP	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg20999797	chr1:1681921	NA	0.51	7.94	0.45	7.37e-14	Body mass index;
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg02462569	chr6:150064036	NUP43	-0.33	-4.97	-0.3	1.28e-6	Lung cancer;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg17584085	chr17:46688329	HOXB7	-0.62	-6.35	-0.38	1.02e-9	Response to statin therapy;
KIRP	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7688540	0.771	rs10005733	chr4:292001	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.42	4.92	0.3	1.59e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg18882449	chr10:104885122	NT5C2	-0.38	-4.97	-0.3	1.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06109949	chr2:178937838	PDE11A	0.62	6.32	0.37	1.22e-9	Lung function (FEV1);
KIRP	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg05347473	chr6:146136440	FBXO30	0.6	8.57	0.48	1.15e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7937612	0.965	rs7118391	chr11:120270709	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.16	-0.42	9.22e-12	Intraocular pressure;
KIRP	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.67	7.74	0.44	2.62e-13	Lung cancer;
KIRP	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.66	7.84	0.45	1.4e-13	Body mass index;
KIRP	cis	rs2820292	0.804	rs2644120	chr1:201882277	C/G	cg06775570	chr1:201857621	SHISA4	0.3	5.28	0.32	2.89e-7	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
KIRP	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.83	9.96	0.54	7.25e-20	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10800082	chr10:112631596	LOC282997;PDCD4	-0.53	-6.34	-0.37	1.07e-9	Interleukin-4 levels;
KIRP	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.05	0.41	1.78e-11	Height;
KIRP	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.98	-0.64	1.09e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.48	5.54	0.33	7.82e-8	Huntington's disease progression;
KIRP	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg07701084	chr6:150067640	NUP43	0.61	7.89	0.45	1e-13	Lung cancer;
KIRP	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg02503808	chr4:7069936	GRPEL1	-1.02	-10.77	-0.57	2.08e-22	Monocyte percentage of white cells;
KIRP	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg00802000	chr16:706648	WDR90	-0.44	-5.48	-0.33	1.08e-7	Height;
KIRP	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-4.98	-0.3	1.21e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg03714773	chr7:91764589	CYP51A1	0.33	4.92	0.3	1.6e-6	Breast cancer;
KIRP	cis	rs77972916	0.536	rs6751209	chr2:43588302	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-6.36	-0.38	9.71e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg25019033	chr10:957182	NA	-0.69	-8.82	-0.49	2.11e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg15676125	chr6:33679581	C6orf125	0.39	5.06	0.31	8.23e-7	Plateletcrit;
KIRP	trans	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg23484912	chr5:273055	PDCD6	0.62	7.43	0.43	1.82e-12	Pancreatic cancer;
KIRP	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg05370193	chr1:21551575	ECE1	-0.42	-5.9	-0.35	1.17e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg04369109	chr6:150039330	LATS1	-0.46	-5.64	-0.34	4.57e-8	Lung cancer;
KIRP	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.52	-0.33	8.49e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg05251000	chr9:132935664	FREQ	0.52	8.96	0.5	8.1e-17	Alzheimer's disease (cognitive decline);
KIRP	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	11.38	0.59	2.19e-24	Platelet count;
KIRP	trans	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17183009	chr3:120277827	NA	0.53	6.18	0.37	2.57e-9	Corneal astigmatism;
KIRP	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-6.6	-0.39	2.53e-10	Response to antipsychotic treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02623684	chr3:5229378	EDEM1	0.5	6.14	0.36	3.27e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17283899	chr5:10564369	ANKRD33B	0.51	6.52	0.38	3.97e-10	Parkinson's disease;
KIRP	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg16127683	chr15:40268777	EIF2AK4	-0.57	-6.26	-0.37	1.7e-9	Corneal curvature;
KIRP	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg04132472	chr17:19861366	AKAP10	0.43	5.93	0.35	1e-8	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.85	11.87	0.6	5.45e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs11166927	0.967	rs7834010	chr8:140791732	A/C	cg16909799	chr8:140841666	TRAPPC9	0.7	9.79	0.53	2.47e-19	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg01879757	chr17:41196368	BRCA1	-0.53	-7.22	-0.42	6.52e-12	Menopause (age at onset);
KIRP	cis	rs12230513	0.732	rs67290413	chr12:55869876	T/C	cg11794356	chr12:55725991	OR6C3	-0.5	-6.11	-0.36	3.94e-9	Contrast sensitivity;
KIRP	cis	rs580438	0.529	rs13087341	chr3:13422792	C/A	cg10657019	chr3:13328039	NA	-0.52	-6.71	-0.39	1.33e-10	Myringotomy;
KIRP	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.4	-4.84	-0.3	2.25e-6	Monocyte count;
KIRP	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-6.74	-0.39	1.13e-10	Body mass index;
KIRP	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-8.73	-0.49	3.92e-16	Alzheimer's disease (survival time);
KIRP	cis	rs4073416	0.568	rs8012834	chr14:65966555	C/T	cg03016385	chr14:66212404	NA	-0.5	-6.25	-0.37	1.75e-9	N-glycan levels;
KIRP	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.2	0.42	7.39e-12	Bipolar disorder;
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg26516362	chr5:178986906	RUFY1	0.4	6.74	0.39	1.11e-10	Lung cancer;
KIRP	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	12.62	0.63	1.77e-28	Eye color traits;
KIRP	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.84	-11.93	-0.61	3.38e-26	Colorectal cancer;
KIRP	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.86	-0.53	1.5e-19	Neuroticism;
KIRP	cis	rs10211205	1.000	rs10166654	chr2:236611263	C/T	cg13770573	chr2:236586376	AGAP1	-0.58	-6.22	-0.37	2.13e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg24209194	chr3:40518798	ZNF619	0.42	5.29	0.32	2.73e-7	Renal cell carcinoma;
KIRP	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg23307798	chr14:103986281	CKB	-0.51	-6.93	-0.4	3.59e-11	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg02775129	chr4:119771670	NA	-0.87	-4.91	-0.3	1.62e-6	Cannabis dependence symptom count;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17428704	0.571	rs16903453	chr5:14388636	A/G	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg06935464	chr4:38784597	TLR10	0.52	5.22	0.32	3.81e-7	Breast cancer;
KIRP	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.64	8.34	0.47	5.51e-15	Height;
KIRP	cis	rs7078219	1.000	rs6584278	chr10:101278099	C/T	cg07044859	chr10:101282883	NA	-0.33	-5.66	-0.34	4.15e-8	Dental caries;
KIRP	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg10790698	chr19:18539756	SSBP4	-0.33	-7.1	-0.41	1.35e-11	Breast cancer;
KIRP	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.83	9.96	0.54	7.43e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	1.05	18.92	0.77	7.07e-50	Monocyte count;
KIRP	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-6.83	-0.4	6.74e-11	Vitiligo;
KIRP	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.75	-10.42	-0.55	2.78e-21	Hypospadias;
KIRP	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.68	-8.69	-0.48	5.34e-16	Body mass index;
KIRP	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.46	-5.43	-0.33	1.36e-7	Carotid intima media thickness;
KIRP	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.78	-9.96	-0.54	7.69e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.58	-6.54	-0.38	3.51e-10	Hypospadias;
KIRP	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.52	-6.68	-0.39	1.54e-10	White matter hyperintensity burden;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.79	-14.04	-0.67	2.78e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg06121193	chr1:90282411	NA	0.5	7.15	0.42	9.58e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs220519	0.811	rs220497	chr20:37298929	A/G	cg24308336	chr20:37270989	C20orf95	0.24	5.16	0.31	5.13e-7	Schizophrenia;
KIRP	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.29	0.55	6.83e-21	Cognitive test performance;
KIRP	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg09473613	chr1:24152604	HMGCL	0.47	6.27	0.37	1.64e-9	Immature fraction of reticulocytes;
KIRP	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs4631830	0.600	rs11004246	chr10:51495349	T/C	cg10326726	chr10:51549505	MSMB	0.63	8.44	0.47	2.76e-15	Prostate-specific antigen levels;
KIRP	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.92	0.4	3.98e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2150410	0.833	rs3746885	chr21:40685590	T/C	cg11890956	chr21:40555474	PSMG1	0.83	5.8	0.35	2.02e-8	Temperament (bipolar disorder);
KIRP	cis	rs8018808	0.902	rs8006688	chr14:77926649	G/A	cg18872420	chr14:78023429	SPTLC2	0.37	5.41	0.33	1.48e-7	Myeloid white cell count;
KIRP	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg05639522	chr1:247681581	NA	-0.63	-7.11	-0.41	1.24e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs13418717	1.000	rs13411697	chr2:127657951	C/T	cg25501666	chr2:127640322	NA	1.07	7.35	0.42	2.95e-12	Heart failure;
KIRP	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.64	-8.32	-0.47	5.91e-15	IgG glycosylation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24599037	chr3:113405689	KIAA2018	0.44	6.05	0.36	5.23e-9	Interleukin-4 levels;
KIRP	cis	rs3741151	0.686	rs7944346	chr11:73244230	C/T	cg17517138	chr11:73019481	ARHGEF17	0.6	5.47	0.33	1.13e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	trans	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg11693508	chr17:37793320	STARD3	0.57	7.32	0.42	3.54e-12	Neuroticism;
KIRP	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	7.38	0.43	2.48e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg18833306	chr6:118973337	C6orf204	0.41	5.11	0.31	6.42e-7	Electrocardiographic conduction measures;
KIRP	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg10047753	chr17:41438598	NA	-0.73	-10.56	-0.56	9.37e-22	Menopause (age at onset);
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00933542	chr6:150070202	PCMT1	0.27	5.27	0.32	2.99e-7	Lung cancer;
KIRP	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg19400113	chr3:189546778	TP63;MIR944	-0.28	-4.93	-0.3	1.53e-6	Lung adenocarcinoma;
KIRP	cis	rs9302065	0.595	rs1547746	chr13:95964267	G/A	cg24476569	chr13:95954382	ABCC4	-0.46	-6.75	-0.4	1.05e-10	Blood metabolite levels;
KIRP	cis	rs3112255	0.967	rs2971019	chr2:101298126	C/G	cg01042948	chr2:101319752	NA	0.43	6.15	0.36	3.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2172802	0.693	rs10004368	chr4:62496325	A/G	cg04118610	chr4:62707027	LPHN3	-0.52	-5.88	-0.35	1.34e-8	Partial epilepsies;
KIRP	cis	rs7116495	0.881	rs7930722	chr11:71737484	C/G	cg26138937	chr11:71823887	C11orf51	-0.7	-5.65	-0.34	4.46e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs644148	0.676	rs2571114	chr19:44997579	A/G	cg15540054	chr19:45004280	ZNF180	-0.56	-6.66	-0.39	1.78e-10	Personality dimensions;
KIRP	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	1.07	19.23	0.77	6.27e-51	Systemic lupus erythematosus;
KIRP	cis	rs9815354	1.000	rs1716993	chr3:41974556	G/C	cg03022575	chr3:42003672	ULK4	-0.56	-6.6	-0.39	2.52e-10	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs6601327	0.543	rs11249948	chr8:9648686	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.64	0.44	4.92e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg15252951	chr6:33757062	LEMD2	0.47	5.47	0.33	1.1e-7	Crohn's disease;
KIRP	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.76	10.52	0.56	1.34e-21	Menarche (age at onset);
KIRP	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.44	-5.49	-0.33	1.01e-7	Aortic root size;
KIRP	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.42	5.0	0.3	1.07e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-7.16	-0.42	9.43e-12	Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg09264619	chr17:80180166	NA	-0.41	-5.93	-0.35	1.02e-8	Life satisfaction;
KIRP	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg19773385	chr1:10388646	KIF1B	-0.66	-8.56	-0.48	1.2e-15	Hepatocellular carcinoma;
KIRP	cis	rs7027203	0.557	rs2487015	chr9:96521240	T/G	cg14598338	chr9:96623480	NA	-0.44	-6.69	-0.39	1.49e-10	DNA methylation (variation);
KIRP	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.42	-0.38	6.92e-10	Daytime sleep phenotypes;
KIRP	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg22431228	chr1:16359049	CLCNKA	-0.58	-7.84	-0.45	1.41e-13	Systolic blood pressure;
KIRP	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg24488311	chr11:68621650	NA	0.49	5.87	0.35	1.41e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.8	-10.03	-0.54	4.38e-20	Breast cancer;
KIRP	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.78	-0.4	9.05e-11	Aortic root size;
KIRP	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg25174290	chr11:3078921	CARS	-0.69	-8.96	-0.5	8.06e-17	Calcium levels;
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.47	6.53	0.38	3.79e-10	Testicular germ cell tumor;
KIRP	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.87	-0.4	5.12e-11	Response to antipsychotic treatment;
KIRP	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.62	-5.96	-0.36	8.78e-9	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg09507567	chr10:124027408	NA	-0.3	-5.57	-0.33	6.64e-8	Total body bone mineral density;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26231243	chr19:9945826	PIN1	-0.61	-6.66	-0.39	1.79e-10	Menopause (age at onset);
KIRP	cis	rs1832871	0.672	rs9457344	chr6:158742043	C/T	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.6	-6.94	-0.4	3.44e-11	Menopause (age at onset);
KIRP	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10865541	0.869	rs13020433	chr2:3417577	G/A	cg11642891	chr2:3452563	TTC15	-0.48	-6.31	-0.37	1.31e-9	Obesity-related traits;
KIRP	cis	rs7458708	1	rs7458708	chr7:83111837	C/T	cg14519356	chr7:83097669	SEMA3E	-0.47	-6.43	-0.38	6.58e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7398996	1	rs7398996	chr12:53659448	C/T	cg16917193	chr12:54089295	NA	0.45	5.69	0.34	3.54e-8	Total body bone mineral density (age 45-60);
KIRP	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.65	6.5	0.38	4.41e-10	Axial length;
KIRP	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12292205	chr6:26970375	C6orf41	-0.71	-7.55	-0.43	8.24e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.89	0.45	9.65e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.38	5.1	0.31	6.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.41	0.47	3.36e-15	Electroencephalogram traits;
KIRP	cis	rs698833	0.886	rs4953090	chr2:44565194	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.47	0.33	1.08e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-1.01	-12.32	-0.62	1.77e-27	Exhaled nitric oxide output;
KIRP	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.51e-11	Iron status biomarkers;
KIRP	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg11663144	chr21:46675770	NA	-0.59	-8.83	-0.49	1.97e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.95	12.55	0.62	3.07e-28	Menopause (age at onset);
KIRP	cis	rs3931020	0.657	rs277369	chr1:75234661	T/C	cg00121533	chr1:75199117	CRYZ;TYW3	-0.42	-5.0	-0.3	1.07e-6	Resistin levels;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.68	-8.54	-0.48	1.45e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8054556	0.647	rs8048433	chr16:29931593	T/C	cg05445914	chr16:30134068	MAPK3	0.44	5.48	0.33	1.06e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg18016565	chr1:150552671	MCL1	0.4	6.05	0.36	5.49e-9	Melanoma;
KIRP	cis	rs6832769	1.000	rs7667849	chr4:56388199	A/G	cg05960024	chr4:56376020	CLOCK	-0.73	-9.48	-0.52	2.34e-18	Personality dimensions;
KIRP	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.32	-6.83	-0.4	6.44e-11	Cutaneous nevi;
KIRP	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg20673091	chr1:2541236	MMEL1	0.78	12.61	0.63	1.94e-28	Ulcerative colitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17831554	chr5:54684689	SKIV2L2	-0.39	-6.31	-0.37	1.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10173297	0.686	rs6738533	chr2:3711919	G/T	cg00933835	chr2:3705271	ALLC	0.39	5.24	0.32	3.54e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg08392591	chr16:89556376	ANKRD11	0.41	5.2	0.31	4.11e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-5.45	-0.33	1.2e-7	Personality dimensions;
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg21226059	chr5:178986404	RUFY1	0.51	8.14	0.46	1.97e-14	Lung cancer;
KIRP	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.67	0.34	3.94e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18378453	chr4:53617443	NA	0.48	6.92	0.4	4.01e-11	Parkinson's disease;
KIRP	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg03098644	chr7:100410630	EPHB4	0.52	5.31	0.32	2.4e-7	Other erythrocyte phenotypes;
KIRP	cis	rs2072732	0.861	rs12044848	chr1:2960790	C/T	cg11731671	chr1:2995604	PRDM16	-0.42	-5.23	-0.32	3.59e-7	Plateletcrit;
KIRP	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.58e-7	Body mass index;
KIRP	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg10304824	chr2:177028804	HOXD3	0.26	5.24	0.32	3.47e-7	IgG glycosylation;
KIRP	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.72	8.92	0.49	1.1e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg23594656	chr7:65796392	TPST1	0.39	5.9	0.35	1.2e-8	Aortic root size;
KIRP	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.63	9.11	0.5	3.06e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg07653901	chr22:50250238	ZBED4	-0.63	-6.91	-0.4	4.15e-11	Schizophrenia;
KIRP	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.69	-7.5	-0.43	1.16e-12	Gut microbiome composition (summer);
KIRP	cis	rs7429990	0.870	rs13089844	chr3:48140231	G/A	cg11946769	chr3:48343235	NME6	-0.43	-5.16	-0.31	4.97e-7	Educational attainment (years of education);
KIRP	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg13512537	chr8:22265999	SLC39A14	-0.38	-4.84	-0.3	2.26e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4006360	0.601	rs349785	chr17:39254557	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.57	-8.64	-0.48	7.18e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs72772090	0.614	rs10447215	chr5:96056373	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.61	-5.15	-0.31	5.27e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.63	8.61	0.48	9.15e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.38	5.3	0.32	2.6e-7	Aortic root size;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-6.04	-0.36	5.6e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9815354	0.857	rs9852020	chr3:41830206	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9400467	0.537	rs73530977	chr6:111504819	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.17	0.31	4.91e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg03188948	chr7:1209495	NA	0.76	5.2	0.31	4.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.99	13.45	0.65	2.87e-31	Menopause (age at onset);
KIRP	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg23682824	chr7:23144976	KLHL7	-0.46	-5.59	-0.34	6.13e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15676371	chr5:176518013	FGFR4	0.53	6.57	0.39	3.04e-10	Interleukin-4 levels;
KIRP	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.74	-9.4	-0.51	3.95e-18	Facial morphology (factor 19);
KIRP	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.77	9.03	0.5	5.01e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg14517863	chr17:44321492	NA	0.44	5.12	0.31	6.31e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.94	0.54	8.77e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20307385	chr11:47447363	PSMC3	0.49	5.16	0.31	5.03e-7	Subjective well-being;
KIRP	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg17507749	chr15:85114479	UBE2QP1	0.81	8.44	0.47	2.75e-15	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Bipolar disorder;
KIRP	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg09695851	chr17:3907499	NA	0.83	15.23	0.7	2.42e-37	Type 2 diabetes;
KIRP	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg18154014	chr19:37997991	ZNF793	-0.63	-6.84	-0.4	6.4e-11	Coronary artery calcification;
KIRP	cis	rs1298908	0.897	rs2573326	chr10:82013146	T/C	cg09936400	chr10:82049201	MAT1A	0.29	4.9	0.3	1.73e-6	Diabetic kidney disease;
KIRP	cis	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg19171272	chr22:38449367	NA	-0.66	-9.81	-0.53	2.16e-19	Glioblastoma;Glioma;
KIRP	trans	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.37	0.47	4.51e-15	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.55	-5.45	-0.33	1.19e-7	Pubertal anthropometrics;
KIRP	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg06289844	chr6:126071538	HEY2	0.41	6.05	0.36	5.39e-9	Brugada syndrome;
KIRP	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-1.05	-9.58	-0.52	1.11e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg24009623	chr19:33667908	NA	0.48	6.25	0.37	1.84e-9	Bone properties (heel);
KIRP	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.7	-0.6	2e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07777352	chr7:75958866	YWHAG	0.43	6.06	0.36	5e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.44	0.62	7.1e-28	Diabetic retinopathy;
KIRP	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg20487152	chr13:99095054	FARP1	-0.41	-5.37	-0.32	1.79e-7	Neuroticism;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.84	-12.85	-0.63	3.02e-29	Height;
KIRP	cis	rs6738485	0.695	rs11889931	chr2:106775375	C/T	cg16099169	chr2:106886729	NA	-0.44	-6.38	-0.38	8.82e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs2594989	0.943	rs2454500	chr3:11500103	C/T	cg01796438	chr3:11312864	ATG7	-0.67	-8.19	-0.46	1.45e-14	Circulating chemerin levels;
KIRP	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.45	1.59e-13	Morning vs. evening chronotype;
KIRP	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg15557168	chr22:42548783	NA	-0.37	-5.1	-0.31	6.77e-7	Cognitive function;
KIRP	cis	rs2120243	0.641	rs7639254	chr3:157141041	A/G	cg24825693	chr3:157122686	VEPH1	-0.51	-8.1	-0.46	2.65e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.01	-0.3	1.03e-6	Pulmonary function;
KIRP	cis	rs2970992	0.728	rs3112256	chr2:101321822	A/G	cg01042948	chr2:101319752	NA	-0.39	-6.06	-0.36	5.02e-9	Educational attainment;
KIRP	cis	rs6700559	0.740	rs10919997	chr1:200646650	C/T	cg07804481	chr1:200639085	DDX59	0.5	6.6	0.39	2.52e-10	Coronary artery disease;
KIRP	cis	rs71277158	0.688	rs73879167	chr3:169776194	T/G	cg04067573	chr3:169899625	PHC3	0.53	4.88	0.3	1.94e-6	Prostate cancer;
KIRP	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg03834567	chr2:218808745	TNS1	0.46	5.62	0.34	5.08e-8	Ulcerative colitis;
KIRP	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.25	0.62	2.92e-27	Blood protein levels;
KIRP	cis	rs13065560	0.594	rs7633981	chr3:38889901	A/C	cg01426195	chr3:39028469	NA	-0.45	-7.21	-0.42	6.67e-12	Interleukin-18 levels;
KIRP	cis	rs12444979	0.507	rs8062735	chr16:19839538	C/T	cg03144643	chr16:19078864	COQ7	-0.43	-4.94	-0.3	1.47e-6	Body mass index;
KIRP	cis	rs714031	0.934	rs2235341	chr22:40068679	T/G	cg21377881	chr22:40064566	CACNA1I	-0.66	-10.2	-0.55	1.36e-20	Schizophrenia;
KIRP	cis	rs397969	0.646	rs1638527	chr17:19845393	A/G	cg13482628	chr17:19912719	NA	-0.48	-5.42	-0.33	1.39e-7	Platelet count;
KIRP	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg06634786	chr22:41940651	POLR3H	-0.45	-4.87	-0.3	2.03e-6	Neuroticism;
KIRP	cis	rs6681460	0.565	rs6689755	chr1:67113050	G/A	cg02459107	chr1:67143332	SGIP1	0.36	5.08	0.31	7.5e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs73198271	0.960	rs73198286	chr8:8612022	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-6.15	-0.36	3.16e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7551222	0.614	rs7519417	chr1:204449952	T/C	cg20240347	chr1:204465584	NA	-0.41	-7.42	-0.43	1.85e-12	Schizophrenia;
KIRP	cis	rs7508	0.511	rs208026	chr8:17878155	A/G	cg01800426	chr8:17659068	MTUS1	-0.55	-5.55	-0.33	7.32e-8	Atrial fibrillation;
KIRP	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.52	5.35	0.32	2.05e-7	Initial pursuit acceleration;
KIRP	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.23	0.46	1.12e-14	Body mass index;
KIRP	cis	rs77861329	0.748	rs4687810	chr3:52169095	T/C	cg08692210	chr3:52188851	WDR51A	0.61	6.16	0.37	3.02e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.72	10.08	0.54	3.18e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg05784532	chr1:230284198	GALNT2	0.47	7.37	0.43	2.63e-12	Coronary artery disease;
KIRP	cis	rs10129255	0.517	rs11625572	chr14:107112442	A/G	cg23076370	chr14:107095027	NA	-0.44	-5.11	-0.31	6.41e-7	Kawasaki disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03421212	chr3:131221699	MRPL3	0.57	7.46	0.43	1.45e-12	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03312251	chr10:135086871	ADAM8	0.51	6.33	0.37	1.13e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.65	7.94	0.45	7.13e-14	Schizophrenia;
KIRP	cis	rs2708977	0.665	rs772173	chr2:97000396	C/T	cg01950434	chr2:97203154	ARID5A	0.43	5.21	0.32	3.91e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9434723	0.844	rs2268174	chr1:9300668	C/A	cg04199779	chr1:9294473	H6PD	0.44	5.34	0.32	2.15e-7	Height;
KIRP	cis	rs9473924	0.580	rs67092917	chr6:50815333	G/T	cg14470998	chr6:50812995	TFAP2B	0.99	8.81	0.49	2.24e-16	Body mass index;
KIRP	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg19913688	chr11:428466	ANO9	-0.72	-5.46	-0.33	1.16e-7	Body mass index;
KIRP	cis	rs10203711	0.966	rs4605316	chr2:239595344	C/T	cg14580085	chr2:239553406	NA	0.39	5.16	0.31	5.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg09184832	chr6:79620586	NA	-0.39	-4.98	-0.3	1.21e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	7.02	0.41	2.17e-11	Menarche (age at onset);
KIRP	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.99	-12.73	-0.63	7.68e-29	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	0.83	5.85	0.35	1.53e-8	IgG glycosylation;
KIRP	cis	rs7582720	0.945	rs72932711	chr2:203639846	T/A	cg08076091	chr2:203926405	NBEAL1	0.83	8.27	0.47	8.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	0.94	11.02	0.57	3.32e-23	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2882667	0.861	rs11242445	chr5:138417054	G/T	cg04439458	chr5:138467593	SIL1	-0.42	-7.15	-0.41	9.66e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14417372	chr11:119455230	NA	0.46	6.35	0.38	1.02e-9	Parkinson's disease;
KIRP	cis	rs11638352	1.000	rs2623017	chr15:44403285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-5.1	-0.31	6.83e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg27087555	chr16:88793112	FAM38A	-1.39	-13.91	-0.66	7.49e-33	Plateletcrit;
KIRP	cis	rs9815354	0.812	rs73077358	chr3:41850005	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6815814	0.950	rs9306967	chr4:38807911	G/C	cg06935464	chr4:38784597	TLR10	0.57	6.85	0.4	5.8200000000000003e-11	Breast cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04077077	chr17:47841656	FAM117A	0.6	6.99	0.41	2.54e-11	Smoking initiation;
KIRP	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.48	-4.91	-0.3	1.65e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.49	5.14	0.31	5.57e-7	Alzheimer's disease;
KIRP	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.08e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.97	11.91	0.6	4.09e-26	Alzheimer's disease;
KIRP	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.01	-7.57	-0.43	7.63e-13	Mitochondrial DNA levels;
KIRP	cis	rs829661	0.947	rs2167969	chr2:30773746	A/T	cg10949345	chr2:30726833	LCLAT1	0.73	10.58	0.56	8.21e-22	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17120908	chr11:65337727	SSSCA1	0.56	7.09	0.41	1.43e-11	Parkinson's disease;
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.25	-0.32	3.23e-7	Life satisfaction;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11212172	chr10:53459438	PRKG1;CSTF2T	0.73	6.52	0.38	3.92e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg11693508	chr17:37793320	STARD3	-0.64	-7.12	-0.41	1.15e-11	Bipolar disorder;
KIRP	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.85	-10.54	-0.56	1.12e-21	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg21698718	chr17:80085957	CCDC57	-0.33	-4.86	-0.3	2.13e-6	Life satisfaction;
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.76	12.09	0.61	1.02e-26	Plasma homocysteine levels (post-methionine load test);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13758646	chr9:101469711	GABBR2	0.53	6.8	0.4	7.81e-11	Parkinson's disease;
KIRP	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.92	-14.06	-0.67	2.41e-33	Height;
KIRP	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.15e-20	Dupuytren's disease;
KIRP	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.59	-9.25	-0.51	1.12e-17	Longevity;
KIRP	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg00310523	chr12:86230176	RASSF9	0.49	7.78	0.44	1.94e-13	Major depressive disorder;
KIRP	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg16141378	chr3:129829833	LOC729375	0.53	6.54	0.38	3.54e-10	Joint mobility (Beighton score);
KIRP	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg16179182	chr5:140090404	VTRNA1-1	0.5	6.81	0.4	7.36e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg03433033	chr1:76189801	ACADM	0.42	6.21	0.37	2.22e-9	Daytime sleep phenotypes;
KIRP	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg08603382	chr10:743973	NA	0.46	6.75	0.4	1.07e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.49	5.7	0.34	3.41e-8	Platelet distribution width;
KIRP	cis	rs838147	0.844	rs11672046	chr19:49247601	C/T	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.27e-7	Dietary macronutrient intake;
KIRP	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.63	-0.39	2.07e-10	Blood pressure;
KIRP	cis	rs17023223	0.537	rs2765542	chr1:119560326	T/A	cg05756136	chr1:119680316	WARS2	-0.54	-7.28	-0.42	4.42e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.52	-6.6	-0.39	2.44e-10	Initial pursuit acceleration in psychotic disorders;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00177013	chr20:62339100	ARFRP1;ZGPAT	0.57	6.66	0.39	1.73e-10	Smoking initiation;
KIRP	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.88	14.16	0.67	1.12e-33	Heart rate;
KIRP	cis	rs12210905	0.920	rs72839451	chr6:27265437	G/C	cg11502198	chr6:26597334	ABT1	-0.8	-4.94	-0.3	1.43e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.91	-14.79	-0.69	7.94e-36	Height;
KIRP	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06481639	chr22:41940642	POLR3H	0.66	6.59	0.39	2.69e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2072732	0.861	rs55863899	chr1:2955245	C/G	cg11731671	chr1:2995604	PRDM16	-0.59	-6.77	-0.4	9.65e-11	Plateletcrit;
KIRP	trans	rs11165623	0.792	rs6701031	chr1:96975515	C/T	cg10631902	chr5:14652156	NA	-0.62	-9.4	-0.51	3.94e-18	Hip circumference;Waist circumference;
KIRP	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg15655495	chr12:38532458	NA	0.25	4.84	0.3	2.26e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	8.1e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08439880	chr3:133502540	NA	-0.51	-6.23	-0.37	1.99e-9	Iron status biomarkers;
KIRP	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.24e-8	Lung cancer;
KIRP	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg01631408	chr1:248437212	OR2T33	-0.71	-9.59	-0.52	1.04e-18	Common traits (Other);
KIRP	cis	rs3789045	0.774	rs898388	chr1:204500257	C/T	cg18185008	chr1:204589407	LRRN2	-0.62	-6.73	-0.39	1.18e-10	Educational attainment (college completion);
KIRP	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg20636351	chr8:55087400	NA	-0.53	-6.6	-0.39	2.54e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.13	0.31	5.85e-7	Colorectal cancer;
KIRP	trans	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg01620082	chr3:125678407	NA	-0.83	-6.15	-0.37	3.19e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.35	0.51	5.44e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg23920097	chr1:209922102	NA	-0.45	-6.24	-0.37	1.87e-9	Red blood cell count;
KIRP	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.6	-9.1	-0.5	3.13e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27297192	chr10:134578999	INPP5A	0.61	7.89	0.45	9.76e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.71	8.03	0.46	4e-14	Sudden cardiac arrest;
KIRP	cis	rs76793172	1.000	rs10406609	chr19:46345208	T/G	cg00442267	chr19:46317840	RSPH6A	-0.7	-5.98	-0.36	7.61e-9	Eosinophil counts;
KIRP	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg01620082	chr3:125678407	NA	-0.88	-6.23	-0.37	2e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7289126	0.500	rs9610927	chr22:38653689	C/T	cg25457927	chr22:38595422	NA	0.29	5.52	0.33	8.48e-8	Mammographic density (dense area);Percent mammographic density;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01132056	chr4:178170788	NA	0.38	6.34	0.37	1.1e-9	C-reactive protein;
KIRP	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.49	-6.27	-0.37	1.6e-9	Corneal astigmatism;
KIRP	cis	rs7605378	1.000	rs2689766	chr2:200697539	A/T	cg23649088	chr2:200775458	C2orf69	0.61	7.28	0.42	4.41e-12	Osteoporosis;
KIRP	cis	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg21546286	chr11:48923668	NA	-0.47	-6.15	-0.36	3.17e-9	HDL cholesterol;
KIRP	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg06064525	chr11:970664	AP2A2	-0.34	-6.82	-0.4	6.9e-11	Alzheimer's disease (late onset);
KIRP	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.27	-0.55	8.11e-21	Hemoglobin concentration;
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	0.73	6.54	0.38	3.57e-10	Skin colour saturation;
KIRP	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg07689907	chr11:61582574	FADS1	0.49	6.12	0.36	3.57e-9	Trans fatty acid levels;
KIRP	cis	rs7221595	0.825	rs8074860	chr17:3986657	C/G	cg21851534	chr17:3907994	ZZEF1	0.53	5.16	0.31	5.21e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	0.96	10.41	0.55	2.96e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg02367723	chr1:46378857	MAST2	0.42	4.92	0.3	1.56e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.62	7.59	0.44	6.73e-13	Alcohol dependence;
KIRP	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.72	-11.04	-0.58	2.74e-23	Hepatocellular carcinoma;
KIRP	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg00982548	chr2:198649783	BOLL	-0.53	-5.37	-0.32	1.81e-7	Ulcerative colitis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13905264	chr9:132020949	NA	-0.48	-6.57	-0.39	3.06e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	15.55	0.7	1.87e-38	Chronic sinus infection;
KIRP	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.68	10.52	0.56	1.28e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg00225070	chr15:80189496	MTHFS	0.42	4.95	0.3	1.41e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.87	-0.73	5.9e-43	Height;
KIRP	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg13147721	chr7:65941812	NA	-0.99	-6.89	-0.4	4.57e-11	Diabetic kidney disease;
KIRP	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs7582720	0.945	rs72932709	chr2:203639501	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	9.63	0.52	8.09e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7215564	0.818	rs1872431	chr17:78635200	T/C	cg06153925	chr17:78755379	RPTOR	0.39	5.54	0.33	7.68e-8	Myopia (pathological);
KIRP	cis	rs6882046	0.513	rs651666	chr5:88048767	A/G	cg22951263	chr5:87985283	NA	-0.48	-6.79	-0.4	8.41e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24492508	chr12:19386397	PLEKHA5	-0.39	-6.08	-0.36	4.65e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6867032	1.000	rs4074914	chr5:2020274	C/T	cg26168224	chr5:2018326	NA	1.13	19.83	0.78	6.07e-53	Gut microbiome composition (winter);
KIRP	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg21918786	chr6:109611834	NA	0.34	4.98	0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs8133932	0.608	rs413246	chr21:47346066	G/A	cg11214348	chr21:47283868	PCBP3	-0.47	-5.32	-0.32	2.29e-7	Schizophrenia;
KIRP	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.99	-0.73	2.29e-43	Height;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg01765077	chr12:122356316	WDR66	0.63	8.42	0.47	3.18e-15	Mean corpuscular volume;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04132851	chr1:85155548	SSX2IP	-0.45	-6.08	-0.36	4.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4671458	0.626	rs12476015	chr2:63807694	A/G	cg17519650	chr2:63277830	OTX1	-0.49	-4.97	-0.3	1.25e-6	Subjective well-being;
KIRP	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg07511934	chr16:89386912	ANKRD11	0.42	5.16	0.31	5.09e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg15028436	chr7:37888078	TXNDC3	0.76	10.4	0.55	3.03e-21	Alzheimer's disease (late onset);
KIRP	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.7	9.59	0.52	1.01e-18	Mean corpuscular volume;
KIRP	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.62	6.99	0.41	2.54e-11	Aortic root size;
KIRP	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg07596299	chr11:71824057	C11orf51	-0.87	-5.44	-0.33	1.27e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7534824	0.625	rs6686202	chr1:101493078	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.16	0.42	9.39e-12	Refractive astigmatism;
KIRP	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.82	-13.89	-0.66	8.67e-33	Prostate cancer;
KIRP	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	5.05	0.31	8.65e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2548003	0.518	rs2554901	chr5:28733310	T/C	cg22863700	chr5:28928346	NA	0.51	5.46	0.33	1.16e-7	Hip geometry;
KIRP	cis	rs6901250	0.569	rs594940	chr6:117090358	C/T	cg12892004	chr6:117198278	RFX6	0.38	6.24	0.37	1.91e-9	C-reactive protein levels;
KIRP	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.6	6.53	0.38	3.74e-10	Alcohol dependence;
KIRP	cis	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg16898833	chr6:26189333	HIST1H4D	1.14	6.7	0.39	1.38e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs77861329	1.000	rs114209632	chr3:52188361	C/T	cg08692210	chr3:52188851	WDR51A	0.84	5.86	0.35	1.48e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs7623687	0.786	rs73082337	chr3:49009570	C/G	cg19401529	chr3:49056140	DALRD3	1.03	7.67	0.44	4.08e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg07395648	chr5:131743802	NA	0.59	6.67	0.39	1.72e-10	Lymphocyte counts;Fibrinogen;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg22713345	chr19:8070804	ELAVL1	0.5	6.38	0.38	8.56e-10	Educational attainment;
KIRP	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg08313168	chr12:7315531	NA	0.63	6.07	0.36	4.69e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08677398	chr8:58056175	NA	-0.61	-4.96	-0.3	1.33e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1975974	0.511	rs112710683	chr17:21741695	C/A	cg18423549	chr17:21743878	NA	-0.45	-4.89	-0.3	1.83e-6	Psoriasis;
KIRP	cis	rs2625529	0.730	rs8182011	chr15:72389948	C/T	cg16672083	chr15:72433130	SENP8	0.41	5.28	0.32	2.85e-7	Red blood cell count;
KIRP	cis	rs4654899	0.865	rs9426730	chr1:21452255	A/T	cg05370193	chr1:21551575	ECE1	0.4	5.41	0.33	1.48e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.53	7.99	0.45	5.36e-14	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs13102973	0.864	rs7435952	chr4:135900983	C/T	cg14419869	chr4:135874104	NA	0.48	7.52	0.43	1.02e-12	Subjective well-being;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg08719095	chr7:1135190	C7orf50	-0.42	-4.9	-0.3	1.78e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg02733842	chr7:1102375	C7orf50	0.47	4.97	0.3	1.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.3	-6.02	-0.36	6.21e-9	Schizophrenia;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15238008	chr12:9600875	DDX12	1.0	6.62	0.39	2.19e-10	P wave terminal force;
KIRP	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.41	5.13	0.31	5.83e-7	Aortic root size;
KIRP	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.39	5.98	0.36	7.84e-9	Body mass index;
KIRP	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24713499	chr18:29523063	KIAA1012	0.53	6.51	0.38	4.28e-10	Parkinson's disease;
KIRP	cis	rs1359582	0.836	rs10788607	chr10:90377114	C/A	cg15661332	chr10:90342814	RNLS	0.58	6.1	0.36	4.14e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.97	11.94	0.61	3.28e-26	Migraine;
KIRP	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.32e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg16691251	chr5:66510806	NA	-0.43	-5.83	-0.35	1.75e-8	Breast cancer;
KIRP	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg12181417	chr19:49337499	HSD17B14	-0.49	-5.44	-0.33	1.31e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.44	0.38	6.07e-10	Mean platelet volume;
KIRP	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg02527881	chr3:46936655	PTH1R	-0.41	-5.77	-0.35	2.32e-8	Colorectal cancer;
KIRP	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.49	-0.33	1.01e-7	Aortic root size;
KIRP	cis	rs2150410	0.764	rs2070867	chr21:40715132	C/T	cg11890956	chr21:40555474	PSMG1	0.66	4.85	0.3	2.15e-6	Temperament (bipolar disorder);
KIRP	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.91	-0.3	1.67e-6	Breast cancer;
KIRP	cis	rs9290877	0.667	rs62291298	chr3:188460544	A/G	cg17392043	chr3:188495102	LPP	-0.49	-6.34	-0.37	1.1e-9	IgE levels;
KIRP	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.65	7.8	0.45	1.71e-13	Metabolic traits;
KIRP	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.34	5.39	0.33	1.62e-7	Testicular germ cell tumor;
KIRP	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg14993813	chr1:46806288	NSUN4	-0.63	-7.0	-0.41	2.46e-11	Menopause (age at onset);
KIRP	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.91	-14.52	-0.68	6.43e-35	Morning vs. evening chronotype;
KIRP	cis	rs12476592	0.543	rs262470	chr2:63830559	C/T	cg17519650	chr2:63277830	OTX1	-0.46	-5.15	-0.31	5.47e-7	Childhood ear infection;
KIRP	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.74	9.34	0.51	5.8e-18	Corneal astigmatism;
KIRP	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.63	-5.75	-0.34	2.58e-8	Narcolepsy;
KIRP	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.04e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12496230	0.794	rs34113192	chr3:66863668	A/G	cg04995300	chr3:66848608	NA	0.44	6.65	0.39	1.93e-10	Type 2 diabetes;
KIRP	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg16586182	chr3:47516702	SCAP	0.69	9.39	0.51	4.21e-18	Colorectal cancer;
KIRP	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.8	10.99	0.57	4.09e-23	Breast cancer;
KIRP	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg12826209	chr6:26865740	GUSBL1	0.78	5.31	0.32	2.41e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7615316	0.779	rs7627694	chr3:142100478	T/C	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.35e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	5.79	0.35	2.15e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg20240347	chr1:204465584	NA	0.4	7.51	0.43	1.07e-12	Schizophrenia;
KIRP	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.58	-8.14	-0.46	1.92e-14	Diastolic blood pressure;
KIRP	cis	rs2742417	0.532	rs2673053	chr3:45732044	T/C	cg04037228	chr3:45636386	LIMD1	0.44	5.85	0.35	1.55e-8	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg07843065	chr1:150265600	MRPS21	0.44	6.22	0.37	2.14e-9	Migraine;
KIRP	trans	rs13170463	0.579	rs13185424	chr5:8051329	T/C	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg18404041	chr3:52824283	ITIH1	0.35	5.04	0.31	8.91e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.53	-9.4	-0.51	4.04e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg23594656	chr7:65796392	TPST1	-0.42	-5.96	-0.36	8.47e-9	Aortic root size;
KIRP	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.97	-15.58	-0.7	1.58e-38	Primary sclerosing cholangitis;
KIRP	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	1.09	19.31	0.78	3.45e-51	Schizophrenia;
KIRP	cis	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.43	-5.37	-0.32	1.86e-7	Leprosy;
KIRP	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.5	-6.2	-0.37	2.43e-9	Testicular germ cell tumor;
KIRP	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.34	0.47	5.51e-15	Asthma (sex interaction);
KIRP	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg01843034	chr6:37503916	NA	0.68	9.31	0.51	7.63e-18	Cognitive performance;
KIRP	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.53	7.32	0.42	3.42e-12	Menarche (age at onset);
KIRP	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.69	-9.11	-0.5	2.94e-17	Huntington's disease progression;
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.9	11.39	0.59	1.99e-24	Platelet distribution width;
KIRP	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.66	5.43	0.33	1.34e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg25287198	chr4:183728479	NA	0.55	4.94	0.3	1.43e-6	Pediatric autoimmune diseases;
KIRP	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.59	-7.74	-0.44	2.56e-13	Bladder cancer;
KIRP	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-14.24	-0.67	5.56e-34	Chronic sinus infection;
KIRP	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	5.96	0.36	8.57e-9	Putamen volume;
KIRP	cis	rs6450176	0.633	rs10054623	chr5:53343821	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.73	-9.01	-0.5	5.75e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs7999699	0.841	rs66867676	chr13:48307568	A/G	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs7566780	0.575	rs4560110	chr2:16702136	A/G	cg09580478	chr2:16689509	NA	0.44	5.07	0.31	7.82e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs7630877	0.962	rs9836757	chr3:179642221	C/T	cg18765712	chr3:179670323	PEX5L	0.46	5.71	0.34	3.22e-8	Type 2 diabetes;
KIRP	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.62	-8.43	-0.47	2.93e-15	Platelet count;
KIRP	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg00405596	chr8:11794950	NA	0.48	6.09	0.36	4.25e-9	Retinal vascular caliber;
KIRP	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.43	-5.24	-0.32	3.49e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6662572	0.774	rs9429188	chr1:46570879	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.77	0.35	2.41e-8	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.32	-0.37	1.24e-9	Aortic root size;
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.62	9.38	0.51	4.49e-18	Immature fraction of reticulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25572477	chr3:171757506	FNDC3B	0.51	6.56	0.39	3.24e-10	Parkinson's disease;
KIRP	cis	rs34929064	0.512	rs2157958	chr7:22706707	C/T	cg23521230	chr7:22704884	NA	0.41	5.47	0.33	1.08e-7	Major depression and alcohol dependence;
KIRP	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.79	0.57	1.78e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs6001982	0.510	rs55844816	chr22:40803112	C/T	cg07138101	chr22:40742427	ADSL	0.74	6.19	0.37	2.48e-9	Breast cancer;
KIRP	cis	rs6832769	1.000	rs2177129	chr4:56365414	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs68170813	0.617	rs7797791	chr7:107197222	T/C	cg02696742	chr7:106810147	HBP1	-0.8	-7.27	-0.42	4.82e-12	Coronary artery disease;
KIRP	cis	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-5.5	-0.33	9.46e-8	Height;
KIRP	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	8.68	0.48	5.41e-16	Personality dimensions;
KIRP	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg09264619	chr17:80180166	NA	-0.41	-5.99	-0.36	7.52e-9	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg09699651	chr6:150184138	LRP11	0.47	6.08	0.36	4.45e-9	Lung cancer;
KIRP	cis	rs35740288	0.770	rs35447727	chr15:86174399	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg02475777	chr4:1388615	CRIPAK	-0.54	-5.06	-0.31	8.28e-7	Recombination rate (females);
KIRP	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	1.03	11.32	0.59	3.36e-24	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.57	7.35	0.42	2.99e-12	Iron status biomarkers;
KIRP	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.79	-12.19	-0.61	4.8e-27	Asthma;
KIRP	cis	rs35110281	0.755	rs8127297	chr21:45063847	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.51	-0.43	1.07e-12	Mean corpuscular volume;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.83	-14.92	-0.69	2.79e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.59	-6.75	-0.4	1.07e-10	Vitiligo;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09844907	chr16:15489619	MPV17L	-0.44	-6.7	-0.39	1.44e-10	Myopia;
KIRP	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.11	0.46	2.36e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg21433313	chr16:3507492	NAT15	0.65	7.15	0.41	9.73e-12	Tuberculosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24596729	chr1:165345813	NA	0.5	7.49	0.43	1.25e-12	Parkinson's disease;
KIRP	cis	rs10203711	1.000	rs12692240	chr2:239558688	A/G	cg14580085	chr2:239553406	NA	0.39	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg08807101	chr21:30365312	RNF160	-0.58	-5.79	-0.35	2.11e-8	Cognitive test performance;
KIRP	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg06636001	chr8:8085503	FLJ10661	0.59	8.27	0.47	8.34e-15	Neuroticism;
KIRP	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg21643547	chr1:205240462	TMCC2	-0.54	-7.86	-0.45	1.23e-13	Red blood cell count;
KIRP	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.97e-44	Breast cancer;
KIRP	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg01879757	chr17:41196368	BRCA1	-0.78	-10.85	-0.57	1.18e-22	Menopause (age at onset);
KIRP	cis	rs9420	0.528	rs11607122	chr11:57389737	G/A	cg19752551	chr11:57585705	CTNND1	-0.6	-8.41	-0.47	3.42e-15	Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11480830	chr2:198175037	NA	-0.56	-6.17	-0.37	2.78e-9	Menopause (age at onset);
KIRP	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.51	-7.32	-0.42	3.46e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.26e-12	Prudent dietary pattern;
KIRP	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg10047753	chr17:41438598	NA	-0.9	-12.89	-0.64	2.12e-29	Menopause (age at onset);
KIRP	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	11.26	0.58	5.58e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg11204139	chr17:3907470	NA	0.81	15.0	0.69	1.48e-36	Type 2 diabetes;
KIRP	cis	rs2494663	0.610	rs10908691	chr1:154062342	C/T	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.98	-0.3	1.21e-6	Mean platelet volume;
KIRP	cis	rs2380205	0.935	rs7901964	chr10:5896901	C/T	cg27141509	chr10:5886111	NA	-0.38	-5.53	-0.33	8.01e-8	Breast cancer;
KIRP	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.6	6.2	0.37	2.33e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg23743428	chr13:21893420	NA	-0.38	-5.35	-0.32	2.04e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1978968	0.640	rs2083882	chr22:18395241	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	0.62	7.85	0.45	1.24e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs1776883	0.502	rs4713758	chr6:34145361	A/G	cg10661734	chr6:34122502	NA	-0.4	-4.91	-0.3	1.7e-6	Asthma;Asthma (childhood onset);
KIRP	cis	rs6542838	0.641	rs4499468	chr2:99475204	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-5.28	-0.32	2.84e-7	Fear of minor pain;
KIRP	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.55	6.68	0.39	1.61e-10	Menopause (age at onset);
KIRP	trans	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.5	-6.53	-0.38	3.82e-10	Mean corpuscular volume;
KIRP	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg07741184	chr6:167504864	NA	0.24	6.51	0.38	4.18e-10	Crohn's disease;
KIRP	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.56	-5.4	-0.33	1.59e-7	Narcolepsy;
KIRP	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg05370193	chr1:21551575	ECE1	-0.37	-5.04	-0.31	9.19e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7215564	0.908	rs35112467	chr17:78677562	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.39e-7	Myopia (pathological);
KIRP	cis	rs4805272	1.000	rs7246224	chr19:29323438	T/C	cg15000279	chr19:29285009	NA	-0.35	-4.98	-0.3	1.19e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs17095355	1.000	rs17126886	chr10:111695257	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.09	-0.36	4.42e-9	Biliary atresia;
KIRP	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.4e-21	Educational attainment;
KIRP	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.57	-6.46	-0.38	5.69e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.59	-12.45	-0.62	6.65e-28	Diabetic kidney disease;
KIRP	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg00800569	chr2:239229395	TRAF3IP1	0.41	4.89	0.3	1.82e-6	Multiple system atrophy;
KIRP	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg18833306	chr6:118973337	C6orf204	0.39	4.88	0.3	1.91e-6	Electrocardiographic conduction measures;
KIRP	cis	rs3857747	0.931	rs10256660	chr7:40364588	A/G	cg00420559	chr7:40367873	C7orf10	-0.6	-8.46	-0.47	2.37e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg13409248	chr3:40428643	ENTPD3	-0.36	-4.97	-0.3	1.26e-6	Renal cell carcinoma;
KIRP	cis	rs7923609	0.846	rs7073753	chr10:65062820	C/T	cg01631684	chr10:65280961	REEP3	-0.5	-5.73	-0.34	2.96e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs472402	0.540	rs3776431	chr5:6618756	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-4.97	-0.3	1.24e-6	Response to amphetamines;
KIRP	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.79	-0.35	2.16e-8	Pulmonary function;
KIRP	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.89	-0.4	4.75e-11	Blood metabolite levels;
KIRP	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg18850127	chr7:39170497	POU6F2	0.27	5.15	0.31	5.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2797160	0.904	rs1777197	chr6:126007401	G/A	cg05901451	chr6:126070800	HEY2	0.41	5.78	0.35	2.26e-8	Endometrial cancer;
KIRP	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-7.73	-0.44	2.67e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	1.09	17.81	0.75	3.82e-46	Cognitive function;
KIRP	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg02475777	chr4:1388615	CRIPAK	0.52	4.85	0.3	2.19e-6	Recombination rate (females);
KIRP	cis	rs6662572	1.000	rs7541935	chr1:46217493	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.4	0.33	1.59e-7	Blood protein levels;
KIRP	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.55	6.69	0.39	1.47e-10	Breast cancer;
KIRP	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.74	8.43	0.47	2.92e-15	High light scatter reticulocyte count;
KIRP	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.13	-9.68	-0.53	5.55e-19	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17856907	chr10:91353162	MIR107;PANK1	0.44	6.23	0.37	2e-9	Survival in pancreatic cancer;
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg06815112	chr8:27182871	PTK2B	0.51	6.57	0.39	2.97e-10	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07645888	chr2:62932961	EHBP1	0.45	6.55	0.39	3.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6684514	0.961	rs11264469	chr1:156276746	A/G	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.54e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2692947	0.794	rs2140938	chr2:96751395	T/C	cg23100626	chr2:96804247	ASTL	0.47	6.01	0.36	6.66e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.78	-13.46	-0.65	2.59e-31	Neuroticism;
KIRP	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.57	-7.47	-0.43	1.43e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg22974920	chr21:40686053	BRWD1	-0.43	-5.0	-0.3	1.08e-6	Cognitive function;
KIRP	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg24879335	chr3:133465180	TF	0.5	8.02	0.46	4.34e-14	Iron status biomarkers;
KIRP	cis	rs151997	0.629	rs152808	chr5:50207382	G/C	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg04166393	chr7:2884313	GNA12	0.47	6.09	0.36	4.41e-9	Height;
KIRP	cis	rs12936587	0.633	rs12952629	chr17:17513189	G/A	cg01246520	chr17:17644344	RAI1	-0.36	-5.34	-0.32	2.09e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg24315340	chr6:146058215	EPM2A	-0.4	-5.05	-0.31	8.77e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg24879335	chr3:133465180	TF	0.39	5.53	0.33	8.08e-8	Iron status biomarkers;
KIRP	cis	rs72634258	0.503	rs697674	chr1:7837878	C/G	cg26816564	chr1:7831052	VAMP3	0.81	8.07	0.46	3.08e-14	Inflammatory bowel disease;
KIRP	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg24579218	chr15:68104479	NA	-0.55	-7.81	-0.45	1.6e-13	Restless legs syndrome;
KIRP	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-8.58	-0.48	1.09e-15	Platelet count;
KIRP	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	7.74	0.44	2.54e-13	Schizophrenia;
KIRP	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg19731401	chr7:2775893	GNA12	0.65	6.23	0.37	1.99e-9	Childhood ear infection;
KIRP	cis	rs1456297	0.840	rs1471072	chr15:51968401	C/T	cg14296394	chr15:51910925	DMXL2	0.6	8.17	0.46	1.59e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.99	17.31	0.74	1.93e-44	Breast cancer;
KIRP	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg01877450	chr7:97915802	BRI3	-0.55	-7.18	-0.42	8.33e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8077577	0.895	rs11078412	chr17:18100618	C/T	cg18869244	chr17:18121946	NA	-0.46	-5.21	-0.32	4.04e-7	Obesity-related traits;
KIRP	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg16917193	chr12:54089295	NA	0.41	5.21	0.32	4.05e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg10254082	chr7:997346	NA	0.46	4.86	0.3	2.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.94	-0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg15038512	chr6:170123185	PHF10	0.46	5.15	0.31	5.44e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.12	-0.36	3.7e-9	Type 2 diabetes;
KIRP	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg13165212	chr22:42675999	NA	-0.36	-6.17	-0.37	2.84e-9	Cognitive function;
KIRP	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg17376030	chr22:41985996	PMM1	-0.82	-8.9	-0.49	1.25e-16	Vitiligo;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg07701084	chr6:150067640	NUP43	0.71	9.96	0.54	7.67e-20	Lung cancer;
KIRP	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg06634786	chr22:41940651	POLR3H	-0.43	-5.17	-0.31	4.81e-7	Neuroticism;
KIRP	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.93	15.19	0.7	3.37e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg08076091	chr2:203926405	NBEAL1	0.89	9.25	0.51	1.1e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2963155	0.518	rs72801054	chr5:142687742	T/C	cg17617527	chr5:142782415	NR3C1	0.74	6.72	0.39	1.24e-10	Breast cancer;
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.2	-0.31	4.22e-7	Obesity-related traits;
KIRP	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg03465714	chr1:152285911	FLG	0.49	5.29	0.32	2.69e-7	Atopic dermatitis;
KIRP	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.02	-0.64	7.65e-30	Alzheimer's disease;
KIRP	cis	rs2151522	0.788	rs9375462	chr6:127165942	C/A	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.36	-6.56	-0.39	3.2e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.7	-9.62	-0.52	8.37e-19	Longevity;
KIRP	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-8.07	-0.46	3.06e-14	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22517316	chr8:42128500	IKBKB	0.53	6.94	0.4	3.48e-11	Parkinson's disease;
KIRP	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg13660082	chr14:53194042	PSMC6	-0.72	-7.34	-0.42	3.12e-12	Alzheimer's disease (late onset);
KIRP	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.64	-5.81	-0.35	1.89e-8	Schizophrenia;
KIRP	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	1.11	11.2	0.58	8.73e-24	Blood protein levels;
KIRP	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg08508325	chr11:3079039	CARS	0.33	5.89	0.35	1.26e-8	Calcium levels;
KIRP	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg04727924	chr7:799746	HEATR2	0.61	5.74	0.34	2.77e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.66	7.82	0.45	1.51e-13	Type 2 diabetes;
KIRP	cis	rs42648	0.564	rs39283	chr7:89788806	C/A	cg25739043	chr7:89950458	NA	-0.39	-6.11	-0.36	3.91e-9	Homocysteine levels;
KIRP	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg17133734	chr15:86042851	AKAP13	-0.41	-5.1	-0.31	6.87e-7	Interstitial lung disease;
KIRP	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg02569458	chr12:86230093	RASSF9	0.34	4.89	0.3	1.83e-6	Major depressive disorder;
KIRP	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.19	0.42	7.71e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.61	-0.39	2.34e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.86	10.7	0.56	3.52e-22	Platelet distribution width;
KIRP	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.43	-5.33	-0.32	2.22e-7	Body mass index;
KIRP	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.64	7.66	0.44	4.38e-13	Height;
KIRP	trans	rs7999699	0.902	rs17337616	chr13:48300415	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24452069	chr19:4867631	PLIN3	0.54	7.56	0.43	7.77e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.83	-11.49	-0.59	9.46e-25	Alzheimer's disease (survival time);
KIRP	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.12	-0.46	2.32e-14	Colorectal cancer;
KIRP	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06481639	chr22:41940642	POLR3H	-0.67	-6.71	-0.39	1.34e-10	Vitiligo;
KIRP	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.92	-0.61	3.66e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg25019033	chr10:957182	NA	-0.62	-7.27	-0.42	4.76e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.61	-7.92	-0.45	8.27e-14	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs6120849	0.951	rs55670307	chr20:33720494	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	7.69	0.44	3.45e-13	Protein C levels;
KIRP	cis	rs1832871	1.000	rs827864	chr6:158711023	A/G	cg07215822	chr6:158701037	NA	-0.49	-6.28	-0.37	1.55e-9	Height;
KIRP	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg08999081	chr20:33150536	PIGU	0.45	5.73	0.34	2.92e-8	Height;
KIRP	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg14952266	chr13:112191215	NA	0.45	6.71	0.39	1.32e-10	Hepatitis;
KIRP	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	1.09	8.01	0.45	4.71e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs10875746	0.669	rs11168499	chr12:48662670	A/G	cg20731937	chr12:48336164	NA	0.48	5.91	0.35	1.15e-8	Longevity (90 years and older);
KIRP	cis	rs72781680	0.611	rs72783605	chr2:24287864	A/G	cg20701182	chr2:24300061	SF3B14	1.0	11.0	0.57	3.72e-23	Lymphocyte counts;
KIRP	cis	rs7224685	0.569	rs35977026	chr17:4036528	G/A	cg05562828	chr17:3906858	NA	0.52	5.37	0.32	1.83e-7	Type 2 diabetes;
KIRP	cis	rs738322	0.868	rs8139952	chr22:38606989	C/A	cg25457927	chr22:38595422	NA	0.41	9.16	0.5	2.14e-17	Cutaneous nevi;
KIRP	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.7	9.35	0.51	5.53e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.67	-9.23	-0.51	1.32e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg03959625	chr15:84868606	LOC388152	0.66	8.03	0.46	3.94e-14	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.66	8.08	0.46	2.97e-14	Vitiligo;
KIRP	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs7084402	0.967	rs2170779	chr10:60277249	G/A	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg09695851	chr17:3907499	NA	0.54	5.14	0.31	5.72e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.66	8.06	0.46	3.31e-14	Aortic root size;
KIRP	cis	rs4902647	0.678	rs11626883	chr14:69279460	G/C	cg03189333	chr14:69283534	NA	0.4	5.05	0.31	8.42e-7	Multiple sclerosis;
KIRP	trans	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg06521331	chr12:34319734	NA	-0.63	-7.42	-0.43	1.92e-12	Bladder cancer;
KIRP	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.48	-0.33	1.07e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg04733989	chr22:42467013	NAGA	0.5	5.93	0.35	1.02e-8	Cognitive function;
KIRP	cis	rs888405	1.000	rs888407	chr3:64212532	A/G	cg02147797	chr3:64211204	PRICKLE2	-0.31	-5.38	-0.32	1.77e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
KIRP	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg10144569	chr3:42726640	KBTBD5	-0.46	-5.01	-0.3	1.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg16141378	chr3:129829833	LOC729375	0.6	7.97	0.45	5.78e-14	Neuroticism;
KIRP	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg15691649	chr6:25882328	NA	0.56	6.12	0.36	3.59e-9	Blood metabolite levels;
KIRP	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.6	-6.82	-0.4	7.11e-11	Bipolar disorder;
KIRP	cis	rs78545713	0.502	rs3823157	chr6:26272039	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.71	-6.7	-0.39	1.38e-10	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.6	-7.55	-0.43	8.38e-13	Arsenic metabolism;
KIRP	cis	rs16973500	0.808	rs112121746	chr16:71874983	G/A	cg09427745	chr16:71932006	KIAA0174	-0.58	-4.95	-0.3	1.35e-6	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs12249377	0.519	rs11186320	chr10:92576448	C/T	cg14313238	chr10:92632228	RPP30	-0.49	-6.19	-0.37	2.49e-9	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs9652601	0.779	rs9929994	chr16:11178245	A/G	cg04616529	chr16:11181986	CLEC16A	0.38	5.11	0.31	6.32e-7	Systemic lupus erythematosus;
KIRP	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg00074818	chr8:8560427	CLDN23	0.42	6.28	0.37	1.5e-9	Obesity-related traits;
KIRP	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg15605315	chr1:45957053	TESK2	-0.49	-6.02	-0.36	6.44e-9	High light scatter reticulocyte count;
KIRP	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg01620082	chr3:125678407	NA	-1.01	-6.67	-0.39	1.66e-10	Urinary tract infection frequency;
KIRP	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.82	0.49	2.21e-16	Bladder cancer;
KIRP	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.58	0.39	2.81e-10	IgG glycosylation;
KIRP	cis	rs7615316	0.751	rs11925693	chr3:142153453	A/G	cg20824294	chr3:142316082	PLS1	0.24	5.38	0.32	1.72e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-6.85	-0.4	5.97e-11	Hip circumference adjusted for BMI;
KIRP	trans	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.72	0.39	1.27e-10	Mean corpuscular volume;
KIRP	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.86	10.45	0.55	2.09e-21	Neutrophil percentage of white cells;
KIRP	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg05802129	chr4:122689817	NA	-0.58	-7.46	-0.43	1.51e-12	Type 2 diabetes;
KIRP	cis	rs7638909	0.512	rs11720166	chr3:38599812	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.44	-5.49	-0.33	9.85e-8	Electrocardiographic conduction measures;
KIRP	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.35	-0.32	2.02e-7	Height;
KIRP	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg22705602	chr4:152727874	NA	0.55	9.69	0.53	4.97e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	0.94	9.63	0.52	8.01e-19	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15042747	chr11:12399060	PARVA	0.56	7.49	0.43	1.21e-12	Smoking initiation;
KIRP	cis	rs4074493	0.963	rs6541251	chr1:231173596	T/C	cg22172038	chr1:231176991	FAM89A	0.28	4.87	0.3	1.96e-6	Carotid plaque burden (smoking interaction);
KIRP	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08822215	chr16:89438651	ANKRD11	-0.45	-6.05	-0.36	5.45e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.65	8.32	0.47	6.09e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20135002	chr11:47629003	NA	-0.45	-5.09	-0.31	7.27e-7	Subjective well-being;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.42	4.91	0.3	1.64e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.65	8.08	0.46	2.97e-14	Breast cancer;
KIRP	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg25486957	chr4:152246857	NA	-0.45	-4.99	-0.3	1.13e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.74	6.6	0.39	2.53e-10	Obesity-related traits;
KIRP	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	14.58	0.68	3.99e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.68	-0.34	3.72e-8	Electroencephalogram traits;
KIRP	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg05343316	chr1:45956843	TESK2	0.73	8.21	0.46	1.29e-14	Platelet count;
KIRP	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-0.76	-9.23	-0.51	1.28e-17	Gut microbiome composition (summer);
KIRP	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	9.31	0.51	7.34e-18	Total body bone mineral density;
KIRP	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.03	-0.36	6.05e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.33	5.03	0.31	9.44e-7	P wave duration;
KIRP	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg10047753	chr17:41438598	NA	1.12	17.92	0.75	1.57e-46	Menopause (age at onset);
KIRP	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg23791538	chr6:167370224	RNASET2	-0.47	-5.71	-0.34	3.2e-8	Crohn's disease;
KIRP	cis	rs4908768	0.657	rs11121229	chr1:8831283	C/T	cg25722041	chr1:8623473	RERE	-0.59	-6.98	-0.41	2.76e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6681460	0.966	rs10789214	chr1:67146817	C/T	cg02459107	chr1:67143332	SGIP1	0.53	7.47	0.43	1.43e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21545522	chr1:205238299	TMCC2	0.5	6.57	0.39	2.91e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7221595	0.825	rs2290437	chr17:3923115	G/A	cg21851534	chr17:3907994	ZZEF1	0.61	6.5	0.38	4.35e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18791136	chr2:201237307	SPATS2L	0.47	6.81	0.4	7.34e-11	Survival in pancreatic cancer;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	0.64	5.84	0.35	1.69e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.46	-6.71	-0.39	1.29e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs883565	0.569	rs1274969	chr3:39169712	T/C	cg01426195	chr3:39028469	NA	0.5	8.01	0.45	4.48e-14	Handedness;
KIRP	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	11.14	0.58	1.33e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.64	8.66	0.48	6.19e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs4865169	1.000	rs4865169	chr4:57879792	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-5.65	-0.34	4.33e-8	Breast cancer;
KIRP	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.47	0.48	2.25e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	1.06	19.85	0.78	5.41e-53	Height;
KIRP	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11987759	chr7:65425863	GUSB	0.48	6.22	0.37	2.12e-9	Aortic root size;
KIRP	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg01294253	chr9:136912663	BRD3	0.43	5.53	0.33	8.31e-8	Platelet distribution width;
KIRP	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.86	12.94	0.64	1.51e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22110998	chr11:121316813	NA	-0.41	-6.06	-0.36	5e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg16797656	chr11:68205561	LRP5	0.37	4.95	0.3	1.37e-6	Total body bone mineral density;
KIRP	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.64	-7.97	-0.45	5.83e-14	Metabolite levels;
KIRP	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.75	0.4	1.06e-10	Height;
KIRP	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.56	8.98	0.5	7e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.52	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.23	0.37	1.98e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg18190219	chr22:46762943	CELSR1	-0.7	-5.95	-0.35	9.02e-9	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs11989744	0.500	rs7826517	chr8:23568841	G/A	cg03492747	chr16:86543808	FOXF1	-0.54	-7.07	-0.41	1.61e-11	Waist-hip ratio;
KIRP	cis	rs7404928	0.609	rs56213545	chr16:23936910	G/A	cg21745164	chr16:23765304	CHP2	-0.63	-6.67	-0.39	1.68e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs514024	0.729	rs4836575	chr9:130446493	C/T	cg13643465	chr9:130375613	STXBP1	-0.45	-5.74	-0.34	2.8e-8	Eating disorders (purging via substances);
KIRP	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg19445457	chr11:5799446	OR52N5	-0.47	-5.61	-0.34	5.3e-8	DNA methylation (variation);
KIRP	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.69	-6.67	-0.39	1.71e-10	Migraine;Coronary artery disease;
KIRP	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-8.42	-0.47	3.2e-15	Chronic sinus infection;
KIRP	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.95	11.05	0.58	2.64e-23	Corneal astigmatism;
KIRP	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	6.56	0.39	3.15e-10	Schizophrenia;
KIRP	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	1.04	18.14	0.76	3.02e-47	Heart rate;
KIRP	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.75	-7.6	-0.44	6.22e-13	Gut microbiome composition (summer);
KIRP	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.43	0.38	6.59e-10	Electroencephalogram traits;
KIRP	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg17376030	chr22:41985996	PMM1	-0.82	-8.9	-0.49	1.25e-16	Vitiligo;
KIRP	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.56	-7.24	-0.42	5.79e-12	Eye color traits;
KIRP	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg15848620	chr12:58087721	OS9	0.45	5.16	0.31	5.21e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs4143844	0.867	rs11629851	chr15:62155087	T/C	cg04814990	chr13:111957387	ARHGEF7	0.96	6.22	0.37	2.08e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg07116693	chr15:90310901	NA	-0.23	-4.99	-0.3	1.14e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.71	10.4	0.55	3.06e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg02574844	chr11:5959923	NA	-0.54	-5.65	-0.34	4.32e-8	DNA methylation (variation);
KIRP	cis	rs6102059	0.719	rs62211685	chr20:39230821	G/C	cg06665391	chr20:39312290	NA	0.41	5.33	0.32	2.21e-7	LDL cholesterol;
KIRP	cis	rs62355272	0.580	rs1345827	chr5:35904889	A/C	cg13894535	chr5:35919491	CAPSL	0.37	4.96	0.3	1.32e-6	Lymphocyte counts;
KIRP	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.56	6.21	0.37	2.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs3768617	0.745	rs4546885	chr1:183025555	C/G	cg12689670	chr1:183009347	LAMC1	0.5	6.77	0.4	9.65e-11	Fuchs's corneal dystrophy;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg16725865	chr1:92546135	BTBD8	-0.48	-6.03	-0.36	5.85e-9	Neuroticism;
KIRP	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.42	0.7	5.26e-38	Platelet count;
KIRP	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	1.13	10.74	0.56	2.64e-22	Opioid sensitivity;
KIRP	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg26116260	chr4:7069785	GRPEL1	-0.89	-4.88	-0.3	1.91e-6	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg04132472	chr17:19861366	AKAP10	0.64	9.47	0.52	2.48e-18	Schizophrenia;
KIRP	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.09	0.46	2.7e-14	Body mass index;
KIRP	cis	rs4356932	0.967	rs4318674	chr4:76934422	C/G	cg00809888	chr4:76862425	NAAA	0.44	6.17	0.37	2.79e-9	Blood protein levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09038717	chr11:68675878	IGHMBP2	0.47	6.59	0.39	2.7e-10	Interleukin-4 levels;
KIRP	cis	rs71597109	0.639	rs66638185	chr4:102729417	T/C	cg14855874	chr4:102712397	BANK1	0.42	5.36	0.32	1.92e-7	Chronic lymphocytic leukemia;
KIRP	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg16141378	chr3:129829833	LOC729375	0.59	7.4	0.43	2.11e-12	Triglycerides;
KIRP	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	cg04338863	chr8:33670619	NA	0.5	6.62	0.39	2.3e-10	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23838308	chr17:57785056	PTRH2;TMEM49	-0.61	-7.19	-0.42	7.8e-12	Interleukin-4 levels;
KIRP	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.5e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4740619	0.741	rs10756728	chr9:15973288	G/A	cg14451791	chr9:16040625	NA	-0.39	-4.95	-0.3	1.38e-6	Body mass index;
KIRP	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.49	5.8	0.35	2e-8	Huntington's disease progression;
KIRP	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.69	8.76	0.49	3.16e-16	Resting heart rate;
KIRP	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.87	0.49	1.56e-16	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs7084921	0.608	rs1853700	chr10:101862694	T/C	cg13808641	chr9:96006533	WNK2	-0.4	-6.2	-0.37	2.41e-9	Bone mineral density;
KIRP	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	1.21	13.08	0.64	5.04e-30	Corneal structure;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03952736	chr11:3803470	NUP98	0.41	6.43	0.38	6.46e-10	C-reactive protein;
KIRP	cis	rs2997447	0.792	rs61775432	chr1:26416376	A/G	cg19633962	chr1:26362018	EXTL1	-0.68	-5.76	-0.34	2.56e-8	QRS complex (12-leadsum);
KIRP	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg18016565	chr1:150552671	MCL1	0.39	5.47	0.33	1.11e-7	Melanoma;
KIRP	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg03959625	chr15:84868606	LOC388152	0.59	6.6	0.39	2.5e-10	Schizophrenia;
KIRP	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.66	-7.88	-0.45	1.05e-13	Testicular germ cell tumor;
KIRP	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.77	-0.77	2.27e-49	Schizophrenia;
KIRP	cis	rs2275565	0.872	rs10925257	chr1:237046160	A/G	cg17297354	chr1:237056641	MTR	-0.41	-5.36	-0.32	1.92e-7	Homocysteine levels;
KIRP	cis	rs7808935	0.914	rs757136	chr7:27988939	C/T	cg22168087	chr7:27702803	HIBADH	-0.73	-7.39	-0.43	2.29e-12	Prostate cancer;
KIRP	cis	rs7712401	0.562	rs30046	chr5:122271233	G/C	cg19412675	chr5:122181750	SNX24	0.48	5.23	0.32	3.58e-7	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.17	0.37	2.84e-9	Lung cancer;
KIRP	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg22676075	chr6:135203613	NA	0.47	6.82	0.4	7.04e-11	Red blood cell count;
KIRP	cis	rs10073892	0.660	rs35369487	chr5:101959169	C/A	cg19774478	chr5:101632501	SLCO4C1	0.54	5.31	0.32	2.39e-7	Cognitive decline (age-related);
KIRP	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.45	-0.33	1.23e-7	Schizophrenia;
KIRP	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg12560992	chr17:57184187	TRIM37	0.59	5.24	0.32	3.46e-7	Cognitive test performance;
KIRP	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg14324370	chr2:177042789	NA	-0.71	-8.81	-0.49	2.31e-16	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.35	-5.19	-0.31	4.34e-7	Monocyte count;
KIRP	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg09175582	chr1:161736000	ATF6	0.73	5.9	0.35	1.18e-8	IgG glycosylation;
KIRP	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.23	-0.32	3.6e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg08461772	chr7:95026248	PON3	0.39	5.51	0.33	9.02e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs1106684	1.000	rs1477227	chr7:131455391	T/G	cg13607082	chr12:122652224	LRRC43	-0.6	-6.12	-0.36	3.64e-9	Body mass index;
KIRP	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.53	6.62	0.39	2.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg08975724	chr8:8085496	FLJ10661	-0.76	-10.83	-0.57	1.3e-22	Neuroticism;
KIRP	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.58	7.88	0.45	1.03e-13	Height;
KIRP	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg07570687	chr10:102243282	WNT8B	-0.55	-7.42	-0.43	1.87e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg17691542	chr6:26056736	HIST1H1C	0.47	6.12	0.36	3.6e-9	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.65	0.39	1.89e-10	Breast cancer;
KIRP	cis	rs9790314	0.663	rs12639128	chr3:160639645	A/G	cg04691961	chr3:161091175	C3orf57	0.43	6.3	0.37	1.4e-9	Morning vs. evening chronotype;
KIRP	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg03315344	chr16:75512273	CHST6	0.55	5.21	0.32	3.91e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.75	8.53	0.48	1.55e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs151997	0.925	rs27624	chr5:50167662	C/T	cg06027927	chr5:50259733	NA	0.58	6.84	0.4	6.25e-11	Callous-unemotional behaviour;
KIRP	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.72	-0.39	1.23e-10	Inflammatory bowel disease;
KIRP	cis	rs10214930	0.697	rs1404276	chr7:27590847	A/G	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg15507776	chr3:136538369	TMEM22	0.38	5.18	0.31	4.55e-7	Neuroticism;
KIRP	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg25650185	chr19:21324782	ZNF431	0.48	5.19	0.31	4.46e-7	Pain;
KIRP	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.36	0.42	2.82e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.41	10.46	0.55	2.08e-21	Prostate cancer;
KIRP	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg06521331	chr12:34319734	NA	-0.57	-6.91	-0.4	4.02e-11	Morning vs. evening chronotype;
KIRP	cis	rs2625529	0.824	rs11072338	chr15:72245447	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-6.18	-0.37	2.7e-9	Red blood cell count;
KIRP	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.66	9.25	0.51	1.11e-17	Lymphocyte counts;
KIRP	cis	rs17453880	0.889	rs6871986	chr5:151947459	T/C	cg12297329	chr5:152029980	NA	-0.71	-10.03	-0.54	4.49e-20	Subjective well-being;
KIRP	cis	rs4656940	0.574	rs6427545	chr1:160770515	A/G	cg17331569	chr1:160788135	LY9	0.5	6.09	0.36	4.25e-9	Crohn's disease;
KIRP	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg01631408	chr1:248437212	OR2T33	-0.36	-5.0	-0.3	1.1e-6	Common traits (Other);
KIRP	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.16	13.04	0.64	6.71e-30	Uric acid levels;
KIRP	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg11234688	chr2:1609660	NA	0.58	5.28	0.32	2.79e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs787274	1.000	rs4979153	chr9:115554984	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-8.39	-0.47	3.78e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg10169327	chr19:45448959	APOC2	0.33	4.93	0.3	1.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.87	13.44	0.65	2.98e-31	Ulcerative colitis;
KIRP	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg10047753	chr17:41438598	NA	1.13	17.99	0.75	9.13e-47	Menopause (age at onset);
KIRP	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs17412403	0.779	rs9661436	chr1:65953970	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-4.98	-0.3	1.17e-6	Blood protein levels;
KIRP	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg12559939	chr2:27858050	GPN1	-0.41	-5.15	-0.31	5.35e-7	Oral cavity cancer;
KIRP	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.14	0.41	1.06e-11	Bipolar disorder;
KIRP	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg07274523	chr3:49395745	GPX1	0.72	8.8	0.49	2.54e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4517514	0.509	rs12417652	chr11:89905239	T/G	cg06174606	chr11:89959870	NA	-0.57	-5.91	-0.35	1.11e-8	Trans fatty acid levels;
KIRP	cis	rs7719624	0.967	rs34098140	chr5:135362550	T/C	cg16684184	chr5:135415129	NA	0.35	5.25	0.32	3.27e-7	Response to cytidine analogues (gemcitabine);
KIRP	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	1.03	11.39	0.59	2.08e-24	IgG glycosylation;
KIRP	trans	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg16141378	chr3:129829833	LOC729375	-0.51	-6.57	-0.39	2.96e-10	Mood instability;
KIRP	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.95	-16.56	-0.73	7.11e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg18132916	chr6:79620363	NA	-0.44	-6.1	-0.36	4.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.76	-8.97	-0.5	7.53e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs12643440	0.881	rs34197802	chr4:17222687	C/A	cg22650099	chr4:17144496	NA	-0.53	-6.24	-0.37	1.85e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9840812	0.592	rs12489577	chr3:136213145	C/T	cg15507776	chr3:136538369	TMEM22	0.42	5.44	0.33	1.27e-7	Fibrinogen levels;
KIRP	cis	rs1355223	0.902	rs2226113	chr11:34746289	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.98e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7903847	0.642	rs12359257	chr10:99136359	A/T	cg20016023	chr10:99160130	RRP12	-0.41	-5.43	-0.33	1.35e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.35e-7	Oral cavity cancer;
KIRP	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	7.68	0.44	3.69e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12976411	0.867	rs71351159	chr19:32860964	C/T	cg02282382	chr19:32836354	ZNF507	0.67	5.55	0.33	7.37e-8	Coronary artery disease;
KIRP	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.34	-5.15	-0.31	5.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.58	-6.87	-0.4	5.23e-11	Mosquito bite size;
KIRP	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05347473	chr6:146136440	FBXO30	-0.64	-9.35	-0.51	5.65e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10465746	0.657	rs67045520	chr1:84414998	G/T	cg10977910	chr1:84465055	TTLL7	0.52	6.41	0.38	7.21e-10	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16762072	chr21:35014947	ITSN1;CRYZL1	0.45	6.29	0.37	1.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.58	6.33	0.37	1.14e-9	Monocyte percentage of white cells;
KIRP	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg04370829	chr17:406249	NA	0.4	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.32e-9	Obesity-related traits;
KIRP	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg03311606	chr2:173292277	ITGA6	0.5	6.08	0.36	4.46e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.23	5.87	0.35	1.42e-8	Crohn's disease;
KIRP	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg26207909	chr14:103986467	CKB	-0.44	-5.36	-0.32	1.9e-7	Coronary artery disease;
KIRP	cis	rs57590327	0.503	rs2372906	chr3:81504673	G/A	cg07356753	chr3:81810745	GBE1	0.49	6.19	0.37	2.46e-9	Extraversion;
KIRP	trans	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg21784716	chr13:70680712	KLHL1;ATXN8OS	-0.34	-6.19	-0.37	2.46e-9	Response to metformin in type 2 diabetes (glycemic);
KIRP	cis	rs4073416	0.569	rs11158607	chr14:66110797	T/G	cg03016385	chr14:66212404	NA	-0.43	-5.6	-0.34	5.84e-8	N-glycan levels;
KIRP	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg26681399	chr22:41777847	TEF	0.51	5.27	0.32	3.03e-7	Vitiligo;
KIRP	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.86	11.6	0.59	4.19e-25	Selective IgA deficiency;
KIRP	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg12856521	chr11:46389249	DGKZ	0.64	7.51	0.43	1.1e-12	Crohn's disease;
KIRP	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg09695851	chr17:3907499	NA	-0.53	-4.86	-0.3	2.06e-6	Type 2 diabetes;
KIRP	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs17453880	0.890	rs4958563	chr5:151981337	A/G	cg12297329	chr5:152029980	NA	-0.68	-10.16	-0.54	1.77e-20	Subjective well-being;
KIRP	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.52	6.85	0.4	5.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.57	-5.96	-0.36	8.57e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs17834760	0.909	rs62423544	chr6:62041376	A/C	cg24246628	chr6:168435914	KIF25	0.53	6.04	0.36	5.6e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg10760299	chr15:45669010	GATM	0.34	5.09	0.31	6.96e-7	Homoarginine levels;
KIRP	cis	rs859767	0.501	rs6705916	chr2:135397569	C/T	cg12500956	chr2:135428796	TMEM163	-0.42	-5.75	-0.34	2.62e-8	Neuroticism;
KIRP	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	1.02	22.11	0.82	2.18e-60	Multiple myeloma;
KIRP	cis	rs1440410	0.835	rs4626148	chr4:144052460	A/C	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.13e-10	Ischemic stroke;
KIRP	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.37	-5.31	-0.32	2.44e-7	Mean platelet volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04188362	chr10:21823475	MLLT10	-0.5	-6.11	-0.36	3.82e-9	Interleukin-4 levels;
KIRP	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.1	0.61	9.1e-27	Menopause (age at onset);
KIRP	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.39	6.32	0.37	1.23e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1165472	1.000	rs769995	chr1:56102749	C/T	cg11523071	chr1:56160889	NA	-0.4	-5.14	-0.31	5.65e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	1.1	14.88	0.69	3.65e-36	Pulmonary function decline;
KIRP	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.82	11.05	0.58	2.67e-23	Height;
KIRP	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	11.56	0.59	5.85e-25	Hip circumference adjusted for BMI;
KIRP	cis	rs4851254	0.920	rs11686599	chr2:100753475	A/G	cg17356467	chr2:100759845	AFF3	0.54	6.87	0.4	5.37e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	1.1	17.86	0.75	2.62e-46	Migraine;
KIRP	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.1	-0.36	4e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.52	-6.39	-0.38	8.29e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg21775007	chr8:11205619	TDH	0.7	9.66	0.52	6.43e-19	Retinal vascular caliber;
KIRP	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.55	0.62	2.88e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg05418105	chr22:50981406	NA	-0.57	-7.03	-0.41	1.97e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg03808351	chr9:123631620	PHF19	0.43	5.87	0.35	1.42e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg08901578	chr4:187885870	NA	-0.54	-8.85	-0.49	1.74e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.84	-12.03	-0.61	1.64e-26	Total body bone mineral density;
KIRP	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg07148914	chr20:33460835	GGT7	-0.54	-7.12	-0.41	1.21e-11	Height;
KIRP	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.92	12.49	0.62	4.64e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.44	5.91	0.35	1.12e-8	Hemoglobin concentration;
KIRP	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.61	7.93	0.45	7.86e-14	Joint mobility (Beighton score);
KIRP	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg23788917	chr6:8435910	SLC35B3	-0.45	-5.57	-0.33	6.63e-8	Motion sickness;
KIRP	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg17279839	chr7:150038598	RARRES2	0.52	6.66	0.39	1.73e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12826209	chr6:26865740	GUSBL1	0.45	5.58	0.34	6.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11967485	0.534	rs62435827	chr6:157189490	A/C	cg23222435	chr6:157204239	ARID1B	-0.75	-4.9	-0.3	1.73e-6	Calcium levels;
KIRP	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	1.17	9.35	0.51	5.67e-18	LDL cholesterol;
KIRP	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02324249	chr8:24473569	NA	-0.42	-6.41	-0.38	7.32e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	1.07	17.19	0.74	5.02e-44	Cognitive function;
KIRP	cis	rs2281558	0.917	rs3787080	chr20:25232604	C/G	cg08601574	chr20:25228251	PYGB	0.47	4.91	0.3	1.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
KIRP	cis	rs73200209	0.744	rs3214009	chr12:116486852	C/T	cg01776926	chr12:116560359	MED13L	0.53	5.82	0.35	1.81e-8	Total body bone mineral density;
KIRP	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.77	-10.88	-0.57	9.13e-23	Blood metabolite levels;
KIRP	cis	rs1829883	0.898	rs2460686	chr5:98770831	T/C	cg08333243	chr5:99726346	NA	-0.41	-5.45	-0.33	1.24e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs240764	0.746	rs239197	chr6:101133600	T/C	cg09795085	chr6:101329169	ASCC3	0.47	5.67	0.34	4.08e-8	Neuroticism;
KIRP	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg00321850	chr1:175162397	KIAA0040	-0.37	-6.68	-0.39	1.56e-10	Alcohol dependence;
KIRP	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.34	-0.32	2.09e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6669919	0.967	rs7513031	chr1:211671900	C/T	cg10512769	chr1:211675356	NA	0.64	10.12	0.54	2.4e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-8.5	-0.48	1.85e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg12132617	chr1:202928820	ADIPOR1	0.46	6.11	0.36	3.8e-9	Schizophrenia;
KIRP	cis	rs8014252	0.708	rs74062730	chr14:70991650	A/C	cg11204974	chr14:71022665	NA	-0.75	-7.45	-0.43	1.54e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.48	7.27	0.42	4.83e-12	Resting heart rate;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg08761264	chr16:28874980	SH2B1	-0.47	-5.47	-0.33	1.09e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23598886	chr18:12777645	NA	0.68	5.66	0.34	4.25e-8	Inflammatory skin disease;
KIRP	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-6.43	-0.38	6.61e-10	Type 2 diabetes;
KIRP	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-7.51	-0.43	1.09e-12	Coffee consumption (cups per day);
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.87	-10.66	-0.56	4.68e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.45	-5.0	-0.3	1.07e-6	Carotid intima media thickness;
KIRP	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg12559939	chr2:27858050	GPN1	-0.42	-5.26	-0.32	3.16e-7	Oral cavity cancer;
KIRP	cis	rs7301016	1.000	rs10877855	chr12:62870510	C/G	cg01804193	chr12:63026212	NA	0.53	5.36	0.32	1.91e-7	IgG glycosylation;
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg13395646	chr4:1353034	KIAA1530	-0.47	-6.52	-0.38	4.04e-10	Obesity-related traits;
KIRP	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.86	10.03	0.54	4.6e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.08	0.41	1.48e-11	Bipolar disorder;
KIRP	cis	rs1629083	0.967	rs17121997	chr11:118131049	T/C	cg18857871	chr11:118064634	AMICA1	0.62	8.29	0.47	7.34e-15	Lung cancer;
KIRP	cis	rs34286592	1.000	rs28599680	chr16:29860685	A/C	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	4.91	0.3	1.63e-6	Multiple sclerosis;
KIRP	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg17554472	chr22:41940697	POLR3H	-0.46	-5.21	-0.32	4.05e-7	Neuroticism;
KIRP	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg17294928	chr15:75287854	SCAMP5	0.65	5.89	0.35	1.3e-8	Lung cancer;
KIRP	cis	rs7932354	0.798	rs2282686	chr11:46750638	T/C	cg16389345	chr11:46697382	NA	-0.41	-5.04	-0.31	9.23e-7	Bone mineral density (hip);Bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18956956	chr14:31028000	G2E3	-0.53	-6.43	-0.38	6.72e-10	Interleukin-4 levels;
KIRP	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg19507638	chr5:93509721	C5orf36	-0.61	-5.62	-0.34	5.27e-8	Diabetic retinopathy;
KIRP	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg11707556	chr5:10655725	ANKRD33B	0.56	7.1	0.41	1.32e-11	Coronary artery disease;
KIRP	cis	rs1322639	0.542	rs9689153	chr6:169586825	T/C	cg04662567	chr6:169592167	NA	0.67	6.46	0.38	5.64e-10	Pulse pressure;
KIRP	cis	rs258892	0.895	rs13158966	chr5:72059510	C/T	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg25902810	chr10:99078978	FRAT1	0.62	7.89	0.45	9.82e-14	Monocyte count;
KIRP	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.82	-0.71	2.23e-39	Immature fraction of reticulocytes;
KIRP	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg23127183	chr11:57508653	C11orf31	-0.54	-6.99	-0.41	2.55e-11	Schizophrenia;
KIRP	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg00792783	chr2:198669748	PLCL1	-0.47	-5.02	-0.3	1e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-0.75	-9.28	-0.51	9.13e-18	Blood trace element (Zn levels);
KIRP	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	6.37	0.38	9.1e-10	Personality dimensions;
KIRP	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg00530320	chr1:46809349	NSUN4	0.43	5.33	0.32	2.19e-7	Menopause (age at onset);
KIRP	cis	rs4666002	0.750	rs13021208	chr2:27901728	C/T	cg05484376	chr2:27715224	FNDC4	-0.46	-5.74	-0.34	2.82e-8	Phospholipid levels (plasma);
KIRP	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.2	0.51	1.62e-17	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.32	0.59	3.56e-24	Height;
KIRP	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.46	-0.33	1.19e-7	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14565439	chr5:107702185	FBXL17	0.39	6.3	0.37	1.37e-9	Survival in pancreatic cancer;
KIRP	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	5.86	0.35	1.47e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.75	-10.44	-0.55	2.28e-21	Hypospadias;
KIRP	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.83	-9.76	-0.53	3.05e-19	Body mass index;
KIRP	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg25338242	chr13:114786047	RASA3	0.43	5.16	0.31	5.16e-7	Schizophrenia;
KIRP	cis	rs9513627	1.000	rs7321381	chr13:100126156	G/A	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg03474202	chr17:45855739	NA	-0.46	-6.37	-0.38	9.27e-10	IgG glycosylation;
KIRP	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.28	7.49	0.43	1.2e-12	Primary biliary cholangitis;
KIRP	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg07653901	chr22:50250238	ZBED4	-0.61	-6.63	-0.39	2.15e-10	Schizophrenia;
KIRP	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.87e-32	Mean platelet volume;
KIRP	cis	rs2882667	0.931	rs10070021	chr5:138324706	A/G	cg04439458	chr5:138467593	SIL1	-0.44	-7.16	-0.42	9.36e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-9.57	-0.52	1.2e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6088813	0.885	rs6142353	chr20:33942685	G/A	cg14752227	chr20:34000481	UQCC	-0.52	-6.91	-0.4	4.24e-11	Height;
KIRP	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.87	-0.49	1.57e-16	Blood trace element (Zn levels);
KIRP	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.95	-16.2	-0.72	1.16e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.55	7.67	0.44	4.11e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.44	5.63	0.34	5e-8	Vitiligo;
KIRP	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00166722	chr3:10149974	C3orf24	0.47	4.85	0.3	2.16e-6	Alzheimer's disease;
KIRP	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	1.01	17.67	0.75	1.13e-45	Breast cancer;
KIRP	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.95	13.22	0.64	1.68e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.68	-0.34	3.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.65	-11.93	-0.61	3.35e-26	White blood cell count (basophil);
KIRP	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg11498726	chr8:26250323	BNIP3L	-0.56	-7.55	-0.43	8.55e-13	Red cell distribution width;
KIRP	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.08	0.41	1.55e-11	Retinal vascular caliber;
KIRP	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.76	9.36	0.51	5.38e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-1.03	-17.36	-0.74	1.26e-44	Height;
KIRP	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg03060546	chr3:49711283	APEH	0.46	5.88	0.35	1.33e-8	Parkinson's disease;
KIRP	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs6540559	0.673	rs4556361	chr1:210019654	C/G	cg22029157	chr1:209979665	IRF6	-0.47	-5.21	-0.32	4.02e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.01	-0.36	6.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7084402	0.934	rs1649021	chr10:60286028	C/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg21475434	chr5:93447410	FAM172A	0.44	5.11	0.31	6.56e-7	Diabetic retinopathy;
KIRP	cis	rs2916247	1.000	rs35749070	chr8:93053007	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.61	-8.01	-0.46	4.46e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4132509	1.000	rs2125230	chr1:243885848	A/G	cg25706552	chr1:244017396	NA	-0.47	-6.04	-0.36	5.78e-9	RR interval (heart rate);
KIRP	cis	rs12780845	0.505	rs11598987	chr10:17250230	C/G	cg01003015	chr10:17271136	VIM	-0.39	-4.85	-0.3	2.17e-6	Homocysteine levels;
KIRP	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg17366294	chr4:99064904	C4orf37	-0.39	-5.31	-0.32	2.43e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	1.01	19.74	0.78	1.25e-52	Parkinson's disease;
KIRP	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.89	0.4	4.52e-11	Neuroticism;
KIRP	cis	rs2224391	0.628	rs2773314	chr6:5253800	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.56	-0.39	3.08e-10	Height;
KIRP	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.4e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-10.27	-0.55	7.88e-21	Menarche (age at onset);
KIRP	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg05272587	chr13:111038400	COL4A2	0.34	5.09	0.31	7.1e-7	White matter hyperintensity burden;
KIRP	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-12.91	-0.64	1.9e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg23024343	chr7:107201750	COG5	0.4	4.88	0.3	1.9e-6	Coronary artery disease;
KIRP	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg12131826	chr15:77904385	NA	-0.4	-5.04	-0.31	9.22e-7	Type 2 diabetes;
KIRP	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg12480562	chr20:23434244	CST11	0.57	5.64	0.34	4.71e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg25338242	chr13:114786047	RASA3	0.42	4.93	0.3	1.53e-6	Schizophrenia;
KIRP	cis	rs911119	0.913	rs6036461	chr20:23576754	C/G	cg16589663	chr20:23618590	CST3	0.49	4.96	0.3	1.3e-6	Chronic kidney disease;
KIRP	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-6.81	-0.4	7.35e-11	Life satisfaction;
KIRP	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.83e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.11	0.41	1.29e-11	IgG glycosylation;
KIRP	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg11150807	chr10:43354902	NA	0.62	6.9	0.4	4.41e-11	Blood protein levels;
KIRP	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.38	-0.32	1.72e-7	Neuroticism;
KIRP	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.86	12.34	0.62	1.49e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs11644362	1.000	rs12918494	chr16:12988455	C/T	cg06890432	chr16:12997467	SHISA9	-0.39	-6.04	-0.36	5.8e-9	Positive affect;Subjective well-being;
KIRP	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.66	9.02	0.5	5.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.91	-12.42	-0.62	8.05e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs931127	0.658	rs12787843	chr11:65477306	A/C	cg11569703	chr11:65557185	OVOL1	0.46	8.04	0.46	3.68e-14	Systemic lupus erythematosus;
KIRP	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg00310523	chr12:86230176	RASSF9	0.39	5.86	0.35	1.49e-8	Major depressive disorder;
KIRP	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg23280166	chr11:118938394	VPS11	0.58	7.12	0.41	1.17e-11	Coronary artery disease;
KIRP	cis	rs9815354	1.000	rs9852303	chr3:41759525	C/T	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.31e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg01444801	chr10:135216882	MTG1	-0.56	-6.0	-0.36	6.96e-9	Systemic lupus erythematosus;
KIRP	cis	rs3026101	0.576	rs56188406	chr17:5316769	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.19	0.37	2.55e-9	Body mass index;
KIRP	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.03	-0.31	9.58e-7	Pulmonary function;
KIRP	cis	rs66731853	0.769	rs530104	chr1:20895721	A/G	cg04087271	chr1:20915334	CDA	-0.49	-5.29	-0.32	2.69e-7	Mean corpuscular volume;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg22022973	chr19:21933745	LOC641367;ZNF100	0.46	6.35	0.38	1.01e-9	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19841237	chr4:110226500	NA	0.44	6.38	0.38	8.79e-10	Interleukin-4 levels;
KIRP	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg05669848	chr5:237993	SDHA	-0.5	-5.19	-0.31	4.39e-7	Breast cancer;
KIRP	cis	rs12476592	0.602	rs1867849	chr2:63726932	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-4.85	-0.3	2.24e-6	Childhood ear infection;
KIRP	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs75920871	0.623	rs56227539	chr11:116964469	T/C	cg04087571	chr11:116723030	SIK3	-0.28	-5.56	-0.33	7.1e-8	Subjective well-being;
KIRP	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.65	8.12	0.46	2.27e-14	Corneal astigmatism;
KIRP	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.57	0.73	6.1e-42	Electrocardiographic conduction measures;
KIRP	cis	rs7590368	0.561	rs80325720	chr2:10958803	T/C	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2117029	0.619	rs9325145	chr12:49525884	A/G	cg24176009	chr12:49580217	TUBA1A	-0.38	-5.16	-0.31	5.21e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2574975	0.531	rs1203399	chr10:52200266	A/G	cg10034176	chr10:52120283	SGMS1	-0.4	-5.74	-0.34	2.71e-8	Response to amphetamines;
KIRP	trans	rs55728055	0.661	rs55931230	chr22:32028028	T/A	cg02791973	chr19:1132256	SBNO2	-0.61	-6.64	-0.39	1.96e-10	Age-related hearing impairment;
KIRP	cis	rs6750795	0.602	rs1667317	chr2:232412036	T/C	cg19187155	chr2:232395269	NMUR1	0.81	8.89	0.49	1.31e-16	Height;
KIRP	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.89	-11.13	-0.58	1.38e-23	Vitiligo;
KIRP	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg06671706	chr8:8559999	CLDN23	0.52	6.24	0.37	1.91e-9	Obesity-related traits;
KIRP	cis	rs9859260	1.000	rs2284889	chr3:195788247	G/A	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg22563815	chr15:78856949	CHRNA5	-0.44	-6.95	-0.41	3.25e-11	Sudden cardiac arrest;
KIRP	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg11642891	chr2:3452563	TTC15	-0.54	-7.12	-0.41	1.2e-11	Obesity-related traits;
KIRP	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg07511668	chr11:68622177	NA	0.39	4.86	0.3	2.1e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.92	-0.45	8.3e-14	IgG glycosylation;
KIRP	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.74	7.62	0.44	5.42e-13	Migraine;Coronary artery disease;
KIRP	cis	rs9479482	0.638	rs472469	chr6:150383174	T/C	cg25797454	chr6:150327115	RAET1K	0.31	5.63	0.34	4.95e-8	Alopecia areata;
KIRP	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.62e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16619721	chr3:160942782	NMD3	0.42	6.46	0.38	5.41e-10	Interleukin-4 levels;
KIRP	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.38	4.96	0.3	1.29e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg01522456	chr1:115632236	TSPAN2	0.38	5.04	0.31	8.86e-7	Autism;
KIRP	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg15445000	chr17:37608096	MED1	-0.48	-5.22	-0.32	3.8e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg08847533	chr14:75593920	NEK9	-0.61	-6.86	-0.4	5.46e-11	Caffeine consumption;
KIRP	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg18016565	chr1:150552671	MCL1	0.4	6.04	0.36	5.63e-9	Tonsillectomy;
KIRP	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.4	-0.43	2.14e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	1.33	9.59	0.52	1.07e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg14169450	chr9:139327907	INPP5E	0.58	7.19	0.42	7.72e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg23594656	chr7:65796392	TPST1	-0.45	-7.11	-0.41	1.28e-11	Aortic root size;
KIRP	trans	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg16141378	chr3:129829833	LOC729375	0.47	6.21	0.37	2.19e-9	Mood instability;
KIRP	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg13606994	chr1:44402422	ARTN	-0.29	-5.46	-0.33	1.15e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	10.06	0.54	3.54e-20	Hip circumference adjusted for BMI;
KIRP	trans	rs9650657	0.836	rs2898252	chr8:10604164	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.37	-0.38	9.06e-10	Neuroticism;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg01391022	chr12:122360665	WDR66	-0.4	-5.68	-0.34	3.79e-8	Mean corpuscular volume;
KIRP	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	0.98	11.44	0.59	1.44e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs1010254	0.559	rs55920366	chr5:151741037	G/A	cg12297329	chr5:152029980	NA	-0.61	-6.25	-0.37	1.81e-9	Optic nerve measurement (cup area);
KIRP	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.85	0.35	1.6e-8	Total cholesterol levels;
KIRP	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.34	-0.32	2.15e-7	Total body bone mineral density;
KIRP	cis	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg03511173	chr18:77590860	NA	0.59	5.86	0.35	1.46e-8	Opioid sensitivity;
KIRP	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg15448220	chr1:150897856	SETDB1	-0.38	-4.95	-0.3	1.35e-6	Tonsillectomy;
KIRP	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.9e-11	Retinal vascular caliber;
KIRP	cis	rs6662572	0.542	rs72677553	chr1:46592278	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.7	0.34	3.5e-8	Blood protein levels;
KIRP	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.87	0.35	1.38e-8	Motion sickness;
KIRP	cis	rs7923609	0.846	rs10761739	chr10:65062008	C/G	cg01631684	chr10:65280961	REEP3	0.5	5.81	0.35	1.88e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	1.01	20.02	0.79	1.42e-53	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.83	10.23	0.55	1.1e-20	Neutrophil percentage of white cells;
KIRP	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg06647332	chr5:131281008	NA	0.44	4.87	0.3	2e-6	Life satisfaction;
KIRP	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg05315796	chr3:52349193	DNAH1	0.45	6.92	0.4	3.91e-11	Bipolar disorder;
KIRP	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.21	-0.67	7.22e-34	Alzheimer's disease;
KIRP	cis	rs6693295	0.536	rs6662962	chr1:246226180	T/A	cg11798871	chr1:246315928	SMYD3	-0.66	-7.27	-0.42	4.74e-12	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.98	-9.74	-0.53	3.65e-19	Multiple sclerosis;
KIRP	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg25797454	chr6:150327115	RAET1K	0.29	5.59	0.34	6e-8	Alopecia areata;
KIRP	cis	rs918629	0.761	rs10073752	chr5:95279233	A/C	cg16656078	chr5:95278638	ELL2	-0.49	-7.13	-0.41	1.14e-11	IgG glycosylation;
KIRP	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.3	-0.47	7.13e-15	Response to antipsychotic treatment;
KIRP	cis	rs55675132	0.548	rs12126634	chr1:115343885	T/C	cg12756093	chr1:115239321	AMPD1	0.58	5.51	0.33	9.26e-8	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.14	-0.31	5.61e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2191566	0.576	rs448692	chr19:44494730	A/G	cg18700516	chr19:44507157	ZNF230	-0.42	-4.85	-0.3	2.23e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs72820985	0.540	rs3114385	chr16:80824154	A/G	cg04448709	chr16:81349954	GAN	-0.54	-5.18	-0.31	4.55e-7	Breast cancer;
KIRP	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.62	-7.53	-0.43	9.32e-13	Glomerular filtration rate;
KIRP	cis	rs1620921	0.967	rs783173	chr6:161172942	C/G	cg01280913	chr6:161186852	NA	-0.44	-6.13	-0.36	3.48e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg12855166	chr17:30846586	MYO1D	0.39	5.61	0.34	5.33e-8	Schizophrenia;
KIRP	cis	rs1010254	0.510	rs72806402	chr5:151712525	C/A	cg12297329	chr5:152029980	NA	-0.65	-6.6	-0.39	2.56e-10	Optic nerve measurement (cup area);
KIRP	cis	rs6921919	0.583	rs1054372	chr6:28336742	G/T	cg18815343	chr6:28367644	ZSCAN12	-0.42	-6.03	-0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.55	7.54	0.43	9.01e-13	Colorectal cancer;
KIRP	cis	rs17092148	1.000	rs910872	chr20:33334540	T/C	cg16810054	chr20:33298113	TP53INP2	-0.46	-5.69	-0.34	3.59e-8	Neuroticism;
KIRP	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.18	-0.37	2.57e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg12963866	chr19:57752005	ZNF805	-0.49	-6.16	-0.37	3.02e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs7975161	0.640	rs4477504	chr12:104710465	T/C	cg25273343	chr12:104657179	TXNRD1	-0.62	-5.65	-0.34	4.46e-8	Toenail selenium levels;
KIRP	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs6782228	0.509	rs6780447	chr3:128413808	T/C	cg18648031	chr3:128330563	NA	0.26	5.27	0.32	3.03e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.39	-4.99	-0.3	1.15e-6	IgG glycosylation;
KIRP	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg12437481	chr16:420112	MRPL28	-0.53	-5.84	-0.35	1.66e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.86	-0.49	1.61e-16	Resting heart rate;
KIRP	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.51	-6.16	-0.37	2.91e-9	HDL cholesterol;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-1.09	-21.59	-0.81	1.07e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.58	7.55	0.43	8.25e-13	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.75	11.39	0.59	2.1e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg01403660	chr11:68851641	TPCN2	0.71	7.66	0.44	4.26e-13	Blond vs. brown hair color;
KIRP	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.3	-0.37	1.39e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.66	-9.67	-0.52	5.94e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	6.97	0.41	2.9100000000000002e-11	Obesity-related traits;
KIRP	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg14458575	chr2:238380390	NA	0.57	7.52	0.43	1.02e-12	Prostate cancer;
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.7	9.67	0.52	5.75e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.23	-0.32	3.6e-7	Mean platelet volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07899794	chr17:19266098	B9D1	-0.44	-6.07	-0.36	4.87e-9	Metabolic traits;
KIRP	cis	rs829661	1.000	rs829642	chr2:30699970	A/G	cg10949345	chr2:30726833	LCLAT1	0.7	9.79	0.53	2.51e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01994542	chr14:103800472	EIF5	-0.6	-6.62	-0.39	2.23e-10	Menopause (age at onset);
KIRP	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg21573476	chr21:45109991	RRP1B	-0.54	-7.39	-0.43	2.34e-12	Mean corpuscular volume;
KIRP	cis	rs4889855	0.530	rs12451459	chr17:78589668	G/A	cg09596252	chr17:78655493	RPTOR	-0.49	-5.49	-0.33	9.98e-8	Fractional excretion of uric acid;
KIRP	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg21926883	chr2:100939477	LONRF2	0.54	7.06	0.41	1.74e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.69	4.87	0.3	1.97e-6	Childhood ear infection;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17677112	chr7:77428730	PHTF2;TMEM60	0.49	6.43	0.38	6.43e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.38	-6.1	-0.36	4.14e-9	Testicular germ cell tumor;
KIRP	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg06636001	chr8:8085503	FLJ10661	0.65	8.11	0.46	2.36e-14	Neuroticism;
KIRP	cis	rs1760803	0.754	rs2340473	chr1:154225344	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.36	5.39	0.33	1.64e-7	Nicotine dependence;
KIRP	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.79	-7.47	-0.43	1.44e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg15556689	chr8:8085844	FLJ10661	0.63	8.45	0.47	2.6e-15	Retinal vascular caliber;
KIRP	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg22138327	chr13:27999177	GTF3A	0.89	6.55	0.39	3.28e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg24881330	chr22:46731750	TRMU	0.66	5.8	0.35	2.02e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6585424	1.000	rs35497678	chr10:81921078	C/T	cg27417294	chr10:81904244	PLAC9	0.56	5.46	0.33	1.14e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.42	-6.27	-0.37	1.65e-9	Colorectal cancer;
KIRP	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05025164	chr4:1340916	KIAA1530	0.41	5.09	0.31	7.1e-7	Obesity-related traits;
KIRP	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.12e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.77	-0.4	9.13e-11	Hemoglobin concentration;
KIRP	cis	rs72820985	1.000	rs8058727	chr16:80844572	T/G	cg04448709	chr16:81349954	GAN	-0.49	-5.01	-0.3	1.06e-6	Breast cancer;
KIRP	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs56079296	0.929	rs73795208	chr5:121365578	T/C	cg05256605	chr5:121412184	LOX	-0.47	-5.32	-0.32	2.39e-7	Coronary artery disease;
KIRP	cis	rs7551222	0.749	rs11240764	chr1:204569376	A/G	cg20240347	chr1:204465584	NA	-0.4	-7.83	-0.45	1.5e-13	Schizophrenia;
KIRP	cis	rs745080	0.698	rs2767539	chr14:52903642	C/T	cg23333723	chr14:53022898	GPR137C	-0.38	-5.29	-0.32	2.7e-7	Orofacial clefts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02007381	chr6:42018347	TAF8	0.46	6.33	0.37	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg13180566	chr4:1052158	NA	-0.5	-5.07	-0.31	7.96e-7	Recombination rate (females);
KIRP	cis	rs920590	0.600	rs4921678	chr8:19663449	A/G	cg03894339	chr8:19674705	INTS10	0.41	4.95	0.3	1.39e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs712039	0.652	rs1829453	chr17:35809843	A/G	cg16670864	chr17:35848621	DUSP14	0.43	5.38	0.32	1.71e-7	Tuberculosis;
KIRP	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.01	11.42	0.59	1.65e-24	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.03e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg10189774	chr4:17578691	LAP3	0.45	5.49	0.33	9.92e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.67	-7.54	-0.43	9.3e-13	Vitiligo;
KIRP	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg23172400	chr8:95962367	TP53INP1	-0.29	-5.62	-0.34	5.27e-8	Type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg19847130	chr8:10466454	RP1L1	0.32	4.93	0.3	1.51e-6	Neuroticism;
KIRP	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg11846333	chr4:119757529	SEC24D	1.07	6.27	0.37	1.62e-9	Cannabis dependence symptom count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13476336	chr17:38255694	NR1D1	0.51	6.89	0.4	4.74e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.78	8.06	0.46	3.42e-14	Obesity-related traits;
KIRP	cis	rs7721647	0.810	rs10038508	chr5:90797244	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.44	4.9	0.3	1.77e-6	Breast cancer;
KIRP	cis	rs9381107	1.000	rs9381212	chr6:9476532	C/T	cg14735645	chr6:9486422	NA	-0.54	-6.58	-0.39	2.76e-10	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg13385521	chr17:29058706	SUZ12P	0.55	5.4	0.33	1.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg18154014	chr19:37997991	ZNF793	0.91	9.16	0.5	2.08e-17	Coronary artery calcification;
KIRP	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.68	-8.4	-0.47	3.67e-15	Cognitive function;
KIRP	cis	rs9400467	0.506	rs12190135	chr6:111698204	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.39	-4.92	-0.3	1.55e-6	HDL cholesterol;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23335946	chr1:185125966	C1orf25;C1orf26	0.5	6.26	0.37	1.74e-9	Smoking initiation;
KIRP	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-6.19	-0.37	2.52e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.69	7.38	0.43	2.43e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3736594	0.513	rs76013440	chr2:27816315	G/A	cg27432699	chr2:27873401	GPN1	0.57	6.01	0.36	6.55e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg17971929	chr21:40555470	PSMG1	-0.58	-6.58	-0.39	2.85e-10	Menarche (age at onset);
KIRP	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.98	13.58	0.65	1.02e-31	Neutrophil percentage of white cells;
KIRP	cis	rs4805834	0.764	rs4805837	chr19:33459592	A/G	cg07201929	chr19:33182834	NUDT19	0.62	4.85	0.3	2.19e-6	Creatinine levels;
KIRP	cis	rs3112255	0.597	rs2970991	chr2:101322193	C/G	cg01042948	chr2:101319752	NA	-0.44	-6.82	-0.4	6.93e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25517755	chr10:38738941	LOC399744	0.38	5.09	0.31	7.18e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs467650	0.509	rs152985	chr5:97988807	C/G	cg12450016	chr5:98112437	RGMB	0.4	5.15	0.31	5.41e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs1497828	0.956	rs2646828	chr1:217542361	C/T	cg04411442	chr1:217543379	NA	0.43	6.67	0.39	1.65e-10	Dialysis-related mortality;
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.86	-17.02	-0.74	1.82e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.03	-0.36	5.91e-9	Diastolic blood pressure;
KIRP	cis	rs829661	0.739	rs3862977	chr2:30764048	A/G	cg10949345	chr2:30726833	LCLAT1	1.13	14.14	0.67	1.28e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs10242455	0.702	rs41385645	chr7:98974038	A/T	cg18809830	chr7:99032528	PTCD1	-0.81	-5.93	-0.35	1.01e-8	Blood metabolite levels;
KIRP	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg00800569	chr2:239229395	TRAF3IP1	0.43	5.16	0.31	5.15e-7	Multiple system atrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19611786	chr2:61698739	USP34	0.49	6.12	0.36	3.74e-9	Parkinson's disease;
KIRP	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.65	-7.89	-0.45	9.99e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04362095	chr11:63592001	C11orf84	-0.78	-12.21	-0.61	4.07e-27	Pulse pressure;
KIRP	cis	rs17221829	0.673	rs10830330	chr11:89392799	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-4.93	-0.3	1.5e-6	Anxiety in major depressive disorder;
KIRP	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.59	8.69	0.48	5.34e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18864164	chr10:115934049	MIR2110;C10orf118	0.55	6.51	0.38	4.1e-10	Smoking initiation;
KIRP	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg22117172	chr7:91764530	CYP51A1	-0.39	-5.46	-0.33	1.15e-7	Breast cancer;
KIRP	cis	rs1971762	0.762	rs7312853	chr12:54073597	C/G	cg09709951	chr12:54017699	ATF7	-0.39	-4.92	-0.3	1.62e-6	Height;
KIRP	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.78	-7.68	-0.44	3.73e-13	Bipolar disorder;
KIRP	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.56	7.24	0.42	5.78e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg19554555	chr3:13937349	NA	-0.45	-6.09	-0.36	4.39e-9	Ovarian reserve;
KIRP	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg04731861	chr2:219085781	ARPC2	-0.2	-4.97	-0.3	1.25e-6	Colorectal cancer;
KIRP	cis	rs4006360	0.575	rs7501893	chr17:39311411	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-6.55	-0.39	3.29e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.09	12.01	0.61	1.9e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg16453901	chr6:170730693	NA	-0.79	-4.94	-0.3	1.41e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg13038030	chr17:73267041	MIF4GD	0.52	6.15	0.37	3.19e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.66	-5.18	-0.31	4.72e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.32e-7	Lymphocyte counts;
KIRP	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.54	-0.33	7.68e-8	Type 2 diabetes;
KIRP	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg12623918	chr2:306882	NA	0.48	5.86	0.35	1.49e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg10755058	chr3:40428713	ENTPD3	0.49	6.59	0.39	2.71e-10	Renal cell carcinoma;
KIRP	cis	rs4302748	0.862	rs73337008	chr7:36187715	G/T	cg24442661	chr7:36192818	EEPD1	0.61	6.87	0.4	5.16e-11	Platelet count;
KIRP	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08508325	chr11:3079039	CARS	0.33	6.12	0.36	3.77e-9	Calcium levels;
KIRP	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg26138937	chr11:71823887	C11orf51	-1.01	-6.94	-0.4	3.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05665937	chr4:1216051	CTBP1	0.56	7.84	0.45	1.34e-13	Obesity-related traits;
KIRP	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.53	-0.56	1.22e-21	Height;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg26428073	chr6:150039728	LATS1	0.98	6.41	0.38	7.28e-10	P wave terminal force;
KIRP	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.79	10.61	0.56	6.58e-22	Coffee consumption (cups per day);
KIRP	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg22437258	chr11:111473054	SIK2	0.63	7.68	0.44	3.81e-13	Primary sclerosing cholangitis;
KIRP	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.81	-0.35	1.9e-8	Endometrial cancer;
KIRP	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.54	0.43	9.26e-13	Acne (severe);
KIRP	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	cis	rs9815354	1.000	rs1613759	chr3:41906183	G/A	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7534824	0.860	rs1983968	chr1:101606862	G/A	cg17443007	chr1:101659419	NA	0.64	5.1	0.31	6.86e-7	Refractive astigmatism;
KIRP	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.3	-0.37	1.36e-9	Personality dimensions;
KIRP	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg04374321	chr14:90722782	PSMC1	-0.9	-12.9	-0.64	1.98e-29	Mortality in heart failure;
KIRP	cis	rs6580649	0.941	rs12580764	chr12:48453882	G/A	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.49	-0.38	4.57e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.71	-0.39	1.36e-10	Renal cell carcinoma;
KIRP	cis	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg03999872	chr20:62272968	STMN3	-0.59	-6.77	-0.4	9.54e-11	Atopic dermatitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08109969	chr3:111697754	ABHD10	-0.57	-7.13	-0.41	1.12e-11	Interleukin-4 levels;
KIRP	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.6	-6.73	-0.39	1.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-8.34	-0.47	5.26e-15	Colorectal cancer;
KIRP	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.86	0.53	1.53e-19	Schizophrenia;
KIRP	cis	rs6732160	0.691	rs6728147	chr2:73423490	A/G	cg01422370	chr2:73384389	NA	-0.41	-5.48	-0.33	1.03e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.68	-8.63	-0.48	7.51e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg02461776	chr11:598696	PHRF1	0.7	7.67	0.44	4e-13	Systemic lupus erythematosus;
KIRP	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg06808227	chr14:105710500	BRF1	-0.79	-10.14	-0.54	1.98e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1497828	0.956	rs2815223	chr1:217527843	C/A	cg04411442	chr1:217543379	NA	-0.3	-4.88	-0.3	1.92e-6	Dialysis-related mortality;
KIRP	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08280861	chr8:58055591	NA	0.71	5.5	0.33	9.34e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs300890	0.513	rs4270544	chr4:144044338	C/T	cg01719995	chr4:144104893	USP38	-0.42	-5.43	-0.33	1.35e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs2554380	0.943	rs2033071	chr15:84365434	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.7	-0.49	4.7e-16	Height;
KIRP	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	5.3	0.32	2.63e-7	Renal cell carcinoma;
KIRP	cis	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg19847130	chr8:10466454	RP1L1	-0.33	-5.19	-0.31	4.36e-7	Neuroticism;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12659159	chr3:197463876	KIAA0226	-0.51	-6.73	-0.39	1.17e-10	Metabolic traits;
KIRP	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg21466736	chr12:48725269	NA	-0.48	-6.41	-0.38	7.58e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg00656387	chr3:40428638	ENTPD3	0.39	5.01	0.3	1.03e-6	Renal cell carcinoma;
KIRP	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg15117754	chr3:10150083	C3orf24	0.56	5.36	0.32	1.88e-7	Alzheimer's disease;
KIRP	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.69	11.07	0.58	2.15e-23	Weight;
KIRP	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg21775007	chr8:11205619	TDH	0.47	5.92	0.35	1.06e-8	Morning vs. evening chronotype;
KIRP	cis	rs10929159	0.928	rs10179607	chr2:236915645	C/G	cg20128773	chr2:236923534	AGAP1	0.29	4.86	0.3	2.05e-6	Parkinson's disease;
KIRP	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	6.03	0.36	6.1e-9	Motion sickness;
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg07701084	chr6:150067640	NUP43	0.69	9.81	0.53	2.12e-19	Lung cancer;
KIRP	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.5	0.38	4.36e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.8	8.9	0.49	1.25e-16	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs6142102	0.812	rs6059578	chr20:32527706	G/C	cg24642439	chr20:33292090	TP53INP2	0.57	6.15	0.37	3.09e-9	Skin pigmentation;
KIRP	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.37	-5.08	-0.31	7.56e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.95	-0.3	1.38e-6	Obesity-related traits;
KIRP	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.23	0.37	2.05e-9	Bladder cancer;
KIRP	cis	rs4704187	0.687	rs12653162	chr5:74391666	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.25	-20.79	-0.8	4.13e-56	Breast cancer;
KIRP	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg03808351	chr9:123631620	PHF19	0.45	6.16	0.37	2.97e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21123913	chr4:89513664	HERC3	0.49	6.13	0.36	3.54e-9	Parkinson's disease;
KIRP	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg01689657	chr7:91764605	CYP51A1	0.44	6.36	0.38	9.65e-10	Breast cancer;
KIRP	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg18350739	chr11:68623251	NA	-0.56	-8.12	-0.46	2.31e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.35	0.42	2.95e-12	Coronary artery disease;
KIRP	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg14683738	chr19:37701593	ZNF585B	0.47	4.86	0.3	2.08e-6	Coronary artery calcification;
KIRP	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg11235152	chr1:67600687	NA	0.71	10.48	0.56	1.71e-21	Psoriasis;
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg27189623	chr16:705930	WDR90	0.43	5.94	0.35	9.7e-9	Height;
KIRP	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.52	-0.43	1.05e-12	Total cholesterol levels;
KIRP	cis	rs887797	0.507	rs28625506	chr17:64554102	C/T	cg27019712	chr17:64599478	PRKCA	0.39	4.86	0.3	2.05e-6	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
KIRP	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-5.96	-0.36	8.75e-9	Bone mineral density;
KIRP	cis	rs7149242	1.000	rs11620937	chr14:101151012	C/G	cg10189261	chr14:101176105	NA	-0.55	-7.45	-0.43	1.62e-12	Platelet count;
KIRP	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.57	-8.1	-0.46	2.5e-14	Colorectal cancer;
KIRP	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.87	-14.78	-0.69	8.42e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.77	-10.29	-0.55	7.1e-21	Adiposity;
KIRP	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.91	0.49	1.19e-16	Electroencephalogram traits;
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05564831	chr3:52568323	NT5DC2	0.44	7.07	0.41	1.61e-11	Electroencephalogram traits;
KIRP	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.17	0.31	4.87e-7	Coronary artery disease;
KIRP	cis	rs6504950	0.830	rs3087650	chr17:53029328	G/A	cg26251398	chr17:52985966	TOM1L1	0.42	5.2	0.31	4.12e-7	Breast cancer;
KIRP	trans	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg02030672	chr11:45687055	CHST1	0.57	7.13	0.41	1.1e-11	Obesity-related traits;
KIRP	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.71	0.44	3.2e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	5.78	0.35	2.22e-8	HIV-1 control;
KIRP	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg16434002	chr17:42200994	HDAC5	0.47	5.85	0.35	1.55e-8	Total body bone mineral density;
KIRP	cis	rs580438	0.548	rs354475	chr3:13356901	C/T	cg10657019	chr3:13328039	NA	0.6	7.89	0.45	1.02e-13	Myringotomy;
KIRP	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg05709478	chr1:6581295	PLEKHG5	0.63	5.61	0.34	5.49e-8	Body mass index;
KIRP	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg17724175	chr1:150552817	MCL1	0.33	5.73	0.34	2.86e-8	Tonsillectomy;
KIRP	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg14675211	chr2:100938903	LONRF2	0.5	6.43	0.38	6.66e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17421021	chr10:114879663	TCF7L2	0.42	6.02	0.36	6.31e-9	Survival in pancreatic cancer;
KIRP	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.66	9.07	0.5	4.02e-17	Height;
KIRP	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg20673091	chr1:2541236	MMEL1	0.66	9.78	0.53	2.75e-19	Ulcerative colitis;
KIRP	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.75	-7.75	-0.44	2.43e-13	Vitiligo;
KIRP	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.01	0.41	2.24e-11	Bipolar disorder;
KIRP	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	0.83	9.53	0.52	1.61e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.44	5.44	0.33	1.31e-7	Lymphocyte counts;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg17492891	chr22:41843204	TOB2	0.52	6.11	0.36	3.95e-9	Sleep duration;
KIRP	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.34	-5.15	-0.31	5.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.71	9.37	0.51	4.84e-18	Height;
KIRP	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.73	11.56	0.59	5.8e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9426935	0.604	rs3001365	chr1:154019182	C/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.34	-5.02	-0.3	1.01e-6	Lentiform nucleus volume;
KIRP	cis	rs9436747	0.626	rs17412368	chr1:65939158	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-4.87	-0.3	1.96e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.14	0.31	5.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7539542	0.529	rs7530468	chr1:202871581	C/G	cg19681188	chr1:202830198	LOC148709	-0.48	-5.15	-0.31	5.33e-7	Mean platelet volume;
KIRP	cis	rs11955175	1.000	rs11956743	chr5:40677593	G/A	cg04002187	chr5:40835754	RPL37	0.68	5.28	0.32	2.84e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg13939156	chr17:80058883	NA	0.48	5.64	0.34	4.67e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4356975	0.563	rs7663584	chr4:69956110	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs8523	0.774	rs6456810	chr6:11052418	C/A	cg13562911	chr6:11044106	ELOVL2	0.41	5.43	0.33	1.38e-7	Red blood cell fatty acid levels;
KIRP	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg24747557	chr10:131355152	MGMT	-0.43	-5.71	-0.34	3.24e-8	Response to temozolomide;
KIRP	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg07001201	chr5:642380	CEP72	0.67	6.2	0.37	2.42e-9	Obesity-related traits;
KIRP	cis	rs698813	0.774	rs2304769	chr2:44569474	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.24	0.37	1.89e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs9815354	1.000	rs13325965	chr3:41914942	G/T	cg03022575	chr3:42003672	ULK4	0.63	6.61	0.39	2.37e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg21253087	chr9:139290292	SNAPC4	0.47	6.74	0.4	1.09e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1062177	0.756	rs2964591	chr5:151117397	A/G	cg00977110	chr5:151150581	G3BP1	-0.55	-5.82	-0.35	1.79e-8	Preschool internalizing problems;
KIRP	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-7.47	-0.43	1.42e-12	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.91	-0.4	4.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.39	-0.43	2.34e-12	Mean corpuscular volume;
KIRP	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.73	8.98	0.5	7.44e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg11952622	chr19:58962976	ZNF324B	0.43	5.03	0.31	9.38e-7	Uric acid clearance;
KIRP	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg11498726	chr8:26250323	BNIP3L	-0.46	-7.07	-0.41	1.64e-11	Red cell distribution width;
KIRP	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.67	7.18	0.42	8.38e-12	Pediatric autoimmune diseases;
KIRP	cis	rs6546324	0.592	rs9309402	chr2:67869338	T/C	cg15745817	chr2:67799979	NA	-0.68	-7.32	-0.42	3.57e-12	Endometriosis;
KIRP	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.43e-9	Obesity-related traits;
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.62	8.66	0.48	6.5e-16	Mean corpuscular volume;
KIRP	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.34	0.42	3.03e-12	Bipolar disorder;
KIRP	trans	rs2867695	0.591	rs72656551	chr4:81135386	C/T	cg01441113	chr4:186560403	SORBS2	0.53	6.2	0.37	2.35e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg26441486	chr22:50317300	CRELD2	0.5	5.05	0.31	8.44e-7	Acne (severe);
KIRP	trans	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg12929700	chr20:62947519	NA	-0.59	-6.11	-0.36	3.9e-9	Refractive error;
KIRP	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg03854865	chr6:26224070	HIST1H3E	0.62	4.85	0.3	2.16e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.61	8.25	0.47	9.49e-15	Longevity;Endometriosis;
KIRP	cis	rs7923609	0.967	rs7920058	chr10:65293924	T/G	cg01631684	chr10:65280961	REEP3	-0.49	-5.77	-0.35	2.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.65	0.34	4.43e-8	Homoarginine levels;
KIRP	cis	rs4132509	1.000	rs10927067	chr1:243923244	C/T	cg21452805	chr1:244014465	NA	0.48	5.06	0.31	8.17e-7	RR interval (heart rate);
KIRP	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg03342759	chr3:160939853	NMD3	-0.48	-5.28	-0.32	2.89e-7	Parkinson's disease;
KIRP	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	1.01	16.31	0.72	4.86e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs13102973	0.965	rs13103954	chr4:135844189	A/G	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.08e-16	Subjective well-being;
KIRP	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.45	-0.43	1.62e-12	Type 2 diabetes;
KIRP	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg05370193	chr1:21551575	ECE1	-0.36	-4.96	-0.3	1.29e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.98e-14	Body mass index;
KIRP	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.48	-5.89	-0.35	1.25e-8	Initial pursuit acceleration;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.84	12.7	0.63	9.61e-29	Menarche (age at onset);
KIRP	trans	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg04373760	chr16:53404718	NA	0.64	7.13	0.41	1.11e-11	Hypertriglyceridemia;
KIRP	cis	rs73200209	0.744	rs61939693	chr12:116540478	G/A	cg01776926	chr12:116560359	MED13L	-0.57	-6.28	-0.37	1.56e-9	Total body bone mineral density;
KIRP	cis	rs6991838	0.584	rs57042777	chr8:66489090	T/A	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.73	-0.34	2.96e-8	Longevity;
KIRP	cis	rs7582720	1.000	rs72932765	chr2:203679183	C/T	cg08076091	chr2:203926405	NBEAL1	0.84	8.62	0.48	8.49e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12576082	chr20:30102058	HM13	0.55	7.13	0.41	1.11e-11	Parkinson's disease;
KIRP	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg23719950	chr11:63933701	MACROD1	-0.68	-6.56	-0.39	3.11e-10	Mean platelet volume;
KIRP	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg07384165	chr1:10488281	NA	-0.45	-5.68	-0.34	3.82e-8	Prostate cancer;
KIRP	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg01411142	chr8:19674711	INTS10	0.93	9.07	0.5	3.99e-17	Lipid metabolism phenotypes;
KIRP	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg09455208	chr3:40491958	NA	0.3	5.03	0.31	9.54e-7	Renal cell carcinoma;
KIRP	trans	rs17767392	0.670	rs72726701	chr14:71728329	C/T	cg26589485	chr17:1838439	RTN4RL1	0.47	6.07	0.36	4.73e-9	Mitral valve prolapse;
KIRP	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg13607699	chr17:42295918	UBTF	0.46	5.67	0.34	3.89e-8	Total body bone mineral density;
KIRP	cis	rs4666002	0.789	rs13030973	chr2:27928797	T/C	cg27432699	chr2:27873401	GPN1	0.55	5.27	0.32	2.96e-7	Phospholipid levels (plasma);
KIRP	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg12454167	chr3:186435060	KNG1	0.5	8.52	0.48	1.65e-15	Blood protein levels;
KIRP	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05347473	chr6:146136440	FBXO30	0.58	8.31	0.47	6.67e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg26022315	chr17:47021804	SNF8	0.45	5.86	0.35	1.47e-8	Type 2 diabetes;
KIRP	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.35	6.72	0.39	1.22e-10	Monocyte percentage of white cells;
KIRP	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.82	11.95	0.61	3.03e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.54	5.23	0.32	3.69e-7	Schizophrenia;
KIRP	cis	rs882732	0.947	rs10140765	chr14:95023389	C/T	cg05186455	chr14:95027692	SERPINA4	-0.36	-5.14	-0.31	5.58e-7	Blood protein levels;
KIRP	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.64	-8.78	-0.49	2.81e-16	Total body bone mineral density;
KIRP	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.55	-7.31	-0.42	3.83e-12	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg15055890	chr3:11747650	VGLL4	0.41	6.19	0.37	2.49e-9	Morning vs. evening chronotype;
KIRP	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.48	-6.03	-0.36	5.86e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.3	-0.78	3.67e-51	Schizophrenia;
KIRP	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.78	-10.26	-0.55	8.64e-21	Coronary artery disease;
KIRP	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.88	8.95	0.5	9.14e-17	Eosinophil percentage of granulocytes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14684581	chr8:11627124	NEIL2	0.48	6.46	0.38	5.64e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-1.02	-19.22	-0.77	7.01e-51	Breast cancer;
KIRP	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	8.78	0.49	2.82e-16	Mood instability;
KIRP	cis	rs8084125	0.765	rs72981159	chr18:74945042	A/G	cg18461021	chr18:74961002	GALR1	0.52	5.3	0.32	2.59e-7	Obesity-related traits;
KIRP	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.14	-0.41	1.07e-11	Type 2 diabetes;
KIRP	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg08975724	chr8:8085496	FLJ10661	0.61	7.54	0.43	8.87e-13	Retinal vascular caliber;
KIRP	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.66	7.89	0.45	9.93e-14	Height;
KIRP	cis	rs1760803	0.754	rs12062977	chr1:154211516	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.58	-0.33	6.46e-8	Nicotine dependence;
KIRP	cis	rs9473924	0.583	rs3846905	chr6:50905306	G/A	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	trans	rs1106684	1.000	rs11767140	chr7:131466250	G/A	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg10790698	chr19:18539756	SSBP4	-0.35	-7.71	-0.44	3.12e-13	Breast cancer;
KIRP	cis	rs9513627	1.000	rs6491511	chr13:100198717	C/A	cg25919922	chr13:100150906	NA	0.76	5.68	0.34	3.79e-8	Obesity-related traits;
KIRP	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	5.11e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg08501292	chr6:25962987	TRIM38	1.11	7.79	0.44	1.89e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2916247	0.954	rs4623479	chr8:93038708	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.6	-7.83	-0.45	1.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.69	10.45	0.55	2.19e-21	Hip circumference;
KIRP	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25198584	chr1:4775233	AJAP1	0.48	6.26	0.37	1.7e-9	Interleukin-4 levels;
KIRP	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg13334819	chr7:99746414	C7orf59	0.56	6.37	0.38	8.99e-10	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg01721255	chr8:58191610	C8orf71	0.58	5.64	0.34	4.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs17834760	0.955	rs34413893	chr6:62053908	A/T	cg08476511	chr6:168435923	KIF25	0.52	6.09	0.36	4.37e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.8	9.07	0.5	3.9e-17	Corneal astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18930905	chr4:57180387	KIAA1211	-0.45	-6.17	-0.37	2.85e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.45	-5.59	-0.34	5.96e-8	Schizophrenia;
KIRP	trans	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg25288420	chr1:78511713	GIPC2	0.45	6.1	0.36	4.04e-9	Obesity-related traits;
KIRP	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.11	0.36	3.9e-9	Menopause (age at onset);
KIRP	cis	rs4776059	1.000	rs11070909	chr15:52931601	A/G	cg22715398	chr15:52968154	KIAA1370	-0.58	-7.05	-0.41	1.77e-11	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-5.4	-0.33	1.57e-7	Lung cancer;
KIRP	cis	rs812925	0.537	rs2593620	chr2:61613261	A/G	cg15711740	chr2:61764176	XPO1	0.45	5.68	0.34	3.79e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg18135206	chr14:102964638	TECPR2	-0.46	-5.75	-0.34	2.64e-8	Plateletcrit;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.41	-5.14	-0.31	5.63e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4728302	0.585	rs7798192	chr7:133583841	A/T	cg10665199	chr7:133106180	EXOC4	0.43	5.0	0.3	1.1e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.58	-9.03	-0.5	5.09e-17	Lymphocyte counts;
KIRP	cis	rs7119038	0.818	rs10892294	chr11:118667357	C/G	cg19308663	chr11:118741387	NA	-0.54	-9.12	-0.5	2.71e-17	Sjögren's syndrome;
KIRP	cis	rs1050631	1.000	rs719147	chr18:33698192	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	6.22	0.37	2.06e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.4	-0.43	2.14e-12	Bipolar disorder;
KIRP	cis	rs4812048	0.649	rs6070706	chr20:57628239	C/T	cg14073986	chr20:57617431	SLMO2	0.67	5.77	0.35	2.32e-8	Mean platelet volume;
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg21734707	chr17:3908241	ZZEF1	-0.6	-8.86	-0.49	1.61e-16	Type 2 diabetes;
KIRP	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg06671706	chr8:8559999	CLDN23	0.46	5.28	0.32	2.9e-7	Obesity-related traits;
KIRP	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-14.28	-0.67	4.23e-34	Heart rate;
KIRP	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg00656387	chr3:40428638	ENTPD3	-0.37	-5.05	-0.31	8.42e-7	Renal cell carcinoma;
KIRP	cis	rs3105593	1.000	rs3131582	chr15:50879670	C/T	cg05456662	chr15:50716270	USP8	0.42	5.13	0.31	6.02e-7	QT interval;
KIRP	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.67	-10.12	-0.54	2.44e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.65	0.34	4.41e-8	Breast cancer;
KIRP	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg07636037	chr3:49044803	WDR6	0.64	6.14	0.36	3.34e-9	Menarche (age at onset);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg13407422	chr20:25371439	ABHD12	-0.45	-6.08	-0.36	4.61e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs6969780	1.000	rs6948297	chr7:27149404	A/G	cg26364809	chr7:27145159	NA	-0.61	-5.37	-0.32	1.83e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2071403	0.901	rs938325	chr2:1401447	A/G	cg07083862	chr2:1417248	TPO	0.33	5.29	0.32	2.68e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.67	8.25	0.47	9.69e-15	Type 2 diabetes;
KIRP	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg19913688	chr11:428466	ANO9	-0.77	-6.03	-0.36	6.05e-9	Body mass index;
KIRP	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.59	7.75	0.44	2.4e-13	Total body bone mineral density;
KIRP	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg05072774	chr3:49840536	C3orf54	0.43	5.51	0.33	9.17e-8	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.15	0.67	1.14e-33	Platelet count;
KIRP	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.17	0.31	4.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.23e-8	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-5.04	-0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg18927565	chr5:110847930	STARD4	-0.48	-6.32	-0.37	1.23e-9	Blood metabolite levels;
KIRP	cis	rs4356932	0.935	rs4406046	chr4:76969955	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg09695851	chr17:3907499	NA	0.59	5.82	0.35	1.81e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs17123764	0.818	rs13066	chr12:49960551	C/A	cg02054252	chr12:50078554	FMNL3	0.42	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.22	-0.37	2.08e-9	Type 2 diabetes;
KIRP	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg20673091	chr1:2541236	MMEL1	0.79	12.45	0.62	6.25e-28	Ulcerative colitis;
KIRP	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg01420254	chr6:26195488	NA	1.08	8.72	0.49	4.12e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg19650706	chr5:140594406	PCDHB13	-0.45	-4.92	-0.3	1.6e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg07511668	chr11:68622177	NA	0.38	5.03	0.31	9.39e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11574514	1.000	rs73591936	chr16:67761825	G/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.91	-0.35	1.15e-8	Crohn's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26215807	chr14:89254566	EML5	-0.49	-7.31	-0.42	3.63e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10346111	chr3:10326661	GHRLOS;C3orf42	0.52	6.39	0.38	8.07e-10	Interleukin-4 levels;
KIRP	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.25	-16.73	-0.73	1.84e-42	Breast cancer;
KIRP	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg06636001	chr8:8085503	FLJ10661	0.7	9.07	0.5	3.79e-17	Retinal vascular caliber;
KIRP	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	8.0	0.45	4.77e-14	Iron status biomarkers;
KIRP	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.87	0.35	1.41e-8	Bipolar disorder;
KIRP	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg02811702	chr13:24901961	NA	0.4	5.37	0.32	1.84e-7	Obesity-related traits;
KIRP	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.53	-6.37	-0.38	9.1e-10	Longevity;Endometriosis;
KIRP	cis	rs7520050	0.966	rs7540325	chr1:46338217	A/T	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2635047	0.638	rs2289133	chr18:44602249	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.8	-0.35	2.01e-8	Educational attainment;
KIRP	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg03465714	chr1:152285911	FLG	0.48	5.29	0.32	2.66e-7	Atopic dermatitis;
KIRP	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.7	9.59	0.52	1.01e-18	Mean corpuscular volume;
KIRP	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01616529	chr11:638424	DRD4	-0.42	-5.67	-0.34	3.91e-8	Systemic lupus erythematosus;
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09597638	chr17:3907349	NA	0.76	14.75	0.69	1.05e-35	Type 2 diabetes;
KIRP	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-4.87	-0.3	1.99e-6	IgG glycosylation;
KIRP	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.56	0.33	6.94e-8	Menopause (age at onset);
KIRP	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.5	-0.38	4.47e-10	Type 2 diabetes;
KIRP	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg20488157	chr14:104394430	TDRD9	0.79	10.81	0.57	1.49e-22	Bipolar disorder;
KIRP	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.92	-10.68	-0.56	3.97e-22	Diastolic blood pressure;
KIRP	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.52	6.12	0.36	3.74e-9	Tonsillectomy;
KIRP	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.03	13.95	0.66	5.46e-33	Corneal structure;
KIRP	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.49	-11.39	-0.59	2.03e-24	Diabetic kidney disease;
KIRP	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg16141378	chr3:129829833	LOC729375	0.61	7.74	0.44	2.64e-13	Neuroticism;
KIRP	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.31	-0.32	2.46e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2274273	0.905	rs8007614	chr14:55586575	A/G	cg04306507	chr14:55594613	LGALS3	0.45	7.12	0.41	1.15e-11	Protein biomarker;
KIRP	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.59	-7.33	-0.42	3.36e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1829883	0.898	rs2963577	chr5:98785343	C/T	cg08333243	chr5:99726346	NA	0.41	5.33	0.32	2.25e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.65	8.6	0.48	9.41e-16	Total body bone mineral density;
KIRP	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.74	7.68	0.44	3.79e-13	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs988913	1.000	rs7764641	chr6:54835469	A/T	cg03513858	chr6:54763001	FAM83B	-0.37	-5.37	-0.32	1.8e-7	Menarche (age at onset);
KIRP	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05220968	chr6:146057943	EPM2A	-0.37	-5.03	-0.31	9.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.56	-6.47	-0.38	5.14e-10	HDL cholesterol;
KIRP	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.05	-0.54	4.05e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.59	-8.56	-0.48	1.21e-15	Testicular germ cell tumor;
KIRP	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-0.78	-9.83	-0.53	1.95e-19	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	1.0	16.62	0.73	4.17e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	10.13	0.54	2.25e-20	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg05834845	chr3:195489306	MUC4	0.65	5.93	0.35	1.01e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs258892	0.895	rs11960081	chr5:72064490	C/G	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.91	11.63	0.6	3.43e-25	Menopause (age at onset);
KIRP	cis	rs9826463	0.582	rs73238138	chr3:142041137	T/C	cg20824294	chr3:142316082	PLS1	0.41	5.99	0.36	7.23e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.81	-0.57	1.53e-22	Menopause (age at onset);
KIRP	cis	rs6547631	0.622	rs61191323	chr2:85928631	G/A	cg24620635	chr2:85921963	GNLY	0.31	4.96	0.3	1.31e-6	Blood protein levels;
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg17441377	chr17:3906640	NA	0.55	8.28	0.47	7.81e-15	Type 2 diabetes;
KIRP	cis	rs12643440	0.538	rs2041443	chr4:17137996	G/A	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15146966	chr22:29196915	XBP1	0.57	6.56	0.39	3.12e-10	Lung cancer in ever smokers;
KIRP	cis	rs5743618	0.537	rs10019951	chr4:38765584	A/G	cg06935464	chr4:38784597	TLR10	0.4	4.96	0.3	1.34e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4561483	0.831	rs33648	chr16:11979622	G/A	cg08843971	chr16:11963173	GSPT1	-0.56	-7.29	-0.42	4.3e-12	Testicular germ cell tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13971283	chr19:47207409	PRKD2	0.45	6.12	0.36	3.65e-9	Interleukin-4 levels;
KIRP	cis	rs76917914	0.537	rs3780471	chr9:100847551	G/T	cg03040243	chr9:100819229	NANS	0.48	5.36	0.32	1.92e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6546886	0.912	rs6745792	chr2:74284033	G/A	cg14702570	chr2:74259524	NA	-0.33	-6.78	-0.4	8.87e-11	Dialysis-related mortality;
KIRP	cis	rs11628318	1.000	rs12892184	chr14:103040300	C/A	cg12046867	chr14:103022105	NA	-0.46	-6.19	-0.37	2.54e-9	Platelet count;
KIRP	cis	rs3789045	0.528	rs61817953	chr1:204462612	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.14	-0.36	3.33e-9	Educational attainment (college completion);
KIRP	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg25174290	chr11:3078921	CARS	-0.66	-8.36	-0.47	4.61e-15	Calcium levels;
KIRP	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg02297831	chr4:17616191	MED28	0.53	6.6	0.39	2.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.53	0.33	8.29e-8	Lung cancer;
KIRP	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.4	-0.47	3.67e-15	Neuroticism;
KIRP	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-6.37	-0.38	9.17e-10	Self-reported allergy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18542177	chr7:12726431	ARL4A	0.49	6.25	0.37	1.78e-9	Parkinson's disease;
KIRP	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg26875233	chr11:93583750	C11orf90	-0.36	-6.66	-0.39	1.75e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.85e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.71	-10.05	-0.54	3.9e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.73	-7.34	-0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs6132905	0.548	rs4815444	chr20:2621036	A/G	cg24848351	chr20:2622020	TMC2	-0.61	-5.48	-0.33	1.04e-7	Mumps;
KIRP	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs876084	0.604	rs1543200	chr8:121018826	T/C	cg22335954	chr8:121166405	COL14A1	-0.4	-5.04	-0.31	9.1e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18881247	chr2:157189314	NR4A2	-0.46	-6.44	-0.38	6.06e-10	Myopia;
KIRP	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.0	-11.88	-0.6	5.07e-26	Colorectal cancer;
KIRP	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs6540556	0.608	rs7548781	chr1:209915795	A/G	cg23920097	chr1:209922102	NA	0.38	4.89	0.3	1.8e-6	Red blood cell count;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg23985595	chr17:80112537	CCDC57	-0.35	-5.24	-0.32	3.47e-7	Life satisfaction;
KIRP	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg00204512	chr16:28754710	NA	0.46	5.66	0.34	4.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.66	-7.99	-0.45	5.11e-14	Menarche (age at onset);
KIRP	cis	rs2832270	0.562	rs8133819	chr21:30458754	T/C	cg24692254	chr21:30365293	RNF160	-0.58	-5.51	-0.33	9.05e-8	Response to mTOR inhibitor (everolimus);
KIRP	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15664640	chr17:80829946	TBCD	-0.71	-6.87	-0.4	5.19e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21659725	chr3:3221576	CRBN	-0.49	-6.06	-0.36	5.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs75920871	0.925	rs61903426	chr11:116968268	C/T	cg23684410	chr11:116897558	SIK3	0.51	4.99	0.3	1.12e-6	Subjective well-being;
KIRP	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.98	-11.1	-0.58	1.82e-23	Bronchopulmonary dysplasia;
KIRP	cis	rs490234	0.702	rs10120000	chr9:128288428	C/T	cg14078157	chr9:128172775	NA	-0.66	-7.79	-0.45	1.83e-13	Mean arterial pressure;
KIRP	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	1.07	17.85	0.75	2.8600000000000002e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg10818794	chr15:86012489	AKAP13	-0.49	-7.03	-0.41	1.98e-11	Coronary artery disease;
KIRP	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.59	7.72	0.44	2.99e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg02733842	chr7:1102375	C7orf50	0.56	5.81	0.35	1.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10875746	0.624	rs11168498	chr12:48655088	A/G	cg26205652	chr12:48591994	NA	0.81	10.54	0.56	1.12e-21	Longevity (90 years and older);
KIRP	trans	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.14	-0.36	3.27e-9	Neuroticism;
KIRP	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25214090	chr10:38739885	LOC399744	-0.57	-7.22	-0.42	6.28e-12	Corneal astigmatism;
KIRP	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs55788414	0.932	rs9940186	chr16:81182199	A/T	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.27	-0.47	8.2e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	cg21523751	chr1:182988639	NA	0.44	6.87	0.4	5.26e-11	Hypertriglyceridemia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06934023	chr16:587828	SOLH	0.53	6.86	0.4	5.56e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.48	6.24	0.37	1.89e-9	Childhood ear infection;
KIRP	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg16989719	chr2:238392110	NA	-0.39	-4.91	-0.3	1.63e-6	Prostate cancer;
KIRP	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg03433033	chr1:76189801	ACADM	0.41	5.83	0.35	1.7e-8	Daytime sleep phenotypes;
KIRP	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16524936	chr4:1340807	KIAA1530	-0.5	-6.38	-0.38	8.76e-10	Longevity;
KIRP	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg05347473	chr6:146136440	FBXO30	-0.58	-8.35	-0.47	5.07e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	1.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6684428	0.706	rs12138137	chr1:56325176	C/T	cg11651538	chr1:56320950	NA	-0.92	-12.62	-0.63	1.69e-28	Airflow obstruction;
KIRP	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg10169327	chr19:45448959	APOC2	-0.33	-4.94	-0.3	1.46e-6	Blood protein levels;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11245990	chr11:68621969	NA	0.37	5.02	0.3	1e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20555922	chr20:33880266	FAM83C	0.47	6.09	0.36	4.33e-9	Interleukin-4 levels;
KIRP	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg03929089	chr4:120376271	NA	-0.61	-6.14	-0.36	3.31e-9	D-dimer levels;
KIRP	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg24130564	chr14:104152367	KLC1	-0.51	-6.76	-0.4	9.7e-11	Body mass index;
KIRP	trans	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg06521331	chr12:34319734	NA	-0.58	-6.9	-0.4	4.3e-11	Bladder cancer;
KIRP	cis	rs6438504	0.922	rs6438508	chr3:118943910	A/G	cg25372693	chr3:118959985	B4GALT4	-0.32	-5.41	-0.33	1.5e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg04607699	chr11:48328132	OR4S1	-0.36	-5.05	-0.31	8.64e-7	HDL cholesterol;
KIRP	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.56	-6.5	-0.38	4.54e-10	Bipolar disorder;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13789711	chr9:139743225	PHPT1	0.66	6.09	0.36	4.31e-9	Lung function (FEV1);
KIRP	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	7.62	0.44	5.49e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.43	5.58	0.34	6.35e-8	Menopause (age at onset);
KIRP	cis	rs9972944	0.729	rs7224482	chr17:63777949	C/A	cg07283582	chr17:63770753	CCDC46	0.51	8.35	0.47	4.84e-15	Total body bone mineral density;
KIRP	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9581857	0.547	rs76435345	chr13:28107638	G/A	cg22138327	chr13:27999177	GTF3A	0.72	5.8	0.35	2.02e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9815354	1.000	rs2371623	chr3:41761083	T/C	cg03022575	chr3:42003672	ULK4	0.48	5.36	0.32	1.9e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14256536	chr9:140293439	EXD3	-0.49	-7.11	-0.41	1.23e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg05072774	chr3:49840536	C3orf54	-0.41	-4.84	-0.3	2.26e-6	Resting heart rate;
KIRP	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-5.98	-0.36	8e-9	Arsenic metabolism;
KIRP	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.67	-7.05	-0.41	1.76e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7572644	0.699	rs7577437	chr2:28168415	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.28	-0.32	2.83e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs4356932	1.000	rs4593163	chr4:76976056	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.99	17.53	0.75	3.31e-45	Breast cancer;
KIRP	cis	rs12936587	0.633	rs12949336	chr17:17509063	T/A	cg01246520	chr17:17644344	RAI1	-0.38	-5.75	-0.34	2.65e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs8133932	0.690	rs432338	chr21:47347757	C/T	cg11214348	chr21:47283868	PCBP3	-0.44	-5.13	-0.31	5.89e-7	Schizophrenia;
KIRP	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.55	-6.87	-0.4	5.26e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.71	-7.07	-0.41	1.59e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.64	-8.48	-0.48	2.15e-15	Motion sickness;
KIRP	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg20493526	chr2:3714936	ALLC	0.5	6.28	0.37	1.53e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06456538	chr6:87967386	ZNF292	-0.57	-6.33	-0.37	1.18e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.93	-9.32	-0.51	6.79e-18	Developmental language disorder (linguistic errors);
KIRP	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.72	0.39	1.28e-10	Height;
KIRP	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.56	8.04	0.46	3.68e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg10351095	chr21:47802916	PCNT	-0.41	-4.99	-0.3	1.15e-6	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg13319975	chr6:146136371	FBXO30	0.43	5.8	0.35	2.07e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.42	4.89	0.3	1.81e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg19445457	chr11:5799446	OR52N5	-0.47	-5.61	-0.34	5.3e-8	DNA methylation (variation);
KIRP	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg19847130	chr8:10466454	RP1L1	0.34	5.02	0.3	9.89e-7	Retinal vascular caliber;
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12363545	chr3:107809973	CD47	0.57	7.09	0.41	1.42e-11	Parkinson's disease;
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.76	11.87	0.6	5.41e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9653442	0.564	rs7593261	chr2:100789907	A/G	cg17356467	chr2:100759845	AFF3	0.38	5.22	0.32	3.88e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs193541	0.632	rs119449	chr5:122283741	T/G	cg19412675	chr5:122181750	SNX24	0.63	6.68	0.39	1.6e-10	Glucose homeostasis traits;
KIRP	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.22	-20.64	-0.8	1.37e-55	Breast cancer;
KIRP	cis	rs988913	0.957	rs4712081	chr6:54756529	A/G	cg03513858	chr6:54763001	FAM83B	0.43	5.87	0.35	1.4e-8	Menarche (age at onset);
KIRP	cis	rs12311304	0.965	rs7973089	chr12:15360454	A/G	cg08258403	chr12:15378311	NA	0.31	4.87	0.3	2.03e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg01244601	chr4:120671846	NA	-0.39	-5.14	-0.31	5.6e-7	Corneal astigmatism;
KIRP	cis	rs194045	0.609	rs252344	chr16:29184882	G/A	cg16691023	chr16:29205632	NA	-0.5	-6.47	-0.38	5.34e-10	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19506755	chr20:54967495	AURKA;CSTF1	-0.46	-6.14	-0.36	3.21e-9	Metabolic traits;
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	14.26	0.67	4.87e-34	Platelet count;
KIRP	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg00074818	chr8:8560427	CLDN23	0.43	6.45	0.38	6.04e-10	Obesity-related traits;
KIRP	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.48	5.83	0.35	1.77e-8	Subjective well-being;
KIRP	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	7.86	0.45	1.23e-13	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7630877	0.719	rs12489992	chr3:179664925	A/C	cg18765712	chr3:179670323	PEX5L	0.81	9.32	0.51	6.72e-18	Type 2 diabetes;
KIRP	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.51	-6.41	-0.38	7.2e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.51	5.18	0.31	4.52e-7	Obesity (extreme);
KIRP	cis	rs7116495	1.000	rs4945434	chr11:71759087	A/G	cg26138937	chr11:71823887	C11orf51	0.71	5.68	0.34	3.7e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.16	-0.46	1.75e-14	Personality dimensions;
KIRP	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.92	-12.3	-0.62	1.97e-27	Platelet distribution width;
KIRP	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg27490568	chr2:178487706	NA	0.66	8.99	0.5	6.86e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.74	9.25	0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.49	-5.39	-0.32	1.66e-7	Urate levels in overweight individuals;
KIRP	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17183009	chr3:120277827	NA	0.53	6.18	0.37	2.57e-9	Corneal astigmatism;
KIRP	cis	rs6541297	0.645	rs2296065	chr1:230301776	G/A	cg05784532	chr1:230284198	GALNT2	0.42	5.59	0.34	5.95e-8	Coronary artery disease;
KIRP	cis	rs35079168	0.961	rs66475113	chr9:137284381	C/T	cg13941235	chr9:137270186	RXRA	-0.24	-5.16	-0.31	5.11e-7	Intelligence;
KIRP	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	0.44	6.01	0.36	6.66e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.73	8.23	0.46	1.12e-14	Tourette syndrome;
KIRP	cis	rs1867631	0.585	rs12062570	chr1:67086285	T/C	cg13052034	chr1:66999238	SGIP1	0.43	6.34	0.37	1.1e-9	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg13010199	chr12:38710504	ALG10B	0.45	5.86	0.35	1.45e-8	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.75	-0.57	2.31e-22	Retinal vascular caliber;
KIRP	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.88	-10.59	-0.56	8.01e-22	Vitiligo;
KIRP	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.3	-0.37	1.4e-9	IgG glycosylation;
KIRP	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22509189	chr2:225307070	NA	-0.52	-6.01	-0.36	6.74e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg20673091	chr1:2541236	MMEL1	-0.69	-10.79	-0.57	1.84e-22	Ulcerative colitis;
KIRP	cis	rs59868192	0.925	rs2250635	chr15:42261465	T/C	cg20935245	chr15:42234343	EHD4	-0.49	-5.65	-0.34	4.34e-8	White blood cell count;
KIRP	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg12131826	chr15:77904385	NA	0.47	5.61	0.34	5.49e-8	Type 2 diabetes;
KIRP	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg03395511	chr6:291903	DUSP22	-0.54	-6.18	-0.37	2.62e-9	Menopause (age at onset);
KIRP	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg15028436	chr7:37888078	TXNDC3	0.76	10.36	0.55	4.23e-21	Alzheimer's disease (late onset);
KIRP	trans	rs877282	1.000	rs11253363	chr10:771891	A/G	cg22713356	chr15:30763199	NA	1.15	12.69	0.63	1.05e-28	Uric acid levels;
KIRP	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg00579200	chr11:133705235	NA	-0.42	-5.42	-0.33	1.4e-7	Childhood ear infection;
KIRP	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.84	-0.66	1.33e-32	Primary sclerosing cholangitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12644588	chr1:6845214	CAMTA1	0.54	6.84	0.4	6.21e-11	Parkinson's disease;
KIRP	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs7601312	0.869	rs960533	chr2:229299887	T/G	cg02542817	chr2:229291442	NA	-0.54	-8.15	-0.46	1.82e-14	Schizophrenia;
KIRP	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.93	15.7	0.71	6.19e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6708331	0.517	rs12614547	chr2:70283971	T/A	cg05298696	chr2:70188691	ASPRV1	-0.52	-6.97	-0.41	2.93e-11	Obesity-related traits;
KIRP	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.61	6.64	0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg04379409	chr6:135086445	NA	0.43	6.08	0.36	4.54e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg00629941	chr15:75287862	SCAMP5	-0.5	-5.25	-0.32	3.27e-7	Blood trace element (Zn levels);
KIRP	cis	rs662064	1.000	rs662064	chr1:10557251	T/C	cg19773385	chr1:10388646	KIF1B	0.38	5.24	0.32	3.52e-7	Asthma;
KIRP	cis	rs507506	0.712	rs1875673	chr17:7108506	T/G	cg14660024	chr17:7154518	C17orf81;DULLARD	0.52	7.15	0.41	1.01e-11	Adiponectin levels;
KIRP	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg06740227	chr12:86229804	RASSF9	0.47	5.66	0.34	4.17e-8	Major depressive disorder;
KIRP	cis	rs2997447	0.846	rs61775417	chr1:26393347	C/G	cg19633962	chr1:26362018	EXTL1	-0.74	-6.24	-0.37	1.95e-9	QRS complex (12-leadsum);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16618003	chr1:65432492	JAK1	0.57	6.9	0.4	4.46e-11	Smoking initiation;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08677398	chr8:58056175	NA	0.61	4.86	0.3	2.05e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.42e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs6142102	0.812	rs761236	chr20:32520051	A/G	cg08999081	chr20:33150536	PIGU	0.47	5.54	0.33	7.86e-8	Skin pigmentation;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05739825	chr11:125439882	EI24	0.54	6.46	0.38	5.44e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg21253087	chr9:139290292	SNAPC4	0.39	5.03	0.31	9.51e-7	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg07701084	chr6:150067640	NUP43	0.71	9.68	0.53	5.34e-19	Lung cancer;
KIRP	cis	rs2224391	1.000	rs9504369	chr6:5261575	T/C	cg13962347	chr6:5174647	LYRM4	-0.62	-8.46	-0.47	2.35e-15	Height;
KIRP	cis	rs8033133	0.560	rs12904560	chr15:25315967	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.55	-6.71	-0.39	1.3e-10	Blood osmolality (transformed sodium);
KIRP	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.79	9.7	0.53	4.67e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg21452805	chr1:244014465	NA	0.58	5.62	0.34	5.05e-8	RR interval (heart rate);
KIRP	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.67	9.94	0.54	8.4e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg18402987	chr7:1209562	NA	0.59	6.0	0.36	7.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.56	-15.56	-0.7	1.74e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg01843034	chr6:37503916	NA	-0.84	-11.77	-0.6	1.12e-25	Cognitive performance;
KIRP	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.27	0.37	1.58e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.47	6.19	0.37	2.46e-9	Red blood cell count;
KIRP	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.07	0.36	4.78e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg08975724	chr8:8085496	FLJ10661	-0.76	-10.36	-0.55	4.05e-21	Joint mobility (Beighton score);
KIRP	cis	rs860295	0.775	rs822509	chr1:155850811	G/A	cg02153340	chr1:155202674	NA	0.37	5.0	0.3	1.1e-6	Body mass index;
KIRP	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.58	-6.57	-0.39	2.99e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.08	16.46	0.72	1.56e-41	Primary sclerosing cholangitis;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg20887711	chr4:1340912	KIAA1530	0.42	4.88	0.3	1.94e-6	Obesity-related traits;
KIRP	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs7714584	1.000	rs4958852	chr5:150330631	C/T	cg22134413	chr5:150180641	NA	0.72	5.38	0.32	1.7e-7	Crohn's disease;
KIRP	cis	rs4356932	1.000	rs4422436	chr4:76977784	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.18	0.31	4.67e-7	Blood protein levels;
KIRP	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	14.04	0.67	2.78e-33	Alzheimer's disease;
KIRP	cis	rs2888674	1.000	rs2888674	chr7:150510915	G/A	cg05726600	chr7:150498594	TMEM176B;TMEM176A	0.33	5.31	0.32	2.46e-7	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
KIRP	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg17849569	chr6:28058911	ZSCAN12L1	0.39	4.85	0.3	2.15e-6	Cardiac Troponin-T levels;
KIRP	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.09e-6	Bladder cancer;
KIRP	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.57	-6.47	-0.38	5.27e-10	Breast cancer;
KIRP	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg16414030	chr3:133502952	NA	-0.44	-5.57	-0.33	6.57e-8	Iron status biomarkers;
KIRP	cis	rs17123764	0.892	rs7970674	chr12:50159712	A/G	cg20471783	chr12:50157085	TMBIM6	0.45	5.56	0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.64	-10.96	-0.57	4.89e-23	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg06953865	chr19:18549723	ISYNA1	-0.4	-6.08	-0.36	4.6e-9	Breast cancer;
KIRP	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg09165964	chr15:75287851	SCAMP5	-1.08	-7.31	-0.42	3.72e-12	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26423677	chr2:17935206	SMC6;GEN1	0.45	6.39	0.38	8.23e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.36	7.04	0.41	1.89e-11	Type 2 diabetes;
KIRP	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-9.32	-0.51	6.97e-18	Neuroticism;
KIRP	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.54	7.1	0.41	1.37e-11	Type 2 diabetes;
KIRP	cis	rs732716	0.853	rs72990643	chr19:4454736	C/T	cg03719555	chr19:4455413	UBXN6	0.49	7.46	0.43	1.44e-12	Mean corpuscular volume;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg05627522	chr15:75251581	NA	0.35	5.29	0.32	2.69e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.65	-9.83	-0.53	1.86e-19	Total body bone mineral density;
KIRP	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg15660573	chr17:549704	VPS53	-0.95	-14.9	-0.69	3.25e-36	Prostate cancer;
KIRP	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.93	12.07	0.61	1.18e-26	Primary sclerosing cholangitis;
KIRP	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg18154014	chr19:37997991	ZNF793	0.73	7.78	0.44	1.95e-13	Coronary artery calcification;
KIRP	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.53	-0.48	1.55e-15	Triglycerides;
KIRP	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-0.39	-4.99	-0.3	1.12e-6	Type 2 diabetes;
KIRP	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg04804543	chr8:142233427	SLC45A4	-0.59	-7.63	-0.44	5.28e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg04398451	chr17:18023971	MYO15A	0.7	9.33	0.51	6.26e-18	Total body bone mineral density;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.14	-0.41	1.04e-11	Triglycerides;
KIRP	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.77	-9.9	-0.53	1.12e-19	Aortic root size;
KIRP	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.89	10.59	0.56	7.9e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.67	8.57	0.48	1.15e-15	Electroencephalographic traits in alcoholism;
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg01798813	chr17:3906674	NA	-0.51	-7.02	-0.41	2.13e-11	Type 2 diabetes;
KIRP	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg10381502	chr11:71823885	C11orf51	-1.09	-7.62	-0.44	5.32e-13	Severe influenza A (H1N1) infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26519745	chr21:43639879	ABCG1	0.47	6.23	0.37	1.96e-9	Smoking initiation;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg03653399	chr8:142233436	SLC45A4	-0.94	-14.72	-0.68	1.35e-35	Immature fraction of reticulocytes;
KIRP	cis	rs812925	0.820	rs11692449	chr2:61704451	T/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.41	-0.33	1.52e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg05784532	chr1:230284198	GALNT2	0.4	6.16	0.37	3e-9	Coronary artery disease;
KIRP	cis	rs1847505	0.832	rs1967223	chr13:61520309	C/T	cg25164009	chr13:61490935	NA	-0.58	-6.43	-0.38	6.67e-10	Polychlorinated biphenyl levels;
KIRP	cis	rs12900413	0.603	rs2118848	chr15:90302503	T/C	cg24650279	chr15:90327240	NA	-0.43	-5.37	-0.32	1.84e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs2224391	0.628	rs2773316	chr6:5254448	G/A	cg13962347	chr6:5174647	LYRM4	-0.75	-10.71	-0.56	3.29e-22	Height;
KIRP	cis	rs12643440	0.574	rs62296689	chr4:17139096	G/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.64	7.13	0.41	1.11e-11	Corneal astigmatism;
KIRP	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.36	0.38	9.65e-10	Breast cancer;
KIRP	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4901847	0.643	rs1998101	chr14:58598706	T/C	cg15908186	chr14:58618357	C14orf37	0.62	8.12	0.46	2.21e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg00745463	chr17:30367425	LRRC37B	-0.79	-6.73	-0.39	1.18e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04007841	chr11:65307006	LTBP3	-0.46	-6.46	-0.38	5.57e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg01879757	chr17:41196368	BRCA1	-0.55	-7.39	-0.43	2.3e-12	Menopause (age at onset);
KIRP	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg05484376	chr2:27715224	FNDC4	0.32	4.99	0.3	1.15e-6	Total body bone mineral density;
KIRP	cis	rs12765878	1.000	rs7100920	chr10:105640978	A/G	cg11005552	chr10:105648138	OBFC1	-0.39	-5.63	-0.34	4.89e-8	Coronary artery disease;
KIRP	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg05973401	chr12:123451056	ABCB9	0.48	5.29	0.32	2.71e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg10018233	chr7:150070692	REPIN1	0.6	6.93	0.4	3.66e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.67	-0.44	3.97e-13	Lung cancer;
KIRP	cis	rs13177180	0.705	rs13153908	chr5:114937416	T/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.28	-4.9	-0.3	1.74e-6	Conotruncal heart defects (inherited effects);
KIRP	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.79	10.11	0.54	2.5e-20	Platelet count;
KIRP	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	12.01	0.61	1.9e-26	Smoking behavior;
KIRP	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg08017634	chr8:144659831	NAPRT1	0.84	5.45	0.33	1.2e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-7.88	-0.45	1.06e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	9.23	0.51	1.29e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11987759	chr7:65425863	GUSB	-0.54	-7.14	-0.41	1.04e-11	Aortic root size;
KIRP	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg25902810	chr10:99078978	FRAT1	0.59	7.28	0.42	4.39e-12	Monocyte count;
KIRP	cis	rs12461016	1	rs12461016	chr19:17161687	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.13	0.36	3.48e-9	Diastolic blood pressure;
KIRP	cis	rs7635838	0.855	rs9816564	chr3:11475297	T/C	cg00170343	chr3:11313890	ATG7	0.48	6.16	0.37	2.87e-9	HDL cholesterol;
KIRP	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.56	7.46	0.43	1.47e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg14689365	chr7:158441557	NCAPG2	0.47	5.92	0.35	1.1e-8	Height;
KIRP	cis	rs714027	0.585	rs3958027	chr22:30244835	A/T	cg01021169	chr22:30184971	ASCC2	-0.47	-5.46	-0.33	1.19e-7	Lymphocyte counts;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.81	-8.97	-0.5	7.95e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg05775895	chr3:12838266	CAND2	0.49	8.77	0.49	3.09e-16	QRS complex (12-leadsum);
KIRP	cis	rs12049351	0.774	rs6681212	chr1:229639084	A/C	cg11742688	chr1:229674241	ABCB10	-0.38	-5.96	-0.36	8.55e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg19116668	chr7:99932089	PMS2L1	0.41	5.03	0.31	9.43e-7	Coronary artery disease;
KIRP	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.52	4.85	0.3	2.14e-6	Height;
KIRP	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-11.16	-0.58	1.14e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg03605463	chr16:89740564	NA	-0.44	-5.09	-0.31	6.99e-7	Vitiligo;
KIRP	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.78	9.55	0.52	1.42e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12995491	0.933	rs13023008	chr2:88530933	G/A	cg04511125	chr2:88470314	THNSL2	-0.43	-5.35	-0.32	2.04e-7	Response to metformin (IC50);
KIRP	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg24315340	chr6:146058215	EPM2A	0.44	5.53	0.33	8.31e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.64	-0.52	7.2e-19	Response to antipsychotic treatment;
KIRP	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.51	0.52	1.87e-18	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-1.02	-12.3	-0.62	2e-27	Exhaled nitric oxide output;
KIRP	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.45	6.01	0.36	6.62e-9	Melanoma;
KIRP	cis	rs684232	0.800	rs371318	chr17:555816	A/G	cg04370829	chr17:406249	NA	0.38	5.0	0.3	1.11e-6	Prostate cancer;
KIRP	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg13736514	chr6:26305472	NA	-0.66	-8.83	-0.49	2e-16	Educational attainment;
KIRP	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.99	-0.73	2.29e-43	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19570596	chr22:29977162	NIPSNAP1	-0.42	-6.03	-0.36	6.12e-9	Metabolic traits;
KIRP	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.67	7.1	0.41	1.34e-11	Lymphocyte counts;
KIRP	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.81	10.17	0.54	1.62e-20	Menopause (age at onset);
KIRP	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.59	-7.63	-0.44	5.05e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs3857067	1.000	rs1904094	chr4:95012459	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.35	-0.32	2.02e-7	Renal cell carcinoma;
KIRP	cis	rs4663866	1.000	rs4663867	chr2:239159964	G/C	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	cis	rs2290402	1.000	rs2290402	chr4:941518	C/T	cg14517359	chr4:903473	GAK	-0.57	-5.51	-0.33	8.86e-8	Type 2 diabetes;
KIRP	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg02353165	chr6:42928485	GNMT	0.57	6.87	0.4	5.31e-11	Blood protein levels;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg05457628	chr5:178986728	RUFY1	0.63	10.39	0.55	3.27e-21	Lung cancer;
KIRP	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg24459738	chr19:57751996	ZNF805	-0.55	-6.9	-0.4	4.41e-11	Hyperactive-impulsive symptoms;
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.89	16.13	0.72	2.1e-40	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303542	0.592	rs34378400	chr17:46589265	A/G	cg04904318	chr17:46607828	HOXB1	-0.54	-6.04	-0.36	5.65e-9	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg04370829	chr17:406249	NA	0.39	4.86	0.3	2.11e-6	Prostate cancer;
KIRP	cis	rs4262150	0.846	rs113568682	chr5:152299754	A/T	cg12297329	chr5:152029980	NA	-0.64	-8.36	-0.47	4.75e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg13699009	chr12:122356056	WDR66	0.73	11.92	0.61	3.59e-26	Mean corpuscular volume;
KIRP	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	1.0	16.75	0.73	1.55e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26314531	chr2:26401878	FAM59B	0.45	4.85	0.3	2.19e-6	Gut microbiome composition (summer);
KIRP	cis	rs6594713	0.717	rs13436825	chr5:112817687	T/A	cg12552261	chr5:112820674	MCC	0.68	6.63	0.39	2.12e-10	Brain cytoarchitecture;
KIRP	cis	rs62355272	0.861	rs62355271	chr5:35846145	C/A	cg13894535	chr5:35919491	CAPSL	-0.54	-5.61	-0.34	5.42e-8	Lymphocyte counts;
KIRP	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-7.68	-0.44	3.87e-13	Monocyte percentage of white cells;
KIRP	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.69	-5.79	-0.35	2.14e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs735539	0.521	rs513795	chr13:21427448	T/C	cg04906043	chr13:21280425	IL17D	-0.43	-5.06	-0.31	8.16e-7	Dental caries;
KIRP	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15128208	chr22:42549153	NA	-0.44	-5.6	-0.34	5.73e-8	Cognitive function;
KIRP	cis	rs10875746	0.669	rs4760701	chr12:48698518	A/G	cg20731937	chr12:48336164	NA	0.46	6.36	0.38	9.83e-10	Longevity (90 years and older);
KIRP	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	1.09	10.25	0.55	9.55e-21	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg00319359	chr11:70116639	PPFIA1	0.59	6.04	0.36	5.64e-9	Coronary artery disease;
KIRP	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.45	-5.23	-0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1978968	0.912	rs5992933	chr22:18457043	G/T	cg03078520	chr22:18463400	MICAL3	-0.67	-7.71	-0.44	3.21e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.6	-8.01	-0.45	4.68e-14	Heart rate;
KIRP	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.97	-0.36	8.13e-9	Longevity;
KIRP	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.96	-8.0	-0.45	4.86e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.74	-0.34	2.73e-8	Height;
KIRP	cis	rs3796352	1.000	rs1346719	chr3:53077372	A/G	cg04865290	chr3:52927548	TMEM110	-0.45	-5.62	-0.34	5.22e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-4.85	-0.3	2.22e-6	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.12	-0.36	3.63e-9	Lung cancer;
KIRP	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.4	-5.49	-0.33	1.02e-7	Schizophrenia;
KIRP	cis	rs7870753	0.730	rs7020681	chr9:99146751	T/C	cg25260653	chr9:99212216	HABP4	0.48	5.04	0.31	8.98e-7	Height;
KIRP	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.51	-5.81	-0.35	1.91e-8	Prion diseases;
KIRP	cis	rs2979489	0.945	rs2979472	chr8:30291704	G/C	cg26383811	chr8:30366931	RBPMS	0.41	5.49	0.33	9.79e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.82	10.93	0.57	6.17e-23	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4789452	1.000	rs35971812	chr17:75373362	C/A	cg05184938	chr17:75369939	SEPT9	-0.39	-5.19	-0.31	4.38e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs8084125	1.000	rs871830	chr18:74953607	G/C	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs2071426	0.580	rs11188123	chr10:96759534	C/T	cg09036531	chr10:96991505	NA	-0.46	-5.26	-0.32	3.19e-7	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.9	0.35	1.21e-8	Life satisfaction;
KIRP	cis	rs4908768	1.000	rs4908768	chr1:8654764	G/A	cg25722041	chr1:8623473	RERE	0.85	10.49	0.56	1.56e-21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.45	6.1	0.36	4.06e-9	Dupuytren's disease;
KIRP	cis	rs10924970	0.935	rs12731746	chr1:235392546	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.82	-0.35	1.78e-8	Bipolar disorder;
KIRP	cis	rs66561647	0.520	rs12542175	chr8:128913694	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.49	5.32	0.32	2.29e-7	Hemoglobin concentration;
KIRP	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg15655495	chr12:38532458	NA	0.25	4.88	0.3	1.91e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.47	6.7	0.39	1.4e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.67	10.13	0.54	2.14e-20	Monocyte percentage of white cells;
KIRP	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.47	-5.72	-0.34	3.12e-8	Ulcerative colitis;
KIRP	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.62	-5.89	-0.35	1.29e-8	Breast cancer;
KIRP	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.67	-0.39	1.65e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg09596252	chr17:78655493	RPTOR	-0.54	-7.37	-0.43	2.62e-12	Obesity;
KIRP	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg12560992	chr17:57184187	TRIM37	0.57	5.48	0.33	1.05e-7	Cognitive test performance;
KIRP	cis	rs1832871	1.000	rs827857	chr6:158706497	C/T	cg07215822	chr6:158701037	NA	-0.49	-6.3	-0.37	1.4e-9	Height;
KIRP	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	6.72	0.39	1.27e-10	Menarche (age at onset);
KIRP	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.38	0.38	8.6e-10	Monocyte percentage of white cells;
KIRP	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.53	-6.74	-0.39	1.1e-10	Crohn's disease;
KIRP	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.77e-10	Bipolar disorder;
KIRP	cis	rs2290159	0.800	rs11711419	chr3:12667784	A/T	cg23032965	chr3:12705835	RAF1	0.78	8.52	0.48	1.6e-15	Cholesterol, total;
KIRP	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg21419209	chr3:44054225	NA	-0.71	-8.83	-0.49	2.07e-16	Coronary artery disease;
KIRP	cis	rs4748857	0.947	rs10828426	chr10:23602901	C/T	cg12804278	chr10:23633326	C10orf67	0.45	5.46	0.33	1.18e-7	Systemic lupus erythematosus;
KIRP	cis	rs6547631	0.635	rs4616480	chr2:85897768	C/T	cg07313956	chr2:85895360	SFTPB	0.38	5.59	0.34	6.13e-8	Blood protein levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg01663745	chr11:94706857	KDM4D;CWC15	-0.5	-6.16	-0.37	3.01e-9	Migraine with aura;
KIRP	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.45	-0.33	1.2e-7	Aortic root size;
KIRP	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.63	-7.48	-0.43	1.29e-12	Menarche (age at onset);
KIRP	cis	rs3752645	1.000	rs76434589	chr7:106717217	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-5.44	-0.33	1.26e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.55e-20	Dupuytren's disease;
KIRP	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.98	13.51	0.65	1.73e-31	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.52	0.33	8.65e-8	Alzheimer's disease;
KIRP	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	14.13	0.67	1.36e-33	Cognitive ability;
KIRP	cis	rs7809799	0.571	rs111251485	chr7:98958230	G/A	cg12290671	chr7:99195819	NA	-0.71	-5.37	-0.32	1.84e-7	Ulcerative colitis;
KIRP	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.6	-7.49	-0.43	1.25e-12	Iron status biomarkers;
KIRP	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg05721485	chr17:44071124	MAPT	-0.55	-7.56	-0.43	8.12e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12143943	0.834	rs10900598	chr1:204525568	G/T	cg20240347	chr1:204465584	NA	-0.35	-6.43	-0.38	6.64e-10	Cognitive performance;
KIRP	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg09184832	chr6:79620586	NA	-0.5	-7.02	-0.41	2.17e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.54	-0.48	1.43e-15	Calcium levels;
KIRP	cis	rs3789045	0.774	rs12039365	chr1:204488687	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.29	-0.37	1.42e-9	Educational attainment (college completion);
KIRP	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.39	0.38	8.1e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.8	0.45	1.78e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.6	-9.9	-0.53	1.17e-19	Prostate cancer;
KIRP	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	10.45	0.55	2.22e-21	Total body bone mineral density;
KIRP	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00300879	chr1:26503847	CNKSR1	0.48	6.85	0.4	5.85e-11	Height;
KIRP	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	7.36	0.42	2.78e-12	Menarche (age at onset);
KIRP	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.68	8.04	0.46	3.7e-14	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-11.94	-0.61	3.28e-26	Chronic sinus infection;
KIRP	cis	rs2329775	0.534	rs12701822	chr7:40479723	C/T	cg00420559	chr7:40367873	C7orf10	-0.35	-4.94	-0.3	1.47e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs997295	0.713	rs10518739	chr15:68014971	A/G	cg24579218	chr15:68104479	NA	-0.35	-5.02	-0.3	9.82e-7	Motion sickness;
KIRP	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	0.8	6.54	0.39	3.45e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg08888203	chr3:10149979	C3orf24	0.47	4.98	0.3	1.23e-6	Alzheimer's disease;
KIRP	cis	rs13082711	0.911	rs11716531	chr3:27457208	G/A	cg02860705	chr3:27208620	NA	0.57	7.72	0.44	2.96e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.92	-12.44	-0.62	6.76e-28	Platelet distribution width;
KIRP	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	Neuroticism;
KIRP	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg24747557	chr10:131355152	MGMT	0.39	5.25	0.32	3.36e-7	Response to temozolomide;
KIRP	cis	rs9948	0.881	rs3731941	chr2:97476219	A/G	cg01990225	chr2:97406019	LMAN2L	-1.1	-7.53	-0.43	9.36e-13	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.66	-0.39	1.8e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg03647239	chr10:116582469	FAM160B1	0.48	5.34	0.32	2.08e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18252515	chr7:66147081	NA	0.47	5.55	0.33	7.56e-8	Aortic root size;
KIRP	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg02820040	chr2:241836501	C2orf54	-0.23	-5.19	-0.31	4.41e-7	Urinary metabolites;
KIRP	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg06611532	chr13:114900021	NA	-0.22	-5.22	-0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg00612595	chr21:47717864	NA	-0.4	-5.09	-0.31	7.22e-7	Testicular germ cell tumor;
KIRP	cis	rs58649573	0.552	rs2075064	chr9:126783847	C/T	cg14112217	chr9:126806003	NA	0.37	5.29	0.32	2.64e-7	Post-traumatic stress disorder;
KIRP	cis	rs55962025	0.883	rs362275	chr4:3224602	C/T	cg06533319	chr4:3265114	C4orf44	0.51	5.58	0.34	6.41e-8	Parental longevity (mother's age at death);
KIRP	cis	rs7618501	0.521	rs11712056	chr3:49914397	T/C	cg05623727	chr3:50126028	RBM5	0.35	5.14	0.31	5.54e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg00042356	chr1:8021962	PARK7	-0.49	-4.95	-0.3	1.4e-6	Inflammatory bowel disease;
KIRP	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg18586891	chr4:952366	TMEM175	0.63	5.11	0.31	6.46e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.23	0.32	3.54e-7	Educational attainment;
KIRP	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.73	-8.01	-0.45	4.69e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.87	-12.0	-0.61	2.02e-26	Schizophrenia;
KIRP	cis	rs1712517	0.744	rs4293063	chr10:105052976	G/T	cg05636881	chr10:105038444	INA	0.45	6.6	0.39	2.54e-10	Migraine;
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg21186296	chr8:27182909	PTK2B	-0.48	-5.77	-0.35	2.42e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.38	0.32	1.76e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.47	7.21	0.42	6.93e-12	Resting heart rate;
KIRP	cis	rs9815354	1.000	rs9875083	chr3:41775786	T/A	cg03022575	chr3:42003672	ULK4	0.64	6.58	0.39	2.89e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.73	10.64	0.56	5.57e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00050312	chr17:64299065	PRKCA	0.54	6.23	0.37	2.03e-9	Smoking initiation;
KIRP	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg09904177	chr6:26538194	HMGN4	-0.46	-5.78	-0.35	2.29e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1867631	0.876	rs10889637	chr1:67097465	C/T	cg13052034	chr1:66999238	SGIP1	0.45	6.45	0.38	5.79e-10	Menopause (age at onset);
KIRP	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg21419209	chr3:44054225	NA	-0.75	-9.26	-0.51	1.08e-17	Coronary artery disease;
KIRP	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.97	-12.66	-0.63	1.25e-28	Homoarginine levels;
KIRP	cis	rs12230513	0.732	rs61956331	chr12:55840856	G/A	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg10189774	chr4:17578691	LAP3	0.53	6.4	0.38	7.71e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg19875535	chr5:140030758	IK	-0.69	-9.73	-0.53	3.9e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.55	-6.93	-0.4	3.6e-11	Menopause (age at onset);
KIRP	cis	rs17123764	0.818	rs11169076	chr12:49975408	G/T	cg02054252	chr12:50078554	FMNL3	0.42	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg24315340	chr6:146058215	EPM2A	0.4	5.07	0.31	7.8e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg04705907	chr1:169764193	C1orf112;C1orf156	0.5	6.12	0.36	3.6e-9	Inflammatory biomarkers;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.55	-7.21	-0.42	6.82e-12	Longevity;Endometriosis;
KIRP	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg15534755	chr11:117069859	TAGLN	0.41	4.93	0.3	1.54e-6	Blood protein levels;
KIRP	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg04727924	chr7:799746	HEATR2	0.67	6.33	0.37	1.17e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.26	-0.42	5.05e-12	Body mass index;
KIRP	cis	rs6753739	0.745	rs7572601	chr2:220019484	T/C	cg01749213	chr2:219906749	CCDC108	0.4	4.99	0.3	1.14e-6	Height;
KIRP	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg00405596	chr8:11794950	NA	0.44	5.51	0.33	9.08e-8	Retinal vascular caliber;
KIRP	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24229701	chr12:130821962	PIWIL1	0.43	5.57	0.33	6.54e-8	Menopause (age at onset);
KIRP	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.77	9.83	0.53	1.92e-19	Gestational age at birth (maternal effect);
KIRP	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg05370193	chr1:21551575	ECE1	0.43	6.02	0.36	6.27e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.25	0.74	2.99e-44	Platelet count;
KIRP	cis	rs57338032	0.891	rs16969874	chr15:78754863	T/C	cg06917634	chr15:78832804	PSMA4	0.56	4.95	0.3	1.41e-6	CTACK levels;
KIRP	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg00677455	chr12:58241039	CTDSP2	-0.52	-5.8	-0.35	2.06e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.62	7.74	0.44	2.51e-13	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.9	14.32	0.67	3e-34	IgG glycosylation;
KIRP	cis	rs6690583	0.524	rs12045710	chr1:85451765	T/C	cg22153463	chr1:85462885	MCOLN2	0.59	5.37	0.32	1.84e-7	Serum sulfate level;
KIRP	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg18882449	chr10:104885122	NT5C2	-0.38	-4.89	-0.3	1.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg05774290	chr12:31811203	C12orf72	-0.42	-6.28	-0.37	1.56e-9	Inflammatory biomarkers;
KIRP	cis	rs4073221	0.789	rs4333081	chr3:18245616	C/T	cg07694806	chr3:18168406	NA	-0.79	-6.73	-0.39	1.18e-10	Parkinson's disease;
KIRP	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg04310649	chr10:35416472	CREM	-0.52	-5.93	-0.35	1.03e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg08975724	chr8:8085496	FLJ10661	0.48	5.11	0.31	6.41e-7	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08880486	chr17:66287505	ARSG;SLC16A6	-0.45	-6.53	-0.38	3.74e-10	Metabolic traits;
KIRP	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.53	7.46	0.43	1.46e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg24060327	chr5:131705240	SLC22A5	-0.54	-7.2	-0.42	7.35e-12	Blood metabolite levels;
KIRP	cis	rs1434579	0.865	rs12983645	chr19:44943239	A/G	cg15540054	chr19:45004280	ZNF180	0.54	5.8	0.35	2e-8	Tuberculosis;
KIRP	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.5	-6.73	-0.39	1.18e-10	Mean corpuscular volume;
KIRP	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.16	0.37	2.92e-9	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg16586182	chr3:47516702	SCAP	-0.72	-10.22	-0.55	1.16e-20	Colorectal cancer;
KIRP	cis	rs1355223	0.902	rs1258464	chr11:34731496	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.75e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-7.59	-0.44	6.76e-13	Platelet count;
KIRP	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg10755058	chr3:40428713	ENTPD3	-0.39	-5.23	-0.32	3.56e-7	Renal cell carcinoma;
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.58	5.32	0.32	2.3e-7	Alzheimer's disease;
KIRP	cis	rs2131877	0.599	rs28573813	chr3:194846413	G/A	cg19775763	chr3:194786989	NA	-0.44	-5.42	-0.33	1.42e-7	Non-small cell lung cancer;
KIRP	cis	rs8018808	0.935	rs2242619	chr14:77895119	C/T	cg20045696	chr14:77926864	AHSA1	-0.45	-5.5	-0.33	9.57e-8	Myeloid white cell count;
KIRP	cis	rs12044355	0.927	rs11577035	chr1:231835941	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	5.5	0.33	9.3e-8	Alzheimer's disease;
KIRP	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.16	-0.31	4.99e-7	Gut microbiome composition (summer);
KIRP	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg16867584	chr19:49200180	FUT2	0.31	4.96	0.3	1.34e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19717773	chr7:2847554	GNA12	-0.38	-5.76	-0.34	2.56e-8	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15844443	chr14:91132167	TTC7B	0.46	6.58	0.39	2.83e-10	Interleukin-4 levels;
KIRP	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg27205649	chr11:78285834	NARS2	0.68	9.02	0.5	5.33e-17	Alzheimer's disease (survival time);
KIRP	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg04935436	chr20:30431758	NA	-0.37	-5.0	-0.3	1.1e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg20387954	chr3:183756860	HTR3D	-0.45	-6.48	-0.38	4.92e-10	Anterior chamber depth;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02593601	chr10:17707418	STAM	0.4	6.11	0.36	3.89e-9	C-reactive protein;
KIRP	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.48	6.65	0.39	1.85e-10	Red blood cell count;
KIRP	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Morning vs. evening chronotype;
KIRP	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg11663144	chr21:46675770	NA	-0.55	-7.01	-0.41	2.28e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17253792	0.545	rs35418987	chr14:56017407	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.66	0.34	4.29e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg06115741	chr20:33292138	TP53INP2	-0.38	-5.08	-0.31	7.64e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.03	13.34	0.65	6.39e-31	Exhaled nitric oxide output;
KIRP	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.46	6.13	0.36	3.46e-9	Monocyte count;
KIRP	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg04731861	chr2:219085781	ARPC2	-0.28	-7.01	-0.41	2.32e-11	Colorectal cancer;
KIRP	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg05756136	chr1:119680316	WARS2	-0.61	-8.07	-0.46	3.12e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Parkinson's disease;
KIRP	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg00334542	chr7:100209784	MOSPD3	-0.52	-4.96	-0.3	1.29e-6	Other erythrocyte phenotypes;
KIRP	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg05802129	chr4:122689817	NA	-0.45	-6.55	-0.39	3.3e-10	Type 2 diabetes;
KIRP	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg18825076	chr15:78729989	IREB2	-0.43	-5.0	-0.3	1.11e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs3737883	1.000	rs7538696	chr1:203034309	G/A	cg03900565	chr1:203031815	PPFIA4	0.41	5.92	0.35	1.09e-8	Early onset atrial fibrillation;
KIRP	trans	rs1106684	1.000	rs11768883	chr7:131464527	T/C	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs4006360	0.551	rs2320193	chr17:39243414	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs911119	0.657	rs2145231	chr20:23625547	A/G	cg16589663	chr20:23618590	CST3	-0.56	-4.87	-0.3	2e-6	Chronic kidney disease;
KIRP	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg07843065	chr1:150265600	MRPS21	0.42	5.82	0.35	1.78e-8	Migraine;
KIRP	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	1.1	21.85	0.81	1.46e-59	Height;
KIRP	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg04731861	chr2:219085781	ARPC2	-0.23	-5.64	-0.34	4.76e-8	Colorectal cancer;
KIRP	cis	rs4356932	0.934	rs4859603	chr4:76965747	A/G	cg00809888	chr4:76862425	NAAA	0.43	5.93	0.35	1.02e-8	Blood protein levels;
KIRP	cis	rs282587	0.502	rs393320	chr13:113396469	C/A	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.82e-12	Glycated hemoglobin levels;
KIRP	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.13	0.64	3.37e-30	Bladder cancer;
KIRP	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.69	7.31	0.42	3.7e-12	Bipolar disorder;
KIRP	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.19	-0.31	4.35e-7	Body mass index;
KIRP	cis	rs3820928	0.904	rs2195487	chr2:227759720	G/C	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.02	-0.36	6.23e-9	Pulmonary function;
KIRP	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.87	0.4	5.12e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg00495681	chr13:53174319	NA	-0.37	-5.0	-0.3	1.07e-6	Lewy body disease;
KIRP	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg02733842	chr7:1102375	C7orf50	-0.54	-6.15	-0.37	3.12e-9	Bronchopulmonary dysplasia;
KIRP	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	9.08	0.5	3.68e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg19468946	chr17:37922297	IKZF3	-0.45	-6.34	-0.37	1.11e-9	Self-reported allergy;
KIRP	cis	rs2273669	0.667	rs17070136	chr6:109350550	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.59	-0.34	6.07e-8	Testicular germ cell tumor;
KIRP	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.25	0.32	3.36e-7	Educational attainment;
KIRP	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg23995753	chr2:160760732	LY75	0.4	5.46	0.33	1.16e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg24488311	chr11:68621650	NA	0.5	6.09	0.36	4.2e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9815354	1.000	rs2128834	chr3:41862645	A/G	cg03022575	chr3:42003672	ULK4	0.58	6.7	0.39	1.44e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.41	5.55	0.33	7.28e-8	Endometrial cancer;
KIRP	cis	rs3736485	0.966	rs4774595	chr15:51893161	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.15	-0.31	5.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs501120	0.584	rs61855739	chr10:44679603	G/A	cg09554077	chr10:44749378	NA	0.57	5.95	0.35	9.05e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9810890	1.000	rs73198828	chr3:128489894	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs7084402	0.967	rs1649019	chr10:60288111	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs829883	0.932	rs249840	chr12:98871993	T/C	cg25150519	chr12:98850993	NA	0.87	13.15	0.64	2.97e-30	Colorectal adenoma (advanced);
KIRP	cis	rs9905704	0.633	rs2680712	chr17:56509865	C/T	cg12560992	chr17:57184187	TRIM37	0.51	5.2	0.31	4.23e-7	Testicular germ cell tumor;
KIRP	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-7.41	-0.43	2.06e-12	Systemic lupus erythematosus;
KIRP	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.7	-12.88	-0.63	2.42e-29	Body mass index;
KIRP	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg00262122	chr8:11665843	FDFT1	0.39	4.92	0.3	1.61e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.7	-9.06	-0.5	4.24e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.62	8.1	0.46	2.57e-14	Height;
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20887711	chr4:1340912	KIAA1530	0.49	6.15	0.36	3.19e-9	Longevity;
KIRP	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg23335576	chr14:104009727	NA	0.37	5.13	0.31	5.79e-7	Body mass index;
KIRP	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	5.76	0.34	2.55e-8	Bipolar disorder;
KIRP	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg06243866	chr13:111019493	COL4A2	0.64	9.39	0.51	4.23e-18	White matter hyperintensity burden;
KIRP	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg21640587	chr11:117668038	DSCAML1	0.45	6.87	0.4	5.31e-11	Myopia;
KIRP	cis	rs9896933	0.943	rs6502023	chr17:80909608	T/G	cg20578329	chr17:80767326	TBCD	0.74	7.11	0.41	1.28e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg22256960	chr15:77711686	NA	-0.44	-5.61	-0.34	5.51e-8	Type 2 diabetes;
KIRP	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.14	9.14	0.5	2.44e-17	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.46	-9.13	-0.5	2.53e-17	Rheumatoid arthritis;
KIRP	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg23594656	chr7:65796392	TPST1	0.5	7.71	0.44	3.17e-13	Aortic root size;
KIRP	cis	rs7640424	0.721	rs162064	chr3:107824061	G/T	cg09227934	chr3:107805635	CD47	-0.29	-5.04	-0.31	9.17e-7	Body mass index;
KIRP	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.48	-6.55	-0.39	3.32e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg05342682	chr7:94953680	PON1	-0.45	-4.97	-0.3	1.28e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg08992911	chr2:238395768	MLPH	0.42	5.17	0.31	4.89e-7	Prostate cancer;
KIRP	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg15117754	chr3:10150083	C3orf24	0.56	5.31	0.32	2.42e-7	Alzheimer's disease;
KIRP	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg24253500	chr15:84953950	NA	0.5	5.72	0.34	3.08e-8	Schizophrenia;
KIRP	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.37	0.43	2.56e-12	Aortic root size;
KIRP	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.31	9.77e-7	Initial pursuit acceleration;
KIRP	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.58	-9.43	-0.52	3.13e-18	Prostate cancer;
KIRP	cis	rs13095912	0.512	rs115865582	chr3:185308598	A/C	cg11274856	chr3:185301563	NA	0.6	7.55	0.43	8.75e-13	Systolic blood pressure;
KIRP	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	6.75	0.4	1.06e-10	Educational attainment;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02073427	chr10:15252052	NA	-0.46	-6.3	-0.37	1.33e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.51	0.56	1.39e-21	Exhaled nitric oxide output;
KIRP	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	1e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs10073892	0.511	rs17334060	chr5:101883087	C/T	cg19774478	chr5:101632501	SLCO4C1	0.51	5.58	0.34	6.27e-8	Cognitive decline (age-related);
KIRP	cis	rs12476592	0.602	rs2121351	chr2:63828361	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.15	-0.31	5.47e-7	Childhood ear infection;
KIRP	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.82	-0.35	1.81e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs372883	0.967	rs1153287	chr21:30685611	C/T	cg24692254	chr21:30365293	RNF160	-0.39	-5.08	-0.31	7.58e-7	Pancreatic cancer;
KIRP	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.83	11.8	0.6	9.08e-26	Monocyte count;
KIRP	cis	rs7555523	0.778	rs4233408	chr1:165712960	G/A	cg24409356	chr1:165738333	TMCO1	0.51	4.95	0.3	1.36e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.89	-0.35	1.24e-8	Renal cell carcinoma;
KIRP	cis	rs6681460	0.649	rs1415984	chr1:67002117	A/G	cg02459107	chr1:67143332	SGIP1	0.39	5.31	0.32	2.41e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg19274270	chr17:78178856	CARD14	-0.37	-6.73	-0.39	1.15e-10	Morning vs. evening chronotype;
KIRP	cis	rs13006833	0.668	rs906916	chr2:191166212	G/A	cg21644426	chr2:191273491	MFSD6	0.45	5.59	0.34	5.94e-8	Urinary metabolites;
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.5	-7.03	-0.41	1.97e-11	Obesity-related traits;
KIRP	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg04935436	chr20:30431758	NA	0.48	5.81	0.35	1.95e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.71	9.85	0.53	1.62e-19	Mean corpuscular volume;
KIRP	cis	rs7267005	1.000	rs7274069	chr20:34456679	A/G	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.66	-0.39	1.8e-10	Height;
KIRP	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07754999	chr10:103991057	PITX3	0.41	6.16	0.37	2.95e-9	Parkinson's disease;
KIRP	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.65	9.85	0.53	1.68e-19	Age-related hearing impairment;
KIRP	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg23995753	chr2:160760732	LY75	-0.41	-5.59	-0.34	5.98e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.63	-10.24	-0.55	1.01e-20	Morning vs. evening chronotype;
KIRP	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.38	-0.51	4.7e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg04865290	chr3:52927548	TMEM110	-0.43	-5.51	-0.33	8.86e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	12.42	0.62	8.29e-28	Menarche (age at onset);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg22114827	chr17:4852349	PFN1	-0.46	-6.21	-0.37	2.23e-9	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.88	9.81	0.53	2.15e-19	Gut microbiome composition (summer);
KIRP	cis	rs56079296	0.636	rs10040971	chr5:121404787	C/T	cg01191064	chr5:121408893	LOX	-0.52	-5.0	-0.3	1.07e-6	Coronary artery disease;
KIRP	cis	rs17123764	0.818	rs73305008	chr12:49958911	G/A	cg20471783	chr12:50157085	TMBIM6	0.31	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.65	-8.04	-0.46	3.89e-14	Aortic root size;
KIRP	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	10.57	0.56	8.79e-22	Chronic sinus infection;
KIRP	cis	rs1215050	0.791	rs260889	chr4:98742340	A/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg15605315	chr1:45957053	TESK2	-0.48	-6.13	-0.36	3.53e-9	High light scatter reticulocyte count;
KIRP	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.54	7.54	0.43	8.96e-13	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	4.91	0.3	1.69e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.54	7.38	0.43	2.5e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg00405596	chr8:11794950	NA	0.49	6.02	0.36	6.16e-9	Monocyte count;
KIRP	cis	rs714027	0.585	rs2007446	chr22:30388601	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-4.99	-0.3	1.13e-6	Lymphocyte counts;
KIRP	cis	rs1359582	0.793	rs2182304	chr10:90398927	C/T	cg15661332	chr10:90342814	RNLS	0.56	5.94	0.35	9.84e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	trans	rs2270927	0.510	rs35984318	chr5:75573566	T/G	cg13563193	chr19:33072644	PDCD5	0.93	6.88	0.4	4.95e-11	Mean corpuscular volume;
KIRP	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.67	9.69	0.53	5.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.54	-6.52	-0.38	3.97e-10	Eosinophil percentage of white cells;
KIRP	cis	rs12230513	0.732	rs7971742	chr12:55848486	A/G	cg11794356	chr12:55725991	OR6C3	-0.51	-6.24	-0.37	1.93e-9	Contrast sensitivity;
KIRP	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.74	-7.41	-0.43	2.08e-12	Vitiligo;
KIRP	cis	rs831571	1.000	rs831571	chr3:64048297	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.52	5.11	0.31	6.41e-7	Type 2 diabetes;
KIRP	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	1.0	10.98	0.57	4.31e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg24209194	chr3:40518798	ZNF619	-0.39	-4.99	-0.3	1.16e-6	Renal cell carcinoma;
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.52	6.91	0.4	4.06e-11	Breast cancer;
KIRP	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.2	0.46	1.34e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg00262122	chr8:11665843	FDFT1	-0.41	-5.1	-0.31	6.91e-7	Retinal vascular caliber;
KIRP	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg13119609	chr19:45449297	APOC2	0.41	5.16	0.31	5.08e-7	Blood protein levels;
KIRP	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg09029085	chr17:47094198	IGF2BP1	0.25	5.65	0.34	4.53e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17507749	chr15:85114479	UBE2QP1	0.72	8.1	0.46	2.53e-14	Schizophrenia;
KIRP	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs6032067	0.929	rs1997892	chr20:43810961	A/T	cg10761708	chr20:43804764	PI3	0.48	5.33	0.32	2.23e-7	Blood protein levels;
KIRP	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.61	-0.34	5.51e-8	IgG glycosylation;
KIRP	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.9	-14.1	-0.67	1.79e-33	Total body bone mineral density;
KIRP	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08508325	chr11:3079039	CARS	0.32	5.87	0.35	1.4e-8	Calcium levels;
KIRP	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg08603382	chr10:743973	NA	-0.61	-9.41	-0.51	3.79e-18	Psychosis in Alzheimer's disease;
KIRP	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg27205649	chr11:78285834	NARS2	-0.62	-7.81	-0.45	1.63e-13	Alzheimer's disease (survival time);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00078940	chr5:134734932	H2AFY	0.5	6.44	0.38	6.28e-10	Parkinson's disease;
KIRP	cis	rs7534824	0.625	rs61780328	chr1:101458754	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.03	0.41	2.07e-11	Refractive astigmatism;
KIRP	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.58	7.37	0.43	2.6e-12	Menarche (age at onset);
KIRP	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.63	-6.98	-0.41	2.69e-11	Neuroticism;
KIRP	trans	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg06521331	chr12:34319734	NA	-0.6	-7.13	-0.41	1.08e-11	Bladder cancer;
KIRP	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-9.9	-0.53	1.14e-19	Body mass index;
KIRP	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	1.12	17.09	0.74	1.08e-43	Cognitive function;
KIRP	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	6.02	0.36	6.2e-9	Multiple sclerosis;
KIRP	cis	rs13102973	0.931	rs12643821	chr4:135859614	A/G	cg14419869	chr4:135874104	NA	-0.6	-10.44	-0.55	2.32e-21	Subjective well-being;
KIRP	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg25772418	chr12:131519998	GPR133	-0.4	-5.64	-0.34	4.61e-8	Longevity;
KIRP	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.37	-5.85	-0.35	1.6e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15769486	chr2:85132558	TMSB10	-0.46	-6.04	-0.36	5.63e-9	Myopia;
KIRP	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.42	5.49	0.33	9.81e-8	Neutrophil percentage of white cells;
KIRP	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs8113308	0.810	rs56029016	chr19:52452462	T/A	cg24732339	chr19:52471368	ZNF350	-0.45	-4.93	-0.3	1.52e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg18806716	chr10:30721971	MAP3K8	-0.36	-5.61	-0.34	5.31e-8	Itch intensity from mosquito bite;
KIRP	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.43	7.35	0.42	2.86e-12	Renal cell carcinoma;
KIRP	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.55	6.93	0.4	3.62e-11	Resting heart rate;
KIRP	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.73	-0.39	1.16e-10	Type 2 diabetes;
KIRP	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.06	-0.46	3.29e-14	Mood instability;
KIRP	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.68	9.05	0.5	4.63e-17	Height;
KIRP	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-9.56	-0.52	1.31e-18	Joint mobility (Beighton score);
KIRP	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.59	7.96	0.45	6.5e-14	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Diabetic kidney disease;
KIRP	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.33	8.71	0.49	4.51e-16	Crohn's disease;
KIRP	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg21518248	chr2:162101506	NA	0.49	5.79	0.35	2.09e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg25182066	chr10:30743637	MAP3K8	-0.64	-8.78	-0.49	2.74e-16	Inflammatory bowel disease;
KIRP	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.61	-8.15	-0.46	1.91e-14	Total body bone mineral density;
KIRP	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg26811252	chr16:29126840	RRN3P2	0.64	8.74	0.49	3.69e-16	Menopause (age at onset);
KIRP	cis	rs9584850	0.520	rs10508036	chr13:99157398	C/G	cg20750642	chr13:99100586	FARP1	0.5	5.36	0.32	1.93e-7	Neuroticism;
KIRP	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	trans	rs12517041	1.000	rs10059818	chr5:23292940	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg08461772	chr7:95026248	PON3	0.42	6.09	0.36	4.38e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7561273	0.609	rs6545285	chr2:24340029	T/C	cg20701182	chr2:24300061	SF3B14	0.49	6.09	0.36	4.32e-9	Quantitative traits;
KIRP	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.7	8.44	0.47	2.68e-15	Aortic root size;
KIRP	cis	rs2249694	0.520	rs7095996	chr10:135328948	G/A	cg20169779	chr10:135381914	SYCE1	-0.58	-6.36	-0.38	9.56e-10	Obesity-related traits;
KIRP	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg24881330	chr22:46731750	TRMU	0.68	5.26	0.32	3.19e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-4.92	-0.3	1.57e-6	Menarche (age at onset);
KIRP	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.42	4.89e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg09238746	chr17:78121135	EIF4A3	-0.4	-4.96	-0.3	1.29e-6	Yeast infection;
KIRP	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	8.34	0.47	5.2e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6438504	0.922	rs4422294	chr3:118948716	G/A	cg25372693	chr3:118959985	B4GALT4	0.34	5.53	0.33	8.22e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.76	9.47	0.52	2.43e-18	White matter hyperintensity burden;
KIRP	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24838063	chr12:130822603	PIWIL1	0.52	6.19	0.37	2.52e-9	Menopause (age at onset);
KIRP	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.51	-6.41	-0.38	7.43e-10	Dilated cardiomyopathy;
KIRP	cis	rs2070997	0.938	rs6597644	chr9:133744911	C/T	cg03924115	chr9:133768966	QRFP	0.33	4.89	0.3	1.8e-6	Response to amphetamines;
KIRP	cis	rs55962025	0.842	rs362272	chr4:3234980	C/T	cg13731523	chr4:3047190	NA	0.32	4.87	0.3	1.97e-6	Parental longevity (mother's age at death);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15377988	chr22:37594933	NA	0.51	6.4	0.38	7.66e-10	Parkinson's disease;
KIRP	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg12179176	chr11:130786555	SNX19	0.66	7.51	0.43	1.11e-12	Schizophrenia;
KIRP	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.02	0.31	9.74e-7	Schizophrenia;
KIRP	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg11031976	chr2:198649780	BOLL	-0.5	-4.9	-0.3	1.74e-6	Ulcerative colitis;
KIRP	cis	rs42648	0.564	rs11563564	chr7:89816701	A/G	cg25739043	chr7:89950458	NA	-0.35	-5.41	-0.33	1.52e-7	Homocysteine levels;
KIRP	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs78487399	0.908	rs12474030	chr2:43812317	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-5.34	-0.32	2.14e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20356664	chr18:3262530	MYL12B	0.5	6.23	0.37	1.96e-9	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg05562828	chr17:3906858	NA	0.73	14.53	0.68	5.97e-35	Type 2 diabetes;
KIRP	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.39	-0.43	2.29e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg06115741	chr20:33292138	TP53INP2	-0.38	-5.15	-0.31	5.36e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6142102	0.625	rs2050208	chr20:32543573	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.63	7.74	0.44	2.64e-13	Mosquito bite size;
KIRP	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.63	8.2	0.46	1.37e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.34	-0.42	3.12e-12	Neuroticism;
KIRP	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg15880211	chr22:50250494	ZBED4	-0.68	-7.66	-0.44	4.2e-13	Schizophrenia;
KIRP	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg24747557	chr10:131355152	MGMT	-0.43	-5.85	-0.35	1.52e-8	Response to temozolomide;
KIRP	cis	rs15676	0.783	rs2997917	chr9:131586918	G/A	cg00228799	chr9:131580591	ENDOG	0.57	6.38	0.38	8.5e-10	Blood metabolite levels;
KIRP	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.61	8.43	0.47	3.02e-15	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22352273	chr2:238969464	SCLY	0.46	6.9	0.4	4.26e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1971762	0.527	rs4759211	chr12:53930945	T/C	cg16917193	chr12:54089295	NA	0.66	10.62	0.56	6.07e-22	Height;
KIRP	cis	rs6001982	0.748	rs5995860	chr22:40852671	A/G	cg07138101	chr22:40742427	ADSL	0.69	5.75	0.34	2.64e-8	Breast cancer;
KIRP	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00889227	chr1:205173544	DSTYK	-0.37	-5.23	-0.32	3.66e-7	Red blood cell count;
KIRP	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg10818794	chr15:86012489	AKAP13	-0.5	-7.14	-0.41	1.03e-11	Coronary artery disease;
KIRP	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg19468946	chr17:37922297	IKZF3	-0.5	-6.89	-0.4	4.56e-11	Self-reported allergy;
KIRP	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.41	0.33	1.52e-7	Alzheimer's disease;
KIRP	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.36	5.21	0.32	3.98e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg26876637	chr1:152193138	HRNR	0.72	9.37	0.51	4.87e-18	Atopic dermatitis;
KIRP	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg18154014	chr19:37997991	ZNF793	0.69	7.6	0.44	6.3e-13	Coronary artery calcification;
KIRP	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg21285383	chr16:89894308	SPIRE2	0.29	5.5	0.33	9.27e-8	Vitiligo;
KIRP	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.55	5.51	0.33	9e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs514024	0.700	rs538927	chr9:130488494	C/T	cg13643465	chr9:130375613	STXBP1	0.42	5.67	0.34	3.92e-8	Eating disorders (purging via substances);
KIRP	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.12	-0.41	1.18e-11	Type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg01620082	chr3:125678407	NA	-1.17	-7.48	-0.43	1.33e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg08822215	chr16:89438651	ANKRD11	-0.52	-6.73	-0.39	1.17e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.7	8.29	0.47	7.55e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.47	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.99	-0.57	3.93e-23	Height;
KIRP	trans	rs35607894	0.500	rs2283422	chr14:72462202	A/G	cg09954251	chr8:1278972	NA	0.59	6.41	0.38	7.47e-10	Schizophrenia;
KIRP	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg26566898	chr11:117069891	TAGLN	0.41	5.33	0.32	2.17e-7	Blood protein levels;
KIRP	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.41	-7.39	-0.43	2.29e-12	Refractive error;
KIRP	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg16586182	chr3:47516702	SCAP	0.83	11.16	0.58	1.12e-23	Colorectal cancer;
KIRP	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.19	-0.51	1.68e-17	Mean corpuscular volume;
KIRP	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg03929089	chr4:120376271	NA	-0.53	-6.54	-0.38	3.44e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.73	9.41	0.51	3.73e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.63	5.19	0.31	4.44e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7635838	0.785	rs2574698	chr3:11557126	G/A	cg00170343	chr3:11313890	ATG7	0.44	5.4	0.33	1.57e-7	HDL cholesterol;
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.65	-7.76	-0.44	2.29e-13	Menopause (age at onset);
KIRP	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg18655438	chr5:1077845	SLC12A7	-0.43	-5.2	-0.31	4.25e-7	QT interval;
KIRP	cis	rs2548003	0.518	rs2554901	chr5:28733310	T/C	cg11015470	chr5:28928158	NA	0.44	5.06	0.31	8.37e-7	Hip geometry;
KIRP	cis	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.74	-0.39	1.1e-10	Atopic dermatitis;
KIRP	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs9886651	0.935	rs28660151	chr8:128803578	A/T	cg24514600	chr8:128805414	PVT1	-0.73	-12.62	-0.63	1.71e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	1.2	12.55	0.62	3.06e-28	Alzheimer's disease;
KIRP	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.99	-14.13	-0.67	1.33e-33	Ulcerative colitis;
KIRP	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.57	7.12	0.41	1.18e-11	Breast cancer;
KIRP	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-8.1	-0.46	2.6e-14	Menarche (age at onset);
KIRP	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg00405596	chr8:11794950	NA	-0.48	-6.35	-0.38	1.06e-9	Retinal vascular caliber;
KIRP	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.78	10.06	0.54	3.62e-20	Neutrophil percentage of white cells;
KIRP	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.28	-0.32	2.82e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9815354	0.812	rs59146151	chr3:41949301	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg09624528	chr10:1369823	ADARB2	0.45	5.63	0.34	4.8e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs17213078	0.602	rs4851113	chr2:106747009	G/C	cg16099169	chr2:106886729	NA	0.42	5.99	0.36	7.36e-9	Facial morphology (factor 23);
KIRP	cis	rs11252926	0.732	rs10904541	chr10:744008	A/G	cg03684893	chr10:554711	DIP2C	0.38	5.07	0.31	7.69e-7	Psychosis in Alzheimer's disease;
KIRP	trans	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg02487422	chr3:49467188	NICN1	0.37	4.99	0.3	1.14e-6	Parkinson's disease;
KIRP	cis	rs9581857	0.547	rs9579096	chr13:28084069	T/C	cg22138327	chr13:27999177	GTF3A	0.85	6.58	0.39	2.85e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-10.03	-0.54	4.66e-20	Colorectal cancer;
KIRP	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.65	-9.24	-0.51	1.23e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2554380	0.943	rs2401128	chr15:84347178	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.3	-0.47	6.74e-15	Height;
KIRP	cis	rs6120849	0.901	rs6060270	chr20:33736814	G/T	cg24642439	chr20:33292090	TP53INP2	0.62	6.77	0.4	9.42e-11	Protein C levels;
KIRP	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.62	6.16	0.37	2.96e-9	Plateletcrit;
KIRP	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.52	-5.59	-0.34	5.95e-8	Body mass index;
KIRP	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg21174375	chr14:64681225	SYNE2	0.53	6.23	0.37	2.05e-9	Atrial fibrillation;
KIRP	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg13206674	chr6:150067644	NUP43	0.64	8.73	0.49	3.93e-16	Lung cancer;
KIRP	cis	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg20368463	chr18:77673604	PQLC1	-0.71	-9.74	-0.53	3.54e-19	Schizophrenia;
KIRP	cis	rs2274273	0.682	rs7141975	chr14:55542216	G/C	cg04306507	chr14:55594613	LGALS3	0.41	6.25	0.37	1.79e-9	Protein biomarker;
KIRP	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg24807547	chr6:37504484	NA	-0.62	-10.0	-0.54	5.65e-20	Cognitive performance;
KIRP	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.98	-12.67	-0.63	1.16e-28	Platelet distribution width;
KIRP	cis	rs5758511	0.731	rs12158579	chr22:42351289	C/T	cg15128208	chr22:42549153	NA	0.59	6.7	0.39	1.42e-10	Birth weight;
KIRP	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.28	-0.37	1.49e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.95e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg23587288	chr2:27483067	SLC30A3	0.59	7.16	0.42	9.57e-12	Blood metabolite levels;
KIRP	cis	rs59868192	0.925	rs2598469	chr15:42256589	T/C	cg20935245	chr15:42234343	EHD4	-0.5	-5.68	-0.34	3.7e-8	White blood cell count;
KIRP	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg11382394	chr1:2564504	MMEL1	0.38	4.88	0.3	1.89e-6	Ulcerative colitis;
KIRP	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.88	8.56	0.48	1.23e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs7172677	0.737	rs12442410	chr15:75437510	G/A	cg14082893	chr15:75400931	NA	0.34	5.02	0.31	9.7e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4638749	0.501	rs2171181	chr2:108750391	G/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.92	-0.3	1.57e-6	Blood pressure;
KIRP	cis	rs67385638	0.855	rs3759074	chr11:5257778	C/T	cg12559170	chr11:5275217	HBG2	0.39	5.37	0.32	1.86e-7	Hemoglobin levels;
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs240764	0.746	rs151572	chr6:101110984	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.68	-9.21	-0.51	1.5e-17	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-15.74	-0.71	4.36e-39	Coronary artery disease;
KIRP	trans	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg21775007	chr8:11205619	TDH	-0.49	-6.55	-0.39	3.37e-10	Mood instability;
KIRP	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg14541582	chr5:601475	NA	-0.55	-6.14	-0.36	3.33e-9	Obesity-related traits;
KIRP	cis	rs17221829	0.764	rs12146462	chr11:89385374	T/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.92e-7	Anxiety in major depressive disorder;
KIRP	cis	rs11264213	1.000	rs727005	chr1:36281336	A/G	cg27506609	chr1:36549197	TEKT2	0.75	7.22	0.42	6.45e-12	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg01721255	chr8:58191610	C8orf71	0.54	5.24	0.32	3.4e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13606616	chr19:45926999	ERCC1	0.5	6.34	0.37	1.1e-9	Parkinson's disease;
KIRP	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.43	-0.38	6.48e-10	Aortic root size;
KIRP	cis	rs929596	0.564	rs2741034	chr2:234548814	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-5.43	-0.33	1.33e-7	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	cg12689670	chr1:183009347	LAMC1	0.48	6.91	0.4	4.24e-11	Colorectal cancer;
KIRP	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.7	11.01	0.57	3.56e-23	Metabolite levels;
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg21698718	chr17:80085957	CCDC57	-0.34	-4.99	-0.3	1.16e-6	Life satisfaction;
KIRP	cis	rs4594175	0.926	rs11157804	chr14:51630340	A/G	cg23942311	chr14:51606299	NA	-0.54	-7.08	-0.41	1.51e-11	Cancer;
KIRP	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.41	-7.39	-0.43	2.29e-12	Refractive error;
KIRP	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg04087571	chr11:116723030	SIK3	-0.26	-5.56	-0.33	6.84e-8	Subjective well-being;
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13939156	chr17:80058883	NA	0.49	7.25	0.42	5.43e-12	Life satisfaction;
KIRP	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg09238746	chr17:78121135	EIF4A3	-0.57	-7.06	-0.41	1.65e-11	Yeast infection;
KIRP	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.49	8.39	0.47	3.81e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg17810781	chr1:201082982	CACNA1S	0.41	6.38	0.38	8.88e-10	Permanent tooth development;
KIRP	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.8	9.9	0.53	1.17e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	5.95	0.35	9.41e-9	Menarche (age at onset);
KIRP	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.75	8.79	0.49	2.57e-16	Cognitive test performance;
KIRP	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.94	-12.96	-0.64	1.27e-29	Cognitive function;
KIRP	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.49e-21	Diabetic kidney disease;
KIRP	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg18461458	chr19:21324796	ZNF431	-0.48	-4.96	-0.3	1.29e-6	Pain;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14712846	chr8:38239917	WHSC1L1	0.45	6.11	0.36	3.81e-9	Parkinson's disease;
KIRP	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg18882449	chr10:104885122	NT5C2	-0.42	-5.38	-0.32	1.71e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09130556	chr2:38304030	CYP1B1	0.47	6.38	0.38	8.57e-10	Parkinson's disease;
KIRP	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg02461776	chr11:598696	PHRF1	0.69	7.55	0.43	8.52e-13	Systemic lupus erythematosus;
KIRP	cis	rs745821	0.701	rs11873632	chr18:48100407	C/T	cg18923635	chr18:48083994	NA	0.43	5.12	0.31	6.19e-7	Diastolic blood pressure;
KIRP	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.8	0.35	2.03e-8	Lung cancer;
KIRP	cis	rs6800768	0.633	rs7623348	chr3:24130263	C/A	cg10674438	chr3:24145617	LOC152024	-0.48	-6.27	-0.37	1.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.41	6.3	0.37	1.36e-9	Lipoprotein (a) levels;
KIRP	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs675026	0.963	rs658156	chr6:154441526	A/G	cg07813322	chr6:154414604	OPRM1	-0.51	-6.71	-0.39	1.32e-10	Hypertension;
KIRP	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg17366294	chr4:99064904	C4orf37	0.42	5.95	0.35	9.05e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg10223061	chr2:219282414	VIL1	0.29	4.91	0.3	1.65e-6	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11677212	chr4:183089187	MIR1305	-0.39	-6.25	-0.37	1.82e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg11833968	chr6:79620685	NA	0.44	6.77	0.4	9.33e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg22437258	chr11:111473054	SIK2	-0.57	-6.66	-0.39	1.74e-10	Primary sclerosing cholangitis;
KIRP	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.26	-16.91	-0.73	4.36e-43	Breast cancer;
KIRP	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.02	0.46	4.26e-14	Neuroticism;
KIRP	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.82	-11.95	-0.61	2.87e-26	Calcium levels;
KIRP	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg07984980	chr16:89898383	SPIRE2	-1.08	-7.14	-0.41	1.08e-11	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs9309473	1.000	rs10187416	chr2:73713741	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.36	-0.38	9.8e-10	Metabolite levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14069622	chr12:18608819	PIK3C2G	0.4	6.37	0.38	9.19e-10	Migraine with aura;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10156125	chr4:115520072	UGT8	-0.46	-6.26	-0.37	1.71e-9	Survival in pancreatic cancer;
KIRP	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07570687	chr10:102243282	WNT8B	0.49	6.11	0.36	3.91e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-0.9	-12.04	-0.61	1.47e-26	Blood protein levels;
KIRP	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.92	13.32	0.65	7.38e-31	Tonsillectomy;
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.16	0.37	2.93e-9	Platelet count;
KIRP	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg07395648	chr5:131743802	NA	0.56	7.95	0.45	6.75e-14	Breast cancer;
KIRP	cis	rs963731	0.649	rs2305516	chr2:39198966	C/T	cg04010122	chr2:39346883	SOS1	0.86	5.91	0.35	1.13e-8	Corticobasal degeneration;
KIRP	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	trans	rs10863681	0.764	rs12038701	chr1:222242777	A/G	cg05221544	chr6:150185369	LRP11	0.53	6.05	0.36	5.41e-9	Metabolite levels (HVA-5-HIAA Factor score);
KIRP	cis	rs7119038	0.818	rs17122453	chr11:118683564	G/A	cg19308663	chr11:118741387	NA	0.53	9.1	0.5	3.26e-17	Sjögren's syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03801898	chr10:111767685	ADD3	0.5	6.07	0.36	4.74e-9	Parkinson's disease;
KIRP	cis	rs675026	0.927	rs683945	chr6:154427167	C/T	cg07813322	chr6:154414604	OPRM1	-0.46	-6.12	-0.36	3.67e-9	Hypertension;
KIRP	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	1.09	8.01	0.45	4.65e-14	Skin colour saturation;
KIRP	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	cg04338863	chr8:33670619	NA	0.41	5.18	0.31	4.59e-7	Body mass index;
KIRP	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.69	8.39	0.47	3.86e-15	Neutrophil percentage of white cells;
KIRP	cis	rs698833	0.926	rs786407	chr2:44735865	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	4.9	0.3	1.71e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.18	-0.31	4.63e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13418717	1.000	rs7572403	chr2:127662420	G/A	cg25501666	chr2:127640322	NA	0.82	6.32	0.37	1.19e-9	Heart failure;
KIRP	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21747090	chr2:27597821	SNX17	-0.47	-6.42	-0.38	6.99e-10	Total body bone mineral density;
KIRP	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-0.74	-10.79	-0.57	1.73e-22	Prudent dietary pattern;
KIRP	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-0.62	-5.75	-0.34	2.68e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.58	-6.01	-0.36	6.62e-9	Tuberculosis;
KIRP	cis	rs6545883	0.931	rs778768	chr2:61790289	C/G	cg15711740	chr2:61764176	XPO1	-0.62	-8.57	-0.48	1.15e-15	Tuberculosis;
KIRP	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.32	-5.47	-0.33	1.12e-7	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02056921	chr1:901892	PLEKHN1	0.57	6.71	0.39	1.3e-10	Smoking initiation;
KIRP	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.62	6.57	0.39	2.9e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1656402	0.863	rs6437069	chr2:233456647	C/T	cg03852847	chr2:233439513	NA	-0.69	-9.97	-0.54	7.21e-20	Non-small cell lung cancer (survival);
KIRP	cis	rs8033133	0.602	rs12439159	chr15:25323874	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.42	-5.32	-0.32	2.36e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.71	8.51	0.48	1.69e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg14593290	chr7:50529359	DDC	-0.8	-10.0	-0.54	5.52e-20	Malaria;
KIRP	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-5.45	-0.33	1.23e-7	Neuroticism;
KIRP	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-5.39	-0.33	1.63e-7	Testicular germ cell tumor;
KIRP	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg10755058	chr3:40428713	ENTPD3	0.37	5.32	0.32	2.36e-7	Renal cell carcinoma;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg08132940	chr7:1081526	C7orf50	-0.5	-5.03	-0.31	9.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg11833968	chr6:79620685	NA	-0.46	-7.03	-0.41	2.01e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.75	-0.44	2.42e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg13206674	chr6:150067644	NUP43	0.56	7.89	0.45	9.94e-14	Lung cancer;
KIRP	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg24498760	chr8:49746867	NA	0.41	5.14	0.31	5.55e-7	Blood metabolite ratios;
KIRP	cis	rs3736485	0.966	rs7161973	chr15:51854163	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.43	1.36e-12	Body mass index;
KIRP	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	8.11	0.46	2.43e-14	Educational attainment;
KIRP	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.34	-5.25	-0.32	3.32e-7	Dupuytren's disease;
KIRP	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg12140854	chr5:148520817	ABLIM3	-0.42	-4.84	-0.3	2.25e-6	Breast cancer;
KIRP	cis	rs9914544	0.505	rs7503678	chr17:18776020	A/T	cg26378065	chr17:18585709	ZNF286B	0.38	4.84	0.3	2.25e-6	Educational attainment (years of education);
KIRP	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.55	6.05	0.36	5.26e-9	Bone mineral density (spine);
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg26134248	chr17:3907702	NA	0.41	5.08	0.31	7.36e-7	Type 2 diabetes;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08484984	chr2:61298781	KIAA1841	0.39	6.47	0.38	5.14e-10	C-reactive protein;
KIRP	cis	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg19171272	chr22:38449367	NA	-0.65	-9.83	-0.53	1.86e-19	Glioblastoma;Glioma;
KIRP	cis	rs6684514	1.000	rs10908496	chr1:156264000	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-5.97	-0.36	8.03e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg16255804	chr6:135334527	HBS1L	-0.33	-5.36	-0.32	1.93e-7	Red blood cell count;
KIRP	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-9.5	-0.52	2.03e-18	Hemoglobin concentration;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25104512	chr3:46735454	ALS2CL	-0.43	-6.14	-0.36	3.25e-9	Myopia;
KIRP	cis	rs12431939	0.671	rs2999384	chr14:51650328	G/T	cg23942311	chr14:51606299	NA	0.45	5.23	0.32	3.55e-7	Cancer;
KIRP	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24549020	chr5:56110836	MAP3K1	0.5	4.86	0.3	2.13e-6	Initial pursuit acceleration;
KIRP	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.85	10.14	0.54	2.05e-20	Osteoarthritis;
KIRP	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.94	0.4	3.49e-11	Bipolar disorder;
KIRP	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.83	-0.35	1.69e-8	Parkinson's disease;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.91	14.45	0.68	1.12e-34	Menarche (age at onset);
KIRP	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg11608241	chr8:8085544	FLJ10661	0.4	5.02	0.31	9.69e-7	Mood instability;
KIRP	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg13264159	chr8:625131	ERICH1	-0.86	-6.65	-0.39	1.88e-10	IgG glycosylation;
KIRP	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg18944383	chr4:111397179	ENPEP	0.54	9.58	0.52	1.1e-18	Height;
KIRP	cis	rs7224685	0.569	rs8067427	chr17:3997517	C/T	cg09695851	chr17:3907499	NA	0.55	5.16	0.31	5.21e-7	Type 2 diabetes;
KIRP	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg03808351	chr9:123631620	PHF19	0.38	5.21	0.32	3.96e-7	Rheumatoid arthritis;
KIRP	trans	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-6.77	-0.4	9.38e-11	Obesity-related traits;
KIRP	cis	rs7221595	0.825	rs9896963	chr17:3966591	T/C	cg05562828	chr17:3906858	NA	0.56	6.51	0.38	4.19e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs2898857	0.504	rs12937923	chr17:47408475	G/A	cg11430096	chr6:110968061	CDK19	-0.53	-6.49	-0.38	4.66e-10	Cancer;
KIRP	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.74	-11.36	-0.59	2.63e-24	Hip circumference;
KIRP	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg00074818	chr8:8560427	CLDN23	0.41	6.33	0.37	1.16e-9	Obesity-related traits;
KIRP	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.23	0.37	2.02e-9	Hemoglobin concentration;
KIRP	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.46	-5.6	-0.34	5.57e-8	Diastolic blood pressure;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg09695851	chr17:3907499	NA	0.89	17.43	0.74	7.6e-45	Type 2 diabetes;
KIRP	cis	rs6750047	0.647	rs62136320	chr2:38275953	T/G	cg07380506	chr2:38303506	CYP1B1	0.44	5.8	0.35	2e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg06223162	chr1:101003688	GPR88	0.45	9.01	0.5	5.7e-17	Breast cancer;
KIRP	cis	rs2802369	1	rs2802369	chr10:80960828	C/A	cg18737081	chr10:80999807	ZMIZ1	-0.28	-5.29	-0.32	2.64e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs4901847	0.577	rs11158199	chr14:58585354	T/C	cg15908186	chr14:58618357	C14orf37	0.58	7.45	0.43	1.61e-12	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg19913688	chr11:428466	ANO9	-0.77	-6.03	-0.36	6.05e-9	Body mass index;
KIRP	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9309473	0.528	rs10191517	chr2:73558403	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.89	-0.35	1.28e-8	Metabolite levels;
KIRP	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg12292205	chr6:26970375	C6orf41	-0.7	-8.24	-0.47	9.99e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg22800045	chr5:56110881	MAP3K1	-0.8	-8.55	-0.48	1.33e-15	Initial pursuit acceleration;
KIRP	cis	rs3789045	0.528	rs61817953	chr1:204462612	G/A	cg18185008	chr1:204589407	LRRN2	-0.6	-6.33	-0.37	1.18e-9	Educational attainment (college completion);
KIRP	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.63e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.76	12.66	0.63	1.3e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.6	6.97	0.41	2.92e-11	Pancreatic cancer;
KIRP	cis	rs72960926	0.590	rs117275111	chr6:74750921	G/A	cg03266952	chr6:74778945	NA	-0.86	-5.88	-0.35	1.33e-8	Metabolite levels (MHPG);
KIRP	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.88	0.45	1.03e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.05	11.56	0.59	5.58e-25	Vitiligo;
KIRP	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg14675211	chr2:100938903	LONRF2	0.44	5.42	0.33	1.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	14.37	0.68	2.09e-34	Lymphocyte counts;
KIRP	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18252515	chr7:66147081	NA	-0.46	-5.51	-0.33	9.09e-8	Aortic root size;
KIRP	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.73	-9.43	-0.52	3.3e-18	Response to bleomycin (chromatid breaks);
KIRP	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg19770292	chr5:1868693	NA	0.45	5.29	0.32	2.66e-7	Cardiovascular disease risk factors;
KIRP	cis	rs13006833	0.668	rs2582770	chr2:191136794	A/C	cg27211696	chr2:191398769	TMEM194B	0.38	5.18	0.31	4.61e-7	Urinary metabolites;
KIRP	trans	rs1973993	0.603	rs74796126	chr1:96989053	C/A	cg10631902	chr5:14652156	NA	-0.53	-6.35	-0.38	1.04e-9	Weight;
KIRP	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.78	0.35	2.23e-8	Aortic root size;
KIRP	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg26571870	chr16:85723150	GINS2	-0.63	-6.87	-0.4	5.08e-11	Platelet distribution width;
KIRP	cis	rs4851266	0.898	rs12053126	chr2:100864646	A/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.1	-0.31	6.7e-7	Educational attainment;
KIRP	cis	rs62355272	0.828	rs56113663	chr5:35823554	A/G	cg13894535	chr5:35919491	CAPSL	-0.45	-5.3	-0.32	2.55e-7	Lymphocyte counts;
KIRP	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg09990169	chr2:241835740	C2orf54	-0.38	-5.85	-0.35	1.58e-8	Urinary metabolites;
KIRP	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-8.31	-0.47	6.69e-15	Chronic sinus infection;
KIRP	cis	rs7737355	0.773	rs184949	chr5:130815593	A/G	cg06307176	chr5:131281290	NA	-0.41	-5.04	-0.31	9.07e-7	Life satisfaction;
KIRP	cis	rs10924970	0.967	rs1933251	chr1:235451172	G/T	cg26050004	chr1:235667680	B3GALNT2	0.4	4.96	0.3	1.32e-6	Asthma;
KIRP	cis	rs1971762	0.527	rs7976398	chr12:54028862	T/C	cg23533419	chr12:54090519	NA	-0.34	-5.26	-0.32	3.19e-7	Height;
KIRP	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.89	-14.75	-0.69	1.02e-35	Ulcerative colitis;
KIRP	cis	rs4742903	0.509	rs4743697	chr9:106959800	G/C	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	2.01e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.82	11.23	0.58	6.52e-24	Menopause (age at onset);
KIRP	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	0.96	14.8	0.69	7.24e-36	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.44	5.64	0.34	4.62e-8	Body mass index;
KIRP	cis	rs7221595	0.778	rs62072386	chr17:3896168	T/C	cg11204139	chr17:3907470	NA	0.52	5.46	0.33	1.14e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.45	-5.57	-0.33	6.8e-8	Personality dimensions;
KIRP	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.86	7.12	0.41	1.17e-11	Major depressive disorder;
KIRP	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.66	9.41	0.51	3.76e-18	Coronary artery disease;
KIRP	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09959495	chr2:237029385	AGAP1	-0.49	-7.18	-0.42	8.37e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg11503966	chr20:62272292	STMN3	-0.38	-4.85	-0.3	2.16e-6	Atopic dermatitis;
KIRP	cis	rs16858210	0.874	rs1879256	chr3:183609061	A/G	cg25686905	chr3:183603175	PARL	-0.42	-5.47	-0.33	1.13e-7	Menopause (age at onset);
KIRP	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg18646521	chr2:111875858	NA	0.4	5.76	0.34	2.54e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs883565	0.740	rs6599006	chr3:39114276	T/G	cg01426195	chr3:39028469	NA	-0.67	-11.05	-0.58	2.59e-23	Handedness;
KIRP	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg21252483	chr19:49399788	TULP2	-0.43	-7.97	-0.45	5.97e-14	Red cell distribution width;
KIRP	cis	rs2573652	1.000	rs2581365	chr15:100513318	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.69	-10.02	-0.54	4.91e-20	Height;
KIRP	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg25486957	chr4:152246857	NA	-0.52	-5.47	-0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.0	0.36	7.04e-9	Coronary artery disease;
KIRP	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.07	-11.24	-0.58	6.23e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg17554472	chr22:41940697	POLR3H	-0.45	-5.39	-0.33	1.64e-7	Neuroticism;
KIRP	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.41	-5.29	-0.32	2.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.65	8.28	0.47	7.8e-15	Prudent dietary pattern;
KIRP	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg23161317	chr6:28129485	ZNF389	0.46	5.38	0.32	1.72e-7	Depression;
KIRP	cis	rs894344	0.546	rs10481417	chr8:135551178	T/A	cg04050898	chr8:135490694	ZFAT	-0.38	-5.26	-0.32	3.12e-7	Systolic blood pressure;
KIRP	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.71	9.18	0.5	1.88e-17	Bladder cancer;
KIRP	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-16.83	-0.73	8.37e-43	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg15674680	chr20:60982522	CABLES2	0.45	5.47	0.33	1.12e-7	Colorectal cancer;
KIRP	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.16	-0.37	2.87e-9	Daytime sleep phenotypes;
KIRP	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg09184832	chr6:79620586	NA	-0.44	-5.99	-0.36	7.24e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7903847	0.619	rs9888116	chr10:99159482	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-5.92	-0.35	1.1e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.83	-0.4	6.67e-11	Lung cancer;
KIRP	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.91	-0.4	4.25e-11	Mood instability;
KIRP	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg05340658	chr4:99064831	C4orf37	-0.54	-6.64	-0.39	1.99e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05472934	chr7:22766657	IL6	0.81	10.34	0.55	4.95e-21	Lung cancer;
KIRP	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.43	6.29	0.37	1.45e-9	Reticulocyte fraction of red cells;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00061695	chr17:7311314	NLGN2	-0.32	-6.33	-0.37	1.16e-9	Survival in pancreatic cancer;
KIRP	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.69	0.44	3.53e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7792596	0.964	rs1858823	chr7:94018240	G/A	cg20814616	chr7:94014465	NA	-0.3	-5.15	-0.31	5.31e-7	Intelligence;
KIRP	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg12046867	chr14:103022105	NA	-0.53	-6.16	-0.37	3.02e-9	Platelet count;
KIRP	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg10047753	chr17:41438598	NA	1.08	17.23	0.74	3.69e-44	Menopause (age at onset);
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-9.93	-0.53	9.61e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-5.64	-0.34	4.55e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg25019033	chr10:957182	NA	-0.63	-6.56	-0.39	3.23e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-12.68	-0.63	1.07e-28	Alzheimer's disease;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg07701084	chr6:150067640	NUP43	0.7	9.59	0.52	1.03e-18	Lung cancer;
KIRP	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg23985595	chr17:80112537	CCDC57	0.31	4.86	0.3	2.13e-6	Life satisfaction;
KIRP	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg23752985	chr2:85803571	VAMP8	0.62	9.27	0.51	9.48e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg14784868	chr12:69753453	YEATS4	0.5	5.18	0.31	4.69e-7	Response to diuretic therapy;
KIRP	cis	rs2072732	0.861	rs10909866	chr1:2960372	C/T	cg11731671	chr1:2995604	PRDM16	-0.42	-5.27	-0.32	2.97e-7	Plateletcrit;
KIRP	cis	rs56079296	0.636	rs57483119	chr5:121403838	C/G	cg01191064	chr5:121408893	LOX	0.5	4.86	0.3	2.06e-6	Coronary artery disease;
KIRP	cis	rs2910162	1.000	rs2910162	chr5:159909345	A/G	cg03306240	chr5:159912455	MIR146A	-0.41	-5.96	-0.36	8.87e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.88	0.35	1.32e-8	Total cholesterol levels;
KIRP	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.35	-5.12	-0.31	6.19e-7	Breast size;
KIRP	cis	rs4363385	0.510	rs1500937	chr1:153045483	G/C	cg07796016	chr1:152779584	LCE1C	-0.5	-6.27	-0.37	1.57e-9	Inflammatory skin disease;
KIRP	cis	rs7104764	0.507	rs7121085	chr11:258523	A/G	cg00562011	chr11:252351	PSMD13	-0.52	-6.55	-0.39	3.36e-10	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25372275	chr1:161102558	DEDD	0.47	6.07	0.36	4.89e-9	Parkinson's disease;
KIRP	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg11005552	chr10:105648138	OBFC1	0.41	5.9	0.35	1.2e-8	Coronary artery disease;
KIRP	cis	rs2505998	0.833	rs12767776	chr10:43589513	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.79	-0.35	2.18e-8	Hirschsprung disease;
KIRP	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg18944383	chr4:111397179	ENPEP	0.51	8.58	0.48	1.07e-15	Coronary artery disease;
KIRP	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.68	10.49	0.56	1.58e-21	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.56	0.43	7.89e-13	Menarche (age at onset);
KIRP	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg01528321	chr10:82214614	TSPAN14	0.64	7.82	0.45	1.56e-13	Post bronchodilator FEV1;
KIRP	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	8.65	0.48	6.86e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg15488143	chr7:128924101	AHCYL2	0.62	6.79	0.4	8.54e-11	White matter hyperintensity burden;
KIRP	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg12560992	chr17:57184187	TRIM37	0.62	5.71	0.34	3.2e-8	Cognitive test performance;
KIRP	cis	rs2274273	0.588	rs17128145	chr14:55536406	G/T	cg04306507	chr14:55594613	LGALS3	-0.38	-5.63	-0.34	4.84e-8	Protein biomarker;
KIRP	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26617929	chr16:1858877	NA	-0.63	-5.59	-0.34	5.97e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs7084402	0.967	rs1626606	chr10:60328088	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg16141378	chr3:129829833	LOC729375	0.59	8.05	0.46	3.58e-14	Retinal vascular caliber;
KIRP	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg07856975	chr6:36356162	ETV7	0.43	5.49	0.33	9.97e-8	Platelet distribution width;
KIRP	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.46	-5.13	-0.31	5.89e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.55	-6.19	-0.37	2.56e-9	Menarche (age at onset);
KIRP	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.37	4.9	0.3	1.77e-6	Dupuytren's disease;
KIRP	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg06742321	chr12:123595122	PITPNM2	0.44	5.44	0.33	1.29e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg00806126	chr19:22604979	ZNF98	-0.67	-7.1	-0.41	1.36e-11	Pain;
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.78	14.74	0.68	1.1e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.76	7.64	0.44	4.72e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs2274273	0.673	rs2209808	chr14:55807695	A/T	cg04306507	chr14:55594613	LGALS3	0.4	5.88	0.35	1.33e-8	Protein biomarker;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-1.0	-17.6	-0.75	1.97e-45	Longevity;Endometriosis;
KIRP	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg22676075	chr6:135203613	NA	0.52	7.69	0.44	3.56e-13	Red blood cell count;
KIRP	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-8.94	-0.5	9.44e-17	Colorectal cancer;
KIRP	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs6750795	0.641	rs10933375	chr2:232367296	A/T	cg19187155	chr2:232395269	NMUR1	-0.61	-6.51	-0.38	4.23e-10	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg05876325	chr8:144699783	TSTA3	-0.51	-7.2	-0.42	7.32e-12	Metabolic traits;
KIRP	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg05636881	chr10:105038444	INA	0.71	5.74	0.34	2.82e-8	Arsenic metabolism;
KIRP	cis	rs6782228	0.565	rs12695509	chr3:128417044	A/T	cg18648031	chr3:128330563	NA	0.25	4.99	0.3	1.15e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-9.26	-0.51	1.08e-17	Monocyte count;
KIRP	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12306444	chr21:29093202	NCRNA00113	0.49	7.28	0.42	4.41e-12	Interleukin-4 levels;
KIRP	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-0.92	-7.79	-0.44	1.84e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg05910124	chr8:141057427	TRAPPC9	-0.29	-5.59	-0.34	6.03e-8	Pulse pressure;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg19377384	chr3:140951430	ACPL2	0.53	6.4	0.38	7.62e-10	Sleep duration;
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg11814155	chr7:99998594	ZCWPW1	0.55	5.42	0.33	1.42e-7	Platelet count;
KIRP	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.8	-10.65	-0.56	4.89e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.84	12.9	0.64	1.99e-29	Eye color traits;
KIRP	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26207909	chr14:103986467	CKB	0.74	10.61	0.56	6.71e-22	Body mass index;
KIRP	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg27124370	chr19:33622961	WDR88	0.57	6.97	0.41	2.86e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg19752551	chr11:57585705	CTNND1	-0.66	-10.76	-0.57	2.2e-22	Schizophrenia;
KIRP	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg05484376	chr2:27715224	FNDC4	0.37	6.11	0.36	3.78e-9	Total body bone mineral density;
KIRP	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg13311607	chr8:144451523	RHPN1;C8orf51	0.52	6.49	0.38	4.6e-10	Educational attainment;
KIRP	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.53	0.38	3.79e-10	Lung cancer;
KIRP	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.65	-0.48	6.91e-16	Body mass index;
KIRP	trans	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg06311355	chr22:24577269	SUSD2	0.3	6.12	0.36	3.61e-9	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg26513180	chr16:89883248	FANCA	0.81	5.49	0.33	1e-7	Skin colour saturation;
KIRP	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg06050784	chr16:88016603	BANP	0.41	4.88	0.3	1.95e-6	Menopause (age at onset);
KIRP	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.33	0.79	1.39e-54	Chronic sinus infection;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg22562194	chr17:72209580	TTYH2;MGC16275	0.48	6.25	0.37	1.8e-9	Myopia (pathological);
KIRP	cis	rs9469913	0.668	rs112563428	chr6:34800435	C/T	cg14254433	chr6:34482411	PACSIN1	-0.5	-5.06	-0.31	8.37e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.4	5.16	0.31	5.16e-7	Leprosy;
KIRP	trans	rs61931739	0.963	rs12310956	chr12:33970682	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-6.52	-0.38	4.07e-10	Morning vs. evening chronotype;
KIRP	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.51	-7.73	-0.44	2.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg20991723	chr1:152506922	NA	-0.49	-5.95	-0.35	9.37e-9	Hair morphology;
KIRP	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05347473	chr6:146136440	FBXO30	0.6	8.71	0.49	4.38e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg16141378	chr3:129829833	LOC729375	0.58	8.02	0.46	4.23e-14	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg21095983	chr6:86352623	SYNCRIP	-0.52	-6.79	-0.4	8.15e-11	Smooth-surface caries;
KIRP	cis	rs7221595	0.778	rs57625058	chr17:3914513	T/G	cg09695851	chr17:3907499	NA	0.63	6.05	0.36	5.46e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7951870	1.000	rs61882709	chr11:46472414	G/A	cg16389345	chr11:46697382	NA	-0.49	-5.22	-0.32	3.78e-7	Schizophrenia;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg02876066	chr19:18632993	ELL	-0.65	-6.57	-0.39	2.92e-10	Response to statin therapy;
KIRP	cis	rs897504	0.542	rs10173760	chr2:33687997	G/A	cg17598334	chr2:33700917	RASGRP3	-0.64	-6.3	-0.37	1.37e-9	Multiple system atrophy (pathologically confirmed);
KIRP	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.63	-8.1	-0.46	2.49e-14	Diastolic blood pressure;
KIRP	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.63	-7.08	-0.41	1.5e-11	Neuroticism;
KIRP	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.93	14.68	0.68	1.8e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.23	-0.32	3.64e-7	Mean platelet volume;
KIRP	cis	rs2274273	0.837	rs56949365	chr14:55790078	T/C	cg04306507	chr14:55594613	LGALS3	0.43	6.61	0.39	2.43e-10	Protein biomarker;
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg26831259	chr4:1366826	KIAA1530	-0.38	-5.14	-0.31	5.57e-7	Obesity-related traits;
KIRP	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.51	-5.4	-0.33	1.56e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg06873352	chr17:61820015	STRADA	-0.5	-6.08	-0.36	4.44e-9	Prudent dietary pattern;
KIRP	cis	rs13315871	0.615	rs13066167	chr3:58340175	G/A	cg12435725	chr3:58293450	RPP14	-0.38	-5.47	-0.33	1.13e-7	Cholesterol, total;
KIRP	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.52e-6	Red blood cell count;
KIRP	cis	rs4443100	0.621	rs5996447	chr22:23356946	G/A	cg14186256	chr22:23484241	RTDR1	0.56	5.59	0.34	6.03e-8	Serum parathyroid hormone levels;
KIRP	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.93	15.69	0.71	6.35e-39	Ewing sarcoma;
KIRP	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg21401794	chr1:90099060	LRRC8C	0.71	9.99	0.54	6.14e-20	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg00981070	chr1:2046702	PRKCZ	0.39	6.54	0.38	3.49e-10	Height;
KIRP	cis	rs6750720	0.503	rs10202379	chr2:100596865	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.26	-0.32	3.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.23e-7	Obesity-related traits;
KIRP	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.81	-9.07	-0.5	3.95e-17	Coronary artery disease;
KIRP	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg17554472	chr22:41940697	POLR3H	-0.68	-7.08	-0.41	1.48e-11	Vitiligo;
KIRP	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.82	-11.44	-0.59	1.36e-24	Height;
KIRP	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.25e-10	Hepatitis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15358743	chr18:56807035	SEC11C	0.49	6.68	0.39	1.55e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg19274270	chr17:78178856	CARD14	0.36	6.49	0.38	4.77e-10	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17376030	chr22:41985996	PMM1	0.67	7.02	0.41	2.09e-11	Vitiligo;
KIRP	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.78	8.68	0.48	5.45e-16	Coronary artery disease;
KIRP	cis	rs28595532	0.623	rs34531766	chr4:119230339	T/C	cg21605333	chr4:119757512	SEC24D	0.76	5.9	0.35	1.17e-8	Cannabis dependence symptom count;
KIRP	cis	rs3770081	0.826	rs1019591	chr2:86298599	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-4.95	-0.3	1.4e-6	Facial emotion recognition (sad faces);
KIRP	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg11522683	chr6:37501428	NA	-0.39	-5.11	-0.31	6.52e-7	Cognitive performance;
KIRP	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.54	7.22	0.42	6.28e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11679564	0.714	rs4016031	chr2:37184754	C/T	cg14987922	chr2:37194071	STRN	0.47	5.54	0.33	7.74e-8	Immature fraction of reticulocytes;
KIRP	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-5.72	-0.34	3.09e-8	Coronary artery disease;
KIRP	cis	rs8060686	0.858	rs10468274	chr16:67922342	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-8.49	-0.48	1.97e-15	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg26670100	chr1:212964990	TATDN3;NSL1	-0.46	-6.23	-0.37	2e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.11	0.41	1.23e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg04935436	chr20:30431758	NA	0.47	5.2	0.31	4.23e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg08755490	chr11:65554678	OVOL1	0.38	5.4	0.33	1.58e-7	Acne (severe);
KIRP	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg00405596	chr8:11794950	NA	0.48	6.0	0.36	7.17e-9	Retinal vascular caliber;
KIRP	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.71	7.79	0.44	1.85e-13	Corneal astigmatism;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg07414643	chr4:187882934	NA	0.42	5.38	0.32	1.74e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.61	-7.53	-0.43	9.36e-13	Longevity;Endometriosis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17743085	chr19:18557182	ELL	0.43	6.02	0.36	6.19e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg09408571	chr1:101003634	GPR88	0.24	5.47	0.33	1.12e-7	Monocyte count;
KIRP	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.42	-0.47	3.18e-15	Retinal vascular caliber;
KIRP	cis	rs4748857	0.947	rs6482260	chr10:23526638	G/A	cg12804278	chr10:23633326	C10orf67	0.43	5.3	0.32	2.6e-7	Systemic lupus erythematosus;
KIRP	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg19847130	chr8:10466454	RP1L1	0.37	5.57	0.33	6.71e-8	Retinal vascular caliber;
KIRP	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg14416269	chr4:6271139	WFS1	0.34	5.04	0.31	8.93e-7	Cisplatin-induced ototoxicity;
KIRP	cis	rs4728302	0.595	rs2113338	chr7:133591539	T/C	cg10665199	chr7:133106180	EXOC4	0.42	4.95	0.3	1.39e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg12384639	chr17:618140	VPS53	0.49	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg08313168	chr12:7315531	NA	-0.7	-6.26	-0.37	1.72e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs8018808	0.935	rs11159262	chr14:77928735	A/G	cg20045696	chr14:77926864	AHSA1	0.46	5.58	0.34	6.19e-8	Myeloid white cell count;
KIRP	cis	rs6832769	0.922	rs28726308	chr4:56234406	C/T	cg09317128	chr4:56265301	TMEM165	0.46	5.62	0.34	5.28e-8	Personality dimensions;
KIRP	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.93	15.3	0.7	1.35e-37	Height;
KIRP	cis	rs6500395	0.588	rs6500392	chr16:48564143	A/G	cg04672837	chr16:48644449	N4BP1	0.42	5.9	0.35	1.2e-8	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-1.32	-13.07	-0.64	5.24e-30	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.42	4.86	0.3	2.07e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9682041	0.627	rs6786374	chr3:170105233	A/G	cg11886554	chr3:170076028	SKIL	-0.47	-5.22	-0.32	3.83e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.35	0.42	2.9e-12	Height;
KIRP	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Colorectal cancer;
KIRP	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.95	-8.94	-0.5	9.57e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg16141378	chr3:129829833	LOC729375	-0.5	-6.72	-0.39	1.26e-10	Mood instability;
KIRP	cis	rs2594989	0.943	rs2454508	chr3:11493232	T/C	cg01796438	chr3:11312864	ATG7	-0.61	-7.48	-0.43	1.34e-12	Circulating chemerin levels;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg03258011	chr17:54857409	NA	0.5	6.15	0.37	3.09e-9	Sleep duration;
KIRP	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg11642891	chr2:3452563	TTC15	-0.54	-6.92	-0.4	3.84e-11	Obesity-related traits;
KIRP	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	5.81	0.35	1.94e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs12973672	1.000	rs10414846	chr19:35772471	A/G	cg12095397	chr19:35769544	USF2	-0.63	-6.61	-0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.53	-0.43	9.87e-13	Height;
KIRP	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg12311346	chr5:56204834	C5orf35	-0.37	-5.07	-0.31	7.8e-7	Coronary artery disease;
KIRP	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg08533674	chr1:46993347	NA	-0.45	-5.71	-0.34	3.21e-8	Monobrow;
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg17441377	chr17:3906640	NA	-0.55	-8.0	-0.45	5.01e-14	Type 2 diabetes;
KIRP	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg26513180	chr16:89883248	FANCA	0.39	5.08	0.31	7.6e-7	Vitiligo;
KIRP	cis	rs6561750	1.000	rs1350461	chr13:54437664	C/A	ch.13.53330881F	chr13:54432880	NA	-0.38	-5.17	-0.31	4.87e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.27	-0.37	1.6e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.65	-0.39	1.89e-10	Lung cancer;
KIRP	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg02487331	chr1:146550467	NA	0.48	5.99	0.36	7.43e-9	HIV-1 control;
KIRP	cis	rs5752326	0.510	rs3747134	chr22:26877981	A/G	cg20819150	chr22:26891497	TFIP11	-0.53	-5.0	-0.3	1.11e-6	Ischemic stroke;
KIRP	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg06740227	chr12:86229804	RASSF9	-0.41	-5.23	-0.32	3.56e-7	Major depressive disorder;
KIRP	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.38	-0.38	8.93e-10	Total cholesterol levels;
KIRP	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	14.06	0.67	2.36e-33	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.76	0.34	2.5e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.76	9.09	0.5	3.47e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.5	-0.43	1.17e-12	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.97	0.41	2.92e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg02918577	chr15:93633145	RGMA	0.41	4.98	0.3	1.2e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
KIRP	cis	rs977987	1.000	rs977987	chr16:75506593	G/A	cg03315344	chr16:75512273	CHST6	0.74	11.51	0.59	8.35e-25	Dupuytren's disease;
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	6.49	0.38	4.69e-10	Tonsillectomy;
KIRP	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.68	10.06	0.54	3.75e-20	Dupuytren's disease;
KIRP	cis	rs9403521	0.898	rs12207002	chr6:143975422	G/A	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.1	-0.31	6.93e-7	Obesity-related traits;
KIRP	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg26695010	chr11:65641043	EFEMP2	0.49	5.95	0.35	9.16e-9	Eosinophil percentage of white cells;
KIRP	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg14541582	chr5:601475	NA	-0.57	-6.47	-0.38	5.19e-10	Obesity-related traits;
KIRP	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.56	-6.67	-0.39	1.68e-10	Aortic root size;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07412048	chr10:111967303	MXI1	0.56	6.12	0.36	3.64e-9	Lung cancer in ever smokers;
KIRP	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.68	11.03	0.58	2.94e-23	Total body bone mineral density;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02403951	chr16:24580196	RBBP6	-0.45	-6.22	-0.37	2.08e-9	Select biomarker traits;
KIRP	cis	rs6681460	0.565	rs2147776	chr1:67107403	T/C	cg02459107	chr1:67143332	SGIP1	0.36	5.09	0.31	7.01e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.46	6.26	0.37	1.67e-9	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg18209359	chr17:80159595	CCDC57	0.39	5.18	0.31	4.54e-7	Life satisfaction;
KIRP	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg08508325	chr11:3079039	CARS	0.33	5.95	0.35	9.34e-9	Calcium levels;
KIRP	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.22	-0.46	1.17e-14	Monocyte percentage of white cells;
KIRP	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg18306943	chr3:40428807	ENTPD3	-0.38	-5.26	-0.32	3.16e-7	Renal cell carcinoma;
KIRP	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg23307798	chr14:103986281	CKB	-0.82	-14.17	-0.67	1.03e-33	Body mass index;
KIRP	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.54	5.48	0.33	1.03e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg25036284	chr2:26402008	FAM59B	-0.51	-5.4	-0.33	1.59e-7	Gut microbiome composition (summer);
KIRP	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs2644899	0.821	rs4803368	chr19:41301714	A/G	cg24958765	chr19:41283667	RAB4B	-0.55	-6.01	-0.36	6.75e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.93	0.35	1.03e-8	Motion sickness;
KIRP	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.41	-4.95	-0.3	1.41e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2908197	0.699	rs2860469	chr7:75960506	A/C	cg22830091	chr7:75961684	YWHAG	-0.39	-4.92	-0.3	1.58e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	8.05	0.46	3.45e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg21573476	chr21:45109991	RRP1B	-0.62	-8.29	-0.47	7.54e-15	Mean corpuscular volume;
KIRP	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.58	-0.39	2.74e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	8.5	0.48	1.9e-15	Response to antipsychotic treatment;
KIRP	cis	rs57590327	0.679	rs13082609	chr3:81642131	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-5.83	-0.35	1.76e-8	Extraversion;
KIRP	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg21775007	chr8:11205619	TDH	0.43	5.94	0.35	9.78e-9	Neuroticism;
KIRP	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.48	-5.59	-0.34	6.06e-8	Resistin levels;
KIRP	cis	rs2151522	0.603	rs7752844	chr6:127156800	A/T	cg21431617	chr6:127135037	NA	0.31	5.46	0.33	1.14e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2151522	0.762	rs35018483	chr6:127162406	A/G	cg21431617	chr6:127135037	NA	0.29	5.16	0.31	4.99e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg19847130	chr8:10466454	RP1L1	0.38	5.74	0.34	2.71e-8	Retinal vascular caliber;
KIRP	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg21937377	chr3:194868750	C3orf21	0.24	5.06	0.31	8.04e-7	Non-small cell lung cancer;
KIRP	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg16309518	chr5:176445507	NA	-0.89	-14.15	-0.67	1.19e-33	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg00310523	chr12:86230176	RASSF9	0.42	6.85	0.4	5.76e-11	Major depressive disorder;
KIRP	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg19468946	chr17:37922297	IKZF3	-0.37	-5.35	-0.32	2.03e-7	Self-reported allergy;
KIRP	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg06307176	chr5:131281290	NA	0.55	5.91	0.35	1.15e-8	Life satisfaction;
KIRP	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.43	-5.43	-0.33	1.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.64	0.48	7.36e-16	Morning vs. evening chronotype;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg01391022	chr12:122360665	WDR66	-0.39	-5.61	-0.34	5.45e-8	Mean corpuscular volume;
KIRP	cis	rs4332428	0.892	rs35016422	chr10:4978541	A/G	cg19648686	chr10:5044992	AKR1C2	-0.92	-7.99	-0.45	5.14e-14	Height;
KIRP	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.5	-5.23	-0.32	3.59e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.42	4.97	0.3	1.25e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7010876	0.523	rs10091022	chr8:89216114	A/G	cg08624180	chr8:89339080	MMP16	-0.53	-4.97	-0.3	1.25e-6	Schizophrenia;
KIRP	cis	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg06647332	chr5:131281008	NA	0.48	5.31	0.32	2.46e-7	Life satisfaction;
KIRP	trans	rs7999699	0.902	rs12428786	chr13:48322272	C/T	cg23237801	chr1:16476620	EPHA2	0.52	6.52	0.38	3.86e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs6956675	0.915	rs1608134	chr7:62653607	A/C	cg08930214	chr7:62859557	LOC100287834	0.39	4.93	0.3	1.54e-6	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17791617	chr10:79628941	DLG5	-0.5	-6.95	-0.41	3.29e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.89	13.36	0.65	5.82e-31	Coronary artery disease;
KIRP	cis	rs34421088	0.506	rs4841518	chr8:11145963	G/C	cg00405596	chr8:11794950	NA	0.39	5.04	0.31	9.23e-7	Neuroticism;
KIRP	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg09003973	chr2:102972529	NA	1.22	8.92	0.49	1.05e-16	Gut microbiota (bacterial taxa);
KIRP	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.69	7.95	0.45	6.69e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	cg12689670	chr1:183009347	LAMC1	0.43	5.98	0.36	7.62e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05957736	chr3:111579326	PHLDB2	0.48	6.84	0.4	6.36e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.65	-12.36	-0.62	1.27e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg21734707	chr17:3908241	ZZEF1	0.63	9.51	0.52	1.82e-18	Type 2 diabetes;
KIRP	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.49	-6.15	-0.37	3.08e-9	Post bronchodilator FEV1;
KIRP	cis	rs6684428	1.000	rs58538058	chr1:56370474	G/A	cg11651538	chr1:56320950	NA	-0.86	-10.11	-0.54	2.52e-20	Airflow obstruction;
KIRP	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.47	5.14	0.31	5.66e-7	Type 2 diabetes;
KIRP	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg27205649	chr11:78285834	NARS2	-0.52	-5.85	-0.35	1.54e-8	Testicular germ cell tumor;
KIRP	cis	rs11955398	0.563	rs7730342	chr5:60020645	G/T	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7172677	1.000	rs4243032	chr15:75426884	C/G	cg14664628	chr15:75095509	CSK	-0.48	-5.4	-0.33	1.53e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-7.58	-0.44	6.9e-13	Longevity;Endometriosis;
KIRP	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-6.72	-0.39	1.24e-10	Opioid sensitivity;
KIRP	cis	rs7215564	0.908	rs35542453	chr17:78687242	T/G	cg06153925	chr17:78755379	RPTOR	0.34	5.5	0.33	9.27e-8	Myopia (pathological);
KIRP	cis	rs9462846	0.802	rs1819324	chr6:42859723	G/C	cg02353165	chr6:42928485	GNMT	0.41	5.04	0.31	9.23e-7	Blood protein levels;
KIRP	cis	rs2594989	0.943	rs11128550	chr3:11466828	C/T	cg01796438	chr3:11312864	ATG7	0.55	7.17	0.42	8.98e-12	Circulating chemerin levels;
KIRP	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.86	-12.36	-0.62	1.26e-27	Homoarginine levels;
KIRP	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11064744	chr10:75227339	PPP3CB	0.36	6.14	0.36	3.27e-9	C-reactive protein;
KIRP	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg27398637	chr11:122830231	C11orf63	0.76	10.25	0.55	9.01e-21	Menarche (age at onset);
KIRP	cis	rs4790333	1.000	rs4790332	chr17:2262611	G/A	cg02569219	chr17:2266849	SGSM2	0.59	7.74	0.44	2.64e-13	Proinsulin levels;
KIRP	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg00495681	chr13:53174319	NA	0.44	5.94	0.35	9.44e-9	Lewy body disease;
KIRP	cis	rs9512730	0.906	rs4771136	chr13:28070769	C/G	cg22138327	chr13:27999177	GTF3A	0.83	7.22	0.42	6.36e-12	Schizophrenia;
KIRP	cis	rs78498439	0.544	rs77576048	chr16:90078724	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.13	-7.4	-0.43	2.17e-12	Monobrow;
KIRP	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.81	-0.35	1.91e-8	IgG glycosylation;
KIRP	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg02002194	chr4:3960332	NA	-0.43	-6.31	-0.37	1.3e-9	Mood instability;
KIRP	cis	rs34779708	0.706	rs36027395	chr10:35550323	T/A	cg03585969	chr10:35415529	CREM	0.55	6.22	0.37	2.13e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg22437258	chr11:111473054	SIK2	0.59	7.34	0.42	3.17e-12	Primary sclerosing cholangitis;
KIRP	trans	rs4332037	0.508	rs56758848	chr7:1868727	A/G	cg11693508	chr17:37793320	STARD3	0.71	6.88	0.4	5e-11	Bipolar disorder;
KIRP	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.62	7.41	0.43	2.05e-12	Type 2 diabetes;
KIRP	cis	rs4765905	0.550	rs2098013	chr12:2309023	G/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.93	-0.4	3.58e-11	Schizophrenia;
KIRP	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg17724175	chr1:150552817	MCL1	0.32	5.41	0.33	1.51e-7	Melanoma;
KIRP	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21659725	chr3:3221576	CRBN	-0.6	-7.15	-0.41	1e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.55	-7.28	-0.42	4.53e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.6	-6.61	-0.39	2.41e-10	Pancreatic cancer;
KIRP	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg04733989	chr22:42467013	NAGA	0.53	6.38	0.38	8.97e-10	Cognitive function;
KIRP	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.84	-9.96	-0.54	7.64e-20	Ileal carcinoids;
KIRP	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg00074818	chr8:8560427	CLDN23	0.34	5.39	0.32	1.67e-7	Obesity-related traits;
KIRP	cis	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.57	6.04	0.36	5.56e-9	Uric acid levels;
KIRP	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg12435725	chr3:58293450	RPP14	-0.52	-5.34	-0.32	2.09e-7	Cholesterol, total;
KIRP	cis	rs1021993	0.597	rs79455200	chr1:209507767	G/A	cg24446417	chr1:209558027	NA	-0.48	-4.91	-0.3	1.63e-6	Gut microbiome composition (winter);
KIRP	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.55e-20	Dupuytren's disease;
KIRP	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg20636351	chr8:55087400	NA	-0.63	-7.68	-0.44	3.83e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.87	-9.51	-0.52	1.82e-18	Osteoarthritis;
KIRP	cis	rs4786125	0.516	rs7203888	chr16:6915483	T/C	cg03623568	chr16:6915990	A2BP1	-0.44	-5.37	-0.32	1.87e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.77	12.42	0.62	8.13e-28	Menarche (age at onset);
KIRP	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.84	0.45	1.34e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.46	-0.38	5.41e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.5	-0.38	4.54e-10	Glomerular filtration rate;
KIRP	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.56	-0.43	7.75e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35740288	0.580	rs34526042	chr15:86339956	C/T	cg20737812	chr15:86336631	KLHL25	-0.5	-6.15	-0.37	3.1e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg07741184	chr6:167504864	NA	0.24	6.45	0.38	5.8e-10	Crohn's disease;
KIRP	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18541417	chr15:38856528	RASGRP1	-0.5	-6.09	-0.36	4.2e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.72	-0.34	3.15e-8	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24181188	chr15:89182135	ISG20	0.48	6.33	0.37	1.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg00262122	chr8:11665843	FDFT1	-0.41	-4.97	-0.3	1.26e-6	Retinal vascular caliber;
KIRP	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.81	-11.2	-0.58	8.29e-24	Caffeine consumption;
KIRP	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg26681399	chr22:41777847	TEF	0.48	5.18	0.31	4.72e-7	Vitiligo;
KIRP	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg13444842	chr1:152974279	SPRR3	-0.35	-5.01	-0.3	1.06e-6	Inflammatory skin disease;
KIRP	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg11941060	chr3:133502564	NA	-0.48	-5.77	-0.35	2.38e-8	Iron status biomarkers;
KIRP	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.87	-14.29	-0.67	3.79e-34	Headache;
KIRP	cis	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.39	5.0	0.3	1.11e-6	Leprosy;
KIRP	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg26874164	chr19:58962979	ZNF324B	0.47	5.49	0.33	9.98e-8	Uric acid clearance;
KIRP	cis	rs10875746	0.903	rs11168401	chr12:48481519	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.45	-0.43	1.54e-12	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02932840	chr10:28591940	NA	0.53	6.7	0.39	1.42e-10	Parkinson's disease;
KIRP	cis	rs7113850	0.541	rs80336897	chr11:24224545	G/T	ch.11.24196551F	chr11:24239977	NA	0.94	7.7	0.44	3.28e-13	Bone fracture in osteoporosis;
KIRP	cis	rs4481887	0.508	rs6695316	chr1:248394322	G/C	cg01631408	chr1:248437212	OR2T33	-0.45	-5.26	-0.32	3.15e-7	Common traits (Other);
KIRP	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg13072238	chr3:49761600	GMPPB	0.55	5.17	0.31	4.88e-7	Menarche (age at onset);
KIRP	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.63	-6.81	-0.4	7.49e-11	Schizophrenia;
KIRP	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg23752985	chr2:85803571	VAMP8	0.45	5.37	0.32	1.86e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg22532475	chr10:104410764	TRIM8	-0.29	-4.96	-0.3	1.3e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.89	8.84	0.49	1.84e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.43	-5.22	-0.32	3.77e-7	Blood protein levels;
KIRP	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.28	0.37	1.56e-9	Hemoglobin concentration;
KIRP	cis	rs6575793	0.532	rs11849489	chr14:101037762	C/G	cg18516195	chr14:101012996	BEGAIN	0.5	6.29	0.37	1.46e-9	Menarche (age at onset);
KIRP	cis	rs13315871	1.000	rs11710058	chr3:58383048	G/A	cg12435725	chr3:58293450	RPP14	-0.48	-5.12	-0.31	6.19e-7	Cholesterol, total;
KIRP	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.46	-6.48	-0.38	4.87e-10	Coronary artery disease;
KIRP	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg06636001	chr8:8085503	FLJ10661	0.66	8.76	0.49	3.16e-16	Retinal vascular caliber;
KIRP	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.82	-12.61	-0.63	1.81e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg26513180	chr16:89883248	FANCA	0.63	5.41	0.33	1.52e-7	Skin colour saturation;
KIRP	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg08975724	chr8:8085496	FLJ10661	0.63	8.07	0.46	3.09e-14	Neuroticism;
KIRP	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg26174226	chr8:58114915	NA	0.61	7.12	0.41	1.15e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs780096	0.967	rs1260333	chr2:27748624	A/G	cg05484376	chr2:27715224	FNDC4	0.29	4.88	0.3	1.92e-6	Total body bone mineral density;
KIRP	cis	rs1440410	0.610	rs12640330	chr4:144043024	C/T	cg01719995	chr4:144104893	USP38	0.39	4.97	0.3	1.27e-6	Ischemic stroke;
KIRP	cis	rs789859	1.000	rs789862	chr3:194404522	C/T	cg06483076	chr3:194406458	FAM43A	-0.4	-5.81	-0.35	1.95e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg11941060	chr3:133502564	NA	-0.5	-6.05	-0.36	5.25e-9	Iron status biomarkers;
KIRP	cis	rs17453880	0.929	rs10056328	chr5:152024369	C/G	cg12297329	chr5:152029980	NA	0.71	10.72	0.56	3.03e-22	Subjective well-being;
KIRP	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.64	-0.52	7.32e-19	Neuroticism;
KIRP	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg00310523	chr12:86230176	RASSF9	0.41	6.32	0.37	1.23e-9	Major depressive disorder;
KIRP	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	10.63	0.56	5.97e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7909791	0.743	rs11191832	chr10:105619362	T/C	cg11005552	chr10:105648138	OBFC1	0.45	5.39	0.32	1.66e-7	White matter hyperintensity burden;
KIRP	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.96e-8	Endometrial cancer;
KIRP	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-18.16	-0.76	2.55e-47	Height;
KIRP	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg12131826	chr15:77904385	NA	0.45	5.37	0.32	1.8e-7	Type 2 diabetes;
KIRP	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.63	-5.04	-0.31	8.87e-7	Major depressive disorder;
KIRP	cis	rs11169552	0.510	rs11169493	chr12:50959426	C/T	cg12884762	chr12:50931848	DIP2B	0.41	4.85	0.3	2.24e-6	Colorectal cancer;
KIRP	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.02	0.36	6.16e-9	Depressive symptoms;
KIRP	cis	rs2562456	0.793	rs3853837	chr19:21601974	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.92e-6	Pain;
KIRP	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.83	13.38	0.65	4.83e-31	Metabolic syndrome;
KIRP	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs2224391	0.822	rs36055504	chr6:5262230	A/G	cg13962347	chr6:5174647	LYRM4	-0.62	-8.42	-0.47	3.16e-15	Height;
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg23693289	chr8:27183097	PTK2B	0.55	6.88	0.4	5.07e-11	Neuroticism;
KIRP	cis	rs2219968	1.000	rs13248343	chr8:78975745	A/G	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06481639	chr22:41940642	POLR3H	0.45	5.29	0.32	2.76e-7	Vitiligo;
KIRP	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg14825688	chr5:132208181	LEAP2	-0.53	-4.87	-0.3	1.98e-6	Apolipoprotein A-IV levels;
KIRP	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-8.99	-0.5	6.91e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.92	11.93	0.61	3.34e-26	Schizophrenia;
KIRP	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	8.47	0.48	2.28e-15	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6001982	0.748	rs73167097	chr22:40895706	T/A	cg07138101	chr22:40742427	ADSL	0.72	5.81	0.35	1.9e-8	Breast cancer;
KIRP	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.45	6.72	0.39	1.24e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.97	13.78	0.66	2.18e-32	Cognitive function;
KIRP	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.8	12.06	0.61	1.23e-26	Ulcerative colitis;
KIRP	cis	rs2296225	0.722	rs10916853	chr1:21053887	C/T	cg14666476	chr1:21112556	HP1BP3	0.65	6.08	0.36	4.63e-9	Eosinophilic esophagitis;
KIRP	cis	rs4954585	0.683	rs13024450	chr2:137014611	C/T	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.14e-13	Colorectal cancer;
KIRP	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg00646381	chr17:77835854	NA	0.54	7.66	0.44	4.38e-13	Electroencephalogram traits;
KIRP	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.62	-8.09	-0.46	2.75e-14	Breast cancer;
KIRP	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg23479056	chr15:41276147	INO80	-0.41	-6.08	-0.36	4.64e-9	Menopause (age at onset);
KIRP	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg19292749	chr17:79650816	ARL16;HGS	0.52	4.92	0.3	1.57e-6	Dental caries;
KIRP	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.44	-0.38	6.37e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06070508	chr11:68519174	MTL5	0.46	6.2	0.37	2.39e-9	Parkinson's disease;
KIRP	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.84	-8.32	-0.47	6.21e-15	Coronary artery calcification;
KIRP	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.43	-4.89	-0.3	1.84e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03388025	chr16:89894329	SPIRE2	0.34	6.09	0.36	4.2e-9	Vitiligo;
KIRP	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg17736920	chr1:242011382	EXO1	0.48	5.92	0.35	1.1e-8	Menopause (age at onset);
KIRP	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.9	12.38	0.62	1.06e-27	Schizophrenia;
KIRP	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg26248373	chr2:1572462	NA	-0.82	-10.99	-0.57	4.15e-23	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs75920871	0.528	rs1531706	chr11:116943952	C/A	cg04087571	chr11:116723030	SIK3	-0.25	-5.33	-0.32	2.26e-7	Subjective well-being;
KIRP	trans	rs10782582	0.758	rs1908089	chr1:76359308	C/T	cg10283277	chr11:111472630	SIK2	-0.3	-6.08	-0.36	4.53e-9	Daytime sleep phenotypes;
KIRP	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs4663866	0.901	rs2304672	chr2:239186589	C/G	cg16914508	chr2:239161102	PER2	-0.66	-4.91	-0.3	1.66e-6	Irritable bowel syndrome;
KIRP	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.59	0.39	2.72e-10	Retinal vascular caliber;
KIRP	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.69	-0.39	1.52e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg03465714	chr1:152285911	FLG	-0.42	-5.13	-0.31	5.97e-7	Atopic dermatitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02568374	chr16:4588917	C16orf5	0.46	6.26	0.37	1.68e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6960043	0.818	rs6947830	chr7:15064984	A/G	cg19272540	chr7:15055459	NA	0.23	6.57	0.39	3.04e-10	Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.64	-0.56	5.29e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg04310649	chr10:35416472	CREM	-0.59	-6.97	-0.41	2.95e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3820928	0.560	rs55635053	chr2:227952154	G/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-4.98	-0.3	1.21e-6	Pulmonary function;
KIRP	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg17376030	chr22:41985996	PMM1	0.62	6.84	0.4	6.19e-11	Vitiligo;
KIRP	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg27205649	chr11:78285834	NARS2	-0.54	-5.16	-0.31	5.15e-7	Testicular germ cell tumor;
KIRP	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg11970804	chr8:8084126	NA	0.38	4.91	0.3	1.7e-6	Joint mobility (Beighton score);
KIRP	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.32	-0.37	1.2e-9	Response to antipsychotic treatment;
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg02931644	chr1:25747376	RHCE	-0.36	-6.52	-0.38	3.87e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg08992911	chr2:238395768	MLPH	0.54	5.05	0.31	8.62e-7	Prostate cancer;
KIRP	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.4	-0.43	2.16e-12	Morning vs. evening chronotype;
KIRP	cis	rs9326248	0.515	rs2727793	chr11:116683374	C/T	cg11861562	chr11:117069780	TAGLN	0.4	5.11	0.31	6.53e-7	Blood protein levels;
KIRP	cis	rs9898058	0.660	rs9915811	chr17:47786332	G/C	cg06375292	chr17:47786311	SLC35B1	-0.75	-6.16	-0.37	2.91e-9	Milk allergy;
KIRP	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	1.07	19.24	0.78	5.92e-51	Systemic lupus erythematosus;
KIRP	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.59	-6.31	-0.37	1.29e-9	Aortic root size;
KIRP	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.61	-7.02	-0.41	2.19e-11	Mean platelet volume;
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg18402987	chr7:1209562	NA	0.46	5.28	0.32	2.87e-7	Longevity;Endometriosis;
KIRP	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg13482628	chr17:19912719	NA	0.57	7.94	0.45	7.2e-14	Schizophrenia;
KIRP	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.42	-6.2	-0.37	2.38e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.98	10.48	0.56	1.77e-21	HIV-1 control;
KIRP	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.57	-9.09	-0.5	3.44e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs494562	0.892	rs7767800	chr6:86124526	G/A	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	cg21523751	chr1:182988639	NA	0.4	6.2	0.37	2.31e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs10102274	1.000	rs7815900	chr8:91765220	C/T	cg16814680	chr8:91681699	NA	-0.8	-4.9	-0.3	1.71e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10174797	chr19:8464628	RAB11B	0.51	6.4	0.38	7.87e-10	HDL cholesterol;
KIRP	trans	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg16141378	chr3:129829833	LOC729375	-0.56	-7.21	-0.42	6.98e-12	Systolic blood pressure;
KIRP	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	ch.5.1024479R	chr5:53302184	ARL15	-1.18	-14.61	-0.68	3.26e-35	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7011049	1.000	rs74457055	chr8:53842669	T/G	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.88	0.4	4.84e-11	Electroencephalogram traits;
KIRP	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.59	6.95	0.41	3.29e-11	Corneal astigmatism;
KIRP	cis	rs9890032	0.618	rs1979507	chr17:29138020	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.46	-5.79	-0.35	2.15e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.08	0.31	7.51e-7	Smoking behavior;
KIRP	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg16141378	chr3:129829833	LOC729375	0.53	6.9	0.4	4.39e-11	Neuroticism;
KIRP	cis	rs10186029	0.509	rs13387516	chr2:213945341	T/C	cg08319019	chr2:214017104	IKZF2	-0.43	-5.11	-0.31	6.38e-7	Systemic sclerosis;
KIRP	cis	rs6832769	1.000	rs7670225	chr4:56368018	C/T	cg05960024	chr4:56376020	CLOCK	0.73	9.43	0.52	3.31e-18	Personality dimensions;
KIRP	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.86	13.5	0.65	1.84e-31	Height;
KIRP	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg11707556	chr5:10655725	ANKRD33B	0.54	6.93	0.4	3.77e-11	Coronary artery disease;
KIRP	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg03808351	chr9:123631620	PHF19	0.4	5.43	0.33	1.34e-7	Rheumatoid arthritis;
KIRP	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	9.11	0.5	2.96e-17	Systemic lupus erythematosus;
KIRP	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23161317	chr6:28129485	ZNF389	0.44	5.13	0.31	5.92e-7	Depression;
KIRP	cis	rs1847505	0.609	rs17819716	chr13:61423429	C/T	cg25164009	chr13:61490935	NA	0.57	6.15	0.37	3.07e-9	Polychlorinated biphenyl levels;
KIRP	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.06	0.36	5.07e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7116495	0.619	rs7116188	chr11:71841753	A/G	cg26138937	chr11:71823887	C11orf51	0.69	5.49	0.33	9.81e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	9.98	0.54	6.49e-20	Bone mineral density;
KIRP	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	12.75	0.63	6.59e-29	Multiple sclerosis;
KIRP	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.45	-0.38	5.76e-10	Aortic root size;
KIRP	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.58	8.5	0.48	1.91e-15	Ovarian reserve;
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.44	5.85	0.35	1.53e-8	Menarche (age at onset);
KIRP	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.86	11.77	0.6	1.12e-25	Coronary artery disease or large artery stroke;
KIRP	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.42	5.36	0.32	1.91e-7	Aortic root size;
KIRP	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs753955	0.554	rs2031587	chr13:24417335	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	5.36	0.32	1.89e-7	Lung cancer;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg09597638	chr17:3907349	NA	0.82	16.53	0.73	9e-42	Type 2 diabetes;
KIRP	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg22117172	chr7:91764530	CYP51A1	0.48	6.61	0.39	2.4e-10	Breast cancer;
KIRP	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.17	-0.37	2.76e-9	IgG glycosylation;
KIRP	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	1.0	9.22	0.51	1.42e-17	Systolic blood pressure;
KIRP	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.33	0.59	3.23e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.83	10.37	0.55	3.96e-21	Multiple sclerosis;
KIRP	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg25547332	chr5:131281432	NA	0.46	5.33	0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-1.04	-12.81	-0.63	3.98e-29	Breast cancer;
KIRP	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg05347473	chr6:146136440	FBXO30	0.62	8.75	0.49	3.48e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg17376030	chr22:41985996	PMM1	-0.83	-9.0	-0.5	6.35e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg18404041	chr3:52824283	ITIH1	-0.48	-6.86	-0.4	5.68e-11	Bipolar disorder;
KIRP	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04398451	chr17:18023971	MYO15A	-0.86	-12.47	-0.62	5.52e-28	Total body bone mineral density;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21016266	chr12:122356598	WDR66	0.65	8.81	0.49	2.24e-16	Mean corpuscular volume;
KIRP	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg14703610	chr5:56206110	C5orf35	0.49	6.78	0.4	8.88e-11	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.93	-15.72	-0.71	5.08e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6545883	0.524	rs4599092	chr2:61498968	T/G	cg15711740	chr2:61764176	XPO1	0.45	5.55	0.33	7.45e-8	Tuberculosis;
KIRP	cis	rs580438	1.000	rs57635268	chr3:13347705	T/C	cg10657019	chr3:13328039	NA	0.73	9.6	0.52	9.86e-19	Myringotomy;
KIRP	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.89	14.75	0.68	1.08e-35	Prostate cancer;
KIRP	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg00852783	chr1:26633632	UBXN11	-0.52	-5.13	-0.31	5.94e-7	Obesity-related traits;
KIRP	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.55	-0.52	1.39e-18	Hemoglobin concentration;
KIRP	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg27490568	chr2:178487706	NA	-0.41	-5.48	-0.33	1.07e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg20578329	chr17:80767326	TBCD	-0.69	-8.0	-0.45	4.79e-14	Breast cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23715700	chr19:16188274	TPM4	0.52	6.05	0.36	5.48e-9	Smoking initiation;
KIRP	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg23958373	chr8:599963	NA	1.01	7.2	0.42	7.17e-12	IgG glycosylation;
KIRP	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.51	-5.46	-0.33	1.14e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.54	8.93	0.49	9.92e-17	Eye color traits;
KIRP	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.42	-9.75	-0.53	3.34e-19	Cutaneous nevi;
KIRP	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg01346077	chr3:125931526	NA	0.48	8.01	0.45	4.51e-14	Metabolite levels;
KIRP	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg07274523	chr3:49395745	GPX1	0.69	8.63	0.48	7.63e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg02569458	chr12:86230093	RASSF9	0.45	6.36	0.38	9.88e-10	Major depressive disorder;
KIRP	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	1.15	21.01	0.8	8.08e-57	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs548987	0.507	rs35875210	chr6:25827484	A/G	cg03264133	chr6:25882463	NA	-0.42	-5.0	-0.3	1.09e-6	Homocysteine levels;
KIRP	cis	rs74181299	0.684	rs11126028	chr2:65338150	C/G	cg05010058	chr2:65284262	CEP68	-0.43	-5.87	-0.35	1.4e-8	Pulse pressure;
KIRP	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02475777	chr4:1388615	CRIPAK	0.57	7.48	0.43	1.31e-12	Longevity;
KIRP	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.74	-8.96	-0.5	8.37e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg15655495	chr12:38532458	NA	-0.25	-4.84	-0.3	2.26e-6	Heart rate;
KIRP	cis	rs4865875	0.579	rs7730464	chr5:54184745	T/C	cg08820104	chr5:54183619	NA	-0.73	-5.13	-0.31	5.79e-7	Sense of smell;
KIRP	cis	rs2072732	0.756	rs7514166	chr1:2949607	G/C	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.56e-7	Plateletcrit;
KIRP	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg05868516	chr6:26286170	HIST1H4H	0.4	5.32	0.32	2.36e-7	Educational attainment;
KIRP	cis	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg21775007	chr8:11205619	TDH	-0.58	-7.27	-0.42	4.68e-12	Retinal vascular caliber;
KIRP	cis	rs2594989	0.943	rs7349536	chr3:11442503	C/T	cg01796438	chr3:11312864	ATG7	0.56	7.16	0.42	9.5e-12	Circulating chemerin levels;
KIRP	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg00343986	chr7:65444356	GUSB	0.39	4.86	0.3	2.12e-6	Aortic root size;
KIRP	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.84	-11.24	-0.58	6.31e-24	Obesity-related traits;
KIRP	cis	rs12580194	0.593	rs12580661	chr12:55803129	G/A	cg19537932	chr12:55886519	OR6C68	-0.53	-6.63	-0.39	2.09e-10	Cancer;
KIRP	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.79	-0.4	8.26e-11	Inflammatory bowel disease;
KIRP	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.41	6.8	0.4	7.69e-11	Electroencephalogram traits;
KIRP	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	6.92	0.4	3.96e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9948	1.000	rs12172	chr2:97500852	C/G	cg01990225	chr2:97406019	LMAN2L	-1.05	-7.43	-0.43	1.78e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.63	10.55	0.56	1.05e-21	Coronary artery disease;
KIRP	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26850624	chr5:429559	AHRR	0.32	5.8	0.35	2e-8	Cystic fibrosis severity;
KIRP	cis	rs9297145	0.678	rs62473007	chr7:98749598	G/C	cg05967295	chr7:98741636	SMURF1	0.87	10.46	0.55	2.06e-21	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06481639	chr22:41940642	POLR3H	-0.53	-6.05	-0.36	5.46e-9	Vitiligo;
KIRP	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.52	-6.07	-0.36	4.89e-9	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.42	5.01	0.3	1.03e-6	Type 2 diabetes;
KIRP	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.83	-0.35	1.7e-8	Parkinson's disease;
KIRP	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg27490568	chr2:178487706	NA	0.53	7.3	0.42	3.99e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg27542767	chr6:40253980	NA	0.41	6.11	0.36	3.94e-9	Breast size;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg12469257	chr3:25761040	NGLY1	0.41	6.29	0.37	1.4e-9	C-reactive protein;
KIRP	cis	rs1485395	0.891	rs7976278	chr12:54045121	C/G	cg16917193	chr12:54089295	NA	0.61	5.95	0.35	9.41e-9	Migraine without aura;
KIRP	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.78	10.16	0.54	1.79e-20	Aortic root size;
KIRP	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Life satisfaction;
KIRP	cis	rs1185460	0.934	rs1006195	chr11:118958869	A/C	cg23280166	chr11:118938394	VPS11	-0.56	-6.84	-0.4	6.07e-11	Coronary artery disease;
KIRP	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.48	-4.89	-0.3	1.8e-6	Pubertal anthropometrics;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.4e-8	Life satisfaction;
KIRP	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15128208	chr22:42549153	NA	-0.45	-5.7	-0.34	3.45e-8	Cognitive function;
KIRP	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg17507749	chr15:85114479	UBE2QP1	0.73	6.76	0.4	9.82e-11	Schizophrenia;
KIRP	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg12140854	chr5:148520817	ABLIM3	0.53	6.06	0.36	5.07e-9	Breast cancer;
KIRP	cis	rs7809615	0.792	rs45618033	chr7:99046617	G/A	cg24024660	chr7:99195788	NA	-0.57	-5.07	-0.31	7.78e-7	Blood metabolite ratios;
KIRP	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg14459158	chr9:96720562	NA	0.28	5.4	0.33	1.56e-7	Esophageal adenocarcinoma;
KIRP	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.83	-0.4	6.49e-11	Aortic root size;
KIRP	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg26248373	chr2:1572462	NA	-0.64	-6.48	-0.38	4.96e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg23565292	chr14:50234668	KLHDC2	-0.4	-4.89	-0.3	1.82e-6	Carotid intima media thickness;
KIRP	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg00977110	chr5:151150581	G3BP1	0.63	6.35	0.38	1.02e-9	Preschool internalizing problems;
KIRP	cis	rs4148660	1.000	rs2418021	chr12:22064188	T/C	cg14669847	chr12:22099120	NA	0.35	5.98	0.36	7.7e-9	Gout;
KIRP	cis	rs6568686	0.627	rs117205661	chr6:111624557	T/A	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs9535307	0.584	rs1198328	chr13:50389885	A/G	cg04663916	chr13:50265991	EBPL	0.66	5.8	0.35	2.04e-8	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7267005	1.000	rs57923067	chr20:34497139	G/A	cg17201900	chr20:34330562	RBM39	0.87	4.9	0.3	1.71e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg23594656	chr7:65796392	TPST1	0.4	6.1	0.36	3.99e-9	Aortic root size;
KIRP	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg11693508	chr17:37793320	STARD3	0.77	8.36	0.47	4.59e-15	Bipolar disorder;
KIRP	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.11	-11.78	-0.6	1.1e-25	Mitochondrial DNA levels;
KIRP	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Bipolar disorder;
KIRP	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.74	-0.39	1.11e-10	Joint mobility (Beighton score);
KIRP	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	9.48	0.52	2.23e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	6.95	0.41	3.28e-11	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-5.06	-0.31	8.12e-7	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg16263701	chr12:48213605	HDAC7	-0.5	-6.26	-0.37	1.73e-9	Neuroticism;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24141233	chr1:212781895	ATF3	-0.46	-6.12	-0.36	3.74e-9	Myopia;
KIRP	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg08885076	chr2:99613938	TSGA10	0.55	9.52	0.52	1.67e-18	Chronic sinus infection;
KIRP	cis	rs4835473	0.932	rs10021860	chr4:144675746	G/A	cg08833778	chr4:144622313	FREM3	0.36	5.17	0.31	4.8e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.68	-6.18	-0.37	2.65e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.74	-11.98	-0.61	2.34e-26	Prostate cancer;
KIRP	cis	rs1776421	1.000	rs1288593	chr1:53901655	C/T	cg22073262	chr1:53904065	FLJ40434	0.47	5.21	0.32	3.92e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg05998816	chr21:47859926	PCNT	0.57	6.14	0.36	3.21e-9	Lymphocyte counts;
KIRP	cis	rs2278796	0.918	rs11240324	chr1:204955319	G/A	cg17449235	chr1:204966235	NFASC	0.47	6.33	0.37	1.15e-9	Mean platelet volume;
KIRP	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	5.27	0.32	2.95e-7	Renal cell carcinoma;
KIRP	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.27	0.32	3.04e-7	Lung cancer;
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg15117754	chr3:10150083	C3orf24	0.59	5.07	0.31	7.91e-7	Alzheimer's disease;
KIRP	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.8	-10.51	-0.56	1.4e-21	Body mass index;
KIRP	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.76	11.45	0.59	1.32e-24	Blood metabolite ratios;
KIRP	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg08648136	chr8:956695	NA	0.44	6.25	0.37	1.77e-9	Schizophrenia;
KIRP	cis	rs45544231	0.569	rs12934308	chr16:52538096	A/G	cg09051775	chr16:52580266	TOX3	-0.39	-5.16	-0.31	5.1e-7	Restless legs syndrome;
KIRP	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg21466736	chr12:48725269	NA	-0.45	-5.93	-0.35	1e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs1858037	0.867	rs67817304	chr2:65574116	C/T	cg08085232	chr2:65598271	SPRED2	-0.52	-6.17	-0.37	2.85e-9	Rheumatoid arthritis;
KIRP	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4242434	1.000	rs4242434	chr8:22501830	C/A	cg03733263	chr8:22462867	KIAA1967	1.06	14.81	0.69	6.43e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs745080	0.674	rs2168823	chr14:53027908	C/T	cg23333723	chr14:53022898	GPR137C	-0.42	-5.96	-0.36	8.76e-9	Orofacial clefts;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13463167	chr1:197523608	DENND1B	0.39	6.24	0.37	1.9e-9	C-reactive protein;
KIRP	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg17507749	chr15:85114479	UBE2QP1	0.85	9.43	0.52	3.23e-18	Schizophrenia;
KIRP	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg00092383	chr7:157075207	NA	0.39	4.88	0.3	1.91e-6	Body mass index;
KIRP	cis	rs11955175	1.000	rs78426328	chr5:40673176	G/T	cg05478818	chr5:40835740	RPL37	0.7	5.44	0.33	1.32e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg06219351	chr7:158114137	PTPRN2	-0.62	-8.82	-0.49	2.12e-16	Calcium levels;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	6.4	0.38	7.87e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4851254	0.618	rs35840153	chr2:100669829	A/G	cg17356467	chr2:100759845	AFF3	0.54	5.63	0.34	4.87e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14335767	chr8:124286570	ZHX1	0.51	6.99	0.41	2.53e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.75	7.66	0.44	4.22e-13	Hip geometry;
KIRP	cis	rs55986470	0.763	rs11888775	chr2:239424876	C/T	cg18131467	chr2:239335373	ASB1	0.62	6.0	0.36	6.96e-9	Chronotype;
KIRP	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg05527609	chr1:210001259	C1orf107	-0.53	-5.19	-0.31	4.37e-7	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25968835	chr15:93631754	RGMA	0.48	6.89	0.4	4.75e-11	Parkinson's disease;
KIRP	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.53	-0.33	8.03e-8	Height;
KIRP	cis	rs10794720	0.867	rs78029387	chr10:1138589	C/T	cg08668510	chr10:1095578	IDI1	0.95	5.63	0.34	4.79e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
KIRP	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg11266682	chr4:10021025	SLC2A9	0.63	11.93	0.61	3.54e-26	Bone mineral density;
KIRP	cis	rs240764	0.817	rs239219	chr6:101116146	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.58	6.64	0.39	2.01e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.76	-9.81	-0.53	2.18e-19	Aortic root size;
KIRP	cis	rs11138902	0.673	rs12553491	chr9:72132996	G/A	cg14397918	chr9:72078829	APBA1	0.33	5.16	0.31	5.2e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.73	7.76	0.44	2.27e-13	Vitiligo;
KIRP	trans	rs7246760	1.000	rs58137206	chr19:9856624	G/A	cg02900749	chr2:68251473	NA	-1.06	-8.71	-0.49	4.62e-16	Pursuit maintenance gain;
KIRP	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.26	0.55	8.32e-21	Morning vs. evening chronotype;
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg13699009	chr12:122356056	WDR66	0.73	11.62	0.6	3.47e-25	Mean corpuscular volume;
KIRP	cis	rs7932354	0.710	rs10838621	chr11:46851459	C/T	cg16389345	chr11:46697382	NA	0.43	5.24	0.32	3.48e-7	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs4262150	0.883	rs12153071	chr5:152247852	C/A	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6840360	0.870	rs6814554	chr4:152454334	G/A	cg25486957	chr4:152246857	NA	-0.47	-5.47	-0.33	1.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg02807482	chr3:125708958	NA	-0.54	-5.1	-0.31	6.86e-7	Blood pressure (smoking interaction);
KIRP	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-9.4	-0.51	3.82e-18	Response to antipsychotic treatment;
KIRP	cis	rs4704187	0.687	rs9763362	chr5:74406316	T/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.76	7.94	0.45	7.29e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7692976	0.868	rs11098057	chr4:110900692	G/C	cg06981781	chr4:110842888	EGF	-0.22	-4.87	-0.3	2.04e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.36	-0.65	5.5e-31	Primary sclerosing cholangitis;
KIRP	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg16434002	chr17:42200994	HDAC5	0.63	7.9	0.45	9.58e-14	Total body bone mineral density;
KIRP	trans	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg27542767	chr6:40253980	NA	0.41	6.09	0.36	4.35e-9	Breast size;
KIRP	cis	rs600806	0.672	rs1144594	chr1:110029475	A/G	cg16988986	chr1:109941118	SORT1	-0.26	-5.07	-0.31	7.89e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs12517041	1.000	rs2081952	chr5:23295605	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg11271282	chr2:238384023	NA	0.56	6.5	0.38	4.33e-10	Prostate cancer;
KIRP	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.89	-12.59	-0.63	2.23e-28	Coronary artery disease;
KIRP	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg03128534	chr1:43423976	SLC2A1	0.54	5.93	0.35	1.04e-8	Red cell distribution width;
KIRP	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg14003231	chr6:33640908	ITPR3	-0.3	-5.1	-0.31	6.83e-7	Plateletcrit;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg17417193	chr6:45983110	CLIC5	0.44	6.16	0.37	2.94e-9	DNA methylation (variation);
KIRP	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11987759	chr7:65425863	GUSB	-0.4	-4.93	-0.3	1.51e-6	Aortic root size;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21866054	chr4:103748674	UBE2D3	0.57	6.22	0.37	2.16e-9	Lung cancer in ever smokers;
KIRP	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.82	-11.46	-0.59	1.21e-24	Eosinophil percentage of white cells;
KIRP	cis	rs6907629	0.965	rs723558	chr6:167578405	A/G	cg21144340	chr6:167633022	NA	-0.4	-4.85	-0.3	2.21e-6	Asthma (childhood onset);
KIRP	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg01872077	chr2:219646372	CYP27A1	-0.37	-4.94	-0.3	1.42e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.6	8.09	0.46	2.76e-14	Mood instability;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26413987	chr12:121124951	MLEC	-0.57	-6.31	-0.37	1.26e-9	Menopause (age at onset);
KIRP	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg07309820	chr7:148901717	ZNF282	-0.4	-5.2	-0.31	4.18e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg02570527	chr1:10970165	NA	-0.4	-4.9	-0.3	1.74e-6	Body mass index;
KIRP	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.25	-0.32	3.37e-7	Pulmonary function;
KIRP	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg23067535	chr8:124195133	FAM83A	-0.8	-7.37	-0.43	2.62e-12	Urinary uromodulin levels;
KIRP	cis	rs35740288	0.617	rs17633749	chr15:86140791	G/A	cg06993955	chr15:86301167	NA	-0.39	-5.04	-0.31	9.08e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg26965718	chr17:79658957	HGS	-0.61	-5.82	-0.35	1.78e-8	Dental caries;
KIRP	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg00656387	chr3:40428638	ENTPD3	0.4	5.1	0.31	6.79e-7	Renal cell carcinoma;
KIRP	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	1.05	14.82	0.69	6.03e-36	Menopause (age at onset);
KIRP	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.17	0.42	8.63e-12	Bipolar disorder;
KIRP	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg15655495	chr12:38532458	NA	-0.31	-5.33	-0.32	2.21e-7	Bladder cancer;
KIRP	cis	rs2625529	0.824	rs12899485	chr15:72143215	A/G	cg16672083	chr15:72433130	SENP8	0.5	6.08	0.36	4.49e-9	Red blood cell count;
KIRP	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.48	6.67	0.39	1.72e-10	Red blood cell count;
KIRP	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.1	-0.31	6.84e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15750611	chr11:68191055	LRP5	0.52	6.22	0.37	2.08e-9	Interleukin-4 levels;
KIRP	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.52	-5.52	-0.33	8.58e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs877282	0.533	rs10904565	chr10:819991	G/T	cg22713356	chr15:30763199	NA	0.88	8.61	0.48	8.7e-16	Uric acid levels;
KIRP	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.46	-0.52	2.57e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs76935404	0.773	rs72480748	chr19:41414481	G/A	cg09508736	chr19:41385865	CYP2A7	-0.5	-5.69	-0.34	3.61e-8	nicotine metabolite ratio in current smokers;
KIRP	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg17366294	chr4:99064904	C4orf37	0.44	6.31	0.37	1.29e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg13147721	chr7:65941812	NA	-0.97	-6.6	-0.39	2.52e-10	Diabetic kidney disease;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.62	8.8	0.49	2.53e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg26681399	chr22:41777847	TEF	-0.53	-5.3	-0.32	2.62e-7	Vitiligo;
KIRP	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg03315344	chr16:75512273	CHST6	0.55	5.5	0.33	9.4e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.51	-0.43	1.06e-12	Neuroticism;
KIRP	cis	rs10814247	0.730	rs6476480	chr9:35249455	C/T	cg15271616	chr9:35490515	RUSC2	-0.36	-5.16	-0.31	5.01e-7	Psoriasis;
KIRP	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.6	-7.08	-0.41	1.5e-11	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-19.23	-0.77	6.44e-51	Height;
KIRP	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.54	-0.68	5.66e-35	Primary sclerosing cholangitis;
KIRP	trans	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg10756647	chr7:56101905	PSPH	0.91	6.41	0.38	7.32e-10	Diabetic kidney disease;
KIRP	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.56	6.86	0.4	5.6e-11	Breast cancer;
KIRP	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.19	13.66	0.66	5.23e-32	Uric acid levels;
KIRP	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28834970	0.675	rs17057051	chr8:27227554	C/T	cg23736307	chr8:27182930	PTK2B	0.53	5.98	0.36	7.94e-9	Alzheimer's disease (late onset);
KIRP	trans	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.47	-6.55	-0.39	3.33e-10	Mean corpuscular volume;
KIRP	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg13385521	chr17:29058706	SUZ12P	0.55	5.4	0.33	1.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08308934	chr14:91976742	SMEK1	0.48	6.46	0.38	5.72e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg19847130	chr8:10466454	RP1L1	0.37	5.35	0.32	2.03e-7	Retinal vascular caliber;
KIRP	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg06965744	chr5:177196865	FAM153A	0.39	5.95	0.35	9.11e-9	Methadone dose in opioid dependence;
KIRP	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg18882449	chr10:104885122	NT5C2	-0.39	-5.0	-0.3	1.07e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg16435858	chr3:129158884	IFT122;MBD4	-0.49	-6.2	-0.37	2.4e-9	Myopia;
KIRP	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.4	-4.89	-0.3	1.85e-6	Diabetic retinopathy;
KIRP	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.57	-7.24	-0.42	5.9e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-15.48	-0.7	3.47e-38	Electrocardiographic conduction measures;
KIRP	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg24488311	chr11:68621650	NA	0.5	6.01	0.36	6.64e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg01620082	chr3:125678407	NA	-1.1	-6.82	-0.4	7.13e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14347670	chr6:41908995	CCND3	0.46	6.07	0.36	4.7e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.42	-0.51	3.49e-18	Neuroticism;
KIRP	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.91	-0.3	1.65e-6	Type 2 diabetes;
KIRP	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.92	13.16	0.64	2.65e-30	Tonsillectomy;
KIRP	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg04935436	chr20:30431758	NA	0.44	5.61	0.34	5.55e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.74	-9.39	-0.51	4.25e-18	Huntington's disease progression;
KIRP	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg26338869	chr17:61819248	STRADA	0.43	4.97	0.3	1.26e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs675026	1.000	rs533586	chr6:154413674	C/T	cg07813322	chr6:154414604	OPRM1	-0.58	-7.42	-0.43	1.95e-12	Hypertension;
KIRP	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00585698	chr12:123750864	CDK2AP1	0.52	5.25	0.32	3.33e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.53	7.09	0.41	1.37e-11	Adiposity;
KIRP	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg21926883	chr2:100939477	LONRF2	-0.58	-7.81	-0.45	1.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4727443	0.866	rs12531809	chr7:99620473	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.4	5.19	0.31	4.42e-7	Interstitial lung disease;
KIRP	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.57	-6.08	-0.36	4.66e-9	Obesity-related traits;
KIRP	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.84	12.58	0.63	2.42e-28	Longevity;
KIRP	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg01028140	chr2:1542097	TPO	-0.78	-6.92	-0.4	3.9e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs3026101	0.578	rs55747983	chr17:5297742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.93	0.35	1.02e-8	Body mass index;
KIRP	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg15507776	chr3:136538369	TMEM22	0.39	5.31	0.32	2.42e-7	Neuroticism;
KIRP	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg20243544	chr17:37824526	PNMT	0.47	6.46	0.38	5.48e-10	Asthma;
KIRP	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.43	-0.33	1.35e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26229968	chr15:51915370	DMXL2	0.48	6.93	0.4	3.64e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg26441486	chr22:50317300	CRELD2	0.55	9.24	0.51	1.19e-17	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg22617819	chr1:44378782	ST3GAL3	-0.32	-5.31	-0.32	2.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg22284058	chr8:142237359	SLC45A4	-0.46	-5.49	-0.33	1.01e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.34	-0.32	2.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28489187	0.597	rs233053	chr1:85839507	G/A	cg16011679	chr1:85725395	C1orf52	0.44	5.52	0.33	8.66e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17554472	chr22:41940697	POLR3H	-0.69	-7.16	-0.42	9.11e-12	Vitiligo;
KIRP	trans	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09375338	chr21:35445901	SLC5A3;MRPS6	0.51	6.2	0.37	2.43e-9	Parkinson's disease;
KIRP	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg01877450	chr7:97915802	BRI3	-0.52	-6.53	-0.38	3.68e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.65	5.19	0.31	4.49e-7	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.99	-11.63	-0.6	3.29e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.54	-6.54	-0.38	3.53e-10	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg06243866	chr13:111019493	COL4A2	-0.75	-11.17	-0.58	1.03e-23	White matter hyperintensity burden;
KIRP	cis	rs698833	0.562	rs10182045	chr2:44704236	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.43	0.33	1.34e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.97	0.36	8.09e-9	Platelet count;
KIRP	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.73	9.81	0.53	2.13e-19	Height;
KIRP	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.32	0.47	5.92e-15	Morning vs. evening chronotype;
KIRP	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.55	-0.39	3.25e-10	Daytime sleep phenotypes;
KIRP	cis	rs2671245	0.933	rs2671241	chr1:56159340	G/A	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13224999	chr1:234509444	C1orf31	0.5	6.47	0.38	5.39e-10	Parkinson's disease;
KIRP	cis	rs918629	0.528	rs2547997	chr5:95254171	G/T	cg16656078	chr5:95278638	ELL2	-0.35	-5.28	-0.32	2.9e-7	IgG glycosylation;
KIRP	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.41	11.11	0.58	1.7e-23	Prostate cancer;
KIRP	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg19847130	chr8:10466454	RP1L1	-0.38	-5.38	-0.32	1.75e-7	Retinal vascular caliber;
KIRP	cis	rs13166103	0.571	rs963615	chr5:57755936	C/T	cg25141757	chr5:57759521	NA	0.44	5.06	0.31	8.05e-7	Type 2 diabetes (age of onset);
KIRP	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg05973401	chr12:123451056	ABCB9	0.6	7.07	0.41	1.64e-11	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs6840360	0.573	rs4696250	chr4:152266321	T/C	cg25486957	chr4:152246857	NA	-0.47	-5.66	-0.34	4.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21643547	chr1:205240462	TMCC2	-0.81	-12.49	-0.62	4.68e-28	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.09	-0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg24747557	chr10:131355152	MGMT	-0.42	-5.59	-0.34	6.05e-8	Response to temozolomide;
KIRP	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.9	0.35	1.17e-8	Lung cancer;
KIRP	cis	rs787274	0.867	rs2798316	chr9:115462552	T/C	cg13803584	chr9:115635662	SNX30	0.54	6.27	0.37	1.58e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04362095	chr11:63592001	C11orf84	-0.62	-8.4	-0.47	3.71e-15	Schizophrenia;
KIRP	cis	rs367943	0.712	rs9326884	chr5:112697520	C/A	cg12552261	chr5:112820674	MCC	0.56	6.56	0.39	3.14e-10	Type 2 diabetes;
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg02462569	chr6:150064036	NUP43	-0.4	-6.19	-0.37	2.48e-9	Lung cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20285609	chr1:41622030	SCMH1	-0.54	-7.04	-0.41	1.9e-11	Inflammatory biomarkers;
KIRP	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg03929089	chr4:120376271	NA	0.69	6.17	0.37	2.74e-9	Axial length;
KIRP	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg25902810	chr10:99078978	FRAT1	0.61	7.82	0.45	1.5700000000000001e-13	Monocyte count;
KIRP	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-1.0	-16.23	-0.72	9.12e-41	Height;
KIRP	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg13798780	chr7:105162888	PUS7	0.65	6.0	0.36	6.85e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6499255	0.904	rs7187653	chr16:69562838	G/C	cg15192750	chr16:69999425	NA	0.47	4.86	0.3	2.07e-6	IgE levels;
KIRP	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.46	5.63	0.34	5.01e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg23791538	chr6:167370224	RNASET2	-0.54	-6.21	-0.37	2.29e-9	Primary biliary cholangitis;
KIRP	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.48	-5.89	-0.35	1.25e-8	Initial pursuit acceleration;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15545021	chr2:30802226	LCLAT1	0.37	6.32	0.37	1.21e-9	C-reactive protein;
KIRP	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.64	-6.83	-0.4	6.75e-11	Bipolar disorder;
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg19923238	chr8:142232952	SLC45A4	-0.41	-4.87	-0.3	2e-6	Immature fraction of reticulocytes;
KIRP	cis	rs7084402	0.967	rs1649082	chr10:60292434	A/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.96	-0.57	5.02e-23	Refractive error;
KIRP	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.62	5.34	0.32	2.13e-7	Cognitive test performance;
KIRP	cis	rs6901250	0.788	rs591794	chr6:117089018	G/A	cg12892004	chr6:117198278	RFX6	0.56	8.8	0.49	2.51e-16	C-reactive protein levels;
KIRP	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.57	7.22	0.42	6.48e-12	Coronary artery disease;
KIRP	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.5	-5.97	-0.36	8.1e-9	Colorectal cancer;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg01721255	chr8:58191610	C8orf71	-0.59	-5.38	-0.32	1.77e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg08761264	chr16:28874980	SH2B1	-0.52	-6.03	-0.36	6.09e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.89	-12.75	-0.63	6.19e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14162927	chr1:155145774	TRIM46;KRTCAP2	0.47	6.22	0.37	2.08e-9	Myopia (pathological);
KIRP	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg03714773	chr7:91764589	CYP51A1	-0.39	-5.67	-0.34	3.94e-8	Breast cancer;
KIRP	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17123764	0.818	rs1902330	chr12:49939953	G/A	cg02054252	chr12:50078554	FMNL3	0.43	4.89	0.3	1.85e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.49	0.38	4.76e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg23594656	chr7:65796392	TPST1	0.54	8.33	0.47	5.86e-15	Aortic root size;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-7.67	-0.44	4.03e-13	Lymphocyte counts;
KIRP	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	0.88	14.96	0.69	2.05e-36	Vitiligo;
KIRP	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg04369109	chr6:150039330	LATS1	-0.66	-8.72	-0.49	4.13e-16	Lung cancer;
KIRP	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg09699651	chr6:150184138	LRP11	0.48	6.25	0.37	1.84e-9	Lung cancer;
KIRP	trans	rs1223583	0.743	rs1223580	chr10:95771829	C/G	cg21774281	chr1:72750124	NA	-0.41	-6.41	-0.38	7.48e-10	Coronary artery disease;
KIRP	cis	rs10510057	0.637	rs2917939	chr10:121313621	G/A	cg06765389	chr10:121379685	NA	-0.44	-6.95	-0.41	3.28e-11	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.49	6.33	0.37	1.13e-9	Testicular germ cell tumor;
KIRP	cis	rs17123764	0.605	rs7954994	chr12:50068089	C/T	cg20471783	chr12:50157085	TMBIM6	0.32	5.05	0.31	8.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6900992	1	rs6900992	chr6:141021851	T/C	cg24154271	chr6:140957775	NA	0.36	4.94	0.3	1.41e-6	Night sleep phenotypes;
KIRP	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg05044414	chr3:183734942	ABCC5	0.38	5.75	0.34	2.62e-8	Anterior chamber depth;
KIRP	cis	rs3007168	1.000	rs2999356	chr14:51606543	A/G	cg23942311	chr14:51606299	NA	0.52	5.54	0.33	7.92e-8	Cancer;
KIRP	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg04691961	chr3:161091175	C3orf57	-0.39	-5.39	-0.32	1.65e-7	Parkinson's disease;
KIRP	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg00677455	chr12:58241039	CTDSP2	-0.52	-5.78	-0.35	2.28e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.52	-6.19	-0.37	2.46e-9	Ulcerative colitis;
KIRP	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.22e-13	Coronary artery calcification;
KIRP	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.55	-0.39	3.32e-10	Recombination measurement;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg21036854	chr14:77506705	NA	0.68	6.42	0.38	7.09e-10	Lung function (FEV1);
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg09695851	chr17:3907499	NA	0.81	14.63	0.68	2.67e-35	Type 2 diabetes;
KIRP	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.62	-8.8	-0.49	2.45e-16	Colorectal cancer;
KIRP	cis	rs7404928	0.681	rs16972959	chr16:23901376	G/A	cg21745164	chr16:23765304	CHP2	-0.65	-7.41	-0.43	2e-12	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg07741184	chr6:167504864	NA	-0.2	-5.07	-0.31	7.79e-7	Graves' disease;
KIRP	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg18105134	chr13:113819100	PROZ	-1.09	-12.27	-0.62	2.56e-27	Platelet distribution width;
KIRP	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.2	13.88	0.66	9.98e-33	Sexual dysfunction (female);
KIRP	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg16989719	chr2:238392110	NA	-0.61	-8.55	-0.48	1.36e-15	Prostate cancer;
KIRP	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.54	5.44	0.33	1.28e-7	Gut microbiome composition (summer);
KIRP	trans	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg01311341	chr22:25575246	KIAA1671	-0.63	-7.55	-0.43	8.25e-13	Atopic dermatitis;
KIRP	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.69	0.63	9.93e-29	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02172790	chr2:61404147	AHSA2	0.55	7.01	0.41	2.28e-11	Parkinson's disease;
KIRP	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg09596252	chr17:78655493	RPTOR	0.53	6.12	0.36	3.77e-9	Fractional excretion of uric acid;
KIRP	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg10223061	chr2:219282414	VIL1	0.45	7.27	0.42	4.7e-12	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.56	0.33	7.12e-8	Breast cancer;
KIRP	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg00631329	chr6:26305371	NA	0.55	6.96	0.41	3.14e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.53	-0.33	8.2e-8	Aortic root size;
KIRP	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-8.27	-0.47	8.71e-15	Diastolic blood pressure;
KIRP	cis	rs17101923	0.853	rs12422370	chr12:66363539	C/G	cg06712651	chr12:66351869	HMGA2	-0.56	-5.98	-0.36	7.63e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.66	9.47	0.52	2.42e-18	Menarche (age at onset);
KIRP	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.59	-7.38	-0.43	2.44e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.16	0.37	2.93e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg04660111	chr19:49199234	FUT2	0.33	4.91	0.3	1.66e-6	Dietary macronutrient intake;
KIRP	cis	rs2802372	0.801	rs1108618	chr10:81043743	C/T	cg18688392	chr10:81059414	ZMIZ1	0.44	5.9	0.35	1.18e-8	Granulocyte count;
KIRP	cis	rs17772222	0.606	rs1955598	chr14:88823655	C/T	cg21796528	chr14:89672919	FOXN3	-0.39	-5.06	-0.31	8.23e-7	Coronary artery calcification;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11512797	chr11:9448817	IPO7;SNORA23	0.42	6.02	0.36	6.2e-9	Survival in pancreatic cancer;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg10534938	chr5:1868639	NA	0.38	5.15	0.31	5.38e-7	Cardiovascular disease risk factors;
KIRP	cis	rs2273669	0.667	rs12200531	chr6:109320441	T/C	cg05315195	chr6:109294784	ARMC2	-0.62	-6.19	-0.37	2.5e-9	Prostate cancer;
KIRP	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.34	0.42	3.2e-12	Bipolar disorder;
KIRP	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.71	6.93	0.4	3.66e-11	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15059257	chr1:43147884	YBX1	0.45	6.17	0.37	2.81e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2040771	0.740	rs9617783	chr22:19260575	C/A	cg02655711	chr22:19163373	SLC25A1	0.48	6.68	0.39	1.58e-10	Metabolite levels (small molecules and protein measures);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19649564	chr11:124932892	SLC37A2	0.44	6.12	0.36	3.73e-9	Parkinson's disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17762617	chr12:118573850	PEBP1	0.46	6.1	0.36	4.13e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg10047753	chr17:41438598	NA	1.08	17.23	0.74	3.69e-44	Menopause (age at onset);
KIRP	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg24747557	chr10:131355152	MGMT	-0.38	-5.05	-0.31	8.72e-7	Response to temozolomide;
KIRP	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23903597	chr17:61704154	MAP3K3	-0.49	-5.6	-0.34	5.7e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-0.83	-9.6	-0.52	9.95e-19	Gut microbiome composition (summer);
KIRP	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.82	8.81	0.49	2.37e-16	Iron status biomarkers;
KIRP	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.62	0.34	5.12e-8	Blood protein levels;
KIRP	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg08885076	chr2:99613938	TSGA10	-0.49	-6.04	-0.36	5.68e-9	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19386159	chr12:109125243	CORO1C	0.52	6.62	0.39	2.18e-10	Parkinson's disease;
KIRP	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.63	0.39	2.06e-10	Educational attainment;
KIRP	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.6	8.95	0.5	8.79e-17	Itch intensity from mosquito bite;
KIRP	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.31	-0.42	3.77e-12	Morning vs. evening chronotype;
KIRP	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg15655495	chr12:38532458	NA	0.26	4.9	0.3	1.73e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15557168	chr22:42548783	NA	0.42	5.41	0.33	1.51e-7	Cognitive function;
KIRP	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg06640241	chr16:89574553	SPG7	0.65	8.79	0.49	2.7e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg22138327	chr13:27999177	GTF3A	0.75	6.78	0.4	9.05e-11	Weight;
KIRP	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg25124228	chr12:125621409	AACS	-0.55	-6.28	-0.37	1.54e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.48	5.62	0.34	5.1e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	7.13	0.41	1.09e-11	Height;
KIRP	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg06740227	chr12:86229804	RASSF9	-0.47	-6.04	-0.36	5.54e-9	Major depressive disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21790971	chr4:54244117	FIP1L1	0.58	6.98	0.41	2.68e-11	Smoking initiation;
KIRP	cis	rs72827839	0.761	rs79541578	chr17:46102728	G/A	cg03171361	chr17:47075758	IGF2BP1	-0.47	-4.85	-0.3	2.2e-6	Ease of getting up in the morning;
KIRP	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg00409905	chr10:38381863	ZNF37A	0.59	6.42	0.38	7.09e-10	Obesity (extreme);
KIRP	cis	rs7553864	1.000	rs4551570	chr1:87614019	C/A	cg17420885	chr1:87600446	LOC339524	-0.46	-6.15	-0.37	3.03e-9	Smoking behavior;
KIRP	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.71	-10.46	-0.55	2.06e-21	Hip circumference;
KIRP	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg14289246	chr4:154710475	SFRP2	0.55	6.7	0.39	1.44e-10	Response to statins (LDL cholesterol change);
KIRP	cis	rs11608355	0.521	rs6606703	chr12:109813665	C/T	cg19025524	chr12:109796872	NA	-0.51	-7.03	-0.41	2.06e-11	Neuroticism;
KIRP	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.76	9.13	0.5	2.54e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26002218	chr14:103986227	CKB	0.26	5.02	0.31	9.69e-7	Body mass index;
KIRP	trans	rs12517041	0.935	rs10061491	chr5:23296773	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10208594	chr10:52383849	SGMS1	0.53	6.62	0.39	2.25e-10	Parkinson's disease;
KIRP	cis	rs28595532	0.545	rs17516512	chr4:119258491	T/C	cg21605333	chr4:119757512	SEC24D	0.69	5.84	0.35	1.67e-8	Cannabis dependence symptom count;
KIRP	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-10.86	-0.57	1.09e-22	Chronic sinus infection;
KIRP	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg10950524	chr7:2139216	MAD1L1	0.32	5.1	0.31	6.71e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg06521331	chr12:34319734	NA	-0.61	-7.38	-0.43	2.39e-12	Morning vs. evening chronotype;
KIRP	cis	rs7903847	0.642	rs11812223	chr10:99158455	T/C	cg20016023	chr10:99160130	RRP12	-0.43	-5.82	-0.35	1.79e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg16482183	chr6:26056742	HIST1H1C	0.38	5.02	0.31	9.72e-7	Schizophrenia;
KIRP	cis	rs6142102	1.000	rs4911410	chr20:32710974	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	6.41	0.38	7.33e-10	Skin pigmentation;
KIRP	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.75	9.75	0.53	3.45e-19	Renal function-related traits (BUN);
KIRP	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.72	-7.53	-0.43	9.56e-13	DNA methylation (variation);
KIRP	cis	rs1476679	1.000	rs1476679	chr7:100004446	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.5	-5.43	-0.33	1.35e-7	Alzheimer's disease (late onset);
KIRP	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.33	-0.37	1.17e-9	Bipolar disorder;
KIRP	cis	rs4742903	0.901	rs10122512	chr9:106898410	C/T	cg14250997	chr9:106856677	SMC2	0.38	5.01	0.3	1.06e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg01620082	chr3:125678407	NA	-1.14	-7.28	-0.42	4.53e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.76	-11.28	-0.58	4.71e-24	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg00129232	chr17:37814104	STARD3	-0.62	-7.56	-0.43	7.94e-13	Lymphocyte counts;
KIRP	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg05484376	chr2:27715224	FNDC4	-0.33	-5.45	-0.33	1.19e-7	Total body bone mineral density;
KIRP	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-7.82	-0.45	1.54e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10924309	0.882	rs10924306	chr1:245857065	G/A	cg00036263	chr1:245852353	KIF26B	-0.5	-6.76	-0.4	1.01e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.46	5.72	0.34	3.1e-8	Height;
KIRP	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg26554054	chr8:600488	NA	0.69	5.35	0.32	2.05e-7	IgG glycosylation;
KIRP	cis	rs57994353	0.796	rs3923776	chr9:139331221	G/C	cg14169450	chr9:139327907	INPP5E	0.58	6.95	0.41	3.29e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.71	7.27	0.42	4.79e-12	Vitiligo;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11733266	chr13:99096847	FARP1	0.44	6.02	0.36	6.36e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-5.48	-0.33	1.08e-7	Neuroticism;
KIRP	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg16988262	chr1:15930761	NA	0.38	4.9	0.3	1.77e-6	Systolic blood pressure;
KIRP	cis	rs4671400	0.516	rs1809028	chr2:61413723	A/G	cg15711740	chr2:61764176	XPO1	-0.62	-6.05	-0.36	5.44e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03352830	chr11:487213	PTDSS2	0.77	6.22	0.37	2.15e-9	Body mass index;
KIRP	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg02775129	chr4:119771670	NA	-0.87	-4.93	-0.3	1.54e-6	Cannabis dependence symptom count;
KIRP	cis	rs12643440	0.538	rs62296684	chr4:17137455	A/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.92	15.68	0.71	6.93e-39	Metabolic syndrome;
KIRP	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.63	0.34	5.02e-8	Total cholesterol levels;
KIRP	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg14228332	chr4:119757509	SEC24D	0.84	4.99	0.3	1.15e-6	Cannabis dependence symptom count;
KIRP	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.59	8.74	0.49	3.74e-16	Mean corpuscular volume;
KIRP	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg24579218	chr15:68104479	NA	-0.51	-7.42	-0.43	1.92e-12	Restless legs syndrome;
KIRP	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.71	10.64	0.56	5.37e-22	Lewy body disease;
KIRP	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg15832292	chr6:96025679	MANEA	0.64	4.97	0.3	1.24e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7180079	0.620	rs571441	chr15:64910945	G/T	cg15337035	chr15:64978493	NA	-0.47	-5.19	-0.31	4.49e-7	Monocyte count;
KIRP	cis	rs714027	0.585	rs41157	chr22:30405151	T/C	cg27665648	chr22:30112403	NA	-0.39	-5.32	-0.32	2.34e-7	Lymphocyte counts;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26133196	chr11:64727603	C11orf85	0.48	7.2	0.42	7.13e-12	Interleukin-4 levels;
KIRP	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.57	-7.94	-0.45	7.37e-14	Brugada syndrome;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25853020	chr1:154377621	IL6R	0.57	7.29	0.42	4.15e-12	Smoking initiation;
KIRP	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.73	0.39	1.21e-10	Coffee consumption (cups per day);
KIRP	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg21395723	chr22:39101663	GTPBP1	0.41	4.85	0.3	2.15e-6	Menopause (age at onset);
KIRP	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.2	-0.31	4.12e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10214930	0.781	rs6943883	chr7:27692893	A/T	cg22168087	chr7:27702803	HIBADH	0.51	4.99	0.3	1.12e-6	Hypospadias;
KIRP	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.35	9.02	0.5	5.38e-17	Crohn's disease;
KIRP	cis	rs1829883	0.804	rs114992703	chr5:98813521	A/G	cg08333243	chr5:99726346	NA	-0.38	-5.11	-0.31	6.51e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.66	7.54	0.43	8.93e-13	Corneal astigmatism;
KIRP	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.84	-10.71	-0.56	3.25e-22	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	trans	rs1106684	1.000	rs67445850	chr7:131457430	G/A	cg13607082	chr12:122652224	LRRC43	-0.64	-6.71	-0.39	1.32e-10	Body mass index;
KIRP	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.33	-5.91	-0.35	1.14e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg00614314	chr15:82944287	LOC80154	0.54	6.16	0.37	3.03e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg15590007	chr10:45870220	ALOX5	0.6	6.28	0.37	1.56e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.77	-11.02	-0.58	3.15e-23	Height;
KIRP	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26002218	chr14:103986227	CKB	0.26	4.95	0.3	1.41e-6	Body mass index;
KIRP	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.89	-0.3	1.86e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02034447	chr16:89574710	SPG7	0.38	4.86	0.3	2.12e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.6e-16	Motion sickness;
KIRP	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg00864860	chr1:7907996	UTS2	-0.48	-5.69	-0.34	3.55e-8	Crohn's disease;
KIRP	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg07796016	chr1:152779584	LCE1C	-0.46	-5.89	-0.35	1.3e-8	Inflammatory skin disease;
KIRP	cis	rs4356932	0.935	rs6532155	chr4:76974097	G/T	cg19388996	chr4:76862389	NAAA	0.4	5.13	0.31	5.78e-7	Blood protein levels;
KIRP	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg24375607	chr4:120327624	NA	0.59	6.16	0.37	2.9e-9	Corneal astigmatism;
KIRP	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg00981070	chr1:2046702	PRKCZ	-0.31	-5.5	-0.33	9.46e-8	Height;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg20673091	chr1:2541236	MMEL1	0.78	12.84	0.63	3.09e-29	Ulcerative colitis;
KIRP	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.45	-5.7	-0.34	3.41e-8	Blood metabolite levels;
KIRP	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.48	-6.21	-0.37	2.25e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.87	12.26	0.62	2.85e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.82	-0.35	1.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4924935	0.851	rs17743944	chr17:18809268	A/G	cg26378065	chr17:18585709	ZNF286B	-0.47	-4.94	-0.3	1.46e-6	Pancreatic cancer;
KIRP	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.65	8.96	0.5	8.16e-17	Brugada syndrome;
KIRP	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.7	7.65	0.44	4.6e-13	Vitiligo;
KIRP	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.72	-7.17	-0.42	8.9e-12	Menarche (age at onset);
KIRP	cis	rs830383	0.509	rs153284	chr5:165411778	A/G	cg13976338	chr5:165423657	NA	-0.46	-5.05	-0.31	8.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg26875233	chr11:93583750	C11orf90	-0.4	-7.52	-0.43	1.02e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2273669	0.588	rs12205061	chr6:109338161	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.48	-0.38	4.91e-10	Prostate cancer;
KIRP	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.75e-15	Aortic root size;
KIRP	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.76	8.52	0.48	1.58e-15	Coronary artery disease;
KIRP	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.15	-0.41	9.94e-12	Alzheimer's disease (late onset);
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.7	-8.98	-0.5	6.99e-17	Body mass index;
KIRP	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.27	-0.32	3.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	9.55	0.52	1.34e-18	Coronary artery disease;
KIRP	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg10117171	chr1:25599238	RHD	-0.39	-5.43	-0.33	1.36e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	1.2	15.26	0.7	1.98e-37	Response to hepatitis C treatment;
KIRP	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.19	0.31	4.32e-7	Lung cancer;
KIRP	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg02462569	chr6:150064036	NUP43	-0.37	-5.62	-0.34	5.03e-8	Lung cancer;
KIRP	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg08975724	chr8:8085496	FLJ10661	0.54	7.25	0.42	5.25e-12	Joint mobility (Beighton score);
KIRP	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg06740227	chr12:86229804	RASSF9	0.41	5.14	0.31	5.53e-7	Major depressive disorder;
KIRP	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg10326726	chr10:51549505	MSMB	-0.58	-8.43	-0.47	2.87e-15	Prostate-specific antigen levels;
KIRP	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.71	-11.05	-0.58	2.59e-23	Educational attainment;
KIRP	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg03388025	chr16:89894329	SPIRE2	0.31	5.86	0.35	1.5e-8	Vitiligo;
KIRP	cis	rs7932354	0.528	rs7121418	chr11:47165106	G/A	cg16389345	chr11:46697382	NA	0.39	5.22	0.32	3.86e-7	Bone mineral density (hip);Bone mineral density;
KIRP	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.18	-16.33	-0.72	4.28e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg05360138	chr12:110035743	NA	0.49	5.54	0.33	7.95e-8	Neuroticism;
KIRP	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg10755058	chr3:40428713	ENTPD3	0.38	5.41	0.33	1.53e-7	Renal cell carcinoma;
KIRP	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-6.19	-0.37	2.45e-9	Asthma;
KIRP	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs2273156	0.570	rs57075379	chr14:35577801	A/G	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.05	-0.31	8.58e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.61	-7.64	-0.44	4.71e-13	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18794809	chr3:156480627	NA	0.45	6.82	0.4	6.95e-11	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05153820	chr5:149829439	RPS14	0.54	6.96	0.41	3.16e-11	Parkinson's disease;
KIRP	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.87	-0.35	1.37e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.08	-0.31	7.48e-7	Pulmonary function;
KIRP	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg11941060	chr3:133502564	NA	-0.48	-5.95	-0.35	8.95e-9	Iron status biomarkers;
KIRP	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.61	-0.34	5.5e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.97	0.36	8.39e-9	Lung cancer;
KIRP	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.51e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs2540949	0.538	rs2540970	chr2:65255099	C/T	cg05010058	chr2:65284262	CEP68	-0.4	-5.51	-0.33	9.19e-8	Atrial fibrillation;
KIRP	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.76	9.35	0.51	5.67e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg25059588	chr2:220286185	DES	0.41	6.15	0.37	3.19e-9	Serum protein levels (sST2);
KIRP	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg26138937	chr11:71823887	C11orf51	-0.7	-5.64	-0.34	4.56e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg17554472	chr22:41940697	POLR3H	-0.51	-5.72	-0.34	3.05e-8	Neuroticism;
KIRP	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.46	-5.11	-0.31	6.57e-7	Neuroticism;
KIRP	cis	rs4237845	0.611	rs6581159	chr12:58323876	C/T	cg02175503	chr12:58329896	NA	-0.57	-7.44	-0.43	1.71e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg10018233	chr7:150070692	REPIN1	0.61	6.92	0.4	3.79e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg17441377	chr17:3906640	NA	0.52	7.77	0.44	2.12e-13	Type 2 diabetes;
KIRP	cis	rs2380205	0.967	rs7898042	chr10:5893402	T/C	cg27141509	chr10:5886111	NA	-0.37	-5.33	-0.32	2.22e-7	Breast cancer;
KIRP	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.74	10.5	0.56	1.47e-21	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.84	-0.45	1.38e-13	Retinal vascular caliber;
KIRP	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg03264133	chr6:25882463	NA	0.37	4.96	0.3	1.34e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6142102	0.812	rs761236	chr20:32520051	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	5.85	0.35	1.59e-8	Skin pigmentation;
KIRP	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.68	-8.65	-0.48	6.85e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.97	16.51	0.73	1e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.41	-7.93	-0.45	7.43e-14	Longevity;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00259882	chr11:70049130	FADD	-0.46	-6.69	-0.39	1.48e-10	Metabolic traits;
KIRP	cis	rs4812048	0.793	rs7266693	chr20:57593158	T/C	cg14073986	chr20:57617431	SLMO2	0.56	5.15	0.31	5.35e-7	Mean platelet volume;
KIRP	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg10223061	chr2:219282414	VIL1	-0.32	-5.3	-0.32	2.57e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1065852	0.510	rs5751247	chr22:42633054	T/C	cg15128208	chr22:42549153	NA	0.55	6.66	0.39	1.78e-10	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs2790457	0.833	rs1265847	chr10:28929686	G/A	cg05705492	chr10:28955341	NA	-0.54	-8.11	-0.46	2.44e-14	Multiple myeloma;
KIRP	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.64	-9.62	-0.52	8.51e-19	Endometriosis;
KIRP	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.2	-0.46	1.37e-14	Monocyte percentage of white cells;
KIRP	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg14703610	chr5:56206110	C5orf35	0.49	6.68	0.39	1.59e-10	Coronary artery disease;
KIRP	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.82	8.74	0.49	3.67e-16	Prostate cancer;
KIRP	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.93	13.81	0.66	1.62e-32	Tonsillectomy;
KIRP	cis	rs7633787	0.511	rs537660	chr3:23054508	A/G	cg00327796	chr3:23032191	NA	-0.42	-5.4	-0.33	1.55e-7	Facial morphology (factor 7, width of cartilaginous portion of nose);
KIRP	cis	rs3821902	0.646	rs17344723	chr3:64019808	G/A	cg09006292	chr3:64049408	NA	-0.51	-5.18	-0.31	4.52e-7	Breast cancer;
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19500275	chr17:80737654	TBCD	0.45	5.35	0.32	2.05e-7	Glycated hemoglobin levels;
KIRP	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.4	6.74	0.39	1.13e-10	Heart rate;
KIRP	cis	rs4006360	0.686	rs1848814	chr17:39240281	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.62	-9.53	-0.52	1.57e-18	Bipolar disorder and schizophrenia;
KIRP	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18867708	chr6:26865862	GUSBL1	0.48	6.04	0.36	5.76e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.64	-12.2	-0.61	4.29e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg08795948	chr3:128337044	NA	0.52	6.45	0.38	5.75e-10	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.79	-10.64	-0.56	5.32e-22	Lung cancer;
KIRP	cis	rs7524258	0.517	rs6577430	chr1:7324468	C/T	cg08033730	chr1:7319125	CAMTA1	0.56	8.64	0.48	7.22e-16	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs4728302	0.869	rs6467510	chr7:133607968	A/G	cg10665199	chr7:133106180	EXOC4	0.45	5.5	0.33	9.72e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs17401966	0.540	rs6674949	chr1:10458480	A/G	cg19773385	chr1:10388646	KIF1B	-0.44	-6.36	-0.38	9.89e-10	Hepatocellular carcinoma;
KIRP	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.02	0.46	4.26e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22880420	chr2:33824856	FAM98A	0.56	6.44	0.38	6.33e-10	Smoking initiation;
KIRP	cis	rs17453880	0.929	rs10037655	chr5:152040281	C/T	cg12297329	chr5:152029980	NA	-0.7	-10.7	-0.56	3.46e-22	Subjective well-being;
KIRP	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.74	0.34	2.79e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	12.73	0.63	7.19e-29	Exhaled nitric oxide output;
KIRP	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	cis	rs12476592	0.571	rs196125	chr2:63859268	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs11603020	0.950	rs28362947	chr11:57369008	C/G	cg19752551	chr11:57585705	CTNND1	-0.67	-9.2	-0.51	1.61e-17	Blood protein levels;
KIRP	cis	rs7818345	1.000	rs7833166	chr8:19294634	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.75	0.34	2.66e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs2916247	1.000	rs734113	chr8:93060095	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.55	7.36	0.42	2.71e-12	Colorectal cancer;
KIRP	cis	rs7712401	0.580	rs35902490	chr5:122323398	G/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-4.97	-0.3	1.27e-6	Triglycerides;
KIRP	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg13409248	chr3:40428643	ENTPD3	0.36	5.02	0.3	9.92e-7	Renal cell carcinoma;
KIRP	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg24848339	chr3:12840334	CAND2	0.34	5.13	0.31	5.83e-7	QRS complex (12-leadsum);
KIRP	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.53	5.06	0.31	8.27e-7	Height;
KIRP	cis	rs13102973	0.965	rs4331828	chr4:135849100	C/G	cg14419869	chr4:135874104	NA	0.52	8.63	0.48	7.65e-16	Subjective well-being;
KIRP	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	trans	rs10874322	1.000	rs2011057	chr1:83058155	C/T	cg12753787	chr1:3239712	PRDM16	0.67	6.62	0.39	2.29e-10	Response to taxane treatment (docetaxel);
KIRP	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.94	14.12	0.67	1.48e-33	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1847505	0.562	rs11840753	chr13:61451581	C/T	cg25164009	chr13:61490935	NA	0.47	5.26	0.32	3.15e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.83	-10.07	-0.54	3.45e-20	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	10.93	0.57	6.27e-23	Coronary artery disease;
KIRP	cis	rs11264213	0.901	rs661233	chr1:36364716	A/G	cg27506609	chr1:36549197	TEKT2	0.96	9.92	0.53	1.03e-19	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.34	12.3	0.62	2.1e-27	Diabetic retinopathy;
KIRP	cis	rs7737355	0.947	rs58991576	chr5:130589540	T/C	cg06307176	chr5:131281290	NA	-0.51	-5.46	-0.33	1.17e-7	Life satisfaction;
KIRP	cis	rs918629	0.567	rs1841010	chr5:95251911	G/C	cg16656078	chr5:95278638	ELL2	-0.36	-5.39	-0.32	1.68e-7	IgG glycosylation;
KIRP	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.63	7.81	0.45	1.6e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg00024416	chr22:24240387	NA	-0.57	-7.1	-0.41	1.33e-11	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs12143943	0.835	rs12402641	chr1:204452779	G/A	cg20240347	chr1:204465584	NA	-0.38	-6.87	-0.4	5.37e-11	Cognitive performance;
KIRP	cis	rs11637445	0.627	rs72751453	chr15:68124665	C/A	cg24579218	chr15:68104479	NA	0.44	6.39	0.38	8.47e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.41	6.9	0.4	4.35e-11	Heart rate;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg26876637	chr1:152193138	HRNR	0.71	9.19	0.51	1.71e-17	Atopic dermatitis;
KIRP	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg04013166	chr16:89971882	TCF25	0.62	5.47	0.33	1.08e-7	Interleukin-17 levels;
KIRP	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg25486957	chr4:152246857	NA	-0.54	-5.83	-0.35	1.72e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	17.57	0.75	2.51e-45	Homoarginine levels;
KIRP	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg21548813	chr6:291882	DUSP22	-0.53	-6.2	-0.37	2.3e-9	Menopause (age at onset);
KIRP	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.56	6.92	0.4	3.89e-11	Renal function-related traits (BUN);
KIRP	cis	rs4077515	0.649	rs3087886	chr9:139301583	T/C	cg14169450	chr9:139327907	INPP5E	0.36	4.97	0.3	1.23e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07428648	chr11:118306105	MLL	0.47	7.07	0.41	1.57e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg01765077	chr12:122356316	WDR66	0.63	9.0	0.5	6.17e-17	Mean corpuscular volume;
KIRP	cis	rs2692947	0.759	rs2692937	chr2:96751871	G/A	cg23100626	chr2:96804247	ASTL	0.47	6.01	0.36	6.66e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Smoking initiation;
KIRP	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg10360139	chr7:1886902	MAD1L1	-0.53	-5.93	-0.35	1.02e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.37	0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg22681709	chr2:178499509	PDE11A	0.65	9.39	0.51	4.36e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs258892	0.947	rs17606	chr5:72184098	C/T	cg21869765	chr5:72125136	TNPO1	0.58	6.4	0.38	7.9e-10	Small cell lung carcinoma;
KIRP	cis	rs7688540	0.723	rs1986386	chr4:228809	T/C	cg17891759	chr4:299121	NA	-0.48	-4.89	-0.3	1.86e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	1.24	10.39	0.55	3.37e-21	Gut microbiota (bacterial taxa);
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg01238044	chr22:24384105	GSTT1	-0.49	-6.17	-0.37	2.76e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9583531	0.891	rs3742182	chr13:111375132	C/T	cg24331049	chr13:111365604	ING1	0.81	7.26	0.42	5.13e-12	Coronary artery disease;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.36	-5.39	-0.32	1.68e-7	Lymphocyte counts;
KIRP	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.6	-7.45	-0.43	1.6e-12	Neuroticism;
KIRP	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg05361325	chr10:32636312	EPC1	-0.65	-6.2	-0.37	2.38e-9	Sexual dysfunction (female);
KIRP	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg13319975	chr6:146136371	FBXO30	0.49	6.95	0.41	3.25e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.34	12.31	0.62	1.86e-27	Diabetic retinopathy;
KIRP	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs11650494	0.710	rs73987293	chr17:47474728	A/G	cg08112188	chr17:47440006	ZNF652	1.11	7.26	0.42	5.04e-12	Prostate cancer;
KIRP	cis	rs6577655	0.517	rs2241893	chr8:135586659	C/T	cg17885191	chr8:135476712	NA	0.7	6.65	0.39	1.86e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.54	-6.09	-0.36	4.37e-9	Diabetic retinopathy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17808901	chr3:39093368	WDR48	0.51	6.19	0.37	2.54e-9	Smoking initiation;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg19698572	chr12:110152093	C12orf34	-0.58	-6.7	-0.39	1.38e-10	Menopause (age at onset);
KIRP	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.25	6.8	0.4	8.11e-11	Crohn's disease;
KIRP	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg26338869	chr17:61819248	STRADA	0.53	6.34	0.37	1.1e-9	Prudent dietary pattern;
KIRP	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.58	0.39	2.76e-10	Diabetic retinopathy;
KIRP	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.67	7.27	0.42	4.82e-12	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10296153	chr3:3168554	TRNT1	0.49	6.52	0.38	3.98e-10	Parkinson's disease;
KIRP	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg12315302	chr6:26189340	HIST1H4D	0.71	5.24	0.32	3.44e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.61	-8.64	-0.48	7.26e-16	Menarche (age at onset);
KIRP	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.43	-0.47	2.89e-15	Neuroticism;
KIRP	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.95	10.09	0.54	3e-20	Alzheimer's disease;
KIRP	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs6921919	0.583	rs34513104	chr6:28343343	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8054556	0.647	rs11863174	chr16:30019375	A/C	cg06326092	chr16:30034487	C16orf92	0.43	6.39	0.38	8.15e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg08890418	chr1:21044141	KIF17	0.34	5.08	0.31	7.36e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8018808	1.000	rs12432247	chr14:77856321	T/C	cg20045696	chr14:77926864	AHSA1	-0.41	-5.11	-0.31	6.62e-7	Myeloid white cell count;
KIRP	cis	rs34779708	0.741	rs34397613	chr10:35550313	A/G	cg03585969	chr10:35415529	CREM	0.56	6.27	0.37	1.65e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.16	-0.42	9.19e-12	Triglycerides;
KIRP	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.55	5.24	0.32	3.41e-7	Crohn's disease;
KIRP	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.53	6.98	0.41	2.79e-11	Mean corpuscular volume;
KIRP	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	trans	rs3013648	0.777	rs10871193	chr13:85383427	C/T	cg21827674	chr12:133007847	NA	-0.7	-6.24	-0.37	1.93e-9	Huntington's disease progression;
KIRP	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg10223061	chr2:219282414	VIL1	-0.32	-5.19	-0.31	4.39e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.67	-11.37	-0.59	2.3e-24	Lung cancer;
KIRP	cis	rs9826463	0.582	rs55687115	chr3:142148372	G/A	cg20824294	chr3:142316082	PLS1	0.41	5.99	0.36	7.5e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.6	-6.11	-0.36	3.95e-9	Platelet count;
KIRP	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg22633769	chr20:60982531	CABLES2	-0.41	-4.94	-0.3	1.45e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg11635098	chr7:100497156	NA	-0.63	-6.7	-0.39	1.4e-10	Resting heart rate;
KIRP	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg22852734	chr6:133119734	C6orf192	1.05	11.5	0.59	8.76e-25	Type 2 diabetes nephropathy;
KIRP	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.6	9.07	0.5	3.93e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21263890	chr20:42839731	C20orf111	0.46	6.52	0.38	3.9e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs7615316	0.751	rs1825522	chr3:142003664	A/G	cg20824294	chr3:142316082	PLS1	0.23	5.44	0.33	1.29e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.46	-6.58	-0.39	2.82e-10	Refractive error;
KIRP	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg24972876	chr7:65420302	NA	0.41	5.58	0.34	6.38e-8	Aortic root size;
KIRP	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg00343986	chr7:65444356	GUSB	0.43	5.11	0.31	6.5e-7	Aortic root size;
KIRP	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.62e-8	Coronary artery disease;
KIRP	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.19	14.32	0.67	3.19e-34	Corneal structure;
KIRP	cis	rs2718058	0.606	rs2598077	chr7:37870427	G/C	cg15028436	chr7:37888078	TXNDC3	0.48	5.12	0.31	6.12e-7	Alzheimer's disease (late onset);
KIRP	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.24	16.75	0.73	1.59e-42	Corneal structure;
KIRP	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12826209	chr6:26865740	GUSBL1	0.67	6.27	0.37	1.6e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg06219351	chr7:158114137	PTPRN2	-0.61	-8.71	-0.49	4.4e-16	Calcium levels;
KIRP	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.76	7.79	0.44	1.88e-13	Iron status biomarkers;
KIRP	cis	rs1620921	0.505	rs9456586	chr6:161207643	G/A	cg01280913	chr6:161186852	NA	-0.61	-8.32	-0.47	6.11e-15	Lipoprotein (a) - cholesterol levels;
KIRP	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.86	-8.91	-0.49	1.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00908189	chr16:619842	PIGQ	0.83	10.96	0.57	5e-23	Height;
KIRP	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg16255804	chr6:135334527	HBS1L	-0.31	-4.89	-0.3	1.8e-6	Red blood cell count;
KIRP	trans	rs78438709	1.000	rs12571580	chr10:124131357	G/C	cg08224212	chr11:34196093	ABTB2	-0.96	-6.26	-0.37	1.74e-9	Headache;
KIRP	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.86	0.4	5.51e-11	Bipolar disorder;
KIRP	cis	rs13401104	0.587	rs56146026	chr2:237145629	A/G	cg02367144	chr2:237146137	ASB18	0.4	5.25	0.32	3.26e-7	Educational attainment;
KIRP	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg18761221	chr20:60518478	NA	0.51	5.65	0.34	4.51e-8	Obesity-related traits;
KIRP	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg13180566	chr4:1052158	NA	-0.52	-5.28	-0.32	2.81e-7	Recombination rate (females);
KIRP	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg06060754	chr5:176797920	RGS14	-0.43	-6.46	-0.38	5.55e-10	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.75	7.77	0.44	2.09e-13	Uric acid levels;
KIRP	cis	rs7119167	0.901	rs7127171	chr11:73165329	T/C	cg17517138	chr11:73019481	ARHGEF17	0.47	4.91	0.3	1.68e-6	Blood protein levels;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg00738919	chr7:1100172	C7orf50	0.42	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg08133631	chr1:26527909	CATSPER4	-0.44	-4.91	-0.3	1.67e-6	Obesity-related traits;
KIRP	trans	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg06521331	chr12:34319734	NA	-0.57	-6.99	-0.41	2.52e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs62413470	0.872	rs12189737	chr6:55941199	G/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	1.96e-6	Joint mobility (Beighton score);
KIRP	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg02524346	chr8:600233	NA	-0.69	-4.92	-0.3	1.56e-6	IgG glycosylation;
KIRP	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.0	0.36	7.14e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7555523	0.887	rs4657471	chr1:165686873	T/C	cg24409356	chr1:165738333	TMCO1	0.69	5.88	0.35	1.34e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg21226059	chr5:178986404	RUFY1	-0.53	-8.84	-0.49	1.87e-16	Lung cancer;
KIRP	cis	rs57502260	0.764	rs7105218	chr11:68222461	C/A	cg16797656	chr11:68205561	LRP5	0.47	4.93	0.3	1.51e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs7113850	0.541	rs4367945	chr11:24215605	A/C	ch.11.24196551F	chr11:24239977	NA	0.96	7.66	0.44	4.38e-13	Bone fracture in osteoporosis;
KIRP	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg18882449	chr10:104885122	NT5C2	-0.5	-6.47	-0.38	5.22e-10	Arsenic metabolism;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14027161	chr18:9913006	VAPA	-0.52	-7.16	-0.42	9.54e-12	Inflammatory biomarkers;
KIRP	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.46	5.86	0.35	1.51e-8	HDL cholesterol;
KIRP	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg02023728	chr11:77925099	USP35	-0.32	-5.58	-0.34	6.25e-8	Alzheimer's disease (survival time);
KIRP	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg13092806	chr2:177043255	NA	-0.66	-7.04	-0.41	1.86e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs13095912	0.785	rs6800725	chr3:185298156	C/A	cg11274856	chr3:185301563	NA	0.62	7.62	0.44	5.51e-13	Systolic blood pressure;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13445258	chr3:128369860	RPN1	0.71	6.6	0.39	2.51e-10	Lung function (FEV1);
KIRP	cis	rs2790457	0.958	rs2772433	chr10:28895946	A/G	cg05705492	chr10:28955341	NA	0.52	7.85	0.45	1.31e-13	Multiple myeloma;
KIRP	trans	rs9329221	0.502	rs11777364	chr8:10288546	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.01	0.41	2.34e-11	Neuroticism;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.82	13.15	0.64	2.8e-30	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-8.55	-0.48	1.36e-15	Response to antipsychotic treatment;
KIRP	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22531663	chr4:967528	DGKQ	0.48	6.18	0.37	2.6e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg24315340	chr6:146058215	EPM2A	0.42	5.31	0.32	2.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.75	-10.39	-0.55	3.38e-21	Childhood ear infection;
KIRP	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs17123764	0.818	rs74089570	chr12:49973282	G/C	cg20471783	chr12:50157085	TMBIM6	0.42	5.55	0.33	7.21e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.75	10.44	0.55	2.27e-21	Red blood cell count;
KIRP	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg21926883	chr2:100939477	LONRF2	-0.57	-7.88	-0.45	1.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-1.06	-20.78	-0.8	4.58e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12208915	0.945	rs12190108	chr6:79562655	T/C	cg18132916	chr6:79620363	NA	0.57	5.05	0.31	8.76e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	8.21	0.46	1.22e-14	Myopia (pathological);
KIRP	cis	rs2742234	0.955	rs2503841	chr10:43675721	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.54	-6.59	-0.39	2.69e-10	Hirschsprung disease;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.88e-7	Life satisfaction;
KIRP	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg06636001	chr8:8085503	FLJ10661	0.54	6.73	0.39	1.19e-10	Retinal vascular caliber;
KIRP	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg27205649	chr11:78285834	NARS2	-0.54	-5.0	-0.3	1.07e-6	Testicular germ cell tumor;
KIRP	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.05	-0.31	8.55e-7	Chronic sinus infection;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16101572	chr14:21566698	ZNF219;C14orf176	0.51	6.86	0.4	5.54e-11	Myopia (pathological);
KIRP	cis	rs684232	0.901	rs461251	chr17:619162	A/G	cg04370829	chr17:406249	NA	-0.41	-5.28	-0.32	2.82e-7	Prostate cancer;
KIRP	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.35	4.99	0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.68	9.37	0.51	5.05e-18	Body mass index;
KIRP	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	4.04e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-0.58	-8.32	-0.47	5.98e-15	Coronary artery disease;
KIRP	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.73	5.9	0.35	1.17e-8	Diabetic retinopathy;
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg15586392	chr8:142238691	SLC45A4	0.37	5.08	0.31	7.3e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.64	-6.33	-0.37	1.14e-9	White matter integrity;
KIRP	cis	rs9549328	0.765	rs1317506	chr13:113631143	C/T	cg17524180	chr13:113633600	MCF2L	-0.26	-5.14	-0.31	5.63e-7	Systolic blood pressure;
KIRP	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg09408571	chr1:101003634	GPR88	0.24	5.47	0.33	1.12e-7	Monocyte count;
KIRP	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.72	10.41	0.55	2.85e-21	Hip circumference;
KIRP	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.41	-0.33	1.48e-7	Asthma;
KIRP	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg13289132	chr10:30722225	MAP3K8	-0.44	-5.9	-0.35	1.23e-8	Inflammatory bowel disease;
KIRP	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg02775129	chr4:119771670	NA	-0.82	-4.88	-0.3	1.94e-6	Cannabis dependence symptom count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19050596	chr2:191879164	STAT1	0.52	7.09	0.41	1.4e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs997295	0.684	rs4776970	chr15:68080886	A/T	cg24579218	chr15:68104479	NA	-0.49	-7.74	-0.44	2.51e-13	Motion sickness;
KIRP	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg16497661	chr14:103986332	CKB	-0.48	-6.28	-0.37	1.5e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6686643	0.630	rs7554034	chr1:165610464	G/A	cg16553119	chr1:165599451	MGST3	-0.44	-4.88	-0.3	1.94e-6	Total ventricular volume;
KIRP	cis	rs4950322	0.570	rs72692979	chr1:146807832	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.39	-0.33	1.63e-7	Protein quantitative trait loci;
KIRP	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	1.17	11.61	0.59	3.93e-25	Red blood cell traits;
KIRP	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.56	10.14	0.54	1.98e-20	Iron status biomarkers (transferrin levels);
KIRP	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg07395648	chr5:131743802	NA	-0.5	-6.0	-0.36	7.04e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs11203032	0.831	rs10887932	chr10:90966996	C/G	cg16672925	chr10:90967113	CH25H	0.86	8.44	0.47	2.67e-15	Heart failure;
KIRP	cis	rs1485395	0.735	rs12818931	chr12:54072180	G/A	cg16917193	chr12:54089295	NA	0.77	5.18	0.31	4.71e-7	Migraine without aura;
KIRP	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3857067	0.934	rs899132	chr4:95040022	A/C	cg11021082	chr4:95130006	SMARCAD1	0.39	5.04	0.31	8.98e-7	QT interval;
KIRP	cis	rs2916247	1.000	rs6986808	chr8:93024393	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.47	-0.48	2.27e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.88	12.81	0.63	3.9e-29	Birth weight;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04738309	chr5:111093624	C5orf13	0.56	6.54	0.38	3.46e-10	Smoking initiation;
KIRP	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg11234688	chr2:1609660	NA	0.53	5.01	0.3	1.05e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg25828445	chr12:7781288	NA	0.51	5.1	0.31	6.7e-7	HDL cholesterol levels;
KIRP	cis	rs9473924	0.583	rs7768200	chr6:50931428	G/C	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg23161317	chr6:28129485	ZNF389	0.49	5.8	0.35	2.02e-8	Depression;
KIRP	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.5	6.8	0.4	7.66e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg12435725	chr3:58293450	RPP14	-0.47	-5.47	-0.33	1.12e-7	Cholesterol, total;
KIRP	cis	rs6815814	0.808	rs56245262	chr4:38845609	T/A	cg06935464	chr4:38784597	TLR10	0.45	5.38	0.32	1.72e-7	Breast cancer;
KIRP	cis	rs698833	0.828	rs786623	chr2:44606171	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.91	0.3	1.66e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg19274270	chr17:78178856	CARD14	0.37	6.67	0.39	1.72e-10	Morning vs. evening chronotype;
KIRP	trans	rs10107145	0.509	rs73209954	chr8:10760667	G/C	cg16141378	chr3:129829833	LOC729375	0.55	6.6	0.39	2.57e-10	Systolic blood pressure;
KIRP	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg03735888	chr19:58951602	ZNF132	0.48	5.85	0.35	1.54e-8	Uric acid clearance;
KIRP	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.57	9.09	0.5	3.4e-17	Body mass index (alcohol intake interaction);
KIRP	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg27624424	chr6:160112604	SOD2	0.47	4.94	0.3	1.46e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	0.83	11.47	0.59	1.12e-24	Essential tremor;
KIRP	cis	rs6882076	0.961	rs55776147	chr5:156400808	A/G	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.33	-0.42	3.31e-12	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg04287289	chr16:89883240	FANCA	0.58	7.76	0.44	2.33e-13	Vitiligo;
KIRP	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.05	0.41	1.83e-11	Mean platelet volume;
KIRP	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.26	11.86	0.6	5.96e-26	Alzheimer's disease (late onset);
KIRP	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs6450176	0.564	rs6874524	chr5:53343529	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.69	8.76	0.49	3.27e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs757081	0.671	rs214091	chr11:17296463	A/C	cg15432903	chr11:17409602	KCNJ11	-0.62	-7.24	-0.42	5.88e-12	Systolic blood pressure;
KIRP	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg23625390	chr15:77176239	SCAPER	0.51	6.79	0.4	8.43e-11	Blood metabolite levels;
KIRP	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg16586182	chr3:47516702	SCAP	0.81	11.17	0.58	1.08e-23	Colorectal cancer;
KIRP	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	0.9	9.92	0.53	9.71e-20	Corneal structure;
KIRP	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.48	-7.45	-0.43	1.56e-12	IgG glycosylation;
KIRP	cis	rs754423	0.543	rs10137154	chr14:52509887	A/G	cg05884192	chr14:52515736	NID2	0.53	5.83	0.35	1.71e-8	Craniofacial microsomia;
KIRP	cis	rs2916247	1.000	rs7825562	chr8:93022696	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.55	-6.94	-0.4	3.46e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg27129171	chr3:47204927	SETD2	0.51	6.29	0.37	1.47e-9	Birth weight;
KIRP	cis	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg04607699	chr11:48328132	OR4S1	-0.35	-4.94	-0.3	1.46e-6	HDL cholesterol;
KIRP	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.12	22.77	0.82	1.63e-62	Testicular germ cell tumor;
KIRP	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.24	-0.37	1.9e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.83	8.9	0.49	1.22e-16	Alzheimer's disease;
KIRP	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg20701182	chr2:24300061	SF3B14	0.91	10.13	0.54	2.24e-20	Lymphocyte counts;
KIRP	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg17178900	chr1:205818956	PM20D1	0.44	4.89	0.3	1.85e-6	Parkinson's disease;
KIRP	cis	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg19847130	chr8:10466454	RP1L1	0.35	5.05	0.31	8.66e-7	Neuroticism;
KIRP	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg03684893	chr10:554711	DIP2C	-0.35	-4.88	-0.3	1.89e-6	Psychosis in Alzheimer's disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09585974	chr10:31076192	NA	-0.53	-7.09	-0.41	1.41e-11	Inflammatory biomarkers;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00968012	chr17:46048404	CDK5RAP3	-0.46	-6.02	-0.36	6.33e-9	Myopia;
KIRP	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg05163923	chr11:71159392	DHCR7	-0.84	-8.45	-0.47	2.65e-15	Vitamin D levels;
KIRP	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg14517863	chr17:44321492	NA	0.5	5.8	0.35	2.06e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg12317470	chr15:67143691	NA	0.66	5.44	0.33	1.28e-7	Lung cancer (smoking interaction);
KIRP	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.6	-7.57	-0.43	7.49e-13	Obesity-related traits;
KIRP	cis	rs13006833	0.668	rs2664252	chr2:191148347	G/A	cg27211696	chr2:191398769	TMEM194B	0.38	5.41	0.33	1.53e-7	Urinary metabolites;
KIRP	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg13319975	chr6:146136371	FBXO30	0.41	5.64	0.34	4.61e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.86	13.18	0.64	2.19e-30	Colorectal cancer;
KIRP	trans	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg06521331	chr12:34319734	NA	-0.54	-6.89	-0.4	4.61e-11	Heart rate;
KIRP	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg03563238	chr19:33554763	RHPN2	-0.34	-5.93	-0.35	1.01e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.97	-0.3	1.28e-6	Renal cell carcinoma;
KIRP	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.52	7.3	0.42	4.06e-12	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12630409	chr1:36916195	OSCP1	0.5	6.53	0.38	3.77e-10	Parkinson's disease;
KIRP	cis	rs1440410	0.830	rs4690715	chr4:144180339	G/T	cg01719995	chr4:144104893	USP38	0.39	5.02	0.3	1.01e-6	Ischemic stroke;
KIRP	cis	rs12049351	0.665	rs3738186	chr1:229657230	A/C	cg11742688	chr1:229674241	ABCB10	-0.37	-5.57	-0.33	6.67e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-5.0	-0.3	1.11e-6	Blood protein levels;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg13880726	chr7:1868755	MAD1L1	0.52	6.03	0.36	5.95e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18679782	chr19:10216839	SNORD105;PPAN-P2RY11;PPAN	0.51	6.64	0.39	1.95e-10	Parkinson's disease;
KIRP	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.31	-0.32	2.41e-7	Schizophrenia;
KIRP	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.88	-10.41	-0.55	2.81e-21	Gut microbiome composition (summer);
KIRP	cis	rs4654899	0.580	rs1977296	chr1:21091543	G/T	cg08890418	chr1:21044141	KIF17	0.33	4.99	0.3	1.15e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs1318772	1.000	rs26962	chr5:112737010	C/A	cg12552261	chr5:112820674	MCC	0.77	4.97	0.3	1.24e-6	F-cell distribution;
KIRP	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.55	-6.64	-0.39	1.97e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.45	6.01	0.36	6.8e-9	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07305215	chr18:5296031	ZFP161	0.49	6.14	0.36	3.25e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg21698718	chr17:80085957	CCDC57	-0.34	-4.93	-0.3	1.49e-6	Life satisfaction;
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg13699009	chr12:122356056	WDR66	0.6	9.24	0.51	1.24e-17	Mean corpuscular volume;
KIRP	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05665937	chr4:1216051	CTBP1	0.57	7.91	0.45	8.6e-14	Obesity-related traits;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg04025307	chr7:1156635	C7orf50	0.74	7.73	0.44	2.73e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg14541582	chr5:601475	NA	-0.54	-5.94	-0.35	9.55e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.66	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	cis	rs11731606	0.668	rs774988	chr4:95420010	C/G	cg20625393	chr4:95128694	SMARCAD1	-0.5	-4.86	-0.3	2.1e-6	Mean platelet volume;
KIRP	cis	rs3767633	0.748	rs6667896	chr1:161837407	G/A	cg09175582	chr1:161736000	ATF6	0.74	5.98	0.36	7.87e-9	IgG glycosylation;
KIRP	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg23752985	chr2:85803571	VAMP8	-0.56	-8.16	-0.46	1.75e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.18	0.64	2.35e-30	Tonsillectomy;
KIRP	cis	rs2275565	0.752	rs1804742	chr1:237062628	C/T	cg17297354	chr1:237056641	MTR	-0.43	-5.29	-0.32	2.69e-7	Homocysteine levels;
KIRP	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-6.73	-0.39	1.21e-10	Bladder cancer;
KIRP	cis	rs3752645	0.764	rs79184476	chr7:106693670	T/G	cg02696742	chr7:106810147	HBP1	-0.75	-5.19	-0.31	4.35e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg12962167	chr3:53033115	SFMBT1	0.71	5.19	0.31	4.44e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg26174226	chr8:58114915	NA	-0.62	-7.29	-0.42	4.1e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.76	8.33	0.47	5.79e-15	Corneal astigmatism;
KIRP	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.62	6.67	0.39	1.64e-10	Corneal astigmatism;
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.52	7.96	0.45	6.31e-14	Lung cancer;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg20654260	chr6:44238905	TMEM151B	0.55	6.27	0.37	1.64e-9	Response to statin therapy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25523509	chr10:102504039	PAX2	0.54	7.1	0.41	1.31e-11	Parkinson's disease;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg09165964	chr15:75287851	SCAMP5	0.55	7.29	0.42	4.13e-12	Breast cancer;
KIRP	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-1.01	-20.59	-0.8	1.92e-55	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7712401	0.691	rs62377436	chr5:122353702	C/G	cg19412675	chr5:122181750	SNX24	-0.47	-5.2	-0.31	4.1e-7	Mean platelet volume;
KIRP	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg10223061	chr2:219282414	VIL1	-0.32	-5.14	-0.31	5.68e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg21775007	chr8:11205619	TDH	-0.48	-6.42	-0.38	6.95e-10	Triglycerides;
KIRP	cis	rs1318772	0.932	rs348939	chr5:112824737	G/C	cg12552261	chr5:112820674	MCC	-0.83	-5.93	-0.35	9.94e-9	F-cell distribution;
KIRP	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg05861140	chr6:150128134	PCMT1	-0.52	-7.22	-0.42	6.56e-12	Lung cancer;
KIRP	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.57	7.48	0.43	1.3e-12	Hip circumference;
KIRP	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.42	-0.43	1.91e-12	Bipolar disorder;
KIRP	cis	rs796825	0.530	rs1907683	chr3:119950617	A/C	cg21790991	chr3:120137480	FSTL1	-0.29	-5.03	-0.31	9.39e-7	HIV-1 susceptibility;
KIRP	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.82	11.91	0.6	3.85e-26	Bladder cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg25683012	chr12:57030113	BAZ2A	0.51	6.46	0.38	5.66e-10	Asthma;
KIRP	cis	rs710913	0.618	rs12030495	chr1:40089595	C/T	cg27567593	chr1:39956653	BMP8A	-0.38	-5.31	-0.32	2.47e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg21698718	chr17:80085957	CCDC57	0.34	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.9	-0.57	7.72e-23	Chronic sinus infection;
KIRP	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.63	6.56	0.39	3.15e-10	Response to diuretic therapy;
KIRP	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.49	7.08	0.41	1.53e-11	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg04132472	chr17:19861366	AKAP10	0.43	5.96	0.36	8.7e-9	Schizophrenia;
KIRP	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg07451762	chr16:28383216	NA	0.4	5.19	0.31	4.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.59	-0.34	5.96e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg04865290	chr3:52927548	TMEM110	-0.57	-7.36	-0.42	2.7e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	8.1	0.46	2.62e-14	Iron status biomarkers;
KIRP	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.42	4.86	0.3	2.06e-6	Menarche (age at onset);
KIRP	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.8	0.35	2.03e-8	Morning vs. evening chronotype;
KIRP	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg11494091	chr17:61959527	GH2	0.48	6.07	0.36	4.8e-9	Height;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg08740088	chr10:60532792	BICC1	-0.45	-6.29	-0.37	1.42e-9	Inflammatory biomarkers;
KIRP	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg09137382	chr11:130731461	NA	0.54	7.74	0.44	2.5e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg05562828	chr17:3906858	NA	-0.72	-14.64	-0.68	2.49e-35	Type 2 diabetes;
KIRP	cis	rs728478	0.967	rs12600623	chr17:57456292	G/A	cg16535752	chr17:57448097	YPEL2	-0.23	-5.28	-0.32	2.86e-7	QT interval;
KIRP	cis	rs4654899	0.680	rs4654879	chr1:21186378	G/A	cg08890418	chr1:21044141	KIF17	-0.34	-5.06	-0.31	8.18e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.68	0.39	1.57e-10	Mean corpuscular volume;
KIRP	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg12218747	chr21:37451666	NA	0.44	5.58	0.34	6.34e-8	Mitral valve prolapse;
KIRP	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.74	0.53	3.72e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/A	cg16427107	chr15:75912924	SNUPN	-0.46	-5.42	-0.33	1.44e-7	Sudden cardiac arrest;
KIRP	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-6.13	-0.36	3.51e-9	Bone mineral density;
KIRP	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19671926	chr4:122722719	EXOSC9	-0.43	-4.91	-0.3	1.65e-6	Type 2 diabetes;
KIRP	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.96	11.29	0.58	4.45e-24	Corneal astigmatism;
KIRP	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.87	-0.53	1.41e-19	Response to antipsychotic treatment;
KIRP	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	6.26	0.37	1.69e-9	Personality dimensions;
KIRP	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-4.94	-0.3	1.45e-6	Schizophrenia;
KIRP	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg21360079	chr12:107162445	NA	-0.67	-9.52	-0.52	1.68e-18	Heart rate;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21016266	chr12:122356598	WDR66	0.48	6.53	0.38	3.83e-10	Mean corpuscular volume;
KIRP	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg13978929	chr19:21580086	ZNF493	-0.5	-4.95	-0.3	1.39e-6	Pain;
KIRP	trans	rs2975734	0.709	rs4841298	chr8:10111637	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.52	-0.38	3.92e-10	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg21775007	chr8:11205619	TDH	-0.41	-5.16	-0.31	5.02e-7	Morning vs. evening chronotype;
KIRP	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20913106	chr8:38324522	FGFR1	0.47	6.49	0.38	4.63e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg12962167	chr3:53033115	SFMBT1	0.71	5.28	0.32	2.8e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-16.01	-0.71	5.21e-40	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.73	7.35	0.42	2.91e-12	Bipolar disorder;
KIRP	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.09	-0.31	7.28e-7	Rheumatoid arthritis;
KIRP	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg07596299	chr11:71824057	C11orf51	-0.9	-5.96	-0.36	8.71e-9	Severe influenza A (H1N1) infection;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg00758229	chr3:25469148	RARB	-0.44	-6.2	-0.37	2.34e-9	Bladder cancer;
KIRP	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg02487422	chr3:49467188	NICN1	0.4	5.72	0.34	3.07e-8	Menarche (age at onset);
KIRP	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.57	0.43	7.72e-13	Lung cancer;
KIRP	cis	rs10114408	0.918	rs10992943	chr9:96640493	G/A	cg14598338	chr9:96623480	NA	-0.33	-4.85	-0.3	2.24e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg25457927	chr22:38595422	NA	-0.3	-6.16	-0.37	2.88e-9	Breast cancer;
KIRP	cis	rs7546094	1.000	rs3013440	chr1:113195789	G/A	cg22162597	chr1:113214053	CAPZA1	-0.5	-7.06	-0.41	1.67e-11	Platelet distribution width;
KIRP	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.68	8.69	0.48	5.13e-16	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg01620082	chr3:125678407	NA	-1.14	-6.67	-0.39	1.7e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg09695851	chr17:3907499	NA	0.54	5.14	0.31	5.72e-7	Type 2 diabetes;
KIRP	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg05315796	chr3:52349193	DNAH1	-0.39	-5.54	-0.33	7.64e-8	Bipolar disorder;
KIRP	cis	rs11723261	0.582	rs11735742	chr4:142550	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.45	-4.86	-0.3	2.11e-6	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.77	9.71	0.53	4.6e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2658782	0.654	rs2605623	chr11:93249359	A/G	cg15737290	chr11:93063684	CCDC67	0.66	7.68	0.44	3.74e-13	Pulmonary function decline;
KIRP	cis	rs7246657	0.551	rs62108899	chr19:37595183	C/T	cg23950597	chr19:37808831	NA	-0.71	-4.92	-0.3	1.59e-6	Coronary artery calcification;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg08604594	chr10:33798231	NA	-0.49	-6.13	-0.36	3.45e-9	Obesity-related traits;
KIRP	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.59	7.79	0.44	1.88e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	10.81	0.57	1.57e-22	Menopause (age at onset);
KIRP	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-7.82	-0.45	1.55e-13	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13409248	chr3:40428643	ENTPD3	-0.38	-4.97	-0.3	1.25e-6	Renal cell carcinoma;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.72	11.26	0.58	5.27e-24	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.41e-13	Life satisfaction;
KIRP	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.6	-6.42	-0.38	6.93e-10	HDL cholesterol levels;
KIRP	cis	rs2411233	0.967	rs2164010	chr15:39287452	A/T	cg02291532	chr15:39874776	THBS1	-0.39	-5.38	-0.32	1.73e-7	Platelet count;
KIRP	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg08603382	chr10:743973	NA	0.59	8.83	0.49	2.06e-16	Psychosis in Alzheimer's disease;
KIRP	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg09355771	chr2:177043147	NA	-0.43	-5.06	-0.31	8.4e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15481429	chr15:94945799	MCTP2	-0.44	-6.25	-0.37	1.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05025164	chr4:1340916	KIAA1530	0.41	5.07	0.31	7.94e-7	Obesity-related traits;
KIRP	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg24826892	chr11:71159390	DHCR7	0.45	5.46	0.33	1.17e-7	Vitamin D levels;
KIRP	cis	rs9658691	0.920	rs55803311	chr10:90753135	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.81	-4.88	-0.3	1.91e-6	Mosquito bite size;
KIRP	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	10.32	0.55	5.56e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg09163369	chr1:210001066	C1orf107	-0.51	-5.48	-0.33	1.04e-7	Orofacial clefts;
KIRP	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.02	-0.36	6.43e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs73058052	0.597	rs7251877	chr19:50097547	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.96	0.36	8.47e-9	Fibrinogen levels;
KIRP	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.94	12.24	0.62	3.2e-27	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs3105593	1.000	rs3101852	chr15:50848370	C/T	cg05456662	chr15:50716270	USP8	-0.39	-4.96	-0.3	1.3e-6	QT interval;
KIRP	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.68	7.01	0.41	2.32e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1978968	0.912	rs28478894	chr22:18454600	G/A	cg02610425	chr22:18483192	MICAL3	0.39	5.18	0.31	4.66e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17749735	chr1:155051360	EFNA3	0.47	6.5	0.38	4.51e-10	Parkinson's disease;
KIRP	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.74	8.99	0.5	6.89e-17	Mammographic density (dense area);
KIRP	cis	rs11255291	1.000	rs2182652	chr10:7735876	C/T	cg26051552	chr10:7670683	ITIH5	-0.39	-5.06	-0.31	8.09e-7	Ovarian reserve;
KIRP	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	4.9	0.3	1.72e-6	Diisocyanate-induced asthma;
KIRP	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.73	0.39	1.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9948	0.521	rs61750875	chr2:97359364	A/G	cg26665480	chr2:98280029	ACTR1B	-0.62	-5.36	-0.32	1.92e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg00361562	chr2:198649771	BOLL	-0.49	-5.06	-0.31	8.28e-7	Ulcerative colitis;
KIRP	cis	rs6142102	0.602	rs4911145	chr20:32615223	C/T	cg08999081	chr20:33150536	PIGU	-0.38	-4.89	-0.3	1.8e-6	Skin pigmentation;
KIRP	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.57	-7.52	-0.43	1.02e-12	Height;
KIRP	trans	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg00938859	chr5:1591904	SDHAP3	0.6	8.0	0.45	5.04e-14	Breast cancer;
KIRP	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.24	-0.32	3.42e-7	Inflammatory bowel disease;
KIRP	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.22	0.32	3.72e-7	Melanoma;
KIRP	cis	rs55962025	0.855	rs6855981	chr4:3148276	A/G	cg06533319	chr4:3265114	C4orf44	-0.42	-5.24	-0.32	3.42e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20866711	chr17:47647861	NA	0.49	6.8	0.4	7.86e-11	Lung cancer in ever smokers;
KIRP	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.5	-6.65	-0.39	1.85e-10	Response to temozolomide;
KIRP	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg09638344	chr4:6271000	WFS1	-0.38	-4.96	-0.3	1.29e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg05717871	chr11:638507	DRD4	-0.38	-5.22	-0.32	3.87e-7	Systemic lupus erythematosus;
KIRP	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.71	-9.02	-0.5	5.65e-17	Hypospadias;
KIRP	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg17182837	chr8:41585554	ANK1	-0.49	-5.2	-0.31	4.24e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg10253484	chr15:75165896	SCAMP2	-0.51	-5.99	-0.36	7.3e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs11997175	0.603	rs6468199	chr8:33738770	A/C	cg04338863	chr8:33670619	NA	0.48	6.06	0.36	4.95e-9	Body mass index;
KIRP	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg22903471	chr2:27725779	GCKR	0.41	5.63	0.34	4.85e-8	Oral cavity cancer;
KIRP	cis	rs2033732	0.706	rs4598249	chr8:85073702	C/T	cg05716166	chr8:85095498	RALYL	0.54	6.13	0.36	3.39e-9	Body mass index;
KIRP	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.27	0.37	1.62e-9	Total body bone mineral density;
KIRP	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.89	-9.46	-0.52	2.57e-18	Exhaled nitric oxide output;
KIRP	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg00700412	chr12:58011837	NA	0.31	5.11	0.31	6.47e-7	Multiple sclerosis;
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.63	9.48	0.52	2.25e-18	Vitiligo;
KIRP	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg12435725	chr3:58293450	RPP14	-0.55	-5.67	-0.34	3.92e-8	Cholesterol, total;
KIRP	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg05043794	chr9:111880884	C9orf5	-0.26	-5.35	-0.32	2.05e-7	Menarche (age at onset);
KIRP	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.57	8.65	0.48	6.71e-16	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13424612	1.000	rs4854058	chr2:240923677	C/A	cg01812947	chr2:240904978	NDUFA10	0.47	6.15	0.37	3.1e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg07606381	chr6:8435919	SLC35B3	-0.44	-5.35	-0.32	2.01e-7	Motion sickness;
KIRP	cis	rs17092148	0.636	rs66535774	chr20:33448560	T/C	cg24642439	chr20:33292090	TP53INP2	-0.51	-5.57	-0.33	6.7e-8	Neuroticism;
KIRP	cis	rs11785693	0.862	rs62489554	chr8:4960685	T/C	cg26367366	chr8:4980734	NA	0.56	5.74	0.34	2.72e-8	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs2562456	0.834	rs2650848	chr19:21586637	C/T	cg18461458	chr19:21324796	ZNF431	-0.55	-5.33	-0.32	2.27e-7	Pain;
KIRP	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg08501292	chr6:25962987	TRIM38	1.01	6.08	0.36	4.5e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.59	-9.64	-0.52	7.23e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.65	8.39	0.47	3.8e-15	Coronary artery disease;
KIRP	cis	rs3736594	0.513	rs62131881	chr2:27764781	G/T	cg27432699	chr2:27873401	GPN1	0.56	6.13	0.36	3.4e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.42	6.85	0.4	5.96e-11	Testicular germ cell tumor;
KIRP	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg20701182	chr2:24300061	SF3B14	0.67	6.0	0.36	7.01e-9	Lymphocyte counts;
KIRP	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	13.27	0.65	1.14e-30	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.78	-13.08	-0.64	5.02e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.48	6.66	0.39	1.77e-10	Schizophrenia;
KIRP	cis	rs7582720	1.000	rs72932752	chr2:203667526	G/T	cg08076091	chr2:203926405	NBEAL1	0.83	8.59	0.48	1.01e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg27411982	chr8:10470053	RP1L1	0.42	5.64	0.34	4.72e-8	Neuroticism;
KIRP	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg17401720	chr7:158221031	PTPRN2	0.34	5.15	0.31	5.43e-7	Obesity-related traits;
KIRP	cis	rs35955747	0.869	rs28715	chr22:31730169	C/T	cg02404636	chr22:31891804	SFI1	0.37	4.84	0.3	2.25e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.51e-7	Life satisfaction;
KIRP	cis	rs1949733	0.598	rs55765509	chr4:8532732	T/A	cg11789530	chr4:8429930	ACOX3	-0.7	-7.68	-0.44	3.71e-13	Response to antineoplastic agents;
KIRP	cis	rs12210905	1.000	rs9393796	chr6:27226965	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-6.04	-0.36	5.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs5770917	1.000	rs5770917	chr22:51017353	A/G	cg25309564	chr22:51001381	C22orf41	0.88	5.61	0.34	5.38e-8	Narcolepsy;
KIRP	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.47	6.48	0.38	4.94e-10	Testicular germ cell tumor;
KIRP	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg21972741	chr5:435613	AHRR	0.44	5.0	0.3	1.11e-6	Cystic fibrosis severity;
KIRP	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg21573476	chr21:45109991	RRP1B	-0.79	-10.23	-0.55	1.07e-20	Mean corpuscular volume;
KIRP	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg06042504	chr8:55087323	NA	-0.59	-7.23	-0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg06115741	chr20:33292138	TP53INP2	0.36	4.9	0.3	1.73e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.74	0.34	2.75e-8	Lung cancer;
KIRP	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg22777020	chr22:31556080	RNF185	0.48	5.16	0.31	5.12e-7	Colorectal cancer;
KIRP	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-6.36	-0.38	9.55e-10	Blood metabolite levels;
KIRP	cis	rs9896052	0.649	rs6501798	chr17:73444647	C/T	cg25649188	chr17:73499917	CASKIN2	0.45	5.97	0.36	8.16e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.74	11.25	0.58	5.74e-24	Hip circumference;
KIRP	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg07884673	chr3:53033167	SFMBT1	0.98	7.6	0.44	6.35e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6959887	0.962	rs2024344	chr7:35297565	A/G	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.44	-5.72	-0.34	3.04e-8	Red blood cell count;
KIRP	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-4.9	-0.3	1.78e-6	Coronary artery disease;
KIRP	cis	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg18016565	chr1:150552671	MCL1	0.4	4.87	0.3	2.04e-6	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs77688320	0.553	rs2080323	chr2:202378849	T/C	cg06431681	chr2:202330990	STRADB	-0.44	-5.23	-0.32	3.65e-7	Breast cancer;
KIRP	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg03609598	chr5:56110824	MAP3K1	0.46	5.35	0.32	2.03e-7	Initial pursuit acceleration;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18476049	chr13:114898203	RASA3	-0.57	-6.31	-0.37	1.26e-9	Menopause (age at onset);
KIRP	cis	rs12200782	0.929	rs72841519	chr6:26371901	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.56	-5.24	-0.32	3.43e-7	Small cell lung carcinoma;
KIRP	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.5	7.44	0.43	1.66e-12	Immature fraction of reticulocytes;
KIRP	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.42	0.47	3.14e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg05973401	chr12:123451056	ABCB9	0.58	6.63	0.39	2.15e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg22676075	chr6:135203613	NA	-0.61	-8.15	-0.46	1.86e-14	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg17595323	chr11:93583763	C11orf90	0.31	5.37	0.32	1.86e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6563943	0.857	rs8053046	chr16:83636775	C/G	cg01935413	chr16:83636749	CDH13	0.46	6.66	0.39	1.73e-10	Height;
KIRP	cis	rs6893300	0.961	rs11739042	chr5:179182495	G/A	cg14593053	chr5:179126677	CANX	-0.57	-6.46	-0.38	5.65e-10	Resting heart rate;
KIRP	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.83	0.53	1.94e-19	Corneal astigmatism;
KIRP	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg25182066	chr10:30743637	MAP3K8	-0.71	-9.16	-0.5	2.15e-17	Inflammatory bowel disease;
KIRP	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg26513180	chr16:89883248	FANCA	0.82	5.42	0.33	1.43e-7	Skin colour saturation;
KIRP	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.87	-10.66	-0.56	4.68e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.66	-7.65	-0.44	4.59e-13	Personality dimensions;
KIRP	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.64	-7.61	-0.44	5.82e-13	Menarche (age at onset);
KIRP	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.54	0.38	3.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10861661	1.000	rs4964491	chr12:107222515	G/A	cg15890332	chr12:107067104	RFX4	0.35	5.19	0.31	4.31e-7	Triglyceride levels;
KIRP	cis	rs8179	0.761	rs42032	chr7:92237426	G/A	cg15732164	chr7:92237376	CDK6	-0.59	-7.78	-0.44	1.97e-13	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs7116495	1.000	rs3018302	chr11:71790942	A/C	cg18441811	chr11:71824068	C11orf51	-0.64	-5.22	-0.32	3.79e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg01420254	chr6:26195488	NA	-1.17	-8.91	-0.49	1.18e-16	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14796605	chr10:129537990	FOXI2	-0.46	-6.49	-0.38	4.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13343954	0.778	rs10425798	chr19:33541539	C/G	cg27124370	chr19:33622961	WDR88	0.6	6.6	0.39	2.45e-10	Colorectal cancer;
KIRP	cis	rs10046574	0.561	rs10215176	chr7:135198589	A/G	cg27474649	chr7:135195673	CNOT4	0.55	4.97	0.3	1.24e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	0.98	8.54	0.48	1.39e-15	Prostate cancer;
KIRP	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg23307798	chr14:103986281	CKB	-0.5	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg24874828	chr4:187887005	NA	-0.56	-8.98	-0.5	7.06e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg02696790	chr15:75250997	RPP25	0.28	5.17	0.31	4.75e-7	Breast cancer;
KIRP	cis	rs11603020	0.851	rs10896631	chr11:57381263	T/C	cg19752551	chr11:57585705	CTNND1	-0.71	-9.83	-0.53	1.91e-19	Blood protein levels;
KIRP	cis	rs4658101	0.815	rs12117800	chr1:92049014	C/T	cg09075522	chr1:92031145	NA	-0.43	-5.23	-0.32	3.66e-7	Optic disc area;Vertical cup-disc ratio;
KIRP	trans	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.47	-0.38	5.2400000000000005e-10	Systolic blood pressure;
KIRP	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.84	0.53	1.75e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1983891	0.706	rs3800285	chr6:41558443	C/T	cg20194872	chr6:41519635	FOXP4	-0.47	-6.09	-0.36	4.4e-9	Prostate cancer;
KIRP	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.11	-0.41	1.27e-11	Retinal vascular caliber;
KIRP	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.64	7.86	0.45	1.23e-13	Vitiligo;
KIRP	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg06953865	chr19:18549723	ISYNA1	-0.34	-4.89	-0.3	1.81e-6	Breast cancer;
KIRP	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.95	-0.45	6.89e-14	Response to antipsychotic treatment;
KIRP	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.69	-9.01	-0.5	5.9e-17	Huntington's disease progression;
KIRP	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg12131826	chr15:77904385	NA	0.41	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs4742903	0.509	rs7020317	chr9:106872682	T/A	cg14250997	chr9:106856677	SMC2	0.43	5.84	0.35	1.62e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7560272	0.538	rs2001436	chr2:73928965	A/T	cg20560298	chr2:73613845	ALMS1	0.52	6.29	0.37	1.47e-9	Schizophrenia;
KIRP	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.05	-8.12	-0.46	2.22e-14	Mitochondrial DNA levels;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg22284058	chr8:142237359	SLC45A4	-0.52	-6.65	-0.39	1.85e-10	Immature fraction of reticulocytes;
KIRP	cis	rs1570884	1.000	rs1570884	chr13:50121511	A/G	cg11801959	chr13:50123613	RCBTB1	-0.36	-5.03	-0.31	9.3e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg08773314	chr2:239334832	ASB1	-0.54	-5.41	-0.33	1.47e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg13731523	chr4:3047190	NA	-0.34	-5.91	-0.35	1.13e-8	Serum sulfate level;
KIRP	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.71	8.8	0.49	2.42e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12476592	0.571	rs7606045	chr2:63826528	T/G	cg17519650	chr2:63277830	OTX1	-0.41	-5.12	-0.31	6.22e-7	Childhood ear infection;
KIRP	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg21926883	chr2:100939477	LONRF2	-0.51	-6.89	-0.4	4.59e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg19760965	chr3:194868843	C3orf21	0.32	5.19	0.31	4.45e-7	Non-small cell lung cancer;
KIRP	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg03929089	chr4:120376271	NA	0.71	6.29	0.37	1.44e-9	Axial length;
KIRP	trans	rs10782582	0.758	rs12087636	chr1:76376846	T/C	cg10283277	chr11:111472630	SIK2	-0.31	-6.21	-0.37	2.23e-9	Daytime sleep phenotypes;
KIRP	cis	rs988913	0.629	rs34685175	chr6:54866737	G/C	cg03513858	chr6:54763001	FAM83B	-0.37	-5.14	-0.31	5.66e-7	Menarche (age at onset);
KIRP	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg16797656	chr11:68205561	LRP5	0.49	5.82	0.35	1.79e-8	Bone mineral density (spine);
KIRP	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.36	-5.49	-0.33	1e-7	Body mass index;
KIRP	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.53	-7.28	-0.42	4.62e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-5.89	-0.35	1.23e-8	Educational attainment (years of education);
KIRP	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg01557791	chr16:72042693	DHODH	-0.4	-4.97	-0.3	1.23e-6	Fibrinogen levels;
KIRP	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg02023728	chr11:77925099	USP35	-0.32	-5.6	-0.34	5.58e-8	Alzheimer's disease (survival time);
KIRP	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.46	-0.38	5.72e-10	Breast cancer;
KIRP	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg10932868	chr11:921992	NA	0.55	7.01	0.41	2.25e-11	Alzheimer's disease (late onset);
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05665937	chr4:1216051	CTBP1	0.45	6.36	0.38	9.56e-10	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26224671	chr13:43148935	TNFSF11	0.44	6.86	0.4	5.66e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs988913	0.697	rs9475159	chr6:54995517	A/G	cg03513858	chr6:54763001	FAM83B	0.38	5.46	0.33	1.14e-7	Menarche (age at onset);
KIRP	cis	rs4776059	1.000	rs2414166	chr15:52901977	C/T	cg25063058	chr15:52860530	ARPP19	0.61	6.84	0.4	6.4e-11	Schizophrenia;
KIRP	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.64	-8.39	-0.47	3.92e-15	Red blood cell count;
KIRP	cis	rs7614311	0.555	rs58676857	chr3:63903883	G/A	cg22134162	chr3:63841271	THOC7	-0.42	-5.85	-0.35	1.55e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg20673841	chr7:107026890	COG5	0.41	5.13	0.31	6.02e-7	Coronary artery disease;
KIRP	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg25019033	chr10:957182	NA	-0.61	-6.76	-0.4	9.98e-11	Eosinophil percentage of granulocytes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15896624	chr4:164246900	NPY1R	0.39	6.02	0.36	6.19e-9	Survival in pancreatic cancer;
KIRP	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.46	-5.79	-0.35	2.13e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.66	9.09	0.5	3.47e-17	Obesity-related traits;
KIRP	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg18016565	chr1:150552671	MCL1	-0.5	-7.5	-0.43	1.18e-12	Urate levels;
KIRP	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg24699146	chr1:24152579	HMGCL	-0.48	-6.12	-0.36	3.77e-9	Immature fraction of reticulocytes;
KIRP	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg02487422	chr3:49467188	NICN1	0.43	5.79	0.35	2.18e-8	Resting heart rate;
KIRP	trans	rs16935279	1.000	rs12056370	chr8:69872567	A/G	cg15812586	chr7:139953117	NA	0.55	6.08	0.36	4.45e-9	Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio);
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg18234130	chr8:27182889	PTK2B	0.54	6.97	0.41	2.89e-11	Neuroticism;
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg01763666	chr17:80159506	CCDC57	0.36	4.96	0.3	1.31e-6	Life satisfaction;
KIRP	cis	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg20368463	chr18:77673604	PQLC1	-0.45	-5.64	-0.34	4.55e-8	Schizophrenia;
KIRP	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.9	10.47	0.56	1.88e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.07	-0.41	1.62e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.41	-0.59	1.76e-24	Monocyte count;
KIRP	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg27624424	chr6:160112604	SOD2	0.47	4.95	0.3	1.4e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg00677455	chr12:58241039	CTDSP2	0.58	6.88	0.4	4.97e-11	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03264133	chr6:25882463	NA	-0.4	-5.69	-0.34	3.56e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1642645	0.831	rs784103	chr1:42487059	A/G	cg26038582	chr1:42384390	HIVEP3	0.27	5.02	0.3	9.93e-7	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs1134634	0.520	rs7682586	chr4:15626243	G/A	cg16509355	chr4:15471240	CC2D2A	-0.35	-5.98	-0.36	7.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.76	-9.26	-0.51	1.04e-17	Response to antipsychotic treatment;
KIRP	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg02023728	chr11:77925099	USP35	-0.32	-5.6	-0.34	5.84e-8	Alzheimer's disease (survival time);
KIRP	cis	rs2979489	0.945	rs17627903	chr8:30351812	T/C	cg26383811	chr8:30366931	RBPMS	-0.4	-5.5	-0.33	9.39e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs2017305	0.834	rs12244293	chr10:70783580	A/G	cg01024728	chr10:70782572	NA	0.67	5.59	0.34	6.15e-8	Depression (quantitative trait);
KIRP	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.56	5.81	0.35	1.89e-8	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.57	-0.33	6.64e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11255291	1.000	rs10905218	chr10:7733898	C/T	cg26051552	chr10:7670683	ITIH5	0.43	5.59	0.34	6.13e-8	Ovarian reserve;
KIRP	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg23625390	chr15:77176239	SCAPER	0.5	6.59	0.39	2.58e-10	Blood metabolite levels;
KIRP	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-6.37	-0.38	9.04e-10	Height;
KIRP	cis	rs7005380	0.581	rs9987139	chr8:120936859	G/A	cg21645572	chr8:120931649	DEPDC6	-0.49	-6.41	-0.38	7.27e-10	Interstitial lung disease;
KIRP	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg11972305	chr2:233791962	NGEF	-0.41	-5.19	-0.31	4.4e-7	Schizophrenia;
KIRP	cis	rs9815354	0.680	rs7649989	chr3:41865843	A/C	cg03022575	chr3:42003672	ULK4	0.51	5.96	0.36	8.8e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg04398451	chr17:18023971	MYO15A	0.58	7.46	0.43	1.47e-12	Total body bone mineral density;
KIRP	cis	rs1639906	0.965	rs1639909	chr7:2233045	A/C	cg18044113	chr7:2236405	MAD1L1	-0.31	-5.04	-0.31	9.05e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.8	11.18	0.58	9.61e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg13939156	chr17:80058883	NA	-0.47	-5.51	-0.33	9.26e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3126085	0.560	rs3818831	chr1:152331240	G/A	cg26876637	chr1:152193138	HRNR	-0.53	-6.19	-0.37	2.46e-9	Atopic dermatitis;
KIRP	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg23894439	chr1:183413866	NA	0.39	5.17	0.31	4.76e-7	Systemic lupus erythematosus;
KIRP	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs9810890	1.000	rs73198862	chr3:128524945	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg10360139	chr7:1886902	MAD1L1	0.45	5.1	0.31	6.94e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.86	10.87	0.57	9.86e-23	Coronary artery disease;
KIRP	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	trans	rs7980799	0.935	rs4931717	chr12:33521151	A/G	cg26384229	chr12:38710491	ALG10B	0.53	6.56	0.39	3.19e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg19847866	chr10:1019161	NA	-0.65	-5.92	-0.35	1.07e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg20965017	chr5:231967	SDHA	-0.58	-6.78	-0.4	8.71e-11	Breast cancer;
KIRP	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg13319975	chr6:146136371	FBXO30	0.45	5.96	0.36	8.51e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.74	-0.39	1.1e-10	Joint mobility (Beighton score);
KIRP	cis	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-5.27	-0.32	3.05e-7	Height;
KIRP	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg08975724	chr8:8085496	FLJ10661	0.58	8.08	0.46	2.89e-14	Myopia (pathological);
KIRP	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg23594656	chr7:65796392	TPST1	-0.52	-8.24	-0.47	1.04e-14	Aortic root size;
KIRP	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg22563815	chr15:78856949	CHRNA5	0.46	7.1	0.41	1.34e-11	Sudden cardiac arrest;
KIRP	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.88	13.74	0.66	2.93e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8014252	0.518	rs58919501	chr14:71069022	G/A	cg19730268	chr14:71022823	NA	-0.51	-5.14	-0.31	5.52e-7	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9921338	0.961	rs77552156	chr16:11426399	C/A	cg00044050	chr16:11439710	C16orf75	-0.55	-5.86	-0.35	1.51e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg01879757	chr17:41196368	BRCA1	-0.6	-7.9	-0.45	9.31e-14	Menopause (age at onset);
KIRP	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-6.06	-0.36	5.11e-9	Morning vs. evening chronotype;
KIRP	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.31	-6.28	-0.37	1.49e-9	Breast cancer;
KIRP	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-7.61	-0.44	5.89e-13	Lung cancer;
KIRP	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17554472	chr22:41940697	POLR3H	0.7	7.17	0.42	9.01e-12	Vitiligo;
KIRP	cis	rs2625529	0.668	rs72733369	chr15:72567260	G/A	cg16672083	chr15:72433130	SENP8	-0.45	-5.26	-0.32	3.08e-7	Red blood cell count;
KIRP	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg17724175	chr1:150552817	MCL1	0.36	6.19	0.37	2.49e-9	Melanoma;
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg08662619	chr6:150070041	PCMT1	0.37	6.18	0.37	2.68e-9	Lung cancer;
KIRP	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg10047753	chr17:41438598	NA	0.83	11.1	0.58	1.72e-23	Menopause (age at onset);
KIRP	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21605333	chr4:119757512	SEC24D	-1.1	-9.02	-0.5	5.65e-17	Cannabis dependence symptom count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22485171	chr5:169010600	CCDC99	0.47	6.45	0.38	5.93e-10	Survival in pancreatic cancer;
KIRP	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg00802000	chr16:706648	WDR90	-0.44	-5.48	-0.33	1.08e-7	Height;
KIRP	cis	rs10140922	0.966	rs4982260	chr14:35822105	T/A	cg07166546	chr14:35805898	NA	-0.24	-6.03	-0.36	5.97e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	1.09	18.11	0.76	3.77e-47	Cognitive function;
KIRP	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.37e-10	Aortic root size;
KIRP	cis	rs1035491	0.715	rs2366901	chr5:63923514	T/C	cg01791865	chr5:63954708	NA	0.34	5.32	0.32	2.38e-7	Body mass index;
KIRP	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.57	7.72	0.44	2.83e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg05315796	chr3:52349193	DNAH1	0.44	6.77	0.4	9.34e-11	Bipolar disorder;
KIRP	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs35995292	0.963	rs10239557	chr7:38950137	C/T	cg19327137	chr7:38886074	VPS41	0.47	5.43	0.33	1.32e-7	Subjective well-being (multi-trait analysis);
KIRP	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.09e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.63	6.57	0.39	3.02e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.22	0.42	6.29e-12	Bipolar disorder;
KIRP	trans	rs10203711	0.509	rs11684544	chr2:239601424	G/A	cg03809021	chr16:89831123	FANCA	-0.52	-6.07	-0.36	4.92e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	0.573	rs6810430	chr4:152259759	C/T	cg25486957	chr4:152246857	NA	-0.43	-5.44	-0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.8	0.57	1.62e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24873842	chr1:90473060	ZNF326	0.4	6.19	0.37	2.5e-9	Migraine with aura;
KIRP	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg06766960	chr11:133703094	NA	-0.46	-5.95	-0.35	8.93e-9	Childhood ear infection;
KIRP	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg03128060	chr6:142623767	GPR126	0.38	5.37	0.32	1.87e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.85	9.81	0.53	2.24e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.91	13.76	0.66	2.5e-32	Monocyte count;
KIRP	cis	rs1413885	0.516	rs10158873	chr1:65836244	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.57	6.1	0.36	4.19e-9	Anticoagulant levels;
KIRP	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.82	-6.89	-0.4	4.69e-11	Obesity-related traits;
KIRP	cis	rs2289125	0.762	rs10830278	chr11:89216425	T/A	cg11670211	chr11:89224288	NOX4	0.46	5.09	0.31	7.03e-7	Pulse pressure;
KIRP	cis	rs10207628	0.823	rs749006	chr2:127859766	G/A	cg06223080	chr2:127868745	NA	-0.6	-7.93	-0.45	7.63e-14	Psychosis and Alzheimer's disease;
KIRP	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.8	0.35	1.98e-8	Renal cell carcinoma;
KIRP	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg21361702	chr7:150065534	REPIN1	0.61	6.44	0.38	6.27e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs831571	0.955	rs35839	chr3:64013417	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.6	-5.51	-0.33	8.86e-8	Type 2 diabetes;
KIRP	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs13102973	1.000	rs4611981	chr4:135902585	C/T	cg14419869	chr4:135874104	NA	0.5	8.1	0.46	2.63e-14	Subjective well-being;
KIRP	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.8	-7.98	-0.45	5.58e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8028182	0.609	rs8038760	chr15:75742095	A/C	cg20655648	chr15:75932815	IMP3	0.53	6.71	0.39	1.3e-10	Sudden cardiac arrest;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07460449	chr16:67840720	TSNAXIP1;RANBP10	0.5	7.26	0.42	5.1e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.72	11.12	0.58	1.57e-23	Blood metabolite ratios;
KIRP	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.42	-6.45	-0.38	6.05e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg03060546	chr3:49711283	APEH	-0.65	-6.04	-0.36	5.71e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9972944	0.691	rs7225471	chr17:63777913	T/C	cg07283582	chr17:63770753	CCDC46	0.52	8.57	0.48	1.2e-15	Total body bone mineral density;
KIRP	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-5.09	-0.31	7.06e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15563057	chr5:139493612	PURA	0.65	8.15	0.46	1.86e-14	Smoking initiation;
KIRP	cis	rs582384	0.630	rs600040	chr2:45867332	T/G	cg05208381	chr2:45870771	NA	-0.36	-5.16	-0.31	4.98e-7	Coronary artery disease;
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.96	0.3	1.31e-6	Life satisfaction;
KIRP	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.5	-0.78	7.81e-52	Height;
KIRP	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg13482628	chr17:19912719	NA	0.5	6.55	0.39	3.39e-10	Schizophrenia;
KIRP	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg05802129	chr4:122689817	NA	-0.67	-9.43	-0.52	3.22e-18	Type 2 diabetes;
KIRP	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg19683494	chr5:74908142	NA	0.55	5.46	0.33	1.16e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg09238746	chr17:78121135	EIF4A3	-0.44	-5.58	-0.34	6.37e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg05342682	chr7:94953680	PON1	-0.47	-5.39	-0.32	1.66e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs9912468	1.000	rs7210446	chr17:64307014	C/T	cg19474267	chr17:64306194	PRKCA	-0.63	-9.37	-0.51	4.93e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.71	7.71	0.44	3.09e-13	Corneal astigmatism;
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg11814155	chr7:99998594	ZCWPW1	0.54	5.26	0.32	3.13e-7	Platelet count;
KIRP	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg16141378	chr3:129829833	LOC729375	0.6	8.0	0.45	5.02e-14	Triglycerides;
KIRP	cis	rs6499755	0.686	rs31102	chr16:55372522	C/T	cg05099576	chr16:55362342	IRX6	0.28	5.74	0.34	2.84e-8	Hypospadias;
KIRP	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg18240653	chr6:144019428	PHACTR2	-0.47	-4.94	-0.3	1.43e-6	Obesity-related traits;
KIRP	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.15	-0.41	1.01e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7246657	0.722	rs12979640	chr19:38179156	T/C	cg23950597	chr19:37808831	NA	0.5	5.54	0.33	7.65e-8	Coronary artery calcification;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg00078996	chr12:132293329	NA	-0.45	-5.79	-0.35	2.09e-8	Migraine;
KIRP	cis	rs6859018	1.000	rs6859018	chr5:158736992	C/T	cg26646896	chr5:158686746	NA	-0.36	-5.18	-0.31	4.56e-7	Serum sulfate level;
KIRP	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg02820040	chr2:241836501	C2orf54	-0.24	-5.38	-0.32	1.75e-7	Urinary metabolites;
KIRP	trans	rs933360	0.585	rs2074721	chr7:50834583	A/T	cg20003124	chr12:4557277	NA	0.53	6.46	0.38	5.69e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg04374321	chr14:90722782	PSMC1	0.99	18.01	0.75	7.75e-47	Mortality in heart failure;
KIRP	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	11.59	0.59	4.49e-25	Platelet count;
KIRP	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg12598211	chr12:123634384	NA	-0.43	-5.29	-0.32	2.73e-7	Neutrophil percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15731816	chr14:75230414	YLPM1	0.62	7.4	0.43	2.1e-12	Smoking initiation;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.57	8.1	0.46	2.49e-14	Longevity;Endometriosis;
KIRP	cis	rs4790312	0.875	rs9901671	chr17:1978484	T/C	cg15816464	chr17:2026533	SMG6	0.32	4.87	0.3	2e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	0.84	9.93	0.54	8.99e-20	Left atrial antero-posterior diameter;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.72	-0.39	1.28e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	11.92	0.61	3.83e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs15676	0.783	rs10988120	chr9:131564695	G/C	cg00228799	chr9:131580591	ENDOG	-0.49	-4.99	-0.3	1.14e-6	Blood metabolite levels;
KIRP	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.7	6.9	0.4	4.49e-11	Breast cancer;
KIRP	cis	rs17453880	0.963	rs6868331	chr5:151950825	A/G	cg12297329	chr5:152029980	NA	-0.7	-9.89	-0.53	1.24e-19	Subjective well-being;
KIRP	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.27	-0.32	2.95e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs259282	0.605	rs3760939	chr19:33106911	A/C	cg02997394	chr19:33096574	ANKRD27	-0.55	-6.75	-0.4	1.08e-10	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.6	8.84	0.49	1.87e-16	Lung cancer;
KIRP	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.08	0.5	3.62e-17	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg26531700	chr6:26746687	NA	0.46	6.56	0.39	3.15e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.71	9.85	0.53	1.61e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9972944	0.902	rs9972947	chr17:63771088	G/A	cg07283582	chr17:63770753	CCDC46	0.48	7.94	0.45	7.1e-14	Total body bone mineral density;
KIRP	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg18190219	chr22:46762943	CELSR1	-0.63	-5.7	-0.34	3.44e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7116495	1.000	rs2511114	chr11:71792147	T/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.48	-0.33	1.06e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs11203032	0.831	rs11203023	chr10:90954240	T/C	cg16672925	chr10:90967113	CH25H	0.42	5.19	0.31	4.49e-7	Heart failure;
KIRP	trans	rs1928295	0.750	rs10818054	chr9:120388017	G/C	cg04204072	chr16:20752857	THUMPD1	-0.5	-6.31	-0.37	1.29e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10904887	1.000	rs7900163	chr10:17188637	C/T	cg01003015	chr10:17271136	VIM	-0.48	-6.29	-0.37	1.4e-9	Telomere length;
KIRP	cis	rs75426604	0.568	rs17091835	chr14:35845591	C/T	cg09327582	chr14:35236912	BAZ1A	0.56	5.35	0.32	1.98e-7	Eotaxin levels;
KIRP	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.75	0.34	2.67e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg00319359	chr11:70116639	PPFIA1	-0.75	-6.76	-0.4	1.02e-10	Coronary artery disease;
KIRP	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.09e-8	Motion sickness;
KIRP	cis	rs7180079	0.620	rs4442756	chr15:64751162	A/G	cg15337035	chr15:64978493	NA	-0.48	-5.25	-0.32	3.24e-7	Monocyte count;
KIRP	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg24296786	chr1:45957014	TESK2	-0.43	-5.43	-0.33	1.36e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg03563238	chr19:33554763	RHPN2	-0.34	-5.79	-0.35	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg21545522	chr1:205238299	TMCC2	0.41	5.54	0.33	7.73e-8	Red blood cell count;
KIRP	cis	rs17407555	0.683	rs6823180	chr4:10275831	C/T	cg11266682	chr4:10021025	SLC2A9	0.34	5.18	0.31	4.55e-7	Schizophrenia (age at onset);
KIRP	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg21285383	chr16:89894308	SPIRE2	0.3	5.51	0.33	9.19e-8	Vitiligo;
KIRP	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs61542988	0.606	rs4722185	chr7:22832711	G/A	cg11367502	chr7:22862612	TOMM7	0.52	5.5	0.33	9.5e-8	Fibrinogen levels;
KIRP	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.47	-6.08	-0.36	4.53e-9	Body mass index;
KIRP	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg09491104	chr22:46646882	C22orf40	-0.53	-6.59	-0.39	2.71e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.49	5.14	0.31	5.57e-7	Alzheimer's disease;
KIRP	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.49	-0.43	1.2e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00902415	chr17:41174425	VAT1	0.5	6.21	0.37	2.22e-9	Parkinson's disease;
KIRP	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg22089800	chr15:90895588	ZNF774	0.49	5.98	0.36	8.02e-9	Rheumatoid arthritis;
KIRP	cis	rs580438	0.529	rs6442378	chr3:13420624	C/T	cg10657019	chr3:13328039	NA	-0.52	-6.74	-0.39	1.14e-10	Myringotomy;
KIRP	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21643547	chr1:205240462	TMCC2	-0.8	-13.13	-0.64	3.38e-30	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11225247	0.881	rs12282486	chr11:102253554	C/G	cg06323957	chr11:102217781	BIRC2	0.93	5.96	0.36	8.49e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.69	9.92	0.53	9.8e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	6.18	0.37	2.68e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.06e-7	Coronary artery disease;
KIRP	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01256987	chr12:42539512	GXYLT1	-0.45	-5.85	-0.35	1.57e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7178572	0.625	rs907372	chr15:77844516	G/T	cg12131826	chr15:77904385	NA	0.43	6.08	0.36	4.53e-9	Type 2 diabetes;
KIRP	cis	rs10267417	0.603	rs10228558	chr7:19911915	A/G	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs7666738	0.609	rs28833816	chr4:98868866	T/C	cg05340658	chr4:99064831	C4orf37	0.67	7.98	0.45	5.53e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg10189774	chr4:17578691	LAP3	0.44	5.22	0.32	3.75e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7106204	0.609	rs16912359	chr11:24290818	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.39	0.33	1.64e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.94	-0.5	9.2e-17	Myopia (pathological);
KIRP	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.4	0.38	7.84e-10	Diabetic retinopathy;
KIRP	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg16867584	chr19:49200180	FUT2	0.33	5.29	0.32	2.77e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.75	0.49	3.51e-16	Bipolar disorder;
KIRP	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.67	8.69	0.48	5.02e-16	Breast cancer;
KIRP	trans	rs10517437	1.000	rs1433409	chr4:59006847	G/A	cg05928656	chr16:88958527	CBFA2T3	0.44	6.05	0.36	5.47e-9	Cognitive performance;
KIRP	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.82	6.92	0.4	3.84e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.4	5.33	0.32	2.26e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs12517041	0.938	rs10037500	chr5:23270158	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.63	6.78	0.4	8.75e-11	Calcium levels;
KIRP	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.81	0.66	1.7e-32	Cognitive function;
KIRP	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.78	9.99	0.54	5.96e-20	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02737830	chr12:64616354	C12orf66	0.62	7.27	0.42	4.69e-12	Smoking initiation;
KIRP	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.81	-0.35	1.89e-8	Reticulocyte count;
KIRP	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg00262122	chr8:11665843	FDFT1	0.4	5.07	0.31	7.98e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.37	-0.43	2.63e-12	Aortic root size;
KIRP	cis	rs8177876	0.749	rs10459871	chr16:81093067	C/G	cg08591886	chr16:81111003	C16orf46	-0.68	-5.63	-0.34	4.91e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs7560272	0.723	rs1320374	chr2:73828310	T/C	cg20560298	chr2:73613845	ALMS1	0.45	5.51	0.33	8.96e-8	Schizophrenia;
KIRP	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg20936604	chr3:58311152	NA	-0.68	-5.23	-0.32	3.64e-7	Cholesterol, total;
KIRP	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.53	-7.57	-0.43	7.4e-13	Coronary artery disease;
KIRP	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-0.95	-11.17	-0.58	1.03e-23	Blood pressure (smoking interaction);
KIRP	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.75	-11.94	-0.61	3.24e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-4.89	-0.3	1.85e-6	Lung cancer;
KIRP	cis	rs10875746	0.669	rs1021313	chr12:48638041	T/A	cg26205652	chr12:48591994	NA	0.63	8.22	0.46	1.14e-14	Longevity (90 years and older);
KIRP	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg11693508	chr17:37793320	STARD3	0.69	7.17	0.42	8.69e-12	Bipolar disorder;
KIRP	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg00360474	chr6:37504404	NA	-0.52	-7.72	-0.44	2.99e-13	Cognitive performance;
KIRP	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.89	-14.47	-0.68	9.19e-35	Dental caries;
KIRP	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg06740227	chr12:86229804	RASSF9	0.44	5.61	0.34	5.44e-8	Major depressive disorder;
KIRP	cis	rs995000	0.931	rs626787	chr1:62901243	C/G	cg19896129	chr1:63156450	NA	0.37	4.9	0.3	1.76e-6	Triglyceride levels;
KIRP	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg10755058	chr3:40428713	ENTPD3	0.49	6.71	0.39	1.3100000000000001e-10	Renal cell carcinoma;
KIRP	cis	rs651907	0.640	rs771574	chr3:101620682	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.09	0.31	7.05e-7	Colorectal cancer;
KIRP	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg15880211	chr22:50250494	ZBED4	-0.68	-7.66	-0.44	4.2e-13	Schizophrenia;
KIRP	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.53	6.17	0.37	2.81e-9	QRS duration;
KIRP	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.71	-0.53	4.59e-19	Morning vs. evening chronotype;
KIRP	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08919224	chr12:9569744	NA	-0.45	-5.65	-0.34	4.46e-8	IgG glycosylation;
KIRP	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg13271783	chr10:134563150	INPP5A	-0.63	-7.93	-0.45	7.65e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.92	-12.28	-0.62	2.45e-27	Cognitive function;
KIRP	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.41	4.99	0.3	1.16e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg11234688	chr2:1609660	NA	0.61	5.41	0.33	1.46e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg19773385	chr1:10388646	KIF1B	-0.68	-9.0	-0.5	6.27e-17	Hepatocellular carcinoma;
KIRP	cis	rs7562790	0.651	rs4670557	chr2:36654580	G/A	cg09467607	chr2:36825704	FEZ2	0.41	5.02	0.3	1.02e-6	QRS duration;QRS complex (Cornell);
KIRP	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.96	-11.74	-0.6	1.4e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs75804782	0.522	rs7561954	chr2:239318280	G/A	cg18131467	chr2:239335373	ASB1	-0.62	-6.26	-0.37	1.66e-9	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg06521331	chr12:34319734	NA	-0.53	-6.47	-0.38	5.4e-10	Bladder cancer;
KIRP	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.94	-14.19	-0.67	8.62e-34	Schizophrenia;
KIRP	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg26384229	chr12:38710491	ALG10B	0.65	8.14	0.46	1.97e-14	Resting heart rate;
KIRP	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg22852734	chr6:133119734	C6orf192	1.19	11.15	0.58	1.22e-23	Type 2 diabetes nephropathy;
KIRP	cis	rs61332075	0.531	rs11885695	chr2:239338632	G/A	cg21699342	chr2:239360505	ASB1	-0.48	-5.37	-0.32	1.84e-7	Lung function (FEV1/FVC);
KIRP	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg16141378	chr3:129829833	LOC729375	0.53	6.53	0.38	3.65e-10	Neuroticism;
KIRP	trans	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg18187862	chr3:45730750	SACM1L	0.52	6.11	0.36	3.81e-9	Primary sclerosing cholangitis;
KIRP	cis	rs12318506	0.826	rs34128238	chr12:75731819	T/C	cg04728562	chr12:75699417	CAPS2	-1.31	-8.78	-0.49	2.76e-16	Coronary artery calcification;
KIRP	cis	rs7252505	1.000	rs7256513	chr19:33588266	C/T	cg17764715	chr19:33622953	WDR88	0.63	5.27	0.32	3.01e-7	Colorectal cancer;
KIRP	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.54	-0.33	7.59e-8	Aortic root size;
KIRP	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg06740227	chr12:86229804	RASSF9	0.46	5.84	0.35	1.64e-8	Major depressive disorder;
KIRP	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.85	-0.35	1.56e-8	Electroencephalogram traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26146949	chr15:42264823	EHD4	0.49	6.71	0.39	1.35e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg12315302	chr6:26189340	HIST1H4D	0.99	6.91	0.4	4.16e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg16586182	chr3:47516702	SCAP	0.65	8.78	0.49	2.74e-16	Colorectal cancer;
KIRP	cis	rs4664293	0.867	rs34893664	chr2:160588777	T/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17794905	chr4:108827503	SGMS2	0.45	6.21	0.37	2.23e-9	Interleukin-4 levels;
KIRP	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.83	8.31	0.47	6.55e-15	Coronary artery calcification;
KIRP	cis	rs2587695	0.839	rs2579622	chr2:120294993	A/G	cg07176264	chr2:120281999	SCTR	0.32	4.88	0.3	1.89e-6	Attention deficit hyperactivity disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21158476	chr5:135527863	LOC389332	0.5	6.5	0.38	4.33e-10	Smoking initiation;
KIRP	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.09	0.5	3.3e-17	Lymphocyte counts;
KIRP	cis	rs9608946	1.000	rs9606736	chr22:30886577	C/T	cg23383138	chr22:30885012	SEC14L4	0.4	4.93	0.3	1.52e-6	Red cell distribution width;
KIRP	cis	rs11627756	0.957	rs4906236	chr14:103077242	G/A	cg01864069	chr14:103024347	NA	-0.53	-6.28	-0.37	1.51e-9	Mean platelet volume;
KIRP	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14169450	chr9:139327907	INPP5E	0.6	6.92	0.4	3.88e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.54	5.96	0.36	8.54e-9	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
KIRP	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.84	-0.35	1.62e-8	Lung cancer;
KIRP	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg00321850	chr1:175162397	KIAA0040	0.36	6.6	0.39	2.49e-10	Alcohol dependence;
KIRP	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.59	7.04	0.41	1.88e-11	Gut microbiome composition (summer);
KIRP	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.42	7.35	0.42	2.98e-12	Renal cell carcinoma;
KIRP	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12292205	chr6:26970375	C6orf41	-0.56	-6.09	-0.36	4.41e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.36	-0.32	1.91e-7	Coronary artery disease;
KIRP	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.68	-9.42	-0.51	3.49e-18	Colorectal cancer;
KIRP	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg10223061	chr2:219282414	VIL1	-0.4	-6.41	-0.38	7.18e-10	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.67	6.18	0.37	2.7e-9	Alzheimer's disease;
KIRP	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.79	-9.17	-0.5	1.96e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6594713	0.679	rs34147627	chr5:112948161	G/A	cg12552261	chr5:112820674	MCC	0.55	4.95	0.3	1.35e-6	Brain cytoarchitecture;
KIRP	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs4664293	0.715	rs13002625	chr2:160504625	T/C	cg08347373	chr2:160653686	CD302	0.36	5.52	0.33	8.54e-8	Monocyte percentage of white cells;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26961332	chr19:18420631	LSM4	0.5	6.62	0.39	2.25e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.8	8.03	0.46	4.13e-14	Bipolar disorder;
KIRP	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg21775007	chr8:11205619	TDH	-0.4	-5.14	-0.31	5.54e-7	Neuroticism;
KIRP	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg00250761	chr1:31883323	NA	-0.28	-4.88	-0.3	1.94e-6	Alcohol dependence;
KIRP	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs897080	0.515	rs1067401	chr2:44676541	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.53	0.33	8.08e-8	Height;
KIRP	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg21191810	chr6:118973309	C6orf204	-0.42	-4.88	-0.3	1.87e-6	Diastolic blood pressure;
KIRP	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	11.5	0.59	8.68e-25	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.97	13.45	0.65	2.79e-31	Multiple sclerosis;
KIRP	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg12861170	chr19:19639553	YJEFN3	-0.49	-5.07	-0.31	8e-7	Bipolar disorder;
KIRP	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg09184832	chr6:79620586	NA	-0.38	-4.9	-0.3	1.76e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10858047	0.883	rs6681386	chr1:115183183	G/A	cg12756093	chr1:115239321	AMPD1	-0.67	-6.46	-0.38	5.42e-10	Autism;
KIRP	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.34	-0.32	2.13e-7	Autism;
KIRP	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.05	0.46	3.66e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08280861	chr8:58055591	NA	0.72	5.71	0.34	3.31e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg19847130	chr8:10466454	RP1L1	0.33	5.03	0.31	9.57e-7	Morning vs. evening chronotype;
KIRP	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.29	5.72	0.34	3.13e-8	Schizophrenia;
KIRP	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.98	-0.41	2.75e-11	Daytime sleep phenotypes;
KIRP	cis	rs829661	0.739	rs2593460	chr2:30870886	C/A	cg10949345	chr2:30726833	LCLAT1	1.09	13.34	0.65	6.7e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs490234	0.756	rs10986849	chr9:128469683	A/G	cg14078157	chr9:128172775	NA	-0.56	-6.68	-0.39	1.54e-10	Mean arterial pressure;
KIRP	cis	rs5756391	0.546	rs9610607	chr22:37315759	T/C	cg16356956	chr22:37317934	CSF2RB	0.37	5.12	0.31	6.02e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg10047753	chr17:41438598	NA	1.14	18.88	0.77	9.76e-50	Menopause (age at onset);
KIRP	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	1.01	15.4	0.7	6.13e-38	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.34	-0.37	1.07e-9	Aortic root size;
KIRP	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Bipolar disorder;
KIRP	cis	rs12210905	1.000	rs9368493	chr6:27228300	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-5.7	-0.34	3.48e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs9914544	0.545	rs35911764	chr17:18782582	C/T	cg26378065	chr17:18585709	ZNF286B	0.4	5.08	0.31	7.55e-7	Educational attainment (years of education);
KIRP	cis	rs4262150	0.726	rs10515676	chr5:152013887	G/A	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.18e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg19847130	chr8:10466454	RP1L1	-0.36	-5.39	-0.33	1.65e-7	Retinal vascular caliber;
KIRP	trans	rs7157940	0.692	rs4905163	chr14:94570770	A/G	cg27409650	chr22:37915342	CARD10	0.54	6.03	0.36	6.03e-9	Anthropometric traits;
KIRP	cis	rs7084402	0.935	rs2393449	chr10:60343030	A/G	cg05938607	chr10:60274200	BICC1	-0.46	-11.41	-0.59	1.78e-24	Refractive error;
KIRP	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.47	7.08	0.41	1.47e-11	Tuberculosis;
KIRP	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg17133734	chr15:86042851	AKAP13	-0.41	-5.13	-0.31	5.97e-7	Interstitial lung disease;
KIRP	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg00278547	chr2:177037212	HOXD3	-0.39	-5.17	-0.31	4.91e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03388025	chr16:89894329	SPIRE2	0.34	6.11	0.36	3.8e-9	Vitiligo;
KIRP	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg09915433	chr19:53449742	NA	0.38	5.53	0.33	8.34e-8	Psoriasis;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg13476336	chr17:38255694	NR1D1	0.72	6.28	0.37	1.56e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg11271282	chr2:238384023	NA	0.51	5.87	0.35	1.42e-8	Prostate cancer;
KIRP	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.52	-4.88	-0.3	1.94e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-0.89	-8.45	-0.47	2.6e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg10503236	chr1:231470652	EXOC8	-0.51	-7.18	-0.42	8.15e-12	Hemoglobin concentration;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02834497	chr19:12405873	ZNF44	-0.57	-6.42	-0.38	7.16e-10	Interleukin-4 levels;
KIRP	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.65	-10.05	-0.54	3.8e-20	Total body bone mineral density;
KIRP	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	0.92	11.93	0.61	3.31e-26	Primary sclerosing cholangitis;
KIRP	cis	rs10073892	0.956	rs10040867	chr5:101842843	T/C	cg19774478	chr5:101632501	SLCO4C1	0.62	6.62	0.39	2.28e-10	Cognitive decline (age-related);
KIRP	cis	rs12049351	0.774	rs2145395	chr1:229670981	T/C	cg11742688	chr1:229674241	ABCB10	-0.38	-5.52	-0.33	8.56e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-9.87	-0.53	1.45e-19	Total body bone mineral density;
KIRP	trans	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg06521331	chr12:34319734	NA	-0.59	-7.15	-0.41	9.72e-12	Bladder cancer;
KIRP	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg13319975	chr6:146136371	FBXO30	0.47	6.27	0.37	1.6e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.61	7.68	0.44	3.82e-13	Total body bone mineral density;
KIRP	cis	rs35740288	0.822	rs2016517	chr15:86229618	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-5.0	-0.3	1.1e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.58	-8.22	-0.46	1.14e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4959270	0.967	rs4246068	chr6:457987	G/A	cg13299325	chr6:447777	NA	0.25	5.01	0.3	1.04e-6	Limited cutaneous systemic scleroderma;
KIRP	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg17356467	chr2:100759845	AFF3	0.55	5.64	0.34	4.69e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg22117172	chr7:91764530	CYP51A1	0.44	5.99	0.36	7.6e-9	Breast cancer;
KIRP	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg05360138	chr12:110035743	NA	0.72	8.06	0.46	3.29e-14	Bipolar disorder lithium response (categorical) or schizophrenia;
KIRP	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.72	11.18	0.58	9.78e-24	Calcium levels;
KIRP	cis	rs4722404	0.592	rs13221367	chr7:3119823	C/T	cg19214707	chr7:3157722	NA	-0.49	-5.7	-0.34	3.5e-8	Atopic dermatitis;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.38e-8	Life satisfaction;
KIRP	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg26874164	chr19:58962979	ZNF324B	0.46	5.32	0.32	2.37e-7	Uric acid clearance;
KIRP	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg20636351	chr8:55087400	NA	-0.53	-6.6	-0.39	2.54e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg04497390	chr17:78327823	RNF213;LOC100294362	-0.45	-5.01	-0.3	1.02e-6	Electroencephalogram traits;
KIRP	cis	rs1635	0.655	rs16893973	chr6:28302113	C/T	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.26	0.42	5.06e-12	Lung cancer;
KIRP	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.92	0.3	1.61e-6	Childhood ear infection;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.52	-0.33	8.8e-8	Life satisfaction;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.56	-6.19	-0.37	2.43e-9	Menopause (age at onset);
KIRP	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg00631329	chr6:26305371	NA	-0.65	-8.7	-0.49	4.78e-16	Educational attainment;
KIRP	cis	rs2997447	0.846	rs3008414	chr1:26404747	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.52	-0.33	8.47e-8	QRS complex (12-leadsum);
KIRP	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	1.0	15.88	0.71	1.42e-39	Vitamin D levels;
KIRP	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg20060108	chr2:102954350	IL1RL1	-0.67	-5.65	-0.34	4.32e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg24642439	chr20:33292090	TP53INP2	-0.59	-7.67	-0.44	3.93e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg03959625	chr15:84868606	LOC388152	0.61	7.09	0.41	1.43e-11	Schizophrenia;
KIRP	cis	rs787274	1.000	rs2645991	chr9:115519035	T/C	cg13803584	chr9:115635662	SNX30	-0.73	-6.57	-0.39	2.91e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.93	14.18	0.67	8.93e-34	Mean platelet volume;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.37	4.93	0.3	1.52e-6	Vitiligo;
KIRP	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.4	0.33	1.54e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.6	-6.42	-0.38	6.92e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4262150	0.810	rs72797243	chr5:151999906	G/A	cg12297329	chr5:152029980	NA	-0.67	-8.11	-0.46	2.42e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs3784262	0.739	rs1530293	chr15:58210398	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.47	-6.14	-0.36	3.25e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.64	7.16	0.42	9.17e-12	Aortic root size;
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg08662619	chr6:150070041	PCMT1	0.36	5.98	0.36	7.89e-9	Lung cancer;
KIRP	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.45	-0.38	6e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.66	9.73	0.53	3.81e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-7.4	-0.43	2.19e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg05998816	chr21:47859926	PCNT	0.52	5.67	0.34	3.95e-8	Lymphocyte counts;
KIRP	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.42	5.42	0.33	1.4e-7	Gout;
KIRP	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.44	-5.7	-0.34	3.45e-8	Aortic root size;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg12868349	chr11:71639594	RNF121;LOC100133315	0.53	6.54	0.38	3.62e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg26116260	chr4:7069785	GRPEL1	0.62	8.3	0.47	6.96e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.87	0.3	1.99e-6	Tonsillectomy;
KIRP	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.23	-5.01	-0.3	1.02e-6	Menarche (age at onset);
KIRP	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.36	-0.32	1.9e-7	Obesity-related traits;
KIRP	cis	rs829661	0.739	rs7566983	chr2:30776860	C/G	cg10949345	chr2:30726833	LCLAT1	1.13	14.28	0.67	4.33e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.61	8.9	0.49	1.27e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16222698	chr11:114310578	REXO2	0.48	6.55	0.39	3.36e-10	Parkinson's disease;
KIRP	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.86	16.01	0.71	5.16e-40	Anterior chamber depth;
KIRP	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.83	-13.09	-0.64	4.6e-30	Dental caries;
KIRP	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.63	-7.65	-0.44	4.59e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3026101	0.723	rs1806248	chr17:5310411	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-1.04	-12.83	-0.63	3.43e-29	Breast cancer;
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.53	7.04	0.41	1.88e-11	Breast cancer;
KIRP	cis	rs4356932	0.935	rs7677924	chr4:76977023	C/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg00852783	chr1:26633632	UBXN11	-0.52	-5.12	-0.31	6.03e-7	Obesity-related traits;
KIRP	cis	rs963731	0.649	rs2278913	chr2:39199880	A/G	cg04010122	chr2:39346883	SOS1	-0.86	-5.91	-0.35	1.13e-8	Corticobasal degeneration;
KIRP	cis	rs2242194	0.515	rs10908453	chr1:155006091	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.58	11.91	0.6	3.99e-26	Schizophrenia;
KIRP	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.51	-7.22	-0.42	6.49e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.19	0.37	2.51e-9	Morning vs. evening chronotype;
KIRP	cis	rs986417	1.000	rs9989167	chr14:60942374	T/C	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	0.94	10.38	0.55	3.55e-21	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07393414	chr8:124286746	ZHX1	0.46	6.04	0.36	5.75e-9	Parkinson's disease;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.51	6.45	0.38	5.97e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg20368463	chr18:77673604	PQLC1	-0.45	-5.6	-0.34	5.85e-8	Schizophrenia;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg05935374	chr11:82782929	RAB30	0.52	6.17	0.37	2.8e-9	Sleep duration;
KIRP	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.29	-0.47	7.63e-15	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg07701084	chr6:150067640	NUP43	0.59	7.57	0.43	7.57e-13	Lung cancer;
KIRP	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg00579200	chr11:133705235	NA	-0.42	-5.42	-0.33	1.4e-7	Childhood ear infection;
KIRP	cis	rs62355272	0.900	rs6893803	chr5:35831744	C/T	cg13894535	chr5:35919491	CAPSL	0.4	4.99	0.3	1.16e-6	Lymphocyte counts;
KIRP	cis	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	trans	rs13170463	0.579	rs35047355	chr5:8048621	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.74	7.64	0.44	4.69e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	12.64	0.63	1.43e-28	Exhaled nitric oxide output;
KIRP	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.77	10.16	0.54	1.76e-20	Breast cancer;
KIRP	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	cg04338863	chr8:33670619	NA	0.5	6.62	0.39	2.3e-10	Body mass index;
KIRP	cis	rs17592366	0.775	rs4981254	chr14:35337835	C/T	cg09327582	chr14:35236912	BAZ1A	0.68	5.19	0.31	4.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs6005807	0.719	rs12169460	chr22:29042079	A/G	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg02725872	chr8:58115012	NA	-0.53	-6.08	-0.36	4.68e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.44	-0.52	3.07e-18	Colorectal cancer;
KIRP	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.49	6.25	0.37	1.8e-9	Menarche (age at onset);
KIRP	cis	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.48	6.51	0.38	4.14e-10	Leprosy;
KIRP	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg23587288	chr2:27483067	SLC30A3	-0.39	-4.96	-0.3	1.32e-6	Total body bone mineral density;
KIRP	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg23740940	chr11:68924746	NA	0.3	5.23	0.32	3.66e-7	Blond vs. brown hair color;
KIRP	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg04490037	chr7:50633773	DDC	-0.43	-5.42	-0.33	1.44e-7	Malaria;
KIRP	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg22117172	chr7:91764530	CYP51A1	0.44	6.05	0.36	5.23e-9	Breast cancer;
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.63	5.83	0.35	1.76e-8	Alzheimer's disease;
KIRP	cis	rs3752645	0.764	rs76270442	chr7:106689254	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-5.08	-0.31	7.31e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.04	-0.41	1.89e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.6	-9.46	-0.52	2.67e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.45	-0.47	2.6e-15	Common traits (Other);
KIRP	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg03474202	chr17:45855739	NA	0.32	5.2	0.31	4.24e-7	IgG glycosylation;
KIRP	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.61	7.02	0.41	2.15e-11	Testicular germ cell tumor;
KIRP	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.48	-0.48	2.11e-15	Coronary artery disease;
KIRP	cis	rs6005807	0.719	rs12167434	chr22:29040821	C/T	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.06	0.31	8.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg20999797	chr1:1681921	NA	0.52	8.06	0.46	3.27e-14	Body mass index;
KIRP	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.41	4.98	0.3	1.22e-6	Lung cancer;
KIRP	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg16989719	chr2:238392110	NA	-0.54	-7.58	-0.44	7.12e-13	Prostate cancer;
KIRP	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-8.58	-0.48	1.1e-15	Alzheimer's disease;
KIRP	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.58	-7.57	-0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7688540	0.771	rs11724417	chr4:223352	A/C	cg17891759	chr4:299121	NA	-0.52	-5.39	-0.33	1.62e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.59	7.61	0.44	5.93e-13	Prudent dietary pattern;
KIRP	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg06204229	chr3:52865917	ITIH4	0.47	5.4	0.33	1.59e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4930561	0.765	rs1894204	chr11:67929671	C/T	cg16338278	chr11:67432957	ALDH3B2	0.39	5.01	0.3	1.06e-6	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	0.86	7.87	0.45	1.11e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg13180566	chr4:1052158	NA	-0.51	-5.09	-0.31	7.19e-7	Recombination rate (females);
KIRP	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.61	8.31	0.47	6.63e-15	Pulse pressure;
KIRP	cis	rs4363506	1.000	rs1931727	chr10:129273606	G/A	cg07804728	chr10:129284050	NA	0.41	5.83	0.35	1.73e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.32	0.59	3.48e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	6.17	0.37	2.83e-9	Platelet count;
KIRP	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.6	9.42	0.51	3.42e-18	Anterior chamber depth;
KIRP	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.2	-0.8	1.87e-57	Ulcerative colitis;
KIRP	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.47	6.22	0.37	2.14e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs7709377	0.620	rs1396482	chr5:115475502	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.02	0.3	9.97e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.67	5.78	0.35	2.2e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg25482853	chr8:67687455	SGK3	0.82	7.16	0.42	9.18e-12	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	1.08	16.92	0.73	4.2e-43	Homoarginine levels;
KIRP	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14829155	chr15:31115871	NA	-0.78	-9.53	-0.52	1.62e-18	Huntington's disease progression;
KIRP	cis	rs9815354	0.951	rs9864331	chr3:41762217	G/A	cg03022575	chr3:42003672	ULK4	0.65	6.63	0.39	2.16e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12282928	0.959	rs2007961	chr11:48273208	G/C	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.65	-6.87	-0.4	5.12e-11	Body mass index;
KIRP	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg07382826	chr16:28625726	SULT1A1	0.52	6.23	0.37	1.99e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4666002	0.789	rs12998770	chr2:27913188	T/C	cg05484376	chr2:27715224	FNDC4	-0.45	-5.65	-0.34	4.48e-8	Phospholipid levels (plasma);
KIRP	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23903597	chr17:61704154	MAP3K3	-0.55	-6.56	-0.39	3.13e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg04691961	chr3:161091175	C3orf57	-0.66	-11.01	-0.57	3.51e-23	Morning vs. evening chronotype;
KIRP	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-0.84	-10.86	-0.57	1.06e-22	Prostate cancer;
KIRP	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	5.56	0.33	6.84e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.23	20.43	0.79	6.29e-55	Cognitive function;
KIRP	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg01475377	chr6:109611718	NA	0.37	5.14	0.31	5.73e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs920590	0.523	rs4464983	chr8:19680979	C/T	cg03894339	chr8:19674705	INTS10	-0.51	-6.07	-0.36	4.88e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.82	-0.35	1.87e-8	Breast cancer;
KIRP	cis	rs4765905	0.702	rs1108221	chr12:2332795	A/T	cg10668781	chr12:2307325	CACNA1C	-0.31	-5.82	-0.35	1.83e-8	Schizophrenia;
KIRP	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.8	8.94	0.5	9.79e-17	Corneal astigmatism;
KIRP	cis	rs1355223	0.902	rs1539251	chr11:34742772	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.38	-4.87	-0.3	2.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3809566	0.710	rs4075583	chr15:63340227	C/T	cg05507819	chr15:63340323	TPM1	0.41	5.13	0.31	5.82e-7	Platelet count;
KIRP	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.6	9.16	0.5	2.13e-17	Platelet distribution width;
KIRP	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg26513180	chr16:89883248	FANCA	0.56	7.32	0.42	3.42e-12	Vitiligo;
KIRP	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg24998770	chr7:37888106	TXNDC3	0.44	5.83	0.35	1.71e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	5.77	0.35	2.42e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7849270	0.879	rs7042928	chr9:131855275	G/T	cg13538475	chr9:131942899	NA	0.36	5.4	0.33	1.54e-7	Blood metabolite ratios;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.09e-16	Life satisfaction;
KIRP	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg13010199	chr12:38710504	ALG10B	0.57	7.03	0.41	1.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.75	7.52	0.43	1.02e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4704187	0.687	rs4704196	chr5:74537606	A/G	cg03227963	chr5:74354835	NA	0.4	5.84	0.35	1.67e-8	Response to amphetamines;
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04871131	chr7:94954202	PON1	-0.63	-8.04	-0.46	3.69e-14	Paraoxonase activity;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.52	5.14	0.31	5.7e-7	Alzheimer's disease;
KIRP	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.77	8.6	0.48	9.53e-16	Corneal astigmatism;
KIRP	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.77	-10.31	-0.55	6.15e-21	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg12486944	chr17:80159399	CCDC57	-0.38	-4.99	-0.3	1.16e-6	Life satisfaction;
KIRP	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg06102954	chr21:42741788	MX2	0.53	7.43	0.43	1.8e-12	Melanoma;
KIRP	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg02753203	chr1:228287806	NA	0.7	9.4	0.51	3.91e-18	Diastolic blood pressure;
KIRP	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg09307838	chr4:120376055	NA	0.7	7.83	0.45	1.47e-13	Corneal astigmatism;
KIRP	cis	rs13361707	0.700	rs10055925	chr5:40688059	A/G	cg01087697	chr5:40835557	RPL37	-0.49	-5.37	-0.32	1.83e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.55	-6.77	-0.4	9.18e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.86	-12.46	-0.62	5.84e-28	Calcium levels;
KIRP	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.34	-7.05	-0.41	1.79e-11	Urinary metabolites;
KIRP	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg16917193	chr12:54089295	NA	0.85	16.31	0.72	4.89e-41	Height;
KIRP	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	4.88	0.3	1.87e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.48	-6.52	-0.38	3.94e-10	Schizophrenia;
KIRP	cis	rs12130219	1.000	rs12733173	chr1:152173972	C/T	cg17718321	chr1:152188247	HRNR	0.44	5.35	0.32	2.03e-7	Inflammatory skin disease;
KIRP	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg12480562	chr20:23434244	CST11	0.58	5.67	0.34	3.95e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs57590327	0.679	rs34880320	chr3:81510666	T/C	cg07356753	chr3:81810745	GBE1	-0.55	-6.02	-0.36	6.33e-9	Extraversion;
KIRP	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.97	-0.41	2.98e-11	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24938498	chr3:42642146	NKTR	0.49	6.12	0.36	3.59e-9	Parkinson's disease;
KIRP	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.62	-9.35	-0.51	5.53e-18	Body mass index;
KIRP	cis	rs4664293	1.000	rs4665083	chr2:160430127	C/T	cg08347373	chr2:160653686	CD302	0.39	5.97	0.36	8.08e-9	Monocyte percentage of white cells;
KIRP	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20135002	chr11:47629003	NA	-0.48	-5.82	-0.35	1.87e-8	Subjective well-being;
KIRP	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg02158880	chr13:53174818	NA	0.38	5.14	0.31	5.53e-7	Lewy body disease;
KIRP	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.65	-9.84	-0.53	1.82e-19	Educational attainment;
KIRP	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg12549451	chr6:135224345	NA	-0.51	-6.71	-0.39	1.35e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.48	-6.54	-0.38	3.59e-10	Leprosy;
KIRP	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.64	-7.82	-0.45	1.53e-13	Systemic lupus erythematosus;
KIRP	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg26513180	chr16:89883248	FANCA	0.71	5.11	0.31	6.54e-7	Skin colour saturation;
KIRP	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg22563815	chr15:78856949	CHRNA5	0.5	7.71	0.44	3.07e-13	Sudden cardiac arrest;
KIRP	cis	rs10214930	0.767	rs6957378	chr7:27696949	C/T	cg22168087	chr7:27702803	HIBADH	-0.52	-5.26	-0.32	3.18e-7	Hypospadias;
KIRP	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	cis	rs7553864	1.000	rs975038	chr1:87613583	C/G	cg17420885	chr1:87600446	LOC339524	-0.48	-6.36	-0.38	9.86e-10	Smoking behavior;
KIRP	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg03808351	chr9:123631620	PHF19	0.46	6.42	0.38	6.99e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs11671005	0.656	rs11672609	chr19:59006924	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.57	-5.6	-0.34	5.58e-8	Mean platelet volume;
KIRP	cis	rs6969780	1.000	rs929249	chr7:27167537	T/C	cg26364809	chr7:27145159	NA	-0.6	-5.31	-0.32	2.47e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	trans	rs921874	0.586	rs2512358	chr11:86775294	C/T	cg22937172	chr2:240168862	HDAC4	0.5	6.46	0.38	5.62e-10	Total body bone mineral density;
KIRP	cis	rs28489187	0.597	rs506082	chr1:85899215	A/C	cg16011679	chr1:85725395	C1orf52	-0.46	-5.67	-0.34	4e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1864400	0.605	rs12360493	chr10:43718613	A/G	cg15436174	chr10:43711423	RASGEF1A	0.55	6.03	0.36	5.82e-9	Hirschsprung disease;
KIRP	cis	rs11638352	1.000	rs12324261	chr15:44318471	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-5.76	-0.34	2.49e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg10189774	chr4:17578691	LAP3	0.43	5.13	0.31	5.85e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	5.1	0.31	6.85e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2071403	1.000	rs4927604	chr2:1416435	A/G	cg06500727	chr2:1417164	TPO	0.44	6.94	0.4	3.5e-11	Thyroid peroxidase antibody positivity;
KIRP	cis	rs35740288	0.770	rs55740125	chr15:86155736	G/A	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4650994	0.593	rs16853043	chr1:178545926	A/G	cg12486710	chr1:178512616	C1orf220	-0.25	-5.35	-0.32	2.03e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg01028140	chr2:1542097	TPO	-0.54	-5.97	-0.36	8.33e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.24	-0.32	3.46e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg19774624	chr17:42201019	HDAC5	0.68	9.08	0.5	3.74e-17	Total body bone mineral density;
KIRP	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.62	8.81	0.49	2.24e-16	Multiple system atrophy;
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg04369109	chr6:150039330	LATS1	-0.65	-8.51	-0.48	1.75e-15	Lung cancer;
KIRP	cis	rs1270639	0.778	rs2530405	chr7:157446021	C/G	cg13357408	chr7:157437802	PTPRN2	0.62	6.02	0.36	6.47e-9	Colorectal cancer;
KIRP	cis	rs62413470	1.000	rs12194997	chr6:55970434	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs72634258	0.945	rs35675666	chr1:8021973	G/T	cg00042356	chr1:8021962	PARK7	0.79	7.28	0.42	4.51e-12	Inflammatory bowel disease;
KIRP	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg16141378	chr3:129829833	LOC729375	0.54	7.07	0.41	1.62e-11	Retinal vascular caliber;
KIRP	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.31	5.24	0.32	3.5e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08026941	chr19:17336882	OCEL1	-0.5	-6.23	-0.37	2.06e-9	Interleukin-4 levels;
KIRP	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5753037	0.745	rs9306465	chr22:30221826	T/A	cg01021169	chr22:30184971	ASCC2	-0.41	-4.97	-0.3	1.24e-6	Type 1 diabetes;
KIRP	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg18234130	chr8:27182889	PTK2B	0.45	5.84	0.35	1.64e-8	Neuroticism;
KIRP	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.83	-11.5	-0.59	8.65e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4073416	0.508	rs7146993	chr14:66048872	A/G	cg03016385	chr14:66212404	NA	0.51	6.13	0.36	3.53e-9	N-glycan levels;
KIRP	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-9.37	-0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs10073892	0.703	rs13357585	chr5:101641034	A/C	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg07775675	chr17:74379922	SPHK1	0.48	6.09	0.36	4.29e-9	Sleep duration;
KIRP	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	cg12689670	chr1:183009347	LAMC1	-0.42	-6.07	-0.36	4.84e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs714027	0.605	rs193471	chr22:30447305	A/G	cg27665648	chr22:30112403	NA	-0.4	-5.25	-0.32	3.29e-7	Lymphocyte counts;
KIRP	cis	rs911119	0.913	rs2405392	chr20:23569186	C/T	cg09631192	chr20:23583594	CST9	-0.48	-5.04	-0.31	9e-7	Chronic kidney disease;
KIRP	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.59	-12.11	-0.61	8.67e-27	Diabetic kidney disease;
KIRP	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.42	-5.21	-0.32	4.04e-7	Aortic root size;
KIRP	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.1	0.36	4.18e-9	Educational attainment;
KIRP	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg21905437	chr5:178450457	ZNF879	0.55	6.37	0.38	9.16e-10	Pubertal anthropometrics;
KIRP	cis	rs9914544	0.545	rs9903574	chr17:18768582	C/T	cg26378065	chr17:18585709	ZNF286B	0.38	4.98	0.3	1.19e-6	Educational attainment (years of education);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04207741	chr12:57482553	NAB2	-0.46	-6.81	-0.4	7.4e-11	Metabolic traits;
KIRP	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.69	8.08	0.46	2.98e-14	Corneal astigmatism;
KIRP	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg11005552	chr10:105648138	OBFC1	-0.41	-5.95	-0.35	9.29e-9	Coronary artery disease;
KIRP	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11613427	chr3:52932208	TMEM110	0.3	4.93	0.3	1.5e-6	Schizophrenia;
KIRP	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg26695010	chr11:65641043	EFEMP2	-0.41	-5.14	-0.31	5.71e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs78049276	0.736	rs73855810	chr4:148383424	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-7.07	-0.41	1.61e-11	Pulse pressure;
KIRP	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	10.94	0.57	5.97e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-6.66	-0.39	1.76e-10	Obesity-related traits;
KIRP	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg18709589	chr6:96969512	KIAA0776	0.34	5.15	0.31	5.36e-7	Headache;
KIRP	cis	rs494562	0.892	rs520090	chr6:86116635	G/A	cg27039625	chr6:86159096	NT5E	0.42	5.34	0.32	2.07e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.72	12.71	0.63	8.8e-29	Obesity-related traits;
KIRP	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg06027949	chr8:82754900	SNX16	-0.61	-6.65	-0.39	1.86e-10	Diastolic blood pressure;
KIRP	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs35740288	0.770	rs11631660	chr15:86215412	G/T	cg10818794	chr15:86012489	AKAP13	0.46	5.66	0.34	4.22e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg26248373	chr2:1572462	NA	-0.65	-5.91	-0.35	1.16e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg26513180	chr16:89883248	FANCA	-0.41	-5.05	-0.31	8.68e-7	Vitiligo;
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02807482	chr3:125708958	NA	-0.55	-5.19	-0.31	4.5e-7	Blood pressure (smoking interaction);
KIRP	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg24498760	chr8:49746867	NA	0.41	4.93	0.3	1.5e-6	Blood metabolite ratios;
KIRP	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.85	-12.63	-0.63	1.59e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7712401	0.601	rs30038	chr5:122277362	A/C	cg19412675	chr5:122181750	SNX24	0.46	5.08	0.31	7.35e-7	Mean platelet volume;
KIRP	cis	rs785830	0.558	rs9408082	chr9:262207	G/C	cg14500300	chr9:211689	NA	0.41	5.45	0.33	1.25e-7	Platelet distribution width;
KIRP	cis	rs2273156	0.636	rs12892552	chr14:35505414	A/G	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.09	-0.31	7.16e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.18	-0.51	1.77e-17	Personality dimensions;
KIRP	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg13512537	chr8:22265999	SLC39A14	-0.38	-5.15	-0.31	5.26e-7	Verbal declarative memory;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00920043	chr1:11333412	UBIAD1	0.61	7.19	0.42	7.66e-12	Smoking initiation;
KIRP	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg23594656	chr7:65796392	TPST1	-0.38	-5.55	-0.33	7.52e-8	Aortic root size;
KIRP	cis	rs2562456	0.520	rs582992	chr19:21449546	G/T	cg13978929	chr19:21580086	ZNF493	0.56	4.94	0.3	1.45e-6	Pain;
KIRP	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	trans	rs76288851	0.740	rs11714878	chr3:126573995	A/G	cg13821433	chr2:26726535	OTOF	0.53	6.04	0.36	5.6e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs2071403	0.933	rs12329063	chr2:1400686	G/A	cg06500727	chr2:1417164	TPO	0.47	7.31	0.42	3.82e-12	Thyroid peroxidase antibody positivity;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg07866137	chr8:67579786	VCPIP1	0.77	6.73	0.39	1.17e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9469913	0.740	rs2744977	chr6:34563060	A/G	cg17674042	chr6:34482479	PACSIN1	-0.49	-6.53	-0.38	3.68e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg21937377	chr3:194868750	C3orf21	0.24	5.06	0.31	8.04e-7	Non-small cell lung cancer;
KIRP	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08280861	chr8:58055591	NA	0.69	6.41	0.38	7.56e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs1298062	0.563	rs2445828	chr19:50941807	A/G	cg17071417	chr19:50962282	MYBPC2	0.48	5.74	0.34	2.76e-8	Age of smoking initiation;
KIRP	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.58	-9.05	-0.5	4.52e-17	Coronary artery disease;
KIRP	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.82	9.99	0.54	6.1e-20	Corneal astigmatism;
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg21851534	chr17:3907994	ZZEF1	-0.62	-9.77	-0.53	2.93e-19	Type 2 diabetes;
KIRP	cis	rs1829883	0.668	rs3899445	chr5:98986269	G/A	cg08333243	chr5:99726346	NA	0.41	5.25	0.32	3.22e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7326068	0.524	rs9506531	chr13:21232983	C/T	cg05130518	chr13:21295590	IL17D	0.38	4.86	0.3	2.11e-6	Schizophrenia, bipolar disorder and depression (combined);
KIRP	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.46	-5.72	-0.34	3.12e-8	Coronary artery disease;
KIRP	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.25	6.69	0.39	1.52e-10	Crohn's disease;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26002218	chr14:103986227	CKB	0.29	5.92	0.35	1.08e-8	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17973739	chr1:43232666	LEPRE1;C1orf50	-0.46	-6.07	-0.36	4.77e-9	Metabolic traits;
KIRP	cis	rs7224685	0.569	rs8082227	chr17:3991563	C/T	cg09597638	chr17:3907349	NA	0.54	5.3	0.32	2.56e-7	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg09455208	chr3:40491958	NA	0.37	6.71	0.39	1.36e-10	Renal cell carcinoma;
KIRP	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg17554472	chr22:41940697	POLR3H	-0.51	-5.74	-0.34	2.77e-8	Neuroticism;
KIRP	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.48	5.99	0.36	7.41e-9	Tonsillectomy;
KIRP	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg01620082	chr3:125678407	NA	-1.13	-7.31	-0.42	3.7e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	0.763	rs9605474	chr22:18463297	A/G	cg03078520	chr22:18463400	MICAL3	-0.84	-12.0	-0.61	2.05e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg01798813	chr17:3906674	NA	0.6	8.44	0.47	2.69e-15	Type 2 diabetes;
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg21523564	chr15:75251491	NA	0.39	6.32	0.37	1.23e-9	Breast cancer;
KIRP	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Educational attainment;
KIRP	cis	rs524023	0.914	rs555456	chr11:64418259	T/C	cg09231725	chr11:64357281	SLC22A12	0.6	8.05	0.46	3.44e-14	Urate levels in obese individuals;
KIRP	trans	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.06	-0.36	5.2e-9	Neuroticism;
KIRP	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.81	10.49	0.56	1.63e-21	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg26818010	chr10:134567672	INPP5A	-0.66	-7.33	-0.42	3.4e-12	Migraine;
KIRP	trans	rs1864585	0.520	rs10503409	chr8:10669654	C/G	cg26278703	chr11:58910052	FAM111A	-0.6	-6.18	-0.37	2.63e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.65	8.32	0.47	5.99e-15	Red blood cell count;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg08901578	chr4:187885870	NA	-0.5	-7.42	-0.43	1.95e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg21546286	chr11:48923668	NA	-0.43	-5.22	-0.32	3.75e-7	HDL cholesterol;
KIRP	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.84	11.76	0.6	1.28e-25	Schizophrenia;
KIRP	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.72	6.42	0.38	6.85e-10	Diabetic retinopathy;
KIRP	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg25547332	chr5:131281432	NA	0.5	5.94	0.35	9.55e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.52	5.1	0.31	6.66e-7	Diastolic blood pressure;
KIRP	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.35	-5.33	-0.32	2.19e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.61	-0.44	5.89e-13	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09820084	chr6:18387507	RNF144B	0.67	8.24	0.47	1.02e-14	Smoking initiation;
KIRP	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	11.72	0.6	1.74e-25	Response to antipsychotic treatment;
KIRP	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-1.06	-17.17	-0.74	5.89e-44	Cognitive function;
KIRP	cis	rs2278796	0.724	rs2794860	chr1:204968392	A/G	cg04862289	chr1:204966208	NFASC	0.61	9.15	0.5	2.27e-17	Mean platelet volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14448765	chr9:136729858	VAV2	0.52	6.08	0.36	4.58e-9	Interleukin-4 levels;
KIRP	trans	rs76288851	0.733	rs11718344	chr3:126466465	A/G	cg13821433	chr2:26726535	OTOF	0.59	6.48	0.38	4.99e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.18	0.37	2.58e-9	Total cholesterol levels;
KIRP	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.79	10.84	0.57	1.22e-22	Huntington's disease progression;
KIRP	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg00074818	chr8:8560427	CLDN23	0.4	6.33	0.37	1.16e-9	Obesity-related traits;
KIRP	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg11859384	chr17:80120422	CCDC57	0.46	6.17	0.37	2.79e-9	Life satisfaction;
KIRP	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.7	0.48	4.9e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.94	8.93	0.49	9.85e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	0.83	7.44	0.43	1.73e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04786791	chr1:218458496	RRP15	0.52	6.19	0.37	2.52e-9	Smoking initiation;
KIRP	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.42	-0.51	3.49e-18	Triglycerides;
KIRP	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.77	13.05	0.64	6.15e-30	Cancer;
KIRP	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.73	10.72	0.56	3.04e-22	Oral cavity cancer;
KIRP	cis	rs11997175	0.545	rs66789266	chr8:33888156	C/T	ch.8.33884649F	chr8:33765107	NA	0.47	5.21	0.32	4.07e-7	Body mass index;
KIRP	trans	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg07211511	chr3:129823064	LOC729375	-0.72	-7.3	-0.42	3.98e-12	Blood pressure (smoking interaction);
KIRP	cis	rs4722404	0.570	rs1968924	chr7:3137677	G/T	cg19214707	chr7:3157722	NA	-0.42	-5.28	-0.32	2.78e-7	Atopic dermatitis;
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg14338887	chr6:42928500	GNMT	0.46	6.78	0.4	8.95e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.0	-0.3	1.1e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-5.47	-0.33	1.12e-7	Alzheimer's disease (late onset);
KIRP	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg13180566	chr4:1052158	NA	-0.53	-5.43	-0.33	1.38e-7	Recombination rate (females);
KIRP	cis	rs4400599	0.618	rs2220390	chr1:154233016	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.44	-6.75	-0.4	1.05e-10	Platelet distribution width;
KIRP	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08975724	chr8:8085496	FLJ10661	0.69	9.45	0.52	2.76e-18	Joint mobility (Beighton score);
KIRP	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg04691961	chr3:161091175	C3orf57	-0.47	-6.68	-0.39	1.54e-10	Morning vs. evening chronotype;
KIRP	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.23	17.83	0.75	3.24e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg21226059	chr5:178986404	RUFY1	0.49	7.74	0.44	2.65e-13	Lung cancer;
KIRP	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-5.24	-0.32	3.39e-7	Height;
KIRP	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg15832292	chr6:96025679	MANEA	-0.76	-6.8	-0.4	8e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.74	10.23	0.55	1.04e-20	Red blood cell count;
KIRP	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg16898833	chr6:26189333	HIST1H4D	0.81	5.81	0.35	1.95e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.66	6.56	0.39	3.14e-10	Menarche (age at onset);
KIRP	cis	rs4984778	0.717	rs2738892	chr16:1268758	A/G	cg07748719	chr16:1272498	TPSG1	0.62	8.9	0.49	1.28e-16	Blood protein levels;
KIRP	cis	rs7119038	0.779	rs11217045	chr11:118697865	C/A	cg19308663	chr11:118741387	NA	0.62	10.13	0.54	2.23e-20	Sjögren's syndrome;
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg09699651	chr6:150184138	LRP11	0.46	6.13	0.36	3.45e-9	Lung cancer;
KIRP	cis	rs13401104	0.716	rs11677595	chr2:237140651	A/G	cg26422059	chr2:237146110	ASB18	0.51	5.22	0.32	3.77e-7	Educational attainment;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg22115596	chr1:29214297	EPB41	0.49	6.2	0.37	2.31e-9	Asthma;
KIRP	cis	rs2072732	0.821	rs1005471	chr1:2952614	T/C	cg11731671	chr1:2995604	PRDM16	-0.41	-5.56	-0.33	7.17e-8	Plateletcrit;
KIRP	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.67	-8.76	-0.49	3.22e-16	Calcium levels;
KIRP	cis	rs5743618	0.537	rs7694115	chr4:38779094	A/G	cg06935464	chr4:38784597	TLR10	0.39	4.93	0.3	1.49e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs258892	0.895	rs13187277	chr5:72029986	T/C	cg21869765	chr5:72125136	TNPO1	-0.53	-6.05	-0.36	5.23e-9	Small cell lung carcinoma;
KIRP	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg23533419	chr12:54090519	NA	-0.34	-5.17	-0.31	4.83e-7	Height;
KIRP	trans	rs76288851	0.866	rs73203677	chr3:126561577	A/G	cg13821433	chr2:26726535	OTOF	0.58	6.41	0.38	7.31e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs2554380	0.843	rs1019665	chr15:84380619	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.5	-7.2	-0.42	7.09e-12	Height;
KIRP	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg21573476	chr21:45109991	RRP1B	-0.65	-9.2	-0.51	1.64e-17	Mean corpuscular volume;
KIRP	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg00677455	chr12:58241039	CTDSP2	-0.74	-8.94	-0.5	9.38e-17	Multiple sclerosis;
KIRP	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.62	8.58	0.48	1.08e-15	Lymphocyte counts;
KIRP	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg11569703	chr11:65557185	OVOL1	0.37	5.73	0.34	2.89e-8	Eosinophil percentage of white cells;
KIRP	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.42e-48	Height;
KIRP	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg19468946	chr17:37922297	IKZF3	-0.44	-6.04	-0.36	5.67e-9	Asthma;
KIRP	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg16306078	chr6:126000798	NA	-0.27	-5.09	-0.31	7.12e-7	Endometrial cancer;
KIRP	cis	rs12580194	0.593	rs7485053	chr12:55770126	T/C	cg19537932	chr12:55886519	OR6C68	-0.51	-6.58	-0.39	2.8e-10	Cancer;
KIRP	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg24250549	chr1:154909240	PMVK	-0.48	-6.52	-0.38	4.01e-10	Prostate cancer;
KIRP	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12826209	chr6:26865740	GUSBL1	-0.49	-5.98	-0.36	7.87e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15123824	chr2:85581917	ELMOD3;RETSAT	1.03	6.71	0.39	1.33e-10	P wave terminal force;
KIRP	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.84	-12.44	-0.62	6.81e-28	Strep throat;
KIRP	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.71	8.34	0.47	5.37e-15	Corneal astigmatism;
KIRP	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.84	-12.49	-0.62	4.66e-28	Strep throat;
KIRP	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg22563815	chr15:78856949	CHRNA5	0.5	7.89	0.45	9.93e-14	Sudden cardiac arrest;
KIRP	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.71	7.97	0.45	6.09e-14	Corneal astigmatism;
KIRP	cis	rs4742903	0.935	rs1413341	chr9:106973013	C/T	cg14250997	chr9:106856677	SMC2	0.37	4.89	0.3	1.8e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10984505	chr6:36410951	PXT1;KCTD20	0.52	6.54	0.38	3.63e-10	Parkinson's disease;
KIRP	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg19875535	chr5:140030758	IK	-0.72	-10.43	-0.55	2.52e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.6	-7.93	-0.45	7.5e-14	Total body bone mineral density;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13544758	chr6:35889047	SRPK1	-0.47	-6.3	-0.37	1.4e-9	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08085208	chr14:75348779	DLST	0.5	6.16	0.37	2.89e-9	Parkinson's disease;
KIRP	cis	rs9863706	0.520	rs9870681	chr3:72398604	C/T	cg05607079	chr3:72387937	NA	0.46	5.84	0.35	1.66e-8	Height;
KIRP	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.86	-0.35	1.46e-8	Bipolar disorder;
KIRP	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg22903471	chr2:27725779	GCKR	0.39	5.4	0.33	1.58e-7	Oral cavity cancer;
KIRP	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.82	-12.75	-0.63	6.5e-29	Breast cancer;
KIRP	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.75	-0.34	2.61e-8	Educational attainment;
KIRP	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.52	-8.01	-0.45	4.63e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs981844	0.712	rs2405208	chr4:154755774	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.15	0.31	5.47e-7	Menopause (age at onset);
KIRP	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg11657440	chr19:46296263	DMWD	0.93	14.99	0.69	1.59e-36	Coronary artery disease;
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg05562828	chr17:3906858	NA	-0.7	-13.57	-0.65	1.13e-31	Type 2 diabetes;
KIRP	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06544989	chr22:39130855	UNC84B	0.48	7.35	0.42	3e-12	Menopause (age at onset);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg11686214	chr19:59084984	MZF1;LOC100131691	0.53	6.59	0.39	2.6e-10	DNA methylation (variation);
KIRP	cis	rs4740619	0.587	rs10756740	chr9:16037723	T/C	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs7937612	1.000	rs11601535	chr11:120333801	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.61	-0.39	2.34e-10	Intraocular pressure;
KIRP	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg21775007	chr8:11205619	TDH	-0.4	-5.27	-0.32	2.96e-7	Neuroticism;
KIRP	cis	rs9921338	0.961	rs7202814	chr16:11389774	C/T	cg00044050	chr16:11439710	C16orf75	-0.54	-5.65	-0.34	4.54e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.89	10.23	0.55	1.05e-20	Menopause (age at onset);
KIRP	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.86	-15.12	-0.69	5.83e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.58	0.39	2.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-8.69	-0.48	5.26e-16	Platelet count;
KIRP	cis	rs55675132	0.510	rs72691963	chr1:115297986	T/C	cg12756093	chr1:115239321	AMPD1	0.65	6.41	0.38	7.5e-10	Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg05755239	chr4:166128480	KLHL2	-0.48	-6.45	-0.38	5.75e-10	Metabolic traits;
KIRP	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg18643199	chr10:82363313	SH2D4B	0.45	5.08	0.31	7.53e-7	Post bronchodilator FEV1;
KIRP	cis	rs504918	0.588	rs34251299	chr3:124029086	A/G	cg05766129	chr3:123988013	KALRN	-0.44	-5.57	-0.33	6.58e-8	Schizophrenia;
KIRP	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg24498760	chr8:49746867	NA	0.42	5.2	0.31	4.14e-7	Blood metabolite ratios;
KIRP	cis	rs3784262	0.679	rs8031578	chr15:58369145	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.07	-0.31	7.86e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22077997	chr3:127399377	ABTB1	-0.48	-6.16	-0.37	2.96e-9	Parkinson's disease;
KIRP	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	5.45	0.33	1.2e-7	Myopia (pathological);
KIRP	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.62	-0.39	2.17e-10	Initial pursuit acceleration;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg08901578	chr4:187885870	NA	-0.47	-7.09	-0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.52	0.38	4.04e-10	Menarche (age at onset);
KIRP	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg22617819	chr1:44378782	ST3GAL3	-0.33	-5.03	-0.31	9.58e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg26205652	chr12:48591994	NA	-0.48	-5.23	-0.32	3.68e-7	Lung cancer;
KIRP	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.22	-0.32	3.9e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.92	12.57	0.63	2.49e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs6752107	0.503	rs2304774	chr2:234235749	G/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.47	5.71	0.34	3.27e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.09	-19.83	-0.78	6.26e-53	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04100724	chr12:92539208	BTG1	0.61	7.25	0.42	5.37e-12	Smoking initiation;
KIRP	cis	rs6723108	0.967	rs10928513	chr2:135456759	C/T	cg12500956	chr2:135428796	TMEM163	0.46	5.77	0.35	2.33e-8	Type 2 diabetes;
KIRP	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	8.91	0.49	1.18e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.24	-0.32	3.41e-7	Triglycerides;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11492041	chr2:139259481	SPOPL	0.45	6.12	0.36	3.66e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11809207	0.810	rs17356937	chr1:26504036	G/A	cg19633962	chr1:26362018	EXTL1	-0.59	-5.41	-0.33	1.52e-7	Height;
KIRP	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg12549451	chr6:135224345	NA	0.42	5.12	0.31	6.27e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg08283408	chr3:49949060	MON1A	0.37	5.05	0.31	8.77e-7	Body mass index;
KIRP	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.27	5.03	0.31	9.27e-7	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
KIRP	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg18404041	chr3:52824283	ITIH1	0.4	5.21	0.32	4.07e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.82	9.42	0.51	3.5e-18	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05134013	chr20:61288351	SLCO4A1	-0.49	-6.24	-0.37	1.91e-9	Parkinson's disease;
KIRP	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	cg04338863	chr8:33670619	NA	0.48	6.22	0.37	2.11e-9	Body mass index;
KIRP	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.79	-8.08	-0.46	3.01e-14	Coronary artery calcification;
KIRP	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.73	9.46	0.52	2.59e-18	Mosquito bite size;
KIRP	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg23307798	chr14:103986281	CKB	0.76	13.18	0.64	2.31e-30	Body mass index;
KIRP	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.81	0.53	2.22e-19	Bipolar disorder;
KIRP	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg16141378	chr3:129829833	LOC729375	-0.5	-6.15	-0.37	3.13e-9	Neuroticism;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.69	10.97	0.57	4.53e-23	Lung cancer;
KIRP	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	cg12689670	chr1:183009347	LAMC1	0.58	8.07	0.46	3.21e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.75	-10.63	-0.56	5.74e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs7523050	0.643	rs34096625	chr1:109401101	G/A	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.47	-5.58	-0.34	6.19e-8	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	10.49	0.56	1.61e-21	Cognitive test performance;
KIRP	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg17376030	chr22:41985996	PMM1	-0.76	-8.35	-0.47	5.06e-15	Vitiligo;
KIRP	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg02375832	chr11:62437615	C11orf48	-0.42	-5.45	-0.33	1.23e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.47	-10.47	-0.56	1.86e-21	Alzheimer's disease (late onset);
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.0	0.69	1.45e-36	Platelet count;
KIRP	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.7	-7.16	-0.42	9.09e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.59	8.21	0.46	1.25e-14	Neurofibrillary tangles;
KIRP	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg07001201	chr5:642380	CEP72	0.66	6.58	0.39	2.88e-10	Obesity-related traits;
KIRP	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.86	-0.4	5.6e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.7	-8.28	-0.47	7.7e-15	Lung cancer;
KIRP	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg18888403	chr1:24152774	HMGCL	0.35	5.04	0.31	8.95e-7	Immature fraction of reticulocytes;
KIRP	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs2273156	1.000	rs71421920	chr14:35446745	T/C	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.5	-0.33	9.3e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg02993010	chr8:124780839	FAM91A1	-0.6	-6.19	-0.37	2.53e-9	Pancreatic cancer;
KIRP	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16576597	chr16:28551801	NUPR1	0.34	5.0	0.3	1.08e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.62	4.94	0.3	1.47e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs12153243	0.714	rs66524576	chr5:142895661	G/A	cg13907255	chr5:142895549	NA	-0.39	-4.98	-0.3	1.2e-6	Migraine;
KIRP	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.48	5.65	0.34	4.41e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.4	5.13	0.31	5.98e-7	Pulmonary function;
KIRP	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.18	0.37	2.62e-9	Height;
KIRP	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6088813	0.645	rs7267783	chr20:34023219	C/T	cg14752227	chr20:34000481	UQCC	0.48	5.25	0.32	3.28e-7	Height;
KIRP	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.79	-10.78	-0.57	1.96e-22	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18654971	chr5:54469363	MIR449C;CDC20B	0.55	6.69	0.39	1.49e-10	Smoking initiation;
KIRP	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg12432903	chr7:1882776	MAD1L1	-0.57	-5.3	-0.32	2.62e-7	Bipolar disorder;
KIRP	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-11.97	-0.61	2.55e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-10.33	-0.55	5.32e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs210138	1.000	rs210137	chr6:33542478	C/T	cg04201373	chr6:33551533	GGNBP1	0.41	5.07	0.31	7.7e-7	Testicular germ cell tumor;
KIRP	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg01097406	chr16:89675127	NA	0.53	9.3	0.51	8.18e-18	Vitiligo;
KIRP	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.74	10.2	0.55	1.33e-20	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.48e-12	Aortic root size;
KIRP	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	trans	rs73191547	0.615	rs10089666	chr8:10083040	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.23	0.42	6.05e-12	Schizophrenia;
KIRP	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10267417	0.603	rs10215844	chr7:19909227	T/C	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg17519650	chr2:63277830	OTX1	0.64	9.48	0.52	2.32e-18	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	cis	rs745080	0.634	rs1951448	chr14:53050269	A/C	cg23333723	chr14:53022898	GPR137C	0.42	5.97	0.36	8.14e-9	Orofacial clefts;
KIRP	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.32	0.37	1.25e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs883565	0.682	rs35219579	chr3:39044665	A/T	cg01426195	chr3:39028469	NA	-0.72	-12.24	-0.62	3.33e-27	Handedness;
KIRP	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg11130432	chr3:121712080	ILDR1	0.44	5.74	0.34	2.72e-8	Multiple sclerosis;
KIRP	cis	rs6959887	0.890	rs7790990	chr7:35299924	C/T	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs3931020	0.679	rs28671241	chr1:75181881	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.4	5.04	0.31	8.93e-7	Resistin levels;
KIRP	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg25319279	chr11:5960081	NA	-0.63	-6.49	-0.38	4.7e-10	DNA methylation (variation);
KIRP	cis	rs829883	0.646	rs249838	chr12:98874749	C/G	cg25150519	chr12:98850993	NA	0.56	7.51	0.43	1.08e-12	Colorectal adenoma (advanced);
KIRP	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.96	0.5	8.26e-17	IgG glycosylation;
KIRP	cis	rs6800768	0.633	rs826372	chr3:24163705	T/C	cg10674438	chr3:24145617	LOC152024	-0.47	-6.3	-0.37	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg27305525	chr1:154955752	FLAD1	0.47	6.11	0.36	3.85e-9	Plasma plasminogen activator levels;
KIRP	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.48	-5.89	-0.35	1.27e-8	Testicular germ cell tumor;
KIRP	cis	rs2301888	0.962	rs2240338	chr1:17674185	C/T	cg01790353	chr1:17674483	PADI4	0.41	5.32	0.32	2.3e-7	Rheumatoid arthritis;
KIRP	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.42	0.33	1.41e-7	Putamen volume;
KIRP	cis	rs10788264	0.569	rs3901289	chr10:124027433	T/C	cg09507567	chr10:124027408	NA	0.33	6.32	0.37	1.19e-9	Total body bone mineral density;
KIRP	cis	rs2213920	0.619	rs4979529	chr9:118197686	T/A	cg13918206	chr9:118159781	DEC1	1.0	10.34	0.55	4.68e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.99	9.14	0.5	2.43e-17	Systolic blood pressure;
KIRP	cis	rs76793172	0.557	rs6509234	chr19:46229711	T/G	cg00442267	chr19:46317840	RSPH6A	0.66	5.72	0.34	3.12e-8	Eosinophil counts;
KIRP	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg11459648	chr5:138714337	SLC23A1	0.51	7.25	0.42	5.26e-12	Esophageal squamous cell carcinoma;
KIRP	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg07541023	chr7:19748670	TWISTNB	0.63	5.51	0.33	9.17e-8	Thyroid stimulating hormone;
KIRP	cis	rs758747	0.531	rs13332500	chr16:3575270	A/C	cg07396092	chr16:3662230	BTBD12	0.42	5.23	0.32	3.66e-7	Body mass index;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg08901578	chr4:187885870	NA	-0.54	-8.84	-0.49	1.82e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.54	7.68	0.44	3.85e-13	Schizophrenia;
KIRP	cis	rs7033996	1.000	rs62541933	chr9:35947602	G/A	cg00918944	chr9:35908117	LOC158376	0.38	5.34	0.32	2.12e-7	Urate levels (BMI interaction);
KIRP	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.11	-0.36	3.84e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg03808351	chr9:123631620	PHF19	0.37	4.93	0.3	1.48e-6	Rheumatoid arthritis;
KIRP	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg21475434	chr5:93447410	FAM172A	-0.42	-4.91	-0.3	1.68e-6	Diabetic retinopathy;
KIRP	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27180563	chr19:13056485	RAD23A	0.46	6.21	0.37	2.21e-9	Survival in pancreatic cancer;
KIRP	cis	rs4474465	1.000	rs4944202	chr11:78189558	T/C	cg02023728	chr11:77925099	USP35	0.35	5.53	0.33	8.3e-8	Alzheimer's disease (survival time);
KIRP	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.4	-5.31	-0.32	2.42e-7	Blood metabolite levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg18500431	chr7:1709489	NA	0.45	6.45	0.38	5.73e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4666002	0.564	rs13030345	chr2:28003174	A/C	cg05484376	chr2:27715224	FNDC4	0.46	5.6	0.34	5.78e-8	Phospholipid levels (plasma);
KIRP	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.24e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg14768367	chr16:72042858	DHODH	0.44	5.35	0.32	2.05e-7	Fibrinogen levels;
KIRP	cis	rs6450176	0.587	rs10471884	chr5:53344135	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.73	-9.01	-0.5	5.75e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg03609598	chr5:56110824	MAP3K1	-0.42	-4.94	-0.3	1.45e-6	Coronary artery disease;
KIRP	cis	rs714027	0.565	rs9614099	chr22:30288338	A/T	cg27665648	chr22:30112403	NA	0.42	5.77	0.35	2.41e-8	Lymphocyte counts;
KIRP	cis	rs10761482	0.813	rs12776510	chr10:62167928	C/T	cg01186212	chr10:62110162	ANK3	-0.29	-4.92	-0.3	1.58e-6	Schizophrenia;
KIRP	cis	rs7808935	0.768	rs757137	chr7:27989343	T/C	cg22168087	chr7:27702803	HIBADH	0.6	7.17	0.42	8.73e-12	Prostate cancer;
KIRP	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs775227	0.574	rs3732809	chr3:113045561	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-5.48	-0.33	1.04e-7	Dental caries;
KIRP	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg18825076	chr15:78729989	IREB2	-0.43	-4.98	-0.3	1.19e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	1.09	8.1	0.46	2.61e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	1.13	17.21	0.74	4.33e-44	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.87	0.3	1.97e-6	Lung cancer;
KIRP	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.93	-14.58	-0.68	3.92e-35	Systemic lupus erythematosus;
KIRP	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg01631408	chr1:248437212	OR2T33	-0.63	-8.4	-0.47	3.7e-15	Common traits (Other);
KIRP	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg00310523	chr12:86230176	RASSF9	0.38	6.01	0.36	6.48e-9	Major depressive disorder;
KIRP	cis	rs112591243	0.685	rs80124066	chr21:47912913	A/G	cg26904215	chr21:47823096	PCNT	-0.79	-5.78	-0.35	2.3e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18880946	chr13:94422696	GPC6	0.39	6.33	0.37	1.14e-9	Survival in pancreatic cancer;
KIRP	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.32e-12	HDL cholesterol levels;
KIRP	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg17554472	chr22:41940697	POLR3H	0.47	5.35	0.32	2.04e-7	Vitiligo;
KIRP	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg03465714	chr1:152285911	FLG	0.51	5.43	0.33	1.35e-7	Atopic dermatitis;
KIRP	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.55	-7.35	-0.42	2.97e-12	Ulcerative colitis;
KIRP	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs2273669	0.667	rs76732622	chr6:109318280	A/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg12437481	chr16:420112	MRPL28	-0.49	-6.37	-0.38	9.42e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs7834588	0.736	rs16929982	chr8:63880843	G/A	cg04220482	chr8:63952370	GGH	0.42	4.89	0.3	1.85e-6	Response to Vitamin E supplementation;
KIRP	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg04865290	chr3:52927548	TMEM110	0.46	6.09	0.36	4.4e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7615316	1.000	rs6784089	chr3:142356496	T/C	cg20824294	chr3:142316082	PLS1	0.24	5.32	0.32	2.31e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg12311346	chr5:56204834	C5orf35	-0.37	-5.03	-0.31	9.44e-7	Breast cancer;Breast cancer (early onset);
KIRP	trans	rs1133906	0.522	rs4267	chr7:92759462	A/G	cg14519598	chr9:36906608	PAX5	0.61	6.14	0.36	3.36e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg11812906	chr14:75593930	NEK9	-0.48	-5.78	-0.35	2.24e-8	Neuroticism;
KIRP	cis	rs6681460	1.000	rs6680876	chr1:67129482	G/A	cg13052034	chr1:66999238	SGIP1	0.44	6.11	0.36	3.88e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs35740288	0.770	rs62022909	chr15:86207481	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-5.31	-0.32	2.45e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2905347	0.591	rs12155285	chr7:22678637	G/A	cg23521230	chr7:22704884	NA	0.4	4.96	0.3	1.31e-6	Major depression and alcohol dependence;
KIRP	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.54	-0.52	1.48e-18	Personality dimensions;
KIRP	cis	rs62109865	0.655	rs62113567	chr19:12625462	G/A	cg19721055	chr19:12753329	NA	-0.88	-5.14	-0.31	5.71e-7	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg11906718	chr8:101322791	RNF19A	0.64	8.17	0.46	1.62e-14	Atrioventricular conduction;
KIRP	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.56	-6.75	-0.4	1.03e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4704187	0.595	rs7717337	chr5:74377001	T/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs6429082	0.702	rs2131922	chr1:235705001	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.51	-5.89	-0.35	1.23e-8	Adiposity;
KIRP	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.3	-0.37	1.4e-9	IgG glycosylation;
KIRP	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.93	12.24	0.62	3.17e-27	Menopause (age at onset);
KIRP	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	8.18	0.46	1.49e-14	Retinal vascular caliber;
KIRP	cis	rs61935443	0.720	rs10859783	chr12:95285339	A/G	cg21533806	chr12:95267307	NA	0.65	6.46	0.38	5.49e-10	Schizophrenia;
KIRP	cis	rs1999930	0.505	rs1416190	chr6:116240514	T/A	cg15226275	chr6:116381976	FRK	0.22	5.39	0.33	1.63e-7	Age-related macular degeneration;
KIRP	cis	rs75920871	0.528	rs7950093	chr11:116963519	G/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.19	-0.31	4.35e-7	Subjective well-being;
KIRP	trans	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg24644049	chr4:85504048	CDS1	1.0	6.95	0.41	3.31e-11	Skin colour saturation;
KIRP	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg01304814	chr3:48885189	PRKAR2A	0.56	4.95	0.3	1.38e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.63	0.39	2.1e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg13753209	chr17:57696993	CLTC	0.57	5.5	0.33	9.33e-8	Hemoglobin concentration;
KIRP	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.42	-0.33	1.41e-7	Aortic root size;
KIRP	cis	rs15676	0.783	rs2417126	chr9:131562457	C/T	cg00228799	chr9:131580591	ENDOG	-0.49	-4.99	-0.3	1.14e-6	Blood metabolite levels;
KIRP	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.55	6.57	0.39	3.06e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs9790314	0.613	rs6799160	chr3:160634889	A/G	cg19274270	chr17:78178856	CARD14	0.35	6.11	0.36	3.88e-9	Morning vs. evening chronotype;
KIRP	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg19847866	chr10:1019161	NA	-0.64	-5.82	-0.35	1.82e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg20243544	chr17:37824526	PNMT	0.38	4.93	0.3	1.49e-6	Self-reported allergy;
KIRP	cis	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.98	17.17	0.74	5.8e-44	Breast cancer;
KIRP	cis	rs11209002	0.956	rs10749772	chr1:67586231	A/G	cg02640540	chr1:67518911	SLC35D1	0.57	4.9	0.3	1.73e-6	Crohn's disease;
KIRP	cis	rs2457480	0.571	rs61857479	chr10:44705516	A/G	cg09554077	chr10:44749378	NA	0.5	6.45	0.38	5.83e-10	Coronary artery disease;
KIRP	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.47	-5.04	-0.31	9.06e-7	Alzheimer's disease;
KIRP	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.8	0.49	2.47e-16	Motion sickness;
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.32	5.08	0.31	7.36e-7	Electroencephalogram traits;
KIRP	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg04990556	chr1:26633338	UBXN11	0.66	6.39	0.38	8.1e-10	Obesity-related traits;
KIRP	cis	rs7215564	0.818	rs34754307	chr17:78652758	C/G	cg06153925	chr17:78755379	RPTOR	0.32	5.21	0.32	3.97e-7	Myopia (pathological);
KIRP	cis	rs4363506	0.625	rs10765117	chr10:129284915	T/A	cg07804728	chr10:129284050	NA	0.42	5.78	0.35	2.25e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg21698718	chr17:80085957	CCDC57	0.34	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.48	7.58	0.44	6.91e-13	Testicular germ cell tumor;
KIRP	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg02775129	chr4:119771670	NA	-0.79	-4.89	-0.3	1.79e-6	Cannabis dependence symptom count;
KIRP	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	0.95	12.19	0.61	4.87e-27	Blood protein levels;
KIRP	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg24550644	chr17:30846204	MYO1D	-0.26	-5.16	-0.31	5.2e-7	Schizophrenia;
KIRP	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg16482183	chr6:26056742	HIST1H1C	0.39	5.17	0.31	4.85e-7	Schizophrenia;
KIRP	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.51	-6.27	-0.37	1.63e-9	Diastolic blood pressure;
KIRP	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg09137382	chr11:130731461	NA	0.55	8.08	0.46	2.95e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.53	6.48	0.38	4.87e-10	Eye color traits;
KIRP	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg05991184	chr2:219186017	PNKD	0.35	5.12	0.31	6.05e-7	Colorectal cancer;
KIRP	cis	rs40363	0.594	rs250626	chr16:3511892	G/A	cg21433313	chr16:3507492	NAT15	0.56	7.86	0.45	1.18e-13	Tuberculosis;
KIRP	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg08885076	chr2:99613938	TSGA10	0.5	6.26	0.37	1.74e-9	Chronic sinus infection;
KIRP	trans	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg01311341	chr22:25575246	KIAA1671	-0.58	-6.3	-0.37	1.35e-9	Glioblastoma;
KIRP	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg17366294	chr4:99064904	C4orf37	0.36	4.97	0.3	1.28e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-0.98	-9.05	-0.5	4.35e-17	Blood pressure (smoking interaction);
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg24633833	chr3:10029261	TMEM111	0.59	5.04	0.31	9.22e-7	Alzheimer's disease;
KIRP	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.52e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.42	-0.33	1.45e-7	Total body bone mineral density;
KIRP	cis	rs6467136	0.668	rs10275319	chr7:127162710	G/A	cg23081781	chr7:127225937	GCC1	-0.38	-5.14	-0.31	5.66e-7	Type 2 diabetes;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg08132940	chr7:1081526	C7orf50	-0.53	-5.52	-0.33	8.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6746082	0.519	rs637519	chr2:25760891	G/A	cg23192403	chr2:25781496	DTNB	-0.25	-5.02	-0.3	1.01e-6	Multiple myeloma;
KIRP	cis	rs631288	0.793	rs1822311	chr1:146681517	T/C	cg25205988	chr1:146714368	CHD1L	1.01	5.52	0.33	8.62e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	0.81	9.23	0.51	1.28e-17	Gut microbiome composition (summer);
KIRP	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg20701182	chr2:24300061	SF3B14	0.48	5.11	0.31	6.54e-7	Asthma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07818431	chr1:228291118	C1orf35	0.51	6.67	0.39	1.63e-10	Parkinson's disease;
KIRP	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg15488143	chr7:128924101	AHCYL2	0.62	6.95	0.41	3.28e-11	White matter hyperintensity burden;
KIRP	cis	rs1413885	0.516	rs4329545	chr1:65861060	T/C	cg13202122	chr1:65886182	LEPROT;LEPR	0.45	5.28	0.32	2.79e-7	Anticoagulant levels;
KIRP	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.56	-0.56	9.73e-22	Height;
KIRP	cis	rs72781680	0.752	rs12616649	chr2:23890913	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	8.7	0.49	4.86e-16	Lymphocyte counts;
KIRP	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.03	0.31	9.27e-7	Menopause (age at onset);
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.64	-8.28	-0.47	7.88e-15	Longevity;Endometriosis;
KIRP	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.44	15.12	0.69	5.73e-37	Schizophrenia;
KIRP	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.5	-6.57	-0.39	3.04e-10	Schizophrenia;
KIRP	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg12046867	chr14:103022105	NA	-0.54	-6.99	-0.41	2.6e-11	Platelet count;
KIRP	cis	rs13394619	0.605	rs12476319	chr2:11748406	A/G	cg07314298	chr2:11723111	GREB1	0.5	7.16	0.42	9.07e-12	Endometriosis;
KIRP	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.06	-22.73	-0.82	2.16e-62	Myeloid white cell count;
KIRP	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.64	-9.35	-0.51	5.77e-18	Educational attainment;
KIRP	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.92	15.72	0.71	5e-39	Menarche (age at onset);
KIRP	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg26084005	chr2:241760190	KIF1A	-0.47	-6.19	-0.37	2.53e-9	Urinary metabolites;
KIRP	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.65	-10.08	-0.54	3.08e-20	Menopause (age at onset);
KIRP	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.46	6.04	0.36	5.61e-9	Neutrophil percentage of white cells;
KIRP	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg26207909	chr14:103986467	CKB	-0.49	-6.19	-0.37	2.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg04362960	chr10:104952993	NT5C2	0.51	6.17	0.37	2.73e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.58	7.35	0.42	2.92e-12	Aortic root size;
KIRP	cis	rs1961637	0.514	rs2395945	chr2:223890360	C/T	cg02552189	chr2:223891284	NA	0.52	7.42	0.43	1.95e-12	Oropharynx cancer;
KIRP	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg17294928	chr15:75287854	SCAMP5	-0.63	-5.34	-0.32	2.07e-7	Lung cancer;
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.95	0.54	8.01e-20	Lung cancer;
KIRP	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs74400468	0.529	rs74137928	chr10:43203753	A/C	cg11229571	chr10:43362202	NA	0.93	5.25	0.32	3.25e-7	Cannabis dependence symptom count;
KIRP	cis	rs2637030	0.533	rs2607511	chr5:52930471	G/A	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg25110126	chr1:46999211	NA	-0.45	-5.63	-0.34	5.01e-8	Monobrow;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg16520800	chr1:202936341	CYB5R1	0.51	6.17	0.37	2.76e-9	Beard thickness;
KIRP	cis	rs7560272	0.501	rs12713798	chr2:73986421	C/T	cg20560298	chr2:73613845	ALMS1	0.47	5.73	0.34	2.98e-8	Schizophrenia;
KIRP	cis	rs775227	0.636	rs3773697	chr3:113023509	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-5.11	-0.31	6.53e-7	Dental caries;
KIRP	cis	rs2479106	0.609	rs7860055	chr9:126462707	G/T	cg16191174	chr9:126692580	DENND1A	-0.43	-5.44	-0.33	1.31e-7	Polycystic ovary syndrome;
KIRP	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg01631408	chr1:248437212	OR2T33	-0.59	-7.39	-0.43	2.3e-12	Common traits (Other);
KIRP	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.38e-10	Diabetic retinopathy;
KIRP	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.59	-6.55	-0.39	3.27e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs10875746	0.579	rs10875778	chr12:48624655	T/C	cg26205652	chr12:48591994	NA	0.81	10.54	0.56	1.12e-21	Longevity (90 years and older);
KIRP	cis	rs35883536	0.528	rs1855800	chr1:101030641	G/A	cg09408571	chr1:101003634	GPR88	0.24	5.36	0.32	1.91e-7	Monocyte count;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.88	8.35	0.47	4.9e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg20673091	chr1:2541236	MMEL1	0.41	5.65	0.34	4.5e-8	Ulcerative colitis;
KIRP	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs7252505	0.892	rs3786934	chr19:33602856	A/G	cg17764715	chr19:33622953	WDR88	0.71	6.0	0.36	6.84e-9	Colorectal cancer;
KIRP	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.93	-0.49	1.01e-16	Total body bone mineral density;
KIRP	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg06742321	chr12:123595122	PITPNM2	0.42	5.23	0.32	3.58e-7	Platelet count;
KIRP	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg05887092	chr17:76393375	PGS1	0.54	7.49	0.43	1.22e-12	HDL cholesterol levels;
KIRP	cis	rs5995756	0.761	rs6001637	chr22:40001083	A/G	cg10455938	chr22:40058150	CACNA1I	-0.53	-7.99	-0.45	5.09e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.06	0.31	8.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.46	6.6	0.39	2.57e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg06223162	chr1:101003688	GPR88	-0.43	-8.54	-0.48	1.4e-15	Monocyte count;
KIRP	cis	rs9534288	0.577	rs7999168	chr13:46680264	A/C	cg15192986	chr13:46630673	CPB2	-0.67	-7.8	-0.45	1.75e-13	Blood protein levels;
KIRP	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg03734594	chr13:111297400	CARS2	0.36	5.7	0.34	3.42e-8	Coronary artery disease;
KIRP	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.47	6.6	0.39	2.57e-10	Coronary artery disease;
KIRP	trans	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg16141378	chr3:129829833	LOC729375	0.56	6.61	0.39	2.4e-10	Neuroticism;
KIRP	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.36	7.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg26373071	chr5:1325741	CLPTM1L	0.57	7.46	0.43	1.46e-12	Lung cancer;
KIRP	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.65	-10.17	-0.54	1.69e-20	Lung function (FVC);
KIRP	cis	rs2652822	0.525	rs11632192	chr15:63515946	A/G	cg02713581	chr15:63449717	RPS27L	0.47	5.37	0.32	1.82e-7	Metabolic traits;
KIRP	cis	rs911119	0.913	rs6036461	chr20:23576754	C/G	cg09631192	chr20:23583594	CST9	-0.49	-5.2	-0.31	4.26e-7	Chronic kidney disease;
KIRP	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.89	-13.39	-0.65	4.43e-31	Height;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg15117754	chr3:10150083	C3orf24	0.55	5.24	0.32	3.5e-7	Alzheimer's disease;
KIRP	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg17507749	chr15:85114479	UBE2QP1	0.84	9.66	0.52	6.19e-19	Schizophrenia;
KIRP	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.47	-0.38	5.38e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10211454	chr13:31195985	USPL1	-0.51	-7.88	-0.45	1.04e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.71	6.56	0.39	3.15e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.22	0.58	7.06e-24	Morning vs. evening chronotype;
KIRP	trans	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg04701034	chr14:52536175	NID2	-0.43	-6.36	-0.38	9.58e-10	QT interval;
KIRP	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.93	-0.35	9.97e-9	Pulmonary function;
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg02462569	chr6:150064036	NUP43	-0.43	-6.55	-0.39	3.4e-10	Lung cancer;
KIRP	cis	rs6568686	0.627	rs4245546	chr6:111903950	C/A	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.84	-0.3	2.27e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg21184320	chr1:21044207	KIF17	-0.36	-5.49	-0.33	9.9e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.56	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs6832769	0.961	rs12647034	chr4:56310622	A/G	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16974379	chr10:38146505	ZNF248	0.53	6.31	0.37	1.3e-9	Smoking initiation;
KIRP	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg17554472	chr22:41940697	POLR3H	0.59	6.41	0.38	7.48e-10	Vitiligo;
KIRP	trans	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg24644049	chr4:85504048	CDS1	1.0	6.58	0.39	2.8e-10	Skin colour saturation;
KIRP	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.92	12.48	0.62	4.92e-28	Vitamin D levels;
KIRP	cis	rs1881797	0.527	rs77059530	chr1:247648916	G/A	cg18198730	chr1:247681584	NA	0.83	5.43	0.33	1.35e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.65	8.53	0.48	1.48e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.68	-8.1	-0.46	2.52e-14	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05993854	chr4:90032464	NA	0.48	6.41	0.38	7.36e-10	Parkinson's disease;
KIRP	cis	rs9596863	0.898	rs9568908	chr13:54336521	A/C	ch.13.53330881F	chr13:54432880	NA	0.6	5.82	0.35	1.86e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.96	-16.64	-0.73	3.62e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.39	-5.24	-0.32	3.39e-7	Neuroticism;
KIRP	cis	rs9547692	1.000	rs1328042	chr13:37466947	G/A	cg01493522	chr13:37497338	NA	-0.41	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg21095983	chr6:86352623	SYNCRIP	0.54	7.1	0.41	1.34e-11	Smooth-surface caries;
KIRP	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.18	21.46	0.81	2.71e-58	Cognitive function;
KIRP	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.52	8.21	0.46	1.26e-14	Schizophrenia;
KIRP	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs11955398	0.502	rs2085411	chr5:60024558	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.22	-0.32	3.81e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg02569458	chr12:86230093	RASSF9	-0.44	-6.51	-0.38	4.3e-10	Major depressive disorder;
KIRP	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg24826892	chr11:71159390	DHCR7	0.47	5.32	0.32	2.32e-7	Vitamin D levels;
KIRP	cis	rs11651000	0.625	rs2074190	chr17:45811210	A/G	cg24803719	chr17:45855879	NA	-0.37	-5.28	-0.32	2.89e-7	IgG glycosylation;
KIRP	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg05785598	chr3:49045655	WDR6	0.32	5.69	0.34	3.63e-8	Parkinson's disease;
KIRP	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.86	12.5	0.62	4.28e-28	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.73	-0.39	1.19e-10	Myopia (pathological);
KIRP	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg03609598	chr5:56110824	MAP3K1	0.48	5.51	0.33	9.24e-8	Initial pursuit acceleration;
KIRP	cis	rs12976411	0.867	rs34877796	chr19:32829045	C/T	cg02282382	chr19:32836354	ZNF507	0.63	5.27	0.32	3.02e-7	Coronary artery disease;
KIRP	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-4.86	-0.3	2.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2273669	0.667	rs12202145	chr6:109357829	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs2904967	0.571	rs1212391	chr11:65017277	T/A	cg12562828	chr11:65076843	NA	-0.47	-7.07	-0.41	1.6e-11	Mean corpuscular volume;
KIRP	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.33	-0.47	5.84e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg07274523	chr3:49395745	GPX1	0.69	5.01	0.3	1.03e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg05861140	chr6:150128134	PCMT1	-0.46	-6.54	-0.38	3.56e-10	Lung cancer;
KIRP	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.85	0.4	6.04e-11	Bipolar disorder;
KIRP	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.03	11.62	0.6	3.71e-25	Vitiligo;
KIRP	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg17308606	chr9:130706144	FAM102A	-0.34	-5.74	-0.34	2.81e-8	Glaucoma (primary angle closure);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26478621	chr2:73461243	CCT7;C2orf7	0.46	6.12	0.36	3.64e-9	Parkinson's disease;
KIRP	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.53	-0.43	9.76e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg16322655	chr11:31391333	DNAJC24;DCDC1	0.48	6.33	0.37	1.14e-9	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15380588	chr6:144606480	NA	0.47	6.1	0.36	4.03e-9	Parkinson's disease;
KIRP	cis	rs12541635	0.677	rs1603357	chr8:107000565	G/C	cg10147462	chr8:107024639	NA	0.34	5.11	0.31	6.33e-7	Age of smoking initiation;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg00684032	chr4:1343700	KIAA1530	0.56	7.45	0.43	1.56e-12	Longevity;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-1.08	-21.68	-0.81	5.5099999999999996e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg26681399	chr22:41777847	TEF	-0.49	-5.07	-0.31	7.86e-7	Vitiligo;
KIRP	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg22800045	chr5:56110881	MAP3K1	0.44	4.92	0.3	1.61e-6	Coronary artery disease;
KIRP	cis	rs7665939	0.860	rs72709247	chr4:190126086	A/G	cg09826759	chr4:190284978	NA	-0.81	-5.66	-0.34	4.27e-8	Amyotrophic lateral sclerosis;
KIRP	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.73	-10.18	-0.54	1.49e-20	Mean corpuscular volume;
KIRP	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg07395648	chr5:131743802	NA	-0.54	-7.68	-0.44	3.73e-13	Breast cancer;
KIRP	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg21775007	chr8:11205619	TDH	0.43	5.87	0.35	1.41e-8	Neuroticism;
KIRP	cis	rs10463316	0.817	rs10052992	chr5:150788602	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.02	-0.36	6.18e-9	Metabolite levels (Pyroglutamine);
KIRP	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg02002194	chr4:3960332	NA	-0.44	-6.23	-0.37	2.06e-9	Neuroticism;
KIRP	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	cg12689670	chr1:183009347	LAMC1	0.57	7.95	0.45	6.96e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.33	0.42	3.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.63	8.11	0.46	2.33e-14	Prudent dietary pattern;
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs7119167	0.901	rs11235746	chr11:73127168	T/G	cg17517138	chr11:73019481	ARHGEF17	0.51	5.33	0.32	2.24e-7	Blood protein levels;
KIRP	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg14972814	chr11:95582409	MTMR2	0.36	5.95	0.35	9.02e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18252515	chr7:66147081	NA	0.43	5.04	0.31	8.83e-7	Aortic root size;
KIRP	cis	rs7656342	0.579	rs6848689	chr4:9884197	A/G	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.53	-0.33	8.01e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1420338	1.000	rs1420338	chr7:34143256	G/A	cg01275685	chr7:34179230	BMPER	-0.48	-6.75	-0.4	1.03e-10	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.6	-0.39	2.47e-10	Glomerular filtration rate;
KIRP	cis	rs7800944	0.715	rs12540011	chr7:72991704	G/A	cg07452164	chr7:72993570	TBL2	0.55	6.17	0.37	2.78e-9	Coffee consumption (cups per day);
KIRP	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	0.95	7.25	0.42	5.31e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.47	-6.28	-0.37	1.5e-9	Acne (severe);
KIRP	trans	rs7580658	0.676	rs4662717	chr2:128013504	C/T	cg00022858	chr4:55096616	PDGFRA	-0.45	-6.24	-0.37	1.92e-9	Protein C levels;
KIRP	trans	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.01	0.41	2.35e-11	Triglycerides;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.87	-0.3	1.97e-6	Life satisfaction;
KIRP	cis	rs8018808	0.935	rs4899655	chr14:77898077	G/A	cg18872420	chr14:78023429	SPTLC2	0.34	4.95	0.3	1.41e-6	Myeloid white cell count;
KIRP	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	12.07	0.61	1.21e-26	Smoking behavior;
KIRP	cis	rs6450176	1.000	rs4334835	chr5:53300612	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.46	-0.59	1.19e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.43	5.14	0.31	5.5e-7	Aortic root size;
KIRP	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.67	-8.33	-0.47	5.71e-15	Recalcitrant atopic dermatitis;
KIRP	cis	rs1555895	0.611	rs12774722	chr10:854675	G/A	cg10017260	chr10:834428	NA	-0.5	-7.55	-0.43	8.59e-13	Survival in rectal cancer;
KIRP	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	4.03e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.97e-10	Fibrinogen levels;
KIRP	cis	rs6142102	0.961	rs2300204	chr20:32588773	G/A	cg08999081	chr20:33150536	PIGU	0.5	6.48	0.38	5e-10	Skin pigmentation;
KIRP	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg08847533	chr14:75593920	NEK9	0.5	6.09	0.36	4.41e-9	IgG glycosylation;
KIRP	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.61	-0.44	5.77e-13	Retinal vascular caliber;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-4.91	-0.3	1.68e-6	Electroencephalogram traits;
KIRP	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26207909	chr14:103986467	CKB	0.76	11.84	0.6	6.72e-26	Body mass index;
KIRP	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.84	12.38	0.62	1.08e-27	Mean corpuscular volume;
KIRP	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg08885076	chr2:99613938	TSGA10	-0.42	-6.37	-0.38	9.13e-10	Fear of minor pain;
KIRP	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg04609801	chr16:28609176	SULT1A2	-0.57	-5.61	-0.34	5.57e-8	Platelet distribution width;
KIRP	cis	rs12210905	0.688	rs72845028	chr6:27528408	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-5.83	-0.35	1.72e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs2273669	0.915	rs4470881	chr6:109309287	A/G	cg05315195	chr6:109294784	ARMC2	-0.48	-5.48	-0.33	1.06e-7	Prostate cancer;
KIRP	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.14	-0.46	2e-14	Aortic root size;
KIRP	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.69	0.44	3.42e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg18093559	chr17:18951025	GRAP	-0.53	-6.61	-0.39	2.34e-10	Schizophrenia;
KIRP	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg01631408	chr1:248437212	OR2T33	-0.65	-8.45	-0.47	2.6e-15	Common traits (Other);
KIRP	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg00290607	chr11:67383545	NA	-0.4	-5.51	-0.33	9.19e-8	Mean corpuscular volume;
KIRP	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg24747557	chr10:131355152	MGMT	-0.46	-6.37	-0.38	9.12e-10	Response to temozolomide;
KIRP	cis	rs3762637	0.882	rs9856011	chr3:122093570	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.66	-0.34	4.13e-8	LDL cholesterol levels;
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.8	-0.4	7.85e-11	Immature fraction of reticulocytes;
KIRP	cis	rs829883	0.966	rs249853	chr12:98864908	A/C	cg25150519	chr12:98850993	NA	0.81	11.49	0.59	9.74e-25	Colorectal adenoma (advanced);
KIRP	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.71	9.51	0.52	1.88e-18	Height;
KIRP	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.68	-0.39	1.6e-10	Type 2 diabetes;
KIRP	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.57	5.02	0.3	9.89e-7	Skin colour saturation;
KIRP	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs612683	0.560	rs491675	chr1:100902936	A/G	cg06223162	chr1:101003688	GPR88	0.44	8.92	0.49	1.07e-16	Breast cancer;
KIRP	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg22974920	chr21:40686053	BRWD1	-0.42	-4.92	-0.3	1.57e-6	Cognitive function;
KIRP	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.05	0.46	3.44e-14	Menarche (age at onset);
KIRP	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6725041	0.717	rs1357138	chr2:213098546	A/T	cg20637307	chr2:213403960	ERBB4	-0.4	-5.46	-0.33	1.18e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.45	5.16	0.31	5.17e-7	Dermatomyositis;
KIRP	cis	rs9420	0.703	rs10896661	chr11:57679029	C/A	cg19752551	chr11:57585705	CTNND1	-0.76	-10.74	-0.57	2.56e-22	Schizophrenia;
KIRP	cis	rs12311304	0.966	rs7310253	chr12:15381237	G/A	cg08258403	chr12:15378311	NA	0.37	5.55	0.33	7.33e-8	Behavioural disinhibition (generation interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06349981	chr2:10443745	HPCAL1	0.53	6.71	0.39	1.36e-10	Parkinson's disease;
KIRP	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.06	0.58	2.33e-23	Morning vs. evening chronotype;
KIRP	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.75	11.36	0.59	2.5e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.72	9.26	0.51	1.08e-17	Coronary artery disease;
KIRP	cis	rs58785573	0.513	rs6531651	chr4:38592424	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	5.63	0.34	4.94e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs1468333	1.000	rs17171767	chr5:137493528	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	-0.46	-5.42	-0.33	1.43e-7	Resting heart rate;
KIRP	cis	rs55692468	0.848	rs55882252	chr2:153361700	T/C	cg04681845	chr2:153283485	FMNL2	0.47	5.98	0.36	7.78e-9	Intraocular pressure;
KIRP	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg13770153	chr20:60521292	NA	-0.45	-5.46	-0.33	1.19e-7	Body mass index;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02784301	chr16:23194194	SCNN1G	-0.47	-6.34	-0.37	1.09e-9	Myopia;
KIRP	cis	rs10861342	0.892	rs11112378	chr12:105514033	A/G	cg23923672	chr12:105501055	KIAA1033	0.85	6.54	0.39	3.44e-10	IgG glycosylation;
KIRP	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.32	-6.86	-0.4	5.66e-11	Diastolic blood pressure;
KIRP	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.12	-0.5	2.74e-17	Asthma;
KIRP	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg08668510	chr10:1095578	IDI1	-0.87	-5.81	-0.35	1.97e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg02696790	chr15:75250997	RPP25	0.32	5.34	0.32	2.16e-7	Breast cancer;
KIRP	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg24881330	chr22:46731750	TRMU	0.72	5.99	0.36	7.4e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg15839431	chr19:19639596	YJEFN3	-0.52	-5.17	-0.31	4.92e-7	Bipolar disorder;
KIRP	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.81	11.87	0.6	5.26e-26	Urate levels in overweight individuals;
KIRP	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg18944383	chr4:111397179	ENPEP	0.53	9.28	0.51	9.05e-18	Height;
KIRP	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	0.63	8.22	0.46	1.16e-14	Gut microbiota (bacterial taxa);
KIRP	cis	rs9603616	0.902	rs9603605	chr13:40308307	T/C	cg26701198	chr13:40229707	COG6	-0.51	-5.38	-0.32	1.71e-7	Rheumatoid arthritis;
KIRP	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg16586182	chr3:47516702	SCAP	0.76	10.94	0.57	5.82e-23	Colorectal cancer;
KIRP	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.65	-6.62	-0.39	2.26e-10	Breast cancer;
KIRP	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs490234	0.841	rs548793	chr9:128301931	C/T	cg14078157	chr9:128172775	NA	0.4	5.01	0.3	1.04e-6	Mean arterial pressure;
KIRP	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.32	-0.37	1.2e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.01	0.3	1.05e-6	Educational attainment;
KIRP	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg03684893	chr10:554711	DIP2C	0.4	5.65	0.34	4.43e-8	Psychosis in Alzheimer's disease;
KIRP	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg25547332	chr5:131281432	NA	0.46	5.09	0.31	7e-7	Life satisfaction;
KIRP	cis	rs4727443	1.000	rs4727443	chr7:99593346	C/A	cg22004693	chr7:99632812	ZKSCAN1	0.41	5.49	0.33	1.01e-7	Interstitial lung disease;
KIRP	cis	rs4523957	0.583	rs6503302	chr17:2052704	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-12.52	-0.62	3.67e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg10189774	chr4:17578691	LAP3	0.49	5.97	0.36	8.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg26022315	chr17:47021804	SNF8	-0.43	-5.37	-0.32	1.82e-7	Type 2 diabetes;
KIRP	cis	rs4494114	1.000	rs6675245	chr1:39356820	T/A	cg25970120	chr1:39325951	RRAGC	-0.41	-5.12	-0.31	6.08e-7	Blood protein levels;
KIRP	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg07701084	chr6:150067640	NUP43	0.56	7.26	0.42	4.92e-12	Testicular germ cell tumor;
KIRP	trans	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg10756647	chr7:56101905	PSPH	1.06	8.28	0.47	8.09e-15	Diabetic kidney disease;
KIRP	cis	rs11203032	0.831	rs2902445	chr10:90934154	A/G	cg16672925	chr10:90967113	CH25H	0.74	7.34	0.42	3.07e-12	Heart failure;
KIRP	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.64	8.82	0.49	2.14e-16	Blood protein levels;
KIRP	cis	rs17092148	1.000	rs6088579	chr20:33284624	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	4.97	0.3	1.28e-6	Neuroticism;
KIRP	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg26850624	chr5:429559	AHRR	-0.39	-6.42	-0.38	6.9e-10	Cystic fibrosis severity;
KIRP	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.35	8.98	0.5	7e-17	Crohn's disease;
KIRP	cis	rs4936894	0.500	rs10893197	chr11:124148690	A/G	cg27160556	chr11:124181099	OR8D1	-0.39	-5.76	-0.34	2.54e-8	Aging (time to death);
KIRP	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.73	-8.93	-0.49	1.01e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07167192	chr14:103524430	CDC42BPB	0.52	6.69	0.39	1.46e-10	Parkinson's disease;
KIRP	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg22906224	chr7:99728672	NA	0.61	6.88	0.4	4.92e-11	Coronary artery disease;
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.47	5.52	0.33	8.59e-8	Glycated hemoglobin levels;
KIRP	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.42	5.96	0.36	8.55e-9	Optic cup area;
KIRP	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg18461458	chr19:21324796	ZNF431	-0.48	-4.96	-0.3	1.29e-6	Pain;
KIRP	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs3789045	1.000	rs61817485	chr1:204595592	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-5.11	-0.31	6.61e-7	Educational attainment (college completion);
KIRP	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.51	-8.06	-0.46	3.3e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	15.2	0.7	3.13e-37	Body mass index (adult);
KIRP	cis	rs7301016	1.000	rs11174518	chr12:62902550	T/C	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.17	-0.31	4.89e-7	Obesity-related traits;
KIRP	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	9.97	0.54	7.15e-20	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3857536	0.730	rs2157962	chr6:66966203	C/T	cg07460842	chr6:66804631	NA	-0.46	-5.48	-0.33	1.07e-7	Blood trace element (Cu levels);
KIRP	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18357526	chr6:26021779	HIST1H4A	0.53	6.94	0.4	3.42e-11	Height;
KIRP	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-1.04	-10.02	-0.54	5.01e-20	Blood protein levels;
KIRP	trans	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg24644049	chr4:85504048	CDS1	1.0	6.97	0.41	2.88e-11	Skin colour saturation;
KIRP	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.02	-0.3	1.01e-6	Pulmonary function;
KIRP	cis	rs35955747	0.934	rs5997981	chr22:31808827	A/G	cg02404636	chr22:31891804	SFI1	-0.39	-5.25	-0.32	3.36e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs12765878	1.000	rs61277100	chr10:105643352	A/G	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.32	-0.37	1.19e-9	Hemoglobin concentration;
KIRP	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg06781948	chr3:72941472	GXYLT2	0.43	5.83	0.35	1.77e-8	Motion sickness;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20583141	chr14:88461098	GALC	-0.44	-6.04	-0.36	5.69e-9	Inflammatory biomarkers;
KIRP	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.62	-9.79	-0.53	2.6e-19	Prostate cancer;
KIRP	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.35	0.42	2.95e-12	Mood instability;
KIRP	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg01529538	chr14:23388837	RBM23	0.41	5.14	0.31	5.64e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs12643440	0.569	rs644174	chr4:17138293	C/T	cg22650099	chr4:17144496	NA	0.34	4.86	0.3	2.13e-6	Metabolite levels (Pyroglutamine);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09532503	chr4:119711185	SEC24D	0.48	6.96	0.41	3.13e-11	C-reactive protein;
KIRP	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg08079166	chr15:68083412	MAP2K5	0.37	4.87	0.3	1.98e-6	Restless legs syndrome;
KIRP	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg03959625	chr15:84868606	LOC388152	0.69	7.68	0.44	3.86e-13	Schizophrenia;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.65	8.08	0.46	2.99e-14	Menarche (age at onset);
KIRP	cis	rs12615966	1.000	rs72830442	chr2:105375329	G/C	cg16465502	chr2:105461796	NA	0.65	5.82	0.35	1.83e-8	Pancreatic cancer;
KIRP	cis	rs7560272	0.512	rs13015885	chr2:73920482	G/T	cg20560298	chr2:73613845	ALMS1	0.5	6.02	0.36	6.24e-9	Schizophrenia;
KIRP	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.6	7.78	0.44	2.04e-13	Platelet distribution width;
KIRP	cis	rs282587	0.597	rs390177	chr13:113413033	A/G	cg04656015	chr13:113407548	ATP11A	0.6	6.88	0.4	5.07e-11	Glycated hemoglobin levels;
KIRP	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	5.36	0.32	1.96e-7	Diastolic blood pressure;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.67	8.95	0.5	9.05e-17	Longevity;
KIRP	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.95e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.7	8.46	0.47	2.41e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg07052231	chr12:7363540	PEX5	0.38	5.16	0.31	5.16e-7	IgG glycosylation;
KIRP	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg16141378	chr3:129829833	LOC729375	-0.5	-6.53	-0.38	3.83e-10	Mood instability;
KIRP	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs11169552	0.510	rs10747587	chr12:51105300	T/C	cg12884762	chr12:50931848	DIP2B	-0.45	-5.12	-0.31	6.15e-7	Colorectal cancer;
KIRP	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.63	0.34	5.02e-8	Lung cancer;
KIRP	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	6.36	0.38	9.78e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs12143943	0.966	rs2169136	chr1:204564237	G/C	cg20240347	chr1:204465584	NA	-0.37	-6.94	-0.4	3.5e-11	Cognitive performance;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg14289826	chr9:140003911	NA	-0.56	-10.78	-0.57	1.98e-22	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10484885	0.553	rs17707975	chr6:90622318	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.64	-6.16	-0.37	2.91e-9	QRS interval (sulfonylurea treatment interaction);
KIRP	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.7	-9.91	-0.53	1.05e-19	Brugada syndrome;
KIRP	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.66	-8.46	-0.47	2.39e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.53	6.7	0.39	1.44e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9513593	1.000	rs2296044	chr13:100038825	T/C	cg21788972	chr13:99853209	UBAC2	0.58	5.97	0.36	8.1e-9	Psoriasis;
KIRP	cis	rs73198271	0.710	rs3827808	chr8:8679357	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.7	-0.39	1.45e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.2	0.31	4.26e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14271438	chr4:119757241	SEC24D	0.51	6.73	0.39	1.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.63	0.56	5.86e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs2688419	0.537	rs711725	chr3:23053020	A/T	cg00327796	chr3:23032191	NA	0.39	5.21	0.32	3.92e-7	Type 2 diabetes;
KIRP	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.74	0.39	1.1e-10	Bipolar disorder;
KIRP	trans	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg10756647	chr7:56101905	PSPH	0.97	7.2	0.42	7.51e-12	Diabetic kidney disease;
KIRP	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg21186296	chr8:27182909	PTK2B	0.44	5.7	0.34	3.44e-8	Neuroticism;
KIRP	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg06219351	chr7:158114137	PTPRN2	0.58	8.37	0.47	4.5e-15	Calcium levels;
KIRP	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	8.3	0.47	6.96e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg24579218	chr15:68104479	NA	-0.42	-6.14	-0.36	3.21e-9	Obesity;
KIRP	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg23163573	chr2:108905468	SULT1C2	-0.26	-5.01	-0.3	1.03e-6	Blood pressure;
KIRP	cis	rs2191566	0.960	rs8105571	chr19:44510341	C/T	cg18700516	chr19:44507157	ZNF230	-0.48	-5.6	-0.34	5.65e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.07	8.84	0.49	1.91e-16	Mitochondrial DNA levels;
KIRP	cis	rs12042938	0.622	rs58403453	chr1:231813438	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	5.4	0.33	1.58e-7	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-7.78	-0.44	2.06e-13	Longevity;Endometriosis;
KIRP	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08109568	chr15:31115862	NA	-0.76	-9.45	-0.52	2.75e-18	Huntington's disease progression;
KIRP	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs7116495	1.000	rs1939247	chr11:71740521	A/T	cg18441811	chr11:71824068	C11orf51	-0.61	-4.87	-0.3	1.97e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.67	-8.98	-0.5	7.01e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg18306943	chr3:40428807	ENTPD3	0.47	6.45	0.38	5.94e-10	Renal cell carcinoma;
KIRP	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.71	-10.06	-0.54	3.66e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02037518	chr11:57283212	SLC43A1	0.45	6.76	0.4	1.01e-10	Cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17895363	chr1:193070292	GLRX2	0.38	6.31	0.37	1.3e-9	C-reactive protein;
KIRP	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.92e-34	Menopause (age at onset);
KIRP	cis	rs3136516	0.504	rs11038910	chr11:46543524	C/T	cg16389345	chr11:46697382	NA	-0.52	-7.17	-0.42	8.8e-12	Venous thromboembolism;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg00338852	chr3:93773657	ARL13B	0.41	6.22	0.37	2.15e-9	Migraine with aura;
KIRP	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-7.24	-0.42	5.67e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.65	7.79	0.44	1.91e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs57602752	0.793	rs79277226	chr10:120660716	G/A	cg02768671	chr6:169470822	NA	0.6	6.9	0.4	4.27e-11	Cannabis dependence;
KIRP	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.45	6.32	0.37	1.19e-9	Dupuytren's disease;
KIRP	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg26879891	chr1:152191343	HRNR	0.49	5.94	0.35	9.89e-9	Inflammatory skin disease;
KIRP	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg21360079	chr12:107162445	NA	0.66	9.23	0.51	1.33e-17	Heart rate;
KIRP	cis	rs2652822	0.525	rs11634159	chr15:63507422	C/T	cg02713581	chr15:63449717	RPS27L	0.47	5.37	0.32	1.82e-7	Metabolic traits;
KIRP	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg17192681	chr2:10953115	PDIA6	0.8	6.88	0.4	4.82e-11	Hirschsprung disease;
KIRP	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg23594656	chr7:65796392	TPST1	0.46	7.18	0.42	8.37e-12	Aortic root size;
KIRP	cis	rs9928842	0.941	rs8057145	chr16:75256251	A/G	cg09066997	chr16:75300724	BCAR1	0.62	5.21	0.32	3.99e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs6545883	0.859	rs2600661	chr2:61543081	T/C	cg15711740	chr2:61764176	XPO1	0.57	7.69	0.44	3.55e-13	Tuberculosis;
KIRP	cis	rs1030268	0.505	rs80305547	chr7:133259400	A/G	cg10665199	chr7:133106180	EXOC4	0.58	5.73	0.34	2.89e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.88	-0.4	4.91e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs860295	0.676	rs10908466	chr1:155429725	A/C	cg02153340	chr1:155202674	NA	-0.56	-7.68	-0.44	3.69e-13	Body mass index;
KIRP	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg04166393	chr7:2884313	GNA12	0.5	6.46	0.38	5.54e-10	Height;
KIRP	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg00405596	chr8:11794950	NA	0.6	8.7	0.48	4.9e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.13	0.46	2.05e-14	Neutrophil percentage of white cells;
KIRP	trans	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg14791747	chr16:20752902	THUMPD1	0.63	6.73	0.39	1.16e-10	Cognitive test performance;
KIRP	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	6.02	0.36	6.43e-9	Motion sickness;
KIRP	cis	rs4006360	0.685	rs2320221	chr17:39251266	A/C	cg25341923	chr17:39239918	KRTAP4-7	0.49	7.16	0.42	9.21e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg17507749	chr15:85114479	UBE2QP1	0.77	7.16	0.42	9.27e-12	Schizophrenia;
KIRP	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.38	-5.24	-0.32	3.47e-7	Multiple myeloma;
KIRP	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg03959625	chr15:84868606	LOC388152	0.52	6.08	0.36	4.64e-9	Schizophrenia;
KIRP	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg23533926	chr12:111358616	MYL2	-0.53	-7.07	-0.41	1.57e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.64	6.94	0.4	3.5e-11	Bronchopulmonary dysplasia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08849875	chr10:127452086	C10orf137	0.46	6.34	0.37	1.12e-9	Interleukin-4 levels;
KIRP	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	6.74	0.39	1.11e-10	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg19847130	chr8:10466454	RP1L1	-0.36	-5.23	-0.32	3.55e-7	Retinal vascular caliber;
KIRP	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.76	-0.34	2.52e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg06521331	chr12:34319734	NA	-0.52	-6.42	-0.38	6.95e-10	Bladder cancer;
KIRP	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.16	0.58	1.11e-23	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26361892	chr19:13067683	GADD45GIP1	0.57	7.44	0.43	1.69e-12	Parkinson's disease;
KIRP	cis	rs981844	0.885	rs62325082	chr4:154661274	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs501120	0.706	rs1657346	chr10:44777560	G/C	cg09554077	chr10:44749378	NA	0.67	7.44	0.43	1.73e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1010254	0.510	rs80091187	chr5:151694855	T/C	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg11584989	chr19:19387371	SF4	0.41	5.28	0.32	2.81e-7	Tonsillectomy;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.73	10.96	0.57	4.97e-23	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg12549451	chr6:135224345	NA	0.42	5.14	0.31	5.72e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg23752985	chr2:85803571	VAMP8	0.49	6.0	0.36	6.96e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.71	0.49	4.5e-16	Motion sickness;
KIRP	cis	rs4236601	0.720	rs3779511	chr7:116141778	T/G	cg05166801	chr7:116143459	CAV2	0.49	5.97	0.36	8.28e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg20302533	chr7:39170763	POU6F2	0.25	5.4	0.33	1.58e-7	IgG glycosylation;
KIRP	cis	rs3850699	0.886	rs12773833	chr10:104418350	C/T	cg04362960	chr10:104952993	NT5C2	0.53	6.19	0.37	2.51e-9	Prostate cancer;
KIRP	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.5	-0.38	4.37e-10	Morning vs. evening chronotype;
KIRP	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	trans	rs10782582	0.706	rs964024	chr1:76365637	A/C	cg10283277	chr11:111472630	SIK2	-0.31	-6.31	-0.37	1.28e-9	Daytime sleep phenotypes;
KIRP	cis	rs2456568	0.571	rs1105114	chr11:93693511	C/T	cg26875233	chr11:93583750	C11orf90	0.29	5.32	0.32	2.32e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.66	7.99	0.45	5.37e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg14092571	chr14:90743983	NA	-0.38	-4.9	-0.3	1.73e-6	Mortality in heart failure;
KIRP	cis	rs1978968	0.763	rs9605478	chr22:18464410	G/A	cg02610425	chr22:18483192	MICAL3	0.35	5.24	0.32	3.41e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7122257	0.507	rs7103691	chr11:11150830	A/C	cg16931664	chr11:11169707	NA	-0.48	-6.75	-0.4	1.06e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg25173405	chr17:45401733	C17orf57	0.46	5.98	0.36	7.96e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07835289	chr1:236030215	LYST	0.55	7.17	0.42	8.93e-12	Parkinson's disease;
KIRP	trans	rs4084594	0.509	rs17484837	chr5:63226451	C/G	cg22673688	chr1:246148901	SMYD3	0.54	6.12	0.36	3.66e-9	Schizophrenia;
KIRP	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg03468072	chr12:39539422	NA	0.44	5.98	0.36	7.98e-9	Morning vs. evening chronotype;
KIRP	cis	rs1823913	0.592	rs7588555	chr2:192165638	A/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs10242455	0.850	rs3779354	chr7:99052428	T/C	cg18809830	chr7:99032528	PTCD1	-0.6	-5.33	-0.32	2.24e-7	Blood metabolite levels;
KIRP	cis	rs2594989	0.895	rs2606759	chr3:11349494	T/C	cg01796438	chr3:11312864	ATG7	-0.61	-7.31	-0.42	3.66e-12	Circulating chemerin levels;
KIRP	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.4	5.39	0.32	1.66e-7	Educational attainment;
KIRP	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.97	-0.36	8.05e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.04	-0.46	3.88e-14	Neuroticism;
KIRP	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.61	-0.6	3.83e-25	Body mass index;
KIRP	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg24565620	chr2:194026	NA	0.63	7.44	0.43	1.66e-12	Blood protein levels;
KIRP	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.18	-0.37	2.7e-9	Obesity-related traits;
KIRP	cis	rs8014252	0.803	rs74062726	chr14:70986179	A/G	cg19730268	chr14:71022823	NA	-0.57	-5.49	-0.33	9.97e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg13906792	chr15:75199810	C15orf17	-0.38	-5.4	-0.33	1.57e-7	Breast cancer;
KIRP	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg22138327	chr13:27999177	GTF3A	0.59	5.93	0.35	1.01e-8	Weight;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07817967	chr1:184721222	EDEM3	-0.44	-6.62	-0.39	2.23e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4849845	0.849	rs11893180	chr2:121018469	A/G	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.72	8.3	0.47	7.11e-15	Type 2 diabetes;
KIRP	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	9.13	0.5	2.57e-17	Mood instability;
KIRP	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.54	6.33	0.37	1.12e-9	Aortic root size;
KIRP	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.38	-5.52	-0.33	8.42e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.56	7.71	0.44	3.03e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6032067	0.925	rs6032061	chr20:43853276	C/T	cg10761708	chr20:43804764	PI3	0.51	5.22	0.32	3.78e-7	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11048311	chr10:12084973	UPF2	0.58	7.47	0.43	1.37e-12	Parkinson's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02879967	chr11:14477198	NA	0.4	6.59	0.39	2.66e-10	C-reactive protein;
KIRP	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	4.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.62e-12	Menopause (age at onset);
KIRP	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.96	12.78	0.63	4.97e-29	Menopause (age at onset);
KIRP	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg09137382	chr11:130731461	NA	0.56	8.2	0.46	1.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs8103278	0.507	rs10415988	chr19:46246704	C/T	cg11657440	chr19:46296263	DMWD	0.94	14.86	0.69	4.4e-36	Coronary artery disease;
KIRP	cis	rs1210638	0.756	rs2518800	chr22:18973471	C/T	cg12798833	chr22:18958832	DGCR5	0.46	6.01	0.36	6.69e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.12	-0.31	6.21e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg06935464	chr4:38784597	TLR10	0.51	5.21	0.31	4.09e-7	Breast cancer;
KIRP	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg13877915	chr19:58951672	ZNF132	0.6	5.49	0.33	9.92e-8	Mean platelet volume;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg22903657	chr4:1355424	KIAA1530	-0.52	-7.44	-0.43	1.68e-12	Obesity-related traits;
KIRP	cis	rs13006833	1.000	rs13006833	chr2:191205499	G/C	cg27211696	chr2:191398769	TMEM194B	0.41	5.86	0.35	1.48e-8	Urinary metabolites;
KIRP	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.47	-6.73	-0.39	1.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-16.59	-0.73	5.24e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-6.13	-0.36	3.46e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.83	12.12	0.61	7.91e-27	Colorectal cancer;
KIRP	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg14541582	chr5:601475	NA	-0.54	-6.08	-0.36	4.58e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11235843	0.636	rs10736793	chr11:73402576	A/C	cg18195628	chr11:73498948	MRPL48	-0.48	-5.01	-0.3	1.05e-6	Hand grip strength;
KIRP	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg03684893	chr10:554711	DIP2C	0.42	6.24	0.37	1.85e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.57	7.03	0.41	2e-11	Height;
KIRP	trans	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg16141378	chr3:129829833	LOC729375	0.57	7.67	0.44	4.03e-13	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03861593	chr6:108881876	FOXO3	0.52	6.41	0.38	7.52e-10	Parkinson's disease;
KIRP	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.31	5.02	0.3	1e-6	Iron status biomarkers (transferrin levels);
KIRP	cis	rs26949	0.526	rs3899221	chr5:60036377	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.35	-0.32	2.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg13906792	chr15:75199810	C15orf17	-0.36	-5.23	-0.32	3.59e-7	Breast cancer;
KIRP	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-6.79	-0.4	8.16e-11	Obesity-related traits;
KIRP	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg10503236	chr1:231470652	EXOC8	-0.53	-7.35	-0.42	2.94e-12	Hemoglobin concentration;
KIRP	cis	rs7539542	0.529	rs10800877	chr1:202884063	C/T	cg19681188	chr1:202830198	LOC148709	-0.47	-5.11	-0.31	6.54e-7	Mean platelet volume;
KIRP	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg25902810	chr10:99078978	FRAT1	0.61	7.71	0.44	3.1400000000000003e-13	Monocyte count;
KIRP	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.92	10.97	0.57	4.58e-23	Post bronchodilator FEV1;
KIRP	trans	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg19274270	chr17:78178856	CARD14	-0.37	-6.65	-0.39	1.85e-10	Morning vs. evening chronotype;
KIRP	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-8.99	-0.5	6.64e-17	Menarche (age at onset);
KIRP	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg17304646	chr3:125932534	NA	0.32	5.32	0.32	2.3e-7	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-0.98	-15.16	-0.7	4.1e-37	Dilated cardiomyopathy;
KIRP	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg21095983	chr6:86352623	SYNCRIP	0.52	6.83	0.4	6.56e-11	Smooth-surface caries;
KIRP	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.2	-0.61	4.35e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg17764715	chr19:33622953	WDR88	0.68	8.45	0.47	2.5e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13385	0.769	rs4913074	chr5:139613567	T/C	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.68	9.19	0.51	1.7e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.33	0.72	4.03e-41	Electrocardiographic conduction measures;
KIRP	cis	rs2051773	0.567	rs58047221	chr11:17056634	G/T	cg15432903	chr11:17409602	KCNJ11	-0.54	-6.08	-0.36	4.57e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.3	-0.32	2.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.8	11.1	0.58	1.77e-23	Menarche (age at onset);
KIRP	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18932078	chr1:2524107	MMEL1	-0.45	-6.22	-0.37	2.11e-9	Ulcerative colitis;
KIRP	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.51	-6.42	-0.38	6.87e-10	Body mass index;
KIRP	cis	rs7178909	0.800	rs3825866	chr15:90437638	A/T	cg19708238	chr15:90437601	AP3S2	0.59	8.2	0.46	1.35e-14	Common traits (Other);
KIRP	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.62	9.23	0.51	1.26e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg02297831	chr4:17616191	MED28	0.5	6.34	0.37	1.07e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.65	-7.17	-0.42	9e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs6076960	0.711	rs6085426	chr20:6165768	A/G	cg17788362	chr6:86352627	SYNCRIP	0.47	6.16	0.37	2.93e-9	Smooth-surface caries;
KIRP	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.42	-0.33	1.44e-7	Triglycerides;
KIRP	cis	rs10073892	0.660	rs13357340	chr5:101644914	C/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.22	0.37	2.07e-9	Cognitive decline (age-related);
KIRP	cis	rs4789452	0.902	rs4789454	chr17:75375199	C/T	cg05184938	chr17:75369939	SEPT9	-0.37	-5.06	-0.31	8.35e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg17376030	chr22:41985996	PMM1	0.81	8.3	0.47	6.9e-15	Vitiligo;
KIRP	cis	rs10489525	0.556	rs11102882	chr1:115612222	T/A	cg01522456	chr1:115632236	TSPAN2	0.5	6.83	0.4	6.59e-11	Autism;
KIRP	cis	rs539514	0.690	rs528783	chr13:76319460	T/C	cg04757411	chr13:76259545	LMO7	-0.36	-5.17	-0.31	4.88e-7	Type 1 diabetes;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06550546	chr17:4166847	ANKFY1	0.51	6.17	0.37	2.84e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	10.28	0.55	7.28e-21	Cognitive test performance;
KIRP	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg05484376	chr2:27715224	FNDC4	0.41	6.76	0.4	1.01e-10	Total body bone mineral density;
KIRP	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg13334819	chr7:99746414	C7orf59	-0.49	-5.75	-0.34	2.62e-8	Coronary artery disease;
KIRP	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg06026331	chr20:60912101	LAMA5	0.4	4.95	0.3	1.35e-6	Colorectal cancer;
KIRP	cis	rs12822507	0.732	rs10845589	chr12:12764446	T/A	cg11838227	chr12:12764436	CREBL2	0.48	5.72	0.34	3.15e-8	Systemic lupus erythematosus;
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.84	13.66	0.66	5.56e-32	Longevity;Endometriosis;
KIRP	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.77	-0.49	3.03e-16	Total cholesterol levels;
KIRP	cis	rs58649573	0.509	rs2055032	chr9:126789506	A/G	cg14112217	chr9:126806003	NA	0.37	5.28	0.32	2.85e-7	Post-traumatic stress disorder;
KIRP	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08280861	chr8:58055591	NA	0.74	6.07	0.36	4.86e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg21838880	chr19:37157633	ZNF461	0.74	6.51	0.38	4.18e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	7.04	0.41	1.96e-11	Height;
KIRP	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05347473	chr6:146136440	FBXO30	0.58	8.31	0.47	6.67e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg09571762	chr12:39539558	NA	0.34	5.04	0.31	8.93e-7	Morning vs. evening chronotype;
KIRP	cis	rs2273669	0.915	rs10872027	chr6:109289540	T/C	cg05315195	chr6:109294784	ARMC2	-0.47	-5.27	-0.32	3.03e-7	Prostate cancer;
KIRP	cis	rs554111	0.656	rs10753514	chr1:21492531	T/C	cg21184320	chr1:21044207	KIF17	-0.37	-5.57	-0.33	6.6e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs981844	0.712	rs4538465	chr4:154746763	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg17595323	chr11:93583763	C11orf90	-0.32	-5.36	-0.32	1.91e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.52	6.94	0.4	3.38e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg05692746	chr2:100937584	LONRF2	-0.38	-4.99	-0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.87	14.37	0.68	2.06e-34	Prostate cancer;
KIRP	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.87	-0.35	1.41e-8	Crohn's disease;
KIRP	cis	rs11587400	0.679	rs6537834	chr1:115108870	T/C	cg12756093	chr1:115239321	AMPD1	0.43	5.34	0.32	2.07e-7	Autism;
KIRP	cis	rs4704187	0.687	rs2216638	chr5:74512987	A/G	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.74e-8	Response to amphetamines;
KIRP	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.57	-7.79	-0.44	1.84e-13	Prudent dietary pattern;
KIRP	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.74	-9.36	-0.51	5.15e-18	Menopause (age at onset);
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.05	0.41	1.77e-11	Electroencephalogram traits;
KIRP	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg24315340	chr6:146058215	EPM2A	-0.43	-5.48	-0.33	1.03e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02382517	chr4:124316019	NA	-0.41	-6.34	-0.37	1.11e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20135002	chr11:47629003	NA	0.44	4.94	0.3	1.44e-6	Subjective well-being;
KIRP	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.85	-12.92	-0.64	1.72e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.52	7.27	0.42	4.65e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs56161922	1.000	rs74184055	chr1:207852226	G/A	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.8	0.35	2.04e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.9	13.01	0.64	8.44e-30	Morning vs. evening chronotype;
KIRP	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	1.03	11.0	0.57	3.74e-23	Alzheimer's disease;
KIRP	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	9.82	0.53	2.03e-19	Cognitive test performance;
KIRP	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.66	8.81	0.49	2.33e-16	Bladder cancer;
KIRP	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg08885076	chr2:99613938	TSGA10	-0.39	-5.46	-0.33	1.14e-7	Fear of minor pain;
KIRP	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg01988459	chr11:68622903	NA	-0.43	-5.97	-0.36	8.05e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7127900	0.898	rs11043135	chr11:2232696	A/C	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg21395723	chr22:39101663	GTPBP1	0.42	5.51	0.33	8.97e-8	Menopause (age at onset);
KIRP	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.16	-0.37	2.91e-9	Cardiac Troponin-T levels;
KIRP	cis	rs4523957	0.928	rs4790321	chr17:2173499	C/T	cg16513277	chr17:2031491	SMG6	-0.6	-8.46	-0.47	2.45e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.89	-0.4	4.59e-11	Mean corpuscular volume;
KIRP	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26207909	chr14:103986467	CKB	0.77	11.88	0.6	5.01e-26	Body mass index;
KIRP	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg06204229	chr3:52865917	ITIH4	0.59	6.33	0.37	1.15e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.6	-8.07	-0.46	3.08e-14	Total body bone mineral density;
KIRP	cis	rs2274273	0.624	rs7157308	chr14:55782043	A/G	cg04306507	chr14:55594613	LGALS3	0.39	5.33	0.32	2.24e-7	Protein biomarker;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg10254082	chr7:997346	NA	0.48	5.03	0.31	9.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.77	8.98	0.5	7.06e-17	Corneal astigmatism;
KIRP	cis	rs986417	0.818	rs1955702	chr14:61074301	T/A	cg27398547	chr14:60952738	C14orf39	0.64	6.03	0.36	6.1e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7116495	1.000	rs1939245	chr11:71742532	C/T	cg11196788	chr11:71737549	NUMA1	0.56	4.94	0.3	1.45e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.75	-9.72	-0.53	4.23e-19	Breast cancer;
KIRP	cis	rs6430538	0.671	rs6736792	chr2:135572090	T/C	cg25422880	chr2:135218333	TMEM163	-0.44	-6.13	-0.36	3.4e-9	Parkinson's disease;
KIRP	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.51	6.42	0.38	6.9e-10	Bone mineral density;
KIRP	cis	rs12190007	0.776	rs3006188	chr6:169787872	C/T	cg15038512	chr6:170123185	PHF10	-0.43	-5.79	-0.35	2.18e-8	Obesity-related traits;
KIRP	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.1	-0.41	1.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72653721	0.730	rs56074859	chr6:11044089	C/T	cg13562911	chr6:11044106	ELOVL2	0.54	5.21	0.31	4.09e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.1	-0.36	4.01e-9	Ulcerative colitis;
KIRP	cis	rs1873147	0.861	rs2899687	chr15:63325548	C/T	cg12160578	chr15:63334699	TPM1	-0.5	-5.64	-0.34	4.63e-8	Orofacial clefts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10864791	chr13:22178445	EFHA1	0.46	6.62	0.39	2.27e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	7.7	0.44	3.3e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6750047	0.546	rs985257	chr2:38283228	A/T	cg07380506	chr2:38303506	CYP1B1	-0.53	-6.81	-0.4	7.23e-11	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg05361325	chr10:32636312	EPC1	-0.66	-6.28	-0.37	1.53e-9	Sexual dysfunction (female);
KIRP	cis	rs2554380	0.891	rs2562781	chr15:84312568	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.34	-0.47	5.33e-15	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01511804	chr14:74318438	PTGR2	-0.54	-6.35	-0.38	1.04e-9	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01434121	chr11:118901659	SLC37A4	0.49	6.11	0.36	3.85e-9	Parkinson's disease;
KIRP	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26207909	chr14:103986467	CKB	0.74	10.66	0.56	4.51e-22	Body mass index;
KIRP	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg24110177	chr3:50126178	RBM5	-0.41	-5.34	-0.32	2.07e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17507749	chr15:85114479	UBE2QP1	0.7	7.87	0.45	1.14e-13	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.46	6.19	0.37	2.45e-9	Monocyte count;
KIRP	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.4	0.43	2.15e-12	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg19752551	chr11:57585705	CTNND1	-0.82	-13.58	-0.65	1.02e-31	Schizophrenia;
KIRP	cis	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.36	-0.42	2.82e-12	Morning vs. evening chronotype;
KIRP	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	cg21523751	chr1:182988639	NA	0.45	7.01	0.41	2.24e-11	Colorectal cancer;
KIRP	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.52	6.71	0.39	1.3e-10	Crohn's disease;
KIRP	trans	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg03735916	chr2:200715285	NA	-0.45	-6.04	-0.36	5.63e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.82	9.33	0.51	6.39e-18	Response to diuretic therapy;
KIRP	cis	rs78487399	0.908	rs6759861	chr2:43805608	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-4.96	-0.3	1.33e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00889227	chr1:205173544	DSTYK	0.36	5.15	0.31	5.27e-7	Red blood cell count;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.28	0.32	2.79e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18872881	chr4:102199803	PPP3CA	0.47	6.77	0.4	9.52e-11	Interleukin-4 levels;
KIRP	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.63	0.39	2.09e-10	Protein C levels;
KIRP	cis	rs193541	0.632	rs1363200	chr5:122163802	G/T	cg19412675	chr5:122181750	SNX24	0.57	5.98	0.36	7.94e-9	Glucose homeostasis traits;
KIRP	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg06609049	chr19:2785107	THOP1	0.89	11.39	0.59	2.01e-24	Total cholesterol levels;
KIRP	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.47	-6.21	-0.37	2.19e-9	Schizophrenia;
KIRP	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg10189774	chr4:17578691	LAP3	0.5	5.95	0.35	9.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg26531700	chr6:26746687	NA	0.47	6.71	0.39	1.36e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	0.87	12.35	0.62	1.43e-27	Homoarginine levels;
KIRP	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	8.9	0.49	1.23e-16	Personality dimensions;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03330022	chr1:53072410	GPX7	0.53	6.62	0.39	2.18e-10	Interleukin-4 levels;
KIRP	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg08126542	chr6:37504118	NA	-0.57	-7.31	-0.42	3.78e-12	Cognitive performance;
KIRP	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	1.03	16.71	0.73	2.12e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.8	8.44	0.47	2.85e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.45	5.03	0.31	9.39e-7	Bipolar disorder;
KIRP	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg14541582	chr5:601475	NA	-0.58	-6.61	-0.39	2.32e-10	Obesity-related traits;
KIRP	trans	rs11199874	0.741	rs11199862	chr10:123022956	C/T	cg03091752	chr19:51221605	SHANK1	-0.51	-6.04	-0.36	5.56e-9	Prostate cancer;
KIRP	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg03563238	chr19:33554763	RHPN2	0.33	5.72	0.34	3.11e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.66	6.53	0.38	3.7e-10	Eotaxin levels;
KIRP	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02034447	chr16:89574710	SPG7	0.38	4.91	0.3	1.65e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg07884673	chr3:53033167	SFMBT1	0.8	6.41	0.38	7.38e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	6.03	0.36	5.84e-9	Breast cancer;
KIRP	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg21361702	chr7:150065534	REPIN1	0.54	5.73	0.34	2.86e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8067287	0.708	rs1004439	chr17:16841924	A/G	cg26910001	chr17:16838321	NA	-0.63	-6.02	-0.36	6.23e-9	Diabetic kidney disease;
KIRP	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg04166393	chr7:2884313	GNA12	0.42	5.53	0.33	8.16e-8	Height;
KIRP	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs6977660	0.943	rs9639334	chr7:19838810	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	5.22	0.32	3.73e-7	Thyroid stimulating hormone;
KIRP	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg01689657	chr7:91764605	CYP51A1	0.36	5.09	0.31	7.25e-7	Breast cancer;
KIRP	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg01304814	chr3:48885189	PRKAR2A	0.6	5.42	0.33	1.42e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.61	0.44	5.99e-13	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11361923	1	rs11361923	chr14:77862679	GC/G	cg20045696	chr14:77926864	AHSA1	-0.41	-5.23	-0.32	3.64e-7	Sum basophil neutrophil counts;White blood cell count;Granulocyte count;
KIRP	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	ch.11.42038R	chr11:967971	AP2A2	0.41	5.31	0.32	2.4e-7	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-4.94	-0.3	1.41e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6430538	0.621	rs6430540	chr2:135551563	T/C	cg12500956	chr2:135428796	TMEM163	0.41	5.2	0.31	4.29e-7	Parkinson's disease;
KIRP	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg18854424	chr1:2615690	NA	0.34	5.22	0.32	3.82e-7	Ulcerative colitis;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.78	13.72	0.66	3.27e-32	Height;
KIRP	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.88	0.3	1.88e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.46	5.84	0.35	1.66e-8	High light scatter reticulocyte count;
KIRP	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg06885757	chr1:42089581	HIVEP3	0.49	7.39	0.43	2.26e-12	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.04	0.36	5.72e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg05562828	chr17:3906858	NA	-0.71	-13.58	-0.65	1.05e-31	Type 2 diabetes;
KIRP	cis	rs67478160	0.575	rs8014294	chr14:104322983	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.58	-7.54	-0.43	9.28e-13	Schizophrenia;
KIRP	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg15934090	chr1:100435551	SLC35A3	0.52	6.46	0.38	5.5e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.98	-15.7	-0.71	5.89e-39	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24928900	chr6:147705971	STXBP5	-0.45	-6.52	-0.38	4.03e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6442310	0.534	rs709150	chr3:12451337	C/G	cg22839075	chr3:12045461	SYN2	-0.38	-5.58	-0.34	6.21e-8	Hematocrit;
KIRP	cis	rs12220238	1.000	rs10824101	chr10:75947438	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.12	0.41	1.2e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2970992	0.764	rs4851368	chr2:101324320	G/A	cg01042948	chr2:101319752	NA	0.49	7.18	0.42	8.1e-12	Educational attainment;
KIRP	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg01777586	chr17:80163174	CCDC57	-0.46	-4.95	-0.3	1.38e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs11690462	0.528	rs11691698	chr2:26642190	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.5	5.5	0.33	9.6e-8	Coronary artery disease;
KIRP	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.83	12.9	0.64	2.03e-29	Eye color traits;
KIRP	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.46e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.93	-12.35	-0.62	1.37e-27	Cognitive function;
KIRP	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.77	-10.36	-0.55	4.28e-21	Huntington's disease progression;
KIRP	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg14458575	chr2:238380390	NA	0.56	6.03	0.36	5.91e-9	Prostate cancer;
KIRP	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.19	-0.31	4.35e-7	Body mass index;
KIRP	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg06027949	chr8:82754900	SNX16	0.61	6.41	0.38	7.57e-10	Diastolic blood pressure;
KIRP	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.45	-6.33	-0.37	1.17e-9	Lewy body disease;
KIRP	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.51	6.58	0.39	2.81e-10	Menopause (age at onset);
KIRP	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.66	-7.97	-0.45	5.99e-14	Pancreatic cancer;
KIRP	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg18441811	chr11:71824068	C11orf51	-0.77	-5.12	-0.31	6.29e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-1.05	-14.64	-0.68	2.43e-35	Orofacial clefts;
KIRP	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	6.66	0.39	1.74e-10	Breast cancer;
KIRP	cis	rs2273669	0.667	rs12196010	chr6:109302173	C/A	cg05315195	chr6:109294784	ARMC2	-0.62	-5.98	-0.36	7.88e-9	Prostate cancer;
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.53	0.33	8.16e-8	Lung cancer;
KIRP	cis	rs2562456	0.833	rs62107479	chr19:21506764	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.16	0.42	9.51e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03300805	chr3:127266751	NA	0.51	6.85	0.4	5.91e-11	Parkinson's disease;
KIRP	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg01864069	chr14:103024347	NA	-0.97	-12.94	-0.64	1.44e-29	Platelet count;
KIRP	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.76	7.61	0.44	5.85e-13	Methadone dose in opioid dependence;
KIRP	cis	rs7560272	0.723	rs780391	chr2:73703904	C/T	cg20560298	chr2:73613845	ALMS1	0.39	4.88	0.3	1.88e-6	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13827458	chr14:53109146	ERO1L	-0.47	-7.09	-0.41	1.37e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10425738	0.830	rs3844444	chr19:41434047	A/G	cg09508736	chr19:41385865	CYP2A7	-0.46	-5.1	-0.31	6.68e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs698833	0.848	rs696596	chr2:44718058	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.43	0.33	1.33e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs4523957	0.928	rs1122645	chr17:2170858	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.35	-0.47	5.1e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg18764771	chr6:116381957	FRK	-0.18	-5.07	-0.31	7.79e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1801239	1.000	rs74375025	chr10:16947664	G/A	cg24571822	chr10:17009592	CUBN	0.61	4.86	0.3	2.07e-6	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
KIRP	cis	rs11203032	0.831	rs4269843	chr10:90944216	G/A	cg16672925	chr10:90967113	CH25H	0.45	5.46	0.33	1.15e-7	Heart failure;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg09264619	chr17:80180166	NA	-0.41	-5.93	-0.35	1.02e-8	Life satisfaction;
KIRP	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.04	-0.46	3.68e-14	Coronary artery disease;
KIRP	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg12140854	chr5:148520817	ABLIM3	-0.43	-4.95	-0.3	1.37e-6	Breast cancer;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs12615966	0.651	rs72830476	chr2:105414655	A/C	cg16465502	chr2:105461796	NA	0.95	7.85	0.45	1.29e-13	Pancreatic cancer;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg20220436	chr3:50541011	CACNA2D2	0.52	6.52	0.38	3.93e-10	DNA methylation (variation);
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.65	-9.6	-0.52	9.52e-19	Lung cancer;
KIRP	cis	rs57590327	0.679	rs1907880	chr3:81567861	C/T	cg07356753	chr3:81810745	GBE1	-0.56	-6.05	-0.36	5.44e-9	Extraversion;
KIRP	cis	rs2000999	0.524	rs36125653	chr16:72190805	G/A	cg04254540	chr16:71951199	KIAA0174	-0.82	-5.49	-0.33	1.01e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg07001201	chr5:642380	CEP72	0.7	6.58	0.39	2.86e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.67	-7.06	-0.41	1.72e-11	Vitiligo;
KIRP	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.37	4.91	0.3	1.67e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4742903	0.527	rs9776198	chr9:106977616	G/A	cg14250997	chr9:106856677	SMC2	0.37	5.08	0.31	7.64e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs17428704	0.571	rs56689214	chr5:14394744	C/A	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.8	7.28	0.42	4.61e-12	Methadone dose in opioid dependence;
KIRP	cis	rs687432	0.851	rs7946863	chr11:57699526	C/T	cg19752551	chr11:57585705	CTNND1	-0.52	-7.18	-0.42	8.26e-12	Parkinson's disease;
KIRP	cis	rs1978968	0.763	rs5992137	chr22:18457986	T/C	cg03078520	chr22:18463400	MICAL3	-0.79	-11.08	-0.58	2.08e-23	Presence of antiphospholipid antibodies;
KIRP	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.13	-0.31	5.82e-7	Retinal vascular caliber;
KIRP	cis	rs2033908	0.620	rs1371753	chr11:12853703	G/A	cg25843174	chr11:12811716	TEAD1	-0.35	-6.6	-0.39	2.52e-10	Sitting height ratio;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12930422	chr15:55968637	PRTG	-0.46	-7.01	-0.41	2.28e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.75	-10.68	-0.56	3.9e-22	Waist circumference;Body mass index;
KIRP	cis	rs13102973	0.720	rs7687641	chr4:135885739	C/T	cg14419869	chr4:135874104	NA	0.4	6.35	0.38	1.01e-9	Subjective well-being;
KIRP	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23903597	chr17:61704154	MAP3K3	-0.5	-6.06	-0.36	5.07e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1958560	0.867	rs2185454	chr14:65870594	G/T	cg03016385	chr14:66212404	NA	-0.54	-6.64	-0.39	1.95e-10	Menarche (age at onset);
KIRP	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.16	-0.31	5.18e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1800469	0.965	rs11668109	chr19:41863777	A/C	cg09537434	chr19:41945824	ATP5SL	-0.53	-5.98	-0.36	7.88e-9	Colorectal cancer;
KIRP	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.6	7.41	0.43	1.99e-12	Mosquito bite size;
KIRP	cis	rs2712184	0.729	rs2541397	chr2:217646693	G/A	cg05032264	chr2:217675019	NA	-0.47	-6.83	-0.4	6.46e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs4006360	0.546	rs2874201	chr17:39238382	A/G	cg15015397	chr17:39261100	KRTAP4-9	0.56	8.59	0.48	9.97e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-6.18	-0.37	2.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg03289416	chr15:75166202	SCAMP2	-0.4	-5.58	-0.34	6.26e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7116495	0.609	rs949324	chr11:71714526	G/C	cg26138937	chr11:71823887	C11orf51	-1.1	-7.72	-0.44	2.89e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg26354017	chr1:205819088	PM20D1	0.54	5.77	0.35	2.37e-8	Basophil percentage of granulocytes;
KIRP	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg02073558	chr3:44770973	ZNF501	0.57	7.89	0.45	9.72e-14	Depressive symptoms;
KIRP	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-6.92	-0.4	3.92e-11	Educational attainment;
KIRP	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-7.78	-0.44	2e-13	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.88	11.49	0.59	9.89e-25	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15189764	chr17:27282064	SEZ6	0.45	6.16	0.37	2.89e-9	Interleukin-4 levels;
KIRP	cis	rs960902	0.592	rs7588494	chr2:37736881	C/A	cg25341268	chr2:37734390	NA	-0.58	-7.89	-0.45	9.84e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-7.45	-0.43	1.58e-12	Personality dimensions;
KIRP	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.39e-10	Bipolar disorder;
KIRP	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg15488143	chr7:128924101	AHCYL2	-0.54	-5.86	-0.35	1.51e-8	White matter hyperintensity burden;
KIRP	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.9	-0.49	1.21e-16	Urate levels in overweight individuals;
KIRP	cis	rs6088813	0.883	rs2425061	chr20:33915571	A/G	cg14752227	chr20:34000481	UQCC	0.47	6.02	0.36	6.25e-9	Height;
KIRP	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.55	-7.67	-0.44	4.09e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs1106684	1.000	rs12538163	chr7:131459298	C/G	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.81e-31	Diabetic retinopathy;
KIRP	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7172677	0.538	rs1806795	chr15:75422744	A/G	cg14664628	chr15:75095509	CSK	-0.45	-4.96	-0.3	1.32e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-8.79	-0.49	2.65e-16	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.78	0.35	2.24e-8	Menopause (age at onset);
KIRP	cis	rs860295	0.557	rs11264371	chr1:155412037	C/T	cg02153340	chr1:155202674	NA	-0.51	-6.81	-0.4	7.61e-11	Body mass index;
KIRP	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs2119480	0.731	rs369788	chr13:111305787	C/T	cg16216153	chr13:111290848	CARKD	-0.38	-5.09	-0.31	7.08e-7	Diastolic blood pressure;
KIRP	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14298792	chr15:30685198	CHRFAM7A	0.49	5.8	0.35	2e-8	Huntington's disease progression;
KIRP	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg10223061	chr2:219282414	VIL1	-0.32	-5.15	-0.31	5.32e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.44	-8.14	-0.46	1.96e-14	Educational attainment (years of education);
KIRP	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	1.03	20.12	0.79	6.78e-54	Heart rate;
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.45	-6.45	-0.38	5.8e-10	Testicular germ cell tumor;
KIRP	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg01200585	chr1:228362443	C1orf69	0.41	5.14	0.31	5.47e-7	Diastolic blood pressure;
KIRP	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg02461776	chr11:598696	PHRF1	0.57	6.24	0.37	1.91e-9	Systemic lupus erythematosus;
KIRP	cis	rs2250402	0.655	rs2307101	chr15:40322460	C/T	cg20255370	chr15:40268687	EIF2AK4	0.5	5.19	0.31	4.3e-7	Corneal curvature;
KIRP	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg00094735	chr5:1949198	NA	0.46	5.52	0.33	8.53e-8	Gut microbiome composition (winter);
KIRP	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg23958373	chr8:599963	NA	0.89	7.01	0.41	2.24e-11	IgG glycosylation;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg21774377	chr6:34760070	UHRF1BP1	0.69	6.33	0.37	1.14e-9	Lung function (FEV1);
KIRP	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg06212747	chr3:49208901	KLHDC8B	0.58	5.43	0.33	1.37e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.62	-8.72	-0.49	4.17e-16	Blood metabolite levels;
KIRP	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.38	-0.32	1.75e-7	Aortic root size;
KIRP	cis	rs5753037	0.869	rs4287865	chr22:30307558	A/T	cg27665648	chr22:30112403	NA	0.38	5.43	0.33	1.37e-7	Type 1 diabetes;
KIRP	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.8	-0.45	1.8e-13	Type 2 diabetes;
KIRP	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.56	-9.08	-0.5	3.59e-17	Total body bone mineral density;
KIRP	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-9.08	-0.5	3.71e-17	Coronary artery disease;
KIRP	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.78	0.49	2.79e-16	Menopause (age at onset);
KIRP	trans	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg18944383	chr4:111397179	ENPEP	-0.52	-6.35	-0.38	1.03e-9	Intraocular pressure;
KIRP	cis	rs12476592	0.602	rs959195	chr2:63804125	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.64	-9.7	-0.53	4.74e-19	Educational attainment;
KIRP	cis	rs300890	0.536	rs9996072	chr4:144129961	A/G	cg01719995	chr4:144104893	USP38	0.39	5.04	0.31	8.83e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg11266682	chr4:10021025	SLC2A9	0.43	5.45	0.33	1.19e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7709377	0.570	rs1396479	chr5:115454833	A/G	cg23108291	chr5:115420582	COMMD10	0.41	4.95	0.3	1.39e-6	Metabolite levels  (X-11787);
KIRP	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg21551340	chr2:1609508	NA	0.51	4.9	0.3	1.74e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs754423	0.701	rs10143490	chr14:52504261	G/C	cg05884192	chr14:52515736	NID2	0.54	5.68	0.34	3.76e-8	Craniofacial microsomia;
KIRP	cis	rs876084	0.604	rs9297609	chr8:121007998	T/C	cg22335954	chr8:121166405	COL14A1	-0.41	-5.21	-0.32	3.95e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg01631408	chr1:248437212	OR2T33	0.51	6.61	0.39	2.34e-10	Common traits (Other);
KIRP	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	6.64	0.39	1.97e-10	Rheumatoid arthritis;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.66	-5.91	-0.35	1.16e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.04	-16.99	-0.73	2.36e-43	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.84	-13.35	-0.65	6.12e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.75	-9.34	-0.51	6.1e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.2	-0.37	2.32e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.32e-15	Life satisfaction;
KIRP	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.56	7.61	0.44	5.78e-13	Gout;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg18234130	chr8:27182889	PTK2B	0.57	7.42	0.43	1.92e-12	Neuroticism;
KIRP	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	9.45	0.52	2.74e-18	Post bronchodilator FEV1;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg15181151	chr6:150070149	PCMT1	0.29	4.87	0.3	1.97e-6	Lung cancer;
KIRP	cis	rs7224685	0.530	rs36019144	chr17:3987499	T/C	cg05562828	chr17:3906858	NA	0.58	6.1	0.36	4.13e-9	Type 2 diabetes;
KIRP	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs5756391	0.546	rs4821565	chr22:37314415	C/T	cg16356956	chr22:37317934	CSF2RB	-0.4	-5.6	-0.34	5.73e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00376283	chr12:123451042	ABCB9	-0.62	-7.19	-0.42	7.95e-12	Neutrophil percentage of white cells;
KIRP	cis	rs17092148	1.000	rs7265992	chr20:33525407	G/A	cg16810054	chr20:33298113	TP53INP2	0.44	5.36	0.32	1.88e-7	Neuroticism;
KIRP	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg06223162	chr1:101003688	GPR88	0.42	8.33	0.47	5.68e-15	Monocyte count;
KIRP	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg26116260	chr4:7069785	GRPEL1	-0.8	-5.13	-0.31	6e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12900413	0.687	rs12911196	chr15:90310734	G/C	cg24650279	chr15:90327240	NA	-0.41	-5.23	-0.32	3.7e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.53	-6.38	-0.38	8.76e-10	Schizophrenia;
KIRP	cis	rs11574514	1.000	rs59343240	chr16:67850529	C/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.64	-0.34	4.6e-8	Crohn's disease;
KIRP	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.78	-8.02	-0.46	4.37e-14	Response to antipsychotic treatment;
KIRP	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.47	5.35	0.32	2.03e-7	Corneal astigmatism;
KIRP	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.69	0.44	3.53e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.24	-0.32	3.37e-7	Coronary artery disease;
KIRP	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg25019033	chr10:957182	NA	0.61	7.16	0.42	9.48e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg14784868	chr12:69753453	YEATS4	0.5	5.18	0.31	4.59e-7	Response to diuretic therapy;
KIRP	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.12	-0.5	2.68e-17	Hirschsprung disease;
KIRP	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-0.53	-7.49	-0.43	1.23e-12	Coronary artery disease;
KIRP	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.41	-5.95	-0.35	9.26e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg13271783	chr10:134563150	INPP5A	-0.55	-7.09	-0.41	1.39e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg21775007	chr8:11205619	TDH	-0.48	-6.24	-0.37	1.85e-9	Mood instability;
KIRP	cis	rs8060686	0.920	rs56047901	chr16:67742326	G/A	cg04539111	chr16:67997858	SLC12A4	-0.59	-5.81	-0.35	1.88e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3136516	0.537	rs2291443	chr11:47179861	C/A	cg16389345	chr11:46697382	NA	-0.48	-5.98	-0.36	7.71e-9	Venous thromboembolism;
KIRP	trans	rs4819052	0.851	rs2256000	chr21:46685909	T/C	cg17401890	chr11:36426482	PRR5L	0.41	6.09	0.36	4.25e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7614311	1.000	rs7614311	chr3:63813654	A/C	cg22134162	chr3:63841271	THOC7	-0.35	-5.23	-0.32	3.64e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.65	11.42	0.59	1.57e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs7809615	0.901	rs17161761	chr7:99156934	C/T	cg12290671	chr7:99195819	NA	-0.75	-6.99	-0.41	2.57e-11	Blood metabolite ratios;
KIRP	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.3	0.42	4.07e-12	Prudent dietary pattern;
KIRP	cis	rs10267417	0.603	rs10224406	chr7:19904088	T/C	cg05791153	chr7:19748676	TWISTNB	0.51	5.27	0.32	3e-7	Night sleep phenotypes;
KIRP	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.77	-0.44	2.11e-13	Height;
KIRP	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.61	0.44	5.66e-13	Tonsillectomy;
KIRP	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.45	6.4	0.38	7.98e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs2658782	0.688	rs2658768	chr11:93250827	T/C	cg15737290	chr11:93063684	CCDC67	0.67	7.74	0.44	2.64e-13	Pulmonary function decline;
KIRP	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.37	-0.32	1.78e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	13.81	0.66	1.64e-32	Platelet count;
KIRP	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.38	6.82	0.4	7.08e-11	Erythrocyte sedimentation rate;
KIRP	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.66	-9.79	-0.53	2.61e-19	Retinal vascular caliber;
KIRP	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg21427119	chr20:30132790	HM13	-0.5	-5.68	-0.34	3.88e-8	Mean corpuscular hemoglobin;
KIRP	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.76	11.23	0.58	6.52e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.26	0.51	1.03e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg04691961	chr3:161091175	C3orf57	-0.35	-5.06	-0.31	8.4e-7	Kawasaki disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18136681	chr1:24969531	SRRM1	0.58	7.84	0.45	1.35e-13	Parkinson's disease;
KIRP	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.7	6.7	0.39	1.39e-10	Gut microbiome composition (summer);
KIRP	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.75	-10.99	-0.57	4.12e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8077577	0.945	rs62073609	chr17:18071843	T/C	cg18869244	chr17:18121946	NA	0.48	5.45	0.33	1.2e-7	Obesity-related traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07866137	chr8:67579786	VCPIP1	0.59	7.1	0.41	1.37e-11	Smoking initiation;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.76	6.72	0.39	1.23e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7096127	0.934	rs7089018	chr10:24502045	T/C	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.91	0.3	1.65e-6	Lobe attachment (rater scored);
KIRP	cis	rs7172677	1.000	rs4886659	chr15:75414760	A/G	cg14664628	chr15:75095509	CSK	-0.56	-6.17	-0.37	2.75e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4356975	0.563	rs6600874	chr4:69953413	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg11663144	chr21:46675770	NA	-0.69	-8.7	-0.49	4.78e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4716602	0.596	rs10244786	chr7:156157989	C/T	cg16983916	chr7:156159713	NA	-0.43	-5.48	-0.33	1.06e-7	Anti-saccade response;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg05627522	chr15:75251581	NA	0.36	5.4	0.33	1.58e-7	Breast cancer;
KIRP	cis	rs859767	0.501	rs4954160	chr2:135431692	A/C	cg12500956	chr2:135428796	TMEM163	-0.41	-5.59	-0.34	6.16e-8	Neuroticism;
KIRP	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26207909	chr14:103986467	CKB	-0.76	-11.75	-0.6	1.32e-25	Body mass index;
KIRP	cis	rs78487399	0.808	rs74821293	chr2:43742923	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.08	-0.31	7.5e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg00360474	chr6:37504404	NA	-0.45	-6.27	-0.37	1.57e-9	Cognitive performance;
KIRP	cis	rs10024216	0.928	rs4458462	chr4:38768083	A/G	cg06935464	chr4:38784597	TLR10	0.39	4.89	0.3	1.82e-6	Systemic sclerosis (anti-topoisomerase-positive);
KIRP	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg07972983	chr1:205091412	RBBP5	0.44	5.26	0.32	3.11e-7	Red blood cell count;
KIRP	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.41	5.73	0.34	2.98e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs9612	1.000	rs346528	chr19:44259232	G/T	cg08581076	chr19:44259116	C19orf61	0.6	6.57	0.39	2.99e-10	Exhaled nitric oxide output;
KIRP	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	0.89	10.11	0.54	2.55e-20	Pediatric areal bone mineral density (radius);
KIRP	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg16434002	chr17:42200994	HDAC5	-0.52	-6.47	-0.38	5.12e-10	Total body bone mineral density;
KIRP	cis	rs1620921	1.000	rs1620921	chr6:161197087	C/T	cg01280913	chr6:161186852	NA	0.36	4.95	0.3	1.39e-6	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.89	-0.35	1.29e-8	IgG glycosylation;
KIRP	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	1.07	19.38	0.78	2.03e-51	Leprosy;
KIRP	cis	rs11587400	0.514	rs222499	chr1:115146488	C/A	cg12756093	chr1:115239321	AMPD1	-0.38	-4.84	-0.3	2.25e-6	Autism;
KIRP	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg10434728	chr15:90938212	IQGAP1	-0.39	-7.08	-0.41	1.5e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs922692	0.715	rs11072803	chr15:79077878	G/A	cg04896959	chr15:78267971	NA	0.53	6.88	0.4	4.9e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg16524733	chr11:117070046	TAGLN	0.39	4.94	0.3	1.47e-6	Blood protein levels;
KIRP	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg25801113	chr15:45476975	SHF	0.48	9.43	0.52	3.12e-18	Uric acid levels;
KIRP	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.69	7.83	0.45	1.48e-13	Monocyte count;
KIRP	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg17691542	chr6:26056736	HIST1H1C	0.48	6.31	0.37	1.28e-9	Height;
KIRP	trans	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg06521331	chr12:34319734	NA	-0.59	-7.15	-0.41	9.72e-12	Bladder cancer;
KIRP	cis	rs4280164	1.000	rs4280164	chr14:24771285	G/A	cg18688254	chr14:24701745	GMPR2;NEDD8	-0.49	-4.84	-0.3	2.25e-6	Parent of origin effect on language impairment (paternal);
KIRP	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.57	-7.35	-0.42	2.98e-12	Type 2 diabetes;
KIRP	cis	rs35160687	0.722	rs6728029	chr2:86555381	C/T	cg10973622	chr2:86423274	IMMT	-0.45	-5.8	-0.35	2.04e-8	Night sleep phenotypes;
KIRP	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-5.1	-0.31	6.64e-7	Ulcerative colitis;
KIRP	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.45	0.38	6.03e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13190036	0.681	rs28461408	chr5:176662293	G/A	cg04708888	chr5:176739561	MXD3	-0.67	-5.15	-0.31	5.4e-7	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4363385	0.588	rs11586559	chr1:153025714	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-6.12	-0.36	3.72e-9	Inflammatory skin disease;
KIRP	cis	rs2150410	0.915	rs8132230	chr21:40584081	C/T	cg11890956	chr21:40555474	PSMG1	0.7	5.06	0.31	8.22e-7	Temperament (bipolar disorder);
KIRP	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg24209194	chr3:40518798	ZNF619	0.41	5.34	0.32	2.07e-7	Renal cell carcinoma;
KIRP	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.95	16.62	0.73	4.17e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.84	10.43	0.55	2.59e-21	Platelet distribution width;
KIRP	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.81	0.49	2.28e-16	Coronary artery disease;
KIRP	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.55	-7.76	-0.44	2.22e-13	Multiple sclerosis;Ankylosing spondylitis;
KIRP	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg07936489	chr17:37558343	FBXL20	-0.41	-5.01	-0.3	1.05e-6	Asthma;
KIRP	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	8.96	0.5	8.15e-17	IgG glycosylation;
KIRP	cis	rs12711979	0.513	rs4849991	chr2:3840545	T/G	cg17052675	chr2:3827356	NA	-0.36	-4.96	-0.3	1.3e-6	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.62	0.48	8.32e-16	Personality dimensions;
KIRP	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.48	-7.43	-0.43	1.78e-12	Coronary artery disease;
KIRP	cis	rs2371030	0.965	rs4672590	chr2:211575322	G/C	cg18417063	chr2:211583084	NA	-0.51	-7.48	-0.43	1.31e-12	Non-small cell lung cancer;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21016266	chr12:122356598	WDR66	0.66	9.1	0.5	3.12e-17	Mean corpuscular volume;
KIRP	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.04	17.57	0.75	2.54e-45	Multiple system atrophy;
KIRP	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg21775007	chr8:11205619	TDH	0.45	6.09	0.36	4.29e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg20573242	chr4:122745356	CCNA2	0.41	5.11	0.31	6.44e-7	Type 2 diabetes;
KIRP	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	0.7	8.47	0.48	2.3e-15	Vitiligo;
KIRP	cis	rs76693355	0.512	rs4938807	chr11:120331701	C/A	cg24566217	chr11:120254723	ARHGEF12	-0.45	-5.86	-0.35	1.51e-8	Intraocular pressure;
KIRP	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.43	-5.61	-0.34	5.55e-8	Parkinson's disease;
KIRP	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.46	-7.64	-0.44	4.87e-13	Obesity-related traits;
KIRP	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	8.96	0.5	8.18e-17	Cognitive test performance;
KIRP	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.78	0.4	8.9e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4713118	0.662	rs149900	chr6:28014597	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.48	-4.86	-0.3	2.1e-6	Parkinson's disease;
KIRP	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg11031976	chr2:198649780	BOLL	-0.47	-4.87	-0.3	2.01e-6	Ulcerative colitis;
KIRP	cis	rs6256	1.000	rs12418203	chr11:13560725	A/T	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg18261050	chr1:119551319	NA	0.51	6.7	0.39	1.4e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01112249	chr10:28591961	NA	-0.64	-7.02	-0.41	2.14e-11	Menopause (age at onset);
KIRP	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg20703242	chr1:230279135	GALNT2	-0.3	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02275930	chr1:2372054	NA	-0.45	-5.96	-0.36	8.83e-9	Schizophrenia;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.64	5.95	0.35	9.21e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.68	-7.3	-0.42	4.01e-12	Body mass index;
KIRP	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.5	-0.38	4.49e-10	Morning vs. evening chronotype;
KIRP	cis	rs4646404	0.582	rs4646344	chr17:17492060	A/G	cg01246520	chr17:17644344	RAI1	-0.3	-5.02	-0.3	9.9e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs6496044	0.507	rs410522	chr15:86207044	G/T	cg10818794	chr15:86012489	AKAP13	0.42	5.71	0.34	3.27e-8	Interstitial lung disease;
KIRP	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg01411142	chr8:19674711	INTS10	0.62	6.14	0.36	3.21e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg26354017	chr1:205819088	PM20D1	-0.56	-5.66	-0.34	4.22e-8	Menarche (age at onset);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06621132	chr4:25623424	NA	0.48	6.09	0.36	4.29e-9	Myopia (pathological);
KIRP	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.77	11.02	0.57	3.32e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg07936489	chr17:37558343	FBXL20	-0.42	-5.14	-0.31	5.63e-7	Asthma;
KIRP	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg13256891	chr4:100009986	ADH5	-0.47	-5.88	-0.35	1.34e-8	Alcohol dependence;
KIRP	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg03468072	chr12:39539422	NA	0.41	5.87	0.35	1.43e-8	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs2554380	0.628	rs2081541	chr15:84443686	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.34	-5.11	-0.31	6.5e-7	Height;
KIRP	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg22366001	chr1:2066006	PRKCZ	-0.39	-5.21	-0.32	3.92e-7	Height;
KIRP	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.74	-10.31	-0.55	5.91e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.25	-0.47	9.48e-15	Joint mobility (Beighton score);
KIRP	cis	rs735539	0.517	rs3809357	chr13:21140781	T/A	cg04906043	chr13:21280425	IL17D	-0.53	-6.4	-0.38	7.86e-10	Dental caries;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15124968	chr5:140855469	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGC3;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.53	6.7	0.39	1.39e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg00405596	chr8:11794950	NA	-0.47	-6.25	-0.37	1.81e-9	Mood instability;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08058610	chr19:52674483	ZNF836	0.51	6.31	0.37	1.27e-9	Smoking initiation;
KIRP	cis	rs7106204	0.748	rs4598670	chr11:24236524	G/A	ch.11.24196551F	chr11:24239977	NA	0.82	10.54	0.56	1.15e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg26819193	chr1:118412541	GDAP2	-0.48	-6.24	-0.37	1.9e-9	Inflammatory biomarkers;
KIRP	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg15655495	chr12:38532458	NA	-0.3	-5.23	-0.32	3.69e-7	Bladder cancer;
KIRP	cis	rs72945132	0.882	rs59681006	chr11:70179401	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.27	-0.32	3.01e-7	Coronary artery disease;
KIRP	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg13147721	chr7:65941812	NA	-0.99	-6.89	-0.4	4.68e-11	Diabetic kidney disease;
KIRP	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.62	-0.34	5.11e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg15655495	chr12:38532458	NA	-0.28	-5.42	-0.33	1.44e-7	Bladder cancer;
KIRP	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05347473	chr6:146136440	FBXO30	-0.58	-8.16	-0.46	1.7e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.72	-0.34	3.01e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7082209	1.000	rs7082209	chr10:44814336	C/T	cg09554077	chr10:44749378	NA	-0.47	-6.17	-0.37	2.8e-9	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11379888	chr6:170102082	WDR27;C6orf120	-0.49	-6.31	-0.37	1.27e-9	Myopia;
KIRP	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.66	9.07	0.5	3.89e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.84	11.43	0.59	1.49e-24	Height;
KIRP	cis	rs12701220	1.000	rs12701220	chr7:1022728	T/C	cg00990874	chr7:1149470	C7orf50	-0.72	-7.6	-0.44	6.4e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.75	11.07	0.58	2.15e-23	Colorectal cancer;
KIRP	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg21395723	chr22:39101663	GTPBP1	0.39	5.21	0.32	4.05e-7	Menopause (age at onset);
KIRP	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06481639	chr22:41940642	POLR3H	0.7	6.97	0.41	2.96e-11	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08677398	chr8:58056175	NA	0.61	4.86	0.3	2.05e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.08	-0.41	1.46e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2625529	0.824	rs12903484	chr15:72299481	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-6.19	-0.37	2.56e-9	Red blood cell count;
KIRP	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.7	0.39	1.42e-10	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg16396542	chr1:89473148	GBP3	-0.44	-6.34	-0.37	1.1e-9	Carotid intima media thickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24856234	chr11:64948848	CAPN1	0.49	6.11	0.36	3.92e-9	Parkinson's disease;
KIRP	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.13	-0.31	5.84e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02653270	chr7:150948861	SMARCD3	0.48	6.23	0.37	1.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg08901578	chr4:187885870	NA	-0.48	-7.25	-0.42	5.36e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.74	-10.93	-0.57	6.31e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2172802	0.570	rs10007614	chr4:62534527	G/C	cg04118610	chr4:62707027	LPHN3	-0.45	-5.54	-0.33	7.95e-8	Partial epilepsies;
KIRP	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23281280	chr6:28129359	ZNF389	0.48	4.97	0.3	1.27e-6	Depression;
KIRP	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.53	5.21	0.32	4.06e-7	Diastolic blood pressure;
KIRP	cis	rs4262150	0.846	rs111658964	chr5:152190325	T/C	cg12297329	chr5:152029980	NA	-0.63	-8.29	-0.47	7.43e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.64	6.42	0.38	6.89e-10	Gastritis;
KIRP	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg21890820	chr11:65308645	LTBP3	-0.41	-4.88	-0.3	1.91e-6	Bone mineral density;
KIRP	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg05579598	chr16:88989069	CBFA2T3	0.26	5.44	0.33	1.29e-7	Social autistic-like traits;
KIRP	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg11130432	chr3:121712080	ILDR1	-0.45	-5.45	-0.33	1.22e-7	Multiple sclerosis;
KIRP	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg13147721	chr7:65941812	NA	1.04	7.43	0.43	1.73e-12	Diabetic kidney disease;
KIRP	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg26913058	chr16:419975	MRPL28	0.56	6.7	0.39	1.42e-10	Body mass index;
KIRP	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg23188430	chr6:125850052	NA	-0.34	-5.33	-0.32	2.27e-7	Brugada syndrome;
KIRP	cis	rs6732160	0.574	rs1991612	chr2:73480501	G/C	cg01422370	chr2:73384389	NA	0.43	5.68	0.34	3.84e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg14324370	chr2:177042789	NA	-0.71	-8.81	-0.49	2.31e-16	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs367943	0.666	rs7725589	chr5:112693366	G/A	cg12552261	chr5:112820674	MCC	0.52	6.16	0.37	3.02e-9	Type 2 diabetes;
KIRP	cis	rs9596863	1.000	rs9596856	chr13:54409401	C/T	ch.13.53330881F	chr13:54432880	NA	0.66	6.68	0.39	1.56e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.62	8.66	0.48	6.48e-16	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09760210	chr2:192289158	MYO1B	0.41	6.19	0.37	2.48e-9	Survival in pancreatic cancer;
KIRP	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.12	0.36	3.59e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg07621104	chr11:117668040	DSCAML1	0.48	5.94	0.35	9.43e-9	Myopia;
KIRP	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg18585693	chr11:117668161	DSCAML1	0.31	5.03	0.31	9.27e-7	Myopia;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-6.11	-0.36	3.93e-9	Lung cancer;
KIRP	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	6.03	0.36	6.08e-9	Schizophrenia;
KIRP	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg05991184	chr2:219186017	PNKD	0.36	5.05	0.31	8.61e-7	Colorectal cancer;
KIRP	cis	rs735860	0.674	rs209485	chr6:53174448	C/T	cg10236188	chr6:53219634	NA	-0.43	-5.88	-0.35	1.36e-8	Glaucoma;
KIRP	cis	rs56399783	0.901	rs12540539	chr7:2873294	C/T	cg19731401	chr7:2775893	GNA12	0.71	6.87	0.4	5.24e-11	Childhood ear infection;
KIRP	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.1	-0.41	1.3e-11	Hemoglobin concentration;
KIRP	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.79	-12.12	-0.61	7.92e-27	Dental caries;
KIRP	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg25486957	chr4:152246857	NA	-0.44	-5.29	-0.32	2.72e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03777405	chr17:46125833	NFE2L1	0.46	6.25	0.37	1.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03837726	chr12:119633116	NA	-0.53	-7.9	-0.45	9.47e-14	Survival in pancreatic cancer;
KIRP	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg06115741	chr20:33292138	TP53INP2	0.57	6.86	0.4	5.41e-11	Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg13147721	chr7:65941812	NA	-0.99	-6.77	-0.4	9.48e-11	Diabetic kidney disease;
KIRP	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.11	-0.41	1.27e-11	Type 2 diabetes;
KIRP	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-9.62	-0.52	8.33e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg03060546	chr3:49711283	APEH	0.52	6.88	0.4	4.94e-11	Menarche (age at onset);
KIRP	trans	rs1941687	0.769	rs1493911	chr18:31356019	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-7.11	-0.41	1.27e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs3087591	1.000	rs12948444	chr17:29443614	A/G	cg24425628	chr17:29625626	OMG;NF1	0.72	10.05	0.54	4.03e-20	Hip circumference;
KIRP	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.89	0.4	4.55e-11	Breast cancer;
KIRP	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.28	0.67	4.17e-34	Platelet count;
KIRP	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.45	-5.29	-0.32	2.65e-7	Monocyte count;
KIRP	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.27e-9	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	5.24	0.32	3.5e-7	Renal cell carcinoma;
KIRP	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.67	-0.44	4.03e-13	Type 2 diabetes;
KIRP	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.52	-6.51	-0.38	4.28e-10	Alzheimer's disease (late onset);
KIRP	cis	rs12318506	0.793	rs11180432	chr12:75661314	C/T	cg04728562	chr12:75699417	CAPS2	-0.92	-6.4	-0.38	7.72e-10	Coronary artery calcification;
KIRP	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.81	-0.4	7.63e-11	Alzheimer's disease (late onset);
KIRP	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.55	6.58	0.39	2.87e-10	Axial length;
KIRP	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.73	0.44	2.71e-13	Coffee consumption (cups per day);
KIRP	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.59	-7.61	-0.44	5.8e-13	Menarche (age at onset);
KIRP	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg26681399	chr22:41777847	TEF	-0.45	-5.3	-0.32	2.64e-7	Vitiligo;
KIRP	cis	rs732716	0.889	rs11085074	chr19:4386352	A/G	cg21720385	chr19:4455239	UBXN6	0.7	8.57	0.48	1.14e-15	Mean corpuscular volume;
KIRP	cis	rs6725041	0.819	rs10196424	chr2:213089563	A/T	cg20637307	chr2:213403960	ERBB4	-0.4	-5.2	-0.31	4.17e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg21523564	chr15:75251491	NA	0.36	5.67	0.34	4.08e-8	Breast cancer;
KIRP	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.82	11.11	0.58	1.66e-23	Systemic lupus erythematosus;
KIRP	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg19592336	chr6:28129416	ZNF389	0.48	5.51	0.33	8.85e-8	Depression;
KIRP	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg04935436	chr20:30431758	NA	0.35	4.85	0.3	2.24e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs6725041	0.547	rs1394784	chr2:213209325	G/A	cg20637307	chr2:213403960	ERBB4	-0.48	-6.03	-0.36	5.84e-9	QT interval (ambient particulate matter interaction);
KIRP	trans	rs7939886	0.920	rs74707325	chr11:56005562	T/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs16828019	0.852	rs12742379	chr1:41526381	A/G	cg18742814	chr1:41828276	NA	0.61	5.43	0.33	1.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.9	14.24	0.67	5.97e-34	Mean corpuscular volume;
KIRP	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.46	-6.22	-0.37	2.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1003719	0.667	rs8127496	chr21:38442482	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.74	9.6	0.52	9.6e-19	Eye color traits;
KIRP	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg18200150	chr17:30822561	MYO1D	0.49	6.1	0.36	4.08e-9	Schizophrenia;
KIRP	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.89	-14.7	-0.68	1.59e-35	Prostate cancer;
KIRP	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg04780086	chr2:111875790	ACOXL	0.47	6.53	0.38	3.84e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg00204512	chr16:28754710	NA	0.44	5.52	0.33	8.68e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.77	-9.97	-0.54	6.93e-20	Lung cancer;
KIRP	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg19901468	chr14:105411992	AHNAK2	0.66	9.67	0.52	5.85e-19	Rheumatoid arthritis;
KIRP	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	7.12	0.41	1.15e-11	Protein C levels;
KIRP	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.8	-11.21	-0.58	8.14e-24	Extrinsic epigenetic age acceleration;
KIRP	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.62	-7.76	-0.44	2.33e-13	Eosinophil percentage of white cells;
KIRP	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg03235661	chr20:60525775	NA	-0.32	-5.32	-0.32	2.3e-7	Body mass index;
KIRP	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.22	0.55	1.13e-20	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg11586189	chr1:201857591	SHISA4	-0.47	-7.76	-0.44	2.28e-13	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs7551222	0.749	rs10900600	chr1:204559707	G/T	cg20240347	chr1:204465584	NA	-0.43	-8.35	-0.47	5.03e-15	Schizophrenia;
KIRP	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg16586182	chr3:47516702	SCAP	0.81	11.59	0.59	4.67e-25	Colorectal cancer;
KIRP	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.81	7.22	0.42	6.41e-12	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	6.02	0.36	6.4e-9	Bipolar disorder;
KIRP	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg02187348	chr16:89574699	SPG7	0.45	5.49	0.33	9.91e-8	Multiple myeloma (IgH translocation);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12506373	chr2:27440548	CAD	0.52	6.18	0.37	2.59e-9	Smoking initiation;
KIRP	cis	rs9470361	0.506	rs4568449	chr6:36621143	A/G	cg08179530	chr6:36648295	CDKN1A	0.44	5.64	0.34	4.72e-8	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
KIRP	cis	rs1524927	0.966	rs2260	chr7:96364457	T/C	cg00227355	chr7:96336147	SHFM1	-0.32	-4.87	-0.3	2.01e-6	Total body bone mineral density;
KIRP	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.29	18.41	0.76	3.52e-48	Atopic dermatitis;
KIRP	cis	rs1635	0.574	rs73400572	chr6:28179523	C/A	cg24848467	chr6:28134517	ZNF389	-0.74	-5.2	-0.31	4.18e-7	Schizophrenia;
KIRP	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.49	-6.0	-0.36	6.96e-9	Iron status biomarkers;
KIRP	cis	rs879620	1.000	rs879620	chr16:4015729	A/G	cg09300795	chr16:4042428	ADCY9	-0.41	-5.21	-0.32	4.01e-7	Hip circumference;Body mass index;
KIRP	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.56	-6.23	-0.37	2.05e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2151522	0.762	rs1930947	chr6:127187862	T/G	cg21431617	chr6:127135037	NA	0.28	5.07	0.31	7.83e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg09597638	chr17:3907349	NA	0.75	14.25	0.67	5.14e-34	Type 2 diabetes;
KIRP	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.63	-7.34	-0.42	3.17e-12	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg12311346	chr5:56204834	C5orf35	-0.39	-5.28	-0.32	2.86e-7	Coronary artery disease;
KIRP	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	0.94	11.14	0.58	1.29e-23	Vitiligo;
KIRP	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg16068336	chr17:48637367	CACNA1G	-0.41	-5.24	-0.32	3.43e-7	Type 2 diabetes;
KIRP	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.51	5.05	0.31	8.63e-7	Alzheimer's disease;
KIRP	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	0.79	8.48	0.48	2.06e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs7119	0.717	rs12898656	chr15:77807995	C/T	cg12131826	chr15:77904385	NA	-0.48	-5.79	-0.35	2.14e-8	Type 2 diabetes;
KIRP	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg20302533	chr7:39170763	POU6F2	0.31	6.6	0.39	2.49e-10	IgG glycosylation;
KIRP	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.5	6.14	0.36	3.33e-9	Asthma;
KIRP	cis	rs8038465	0.904	rs12594627	chr15:73986264	G/T	cg15420318	chr15:73925796	NPTN	0.48	5.89	0.35	1.27e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19988671	chr7:155589783	NA	0.49	6.41	0.38	7.23e-10	Smoking initiation;
KIRP	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.09	-0.77	1.92e-50	Schizophrenia;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg17688381	chr15:40734271	BAHD1	0.52	6.28	0.37	1.53e-9	Educational attainment;
KIRP	cis	rs6684514	1.000	rs10908494	chr1:156263097	A/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg24579218	chr15:68104479	NA	-0.44	-7.16	-0.42	9.33e-12	Restless legs syndrome;
KIRP	cis	rs7582720	1.000	rs72932725	chr2:203649341	G/A	cg08076091	chr2:203926405	NBEAL1	0.85	8.37	0.47	4.49e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.7	9.12	0.5	2.73e-17	Cognitive function;
KIRP	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.91	14.14	0.67	1.28e-33	Testicular germ cell tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18877309	chr1:2105343	PRKCZ	0.58	7.25	0.42	5.24e-12	Interleukin-4 levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02750587	chr1:85156370	SSX2IP	0.97	6.8	0.4	7.89e-11	P wave terminal force;
KIRP	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.47	5.83	0.35	1.72e-8	Height;
KIRP	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.38	-5.0	-0.3	1.11e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	0.84	7.54	0.43	8.76e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg06636001	chr8:8085503	FLJ10661	0.79	10.34	0.55	4.87e-21	Parkinson's disease;
KIRP	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.91	11.86	0.6	5.98e-26	Homoarginine levels;
KIRP	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.3	13.3	0.65	8.84e-31	Diabetic retinopathy;
KIRP	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg17425144	chr1:10567563	PEX14	0.52	10.36	0.55	4.13e-21	Breast size;
KIRP	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.62	8.48	0.48	2.14e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs28595532	0.545	rs17516582	chr4:119296763	C/G	cg21605333	chr4:119757512	SEC24D	0.87	7.01	0.41	2.29e-11	Cannabis dependence symptom count;
KIRP	trans	rs12436689	0.571	rs1667521	chr14:85682017	G/T	cg12873610	chr17:27044322	RAB34	-0.37	-6.06	-0.36	4.99e-9	Pulmonary function decline;
KIRP	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.6	6.78	0.4	8.85e-11	Aortic root size;
KIRP	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.09	-0.36	4.37e-9	Neuroticism;
KIRP	cis	rs787274	0.557	rs7026450	chr9:115666976	T/C	cg13803584	chr9:115635662	SNX30	-0.64	-5.61	-0.34	5.54e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.57	7.96	0.45	6.33e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg06740227	chr12:86229804	RASSF9	0.39	4.9	0.3	1.71e-6	Major depressive disorder;
KIRP	cis	rs9513593	1.000	rs4772186	chr13:99957987	G/A	cg21788972	chr13:99853209	UBAC2	0.6	6.25	0.37	1.83e-9	Psoriasis;
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg03388025	chr16:89894329	SPIRE2	-0.37	-7.65	-0.44	4.68e-13	Vitiligo;
KIRP	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg10210624	chr19:58662595	ZNF329	0.63	5.99	0.36	7.38e-9	Cholesterol, total;
KIRP	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.34	19.21	0.77	7.28e-51	Corneal structure;
KIRP	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg14541582	chr5:601475	NA	-0.54	-5.94	-0.35	9.55e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg25039879	chr17:56429692	SUPT4H1	0.52	4.84	0.3	2.27e-6	Cognitive test performance;
KIRP	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.95	0.57	5.4e-23	Personality dimensions;
KIRP	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg09990169	chr2:241835740	C2orf54	-0.47	-7.3	-0.42	3.94e-12	Urinary metabolites;
KIRP	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.69	0.48	5.17e-16	Bipolar disorder;
KIRP	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.77	-0.49	2.93e-16	Neuroticism;
KIRP	cis	rs1620921	0.505	rs1991598	chr6:161204488	G/A	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2273156	1.000	rs12890307	chr14:35452132	G/A	cg09327582	chr14:35236912	BAZ1A	-0.48	-5.24	-0.32	3.51e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg17470449	chr10:769945	NA	0.71	7.42	0.43	1.9e-12	Uric acid levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10856509	chr5:148737559	PCYOX1L	-0.47	-6.65	-0.39	1.92e-10	Myopia;
KIRP	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs71403859	0.803	rs34381861	chr16:71640230	T/C	cg08717414	chr16:71523259	ZNF19	-1.11	-9.86	-0.53	1.55e-19	Post bronchodilator FEV1;
KIRP	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg05991184	chr2:219186017	PNKD	0.35	4.85	0.3	2.22e-6	Colorectal cancer;
KIRP	cis	rs71403859	0.730	rs12927768	chr16:71645263	G/A	cg08717414	chr16:71523259	ZNF19	-1.09	-9.08	-0.5	3.75e-17	Post bronchodilator FEV1;
KIRP	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-7.08	-0.41	1.54e-11	Morning vs. evening chronotype;
KIRP	cis	rs1858037	0.836	rs17475335	chr2:65605780	G/C	cg08085232	chr2:65598271	SPRED2	-0.54	-6.49	-0.38	4.78e-10	Rheumatoid arthritis;
KIRP	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg15047889	chr8:124780837	FAM91A1	-0.5	-4.98	-0.3	1.19e-6	Pancreatic cancer;
KIRP	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07570687	chr10:102243282	WNT8B	0.51	6.76	0.4	9.73e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11987759	chr7:65425863	GUSB	-0.52	-6.93	-0.4	3.69e-11	Aortic root size;
KIRP	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.66	10.11	0.54	2.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs10421328	0.821	rs10405234	chr19:19756662	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.43	0.33	1.38e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.73	9.36	0.51	5.41e-18	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs9659323	0.730	rs10923720	chr1:119541879	T/C	cg18261050	chr1:119551319	NA	0.42	5.95	0.35	9.29e-9	Body mass index;
KIRP	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg14952266	chr13:112191215	NA	0.46	6.85	0.4	5.96e-11	Hepatitis;
KIRP	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg18306943	chr3:40428807	ENTPD3	0.46	5.9	0.35	1.19e-8	Renal cell carcinoma;
KIRP	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07343612	chr16:622815	PIGQ	0.49	5.57	0.33	6.77e-8	Height;
KIRP	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	0.93	12.47	0.62	5.58e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.97	0.36	8.41e-9	Breast cancer;
KIRP	cis	rs9810890	1.000	rs73198843	chr3:128502514	G/A	cg15033153	chr3:128514015	RAB7A	0.54	5.07	0.31	7.74e-7	Dental caries;
KIRP	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.5	-0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg02487422	chr3:49467188	NICN1	0.36	5.05	0.31	8.43e-7	Parkinson's disease;
KIRP	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12016809	chr21:47604291	C21orf56	-0.37	-4.95	-0.3	1.35e-6	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.67	-0.34	3.93e-8	Life satisfaction;
KIRP	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.91	11.85	0.6	6.2e-26	Homoarginine levels;
KIRP	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	1.1	23.36	0.83	2.19e-64	Parkinson's disease;
KIRP	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg00343986	chr7:65444356	GUSB	0.48	5.69	0.34	3.52e-8	Aortic root size;
KIRP	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg16797656	chr11:68205561	LRP5	0.39	5.18	0.31	4.52e-7	Total body bone mineral density;
KIRP	cis	rs2274273	0.840	rs6573013	chr14:55735873	A/C	cg04306507	chr14:55594613	LGALS3	0.52	7.97	0.45	5.89e-14	Protein biomarker;
KIRP	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.8	12.15	0.61	6.43e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.82	10.21	0.55	1.23e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs9488822	0.662	rs536160	chr6:116267166	T/C	cg05304507	chr6:116381966	FRK	-0.2	-5.38	-0.32	1.75e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg19770292	chr5:1868693	NA	0.43	5.16	0.31	5.06e-7	Cardiovascular disease risk factors;
KIRP	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	5.2	0.31	4.18e-7	Renal cell carcinoma;
KIRP	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.43	5.66	0.34	4.19e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.91	-12.78	-0.63	5.13e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs831571	0.955	rs35839	chr3:64013417	G/A	cg17941049	chr3:63904683	ATXN7	0.52	4.96	0.3	1.3e-6	Type 2 diabetes;
KIRP	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg00631329	chr6:26305371	NA	0.56	7.2	0.42	7.25e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg06647332	chr5:131281008	NA	0.45	4.98	0.3	1.2e-6	Life satisfaction;
KIRP	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.77	0.49	2.96e-16	Motion sickness;
KIRP	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg25547332	chr5:131281432	NA	0.47	5.31	0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg18209359	chr17:80159595	CCDC57	-0.45	-5.61	-0.34	5.56e-8	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18852630	chr5:82937299	HAPLN1	-0.38	-6.03	-0.36	5.87e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg26681399	chr22:41777847	TEF	-0.53	-5.3	-0.32	2.62e-7	Vitiligo;
KIRP	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.86e-11	Retinal vascular caliber;
KIRP	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	7.75	0.44	2.37e-13	Menarche (age at onset);
KIRP	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.69	8.11	0.46	2.33e-14	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg06204229	chr3:52865917	ITIH4	0.47	5.42	0.33	1.39e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1832871	0.965	rs262827	chr6:158683646	A/T	cg07215822	chr6:158701037	NA	-0.47	-6.11	-0.36	3.92e-9	Height;
KIRP	cis	rs501120	0.584	rs11238889	chr10:44668724	G/A	cg09554077	chr10:44749378	NA	0.58	6.12	0.36	3.73e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg13731523	chr4:3047190	NA	-0.39	-6.43	-0.38	6.45e-10	Serum sulfate level;
KIRP	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg09473613	chr1:24152604	HMGCL	0.48	6.34	0.37	1.11e-9	Immature fraction of reticulocytes;
KIRP	cis	rs7523273	0.925	rs4844394	chr1:208000625	C/T	cg22525895	chr1:207977042	MIR29B2	-0.66	-8.24	-0.47	1.03e-14	Schizophrenia;
KIRP	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.64	7.07	0.41	1.62e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg20607798	chr8:58055168	NA	0.57	5.03	0.31	9.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9311676	0.656	rs55668308	chr3:58388453	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.45	-5.89	-0.35	1.24e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-0.64	-5.81	-0.35	1.95e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.94	15.87	0.71	1.62e-39	Menarche (age at onset);
KIRP	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.87	-0.3	2e-6	Prostate cancer;
KIRP	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg05082376	chr22:42548792	NA	-0.45	-5.86	-0.35	1.48e-8	Schizophrenia;
KIRP	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.91	14.47	0.68	9.51e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.69	-8.12	-0.46	2.32e-14	Cocaine dependence;
KIRP	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg07741184	chr6:167504864	NA	-0.24	-6.29	-0.37	1.42e-9	Primary biliary cholangitis;
KIRP	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg13264159	chr8:625131	ERICH1	-0.83	-7.12	-0.41	1.15e-11	IgG glycosylation;
KIRP	cis	rs7404928	0.589	rs7189218	chr16:23851970	T/C	cg21745164	chr16:23765304	CHP2	0.57	7.32	0.42	3.48e-12	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	trans	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg25042112	chr7:64838748	ZNF92	0.58	6.06	0.36	5.19e-9	Pain;
KIRP	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg07537917	chr2:241836409	C2orf54	-0.33	-6.8	-0.4	7.79e-11	Urinary metabolites;
KIRP	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg24631222	chr15:78858424	CHRNA5	-0.44	-4.92	-0.3	1.57e-6	Post bronchodilator FEV1;
KIRP	cis	rs240764	0.541	rs9390693	chr6:101239935	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.22	0.32	3.85e-7	Neuroticism;
KIRP	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs56079296	0.518	rs7722155	chr5:121330638	A/G	cg05256605	chr5:121412184	LOX	0.51	5.45	0.33	1.23e-7	Coronary artery disease;
KIRP	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg19899395	chr1:46959349	NA	-0.39	-4.9	-0.3	1.76e-6	Monobrow;
KIRP	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.79	-12.29	-0.62	2.18e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg13072238	chr3:49761600	GMPPB	-0.57	-4.93	-0.3	1.54e-6	Menarche (age at onset);
KIRP	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.81	8.28	0.47	7.74e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.8	10.31	0.55	5.92e-21	Platelet count;
KIRP	cis	rs8038465	1.000	rs8032531	chr15:73977271	A/G	cg15420318	chr15:73925796	NPTN	0.57	7.26	0.42	5.16e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg24807547	chr6:37504484	NA	-0.61	-9.14	-0.5	2.42e-17	Cognitive performance;
KIRP	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg11839771	chr15:80205821	ST20	-0.37	-5.26	-0.32	3.11e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1620921	0.774	rs783156	chr6:161231177	T/C	cg01280913	chr6:161186852	NA	-0.42	-6.02	-0.36	6.19e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg25019033	chr10:957182	NA	-0.62	-7.27	-0.42	4.76e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg26408565	chr15:76604113	ETFA	-0.42	-5.63	-0.34	4.89e-8	Blood metabolite levels;
KIRP	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.46	5.69	0.34	3.57e-8	Common traits (Other);
KIRP	cis	rs7119038	0.774	rs2004781	chr11:118619253	C/T	cg19308663	chr11:118741387	NA	0.57	8.83	0.49	2.06e-16	Sjögren's syndrome;
KIRP	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg25174290	chr11:3078921	CARS	-0.69	-8.98	-0.5	7.09e-17	Calcium levels;
KIRP	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg06223162	chr1:101003688	GPR88	-0.4	-7.92	-0.45	8.3e-14	Monocyte count;
KIRP	cis	rs287982	1.000	rs287977	chr2:9970018	T/C	cg18436444	chr2:10917754	ATP6V1C2	0.34	5.01	0.3	1.02e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs4959799	0.557	rs9501970	chr6:3271509	T/C	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.25	-0.32	3.34e-7	Survival in rectal cancer;
KIRP	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg23422044	chr7:1970798	MAD1L1	-0.5	-6.13	-0.36	3.49e-9	Neuroticism;
KIRP	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.4	-5.26	-0.32	3.08e-7	Coronary artery disease;
KIRP	cis	rs6540559	0.673	rs6540564	chr1:210019910	T/C	cg22029157	chr1:209979665	IRF6	0.46	5.0	0.3	1.11e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.9	0.53	1.18e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs57994353	0.600	rs10870163	chr9:139315594	G/A	cg14169450	chr9:139327907	INPP5E	0.52	5.72	0.34	3.07e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.97	10.57	0.56	9.19e-22	Gut microbiome composition (summer);
KIRP	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.58	-12.17	-0.61	5.64e-27	Diabetic kidney disease;
KIRP	cis	rs988913	1.000	rs6941291	chr6:54837376	A/G	cg03513858	chr6:54763001	FAM83B	-0.38	-5.57	-0.33	6.75e-8	Menarche (age at onset);
KIRP	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.72	8.13	0.46	2.11e-14	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg19847130	chr8:10466454	RP1L1	0.38	5.75	0.34	2.59e-8	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01756564	chr11:108093812	ATM;NPAT	0.49	7.13	0.41	1.1e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.93	10.96	0.57	5.23e-23	Corneal astigmatism;
KIRP	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg15880211	chr22:50250494	ZBED4	-0.66	-7.43	-0.43	1.74e-12	Schizophrenia;
KIRP	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg22437258	chr11:111473054	SIK2	0.6	7.02	0.41	2.14e-11	Primary sclerosing cholangitis;
KIRP	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.24	-0.7	2.19e-37	Gut microbiome composition (summer);
KIRP	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg02297831	chr4:17616191	MED28	0.51	6.51	0.38	4.14e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg10381502	chr11:71823885	C11orf51	-1.03	-7.17	-0.42	8.64e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg23587288	chr2:27483067	SLC30A3	-0.66	-7.43	-0.43	1.82e-12	Blood metabolite levels;
KIRP	cis	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg21775007	chr8:11205619	TDH	-0.41	-5.41	-0.33	1.47e-7	Triglycerides;
KIRP	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg18135555	chr8:22132992	PIWIL2	0.42	6.32	0.37	1.25e-9	Hypertriglyceridemia;
KIRP	cis	rs10046574	0.561	rs11505984	chr7:135208359	G/A	cg27474649	chr7:135195673	CNOT4	0.55	5.18	0.31	4.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-7.09	-0.41	1.42e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg19636519	chr7:99541626	NA	0.3	5.13	0.31	5.88e-7	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs41298997	1	rs41298997	chr1:206655331	C/T	cg11166312	chr1:206654246	IKBKE	0.6	7.32	0.42	3.61e-12	Psoriasis;
KIRP	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg05234568	chr11:5960015	NA	-0.6	-6.18	-0.37	2.71e-9	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20180092	chr3:39425780	SLC25A38	0.49	6.31	0.37	1.31e-9	Parkinson's disease;
KIRP	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.62	-9.33	-0.51	6.24e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.1	-0.41	1.3e-11	Platelet count;
KIRP	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-1.05	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	trans	rs440932	0.798	rs330942	chr8:9020439	A/C	cg16141378	chr3:129829833	LOC729375	-0.5	-6.24	-0.37	1.9e-9	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs3925075	0.966	rs12935192	chr16:31359330	G/A	cg02846316	chr16:31340340	ITGAM	0.63	9.75	0.53	3.46e-19	IgA nephropathy;
KIRP	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12049351	0.719	rs2145394	chr1:229670964	G/A	cg11742688	chr1:229674241	ABCB10	-0.36	-5.43	-0.33	1.36e-7	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23722778	chr6:46112967	ENPP4	0.4	6.03	0.36	6.03e-9	Migraine with aura;
KIRP	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg26531700	chr6:26746687	NA	0.41	5.57	0.33	6.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07570687	chr10:102243282	WNT8B	0.49	6.07	0.36	4.7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg01246520	chr17:17644344	RAI1	-0.48	-8.25	-0.47	9.81e-15	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.31	-0.59	3.59e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg00405596	chr8:11794950	NA	-0.45	-5.52	-0.33	8.69e-8	Neuroticism;
KIRP	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	6.42	0.38	6.91e-10	Cognitive test performance;
KIRP	cis	rs10029851	0.645	rs9996443	chr4:109619590	C/A	cg16525761	chr4:109541525	LOC285456;RPL34	-0.45	-5.04	-0.31	9.2e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs448720	0.776	rs1001870	chr15:68151448	C/T	cg24579218	chr15:68104479	NA	-0.37	-5.62	-0.34	5.27e-8	Cognitive performance;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.61	-8.28	-0.47	7.9e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg16486109	chr11:613632	IRF7	0.41	5.0	0.3	1.08e-6	Systemic lupus erythematosus;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10276623	chr14:94770592	SERPINA6	0.47	6.49	0.38	4.68e-10	Survival in pancreatic cancer;
KIRP	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg03834567	chr2:218808745	TNS1	0.47	5.73	0.34	3e-8	Ulcerative colitis;
KIRP	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg25649188	chr17:73499917	CASKIN2	0.38	5.05	0.31	8.44e-7	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.51	5.84	0.35	1.62e-8	Platelet distribution width;
KIRP	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.32	0.37	1.22e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg24498760	chr8:49746867	NA	0.39	4.88	0.3	1.93e-6	Blood metabolite ratios;
KIRP	cis	rs1620921	0.901	rs783180	chr6:161168961	G/T	cg01280913	chr6:161186852	NA	-0.41	-5.85	-0.35	1.52e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.89	0.3	1.86e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg12559939	chr2:27858050	GPN1	-0.41	-5.08	-0.31	7.49e-7	Total body bone mineral density;
KIRP	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.44	-6.53	-0.38	3.67e-10	Coronary artery disease;
KIRP	cis	rs17095355	0.901	rs12569425	chr10:111758177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.09	-0.36	4.33e-9	Biliary atresia;
KIRP	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-0.65	-9.51	-0.52	1.83e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7665939	0.860	rs72709255	chr4:190129201	C/T	cg01790032	chr4:190285510	NA	-0.73	-5.02	-0.3	9.89e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs7572263	0.724	rs11883992	chr2:209047468	A/T	cg23998903	chr2:209048830	C2orf80	0.34	5.21	0.32	3.95e-7	Glioma;Non-glioblastoma glioma;
KIRP	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.5	-0.48	1.88e-15	Neuroticism;
KIRP	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-6.1	-0.36	4.01e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-5.08	-0.31	7.52e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.74	9.93	0.54	9.1e-20	Height;
KIRP	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.58	-7.15	-0.41	9.81e-12	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	5.76	0.34	2.46e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg09085632	chr11:111637200	PPP2R1B	0.5	6.44	0.38	6.16e-10	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-4.89	-0.3	1.84e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10150615	chr22:24372951	LOC391322	-0.6	-8.24	-0.47	1.02e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg11786666	chr7:105173132	RINT1	0.47	6.4	0.38	7.89e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09002469	chr12:123459295	OGFOD2;ABCB9	0.55	6.4	0.38	7.67e-10	Smoking initiation;
KIRP	cis	rs1538970	0.962	rs2298018	chr1:45813441	T/C	cg05343316	chr1:45956843	TESK2	0.62	7.26	0.42	4.95e-12	Platelet count;
KIRP	cis	rs4975616	0.843	rs6866783	chr5:1312020	T/C	cg26373071	chr5:1325741	CLPTM1L	-0.53	-6.73	-0.39	1.2e-10	Lung cancer;
KIRP	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.48	6.08	0.36	4.61e-9	Height;
KIRP	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg05044414	chr3:183734942	ABCC5	0.38	5.75	0.34	2.62e-8	Anterior chamber depth;
KIRP	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.7	9.22	0.51	1.43e-17	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg02187348	chr16:89574699	SPG7	0.47	5.76	0.34	2.53e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.66	-10.41	-0.55	2.97e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.6	-8.52	-0.48	1.57e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.38	-6.92	-0.4	3.98e-11	Renal cell carcinoma;
KIRP	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.39	-6.16	-0.37	3.03e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg11569703	chr11:65557185	OVOL1	-0.51	-9.3	-0.51	7.69e-18	Acne (severe);
KIRP	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.38	4.87	0.3	1.99e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18867708	chr6:26865862	GUSBL1	0.47	5.91	0.35	1.11e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.56	6.72	0.39	1.25e-10	Uric acid levels;
KIRP	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg05527609	chr1:210001259	C1orf107	-0.41	-5.1	-0.31	6.85e-7	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25383309	chr10:23292103	ARMC3	0.44	6.14	0.36	3.34e-9	Interleukin-4 levels;
KIRP	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.95e-7	Red blood cell count;
KIRP	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.27	-0.37	1.63e-9	Breast cancer;
KIRP	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.75	12.19	0.61	4.71e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.45	-0.38	5.77e-10	Daytime sleep phenotypes;
KIRP	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg10096100	chr1:26503862	CNKSR1	0.43	6.08	0.36	4.63e-9	Height;
KIRP	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.83	0.53	1.87e-19	Dupuytren's disease;
KIRP	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.63	7.24	0.42	5.61e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.76	-10.44	-0.55	2.32e-21	Resting heart rate;
KIRP	cis	rs72843166	0.947	rs72843170	chr17:61120113	G/A	cg19683800	chr17:61518354	CYB561	-0.41	-5.0	-0.3	1.09e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs61884328	0.777	rs61897777	chr11:47133604	C/G	cg23433285	chr11:47201945	PACSIN3	0.69	5.6	0.34	5.68e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs7553864	1.000	rs975040	chr1:87613682	G/A	cg17420885	chr1:87600446	LOC339524	-0.47	-6.07	-0.36	4.94e-9	Smoking behavior;
KIRP	cis	rs6921919	0.583	rs13201726	chr6:28385551	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.38	-0.38	8.49e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg26629188	chr21:47878281	DIP2A	0.46	6.05	0.36	5.28e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg21709803	chr11:61594965	FADS2	-0.42	-4.9	-0.3	1.76e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg11569703	chr11:65557185	OVOL1	-0.49	-8.61	-0.48	8.68e-16	Acne (severe);
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg08741688	chr4:3415352	RGS12	-0.43	-4.87	-0.3	2.03e-6	Serum sulfate level;
KIRP	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-1.01	-15.73	-0.71	4.6e-39	Coronary artery disease;
KIRP	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.62	-8.69	-0.48	5.35e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00889227	chr1:205173544	DSTYK	-0.4	-5.55	-0.33	7.53e-8	Red blood cell count;
KIRP	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.74	9.51	0.52	1.78e-18	Nonalcoholic fatty liver disease;
KIRP	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.64	-6.94	-0.4	3.52e-11	Vitiligo;
KIRP	cis	rs2067663	0.786	rs412458	chr5:88029627	C/T	cg18498987	chr5:88179539	MEF2C	-0.39	-5.18	-0.31	4.6e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg22974920	chr21:40686053	BRWD1	0.51	6.07	0.36	4.86e-9	Cognitive function;
KIRP	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg18016565	chr1:150552671	MCL1	0.38	5.79	0.35	2.14e-8	Melanoma;
KIRP	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.18	0.42	8e-12	Educational attainment;
KIRP	cis	rs7127900	0.561	rs7109219	chr11:2233041	G/A	cg25635251	chr11:2234043	NA	0.44	6.85	0.4	5.8e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.56	-6.91	-0.4	4.03e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-1.13	-9.4	-0.51	4e-18	Blood pressure (smoking interaction);
KIRP	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg25019033	chr10:957182	NA	-0.61	-7.2	-0.42	7.49e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs6540556	0.723	rs12086634	chr1:209880259	T/G	cg23920097	chr1:209922102	NA	-0.48	-5.39	-0.33	1.65e-7	Red blood cell count;
KIRP	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7246760	1.000	rs2081066	chr19:9928044	C/T	cg02900749	chr2:68251473	NA	-0.89	-8.06	-0.46	3.38e-14	Pursuit maintenance gain;
KIRP	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.36	7.66	0.44	4.31e-13	Corneal astigmatism;
KIRP	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg15117754	chr3:10150083	C3orf24	0.55	5.21	0.31	4.09e-7	Alzheimer's disease;
KIRP	cis	rs7011507	1.000	rs77193645	chr8:49140500	G/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.54	-7.42	-0.43	1.96e-12	Schizophrenia;
KIRP	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.3	0.62	2.03e-27	Bipolar disorder;
KIRP	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg10547527	chr2:198650123	BOLL	-0.5	-4.93	-0.3	1.54e-6	Ulcerative colitis;
KIRP	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg23791538	chr6:167370224	RNASET2	-0.41	-5.2	-0.31	4.28e-7	Crohn's disease;
KIRP	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.7	-6.05	-0.36	5.39e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg17264618	chr3:40429014	ENTPD3	0.31	4.89	0.3	1.81e-6	Renal cell carcinoma;
KIRP	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.53	6.81	0.4	7.26e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-6.78	-0.4	8.89e-11	Menarche (age at onset);
KIRP	cis	rs7903847	0.642	rs2275090	chr10:99148151	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.72	0.49	4.18e-16	Schizophrenia;
KIRP	cis	rs9475752	0.793	rs71564871	chr6:56830895	G/T	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.56	-6.23	-0.37	2.05e-9	Menarche (age at onset);
KIRP	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10174797	chr19:8464628	RAB11B	0.51	6.4	0.38	7.87e-10	HDL cholesterol;
KIRP	trans	rs12517041	1.000	rs6888168	chr5:23304401	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-1.2	-10.38	-0.55	3.59e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.9	13.11	0.64	3.96e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27315947	chr21:34915270	GART;SON	0.53	6.72	0.39	1.23e-10	Parkinson's disease;
KIRP	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.77	10.32	0.55	5.41e-21	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg26876637	chr1:152193138	HRNR	0.73	9.51	0.52	1.88e-18	Atopic dermatitis;
KIRP	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg00147788	chr6:125855365	NA	0.31	4.96	0.3	1.3e-6	Brugada syndrome;
KIRP	cis	rs11945232	0.929	rs28736552	chr4:88356111	T/C	cg23841344	chr4:88312519	HSD17B11	-0.59	-7.47	-0.43	1.42e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1957429	0.520	rs72625645	chr14:65343431	G/C	cg23373153	chr14:65346875	NA	-0.72	-4.96	-0.3	1.35e-6	Pediatric areal bone mineral density (radius);
KIRP	cis	rs2273156	1.000	rs17102967	chr14:35480388	A/G	cg09327582	chr14:35236912	BAZ1A	-0.55	-5.73	-0.34	2.86e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg09462578	chr12:12878428	APOLD1	-0.65	-6.94	-0.4	3.47e-11	Systemic lupus erythematosus;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17358899	chr7:148580458	EZH2	0.72	6.77	0.4	9.26e-11	Lung function (FEV1);
KIRP	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	1.03	14.23	0.67	6.42e-34	Menopause (age at onset);
KIRP	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg19731401	chr7:2775893	GNA12	0.8	7.5	0.43	1.16e-12	Childhood ear infection;
KIRP	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	14.51	0.68	6.89e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs854624	0.892	rs1734954	chr17:34337888	C/G	cg23743114	chr17:34328396	CCL15;CCL14-CCL15	0.53	4.94	0.3	1.45e-6	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3818285	0.655	rs2475277	chr10:111639730	C/T	cg00817464	chr10:111662876	XPNPEP1	0.5	9.03	0.5	5.08e-17	Superior crus of antihelix expression;
KIRP	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.31	5.73	0.34	2.97e-8	Calcium levels;
KIRP	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg27087555	chr16:88793112	FAM38A	-1.38	-10.91	-0.57	7.38e-23	Plateletcrit;
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-5.01	-0.3	1.03e-6	Electroencephalogram traits;
KIRP	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg04727924	chr7:799746	HEATR2	0.63	5.81	0.35	1.9e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs3818285	0.959	rs3740137	chr10:111630917	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.21	-0.32	4.06e-7	Superior crus of antihelix expression;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg21851534	chr17:3907994	ZZEF1	0.49	6.54	0.38	3.51e-10	Type 2 diabetes;
KIRP	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg11161011	chr14:65562177	MAX	-0.62	-8.03	-0.46	4.02e-14	Obesity-related traits;
KIRP	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.69	-0.34	3.64e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg25547332	chr5:131281432	NA	-0.47	-5.21	-0.32	4.06e-7	Life satisfaction;
KIRP	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.51	6.17	0.37	2.75e-9	Longevity;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20080590	chr4:24831413	CCDC149	0.58	6.52	0.38	4.02e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg00147788	chr6:125855365	NA	-0.31	-4.94	-0.3	1.43e-6	Brugada syndrome;
KIRP	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg20003494	chr4:90757398	SNCA	-0.37	-4.87	-0.3	2.01e-6	Neuroticism;
KIRP	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.72	6.22	0.37	2.14e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs754423	0.674	rs979481	chr14:52533443	A/G	cg05884192	chr14:52515736	NID2	0.48	6.14	0.36	3.32e-9	Craniofacial microsomia;
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs9912468	0.802	rs11079650	chr17:64322017	A/C	cg19474267	chr17:64306194	PRKCA	-0.65	-9.46	-0.52	2.69e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-7.83	-0.45	1.46e-13	Monocyte percentage of white cells;
KIRP	cis	rs830124	0.714	rs1177589	chr12:122403933	A/G	cg21016266	chr12:122356598	WDR66	0.56	5.77	0.35	2.4e-8	Urinary metabolites;
KIRP	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg11038491	chr20:34638489	LOC647979	-0.7	-7.53	-0.43	9.83e-13	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.92	8.48	0.48	2.08e-15	Systolic blood pressure;
KIRP	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg22947322	chr17:47091978	IGF2BP1	-0.46	-5.99	-0.36	7.39e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg12131826	chr15:77904385	NA	0.46	5.49	0.33	1.01e-7	Type 2 diabetes;
KIRP	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg05315796	chr3:52349193	DNAH1	0.49	7.74	0.44	2.58e-13	Electroencephalogram traits;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-1.05	-20.72	-0.8	7.03e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.27	-0.32	3.03e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7113850	0.541	rs4451727	chr11:24216855	G/C	ch.11.24196551F	chr11:24239977	NA	0.85	8.61	0.48	8.68e-16	Bone fracture in osteoporosis;
KIRP	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.09	0.54	2.93e-20	Dupuytren's disease;
KIRP	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg23791538	chr6:167370224	RNASET2	-0.47	-5.48	-0.33	1.04e-7	Primary biliary cholangitis;
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg14004847	chr7:1930337	MAD1L1	-0.48	-5.31	-0.32	2.44e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3026101	0.671	rs56113612	chr17:5297761	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.93	0.35	1.02e-8	Body mass index;
KIRP	cis	rs300774	0.800	rs300701	chr2:187396	C/G	cg21211680	chr2:198530	NA	-0.59	-6.17	-0.37	2.73e-9	Suicide attempts in bipolar disorder;
KIRP	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg01879757	chr17:41196368	BRCA1	0.56	7.42	0.43	1.95e-12	Menopause (age at onset);
KIRP	cis	rs12693043	0.845	rs1367223	chr2:175391970	A/C	cg11778734	chr2:175439522	WIPF1	0.48	6.59	0.39	2.65e-10	Urate levels (BMI interaction);
KIRP	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.47	-4.94	-0.3	1.46e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs17253792	0.822	rs77408754	chr14:56082047	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.54	0.33	7.92e-8	Putamen volume;
KIRP	cis	rs12643440	0.573	rs566597	chr4:17236161	C/A	cg22650099	chr4:17144496	NA	0.36	4.93	0.3	1.5e-6	Metabolite levels (Pyroglutamine);
KIRP	cis	rs687432	0.774	rs7949558	chr11:57913286	C/A	cg19752551	chr11:57585705	CTNND1	-0.59	-7.56	-0.43	8.16e-13	Parkinson's disease;
KIRP	cis	rs17123764	0.892	rs12306481	chr12:50124076	T/C	cg20471783	chr12:50157085	TMBIM6	0.41	5.87	0.35	1.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg22717608	chr11:34937665	PDHX;APIP	-0.4	-4.91	-0.3	1.67e-6	Lung disease severity in cystic fibrosis;
KIRP	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.74	9.33	0.51	6.49e-18	Corneal astigmatism;
KIRP	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg23803603	chr1:2058230	PRKCZ	-0.36	-5.55	-0.33	7.28e-8	Height;
KIRP	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.6	7.67	0.44	3.91e-13	Aortic root size;
KIRP	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.21	-0.32	4.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs732765	1.000	rs732765	chr14:75365729	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.46	-5.76	-0.34	2.53e-8	Non-small cell lung cancer;
KIRP	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.64	9.28	0.51	9.23e-18	Hip circumference;
KIRP	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.48	-7.45	-0.43	1.55e-12	IgG glycosylation;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18197146	chr6:41747905	FRS3;PRICKLE4	-0.59	-6.56	-0.39	3.1e-10	Menopause (age at onset);
KIRP	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.46	6.34	0.37	1.09e-9	Coronary artery disease;
KIRP	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.47	7.8	0.45	1.78e-13	Erythrocyte sedimentation rate;
KIRP	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.43	6.16	0.37	2.89e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg18306943	chr3:40428807	ENTPD3	0.48	6.54	0.38	3.54e-10	Renal cell carcinoma;
KIRP	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-4.94	-0.3	1.42e-6	Platelet distribution width;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg02619135	chr3:51428440	RBM15B	0.68	6.21	0.37	2.24e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.87	-0.53	1.39e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6690583	0.623	rs6679539	chr1:85479457	G/T	cg22153463	chr1:85462885	MCOLN2	-0.61	-5.3	-0.32	2.51e-7	Serum sulfate level;
KIRP	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.84	-9.71	-0.53	4.35e-19	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs16828019	0.777	rs12739052	chr1:41464455	C/A	cg03387723	chr1:41708464	SCMH1	-0.75	-6.0	-0.36	6.86e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05737417	chr18:29522262	KIAA1012	-0.49	-6.32	-0.37	1.19e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.69	9.58	0.52	1.08e-18	Longevity;
KIRP	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg23479056	chr15:41276147	INO80	-0.43	-6.26	-0.37	1.74e-9	Menopause (age at onset);
KIRP	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-1.06	-9.44	-0.52	3.09e-18	Thyroid stimulating hormone;
KIRP	trans	rs61904987	0.631	rs115800833	chr11:113741122	G/A	cg02842869	chr17:79921131	NA	0.37	6.35	0.38	1.05e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs1355223	0.902	rs860712	chr11:34743494	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg25547332	chr5:131281432	NA	0.46	5.33	0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13185784	0.703	rs6894217	chr5:179667806	G/A	cg23248424	chr5:179741104	GFPT2	0.49	5.45	0.33	1.24e-7	TRAIL levels;
KIRP	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg05991184	chr2:219186017	PNKD	0.36	5.1	0.31	6.71e-7	Colorectal cancer;
KIRP	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg00792783	chr2:198669748	PLCL1	0.46	5.4	0.33	1.55e-7	Intracranial aneurysm;
KIRP	cis	rs6838801	0.725	rs1493362	chr4:77606024	G/A	cg17476223	chr4:77663285	SHROOM3	0.52	7.09	0.41	1.45e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs7267005	0.661	rs78595762	chr20:34394462	A/G	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	1.1	12.09	0.61	1.05e-26	Post bronchodilator FEV1;
KIRP	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.13	-0.61	7.34e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs864537	0.676	rs2949669	chr1:167417884	C/T	cg22356347	chr1:167427500	CD247	-0.46	-6.14	-0.36	3.22e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.92	-0.35	1.1e-8	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09427374	chr2:86095320	ST3GAL5	0.45	6.2	0.37	2.33e-9	Survival in pancreatic cancer;
KIRP	cis	rs2411233	1.000	rs12910064	chr15:39283736	T/A	cg02291532	chr15:39874776	THBS1	0.38	5.17	0.31	4.92e-7	Platelet count;
KIRP	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg24009623	chr19:33667908	NA	0.5	6.19	0.37	2.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02073427	chr10:15252052	NA	0.54	6.71	0.39	1.33e-10	Smoking initiation;
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.83	0.4	6.44e-11	Electroencephalogram traits;
KIRP	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.22	0.32	3.87e-7	Blood metabolite levels;
KIRP	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.33	-0.42	3.27e-12	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.47	0.43	1.41e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4132509	0.947	rs320339	chr1:243870910	G/T	cg21452805	chr1:244014465	NA	0.48	5.13	0.31	5.93e-7	RR interval (heart rate);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17313118	chr5:127157258	NA	0.52	6.83	0.4	6.8e-11	Interleukin-4 levels;
KIRP	cis	rs17121403	0.661	rs12137577	chr1:100518672	A/G	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg23335576	chr14:104009727	NA	0.38	5.47	0.33	1.12e-7	Body mass index;
KIRP	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg10253484	chr15:75165896	SCAMP2	0.55	5.89	0.35	1.28e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg25039879	chr17:56429692	SUPT4H1	0.58	5.13	0.31	5.85e-7	Cognitive test performance;
KIRP	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg07274523	chr3:49395745	GPX1	0.69	8.35	0.47	5.14e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	7.18	0.42	8.17e-12	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07923305	chr1:46598507	PIK3R3	0.54	6.29	0.37	1.42e-9	Smoking initiation;
KIRP	cis	rs10203711	0.966	rs6716938	chr2:239599283	A/G	cg14580085	chr2:239553406	NA	0.4	5.3	0.32	2.59e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.65	7.75	0.44	2.43e-13	Testicular germ cell tumor;
KIRP	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.35	0.62	1.34e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg25566285	chr7:158114605	PTPRN2	-0.77	-12.65	-0.63	1.36e-28	Calcium levels;
KIRP	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs6670533	0.571	rs56404812	chr1:24864228	A/T	cg07475527	chr1:24864545	NA	-0.89	-6.22	-0.37	2.13e-9	Fasting blood insulin (BMI interaction);
KIRP	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.7	-0.56	3.53e-22	Breast cancer;
KIRP	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.54	-0.38	3.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs860413	0.502	rs62352047	chr5:36028451	G/A	cg19897071	chr5:35991382	UGT3A1	0.6	5.71	0.34	3.22e-8	Primary biliary cholangitis;
KIRP	trans	rs61931739	0.620	rs4323992	chr12:33693639	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-6.12	-0.36	3.72e-9	Morning vs. evening chronotype;
KIRP	cis	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg19680485	chr15:31195859	MTMR15	-0.52	-4.89	-0.3	1.8e-6	Hypertriglyceridemia;
KIRP	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg25019033	chr10:957182	NA	0.41	5.43	0.33	1.37e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg01304814	chr3:48885189	PRKAR2A	0.54	5.02	0.3	1.01e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg23335576	chr14:104009727	NA	0.39	5.43	0.33	1.33e-7	Body mass index;
KIRP	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.89	-0.45	9.74e-14	Retinal vascular caliber;
KIRP	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.03	-0.58	3.04e-23	Height;
KIRP	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg10760299	chr15:45669010	GATM	0.35	5.11	0.31	6.47e-7	Homoarginine levels;
KIRP	cis	rs1035491	0.715	rs2366903	chr5:63923711	G/C	cg01791865	chr5:63954708	NA	0.33	5.2	0.31	4.12e-7	Body mass index;
KIRP	cis	rs7849270	0.959	rs2297111	chr9:131904294	G/A	cg13538475	chr9:131942899	NA	-0.35	-5.71	-0.34	3.26e-8	Blood metabolite ratios;
KIRP	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg10517650	chr3:113235015	CCDC52	-0.53	-6.33	-0.37	1.17e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg24579218	chr15:68104479	NA	0.32	4.92	0.3	1.62e-6	Motion sickness;
KIRP	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.59	0.39	2.6200000000000003e-10	Educational attainment;
KIRP	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.67	-6.15	-0.37	3.09e-9	Tuberculosis;
KIRP	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.35	-0.42	2.98e-12	Mood instability;
KIRP	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-4.99	-0.3	1.12e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.45	0.38	5.85e-10	Breast cancer;
KIRP	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	9.89	0.53	1.21e-19	Blood protein levels;
KIRP	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg16558253	chr16:72132732	DHX38	-0.44	-5.37	-0.32	1.82e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9400467	0.537	rs73528983	chr6:111433641	A/G	cg15721981	chr6:111408429	SLC16A10	0.7	6.3	0.37	1.33e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs35740288	0.770	rs11630286	chr15:86202529	T/C	cg17133734	chr15:86042851	AKAP13	-0.5	-5.63	-0.34	4.92e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-1.06	-17.66	-0.75	1.28e-45	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11654769	chr5:148206180	ADRB2	0.47	6.2	0.37	2.38e-9	Smoking initiation;
KIRP	cis	rs2377585	0.563	rs10842109	chr12:8841077	G/A	cg03761649	chr12:8850719	RIMKLB	0.49	4.9	0.3	1.72e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-6.07	-0.36	4.74e-9	Morning vs. evening chronotype;
KIRP	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.71	-9.55	-0.52	1.35e-18	Longevity;
KIRP	cis	rs7122257	0.507	rs2403459	chr11:11146473	G/A	cg16931664	chr11:11169707	NA	-0.4	-5.19	-0.31	4.37e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.9	-0.35	1.17e-8	Diastolic blood pressure;
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg02696790	chr15:75250997	RPP25	0.32	5.5	0.33	9.61e-8	Breast cancer;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg27532560	chr4:187881888	NA	-0.74	-12.39	-0.62	9.92e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4262150	0.508	rs4342320	chr5:151909029	T/A	cg12297329	chr5:152029980	NA	-0.71	-8.85	-0.49	1.73e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg23625390	chr15:77176239	SCAPER	0.5	6.55	0.39	3.4e-10	Blood metabolite levels;
KIRP	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Bipolar disorder;
KIRP	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg19847866	chr10:1019161	NA	0.46	5.34	0.32	2.13e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4262150	0.960	rs7736377	chr5:152309801	G/A	cg12297329	chr5:152029980	NA	0.49	6.9	0.4	4.36e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg19875535	chr5:140030758	IK	0.64	8.75	0.49	3.4e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg21775007	chr8:11205619	TDH	0.43	5.67	0.34	3.91e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg14092571	chr14:90743983	NA	0.42	5.16	0.31	5.15e-7	Mortality in heart failure;
KIRP	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.54	-0.43	9.13e-13	Height;
KIRP	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.81	11.71	0.6	1.85e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.97	-16.74	-0.73	1.72e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs7660760	0.606	rs17063303	chr4:177497111	C/T	cg11970806	chr17:56066485	VEZF1	-0.42	-6.62	-0.39	2.2e-10	Left ventricle wall thickness;
KIRP	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.69	-0.34	3.65e-8	Fear of minor pain;
KIRP	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg13271783	chr10:134563150	INPP5A	-0.47	-5.84	-0.35	1.62e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.83	-10.4	-0.55	3.22e-21	Vitamin D levels;
KIRP	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.6	7.18	0.42	8.06e-12	Platelet count;
KIRP	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg18753928	chr3:113234510	CCDC52	-0.55	-5.57	-0.33	6.69e-8	Dental caries;
KIRP	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04309227	chr1:26561027	CCDC21	0.58	6.83	0.4	6.51e-11	Smoking initiation;
KIRP	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg06289844	chr6:126071538	HEY2	0.35	4.88	0.3	1.93e-6	Brugada syndrome;
KIRP	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.87e-32	Mean platelet volume;
KIRP	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg15226275	chr6:116381976	FRK	0.21	5.69	0.34	3.57e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.96	0.36	8.57e-9	Lung cancer;
KIRP	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.22	16.64	0.73	3.75e-42	White matter hyperintensity burden;
KIRP	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.68	8.96	0.5	8.21e-17	Motion sickness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12133103	chr8:75946479	CRISPLD1	-0.39	-6.25	-0.37	1.84e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.27	-0.37	1.65e-9	Breast cancer;
KIRP	cis	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-5.46	-0.33	1.17e-7	Myopia (pathological);
KIRP	cis	rs59698941	0.527	rs1032764	chr5:132185419	A/C	cg14825688	chr5:132208181	LEAP2	-0.37	-4.95	-0.3	1.36e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs62229266	0.804	rs12483151	chr21:37419578	C/T	cg12218747	chr21:37451666	NA	-0.43	-5.42	-0.33	1.42e-7	Mitral valve prolapse;
KIRP	cis	rs12208915	0.848	rs9350786	chr6:79517306	G/T	cg18132916	chr6:79620363	NA	0.54	5.1	0.31	6.69e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg03714773	chr7:91764589	CYP51A1	-0.38	-5.46	-0.33	1.17e-7	Breast cancer;
KIRP	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs6058796	0.892	rs6141780	chr20:31262423	C/G	cg13636640	chr20:31349939	DNMT3B	-0.58	-5.1	-0.31	6.86e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg06243866	chr13:111019493	COL4A2	-0.78	-12.23	-0.61	3.58e-27	Coronary artery disease;
KIRP	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg05973401	chr12:123451056	ABCB9	-0.49	-5.47	-0.33	1.12e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.33	-0.37	1.15e-9	Hemoglobin concentration;
KIRP	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.23	-24.88	-0.85	4.03e-69	Exhaled nitric oxide output;
KIRP	cis	rs6577655	0.517	rs11998030	chr8:135585325	C/T	cg17885191	chr8:135476712	NA	0.66	6.55	0.39	3.25e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04733431	chr4:39640740	C4orf34	0.48	6.46	0.38	5.43e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.99	12.13	0.61	7.29e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg20673841	chr7:107026890	COG5	-0.4	-5.02	-0.3	9.89e-7	Coronary artery disease;
KIRP	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg17736920	chr1:242011382	EXO1	0.42	5.14	0.31	5.66e-7	Menopause (age at onset);
KIRP	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg23920097	chr1:209922102	NA	0.41	5.47	0.33	1.11e-7	Red blood cell count;
KIRP	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.61	-8.61	-0.48	8.65e-16	Menarche (age at onset);
KIRP	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs2904967	0.929	rs1195733	chr11:65016838	C/A	cg12562828	chr11:65076843	NA	-0.48	-7.18	-0.42	8.45e-12	Mean corpuscular volume;
KIRP	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.57	0.33	6.71e-8	Ovarian reserve;
KIRP	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.86	-8.61	-0.48	8.68e-16	Obesity-related traits;
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg18402987	chr7:1209562	NA	0.44	5.04	0.31	9.11e-7	Longevity;Endometriosis;
KIRP	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg23422044	chr7:1970798	MAD1L1	-0.69	-7.03	-0.41	2.03e-11	Bipolar disorder;
KIRP	cis	rs829661	0.532	rs11678346	chr2:30767508	C/T	cg10949345	chr2:30726833	LCLAT1	0.41	5.8	0.35	2.03e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12360000	0.797	rs12768776	chr10:1901587	C/T	cg26364871	chr10:1889757	NA	-0.57	-6.95	-0.41	3.28e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg05156742	chr15:59063176	FAM63B	0.57	7.26	0.42	5.18e-12	Schizophrenia;
KIRP	trans	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.38	-0.43	2.39e-12	Blood trace element (Cu levels);
KIRP	cis	rs4478137	0.931	rs56233753	chr4:164249023	A/G	cg06758707	chr4:164254230	NPY1R	0.69	8.81	0.49	2.29e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.45	-0.38	5.8e-10	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23396974	chr7:45151349	TBRG4	0.52	6.81	0.4	7.26e-11	Parkinson's disease;
KIRP	cis	rs17121403	0.661	rs12143495	chr1:100464364	A/G	cg24955406	chr1:100503596	HIAT1	0.75	4.99	0.3	1.12e-6	Pulmonary function decline;
KIRP	cis	rs11997175	0.646	rs7386741	chr8:33769709	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	6.41	0.38	7.17e-10	Body mass index;
KIRP	cis	rs4129585	0.521	rs8180995	chr8:143326237	A/G	cg24996280	chr8:143481281	TSNARE1	0.39	5.48	0.33	1.06e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg05692746	chr2:100937584	LONRF2	-0.41	-5.32	-0.32	2.31e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06891663	chr14:74227101	C14orf43	0.54	6.76	0.4	9.76e-11	Parkinson's disease;
KIRP	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg16851402	chr8:90636522	NA	0.51	6.47	0.38	5.14e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg10664184	chr19:17420304	DDA1	0.72	8.39	0.47	3.72e-15	Systemic lupus erythematosus;
KIRP	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00632549	chr16:90063942	AFG3L1	0.57	6.86	0.4	5.62e-11	Interleukin-4 levels;
KIRP	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.7	8.94	0.5	9.64e-17	Blood metabolite levels;
KIRP	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.46	-0.38	5.62e-10	Monocyte percentage of white cells;
KIRP	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.46	8.62	0.48	8.39e-16	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs198389	0.589	rs12404124	chr1:11873869	A/C	cg24844545	chr1:11908347	NPPA	-0.35	-5.07	-0.31	7.88e-7	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
KIRP	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.77	0.44	2.19e-13	Morning vs. evening chronotype;
KIRP	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg10845886	chr2:3471009	TTC15	-0.54	-7.91	-0.45	8.99e-14	Neurofibrillary tangles;
KIRP	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.77	6.8	0.4	7.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg02023728	chr11:77925099	USP35	-0.29	-5.04	-0.31	8.95e-7	Alzheimer's disease (survival time);
KIRP	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg01843034	chr6:37503916	NA	-0.67	-8.86	-0.49	1.67e-16	Cognitive performance;
KIRP	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	5.32	0.32	2.34e-7	Menarche (age at onset);
KIRP	cis	rs7712401	0.601	rs34707663	chr5:122320463	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06492699	chr3:39149242	GORASP1;TTC21A	-0.45	-6.1	-0.36	4.05e-9	Metabolic traits;
KIRP	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs7560272	0.538	rs11126415	chr2:73936500	C/T	cg20560298	chr2:73613845	ALMS1	0.47	5.61	0.34	5.53e-8	Schizophrenia;
KIRP	cis	rs9381107	0.932	rs9394703	chr6:9455062	C/T	cg14735645	chr6:9486422	NA	0.45	5.34	0.32	2.11e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.47	-5.62	-0.34	5.22e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs675026	0.926	rs660756	chr6:154415434	G/T	cg07813322	chr6:154414604	OPRM1	-0.57	-7.35	-0.42	2.86e-12	Hypertension;
KIRP	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	cg21523751	chr1:182988639	NA	-0.43	-6.7	-0.39	1.44e-10	Hypertriglyceridemia;
KIRP	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg07005513	chr11:61595956	FADS2	-0.57	-4.95	-0.3	1.37e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.48	1.43e-15	Motion sickness;
KIRP	cis	rs6708331	0.564	rs4632370	chr2:70376825	A/T	cg05298696	chr2:70188691	ASPRV1	-0.46	-6.13	-0.36	3.51e-9	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23281280	chr6:28129359	ZNF389	0.46	5.16	0.31	5.09e-7	Depression;
KIRP	cis	rs2625529	0.689	rs4526973	chr15:72138719	A/G	cg16672083	chr15:72433130	SENP8	-0.44	-6.14	-0.36	3.27e-9	Red blood cell count;
KIRP	cis	rs6725041	0.717	rs10168128	chr2:213097908	C/A	cg20637307	chr2:213403960	ERBB4	-0.39	-5.24	-0.32	3.45e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.76	-10.47	-0.56	1.82e-21	Blood metabolite levels;
KIRP	cis	rs7614311	0.681	rs6776209	chr3:63858633	G/C	cg22134162	chr3:63841271	THOC7	-0.39	-5.14	-0.31	5.58e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs10073892	0.660	rs35664711	chr5:101959194	C/T	cg19774478	chr5:101632501	SLCO4C1	0.54	5.31	0.32	2.39e-7	Cognitive decline (age-related);
KIRP	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-0.93	-8.28	-0.47	7.74e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4737010	0.578	rs4466386	chr8:41679853	A/G	cg08923054	chr8:41654455	ANK1	0.57	6.91	0.4	4.03e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.24	0.8	1.38e-57	Prudent dietary pattern;
KIRP	cis	rs7523050	0.908	rs12405585	chr1:109397229	C/A	cg08274380	chr1:109419600	GPSM2	0.66	6.26	0.37	1.69e-9	Fat distribution (HIV);
KIRP	cis	rs6942756	0.876	rs822039	chr7:129065774	A/G	cg02491457	chr7:128862824	NA	-0.56	-6.46	-0.38	5.55e-10	White matter hyperintensity burden;
KIRP	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.47	-9.29	-0.51	8.79e-18	Longevity;
KIRP	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg18944383	chr4:111397179	ENPEP	0.41	6.35	0.38	1.03e-9	Coronary artery disease;
KIRP	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.41	-0.47	3.44e-15	Common traits (Other);
KIRP	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-7.59	-0.44	6.68e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.19	0.42	7.7e-12	Height;
KIRP	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg20636351	chr8:55087400	NA	-0.63	-7.83	-0.45	1.45e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.94	-0.3	1.43e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.25	0.62	3.02e-27	Bladder cancer;
KIRP	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg23460707	chr10:133558971	NA	0.35	5.34	0.32	2.07e-7	Survival in rectal cancer;
KIRP	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-6.53	-0.38	3.84e-10	Colorectal cancer;
KIRP	cis	rs2708977	0.730	rs674920	chr2:97070156	C/G	cg22654517	chr2:96458247	NA	0.33	5.22	0.32	3.89e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9912468	0.738	rs12945884	chr17:64300281	T/C	cg19474267	chr17:64306194	PRKCA	-0.58	-7.74	-0.44	2.6e-13	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg11569703	chr11:65557185	OVOL1	0.74	13.39	0.65	4.4e-31	Acne (severe);
KIRP	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.58	-0.44	7.08e-13	Retinal vascular caliber;
KIRP	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.57	8.17	0.46	1.66e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72627123	0.867	rs73303107	chr14:74477284	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.17	0.37	2.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs7172677	1.000	rs2029520	chr15:75415768	A/G	cg10253484	chr15:75165896	SCAMP2	-0.53	-5.76	-0.34	2.55e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg03999872	chr20:62272968	STMN3	0.62	7.11	0.41	1.27e-11	Atopic dermatitis;
KIRP	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.55	7.19	0.42	7.87e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.52	-6.35	-0.38	1.01e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19717773	chr7:2847554	GNA12	-0.37	-6.48	-0.38	5.02e-10	Height;
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.88	-0.45	1.07e-13	Platelet count;
KIRP	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-12.08	-0.61	1.13e-26	Morning vs. evening chronotype;
KIRP	cis	rs6942756	0.531	rs7800983	chr7:128971130	C/T	cg15488143	chr7:128924101	AHCYL2	-0.46	-6.07	-0.36	4.84e-9	White matter hyperintensity burden;
KIRP	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg18190219	chr22:46762943	CELSR1	-0.72	-7.58	-0.44	7.01e-13	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.78	10.61	0.56	6.54e-22	Resting heart rate;
KIRP	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg07741184	chr6:167504864	NA	0.24	6.53	0.38	3.77e-10	Crohn's disease;
KIRP	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	0.94	11.06	0.58	2.41e-23	Testicular germ cell tumor;
KIRP	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.59	0.44	6.48e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg07451762	chr16:28383216	NA	0.38	4.93	0.3	1.52e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg17366294	chr4:99064904	C4orf37	-0.36	-4.99	-0.3	1.13e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9309473	1.000	rs3813227	chr2:73651967	A/G	cg20560298	chr2:73613845	ALMS1	0.45	5.27	0.32	2.95e-7	Metabolite levels;
KIRP	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.54	0.33	7.68e-8	Putamen volume;
KIRP	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg00990874	chr7:1149470	C7orf50	-0.83	-7.41	-0.43	1.96e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg06565975	chr8:143823917	SLURP1	-0.48	-7.48	-0.43	1.29e-12	Urinary tract infection frequency;
KIRP	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.55	-6.3	-0.37	1.37e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9398803	0.835	rs9321065	chr6:126744087	G/A	cg19875578	chr6:126661172	C6orf173	0.49	6.44	0.38	6.13e-10	Male-pattern baldness;
KIRP	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg14768367	chr16:72042858	DHODH	-1.06	-11.56	-0.59	5.88e-25	Blood protein levels;
KIRP	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-11.92	-0.6	3.77e-26	Systemic lupus erythematosus;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.71	-9.64	-0.52	7.29e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg16141378	chr3:129829833	LOC729375	0.53	7.01	0.41	2.27e-11	Retinal vascular caliber;
KIRP	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.69	-0.39	1.51e-10	Menopause (age at onset);
KIRP	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg25547332	chr5:131281432	NA	-0.47	-5.26	-0.32	3.19e-7	Life satisfaction;
KIRP	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg08975724	chr8:8085496	FLJ10661	-0.67	-9.15	-0.5	2.19e-17	Triglycerides;
KIRP	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.09	-0.31	7.28e-7	Rheumatoid arthritis;
KIRP	cis	rs9815354	0.680	rs57945879	chr3:42038842	C/G	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg02023728	chr11:77925099	USP35	-0.33	-4.94	-0.3	1.46e-6	Alzheimer's disease (survival time);
KIRP	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.49	6.36	0.38	1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg06917634	chr15:78832804	PSMA4	0.67	6.99	0.41	2.57e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg16988262	chr1:15930761	NA	0.4	5.11	0.31	6.32e-7	Systolic blood pressure;
KIRP	cis	rs9469913	0.799	rs2744954	chr6:34621470	A/G	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.13	-0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs4664293	0.867	rs3764968	chr2:160647090	C/T	cg08347373	chr2:160653686	CD302	-0.44	-6.53	-0.38	3.83e-10	Monocyte percentage of white cells;
KIRP	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	1.03	20.38	0.79	9.8e-55	Breast cancer;
KIRP	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg13770153	chr20:60521292	NA	-0.43	-5.08	-0.31	7.5e-7	Body mass index;
KIRP	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.66	-7.66	-0.44	4.38e-13	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg00656387	chr3:40428638	ENTPD3	0.38	4.96	0.3	1.3e-6	Renal cell carcinoma;
KIRP	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20135002	chr11:47629003	NA	-0.45	-5.3	-0.32	2.63e-7	Subjective well-being;
KIRP	trans	rs7939886	0.920	rs74962317	chr11:56036589	C/T	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg01798813	chr17:3906674	NA	-0.57	-8.08	-0.46	2.94e-14	Type 2 diabetes;
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg15147215	chr3:52552868	STAB1	0.33	5.77	0.35	2.34e-8	Electroencephalogram traits;
KIRP	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.54	-7.07	-0.41	1.57e-11	Schizophrenia;
KIRP	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-11.31	-0.59	3.59e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7615316	0.779	rs6802631	chr3:142080583	G/T	cg20824294	chr3:142316082	PLS1	0.24	5.52	0.33	8.39e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.8	11.73	0.6	1.55e-25	Bladder cancer;
KIRP	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-11.09	-0.58	1.99e-23	Personality dimensions;
KIRP	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.68	9.67	0.52	5.78e-19	Mean platelet volume;
KIRP	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg00405596	chr8:11794950	NA	0.56	6.83	0.4	6.62e-11	Mood instability;
KIRP	cis	rs9914988	0.560	rs731970	chr17:27266440	C/T	cg10538030	chr17:27276405	PHF12	-0.6	-5.13	-0.31	5.77e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.85	-0.49	1.74e-16	Neuroticism;
KIRP	cis	rs4356975	0.563	rs7659306	chr4:69950278	T/A	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.77	-0.44	2.09e-13	Retinal vascular caliber;
KIRP	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.25	11.68	0.6	2.36e-25	Diabetic retinopathy;
KIRP	cis	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg06521331	chr12:34319734	NA	-0.61	-7.36	-0.42	2.77e-12	Morning vs. evening chronotype;
KIRP	cis	rs9900972	0.918	rs8065599	chr17:76877073	T/C	cg20937029	chr17:76870563	TIMP2	0.46	5.31	0.32	2.41e-7	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.97	0.36	8.09e-9	Platelet count;
KIRP	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-7.0	-0.41	2.46e-11	Daytime sleep phenotypes;
KIRP	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.62	9.98	0.54	6.62e-20	Prostate cancer;
KIRP	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg18016565	chr1:150552671	MCL1	0.4	6.06	0.36	5e-9	Melanoma;
KIRP	cis	rs6693295	1.000	rs10924472	chr1:246222160	A/C	cg11798871	chr1:246315928	SMYD3	-0.44	-5.21	-0.32	4e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.22	-0.51	1.4e-17	Parkinson's disease;
KIRP	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14159672	chr1:205819179	PM20D1	0.48	5.38	0.32	1.72e-7	Parkinson's disease;
KIRP	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	cg12689670	chr1:183009347	LAMC1	0.42	6.12	0.36	3.75e-9	Colorectal cancer;
KIRP	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.02	-0.41	2.13e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.56	8.0	0.45	4.83e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.35	5.19	0.31	4.33e-7	Hypertriglyceridemia;
KIRP	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6807915	0.647	rs310756	chr3:12277612	C/T	cg15873301	chr3:12045459	SYN2	0.38	5.03	0.31	9.56e-7	Leprosy;
KIRP	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.51	-0.33	9.16e-8	IgG glycosylation;
KIRP	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18252515	chr7:66147081	NA	0.4	4.85	0.3	2.2e-6	Aortic root size;
KIRP	trans	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg06521331	chr12:34319734	NA	-0.52	-6.34	-0.37	1.08e-9	Bladder cancer;
KIRP	cis	rs920590	0.643	rs3855754	chr8:19659499	C/G	cg03894339	chr8:19674705	INTS10	0.41	4.95	0.3	1.39e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.57	0.33	6.76e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg07001201	chr5:642380	CEP72	0.66	6.06	0.36	4.99e-9	Obesity-related traits;
KIRP	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg24807547	chr6:37504484	NA	-0.6	-8.96	-0.5	8.55e-17	Cognitive performance;
KIRP	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.98	-0.36	7.98e-9	Breast cancer;
KIRP	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg04691961	chr3:161091175	C3orf57	-0.5	-7.61	-0.44	5.98e-13	Morning vs. evening chronotype;
KIRP	cis	rs28489187	0.577	rs3920521	chr1:85848866	A/C	cg16011679	chr1:85725395	C1orf52	0.46	5.68	0.34	3.75e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.81	-11.33	-0.59	3.23e-24	Educational attainment;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.58	5.32	0.32	2.3e-7	Alzheimer's disease;
KIRP	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.4	5.56	0.33	6.95e-8	Endometrial cancer;
KIRP	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs7116495	0.881	rs1892921	chr11:71702138	G/A	cg11196788	chr11:71737549	NUMA1	0.56	5.04	0.31	9.07e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21240523	chr9:130965902	CIZ1;DNM1	0.47	6.07	0.36	4.81e-9	Parkinson's disease;
KIRP	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.31	-0.62	1.85e-27	Primary sclerosing cholangitis;
KIRP	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg00204512	chr16:28754710	NA	0.41	5.07	0.31	7.77e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.81	7.29	0.42	4.17e-12	Obesity-related traits;
KIRP	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg19743168	chr1:23544995	NA	-0.49	-6.48	-0.38	4.87e-10	Height;
KIRP	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.73	-8.43	-0.47	2.94e-15	Diastolic blood pressure;
KIRP	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05601917	chr6:125855416	NA	-0.33	-4.96	-0.3	1.29e-6	Brugada syndrome;
KIRP	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.74	-12.09	-0.61	9.95e-27	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs12449568	0.874	rs11652141	chr17:54410266	T/G	cg04456437	chr3:119217424	C3orf1	0.48	6.12	0.36	3.66e-9	Height;
KIRP	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg03653399	chr8:142233436	SLC45A4	-0.56	-6.98	-0.41	2.77e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg03465714	chr1:152285911	FLG	0.48	5.39	0.33	1.64e-7	Atopic dermatitis;
KIRP	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg10617943	chr7:1981403	MAD1L1	-0.36	-4.97	-0.3	1.28e-6	Neuroticism;
KIRP	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-5.77	-0.35	2.36e-8	Parkinson's disease;
KIRP	cis	rs6681460	1.000	rs1562217	chr1:67073566	C/T	cg13052034	chr1:66999238	SGIP1	-0.38	-5.18	-0.31	4.62e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg19743168	chr1:23544995	NA	0.52	7.29	0.42	4.27e-12	Height;
KIRP	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg00204512	chr16:28754710	NA	0.48	6.23	0.37	2.03e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.43	7.62	0.44	5.58e-13	Systemic lupus erythematosus;
KIRP	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-7.46	-0.43	1.44e-12	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg22676075	chr6:135203613	NA	0.49	6.95	0.41	3.3e-11	Red blood cell count;
KIRP	cis	rs55962025	0.842	rs363088	chr4:3210330	A/T	cg06533319	chr4:3265114	C4orf44	0.47	4.97	0.3	1.28e-6	Parental longevity (mother's age at death);
KIRP	cis	rs6504622	0.905	rs2317997	chr17:45027648	T/C	cg24703533	chr17:45055318	NA	0.38	5.31	0.32	2.39e-7	Orofacial clefts;
KIRP	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.63	-0.34	4.98e-8	Renal cell carcinoma;
KIRP	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.5	-6.24	-0.37	1.94e-9	Post bronchodilator FEV1;
KIRP	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg19402173	chr7:128379420	CALU	-0.6	-8.08	-0.46	2.83e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg12591125	chr7:1885375	MAD1L1	0.58	5.81	0.35	1.9e-8	Bipolar disorder;
KIRP	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg05347473	chr6:146136440	FBXO30	0.47	6.82	0.4	7.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg10047753	chr17:41438598	NA	0.86	11.65	0.6	2.81e-25	Menopause (age at onset);
KIRP	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg23587288	chr2:27483067	SLC30A3	-0.54	-6.83	-0.4	6.48e-11	Blood metabolite levels;
KIRP	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.71	-11.25	-0.58	5.64e-24	Hepatocellular carcinoma;
KIRP	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.77	-10.17	-0.54	1.65e-20	Body mass index;
KIRP	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg08603382	chr10:743973	NA	-0.51	-7.38	-0.43	2.42e-12	Psychosis in Alzheimer's disease;
KIRP	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.63e-8	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17524854	chr12:67663046	CAND1	0.56	6.8	0.4	7.75e-11	Smoking initiation;
KIRP	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.96	15.19	0.7	3.33e-37	Monocyte count;
KIRP	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs2224391	0.518	rs17736905	chr6:5291511	G/A	cg13962347	chr6:5174647	LYRM4	-0.7	-6.28	-0.37	1.49e-9	Height;
KIRP	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg19000871	chr14:103996768	TRMT61A	0.79	9.42	0.51	3.48e-18	Coronary artery disease;
KIRP	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.12	-0.5	2.68e-17	Hirschsprung disease;
KIRP	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs62413470	1.000	rs17683841	chr6:55944441	C/T	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.4	-6.24	-0.37	1.87e-9	Body mass index;
KIRP	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg08126542	chr6:37504118	NA	-0.68	-9.56	-0.52	1.3e-18	Cognitive performance;
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg06654118	chr4:1303317	MAEA	0.27	5.12	0.31	6.31e-7	Longevity;
KIRP	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.71	8.99	0.5	6.71e-17	Morning vs. evening chronotype;
KIRP	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.62	6.74	0.39	1.1e-10	Eotaxin levels;
KIRP	trans	rs11023787	1.000	rs12280756	chr11:15928731	C/T	cg19973338	chr17:76141249	C17orf99	0.49	6.26	0.37	1.73e-9	Bone mineral density (wrist);
KIRP	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.75	-0.34	2.58e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg07862535	chr7:139043722	LUC7L2	0.47	5.35	0.32	2.03e-7	Diisocyanate-induced asthma;
KIRP	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.61	-8.72	-0.49	4.27e-16	Total body bone mineral density;
KIRP	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg18154014	chr19:37997991	ZNF793	0.68	6.04	0.36	5.79e-9	Coronary artery calcification;
KIRP	cis	rs11209002	1.000	rs2863202	chr1:67584335	T/C	cg02640540	chr1:67518911	SLC35D1	0.57	4.9	0.3	1.73e-6	Crohn's disease;
KIRP	trans	rs3779273	0.740	rs4727630	chr7:77834201	A/G	cg05596911	chr5:118502651	DMXL1	-0.4	-6.53	-0.38	3.81e-10	Body mass index;
KIRP	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg16989719	chr2:238392110	NA	-0.56	-7.7	-0.44	3.27e-13	Prostate cancer;
KIRP	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg13319975	chr6:146136371	FBXO30	0.54	7.44	0.43	1.71e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.37	0.65	5.21e-31	Platelet count;
KIRP	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.55	-7.92	-0.45	8.23e-14	Colorectal cancer;
KIRP	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	1.02	18.36	0.76	5.48e-48	Breast cancer;
KIRP	cis	rs7027203	0.557	rs9299411	chr9:96523104	C/A	cg14598338	chr9:96623480	NA	-0.44	-6.69	-0.39	1.49e-10	DNA methylation (variation);
KIRP	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.74	9.48	0.52	2.18e-18	Migraine;Coronary artery disease;
KIRP	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg16924664	chr22:36878180	TXN2	0.4	4.86	0.3	2.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg05692746	chr2:100937584	LONRF2	-0.39	-5.06	-0.31	8.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7174755	0.608	rs10162905	chr15:68396047	A/G	cg17095910	chr15:68523075	CLN6	0.38	4.9	0.3	1.7e-6	Major depressive disorder;
KIRP	cis	rs2071426	0.959	rs11188144	chr10:96789707	C/G	cg09036531	chr10:96991505	NA	-0.62	-6.74	-0.39	1.13e-10	Blood metabolite levels;
KIRP	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.39	5.53	0.33	8.32e-8	Coronary artery disease;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.7	-0.34	3.48e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg02784301	chr16:23194194	SCNN1G	-0.47	-6.23	-0.37	1.96e-9	Blood metabolite levels;
KIRP	cis	rs2130392	0.542	rs4862407	chr4:185654683	T/C	cg21366198	chr4:185655624	MLF1IP	0.42	5.65	0.34	4.43e-8	Kawasaki disease;
KIRP	cis	rs357618	0.897	rs357630	chr5:150851258	A/G	cg22672639	chr5:150884813	FAT2	0.36	5.37	0.32	1.81e-7	Basophil percentage of white cells;
KIRP	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.78	-9.21	-0.51	1.46e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg06060754	chr5:176797920	RGS14	-0.6	-6.94	-0.4	3.49e-11	Urate levels in lean individuals;
KIRP	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.49	2.59e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7590368	0.715	rs7571007	chr2:10961297	C/T	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg09873164	chr1:152488093	CRCT1	0.51	6.43	0.38	6.44e-10	Hair morphology;
KIRP	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	0.62	5.2	0.31	4.1e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2692947	0.727	rs2692950	chr2:96673524	T/C	cg23100626	chr2:96804247	ASTL	0.42	5.65	0.34	4.43e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.49	-4.98	-0.3	1.22e-6	Alzheimer's disease;
KIRP	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	6.86	0.4	5.42e-11	Coffee consumption (cups per day);
KIRP	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.93	0.53	9.33e-20	Schizophrenia;
KIRP	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.91e-9	Response to antipsychotic treatment;
KIRP	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.83	11.88	0.6	5.09e-26	Monocyte count;
KIRP	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg27494647	chr7:150038898	RARRES2	0.37	6.29	0.37	1.4e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg11161011	chr14:65562177	MAX	-0.61	-7.89	-0.45	1.02e-13	Obesity-related traits;
KIRP	cis	rs17373728	0.526	rs9298251	chr8:76155416	C/A	cg07016329	chr8:76221503	NA	0.45	6.03	0.36	6.09e-9	Diabetic kidney disease;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-5.6	-0.34	5.71e-8	Lung cancer;
KIRP	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg19052272	chr2:3704530	ALLC	-0.37	-5.19	-0.31	4.3e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg26134248	chr17:3907702	NA	-0.57	-8.47	-0.48	2.26e-15	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09648697	chr11:66383678	RBM14	0.5	6.24	0.37	1.89e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08673532	chr16:87422913	FBXO31	-0.42	-6.23	-0.37	1.98e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.66	-0.48	6.24e-16	Neuroticism;
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg05941025	chr16:89927596	SPIRE2	0.35	5.48	0.33	1.05e-7	Vitiligo;
KIRP	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19524238	chr7:2802976	GNA12	-0.37	-4.9	-0.3	1.71e-6	Height;
KIRP	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg24826892	chr11:71159390	DHCR7	-0.43	-5.12	-0.31	6.26e-7	Vitamin D levels;
KIRP	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.59	7.23	0.42	5.95e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs26949	0.526	rs10069929	chr5:60040060	A/T	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.35	-0.32	2.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6783573	0.895	rs1049667	chr3:46623690	C/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.55	-7.47	-0.43	1.39e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg21419209	chr3:44054225	NA	-0.71	-8.83	-0.49	2.07e-16	Coronary artery disease;
KIRP	cis	rs6684514	0.961	rs12048077	chr1:156299916	T/A	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.67e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg16797656	chr11:68205561	LRP5	0.51	8.02	0.46	4.42e-14	Total body bone mineral density;
KIRP	cis	rs1978968	1.000	rs11705221	chr22:18443287	T/C	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs7083	0.716	rs687740	chr11:117177603	A/C	cg11523350	chr11:117171073	BACE1	0.3	5.56	0.33	7.1e-8	Blood protein levels;
KIRP	trans	rs10772939	0.574	rs1990698	chr12:16596392	T/G	cg20863947	chr2:120124202	DBI;C2orf76	-0.5	-6.05	-0.36	5.29e-9	Economic and political preferences;
KIRP	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.64	-6.86	-0.4	5.64e-11	Corneal astigmatism;
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg16341495	chr8:142228727	SLC45A4	-0.4	-4.92	-0.3	1.57e-6	Immature fraction of reticulocytes;
KIRP	cis	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.21e-12	Morning vs. evening chronotype;
KIRP	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg19847130	chr8:10466454	RP1L1	0.38	5.79	0.35	2.13e-8	Retinal vascular caliber;
KIRP	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs997295	1.000	rs938875	chr15:67952922	A/G	cg24579218	chr15:68104479	NA	0.35	5.17	0.31	4.91e-7	Motion sickness;
KIRP	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg24044776	chr19:53454761	ZNF816A	-0.45	-6.47	-0.38	5.39e-10	Psoriasis;
KIRP	cis	rs35934224	0.831	rs8141610	chr22:19870147	A/G	cg11182965	chr22:19864308	TXNRD2	0.41	5.78	0.35	2.29e-8	Glaucoma (primary open-angle);
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.4e-8	Life satisfaction;
KIRP	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.47	-0.33	1.09e-7	Metabolite levels;
KIRP	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg11211951	chr8:145729740	GPT	-0.34	-5.64	-0.34	4.7e-8	Age at first birth;
KIRP	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.77	11.16	0.58	1.15e-23	Hip circumference;
KIRP	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs933360	0.585	rs6593173	chr7:50832939	C/T	cg14240098	chr7:50518052	FIGNL1	0.43	4.92	0.3	1.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	trans	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg17145862	chr1:211918768	LPGAT1	-0.54	-6.92	-0.4	3.86e-11	Leprosy;
KIRP	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg07001201	chr5:642380	CEP72	0.69	6.47	0.38	5.38e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9308731	0.591	rs6542350	chr2:111944740	C/T	cg04780086	chr2:111875790	ACOXL	0.38	5.1	0.31	6.72e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs11834862	0.663	rs11246993	chr12:132689052	T/A	cg19601865	chr12:132687172	GALNT9	-0.45	-4.99	-0.3	1.14e-6	Anti-saccade response;
KIRP	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.14	-0.31	5.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.23e-8	Life satisfaction;
KIRP	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg17385448	chr1:15911702	AGMAT	0.24	4.97	0.3	1.23e-6	Systolic blood pressure;
KIRP	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg02612397	chr6:125855124	NA	0.33	4.91	0.3	1.67e-6	Brugada syndrome;
KIRP	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.88	0.63	2.4e-29	Morning vs. evening chronotype;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24396745	chr15:73660614	HCN4	-0.45	-6.28	-0.37	1.49e-9	Myopia;
KIRP	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.48	-6.09	-0.36	4.21e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.51	7.16	0.42	9.09e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.75	9.33	0.51	6.45e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg07741184	chr6:167504864	NA	-0.21	-5.29	-0.32	2.77e-7	Crohn's disease;
KIRP	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.92	-11.87	-0.6	5.25e-26	Blood protein levels;
KIRP	cis	rs10510057	0.637	rs10749324	chr10:121316744	A/C	cg06765389	chr10:121379685	NA	-0.47	-7.5	-0.43	1.15e-12	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs7572644	0.640	rs13027666	chr2:28058433	T/C	cg27432699	chr2:27873401	GPN1	0.47	5.67	0.34	3.96e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.72	11.54	0.59	6.64e-25	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg15556689	chr8:8085844	FLJ10661	0.57	7.31	0.42	3.7e-12	Joint mobility (Beighton score);
KIRP	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.35	19.1	0.77	1.66e-50	Corneal structure;
KIRP	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg00405596	chr8:11794950	NA	0.43	5.58	0.34	6.21e-8	Retinal vascular caliber;
KIRP	cis	rs6547631	0.595	rs34702373	chr2:85927404	C/T	cg24620635	chr2:85921963	GNLY	0.32	5.05	0.31	8.46e-7	Blood protein levels;
KIRP	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg08712631	chr7:1960676	MAD1L1	-0.44	-5.6	-0.34	5.86e-8	Neuroticism;
KIRP	trans	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.63	6.1	0.36	4.19e-9	Ulcerative colitis;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg10547527	chr2:198650123	BOLL	-0.54	-4.86	-0.3	2.08e-6	Ulcerative colitis;
KIRP	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.47	-5.65	-0.34	4.43e-8	Initial pursuit acceleration;
KIRP	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg02569458	chr12:86230093	RASSF9	0.37	5.35	0.32	2.04e-7	Major depressive disorder;
KIRP	cis	rs6546324	0.625	rs2861701	chr2:67855980	T/G	cg15745817	chr2:67799979	NA	-0.65	-7.12	-0.41	1.21e-11	Endometriosis;
KIRP	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.97	0.36	8.12e-9	Total cholesterol levels;
KIRP	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.24	0.32	3.53e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.97	16.42	0.72	2.02e-41	Breast cancer;
KIRP	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-7.44	-0.43	1.7e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9420	0.796	rs685149	chr11:57657413	A/G	cg23127183	chr11:57508653	C11orf31	0.5	6.66	0.39	1.8e-10	Schizophrenia;
KIRP	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg16296679	chr22:42394374	WBP2NL	0.36	4.95	0.3	1.39e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg02792322	chr13:21280448	IL17D	0.33	5.52	0.33	8.42e-8	Dental caries;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.41	8.41	0.47	3.26e-15	Vitiligo;
KIRP	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.81	9.21	0.51	1.53e-17	High light scatter reticulocyte count;
KIRP	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.99	-16.77	-0.73	1.36e-42	Menopause (age at onset);
KIRP	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.69	9.91	0.53	1.04e-19	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	ch.8.33884649F	chr8:33765107	NA	0.59	7.33	0.42	3.21e-12	Body mass index;
KIRP	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg08975724	chr8:8085496	FLJ10661	0.58	7.68	0.44	3.86e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.83	-13.02	-0.64	8.19e-30	Breast cancer;
KIRP	cis	rs876084	0.505	rs4409431	chr8:121104019	C/G	cg06265175	chr8:121136014	COL14A1	0.5	6.28	0.37	1.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08280861	chr8:58055591	NA	-0.72	-6.13	-0.36	3.38e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg02073558	chr3:44770973	ZNF501	0.62	8.89	0.49	1.32e-16	Depressive symptoms;
KIRP	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.83	10.44	0.55	2.32e-21	Gestational age at birth (maternal effect);
KIRP	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg25039879	chr17:56429692	SUPT4H1	0.54	4.93	0.3	1.53e-6	Cognitive test performance;
KIRP	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg24531977	chr5:56204891	C5orf35	-0.39	-5.04	-0.31	9.13e-7	Coronary artery disease;
KIRP	cis	rs2012796	1.000	rs10450939	chr14:81825202	A/T	cg02996355	chr14:81879375	NA	0.4	5.48	0.33	1.08e-7	Night sleep phenotypes;
KIRP	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg04780086	chr2:111875790	ACOXL	0.41	5.63	0.34	4.9e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs490234	0.756	rs2416963	chr9:128241414	C/T	cg14078157	chr9:128172775	NA	-0.39	-5.01	-0.3	1.05e-6	Mean arterial pressure;
KIRP	cis	rs1505368	0.563	rs1394798	chr2:213230641	G/A	cg16329650	chr2:213403929	ERBB4	0.4	5.51	0.33	9.09e-8	Symmetrical dimethylarginine levels;
KIRP	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.24	17.16	0.74	6.15e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs787274	0.850	rs10759603	chr9:115639581	C/G	cg13803584	chr9:115635662	SNX30	-0.75	-7.96	-0.45	6.36e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.45	5.7	0.34	3.38e-8	Response to temozolomide;
KIRP	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg01777586	chr17:80163174	CCDC57	0.46	4.9	0.3	1.76e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.7	-9.27	-0.51	9.93e-18	Breast cancer;
KIRP	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-1.01	-18.78	-0.77	1.97e-49	Height;
KIRP	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.66	7.58	0.44	6.88e-13	Corneal astigmatism;
KIRP	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-0.75	-8.94	-0.5	9.59e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg03171003	chr2:111875934	NA	0.38	5.37	0.32	1.83e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.84	-10.12	-0.54	2.33e-20	Menopause (age at onset);
KIRP	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.16	-0.31	5e-7	Red blood cell count;
KIRP	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.98	10.91	0.57	7.13e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg19507638	chr5:93509721	C5orf36	-0.55	-5.0	-0.3	1.09e-6	Diabetic retinopathy;
KIRP	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	5.63	0.34	4.92e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs7666738	0.539	rs13150465	chr4:99094892	C/T	cg05340658	chr4:99064831	C4orf37	-0.55	-5.21	-0.31	4.09e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3126085	0.560	rs11803108	chr1:152344386	G/A	cg26876637	chr1:152193138	HRNR	-0.57	-6.35	-0.38	1.01e-9	Atopic dermatitis;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.13e-8	Life satisfaction;
KIRP	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg05362011	chr13:21860987	NA	-0.47	-5.02	-0.31	9.77e-7	White matter hyperintensity burden;
KIRP	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.8	-0.35	2.02e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4728302	0.869	rs6962865	chr7:133599433	T/A	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27577070	chr4:2263840	MXD4	0.49	6.29	0.37	1.4e-9	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18640608	chr19:13001970	GCDH	0.54	6.23	0.37	1.99e-9	Smoking initiation;
KIRP	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21214613	chr1:16344536	HSPB7	0.34	5.12	0.31	6.24e-7	Systolic blood pressure;
KIRP	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg13319975	chr6:146136371	FBXO30	-0.5	-6.53	-0.38	3.66e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.94	0.45	7.33e-14	Coffee consumption (cups per day);
KIRP	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg19847866	chr10:1019161	NA	0.5	5.94	0.35	9.44e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg14673194	chr17:80132900	CCDC57	0.76	8.72	0.49	4.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4783244	0.901	rs12444338	chr16:82660155	G/T	cg09415485	chr16:82663111	CDH13	-0.27	-5.21	-0.32	3.95e-7	Adiponectin levels;
KIRP	cis	rs6800768	0.663	rs59911620	chr3:24092004	G/C	cg10674438	chr3:24145617	LOC152024	-0.43	-5.82	-0.35	1.82e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.68	-12.44	-0.62	6.84e-28	White blood cell count (basophil);
KIRP	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.98	18.74	0.77	2.71e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.86	0.81	1.42e-59	Prudent dietary pattern;
KIRP	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg00800038	chr16:89945340	TCF25	-0.76	-5.13	-0.31	5.85e-7	Skin colour saturation;
KIRP	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg12292205	chr6:26970375	C6orf41	0.33	4.87	0.3	2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.79	-0.4	8.43e-11	Lung cancer;
KIRP	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg18944383	chr4:111397179	ENPEP	0.71	13.3	0.65	9.3e-31	Coronary artery disease;
KIRP	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg10523679	chr1:76189770	ACADM	-0.47	-6.25	-0.37	1.83e-9	Daytime sleep phenotypes;
KIRP	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.57	7.26	0.42	4.98e-12	Breast cancer;
KIRP	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.76	9.04	0.5	4.77e-17	Lymphocyte percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19752117	chr17:4850710	PFN1	0.57	6.71	0.39	1.29e-10	Smoking initiation;
KIRP	cis	rs4262150	0.667	rs4246037	chr5:152249065	C/T	cg12297329	chr5:152029980	NA	0.47	6.6	0.39	2.48e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg23307798	chr14:103986281	CKB	-0.5	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs9843304	0.529	rs72996050	chr3:149202633	T/C	cg08667024	chr3:149219783	TM4SF4	-0.41	-6.13	-0.36	3.4e-9	Gallstone disease;
KIRP	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg16898833	chr6:26189333	HIST1H4D	0.64	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11581903	0.568	rs11205977	chr1:53068093	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.9	7.5	0.43	1.14e-12	Joint mobility (Beighton score);
KIRP	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg24375607	chr4:120327624	NA	-0.47	-5.69	-0.34	3.56e-8	Corneal astigmatism;
KIRP	cis	rs2802369	1	rs2802369	chr10:80960828	C/A	cg20744163	chr10:80999841	ZMIZ1	-0.29	-4.92	-0.3	1.57e-6	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs6910061	1.000	rs6913027	chr6:11107276	G/A	cg27233058	chr6:11094804	LOC221710	0.57	5.68	0.34	3.75e-8	Diabetic kidney disease;
KIRP	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.78	6.25	0.37	1.75e-9	Initial pursuit acceleration;
KIRP	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.54	-7.1	-0.41	1.37e-11	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg03714773	chr7:91764589	CYP51A1	0.36	5.22	0.32	3.73e-7	Breast cancer;
KIRP	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	9.21	0.51	1.47e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	1.12	8.08	0.46	2.97e-14	LDL cholesterol;
KIRP	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	6.09	0.36	4.41e-9	Motion sickness;
KIRP	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.73	8.94	0.5	9.54e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg23803603	chr1:2058230	PRKCZ	-0.38	-6.13	-0.36	3.55e-9	Height;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	8.01	0.45	4.62e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.53	6.69	0.39	1.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10518128	1.000	rs72855860	chr4:75714054	G/A	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg10207240	chr12:122356781	WDR66	0.64	8.99	0.5	6.73e-17	Mean platelet volume;
KIRP	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.2	0.64	1.95e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.51	0.43	1.08e-12	Diabetic kidney disease;
KIRP	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.2	0.31	4.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.56	-0.43	7.84e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.73	10.51	0.56	1.4e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12195424	0.558	rs76569072	chr6:56299479	G/T	cg20782286	chr6:56298173	NA	-0.66	-5.16	-0.31	5.16e-7	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs28834970	0.675	rs17057051	chr8:27227554	C/T	cg06815112	chr8:27182871	PTK2B	0.49	5.53	0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	trans	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg02002194	chr4:3960332	NA	0.42	6.3	0.37	1.33e-9	Mood instability;
KIRP	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg10189774	chr4:17578691	LAP3	0.45	5.39	0.33	1.65e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg14345882	chr6:26364793	BTN3A2	-0.55	-5.05	-0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15625324	chr3:151073249	MED12L;P2RY12	-0.43	-6.52	-0.38	4.04e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7172677	0.737	rs8027604	chr15:75447773	C/T	cg14664628	chr15:75095509	CSK	-0.5	-5.67	-0.34	3.98e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg25767906	chr1:53392781	SCP2	-0.35	-4.98	-0.3	1.21e-6	Monocyte count;
KIRP	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.82	11.33	0.59	3.17e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.08	0.5	3.64e-17	Lung cancer in ever smokers;
KIRP	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg11608241	chr8:8085544	FLJ10661	0.42	4.91	0.3	1.68e-6	Mood instability;
KIRP	cis	rs2976388	0.967	rs2978981	chr8:143759137	C/T	cg06565975	chr8:143823917	SLURP1	-0.42	-6.32	-0.37	1.22e-9	Urinary tract infection frequency;
KIRP	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.64	10.07	0.54	3.52e-20	Bone mineral density;
KIRP	cis	rs4692589	0.965	rs7657455	chr4:170958843	C/G	cg19918862	chr4:170955249	NA	0.49	6.1	0.36	4e-9	Anxiety disorder;
KIRP	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg11641102	chr8:27183873	PTK2B	0.46	6.1	0.36	3.98e-9	Neuroticism;
KIRP	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg06795125	chr2:108905320	SULT1C2	-0.39	-6.86	-0.4	5.56e-11	Blood pressure;
KIRP	cis	rs4523957	0.891	rs216200	chr17:2199846	C/T	cg16513277	chr17:2031491	SMG6	0.6	8.26	0.47	8.87e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs238295	0.631	rs6038205	chr20:5549073	T/A	cg24001556	chr20:5591874	RP5-1022P6.2	-0.5	-5.08	-0.31	7.56e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.52	-0.56	1.25e-21	Chronic sinus infection;
KIRP	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.56	-0.56	9.73e-22	Height;
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg13327503	chr12:2113653	DCP1B	-0.48	-6.23	-0.37	2.01e-9	Breast cancer;
KIRP	cis	rs8005677	0.828	rs4981450	chr14:23389304	A/G	cg25600027	chr14:23388339	RBM23	-0.42	-4.98	-0.3	1.22e-6	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg11845111	chr2:191398756	TMEM194B	-0.95	-10.49	-0.56	1.6e-21	Diastolic blood pressure;
KIRP	trans	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg22369252	chr19:55851102	SUV420H2	-0.48	-6.07	-0.36	4.91e-9	Fibroblast growth factor basic levels;
KIRP	cis	rs2274273	0.804	rs28428911	chr14:55843596	G/T	cg04306507	chr14:55594613	LGALS3	0.44	6.91	0.4	4.14e-11	Protein biomarker;
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg09699651	chr6:150184138	LRP11	0.46	5.96	0.36	8.85e-9	Lung cancer;
KIRP	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg17554472	chr22:41940697	POLR3H	-0.54	-5.9	-0.35	1.18e-8	Neuroticism;
KIRP	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	4.92	0.3	1.56e-6	Axial length;
KIRP	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.84	-7.34	-0.42	3.14e-12	Body mass index;
KIRP	cis	rs12949688	0.967	rs12451748	chr17:55822171	T/C	cg12582317	chr17:55822272	NA	0.63	10.62	0.56	6.06e-22	Schizophrenia;
KIRP	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.85	12.67	0.63	1.21e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6681460	0.934	rs4655628	chr1:67052609	T/C	cg13052034	chr1:66999238	SGIP1	0.41	5.65	0.34	4.45e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs2224391	1.000	rs2773320	chr6:5261681	A/G	cg13962347	chr6:5174647	LYRM4	-0.62	-8.46	-0.47	2.35e-15	Height;
KIRP	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg03474202	chr17:45855739	NA	-0.43	-6.06	-0.36	5.15e-9	IgG glycosylation;
KIRP	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.27	-0.42	4.81e-12	Mood instability;
KIRP	cis	rs1468333	1.000	rs1468333	chr5:137552970	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.47	5.45	0.33	1.19e-7	Resting heart rate;
KIRP	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18876405	chr7:65276391	NA	0.41	5.01	0.3	1.05e-6	Aortic root size;
KIRP	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.76	9.75	0.53	3.42e-19	Menopause (age at onset);
KIRP	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg11833968	chr6:79620685	NA	-0.47	-7.11	-0.41	1.26e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.39	6.15	0.37	3.12e-9	Ulcerative colitis;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg24953514	chr11:22809205	GAS2	-0.42	-6.18	-0.37	2.63e-9	Obesity-related traits;
KIRP	cis	rs6752107	0.935	rs10929325	chr2:234151031	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.69	0.44	3.56e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25309564	chr22:51001381	C22orf41	0.57	6.83	0.4	6.62e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg11846333	chr4:119757529	SEC24D	1.17	7.18	0.42	8.16e-12	Cannabis dependence symptom count;
KIRP	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.58	7.1	0.41	1.3e-11	Renal function-related traits (BUN);
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg07402062	chr16:89894098	SPIRE2	0.33	6.83	0.4	6.66e-11	Vitiligo;
KIRP	cis	rs10114408	0.959	rs7863529	chr9:96639160	T/G	cg14598338	chr9:96623480	NA	-0.33	-4.9	-0.3	1.7e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg10755058	chr3:40428713	ENTPD3	0.4	5.49	0.33	1.01e-7	Renal cell carcinoma;
KIRP	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.64	11.79	0.6	9.71e-26	Total body bone mineral density;
KIRP	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-1.07	-11.76	-0.6	1.21e-25	Height;
KIRP	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-8.66	-0.48	6.53e-16	Asthma;
KIRP	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.16e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4302748	0.862	rs11772400	chr7:36186371	G/C	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg00122941	chr17:4613640	ARRB2	0.77	8.26	0.47	9.05e-15	Lymphocyte counts;
KIRP	cis	rs7771547	0.642	rs629560	chr6:36511391	A/G	cg07856975	chr6:36356162	ETV7	0.36	5.15	0.31	5.37e-7	Platelet distribution width;
KIRP	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs10073892	1.000	rs10062073	chr5:101710089	T/C	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.96e-11	Cognitive decline (age-related);
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg10304824	chr2:177028804	HOXD3	0.26	5.21	0.32	3.96e-7	IgG glycosylation;
KIRP	cis	rs9929218	0.817	rs3114399	chr16:68713385	C/G	cg02972257	chr16:68554789	NA	0.57	5.07	0.31	7.69e-7	Colorectal cancer;
KIRP	cis	rs6545883	0.929	rs3732171	chr2:61749690	C/T	cg15711740	chr2:61764176	XPO1	-0.58	-7.82	-0.45	1.53e-13	Tuberculosis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04059965	chr5:179285867	C5orf45	-0.54	-6.03	-0.36	6.02e-9	Menopause (age at onset);
KIRP	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.8	9.11	0.5	2.92e-17	Corneal astigmatism;
KIRP	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg27494647	chr7:150038898	RARRES2	0.45	6.55	0.39	3.3e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs448720	1.000	rs2219800	chr15:68208760	G/A	cg24579218	chr15:68104479	NA	-0.35	-4.98	-0.3	1.2e-6	Cognitive performance;
KIRP	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.94	10.27	0.55	8.28e-21	Alzheimer's disease;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.73	9.1	0.5	3.26e-17	Longevity;
KIRP	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06481639	chr22:41940642	POLR3H	-0.59	-6.93	-0.4	3.64e-11	Vitiligo;
KIRP	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.54	-6.59	-0.39	2.72e-10	Uric acid levels;
KIRP	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.95	9.29	0.51	8.38e-18	Gut microbiome composition (summer);
KIRP	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg01346077	chr3:125931526	NA	-0.55	-8.48	-0.48	2.17e-15	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs35740288	0.731	rs35085180	chr15:86102612	T/C	cg10818794	chr15:86012489	AKAP13	-0.47	-5.55	-0.33	7.54e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg16141378	chr3:129829833	LOC729375	0.57	7.37	0.43	2.54e-12	Neuroticism;
KIRP	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.89	11.01	0.57	3.4e-23	Response to bleomycin (chromatid breaks);
KIRP	cis	rs918629	1.000	rs3777164	chr5:95293261	C/T	cg16656078	chr5:95278638	ELL2	-0.44	-6.58	-0.39	2.85e-10	IgG glycosylation;
KIRP	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26002218	chr14:103986227	CKB	0.3	6.14	0.36	3.27e-9	Body mass index;
KIRP	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	8.51	0.48	1.7e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.46	-6.15	-0.37	3.12e-9	Mean corpuscular volume;
KIRP	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs1829883	0.804	rs1523371	chr5:98811969	A/C	cg08333243	chr5:99726346	NA	-0.37	-5.0	-0.3	1.09e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.66	0.39	1.79e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg15691649	chr6:25882328	NA	-0.49	-5.2	-0.31	4.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg20578329	chr17:80767326	TBCD	-0.67	-7.5	-0.43	1.17e-12	Breast cancer;
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.64e-16	Life satisfaction;
KIRP	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg23950597	chr19:37808831	NA	-0.64	-6.8	-0.4	7.79e-11	Coronary artery calcification;
KIRP	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg03834567	chr2:218808745	TNS1	0.39	4.91	0.3	1.66e-6	Ulcerative colitis;
KIRP	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.81	7.01	0.41	2.32e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg24253500	chr15:84953950	NA	0.68	7.83	0.45	1.49e-13	Schizophrenia;
KIRP	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-9.86	-0.53	1.51e-19	Schizophrenia;
KIRP	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.46	5.72	0.34	3.15e-8	IgG glycosylation;
KIRP	cis	rs17095355	1.000	rs4565840	chr10:111717140	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.24	-0.37	1.94e-9	Biliary atresia;
KIRP	cis	rs34375054	0.660	rs12305181	chr12:125594156	C/A	cg25124228	chr12:125621409	AACS	-0.57	-6.94	-0.4	3.41e-11	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-13.23	-0.64	1.6e-30	Tonsillectomy;
KIRP	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg18657303	chr4:1051139	NA	0.55	5.08	0.31	7.44e-7	Recombination rate (females);
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-5.86	-0.35	1.5e-8	Longevity;Endometriosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19701416	chr10:28592092	NA	0.66	8.2	0.46	1.36e-14	Smoking initiation;
KIRP	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg11846333	chr4:119757529	SEC24D	1.14	6.64	0.39	2.01e-10	Cannabis dependence symptom count;
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg05562828	chr17:3906858	NA	0.78	16.23	0.72	9.22e-41	Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.66	-9.78	-0.53	2.76e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg11833968	chr6:79620685	NA	-0.46	-6.99	-0.41	2.58e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.76	0.44	2.31e-13	Coffee consumption (cups per day);
KIRP	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg10503236	chr1:231470652	EXOC8	-0.53	-7.0	-0.41	2.42e-11	Red blood cell count;
KIRP	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.86	13.53	0.65	1.44e-31	Prostate cancer;
KIRP	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg07599136	chr5:415885	AHRR	0.77	6.74	0.39	1.1e-10	Fat distribution (HIV);
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.44	-0.52	2.97e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.67	9.32	0.51	6.68e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.1	0.5	3.22e-17	Lung cancer in ever smokers;
KIRP	cis	rs2219968	0.828	rs1486923	chr8:78883445	T/C	cg00738934	chr8:78996279	NA	-0.39	-5.24	-0.32	3.4e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.41	-5.55	-0.33	7.52e-8	Schizophrenia;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	5.95	0.35	9.13e-9	Longevity;
KIRP	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.88	0.35	1.31e-8	Motion sickness;
KIRP	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.57	5.26	0.32	3.2e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.44	-0.33	1.29e-7	Bipolar disorder;
KIRP	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	1.11	18.1	0.76	4.1e-47	Cognitive function;
KIRP	cis	rs17453880	0.643	rs7701534	chr5:151952520	T/G	cg12297329	chr5:152029980	NA	-0.68	-10.08	-0.54	3.15e-20	Subjective well-being;
KIRP	cis	rs7326068	0.610	rs4769134	chr13:21438871	G/A	cg04906043	chr13:21280425	IL17D	-0.42	-4.93	-0.3	1.53e-6	Schizophrenia, bipolar disorder and depression (combined);
KIRP	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg22089800	chr15:90895588	ZNF774	-0.42	-4.92	-0.3	1.61e-6	Rheumatoid arthritis;
KIRP	trans	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.82	0.49	2.17e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.61	-8.91	-0.49	1.15e-16	Urate levels in overweight individuals;
KIRP	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg04132472	chr17:19861366	AKAP10	0.4	5.21	0.32	4.01e-7	Schizophrenia;
KIRP	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.61	-9.55	-0.52	1.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.3	-0.37	1.39e-9	Migraine - clinic-based;
KIRP	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.2	-0.31	4.14e-7	Pulmonary function;
KIRP	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg22987457	chr7:157211561	NA	0.4	5.17	0.31	4.91e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg03929089	chr4:120376271	NA	-0.55	-6.7	-0.39	1.42e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg24642844	chr7:1081250	C7orf50	-0.92	-7.81	-0.45	1.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs526231	0.543	rs34377	chr5:102400556	C/T	cg23492399	chr5:102201601	PAM	-0.49	-5.41	-0.33	1.48e-7	Primary biliary cholangitis;
KIRP	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.76	-0.4	9.79e-11	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg10760299	chr15:45669010	GATM	-0.33	-5.15	-0.31	5.29e-7	Homoarginine levels;
KIRP	trans	rs13170463	0.579	rs17268643	chr5:8034498	G/A	cg03862380	chr20:43029895	HNF4A	0.39	6.03	0.36	6.1e-9	Colorectal cancer;
KIRP	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.2	-0.37	2.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.59	-7.36	-0.42	2.73e-12	Waist circumference;Body mass index;
KIRP	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-5.95	-0.35	9.23e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg10503236	chr1:231470652	EXOC8	0.51	7.07	0.41	1.61e-11	Hemoglobin concentration;
KIRP	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.44	6.16	0.37	2.87e-9	Coronary artery disease;
KIRP	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg19554555	chr3:13937349	NA	-0.46	-6.14	-0.36	3.29e-9	Ovarian reserve;
KIRP	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.04	-0.46	3.68e-14	Coronary artery disease;
KIRP	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg21775007	chr8:11205619	TDH	-0.46	-6.12	-0.36	3.61e-9	Retinal vascular caliber;
KIRP	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg12046867	chr14:103022105	NA	-0.57	-7.06	-0.41	1.68e-11	Platelet count;
KIRP	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	8.89	0.49	1.32e-16	Bipolar disorder;
KIRP	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Tonsillectomy;
KIRP	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.38	-0.32	1.74e-7	Ovarian reserve;
KIRP	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg26876637	chr1:152193138	HRNR	0.72	9.37	0.51	4.87e-18	Atopic dermatitis;
KIRP	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.54	-0.52	1.53e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.36	0.47	4.81e-15	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23243652	chr5:72921812	RGNEF	0.47	6.21	0.37	2.27e-9	Parkinson's disease;
KIRP	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg18357526	chr6:26021779	HIST1H4A	0.45	5.9	0.35	1.19e-8	Height;
KIRP	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.83	8.88	0.49	1.4e-16	Phospholipid levels (plasma);
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05347473	chr6:146136440	FBXO30	-0.64	-9.37	-0.51	4.91e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg00684032	chr4:1343700	KIAA1530	-0.54	-7.07	-0.41	1.56e-11	Obesity-related traits;
KIRP	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg12315302	chr6:26189340	HIST1H4D	0.97	6.76	0.4	9.72e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.78	-10.38	-0.55	3.58e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.79	-0.35	2.16e-8	Menarche (age at onset);
KIRP	cis	rs6662572	1.000	rs6662572	chr1:46146812	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.62	0.34	5.09e-8	Blood protein levels;
KIRP	cis	rs9308731	0.591	rs60982612	chr2:111940939	C/T	cg04780086	chr2:111875790	ACOXL	0.38	5.13	0.31	5.76e-7	Chronic lymphocytic leukemia;
KIRP	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.31	10.77	0.57	2.13e-22	Diabetic kidney disease;
KIRP	cis	rs12042938	0.579	rs6692440	chr1:231760047	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-6.59	-0.39	2.7e-10	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg17724175	chr1:150552817	MCL1	0.3	5.15	0.31	5.23e-7	Melanoma;
KIRP	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.56	7.51	0.43	1.11e-12	Pancreatic cancer;
KIRP	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00889227	chr1:205173544	DSTYK	-0.41	-5.87	-0.35	1.37e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs9841504	1.000	rs56298435	chr3:114363401	C/T	cg24348448	chr19:55493930	NLRP2	-0.82	-6.72	-0.39	1.23e-10	Gastric cancer;
KIRP	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg14221460	chr8:27183342	PTK2B	0.45	5.84	0.35	1.66e-8	Neuroticism;
KIRP	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.51	6.84	0.4	6.2e-11	Mean corpuscular volume;
KIRP	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.43	6.42	0.38	7.12e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7615316	0.902	rs6799752	chr3:142311712	T/C	cg20824294	chr3:142316082	PLS1	0.22	4.97	0.3	1.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg21253087	chr9:139290292	SNAPC4	0.44	6.14	0.36	3.21e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6142102	0.961	rs909884	chr20:32646063	G/T	cg08999081	chr20:33150536	PIGU	0.51	5.94	0.35	9.75e-9	Skin pigmentation;
KIRP	cis	rs42648	0.564	rs7783739	chr7:89801787	T/C	cg25739043	chr7:89950458	NA	-0.34	-5.29	-0.32	2.7e-7	Homocysteine levels;
KIRP	trans	rs1106684	1.000	rs61212111	chr7:131465802	T/C	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	cis	rs7209700	0.889	rs16941801	chr17:45354543	G/C	cg25173405	chr17:45401733	C17orf57	0.41	5.11	0.31	6.39e-7	IgG glycosylation;
KIRP	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.44	-0.47	2.76e-15	Menarche (age at onset);
KIRP	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg25772418	chr12:131519998	GPR133	-0.36	-5.06	-0.31	8.04e-7	Longevity;
KIRP	cis	rs2151522	0.762	rs17570053	chr6:127178726	G/A	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.06	0.31	8.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg05283184	chr6:79620031	NA	-0.35	-5.08	-0.31	7.3e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20040772	chr7:100026353	MEPCE;ZCWPW1	0.49	6.11	0.36	3.82e-9	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg26134248	chr17:3907702	NA	-0.54	-7.94	-0.45	7.28e-14	Type 2 diabetes;
KIRP	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-6.71	-0.39	1.33e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.82	9.91	0.53	1.08e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.56	6.19	0.37	2.52e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6832769	1.000	rs576779	chr4:56274307	G/A	cg09317128	chr4:56265301	TMEM165	0.54	7.25	0.42	5.54e-12	Personality dimensions;
KIRP	cis	rs13102973	0.965	rs11099306	chr4:135895674	A/G	cg14419869	chr4:135874104	NA	0.5	8.3	0.47	6.96e-15	Subjective well-being;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16506172	chr14:50778832	L2HGDH;ATP5S	0.47	6.71	0.39	1.34e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2239815	0.515	rs9625595	chr22:29238913	C/T	cg15103426	chr22:29168792	CCDC117	0.55	5.34	0.32	2.07e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs6504950	0.888	rs244319	chr17:53222874	G/A	cg26251398	chr17:52985966	TOM1L1	0.38	5.02	0.3	1e-6	Breast cancer;
KIRP	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg18833306	chr6:118973337	C6orf204	0.41	5.13	0.31	5.81e-7	Electrocardiographic conduction measures;
KIRP	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg08890418	chr1:21044141	KIF17	0.71	11.05	0.58	2.57e-23	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs11628318	0.614	rs3783383	chr14:103177420	G/C	cg01864069	chr14:103024347	NA	0.44	5.36	0.32	1.96e-7	Platelet count;
KIRP	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.53	-0.43	9.55e-13	Initial pursuit acceleration;
KIRP	cis	rs427941	0.741	rs1297617	chr7:101859783	C/T	cg06246474	chr7:101738831	CUX1	-0.44	-5.2	-0.31	4.11e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs3741151	0.686	rs7129990	chr11:73124441	A/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.07	0.31	7.94e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.62	0.48	8.18e-16	Motion sickness;
KIRP	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.45	5.55	0.33	7.37e-8	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.73	10.15	0.54	1.95e-20	Lung cancer;
KIRP	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.58	-8.55	-0.48	1.34e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs6438504	0.922	rs35625431	chr3:118936301	A/T	cg25372693	chr3:118959985	B4GALT4	0.33	5.55	0.33	7.24e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.7	9.08	0.5	3.63e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg07274523	chr3:49395745	GPX1	0.57	5.44	0.33	1.31e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.09e-6	Bladder cancer;
KIRP	cis	rs6585424	1.000	rs35025775	chr10:81924285	C/A	cg27417294	chr10:81904244	PLAC9	0.56	5.43	0.33	1.35e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04312406	chr1:226497240	LIN9	-0.58	-6.66	-0.39	1.8e-10	Interleukin-4 levels;
KIRP	cis	rs7078219	0.743	rs11190128	chr10:101275149	A/C	cg07044859	chr10:101282883	NA	-0.38	-5.97	-0.36	8.43e-9	Dental caries;
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg05709478	chr1:6581295	PLEKHG5	0.58	5.38	0.32	1.72e-7	Body mass index;
KIRP	cis	rs7560272	0.501	rs12615807	chr2:73947583	T/C	cg20560298	chr2:73613845	ALMS1	0.44	5.25	0.32	3.32e-7	Schizophrenia;
KIRP	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg21184320	chr1:21044207	KIF17	0.46	6.73	0.39	1.16e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg12131826	chr15:77904385	NA	-0.38	-4.88	-0.3	1.88e-6	Type 2 diabetes;
KIRP	cis	rs710913	0.614	rs6672296	chr1:40070788	T/C	cg27567593	chr1:39956653	BMP8A	-0.35	-4.93	-0.3	1.55e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23151374	chr4:164415611	C4orf43	0.47	6.13	0.36	3.53e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00629816	chr9:37784931	EXOSC3	0.55	6.37	0.38	9.27e-10	Smoking initiation;
KIRP	trans	rs3858145	0.588	rs76854765	chr10:70037456	C/T	cg04882175	chr6:131122610	NA	-0.61	-7.38	-0.43	2.48e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.53	6.91	0.4	4.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg23693289	chr8:27183097	PTK2B	0.56	7.3	0.42	4.04e-12	Neuroticism;
KIRP	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.49	-7.94	-0.45	7.15e-14	Huntington's disease progression;
KIRP	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.59	8.65	0.48	6.76e-16	Blood metabolite levels;
KIRP	cis	rs6001982	0.667	rs73167072	chr22:40879105	G/A	cg07138101	chr22:40742427	ADSL	0.71	4.91	0.3	1.63e-6	Breast cancer;
KIRP	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.61	-8.02	-0.46	4.27e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06481639	chr22:41940642	POLR3H	-0.47	-5.39	-0.33	1.65e-7	Neuroticism;
KIRP	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.88e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg21775007	chr8:11205619	TDH	-0.37	-4.99	-0.3	1.15e-6	Neuroticism;
KIRP	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.57	6.57	0.39	2.98e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.46	4.93	0.3	1.53e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg13319975	chr6:146136371	FBXO30	0.39	5.08	0.31	7.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10017260	chr10:834428	NA	-0.58	-5.56	-0.33	7e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7215564	0.908	rs35151535	chr17:78661695	C/T	cg06153925	chr17:78755379	RPTOR	0.3	4.93	0.3	1.51e-6	Myopia (pathological);
KIRP	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4959799	0.557	rs45629235	chr6:3271298	A/G	cg10513992	chr6:3293720	SLC22A23	-0.75	-5.54	-0.33	7.82e-8	Survival in rectal cancer;
KIRP	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.54	6.31	0.37	1.27e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.6	-5.19	-0.31	4.45e-7	Narcolepsy;
KIRP	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.67	-8.62	-0.48	8.51e-16	Extraversion;
KIRP	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.23	0.37	1.97e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg22974920	chr21:40686053	BRWD1	0.47	5.57	0.33	6.82e-8	Cognitive function;
KIRP	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.82	-0.53	2.04e-19	Gut microbiome composition (summer);
KIRP	cis	rs8050907	1.000	rs13335998	chr16:4651921	G/T	cg09164920	chr16:4526354	HMOX2;NMRAL1	0.84	5.12	0.31	6.14e-7	Obesity-related traits;
KIRP	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.29	-0.37	1.4e-9	Arsenic metabolism;
KIRP	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.37	0.65	5.09e-31	Eye color traits;
KIRP	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg24579218	chr15:68104479	NA	-0.59	-9.34	-0.51	6.22e-18	Restless legs syndrome;
KIRP	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg21643547	chr1:205240462	TMCC2	-0.53	-7.77	-0.44	2.11e-13	Red blood cell count;
KIRP	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg06212747	chr3:49208901	KLHDC8B	0.72	9.85	0.53	1.65e-19	Parkinson's disease;
KIRP	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.53	-6.31	-0.37	1.32e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.74	0.34	2.79e-8	Menopause (age at onset);
KIRP	trans	rs1973993	0.903	rs2038646	chr1:96940371	C/G	cg10631902	chr5:14652156	NA	0.65	10.05	0.54	3.91e-20	Weight;
KIRP	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.63	12.12	0.61	8.06e-27	Bone mineral density;
KIRP	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.52e-7	Tonsillectomy;
KIRP	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg00852783	chr1:26633632	UBXN11	-0.58	-5.96	-0.36	8.73e-9	Obesity-related traits;
KIRP	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg25019033	chr10:957182	NA	-0.56	-5.85	-0.35	1.56e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.58	8.49	0.48	2e-15	Testicular germ cell tumor;
KIRP	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg26116260	chr4:7069785	GRPEL1	-0.82	-6.55	-0.39	3.27e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2274273	0.624	rs67412516	chr14:55853237	A/T	cg04306507	chr14:55594613	LGALS3	0.39	5.55	0.33	7.25e-8	Protein biomarker;
KIRP	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg00792783	chr2:198669748	PLCL1	0.47	5.25	0.32	3.3e-7	Dermatomyositis;
KIRP	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg05347473	chr6:146136440	FBXO30	0.5	6.88	0.4	4.94e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs830233	0.779	rs56257374	chr5:165375244	G/A	cg13976338	chr5:165423657	NA	-0.6	-6.34	-0.37	1.08e-9	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.62	-0.39	2.23e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs829661	0.895	rs9309680	chr2:30785950	T/C	cg10949345	chr2:30726833	LCLAT1	0.71	9.41	0.51	3.73e-18	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.08	-0.36	4.5e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.88e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg06815112	chr8:27182871	PTK2B	0.53	6.88	0.4	5.05e-11	Neuroticism;
KIRP	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg15247329	chr7:2764246	NA	-0.36	-5.16	-0.31	5.16e-7	Height;
KIRP	trans	rs933360	0.585	rs6966774	chr7:50838415	C/T	cg20003124	chr12:4557277	NA	0.55	6.73	0.39	1.19e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27499259	chr13:28400924	NA	0.52	6.14	0.36	3.34e-9	Smoking initiation;
KIRP	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg19000871	chr14:103996768	TRMT61A	-0.51	-5.7	-0.34	3.45e-8	Reticulocyte count;
KIRP	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg07741184	chr6:167504864	NA	-0.24	-6.45	-0.38	5.8e-10	Crohn's disease;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-1.06	-20.72	-0.8	7.31e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg24488311	chr11:68621650	NA	0.48	5.64	0.34	4.57e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9815354	1.000	rs1994157	chr3:41897482	G/A	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.07	-0.36	4.75e-9	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs10267417	0.603	rs12668717	chr7:19932912	G/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.11	0.31	6.44e-7	Night sleep phenotypes;
KIRP	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.81	9.86	0.53	1.54e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.26	-0.62	2.69e-27	Blood trace element (Zn levels);
KIRP	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.9	-0.35	1.21e-8	Height;
KIRP	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.98	0.8	9.97e-57	Prudent dietary pattern;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg18555811	chr3:193852889	HES1	0.52	6.11	0.36	3.79e-9	Electroencephalogram traits;
KIRP	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21385522	chr1:16154831	NA	0.48	6.15	0.36	3.13e-9	Dilated cardiomyopathy;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04892060	chr14:75643373	TMED10	0.63	6.99	0.41	2.62e-11	Lung cancer in ever smokers;
KIRP	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.58	-4.93	-0.3	1.54e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	15.11	0.69	6.38e-37	Platelet count;
KIRP	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg03146154	chr1:46216737	IPP	0.47	5.07	0.31	8e-7	Platelet count;
KIRP	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg19731401	chr7:2775893	GNA12	0.54	5.73	0.34	2.88e-8	Childhood ear infection;
KIRP	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.71	9.19	0.51	1.73e-17	Bladder cancer;
KIRP	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg13819577	chr1:248512075	OR14C36	-0.37	-5.28	-0.32	2.89e-7	Common traits (Other);
KIRP	cis	rs735539	0.521	rs2585906	chr13:21407492	C/G	cg04906043	chr13:21280425	IL17D	-0.45	-5.42	-0.33	1.44e-7	Dental caries;
KIRP	cis	rs56161922	1.000	rs4562622	chr1:207876577	A/C	cg09557387	chr1:207818395	CR1L	-1.04	-6.29	-0.37	1.41e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg10189774	chr4:17578691	LAP3	0.41	5.02	0.3	9.83e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg27124370	chr19:33622961	WDR88	0.72	10.11	0.54	2.56e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.43	-0.38	6.7e-10	Longevity;Endometriosis;
KIRP	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg07395648	chr5:131743802	NA	-0.34	-5.08	-0.31	7.52e-7	Blood metabolite levels;
KIRP	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	9.19	0.51	1.75e-17	Mood instability;
KIRP	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.42	0.33	1.43e-7	Cognitive test performance;
KIRP	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.37	4.99	0.3	1.15e-6	Dupuytren's disease;
KIRP	cis	rs5753618	0.555	rs9609304	chr22:31897795	T/C	cg02404636	chr22:31891804	SFI1	0.54	5.92	0.35	1.06e-8	Colorectal cancer;
KIRP	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg15247329	chr7:2764246	NA	-0.4	-5.8	-0.35	2.02e-8	Height;
KIRP	cis	rs2458413	0.542	rs35723041	chr8:105369123	A/C	cg08657449	chr8:105351661	TM7SF4	-0.34	-5.61	-0.34	5.37e-8	Paget's disease;
KIRP	cis	rs10489525	0.528	rs360604	chr1:115390019	G/A	cg01522456	chr1:115632236	TSPAN2	-0.47	-6.11	-0.36	3.78e-9	Autism;
KIRP	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg25233709	chr10:116636983	FAM160B1	0.33	5.11	0.31	6.59e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg19116668	chr7:99932089	PMS2L1	-0.49	-5.92	-0.35	1.05e-8	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07385490	chr5:1318548	CLPTM1L	0.43	6.58	0.39	2.88e-10	Survival in pancreatic cancer;
KIRP	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg08499158	chr17:42289980	UBTF	-0.49	-6.31	-0.37	1.28e-9	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.45	-5.14	-0.31	5.47e-7	Neuroticism;
KIRP	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.23	-0.32	3.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.13e-6	IgM levels;
KIRP	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg02404636	chr22:31891804	SFI1	0.51	5.74	0.34	2.82e-8	Colorectal cancer;
KIRP	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.71e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg22903471	chr2:27725779	GCKR	0.41	5.67	0.34	4.03e-8	Oral cavity cancer;
KIRP	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.61	6.82	0.4	7.11e-11	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.6	8.01	0.45	4.57e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.49	6.36	0.38	1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4959799	0.557	rs6901656	chr6:3273988	T/C	cg03657281	chr6:3270030	SLC22A23	0.79	6.06	0.36	5.14e-9	Survival in rectal cancer;
KIRP	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg12160578	chr15:63334699	TPM1	0.64	6.78	0.4	8.89e-11	Orofacial clefts;
KIRP	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.84	10.64	0.56	5.31e-22	Gestational age at birth (maternal effect);
KIRP	trans	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg24644049	chr4:85504048	CDS1	1.0	6.97	0.41	2.88e-11	Skin colour saturation;
KIRP	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.46	-6.25	-0.37	1.8e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs7503807	0.664	rs9913181	chr17:78573872	A/C	cg09596252	chr17:78655493	RPTOR	0.49	5.42	0.33	1.41e-7	Obesity;
KIRP	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.83e-16	Immature fraction of reticulocytes;
KIRP	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16083429	chr3:49237500	CCDC36	-0.39	-4.92	-0.3	1.58e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9398803	0.865	rs4897181	chr6:126753564	C/T	cg19875578	chr6:126661172	C6orf173	0.49	6.34	0.37	1.1e-9	Male-pattern baldness;
KIRP	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg26354017	chr1:205819088	PM20D1	0.61	6.08	0.36	4.51e-9	Menarche (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23374834	chr10:131631671	NA	0.43	6.58	0.39	2.85e-10	Survival in pancreatic cancer;
KIRP	cis	rs4671458	0.656	rs4671518	chr2:63820219	T/G	cg17519650	chr2:63277830	OTX1	-0.49	-5.01	-0.3	1.02e-6	Subjective well-being;
KIRP	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.31e-13	Life satisfaction;
KIRP	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg07424592	chr7:64974309	NA	0.75	4.93	0.3	1.51e-6	Diabetic kidney disease;
KIRP	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.59	-0.39	2.66e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1620921	0.711	rs9346839	chr6:161255046	C/T	cg01280913	chr6:161186852	NA	-0.39	-5.43	-0.33	1.32e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	6.8	0.4	7.76e-11	Menarche (age at onset);
KIRP	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.5	-0.33	9.71e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg10047753	chr17:41438598	NA	1.12	17.85	0.75	2.87e-46	Menopause (age at onset);
KIRP	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg18306943	chr3:40428807	ENTPD3	-0.46	-6.46	-0.38	5.44e-10	Renal cell carcinoma;
KIRP	cis	rs4776059	1.000	rs4776065	chr15:52929716	A/G	cg25063058	chr15:52860530	ARPP19	-0.51	-5.79	-0.35	2.18e-8	Schizophrenia;
KIRP	cis	rs2637030	0.559	rs1559266	chr5:52851931	C/T	cg06476337	chr5:52856530	NDUFS4	0.56	5.98	0.36	7.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs76793172	0.925	rs111404322	chr19:46360739	C/T	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.26	-0.37	1.69e-9	Eosinophil counts;
KIRP	cis	rs883565	0.655	rs7633233	chr3:39146724	G/T	cg01426195	chr3:39028469	NA	-0.72	-12.13	-0.61	7.53e-27	Handedness;
KIRP	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.62	5.56	0.33	7.18e-8	Gut microbiome composition (summer);
KIRP	cis	rs7267005	0.661	rs8116093	chr20:34415114	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs10203711	1.000	rs10191070	chr2:239565413	A/G	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.46	-8.24	-0.47	1.04e-14	Menarche (age at onset);
KIRP	cis	rs10107145	0.509	rs73209953	chr8:10760112	G/C	cg21625330	chr8:9911636	MSRA	0.43	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg21775007	chr8:11205619	TDH	-0.54	-6.93	-0.4	3.74e-11	Joint mobility (Beighton score);
KIRP	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.34	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.85	10.68	0.56	3.98e-22	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24974229	chr11:62554681	TMEM179B;TAF6L	0.5	6.09	0.36	4.32e-9	Parkinson's disease;
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.66	0.68	2.07e-35	Platelet count;
KIRP	cis	rs12476592	0.602	rs262472	chr2:63833616	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.15	-0.31	5.47e-7	Childhood ear infection;
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.15	-0.31	5.29e-7	Longevity;
KIRP	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs17384381	1.000	rs71652696	chr1:85831792	A/C	cg16011679	chr1:85725395	C1orf52	0.82	7.18	0.42	8.06e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.81	0.45	1.7e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg18461021	chr18:74961002	GALR1	0.52	5.32	0.32	2.29e-7	Obesity-related traits;
KIRP	cis	rs7615316	0.902	rs7610557	chr3:142312371	A/G	cg20824294	chr3:142316082	PLS1	0.22	4.86	0.3	2.07e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9409565	0.826	rs639276	chr9:97206737	G/T	cg04523069	chr9:97136363	HIATL1	0.47	6.19	0.37	2.56e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.56	8.06	0.46	3.34e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.78	9.95	0.54	8.15e-20	Neutrophil percentage of white cells;
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.41	-5.07	-0.31	7.7300000000000005e-07	Longevity;Endometriosis;
KIRP	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.48	-7.03	-0.41	2.07e-11	Schizophrenia;
KIRP	cis	rs4716602	0.596	rs28451598	chr7:156158974	G/A	cg16983916	chr7:156159713	NA	-0.44	-5.54	-0.33	7.93e-8	Anti-saccade response;
KIRP	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs5752773	0.610	rs695700	chr22:28882842	A/T	cg16849201	chr22:29715310	NA	-0.3	-5.07	-0.31	7.84e-7	Vertical cup-disc ratio;
KIRP	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg05370193	chr1:21551575	ECE1	0.43	6.09	0.36	4.31e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg13010199	chr12:38710504	ALG10B	0.58	7.7	0.44	3.36e-13	Heart rate;
KIRP	cis	rs12900413	0.687	rs6496599	chr15:90314582	C/T	cg07116693	chr15:90310901	NA	-0.23	-4.99	-0.3	1.14e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	0.99	18.49	0.76	1.97e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12580194	0.554	rs59097302	chr12:55719030	C/T	cg19537932	chr12:55886519	OR6C68	-0.46	-6.09	-0.36	4.28e-9	Cancer;
KIRP	cis	rs1355223	0.573	rs1148930	chr11:34732225	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.55	6.34	0.37	1.09e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.77	9.88	0.53	1.36e-19	Gestational age at birth (maternal effect);
KIRP	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg10761708	chr20:43804764	PI3	-0.54	-5.6	-0.34	5.61e-8	Blood protein levels;
KIRP	cis	rs7106204	0.748	rs2403891	chr11:24213130	C/T	ch.11.24196551F	chr11:24239977	NA	0.81	9.58	0.52	1.13e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs17801127	1.000	rs17801127	chr2:150564484	C/T	cg05023168	chr6:90351415	NA	0.76	6.13	0.36	3.42e-9	Liver enzyme levels (alanine transaminase);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18722615	chr11:40359642	NA	-0.35	-6.09	-0.36	4.33e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg00405596	chr8:11794950	NA	0.48	6.12	0.36	3.59e-9	Retinal vascular caliber;
KIRP	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg25486957	chr4:152246857	NA	-0.49	-5.54	-0.33	7.86e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2302729	0.578	rs10774052	chr12:2772171	C/T	cg19945202	chr12:2788847	CACNA1C	-0.75	-10.84	-0.57	1.22e-22	Sleep quality;
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg26754761	chr2:177040938	NA	0.3	5.27	0.32	3.04e-7	IgG glycosylation;
KIRP	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg21890820	chr11:65308645	LTBP3	0.38	4.91	0.3	1.7e-6	Bone mineral density;
KIRP	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.12	0.5	2.73e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.35	-7.69	-0.44	3.43e-13	Body mass index;
KIRP	cis	rs1440410	0.795	rs11728962	chr4:144079871	T/G	cg01719995	chr4:144104893	USP38	0.41	5.37	0.32	1.86e-7	Ischemic stroke;
KIRP	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.36	-0.42	2.8e-12	Type 2 diabetes;
KIRP	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs231513	0.954	rs425135	chr17:41984517	A/C	cg26893861	chr17:41843967	DUSP3	-0.51	-4.91	-0.3	1.65e-6	Cognitive function;
KIRP	cis	rs4262150	0.883	rs12186623	chr5:152214254	T/C	cg12297329	chr5:152029980	NA	-0.61	-8.04	-0.46	3.74e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	14.4	0.68	1.68e-34	Gut microbiome composition (summer);
KIRP	cis	rs7536201	1.000	rs1609996	chr1:25301869	T/C	cg23273869	chr1:25296894	NA	-0.41	-5.94	-0.35	9.82e-9	Psoriasis vulgaris;
KIRP	cis	rs9473924	0.657	rs9349560	chr6:50834379	T/C	cg03432817	chr6:50765336	NA	0.35	5.45	0.33	1.23e-7	Body mass index;
KIRP	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg02146966	chr17:18967117	NA	0.43	4.98	0.3	1.22e-6	Schizophrenia;
KIRP	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs6681460	0.576	rs6588203	chr1:66990851	C/T	cg13052034	chr1:66999238	SGIP1	0.43	5.83	0.35	1.74e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9912468	0.966	rs9303504	chr17:64315366	G/C	cg19474267	chr17:64306194	PRKCA	-0.65	-9.32	-0.51	7.11e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs2562456	0.833	rs11880624	chr19:21523830	C/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26314531	chr2:26401878	FAM59B	-0.49	-5.07	-0.31	7.82e-7	Gut microbiome composition (summer);
KIRP	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg01721255	chr8:58191610	C8orf71	0.5	4.89	0.3	1.85e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs7215564	0.908	rs2315922	chr17:78695127	C/T	cg06153925	chr17:78755379	RPTOR	0.49	6.42	0.38	6.88e-10	Myopia (pathological);
KIRP	cis	rs12318506	0.826	rs11180431	chr12:75661200	G/A	cg04728562	chr12:75699417	CAPS2	-0.92	-6.4	-0.38	7.72e-10	Coronary artery calcification;
KIRP	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.85	10.36	0.55	4.24e-21	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs17401966	0.597	rs6667639	chr1:10246471	C/A	cg19773385	chr1:10388646	KIF1B	-0.48	-6.99	-0.41	2.52e-11	Hepatocellular carcinoma;
KIRP	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.7e-15	Calcium levels;
KIRP	cis	rs4332428	1.000	rs67466576	chr10:4977394	A/G	cg19648686	chr10:5044992	AKR1C2	-0.9	-7.89	-0.45	1e-13	Height;
KIRP	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.7	7.14	0.41	1.02e-11	D-dimer levels;
KIRP	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09509909	chr10:93672748	NA	0.43	6.06	0.36	5.16e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg12315302	chr6:26189340	HIST1H4D	0.97	6.82	0.4	7.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16582344	chr1:228270207	ARF1	0.44	6.27	0.37	1.58e-9	Survival in pancreatic cancer;
KIRP	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg11189052	chr15:85197271	WDR73	0.51	5.33	0.32	2.24e-7	Schizophrenia;
KIRP	cis	rs2281603	0.570	rs10133696	chr14:64971159	T/C	cg01860774	chr14:64969374	ZBTB25	0.35	5.65	0.34	4.35e-8	Lymphocyte counts;
KIRP	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-11.45	-0.59	1.25e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.02	0.36	6.47e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs737693	0.573	rs626750	chr11:102720945	G/A	cg19620758	chr11:102826565	MMP13	0.55	5.76	0.34	2.51e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	0.85	11.14	0.58	1.32e-23	Primary sclerosing cholangitis;
KIRP	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.5	-0.78	7.71e-52	Height;
KIRP	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.58	6.25	0.37	1.82e-9	Monocyte percentage of white cells;
KIRP	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg27411982	chr8:10470053	RP1L1	-0.41	-5.22	-0.32	3.85e-7	Triglycerides;
KIRP	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.53	5.25	0.32	3.29e-7	Initial pursuit acceleration;
KIRP	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.83	11.1	0.58	1.83e-23	Menarche (age at onset);
KIRP	cis	rs4363385	0.510	rs7543689	chr1:153046803	A/T	cg07796016	chr1:152779584	LCE1C	-0.46	-5.89	-0.35	1.3e-8	Inflammatory skin disease;
KIRP	cis	rs6838801	0.857	rs903044	chr4:77578750	A/G	cg17476223	chr4:77663285	SHROOM3	0.54	7.58	0.44	7.06e-13	Cleft lip with or without cleft palate;
KIRP	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.68	-13.03	-0.64	7.35e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs3026101	0.671	rs2301740	chr17:5319620	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg14558114	chr2:88469736	THNSL2	0.66	5.37	0.32	1.81e-7	Plasma clusterin levels;
KIRP	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg18944383	chr4:111397179	ENPEP	-0.42	-6.73	-0.39	1.21e-10	Coronary artery disease;
KIRP	trans	rs6902257	0.744	rs2496679	chr6:81319092	T/C	cg06063519	chr15:99274532	IGF1R	-0.61	-6.03	-0.36	5.85e-9	Obesity-related traits;
KIRP	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg25486957	chr4:152246857	NA	-0.48	-5.36	-0.32	1.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	7.59	0.44	6.67e-13	Lymphocyte counts;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22099404	chr17:4458623	MYBBP1A	-0.46	-6.22	-0.37	2.1e-9	Myopia;
KIRP	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	5.93	0.35	1.02e-8	Joint mobility (Beighton score);
KIRP	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.55	7.0	0.41	2.37e-11	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	6.25	0.37	1.81e-9	Breast cancer;
KIRP	cis	rs963731	0.677	rs297122	chr2:39309141	T/C	cg04010122	chr2:39346883	SOS1	-0.94	-5.82	-0.35	1.84e-8	Corticobasal degeneration;
KIRP	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06173319	chr16:90148775	NA	-0.55	-5.17	-0.31	4.78e-7	Skin colour saturation;
KIRP	trans	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs1440410	0.795	rs11100785	chr4:144195557	T/C	cg01719995	chr4:144104893	USP38	0.41	5.28	0.32	2.81e-7	Ischemic stroke;
KIRP	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.93	16.71	0.73	2.1e-42	Height;
KIRP	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.52	-11.26	-0.58	5.57e-24	Refractive error;
KIRP	cis	rs7202877	0.656	rs4888374	chr16:75322228	T/C	cg03315344	chr16:75512273	CHST6	0.59	5.74	0.34	2.72e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs861020	0.560	rs649275	chr1:209950681	T/C	cg22029157	chr1:209979665	IRF6	-0.39	-5.99	-0.36	7.58e-9	Orofacial clefts;
KIRP	cis	rs8079658	0.904	rs11658709	chr17:63774643	A/G	cg18091269	chr17:63822838	CCDC46	-0.52	-6.46	-0.38	5.71e-10	Post bronchodilator FEV1;
KIRP	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.51	-5.97	-0.36	8.44e-9	Lung cancer;
KIRP	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg15691649	chr6:25882328	NA	-0.43	-5.29	-0.32	2.74e-7	Blood metabolite levels;
KIRP	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.3	-0.37	1.33e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	14.19	0.67	8.5e-34	Platelet count;
KIRP	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.42	-0.55	2.65e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs662064	0.890	rs1632108	chr1:10561923	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-5.06	-0.31	8.16e-7	Asthma;
KIRP	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.75	-9.36	-0.51	5.24e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.43	-0.38	6.62e-10	Aortic root size;
KIRP	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg07596299	chr11:71824057	C11orf51	-0.89	-5.94	-0.35	9.61e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	1.07	17.81	0.75	3.93e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs580438	0.529	rs9811159	chr3:13400721	C/G	cg10657019	chr3:13328039	NA	-0.49	-6.42	-0.38	7.12e-10	Myringotomy;
KIRP	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.2	-0.46	1.38e-14	Monocyte percentage of white cells;
KIRP	cis	rs10908557	0.709	rs72694300	chr1:154056834	A/T	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.33	-4.85	-0.3	2.22e-6	Age at first birth;
KIRP	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg19899395	chr1:46959349	NA	0.45	5.45	0.33	1.21e-7	Monobrow;
KIRP	trans	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg16141378	chr3:129829833	LOC729375	-0.55	-7.06	-0.41	1.68e-11	Neuroticism;
KIRP	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.05	-0.31	8.61e-7	Retinal vascular caliber;
KIRP	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.89	-11.65	-0.6	2.84e-25	Type 2 diabetes;
KIRP	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.96	-0.54	7.46e-20	Response to antipsychotic treatment;
KIRP	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-7.91	-0.45	8.6e-14	Vitiligo;
KIRP	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.25	-0.42	5.26e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs3767633	0.858	rs2341468	chr1:161862312	G/A	cg09175582	chr1:161736000	ATF6	0.74	6.03	0.36	5.88e-9	IgG glycosylation;
KIRP	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.8	11.86	0.6	6.04e-26	Height;
KIRP	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.29	-0.32	2.71e-7	Neuroticism;
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg09699651	chr6:150184138	LRP11	0.47	6.01	0.36	6.54e-9	Lung cancer;
KIRP	cis	rs41464348	0.720	rs3754829	chr2:33499107	G/A	cg16572410	chr2:33467199	LTBP1	0.38	4.99	0.3	1.15e-6	Height;
KIRP	cis	rs7712401	0.601	rs35479600	chr5:122324470	G/T	cg19412675	chr5:122181750	SNX24	-0.51	-5.5	-0.33	9.7e-8	Mean platelet volume;
KIRP	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.6e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16936870	0.543	rs2977986	chr8:71143556	A/C	cg14232793	chr8:71155543	NCOA2	-0.59	-7.2	-0.42	7.33e-12	QT interval;
KIRP	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg24315340	chr6:146058215	EPM2A	-0.43	-5.62	-0.34	5.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	1.06	11.97	0.61	2.61e-26	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg16486109	chr11:613632	IRF7	0.43	5.22	0.32	3.9e-7	Systemic lupus erythematosus;
KIRP	cis	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg00405596	chr8:11794950	NA	-0.43	-5.68	-0.34	3.74e-8	Retinal vascular caliber;
KIRP	cis	rs34286592	0.929	rs10204	chr16:29826538	C/T	cg08218971	chr16:29826754	C16orf53;PRRT2	0.33	5.25	0.32	3.26e-7	Multiple sclerosis;
KIRP	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-0.83	-8.87	-0.49	1.55e-16	Gut microbiome composition (summer);
KIRP	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.87	-11.61	-0.59	3.93e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.38	-5.0	-0.3	1.1e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.43	-6.17	-0.37	2.84e-9	Platelet count;
KIRP	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-12.64	-0.63	1.47e-28	Vitiligo;
KIRP	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg26876637	chr1:152193138	HRNR	-0.78	-9.06	-0.5	4.14e-17	Atopic dermatitis;
KIRP	cis	rs258892	1.000	rs686233	chr5:72398895	C/T	cg21869765	chr5:72125136	TNPO1	-0.54	-6.62	-0.39	2.22e-10	Small cell lung carcinoma;
KIRP	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-4.97	-0.3	1.23e-6	Alzheimer's disease (late onset);
KIRP	cis	rs17453880	0.929	rs11951715	chr5:151953104	A/G	cg12297329	chr5:152029980	NA	-0.68	-10.18	-0.54	1.55e-20	Subjective well-being;
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.59e-8	Life satisfaction;
KIRP	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.64	-8.34	-0.47	5.49e-15	Inflammatory bowel disease;
KIRP	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs2071403	0.933	rs12329058	chr2:1400608	C/G	cg07083862	chr2:1417248	TPO	-0.33	-5.29	-0.32	2.64e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs4851254	0.961	rs13000759	chr2:100753903	A/T	cg17356467	chr2:100759845	AFF3	-0.6	-7.17	-0.42	8.7e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2249694	0.960	rs11101890	chr10:135421321	G/A	cg20169779	chr10:135381914	SYCE1	-0.41	-4.91	-0.3	1.64e-6	Obesity-related traits;
KIRP	cis	rs2274273	0.686	rs66842809	chr14:55630571	T/C	cg10130446	chr14:55658398	DLGAP5	-0.46	-5.31	-0.32	2.47e-7	Protein biomarker;
KIRP	cis	rs7799006	0.898	rs34418140	chr7:2278183	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.02	-0.3	1.01e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.84	-12.27	-0.62	2.61e-27	Systemic lupus erythematosus;
KIRP	cis	rs4363385	0.510	rs11590835	chr1:153047166	T/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.23	-0.37	2.01e-9	Inflammatory skin disease;
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg08901578	chr4:187885870	NA	-0.44	-6.6	-0.39	2.45e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7173389	0.560	rs7174643	chr15:73680301	A/C	cg01796676	chr15:73680284	NA	0.48	5.44	0.33	1.29e-7	Resting heart rate;
KIRP	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.59	7.16	0.42	9.24e-12	Multiple sclerosis;
KIRP	cis	rs67366981	0.841	rs55903932	chr14:77706389	T/C	cg22824376	chr14:77648248	TMEM63C	0.83	6.19	0.37	2.49e-9	Obsessive-compulsive symptoms;
KIRP	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.63	9.17	0.5	1.92e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg07116693	chr15:90310901	NA	-0.23	-4.99	-0.3	1.14e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7929679	0.602	rs11032872	chr11:34806192	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.35	0.32	1.98e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.71	-10.15	-0.54	1.85e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01011614	chr20:44600351	ZNF335	0.45	6.04	0.36	5.77e-9	Pancreatic cancer;
KIRP	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.15e-20	Dupuytren's disease;
KIRP	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.42	0.62	7.93e-28	Smoking behavior;
KIRP	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03934478	chr11:495069	RNH1	0.78	6.45	0.38	5.86e-10	Body mass index;
KIRP	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.43	-0.38	6.59e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.37	0.38	9.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22701913	chr19:11457250	TMEM205;CCDC159	0.47	6.02	0.36	6.37e-9	Parkinson's disease;
KIRP	cis	rs867371	1.000	rs6495642	chr15:82457497	G/C	cg00614314	chr15:82944287	LOC80154	0.55	6.61	0.39	2.4e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.9	-0.3	1.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.96	-12.99	-0.64	1.02e-29	Menopause (age at onset);
KIRP	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.86	-13.89	-0.66	8.89e-33	Breast cancer;
KIRP	cis	rs12049351	0.667	rs34382491	chr1:229620630	G/A	cg11742688	chr1:229674241	ABCB10	-0.38	-5.55	-0.33	7.45e-8	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11838876	chr1:75668600	SLC44A5	-0.44	-6.05	-0.36	5.32e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.47	-5.85	-0.35	1.56e-8	Longevity;Endometriosis;
KIRP	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.72	0.39	1.23e-10	Platelet count;
KIRP	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg10935138	chr17:73851978	WBP2	0.59	7.7	0.44	3.35e-13	Psoriasis;
KIRP	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg25173405	chr17:45401733	C17orf57	0.42	5.37	0.32	1.79e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.16	10.11	0.54	2.63e-20	Atopic dermatitis;
KIRP	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.5	-0.38	4.42e-10	Total cholesterol levels;
KIRP	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg04865290	chr3:52927548	TMEM110	-0.62	-6.81	-0.4	7.65e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg24881330	chr22:46731750	TRMU	0.78	5.27	0.32	2.96e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2224391	0.578	rs766339	chr6:5243506	G/A	cg13962347	chr6:5174647	LYRM4	-0.76	-10.53	-0.56	1.21e-21	Height;
KIRP	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.71	10.77	0.57	2.11e-22	Dupuytren's disease;
KIRP	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.1	12.58	0.63	2.31e-28	Vitiligo;
KIRP	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.7	-9.6	-0.52	9.98e-19	Menopause (age at onset);
KIRP	cis	rs6142102	0.961	rs2056990	chr20:32623464	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	6.79	0.4	8.18e-11	Skin pigmentation;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07775675	chr17:74379922	SPHK1	0.6	6.04	0.36	5.59e-9	Lung function (FEV1);
KIRP	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.41	-5.36	-0.32	1.94e-7	Renal cell carcinoma;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.5	6.9	0.4	4.45e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7714584	1.000	rs11747065	chr5:150295486	C/T	cg22134413	chr5:150180641	NA	0.82	6.59	0.39	2.68e-10	Crohn's disease;
KIRP	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.59	7.59	0.44	6.72e-13	Myopia (pathological);
KIRP	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.65	7.89	0.45	1.01e-13	Aortic root size;
KIRP	cis	rs12496230	0.794	rs2083928	chr3:66860014	T/C	cg04995300	chr3:66848608	NA	0.45	6.97	0.41	2.88e-11	Type 2 diabetes;
KIRP	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg15352829	chr14:105391018	PLD4	0.5	10.37	0.55	3.98e-21	Rheumatoid arthritis;
KIRP	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg01304814	chr3:48885189	PRKAR2A	0.78	5.66	0.34	4.19e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4566357	0.930	rs13424003	chr2:227926860	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-8.23	-0.46	1.07e-14	Colorectal cancer;
KIRP	cis	rs4474465	0.850	rs10899536	chr11:78216992	C/A	cg27205649	chr11:78285834	NARS2	0.62	7.87	0.45	1.16e-13	Alzheimer's disease (survival time);
KIRP	cis	rs4443100	0.621	rs5996447	chr22:23356946	G/A	cg21100191	chr22:23484243	RTDR1	0.56	5.55	0.33	7.54e-8	Serum parathyroid hormone levels;
KIRP	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs3126085	0.935	rs11589587	chr1:152184129	T/C	cg26876637	chr1:152193138	HRNR	-0.85	-8.46	-0.47	2.4e-15	Atopic dermatitis;
KIRP	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.63	7.82	0.45	1.51e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.43	-5.03	-0.31	9.35e-7	Schizophrenia;
KIRP	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.45	5.76	0.34	2.54e-8	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.31	5.03	0.31	9.25e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	6.85	0.4	5.81e-11	Obesity-related traits;
KIRP	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg12598211	chr12:123634384	NA	0.43	5.32	0.32	2.32e-7	Neutrophil percentage of white cells;
KIRP	cis	rs11574514	1.000	rs59376497	chr16:67681170	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.43	-0.33	1.39e-7	Crohn's disease;
KIRP	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.98	15.04	0.69	1.04e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2953174	1.000	rs2975754	chr2:241522634	G/A	cg07929629	chr2:241523174	NA	0.62	5.24	0.32	3.52e-7	Bipolar disorder;
KIRP	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.71	-6.53	-0.38	3.65e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg16497661	chr14:103986332	CKB	0.81	13.7	0.66	3.82e-32	Body mass index;
KIRP	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg11663144	chr21:46675770	NA	-0.57	-7.92	-0.45	8.03e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12963246	chr6:28129442	ZNF389	0.42	5.08	0.31	7.36e-7	Parkinson's disease;
KIRP	cis	rs2425143	0.818	rs6060726	chr20:34555878	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs11783469	0.522	rs11781808	chr8:23256905	G/A	cg00472375	chr8:23315376	ENTPD4	0.48	4.88	0.3	1.89e-6	Reticulocyte count;
KIRP	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.25	6.69	0.39	1.52e-10	Crohn's disease;
KIRP	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03971828	chr1:25071582	CLIC4	0.52	6.4	0.38	7.85e-10	Parkinson's disease;
KIRP	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.64	-0.39	2.03e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg06937882	chr20:24974362	C20orf3	-0.44	-4.97	-0.3	1.24e-6	Blood protein levels;
KIRP	cis	rs28374715	0.510	rs28478807	chr15:41558620	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-10.3	-0.55	6.33e-21	Ulcerative colitis;
KIRP	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-5.83	-0.35	1.77e-8	Hepatocellular carcinoma;
KIRP	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg06917634	chr15:78832804	PSMA4	0.5	5.74	0.34	2.82e-8	Sudden cardiac arrest;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17832277	chr13:103249000	TPP2	0.68	6.27	0.37	1.6e-9	Lung function (FEV1);
KIRP	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.4	-0.33	1.6e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs72730918	0.564	rs6493511	chr15:51901605	A/G	cg14296394	chr15:51910925	DMXL2	-0.77	-10.66	-0.56	4.73e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs220324	0.647	rs9981668	chr21:43559780	G/T	cg09727148	chr21:43560719	UMODL1	0.44	5.21	0.32	4e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.31	9.77e-7	Initial pursuit acceleration;
KIRP	trans	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs8014252	0.803	rs8012025	chr14:71012205	T/C	cg11204974	chr14:71022665	NA	-0.61	-6.41	-0.38	7.33e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg23533926	chr12:111358616	MYL2	-0.49	-6.43	-0.38	6.65e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10858047	0.883	rs7555301	chr1:115199930	G/A	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.53	-7.48	-0.43	1.29e-12	Motion sickness;
KIRP	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.69	9.9	0.53	1.19e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs4704187	0.649	rs58999738	chr5:74545798	A/G	cg03227963	chr5:74354835	NA	0.41	5.96	0.36	8.61e-9	Response to amphetamines;
KIRP	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg01411142	chr8:19674711	INTS10	0.45	4.92	0.3	1.62e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg03678062	chr6:149772716	ZC3H12D	0.31	4.99	0.3	1.13e-6	Dupuytren's disease;
KIRP	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg18944383	chr4:111397179	ENPEP	0.48	8.15	0.46	1.83e-14	Height;
KIRP	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg26513180	chr16:89883248	FANCA	0.84	5.81	0.35	1.96e-8	Skin colour saturation;
KIRP	cis	rs7267005	1.000	rs75473099	chr20:34450706	G/A	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs12311304	1.000	rs1120565	chr12:15401796	A/T	cg08258403	chr12:15378311	NA	0.34	5.15	0.31	5.26e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs8014252	0.803	rs73283917	chr14:71033156	G/A	cg11204974	chr14:71022665	NA	-0.61	-6.38	-0.38	8.6e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9653442	0.545	rs11123814	chr2:100767082	A/G	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13547925	chr1:42501737	NA	-0.48	-6.42	-0.38	6.89e-10	Metabolic traits;
KIRP	cis	rs963731	0.649	rs6704656	chr2:39210398	A/T	cg04010122	chr2:39346883	SOS1	0.75	5.12	0.31	6.25e-7	Corticobasal degeneration;
KIRP	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg13798780	chr7:105162888	PUS7	0.64	5.71	0.34	3.17e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7010267	0.740	rs7464496	chr8:119954842	T/C	cg13268132	chr8:119964037	TNFRSF11B	0.41	4.95	0.3	1.39e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs73200209	0.744	rs3741768	chr12:116446445	C/T	cg01776926	chr12:116560359	MED13L	-0.55	-5.84	-0.35	1.62e-8	Total body bone mineral density;
KIRP	cis	rs6746896	0.614	rs7582249	chr2:97463529	G/A	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.49	-0.43	1.2e-12	Bipolar disorder;
KIRP	cis	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.85e-9	Leprosy;
KIRP	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.12	8.29	0.47	7.26e-15	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.88	-12.41	-0.62	8.82e-28	Cocaine dependence;
KIRP	cis	rs71636778	0.596	rs2095637	chr1:27232845	A/G	cg12203394	chr1:27248618	NUDC	0.62	5.31	0.32	2.48e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.0	0.36	7e-9	Menopause (age at onset);
KIRP	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.24	13.38	0.65	4.91e-31	Uric acid levels;
KIRP	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-4.91	-0.3	1.69e-6	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs8073060	0.785	rs11659054	chr17:33867678	C/T	cg19694781	chr19:47549865	TMEM160	0.66	8.27	0.47	8.23e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.68	-0.48	5.64e-16	Neuroticism;
KIRP	cis	rs4478137	0.824	rs4691905	chr4:164221437	T/C	cg06758707	chr4:164254230	NPY1R	0.75	9.96	0.54	7.31e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08048268	chr3:133502702	NA	-0.45	-5.2	-0.31	4.12e-7	Iron status biomarkers;
KIRP	cis	rs17123764	0.539	rs7979262	chr12:50065146	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.93	0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7084402	0.967	rs1626532	chr10:60294685	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.71	-0.56	3.12e-22	Refractive error;
KIRP	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg16989719	chr2:238392110	NA	-0.38	-4.93	-0.3	1.49e-6	Prostate cancer;
KIRP	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg03351412	chr1:154909251	PMVK	0.59	7.05	0.41	1.83e-11	Prostate cancer;
KIRP	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg22437258	chr11:111473054	SIK2	-0.69	-7.71	-0.44	3.08e-13	Primary sclerosing cholangitis;
KIRP	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	9.95e-11	Bipolar disorder;
KIRP	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg00784671	chr22:46762841	CELSR1	-0.85	-8.28	-0.47	8e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg06204229	chr3:52865917	ITIH4	0.53	5.93	0.35	1.02e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16447950	chr5:562315	NA	-0.47	-5.68	-0.34	3.78e-8	Obesity-related traits;
KIRP	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.13	-0.31	5.79e-7	Tonsillectomy;
KIRP	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.65	6.5	0.38	4.41e-10	Axial length;
KIRP	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg03929089	chr4:120376271	NA	-0.55	-6.38	-0.38	8.81e-10	HDL cholesterol;
KIRP	cis	rs1978968	0.956	rs7291155	chr22:18444599	C/T	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14765337	chr11:45931715	PEX16	0.49	6.74	0.39	1.1e-10	Survival in pancreatic cancer;
KIRP	cis	rs193541	0.555	rs2438151	chr5:122199197	A/G	cg19412675	chr5:122181750	SNX24	0.6	6.37	0.38	9.17e-10	Glucose homeostasis traits;
KIRP	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg24803719	chr17:45855879	NA	-0.4	-5.43	-0.33	1.35e-7	IgG glycosylation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10352719	chr14:24769404	DHRS1;C14orf21	0.54	6.29	0.37	1.45e-9	Smoking initiation;
KIRP	cis	rs7945718	0.870	rs10831903	chr11:12758660	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.45	-5.43	-0.33	1.37e-7	Educational attainment (years of education);
KIRP	cis	rs934734	0.563	rs11126034	chr2:65580221	C/T	cg08085232	chr2:65598271	SPRED2	0.56	7.15	0.41	1.01e-11	Rheumatoid arthritis;
KIRP	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.59	-6.75	-0.4	1.06e-10	Urate levels;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.8	-13.67	-0.66	5.13e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.76	-9.53	-0.52	1.54e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg18612461	chr15:75251733	NA	0.33	5.12	0.31	6.14e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs72820985	1.000	rs8053858	chr16:80844404	A/G	cg04448709	chr16:81349954	GAN	-0.5	-5.07	-0.31	7.99e-7	Breast cancer;
KIRP	cis	rs2271400	1.000	rs2271400	chr8:56791244	C/T	cg08894788	chr8:56792171	LYN	-0.36	-5.65	-0.34	4.34e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
KIRP	trans	rs399593	0.767	rs389258	chr10:30904892	T/C	cg02831383	chr1:3329820	PRDM16	0.59	6.1	0.36	4.06e-9	Dental caries;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26733140	chr11:63993641	NUDT22;TRPT1	0.44	6.19	0.37	2.45e-9	Parkinson's disease;
KIRP	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.62	7.93	0.45	7.51e-14	Crohn's disease;
KIRP	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-5.03	-0.31	9.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.43	-6.25	-0.37	1.83e-9	Personality dimensions;
KIRP	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg00495681	chr13:53174319	NA	0.39	5.28	0.32	2.79e-7	Lewy body disease;
KIRP	cis	rs11203032	0.831	rs11203028	chr10:90956550	C/T	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg25319279	chr11:5960081	NA	-0.6	-6.12	-0.36	3.73e-9	DNA methylation (variation);
KIRP	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4936894	0.500	rs11602170	chr11:124167103	C/G	cg27160556	chr11:124181099	OR8D1	-0.45	-6.5	-0.38	4.36e-10	Aging (time to death);
KIRP	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg11189052	chr15:85197271	WDR73	0.52	4.93	0.3	1.51e-6	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.47	-6.09	-0.36	4.37e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg24253500	chr15:84953950	NA	0.51	5.85	0.35	1.6e-8	Schizophrenia;
KIRP	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.76	-6.51	-0.38	4.09e-10	Schizophrenia;
KIRP	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg18825076	chr15:78729989	IREB2	-0.43	-5.07	-0.31	7.81e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs984222	0.527	rs2247883	chr1:119577837	A/T	cg18261050	chr1:119551319	NA	0.34	4.87	0.3	1.97e-6	Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg07269724	chr19:12904655	NA	0.72	6.14	0.36	3.31e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg17718321	chr1:152188247	HRNR	-0.54	-7.97	-0.45	5.81e-14	Inflammatory skin disease;
KIRP	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.45	-0.38	6.04e-10	Mood instability;
KIRP	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.42	-0.38	6.83e-10	Daytime sleep phenotypes;
KIRP	cis	rs28489187	0.643	rs2011825	chr1:85844671	T/C	cg16011679	chr1:85725395	C1orf52	0.5	6.16	0.37	2.87e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2882667	0.931	rs10074461	chr5:138319815	G/T	cg04439458	chr5:138467593	SIL1	-0.42	-6.83	-0.4	6.75e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.79	-8.76	-0.49	3.17e-16	Diastolic blood pressure;
KIRP	trans	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg13565492	chr6:43139072	SRF	-0.94	-8.67	-0.48	5.79e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg00405596	chr8:11794950	NA	-0.48	-6.32	-0.37	1.22e-9	Retinal vascular caliber;
KIRP	cis	rs2067615	0.931	rs1216006	chr12:107187780	G/A	cg21360079	chr12:107162445	NA	-0.49	-6.33	-0.37	1.15e-9	Heart rate;
KIRP	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	5.06	0.31	8.33e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9826463	1.000	rs28378300	chr3:142333064	T/C	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.56	6.78	0.4	8.98e-11	Height;
KIRP	cis	rs4740619	0.619	rs11788695	chr9:16032323	G/A	cg14451791	chr9:16040625	NA	-0.41	-5.3	-0.32	2.53e-7	Body mass index;
KIRP	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg02887458	chr19:19495540	GATAD2A	0.47	5.69	0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14388783	chr9:103115158	TEX10	0.49	6.07	0.36	4.74e-9	Parkinson's disease;
KIRP	cis	rs15676	0.783	rs7033070	chr9:131586374	G/A	cg00228799	chr9:131580591	ENDOG	-0.51	-5.63	-0.34	4.84e-8	Blood metabolite levels;
KIRP	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg23594656	chr7:65796392	TPST1	0.47	7.39	0.43	2.33e-12	Aortic root size;
KIRP	cis	rs10761482	0.500	rs1938535	chr10:62273900	A/G	cg01186212	chr10:62110162	ANK3	-0.31	-5.24	-0.32	3.37e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23819286	chr1:185984412	HMCN1	-0.39	-6.04	-0.36	5.54e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4363385	0.510	rs11488175	chr1:153039778	A/G	cg07796016	chr1:152779584	LCE1C	0.47	5.91	0.35	1.13e-8	Inflammatory skin disease;
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs78487399	0.808	rs78108161	chr2:43663848	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.24	-0.32	3.4e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9420	0.784	rs12798206	chr11:57668479	T/G	cg23127183	chr11:57508653	C11orf31	-0.48	-5.59	-0.34	5.93e-8	Schizophrenia;
KIRP	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.83	9.39	0.51	4.26e-18	High light scatter reticulocyte count;
KIRP	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.67	8.28	0.47	7.71e-15	Schizophrenia;
KIRP	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.56	7.75	0.44	2.43e-13	Schizophrenia;
KIRP	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.38	0.55	3.66e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs11169552	0.510	rs10876058	chr12:50956266	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-4.95	-0.3	1.39e-6	Colorectal cancer;
KIRP	trans	rs10027350	0.734	rs313555	chr4:25245437	A/G	cg09449104	chr2:200935	NA	-0.38	-6.14	-0.36	3.31e-9	Childhood ear infection;
KIRP	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg21775007	chr8:11205619	TDH	0.52	6.89	0.4	4.52e-11	Mood instability;
KIRP	cis	rs9309473	1.000	rs2901438	chr2:73665656	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.7	-0.34	3.36e-8	Metabolite levels;
KIRP	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-6.1	-0.36	4.2e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15653491	chr7:102722230	ARMC10	0.51	6.14	0.36	3.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg00579200	chr11:133705235	NA	-0.38	-4.86	-0.3	2.13e-6	Childhood ear infection;
KIRP	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.33	-0.32	2.26e-7	Pulmonary function;
KIRP	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.08	0.58	2.02e-23	Exhaled nitric oxide levels;
KIRP	cis	rs6142102	0.502	rs58393429	chr20:32545802	C/G	cg08999081	chr20:33150536	PIGU	0.39	4.87	0.3	1.98e-6	Skin pigmentation;
KIRP	cis	rs7611694	0.507	rs7642163	chr3:113223410	C/T	cg11138929	chr3:113251189	SIDT1	0.38	4.92	0.3	1.59e-6	Prostate cancer;
KIRP	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg04990556	chr1:26633338	UBXN11	0.67	6.44	0.38	6.12e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.58	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.56	-4.95	-0.3	1.41e-6	Mosquito bite size;
KIRP	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.34	-0.32	2.07e-7	Subjective well-being;
KIRP	cis	rs4774899	1.000	rs12901780	chr15:57258531	T/A	cg13626582	chr15:57592083	LOC283663	-0.21	-5.04	-0.31	8.99e-7	Urinary tract infection frequency;
KIRP	cis	rs8028182	0.636	rs28432989	chr15:75768297	T/C	cg20655648	chr15:75932815	IMP3	0.54	6.89	0.4	4.7e-11	Sudden cardiac arrest;
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.48	6.07	0.36	4.93e-9	Testicular germ cell tumor;
KIRP	cis	rs858239	0.600	rs7788821	chr7:23133645	A/T	cg23682824	chr7:23144976	KLHL7	0.45	5.34	0.32	2.15e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.62	9.52	0.52	1.68e-18	Lung cancer;
KIRP	cis	rs4654899	0.802	rs7519685	chr1:21192623	G/A	cg05370193	chr1:21551575	ECE1	0.41	5.24	0.32	3.45e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2904967	0.852	rs1633466	chr11:65016173	C/G	cg12562828	chr11:65076843	NA	-0.61	-8.96	-0.5	8.45e-17	Mean corpuscular volume;
KIRP	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.81	0.49	2.34e-16	Bipolar disorder;
KIRP	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg16230307	chr14:35515116	FAM177A1	0.75	7.1	0.41	1.32e-11	Psoriasis;
KIRP	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.28	-0.58	4.81e-24	Breast cancer;
KIRP	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.37	5.03	0.31	9.61e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7554547	0.630	rs4845889	chr1:11971345	T/C	cg07603449	chr1:11986842	KIAA2013	-0.39	-5.04	-0.31	9.22e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg06917634	chr15:78832804	PSMA4	0.47	4.96	0.3	1.3e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg10253484	chr15:75165896	SCAMP2	-0.61	-7.14	-0.41	1.03e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg09754948	chr16:28834200	ATXN2L	0.5	5.66	0.34	4.28e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.89	0.35	1.26e-8	Morning vs. evening chronotype;
KIRP	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg20891283	chr12:69753455	YEATS4	0.63	6.56	0.39	3.19e-10	Response to diuretic therapy;
KIRP	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	10.66	0.56	4.79e-22	Blood protein levels;
KIRP	cis	rs2625529	0.641	rs11852789	chr15:72265494	G/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-5.05	-0.31	8.71e-7	Eosinophil percentage of white cells;
KIRP	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.34	4.95	0.3	1.35e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.12	0.36	3.59e-9	Menopause (age at onset);
KIRP	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg10047753	chr17:41438598	NA	-1.0	-15.14	-0.69	4.93e-37	Menopause (age at onset);
KIRP	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg23594656	chr7:65796392	TPST1	-0.44	-6.16	-0.37	2.93e-9	Aortic root size;
KIRP	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg18306943	chr3:40428807	ENTPD3	0.44	5.64	0.34	4.74e-8	Renal cell carcinoma;
KIRP	cis	rs77861329	1.000	rs1237830	chr3:52202820	T/C	cg08692210	chr3:52188851	WDR51A	0.96	7.46	0.43	1.52e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs7221595	0.825	rs12942967	chr17:3921834	C/T	cg11204139	chr17:3907470	NA	0.57	5.79	0.35	2.14e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.94	0.3	1.41e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6547631	0.622	rs4240200	chr2:85925529	A/G	cg24620635	chr2:85921963	GNLY	0.32	5.06	0.31	8.31e-7	Blood protein levels;
KIRP	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg03585969	chr10:35415529	CREM	0.84	10.09	0.54	2.9e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg08405219	chr6:89855764	PM20D2	0.5	6.06	0.36	5.09e-9	DNA methylation (variation);
KIRP	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg09507567	chr10:124027408	NA	0.32	5.79	0.35	2.09e-8	Total body bone mineral density;
KIRP	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.31	-0.32	2.5e-7	Blood metabolite levels;
KIRP	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.79	-15.03	-0.69	1.2e-36	Obesity-related traits;
KIRP	cis	rs6083	0.571	rs17190678	chr15:58847372	C/G	cg05156742	chr15:59063176	FAM63B	-0.5	-6.16	-0.37	2.88e-9	Schizophrenia;
KIRP	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.03	-16.93	-0.73	3.61e-43	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1538970	0.962	rs4660301	chr1:45820149	T/A	cg05343316	chr1:45956843	TESK2	0.63	7.32	0.42	3.56e-12	Platelet count;
KIRP	cis	rs55788414	0.651	rs2317121	chr16:81182826	T/G	cg06400318	chr16:81190750	PKD1L2	-1.01	-8.67	-0.48	5.91e-16	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg24375607	chr4:120327624	NA	0.55	6.25	0.37	1.77e-9	Corneal astigmatism;
KIRP	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-9.33	-0.51	6.64e-18	Chronic sinus infection;
KIRP	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.47	-6.36	-0.38	9.59e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs9929218	0.748	rs34592833	chr16:68739125	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-11.03	-0.58	2.93e-23	Colorectal cancer;
KIRP	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg25801113	chr15:45476975	SHF	0.43	7.89	0.45	9.79e-14	Uric acid levels;
KIRP	cis	rs16912285	0.688	rs12277966	chr11:24286633	G/A	ch.11.24196551F	chr11:24239977	NA	0.78	7.23	0.42	6.12e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06481639	chr22:41940642	POLR3H	0.69	7.02	0.41	2.2e-11	Vitiligo;
KIRP	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.55	-0.33	7.55e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.49	5.72	0.34	3.14e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs28595532	0.557	rs28657902	chr4:119305491	C/T	cg21605333	chr4:119757512	SEC24D	0.58	5.82	0.35	1.86e-8	Cannabis dependence symptom count;
KIRP	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.55	0.43	8.31e-13	White blood cell count;
KIRP	cis	rs17065868	1.000	rs61947966	chr13:45076592	A/G	cg10246903	chr13:45222710	NA	0.6	6.1	0.36	4.2e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1620921	0.505	rs4708882	chr6:161203182	C/T	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs888194	0.738	rs731178	chr12:109981678	C/T	cg05360138	chr12:110035743	NA	0.4	4.89	0.3	1.84e-6	Neuroticism;
KIRP	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.44	-0.43	1.71e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs12823128	0.766	rs35781849	chr12:26926197	A/G	cg14081884	chr12:26986758	ITPR2	0.39	4.9	0.3	1.76e-6	Birth weight;
KIRP	cis	rs7289126	1.000	rs5756986	chr22:38640841	A/G	cg25457927	chr22:38595422	NA	-0.31	-6.6	-0.39	2.53e-10	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06173319	chr16:90148775	NA	0.57	5.28	0.32	2.82e-7	Skin colour saturation;
KIRP	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.93	15.23	0.7	2.33e-37	Height;
KIRP	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.85	0.35	1.58e-8	Total cholesterol levels;
KIRP	cis	rs3922844	0.609	rs11721012	chr3:38635874	G/A	cg22884020	chr3:38081186	DLEC1	-0.39	-4.91	-0.3	1.69e-6	P wave duration;PR interval;QT interval;QRS duration;
KIRP	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.91	-10.63	-0.56	5.77e-22	Body mass index;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.71e-7	Life satisfaction;
KIRP	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.03e-7	Coronary artery disease;
KIRP	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg10645314	chr2:3704589	ALLC	-0.49	-6.29	-0.37	1.44e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08805041	chr16:621841	PIGQ	-0.38	-5.27	-0.32	3.01e-7	Height;
KIRP	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.09	0.54	3.04e-20	Total body bone mineral density;
KIRP	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.67	7.7	0.44	3.37e-13	Carotid intima media thickness;
KIRP	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.43	4.94	0.3	1.43e-6	Tonsillectomy;
KIRP	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg06585982	chr3:143692056	C3orf58	0.61	7.73	0.44	2.67e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.44	6.05	0.36	5.49e-9	Sitting height ratio;
KIRP	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg18441811	chr11:71824068	C11orf51	-0.78	-5.29	-0.32	2.67e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04597389	chr17:79935740	ASPSCR1	0.47	6.1	0.36	4e-9	Myopia (pathological);
KIRP	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.51	1.4e-17	Morning vs. evening chronotype;
KIRP	cis	rs17030434	0.682	rs1339	chr4:154631563	T/C	cg14289246	chr4:154710475	SFRP2	-0.72	-8.19	-0.46	1.42e-14	Electrocardiographic conduction measures;
KIRP	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg11833968	chr6:79620685	NA	-0.45	-6.93	-0.4	3.73e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12936587	0.869	rs9630706	chr17:17531791	C/T	cg01246520	chr17:17644344	RAI1	-0.34	-5.56	-0.33	7.16e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.08	-0.36	4.49e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs16936870	0.543	rs877181	chr8:71077288	G/A	cg14232793	chr8:71155543	NCOA2	-0.55	-6.32	-0.37	1.21e-9	QT interval;
KIRP	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.53	-6.62	-0.39	2.28e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	8.7	0.48	4.94e-16	Platelet count;
KIRP	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.05	-0.36	5.4e-9	Neuroticism;
KIRP	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg02297831	chr4:17616191	MED28	0.52	6.57	0.39	2.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17125944	0.556	rs11625479	chr14:53354172	A/C	cg00686598	chr14:53173677	PSMC6	-0.69	-6.46	-0.38	5.67e-10	Alzheimer's disease (late onset);
KIRP	cis	rs4974559	0.585	rs1680025	chr4:1265477	T/C	cg02980000	chr4:1222292	CTBP1	-0.7	-7.77	-0.44	2.09e-13	Systolic blood pressure;
KIRP	cis	rs8177876	0.749	rs1035541	chr16:81098854	G/C	cg08591886	chr16:81111003	C16orf46	-0.74	-5.93	-0.35	1.03e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg18306943	chr3:40428807	ENTPD3	0.45	5.91	0.35	1.12e-8	Renal cell carcinoma;
KIRP	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.73e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02602480	chr2:62422689	B3GNT2	0.46	6.05	0.36	5.32e-9	Smoking initiation;
KIRP	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg14580859	chr9:123691850	NA	0.36	5.1	0.31	6.75e-7	Rheumatoid arthritis;
KIRP	cis	rs6546324	1.000	rs2902026	chr2:67856440	G/C	cg15745817	chr2:67799979	NA	-0.43	-5.63	-0.34	4.87e-8	Endometriosis;
KIRP	cis	rs7715811	1.000	rs7715811	chr5:13769974	C/T	cg07548982	chr5:13769939	DNAH5	-0.52	-6.36	-0.38	9.53e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg05315796	chr3:52349193	DNAH1	0.55	8.76	0.49	3.28e-16	Bipolar disorder;
KIRP	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg22875332	chr1:76189707	ACADM	-0.36	-5.37	-0.32	1.84e-7	Daytime sleep phenotypes;
KIRP	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.53	7.17	0.42	8.65e-12	Schizophrenia;
KIRP	cis	rs2573652	0.674	rs11630619	chr15:100543367	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.23	-0.42	6.12e-12	Height;
KIRP	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg17443007	chr1:101659419	NA	0.39	5.53	0.33	8.14e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg15711240	chr10:32856510	CCDC7;C10orf68	0.42	6.54	0.38	3.62e-10	Migraine with aura;
KIRP	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.57	-6.26	-0.37	1.72e-9	Aortic root size;
KIRP	cis	rs7011507	1.000	rs79650400	chr8:49181260	A/G	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg13628971	chr7:2884303	GNA12	0.39	4.97	0.3	1.28e-6	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02866931	chr12:70732479	CNOT2	-0.41	-6.18	-0.37	2.63e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg03146154	chr1:46216737	IPP	0.43	5.38	0.32	1.75e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09606734	chr11:47511307	CUGBP1	0.58	6.56	0.39	3.21e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg05973401	chr12:123451056	ABCB9	0.63	7.53	0.43	9.88e-13	Platelet count;
KIRP	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg14092571	chr14:90743983	NA	-0.38	-4.89	-0.3	1.85e-6	Mortality in heart failure;
KIRP	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg23594656	chr7:65796392	TPST1	-0.44	-6.04	-0.36	5.67e-9	Aortic root size;
KIRP	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.53	5.53	0.33	8.28e-8	Height;
KIRP	cis	rs9914578	1.000	rs62067978	chr17:2013058	G/A	cg16513277	chr17:2031491	SMG6	-0.71	-8.51	-0.48	1.7e-15	Body mass index;
KIRP	cis	rs7113850	0.541	rs77699762	chr11:24236448	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	7.77	0.44	2.13e-13	Bone fracture in osteoporosis;
KIRP	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg06647332	chr5:131281008	NA	0.46	4.99	0.3	1.14e-6	Life satisfaction;
KIRP	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-7.13	-0.41	1.09e-11	HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.98	0.36	7.63e-9	Schizophrenia;
KIRP	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg00277334	chr10:82204260	NA	-0.5	-5.76	-0.34	2.53e-8	Post bronchodilator FEV1;
KIRP	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg24110177	chr3:50126178	RBM5	0.59	7.43	0.43	1.75e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2742234	0.541	rs12220534	chr10:43734306	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.74	-8.3	-0.47	6.97e-15	Hirschsprung disease;
KIRP	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.45	0.52	2.72e-18	Bipolar disorder;
KIRP	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.95	-0.61	2.92e-26	Eye color traits;
KIRP	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.59	-8.01	-0.45	4.64e-14	Pulse pressure;
KIRP	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.91	12.95	0.64	1.39e-29	Height;
KIRP	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	1.06	16.09	0.72	2.76e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.65	0.39	1.92e-10	Height;
KIRP	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.53	0.48	1.5e-15	Prudent dietary pattern;
KIRP	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.06	0.36	5e-9	Neuroticism;
KIRP	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-1.01	-10.18	-0.54	1.49e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	1.12	21.43	0.81	3.36e-58	Monocyte count;
KIRP	cis	rs2371030	0.833	rs2371027	chr2:211566074	T/C	cg18417063	chr2:211583084	NA	-0.47	-6.54	-0.39	3.45e-10	Non-small cell lung cancer;
KIRP	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.52	-7.12	-0.41	1.18e-11	IgG glycosylation;
KIRP	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.65	8.12	0.46	2.3e-14	Schizophrenia;
KIRP	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg02570527	chr1:10970165	NA	-0.41	-5.05	-0.31	8.61e-7	Body mass index;
KIRP	cis	rs3733418	0.929	rs1401399	chr4:165927906	G/T	cg10852876	chr4:165953100	TRIM60	-0.44	-4.92	-0.3	1.56e-6	Obesity-related traits;
KIRP	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Bladder cancer;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.8	10.29	0.55	6.71e-21	Mean platelet volume;
KIRP	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg04539111	chr16:67997858	SLC12A4	0.57	4.89	0.3	1.84e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4908768	0.906	rs56305243	chr1:8725420	T/C	cg25722041	chr1:8623473	RERE	0.71	8.83	0.49	1.95e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg03031660	chr17:73257791	MRPS7;GGA3	0.99	6.84	0.4	6.1e-11	P wave terminal force;
KIRP	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg05340658	chr4:99064831	C4orf37	0.68	7.87	0.45	1.15e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.45	-6.2	-0.37	2.32e-9	Multiple sclerosis;
KIRP	cis	rs1978968	1.000	rs1110659	chr22:18444675	T/C	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.99	13.45	0.65	2.87e-31	Menopause (age at onset);
KIRP	cis	rs11874712	0.545	rs9950234	chr18:43653200	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.35	-5.05	-0.31	8.55e-7	Migraine - clinic-based;
KIRP	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.58	6.15	0.37	3.13e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.61	-7.53	-0.43	9.34e-13	Iron status biomarkers;
KIRP	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.69	8.67	0.48	6.08e-16	Coronary artery disease;
KIRP	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.02	0.41	2.12e-11	Iron status biomarkers;
KIRP	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg25664220	chr3:72788482	NA	-0.33	-5.01	-0.3	1.03e-6	Motion sickness;
KIRP	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.38	5.16	0.31	5.07e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.89	-11.65	-0.6	2.84e-25	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2594989	0.831	rs2443703	chr3:11564191	C/T	cg01796438	chr3:11312864	ATG7	0.67	7.78	0.44	2e-13	Circulating chemerin levels;
KIRP	cis	rs6142102	1.000	rs4911412	chr20:32716435	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	6.01	0.36	6.52e-9	Skin pigmentation;
KIRP	cis	rs4148660	1.000	rs10770871	chr12:22075960	T/G	cg14669847	chr12:22099120	NA	0.35	5.85	0.35	1.56e-8	Gout;
KIRP	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.59	-0.39	2.66e-10	Obesity-related traits;
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-1.09	-21.67	-0.81	5.86e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg22138327	chr13:27999177	GTF3A	0.89	7.04	0.41	1.88e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg02461776	chr11:598696	PHRF1	0.71	7.59	0.44	6.44e-13	Systemic lupus erythematosus;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14930269	chr3:49142045	QARS	0.5	6.32	0.37	1.25e-9	Myopia (pathological);
KIRP	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.44	5.67	0.34	3.97e-8	Body mass index;
KIRP	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.19	0.51	1.69e-17	Bipolar disorder;
KIRP	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.98	15.69	0.71	6.25e-39	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07849581	chr4:48272077	TEC	0.56	7.11	0.41	1.23e-11	Parkinson's disease;
KIRP	cis	rs13102973	0.640	rs4864245	chr4:135882847	G/C	cg14419869	chr4:135874104	NA	-0.41	-5.88	-0.35	1.35e-8	Subjective well-being;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11138794	chr3:122283215	PARP9;DTX3L	0.5	6.24	0.37	1.86e-9	Parkinson's disease;
KIRP	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-1.1	-17.81	-0.75	3.75e-46	Migraine;
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	7.54	0.43	9.16e-13	Obesity-related traits;
KIRP	cis	rs17655565	0.553	rs17713256	chr12:52724479	C/G	cg07925835	chr12:52762777	KRT85	0.44	4.88	0.3	1.91e-6	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.57	-7.23	-0.42	5.9e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7011507	1.000	rs79016749	chr8:49140353	A/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2224391	0.628	rs9405261	chr6:5249702	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.57	-0.39	3.06e-10	Height;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg09699651	chr6:150184138	LRP11	0.44	5.81	0.35	1.96e-8	Lung cancer;
KIRP	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	6.85	0.4	5.87e-11	Diastolic blood pressure;
KIRP	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg01879757	chr17:41196368	BRCA1	-0.79	-10.86	-0.57	1.09e-22	Menopause (age at onset);
KIRP	cis	rs6445967	0.695	rs2292675	chr3:58235727	T/C	cg16569813	chr3:58235849	ABHD6	-0.35	-5.37	-0.32	1.79e-7	Platelet count;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20456258	chr4:962124	DGKQ	0.49	6.63	0.39	2.16e-10	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs3762637	0.941	rs28679619	chr3:122100349	C/A	cg24169773	chr3:122142474	KPNA1	-0.56	-5.7	-0.34	3.46e-8	LDL cholesterol levels;
KIRP	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.68	6.61	0.39	2.39e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.47	5.22	0.32	3.83e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-5.73	-0.34	2.91e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg06740227	chr12:86229804	RASSF9	0.42	5.24	0.32	3.51e-7	Major depressive disorder;
KIRP	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.07	-0.36	4.9e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.58	-6.85	-0.4	5.89e-11	Multiple sclerosis;
KIRP	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg12598211	chr12:123634384	NA	-0.44	-5.1	-0.31	6.65e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9296661	1.000	rs1326589	chr6:51674161	A/G	cg12963312	chr6:52441723	TRAM2	-0.39	-5.37	-0.32	1.82e-7	Weight loss (gastric bypass surgery);
KIRP	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.11	-0.64	3.87e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs7560272	0.501	rs4852978	chr2:73943110	G/A	cg20560298	chr2:73613845	ALMS1	0.47	5.58	0.33	6.49e-8	Schizophrenia;
KIRP	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg14650228	chr8:144573510	ZC3H3	-0.75	-5.36	-0.32	1.9e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	1.05	9.24	0.51	1.19e-17	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg02462569	chr6:150064036	NUP43	-0.42	-6.52	-0.38	4.07e-10	Lung cancer;
KIRP	cis	rs73058052	0.597	rs2890072	chr19:50087876	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.96	0.36	8.57e-9	Fibrinogen levels;
KIRP	cis	rs7520050	0.966	rs12405451	chr1:46384326	T/A	cg03146154	chr1:46216737	IPP	-0.41	-5.19	-0.31	4.51e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00938859	chr5:1591904	SDHAP3	0.62	8.43	0.47	3.02e-15	Breast cancer;
KIRP	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.4	-0.38	7.76e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.5	0.38	4.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.53	-6.35	-0.38	1e-9	Longevity;Endometriosis;
KIRP	cis	rs10940138	0.501	rs2087621	chr5:67248930	A/T	ch.5.1281357F	chr5:67228439	NA	-0.5	-7.4	-0.43	2.19e-12	Menarche (age at onset);
KIRP	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	12.29	0.62	2.16e-27	Blood protein levels;
KIRP	cis	rs2997447	0.761	rs74384164	chr1:26430379	C/T	cg19633962	chr1:26362018	EXTL1	-0.65	-5.54	-0.33	7.79e-8	QRS complex (12-leadsum);
KIRP	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.66	0.39	1.75e-10	Height;
KIRP	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.54	0.59	6.69e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg03834567	chr2:218808745	TNS1	0.46	5.64	0.34	4.55e-8	Ulcerative colitis;
KIRP	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg05340658	chr4:99064831	C4orf37	-0.54	-6.74	-0.39	1.12e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg13010199	chr12:38710504	ALG10B	0.49	6.41	0.38	7.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs2625529	0.878	rs71395051	chr15:72239789	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.04	-0.36	5.57e-9	Red blood cell count;
KIRP	cis	rs1832871	0.711	rs9459924	chr6:158703902	G/A	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs9815354	0.812	rs73071208	chr3:41978738	A/T	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.48	1.5e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	6.33	0.37	1.14e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.95	-15.05	-0.69	9.6e-37	Height;
KIRP	cis	rs1873147	1.000	rs7179658	chr15:63312695	T/C	cg12160578	chr15:63334699	TPM1	-0.46	-5.62	-0.34	5.09e-8	Orofacial clefts;
KIRP	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg04226714	chr8:49833948	SNAI2	-0.52	-7.0	-0.41	2.38e-11	Life satisfaction;
KIRP	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.09	0.41	1.41e-11	Prudent dietary pattern;
KIRP	cis	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg06521331	chr12:34319734	NA	-0.56	-6.92	-0.4	3.9e-11	Morning vs. evening chronotype;
KIRP	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	8.19	0.46	1.46e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs3857536	0.730	rs6927862	chr6:66971450	A/C	cg07460842	chr6:66804631	NA	-0.45	-5.32	-0.32	2.38e-7	Blood trace element (Cu levels);
KIRP	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg27205649	chr11:78285834	NARS2	-0.62	-7.38	-0.43	2.44e-12	Alzheimer's disease (survival time);
KIRP	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg10935138	chr17:73851978	WBP2	0.4	4.92	0.3	1.6e-6	White matter hyperintensity burden;
KIRP	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.8	-11.22	-0.58	7.23e-24	Total body bone mineral density;
KIRP	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-6.97	-0.41	2.86e-11	Parkinson's disease;
KIRP	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg06174606	chr11:89959870	NA	-0.43	-4.99	-0.3	1.16e-6	White blood cell types;
KIRP	cis	rs7113874	0.802	rs1502317	chr11:8682018	C/T	cg08015107	chr11:8618950	NA	-0.41	-5.73	-0.34	2.91e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.38	5.66	0.34	4.23e-8	Mean platelet volume;
KIRP	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-0.9	-10.63	-0.56	5.71e-22	Gut microbiome composition (summer);
KIRP	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.51	5.92	0.35	1.08e-8	Mean platelet volume;
KIRP	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.77	-10.68	-0.56	4e-22	Blood metabolite levels;
KIRP	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.26	0.37	1.74e-9	Axial length;
KIRP	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg05072774	chr3:49840536	C3orf54	0.44	5.52	0.33	8.55e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15977278	chr12:104234975	NT5DC3	0.56	6.4	0.38	7.81e-10	Smoking initiation;
KIRP	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.1	13.38	0.65	4.64e-31	IgG glycosylation;
KIRP	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg08126542	chr6:37504118	NA	-0.81	-11.58	-0.59	4.79e-25	Cognitive performance;
KIRP	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.44	-5.47	-0.33	1.11e-7	P wave terminal force;
KIRP	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg14458575	chr2:238380390	NA	0.54	7.09	0.41	1.41e-11	Prostate cancer;
KIRP	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06850241	chr22:41845214	NA	-0.44	-5.59	-0.34	6.03e-8	Vitiligo;
KIRP	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	7.9	0.45	9.31e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg16578609	chr1:2399051	NA	-0.44	-5.22	-0.32	3.81e-7	Non-obstructive azoospermia;
KIRP	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg22633769	chr20:60982531	CABLES2	-0.44	-5.57	-0.33	6.75e-8	Colorectal cancer;
KIRP	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg17764715	chr19:33622953	WDR88	0.68	8.32	0.47	5.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4356975	0.563	rs7437039	chr4:69959476	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25108841	chr1:20959920	PINK1	0.44	6.16	0.37	2.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.49	-0.43	1.21e-12	Type 2 diabetes;
KIRP	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.13	0.46	2.05e-14	Morning vs. evening chronotype;
KIRP	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.86	0.45	1.21e-13	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08299755	chr10:99496695	ZFYVE27	0.45	6.15	0.37	3.15e-9	Survival in pancreatic cancer;
KIRP	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg09238746	chr17:78121135	EIF4A3	-0.51	-6.41	-0.38	7.44e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs12496230	0.794	rs4856827	chr3:66867603	A/G	cg17646820	chr3:66848679	NA	0.39	6.3	0.37	1.38e-9	Type 2 diabetes;
KIRP	trans	rs56346965	1.000	rs2192008	chr2:191545147	C/T	cg05986680	chr2:55496552	MTIF2	-0.47	-6.16	-0.37	2.92e-9	Bone mineral density (Ward's triangle area);
KIRP	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg19773385	chr1:10388646	KIF1B	-0.7	-10.74	-0.57	2.54e-22	Hepatocellular carcinoma;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16524936	chr4:1340807	KIAA1530	-0.49	-6.22	-0.37	2.14e-9	Longevity;
KIRP	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.26	-0.32	3.1e-7	Bladder cancer;
KIRP	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.34	-0.32	2.11e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.6	8.07	0.46	3.18e-14	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	11.16	0.58	1.15e-23	Personality dimensions;
KIRP	cis	rs526231	0.578	rs10463553	chr5:102249207	T/C	cg23492399	chr5:102201601	PAM	-0.43	-4.86	-0.3	2.14e-6	Primary biliary cholangitis;
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.67	-9.38	-0.51	4.42e-18	Longevity;
KIRP	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.25	0.62	3.06e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2802372	0.785	rs1250565	chr10:81047015	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.47	-6.1	-0.36	4.18e-9	Granulocyte count;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.34	-0.32	2.15e-7	Electroencephalogram traits;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02475777	chr4:1388615	CRIPAK	0.43	5.66	0.34	4.16e-8	Longevity;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs918629	0.567	rs2270554	chr5:95246134	G/T	cg16656078	chr5:95278638	ELL2	0.35	5.38	0.32	1.77e-7	IgG glycosylation;
KIRP	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg06598544	chr20:61472147	COL9A3	-0.83	-6.85	-0.4	5.8e-11	Obesity-related traits;
KIRP	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.81	-0.53	2.23e-19	Response to antipsychotic treatment;
KIRP	cis	rs741951	0.667	rs2838721	chr21:46287580	C/T	cg08823554	chr21:46269191	NA	-0.7	-5.98	-0.36	7.97e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-6.72	-0.39	1.24e-10	Vitiligo;
KIRP	cis	rs2882667	0.858	rs2043271	chr5:138459108	A/G	cg04439458	chr5:138467593	SIL1	-0.49	-7.45	-0.43	1.62e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12362504	0.520	rs360169	chr11:9875519	C/T	cg25247837	chr11:9897069	SBF2	0.4	5.64	0.34	4.67e-8	Survival in pancreatic cancer;
KIRP	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.66	-10.07	-0.54	3.3e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.79	7.65	0.44	4.67e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.48	-6.65	-0.39	1.9e-10	Coronary artery disease;
KIRP	cis	rs4862307	0.688	rs6552743	chr4:184990516	C/G	cg06737308	chr4:185021514	ENPP6	0.53	7.23	0.42	6.22e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs1823913	0.637	rs11677694	chr2:192167929	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10707110	chr22:38227306	ANKRD54	0.45	6.23	0.37	1.97e-9	Survival in pancreatic cancer;
KIRP	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg23791538	chr6:167370224	RNASET2	-0.47	-5.66	-0.34	4.19e-8	Crohn's disease;
KIRP	cis	rs7015630	0.657	rs2338882	chr8:90822198	G/A	cg18493113	chr8:90847772	NA	-0.45	-4.84	-0.3	2.25e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4728302	0.807	rs10226267	chr7:133601862	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.510	rs10494282	chr1:152923762	G/C	cg13444842	chr1:152974279	SPRR3	-0.47	-6.66	-0.39	1.8e-10	Inflammatory skin disease;
KIRP	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Colorectal cancer;
KIRP	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg23100626	chr2:96804247	ASTL	0.46	5.73	0.34	3e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.05	-13.06	-0.64	5.93e-30	Exhaled nitric oxide output;
KIRP	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.62	8.24	0.47	9.97e-15	Lymphocyte counts;
KIRP	cis	rs6754311	0.773	rs2322818	chr2:136775898	T/C	cg07169764	chr2:136633963	MCM6	0.59	7.16	0.42	9.13e-12	Mosquito bite size;
KIRP	cis	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg04850286	chr10:81895943	PLAC9	0.3	4.98	0.3	1.19e-6	Sarcoidosis;
KIRP	cis	rs17123764	0.818	rs876889	chr12:49983378	C/T	cg02054252	chr12:50078554	FMNL3	0.44	5.28	0.32	2.84e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg00647317	chr7:50633725	DDC	0.45	6.0	0.36	6.87e-9	Malaria;
KIRP	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	cg04338863	chr8:33670619	NA	0.43	5.65	0.34	4.41e-8	Body mass index;
KIRP	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16725865	chr1:92546135	BTBD8	0.48	6.31	0.37	1.31e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs13102973	0.965	rs13131455	chr4:135883112	A/C	cg14419869	chr4:135874104	NA	-0.5	-8.21	-0.46	1.22e-14	Subjective well-being;
KIRP	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.57	7.29	0.42	4.13e-12	Coronary artery disease;
KIRP	cis	rs4006360	0.600	rs6503595	chr17:39257008	C/G	cg15015397	chr17:39261100	KRTAP4-9	-0.45	-6.47	-0.38	5.19e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg12292205	chr6:26970375	C6orf41	0.48	6.96	0.41	3.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.87	-0.35	1.44e-8	IgG glycosylation;
KIRP	cis	rs68170813	0.876	rs34523267	chr7:107226156	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-6.19	-0.37	2.53e-9	Coronary artery disease;
KIRP	cis	rs6545883	0.826	rs777590	chr2:61417145	C/G	cg15711740	chr2:61764176	XPO1	-0.6	-8.01	-0.46	4.45e-14	Tuberculosis;
KIRP	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.69	0.39	1.46e-10	Colorectal cancer;
KIRP	cis	rs7178909	0.732	rs57163265	chr15:90400650	A/T	cg19708238	chr15:90437601	AP3S2	0.54	7.33	0.42	3.26e-12	Common traits (Other);
KIRP	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg24747557	chr10:131355152	MGMT	0.44	6.05	0.36	5.43e-9	Response to temozolomide;
KIRP	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.68	6.8	0.4	8.04e-11	Vitiligo;
KIRP	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.44	5.48	0.33	1.06e-7	Common traits (Other);
KIRP	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg04517722	chr19:17905589	B3GNT3	0.38	5.94	0.35	9.61e-9	Tumor biomarkers;
KIRP	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg12131826	chr15:77904385	NA	0.41	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs4845459	0.967	rs6700160	chr1:152593024	A/C	cg07796016	chr1:152779584	LCE1C	-0.49	-5.95	-0.35	9.1e-9	Psoriasis;
KIRP	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg22617819	chr1:44378782	ST3GAL3	-0.34	-5.58	-0.34	6.18e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg10503236	chr1:231470652	EXOC8	-0.45	-6.41	-0.38	7.4e-10	Hemoglobin concentration;
KIRP	cis	rs745080	0.674	rs6572850	chr14:53018461	C/T	cg23333723	chr14:53022898	GPR137C	-0.42	-5.87	-0.35	1.42e-8	Orofacial clefts;
KIRP	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg07395648	chr5:131743802	NA	-0.35	-4.86	-0.3	2.14e-6	Blood metabolite levels;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11905131	chr22:24372483	LOC391322	-0.58	-7.44	-0.43	1.68e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg10189774	chr4:17578691	LAP3	0.55	6.87	0.4	5.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-22.18	-0.82	1.27e-60	Height;
KIRP	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg07169764	chr2:136633963	MCM6	0.53	6.16	0.37	2.94e-9	Mosquito bite size;
KIRP	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg11572305	chr2:56410780	CCDC85A	0.43	6.1	0.36	4.18e-9	Myopia (pathological);
KIRP	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg15488143	chr7:128924101	AHCYL2	0.44	4.92	0.3	1.61e-6	White matter hyperintensity burden;
KIRP	cis	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.03	0.31	9.3e-7	Leprosy;
KIRP	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.96	-11.23	-0.58	6.71e-24	Corneal astigmatism;
KIRP	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.68	0.48	5.49e-16	Motion sickness;
KIRP	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg01631408	chr1:248437212	OR2T33	-0.72	-9.68	-0.53	5.47e-19	Common traits (Other);
KIRP	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg04398451	chr17:18023971	MYO15A	0.78	11.18	0.58	9.55e-24	Total body bone mineral density;
KIRP	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.35	-0.32	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.85	-12.88	-0.63	2.35e-29	Height;
KIRP	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-20.78	-0.8	4.71e-56	Height;
KIRP	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg18306943	chr3:40428807	ENTPD3	0.46	6.05	0.36	5.36e-9	Renal cell carcinoma;
KIRP	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	6.51	0.38	4.2e-10	Menarche (age at onset);
KIRP	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.43	4.88	0.3	1.91e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg27121462	chr16:89883253	FANCA	0.5	6.04	0.36	5.8e-9	Vitiligo;
KIRP	cis	rs2235544	0.513	rs10158824	chr1:54480398	C/G	cg25741118	chr1:54482237	LDLRAD1	0.32	6.02	0.36	6.32e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.61	-6.04	-0.36	5.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.42	-0.38	7.07e-10	Axial length;
KIRP	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg11621586	chr10:70884670	VPS26A	1.17	15.03	0.69	1.17e-36	Left atrial antero-posterior diameter;
KIRP	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.2	0.42	7.39e-12	Bipolar disorder;
KIRP	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg24101359	chr6:42928495	GNMT	-0.47	-5.08	-0.31	7.32e-7	Blood protein levels;
KIRP	cis	rs9308731	0.563	rs6760053	chr2:111932997	C/G	cg18646521	chr2:111875858	NA	0.39	5.41	0.33	1.51e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.24	-0.32	3.49e-7	Resting heart rate;
KIRP	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.58	-0.59	4.98e-25	Caffeine consumption;
KIRP	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.48	-0.33	1.05e-7	Autism;
KIRP	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg12615879	chr12:58013172	SLC26A10	0.35	5.08	0.31	7.44e-7	Multiple sclerosis;
KIRP	cis	rs1635	0.655	rs3734564	chr6:28227860	G/A	cg24848467	chr6:28134517	ZNF389	-0.86	-5.33	-0.32	2.22e-7	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15407517	chr5:78280882	ARSB	0.49	6.06	0.36	5.21e-9	Parkinson's disease;
KIRP	cis	rs4889855	0.556	rs11150863	chr17:78532321	A/G	cg09596252	chr17:78655493	RPTOR	0.43	4.95	0.3	1.35e-6	Fractional excretion of uric acid;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-1.02	-11.57	-0.59	5.35e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07343612	chr16:622815	PIGQ	-0.88	-13.31	-0.65	8.36e-31	Height;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg26260369	chr14:68141723	VTI1B	0.99	6.72	0.39	1.29e-10	P wave terminal force;
KIRP	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.46	5.22	0.32	3.81e-7	Osteoporosis;
KIRP	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.64	-0.39	2.02e-10	Menopause (age at onset);
KIRP	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.9	14.71	0.68	1.41e-35	Prostate cancer;
KIRP	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	1.04	19.9	0.79	3.56e-53	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg02574844	chr11:5959923	NA	-0.62	-6.36	-0.38	9.95e-10	DNA methylation (variation);
KIRP	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg09658497	chr7:2847517	GNA12	-0.36	-4.99	-0.3	1.14e-6	Height;
KIRP	cis	rs7221595	0.825	rs12450845	chr17:3972784	G/A	cg21851534	chr17:3907994	ZZEF1	0.54	5.18	0.31	4.72e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.76	8.51	0.48	1.71e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg18350739	chr11:68623251	NA	-0.48	-7.42	-0.43	1.95e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.25	0.47	9.85e-15	Motion sickness;
KIRP	cis	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg02972257	chr16:68554789	NA	-0.58	-5.65	-0.34	4.4e-8	Ulcerative colitis;
KIRP	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.64	8.83	0.49	2e-16	Colorectal cancer;
KIRP	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg01777586	chr17:80163174	CCDC57	0.46	4.98	0.3	1.18e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.42	-0.43	1.88e-12	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01221623	chr19:14142963	IL27RA	0.54	7.26	0.42	5.08e-12	Parkinson's disease;
KIRP	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.71	6.82	0.4	7.13e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.02	-0.3	9.9e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	1.99e-8	Lung cancer;
KIRP	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.61	0.39	2.4e-10	Breast cancer;
KIRP	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.47	-6.09	-0.36	4.23e-9	Height;
KIRP	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.11	0.31	6.58e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs12580194	0.593	rs61957946	chr12:55755778	T/C	cg11794356	chr12:55725991	OR6C3	-0.53	-7.02	-0.41	2.15e-11	Cancer;
KIRP	cis	rs11264213	0.901	rs665521	chr1:36445837	T/C	cg27506609	chr1:36549197	TEKT2	0.97	10.16	0.54	1.81e-20	Schizophrenia;
KIRP	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.04e-14	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04392234	chr4:74608458	IL8	-0.39	-6.02	-0.36	6.4e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.78	-0.35	2.21e-8	Neutrophil percentage of white cells;
KIRP	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.49	0.43	1.24e-12	Educational attainment;
KIRP	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.84	-0.35	1.66e-8	Crohn's disease;
KIRP	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg24110177	chr3:50126178	RBM5	-0.44	-5.59	-0.34	6.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.85	10.68	0.56	3.98e-22	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.05	0.36	5.47e-9	Mean corpuscular volume;
KIRP	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.67	7.87	0.45	1.11e-13	Obesity-related traits;
KIRP	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.5	6.06	0.36	5.18e-9	Subjective well-being;
KIRP	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg19507638	chr5:93509721	C5orf36	-0.6	-5.26	-0.32	3.06e-7	Diabetic retinopathy;
KIRP	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.47	5.49	0.33	9.94e-8	Colorectal cancer;
KIRP	cis	rs8113308	0.752	rs11879758	chr19:52490164	G/C	cg25782003	chr19:52490127	ZNF350	0.98	9.3	0.51	8.02e-18	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-5.57	-0.33	6.55e-8	Lung cancer;
KIRP	cis	rs1318772	1.000	rs13177178	chr5:112625124	C/T	cg12552261	chr5:112820674	MCC	0.82	5.09	0.31	6.97e-7	F-cell distribution;
KIRP	cis	rs72960926	0.744	rs72953763	chr6:74983753	G/C	cg03266952	chr6:74778945	NA	-0.77	-5.8	-0.35	2e-8	Metabolite levels (MHPG);
KIRP	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	6.84	0.4	6.37e-11	Multiple sclerosis;
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg23985595	chr17:80112537	CCDC57	-0.35	-5.29	-0.32	2.73e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21107223	chr15:75182455	MPI	0.48	6.29	0.37	1.46e-9	Parkinson's disease;
KIRP	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-14.67	-0.68	1.99e-35	Coronary artery disease;
KIRP	cis	rs7555523	1.000	rs7555523	chr1:165718979	C/A	cg24409356	chr1:165738333	TMCO1	0.71	6.02	0.36	6.24e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs9921338	0.961	rs6498185	chr16:11444726	C/T	cg00044050	chr16:11439710	C16orf75	-0.54	-6.01	-0.36	6.69e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs16936870	0.543	rs16936926	chr8:71256758	T/C	cg14232793	chr8:71155543	NCOA2	0.53	6.11	0.36	3.87e-9	QT interval;
KIRP	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.42	6.44	0.38	6.35e-10	Lipoprotein (a) levels;
KIRP	cis	rs36715	0.953	rs2617613	chr5:127552589	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	6.78	0.4	8.73e-11	Breast cancer;
KIRP	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.1	0.31	6.66e-7	Educational attainment;
KIRP	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.82	-0.4	7.18e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg11846333	chr4:119757529	SEC24D	1.11	5.88	0.35	1.37e-8	Cannabis dependence symptom count;
KIRP	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-1.09	-13.28	-0.65	1.01e-30	Exhaled nitric oxide output;
KIRP	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg26384229	chr12:38710491	ALG10B	0.66	8.95	0.5	9.12e-17	Morning vs. evening chronotype;
KIRP	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg00204512	chr16:28754710	NA	0.41	5.08	0.31	7.48e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.5	-6.63	-0.39	2.13e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16857609	0.564	rs6734808	chr2:218294571	C/T	cg15335768	chr2:218268053	DIRC3	-0.55	-7.06	-0.41	1.67e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.49	8.47	0.48	2.18e-15	Iron status biomarkers (transferrin levels);
KIRP	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg01320579	chr17:75405842	SEPT9	0.49	7.77	0.44	2.08e-13	Airflow obstruction;
KIRP	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs7656342	0.599	rs6847871	chr4:9853074	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.89	-0.35	1.24e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs662064	0.962	rs596537	chr1:10554709	G/T	cg19773385	chr1:10388646	KIF1B	0.36	4.9	0.3	1.7e-6	Asthma;
KIRP	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg17366294	chr4:99064904	C4orf37	0.45	6.43	0.38	6.76e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg25233709	chr10:116636983	FAM160B1	0.36	5.6	0.34	5.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9400467	0.537	rs73528979	chr6:111430404	G/A	cg15721981	chr6:111408429	SLC16A10	0.7	6.3	0.37	1.33e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg08890418	chr1:21044141	KIF17	0.35	5.27	0.32	2.95e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.19	0.51	1.69e-17	Lymphocyte counts;
KIRP	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg12963246	chr6:28129442	ZNF389	0.46	5.76	0.34	2.55e-8	Parkinson's disease;
KIRP	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	0.75	10.85	0.57	1.16e-22	Lewy body disease;
KIRP	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg13010199	chr12:38710504	ALG10B	0.56	7.02	0.41	2.11e-11	Bladder cancer;
KIRP	cis	rs7546668	1.000	rs4646061	chr1:15829916	G/A	cg21858823	chr1:15850916	CASP9	0.48	5.32	0.32	2.39e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs225245	0.782	rs321617	chr17:33915246	A/G	cg19694781	chr19:47549865	TMEM160	-0.51	-6.2	-0.37	2.34e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg04289385	chr6:36355825	ETV7	-0.45	-7.2	-0.42	7.28e-12	Platelet distribution width;
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.93	16.6	0.73	4.96e-42	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7760949	0.963	rs7453814	chr6:13918291	C/G	cg27413430	chr6:13925136	RNF182	0.43	5.46	0.33	1.14e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.62	-7.59	-0.44	6.44e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7737355	0.812	rs10063264	chr5:130898197	C/G	cg25547332	chr5:131281432	NA	0.39	4.91	0.3	1.63e-6	Life satisfaction;
KIRP	cis	rs7332672	0.501	rs2015338	chr13:100060455	G/A	cg25919922	chr13:100150906	NA	0.47	5.2	0.31	4.26e-7	Eosinophil counts;
KIRP	cis	rs7555523	0.887	rs2790053	chr1:165737704	C/G	cg24409356	chr1:165738333	TMCO1	0.72	6.05	0.36	5.25e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs10073892	0.704	rs62372218	chr5:101650986	C/A	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg08755490	chr11:65554678	OVOL1	0.36	4.98	0.3	1.22e-6	Acne (severe);
KIRP	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg05775895	chr3:12838266	CAND2	0.34	5.7	0.34	3.48e-8	QRS complex (12-leadsum);
KIRP	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg21523564	chr15:75251491	NA	-0.36	-6.05	-0.36	5.42e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg17207736	chr8:142237307	SLC45A4	0.51	6.3	0.37	1.39e-9	Immature fraction of reticulocytes;
KIRP	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg10223061	chr2:219282414	VIL1	-0.4	-6.27	-0.37	1.57e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3789045	0.560	rs1008833	chr1:204426295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.89	-7.75	-0.44	2.39e-13	Educational attainment (college completion);
KIRP	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.74	11.06	0.58	2.37e-23	Blood metabolite ratios;
KIRP	cis	rs9815354	1.000	rs1717027	chr3:41987920	T/C	cg03022575	chr3:42003672	ULK4	-0.5	-5.66	-0.34	4.2e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg06212747	chr3:49208901	KLHDC8B	0.7	8.29	0.47	7.34e-15	Menarche (age at onset);
KIRP	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.77	-10.17	-0.54	1.65e-20	Body mass index;
KIRP	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.35	0.42	2.99e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	1.000	rs10793016	chr11:71755063	A/G	cg11196788	chr11:71737549	NUMA1	-0.55	-4.91	-0.3	1.65e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-5.43	-0.33	1.38e-7	Schizophrenia;
KIRP	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg08807101	chr21:30365312	RNF160	0.6	7.23	0.42	6.08e-12	Pancreatic cancer;
KIRP	cis	rs11779988	0.545	rs438873	chr8:17786516	G/A	cg01800426	chr8:17659068	MTUS1	-0.61	-6.09	-0.36	4.27e-9	Breast cancer;
KIRP	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.86	8.49	0.48	1.96e-15	Methadone dose in opioid dependence;
KIRP	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	12.22	0.61	3.86e-27	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00437399	chr15:40886176	CASC5	-0.49	-6.53	-0.38	3.81e-10	Interleukin-4 levels;
KIRP	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.48	-0.79	4.47e-55	Height;
KIRP	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg19116668	chr7:99932089	PMS2L1	-0.41	-5.06	-0.31	8.38e-7	Coronary artery disease;
KIRP	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23903597	chr17:61704154	MAP3K3	-0.53	-6.61	-0.39	2.41e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg13147721	chr7:65941812	NA	-1.0	-7.02	-0.41	2.12e-11	Diabetic kidney disease;
KIRP	cis	rs4742903	0.875	rs10820609	chr9:106907332	G/A	cg14250997	chr9:106856677	SMC2	0.37	4.89	0.3	1.8e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs745821	0.701	rs59538792	chr18:48092547	A/T	cg18923635	chr18:48083994	NA	0.43	4.94	0.3	1.45e-6	Diastolic blood pressure;
KIRP	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.51	-6.89	-0.4	4.78e-11	Ulcerative colitis;
KIRP	cis	rs7973719	1.000	rs12828040	chr12:7326541	T/C	cg07052231	chr12:7363540	PEX5	0.38	4.9	0.3	1.7e-6	IgG glycosylation;
KIRP	cis	rs8038465	1.000	rs8041181	chr15:73982336	C/T	cg15420318	chr15:73925796	NPTN	0.55	7.03	0.41	1.98e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17192681	chr2:10953115	PDIA6	-0.59	-6.93	-0.4	3.62e-11	Interleukin-4 levels;
KIRP	cis	rs6256	1.000	rs11600801	chr11:13526239	A/G	cg11976911	chr11:13509032	NA	-0.64	-5.58	-0.33	6.49e-8	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	trans	rs6445797	0.662	rs6784555	chr3:56527268	A/G	cg26885220	chr1:65775570	DNAJC6	0.38	6.16	0.37	2.87e-9	Gastritis;
KIRP	cis	rs2299587	0.554	rs2283106	chr8:17754330	G/A	cg01800426	chr8:17659068	MTUS1	-0.44	-5.22	-0.32	3.79e-7	Economic and political preferences;
KIRP	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg19292749	chr17:79650816	ARL16;HGS	0.54	4.92	0.3	1.6e-6	Dental caries;
KIRP	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.77	-11.55	-0.59	6.31e-25	Obesity-related traits;
KIRP	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg09408571	chr1:101003634	GPR88	0.22	5.02	0.3	9.8e-7	Monocyte count;
KIRP	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.26	-12.71	-0.63	8.46e-29	Diabetic retinopathy;
KIRP	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg17595323	chr11:93583763	C11orf90	0.3	4.99	0.3	1.12e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4389656	0.625	rs274681	chr5:6748659	T/C	cg10857441	chr5:6722123	POLS	-0.44	-6.04	-0.36	5.53e-9	Coronary artery disease;
KIRP	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.32	4.88	0.3	1.87e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	1.2	10.9	0.57	7.84e-23	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.94	-11.4	-0.59	1.93e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.66	9.81	0.53	2.24e-19	Monocyte percentage of white cells;
KIRP	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg08888203	chr3:10149979	C3orf24	0.49	4.96	0.3	1.33e-6	Alzheimer's disease;
KIRP	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	trans	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.12	0.41	1.2e-11	Mean corpuscular volume;
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg13092806	chr2:177043255	NA	0.59	7.93	0.45	7.91e-14	IgG glycosylation;
KIRP	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	11.31	0.58	3.62e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11779988	0.545	rs208058	chr8:17820433	G/A	cg01800426	chr8:17659068	MTUS1	-0.58	-5.85	-0.35	1.55e-8	Breast cancer;
KIRP	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.67	8.73	0.49	4.04e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9469913	0.668	rs2764205	chr6:34712010	G/C	cg17674042	chr6:34482479	PACSIN1	-0.39	-5.37	-0.32	1.84e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg13266496	chr6:110720918	DDO	-0.37	-5.82	-0.35	1.83e-8	Platelet distribution width;
KIRP	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.84	12.61	0.63	1.93e-28	Uric acid clearance;
KIRP	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg24488311	chr11:68621650	NA	0.48	5.85	0.35	1.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg19743168	chr1:23544995	NA	0.56	7.76	0.44	2.32e-13	Height;
KIRP	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.86	0.35	1.45e-8	Menopause (age at onset);
KIRP	cis	rs9469913	0.799	rs2744956	chr6:34618937	T/C	cg17674042	chr6:34482479	PACSIN1	-0.48	-6.41	-0.38	7.34e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	7.01	0.41	2.35e-11	Bipolar disorder;
KIRP	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.19	0.31	4.42e-7	Breast cancer;
KIRP	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	cg12689670	chr1:183009347	LAMC1	0.44	6.35	0.38	1.02e-9	Colorectal cancer;
KIRP	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14598338	chr9:96623480	NA	-0.67	-11.44	-0.59	1.38e-24	DNA methylation (variation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08967837	chr4:186392746	CCDC110	0.49	6.88	0.4	4.8e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.78	11.58	0.59	4.93e-25	Hip circumference;
KIRP	cis	rs2273669	0.585	rs6900472	chr6:109372120	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-6.41	-0.38	7.27e-10	Prostate cancer;
KIRP	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.6	-7.85	-0.45	1.24e-13	Total body bone mineral density;
KIRP	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.69	8.1	0.46	2.61e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg20673841	chr7:107026890	COG5	0.41	5.13	0.31	5.99e-7	Coronary artery disease;
KIRP	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.76	-9.81	-0.53	2.19e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg11130432	chr3:121712080	ILDR1	-0.42	-5.58	-0.34	6.38e-8	Multiple sclerosis;
KIRP	cis	rs4363385	0.530	rs61815714	chr1:152921380	C/T	cg13444842	chr1:152974279	SPRR3	-0.46	-6.65	-0.39	1.84e-10	Inflammatory skin disease;
KIRP	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.56	-0.39	3.21e-10	Alcohol dependence;
KIRP	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg25039879	chr17:56429692	SUPT4H1	0.57	5.11	0.31	6.58e-7	Cognitive test performance;
KIRP	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg07395648	chr5:131743802	NA	-0.54	-7.65	-0.44	4.46e-13	Breast cancer;
KIRP	cis	rs9653442	0.564	rs7590378	chr2:100789877	A/G	cg17356467	chr2:100759845	AFF3	0.38	5.35	0.32	2.01e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2250417	0.935	rs10891343	chr11:112080384	T/C	cg03304763	chr11:112037427	TEX12	-0.54	-6.74	-0.39	1.12e-10	Inflammatory biomarkers;Protein quantitative trait loci;
KIRP	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.52	-0.43	1e-12	Neuroticism;
KIRP	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	0.95	7.09	0.41	1.41e-11	IgG glycosylation;
KIRP	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-7.25	-0.42	5.3e-12	Electroencephalogram traits;
KIRP	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.82	-9.13	-0.5	2.63e-17	Blood pressure (smoking interaction);
KIRP	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.51	6.22	0.37	2.11e-9	Metabolite levels;
KIRP	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.43	-5.83	-0.35	1.73e-8	Monocyte count;
KIRP	trans	rs4349753	0.874	rs2108421	chr5:144189621	A/T	cg16033277	chr17:80885358	TBCD	0.4	6.24	0.37	1.9e-9	Photic sneeze reflex;
KIRP	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg01872077	chr2:219646372	CYP27A1	-0.37	-5.1	-0.31	6.78e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs829661	1.000	rs2609951	chr2:30870614	A/G	cg10949345	chr2:30726833	LCLAT1	0.69	8.73	0.49	3.98e-16	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg04013166	chr16:89971882	TCF25	0.67	5.48	0.33	1.04e-7	Skin colour saturation;
KIRP	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.23	-0.46	1.08e-14	Rheumatoid arthritis;
KIRP	cis	rs7395662	1.000	rs4882132	chr11:48593125	C/T	cg21546286	chr11:48923668	NA	-0.47	-5.66	-0.34	4.25e-8	HDL cholesterol;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09820084	chr6:18387507	RNF144B	-0.53	-6.82	-0.4	6.91e-11	Neuroticism;
KIRP	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.48	5.72	0.34	3.09e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	7.4	0.43	2.1e-12	Body mass index;
KIRP	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg02487422	chr3:49467188	NICN1	0.39	5.51	0.33	8.88e-8	Menarche (age at onset);
KIRP	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg02524346	chr8:600233	NA	-0.92	-5.63	-0.34	4.95e-8	IgG glycosylation;
KIRP	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.52	0.48	1.64e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.96	12.71	0.63	8.76e-29	Vitamin D levels;
KIRP	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg19534769	chr4:3451126	HGFAC	-0.45	-6.15	-0.36	3.2e-9	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
KIRP	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg22800045	chr5:56110881	MAP3K1	0.67	7.33	0.42	3.21e-12	Initial pursuit acceleration;
KIRP	cis	rs4762326	1.000	rs4762326	chr12:95668951	C/T	cg07737802	chr12:95537812	FGD6	0.44	6.25	0.37	1.77e-9	Endometriosis;
KIRP	cis	rs151997	0.777	rs3846500	chr5:50254488	A/T	cg06027927	chr5:50259733	NA	-0.59	-7.8	-0.45	1.8e-13	Callous-unemotional behaviour;
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21016266	chr12:122356598	WDR66	0.5	6.71	0.39	1.33e-10	Mean corpuscular volume;
KIRP	cis	rs17123764	0.710	rs59849800	chr12:50116773	C/T	cg20471783	chr12:50157085	TMBIM6	0.32	4.91	0.3	1.69e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14769373	chr6:40998127	UNC5CL	0.53	5.61	0.34	5.29e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2950163	0.898	rs1608988	chr2:6187635	A/G	cg26659079	chr2:5836181	SOX11	0.38	4.96	0.3	1.33e-6	Response to metformin (IC50);
KIRP	cis	rs5753037	0.869	rs5752973	chr22:30264274	G/A	cg01021169	chr22:30184971	ASCC2	-0.4	-5.26	-0.32	3.19e-7	Type 1 diabetes;
KIRP	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.55	-5.22	-0.32	3.79e-7	Hip geometry;
KIRP	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.95	0.45	6.65e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs440932	0.717	rs330944	chr8:9021293	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.47	0.38	5.38e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.8	10.84	0.57	1.23e-22	Height;
KIRP	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.49	-5.12	-0.31	6.07e-7	Fibroblast growth factor basic levels;
KIRP	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.02	-11.33	-0.59	3.24e-24	Colorectal cancer;
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.55	-5.29	-0.32	2.69e-7	Platelet count;
KIRP	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg13010199	chr12:38710504	ALG10B	0.71	8.97	0.5	7.99e-17	Bladder cancer;
KIRP	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg09640425	chr7:158790006	NA	-0.43	-5.63	-0.34	5e-8	Facial morphology (factor 20);
KIRP	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	21.61	0.81	8.72e-59	Prudent dietary pattern;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg11522683	chr6:37501428	NA	-0.37	-4.97	-0.3	1.24e-6	Cognitive performance;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16804899	chr2:27805965	ZNF512	0.41	6.11	0.36	3.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.45	6.38	0.38	8.81e-10	Sitting height ratio;
KIRP	cis	rs9426935	0.932	rs11264736	chr1:153939130	C/T	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.31	-5.32	-0.32	2.31e-7	Lentiform nucleus volume;
KIRP	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg03060546	chr3:49711283	APEH	0.46	5.95	0.35	9.13e-9	Parkinson's disease;
KIRP	cis	rs4356932	1.000	rs7665152	chr4:76960205	T/G	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg07972983	chr1:205091412	RBBP5	0.43	5.11	0.31	6.59e-7	Red blood cell count;
KIRP	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg18944383	chr4:111397179	ENPEP	0.41	6.52	0.38	3.97e-10	Coronary artery disease;
KIRP	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.34	-0.42	3.04e-12	Type 2 diabetes;
KIRP	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.97	-0.41	2.94e-11	Joint mobility (Beighton score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04235519	chr10:102505365	PAX2	0.52	6.99	0.41	2.57e-11	Parkinson's disease;
KIRP	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg12962167	chr3:53033115	SFMBT1	0.67	5.04	0.31	8.99e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg03060546	chr3:49711283	APEH	0.48	6.17	0.37	2.86e-9	Parkinson's disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24926775	chr1:151584391	SNX27	0.65	7.34	0.42	3.06e-12	Lung cancer in ever smokers;
KIRP	cis	rs4953911	0.614	rs11674550	chr2:135082444	G/A	cg18482303	chr2:135041380	MGAT5	-0.27	-4.95	-0.3	1.36e-6	Multiple sclerosis (severity);
KIRP	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.47	-9.66	-0.52	6.27e-19	Longevity;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.63	8.51	0.48	1.76e-15	Longevity;Endometriosis;
KIRP	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.67	-9.15	-0.5	2.19e-17	Coronary artery disease;
KIRP	cis	rs7225151	0.710	rs75367124	chr17:5264285	G/A	cg24500398	chr17:5266808	RABEP1	-0.52	-4.92	-0.3	1.56e-6	Alzheimer's disease (late onset);
KIRP	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.74	9.05	0.5	4.49e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.7	9.83	0.53	1.85e-19	Primary sclerosing cholangitis;
KIRP	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.35	-0.42	2.96e-12	Red cell distribution width;
KIRP	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg00933542	chr6:150070202	PCMT1	0.27	5.14	0.31	5.53e-7	Testicular germ cell tumor;
KIRP	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.81	-11.95	-0.61	2.95e-26	Asthma;
KIRP	cis	rs4006360	0.601	rs349785	chr17:39254557	C/T	cg20663846	chr17:39254439	KRTAP4-8	0.38	5.18	0.31	4.65e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.79	-11.62	-0.6	3.51e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg04998671	chr14:104000505	TRMT61A	-0.54	-6.38	-0.38	8.83e-10	Coronary artery disease;
KIRP	cis	rs9398803	0.687	rs1538956	chr6:126964026	G/T	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs7520050	0.778	rs2934857	chr1:46039612	A/G	cg24296786	chr1:45957014	TESK2	-0.46	-5.86	-0.35	1.47e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs714027	0.585	rs737911	chr22:30399417	A/G	cg27665648	chr22:30112403	NA	-0.39	-5.12	-0.31	6.28e-7	Lymphocyte counts;
KIRP	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.67	6.77	0.4	9.24e-11	Vitiligo;
KIRP	cis	rs6142102	0.962	rs2206448	chr20:32709525	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	6.24	0.37	1.86e-9	Skin pigmentation;
KIRP	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg12756093	chr1:115239321	AMPD1	0.54	7.26	0.42	5.21e-12	Autism;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg04025307	chr7:1156635	C7orf50	0.66	7.29	0.42	4.17e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg03808351	chr9:123631620	PHF19	0.41	5.54	0.33	7.78e-8	Rheumatoid arthritis;
KIRP	cis	rs2671245	0.933	rs2819482	chr1:56159441	C/T	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.61	-8.6	-0.48	9.36e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18610977	chr5:31532447	RNASEN;C5orf22	0.47	6.16	0.37	2.88e-9	Parkinson's disease;
KIRP	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.18	-0.37	2.58e-9	Aortic root size;
KIRP	cis	rs3761847	0.500	rs10760132	chr9:123739993	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	5.2	0.31	4.21e-7	Rheumatoid arthritis;
KIRP	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg19847130	chr8:10466454	RP1L1	0.35	5.25	0.32	3.23e-7	Retinal vascular caliber;
KIRP	cis	rs6977660	0.652	rs10254427	chr7:19816240	C/T	cg05791153	chr7:19748676	TWISTNB	0.55	5.6	0.34	5.8e-8	Thyroid stimulating hormone;
KIRP	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg13180566	chr4:1052158	NA	-0.5	-5.07	-0.31	7.96e-7	Recombination rate (females);
KIRP	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.79	12.67	0.63	1.2e-28	Blood metabolite levels;
KIRP	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.59	7.07	0.41	1.59e-11	Coronary artery disease;
KIRP	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.59	-0.48	9.97e-16	Morning vs. evening chronotype;
KIRP	cis	rs687432	0.718	rs3851121	chr11:57787039	C/G	cg19752551	chr11:57585705	CTNND1	0.45	5.71	0.34	3.3e-8	Parkinson's disease;
KIRP	cis	rs1843834	0.755	rs11898692	chr2:225575173	T/C	cg22455342	chr2:225449267	CUL3	0.49	5.6	0.34	5.84e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.45	-0.38	5.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg07741184	chr6:167504864	NA	-0.2	-5.03	-0.31	9.56e-7	Crohn's disease;
KIRP	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg18198730	chr1:247681584	NA	0.82	5.54	0.33	7.87e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs8053891	0.906	rs12149877	chr16:71996067	T/C	cg04254540	chr16:71951199	KIAA0174	-0.42	-4.86	-0.3	2.13e-6	Coronary artery disease;
KIRP	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.77	9.69	0.53	4.97e-19	Menarche (age at onset);
KIRP	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.29	-0.37	1.4e-9	QT interval;
KIRP	cis	rs6558530	0.692	rs12335115	chr8:1699852	C/G	cg08198773	chr8:1697536	NA	0.5	6.21	0.37	2.22e-9	Systolic blood pressure;
KIRP	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.79	-10.22	-0.55	1.11e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs490234	0.702	rs4838274	chr9:128345994	C/A	cg14078157	chr9:128172775	NA	-0.6	-6.83	-0.4	6.73e-11	Mean arterial pressure;
KIRP	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.74	-8.73	-0.49	4.01e-16	Platelet distribution width;
KIRP	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.13	-0.46	2.11e-14	Neuroticism;
KIRP	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.71	0.39	1.29e-10	Height;
KIRP	cis	rs9863706	0.520	rs9832502	chr3:72398979	G/A	cg05607079	chr3:72387937	NA	0.44	5.66	0.34	4.15e-8	Height;
KIRP	cis	rs918629	0.567	rs56219066	chr5:95242931	T/C	cg16656078	chr5:95278638	ELL2	-0.38	-5.81	-0.35	1.95e-8	IgG glycosylation;
KIRP	cis	rs9393813	0.516	rs4711152	chr6:27380202	C/T	cg03332623	chr6:27441972	ZNF184	0.38	5.23	0.32	3.61e-7	Bipolar disorder;
KIRP	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg06640241	chr16:89574553	SPG7	0.66	8.6	0.48	9.63e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs889512	0.642	rs8046145	chr16:75295021	G/C	cg03315344	chr16:75512273	CHST6	-0.62	-4.92	-0.3	1.58e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs12659622	0.850	rs6892081	chr5:15636890	G/A	cg25746134	chr1:202129865	PTPN7	-0.48	-6.07	-0.36	4.73e-9	Obesity-related traits;
KIRP	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.36	-0.47	4.71e-15	Coronary artery disease;
KIRP	cis	rs6973256	0.795	rs763643	chr7:133343243	T/A	cg10665199	chr7:133106180	EXOC4	-0.51	-6.38	-0.38	8.55e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg00857998	chr1:205179979	DSTYK	0.49	6.54	0.38	3.62e-10	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
KIRP	cis	rs10875746	0.669	rs61941003	chr12:48619625	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-5.03	-0.31	9.32e-7	Longevity (90 years and older);
KIRP	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg05347473	chr6:146136440	FBXO30	0.57	8.03	0.46	3.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs258892	0.895	rs13170247	chr5:72069684	A/G	cg21869765	chr5:72125136	TNPO1	-0.52	-5.83	-0.35	1.78e-8	Small cell lung carcinoma;
KIRP	cis	rs4389656	0.592	rs187994	chr5:6742168	A/G	cg10857441	chr5:6722123	POLS	-0.35	-5.0	-0.3	1.11e-6	Coronary artery disease;
KIRP	cis	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.04	-0.36	5.56e-9	Obesity-related traits;
KIRP	cis	rs7523273	1.000	rs12123251	chr1:207992546	G/A	cg22525895	chr1:207977042	MIR29B2	-0.66	-8.2	-0.46	1.36e-14	Schizophrenia;
KIRP	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.37	0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg04725166	chr1:7887271	PER3	-0.34	-5.37	-0.32	1.87e-7	Crohn's disease;
KIRP	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg14829155	chr15:31115871	NA	-0.78	-9.41	-0.51	3.81e-18	Huntington's disease progression;
KIRP	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.6	-6.04	-0.36	5.51e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-6.99	-0.41	2.59e-11	Lung cancer;
KIRP	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.88	-0.45	1.03e-13	Sudden cardiac arrest;
KIRP	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07234876	chr8:600039	NA	1.04	7.72	0.44	2.99e-13	IgG glycosylation;
KIRP	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.37	7.07	0.41	1.61e-11	Height;
KIRP	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg24253500	chr15:84953950	NA	0.69	7.84	0.45	1.38e-13	Schizophrenia;
KIRP	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg11608241	chr8:8085544	FLJ10661	0.49	5.8	0.35	1.99e-8	Systolic blood pressure;
KIRP	cis	rs6952809	1.000	rs6944568	chr7:2448317	A/C	cg06995285	chr7:2418615	EIF3B	0.36	4.86	0.3	2.05e-6	Multiple sclerosis;
KIRP	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.04	7.94	0.45	7.05e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg19468946	chr17:37922297	IKZF3	-0.37	-5.03	-0.31	9.5e-7	Self-reported allergy;
KIRP	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.86	-14.38	-0.68	1.98e-34	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs33912345	0.669	rs1314620	chr14:60877853	A/T	cg27398547	chr14:60952738	C14orf39	-0.4	-5.44	-0.33	1.3e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs7595037	0.663	rs11126185	chr2:68652580	G/A	cg12452813	chr2:68675892	NA	-0.43	-5.2	-0.31	4.14e-7	Multiple sclerosis;
KIRP	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.8	-12.43	-0.62	7.36e-28	Oral cavity cancer;
KIRP	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg00784671	chr22:46762841	CELSR1	-0.76	-6.8	-0.4	7.85e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs662064	0.962	rs622623	chr1:10555257	C/T	cg17425144	chr1:10567563	PEX14	0.33	5.44	0.33	1.29e-7	Asthma;
KIRP	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	trans	rs12517041	1.000	rs10079487	chr5:23294939	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.18	-0.37	2.66e-9	Neuroticism;
KIRP	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg27124370	chr19:33622961	WDR88	0.57	6.97	0.41	2.86e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.71	-9.69	-0.53	5.01e-19	Waist circumference;Body mass index;
KIRP	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.73	-11.42	-0.59	1.63e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6540559	1.000	rs1044516	chr1:209959614	G/T	cg22029157	chr1:209979665	IRF6	0.55	6.7	0.39	1.39e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.58	6.74	0.39	1.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62355272	1.000	rs11567699	chr5:35859011	C/G	cg13894535	chr5:35919491	CAPSL	-0.55	-6.34	-0.37	1.09e-9	Lymphocyte counts;
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.8	7.79	0.44	1.89e-13	Lung function (FEV1/FVC);
KIRP	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.83	12.01	0.61	1.81e-26	Mean corpuscular hemoglobin;
KIRP	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.45e-9	Breast cancer;
KIRP	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg23719950	chr11:63933701	MACROD1	-0.68	-6.55	-0.39	3.26e-10	Mean platelet volume;
KIRP	trans	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg13565492	chr6:43139072	SRF	-0.94	-8.67	-0.48	5.79e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg03060546	chr3:49711283	APEH	-0.66	-6.22	-0.37	2.14e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg04306507	chr14:55594613	LGALS3	0.52	8.15	0.46	1.9e-14	Protein biomarker;
KIRP	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.46	5.55	0.33	7.55e-8	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg07382826	chr16:28625726	SULT1A1	0.47	5.32	0.32	2.33e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.62	8.09	0.46	2.72e-14	Coronary artery disease;
KIRP	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg22676075	chr6:135203613	NA	0.47	6.84	0.4	6.37e-11	Red blood cell count;
KIRP	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-7.18	-0.42	8.32e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs75920871	1.000	rs11823013	chr11:116839535	T/C	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs71597109	0.681	rs4699260	chr4:102725298	C/T	cg14855874	chr4:102712397	BANK1	0.4	5.05	0.31	8.67e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.12	-0.31	6.3e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg27654529	chr19:35418345	ZNF30	0.46	6.15	0.37	3.06e-9	Ischemic stroke;
KIRP	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.8	8.65	0.48	6.89e-16	Gastritis;
KIRP	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.75	0.4	1.04e-10	Joint mobility (Beighton score);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg14000065	chr8:75764774	PI15	0.4	6.45	0.38	6e-10	Educational attainment;
KIRP	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.65	-0.34	4.48e-8	Metabolite levels;
KIRP	cis	rs741951	0.635	rs235318	chr21:46276825	G/A	cg08823554	chr21:46269191	NA	-0.62	-5.34	-0.32	2.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.78	0.57	1.95e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00950418	chr7:105029125	SRPK2	-0.54	-6.75	-0.4	1.05e-10	Height;
KIRP	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg06212747	chr3:49208901	KLHDC8B	0.63	8.85	0.49	1.77e-16	Resting heart rate;
KIRP	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg16141378	chr3:129829833	LOC729375	-0.6	-7.56	-0.43	7.9e-13	Neuroticism;
KIRP	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.54	6.94	0.4	3.5e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.77	-12.29	-0.62	2.16e-27	Breast cancer;
KIRP	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.61	6.64	0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	1.12	8.11	0.46	2.4e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg26441486	chr22:50317300	CRELD2	0.42	6.88	0.4	5.03e-11	Schizophrenia;
KIRP	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg05315796	chr3:52349193	DNAH1	0.4	5.92	0.35	1.09e-8	Bipolar disorder;
KIRP	cis	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.51	-0.33	9.06e-8	HDL cholesterol;
KIRP	cis	rs2599510	0.811	rs62136345	chr2:32807223	G/T	cg02381751	chr2:32503542	YIPF4	0.48	5.5	0.33	9.64e-8	Interleukin-18 levels;
KIRP	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.85	10.09	0.54	2.99e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg13010199	chr12:38710504	ALG10B	0.48	6.27	0.37	1.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs4733601	1.000	rs4733601	chr8:129269466	A/G	cg24899361	chr22:43547448	TSPO	0.44	6.05	0.36	5.43e-9	Diffuse large B cell lymphoma;
KIRP	cis	rs2594989	0.779	rs2443701	chr3:11588773	C/T	cg01796438	chr3:11312864	ATG7	0.45	5.83	0.35	1.76e-8	Circulating chemerin levels;
KIRP	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.49	-6.05	-0.36	5.28e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9473924	0.505	rs9296644	chr6:50828247	G/A	cg14470998	chr6:50812995	TFAP2B	0.79	7.35	0.42	2.84e-12	Body mass index;
KIRP	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.86	-10.9	-0.57	7.61e-23	Blood protein levels;
KIRP	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.67	6.72	0.39	1.24e-10	Menarche (age at onset);
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19062689	chr19:23871092	ZNF675	-0.45	-6.75	-0.4	1.07e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6977660	0.714	rs10224920	chr7:19816173	A/T	cg07541023	chr7:19748670	TWISTNB	0.56	5.5	0.33	9.73e-8	Thyroid stimulating hormone;
KIRP	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.51	6.82	0.4	7.22e-11	Schizophrenia;
KIRP	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.73	9.27	0.51	9.46e-18	Corneal astigmatism;
KIRP	trans	rs28595532	0.557	rs13435618	chr4:119308814	C/T	cg26518628	chr1:97050305	NA	-0.82	-8.82	-0.49	2.13e-16	Cannabis dependence symptom count;
KIRP	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06481639	chr22:41940642	POLR3H	0.49	5.95	0.35	8.97e-9	Vitiligo;
KIRP	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg05315796	chr3:52349193	DNAH1	0.45	6.95	0.41	3.3e-11	Bipolar disorder;
KIRP	cis	rs10073892	0.743	rs10076313	chr5:101657353	T/C	cg19774478	chr5:101632501	SLCO4C1	0.65	6.74	0.39	1.14e-10	Cognitive decline (age-related);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20648385	chr11:72525603	ATG16L2	0.51	6.4	0.38	7.83e-10	Parkinson's disease;
KIRP	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg10189774	chr4:17578691	LAP3	0.42	5.1	0.31	6.66e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg00646381	chr17:77835854	NA	-0.55	-7.29	-0.42	4.3e-12	Electroencephalogram traits;
KIRP	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.79	-0.35	2.16e-8	Pulmonary function;
KIRP	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.48	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.15	-0.31	5.4e-7	Atopic dermatitis;
KIRP	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Bipolar disorder;
KIRP	cis	rs9400467	0.537	rs73530951	chr6:111484814	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.03	0.31	9.56e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9611198	0.792	rs5757727	chr22:39963173	G/A	cg03390717	chr22:39966585	CACNA1I	0.39	6.92	0.4	3.9e-11	Schizophrenia;
KIRP	cis	rs743757	1.000	rs2236954	chr3:50425177	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.32	0.32	2.38e-7	Diastolic blood pressure;
KIRP	cis	rs5753037	0.869	rs5763651	chr22:30364261	T/C	cg27665648	chr22:30112403	NA	0.38	5.29	0.32	2.66e-7	Type 1 diabetes;
KIRP	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.86	-8.83	-0.49	2.01e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.29e-11	Type 2 diabetes;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg01798033	chr11:19368221	NA	0.46	6.5	0.38	4.37e-10	DNA methylation (variation);
KIRP	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg27205649	chr11:78285834	NARS2	-0.55	-6.24	-0.37	1.86e-9	Testicular germ cell tumor;
KIRP	cis	rs4936894	0.500	rs7931968	chr11:124134686	C/T	cg27160556	chr11:124181099	OR8D1	-0.42	-6.14	-0.36	3.24e-9	Aging (time to death);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27221554	chr8:29924188	TMEM66	0.44	6.06	0.36	4.98e-9	Interleukin-4 levels;
KIRP	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.59	7.31	0.42	3.7e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.64	0.39	2.04e-10	Major depressive disorder;
KIRP	cis	rs7246657	0.722	rs12974225	chr19:38240098	G/T	cg18154014	chr19:37997991	ZNF793	-0.53	-5.66	-0.34	4.3e-8	Coronary artery calcification;
KIRP	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.6	-8.71	-0.49	4.61e-16	Bipolar disorder;
KIRP	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.5	7.16	0.42	9.24e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg17946497	chr5:172198141	DUSP1	0.53	6.19	0.37	2.5e-9	Electroencephalogram traits;
KIRP	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	7.6	0.44	6.32e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.44	7.1	0.41	1.34e-11	Testicular germ cell tumor;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.69	-10.07	-0.54	3.45e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.16	0.31	5.15e-7	Myopia (pathological);
KIRP	cis	rs78487399	0.808	rs13413856	chr2:43764825	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.92	-0.3	1.59e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs867371	1.000	rs867370	chr15:82438262	T/A	cg00614314	chr15:82944287	LOC80154	-0.52	-6.19	-0.37	2.49e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg15841412	chr13:111365552	ING1	0.55	6.1	0.36	3.99e-9	Coronary artery disease;
KIRP	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.9	12.48	0.62	5.01e-28	Blood protein levels;
KIRP	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-8.57	-0.48	1.13e-15	Colorectal cancer;
KIRP	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-6.78	-0.4	9.1e-11	Urate levels in overweight individuals;
KIRP	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.92	-12.55	-0.62	2.87e-28	Homoarginine levels;
KIRP	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg25319279	chr11:5960081	NA	0.45	5.01	0.3	1.04e-6	DNA methylation (variation);
KIRP	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.24e-6	Depression;
KIRP	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	cg12689670	chr1:183009347	LAMC1	0.43	6.25	0.37	1.77e-9	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26487082	chr11:123172662	NA	0.44	6.07	0.36	4.87e-9	Parkinson's disease;
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.51	6.19	0.37	2.52e-9	Glycated hemoglobin levels;
KIRP	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg12311346	chr5:56204834	C5orf35	-0.36	-5.03	-0.31	9.34e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs7951870	1.000	rs12292425	chr11:46644143	T/G	cg16389345	chr11:46697382	NA	-0.47	-4.87	-0.3	2.02e-6	Schizophrenia;
KIRP	cis	rs2979489	0.945	rs13250272	chr8:30294942	A/G	cg26383811	chr8:30366931	RBPMS	0.41	5.4	0.33	1.54e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-7.51	-0.43	1.06e-12	Glycated hemoglobin levels;
KIRP	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.74	-0.44	2.64e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.8	-11.79	-0.6	9.66e-26	Obesity-related traits;
KIRP	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg17366294	chr4:99064904	C4orf37	0.47	6.03	0.36	6e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11214589	0.935	rs2186800	chr11:113242860	G/A	cg14159747	chr11:113255604	NA	0.41	6.23	0.37	2.01e-9	Neuroticism;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.61	8.18	0.46	1.51e-14	Mean corpuscular volume;
KIRP	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs16976116	0.901	rs9920219	chr15:55503964	T/C	cg11288833	chr15:55489084	RSL24D1	0.65	7.17	0.42	8.78e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.54	6.55	0.39	3.27e-10	Total body bone mineral density;
KIRP	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.29	0.62	2.18e-27	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04879506	chr3:9773229	BRPF1	0.57	7.6	0.44	6.16e-13	Parkinson's disease;
KIRP	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.66	8.13	0.46	2.08e-14	Dilated cardiomyopathy;
KIRP	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg26205652	chr12:48591994	NA	-0.46	-5.06	-0.31	8.12e-7	Lung cancer;
KIRP	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg02725872	chr8:58115012	NA	-0.55	-6.18	-0.37	2.66e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.62	-7.0	-0.41	2.47e-11	Coronary artery disease;
KIRP	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg03808351	chr9:123631620	PHF19	0.45	6.08	0.36	4.47e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.7	-7.97	-0.45	6.09e-14	Sudden cardiac arrest;
KIRP	cis	rs13361707	1.000	rs3805487	chr5:40796033	C/T	cg01087697	chr5:40835557	RPL37	-0.47	-5.34	-0.32	2.09e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.96	0.36	8.66e-9	Renal cell carcinoma;
KIRP	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.74	10.7	0.56	3.48e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08274821	chr1:214557901	PTPN14	-0.42	-6.03	-0.36	6.03e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.25	-5.27	-0.32	3.01e-7	Menarche (age at onset);
KIRP	cis	rs35740288	0.770	rs11631018	chr15:86140534	G/A	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.93	12.82	0.63	3.81e-29	Glomerular filtration rate (creatinine);
KIRP	cis	rs1147199	0.585	rs72737611	chr9:87239792	A/G	cg22402007	chr9:87282823	NTRK2	0.4	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg07936489	chr17:37558343	FBXL20	-0.56	-7.54	-0.43	9.29e-13	Asthma;
KIRP	cis	rs6815814	0.808	rs56083757	chr4:38846345	C/G	cg06935464	chr4:38784597	TLR10	0.46	5.49	0.33	9.76e-8	Breast cancer;
KIRP	cis	rs62344088	1.000	rs6898413	chr5:173927	A/C	cg22857025	chr5:266934	NA	-0.78	-5.87	-0.35	1.39e-8	Asthma (childhood onset);
KIRP	cis	rs7404928	0.794	rs11074584	chr16:23875929	G/A	cg05497750	chr16:23765381	CHP2	-0.43	-4.95	-0.3	1.35e-6	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.46	5.88	0.35	1.33e-8	Blood protein levels;
KIRP	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs72843166	0.562	rs2286572	chr17:61518242	G/T	cg19683800	chr17:61518354	CYB561	-0.45	-5.83	-0.35	1.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.53	5.8	0.35	2.02e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21388527	chr3:96532024	EPHA6	0.48	6.57	0.39	2.92e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.91	-0.53	1.04e-19	Hemoglobin concentration;
KIRP	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.07	-0.31	7.85e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22249735	chr2:206700458	NA	0.46	6.52	0.38	4.02e-10	Interleukin-4 levels;
KIRP	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.74	8.32	0.47	5.99e-15	Corneal astigmatism;
KIRP	cis	rs6973256	0.897	rs2991242	chr7:133336459	A/T	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.55e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.64	8.93	0.49	1.05e-16	Alcohol dependence;
KIRP	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg17810781	chr1:201082982	CACNA1S	0.46	7.3	0.42	3.86e-12	Permanent tooth development;
KIRP	cis	rs7640424	0.691	rs161880	chr3:107838805	T/C	cg09227934	chr3:107805635	CD47	0.29	5.09	0.31	6.97e-7	Body mass index;
KIRP	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg00579200	chr11:133705235	NA	-0.38	-4.95	-0.3	1.38e-6	Childhood ear infection;
KIRP	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22022881	chr2:105853494	NA	-0.36	-5.38	-0.32	1.7e-7	Type 2 diabetes;
KIRP	cis	rs74181299	0.784	rs2723085	chr2:65297359	C/G	cg05010058	chr2:65284262	CEP68	0.43	5.74	0.34	2.71e-8	Pulse pressure;
KIRP	cis	rs4654899	0.743	rs61781069	chr1:21130735	T/C	cg05370193	chr1:21551575	ECE1	0.44	5.43	0.33	1.32e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.28	0.51	8.86e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.05	12.74	0.63	6.87e-29	Smoking behavior;
KIRP	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.36	-0.38	1e-9	Aortic root size;
KIRP	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	6.83	0.4	6.5e-11	Iron status biomarkers;
KIRP	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-9.02	-0.5	5.45e-17	Resting heart rate;
KIRP	cis	rs5753037	0.629	rs140138	chr22:30164628	T/G	cg01021169	chr22:30184971	ASCC2	-0.45	-5.58	-0.34	6.26e-8	Type 1 diabetes;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20253574	chr1:10927403	NA	-0.49	-6.45	-0.38	5.74e-10	Myopia;
KIRP	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.87	13.71	0.66	3.62e-32	Blood protein levels;
KIRP	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.4	9.92	0.53	9.65e-20	Corneal astigmatism;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.61	5.77	0.35	2.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00933542	chr6:150070202	PCMT1	0.26	5.07	0.31	7.77e-7	Lung cancer;
KIRP	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.82	10.93	0.57	6.17e-23	Morning vs. evening chronotype;
KIRP	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06544989	chr22:39130855	UNC84B	0.5	8.99	0.5	6.8e-17	Menopause (age at onset);
KIRP	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.71	-9.42	-0.51	3.37e-18	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.22	-17.12	-0.74	8.58e-44	Breast cancer;
KIRP	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.62	9.19	0.51	1.76e-17	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg04369109	chr6:150039330	LATS1	-0.52	-6.62	-0.39	2.18e-10	Lung cancer;
KIRP	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg21918786	chr6:109611834	NA	-0.39	-5.48	-0.33	1.03e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg05347473	chr6:146136440	FBXO30	0.61	8.62	0.48	8.4e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6495367	1.000	rs745030	chr15:79381705	G/A	cg17916960	chr15:79447300	NA	0.3	5.07	0.31	7.89e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19717773	chr7:2847554	GNA12	-0.4	-6.03	-0.36	6.07e-9	Height;
KIRP	trans	rs2055729	0.645	rs612689	chr8:9752965	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	6.27	0.37	1.57e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-5.33	-0.32	2.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.62	9.41	0.51	3.77e-18	Fibrinogen levels;
KIRP	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21643547	chr1:205240462	TMCC2	-0.81	-12.85	-0.63	3.01e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4523957	0.928	rs177567	chr17:2197637	A/G	cg16513277	chr17:2031491	SMG6	-0.61	-8.46	-0.47	2.48e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg05335186	chr13:53173507	NA	0.35	5.5	0.33	9.46e-8	Lewy body disease;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.11e-7	Life satisfaction;
KIRP	cis	rs3750082	0.603	rs2278818	chr7:32961180	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.47	-5.16	-0.31	5.19e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	11.08	0.58	2.09e-23	Response to antipsychotic treatment;
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg04369109	chr6:150039330	LATS1	-0.63	-8.12	-0.46	2.27e-14	Lung cancer;
KIRP	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.04	0.41	1.87e-11	Arsenic metabolism;
KIRP	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs10899021	0.512	rs10219168	chr11:74374453	A/T	cg25880958	chr11:74394337	NA	0.45	5.33	0.32	2.25e-7	Response to metformin (IC50);
KIRP	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	0.86	7.04	0.41	1.93e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15731816	chr14:75230414	YLPM1	0.66	6.04	0.36	5.51e-9	Lung function (FEV1);
KIRP	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-9.35	-0.51	5.55e-18	Morning vs. evening chronotype;
KIRP	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.51	6.42	0.38	7.07e-10	Type 2 diabetes;
KIRP	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.91	8.87	0.49	1.5e-16	Eosinophil percentage of granulocytes;
KIRP	trans	rs6499100	0.695	rs4784258	chr16:52837310	C/T	cg13050766	chr1:63249793	ATG4C	0.43	6.16	0.37	2.91e-9	Tetralogy of Fallot;
KIRP	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-11.27	-0.58	5.16e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs17123764	0.892	rs77056500	chr12:50149604	C/T	cg20471783	chr12:50157085	TMBIM6	0.42	5.5	0.33	9.61e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11997175	1.000	rs6468203	chr8:33749572	T/A	cg04338863	chr8:33670619	NA	0.43	5.5	0.33	9.38e-8	Body mass index;
KIRP	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-5.45	-0.33	1.21e-7	Schizophrenia;
KIRP	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-0.97	-8.12	-0.46	2.29e-14	Blood protein levels;
KIRP	trans	rs62056376	0.736	rs1233651	chr17:32639361	C/T	cg09712683	chr2:95692352	MAL	0.47	6.35	0.38	1.06e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.5	5.83	0.35	1.73e-8	Uric acid levels;
KIRP	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1847505	1.000	rs1847505	chr13:61532597	G/C	cg25164009	chr13:61490935	NA	-0.58	-6.34	-0.37	1.12e-9	Polychlorinated biphenyl levels;
KIRP	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.21	-0.37	2.22e-9	Depression;
KIRP	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg25801113	chr15:45476975	SHF	0.41	7.43	0.43	1.82e-12	Uric acid levels;
KIRP	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg26035817	chr1:114414802	PTPN22	0.64	8.39	0.47	3.87e-15	Bacteremia;
KIRP	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.8	8.03	0.46	4.1e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.56	5.02	0.3	1e-6	Bipolar disorder;
KIRP	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg15556689	chr8:8085844	FLJ10661	0.56	7.25	0.42	5.36e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg25036284	chr2:26402008	FAM59B	0.53	5.51	0.33	9.02e-8	Gut microbiome composition (summer);
KIRP	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg22437258	chr11:111473054	SIK2	0.63	7.68	0.44	3.81e-13	Primary sclerosing cholangitis;
KIRP	cis	rs3026101	0.671	rs929262	chr17:5312271	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07114627	chr1:110155839	GNAT2	0.51	7.15	0.41	1.01e-11	Interleukin-4 levels;
KIRP	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg20651018	chr11:3035856	CARS	-0.36	-5.0	-0.3	1.08e-6	Longevity;
KIRP	cis	rs12586317	0.552	rs78139839	chr14:35789347	C/T	cg07166546	chr14:35805898	NA	-0.31	-7.24	-0.42	5.55e-12	Psoriasis;
KIRP	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg13147721	chr7:65941812	NA	1.03	7.08	0.41	1.49e-11	Diabetic kidney disease;
KIRP	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.33	-0.37	1.17e-9	Testicular germ cell tumor;
KIRP	trans	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg19894588	chr14:64061835	NA	-0.49	-6.6	-0.39	2.54e-10	Fat distribution (HIV);
KIRP	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.56	-0.48	1.24e-15	Neuroticism;
KIRP	trans	rs7404928	0.718	rs11644103	chr16:23860388	T/A	cg06734812	chr19:3223915	BRUNOL5	0.61	6.12	0.36	3.59e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.45	-5.74	-0.34	2.82e-8	Type 2 diabetes;
KIRP	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg25486957	chr4:152246857	NA	-0.5	-5.59	-0.34	6.1e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg10840412	chr1:235813424	GNG4	0.68	6.11	0.36	3.91e-9	Bipolar disorder;
KIRP	cis	rs4638749	0.677	rs7570544	chr2:108848137	C/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.32	-0.37	1.22e-9	Blood pressure;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09793807	chr17:46125678	NFE2L1	-0.47	-6.06	-0.36	5.06e-9	Myopia;
KIRP	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg14458575	chr2:238380390	NA	0.55	5.76	0.34	2.45e-8	Prostate cancer;
KIRP	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg21361702	chr7:150065534	REPIN1	0.62	6.54	0.38	3.48e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg09699651	chr6:150184138	LRP11	0.47	6.05	0.36	5.31e-9	Lung cancer;
KIRP	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg23995753	chr2:160760732	LY75	-0.43	-5.68	-0.34	3.76e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg00405596	chr8:11794950	NA	-0.43	-5.58	-0.34	6.44e-8	Triglycerides;
KIRP	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.5	6.5	0.38	4.51e-10	HDL cholesterol levels;
KIRP	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.59e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08280861	chr8:58055591	NA	0.55	5.18	0.31	4.67e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.07	0.31	7.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.15	-0.5	2.19e-17	Personality dimensions;
KIRP	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-0.84	-9.22	-0.51	1.42e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07234876	chr8:600039	NA	0.72	5.4	0.33	1.58e-7	IgG glycosylation;
KIRP	cis	rs2072732	0.861	rs10489589	chr1:2951244	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs12786942	0.660	rs7952146	chr11:101308038	T/A	cg03942599	chr11:101341554	TRPC6	0.47	5.94	0.35	9.43e-9	Facial depth;
KIRP	cis	rs9915657	0.715	rs34624256	chr17:70105848	C/T	cg04438997	chr17:70115868	SOX9	0.4	5.33	0.32	2.17e-7	Thyroid hormone levels;
KIRP	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg01620082	chr3:125678407	NA	-1.09	-6.86	-0.4	5.53e-11	Depression;
KIRP	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg19847130	chr8:10466454	RP1L1	-0.34	-5.12	-0.31	6.06e-7	Retinal vascular caliber;
KIRP	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg12454167	chr3:186435060	KNG1	0.53	9.25	0.51	1.15e-17	Blood protein levels;
KIRP	cis	rs8018808	0.935	rs17824034	chr14:77878683	A/G	cg20045696	chr14:77926864	AHSA1	0.46	5.7	0.34	3.36e-8	Myeloid white cell count;
KIRP	cis	rs12476592	0.571	rs2604617	chr2:63898663	A/G	cg17519650	chr2:63277830	OTX1	-0.46	-4.89	-0.3	1.79e-6	Childhood ear infection;
KIRP	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	1.24	12.4	0.62	9.63e-28	Uric acid levels;
KIRP	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-11.56	-0.59	5.85e-25	Idiopathic membranous nephropathy;
KIRP	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg02151108	chr14:50098012	C14orf104	-0.45	-5.7	-0.34	3.5e-8	Carotid intima media thickness;
KIRP	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07570687	chr10:102243282	WNT8B	0.52	6.7	0.39	1.41e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg06223162	chr1:101003688	GPR88	-0.53	-10.69	-0.56	3.69e-22	Breast cancer;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg03960681	chr15:60769981	NARG2	0.48	6.02	0.36	6.47e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg13400516	chr1:2159040	SKI	0.49	6.1	0.36	4.11e-9	Colorectal cancer;
KIRP	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.75	-0.4	1.03e-10	Type 2 diabetes;
KIRP	cis	rs7116495	1.000	rs116781589	chr11:71825006	G/T	cg18441811	chr11:71824068	C11orf51	0.61	4.9	0.3	1.73e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs4478037	0.822	rs4528891	chr3:33121392	G/T	cg19404215	chr3:33155277	CRTAP	0.56	5.36	0.32	1.91e-7	Major depressive disorder;
KIRP	cis	rs6782228	0.527	rs6767383	chr3:128413587	C/A	cg18648031	chr3:128330563	NA	0.26	5.27	0.32	3.03e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg17376030	chr22:41985996	PMM1	0.62	6.84	0.4	6.19e-11	Vitiligo;
KIRP	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg06217071	chr17:408420	NA	0.51	7.24	0.42	5.78e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.39	-0.43	2.25e-12	Neuroticism;
KIRP	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg01304814	chr3:48885189	PRKAR2A	0.54	5.02	0.3	1.01e-6	Parkinson's disease;
KIRP	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg08514558	chr10:81106712	PPIF	0.42	5.81	0.35	1.96e-8	Height;
KIRP	cis	rs1847202	1.000	rs7634188	chr3:72941289	A/G	cg06781948	chr3:72941472	GXYLT2	-0.39	-5.19	-0.31	4.37e-7	Motion sickness;
KIRP	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg17145862	chr1:211918768	LPGAT1	0.64	7.27	0.42	4.89e-12	Crohn's disease;
KIRP	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg00684032	chr4:1343700	KIAA1530	-0.54	-7.09	-0.41	1.45e-11	Obesity-related traits;
KIRP	cis	rs16936870	0.543	rs2926712	chr8:71157071	C/A	cg14232793	chr8:71155543	NCOA2	-0.58	-6.92	-0.4	4e-11	QT interval;
KIRP	cis	rs6815814	0.808	rs7687447	chr4:38846979	C/G	cg06935464	chr4:38784597	TLR10	0.48	5.86	0.35	1.5e-8	Breast cancer;
KIRP	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.47	-14.89	-0.69	3.51e-36	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg05692746	chr2:100937584	LONRF2	0.42	5.58	0.34	6.44e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	1.000	rs9867627	chr3:41795841	G/T	cg03022575	chr3:42003672	ULK4	-0.53	-5.82	-0.35	1.83e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4363385	0.553	rs11580383	chr1:152942192	A/G	cg13444842	chr1:152974279	SPRR3	-0.48	-6.91	-0.4	4.25e-11	Inflammatory skin disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07581922	chr16:3086538	CCDC64B	0.54	7.55	0.43	8.47e-13	Parkinson's disease;
KIRP	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.58	-6.61	-0.39	2.33e-10	Menarche (age at onset);
KIRP	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.06	-0.36	5.12e-9	Joint mobility (Beighton score);
KIRP	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg19445457	chr11:5799446	OR52N5	-0.45	-5.35	-0.32	2.03e-7	DNA methylation (variation);
KIRP	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.46	5.87	0.35	1.4e-8	Initial pursuit acceleration;
KIRP	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs4805272	1.000	rs888833	chr19:29324482	A/G	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.71	-6.42	-0.38	7.11e-10	Body mass index;
KIRP	cis	rs7539542	0.529	rs10800880	chr1:202892917	T/C	cg19681188	chr1:202830198	LOC148709	-0.48	-5.14	-0.31	5.68e-7	Mean platelet volume;
KIRP	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.04	-13.22	-0.64	1.67e-30	Exhaled nitric oxide output;
KIRP	trans	rs7157940	0.692	rs4905163	chr14:94570770	A/G	cg03390211	chr16:325826	RGS11	0.54	6.76	0.4	9.76e-11	Anthropometric traits;
KIRP	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg12315302	chr6:26189340	HIST1H4D	1.1	6.39	0.38	8.08e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8053891	0.906	rs8047643	chr16:71996498	A/G	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.04	-0.31	8.87e-7	Coronary artery disease;
KIRP	cis	rs3126085	0.560	rs12408401	chr1:152371801	G/T	cg26876637	chr1:152193138	HRNR	-0.68	-6.74	-0.4	1.09e-10	Atopic dermatitis;
KIRP	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.83	7.87	0.45	1.14e-13	Menopause (age at onset);
KIRP	cis	rs860295	0.702	rs2048431	chr1:155618630	G/A	cg02153340	chr1:155202674	NA	-0.5	-6.68	-0.39	1.6e-10	Body mass index;
KIRP	cis	rs11574514	1.000	rs9939085	chr16:67733237	C/T	cg26727032	chr16:67993705	SLC12A4	-0.69	-5.5	-0.33	9.37e-8	Crohn's disease;
KIRP	cis	rs4845459	0.967	rs10888503	chr1:152593549	C/T	cg07796016	chr1:152779584	LCE1C	-0.46	-5.53	-0.33	8.12e-8	Psoriasis;
KIRP	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg18404041	chr3:52824283	ITIH1	-0.37	-5.26	-0.32	3.19e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs61884328	0.852	rs17197500	chr11:47077032	A/G	cg23433285	chr11:47201945	PACSIN3	0.79	6.35	0.38	1.04e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.52	-6.71	-0.39	1.33e-10	Body mass index;
KIRP	cis	rs2057178	0.696	rs12278882	chr11:32352400	C/G	cg07934552	chr11:32355483	NA	0.4	5.11	0.31	6.34e-7	Tuberculosis;
KIRP	cis	rs2531992	0.620	rs2041248	chr16:4032489	T/G	cg05927578	chr16:4029543	ADCY9	0.51	5.55	0.33	7.46e-8	Waist circumference;
KIRP	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.62	7.27	0.42	4.85e-12	Neuroticism;
KIRP	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.91	-10.18	-0.54	1.49e-20	Blood protein levels;
KIRP	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00960509	chr1:21671908	ECE1	0.52	6.62	0.39	2.22e-10	Parkinson's disease;
KIRP	cis	rs6772849	0.662	rs12494372	chr3:128401693	A/C	cg08795948	chr3:128337044	NA	0.46	5.5	0.33	9.45e-8	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg23978390	chr7:1156363	C7orf50	0.56	5.48	0.33	1.08e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg12692727	chr7:1102344	C7orf50	0.47	5.04	0.31	9.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17030434	0.871	rs74380369	chr4:154730273	C/T	cg14289246	chr4:154710475	SFRP2	-0.7	-8.5	-0.48	1.82e-15	Electrocardiographic conduction measures;
KIRP	cis	rs911119	0.866	rs6048925	chr20:23579056	C/A	cg09631192	chr20:23583594	CST9	-0.47	-4.98	-0.3	1.22e-6	Chronic kidney disease;
KIRP	cis	rs882300	0.934	rs13431630	chr2:136930587	T/C	cg05194412	chr2:137003533	NA	-0.36	-4.94	-0.3	1.42e-6	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.67	-0.34	4.08e-8	Pulmonary function;
KIRP	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg00103785	chr1:155043322	NA	-0.29	-5.26	-0.32	3.15e-7	Breast cancer;
KIRP	cis	rs10849893	0.557	rs10849890	chr12:121902725	T/C	cg01154721	chr12:121881891	KDM2B	-0.43	-5.65	-0.34	4.53e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.39	-0.32	1.67e-7	Aortic root size;
KIRP	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	0.82	9.05	0.5	4.52e-17	Gut microbiome composition (summer);
KIRP	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg01304814	chr3:48885189	PRKAR2A	0.58	5.18	0.31	4.58e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg01420254	chr6:26195488	NA	1.16	10.2	0.55	1.31e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg21479132	chr6:26055353	NA	0.81	5.66	0.34	4.21e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg24579218	chr15:68104479	NA	-0.37	-5.34	-0.32	2.15e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	0.65	8.1	0.46	2.54e-14	Prostate cancer;
KIRP	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.28	-0.37	1.51e-9	Lung function (FEV1/FVC);
KIRP	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3779273	1.000	rs3779273	chr7:77828940	G/A	cg05596911	chr5:118502651	DMXL1	0.39	6.08	0.36	4.47e-9	Body mass index;
KIRP	cis	rs6585424	1.000	rs34148644	chr10:81923456	G/C	cg27417294	chr10:81904244	PLAC9	0.57	5.45	0.33	1.25e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.67	-0.44	4.11e-13	Morning vs. evening chronotype;
KIRP	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg01420254	chr6:26195488	NA	1.24	11.27	0.58	4.85e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg01244601	chr4:120671846	NA	-0.39	-4.94	-0.3	1.43e-6	Corneal astigmatism;
KIRP	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-7.3	-0.42	3.87e-12	Aortic root size;
KIRP	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-6.26	-0.37	1.67e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs71277158	0.688	rs12488988	chr3:169879860	T/C	cg04067573	chr3:169899625	PHC3	0.66	6.26	0.37	1.69e-9	Prostate cancer;
KIRP	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	0.84	7.7	0.44	3.32e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs174601	0.582	rs108499	chr11:61547237	C/T	cg07689907	chr11:61582574	FADS1	0.45	5.52	0.33	8.38e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs62355272	0.759	rs9292614	chr5:35824121	A/G	cg13894535	chr5:35919491	CAPSL	-0.44	-5.28	-0.32	2.79e-7	Lymphocyte counts;
KIRP	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7520050	0.966	rs7515491	chr1:46355079	A/G	cg03146154	chr1:46216737	IPP	-0.4	-5.05	-0.31	8.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.74	9.57	0.52	1.16e-18	Psoriasis;
KIRP	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.57	6.88	0.4	4.95e-11	Osteoporosis;
KIRP	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	trans	rs7939886	0.920	rs7112815	chr11:55960104	T/C	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.39	4.85	0.3	2.16e-6	Sitting height ratio;
KIRP	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg17425144	chr1:10567563	PEX14	-0.3	-5.07	-0.31	8e-7	Asthma;
KIRP	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.73	6.23	0.37	1.96e-9	Diabetic retinopathy;
KIRP	cis	rs699	0.597	rs2478523	chr1:230841509	A/G	cg07390013	chr1:230838294	AGT	0.37	4.85	0.3	2.19e-6	Coronary artery disease;
KIRP	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.42	-4.98	-0.3	1.17e-6	Iron status biomarkers;
KIRP	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.08	0.41	1.47e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.59	-7.32	-0.42	3.55e-12	Colorectal cancer;
KIRP	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg25783544	chr11:47291846	MADD	0.44	4.92	0.3	1.58e-6	HDL cholesterol;
KIRP	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.84	11.07	0.58	2.19e-23	Childhood ear infection;
KIRP	cis	rs687432	0.924	rs12801755	chr11:57730986	C/T	cg19752551	chr11:57585705	CTNND1	-0.54	-7.43	-0.43	1.82e-12	Parkinson's disease;
KIRP	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.73	-7.35	-0.42	2.89e-12	Bipolar disorder;
KIRP	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.51	-0.33	9.2e-8	Ileal carcinoids;
KIRP	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs1035491	0.896	rs1459194	chr5:63966889	A/G	cg01791865	chr5:63954708	NA	-0.31	-4.85	-0.3	2.24e-6	Body mass index;
KIRP	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.54	7.65	0.44	4.47e-13	Mean corpuscular volume;
KIRP	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg23422044	chr7:1970798	MAD1L1	-0.66	-6.47	-0.38	5.2400000000000005e-10	Bipolar disorder;
KIRP	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg04731861	chr2:219085781	ARPC2	0.24	5.97	0.36	8.36e-9	Colorectal cancer;
KIRP	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.38	16.32	0.72	4.43e-41	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21659725	chr3:3221576	CRBN	-0.59	-7.01	-0.41	2.32e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Bladder cancer;
KIRP	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.96	-0.36	8.85e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6700559	0.545	rs12744758	chr1:200593138	G/A	cg07804481	chr1:200639085	DDX59	0.43	5.53	0.33	8.26e-8	Coronary artery disease;
KIRP	cis	rs11264213	0.901	rs72661646	chr1:36454954	A/T	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg08283408	chr3:49949060	MON1A	-0.38	-5.06	-0.31	8.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg05527609	chr1:210001259	C1orf107	-0.45	-5.5	-0.33	9.65e-8	Red blood cell count;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg00376283	chr12:123451042	ABCB9	0.63	7.42	0.43	1.93e-12	Neutrophil percentage of white cells;
KIRP	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs2594989	0.779	rs2596815	chr3:11594930	A/G	cg01796438	chr3:11312864	ATG7	0.44	5.65	0.34	4.33e-8	Circulating chemerin levels;
KIRP	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23544223	chr18:12777786	NA	0.76	6.41	0.38	7.43e-10	Inflammatory skin disease;
KIRP	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.67	7.11	0.41	1.23e-11	Lymphocyte counts;
KIRP	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.12	-0.41	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.9e-8	Glomerular filtration rate;
KIRP	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg01631408	chr1:248437212	OR2T33	-0.67	-8.98	-0.5	7.24e-17	Common traits (Other);
KIRP	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg18944383	chr4:111397179	ENPEP	0.54	8.64	0.48	7.06e-16	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg25251562	chr2:3704773	ALLC	0.46	5.68	0.34	3.73e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg26022315	chr17:47021804	SNF8	0.44	5.69	0.34	3.57e-8	Type 2 diabetes;
KIRP	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg11522683	chr6:37501428	NA	-0.38	-4.98	-0.3	1.18e-6	Cognitive performance;
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg15181151	chr6:150070149	PCMT1	0.28	4.87	0.3	2.01e-6	Lung cancer;
KIRP	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg13482628	chr17:19912719	NA	0.6	8.38	0.47	4.08e-15	Schizophrenia;
KIRP	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.7	8.98	0.5	7.04e-17	Bladder cancer;
KIRP	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg19773385	chr1:10388646	KIF1B	-0.65	-8.94	-0.5	9.35e-17	Hepatocellular carcinoma;
KIRP	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg22563815	chr15:78856949	CHRNA5	0.46	6.24	0.37	1.91e-9	Sudden cardiac arrest;
KIRP	cis	rs7561273	0.586	rs116650625	chr2:24353212	C/G	cg20701182	chr2:24300061	SF3B14	0.48	5.97	0.36	8.46e-9	Quantitative traits;
KIRP	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.78	-11.04	-0.58	2.83e-23	Blood metabolite levels;
KIRP	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.64	-0.34	4.64e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg25486957	chr4:152246857	NA	-0.52	-5.69	-0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7635838	0.963	rs7627171	chr3:11413429	G/C	cg00170343	chr3:11313890	ATG7	0.42	5.42	0.33	1.45e-7	HDL cholesterol;
KIRP	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg24130564	chr14:104152367	KLC1	-0.41	-5.44	-0.33	1.27e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	0.97	10.19	0.54	1.48e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.52	-0.33	8.51e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9828933	0.577	rs832193	chr3:63854445	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	1.01	9.2	0.51	1.63e-17	Type 2 diabetes;
KIRP	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg09631192	chr20:23583594	CST9	-0.55	-5.29	-0.32	2.71e-7	Chronic kidney disease;
KIRP	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.81	7.77	0.44	2.16e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.71	-7.04	-0.41	1.9e-11	Ulcerative colitis;
KIRP	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.24	-0.37	1.88e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg22800045	chr5:56110881	MAP3K1	0.79	8.55	0.48	1.35e-15	Initial pursuit acceleration;
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg04369109	chr6:150039330	LATS1	-0.65	-8.66	-0.48	6.51e-16	Lung cancer;
KIRP	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs10131728	1.000	rs12878503	chr14:81643053	T/C	cg01989461	chr14:81687754	GTF2A1	-0.81	-5.98	-0.36	7.68e-9	IgG glycosylation;
KIRP	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.64	7.72	0.44	2.86e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.9	-0.49	1.29e-16	Hirschsprung disease;
KIRP	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.67	9.69	0.53	5.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg17294928	chr15:75287854	SCAMP5	0.54	7.06	0.41	1.73e-11	Breast cancer;
KIRP	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.85	10.33	0.55	5.21e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs4728302	0.869	rs10155909	chr7:133593036	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg08923054	chr8:41654455	ANK1	0.74	7.99	0.45	5.27e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6691722	0.503	rs7546875	chr1:24703667	T/C	cg18323236	chr1:24743029	NIPAL3	0.43	6.16	0.37	2.99e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.93	-15.28	-0.7	1.62e-37	Breast cancer;
KIRP	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.19	-0.31	4.49e-7	Neuroticism;
KIRP	cis	rs7143963	0.666	rs57613851	chr14:103319835	C/T	cg24154132	chr14:103367632	TRAF3	0.31	6.21	0.37	2.24e-9	Body mass index;
KIRP	cis	rs7638995	0.651	rs4635707	chr3:69197507	C/T	cg26574240	chr3:69171822	LMOD3	-0.53	-7.8	-0.45	1.74e-13	Alzheimer's disease (late onset);
KIRP	cis	rs2901460	0.509	rs66481227	chr2:62117600	C/T	cg02183531	chr2:62113199	CCT4	-0.5	-5.04	-0.31	8.92e-7	Mean corpuscular volume;
KIRP	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.86	-0.63	2.63e-29	Extrinsic epigenetic age acceleration;
KIRP	trans	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.61	-0.44	5.91e-13	Myopia (pathological);
KIRP	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg12560992	chr17:57184187	TRIM37	0.6	5.49	0.33	9.83e-8	Cognitive test performance;
KIRP	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-6.01	-0.36	6.71e-9	Coronary artery disease;
KIRP	cis	rs7766436	0.553	rs6939284	chr6:22556885	C/G	cg13666174	chr6:22585274	NA	0.4	4.9	0.3	1.73e-6	Coronary artery disease;
KIRP	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.47e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.59	8.12	0.46	2.19e-14	Height;
KIRP	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.53	-4.93	-0.3	1.54e-6	Other erythrocyte phenotypes;
KIRP	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.5	-8.5	-0.48	1.84e-15	Refractive error;
KIRP	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.88	8.09	0.46	2.68e-14	Nonalcoholic fatty liver disease;
KIRP	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.74	-9.01	-0.5	5.8e-17	Vitiligo;
KIRP	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg00129232	chr17:37814104	STARD3	0.66	8.46	0.47	2.46e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs6662572	0.737	rs56295206	chr1:46551026	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.49	0.33	1e-7	Blood protein levels;
KIRP	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.91	-12.84	-0.63	3.13e-29	Height;
KIRP	cis	rs526231	0.578	rs34786	chr5:102458113	C/G	cg23492399	chr5:102201601	PAM	-0.49	-5.42	-0.33	1.4e-7	Primary biliary cholangitis;
KIRP	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg18478394	chr8:109455254	TTC35	0.51	6.26	0.37	1.71e-9	Dupuytren's disease;
KIRP	cis	rs7923609	1.000	rs2393969	chr10:65140440	A/C	cg08743896	chr10:65200160	JMJD1C	-0.36	-5.39	-0.33	1.62e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.49	-6.13	-0.36	3.55e-9	Facial morphology (factor 20);
KIRP	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.41	0.33	1.5e-7	Putamen volume;
KIRP	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.55	7.18	0.42	8.35e-12	Mean corpuscular volume;
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.59e-6	Lung cancer;
KIRP	cis	rs9596863	0.808	rs9596844	chr13:54302585	G/A	ch.13.53330881F	chr13:54432880	NA	0.54	5.25	0.32	3.36e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.65	8.35	0.47	5.02e-15	Red blood cell count;
KIRP	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg25482853	chr8:67687455	SGK3	0.82	7.16	0.42	9.18e-12	Obesity-related traits;
KIRP	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg22138327	chr13:27999177	GTF3A	0.84	6.44	0.38	6.13e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg08890418	chr1:21044141	KIF17	0.34	5.06	0.31	8.07e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	1.09	23.3	0.83	3.51e-64	Parkinson's disease;
KIRP	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg06121193	chr1:90282411	NA	-0.42	-5.94	-0.35	9.84e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg02527881	chr3:46936655	PTH1R	-0.59	-9.24	-0.51	1.16e-17	Birth weight;
KIRP	cis	rs3849570	0.643	rs11705789	chr3:81969196	G/T	cg07356753	chr3:81810745	GBE1	-0.55	-7.25	-0.42	5.39e-12	Waist circumference;Body mass index;
KIRP	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.97	-0.36	8.36e-9	Breast cancer;
KIRP	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg08807101	chr21:30365312	RNF160	0.67	8.2	0.46	1.3e-14	Pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07706279	chr3:39149020	GORASP1;TTC21A	0.49	6.03	0.36	6.09e-9	Parkinson's disease;
KIRP	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.52	6.62	0.39	2.19e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg13147721	chr7:65941812	NA	-0.99	-6.77	-0.4	9.56e-11	Diabetic kidney disease;
KIRP	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg07451762	chr16:28383216	NA	0.37	4.91	0.3	1.63e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs34779708	0.931	rs4351760	chr10:35280254	A/G	cg03585969	chr10:35415529	CREM	0.84	10.09	0.54	2.9e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2299587	0.610	rs7010747	chr8:17778651	A/C	cg01800426	chr8:17659068	MTUS1	-0.54	-6.48	-0.38	5.08e-10	Economic and political preferences;
KIRP	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14159672	chr1:205819179	PM20D1	0.48	5.43	0.33	1.37e-7	Parkinson's disease;
KIRP	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg17133734	chr15:86042851	AKAP13	-0.47	-5.99	-0.36	7.38e-9	Coronary artery disease;
KIRP	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Parkinson's disease;
KIRP	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-7.45	-0.43	1.62e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-6.95	-0.41	3.3e-11	Morning vs. evening chronotype;
KIRP	trans	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg19894588	chr14:64061835	NA	-0.48	-6.48	-0.38	4.98e-10	Fat distribution (HIV);
KIRP	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.93	12.35	0.62	1.34e-27	Vitamin D levels;
KIRP	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.38	5.58	0.34	6.39e-8	Survival in rectal cancer;
KIRP	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.58	-0.34	6.36e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg15848620	chr12:58087721	OS9	-0.5	-5.86	-0.35	1.52e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.4	-4.99	-0.3	1.12e-6	Aortic root size;
KIRP	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg03563238	chr19:33554763	RHPN2	-0.32	-5.74	-0.34	2.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	trans	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg24644049	chr4:85504048	CDS1	0.99	6.64	0.39	2.03e-10	Skin colour saturation;
KIRP	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.92	14.34	0.67	2.56e-34	Blood protein levels;
KIRP	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-7.29	-0.42	4.12e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4740619	0.619	rs2026661	chr9:16045125	C/G	cg14451791	chr9:16040625	NA	0.38	4.97	0.3	1.26e-6	Body mass index;
KIRP	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg00990874	chr7:1149470	C7orf50	-0.42	-5.28	-0.32	2.87e-7	Longevity;Endometriosis;
KIRP	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg02569458	chr12:86230093	RASSF9	-0.39	-5.69	-0.34	3.67e-8	Major depressive disorder;
KIRP	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.46	5.43	0.33	1.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.58	6.69	0.39	1.47e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs74181299	0.927	rs2723064	chr2:65279805	T/C	cg05010058	chr2:65284262	CEP68	0.48	6.76	0.4	1.01e-10	Pulse pressure;
KIRP	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.66	8.69	0.48	5.05e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg13319975	chr6:146136371	FBXO30	0.46	6.11	0.36	3.89e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2278796	0.639	rs12139426	chr1:204970708	A/G	cg17947172	chr1:204966197	NFASC	-0.62	-8.2	-0.46	1.34e-14	Mean platelet volume;
KIRP	trans	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg26043149	chr18:55253948	FECH	-0.52	-6.11	-0.36	3.96e-9	Bone mineral density;
KIRP	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.59	8.93	0.49	1.02e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.95	0.54	8.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4780401	0.755	rs7194034	chr16:11770777	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.04	-0.31	9.05e-7	Rheumatoid arthritis;
KIRP	cis	rs1656402	0.911	rs2880817	chr2:233453705	G/A	cg03852847	chr2:233439513	NA	-0.7	-11.21	-0.58	7.98e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.32	-5.35	-0.32	2e-7	Height;
KIRP	cis	rs427941	0.609	rs4729776	chr7:101830064	A/G	cg06246474	chr7:101738831	CUX1	0.53	6.4	0.38	7.79e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4704187	0.687	rs11950665	chr5:74423339	A/G	cg03227963	chr5:74354835	NA	0.42	6.11	0.36	3.87e-9	Response to amphetamines;
KIRP	cis	rs12476592	0.571	rs1031221	chr2:63742810	C/T	cg17519650	chr2:63277830	OTX1	0.45	4.99	0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg16586182	chr3:47516702	SCAP	0.72	8.71	0.49	4.64e-16	Colorectal cancer;
KIRP	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.97	-16.86	-0.73	6.59e-43	Breast cancer;
KIRP	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-8.41	-0.47	3.31e-15	Triglycerides;
KIRP	cis	rs1408799	0.521	rs2224863	chr9:12702890	C/A	cg05274944	chr9:12693694	TYRP1	0.44	6.53	0.38	3.74e-10	Eye color;Blue vs. green eyes;
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg16611736	chr16:25123254	LCMT1	-0.45	-6.03	-0.36	5.98e-9	Breast cancer;
KIRP	cis	rs73526541	0.541	rs76940447	chr8:1070632	A/G	cg01049933	chr8:1047734	NA	0.76	5.72	0.34	3.08e-8	Verbal memory performance (immediate recall change);
KIRP	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.82	-0.4	7.1e-11	Alzheimer's disease (late onset);
KIRP	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.76	-9.89	-0.53	1.25e-19	N-glycan levels;
KIRP	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	11.41	0.59	1.74e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg11846333	chr4:119757529	SEC24D	1.12	6.6	0.39	2.44e-10	Cannabis dependence symptom count;
KIRP	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.4	-0.43	2.14e-12	Bipolar disorder;
KIRP	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg08992911	chr2:238395768	MLPH	0.54	5.05	0.31	8.62e-7	Prostate cancer;
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg11204139	chr17:3907470	NA	0.78	11.97	0.61	2.56e-26	Type 2 diabetes;
KIRP	cis	rs73086581	0.945	rs6052222	chr20:3972793	G/A	cg02187196	chr20:3869020	PANK2	0.49	5.11	0.31	6.53e-7	Response to antidepressants in depression;
KIRP	cis	rs9880211	1.000	rs9826454	chr3:135953220	A/G	cg21827317	chr3:136751795	NA	-0.45	-4.93	-0.3	1.54e-6	Body mass index;Height;
KIRP	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.32	1.66e-7	Aortic root size;
KIRP	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg00129232	chr17:37814104	STARD3	0.52	6.56	0.39	3.07e-10	Self-reported allergy;
KIRP	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06850241	chr22:41845214	NA	-0.46	-5.7	-0.34	3.34e-8	Vitiligo;
KIRP	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.76	11.15	0.58	1.24e-23	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.73	6.47	0.38	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-10.52	-0.56	1.29e-21	Ulcerative colitis;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg08901578	chr4:187885870	NA	-0.56	-9.26	-0.51	1.04e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg10047753	chr17:41438598	NA	1.14	17.79	0.75	4.34e-46	Menopause (age at onset);
KIRP	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.83	10.86	0.57	1.03e-22	Menarche (age at onset);
KIRP	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.56	-5.4	-0.33	1.59e-7	Narcolepsy;
KIRP	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg18932078	chr1:2524107	MMEL1	0.41	5.64	0.34	4.57e-8	Ulcerative colitis;
KIRP	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4819052	0.851	rs2256000	chr21:46685909	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.24	0.51	1.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs61542988	0.532	rs12673996	chr7:22833400	C/T	cg11367502	chr7:22862612	TOMM7	0.47	5.43	0.33	1.34e-7	Fibrinogen levels;
KIRP	cis	rs12431939	0.947	rs59298295	chr14:51659047	T/G	cg23942311	chr14:51606299	NA	-0.6	-5.12	-0.31	6.08e-7	Cancer;
KIRP	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg15848620	chr12:58087721	OS9	-0.49	-5.67	-0.34	3.99e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24044651	chr1:24105262	C1orf128	0.58	6.74	0.39	1.15e-10	Smoking initiation;
KIRP	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-7.51	-0.43	1.08e-12	Lung cancer;
KIRP	cis	rs4262150	0.774	rs4958326	chr5:152053477	A/T	cg12297329	chr5:152029980	NA	-0.67	-8.11	-0.46	2.43e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg01874867	chr7:94954059	PON1	0.44	5.21	0.32	4.04e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg13679303	chr9:96623674	NA	-0.51	-7.27	-0.42	4.74e-12	DNA methylation (variation);
KIRP	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.61	7.35	0.42	2.87e-12	Sum neutrophil eosinophil counts;
KIRP	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.45	6.13	0.36	3.44e-9	Sitting height ratio;
KIRP	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.67	9.59	0.52	1.01e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.57	-0.43	7.72e-13	Mood instability;
KIRP	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02972257	chr16:68554789	NA	-0.65	-6.64	-0.39	2.05e-10	Ulcerative colitis;
KIRP	trans	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.98e-12	Bladder cancer;
KIRP	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.12e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-1.11	-15.09	-0.69	7.24e-37	Platelet distribution width;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14576291	chr9:134526136	RAPGEF1	-0.51	-6.26	-0.37	1.72e-9	Inflammatory biomarkers;
KIRP	cis	rs12311304	0.965	rs12320285	chr12:15372062	G/T	cg08258403	chr12:15378311	NA	0.37	5.64	0.34	4.62e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs75920871	0.925	rs56134734	chr11:116833055	G/A	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.77	9.59	0.52	1.02e-18	Response to antipsychotic treatment;
KIRP	cis	rs2625529	0.652	rs2957745	chr15:72288077	T/C	cg16672083	chr15:72433130	SENP8	0.42	6.01	0.36	6.71e-9	Red blood cell count;
KIRP	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg10755058	chr3:40428713	ENTPD3	0.48	6.57	0.39	2.91e-10	Renal cell carcinoma;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05617927	chr15:83654886	FAM103A1	0.6	6.68	0.39	1.58e-10	Lung cancer in ever smokers;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20930514	chr14:77499758	NA	0.72	6.77	0.4	9.54e-11	Lung function (FEV1);
KIRP	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07709080	chr15:69113453	ANP32A	0.54	7.49	0.43	1.23e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8070740	0.898	rs4790770	chr17:5324893	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	7.43	0.43	1.84e-12	Menopause (age at onset);
KIRP	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg17718321	chr1:152188247	HRNR	-0.56	-8.32	-0.47	5.99e-15	Inflammatory skin disease;
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg05025164	chr4:1340916	KIAA1530	0.53	7.0	0.41	2.48e-11	Longevity;
KIRP	trans	rs7939886	0.920	rs7124734	chr11:55960339	C/T	cg03929089	chr4:120376271	NA	0.98	6.7	0.39	1.44e-10	Myopia (pathological);
KIRP	cis	rs981844	0.743	rs17371461	chr4:154759220	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.68	0.44	3.66e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.68	9.94	0.54	8.85e-20	Dupuytren's disease;
KIRP	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg07395648	chr5:131743802	NA	-0.58	-8.08	-0.46	2.89e-14	Breast cancer;Mosquito bite size;
KIRP	cis	rs7221595	0.825	rs12938597	chr17:3961200	C/T	cg09597638	chr17:3907349	NA	0.49	5.02	0.3	1.01e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15819405	chr7:128079085	NA	0.43	6.65	0.39	1.91e-10	Survival in pancreatic cancer;
KIRP	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.91	15.17	0.7	3.76e-37	Metabolic syndrome;
KIRP	cis	rs8018808	0.935	rs8018711	chr14:77921749	G/A	cg20045696	chr14:77926864	AHSA1	0.44	5.3	0.32	2.62e-7	Myeloid white cell count;
KIRP	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.56	-0.33	6.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.55	-0.33	7.54e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2882667	0.858	rs6596460	chr5:138414180	G/A	cg04439458	chr5:138467593	SIL1	-0.49	-7.45	-0.43	1.57e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-6.44	-0.38	6.09e-10	Personality dimensions;
KIRP	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06044117	chr11:95523445	FAM76B;CEP57	0.47	6.72	0.39	1.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6681460	0.932	rs2483705	chr1:67191180	C/G	cg13052034	chr1:66999238	SGIP1	-0.36	-5.2	-0.31	4.29e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2764980	1.000	rs2764980	chr10:3284007	C/T	cg11630169	chr10:3283847	NA	0.48	6.56	0.39	3.07e-10	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg02725872	chr8:58115012	NA	-0.49	-5.39	-0.33	1.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.38	0.32	1.71e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	12.06	0.61	1.29e-26	Multiple sclerosis;
KIRP	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs501120	0.564	rs11238904	chr10:44684707	C/T	cg09554077	chr10:44749378	NA	0.51	6.85	0.4	5.8e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg01721255	chr8:58191610	C8orf71	0.56	5.76	0.34	2.5e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs10875746	0.768	rs10875724	chr12:48420253	C/A	cg26205652	chr12:48591994	NA	0.77	9.92	0.53	9.71e-20	Longevity (90 years and older);
KIRP	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.67	-7.3	-0.42	3.88e-12	Diabetic retinopathy;
KIRP	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	cg12689670	chr1:183009347	LAMC1	0.46	6.65	0.39	1.84e-10	Hypertriglyceridemia;
KIRP	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg23307798	chr14:103986281	CKB	-0.51	-6.74	-0.4	1.09e-10	Coronary artery disease;
KIRP	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg24130564	chr14:104152367	KLC1	-0.44	-5.96	-0.36	8.85e-9	Body mass index;
KIRP	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg25039879	chr17:56429692	SUPT4H1	0.57	5.19	0.31	4.38e-7	Cognitive test performance;
KIRP	cis	rs698833	0.741	rs2340808	chr2:44511861	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.07	0.31	7.7e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs13132184	0.507	rs73241092	chr4:38094897	G/A	cg14409701	chr4:38048871	TBC1D1	-0.73	-6.78	-0.4	8.82e-11	Verbal declarative memory;
KIRP	cis	rs9473924	0.586	rs9296646	chr6:50844617	C/G	cg03432817	chr6:50765336	NA	0.35	5.45	0.33	1.2e-7	Body mass index;
KIRP	cis	rs1256061	0.624	rs7229	chr14:64692825	G/A	cg21174375	chr14:64681225	SYNE2	0.51	5.67	0.34	4.07e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs12973672	0.812	rs2073899	chr19:35752917	C/T	cg12095397	chr19:35769544	USF2	0.65	6.03	0.36	6.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg06521331	chr12:34319734	NA	-0.51	-6.26	-0.37	1.72e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs735539	0.521	rs2585896	chr13:21398861	A/G	cg04906043	chr13:21280425	IL17D	-0.44	-5.18	-0.31	4.53e-7	Dental caries;
KIRP	trans	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg06521331	chr12:34319734	NA	-0.53	-6.47	-0.38	5.4e-10	Bladder cancer;
KIRP	cis	rs4237845	0.591	rs3751326	chr12:58335330	C/G	cg00677455	chr12:58241039	CTDSP2	0.69	7.81	0.45	1.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11924390	0.789	rs822366	chr3:186452490	A/G	cg12454167	chr3:186435060	KNG1	0.5	8.51	0.48	1.77e-15	Adiponectin levels;
KIRP	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg08890418	chr1:21044141	KIF17	0.35	5.18	0.31	4.51e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.29	0.37	1.45e-9	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs4783244	0.794	rs10514547	chr16:82645822	A/G	cg09415485	chr16:82663111	CDH13	-0.26	-4.86	-0.3	2.14e-6	Adiponectin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07876271	chr5:5422799	KIAA0947	0.45	6.39	0.38	8.27e-10	Survival in pancreatic cancer;
KIRP	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs6142102	0.961	rs2235597	chr20:32665614	G/T	cg08999081	chr20:33150536	PIGU	0.53	6.29	0.37	1.48e-9	Skin pigmentation;
KIRP	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg22676075	chr6:135203613	NA	0.49	7.14	0.41	1.08e-11	Red blood cell count;
KIRP	cis	rs1440410	0.930	rs4618266	chr4:144036127	C/T	cg01719995	chr4:144104893	USP38	0.47	6.3	0.37	1.34e-9	Ischemic stroke;
KIRP	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg13319975	chr6:146136371	FBXO30	-0.45	-5.35	-0.32	1.98e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.79	11.55	0.59	6.21e-25	Heart rate;
KIRP	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.68	-0.39	1.57e-10	Metabolite levels;
KIRP	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.85	-0.53	1.68e-19	Height;
KIRP	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.05	-0.58	2.53e-23	Height;
KIRP	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg08648136	chr8:956695	NA	0.45	7.01	0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.85	16.14	0.72	1.83e-40	Anterior chamber depth;
KIRP	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg17507749	chr15:85114479	UBE2QP1	0.89	9.93	0.53	9.33e-20	Schizophrenia;
KIRP	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.47	5.72	0.34	3.07e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg19500275	chr17:80737654	TBCD	0.44	5.3	0.32	2.61e-7	Glycated hemoglobin levels;
KIRP	cis	rs6969780	1.000	rs6973182	chr7:27172321	C/T	cg19142026	chr7:27170394	HOXA4	0.43	5.06	0.31	8.36e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	trans	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.69	0.44	3.56e-13	Breast cancer;
KIRP	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.29	7.75	0.44	2.39e-13	Crohn's disease;
KIRP	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg05342945	chr12:48394962	COL2A1	-0.46	-5.04	-0.31	9e-7	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16716883	chr10:74079772	NA	0.52	6.41	0.38	7.36e-10	Smoking initiation;
KIRP	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.9	-0.71	1.23e-39	Chronic sinus infection;
KIRP	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg19468946	chr17:37922297	IKZF3	-0.49	-6.81	-0.4	7.36e-11	Self-reported allergy;
KIRP	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.58	-7.79	-0.44	1.88e-13	Diastolic blood pressure;
KIRP	cis	rs1961637	0.960	rs4674737	chr2:223911857	T/A	cg02552189	chr2:223891284	NA	-0.36	-4.94	-0.3	1.47e-6	Oropharynx cancer;
KIRP	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	5.9	0.35	1.21e-8	Lung cancer;
KIRP	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.46	6.72	0.39	1.24e-10	Urate levels in lean individuals;
KIRP	cis	rs6589219	0.908	rs10789822	chr11:111162691	A/G	cg25129781	chr11:111156908	C11orf53	-0.5	-6.57	-0.39	2.93e-10	Colorectal cancer;
KIRP	trans	rs12043259	1.000	rs6665712	chr1:204826884	C/A	cg11485465	chr5:54518469	NA	0.41	6.46	0.38	5.59e-10	Addiction;
KIRP	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg00405596	chr8:11794950	NA	-0.45	-6.16	-0.37	3.01e-9	Monocyte count;
KIRP	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg16898833	chr6:26189333	HIST1H4D	0.79	5.68	0.34	3.87e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.6	7.62	0.44	5.61e-13	Diastolic blood pressure;
KIRP	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg08890418	chr1:21044141	KIF17	0.36	5.38	0.32	1.77e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.69	-10.42	-0.55	2.67e-21	Educational attainment;
KIRP	cis	rs1712790	0.665	rs11215189	chr11:114631834	T/C	cg19465033	chr11:114479364	NA	0.39	5.17	0.31	4.89e-7	Urinary albumin excretion;
KIRP	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.17	12.83	0.63	3.51e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg20255370	chr15:40268687	EIF2AK4	-0.53	-6.27	-0.37	1.63e-9	Corneal curvature;
KIRP	trans	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg25288420	chr1:78511713	GIPC2	0.61	8.16	0.46	1.73e-14	Obesity-related traits;
KIRP	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg10547527	chr2:198650123	BOLL	-0.55	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs61884328	0.852	rs61896126	chr11:47099167	T/G	cg23433285	chr11:47201945	PACSIN3	0.78	6.3	0.37	1.34e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	6.01e-16	Bladder cancer;
KIRP	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	11.26	0.58	5.49e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg07701084	chr6:150067640	NUP43	0.63	8.17	0.46	1.62e-14	Lung cancer;
KIRP	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg25447019	chr17:19030144	GRAPL	0.57	7.83	0.45	1.41e-13	Schizophrenia;
KIRP	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg07001201	chr5:642380	CEP72	0.7	6.47	0.38	5.25e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg18404041	chr3:52824283	ITIH1	0.42	5.21	0.32	4.07e-7	Schizophrenia;
KIRP	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.16	-0.5	2.09e-17	Colorectal cancer;
KIRP	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg22117172	chr7:91764530	CYP51A1	0.43	5.74	0.34	2.73e-8	Breast cancer;
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg01798813	chr17:3906674	NA	-0.5	-6.89	-0.4	4.54e-11	Type 2 diabetes;
KIRP	cis	rs4478137	0.501	rs6828820	chr4:164230540	C/T	cg06758707	chr4:164254230	NPY1R	-0.5	-5.85	-0.35	1.53e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.7	-9.39	-0.51	4.2e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7301016	0.846	rs73124315	chr12:62970437	C/T	cg01804193	chr12:63026212	NA	0.53	5.9	0.35	1.23e-8	IgG glycosylation;
KIRP	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-6.85	-0.4	5.99e-11	Mood instability;
KIRP	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg02569458	chr12:86230093	RASSF9	0.54	7.92	0.45	8e-14	Major depressive disorder;
KIRP	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.87	-7.85	-0.45	1.24e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21747090	chr2:27597821	SNX17	-0.49	-6.77	-0.4	9.54e-11	Total body bone mineral density;
KIRP	cis	rs2865126	0.818	rs8087370	chr18:10764174	C/T	cg21165219	chr18:10698044	FAM38B	-0.51	-4.94	-0.3	1.44e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
KIRP	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.43	0.38	6.5e-10	Morning vs. evening chronotype;
KIRP	cis	rs12049351	0.719	rs10916493	chr1:229634397	G/T	cg11742688	chr1:229674241	ABCB10	-0.37	-5.52	-0.33	8.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs812925	0.537	rs10865324	chr2:61621307	G/A	cg15711740	chr2:61764176	XPO1	0.48	6.23	0.37	1.99e-9	Immature fraction of reticulocytes;
KIRP	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg07148914	chr20:33460835	GGT7	-0.54	-7.15	-0.41	9.81e-12	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01218756	chr4:48695242	FRYL	-0.41	-6.2	-0.37	2.32e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg05564831	chr3:52568323	NT5DC2	0.37	5.84	0.35	1.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.69	0.53	4.95e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg12591125	chr7:1885375	MAD1L1	0.56	5.36	0.32	1.91e-7	Bipolar disorder;
KIRP	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg02725872	chr8:58115012	NA	-0.36	-4.91	-0.3	1.68e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg24375607	chr4:120327624	NA	0.58	6.57	0.39	3.03e-10	Corneal astigmatism;
KIRP	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.73	9.4	0.51	3.9e-18	Coronary artery disease;
KIRP	cis	rs4936894	0.500	rs4935872	chr11:124075995	A/G	cg27160556	chr11:124181099	OR8D1	-0.39	-5.72	-0.34	3.1e-8	Aging (time to death);
KIRP	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.62	8.38	0.47	4.22e-15	Coronary artery disease;
KIRP	cis	rs62413470	0.872	rs12201531	chr6:55933519	C/T	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	trans	rs12043259	1.000	rs4951141	chr1:204825270	T/G	cg11485465	chr5:54518469	NA	0.4	6.37	0.38	9.29e-10	Addiction;
KIRP	cis	rs6088813	0.961	rs981818	chr20:33924130	C/A	cg14752227	chr20:34000481	UQCC	0.47	6.02	0.36	6.19e-9	Height;
KIRP	cis	rs77861329	1.000	rs9811707	chr3:52190657	G/A	cg08692210	chr3:52188851	WDR51A	0.95	7.63	0.44	5.21e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2278796	0.639	rs6661381	chr1:204971553	A/G	cg17947172	chr1:204966197	NFASC	0.65	8.54	0.48	1.39e-15	Mean platelet volume;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15539395	chr19:59086703	MGC2752	0.71	6.57	0.39	2.98e-10	Lung function (FEV1);
KIRP	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.94	-10.92	-0.57	7.03e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.76	-10.54	-0.56	1.11e-21	Morning vs. evening chronotype;
KIRP	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.78	-11.04	-0.58	2.78e-23	Blood metabolite levels;
KIRP	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg16586182	chr3:47516702	SCAP	-0.67	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs3736485	0.966	rs8040080	chr15:51904459	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.16e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12714314	0.560	rs1864881	chr2:1940723	G/A	cg20846728	chr2:1843184	MYT1L	-0.38	-6.36	-0.38	9.71e-10	Type 2 diabetes (age of onset);
KIRP	cis	rs13190036	1.000	rs34446750	chr5:176595080	A/G	cg04708888	chr5:176739561	MXD3	0.63	4.91	0.3	1.64e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.67	-7.44	-0.43	1.67e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg23422044	chr7:1970798	MAD1L1	-0.68	-6.36	-0.38	9.9e-10	Neuroticism;
KIRP	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg07701084	chr6:150067640	NUP43	0.58	7.5	0.43	1.14e-12	Lung cancer;
KIRP	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.16	-0.37	2.97e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6558530	0.579	rs6558528	chr8:1703063	C/T	cg08198773	chr8:1697536	NA	0.49	5.98	0.36	7.65e-9	Systolic blood pressure;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg10150615	chr22:24372951	LOC391322	0.52	6.29	0.37	1.41e-9	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg17724175	chr1:150552817	MCL1	0.29	4.96	0.3	1.32e-6	Melanoma;
KIRP	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12379764	chr21:47803548	PCNT	-0.45	-5.43	-0.33	1.35e-7	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg04369109	chr6:150039330	LATS1	-0.52	-6.61	-0.39	2.35e-10	Lung cancer;
KIRP	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg24631222	chr15:78858424	CHRNA5	0.44	5.72	0.34	3.13e-8	Sudden cardiac arrest;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08368094	chr4:74286665	ALB	0.4	6.27	0.37	1.57e-9	C-reactive protein;
KIRP	cis	rs5766691	0.901	rs5766687	chr22:47528634	A/G	cg15757745	chr22:47558489	TBC1D22A	-0.42	-5.08	-0.31	7.52e-7	Longevity;
KIRP	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	7.9	0.45	9.22e-14	Body mass index;
KIRP	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	5.22	0.32	3.86e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs885389	1.000	rs885389	chr12:131621762	C/T	cg07124762	chr12:131619285	GPR133	0.38	4.94	0.3	1.45e-6	RR interval (heart rate);
KIRP	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.88e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.18	-0.31	4.53e-7	Parkinson's disease;
KIRP	cis	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs6693295	0.605	rs6692457	chr1:246216326	A/C	cg11798871	chr1:246315928	SMYD3	-0.42	-5.26	-0.32	3.17e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.87	-10.84	-0.57	1.23e-22	Eosinophil percentage of white cells;
KIRP	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.59	-0.39	2.67e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7624766	0.555	rs59542611	chr3:160541470	G/A	cg22637730	chr3:160473554	PPM1L	0.4	4.96	0.3	1.31e-6	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.78	0.4	9.11e-11	Menarche (age at onset);
KIRP	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.91	-0.4	4.03e-11	Neuroticism;
KIRP	trans	rs17267292	0.960	rs10507992	chr13:93319713	C/T	cg13177052	chr17:7319319	NLGN2	-0.64	-6.08	-0.36	4.46e-9	Metabolite levels;
KIRP	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	cg12689670	chr1:183009347	LAMC1	0.44	6.32	0.37	1.25e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4936894	0.500	rs10893207	chr11:124178236	C/T	cg27160556	chr11:124181099	OR8D1	-0.47	-6.77	-0.4	9.54e-11	Aging (time to death);
KIRP	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	8.21	0.46	1.24e-14	Red cell distribution width;
KIRP	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg23594656	chr7:65796392	TPST1	-0.42	-5.93	-0.35	1.01e-8	Aortic root size;
KIRP	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg10792982	chr14:105748885	BRF1	0.91	14.31	0.67	3.26e-34	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.22	17.01	0.74	1.96e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.28	-0.42	4.55e-12	Bladder cancer;
KIRP	cis	rs2119480	0.559	rs381835	chr13:111300957	A/T	cg16216153	chr13:111290848	CARKD	-0.37	-4.87	-0.3	2e-6	Diastolic blood pressure;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	trans	rs6601327	0.601	rs11249939	chr8:9556500	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.97	-0.41	2.94e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg06204229	chr3:52865917	ITIH4	0.58	7.26	0.42	5.08e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.53	5.17	0.31	4.93e-7	Alzheimer's disease;
KIRP	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	14.29	0.67	3.89e-34	Alzheimer's disease;
KIRP	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg24296786	chr1:45957014	TESK2	0.43	5.39	0.32	1.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg05347473	chr6:146136440	FBXO30	0.6	8.5	0.48	1.81e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6684514	0.961	rs10908497	chr1:156274740	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-6.0	-0.36	6.84e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.82	-0.4	6.94e-11	Height;
KIRP	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg12591125	chr7:1885375	MAD1L1	0.64	6.12	0.36	3.61e-9	Bipolar disorder;
KIRP	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.66	-8.0	-0.45	4.96e-14	Coronary artery disease;
KIRP	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg12560992	chr17:57184187	TRIM37	0.6	6.46	0.38	5.66e-10	Testicular germ cell tumor;
KIRP	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg22705602	chr4:152727874	NA	-0.55	-9.5	-0.52	2.03e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1468333	0.897	rs2269957	chr5:137501396	A/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.56	0.33	7.15e-8	Resting heart rate;
KIRP	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.61	-7.43	-0.43	1.83e-12	Glomerular filtration rate;
KIRP	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.85	8.67	0.48	6.04e-16	Methadone dose in opioid dependence;
KIRP	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg21775007	chr8:11205619	TDH	0.46	6.28	0.37	1.53e-9	Mood instability;
KIRP	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg10130564	chr11:117069849	TAGLN	0.42	4.94	0.3	1.48e-6	Blood protein levels;
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.88	-15.13	-0.69	5.22e-37	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs17092148	0.945	rs6142237	chr20:33340993	C/T	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.53	-0.33	8.12e-8	Neuroticism;
KIRP	cis	rs2230307	0.536	rs834278	chr1:100510882	T/C	cg24955406	chr1:100503596	HIAT1	0.69	7.93	0.45	7.78e-14	Carotid intima media thickness;
KIRP	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.2	-0.8	1.87e-57	Ulcerative colitis;
KIRP	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.99	13.17	0.64	2.39e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg10189774	chr4:17578691	LAP3	0.51	5.87	0.35	1.38e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg14458575	chr2:238380390	NA	0.72	7.48	0.43	1.35e-12	Prostate cancer;
KIRP	cis	rs193541	0.632	rs34714850	chr5:122332695	A/G	cg19412675	chr5:122181750	SNX24	-0.6	-6.45	-0.38	6.03e-10	Glucose homeostasis traits;
KIRP	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg26531700	chr6:26746687	NA	0.41	5.63	0.34	4.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.643	rs2236903	chr1:209883480	A/T	cg23920097	chr1:209922102	NA	-0.42	-5.66	-0.34	4.31e-8	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13331940	chr15:59663987	MYO1E	0.47	6.38	0.38	8.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.07e-10	Height;
KIRP	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.19e-9	Body mass index;
KIRP	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg25019033	chr10:957182	NA	0.38	5.19	0.31	4.47e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs10924970	0.967	rs6677573	chr1:235377979	T/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg10818794	chr15:86012489	AKAP13	-0.52	-7.33	-0.42	3.38e-12	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.9	0.35	1.2e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23209098	chr14:100149367	CYP46A1	0.47	6.78	0.4	9.07e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg05721485	chr17:44071124	MAPT	-0.55	-7.56	-0.43	8.12e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4262150	0.764	rs72795376	chr5:151930769	T/C	cg12297329	chr5:152029980	NA	-0.66	-8.0	-0.45	4.94e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg10169327	chr19:45448959	APOC2	0.32	4.91	0.3	1.67e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	14.56	0.68	4.64e-35	Platelet count;
KIRP	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg23974023	chr2:113544294	IL1A	-0.36	-5.2	-0.31	4.21e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs12476592	0.602	rs2121353	chr2:63899330	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.94	-0.3	1.41e-6	Childhood ear infection;
KIRP	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg14078157	chr9:128172775	NA	-0.62	-7.13	-0.41	1.12e-11	Mean arterial pressure;
KIRP	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg15038512	chr6:170123185	PHF10	0.46	5.02	0.3	9.95e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg24699146	chr1:24152579	HMGCL	0.44	5.67	0.34	3.94e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.79	-9.17	-0.5	1.96e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.62	8.55	0.48	1.31e-15	Menarche (age at onset);
KIRP	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.49	6.24	0.37	1.85e-9	Schizophrenia;
KIRP	cis	rs4936894	0.500	rs10893205	chr11:124172565	A/G	cg27160556	chr11:124181099	OR8D1	0.46	6.61	0.39	2.4e-10	Aging (time to death);
KIRP	cis	rs3733418	0.860	rs2056252	chr4:165947490	A/G	cg10852876	chr4:165953100	TRIM60	0.49	5.33	0.32	2.22e-7	Obesity-related traits;
KIRP	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.59e-8	Aortic root size;
KIRP	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg05768032	chr16:30646687	NA	0.44	5.09	0.31	6.99e-7	Multiple myeloma;
KIRP	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.8	-10.28	-0.55	7.55e-21	Menopause (age at onset);
KIRP	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	7.81	0.45	1.67e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg17724175	chr1:150552817	MCL1	0.38	6.19	0.37	2.53e-9	Melanoma;
KIRP	cis	rs7481311	0.956	rs6484308	chr11:27521802	T/G	cg18117895	chr11:27722066	BDNF	0.5	5.37	0.32	1.81e-7	Body mass index;Weight;
KIRP	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.91	12.32	0.62	1.68e-27	Cognitive function;
KIRP	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.35	-5.49	-0.33	9.75e-8	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13989455	chr1:12628244	DHRS3	0.46	6.05	0.36	5.4e-9	Survival in pancreatic cancer;
KIRP	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg12483005	chr1:23474871	LUZP1	-0.37	-4.89	-0.3	1.83e-6	Height;
KIRP	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	trans	rs2302464	1.000	rs10011868	chr4:15660828	T/A	cg03228132	chr7:129781429	NA	-0.72	-7.06	-0.41	1.69e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-7.85	-0.45	1.32e-13	Coronary artery disease;
KIRP	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg17554472	chr22:41940697	POLR3H	0.47	5.29	0.32	2.73e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4903604	0.513	rs12880891	chr14:78035233	T/C	cg18872420	chr14:78023429	SPTLC2	0.36	5.62	0.34	5.2e-8	Gut microbiome composition (winter);
KIRP	cis	rs2072732	0.656	rs113272167	chr1:2954051	C/T	cg11731671	chr1:2995604	PRDM16	-0.44	-5.63	-0.34	4.87e-8	Plateletcrit;
KIRP	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.37e-14	Aortic root size;
KIRP	cis	rs4262150	0.846	rs72802861	chr5:152230416	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.08e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg02030672	chr11:45687055	CHST1	0.63	8.08	0.46	2.89e-14	Obesity-related traits;
KIRP	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg12384639	chr17:618140	VPS53	0.47	5.97	0.36	8.17e-9	Prostate cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09747230	chr5:43613142	NNT	0.49	6.72	0.39	1.22e-10	Survival in pancreatic cancer;
KIRP	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg10556349	chr10:835070	NA	-0.39	-4.85	-0.3	2.24e-6	Survival in rectal cancer;
KIRP	cis	rs494562	0.892	rs522129	chr6:86116381	A/G	cg27039625	chr6:86159096	NT5E	0.42	5.34	0.32	2.07e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.34	6.11	0.36	3.89e-9	Renal cell carcinoma;
KIRP	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg24304309	chr1:154577895	ADAR	0.37	5.55	0.33	7.45e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg12453748	chr11:64085041	PRDX5;TRMT112	-0.48	-5.0	-0.3	1.1e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04436714	chr1:90309218	LRRC8D	0.52	6.57	0.39	3.01e-10	Lung cancer in ever smokers;
KIRP	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.49	-0.59	9.46e-25	Total body bone mineral density;
KIRP	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg26441486	chr22:50317300	CRELD2	0.56	8.68	0.48	5.45e-16	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.2e-8	Lung cancer;
KIRP	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.66	9.09	0.5	3.47e-17	Obesity-related traits;
KIRP	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg20368463	chr18:77673604	PQLC1	0.67	5.43	0.33	1.38e-7	Opioid sensitivity;
KIRP	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06544989	chr22:39130855	UNC84B	-0.45	-7.84	-0.45	1.34e-13	Menopause (age at onset);
KIRP	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg02725872	chr8:58115012	NA	-0.58	-5.05	-0.31	8.57e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2223471	0.602	rs9349552	chr6:50705048	T/A	cg03432817	chr6:50765336	NA	-0.35	-5.19	-0.31	4.31e-7	Subcutaneous adipose tissue;
KIRP	cis	rs7719624	0.756	rs6880837	chr5:135396669	A/G	cg00308130	chr5:135415190	NA	0.31	5.06	0.31	8.03e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg18016565	chr1:150552671	MCL1	-0.34	-5.13	-0.31	6.01e-7	Tonsillectomy;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19482537	chr5:156692823	CYFIP2	-0.41	-6.16	-0.37	2.96e-9	Metabolic traits;
KIRP	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs1497828	0.912	rs2810764	chr1:217573645	T/C	cg04411442	chr1:217543379	NA	0.43	6.44	0.38	6.18e-10	Dialysis-related mortality;
KIRP	cis	rs13161895	1.000	rs3797763	chr5:179439516	C/T	cg02702477	chr5:179499311	RNF130	-0.69	-5.36	-0.32	1.95e-7	LDL cholesterol;
KIRP	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.9	13.34	0.65	6.68e-31	Neuroticism;
KIRP	cis	rs300890	0.513	rs72719160	chr4:144051276	A/T	cg01719995	chr4:144104893	USP38	-0.43	-5.59	-0.34	6.14e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-5.51	-0.33	9.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg16898833	chr6:26189333	HIST1H4D	0.67	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg16917193	chr12:54089295	NA	0.86	16.52	0.73	9.67e-42	Height;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg09699651	chr6:150184138	LRP11	0.45	6.04	0.36	5.8e-9	Lung cancer;
KIRP	trans	rs7999699	0.967	rs11148085	chr13:48326615	T/C	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.43	6.12	0.36	3.76e-9	Mean corpuscular volume;
KIRP	cis	rs13177180	0.671	rs746566	chr5:114922047	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.28	-4.98	-0.3	1.21e-6	Conotruncal heart defects (inherited effects);
KIRP	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.64	9.2	0.51	1.57e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg13264159	chr8:625131	ERICH1	0.92	6.13	0.36	3.49e-9	IgG glycosylation;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg10729496	chr3:10149963	C3orf24	0.55	5.01	0.3	1.04e-6	Alzheimer's disease;
KIRP	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.45	5.7	0.34	3.4e-8	White matter hyperintensity burden;
KIRP	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.69	-12.51	-0.62	4.11e-28	White blood cell count (basophil);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06734429	chr19:39926689	RPS16	0.54	6.9	0.4	4.34e-11	Parkinson's disease;
KIRP	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.35	-10.28	-0.55	7.71e-21	Diabetic kidney disease;
KIRP	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27556566	chr18:29671984	RNF138	0.61	7.12	0.41	1.17e-11	Smoking initiation;
KIRP	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.76	11.13	0.58	1.41e-23	Gut microbiome composition (winter);
KIRP	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg17764715	chr19:33622953	WDR88	0.66	8.29	0.47	7.25e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.46	6.42	0.38	6.87e-10	Testicular germ cell tumor;
KIRP	cis	rs3784262	0.669	rs4646564	chr15:58351797	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.87	-0.3	2.04e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.62	8.72	0.49	4.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-5.83	-0.35	1.76e-8	Cutaneous nevi;
KIRP	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg07541023	chr7:19748670	TWISTNB	-0.54	-5.32	-0.32	2.36e-7	Thyroid stimulating hormone;
KIRP	cis	rs11255291	1.000	rs7080828	chr10:7733770	G/A	cg26051552	chr10:7670683	ITIH5	0.41	5.26	0.32	3.17e-7	Ovarian reserve;
KIRP	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg23216685	chr1:86174607	ZNHIT6	-0.54	-6.91	-0.4	4.1e-11	Urate levels in overweight individuals;
KIRP	cis	rs238295	0.766	rs6038204	chr20:5549071	T/A	cg24001556	chr20:5591874	RP5-1022P6.2	-0.5	-5.08	-0.31	7.56e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-6.32	-0.37	1.24e-9	Educational attainment;
KIRP	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.24	11.64	0.6	3.02e-25	Diabetic retinopathy;
KIRP	cis	rs9921338	0.961	rs56136462	chr16:11415595	A/G	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.87	-11.4	-0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg18440316	chr19:18077727	KCNN1	0.4	5.7	0.34	3.4e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.96	-12.69	-0.63	1e-28	Platelet distribution width;
KIRP	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.51	7.36	0.43	2.67e-12	Schizophrenia;
KIRP	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	0.96	12.26	0.62	2.71e-27	Blood protein levels;
KIRP	trans	rs933360	0.585	rs10258458	chr7:50825947	C/A	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs6732160	0.741	rs6546806	chr2:73386160	T/C	cg01422370	chr2:73384389	NA	0.42	5.61	0.34	5.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-1.07	-20.05	-0.79	1.18e-53	Height;
KIRP	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg16434002	chr17:42200994	HDAC5	0.52	6.43	0.38	6.69e-10	Total body bone mineral density;
KIRP	cis	rs5744897	0.655	rs35131280	chr12:133275974	A/G	cg09320662	chr12:133180698	NA	0.44	4.95	0.3	1.36e-6	Urate levels in overweight individuals;
KIRP	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg07274523	chr3:49395745	GPX1	0.72	8.76	0.49	3.15e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg08662619	chr6:150070041	PCMT1	0.37	5.96	0.36	8.6e-9	Lung cancer;
KIRP	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg26811252	chr16:29126840	RRN3P2	0.66	8.95	0.5	8.85e-17	Menopause (age at onset);
KIRP	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.88	10.45	0.55	2.19e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.65	-8.31	-0.47	6.44e-15	Glomerular filtration rate;
KIRP	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.58	-6.06	-0.36	5.02e-9	Ulcerative colitis;
KIRP	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.4	-8.27	-0.47	8.33e-15	Urinary metabolites;
KIRP	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.72	8.96	0.5	8.09e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.62	-8.11	-0.46	2.38e-14	Inhibitory control;
KIRP	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.52	-5.34	-0.32	2.14e-7	Subjective well-being;
KIRP	cis	rs7267005	0.661	rs58121874	chr20:34431660	C/T	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.44	-0.33	1.31e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg01879757	chr17:41196368	BRCA1	-0.78	-10.64	-0.56	5.55e-22	Menopause (age at onset);
KIRP	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.48	-6.99	-0.41	2.52e-11	Schizophrenia;
KIRP	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg06392426	chr19:10676186	KRI1	0.41	5.24	0.32	3.51e-7	Red cell distribution width;
KIRP	cis	rs9473924	0.505	rs28360639	chr6:50783501	G/A	cg14470998	chr6:50812995	TFAP2B	1.0	8.9	0.49	1.22e-16	Body mass index;
KIRP	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.39	-0.51	4.37e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00074818	chr8:8560427	CLDN23	0.4	7.35	0.42	2.84e-12	Obesity-related traits;
KIRP	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.46	-0.52	2.67e-18	Coronary artery disease;
KIRP	cis	rs7172677	0.732	rs55655136	chr15:75285114	G/A	cg14664628	chr15:75095509	CSK	0.62	6.54	0.38	3.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg09597638	chr17:3907349	NA	0.74	14.05	0.67	2.62e-33	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg13072238	chr3:49761600	GMPPB	-0.59	-5.64	-0.34	4.58e-8	Menarche (age at onset);
KIRP	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.49	0.48	1.96e-15	Motion sickness;
KIRP	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.61	-9.6	-0.52	9.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg09754948	chr16:28834200	ATXN2L	0.43	5.1	0.31	6.75e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2997447	0.846	rs3008226	chr1:26394997	A/C	cg19633962	chr1:26362018	EXTL1	-0.58	-5.41	-0.33	1.49e-7	QRS complex (12-leadsum);
KIRP	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-6.9	-0.4	4.34e-11	Mood instability;
KIRP	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg00982548	chr2:198649783	BOLL	-0.55	-5.47	-0.33	1.1e-7	Ulcerative colitis;
KIRP	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.89	0.3	1.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.52	8.65	0.48	6.59e-16	Rheumatoid arthritis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13722821	chr5:892710	TRIP13;BRD9	-0.59	-6.53	-0.38	3.82e-10	Menopause (age at onset);
KIRP	cis	rs4750440	0.702	rs11258774	chr10:14029701	G/A	cg27542038	chr10:14027202	FRMD4A	-0.48	-6.7	-0.39	1.41e-10	Adiponectin levels;
KIRP	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.58	11.96	0.61	2.68e-26	Diabetic kidney disease;
KIRP	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	cg04338863	chr8:33670619	NA	0.44	5.58	0.34	6.29e-8	Body mass index;
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg23594656	chr7:65796392	TPST1	0.35	5.03	0.31	9.67e-7	Aortic root size;
KIRP	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg18306943	chr3:40428807	ENTPD3	-0.42	-5.76	-0.34	2.47e-8	Renal cell carcinoma;
KIRP	cis	rs228437	0.586	rs12663941	chr6:134916963	A/G	cg24504307	chr6:134963096	NA	-0.29	-4.92	-0.3	1.58e-6	Melanoma;
KIRP	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.93	0.53	9.33e-20	Schizophrenia;
KIRP	cis	rs13102973	0.965	rs13129208	chr4:135858263	A/G	cg14419869	chr4:135874104	NA	0.53	8.8	0.49	2.5e-16	Subjective well-being;
KIRP	cis	rs4774830	0.661	rs62045239	chr15:56294642	G/A	cg24530489	chr15:56299380	NA	-0.82	-5.62	-0.34	5.19e-8	Delta-5 desaturase activity;
KIRP	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.64	7.77	0.44	2.14e-13	Coronary artery disease;
KIRP	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.58	5.01	0.3	1.05e-6	Fat distribution (HIV);
KIRP	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg21401794	chr1:90099060	LRRC8C	-0.7	-9.95	-0.54	8.24e-20	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg22283653	chr8:49824208	NA	0.48	6.64	0.39	1.94e-10	Sudden cardiac arrest;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg22515201	chr22:38577827	PLA2G6	-0.47	-5.11	-0.31	6.54e-7	Menopause (age at onset);
KIRP	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.7	10.27	0.55	8.14e-21	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.76	13.81	0.66	1.69e-32	Anterior chamber depth;
KIRP	cis	rs4356932	1.000	rs4302486	chr4:76953077	C/T	cg00809888	chr4:76862425	NAAA	-0.45	-6.39	-0.38	8.42e-10	Blood protein levels;
KIRP	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	1.1	17.98	0.75	1.01e-46	Cognitive function;
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-0.95	-11.41	-0.59	1.72e-24	Vitiligo;
KIRP	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.44	6.36	0.38	9.95e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg06627628	chr2:24431161	ITSN2	-0.52	-4.93	-0.3	1.49e-6	Lymphocyte counts;
KIRP	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26617929	chr16:1858877	NA	-0.62	-5.5	-0.33	9.66e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs17023223	0.537	rs2765532	chr1:119591546	T/C	cg05756136	chr1:119680316	WARS2	-0.56	-7.64	-0.44	4.86e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.71e-7	Life satisfaction;
KIRP	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg00204512	chr16:28754710	NA	0.45	6.0	0.36	6.85e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg14650228	chr8:144573510	ZC3H3	-0.7	-4.91	-0.3	1.69e-6	Attention deficit hyperactivity disorder;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04424940	chr17:42264171	TMUB2;C17orf65	-0.55	-6.02	-0.36	6.38e-9	Menopause (age at onset);
KIRP	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg22138327	chr13:27999177	GTF3A	0.75	6.78	0.4	9.05e-11	Weight;
KIRP	cis	rs6732160	0.845	rs11894833	chr2:73388418	G/T	cg01422370	chr2:73384389	NA	-0.44	-5.96	-0.36	8.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg09695851	chr17:3907499	NA	0.89	17.43	0.74	7.6e-45	Type 2 diabetes;
KIRP	trans	rs301901	0.796	rs4869520	chr5:37509083	G/A	cg00076645	chr5:171711562	UBTD2	0.47	6.18	0.37	2.57e-9	Height;
KIRP	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs7560272	0.723	rs6744697	chr2:73765438	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.5	-0.33	9.61e-8	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.54	-5.27	-0.32	2.93e-7	Initial pursuit acceleration;
KIRP	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg17863274	chr19:49399704	TULP2	-0.41	-5.81	-0.35	1.88e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7011507	1.000	rs4518697	chr8:49149908	G/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.65	-7.53	-0.43	9.54e-13	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg10505658	chr17:80084571	CCDC57	0.27	5.17	0.31	4.76e-7	Life satisfaction;
KIRP	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.72	-10.07	-0.54	3.47e-20	Sudden cardiac arrest;
KIRP	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.62	-0.34	5.11e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs1692580	0.807	rs12138597	chr1:2189477	T/C	cg21194808	chr1:2205498	SKI	0.35	5.16	0.31	4.99e-7	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.93	6.55	0.39	3.38e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.3	-0.55	6.24e-21	Hemoglobin concentration;
KIRP	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg05714579	chr10:131428358	MGMT	0.41	5.1	0.31	6.9e-7	Response to temozolomide;
KIRP	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg21775007	chr8:11205619	TDH	-0.5	-6.42	-0.38	6.97e-10	Systolic blood pressure;
KIRP	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg23752985	chr2:85803571	VAMP8	0.56	8.29	0.47	7.51e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7523273	0.925	rs10863593	chr1:208018074	C/T	cg22525895	chr1:207977042	MIR29B2	0.6	7.07	0.41	1.6e-11	Schizophrenia;
KIRP	trans	rs7246760	1.000	rs73507215	chr19:9887312	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.06	-0.54	3.62e-20	Pursuit maintenance gain;
KIRP	trans	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg06521331	chr12:34319734	NA	-0.49	-6.24	-0.37	1.88e-9	Bladder cancer;
KIRP	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg03929089	chr4:120376271	NA	0.68	6.64	0.39	2.05e-10	Axial length;
KIRP	cis	rs2441986	0.894	rs61902801	chr11:57920597	C/A	cg19752551	chr11:57585705	CTNND1	-0.44	-5.26	-0.32	3.07e-7	Systolic blood pressure;
KIRP	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.64	8.11	0.46	2.43e-14	Schizophrenia;
KIRP	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18252515	chr7:66147081	NA	0.46	5.41	0.33	1.48e-7	Aortic root size;
KIRP	cis	rs68170813	0.617	rs12535761	chr7:107139275	A/C	cg02696742	chr7:106810147	HBP1	-0.75	-6.88	-0.4	4.87e-11	Coronary artery disease;
KIRP	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.5	5.08	0.31	7.63e-7	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18505495	chr10:104179494	FBXL15;PSD	0.48	6.19	0.37	2.56e-9	Parkinson's disease;
KIRP	cis	rs7215564	0.908	rs8070102	chr17:78683982	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.39e-7	Myopia (pathological);
KIRP	cis	rs7624766	0.508	rs9833075	chr3:160527846	T/G	cg22637730	chr3:160473554	PPM1L	0.44	5.46	0.33	1.19e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.47	6.7	0.39	1.44e-10	Coronary artery disease;
KIRP	cis	rs2274273	0.553	rs56166765	chr14:55738018	T/C	cg04306507	chr14:55594613	LGALS3	0.4	5.55	0.33	7.27e-8	Protein biomarker;
KIRP	cis	rs7714584	1.000	rs17111376	chr5:150226899	T/C	cg22134413	chr5:150180641	NA	0.58	5.21	0.32	3.98e-7	Crohn's disease;
KIRP	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.43	-6.0	-0.36	7.14e-9	Bone mineral density (spine);
KIRP	cis	rs9381107	0.932	rs10484246	chr6:9451197	T/A	cg14735645	chr6:9486422	NA	-0.44	-5.3	-0.32	2.57e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs11923600	0.592	rs12489622	chr3:175972919	C/T	cg00728300	chr16:87903283	SLC7A5	0.48	6.06	0.36	5.21e-9	Height;
KIRP	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6738028	0.524	rs7565457	chr2:111935478	C/T	cg03171003	chr2:111875934	NA	0.36	4.9	0.3	1.76e-6	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-9.04	-0.5	4.65e-17	Total cholesterol levels;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg14893161	chr1:205819251	PM20D1	0.44	5.14	0.31	5.53e-7	White blood cell types;
KIRP	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg23594656	chr7:65796392	TPST1	0.39	5.9	0.35	1.2e-8	Aortic root size;
KIRP	cis	rs526231	0.547	rs72783895	chr5:102287496	C/A	cg23492399	chr5:102201601	PAM	-0.6	-6.65	-0.39	1.83e-10	Primary biliary cholangitis;
KIRP	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs6690583	0.623	rs12042845	chr1:85429801	A/G	cg22153463	chr1:85462885	MCOLN2	0.59	4.92	0.3	1.6e-6	Serum sulfate level;
KIRP	cis	rs8077577	0.895	rs62072500	chr17:18126918	A/C	cg18869244	chr17:18121946	NA	0.49	5.53	0.33	8.28e-8	Obesity-related traits;
KIRP	cis	rs3818717	0.538	rs4925108	chr17:17649423	C/T	cg01246520	chr17:17644344	RAI1	-0.36	-5.83	-0.35	1.77e-8	Lymphocyte counts;
KIRP	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.78	-7.82	-0.45	1.56e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg27432699	chr2:27873401	GPN1	0.52	6.51	0.38	4.21e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg26670450	chr1:169862883	SCYL3	0.52	6.18	0.37	2.71e-9	DNA methylation (variation);
KIRP	cis	rs6540559	0.611	rs926347	chr1:209965193	T/C	cg22029157	chr1:209979665	IRF6	0.52	5.75	0.34	2.7e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.52	6.41	0.38	7.51e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9303542	0.625	rs62065846	chr17:46592858	G/A	cg04904318	chr17:46607828	HOXB1	-0.49	-5.6	-0.34	5.59e-8	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.32	-0.42	3.43e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.42	0.33	1.41e-7	Putamen volume;
KIRP	cis	rs5747327	0.874	rs713701	chr22:18131546	A/G	cg19898043	chr22:18121309	BCL2L13	-0.4	-4.85	-0.3	2.24e-6	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7714584	1.000	rs59715748	chr5:150189287	G/A	cg22134413	chr5:150180641	NA	1.05	7.58	0.44	6.99e-13	Crohn's disease;
KIRP	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg23301140	chr18:77439876	CTDP1	0.44	5.06	0.31	8.14e-7	Monocyte count;
KIRP	cis	rs13095912	1.000	rs10937226	chr3:185302885	G/A	cg11274856	chr3:185301563	NA	0.54	6.9	0.4	4.31e-11	Systolic blood pressure;
KIRP	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6028335	0.674	rs974561	chr20:37591184	G/C	cg16355469	chr20:37678765	NA	0.56	5.55	0.33	7.42e-8	Alcohol and nicotine co-dependence;
KIRP	cis	rs17023223	0.537	rs7532510	chr1:119594236	A/G	cg18261050	chr1:119551319	NA	0.55	7.34	0.42	3.08e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17879804	chr3:44752500	NA	0.44	6.52	0.38	3.9e-10	Cancer;
KIRP	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	1.13	7.52	0.43	1.02e-12	Type 2 diabetes nephropathy;
KIRP	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg24296786	chr1:45957014	TESK2	0.4	5.05	0.31	8.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg22705602	chr4:152727874	NA	-0.55	-9.44	-0.52	3.06e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.7	-0.34	3.48e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg18357526	chr6:26021779	HIST1H4A	0.39	5.11	0.31	6.38e-7	Height;
KIRP	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.42	0.33	1.41e-7	Breast cancer;
KIRP	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05601917	chr6:125855416	NA	-0.34	-5.21	-0.31	4.09e-7	Brugada syndrome;
KIRP	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.28	-0.37	1.55e-9	Monocyte percentage of white cells;
KIRP	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.98	-0.3	1.22e-6	Inflammatory bowel disease;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	0.97	16.81	0.73	9.85e-43	Menarche (age at onset);
KIRP	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg00310523	chr12:86230176	RASSF9	0.4	6.19	0.37	2.46e-9	Major depressive disorder;
KIRP	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-1.22	-12.87	-0.63	2.42e-29	Alzheimer's disease;
KIRP	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs367943	0.666	rs6594705	chr5:112692851	T/G	cg12552261	chr5:112820674	MCC	0.52	6.12	0.36	3.63e-9	Type 2 diabetes;
KIRP	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg21064579	chr19:49206444	FUT2	0.56	8.42	0.47	3.14e-15	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.86	0.49	1.61e-16	Electroencephalogram traits;
KIRP	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.05	0.36	5.39e-9	Depressive symptoms;
KIRP	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg21926883	chr2:100939477	LONRF2	0.56	7.53	0.43	9.34e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg24253500	chr15:84953950	NA	0.48	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs11955398	0.585	rs12655977	chr5:60034475	A/G	cg02684056	chr5:59996105	DEPDC1B	0.41	5.15	0.31	5.46e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg08132940	chr7:1081526	C7orf50	-0.7	-7.03	-0.41	1.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg03808351	chr9:123631620	PHF19	0.43	5.98	0.36	7.62e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs4132509	1.000	rs10927076	chr1:243958293	A/G	cg25706552	chr1:244017396	NA	0.6	6.98	0.41	2.68e-11	RR interval (heart rate);
KIRP	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.66	-8.54	-0.48	1.38e-15	Brain structure;
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02475777	chr4:1388615	CRIPAK	0.4	5.42	0.33	1.43e-7	Longevity;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.72	11.2	0.58	8.25e-24	Menarche (age at onset);
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg02804510	chr19:49199965	FUT2	0.35	5.12	0.31	6.24e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.6	0.44	6.12e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	4.95e-11	Aortic root size;
KIRP	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.01	0.3	1.06e-6	Educational attainment;
KIRP	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg03152288	chr2:177042942	NA	-0.5	-5.99	-0.36	7.38e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.86	-9.9	-0.53	1.17e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11987759	chr7:65425863	GUSB	-0.46	-5.42	-0.33	1.43e-7	Aortic root size;
KIRP	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.78	-0.35	2.21e-8	Neuroticism;
KIRP	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.91	0.4	4.19e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	1.26	12.91	0.64	1.8e-29	Diabetic retinopathy;
KIRP	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.73	-9.51	-0.52	1.77e-18	Mosquito bite size;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.17	0.42	8.93e-12	Lymphocyte counts;
KIRP	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg06212747	chr3:49208901	KLHDC8B	0.83	9.34	0.51	5.87e-18	Menarche (age at onset);
KIRP	cis	rs4363385	0.747	rs4240867	chr1:152954921	A/G	cg13444842	chr1:152974279	SPRR3	0.38	5.5	0.33	9.43e-8	Inflammatory skin disease;
KIRP	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg04226714	chr8:49833948	SNAI2	-0.51	-6.84	-0.4	6.2e-11	Life satisfaction;
KIRP	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.04	0.41	1.86e-11	Bipolar disorder;
KIRP	cis	rs11877825	0.826	rs6505573	chr18:10579542	G/A	cg07277756	chr18:10589357	NA	0.49	5.97	0.36	8.11e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.49e-13	IgG glycosylation;
KIRP	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.49	-5.75	-0.34	2.65e-8	Monocyte count;
KIRP	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.32	-0.42	3.47e-12	Bipolar disorder;
KIRP	cis	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.28	-0.37	1.53e-9	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18076651	chr12:53625605	RARG	-0.37	-6.06	-0.36	5.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	1.04	18.44	0.76	2.77e-48	Leprosy;
KIRP	cis	rs10468482	0.528	rs4792590	chr17:8117115	A/G	cg06726167	chr17:8076949	TMEM107	0.61	5.63	0.34	4.81e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs12190007	0.934	rs10945427	chr6:169743864	T/C	cg15038512	chr6:170123185	PHF10	-0.38	-5.46	-0.33	1.17e-7	Obesity-related traits;
KIRP	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg06671706	chr8:8559999	CLDN23	0.48	5.74	0.34	2.78e-8	Obesity-related traits;
KIRP	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs1829883	1.000	rs2461989	chr5:98793999	T/A	cg08333243	chr5:99726346	NA	-0.37	-5.08	-0.31	7.5e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg25338242	chr13:114786047	RASA3	0.41	4.94	0.3	1.42e-6	Schizophrenia;
KIRP	cis	rs77688320	0.509	rs2714487	chr2:202249560	C/T	cg06431681	chr2:202330990	STRADB	-0.48	-5.65	-0.34	4.4e-8	Breast cancer;
KIRP	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	7.22	0.42	6.57e-12	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg06562184	chr8:19319451	CSGALNACT1	0.35	4.89	0.3	1.86e-6	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.54	5.96	0.36	8.57e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-8.06	-0.46	3.32e-14	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-6.63	-0.39	2.09e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	1.0	14.74	0.68	1.15e-35	Cognitive function;
KIRP	cis	rs742134	1.000	rs760699	chr22:43523188	T/C	cg26453588	chr22:43506021	BIK	0.4	5.4	0.33	1.54e-7	Prostate cancer;
KIRP	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg23743428	chr13:21893420	NA	-0.34	-4.96	-0.3	1.3e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07169764	chr2:136633963	MCM6	-0.55	-6.46	-0.38	5.55e-10	Mosquito bite size;
KIRP	cis	rs14403	1.000	rs67027895	chr1:243667216	C/T	cg21452805	chr1:244014465	NA	0.52	5.31	0.32	2.51e-7	Schizophrenia;
KIRP	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	15.05	0.69	1e-36	Chronic sinus infection;
KIRP	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg10645314	chr2:3704589	ALLC	-0.49	-6.22	-0.37	2.17e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.41	5.11	0.31	6.38e-7	High light scatter reticulocyte count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11545072	chr4:128548799	NA	-0.42	-6.5	-0.38	4.38e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg24375607	chr4:120327624	NA	0.49	5.8	0.35	2.07e-8	Corneal astigmatism;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg07219710	chr6:74230925	EEF1A1	0.52	6.36	0.38	9.84e-10	Educational attainment;
KIRP	trans	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg25288420	chr1:78511713	GIPC2	0.54	7.34	0.42	3.02e-12	Obesity-related traits;
KIRP	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.52	-7.61	-0.44	5.66e-13	Daytime sleep phenotypes;
KIRP	cis	rs6593803	0.921	rs4469765	chr1:147207012	A/C	cg27546670	chr1:147246839	GJA5	0.59	7.01	0.41	2.23e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs10073892	0.830	rs13356480	chr5:101603504	T/A	cg19774478	chr5:101632501	SLCO4C1	0.65	6.3	0.37	1.33e-9	Cognitive decline (age-related);
KIRP	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg05315796	chr3:52349193	DNAH1	0.46	7.0	0.41	2.41e-11	Bipolar disorder;
KIRP	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.95	14.97	0.69	1.92e-36	Metabolite levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14513222	chr9:140079404	ANAPC2	0.49	6.16	0.37	3e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg23978390	chr7:1156363	C7orf50	0.49	4.95	0.3	1.36e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg05669848	chr5:237993	SDHA	-0.48	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.53	-7.73	-0.44	2.72e-13	HDL cholesterol levels;
KIRP	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg21361702	chr7:150065534	REPIN1	0.54	5.86	0.35	1.46e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.26	-5.48	-0.33	1.05e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs7582180	1.000	rs4851286	chr2:100915629	T/C	cg14675211	chr2:100938903	LONRF2	0.5	6.04	0.36	5.76e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1035491	0.574	rs10461497	chr5:63942398	A/G	cg01791865	chr5:63954708	NA	0.38	6.4	0.38	7.66e-10	Body mass index;
KIRP	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.4	-5.64	-0.34	4.75e-8	Height;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.58	7.67	0.44	4.06e-13	Renal function-related traits (BUN);
KIRP	trans	rs291748	0.793	rs296661	chr9:93710325	C/T	cg11854981	chr6:42219847	TRERF1	0.69	6.34	0.37	1.09e-9	Anti-saccade response;
KIRP	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.5	-6.52	-0.38	3.92e-10	Blood metabolite levels;
KIRP	cis	rs73200209	0.912	rs59560959	chr12:116476998	C/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.71	-0.34	3.17e-8	Total body bone mineral density;
KIRP	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.75	-10.87	-0.57	9.82e-23	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.97	13.12	0.64	3.54e-30	Menopause (age at onset);
KIRP	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.2	-0.51	1.59e-17	Brugada syndrome;
KIRP	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg01843034	chr6:37503916	NA	-0.96	-15.55	-0.7	1.97e-38	Cognitive performance;
KIRP	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.95	16.16	0.72	1.55e-40	Monocyte count;
KIRP	trans	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg10756647	chr7:56101905	PSPH	0.93	7.09	0.41	1.43e-11	Diabetic kidney disease;
KIRP	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.65	-7.66	-0.44	4.35e-13	Mean platelet volume;
KIRP	cis	rs35995292	0.927	rs2190666	chr7:38919395	C/T	cg19327137	chr7:38886074	VPS41	0.48	5.65	0.34	4.48e-8	Subjective well-being (multi-trait analysis);
KIRP	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-9.39	-0.51	4.19e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7553864	0.966	rs11161936	chr1:87614507	G/C	cg17420885	chr1:87600446	LOC339524	-0.49	-6.63	-0.39	2.11e-10	Smoking behavior;
KIRP	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.37	0.59	2.42e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs2019216	0.500	rs12938673	chr17:21941987	C/G	cg22648282	chr17:21454238	C17orf51	-0.47	-5.03	-0.31	9.42e-7	Pelvic organ prolapse;
KIRP	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.88	0.35	1.3e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg25358565	chr5:93447407	FAM172A	0.6	6.93	0.4	3.59e-11	Diabetic retinopathy;
KIRP	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.68	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs953387	1.000	rs4954568	chr2:136910690	T/A	cg05194412	chr2:137003533	NA	-0.42	-5.52	-0.33	8.6e-8	Arthritis (juvenile idiopathic);
KIRP	trans	rs2746347	0.915	rs4912407	chr1:57113001	A/G	cg21149967	chr12:58224502	CTDSP2	-0.65	-6.01	-0.36	6.49e-9	Lymphocyte counts;
KIRP	cis	rs17193922	0.876	rs55813797	chr16:53551310	A/G	cg09728985	chr16:53543985	NA	-0.48	-5.54	-0.33	7.8e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs938554	0.577	rs4591605	chr4:10002719	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	4.87	0.3	2.01e-6	Blood metabolite levels;
KIRP	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.4	-0.33	1.54e-7	Personality dimensions;
KIRP	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg17145862	chr1:211918768	LPGAT1	0.76	10.56	0.56	9.48e-22	Leprosy;
KIRP	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02725872	chr8:58115012	NA	-0.73	-7.64	-0.44	4.73e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.51	-6.29	-0.37	1.48e-9	Longevity;Endometriosis;
KIRP	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12187069	chr19:41082589	SHKBP1	-0.45	-6.14	-0.36	3.23e-9	Metabolic traits;
KIRP	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.91	10.99	0.57	4.07e-23	Post bronchodilator FEV1;
KIRP	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.41	5.09	0.31	7.02e-7	Aortic root size;
KIRP	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg18753928	chr3:113234510	CCDC52	0.49	5.12	0.31	6.31e-7	Dental caries;
KIRP	cis	rs7714584	1.000	rs2004711	chr5:150225068	C/T	cg22134413	chr5:150180641	NA	0.56	5.03	0.31	9.56e-7	Crohn's disease;
KIRP	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18252515	chr7:66147081	NA	-0.48	-5.59	-0.34	6.17e-8	Aortic root size;
KIRP	cis	rs16976116	1.000	rs16976116	chr15:55480467	T/C	cg11288833	chr15:55489084	RSL24D1	0.64	7.0	0.41	2.48e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17221829	0.699	rs7129641	chr11:89383706	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-4.9	-0.3	1.71e-6	Anxiety in major depressive disorder;
KIRP	cis	rs4740619	0.711	rs10756731	chr9:15975600	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.9	-0.3	1.72e-6	Body mass index;
KIRP	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.74	11.18	0.58	9.91e-24	Lewy body disease;
KIRP	cis	rs4671458	0.739	rs72806056	chr2:63837680	T/C	cg17519650	chr2:63277830	OTX1	-0.52	-5.36	-0.32	1.89e-7	Subjective well-being;
KIRP	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	cis	rs3818717	0.538	rs752579	chr17:17660347	C/T	cg02336718	chr17:17403227	NA	-0.33	-5.11	-0.31	6.46e-7	Lymphocyte counts;
KIRP	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.75	-8.36	-0.47	4.72e-15	Parkinson's disease;
KIRP	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.47e-13	Bipolar disorder;
KIRP	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg02751453	chr18:77725136	HSBP1L1	0.42	5.58	0.33	6.45e-8	Opioid sensitivity;
KIRP	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs662064	0.852	rs2483677	chr1:10580891	C/T	cg19773385	chr1:10388646	KIF1B	-0.43	-5.66	-0.34	4.12e-8	Asthma;
KIRP	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.63	-8.51	-0.48	1.74e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.83	-12.33	-0.62	1.58e-27	Colorectal cancer;
KIRP	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	8.95	0.5	8.75e-17	Response to antipsychotic treatment;
KIRP	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.94	-13.68	-0.66	4.61e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.56	-7.19	-0.42	7.77e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg10189774	chr4:17578691	LAP3	0.44	5.28	0.32	2.9e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17193922	0.798	rs7203644	chr16:53547209	C/T	cg09728985	chr16:53543985	NA	-0.49	-5.62	-0.34	5.09e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.8	9.52	0.52	1.7e-18	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.14	-21.75	-0.81	3.16e-59	Prudent dietary pattern;
KIRP	trans	rs4775041	1.000	rs4775041	chr15:58674695	C/G	cg21369679	chr16:47007757	DNAJA2	-0.57	-6.53	-0.38	3.71e-10	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.42	-5.17	-0.31	4.75e-7	Diabetic retinopathy;
KIRP	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-6.84	-0.4	6.08e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg27170947	chr2:26402098	FAM59B	0.65	6.93	0.4	3.61e-11	Gut microbiome composition (summer);
KIRP	cis	rs2273156	1.000	rs12161905	chr14:35422293	T/C	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.69	-0.34	3.54e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.45	-5.42	-0.33	1.4e-7	Acne (severe);
KIRP	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg26207909	chr14:103986467	CKB	-0.43	-5.24	-0.32	3.51e-7	Coronary artery disease;
KIRP	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-7.15	-0.41	1e-11	Morning vs. evening chronotype;
KIRP	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.53	-7.58	-0.44	6.94e-13	Breast cancer;
KIRP	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	0.84	6.23	0.37	2e-9	IgG glycosylation;
KIRP	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg01629716	chr15:45996671	NA	0.37	6.7	0.39	1.44e-10	Waist circumference;Weight;
KIRP	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.57	-7.97	-0.45	5.94e-14	Gut microbiome composition (summer);
KIRP	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg16989719	chr2:238392110	NA	-0.54	-7.27	-0.42	4.66e-12	Prostate cancer;
KIRP	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.65	6.14	0.36	3.34e-9	Breast cancer;
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.53	-7.65	-0.44	4.62e-13	Electroencephalogram traits;
KIRP	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg17888390	chr10:101282816	NA	0.28	4.92	0.3	1.59e-6	Dental caries;
KIRP	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.72	-9.06	-0.5	4.16e-17	Mood instability;
KIRP	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16414030	chr3:133502952	NA	-0.48	-5.5	-0.33	9.55e-8	Iron status biomarkers;
KIRP	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg24110177	chr3:50126178	RBM5	-0.42	-5.5	-0.33	9.29e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg05673287	chr15:77411982	SGK269	-0.39	-5.0	-0.3	1.08e-6	Type 2 diabetes;
KIRP	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.84	0.35	1.67e-8	Coronary artery disease;
KIRP	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg04519387	chr11:65556438	OVOL1	0.35	5.41	0.33	1.52e-7	Acne (severe);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03982568	chr5:143551489	KCTD16;YIPF5	-0.39	-6.02	-0.36	6.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg08017634	chr8:144659831	NAPRT1	0.84	5.45	0.33	1.2e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.19	-0.31	4.35e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.81	-11.96	-0.61	2.66e-26	Dental caries;
KIRP	cis	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg00405596	chr8:11794950	NA	0.55	7.79	0.44	1.91e-13	Monocyte count;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg26149184	chr10:133730230	NA	0.41	4.86	0.3	2.09e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.74	10.24	0.55	9.97e-21	Diastolic blood pressure;
KIRP	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs73198271	0.603	rs777705	chr8:8586868	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.35	-0.32	2.03e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg14972814	chr11:95582409	MTMR2	0.34	5.26	0.32	3.07e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg06815112	chr8:27182871	PTK2B	0.53	6.89	0.4	4.58e-11	Neuroticism;
KIRP	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg13319975	chr6:146136371	FBXO30	-0.38	-4.98	-0.3	1.18e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.66	-8.18	-0.46	1.48e-14	IgG glycosylation;
KIRP	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.27	14.24	0.67	5.85e-34	Uric acid levels;
KIRP	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.49	-0.33	9.99e-8	Colorectal cancer;
KIRP	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.91	-0.35	1.12e-8	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg15117754	chr3:10150083	C3orf24	0.54	5.15	0.31	5.25e-7	Alzheimer's disease;
KIRP	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.54	-0.43	9.12e-13	Response to antipsychotic treatment;
KIRP	cis	rs11955398	0.678	rs12522801	chr5:59978406	A/G	cg02684056	chr5:59996105	DEPDC1B	0.42	5.09	0.31	7.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg17457637	chr7:27170717	HOXA4	-0.31	-4.86	-0.3	2.09e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.39	-4.92	-0.3	1.58e-6	Platelet count;
KIRP	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg15507776	chr3:136538369	TMEM22	0.39	5.39	0.33	1.65e-7	Neuroticism;
KIRP	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg18932078	chr1:2524107	MMEL1	0.41	5.64	0.34	4.57e-8	Ulcerative colitis;
KIRP	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.6	-6.82	-0.4	7.09e-11	Hypertension (SNP x SNP interaction);
KIRP	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22509189	chr2:225307070	NA	-0.44	-5.09	-0.31	6.96e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs66696671	0.559	rs7919868	chr10:121356382	C/T	cg06765389	chr10:121379685	NA	-0.39	-5.32	-0.32	2.34e-7	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.17	-0.46	1.63e-14	Neuroticism;
KIRP	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg25447019	chr17:19030144	GRAPL	0.6	8.44	0.47	2.69e-15	Schizophrenia;
KIRP	cis	rs9309473	0.500	rs7608328	chr2:73914019	G/A	cg20560298	chr2:73613845	ALMS1	0.47	5.64	0.34	4.58e-8	Metabolite levels;
KIRP	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	6.8	0.4	7.76e-11	Menarche (age at onset);
KIRP	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.4	-5.6	-0.34	5.75e-8	Endometrial cancer;
KIRP	cis	rs7615316	0.934	rs13093869	chr3:142319213	G/C	cg20824294	chr3:142316082	PLS1	0.22	4.96	0.3	1.29e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.97	-14.47	-0.68	9.84e-35	Height;
KIRP	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.51	7.4	0.43	2.14e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.63	-7.21	-0.42	6.86e-12	Body mass index;
KIRP	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09351035	chr11:748060	TALDO1	0.58	7.01	0.41	2.31e-11	Smoking initiation;
KIRP	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg04025307	chr7:1156635	C7orf50	0.64	6.86	0.4	5.57e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.53	-6.54	-0.38	3.53e-10	Corneal curvature;
KIRP	cis	rs2274273	0.901	rs68046603	chr14:55762803	T/A	cg04306507	chr14:55594613	LGALS3	0.41	6.02	0.36	6.24e-9	Protein biomarker;
KIRP	cis	rs3784262	0.692	rs1822205	chr15:58284657	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.89	-0.3	1.84e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.59	10.27	0.55	8.01e-21	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.99	-12.89	-0.64	2.09e-29	Ulcerative colitis;
KIRP	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.83	-9.09	-0.5	3.43e-17	Educational attainment;
KIRP	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg23565292	chr14:50234668	KLHDC2	-0.43	-5.22	-0.32	3.83e-7	Carotid intima media thickness;
KIRP	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg24304309	chr1:154577895	ADAR	0.38	6.13	0.36	3.4e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.62	-7.37	-0.43	2.63e-12	Initial pursuit acceleration;
KIRP	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg03735888	chr19:58951602	ZNF132	0.46	5.49	0.33	1.02e-7	Uric acid clearance;
KIRP	cis	rs7127900	0.950	rs11603101	chr11:2232814	C/T	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.8	-0.4	7.8e-11	Lung cancer;
KIRP	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.61	7.73	0.44	2.76e-13	Resting heart rate;
KIRP	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg09555818	chr19:45449301	APOC2	0.52	7.61	0.44	5.85e-13	Blood protein levels;
KIRP	cis	rs4132509	0.793	rs6694738	chr1:243715210	C/A	cg25706552	chr1:244017396	NA	0.58	6.11	0.36	3.94e-9	RR interval (heart rate);
KIRP	cis	rs4474465	1.000	rs4945282	chr11:78188795	G/A	cg02023728	chr11:77925099	USP35	0.3	5.25	0.32	3.3e-7	Alzheimer's disease (survival time);
KIRP	cis	rs77861329	1.000	rs9816434	chr3:52197513	C/T	cg08692210	chr3:52188851	WDR51A	0.95	7.34	0.42	3.15e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.92	12.51	0.62	4.12e-28	Menopause (age at onset);
KIRP	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6546324	0.559	rs4671806	chr2:67777158	C/G	cg15745817	chr2:67799979	NA	-0.63	-6.49	-0.38	4.78e-10	Endometriosis;
KIRP	cis	rs4974559	0.501	rs2101094	chr4:1235643	A/G	cg02980000	chr4:1222292	CTBP1	-0.96	-9.86	-0.53	1.52e-19	Systolic blood pressure;
KIRP	cis	rs6580649	0.941	rs17122613	chr12:48460016	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg16482183	chr6:26056742	HIST1H1C	0.59	6.76	0.4	1.01e-10	Iron status biomarkers;
KIRP	trans	rs1864585	0.520	rs9650659	chr8:10667765	G/T	cg26278703	chr11:58910052	FAM111A	0.64	6.58	0.39	2.83e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6783573	0.895	rs1049667	chr3:46623690	C/A	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.37	-5.84	-0.35	1.67e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.57	-7.31	-0.42	3.79e-12	Bipolar disorder;
KIRP	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.48	-0.59	1.02e-24	Caffeine consumption;
KIRP	cis	rs6832769	1.000	rs35767091	chr4:56346723	G/A	cg05960024	chr4:56376020	CLOCK	0.73	9.49	0.52	2.04e-18	Personality dimensions;
KIRP	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.43	-5.16	-0.31	4.99e-7	IgG glycosylation;
KIRP	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.64	0.34	4.58e-8	Breast cancer;
KIRP	cis	rs1030268	0.715	rs13235840	chr7:133505091	A/T	cg10665199	chr7:133106180	EXOC4	0.51	4.85	0.3	2.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3789045	0.615	rs11240748	chr1:204453320	C/T	cg18185008	chr1:204589407	LRRN2	-0.44	-5.11	-0.31	6.61e-7	Educational attainment (college completion);
KIRP	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.63	-6.89	-0.4	4.64e-11	Corneal structure;
KIRP	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.48	-0.43	1.31e-12	Breast cancer;
KIRP	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg04025307	chr7:1156635	C7orf50	0.53	7.42	0.43	1.93e-12	Longevity;Endometriosis;
KIRP	cis	rs372883	0.967	rs2832292	chr21:30738760	C/A	cg24692254	chr21:30365293	RNF160	0.41	5.17	0.31	4.8e-7	Pancreatic cancer;
KIRP	cis	rs1018836	0.828	rs7008172	chr8:91551613	C/T	cg16814680	chr8:91681699	NA	-0.53	-6.1	-0.36	4e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.85	-0.35	1.58e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7395581	0.918	rs3816725	chr11:47305669	T/G	cg26139080	chr11:47293733	MADD	-0.43	-5.45	-0.33	1.22e-7	HDL cholesterol;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.61	-5.68	-0.34	3.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.06	0.31	8.32e-7	Tonsillectomy;
KIRP	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.79	10.49	0.56	1.67e-21	Menopause (age at onset);
KIRP	cis	rs73200209	0.744	rs17427101	chr12:116722210	T/C	cg01776926	chr12:116560359	MED13L	-0.53	-5.84	-0.35	1.65e-8	Total body bone mineral density;
KIRP	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.14	0.64	3.03e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.76	-11.62	-0.6	3.64e-25	Prostate cancer;
KIRP	cis	rs240764	0.717	rs6916468	chr6:101160325	G/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.17	-0.31	4.77e-7	Neuroticism;
KIRP	cis	rs988913	1.000	rs9349740	chr6:54825708	A/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.7	-0.34	3.41e-8	Menarche (age at onset);
KIRP	cis	rs2665103	0.589	rs3858953	chr15:82530390	A/G	cg00614314	chr15:82944287	LOC80154	0.39	5.05	0.31	8.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7221595	0.825	rs62072388	chr17:3899567	C/A	cg21851534	chr17:3907994	ZZEF1	0.56	5.57	0.33	6.62e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04381380	chr17:18266459	SHMT1	0.53	6.7	0.39	1.42e-10	Parkinson's disease;
KIRP	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-4.98	-0.3	1.18e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs17767294	0.541	rs72845044	chr6:27572479	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-5.85	-0.35	1.57e-8	Parkinson's disease;
KIRP	cis	rs6859018	0.950	rs3212217	chr5:158755130	C/G	cg26646896	chr5:158686746	NA	-0.33	-4.86	-0.3	2.13e-6	Serum sulfate level;
KIRP	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7116495	1.000	rs10128658	chr11:71733519	C/T	cg26138937	chr11:71823887	C11orf51	-0.7	-5.65	-0.34	4.46e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg05315796	chr3:52349193	DNAH1	0.53	8.29	0.47	7.51e-15	Bipolar disorder;
KIRP	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg11833968	chr6:79620685	NA	-0.47	-7.11	-0.41	1.26e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.73	6.41	0.38	7.35e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05472934	chr7:22766657	IL6	0.78	10.27	0.55	8.26e-21	Lung cancer;
KIRP	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.47	6.44	0.38	6.18e-10	Age-related hearing impairment;
KIRP	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg22676075	chr6:135203613	NA	0.53	7.81	0.45	1.66e-13	Red blood cell count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09289335	chr20:42144161	L3MBTL	0.43	6.02	0.36	6.45e-9	Survival in pancreatic cancer;
KIRP	cis	rs4704187	0.663	rs28448485	chr5:74425775	G/A	cg03227963	chr5:74354835	NA	0.4	5.95	0.35	9.27e-9	Response to amphetamines;
KIRP	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg26248373	chr2:1572462	NA	-0.82	-11.0	-0.57	3.86e-23	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg21605333	chr4:119757512	SEC24D	1.48	10.22	0.55	1.18e-20	Cannabis dependence symptom count;
KIRP	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10861342	1.000	rs12316054	chr12:105569143	T/C	cg23923672	chr12:105501055	KIAA1033	0.8	6.09	0.36	4.33e-9	IgG glycosylation;
KIRP	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.84	14.05	0.67	2.49e-33	Longevity;
KIRP	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg05418105	chr22:50981406	NA	-0.58	-7.25	-0.42	5.25e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.73	9.36	0.51	5.41e-18	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05043032	chr1:95583073	TMEM56	-0.52	-6.12	-0.36	3.75e-9	Interleukin-4 levels;
KIRP	cis	rs8028182	0.636	rs11634863	chr15:75766672	C/A	cg20655648	chr15:75932815	IMP3	0.51	6.53	0.38	3.67e-10	Sudden cardiac arrest;
KIRP	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg27471124	chr11:109292789	C11orf87	0.48	5.57	0.33	6.75e-8	Schizophrenia;
KIRP	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.48	-0.43	1.33e-12	Morning vs. evening chronotype;
KIRP	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.41	4.9	0.3	1.78e-6	Refractive astigmatism;
KIRP	cis	rs7714584	1.000	rs4958424	chr5:150225036	C/T	cg22134413	chr5:150180641	NA	0.57	5.08	0.31	7.4e-7	Crohn's disease;
KIRP	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.2	-0.31	4.21e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-4.89	-0.3	1.84e-6	Fear of minor pain;
KIRP	cis	rs12190007	0.810	rs12216263	chr6:169767163	G/A	cg15038512	chr6:170123185	PHF10	-0.42	-5.87	-0.35	1.44e-8	Obesity-related traits;
KIRP	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.54	-6.64	-0.39	2.04e-10	Total body bone mineral density;
KIRP	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.6	-6.75	-0.4	1.08e-10	Testicular germ cell tumor;Testicular germ cell cancer;
KIRP	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg17376030	chr22:41985996	PMM1	0.59	6.3	0.37	1.35e-9	Vitiligo;
KIRP	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.84	-12.0	-0.61	2.06e-26	Coronary artery disease;
KIRP	cis	rs9890032	0.532	rs1808257	chr17:29039966	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.47	-6.02	-0.36	6.2e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.77	-10.89	-0.57	8.41e-23	Asthma;
KIRP	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26207909	chr14:103986467	CKB	0.56	7.51	0.43	1.06e-12	Body mass index;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.97	-14.1	-0.67	1.79e-33	Longevity;Endometriosis;
KIRP	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg16434002	chr17:42200994	HDAC5	-0.52	-6.47	-0.38	5.12e-10	Total body bone mineral density;
KIRP	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.59	7.98	0.45	5.46e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3026101	0.624	rs60691290	chr17:5318503	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.58	-6.69	-0.39	1.53e-10	Menarche (age at onset);
KIRP	cis	rs4262150	0.726	rs6876723	chr5:151929344	C/T	cg12297329	chr5:152029980	NA	-0.59	-7.44	-0.43	1.65e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	1.08	17.18	0.74	5.22e-44	Cognitive function;
KIRP	cis	rs7224685	0.515	rs7207986	chr17:3979949	G/A	cg09597638	chr17:3907349	NA	0.57	5.81	0.35	1.97e-8	Type 2 diabetes;
KIRP	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.56	7.69	0.44	3.58e-13	Colorectal cancer;
KIRP	cis	rs4751006	0.543	rs78526511	chr10:128769686	C/T	cg05702161	chr10:128779687	DOCK1	-1.17	-9.14	-0.5	2.38e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg10326726	chr10:51549505	MSMB	-0.59	-8.42	-0.47	3.2e-15	Prostate-specific antigen levels;
KIRP	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg14061069	chr19:46274453	DMPK	-0.6	-9.51	-0.52	1.82e-18	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.05	0.41	1.82e-11	Aortic root size;
KIRP	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg12131826	chr15:77904385	NA	0.41	5.38	0.32	1.75e-7	Type 2 diabetes;
KIRP	cis	rs661054	0.956	rs513152	chr11:114441123	T/C	cg19465033	chr11:114479364	NA	0.4	5.55	0.33	7.24e-8	Ulcerative colitis;
KIRP	cis	rs35740288	0.545	rs12916187	chr15:86326124	A/C	cg20737812	chr15:86336631	KLHL25	-0.51	-6.05	-0.36	5.37e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg00507259	chr4:95128692	SMARCAD1	0.41	5.24	0.32	3.37e-7	QT interval;
KIRP	cis	rs6594713	0.717	rs10065790	chr5:112911165	C/T	cg12552261	chr5:112820674	MCC	0.54	5.3	0.32	2.63e-7	Brain cytoarchitecture;
KIRP	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.74	9.23	0.51	1.27e-17	Resting heart rate;
KIRP	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.92	9.92	0.53	1.02e-19	Type 2 diabetes nephropathy;
KIRP	trans	rs9914544	0.628	rs9908821	chr17:18679404	A/G	cg04702396	chr17:15466718	FAM18B2	0.68	9.96	0.54	7.29e-20	Educational attainment (years of education);
KIRP	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg18200741	chr2:33780366	RASGRP3	-0.21	-6.08	-0.36	4.44e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg00319359	chr11:70116639	PPFIA1	0.62	6.09	0.36	4.42e-9	Coronary artery disease;
KIRP	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.64	-10.49	-0.56	1.66e-21	Morning vs. evening chronotype;
KIRP	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.58	7.31	0.42	3.74e-12	Resting heart rate;
KIRP	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.36	-5.69	-0.34	3.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.21	-0.32	3.99e-7	Alcohol dependence;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.98	0.71	6.44e-40	Bipolar disorder;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.62	8.06	0.46	3.41e-14	Resistin levels;
KIRP	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg23974023	chr2:113544294	IL1A	-0.34	-5.11	-0.31	6.47e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs1021993	1.000	rs1395747	chr1:209488564	C/T	cg06155620	chr1:209527581	NA	-0.38	-4.94	-0.3	1.42e-6	Gut microbiome composition (winter);
KIRP	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.75	-11.08	-0.58	2.12e-23	Morning vs. evening chronotype;
KIRP	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg18154014	chr19:37997991	ZNF793	0.91	9.35	0.51	5.71e-18	Coronary artery calcification;
KIRP	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg04691961	chr3:161091175	C3orf57	-0.47	-7.07	-0.41	1.55e-11	Morning vs. evening chronotype;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01962510	chr22:18957837	DGCR5	-0.61	-6.79	-0.4	8.32e-11	Menopause (age at onset);
KIRP	trans	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg08975724	chr8:8085496	FLJ10661	0.52	6.25	0.37	1.84e-9	Neuroticism;
KIRP	cis	rs8054556	0.760	rs12598856	chr16:30029548	C/T	cg06326092	chr16:30034487	C16orf92	0.42	5.7	0.34	3.34e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3857747	0.931	rs11771964	chr7:40386172	C/A	cg00420559	chr7:40367873	C7orf10	-0.59	-8.1	-0.46	2.63e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7179456	0.610	rs650366	chr15:59061142	A/G	cg05156742	chr15:59063176	FAM63B	0.64	8.39	0.47	3.93e-15	Asperger disorder;
KIRP	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg01557791	chr16:72042693	DHODH	-0.49	-6.15	-0.36	3.15e-9	Fibrinogen levels;
KIRP	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg20255370	chr15:40268687	EIF2AK4	-0.55	-6.57	-0.39	3.01e-10	Corneal curvature;
KIRP	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg22089800	chr15:90895588	ZNF774	0.44	5.35	0.32	2.04e-7	Rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg08662619	chr6:150070041	PCMT1	0.38	6.21	0.37	2.24e-9	Lung cancer;
KIRP	cis	rs7799006	0.929	rs745566	chr7:2256406	T/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-5.28	-0.32	2.85e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg17376030	chr22:41985996	PMM1	-0.52	-6.38	-0.38	8.83e-10	Vitiligo;
KIRP	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg02678768	chr17:74002944	EVPL	0.42	5.56	0.33	7.02e-8	White matter hyperintensity burden;
KIRP	cis	rs11601602	0.531	rs35031414	chr11:28545563	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.65	6.19	0.37	2.57e-9	Obesity-related traits;
KIRP	cis	rs4132509	1.000	rs4553169	chr1:243900640	G/A	cg25706552	chr1:244017396	NA	0.6	8.0	0.45	4.88e-14	RR interval (heart rate);
KIRP	cis	rs988913	0.678	rs9367615	chr6:54991283	A/G	cg03513858	chr6:54763001	FAM83B	-0.36	-4.99	-0.3	1.13e-6	Menarche (age at onset);
KIRP	cis	rs9810890	1.000	rs73198846	chr3:128505472	A/C	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-7.93	-0.45	7.52e-14	Personality dimensions;
KIRP	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-1.09	-8.5	-0.48	1.9e-15	Plasma clusterin levels;
KIRP	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg23340505	chr13:114927933	NA	0.32	5.02	0.3	9.88e-7	Schizophrenia;
KIRP	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	5.31	0.32	2.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.57	-6.33	-0.37	1.18e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-0.75	-11.89	-0.6	4.55e-26	Prudent dietary pattern;
KIRP	cis	rs3755132	0.929	rs57670756	chr2:15753821	G/A	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg22903657	chr4:1355424	KIAA1530	0.45	6.77	0.4	9.49e-11	Obesity-related traits;
KIRP	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs9962915	0.967	rs1785418	chr18:5601403	A/G	cg12967001	chr18:5544089	EPB41L3	0.44	5.72	0.34	3.02e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	9.1	0.5	3.07e-17	Cognitive test performance;
KIRP	cis	rs4664293	0.769	rs2729726	chr2:160668108	A/C	cg08347373	chr2:160653686	CD302	-0.37	-5.65	-0.34	4.49e-8	Monocyte percentage of white cells;
KIRP	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18255839	chr2:239335447	ASB1	-0.43	-5.17	-0.31	4.92e-7	Multiple system atrophy;
KIRP	cis	rs7590368	0.673	rs56147885	chr2:10937095	T/A	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs42648	0.869	rs1134956	chr7:89938680	C/T	cg25739043	chr7:89950458	NA	-0.45	-7.2	-0.42	7.2e-12	Homocysteine levels;
KIRP	cis	rs2151522	0.762	rs9388534	chr6:127167715	T/C	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.91	-0.3	1.65e-6	Type 2 diabetes;
KIRP	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg13607699	chr17:42295918	UBTF	0.54	6.9	0.4	4.46e-11	Total body bone mineral density;
KIRP	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg10818794	chr15:86012489	AKAP13	-0.49	-6.88	-0.4	4.79e-11	Coronary artery disease;
KIRP	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.16	-0.31	5.13e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg26681399	chr22:41777847	TEF	-0.53	-5.3	-0.32	2.62e-7	Vitiligo;
KIRP	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.62	7.48	0.43	1.32e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg07777115	chr5:623756	CEP72	-0.61	-6.17	-0.37	2.77e-9	Obesity-related traits;
KIRP	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	7.64	0.44	4.95e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2387326	0.830	rs10741146	chr10:129920709	A/C	cg16087940	chr10:129947807	NA	-0.43	-5.6	-0.34	5.86e-8	Select biomarker traits;
KIRP	cis	rs12210905	0.688	rs12196452	chr6:27344415	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.51	5.86	0.35	1.5e-8	Platelet count;
KIRP	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	8.7	0.49	4.73e-16	Colorectal cancer;
KIRP	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg00792783	chr2:198669748	PLCL1	0.47	5.32	0.32	2.37e-7	Intracranial aneurysm;
KIRP	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg04025307	chr7:1156635	C7orf50	0.89	14.24	0.67	5.97e-34	Longevity;Endometriosis;
KIRP	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.73	10.7	0.56	3.5e-22	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg24499839	chr1:231762238	TSNAX-DISC1;DISC1	-0.35	-5.01	-0.3	1.05e-6	Neuranatomic and neurocognitive phenotypes;
KIRP	trans	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg10756647	chr7:56101905	PSPH	0.92	6.69	0.39	1.47e-10	Diabetic kidney disease;
KIRP	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg08283408	chr3:49949060	MON1A	-0.44	-5.84	-0.35	1.68e-8	Body mass index;
KIRP	cis	rs12476592	0.571	rs964903	chr2:63741548	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.4e-11	Response to antipsychotic treatment;
KIRP	cis	rs4954585	0.593	rs12691881	chr2:137029668	A/G	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.36e-13	Colorectal cancer;
KIRP	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg18932078	chr1:2524107	MMEL1	0.46	6.09	0.36	4.27e-9	Ulcerative colitis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25019777	chr4:53525403	USP46	-0.56	-6.06	-0.36	4.97e-9	Menopause (age at onset);
KIRP	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg26441486	chr22:50317300	CRELD2	0.56	8.68	0.48	5.45e-16	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg06618935	chr21:46677482	NA	-0.4	-5.23	-0.32	3.64e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12042938	0.935	rs823159	chr1:231777168	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.72	0.39	1.28e-10	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs3755605	0.520	rs1082978	chr3:169936992	A/T	cg02973263	chr3:169940162	PRKCI	0.43	4.85	0.3	2.19e-6	Testicular germ cell tumor;
KIRP	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.85	12.18	0.61	5.14e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs975752	0.867	rs2270962	chr10:102016044	C/T	cg13817732	chr10:102046368	BLOC1S2	0.71	5.98	0.36	7.85e-9	Schizophrenia;
KIRP	cis	rs629922	0.893	rs663516	chr11:114046429	A/G	cg25009965	chr11:114031120	ZBTB16	0.47	6.14	0.36	3.21e-9	Paneth cell defects in Crohn's disease;
KIRP	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20087917	chr14:77924039	C14orf133;AHSA1	0.6	7.47	0.43	1.44e-12	Smoking initiation;
KIRP	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.55	6.16	0.37	3.02e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs230014	0.584	rs230033	chr20:49761196	A/G	cg05573182	chr20:39318437	MAFB	-0.5	-6.05	-0.36	5.22e-9	QT interval (drug interaction);
KIRP	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg00094735	chr5:1949198	NA	0.43	5.19	0.31	4.35e-7	Gut microbiome composition (winter);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21925296	chr8:22102597	POLR3D;MIR320A	0.5	6.88	0.4	4.95e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.92	-15.23	-0.7	2.42e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg27426351	chr10:43362370	NA	-0.45	-6.32	-0.37	1.25e-9	Blood protein levels;
KIRP	cis	rs13065560	0.594	rs7620018	chr3:38886649	C/T	cg01426195	chr3:39028469	NA	-0.45	-7.19	-0.42	7.77e-12	Interleukin-18 levels;
KIRP	cis	rs3540	1.000	rs6496678	chr15:91034456	A/G	cg10434728	chr15:90938212	IQGAP1	0.29	4.99	0.3	1.12e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs17381785	0.640	rs1494955	chr4:14911413	C/T	cg12377275	chr4:15005593	CPEB2	0.46	5.58	0.34	6.25e-8	Urate levels in overweight individuals;
KIRP	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-21.77	-0.81	2.69e-59	Exhaled nitric oxide output;
KIRP	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.32	8.55	0.48	1.33e-15	Crohn's disease;
KIRP	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg25828445	chr12:7781288	NA	0.56	5.68	0.34	3.71e-8	HDL cholesterol levels;
KIRP	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg22705602	chr4:152727874	NA	-0.54	-9.57	-0.52	1.16e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg20253172	chr1:3107290	PRDM16	0.56	6.93	0.4	3.68e-11	Migraine;
KIRP	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg23625390	chr15:77176239	SCAPER	0.52	6.75	0.4	1.04e-10	Blood metabolite levels;
KIRP	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg23587288	chr2:27483067	SLC30A3	-0.38	-4.86	-0.3	2.07e-6	Total body bone mineral density;
KIRP	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.71	-9.28	-0.51	9.15e-18	Total body bone mineral density;
KIRP	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	10.48	0.56	1.74e-21	Hip circumference;
KIRP	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg22676075	chr6:135203613	NA	0.52	7.71	0.44	3.17e-13	Red blood cell count;
KIRP	cis	rs17209837	1.000	rs66510518	chr7:87111875	C/G	cg00919237	chr7:87102261	ABCB4	-0.69	-7.27	-0.42	4.72e-12	Gallbladder cancer;
KIRP	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.86	-12.55	-0.62	2.94e-28	Height;
KIRP	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.56	6.69	0.39	1.46e-10	Height;
KIRP	cis	rs4748857	0.947	rs4748851	chr10:23565338	T/C	cg12804278	chr10:23633326	C10orf67	0.44	5.47	0.33	1.1e-7	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	8.92e-8	Life satisfaction;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02833127	chr4:177116733	SPATA4	-0.91	-6.1	-0.36	4.1e-9	P wave terminal force;
KIRP	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg21161173	chr5:140098174	VTRNA1-2	-0.37	-4.9	-0.3	1.77e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-5.04	-0.31	9.21e-7	Ulcerative colitis;
KIRP	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	trans	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	6.43	0.38	6.69e-10	Ulcerative colitis;
KIRP	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg18016565	chr1:150552671	MCL1	0.4	5.85	0.35	1.59e-8	Melanoma;
KIRP	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg20936604	chr3:58311152	NA	-0.69	-5.92	-0.35	1.05e-8	Cholesterol, total;
KIRP	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.4	6.8	0.4	7.91e-11	Heart rate;
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg05861140	chr6:150128134	PCMT1	-0.49	-6.95	-0.41	3.3e-11	Lung cancer;
KIRP	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.34	-0.47	5.49e-15	Mood instability;
KIRP	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg10047753	chr17:41438598	NA	-1.15	-18.77	-0.77	2.12e-49	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg22907277	chr7:1156413	C7orf50	0.87	8.2	0.46	1.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.54	-0.43	8.95e-13	Bipolar disorder;
KIRP	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg26617929	chr16:1858877	NA	0.61	5.33	0.32	2.19e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs17123764	0.818	rs7953911	chr12:49948500	T/C	cg02054252	chr12:50078554	FMNL3	0.46	5.46	0.33	1.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.85	13.63	0.66	6.78e-32	Menarche (age at onset);
KIRP	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.28	-0.37	1.53e-9	Joint mobility (Beighton score);
KIRP	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.07	-0.36	4.92e-9	Lung cancer;
KIRP	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg02336718	chr17:17403227	NA	0.36	5.42	0.33	1.44e-7	Total body bone mineral density;
KIRP	trans	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg06521331	chr12:34319734	NA	-0.54	-6.71	-0.39	1.32e-10	Bladder cancer;
KIRP	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25517755	chr10:38738941	LOC399744	0.52	7.24	0.42	5.64e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg25233709	chr10:116636983	FAM160B1	0.34	5.22	0.32	3.76e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.85	0.49	1.76e-16	Morning vs. evening chronotype;
KIRP	cis	rs1975991	0.597	rs715790	chr3:187985004	A/G	cg17585528	chr3:187988060	LPP	0.53	6.86	0.4	5.43e-11	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.74	8.95	0.5	8.61e-17	Mammographic density (dense area);
KIRP	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.91	10.72	0.56	2.92e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.6	7.43	0.43	1.76e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.7	8.03	0.46	4.07e-14	IgG glycosylation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07781040	chr3:8664898	C3orf32	0.55	6.5	0.38	4.39e-10	Smoking initiation;
KIRP	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg23067535	chr8:124195133	FAM83A	-0.78	-7.63	-0.44	5.05e-13	Urinary uromodulin levels;
KIRP	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg21361702	chr7:150065534	REPIN1	0.58	6.3	0.37	1.38e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.57	-9.08	-0.5	3.73e-17	Longevity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23278267	chr1:202679165	SYT2	0.45	6.26	0.37	1.7e-9	Parkinson's disease;
KIRP	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	8.28	0.47	8.18e-15	Lung cancer in ever smokers;
KIRP	cis	rs2594989	0.806	rs2606746	chr3:11375120	A/G	cg01796438	chr3:11312864	ATG7	-0.39	-4.96	-0.3	1.33e-6	Circulating chemerin levels;
KIRP	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.9	-10.93	-0.57	6.3e-23	Response to antipsychotic treatment;
KIRP	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.64	-8.95	-0.5	8.65e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs714027	1.000	rs5997579	chr22:30537526	A/G	cg27665648	chr22:30112403	NA	-0.41	-5.88	-0.35	1.31e-8	Lymphocyte counts;
KIRP	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.42	0.38	6.91e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2299587	0.552	rs10503644	chr8:17697376	A/G	cg01800426	chr8:17659068	MTUS1	-0.42	-5.03	-0.31	9.29e-7	Economic and political preferences;
KIRP	cis	rs9462846	0.802	rs1819324	chr6:42859723	G/C	cg05552183	chr6:42928497	GNMT	0.39	4.87	0.3	2e-6	Blood protein levels;
KIRP	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.94	7.73	0.44	2.83e-13	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.46	5.87	0.35	1.41e-8	Aortic root size;
KIRP	cis	rs2230307	0.536	rs496798	chr1:100507990	G/A	cg24955406	chr1:100503596	HIAT1	0.69	7.93	0.45	7.78e-14	Carotid intima media thickness;
KIRP	cis	rs911119	1.000	rs13041070	chr20:23614261	G/A	cg16589663	chr20:23618590	CST3	0.72	6.74	0.4	1.09e-10	Chronic kidney disease;
KIRP	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg12091567	chr17:66097778	LOC651250	-0.82	-8.86	-0.49	1.59e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg04824913	chr4:887549	GAK	0.46	5.2	0.31	4.1e-7	Parkinson's disease;
KIRP	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg27211696	chr2:191398769	TMEM194B	-0.56	-6.58	-0.39	2.82e-10	Diastolic blood pressure;
KIRP	cis	rs17030434	0.834	rs28658020	chr4:154759048	C/T	cg14289246	chr4:154710475	SFRP2	-0.66	-8.26	-0.47	9.23e-15	Electrocardiographic conduction measures;
KIRP	cis	rs4764487	0.901	rs3181295	chr12:6344174	A/G	cg08284733	chr12:6341482	CD9	0.47	7.47	0.43	1.41e-12	Mean platelet volume;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03226425	chr6:170151538	C6orf70;TCTE3	0.48	6.5	0.38	4.31e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.47	-5.56	-0.33	6.93e-8	Glomerular filtration rate;
KIRP	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg01620082	chr3:125678407	NA	-1.13	-7.31	-0.42	3.7e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg02574844	chr11:5959923	NA	-0.57	-5.9	-0.35	1.18e-8	DNA methylation (variation);
KIRP	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg13180566	chr4:1052158	NA	0.47	4.95	0.3	1.41e-6	Recombination rate (females);
KIRP	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.52	-5.37	-0.32	1.79e-7	Tuberculosis;
KIRP	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.31	-5.48	-0.33	1.07e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg15655495	chr12:38532458	NA	-0.28	-5.09	-0.31	7.03e-7	Heart rate;
KIRP	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.67	-0.34	3.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.58	7.13	0.41	1.1e-11	Arsenic metabolism;
KIRP	cis	rs9381040	0.692	rs3088370	chr6:41157670	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.53	-6.6	-0.39	2.52e-10	Alzheimer's disease (late onset);
KIRP	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.18	21.1	0.8	4.09e-57	Cognitive function;
KIRP	cis	rs6921919	0.583	rs9468367	chr6:28360246	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg19773385	chr1:10388646	KIF1B	-0.68	-9.0	-0.5	6.27e-17	Hepatocellular carcinoma;
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.41	0.47	3.31e-15	Electroencephalogram traits;
KIRP	cis	rs883565	0.771	rs2056613	chr3:39125293	G/T	cg01426195	chr3:39028469	NA	-0.67	-10.71	-0.56	3.32e-22	Handedness;
KIRP	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-7.5	-0.43	1.14e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg03161606	chr19:29218774	NA	0.64	5.73	0.34	2.89e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16795821	chr3:142720237	SR140	-0.5	-6.22	-0.37	2.13e-9	Interleukin-4 levels;
KIRP	cis	rs287982	1.000	rs112307255	chr2:9982266	A/G	cg10881225	chr2:9984929	TAF1B	0.5	5.48	0.33	1.06e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg03929089	chr4:120376271	NA	-0.55	-6.46	-0.38	5.42e-10	HDL cholesterol;
KIRP	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.62	-7.8	-0.45	1.8e-13	Body mass index;
KIRP	cis	rs7624766	0.555	rs9814394	chr3:160490977	T/C	cg22637730	chr3:160473554	PPM1L	0.44	5.52	0.33	8.38e-8	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs1978968	0.763	rs9605479	chr22:18464611	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.77	-10.7	-0.56	3.41e-22	Presence of antiphospholipid antibodies;
KIRP	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg21253087	chr9:139290292	SNAPC4	0.4	5.1	0.31	6.82e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.43	-0.33	1.37e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11997175	0.550	rs7459565	chr8:33836717	C/T	ch.8.33884649F	chr8:33765107	NA	0.58	7.16	0.42	9.11e-12	Body mass index;
KIRP	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.79	8.71	0.49	4.52e-16	Diastolic blood pressure;
KIRP	cis	rs405956	1.000	rs405956	chr6:105554355	A/G	cg22580625	chr6:105627791	POPDC3	0.62	6.68	0.39	1.54e-10	QT interval;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16097330	chr5:171615472	STK10	0.54	6.28	0.37	1.51e-9	Smoking initiation;
KIRP	cis	rs72925845	0.577	rs691346	chr17:76429137	G/T	cg03830375	chr17:76426088	DNAH17	0.5	5.14	0.31	5.61e-7	Triglycerides;
KIRP	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg00405596	chr8:11794950	NA	-0.42	-5.66	-0.34	4.27e-8	Triglycerides;
KIRP	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg11161011	chr14:65562177	MAX	-0.51	-6.46	-0.38	5.53e-10	Obesity-related traits;
KIRP	cis	rs7582720	1.000	rs72932725	chr2:203649341	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	9.98	0.54	6.57e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.96	-15.56	-0.7	1.76e-38	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs10121009	0.565	rs10972462	chr9:35427324	C/T	cg15271616	chr9:35490515	RUSC2	-0.38	-5.2	-0.31	4.21e-7	Parkinson's disease;
KIRP	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg23594656	chr7:65796392	TPST1	-0.43	-5.94	-0.35	9.75e-9	Aortic root size;
KIRP	trans	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg25288420	chr1:78511713	GIPC2	0.43	6.05	0.36	5.3e-9	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.45	5.9	0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.58	-6.51	-0.38	4.12e-10	Fear of minor pain;
KIRP	cis	rs2944755	0.919	rs6578115	chr8:141575859	C/T	cg26074100	chr8:141568712	EIF2C2	0.44	6.69	0.39	1.49e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25426716	chr5:125695699	GRAMD3	0.51	6.67	0.39	1.68e-10	Interleukin-4 levels;
KIRP	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.1	0.69	6.82e-37	Platelet count;
KIRP	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-8.5	-0.48	1.84e-15	Colorectal cancer;
KIRP	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.54	-6.33	-0.37	1.15e-9	Renal function-related traits (BUN);
KIRP	cis	rs6546324	0.625	rs1430789	chr2:67866370	T/C	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs3126085	0.560	rs12031363	chr1:152350645	G/A	cg26876637	chr1:152193138	HRNR	-0.73	-7.13	-0.41	1.09e-11	Atopic dermatitis;
KIRP	cis	rs9596863	0.898	rs9596850	chr13:54371713	C/T	ch.13.53330881F	chr13:54432880	NA	0.59	5.76	0.34	2.49e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-9.74	-0.53	3.71e-19	Parkinson's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05462328	chr2:172963910	NA	0.51	6.7	0.39	1.41e-10	Myopia (pathological);
KIRP	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.76	-8.21	-0.46	1.24e-14	Vitiligo;
KIRP	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.97	-0.36	8.23e-9	Renal cell carcinoma;
KIRP	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg25173405	chr17:45401733	C17orf57	0.43	5.43	0.33	1.36e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Corneal astigmatism;
KIRP	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.29	-0.32	2.65e-7	Pulmonary function;
KIRP	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.92	12.96	0.64	1.22e-29	Bladder cancer;
KIRP	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg12549451	chr6:135224345	NA	0.44	5.6	0.34	5.68e-8	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15606180	chr19:3557658	C19orf28	0.54	6.58	0.39	2.74e-10	Parkinson's disease;
KIRP	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg21573476	chr21:45109991	RRP1B	-0.6	-8.5	-0.48	1.8e-15	Mean corpuscular volume;
KIRP	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg20701182	chr2:24300061	SF3B14	-0.41	-5.27	-0.32	3.03e-7	Asthma;
KIRP	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10782582	0.758	rs11161887	chr1:76386305	A/G	cg03433033	chr1:76189801	ACADM	0.34	5.12	0.31	6.18e-7	Daytime sleep phenotypes;
KIRP	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.45	-5.4	-0.33	1.58e-7	Red blood cell count;
KIRP	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.56	-6.44	-0.38	6.1e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17554472	chr22:41940697	POLR3H	-0.65	-6.75	-0.4	1.03e-10	Vitiligo;
KIRP	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9400467	0.508	rs11153293	chr6:111725899	A/T	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.67	-0.34	4.06e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.33	-0.32	2.18e-7	Personality dimensions;
KIRP	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-4.92	-0.3	1.6e-6	Menarche (age at onset);
KIRP	trans	rs429017	1.000	rs412685	chr5:41266229	A/G	cg06122825	chr1:203488764	NA	0.41	6.05	0.36	5.34e-9	Blood protein levels;
KIRP	cis	rs4332428	0.892	rs35231678	chr10:4985193	T/C	cg19648686	chr10:5044992	AKR1C2	-0.89	-8.08	-0.46	2.87e-14	Height;
KIRP	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.48	6.68	0.39	1.54e-10	Hematocrit;
KIRP	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg23803603	chr1:2058230	PRKCZ	0.38	5.56	0.33	6.96e-8	Height;
KIRP	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg06223162	chr1:101003688	GPR88	-0.43	-8.49	-0.48	2e-15	Monocyte count;
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg04317399	chr7:27170313	HOXA4	-0.35	-4.96	-0.3	1.32e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.67	8.61	0.48	8.67e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg22800045	chr5:56110881	MAP3K1	0.72	7.71	0.44	3.09e-13	Initial pursuit acceleration;
KIRP	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.16	-0.46	1.71e-14	Vitiligo;
KIRP	cis	rs259282	0.605	rs2302970	chr19:33098632	G/C	cg02997394	chr19:33096574	ANKRD27	-0.42	-4.93	-0.3	1.52e-6	Schizophrenia;
KIRP	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg06243866	chr13:111019493	COL4A2	-0.78	-11.94	-0.61	3.28e-26	White matter hyperintensity burden;
KIRP	cis	rs60311166	1.000	rs17052404	chr3:52776664	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	1.0	7.06	0.41	1.65e-11	CTACK levels;
KIRP	cis	rs7224685	0.569	rs12452393	chr17:3985427	G/A	cg21851534	chr17:3907994	ZZEF1	0.53	5.11	0.31	6.33e-7	Type 2 diabetes;
KIRP	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg15556689	chr8:8085844	FLJ10661	0.5	6.54	0.38	3.45e-10	Triglycerides;
KIRP	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg10503236	chr1:231470652	EXOC8	-0.52	-7.14	-0.41	1.06e-11	Hemoglobin concentration;
KIRP	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg05220968	chr6:146057943	EPM2A	0.4	5.17	0.31	4.83e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.41e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	5.05	0.31	8.6e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.05	-0.41	1.8e-11	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.53	-0.33	8.38e-8	Life satisfaction;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03647317	chr4:187891568	NA	0.59	9.06	0.5	4.29e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg20999797	chr1:1681921	NA	0.53	8.22	0.46	1.15e-14	Body mass index;
KIRP	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.65	8.59	0.48	1.02e-15	Total body bone mineral density;
KIRP	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	1.01	13.52	0.65	1.66e-31	Neutrophil percentage of white cells;
KIRP	trans	rs199950	0.911	rs199943	chr1:181598400	C/A	cg04237608	chr1:18659049	IGSF21	0.39	6.56	0.39	3.22e-10	Body mass index (change over time);
KIRP	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.63	-0.44	5.11e-13	Retinal vascular caliber;
KIRP	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg00262122	chr8:11665843	FDFT1	0.44	5.44	0.33	1.27e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-7.42	-0.43	1.86e-12	Arsenic metabolism;
KIRP	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.1	-0.61	9.19e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.08	-0.36	4.65e-9	Aortic root size;
KIRP	cis	rs4722404	0.502	rs7804033	chr7:3110005	G/A	cg19214707	chr7:3157722	NA	-0.56	-6.61	-0.39	2.35e-10	Atopic dermatitis;
KIRP	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg24375607	chr4:120327624	NA	0.61	6.58	0.39	2.76e-10	Corneal astigmatism;
KIRP	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg15068132	chr12:102092402	CHPT1	-0.39	-5.09	-0.31	7.05e-7	Blood protein levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19793034	chr4:1284190	MAEA	0.47	6.1	0.36	4e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.89	-11.79	-0.6	9.82e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05746407	chr16:85646856	KIAA0182	-0.53	-6.02	-0.36	6.26e-9	Interleukin-4 levels;
KIRP	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.75	8.33	0.47	5.85e-15	Cholesterol, total;
KIRP	trans	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	6.05	0.36	5.23e-9	Metabolite levels;
KIRP	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg01872077	chr2:219646372	CYP27A1	-0.38	-5.25	-0.32	3.23e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.32	5.9	0.35	1.2e-8	Monocyte percentage of white cells;
KIRP	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg11344533	chr11:111475393	SIK2	0.3	5.02	0.3	9.92e-7	Primary sclerosing cholangitis;
KIRP	cis	rs12615966	0.932	rs60048061	chr2:105368969	G/A	cg16465502	chr2:105461796	NA	0.68	6.06	0.36	5.11e-9	Pancreatic cancer;
KIRP	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg23517279	chr6:96025343	MANEA	0.58	5.18	0.31	4.72e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg00405596	chr8:11794950	NA	0.41	5.08	0.31	7.59e-7	Systolic blood pressure;
KIRP	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.63	5.48	0.33	1.07e-7	Putamen volume;
KIRP	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg22705602	chr4:152727874	NA	0.54	9.29	0.51	8.44e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.86	11.33	0.59	3.27e-24	Selective IgA deficiency;
KIRP	cis	rs55788414	0.932	rs12716908	chr16:81186245	T/C	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.24	-0.47	1e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.39	-0.43	2.24e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs11967485	0.614	rs62435825	chr6:157178775	C/A	cg23222435	chr6:157204239	ARID1B	-0.73	-5.13	-0.31	5.82e-7	Calcium levels;
KIRP	cis	rs2280630	0.529	rs1274957	chr3:39185077	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.45	-5.03	-0.31	9.59e-7	Verbal declarative memory;
KIRP	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.99	-0.3	1.14e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4664304	0.620	rs11675122	chr2:160713446	C/A	cg03641300	chr2:160917029	PLA2R1	0.38	5.68	0.34	3.87e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7590368	0.715	rs72779453	chr2:10959475	G/C	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7129556	0.911	rs11237244	chr11:77335336	A/G	cg12586386	chr11:77299805	AQP11	0.46	5.72	0.34	3.1e-8	Weight loss (gastric bypass surgery);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13496359	chr9:109686439	ZNF462;MIR548Q	-0.43	-6.45	-0.38	5.84e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.28	0.62	2.28e-27	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.08	-0.31	7.31e-7	Bipolar disorder;
KIRP	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.27	-0.37	1.65e-9	Neuroticism;
KIRP	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg22117172	chr7:91764530	CYP51A1	0.41	5.53	0.33	8.09e-8	Breast cancer;
KIRP	cis	rs240764	0.658	rs11155666	chr6:101234841	G/C	cg09795085	chr6:101329169	ASCC3	-0.47	-5.47	-0.33	1.12e-7	Neuroticism;
KIRP	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.81e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4663866	1.000	rs4663868	chr2:239161091	C/T	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg08890418	chr1:21044141	KIF17	0.34	5.08	0.31	7.5e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.84	10.48	0.56	1.68e-21	Gestational age at birth (maternal effect);
KIRP	cis	rs220519	0.811	rs220503	chr20:37294883	A/G	cg24308336	chr20:37270989	C20orf95	-0.23	-5.2	-0.31	4.24e-7	Schizophrenia;
KIRP	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg10381502	chr11:71823885	C11orf51	-1.16	-8.05	-0.46	3.64e-14	Severe influenza A (H1N1) infection;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17482706	chr9:77643371	C9orf41	-0.51	-6.35	-0.38	1.02e-9	Neuroticism;
KIRP	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg02534363	chr3:47050950	NBEAL2	-0.28	-4.86	-0.3	2.05e-6	Colorectal cancer;
KIRP	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg00277334	chr10:82204260	NA	0.47	5.55	0.33	7.25e-8	Post bronchodilator FEV1;
KIRP	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.64	8.98	0.5	7.32e-17	Multiple system atrophy;
KIRP	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.75	0.34	2.66e-8	Total cholesterol levels;
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.27	5.11	0.31	6.61e-7	Lymphocyte counts;
KIRP	cis	rs6681460	1.000	rs9662962	chr1:67121364	C/T	cg02459107	chr1:67143332	SGIP1	0.49	6.99	0.41	2.64e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg03060546	chr3:49711283	APEH	0.43	5.46	0.33	1.14e-7	Parkinson's disease;
KIRP	cis	rs6838801	0.927	rs4397016	chr4:77515877	T/G	cg17476223	chr4:77663285	SHROOM3	0.52	7.1	0.41	1.34e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg17554472	chr22:41940697	POLR3H	0.59	6.41	0.38	7.48e-10	Vitiligo;
KIRP	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	0.64	5.89	0.35	1.29e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg03714773	chr7:91764589	CYP51A1	0.36	5.15	0.31	5.33e-7	Breast cancer;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.82e-8	Life satisfaction;
KIRP	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg13978929	chr19:21580086	ZNF493	0.5	4.92	0.3	1.58e-6	Pain;
KIRP	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-5.79	-0.35	2.09e-8	Schizophrenia;
KIRP	cis	rs3812111	0.510	rs17077755	chr6:116592033	C/T	cg18828861	chr6:116576566	TSPYL4	0.42	4.87	0.3	1.98e-6	Age-related macular degeneration;
KIRP	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg20701182	chr2:24300061	SF3B14	0.91	10.13	0.54	2.24e-20	Lymphocyte counts;
KIRP	cis	rs2637030	0.515	rs381374	chr5:52927813	A/G	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-5.17	-0.31	4.93e-7	Cognitive function;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02666966	chr16:28857347	TUFM	-0.49	-6.54	-0.38	3.56e-10	Metabolic traits;
KIRP	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23939001	chr4:940644	TMEM175	-0.49	-6.87	-0.4	5.09e-11	Parkinson's disease;
KIRP	cis	rs42648	0.935	rs42621	chr7:89956484	A/G	cg25739043	chr7:89950458	NA	-0.47	-7.3	-0.42	3.87e-12	Homocysteine levels;
KIRP	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.77	-9.91	-0.53	1.04e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg15790184	chr11:494944	RNH1	0.4	4.98	0.3	1.18e-6	Systemic lupus erythematosus;
KIRP	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg26695010	chr11:65641043	EFEMP2	0.45	5.52	0.33	8.38e-8	Eosinophil percentage of white cells;
KIRP	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	1.1	13.38	0.65	4.62e-31	Red blood cell traits;
KIRP	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.06	0.46	3.38e-14	Menarche (age at onset);
KIRP	cis	rs714515	1.000	rs714515	chr1:172352990	G/A	cg01573306	chr1:172330400	DNM3	0.45	5.83	0.35	1.69e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7903847	0.642	rs2297668	chr10:99160046	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.82	-0.35	1.78e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg12598211	chr12:123634384	NA	-0.41	-5.07	-0.31	7.97e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.73	-0.34	2.88e-8	Educational attainment;
KIRP	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg26513180	chr16:89883248	FANCA	0.81	5.5	0.33	9.37e-8	Skin colour saturation;
KIRP	cis	rs7589728	1.000	rs75181745	chr2:88520408	C/T	cg04511125	chr2:88470314	THNSL2	0.72	5.59	0.34	6.14e-8	Plasma clusterin levels;
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg11641102	chr8:27183873	PTK2B	0.43	5.69	0.34	3.65e-8	Neuroticism;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg00738919	chr7:1100172	C7orf50	0.42	4.97	0.3	1.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1958560	0.932	rs6573615	chr14:66046534	G/A	cg03016385	chr14:66212404	NA	-0.44	-5.47	-0.33	1.09e-7	Menarche (age at onset);
KIRP	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.4	-0.38	7.84e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72827839	0.846	rs72823591	chr17:46122628	C/T	cg03171361	chr17:47075758	IGF2BP1	-0.48	-4.89	-0.3	1.8e-6	Ease of getting up in the morning;
KIRP	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg25486957	chr4:152246857	NA	-0.41	-4.92	-0.3	1.57e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-6.3	-0.37	1.37e-9	Longevity;Endometriosis;
KIRP	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.53	-0.48	1.51e-15	Type 2 diabetes;
KIRP	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg05861140	chr6:150128134	PCMT1	-0.46	-5.87	-0.35	1.37e-8	Lung cancer;
KIRP	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.71	10.48	0.56	1.7e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg14289246	chr4:154710475	SFRP2	-0.55	-7.14	-0.41	1.08e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.58	7.18	0.42	8.03e-12	Aortic root size;
KIRP	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg03171003	chr2:111875934	NA	0.39	5.4	0.33	1.56e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg23555395	chr2:238036564	NA	-0.57	-6.72	-0.39	1.27e-10	Systemic lupus erythematosus;
KIRP	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	5.4	0.33	1.6e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg01864069	chr14:103024347	NA	-0.85	-10.08	-0.54	3.14e-20	Platelet count;
KIRP	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg20302533	chr7:39170763	POU6F2	0.3	6.54	0.38	3.57e-10	IgG glycosylation;
KIRP	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.55	-5.83	-0.35	1.76e-8	Smoking behavior;
KIRP	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.89	-11.74	-0.6	1.42e-25	Gut microbiota (bacterial taxa);
KIRP	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg24315340	chr6:146058215	EPM2A	-0.37	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12049351	0.524	rs4925495	chr1:229624424	C/T	cg00551153	chr21:47333731	PCBP3	-0.49	-6.11	-0.36	3.9e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs1062746	0.527	rs12934628	chr16:87335161	A/G	cg02258303	chr16:87377426	FBXO31	-0.42	-5.25	-0.32	3.22e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.17	0.37	2.73e-9	Mean corpuscular volume;
KIRP	cis	rs151997	1.000	rs27247	chr5:50232299	T/C	cg06027927	chr5:50259733	NA	-0.57	-7.18	-0.42	8.25e-12	Callous-unemotional behaviour;
KIRP	cis	rs8113308	0.810	rs8108525	chr19:52444136	G/T	cg25782003	chr19:52490127	ZNF350	0.53	4.94	0.3	1.47e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg11569703	chr11:65557185	OVOL1	0.73	14.1	0.67	1.69e-33	Acne (severe);
KIRP	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg21077578	chr7:1022970	CYP2W1	0.35	4.9	0.3	1.71e-6	Longevity;Endometriosis;
KIRP	cis	rs6684514	1.000	rs12027103	chr1:156244856	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs7011049	1.000	rs72643590	chr8:53849595	A/G	cg26025543	chr8:53854495	NA	0.77	8.02	0.46	4.17e-14	Systolic blood pressure;
KIRP	cis	rs78487399	0.808	rs6726643	chr2:43753746	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.12	-0.31	6.04e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg24315340	chr6:146058215	EPM2A	-0.46	-5.62	-0.34	5.09e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3026101	0.671	rs13341936	chr17:5298858	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.65	0.39	1.84e-10	Body mass index;
KIRP	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.55	-0.39	3.42e-10	Response to antipsychotic treatment;
KIRP	cis	rs35740288	0.770	rs11633893	chr15:86148438	A/G	cg10818794	chr15:86012489	AKAP13	0.46	5.58	0.34	6.26e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg20731937	chr12:48336164	NA	0.41	5.28	0.32	2.8e-7	Longevity (90 years and older);
KIRP	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-7.81	-0.45	1.62e-13	Tonsillectomy;
KIRP	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.72	7.03	0.41	2.04e-11	Breast cancer;
KIRP	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.28	14.54	0.68	5.29e-35	Uric acid levels;
KIRP	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg22089800	chr15:90895588	ZNF774	0.42	4.94	0.3	1.44e-6	Rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18820063	chr10:90814440	NA	0.41	6.07	0.36	4.88e-9	Interleukin-4 levels;
KIRP	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.71	-8.76	-0.49	3.21e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg11839771	chr15:80205821	ST20	-0.38	-5.36	-0.32	1.95e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs10484761	1.000	rs1929781	chr6:40804560	C/T	cg02680909	chr6:39899321	MOCS1	-0.22	-4.84	-0.3	2.27e-6	Esophageal cancer;
KIRP	cis	rs1950626	0.699	rs12896504	chr14:101467948	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.59	-6.33	-0.37	1.18e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.13	-0.36	3.54e-9	Systolic blood pressure;
KIRP	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	trans	rs1738074	0.536	rs3117151	chr6:159445947	G/A	cg25738688	chr12:89138236	NA	0.43	6.03	0.36	5.86e-9	Multiple sclerosis;Celiac disease;
KIRP	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.75	0.73	1.54e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg04731861	chr2:219085781	ARPC2	0.3	7.65	0.44	4.53e-13	Colorectal cancer;
KIRP	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.81	-11.54	-0.59	6.7e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.44	-5.58	-0.34	6.4e-8	Rheumatoid arthritis;
KIRP	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg18016565	chr1:150552671	MCL1	0.41	5.12	0.31	6.27e-7	Tonsillectomy;
KIRP	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg25183470	chr7:39605805	C7orf36	-0.45	-6.21	-0.37	2.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg08999081	chr20:33150536	PIGU	0.46	6.16	0.37	2.91e-9	Height;
KIRP	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.16	-0.46	1.68e-14	Morning vs. evening chronotype;
KIRP	cis	rs1440410	0.597	rs4690766	chr4:144030040	C/G	cg01719995	chr4:144104893	USP38	0.45	5.94	0.35	9.57e-9	Ischemic stroke;
KIRP	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07234876	chr8:600039	NA	0.81	6.28	0.37	1.51e-9	IgG glycosylation;
KIRP	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.08	-0.41	1.46e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.96	-0.57	5.1e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.96	0.57	5.14e-23	Lung cancer in ever smokers;
KIRP	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.88	-0.4	4.91e-11	Mood instability;
KIRP	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg13072238	chr3:49761600	GMPPB	-0.59	-5.62	-0.34	5.22e-8	Menarche (age at onset);
KIRP	cis	rs62229266	0.804	rs2835263	chr21:37430245	A/G	cg08632701	chr21:37451849	NA	0.44	5.58	0.34	6.25e-8	Mitral valve prolapse;
KIRP	cis	rs12143943	0.966	rs898385	chr1:204579860	A/G	cg20240347	chr1:204465584	NA	-0.34	-6.29	-0.37	1.45e-9	Cognitive performance;
KIRP	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg01304814	chr3:48885189	PRKAR2A	0.78	5.9	0.35	1.19e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2425143	0.915	rs6060597	chr20:34370100	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	6.0	0.36	7.1e-9	Blood protein levels;
KIRP	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.24	0.42	5.66e-12	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.02	0.3	9.93e-7	Renal cell carcinoma;
KIRP	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.43	6.45	0.38	5.87e-10	Major depressive disorder;
KIRP	cis	rs7870753	0.634	rs10123368	chr9:99111384	T/C	cg25260653	chr9:99212216	HABP4	0.49	5.14	0.31	5.51e-7	Height;
KIRP	cis	rs6578185	0.782	rs10109519	chr8:142453669	T/C	cg15142913	chr8:142440250	PTP4A3	0.4	5.31	0.32	2.44e-7	Endometriosis;
KIRP	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.2	-0.8	1.87e-57	Ulcerative colitis;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	9.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6540556	0.723	rs11119327	chr1:209883804	T/C	cg23920097	chr1:209922102	NA	-0.49	-5.73	-0.34	2.94e-8	Red blood cell count;
KIRP	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.67	7.62	0.44	5.62e-13	Body mass index;
KIRP	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.83	-7.8	-0.45	1.75e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7221595	0.825	rs12938597	chr17:3961200	C/T	cg05562828	chr17:3906858	NA	0.51	5.48	0.33	1.06e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.58	-6.11	-0.36	3.85e-9	Obesity-related traits;
KIRP	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.81	10.18	0.54	1.59e-20	Corneal astigmatism;
KIRP	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg16558253	chr16:72132732	DHX38	-0.59	-6.73	-0.39	1.22e-10	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg03115019	chr17:80708279	FN3K	0.42	4.96	0.3	1.3e-6	Glycated hemoglobin levels;
KIRP	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg15893493	chr8:124194847	FAM83A	-0.83	-7.09	-0.41	1.38e-11	Urinary uromodulin levels;
KIRP	cis	rs4494114	1.000	rs4607833	chr1:39354272	G/C	cg25970120	chr1:39325951	RRAGC	-0.41	-5.11	-0.31	6.4e-7	Blood protein levels;
KIRP	cis	rs6430538	0.582	rs1942053	chr2:135579205	G/C	cg12500956	chr2:135428796	TMEM163	0.41	5.21	0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg16512390	chr1:228756714	NA	0.45	5.09	0.31	7.13e-7	Diastolic blood pressure;
KIRP	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.22	-0.37	2.13e-9	Retinal vascular caliber;
KIRP	cis	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg06521331	chr12:34319734	NA	-0.47	-6.01	-0.36	6.8e-9	Morning vs. evening chronotype;
KIRP	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18357526	chr6:26021779	HIST1H4A	0.86	10.56	0.56	9.92e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs7939886	0.920	rs61887958	chr11:55938234	A/G	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs6430538	0.597	rs1942054	chr2:135579213	A/G	cg12500956	chr2:135428796	TMEM163	0.41	5.21	0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs72627123	0.656	rs17096314	chr14:74567952	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.91	0.3	1.7e-6	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg13010199	chr12:38710504	ALG10B	0.52	6.71	0.39	1.3e-10	Morning vs. evening chronotype;
KIRP	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.37	-0.32	1.8e-7	Red blood cell count;
KIRP	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.13	0.46	2.05e-14	Morning vs. evening chronotype;
KIRP	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.6	7.77	0.44	2.13e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	0.77	8.48	0.48	2.14e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.63	7.46	0.43	1.51e-12	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07888926	chr16:70834945	VAC14	0.5	6.19	0.37	2.55e-9	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.18	0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg23301140	chr18:77439876	CTDP1	0.43	5.0	0.3	1.08e-6	Monocyte count;
KIRP	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	10.61	0.56	6.62e-22	Lung cancer in ever smokers;
KIRP	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg01280390	chr8:19363452	CSGALNACT1	-0.44	-5.97	-0.36	8.4e-9	Oropharynx cancer;
KIRP	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.2	-0.31	4.23e-7	Pulmonary function;
KIRP	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg18944383	chr4:111397179	ENPEP	0.43	6.91	0.4	4.19e-11	Height;
KIRP	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.38	7.21	0.42	6.97e-12	Multiple system atrophy;
KIRP	cis	rs8070740	0.838	rs1050456	chr17:5336188	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	6.48	0.38	5.04e-10	Menopause (age at onset);
KIRP	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.02	0.3	1.01e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26035522	chr14:78174277	ALKBH1;C14orf156	0.53	6.9	0.4	4.42e-11	Parkinson's disease;
KIRP	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg24375607	chr4:120327624	NA	0.43	5.31	0.32	2.51e-7	Diastolic blood pressure;
KIRP	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.8	-11.19	-0.58	8.81e-24	Monocyte count;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg15181151	chr6:150070149	PCMT1	0.31	5.27	0.32	3.04e-7	Lung cancer;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.09e-16	Life satisfaction;
KIRP	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.3	-7.71	-0.44	3.02e-13	Primary biliary cholangitis;
KIRP	cis	rs10073892	0.620	rs1354618	chr5:101985120	A/G	cg19774478	chr5:101632501	SLCO4C1	0.58	5.74	0.34	2.83e-8	Cognitive decline (age-related);
KIRP	cis	rs2562456	0.793	rs116057198	chr19:21508451	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-5.04	-0.31	8.96e-7	Pain;
KIRP	trans	rs972578	0.818	rs2267463	chr22:43283255	A/C	cg15321293	chr3:36422198	STAC	-0.47	-6.07	-0.36	4.84e-9	Mean platelet volume;
KIRP	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg21890820	chr11:65308645	LTBP3	0.99	5.89	0.35	1.29e-8	Height;
KIRP	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.8	12.61	0.63	1.93e-28	Monocyte percentage of white cells;
KIRP	cis	rs1635	0.655	rs16893929	chr6:28270817	C/T	cg15743358	chr6:28303923	ZNF323	-0.76	-5.47	-0.33	1.13e-7	Schizophrenia;
KIRP	cis	rs13185784	0.662	rs6867398	chr5:179712060	A/G	cg23248424	chr5:179741104	GFPT2	0.46	4.97	0.3	1.28e-6	TRAIL levels;
KIRP	cis	rs6684428	0.901	rs11206681	chr1:56364528	T/C	cg11651538	chr1:56320950	NA	-0.86	-10.11	-0.54	2.52e-20	Airflow obstruction;
KIRP	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg25486957	chr4:152246857	NA	-0.48	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	0.89	13.02	0.64	8.03e-30	Dupuytren's disease;
KIRP	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.8	10.26	0.55	8.74e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.1e-9	Morning vs. evening chronotype;
KIRP	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg01559446	chr3:44596178	ZNF167	-0.35	-5.14	-0.31	5.54e-7	Depressive symptoms;
KIRP	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.82	-12.45	-0.62	6.35e-28	Blood metabolite levels;
KIRP	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg02336718	chr17:17403227	NA	0.32	4.94	0.3	1.43e-6	Total body bone mineral density;
KIRP	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg24250549	chr1:154909240	PMVK	0.49	6.67	0.39	1.64e-10	Prostate cancer;
KIRP	cis	rs4356932	0.875	rs6826408	chr4:76973564	A/C	cg00809888	chr4:76862425	NAAA	0.44	6.2	0.37	2.42e-9	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26319343	chr19:5623198	SAFB2;SAFB	0.53	6.75	0.4	1.06e-10	Parkinson's disease;
KIRP	cis	rs1867631	1.000	rs10789212	chr1:67128155	G/A	cg13052034	chr1:66999238	SGIP1	0.47	6.63	0.39	2.11e-10	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg00656387	chr3:40428638	ENTPD3	-0.37	-5.06	-0.31	8.02e-7	Renal cell carcinoma;
KIRP	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-5.05	-0.31	8.53e-7	Skin colour saturation;
KIRP	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs1595825	0.735	rs6752760	chr2:198918164	G/T	cg11031976	chr2:198649780	BOLL	-0.53	-4.85	-0.3	2.22e-6	Ulcerative colitis;
KIRP	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.79	0.35	2.16e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-12.47	-0.62	5.56e-28	Cognitive function;
KIRP	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	10.6	0.56	7.31e-22	Lung cancer in ever smokers;
KIRP	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg16606324	chr3:10149918	C3orf24	0.54	5.02	0.3	9.99e-7	Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18134731	chr7:77394822	RSBN1L	-0.48	-7.64	-0.44	4.7e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg18032046	chr6:28092343	ZSCAN16	0.49	5.32	0.32	2.35e-7	Depression;
KIRP	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-7.17	-0.42	8.53e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs977987	0.868	rs10871313	chr16:75507094	C/T	cg03315344	chr16:75512273	CHST6	0.74	10.56	0.56	9.55e-22	Dupuytren's disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg16025584	chr9:139887217	C9orf142	-0.51	-6.5	-0.38	4.55e-10	Neuroticism;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg06665941	chr21:34602869	IFNAR2	0.57	6.65	0.39	1.84e-10	Sleep duration;
KIRP	cis	rs4924935	0.781	rs2472694	chr17:18848498	A/G	cg26378065	chr17:18585709	ZNF286B	0.52	5.27	0.32	2.92e-7	Pancreatic cancer;
KIRP	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg17376030	chr22:41985996	PMM1	-0.83	-8.8	-0.49	2.39e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg27487796	chr7:28973253	NA	-0.21	-4.91	-0.3	1.66e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs1011018	0.955	rs28656273	chr7:139467676	T/C	cg03224163	chr7:139420300	HIPK2	-0.48	-5.11	-0.31	6.56e-7	Systolic blood pressure;
KIRP	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg13119609	chr19:45449297	APOC2	0.39	5.03	0.31	9.52e-7	Blood protein levels;
KIRP	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	1.06	20.02	0.79	1.53e-53	Heart rate;
KIRP	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.67	9.55	0.52	1.42e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.53	-6.31	-0.37	1.32e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1699337	1.000	rs1699337	chr3:12450093	G/A	cg02700894	chr3:12045449	SYN2	-0.41	-5.23	-0.32	3.71e-7	Cholesterol, total;
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg09699651	chr6:150184138	LRP11	0.48	6.31	0.37	1.26e-9	Lung cancer;
KIRP	cis	rs7539542	0.556	rs10753925	chr1:202854488	C/T	cg08940984	chr1:202857613	RABIF	0.44	5.52	0.33	8.6e-8	Mean platelet volume;
KIRP	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg19197139	chr17:4613644	ARRB2	0.74	7.6	0.44	6.1e-13	Lymphocyte counts;
KIRP	cis	rs787274	0.867	rs786983	chr9:115458629	T/C	cg13803584	chr9:115635662	SNX30	0.58	7.17	0.42	8.8e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-7.5	-0.43	1.14e-12	Longevity;Endometriosis;
KIRP	cis	rs412050	0.842	rs1530229	chr22:22300678	A/G	cg17089214	chr22:22089827	YPEL1	0.49	4.89	0.3	1.84e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.57	0.43	7.5e-13	Coffee consumption (cups per day);
KIRP	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-6.1	-0.36	4.06e-9	Monocyte percentage of white cells;
KIRP	cis	rs17102423	0.651	rs2296316	chr14:65520246	A/G	cg11161011	chr14:65562177	MAX	-0.42	-5.43	-0.33	1.36e-7	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs9308433	0.529	rs11800749	chr1:214499754	A/G	cg06198575	chr1:214491504	SMYD2	-0.54	-6.99	-0.41	2.58e-11	IgG glycosylation;
KIRP	cis	rs6977660	0.562	rs12112698	chr7:19781431	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	6.0	0.36	7.07e-9	Thyroid stimulating hormone;
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg23985595	chr17:80112537	CCDC57	-0.35	-5.18	-0.31	4.59e-7	Life satisfaction;
KIRP	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.5	7.0	0.41	2.42e-11	Glioblastoma;Glioma;
KIRP	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.42	5.35	0.32	2.01e-7	Aortic root size;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg13453750	chr1:205783389	SLC41A1	-0.49	-7.67	-0.44	4.08e-13	Menarche (age at onset);
KIRP	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.79	10.28	0.55	7.42e-21	Menopause (age at onset);
KIRP	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-7.31	-0.42	3.77e-12	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg08392591	chr16:89556376	ANKRD11	0.47	6.03	0.36	6.12e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg01200585	chr1:228362443	C1orf69	0.42	5.21	0.32	3.91e-7	Diastolic blood pressure;
KIRP	cis	rs17123764	0.818	rs12311839	chr12:49963405	A/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	1.07	19.64	0.78	2.64e-52	Gut microbiome composition (winter);
KIRP	cis	rs28489187	0.683	rs233050	chr1:85837793	T/C	cg16011679	chr1:85725395	C1orf52	0.55	6.7	0.39	1.37e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg22800045	chr5:56110881	MAP3K1	-0.43	-4.99	-0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg26695010	chr11:65641043	EFEMP2	-0.42	-5.26	-0.32	3.08e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg07884673	chr3:53033167	SFMBT1	-0.77	-6.32	-0.37	1.24e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6005807	0.563	rs12169262	chr22:29079353	C/T	cg12565055	chr22:29076175	TTC28	0.6	5.11	0.31	6.37e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg06742321	chr12:123595122	PITPNM2	0.42	5.13	0.31	5.86e-7	Neutrophil percentage of white cells;
KIRP	trans	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	-0.76	-10.61	-0.56	6.5600000000000005e-22	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.57	8.22	0.46	1.16e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.75	-7.6	-0.44	6.22e-13	Gut microbiome composition (summer);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg24069935	chr14:74226554	C14orf43	-0.56	-6.09	-0.36	4.35e-9	Menopause (age at onset);
KIRP	cis	rs8179	0.552	rs740047	chr7:92230162	A/G	cg15732164	chr7:92237376	CDK6	-0.49	-5.74	-0.34	2.78e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs3134353	0.734	rs2923781	chr8:101976510	G/A	cg07585502	chr8:101912084	NA	0.42	5.26	0.32	3.1e-7	Body mass index;
KIRP	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.26	-0.37	1.74e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg09872104	chr7:134855509	C7orf49	-0.94	-6.04	-0.36	5.7e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-9.59	-0.52	1.01e-18	Body mass index;
KIRP	cis	rs2371030	1.000	rs10211079	chr2:211575735	C/G	cg18417063	chr2:211583084	NA	-0.51	-7.34	-0.42	3.08e-12	Non-small cell lung cancer;
KIRP	cis	rs508618	0.638	rs479200	chr1:231543780	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-5.84	-0.35	1.64e-8	Red blood cell count;
KIRP	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.81	9.6	0.52	9.45e-19	Schizophrenia;
KIRP	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.36	7.46	0.43	1.53e-12	IgG glycosylation;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg18247177	chr17:7745472	KDM6B	0.45	6.17	0.37	2.87e-9	Ischemic stroke;
KIRP	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.62	-7.83	-0.45	1.46e-13	Extraversion;
KIRP	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg11465639	chr17:19241549	NA	0.39	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	trans	rs7830939	1.000	rs7830939	chr8:9380132	A/G	cg16141378	chr3:129829833	LOC729375	0.54	6.94	0.4	3.51e-11	Neuroticism;
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg09264619	chr17:80180166	NA	0.34	4.89	0.3	1.82e-6	Life satisfaction;
KIRP	cis	rs35740288	0.770	rs11635190	chr15:86148531	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12210905	0.688	rs12215878	chr6:27336844	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.86	-6.22	-0.37	2.09e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg27205649	chr11:78285834	NARS2	0.86	12.48	0.62	5.12e-28	Alzheimer's disease (survival time);
KIRP	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-7.32	-0.42	3.57e-12	Platelet count;
KIRP	cis	rs9815354	1.000	rs6768128	chr3:41865080	G/A	cg03022575	chr3:42003672	ULK4	0.54	5.94	0.35	9.53e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.94	-13.91	-0.66	7.87e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.44	5.33	0.32	2.23e-7	Asthma;
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg18183042	chr17:80733038	TBCD	-0.38	-4.96	-0.3	1.31e-6	Glycated hemoglobin levels;
KIRP	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.43	-0.38	6.65e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.9	-12.18	-0.61	5e-27	Cognitive function;
KIRP	cis	rs4262150	0.767	rs13182323	chr5:152329944	T/C	cg12297329	chr5:152029980	NA	0.42	5.59	0.34	5.88e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg01631408	chr1:248437212	OR2T33	-0.46	-6.04	-0.36	5.62e-9	Common traits (Other);
KIRP	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.21	22.13	0.82	1.89e-60	Cognitive function;
KIRP	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg24203234	chr3:128598194	ACAD9	0.44	5.06	0.31	8.3e-7	IgG glycosylation;
KIRP	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg04691961	chr3:161091175	C3orf57	-0.66	-10.79	-0.57	1.72e-22	Morning vs. evening chronotype;
KIRP	cis	rs17065868	1.000	rs9645990	chr13:45130934	G/A	cg10246903	chr13:45222710	NA	0.73	6.49	0.38	4.81e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9840812	0.598	rs1145101	chr3:136069286	T/C	cg15507776	chr3:136538369	TMEM22	0.48	5.14	0.31	5.7e-7	Fibrinogen levels;
KIRP	trans	rs587242	1.000	rs662450	chr1:96891547	C/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.88	0.35	1.32e-8	Multiple sclerosis;
KIRP	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.33	-0.32	2.27e-7	Bipolar disorder;
KIRP	cis	rs4660306	0.677	rs10493120	chr1:45903488	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.54	6.33	0.37	1.18e-9	Homocysteine levels;
KIRP	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg17507749	chr15:85114479	UBE2QP1	0.89	9.87	0.53	1.44e-19	Schizophrenia;
KIRP	cis	rs7903847	0.642	rs10882913	chr10:99141845	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.2	13.21	0.64	1.84e-30	Nonalcoholic fatty liver disease;
KIRP	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg09658497	chr7:2847517	GNA12	-0.38	-5.1	-0.31	6.69e-7	Height;
KIRP	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg04935436	chr20:30431758	NA	-0.49	-6.44	-0.38	6.31e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg25418670	chr11:30344373	C11orf46	-0.6	-5.02	-0.3	1e-6	Morning vs. evening chronotype;
KIRP	cis	rs2278796	0.697	rs2278798	chr1:204949767	A/G	cg04862289	chr1:204966208	NFASC	0.36	5.11	0.31	6.55e-7	Mean platelet volume;
KIRP	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg19847130	chr8:10466454	RP1L1	0.38	5.81	0.35	1.95e-8	Retinal vascular caliber;
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.98	0.36	7.89e-9	Lung cancer;
KIRP	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.69	10.51	0.56	1.39e-21	Height;
KIRP	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg08992911	chr2:238395768	MLPH	0.49	5.28	0.32	2.88e-7	Prostate cancer;
KIRP	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg01320579	chr17:75405842	SEPT9	0.46	7.58	0.44	7.12e-13	Airflow obstruction;
KIRP	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg10755058	chr3:40428713	ENTPD3	-0.4	-5.8	-0.35	2.03e-8	Renal cell carcinoma;
KIRP	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg01631408	chr1:248437212	OR2T33	-0.58	-7.98	-0.45	5.43e-14	Common traits (Other);
KIRP	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.7	10.02	0.54	4.86e-20	Lymphocyte counts;
KIRP	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.63	-0.44	5.02e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7246657	0.722	rs6508736	chr19:38061757	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.53	-6.8	-0.4	7.8e-11	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg11569703	chr11:65557185	OVOL1	0.36	5.72	0.34	3.1e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg19077165	chr18:44547161	KATNAL2	0.48	5.95	0.35	9.31e-9	Personality dimensions;
KIRP	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg26116260	chr4:7069785	GRPEL1	-0.81	-5.21	-0.32	3.99e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg02023728	chr11:77925099	USP35	0.36	5.58	0.33	6.46e-8	Alzheimer's disease (survival time);
KIRP	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg22916017	chr11:64110731	CCDC88B	0.55	6.25	0.37	1.78e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4908768	0.859	rs55802878	chr1:8666411	T/C	cg25722041	chr1:8623473	RERE	0.83	10.07	0.54	3.31e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs3741798	1.000	rs118108016	chr12:12482820	C/A	cg08615371	chr12:12503544	MANSC1	0.97	8.56	0.48	1.27e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.61	-0.39	2.41e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.81	11.42	0.59	1.65e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs17023223	0.537	rs56708249	chr1:119593205	C/G	cg05756136	chr1:119680316	WARS2	-0.56	-7.64	-0.44	4.86e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.53	7.11	0.41	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7909074	0.509	rs2183994	chr10:45389940	T/C	cg05187965	chr10:45406764	TMEM72	-0.24	-5.33	-0.32	2.26e-7	Mean corpuscular volume;
KIRP	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10019123	chr2:85792697	NA	0.49	6.17	0.37	2.81e-9	Interleukin-4 levels;
KIRP	cis	rs918629	0.530	rs17085249	chr5:95236415	C/T	cg16656078	chr5:95278638	ELL2	-0.38	-5.69	-0.34	3.54e-8	IgG glycosylation;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09131032	chr2:238969491	SCLY	0.47	6.41	0.38	7.18e-10	Cancer;
KIRP	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08439880	chr3:133502540	NA	0.49	6.27	0.37	1.57e-9	Iron status biomarkers;
KIRP	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg21926883	chr2:100939477	LONRF2	-0.59	-8.26	-0.47	9e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg23479056	chr15:41276147	INO80	0.35	4.94	0.3	1.47e-6	Menopause (age at onset);
KIRP	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.08	-0.67	2e-33	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18059449	chr4:106629662	INTS12;GSTCD	-0.4	-6.02	-0.36	6.36e-9	Warfarin maintenance dose;
KIRP	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21747090	chr2:27597821	SNX17	-0.49	-6.77	-0.4	9.54e-11	Total body bone mineral density;
KIRP	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg11945507	chr8:142233382	SLC45A4	-0.49	-6.6	-0.39	2.5e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg27411982	chr8:10470053	RP1L1	-0.54	-6.77	-0.4	9.6e-11	Neuroticism;
KIRP	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg14768367	chr16:72042858	DHODH	0.74	4.86	0.3	2.05e-6	LDL cholesterol levels;Total cholesterol levels;
KIRP	cis	rs524023	0.914	rs4930556	chr11:64377726	G/C	cg09231725	chr11:64357281	SLC22A12	0.61	8.01	0.45	4.6e-14	Urate levels in obese individuals;
KIRP	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg07661805	chr8:143867942	LY6D	-0.29	-5.08	-0.31	7.4e-7	Urinary tract infection frequency;
KIRP	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.75	-8.42	-0.47	3.2e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10875746	0.551	rs2054904	chr12:48724354	C/G	cg20731937	chr12:48336164	NA	0.45	5.51	0.33	8.94e-8	Longevity (90 years and older);
KIRP	cis	rs10875746	0.951	rs8804	chr12:48541757	A/G	cg20731937	chr12:48336164	NA	0.39	5.14	0.31	5.5e-7	Longevity (90 years and older);
KIRP	cis	rs8113308	0.810	rs8105110	chr19:52452116	C/T	cg24732339	chr19:52471368	ZNF350	-0.45	-5.05	-0.31	8.66e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.88	-10.29	-0.55	6.87e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.49e-6	Red blood cell count;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg17441377	chr17:3906640	NA	0.58	8.71	0.49	4.49e-16	Type 2 diabetes;
KIRP	trans	rs7939886	0.920	rs57730678	chr11:56005204	C/T	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.78	-9.49	-0.52	2.03e-18	Response to antipsychotic treatment;
KIRP	cis	rs6841333	0.857	rs13130917	chr4:76985365	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.48	-5.24	-0.32	3.42e-7	Monokine induced by gamma interferon levels;
KIRP	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.87	13.37	0.65	5.1e-31	Menarche (age at onset);
KIRP	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg03714773	chr7:91764589	CYP51A1	0.35	4.92	0.3	1.56e-6	Breast cancer;
KIRP	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg18944383	chr4:111397179	ENPEP	-0.38	-6.06	-0.36	4.99e-9	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17694069	chr10:75561490	KIAA0913	-0.42	-6.42	-0.38	7.05e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs7923609	1.000	rs10822149	chr10:64987412	G/A	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.61	-0.34	5.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.45	6.17	0.37	2.75e-9	Leprosy;
KIRP	cis	rs72634258	0.945	rs7517357	chr1:8025275	C/T	cg00042356	chr1:8021962	PARK7	0.92	7.39	0.43	2.24e-12	Inflammatory bowel disease;
KIRP	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg22617819	chr1:44378782	ST3GAL3	-0.33	-5.51	-0.33	9.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs300890	0.513	rs2323077	chr4:144152185	C/G	cg01719995	chr4:144104893	USP38	0.4	5.16	0.31	5.18e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs75920871	0.623	rs7930409	chr11:116958943	A/G	cg04087571	chr11:116723030	SIK3	-0.28	-5.62	-0.34	5.05e-8	Subjective well-being;
KIRP	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.48	-7.13	-0.41	1.09e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.62	8.28	0.47	8.01e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg20140201	chr2:241835670	C2orf54	-0.31	-4.94	-0.3	1.43e-6	Urinary metabolites;
KIRP	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.63	8.52	0.48	1.57e-15	Myopia (pathological);
KIRP	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-5.02	-0.3	1e-6	Schizophrenia;
KIRP	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19524238	chr7:2802976	GNA12	-0.39	-5.48	-0.33	1.07e-7	Height;
KIRP	cis	rs17428704	0.571	rs16903464	chr5:14395264	A/G	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs1443512	0.812	rs4759058	chr12:54339052	C/A	cg17410650	chr12:54324560	NA	-0.46	-5.91	-0.35	1.12e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg05484376	chr2:27715224	FNDC4	0.39	6.41	0.38	7.37e-10	Total body bone mineral density;
KIRP	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs10181042	0.514	rs1177289	chr2:61353256	T/C	cg15711740	chr2:61764176	XPO1	-0.48	-5.89	-0.35	1.25e-8	Crohn's disease;
KIRP	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg08283408	chr3:49949060	MON1A	0.42	5.56	0.33	7.19e-8	Body mass index;
KIRP	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.72	6.07	0.36	4.82e-9	Bipolar disorder;
KIRP	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.62	0.44	5.57e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg16586182	chr3:47516702	SCAP	-0.75	-10.78	-0.57	1.87e-22	Colorectal cancer;
KIRP	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg08975724	chr8:8085496	FLJ10661	0.78	10.2	0.55	1.29e-20	Systolic blood pressure;
KIRP	cis	rs9475752	0.793	rs6901944	chr6:56862805	A/G	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23598886	chr18:12777645	NA	-0.67	-5.03	-0.31	9.47e-7	Inflammatory skin disease;
KIRP	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg07044859	chr10:101282883	NA	-0.29	-5.07	-0.31	7.65e-7	Dental caries;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16400025	chr22:43045209	CYB5R3	0.49	6.02	0.36	6.27e-9	Parkinson's disease;
KIRP	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	0.95	14.83	0.69	5.65e-36	Breast cancer;
KIRP	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.63	-7.45	-0.43	1.61e-12	Menarche (age at onset);
KIRP	cis	rs2151522	0.762	rs35108222	chr6:127203865	G/A	cg21431617	chr6:127135037	NA	0.28	4.92	0.3	1.57e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.47	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg27462398	chr1:86174642	ZNHIT6	-0.46	-5.6	-0.34	5.77e-8	Urate levels in overweight individuals;
KIRP	cis	rs4919044	0.674	rs115089490	chr10:94793496	G/C	cg05127821	chr10:94822908	CYP26C1	-1.05	-10.78	-0.57	1.9e-22	Coronary artery disease;
KIRP	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg01557791	chr16:72042693	DHODH	-0.66	-7.26	-0.42	5.16e-12	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3105593	1.000	rs62017189	chr15:50922032	T/A	cg08437265	chr15:50716283	USP8	0.39	4.97	0.3	1.28e-6	QT interval;
KIRP	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02034447	chr16:89574710	SPG7	0.38	4.91	0.3	1.66e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg02023728	chr11:77925099	USP35	-0.33	-4.99	-0.3	1.14e-6	Alzheimer's disease (survival time);
KIRP	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.93	13.42	0.65	3.62e-31	Menopause (age at onset);
KIRP	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg03714773	chr7:91764589	CYP51A1	-0.39	-6.02	-0.36	6.35e-9	Breast cancer;
KIRP	cis	rs10073892	0.591	rs1349589	chr5:101647474	A/G	cg19774478	chr5:101632501	SLCO4C1	0.62	6.58	0.39	2.79e-10	Cognitive decline (age-related);
KIRP	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.52	-6.46	-0.38	5.64e-10	HDL cholesterol;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg24732702	chr12:3393810	TSPAN9	-0.37	-6.72	-0.39	1.29e-10	Bladder cancer;
KIRP	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg11895451	chr1:16533891	ARHGEF19	-0.41	-5.37	-0.32	1.84e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg11555438	chr13:111297484	CARS2	0.38	5.95	0.35	9.17e-9	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs10231759	0.583	rs4015632	chr7:150516826	A/G	cg05726600	chr7:150498594	TMEM176B;TMEM176A	0.38	5.17	0.31	4.92e-7	Height;
KIRP	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.36	0.38	9.65e-10	Breast cancer;
KIRP	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.73	-10.96	-0.57	4.93e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	8.09e-24	Menopause (age at onset);
KIRP	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.66	-10.35	-0.55	4.61e-21	Total body bone mineral density;
KIRP	cis	rs798766	1.000	rs2305188	chr4:1739592	A/G	cg07775547	chr4:1625484	NA	-0.45	-5.4	-0.33	1.55e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg01528321	chr10:82214614	TSPAN14	-0.44	-5.48	-0.33	1.06e-7	Diabetic kidney disease;
KIRP	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.63	-7.93	-0.45	7.58e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.78	-0.4	8.87e-11	Capecitabine sensitivity;
KIRP	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg17691542	chr6:26056736	HIST1H1C	-0.39	-4.87	-0.3	2.03e-6	Blood metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02636585	chr1:172543864	C1orf9	-0.47	-6.91	-0.4	4.19e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg17524265	chr8:144659883	NAPRT1	0.8	5.1	0.31	6.64e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.52	8.21	0.46	1.26e-14	Schizophrenia;
KIRP	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12049351	0.774	rs12033236	chr1:229640471	A/G	cg11742688	chr1:229674241	ABCB10	-0.37	-5.45	-0.33	1.2e-7	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.84	-0.53	1.76e-19	Height;
KIRP	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11987759	chr7:65425863	GUSB	0.57	7.58	0.44	6.93e-13	Aortic root size;
KIRP	cis	rs8179	0.593	rs17164683	chr7:92286980	C/T	cg15732164	chr7:92237376	CDK6	-0.42	-5.68	-0.34	3.82e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08280861	chr8:58055591	NA	0.71	5.87	0.35	1.41e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.65	8.43	0.47	2.86e-15	Alzheimer's disease;
KIRP	cis	rs6125597	0.935	rs6067034	chr20:47900164	G/A	cg03212862	chr20:47662828	CSE1L	-0.41	-5.29	-0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg18093559	chr17:18951025	GRAP	0.48	5.71	0.34	3.21e-8	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00933542	chr6:150070202	PCMT1	0.28	5.62	0.34	5.17e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19486585	chr2:109151054	NA	0.45	6.06	0.36	5.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.71	-11.0	-0.57	3.79e-23	Prostate cancer;
KIRP	cis	rs8177876	0.822	rs9925940	chr16:81110984	T/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.97	-0.36	8.23e-9	Renal cell carcinoma;
KIRP	cis	rs829661	1.000	rs2593457	chr2:30869144	G/A	cg10949345	chr2:30726833	LCLAT1	0.68	8.66	0.48	6.55e-16	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.67	-6.22	-0.37	2.09e-9	Menarche (age at onset);
KIRP	cis	rs10924309	1.000	rs10924309	chr1:245863222	A/G	cg00036263	chr1:245852353	KIF26B	0.47	6.24	0.37	1.86e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.51	6.37	0.38	9.11e-10	Menarche (age at onset);
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg04369109	chr6:150039330	LATS1	-0.47	-5.69	-0.34	3.66e-8	Lung cancer;
KIRP	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.57	-9.15	-0.5	2.31e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.91	-0.3	1.69e-6	Cognitive function;
KIRP	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-8.68	-0.48	5.68e-16	Retinal vascular caliber;
KIRP	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg04511125	chr2:88470314	THNSL2	0.74	6.4	0.38	7.61e-10	Plasma clusterin levels;
KIRP	cis	rs7187994	0.848	rs34179694	chr16:84776522	A/G	cg07647771	chr16:84786436	USP10	-0.42	-5.34	-0.32	2.07e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2290159	0.509	rs6763925	chr3:12515602	T/C	cg23032965	chr3:12705835	RAF1	0.47	5.39	0.32	1.66e-7	Cholesterol, total;
KIRP	cis	rs6009824	0.579	rs34296882	chr22:50098333	C/T	cg18178197	chr22:50098317	NA	0.85	9.88	0.53	1.28e-19	Natriuretic peptide levels;
KIRP	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.54	0.43	9.19e-13	Aortic root size;
KIRP	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.66	9.89	0.53	1.21e-19	Height;
KIRP	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.34	0.37	1.08e-9	Rheumatoid arthritis;
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg14221460	chr8:27183342	PTK2B	0.5	6.39	0.38	8.12e-10	Neuroticism;
KIRP	trans	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg10756647	chr7:56101905	PSPH	-0.94	-6.9	-0.4	4.35e-11	Diabetic kidney disease;
KIRP	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.02	11.36	0.59	2.46e-24	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7520050	0.966	rs10890383	chr1:46588503	A/G	cg24296786	chr1:45957014	TESK2	0.42	5.0	0.3	1.07e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs986417	0.901	rs3759688	chr14:60975579	A/C	cg27398547	chr14:60952738	C14orf39	0.67	5.72	0.34	3.02e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.38	0.47	4.15e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg18944383	chr4:111397179	ENPEP	0.54	9.67	0.52	5.74e-19	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12736359	chr6:126964499	NA	-0.41	-6.49	-0.38	4.71e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8079658	1.000	rs58176400	chr17:63816098	T/G	cg18091269	chr17:63822838	CCDC46	-0.56	-7.66	-0.44	4.32e-13	Post bronchodilator FEV1;
KIRP	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg00262122	chr8:11665843	FDFT1	0.4	5.07	0.31	7.81e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.71	-8.82	-0.49	2.22e-16	Blood pressure (smoking interaction);
KIRP	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-1.08	-11.61	-0.59	3.94e-25	Exhaled nitric oxide output;
KIRP	cis	rs2120243	0.539	rs1456108	chr3:157119054	A/G	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	7.19e-7	Bladder cancer;
KIRP	cis	rs6901004	0.803	rs354524	chr6:111508109	A/G	cg15721981	chr6:111408429	SLC16A10	0.47	6.02	0.36	6.42e-9	Blood metabolite levels;
KIRP	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg25866889	chr13:114914595	NA	-0.38	-5.29	-0.32	2.68e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16982658	chr22:20104937	RANBP1;TRMT2A	-0.44	-6.45	-0.38	5.73e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.7	-10.23	-0.55	1.1e-20	Multiple sclerosis;
KIRP	cis	rs9972944	0.756	rs4791133	chr17:63769118	T/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.16e-13	Total body bone mineral density;
KIRP	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg05044414	chr3:183734942	ABCC5	0.38	5.79	0.35	2.17e-8	Anterior chamber depth;
KIRP	cis	rs11638352	1.000	rs12900880	chr15:44339598	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.67	-5.24	-0.32	3.5e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7224685	0.569	rs35977026	chr17:4036528	G/A	cg09695851	chr17:3907499	NA	0.55	5.03	0.31	9.57e-7	Type 2 diabetes;
KIRP	trans	rs2055729	0.677	rs59880252	chr8:9741032	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	6.1	0.36	4.06e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6681460	0.899	rs502690	chr1:67182403	A/T	cg02459107	chr1:67143332	SGIP1	0.42	6.0	0.36	6.99e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg14675211	chr2:100938903	LONRF2	0.54	6.98	0.41	2.79e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg08662619	chr6:150070041	PCMT1	0.36	5.96	0.36	8.48e-9	Lung cancer;
KIRP	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.51	-6.03	-0.36	5.99e-9	White matter hyperintensity burden;
KIRP	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg14082893	chr15:75400931	NA	-0.34	-5.11	-0.31	6.59e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.37	-0.55	4e-21	Hemoglobin concentration;
KIRP	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg17764715	chr19:33622953	WDR88	-0.86	-12.67	-0.63	1.19e-28	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs12517041	1.000	rs35411935	chr5:23282784	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.48	6.24	0.37	1.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03646922	chr17:4167316	ANKFY1	-0.52	-7.12	-0.41	1.21e-11	Electrocardiographic conduction measures;
KIRP	cis	rs1359582	0.836	rs875050	chr10:90357105	A/C	cg15661332	chr10:90342814	RNLS	0.57	5.84	0.35	1.63e-8	Depressive and manic episodes in bipolar disorder;
KIRP	trans	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19894588	chr14:64061835	NA	0.5	6.72	0.39	1.26e-10	Glioblastoma;Glioma;
KIRP	cis	rs365132	0.715	rs181330	chr5:176404962	A/G	cg16309518	chr5:176445507	NA	-0.81	-12.38	-0.62	1.06e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg21854759	chr1:92012499	NA	-0.47	-6.05	-0.36	5.32e-9	Breast cancer;
KIRP	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg21926883	chr2:100939477	LONRF2	-0.55	-7.57	-0.43	7.49e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.45	-5.89	-0.35	1.29e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg14917874	chr2:235941519	SH3BP4	0.47	5.61	0.34	5.49e-8	Dialysis-related mortality;
KIRP	cis	rs7601312	0.869	rs7605420	chr2:229284010	C/G	cg02542817	chr2:229291442	NA	-0.56	-8.62	-0.48	8.52e-16	Schizophrenia;
KIRP	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg06521331	chr12:34319734	NA	-0.55	-6.97	-0.41	2.85e-11	Morning vs. evening chronotype;
KIRP	trans	rs12529514	1.000	rs74405933	chr6:14095755	G/A	cg02955631	chr11:119293601	THY1	-0.66	-6.16	-0.37	2.96e-9	Rheumatoid arthritis;
KIRP	cis	rs867371	1.000	rs867371	chr15:82438346	A/T	cg06066596	chr15:83166174	LOC80154	0.44	5.27	0.32	3e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.69	-9.53	-0.52	1.6e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.33e-13	Life satisfaction;
KIRP	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.49	-0.48	2.01e-15	Total cholesterol levels;
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.71	10.39	0.55	3.36e-21	Glycated hemoglobin levels;
KIRP	trans	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-7.05	-0.41	1.75e-11	Mean corpuscular volume;
KIRP	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg01097406	chr16:89675127	NA	-0.35	-5.53	-0.33	8.12e-8	Vitiligo;
KIRP	cis	rs6723108	0.846	rs998451	chr2:135429288	G/A	cg25422880	chr2:135218333	TMEM163	0.4	5.56	0.33	6.96e-8	Type 2 diabetes;
KIRP	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.71	-9.1	-0.5	3.28e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg15534755	chr11:117069859	TAGLN	-0.39	-5.01	-0.3	1.04e-6	Blood protein levels;
KIRP	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg08975724	chr8:8085496	FLJ10661	0.67	8.5	0.48	1.79e-15	Neuroticism;
KIRP	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg13978929	chr19:21580086	ZNF493	0.5	4.86	0.3	2.06e-6	Pain;
KIRP	cis	rs73200209	0.744	rs11615689	chr12:116699675	T/C	cg01776926	chr12:116560359	MED13L	-0.55	-6.03	-0.36	6.03e-9	Total body bone mineral density;
KIRP	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg22916017	chr11:64110731	CCDC88B	0.56	6.4	0.38	7.9e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.23	-0.37	2.02e-9	Type 2 diabetes;
KIRP	cis	rs963731	0.649	rs297153	chr2:39326835	C/G	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs7432375	0.579	rs10935199	chr3:136563535	G/C	cg15507776	chr3:136538369	TMEM22	0.44	5.6	0.34	5.79e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.4	5.01	0.3	1.06e-6	Blood protein levels;
KIRP	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.7	10.29	0.55	6.84e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.64	8.99	0.5	6.64e-17	Alcohol dependence;
KIRP	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.8e-7	Major depressive disorder;
KIRP	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.46e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg15117754	chr3:10150083	C3orf24	0.52	5.09	0.31	7.16e-7	Alzheimer's disease;
KIRP	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.46	-5.95	-0.35	9.28e-9	Age at first birth;
KIRP	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.74	9.05	0.5	4.33e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg25019722	chr6:37503610	NA	-0.89	-12.88	-0.63	2.31e-29	Cognitive performance;
KIRP	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs9473924	0.505	rs34793301	chr6:50859462	G/T	cg14470998	chr6:50812995	TFAP2B	1.01	9.02	0.5	5.43e-17	Body mass index;
KIRP	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.64	8.78	0.49	2.87e-16	High light scatter reticulocyte count;
KIRP	cis	rs75920871	0.843	rs17120111	chr11:116744018	C/T	cg23684410	chr11:116897558	SIK3	0.55	5.56	0.33	7.1e-8	Subjective well-being;
KIRP	cis	rs8038465	0.874	rs11072434	chr15:74002854	A/G	cg15420318	chr15:73925796	NPTN	-0.5	-6.29	-0.37	1.4e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7523273	1.000	rs7523273	chr1:207977083	A/G	cg22525895	chr1:207977042	MIR29B2	-0.68	-8.85	-0.49	1.7e-16	Schizophrenia;
KIRP	cis	rs236907	0.640	rs235875	chr1:171613756	A/G	cg01410279	chr1:171621941	MYOC	0.45	4.94	0.3	1.45e-6	Mean platelet volume;
KIRP	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-6.34	-0.37	1.11e-9	Schizophrenia;
KIRP	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26314531	chr2:26401878	FAM59B	-0.48	-4.99	-0.3	1.17e-6	Gut microbiome composition (summer);
KIRP	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-8.18	-0.46	1.48e-14	Morning vs. evening chronotype;
KIRP	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.93	-0.35	1.03e-8	Hip circumference adjusted for BMI;
KIRP	trans	rs933360	0.585	rs6946194	chr7:50839837	A/G	cg20003124	chr12:4557277	NA	0.54	6.65	0.39	1.87e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg12598211	chr12:123634384	NA	-0.44	-5.43	-0.33	1.38e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg07274523	chr3:49395745	GPX1	0.69	8.6	0.48	9.42e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.75	9.39	0.51	4.29e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	14.98	0.69	1.77e-36	Electrocardiographic conduction measures;
KIRP	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg26875233	chr11:93583750	C11orf90	0.36	6.63	0.39	2.07e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.42	-0.62	8.1e-28	Vitiligo;
KIRP	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.72	9.36	0.51	5.26e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg27189623	chr16:705930	WDR90	0.44	5.97	0.36	8.26e-9	Height;
KIRP	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.61	-9.57	-0.52	1.19e-18	Sense of smell;
KIRP	cis	rs4523957	0.553	rs2476355	chr17:2029559	A/G	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06505273	chr16:24850292	NA	0.42	5.46	0.33	1.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg14221460	chr8:27183342	PTK2B	0.54	7.06	0.41	1.69e-11	Neuroticism;
KIRP	cis	rs6545883	0.929	rs2592352	chr2:61665336	C/T	cg15711740	chr2:61764176	XPO1	-0.6	-8.0	-0.45	4.99e-14	Tuberculosis;
KIRP	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg22089800	chr15:90895588	ZNF774	0.45	5.28	0.32	2.87e-7	Rheumatoid arthritis;
KIRP	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.42	4.9	0.3	1.74e-6	Aortic root size;
KIRP	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg17366294	chr4:99064904	C4orf37	0.36	4.97	0.3	1.28e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.49	-6.36	-0.38	9.97e-10	Lung cancer;
KIRP	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.67	0.63	1.15e-28	Morning vs. evening chronotype;
KIRP	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.55	7.39	0.43	2.26e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg00405596	chr8:11794950	NA	-0.45	-5.43	-0.33	1.34e-7	Neuroticism;
KIRP	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.38	-0.43	2.39e-12	Morning vs. evening chronotype;
KIRP	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg23479056	chr15:41276147	INO80	-0.38	-5.54	-0.33	7.89e-8	Menopause (age at onset);
KIRP	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.71	7.18	0.42	8.11e-12	Vitiligo;
KIRP	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg09117114	chr16:67998030	SLC12A4	-0.48	-5.0	-0.3	1.09e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19671926	chr4:122722719	EXOSC9	0.5	6.01	0.36	6.5e-9	Type 2 diabetes;
KIRP	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg14703610	chr5:56206110	C5orf35	-0.51	-6.77	-0.4	9.65e-11	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.04	0.36	5.51e-9	Lung cancer;
KIRP	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	24.1	0.84	1.03e-66	Chronic sinus infection;
KIRP	cis	rs986417	0.818	rs1254325	chr14:60909689	A/G	cg27398547	chr14:60952738	C14orf39	-0.67	-6.8	-0.4	8.1e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs13185784	0.667	rs4309929	chr5:179650988	A/C	cg13944838	chr5:179740914	GFPT2	-0.47	-4.86	-0.3	2.08e-6	TRAIL levels;
KIRP	cis	rs12986413	0.789	rs12971884	chr19:2160259	G/T	cg09261902	chr19:2140048	AP3D1	0.44	5.3	0.32	2.63e-7	Height;
KIRP	cis	rs1134634	0.520	rs28528670	chr4:15592918	A/G	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.69	-0.34	3.55e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1555895	0.566	rs11253451	chr10:852885	C/T	cg10017260	chr10:834428	NA	-0.44	-6.26	-0.37	1.67e-9	Survival in rectal cancer;
KIRP	trans	rs12517041	0.873	rs10039144	chr5:23272483	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.64	-6.54	-0.38	3.46e-10	Calcium levels;
KIRP	cis	rs7188697	0.848	rs37062	chr16:58567238	A/G	cg21335942	chr16:58549945	SETD6	0.47	5.16	0.31	5e-7	QT interval;
KIRP	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg18032046	chr6:28092343	ZSCAN16	0.53	5.73	0.34	2.86e-8	Depression;
KIRP	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg18944383	chr4:111397179	ENPEP	0.52	9.2	0.51	1.64e-17	Height;
KIRP	cis	rs2274273	0.870	rs66696758	chr14:55766509	G/A	cg04306507	chr14:55594613	LGALS3	0.44	6.56	0.39	3.08e-10	Protein biomarker;
KIRP	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg09699651	chr6:150184138	LRP11	0.4	5.23	0.32	3.65e-7	Lung cancer;
KIRP	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg02887458	chr19:19495540	GATAD2A	-0.5	-5.95	-0.35	8.94e-9	Bipolar disorder;
KIRP	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg21775007	chr8:11205619	TDH	-0.5	-6.45	-0.38	5.95e-10	Systolic blood pressure;
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.49	-0.43	1.24e-12	Platelet count;
KIRP	cis	rs7712401	0.678	rs401535	chr5:122358685	A/G	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	1.01	10.92	0.57	6.89e-23	Height;
KIRP	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.65	-7.22	-0.42	6.39e-12	Recalcitrant atopic dermatitis;
KIRP	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg15704280	chr7:45808275	SEPT13	0.7	6.3	0.37	1.39e-9	Axial length;
KIRP	cis	rs35740288	0.822	rs2306225	chr15:86227952	A/G	cg10818794	chr15:86012489	AKAP13	-0.42	-4.98	-0.3	1.18e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	6.48	0.38	4.94e-10	Breast cancer;
KIRP	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26002218	chr14:103986227	CKB	0.35	7.21	0.42	6.7e-12	Body mass index;
KIRP	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.4	-5.39	-0.33	1.63e-7	Hypertriglyceridemia;
KIRP	cis	rs2290402	0.505	rs17165087	chr4:845841	C/T	cg14517359	chr4:903473	GAK	-0.55	-5.97	-0.36	8.07e-9	Type 2 diabetes;
KIRP	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg15556689	chr8:8085844	FLJ10661	0.65	8.32	0.47	6.05e-15	Retinal vascular caliber;
KIRP	cis	rs240764	0.559	rs9404049	chr6:101237129	C/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.09	-0.31	7.24e-7	Neuroticism;
KIRP	cis	rs526231	0.578	rs34794	chr5:102423368	T/A	cg23492399	chr5:102201601	PAM	-0.49	-5.41	-0.33	1.48e-7	Primary biliary cholangitis;
KIRP	cis	rs16976116	0.901	rs28478777	chr15:55512746	G/T	cg11288833	chr15:55489084	RSL24D1	0.55	5.59	0.34	5.94e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.47	7.7	0.44	3.27e-13	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24734643	chr22:39898247	SMCR7L	0.49	6.03	0.36	6.01e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.82	0.4	7.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-0.65	-7.66	-0.44	4.4e-13	Gestational age at birth (maternal effect);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg20024953	chr12:57584802	LRP1	0.43	6.07	0.36	4.7e-9	Serum protein levels (sST2);
KIRP	trans	rs1864585	0.520	rs17721089	chr8:10705438	C/T	cg26278703	chr11:58910052	FAM111A	0.62	6.29	0.37	1.44e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg13147721	chr7:65941812	NA	-1.0	-6.94	-0.4	3.42e-11	Diabetic kidney disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25516151	chr8:18413889	PSD3	0.47	6.87	0.4	5.19e-11	Survival in pancreatic cancer;
KIRP	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg12559939	chr2:27858050	GPN1	0.42	5.29	0.32	2.75e-7	Oral cavity cancer;
KIRP	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.18	12.61	0.63	1.83e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.75	12.04	0.61	1.46e-26	Vitiligo;
KIRP	cis	rs10518128	1.000	rs72867590	chr4:75706651	A/G	cg20122727	chr4:75719957	BTC	0.58	5.86	0.35	1.49e-8	Electroencephalogram traits;
KIRP	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.58	5.41	0.33	1.48e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg04935436	chr20:30431758	NA	-0.47	-6.58	-0.39	2.87e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg07116693	chr15:90310901	NA	0.23	4.96	0.3	1.31e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7546668	1.000	rs4233535	chr1:15845197	G/C	cg21858823	chr1:15850916	CASP9	0.46	5.13	0.31	5.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg24397884	chr7:158709396	WDR60	0.83	5.21	0.32	4.08e-7	Hippocampal volume;
KIRP	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.51	6.47	0.38	5.34e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg24375607	chr4:120327624	NA	0.58	6.64	0.39	1.98e-10	Corneal astigmatism;
KIRP	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.78	-9.99	-0.54	5.96e-20	Coronary artery disease;
KIRP	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.37	-5.39	-0.32	1.68e-7	Body mass index;
KIRP	cis	rs73206853	0.563	rs7301623	chr12:111170903	T/C	cg12870014	chr12:110450643	ANKRD13A	0.49	4.85	0.3	2.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.81	8.3	0.47	6.91e-15	Educational attainment;
KIRP	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg11584989	chr19:19387371	SF4	0.41	5.27	0.32	2.99e-7	Tonsillectomy;
KIRP	cis	rs988913	1.000	rs9475081	chr6:54813738	G/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.31	-0.32	2.43e-7	Menarche (age at onset);
KIRP	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.26e-9	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg12692727	chr7:1102344	C7orf50	0.48	5.12	0.31	6.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg08662619	chr6:150070041	PCMT1	0.37	6.21	0.37	2.24e-9	Lung cancer;
KIRP	cis	rs12282928	1.000	rs10769346	chr11:48336287	T/C	cg26585981	chr11:48327164	OR4S1	0.52	6.35	0.38	1.03e-9	Migraine - clinic-based;
KIRP	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.58	7.83	0.45	1.42e-13	Caffeine consumption;
KIRP	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.71	-10.46	-0.55	2.02e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg16141378	chr3:129829833	LOC729375	0.54	6.99	0.41	2.58e-11	Neuroticism;
KIRP	cis	rs76793172	1.000	rs10420834	chr19:46347542	G/T	cg00442267	chr19:46317840	RSPH6A	-0.71	-6.1	-0.36	4.03e-9	Eosinophil counts;
KIRP	cis	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.44	5.68	0.34	3.78e-8	Leprosy;
KIRP	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.16	0.31	4.98e-7	Neuroticism;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24842740	chr1:9973750	NA	0.45	6.29	0.37	1.47e-9	Warfarin maintenance dose;
KIRP	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg03315344	chr16:75512273	CHST6	-0.57	-5.46	-0.33	1.18e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg13770153	chr20:60521292	NA	-0.48	-5.76	-0.34	2.48e-8	Body mass index;
KIRP	cis	rs7119167	0.712	rs6592521	chr11:73056987	A/T	cg17517138	chr11:73019481	ARHGEF17	0.5	5.25	0.32	3.33e-7	Blood protein levels;
KIRP	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-5.56	-0.33	6.98e-8	Bipolar disorder;
KIRP	cis	rs9826463	0.702	rs73228762	chr3:142325220	A/C	cg20824294	chr3:142316082	PLS1	0.53	7.05	0.41	1.8e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.76	6.76	0.4	9.82e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16092018	chr15:40531352	PAK6	0.52	6.6	0.39	2.5e-10	Parkinson's disease;
KIRP	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg08999081	chr20:33150536	PIGU	0.46	4.93	0.3	1.54e-6	Protein C levels;
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	15.51	0.7	2.58e-38	Platelet count;
KIRP	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.44	5.8	0.35	2.03e-8	Blood metabolite levels;
KIRP	cis	rs10788264	0.518	rs1028632	chr10:124044657	C/G	cg09507567	chr10:124027408	NA	0.33	6.17	0.37	2.78e-9	Total body bone mineral density;
KIRP	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg22532475	chr10:104410764	TRIM8	-0.29	-5.02	-0.3	1e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-5.97	-0.36	8.17e-9	Height;
KIRP	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg09491104	chr22:46646882	C22orf40	-0.54	-5.86	-0.35	1.5e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.31	-0.32	2.4e-7	Headache;
KIRP	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	0.98	7.54	0.43	8.9e-13	Arsenic metabolism;
KIRP	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg13010199	chr12:38710504	ALG10B	0.45	5.85	0.35	1.56e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2274273	0.624	rs3783651	chr14:55850973	G/C	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.4e-7	Protein biomarker;
KIRP	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-4.96	-0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.62	6.77	0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.77	13.77	0.66	2.33e-32	Weight;
KIRP	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs35740288	0.571	rs11629608	chr15:86330124	C/G	cg20737812	chr15:86336631	KLHL25	-0.54	-6.92	-0.4	3.85e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg00319359	chr11:70116639	PPFIA1	0.67	6.5	0.38	4.44e-10	Coronary artery disease;
KIRP	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.61	7.47	0.43	1.36e-12	White blood cell count;
KIRP	trans	rs9650657	0.836	rs2898252	chr8:10604164	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.26	-0.37	1.68e-9	Neuroticism;
KIRP	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg02023728	chr11:77925099	USP35	0.32	5.15	0.31	5.27e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-0.66	-7.7	-0.44	3.38e-13	Initial pursuit acceleration;
KIRP	cis	rs2274273	0.588	rs9919932	chr14:55814080	A/G	cg04306507	chr14:55594613	LGALS3	0.39	5.32	0.32	2.35e-7	Protein biomarker;
KIRP	cis	rs533123	0.877	rs1042114	chr1:29138975	G/T	cg08366446	chr1:29138936	OPRD1	1.01	8.17	0.46	1.66e-14	Schizophrenia;
KIRP	trans	rs7246760	1.000	rs12462027	chr19:9926860	G/A	cg02900749	chr2:68251473	NA	-1.1	-9.28	-0.51	8.96e-18	Pursuit maintenance gain;
KIRP	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.91	14.33	0.67	2.95e-34	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19750657	chr13:38935967	UFM1	0.33	6.23	0.37	1.96e-9	Survival in pancreatic cancer;
KIRP	cis	rs6496667	0.779	rs7168898	chr15:90943065	G/A	cg10434728	chr15:90938212	IQGAP1	0.42	5.44	0.33	1.3e-7	Rheumatoid arthritis;
KIRP	cis	rs2617583	0.509	rs62331137	chr5:1459573	A/G	cg07151155	chr5:1473589	LPCAT1	-0.41	-5.08	-0.31	7.36e-7	Breast cancer;
KIRP	cis	rs9311676	0.656	rs59643048	chr3:58390248	A/G	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.95	-0.5	9.1e-17	Coronary artery disease;
KIRP	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg20933634	chr6:27740509	NA	0.36	4.88	0.3	1.87e-6	Parkinson's disease;
KIRP	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.39	-0.47	3.75e-15	Inflammatory bowel disease;
KIRP	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.45	6.29	0.37	1.42e-9	Dupuytren's disease;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.68	8.32	0.47	6.01e-15	Neutrophil percentage of white cells;
KIRP	cis	rs12230513	0.732	rs12582120	chr12:55830064	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs2274273	1.000	rs4644	chr14:55604935	C/A	cg04306507	chr14:55594613	LGALS3	0.47	7.1	0.41	1.36e-11	Protein biomarker;
KIRP	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs10861661	0.963	rs10861669	chr12:107200068	C/A	cg21360079	chr12:107162445	NA	-0.6	-6.49	-0.38	4.65e-10	Triglyceride levels;
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg19770292	chr5:1868693	NA	0.41	5.28	0.32	2.82e-7	Cardiovascular disease risk factors;
KIRP	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	0.84	7.39	0.43	2.33e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.71	-10.73	-0.56	2.8e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.37	-5.94	-0.35	9.77e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.87	-11.18	-0.58	1.01e-23	Parkinson's disease;
KIRP	cis	rs2411233	0.967	rs11070167	chr15:39288601	A/C	cg02291532	chr15:39874776	THBS1	0.42	5.65	0.34	4.4e-8	Platelet count;
KIRP	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.42e-11	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	trans	rs1928295	0.786	rs10983712	chr9:120368736	T/C	cg04204072	chr16:20752857	THUMPD1	-0.51	-6.27	-0.37	1.58e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6987853	0.787	rs2974358	chr8:42434403	T/C	cg09913449	chr8:42400586	C8orf40	0.39	5.3	0.32	2.58e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7709377	0.595	rs784481	chr5:115616830	C/T	cg23108291	chr5:115420582	COMMD10	-0.45	-5.57	-0.33	6.52e-8	Metabolite levels  (X-11787);
KIRP	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg18016565	chr1:150552671	MCL1	0.4	5.97	0.36	8.15e-9	Tonsillectomy;
KIRP	cis	rs754133	0.891	rs12426399	chr12:54419910	G/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.31	6.48	0.38	5.02e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
KIRP	cis	rs7116495	1.000	rs6592455	chr11:71689541	C/T	cg18441811	chr11:71824068	C11orf51	0.64	5.12	0.31	6.1e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.3	0.32	2.61e-7	Bipolar disorder;
KIRP	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	0.88	10.04	0.54	4.24e-20	Testicular germ cell tumor;
KIRP	cis	rs14403	0.913	rs12042298	chr1:243651806	C/T	cg21452805	chr1:244014465	NA	0.54	5.32	0.32	2.35e-7	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg13385521	chr17:29058706	SUZ12P	-0.59	-5.14	-0.31	5.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.62	-0.34	5.09e-8	Common traits (Other);
KIRP	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.42	5.43	0.33	1.37e-7	Childhood ear infection;
KIRP	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.56	5.06	0.31	8.24e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.73	-9.38	-0.51	4.44e-18	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12370248	chr3:48481622	CCDC51;CCDC72	0.52	6.52	0.38	3.98e-10	Parkinson's disease;
KIRP	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg14440974	chr22:39074834	NA	-0.38	-4.95	-0.3	1.4e-6	Menopause (age at onset);
KIRP	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.72	-10.14	-0.54	2.02e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg21518248	chr2:162101506	NA	-0.42	-4.9	-0.3	1.73e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs600806	0.676	rs573491	chr1:110026891	T/G	cg23032129	chr1:109941072	SORT1	0.29	5.14	0.31	5.56e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.75	-5.13	-0.31	5.77e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg01798813	chr17:3906674	NA	-0.54	-7.62	-0.44	5.52e-13	Type 2 diabetes;
KIRP	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg24315340	chr6:146058215	EPM2A	-0.39	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg08975724	chr8:8085496	FLJ10661	0.64	8.48	0.48	2.15e-15	Mood instability;
KIRP	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg17554472	chr22:41940697	POLR3H	-0.52	-5.97	-0.36	8.31e-9	Vitiligo;
KIRP	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15557168	chr22:42548783	NA	-0.45	-5.86	-0.35	1.44e-8	Cognitive function;
KIRP	cis	rs16976116	0.901	rs8027256	chr15:55492323	C/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.35	0.42	3.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg09455208	chr3:40491958	NA	-0.3	-5.27	-0.32	3.05e-7	Renal cell carcinoma;
KIRP	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06481639	chr22:41940642	POLR3H	0.66	6.72	0.39	1.24e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.31	-0.32	2.49e-7	Coronary artery disease;
KIRP	cis	rs4852324	0.536	rs17009553	chr2:74220035	A/G	cg20891558	chr2:74357851	NA	-0.64	-4.93	-0.3	1.54e-6	Systemic lupus erythematosus;
KIRP	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg24296786	chr1:45957014	TESK2	0.52	5.73	0.34	2.94e-8	Homocysteine levels;
KIRP	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg15448220	chr1:150897856	SETDB1	0.38	5.1	0.31	6.71e-7	Melanoma;
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg05941025	chr16:89927596	SPIRE2	-0.33	-5.17	-0.31	4.88e-7	Vitiligo;
KIRP	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.75	9.28	0.51	8.86e-18	Coronary artery disease;
KIRP	cis	rs8077577	0.747	rs62072509	chr17:18182393	G/A	cg18869244	chr17:18121946	NA	0.47	5.31	0.32	2.51e-7	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14021564	chr10:104169126	PSD	0.44	6.64	0.39	1.97e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg26441486	chr22:50317300	CRELD2	0.56	8.68	0.48	5.45e-16	Schizophrenia;
KIRP	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg23587288	chr2:27483067	SLC30A3	-0.67	-7.63	-0.44	5.03e-13	Blood metabolite levels;
KIRP	cis	rs6504950	0.800	rs7208123	chr17:53006339	G/A	cg26251398	chr17:52985966	TOM1L1	0.45	5.67	0.34	4.04e-8	Breast cancer;
KIRP	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.47	6.55	0.39	3.33e-10	Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	18.99	0.77	4.07e-50	Colorectal cancer;
KIRP	cis	rs12643440	0.504	rs16894581	chr4:17186933	A/G	cg22650099	chr4:17144496	NA	-0.68	-8.17	-0.46	1.64e-14	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg19077165	chr18:44547161	KATNAL2	0.46	5.69	0.34	3.6e-8	Personality dimensions;
KIRP	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg04306507	chr14:55594613	LGALS3	0.52	8.01	0.45	4.7e-14	Protein biomarker;
KIRP	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg01620082	chr3:125678407	NA	-1.13	-6.98	-0.41	2.76e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.71	-10.43	-0.55	2.57e-21	Blood metabolite levels;
KIRP	cis	rs7172677	0.737	rs7163083	chr15:75442337	A/C	cg03289416	chr15:75166202	SCAMP2	0.4	4.95	0.3	1.4e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.1e-23	Prudent dietary pattern;
KIRP	cis	rs548987	0.507	rs1408268	chr6:25826986	T/A	cg12310025	chr6:25882481	NA	-0.43	-5.04	-0.31	8.84e-7	Homocysteine levels;
KIRP	cis	rs290268	0.874	rs290990	chr9:93561695	A/G	cg02608019	chr9:93564028	SYK	-0.78	-11.28	-0.58	4.78e-24	Platelet count;
KIRP	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.76	10.36	0.55	4.04e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg01403660	chr11:68851641	TPCN2	0.66	6.36	0.38	9.63e-10	Blond vs. brown hair color;
KIRP	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg25902810	chr10:99078978	FRAT1	0.58	7.32	0.42	3.47e-12	Monocyte count;
KIRP	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.53	6.16	0.37	2.89e-9	Aortic root size;
KIRP	cis	rs2425143	0.908	rs75331436	chr20:34391052	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.08	-0.31	7.38e-7	Blood protein levels;
KIRP	cis	rs12580194	0.556	rs61249728	chr12:55728922	A/G	cg11794356	chr12:55725991	OR6C3	-0.62	-8.93	-0.49	1.02e-16	Cancer;
KIRP	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.72	7.46	0.43	1.48e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.6	9.78	0.53	2.79e-19	Obesity-related traits;
KIRP	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg10645314	chr2:3704589	ALLC	-0.4	-5.03	-0.31	9.45e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs8049040	0.502	rs35885273	chr16:71417783	C/T	cg08717414	chr16:71523259	ZNF19	-0.46	-5.44	-0.33	1.3e-7	Blood protein levels;
KIRP	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.56	0.48	1.23e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg19913688	chr11:428466	ANO9	0.76	5.99	0.36	7.39e-9	Body mass index;
KIRP	cis	rs1656402	1.000	rs1656400	chr2:233427783	A/G	cg03852847	chr2:233439513	NA	-0.58	-10.64	-0.56	5.3e-22	Non-small cell lung cancer (survival);
KIRP	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.4	0.33	1.54e-7	Type 2 diabetes;
KIRP	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg00405596	chr8:11794950	NA	0.59	8.41	0.47	3.31e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs656319	0.729	rs671370	chr8:9813317	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.3	-0.37	1.33e-9	Myopia (pathological);
KIRP	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.65	-8.68	-0.48	5.66e-16	Age at first birth;
KIRP	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.61	-0.52	9.31e-19	Hemoglobin concentration;
KIRP	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg05835009	chr4:710272	PCGF3	0.58	7.04	0.41	1.9e-11	White blood cell count;
KIRP	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.43	5.41	0.33	1.51e-7	Crohn's disease;
KIRP	cis	rs4805272	0.927	rs7251289	chr19:29332373	G/A	cg15000279	chr19:29285009	NA	0.37	5.46	0.33	1.19e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg12756093	chr1:115239321	AMPD1	0.52	7.01	0.41	2.34e-11	Autism;
KIRP	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg25866889	chr13:114914595	NA	-0.4	-5.6	-0.34	5.83e-8	Schizophrenia;
KIRP	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.64	-7.7	-0.44	3.35e-13	Aortic root size;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg11641102	chr8:27183873	PTK2B	0.43	5.7	0.34	3.37e-8	Neuroticism;
KIRP	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.57	5.02	0.3	9.89e-7	Skin colour saturation;
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg20578329	chr17:80767326	TBCD	-0.47	-6.03	-0.36	5.82e-9	Glycated hemoglobin levels;
KIRP	cis	rs16828019	0.852	rs11209531	chr1:41571021	C/T	cg08144172	chr1:41849203	NA	0.63	5.17	0.31	4.96e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs687432	0.924	rs12788836	chr11:57689210	G/A	cg19752551	chr11:57585705	CTNND1	-0.67	-8.43	-0.47	2.95e-15	Parkinson's disease;
KIRP	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg06611532	chr13:114900021	NA	0.22	5.06	0.31	8.19e-7	Schizophrenia;
KIRP	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg05991184	chr2:219186017	PNKD	-0.43	-6.26	-0.37	1.74e-9	Colorectal cancer;
KIRP	cis	rs17065868	1.000	rs9533907	chr13:45131721	G/C	cg10246903	chr13:45222710	NA	0.72	6.4	0.38	7.86e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.78	-12.08	-0.61	1.06e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9549328	0.800	rs9549620	chr13:113633421	T/A	cg17524180	chr13:113633600	MCF2L	-0.3	-5.44	-0.33	1.3e-7	Systolic blood pressure;
KIRP	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.62	7.81	0.45	1.68e-13	Type 2 diabetes;
KIRP	cis	rs6800768	0.663	rs62253424	chr3:24093919	C/A	cg10674438	chr3:24145617	LOC152024	-0.39	-5.45	-0.33	1.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg02030672	chr11:45687055	CHST1	0.56	6.94	0.4	3.45e-11	Obesity-related traits;
KIRP	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg12435725	chr3:58293450	RPP14	-0.5	-5.43	-0.33	1.36e-7	Cholesterol, total;
KIRP	trans	rs9784649	1.000	rs56205870	chr5:24958870	A/G	cg08600765	chr20:34638493	LOC647979	-0.66	-6.48	-0.38	5.03e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-1.05	-14.43	-0.68	1.27e-34	Body mass index;
KIRP	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg23477460	chr3:66848765	NA	0.63	7.72	0.44	2.85e-13	Type 2 diabetes;
KIRP	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15128208	chr22:42549153	NA	-0.41	-5.2	-0.31	4.28e-7	Cognitive function;
KIRP	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.77	-0.63	5.49e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.56	-7.57	-0.43	7.36e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.94	-6.96	-0.41	3.03e-11	IgG glycosylation;
KIRP	cis	rs76248362	0.541	rs9510848	chr13:24334969	A/C	cg03790740	chr13:24337521	MIPEP	0.49	5.83	0.35	1.76e-8	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg22322834	chr12:50135138	TMBIM6	0.97	6.15	0.37	3.13e-9	P wave terminal force;
KIRP	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.56	-0.65	1.18e-31	Monocyte count;
KIRP	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg21926883	chr2:100939477	LONRF2	-0.59	-8.64	-0.48	7.41e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.91	15.28	0.7	1.66e-37	Breast cancer;
KIRP	cis	rs5995756	0.736	rs9611204	chr22:40010383	G/A	cg10455938	chr22:40058150	CACNA1I	-0.56	-8.33	-0.47	5.89e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3748682	0.821	rs12025519	chr1:38252653	G/T	cg12658694	chr1:38397304	INPP5B	0.57	6.11	0.36	3.77e-9	Hypothyroidism;
KIRP	cis	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14085500	chr9:119460334	TRIM32;ASTN2	0.41	5.44	0.33	1.26e-7	Survival in pancreatic cancer;
KIRP	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg23422044	chr7:1970798	MAD1L1	0.58	5.85	0.35	1.59e-8	Bipolar disorder;
KIRP	cis	rs2239815	0.515	rs5762849	chr22:29238086	G/A	cg15103426	chr22:29168792	CCDC117	0.53	5.1	0.31	6.68e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg12532653	chr5:140090559	VTRNA1-1	0.39	5.17	0.31	4.92e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.32	-0.37	1.24e-9	Aortic root size;
KIRP	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg27205649	chr11:78285834	NARS2	0.69	9.1	0.5	3.17e-17	Alzheimer's disease (survival time);
KIRP	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	8.21	0.46	1.22e-14	Myopia (pathological);
KIRP	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11987759	chr7:65425863	GUSB	-0.49	-5.95	-0.35	9.3e-9	Aortic root size;
KIRP	cis	rs6142102	0.602	rs68051854	chr20:32701956	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	5.17	0.31	4.96e-7	Skin pigmentation;
KIRP	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.28	7.35	0.42	2.84e-12	Primary biliary cholangitis;
KIRP	cis	rs6142102	0.517	rs6059577	chr20:32527686	T/C	cg24642439	chr20:33292090	TP53INP2	0.46	5.34	0.32	2.12e-7	Skin pigmentation;
KIRP	cis	rs6496667	0.657	rs111556347	chr15:90858020	G/A	cg10434728	chr15:90938212	IQGAP1	0.39	5.33	0.32	2.23e-7	Rheumatoid arthritis;
KIRP	cis	rs42648	0.869	rs10251227	chr7:89892286	T/G	cg25739043	chr7:89950458	NA	-0.39	-5.68	-0.34	3.87e-8	Homocysteine levels;
KIRP	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	12.97	0.64	1.18e-29	Smoking behavior;
KIRP	cis	rs282587	0.502	rs375741	chr13:113397794	G/C	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.64e-12	Glycated hemoglobin levels;
KIRP	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg03808351	chr9:123631620	PHF19	-0.45	-6.26	-0.37	1.66e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs730775	0.505	rs325001	chr6:44270936	A/G	cg21130236	chr6:44246755	TMEM151B	0.42	6.17	0.37	2.83e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.84	-0.35	1.63e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.66	-6.57	-0.39	2.96e-10	Blood trace element (Zn levels);
KIRP	cis	rs7570971	0.792	rs56369224	chr2:136328890	A/T	cg07169764	chr2:136633963	MCM6	0.46	5.26	0.32	3.07e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg07701084	chr6:150067640	NUP43	0.57	7.23	0.42	6.13e-12	Testicular germ cell tumor;
KIRP	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	10.36	0.55	4.07e-21	Menopause (age at onset);
KIRP	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.13	-0.41	1.08e-11	Aortic root size;
KIRP	cis	rs4654899	0.772	rs12404954	chr1:21074727	A/G	cg05370193	chr1:21551575	ECE1	0.41	5.42	0.33	1.39e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg25174290	chr11:3078921	CARS	-0.69	-8.96	-0.5	8.26e-17	Calcium levels;
KIRP	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.66	-9.38	-0.51	4.69e-18	Retinal vascular caliber;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.97	16.8	0.73	1.07e-42	Menarche (age at onset);
KIRP	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.53	0.33	8.23e-8	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg18209359	chr17:80159595	CCDC57	-0.41	-5.26	-0.32	3.14e-7	Life satisfaction;
KIRP	cis	rs72627123	0.656	rs6574169	chr14:74637178	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.81	-5.03	-0.31	9.67e-7	Morning vs. evening chronotype;
KIRP	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.61	-0.34	5.55e-8	Electroencephalogram traits;
KIRP	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.79	10.65	0.56	5.06e-22	Platelet count;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06620762	chr15:76136437	UBE2Q2	0.68	6.43	0.38	6.76e-10	Lung function (FEV1);
KIRP	cis	rs17023223	0.537	rs10923754	chr1:119668640	T/C	cg05756136	chr1:119680316	WARS2	-0.59	-7.81	-0.45	1.63e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs28595532	0.925	rs10000445	chr4:119485311	C/T	cg11846333	chr4:119757529	SEC24D	0.96	5.72	0.34	3.04e-8	Cannabis dependence symptom count;
KIRP	cis	rs714027	0.967	rs193477	chr22:30451486	C/T	cg27665648	chr22:30112403	NA	-0.37	-5.22	-0.32	3.84e-7	Lymphocyte counts;
KIRP	cis	rs9513627	0.920	rs7320057	chr13:100155586	G/A	cg25919922	chr13:100150906	NA	0.67	5.28	0.32	2.9e-7	Obesity-related traits;
KIRP	cis	rs151997	0.962	rs27612	chr5:50179120	G/A	cg06027927	chr5:50259733	NA	0.6	7.49	0.43	1.24e-12	Callous-unemotional behaviour;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg22105103	chr4:187893119	NA	0.72	10.27	0.55	8.13e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10015142	chr19:41903169	EXOSC5;BCKDHA	-0.49	-6.24	-0.37	1.86e-9	Myopia;
KIRP	cis	rs61884328	0.866	rs17790156	chr11:46905318	A/T	cg23433285	chr11:47201945	PACSIN3	0.66	5.03	0.31	9.67e-7	Total body bone mineral density (age over 60);
KIRP	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.05	-0.41	1.77e-11	Neuroticism;
KIRP	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.51	-8.53	-0.48	1.54e-15	Pneumonia;
KIRP	cis	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg26585981	chr11:48327164	OR4S1	-0.43	-5.29	-0.32	2.74e-7	HDL cholesterol;
KIRP	cis	rs12752838	0.777	rs11121245	chr1:8916224	T/C	cg06972019	chr1:8937448	ENO1	-0.35	-5.01	-0.3	1.06e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs12049351	0.665	rs6663689	chr1:229630163	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.87	-0.35	1.42e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs4262150	0.810	rs17566118	chr5:152088546	C/T	cg12297329	chr5:152029980	NA	-0.65	-8.06	-0.46	3.3e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg19507638	chr5:93509721	C5orf36	-0.54	-5.08	-0.31	7.32e-7	Diabetic retinopathy;
KIRP	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.49	5.97	0.36	8.39e-9	Height;
KIRP	cis	rs959260	1.000	rs2053158	chr17:73393459	A/T	cg20590849	chr17:73267439	MIF4GD	0.59	6.57	0.39	3.04e-10	Systemic lupus erythematosus;
KIRP	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg27446573	chr6:127587934	RNF146	0.57	7.41	0.43	2.05e-12	Breast cancer;
KIRP	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-9.9	-0.53	1.14e-19	Breast cancer;
KIRP	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg08717414	chr16:71523259	ZNF19	-0.45	-4.85	-0.3	2.23e-6	Post bronchodilator FEV1;
KIRP	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.47	4.94	0.3	1.47e-6	Red blood cell count;
KIRP	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg09888468	chr15:81410853	NA	-0.47	-6.14	-0.36	3.37e-9	QT interval (drug interaction);
KIRP	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.68	-7.56	-0.43	8e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg03399598	chr4:174091002	GALNT7	0.57	6.82	0.4	6.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.68	0.48	5.49e-16	Motion sickness;
KIRP	cis	rs10214930	0.781	rs961723	chr7:27657973	G/A	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.67	9.32	0.51	6.68e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.17	0.42	8.85e-12	Mood instability;
KIRP	cis	rs6840360	0.547	rs9991859	chr4:152265572	T/C	cg25486957	chr4:152246857	NA	-0.47	-5.88	-0.35	1.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg09699651	chr6:150184138	LRP11	0.45	5.86	0.35	1.51e-8	Lung cancer;
KIRP	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.77	8.68	0.48	5.52e-16	Corneal astigmatism;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.72	-10.66	-0.56	4.78e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4786125	0.581	rs1473519	chr16:6921533	G/A	cg03623568	chr16:6915990	A2BP1	-0.41	-4.93	-0.3	1.54e-6	Heart rate variability traits (SDNN);
KIRP	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg09264619	chr17:80180166	NA	-0.52	-6.0	-0.36	6.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.39	-6.13	-0.36	3.52e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-0.41	-5.11	-0.31	6.43e-7	Type 2 diabetes;
KIRP	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.55	-7.46	-0.43	1.51e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg21775007	chr8:11205619	TDH	-0.43	-5.32	-0.32	2.3e-7	Triglycerides;
KIRP	cis	rs10114408	0.879	rs10821244	chr9:96638449	A/G	cg14598338	chr9:96623480	NA	-0.33	-4.85	-0.3	2.24e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08307369	chr7:128379382	CALU	0.44	6.15	0.37	3.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg11494091	chr17:61959527	GH2	-0.48	-6.04	-0.36	5.66e-9	Height;
KIRP	cis	rs7814319	0.700	rs7838479	chr8:97268077	G/A	cg20787634	chr8:97240163	UQCRB	-0.57	-7.57	-0.43	7.38e-13	Lung function (FVC);
KIRP	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg21545522	chr1:205238299	TMCC2	0.39	5.12	0.31	6.16e-7	Red blood cell count;
KIRP	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.68	8.71	0.49	4.52e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4789452	0.774	rs67129266	chr17:75381103	A/G	cg12985929	chr17:75370611	SEPT9	-0.36	-4.97	-0.3	1.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	0.51	6.43	0.38	6.67e-10	Myopia;
KIRP	cis	rs4478858	0.735	rs1566963	chr1:31772206	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.52	-0.33	8.44e-8	Alcohol dependence;
KIRP	cis	rs7394190	0.810	rs7394152	chr10:75421446	C/T	cg04833713	chr10:74871078	NUDT13	0.45	5.42	0.33	1.4e-7	Incident atrial fibrillation;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16639922	chr3:9975056	IL17RC;CRELD1	-0.58	-6.3	-0.37	1.39e-9	Menopause (age at onset);
KIRP	cis	rs10214930	0.813	rs2391446	chr7:27648920	C/T	cg22168087	chr7:27702803	HIBADH	0.51	5.09	0.31	7.04e-7	Hypospadias;
KIRP	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg13319975	chr6:146136371	FBXO30	0.48	6.92	0.4	3.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg08662619	chr6:150070041	PCMT1	0.38	6.2	0.37	2.33e-9	Lung cancer;
KIRP	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.04	0.36	5.67e-9	Depression;
KIRP	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg06917634	chr15:78832804	PSMA4	0.56	6.25	0.37	1.77e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg23173402	chr1:227635558	NA	0.88	6.74	0.39	1.15e-10	Major depressive disorder;
KIRP	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.51	-5.77	-0.35	2.34e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs17221829	0.703	rs11018682	chr11:89364451	A/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg06815112	chr8:27182871	PTK2B	0.52	6.62	0.39	2.29e-10	Neuroticism;
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg22907277	chr7:1156413	C7orf50	0.56	6.87	0.4	5.19e-11	Longevity;Endometriosis;
KIRP	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg02836325	chr17:76403955	PGS1	0.39	6.65	0.39	1.92e-10	HDL cholesterol levels;
KIRP	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg14228332	chr4:119757509	SEC24D	0.74	4.86	0.3	2.05e-6	Cannabis dependence symptom count;
KIRP	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.47	6.23	0.37	2.01e-9	Hypertriglyceridemia;
KIRP	cis	rs9392653	0.655	rs200852	chr6:5081745	A/G	cg13207534	chr6:5087447	PPP1R3G	-0.5	-6.03	-0.36	5.95e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.62	7.7	0.44	3.24e-13	P wave terminal force;
KIRP	cis	rs2908197	0.737	rs6465097	chr7:75972914	T/C	cg22830091	chr7:75961684	YWHAG	-0.39	-4.89	-0.3	1.78e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	8.59	0.48	1.04e-15	Menopause (age at onset);
KIRP	cis	rs2671245	0.933	rs1165486	chr1:56186258	C/T	cg11523071	chr1:56160889	NA	-0.32	-5.08	-0.31	7.32e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg08392591	chr16:89556376	ANKRD11	0.38	4.89	0.3	1.8e-6	Multiple myeloma (IgH translocation);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg00851146	chr20:36156184	BLCAP	-0.52	-6.91	-0.4	4.08e-11	Blood metabolite levels;
KIRP	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg26513180	chr16:89883248	FANCA	-0.4	-5.03	-0.31	9.61e-7	Vitiligo;
KIRP	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.28	-0.32	2.88e-7	Renal cell carcinoma;
KIRP	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16729016	chr1:213298061	RPS6KC1	0.58	8.42	0.47	3.14e-15	Survival in pancreatic cancer;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg24714147	chr19:14629240	DNAJB1	-0.48	-6.07	-0.36	4.81e-9	Blood metabolite levels;
KIRP	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21385522	chr1:16154831	NA	0.44	5.47	0.33	1.12e-7	Systolic blood pressure;
KIRP	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.74	-9.2	-0.51	1.55e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg19761014	chr17:28927070	LRRC37B2	0.61	6.19	0.37	2.53e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs231513	0.911	rs231511	chr17:41966335	T/C	cg26893861	chr17:41843967	DUSP3	-0.58	-5.06	-0.31	8.04e-7	Cognitive function;
KIRP	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg25486957	chr4:152246857	NA	-0.52	-5.69	-0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.8	9.68	0.53	5.48e-19	Corneal astigmatism;
KIRP	cis	rs3736485	0.609	rs11637716	chr15:51965186	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.03	-0.31	9.44e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6142102	0.961	rs4911393	chr20:32570926	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	6.79	0.4	8.12e-11	Skin pigmentation;
KIRP	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.52	5.46	0.33	1.16e-7	Tourette syndrome;
KIRP	cis	rs78487399	0.908	rs12471686	chr2:43831083	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.05	-0.31	8.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg24110177	chr3:50126178	RBM5	-0.62	-7.32	-0.42	3.53e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.56	-7.5	-0.43	1.12e-12	Mean corpuscular volume;
KIRP	cis	rs4666002	0.789	rs4616435	chr2:27933642	C/T	cg05484376	chr2:27715224	FNDC4	-0.48	-5.84	-0.35	1.63e-8	Phospholipid levels (plasma);
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-1.1	-21.38	-0.81	5.05e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.24	6.07	0.36	4.94e-9	Crohn's disease;
KIRP	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.88	9.85	0.53	1.64e-19	Gut microbiome composition (summer);
KIRP	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.55	-0.33	7.26e-8	Aortic root size;
KIRP	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg00800038	chr16:89945340	TCF25	-0.83	-6.23	-0.37	2.06e-9	Skin colour saturation;
KIRP	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.28	25.03	0.85	1.39e-69	IgG glycosylation;
KIRP	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.92	-15.96	-0.71	7.88e-40	Breast cancer;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg18209359	chr17:80159595	CCDC57	0.41	5.31	0.32	2.47e-7	Life satisfaction;
KIRP	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.09	-0.46	2.78e-14	Mood instability;
KIRP	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.48	-0.38	5e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17123764	0.786	rs60613973	chr12:50058261	G/T	cg20471783	chr12:50157085	TMBIM6	0.42	5.62	0.34	5.13e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-6.48	-0.38	5.01e-10	Schizophrenia;
KIRP	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.21	-0.37	2.26e-9	Daytime sleep phenotypes;
KIRP	cis	rs4474465	0.920	rs7944485	chr11:78225261	T/C	cg27205649	chr11:78285834	NARS2	0.74	8.87	0.49	1.5e-16	Alzheimer's disease (survival time);
KIRP	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg08968635	chr6:28129556	ZNF389	0.44	4.85	0.3	2.17e-6	Depression;
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.96	0.54	7.3e-20	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17553389	chr17:66243667	AMZ2	0.52	6.58	0.39	2.8e-10	Parkinson's disease;
KIRP	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.39	5.57	0.33	6.81e-8	Monocyte count;
KIRP	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00700412	chr12:58011837	NA	-0.35	-6.23	-0.37	1.98e-9	Multiple sclerosis;
KIRP	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.85	10.35	0.55	4.59e-21	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.42e-6	Life satisfaction;
KIRP	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.69	0.39	1.46e-10	Colorectal cancer;
KIRP	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-6.95	-0.4	3.31e-11	Colorectal cancer;
KIRP	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.37	-0.43	2.67e-12	Aortic root size;
KIRP	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg03465714	chr1:152285911	FLG	-0.41	-4.92	-0.3	1.57e-6	Atopic dermatitis;
KIRP	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	1.02	12.93	0.64	1.53e-29	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs13161895	1.000	rs17079966	chr5:179443190	G/T	cg02702477	chr5:179499311	RNF130	0.67	5.19	0.31	4.38e-7	LDL cholesterol;
KIRP	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-1.02	-19.76	-0.78	1.04e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10901296	0.660	rs11991	chr9:133762558	T/C	cg13397898	chr9:133768931	QRFP	0.34	5.85	0.35	1.53e-8	Bilirubin levels;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg23693289	chr8:27183097	PTK2B	0.58	7.41	0.43	1.98e-12	Neuroticism;
KIRP	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.84	0.45	1.39e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs7083	0.935	rs529470	chr11:117132808	A/G	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	6.6	0.39	2.54e-10	Breast cancer;
KIRP	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.35	-0.38	1.03e-9	Blood pressure;
KIRP	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg15557168	chr22:42548783	NA	-0.4	-5.63	-0.34	4.96e-8	Cognitive function;
KIRP	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-5.68	-0.34	3.77e-8	Colorectal cancer;
KIRP	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.53	0.43	9.41e-13	Mean corpuscular volume;
KIRP	trans	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.13	0.36	3.48e-9	Primary sclerosing cholangitis;
KIRP	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg15117754	chr3:10150083	C3orf24	0.49	4.96	0.3	1.3e-6	Alzheimer's disease;
KIRP	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.8	11.04	0.58	2.81e-23	Aortic root size;
KIRP	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg13514129	chr1:39547527	MACF1	0.54	7.76	0.44	2.29e-13	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.63	-0.34	4.82e-8	Life satisfaction;
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.41	-6.32	-0.37	1.2e-9	Lung cancer;
KIRP	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.27	14.24	0.67	5.85e-34	Uric acid levels;
KIRP	cis	rs17065868	1.000	rs9533890	chr13:45098674	C/G	cg10246903	chr13:45222710	NA	-0.72	-6.81	-0.4	7.51e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.8	10.26	0.55	8.79e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.44	-5.99	-0.36	7.45e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10177748	chr19:41770160	HNRNPUL1	-0.53	-6.13	-0.36	3.56e-9	Interleukin-4 levels;
KIRP	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg04935436	chr20:30431758	NA	0.49	6.44	0.38	6.31e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs12210905	1.000	rs12208534	chr6:27066759	A/T	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6959887	0.962	rs2024346	chr7:35297115	G/A	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.67	-8.57	-0.48	1.13e-15	Prudent dietary pattern;
KIRP	cis	rs520865	0.786	rs579492	chr5:80341456	C/T	cg17330048	chr5:80257322	RASGRF2	-0.46	-6.77	-0.4	9.45e-11	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15506890	chr2:3487001	NA	-0.52	-6.37	-0.38	9.4e-10	Neurofibrillary tangles;
KIRP	cis	rs151349	0.743	rs151353	chr20:57604343	A/C	cg23907860	chr20:57583709	CTSZ	-0.48	-6.57	-0.39	3.04e-10	Platelet distribution width;
KIRP	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.82	-10.41	-0.55	2.98e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs72781680	0.611	rs7596820	chr2:24335036	G/C	cg20701182	chr2:24300061	SF3B14	0.94	10.33	0.55	5.11e-21	Lymphocyte counts;
KIRP	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.54	0.38	3.53e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-10.68	-0.56	3.96e-22	Schizophrenia;
KIRP	cis	rs9393777	0.668	rs3800318	chr6:27263641	A/T	cg12292205	chr6:26970375	C6orf41	-0.46	-4.93	-0.3	1.53e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg13565492	chr6:43139072	SRF	-0.94	-8.66	-0.48	6.42e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11690462	0.963	rs17529423	chr2:26583506	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.41	4.88	0.3	1.89e-6	Coronary artery disease;
KIRP	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.55	6.87	0.4	5.33e-11	Resting heart rate;
KIRP	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg07862535	chr7:139043722	LUC7L2	0.48	5.41	0.33	1.46e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs600806	0.778	rs491285	chr1:110019002	C/T	cg02175308	chr1:109941060	SORT1	0.27	4.94	0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7760949	0.925	rs9464420	chr6:13925892	C/T	cg27413430	chr6:13925136	RNF182	0.56	6.58	0.39	2.78e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg26681399	chr22:41777847	TEF	-0.5	-5.16	-0.31	5.07e-7	Vitiligo;
KIRP	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg02569458	chr12:86230093	RASSF9	0.36	5.27	0.32	3.03e-7	Major depressive disorder;
KIRP	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12976411	0.575	rs59290294	chr19:32827336	T/C	cg02282382	chr19:32836354	ZNF507	0.66	5.51	0.33	9.23e-8	Coronary artery disease;
KIRP	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg22029157	chr1:209979665	IRF6	0.58	7.06	0.41	1.73e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs698833	0.798	rs4953082	chr2:44524064	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.35	0.32	2.03e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs57338032	0.891	rs79944246	chr15:78770418	A/G	cg06917634	chr15:78832804	PSMA4	0.65	5.45	0.33	1.25e-7	CTACK levels;
KIRP	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg22117172	chr7:91764530	CYP51A1	-0.4	-5.13	-0.31	5.96e-7	Breast cancer;
KIRP	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.37	-5.39	-0.32	1.65e-7	Temporomandibular joint disorder;
KIRP	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.59	0.34	6.03e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg07884673	chr3:53033167	SFMBT1	0.73	5.86	0.35	1.5e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.8	10.71	0.56	3.11e-22	Osteoporosis;
KIRP	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.73e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs17592366	0.540	rs7145614	chr14:35290846	C/T	cg09327582	chr14:35236912	BAZ1A	-0.54	-5.84	-0.35	1.62e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg03183215	chr10:1252341	ADARB2	-0.71	-9.71	-0.53	4.3e-19	Migraine;
KIRP	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg17691542	chr6:26056736	HIST1H1C	0.5	6.47	0.38	5.32e-10	Height;
KIRP	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.55	0.33	7.32e-8	Lung cancer;
KIRP	cis	rs4919044	0.562	rs79873247	chr10:94622388	A/C	cg05127821	chr10:94822908	CYP26C1	-0.89	-7.08	-0.41	1.47e-11	Coronary artery disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13683282	chr1:40723560	ZMPSTE24	-0.45	-6.07	-0.36	4.78e-9	Metabolic traits;
KIRP	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg18016565	chr1:150552671	MCL1	0.39	5.97	0.36	8.16e-9	Melanoma;
KIRP	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg02527881	chr3:46936655	PTH1R	-0.35	-4.89	-0.3	1.81e-6	Colorectal cancer;
KIRP	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.74	11.25	0.58	5.74e-24	Oral cavity cancer;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15176678	chr19:10230499	EIF3G	0.51	6.34	0.37	1.12e-9	Parkinson's disease;
KIRP	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15369054	chr17:80825471	TBCD	0.54	5.0	0.3	1.08e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg05555928	chr11:63887634	MACROD1	0.49	5.09	0.31	7.17e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6723108	0.515	rs1942049	chr2:135574368	G/A	cg12500956	chr2:135428796	TMEM163	0.43	5.41	0.33	1.51e-7	Type 2 diabetes;
KIRP	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-8.63	-0.48	7.6e-16	Personality dimensions;
KIRP	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.25	-0.32	3.36e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg10223061	chr2:219282414	VIL1	0.31	5.15	0.31	5.32e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg06565975	chr8:143823917	SLURP1	0.43	6.26	0.37	1.67e-9	Urinary tract infection frequency;
KIRP	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.6	-6.77	-0.4	9.43e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	trans	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg03060546	chr3:49711283	APEH	-0.63	-6.31	-0.37	1.28e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.3	7.98	0.45	5.67e-14	Crohn's disease;
KIRP	cis	rs4666002	0.871	rs10208529	chr2:27786188	A/T	cg05484376	chr2:27715224	FNDC4	-0.37	-5.49	-0.33	1e-7	Phospholipid levels (plasma);
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.79	-14.76	-0.69	9.62e-36	Lymphocyte counts;
KIRP	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs2299587	0.553	rs2299580	chr8:17734567	C/A	cg01800426	chr8:17659068	MTUS1	-0.42	-4.99	-0.3	1.17e-6	Economic and political preferences;
KIRP	cis	rs10875746	0.669	rs11168510	chr12:48685555	A/G	cg20731937	chr12:48336164	NA	0.49	5.94	0.35	9.58e-9	Longevity (90 years and older);
KIRP	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg06917634	chr15:78832804	PSMA4	0.57	6.15	0.37	3.06e-9	Sudden cardiac arrest;
KIRP	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.05	0.61	1.42e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.75	-8.47	-0.48	2.24e-15	Tonsillectomy;
KIRP	cis	rs73206853	0.698	rs59574270	chr12:111112098	A/C	cg12870014	chr12:110450643	ANKRD13A	0.51	4.94	0.3	1.42e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.27	-0.37	1.59e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17102069	chr6:37139542	PIM1	0.47	6.34	0.37	1.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24564603	chr7:158456404	NCAPG2	0.41	4.95	0.3	1.4e-6	Height;
KIRP	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.54	-5.77	-0.35	2.43e-8	Subjective well-being;
KIRP	trans	rs972578	0.791	rs5759003	chr22:43264851	T/C	cg15321293	chr3:36422198	STAC	-0.49	-6.35	-0.38	1.05e-9	Mean platelet volume;
KIRP	cis	rs5753037	0.564	rs131298	chr22:30180001	C/T	cg01021169	chr22:30184971	ASCC2	0.49	7.02	0.41	2.1e-11	Type 1 diabetes;
KIRP	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.19	0.42	7.95e-12	Prudent dietary pattern;
KIRP	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg10578777	chr12:7781093	NA	0.56	5.66	0.34	4.17e-8	HDL cholesterol levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20910303	chr4:147443095	SLC10A7	-0.46	-6.13	-0.36	3.39e-9	Survival in pancreatic cancer;
KIRP	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-23.41	-0.83	1.51e-64	Myeloid white cell count;
KIRP	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg20891283	chr12:69753455	YEATS4	0.62	6.49	0.38	4.64e-10	Response to diuretic therapy;
KIRP	cis	rs6466055	0.556	rs12533348	chr7:105024595	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.1	0.31	6.89e-7	Schizophrenia;
KIRP	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.81	-11.7	-0.6	1.96e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.7	0.44	3.3e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.73	8.26	0.47	8.9e-15	Corneal astigmatism;
KIRP	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24229701	chr12:130821962	PIWIL1	0.43	5.53	0.33	8e-8	Menopause (age at onset);
KIRP	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.82	0.53	2.11e-19	Pulse pressure;
KIRP	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.47	4.2e-15	Motion sickness;
KIRP	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	5.02e-11	Blood metabolite levels;
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg17178900	chr1:205818956	PM20D1	0.61	8.06	0.46	3.31e-14	Monocyte percentage of white cells;
KIRP	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.61	-0.52	8.92e-19	Response to antipsychotic treatment;
KIRP	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.59	-6.64	-0.39	2.01e-10	Coronary artery disease;
KIRP	cis	rs11227306	0.934	rs2234458	chr11:65639374	C/T	cg00576331	chr11:65640516	EFEMP2	0.55	7.45	0.43	1.59e-12	DNA methylation (variation);
KIRP	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg04369109	chr6:150039330	LATS1	-0.47	-4.91	-0.3	1.69e-6	Lung cancer;
KIRP	cis	rs6466055	0.589	rs6963395	chr7:104721374	T/C	cg04380332	chr7:105027541	SRPK2	-0.4	-5.48	-0.33	1.03e-7	Schizophrenia;
KIRP	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.55	7.39	0.43	2.25e-12	Mean corpuscular volume;
KIRP	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.57	-6.53	-0.38	3.75e-10	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-6.3	-0.37	1.37e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg26876637	chr1:152193138	HRNR	0.72	9.79	0.53	2.59e-19	Atopic dermatitis;
KIRP	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg08975724	chr8:8085496	FLJ10661	0.54	7.15	0.41	9.77e-12	Retinal vascular caliber;
KIRP	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg12292205	chr6:26970375	C6orf41	0.43	6.35	0.38	1.03e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg26398791	chr1:38455867	SF3A3	-0.41	-5.06	-0.31	8.13e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13686307	chr2:232651122	COPS7B	0.53	6.53	0.38	3.8e-10	Parkinson's disease;
KIRP	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.16	-0.46	1.71e-14	Vitiligo;
KIRP	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.1	-19.49	-0.78	8.54e-52	Colorectal cancer;
KIRP	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg09788416	chr12:39539408	NA	0.4	5.31	0.32	2.46e-7	Morning vs. evening chronotype;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.71	11.45	0.59	1.27e-24	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs78487399	0.710	rs78314405	chr2:43604741	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.04	-0.31	9.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.56	-6.17	-0.37	2.86e-9	Subjective well-being;
KIRP	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg21775007	chr8:11205619	TDH	-0.51	-6.49	-0.38	4.67e-10	Joint mobility (Beighton score);
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11987759	chr7:65425863	GUSB	0.69	9.65	0.52	7.05e-19	Aortic root size;
KIRP	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06173319	chr16:90148775	NA	-0.51	-5.37	-0.32	1.78e-7	Skin colour saturation;
KIRP	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.68	-0.34	3.71e-8	Multiple sclerosis;
KIRP	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.27e-11	Diabetic kidney disease;
KIRP	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg03171003	chr2:111875934	NA	0.44	6.29	0.37	1.46e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg04780086	chr2:111875790	ACOXL	0.43	6.04	0.36	5.78e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.41	-5.39	-0.32	1.67e-7	Blood protein levels;
KIRP	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.72	-0.34	3.07e-8	Height;
KIRP	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg16586182	chr3:47516702	SCAP	-0.83	-11.89	-0.6	4.6e-26	Colorectal cancer;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12982744	0.613	rs1859953	chr19:2145450	C/T	cg09261902	chr19:2140048	AP3D1	-0.43	-5.64	-0.34	4.78e-8	Osteoarthritis;Height;
KIRP	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.74	-0.39	1.14e-10	Morning vs. evening chronotype;
KIRP	cis	rs73200209	0.744	rs55837280	chr12:116645483	A/G	cg01776926	chr12:116560359	MED13L	-0.56	-6.24	-0.37	1.91e-9	Total body bone mineral density;
KIRP	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg08603382	chr10:743973	NA	0.46	6.66	0.39	1.78e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs259282	0.524	rs3760941	chr19:33130866	T/C	cg07862575	chr19:33878938	PEPD	-0.45	-5.01	-0.3	1.03e-6	Schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg12740577	chr2:86371316	IMMT	0.46	6.4	0.38	7.59e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4478037	0.558	rs72854780	chr3:33072557	C/T	cg19404215	chr3:33155277	CRTAP	0.83	5.29	0.32	2.69e-7	Major depressive disorder;
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg13206674	chr6:150067644	NUP43	0.53	7.44	0.43	1.72e-12	Lung cancer;
KIRP	cis	rs28595532	0.545	rs55699931	chr4:119249835	G/A	cg21605333	chr4:119757512	SEC24D	0.69	5.81	0.35	1.96e-8	Cannabis dependence symptom count;
KIRP	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.49	-6.03	-0.36	5.83e-9	Rheumatoid arthritis;
KIRP	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg24851858	chr13:114927579	NA	0.41	4.92	0.3	1.6e-6	Schizophrenia;
KIRP	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg16953067	chr3:9005230	RAD18	-0.57	-7.55	-0.43	8.55e-13	Morning vs. evening chronotype;
KIRP	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.29e-11	Type 2 diabetes;
KIRP	cis	rs12936587	0.536	rs8075153	chr17:17622666	C/T	cg01246520	chr17:17644344	RAI1	-0.48	-8.43	-0.47	3e-15	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	9.7	0.53	4.79e-19	Ileal carcinoids;
KIRP	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.43	-6.49	-0.38	4.62e-10	Major depressive disorder;
KIRP	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg01620082	chr3:125678407	NA	-1.25	-7.73	-0.44	2.8e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.43	5.61	0.34	5.34e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg16988262	chr1:15930761	NA	0.4	5.11	0.31	6.32e-7	Systolic blood pressure;
KIRP	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.32e-10	Aortic root size;
KIRP	cis	rs1971762	0.545	rs876252	chr12:54071422	A/G	cg16917193	chr12:54089295	NA	0.94	17.34	0.74	1.54e-44	Height;
KIRP	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.33	5.44	0.33	1.28e-7	Monocyte count;
KIRP	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.72	6.57	0.39	2.92e-10	Type 2 diabetes nephropathy;
KIRP	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.54	0.56	1.09e-21	Cognitive test performance;
KIRP	cis	rs4356932	1.000	rs12502834	chr4:76980499	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs3829109	0.502	rs4320648	chr9:139294271	G/A	cg21253087	chr9:139290292	SNAPC4	0.52	6.05	0.36	5.39e-9	Peak insulin response;Acute insulin response;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03313666	chr22:38142162	TRIOBP	-0.61	-6.93	-0.4	3.62e-11	Menopause (age at onset);
KIRP	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg02153584	chr22:29168773	CCDC117	-0.47	-6.23	-0.37	2e-9	Red cell distribution width;
KIRP	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg18867708	chr6:26865862	GUSBL1	0.46	5.73	0.34	2.85e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12826209	chr6:26865740	GUSBL1	0.7	6.57	0.39	2.98e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg06307176	chr5:131281290	NA	-0.59	-6.53	-0.38	3.71e-10	Life satisfaction;
KIRP	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs3120667	0.790	rs11205001	chr1:152395948	T/C	cg26876637	chr1:152193138	HRNR	-0.52	-6.15	-0.37	3.05e-9	Eating disorders;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08125682	chr16:11038455	CLEC16A	0.47	6.38	0.38	8.79e-10	Parkinson's disease;
KIRP	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2380205	0.967	rs4330991	chr10:5898180	A/C	cg27141509	chr10:5886111	NA	-0.39	-5.61	-0.34	5.31e-8	Breast cancer;
KIRP	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.75	-10.27	-0.55	7.76e-21	Personality dimensions;
KIRP	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg17691542	chr6:26056736	HIST1H1C	0.42	5.65	0.34	4.45e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg19274270	chr17:78178856	CARD14	0.36	6.54	0.38	3.49e-10	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg22117172	chr7:91764530	CYP51A1	0.39	5.37	0.32	1.83e-7	Breast cancer;
KIRP	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.82	9.76	0.53	3.16e-19	Pulmonary function decline;
KIRP	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.36e-11	Arsenic metabolism;
KIRP	cis	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg19743168	chr1:23544995	NA	-0.58	-7.72	-0.44	2.87e-13	Height;
KIRP	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.62	6.81	0.4	7.47e-11	Vitiligo;
KIRP	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.5	6.52	0.38	4.01e-10	Coronary artery disease;
KIRP	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.57	-6.17	-0.37	2.72e-9	Aortic root size;
KIRP	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg08901578	chr4:187885870	NA	-0.45	-6.79	-0.4	8.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.28	5.74	0.34	2.83e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	9.05	0.5	4.57e-17	Cognitive test performance;
KIRP	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg07414643	chr4:187882934	NA	0.37	5.1	0.31	6.95e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	17.22	0.74	3.75e-44	Platelet count;
KIRP	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.29	0.37	1.41e-9	Leprosy;
KIRP	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.51	-5.89	-0.35	1.26e-8	Renal function-related traits (BUN);
KIRP	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.23e-9	Breast cancer;
KIRP	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg08662619	chr6:150070041	PCMT1	0.34	5.41	0.33	1.47e-7	Lung cancer;
KIRP	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg18944383	chr4:111397179	ENPEP	0.39	6.35	0.38	1.05e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.43	0.38	6.53e-10	Breast cancer;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs7428	0.847	rs1969260	chr2:85568810	C/T	cg24342717	chr2:85555507	TGOLN2	-0.52	-6.28	-0.37	1.49e-9	Ear protrusion;
KIRP	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg17133734	chr15:86042851	AKAP13	-0.44	-5.49	-0.33	1.01e-7	Coronary artery disease;
KIRP	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	6.82	0.4	6.89e-11	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.37	-6.18	-0.37	2.58e-9	Colorectal or endometrial cancer;
KIRP	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg25036284	chr2:26402008	FAM59B	-0.6	-6.0	-0.36	7.17e-9	Gut microbiome composition (summer);
KIRP	cis	rs412050	0.744	rs735244	chr22:22292099	C/T	cg17089214	chr22:22089827	YPEL1	0.54	4.94	0.3	1.48e-6	Attention deficit hyperactivity disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06322403	chr11:70963994	NA	0.4	6.33	0.37	1.15e-9	Smoking initiation;
KIRP	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.42	-5.29	-0.32	2.69e-7	Testicular germ cell tumor;
KIRP	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	9.9	0.53	1.18e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg14703610	chr5:56206110	C5orf35	0.43	6.07	0.36	4.91e-9	Coronary artery disease;
KIRP	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg16926213	chr1:1841314	NA	0.33	5.51	0.33	9.24e-8	Body mass index;
KIRP	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.82	-10.15	-0.54	1.95e-20	Menarche (age at onset);
KIRP	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.43	5.49	0.33	9.75e-8	Melanoma;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15998773	chr1:15987116	RSC1A1	0.51	6.25	0.37	1.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg19000871	chr14:103996768	TRMT61A	-0.54	-5.83	-0.35	1.73e-8	Reticulocyte count;
KIRP	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.87	-13.0	-0.64	8.91e-30	Systemic sclerosis;
KIRP	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.93	-0.35	1.04e-8	Coronary artery disease;
KIRP	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg04310649	chr10:35416472	CREM	-0.59	-6.94	-0.4	3.39e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs997295	1.000	rs997295	chr15:68016343	G/T	cg24579218	chr15:68104479	NA	0.37	5.61	0.34	5.54e-8	Motion sickness;
KIRP	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.55	-0.43	8.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.83	-0.4	6.8e-11	Aortic root size;
KIRP	cis	rs4523957	0.890	rs9900379	chr17:2101134	G/A	cg16513277	chr17:2031491	SMG6	-0.69	-9.77	-0.53	3e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.13	0.64	3.44e-30	Exhaled nitric oxide output;
KIRP	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.47	7.2	0.42	7.46e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6859018	1.000	rs3212219	chr5:158754461	C/A	cg26646896	chr5:158686746	NA	-0.34	-4.95	-0.3	1.39e-6	Serum sulfate level;
KIRP	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg17366294	chr4:99064904	C4orf37	-0.37	-5.16	-0.31	5.05e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27286337	chr10:134555280	INPP5A	0.77	8.69	0.48	5.29e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg22029157	chr1:209979665	IRF6	0.38	5.89	0.35	1.26e-8	Monobrow;
KIRP	cis	rs13161895	1.000	rs34603792	chr5:179459287	A/G	cg02702477	chr5:179499311	RNF130	0.72	5.56	0.33	7.07e-8	LDL cholesterol;
KIRP	cis	rs17036350	1	rs17036350	chr1:11171226	C/T	cg18435880	chr1:11160013	EXOSC10	0.85	5.68	0.34	3.78e-8	Corneal curvature;
KIRP	cis	rs10029851	0.738	rs1436507	chr4:109630997	T/C	cg16525761	chr4:109541525	LOC285456;RPL34	-0.5	-5.48	-0.33	1.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.16e-51	Leprosy;
KIRP	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg00745463	chr17:30367425	LRRC37B	-1.12	-8.99	-0.5	6.63e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	22.53	0.82	9.97e-62	Chronic sinus infection;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.32	0.47	6.21e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg25182066	chr10:30743637	MAP3K8	-0.59	-7.33	-0.42	3.34e-12	Inflammatory bowel disease;
KIRP	cis	rs9311676	0.656	rs11130634	chr3:58379123	A/C	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00300879	chr1:26503847	CNKSR1	-0.47	-6.74	-0.4	1.09e-10	Height;
KIRP	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.88	0.4	5e-11	Lung cancer;
KIRP	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.76	-8.59	-0.48	9.98e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs17767294	0.541	rs72845044	chr6:27572479	G/A	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.42e-7	Parkinson's disease;
KIRP	cis	rs7404928	0.507	rs114556512	chr16:23888311	G/A	cg21745164	chr16:23765304	CHP2	-0.46	-5.97	-0.36	8.11e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs1971762	0.527	rs6580952	chr12:53937452	C/T	cg16917193	chr12:54089295	NA	0.66	10.86	0.57	1.05e-22	Height;
KIRP	cis	rs3741151	0.686	rs7938391	chr11:73221957	A/G	cg17517138	chr11:73019481	ARHGEF17	0.6	5.3	0.32	2.62e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg13332499	chr17:408570	NA	0.59	8.12	0.46	2.19e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs10924309	0.889	rs10802246	chr1:245858493	T/G	cg00036263	chr1:245852353	KIF26B	-0.51	-6.78	-0.4	8.99e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.65	8.33	0.47	5.62e-15	Colorectal cancer;
KIRP	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs7903847	0.544	rs61861865	chr10:99144867	C/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg12598211	chr12:123634384	NA	0.4	4.91	0.3	1.64e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.44	9.17	0.5	2.02e-17	Vitiligo;
KIRP	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18252515	chr7:66147081	NA	0.46	5.63	0.34	4.85e-8	Aortic root size;
KIRP	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.37	0.43	2.58e-12	Major depressive disorder;
KIRP	cis	rs4478037	0.749	rs9681623	chr3:33131375	G/T	cg19404215	chr3:33155277	CRTAP	0.54	5.53	0.33	8.32e-8	Major depressive disorder;
KIRP	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.49	6.55	0.39	3.42e-10	Hemoglobin concentration;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.92	-15.11	-0.69	6.2e-37	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13071306	chr1:6314113	GPR153	0.46	6.19	0.37	2.48e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.54	0.33	7.89e-8	Lung cancer;
KIRP	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg17133734	chr15:86042851	AKAP13	-0.44	-5.4	-0.33	1.57e-7	Coronary artery disease;
KIRP	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-15.16	-0.69	4.11e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.48	-6.65	-0.39	1.88e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.35e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.22	-0.32	3.76e-7	Dilated cardiomyopathy;
KIRP	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg18190219	chr22:46762943	CELSR1	-0.93	-7.24	-0.42	5.87e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Parkinson's disease;
KIRP	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg14972814	chr11:95582409	MTMR2	0.35	5.56	0.33	7.04e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg00383909	chr3:49044727	WDR6	0.59	5.97	0.36	8.21e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg00543991	chr22:32367038	NA	0.54	5.36	0.32	1.92e-7	Childhood ear infection;
KIRP	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.5	-0.52	1.95e-18	Colorectal cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10363549	chr4:91701954	FAM190A	0.47	6.69	0.39	1.47e-10	Interleukin-4 levels;
KIRP	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	8.46	0.47	2.37e-15	Ileal carcinoids;
KIRP	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.29	27.98	0.87	2.06e-78	IgG glycosylation;
KIRP	cis	rs6681460	0.932	rs618093	chr1:67178428	T/G	cg02459107	chr1:67143332	SGIP1	0.4	5.72	0.34	3.08e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.78	10.82	0.57	1.43e-22	Blood protein levels;
KIRP	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.25	-0.37	1.76e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.51	-8.55	-0.48	1.33e-15	Rheumatoid arthritis;
KIRP	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.29	6.03	0.36	6.03e-9	Body mass index;
KIRP	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg05362011	chr13:21860987	NA	-0.46	-5.01	-0.3	1.06e-6	White matter hyperintensity burden;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg21734707	chr17:3908241	ZZEF1	0.62	9.33	0.51	6.47e-18	Type 2 diabetes;
KIRP	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg22916017	chr11:64110731	CCDC88B	0.5	5.7	0.34	3.4e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.71	7.43	0.43	1.76e-12	Corneal astigmatism;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20486294	chr6:143266300	HIVEP2	-0.59	-6.41	-0.38	7.42e-10	Menopause (age at onset);
KIRP	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.51	-7.24	-0.42	5.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg15848620	chr12:58087721	OS9	-0.49	-5.7	-0.34	3.49e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4654899	1.000	rs12133780	chr1:21270808	G/A	cg05370193	chr1:21551575	ECE1	0.45	6.23	0.37	1.99e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg17554472	chr22:41940697	POLR3H	-0.54	-5.95	-0.35	9.04e-9	Vitiligo;
KIRP	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg15117754	chr3:10150083	C3orf24	0.62	5.09	0.31	7.01e-7	Alzheimer's disease;
KIRP	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg18944383	chr4:111397179	ENPEP	-0.53	-6.29	-0.37	1.43e-9	Axial length;
KIRP	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg12856521	chr11:46389249	DGKZ	0.5	6.89	0.4	4.7e-11	Leprosy;
KIRP	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs6142102	0.961	rs6059596	chr20:32557119	C/T	cg24642439	chr20:33292090	TP53INP2	0.58	6.45	0.38	5.82e-10	Skin pigmentation;
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01283332	chr5:1856932	NA	-0.51	-6.61	-0.39	2.41e-10	Cardiovascular disease risk factors;
KIRP	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.62	-0.44	5.5e-13	Height;
KIRP	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-7.84	-0.45	1.36e-13	Personality dimensions;
KIRP	cis	rs28595532	0.557	rs13435618	chr4:119308814	C/T	cg21605333	chr4:119757512	SEC24D	0.55	5.76	0.34	2.53e-8	Cannabis dependence symptom count;
KIRP	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg20628663	chr10:43360327	NA	0.54	6.22	0.37	2.14e-9	Blood protein levels;
KIRP	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.52	0.52	1.72e-18	Coffee consumption (cups per day);
KIRP	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.47	6.15	0.37	3.08e-9	High light scatter reticulocyte count;
KIRP	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs1569175	0.655	rs166847	chr2:200840612	A/G	cg17644776	chr2:200775616	C2orf69	-0.64	-4.88	-0.3	1.9e-6	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg18461021	chr18:74961002	GALR1	0.51	5.21	0.32	4.08e-7	Obesity-related traits;
KIRP	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg08885076	chr2:99613938	TSGA10	0.48	8.21	0.46	1.27e-14	Chronic sinus infection;
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg11814155	chr7:99998594	ZCWPW1	0.58	5.41	0.33	1.53e-7	Platelet count;
KIRP	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.58	6.75	0.4	1.03e-10	Height;
KIRP	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.55	-6.37	-0.38	9.25e-10	Systemic lupus erythematosus;
KIRP	trans	rs1864729	1.000	rs2635162	chr8:98283629	C/T	cg08679828	chr8:102218111	ZNF706	-0.68	-6.2	-0.37	2.4e-9	Estradiol plasma levels (breast cancer);
KIRP	cis	rs12643440	0.569	rs10018430	chr4:17145778	C/T	cg22650099	chr4:17144496	NA	0.35	4.92	0.3	1.61e-6	Metabolite levels (Pyroglutamine);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13395698	chr11:74146974	NA	0.48	6.35	0.38	1.04e-9	Interleukin-4 levels;
KIRP	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.48	6.73	0.39	1.21e-10	Personality dimensions;
KIRP	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-7.44	-0.43	1.71e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14346362	chr20:5918840	TRMT6	0.45	6.08	0.36	4.45e-9	Interleukin-4 levels;
KIRP	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.62	-6.99	-0.41	2.62e-11	Migraine;
KIRP	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-5.93	-0.35	1.02e-8	Lung cancer;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg04197313	chr15:67547198	IQCH;AAGAB	-0.48	-6.69	-0.39	1.53e-10	Morning vs. evening chronotype;
KIRP	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg05315796	chr3:52349193	DNAH1	0.37	5.2	0.31	4.29e-7	Schizophrenia;
KIRP	cis	rs16828019	0.852	rs34386859	chr1:41564024	C/T	cg24596898	chr1:41849189	NA	0.62	5.18	0.31	4.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg05347473	chr6:146136440	FBXO30	0.61	8.62	0.48	8.4e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.83	11.56	0.59	5.58e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.59	0.44	6.54e-13	Migraine;Coronary artery disease;
KIRP	cis	rs17092148	1.000	rs2378260	chr20:33374897	G/A	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.6	-0.34	5.78e-8	Neuroticism;
KIRP	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.76	10.97	0.57	4.71e-23	Mood instability;
KIRP	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg06618935	chr21:46677482	NA	-0.43	-5.42	-0.33	1.45e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.7	-8.39	-0.47	3.94e-15	Obesity-related traits;
KIRP	trans	rs982100	1.000	rs2551683	chr2:118415682	C/T	cg09538006	chr2:3337909	TSSC1	0.68	6.44	0.38	6.12e-10	Alzheimer disease and age of onset;
KIRP	cis	rs737693	0.607	rs586701	chr11:102724730	T/G	cg19620758	chr11:102826565	MMP13	0.54	5.65	0.34	4.34e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.55	8.03	0.46	4.16e-14	Reticulocyte fraction of red cells;
KIRP	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs7429990	0.864	rs6777081	chr3:48155569	T/C	cg11946769	chr3:48343235	NME6	-0.52	-5.94	-0.35	9.81e-9	Educational attainment (years of education);
KIRP	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.37	-5.07	-0.31	7.99e-7	Total body bone mineral density;
KIRP	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg11502198	chr6:26597334	ABT1	0.53	6.66	0.39	1.82e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1971762	0.762	rs7976793	chr12:54073069	G/T	cg16917193	chr12:54089295	NA	0.69	9.55	0.52	1.43e-18	Height;
KIRP	trans	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-6.9	-0.4	4.4e-11	Neuroticism;
KIRP	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.99	-0.45	5.32e-14	Monocyte percentage of white cells;
KIRP	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg00647317	chr7:50633725	DDC	-0.43	-5.71	-0.34	3.22e-8	Malaria;
KIRP	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg12131826	chr15:77904385	NA	0.47	6.33	0.37	1.13e-9	Type 2 diabetes;
KIRP	cis	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs11628318	0.614	rs8013886	chr14:103117389	A/G	cg01864069	chr14:103024347	NA	0.42	5.16	0.31	5.03e-7	Platelet count;
KIRP	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.48	6.31	0.37	1.32e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.96	10.92	0.57	6.86e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs8060686	0.920	rs112894876	chr16:67812039	G/C	cg04539111	chr16:67997858	SLC12A4	-0.6	-5.98	-0.36	7.69e-9	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-0.96	-9.46	-0.52	2.63e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.83	-12.72	-0.63	7.88e-29	Height;
KIRP	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg00507259	chr4:95128692	SMARCAD1	0.41	5.24	0.32	3.37e-7	QT interval;
KIRP	cis	rs737693	0.564	rs72983568	chr11:102773998	T/G	cg14995062	chr11:102826570	MMP13	0.61	5.76	0.34	2.52e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs78487399	0.808	rs6731980	chr2:43703183	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.02	-0.3	9.94e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.51	0.48	1.71e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.64	9.4	0.51	3.93e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg02487422	chr3:49467188	NICN1	0.36	5.05	0.31	8.43e-7	Parkinson's disease;
KIRP	cis	rs6681460	0.966	rs1325261	chr1:67110516	G/A	cg02459107	chr1:67143332	SGIP1	0.47	6.57	0.39	2.94e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.23	0.58	6.56e-24	Alzheimer's disease;
KIRP	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg19901468	chr14:105411992	AHNAK2	-0.77	-11.91	-0.6	4.11e-26	Rheumatoid arthritis;
KIRP	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.22	-0.46	1.2e-14	Monocyte percentage of white cells;
KIRP	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	6.26	0.37	1.67e-9	Myopia (pathological);
KIRP	cis	rs5747327	1.000	rs5747327	chr22:18169212	T/G	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.04	-0.31	9.17e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.74	-0.53	3.55e-19	Response to antipsychotic treatment;
KIRP	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.48	-6.3	-0.37	1.34e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg20069020	chr7:108166782	PNPLA8	-0.54	-6.74	-0.39	1.13e-10	Brain structure;
KIRP	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg11130432	chr3:121712080	ILDR1	-0.46	-5.42	-0.33	1.42e-7	Multiple sclerosis;
KIRP	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.43	5.54	0.33	7.66e-8	Aortic root size;
KIRP	cis	rs13401104	0.716	rs10929176	chr2:237129131	G/A	cg19324714	chr2:237145437	ASB18	0.52	5.44	0.33	1.3e-7	Educational attainment;
KIRP	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.42	-6.05	-0.36	5.48e-9	Height;
KIRP	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.58	7.09	0.41	1.42e-11	Tonsillectomy;
KIRP	cis	rs2275565	0.872	rs72762132	chr1:237056713	C/A	cg17297354	chr1:237056641	MTR	-0.47	-5.02	-0.31	9.69e-7	Homocysteine levels;
KIRP	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg17554472	chr22:41940697	POLR3H	-0.61	-6.53	-0.38	3.74e-10	Vitiligo;
KIRP	cis	rs4654899	0.643	rs12123092	chr1:21067001	A/G	cg08890418	chr1:21044141	KIF17	-0.32	-4.9	-0.3	1.74e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg08499158	chr17:42289980	UBTF	-0.71	-9.64	-0.52	7.5e-19	Total body bone mineral density;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.59	-7.52	-0.43	1.03e-12	Sudden cardiac arrest;
KIRP	cis	rs143699489	1	rs143699489	chr3:140927121	A/G	cg16418163	chr3:140950828	ACPL2	0.59	6.05	0.36	5.43e-9	White blood cell count;Granulocyte count;Sum neutrophil eosinophil counts;
KIRP	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	0.96	17.21	0.74	4.03e-44	Dental caries;
KIRP	cis	rs6728642	0.908	rs9973669	chr2:97679094	T/C	cg26665480	chr2:98280029	ACTR1B	-0.57	-5.23	-0.32	3.65e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs4466137	0.868	rs6866067	chr5:83022369	A/G	cg16102102	chr5:83017553	HAPLN1	-0.82	-10.74	-0.56	2.66e-22	Prostate cancer;
KIRP	cis	rs7551222	0.716	rs4951083	chr1:204582730	A/G	cg20240347	chr1:204465584	NA	-0.3	-5.13	-0.31	5.86e-7	Schizophrenia;
KIRP	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg13798780	chr7:105162888	PUS7	0.66	6.09	0.36	4.31e-9	Bipolar disorder (body mass index interaction);
KIRP	trans	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.52	6.1	0.36	4.14e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9986765	1.000	rs73452567	chr7:142816043	T/G	cg11323483	chr7:142828068	PIP	-0.64	-5.47	-0.33	1.09e-7	Cancer;Dermatomyositis;
KIRP	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-7.43	-0.43	1.83e-12	Bladder cancer;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg10503236	chr1:231470652	EXOC8	0.53	7.0	0.41	2.42e-11	Red blood cell count;
KIRP	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.68	-0.34	3.74e-8	Response to antipsychotic treatment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25394572	chr11:56457777	OR8U8	-0.48	-6.91	-0.4	4.21e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg08132940	chr7:1081526	C7orf50	-0.62	-6.28	-0.37	1.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.73	-9.16	-0.5	2.04e-17	Multiple sclerosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01685689	chr11:126081170	FAM118B;RPUSD4	0.58	6.78	0.4	8.89e-11	Smoking initiation;
KIRP	cis	rs6748734	0.543	rs73012754	chr2:241754034	G/A	cg04034577	chr2:241836375	C2orf54	0.31	5.24	0.32	3.52e-7	Urinary metabolites;
KIRP	trans	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg10756647	chr7:56101905	PSPH	-0.97	-7.05	-0.41	1.76e-11	Diabetic kidney disease;
KIRP	cis	rs10875746	0.903	rs10875740	chr12:48489117	C/T	cg20731937	chr12:48336164	NA	0.41	5.25	0.32	3.23e-7	Longevity (90 years and older);
KIRP	cis	rs9488822	0.662	rs580396	chr6:116263181	T/C	cg26893134	chr6:116381904	FRK	-0.19	-5.14	-0.31	5.72e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.7	-9.53	-0.52	1.62e-18	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05000123	chr14:20937394	PNP	0.53	6.63	0.39	2.12e-10	Smoking initiation;
KIRP	cis	rs17123764	0.892	rs60126713	chr12:50115676	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.47	0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg22312127	chr12:132628967	NOC4L;DDX51	0.58	6.97	0.41	2.92e-11	Myopia (pathological);
KIRP	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.59	7.74	0.44	2.61e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15309264	chr2:58274034	VRK2	0.62	7.53	0.43	9.75e-13	Smoking initiation;
KIRP	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-0.65	-5.73	-0.34	2.96e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-9.18	-0.51	1.77e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.61	-9.0	-0.5	6.44e-17	Menopause (age at onset);
KIRP	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg06742321	chr12:123595122	PITPNM2	-0.44	-5.41	-0.33	1.49e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7106204	0.686	rs12803558	chr11:24288205	C/A	ch.11.24196551F	chr11:24239977	NA	0.72	5.61	0.34	5.3e-8	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-0.77	-7.06	-0.41	1.72e-11	Developmental language disorder (linguistic errors);
KIRP	trans	rs7246760	1.000	rs73014068	chr19:9922783	T/C	cg02900749	chr2:68251473	NA	-1.1	-9.28	-0.51	8.96e-18	Pursuit maintenance gain;
KIRP	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.48	-4.91	-0.3	1.65e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.49	-5.98	-0.36	7.61e-9	Iron status biomarkers;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg23698023	chr8:27181813	PTK2B	0.33	5.03	0.31	9.45e-7	Neuroticism;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.8e-7	Life satisfaction;
KIRP	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.47	-5.65	-0.34	4.32e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.47	5.51	0.33	9.11e-8	Neurofibrillary tangles;
KIRP	trans	rs3800131	0.805	rs2325721	chr6:1958286	G/C	cg17165055	chr3:192584827	C3orf59	0.46	6.11	0.36	3.92e-9	Obesity-related traits;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12233208	chr19:47729796	BBC3	0.41	6.03	0.36	6.02e-9	Cancer;
KIRP	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg13010199	chr12:38710504	ALG10B	0.51	6.46	0.38	5.52e-10	Resting heart rate;
KIRP	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg04002187	chr5:40835754	RPL37	0.79	5.82	0.35	1.84e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs904251	0.620	rs883372	chr6:37477605	A/C	cg25019722	chr6:37503610	NA	-0.72	-7.16	-0.42	9.4e-12	Cognitive performance;
KIRP	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.51	-7.38	-0.43	2.5e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg21395723	chr22:39101663	GTPBP1	0.39	5.19	0.31	4.43e-7	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	9.05	0.5	4.35e-17	Personality dimensions;
KIRP	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	7.39	0.43	2.35e-12	Neuroticism;
KIRP	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-5.02	-0.3	9.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.68	9.05	0.5	4.53e-17	Coronary artery disease;
KIRP	cis	rs888194	0.577	rs10850435	chr12:110033270	G/C	cg05360138	chr12:110035743	NA	0.46	5.66	0.34	4.18e-8	Neuroticism;
KIRP	trans	rs7631394	0.857	rs11922577	chr3:23990241	A/G	cg09947844	chr16:4163819	ADCY9	0.49	6.04	0.36	5.58e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.7	-7.64	-0.44	4.88e-13	DNA methylation (variation);
KIRP	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4971059	0.654	rs4971073	chr1:155113104	G/T	cg02153340	chr1:155202674	NA	-0.38	-5.17	-0.31	4.74e-7	Breast cancer;
KIRP	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.51	-0.52	1.79e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg10017260	chr10:834428	NA	-0.52	-5.37	-0.32	1.8e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17341955	chr3:43662933	ANO10	-0.55	-6.62	-0.39	2.25e-10	Interleukin-4 levels;
KIRP	cis	rs80130819	0.515	rs7315258	chr12:48572670	T/C	cg26205652	chr12:48591994	NA	0.5	5.8	0.35	1.98e-8	Prostate cancer;
KIRP	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg00647317	chr7:50633725	DDC	0.43	5.69	0.34	3.52e-8	Malaria;
KIRP	cis	rs72829446	0.530	rs4796430	chr17:7401903	A/G	cg02795151	chr17:7402630	POLR2A	0.77	8.07	0.46	3.15e-14	Androgen levels;
KIRP	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	1.03	10.57	0.56	9.02e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.88	-11.74	-0.6	1.42e-25	Prostate cancer;
KIRP	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg14132834	chr19:41945861	ATP5SL	0.57	7.8	0.45	1.77e-13	Height;
KIRP	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.28	0.67	4.17e-34	Platelet count;
KIRP	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.44	-0.43	1.63e-12	Mood instability;
KIRP	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.39	0.47	3.81e-15	Mood instability;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-6.76	-0.4	9.98e-11	Longevity;Endometriosis;
KIRP	cis	rs6681460	0.932	rs523188	chr1:67174422	A/G	cg02459107	chr1:67143332	SGIP1	0.43	6.15	0.37	3.11e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs2033908	0.620	rs7113256	chr11:12845849	T/C	cg25843174	chr11:12811716	TEAD1	-0.29	-5.47	-0.33	1.1e-7	Sitting height ratio;
KIRP	cis	rs7688540	0.609	rs78896226	chr4:232533	C/T	cg17891759	chr4:299121	NA	-0.47	-4.85	-0.3	2.24e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg06740227	chr12:86229804	RASSF9	0.47	6.0	0.36	7.18e-9	Major depressive disorder;
KIRP	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.6	7.83	0.45	1.46e-13	White matter hyperintensity burden;
KIRP	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.24	26.08	0.86	8.75e-73	IgG glycosylation;
KIRP	cis	rs16828019	0.852	rs35190461	chr1:41543135	T/C	cg18742814	chr1:41828276	NA	0.61	5.55	0.33	7.25e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.82	9.79	0.53	2.5e-19	Multiple sclerosis;
KIRP	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.75	6.89	0.4	4.58e-11	Mean platelet volume;
KIRP	cis	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg02972257	chr16:68554789	NA	-0.53	-5.65	-0.34	4.32e-8	Ulcerative colitis;
KIRP	trans	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg01620082	chr3:125678407	NA	-1.29	-7.68	-0.44	3.71e-13	Depression;
KIRP	cis	rs520865	0.786	rs580004	chr5:80348469	A/G	cg17330048	chr5:80257322	RASGRF2	-0.45	-6.45	-0.38	6.03e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg19761014	chr17:28927070	LRRC37B2	0.67	4.91	0.3	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.29	-0.32	2.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.69	9.42	0.51	3.51e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs2346160	0.831	rs1467391	chr6:167690062	A/G	cg04673565	chr6:167680447	NA	-0.39	-4.95	-0.3	1.35e-6	Parental extreme longevity (95 years and older);
KIRP	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg05527609	chr1:210001259	C1orf107	-0.44	-5.46	-0.33	1.14e-7	Red blood cell count;
KIRP	cis	rs1035491	0.715	rs7706303	chr5:63919136	A/G	cg01791865	chr5:63954708	NA	0.33	5.14	0.31	5.5e-7	Body mass index;
KIRP	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg23067535	chr8:124195133	FAM83A	-0.68	-5.77	-0.35	2.33e-8	Urinary uromodulin levels;
KIRP	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.67	-0.39	1.72e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg13198984	chr17:80129470	CCDC57	0.59	8.96	0.5	8.46e-17	Life satisfaction;
KIRP	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.41	-4.86	-0.3	2.09e-6	Eosinophil percentage of white cells;
KIRP	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.75	10.38	0.55	3.59e-21	Parkinson's disease;
KIRP	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.49	-5.83	-0.35	1.69e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.06e-6	Calcium levels;
KIRP	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9469890	0.604	rs78121911	chr6:34503739	T/C	cg17674042	chr6:34482479	PACSIN1	-0.45	-5.37	-0.32	1.83e-7	Pubertal anthropometrics;Coronary artery disease;
KIRP	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg12131826	chr15:77904385	NA	0.46	5.55	0.33	7.46e-8	Type 2 diabetes;
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg08805041	chr16:621841	PIGQ	-0.37	-5.02	-0.3	1.01e-6	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21727117	chr19:2269525	OAZ1	0.45	6.08	0.36	4.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7553864	0.667	rs6576866	chr1:87601471	T/C	cg17420885	chr1:87600446	LOC339524	-0.58	-7.4	-0.43	2.11e-12	Smoking behavior;
KIRP	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-6.97	-0.41	2.94e-11	Bipolar disorder;
KIRP	cis	rs7523050	0.908	rs67425757	chr1:109398656	T/G	cg08274380	chr1:109419600	GPSM2	0.69	6.46	0.38	5.72e-10	Fat distribution (HIV);
KIRP	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.38	-0.32	1.74e-7	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26225646	chr19:50381231	AKT1S1;TBC1D17	0.52	6.61	0.39	2.3e-10	Parkinson's disease;
KIRP	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg13798780	chr7:105162888	PUS7	0.49	5.13	0.31	5.79e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg26248373	chr2:1572462	NA	-0.63	-5.92	-0.35	1.08e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg13147721	chr7:65941812	NA	-0.98	-6.93	-0.4	3.75e-11	Diabetic kidney disease;
KIRP	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.47	0.33	1.12e-7	Type 2 diabetes;
KIRP	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.44	-6.7	-0.39	1.43e-10	Refractive error;
KIRP	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg14983838	chr19:29218262	NA	0.73	7.06	0.41	1.66e-11	Methadone dose in opioid dependence;
KIRP	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.79	-10.47	-0.56	1.82e-21	Blood metabolite levels;
KIRP	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.58	-7.76	-0.44	2.25e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.73	10.85	0.57	1.14e-22	Prudent dietary pattern;
KIRP	cis	rs698833	0.828	rs2165421	chr2:44526010	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.03	0.36	5.97e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.55	7.17	0.42	8.89e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7923609	0.936	rs10740125	chr10:65209609	T/C	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.21	0.51	1.46e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21144940	chr19:1993265	BTBD2	-0.48	-6.95	-0.41	3.24e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1829883	0.775	rs1939402	chr5:98884847	G/A	cg08333243	chr5:99726346	NA	-0.43	-5.44	-0.33	1.29e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg10189774	chr4:17578691	LAP3	0.51	6.18	0.37	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg07701084	chr6:150067640	NUP43	0.57	7.36	0.42	2.7e-12	Testicular germ cell tumor;
KIRP	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.35	-7.85	-0.45	1.27e-13	Breast cancer;
KIRP	cis	rs930036	0.604	rs17282929	chr2:172041260	T/C	cg12801329	chr2:171670795	NA	0.47	5.59	0.34	5.99e-8	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.44	5.2	0.31	4.2e-7	Aortic root size;
KIRP	cis	rs9653442	0.545	rs12987212	chr2:100761156	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg18016565	chr1:150552671	MCL1	0.39	5.99	0.36	7.24e-9	Melanoma;
KIRP	cis	rs34421088	0.560	rs11780851	chr8:11401116	G/A	cg21775007	chr8:11205619	TDH	-0.41	-4.95	-0.3	1.36e-6	Neuroticism;
KIRP	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-7.03	-0.41	2.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg07001201	chr5:642380	CEP72	0.55	6.96	0.41	3.11e-11	Obesity-related traits;
KIRP	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.58e-14	Coffee consumption (cups per day);
KIRP	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.84	-14.42	-0.68	1.39e-34	Brugada syndrome;
KIRP	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg10189774	chr4:17578691	LAP3	0.43	5.06	0.31	8.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.71	9.06	0.5	4.3e-17	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23531873	chr3:25705861	TOP2B	0.47	6.08	0.36	4.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.28	0.32	2.79e-7	Diabetic retinopathy;
KIRP	cis	rs9400467	0.537	rs12202411	chr6:111488518	G/A	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-8.28	-0.47	7.76e-15	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9308731	0.583	rs7567184	chr2:111931072	C/G	cg03171003	chr2:111875934	NA	0.42	5.75	0.34	2.57e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg04166393	chr7:2884313	GNA12	0.64	7.58	0.44	6.88e-13	Height;
KIRP	cis	rs6120849	0.754	rs3818253	chr20:33596876	C/T	cg24642439	chr20:33292090	TP53INP2	0.65	6.58	0.39	2.74e-10	Protein C levels;
KIRP	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.72	0.49	4.27e-16	IgG glycosylation;
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.55	-7.06	-0.41	1.7e-11	Obesity-related traits;
KIRP	cis	rs10147008	1	rs10147008	chr14:59990474	G/A	cg22995959	chr14:59931024	GPR135	0.36	4.96	0.3	1.29e-6	Tonsillectomy;
KIRP	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg20991723	chr1:152506922	NA	-0.45	-5.48	-0.33	1.04e-7	Hair morphology;
KIRP	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg08885076	chr2:99613938	TSGA10	-0.37	-4.97	-0.3	1.23e-6	Chronic sinus infection;
KIRP	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.97	-12.64	-0.63	1.53e-28	Platelet distribution width;
KIRP	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.3	0.37	1.35e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg08761264	chr16:28874980	SH2B1	-0.51	-5.89	-0.35	1.29e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9796	0.835	rs28455998	chr15:41430969	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.84	-0.4	6.27e-11	Menopause (age at onset);
KIRP	cis	rs13361707	1.000	rs13361707	chr5:40791884	C/T	cg01087697	chr5:40835557	RPL37	-0.46	-5.34	-0.32	2.14e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs57590327	0.504	rs4856348	chr3:81502923	T/G	cg07356753	chr3:81810745	GBE1	0.5	6.32	0.37	1.2e-9	Extraversion;
KIRP	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.74	-8.94	-0.5	9.25e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg23067535	chr8:124195133	FAM83A	-0.71	-7.16	-0.42	9.25e-12	Urinary uromodulin levels;
KIRP	cis	rs7712401	0.601	rs425573	chr5:122326008	G/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg27398547	chr14:60952738	C14orf39	0.54	5.48	0.33	1.05e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg24375607	chr4:120327624	NA	0.55	6.39	0.38	8.05e-10	Corneal astigmatism;
KIRP	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.51	0.48	1.67e-15	Retinal vascular caliber;
KIRP	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.52	-7.2	-0.42	7.37e-12	Platelet distribution width;
KIRP	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg10104451	chr8:143696006	ARC	-0.68	-7.44	-0.43	1.7e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg24315340	chr6:146058215	EPM2A	0.41	5.33	0.32	2.26e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.04e-10	Height;
KIRP	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.63	-6.97	-0.41	2.83e-11	Cisplatin-induced ototoxicity;
KIRP	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.51	0.33	9.08e-8	Educational attainment;
KIRP	cis	rs2119480	0.762	rs401084	chr13:111310086	C/G	cg16216153	chr13:111290848	CARKD	-0.42	-5.68	-0.34	3.81e-8	Diastolic blood pressure;
KIRP	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-5.43	-0.33	1.36e-7	Educational attainment (years of education);
KIRP	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg18306943	chr3:40428807	ENTPD3	0.45	5.88	0.35	1.33e-8	Renal cell carcinoma;
KIRP	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.79	-0.49	2.64e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.42	-6.08	-0.36	4.61e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs4926611	0.698	rs4307514	chr1:54060248	T/C	cg08927728	chr1:54059983	GLIS1	0.29	6.24	0.37	1.89e-9	Hand grip strength;
KIRP	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg02725872	chr8:58115012	NA	-0.44	-4.97	-0.3	1.25e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg19875535	chr5:140030758	IK	0.62	8.37	0.47	4.27e-15	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg01708552	chr7:100815485	C7orf52	0.45	6.11	0.36	3.97e-9	Asthma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15065896	chr3:37285038	GOLGA4	0.55	6.58	0.39	2.87e-10	Smoking initiation;
KIRP	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	1.16	14.94	0.69	2.34e-36	Response to hepatitis C treatment;
KIRP	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg01843524	chr15:80216276	C15orf37;ST20	0.46	5.8	0.35	2.03e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs13401104	0.796	rs10929173	chr2:237116777	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg05231480	chr19:49170277	SEC1;NTN5	-0.32	-4.87	-0.3	1.96e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.61	6.98	0.41	2.74e-11	Height;
KIRP	cis	rs3752645	1.000	rs6978486	chr7:106777045	G/A	cg02696742	chr7:106810147	HBP1	-0.59	-5.18	-0.31	4.61e-7	Bladder cancer (smoking interaction);
KIRP	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.18	-16.24	-0.72	8.32e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg00405596	chr8:11794950	NA	-0.5	-6.58	-0.39	2.87e-10	Retinal vascular caliber;
KIRP	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23544223	chr18:12777786	NA	0.75	6.3	0.37	1.4e-9	Inflammatory skin disease;
KIRP	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg07451762	chr16:28383216	NA	-0.39	-4.86	-0.3	2.08e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.54	17.6	0.75	1.98e-45	Opioid sensitivity;
KIRP	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18867708	chr6:26865862	GUSBL1	0.48	6.04	0.36	5.76e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.22	-0.37	2.13e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.94	-0.35	9.81e-9	Menarche (age at onset);
KIRP	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.49	-5.12	-0.31	6.07e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.01	0.36	6.83e-9	Height;
KIRP	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.83	11.24	0.58	6.42e-24	Menarche (age at onset);
KIRP	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg19849509	chr2:175204996	NA	-0.53	-6.34	-0.37	1.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.84	0.3	2.25e-6	Menarche (age at onset);
KIRP	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg21419209	chr3:44054225	NA	-0.69	-8.28	-0.47	8.11e-15	Coronary artery disease;
KIRP	cis	rs78487399	0.808	rs7591387	chr2:43756032	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.0	-0.3	1.11e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg16497661	chr14:103986332	CKB	0.82	13.61	0.66	7.83e-32	Body mass index;
KIRP	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg22117172	chr7:91764530	CYP51A1	0.41	5.77	0.35	2.39e-8	Breast cancer;
KIRP	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.66	-0.34	4.27e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17030434	1.000	rs12645134	chr4:154713430	T/C	cg14289246	chr4:154710475	SFRP2	-0.8	-9.58	-0.52	1.09e-18	Electrocardiographic conduction measures;
KIRP	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.4	-5.78	-0.35	2.2e-8	Monocyte count;
KIRP	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg10932868	chr11:921992	NA	0.59	7.53	0.43	9.88e-13	Alzheimer's disease (late onset);
KIRP	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg26727032	chr16:67993705	SLC12A4	-0.64	-5.67	-0.34	3.96e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35661897	0.920	rs12463838	chr2:227310093	G/A	cg03426602	chr2:227312417	NA	-0.52	-6.82	-0.4	6.98e-11	Urinary tract infection frequency;
KIRP	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg26893134	chr6:116381904	FRK	0.21	5.82	0.35	1.84e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs77861329	1.000	rs9882775	chr3:52149649	C/T	cg08692210	chr3:52188851	WDR51A	0.84	5.86	0.35	1.48e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.59	7.88	0.45	1.03e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.97	0.41	2.93e-11	Coffee consumption (cups per day);
KIRP	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg17441377	chr17:3906640	NA	0.4	5.06	0.31	8.21e-7	Type 2 diabetes;
KIRP	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg26513180	chr16:89883248	FANCA	0.79	5.63	0.34	4.9e-8	Skin colour saturation;
KIRP	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg06565975	chr8:143823917	SLURP1	-0.55	-7.59	-0.44	6.48e-13	Urinary tract infection frequency;
KIRP	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.57	7.34	0.42	3.04e-12	Iron status biomarkers;
KIRP	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg27170947	chr2:26402098	FAM59B	-0.55	-6.03	-0.36	5.97e-9	Gut microbiome composition (summer);
KIRP	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.76	9.49	0.52	2.06e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma (childhood onset);
KIRP	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.56	-6.97	-0.41	2.81e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6540555	0.505	rs11811440	chr1:209882900	C/A	cg23920097	chr1:209922102	NA	-0.48	-5.4	-0.33	1.54e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg07701084	chr6:150067640	NUP43	-0.54	-6.1	-0.36	4.19e-9	Lung cancer;
KIRP	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.73	10.07	0.54	3.36e-20	Colorectal cancer;
KIRP	trans	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg16141378	chr3:129829833	LOC729375	-0.57	-7.53	-0.43	9.73e-13	Mood instability;
KIRP	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.87e-7	Bladder cancer;
KIRP	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17554472	chr22:41940697	POLR3H	-0.68	-7.04	-0.41	1.96e-11	Vitiligo;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.8	-0.53	2.27e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg00405596	chr8:11794950	NA	-0.48	-5.9	-0.35	1.2e-8	Triglycerides;
KIRP	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-8.03	-0.46	3.97e-14	Common traits (Other);
KIRP	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg18135206	chr14:102964638	TECPR2	0.46	5.21	0.32	3.93e-7	Blood protein levels;
KIRP	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.44e-11	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs300890	0.664	rs7690761	chr4:144208762	G/A	cg19876092	chr4:144208277	NA	0.41	6.59	0.39	2.6e-10	Nasopharyngeal carcinoma;
KIRP	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.7	0.39	1.44e-10	Height;
KIRP	cis	rs6908034	0.660	rs7750716	chr6:19804839	C/T	cg02682789	chr6:19804855	NA	0.87	6.54	0.38	3.52e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
KIRP	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg22676075	chr6:135203613	NA	0.47	6.59	0.39	2.69e-10	Red blood cell count;
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02359409	chr6:42947317	PEX6	-0.5	-6.92	-0.4	3.95e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.56	7.34	0.42	3.18e-12	Coronary artery disease;
KIRP	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.5	-0.33	9.37e-8	Life satisfaction;
KIRP	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.54	8.95	0.5	8.72e-17	Eye color traits;
KIRP	cis	rs501120	1.000	rs622956	chr10:44755183	A/G	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.26e-12	Prudent dietary pattern;
KIRP	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg00343986	chr7:65444356	GUSB	0.45	5.37	0.32	1.84e-7	Aortic root size;
KIRP	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.44	5.58	0.33	6.47e-8	QT interval;
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.27	-5.53	-0.33	8.04e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.44	6.19	0.37	2.45e-9	Testicular germ cell tumor;
KIRP	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19346786	chr7:2764209	NA	-0.43	-6.92	-0.4	3.83e-11	Height;
KIRP	cis	rs7666738	0.546	rs13149516	chr4:98913030	T/A	cg05340658	chr4:99064831	C4orf37	0.67	7.99	0.45	5.36e-14	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10632969	chr11:134023334	NCAPD3	0.47	6.03	0.36	5.96e-9	Pancreatic cancer;
KIRP	cis	rs10861342	1.000	rs10861337	chr12:105452442	G/A	cg23923672	chr12:105501055	KIAA1033	0.66	4.86	0.3	2.13e-6	IgG glycosylation;
KIRP	cis	rs1461503	0.900	rs3751047	chr11:122828439	G/A	cg27398637	chr11:122830231	C11orf63	-0.81	-11.77	-0.6	1.18e-25	Menarche (age at onset);
KIRP	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.97	-12.53	-0.62	3.41e-28	Response to antineoplastic agents;
KIRP	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs7580658	0.545	rs12477559	chr2:127951797	C/T	cg16751203	chr2:127950803	CYP27C1	0.4	5.64	0.34	4.56e-8	Protein C levels;
KIRP	cis	rs1485395	0.541	rs11170614	chr12:54017647	G/A	cg16917193	chr12:54089295	NA	0.63	5.15	0.31	5.34e-7	Migraine without aura;
KIRP	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg25790453	chr13:113633590	MCF2L	-0.22	-5.11	-0.31	6.51e-7	Systolic blood pressure;
KIRP	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg00262122	chr8:11665843	FDFT1	0.42	5.23	0.32	3.67e-7	Triglycerides;
KIRP	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.74	-10.97	-0.57	4.59e-23	Hip circumference;
KIRP	cis	rs8077889	0.750	rs4793041	chr17:41932829	C/G	cg26893861	chr17:41843967	DUSP3	0.85	9.24	0.51	1.19e-17	Triglycerides;
KIRP	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg25309564	chr22:51001381	C22orf41	0.74	5.17	0.31	4.9e-7	Narcolepsy;
KIRP	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.91	13.42	0.65	3.48e-31	Monocyte count;
KIRP	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-11.12	-0.58	1.49e-23	Total body bone mineral density;
KIRP	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.53	-6.22	-0.37	2.11e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg16989719	chr2:238392110	NA	-0.55	-5.78	-0.35	2.3e-8	Prostate cancer;
KIRP	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg25281562	chr12:121454272	C12orf43	0.47	5.18	0.31	4.69e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.75	-9.62	-0.52	8.56e-19	Homoarginine levels;
KIRP	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.59	-6.64	-0.39	1.95e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.22	-12.68	-0.63	1.09e-28	Post bronchodilator FEV1;
KIRP	cis	rs732716	0.785	rs11667543	chr19:4374850	C/T	cg19820705	chr19:4455316	UBXN6	0.67	8.04	0.46	3.83e-14	Mean corpuscular volume;
KIRP	cis	rs2882667	0.898	rs11950819	chr5:138397100	T/C	cg04439458	chr5:138467593	SIL1	-0.45	-7.52	-0.43	1.02e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.41	5.14	0.31	5.68e-7	Aortic root size;
KIRP	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.54	7.94	0.45	7.33e-14	Major depressive disorder;
KIRP	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg22437258	chr11:111473054	SIK2	-0.55	-5.99	-0.36	7.5e-9	Primary sclerosing cholangitis;
KIRP	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	7.31	0.42	3.82e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Retinal vascular caliber;
KIRP	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.53	0.33	8.05e-8	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.05e-8	Motion sickness;
KIRP	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg24881330	chr22:46731750	TRMU	0.81	5.68	0.34	3.85e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2273156	0.673	rs12887885	chr14:35376082	G/T	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.94	-0.35	9.56e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06544989	chr22:39130855	UNC84B	0.49	7.49	0.43	1.26e-12	Menopause (age at onset);
KIRP	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg22563815	chr15:78856949	CHRNA5	-0.4	-5.85	-0.35	1.54e-8	Sudden cardiac arrest;
KIRP	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.43	-5.46	-0.33	1.17e-7	Menopause (age at onset);
KIRP	cis	rs7084402	0.967	rs1658418	chr10:60333003	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.49	-0.56	1.59e-21	Refractive error;
KIRP	cis	rs7551222	0.749	rs11240761	chr1:204566700	C/A	cg20240347	chr1:204465584	NA	-0.41	-7.94	-0.45	7.24e-14	Schizophrenia;
KIRP	trans	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg06521331	chr12:34319734	NA	-0.57	-6.99	-0.41	2.52e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07648498	chr16:89883185	FANCA	0.41	5.38	0.32	1.69e-7	Vitiligo;
KIRP	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.86	9.94	0.54	8.56e-20	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs17123764	0.892	rs80071141	chr12:50159414	A/G	cg20471783	chr12:50157085	TMBIM6	0.42	5.5	0.33	9.61e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9513593	1.000	rs2182954	chr13:99937082	A/G	cg21788972	chr13:99853209	UBAC2	0.45	4.89	0.3	1.79e-6	Psoriasis;
KIRP	cis	rs10924970	0.967	rs12035746	chr1:235405654	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.42	5.65	0.34	4.5e-8	Melanoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01717063	chr16:57570057	CCDC102A	0.49	6.17	0.37	2.73e-9	Parkinson's disease;
KIRP	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg18461021	chr18:74961002	GALR1	0.51	5.21	0.32	4.08e-7	Obesity-related traits;
KIRP	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.46	-4.98	-0.3	1.17e-6	Initial pursuit acceleration;
KIRP	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg06289844	chr6:126071538	HEY2	-0.35	-4.87	-0.3	1.95e-6	Endometrial cancer;
KIRP	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg14703610	chr5:56206110	C5orf35	0.49	6.79	0.4	8.18e-11	Coronary artery disease;
KIRP	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.76	10.27	0.55	8.04e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg05220968	chr6:146057943	EPM2A	0.38	4.99	0.3	1.15e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-1.05	-12.45	-0.62	6.26e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.87	-8.14	-0.46	1.92e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg16235748	chr6:149772707	ZC3H12D	0.31	5.15	0.31	5.33e-7	Dupuytren's disease;
KIRP	cis	rs9513627	0.915	rs9582298	chr13:100118707	T/C	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg17401720	chr7:158221031	PTPRN2	0.35	5.41	0.33	1.51e-7	Obesity-related traits;
KIRP	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.41	5.04	0.31	9.06e-7	Asthma;
KIRP	cis	rs2274459	0.749	rs12190155	chr6:33663241	G/A	cg06253072	chr6:33679850	C6orf125	0.48	5.16	0.31	5.03e-7	Obesity (extreme);
KIRP	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.41	-0.51	3.65e-18	Coronary artery disease;
KIRP	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs1524927	1.000	rs12704873	chr7:96336279	G/C	cg03808172	chr7:96339361	SHFM1	0.37	4.9	0.3	1.74e-6	Total body bone mineral density;
KIRP	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg16141378	chr3:129829833	LOC729375	0.5	6.1	0.36	4.01e-9	Neuroticism;
KIRP	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg02297831	chr4:17616191	MED28	-0.6	-7.71	-0.44	3.1400000000000003e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.76	9.02	0.5	5.57e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg08668510	chr10:1095578	IDI1	0.94	6.97	0.41	2.92e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs4950322	0.518	rs56151278	chr1:146589003	T/C	cg22381352	chr1:146742008	CHD1L	-0.42	-4.86	-0.3	2.12e-6	Protein quantitative trait loci;
KIRP	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.54	-6.12	-0.36	3.74e-9	Coronary artery disease;
KIRP	cis	rs7751419	0.675	rs6458096	chr6:39107698	C/T	cg25014318	chr6:39016776	GLP1R	0.36	5.12	0.31	6.1e-7	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg14593290	chr7:50529359	DDC	0.8	10.01	0.54	5.36e-20	Malaria;
KIRP	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.61	-0.39	2.41e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.63	0.48	7.94e-16	Motion sickness;
KIRP	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	0.88	13.5	0.65	1.84e-31	Body mass index;
KIRP	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.32	-0.42	3.62e-12	Red cell distribution width;
KIRP	cis	rs17209837	0.564	rs117373803	chr7:87096783	A/G	cg00919237	chr7:87102261	ABCB4	-0.69	-8.77	-0.49	2.97e-16	Gallbladder cancer;
KIRP	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.63	8.34	0.47	5.34e-15	Menarche (age at onset);
KIRP	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg00800569	chr2:239229395	TRAF3IP1	-0.52	-5.03	-0.31	9.58e-7	Multiple system atrophy;
KIRP	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg23587288	chr2:27483067	SLC30A3	-0.59	-7.22	-0.42	6.61e-12	Blood metabolite levels;
KIRP	cis	rs2131877	0.529	rs7644208	chr3:194855954	G/A	cg13868855	chr3:194833887	C3orf21	-0.43	-4.9	-0.3	1.74e-6	Non-small cell lung cancer;
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg21775007	chr8:11205619	TDH	-0.4	-5.14	-0.31	5.62e-7	Neuroticism;
KIRP	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	7.87	0.45	1.12e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.23	-0.42	6.24e-12	Migraine;Coronary artery disease;
KIRP	cis	rs9398803	0.723	rs853975	chr6:127070234	C/T	cg19875578	chr6:126661172	C6orf173	-0.44	-5.77	-0.35	2.33e-8	Male-pattern baldness;
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg21523564	chr15:75251491	NA	0.48	8.18	0.46	1.55e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.9	0.45	9.25e-14	Calcium levels;
KIRP	trans	rs12517041	0.935	rs71611217	chr5:23270864	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.59	-6.22	-0.37	2.12e-9	Calcium levels;
KIRP	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.82	10.23	0.55	1.09e-20	Bipolar disorder and schizophrenia;
KIRP	cis	rs17381785	0.531	rs34479500	chr4:14939389	G/A	cg12377275	chr4:15005593	CPEB2	0.57	6.34	0.37	1.11e-9	Urate levels in overweight individuals;
KIRP	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg13256891	chr4:100009986	ADH5	0.46	5.1	0.31	6.91e-7	Alcohol dependence;
KIRP	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg06742321	chr12:123595122	PITPNM2	0.43	5.47	0.33	1.13e-7	Platelet count;
KIRP	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Body mass index;
KIRP	cis	rs2635047	0.638	rs9961383	chr18:44604001	C/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.88	-0.35	1.33e-8	Educational attainment;
KIRP	cis	rs9547692	0.938	rs17217404	chr13:37466215	C/T	cg01493522	chr13:37497338	NA	-0.45	-5.5	-0.33	9.35e-8	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11810498	chr9:130477698	PTRH1;TTC16	0.52	6.09	0.36	4.26e-9	Smoking initiation;
KIRP	cis	rs7760949	0.963	rs7761500	chr6:13917140	G/A	cg27413430	chr6:13925136	RNF182	0.39	4.99	0.3	1.13e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2249694	0.520	rs7077457	chr10:135324370	G/T	cg20169779	chr10:135381914	SYCE1	-0.58	-6.51	-0.38	4.15e-10	Obesity-related traits;
KIRP	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg26022315	chr17:47021804	SNF8	0.43	5.49	0.33	9.78e-8	Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs4523957	0.651	rs7223390	chr17:2085653	T/C	cg16513277	chr17:2031491	SMG6	-0.8	-11.7	-0.6	1.93e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.72	9.66	0.52	6.26e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg13628971	chr7:2884303	GNA12	0.39	4.97	0.3	1.24e-6	Height;
KIRP	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.41	-0.47	3.36e-15	Inflammatory bowel disease;
KIRP	cis	rs55788414	0.932	rs12102293	chr16:81181607	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.19	-0.46	1.46e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.7	6.34	0.37	1.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs807029	0.577	rs701835	chr10:102762127	A/G	cg04662943	chr10:102668895	NA	0.48	5.24	0.32	3.49e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg24644049	chr4:85504048	CDS1	1.06	6.86	0.4	5.62e-11	Skin colour saturation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15777606	chr6:15496615	JARID2	-0.43	-6.14	-0.36	3.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	8.18	0.46	1.57e-14	Neuroticism;
KIRP	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg17470723	chr8:74884337	TCEB1	0.64	8.24	0.47	1.02e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg13736514	chr6:26305472	NA	0.53	6.64	0.39	2.01e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	15.39	0.7	6.8e-38	Alzheimer's disease;
KIRP	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg17264618	chr3:40429014	ENTPD3	0.33	4.95	0.3	1.37e-6	Renal cell carcinoma;
KIRP	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs290986	0.812	rs290258	chr9:93555739	A/G	cg02608019	chr9:93564028	SYK	0.62	5.82	0.35	1.82e-8	Multiple sclerosis;
KIRP	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg03060546	chr3:49711283	APEH	0.44	5.8	0.35	2e-8	Parkinson's disease;
KIRP	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.99	6.82	0.4	7.08e-11	LDL cholesterol;
KIRP	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg22283653	chr8:49824208	NA	-0.45	-6.2	-0.37	2.39e-9	Sudden cardiac arrest;
KIRP	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.2	0.42	7.23e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg12591125	chr7:1885375	MAD1L1	0.54	5.42	0.33	1.42e-7	Neuroticism;
KIRP	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.48	5.92	0.35	1.09e-8	Height;
KIRP	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.72	-8.57	-0.48	1.15e-15	Cognitive function;
KIRP	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.43	0.38	6.58e-10	Aortic root size;
KIRP	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26378065	chr17:18585709	ZNF286B	0.55	6.83	0.4	6.62e-11	Educational attainment (years of education);
KIRP	cis	rs6968419	0.747	rs12670683	chr7:115874466	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.03	-0.36	6.12e-9	Intraocular pressure;
KIRP	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.43	5.08	0.31	7.51e-7	Metabolite levels (MHPG);
KIRP	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.31	0.42	3.78e-12	Height;
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.82	-0.71	2.23e-39	Immature fraction of reticulocytes;
KIRP	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg01559446	chr3:44596178	ZNF167	-0.36	-5.03	-0.31	9.29e-7	Depressive symptoms;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25486615	chr20:5591870	RP5-1022P6.2	0.52	6.09	0.36	4.34e-9	Smoking initiation;
KIRP	cis	rs71277158	0.688	rs73879182	chr3:169879695	C/T	cg04067573	chr3:169899625	PHC3	0.66	6.26	0.37	1.69e-9	Prostate cancer;
KIRP	cis	rs7919006	0.793	rs72803449	chr10:76773799	C/T	cg01390419	chr10:76803856	DUPD1	0.51	5.91	0.35	1.13e-8	Weight;
KIRP	cis	rs34524635	1	rs34524635	chr10:65261176	CT/C	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.81	-0.35	1.97e-8	Vascular endothelial growth factor levels;
KIRP	cis	rs1950626	0.833	rs2400963	chr14:101395706	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.87	0.4	5.13e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg00405596	chr8:11794950	NA	-0.48	-6.32	-0.37	1.22e-9	Retinal vascular caliber;
KIRP	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.09	-0.31	7.11e-7	Pulmonary function;
KIRP	cis	rs6142102	0.812	rs761238	chr20:32519988	A/C	cg08999081	chr20:33150536	PIGU	-0.48	-5.99	-0.36	7.48e-9	Skin pigmentation;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg23693289	chr8:27183097	PTK2B	0.55	7.02	0.41	2.11e-11	Neuroticism;
KIRP	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.77	10.44	0.55	2.34e-21	Adiposity;
KIRP	cis	rs2274273	0.662	rs67588230	chr14:55667030	C/T	cg04306507	chr14:55594613	LGALS3	0.4	5.19	0.31	4.43e-7	Protein biomarker;
KIRP	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.64	-6.97	-0.41	2.82e-11	Mean corpuscular hemoglobin;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13370280	chr6:137539688	IFNGR1	0.47	6.47	0.38	5.39e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs911119	0.657	rs2104005	chr20:23630761	G/A	cg16589663	chr20:23618590	CST3	0.61	5.13	0.31	5.82e-7	Chronic kidney disease;
KIRP	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.76	-11.23	-0.58	6.52e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.88	-11.96	-0.61	2.74e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg16479474	chr6:28041457	NA	-0.46	-5.01	-0.3	1.04e-6	Depression;
KIRP	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg27462398	chr1:86174642	ZNHIT6	-0.53	-7.12	-0.41	1.19e-11	Urate levels in overweight individuals;
KIRP	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg08461772	chr7:95026248	PON3	0.41	6.0	0.36	7.12e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg17425144	chr1:10567563	PEX14	0.45	8.12	0.46	2.19e-14	Prostate cancer;
KIRP	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg22117172	chr7:91764530	CYP51A1	0.46	6.43	0.38	6.53e-10	Breast cancer;
KIRP	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.55	-8.05	-0.46	3.51e-14	Mean corpuscular volume;
KIRP	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg21361702	chr7:150065534	REPIN1	0.67	6.66	0.39	1.79e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs12517041	0.938	rs71611218	chr5:23270886	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.58	-6.17	-0.37	2.79e-9	Calcium levels;
KIRP	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg18154014	chr19:37997991	ZNF793	-0.76	-7.89	-0.45	1e-13	Coronary artery calcification;
KIRP	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg01849466	chr14:104193079	ZFYVE21	0.66	9.25	0.51	1.11e-17	Schizophrenia;
KIRP	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg15896084	chr13:114927664	NA	0.44	5.65	0.34	4.38e-8	Schizophrenia;
KIRP	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs12949688	1.000	rs12949688	chr17:55825701	C/T	cg12582317	chr17:55822272	NA	-0.56	-8.7	-0.49	4.75e-16	Schizophrenia;
KIRP	cis	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.03e-11	Morning vs. evening chronotype;
KIRP	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg07382826	chr16:28625726	SULT1A1	0.53	5.77	0.35	2.38e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.91	0.3	1.63e-6	Renal cell carcinoma;
KIRP	cis	rs6142102	0.961	rs4911405	chr20:32674967	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	6.39	0.38	8.35e-10	Skin pigmentation;
KIRP	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	8.96	0.5	8.31e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.3	-0.32	2.54e-7	Parkinson's disease;
KIRP	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.67	9.22	0.51	1.37e-17	Colorectal cancer;
KIRP	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg13334819	chr7:99746414	C7orf59	-0.51	-5.85	-0.35	1.55e-8	Coronary artery disease;
KIRP	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.6	7.35	0.42	2.94e-12	Corneal astigmatism;
KIRP	cis	rs9462846	0.841	rs66541797	chr6:42825942	C/T	cg02353165	chr6:42928485	GNMT	0.46	5.16	0.31	5.12e-7	Blood protein levels;
KIRP	cis	rs12580194	0.598	rs12582005	chr12:55772837	A/T	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.65	-9.98	-0.54	6.71e-20	Obesity-related traits;
KIRP	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.56	-7.68	-0.44	3.84e-13	Type 2 diabetes;
KIRP	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg05717871	chr11:638507	DRD4	-0.38	-5.49	-0.33	1.02e-7	Systemic lupus erythematosus;
KIRP	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg10645314	chr2:3704589	ALLC	-0.63	-6.97	-0.41	2.95e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg00125455	chr20:44574271	PCIF1	0.45	9.14	0.5	2.48e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.39	0.33	1.62e-7	Coronary artery disease;
KIRP	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.16	0.5	2.15e-17	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.73	10.22	0.55	1.18e-20	Lung cancer;
KIRP	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.12	-0.5	2.86e-17	Neuroticism;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.79e-8	Lung cancer;
KIRP	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg06064525	chr11:970664	AP2A2	-0.31	-5.68	-0.34	3.79e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg20140201	chr2:241835670	C2orf54	-0.35	-4.98	-0.3	1.19e-6	Urinary metabolites;
KIRP	cis	rs10203711	1.000	rs4663940	chr2:239570382	C/T	cg14580085	chr2:239553406	NA	0.39	5.14	0.31	5.62e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08839451	chr12:125478775	BRI3BP	0.48	6.14	0.36	3.36e-9	Myopia (pathological);
KIRP	cis	rs78487399	0.808	rs7564886	chr2:43733028	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.21	-0.32	3.95e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10761482	0.601	rs10733764	chr10:62210345	C/G	cg01186212	chr10:62110162	ANK3	-0.3	-5.06	-0.31	8.07e-7	Schizophrenia;
KIRP	cis	rs2151522	0.762	rs1361831	chr6:127181089	C/T	cg21431617	chr6:127135037	NA	-0.29	-5.23	-0.32	3.66e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4363385	0.510	rs11577384	chr1:152899728	C/T	cg25856811	chr1:152973957	SPRR3	-0.4	-5.54	-0.33	7.63e-8	Inflammatory skin disease;
KIRP	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg27121462	chr16:89883253	FANCA	0.52	6.68	0.39	1.6e-10	Vitiligo;
KIRP	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.96	-12.51	-0.62	3.99e-28	Platelet distribution width;
KIRP	cis	rs2139634	0.718	rs6775724	chr3:46566729	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.38	-5.28	-0.32	2.82e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg04733989	chr22:42467013	NAGA	-0.54	-6.63	-0.39	2.14e-10	Cognitive function;
KIRP	cis	rs1461503	0.934	rs7119533	chr11:122832683	A/T	cg27398637	chr11:122830231	C11orf63	-0.7	-9.17	-0.5	1.92e-17	Menarche (age at onset);
KIRP	cis	rs3736485	0.966	rs12443007	chr15:51892192	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.19	-0.31	4.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1669338	0.588	rs6784329	chr3:3200013	C/T	cg16797762	chr3:3221439	CRBN	-0.68	-6.34	-0.37	1.1e-9	White matter integrity;
KIRP	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg06654118	chr4:1303317	MAEA	0.28	5.28	0.32	2.81e-7	Obesity-related traits;
KIRP	cis	rs4908768	0.871	rs7553298	chr1:8770883	A/G	cg25722041	chr1:8623473	RERE	0.62	7.96	0.45	6.3e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg00343986	chr7:65444356	GUSB	0.41	4.94	0.3	1.44e-6	Aortic root size;
KIRP	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.77	9.81	0.53	2.23e-19	Menopause (age at onset);
KIRP	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	10.59	0.56	7.65e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg00745463	chr17:30367425	LRRC37B	0.96	6.43	0.38	6.53e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06850241	chr22:41845214	NA	-0.49	-5.51	-0.33	9.05e-8	Vitiligo;
KIRP	cis	rs9475752	0.793	rs71564872	chr6:56838484	A/G	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs35883536	1.000	rs11547648	chr1:101106268	G/T	cg06223162	chr1:101003688	GPR88	0.32	6.61	0.39	2.42e-10	Monocyte count;
KIRP	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.78	0.66	2.12e-32	Alzheimer's disease;
KIRP	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.13	0.46	2.1e-14	Type 2 diabetes;
KIRP	cis	rs62413470	1.000	rs17751085	chr6:55945212	A/C	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs6568686	0.577	rs174394	chr6:111918999	T/G	cg22127309	chr6:111907043	TRAF3IP2	0.55	5.15	0.31	5.33e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.72	8.38	0.47	4.19e-15	Corneal astigmatism;
KIRP	cis	rs17121403	0.661	rs12138380	chr1:100440561	G/A	cg24955406	chr1:100503596	HIAT1	0.75	4.99	0.3	1.12e-6	Pulmonary function decline;
KIRP	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	0.9	13.86	0.66	1.17e-32	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1957429	0.708	rs8019346	chr14:65353011	G/A	cg23373153	chr14:65346875	NA	-0.6	-5.0	-0.3	1.08e-6	Pediatric areal bone mineral density (radius);
KIRP	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-4.94	-0.3	1.41e-6	Schizophrenia;
KIRP	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs1864585	0.520	rs17776622	chr8:10676497	T/C	cg21775007	chr8:11205619	TDH	-0.49	-4.86	-0.3	2.09e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	8.59	0.48	1.01e-15	Motion sickness;
KIRP	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	cis	rs9308731	0.614	rs6755484	chr2:111949096	T/C	cg04780086	chr2:111875790	ACOXL	0.38	5.26	0.32	3.16e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs7011049	1.000	rs72648413	chr8:53860576	C/T	cg26025543	chr8:53854495	NA	0.64	6.1	0.36	4.02e-9	Systolic blood pressure;
KIRP	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.51	-6.19	-0.37	2.47e-9	Squamous cell lung carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19510075	chr4:184580508	C4orf41;RWDD4A	0.55	6.88	0.4	4.94e-11	Parkinson's disease;
KIRP	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.22	-5.2	-0.31	4.16e-7	Coronary artery disease;
KIRP	cis	rs4789452	0.967	rs7217986	chr17:75369578	T/C	cg02320862	chr17:75370284	SEPT9	-0.35	-4.92	-0.3	1.55e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg00599163	chr2:162100495	NA	-0.44	-5.04	-0.31	8.88e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09332650	chr19:50120000	PRR12	0.51	7.08	0.41	1.48e-11	Survival in pancreatic cancer;
KIRP	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg26248373	chr2:1572462	NA	-0.8	-10.76	-0.57	2.17e-22	IgG glycosylation;
KIRP	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg04132472	chr17:19861366	AKAP10	0.47	6.61	0.39	2.42e-10	Schizophrenia;
KIRP	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg20243544	chr17:37824526	PNMT	-0.4	-4.93	-0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg01733459	chr4:1388830	CRIPAK	-0.44	-5.02	-0.3	9.8e-7	Systolic blood pressure;
KIRP	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.81	8.98	0.5	7.3e-17	Alzheimer's disease;
KIRP	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.77	8.72	0.49	4.28e-16	Adiposity;
KIRP	cis	rs1440410	0.830	rs2010767	chr4:144176546	G/T	cg01719995	chr4:144104893	USP38	0.37	4.88	0.3	1.89e-6	Ischemic stroke;
KIRP	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.53	6.21	0.37	2.23e-9	Aortic root size;
KIRP	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg05082376	chr22:42548792	NA	-0.47	-6.04	-0.36	5.7e-9	Schizophrenia;
KIRP	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.54	-6.38	-0.38	8.84e-10	Macular telangiectasia type 2;
KIRP	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg16898833	chr6:26189333	HIST1H4D	0.97	5.87	0.35	1.38e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.74	-0.34	2.82e-8	Depression;
KIRP	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.03e-12	Bipolar disorder;
KIRP	cis	rs7215564	0.908	rs34384177	chr17:78667040	A/T	cg06153925	chr17:78755379	RPTOR	0.32	5.22	0.32	3.83e-7	Myopia (pathological);
KIRP	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.79	9.18	0.51	1.77e-17	Corneal astigmatism;
KIRP	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.41	-0.43	1.97e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.33	0.37	1.15e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.46	-6.21	-0.37	2.24e-9	Multiple sclerosis;
KIRP	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg12091567	chr17:66097778	LOC651250	-0.79	-7.65	-0.44	4.63e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg13482628	chr17:19912719	NA	-0.53	-6.91	-0.4	4.08e-11	Schizophrenia;
KIRP	cis	rs10484761	1.000	rs6921765	chr6:40804354	A/G	cg02680909	chr6:39899321	MOCS1	-0.23	-4.94	-0.3	1.45e-6	Esophageal cancer;
KIRP	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg18306943	chr3:40428807	ENTPD3	-0.45	-6.23	-0.37	2.04e-9	Renal cell carcinoma;
KIRP	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.46	-0.33	1.13e-7	Endometrial cancer;
KIRP	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.53	-6.54	-0.38	3.54e-10	Neurofibrillary tangles;
KIRP	cis	rs6968419	0.674	rs4730726	chr7:115913336	T/A	cg02561103	chr7:115862891	TES	-0.43	-6.02	-0.36	6.36e-9	Intraocular pressure;
KIRP	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	cis	rs501120	0.584	rs11591406	chr10:44690710	G/A	cg09554077	chr10:44749378	NA	0.54	5.78	0.35	2.29e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg05562828	chr17:3906858	NA	0.53	5.49	0.33	9.76e-8	Type 2 diabetes;
KIRP	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg12940439	chr1:67600707	NA	0.43	6.49	0.38	4.78e-10	Psoriasis;
KIRP	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg18154014	chr19:37997991	ZNF793	0.73	7.78	0.44	1.95e-13	Coronary artery calcification;
KIRP	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg16099169	chr2:106886729	NA	-0.47	-7.03	-0.41	1.97e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-13.06	-0.64	5.97e-30	Chronic sinus infection;
KIRP	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg00666640	chr1:248458726	OR2T12	-0.46	-5.44	-0.33	1.29e-7	Common traits (Other);
KIRP	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	5.85	0.35	1.53e-8	Depressive symptoms;
KIRP	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg01294253	chr9:136912663	BRD3	0.42	5.43	0.33	1.33e-7	Platelet distribution width;
KIRP	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg00376283	chr12:123451042	ABCB9	0.81	10.81	0.57	1.57e-22	Platelet count;
KIRP	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg26893134	chr6:116381904	FRK	0.2	5.18	0.31	4.72e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs911119	0.913	rs12710327	chr20:23569689	C/T	cg16589663	chr20:23618590	CST3	0.47	4.85	0.3	2.22e-6	Chronic kidney disease;
KIRP	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.75	11.03	0.58	3.04e-23	Schizophrenia;
KIRP	cis	rs920590	0.643	rs6982084	chr8:19669333	G/A	cg03894339	chr8:19674705	INTS10	-0.41	-4.88	-0.3	1.93e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.96	13.05	0.64	6.47e-30	Multiple sclerosis;
KIRP	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg24304309	chr1:154577895	ADAR	0.37	5.56	0.33	7.12e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6681460	0.649	rs4655494	chr1:67002876	G/A	cg13052034	chr1:66999238	SGIP1	0.41	5.88	0.35	1.35e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs17209837	1.000	rs7802555	chr7:87130350	A/C	cg00919237	chr7:87102261	ABCB4	-0.65	-6.49	-0.38	4.61e-10	Gallbladder cancer;
KIRP	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.3	9.05	0.5	4.47e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19596790	chr3:9691124	MTMR14	0.49	6.41	0.38	7.4e-10	Parkinson's disease;
KIRP	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg06636001	chr8:8085503	FLJ10661	0.79	9.43	0.52	3.23e-18	Red cell distribution width;
KIRP	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg19875535	chr5:140030758	IK	0.65	8.72	0.49	4.12e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs1544756	chr5:74508412	G/T	cg03227963	chr5:74354835	NA	0.4	5.86	0.35	1.46e-8	Response to amphetamines;
KIRP	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.44	-5.33	-0.32	2.28e-7	Coronary artery disease;
KIRP	cis	rs830124	0.673	rs529736	chr12:122384457	A/C	cg21016266	chr12:122356598	WDR66	0.56	5.7	0.34	3.43e-8	Urinary metabolites;
KIRP	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.7e-10	Reticulocyte count;High light scatter reticulocyte count;
KIRP	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.83	-12.42	-0.62	8.23e-28	Strep throat;
KIRP	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg01941274	chr14:50234650	KLHDC2	0.4	4.94	0.3	1.47e-6	Carotid intima media thickness;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14119137	chr6:24477147	GPLD1	0.45	6.05	0.36	5.48e-9	Interleukin-4 levels;
KIRP	cis	rs13315871	1.000	rs9819072	chr3:58353647	A/C	cg12435725	chr3:58293450	RPP14	-0.5	-5.39	-0.33	1.62e-7	Cholesterol, total;
KIRP	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.61	-0.48	8.85e-16	Life satisfaction;
KIRP	cis	rs17065868	1.000	rs73174004	chr13:45167628	G/A	cg10246903	chr13:45222710	NA	0.74	6.66	0.39	1.75e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs490234	0.702	rs35129945	chr9:128320134	C/T	cg14078157	chr9:128172775	NA	-0.62	-7.48	-0.43	1.3e-12	Mean arterial pressure;
KIRP	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg22604316	chr1:46958801	NA	-0.35	-5.02	-0.3	9.88e-7	Monobrow;
KIRP	cis	rs6959887	0.962	rs1120204	chr7:35300376	A/G	cg06685737	chr7:35301730	NA	0.45	6.61	0.39	2.42e-10	Birth weight;
KIRP	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg04132472	chr17:19861366	AKAP10	0.42	5.68	0.34	3.72e-8	Schizophrenia;
KIRP	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg24009623	chr19:33667908	NA	-0.42	-4.98	-0.3	1.19e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg17595323	chr11:93583763	C11orf90	-0.37	-6.25	-0.37	1.82e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg08992911	chr2:238395768	MLPH	0.67	6.52	0.38	4.01e-10	Prostate cancer;
KIRP	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg09526685	chr4:187126073	CYP4V2	0.67	6.19	0.37	2.56e-9	Blood protein levels;
KIRP	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs6832769	0.961	rs480479	chr4:56274330	C/T	cg05960024	chr4:56376020	CLOCK	0.62	8.17	0.46	1.67e-14	Personality dimensions;
KIRP	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.59	8.01	0.45	4.55e-14	Depressive symptoms;
KIRP	cis	rs5753037	0.745	rs9306465	chr22:30221826	T/A	cg27665648	chr22:30112403	NA	0.47	6.52	0.38	3.97e-10	Type 1 diabetes;
KIRP	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg12685995	chr10:126849062	CTBP2	-0.46	-6.04	-0.36	5.61e-9	N-glycan levels;
KIRP	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-11.17	-0.58	1.08e-23	Chronic sinus infection;
KIRP	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	1.11	12.99	0.64	9.66e-30	Eosinophil percentage of granulocytes;
KIRP	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.47	0.43	1.4e-12	Myeloid white cell count;
KIRP	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07570687	chr10:102243282	WNT8B	0.53	7.11	0.41	1.22e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.6	-6.98	-0.41	2.78e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs77372450	0.636	rs6879084	chr5:157029188	C/T	cg05585991	chr5:157099197	C5orf52	0.44	5.17	0.31	4.94e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9400467	0.509	rs463854	chr6:111673207	C/G	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1823913	0.637	rs11688994	chr2:192130968	A/G	cg12404831	chr2:192114017	MYO1B	0.48	6.52	0.38	3.93e-10	Obesity-related traits;
KIRP	cis	rs11169225	1.000	rs11169225	chr12:50345671	T/A	cg04450003	chr12:50355995	AQP5	0.57	9.09	0.5	3.3e-17	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs78761021	0.685	rs17744107	chr17:9795735	C/G	cg26853458	chr17:9805074	RCVRN	-0.51	-4.92	-0.3	1.55e-6	Type 2 diabetes;
KIRP	cis	rs4073416	0.707	rs8003811	chr14:66211250	C/T	cg03016385	chr14:66212404	NA	-0.39	-5.08	-0.31	7.47e-7	N-glycan levels;
KIRP	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg04362960	chr10:104952993	NT5C2	0.64	7.5	0.43	1.16e-12	Arsenic metabolism;
KIRP	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.65	7.97	0.45	5.76e-14	Obesity-related traits;
KIRP	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg25902810	chr10:99078978	FRAT1	0.53	6.49	0.38	4.7e-10	Monocyte count;
KIRP	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14895029	chr7:2775587	GNA12	-0.44	-5.18	-0.31	4.63e-7	Height;
KIRP	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.4	4.98	0.3	1.22e-6	Cardiac Troponin-T levels;
KIRP	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.71	0.53	4.52e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg08992911	chr2:238395768	MLPH	0.42	5.35	0.32	2e-7	Prostate cancer;
KIRP	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.86	12.96	0.64	1.23e-29	Birth weight;
KIRP	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.21	-0.46	1.26e-14	Monocyte percentage of white cells;
KIRP	cis	rs10114408	0.959	rs7033812	chr9:96663902	A/G	cg14598338	chr9:96623480	NA	-0.33	-5.04	-0.31	8.82e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg03609598	chr5:56110824	MAP3K1	0.47	5.43	0.33	1.33e-7	Coronary artery disease;
KIRP	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.15	0.31	5.37e-7	Height;
KIRP	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg20744362	chr22:50050164	C22orf34	0.33	5.73	0.34	2.99e-8	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.52	-6.25	-0.37	1.78e-9	Coronary artery disease;
KIRP	cis	rs4132509	0.516	rs10927031	chr1:243685760	G/C	cg21452805	chr1:244014465	NA	0.61	5.7	0.34	3.38e-8	RR interval (heart rate);
KIRP	cis	rs10788264	0.513	rs10749455	chr10:124035030	A/G	cg09507567	chr10:124027408	NA	0.31	5.75	0.34	2.68e-8	Total body bone mineral density;
KIRP	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.97	0.5	7.97e-17	Motion sickness;
KIRP	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg01629716	chr15:45996671	NA	0.36	6.48	0.38	4.85e-10	Waist circumference;Weight;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13546937	chr9:127632120	ARPC5L	-0.5	-6.43	-0.38	6.67e-10	Myopia;
KIRP	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.41	-0.38	7.22e-10	Uric acid levels;
KIRP	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg25797454	chr6:150327115	RAET1K	0.33	6.18	0.37	2.63e-9	Alopecia areata;
KIRP	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.17e-6	Pulmonary function;
KIRP	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.61	-6.22	-0.37	2.18e-9	Body mass index;
KIRP	cis	rs6750047	0.647	rs11124632	chr2:38276412	G/C	cg07380506	chr2:38303506	CYP1B1	0.44	5.8	0.35	2e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg16989719	chr2:238392110	NA	-0.56	-6.09	-0.36	4.36e-9	Prostate cancer;
KIRP	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.71	9.01	0.5	5.88e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	0.89	8.8	0.49	2.44e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.51	7.13	0.41	1.12e-11	Mean corpuscular volume;
KIRP	cis	rs3767633	0.764	rs2490429	chr1:161942509	A/G	cg09175582	chr1:161736000	ATF6	0.77	4.98	0.3	1.17e-6	IgG glycosylation;
KIRP	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.78	-0.4	8.73e-11	Systemic lupus erythematosus;
KIRP	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.85	11.21	0.58	7.87e-24	Menarche (age at onset);
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg12705353	chr12:122356852	WDR66	0.5	6.78	0.4	8.97e-11	Mean corpuscular volume;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg03238298	chr18:32073112	DTNA	-0.43	-6.3	-0.37	1.37e-9	Warfarin maintenance dose;
KIRP	cis	rs5753037	0.653	rs140121	chr22:30138689	C/T	cg27665648	chr22:30112403	NA	0.34	5.01	0.3	1.06e-6	Type 1 diabetes;
KIRP	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.16	-0.42	9.44e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg03714773	chr7:91764589	CYP51A1	0.39	5.64	0.34	4.58e-8	Breast cancer;
KIRP	cis	rs6544713	1.000	rs4299376	chr2:44072576	G/T	cg21783355	chr2:44066198	ABCG5;ABCG8	0.38	5.18	0.31	4.59e-7	Coronary artery disease;LDL cholesterol;
KIRP	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.34	-0.32	2.14e-7	Primary biliary cholangitis;
KIRP	cis	rs7578199	0.924	rs13423900	chr2:242335424	T/C	cg01632474	chr2:242799312	PDCD1	0.38	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg12486944	chr17:80159399	CCDC57	-0.39	-5.25	-0.32	3.22e-7	Life satisfaction;
KIRP	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg08738300	chr3:44038990	NA	0.66	9.08	0.5	3.52e-17	Coronary artery disease;
KIRP	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	1.55	10.26	0.55	8.38e-21	Cannabis dependence symptom count;
KIRP	cis	rs4954585	0.708	rs13034241	chr2:137021263	G/A	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.23e-13	Colorectal cancer;
KIRP	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg20731937	chr12:48336164	NA	0.41	5.26	0.32	3.15e-7	Longevity (90 years and older);
KIRP	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg02023728	chr11:77925099	USP35	0.49	7.68	0.44	3.77e-13	Testicular germ cell tumor;
KIRP	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.64	5.94	0.35	9.74e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6585424	1.000	rs34100029	chr10:81923598	C/G	cg27417294	chr10:81904244	PLAC9	0.56	5.46	0.33	1.14e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs28595532	0.702	rs56217716	chr4:119338490	T/G	cg21605333	chr4:119757512	SEC24D	1.1	8.23	0.46	1.06e-14	Cannabis dependence symptom count;
KIRP	cis	rs35955747	0.870	rs5997986	chr22:31834939	C/T	cg02404636	chr22:31891804	SFI1	-0.39	-5.41	-0.33	1.5e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.29	0.32	2.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23978390	chr7:1156363	C7orf50	0.47	6.47	0.38	5.26e-10	Longevity;Endometriosis;
KIRP	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg06565975	chr8:143823917	SLURP1	0.47	7.42	0.43	1.88e-12	Urinary tract infection frequency;
KIRP	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg16736954	chr20:23401023	NAPB	0.63	4.97	0.3	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.49	-0.33	1.02e-7	Life satisfaction;
KIRP	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.28	-22.72	-0.82	2.36e-62	Breast cancer;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.55	7.04	0.41	1.87e-11	Longevity;Endometriosis;
KIRP	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg10755058	chr3:40428713	ENTPD3	-0.35	-5.14	-0.31	5.64e-7	Renal cell carcinoma;
KIRP	cis	rs732765	0.734	rs10130425	chr14:75185394	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.88	-0.3	1.9e-6	Non-small cell lung cancer;
KIRP	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.69	8.85	0.49	1.74e-16	Neuroticism;
KIRP	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14030997	chr9:108420639	NA	0.5	6.2	0.37	2.37e-9	Interleukin-4 levels;
KIRP	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg00405596	chr8:11794950	NA	0.42	5.35	0.32	2e-7	Retinal vascular caliber;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg10305451	chr2:177043427	NA	0.53	7.26	0.42	5.16e-12	IgG glycosylation;
KIRP	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	1.25	9.13	0.5	2.52e-17	LDL cholesterol;
KIRP	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg10117171	chr1:25599238	RHD	-0.48	-6.68	-0.39	1.54e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.54	-6.79	-0.4	8.16e-11	Monocyte count;
KIRP	cis	rs7106204	0.534	rs75423384	chr11:24273691	A/T	ch.11.24196551F	chr11:24239977	NA	0.71	4.93	0.3	1.52e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs11638352	1.000	rs7176955	chr15:44308905	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.81	-5.58	-0.34	6.42e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs4740619	0.619	rs1359957	chr9:16044182	G/A	cg14451791	chr9:16040625	NA	-0.39	-4.99	-0.3	1.16e-6	Body mass index;
KIRP	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-9.66	-0.52	6.42e-19	Coffee consumption (cups per day);
KIRP	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	10.32	0.55	5.58e-21	Electrocardiographic conduction measures;
KIRP	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.22	0.42	6.36e-12	Bipolar disorder;
KIRP	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs77956314	0.901	rs7133290	chr12:117335944	C/T	cg02017074	chr12:117425053	FBXW8	-0.56	-4.97	-0.3	1.25e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.26	-0.55	8.79e-21	Chronic sinus infection;
KIRP	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg06360820	chr2:242988706	NA	-0.74	-6.49	-0.38	4.59e-10	Obesity-related traits;
KIRP	cis	rs10875746	0.855	rs10875731	chr12:48432743	G/A	cg20731937	chr12:48336164	NA	0.41	5.25	0.32	3.25e-7	Longevity (90 years and older);
KIRP	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg13010199	chr12:38710504	ALG10B	0.55	6.78	0.4	9.1e-11	Morning vs. evening chronotype;
KIRP	cis	rs1850744	0.702	rs13136217	chr4:9722292	G/T	cg15442990	chr4:9534313	NA	0.84	6.22	0.37	2.09e-9	Economic and political preferences;
KIRP	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg16898833	chr6:26189333	HIST1H4D	0.83	5.36	0.32	1.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs364477	0.818	rs279883	chr9:984459	A/T	cg13952963	chr9:998547	NA	0.59	4.93	0.3	1.5e-6	Major depressive disorder;
KIRP	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.6	-8.83	-0.49	1.95e-16	Urate levels in overweight individuals;
KIRP	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.41	5.92	0.35	1.09e-8	Red blood cell count;
KIRP	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.87	13.71	0.66	3.62e-32	Blood protein levels;
KIRP	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06505273	chr16:24850292	NA	0.44	5.92	0.35	1.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs55788414	0.789	rs4630561	chr16:81183108	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg17691542	chr6:26056736	HIST1H1C	0.65	7.8	0.45	1.72e-13	Iron status biomarkers;
KIRP	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.56	-7.53	-0.43	9.36e-13	Ulcerative colitis;
KIRP	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg03735888	chr19:58951602	ZNF132	0.44	5.16	0.31	4.97e-7	Uric acid clearance;
KIRP	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	cg12689670	chr1:183009347	LAMC1	0.45	6.43	0.38	6.62e-10	Hypertriglyceridemia;
KIRP	cis	rs3106136	1.000	rs3106134	chr4:95128091	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-4.92	-0.3	1.61e-6	Capecitabine sensitivity;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.57	7.87	0.45	1.13e-13	Longevity;Endometriosis;
KIRP	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg23202291	chr11:1979235	NA	0.4	5.17	0.31	4.96e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.43	-0.33	1.37e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.92	11.99	0.61	2.23e-26	Coronary artery disease;
KIRP	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.78	-0.49	2.9e-16	Blood metabolite levels;
KIRP	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg13206674	chr6:150067644	NUP43	0.46	6.6	0.39	2.48e-10	Testicular germ cell tumor;
KIRP	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs7709377	0.570	rs12656463	chr5:115443812	A/T	cg23108291	chr5:115420582	COMMD10	0.41	4.92	0.3	1.56e-6	Metabolite levels  (X-11787);
KIRP	cis	rs829661	0.532	rs829628	chr2:30756888	C/T	cg10949345	chr2:30726833	LCLAT1	0.49	7.2	0.42	7.48e-12	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs1912785	0.545	rs3843364	chr3:146503157	C/T	cg23963136	chr19:8372973	CD320	0.51	6.38	0.38	8.9e-10	Barrett's esophagus;
KIRP	cis	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg27411982	chr8:10470053	RP1L1	0.51	6.2	0.37	2.42e-9	Neuroticism;
KIRP	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.39	-0.32	1.65e-7	Parkinson's disease;
KIRP	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.45	-0.43	1.57e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02475777	chr4:1388615	CRIPAK	0.4	5.33	0.32	2.17e-7	Longevity;
KIRP	trans	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.43	-0.43	1.77e-12	Neuroticism;
KIRP	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	cg21523751	chr1:182988639	NA	0.4	6.17	0.37	2.74e-9	Colorectal cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03705947	chr1:68152081	GADD45A	0.52	6.92	0.4	3.84e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg07004394	chr14:106090750	NA	-0.44	-5.15	-0.31	5.34e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs9826463	1.000	rs56383228	chr3:142330863	T/C	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.0	0.36	6.85e-9	Schizophrenia;
KIRP	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg13628971	chr7:2884303	GNA12	0.39	5.03	0.31	9.67e-7	Height;
KIRP	cis	rs8093481	1.000	rs34108975	chr18:10692965	C/T	cg21165219	chr18:10698044	FAM38B	-0.44	-5.48	-0.33	1.03e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.94	15.14	0.69	4.99e-37	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg21285383	chr16:89894308	SPIRE2	0.3	5.78	0.35	2.27e-8	Vitiligo;
KIRP	cis	rs7640424	0.649	rs35710439	chr3:107913059	C/A	cg09227934	chr3:107805635	CD47	-0.36	-6.07	-0.36	4.71e-9	Body mass index;
KIRP	cis	rs9581857	0.546	rs9581837	chr13:27965764	G/T	cg22138327	chr13:27999177	GTF3A	1.03	7.44	0.43	1.72e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg08994789	chr17:28903642	LRRC37B2	0.62	5.33	0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.49	-0.33	1.02e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.88	13.82	0.66	1.59e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4765905	0.610	rs758172	chr12:2314997	T/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.87	-0.4	5.37e-11	Schizophrenia;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.59	8.27	0.47	8.48e-15	Longevity;Endometriosis;
KIRP	cis	rs6977660	0.943	rs9638765	chr7:19840616	G/A	cg05791153	chr7:19748676	TWISTNB	0.47	5.21	0.32	3.95e-7	Thyroid stimulating hormone;
KIRP	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg13444842	chr1:152974279	SPRR3	-0.42	-6.07	-0.36	4.73e-9	Inflammatory skin disease;
KIRP	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	1.07	20.67	0.8	1.04e-55	Bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15463457	chr4:90823130	MMRN1	0.44	6.13	0.36	3.38e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg17372223	chr3:52568218	NT5DC2	0.3	4.85	0.3	2.19e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.42	5.79	0.35	2.19e-8	Coronary artery disease;
KIRP	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	1.07	21.56	0.81	1.32e-58	Parkinson's disease;
KIRP	cis	rs7560272	0.538	rs35767294	chr2:73922834	A/G	cg20560298	chr2:73613845	ALMS1	0.55	6.66	0.39	1.77e-10	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg08132940	chr7:1081526	C7orf50	-0.68	-7.33	-0.42	3.39e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg19847130	chr8:10466454	RP1L1	0.35	5.1	0.31	6.78e-7	Neuroticism;
KIRP	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg11235152	chr1:67600687	NA	0.76	11.43	0.59	1.45e-24	Psoriasis;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs4908768	0.906	rs11121207	chr1:8681848	C/A	cg25722041	chr1:8623473	RERE	0.82	9.65	0.52	6.82e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg01557791	chr16:72042693	DHODH	-0.42	-5.14	-0.31	5.62e-7	Fibrinogen levels;
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg22325292	chr17:80708367	FN3K	0.38	5.14	0.31	5.63e-7	Glycated hemoglobin levels;
KIRP	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg13319975	chr6:146136371	FBXO30	-0.38	-5.25	-0.32	3.23e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg09698166	chr20:21106763	PLK1S1	0.5	6.07	0.36	4.94e-9	Asthma;
KIRP	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg24503407	chr1:205819492	PM20D1	0.48	5.21	0.32	3.97e-7	Parkinson's disease;
KIRP	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	4.95	0.3	1.38e-6	Height;
KIRP	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg08648136	chr8:956695	NA	0.43	6.47	0.38	5.14e-10	Schizophrenia;
KIRP	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.34	0.32	2.15e-7	Educational attainment;
KIRP	cis	rs687432	0.718	rs10896687	chr11:57786845	A/C	cg19752551	chr11:57585705	CTNND1	-0.42	-5.79	-0.35	2.18e-8	Parkinson's disease;
KIRP	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.68	0.48	5.5e-16	Prudent dietary pattern;
KIRP	cis	rs2904967	0.703	rs4149813	chr11:65082673	G/A	cg09225861	chr11:65069680	NA	0.44	5.84	0.35	1.61e-8	Mean corpuscular volume;
KIRP	cis	rs9913711	0.868	rs7216619	chr17:70079708	C/A	cg04438997	chr17:70115868	SOX9	0.4	5.36	0.32	1.94e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11673344	0.734	rs320887	chr19:37693438	T/C	cg14683738	chr19:37701593	ZNF585B	0.44	5.12	0.31	6.28e-7	Obesity-related traits;
KIRP	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.57	7.13	0.41	1.14e-11	Height;
KIRP	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.12	-0.46	2.25e-14	Mean corpuscular volume;
KIRP	cis	rs9815354	0.812	rs73071325	chr3:41809989	T/G	cg03022575	chr3:42003672	ULK4	0.81	8.32	0.47	6.13e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-11.07	-0.58	2.29e-23	Dental caries;
KIRP	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.43	-0.33	1.36e-7	Aortic root size;
KIRP	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg02931644	chr1:25747376	RHCE	0.36	6.53	0.38	3.83e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg11650704	chr1:154556575	ADAR	-0.41	-5.05	-0.31	8.41e-7	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11616701	chr5:122950706	CSNK1G3	0.44	6.27	0.37	1.6e-9	Survival in pancreatic cancer;
KIRP	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.16e-51	Leprosy;
KIRP	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.7	-10.53	-0.56	1.19e-21	Airway imaging phenotypes;
KIRP	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.51	7.44	0.43	1.63e-12	Lewy body disease;
KIRP	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs62413470	0.935	rs12192902	chr6:55953831	G/A	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.63	6.76	0.4	9.81e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg08126542	chr6:37504118	NA	0.67	9.48	0.52	2.29e-18	Cognitive performance;
KIRP	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg21184320	chr1:21044207	KIF17	-0.36	-5.49	-0.33	9.91e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-1.01	-12.06	-0.61	1.27e-26	Exhaled nitric oxide output;
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg13198984	chr17:80129470	CCDC57	-0.55	-8.35	-0.47	4.85e-15	Life satisfaction;
KIRP	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.47	-0.33	1.09e-7	Ileal carcinoids;
KIRP	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg12940439	chr1:67600707	NA	0.58	8.1	0.46	2.58e-14	Psoriasis;
KIRP	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.95	-0.45	6.89e-14	Response to antipsychotic treatment;
KIRP	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-8.13	-0.46	2.16e-14	Platelet distribution width;
KIRP	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.05	0.75	6.05e-47	Chronic sinus infection;
KIRP	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.57	-6.08	-0.36	4.68e-9	DNA methylation (variation);
KIRP	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg18944383	chr4:111397179	ENPEP	0.6	11.1	0.58	1.77e-23	Height;
KIRP	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg01320579	chr17:75405842	SEPT9	0.48	7.79	0.44	1.91e-13	Airflow obstruction;
KIRP	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.66	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg25486957	chr4:152246857	NA	-0.48	-5.39	-0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.65	-8.21	-0.46	1.28e-14	Extraversion;
KIRP	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.37	-8.04	-0.46	3.86e-14	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18923906	chr10:82225771	TSPAN14	0.31	6.25	0.37	1.81e-9	Survival in pancreatic cancer;
KIRP	cis	rs1823913	0.637	rs12622194	chr2:192163406	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.57e-9	Obesity-related traits;
KIRP	trans	rs61931739	0.629	rs1842886	chr12:33704257	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.13	-0.36	3.47e-9	Morning vs. evening chronotype;
KIRP	cis	rs4262150	0.810	rs4958323	chr5:152021767	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.17	-0.46	1.62e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg00677455	chr12:58241039	CTDSP2	-0.5	-5.65	-0.34	4.38e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19934382	chr11:94145963	NA	-0.39	-6.04	-0.36	5.57e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	8.45	0.47	2.55e-15	Motion sickness;
KIRP	cis	rs13102973	0.931	rs6822196	chr4:135855582	T/A	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.12e-16	Subjective well-being;
KIRP	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg21466736	chr12:48725269	NA	-0.49	-6.47	-0.38	5.25e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.69	6.17	0.37	2.81e-9	Schizophrenia;
KIRP	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg23594656	chr7:65796392	TPST1	-0.44	-6.08	-0.36	4.54e-9	Aortic root size;
KIRP	cis	rs6132905	0.590	rs74681083	chr20:2623992	A/C	cg24848351	chr20:2622020	TMC2	-0.65	-5.79	-0.35	2.12e-8	Mumps;
KIRP	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg04166393	chr7:2884313	GNA12	0.44	5.51	0.33	8.93e-8	Height;
KIRP	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.43	0.52	3.27e-18	Morning vs. evening chronotype;
KIRP	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.07e-7	Bipolar disorder;
KIRP	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-9.13	-0.5	2.65e-17	Resting heart rate;
KIRP	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs6466055	0.661	rs1558048	chr7:104829241	G/C	cg04380332	chr7:105027541	SRPK2	0.37	4.98	0.3	1.23e-6	Schizophrenia;
KIRP	cis	rs2273669	0.667	rs2145763	chr6:109306963	C/A	cg05315195	chr6:109294784	ARMC2	-0.62	-5.98	-0.36	7.88e-9	Prostate cancer;
KIRP	cis	rs234043	1.000	rs234043	chr3:172313367	T/C	cg03055671	chr3:172231528	TNFSF10	-0.4	-5.78	-0.35	2.28e-8	Renal cell carcinoma;
KIRP	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.9	-14.93	-0.69	2.53e-36	Prostate cancer;
KIRP	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg06740227	chr12:86229804	RASSF9	0.44	5.59	0.34	5.9e-8	Major depressive disorder;
KIRP	cis	rs1829883	0.701	rs9285876	chr5:98978212	A/T	cg08333243	chr5:99726346	NA	0.39	4.95	0.3	1.38e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs8077577	0.708	rs3862147	chr17:18133713	G/T	cg18869244	chr17:18121946	NA	-0.43	-4.93	-0.3	1.53e-6	Obesity-related traits;
KIRP	cis	rs882732	0.576	rs10139508	chr14:95035399	A/G	cg05186455	chr14:95027692	SERPINA4	-0.34	-5.4	-0.33	1.54e-7	Blood protein levels;
KIRP	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.63	7.24	0.42	5.61e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.36	-4.97	-0.3	1.25e-6	Neuroticism;
KIRP	cis	rs6132905	0.590	rs7264710	chr20:2622574	C/T	cg24848351	chr20:2622020	TMC2	-0.61	-5.49	-0.33	1.01e-7	Mumps;
KIRP	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.81	10.15	0.54	1.86e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.64	-8.64	-0.48	7.19e-16	Breast cancer;
KIRP	cis	rs59868192	0.925	rs72726031	chr15:42252340	C/A	cg20935245	chr15:42234343	EHD4	-0.55	-5.4	-0.33	1.58e-7	White blood cell count;
KIRP	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg12861170	chr19:19639553	YJEFN3	-0.49	-4.9	-0.3	1.77e-6	Bipolar disorder;
KIRP	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.46	-5.69	-0.34	3.58e-8	Facial morphology (factor 20);
KIRP	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.12	-0.5	2.68e-17	Hirschsprung disease;
KIRP	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg04218760	chr10:45406644	TMEM72	-0.24	-6.14	-0.36	3.26e-9	Mean corpuscular volume;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01947301	chr1:205718900	NUCKS1	-0.47	-6.51	-0.38	4.14e-10	Electrocardiographic conduction measures;
KIRP	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	9.21	0.51	1.51e-17	Cognitive test performance;
KIRP	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg09264619	chr17:80180166	NA	-0.37	-5.35	-0.32	1.96e-7	Life satisfaction;
KIRP	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg07636037	chr3:49044803	WDR6	-0.74	-5.59	-0.34	6.11e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7116495	1.000	rs10793016	chr11:71755063	A/G	cg26138937	chr11:71823887	C11orf51	0.69	5.52	0.33	8.63e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs72772090	0.539	rs72775807	chr5:96179761	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.71	-6.1	-0.36	4.1e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs17834760	0.913	rs7767881	chr6:62065006	G/A	cg08476511	chr6:168435923	KIF25	0.51	6.09	0.36	4.25e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.47	-5.8	-0.35	2.04e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg06565975	chr8:143823917	SLURP1	0.45	7.01	0.41	2.26e-11	Urinary tract infection frequency;
KIRP	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg08999081	chr20:33150536	PIGU	-0.38	-4.93	-0.3	1.52e-6	Height;
KIRP	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg12591125	chr7:1885375	MAD1L1	0.58	5.81	0.35	1.9e-8	Bipolar disorder;
KIRP	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg00310523	chr12:86230176	RASSF9	-0.4	-6.06	-0.36	5.19e-9	Major depressive disorder;
KIRP	cis	rs16976116	0.901	rs28449712	chr15:55500681	A/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg11189052	chr15:85197271	WDR73	0.51	5.32	0.32	2.32e-7	Schizophrenia;
KIRP	cis	rs4594175	0.926	rs4617765	chr14:51598843	T/C	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs12580194	0.593	rs60230359	chr12:55736550	T/C	cg19537932	chr12:55886519	OR6C68	-0.5	-6.45	-0.38	5.96e-10	Cancer;
KIRP	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.82	12.52	0.62	3.78e-28	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11166466	chr11:125932389	CDON	0.49	7.16	0.42	9.21e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg08501292	chr6:25962987	TRIM38	-1.1	-8.13	-0.46	2.09e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	5.02	0.3	1.01e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs745821	0.788	rs745823	chr18:48142784	A/G	cg18923635	chr18:48083994	NA	0.42	4.9	0.3	1.71e-6	Diastolic blood pressure;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.95	-8.4	-0.47	3.47e-15	Rheumatoid arthritis;
KIRP	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg03894339	chr8:19674705	INTS10	0.51	5.92	0.35	1.09e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.68	-7.09	-0.41	1.42e-11	Urate levels in lean individuals;
KIRP	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg09163369	chr1:210001066	C1orf107	-0.45	-5.88	-0.35	1.34e-8	Monobrow;
KIRP	cis	rs6466055	0.612	rs12154942	chr7:104859435	T/C	cg04380332	chr7:105027541	SRPK2	0.38	5.24	0.32	3.42e-7	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17804177	chr7:56019372	MRPS17	-0.49	-6.48	-0.38	5.06e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg09596252	chr17:78655493	RPTOR	0.51	5.89	0.35	1.23e-8	Fractional excretion of uric acid;
KIRP	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg02403541	chr12:121454288	C12orf43	-0.52	-6.47	-0.38	5.37e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs73198271	0.628	rs11777742	chr8:8589858	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg11005552	chr10:105648138	OBFC1	0.4	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg11130432	chr3:121712080	ILDR1	-0.46	-5.4	-0.33	1.58e-7	Multiple sclerosis;
KIRP	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg20573242	chr4:122745356	CCNA2	-0.43	-5.28	-0.32	2.78e-7	Type 2 diabetes;
KIRP	cis	rs16828019	0.852	rs3904243	chr1:41574852	T/G	cg18742814	chr1:41828276	NA	0.67	5.89	0.35	1.24e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6102059	0.598	rs4812443	chr20:39198836	T/G	cg22477343	chr20:39312069	NA	0.51	6.61	0.39	2.42e-10	LDL cholesterol;
KIRP	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.61	8.57	0.48	1.16e-15	Lymphocyte counts;
KIRP	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg14703610	chr5:56206110	C5orf35	0.48	6.78	0.4	8.67e-11	Coronary artery disease;
KIRP	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	1.11	7.89	0.45	9.87e-14	Skin colour saturation;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19530883	chr19:5903870	NDUFA11;VMAC	0.49	6.1	0.36	4.17e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	11.54	0.59	6.57e-25	Platelet count;
KIRP	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg19683494	chr5:74908142	NA	-0.43	-5.03	-0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-8.0	-0.45	5.04e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs2380205	0.967	rs7072174	chr10:5898802	T/C	cg27141509	chr10:5886111	NA	-0.38	-5.5	-0.33	9.65e-8	Breast cancer;
KIRP	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs4789693	0.518	rs6502108	chr17:80374899	A/C	cg04308225	chr17:80449738	NA	-0.49	-5.28	-0.32	2.82e-7	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-12.38	-0.62	1.08e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs7709377	0.595	rs784479	chr5:115617538	G/A	cg23108291	chr5:115420582	COMMD10	-0.44	-5.36	-0.32	1.88e-7	Metabolite levels  (X-11787);
KIRP	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg05347473	chr6:146136440	FBXO30	0.6	8.46	0.47	2.47e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg15128208	chr22:42549153	NA	0.64	5.35	0.32	1.98e-7	Birth weight;
KIRP	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.54	8.08	0.46	3e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.4	8.28	0.47	7.84e-15	IgG glycosylation;
KIRP	cis	rs775227	0.574	rs13068107	chr3:113029530	A/C	cg18753928	chr3:113234510	CCDC52	-0.55	-5.46	-0.33	1.18e-7	Dental caries;
KIRP	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg15212455	chr7:39170539	POU6F2	0.21	4.87	0.3	1.98e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.44	6.67	0.39	1.73e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.67	7.91	0.45	8.64e-14	Alcohol dependence;
KIRP	cis	rs4663866	0.901	rs34040298	chr2:239191607	T/C	cg16914508	chr2:239161102	PER2	0.72	5.17	0.31	4.81e-7	Irritable bowel syndrome;
KIRP	cis	rs17221829	0.574	rs2773245	chr11:89372626	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.04	-0.31	8.84e-7	Anxiety in major depressive disorder;
KIRP	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg10223061	chr2:219282414	VIL1	-0.29	-4.96	-0.3	1.31e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-0.83	-12.83	-0.63	3.47e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.9e-8	Glomerular filtration rate;
KIRP	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg23484912	chr5:273055	PDCD6	0.6	7.46	0.43	1.47e-12	Pancreatic cancer;
KIRP	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.42	-5.95	-0.35	9.27e-9	Blood metabolite levels;
KIRP	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-8.93	-0.49	9.92e-17	Monocyte count;
KIRP	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.23	-0.55	1.04e-20	Hemoglobin concentration;
KIRP	cis	rs11078597	0.671	rs62090058	chr17:1645624	G/C	cg17514665	chr17:1657533	SERPINF2	0.46	5.69	0.34	3.64e-8	Serum albumin level;
KIRP	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg01631408	chr1:248437212	OR2T33	0.65	8.07	0.46	3.1e-14	Common traits (Other);
KIRP	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.93	0.57	6.29e-23	Personality dimensions;
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs12615966	0.789	rs6758786	chr2:105367587	A/G	cg16465502	chr2:105461796	NA	-0.68	-5.9	-0.35	1.19e-8	Pancreatic cancer;
KIRP	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.15	0.41	9.99e-12	Neuroticism;
KIRP	cis	rs59197085	0.515	rs17165121	chr7:128442479	A/G	cg00734629	chr7:128471146	FLNC	0.41	5.08	0.31	7.41e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs6450176	0.564	rs255759	chr5:53328549	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-8.71	-0.49	4.54e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7520050	0.966	rs6675946	chr1:46371774	G/T	cg03146154	chr1:46216737	IPP	-0.42	-5.32	-0.32	2.37e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22509189	chr2:225307070	NA	-0.48	-5.63	-0.34	4.79e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs883565	0.569	rs7614000	chr3:39152575	C/G	cg01426195	chr3:39028469	NA	-0.53	-8.34	-0.47	5.43e-15	Handedness;
KIRP	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.84	11.76	0.6	1.28e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.49	5.86	0.35	1.46e-8	Metabolite levels;
KIRP	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg16574807	chr4:6945745	TBC1D14	-0.42	-4.95	-0.3	1.38e-6	Monocyte percentage of white cells;
KIRP	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.91	-0.3	1.67e-6	Pulmonary function;
KIRP	cis	rs2425143	0.687	rs6119649	chr20:34369596	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	6.0	0.36	7.1e-9	Blood protein levels;
KIRP	cis	rs3818717	0.507	rs12940675	chr17:17651214	C/T	cg02336718	chr17:17403227	NA	-0.32	-5.15	-0.31	5.39e-7	Lymphocyte counts;
KIRP	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs6747488	0.512	rs7569264	chr2:32316921	A/C	cg02381751	chr2:32503542	YIPF4	-0.61	-5.83	-0.35	1.74e-8	Interleukin-18 levels;
KIRP	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.68	0.39	1.55e-10	Monocyte percentage of white cells;
KIRP	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.76	9.99	0.54	6.25e-20	Breast cancer;
KIRP	cis	rs3924048	0.519	rs11121927	chr1:12614403	G/C	cg00291366	chr1:12616550	NA	0.44	5.34	0.32	2.11e-7	Optic cup area;
KIRP	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg17644776	chr2:200775616	C2orf69	-0.68	-5.99	-0.36	7.41e-9	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs9400467	0.506	rs1061388	chr6:111620294	A/C	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.79	-10.5	-0.56	1.56e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg23594656	chr7:65796392	TPST1	0.5	7.85	0.45	1.29e-13	Aortic root size;
KIRP	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg03714773	chr7:91764589	CYP51A1	0.4	5.89	0.35	1.24e-8	Breast cancer;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg10254082	chr7:997346	NA	0.48	5.16	0.31	4.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-9.35	-0.51	5.67e-18	Coffee consumption (cups per day);
KIRP	cis	rs3739034	0.646	rs114658932	chr2:135491302	T/G	cg15546071	chr2:135691756	CCNT2	-0.52	-4.93	-0.3	1.5e-6	Gut microbiome composition (winter);
KIRP	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg16141378	chr3:129829833	LOC729375	0.6	8.1	0.46	2.51e-14	Triglycerides;
KIRP	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg11161011	chr14:65562177	MAX	-0.6	-7.69	-0.44	3.55e-13	Obesity-related traits;
KIRP	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg21523564	chr15:75251491	NA	-0.38	-6.38	-0.38	8.51e-10	Breast cancer;
KIRP	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.64	-6.33	-0.37	1.16e-9	Body mass index;
KIRP	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.49	-6.13	-0.36	3.52e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.87	-0.35	1.38e-8	Monocyte count;
KIRP	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.44	5.64	0.34	4.65e-8	Crohn's disease;
KIRP	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.64	8.49	0.48	1.91e-15	Calcium levels;
KIRP	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg00677455	chr12:58241039	CTDSP2	0.88	8.78	0.49	2.87e-16	Multiple sclerosis;
KIRP	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.45	-6.57	-0.39	2.98e-10	Refractive error;
KIRP	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.59	7.79	0.44	1.91e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	cg21523751	chr1:182988639	NA	0.44	6.89	0.4	4.54e-11	Hypertriglyceridemia;
KIRP	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	1.02	11.15	0.58	1.2e-23	Height;
KIRP	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg13819577	chr1:248512075	OR14C36	-0.39	-5.12	-0.31	6.07e-7	Common traits (Other);
KIRP	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08439880	chr3:133502540	NA	-0.51	-6.41	-0.38	7.39e-10	Iron status biomarkers;
KIRP	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.57	-7.3	-0.42	3.94e-12	Retinal vascular caliber;
KIRP	cis	rs6693567	0.565	rs11205355	chr1:150252329	G/A	cg07843065	chr1:150265600	MRPS21	-0.43	-6.12	-0.36	3.67e-9	Migraine;
KIRP	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.27	-5.6	-0.34	5.6e-8	Menarche (age at onset);
KIRP	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg05775895	chr3:12838266	CAND2	0.34	5.26	0.32	3.18e-7	QRS complex (12-leadsum);
KIRP	trans	rs28573326	0.563	rs6833833	chr4:166338335	A/G	cg13437084	chr2:26467494	HADHB;HADHA	-0.48	-6.75	-0.4	1.08e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs2075277	1.000	rs4822862	chr22:21386477	C/T	cg25095814	chr2:202098016	CASP8	-0.59	-6.03	-0.36	5.84e-9	Eosinophilic esophagitis;
KIRP	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-4.85	-0.3	2.2e-6	Mean platelet volume;
KIRP	cis	rs4704187	0.663	rs6889760	chr5:74503704	A/C	cg03227963	chr5:74354835	NA	0.4	5.8	0.35	2.01e-8	Response to amphetamines;
KIRP	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg24631222	chr15:78858424	CHRNA5	-0.81	-9.72	-0.53	4.27e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.68	-7.62	-0.44	5.35e-13	Blood protein levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21294616	chr7:143093848	EPHA1	-0.46	-6.41	-0.38	7.2e-10	Inflammatory biomarkers;
KIRP	trans	rs11722228	0.790	rs13126729	chr4:9974186	G/A	cg26043149	chr18:55253948	FECH	-0.77	-8.54	-0.48	1.46e-15	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg14250997	chr9:106856677	SMC2	-0.43	-6.09	-0.36	4.34e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.62	7.57	0.43	7.65e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.76	10.61	0.56	6.72e-22	Schizophrenia;
KIRP	cis	rs1823913	0.599	rs2124095	chr2:192166454	C/T	cg12404831	chr2:192114017	MYO1B	0.54	7.44	0.43	1.7e-12	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11411707	chr1:151043197	GABPB2	-0.48	-6.05	-0.36	5.34e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg26874229	chr2:105853672	NA	-0.39	-5.52	-0.33	8.42e-8	Type 2 diabetes;
KIRP	cis	rs68170813	0.652	rs117775624	chr7:107124113	C/T	cg02696742	chr7:106810147	HBP1	-0.7	-6.34	-0.37	1.09e-9	Coronary artery disease;
KIRP	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg04490037	chr7:50633773	DDC	-0.42	-5.12	-0.31	6.28e-7	Malaria;
KIRP	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg24879335	chr3:133465180	TF	0.38	5.59	0.34	5.96e-8	Iron status biomarkers;
KIRP	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.18	-0.46	1.51e-14	Morning vs. evening chronotype;
KIRP	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.91	10.58	0.56	8.33e-22	Menopause (age at onset);
KIRP	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.36	-0.51	5.37e-18	Morning vs. evening chronotype;
KIRP	cis	rs1011018	0.955	rs4132078	chr7:139419930	T/C	cg03224163	chr7:139420300	HIPK2	-0.47	-4.91	-0.3	1.69e-6	Systolic blood pressure;
KIRP	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg14593290	chr7:50529359	DDC	0.44	5.52	0.33	8.49e-8	Malaria;
KIRP	cis	rs6681460	1.000	rs6697088	chr1:67044724	C/G	cg02459107	chr1:67143332	SGIP1	-0.44	-6.26	-0.37	1.66e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.39	5.0	0.3	1.11e-6	Leprosy;
KIRP	cis	rs10754283	0.934	rs6661282	chr1:90119992	C/T	cg06121193	chr1:90282411	NA	-0.46	-6.5	-0.38	4.53e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg24253500	chr15:84953950	NA	0.48	5.44	0.33	1.32e-7	Schizophrenia;
KIRP	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.48	-6.17	-0.37	2.86e-9	Crohn's disease;
KIRP	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg15128208	chr22:42549153	NA	0.75	6.99	0.41	2.58e-11	Birth weight;
KIRP	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.46e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	cg12689670	chr1:183009347	LAMC1	0.48	6.88	0.4	4.92e-11	Colorectal cancer;
KIRP	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg10434728	chr15:90938212	IQGAP1	0.3	5.03	0.31	9.25e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs151997	1.000	rs42736	chr5:50244838	G/C	cg06027927	chr5:50259733	NA	0.57	7.2	0.42	7.13e-12	Callous-unemotional behaviour;
KIRP	cis	rs17065868	1.000	rs28405066	chr13:45098388	C/T	cg10246903	chr13:45222710	NA	0.64	6.95	0.41	3.22e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9921338	0.923	rs4563054	chr16:11447546	T/G	cg00044050	chr16:11439710	C16orf75	-0.56	-5.83	-0.35	1.69e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.56	6.52	0.38	3.99e-10	Obesity-related traits;
KIRP	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.59	-6.36	-0.38	9.6e-10	Colorectal adenoma (advanced);
KIRP	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.84	11.59	0.59	4.56e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	0.96	9.39	0.51	4.19e-18	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.66	-9.29	-0.51	8.3e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6540559	0.546	rs634601	chr1:210421594	C/T	cg09074223	chr1:210466472	NA	0.59	5.8	0.35	2.06e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs6102059	0.692	rs6129647	chr20:39229982	A/G	cg22477343	chr20:39312069	NA	-0.48	-6.38	-0.38	8.63e-10	LDL cholesterol;
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.51	-0.38	4.2e-10	Lung cancer;
KIRP	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg06558623	chr16:89946397	TCF25	1.11	8.08	0.46	2.97e-14	Skin colour saturation;
KIRP	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	9.54	0.52	1.5e-18	Cognitive test performance;
KIRP	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.11	12.04	0.61	1.53e-26	Vitiligo;
KIRP	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg24633833	chr3:10029261	TMEM111	0.56	5.25	0.32	3.33e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs28489187	0.706	rs233058	chr1:85798865	G/T	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg17764715	chr19:33622953	WDR88	0.65	7.86	0.45	1.22e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.5	7.48	0.43	1.34e-12	Bipolar disorder;
KIRP	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg06634786	chr22:41940651	POLR3H	-0.48	-5.29	-0.32	2.77e-7	Neuroticism;
KIRP	cis	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.31	-0.32	2.44e-7	Leprosy;
KIRP	cis	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs981844	1.000	rs2606328	chr4:154653864	C/T	cg14289246	chr4:154710475	SFRP2	0.64	7.31	0.42	3.69e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	0.72	6.84	0.4	6.42e-11	Methadone dose in opioid dependence;
KIRP	cis	rs738322	0.868	rs8139952	chr22:38606989	C/A	cg17652424	chr22:38574118	PLA2G6	0.26	5.3	0.32	2.51e-7	Cutaneous nevi;
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19893067	chr17:80732956	TBCD	-0.36	-4.9	-0.3	1.76e-6	Glycated hemoglobin levels;
KIRP	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg12131826	chr15:77904385	NA	0.5	6.0	0.36	7.21e-9	Type 2 diabetes;
KIRP	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg24130564	chr14:104152367	KLC1	-0.5	-6.78	-0.4	8.69e-11	Body mass index;
KIRP	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs17065868	1.000	rs9533872	chr13:45053542	C/T	cg10246903	chr13:45222710	NA	0.58	5.96	0.36	8.8e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.78	11.15	0.58	1.23e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg24375607	chr4:120327624	NA	0.6	6.49	0.38	4.71e-10	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs2882667	0.627	rs1549203	chr5:138468344	A/G	cg04439458	chr5:138467593	SIL1	0.42	6.63	0.39	2.17e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.66	-12.19	-0.61	4.87e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg07117364	chr1:16154769	NA	-0.41	-5.04	-0.31	9.22e-7	Dilated cardiomyopathy;
KIRP	trans	rs12517041	1.000	rs6866732	chr5:23307656	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.58	-0.44	6.94e-13	Calcium levels;
KIRP	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.48	5.72	0.34	3.07e-8	Colorectal cancer;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26227975	chr3:9773404	BRPF1	0.51	6.74	0.39	1.1e-10	Myopia (pathological);
KIRP	cis	rs11605924	0.901	rs7112505	chr11:45840939	A/T	cg23097878	chr11:45879730	CRY2	0.32	6.53	0.38	3.77e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs4711336	0.664	rs4713662	chr6:33674188	A/G	cg15676125	chr6:33679581	C6orf125	0.42	5.48	0.33	1.07e-7	Height;
KIRP	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg08996748	chr15:40651036	DISP2	-0.45	-4.89	-0.3	1.78e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg18882449	chr10:104885122	NT5C2	-0.42	-5.41	-0.33	1.49e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg14914422	chr1:46958856	NA	0.42	5.25	0.32	3.35e-7	Monobrow;
KIRP	cis	rs2273669	0.504	rs77373614	chr6:109418075	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.17	-0.31	4.79e-7	Prostate cancer;
KIRP	cis	rs7172677	0.737	rs4886668	chr15:75448034	T/C	cg14664628	chr15:75095509	CSK	-0.5	-5.67	-0.34	3.98e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.77	-10.29	-0.55	6.96e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg23188430	chr6:125850052	NA	-0.36	-5.46	-0.33	1.19e-7	High light scatter reticulocyte count;
KIRP	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.0	-8.39	-0.47	3.74e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.67	-6.73	-0.39	1.2e-10	Systemic lupus erythematosus;
KIRP	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg12741994	chr3:170137321	CLDN11	-0.5	-5.55	-0.33	7.5e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.66	-9.3	-0.51	7.94e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-5.3	-0.32	2.62e-7	HDL cholesterol;
KIRP	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.41	-0.43	2.06e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg00409905	chr10:38381863	ZNF37A	-0.55	-6.07	-0.36	4.86e-9	Obesity (extreme);
KIRP	cis	rs1978968	1.000	rs12158906	chr22:18437382	A/G	cg02610425	chr22:18483192	MICAL3	0.39	5.85	0.35	1.58e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.9	-0.45	9.18e-14	Life satisfaction;
KIRP	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg12705353	chr12:122356852	WDR66	0.52	6.97	0.41	2.96e-11	Mean corpuscular volume;
KIRP	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-1.02	-20.11	-0.79	7.17e-54	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.05	0.41	1.81e-11	Rheumatoid arthritis;
KIRP	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	10.49	0.56	1.64e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.97	-10.7	-0.56	3.58e-22	Body mass index;
KIRP	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg22903471	chr2:27725779	GCKR	0.41	5.65	0.34	4.34e-8	Oral cavity cancer;
KIRP	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg24296786	chr1:45957014	TESK2	-0.65	-8.68	-0.48	5.47e-16	High light scatter reticulocyte count;
KIRP	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.5	5.87	0.35	1.38e-8	Response to antipsychotic treatment;
KIRP	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.79	7.23	0.42	6.16e-12	Mean platelet volume;
KIRP	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.59	8.57	0.48	1.15e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14835575	chr10:16859367	RSU1	0.68	8.57	0.48	1.14e-15	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	trans	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	20.06	0.79	1.12e-53	Chronic sinus infection;
KIRP	cis	rs4764487	0.735	rs2072370	chr12:6345080	A/G	cg08284733	chr12:6341482	CD9	-0.6	-10.38	-0.55	3.63e-21	Mean platelet volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17164693	chr10:124913828	BUB3	0.57	7.02	0.41	2.15e-11	Smoking initiation;
KIRP	cis	rs2625529	0.824	rs12595464	chr15:72294398	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.12e-9	Red blood cell count;
KIRP	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg04310649	chr10:35416472	CREM	-0.58	-6.81	-0.4	7.5e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg04539111	chr16:67997858	SLC12A4	-0.58	-5.25	-0.32	3.25e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.98	13.11	0.64	3.78e-30	Cognitive ability;
KIRP	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.83	-12.79	-0.63	4.53e-29	Asthma;
KIRP	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.78	8.2	0.46	1.34e-14	Corneal astigmatism;
KIRP	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.93	-0.35	1.01e-8	Menarche (age at onset);
KIRP	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.76	-9.14	-0.5	2.39e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg02404636	chr22:31891804	SFI1	-0.47	-5.2	-0.31	4.22e-7	Colorectal cancer;
KIRP	cis	rs7202877	0.656	rs37596	chr16:75498320	C/A	cg03315344	chr16:75512273	CHST6	-0.56	-5.91	-0.35	1.12e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	trans	rs9790314	0.582	rs6796201	chr3:160634313	A/G	cg19274270	chr17:78178856	CARD14	0.34	6.02	0.36	6.23e-9	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18771195	chr17:182656	RPH3AL	0.45	6.71	0.39	1.3e-10	Survival in pancreatic cancer;
KIRP	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.28	-0.32	2.84e-7	Triglycerides;
KIRP	cis	rs675026	0.963	rs680796	chr6:154449525	G/A	cg07813322	chr6:154414604	OPRM1	-0.44	-5.77	-0.35	2.4e-8	Hypertension;
KIRP	trans	rs2270927	0.510	rs6453214	chr5:75584423	A/G	cg13563193	chr19:33072644	PDCD5	0.91	6.67	0.39	1.7e-10	Mean corpuscular volume;
KIRP	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.45	-5.51	-0.33	9.03e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.38	-0.32	1.72e-7	Life satisfaction;
KIRP	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg06392426	chr19:10676186	KRI1	0.41	5.47	0.33	1.13e-7	Red cell distribution width;
KIRP	cis	rs2120243	0.539	rs12638732	chr3:157113871	T/C	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg25008857	chr14:105974488	NA	0.43	4.89	0.3	1.79e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs10864907	0.614	rs12468164	chr2:113712783	C/T	cg06156847	chr2:113672199	IL1F7	0.45	6.51	0.38	4.16e-10	Pulmonary function;
KIRP	cis	rs78761021	0.720	rs731541	chr17:9799162	A/C	cg26853458	chr17:9805074	RCVRN	0.53	4.97	0.3	1.26e-6	Type 2 diabetes;
KIRP	cis	rs703970	0.560	rs2764817	chr10:80972653	C/G	cg18737081	chr10:80999807	ZMIZ1	-0.31	-5.16	-0.31	4.99e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4702718	0.616	rs7733385	chr5:10712199	G/A	cg14521931	chr5:10832172	NA	-0.45	-5.99	-0.36	7.36e-9	Obesity-related traits;
KIRP	cis	rs9815354	0.767	rs73081335	chr3:41895177	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg21775007	chr8:11205619	TDH	0.52	7.15	0.41	9.61e-12	Mood instability;
KIRP	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.46	0.59	1.19e-24	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.91	0.45	8.91e-14	Aortic root size;
KIRP	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg02151108	chr14:50098012	C14orf104	-0.58	-8.24	-0.46	1.05e-14	Carotid intima media thickness;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.45	5.34	0.32	2.1e-7	Longevity;Endometriosis;
KIRP	cis	rs2273156	1.000	rs35797365	chr14:35452759	A/G	cg09327582	chr14:35236912	BAZ1A	-0.48	-5.25	-0.32	3.27e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg03959625	chr15:84868606	LOC388152	0.64	7.2	0.42	7.51e-12	Bipolar disorder lithium response (categorical) or schizophrenia;
KIRP	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	cis	rs1712517	0.873	rs7916056	chr10:104997914	T/C	cg05636881	chr10:105038444	INA	-0.44	-6.36	-0.38	9.82e-10	Migraine;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12152193	chr5:175954583	RNF44	0.4	6.07	0.36	4.86e-9	Cancer;
KIRP	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00629928	chr5:358741	AHRR	0.46	4.96	0.3	1.32e-6	Breast cancer;
KIRP	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	1.1	17.93	0.75	1.54e-46	Cognitive function;
KIRP	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg11993925	chr19:44307056	LYPD5	0.42	5.79	0.35	2.13e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.7	-10.28	-0.55	7.42e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg17644776	chr2:200775616	C2orf69	0.57	6.04	0.36	5.71e-9	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.37	4.87	0.3	1.98e-6	Educational attainment;
KIRP	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.29	-5.42	-0.33	1.43e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.46	5.86	0.35	1.49e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.81	-0.4	7.25e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	7.8	0.45	1.71e-13	Mean corpuscular volume;
KIRP	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.45	0.33	1.24e-7	Height;
KIRP	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-8.39	-0.47	3.81e-15	Coronary artery disease;
KIRP	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg04731861	chr2:219085781	ARPC2	0.26	6.66	0.39	1.82e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05220968	chr6:146057943	EPM2A	0.39	5.05	0.31	8.65e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4666360	1.000	rs4666361	chr2:20336215	G/C	cg07142377	chr2:20335552	NA	-0.27	-4.85	-0.3	2.15e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
KIRP	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg10523679	chr1:76189770	ACADM	-0.46	-6.38	-0.38	8.71e-10	Daytime sleep phenotypes;
KIRP	cis	rs2278796	0.697	rs2278795	chr1:204954993	A/G	cg04862289	chr1:204966208	NFASC	0.36	5.0	0.3	1.11e-6	Mean platelet volume;
KIRP	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-5.78	-0.35	2.21e-8	Airflow obstruction;
KIRP	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-7.1	-0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs1832871	0.711	rs9459918	chr6:158703604	A/C	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs9815354	0.812	rs73077386	chr3:41857652	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg13010199	chr12:38710504	ALG10B	-0.63	-7.8	-0.45	1.8e-13	Morning vs. evening chronotype;
KIRP	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-8.91	-0.49	1.15e-16	Chronic sinus infection;
KIRP	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.51	5.71	0.34	3.26e-8	Vitiligo;
KIRP	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.87	-10.22	-0.55	1.17e-20	Homoarginine levels;
KIRP	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg24130564	chr14:104152367	KLC1	-0.52	-7.08	-0.41	1.53e-11	Body mass index;
KIRP	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.82	12.29	0.62	2.12e-27	Menarche (age at onset);
KIRP	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg26681399	chr22:41777847	TEF	-0.45	-5.06	-0.31	8.04e-7	Vitiligo;
KIRP	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.57	8.74	0.49	3.77e-16	Personality dimensions;
KIRP	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.63	-8.02	-0.46	4.23e-14	Diastolic blood pressure;
KIRP	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.73	-8.02	-0.46	4.2e-14	Body mass index;
KIRP	cis	rs2395528	0.514	rs2670219	chr10:80123674	A/G	cg08356028	chr10:80217969	NA	0.32	4.97	0.3	1.23e-6	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.31	7.38	0.43	2.47e-12	IgG glycosylation;
KIRP	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg25547332	chr5:131281432	NA	0.47	5.35	0.32	2.04e-7	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.66	0.34	4.11e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.45	-6.96	-0.41	3.14e-11	Coronary artery disease;
KIRP	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.52	6.24	0.37	1.85e-9	Multiple sclerosis;
KIRP	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg05519781	chr21:40033154	ERG	0.64	8.57	0.48	1.16e-15	Coronary artery disease;
KIRP	cis	rs911119	0.913	rs6048924	chr20:23578996	G/A	cg16589663	chr20:23618590	CST3	0.49	4.99	0.3	1.14e-6	Chronic kidney disease;
KIRP	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg22771759	chr13:24902376	NA	0.42	5.35	0.32	2.01e-7	Obesity-related traits;
KIRP	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg06611532	chr13:114900021	NA	0.22	5.06	0.31	8.34e-7	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.11	-0.31	6.62e-7	Lung cancer;
KIRP	cis	rs16857609	0.628	rs2068972	chr2:218346451	A/G	cg15335768	chr2:218268053	DIRC3	0.38	5.66	0.34	4.17e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg03060546	chr3:49711283	APEH	0.46	6.05	0.36	5.49e-9	Parkinson's disease;
KIRP	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.15	0.61	6.43e-27	Ileal carcinoids;
KIRP	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg05507819	chr15:63340323	TPM1	-0.45	-5.04	-0.31	8.82e-7	HDL cholesterol;
KIRP	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs785830	0.721	rs682251	chr9:271455	C/T	cg14500300	chr9:211689	NA	-0.49	-6.4	-0.38	7.6e-10	Platelet distribution width;
KIRP	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.59	9.13	0.5	2.54e-17	Personality dimensions;
KIRP	cis	rs62413470	1.000	rs4544908	chr6:55946166	C/T	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.44	5.64	0.34	4.55e-8	Height;
KIRP	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.33	-0.47	5.7e-15	Neuroticism;
KIRP	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.56	-0.39	3.16e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-4.94	-0.3	1.43e-6	Ulcerative colitis;
KIRP	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg26248373	chr2:1572462	NA	-0.61	-6.02	-0.36	6.42e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg04287289	chr16:89883240	FANCA	-0.39	-5.13	-0.31	5.82e-7	Vitiligo;
KIRP	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg08076091	chr2:203926405	NBEAL1	0.92	9.52	0.52	1.69e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg07701084	chr6:150067640	NUP43	0.55	7.1	0.41	1.34e-11	Lung cancer;
KIRP	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg20999797	chr1:1681921	NA	0.52	8.19	0.46	1.39e-14	Body mass index;
KIRP	cis	rs7075426	0.905	rs10887612	chr10:88213946	T/C	cg07322936	chr10:88137208	NA	0.43	4.9	0.3	1.74e-6	Migraine without aura;
KIRP	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg12861170	chr19:19639553	YJEFN3	-0.45	-4.99	-0.3	1.14e-6	Bipolar disorder;
KIRP	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.75	9.62	0.52	8.21e-19	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17898823	chr4:25032472	LGI2	0.56	7.03	0.41	2.08e-11	Parkinson's disease;
KIRP	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.33	0.59	3.17e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2625529	0.652	rs11634608	chr15:72255718	A/G	cg16672083	chr15:72433130	SENP8	0.46	6.42	0.38	6.93e-10	Red blood cell count;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg08132940	chr7:1081526	C7orf50	-0.7	-7.04	-0.41	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg16141378	chr3:129829833	LOC729375	0.51	6.89	0.4	4.72e-11	Mood instability;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg03188948	chr7:1209495	NA	0.69	6.31	0.37	1.26e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07835289	chr1:236030215	LYST	0.45	6.25	0.37	1.76e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.55	-6.55	-0.39	3.25e-10	Prudent dietary pattern;
KIRP	cis	rs6142618	0.555	rs242602	chr20:30666948	T/C	cg09796376	chr20:30640595	HCK	0.4	5.45	0.33	1.22e-7	Inflammatory bowel disease;
KIRP	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg02175308	chr1:109941060	SORT1	0.27	4.94	0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg01114163	chr5:1856713	NA	-0.44	-5.45	-0.33	1.2e-7	Cardiovascular disease risk factors;
KIRP	cis	rs687432	0.847	rs1376489	chr11:57810886	C/G	cg19752551	chr11:57585705	CTNND1	-0.68	-8.7	-0.49	4.74e-16	Parkinson's disease;
KIRP	cis	rs10267417	0.603	rs1557772	chr7:19908535	A/C	cg05791153	chr7:19748676	TWISTNB	0.5	5.13	0.31	6.01e-7	Night sleep phenotypes;
KIRP	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg17691542	chr6:26056736	HIST1H1C	0.48	6.27	0.37	1.62e-9	Height;
KIRP	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.78	10.06	0.54	3.62e-20	Neutrophil percentage of white cells;
KIRP	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-0.56	-7.98	-0.45	5.69e-14	Coronary artery disease;
KIRP	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg22029157	chr1:209979665	IRF6	0.4	6.0	0.36	7.08e-9	Monobrow;
KIRP	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.57	-7.74	-0.44	2.56e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg07843065	chr1:150265600	MRPS21	0.44	6.04	0.36	5.65e-9	Migraine;
KIRP	cis	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg08773314	chr2:239334832	ASB1	-0.49	-4.9	-0.3	1.78e-6	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.56	-5.92	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs76793172	0.588	rs659444	chr19:46284947	T/C	cg00442267	chr19:46317840	RSPH6A	0.64	5.64	0.34	4.7e-8	Eosinophil counts;
KIRP	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.37e-8	Motion sickness;
KIRP	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	8.6	0.48	9.63e-16	Ileal carcinoids;
KIRP	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg12384639	chr17:618140	VPS53	0.49	5.96	0.36	8.84e-9	Prostate cancer;
KIRP	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg03388025	chr16:89894329	SPIRE2	0.32	6.25	0.37	1.79e-9	Vitiligo;
KIRP	cis	rs28595532	0.800	rs67686161	chr4:119336720	C/T	cg21605333	chr4:119757512	SEC24D	0.94	7.19	0.42	7.56e-12	Cannabis dependence symptom count;
KIRP	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.88	0.4	4.85e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg18560240	chr7:107437656	SLC26A3	-0.44	-5.75	-0.34	2.63e-8	Ulcerative colitis;
KIRP	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg03929089	chr4:120376271	NA	0.97	6.95	0.41	3.17e-11	Myopia (pathological);
KIRP	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.47	5.35	0.32	2.03e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2617583	0.509	rs4738	chr5:1461568	C/T	cg07151155	chr5:1473589	LPCAT1	-0.41	-5.08	-0.31	7.64e-7	Breast cancer;
KIRP	cis	rs17123764	0.792	rs11169073	chr12:49968426	T/C	cg02054252	chr12:50078554	FMNL3	0.43	5.19	0.31	4.37e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs72991	0.639	rs1529579	chr11:121235871	G/T	cg27192990	chr6:129479024	LAMA2	-0.47	-6.07	-0.36	4.83e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7721647	0.778	rs231383	chr5:90830204	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.39	-4.88	-0.3	1.94e-6	Breast cancer;
KIRP	cis	rs10114408	0.885	rs10821243	chr9:96638066	C/A	cg14598338	chr9:96623480	NA	-0.33	-4.9	-0.3	1.7e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.6	0.34	5.75e-8	Lung cancer;
KIRP	trans	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg06521331	chr12:34319734	NA	-0.59	-7.15	-0.41	9.72e-12	Bladder cancer;
KIRP	cis	rs11578119	0.902	rs2421326	chr1:170512369	T/A	cg09767346	chr1:170501363	GORAB	-0.35	-4.87	-0.3	2e-6	Male-pattern baldness;
KIRP	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg04691961	chr3:161091175	C3orf57	-0.46	-6.57	-0.39	2.98e-10	Morning vs. evening chronotype;
KIRP	cis	rs6907629	1.000	rs928344	chr6:167571430	A/T	cg13805183	chr6:167554790	NA	0.36	5.07	0.31	7.97e-7	Asthma (childhood onset);
KIRP	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	1.11	16.18	0.72	1.36e-40	Breast cancer;
KIRP	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.78	0.4	8.91e-11	Coffee consumption (cups per day);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg01442132	chr2:62424496	B3GNT2	0.53	6.42	0.38	7.11e-10	Educational attainment;
KIRP	cis	rs35740288	0.770	rs34048547	chr15:86181067	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-5.29	-0.32	2.73e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg10950524	chr7:2139216	MAD1L1	0.29	4.84	0.3	2.25e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.86	-10.62	-0.56	6.26e-22	Homoarginine levels;
KIRP	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.47	7.54	0.43	8.85e-13	Eye color traits;
KIRP	cis	rs13161895	1.000	rs248318	chr5:179430530	C/T	cg02702477	chr5:179499311	RNF130	0.69	5.36	0.32	1.95e-7	LDL cholesterol;
KIRP	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.43	-7.89	-0.45	9.61e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07167872	chr1:205819463	PM20D1	0.48	5.69	0.34	3.6e-8	Parkinson's disease;
KIRP	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-9.36	-0.51	5.14e-18	Triglycerides;
KIRP	cis	rs13132184	0.507	rs13129650	chr4:38025101	A/G	cg14409701	chr4:38048871	TBC1D1	-0.79	-7.42	-0.43	1.84e-12	Verbal declarative memory;
KIRP	cis	rs3784262	0.528	rs8027964	chr15:58335272	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.86	-0.3	2.11e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2591576	0.543	rs62382145	chr5:165345212	G/T	cg13976338	chr5:165423657	NA	-0.66	-8.69	-0.48	5.29e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg14228332	chr4:119757509	SEC24D	0.78	4.87	0.3	2.02e-6	Cannabis dependence symptom count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11189022	chr11:108829471	NA	0.43	6.1	0.36	4.05e-9	Interleukin-4 levels;
KIRP	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg05527609	chr1:210001259	C1orf107	-0.48	-5.23	-0.32	3.69e-7	Red blood cell count;
KIRP	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.7	-0.34	3.45e-8	IgG glycosylation;
KIRP	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21972741	chr5:435613	AHRR	0.53	7.0	0.41	2.45e-11	Cystic fibrosis severity;
KIRP	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.52	6.91	0.4	4.13e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.57	-6.4	-0.38	7.82e-10	Corneal structure;
KIRP	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg17120908	chr11:65337727	SSSCA1	0.53	5.85	0.35	1.53e-8	Plateletcrit;
KIRP	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-8.87	-0.49	1.5e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg02612397	chr6:125855124	NA	-0.34	-5.09	-0.31	7.08e-7	Brugada syndrome;
KIRP	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.46	0.33	1.16e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2071426	0.755	rs11572177	chr10:96797270	T/C	cg09036531	chr10:96991505	NA	-0.43	-4.92	-0.3	1.55e-6	Blood metabolite levels;
KIRP	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg25801113	chr15:45476975	SHF	0.42	7.76	0.44	2.23e-13	Uric acid levels;
KIRP	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.78	9.12	0.5	2.81e-17	Schizophrenia;
KIRP	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg25486957	chr4:152246857	NA	-0.5	-5.48	-0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.07	-0.31	7.76e-7	Schizophrenia;
KIRP	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg11569703	chr11:65557185	OVOL1	-0.52	-9.52	-0.52	1.72e-18	Acne (severe);
KIRP	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.38	6.39	0.38	8.39e-10	Heart rate;
KIRP	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.89	-15.73	-0.71	4.62e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.27	-0.37	1.64e-9	Total body bone mineral density;
KIRP	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg12962167	chr3:53033115	SFMBT1	0.76	5.68	0.34	3.74e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7116495	1.000	rs3886589	chr11:71669487	G/T	cg11196788	chr11:71737549	NUMA1	0.55	4.94	0.3	1.45e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	Neuroticism;
KIRP	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.06	0.31	8.26e-7	Breast cancer;
KIRP	cis	rs282587	0.502	rs377971	chr13:113417014	G/A	cg04656015	chr13:113407548	ATP11A	0.59	6.36	0.38	9.76e-10	Glycated hemoglobin levels;
KIRP	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg16917193	chr12:54089295	NA	-0.53	-6.59	-0.39	2.72e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.53	-0.33	8.05e-8	Life satisfaction;
KIRP	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg25319279	chr11:5960081	NA	-0.58	-6.05	-0.36	5.3300000000000004e-09	DNA methylation (variation);
KIRP	cis	rs17123764	0.748	rs55686423	chr12:49963534	A/T	cg20471783	chr12:50157085	TMBIM6	0.41	5.81	0.35	1.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6494488	0.500	rs66586340	chr15:64983249	A/G	cg03791955	chr15:65024147	NA	-0.56	-4.87	-0.3	2.01e-6	Coronary artery disease;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-1.08	-21.46	-0.81	2.78e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.63	9.07	0.5	3.89e-17	Resting heart rate;
KIRP	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.47	6.13	0.36	3.44e-9	Platelet count;
KIRP	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.7	-8.05	-0.46	3.48e-14	Exhaled nitric oxide output;
KIRP	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg25457927	chr22:38595422	NA	-0.26	-5.4	-0.33	1.61e-7	Cutaneous nevi;
KIRP	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.37	-5.04	-0.31	8.87e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg18753928	chr3:113234510	CCDC52	-0.58	-5.65	-0.34	4.5e-8	Dental caries;
KIRP	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg20701182	chr2:24300061	SF3B14	0.57	5.08	0.31	7.61e-7	Lymphocyte counts;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg23985595	chr17:80112537	CCDC57	-0.35	-5.18	-0.31	4.59e-7	Life satisfaction;
KIRP	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.77	11.16	0.58	1.13e-23	Hip circumference;
KIRP	cis	rs4666002	0.956	rs2384656	chr2:27832055	A/G	cg05484376	chr2:27715224	FNDC4	-0.37	-5.48	-0.33	1.06e-7	Phospholipid levels (plasma);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25544073	chr8:98656304	MTDH	-0.58	-6.5	-0.38	4.48e-10	Menopause (age at onset);
KIRP	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-9.69	-0.53	5.1e-19	Chronic sinus infection;
KIRP	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	22.32	0.82	4.66e-61	Chronic sinus infection;
KIRP	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.88	-10.19	-0.54	1.45e-20	Corneal astigmatism;
KIRP	cis	rs9611198	0.846	rs5757730	chr22:39967430	A/G	cg03390717	chr22:39966585	CACNA1I	0.38	6.8	0.4	8.09e-11	Schizophrenia;
KIRP	cis	rs3779635	0.713	rs4733063	chr8:27302885	A/G	cg23693289	chr8:27183097	PTK2B	0.45	5.65	0.34	4.4e-8	Neuroticism;
KIRP	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25332826	chr17:54893286	C17orf67	0.46	6.94	0.4	3.42e-11	Interleukin-4 levels;
KIRP	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg23173402	chr1:227635558	NA	0.61	4.94	0.3	1.46e-6	Major depressive disorder;
KIRP	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg17207736	chr8:142237307	SLC45A4	-0.45	-5.68	-0.34	3.71e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7665939	0.790	rs72709294	chr4:190142270	G/C	cg09826759	chr4:190284978	NA	-0.85	-5.19	-0.31	4.38e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg18709589	chr6:96969512	KIAA0776	0.34	5.04	0.31	8.89e-7	Headache;
KIRP	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs2554380	0.891	rs2554383	chr15:84356316	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.64	-8.95	-0.5	8.71e-17	Height;
KIRP	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-5.22	-0.32	3.81e-7	Cognitive function;
KIRP	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.66	0.48	6.17e-16	Electroencephalogram traits;
KIRP	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.15	20.66	0.8	1.15e-55	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.49	5.36	0.32	1.93e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg17652424	chr22:38574118	PLA2G6	-0.28	-5.81	-0.35	1.94e-8	Cutaneous nevi;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg11016749	chr4:921637	GAK	-0.55	-5.09	-0.31	6.99e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.62	5.85	0.35	1.58e-8	Alzheimer's disease;
KIRP	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg21926883	chr2:100939477	LONRF2	-0.56	-7.59	-0.44	6.62e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.15	9.34	0.51	5.98e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4908768	0.906	rs11121182	chr1:8522553	G/T	cg25722041	chr1:8623473	RERE	0.78	9.91	0.53	1.1e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs8077577	0.708	rs2290504	chr17:18136988	T/C	cg18869244	chr17:18121946	NA	-0.42	-4.88	-0.3	1.9e-6	Obesity-related traits;
KIRP	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.76	8.17	0.46	1.6e-14	Gut microbiome composition (summer);
KIRP	cis	rs3134353	0.932	rs3134358	chr8:101958433	G/T	cg07585502	chr8:101912084	NA	-0.4	-4.92	-0.3	1.55e-6	Body mass index;
KIRP	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.12	-0.41	1.18e-11	Glomerular filtration rate;
KIRP	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	10.43	0.55	2.51e-21	Total body bone mineral density;
KIRP	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.93	10.11	0.54	2.5e-20	Alzheimer's disease;
KIRP	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.67	9.2	0.51	1.6e-17	Lymphocyte counts;
KIRP	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	6.99	0.41	2.59e-11	Menarche (age at onset);
KIRP	cis	rs9426935	0.570	rs1591902	chr1:154043693	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.35	-5.1	-0.31	6.88e-7	Lentiform nucleus volume;
KIRP	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs17023223	0.537	rs2645301	chr1:119590420	C/T	cg18261050	chr1:119551319	NA	0.52	6.97	0.41	2.82e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9815354	0.680	rs73075204	chr3:42030392	G/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.81	-13.21	-0.64	1.82e-30	Pulse pressure;
KIRP	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg03714773	chr7:91764589	CYP51A1	0.41	6.13	0.36	3.39e-9	Breast cancer;
KIRP	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.03	16.72	0.73	1.9e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg19773385	chr1:10388646	KIF1B	-0.7	-10.66	-0.56	4.55e-22	Hepatocellular carcinoma;
KIRP	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg15488143	chr7:128924101	AHCYL2	0.58	6.25	0.37	1.82e-9	White matter hyperintensity burden;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg08901578	chr4:187885870	NA	-0.51	-7.58	-0.43	7.24e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.45	-0.47	2.64e-15	Joint mobility (Beighton score);
KIRP	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.33	19.17	0.77	1.03e-50	Corneal structure;
KIRP	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.67	-10.04	-0.54	4.13e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs10773046	0.740	rs9669530	chr12:124369811	C/A	cg18594669	chr12:124364423	DNAH10	0.37	4.9	0.3	1.75e-6	Osteoarthritis (hip);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09137423	chr10:51827642	FAM21A	0.68	6.51	0.38	4.19e-10	Lung function (FEV1);
KIRP	cis	rs3762637	0.943	rs7629285	chr3:122265739	A/G	cg24169773	chr3:122142474	KPNA1	0.54	5.91	0.35	1.12e-8	LDL cholesterol levels;
KIRP	cis	rs4789693	0.808	rs12935995	chr17:80394883	C/T	cg04308225	chr17:80449738	NA	0.59	5.7	0.34	3.33e-8	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs7011507	1.000	rs74538830	chr8:49166188	C/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09343402	chr19:24216269	NA	0.58	6.74	0.39	1.1e-10	Smoking initiation;
KIRP	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg19468946	chr17:37922297	IKZF3	-0.42	-5.92	-0.35	1.06e-8	Asthma;
KIRP	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg14673194	chr17:80132900	CCDC57	-0.73	-7.84	-0.45	1.35e-13	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg24494008	chr3:160116838	IFT80;SMC4	-0.48	-6.04	-0.36	5.58e-9	Obesity-related traits;
KIRP	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg23601095	chr6:26197514	HIST1H3D	1.02	8.6	0.48	9.47e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.0	0.41	2.39e-11	Tonsillectomy;
KIRP	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg01620082	chr3:125678407	NA	-1.16	-7.26	-0.42	4.96e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.86	13.04	0.64	6.53e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19852058	chr3:105293613	ALCAM	-0.4	-6.04	-0.36	5.52e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.86	12.89	0.63	2.17e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg14086364	chr5:150678334	SLC36A3	0.35	5.84	0.35	1.66e-8	Skin aging (microtopography measurement);
KIRP	cis	rs9843304	0.616	rs4131174	chr3:149203910	C/T	cg08667024	chr3:149219783	TM4SF4	-0.42	-6.14	-0.36	3.22e-9	Gallstone disease;
KIRP	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.77	-10.48	-0.56	1.72e-21	Aortic root size;
KIRP	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.82	-9.13	-0.5	2.61e-17	Blood pressure (smoking interaction);
KIRP	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg24315340	chr6:146058215	EPM2A	0.39	4.93	0.3	1.51e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11026330	chr4:18023101	LCORL	0.56	7.48	0.43	1.33e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6504340	0.739	rs1123630	chr17:46671816	C/T	cg05487507	chr17:46671861	LOC404266;HOXB5	0.51	6.09	0.36	4.35e-9	Primary tooth development (number of teeth);
KIRP	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs882732	1.000	rs3762122	chr14:95029351	A/T	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.57	-0.33	6.63e-8	Blood protein levels;
KIRP	cis	rs4356932	0.905	rs4859597	chr4:76956630	A/T	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11564339	chr21:36261702	RUNX1	0.52	6.89	0.4	4.6e-11	Parkinson's disease;
KIRP	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	trans	rs62056376	0.736	rs1233651	chr17:32639361	C/T	cg12726354	chr15:28342256	OCA2	0.55	6.24	0.37	1.87e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs17065868	1.000	rs61948010	chr13:45186674	T/G	cg10246903	chr13:45222710	NA	0.6	6.39	0.38	8.32e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.77e-8	Electroencephalogram traits;
KIRP	cis	rs13065560	0.659	rs6599266	chr3:38926912	C/G	cg01426195	chr3:39028469	NA	-0.41	-6.22	-0.37	2.11e-9	Interleukin-18 levels;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.6	11.24	0.58	6.27e-24	Bone mineral density;
KIRP	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.48	-6.01	-0.36	6.7e-9	Refractive error;
KIRP	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.54	-5.74	-0.34	2.81e-8	Vitiligo;
KIRP	cis	rs6681460	0.934	rs10889635	chr1:67075575	G/A	cg13052034	chr1:66999238	SGIP1	0.38	5.22	0.32	3.75e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.29	-0.32	2.74e-7	Colorectal cancer;
KIRP	cis	rs17401966	0.597	rs11121555	chr1:10442856	C/T	cg19773385	chr1:10388646	KIF1B	-0.5	-7.15	-0.41	1e-11	Hepatocellular carcinoma;
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg01763666	chr17:80159506	CCDC57	-0.36	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs12903285	1	rs12903285	chr15:78778953	A/G	cg24631222	chr15:78858424	CHRNA5	-0.39	-4.88	-0.3	1.94e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg11555438	chr13:111297484	CARS2	0.37	5.85	0.35	1.55e-8	Coronary artery disease;
KIRP	cis	rs300890	0.786	rs300910	chr4:144276999	T/G	cg19876092	chr4:144208277	NA	0.34	5.34	0.32	2.06e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg25801113	chr15:45476975	SHF	-0.42	-7.69	-0.44	3.6e-13	Uric acid levels;
KIRP	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg01028140	chr2:1542097	TPO	-0.5	-5.73	-0.34	2.92e-8	IgG glycosylation;
KIRP	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.41	-7.22	-0.42	6.59e-12	Refractive error;
KIRP	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg13147721	chr7:65941812	NA	-1.02	-7.05	-0.41	1.77e-11	Diabetic kidney disease;
KIRP	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg25036284	chr2:26402008	FAM59B	-0.6	-6.0	-0.36	7.17e-9	Gut microbiome composition (summer);
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg21523564	chr15:75251491	NA	0.41	6.67	0.39	1.65e-10	Breast cancer;
KIRP	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.73	-5.87	-0.35	1.42e-8	Diabetic retinopathy;
KIRP	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.61	8.76	0.49	3.15e-16	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.88	10.44	0.55	2.25e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs10463316	0.925	rs6877344	chr5:150742650	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.83	-0.35	1.69e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs68170813	1.000	rs7785962	chr7:107243995	A/C	cg02696742	chr7:106810147	HBP1	0.65	6.63	0.39	2.08e-10	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg05669848	chr5:237993	SDHA	-0.48	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg12756093	chr1:115239321	AMPD1	0.58	7.38	0.43	2.45e-12	Autism;
KIRP	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg17376030	chr22:41985996	PMM1	-0.52	-6.32	-0.37	1.2e-9	Vitiligo;
KIRP	cis	rs6832769	1.000	rs4865010	chr4:56414962	A/C	cg05960024	chr4:56376020	CLOCK	-0.71	-9.34	-0.51	6.07e-18	Personality dimensions;
KIRP	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Osteoarthritis;
KIRP	cis	rs2299587	0.932	rs6996133	chr8:17828355	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-4.9	-0.3	1.7e-6	Economic and political preferences;
KIRP	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg17554472	chr22:41940697	POLR3H	0.46	5.25	0.32	3.29e-7	Vitiligo;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg13465955	chr19:7953354	LRRC8E	-0.45	-6.17	-0.37	2.86e-9	Morning vs. evening chronotype;
KIRP	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	cg12689670	chr1:183009347	LAMC1	0.57	8.02	0.46	4.2e-14	Fuchs's corneal dystrophy;
KIRP	trans	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg13565492	chr6:43139072	SRF	-0.93	-8.53	-0.48	1.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.96	-0.5	8.41e-17	Platelet count;
KIRP	cis	rs12580194	0.593	rs61556775	chr12:55745640	A/C	cg19537932	chr12:55886519	OR6C68	-0.5	-6.47	-0.38	5.14e-10	Cancer;
KIRP	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.69	-10.05	-0.54	3.98e-20	Retinal vascular caliber;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00648153	chr6:74364149	SLC17A5	0.64	6.05	0.36	5.48e-9	Lung function (FEV1);
KIRP	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.64	-0.44	4.86e-13	Body mass index;
KIRP	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.52	5.4	0.33	1.55e-7	DNA methylation (variation);
KIRP	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg06521852	chr22:38141419	TRIOBP	0.35	4.92	0.3	1.55e-6	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs4950322	0.570	rs80070044	chr1:146801969	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.3	0.37	1.35e-9	Mean platelet volume;
KIRP	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg00343986	chr7:65444356	GUSB	0.49	6.0	0.36	6.94e-9	Aortic root size;
KIRP	cis	rs76793172	0.588	rs8110017	chr19:46289392	G/C	cg11657440	chr19:46296263	DMWD	0.72	5.21	0.32	3.93e-7	Eosinophil counts;
KIRP	cis	rs526231	0.543	rs42431	chr5:102400063	C/T	cg23492399	chr5:102201601	PAM	0.48	5.3	0.32	2.56e-7	Primary biliary cholangitis;
KIRP	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs2398893	0.889	rs7870790	chr9:96779553	G/A	cg14459158	chr9:96720562	NA	0.29	5.3	0.32	2.58e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4787491	0.729	rs12446378	chr16:30043110	T/G	cg06326092	chr16:30034487	C16orf92	0.5	7.82	0.45	1.5e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05821866	chr1:167905319	DCAF6;BRP44	-0.45	-6.26	-0.37	1.7e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg01872077	chr2:219646372	CYP27A1	-0.36	-4.88	-0.3	1.9e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16411256	chr8:27348931	EPHX2	0.51	6.78	0.4	8.84e-11	Smoking initiation;
KIRP	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.41	5.13	0.31	5.83e-7	Aortic root size;
KIRP	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.84	10.48	0.56	1.68e-21	Gestational age at birth (maternal effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21127189	chr4:39368001	RFC1	0.52	6.53	0.38	3.78e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26500773	chr2:232646331	PDE6D	0.5	6.07	0.36	4.7e-9	Parkinson's disease;
KIRP	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.22	0.37	2.11e-9	IgG glycosylation;
KIRP	cis	rs7536201	1.000	rs10903121	chr1:25300042	G/A	cg23273869	chr1:25296894	NA	-0.39	-5.64	-0.34	4.6e-8	Psoriasis vulgaris;
KIRP	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.93	12.16	0.61	5.78e-27	Breast cancer;
KIRP	trans	rs76288851	0.799	rs73201802	chr3:126540101	T/C	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs9372498	0.505	rs17080456	chr6:118985938	G/C	cg18833306	chr6:118973337	C6orf204	-0.47	-5.04	-0.31	9.1e-7	Diastolic blood pressure;
KIRP	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg03060546	chr3:49711283	APEH	-0.64	-6.03	-0.36	5.86e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4523957	0.583	rs2760735	chr17:2036835	A/G	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.65	9.03	0.5	5.09e-17	Coronary artery disease;
KIRP	cis	rs12220238	0.841	rs10824163	chr10:76136589	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.64	0.39	1.96e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs883115	0.686	rs12730234	chr1:224863428	C/T	cg01808320	chr1:224927238	CNIH3	0.34	4.84	0.3	2.25e-6	Cancer;
KIRP	trans	rs12043259	0.730	rs1322672	chr1:204795343	C/T	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.23	0.37	2.06e-9	Lung cancer;
KIRP	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg25039879	chr17:56429692	SUPT4H1	0.56	4.95	0.3	1.39e-6	Cognitive test performance;
KIRP	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.58	0.39	2.74e-10	Prudent dietary pattern;
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.45	5.58	0.34	6.35e-8	Longevity;Endometriosis;
KIRP	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg06740227	chr12:86229804	RASSF9	0.41	5.16	0.31	5.03e-7	Major depressive disorder;
KIRP	cis	rs17453880	0.708	rs7711928	chr5:151928442	G/A	cg12297329	chr5:152029980	NA	-0.56	-8.04	-0.46	3.82e-14	Subjective well-being;
KIRP	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.38	5.91	0.35	1.15e-8	Colorectal cancer;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.84	-9.74	-0.53	3.68e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.91	0.35	1.14e-8	Lung cancer;
KIRP	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg13271783	chr10:134563150	INPP5A	-0.51	-6.84	-0.4	6.42e-11	Migraine;
KIRP	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.45	-0.33	1.22e-7	Hip geometry;
KIRP	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg21926883	chr2:100939477	LONRF2	-0.56	-7.59	-0.44	6.64e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04369958	chr19:39935932	SUPT5H	0.5	6.12	0.36	3.71e-9	Parkinson's disease;
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02359409	chr6:42947317	PEX6	-0.38	-5.01	-0.3	1.04e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.73	8.58	0.48	1.07e-15	Response to bleomycin (chromatid breaks);
KIRP	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg15880211	chr22:50250494	ZBED4	0.44	5.28	0.32	2.89e-7	Schizophrenia;
KIRP	trans	rs6535028	0.881	rs4438807	chr4:135457940	A/G	cg02011446	chr19:13213716	LYL1	0.7	6.22	0.37	2.12e-9	Response to radiotherapy in prostate cancer (overall toxicity);
KIRP	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg27205649	chr11:78285834	NARS2	0.66	8.75	0.49	3.35e-16	Alzheimer's disease (survival time);
KIRP	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg11608241	chr8:8085544	FLJ10661	-0.48	-6.06	-0.36	4.97e-9	Neuroticism;
KIRP	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg24375607	chr4:120327624	NA	0.73	8.21	0.46	1.23e-14	Corneal astigmatism;
KIRP	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.7	5.81	0.35	1.89e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9398803	0.713	rs9401888	chr6:126877523	A/G	cg19875578	chr6:126661172	C6orf173	0.41	5.2	0.31	4.26e-7	Male-pattern baldness;
KIRP	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	7.59	0.44	6.48e-13	Height;
KIRP	cis	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg11409572	chr10:103453901	FBXW4	0.44	5.17	0.31	4.88e-7	Educational attainment;
KIRP	cis	rs7712401	0.601	rs30072	chr5:122292220	C/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.42	-0.33	1.41e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg12826209	chr6:26865740	GUSBL1	0.81	5.43	0.33	1.32e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.12	0.36	3.7e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08078213	chr17:79479165	ACTG1	0.62	8.21	0.46	1.23e-14	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	5.76	0.34	2.48e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-6.08	-0.36	4.48e-9	Life satisfaction;
KIRP	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.89	14.75	0.68	1.08e-35	Prostate cancer;
KIRP	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.11	0.41	1.27e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.49	-5.43	-0.33	1.33e-7	Lung cancer;
KIRP	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	0.94	12.37	0.62	1.17e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs13033859	0.526	rs6548221	chr2:295255	C/T	cg12623918	chr2:306882	NA	-0.46	-5.37	-0.32	1.86e-7	Mitochondrial DNA levels;
KIRP	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-7.54	-0.43	9.31e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.65	-12.16	-0.61	5.89e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg02931644	chr1:25747376	RHCE	0.37	6.53	0.38	3.64e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.82	-8.31	-0.47	6.6e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg23649088	chr2:200775458	C2orf69	-0.56	-4.88	-0.3	1.92e-6	Schizophrenia;
KIRP	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg21890820	chr11:65308645	LTBP3	0.58	5.57	0.33	6.67e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9309473	0.500	rs4286298	chr2:73882108	T/A	cg20560298	chr2:73613845	ALMS1	0.44	5.43	0.33	1.33e-7	Metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02599293	chr5:137090023	HNRNPA0	0.49	6.46	0.38	5.55e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg22705602	chr4:152727874	NA	-0.53	-9.28	-0.51	9.09e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2219968	0.828	rs10808823	chr8:78903013	C/T	cg00738934	chr8:78996279	NA	-0.38	-4.97	-0.3	1.23e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg19774624	chr17:42201019	HDAC5	-0.69	-9.0	-0.5	6.4e-17	Total body bone mineral density;
KIRP	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.66	9.76	0.53	3.03e-19	Retinal vascular caliber;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25492971	chr8:91072389	CALB1	-0.42	-6.77	-0.4	9.52e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	1.05	10.98	0.57	4.26e-23	Cerebrospinal P-tau181p levels;
KIRP	cis	rs735539	0.521	rs2818992	chr13:21398087	G/A	cg04906043	chr13:21280425	IL17D	-0.43	-5.05	-0.31	8.77e-7	Dental caries;
KIRP	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.51	5.34	0.32	2.16e-7	Subjective well-being;
KIRP	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	5.6	0.34	5.62e-8	Schizophrenia;
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	15.56	0.7	1.73e-38	Platelet count;
KIRP	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg01268866	chr2:3683757	COLEC11	-0.52	-5.85	-0.35	1.55e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg05973401	chr12:123451056	ABCB9	-0.59	-6.94	-0.4	3.43e-11	Neutrophil percentage of white cells;
KIRP	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg15448220	chr1:150897856	SETDB1	-0.41	-5.35	-0.32	2.04e-7	Tonsillectomy;
KIRP	cis	rs71636778	0.543	rs36109400	chr1:27247822	G/A	cg12203394	chr1:27248618	NUDC	0.61	5.37	0.32	1.82e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg03653399	chr8:142233436	SLC45A4	-0.7	-8.58	-0.48	1.09e-15	Immature fraction of reticulocytes;
KIRP	cis	rs73200209	0.912	rs10507267	chr12:116500910	T/C	cg01776926	chr12:116560359	MED13L	-0.47	-5.55	-0.33	7.45e-8	Total body bone mineral density;
KIRP	cis	rs4919087	0.715	rs8181326	chr10:98998195	G/A	cg25902810	chr10:99078978	FRAT1	0.5	5.81	0.35	1.92e-8	Monocyte count;
KIRP	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg23719950	chr11:63933701	MACROD1	-0.68	-6.55	-0.39	3.26e-10	Mean platelet volume;
KIRP	trans	rs7999699	0.704	rs35723417	chr13:48309123	A/G	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg21186296	chr8:27182909	PTK2B	0.48	6.0	0.36	6.92e-9	Neuroticism;
KIRP	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg00931491	chr16:28608288	SULT1A2	-0.25	-4.97	-0.3	1.28e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg19899395	chr1:46959349	NA	-0.4	-5.05	-0.31	8.6e-7	Monobrow;
KIRP	cis	rs10267417	0.603	rs10273239	chr7:19911524	T/C	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg08975724	chr8:8085496	FLJ10661	-0.73	-9.46	-0.52	2.66e-18	Triglycerides;
KIRP	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs2425143	0.730	rs7263640	chr20:34314725	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.74	9.17	0.5	1.98e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs12986445	0.711	rs12713701	chr2:26136031	T/A	cg18516150	chr3:148614668	CPA3	0.44	6.35	0.38	1.02e-9	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
KIRP	cis	rs6681460	0.625	rs2872079	chr1:67130071	G/A	cg13052034	chr1:66999238	SGIP1	0.37	5.2	0.31	4.12e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg00800569	chr2:239229395	TRAF3IP1	0.46	4.92	0.3	1.6e-6	Multiple system atrophy;
KIRP	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg18478394	chr8:109455254	TTC35	0.53	6.55	0.39	3.34e-10	Dupuytren's disease;
KIRP	cis	rs6901004	0.712	rs367734	chr6:111512378	C/G	cg15721981	chr6:111408429	SLC16A10	-0.52	-7.2	-0.42	7.5e-12	Blood metabolite levels;
KIRP	cis	rs3105593	0.547	rs3131559	chr15:50780214	C/A	cg05456662	chr15:50716270	USP8	0.46	6.0	0.36	6.98e-9	QT interval;
KIRP	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg26554054	chr8:600488	NA	0.69	5.35	0.32	2.05e-7	IgG glycosylation;
KIRP	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-0.77	-11.61	-0.6	3.83e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs526231	0.543	rs171558	chr5:102577894	G/C	cg23492399	chr5:102201601	PAM	-0.51	-5.39	-0.32	1.69e-7	Primary biliary cholangitis;
KIRP	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-6.06	-0.36	4.95e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.63	-7.92	-0.45	8.22e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9596863	1.000	rs9568943	chr13:54423065	G/T	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-12.72	-0.63	7.95e-29	Breast cancer;
KIRP	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg16077055	chr2:106428750	NCK2	0.26	5.2	0.31	4.16e-7	Addiction;
KIRP	cis	rs580438	0.792	rs357131	chr3:13330746	C/G	cg10657019	chr3:13328039	NA	-0.87	-12.0	-0.61	1.99e-26	Myringotomy;
KIRP	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.6	-6.56	-0.39	3.21e-10	Gut microbiome composition (summer);
KIRP	cis	rs6256	0.860	rs113194319	chr11:13567042	T/C	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg11906718	chr8:101322791	RNF19A	-0.48	-6.04	-0.36	5.57e-9	Atrioventricular conduction;
KIRP	cis	rs57994353	0.600	rs4400499	chr9:139305041	C/T	cg14169450	chr9:139327907	INPP5E	0.5	5.54	0.33	7.95e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27544191	chr22:50913719	SBF1	0.5	6.13	0.36	3.55e-9	Parkinson's disease;
KIRP	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg12131826	chr15:77904385	NA	0.47	5.61	0.34	5.49e-8	Type 2 diabetes;
KIRP	cis	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.13	0.31	5.94e-7	Leprosy;
KIRP	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.36	-0.38	9.7e-10	Lung cancer;
KIRP	cis	rs4363385	0.510	rs11812015	chr1:153045584	G/T	cg13444842	chr1:152974279	SPRR3	-0.43	-6.19	-0.37	2.46e-9	Inflammatory skin disease;
KIRP	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs62413470	1.000	rs62404869	chr6:55958205	A/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg03806693	chr22:41940476	POLR3H	-0.67	-7.31	-0.42	3.7e-12	Neuroticism;
KIRP	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg10381502	chr11:71823885	C11orf51	-1.2	-7.89	-0.45	1.01e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs2882667	0.861	rs13176902	chr5:138393329	T/C	cg04439458	chr5:138467593	SIL1	-0.45	-7.47	-0.43	1.4e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8077577	0.708	rs28364628	chr17:18163262	C/T	cg18869244	chr17:18121946	NA	0.47	5.17	0.31	4.85e-7	Obesity-related traits;
KIRP	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.71	0.44	3.19e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.82	-11.69	-0.6	2.19e-25	Glomerular filtration rate (creatinine);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03286899	chr6:36561965	SFRS3	-0.47	-6.53	-0.38	3.79e-10	Metabolic traits;
KIRP	cis	rs73086581	0.947	rs55794220	chr20:3956402	C/T	cg02187196	chr20:3869020	PANK2	0.5	5.02	0.3	9.9e-7	Response to antidepressants in depression;
KIRP	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.83	11.79	0.6	9.85e-26	Dental caries;
KIRP	cis	rs10170846	0.530	rs56353541	chr2:223421187	G/C	cg25565276	chr2:223520875	FARSB	0.6	7.18	0.42	8.24e-12	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-0.93	-10.36	-0.55	4.15e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2735413	0.794	rs55951868	chr16:78078804	C/A	cg04733911	chr16:78082701	NA	-0.43	-4.9	-0.3	1.74e-6	Systolic blood pressure (alcohol consumption interaction);
KIRP	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg18016565	chr1:150552671	MCL1	-0.47	-7.37	-0.43	2.59e-12	Tonsillectomy;
KIRP	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.48	6.28	0.37	1.54e-9	Response to temozolomide;
KIRP	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.79	-0.49	2.7e-16	Morning vs. evening chronotype;
KIRP	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg10223061	chr2:219282414	VIL1	0.28	4.89	0.3	1.85e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.67	8.67	0.48	5.79e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs988913	0.723	rs7761785	chr6:55002037	C/T	cg03513858	chr6:54763001	FAM83B	0.37	5.37	0.32	1.79e-7	Menarche (age at onset);
KIRP	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg12591125	chr7:1885375	MAD1L1	0.59	5.64	0.34	4.57e-8	Neuroticism;
KIRP	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg04609801	chr16:28609176	SULT1A2	-0.55	-5.3	-0.32	2.56e-7	Platelet distribution width;
KIRP	cis	rs882732	1.000	rs17091071	chr14:95033708	A/C	cg08495878	chr14:95027859	SERPINA4	-0.41	-5.09	-0.31	7.07e-7	Blood protein levels;
KIRP	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg12384639	chr17:618140	VPS53	0.49	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.67	-6.42	-0.38	7.1e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg23788592	chr10:120925342	SFXN4	-0.58	-6.25	-0.37	1.82e-9	Menopause (age at onset);
KIRP	cis	rs8028182	0.636	rs28783769	chr15:75849009	C/A	cg20655648	chr15:75932815	IMP3	0.54	6.77	0.4	9.49e-11	Sudden cardiac arrest;
KIRP	trans	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.38	-0.43	2.39e-12	Blood trace element (Cu levels);
KIRP	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.6	-7.94	-0.45	7.23e-14	Huntington's disease progression;
KIRP	cis	rs7814319	1.000	rs2643338	chr8:97247469	A/G	cg20787634	chr8:97240163	UQCRB	-0.59	-9.37	-0.51	4.83e-18	Lung function (FVC);
KIRP	cis	rs3126085	1.000	rs72696969	chr1:152196339	G/A	cg26876637	chr1:152193138	HRNR	-0.85	-8.4	-0.47	3.57e-15	Atopic dermatitis;
KIRP	cis	rs7011049	1.000	rs11985185	chr8:53834494	T/C	cg26025543	chr8:53854495	NA	0.72	7.58	0.44	6.99e-13	Systolic blood pressure;
KIRP	cis	rs2964802	0.505	rs4314375	chr5:10803435	C/T	cg14521931	chr5:10832172	NA	0.69	10.27	0.55	7.76e-21	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.17	0.37	2.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-0.89	-12.68	-0.63	1.1e-28	Dupuytren's disease;
KIRP	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg06671706	chr8:8559999	CLDN23	0.56	6.26	0.37	1.71e-9	Obesity-related traits;
KIRP	trans	rs73017364	0.688	rs4657164	chr1:162160920	A/G	cg13533616	chr9:131889368	PPP2R4	0.63	6.32	0.37	1.24e-9	QT interval;
KIRP	trans	rs1106684	1.000	rs34741957	chr7:131459513	T/C	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.41	5.27	0.32	2.94e-7	Aortic root size;
KIRP	cis	rs6832769	1.000	rs6819660	chr4:56374577	T/G	cg05960024	chr4:56376020	CLOCK	0.63	8.03	0.46	3.93e-14	Personality dimensions;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10487770	chr5:57879443	RAB3C	0.47	6.15	0.37	3.12e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8077577	0.708	rs4556848	chr17:18134867	C/G	cg18869244	chr17:18121946	NA	-0.43	-4.99	-0.3	1.16e-6	Obesity-related traits;
KIRP	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.19	-0.37	2.49e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9532580	0.619	rs2755211	chr13:41142223	C/T	cg21288729	chr13:41239152	FOXO1	0.7	9.34	0.51	5.92e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.73e-10	Diabetic kidney disease;
KIRP	cis	rs2839627	0.683	rs6586259	chr21:44315266	G/A	cg03543861	chr21:44258195	NA	0.57	6.06	0.36	5.21e-9	Information processing speed;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07047347	chr8:96281113	C8orf37	0.46	6.55	0.39	3.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.69	8.11	0.46	2.35e-14	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg22974920	chr21:40686053	BRWD1	-0.48	-5.79	-0.35	2.14e-8	Cognitive function;
KIRP	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.86	-14.95	-0.69	2.24e-36	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs60311166	1.000	rs72950437	chr3:52714400	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.95	6.67	0.39	1.72e-10	CTACK levels;
KIRP	cis	rs10864907	0.805	rs2466452	chr2:113622825	T/G	cg03712744	chr2:113669835	IL1F7	-0.41	-6.0	-0.36	7.13e-9	Pulmonary function;
KIRP	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.95	-0.61	2.84e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg15117754	chr3:10150083	C3orf24	0.5	5.01	0.3	1.03e-6	Alzheimer's disease;
KIRP	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.77	0.44	2.07e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg11569703	chr11:65557185	OVOL1	0.74	13.95	0.66	5.72e-33	Acne (severe);
KIRP	cis	rs4262150	0.883	rs72802852	chr5:152216893	G/T	cg12297329	chr5:152029980	NA	-0.62	-8.12	-0.46	2.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15128208	chr22:42549153	NA	0.45	5.69	0.34	3.57e-8	Cognitive function;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20814826	chr17:2206919	SRR;SMG6	0.48	7.12	0.41	1.16e-11	Survival in pancreatic cancer;
KIRP	cis	rs7267005	1.000	rs58175634	chr20:34553872	G/C	cg17201900	chr20:34330562	RBM39	0.89	5.37	0.32	1.87e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.55	-6.23	-0.37	1.98e-9	Coronary artery disease;
KIRP	cis	rs2649	0.518	rs7162745	chr15:63878889	T/A	cg22599514	chr15:63798201	USP3	0.46	5.72	0.34	3.11e-8	Aortic root size;
KIRP	cis	rs7715806	0.500	rs17649332	chr5:75003878	T/C	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.99	0.45	5.16e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.54	7.15	0.41	1e-11	Response to temozolomide;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09818912	chr17:20140352	CYTSB	0.52	6.62	0.39	2.21e-10	Interleukin-4 levels;
KIRP	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.81	-12.29	-0.62	2.27e-27	Breast cancer;
KIRP	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	1.03	20.38	0.79	9.8e-55	Breast cancer;
KIRP	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg12661370	chr5:149340060	SLC26A2	-0.49	-4.86	-0.3	2.13e-6	HIV-1 control;
KIRP	cis	rs9549260	0.564	rs7998724	chr13:41324793	G/T	cg21288729	chr13:41239152	FOXO1	0.57	7.26	0.42	5.15e-12	Red blood cell count;
KIRP	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-0.67	-5.48	-0.33	1.07e-7	Major depressive disorder;
KIRP	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg12573674	chr2:1569213	NA	-0.6	-5.56	-0.33	6.95e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg10402321	chr1:26617780	UBXN11	-0.43	-5.74	-0.34	2.84e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg22676075	chr6:135203613	NA	0.5	7.18	0.42	8.21e-12	Red blood cell count;
KIRP	trans	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	7.7	0.44	3.36e-13	Mean corpuscular volume;
KIRP	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-11.82	-0.6	7.68e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.8	-0.4	8.1e-11	Inflammatory bowel disease;
KIRP	cis	rs12282928	1.000	rs11039667	chr11:48326063	C/G	cg26585981	chr11:48327164	OR4S1	0.51	6.22	0.37	2.09e-9	Migraine - clinic-based;
KIRP	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg08131204	chr22:41487073	MIR1281	-0.44	-5.13	-0.31	6e-7	Neuroticism;
KIRP	cis	rs7688540	0.723	rs80316648	chr4:232215	G/A	cg17891759	chr4:299121	NA	-0.44	-5.03	-0.31	9.55e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.5	-7.61	-0.44	5.81e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg15507776	chr3:136538369	TMEM22	0.39	5.25	0.32	3.34e-7	Neuroticism;
KIRP	cis	rs3857747	0.895	rs34487990	chr7:40412731	G/A	cg00420559	chr7:40367873	C7orf10	0.66	8.46	0.47	2.48e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg15586392	chr8:142238691	SLC45A4	-0.36	-4.87	-0.3	2e-6	Immature fraction of reticulocytes;
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg11814155	chr7:99998594	ZCWPW1	0.56	5.45	0.33	1.2e-7	Platelet count;
KIRP	cis	rs6991838	0.584	rs6993876	chr8:66513475	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.19	0.31	4.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg15655495	chr12:38532458	NA	-0.3	-5.2	-0.31	4.15e-7	Bladder cancer;
KIRP	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg26531700	chr6:26746687	NA	-0.4	-5.48	-0.33	1.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3755132	0.929	rs3770470	chr2:15770507	G/T	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg03465714	chr1:152285911	FLG	0.41	5.06	0.31	8.37e-7	Atopic dermatitis;
KIRP	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	0.89	8.16	0.46	1.72e-14	Gut microbiota (bacterial taxa);
KIRP	cis	rs9381107	0.505	rs13208500	chr6:9479707	T/C	cg14735645	chr6:9486422	NA	-0.56	-7.74	-0.44	2.64e-13	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.54	7.11	0.41	1.24e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20449327	chr14:59951241	C14orf149;JKAMP	0.47	6.28	0.37	1.55e-9	Parkinson's disease;
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.42	5.28	0.32	2.9e-7	Resistin levels;
KIRP	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24549020	chr5:56110836	MAP3K1	0.5	5.13	0.31	5.95e-7	Initial pursuit acceleration;
KIRP	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-7.46	-0.43	1.45e-12	Coffee consumption (cups per day);
KIRP	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.79	-9.84	-0.53	1.74e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27297192	chr10:134578999	INPP5A	0.49	6.15	0.36	3.18e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.5	6.87	0.4	5.31e-11	Mean corpuscular volume;
KIRP	cis	rs3812111	0.510	rs1569824	chr6:116590802	T/A	cg18828861	chr6:116576566	TSPYL4	0.43	5.0	0.3	1.07e-6	Age-related macular degeneration;
KIRP	cis	rs2041895	0.509	rs7970139	chr12:107312430	T/C	cg21360079	chr12:107162445	NA	-0.46	-4.96	-0.3	1.3e-6	Glaucoma (low intraocular pressure);
KIRP	cis	rs6835098	0.692	rs6553680	chr4:174077044	A/G	cg08422745	chr4:174089978	GALNT7	-0.68	-9.03	-0.5	5e-17	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.55	-5.8	-0.35	2.04e-8	Obesity-related traits;
KIRP	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.78	-11.59	-0.59	4.52e-25	Obesity-related traits;
KIRP	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg23460707	chr10:133558971	NA	0.34	5.18	0.31	4.73e-7	Survival in rectal cancer;
KIRP	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	cis	rs735860	0.737	rs2115564	chr6:53173482	C/A	cg10236188	chr6:53219634	NA	-0.45	-5.99	-0.36	7.24e-9	Glaucoma;
KIRP	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.62	-8.79	-0.49	2.56e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7178572	0.598	rs907373	chr15:77844554	T/C	cg12131826	chr15:77904385	NA	0.42	6.04	0.36	5.65e-9	Type 2 diabetes;
KIRP	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg23100626	chr2:96804247	ASTL	-0.48	-6.56	-0.39	3.2e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg00319359	chr11:70116639	PPFIA1	0.66	6.46	0.38	5.58e-10	Coronary artery disease;
KIRP	cis	rs1978968	0.717	rs35645198	chr22:18408322	C/T	cg03078520	chr22:18463400	MICAL3	-0.59	-6.92	-0.4	3.95e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg08779649	chr13:50194554	NA	0.49	6.87	0.4	5.24e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg17443007	chr1:101659419	NA	0.4	5.58	0.34	6.26e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.71	8.17	0.46	1.6e-14	Corneal astigmatism;
KIRP	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.61	-6.36	-0.38	9.52e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg12315302	chr6:26189340	HIST1H4D	1.09	6.45	0.38	5.72e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	5.26	0.32	3.21e-7	Schizophrenia;
KIRP	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg21858823	chr1:15850916	CASP9	0.52	5.54	0.33	7.76e-8	Systolic blood pressure;
KIRP	cis	rs6547631	0.635	rs934773	chr2:85898094	A/G	cg07313956	chr2:85895360	SFTPB	0.42	6.1	0.36	4.11e-9	Blood protein levels;
KIRP	cis	rs9815354	1.000	rs6783001	chr3:41862232	C/A	cg03022575	chr3:42003672	ULK4	0.5	5.75	0.34	2.62e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg09491104	chr22:46646882	C22orf40	-0.5	-5.57	-0.33	6.64e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10861342	0.892	rs9634185	chr12:105624825	C/T	cg23923672	chr12:105501055	KIAA1033	0.62	5.49	0.33	1e-7	IgG glycosylation;
KIRP	trans	rs62056376	0.736	rs62054939	chr17:32645165	T/C	cg13554086	chr5:76507100	PDE8B	-0.56	-6.56	-0.39	3.21e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18364779	chr6:26104403	HIST1H4C	-0.46	-5.15	-0.31	5.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.89	14.09	0.67	1.91e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.84e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg10932868	chr11:921992	NA	0.49	5.8	0.35	2.05e-8	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.97	0.45	5.76e-14	Aortic root size;
KIRP	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.46e-8	Life satisfaction;
KIRP	trans	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.3	0.37	1.4e-9	Mean corpuscular volume;
KIRP	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.43	8.47	0.48	2.31e-15	Coronary artery disease;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	0.37	5.54	0.33	7.69e-8	Renal function-related traits (BUN);
KIRP	cis	rs12580194	0.556	rs61249728	chr12:55728922	A/G	cg19537932	chr12:55886519	OR6C68	-0.5	-6.67	-0.39	1.68e-10	Cancer;
KIRP	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg25319279	chr11:5960081	NA	-0.59	-6.12	-0.36	3.73e-9	DNA methylation (variation);
KIRP	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg02725872	chr8:58115012	NA	0.48	5.53	0.33	8.15e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1570884	0.539	rs2407696	chr13:50112525	G/A	cg08779649	chr13:50194554	NA	0.47	5.94	0.35	9.71e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg12486944	chr17:80159399	CCDC57	0.36	4.9	0.3	1.73e-6	Life satisfaction;
KIRP	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.9	-0.53	1.11e-19	Response to antipsychotic treatment;
KIRP	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	8.7	0.49	4.73e-16	Breast cancer;
KIRP	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg08648136	chr8:956695	NA	0.53	8.36	0.47	4.74e-15	Schizophrenia;
KIRP	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.85	-11.58	-0.59	4.87e-25	Total body bone mineral density;
KIRP	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.46	5.91	0.35	1.15e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7312774	0.881	rs60941459	chr12:107318583	T/C	cg16260113	chr12:107380972	MTERFD3	0.72	6.55	0.39	3.42e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg01097406	chr16:89675127	NA	-0.32	-5.29	-0.32	2.73e-7	Vitiligo;
KIRP	cis	rs2230307	0.572	rs11805428	chr1:100641716	T/C	cg24955406	chr1:100503596	HIAT1	-0.58	-5.92	-0.35	1.09e-8	Carotid intima media thickness;
KIRP	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.27	-0.37	1.59e-9	Breast cancer;
KIRP	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.54	7.29	0.42	4.18e-12	Bipolar disorder;
KIRP	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05025164	chr4:1340916	KIAA1530	0.41	5.14	0.31	5.53e-7	Obesity-related traits;
KIRP	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.32	-5.77	-0.35	2.41e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg18105134	chr13:113819100	PROZ	-0.89	-10.19	-0.54	1.46e-20	Platelet distribution width;
KIRP	cis	rs12282928	0.917	rs7115127	chr11:48275890	T/C	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs13095912	0.752	rs9758141	chr3:185315085	A/T	cg11274856	chr3:185301563	NA	0.63	7.97	0.45	5.92e-14	Systolic blood pressure;
KIRP	cis	rs490234	0.783	rs13284243	chr9:128381785	A/G	cg14078157	chr9:128172775	NA	-0.56	-6.52	-0.38	3.92e-10	Mean arterial pressure;
KIRP	cis	rs3755132	1.000	rs60016948	chr2:15728544	G/T	cg12888861	chr2:15731646	DDX1	0.38	4.96	0.3	1.31e-6	Wilms tumor;
KIRP	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.78	-10.96	-0.57	4.94e-23	Asthma;
KIRP	cis	rs516946	0.545	rs890222	chr8:41481037	G/T	cg19441908	chr8:41529140	ANK1	0.37	5.04	0.31	8.83e-7	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg24315340	chr6:146058215	EPM2A	0.43	5.45	0.33	1.21e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7258015	1.000	rs7250300	chr19:10448660	C/A	cg25279553	chr19:10444815	RAVER1;ICAM3	0.48	6.21	0.37	2.22e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	trans	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg27542767	chr6:40253980	NA	0.41	6.09	0.36	4.35e-9	Breast size;
KIRP	trans	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg13565492	chr6:43139072	SRF	-0.94	-8.58	-0.48	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs501120	0.584	rs7086639	chr10:44698695	C/T	cg09554077	chr10:44749378	NA	0.51	5.54	0.33	7.93e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs7224685	0.569	rs8070737	chr17:3981066	G/T	cg11204139	chr17:3907470	NA	0.59	5.62	0.34	5.14e-8	Type 2 diabetes;
KIRP	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.83	12.48	0.62	5.1e-28	Body mass index;
KIRP	cis	rs9381040	1.000	rs9394766	chr6:41159801	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.52	-5.39	-0.32	1.69e-7	Alzheimer's disease (late onset);
KIRP	trans	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	6.21	0.37	2.26e-9	Ulcerative colitis;
KIRP	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg00982548	chr2:198649783	BOLL	-0.53	-4.9	-0.3	1.72e-6	Ulcerative colitis;
KIRP	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.79	0.4	8.31e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2733310	0.895	rs1612205	chr15:57110853	G/C	cg13626582	chr15:57592083	LOC283663	-0.23	-5.1	-0.31	6.94e-7	Mean platelet volume;
KIRP	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.23	0.42	5.95e-12	Retinal vascular caliber;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg07216194	chr8:27182965	PTK2B	0.43	5.37	0.32	1.78e-7	Neuroticism;
KIRP	cis	rs1978968	0.763	rs9605481	chr22:18465677	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.7	-8.33	-0.47	5.87e-15	Presence of antiphospholipid antibodies;
KIRP	cis	rs6662572	0.737	rs11211206	chr1:46323192	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.64	7.99	0.45	5.14e-14	Breast cancer;
KIRP	cis	rs10203711	1.000	rs6713610	chr2:239566874	C/A	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6977660	0.714	rs6976972	chr7:19818315	C/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg26597838	chr10:835615	NA	0.85	8.82	0.49	2.14e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.2	-0.31	4.1e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-6.9	-0.4	4.34e-11	Platelet count;
KIRP	trans	rs76288851	0.733	rs11718070	chr3:126448560	C/T	cg13821433	chr2:26726535	OTOF	0.57	6.24	0.37	1.88e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.58	0.39	2.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.55	-0.33	7.54e-8	Neutrophil percentage of white cells;
KIRP	cis	rs8060686	0.623	rs28700885	chr16:68154544	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.62	-0.44	5.48e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6681460	0.625	rs4488004	chr1:67073314	T/C	cg13052034	chr1:66999238	SGIP1	0.35	4.88	0.3	1.88e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg05555928	chr11:63887634	MACROD1	-0.58	-5.37	-0.32	1.78e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg06766960	chr11:133703094	NA	-0.56	-7.08	-0.41	1.48e-11	Childhood ear infection;
KIRP	cis	rs35740288	0.822	rs11629690	chr15:86287724	G/A	cg10818794	chr15:86012489	AKAP13	-0.42	-4.92	-0.3	1.61e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9311676	0.656	rs11721168	chr3:58408679	G/A	cg06643156	chr3:58380774	PXK	0.35	4.88	0.3	1.88e-6	Systemic lupus erythematosus;
KIRP	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg14517359	chr4:903473	GAK	-0.59	-5.98	-0.36	7.71e-9	Type 2 diabetes;
KIRP	cis	rs1595825	0.735	rs16827267	chr2:198924967	G/A	cg11031976	chr2:198649780	BOLL	-0.53	-5.09	-0.31	7.14e-7	Ulcerative colitis;
KIRP	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.0	0.36	6.95e-9	Thyroid stimulating hormone;
KIRP	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.77	11.46	0.59	1.22e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg09003973	chr2:102972529	NA	1.13	8.55	0.48	1.33e-15	Gut microbiota (bacterial taxa);
KIRP	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.47	5.77	0.35	2.36e-8	Height;
KIRP	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.84	-10.48	-0.56	1.74e-21	Sleep quality;
KIRP	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg00677455	chr12:58241039	CTDSP2	0.62	7.43	0.43	1.74e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.53	5.48	0.33	1.04e-7	Height;
KIRP	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.55	-4.87	-0.3	2.04e-6	Bipolar disorder;
KIRP	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.84	11.91	0.6	4.04e-26	Body mass index;
KIRP	cis	rs4786125	0.587	rs9938245	chr16:6926744	T/G	cg03623568	chr16:6915990	A2BP1	-0.47	-5.83	-0.35	1.69e-8	Heart rate variability traits (SDNN);
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg09263875	chr16:632152	PIGQ	0.74	12.53	0.62	3.4e-28	Height;
KIRP	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg12046867	chr14:103022105	NA	-0.54	-6.87	-0.4	5.29e-11	Platelet count;
KIRP	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg16586182	chr3:47516702	SCAP	-0.77	-10.87	-0.57	9.54e-23	Colorectal cancer;
KIRP	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg10761708	chr20:43804764	PI3	0.5	5.2	0.31	4.22e-7	Blood protein levels;
KIRP	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.17	-0.31	4.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-14.3	-0.67	3.67e-34	Heart rate;
KIRP	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.01	0.45	4.63e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg20651018	chr11:3035856	CARS	0.36	4.93	0.3	1.49e-6	Longevity;
KIRP	cis	rs4006360	0.522	rs2874188	chr17:39244590	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg24579218	chr15:68104479	NA	-0.37	-5.45	-0.33	1.25e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg22437258	chr11:111473054	SIK2	-0.55	-5.99	-0.36	7.59e-9	Primary sclerosing cholangitis;
KIRP	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg08822215	chr16:89438651	ANKRD11	-0.49	-6.41	-0.38	7.37e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6783573	1.000	rs6783573	chr3:46600520	A/G	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.36	-5.82	-0.35	1.87e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg07701084	chr6:150067640	NUP43	0.55	6.82	0.4	6.9e-11	Lung cancer;
KIRP	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.67	6.2	0.37	2.38e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg14541582	chr5:601475	NA	-0.55	-6.12	-0.36	3.63e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.68	8.34	0.47	5.5e-15	Multiple sclerosis;
KIRP	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg11038491	chr20:34638489	LOC647979	-0.75	-7.66	-0.44	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	9.24	0.51	1.2e-17	Prudent dietary pattern;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.29	5.57	0.33	6.66e-8	Tonsillectomy;
KIRP	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.73	9.28	0.51	8.99e-18	Coronary artery disease;
KIRP	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg04990556	chr1:26633338	UBXN11	0.63	5.87	0.35	1.4e-8	Obesity-related traits;
KIRP	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg18132916	chr6:79620363	NA	-0.41	-5.63	-0.34	4.98e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.46	-0.43	1.52e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06699275	chr11:68518961	MTL5	0.5	7.85	0.45	1.32e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg21734707	chr17:3908241	ZZEF1	0.39	4.98	0.3	1.18e-6	Type 2 diabetes;
KIRP	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.7	-6.43	-0.38	6.64e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg04672837	chr16:48644449	N4BP1	0.55	7.47	0.43	1.4e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg18461458	chr19:21324796	ZNF431	-0.48	-5.06	-0.31	8.19e-7	Pain;
KIRP	cis	rs2742234	0.955	rs2075910	chr10:43614230	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.63	-7.59	-0.44	6.47e-13	Hirschsprung disease;
KIRP	cis	rs7945071	0.507	rs12417004	chr11:110297827	T/C	cg04157658	chr11:110243994	NA	0.31	4.89	0.3	1.83e-6	Cognitive function;
KIRP	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.18	-0.37	2.58e-9	Neuroticism;
KIRP	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.89	9.32	0.51	7.12e-18	Schizophrenia;
KIRP	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg02725872	chr8:58115012	NA	-0.63	-5.65	-0.34	4.43e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.92	-0.4	3.89e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs909341	0.909	rs67616625	chr20:62363487	A/G	cg03999872	chr20:62272968	STMN3	-0.59	-6.8	-0.4	7.85e-11	Atopic dermatitis;
KIRP	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-7.07	-0.41	1.59e-11	Response to antipsychotic treatment;
KIRP	cis	rs13065560	0.659	rs4234135	chr3:38882479	C/T	cg01426195	chr3:39028469	NA	-0.41	-6.18	-0.37	2.63e-9	Interleukin-18 levels;
KIRP	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.85	-11.66	-0.6	2.65e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg22764044	chr5:178986830	RUFY1	0.5	7.51	0.43	1.09e-12	Lung cancer;
KIRP	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg19592336	chr6:28129416	ZNF389	0.53	5.95	0.35	9.17e-9	Depression;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15739181	chr3:182697352	DCUN1D1	0.55	6.1	0.36	4e-9	Lung cancer in ever smokers;
KIRP	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg10761708	chr20:43804764	PI3	0.5	5.19	0.31	4.45e-7	Blood protein levels;
KIRP	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg25342872	chr17:79175132	AZI1	0.58	8.0	0.45	4.93e-14	Frontotemporal dementia;
KIRP	cis	rs9608946	0.956	rs7289820	chr22:30878664	T/C	cg23383138	chr22:30885012	SEC14L4	0.4	4.88	0.3	1.92e-6	Red cell distribution width;
KIRP	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-5.77	-0.35	2.32e-8	HDL cholesterol;
KIRP	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs4955124	0.558	rs76673738	chr3:32016935	A/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.81	7.03	0.41	2.01e-11	Schizophrenia;
KIRP	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-7.24	-0.42	5.67e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9398803	0.931	rs9375435	chr6:126661858	C/T	cg19875578	chr6:126661172	C6orf173	0.49	6.5	0.38	4.41e-10	Male-pattern baldness;
KIRP	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg26681399	chr22:41777847	TEF	-0.54	-5.27	-0.32	3e-7	Vitiligo;
KIRP	cis	rs12580194	0.554	rs59097302	chr12:55719030	C/T	cg11794356	chr12:55725991	OR6C3	-0.6	-8.56	-0.48	1.23e-15	Cancer;
KIRP	cis	rs9311676	0.656	rs62258093	chr3:58371745	T/C	cg06643156	chr3:58380774	PXK	0.35	4.92	0.3	1.56e-6	Systemic lupus erythematosus;
KIRP	cis	rs1011018	0.868	rs1011017	chr7:139463565	A/G	cg03224163	chr7:139420300	HIPK2	-0.46	-5.02	-0.3	9.97e-7	Systolic blood pressure;
KIRP	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.83	12.9	0.64	2.05e-29	Testicular germ cell tumor;
KIRP	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg08923054	chr8:41654455	ANK1	0.71	7.77	0.44	2.07e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg12963866	chr19:57752005	ZNF805	-0.49	-6.28	-0.37	1.53e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs56146971	0.714	rs79810056	chr14:91852929	A/G	cg16433844	chr14:91963127	SMEK1	-0.51	-4.84	-0.3	2.26e-6	Alzheimer disease and age of onset;
KIRP	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg23995753	chr2:160760732	LY75	-0.42	-5.58	-0.34	6.29e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18932078	chr1:2524107	MMEL1	-0.46	-6.29	-0.37	1.45e-9	Ulcerative colitis;
KIRP	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.88	-14.96	-0.69	1.95e-36	Monocyte percentage of white cells;
KIRP	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg05165339	chr4:1420672	NA	-0.39	-5.66	-0.34	4.3e-8	Longevity;
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.49	5.14	0.31	5.69e-7	Lung function (FEV1/FVC);
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.68	5.4	0.33	1.54e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.94	0.4	3.44e-11	Schizophrenia;
KIRP	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-16.83	-0.73	8.49e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg14650228	chr8:144573510	ZC3H3	-0.75	-5.36	-0.32	1.88e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg17376030	chr22:41985996	PMM1	-0.58	-6.56	-0.39	3.19e-10	Vitiligo;
KIRP	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg17691542	chr6:26056736	HIST1H1C	0.63	7.52	0.43	1.02e-12	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00366814	chr2:75061219	HK2	0.46	6.2	0.37	2.41e-9	Parkinson's disease;
KIRP	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.58	6.51	0.38	4.1e-10	Initial pursuit acceleration;
KIRP	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.57	0.52	1.18e-18	Dupuytren's disease;
KIRP	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2274273	0.934	rs10140869	chr14:55795283	G/A	cg04306507	chr14:55594613	LGALS3	0.42	6.06	0.36	5.08e-9	Protein biomarker;
KIRP	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg13482628	chr17:19912719	NA	0.53	6.85	0.4	5.99e-11	Schizophrenia;
KIRP	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg26513180	chr16:89883248	FANCA	0.82	5.64	0.34	4.71e-8	Skin colour saturation;
KIRP	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg07777115	chr5:623756	CEP72	-0.56	-5.54	-0.33	7.77e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-6.83	-0.4	6.66e-11	Gut microbiome composition (summer);
KIRP	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg06108461	chr20:60628389	TAF4	-0.55	-6.87	-0.4	5.37e-11	Body mass index;
KIRP	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg03351412	chr1:154909251	PMVK	0.42	5.57	0.33	6.59e-8	Prostate cancer;
KIRP	trans	rs12517041	1.000	rs1428624	chr5:23290393	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.96	-0.5	8.24e-17	Calcium levels;
KIRP	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-8.55	-0.48	1.3e-15	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-6.45	-0.38	5.76e-10	Electroencephalogram traits;
KIRP	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.61	7.77	0.44	2.08e-13	Total body bone mineral density;
KIRP	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg07309820	chr7:148901717	ZNF282	-0.38	-4.94	-0.3	1.44e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs4262150	0.667	rs4145743	chr5:152275279	G/T	cg12297329	chr5:152029980	NA	0.46	6.48	0.38	4.92e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs34286592	0.929	rs1045968	chr16:29826365	G/T	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	5.15	0.31	5.27e-7	Multiple sclerosis;
KIRP	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.71	0.44	3.11e-13	Educational attainment;
KIRP	cis	rs6959887	0.962	rs6977095	chr7:35285754	C/A	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	1.22	11.23	0.58	6.87e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00452530	chr13:46543059	ZC3H13	-0.43	-6.3	-0.37	1.34e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg27144592	chr16:783916	NARFL	0.37	5.17	0.31	4.76e-7	Height;
KIRP	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg03254818	chr6:169586852	NA	-0.48	-7.44	-0.43	1.71e-12	Pulse pressure;
KIRP	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg02570527	chr1:10970165	NA	0.42	5.0	0.3	1.07e-6	Body mass index;
KIRP	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg17724175	chr1:150552817	MCL1	0.35	5.81	0.35	1.94e-8	Melanoma;
KIRP	cis	rs7113850	0.541	rs7928230	chr11:24220604	A/G	ch.11.24196551F	chr11:24239977	NA	0.9	8.35	0.47	5.02e-15	Bone fracture in osteoporosis;
KIRP	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.72	-0.34	3.11e-8	Height;
KIRP	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.91	-0.35	1.12e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg24296786	chr1:45957014	TESK2	0.51	5.69	0.34	3.65e-8	Homocysteine levels;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.91e-8	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg18306943	chr3:40428807	ENTPD3	0.46	5.87	0.35	1.4e-8	Renal cell carcinoma;
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg16268157	chr7:99778414	STAG3	-0.51	-5.42	-0.33	1.42e-7	Lung function (FEV1/FVC);
KIRP	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.74	11.68	0.6	2.29e-25	Resting heart rate;
KIRP	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg17554472	chr22:41940697	POLR3H	-0.59	-6.48	-0.38	5e-10	Vitiligo;
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg02462569	chr6:150064036	NUP43	0.4	5.96	0.36	8.7e-9	Lung cancer;
KIRP	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs16828019	0.852	rs12742379	chr1:41526381	A/G	cg08144172	chr1:41849203	NA	0.61	4.97	0.3	1.28e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg08648136	chr8:956695	NA	0.37	5.17	0.31	4.83e-7	Schizophrenia;
KIRP	cis	rs6832769	0.961	rs2412646	chr4:56318772	T/C	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs4704187	0.687	rs10036527	chr5:74481837	T/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.91	0.3	1.64e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg08126542	chr6:37504118	NA	-0.85	-13.45	-0.65	2.72e-31	Cognitive performance;
KIRP	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	17.34	0.74	1.51e-44	Homoarginine levels;
KIRP	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg13354988	chr2:263656	ACP1;SH3YL1	0.41	5.32	0.32	2.38e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg25428297	chr7:1022841	CYP2W1	0.33	5.21	0.32	3.97e-7	Longevity;Endometriosis;
KIRP	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg19554555	chr3:13937349	NA	0.54	7.98	0.45	5.72e-14	Ovarian reserve;
KIRP	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23281280	chr6:28129359	ZNF389	-0.47	-5.05	-0.31	8.44e-7	Depression;
KIRP	cis	rs56079296	0.929	rs9327237	chr5:121279089	T/C	cg05256605	chr5:121412184	LOX	0.52	5.48	0.33	1.06e-7	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg10756647	chr7:56101905	PSPH	1.09	8.55	0.48	1.29e-15	Diabetic kidney disease;
KIRP	cis	rs9318086	0.534	rs1011362	chr13:24377157	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.43	5.28	0.32	2.8e-7	Myopia (pathological);
KIRP	cis	rs7481584	0.717	rs3759025	chr11:3017377	G/A	cg25174290	chr11:3078921	CARS	-0.62	-7.68	-0.44	3.81e-13	Calcium levels;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.25	-0.42	5.37e-12	Type 2 diabetes;
KIRP	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18255839	chr2:239335447	ASB1	0.45	5.48	0.33	1.06e-7	Multiple system atrophy;
KIRP	cis	rs14057	0.930	rs3789573	chr1:6730905	T/C	cg16431369	chr1:6694556	THAP3;DNAJC11	-0.4	-4.93	-0.3	1.51e-6	Systolic blood pressure;
KIRP	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17376030	chr22:41985996	PMM1	-0.6	-6.48	-0.38	5.1e-10	Vitiligo;
KIRP	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.62	0.39	2.2e-10	Breast cancer;
KIRP	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11613427	chr3:52932208	TMEM110	-0.3	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-12.34	-0.62	1.44e-27	Chronic sinus infection;
KIRP	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg02297831	chr4:17616191	MED28	-0.59	-7.32	-0.42	3.53e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4704187	0.687	rs7711762	chr5:74461675	C/T	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26207909	chr14:103986467	CKB	0.75	11.54	0.59	6.48e-25	Body mass index;
KIRP	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg22508957	chr16:3507546	NAT15	0.58	7.16	0.42	9.46e-12	Tuberculosis;
KIRP	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg20060108	chr2:102954350	IL1RL1	-0.64	-5.67	-0.34	4.06e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg14338887	chr6:42928500	GNMT	0.47	6.94	0.4	3.44e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.8	-11.59	-0.59	4.62e-25	Total body bone mineral density;
KIRP	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg12560992	chr17:57184187	TRIM37	0.68	6.54	0.38	3.5e-10	Cognitive test performance;
KIRP	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.57	-0.33	6.83e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	7.03	0.41	1.99e-11	Eotaxin levels;
KIRP	cis	rs2299587	0.585	rs2285304	chr8:17797931	T/A	cg01800426	chr8:17659068	MTUS1	-0.59	-6.89	-0.4	4.76e-11	Economic and political preferences;
KIRP	trans	rs1048886	0.872	rs2639297	chr6:71219057	A/T	cg00202190	chr7:148333974	NA	-0.62	-6.41	-0.38	7.27e-10	Type 2 diabetes;
KIRP	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg12560992	chr17:57184187	TRIM37	0.46	5.41	0.33	1.49e-7	Cognitive test performance;
KIRP	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg18190219	chr22:46762943	CELSR1	-0.73	-7.34	-0.42	3.07e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg02733842	chr7:1102375	C7orf50	0.43	5.09	0.31	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.72	6.42	0.38	6.82e-10	Thyroid stimulating hormone;
KIRP	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.78	9.85	0.53	1.62e-19	Corneal astigmatism;
KIRP	cis	rs13385	0.769	rs4913073	chr5:139612854	A/G	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.89	15.03	0.69	1.13e-36	Mortality in heart failure;
KIRP	cis	rs2742234	0.868	rs2505512	chr10:43633596	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.6	-7.33	-0.42	3.31e-12	Hirschsprung disease;
KIRP	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-7.26	-0.42	5.22e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	7.25	0.42	5.45e-12	Caffeine consumption;
KIRP	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17554472	chr22:41940697	POLR3H	-0.69	-6.91	-0.4	4.24e-11	Vitiligo;
KIRP	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.69	-8.33	-0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.58	-6.64	-0.39	1.99e-10	Menarche (age at onset);
KIRP	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.82	9.87	0.53	1.39e-19	Corneal astigmatism;
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.67	6.21	0.37	2.18e-9	Alzheimer's disease;
KIRP	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg26876637	chr1:152193138	HRNR	0.73	10.07	0.54	3.34e-20	Atopic dermatitis;
KIRP	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg24296786	chr1:45957014	TESK2	0.53	6.31	0.37	1.29e-9	Homocysteine levels;
KIRP	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg17691542	chr6:26056736	HIST1H1C	0.51	6.62	0.39	2.21e-10	Height;
KIRP	cis	rs7011507	1.000	rs75265401	chr8:49142091	C/G	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7174755	0.743	rs4777035	chr15:68605169	C/T	cg17095910	chr15:68523075	CLN6	-0.36	-5.08	-0.31	7.33e-7	Major depressive disorder;
KIRP	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	6.89	0.4	4.68e-11	Coffee consumption (cups per day);
KIRP	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg00129232	chr17:37814104	STARD3	-0.62	-7.73	-0.44	2.77e-13	Self-reported allergy;
KIRP	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.72	-0.34	3.02e-8	Aortic root size;
KIRP	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg14673194	chr17:80132900	CCDC57	0.77	8.69	0.48	5.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.59	-0.39	2.58e-10	Blood pressure;
KIRP	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.45	6.47	0.38	5.2e-10	Electroencephalogram traits;
KIRP	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.58	-0.34	6.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg26134248	chr17:3907702	NA	0.56	8.24	0.47	1.01e-14	Type 2 diabetes;
KIRP	cis	rs7084402	0.902	rs1658417	chr10:60333039	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.49	-0.56	1.59e-21	Refractive error;
KIRP	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg00071950	chr4:10020882	SLC2A9	0.48	6.83	0.4	6.76e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4389656	0.845	rs13163920	chr5:6759714	C/T	cg10857441	chr5:6722123	POLS	0.43	5.46	0.33	1.18e-7	Coronary artery disease;
KIRP	cis	rs2802372	0.620	rs11002908	chr10:81041793	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.47	-5.81	-0.35	1.95e-8	Granulocyte count;
KIRP	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs7714670	0.753	rs4401557	chr5:73083183	C/T	cg04480106	chr5:72934606	RGNEF	0.38	4.89	0.3	1.79e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg21186296	chr8:27182909	PTK2B	-0.51	-6.34	-0.37	1.11e-9	Neuroticism;
KIRP	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.03	0.41	2.09e-11	Caffeine consumption;
KIRP	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06481639	chr22:41940642	POLR3H	0.75	7.98	0.45	5.56e-14	Vitiligo;
KIRP	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg18944383	chr4:111397179	ENPEP	0.39	6.35	0.38	1.05e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.61	-9.57	-0.52	1.19e-18	Sense of smell;
KIRP	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg18154014	chr19:37997991	ZNF793	0.91	9.33	0.51	6.56e-18	Coronary artery calcification;
KIRP	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.48	7.39	0.43	2.33e-12	Tumor biomarkers;
KIRP	cis	rs12474201	0.778	rs62134773	chr2:47015417	G/A	cg06386533	chr2:46925753	SOCS5	1.06	14.28	0.67	4.07e-34	Height;
KIRP	cis	rs10924970	0.870	rs2382569	chr1:235469032	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	4.94	0.3	1.41e-6	Asthma;
KIRP	cis	rs4835473	0.571	rs1992655	chr4:144776443	G/T	cg08833778	chr4:144622313	FREM3	0.35	5.07	0.31	7.8e-7	Immature fraction of reticulocytes;
KIRP	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	0.96	18.46	0.76	2.35e-48	Dental caries;
KIRP	cis	rs4654899	0.680	rs4654881	chr1:21209769	T/C	cg05370193	chr1:21551575	ECE1	-0.37	-5.16	-0.31	5.02e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.53	5.24	0.32	3.51e-7	Initial pursuit acceleration;
KIRP	cis	rs6959887	0.926	rs77553582	chr7:35299657	T/C	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg17736920	chr1:242011382	EXO1	0.48	5.89	0.35	1.25e-8	Menopause (age at onset);
KIRP	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg06550200	chr5:1325588	CLPTM1L	0.79	10.3	0.55	6.43e-21	Lung cancer;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03647317	chr4:187891568	NA	-0.8	-13.28	-0.65	1.07e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7103648	0.864	rs71475909	chr11:47377283	A/G	cg20307385	chr11:47447363	PSMC3	0.85	10.65	0.56	5.16e-22	Diastolic blood pressure;Systolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10568689	chr11:73591256	PAAF1	0.51	6.18	0.37	2.59e-9	Interleukin-4 levels;
KIRP	cis	rs7582720	1.000	rs115400054	chr2:203676105	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	8.42	0.47	3.25e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Bladder cancer;
KIRP	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.35	-0.32	1.98e-7	Type 2 diabetes;
KIRP	cis	rs12282928	0.959	rs11039640	chr11:48307236	G/A	cg26585981	chr11:48327164	OR4S1	0.5	6.05	0.36	5.29e-9	Migraine - clinic-based;
KIRP	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.66	-6.34	-0.37	1.07e-9	Schizophrenia;
KIRP	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg00852783	chr1:26633632	UBXN11	0.54	7.51	0.43	1.07e-12	Obesity-related traits;
KIRP	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg18944383	chr4:111397179	ENPEP	0.54	9.58	0.52	1.1e-18	Height;
KIRP	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg06042504	chr8:55087323	NA	-0.59	-7.23	-0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.11e-10	Prudent dietary pattern;
KIRP	cis	rs17121403	0.661	rs12121705	chr1:100476815	T/G	cg24955406	chr1:100503596	HIAT1	0.75	4.99	0.3	1.12e-6	Pulmonary function decline;
KIRP	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.64	-0.34	4.73e-8	Parkinson's disease;
KIRP	cis	rs10789491	0.588	rs2099766	chr1:47193987	T/C	cg15501359	chr1:47185051	KIAA0494	0.99	10.64	0.56	5.48e-22	Response to hepatitis C treatment;
KIRP	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.7	8.38	0.47	4.04e-15	Coronary artery disease;
KIRP	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.4	0.51	3.87e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.18	-0.31	4.53e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-7.22	-0.42	6.59e-12	Vitamin D levels;
KIRP	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.73	0.53	3.87e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs7818345	1.000	rs4392915	chr8:19308938	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.37	5.29	0.32	2.69e-7	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.19	0.42	7.63e-12	Aortic root size;
KIRP	trans	rs10895140	0.756	rs4312036	chr11:101519352	C/T	cg23138119	chr2:163218380	GCA	0.45	6.17	0.37	2.72e-9	Menarche (age at onset);
KIRP	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	trans	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg19894588	chr14:64061835	NA	-0.46	-6.15	-0.37	3.13e-9	Fat distribution (HIV);
KIRP	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg11130432	chr3:121712080	ILDR1	-0.43	-5.38	-0.32	1.73e-7	Multiple sclerosis;
KIRP	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.66	7.8	0.45	1.77e-13	Bone mineral density;
KIRP	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.78	0.4	9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.61	-0.52	9.32e-19	Asthma;
KIRP	cis	rs2307121	0.739	rs10054215	chr5:64706585	A/T	cg11190754	chr5:64858552	CENPK;PPWD1	0.43	5.4	0.33	1.55e-7	Corneal structure;
KIRP	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.85	-10.4	-0.55	3.18e-21	Dupuytren's disease;
KIRP	trans	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg06521331	chr12:34319734	NA	-0.49	-6.22	-0.37	2.16e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16376373	chr4:23268516	NA	-0.39	-6.31	-0.37	1.26e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24658737	chr1:220292590	IARS2;MIR194-1;MIR215	0.42	6.33	0.37	1.14e-9	C-reactive protein;
KIRP	trans	rs6601327	0.665	rs10107992	chr8:9653287	G/A	cg16141378	chr3:129829833	LOC729375	0.46	6.1	0.36	4.13e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg09165964	chr15:75287851	SCAMP5	-0.36	-4.84	-0.3	2.25e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4711350	0.765	rs943473	chr6:33743651	G/C	cg25922239	chr6:33757077	LEMD2	0.53	5.7	0.34	3.44e-8	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05347473	chr6:146136440	FBXO30	-0.52	-7.57	-0.43	7.37e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4973397	0.643	rs2369271	chr2:232289244	C/T	cg09339159	chr2:232260559	B3GNT7	-0.41	-5.13	-0.31	5.89e-7	Anti-saccade response;
KIRP	cis	rs6832769	1.000	rs7673908	chr4:56394819	A/G	cg05960024	chr4:56376020	CLOCK	-0.61	-7.73	-0.44	2.67e-13	Personality dimensions;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.58	7.63	0.44	5.31e-13	Schizophrenia;
KIRP	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.64	-7.92	-0.45	8.39e-14	Body mass index;
KIRP	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg00277334	chr10:82204260	NA	-0.44	-5.06	-0.31	8.3e-7	Post bronchodilator FEV1;
KIRP	cis	rs2071426	0.580	rs7910170	chr10:96759180	G/T	cg09036531	chr10:96991505	NA	-0.46	-5.26	-0.32	3.19e-7	Blood metabolite levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02653270	chr7:150948861	SMARCD3	-0.6	-6.52	-0.38	3.97e-10	Menopause (age at onset);
KIRP	cis	rs7580658	0.545	rs59318157	chr2:127950074	G/C	cg16751203	chr2:127950803	CYP27C1	0.41	5.58	0.34	6.41e-8	Protein C levels;
KIRP	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg00576331	chr11:65640516	EFEMP2	0.51	5.65	0.34	4.46e-8	Crohn's disease;
KIRP	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.03	0.46	4.12e-14	Morning vs. evening chronotype;
KIRP	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.63	-9.68	-0.53	5.63e-19	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg21827317	chr3:136751795	NA	0.37	5.35	0.32	1.97e-7	Gestational age at birth (child effect);
KIRP	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.55	-0.43	8.56e-13	Response to antipsychotic treatment;
KIRP	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.47	5.56	0.33	7.18e-8	Resistin levels;
KIRP	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05220968	chr6:146057943	EPM2A	-0.38	-4.98	-0.3	1.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg18192325	chr2:105854051	NA	-0.37	-5.01	-0.3	1.02e-6	Type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02116590	chr2:3207260	TSSC1	0.43	6.06	0.36	5.01e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs35304300	0.779	rs6906971	chr6:139870189	A/G	cg05219445	chr6:139855396	NA	0.45	4.85	0.3	2.15e-6	Mean platelet volume;
KIRP	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg22830091	chr7:75961684	YWHAG	-0.38	-4.86	-0.3	2.12e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	0.9	11.8	0.6	9.39e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4908768	0.906	rs10492966	chr1:8598005	C/T	cg25722041	chr1:8623473	RERE	0.76	9.55	0.52	1.37e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-5.52	-0.33	8.49e-8	Subjective well-being;
KIRP	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg21108841	chr4:24914750	CCDC149	-0.46	-5.54	-0.33	7.67e-8	Heschl's gyrus morphology;
KIRP	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.6	-7.15	-0.41	9.86e-12	Colorectal cancer;
KIRP	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg18833306	chr6:118973337	C6orf204	0.41	5.13	0.31	5.81e-7	Electrocardiographic conduction measures;
KIRP	cis	rs73206853	0.764	rs16940935	chr12:111107470	A/G	cg12870014	chr12:110450643	ANKRD13A	0.5	4.87	0.3	1.96e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg16141378	chr3:129829833	LOC729375	0.52	6.71	0.39	1.36e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10982256	0.875	rs11787667	chr9:117242845	C/T	cg13636371	chr9:117264095	DFNB31	0.56	7.52	0.43	1.03e-12	Bipolar disorder;
KIRP	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg00405596	chr8:11794950	NA	0.47	6.22	0.37	2.11e-9	Mood instability;
KIRP	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg23625390	chr15:77176239	SCAPER	0.54	7.28	0.42	4.53e-12	Blood metabolite levels;
KIRP	cis	rs2599510	0.783	rs13399071	chr2:32793783	C/T	cg02381751	chr2:32503542	YIPF4	0.45	5.12	0.31	6.03e-7	Interleukin-18 levels;
KIRP	cis	rs238295	0.805	rs6116855	chr20:5555317	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-5.1	-0.31	6.67e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.19	15.0	0.69	1.46e-36	Platelet count;
KIRP	cis	rs9513627	1.000	rs4584676	chr13:100160560	A/G	cg25919922	chr13:100150906	NA	0.73	5.45	0.33	1.21e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.31e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10463316	0.894	rs869198	chr5:150745893	G/T	cg03212797	chr5:150827313	SLC36A1	0.5	6.57	0.39	2.92e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg03959625	chr15:84868606	LOC388152	0.48	5.68	0.34	3.78e-8	Schizophrenia;
KIRP	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.53	-0.38	3.71e-10	Neuroticism;
KIRP	trans	rs9822411	0.610	rs116605026	chr3:25402082	T/G	cg04286030	chr1:2313373	MORN1	0.77	6.05	0.36	5.27e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.22	-0.32	3.73e-7	Neuroticism;
KIRP	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.71	8.43	0.47	2.92e-15	Corneal astigmatism;
KIRP	cis	rs9840812	0.655	rs696516	chr3:136067778	G/T	cg15507776	chr3:136538369	TMEM22	0.41	5.15	0.31	5.37e-7	Fibrinogen levels;
KIRP	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	-0.42	-5.18	-0.31	4.65e-7	Monocyte percentage of white cells;
KIRP	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg13482628	chr17:19912719	NA	0.61	8.71	0.49	4.54e-16	Schizophrenia;
KIRP	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.75	12.06	0.61	1.27e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.54	-6.91	-0.4	4.16e-11	Coronary heart disease;
KIRP	cis	rs675026	0.963	rs598160	chr6:154442143	G/A	cg07813322	chr6:154414604	OPRM1	-0.51	-6.71	-0.39	1.32e-10	Hypertension;
KIRP	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg27147174	chr7:100797783	AP1S1	-0.73	-9.34	-0.51	6.12e-18	Life satisfaction;
KIRP	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18867708	chr6:26865862	GUSBL1	0.47	5.9	0.35	1.17e-8	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11351140	chr13:20625630	ZMYM2	-0.48	-7.23	-0.42	5.96e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg04944784	chr2:26401820	FAM59B	-0.51	-6.01	-0.36	6.75e-9	Gut microbiome composition (summer);
KIRP	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.25	6.83	0.4	6.67e-11	Crohn's disease;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.63	-7.74	-0.44	2.58e-13	Longevity;Endometriosis;
KIRP	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg18196295	chr10:418757	DIP2C	0.39	4.89	0.3	1.85e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	0.87	7.59	0.44	6.43e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.44	5.79	0.35	2.14e-8	Height;
KIRP	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.33e-20	Hemoglobin concentration;
KIRP	cis	rs1018697	1.000	rs4919678	chr10:104554363	C/G	cg04362960	chr10:104952993	NT5C2	0.48	5.8	0.35	2.01e-8	Colorectal adenoma (advanced);
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.54	-6.75	-0.4	1.04e-10	Longevity;Endometriosis;
KIRP	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.73	-9.89	-0.53	1.26e-19	Asthma;
KIRP	cis	rs6743226	0.901	rs4675968	chr2:242222492	T/C	cg10021735	chr2:242295487	FARP2	0.47	5.68	0.34	3.76e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg25566285	chr7:158114605	PTPRN2	0.79	13.2	0.64	1.89e-30	Calcium levels;
KIRP	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.77	-11.55	-0.59	6.31e-25	Hip circumference;
KIRP	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.64	7.69	0.44	3.63e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7180079	0.620	rs936689	chr15:64735527	G/A	cg15337035	chr15:64978493	NA	-0.48	-5.25	-0.32	3.24e-7	Monocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07810072	chr11:66610236	RCE1;C11orf80	0.47	6.49	0.38	4.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.85	-11.26	-0.58	5.56e-24	Type 2 diabetes;
KIRP	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.51	7.14	0.41	1.08e-11	Mean corpuscular volume;
KIRP	cis	rs11583043	0.708	rs17123647	chr1:101529018	A/G	cg17443007	chr1:101659419	NA	0.37	5.0	0.3	1.08e-6	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg03468072	chr12:39539422	NA	-0.41	-6.02	-0.36	6.21e-9	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22514987	chr6:52271182	PAQR8	0.42	6.08	0.36	4.47e-9	Survival in pancreatic cancer;
KIRP	cis	rs524023	0.914	rs11607663	chr11:64368670	G/C	cg09231725	chr11:64357281	SLC22A12	0.61	8.05	0.46	3.53e-14	Urate levels in obese individuals;
KIRP	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.16e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-5.43	-0.33	1.38e-7	Neuroticism;
KIRP	trans	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg01620082	chr3:125678407	NA	-1.05	-6.33	-0.37	1.12e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.35	19.06	0.77	2.43e-50	Corneal structure;
KIRP	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	8.79	0.49	2.62e-16	Systolic blood pressure;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.68	-0.44	3.81e-13	Life satisfaction;
KIRP	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.83	-0.53	1.86e-19	Total body bone mineral density;
KIRP	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-5.36	-0.32	1.95e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	0.79	7.15	0.41	1.01e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	7.1	0.41	1.29e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg05083358	chr7:2394359	EIF3B	-0.73	-7.1	-0.41	1.35e-11	Multiple sclerosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11749264	chr6:109940408	AKD1	-0.41	-6.69	-0.39	1.52e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg01557791	chr16:72042693	DHODH	-0.69	-7.44	-0.43	1.7e-12	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg00405596	chr8:11794950	NA	-0.6	-8.63	-0.48	7.64e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7172677	0.737	rs7178625	chr15:75441017	A/G	cg14082893	chr15:75400931	NA	0.33	4.9	0.3	1.72e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg05315796	chr3:52349193	DNAH1	0.41	5.25	0.32	3.29e-7	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.93	12.23	0.61	3.57e-27	Menopause (age at onset);
KIRP	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.93	9.87	0.53	1.38e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.78	9.56	0.52	1.3e-18	Adiposity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25810379	chr11:64578055	MEN1	0.5	6.19	0.37	2.43e-9	Parkinson's disease;
KIRP	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg23387468	chr7:139079360	LUC7L2	0.3	5.17	0.31	4.9e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9488822	0.623	rs195518	chr6:116241693	A/G	cg18764771	chr6:116381957	FRK	0.19	5.1	0.31	6.91e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10073892	0.664	rs12653822	chr5:101878418	A/G	cg19774478	chr5:101632501	SLCO4C1	-0.58	-5.7	-0.34	3.47e-8	Cognitive decline (age-related);
KIRP	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26505371	chr19:5210732	PTPRS	0.52	6.5	0.38	4.53e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11203032	0.831	rs11203014	chr10:90940333	C/G	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg14835575	chr10:16859367	RSU1	-0.59	-7.95	-0.45	6.82e-14	Platelet distribution width;
KIRP	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.74	8.62	0.48	8.48e-16	High light scatter reticulocyte count;
KIRP	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.43	5.94	0.35	9.53e-9	Coronary artery disease;
KIRP	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-12.34	-0.62	1.44e-27	Chronic sinus infection;
KIRP	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.71	8.42	0.47	3.16e-15	High light scatter reticulocyte count;
KIRP	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-8.99	-0.5	6.91e-17	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.61	-0.34	5.4e-8	Coronary artery disease;
KIRP	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg00784671	chr22:46762841	CELSR1	-0.68	-7.94	-0.45	6.99e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.65	8.46	0.47	2.46e-15	Prudent dietary pattern;
KIRP	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Body mass index;
KIRP	cis	rs12142240	0.845	rs4313342	chr1:46801904	T/C	cg00530320	chr1:46809349	NSUN4	0.47	5.81	0.35	1.88e-8	Menopause (age at onset);
KIRP	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-7.6	-0.44	6.16e-13	Gut microbiome composition (summer);
KIRP	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg02228329	chr11:64053129	BAD;GPR137	-0.63	-7.54	-0.43	8.95e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.59	-9.41	-0.51	3.6e-18	Prostate cancer;
KIRP	cis	rs4849845	0.612	rs3806491	chr2:121008675	G/A	cg24070213	chr2:121070622	NA	0.41	6.37	0.38	9.25e-10	Mean platelet volume;
KIRP	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.55	-6.44	-0.38	6.15e-10	Aortic root size;
KIRP	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05025164	chr4:1340916	KIAA1530	0.4	5.22	0.32	3.81e-7	Obesity-related traits;
KIRP	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg20243544	chr17:37824526	PNMT	0.51	7.34	0.42	3.13e-12	Asthma;
KIRP	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg10503236	chr1:231470652	EXOC8	-0.56	-8.17	-0.46	1.66e-14	Hemoglobin concentration;
KIRP	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.64	6.71	0.39	1.32e-10	Response to diuretic therapy;
KIRP	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.4	-0.33	1.6e-7	Pulmonary function;
KIRP	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.73	0.39	1.17e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg23985595	chr17:80112537	CCDC57	0.41	6.22	0.37	2.09e-9	Life satisfaction;
KIRP	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.92	-0.4	4e-11	Monocyte count;
KIRP	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg06647332	chr5:131281008	NA	0.45	5.07	0.31	7.86e-7	Life satisfaction;
KIRP	cis	rs8014252	0.803	rs73282126	chr14:70986041	T/C	cg19730268	chr14:71022823	NA	-0.57	-5.49	-0.33	9.97e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs4742903	0.509	rs12379563	chr9:106956786	G/A	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.09	-0.36	4.22e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg01843034	chr6:37503916	NA	-0.96	-14.28	-0.67	4.21e-34	Cognitive performance;
KIRP	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.54	-6.53	-0.38	3.83e-10	Total body bone mineral density;
KIRP	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg22117172	chr7:91764530	CYP51A1	-0.47	-6.78	-0.4	8.91e-11	Breast cancer;
KIRP	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg18305652	chr10:134549665	INPP5A	-0.48	-7.54	-0.43	9.01e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg26876637	chr1:152193138	HRNR	0.72	9.79	0.53	2.54e-19	Atopic dermatitis;
KIRP	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.49	0.43	1.23e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg09473613	chr1:24152604	HMGCL	0.48	6.33	0.37	1.12e-9	Immature fraction of reticulocytes;
KIRP	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.67	-11.79	-0.6	1.03e-25	White blood cell count (basophil);
KIRP	cis	rs1558375	0.679	rs31671	chr7:87059403	C/G	cg00919237	chr7:87102261	ABCB4	-0.54	-6.88	-0.4	4.95e-11	Gallbladder cancer;
KIRP	trans	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg05059571	chr16:84539110	KIAA1609	0.58	7.83	0.45	1.45e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19388446	chr12:6715730	CHD4	0.58	7.33	0.42	3.31e-12	Parkinson's disease;
KIRP	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.9	14.09	0.67	1.86e-33	Height;
KIRP	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-9.02	-0.5	5.5e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17809414	chr2:206547231	NRP2	0.47	6.05	0.36	5.23e-9	Parkinson's disease;
KIRP	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	0.93	13.51	0.65	1.7e-31	Dupuytren's disease;
KIRP	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.82	11.83	0.6	7.43e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6545883	0.507	rs2123111	chr2:61450454	A/G	cg15711740	chr2:61764176	XPO1	0.46	5.72	0.34	3.09e-8	Tuberculosis;
KIRP	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg13010199	chr12:38710504	ALG10B	0.52	6.74	0.39	1.13e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs2048656	0.605	rs34592740	chr8:9651096	G/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.0	0.41	2.47e-11	Schizophrenia;
KIRP	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.44	-7.15	-0.41	9.94e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs8001976	0.510	rs9526395	chr13:48335077	G/A	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Aging (time to event);
KIRP	cis	rs1867631	1.000	rs11208927	chr1:67089561	T/C	cg13052034	chr1:66999238	SGIP1	0.49	7.0	0.41	2.38e-11	Menopause (age at onset);
KIRP	trans	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg04373760	chr16:53404718	NA	0.6	6.29	0.37	1.4e-9	Hypertriglyceridemia;
KIRP	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	6.42	0.38	7.02e-10	Hemoglobin concentration;
KIRP	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.49	-6.38	-0.38	8.6e-10	White blood cell count;
KIRP	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg14092571	chr14:90743983	NA	-0.39	-5.06	-0.31	8.38e-7	Mortality in heart failure;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg10326726	chr10:51549505	MSMB	-0.59	-8.97	-0.5	7.8e-17	Prostate-specific antigen levels;
KIRP	cis	rs7539409	0.651	rs10747407	chr1:84314754	G/A	cg10977910	chr1:84465055	TTLL7	0.6	5.49	0.33	9.97e-8	Alzheimer's disease;
KIRP	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg15026998	chr2:160761622	LY75	-0.34	-4.94	-0.3	1.43e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17301259	0.548	rs4728772	chr7:88403590	G/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.3	-4.92	-0.3	1.57e-6	Heschl's gyrus morphology;
KIRP	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.57	7.42	0.43	1.87e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.35	-4.94	-0.3	1.43e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-1.06	-14.82	-0.69	5.92e-36	Alopecia areata;
KIRP	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.46	6.71	0.39	1.37e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs4262150	0.810	rs17453775	chr5:151976244	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.15	-0.46	1.9e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg05315796	chr3:52349193	DNAH1	0.43	6.37	0.38	9.16e-10	Bipolar disorder;
KIRP	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.67	-6.56	-0.39	3.23e-10	Bipolar disorder;
KIRP	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg02503808	chr4:7069936	GRPEL1	0.93	12.63	0.63	1.59e-28	Monocyte percentage of white cells;
KIRP	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg26412358	chr1:26503933	CNKSR1	0.4	5.53	0.33	8.05e-8	Height;
KIRP	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.77	9.06	0.5	4.11e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1185460	0.546	rs589925	chr11:118955679	C/T	cg23280166	chr11:118938394	VPS11	-0.61	-7.12	-0.41	1.19e-11	Coronary artery disease;
KIRP	cis	rs2070856	1.000	rs2070856	chr20:23731412	A/G	cg08430598	chr20:23731367	CST1	-0.47	-5.12	-0.31	6.03e-7	Blood protein levels;
KIRP	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.47	-5.67	-0.34	4.08e-8	Glomerular filtration rate;
KIRP	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.54	-6.01	-0.36	6.7e-9	Obesity-related traits;
KIRP	cis	rs3741151	0.686	rs7927344	chr11:73207517	T/C	cg17517138	chr11:73019481	ARHGEF17	0.6	5.37	0.32	1.82e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2882667	0.898	rs4380651	chr5:138391072	A/G	cg04439458	chr5:138467593	SIL1	-0.41	-6.76	-0.4	1.02e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg08712631	chr7:1960676	MAD1L1	-0.43	-5.49	-0.33	9.91e-8	Neuroticism;
KIRP	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg23791538	chr6:167370224	RNASET2	0.44	5.32	0.32	2.33e-7	Primary biliary cholangitis;
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg24296786	chr1:45957014	TESK2	0.4	5.04	0.31	9.24e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs3099143	1.000	rs111908804	chr15:77123773	C/G	cg21673338	chr15:77095150	SCAPER	-0.6	-6.01	-0.36	6.8e-9	Recalcitrant atopic dermatitis;
KIRP	cis	rs1440410	0.835	rs115219342	chr4:144091815	T/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.26e-10	Ischemic stroke;
KIRP	cis	rs8067545	0.717	rs9907788	chr17:20008903	T/C	cg13482628	chr17:19912719	NA	0.65	9.47	0.52	2.37e-18	Schizophrenia;
KIRP	cis	rs7009516	0.604	rs13259526	chr8:24263957	G/C	cg01759110	chr8:24241694	ADAMDEC1	-0.31	-6.6	-0.39	2.5e-10	Hair greying;
KIRP	trans	rs4698048	0.506	rs2080072	chr4:10235622	G/C	cg26043149	chr18:55253948	FECH	-0.56	-6.83	-0.4	6.7e-11	Skin aging (microtopography measurement);
KIRP	cis	rs9534288	0.797	rs7331069	chr13:46564609	A/T	cg15192986	chr13:46630673	CPB2	0.68	8.07	0.46	3.14e-14	Blood protein levels;
KIRP	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.71	10.04	0.54	4.14e-20	High light scatter reticulocyte count;
KIRP	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.63	8.55	0.48	1.36e-15	Alzheimer's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09789939	chr16:88532245	ZFPM1	0.5	6.1	0.36	4.14e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.64	9.32	0.51	7.12e-18	Retinal vascular caliber;
KIRP	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	1.25	13.68	0.66	4.77e-32	Corneal structure;
KIRP	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	6.9	0.4	4.49e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3736485	0.934	rs4143724	chr15:51870413	T/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.53e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg10932868	chr11:921992	NA	0.67	9.06	0.5	4.32e-17	Alzheimer's disease (late onset);
KIRP	cis	rs9409565	0.826	rs2769813	chr9:97151194	C/T	cg04523069	chr9:97136363	HIATL1	-0.46	-6.26	-0.37	1.73e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg23307798	chr14:103986281	CKB	0.72	11.24	0.58	6.34e-24	Body mass index;
KIRP	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.92	-0.53	9.72e-20	Hemoglobin concentration;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg01763666	chr17:80159506	CCDC57	-0.37	-4.97	-0.3	1.24e-6	Life satisfaction;
KIRP	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg16701003	chr16:89028210	CBFA2T3	0.48	6.42	0.38	6.78e-10	Social autistic-like traits;
KIRP	cis	rs4742903	1.000	rs10761010	chr9:106858788	G/A	cg14250997	chr9:106856677	SMC2	0.4	5.29	0.32	2.65e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs3126085	0.515	rs12029633	chr1:152347403	A/C	cg26876637	chr1:152193138	HRNR	-0.52	-6.56	-0.39	3.24e-10	Atopic dermatitis;
KIRP	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.05	-17.95	-0.75	1.29e-46	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.45	0.52	2.83e-18	Lung cancer;
KIRP	cis	rs7851660	0.809	rs7032086	chr9:100656402	T/G	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg09936142	chr19:10668400	KRI1	-0.44	-4.92	-0.3	1.6e-6	Inflammatory skin disease;
KIRP	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-16.01	-0.71	5.21e-40	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg25019722	chr6:37503610	NA	-0.78	-10.84	-0.57	1.22e-22	Cognitive performance;
KIRP	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs501120	1.000	rs1746048	chr10:44775824	A/G	cg09554077	chr10:44749378	NA	-0.7	-10.89	-0.57	8.32e-23	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10114408	0.959	rs7033563	chr9:96663499	T/C	cg14598338	chr9:96623480	NA	-0.32	-4.91	-0.3	1.7e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-5.43	-0.33	1.35e-7	Testicular germ cell tumor;
KIRP	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	1.1	14.45	0.68	1.1e-34	Post bronchodilator FEV1;
KIRP	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-0.97	-7.04	-0.41	1.87e-11	Mitochondrial DNA levels;
KIRP	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.87	0.3	1.99e-6	Tonsillectomy;
KIRP	cis	rs28785552	0.765	rs28850924	chr19:53234323	T/G	cg03571507	chr19:53239146	ZNF611	0.22	5.47	0.33	1.12e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.8	12.9	0.64	2.02e-29	Schizophrenia;
KIRP	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg26531700	chr6:26746687	NA	0.41	5.47	0.33	1.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg04111992	chr7:158790115	NA	0.42	5.17	0.31	4.78e-7	Facial morphology (factor 20);
KIRP	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05220968	chr6:146057943	EPM2A	0.38	4.87	0.3	2.03e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13198984	chr17:80129470	CCDC57	0.56	8.5	0.48	1.85e-15	Life satisfaction;
KIRP	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg18306943	chr3:40428807	ENTPD3	0.45	5.88	0.35	1.33e-8	Renal cell carcinoma;
KIRP	cis	rs858239	0.571	rs2390755	chr7:23190716	A/T	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.61	-8.5	-0.48	1.85e-15	Total body bone mineral density;
KIRP	cis	rs4356932	0.967	rs6835736	chr4:76962494	A/T	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07080007	chr17:41150154	RPL27	0.53	6.22	0.37	2.08e-9	Smoking initiation;
KIRP	cis	rs7246657	0.638	rs7246461	chr19:38196581	C/G	cg18154014	chr19:37997991	ZNF793	-0.55	-6.19	-0.37	2.49e-9	Coronary artery calcification;
KIRP	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg19025524	chr12:109796872	NA	-0.54	-7.61	-0.44	5.84e-13	Neuroticism;
KIRP	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg05347473	chr6:146136440	FBXO30	0.52	7.49	0.43	1.26e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg12486944	chr17:80159399	CCDC57	-0.39	-5.27	-0.32	2.98e-7	Life satisfaction;
KIRP	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg24826892	chr11:71159390	DHCR7	0.45	5.0	0.3	1.09e-6	Vitamin D levels;
KIRP	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11603020	0.904	rs4926	chr11:57381989	G/A	cg19752551	chr11:57585705	CTNND1	-0.71	-9.83	-0.53	1.91e-19	Blood protein levels;
KIRP	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg04166393	chr7:2884313	GNA12	0.46	5.87	0.35	1.41e-8	Height;
KIRP	cis	rs4775041	0.961	rs11858759	chr15:58676821	G/A	cg02971627	chr15:59042282	ADAM10	0.46	4.91	0.3	1.66e-6	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16542473	chr5:123424832	NA	-0.4	-6.29	-0.37	1.48e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg00656387	chr3:40428638	ENTPD3	0.38	4.9	0.3	1.78e-6	Renal cell carcinoma;
KIRP	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg24826892	chr11:71159390	DHCR7	0.44	5.27	0.32	2.99e-7	Vitamin D levels;
KIRP	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg15556689	chr8:8085844	FLJ10661	0.61	7.47	0.43	1.38e-12	Neuroticism;
KIRP	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.69	9.7	0.53	4.9e-19	Retinal vascular caliber;
KIRP	cis	rs2742417	1.000	rs2742385	chr3:45756270	G/A	cg04037228	chr3:45636386	LIMD1	0.35	5.24	0.32	3.51e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.12	-0.46	2.19e-14	Monocyte percentage of white cells;
KIRP	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs17123764	0.786	rs60613973	chr12:50058261	G/T	cg02054252	chr12:50078554	FMNL3	0.51	5.01	0.3	1.05e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20887711	chr4:1340912	KIAA1530	0.46	5.72	0.34	3.12e-8	Obesity-related traits;
KIRP	cis	rs1978968	0.763	rs9605480	chr22:18465105	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.78	-10.85	-0.57	1.16e-22	Presence of antiphospholipid antibodies;
KIRP	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg16473166	chr22:50639996	SELO	0.64	8.17	0.46	1.64e-14	Obesity-related traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13895544	chr3:66550922	LRIG1	-0.46	-6.09	-0.36	4.34e-9	Myopia;
KIRP	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg16989719	chr2:238392110	NA	0.41	5.12	0.31	6.12e-7	Prostate cancer;
KIRP	cis	rs6496667	0.779	rs8027211	chr15:90983706	A/G	cg10434728	chr15:90938212	IQGAP1	0.36	4.87	0.3	1.96e-6	Rheumatoid arthritis;
KIRP	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	1.09	16.27	0.72	6.58e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.78	-11.02	-0.57	3.24e-23	Hip circumference adjusted for BMI;
KIRP	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg05926928	chr17:57297772	GDPD1	0.79	7.67	0.44	4.12e-13	Opioid sensitivity;
KIRP	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg07884673	chr3:53033167	SFMBT1	0.74	5.71	0.34	3.25e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7937682	0.593	rs1944111	chr11:111364432	G/C	cg09085632	chr11:111637200	PPP2R1B	0.45	5.66	0.34	4.22e-8	Primary sclerosing cholangitis;
KIRP	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	9.95	0.54	8.29e-20	Bone mineral density;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg07151059	chr8:61568373	NA	-0.46	-6.43	-0.38	6.58e-10	Select biomarker traits;
KIRP	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg10760299	chr15:45669010	GATM	0.32	5.08	0.31	7.37e-7	Homoarginine levels;
KIRP	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-6.16	-0.37	2.87e-9	Body mass index (adult);
KIRP	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs13185784	0.667	rs4700728	chr5:179647551	T/G	cg02891314	chr5:179741120	GFPT2	-0.47	-4.88	-0.3	1.89e-6	TRAIL levels;
KIRP	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.17	-0.31	4.89e-7	Obesity-related traits;
KIRP	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.47	6.99	0.41	2.62e-11	Motion sickness;
KIRP	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.77	-0.44	2.19e-13	Total cholesterol levels;
KIRP	trans	rs12043259	0.803	rs6702731	chr1:204813730	T/C	cg11485465	chr5:54518469	NA	0.38	6.58	0.39	2.78e-10	Addiction;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.55	-5.17	-0.31	4.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.52	-5.71	-0.34	3.21e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7106204	0.609	rs11828535	chr11:24295565	G/C	ch.11.24196551F	chr11:24239977	NA	0.68	5.11	0.31	6.58e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg21546286	chr11:48923668	NA	-0.45	-5.4	-0.33	1.61e-7	HDL cholesterol;
KIRP	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.19	-0.37	2.46e-9	Bladder cancer;
KIRP	cis	rs9584850	0.708	rs4411372	chr13:99130423	T/C	cg20750642	chr13:99100586	FARP1	-0.52	-6.12	-0.36	3.75e-9	Neuroticism;
KIRP	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.63	-6.88	-0.4	4.97e-11	DNA methylation (variation);
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg08134877	chr2:44394819	PPM1B	0.51	4.99	0.3	1.17e-6	Height;
KIRP	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.11	-0.46	2.35e-14	Bipolar disorder;
KIRP	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.72	-9.58	-0.52	1.14e-18	Dental caries;
KIRP	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.89	9.97	0.54	6.9e-20	Eosinophil percentage of granulocytes;
KIRP	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg13010199	chr12:38710504	ALG10B	0.63	7.79	0.44	1.89e-13	Morning vs. evening chronotype;
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.72	0.39	1.23e-10	Electroencephalogram traits;
KIRP	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.51	6.17	0.37	2.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6484504	0.625	rs672396	chr11:31386165	A/G	cg26647111	chr11:31128758	NA	0.44	5.09	0.31	7.17e-7	Red blood cell count;
KIRP	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-4.87	-0.3	2e-6	Schizophrenia;
KIRP	cis	rs753955	0.567	rs767378	chr13:24364565	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	6.53	0.38	3.84e-10	Lung cancer;
KIRP	cis	rs9298506	1.000	rs28457828	chr8:55451142	C/T	cg19005830	chr8:55467175	NA	-0.56	-4.96	-0.3	1.32e-6	Intracranial aneurysm;
KIRP	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-7.44	-0.43	1.64e-12	Waist circumference adjusted for body mass index;
KIRP	cis	rs2282335	0.507	rs2498421	chr9:71855357	A/G	cg14075627	chr9:71863002	TJP2	0.45	6.09	0.36	4.42e-9	Renal sinus fat;
KIRP	cis	rs11264213	0.901	rs79303353	chr1:36402056	G/A	cg27506609	chr1:36549197	TEKT2	1.21	7.05	0.41	1.77e-11	Schizophrenia;
KIRP	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.61	9.52	0.52	1.71e-18	Personality dimensions;
KIRP	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg25174290	chr11:3078921	CARS	-0.56	-6.02	-0.36	6.41e-9	Calcium levels;
KIRP	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg17145862	chr1:211918768	LPGAT1	1.08	19.39	0.78	1.85e-51	Leprosy;
KIRP	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	7.58	0.43	7.22e-13	Height;
KIRP	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.59	-6.62	-0.39	2.27e-10	Coronary artery disease;
KIRP	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.8	10.94	0.57	5.98e-23	Adiposity;
KIRP	cis	rs853679	0.546	rs200948	chr6:27835272	T/C	cg21204522	chr6:27730016	NA	-0.72	-5.21	-0.32	4.04e-7	Depression;
KIRP	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04396765	chr10:76585478	MYST4	0.44	6.23	0.37	2.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.85	12.38	0.62	1.12e-27	Dental caries;
KIRP	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.53	-0.33	8.29e-8	Carotid intima media thickness;
KIRP	cis	rs1577917	0.545	rs1335443	chr6:86478737	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-5.34	-0.32	2.1e-7	Response to antipsychotic treatment;
KIRP	cis	rs6504340	0.600	rs2325946	chr17:46584631	G/C	cg04904318	chr17:46607828	HOXB1	0.45	5.7	0.34	3.36e-8	Primary tooth development (number of teeth);
KIRP	cis	rs7635838	0.859	rs6779840	chr3:11425423	A/G	cg00170343	chr3:11313890	ATG7	0.45	5.74	0.34	2.84e-8	HDL cholesterol;
KIRP	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.32	4.85	0.3	2.23e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs71403859	0.502	rs75986475	chr16:71464058	C/G	cg08717414	chr16:71523259	ZNF19	-0.96	-9.09	-0.5	3.48e-17	Post bronchodilator FEV1;
KIRP	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00889227	chr1:205173544	DSTYK	-0.37	-4.95	-0.3	1.37e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.61	-7.31	-0.42	3.66e-12	Initial pursuit acceleration;
KIRP	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg23100626	chr2:96804247	ASTL	0.49	7.16	0.42	9.26e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10156125	chr4:115520072	UGT8	0.48	6.24	0.37	1.95e-9	Inflammatory biomarkers;
KIRP	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg25182066	chr10:30743637	MAP3K8	0.62	5.31	0.32	2.4e-7	Itch intensity from mosquito bite;
KIRP	cis	rs7792596	1.000	rs4729126	chr7:94007064	C/T	cg20814616	chr7:94014465	NA	0.31	5.27	0.32	2.95e-7	Intelligence;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08850721	chr3:14716724	C3orf20	0.49	6.21	0.37	2.2e-9	Survival in pancreatic cancer;
KIRP	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	18.95	0.77	5.32e-50	Height;
KIRP	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg18657303	chr4:1051139	NA	-0.53	-4.86	-0.3	2.05e-6	Recombination rate (females);
KIRP	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16386425	chr10:429943	DIP2C	-0.49	-6.73	-0.39	1.16e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg06521331	chr12:34319734	NA	-0.63	-7.41	-0.43	2.03e-12	Morning vs. evening chronotype;
KIRP	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.53	-6.77	-0.4	9.51e-11	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.63	-6.16	-0.37	2.93e-9	Menarche (age at onset);
KIRP	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.57	-6.87	-0.4	5.21e-11	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.64	-8.95	-0.5	8.65e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	ch.11.340609R	chr11:12831013	TEAD1	0.43	5.42	0.33	1.43e-7	Educational attainment (years of education);
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.53	-0.33	8.07e-8	Lung cancer;
KIRP	cis	rs7116495	0.737	rs670802	chr11:71799668	A/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.82e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs882732	1.000	rs10149354	chr14:95038368	C/T	cg05186455	chr14:95027692	SERPINA4	-0.4	-5.49	-0.33	9.89e-8	Blood protein levels;
KIRP	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.43	-5.8	-0.35	2.05e-8	Central corneal thickness;Corneal structure;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.65	-9.16	-0.5	2.08e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Hypertriglyceridemia;
KIRP	cis	rs11203032	0.831	rs10887922	chr10:90930236	G/A	cg16672925	chr10:90967113	CH25H	0.73	7.26	0.42	5.11e-12	Heart failure;
KIRP	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	0.94	10.38	0.55	3.55e-21	Iron status biomarkers;
KIRP	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg01849789	chr22:41697279	ZC3H7B	0.49	5.58	0.34	6.27e-8	Neuroticism;
KIRP	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg26876637	chr1:152193138	HRNR	0.71	9.45	0.52	2.71e-18	Atopic dermatitis;
KIRP	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg17764715	chr19:33622953	WDR88	0.67	8.31	0.47	6.32e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18424115	chr14:24768909	DHRS1;C14orf21	0.56	7.06	0.41	1.72e-11	Parkinson's disease;
KIRP	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.64	-6.43	-0.38	6.48e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1656402	0.954	rs1190454	chr2:233435325	G/T	cg03852847	chr2:233439513	NA	-0.72	-12.0	-0.61	2.03e-26	Non-small cell lung cancer (survival);
KIRP	cis	rs7587476	0.643	rs6714373	chr2:215719014	A/G	cg04004882	chr2:215674386	BARD1	0.72	6.75	0.4	1.07e-10	Neuroblastoma;
KIRP	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.5	6.45	0.38	5.92e-10	Systolic blood pressure;
KIRP	cis	rs6681460	0.565	rs6689755	chr1:67113050	G/A	cg13052034	chr1:66999238	SGIP1	0.39	5.63	0.34	5.03e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg22117172	chr7:91764530	CYP51A1	0.48	6.59	0.39	2.73e-10	Breast cancer;
KIRP	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9815354	1.000	rs7650227	chr3:41794937	T/G	cg03022575	chr3:42003672	ULK4	0.54	6.18	0.37	2.69e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg22676075	chr6:135203613	NA	0.5	7.27	0.42	4.63e-12	Red blood cell count;
KIRP	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.56	6.34	0.37	1.09e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.28	0.37	1.51e-9	Aortic root size;
KIRP	cis	rs75920871	0.858	rs7950501	chr11:116963965	C/T	cg23684410	chr11:116897558	SIK3	0.52	5.21	0.32	3.94e-7	Subjective well-being;
KIRP	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.46	-5.82	-0.35	1.8e-8	Asthma;
KIRP	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg15841412	chr13:111365552	ING1	0.49	5.61	0.34	5.41e-8	Coronary artery disease;
KIRP	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg06042504	chr8:55087323	NA	-0.54	-6.69	-0.39	1.5e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg20290983	chr6:43655470	MRPS18A	1.0	11.19	0.58	8.93e-24	IgG glycosylation;
KIRP	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.62	-7.52	-0.43	1.02e-12	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.84	-12.93	-0.64	1.59e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg10167378	chr1:228756711	NA	0.52	5.93	0.35	1.01e-8	Diastolic blood pressure;
KIRP	cis	rs7709377	0.570	rs10036669	chr5:115444743	G/T	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.64e-7	Metabolite levels  (X-11787);
KIRP	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.49	-6.05	-0.36	5.28e-9	Iron status biomarkers;
KIRP	trans	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	9.15	0.5	2.25e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6888304	0.523	rs13167643	chr5:31059476	C/A	cg10919204	chr5:31193340	CDH6	0.37	4.86	0.3	2.06e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.72	-0.34	3.03e-8	Non-small cell lung cancer;
KIRP	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.61	-7.83	-0.45	1.41e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.88	-0.6	5.1e-26	Eye color traits;
KIRP	cis	rs1816752	0.819	rs7985478	chr13:24991273	C/T	cg02811702	chr13:24901961	NA	0.42	5.45	0.33	1.22e-7	Obesity-related traits;
KIRP	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg20636351	chr8:55087400	NA	-0.53	-6.6	-0.39	2.54e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.68	0.34	3.73e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	6.41	0.38	7.2e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.61	8.89	0.49	1.3e-16	Resting heart rate;
KIRP	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.25	17.47	0.74	5.64e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg02975922	chr3:195473998	MUC4	-0.55	-6.44	-0.38	6.35e-10	Pancreatic cancer;
KIRP	cis	rs10861342	0.892	rs7488014	chr12:105657527	C/T	cg23923672	chr12:105501055	KIAA1033	0.68	6.05	0.36	5.46e-9	IgG glycosylation;
KIRP	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.59	-6.55	-0.39	3.43e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	cis	rs8044868	0.530	rs3890860	chr16:72103409	A/G	cg16558253	chr16:72132732	DHX38	-0.4	-5.35	-0.32	1.98e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg02640540	chr1:67518911	SLC35D1	0.4	4.98	0.3	1.21e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.43	-5.3	-0.32	2.63e-7	Neuroticism;
KIRP	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg17736920	chr1:242011382	EXO1	0.5	6.25	0.37	1.84e-9	Menopause (age at onset);
KIRP	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17554472	chr22:41940697	POLR3H	0.72	7.2	0.42	7.39e-12	Vitiligo;
KIRP	cis	rs883115	0.846	rs7529774	chr1:224794206	A/T	cg01808320	chr1:224927238	CNIH3	-0.37	-5.29	-0.32	2.74e-7	Cancer;
KIRP	cis	rs6746896	0.683	rs6576984	chr2:97454705	C/T	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.45	-0.43	1.59e-12	Bipolar disorder;
KIRP	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.64	-0.34	4.65e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9311676	0.632	rs62258139	chr3:58406836	C/T	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.62	-6.95	-0.4	3.34e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg19500275	chr17:80737654	TBCD	0.45	5.3	0.32	2.54e-7	Glycated hemoglobin levels;
KIRP	cis	rs9393813	0.528	rs4713109	chr6:27476268	G/A	cg03332623	chr6:27441972	ZNF184	-0.35	-5.12	-0.31	6.18e-7	Bipolar disorder;
KIRP	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.45	4.95	0.3	1.37e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg23978390	chr7:1156363	C7orf50	0.41	5.32	0.32	2.28e-7	Longevity;Endometriosis;
KIRP	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	1.07	14.04	0.67	2.88e-33	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg13390998	chr8:145670370	NFKBIL2	0.96	6.58	0.39	2.74e-10	P wave terminal force;
KIRP	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg12131826	chr15:77904385	NA	0.42	5.63	0.34	4.91e-8	Type 2 diabetes;
KIRP	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.21	0.51	1.52e-17	Prudent dietary pattern;
KIRP	cis	rs13401104	0.716	rs11685999	chr2:237143226	G/A	cg26422059	chr2:237146110	ASB18	0.51	5.22	0.32	3.77e-7	Educational attainment;
KIRP	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	1.1	17.98	0.75	1.01e-46	Cognitive function;
KIRP	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07814876	chr1:235492429	GGPS1;ARID4B	0.44	6.32	0.37	1.24e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15755662	chr7:2671535	TTYH3	0.46	6.23	0.37	2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg06871246	chr4:1363661	KIAA1530	-0.56	-7.01	-0.41	2.32e-11	Longevity;
KIRP	cis	rs698833	0.962	rs1067387	chr2:44642797	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.53	0.38	3.83e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.73	-10.11	-0.54	2.62e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg00631329	chr6:26305371	NA	0.62	8.13	0.46	2.15e-14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	6.99	0.41	2.65e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7147624	0.766	rs11158597	chr14:65913536	T/G	cg03016385	chr14:66212404	NA	-1.03	-10.61	-0.56	6.74e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg25486957	chr4:152246857	NA	-0.45	-5.13	-0.31	5.9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	0.47	6.13	0.36	3.56e-9	Systemic lupus erythematosus;
KIRP	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-8.47	-0.48	2.23e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.34	5.25	0.32	3.36e-7	Type 2 diabetes;
KIRP	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.66	9.09	0.5	3.32e-17	Obesity-related traits;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg11204139	chr17:3907470	NA	0.54	7.34	0.42	3.08e-12	Type 2 diabetes;
KIRP	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.82	-7.12	-0.41	1.17e-11	Coronary artery disease;
KIRP	cis	rs7246865	0.510	rs3816550	chr19:17173487	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.52	6.59	0.39	2.68e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg07701084	chr6:150067640	NUP43	0.7	9.53	0.52	1.56e-18	Lung cancer;
KIRP	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4285028	0.715	rs71329249	chr3:121711346	A/G	cg11130432	chr3:121712080	ILDR1	-0.48	-5.75	-0.34	2.66e-8	Multiple sclerosis;
KIRP	cis	rs10858047	0.783	rs6692475	chr1:115209142	C/T	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs9308433	0.505	rs958304	chr1:214474241	C/T	cg06198575	chr1:214491504	SMYD2	0.52	6.74	0.39	1.09e-10	IgG glycosylation;
KIRP	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg17796960	chr10:135278976	LOC619207	-0.46	-5.0	-0.3	1.07e-6	Systemic lupus erythematosus;
KIRP	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg19468946	chr17:37922297	IKZF3	-0.42	-5.92	-0.35	1.06e-8	Asthma;
KIRP	cis	rs7017914	0.935	rs6981435	chr8:71637148	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs10114408	0.918	rs10992944	chr9:96640702	A/G	cg14598338	chr9:96623480	NA	-0.33	-4.9	-0.3	1.7e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.66	-9.03	-0.5	5.24e-17	Hypospadias;
KIRP	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg19847130	chr8:10466454	RP1L1	0.36	5.5	0.33	9.33e-8	Triglycerides;
KIRP	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.29	0.37	1.4e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs687432	0.924	rs609154	chr11:57696234	C/T	cg19752551	chr11:57585705	CTNND1	0.48	6.67	0.39	1.69e-10	Parkinson's disease;
KIRP	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-1.0	-10.51	-0.56	1.39e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs9810890	1.000	rs73196980	chr3:128451396	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.88	8.53	0.48	1.54e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs3752645	1.000	rs2237653	chr7:106760048	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.91	-0.3	1.7e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg07585502	chr8:101912084	NA	-0.63	-7.79	-0.44	1.93e-13	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.63	8.25	0.47	9.92e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg04025307	chr7:1156635	C7orf50	0.47	5.8	0.35	2e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg03609598	chr5:56110824	MAP3K1	0.48	5.43	0.33	1.35e-7	Initial pursuit acceleration;
KIRP	cis	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg03342759	chr3:160939853	NMD3	0.45	5.39	0.33	1.63e-7	Morning vs. evening chronotype;
KIRP	cis	rs2921036	0.503	rs7817832	chr8:8380821	T/C	cg08975724	chr8:8085496	FLJ10661	0.47	4.9	0.3	1.78e-6	Neuroticism;
KIRP	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.53	5.62	0.34	5.19e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-6.8	-0.4	7.77e-11	Mean corpuscular volume;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.49	-6.25	-0.37	1.79e-9	Testicular germ cell tumor;
KIRP	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs4930561	0.765	rs34493482	chr11:67969508	T/C	cg16338278	chr11:67432957	ALDH3B2	0.38	4.88	0.3	1.89e-6	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg08392591	chr16:89556376	ANKRD11	0.39	4.95	0.3	1.37e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg11621586	chr10:70884670	VPS26A	1.23	16.95	0.73	3.27e-43	Left atrial antero-posterior diameter;
KIRP	cis	rs9788682	0.747	rs4887053	chr15:78712699	A/C	cg06917634	chr15:78832804	PSMA4	0.55	5.18	0.31	4.55e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.64	-7.07	-0.41	1.56e-11	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.52	0.43	1.01e-12	Sudden cardiac arrest;
KIRP	cis	rs503734	0.521	rs546105	chr3:100967920	A/G	cg27318481	chr3:100970896	IMPG2	-0.53	-7.21	-0.42	6.79e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14613195	chr9:20996718	NA	0.39	6.05	0.36	5.43e-9	Migraine with aura;
KIRP	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.55	6.96	0.41	2.99e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	1.08	16.95	0.73	3.21e-43	Cognitive function;
KIRP	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-8.68	-0.48	5.73e-16	Neuroticism;
KIRP	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.59	8.57	0.48	1.2e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.75	9.54	0.52	1.48e-18	Aortic root size;
KIRP	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.88	-11.66	-0.6	2.69e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.78	11.68	0.6	2.21e-25	Breast cancer;
KIRP	cis	rs7084402	0.935	rs1593675	chr10:60291694	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14195458	chr4:89381447	HERC5	-0.41	-6.33	-0.37	1.18e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.74	7.18	0.42	8.36e-12	Arsenic metabolism;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26375259	chr19:3985535	EEF2	-0.56	-6.33	-0.37	1.16e-9	Menopause (age at onset);
KIRP	cis	rs6466055	0.661	rs6966539	chr7:104880551	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.16	0.31	5.19e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs2279817	0.780	rs79923328	chr1:18008116	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.54	-0.48	1.38e-15	Neuroticism;
KIRP	cis	rs7929679	0.521	rs10836304	chr11:34794024	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.48	-5.9	-0.35	1.19e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs2072732	0.861	rs6692292	chr1:2959610	C/T	cg11731671	chr1:2995604	PRDM16	0.42	5.18	0.31	4.73e-7	Plateletcrit;
KIRP	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.75	9.03	0.5	5.04e-17	Multiple sclerosis;
KIRP	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg26248373	chr2:1572462	NA	-0.62	-6.01	-0.36	6.48e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs112998813	0.737	rs7994709	chr13:114984796	G/A	cg19814280	chr13:114963695	NA	-0.6	-4.89	-0.3	1.84e-6	Nodular sclerosis Hodgkin lymphoma;
KIRP	trans	rs9841504	1.000	rs9841504	chr3:114362764	C/G	cg24348448	chr19:55493930	NLRP2	-0.74	-6.15	-0.37	3.03e-9	Gastric cancer;
KIRP	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg26571870	chr16:85723150	GINS2	0.48	5.59	0.34	6.08e-8	Platelet distribution width;
KIRP	cis	rs9972944	0.756	rs7215462	chr17:63770498	T/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.79	-0.44	1.85e-13	Total body bone mineral density;
KIRP	trans	rs5760842	0.517	rs2076930	chr22:25495138	T/C	cg16733866	chr21:42792609	MX1	0.66	8.49	0.48	2.01e-15	Recurrent major depressive disorder;
KIRP	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.52	-0.43	1.04e-12	Bipolar disorder;
KIRP	cis	rs13185784	0.703	rs17627536	chr5:179678603	G/A	cg23248424	chr5:179741104	GFPT2	0.57	5.59	0.34	6.16e-8	TRAIL levels;
KIRP	cis	rs612683	0.694	rs6688166	chr1:101000717	G/C	cg06223162	chr1:101003688	GPR88	0.52	10.54	0.56	1.13e-21	Breast cancer;
KIRP	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.92e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg00079169	chr19:2811669	THOP1	0.49	5.29	0.32	2.69e-7	Total cholesterol levels;
KIRP	cis	rs13025591	0.780	rs6431400	chr2:236776369	C/T	cg12269677	chr2:236801884	AGAP1	-0.38	-4.88	-0.3	1.89e-6	Schizophrenia;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg10129547	chr22:31885780	EIF4ENIF1	0.55	6.59	0.39	2.72e-10	Electroencephalogram traits;
KIRP	trans	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs42648	0.869	rs6948139	chr7:89937781	T/A	cg25739043	chr7:89950458	NA	-0.45	-7.1	-0.41	1.3e-11	Homocysteine levels;
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.79	13.82	0.66	1.58e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg18016565	chr1:150552671	MCL1	0.39	5.99	0.36	7.22e-9	Melanoma;
KIRP	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg01988459	chr11:68622903	NA	-0.37	-5.4	-0.33	1.57e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.59	-8.89	-0.49	1.33e-16	Anterior chamber depth;
KIRP	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.43	-0.33	1.36e-7	Aortic root size;
KIRP	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg23920097	chr1:209922102	NA	-0.4	-5.36	-0.32	1.92e-7	Red blood cell count;
KIRP	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.36	-4.93	-0.3	1.49e-6	Neuroticism;
KIRP	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.25	12.89	0.64	2.08e-29	Diabetic retinopathy;
KIRP	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg21890820	chr11:65308645	LTBP3	0.38	4.86	0.3	2.11e-6	Bone mineral density;
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg22903657	chr4:1355424	KIAA1530	-0.53	-7.54	-0.43	9.25e-13	Obesity-related traits;
KIRP	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.96	-0.36	8.86e-9	Parkinson's disease;
KIRP	cis	rs9394841	0.692	rs35085306	chr6:41856002	A/G	cg08135965	chr6:41755394	TOMM6	0.53	5.59	0.34	5.95e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19671926	chr4:122722719	EXOSC9	0.46	5.63	0.34	4.98e-8	Type 2 diabetes;
KIRP	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg01522456	chr1:115632236	TSPAN2	0.41	5.2	0.31	4.14e-7	Autism;
KIRP	cis	rs12693043	0.565	rs4972694	chr2:175411412	G/A	cg11778734	chr2:175439522	WIPF1	0.45	5.17	0.31	4.84e-7	Urate levels (BMI interaction);
KIRP	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.02	0.5	5.51e-17	Lung cancer in ever smokers;
KIRP	cis	rs7301016	0.948	rs12369985	chr12:62918780	A/G	cg01804193	chr12:63026212	NA	0.54	5.64	0.34	4.68e-8	IgG glycosylation;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg02727605	chr2:32236000	MEMO1	0.54	6.7	0.39	1.4e-10	Beard thickness;
KIRP	cis	rs72634258	0.554	rs35123409	chr1:7878568	C/T	cg26816564	chr1:7831052	VAMP3	0.86	7.21	0.42	7.01e-12	Inflammatory bowel disease;
KIRP	cis	rs77861329	1.000	rs9857878	chr3:52109668	A/G	cg08692210	chr3:52188851	WDR51A	-0.79	-5.94	-0.35	9.73e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2594989	0.779	rs7647622	chr3:11590871	G/A	cg01796438	chr3:11312864	ATG7	0.4	5.25	0.32	3.3e-7	Circulating chemerin levels;
KIRP	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	5.99	0.36	7.31e-9	Type 2 diabetes;
KIRP	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	9.9	0.53	1.13e-19	Bipolar disorder;
KIRP	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.79	12.18	0.61	5.24e-27	Prostate cancer;
KIRP	cis	rs2290402	0.536	rs12509561	chr4:850701	C/T	cg14517359	chr4:903473	GAK	-0.54	-5.66	-0.34	4.3e-8	Type 2 diabetes;
KIRP	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.93e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.62	-0.48	8.15e-16	Morning vs. evening chronotype;
KIRP	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg03999872	chr20:62272968	STMN3	0.45	5.18	0.31	4.64e-7	Prostate cancer;
KIRP	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.07	0.5	3.89e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9400467	0.528	rs6913769	chr6:111792897	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.45	-5.84	-0.35	1.66e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12360000	0.770	rs11250852	chr10:1909726	A/G	cg26364871	chr10:1889757	NA	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21643547	chr1:205240462	TMCC2	-0.91	-14.5	-0.68	7.52e-35	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg21466736	chr12:48725269	NA	-0.49	-6.23	-0.37	2.05e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.52	7.02	0.41	2.17e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.22	-5.27	-0.32	3.01e-7	Primary biliary cholangitis;
KIRP	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.69	8.82	0.49	2.21e-16	Bladder cancer;
KIRP	cis	rs3925075	0.966	rs11645917	chr16:31359826	C/T	cg02846316	chr16:31340340	ITGAM	0.63	9.75	0.53	3.4e-19	IgA nephropathy;
KIRP	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg24459738	chr19:57751996	ZNF805	-0.58	-7.21	-0.42	6.96e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.98	-11.89	-0.6	4.55e-26	Dilated cardiomyopathy;
KIRP	cis	rs144861591	1	rs144861591	chr6:26072992	C/T	cg16482183	chr6:26056742	HIST1H1C	0.93	5.6	0.34	5.58e-8	Red cell distribution width;Hemoglobin concentration;Mean corpuscular volume;Hematocrit;Mean corpuscular hemoglobin;
KIRP	cis	rs9815354	0.812	rs17216919	chr3:41888938	G/C	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3105593	0.563	rs644890	chr15:50886493	C/T	cg05456662	chr15:50716270	USP8	0.38	4.89	0.3	1.84e-6	QT interval;
KIRP	cis	rs12615966	1.000	rs6744707	chr2:105371087	G/A	cg16465502	chr2:105461796	NA	0.65	5.82	0.35	1.83e-8	Pancreatic cancer;
KIRP	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	cg21523751	chr1:182988639	NA	-0.41	-6.46	-0.38	5.42e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-0.85	-9.21	-0.51	1.49e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9972944	0.639	rs2052153	chr17:63800382	G/T	cg07283582	chr17:63770753	CCDC46	-0.5	-7.97	-0.45	6.03e-14	Total body bone mineral density;
KIRP	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	cg04338863	chr8:33670619	NA	0.5	6.72	0.39	1.29e-10	Body mass index;
KIRP	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg12257156	chr7:158823799	VIPR2	0.33	5.25	0.32	3.24e-7	Facial morphology (factor 20);
KIRP	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg07001201	chr5:642380	CEP72	0.68	6.21	0.37	2.25e-9	Obesity-related traits;
KIRP	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	7.86	0.45	1.22e-13	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg19694781	chr19:47549865	TMEM160	-0.59	-7.71	-0.44	3.17e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg18125479	chr14:51411049	PYGL	0.47	6.2	0.37	2.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs755109	0.933	rs7870723	chr9:100699242	T/C	cg13688889	chr9:100608707	NA	-0.43	-5.0	-0.3	1.1e-6	Quantitative traits;
KIRP	cis	rs13401104	0.796	rs1377447	chr2:237119709	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.83	-9.29	-0.51	8.53e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-6.08	-0.36	4.53e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg03929089	chr4:120376271	NA	-0.55	-6.7	-0.39	1.42e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.19	0.31	4.37e-7	Tonsillectomy;
KIRP	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg27205649	chr11:78285834	NARS2	-0.66	-8.74	-0.49	3.73e-16	Alzheimer's disease (survival time);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg20080079	chr12:85430174	TSPAN19;LRRIQ1	-0.41	-6.22	-0.37	2.17e-9	Obesity-related traits;
KIRP	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.51	-0.52	1.77e-18	Joint mobility (Beighton score);
KIRP	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.44	-7.14	-0.41	1.06e-11	Height;
KIRP	cis	rs11760633	0.672	rs6460870	chr7:1843200	C/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-4.88	-0.3	1.94e-6	Coronary artery disease;
KIRP	cis	rs7523273	0.568	rs55935450	chr1:208018779	T/A	cg22525895	chr1:207977042	MIR29B2	-0.57	-5.32	-0.32	2.3e-7	Schizophrenia;
KIRP	cis	rs2150410	0.833	rs4818012	chr21:40655453	C/G	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg00800569	chr2:239229395	TRAF3IP1	0.43	5.07	0.31	7.89e-7	Multiple system atrophy;
KIRP	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg13180566	chr4:1052158	NA	0.55	5.59	0.34	6.09e-8	Recombination rate (females);
KIRP	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.98	-0.36	7.94e-9	Obesity-related traits;
KIRP	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg09264619	chr17:80180166	NA	0.51	6.0	0.36	6.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg00277334	chr10:82204260	NA	-0.61	-6.19	-0.37	2.5e-9	Post bronchodilator FEV1;
KIRP	cis	rs13102973	0.564	rs4418034	chr4:135886650	T/A	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg24060327	chr5:131705240	SLC22A5	-0.58	-7.33	-0.42	3.23e-12	Blood metabolite levels;
KIRP	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.2	16.09	0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6466055	0.589	rs12536794	chr7:104990954	T/C	cg04380332	chr7:105027541	SRPK2	0.36	4.93	0.3	1.52e-6	Schizophrenia;
KIRP	cis	rs6681460	1.000	rs6689864	chr1:67068112	T/C	cg02459107	chr1:67143332	SGIP1	0.48	6.93	0.4	3.65e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7178909	0.902	rs8033554	chr15:90441569	C/A	cg19708238	chr15:90437601	AP3S2	0.58	7.86	0.45	1.17e-13	Common traits (Other);
KIRP	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	8.84	0.49	1.86e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg14132834	chr19:41945861	ATP5SL	0.6	7.66	0.44	4.29e-13	Height;
KIRP	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.5	-6.24	-0.37	1.89e-9	Body mass index;
KIRP	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg18478394	chr8:109455254	TTC35	0.6	7.56	0.43	8.17e-13	Dupuytren's disease;
KIRP	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.46	5.27	0.32	2.95e-7	Schizophrenia;
KIRP	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg23484912	chr5:273055	PDCD6	0.59	7.37	0.43	2.6e-12	Pancreatic cancer;
KIRP	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.4	5.39	0.32	1.68e-7	Total body bone mineral density;
KIRP	cis	rs7582720	1.000	rs72932746	chr2:203663498	G/A	cg08076091	chr2:203926405	NBEAL1	0.85	8.53	0.48	1.52e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12210905	1.000	rs12189835	chr6:27198271	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.4	-0.38	7.77e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.87	-0.35	1.44e-8	Menarche (age at onset);
KIRP	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg00405596	chr8:11794950	NA	-0.5	-6.58	-0.39	2.87e-10	Retinal vascular caliber;
KIRP	cis	rs7646501	0.953	rs34312629	chr3:24079795	C/G	cg21910673	chr3:24143257	LOC152024	0.45	5.9	0.35	1.17e-8	Cognitive ability;Intelligence;
KIRP	cis	rs1507153	0.812	rs9359337	chr6:79389316	C/T	cg11833968	chr6:79620685	NA	-0.36	-4.9	-0.3	1.73e-6	Sjögren's syndrome;
KIRP	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg22139774	chr2:100720529	AFF3	0.33	5.97	0.36	8.25e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.89	-11.5	-0.59	9.07e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8098244	0.624	rs117454208	chr18:21499687	C/A	cg07121078	chr18:21242319	ANKRD29	-0.57	-4.98	-0.3	1.18e-6	Epithelial ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg14221460	chr8:27183342	PTK2B	0.54	7.02	0.41	2.2e-11	Neuroticism;
KIRP	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-6.82	-0.4	7.06e-11	Lung cancer;
KIRP	cis	rs4786125	0.665	rs1492371	chr16:6921285	A/C	cg03623568	chr16:6915990	A2BP1	-0.44	-5.31	-0.32	2.48e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg10818794	chr15:86012489	AKAP13	-0.53	-7.53	-0.43	9.9e-13	Coronary artery disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03616195	chr17:29233260	C17orf42	0.51	6.12	0.36	3.72e-9	C-reactive protein;
KIRP	cis	rs5753037	0.754	rs41158	chr22:30405983	A/G	cg01021169	chr22:30184971	ASCC2	-0.35	-4.97	-0.3	1.27e-6	Type 1 diabetes;
KIRP	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg08461772	chr7:95026248	PON3	0.43	5.98	0.36	7.61e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg18753928	chr3:113234510	CCDC52	-0.53	-6.8	-0.4	8.11e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg14458575	chr2:238380390	NA	0.43	5.0	0.3	1.09e-6	Prostate cancer;
KIRP	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg23845249	chr11:68861649	NA	0.61	8.64	0.48	7.34e-16	Blond vs. brown hair color;
KIRP	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg26898376	chr11:64110657	CCDC88B	0.48	5.22	0.32	3.78e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg15676125	chr6:33679581	C6orf125	-0.45	-6.12	-0.36	3.62e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02879661	chr8:101734746	PABPC1	0.52	6.62	0.39	2.29e-10	Parkinson's disease;
KIRP	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.95	12.76	0.63	5.89e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.76	9.94	0.54	8.8e-20	Mean platelet volume;
KIRP	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg13397359	chr6:42928475	GNMT	0.46	5.22	0.32	3.86e-7	Blood protein levels;
KIRP	cis	rs559928	0.502	rs11601686	chr11:64189110	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.47	4.95	0.3	1.4e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02457900	chr2:240322768	HDAC4	0.52	6.46	0.38	5.58e-10	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg07827796	chr19:33622959	WDR88	0.4	4.84	0.3	2.25e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs9290065	0.519	rs6774203	chr3:160705217	G/T	cg04691961	chr3:161091175	C3orf57	-0.35	-5.07	-0.31	7.92e-7	Kawasaki disease;
KIRP	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18932078	chr1:2524107	MMEL1	-0.43	-6.04	-0.36	5.62e-9	Ulcerative colitis;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.87	8.19	0.46	1.39e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-5.02	-0.31	9.7e-7	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08507806	chr6:36996068	FGD2	0.53	6.45	0.38	6.04e-10	Interleukin-4 levels;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.97	-0.61	2.52e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00290607	chr11:67383545	NA	0.39	5.61	0.34	5.39e-8	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14021564	chr10:104169126	PSD	0.49	6.92	0.4	3.9e-11	Parkinson's disease;
KIRP	cis	rs2970992	1.000	rs2970992	chr2:101322309	C/A	cg01042948	chr2:101319752	NA	0.5	7.27	0.42	4.66e-12	Educational attainment;
KIRP	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs13161895	0.702	rs12652904	chr5:179496422	C/T	cg06664874	chr5:179499304	RNF130	0.8	5.19	0.31	4.33e-7	LDL cholesterol;
KIRP	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg01777586	chr17:80163174	CCDC57	-0.46	-4.85	-0.3	2.14e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.51e-19	Prudent dietary pattern;
KIRP	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.54	-7.39	-0.43	2.32e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-5.22	-0.32	3.74e-7	Tonsillectomy;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.53	-7.59	-0.44	6.76e-13	Lymphocyte counts;
KIRP	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg20542592	chr8:11973495	FAM66D	-0.38	-4.9	-0.3	1.76e-6	Triglycerides;
KIRP	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.67	8.83	0.49	1.96e-16	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg08501292	chr6:25962987	TRIM38	1.09	6.52	0.38	4e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14769373	chr6:40998127	UNC5CL	-0.63	-6.93	-0.4	3.68e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	5.72	0.34	3.13e-8	Height;
KIRP	cis	rs6142102	0.961	rs4911405	chr20:32674967	C/T	cg08999081	chr20:33150536	PIGU	0.59	6.7	0.39	1.43e-10	Skin pigmentation;
KIRP	cis	rs909341	0.909	rs1758205	chr20:62355756	G/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.84	-0.35	1.66e-8	Atopic dermatitis;
KIRP	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.59	-0.34	6.13e-8	Aortic root size;
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg27144592	chr16:783916	NARFL	0.37	5.11	0.31	6.5e-7	Height;
KIRP	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.38	-0.68	1.98e-34	Alzheimer's disease;
KIRP	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg13160058	chr8:26243215	BNIP3L	0.38	5.77	0.35	2.36e-8	Height;
KIRP	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-6.19	-0.37	2.45e-9	Morning vs. evening chronotype;
KIRP	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.73	9.43	0.52	3.28e-18	Renal function-related traits (BUN);
KIRP	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.78	0.44	1.97e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22944662	chr1:178062847	LOC100302401;RASAL2	0.45	6.02	0.36	6.28e-9	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16462701	chr11:2416773	CD81	0.53	7.07	0.41	1.6e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg04865290	chr3:52927548	TMEM110	-0.44	-5.89	-0.35	1.3e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.61	5.02	0.3	1.01e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs10924970	0.967	rs4659721	chr1:235426917	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05347473	chr6:146136440	FBXO30	-0.5	-7.27	-0.42	4.79e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.5	-0.68	7.68e-35	Schizophrenia;
KIRP	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg12623918	chr2:306882	NA	0.49	5.99	0.36	7.37e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg02285115	chr14:50329706	NA	-0.41	-6.09	-0.36	4.38e-9	Breast cancer;
KIRP	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.27	0.37	1.62e-9	Total body bone mineral density;
KIRP	trans	rs12517041	1.000	rs4701219	chr5:23284067	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.59	-0.48	9.95e-16	Calcium levels;
KIRP	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	1.96e-14	Testicular germ cell tumor;
KIRP	cis	rs2071426	0.622	rs34707620	chr10:96770019	T/C	cg09036531	chr10:96991505	NA	-0.46	-5.34	-0.32	2.1e-7	Blood metabolite levels;
KIRP	cis	rs4356932	1.000	rs4302486	chr4:76953077	C/T	cg19388996	chr4:76862389	NAAA	-0.4	-5.18	-0.31	4.67e-7	Blood protein levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19000611	chr14:92198288	CATSPERB	0.48	6.76	0.4	9.8e-11	Interleukin-4 levels;
KIRP	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-1.0	-11.52	-0.59	7.69e-25	Exhaled nitric oxide output;
KIRP	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.66	-9.59	-0.52	1.06e-18	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg26248373	chr2:1572462	NA	-0.77	-10.41	-0.55	2.96e-21	IgG glycosylation;
KIRP	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.68	-10.87	-0.57	9.9e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	1.05	9.78	0.53	2.73e-19	Thyroid stimulating hormone;
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.85	11.83	0.6	7.21e-26	Total body bone mineral density;
KIRP	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg10755058	chr3:40428713	ENTPD3	0.41	5.72	0.34	3.03e-8	Renal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg12435725	chr3:58293450	RPP14	-0.54	-5.67	-0.34	4e-8	Cholesterol, total;
KIRP	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.35	0.47	4.93e-15	Motion sickness;
KIRP	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg23594656	chr7:65796392	TPST1	0.49	7.68	0.44	3.74e-13	Aortic root size;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09994117	chr8:75231860	JPH1	0.5	6.46	0.38	5.51e-10	Interleukin-4 levels;
KIRP	trans	rs7656342	0.755	rs13148571	chr4:9873855	C/A	cg26043149	chr18:55253948	FECH	0.51	6.14	0.36	3.35e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.09	-0.31	7.16e-7	Life satisfaction;
KIRP	cis	rs17095355	0.818	rs1009532	chr10:111840725	C/T	cg00817464	chr10:111662876	XPNPEP1	0.48	7.25	0.42	5.51e-12	Biliary atresia;
KIRP	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	cis	rs1971762	0.545	rs4759280	chr12:54064958	C/A	cg23533419	chr12:54090519	NA	-0.37	-5.63	-0.34	4.92e-8	Height;
KIRP	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.42	-0.33	1.45e-7	Coronary artery disease;
KIRP	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg11945507	chr8:142233382	SLC45A4	0.5	7.02	0.41	2.14e-11	Birth weight;
KIRP	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg11062466	chr8:58055876	NA	0.54	4.96	0.3	1.29e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg19507638	chr5:93509721	C5orf36	-0.58	-5.02	-0.3	9.79e-7	Diabetic retinopathy;
KIRP	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.67	8.93	0.49	1.02e-16	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25157839	chr3:43626312	ANO10	0.53	6.68	0.39	1.55e-10	Interleukin-4 levels;
KIRP	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.53	6.06	0.36	4.94e-9	Coronary artery disease;
KIRP	cis	rs9323205	0.773	rs4334206	chr14:51702414	G/C	cg23942311	chr14:51606299	NA	-0.5	-4.89	-0.3	1.78e-6	Cancer;
KIRP	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg16989719	chr2:238392110	NA	-0.64	-6.08	-0.36	4.56e-9	Prostate cancer;
KIRP	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.85	-8.49	-0.48	2.03e-15	Coronary artery calcification;
KIRP	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg15117754	chr3:10150083	C3orf24	0.48	4.91	0.3	1.67e-6	Alzheimer's disease;
KIRP	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg03959625	chr15:84868606	LOC388152	0.53	6.18	0.37	2.7e-9	Schizophrenia;
KIRP	cis	rs1620921	0.505	rs4708892	chr6:161209101	T/C	cg01280913	chr6:161186852	NA	-0.62	-8.39	-0.47	3.77e-15	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.93	0.64	1.57e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	1.22	12.22	0.61	3.81e-27	Alzheimer's disease;
KIRP	cis	rs4494114	1.000	rs9439084	chr1:39345017	A/C	cg25970120	chr1:39325951	RRAGC	-0.4	-5.03	-0.31	9.38e-7	Blood protein levels;
KIRP	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.1	-0.5	3.24e-17	Mood instability;
KIRP	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	5.58	0.34	6.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg08076091	chr2:203926405	NBEAL1	0.83	8.82	0.49	2.17e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.8	11.84	0.6	6.86e-26	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg25683012	chr12:57030113	BAZ2A	0.48	6.37	0.38	9.34e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	0.57	5.75	0.34	2.62e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs17453880	0.929	rs10041415	chr5:152041409	T/C	cg12297329	chr5:152029980	NA	-0.71	-10.74	-0.56	2.59e-22	Subjective well-being;
KIRP	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20135002	chr11:47629003	NA	-0.46	-5.65	-0.34	4.33e-8	Subjective well-being;
KIRP	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs10267417	0.556	rs10229052	chr7:19965180	C/T	cg05791153	chr7:19748676	TWISTNB	0.51	4.94	0.3	1.42e-6	Night sleep phenotypes;
KIRP	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg15556689	chr8:8085844	FLJ10661	0.68	9.65	0.52	6.77e-19	Mood instability;
KIRP	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg22903471	chr2:27725779	GCKR	0.42	5.8	0.35	2.01e-8	Oral cavity cancer;
KIRP	cis	rs7011049	1.000	rs79536146	chr8:53853526	G/A	cg26025543	chr8:53854495	NA	0.75	7.78	0.44	2.06e-13	Systolic blood pressure;
KIRP	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg14703610	chr5:56206110	C5orf35	-0.55	-6.29	-0.37	1.47e-9	Initial pursuit acceleration;
KIRP	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2635047	0.710	rs2684838	chr18:44748079	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.31	0.32	2.41e-7	Educational attainment;
KIRP	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg22117172	chr7:91764530	CYP51A1	0.47	6.52	0.38	3.97e-10	Breast cancer;
KIRP	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg22356347	chr1:167427500	CD247	-0.44	-6.15	-0.36	3.15e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs1485395	1.000	rs7132466	chr12:53996823	C/T	cg16917193	chr12:54089295	NA	0.7	6.92	0.4	3.86e-11	Migraine without aura;
KIRP	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.0	-16.42	-0.72	2.09e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg23387468	chr7:139079360	LUC7L2	0.3	5.24	0.32	3.38e-7	Diisocyanate-induced asthma;
KIRP	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-0.63	-5.63	-0.34	4.84e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.51e-9	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	trans	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg13808641	chr9:96006533	WNK2	-0.4	-6.11	-0.36	3.87e-9	Bone mineral density;
KIRP	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.3	-0.42	4.06e-12	Neuroticism;
KIRP	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.45	-5.76	-0.34	2.45e-8	Mean corpuscular volume;
KIRP	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg04727924	chr7:799746	HEATR2	-0.75	-8.45	-0.47	2.66e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg22325292	chr17:80708367	FN3K	0.37	4.92	0.3	1.58e-6	Glycated hemoglobin levels;
KIRP	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg06953865	chr19:18549723	ISYNA1	-0.4	-6.01	-0.36	6.65e-9	Breast cancer;
KIRP	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.42	0.55	2.77e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.85	14.2	0.67	7.74e-34	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.78	8.95	0.5	8.99e-17	Post bronchodilator FEV1;
KIRP	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.45	5.52	0.33	8.57e-8	Common traits (Other);
KIRP	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg08994789	chr17:28903642	LRRC37B2	0.58	4.86	0.3	2.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs4748857	1.000	rs4633356	chr10:23548027	T/C	cg12804278	chr10:23633326	C10orf67	0.44	5.51	0.33	9.14e-8	Systemic lupus erythematosus;
KIRP	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg09844916	chr14:74004424	HEATR4;ACOT1	-0.39	-5.08	-0.31	7.3e-7	Blood metabolite ratios;
KIRP	cis	rs7084402	0.764	rs2393455	chr10:60374898	C/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.32	-0.55	5.73e-21	Refractive error;
KIRP	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.81	10.69	0.56	3.6e-22	Age at first birth;
KIRP	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density (age 0-15);
KIRP	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg14829155	chr15:31115871	NA	-0.77	-9.28	-0.51	9.28e-18	Huntington's disease progression;
KIRP	cis	rs504918	0.584	rs9847323	chr3:123985684	C/T	cg05766129	chr3:123988013	KALRN	0.51	7.33	0.42	3.34e-12	Schizophrenia;
KIRP	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.45	6.4	0.38	7.98e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg07747251	chr5:1868357	NA	0.46	5.97	0.36	8.12e-9	Cardiovascular disease risk factors;
KIRP	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg26513180	chr16:89883248	FANCA	0.68	5.45	0.33	1.21e-7	Skin colour saturation;
KIRP	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.62	-8.45	-0.47	2.65e-15	Total body bone mineral density;
KIRP	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.5	6.42	0.38	6.87e-10	Response to temozolomide;
KIRP	cis	rs5743618	0.537	rs6837838	chr4:38770576	T/A	cg06935464	chr4:38784597	TLR10	0.39	4.86	0.3	2.05e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs62380364	0.542	rs601499	chr5:88052687	A/C	cg24804195	chr5:87968844	LOC645323	-0.47	-6.18	-0.37	2.59e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg25486957	chr4:152246857	NA	0.43	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.83	-13.12	-0.64	3.59e-30	Prostate cancer;
KIRP	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg14541582	chr5:601475	NA	-0.58	-6.52	-0.38	3.94e-10	Obesity-related traits;
KIRP	cis	rs2281603	0.570	rs2123459	chr14:64952303	G/A	cg01860774	chr14:64969374	ZBTB25	0.33	5.4	0.33	1.58e-7	Lymphocyte counts;
KIRP	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	8.18	0.46	1.5e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06212747	chr3:49208901	KLHDC8B	0.74	9.97	0.54	7.12e-20	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs79387448	0.655	rs75579337	chr2:102917302	C/A	cg20060108	chr2:102954350	IL1RL1	-0.61	-4.88	-0.3	1.94e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7005380	0.581	rs4871786	chr8:120936411	C/T	cg21645572	chr8:120931649	DEPDC6	-0.5	-6.76	-0.4	9.94e-11	Interstitial lung disease;
KIRP	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-1.01	-18.48	-0.76	2.06e-48	Height;
KIRP	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg19077165	chr18:44547161	KATNAL2	-0.46	-6.02	-0.36	6.47e-9	Educational attainment;
KIRP	cis	rs4262150	0.739	rs72795394	chr5:151948590	G/T	cg12297329	chr5:152029980	NA	-0.66	-8.06	-0.46	3.26e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.76	11.52	0.59	7.79e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6142102	0.659	rs6057945	chr20:32517180	A/T	cg24642439	chr20:33292090	TP53INP2	0.53	5.73	0.34	2.95e-8	Skin pigmentation;
KIRP	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	6.48	0.38	5e-10	Height;
KIRP	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.99	11.51	0.59	8e-25	Vitiligo;
KIRP	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.34	6.09	0.36	4.22e-9	Renal cell carcinoma;
KIRP	cis	rs2562456	0.833	rs7258099	chr19:21535743	G/A	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs10207060	0.500	rs28640956	chr2:240714001	G/C	cg20333904	chr2:240724165	NA	-0.41	-4.85	-0.3	2.21e-6	Obesity-related traits;
KIRP	cis	rs17123764	0.892	rs60415769	chr12:49989105	A/T	cg20471783	chr12:50157085	TMBIM6	0.4	5.39	0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.66	7.76	0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.78	8.88	0.49	1.4e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs2048656	0.635	rs7830613	chr8:9649769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.38	-0.38	8.68e-10	Schizophrenia;
KIRP	cis	rs11605924	0.901	rs11607883	chr11:45839709	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.49	-5.9	-0.35	1.2e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-9.02	-0.5	5.52e-17	Morning vs. evening chronotype;
KIRP	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg18404041	chr3:52824283	ITIH1	-0.46	-5.88	-0.35	1.35e-8	Schizophrenia;
KIRP	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.39	0.59	2.07e-24	Alzheimer's disease;
KIRP	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.36	-5.24	-0.32	3.39e-7	Eye color traits;
KIRP	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg08738300	chr3:44038990	NA	0.7	9.83	0.53	1.92e-19	Coronary artery disease;
KIRP	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg20673091	chr1:2541236	MMEL1	0.66	10.03	0.54	4.47e-20	Ulcerative colitis;
KIRP	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.53	-6.61	-0.39	2.43e-10	Rheumatoid arthritis;
KIRP	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	7.13	0.41	1.14e-11	Mean platelet volume;
KIRP	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg12173498	chr6:36355764	ETV7	-0.31	-5.07	-0.31	7.87e-7	Platelet distribution width;
KIRP	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.53	-6.49	-0.38	4.7e-10	Renal function-related traits (BUN);
KIRP	trans	rs1941687	0.831	rs62091190	chr18:31387700	C/T	cg27147174	chr7:100797783	AP1S1	-0.56	-6.85	-0.4	5.84e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.84	-0.4	6.42e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg27170947	chr2:26402098	FAM59B	0.54	5.18	0.31	4.62e-7	Gut microbiome composition (summer);
KIRP	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.68	9.13	0.5	2.52e-17	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13102973	0.965	rs4640720	chr4:135850050	G/T	cg14419869	chr4:135874104	NA	0.52	8.6	0.48	9.21e-16	Subjective well-being;
KIRP	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.37	-0.32	1.79e-7	Alcohol dependence;
KIRP	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.29	-0.42	4.15e-12	Joint mobility (Beighton score);
KIRP	cis	rs787274	0.764	rs787281	chr9:115538568	C/T	cg13803584	chr9:115635662	SNX30	-0.74	-6.66	-0.39	1.8e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.91	0.4	4.09e-11	Asthma;
KIRP	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs2904967	0.929	rs673147	chr11:65060427	G/A	cg12562828	chr11:65076843	NA	0.6	8.85	0.49	1.7e-16	Mean corpuscular volume;
KIRP	cis	rs892085	0.559	rs4804526	chr19:10871470	G/C	cg17710535	chr19:10819994	QTRT1	-0.46	-5.66	-0.34	4.11e-8	Psoriasis vulgaris;Psoriasis;
KIRP	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg04306507	chr14:55594613	LGALS3	0.51	7.88	0.45	1.02e-13	Protein biomarker;
KIRP	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26207909	chr14:103986467	CKB	0.75	11.45	0.59	1.34e-24	Body mass index;
KIRP	cis	rs4704187	0.687	rs10058460	chr5:74498715	C/T	cg03227963	chr5:74354835	NA	0.4	5.8	0.35	2e-8	Response to amphetamines;
KIRP	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg24375607	chr4:120327624	NA	0.58	6.68	0.39	1.6e-10	Corneal astigmatism;
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg14324370	chr2:177042789	NA	0.74	10.39	0.55	3.45e-21	IgG glycosylation;
KIRP	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-9.4	-0.51	4.05e-18	Bladder cancer;
KIRP	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.42	-5.53	-0.33	8.24e-8	Aortic root size;
KIRP	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.51	-0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs67366981	0.844	rs2287385	chr14:77715916	C/A	cg22824376	chr14:77648248	TMEM63C	0.58	5.01	0.3	1.06e-6	Obsessive-compulsive symptoms;
KIRP	trans	rs7677281	0.603	rs4423896	chr4:78340170	C/G	cg01654824	chr4:76943946	ART3;CXCL10	-0.39	-6.04	-0.36	5.75e-9	Lung function (FEV1/FVC);
KIRP	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg02820040	chr2:241836501	C2orf54	0.24	5.39	0.32	1.66e-7	Urinary metabolites;
KIRP	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.81	11.76	0.6	1.26e-25	Itch intensity from mosquito bite;
KIRP	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	7.91	0.45	8.83e-14	Systolic blood pressure;
KIRP	cis	rs4908768	0.906	rs7539382	chr1:8579301	C/T	cg25722041	chr1:8623473	RERE	0.77	9.8	0.53	2.42e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg02527881	chr3:46936655	PTH1R	0.35	4.87	0.3	1.99e-6	Colorectal cancer;
KIRP	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.59	-9.74	-0.53	3.67e-19	Prostate cancer;
KIRP	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.01	-14.05	-0.67	2.57e-33	Response to antipsychotic treatment;
KIRP	cis	rs798766	1.000	rs4865467	chr4:1745500	G/T	cg07775547	chr4:1625484	NA	0.43	5.02	0.31	9.71e-7	Bladder cancer;Urinary bladder cancer;
KIRP	trans	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-7.81	-0.45	1.61e-13	Colorectal cancer;
KIRP	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg06792538	chr1:2954250	NA	0.41	4.91	0.3	1.69e-6	Plateletcrit;
KIRP	trans	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.44e-12	Bladder cancer;
KIRP	cis	rs11577318	0.537	rs12030833	chr1:26689220	A/G	cg00852783	chr1:26633632	UBXN11	-0.46	-5.24	-0.32	3.46e-7	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg16141378	chr3:129829833	LOC729375	0.49	6.34	0.37	1.09e-9	Retinal vascular caliber;
KIRP	trans	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.59	-0.39	2.65e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.61	-8.85	-0.49	1.8e-16	Ulcerative colitis;
KIRP	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg07001201	chr5:642380	CEP72	0.73	11.07	0.58	2.21e-23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg20818283	chr2:191399100	TMEM194B	0.54	6.78	0.4	8.87e-11	Pulse pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14348588	chr9:34523329	ENHO	0.52	6.57	0.39	2.91e-10	Parkinson's disease;
KIRP	cis	rs918629	1.000	rs918629	chr5:95301463	G/A	cg16656078	chr5:95278638	ELL2	-0.45	-6.63	-0.39	2.13e-10	IgG glycosylation;
KIRP	cis	rs7615316	0.621	rs4637328	chr3:142387809	A/G	cg20824294	chr3:142316082	PLS1	0.27	5.38	0.32	1.75e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.89	0.45	9.65e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02279591	chr5:94989328	RFESD	-0.4	-6.17	-0.37	2.79e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9290065	0.538	rs898682	chr3:160773133	G/C	cg04691961	chr3:161091175	C3orf57	-0.37	-5.07	-0.31	7.9e-7	Kawasaki disease;
KIRP	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg18753928	chr3:113234510	CCDC52	-0.46	-6.02	-0.36	6.37e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs921943	1.000	rs2303129	chr5:78324482	A/G	cg26802063	chr5:78281964	ARSB	0.49	6.08	0.36	4.56e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.9	-14.16	-0.67	1.1e-33	Systemic lupus erythematosus;
KIRP	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg10503236	chr1:231470652	EXOC8	-0.53	-7.62	-0.44	5.51e-13	Hemoglobin concentration;
KIRP	cis	rs698833	0.962	rs1065785	chr2:44660699	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.33	0.37	1.17e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg23477460	chr3:66848765	NA	0.66	7.38	0.43	2.45e-12	Type 2 diabetes;
KIRP	trans	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.65e-9	Neuroticism;
KIRP	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.68	0.34	3.73e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19932227	chr3:119298432	ADPRH	-0.39	-6.07	-0.36	4.68e-9	Metabolic traits;
KIRP	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg01620082	chr3:125678407	NA	-0.88	-6.43	-0.38	6.75e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6693295	0.729	rs2185074	chr1:246213781	T/G	cg11798871	chr1:246315928	SMYD3	-0.44	-5.59	-0.34	6.07e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs11731606	0.667	rs17379209	chr4:95411302	G/A	cg20625393	chr4:95128694	SMARCAD1	0.5	5.06	0.31	8.25e-7	Mean platelet volume;
KIRP	cis	rs10465746	0.967	rs1475263	chr1:84339497	A/T	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.87	13.17	0.64	2.5e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.76	-7.33	-0.42	3.22e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg17507749	chr15:85114479	UBE2QP1	0.81	9.33	0.51	6.48e-18	Schizophrenia;
KIRP	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs7923609	0.846	rs7075901	chr10:65280994	C/A	cg01631684	chr10:65280961	REEP3	-0.51	-6.06	-0.36	4.95e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.53	6.37	0.38	9.04e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.7	-7.88	-0.45	1.06e-13	Menarche (age at onset);
KIRP	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.36	-6.62	-0.39	2.18e-10	Graves' disease;
KIRP	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-6.09	-0.36	4.26e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg07648498	chr16:89883185	FANCA	0.41	5.36	0.32	1.94e-7	Vitiligo;
KIRP	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-4.9	-0.3	1.77e-6	Cognitive function;
KIRP	cis	rs370915	0.890	rs28610515	chr4:187835260	A/T	cg19519643	chr4:187840862	NA	-0.54	-7.38	-0.43	2.44e-12	Gout;
KIRP	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg04725166	chr1:7887271	PER3	-0.38	-5.95	-0.35	9.28e-9	Crohn's disease;
KIRP	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg04310649	chr10:35416472	CREM	-0.53	-6.08	-0.36	4.51e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-11.74	-0.6	1.43e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2274273	0.870	rs4366639	chr14:55790516	T/G	cg04306507	chr14:55594613	LGALS3	0.43	6.61	0.39	2.43e-10	Protein biomarker;
KIRP	cis	rs751728	0.965	rs4713683	chr6:33757550	C/G	cg25922239	chr6:33757077	LEMD2	0.7	8.55	0.48	1.31e-15	Crohn's disease;
KIRP	cis	rs3736485	0.934	rs4143721	chr15:51866781	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs61884328	0.713	rs61897791	chr11:47186561	T/G	cg23433285	chr11:47201945	PACSIN3	0.65	5.1	0.31	6.8e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg08885076	chr2:99613938	TSGA10	-0.45	-6.66	-0.39	1.81e-10	Fear of minor pain;
KIRP	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.45	5.14	0.31	5.63e-7	Schizophrenia;
KIRP	cis	rs11997175	0.670	rs34985841	chr8:33661889	C/A	ch.8.33884649F	chr8:33765107	NA	0.47	5.68	0.34	3.73e-8	Body mass index;
KIRP	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.77	-7.19	-0.42	7.93e-12	Fibroblast growth factor basic levels;
KIRP	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.19	10.39	0.55	3.28e-21	Skin colour saturation;
KIRP	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg24642439	chr20:33292090	TP53INP2	-0.59	-7.04	-0.41	1.88e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs874426	0.528	rs7943800	chr11:19573044	T/C	cg13922121	chr11:19575262	NAV2	0.46	5.75	0.34	2.65e-8	Attention deficit hyperactivity disorder (time to onset);
KIRP	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.42	-5.66	-0.34	4.26e-8	Oropharynx cancer;
KIRP	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.58	-6.0	-0.36	6.89e-9	Urate levels in lean individuals;
KIRP	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg10760299	chr15:45669010	GATM	0.32	4.87	0.3	1.98e-6	Homoarginine levels;
KIRP	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.56	-0.33	7.17e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.88	-10.06	-0.54	3.62e-20	Gut microbiome composition (summer);
KIRP	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.47	-6.88	-0.4	4.9e-11	Schizophrenia;
KIRP	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17655565	0.581	rs7294465	chr12:52766001	C/G	cg07925835	chr12:52762777	KRT85	-0.43	-4.98	-0.3	1.2e-6	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg23682824	chr7:23144976	KLHL7	0.59	7.23	0.42	5.96e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg19507638	chr5:93509721	C5orf36	-0.57	-5.0	-0.3	1.08e-6	Diabetic retinopathy;
KIRP	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.73	9.48	0.52	2.27e-18	Facial morphology (factor 19);
KIRP	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg09945482	chr18:12777974	NA	0.64	5.12	0.31	6.05e-7	Inflammatory skin disease;
KIRP	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg00647317	chr7:50633725	DDC	0.42	6.38	0.38	8.96e-10	Body mass index;
KIRP	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg10189774	chr4:17578691	LAP3	0.41	4.93	0.3	1.51e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.58	-9.36	-0.51	5.3e-18	Prostate cancer;
KIRP	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02711726	chr17:80685570	FN3KRP	0.59	8.21	0.46	1.28e-14	Glycated hemoglobin levels;
KIRP	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg10017260	chr10:834428	NA	-0.56	-5.51	-0.33	9.09e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg05562828	chr17:3906858	NA	-0.55	-8.41	-0.47	3.42e-15	Type 2 diabetes;
KIRP	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	1.06	19.21	0.77	7.28e-51	Leprosy;
KIRP	cis	rs259842	0.663	rs4894131	chr2:180728060	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.44	-6.39	-0.38	8.1e-10	Blood protein levels;
KIRP	cis	rs6841333	1.000	rs6841333	chr4:76992785	T/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.44	-5.0	-0.3	1.09e-6	Monokine induced by gamma interferon levels;
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg02493798	chr17:6899577	ALOX12	0.33	6.38	0.38	8.74e-10	Tonsillectomy;
KIRP	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.64	5.54	0.33	7.78e-8	Initial pursuit acceleration;
KIRP	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg07856975	chr6:36356162	ETV7	-0.39	-5.91	-0.35	1.15e-8	Platelet distribution width;
KIRP	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg23594656	chr7:65796392	TPST1	0.48	7.49	0.43	1.23e-12	Aortic root size;
KIRP	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.569	rs12950310	chr17:4001980	T/C	cg05562828	chr17:3906858	NA	0.53	5.59	0.34	5.87e-8	Type 2 diabetes;
KIRP	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.48	-7.61	-0.44	5.8e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16083429	chr3:49237500	CCDC36	-0.41	-5.11	-0.31	6.42e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs4936891	1.000	rs4936890	chr11:123914742	G/A	cg22125253	chr11:123886957	OR10G4	-0.39	-5.75	-0.34	2.58e-8	Male fertility;
KIRP	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.01	-0.36	6.57e-9	Pulmonary function;
KIRP	cis	rs6547631	0.635	rs12714149	chr2:85898898	C/A	cg24620635	chr2:85921963	GNLY	0.37	5.42	0.33	1.41e-7	Blood protein levels;
KIRP	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07169764	chr2:136633963	MCM6	-0.57	-6.75	-0.4	1.06e-10	Mosquito bite size;
KIRP	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.66	8.1	0.46	2.51e-14	Blood metabolite levels;
KIRP	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.48	-6.39	-0.38	8.43e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.66	8.1	0.46	2.51e-14	Blood metabolite levels;
KIRP	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg07274523	chr3:49395745	GPX1	0.69	8.58	0.48	1.08e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg04607235	chr12:12878440	APOLD1	-0.78	-8.09	-0.46	2.66e-14	Systemic lupus erythematosus;
KIRP	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-1.08	-9.99	-0.54	6.03e-20	Post bronchodilator FEV1;
KIRP	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	9.14	0.5	2.37e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8022179	0.566	rs62006258	chr14:103838909	A/C	cg23307798	chr14:103986281	CKB	-0.45	-5.24	-0.32	3.49e-7	Monocyte count;
KIRP	cis	rs7224685	0.722	rs12945048	chr17:4159244	C/A	cg21851534	chr17:3907994	ZZEF1	0.49	5.19	0.31	4.32e-7	Type 2 diabetes;
KIRP	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs1823913	0.571	rs6737307	chr2:192167973	T/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs4761097	0.537	rs7966950	chr12:85229004	T/C	cg00765312	chr12:85674694	ALX1	0.52	6.07	0.36	4.76e-9	Behavioural disinhibition (generation interaction);
KIRP	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.97	0.41	2.93e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1961637	0.960	rs7591554	chr2:223913132	G/T	cg02552189	chr2:223891284	NA	-0.36	-4.87	-0.3	2.02e-6	Oropharynx cancer;
KIRP	cis	rs57994353	0.566	rs10870160	chr9:139312996	C/T	cg21253087	chr9:139290292	SNAPC4	0.48	5.34	0.32	2.15e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Urinary tract infection frequency;
KIRP	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.39	2.66e-10	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.37	0.38	9.41e-10	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13585032	chr7:148788766	ZNF786	0.52	6.16	0.37	2.87e-9	Smoking initiation;
KIRP	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg15660573	chr17:549704	VPS53	-0.85	-12.79	-0.63	4.66e-29	Prostate cancer;
KIRP	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00585698	chr12:123750864	CDK2AP1	0.44	5.58	0.34	6.36e-8	Platelet count;
KIRP	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	8.99	0.5	6.87e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.88e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06347212	chr1:228270676	ARF1	0.58	7.26	0.42	4.97e-12	Parkinson's disease;
KIRP	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg21851534	chr17:3907994	ZZEF1	0.55	5.4	0.33	1.55e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg13047869	chr3:10149882	C3orf24	0.62	5.13	0.31	5.79e-7	Alzheimer's disease;
KIRP	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg17457637	chr7:27170717	HOXA4	-0.39	-5.17	-0.31	4.9e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1873147	1.000	rs12443285	chr15:63313596	C/T	cg12160578	chr15:63334699	TPM1	-0.47	-5.77	-0.35	2.39e-8	Orofacial clefts;
KIRP	cis	rs10802346	0.636	rs10924592	chr1:246402059	A/G	cg15962031	chr1:246363574	SMYD3	0.79	5.92	0.35	1.07e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7246657	0.551	rs11084873	chr19:37583910	A/G	cg23950597	chr19:37808831	NA	-0.7	-6.11	-0.36	3.97e-9	Coronary artery calcification;
KIRP	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.36e-14	Aortic root size;
KIRP	trans	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg05926928	chr17:57297772	GDPD1	0.54	6.38	0.38	8.5e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	trans	rs196889	0.901	rs196894	chr8:24731594	A/G	cg15569292	chr11:3022005	NA	0.37	6.09	0.36	4.23e-9	Seasonality;
KIRP	cis	rs7818345	1.000	rs13278459	chr8:19297583	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.97	0.36	8.26e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs2219968	0.962	rs4573260	chr8:78942894	T/C	cg00738934	chr8:78996279	NA	0.39	5.04	0.31	9.24e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs728616	0.867	rs12781912	chr10:81918128	G/T	cg27417294	chr10:81904244	PLAC9	0.56	5.09	0.31	6.97e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs41278232	1.000	rs73153160	chr20:62675410	G/A	cg03065311	chr20:62601662	ZNF512B	0.48	5.11	0.31	6.47e-7	Tonsillectomy;
KIRP	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.5	7.56	0.43	8.02e-13	Resting heart rate;
KIRP	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg09455208	chr3:40491958	NA	0.31	5.54	0.33	7.94e-8	Renal cell carcinoma;
KIRP	cis	rs986417	0.901	rs1955696	chr14:61028271	A/G	cg27398547	chr14:60952738	C14orf39	0.64	6.25	0.37	1.82e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs16828019	0.852	rs34979067	chr1:41543084	G/A	cg24596898	chr1:41849189	NA	0.62	5.14	0.31	5.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg23307798	chr14:103986281	CKB	0.5	7.09	0.41	1.41e-11	Body mass index;
KIRP	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.95	-8.63	-0.48	7.73e-16	Lung cancer in ever smokers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18336878	chr4:70709536	SULT1E1	-0.4	-6.92	-0.4	3.95e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg06637938	chr14:75390232	RPS6KL1	0.49	6.91	0.4	4.1e-11	Height;
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.88	-13.28	-0.65	1.08e-30	Longevity;
KIRP	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.53	-0.38	3.84e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs16828019	0.632	rs12749196	chr1:41460783	G/A	cg24596898	chr1:41849189	NA	0.64	4.93	0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.6	-7.92	-0.45	8.34e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.85	0.35	1.59e-8	Breast cancer;
KIRP	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-12.41	-0.62	8.78e-28	Vitiligo;
KIRP	cis	rs10769945	0.679	rs7105710	chr11:1918083	T/C	cg23202291	chr11:1979235	NA	0.4	5.27	0.32	2.99e-7	DNA methylation (variation);
KIRP	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.32	-0.47	6.14e-15	Morning vs. evening chronotype;
KIRP	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg01733217	chr16:74700730	RFWD3	-0.71	-10.49	-0.56	1.56e-21	Multiple myeloma;
KIRP	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.3	13.35	0.65	6.19e-31	Diabetic retinopathy;
KIRP	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg22563815	chr15:78856949	CHRNA5	0.52	7.97	0.45	5.95e-14	Sudden cardiac arrest;
KIRP	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6753739	0.826	rs897477	chr2:219941063	G/A	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.08	-0.36	4.46e-9	Breast cancer;
KIRP	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.41	0.51	3.67e-18	Prudent dietary pattern;
KIRP	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg08761264	chr16:28874980	SH2B1	-0.48	-5.56	-0.33	7.17e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs9841504	1.000	rs1274265	chr3:114354308	A/G	cg24348448	chr19:55493930	NLRP2	-0.73	-6.41	-0.38	7.54e-10	Gastric cancer;
KIRP	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.71	8.43	0.47	2.97e-15	Corneal astigmatism;
KIRP	cis	rs2411233	1.000	rs10851375	chr15:39283979	C/T	cg02291532	chr15:39874776	THBS1	0.41	5.6	0.34	5.8e-8	Platelet count;
KIRP	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17394176	chr13:44715948	NA	0.5	7.1	0.41	1.3e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.32	5.08	0.31	7.51e-7	Testicular germ cell tumor;
KIRP	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg05973401	chr12:123451056	ABCB9	-0.64	-6.83	-0.4	6.67e-11	Neutrophil percentage of white cells;
KIRP	cis	rs1823913	0.614	rs6434462	chr2:192167431	A/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-6.99	-0.41	2.59e-11	Daytime sleep phenotypes;
KIRP	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.7	-0.34	3.38e-8	Life satisfaction;
KIRP	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg11271282	chr2:238384023	NA	0.44	4.99	0.3	1.12e-6	Prostate cancer;
KIRP	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.3	-0.47	7e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg25281562	chr12:121454272	C12orf43	0.5	5.54	0.33	7.57e-8	N-glycan levels;
KIRP	cis	rs2274273	0.870	rs11625423	chr14:55795913	G/A	cg04306507	chr14:55594613	LGALS3	0.43	6.66	0.39	1.76e-10	Protein biomarker;
KIRP	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-0.93	-8.32	-0.47	6.1e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs7122539	0.734	rs2513658	chr11:66628249	G/A	cg24851651	chr11:66362959	CCS	-0.41	-5.53	-0.33	8.34e-8	HIV-1 susceptibility;
KIRP	cis	rs9359856	0.636	rs9294440	chr6:90308666	C/G	cg13799429	chr6:90582589	CASP8AP2	0.59	6.39	0.38	8.16e-10	Bipolar disorder;
KIRP	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg12598211	chr12:123634384	NA	-0.43	-5.17	-0.31	4.94e-7	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	9.6	0.52	9.97e-19	Alzheimer's disease;
KIRP	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.78	-7.12	-0.41	1.21e-11	Mean platelet volume;
KIRP	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.78	-10.78	-0.57	1.94e-22	Extrinsic epigenetic age acceleration;
KIRP	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.21	-0.46	1.26e-14	Neuroticism;
KIRP	cis	rs7246865	0.906	rs2278997	chr19:17166981	G/A	cg18440316	chr19:18077727	KCNN1	-0.37	-5.16	-0.31	5.07e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg24296786	chr1:45957014	TESK2	0.51	5.65	0.34	4.39e-8	Homocysteine levels;
KIRP	trans	rs901705	0.846	rs4832768	chr4:38363666	A/G	cg26535325	chr8:1308545	NA	0.48	6.04	0.36	5.62e-9	Monocyte percentage of white cells;
KIRP	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg12560992	chr17:57184187	TRIM37	0.58	5.38	0.32	1.71e-7	Cognitive test performance;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09273012	chr2:45675674	SRBD1	0.4	6.39	0.38	8.4e-10	C-reactive protein;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13708259	chr10:102747346	C10orf2;MRPL43	0.46	6.03	0.36	6.01e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.92	15.29	0.7	1.48e-37	Menarche (age at onset);
KIRP	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-5.44	-0.33	1.26e-7	Neutrophil percentage of white cells;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.34	-0.32	2.1e-7	Obesity-related traits;
KIRP	cis	rs61935443	0.832	rs12367920	chr12:95280752	T/A	cg21533806	chr12:95267307	NA	0.63	5.68	0.34	3.88e-8	Schizophrenia;
KIRP	cis	rs7551222	0.646	rs1398148	chr1:204458328	C/G	cg20240347	chr1:204465584	NA	-0.43	-7.9	-0.45	9.53e-14	Schizophrenia;
KIRP	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg24955955	chr5:415729	AHRR	0.77	6.34	0.37	1.12e-9	Fat distribution (HIV);
KIRP	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg08131204	chr22:41487073	MIR1281	-0.41	-4.85	-0.3	2.19e-6	Neuroticism;
KIRP	cis	rs7113850	0.541	rs7129839	chr11:24208606	C/T	ch.11.24196551F	chr11:24239977	NA	0.85	7.54	0.43	9.12e-13	Bone fracture in osteoporosis;
KIRP	cis	rs9815354	0.812	rs56994465	chr3:42061606	A/G	cg03022575	chr3:42003672	ULK4	0.71	7.46	0.43	1.49e-12	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.88	11.36	0.59	2.5300000000000002e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg04166393	chr7:2884313	GNA12	0.45	5.79	0.35	2.13e-8	Height;
KIRP	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.29	10.41	0.55	2.91e-21	Prostate cancer;
KIRP	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	4.78e-8	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15402992	chr20:44714513	NCOA5	0.47	6.06	0.36	5e-9	Interleukin-4 levels;
KIRP	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	10.32	0.55	5.56e-21	Bone mineral density;
KIRP	cis	rs55675132	0.548	rs12120464	chr1:115377691	C/T	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.71	10.31	0.55	5.99e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.63	-7.6	-0.44	6.36e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	cg04338863	chr8:33670619	NA	0.41	5.26	0.32	3.19e-7	Body mass index;
KIRP	trans	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg24644049	chr4:85504048	CDS1	1.05	7.44	0.43	1.67e-12	Skin colour saturation;
KIRP	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.98	0.71	6.37e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg09408571	chr1:101003634	GPR88	0.26	5.83	0.35	1.74e-8	Monocyte count;
KIRP	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg22974920	chr21:40686053	BRWD1	0.5	5.98	0.36	7.83e-9	Cognitive function;
KIRP	cis	rs2790457	0.958	rs2772431	chr10:28890160	C/T	cg05705492	chr10:28955341	NA	-0.54	-8.1	-0.46	2.51e-14	Multiple myeloma;
KIRP	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-5.15	-0.31	5.29e-7	Total body bone mineral density;
KIRP	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.58	-7.14	-0.41	1.05e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.66	9.57	0.52	1.18e-18	Blood metabolite levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12525736	chr1:228269915	ARF1	-0.42	-6.07	-0.36	4.77e-9	Metabolic traits;
KIRP	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.4	-0.33	1.54e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg08992911	chr2:238395768	MLPH	0.4	5.07	0.31	7.69e-7	Prostate cancer;
KIRP	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg06636001	chr8:8085503	FLJ10661	0.75	10.75	0.57	2.31e-22	Mood instability;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07504288	chr2:175870204	CHN1	0.48	6.48	0.38	4.91e-10	Survival in pancreatic cancer;
KIRP	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg16255804	chr6:135334527	HBS1L	-0.31	-4.97	-0.3	1.26e-6	Red blood cell count;
KIRP	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg04226714	chr8:49833948	SNAI2	-0.49	-6.73	-0.39	1.2e-10	Life satisfaction;
KIRP	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg01630199	chr7:66369076	NA	0.43	6.26	0.37	1.69e-9	Serum protein levels (sST2);
KIRP	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg22437258	chr11:111473054	SIK2	0.59	7.15	0.42	9.62e-12	Primary sclerosing cholangitis;
KIRP	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.09	-0.36	4.3e-9	Mood instability;
KIRP	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.87	-0.35	1.41e-8	Crohn's disease;
KIRP	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg16497661	chr14:103986332	CKB	0.43	5.57	0.33	6.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs516946	1.000	rs28591316	chr8:41524425	A/G	cg19441908	chr8:41529140	ANK1	0.5	7.12	0.41	1.17e-11	Type 2 diabetes;
KIRP	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.53	8.86	0.49	1.67e-16	Rheumatoid arthritis;
KIRP	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg05800321	chr8:143867799	LY6D	0.3	4.84	0.3	2.25e-6	Urinary tract infection frequency;
KIRP	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.24	-0.37	1.85e-9	Educational attainment;
KIRP	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-7.32	-0.42	3.56e-12	Monocyte percentage of white cells;
KIRP	cis	rs12615966	1.000	rs17030308	chr2:105385872	T/C	cg16465502	chr2:105461796	NA	0.55	5.38	0.32	1.77e-7	Pancreatic cancer;
KIRP	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.28	-0.32	2.78e-7	Tonsillectomy;
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.62	-0.39	2.29e-10	Longevity;Endometriosis;
KIRP	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03605463	chr16:89740564	NA	-0.41	-4.98	-0.3	1.2e-6	Vitiligo;
KIRP	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg18944383	chr4:111397179	ENPEP	0.6	10.97	0.57	4.77e-23	Height;
KIRP	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.79	-10.55	-0.56	1.01e-21	Acylcarnitine levels;
KIRP	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.1	21.62	0.81	8.1400000000000009e-59	Platelet distribution width;
KIRP	cis	rs1971256	0.500	rs1971255	chr6:151816094	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.62	6.08	0.36	4.44e-9	Endometriosis;
KIRP	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-13.46	-0.65	2.51e-31	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-1.03	-18.91	-0.77	7.34e-50	Height;
KIRP	trans	rs7554547	0.630	rs4845889	chr1:11971345	T/C	cg03536846	chr8:120886254	DEPDC6	-0.53	-6.18	-0.37	2.67e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23422044	chr7:1970798	MAD1L1	-0.7	-7.17	-0.42	8.53e-12	Bipolar disorder;
KIRP	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.49	5.89	0.35	1.25e-8	Metabolite levels;
KIRP	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.68	10.44	0.55	2.34e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	11.02	0.58	3.14e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.17	-0.46	1.67e-14	Systemic lupus erythematosus;
KIRP	cis	rs74181299	0.819	rs2252867	chr2:65296280	T/C	cg05010058	chr2:65284262	CEP68	0.49	7.09	0.41	1.39e-11	Pulse pressure;
KIRP	cis	rs71403859	0.667	rs35538253	chr16:71677975	C/T	cg08717414	chr16:71523259	ZNF19	-0.95	-8.43	-0.47	3e-15	Post bronchodilator FEV1;
KIRP	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.78	0.4	9.11e-11	Menarche (age at onset);
KIRP	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.25	-0.47	9.91e-15	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23133153	chr13:115000275	CDC16	0.49	6.44	0.38	6.15e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8060686	0.516	rs7206792	chr16:68168200	C/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-7.42	-0.43	1.92e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg18209359	chr17:80159595	CCDC57	-0.42	-5.57	-0.33	6.73e-8	Life satisfaction;
KIRP	cis	rs9463078	0.547	rs116177834	chr6:44738548	C/A	cg25276700	chr6:44698697	NA	0.35	5.06	0.31	8.28e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg27147174	chr7:100797783	AP1S1	-0.59	-7.66	-0.44	4.23e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-1.03	-13.09	-0.64	4.73e-30	Breast cancer;
KIRP	cis	rs1659258	0.568	rs1258408	chr2:88619494	C/T	cg00685853	chr2:88648947	NA	0.51	6.07	0.36	4.89e-9	Visceral fat;
KIRP	cis	rs4356932	1.000	rs11097222	chr4:76987451	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.2	0.37	2.43e-9	Blood protein levels;
KIRP	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg13798912	chr7:905769	UNC84A	0.53	5.38	0.32	1.76e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2882667	0.898	rs13163536	chr5:138377219	A/G	cg04439458	chr5:138467593	SIL1	-0.45	-7.42	-0.43	1.93e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.72e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.78	11.98	0.61	2.39e-26	Menarche (age at onset);
KIRP	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg04691961	chr3:161091175	C3orf57	-0.45	-6.35	-0.38	1e-9	Morning vs. evening chronotype;
KIRP	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	1.03	9.05	0.5	4.42e-17	Blood protein levels;
KIRP	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.61	0.52	9.24e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.99	-17.59	-0.75	2.22e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.2	-0.61	4.44e-27	Ulcerative colitis;
KIRP	cis	rs7582180	0.966	rs4851283	chr2:100894802	C/G	cg14675211	chr2:100938903	LONRF2	0.46	5.05	0.31	8.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.76	-0.4	9.91e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-0.91	-12.23	-0.62	3.35e-27	Blood trace element (Zn levels);
KIRP	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.79	8.18	0.46	1.48e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7709377	0.547	rs253961	chr5:115687715	A/G	cg23108291	chr5:115420582	COMMD10	0.42	4.97	0.3	1.26e-6	Metabolite levels  (X-11787);
KIRP	cis	rs3736485	0.932	rs4774592	chr15:51778879	C/T	cg14296394	chr15:51910925	DMXL2	-0.36	-5.42	-0.33	1.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.2	0.42	7.12e-12	Coffee consumption (cups per day);
KIRP	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg07862535	chr7:139043722	LUC7L2	-0.47	-5.26	-0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg01843034	chr6:37503916	NA	-0.96	-15.46	-0.7	4e-38	Cognitive performance;
KIRP	cis	rs16976116	0.901	rs28489312	chr15:55494048	A/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg08975724	chr8:8085496	FLJ10661	0.63	7.8	0.45	1.76e-13	Neuroticism;
KIRP	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.08	12.97	0.64	1.12e-29	Vitiligo;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13837895	chr19:50145301	SCAF1	0.61	7.21	0.42	6.86e-12	Smoking initiation;
KIRP	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	1.06	23.09	0.83	1.61e-63	Breast cancer;
KIRP	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg09699651	chr6:150184138	LRP11	0.59	8.17	0.46	1.6e-14	Testicular germ cell tumor;
KIRP	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.34	-0.32	2.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.84	-7.89	-0.45	9.68e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.05e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg00933542	chr6:150070202	PCMT1	0.28	5.47	0.33	1.11e-7	Lung cancer;
KIRP	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.61	5.89	0.35	1.26e-8	Breast cancer;
KIRP	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17376030	chr22:41985996	PMM1	0.7	7.71	0.44	3.15e-13	Vitiligo;
KIRP	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.22	0.37	2.11e-9	Morning vs. evening chronotype;
KIRP	cis	rs17221829	0.574	rs7930964	chr11:89377313	A/T	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.23	-0.32	3.62e-7	Anxiety in major depressive disorder;
KIRP	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.57	6.11	0.36	3.82e-9	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg08132940	chr7:1081526	C7orf50	-0.69	-7.03	-0.41	2.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.06	-0.36	5.07e-9	Breast cancer;
KIRP	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.58	5.4	0.33	1.55e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11987759	chr7:65425863	GUSB	0.59	7.83	0.45	1.45e-13	Aortic root size;
KIRP	cis	rs62070183	0.938	rs9912761	chr17:31036493	A/G	cg05781649	chr17:31146240	MYO1D	-0.55	-5.54	-0.33	7.64e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.62	8.26	0.47	8.85e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18252515	chr7:66147081	NA	0.47	5.81	0.35	1.97e-8	Aortic root size;
KIRP	cis	rs732716	0.889	rs55637375	chr19:4386845	A/G	cg19820705	chr19:4455316	UBXN6	0.67	8.28	0.47	8.17e-15	Mean corpuscular volume;
KIRP	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg00631329	chr6:26305371	NA	-0.66	-8.74	-0.49	3.82e-16	Educational attainment;
KIRP	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.01	-0.36	6.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.87	-10.0	-0.54	5.57e-20	White matter hyperintensity burden;
KIRP	cis	rs7760535	0.764	rs240994	chr6:111675757	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.49	-6.55	-0.39	3.24e-10	Metabolic traits;
KIRP	cis	rs17123764	0.818	rs7973389	chr12:49980745	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.97	0.3	1.27e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg14768367	chr16:72042858	DHODH	-0.5	-6.25	-0.37	1.84e-9	Fibrinogen levels;
KIRP	cis	rs4704187	0.687	rs6891023	chr5:74500755	G/A	cg03227963	chr5:74354835	NA	0.4	5.8	0.35	2e-8	Response to amphetamines;
KIRP	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.64	0.44	4.94e-13	Bladder cancer;
KIRP	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.89	11.31	0.59	3.59e-24	Homoarginine levels;
KIRP	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.33	6.29	0.37	1.46e-9	Alcohol dependence;
KIRP	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.65	-0.34	4.54e-8	Depression;
KIRP	cis	rs6997458	0.785	rs10907474	chr8:86362381	C/T	cg02393479	chr8:86352350	CA3	-0.32	-5.01	-0.3	1.02e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg11005552	chr10:105648138	OBFC1	0.4	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.61	-9.45	-0.52	2.72e-18	Sense of smell;
KIRP	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg24476569	chr13:95954382	ABCC4	-0.52	-8.23	-0.46	1.11e-14	Blood metabolite levels;
KIRP	cis	rs9810890	1.000	rs4548	chr3:128525253	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.37	4.96	0.3	1.3e-6	Birth weight;
KIRP	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.57	-9.26	-0.51	1.03e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs3087591	0.683	rs2854303	chr17:29716342	C/G	cg24425628	chr17:29625626	OMG;NF1	0.61	8.75	0.49	3.57e-16	Hip circumference;
KIRP	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg07936489	chr17:37558343	FBXL20	-0.41	-5.03	-0.31	9.62e-7	Asthma;
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	0.72	6.53	0.38	3.81e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-7.17	-0.42	8.59e-12	Coronary artery disease;
KIRP	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.34	-5.91	-0.35	1.17e-8	Iron status biomarkers (transferrin levels);
KIRP	cis	rs4262150	0.767	rs4360032	chr5:151963064	C/T	cg12297329	chr5:152029980	NA	0.66	8.22	0.46	1.21e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.48	6.82	0.4	6.9e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.64	-8.11	-0.46	2.4e-14	Extraversion;
KIRP	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.27	-0.32	3.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.19e-37	Height;
KIRP	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	5.89	0.35	1.25e-8	Cognitive test performance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21219996	chr9:77113070	RORB	-0.51	-6.25	-0.37	1.8e-9	Interleukin-4 levels;
KIRP	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12210905	1.000	rs9379965	chr6:27227061	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.68	-6.04	-0.36	5.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg06671706	chr8:8559999	CLDN23	0.56	6.29	0.37	1.47e-9	Obesity-related traits;
KIRP	cis	rs10924970	1.000	rs4660145	chr1:235350207	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.14	0.31	5.69e-7	Asthma;
KIRP	trans	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg27542767	chr6:40253980	NA	0.41	6.09	0.36	4.35e-9	Breast size;
KIRP	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.6	-7.69	-0.44	3.47e-13	Cocaine dependence;
KIRP	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.51	6.36	0.38	9.86e-10	Subjective well-being;
KIRP	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg18944383	chr4:111397179	ENPEP	0.48	7.68	0.44	3.79e-13	Coronary artery disease;
KIRP	cis	rs17799476	1.000	rs17799476	chr2:46352326	C/G	cg12428440	chr2:46370979	PRKCE	0.49	4.99	0.3	1.14e-6	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.97	13.94	0.66	6.19e-33	Platelet distribution width;
KIRP	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.5	5.69	0.34	3.69e-8	Platelet distribution width;
KIRP	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.64	8.58	0.48	1.09e-15	Renal function-related traits (BUN);
KIRP	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.3	0.32	2.61e-7	Bipolar disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09015484	chr9:96929106	NA	0.7	8.44	0.47	2.84e-15	Smoking initiation;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15819405	chr7:128079085	NA	0.54	6.64	0.39	1.97e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.59	-6.79	-0.4	8.58e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.66	0.39	1.77e-10	Mean corpuscular volume;
KIRP	cis	rs10924309	0.855	rs1807291	chr1:245860210	G/A	cg00036263	chr1:245852353	KIF26B	-0.49	-6.35	-0.38	1.05e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg08648136	chr8:956695	NA	0.39	5.39	0.32	1.68e-7	Schizophrenia;
KIRP	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.82	12.52	0.62	3.78e-28	Height;
KIRP	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg08632701	chr21:37451849	NA	-0.43	-5.45	-0.33	1.2e-7	Mitral valve prolapse;
KIRP	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg05775895	chr3:12838266	CAND2	0.33	5.24	0.32	3.39e-7	QRS complex (12-leadsum);
KIRP	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.52	7.51	0.43	1.12e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.45	6.39	0.38	8.16e-10	Testicular germ cell tumor;
KIRP	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg13978929	chr19:21580086	ZNF493	-0.52	-4.9	-0.3	1.78e-6	Pain;
KIRP	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg21918786	chr6:109611834	NA	-0.36	-4.93	-0.3	1.52e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg02151108	chr14:50098012	C14orf104	-0.51	-7.03	-0.41	2.07e-11	Carotid intima media thickness;
KIRP	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.58	9.41	0.51	3.62e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg22089800	chr15:90895588	ZNF774	0.42	4.94	0.3	1.44e-6	Rheumatoid arthritis;
KIRP	cis	rs981844	1.000	rs2606342	chr4:154659980	C/A	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs981844	0.712	rs4616729	chr4:154746900	T/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6901004	0.935	rs9487602	chr6:111560946	C/T	cg15721981	chr6:111408429	SLC16A10	0.62	9.05	0.5	4.47e-17	Blood metabolite levels;
KIRP	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.79	0.57	1.78e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs7119038	0.818	rs77209083	chr11:118607569	A/G	cg19308663	chr11:118741387	NA	0.55	8.4	0.47	3.54e-15	Sjögren's syndrome;
KIRP	cis	rs2415984	0.600	rs61993295	chr14:46932614	T/C	cg14871534	chr14:47121158	RPL10L	-0.45	-5.4	-0.33	1.56e-7	Number of children ever born;
KIRP	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-5.76	-0.34	2.46e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.7	-6.33	-0.37	1.13e-9	Yeast infection;
KIRP	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg23202291	chr11:1979235	NA	0.38	4.96	0.3	1.32e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg00325661	chr8:49890786	NA	0.39	4.9	0.3	1.74e-6	Sudden cardiac arrest;
KIRP	cis	rs365132	0.517	rs6881002	chr5:176336755	T/C	cg06783121	chr5:176314628	HK3	-0.49	-5.63	-0.34	4.8e-8	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.81	11.0	0.57	3.62e-23	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02470959	chr12:132196036	SFRS8	-0.5	-7.04	-0.41	1.88e-11	Serum protein levels (sST2);
KIRP	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.67	7.36	0.42	2.76e-12	Smoking initiation;
KIRP	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.51	-11.59	-0.59	4.46e-25	Diabetic kidney disease;
KIRP	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg22284058	chr8:142237359	SLC45A4	-0.43	-5.33	-0.32	2.18e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7523273	0.597	rs2761437	chr1:207923081	A/G	cg22525895	chr1:207977042	MIR29B2	0.57	5.67	0.34	3.98e-8	Schizophrenia;
KIRP	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg03260781	chr1:16346299	HSPB7	0.31	5.0	0.3	1.1e-6	Dilated cardiomyopathy;
KIRP	cis	rs4805272	1.000	rs6509059	chr19:29322773	C/T	cg15000279	chr19:29285009	NA	-0.36	-5.22	-0.32	3.85e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-9.79	-0.53	2.58e-19	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.87	-0.53	1.39e-19	Response to antipsychotic treatment;
KIRP	cis	rs11638352	1.000	rs7176955	chr15:44308905	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.72	-4.87	-0.3	2e-6	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs12476592	0.602	rs1446564	chr2:63731682	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.66	5.13	0.31	6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.67	0.39	1.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.88	-12.7	-0.63	9.54e-29	Dupuytren's disease;
KIRP	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.6	9.09	0.5	3.41e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.89	15.28	0.7	1.59e-37	Height;
KIRP	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.53	6.83	0.4	6.53e-11	Eye color traits;
KIRP	cis	rs13102973	0.867	rs11722699	chr4:135907871	G/T	cg14419869	chr4:135874104	NA	0.48	7.44	0.43	1.67e-12	Subjective well-being;
KIRP	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.76	8.84	0.49	1.82e-16	Blood pressure (smoking interaction);
KIRP	cis	rs1568889	0.548	rs34906813	chr11:28508819	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	6.75	0.4	1.05e-10	Bipolar disorder;
KIRP	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-4.95	-0.3	1.38e-6	Tonsillectomy;
KIRP	cis	rs741951	0.832	rs8127770	chr21:46255298	C/A	cg08823554	chr21:46269191	NA	-0.61	-5.47	-0.33	1.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1570884	0.539	rs2407696	chr13:50112525	G/A	cg03651054	chr13:50194643	NA	0.55	6.86	0.4	5.69e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9962915	1.000	rs1719983	chr18:5596822	C/T	cg12967001	chr18:5544089	EPB41L3	-0.43	-5.27	-0.32	3.02e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.66	7.91	0.45	8.7e-14	Mean platelet volume;
KIRP	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.26	0.67	4.94e-34	Electrocardiographic conduction measures;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg08901578	chr4:187885870	NA	-0.51	-7.98	-0.45	5.5e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.84	12.51	0.62	4.02e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg27141850	chr2:20869434	GDF7	-0.39	-6.29	-0.37	1.44e-9	Abdominal aortic aneurysm;
KIRP	trans	rs6506900	0.692	rs8088418	chr18:28901524	T/C	cg10906284	chr12:63544430	AVPR1A	0.37	6.04	0.36	5.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1978968	1.000	rs11704827	chr22:18450287	A/T	cg02610425	chr22:18483192	MICAL3	0.37	5.12	0.31	6.11e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.59e-15	Mortality in heart failure;
KIRP	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.49	-5.8	-0.35	2.01e-8	Body mass index;
KIRP	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.61	5.85	0.35	1.57e-8	Skin colour saturation;
KIRP	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg20991723	chr1:152506922	NA	-0.46	-5.52	-0.33	8.46e-8	Hair morphology;
KIRP	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg00745463	chr17:30367425	LRRC37B	-0.58	-5.74	-0.34	2.81e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.76	-10.37	-0.55	3.97e-21	Huntington's disease progression;
KIRP	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.58	7.16	0.42	9.04e-12	Renal function-related traits (BUN);
KIRP	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg25486957	chr4:152246857	NA	-0.44	-5.1	-0.31	6.73e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3925075	0.934	rs9673522	chr16:31347648	T/C	cg02846316	chr16:31340340	ITGAM	0.61	9.66	0.52	6.57e-19	IgA nephropathy;
KIRP	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg00677455	chr12:58241039	CTDSP2	0.84	10.59	0.56	7.78e-22	Multiple sclerosis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08037420	chr3:172428855	NCEH1	0.48	6.37	0.38	9.38e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg00745463	chr17:30367425	LRRC37B	-0.6	-6.22	-0.37	2.11e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs4711336	0.712	rs942641	chr6:33687007	G/A	cg15676125	chr6:33679581	C6orf125	0.39	5.26	0.32	3.18e-7	Height;
KIRP	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.54	-0.33	7.91e-8	Bipolar disorder;
KIRP	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg18825076	chr15:78729989	IREB2	-0.43	-5.06	-0.31	8.24e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2652822	0.525	rs3784671	chr15:63569184	C/A	cg02713581	chr15:63449717	RPS27L	0.49	5.44	0.33	1.28e-7	Metabolic traits;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.35	0.47	5.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg20913747	chr6:44695427	NA	-0.4	-5.09	-0.31	7.26e-7	Chin dimples;
KIRP	cis	rs3789045	0.819	rs16854023	chr1:204551830	A/G	cg08641003	chr1:204589008	LRRN2	-0.49	-4.99	-0.3	1.17e-6	Educational attainment (college completion);
KIRP	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	1.0	8.16	0.46	1.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07650554	chr16:30457408	SEPHS2	0.48	6.28	0.37	1.53e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.66	-0.34	4.26e-8	Colorectal cancer;
KIRP	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg17252645	chr8:143867129	LY6D	-0.31	-4.94	-0.3	1.44e-6	Urinary tract infection frequency;
KIRP	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.76	-10.77	-0.57	1.99e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.71	-0.49	4.51e-16	Migraine;Coronary artery disease;
KIRP	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14598338	chr9:96623480	NA	-0.65	-10.79	-0.57	1.72e-22	DNA methylation (variation);
KIRP	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg03970086	chr16:88974840	CBFA2T3	0.49	6.29	0.37	1.4e-9	Social autistic-like traits;
KIRP	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg16989719	chr2:238392110	NA	-0.64	-7.01	-0.41	2.32e-11	Prostate cancer;
KIRP	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.41	-5.24	-0.32	3.49e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	cg12689670	chr1:183009347	LAMC1	0.42	5.91	0.35	1.16e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.21	-18.92	-0.77	7.12e-50	Breast cancer;
KIRP	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13102973	0.965	rs11735381	chr4:135850474	T/C	cg14419869	chr4:135874104	NA	0.53	8.85	0.49	1.76e-16	Subjective well-being;
KIRP	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.21	14.04	0.67	2.88e-33	Sexual dysfunction (female);
KIRP	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg23594656	chr7:65796392	TPST1	0.46	7.16	0.42	9.28e-12	Aortic root size;
KIRP	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg04202892	chr2:111875749	ACOXL	0.49	6.85	0.4	5.73e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs8028182	0.636	rs4451914	chr15:75739824	C/T	cg20655648	chr15:75932815	IMP3	0.55	7.0	0.41	2.48e-11	Sudden cardiac arrest;
KIRP	cis	rs6005807	0.719	rs58542867	chr22:28988260	A/G	cg12565055	chr22:29076175	TTC28	0.57	4.87	0.3	2e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg21775007	chr8:11205619	TDH	-0.37	-4.99	-0.3	1.15e-6	Neuroticism;
KIRP	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg15128208	chr22:42549153	NA	0.4	5.21	0.31	4.09e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10116794	chr16:4588889	C16orf5	0.51	7.1	0.41	1.3e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg18441811	chr11:71824068	C11orf51	-0.77	-5.12	-0.31	6.29e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs12044355	0.858	rs3738401	chr1:231830295	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	5.67	0.34	3.99e-8	Alzheimer's disease;
KIRP	cis	rs7614311	0.954	rs2291533	chr3:63817430	C/G	cg22134162	chr3:63841271	THOC7	0.42	6.06	0.36	5.21e-9	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg10305451	chr2:177043427	NA	0.44	5.93	0.35	1.05e-8	IgG glycosylation;
KIRP	cis	rs9420	0.528	rs11229075	chr11:57391023	A/C	cg19752551	chr11:57585705	CTNND1	-0.71	-9.84	-0.53	1.71e-19	Schizophrenia;
KIRP	cis	rs2562456	0.520	rs250001	chr19:21408189	A/G	cg13978929	chr19:21580086	ZNF493	-0.56	-4.94	-0.3	1.45e-6	Pain;
KIRP	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg16309518	chr5:176445507	NA	-0.89	-14.15	-0.67	1.19e-33	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14237674	chr17:43239170	HEXIM2	0.6	7.11	0.41	1.24e-11	Smoking initiation;
KIRP	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg17133734	chr15:86042851	AKAP13	-0.46	-5.93	-0.35	1.04e-8	Coronary artery disease;
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg03152288	chr2:177042942	NA	0.69	9.26	0.51	1.02e-17	IgG glycosylation;
KIRP	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg25547332	chr5:131281432	NA	0.47	5.16	0.31	5.12e-7	Life satisfaction;
KIRP	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs753955	0.592	rs4769288	chr13:24360434	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.46	-5.95	-0.35	9.41e-9	Lung cancer;
KIRP	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg21775007	chr8:11205619	TDH	0.44	6.02	0.36	6.15e-9	Neuroticism;
KIRP	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.74	0.44	2.56e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs75920871	0.623	rs59097294	chr11:116964437	T/C	cg04087571	chr11:116723030	SIK3	-0.28	-5.56	-0.33	7.1e-8	Subjective well-being;
KIRP	cis	rs57338032	1.000	rs57338032	chr15:78798939	A/G	cg06917634	chr15:78832804	PSMA4	0.57	4.97	0.3	1.23e-6	CTACK levels;
KIRP	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg08885076	chr2:99613938	TSGA10	-0.45	-6.58	-0.39	2.83e-10	Fear of minor pain;
KIRP	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.82	-0.49	2.09e-16	Total cholesterol levels;
KIRP	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg18944383	chr4:111397179	ENPEP	0.51	8.49	0.48	1.96e-15	Coronary artery disease;
KIRP	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.84	9.31	0.51	7.31e-18	Iron status biomarkers;
KIRP	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg09231725	chr11:64357281	SLC22A12	0.62	8.18	0.46	1.52e-14	Urate levels in obese individuals;
KIRP	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg19402173	chr7:128379420	CALU	-0.62	-8.05	-0.46	3.59e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.74	6.81	0.4	7.33e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.87	-15.48	-0.7	3.24e-38	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.25	-0.51	1.16e-17	Morning vs. evening chronotype;
KIRP	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg16482183	chr6:26056742	HIST1H1C	0.44	5.57	0.33	6.8e-8	Schizophrenia;
KIRP	cis	rs897080	0.515	rs786403	chr2:44710788	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.6	0.34	5.78e-8	Height;
KIRP	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.62	9.06	0.5	4.04e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg17757837	chr7:157058334	UBE3C	0.78	10.42	0.55	2.69e-21	Body mass index;
KIRP	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-6.91	-0.4	4.18e-11	Gut microbiome composition (summer);
KIRP	cis	rs883115	0.846	rs1566387	chr1:224803787	C/T	cg01808320	chr1:224927238	CNIH3	-0.37	-5.27	-0.32	3.05e-7	Cancer;
KIRP	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-7.32	-0.42	3.57e-12	Tonsillectomy;
KIRP	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.55	-6.38	-0.38	8.92e-10	Smoking behavior;
KIRP	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10463316	0.779	rs6896444	chr5:150777357	T/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.91	-0.35	1.16e-8	Metabolite levels (Pyroglutamine);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg26149645	chr3:100529346	ABI3BP	0.38	6.11	0.36	3.77e-9	C-reactive protein;
KIRP	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.28	-0.55	7.56e-21	Coronary artery disease;
KIRP	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.69	8.92	0.49	1.11e-16	Body mass index;
KIRP	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg07395648	chr5:131743802	NA	0.52	6.42	0.38	6.85e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.25	-0.32	3.36e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg12560992	chr17:57184187	TRIM37	0.61	6.0	0.36	7.19e-9	Cognitive test performance;
KIRP	cis	rs860295	0.627	rs11264410	chr1:155745349	G/A	cg02153340	chr1:155202674	NA	-0.42	-5.83	-0.35	1.69e-8	Body mass index;
KIRP	cis	rs11690961	0.667	rs61759981	chr2:46374181	G/A	cg12428440	chr2:46370979	PRKCE	0.54	5.43	0.33	1.32e-7	Pulse pressure;
KIRP	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg02725872	chr8:58115012	NA	-0.53	-6.05	-0.36	5.35e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg14835575	chr10:16859367	RSU1	0.71	10.03	0.54	4.54e-20	Platelet distribution width;
KIRP	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg25588787	chr5:154027256	NA	-0.41	-5.03	-0.31	9.64e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.51	-0.38	4.16e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg18461458	chr19:21324796	ZNF431	0.48	5.08	0.31	7.57e-7	Pain;
KIRP	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs4740619	0.619	rs10738423	chr9:16027329	A/G	cg14451791	chr9:16040625	NA	-0.41	-5.3	-0.32	2.59e-7	Body mass index;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg23693289	chr8:27183097	PTK2B	0.58	7.46	0.43	1.52e-12	Neuroticism;
KIRP	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg22717608	chr11:34937665	PDHX;APIP	-0.43	-5.4	-0.33	1.61e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg14458575	chr2:238380390	NA	0.72	7.48	0.43	1.35e-12	Prostate cancer;
KIRP	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.53	-0.56	1.24e-21	Menopause (age at onset);
KIRP	cis	rs7635838	0.859	rs7632040	chr3:11427455	A/G	cg00170343	chr3:11313890	ATG7	0.45	5.81	0.35	1.93e-8	HDL cholesterol;
KIRP	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.71	10.6	0.56	7.45e-22	Dupuytren's disease;
KIRP	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.52	0.43	1.05e-12	Height;
KIRP	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg15534755	chr11:117069859	TAGLN	0.4	4.96	0.3	1.32e-6	Blood protein levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25923018	chr1:212587798	TMEM206	0.58	6.58	0.39	2.79e-10	Lung cancer in ever smokers;
KIRP	cis	rs72781680	0.644	rs72783627	chr2:24315685	A/C	cg20701182	chr2:24300061	SF3B14	0.95	10.41	0.55	2.83e-21	Lymphocyte counts;
KIRP	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.43	-5.24	-0.32	3.5e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg11350586	chr17:70115862	SOX9	0.35	5.09	0.31	7.09e-7	Thyroid hormone levels;
KIRP	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	cis	rs7129556	0.859	rs11237236	chr11:77312790	G/A	cg12586386	chr11:77299805	AQP11	0.51	6.08	0.36	4.65e-9	Weight loss (gastric bypass surgery);
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-6.98	-0.41	2.71e-11	Vitiligo;
KIRP	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.92e-15	Aortic root size;
KIRP	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg02023728	chr11:77925099	USP35	-0.32	-5.1	-0.31	6.78e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9815354	1.000	rs6781326	chr3:41777028	T/C	cg03022575	chr3:42003672	ULK4	0.5	5.63	0.34	4.95e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.69	0.56	3.84e-22	Cognitive test performance;
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.67	11.04	0.58	2.83e-23	Cardiovascular disease risk factors;
KIRP	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.77	5.59	0.34	5.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs12986413	0.619	rs1859954	chr19:2145481	G/T	cg09261902	chr19:2140048	AP3D1	-0.65	-10.2	-0.55	1.35e-20	Height;
KIRP	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	-0.65	-5.54	-0.33	7.9e-8	Putamen volume;
KIRP	cis	rs7246657	0.722	rs1564206	chr19:38040076	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.66	-0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.08	0.36	4.56e-9	Menopause (age at onset);
KIRP	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg05973401	chr12:123451056	ABCB9	-0.58	-6.83	-0.4	6.49e-11	Neutrophil percentage of white cells;
KIRP	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	5.78	0.35	2.22e-8	Renal cell carcinoma;
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05315796	chr3:52349193	DNAH1	0.42	6.37	0.38	9.01e-10	Electroencephalogram traits;
KIRP	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.16	-0.37	3e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4638749	0.501	rs13391411	chr2:108789053	A/G	cg25838818	chr2:108905173	SULT1C2	-0.33	-5.03	-0.31	9.57e-7	Blood pressure;
KIRP	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.28	-5.28	-0.32	2.85e-7	Colorectal or endometrial cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00179663	chr4:92189705	FAM190A	0.39	6.41	0.38	7.36e-10	C-reactive protein;
KIRP	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg06740227	chr12:86229804	RASSF9	-0.44	-5.3	-0.32	2.62e-7	Major depressive disorder;
KIRP	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.7	-9.02	-0.5	5.62e-17	Height;
KIRP	trans	rs16904179	0.685	rs16904187	chr8:130998513	A/G	cg07225458	chr11:75066381	NA	0.5	6.29	0.37	1.41e-9	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18393904	chr2:18741879	RDH14	0.58	7.66	0.44	4.34e-13	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00029233	chr17:43227453	HEXIM1	0.61	7.24	0.42	5.89e-12	Smoking initiation;
KIRP	cis	rs12786942	0.569	rs7948940	chr11:101311359	C/T	cg03942599	chr11:101341554	TRPC6	0.55	7.54	0.43	9.17e-13	Facial depth;
KIRP	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.5	0.59	9.01e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17376030	chr22:41985996	PMM1	0.84	8.99	0.5	6.98e-17	Vitiligo;
KIRP	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg02389323	chr16:88786976	FAM38A	1.02	8.24	0.47	1.03e-14	Plateletcrit;
KIRP	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg13962466	chr20:25176127	ENTPD6	0.41	4.99	0.3	1.16e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs16828019	0.850	rs12027691	chr1:41462032	C/T	cg18742814	chr1:41828276	NA	0.68	5.73	0.34	2.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7903847	0.642	rs3814553	chr10:99155984	G/A	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12496230	0.794	rs7641377	chr3:66867094	T/C	cg04995300	chr3:66848608	NA	0.43	6.45	0.38	5.99e-10	Type 2 diabetes;
KIRP	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg03959625	chr15:84868606	LOC388152	0.58	6.34	0.37	1.07e-9	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23408836	chr2:170590490	KLHL23	0.56	7.26	0.42	5.14e-12	Smoking initiation;
KIRP	cis	rs72792276	1.000	rs72794379	chr5:127464965	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	7.21	0.42	6.83e-12	Red cell distribution width;
KIRP	cis	rs4936894	0.500	rs79849070	chr11:124115765	T/A	cg27160556	chr11:124181099	OR8D1	-0.47	-6.69	-0.39	1.51e-10	Aging (time to death);
KIRP	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.2	-0.31	4.17e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-9.66	-0.52	6.42e-19	Coffee consumption (cups per day);
KIRP	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.05e-7	Type 2 diabetes;
KIRP	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.17	0.37	2.77e-9	Personality dimensions;
KIRP	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg02804510	chr19:49199965	FUT2	0.34	4.89	0.3	1.84e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.01	0.45	4.74e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs6495367	1.000	rs4778882	chr15:79382019	A/G	cg17916960	chr15:79447300	NA	0.34	5.8	0.35	1.99e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.76	10.79	0.57	1.79e-22	Waist circumference;Body mass index;
KIRP	cis	rs3764563	0.935	rs643442	chr19:15684087	T/C	cg20725493	chr19:15740067	CYP4F8	0.84	5.85	0.35	1.55e-8	Inflammatory biomarkers;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	trans	rs7246760	1.000	rs59867671	chr19:9933558	G/C	cg02900749	chr2:68251473	NA	-1.09	-9.22	-0.51	1.35e-17	Pursuit maintenance gain;
KIRP	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.65	8.76	0.49	3.33e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs7104764	0.507	rs6598056	chr11:252283	A/G	cg00562011	chr11:252351	PSMD13	0.55	7.17	0.42	8.99e-12	Menarche (age at onset);
KIRP	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.53	-6.57	-0.39	2.99e-10	Uric acid levels;
KIRP	cis	rs897080	0.515	rs1067358	chr2:44662183	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.66	0.34	4.2e-8	Height;
KIRP	trans	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg23963476	chr19:11099907	SMARCA4	0.4	6.09	0.36	4.26e-9	Height;
KIRP	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.8	13.64	0.66	6.41e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg03788504	chr6:150331562	NA	-0.34	-6.48	-0.38	4.95e-10	Alopecia areata;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg15815767	chr2:46769831	RHOQ	-0.48	-6.16	-0.37	3.01e-9	Blood metabolite levels;
KIRP	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs432925	0.625	rs1150188	chr16:355870	G/C	cg26913058	chr16:419975	MRPL28	-0.43	-5.38	-0.32	1.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg00599163	chr2:162100495	NA	0.63	8.22	0.46	1.14e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs11638352	1.000	rs7174819	chr15:44515864	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.68	-5.24	-0.32	3.41e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9547996	0.765	rs9547977	chr13:38185811	G/C	cg13634560	chr13:38173852	POSTN	-0.4	-5.55	-0.33	7.2e-8	Diastolic blood pressure;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-7.5	-0.43	1.16e-12	Lymphocyte counts;
KIRP	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg12751644	chr20:60527061	NA	-0.4	-4.88	-0.3	1.9e-6	Body mass index;
KIRP	cis	rs12580194	1.000	rs7971451	chr12:55699950	G/A	cg11794356	chr12:55725991	OR6C3	-0.38	-5.2	-0.31	4.24e-7	Cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23522862	chr17:79829415	ARHGDIA	0.49	6.37	0.38	9.44e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	10.8	0.57	1.71e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg17207736	chr8:142237307	SLC45A4	0.48	5.93	0.35	1.04e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.55	-0.33	7.2e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2742234	0.955	rs1272142	chr10:43695484	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.59	-7.31	-0.42	3.82e-12	Hirschsprung disease;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.68	0.48	5.38e-16	Life satisfaction;
KIRP	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06544989	chr22:39130855	UNC84B	0.47	7.31	0.42	3.7e-12	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.42	0.38	7.04e-10	Breast cancer;
KIRP	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs9826463	0.702	rs73228757	chr3:142320081	A/G	cg20824294	chr3:142316082	PLS1	0.46	6.95	0.4	3.33e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9840812	0.592	rs900048	chr3:136218930	C/T	cg15507776	chr3:136538369	TMEM22	0.39	5.01	0.3	1.02e-6	Fibrinogen levels;
KIRP	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg24692254	chr21:30365293	RNF160	-0.49	-5.06	-0.31	8.33e-7	Cognitive test performance;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.9	15.37	0.7	7.75e-38	Menarche (age at onset);
KIRP	cis	rs41563	0.547	rs2237612	chr7:104845195	A/C	cg04380332	chr7:105027541	SRPK2	-0.66	-6.78	-0.4	9.02e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg00857998	chr1:205179979	DSTYK	-0.65	-7.75	-0.44	2.36e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.64	7.74	0.44	2.59e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs829661	0.690	rs2593462	chr2:30872475	T/A	cg10949345	chr2:30726833	LCLAT1	1.09	13.36	0.65	5.56e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg06453172	chr10:134556979	INPP5A	-0.54	-5.99	-0.36	7.39e-9	Migraine;
KIRP	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg17595323	chr11:93583763	C11orf90	-0.31	-5.23	-0.32	3.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	trans	rs2270927	0.510	rs2972839	chr5:75572943	C/T	cg13563193	chr19:33072644	PDCD5	0.81	6.13	0.36	3.55e-9	Mean corpuscular volume;
KIRP	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg07382826	chr16:28625726	SULT1A1	0.46	5.22	0.32	3.86e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg02336718	chr17:17403227	NA	0.39	5.99	0.36	7.42e-9	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05519431	chr4:87515674	PTPN13	0.43	6.1	0.36	4.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg05082376	chr22:42548792	NA	-0.41	-5.34	-0.32	2.11e-7	Schizophrenia;
KIRP	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-1.08	-9.97	-0.54	6.92e-20	Post bronchodilator FEV1;
KIRP	cis	rs7766436	0.885	rs12111199	chr6:22578106	C/T	cg13666174	chr6:22585274	NA	-0.43	-5.95	-0.35	9.12e-9	Coronary artery disease;
KIRP	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.41	5.78	0.35	2.3e-8	Optic cup area;
KIRP	cis	rs6546886	0.912	rs4241260	chr2:74293395	C/T	cg14702570	chr2:74259524	NA	-0.27	-5.39	-0.32	1.66e-7	Dialysis-related mortality;
KIRP	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.42	-0.33	1.42e-7	Colorectal cancer;
KIRP	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-0.53	-7.29	-0.42	4.32e-12	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg12742796	chr1:117602840	TTF2	0.45	6.14	0.36	3.23e-9	Inflammatory biomarkers;
KIRP	cis	rs2718058	0.639	rs2597270	chr7:37762014	A/G	cg15028436	chr7:37888078	TXNDC3	-0.49	-5.55	-0.33	7.26e-8	Alzheimer's disease (late onset);
KIRP	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.44	0.52	2.9e-18	Height;
KIRP	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.64	-7.45	-0.43	1.57e-12	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08222081	chr3:150264537	SERP1;EIF2A	0.5	6.3	0.37	1.4e-9	Parkinson's disease;
KIRP	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg03808351	chr9:123631620	PHF19	0.39	5.35	0.32	2.03e-7	Rheumatoid arthritis;
KIRP	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.65	8.89	0.49	1.37e-16	Alcohol dependence;
KIRP	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg09873164	chr1:152488093	CRCT1	0.6	7.85	0.45	1.28e-13	Hair morphology;
KIRP	cis	rs735539	0.521	rs9552282	chr13:21365721	C/T	cg04906043	chr13:21280425	IL17D	-0.43	-4.99	-0.3	1.16e-6	Dental caries;
KIRP	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.34	-0.51	5.94e-18	Platelet count;
KIRP	cis	rs4273100	0.790	rs2048230	chr17:19276199	G/A	cg18093559	chr17:18951025	GRAP	-0.54	-5.05	-0.31	8.49e-7	Schizophrenia;
KIRP	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-5.7	-0.34	3.35e-8	Height;
KIRP	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg20991723	chr1:152506922	NA	-0.45	-5.48	-0.33	1.04e-7	Hair morphology;
KIRP	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg16583315	chr14:65563665	MAX	-0.33	-4.85	-0.3	2.17e-6	Obesity-related traits;
KIRP	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	10.4	0.55	3.19e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.75	9.28	0.51	8.84e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02921472	chr20:5094039	C20orf30	0.52	6.39	0.38	8.44e-10	Parkinson's disease;
KIRP	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	8.76	0.49	3.33e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.93	14.68	0.68	1.8e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11169225	0.590	rs7305534	chr12:50341610	T/C	cg04450003	chr12:50355995	AQP5	0.24	5.03	0.31	9.43e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.0	-0.57	3.88e-23	Chronic sinus infection;
KIRP	cis	rs6939532	0.522	rs9358933	chr6:26363688	C/T	cg12826209	chr6:26865740	GUSBL1	0.46	5.31	0.32	2.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg10017260	chr10:834428	NA	-0.45	-6.27	-0.37	1.59e-9	Survival in rectal cancer;
KIRP	cis	rs8113308	1.000	rs6509600	chr19:52442589	G/T	cg24732339	chr19:52471368	ZNF350	-0.47	-5.65	-0.34	4.35e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs3026101	0.671	rs75669379	chr17:5321355	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.89	0.35	1.27e-8	Body mass index;
KIRP	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.48	-5.89	-0.35	1.25e-8	Initial pursuit acceleration;
KIRP	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg19899395	chr1:46959349	NA	-0.39	-4.9	-0.3	1.76e-6	Monobrow;
KIRP	cis	rs8070740	0.898	rs11078562	chr17:5326857	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.18	0.42	8.06e-12	Menopause (age at onset);
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg01391022	chr12:122360665	WDR66	-0.36	-5.24	-0.32	3.47e-7	Mean corpuscular volume;
KIRP	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.46	0.43	1.49e-12	Aortic root size;
KIRP	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.58	-7.62	-0.44	5.61e-13	White matter hyperintensity burden;
KIRP	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.34	-0.32	2.13e-7	Parkinson's disease;
KIRP	cis	rs988913	1.000	rs1393772	chr6:54838388	C/T	cg03513858	chr6:54763001	FAM83B	-0.37	-5.21	-0.32	3.98e-7	Menarche (age at onset);
KIRP	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs2151522	0.778	rs9388530	chr6:127148295	A/T	cg21431617	chr6:127135037	NA	0.3	5.41	0.33	1.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.66	6.84	0.4	6.21e-11	Corneal astigmatism;
KIRP	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg25801113	chr15:45476975	SHF	0.41	7.56	0.43	7.77e-13	Uric acid levels;
KIRP	cis	rs4356932	1.000	rs4257674	chr4:76945685	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg10326726	chr10:51549505	MSMB	-0.6	-8.92	-0.49	1.09e-16	Prostate-specific antigen levels;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.7	6.81	0.4	7.6e-11	Breast cancer;
KIRP	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg22508957	chr16:3507546	NAT15	0.59	7.2	0.42	7.29e-12	Tuberculosis;
KIRP	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.54	-0.73	8.21e-42	Height;
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg01864069	chr14:103024347	NA	-0.74	-9.86	-0.53	1.58e-19	Platelet count;
KIRP	cis	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.03	-0.46	3.93e-14	Migraine;Coronary artery disease;
KIRP	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.41	-0.43	2.05e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8077577	0.633	rs12939851	chr17:18131585	T/A	cg18869244	chr17:18121946	NA	-0.5	-5.7	-0.34	3.45e-8	Obesity-related traits;
KIRP	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	6.2	0.37	2.38e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	8.12	0.46	2.33e-14	Prudent dietary pattern;
KIRP	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg18132916	chr6:79620363	NA	-0.4	-5.53	-0.33	8.01e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	4.89	0.3	1.79e-6	Renal cell carcinoma;
KIRP	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.79	8.15	0.46	1.81e-14	Bipolar disorder;
KIRP	cis	rs2505998	0.843	rs2506004	chr10:43582273	A/C	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.27	-0.32	2.99e-7	Hirschsprung disease;
KIRP	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg02038168	chr22:39784481	NA	-0.41	-4.99	-0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg00878827	chr14:75229987	YLPM1	0.58	6.1	0.36	4.08e-9	Response to statin therapy;
KIRP	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg22974920	chr21:40686053	BRWD1	0.51	6.18	0.37	2.62e-9	Cognitive function;
KIRP	cis	rs963731	0.649	rs2060989	chr2:39293530	G/A	cg04010122	chr2:39346883	SOS1	-0.7	-5.18	-0.31	4.67e-7	Corticobasal degeneration;
KIRP	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	7.44	0.43	1.7e-12	Response to antipsychotic treatment;
KIRP	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.7	-8.11	-0.46	2.43e-14	Pancreatic cancer;
KIRP	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg26139080	chr11:47293733	MADD	-0.42	-5.29	-0.32	2.68e-7	HDL cholesterol;
KIRP	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg20628663	chr10:43360327	NA	-0.62	-5.75	-0.34	2.62e-8	Blood protein levels;
KIRP	cis	rs193541	0.632	rs154503	chr5:122204499	G/A	cg19412675	chr5:122181750	SNX24	0.6	6.45	0.38	5.95e-10	Glucose homeostasis traits;
KIRP	cis	rs9815354	1.000	rs9840037	chr3:41827522	C/T	cg03022575	chr3:42003672	ULK4	0.49	5.5	0.33	9.73e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.42	-5.22	-0.32	3.79e-7	IgG glycosylation;
KIRP	cis	rs6601327	0.603	rs10104807	chr8:9669775	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-5.07	-0.31	7.79e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.66	7.91	0.45	8.74e-14	Type 2 diabetes;
KIRP	cis	rs11638352	0.661	rs2615286	chr15:44417068	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.08	-0.36	4.49e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs7692976	0.578	rs2298979	chr4:110838126	G/A	cg06981781	chr4:110842888	EGF	-0.24	-5.25	-0.32	3.22e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.58	9.36	0.51	5.2e-18	C-reactive protein levels;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg26134248	chr17:3907702	NA	0.4	5.15	0.31	5.34e-7	Type 2 diabetes;
KIRP	cis	rs7589728	1.000	rs2363731	chr2:88521793	C/T	cg04511125	chr2:88470314	THNSL2	0.69	5.43	0.33	1.38e-7	Plasma clusterin levels;
KIRP	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.59	6.8	0.4	7.68e-11	Corneal astigmatism;
KIRP	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg05181565	chr1:1509872	SSU72	0.48	6.15	0.37	3.11e-9	Schizophrenia;
KIRP	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	5.6	0.34	5.82e-8	Renal cell carcinoma;
KIRP	cis	rs4332428	1.000	rs68005215	chr10:4977435	C/T	cg19648686	chr10:5044992	AKR1C2	-0.92	-7.99	-0.45	5.33e-14	Height;
KIRP	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.81	11.76	0.6	1.26e-25	Itch intensity from mosquito bite;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg26513180	chr16:89883248	FANCA	0.84	14.16	0.67	1.06e-33	Vitiligo;
KIRP	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.71	9.51	0.52	1.79e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg21132104	chr15:45694354	SPATA5L1	0.74	9.32	0.51	7.05e-18	Homoarginine levels;
KIRP	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	1.01	14.57	0.68	4.18e-35	Breast cancer;
KIRP	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.59	-8.62	-0.48	8.18e-16	Height;
KIRP	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.06	0.58	2.42e-23	Smoking behavior;
KIRP	cis	rs13082711	0.911	rs7640957	chr3:27514015	C/A	cg02860705	chr3:27208620	NA	0.56	7.66	0.44	4.33e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg25828445	chr12:7781288	NA	0.5	4.99	0.3	1.14e-6	HDL cholesterol levels;
KIRP	cis	rs6088813	1.000	rs4911180	chr20:33972948	G/A	cg14752227	chr20:34000481	UQCC	-0.5	-6.48	-0.38	4.94e-10	Height;
KIRP	trans	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg15704280	chr7:45808275	SEPT13	0.68	6.31	0.37	1.27e-9	Intraocular pressure;
KIRP	trans	rs6601327	0.603	rs10095171	chr8:9669885	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.15	-0.41	1e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg07972983	chr1:205091412	RBBP5	0.43	5.23	0.32	3.57e-7	Red blood cell count;
KIRP	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18932078	chr1:2524107	MMEL1	0.44	6.07	0.36	4.71e-9	Ulcerative colitis;
KIRP	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.13	-0.31	5.99e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.5	11.86	0.6	5.93e-26	Ewing sarcoma;
KIRP	cis	rs6690583	0.524	rs12029690	chr1:85452867	C/G	cg22153463	chr1:85462885	MCOLN2	0.59	5.37	0.32	1.84e-7	Serum sulfate level;
KIRP	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg17306686	chr7:157230923	NA	-0.39	-4.91	-0.3	1.7e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs56336142	0.619	rs55902013	chr6:39150657	C/G	cg17445213	chr7:47408746	TNS3	0.46	6.25	0.37	1.78e-9	Coronary artery disease;
KIRP	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.88	-13.92	-0.66	6.84e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.62	-7.12	-0.41	1.2e-11	Mean platelet volume;
KIRP	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.75	-9.15	-0.5	2.2e-17	Vitiligo;
KIRP	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg19746982	chr18:77552568	NA	-0.31	-5.25	-0.32	3.3e-7	Schizophrenia;
KIRP	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	1.1	11.05	0.58	2.69e-23	Psoriasis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19878733	chr11:65264897	MALAT1	-0.46	-6.08	-0.36	4.67e-9	Myopia;
KIRP	trans	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00950418	chr7:105029125	SRPK2	-0.55	-6.97	-0.41	2.87e-11	Height;
KIRP	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.65	-9.82	-0.53	1.98e-19	Educational attainment;
KIRP	cis	rs7833787	1.000	rs7007413	chr8:18705432	A/G	cg17701159	chr8:18705777	PSD3	0.38	7.14	0.41	1.06e-11	Obesity-related traits;
KIRP	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.61	-7.71	-0.44	3.13e-13	Extraversion;
KIRP	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.24	0.37	1.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.75	-10.68	-0.56	4.08e-22	Menarche (age at onset);
KIRP	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.51	6.59	0.39	2.71e-10	Iron status biomarkers;
KIRP	cis	rs889312	1.000	rs889312	chr5:56031884	C/A	cg14703610	chr5:56206110	C5orf35	0.42	5.06	0.31	8.22e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg19774624	chr17:42201019	HDAC5	0.58	7.36	0.42	2.69e-12	Total body bone mineral density;
KIRP	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.39	0.38	8.34e-10	Diabetic retinopathy;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.54	6.97	0.41	2.87e-11	Longevity;Endometriosis;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.78	6.84	0.4	6.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12210905	0.688	rs72845031	chr6:27535404	C/T	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.4e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg08501292	chr6:25962987	TRIM38	1.0	5.76	0.34	2.44e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.61	-6.79	-0.4	8.31e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg17747265	chr1:1875780	NA	-0.73	-13.48	-0.65	2.2e-31	Body mass index;
KIRP	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.86	-0.45	1.18e-13	Mood instability;
KIRP	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.57	0.48	1.13e-15	Eosinophil percentage of white cells;
KIRP	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.83	9.96	0.54	7.25e-20	Corneal astigmatism;
KIRP	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.4	4.86	0.3	2.12e-6	Renal cell carcinoma;
KIRP	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.65e-30	Eye color traits;
KIRP	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.69	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.59	7.98	0.45	5.6e-14	Economic and political preferences (feminism/equality);
KIRP	cis	rs2554380	0.891	rs2585055	chr15:84281488	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.55	-7.47	-0.43	1.43e-12	Height;
KIRP	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg00042356	chr1:8021962	PARK7	0.48	4.84	0.3	2.25e-6	Inflammatory bowel disease;
KIRP	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg05768032	chr16:30646687	NA	0.47	5.34	0.32	2.08e-7	Dementia with Lewy bodies;
KIRP	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg00383909	chr3:49044727	WDR6	0.99	7.12	0.41	1.16e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.32	0.51	7.11e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9921338	0.961	rs7195536	chr16:11442028	T/C	cg00044050	chr16:11439710	C16orf75	-0.56	-5.96	-0.36	8.72e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4363385	0.588	rs12082627	chr1:153023650	G/A	cg07796016	chr1:152779584	LCE1C	-0.45	-5.82	-0.35	1.86e-8	Inflammatory skin disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11913218	chr1:10754156	CASZ1	-0.45	-6.16	-0.37	3.03e-9	Metabolic traits;
KIRP	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.8	-9.83	-0.53	1.92e-19	Schizophrenia;
KIRP	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg11555438	chr13:111297484	CARS2	0.36	5.87	0.35	1.41e-8	Coronary artery disease;
KIRP	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.42	-4.87	-0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg26681399	chr22:41777847	TEF	-0.5	-5.05	-0.31	8.77e-7	Vitiligo;
KIRP	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-7.18	-0.42	8.46e-12	Neuroticism;
KIRP	trans	rs1462872	0.736	rs553950	chr8:31791362	T/G	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs8028182	0.636	rs12708519	chr15:75803200	T/C	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	1.0	14.33	0.67	2.74e-34	Menarche (age at onset);
KIRP	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22117172	chr7:91764530	CYP51A1	0.48	6.68	0.39	1.62e-10	Breast cancer;
KIRP	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.27	-0.42	4.9e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg04414720	chr1:150670196	GOLPH3L	-0.4	-5.14	-0.31	5.52e-7	Urate levels;
KIRP	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	1.21	11.4	0.59	1.9e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg24972876	chr7:65420302	NA	-0.42	-5.76	-0.34	2.53e-8	Calcium levels;
KIRP	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27373134	chr22:31090740	OSBP2	0.46	6.38	0.38	8.83e-10	Cancer;
KIRP	cis	rs6901004	0.933	rs12208141	chr6:111572138	A/G	cg15721981	chr6:111408429	SLC16A10	-0.47	-6.03	-0.36	5.89e-9	Blood metabolite levels;
KIRP	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.36	-0.32	1.92e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg08648136	chr8:956695	NA	0.41	6.09	0.36	4.27e-9	Schizophrenia;
KIRP	cis	rs16828019	0.704	rs35071528	chr1:41612657	C/G	cg18742814	chr1:41828276	NA	0.79	5.72	0.34	3.05e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg03468072	chr12:39539422	NA	0.41	6.02	0.36	6.32e-9	Morning vs. evening chronotype;
KIRP	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	1.14	9.06	0.5	4.13e-17	Skin colour saturation;
KIRP	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg08499158	chr17:42289980	UBTF	-0.71	-9.45	-0.52	2.88e-18	Total body bone mineral density;
KIRP	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg07862535	chr7:139043722	LUC7L2	-0.47	-5.28	-0.32	2.88e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.42	-5.08	-0.31	7.56e-7	IgG glycosylation;
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg07216194	chr8:27182965	PTK2B	0.46	5.62	0.34	5.19e-8	Neuroticism;
KIRP	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg21366198	chr4:185655624	MLF1IP	0.39	5.25	0.32	3.28e-7	Kawasaki disease;
KIRP	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg05043794	chr9:111880884	C9orf5	-0.25	-5.11	-0.31	6.42e-7	Menarche (age at onset);
KIRP	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.44	-5.41	-0.33	1.49e-7	Aortic root size;
KIRP	cis	rs752010	0.749	rs10749841	chr1:42112054	G/T	cg06885757	chr1:42089581	HIVEP3	0.45	6.67	0.39	1.71e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-1.04	-10.3	-0.55	6.63e-21	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg26138937	chr11:71823887	C11orf51	1.04	6.95	0.41	3.22e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.55	6.39	0.38	8.41e-10	Dialysis-related mortality;
KIRP	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg01620082	chr3:125678407	NA	-0.88	-6.06	-0.36	5.1e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.78	0.4	8.89e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.84	9.01	0.5	5.88e-17	Pulmonary function decline;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg04025307	chr7:1156635	C7orf50	0.74	7.73	0.44	2.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg07741184	chr6:167504864	NA	-0.24	-6.27	-0.37	1.57e-9	Crohn's disease;
KIRP	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.79	10.62	0.56	6.18e-22	Platelet count;
KIRP	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.46	6.69	0.39	1.52e-10	Urate levels in lean individuals;
KIRP	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.55	-6.33	-0.37	1.16e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-10.05	-0.54	4.05e-20	Exhaled nitric oxide output;
KIRP	cis	rs6832769	0.961	rs2412647	chr4:56319105	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.04	0.41	1.92e-11	Personality dimensions;
KIRP	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg05768032	chr16:30646687	NA	0.51	6.16	0.37	2.88e-9	Multiple myeloma;
KIRP	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	14.45	0.68	1.1e-34	Chronic sinus infection;
KIRP	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.02	-0.31	9.75e-7	Schizophrenia;
KIRP	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg13180566	chr4:1052158	NA	-0.47	-5.07	-0.31	7.89e-7	Recombination rate (females);
KIRP	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg10645314	chr2:3704589	ALLC	-0.42	-5.2	-0.31	4.26e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-5.82	-0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.06	-0.36	5.19e-9	Obesity-related traits;
KIRP	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.24	-0.32	3.53e-7	Lung cancer;
KIRP	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg20240347	chr1:204465584	NA	-0.44	-8.26	-0.47	9.24e-15	Schizophrenia;
KIRP	cis	rs73206853	0.841	rs67974983	chr12:110519237	T/G	cg12870014	chr12:110450643	ANKRD13A	0.59	6.01	0.36	6.72e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs72820985	1.000	rs8052178	chr16:80844437	G/A	cg04448709	chr16:81349954	GAN	-0.51	-5.21	-0.32	4.03e-7	Breast cancer;
KIRP	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.44	-0.38	6.07e-10	Morning vs. evening chronotype;
KIRP	cis	rs42648	0.667	rs2157793	chr7:89880354	C/G	cg25739043	chr7:89950458	NA	-0.41	-6.47	-0.38	5.14e-10	Homocysteine levels;
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02018176	chr4:1364513	KIAA1530	0.44	5.29	0.32	2.68e-7	Longevity;
KIRP	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.58	0.39	2.86e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	1.09	8.89	0.49	1.35e-16	Plasma clusterin levels;
KIRP	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg01988459	chr11:68622903	NA	0.39	5.53	0.33	8e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.74	-0.66	3e-32	Response to antipsychotic treatment;
KIRP	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg12317470	chr15:67143691	NA	0.65	5.37	0.32	1.81e-7	Lung cancer (smoking interaction);
KIRP	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.61	7.47	0.43	1.4e-12	Corneal astigmatism;
KIRP	cis	rs7188697	0.848	rs40187	chr16:58556566	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.05	0.31	8.69e-7	QT interval;
KIRP	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg24505687	chr6:33548425	BAK1	0.27	5.41	0.33	1.52e-7	Platelet count;
KIRP	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg07382826	chr16:28625726	SULT1A1	0.45	5.3	0.32	2.59e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.86	-10.83	-0.57	1.35e-22	Migraine;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs10203711	1.000	rs907102	chr2:239564503	G/A	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9603616	0.712	rs9548884	chr13:40266064	T/A	cg26701198	chr13:40229707	COG6	0.43	5.11	0.31	6.56e-7	Rheumatoid arthritis;
KIRP	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg06558623	chr16:89946397	TCF25	0.68	5.78	0.35	2.21e-8	Skin colour saturation;
KIRP	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.97	0.3	1.24e-6	Lymphocyte counts;
KIRP	cis	rs6421571	0.564	rs11216972	chr11:118585826	C/T	cg19308663	chr11:118741387	NA	0.47	7.29	0.42	4.31e-12	Primary biliary cholangitis;
KIRP	cis	rs2117029	0.587	rs57853986	chr12:49518395	T/G	cg24176009	chr12:49580217	TUBA1A	-0.38	-5.11	-0.31	6.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs698813	0.851	rs698804	chr2:44699720	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.54	0.33	7.67e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.91	15.03	0.69	1.14e-36	Urate levels in lean individuals;
KIRP	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.75	8.93	0.49	1.05e-16	Colorectal adenoma (advanced);
KIRP	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.44	5.41	0.33	1.52e-7	Common traits (Other);
KIRP	cis	rs6991838	0.584	rs10957361	chr8:66531861	C/G	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	9.14	0.5	2.33e-17	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg26621805	chr8:110373460	PKHD1L1	0.52	6.07	0.36	4.81e-9	QT interval;
KIRP	cis	rs17407555	0.632	rs12510727	chr4:10271070	T/G	cg11266682	chr4:10021025	SLC2A9	0.35	5.35	0.32	2e-7	Schizophrenia (age at onset);
KIRP	cis	rs6028335	0.674	rs16987712	chr20:37601243	A/G	cg16355469	chr20:37678765	NA	0.54	5.33	0.32	2.26e-7	Alcohol and nicotine co-dependence;
KIRP	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.89	-12.98	-0.64	1.08e-29	Breast cancer;
KIRP	cis	rs9309473	0.898	rs6546861	chr2:73849861	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.59	-0.34	6.03e-8	Metabolite levels;
KIRP	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg21775007	chr8:11205619	TDH	-0.38	-4.97	-0.3	1.23e-6	Neuroticism;
KIRP	cis	rs9815354	0.812	rs17218441	chr3:41987044	A/G	cg03022575	chr3:42003672	ULK4	0.8	8.3	0.47	6.83e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.64	8.93	0.49	1.05e-16	Alcohol dependence;
KIRP	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-5.3	-0.32	2.55e-7	Schizophrenia;
KIRP	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg22325292	chr17:80708367	FN3K	0.37	4.92	0.3	1.58e-6	Glycated hemoglobin levels;
KIRP	cis	rs7937612	1.000	rs4938808	chr11:120336902	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.11	-0.41	1.23e-11	Intraocular pressure;
KIRP	cis	rs75920871	0.640	rs4938357	chr11:117084040	G/A	cg23684410	chr11:116897558	SIK3	0.5	5.1	0.31	6.94e-7	Subjective well-being;
KIRP	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.06	-0.31	8.2e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.47	6.66	0.39	1.8e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.81	0.45	1.65e-13	Coffee consumption (cups per day);
KIRP	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg26084005	chr2:241760190	KIF1A	-0.51	-6.76	-0.4	1e-10	Urinary metabolites;
KIRP	cis	rs631288	0.793	rs6667498	chr1:146708029	C/G	cg25205988	chr1:146714368	CHD1L	-0.86	-5.11	-0.31	6.56e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg25281562	chr12:121454272	C12orf43	-0.46	-5.1	-0.31	6.89e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg23791538	chr6:167370224	RNASET2	-0.41	-4.93	-0.3	1.54e-6	Crohn's disease;
KIRP	cis	rs975752	0.717	rs4917887	chr10:101950108	G/A	cg13817732	chr10:102046368	BLOC1S2	0.72	6.06	0.36	5.18e-9	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-0.99	-12.12	-0.61	8.36e-27	Breast cancer;
KIRP	cis	rs7005380	0.525	rs7000068	chr8:120922963	C/G	cg21645572	chr8:120931649	DEPDC6	0.52	7.25	0.42	5.39e-12	Interstitial lung disease;
KIRP	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.1e-9	Cognitive function;
KIRP	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.43	5.25	0.32	3.33e-7	Iron status biomarkers;
KIRP	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.38	-9.29	-0.51	8.7e-18	Asthma (sex interaction);
KIRP	cis	rs1440410	1.000	rs1440410	chr4:144158309	T/A	cg01719995	chr4:144104893	USP38	0.45	5.92	0.35	1.07e-8	Ischemic stroke;
KIRP	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.16	0.37	2.93e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg10189774	chr4:17578691	LAP3	0.44	5.28	0.32	2.9e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.65	0.56	4.92e-22	Cognitive test performance;
KIRP	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg11906718	chr8:101322791	RNF19A	0.49	6.52	0.38	4.01e-10	Atrioventricular conduction;
KIRP	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.75	9.61	0.52	8.91e-19	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg24955955	chr5:415729	AHRR	0.77	6.34	0.37	1.12e-9	Fat distribution (HIV);
KIRP	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-9.42	-0.51	3.55e-18	Hepatocellular carcinoma;
KIRP	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg09699651	chr6:150184138	LRP11	0.45	5.81	0.35	1.94e-8	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00161770	chr1:63043009	DOCK7	-0.48	-7.37	-0.43	2.62e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9308731	0.563	rs6760053	chr2:111932997	C/G	cg04202892	chr2:111875749	ACOXL	0.48	6.52	0.38	4.07e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.05	-0.36	5.38e-9	Pulmonary function;
KIRP	cis	rs9581857	0.547	rs927579	chr13:28075079	A/G	cg22138327	chr13:27999177	GTF3A	0.85	6.62	0.39	2.24e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.33	12.07	0.61	1.14e-26	Diabetic retinopathy;
KIRP	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg18190219	chr22:46762943	CELSR1	-0.91	-7.08	-0.41	1.51e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-7.01	-0.41	2.25e-11	Initial pursuit acceleration;
KIRP	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-6.54	-0.38	3.59e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg26354017	chr1:205819088	PM20D1	0.53	5.7	0.34	3.42e-8	Parkinson's disease;
KIRP	cis	rs9604529	1.000	rs9604529	chr13:114622597	A/G	cg13259177	chr13:114761607	RASA3	-0.48	-4.94	-0.3	1.43e-6	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7937612	1.000	rs7104639	chr11:120239456	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.07	-0.41	1.61e-11	Intraocular pressure;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg10328157	chr14:21769240	RPGRIP1	0.5	6.66	0.39	1.77e-10	Educational attainment;
KIRP	cis	rs2574704	1.000	rs2043576	chr3:11649609	T/C	cg07643000	chr3:11666825	VGLL4	0.38	5.51	0.33	9e-8	Body mass index;
KIRP	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.48e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs829883	0.659	rs11109521	chr12:98930809	C/A	cg25150519	chr12:98850993	NA	-0.75	-9.01	-0.5	5.85e-17	Colorectal adenoma (advanced);
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-5.23	-0.32	3.6e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs73198271	0.562	rs11774860	chr8:8651879	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.27	-0.32	3e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21683590	chr13:114145385	TMCO3;DCUN1D2	0.52	6.43	0.38	6.48e-10	Parkinson's disease;
KIRP	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18710412	chr5:90654191	NA	-0.4	-6.12	-0.36	3.73e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.38	4.89	0.3	1.78e-6	Testicular germ cell tumor;
KIRP	cis	rs244899	0.935	rs2445786	chr5:167930877	G/A	cg06604206	chr5:167912465	RARS	-0.52	-7.2	-0.42	7.26e-12	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	12.98	0.64	1.06e-29	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11597475	chr4:57976431	IGFBP7	0.46	6.14	0.36	3.25e-9	Parkinson's disease;
KIRP	cis	rs4776059	1.000	rs8026800	chr15:52933548	C/G	cg25063058	chr15:52860530	ARPP19	0.59	6.47	0.38	5.12e-10	Schizophrenia;
KIRP	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg08454507	chr17:78755406	RPTOR	-0.31	-4.99	-0.3	1.15e-6	Myopia (pathological);
KIRP	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	0.98	10.42	0.55	2.67e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.24	0.37	1.88e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9525927	0.570	rs7400099	chr13:44804480	G/T	cg19190762	chr13:44806055	NA	-0.47	-4.98	-0.3	1.19e-6	Dupuytren's disease;
KIRP	cis	rs10114408	0.918	rs4523325	chr9:96661833	G/A	cg14598338	chr9:96623480	NA	-0.32	-4.88	-0.3	1.95e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9420	0.528	rs10896632	chr11:57390302	G/A	cg19752551	chr11:57585705	CTNND1	-0.6	-8.5	-0.48	1.85e-15	Schizophrenia;
KIRP	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	trans	rs9650657	0.711	rs7007318	chr8:10592278	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.06	-0.36	5.19e-9	Neuroticism;
KIRP	cis	rs7011049	1.000	rs7011049	chr8:53834012	C/A	cg26025543	chr8:53854495	NA	0.72	7.58	0.44	6.99e-13	Systolic blood pressure;
KIRP	cis	rs9611198	0.846	rs5757731	chr22:39967785	C/G	cg03390717	chr22:39966585	CACNA1I	-0.35	-6.44	-0.38	6.17e-10	Schizophrenia;
KIRP	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg05360138	chr12:110035743	NA	0.48	5.41	0.33	1.52e-7	Neuroticism;
KIRP	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg21854759	chr1:92012499	NA	-0.47	-6.05	-0.36	5.32e-9	Breast cancer;
KIRP	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg27211696	chr2:191398769	TMEM194B	-0.7	-8.49	-0.48	1.99e-15	Diastolic blood pressure;
KIRP	trans	rs263156	0.903	rs263116	chr6:142885834	G/A	cg01789478	chr2:182545485	NEUROD1	-0.35	-6.02	-0.36	6.39e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25363886	chr4:71705620	GRSF1	0.5	6.05	0.36	5.24e-9	Parkinson's disease;
KIRP	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg17507749	chr15:85114479	UBE2QP1	0.82	9.15	0.5	2.23e-17	Schizophrenia;
KIRP	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg21174375	chr14:64681225	SYNE2	0.69	9.65	0.52	6.92e-19	Atrial fibrillation;
KIRP	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg00325661	chr8:49890786	NA	-0.49	-6.34	-0.37	1.1e-9	Sudden cardiac arrest;
KIRP	cis	rs9473924	0.632	rs9473936	chr6:50868888	T/A	cg03432817	chr6:50765336	NA	0.34	5.37	0.32	1.81e-7	Body mass index;
KIRP	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg04733989	chr22:42467013	NAGA	0.53	6.46	0.38	5.51e-10	Cognitive function;
KIRP	cis	rs17209837	1.000	rs45593435	chr7:87088772	A/G	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.89	15.44	0.7	4.65e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.61	7.82	0.45	1.52e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10782582	0.609	rs1251584	chr1:76424440	C/T	cg10523679	chr1:76189770	ACADM	0.4	5.4	0.33	1.6e-7	Daytime sleep phenotypes;
KIRP	trans	rs12043259	0.892	rs11240294	chr1:204824655	G/T	cg11485465	chr5:54518469	NA	0.42	6.56	0.39	3.22e-10	Addiction;
KIRP	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg06742321	chr12:123595122	PITPNM2	0.43	5.47	0.33	1.13e-7	Platelet count;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18544085	chr7:45026350	SNORA9;C7orf40	-0.47	-6.16	-0.37	3e-9	Myopia;
KIRP	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg20936604	chr3:58311152	NA	-0.67	-5.03	-0.31	9.56e-7	Cholesterol, total;
KIRP	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.86	12.57	0.63	2.53e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg08742575	chr21:47604166	C21orf56	-0.38	-4.94	-0.3	1.46e-6	Testicular germ cell tumor;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.78	0.4	8.91e-11	Educational attainment;
KIRP	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.51	-5.26	-0.32	3.07e-7	Corneal structure;
KIRP	cis	rs6725041	0.684	rs6755027	chr2:213053239	G/A	cg20637307	chr2:213403960	ERBB4	-0.37	-4.92	-0.3	1.61e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg01529538	chr14:23388837	RBM23	0.41	5.22	0.32	3.8e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg03465714	chr1:152285911	FLG	-0.41	-4.92	-0.3	1.57e-6	Atopic dermatitis;
KIRP	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg11650704	chr1:154556575	ADAR	-0.45	-5.55	-0.33	7.44e-8	Blood protein levels;
KIRP	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.49	0.33	1.01e-7	Height;
KIRP	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2278796	0.639	rs12139426	chr1:204970708	A/G	cg04862289	chr1:204966208	NFASC	-0.63	-8.66	-0.48	6.31e-16	Mean platelet volume;
KIRP	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg26850624	chr5:429559	AHRR	-0.38	-6.4	-0.38	7.99e-10	Cystic fibrosis severity;
KIRP	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	7.33	0.42	3.36e-12	Iron status biomarkers;
KIRP	cis	rs6752107	0.967	rs2880080	chr2:234154139	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.63	8.11	0.46	2.4e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg10223061	chr2:219282414	VIL1	-0.4	-6.45	-0.38	5.97e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17453880	0.700	rs34967219	chr5:152032949	C/T	cg12297329	chr5:152029980	NA	0.72	10.77	0.57	2.09e-22	Subjective well-being;
KIRP	cis	rs7909791	0.743	rs11596104	chr10:105623461	C/A	cg11005552	chr10:105648138	OBFC1	0.44	5.32	0.32	2.3e-7	White matter hyperintensity burden;
KIRP	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.16	-0.37	2.9e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg01721255	chr8:58191610	C8orf71	0.6	5.53	0.33	8.12e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17739167	0.569	rs6493015	chr15:42225260	G/T	cg20935245	chr15:42234343	EHD4	0.52	8.17	0.46	1.67e-14	Monocyte count;
KIRP	trans	rs587242	1.000	rs61786492	chr1:96904739	A/C	cg10631902	chr5:14652156	NA	0.52	6.08	0.36	4.61e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-0.97	-7.72	-0.44	2.88e-13	Mitochondrial DNA levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25564144	chr22:36135459	RBM9	0.4	6.16	0.37	2.9e-9	Survival in pancreatic cancer;
KIRP	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-7.81	-0.45	1.62e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.15	-0.46	1.86e-14	Response to antipsychotic treatment;
KIRP	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.61	7.89	0.45	1e-13	Height;
KIRP	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	11.04	0.58	2.73e-23	Total body bone mineral density;
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.57	-5.07	-0.31	7.72e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs2236918	1.000	rs1635511	chr1:242026172	C/T	cg17736920	chr1:242011382	EXO1	0.72	9.22	0.51	1.43e-17	Menopause (age at onset);
KIRP	cis	rs6725041	0.547	rs59096325	chr2:213203853	C/T	cg20637307	chr2:213403960	ERBB4	-0.48	-6.05	-0.36	5.36e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-7.66	-0.44	4.24e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.65	-0.34	4.43e-8	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24023618	chr6:114292459	HDAC2	0.59	6.93	0.4	3.68e-11	Smoking initiation;
KIRP	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-0.91	-12.52	-0.62	3.71e-28	Gut microbiota (bacterial taxa);
KIRP	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg06026331	chr20:60912101	LAMA5	0.78	9.29	0.51	8.23e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.82	12.18	0.61	5.01e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg15488143	chr7:128924101	AHCYL2	-0.47	-6.05	-0.36	5.47e-9	White matter hyperintensity burden;
KIRP	cis	rs9381040	0.869	rs9357347	chr6:41150591	A/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.59	-6.23	-0.37	2.03e-9	Alzheimer's disease (late onset);
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg22284058	chr8:142237359	SLC45A4	0.51	6.4	0.38	7.84e-10	Immature fraction of reticulocytes;
KIRP	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.73	7.39	0.43	2.32e-12	HIV-1 control;
KIRP	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-8.11	-0.46	2.41e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg19554555	chr3:13937349	NA	-0.45	-6.07	-0.36	4.69e-9	Ovarian reserve;
KIRP	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.9	-0.4	4.51e-11	Systolic blood pressure;
KIRP	cis	rs3741151	0.892	rs7107905	chr11:73061232	A/T	cg17517138	chr11:73019481	ARHGEF17	0.65	5.94	0.35	9.85e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg17077180	chr1:38461687	NA	0.52	7.38	0.43	2.39e-12	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.58	-6.81	-0.4	7.31e-11	Aortic root size;
KIRP	cis	rs8077577	1.000	rs2015336	chr17:18073610	A/G	cg18869244	chr17:18121946	NA	0.51	5.78	0.35	2.31e-8	Obesity-related traits;
KIRP	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.89e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2481665	0.617	rs12732781	chr1:62518459	T/C	cg18591186	chr1:62594603	INADL	-0.43	-6.05	-0.36	5.37e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg24476569	chr13:95954382	ABCC4	-0.49	-7.59	-0.44	6.54e-13	Blood metabolite levels;
KIRP	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	1.01	11.51	0.59	8.35e-25	Vitiligo;
KIRP	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1950626	0.750	rs35820579	chr14:101435515	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.85	0.4	5.79e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs829661	0.793	rs829565	chr2:30693733	T/C	cg10949345	chr2:30726833	LCLAT1	1.14	14.01	0.67	3.64e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-6.08	-0.36	4.52e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07551545	chr19:39466313	FBXO17	0.52	6.42	0.38	6.99e-10	Parkinson's disease;
KIRP	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.6	7.3	0.42	4.03e-12	Eosinophil percentage of white cells;
KIRP	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg11569703	chr11:65557185	OVOL1	0.64	11.73	0.6	1.53e-25	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
KIRP	cis	rs1923539	1.000	rs1923539	chr10:81694950	G/A	cg17004975	chr10:81743287	NA	0.46	5.75	0.34	2.64e-8	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.48	-6.26	-0.37	1.69e-9	Liver enzyme levels;
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg07402062	chr16:89894098	SPIRE2	0.34	7.16	0.42	9.2e-12	Vitiligo;
KIRP	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	1.0	8.01	0.45	4.5e-14	Arsenic metabolism;
KIRP	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg00405596	chr8:11794950	NA	0.45	5.58	0.34	6.42e-8	Retinal vascular caliber;
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.5	6.88	0.4	4.99e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg10932868	chr11:921992	NA	0.55	7.01	0.41	2.25e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7578199	0.886	rs7608676	chr2:242361889	C/T	cg01632474	chr2:242799312	PDCD1	0.38	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs12476592	0.602	rs7570031	chr2:63792265	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.93	-0.3	1.52e-6	Childhood ear infection;
KIRP	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.75	7.54	0.43	9.29e-13	Cannabis dependence symptom count;
KIRP	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.46	-5.28	-0.32	2.88e-7	Cardiac Troponin-T levels;
KIRP	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg07169764	chr2:136633963	MCM6	-0.52	-6.1	-0.36	4.16e-9	Mosquito bite size;
KIRP	cis	rs7188697	0.922	rs246196	chr16:58574253	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.11	0.31	6.47e-7	QT interval;
KIRP	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.76	11.08	0.58	2.0500000000000001e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg04998671	chr14:104000505	TRMT61A	-0.53	-6.05	-0.36	5.44e-9	Coronary artery disease;
KIRP	cis	rs2742417	1.000	rs2251954	chr3:45731784	A/G	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	3.01e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.83	-11.9	-0.6	4.32e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.95	0.57	5.5e-23	Cognitive test performance;
KIRP	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg02297831	chr4:17616191	MED28	0.56	7.04	0.41	1.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.18	-0.46	1.5e-14	Triglycerides;
KIRP	cis	rs4356932	1.000	rs6532156	chr4:76974351	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs6681460	0.625	rs12138066	chr1:67103816	C/T	cg13052034	chr1:66999238	SGIP1	0.36	5.15	0.31	5.24e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.65	-9.01	-0.5	6.05e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.71	9.75	0.53	3.34e-19	Red cell distribution width;
KIRP	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	10.69	0.56	3.73e-22	Blood protein levels;
KIRP	cis	rs7267005	1.000	rs111883395	chr20:34385510	T/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs61160187	0.510	rs4577661	chr5:60040467	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.35	-0.32	2.05e-7	Educational attainment (years of education);Educational attainment (college completion);
KIRP	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg06640241	chr16:89574553	SPG7	0.65	8.61	0.48	9.15e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs6545883	0.929	rs12713436	chr2:61691260	T/C	cg15711740	chr2:61764176	XPO1	-0.61	-7.94	-0.45	7.28e-14	Tuberculosis;
KIRP	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg09699651	chr6:150184138	LRP11	0.44	5.68	0.34	3.81e-8	Lung cancer;
KIRP	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	1.07	17.22	0.74	3.73e-44	Cognitive function;
KIRP	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-7.14	-0.41	1.04e-11	Bipolar disorder;
KIRP	cis	rs600231	0.613	rs1075692	chr11:65212447	A/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-5.56	-0.33	6.93e-8	Bone mineral density;
KIRP	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-6.65	-0.39	1.88e-10	Self-reported allergy;
KIRP	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.97	14.18	0.67	9e-34	Morning vs. evening chronotype;
KIRP	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18932078	chr1:2524107	MMEL1	0.43	5.85	0.35	1.58e-8	Ulcerative colitis;
KIRP	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.56	5.94	0.35	9.81e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs1823913	0.637	rs10931494	chr2:192164168	T/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.26	-0.37	1.67e-9	Obesity-related traits;
KIRP	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg12384639	chr17:618140	VPS53	0.5	6.16	0.37	2.92e-9	Prostate cancer;
KIRP	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg24110177	chr3:50126178	RBM5	-0.63	-7.95	-0.45	6.72e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg01988459	chr11:68622903	NA	-0.42	-5.82	-0.35	1.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.64	-6.8	-0.4	7.75e-11	Vitiligo;
KIRP	cis	rs2692947	0.702	rs4907291	chr2:96654605	T/G	cg23100626	chr2:96804247	ASTL	0.46	6.87	0.4	5.12e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02711726	chr17:80685570	FN3KRP	-0.49	-6.91	-0.4	4.12e-11	Glycated hemoglobin levels;
KIRP	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.73	-9.07	-0.5	3.81e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6688363	0.623	rs6686067	chr1:160102060	C/T	cg01023271	chr1:160068607	IGSF8	0.59	4.85	0.3	2.22e-6	Response to antipsychotic treatment;
KIRP	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg11350586	chr17:70115862	SOX9	0.37	5.38	0.32	1.72e-7	Thyroid hormone levels;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.49	6.13	0.36	3.49e-9	Longevity;Endometriosis;
KIRP	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.95	16.06	0.72	3.57e-40	Breast cancer;
KIRP	cis	rs7116495	1.000	rs6592453	chr11:71683231	C/G	cg26138937	chr11:71823887	C11orf51	-0.72	-5.79	-0.35	2.11e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg21360079	chr12:107162445	NA	0.68	9.44	0.52	3.01e-18	Heart rate;
KIRP	cis	rs7975161	0.638	rs4592489	chr12:104619699	C/T	cg25273343	chr12:104657179	TXNRD1	-0.55	-6.59	-0.39	2.71e-10	Toenail selenium levels;
KIRP	cis	rs9400467	0.506	rs12209969	chr6:111668167	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.05	17.55	0.75	2.84e-45	Multiple system atrophy;
KIRP	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.37	-4.91	-0.3	1.7e-6	Blood metabolite levels;
KIRP	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.35	0.42	2.91e-12	Height;
KIRP	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg21926883	chr2:100939477	LONRF2	-0.53	-7.1	-0.41	1.33e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.73	-0.34	2.88e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	1.000	rs6532111	chr4:76955914	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.44	5.35	0.32	1.99e-7	Blood protein levels;
KIRP	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg21775007	chr8:11205619	TDH	-0.52	-6.66	-0.39	1.81e-10	Neuroticism;
KIRP	cis	rs7301016	0.948	rs7303825	chr12:62921978	A/G	cg01804193	chr12:63026212	NA	0.54	5.64	0.34	4.68e-8	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.77	0.35	2.37e-8	Lung cancer;
KIRP	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg10932868	chr11:921992	NA	0.53	6.73	0.39	1.19e-10	Alzheimer's disease (late onset);
KIRP	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.73	7.34	0.42	3.08e-12	Uric acid levels;
KIRP	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg04691961	chr3:161091175	C3orf57	-0.38	-5.65	-0.34	4.53e-8	Morning vs. evening chronotype;
KIRP	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.74	7.37	0.43	2.55e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg09184832	chr6:79620586	NA	-0.44	-5.94	-0.35	9.52e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.95	0.41	3.24e-11	Triglycerides;
KIRP	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.62	8.25	0.47	9.41e-15	Schizophrenia;
KIRP	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg07777115	chr5:623756	CEP72	-0.52	-5.26	-0.32	3.19e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6580649	0.941	rs11612970	chr12:48451009	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7572644	0.699	rs4390729	chr2:28162861	T/C	cg27432699	chr2:27873401	GPN1	-0.44	-5.3	-0.32	2.57e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.56	-0.33	6.86e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs914615	0.508	rs4390169	chr1:155106054	A/G	cg02153340	chr1:155202674	NA	0.44	6.33	0.37	1.15e-9	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14169450	chr9:139327907	INPP5E	0.39	5.6	0.34	5.62e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg14092571	chr14:90743983	NA	0.44	5.77	0.35	2.36e-8	Mortality in heart failure;
KIRP	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.63	0.34	4.8e-8	Depressive symptoms;
KIRP	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.41	5.14	0.31	5.6e-7	IgG glycosylation;
KIRP	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	5.73	0.34	2.89e-8	Coronary artery disease;
KIRP	cis	rs2494663	0.610	rs72694297	chr1:154050760	C/T	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.98	-0.3	1.21e-6	Mean platelet volume;
KIRP	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.74	10.98	0.57	4.31e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.24e-8	Lung cancer;
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg21698718	chr17:80085957	CCDC57	0.34	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	trans	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg25042112	chr7:64838748	ZNF92	-0.59	-6.26	-0.37	1.67e-9	Pain;
KIRP	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06481639	chr22:41940642	POLR3H	0.65	7.11	0.41	1.23e-11	Vitiligo;
KIRP	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-17.33	-0.74	1.63e-44	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg14703610	chr5:56206110	C5orf35	0.48	6.79	0.4	8.34e-11	Coronary artery disease;
KIRP	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.53	-6.43	-0.38	6.58e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.58	7.58	0.44	7.14e-13	Lung disease severity in cystic fibrosis;
KIRP	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.94	-0.45	7.13e-14	Triglycerides;
KIRP	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.39	5.73	0.34	2.99e-8	Colorectal cancer;
KIRP	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg12559939	chr2:27858050	GPN1	-0.42	-5.25	-0.32	3.34e-7	Oral cavity cancer;
KIRP	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.68	4.95	0.3	1.38e-6	Childhood ear infection;
KIRP	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.04	0.36	5.7e-9	Alzheimer's disease (late onset);
KIRP	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg22508957	chr16:3507546	NAT15	0.43	5.2	0.31	4.21e-7	Body mass index (adult);
KIRP	cis	rs7572644	0.699	rs10171517	chr2:28090059	T/C	cg27432699	chr2:27873401	GPN1	-0.46	-5.3	-0.32	2.61e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg03388025	chr16:89894329	SPIRE2	-0.3	-5.49	-0.33	9.86e-8	Vitiligo;
KIRP	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg22633769	chr20:60982531	CABLES2	-0.41	-4.88	-0.3	1.94e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs3105593	0.933	rs7175532	chr15:50830043	A/G	cg05456662	chr15:50716270	USP8	0.38	4.92	0.3	1.62e-6	QT interval;
KIRP	cis	rs4776059	1.000	rs3751614	chr15:52901638	T/C	cg22715398	chr15:52968154	KIAA1370	-0.67	-8.24	-0.47	9.99e-15	Schizophrenia;
KIRP	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg06307176	chr5:131281290	NA	0.51	5.84	0.35	1.62e-8	Life satisfaction;
KIRP	cis	rs9324022	0.656	rs72698711	chr14:101167563	C/T	cg18089426	chr14:101175970	NA	0.69	6.17	0.37	2.8e-9	Plateletcrit;
KIRP	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-6.02	-0.36	6.16e-9	Aortic root size;
KIRP	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.82	-9.13	-0.5	2.61e-17	Blood pressure (smoking interaction);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10302505	chr8:128748092	MYC	0.56	7.47	0.43	1.39e-12	Myopia (pathological);
KIRP	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg24130564	chr14:104152367	KLC1	-0.53	-7.14	-0.41	1.03e-11	Body mass index;
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.82	11.0	0.57	3.67e-23	Height;
KIRP	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg08975724	chr8:8085496	FLJ10661	0.53	7.01	0.41	2.31e-11	Neuroticism;
KIRP	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.91	-14.58	-0.68	3.93e-35	Height;
KIRP	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	0.59	4.93	0.3	1.53e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg16586182	chr3:47516702	SCAP	0.63	8.15	0.46	1.88e-14	Colorectal cancer;
KIRP	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.41	0.33	1.47e-7	Lung cancer;
KIRP	cis	rs3789045	0.913	rs55678522	chr1:204573481	G/A	cg18185008	chr1:204589407	LRRN2	-0.65	-7.35	-0.42	2.91e-12	Educational attainment (college completion);
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.87	15.38	0.7	7.16e-38	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.8	10.84	0.57	1.21e-22	Systemic lupus erythematosus;
KIRP	cis	rs1712790	0.702	rs12287331	chr11:114627163	A/C	cg19465033	chr11:114479364	NA	0.39	5.17	0.31	4.82e-7	Urinary albumin excretion;
KIRP	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.66	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg08461772	chr7:95026248	PON3	0.4	5.67	0.34	3.92e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg00405596	chr8:11794950	NA	0.45	5.58	0.34	6.42e-8	Retinal vascular caliber;
KIRP	trans	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg06521331	chr12:34319734	NA	-0.62	-7.27	-0.42	4.86e-12	Bladder cancer;
KIRP	cis	rs7215564	0.908	rs34084509	chr17:78696577	C/A	cg06153925	chr17:78755379	RPTOR	0.43	5.93	0.35	1.03e-8	Myopia (pathological);
KIRP	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.93	-12.78	-0.63	4.86e-29	Cognitive function;
KIRP	cis	rs2071426	0.959	rs11188157	chr10:96817076	G/T	cg09036531	chr10:96991505	NA	-0.65	-7.18	-0.42	8.06e-12	Blood metabolite levels;
KIRP	cis	rs78487399	0.908	rs73925554	chr2:43810739	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.44	-0.33	1.32e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.2	-0.51	1.61e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg17420218	chr2:20102066	TTC32	0.95	6.16	0.37	3.01e-9	P wave terminal force;
KIRP	cis	rs2574704	0.532	rs2616553	chr3:11664812	T/C	cg07643000	chr3:11666825	VGLL4	-0.57	-7.11	-0.41	1.28e-11	Body mass index;
KIRP	cis	rs12731740	0.908	rs7512286	chr1:207993102	A/G	cg22525895	chr1:207977042	MIR29B2	-0.64	-4.9	-0.3	1.74e-6	Biomedical quantitative traits;
KIRP	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.38	0.43	2.5e-12	Aortic root size;
KIRP	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg04511125	chr2:88470314	THNSL2	-0.67	-8.89	-0.49	1.32e-16	Response to metformin (IC50);
KIRP	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg13334819	chr7:99746414	C7orf59	-0.5	-5.39	-0.32	1.65e-7	Coronary artery disease;
KIRP	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.24	-0.32	3.46e-7	Coronary artery disease;
KIRP	cis	rs7804356	0.906	rs12532796	chr7:26854828	A/G	cg03456212	chr7:26904342	SKAP2	-0.52	-4.88	-0.3	1.9e-6	Type 1 diabetes;
KIRP	cis	rs4862307	0.688	rs6552741	chr4:184990335	A/G	cg06737308	chr4:185021514	ENPP6	-0.55	-7.07	-0.41	1.59e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg19743168	chr1:23544995	NA	0.55	7.59	0.44	6.72e-13	Height;
KIRP	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.69	-0.44	3.6e-13	Type 2 diabetes;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.62	8.8	0.49	2.53e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs5995756	0.555	rs2413602	chr22:39989216	A/G	cg10455938	chr22:40058150	CACNA1I	0.37	5.22	0.32	3.77e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg25319279	chr11:5960081	NA	-0.58	-6.1	-0.36	4.12e-9	DNA methylation (variation);
KIRP	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.46	-0.33	1.15e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6832769	1.000	rs9684708	chr4:56430381	G/A	cg09317128	chr4:56265301	TMEM165	-0.55	-7.03	-0.41	2.02e-11	Personality dimensions;
KIRP	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-7.34	-0.42	3.12e-12	Electroencephalogram traits;
KIRP	cis	rs2230307	0.536	rs6677998	chr1:100461046	G/A	cg24955406	chr1:100503596	HIAT1	0.68	7.74	0.44	2.53e-13	Carotid intima media thickness;
KIRP	cis	rs1014246	1.000	rs2240706	chr10:118466297	C/G	cg14919929	chr10:118506882	NA	0.59	7.3	0.42	3.98e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs16976116	0.901	rs113679855	chr15:55502428	C/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg17507749	chr15:85114479	UBE2QP1	0.86	9.88	0.53	1.33e-19	Schizophrenia;
KIRP	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg00677455	chr12:58241039	CTDSP2	0.8	10.36	0.55	4.32e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.2	21.98	0.81	5.81e-60	Cognitive function;
KIRP	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg05673287	chr15:77411982	SGK269	-0.38	-4.88	-0.3	1.94e-6	Type 2 diabetes;
KIRP	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg07621104	chr11:117668040	DSCAML1	0.46	6.92	0.4	4.01e-11	Myopia;
KIRP	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20135002	chr11:47629003	NA	-0.44	-4.95	-0.3	1.37e-6	Subjective well-being;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18275142	chr2:131850909	FAM168B	0.53	6.66	0.39	1.8e-10	Parkinson's disease;
KIRP	cis	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg06307176	chr5:131281290	NA	0.52	5.61	0.34	5.5e-8	Life satisfaction;
KIRP	cis	rs10463554	0.727	rs34768	chr5:102491502	A/G	cg23492399	chr5:102201601	PAM	-0.54	-5.84	-0.35	1.67e-8	Parkinson's disease;
KIRP	cis	rs6565681	0.883	rs4523980	chr17:78347664	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.72	-7.14	-0.41	1.07e-11	Moyamoya disease;
KIRP	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.72	-6.02	-0.36	6.3e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg18209359	chr17:80159595	CCDC57	0.41	5.3	0.32	2.62e-7	Life satisfaction;
KIRP	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg02574844	chr11:5959923	NA	-0.57	-5.9	-0.35	1.18e-8	DNA methylation (variation);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg26851496	chr15:81293049	MESDC1	-0.46	-6.38	-0.38	8.56e-10	Myopia;
KIRP	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg23601095	chr6:26197514	HIST1H3D	0.67	6.46	0.38	5.49e-10	Gout;Renal underexcretion gout;
KIRP	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.41	-0.33	1.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg17554472	chr22:41940697	POLR3H	0.65	6.61	0.39	2.39e-10	Vitiligo;
KIRP	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.84	10.17	0.54	1.68e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg08132940	chr7:1081526	C7orf50	-0.69	-7.03	-0.41	2.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.31	-0.32	2.39e-7	Breast cancer;
KIRP	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21984481	chr17:79567631	NPLOC4	0.55	9.06	0.5	4.19e-17	Eye color traits;
KIRP	cis	rs9469913	0.799	rs2492859	chr6:34645266	A/G	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.28	-0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.74	10.49	0.56	1.67e-21	Platelet distribution width;
KIRP	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg08975724	chr8:8085496	FLJ10661	0.65	8.34	0.47	5.47e-15	Neuroticism;
KIRP	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.59	-6.83	-0.4	6.71e-11	Menarche (age at onset);
KIRP	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.57	8.39	0.47	3.95e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.59	6.9	0.4	4.28e-11	Obesity-related traits;
KIRP	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.6	8.09	0.46	2.68e-14	Bladder cancer;
KIRP	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.71	-0.44	3.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.88	-0.4	4.94e-11	Blood pressure;
KIRP	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.32	0.42	3.6e-12	Prudent dietary pattern;
KIRP	cis	rs17030434	0.953	rs10010787	chr4:154692059	G/A	cg14289246	chr4:154710475	SFRP2	-0.8	-9.65	-0.52	6.58e-19	Electrocardiographic conduction measures;
KIRP	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg16255804	chr6:135334527	HBS1L	-0.33	-5.18	-0.31	4.71e-7	Red blood cell count;
KIRP	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.41	-0.43	1.98e-12	Type 2 diabetes;
KIRP	cis	rs4776059	1.000	rs35372377	chr15:52882281	G/A	cg22715398	chr15:52968154	KIAA1370	-0.66	-7.87	-0.45	1.16e-13	Schizophrenia;
KIRP	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-10.12	-0.54	2.38e-20	Heart rate;
KIRP	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg05044414	chr3:183734942	ABCC5	0.38	5.86	0.35	1.45e-8	Anterior chamber depth;
KIRP	cis	rs6921919	0.583	rs6922374	chr6:28381272	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.46	6.61	0.39	2.32e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs13319406	0.546	rs16865077	chr3:189830554	C/T	cg03343083	chr3:189718843	LEPREL1	-0.58	-5.04	-0.31	9.04e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg25457927	chr22:38595422	NA	-0.28	-5.76	-0.34	2.53e-8	Cutaneous nevi;
KIRP	trans	rs62056376	0.736	rs885691	chr17:32641225	C/T	cg06688323	chr4:4858340	NA	-0.57	-6.16	-0.37	3.01e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.96	11.18	0.58	9.95e-24	Corneal astigmatism;
KIRP	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.93	11.47	0.59	1.15e-24	Migraine;
KIRP	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	8.04	0.46	3.67e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	12.4	0.62	9.6e-28	Bone mineral density;
KIRP	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg00791764	chr4:53727839	RASL11B	0.34	5.05	0.31	8.6e-7	Optic nerve measurement (cup area);
KIRP	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg25019033	chr10:957182	NA	-0.61	-6.76	-0.4	9.98e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	cg21523751	chr1:182988639	NA	0.36	5.09	0.31	7.19e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg08603382	chr10:743973	NA	-0.59	-8.89	-0.49	1.36e-16	Psychosis in Alzheimer's disease;
KIRP	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg21132104	chr15:45694354	SPATA5L1	0.59	7.28	0.42	4.51e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs925946	0.666	rs10835211	chr11:27701365	G/A	cg18117895	chr11:27722066	BDNF	-0.51	-4.95	-0.3	1.4e-6	Body mass index;Weight;
KIRP	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg08885076	chr2:99613938	TSGA10	-0.47	-7.88	-0.45	1.05e-13	Chronic sinus infection;
KIRP	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.68	-7.5	-0.43	1.15e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg26513180	chr16:89883248	FANCA	0.79	5.24	0.32	3.5e-7	Skin colour saturation;
KIRP	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs400736	0.930	rs226251	chr1:8024690	T/C	cg25007680	chr1:8021821	PARK7	0.64	8.4	0.47	3.66e-15	Response to antidepressants and depression;
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg01763666	chr17:80159506	CCDC57	0.36	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs7580658	0.509	rs12477653	chr2:127952081	C/T	cg16751203	chr2:127950803	CYP27C1	0.4	5.62	0.34	5.24e-8	Protein C levels;
KIRP	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg05938607	chr10:60274200	BICC1	0.4	9.86	0.53	1.5700000000000001e-19	Refractive error;
KIRP	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg18944383	chr4:111397179	ENPEP	0.44	7.06	0.41	1.66e-11	Coronary artery disease;
KIRP	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.55	-6.7	-0.39	1.44e-10	Smoking behavior;
KIRP	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg22903471	chr2:27725779	GCKR	-0.37	-5.0	-0.3	1.08e-6	Oral cavity cancer;
KIRP	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.0	0.41	2.39e-11	Tonsillectomy;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16875169	chr19:49617695	LIN7B	-0.55	-6.09	-0.36	4.36e-9	Menopause (age at onset);
KIRP	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.12	-0.5	2.7e-17	Personality dimensions;
KIRP	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-4.85	-0.3	2.22e-6	Platelet distribution width;
KIRP	cis	rs8014252	0.803	rs60860517	chr14:71029919	A/C	cg11204974	chr14:71022665	NA	-0.61	-6.39	-0.38	8.25e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs1978968	1.000	rs13057203	chr22:18446024	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6504622	0.905	rs3851785	chr17:45040147	T/G	cg24703533	chr17:45055318	NA	0.39	5.53	0.33	8.33e-8	Orofacial clefts;
KIRP	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-7.81	-0.45	1.68e-13	Total body bone mineral density;
KIRP	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.78	-10.45	-0.55	2.15e-21	Sudden cardiac arrest;
KIRP	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.23	0.42	6.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-1.08	-21.58	-0.81	1.11e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg25487775	chr2:162093969	NA	0.44	5.91	0.35	1.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs12780845	0.931	rs57751544	chr10:17245120	A/G	cg01003015	chr10:17271136	VIM	0.47	5.26	0.32	3.08e-7	Homocysteine levels;
KIRP	cis	rs4664293	0.967	rs7595639	chr2:160533044	A/G	cg08347373	chr2:160653686	CD302	-0.38	-5.86	-0.35	1.45e-8	Monocyte percentage of white cells;
KIRP	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg23748340	chr12:48592721	NA	-0.43	-4.94	-0.3	1.47e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.77	13.05	0.64	6.15e-30	Cancer;
KIRP	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs12200782	0.932	rs12202419	chr6:26465384	G/T	cg11502198	chr6:26597334	ABT1	0.74	5.22	0.32	3.81e-7	Small cell lung carcinoma;
KIRP	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.85	-0.63	3.04e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-1.1	-21.87	-0.81	1.32e-59	Height;
KIRP	cis	rs11645898	0.748	rs72791120	chr16:72224583	G/T	cg14768367	chr16:72042858	DHODH	-0.88	-9.62	-0.52	8.5e-19	Blood protein levels;
KIRP	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.89	10.62	0.56	6.21e-22	Response to antineoplastic agents;
KIRP	cis	rs2302729	0.578	rs10848682	chr12:2771756	C/G	cg19945202	chr12:2788847	CACNA1C	-0.75	-10.8	-0.57	1.59e-22	Sleep quality;
KIRP	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.87	-12.34	-0.62	1.47e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs4262150	0.508	rs10036750	chr5:151920039	T/C	cg12297329	chr5:152029980	NA	-0.68	-8.58	-0.48	1.09e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs57466243	1	rs57466243	chr17:27059666	T/A	cg21795637	chr17:26881880	PIGS	0.51	5.88	0.35	1.31e-8	Reticulocyte count;
KIRP	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.27	0.32	2.98e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.95	14.46	0.68	1e-34	Triglycerides;
KIRP	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.32	-5.79	-0.35	2.19e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs3857747	0.578	rs10256791	chr7:40364726	A/G	cg00420559	chr7:40367873	C7orf10	-0.46	-6.64	-0.39	1.94e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.38	-4.99	-0.3	1.13e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs7851660	0.809	rs7034249	chr9:100653821	C/T	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	5.25	0.32	3.21e-7	Renal cell carcinoma;
KIRP	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.24	0.58	6.2e-24	Alzheimer's disease;
KIRP	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05901451	chr6:126070800	HEY2	0.4	5.59	0.34	5.87e-8	Endometrial cancer;
KIRP	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.7	7.65	0.44	4.6e-13	Vitiligo;
KIRP	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg24110177	chr3:50126178	RBM5	0.51	6.37	0.38	9.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.54	-6.96	-0.41	2.99e-11	Longevity;
KIRP	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.03	-0.36	6.05e-9	Height;
KIRP	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg00122941	chr17:4613640	ARRB2	-0.68	-7.56	-0.43	7.76e-13	Lymphocyte counts;
KIRP	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	6.08	0.36	4.48e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11161853	chr3:67705044	SUCLG2	0.51	6.34	0.37	1.11e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg08280861	chr8:58055591	NA	0.51	4.92	0.3	1.62e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04816434	chr15:22945077	CYFIP1	0.47	6.22	0.37	2.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg23594656	chr7:65796392	TPST1	-0.44	-6.94	-0.4	3.44e-11	Aortic root size;
KIRP	cis	rs7301016	0.707	rs11174587	chr12:63052559	A/T	cg01804193	chr12:63026212	NA	0.53	5.74	0.34	2.83e-8	IgG glycosylation;
KIRP	cis	rs4650994	0.593	rs10753180	chr1:178520653	A/G	cg12486710	chr1:178512616	C1orf220	-0.25	-5.3	-0.32	2.61e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.58	8.47	0.48	2.27e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg09165964	chr15:75287851	SCAMP5	-1.08	-7.37	-0.43	2.64e-12	Blood trace element (Zn levels);
KIRP	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.81	-9.05	-0.5	4.45e-17	Coronary artery disease;
KIRP	cis	rs7033996	1.000	rs7037105	chr9:35928034	T/A	cg00918944	chr9:35908117	LOC158376	0.35	4.98	0.3	1.2e-6	Urate levels (BMI interaction);
KIRP	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg27631724	chr1:11040367	C1orf127	0.45	9.28	0.51	8.87e-18	Male-pattern baldness;
KIRP	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg21204522	chr6:27730016	NA	-0.63	-5.38	-0.32	1.71e-7	Lung cancer in ever smokers;
KIRP	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg11693508	chr17:37793320	STARD3	0.76	8.09	0.46	2.77e-14	Bipolar disorder;
KIRP	cis	rs4666002	0.789	rs6727215	chr2:27934731	G/A	cg05484376	chr2:27715224	FNDC4	-0.48	-5.84	-0.35	1.63e-8	Phospholipid levels (plasma);
KIRP	cis	rs8179	0.553	rs42235	chr7:92248076	C/T	cg15732164	chr7:92237376	CDK6	-0.51	-6.9	-0.4	4.48e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg08847533	chr14:75593920	NEK9	-0.53	-6.2	-0.37	2.31e-9	IgG glycosylation;
KIRP	cis	rs16976116	0.901	rs1061821	chr15:55496111	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.59	6.67	0.39	1.67e-10	Coronary artery disease;
KIRP	cis	rs10875746	0.556	rs4760619	chr12:48499931	A/T	cg24011408	chr12:48396354	COL2A1	-0.52	-5.23	-0.32	3.71e-7	Longevity (90 years and older);
KIRP	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.61	-0.44	5.94e-13	Life satisfaction;
KIRP	cis	rs7027203	0.514	rs2487018	chr9:96513919	G/A	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.88e-10	DNA methylation (variation);
KIRP	trans	rs800082	0.668	rs9856190	chr3:144288547	G/C	cg24215973	chr2:240111563	HDAC4	-0.57	-7.8	-0.45	1.82e-13	Smoking behavior;
KIRP	cis	rs6973256	0.569	rs6944149	chr7:133381365	A/C	cg10665199	chr7:133106180	EXOC4	0.51	6.29	0.37	1.47e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg13789015	chr9:136890014	NCRNA00094	0.83	10.38	0.55	3.69e-21	Platelet distribution width;
KIRP	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg04727924	chr7:799746	HEATR2	-0.75	-8.44	-0.47	2.84e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg19500275	chr17:80737654	TBCD	0.57	6.9	0.4	4.39e-11	Glycated hemoglobin levels;
KIRP	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg26850624	chr5:429559	AHRR	0.47	7.67	0.44	4.02e-13	Cystic fibrosis severity;
KIRP	cis	rs7590368	0.683	rs72779445	chr2:10957707	G/C	cg15705551	chr2:10952987	PDIA6	0.6	5.47	0.33	1.12e-7	Educational attainment (years of education);
KIRP	cis	rs1440410	0.798	rs10019249	chr4:144102193	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.26e-10	Ischemic stroke;
KIRP	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.51	-6.66	-0.39	1.75e-10	Aortic root size;
KIRP	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg18657303	chr4:1051139	NA	0.53	4.97	0.3	1.27e-6	Recombination rate (females);
KIRP	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	ch.11.42038R	chr11:967971	AP2A2	0.46	6.1	0.36	4.01e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6546043	0.710	rs13384707	chr2:63942056	A/C	cg16218715	chr2:63926253	NA	0.41	5.22	0.32	3.75e-7	Clozapine-induced agranulocytosis;
KIRP	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-5.32	-0.32	2.32e-7	Fear of minor pain;
KIRP	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs2671245	0.586	rs9436982	chr1:56141438	G/A	cg11523071	chr1:56160889	NA	0.42	6.35	0.38	1.03e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.55	9.05	0.5	4.54e-17	Huntington's disease progression;
KIRP	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.63	7.15	0.41	9.82e-12	Smoking initiation;
KIRP	trans	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg06521331	chr12:34319734	NA	-0.5	-6.23	-0.37	1.97e-9	Bladder cancer;
KIRP	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg00504896	chr12:9437009	LOC642846	-0.51	-6.33	-0.37	1.18e-9	Breast size;
KIRP	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05665937	chr4:1216051	CTBP1	0.51	7.21	0.42	6.7e-12	Obesity-related traits;
KIRP	cis	rs6840360	0.573	rs11099806	chr4:152269116	G/T	cg25486957	chr4:152246857	NA	-0.48	-6.01	-0.36	6.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg25338242	chr13:114786047	RASA3	0.42	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs367943	0.626	rs7718480	chr5:112704486	G/T	cg12552261	chr5:112820674	MCC	0.55	6.51	0.38	4.22e-10	Type 2 diabetes;
KIRP	cis	rs7246657	0.722	rs2927739	chr19:38149330	C/A	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg22437258	chr11:111473054	SIK2	-0.56	-6.23	-0.37	1.95e-9	Primary sclerosing cholangitis;
KIRP	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.44	-5.34	-0.32	2.17e-7	Iron status biomarkers;
KIRP	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	11.44	0.59	1.39e-24	Lung cancer in ever smokers;
KIRP	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.8	-0.63	4.37e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08822215	chr16:89438651	ANKRD11	0.47	6.23	0.37	2.03e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.93	16.27	0.72	6.71e-41	Mortality in heart failure;
KIRP	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.95	-16.45	-0.72	1.59e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs7215564	0.908	rs2316060	chr17:78663728	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-12.54	-0.62	3.19e-28	Prostate cancer;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03064793	chr4:187517847	FAT1	-0.45	-6.36	-0.38	9.52e-10	Select biomarker traits;
KIRP	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.67	7.93	0.45	7.64e-14	Blood metabolite levels;
KIRP	cis	rs1555895	0.576	rs4881537	chr10:848059	A/T	cg10017260	chr10:834428	NA	-0.39	-5.45	-0.33	1.2e-7	Survival in rectal cancer;
KIRP	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.83	11.27	0.58	4.86e-24	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.05e-8	Motion sickness;
KIRP	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.92	0.71	1.06e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.67	-7.92	-0.45	8.02e-14	Resting heart rate;
KIRP	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21545522	chr1:205238299	TMCC2	0.56	7.81	0.45	1.67e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7520050	0.931	rs6688365	chr1:46329884	G/C	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.61	-7.59	-0.44	6.75e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs16976116	0.901	rs1061874	chr15:55496287	A/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg16497661	chr14:103986332	CKB	0.46	6.07	0.36	4.73e-9	Body mass index;
KIRP	cis	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg07460842	chr6:66804631	NA	-0.57	-7.34	-0.42	3.12e-12	Blood trace element (Cu levels);
KIRP	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.85	12.23	0.61	3.45e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2274471	0.645	rs12237834	chr9:5093646	C/T	cg03390472	chr9:5043263	JAK2	-0.45	-5.12	-0.31	6.02e-7	Crohn's disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg05243042	chr16:23572271	UBFD1	-0.45	-6.53	-0.38	3.64e-10	Inflammatory biomarkers;
KIRP	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04374321	chr14:90722782	PSMC1	0.9	14.53	0.68	5.9e-35	Mortality in heart failure;
KIRP	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-8.66	-0.48	6.27e-16	Alzheimer's disease;
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg18183042	chr17:80733038	TBCD	-0.38	-5.04	-0.31	8.95e-7	Glycated hemoglobin levels;
KIRP	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs1519814	0.956	rs6469900	chr8:121117378	C/T	cg22335954	chr8:121166405	COL14A1	-0.59	-5.99	-0.36	7.34e-9	Breast cancer;
KIRP	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.92	-13.11	-0.64	3.77e-30	Ulcerative colitis;
KIRP	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.61	-8.39	-0.47	3.92e-15	Calcium levels;
KIRP	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg27121462	chr16:89883253	FANCA	-0.46	-5.56	-0.33	7.13e-8	Vitiligo;
KIRP	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.38	5.8	0.35	2.06e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg26134248	chr17:3907702	NA	-0.55	-8.11	-0.46	2.42e-14	Type 2 diabetes;
KIRP	cis	rs4740619	0.619	rs1359956	chr9:16044097	A/G	cg14451791	chr9:16040625	NA	-0.4	-5.29	-0.32	2.77e-7	Body mass index;
KIRP	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.79	9.59	0.52	1.03e-18	Corneal astigmatism;
KIRP	cis	rs9581857	0.547	rs75783371	chr13:28109961	T/C	cg22138327	chr13:27999177	GTF3A	0.71	5.71	0.34	3.21e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.38	-11.06	-0.58	2.36e-23	Plateletcrit;
KIRP	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg04310649	chr10:35416472	CREM	0.54	6.78	0.4	8.61e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.76	-8.85	-0.49	1.76e-16	Corneal astigmatism;
KIRP	trans	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg19694781	chr19:47549865	TMEM160	-0.52	-6.26	-0.37	1.66e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg10117171	chr1:25599238	RHD	-0.39	-5.24	-0.32	3.44e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs4774830	0.744	rs12438427	chr15:56295062	A/T	cg24530489	chr15:56299380	NA	0.82	5.6	0.34	5.78e-8	Delta-5 desaturase activity;
KIRP	cis	rs17739794	0.517	rs35856917	chr8:774395	C/G	cg01971667	chr8:817044	NA	-0.47	-5.63	-0.34	5.02e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs3857067	1.000	rs7682116	chr4:95002704	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.89e-7	QT interval;
KIRP	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.48	7.41	0.43	2.03e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg21699342	chr2:239360505	ASB1	0.48	5.66	0.34	4.16e-8	Multiple system atrophy;
KIRP	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg20607798	chr8:58055168	NA	0.63	5.59	0.34	6.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06850241	chr22:41845214	NA	-0.43	-4.96	-0.3	1.33e-6	Vitiligo;
KIRP	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.85	-9.85	-0.53	1.61e-19	Prostate cancer;
KIRP	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-8.69	-0.48	5.18e-16	Height;
KIRP	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-14.76	-0.69	9.41e-36	Primary sclerosing cholangitis;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02418899	chr7:31092589	ADCYAP1R1	0.55	6.19	0.37	2.53e-9	Lung cancer in ever smokers;
KIRP	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg02487422	chr3:49467188	NICN1	0.36	4.95	0.3	1.35e-6	Parkinson's disease;
KIRP	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.17	-0.42	8.92e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.45	-0.38	6.05e-10	Coronary artery disease;
KIRP	cis	rs3755132	1.000	rs3770460	chr2:15729268	C/T	cg12888861	chr2:15731646	DDX1	-0.38	-5.05	-0.31	8.63e-7	Wilms tumor;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.37	-5.64	-0.34	4.75e-8	Body mass index;
KIRP	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg01557791	chr16:72042693	DHODH	-0.41	-4.97	-0.3	1.27e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.57	8.08	0.46	2.96e-14	Mean corpuscular volume;
KIRP	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg25173405	chr17:45401733	C17orf57	-0.58	-7.38	-0.43	2.36e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg21184320	chr1:21044207	KIF17	0.48	6.74	0.39	1.14e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.59	-0.48	1.04e-15	Morning vs. evening chronotype;
KIRP	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg21419209	chr3:44054225	NA	-0.73	-9.07	-0.5	3.77e-17	Coronary artery disease;
KIRP	cis	rs8054556	0.787	rs12325539	chr16:30033633	T/C	cg06326092	chr16:30034487	C16orf92	0.44	6.01	0.36	6.66e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9290065	0.585	rs716779	chr3:160645428	G/A	cg04691961	chr3:161091175	C3orf57	0.35	5.14	0.31	5.64e-7	Kawasaki disease;
KIRP	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg18944383	chr4:111397179	ENPEP	0.49	8.14	0.46	1.98e-14	Coronary artery disease;
KIRP	cis	rs7561273	0.586	rs7580772	chr2:24357657	T/C	cg20701182	chr2:24300061	SF3B14	0.49	6.02	0.36	6.3e-9	Quantitative traits;
KIRP	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.54	-6.9	-0.4	4.35e-11	Blood metabolite levels;
KIRP	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg04691961	chr3:161091175	C3orf57	-0.46	-7.17	-0.42	8.58e-12	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11987759	chr7:65425863	GUSB	0.49	6.37	0.38	9.01e-10	Aortic root size;
KIRP	cis	rs13343954	0.825	rs2216595	chr19:33533292	C/T	cg17764715	chr19:33622953	WDR88	0.73	8.17	0.46	1.6e-14	Colorectal cancer;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14769373	chr6:40998127	UNC5CL	-0.61	-6.27	-0.37	1.65e-9	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg02551604	chr5:131831745	NA	0.43	5.38	0.32	1.73e-7	Asthma;
KIRP	cis	rs6959887	0.821	rs12536299	chr7:35302478	A/C	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2.05e-9	Birth weight;
KIRP	cis	rs10875746	0.951	rs2269935	chr12:48516464	G/T	cg20731937	chr12:48336164	NA	0.41	5.19	0.31	4.41e-7	Longevity (90 years and older);
KIRP	cis	rs1823913	0.561	rs55790432	chr2:192172448	T/C	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.65e-12	Obesity-related traits;
KIRP	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg24699146	chr1:24152579	HMGCL	-0.44	-5.46	-0.33	1.16e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.6	7.3	0.42	3.89e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.6	-8.52	-0.48	1.57e-15	Airway imaging phenotypes;
KIRP	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg07511934	chr16:89386912	ANKRD11	-0.43	-5.55	-0.33	7.45e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs13161895	1.000	rs13161895	chr5:179471201	C/T	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.89	-8.79	-0.49	2.69e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	9.2	0.51	1.54e-17	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg16736954	chr20:23401023	NAPB	0.61	4.97	0.3	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg00074818	chr8:8560427	CLDN23	-0.35	-5.18	-0.31	4.69e-7	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.27	0.42	4.75e-12	Retinal vascular caliber;
KIRP	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg13731523	chr4:3047190	NA	0.34	5.74	0.34	2.71e-8	Serum sulfate level;
KIRP	cis	rs7015630	0.779	rs13260987	chr8:90866354	G/A	cg18493113	chr8:90847772	NA	-0.44	-4.98	-0.3	1.2e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-8.49	-0.48	1.94e-15	Morning vs. evening chronotype;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg13390975	chr5:34915890	BRIX1;RAD1	0.9	6.05	0.36	5.24e-9	P wave terminal force;
KIRP	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.57	-4.95	-0.3	1.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8054556	1.000	rs4787489	chr16:29995880	G/A	cg06326092	chr16:30034487	C16orf92	0.35	4.88	0.3	1.92e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26617929	chr16:1858877	NA	-0.64	-5.51	-0.33	9.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.65	5.21	0.32	3.96e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.1	-0.54	2.74e-20	Neuroticism;
KIRP	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.76	9.4	0.51	3.82e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.03	18.78	0.77	2.11e-49	Schizophrenia;
KIRP	cis	rs6499755	0.965	rs9932163	chr16:55350683	C/A	cg05099576	chr16:55362342	IRX6	0.29	5.91	0.35	1.12e-8	Hypospadias;
KIRP	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.8	11.04	0.58	2.81e-23	Aortic root size;
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs8077577	0.895	rs1563373	chr17:18114228	G/A	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs16957091	0.909	rs12907826	chr15:43017081	G/A	cg24196017	chr15:43021976	CDAN1	-0.54	-7.25	-0.42	5.26e-12	MGMT methylation in smokers;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg25806613	chr6:131923464	MED23	0.4	6.22	0.37	2.07e-9	C-reactive protein;
KIRP	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg20060108	chr2:102954350	IL1RL1	-0.61	-5.52	-0.33	8.54e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7601312	0.967	rs6436791	chr2:229304051	C/T	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs9525927	0.570	rs9533797	chr13:44799368	A/C	cg19190762	chr13:44806055	NA	0.5	5.4	0.33	1.57e-7	Dupuytren's disease;
KIRP	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg22681709	chr2:178499509	PDE11A	-0.58	-6.84	-0.4	6.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg01872077	chr2:219646372	CYP27A1	0.38	4.92	0.3	1.58e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.26	-0.74	2.8e-44	Coronary artery disease;
KIRP	cis	rs6120849	0.901	rs6088739	chr20:33748724	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.09	0.36	4.39e-9	Protein C levels;
KIRP	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17467752	chr17:38218738	THRA	-0.57	-7.44	-0.43	1.63e-12	White blood cell count;
KIRP	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.74	-11.12	-0.58	1.5e-23	Hip circumference;
KIRP	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-0.78	-10.38	-0.55	3.59e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25072359	chr17:41440525	NA	0.5	6.32	0.37	1.24e-9	Menopause (age at onset);
KIRP	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg18190219	chr22:46762943	CELSR1	-0.72	-7.5	-0.43	1.19e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	1.22	11.22	0.58	7.18e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg02900749	chr2:68251473	NA	-1.1	-9.55	-0.52	1.38e-18	Pursuit maintenance gain;
KIRP	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.63	6.61	0.39	2.3e-10	Gut microbiome composition (summer);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23274123	chr1:229478617	C1orf96	0.51	7.44	0.43	1.73e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg24375607	chr4:120327624	NA	0.48	6.01	0.36	6.72e-9	Diastolic blood pressure;
KIRP	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.49	5.17	0.31	4.78e-7	Alzheimer's disease;
KIRP	cis	rs4481887	0.538	rs4916117	chr1:248387187	G/C	cg01631408	chr1:248437212	OR2T33	-0.45	-5.17	-0.31	4.85e-7	Common traits (Other);
KIRP	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.74	-0.39	1.13e-10	Response to antipsychotic treatment;
KIRP	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.79	-0.45	1.83e-13	Total cholesterol levels;
KIRP	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-5.26	-0.32	3.07e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.83	11.48	0.59	1.01e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06481639	chr22:41940642	POLR3H	-0.47	-5.8	-0.35	1.99e-8	Vitiligo;
KIRP	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-11.05	-0.58	2.64e-23	Monocyte percentage of white cells;
KIRP	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11645453	chr3:52864694	ITIH4	-0.33	-4.98	-0.3	1.21e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1035144	0.546	rs2215981	chr14:81444967	G/A	cg06600135	chr14:81408086	NA	-0.71	-9.35	-0.51	5.77e-18	Male sexual orientation;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.32	0.51	7.04e-18	Lung cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg01879488	chr11:35160498	CD44	0.53	7.06	0.41	1.7e-11	Asthma;
KIRP	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg13611997	chr5:233750	SDHA	-0.45	-5.42	-0.33	1.44e-7	Breast cancer;
KIRP	cis	rs8084125	0.935	rs7238336	chr18:74953540	A/G	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.18	-0.42	8.41e-12	Mood instability;
KIRP	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7570971	0.500	rs13413101	chr2:135859371	A/T	cg07169764	chr2:136633963	MCM6	0.51	5.87	0.35	1.39e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs3751972	0.911	rs2191058	chr17:26232917	T/C	cg18091275	chr17:26120155	NOS2	-0.53	-6.34	-0.37	1.11e-9	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs11030122	0.702	rs10835403	chr11:3990941	A/C	cg18678763	chr11:4115507	RRM1	0.41	5.24	0.32	3.4e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.49	6.18	0.37	2.57e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.43	-7.53	-0.43	9.86e-13	Refractive error;
KIRP	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.61	-0.59	3.93e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9398803	0.865	rs7738135	chr6:126829981	G/A	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.15e-10	Male-pattern baldness;
KIRP	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26306683	chr17:18585705	ZNF286B	0.6	7.53	0.43	9.6e-13	Educational attainment (years of education);
KIRP	cis	rs6782228	0.606	rs2712405	chr3:128332082	T/C	cg18648031	chr3:128330563	NA	0.27	5.64	0.34	4.66e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs6684514	1.000	rs10908500	chr1:156280671	A/T	cg16558208	chr1:156270281	VHLL	-0.43	-5.81	-0.35	1.92e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	14.47	0.68	9.49e-35	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24537383	chr1:64239633	ROR1	0.51	6.79	0.4	8.29e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4950322	0.570	rs72692948	chr1:146792016	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.45	7.63	0.44	5.22e-13	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.71	-10.89	-0.57	8.57e-23	Brugada syndrome;
KIRP	cis	rs1829883	0.666	rs1818865	chr5:98735420	T/G	cg08333243	chr5:99726346	NA	0.37	4.91	0.3	1.69e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-7.42	-0.43	1.9e-12	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	1.0	17.57	0.75	2.47e-45	Breast cancer;
KIRP	cis	rs12049351	0.774	rs10449250	chr1:229640771	A/G	cg11742688	chr1:229674241	ABCB10	-0.4	-6.42	-0.38	7.09e-10	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs1006703	0.544	rs8068362	chr17:3838757	T/C	cg06463185	chr17:3833770	ATP2A3	-0.65	-6.01	-0.36	6.66e-9	Glucose homeostasis traits;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg16315668	chr3:123676816	CCDC14	0.4	6.18	0.37	2.65e-9	Migraine with aura;
KIRP	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg23422044	chr7:1970798	MAD1L1	-0.67	-6.98	-0.41	2.81e-11	Bipolar disorder;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg16804899	chr2:27805965	ZNF512	0.46	6.18	0.37	2.71e-9	Inflammatory biomarkers;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.71	10.41	0.55	2.96e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	13.35	0.65	6.08e-31	Platelet count;
KIRP	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	1.08	9.79	0.53	2.5e-19	Pulse pressure;
KIRP	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.84	0.49	1.91e-16	Bipolar disorder;
KIRP	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg26441486	chr22:50317300	CRELD2	0.52	7.67	0.44	4.06e-13	Schizophrenia;
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.58	-5.32	-0.32	2.3e-7	Alzheimer's disease;
KIRP	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg16989719	chr2:238392110	NA	0.39	5.03	0.31	9.6e-7	Prostate cancer;
KIRP	cis	rs7011507	1.000	rs77883152	chr8:49180246	C/T	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7246967	0.673	rs4933036	chr19:22963069	C/A	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.62	-7.08	-0.41	1.46e-11	Mean platelet volume;
KIRP	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg24642439	chr20:33292090	TP53INP2	0.46	5.45	0.33	1.24e-7	Height;
KIRP	cis	rs12986413	0.624	rs2108825	chr19:2136515	T/C	cg09261902	chr19:2140048	AP3D1	0.71	11.76	0.6	1.22e-25	Height;
KIRP	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-10.93	-0.57	6.36e-23	Personality dimensions;
KIRP	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg16141378	chr3:129829833	LOC729375	-0.53	-6.64	-0.39	2.05e-10	Neuroticism;
KIRP	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.02	-0.31	9.7e-7	IgG glycosylation;
KIRP	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.56	7.54	0.43	9.28e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.84	8.01	0.45	4.57e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-7.03	-0.41	2.02e-11	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs301161	0.703	rs9931644	chr16:85827269	T/C	cg03249995	chr16:85819513	COX4NB	0.51	5.32	0.32	2.34e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01363902	chr12:121022439	NA	0.61	6.19	0.37	2.55e-9	Lung function (FEV1);
KIRP	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.63	-7.79	-0.44	1.88e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg09367891	chr1:107599246	PRMT6	0.7	10.16	0.54	1.78e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-1.0	-10.59	-0.56	7.8e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.73	-10.74	-0.57	2.56e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.76	7.87	0.45	1.15e-13	Resting heart rate;
KIRP	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg18154014	chr19:37997991	ZNF793	0.62	6.67	0.39	1.72e-10	Coronary artery calcification;
KIRP	trans	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Bladder cancer;
KIRP	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg00405596	chr8:11794950	NA	-0.41	-5.51	-0.33	9.12e-8	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.63	7.03	0.41	2.06e-11	Neutrophil percentage of white cells;
KIRP	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.13	0.36	3.43e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17376030	chr22:41985996	PMM1	0.79	8.22	0.46	1.18e-14	Vitiligo;
KIRP	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg08822215	chr16:89438651	ANKRD11	-0.51	-6.58	-0.39	2.77e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.38	0.59	2.27e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.89	-0.35	1.24e-8	Breast cancer;
KIRP	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	8.75	0.49	3.57e-16	Lymphocyte counts;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.73	11.32	0.59	3.32e-24	Menarche (age at onset);
KIRP	cis	rs7084402	0.934	rs1658471	chr10:60291911	A/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs6815814	0.861	rs17616434	chr4:38812876	T/C	cg06935464	chr4:38784597	TLR10	0.49	5.9	0.35	1.19e-8	Breast cancer;
KIRP	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-0.78	-11.33	-0.59	3.23e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs4523957	0.757	rs1002135	chr17:2097583	T/G	cg16513277	chr17:2031491	SMG6	-0.63	-9.14	-0.5	2.42e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs258892	0.895	rs34206264	chr5:72059806	C/G	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.69	10.54	0.56	1.1e-21	Lewy body disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10766792	chr22:42423479	WBP2NL	0.47	6.77	0.4	9.13e-11	Interleukin-4 levels;
KIRP	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.59	-6.83	-0.4	6.59e-11	Corneal astigmatism;
KIRP	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg21625330	chr8:9911636	MSRA	-0.41	-5.03	-0.31	9.59e-7	Neuroticism;
KIRP	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.26	-17.25	-0.74	2.96e-44	Breast cancer;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-1.08	-21.37	-0.81	5.39e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.71	7.07	0.41	1.64e-11	Chronic kidney disease;
KIRP	cis	rs9534288	0.619	rs6561292	chr13:46683560	G/T	cg15192986	chr13:46630673	CPB2	0.69	7.95	0.45	6.93e-14	Blood protein levels;
KIRP	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.65	7.4	0.43	2.09e-12	Vitiligo;
KIRP	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.35	-0.38	1.05e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.71	-7.04	-0.41	1.9e-11	Ulcerative colitis;
KIRP	cis	rs7656342	0.755	rs1320054	chr4:9870125	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.89	0.3	1.78e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.91	-0.3	1.64e-6	Breast cancer;
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.83	-0.45	1.46e-13	Mood instability;
KIRP	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	1.08	20.18	0.79	4.22e-54	Monocyte count;
KIRP	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.66	6.29	0.37	1.43e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-5.41	-0.33	1.47e-7	HDL cholesterol;
KIRP	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg18944383	chr4:111397179	ENPEP	0.42	6.78	0.4	8.89e-11	Coronary artery disease;
KIRP	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.61	-0.52	9.15e-19	Body mass index;
KIRP	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg04691961	chr3:161091175	C3orf57	-0.36	-5.16	-0.31	5.01e-7	Kawasaki disease;
KIRP	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg22431228	chr1:16359049	CLCNKA	0.47	6.34	0.37	1.06e-9	Dilated cardiomyopathy;
KIRP	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.36	-4.96	-0.3	1.29e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.05e-8	Skin colour saturation;
KIRP	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg22777020	chr22:31556080	RNF185	-0.5	-5.25	-0.32	3.32e-7	Colorectal cancer;
KIRP	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20887711	chr4:1340912	KIAA1530	-0.44	-5.46	-0.33	1.14e-7	Obesity-related traits;
KIRP	cis	rs35740288	0.752	rs11635956	chr15:86279928	G/A	cg10818794	chr15:86012489	AKAP13	-0.42	-4.96	-0.3	1.31e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17221829	0.733	rs72952851	chr11:89393495	A/G	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.04	-0.31	9.14e-7	Anxiety in major depressive disorder;
KIRP	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.59	-7.96	-0.45	6.27e-14	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg23594656	chr7:65796392	TPST1	-0.52	-8.11	-0.46	2.47e-14	Aortic root size;
KIRP	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.5	7.25	0.42	5.47e-12	Inattentive symptoms;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02179239	chr10:23002514	PIP4K2A	0.51	6.16	0.37	2.93e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg05315796	chr3:52349193	DNAH1	0.46	7.05	0.41	1.83e-11	Bipolar disorder;
KIRP	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.75	-0.34	2.58e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.68	10.5	0.56	1.51e-21	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8018808	0.902	rs176773	chr14:77882456	C/T	cg20045696	chr14:77926864	AHSA1	0.45	5.43	0.33	1.33e-7	Myeloid white cell count;
KIRP	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg15556689	chr8:8085844	FLJ10661	0.64	8.07	0.46	3.17e-14	Retinal vascular caliber;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.57	7.81	0.45	1.62e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4713118	0.824	rs9468223	chr6:27740666	C/T	cg20933634	chr6:27740509	NA	0.4	5.26	0.32	3.11e-7	Parkinson's disease;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.41	-5.12	-0.31	6.31e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05347473	chr6:146136440	FBXO30	0.65	9.53	0.52	1.59e-18	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03286617	chr2:154336401	RPRM	0.44	6.23	0.37	2.03e-9	Interleukin-4 levels;
KIRP	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.13	0.64	3.48e-30	Breast cancer;
KIRP	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg21395723	chr22:39101663	GTPBP1	0.4	5.28	0.32	2.89e-7	Menopause (age at onset);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg03283124	chr13:67802272	PCDH9	0.43	6.44	0.38	6.18e-10	Migraine with aura;
KIRP	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg20673091	chr1:2541236	MMEL1	-0.67	-10.09	-0.54	2.89e-20	Ulcerative colitis;
KIRP	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg00576331	chr11:65640516	EFEMP2	0.51	5.65	0.34	4.46e-8	Crohn's disease;
KIRP	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.87	0.49	1.55e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05901451	chr6:126070800	HEY2	-0.48	-6.73	-0.39	1.19e-10	Endometrial cancer;
KIRP	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg18016565	chr1:150552671	MCL1	-0.5	-7.55	-0.43	8.44e-13	Blood protein levels;
KIRP	trans	rs9315632	0.806	rs4643179	chr13:39515667	C/T	cg03725309	chr1:109757585	SARS	-0.67	-6.18	-0.37	2.68e-9	Metabolic syndrome;
KIRP	cis	rs13418717	1.000	rs10084325	chr2:127670496	G/A	cg25501666	chr2:127640322	NA	0.99	6.45	0.38	5.86e-10	Heart failure;
KIRP	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.2	-0.31	4.14e-7	Pulmonary function;
KIRP	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.64	6.84	0.4	6.28e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.36	-0.38	9.69e-10	Daytime sleep phenotypes;
KIRP	cis	rs2671245	0.586	rs9436522	chr1:56138040	T/G	cg11523071	chr1:56160889	NA	0.42	6.38	0.38	8.82e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.8	10.31	0.55	5.92e-21	Neutrophil percentage of white cells;
KIRP	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg02753203	chr1:228287806	NA	0.7	9.4	0.51	3.91e-18	Diastolic blood pressure;
KIRP	cis	rs8077889	0.750	rs231539	chr17:41942109	T/C	cg26893861	chr17:41843967	DUSP3	-0.86	-9.22	-0.51	1.42e-17	Triglycerides;
KIRP	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.88	13.73	0.66	3.08e-32	Coronary artery disease;
KIRP	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg20302533	chr7:39170763	POU6F2	0.26	5.18	0.31	4.7e-7	IgG glycosylation;
KIRP	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.31	-0.32	2.5e-7	Skin colour saturation;
KIRP	cis	rs2179367	0.887	rs2789488	chr6:149725290	A/G	cg16235748	chr6:149772707	ZC3H12D	0.29	4.9	0.3	1.77e-6	Dupuytren's disease;
KIRP	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg25358565	chr5:93447407	FAM172A	-0.56	-6.44	-0.38	6.26e-10	Diabetic retinopathy;
KIRP	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.54	6.79	0.4	8.4e-11	Eye color traits;
KIRP	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.93	-12.11	-0.61	8.8e-27	Platelet distribution width;
KIRP	cis	rs61867294	0.794	rs11596606	chr10:106672688	A/C	cg08495770	chr10:106400824	SORCS3	-0.37	-4.86	-0.3	2.13e-6	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05439814	chr16:24550834	RBBP6	0.45	6.07	0.36	4.89e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.7	10.83	0.57	1.28e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg00677455	chr12:58241039	CTDSP2	0.69	7.73	0.44	2.78e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg10169327	chr19:45448959	APOC2	0.33	4.98	0.3	1.18e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs5753618	0.504	rs9609329	chr22:31966313	A/C	cg02404636	chr22:31891804	SFI1	0.54	6.14	0.36	3.27e-9	Colorectal cancer;
KIRP	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.7	7.28	0.42	4.37e-12	Vitiligo;
KIRP	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.41	-0.38	7.33e-10	Neutrophil percentage of white cells;
KIRP	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.58	7.62	0.44	5.35e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg25600027	chr14:23388339	RBM23	-0.5	-6.22	-0.37	2.11e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg17691542	chr6:26056736	HIST1H1C	0.41	5.55	0.33	7.52e-8	Schizophrenia;
KIRP	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.69	-10.18	-0.54	1.54e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.03	-0.36	5.97e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg03128060	chr6:142623767	GPR126	-0.34	-4.95	-0.3	1.36e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs7665939	0.860	rs72709247	chr4:190126086	A/G	cg14840187	chr4:190284988	NA	-0.95	-7.13	-0.41	1.09e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.76	-5.32	-0.32	2.32e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.45	-5.68	-0.34	3.81e-8	Schizophrenia;
KIRP	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.78	-0.4	9e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg01028140	chr2:1542097	TPO	-0.52	-5.91	-0.35	1.16e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.36	-0.38	1e-9	Capecitabine sensitivity;
KIRP	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.92	14.04	0.67	2.77e-33	Menopause (age at onset);
KIRP	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.61	-9.78	-0.53	2.81e-19	Coronary artery disease;
KIRP	cis	rs7106204	0.514	rs1596280	chr11:24250853	T/C	ch.11.24196551F	chr11:24239977	NA	0.87	10.46	0.55	2.02e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs8018808	1.000	rs2193595	chr14:77845121	A/G	cg20045696	chr14:77926864	AHSA1	-0.42	-5.12	-0.31	6.09e-7	Myeloid white cell count;
KIRP	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg18806716	chr10:30721971	MAP3K8	0.37	5.68	0.34	3.74e-8	Inflammatory bowel disease;
KIRP	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg13334819	chr7:99746414	C7orf59	0.46	4.99	0.3	1.14e-6	Alzheimer's disease (late onset);
KIRP	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.25	-0.32	3.22e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.76	9.76	0.53	3.1e-19	Aortic root size;
KIRP	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	6.8	0.4	8.01e-11	Cognitive test performance;
KIRP	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	0.75	11.1	0.58	1.82e-23	Prudent dietary pattern;
KIRP	cis	rs3105593	1.000	rs2899462	chr15:50939254	C/A	cg05456662	chr15:50716270	USP8	0.42	4.96	0.3	1.31e-6	QT interval;
KIRP	cis	rs7084402	0.967	rs1658494	chr10:60280323	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.8	-9.45	-0.52	2.78e-18	Parkinson's disease;
KIRP	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.6	7.8	0.45	1.71e-13	Resting heart rate;
KIRP	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-8.4	-0.47	3.51e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.51	-0.33	9.15e-8	HDL cholesterol;
KIRP	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg11833968	chr6:79620685	NA	-0.44	-6.76	-0.4	9.78e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.45	0.33	1.25e-7	Breast cancer;
KIRP	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.85	-9.63	-0.52	7.62e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg05255149	chr17:80675120	FN3KRP	0.53	6.46	0.38	5.41e-10	Glycated hemoglobin levels;
KIRP	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg01689657	chr7:91764605	CYP51A1	0.4	5.7	0.34	3.38e-8	Breast cancer;
KIRP	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg05519781	chr21:40033154	ERG	0.62	8.48	0.48	2.16e-15	Coronary artery disease;
KIRP	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg07382826	chr16:28625726	SULT1A1	0.44	5.21	0.32	4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg18944383	chr4:111397179	ENPEP	0.61	11.05	0.58	2.53e-23	Height;
KIRP	cis	rs1355223	0.902	rs11819839	chr11:34715778	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.07	-0.31	7.88e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.82	-0.4	6.93e-11	Hemoglobin concentration;
KIRP	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.82	-8.46	-0.47	2.47e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg12559939	chr2:27858050	GPN1	0.42	5.36	0.32	1.95e-7	Oral cavity cancer;
KIRP	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg04132472	chr17:19861366	AKAP10	0.42	5.81	0.35	1.97e-8	Schizophrenia;
KIRP	cis	rs72960926	0.744	rs16884690	chr6:75046076	A/C	cg03266952	chr6:74778945	NA	-0.61	-5.38	-0.32	1.71e-7	Metabolite levels (MHPG);
KIRP	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg12756093	chr1:115239321	AMPD1	0.54	7.26	0.42	5.21e-12	Autism;
KIRP	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.53	6.31	0.37	1.28e-9	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08045063	chr3:43147672	C3orf39	0.45	6.31	0.37	1.32e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg08662619	chr6:150070041	PCMT1	0.32	4.94	0.3	1.46e-6	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02561205	chr11:65479380	KAT5	0.45	6.38	0.38	8.8e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg00204512	chr16:28754710	NA	0.47	6.14	0.36	3.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg12861170	chr19:19639553	YJEFN3	-0.45	-4.99	-0.3	1.14e-6	Bipolar disorder;
KIRP	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09419670	chr9:123605666	PSMD5;LOC253039	0.44	5.17	0.31	4.84e-7	Prostate-specific antigen levels;
KIRP	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.6	-0.34	5.77e-8	Breast cancer;
KIRP	cis	rs2742417	1.000	rs2742392	chr3:45757282	T/C	cg04837898	chr3:45731254	SACM1L	-0.36	-4.84	-0.3	2.25e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg03289416	chr15:75166202	SCAMP2	0.52	7.06	0.41	1.65e-11	Breast cancer;
KIRP	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg25801113	chr15:45476975	SHF	0.48	9.45	0.52	2.76e-18	Uric acid levels;
KIRP	cis	rs7236492	0.572	rs34712138	chr18:77179833	G/A	cg15644404	chr18:77186268	NFATC1	-1.01	-6.48	-0.38	4.95e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2625529	0.730	rs35713471	chr15:72459971	C/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.94	-0.35	9.86e-9	Red blood cell count;
KIRP	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.57	-7.25	-0.42	5.3e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.83	-13.49	-0.65	2.11e-31	Monocyte percentage of white cells;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg20087917	chr14:77924039	C14orf133;AHSA1	0.49	6.09	0.36	4.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.87	9.78	0.53	2.71e-19	Corneal astigmatism;
KIRP	cis	rs9311676	0.656	rs11130636	chr3:58380098	C/A	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19699211	chr17:71640848	SDK2	0.48	5.52	0.33	8.72e-8	Smoking initiation;
KIRP	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.81	-0.57	1.57e-22	Height;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10817093	chr4:174089402	GALNT7	0.57	6.2	0.37	2.4e-9	Lung cancer in ever smokers;
KIRP	trans	rs9650657	0.737	rs4841436	chr8:10594474	A/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.27	0.37	1.65e-9	Neuroticism;
KIRP	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.31	-5.3	-0.32	2.54e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.67	-7.8	-0.45	1.76e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.24	-24.12	-0.84	9.38e-67	Exhaled nitric oxide output;
KIRP	cis	rs5995756	0.761	rs6001639	chr22:40003309	C/A	cg03390717	chr22:39966585	CACNA1I	-0.27	-4.96	-0.3	1.32e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1440410	0.835	rs4582112	chr4:144111732	A/G	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs2741335	0.876	rs2565058	chr8:27337207	G/T	cg00421144	chr8:27336675	CHRNA2	-0.34	-5.31	-0.32	2.49e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	5.41	0.33	1.53e-7	Homoarginine levels;
KIRP	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.87	13.49	0.65	2.07e-31	Mean corpuscular volume;
KIRP	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.99	-0.45	5.06e-14	Mood instability;
KIRP	cis	rs1816752	0.875	rs8001187	chr13:24976414	G/A	cg22771759	chr13:24902376	NA	0.38	4.86	0.3	2.1e-6	Obesity-related traits;
KIRP	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg11993925	chr19:44307056	LYPD5	0.44	6.03	0.36	5.84e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg27129171	chr3:47204927	SETD2	-0.67	-9.13	-0.5	2.65e-17	Colorectal cancer;
KIRP	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.71	10.06	0.54	3.75e-20	Plateletcrit;Platelet count;
KIRP	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26850624	chr5:429559	AHRR	0.32	5.84	0.35	1.65e-8	Cystic fibrosis severity;
KIRP	cis	rs6663390	0.831	rs3754171	chr1:208086939	T/C	cg00387621	chr1:208086895	NA	0.64	5.73	0.34	2.87e-8	Facial morphology (factor 18);
KIRP	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.66	7.46	0.43	1.49e-12	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02386183	chr20:13619553	TASP1	-0.45	-6.25	-0.37	1.77e-9	Myopia;
KIRP	cis	rs9462846	0.725	rs9471969	chr6:42906384	G/T	cg13397359	chr6:42928475	GNMT	0.55	6.08	0.36	4.64e-9	Blood protein levels;
KIRP	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg02733842	chr7:1102375	C7orf50	-0.52	-4.91	-0.3	1.7e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs4006360	0.646	rs3843966	chr17:39250840	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.45	5.82	0.35	1.78e-8	Blood metabolite levels;
KIRP	trans	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg26043149	chr18:55253948	FECH	0.5	6.13	0.36	3.39e-9	Bone mineral density;
KIRP	cis	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg21546286	chr11:48923668	NA	-0.47	-5.97	-0.36	8.44e-9	HDL cholesterol;
KIRP	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg01214346	chr17:406501	NA	0.4	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs9840812	0.623	rs1145106	chr3:136111917	G/A	cg15507776	chr3:136538369	TMEM22	0.39	4.95	0.3	1.41e-6	Fibrinogen levels;
KIRP	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.84	-7.32	-0.42	3.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	11.28	0.58	4.59e-24	Calcium levels;
KIRP	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg04398451	chr17:18023971	MYO15A	0.67	8.96	0.5	8.2e-17	Total body bone mineral density;
KIRP	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07080220	chr10:102295463	HIF1AN	0.75	7.33	0.42	3.29e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.61	-7.64	-0.44	4.78e-13	Sudden cardiac arrest;
KIRP	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.73	10.27	0.55	7.79e-21	Psoriasis;
KIRP	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-6.12	-0.36	3.68e-9	Aortic root size;
KIRP	trans	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.67	-0.39	1.71e-10	Obesity-related traits;
KIRP	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.66	8.14	0.46	1.92e-14	Breast cancer;
KIRP	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14598338	chr9:96623480	NA	0.61	9.38	0.51	4.43e-18	DNA methylation (variation);
KIRP	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg11189052	chr15:85197271	WDR73	0.53	5.45	0.33	1.24e-7	Schizophrenia;
KIRP	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.58	-6.58	-0.39	2.78e-10	Diabetic retinopathy;
KIRP	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg25019033	chr10:957182	NA	-0.6	-7.14	-0.41	1.03e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg10755058	chr3:40428713	ENTPD3	0.49	6.65	0.39	1.9e-10	Renal cell carcinoma;
KIRP	cis	rs11997175	0.766	rs4442096	chr8:33691039	T/C	cg04338863	chr8:33670619	NA	0.4	5.3	0.32	2.55e-7	Body mass index;
KIRP	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	6.06	0.36	5.05e-9	Motion sickness;
KIRP	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-7.45	-0.43	1.59e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.64	-6.46	-0.38	5.64e-10	Blood trace element (Zn levels);
KIRP	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.65	-10.1	-0.54	2.79e-20	Menopause (age at onset);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02467765	chr4:78978708	FRAS1	0.46	6.18	0.37	2.69e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	1.0	10.15	0.54	1.88e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.65	8.92	0.49	1.1e-16	Mood instability;
KIRP	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.39	7.73	0.44	2.82e-13	Multiple system atrophy;
KIRP	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.11	0.31	6.41e-7	Tonsillectomy;
KIRP	cis	rs4812048	0.649	rs6070705	chr20:57625231	A/C	cg14073986	chr20:57617431	SLMO2	0.65	5.77	0.35	2.32e-8	Mean platelet volume;
KIRP	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.61	-7.98	-0.45	5.47e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.9	-15.5	-0.7	2.82e-38	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18364779	chr6:26104403	HIST1H4C	0.38	5.1	0.31	6.88e-7	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg10755058	chr3:40428713	ENTPD3	0.47	6.57	0.39	3.01e-10	Renal cell carcinoma;
KIRP	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.98	-13.93	-0.66	6.32e-33	Cognitive function;
KIRP	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.71	-8.52	-0.48	1.62e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg11605617	chr3:32612461	DYNC1LI1	0.52	6.35	0.38	1.02e-9	Inflammatory biomarkers;
KIRP	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	8.19	0.46	1.4e-14	Type 2 diabetes;
KIRP	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-4.85	-0.3	2.2e-6	Mean platelet volume;
KIRP	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg18306943	chr3:40428807	ENTPD3	0.44	5.7	0.34	3.44e-8	Renal cell carcinoma;
KIRP	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-0.76	-8.11	-0.46	2.41e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs828999	0.654	rs9325363	chr1:108713557	G/T	cg06207961	chr1:108661230	NA	-0.37	-4.94	-0.3	1.47e-6	Monocyte percentage of white cells;
KIRP	cis	rs7809615	1.000	rs7809615	chr7:99184778	G/T	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite ratios;
KIRP	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.46	5.7	0.34	3.42e-8	Common traits (Other);
KIRP	cis	rs6909279	0.933	rs4391273	chr6:151893073	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.48	-6.3	-0.37	1.4e-9	Bone mineral density;
KIRP	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.75	-0.34	2.57e-8	Schizophrenia;
KIRP	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.6	6.42	0.38	6.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg05255149	chr17:80675120	FN3KRP	0.49	5.45	0.33	1.23e-7	Glycated hemoglobin levels;
KIRP	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.72	8.69	0.48	5.33e-16	Tonsillectomy;
KIRP	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.81	11.64	0.6	3.17e-25	Breast cancer;
KIRP	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg03808351	chr9:123631620	PHF19	-0.39	-5.34	-0.32	2.07e-7	Rheumatoid arthritis;
KIRP	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.31	5.56	0.33	7.01e-8	Bipolar disorder;
KIRP	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg16329197	chr12:53359506	NA	-0.51	-9.57	-0.52	1.23e-18	Prostate cancer;
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.15	-0.5	2.26e-17	Triglycerides;
KIRP	trans	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg25214090	chr10:38739885	LOC399744	0.63	7.44	0.43	1.67e-12	Educational attainment;
KIRP	cis	rs17321999	1.000	rs7604484	chr2:30491556	T/G	cg05247661	chr2:30472410	LBH	0.65	6.76	0.4	9.98e-11	Systemic lupus erythematosus;
KIRP	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.89	-12.02	-0.61	1.76e-26	Cognitive function;
KIRP	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg19468946	chr17:37922297	IKZF3	-0.47	-6.95	-0.4	3.35e-11	Asthma;
KIRP	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-6.8	-0.4	7.91e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs9815354	1.000	rs9828398	chr3:41895893	C/T	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.59	0.44	6.49e-13	Coffee consumption (cups per day);
KIRP	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg12560992	chr17:57184187	TRIM37	0.46	5.39	0.33	1.64e-7	Cognitive test performance;
KIRP	cis	rs1165472	0.543	rs79113860	chr1:56148674	A/G	cg11523071	chr1:56160889	NA	-0.54	-6.35	-0.38	1.03e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.42	6.28	0.37	1.55e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	6.63	0.39	2.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg01689657	chr7:91764605	CYP51A1	0.44	6.46	0.38	5.65e-10	Breast cancer;
KIRP	cis	rs4938534	0.533	rs1806397	chr11:111264915	T/C	cg19126910	chr11:111249659	POU2AF1	0.46	5.54	0.33	7.57e-8	Primary biliary cholangitis;
KIRP	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.21	0.32	3.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.61	7.57	0.43	7.35e-13	Neutrophil percentage of white cells;
KIRP	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	cis	rs4006360	0.657	rs72625994	chr17:39253749	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.67	-0.52	5.93e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs981844	0.712	rs6535957	chr4:154749862	C/A	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2151522	0.724	rs6923071	chr6:127188502	C/T	cg21431617	chr6:127135037	NA	0.29	5.13	0.31	5.85e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg26207909	chr14:103986467	CKB	-0.43	-5.21	-0.32	3.96e-7	Coronary artery disease;
KIRP	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.59	-5.9	-0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.72	-8.75	-0.49	3.39e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg26207909	chr14:103986467	CKB	0.4	4.9	0.3	1.75e-6	Coronary artery disease;
KIRP	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.28	-0.37	1.53e-9	Neuroticism;
KIRP	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00495681	chr13:53174319	NA	0.44	6.11	0.36	3.97e-9	Lewy body disease;
KIRP	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.54	0.48	1.38e-15	Bipolar disorder;
KIRP	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.89	12.89	0.63	2.11e-29	Morning vs. evening chronotype;
KIRP	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.67	-0.44	3.89e-13	Total cholesterol levels;
KIRP	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg16482183	chr6:26056742	HIST1H1C	0.44	5.49	0.33	1.01e-7	Height;
KIRP	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg15841412	chr13:111365552	ING1	0.49	5.61	0.34	5.41e-8	Coronary artery disease;
KIRP	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02972257	chr16:68554789	NA	-0.73	-7.13	-0.41	1.12e-11	Ulcerative colitis;
KIRP	cis	rs732716	0.889	rs55637375	chr19:4386845	A/G	cg21720385	chr19:4455239	UBXN6	0.7	8.57	0.48	1.14e-15	Mean corpuscular volume;
KIRP	cis	rs9547996	0.879	rs61957472	chr13:38139860	C/A	cg13634560	chr13:38173852	POSTN	-0.4	-5.49	-0.33	9.78e-8	Diastolic blood pressure;
KIRP	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.54	-7.37	-0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4262150	0.690	rs72795379	chr5:151932354	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.0	-0.45	4.94e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg26134248	chr17:3907702	NA	-0.55	-8.18	-0.46	1.49e-14	Type 2 diabetes;
KIRP	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg23693289	chr8:27183097	PTK2B	0.48	6.01	0.36	6.61e-9	Neuroticism;
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.59	7.91	0.45	8.63e-14	Testicular germ cell tumor;
KIRP	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg02297831	chr4:17616191	MED28	0.54	6.84	0.4	6.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4006360	0.646	rs11868364	chr17:39236968	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	1.03e-19	Bipolar disorder and schizophrenia;
KIRP	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.92e-18	Morning vs. evening chronotype;
KIRP	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg12559939	chr2:27858050	GPN1	0.42	5.29	0.32	2.75e-7	Oral cavity cancer;
KIRP	cis	rs6545883	0.894	rs778148	chr2:61606866	G/A	cg15711740	chr2:61764176	XPO1	0.61	7.92	0.45	8.05e-14	Tuberculosis;
KIRP	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg04370829	chr17:406249	NA	0.39	4.86	0.3	2.11e-6	Prostate cancer;
KIRP	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07317755	chr3:57541798	PDE12	-0.49	-6.9	-0.4	4.37e-11	Interleukin-4 levels;
KIRP	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg23815491	chr16:72088622	HP	0.39	6.22	0.37	2.16e-9	Fibrinogen levels;
KIRP	cis	rs10214930	0.697	rs6462034	chr7:27628584	T/A	cg22168087	chr7:27702803	HIBADH	0.48	5.07	0.31	7.76e-7	Hypospadias;
KIRP	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.54	-6.76	-0.4	9.95e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs34526934	0.566	rs35563571	chr2:177044459	T/G	cg03152288	chr2:177042942	NA	-0.48	-5.85	-0.35	1.54e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.34	0.32	2.1e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg26338869	chr17:61819248	STRADA	0.54	6.41	0.38	7.37e-10	Prudent dietary pattern;
KIRP	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg15445000	chr17:37608096	MED1	0.48	5.65	0.34	4.41e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.95	15.52	0.7	2.41e-38	Testicular germ cell tumor;
KIRP	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg16989719	chr2:238392110	NA	-0.55	-6.0	-0.36	6.99e-9	Prostate cancer;
KIRP	cis	rs997295	1.000	rs35395156	chr15:67962763	A/G	cg24579218	chr15:68104479	NA	0.36	5.44	0.33	1.26e-7	Motion sickness;
KIRP	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.62	0.39	2.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg13660082	chr14:53194042	PSMC6	-0.72	-7.33	-0.42	3.39e-12	Alzheimer's disease (late onset);
KIRP	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.46	-9.95	-0.54	8.09e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg26318627	chr11:63887540	MACROD1	0.38	4.87	0.3	1.96e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2882667	0.898	rs10045761	chr5:138397289	G/A	cg04439458	chr5:138467593	SIL1	-0.43	-7.31	-0.42	3.75e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg13072238	chr3:49761600	GMPPB	-0.6	-5.93	-0.35	1.02e-8	Menarche (age at onset);
KIRP	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	7.88	0.45	1.06e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.33	0.37	1.15e-9	Aortic root size;
KIRP	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.01	-0.5	5.95e-17	Retinal vascular caliber;
KIRP	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.39e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8038465	0.550	rs11072431	chr15:73987642	T/A	cg15420318	chr15:73925796	NPTN	0.56	7.45	0.43	1.57e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.08	-0.5	3.66e-17	Rheumatoid arthritis;
KIRP	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.36	-5.21	-0.32	4.08e-7	Body mass index;
KIRP	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg12463550	chr7:65579703	CRCP	-0.43	-4.89	-0.3	1.79e-6	Aortic root size;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg11641102	chr8:27183873	PTK2B	0.46	5.98	0.36	7.77e-9	Neuroticism;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.81	-0.53	2.18e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg09788416	chr12:39539408	NA	0.39	5.27	0.32	3.03e-7	Morning vs. evening chronotype;
KIRP	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.62	6.28	0.37	1.55e-9	Axial length;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12630974	chr1:28655517	MED18	-0.51	-6.44	-0.38	6.29e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6539288	0.677	rs10735418	chr12:107343376	T/C	cg15890332	chr12:107067104	RFX4	0.37	6.06	0.36	5.14e-9	Total body bone mineral density;
KIRP	cis	rs4356932	0.967	rs4859591	chr4:76948578	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.45	5.15	0.31	5.46e-7	Schizophrenia;
KIRP	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	8.49	0.48	1.98e-15	Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.18	-0.31	4.62e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.78	-0.35	2.26e-8	Schizophrenia;
KIRP	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.61	7.66	0.44	4.37e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.39	-0.33	1.64e-7	Vitiligo;
KIRP	cis	rs7621025	0.500	rs9845460	chr3:136587117	A/G	cg15507776	chr3:136538369	TMEM22	0.78	10.81	0.57	1.58e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.54	0.33	7.73e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs15300	0.661	rs9505461	chr6:8495128	C/G	cg23788917	chr6:8435910	SLC35B3	0.96	5.42	0.33	1.41e-7	Pursuit maintenance gain;
KIRP	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg23307798	chr14:103986281	CKB	-0.51	-6.91	-0.4	4.15e-11	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.28	-0.37	1.49e-9	Neutrophil percentage of white cells;
KIRP	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-7.67	-0.44	3.93e-13	Neuroticism;
KIRP	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg09699651	chr6:150184138	LRP11	0.48	6.35	0.38	1.04e-9	Lung cancer;
KIRP	cis	rs526231	0.543	rs62362541	chr5:102322448	G/A	cg23492399	chr5:102201601	PAM	-0.5	-5.67	-0.34	4.03e-8	Primary biliary cholangitis;
KIRP	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg27121462	chr16:89883253	FANCA	0.51	6.81	0.4	7.41e-11	Vitiligo;
KIRP	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17735131	chr7:86849176	C7orf23	-0.36	-4.93	-0.3	1.5e-6	Interleukin-4 levels;
KIRP	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.56	6.53	0.38	3.67e-10	Type 2 diabetes;
KIRP	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.42	-5.64	-0.34	4.71e-8	Coronary artery disease;
KIRP	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg18404041	chr3:52824283	ITIH1	0.36	5.21	0.32	4.01e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg21546286	chr11:48923668	NA	-0.45	-5.44	-0.33	1.26e-7	HDL cholesterol;
KIRP	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.55	-5.52	-0.33	8.66e-8	Initial pursuit acceleration;
KIRP	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06505273	chr16:24850292	NA	0.37	5.04	0.31	9.18e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.02	-0.3	9.9e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4144743	0.702	rs16941733	chr17:45318289	T/C	cg18085866	chr17:45331354	ITGB3	-0.76	-6.44	-0.38	6.2e-10	Body mass index;
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.49	-0.43	1.24e-12	Platelet count;
KIRP	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg23301140	chr18:77439876	CTDP1	0.44	5.03	0.31	9.65e-7	Monocyte count;
KIRP	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.45	-5.72	-0.34	3.14e-8	Recombination rate (males);
KIRP	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.66	7.61	0.44	5.7e-13	Testicular germ cell tumor;
KIRP	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.44	-15.64	-0.71	9.48e-39	Schizophrenia;
KIRP	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.9e-8	Depression;
KIRP	cis	rs9826463	0.527	rs73238169	chr3:142099367	G/A	cg20824294	chr3:142316082	PLS1	0.49	6.93	0.4	3.75e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg02807482	chr3:125708958	NA	-0.51	-5.22	-0.32	3.81e-7	Blood pressure (smoking interaction);
KIRP	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg02070118	chr4:952128	TMEM175	0.6	5.05	0.31	8.48e-7	Parkinson's disease;
KIRP	cis	rs17033621	1.000	rs1524296	chr2:107622466	A/C	cg17818308	chr2:107502146	ST6GAL2	0.38	5.03	0.31	9.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg27211696	chr2:191398769	TMEM194B	0.75	9.13	0.5	2.59e-17	Diastolic blood pressure;
KIRP	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg10130564	chr11:117069849	TAGLN	0.43	5.34	0.32	2.13e-7	Blood protein levels;
KIRP	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.26	0.37	1.7e-9	Rheumatoid arthritis;
KIRP	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg20813462	chr7:2646259	IQCE	0.65	6.21	0.37	2.3e-9	Urate levels in lean individuals;
KIRP	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00938859	chr5:1591904	SDHAP3	0.59	7.95	0.45	6.54e-14	Breast cancer;
KIRP	cis	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg21546286	chr11:48923668	NA	-0.48	-6.14	-0.36	3.36e-9	HDL cholesterol;
KIRP	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08825223	chr10:81146193	ZCCHC24	0.45	6.23	0.37	1.98e-9	Pancreatic cancer;
KIRP	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.97	-15.05	-0.69	1.02e-36	Height;
KIRP	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg00262122	chr8:11665843	FDFT1	-0.42	-5.15	-0.31	5.3e-7	Triglycerides;
KIRP	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.77	10.16	0.54	1.73e-20	Aortic root size;
KIRP	trans	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.26	-0.37	1.72e-9	Obesity-related traits;
KIRP	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.55	5.9	0.35	1.22e-8	Type 2 diabetes;
KIRP	trans	rs2898857	0.524	rs2072153	chr17:47390014	C/G	cg11430096	chr6:110968061	CDK19	-0.53	-6.48	-0.38	4.89e-10	Cancer;
KIRP	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.29	-0.32	2.7e-7	Blood pressure;
KIRP	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-1.13	-21.08	-0.8	4.6e-57	Monocyte count;
KIRP	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.22e-15	Motion sickness;
KIRP	cis	rs8070740	0.617	rs1058119	chr17:5323125	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.6	7.99	0.45	5.15e-14	Menopause (age at onset);
KIRP	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg05519781	chr21:40033154	ERG	0.63	8.51	0.48	1.73e-15	Coronary artery disease;
KIRP	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25517755	chr10:38738941	LOC399744	0.47	6.13	0.36	3.43e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs62413470	1.000	rs17751143	chr6:55947368	C/T	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg24315340	chr6:146058215	EPM2A	-0.47	-5.89	-0.35	1.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11603020	0.950	rs28362949	chr11:57371911	G/T	cg16592121	chr10:133794558	BNIP3	-0.31	-6.03	-0.36	5.9e-9	Blood protein levels;
KIRP	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.7	9.12	0.5	2.84e-17	Renal function-related traits (BUN);
KIRP	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.88	10.41	0.55	2.81e-21	Gut microbiome composition (summer);
KIRP	cis	rs2236918	1.000	rs2995544	chr1:242020495	C/T	cg17736920	chr1:242011382	EXO1	0.75	9.86	0.53	1.54e-19	Menopause (age at onset);
KIRP	cis	rs12362504	0.504	rs67701335	chr11:9900140	C/T	cg07197493	chr11:9884649	SBF2	-0.43	-6.06	-0.36	5.21e-9	Survival in pancreatic cancer;
KIRP	cis	rs2273669	0.667	rs12205053	chr6:109338110	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.48	-0.38	4.91e-10	Prostate cancer;
KIRP	cis	rs11779988	0.545	rs448882	chr8:17794039	C/T	cg01800426	chr8:17659068	MTUS1	-0.6	-5.97	-0.36	8.16e-9	Breast cancer;
KIRP	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.17	0.46	1.6e-14	Retinal vascular caliber;
KIRP	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.49	-5.99	-0.36	7.25e-9	Coronary artery disease;
KIRP	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.69	-8.34	-0.47	5.38e-15	Aortic root size;
KIRP	cis	rs17286411	0.806	rs952159	chr16:71965915	G/A	cg04254540	chr16:71951199	KIAA0174	-0.41	-5.13	-0.31	5.77e-7	Blood protein levels;
KIRP	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg15445000	chr17:37608096	MED1	0.46	5.43	0.33	1.36e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17301259	0.509	rs3915188	chr7:88415956	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-5.38	-0.32	1.76e-7	Heschl's gyrus morphology;
KIRP	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg23422044	chr7:1970798	MAD1L1	-0.53	-7.13	-0.41	1.1e-11	Neuroticism;
KIRP	cis	rs6499755	0.768	rs31083	chr16:55362131	C/T	cg05099576	chr16:55362342	IRX6	0.33	6.71	0.39	1.33e-10	Hypospadias;
KIRP	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg05315796	chr3:52349193	DNAH1	0.4	6.34	0.37	1.1e-9	Electroencephalogram traits;
KIRP	cis	rs6893300	0.922	rs62406187	chr5:179185686	C/T	cg14593053	chr5:179126677	CANX	-0.56	-6.36	-0.38	9.95e-10	Resting heart rate;
KIRP	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs11603020	0.950	rs28362950	chr11:57371918	G/A	cg19752551	chr11:57585705	CTNND1	-0.67	-9.29	-0.51	8.79e-18	Blood protein levels;
KIRP	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.29	-0.55	6.9299999999999992e-21	Chronic sinus infection;
KIRP	cis	rs494562	0.730	rs9450271	chr6:86114837	G/A	cg21730993	chr6:86159210	NT5E	0.47	4.99	0.3	1.13e-6	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg00981070	chr1:2046702	PRKCZ	0.42	6.86	0.4	5.49e-11	Height;
KIRP	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.76	-10.1	-0.54	2.67e-20	Age at first birth;
KIRP	cis	rs4646312	0.555	rs2078748	chr22:19925414	A/G	cg07194846	chr22:19930177	COMT;TXNRD2	0.46	4.89	0.3	1.8e-6	Schizophrenia;
KIRP	cis	rs2535633	0.631	rs2710313	chr3:52969529	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.43	-5.72	-0.34	3.15e-8	Body mass index;
KIRP	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	14.35	0.68	2.41e-34	Gut microbiome composition (summer);
KIRP	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg02404636	chr22:31891804	SFI1	0.51	5.66	0.34	4.23e-8	Colorectal cancer;
KIRP	cis	rs4908760	0.811	rs301806	chr1:8482078	C/T	cg03610117	chr1:8450231	RERE	0.35	4.99	0.3	1.15e-6	Vitiligo;
KIRP	cis	rs4716602	0.898	rs1534001	chr7:156163283	A/G	cg04090468	chr7:156181990	NA	0.45	5.48	0.33	1.03e-7	Anti-saccade response;
KIRP	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg10360139	chr7:1886902	MAD1L1	-0.44	-4.86	-0.3	2.13e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.65	-9.27	-0.51	9.96e-18	Retinal vascular caliber;
KIRP	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg09165964	chr15:75287851	SCAMP5	-0.43	-5.47	-0.33	1.09e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-6.74	-0.39	1.12e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg10210624	chr19:58662595	ZNF329	0.6	5.55	0.33	7.38e-8	Cholesterol, total;
KIRP	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.96	12.24	0.62	3.27e-27	Homoarginine levels;
KIRP	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.39	0.38	8.2e-10	Major depressive disorder;
KIRP	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg02023728	chr11:77925099	USP35	0.33	5.27	0.32	2.93e-7	Testicular germ cell tumor;
KIRP	cis	rs34651	1.000	rs34651	chr5:72144005	C/T	cg21869765	chr5:72125136	TNPO1	0.72	5.29	0.32	2.67e-7	Mean platelet volume;
KIRP	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.65	-8.26	-0.47	9.13e-15	Age at first birth;
KIRP	cis	rs1978968	1.000	rs1076540	chr22:18439958	C/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.78	-0.44	2e-13	Presence of antiphospholipid antibodies;
KIRP	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.67	0.48	5.96e-16	Resting heart rate;
KIRP	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-7.73	-0.44	2.79e-13	Bipolar disorder;
KIRP	trans	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17712092	chr4:129076599	LARP1B	-0.81	-11.19	-0.58	8.92e-24	Eosinophil percentage of white cells;
KIRP	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.95	14.05	0.67	2.52e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	0.98	11.18	0.58	9.57e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs2625529	0.824	rs16956328	chr15:72143855	A/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.07	-0.36	4.82e-9	Red blood cell count;
KIRP	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg11569703	chr11:65557185	OVOL1	0.33	5.34	0.32	2.11e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	1.0	12.94	0.64	1.49e-29	Neutrophil percentage of white cells;
KIRP	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg18932078	chr1:2524107	MMEL1	0.45	6.38	0.38	8.78e-10	Ulcerative colitis;
KIRP	cis	rs9921338	0.961	rs8048768	chr16:11396840	T/C	cg00044050	chr16:11439710	C16orf75	-0.53	-5.64	-0.34	4.73e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs240764	0.717	rs239236	chr6:101099217	A/G	cg09795085	chr6:101329169	ASCC3	0.42	5.06	0.31	8.38e-7	Neuroticism;
KIRP	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.81	-12.85	-0.63	2.87e-29	Blood metabolite levels;
KIRP	cis	rs4716602	0.596	rs10949585	chr7:156165258	A/C	cg16983916	chr7:156159713	NA	-0.44	-5.6	-0.34	5.73e-8	Anti-saccade response;
KIRP	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.44	6.53	0.38	3.69e-10	Bipolar disorder;
KIRP	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-1.15	-10.73	-0.56	2.84e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.78	0.4	8.61e-11	Hypertriglyceridemia;
KIRP	trans	rs1864729	1.000	rs2053481	chr8:98278923	C/T	cg08679828	chr8:102218111	ZNF706	-0.7	-6.32	-0.37	1.24e-9	Estradiol plasma levels (breast cancer);
KIRP	cis	rs4006360	0.646	rs7501601	chr17:39293957	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.78	-0.44	1.99e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06544989	chr22:39130855	UNC84B	0.35	5.13	0.31	5.89e-7	Menopause (age at onset);
KIRP	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.09e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	9.03	0.5	5.17e-17	Prudent dietary pattern;
KIRP	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.37	5.03	0.31	9.61e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.9	-9.99	-0.54	6.12e-20	Gut microbiome composition (summer);
KIRP	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg21399703	chr1:247681439	NA	0.5	5.16	0.31	5.08e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	1.16	14.73	0.68	1.22e-35	Response to hepatitis C treatment;
KIRP	cis	rs11955398	0.692	rs897672	chr5:59996101	C/G	cg02684056	chr5:59996105	DEPDC1B	0.47	5.53	0.33	8.03e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11074362	chr9:19297575	DENND4C	-0.44	-6.86	-0.4	5.64e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg06307176	chr5:131281290	NA	0.57	6.41	0.38	7.48e-10	Life satisfaction;
KIRP	cis	rs78487399	0.710	rs17031133	chr2:43844833	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.6	5.51	0.33	9.04e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg09699651	chr6:150184138	LRP11	0.59	8.02	0.46	4.41e-14	Testicular germ cell tumor;
KIRP	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.5	-6.56	-0.39	3.09e-10	Schizophrenia;
KIRP	cis	rs7106204	0.514	rs7935857	chr11:24252420	C/T	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	1.01	13.26	0.65	1.22e-30	Alzheimer's disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg01135200	chr6:147524578	STXBP5	0.97	6.25	0.37	1.78e-9	P wave terminal force;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10123224	chr1:104068567	RNPC3	-0.55	-6.79	-0.4	8.17e-11	Interleukin-4 levels;
KIRP	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	1.01e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg04374321	chr14:90722782	PSMC1	-0.85	-11.93	-0.61	3.36e-26	Mortality in heart failure;
KIRP	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11645453	chr3:52864694	ITIH4	0.35	5.22	0.32	3.73e-7	Body mass index;
KIRP	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	5.28	0.32	2.77e-7	Renal cell carcinoma;
KIRP	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg10018233	chr7:150070692	REPIN1	0.71	8.62	0.48	8.47e-16	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2241685	0.850	rs10865521	chr2:1943691	C/G	cg22511877	chr2:1942942	MYT1L	-0.62	-6.06	-0.36	5.12e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs897080	0.515	rs786417	chr2:44688766	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.14	0.36	3.23e-9	Height;
KIRP	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg03060546	chr3:49711283	APEH	-0.59	-5.23	-0.32	3.64e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4926611	1.000	rs6697692	chr1:54116416	A/G	cg08927728	chr1:54059983	GLIS1	-0.27	-5.82	-0.35	1.85e-8	Hand grip strength;
KIRP	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25309564	chr22:51001381	C22orf41	-0.63	-7.5	-0.43	1.15e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.85	10.68	0.56	3.88e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.48	-0.43	1.32e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.86	-0.45	1.2e-13	Bipolar disorder;
KIRP	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg08761264	chr16:28874980	SH2B1	-0.46	-5.09	-0.31	7.09e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.55	7.93	0.45	7.5e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs684232	0.602	rs34167561	chr17:509268	G/A	cg15660573	chr17:549704	VPS53	-0.96	-15.1	-0.69	6.96e-37	Prostate cancer;
KIRP	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.75	8.59	0.48	9.97e-16	High light scatter reticulocyte count;
KIRP	trans	rs12517041	0.938	rs10045757	chr5:23270469	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.59	-6.31	-0.37	1.31e-9	Calcium levels;
KIRP	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg08999081	chr20:33150536	PIGU	0.46	4.91	0.3	1.66e-6	Protein C levels;
KIRP	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg04226714	chr8:49833948	SNAI2	-0.47	-6.6	-0.39	2.51e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.57	7.41	0.43	1.98e-12	Schizophrenia;
KIRP	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg02725872	chr8:58115012	NA	-0.46	-5.35	-0.32	1.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13064049	chr1:38478702	UTP11L	0.41	6.02	0.36	6.29e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	7.13	0.41	1.1e-11	Coronary artery disease;
KIRP	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.95e-7	Red blood cell count;
KIRP	cis	rs7760535	0.597	rs9320368	chr6:111904737	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.58	-7.55	-0.43	8.25e-13	Metabolic traits;
KIRP	trans	rs6601327	0.641	rs10111376	chr8:9615470	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.63	0.39	2.08e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	5.62	0.34	5.19e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg21684588	chr1:67600265	NA	0.41	4.86	0.3	2.12e-6	Psoriasis;
KIRP	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg24315340	chr6:146058215	EPM2A	0.42	5.29	0.32	2.64e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.53	5.65	0.34	4.52e-8	Parkinson's disease;
KIRP	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.66	9.03	0.5	5.06e-17	Personality dimensions;
KIRP	cis	rs2274273	0.840	rs10467798	chr14:55724927	C/T	cg04306507	chr14:55594613	LGALS3	0.54	8.34	0.47	5.26e-15	Protein biomarker;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg12939390	chr2:45795647	SRBD1	0.37	6.03	0.36	6.1e-9	Migraine with aura;
KIRP	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg06795125	chr2:108905320	SULT1C2	-0.5	-8.67	-0.48	6.09e-16	Blood pressure;
KIRP	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.6	-0.34	5.61e-8	Blood metabolite levels;
KIRP	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.48	5.18	0.31	4.55e-7	Subjective well-being;
KIRP	cis	rs509477	1.000	rs7240845	chr18:32574960	G/C	cg23791764	chr18:32556832	MAPRE2	-0.49	-6.09	-0.36	4.21e-9	Cerebrospinal fluid AB1-42 levels;
KIRP	cis	rs2235544	0.579	rs1537322	chr1:54482306	G/T	cg25741118	chr1:54482237	LDLRAD1	-0.32	-6.16	-0.37	2.95e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.75	11.81	0.6	8.79e-26	Resting heart rate;
KIRP	cis	rs580438	0.509	rs13066607	chr3:13438830	A/G	cg10657019	chr3:13328039	NA	-0.45	-5.71	-0.34	3.25e-8	Myringotomy;
KIRP	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.19	13.83	0.66	1.44e-32	Sexual dysfunction (female);
KIRP	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-7.02	-0.41	2.13e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg02151108	chr14:50098012	C14orf104	-0.51	-7.07	-0.41	1.56e-11	Carotid intima media thickness;
KIRP	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg23594656	chr7:65796392	TPST1	0.48	7.56	0.43	8.07e-13	Aortic root size;
KIRP	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-13.54	-0.65	1.43e-31	Chronic sinus infection;
KIRP	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.56	-6.83	-0.4	6.68e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs8084125	0.765	rs72981157	chr18:74944238	A/G	cg15443732	chr18:74961078	GALR1	0.51	4.91	0.3	1.65e-6	Obesity-related traits;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.73	10.4	0.55	3.11e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05711023	chr3:156511814	NA	0.41	6.23	0.37	2e-9	C-reactive protein;
KIRP	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.91	-15.79	-0.71	2.94e-39	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.47	-6.29	-0.37	1.45e-9	Obesity-related traits;
KIRP	trans	rs587242	1.000	rs12744063	chr1:96898431	T/C	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.85	-12.43	-0.62	7.72e-28	Height;
KIRP	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.54	7.97	0.45	5.77e-14	Body mass index;
KIRP	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg05973401	chr12:123451056	ABCB9	0.57	6.53	0.38	3.76e-10	Neutrophil percentage of white cells;
KIRP	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg12435725	chr3:58293450	RPP14	-0.5	-5.32	-0.32	2.35e-7	Cholesterol, total;
KIRP	cis	rs629922	0.507	rs561099	chr11:114054163	C/A	cg01914181	chr11:114070210	ZBTB16	-0.53	-5.43	-0.33	1.33e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg26681399	chr22:41777847	TEF	0.54	5.14	0.31	5.59e-7	Vitiligo;
KIRP	cis	rs1978968	0.763	rs9605474	chr22:18463297	A/G	cg02610425	chr22:18483192	MICAL3	0.37	5.6	0.34	5.79e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11794265	chr5:132073270	KIF3A	0.51	6.37	0.38	9.16e-10	Parkinson's disease;
KIRP	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg00784671	chr22:46762841	CELSR1	-0.87	-8.4	-0.47	3.51e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg08132940	chr7:1081526	C7orf50	-0.63	-6.84	-0.4	6.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4356932	0.691	rs6532078	chr4:76920809	A/G	cg19388996	chr4:76862389	NAAA	0.43	5.48	0.33	1.06e-7	Blood protein levels;
KIRP	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg22800045	chr5:56110881	MAP3K1	0.8	8.48	0.48	2.13e-15	Initial pursuit acceleration;
KIRP	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	cg21523751	chr1:182988639	NA	0.44	6.95	0.41	3.2e-11	Colorectal cancer;
KIRP	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg15934090	chr1:100435551	SLC35A3	0.52	6.46	0.38	5.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1950626	0.623	rs66722144	chr14:101457434	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.53	6.14	0.36	3.37e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-12.19	-0.61	4.9e-27	Lymphocyte percentage of white cells;
KIRP	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg24416660	chr17:73865998	NA	-0.43	-5.81	-0.35	1.9e-8	Psoriasis;
KIRP	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-8.04	-0.46	3.79e-14	Personality dimensions;
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg07984980	chr16:89898383	SPIRE2	0.42	5.17	0.31	4.79e-7	Vitiligo;
KIRP	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.41	-0.59	1.75e-24	Monocyte count;
KIRP	cis	rs4789452	0.538	rs2627207	chr17:75353160	A/G	cg01320579	chr17:75405842	SEPT9	-0.34	-5.62	-0.34	5.07e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs17023223	0.537	rs10802073	chr1:119604655	T/C	cg05756136	chr1:119680316	WARS2	-0.54	-7.17	-0.42	8.73e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg00530320	chr1:46809349	NSUN4	0.42	5.26	0.32	3.11e-7	Menopause (age at onset);
KIRP	trans	rs982100	1.000	rs1559524	chr2:118421277	G/A	cg09538006	chr2:3337909	TSSC1	0.68	6.44	0.38	6.12e-10	Alzheimer disease and age of onset;
KIRP	cis	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg06521331	chr12:34319734	NA	-0.63	-7.59	-0.44	6.56e-13	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.67	-0.48	6.01e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.65	-9.11	-0.5	2.87e-17	Paraoxonase activity;
KIRP	cis	rs4936894	0.500	rs10893166	chr11:124077445	C/T	cg27160556	chr11:124181099	OR8D1	-0.38	-5.67	-0.34	4.07e-8	Aging (time to death);
KIRP	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.61	0.48	9e-16	Retinal vascular caliber;
KIRP	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg13010199	chr12:38710504	ALG10B	-0.53	-6.77	-0.4	9.2e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.18	0.42	8.22e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7999699	0.756	rs6650375	chr13:48303559	A/T	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg25922239	chr6:33757077	LEMD2	0.59	7.54	0.43	9.05e-13	Crohn's disease;
KIRP	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg00792783	chr2:198669748	PLCL1	-0.47	-5.23	-0.32	3.62e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg15556689	chr8:8085844	FLJ10661	0.56	7.25	0.42	5.25e-12	Systolic blood pressure;
KIRP	cis	rs9962915	1.000	rs1785417	chr18:5599479	T/C	cg12967001	chr18:5544089	EPB41L3	-0.45	-5.78	-0.35	2.3e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs745080	0.698	rs1076815	chr14:53015936	A/G	cg23333723	chr14:53022898	GPR137C	-0.42	-5.84	-0.35	1.62e-8	Orofacial clefts;
KIRP	cis	rs3784262	0.669	rs4646602	chr15:58294757	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.93	-0.3	1.55e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg07382826	chr16:28625726	SULT1A1	0.48	5.65	0.34	4.51e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.46	8.62	0.48	8.39e-16	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.52	-6.55	-0.39	3.32e-10	Alzheimer's disease (late onset);
KIRP	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg03146154	chr1:46216737	IPP	0.56	5.87	0.35	1.4e-8	Platelet count;
KIRP	cis	rs735539	0.556	rs9552277	chr13:21352287	T/A	cg04906043	chr13:21280425	IL17D	-0.43	-5.06	-0.31	8.07e-7	Dental caries;
KIRP	cis	rs9309473	0.528	rs11126395	chr2:73564964	A/G	cg20560298	chr2:73613845	ALMS1	-0.51	-6.19	-0.37	2.48e-9	Metabolite levels;
KIRP	cis	rs6466055	0.661	rs6955133	chr7:104915625	A/G	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs9488822	0.585	rs195522	chr6:116245016	G/A	cg18764771	chr6:116381957	FRK	0.19	4.92	0.3	1.61e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg10189774	chr4:17578691	LAP3	0.54	6.81	0.4	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.76	10.35	0.55	4.62e-21	Blood metabolite levels;
KIRP	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg21132104	chr15:45694354	SPATA5L1	0.77	9.73	0.53	3.73e-19	Homoarginine levels;
KIRP	cis	rs17030434	1.000	rs75083896	chr4:154719082	A/G	cg14289246	chr4:154710475	SFRP2	-0.8	-9.61	-0.52	8.78e-19	Electrocardiographic conduction measures;
KIRP	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg21427119	chr20:30132790	HM13	-0.55	-6.53	-0.38	3.69e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.87	0.35	1.38e-8	Motion sickness;
KIRP	cis	rs56399783	0.901	rs73033403	chr7:2877941	G/A	cg19731401	chr7:2775893	GNA12	0.7	6.79	0.4	8.44e-11	Childhood ear infection;
KIRP	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg24315340	chr6:146058215	EPM2A	-0.39	-4.87	-0.3	2.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.24	0.42	5.71e-12	Mean platelet volume;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg05562828	chr17:3906858	NA	0.72	14.37	0.68	2.05e-34	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22976360	chr2:70528671	FAM136A	0.54	6.94	0.4	3.38e-11	Parkinson's disease;
KIRP	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.76	-0.4	1.01e-10	Response to antipsychotic treatment;
KIRP	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26314531	chr2:26401878	FAM59B	0.49	4.96	0.3	1.33e-6	Gut microbiome composition (summer);
KIRP	cis	rs714515	0.934	rs9425587	chr1:172351809	A/C	cg01573306	chr1:172330400	DNM3	0.46	6.01	0.36	6.49e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg06212747	chr3:49208901	KLHDC8B	0.51	5.18	0.31	4.62e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10168434	chr2:71295172	NAGK	0.47	6.17	0.37	2.77e-9	Parkinson's disease;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.53	6.5	0.38	4.46e-10	Menarche (age at onset);
KIRP	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06481639	chr22:41940642	POLR3H	-0.65	-6.84	-0.4	6.39e-11	Vitiligo;
KIRP	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg11503966	chr20:62272292	STMN3	0.34	5.0	0.3	1.09e-6	Prostate cancer;
KIRP	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12580194	0.593	rs61957885	chr12:55720876	C/G	cg19537932	chr12:55886519	OR6C68	-0.47	-6.07	-0.36	4.76e-9	Cancer;
KIRP	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.58	7.73	0.44	2.68e-13	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16268051	chr1:22379390	CDC42	0.48	6.25	0.37	1.83e-9	Parkinson's disease;
KIRP	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg16586182	chr3:47516702	SCAP	-0.84	-11.82	-0.6	7.8e-26	Colorectal cancer;
KIRP	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.56	7.51	0.43	1.1e-12	Methadone dose in opioid dependence;
KIRP	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.74	6.78	0.4	8.66e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.61	8.75	0.49	3.57e-16	Resting heart rate;
KIRP	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg00255919	chr5:131827918	IRF1	0.28	5.8	0.35	2.03e-8	Asthma (sex interaction);
KIRP	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.28	7.44	0.43	1.72e-12	Primary biliary cholangitis;
KIRP	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26378065	chr17:18585709	ZNF286B	0.54	6.77	0.4	9.51e-11	Educational attainment (years of education);
KIRP	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.89	-11.21	-0.58	7.92e-24	Cognitive function;
KIRP	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg05347473	chr6:146136440	FBXO30	-0.57	-8.22	-0.46	1.2e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg00405596	chr8:11794950	NA	-0.45	-5.79	-0.35	2.19e-8	Monocyte count;
KIRP	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.7	8.99	0.5	6.85e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2274273	0.686	rs2182207	chr14:55589803	G/A	cg04306507	chr14:55594613	LGALS3	0.43	5.66	0.34	4.27e-8	Protein biomarker;
KIRP	cis	rs7312774	0.618	rs7979117	chr12:107345883	C/T	cg16260113	chr12:107380972	MTERFD3	0.79	7.08	0.41	1.46e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg18461458	chr19:21324796	ZNF431	0.48	4.89	0.3	1.84e-6	Pain;
KIRP	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.66	9.05	0.5	4.61e-17	Bladder cancer;
KIRP	cis	rs3829109	0.504	rs11145890	chr9:139293851	C/G	cg21253087	chr9:139290292	SNAPC4	0.47	5.4	0.33	1.59e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs11203032	1.000	rs11203030	chr10:90964286	A/G	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg10760299	chr15:45669010	GATM	0.35	5.1	0.31	6.91e-7	Homoarginine levels;
KIRP	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.1	-0.31	6.71e-7	Pulmonary function;
KIRP	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.93	-0.35	1.04e-8	Coronary artery disease;
KIRP	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg26811252	chr16:29126840	RRN3P2	0.66	8.88	0.49	1.4e-16	Menopause (age at onset);
KIRP	cis	rs7107174	0.688	rs10793294	chr11:77996403	G/T	cg02023728	chr11:77925099	USP35	-0.34	-5.66	-0.34	4.19e-8	Testicular germ cell tumor;
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg13880726	chr7:1868755	MAD1L1	0.49	5.9	0.35	1.2e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.23	-0.32	3.61e-7	Primary biliary cholangitis;
KIRP	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.2	-0.46	1.38e-14	Neuroticism;
KIRP	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.74	10.57	0.56	9.16e-22	Graves' disease;
KIRP	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.83	8.59	0.48	1.02e-15	Cerebrospinal P-tau181p levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10909192	chr14:45579847	PRPF39;SNORD127	0.4	6.37	0.38	9.29e-10	C-reactive protein;
KIRP	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-1.19	-13.56	-0.65	1.22e-31	Monocyte percentage of white cells;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.76	6.78	0.4	9.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg20673091	chr1:2541236	MMEL1	0.79	12.78	0.63	4.98e-29	Ulcerative colitis;
KIRP	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.57	-7.99	-0.45	5.1e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg26513180	chr16:89883248	FANCA	0.82	5.61	0.34	5.48e-8	Skin colour saturation;
KIRP	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg00343986	chr7:65444356	GUSB	0.43	5.1	0.31	6.75e-7	Aortic root size;
KIRP	cis	rs4356932	0.935	rs4345214	chr4:76954169	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.57	-0.48	1.15e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg07636037	chr3:49044803	WDR6	0.43	4.99	0.3	1.14e-6	Resting heart rate;
KIRP	trans	rs1501550	0.764	rs57045219	chr1:211209354	C/T	cg03551454	chr6:7245704	RREB1	-0.61	-6.23	-0.37	2.01e-9	Circulating vasoactive peptide levels;
KIRP	trans	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	6.16	0.37	2.89e-9	Ulcerative colitis;
KIRP	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.12	-0.36	3.57e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg16558253	chr16:72132732	DHX38	-0.41	-5.6	-0.34	5.65e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05220968	chr6:146057943	EPM2A	0.38	4.88	0.3	1.88e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.49	-5.07	-0.31	7.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.21	-0.37	2.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.25	0.37	1.78e-9	Platelet count;
KIRP	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17691542	chr6:26056736	HIST1H1C	0.5	6.48	0.38	4.98e-10	Height;
KIRP	cis	rs4728302	0.607	rs6971840	chr7:133585570	A/G	cg10665199	chr7:133106180	EXOC4	0.42	4.98	0.3	1.21e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg08501292	chr6:25962987	TRIM38	0.82	5.58	0.34	6.4e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs526821	0.595	rs499446	chr11:55355722	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-6.12	-0.36	3.57e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs4494114	0.967	rs9438977	chr1:39354958	A/G	cg25970120	chr1:39325951	RRAGC	-0.38	-4.95	-0.3	1.37e-6	Blood protein levels;
KIRP	cis	rs2573652	0.722	rs8041337	chr15:100541808	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.51	-7.23	-0.42	6.05e-12	Height;
KIRP	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg01631408	chr1:248437212	OR2T33	-0.67	-8.98	-0.5	7.24e-17	Common traits (Other);
KIRP	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs17253792	0.545	rs12893676	chr14:56016159	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.14	0.36	3.23e-9	Body mass index;
KIRP	cis	rs6438504	0.922	rs13098335	chr3:118952016	G/A	cg25372693	chr3:118959985	B4GALT4	0.33	5.44	0.33	1.26e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs6684428	0.536	rs4573554	chr1:56398037	C/T	cg11651538	chr1:56320950	NA	-0.54	-7.73	-0.44	2.77e-13	Airflow obstruction;
KIRP	cis	rs1978968	0.717	rs8139578	chr22:18468208	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.75	-10.69	-0.56	3.65e-22	Presence of antiphospholipid antibodies;
KIRP	cis	rs8018808	0.935	rs8005759	chr14:77880493	C/T	cg18872420	chr14:78023429	SPTLC2	0.35	5.09	0.31	7.06e-7	Myeloid white cell count;
KIRP	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.31	0.55	6.14e-21	Coffee consumption (cups per day);
KIRP	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg00579200	chr11:133705235	NA	-0.38	-4.89	-0.3	1.82e-6	Childhood ear infection;
KIRP	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.84	-13.7	-0.66	4.09e-32	Prostate cancer;
KIRP	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg07636037	chr3:49044803	WDR6	-0.6	-5.98	-0.36	7.73e-9	Menarche (age at onset);
KIRP	trans	rs12517041	1.000	rs6452112	chr5:23313498	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	cis	rs17125944	0.686	rs2357946	chr14:53345266	G/C	cg00686598	chr14:53173677	PSMC6	-0.65	-5.87	-0.35	1.44e-8	Alzheimer's disease (late onset);
KIRP	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg20578329	chr17:80767326	TBCD	0.54	7.44	0.43	1.67e-12	Breast cancer;
KIRP	cis	rs2898681	0.770	rs62336795	chr4:53737772	G/A	cg00791764	chr4:53727839	RASL11B	0.37	5.34	0.32	2.16e-7	Optic nerve measurement (cup area);
KIRP	cis	rs4262150	0.883	rs72799200	chr5:152191955	A/T	cg12297329	chr5:152029980	NA	-0.63	-8.1	-0.46	2.54e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00320027	chr8:101734560	PABPC1	0.49	6.24	0.37	1.9e-9	Parkinson's disease;
KIRP	cis	rs6832769	0.925	rs1965467	chr4:56322740	G/A	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs2012796	0.957	rs7151434	chr14:81819468	A/G	cg02996355	chr14:81879375	NA	0.39	5.38	0.32	1.75e-7	Night sleep phenotypes;
KIRP	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.91	-9.61	-0.52	8.73e-19	Left atrial antero-posterior diameter;
KIRP	cis	rs10114408	0.959	rs1987334	chr9:96635909	G/C	cg14598338	chr9:96623480	NA	-0.33	-4.93	-0.3	1.53e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.84	10.31	0.55	5.84e-21	Corneal astigmatism;
KIRP	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg23587288	chr2:27483067	SLC30A3	0.55	6.91	0.4	4.19e-11	Blood metabolite levels;
KIRP	cis	rs8179	0.620	rs73232029	chr7:92287283	G/C	cg15732164	chr7:92237376	CDK6	-0.44	-5.57	-0.33	6.76e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.26	-0.42	4.92e-12	Morning vs. evening chronotype;
KIRP	trans	rs16867225	1.000	rs75011503	chr2:181031699	G/T	cg18179931	chr3:194119058	GP5	-0.41	-6.47	-0.38	5.23e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.76	-5.45	-0.33	1.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.5	-6.12	-0.36	3.66e-9	Red blood cell count;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs1823913	0.599	rs1378155	chr2:192131336	G/A	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.55e-12	Obesity-related traits;
KIRP	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.93	13.81	0.66	1.62e-32	Tonsillectomy;
KIRP	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg25356066	chr3:128598488	ACAD9	0.5	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.58	7.5	0.43	1.15e-12	Platelet count;
KIRP	cis	rs929596	0.674	rs2602374	chr2:234568964	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-5.81	-0.35	1.95e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg08773314	chr2:239334832	ASB1	-0.46	-5.23	-0.32	3.58e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs911119	0.657	rs13037020	chr20:23629222	T/C	cg09631192	chr20:23583594	CST9	-0.74	-5.81	-0.35	1.88e-8	Chronic kidney disease;
KIRP	cis	rs2573652	1.000	rs2581341	chr15:100514494	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.69	-10.37	-0.55	3.91e-21	Height;
KIRP	cis	rs55871839	0.684	rs9298002	chr8:59815118	T/C	cg07426533	chr8:59803705	TOX	-0.52	-8.82	-0.49	2.18e-16	Pneumonia;
KIRP	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs73200209	0.744	rs55819608	chr12:116578300	C/T	cg01776926	chr12:116560359	MED13L	-0.55	-5.65	-0.34	4.4e-8	Total body bone mineral density;
KIRP	cis	rs981844	0.816	rs62325147	chr4:154727568	G/A	cg14289246	chr4:154710475	SFRP2	0.67	7.86	0.45	1.22e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.45e-9	HDL cholesterol;
KIRP	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.27	0.37	1.57e-9	Neuroticism;
KIRP	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg16296679	chr22:42394374	WBP2NL	0.36	4.99	0.3	1.15e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg17736920	chr1:242011382	EXO1	0.48	6.03	0.36	5.87e-9	Menopause (age at onset);
KIRP	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.23	-4.94	-0.3	1.45e-6	Height;
KIRP	cis	rs1497828	1.000	rs2818966	chr1:217569557	G/A	cg04411442	chr1:217543379	NA	0.31	4.9	0.3	1.75e-6	Dialysis-related mortality;
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	trans	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg10756647	chr7:56101905	PSPH	1.07	8.27	0.47	8.36e-15	Diabetic kidney disease;
KIRP	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	1.01	10.05	0.54	3.96e-20	Psoriasis;
KIRP	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	1.08	15.98	0.71	6.61e-40	Menopause (age at onset);
KIRP	cis	rs35883536	1.000	rs4243810	chr1:101139914	T/C	cg06223162	chr1:101003688	GPR88	0.31	6.32	0.37	1.22e-9	Monocyte count;
KIRP	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs9513627	0.920	rs2390280	chr13:100208802	A/G	cg25919922	chr13:100150906	NA	0.68	4.89	0.3	1.82e-6	Obesity-related traits;
KIRP	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.3	-0.32	2.53e-7	Parkinson's disease;
KIRP	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.4	-4.89	-0.3	1.82e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg13736514	chr6:26305472	NA	0.51	6.28	0.37	1.5e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg17366294	chr4:99064904	C4orf37	0.44	6.31	0.37	1.26e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.64	10.52	0.56	1.3e-21	Breast cancer;
KIRP	cis	rs10411262	0.935	rs314661	chr19:47172473	C/T	cg13467550	chr19:47212573	PRKD2	0.37	5.25	0.32	3.21e-7	Tonsillectomy;
KIRP	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.6	7.73	0.44	2.73e-13	Eosinophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24641993	chr5:150537046	ANXA6	-0.46	-6.22	-0.37	2.14e-9	Myopia;
KIRP	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-4.89	-0.3	1.82e-6	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg08822215	chr16:89438651	ANKRD11	0.51	6.54	0.39	3.46e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg04733989	chr22:42467013	NAGA	-0.54	-6.63	-0.39	2.14e-10	Cognitive function;
KIRP	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.64	-6.39	-0.38	8.32e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg23748340	chr12:48592721	NA	-0.43	-4.92	-0.3	1.58e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.78	0.35	2.22e-8	Motion sickness;
KIRP	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.44	0.43	1.67e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.66	-6.3	-0.37	1.38e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg03060546	chr3:49711283	APEH	-0.56	-4.89	-0.3	1.78e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.78	-12.36	-0.62	1.28e-27	Rheumatoid arthritis;
KIRP	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.77	-9.11	-0.5	2.94e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.38	0.51	4.48e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17554472	chr22:41940697	POLR3H	-0.42	-4.85	-0.3	2.17e-6	Vitiligo;
KIRP	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg22705602	chr4:152727874	NA	-0.53	-9.14	-0.5	2.37e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.64	-6.44	-0.38	6.23e-10	Gut microbiome composition (summer);
KIRP	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg26384229	chr12:38710491	ALG10B	0.69	9.52	0.52	1.66e-18	Morning vs. evening chronotype;
KIRP	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg07930552	chr6:133119739	C6orf192	0.91	6.16	0.37	2.87e-9	Type 2 diabetes nephropathy;
KIRP	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs78579285	0.584	rs35265318	chr16:88800785	C/T	cg09054528	chr16:88821542	FAM38A	-0.65	-5.38	-0.32	1.77e-7	Joint mobility (Beighton score);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20136959	chr13:49821950	CDADC1	0.53	6.21	0.37	2.19e-9	Smoking initiation;
KIRP	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	4.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.55	6.05	0.36	5.26e-9	Bone mineral density (spine);
KIRP	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg13332499	chr17:408570	NA	0.63	9.26	0.51	1.02e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	7.76	0.44	2.32e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.52	-6.01	-0.36	6.8e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg24044564	chr13:99115944	STK24	0.5	5.75	0.34	2.61e-8	Obesity-related traits;
KIRP	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04374321	chr14:90722782	PSMC1	0.93	15.78	0.71	3.23e-39	Mortality in heart failure;
KIRP	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.68	6.33	0.37	1.14e-9	Schizophrenia;
KIRP	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.16	-0.42	9.56e-12	Joint mobility (Beighton score);
KIRP	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23281280	chr6:28129359	ZNF389	0.5	5.35	0.32	2.03e-7	Depression;
KIRP	cis	rs4805272	1.000	rs888829	chr19:29324668	T/C	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10507099	chr16:67282837	FHOD1;SLC9A5	-0.44	-6.06	-0.36	5.06e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg09264619	chr17:80180166	NA	-0.41	-5.99	-0.36	7.52e-9	Life satisfaction;
KIRP	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg17554472	chr22:41940697	POLR3H	-0.44	-5.23	-0.32	3.57e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.71	8.4	0.47	3.69e-15	Mammographic density (dense area);
KIRP	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg11569703	chr11:65557185	OVOL1	-0.48	-8.45	-0.47	2.5e-15	Acne (severe);
KIRP	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.58	6.6	0.39	2.51e-10	Vitiligo;
KIRP	cis	rs4936891	0.645	rs74858431	chr11:123902862	T/C	cg22125253	chr11:123886957	OR10G4	0.58	8.59	0.48	1.03e-15	Male fertility;
KIRP	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-6.53	-0.38	3.74e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10491083	1.000	rs10491083	chr17:6558557	A/G	cg16536857	chr17:6538525	KIAA0753	0.74	7.52	0.43	1.05e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.9	10.69	0.56	3.86e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg27494647	chr7:150038898	RARRES2	0.43	6.09	0.36	4.23e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12210905	1.000	rs12209800	chr6:27189517	C/T	cg11502198	chr6:26597334	ABT1	0.87	5.33	0.32	2.22e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg09473613	chr1:24152604	HMGCL	-0.4	-4.87	-0.3	1.96e-6	Immature fraction of reticulocytes;
KIRP	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg22987457	chr7:157211561	NA	0.4	5.09	0.31	7.11e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.81	11.32	0.59	3.46e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs77861329	0.748	rs6786592	chr3:52196241	T/C	cg08692210	chr3:52188851	WDR51A	0.61	6.16	0.37	3.02e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs7106204	0.609	rs11821417	chr11:24279139	G/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.24	0.32	3.43e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg24699146	chr1:24152579	HMGCL	-0.47	-6.84	-0.4	6.4e-11	Immature fraction of reticulocytes;
KIRP	cis	rs859767	0.540	rs17789633	chr2:135386474	G/T	cg25422880	chr2:135218333	TMEM163	-0.36	-5.28	-0.32	2.86e-7	Neuroticism;
KIRP	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.79	9.89	0.53	1.19e-19	Platelet distribution width;
KIRP	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.17	-0.61	5.4e-27	Blood trace element (Zn levels);
KIRP	cis	rs2241685	0.850	rs3748989	chr2:1946968	C/T	cg22511877	chr2:1942942	MYT1L	-0.65	-6.12	-0.36	3.74e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg03959625	chr15:84868606	LOC388152	0.72	8.62	0.48	8.3e-16	Schizophrenia;
KIRP	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.83	0.4	6.43e-11	Platelet count;
KIRP	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	10.06	0.54	3.76e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg16306078	chr6:126000798	NA	-0.26	-4.97	-0.3	1.26e-6	Endometrial cancer;
KIRP	cis	rs9826463	1.000	rs7633021	chr3:142327824	T/C	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6901004	0.935	rs1150078	chr6:111560301	C/T	cg15721981	chr6:111408429	SLC16A10	0.64	9.06	0.5	4.18e-17	Blood metabolite levels;
KIRP	cis	rs9603616	0.719	rs4636783	chr13:40238162	C/G	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs12586317	0.597	rs28452109	chr14:35653056	T/C	cg07166546	chr14:35805898	NA	-0.28	-6.69	-0.39	1.48e-10	Psoriasis;
KIRP	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg07148914	chr20:33460835	GGT7	-0.54	-7.08	-0.41	1.47e-11	Height;
KIRP	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg11645453	chr3:52864694	ITIH4	-0.34	-5.22	-0.32	3.86e-7	Body mass index;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg17978844	chr19:40854664	PLD3;C19orf47	0.54	6.66	0.39	1.83e-10	Beard thickness;
KIRP	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.57	-0.33	6.57e-8	Fractional excretion of uric acid;
KIRP	cis	rs6442310	1.000	rs6442310	chr3:12358230	T/A	cg02700894	chr3:12045449	SYN2	-0.44	-5.63	-0.34	4.94e-8	Hematocrit;
KIRP	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.56	8.58	0.48	1.12e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg19847130	chr8:10466454	RP1L1	-0.34	-5.18	-0.31	4.59e-7	Neuroticism;
KIRP	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.93	-14.39	-0.68	1.75e-34	Sudden cardiac arrest;
KIRP	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg00074818	chr8:8560427	CLDN23	0.39	6.11	0.36	3.85e-9	Obesity-related traits;
KIRP	cis	rs7709377	0.595	rs803967	chr5:115605119	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.04	0.31	9.12e-7	Metabolite levels  (X-11787);
KIRP	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.85	12.78	0.63	5.02e-29	Height;
KIRP	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.19	-23.19	-0.83	7.5e-64	Exhaled nitric oxide output;
KIRP	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg17294928	chr15:75287854	SCAMP5	-0.69	-5.76	-0.34	2.53e-8	Lung cancer;
KIRP	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.96	12.7	0.63	9.03e-29	Menopause (age at onset);
KIRP	cis	rs4363385	0.720	rs9325996	chr1:152965347	A/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.93	-0.3	1.53e-6	Inflammatory skin disease;
KIRP	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg00745463	chr17:30367425	LRRC37B	-0.72	-6.85	-0.4	5.93e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs6585424	1.000	rs12763392	chr10:81934995	C/T	cg27417294	chr10:81904244	PLAC9	-0.49	-4.91	-0.3	1.63e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11997175	0.562	rs58955533	chr8:33829692	C/T	cg04338863	chr8:33670619	NA	0.42	5.38	0.32	1.71e-7	Body mass index;
KIRP	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.75	9.43	0.52	3.32e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.29	-0.32	2.69e-7	Breast cancer;
KIRP	cis	rs865483	0.965	rs853199	chr17:35850225	T/C	cg06716730	chr17:35851459	DUSP14	0.24	5.8	0.35	2.06e-8	Monocyte count;
KIRP	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.58	7.41	0.43	1.99e-12	Aortic root size;
KIRP	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.58	7.74	0.44	2.56e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3736485	0.966	rs2305708	chr15:51909960	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg25783544	chr11:47291846	MADD	0.44	4.99	0.3	1.14e-6	HDL cholesterol;
KIRP	cis	rs7520050	0.966	rs1707335	chr1:46571921	C/T	cg03146154	chr1:46216737	IPP	-0.41	-5.25	-0.32	3.22e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.62	-7.33	-0.42	3.21e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs6539288	0.630	rs1055332	chr12:107348625	T/A	cg15890332	chr12:107067104	RFX4	0.37	6.02	0.36	6.47e-9	Total body bone mineral density;
KIRP	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	1.09	20.52	0.79	3.29e-55	Monocyte count;
KIRP	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	8.66	0.48	6.21e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg18016565	chr1:150552671	MCL1	0.39	5.9	0.35	1.19e-8	Melanoma;
KIRP	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.09	-7.98	-0.45	5.75e-14	Mitochondrial DNA levels;
KIRP	trans	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.25	-0.32	3.28e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg08917208	chr2:24149416	ATAD2B	-0.59	-4.94	-0.3	1.45e-6	Lymphocyte counts;
KIRP	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.35	-0.38	1.05e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7084402	0.967	rs1303970	chr10:60298477	G/T	cg05938607	chr10:60274200	BICC1	-0.43	-10.0	-0.54	5.48e-20	Refractive error;
KIRP	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.72	-8.17	-0.46	1.64e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-1.02	-10.85	-0.57	1.11e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg10117171	chr1:25599238	RHD	-0.38	-5.14	-0.31	5.69e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.63	0.48	7.59e-16	Motion sickness;
KIRP	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-0.76	-7.89	-0.45	9.65e-14	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26222229	chr6:36842844	PPIL1	0.45	6.03	0.36	6.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg20591167	chr15:99602178	NA	0.51	6.3	0.37	1.38e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg25174290	chr11:3078921	CARS	-0.57	-6.11	-0.36	3.92e-9	Calcium levels;
KIRP	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg06917634	chr15:78832804	PSMA4	0.52	5.94	0.35	9.62e-9	Sudden cardiac arrest;
KIRP	cis	rs612683	0.536	rs12042531	chr1:100965942	G/A	cg06223162	chr1:101003688	GPR88	-0.49	-10.72	-0.56	3.08e-22	Breast cancer;
KIRP	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.97	-0.45	5.81e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg23594656	chr7:65796392	TPST1	-0.5	-7.68	-0.44	3.8e-13	Aortic root size;
KIRP	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg06935464	chr4:38784597	TLR10	0.51	4.93	0.3	1.48e-6	Breast cancer;
KIRP	cis	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.12	-0.31	6.27e-7	Neuroticism;
KIRP	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.33	0.37	1.15e-9	Mean corpuscular volume;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg03289416	chr15:75166202	SCAMP2	0.53	7.25	0.42	5.35e-12	Breast cancer;
KIRP	cis	rs7656342	0.636	rs9993652	chr4:9888849	G/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-5.64	-0.34	4.56e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.59	-7.2	-0.42	7.35e-12	Red cell distribution width;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13985979	chr9:140297969	EXD3	0.47	6.25	0.37	1.8e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1823913	1.000	rs11691372	chr2:192114678	A/C	cg12404831	chr2:192114017	MYO1B	-0.5	-6.87	-0.4	5.24e-11	Obesity-related traits;
KIRP	cis	rs911119	0.955	rs59059917	chr20:23595675	C/T	cg09631192	chr20:23583594	CST9	-0.62	-5.83	-0.35	1.69e-8	Chronic kidney disease;
KIRP	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg10047753	chr17:41438598	NA	1.17	19.27	0.78	4.52e-51	Menopause (age at onset);
KIRP	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.24	11.82	0.6	7.8e-26	Diabetic retinopathy;
KIRP	cis	rs1829883	1.000	rs1829883	chr5:98781103	C/T	cg08333243	chr5:99726346	NA	-0.38	-5.04	-0.31	8.97e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg21919602	chr1:242011447	EXO1	-0.49	-6.42	-0.38	7.1e-10	Menopause (age at onset);
KIRP	cis	rs9398803	0.723	rs853973	chr6:127068347	A/G	cg19875578	chr6:126661172	C6orf173	-0.37	-4.86	-0.3	2.05e-6	Male-pattern baldness;
KIRP	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.68	9.37	0.51	5.05e-18	Body mass index;
KIRP	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06677660	chr19:49140777	SEC1;DBP	-0.5	-5.78	-0.35	2.22e-8	Myeloid white cell count;
KIRP	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.57	-0.39	2.95e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs9653442	0.545	rs4851257	chr2:100775297	C/T	cg07810366	chr2:100720526	AFF3	-0.33	-5.28	-0.32	2.77e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs17401966	0.522	rs12133617	chr1:10288463	C/T	cg19773385	chr1:10388646	KIF1B	-0.43	-6.2	-0.37	2.41e-9	Hepatocellular carcinoma;
KIRP	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	1.06	15.34	0.7	1.02e-37	Height;
KIRP	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	0.9	11.8	0.6	9.39e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.54	-5.13	-0.31	5.81e-7	Narcolepsy;
KIRP	cis	rs62380364	0.626	rs618741	chr5:88064012	C/T	cg22951263	chr5:87985283	NA	-0.45	-6.26	-0.37	1.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg07701084	chr6:150067640	NUP43	-0.49	-5.57	-0.33	6.63e-8	Lung cancer;
KIRP	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg00405596	chr8:11794950	NA	-0.48	-6.3	-0.37	1.33e-9	Triglycerides;
KIRP	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.56	-7.83	-0.45	1.42e-13	Bipolar disorder;
KIRP	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.53	6.68	0.39	1.54e-10	Renal function-related traits (BUN);
KIRP	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.67	8.43	0.47	2.86e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.27	0.58	4.98e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg16386425	chr10:429943	DIP2C	-0.44	-5.81	-0.35	1.97e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg18357526	chr6:26021779	HIST1H4A	0.43	5.9	0.35	1.22e-8	Height;
KIRP	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs494562	0.892	rs9353310	chr6:86126199	C/T	cg17644557	chr6:86159103	NT5E	0.55	5.02	0.3	9.79e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15951691	chr7:150065937	REPIN1	0.61	7.09	0.41	1.43e-11	Smoking initiation;
KIRP	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-5.44	-0.33	1.3e-7	Triglycerides;
KIRP	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg03433033	chr1:76189801	ACADM	0.73	10.23	0.55	1.08e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg00405596	chr8:11794950	NA	-0.5	-6.54	-0.38	3.6e-10	Neuroticism;
KIRP	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.41	-5.43	-0.33	1.36e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23814691	chr3:50649161	CISH	0.54	6.64	0.39	2.03e-10	Parkinson's disease;
KIRP	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.01	0.3	1.03e-6	Breast cancer;
KIRP	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.79	-12.75	-0.63	6.38e-29	Prostate cancer;
KIRP	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.56	-6.88	-0.4	4.93e-11	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs9815354	0.516	rs115135603	chr3:42031622	T/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg25173405	chr17:45401733	C17orf57	0.42	5.37	0.32	1.79e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.99	15.75	0.71	4.17e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2048656	0.578	rs7817784	chr8:9682553	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-5.61	-0.34	5.55e-8	Schizophrenia;
KIRP	cis	rs9815354	0.761	rs17280777	chr3:41806167	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.35	0.47	4.88e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg12718519	chr1:2058417	PRKCZ	-0.2	-5.6	-0.34	5.58e-8	Height;
KIRP	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg22366001	chr1:2066006	PRKCZ	-0.39	-5.22	-0.32	3.82e-7	Height;
KIRP	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.4	5.1	0.31	6.79e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-8.88	-0.49	1.39e-16	Joint mobility (Beighton score);
KIRP	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg22283653	chr8:49824208	NA	0.5	6.88	0.4	5.03e-11	Sudden cardiac arrest;
KIRP	cis	rs7225151	0.710	rs75262874	chr17:5243201	G/A	cg24500398	chr17:5266808	RABEP1	-0.58	-5.79	-0.35	2.09e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg21401794	chr1:90099060	LRRC8C	0.7	9.86	0.53	1.51e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs926392	0.640	rs4616534	chr20:37693564	G/A	cg16355469	chr20:37678765	NA	0.52	6.04	0.36	5.62e-9	Dialysis-related mortality;
KIRP	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.53	5.26	0.32	3.17e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.66	0.63	1.24e-28	Ileal carcinoids;
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg09699651	chr6:150184138	LRP11	0.47	6.16	0.37	2.99e-9	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02628353	chr7:26241504	HNRNPA2B1;CBX3	0.57	6.7	0.39	1.38e-10	Smoking initiation;
KIRP	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg22676075	chr6:135203613	NA	0.47	6.6	0.39	2.5e-10	Red blood cell count;
KIRP	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	7.72	0.44	2.9e-13	Menarche (age at onset);
KIRP	cis	rs6893300	0.776	rs55868831	chr5:179157296	T/C	cg14593053	chr5:179126677	CANX	-0.58	-7.05	-0.41	1.84e-11	Resting heart rate;
KIRP	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.48	-0.38	4.93e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg10935138	chr17:73851978	WBP2	0.4	4.92	0.3	1.6e-6	White matter hyperintensity burden;
KIRP	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.71	-8.24	-0.47	1.03e-14	Obesity-related traits;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.25	-0.32	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.69	-10.23	-0.55	1.09e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1018697	1.000	rs7092051	chr10:104559477	C/T	cg04362960	chr10:104952993	NT5C2	0.48	5.82	0.35	1.85e-8	Colorectal adenoma (advanced);
KIRP	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.46	-5.01	-0.3	1.03e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4356975	0.563	rs7680709	chr4:69947463	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg15117754	chr3:10150083	C3orf24	0.51	5.11	0.31	6.46e-7	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.52	-0.33	8.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg19731401	chr7:2775893	GNA12	0.77	7.25	0.42	5.43e-12	Childhood ear infection;
KIRP	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.66	8.14	0.46	2.04e-14	Height;
KIRP	cis	rs4663866	0.908	rs35093813	chr2:239153765	T/A	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.85	0.35	1.59e-8	Motion sickness;
KIRP	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23422044	chr7:1970798	MAD1L1	-0.42	-5.46	-0.33	1.16e-7	Neuroticism;
KIRP	trans	rs2898857	0.524	rs2119931	chr17:47429834	A/G	cg11430096	chr6:110968061	CDK19	-0.54	-6.67	-0.39	1.69e-10	Cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg14598413	chr17:41561277	DHX8	0.55	6.7	0.39	1.45e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.4	-5.34	-0.32	2.17e-7	Menarche (age at onset);
KIRP	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-6.11	-0.36	3.83e-9	Multiple sclerosis;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.61	9.05	0.5	4.56e-17	Lung cancer;
KIRP	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7737355	0.812	rs10515455	chr5:130878789	C/T	cg25547332	chr5:131281432	NA	0.39	4.91	0.3	1.63e-6	Life satisfaction;
KIRP	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.47	6.04	0.36	5.78e-9	IgG glycosylation;
KIRP	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg23517279	chr6:96025343	MANEA	-0.6	-5.33	-0.32	2.2e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.66	9.85	0.53	1.59e-19	Longevity;
KIRP	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.84	-13.31	-0.65	8.52e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg00792783	chr2:198669748	PLCL1	0.46	5.27	0.32	3.05e-7	Dermatomyositis;
KIRP	cis	rs9467773	0.529	rs7356988	chr6:26396727	G/T	cg09904177	chr6:26538194	HMGN4	-0.4	-5.03	-0.31	9.56e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.51	7.25	0.42	5.43e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11987759	chr7:65425863	GUSB	0.48	6.26	0.37	1.69e-9	Aortic root size;
KIRP	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-7.17	-0.42	8.73e-12	Morning vs. evening chronotype;
KIRP	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg27205649	chr11:78285834	NARS2	-0.66	-7.57	-0.43	7.66e-13	Alzheimer's disease (survival time);
KIRP	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.62	-0.48	8.41e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.48e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26449074	chr2:187351671	ZC3H15	0.49	6.22	0.37	2.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg14952266	chr13:112191215	NA	0.45	6.71	0.39	1.32e-10	Hepatitis;
KIRP	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.46	7.32	0.42	3.61e-12	Testicular germ cell tumor;
KIRP	trans	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg27121462	chr16:89883253	FANCA	0.5	6.4	0.38	8.01e-10	Vitiligo;
KIRP	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg06386533	chr2:46925753	SOCS5	0.47	5.09	0.31	7.13e-7	Height;
KIRP	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg25566285	chr7:158114605	PTPRN2	0.73	8.93	0.49	1.01e-16	Response to amphetamines;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.79	6.91	0.4	4.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06961586	chr2:181842270	NA	-0.38	-6.31	-0.37	1.26e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12973672	0.812	rs10421504	chr19:35764701	C/G	cg12095397	chr19:35769544	USF2	0.68	6.3	0.37	1.39e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg15226275	chr6:116381976	FRK	0.21	5.73	0.34	2.9e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg02574844	chr11:5959923	NA	0.6	6.38	0.38	8.6e-10	DNA methylation (variation);
KIRP	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg22903471	chr2:27725779	GCKR	0.41	5.57	0.33	6.52e-8	Oral cavity cancer;
KIRP	cis	rs8038465	0.638	rs56262972	chr15:73946745	G/A	cg15420318	chr15:73925796	NPTN	0.66	9.59	0.52	1.02e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg05973401	chr12:123451056	ABCB9	0.59	5.3	0.32	2.64e-7	Neutrophil percentage of white cells;
KIRP	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg16558253	chr16:72132732	DHX38	-0.51	-7.18	-0.42	8.45e-12	Fibrinogen levels;
KIRP	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21007089	chr15:41408316	INO80	0.45	6.28	0.37	1.56e-9	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.58	-6.45	-0.38	5.93e-10	Aortic root size;
KIRP	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg14517863	chr17:44321492	NA	0.48	5.38	0.32	1.71e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12580194	0.593	rs61956275	chr12:55786423	G/A	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.71	-8.42	-0.47	3.23e-15	Coronary artery disease;
KIRP	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg12573791	chr2:3828286	NA	0.41	5.72	0.34	3.01e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	0.95	13.81	0.66	1.72e-32	Blood trace element (Zn levels);
KIRP	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.46	6.69	0.39	1.51e-10	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg24874828	chr4:187887005	NA	0.48	7.11	0.41	1.28e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg10664184	chr19:17420304	DDA1	0.8	8.91	0.49	1.19e-16	Systemic lupus erythematosus;
KIRP	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.56	6.22	0.37	2.07e-9	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-8.84	-0.49	1.88e-16	Platelet count;
KIRP	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg26924012	chr15:45694286	SPATA5L1	0.85	12.02	0.61	1.74e-26	Homoarginine levels;
KIRP	cis	rs7113850	0.541	rs7935630	chr11:24222206	A/C	ch.11.24196551F	chr11:24239977	NA	0.9	8.35	0.47	5.02e-15	Bone fracture in osteoporosis;
KIRP	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg16917193	chr12:54089295	NA	0.88	16.53	0.73	8.75e-42	Height;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.56	7.42	0.43	1.85e-12	HDL cholesterol;
KIRP	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg00129232	chr17:37814104	STARD3	0.65	6.72	0.39	1.29e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	7.56	0.43	7.95e-13	Triglycerides;
KIRP	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs6060960	0.502	rs6089110	chr20:30486907	A/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.5	5.69	0.34	3.68e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg15848620	chr12:58087721	OS9	-0.51	-5.95	-0.35	9.17e-9	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg18093693	chr15:72668265	HEXA;C15orf34	0.54	6.53	0.38	3.72e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	trans	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.35	0.42	2.88e-12	Exhaled nitric oxide output;
KIRP	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg04315214	chr1:2043799	PRKCZ	0.47	8.24	0.47	1.04e-14	Height;
KIRP	cis	rs12044355	0.865	rs2487453	chr1:231863204	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.56	0.39	3.12e-10	Alzheimer's disease;
KIRP	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.99	9.53	0.52	1.58e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-7.25	-0.42	5.28e-12	Cognitive test performance;
KIRP	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	1.02	10.72	0.56	2.98e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4006360	0.628	rs6416911	chr17:39253311	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.66	-9.15	-0.5	2.24e-17	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14925616	chr19:13125726	NFIX	-0.42	-6.36	-0.38	9.82e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg23594656	chr7:65796392	TPST1	-0.44	-6.17	-0.37	2.75e-9	Aortic root size;
KIRP	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg02503808	chr4:7069936	GRPEL1	-0.43	-5.36	-0.32	1.96e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.48	5.95	0.35	9.35e-9	Height;
KIRP	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.02	-0.46	4.25e-14	Monocyte percentage of white cells;
KIRP	cis	rs9513627	1.000	rs7338537	chr13:100119581	C/A	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg00982548	chr2:198649783	BOLL	-0.53	-4.9	-0.3	1.72e-6	Ulcerative colitis;
KIRP	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.76	-10.65	-0.56	5.04e-22	Height;
KIRP	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg19592336	chr6:28129416	ZNF389	0.49	5.61	0.34	5.49e-8	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.3	0.42	4.01e-12	Prudent dietary pattern;
KIRP	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.5	-6.31	-0.37	1.29e-9	Prudent dietary pattern;
KIRP	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.83	10.36	0.55	4.28e-21	Platelet distribution width;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg21186296	chr8:27182909	PTK2B	0.49	6.27	0.37	1.59e-9	Neuroticism;
KIRP	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.59	6.92	0.4	3.82e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.81	0.6	8.46e-26	Longevity;
KIRP	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.4e-15	Lung cancer in ever smokers;
KIRP	cis	rs3774854	1.000	rs9790440	chr4:5711334	A/G	cg09558315	chr4:5711301	EVC2	-0.35	-5.33	-0.32	2.19e-7	Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease;
KIRP	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.97	-10.08	-0.54	3.19e-20	HIV-1 control;
KIRP	cis	rs477692	0.549	rs7098548	chr10:131455028	A/G	cg05714579	chr10:131428358	MGMT	-0.41	-5.14	-0.31	5.68e-7	Response to temozolomide;
KIRP	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.01	-0.3	1.06e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg07395648	chr5:131743802	NA	0.55	6.58	0.39	2.79e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs17213078	0.505	rs2167531	chr2:106738625	A/G	cg16099169	chr2:106886729	NA	-0.36	-5.04	-0.31	9.19e-7	Facial morphology (factor 23);
KIRP	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.47	6.8	0.4	7.71e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.89	-14.06	-0.67	2.43e-33	Breast cancer;
KIRP	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg09355771	chr2:177043147	NA	-0.43	-5.06	-0.31	8.4e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs1847505	0.609	rs76153604	chr13:61493971	C/G	cg25164009	chr13:61490935	NA	0.52	5.59	0.34	6.01e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.63	6.1	0.36	4.06e-9	Cannabis dependence symptom count;
KIRP	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg06637938	chr14:75390232	RPS6KL1	0.44	6.1	0.36	4e-9	Height;
KIRP	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.44	6.21	0.37	2.25e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.17	-0.31	4.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-15.79	-0.71	2.89e-39	Electrocardiographic conduction measures;
KIRP	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.71	-0.39	1.35e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.02	0.36	6.19e-9	Menopause (age at onset);
KIRP	cis	rs6748734	0.625	rs4312489	chr2:241821068	T/A	cg04034577	chr2:241836375	C2orf54	-0.27	-4.99	-0.3	1.14e-6	Urinary metabolites;
KIRP	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.61	7.9	0.45	9.41e-14	Cognitive test performance;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22292364	chr19:50180326	PRMT1	0.53	6.14	0.36	3.23e-9	Smoking initiation;
KIRP	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.47	-7.2	-0.42	7.12e-12	Coronary artery disease;
KIRP	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.87	-10.47	-0.56	1.9e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.49	-5.0	-0.3	1.1e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.89	-11.77	-0.6	1.17e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs3858145	0.588	rs61854831	chr10:70035837	C/T	cg04882175	chr6:131122610	NA	-0.59	-6.99	-0.41	2.63e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg14768367	chr16:72042858	DHODH	0.5	6.24	0.37	1.88e-9	Fibrinogen levels;
KIRP	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.65	-0.66	5.97e-32	Monocyte count;
KIRP	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg19847130	chr8:10466454	RP1L1	-0.42	-6.13	-0.36	3.5e-9	Retinal vascular caliber;
KIRP	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.56	7.4	0.43	2.13e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs523516	0.645	rs16525	chr17:37321605	C/T	cg07330481	chr17:37322330	ARL5C	0.31	5.11	0.31	6.57e-7	IgG glycosylation;
KIRP	cis	rs72730918	0.564	rs28408214	chr15:51867574	A/T	cg14296394	chr15:51910925	DMXL2	-0.76	-10.53	-0.56	1.23e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.507	rs8107654	chr19:37453534	C/T	cg23950597	chr19:37808831	NA	-0.69	-5.33	-0.32	2.2e-7	Coronary artery calcification;
KIRP	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg15488143	chr7:128924101	AHCYL2	0.54	5.65	0.34	4.5e-8	White matter hyperintensity burden;
KIRP	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.27	-0.42	4.89e-12	Aortic root size;
KIRP	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg05973401	chr12:123451056	ABCB9	0.58	6.75	0.4	1.04e-10	Neutrophil percentage of white cells;
KIRP	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg01320579	chr17:75405842	SEPT9	0.45	7.04	0.41	1.85e-11	Airflow obstruction;
KIRP	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.46	-6.16	-0.37	2.91e-9	IgG glycosylation;
KIRP	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.65	9.45	0.52	2.83e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12963246	chr6:28129442	ZNF389	-0.5	-6.23	-0.37	2.01e-9	Depression;
KIRP	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.44	5.03	0.31	9.65e-7	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6433857	0.505	rs16867320	chr2:181362312	A/G	cg23363182	chr2:181467187	NA	0.36	4.99	0.3	1.15e-6	Body mass index;
KIRP	cis	rs3736485	0.966	rs7176044	chr15:51895343	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.15	-0.31	5.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs225245	0.541	rs321612	chr17:33881631	T/C	cg19694781	chr19:47549865	TMEM160	-0.55	-6.84	-0.4	6.38e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-8.21	-0.46	1.28e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg11812906	chr14:75593930	NEK9	0.53	5.88	0.35	1.36e-8	Caffeine consumption;
KIRP	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg07827796	chr19:33622959	WDR88	0.42	5.0	0.3	1.1e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.3	-6.04	-0.36	5.79e-9	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12120238	chr6:155054535	RBM16	-0.46	-6.11	-0.36	3.81e-9	Metabolic traits;
KIRP	trans	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg23484912	chr5:273055	PDCD6	0.68	8.26	0.47	9.09e-15	Pancreatic cancer;
KIRP	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.96	-10.63	-0.56	5.7e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg25486957	chr4:152246857	NA	-0.48	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs526231	0.575	rs10463990	chr5:102317418	G/A	cg23492399	chr5:102201601	PAM	-0.49	-5.56	-0.33	7.01e-8	Primary biliary cholangitis;
KIRP	cis	rs1468333	1.000	rs4552585	chr5:137533159	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.38	0.32	1.7e-7	Resting heart rate;
KIRP	trans	rs6570726	0.875	rs368744	chr6:145812622	A/G	ch.2.129044566R	chr2:129328096	NA	-0.47	-6.06	-0.36	5.06e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02067580	chr1:153606662	C1orf77;S100A13	-0.46	-6.09	-0.36	4.4e-9	Survival in pancreatic cancer;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg11528984	chr1:228353883	C1orf69	-0.49	-6.31	-0.37	1.28e-9	Blood metabolite levels;
KIRP	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.51	7.07	0.41	1.58e-11	Mean corpuscular volume;
KIRP	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-0.91	-12.32	-0.62	1.72e-27	Blood trace element (Zn levels);
KIRP	cis	rs4363385	0.510	rs11205187	chr1:153053323	T/C	cg07796016	chr1:152779584	LCE1C	-0.45	-5.57	-0.33	6.64e-8	Inflammatory skin disease;
KIRP	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg05717871	chr11:638507	DRD4	-0.4	-5.9	-0.35	1.19e-8	Systemic lupus erythematosus;
KIRP	cis	rs7180079	0.620	rs12101509	chr15:64755580	A/G	cg15337035	chr15:64978493	NA	-0.48	-5.25	-0.32	3.24e-7	Monocyte count;
KIRP	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	11.31	0.58	3.77e-24	Chronic sinus infection;
KIRP	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg13147721	chr7:65941812	NA	-0.99	-6.89	-0.4	4.57e-11	Diabetic kidney disease;
KIRP	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.82	-11.43	-0.59	1.52e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7106204	0.609	rs16912391	chr11:24310637	G/A	ch.11.24196551F	chr11:24239977	NA	0.71	5.26	0.32	3.16e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18567992	chr19:1067389	HMHA1	0.47	6.62	0.39	2.18e-10	Parkinson's disease;
KIRP	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.47	-6.97	-0.41	2.85e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.24	-0.32	3.37e-7	Coronary artery disease;
KIRP	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Bipolar disorder;
KIRP	cis	rs6977660	0.660	rs12531278	chr7:19816439	A/T	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	cg21523751	chr1:182988639	NA	0.4	6.13	0.36	3.48e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4660306	0.614	rs1007859	chr1:45911906	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.11	0.36	3.9e-9	Homocysteine levels;
KIRP	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.59	7.89	0.45	1.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.51	7.29	0.42	4.33e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.61	8.59	0.48	1.04e-15	Schizophrenia;
KIRP	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	11.29	0.58	4.38e-24	Blood protein levels;
KIRP	cis	rs1712517	0.740	rs4917387	chr10:105108455	T/C	cg05636881	chr10:105038444	INA	0.43	6.27	0.37	1.65e-9	Migraine;
KIRP	cis	rs4561483	0.549	rs33659	chr16:11963361	A/G	cg08843971	chr16:11963173	GSPT1	-0.53	-7.44	-0.43	1.72e-12	Testicular germ cell tumor;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg26434548	chr7:129074607	FAM40B	0.56	6.22	0.37	2.15e-9	Response to statin therapy;
KIRP	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg21775007	chr8:11205619	TDH	-0.52	-6.66	-0.39	1.81e-10	Neuroticism;
KIRP	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg13010199	chr12:38710504	ALG10B	0.66	8.6	0.48	9.22e-16	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg09699651	chr6:150184138	LRP11	0.45	6.09	0.36	4.37e-9	Lung cancer;
KIRP	cis	rs654384	0.898	rs1077472	chr7:4175323	G/A	cg21882563	chr7:4172065	SDK1	0.43	5.66	0.34	4.18e-8	Positive affect;
KIRP	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg02073558	chr3:44770973	ZNF501	0.89	14.8	0.69	7.19e-36	Depressive symptoms;
KIRP	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.66	7.37	0.43	2.53e-12	Arsenic metabolism;
KIRP	trans	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.6	-8.23	-0.46	1.13e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg17507749	chr15:85114479	UBE2QP1	0.6	5.99	0.36	7.27e-9	Schizophrenia;
KIRP	cis	rs3741151	0.686	rs11235809	chr11:73290163	A/G	cg17517138	chr11:73019481	ARHGEF17	0.66	5.73	0.34	2.92e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9302690	1.000	rs62037143	chr16:57486583	T/C	cg27017172	chr16:57497170	POLR2C	1.07	8.54	0.48	1.42e-15	Blood protein levels;
KIRP	trans	rs12517041	1.000	rs34157151	chr5:23289755	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg22117172	chr7:91764530	CYP51A1	-0.43	-6.02	-0.36	6.38e-9	Breast cancer;
KIRP	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.39	-5.51	-0.33	8.88e-8	Height;
KIRP	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.63	7.73	0.44	2.68e-13	Height;
KIRP	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg10169327	chr19:45448959	APOC2	0.33	5.06	0.31	8.25e-7	Blood protein levels;
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13198984	chr17:80129470	CCDC57	-0.54	-8.15	-0.46	1.83e-14	Life satisfaction;
KIRP	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	cg04338863	chr8:33670619	NA	0.4	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05601917	chr6:125855416	NA	-0.35	-5.24	-0.32	3.41e-7	Brugada syndrome;
KIRP	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.35	0.38	1.05e-9	Mean platelet volume;
KIRP	cis	rs7737355	0.812	rs2189645	chr5:130804979	A/G	cg25547332	chr5:131281432	NA	-0.39	-4.87	-0.3	1.96e-6	Life satisfaction;
KIRP	cis	rs71636778	0.543	rs12749822	chr1:27221963	T/C	cg12203394	chr1:27248618	NUDC	0.62	5.36	0.32	1.88e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.72	-10.14	-0.54	2.02e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829661	0.894	rs1252624	chr2:30747083	G/T	cg10949345	chr2:30726833	LCLAT1	0.72	9.96	0.54	7.35e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	14.7	0.68	1.54e-35	Chronic sinus infection;
KIRP	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.82	7.86	0.45	1.21e-13	Menopause (age at onset);
KIRP	cis	rs4332428	1.000	rs78836001	chr10:4981992	G/C	cg19648686	chr10:5044992	AKR1C2	-1.02	-8.33	-0.47	5.69e-15	Height;
KIRP	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg07862535	chr7:139043722	LUC7L2	0.46	5.16	0.31	4.99e-7	Diisocyanate-induced asthma;
KIRP	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg00405596	chr8:11794950	NA	-0.4	-4.89	-0.3	1.81e-6	Neuroticism;
KIRP	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.75	7.7	0.44	3.33e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4936891	0.601	rs7929503	chr11:123916160	A/G	cg22125253	chr11:123886957	OR10G4	0.56	8.28	0.47	8.18e-15	Male fertility;
KIRP	cis	rs3087591	0.659	rs8065496	chr17:29720140	T/C	cg24425628	chr17:29625626	OMG;NF1	0.58	8.12	0.46	2.28e-14	Hip circumference;
KIRP	cis	rs6681460	0.932	rs665319	chr1:67175488	A/G	cg02459107	chr1:67143332	SGIP1	0.4	5.82	0.35	1.86e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.43	-6.16	-0.37	2.97e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1829883	0.835	rs2511977	chr5:98819617	A/G	cg08333243	chr5:99726346	NA	0.38	5.11	0.31	6.51e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs3762637	0.943	rs28372690	chr3:122283095	G/A	cg24169773	chr3:122142474	KPNA1	-0.58	-6.0	-0.36	6.85e-9	LDL cholesterol levels;
KIRP	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05347473	chr6:146136440	FBXO30	-0.64	-9.37	-0.51	4.91e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg01283332	chr5:1856932	NA	-0.49	-6.29	-0.37	1.43e-9	Cardiovascular disease risk factors;
KIRP	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg03585969	chr10:35415529	CREM	0.76	9.35	0.51	5.55e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.73	-8.35	-0.47	4.98e-15	Adiposity;
KIRP	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs17033621	0.967	rs726000	chr2:107607024	G/A	cg17818308	chr2:107502146	ST6GAL2	-0.37	-4.89	-0.3	1.81e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23903597	chr17:61704154	MAP3K3	-0.59	-7.15	-0.41	1.01e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.47	-0.52	2.49e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs8018808	0.935	rs760257	chr14:77935145	G/A	cg20045696	chr14:77926864	AHSA1	0.46	5.53	0.33	8.03e-8	Myeloid white cell count;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.67	0.34	3.96e-8	Lung cancer;
KIRP	cis	rs2071403	0.966	rs13400534	chr2:1411883	A/G	cg06500727	chr2:1417164	TPO	-0.47	-7.45	-0.43	1.6e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.73	-0.39	1.19e-10	Capecitabine sensitivity;
KIRP	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	1.05	17.64	0.75	1.47e-45	Schizophrenia;
KIRP	cis	rs6570726	0.516	rs9376932	chr6:145729490	T/C	cg23711669	chr6:146136114	FBXO30	0.46	6.12	0.36	3.61e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1816752	0.905	rs2000153	chr13:24979890	G/A	cg22771759	chr13:24902376	NA	0.4	5.12	0.31	6.23e-7	Obesity-related traits;
KIRP	cis	rs6669919	0.540	rs11579048	chr1:211681919	C/G	cg10512769	chr1:211675356	NA	-0.78	-10.72	-0.56	2.93e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.54	-7.0	-0.41	2.47e-11	Longevity;
KIRP	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11987759	chr7:65425863	GUSB	0.61	7.99	0.45	5.33e-14	Aortic root size;
KIRP	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.66	-0.48	6.39e-16	Coronary artery disease;
KIRP	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg09324608	chr17:30823087	MYO1D	0.47	5.8	0.35	2.04e-8	Schizophrenia;
KIRP	cis	rs7523273	0.853	rs7537216	chr1:208006429	A/T	cg22525895	chr1:207977042	MIR29B2	-0.67	-8.3	-0.47	7e-15	Schizophrenia;
KIRP	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.8	10.24	0.55	1.02e-20	Breast cancer;
KIRP	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.01e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg03684893	chr10:554711	DIP2C	0.36	5.04	0.31	8.98e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg00405596	chr8:11794950	NA	0.46	5.6	0.34	5.7e-8	Monocyte count;
KIRP	cis	rs12973672	0.812	rs12986033	chr19:35748782	A/G	cg12095397	chr19:35769544	USF2	0.67	6.2	0.37	2.33e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs258892	0.739	rs34667	chr5:72160050	T/C	cg21869765	chr5:72125136	TNPO1	0.57	6.26	0.37	1.7e-9	Small cell lung carcinoma;
KIRP	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.55	-6.68	-0.39	1.56e-10	Total body bone mineral density;
KIRP	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg02475777	chr4:1388615	CRIPAK	0.38	4.96	0.3	1.29e-6	Obesity-related traits;
KIRP	cis	rs2274273	0.837	rs8008119	chr14:55831228	T/C	cg04306507	chr14:55594613	LGALS3	0.46	7.22	0.42	6.62e-12	Protein biomarker;
KIRP	cis	rs7976059	0.895	rs73109568	chr12:52249003	A/C	cg09126859	chr12:52244063	NA	0.48	8.16	0.46	1.78e-14	Urate levels;
KIRP	cis	rs9400467	0.528	rs11153288	chr6:111715238	T/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.71	-0.34	3.22e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs986417	0.818	rs12880313	chr14:60935504	T/C	cg27398547	chr14:60952738	C14orf39	0.67	5.77	0.35	2.42e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg03647239	chr10:116582469	FAM160B1	0.5	5.77	0.35	2.36e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.9	-0.35	1.17e-8	Height;
KIRP	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.89	12.52	0.62	3.84e-28	Menopause (age at onset);
KIRP	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs4783244	0.794	rs62040560	chr16:82646066	G/A	cg09415485	chr16:82663111	CDH13	-0.26	-4.86	-0.3	2.14e-6	Adiponectin levels;
KIRP	cis	rs17384381	1.000	rs12140457	chr1:85860170	G/A	cg16011679	chr1:85725395	C1orf52	0.84	8.39	0.47	3.93e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.48	0.33	1.04e-7	Schizophrenia;
KIRP	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.44	-0.38	6.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.7	-0.39	1.44e-10	Type 2 diabetes;
KIRP	cis	rs732505	1.000	rs10417622	chr19:5592547	T/C	cg26242866	chr19:5711310	LONP1	0.66	5.0	0.3	1.11e-6	vWF and FVIII levels;
KIRP	cis	rs3752645	1.000	rs10249866	chr7:106748825	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-5.23	-0.32	3.65e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg23477460	chr3:66848765	NA	0.62	7.71	0.44	3.17e-13	Type 2 diabetes;
KIRP	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	0.77	7.96	0.45	6.21e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg02023728	chr11:77925099	USP35	-0.3	-5.15	-0.31	5.3e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg00405596	chr8:11794950	NA	-0.45	-5.36	-0.32	1.91e-7	Retinal vascular caliber;
KIRP	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg01522456	chr1:115632236	TSPAN2	0.39	5.29	0.32	2.76e-7	Autism;
KIRP	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-7.63	-0.44	5.09e-13	Colorectal cancer;
KIRP	cis	rs9890032	0.618	rs55872374	chr17:29149881	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.45	-5.85	-0.35	1.59e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.9	-12.2	-0.61	4.47e-27	Bipolar disorder;
KIRP	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg10326726	chr10:51549505	MSMB	-0.53	-7.42	-0.43	1.95e-12	Prostate-specific antigen levels;
KIRP	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.85	0.6	6.19e-26	Smoking behavior;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg14849639	chr18:12948029	SEH1L	-0.45	-6.08	-0.36	4.51e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs6681460	1.000	rs6689864	chr1:67068112	T/C	cg13052034	chr1:66999238	SGIP1	0.4	5.49	0.33	1e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.61	-0.34	5.34e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg11972305	chr2:233791962	NGEF	-0.38	-5.23	-0.32	3.68e-7	Schizophrenia;
KIRP	cis	rs10267417	0.556	rs879662	chr7:19970584	C/T	cg05791153	chr7:19748676	TWISTNB	0.48	5.0	0.3	1.08e-6	Night sleep phenotypes;
KIRP	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2223471	0.727	rs2206272	chr6:50765352	C/T	cg03432817	chr6:50765336	NA	0.55	9.43	0.52	3.21e-18	Subcutaneous adipose tissue;
KIRP	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg07435449	chr11:120005650	TRIM29	0.44	5.61	0.34	5.54e-8	Stroke (pediatric);
KIRP	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-1.02	-17.32	-0.74	1.81e-44	Height;
KIRP	cis	rs500492	0.542	rs2744148	chr16:1073552	A/G	cg03495660	chr16:1074500	NA	0.5	5.96	0.35	8.89e-9	Polycystic ovary syndrome;
KIRP	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.92	-0.3	1.6e-6	Obesity-related traits;
KIRP	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg19731401	chr7:2775893	GNA12	0.56	6.02	0.36	6.31e-9	Childhood ear infection;
KIRP	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg20701182	chr2:24300061	SF3B14	0.58	5.24	0.32	3.46e-7	Lymphocyte counts;
KIRP	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-0.58	-8.43	-0.47	2.89e-15	Coronary artery disease;
KIRP	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.46	-6.37	-0.38	9.06e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg00094735	chr5:1949198	NA	-0.41	-4.85	-0.3	2.19e-6	Gut microbiome composition (winter);
KIRP	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.89	0.71	1.37e-39	Metabolic syndrome;
KIRP	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21643547	chr1:205240462	TMCC2	-0.82	-12.76	-0.63	5.73e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.72	-10.39	-0.55	3.23e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9309473	0.898	rs10170786	chr2:73812988	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.34	-0.32	2.14e-7	Metabolite levels;
KIRP	cis	rs12900413	0.687	rs6496599	chr15:90314582	C/T	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.66e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg09695851	chr17:3907499	NA	0.63	8.77	0.49	2.92e-16	Type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.46	-0.38	5.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-1.09	-13.29	-0.65	9.72e-31	Exhaled nitric oxide output;
KIRP	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.43	8.09	0.46	2.66e-14	Educational attainment (years of education);
KIRP	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.71	-4.86	-0.3	2.11e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-6.26	-0.37	1.69e-9	HDL cholesterol;
KIRP	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.46	5.16	0.31	5.09e-7	Schizophrenia;
KIRP	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg26513180	chr16:89883248	FANCA	0.83	5.57	0.33	6.68e-8	Skin colour saturation;
KIRP	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg19116668	chr7:99932089	PMS2L1	-0.46	-5.35	-0.32	2.06e-7	Coronary artery disease;
KIRP	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18932078	chr1:2524107	MMEL1	-0.46	-6.32	-0.37	1.24e-9	Multiple sclerosis;
KIRP	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8014252	0.803	rs11158863	chr14:70981166	G/T	cg11204974	chr14:71022665	NA	0.73	7.08	0.41	1.47e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.65	-9.94	-0.54	8.37e-20	Total body bone mineral density;
KIRP	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.82	10.27	0.55	8.1899999999999992e-21	Vitiligo;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05312574	chr15:65281963	SPG21	0.5	6.84	0.4	6.24e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.63	-0.56	5.75e-22	Height;
KIRP	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg08501292	chr6:25962987	TRIM38	1.1	8.38	0.47	4.03e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.81	-9.08	-0.5	3.74e-17	Pancreatic cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06598631	chr6:88300029	RARS2;ORC3L	0.52	6.25	0.37	1.76e-9	Smoking initiation;
KIRP	cis	rs4474465	0.541	rs10736814	chr11:78286462	C/G	cg27205649	chr11:78285834	NARS2	0.81	9.52	0.52	1.65e-18	Alzheimer's disease (survival time);
KIRP	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg22563815	chr15:78856949	CHRNA5	-0.42	-6.65	-0.39	1.89e-10	Sudden cardiac arrest;
KIRP	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	9.28	0.51	9.06e-18	Breast cancer;
KIRP	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg13147721	chr7:65941812	NA	-0.93	-6.77	-0.4	9.55e-11	Diabetic kidney disease;
KIRP	cis	rs1413885	0.549	rs1334877	chr1:65846406	C/T	cg13202122	chr1:65886182	LEPROT;LEPR	0.42	4.85	0.3	2.15e-6	Anticoagulant levels;
KIRP	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.33	-0.32	2.24e-7	Breast cancer;
KIRP	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	6.43	0.38	6.57e-10	Mean platelet volume;
KIRP	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.67	0.66	4.87e-32	Cognitive function;
KIRP	cis	rs6832769	0.925	rs4371676	chr4:56329008	G/A	cg05960024	chr4:56376020	CLOCK	0.7	8.76	0.49	3.26e-16	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17138289	chr2:118771862	CCDC93	0.5	6.62	0.39	2.21e-10	Parkinson's disease;
KIRP	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.7	9.02	0.5	5.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.74	9.01	0.5	5.7e-17	Post bronchodilator FEV1;
KIRP	cis	rs629922	1.000	rs683900	chr11:114064162	A/G	cg25009965	chr11:114031120	ZBTB16	0.41	5.3	0.32	2.52e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs3026101	0.671	rs739768	chr17:5290703	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs2733310	0.744	rs17415731	chr15:57270286	A/G	cg13626582	chr15:57592083	LOC283663	0.27	6.23	0.37	1.97e-9	Mean platelet volume;
KIRP	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.65	8.69	0.48	5.28e-16	Response to diuretic therapy;
KIRP	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.25	-0.42	5.36e-12	Menopause (age at onset);
KIRP	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg22284058	chr8:142237359	SLC45A4	-0.46	-5.59	-0.34	6.14e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg02574844	chr11:5959923	NA	-0.57	-5.9	-0.35	1.18e-8	DNA methylation (variation);
KIRP	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.29	18.15	0.76	2.69e-47	Atopic dermatitis;
KIRP	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg19913688	chr11:428466	ANO9	-0.8	-5.11	-0.31	6.34e-7	Body mass index;
KIRP	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg16989719	chr2:238392110	NA	-0.56	-7.61	-0.44	5.82e-13	Prostate cancer;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.34	6.51	0.38	4.27e-10	Lymphocyte counts;
KIRP	cis	rs35771425	1.000	rs60555365	chr1:211590328	G/T	cg10512769	chr1:211675356	NA	-0.51	-5.1	-0.31	6.66e-7	Educational attainment (years of education);
KIRP	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg14972814	chr11:95582409	MTMR2	0.35	5.89	0.35	1.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3736594	1.000	rs3792252	chr2:27995931	A/G	cg27432699	chr2:27873401	GPN1	0.42	5.4	0.33	1.61e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6496667	0.738	rs16944500	chr15:91026973	A/T	cg10434728	chr15:90938212	IQGAP1	-0.36	-5.0	-0.3	1.07e-6	Rheumatoid arthritis;
KIRP	cis	rs3818717	0.507	rs12940675	chr17:17651214	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-5.13	-0.31	5.76e-7	Lymphocyte counts;
KIRP	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	7.97	0.45	5.81e-14	Neuroticism;
KIRP	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.09	0.41	1.39e-11	Height;
KIRP	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	0.87	10.04	0.54	4.2e-20	Corneal structure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17157516	chr1:35332203	DLGAP3	0.57	7.38	0.43	2.48e-12	Smoking initiation;
KIRP	cis	rs8067287	0.634	rs11652811	chr17:16843171	A/G	cg26910001	chr17:16838321	NA	-0.46	-5.13	-0.31	5.76e-7	Diabetic kidney disease;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.09	-0.31	7.01e-7	Life satisfaction;
KIRP	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.73	-7.76	-0.44	2.33e-13	Blood pressure (smoking interaction);
KIRP	cis	rs73195822	0.506	rs55948838	chr12:111142793	C/T	cg12870014	chr12:110450643	ANKRD13A	0.52	5.02	0.3	1.01e-6	Itch intensity from mosquito bite;
KIRP	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg13256891	chr4:100009986	ADH5	-0.63	-6.65	-0.39	1.84e-10	Alcohol dependence;
KIRP	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-5.24	-0.32	3.46e-7	Tonsillectomy;
KIRP	cis	rs7224685	0.817	rs9901620	chr17:4165741	G/C	cg11204139	chr17:3907470	NA	0.6	6.57	0.39	3e-10	Type 2 diabetes;
KIRP	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.42	-0.38	6.99e-10	Joint mobility (Beighton score);
KIRP	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00938859	chr5:1591904	SDHAP3	0.6	8.0	0.45	5.04e-14	Breast cancer;
KIRP	cis	rs7172677	0.737	rs8033754	chr15:75439780	C/T	cg03289416	chr15:75166202	SCAMP2	-0.39	-4.86	-0.3	2.12e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg14791747	chr16:20752902	THUMPD1	0.58	6.32	0.37	1.21e-9	Cognitive test performance;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg22907277	chr7:1156413	C7orf50	0.86	8.16	0.46	1.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18364779	chr6:26104403	HIST1H4C	0.41	5.32	0.32	2.34e-7	Schizophrenia;
KIRP	cis	rs4638749	0.501	rs1385957	chr2:108755104	T/G	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.94	-0.3	1.43e-6	Blood pressure;
KIRP	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.57	7.42	0.43	1.9e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12096438	1.000	rs11563	chr1:25894853	G/T	cg21452808	chr1:25900135	NA	0.41	6.55	0.39	3.35e-10	Platelet count;Mean platelet volume;
KIRP	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.24	-0.32	3.39e-7	Alcohol dependence;
KIRP	cis	rs282587	0.530	rs406997	chr13:113417880	G/C	cg04656015	chr13:113407548	ATP11A	0.59	5.85	0.35	1.54e-8	Glycated hemoglobin levels;
KIRP	trans	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg13565492	chr6:43139072	SRF	-0.97	-9.16	-0.5	2.09e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg14541582	chr5:601475	NA	-0.58	-6.59	-0.39	2.73e-10	Obesity-related traits;
KIRP	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg26695010	chr11:65641043	EFEMP2	0.47	5.65	0.34	4.5e-8	Eosinophil percentage of white cells;
KIRP	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.26	-0.37	1.71e-9	Monocyte percentage of white cells;
KIRP	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.39	-4.91	-0.3	1.63e-6	Height;
KIRP	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.01	-0.3	1.02e-6	Schizophrenia;
KIRP	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg16917193	chr12:54089295	NA	-0.53	-6.33	-0.37	1.16e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06544989	chr22:39130855	UNC84B	0.5	7.91	0.45	8.82e-14	Menopause (age at onset);
KIRP	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.55	7.63	0.44	5.07e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs66569888	0.607	rs11687271	chr2:106727456	G/A	cg16099169	chr2:106886729	NA	-0.4	-5.25	-0.32	3.28e-7	Facial morphology (factor 23);
KIRP	cis	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.56	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs12580194	0.593	rs7976828	chr12:55726450	A/T	cg19537932	chr12:55886519	OR6C68	-0.51	-6.55	-0.39	3.35e-10	Cancer;
KIRP	cis	rs240764	0.817	rs239239	chr6:101094554	A/G	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs1476670	0.565	rs942756	chr1:44522274	T/C	cg09470012	chr1:44509516	NA	0.33	5.23	0.32	3.57e-7	Eotaxin levels;
KIRP	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.57	0.73	6.1e-42	Electrocardiographic conduction measures;
KIRP	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.8	-0.35	2e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg21204522	chr6:27730016	NA	-0.71	-5.31	-0.32	2.48e-7	Depression;
KIRP	cis	rs11955398	0.585	rs10063407	chr5:60009063	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.33	1.65e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08934607	chr11:20409647	PRMT3	0.52	6.29	0.37	1.42e-9	Smoking initiation;
KIRP	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.43	6.45	0.38	5.87e-10	Major depressive disorder;
KIRP	trans	rs853308	1.000	rs853307	chr8:133930674	C/T	cg06478102	chr15:73992274	CD276	-0.48	-6.05	-0.36	5.49e-9	Vitiligo;
KIRP	cis	rs7714584	1.000	rs1000113	chr5:150240076	C/T	cg22134413	chr5:150180641	NA	0.79	6.91	0.4	4.03e-11	Crohn's disease;
KIRP	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg09491104	chr22:46646882	C22orf40	-0.55	-5.74	-0.34	2.77e-8	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20743544	chr7:32982957	RP9P	0.66	6.05	0.36	5.39e-9	Lung function (FEV1);
KIRP	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg04037228	chr3:45636386	LIMD1	0.36	5.31	0.32	2.5e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.65	-9.9	-0.53	1.19e-19	Brugada syndrome;
KIRP	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.54	7.2	0.42	7.43e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.66	8.19	0.46	1.42e-14	Mood instability;
KIRP	cis	rs754423	0.703	rs2029974	chr14:52522095	C/T	cg10149976	chr14:52535953	NID2	-0.4	-5.43	-0.33	1.32e-7	Craniofacial microsomia;
KIRP	cis	rs1978968	0.912	rs5992933	chr22:18457043	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-7.06	-0.41	1.67e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg05370193	chr1:21551575	ECE1	-0.42	-5.9	-0.35	1.21e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.28	-0.32	2.81e-7	Menarche (age at onset);
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-8.37	-0.47	4.24e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4690686	0.500	rs4690688	chr4:177264192	G/C	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.7	7.6	0.44	6.03e-13	Corneal astigmatism;
KIRP	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.21	0.37	2.21e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	5.29	0.32	2.74e-7	Renal cell carcinoma;
KIRP	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.11	-0.64	3.87e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.42	6.41	0.38	7.25e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg02378861	chr5:212933	CCDC127	-0.71	-5.6	-0.34	5.82e-8	Fat distribution (HIV);
KIRP	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg03641300	chr2:160917029	PLA2R1	-0.51	-7.97	-0.45	5.79e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.77	-0.53	2.86e-19	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01729820	chr17:17585298	RAI1	0.47	6.6	0.39	2.53e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.52	5.12	0.31	6.27e-7	Schizophrenia;
KIRP	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.19	0.51	1.75e-17	Colorectal cancer;
KIRP	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	8.59	0.48	1.01e-15	Height;
KIRP	cis	rs11874712	1.000	rs13381709	chr18:43670988	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.13e-8	Migraine - clinic-based;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11310629	chr13:45991975	SLC25A30	0.68	6.48	0.38	5.02e-10	Lung function (FEV1);
KIRP	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.33e-20	Hemoglobin concentration;
KIRP	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.42	-4.9	-0.3	1.74e-6	Longevity;Endometriosis;
KIRP	trans	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00950418	chr7:105029125	SRPK2	-0.53	-6.46	-0.38	5.66e-10	Height;
KIRP	cis	rs6681460	0.966	rs10889642	chr1:67143334	T/G	cg13052034	chr1:66999238	SGIP1	0.46	6.37	0.38	9.14e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg18877969	chr2:232395326	NMUR1	-0.36	-5.2	-0.31	4.1e-7	Height;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02475777	chr4:1388615	CRIPAK	0.39	5.27	0.32	2.99e-7	Longevity;
KIRP	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg00262122	chr8:11665843	FDFT1	-0.44	-5.4	-0.33	1.6e-7	Retinal vascular caliber;
KIRP	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg03235661	chr20:60525775	NA	-0.37	-5.64	-0.34	4.68e-8	Body mass index;
KIRP	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg23587288	chr2:27483067	SLC30A3	-0.7	-7.38	-0.43	2.44e-12	Blood metabolite levels;
KIRP	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg00405596	chr8:11794950	NA	-0.45	-5.82	-0.35	1.83e-8	Retinal vascular caliber;
KIRP	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.53	-5.06	-0.31	8.23e-7	Breast cancer;
KIRP	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg04455712	chr21:45112962	RRP1B	0.5	6.87	0.4	5.15e-11	Mean corpuscular volume;
KIRP	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg27494647	chr7:150038898	RARRES2	0.36	5.6	0.34	5.59e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.25	0.42	5.47e-12	Prudent dietary pattern;
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.44	-5.67	-0.34	4.07e-8	Testicular germ cell tumor;
KIRP	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg03476357	chr21:30257390	N6AMT1	0.44	4.87	0.3	2e-6	Cognitive test performance;
KIRP	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg21573476	chr21:45109991	RRP1B	-0.64	-8.62	-0.48	8.44e-16	Mean corpuscular volume;
KIRP	cis	rs6142102	0.602	rs4911145	chr20:32615223	C/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.57	-0.33	6.77e-8	Skin pigmentation;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21016266	chr12:122356598	WDR66	0.48	6.47	0.38	5.2e-10	Mean corpuscular volume;
KIRP	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.57	7.36	0.43	2.67e-12	Bladder cancer;
KIRP	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.51	6.65	0.39	1.84e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg18461458	chr19:21324796	ZNF431	-0.47	-4.96	-0.3	1.3e-6	Pain;
KIRP	cis	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg13456812	chr6:167369504	RNASET2	0.44	5.31	0.32	2.44e-7	Asthma;
KIRP	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.56	8.83	0.49	2.05e-16	Coronary artery disease;
KIRP	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg01763666	chr17:80159506	CCDC57	0.4	5.42	0.33	1.4e-7	Life satisfaction;
KIRP	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.77	-9.83	-0.53	1.85e-19	Aortic root size;
KIRP	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.6	-6.39	-0.38	8.46e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.52	-8.24	-0.47	1.04e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	ch.8.33884649F	chr8:33765107	NA	0.5	5.97	0.36	8.25e-9	Body mass index;
KIRP	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.48	-0.52	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21545522	chr1:205238299	TMCC2	0.5	6.9	0.4	4.34e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.56	-7.09	-0.41	1.38e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-7.49	-0.43	1.26e-12	Lymphocyte counts;
KIRP	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg15839431	chr19:19639596	YJEFN3	0.5	5.14	0.31	5.57e-7	Bipolar disorder;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg17608500	chr1:154955711	FLAD1	-0.5	-6.21	-0.37	2.3e-9	Type 1 diabetes nephropathy;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21016266	chr12:122356598	WDR66	0.65	9.12	0.5	2.82e-17	Mean corpuscular volume;
KIRP	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.0	-12.37	-0.62	1.23e-27	Alzheimer's disease;
KIRP	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.87	-14.78	-0.69	8.11e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.76	-0.44	2.29e-13	Total cholesterol levels;
KIRP	cis	rs2387326	0.767	rs12262323	chr10:129942672	G/A	cg16087940	chr10:129947807	NA	-0.36	-4.93	-0.3	1.49e-6	Select biomarker traits;
KIRP	cis	rs960902	0.643	rs7582414	chr2:37729971	G/C	cg25341268	chr2:37734390	NA	-0.53	-6.85	-0.4	5.96e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg20368463	chr18:77673604	PQLC1	0.64	5.16	0.31	5.08e-7	Opioid sensitivity;
KIRP	cis	rs241257	0.621	rs241271	chr1:4626255	T/C	cg08159291	chr1:4715615	AJAP1	0.44	5.29	0.32	2.64e-7	Anxiety disorder;
KIRP	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.49	-0.43	1.21e-12	Morning vs. evening chronotype;
KIRP	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	6.01e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.33	0.37	1.18e-9	Red blood cell count;
KIRP	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg23307798	chr14:103986281	CKB	0.73	11.44	0.59	1.4e-24	Body mass index;
KIRP	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.63	-8.77	-0.49	2.96e-16	Hip circumference;
KIRP	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.34	5.28	0.32	2.9e-7	Testicular germ cell tumor;
KIRP	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	8.6	0.48	9.19e-16	Lung cancer in ever smokers;
KIRP	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.77	11.34	0.59	3.01e-24	Hip circumference;
KIRP	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	5.54	0.33	7.94e-8	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01560399	chr20:10655464	JAG1	0.54	6.94	0.4	3.49e-11	Parkinson's disease;
KIRP	cis	rs17761864	0.675	rs72815344	chr17:2046947	T/C	cg16513277	chr17:2031491	SMG6	0.44	5.26	0.32	3.19e-7	Esophageal cancer (squamous cell);
KIRP	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg24324837	chr19:49891574	CCDC155	0.64	7.91	0.45	8.83e-14	Multiple sclerosis;
KIRP	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	1.09	20.03	0.79	1.36e-53	Gut microbiome composition (winter);
KIRP	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.26	-0.32	3.15e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg09060608	chr5:178986726	RUFY1	-0.41	-6.06	-0.36	5.12e-9	Lung cancer;
KIRP	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg18709589	chr6:96969512	KIAA0776	-0.37	-5.42	-0.33	1.39e-7	Headache;
KIRP	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg08873628	chr1:175162347	KIAA0040	0.44	6.53	0.38	3.78e-10	Alcohol dependence;
KIRP	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.42	5.35	0.32	2.06e-7	Prostate cancer;
KIRP	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg06995285	chr7:2418615	EIF3B	0.8	8.31	0.47	6.59e-15	Multiple sclerosis;
KIRP	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg09507567	chr10:124027408	NA	0.3	5.44	0.33	1.27e-7	Total body bone mineral density;
KIRP	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg04507495	chr3:47563649	NA	-1.17	-6.43	-0.38	6.65e-10	Stem cell growth factor beta levels;
KIRP	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.39	-5.73	-0.34	2.86e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg00262122	chr8:11665843	FDFT1	0.4	4.9	0.3	1.78e-6	Neuroticism;
KIRP	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.41	-6.36	-0.38	9.86e-10	Eye color traits;
KIRP	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	cis	rs2856321	0.874	rs1009951	chr12:11892896	C/T	cg25165382	chr12:12877503	APOLD1	0.42	5.28	0.32	2.84e-7	Height;
KIRP	cis	rs59868192	0.925	rs72726034	chr15:42258954	C/A	cg20935245	chr15:42234343	EHD4	-0.56	-5.52	-0.33	8.57e-8	White blood cell count;
KIRP	cis	rs2970818	0.831	rs2909380	chr12:4607342	A/T	cg14576962	chr12:4671597	NA	-0.45	-4.96	-0.3	1.31e-6	Phosphorus levels;
KIRP	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.65	0.34	4.31e-8	Skin colour saturation;
KIRP	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs2625529	0.617	rs3784313	chr15:72187519	G/T	cg16672083	chr15:72433130	SENP8	0.46	6.41	0.38	7.49e-10	Red blood cell count;
KIRP	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05233311	chr7:65670241	TPST1	-0.49	-6.51	-0.38	4.3e-10	Myopia;
KIRP	cis	rs1570884	1.000	rs1570884	chr13:50121511	A/G	cg03651054	chr13:50194643	NA	0.59	8.04	0.46	3.69e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs3087591	0.960	rs11868459	chr17:29458197	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	10.21	0.55	1.23e-20	Hip circumference;
KIRP	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	cis	rs7113850	0.541	rs7944769	chr11:24224823	G/C	ch.11.24196551F	chr11:24239977	NA	0.9	8.35	0.47	5.02e-15	Bone fracture in osteoporosis;
KIRP	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.87	14.05	0.67	2.6e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.96	-0.41	3e-11	Joint mobility (Beighton score);
KIRP	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.7	-9.43	-0.52	3.32e-18	Body mass index;
KIRP	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.61	-0.34	5.53e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs4721295	0.540	rs59134428	chr7:2195445	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-5.64	-0.34	4.62e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg04935436	chr20:30431758	NA	0.49	6.54	0.39	3.46e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.42	-6.01	-0.36	6.69e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs883565	0.655	rs6599275	chr3:39050758	C/A	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg18225595	chr11:63971243	STIP1	0.57	5.14	0.31	5.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.77	-7.54	-0.43	8.86e-13	Bipolar disorder;
KIRP	cis	rs11637445	0.603	rs1478941	chr15:68127141	A/G	cg24579218	chr15:68104479	NA	-0.43	-6.57	-0.39	2.97e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.84	0.45	1.38e-13	Coffee consumption (cups per day);
KIRP	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.77	-0.35	2.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg18306943	chr3:40428807	ENTPD3	0.46	5.93	0.35	1.02e-8	Renal cell carcinoma;
KIRP	cis	rs7312774	0.618	rs3759317	chr12:107370252	T/C	cg16260113	chr12:107380972	MTERFD3	0.82	6.96	0.41	3.15e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs1134634	0.520	rs4280724	chr4:15575751	C/T	cg16509355	chr4:15471240	CC2D2A	-0.31	-5.36	-0.32	1.91e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg07638904	chr22:19166425	SLC25A1	0.53	6.39	0.38	8.47e-10	Electroencephalogram traits;
KIRP	cis	rs858239	0.509	rs6962213	chr7:23188109	G/A	cg23682824	chr7:23144976	KLHL7	0.43	4.98	0.3	1.18e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9290877	0.667	rs6801161	chr3:188458169	T/A	cg17392043	chr3:188495102	LPP	-0.53	-6.89	-0.4	4.57e-11	IgE levels;
KIRP	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08280861	chr8:58055591	NA	0.73	5.84	0.35	1.62e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs71277158	0.688	rs2241292	chr3:169798962	C/G	cg04067573	chr3:169899625	PHC3	0.63	5.99	0.36	7.54e-9	Prostate cancer;
KIRP	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg21858823	chr1:15850916	CASP9	0.53	5.14	0.31	5.71e-7	Systolic blood pressure;
KIRP	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.59	8.63	0.48	7.96e-16	Obesity-related traits;
KIRP	cis	rs7638909	0.512	rs6804918	chr3:38598956	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-6.89	-0.4	4.6e-11	Electrocardiographic conduction measures;
KIRP	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.82	13.93	0.66	6.55e-33	Longevity;
KIRP	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg01559446	chr3:44596178	ZNF167	-0.39	-5.41	-0.33	1.49e-7	Depressive symptoms;
KIRP	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg12573791	chr2:3828286	NA	0.41	5.68	0.34	3.88e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg18279126	chr7:2041391	MAD1L1	0.48	5.09	0.31	7.26e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-5.57	-0.33	6.7e-8	Parkinson's disease;
KIRP	cis	rs2219968	0.828	rs28764193	chr8:78942561	T/G	cg00738934	chr8:78996279	NA	-0.37	-5.02	-0.3	1e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg21252483	chr19:49399788	TULP2	-0.43	-5.72	-0.34	3.1e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.02	-0.36	6.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6782380	0.832	rs7650257	chr3:55191554	C/T	cg17926756	chr3:55217960	NA	0.3	4.89	0.3	1.85e-6	Coronary artery calcification;
KIRP	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg15068132	chr12:102092402	CHPT1	-0.39	-5.15	-0.31	5.45e-7	Blood protein levels;
KIRP	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.29	-0.32	2.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.74	-8.48	-0.48	2.08e-15	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.76	-9.87	-0.53	1.46e-19	Coronary artery disease;
KIRP	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg16586182	chr3:47516702	SCAP	0.83	11.9	0.6	4.44e-26	Colorectal cancer;
KIRP	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27297192	chr10:134578999	INPP5A	0.62	7.79	0.44	1.93e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg04990556	chr1:26633338	UBXN11	0.65	6.6	0.39	2.54e-10	Obesity-related traits;
KIRP	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg01721255	chr8:58191610	C8orf71	0.48	5.26	0.32	3.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.42	-0.38	6.9e-10	Neuroticism;
KIRP	cis	rs4702718	0.508	rs9857	chr5:10680547	A/G	cg14521931	chr5:10832172	NA	0.43	5.16	0.31	4.99e-7	Obesity-related traits;
KIRP	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg23307798	chr14:103986281	CKB	0.74	11.83	0.6	7.49e-26	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07293993	chr15:80188894	MTHFS	0.44	6.48	0.38	4.92e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.41	6.2	0.37	2.42e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs981844	0.712	rs4469056	chr4:154745796	A/T	cg14289246	chr4:154710475	SFRP2	0.54	6.97	0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs7404928	0.718	rs12447916	chr16:23858915	G/A	cg21745164	chr16:23765304	CHP2	-0.64	-7.9	-0.45	9.19e-14	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg22307029	chr19:49891270	CCDC155	0.68	6.3	0.37	1.36e-9	Multiple sclerosis;
KIRP	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg13409248	chr3:40428643	ENTPD3	0.41	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.66	9.81	0.53	2.24e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	trans	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg00938859	chr5:1591904	SDHAP3	0.53	6.26	0.37	1.69e-9	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22237459	chr1:206680720	RASSF5	0.48	6.69	0.39	1.52e-10	Parkinson's disease;
KIRP	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg18016565	chr1:150552671	MCL1	0.37	5.52	0.33	8.5e-8	Urate levels;
KIRP	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.56	8.21	0.46	1.23e-14	Huntington's disease progression;
KIRP	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg00784671	chr22:46762841	CELSR1	-0.59	-8.46	-0.47	2.42e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg03678062	chr6:149772716	ZC3H12D	0.31	4.94	0.3	1.43e-6	Dupuytren's disease;
KIRP	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.41	0.33	1.46e-7	Lung cancer;
KIRP	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.6	8.48	0.48	2.14e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9644630	0.930	rs7005075	chr8:19367452	G/C	cg01280390	chr8:19363452	CSGALNACT1	0.38	5.01	0.3	1.04e-6	Oropharynx cancer;
KIRP	cis	rs12210905	1.000	rs12208534	chr6:27066759	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.49	7.05	0.41	1.8e-11	Kawasaki disease;
KIRP	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.28	15.8	0.71	2.74e-39	Corneal structure;
KIRP	cis	rs9815354	0.857	rs794902	chr3:42025939	T/C	cg03022575	chr3:42003672	ULK4	-0.55	-6.06	-0.36	5.17e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg13941235	chr9:137270186	RXRA	0.25	5.08	0.31	7.33e-7	Intelligence;
KIRP	cis	rs9943753	0.508	rs5013021	chr12:109790752	C/A	cg19025524	chr12:109796872	NA	-0.49	-6.93	-0.4	3.75e-11	HDL cholesterol;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg19990977	chr19:10654446	ATG4D	0.49	6.07	0.36	4.88e-9	Beard thickness;
KIRP	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.8	10.76	0.57	2.17e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg27631724	chr1:11040367	C1orf127	0.45	9.27	0.51	9.61e-18	Ewing sarcoma;
KIRP	cis	rs7809799	0.571	rs66478766	chr7:98915401	G/A	cg12290671	chr7:99195819	NA	-0.69	-5.27	-0.32	2.97e-7	Ulcerative colitis;
KIRP	cis	rs60154123	0.730	rs12074229	chr1:210474602	A/G	cg09074223	chr1:210466472	NA	0.52	5.57	0.33	6.53e-8	Coronary artery disease;
KIRP	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg26373071	chr5:1325741	CLPTM1L	0.55	7.38	0.43	2.45e-12	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12656632	chr6:42981813	MEA1;KLHDC3	0.45	6.1	0.36	4.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg25173405	chr17:45401733	C17orf57	-0.51	-6.64	-0.39	2.02e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-5.21	-0.32	3.99e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs17834760	0.955	rs1832208	chr6:62096668	T/C	cg08476511	chr6:168435923	KIF25	0.51	6.04	0.36	5.78e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09997339	chr21:35743006	KCNE2	0.58	6.46	0.38	5.7e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.58	6.52	0.38	4.02e-10	Lung cancer in ever smokers;
KIRP	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	12.98	0.64	1.06e-29	Platelet count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18849300	chr3:48723061	NCKIPSD	0.45	6.45	0.38	5.96e-10	Survival in pancreatic cancer;
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.69	10.4	0.55	3.01e-21	Menarche (age at onset);
KIRP	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg17376030	chr22:41985996	PMM1	-0.83	-8.87	-0.49	1.57e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs5995756	0.736	rs17401961	chr22:40012284	G/A	cg10455938	chr22:40058150	CACNA1I	-0.59	-8.79	-0.49	2.63e-16	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.77	7.67	0.44	3.99e-13	Methadone dose in opioid dependence;
KIRP	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Parkinson's disease;
KIRP	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg09904177	chr6:26538194	HMGN4	0.44	5.94	0.35	9.66e-9	Schizophrenia;
KIRP	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg20991723	chr1:152506922	NA	-0.45	-5.48	-0.33	1.04e-7	Hair morphology;
KIRP	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg10760299	chr15:45669010	GATM	0.33	4.85	0.3	2.21e-6	Homoarginine levels;
KIRP	cis	rs8038465	1.000	rs8032727	chr15:73977336	A/G	cg15420318	chr15:73925796	NPTN	0.57	7.21	0.42	6.94e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg21775007	chr8:11205619	TDH	0.53	6.58	0.39	2.88e-10	Mood instability;
KIRP	cis	rs9972944	0.702	rs6416947	chr17:63763970	C/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.84	-0.45	1.35e-13	Total body bone mineral density;
KIRP	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.55	-6.79	-0.4	8.6e-11	Type 2 diabetes;
KIRP	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.61	-0.39	2.39e-10	Obesity-related traits;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.82	11.24	0.58	6.45e-24	Height;
KIRP	trans	rs4349753	0.904	rs13160749	chr5:144168451	A/T	cg16033277	chr17:80885358	TBCD	0.4	6.25	0.37	1.82e-9	Photic sneeze reflex;
KIRP	cis	rs7191700	0.836	rs28502009	chr16:11426541	G/A	cg00044050	chr16:11439710	C16orf75	0.48	5.02	0.3	9.81e-7	Multiple sclerosis;
KIRP	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg26065057	chr18:74961000	GALR1	0.76	7.73	0.44	2.73e-13	Obesity-related traits;
KIRP	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.53	-6.75	-0.4	1.08e-10	Longevity;
KIRP	trans	rs6596140	0.620	rs62373494	chr5:133030745	T/C	cg08567913	chr11:114082594	ZBTB16	-0.44	-6.25	-0.37	1.8e-9	Hypertension;
KIRP	cis	rs231513	0.954	rs231504	chr17:41970906	C/G	cg26893861	chr17:41843967	DUSP3	-0.5	-5.25	-0.32	3.28e-7	Cognitive function;
KIRP	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg25182066	chr10:30743637	MAP3K8	-0.61	-7.41	-0.43	2.04e-12	Inflammatory bowel disease;
KIRP	trans	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg18187862	chr3:45730750	SACM1L	0.53	6.09	0.36	4.24e-9	Primary sclerosing cholangitis;
KIRP	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg26727032	chr16:67993705	SLC12A4	-0.53	-4.93	-0.3	1.53e-6	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.91	-0.45	8.48e-14	Neuroticism;
KIRP	cis	rs4356932	1.000	rs6845396	chr4:76951550	G/T	cg19388996	chr4:76862389	NAAA	-0.41	-5.2	-0.31	4.21e-7	Blood protein levels;
KIRP	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg12560992	chr17:57184187	TRIM37	0.7	6.76	0.4	9.88e-11	Cognitive test performance;
KIRP	cis	rs7870753	0.838	rs7860447	chr9:99263937	T/C	cg25260653	chr9:99212216	HABP4	0.53	5.77	0.35	2.33e-8	Height;
KIRP	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg00784671	chr22:46762841	CELSR1	-0.73	-9.03	-0.5	5.17e-17	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg13444842	chr1:152974279	SPRR3	-0.37	-5.27	-0.32	3.03e-7	Inflammatory skin disease;
KIRP	cis	rs7215564	0.908	rs36100789	chr17:78701117	C/T	cg06153925	chr17:78755379	RPTOR	0.36	5.71	0.34	3.17e-8	Myopia (pathological);
KIRP	cis	rs4845459	0.967	rs6693105	chr1:152590663	C/T	cg07796016	chr1:152779584	LCE1C	0.47	5.9	0.35	1.21e-8	Psoriasis;
KIRP	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.87	-0.53	1.39e-19	Response to antipsychotic treatment;
KIRP	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg02376097	chr19:46275166	DMPK	0.48	6.54	0.38	3.58e-10	Coronary artery disease;
KIRP	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08822215	chr16:89438651	ANKRD11	-0.47	-6.49	-0.38	4.63e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	trans	rs12517041	1.000	rs6875447	chr5:23305303	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.89	-0.3	1.85e-6	Obesity-related traits;
KIRP	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg02725872	chr8:58115012	NA	-0.5	-6.17	-0.37	2.8e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	1.04	20.17	0.79	4.8e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.7	-7.66	-0.44	4.33e-13	Gut microbiome composition (summer);
KIRP	cis	rs2120243	0.539	rs7629293	chr3:157114462	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.75e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9372498	0.572	rs10484289	chr6:118827836	T/C	cg21191810	chr6:118973309	C6orf204	-0.43	-4.85	-0.3	2.22e-6	Diastolic blood pressure;
KIRP	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.14	16.25	0.72	7.84e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs1451375	0.657	rs12672526	chr7:50657695	C/T	cg00647317	chr7:50633725	DDC	-0.4	-5.19	-0.31	4.51e-7	Malaria;
KIRP	cis	rs17407555	0.821	rs55919137	chr4:10133803	C/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-4.95	-0.3	1.35e-6	Schizophrenia (age at onset);
KIRP	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg18944383	chr4:111397179	ENPEP	0.61	11.1	0.58	1.78e-23	Height;
KIRP	cis	rs78545713	1.000	rs16891484	chr6:26242930	G/A	cg01420254	chr6:26195488	NA	0.65	5.18	0.31	4.67e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs35883536	1.000	rs2050472	chr1:101125560	T/C	cg06223162	chr1:101003688	GPR88	0.34	6.97	0.41	2.96e-11	Monocyte count;
KIRP	trans	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-8.02	-0.46	4.24e-14	Colorectal cancer;
KIRP	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	0.96	13.05	0.64	6.45e-30	Ulcerative colitis;
KIRP	cis	rs4654899	1.000	rs6681064	chr1:21339644	A/G	cg05370193	chr1:21551575	ECE1	0.4	5.34	0.32	2.15e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	11.79	0.6	9.83e-26	Monocyte count;
KIRP	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg25281562	chr12:121454272	C12orf43	0.5	5.58	0.34	6.25e-8	N-glycan levels;
KIRP	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.22	-0.58	7.37e-24	Body mass index;
KIRP	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.75	11.14	0.58	1.28e-23	Blood metabolite ratios;
KIRP	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.73	-10.5	-0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1433375	1.000	rs2391428	chr4:130354547	A/C	cg12478290	chr2:47403936	CALM2	0.5	6.08	0.36	4.44e-9	Problematic alcohol use in trauma-exposed individuals;
KIRP	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg10096100	chr1:26503862	CNKSR1	0.42	5.86	0.35	1.44e-8	Height;
KIRP	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.66	-7.49	-0.43	1.26e-12	Tonometry;
KIRP	cis	rs2070997	0.702	rs2841177	chr9:133764207	C/T	cg13397898	chr9:133768931	QRFP	0.41	5.32	0.32	2.35e-7	Response to amphetamines;
KIRP	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.8	0.6	8.89e-26	Cannabis dependence symptom count;
KIRP	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg16141378	chr3:129829833	LOC729375	0.56	6.74	0.39	1.12e-10	Neuroticism;
KIRP	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00290607	chr11:67383545	NA	0.35	4.89	0.3	1.82e-6	Mean corpuscular volume;
KIRP	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg05802129	chr4:122689817	NA	0.46	6.7	0.39	1.43e-10	Type 2 diabetes;
KIRP	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg09473613	chr1:24152604	HMGCL	0.48	6.47	0.38	5.2e-10	Immature fraction of reticulocytes;
KIRP	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.5	-6.5	-0.38	4.55e-10	Blood metabolite levels;
KIRP	cis	rs60871478	0.853	rs62432222	chr7:787194	T/C	cg13798912	chr7:905769	UNC84A	0.65	6.31	0.37	1.33e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg21174375	chr14:64681225	SYNE2	0.68	9.32	0.51	6.94e-18	Atrial fibrillation;
KIRP	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.97	-12.28	-0.62	2.44e-27	Response to antineoplastic agents;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg05868516	chr6:26286170	HIST1H4H	0.4	5.44	0.33	1.28e-7	Educational attainment;
KIRP	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg20387954	chr3:183756860	HTR3D	0.64	9.43	0.52	3.21e-18	Anterior chamber depth;
KIRP	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21643547	chr1:205240462	TMCC2	-0.88	-14.11	-0.67	1.62e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	1.06	14.59	0.68	3.62e-35	Menopause (age at onset);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg23396286	chr10:99258505	UBTD1;MMS19	0.53	6.35	0.38	1.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.6	11.32	0.59	3.38e-24	Bone mineral density;
KIRP	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.37	5.74	0.34	2.77e-8	Bone mineral density;
KIRP	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	4.06e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.12	-0.61	7.95e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24706213	chr1:109633347	TMEM167B	0.51	6.26	0.37	1.72e-9	Myopia (pathological);
KIRP	cis	rs4356932	1.000	rs7684461	chr4:76962996	G/T	cg00809888	chr4:76862425	NAAA	-0.44	-6.14	-0.36	3.2e-9	Blood protein levels;
KIRP	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.51	-6.78	-0.4	8.68e-11	Hip circumference;Waist circumference;
KIRP	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.66	8.63	0.48	7.86e-16	Bladder cancer;
KIRP	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	1.1	15.29	0.7	1.49e-37	Multiple sclerosis;
KIRP	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.79	10.94	0.57	6.04e-23	Coronary artery disease;
KIRP	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg17376030	chr22:41985996	PMM1	-0.54	-5.77	-0.35	2.43e-8	Vitiligo;
KIRP	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg21466736	chr12:48725269	NA	0.44	5.61	0.34	5.49e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs4790312	0.782	rs4790310	chr17:1966920	C/T	cg24156229	chr17:1948635	NA	-0.39	-4.86	-0.3	2.09e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.42	-0.51	3.4e-18	Bipolar disorder and schizophrenia;
KIRP	cis	rs933360	0.503	rs11238339	chr7:50870629	C/T	cg14997413	chr7:51384937	COBL	0.31	4.85	0.3	2.22e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs4774830	0.744	rs62046394	chr15:56316356	C/A	cg24530489	chr15:56299380	NA	-0.9	-4.89	-0.3	1.86e-6	Delta-5 desaturase activity;
KIRP	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg26898376	chr11:64110657	CCDC88B	0.58	4.9	0.3	1.77e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs17092148	0.652	rs4911154	chr20:32996101	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	4.93	0.3	1.5e-6	Neuroticism;
KIRP	cis	rs1010254	0.510	rs2112538	chr5:151711392	G/T	cg12297329	chr5:152029980	NA	-0.63	-6.45	-0.38	5.82e-10	Optic nerve measurement (cup area);
KIRP	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.54	-8.2	-0.46	1.35e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs10465746	0.780	rs10874423	chr1:84374071	C/T	cg10977910	chr1:84465055	TTLL7	0.55	6.86	0.4	5.6e-11	Obesity-related traits;
KIRP	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.81	-11.27	-0.58	4.9299999999999996e-24	Vitiligo;
KIRP	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.91	10.65	0.56	4.83e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.57	7.4	0.43	2.21e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg03289416	chr15:75166202	SCAMP2	-0.42	-5.44	-0.33	1.28e-7	Systemic lupus erythematosus;
KIRP	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg26207909	chr14:103986467	CKB	-0.42	-5.14	-0.31	5.73e-7	Coronary artery disease;
KIRP	cis	rs17407555	0.657	rs10489076	chr4:10270848	T/C	cg11266682	chr4:10021025	SLC2A9	0.35	5.35	0.32	2e-7	Schizophrenia (age at onset);
KIRP	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg05991184	chr2:219186017	PNKD	0.39	5.62	0.34	5.12e-8	Colorectal cancer;
KIRP	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.62	8.47	0.48	2.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.53	7.11	0.41	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.31	0.37	1.26e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.46	5.8	0.35	2.03e-8	Neuranatomic and neurocognitive phenotypes;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12951224	chr8:38126910	PPAPDC1B	0.51	6.61	0.39	2.3e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6901250	0.589	rs684023	chr6:117092308	T/C	cg05399210	chr6:117082661	FAM162B	-0.48	-6.84	-0.4	6.17e-11	C-reactive protein levels;
KIRP	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg10047753	chr17:41438598	NA	1.15	17.61	0.75	1.76e-45	Menopause (age at onset);
KIRP	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg06808227	chr14:105710500	BRF1	-0.79	-10.14	-0.54	1.98e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.73	-7.13	-0.41	1.14e-11	Cognitive test performance;
KIRP	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.34	6.11	0.36	3.77e-9	Renal cell carcinoma;
KIRP	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.37	0.43	2.56e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.71	-10.89	-0.57	8.26e-23	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.46	-0.33	1.18e-7	Lung cancer;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.76	-9.77	-0.53	2.82e-19	Longevity;Endometriosis;
KIRP	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg02297831	chr4:17616191	MED28	0.58	7.0	0.41	2.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.93	0.64	1.57e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10875746	0.855	rs11168369	chr12:48431168	G/A	cg26205652	chr12:48591994	NA	0.78	10.52	0.56	1.26e-21	Longevity (90 years and older);
KIRP	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg02696790	chr15:75250997	RPP25	0.34	5.54	0.33	7.57e-8	Caffeine consumption;
KIRP	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.92	-14.16	-0.67	1.04e-33	Systemic lupus erythematosus;
KIRP	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14895029	chr7:2775587	GNA12	-0.44	-5.19	-0.31	4.46e-7	Height;
KIRP	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	1.07	17.12	0.74	8.34e-44	Cognitive function;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12894883	chr22:22288473	PPM1F	0.49	6.4	0.38	8e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13102973	0.720	rs13122447	chr4:135887524	C/T	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs11997175	0.510	rs34465523	chr8:33796849	C/T	cg04338863	chr8:33670619	NA	0.48	6.49	0.38	4.75e-10	Body mass index;
KIRP	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.39	5.39	0.33	1.63e-7	Endometrial cancer;
KIRP	trans	rs10782582	0.758	rs6687882	chr1:76364825	C/A	cg10283277	chr11:111472630	SIK2	-0.31	-6.3	-0.37	1.33e-9	Daytime sleep phenotypes;
KIRP	cis	rs752010	0.749	rs12141084	chr1:42117737	C/T	cg06885757	chr1:42089581	HIVEP3	0.43	6.44	0.38	6.23e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs988913	1.000	rs6902422	chr6:54811210	C/T	cg03513858	chr6:54763001	FAM83B	0.37	5.26	0.32	3.15e-7	Menarche (age at onset);
KIRP	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.95	-16.1	-0.72	2.48e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg05315796	chr3:52349193	DNAH1	0.45	6.87	0.4	5.35e-11	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.03	-0.31	9.58e-7	Life satisfaction;
KIRP	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg21972741	chr5:435613	AHRR	0.52	6.43	0.38	6.72e-10	Cystic fibrosis severity;
KIRP	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.33	-0.32	2.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11987759	chr7:65425863	GUSB	-0.46	-5.44	-0.33	1.3e-7	Aortic root size;
KIRP	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg06115741	chr20:33292138	TP53INP2	0.4	4.9	0.3	1.76e-6	Height;
KIRP	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26314531	chr2:26401878	FAM59B	0.49	5.21	0.32	3.95e-7	Gut microbiome composition (summer);
KIRP	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.64	-7.49	-0.43	1.2e-12	Menarche (age at onset);
KIRP	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.71	10.09	0.54	3.02e-20	High light scatter reticulocyte count;
KIRP	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.47	-4.91	-0.3	1.63e-6	Smoking behavior;
KIRP	cis	rs3105593	1.000	rs4509958	chr15:50894175	T/C	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.26e-7	QT interval;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27511208	chr1:33336611	FNDC5	-0.58	-7.23	-0.42	6.08e-12	Menopause (age at onset);
KIRP	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.52	-6.13	-0.36	3.54e-9	Aortic root size;
KIRP	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.21	0.51	1.49e-17	Total body bone mineral density;
KIRP	cis	rs714515	0.867	rs7534393	chr1:172318031	T/C	cg01573306	chr1:172330400	DNM3	-0.49	-6.35	-0.38	1.03e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.69	9.21	0.51	1.44e-17	Height;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg08805041	chr16:621841	PIGQ	-0.39	-5.29	-0.32	2.75e-7	Height;
KIRP	cis	rs9399401	0.626	rs7776356	chr6:142777029	A/G	cg03128060	chr6:142623767	GPR126	0.36	5.2	0.31	4.21e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs7728043	0.609	rs1175369	chr5:5908670	T/G	cg14539658	chr14:21495146	NDRG2	0.38	6.02	0.36	6.45e-9	QT interval;
KIRP	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.9	-14.25	-0.67	5.46e-34	Calcium levels;
KIRP	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.61	-0.6	3.83e-25	Body mass index;
KIRP	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.05	0.36	5.31e-9	Intraocular pressure;
KIRP	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.53	-7.26	-0.42	4.94e-12	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.71	-7.29	-0.42	4.1e-12	Verbal memory performance (residualized delayed recall change);
KIRP	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg15655495	chr12:38532458	NA	0.25	4.93	0.3	1.49e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.76	-11.35	-0.59	2.8e-24	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg04025307	chr7:1156635	C7orf50	0.81	8.28	0.47	8.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs735860	0.712	rs9395855	chr6:53176765	G/T	cg10236188	chr6:53219634	NA	-0.43	-5.74	-0.34	2.83e-8	Glaucoma;
KIRP	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Retinal vascular caliber;
KIRP	trans	rs6993244	1	rs6993244	chr8:8863059	C/G	cg16141378	chr3:129829833	LOC729375	-0.53	-7.11	-0.41	1.25e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.16	-0.37	3e-9	Lung cancer;
KIRP	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg19090574	chr1:205240910	TMCC2	0.38	4.96	0.3	1.34e-6	Platelet count;
KIRP	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg12042659	chr19:58951599	ZNF132	0.53	6.43	0.38	6.43e-10	Uric acid clearance;
KIRP	trans	rs17834760	0.955	rs977382	chr6:62060364	T/C	cg08476511	chr6:168435923	KIF25	0.51	6.09	0.36	4.25e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.62	8.59	0.48	1.01e-15	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-7.39	-0.43	2.27e-12	Lung cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08971769	chr10:75258327	USP54	0.45	6.01	0.36	6.5e-9	Survival in pancreatic cancer;
KIRP	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.21	-0.51	1.51e-17	Response to antipsychotic treatment;
KIRP	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.45	-6.98	-0.41	2.8e-11	Inflammatory bowel disease;
KIRP	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg02336718	chr17:17403227	NA	0.33	5.2	0.31	4.1e-7	Total body bone mineral density;
KIRP	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.15	0.41	9.74e-12	Height;
KIRP	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.84	0.35	1.63e-8	Breast cancer;
KIRP	trans	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg05926928	chr17:57297772	GDPD1	-0.86	-8.85	-0.49	1.7e-16	Opioid sensitivity;
KIRP	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.35	-5.03	-0.31	9.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.78	8.64	0.48	7.04e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg03808351	chr9:123631620	PHF19	0.39	5.3	0.32	2.56e-7	Rheumatoid arthritis;
KIRP	cis	rs12210905	0.841	rs12206996	chr6:27066415	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs2281603	0.570	rs28766386	chr14:64946397	T/C	cg01860774	chr14:64969374	ZBTB25	0.33	5.49	0.33	1e-7	Lymphocyte counts;
KIRP	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	0.47	6.11	0.36	3.82e-9	Systemic lupus erythematosus;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02218214	chr1:63062489	DOCK7;ANGPTL3	-0.45	-6.35	-0.38	1.04e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg20636351	chr8:55087400	NA	-0.53	-6.6	-0.39	2.54e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02915570	chr16:10674663	EMP2	0.47	6.08	0.36	4.65e-9	Parkinson's disease;
KIRP	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg12856521	chr11:46389249	DGKZ	0.54	7.06	0.41	1.68e-11	Crohn's disease;
KIRP	cis	rs4742903	1.000	rs7350148	chr9:106883085	T/G	cg14250997	chr9:106856677	SMC2	0.4	5.33	0.32	2.25e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg06953865	chr19:18549723	ISYNA1	-0.42	-6.38	-0.38	8.96e-10	Breast cancer;
KIRP	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.96	14.54	0.68	5.68e-35	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg27189623	chr16:705930	WDR90	0.43	5.94	0.35	9.7e-9	Height;
KIRP	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.24	0.58	6.2e-24	Alzheimer's disease;
KIRP	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.51	0.33	9.09e-8	Educational attainment;
KIRP	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18252515	chr7:66147081	NA	0.44	5.11	0.31	6.43e-7	Aortic root size;
KIRP	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.03	-0.67	3.08e-33	Primary sclerosing cholangitis;
KIRP	cis	rs4262150	0.774	rs17565839	chr5:152082740	C/T	cg12297329	chr5:152029980	NA	-0.66	-8.08	-0.46	2.99e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.54	6.37	0.38	9.41e-10	Aortic root size;
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg13092806	chr2:177043255	NA	0.63	8.68	0.48	5.45e-16	IgG glycosylation;
KIRP	cis	rs829883	0.622	rs4762498	chr12:98964737	A/G	cg25150519	chr12:98850993	NA	-0.76	-9.28	-0.51	9.44e-18	Colorectal adenoma (advanced);
KIRP	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.41	6.55	0.39	3.3e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.48	-0.38	4.92e-10	Bone mineral density;
KIRP	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.93	-0.49	1.04e-16	Exhaled nitric oxide output;
KIRP	cis	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.36	-0.42	2.75e-12	Morning vs. evening chronotype;
KIRP	trans	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.36	0.42	2.72e-12	Mean corpuscular volume;
KIRP	cis	rs597583	0.671	rs4938401	chr11:117399605	T/G	cg27161313	chr11:117392002	DSCAML1	-0.73	-7.29	-0.42	4.31e-12	Putamen volume;
KIRP	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg24565620	chr2:194026	NA	-0.72	-5.42	-0.33	1.44e-7	Blood protein levels;
KIRP	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.19	0.51	1.75e-17	Colorectal cancer;
KIRP	cis	rs9367716	0.917	rs9349850	chr6:57122627	G/A	cg03371099	chr6:57305889	PRIM2	0.46	6.02	0.36	6.44e-9	Coronary artery disease;
KIRP	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg14580859	chr9:123691850	NA	-0.35	-4.99	-0.3	1.13e-6	Rheumatoid arthritis;
KIRP	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.98	10.63	0.56	5.65e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg25173405	chr17:45401733	C17orf57	0.5	6.89	0.4	4.67e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs981844	0.775	rs17299561	chr4:154765480	C/T	cg14289246	chr4:154710475	SFRP2	0.59	6.98	0.41	2.67e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2820315	1.000	rs2132363	chr1:201826482	C/T	cg11586189	chr1:201857591	SHISA4	-0.39	-5.46	-0.33	1.14e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg25019033	chr10:957182	NA	-0.66	-7.98	-0.45	5.54e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg03128060	chr6:142623767	GPR126	0.35	5.13	0.31	5.87e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs1891498	0.571	rs10793703	chr1:147238752	C/T	cg27546670	chr1:147246839	GJA5	-0.76	-10.68	-0.56	3.94e-22	Cognitive performance;
KIRP	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.78	-10.61	-0.56	6.77e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg23758822	chr17:41437982	NA	0.91	10.41	0.55	3e-21	Menopause (age at onset);
KIRP	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.73	0.53	3.79e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.6	-6.01	-0.36	6.69e-9	Body mass index;
KIRP	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg13753209	chr17:57696993	CLTC	0.51	4.94	0.3	1.42e-6	Hemoglobin concentration;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg07216194	chr8:27182965	PTK2B	0.44	5.52	0.33	8.66e-8	Neuroticism;
KIRP	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.35	0.32	2.04e-7	Vitiligo;
KIRP	cis	rs287982	1.000	rs287981	chr2:9971562	A/G	cg18436444	chr2:10917754	ATP6V1C2	0.34	5.01	0.3	1.05e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7084402	0.967	rs1649046	chr10:60326109	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.9	-0.57	7.95e-23	Refractive error;
KIRP	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.51	7.19	0.42	7.53e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg18187862	chr3:45730750	SACM1L	-0.58	-6.35	-0.38	1.04e-9	Primary sclerosing cholangitis;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg10100747	chr14:71787215	NA	-0.45	-6.03	-0.36	6.03e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs4478137	0.501	rs28477602	chr4:164230477	C/T	cg06758707	chr4:164254230	NPY1R	-0.47	-5.07	-0.31	7.69e-7	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.59	7.05	0.41	1.81e-11	Coronary artery disease;
KIRP	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg23100626	chr2:96804247	ASTL	0.45	6.25	0.37	1.81e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.3	5.96	0.36	8.55e-9	Schizophrenia;
KIRP	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.74	11.46	0.59	1.16e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg21775007	chr8:11205619	TDH	0.43	5.91	0.35	1.14e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs3736594	0.513	rs62131882	chr2:27765480	T/C	cg27432699	chr2:27873401	GPN1	0.56	6.17	0.37	2.74e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg07212818	chr11:638076	DRD4	-0.43	-5.26	-0.32	3.18e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.62	-10.63	-0.56	5.8e-22	Bone mineral density;
KIRP	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg15488143	chr7:128924101	AHCYL2	0.63	6.73	0.39	1.21e-10	White matter hyperintensity burden;
KIRP	cis	rs33912345	0.695	rs1254301	chr14:60885149	T/C	cg27398547	chr14:60952738	C14orf39	-0.41	-5.46	-0.33	1.18e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs17023223	0.537	rs2794311	chr1:119595949	A/G	cg05756136	chr1:119680316	WARS2	0.53	7.11	0.41	1.25e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-7.37	-0.43	2.57e-12	Migraine;
KIRP	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-5.48	-0.33	1.07e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.58	-11.5	-0.59	8.72e-25	Diabetic kidney disease;
KIRP	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg03647239	chr10:116582469	FAM160B1	0.51	5.76	0.34	2.45e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg24315340	chr6:146058215	EPM2A	0.43	5.36	0.32	1.88e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg09699651	chr6:150184138	LRP11	0.45	6.02	0.36	6.28e-9	Lung cancer;
KIRP	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.72	10.91	0.57	7.11e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg19592336	chr6:28129416	ZNF389	0.48	5.51	0.33	8.85e-8	Depression;
KIRP	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs10486722	0.607	rs6463037	chr7:41760000	A/G	cg07952040	chr12:110562126	IFT81	-0.59	-6.22	-0.37	2.07e-9	Pit-and-Fissure caries;
KIRP	cis	rs1978968	0.763	rs9605475	chr22:18463306	T/C	cg03078520	chr22:18463400	MICAL3	-0.84	-12.0	-0.61	2.05e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26306683	chr17:18585705	ZNF286B	0.49	6.29	0.37	1.43e-9	Educational attainment (years of education);
KIRP	trans	rs12517041	1.000	rs28472703	chr5:23281381	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.38	-5.57	-0.33	6.55e-8	Body mass index;
KIRP	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7404928	0.794	rs3826260	chr16:23877229	C/T	cg05497750	chr16:23765381	CHP2	-0.45	-5.31	-0.32	2.5e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-9.87	-0.53	1.45e-19	Total body bone mineral density;
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg22325292	chr17:80708367	FN3K	0.38	5.06	0.31	8.08e-7	Glycated hemoglobin levels;
KIRP	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg08662619	chr6:150070041	PCMT1	0.33	5.18	0.31	4.51e-7	Lung cancer;
KIRP	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.47	6.4	0.38	7.96e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.59	9.73	0.53	3.92e-19	Schizophrenia;
KIRP	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg10326726	chr10:51549505	MSMB	0.61	9.15	0.5	2.23e-17	Prostate-specific antigen levels;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.66e-8	Life satisfaction;
KIRP	cis	rs6142102	0.961	rs4911401	chr20:32654562	C/A	cg08999081	chr20:33150536	PIGU	0.49	5.88	0.35	1.31e-8	Skin pigmentation;
KIRP	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg02151108	chr14:50098012	C14orf104	-0.51	-7.08	-0.41	1.53e-11	Carotid intima media thickness;
KIRP	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.7	10.55	0.56	1.08e-21	Dupuytren's disease;
KIRP	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.79	-10.7	-0.56	3.33e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2119480	0.731	rs378399	chr13:111308040	G/C	cg16216153	chr13:111290848	CARKD	-0.38	-5.09	-0.31	7.08e-7	Diastolic blood pressure;
KIRP	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	4.95	0.3	1.39e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.54	-0.33	7.79e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6772849	0.775	rs67105978	chr3:128415180	C/A	cg08795948	chr3:128337044	NA	0.43	5.13	0.31	5.93e-7	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs11264213	0.901	rs653417	chr1:36356842	G/T	cg27506609	chr1:36549197	TEKT2	0.96	9.92	0.53	1.03e-19	Schizophrenia;
KIRP	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.13	18.85	0.77	1.2e-49	Cognitive function;
KIRP	cis	rs1468333	1.000	rs2967781	chr5:137557609	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.49	5.46	0.33	1.16e-7	Resting heart rate;
KIRP	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.67	-0.34	3.91e-8	Huntington's disease progression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21858106	chr21:46974883	NA	0.46	6.12	0.36	3.66e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg06740227	chr12:86229804	RASSF9	-0.48	-5.88	-0.35	1.34e-8	Major depressive disorder;
KIRP	cis	rs9398803	0.830	rs2039735	chr6:126745076	T/C	cg19875578	chr6:126661172	C6orf173	0.48	6.32	0.37	1.2e-9	Male-pattern baldness;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09970680	chr17:80767424	TBCD	1.2	7.0	0.41	2.36e-11	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg05507819	chr15:63340323	TPM1	-0.51	-6.28	-0.37	1.55e-9	Platelet count;
KIRP	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg09314803	chr17:79180344	AZI1	-0.67	-10.41	-0.55	2.87e-21	Frontotemporal dementia;
KIRP	cis	rs55675132	0.510	rs72687890	chr1:115296524	A/G	cg12756093	chr1:115239321	AMPD1	0.65	6.41	0.38	7.5e-10	Schizophrenia;
KIRP	cis	rs282587	0.502	rs371150	chr13:113397815	C/T	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.64e-12	Glycated hemoglobin levels;
KIRP	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24645602	chr8:130923773	FAM49B	-0.41	-6.03	-0.36	6.13e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.82	-11.14	-0.58	1.29e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.16	-0.54	1.77e-20	Total body bone mineral density;
KIRP	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg10755058	chr3:40428713	ENTPD3	0.49	6.77	0.4	9.31e-11	Renal cell carcinoma;
KIRP	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.39	1.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9603616	1.000	rs9603612	chr13:40334852	C/G	cg26701198	chr13:40229707	COG6	0.45	5.06	0.31	8.26e-7	Rheumatoid arthritis;
KIRP	cis	rs17401966	0.593	rs11121523	chr1:10214442	T/A	cg19773385	chr1:10388646	KIF1B	-0.58	-7.23	-0.42	5.9e-12	Hepatocellular carcinoma;
KIRP	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-5.27	-0.32	3e-7	Testicular germ cell tumor;
KIRP	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.62	0.52	8.32e-19	Dupuytren's disease;
KIRP	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.88	-0.35	1.31e-8	Breast cancer;
KIRP	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.92	-0.49	1.11e-16	Neuroticism;
KIRP	cis	rs17065868	0.881	rs9533889	chr13:45094012	T/C	cg10246903	chr13:45222710	NA	0.71	6.51	0.38	4.12e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg00666640	chr1:248458726	OR2T12	0.47	5.68	0.34	3.77e-8	Common traits (Other);
KIRP	cis	rs11230563	0.501	rs599856	chr11:60818176	G/A	cg10158843	chr11:60776172	CD6	-0.34	-5.11	-0.31	6.45e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.82	-0.35	1.78e-8	Schizophrenia;
KIRP	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg16989719	chr2:238392110	NA	-0.51	-6.55	-0.39	3.42e-10	Prostate cancer;
KIRP	trans	rs7619833	1.000	rs7619833	chr3:27509714	G/C	cg22620680	chr3:122920514	SEC22A	-0.46	-6.12	-0.36	3.71e-9	Breast cancer;
KIRP	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-6.02	-0.36	6.29e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.17	-0.37	2.78e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2594989	0.943	rs77630528	chr3:11314041	A/G	cg01796438	chr3:11312864	ATG7	-0.69	-7.85	-0.45	1.24e-13	Circulating chemerin levels;
KIRP	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.49	6.66	0.39	1.81e-10	Testicular germ cell tumor;
KIRP	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg03388025	chr16:89894329	SPIRE2	0.33	6.05	0.36	5.4e-9	Vitiligo;
KIRP	trans	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.35	-0.42	2.94e-12	Morning vs. evening chronotype;
KIRP	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.75	10.34	0.55	4.9e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26660316	chr5:110077272	SLC25A46	-0.45	-7.07	-0.41	1.56e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	20.06	0.79	1.12e-53	Chronic sinus infection;
KIRP	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg08648136	chr8:956695	NA	0.4	5.4	0.33	1.57e-7	Schizophrenia;
KIRP	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg08742575	chr21:47604166	C21orf56	0.39	5.09	0.31	7.22e-7	Testicular germ cell tumor;
KIRP	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.4e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.94	-0.61	3.15e-26	Eye color traits;
KIRP	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg07972983	chr1:205091412	RBBP5	0.42	4.9	0.3	1.71e-6	Red blood cell count;
KIRP	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.44	8.61	0.48	9.08e-16	Coronary artery disease;
KIRP	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs2281603	0.570	rs57525201	chr14:64955692	C/T	cg01860774	chr14:64969374	ZBTB25	0.33	5.4	0.33	1.58e-7	Lymphocyte counts;
KIRP	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.66	6.59	0.39	2.67e-10	Vitiligo;
KIRP	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg01411142	chr8:19674711	INTS10	0.44	4.85	0.3	2.21e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.65	8.36	0.47	4.73e-15	Prudent dietary pattern;
KIRP	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg15655495	chr12:38532458	NA	-0.29	-5.16	-0.31	5.07e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.94	0.57	5.74e-23	Personality dimensions;
KIRP	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12379764	chr21:47803548	PCNT	0.43	5.18	0.31	4.52e-7	Testicular germ cell tumor;
KIRP	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg18190219	chr22:46762943	CELSR1	-0.7	-6.27	-0.37	1.59e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.78	7.23	0.42	6.01e-12	Mean platelet volume;
KIRP	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.77	9.93	0.53	9.17e-20	Aortic root size;
KIRP	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg21830797	chr15:40226279	EIF2AK4	0.58	5.76	0.34	2.52e-8	Response to haloperidol in psychosis;
KIRP	cis	rs6693295	0.887	rs2885258	chr1:246264809	T/C	cg11798871	chr1:246315928	SMYD3	-0.44	-5.4	-0.33	1.61e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg09165964	chr15:75287851	SCAMP5	0.51	6.71	0.39	1.36e-10	Breast cancer;
KIRP	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg26876637	chr1:152193138	HRNR	0.72	9.53	0.52	1.61e-18	Atopic dermatitis;
KIRP	cis	rs6681460	0.932	rs659291	chr1:67180746	A/C	cg13052034	chr1:66999238	SGIP1	0.36	5.12	0.31	6.23e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4903214	0.895	rs1005740	chr14:74695332	A/G	cg08255017	chr14:74727001	VSX2	-0.4	-4.96	-0.3	1.32e-6	Inflammatory bowel disease;
KIRP	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	1.06	17.87	0.75	2.49e-46	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18495307	chr17:42385942	RUNDC3A	0.48	6.77	0.4	9.55e-11	Parkinson's disease;
KIRP	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.62	-8.26	-0.47	8.92e-15	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09497020	chr5:893046	TRIP13;BRD9	0.49	6.26	0.37	1.68e-9	Parkinson's disease;
KIRP	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.22	0.42	6.43e-12	Prudent dietary pattern;
KIRP	cis	rs17123764	0.786	rs7980979	chr12:50122588	G/T	cg20471783	chr12:50157085	TMBIM6	0.32	4.98	0.3	1.21e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.83	-8.64	-0.48	7.09e-16	Systemic lupus erythematosus;
KIRP	cis	rs4474465	1.000	rs1567889	chr11:78147055	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-7.32	-0.42	3.45e-12	Alzheimer's disease (survival time);
KIRP	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg23533926	chr12:111358616	MYL2	-0.48	-6.35	-0.38	1.01e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg18032289	chr17:61959525	GH2	-0.38	-4.95	-0.3	1.4e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg02023728	chr11:77925099	USP35	-0.33	-5.25	-0.32	3.28e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.4	4.94	0.3	1.44e-6	Height;
KIRP	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.14	20.82	0.8	3.44e-56	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.68	10.92	0.57	6.63e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg02336718	chr17:17403227	NA	0.34	5.08	0.31	7.43e-7	Total body bone mineral density;
KIRP	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.42	-0.51	3.52e-18	Morning vs. evening chronotype;
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg08805041	chr16:621841	PIGQ	-0.37	-5.19	-0.31	4.47e-7	Height;
KIRP	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg19913688	chr11:428466	ANO9	-0.74	-5.6	-0.34	5.77e-8	Body mass index;
KIRP	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.77	10.21	0.55	1.21e-20	Hemoglobin concentration;
KIRP	cis	rs860295	0.702	rs3851912	chr1:155586444	T/G	cg02153340	chr1:155202674	NA	-0.49	-6.71	-0.39	1.34e-10	Body mass index;
KIRP	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	5.92	0.35	1.1e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08880486	chr17:66287505	ARSG;SLC16A6	0.44	6.38	0.38	8.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg10259518	chr2:233765616	NGEF	0.34	4.94	0.3	1.43e-6	Coronary artery disease;
KIRP	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.93	-0.35	1.04e-8	Breast cancer;
KIRP	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg07395648	chr5:131743802	NA	0.38	5.39	0.33	1.65e-7	Blood metabolite levels;
KIRP	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg17385448	chr1:15911702	AGMAT	0.27	5.3	0.32	2.51e-7	Systolic blood pressure;
KIRP	cis	rs300890	0.760	rs6537152	chr4:144202044	C/G	cg19876092	chr4:144208277	NA	0.43	7.18	0.42	8.34e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg23752985	chr2:85803571	VAMP8	-0.57	-8.45	-0.47	2.5e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.88	13.51	0.65	1.71e-31	Colorectal cancer;
KIRP	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg20578329	chr17:80767326	TBCD	0.54	7.46	0.43	1.47e-12	Breast cancer;
KIRP	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg22437258	chr11:111473054	SIK2	0.61	7.13	0.41	1.11e-11	Primary sclerosing cholangitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12201332	chr14:36101127	RALGAPA1	-0.46	-7.1	-0.41	1.34e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg27312727	chr5:77590915	AP3B1	0.96	6.27	0.37	1.6e-9	P wave terminal force;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11886511	chr14:45722532	C14orf106	0.46	6.02	0.36	6.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.65	9.73	0.53	3.8e-19	Lung cancer;
KIRP	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.46	6.32	0.37	1.21e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2411233	1.000	rs8028719	chr15:39270782	C/T	cg02291532	chr15:39874776	THBS1	0.4	5.42	0.33	1.39e-7	Platelet count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05279806	chr3:175128616	NAALADL2	-0.4	-6.11	-0.36	3.81e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05665937	chr4:1216051	CTBP1	0.5	7.11	0.41	1.28e-11	Obesity-related traits;
KIRP	cis	rs4751006	0.543	rs61875504	chr10:128772592	C/T	cg05702161	chr10:128779687	DOCK1	-1.17	-9.14	-0.5	2.38e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5747327	0.874	rs34891900	chr22:18163158	C/T	cg19898043	chr22:18121309	BCL2L13	-0.42	-5.02	-0.3	1.01e-6	Myeloid white cell count;Granulocyte count;
KIRP	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.85	-0.45	1.28e-13	Retinal vascular caliber;
KIRP	cis	rs2219968	0.961	rs12056471	chr8:78962821	T/C	cg00738934	chr8:78996279	NA	0.42	5.3	0.32	2.52e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7119038	0.731	rs28409215	chr11:118679304	G/A	cg19308663	chr11:118741387	NA	0.6	9.95	0.54	8.15e-20	Sjögren's syndrome;
KIRP	cis	rs41563	0.547	rs4730070	chr7:104775968	C/T	cg04380332	chr7:105027541	SRPK2	-0.71	-6.6	-0.39	2.45e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.3	0.58	4.02e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs960902	0.747	rs2216117	chr2:37723168	G/A	cg25341268	chr2:37734390	NA	0.57	7.79	0.45	1.82e-13	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg07653901	chr22:50250238	ZBED4	0.48	5.61	0.34	5.43e-8	Schizophrenia;
KIRP	cis	rs2735413	0.881	rs4888732	chr16:78080505	A/G	cg04733911	chr16:78082701	NA	-0.46	-5.18	-0.31	4.7e-7	Systolic blood pressure (alcohol consumption interaction);
KIRP	cis	rs533123	0.702	rs61787581	chr1:29117151	A/T	cg08366446	chr1:29138936	OPRD1	-0.93	-6.67	-0.39	1.69e-10	Schizophrenia;
KIRP	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.6	7.51	0.43	1.1e-12	Dialysis-related mortality;
KIRP	cis	rs13095912	0.785	rs62291882	chr3:185313278	T/C	cg11274856	chr3:185301563	NA	0.62	7.88	0.45	1.04e-13	Systolic blood pressure;
KIRP	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg26134248	chr17:3907702	NA	-0.57	-8.52	-0.48	1.61e-15	Type 2 diabetes;
KIRP	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.12	-0.31	6.3e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.63	-0.34	4.98e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08822215	chr16:89438651	ANKRD11	-0.51	-6.78	-0.4	8.62e-11	Multiple myeloma (IgH translocation);
KIRP	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.42	4.89e-12	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.63	-0.73	4.1e-42	Height;
KIRP	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg20636351	chr8:55087400	NA	-0.62	-7.63	-0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-5.56	-0.33	7.07e-8	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg12315302	chr6:26189340	HIST1H4D	1.08	6.49	0.38	4.71e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg23923672	chr12:105501055	KIAA1033	-0.83	-8.45	-0.47	2.51e-15	IgG glycosylation;
KIRP	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg24341498	chr9:137217390	RXRA	0.85	6.01	0.36	6.48e-9	P wave terminal force;
KIRP	cis	rs988913	1.000	rs9475106	chr6:54851455	G/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.32	-0.32	2.35e-7	Menarche (age at onset);
KIRP	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.88	-10.52	-0.56	1.31e-21	Bipolar disorder and schizophrenia;
KIRP	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.93	14.18	0.67	8.93e-34	Mean platelet volume;
KIRP	cis	rs1372436	0.557	rs1372435	chr2:151164936	C/A	cg25300694	chr2:151184358	NA	0.71	5.4	0.33	1.54e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.66	5.13	0.31	6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.93	14.68	0.68	1.8e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2901656	0.640	rs9425316	chr1:172400860	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	5.91	0.35	1.11e-8	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.4	0.38	7.67e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg07382826	chr16:28625726	SULT1A1	0.44	5.17	0.31	4.92e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-0.83	-9.05	-0.5	4.46e-17	Gut microbiome composition (summer);
KIRP	cis	rs9815354	0.812	rs17214987	chr3:41810481	C/T	cg03022575	chr3:42003672	ULK4	-0.79	-8.45	-0.47	2.57e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6753739	0.826	rs6732562	chr2:219966862	T/C	cg01749213	chr2:219906749	CCDC108	0.44	5.43	0.33	1.35e-7	Height;
KIRP	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg01872077	chr2:219646372	CYP27A1	0.38	4.92	0.3	1.61e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.59	8.0	0.45	4.88e-14	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21497602	chr12:12715811	DUSP16	-0.96	-6.55	-0.39	3.38e-10	P wave terminal force;
KIRP	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00879163	chr7:66386079	C7orf42	0.53	7.48	0.43	1.27e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg02297831	chr4:17616191	MED28	0.61	7.69	0.44	3.61e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.47	6.31	0.37	1.27e-9	Mean corpuscular volume;
KIRP	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg05304507	chr6:116381966	FRK	0.22	5.84	0.35	1.63e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06481639	chr22:41940642	POLR3H	0.58	6.6	0.39	2.51e-10	Vitiligo;
KIRP	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.67	8.53	0.48	1.52e-15	Prudent dietary pattern;
KIRP	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.48	0.43	1.29e-12	Neuroticism;
KIRP	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.55	7.55	0.43	8.35e-13	Colorectal cancer;
KIRP	cis	rs4262150	0.883	rs56286804	chr5:152150366	G/A	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs422249	0.819	rs174611	chr11:61627881	T/C	cg19610905	chr11:61596333	FADS2	-0.48	-6.12	-0.36	3.69e-9	Trans fatty acid levels;
KIRP	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	0.96	16.12	0.72	2.12e-40	Ulcerative colitis;
KIRP	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg17652424	chr22:38574118	PLA2G6	0.25	5.06	0.31	8.29e-7	Cutaneous nevi;
KIRP	cis	rs66561647	0.661	rs12548864	chr8:128928246	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.5	6.07	0.36	4.87e-9	Hemoglobin concentration;
KIRP	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05220968	chr6:146057943	EPM2A	-0.41	-5.21	-0.32	4.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1062746	0.527	rs35143469	chr16:87335483	T/C	cg02258303	chr16:87377426	FBXO31	-0.4	-4.95	-0.3	1.4e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg06640241	chr16:89574553	SPG7	0.67	8.93	0.49	1.01e-16	Multiple myeloma (IgH translocation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04098458	chr2:149402448	EPC2	0.54	7.59	0.44	6.61e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg09873164	chr1:152488093	CRCT1	0.58	7.77	0.44	2.13e-13	Hair morphology;
KIRP	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg05343316	chr1:45956843	TESK2	0.83	9.11	0.5	2.94e-17	Platelet count;
KIRP	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.93	9.7	0.53	4.62e-19	Neuroticism;
KIRP	cis	rs3135063	0.504	rs78139882	chr4:3287361	C/T	cg03007772	chr4:3409324	RGS12	-0.49	-4.9	-0.3	1.71e-6	Blood protein levels;
KIRP	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19346786	chr7:2764209	NA	-0.54	-9.02	-0.5	5.68e-17	Height;
KIRP	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.86	-0.35	1.45e-8	Breast cancer;
KIRP	cis	rs13095912	1.000	rs13072759	chr3:185326391	G/A	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.17e-11	Systolic blood pressure;
KIRP	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.04	0.36	5.55e-9	Lung cancer;
KIRP	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.74	-8.35	-0.47	5.03e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.18	0.51	1.85e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs8033133	0.602	rs12438531	chr15:25323876	A/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.49	-6.24	-0.37	1.93e-9	Blood osmolality (transformed sodium);
KIRP	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-7.39	-0.43	2.22e-12	Height;
KIRP	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg22532475	chr10:104410764	TRIM8	-0.31	-5.06	-0.31	8.1e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg18198730	chr1:247681584	NA	0.63	5.58	0.34	6.34e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg16497661	chr14:103986332	CKB	0.5	6.87	0.4	5.31e-11	Body mass index;
KIRP	cis	rs2862064	0.929	rs2088917	chr5:156432215	A/G	cg12943317	chr5:156479607	HAVCR1	-0.9	-7.77	-0.44	2.2e-13	Platelet count;
KIRP	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Hypertriglyceridemia;
KIRP	trans	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.88	0.4	4.97e-11	Retinal vascular caliber;
KIRP	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg23752985	chr2:85803571	VAMP8	0.59	8.41	0.47	3.42e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs58141407	1	rs58141407	chr8:21791772	C/T	cg17168535	chr8:21777572	XPO7	0.7	6.62	0.39	2.19e-10	Red blood cell count;Mean corpuscular volume;
KIRP	cis	rs889312	0.961	rs1862626	chr5:56032940	G/T	cg14703610	chr5:56206110	C5orf35	0.42	5.06	0.31	8.22e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25517755	chr10:38738941	LOC399744	-0.36	-5.22	-0.32	3.77e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.06	-0.46	3.37e-14	Coronary artery disease;
KIRP	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg00647317	chr7:50633725	DDC	0.51	7.39	0.43	2.23e-12	Systemic sclerosis;
KIRP	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs9815354	0.812	rs113144620	chr3:42008312	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.95	0.5	9.02e-17	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.52	-0.38	3.91e-10	Morning vs. evening chronotype;
KIRP	cis	rs17023223	0.537	rs2361270	chr1:119603322	T/C	cg05756136	chr1:119680316	WARS2	-0.54	-7.17	-0.42	8.73e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.49	-6.09	-0.36	4.4e-9	Prudent dietary pattern;
KIRP	cis	rs7095944	0.584	rs4962691	chr10:126424137	C/T	cg08799069	chr10:126477246	METTL10	-0.46	-5.98	-0.36	8.02e-9	Asthma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21584983	chr19:11640070	ECSIT	0.64	7.67	0.44	4.1e-13	Smoking initiation;
KIRP	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.84	-0.45	1.39e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg27147174	chr7:100797783	AP1S1	-0.54	-6.99	-0.41	2.63e-11	Life satisfaction;
KIRP	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.77	-9.48	-0.52	2.3e-18	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg22705602	chr4:152727874	NA	-0.52	-8.98	-0.5	7.23e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07570687	chr10:102243282	WNT8B	0.49	6.21	0.37	2.3e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	7.37	0.43	2.6e-12	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22360024	chr11:18124520	SAAL1	-0.36	-6.3	-0.37	1.39e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27367512	chr5:126405711	FLJ44606	-0.4	-6.12	-0.36	3.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.71	-8.14	-0.46	1.99e-14	Platelet count;
KIRP	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg05973401	chr12:123451056	ABCB9	0.63	6.74	0.39	1.12e-10	Neutrophil percentage of white cells;
KIRP	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.51	-7.32	-0.42	3.55e-12	Sense of smell;
KIRP	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	10.31	0.55	6.03e-21	Hip circumference;
KIRP	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-1.2	-12.39	-0.62	1.04e-27	Monocyte percentage of white cells;
KIRP	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.8	9.61	0.52	8.74e-19	Multiple system atrophy;
KIRP	cis	rs11955398	0.625	rs12655515	chr5:59974098	G/C	cg02684056	chr5:59996105	DEPDC1B	0.5	5.59	0.34	5.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg00981070	chr1:2046702	PRKCZ	0.42	5.89	0.35	1.25e-8	Height;
KIRP	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03526503	chr1:28198483	C1orf38	0.45	6.26	0.37	1.72e-9	Gut microbiome composition (summer);
KIRP	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.51	6.29	0.37	1.42e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs199950	0.911	rs199910	chr1:181600665	G/A	cg04237608	chr1:18659049	IGSF21	0.36	6.1	0.36	4.16e-9	Body mass index (change over time);
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg22907277	chr7:1156413	C7orf50	0.58	7.49	0.43	1.26e-12	Longevity;Endometriosis;
KIRP	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg27411982	chr8:10470053	RP1L1	0.43	5.18	0.31	4.67e-7	Neuroticism;
KIRP	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	0.72	7.09	0.41	1.38e-11	Gut microbiome composition (summer);
KIRP	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.69	-9.26	-0.51	1.03e-17	Total body bone mineral density;
KIRP	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.29	-0.32	2.74e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	5.46	0.33	1.14e-7	Longevity;
KIRP	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg00405596	chr8:11794950	NA	-0.5	-6.58	-0.39	2.87e-10	Retinal vascular caliber;
KIRP	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	1.08	17.53	0.75	3.39e-45	Cognitive function;
KIRP	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg25233709	chr10:116636983	FAM160B1	0.34	5.12	0.31	6.26e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7523050	0.730	rs11102650	chr1:109464228	C/G	cg08274380	chr1:109419600	GPSM2	0.81	7.32	0.42	3.59e-12	Fat distribution (HIV);
KIRP	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg26876637	chr1:152193138	HRNR	0.74	9.61	0.52	8.91e-19	Atopic dermatitis;
KIRP	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.6	0.34	5.75e-8	Breast cancer;
KIRP	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg11945507	chr8:142233382	SLC45A4	0.45	6.07	0.36	4.75e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.48	5.18	0.31	4.55e-7	Subjective well-being;
KIRP	cis	rs3789045	0.826	rs55979051	chr1:204567041	A/G	cg18185008	chr1:204589407	LRRN2	-0.63	-6.82	-0.4	7.17e-11	Educational attainment (college completion);
KIRP	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	trans	rs12527818	0.701	rs6454946	chr6:93902683	C/T	cg26628847	chr7:142829304	PIP	-0.39	-6.04	-0.36	5.61e-9	Response to hepatitis C treatment;
KIRP	cis	rs5770917	1.000	rs2269382	chr22:51018911	C/T	cg25309564	chr22:51001381	C22orf41	0.9	5.22	0.32	3.87e-7	Narcolepsy;
KIRP	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.59	-9.79	-0.53	2.54e-19	Total body bone mineral density;
KIRP	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg24296786	chr1:45957014	TESK2	0.46	5.45	0.33	1.21e-7	Platelet count;
KIRP	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.42	5.16	0.31	5.05e-7	Asthma;
KIRP	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg13206674	chr6:150067644	NUP43	0.53	7.44	0.43	1.73e-12	Testicular germ cell tumor;
KIRP	cis	rs6467136	0.754	rs10258162	chr7:127158623	C/T	cg23081781	chr7:127225937	GCC1	-0.36	-4.87	-0.3	1.98e-6	Type 2 diabetes;
KIRP	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.88	-12.49	-0.62	4.77e-28	Bipolar disorder;
KIRP	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.67	-5.78	-0.35	2.2e-8	Schizophrenia;
KIRP	cis	rs9308731	0.605	rs6754738	chr2:111948543	T/C	cg04202892	chr2:111875749	ACOXL	0.39	5.25	0.32	3.31e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs79149102	0.737	rs7163332	chr15:75193623	C/T	cg09165964	chr15:75287851	SCAMP5	-0.89	-5.65	-0.34	4.38e-8	Lung cancer;
KIRP	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.07	0.61	1.14e-26	Blood protein levels;
KIRP	cis	rs13343954	0.778	rs10425324	chr19:33541302	C/T	cg27124370	chr19:33622961	WDR88	0.6	6.73	0.39	1.21e-10	Colorectal cancer;
KIRP	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg26876637	chr1:152193138	HRNR	-0.77	-8.77	-0.49	3.09e-16	Atopic dermatitis;
KIRP	cis	rs539514	0.563	rs7991448	chr13:76334061	G/A	cg04757411	chr13:76259545	LMO7	-0.47	-6.79	-0.4	8.15e-11	Type 1 diabetes;
KIRP	cis	rs10073892	0.664	rs10042544	chr5:101895753	T/C	cg19774478	chr5:101632501	SLCO4C1	0.59	5.8	0.35	2e-8	Cognitive decline (age-related);
KIRP	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg19442545	chr10:75533431	FUT11	-0.38	-5.04	-0.31	9.04e-7	Inflammatory bowel disease;
KIRP	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.27	-0.32	2.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg21226059	chr5:178986404	RUFY1	-0.52	-8.58	-0.48	1.09e-15	Lung cancer;
KIRP	cis	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.08	-0.36	4.59e-9	Small cell lung carcinoma;
KIRP	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.73	-0.34	2.87e-8	Ulcerative colitis;
KIRP	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.8	-0.35	2.07e-8	Breast cancer;
KIRP	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs600806	0.742	rs9429519	chr1:110017105	A/G	cg02175308	chr1:109941060	SORT1	0.28	5.18	0.31	4.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg17724175	chr1:150552817	MCL1	0.38	6.19	0.37	2.53e-9	Melanoma;
KIRP	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg17014757	chr1:203156097	CHI3L1	-0.62	-6.88	-0.4	4.97e-11	YKL-40 levels;
KIRP	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.78	0.44	2e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs42648	0.535	rs39198	chr7:89733818	T/C	cg25739043	chr7:89950458	NA	-0.37	-5.67	-0.34	3.93e-8	Homocysteine levels;
KIRP	cis	rs9399401	1.000	rs9403380	chr6:142652416	T/C	cg03128060	chr6:142623767	GPR126	0.32	5.24	0.32	3.52e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs4901847	0.643	rs7153396	chr14:58596356	C/T	cg15908186	chr14:58618357	C14orf37	-0.61	-8.0	-0.45	5.03e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs72730918	0.564	rs12708427	chr15:51909555	C/T	cg14296394	chr15:51910925	DMXL2	-0.78	-10.99	-0.57	3.96e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.36	-0.38	9.7e-10	Lung cancer;
KIRP	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg01304814	chr3:48885189	PRKAR2A	0.61	5.26	0.32	3.15e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs9650657	0.683	rs7005905	chr8:10585144	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.42	0.38	6.94e-10	Neuroticism;
KIRP	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.81	14.35	0.67	2.51e-34	Height;
KIRP	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00791764	chr4:53727839	RASL11B	0.46	6.32	0.37	1.25e-9	Optic nerve measurement (cup area);
KIRP	cis	rs76793172	1.000	rs61703905	chr19:46370301	C/T	cg00442267	chr19:46317840	RSPH6A	-0.77	-6.47	-0.38	5.36e-10	Eosinophil counts;
KIRP	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.18	21.46	0.81	2.71e-58	Cognitive function;
KIRP	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.72	-0.56	3e-22	Menopause (age at onset);
KIRP	cis	rs13034020	0.522	rs12988616	chr2:61244663	A/C	cg18625361	chr2:61244694	PEX13;PUS10	0.57	6.49	0.38	4.82e-10	Hodgkin's lymphoma;
KIRP	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02725872	chr8:58115012	NA	-0.73	-7.64	-0.44	4.73e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.13e-12	Uric acid levels;
KIRP	cis	rs8177876	0.554	rs56286107	chr16:81117832	C/A	cg08591886	chr16:81111003	C16orf46	-0.71	-5.37	-0.32	1.85e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.93	11.34	0.59	2.96e-24	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.87	0.35	1.38e-8	Motion sickness;
KIRP	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00149659	chr3:10157352	C3orf10	0.96	10.31	0.55	5.78e-21	Alzheimer's disease;
KIRP	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.38	0.59	2.23e-24	Height;
KIRP	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10267417	0.522	rs117382719	chr7:19944660	C/G	cg05791153	chr7:19748676	TWISTNB	0.51	5.12	0.31	6.3e-7	Night sleep phenotypes;
KIRP	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-5.47	-0.33	1.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224314	1.000	rs62085808	chr17:65357692	G/A	cg01507342	chr17:65387096	PITPNC1	-0.5	-6.95	-0.4	3.31e-11	Diisocyanate-induced asthma;
KIRP	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg26875233	chr11:93583750	C11orf90	-0.4	-7.49	-0.43	1.22e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg23335576	chr14:104009727	NA	0.34	4.86	0.3	2.08e-6	Body mass index;
KIRP	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.73	-10.5	-0.56	1.52e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7590368	0.715	rs72779466	chr2:10963180	T/A	cg15705551	chr2:10952987	PDIA6	0.6	5.45	0.33	1.21e-7	Educational attainment (years of education);
KIRP	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.17	0.61	5.54e-27	Morning vs. evening chronotype;
KIRP	cis	rs507080	0.961	rs4938523	chr11:118548838	G/T	cg04173919	chr11:118528438	PHLDB1	0.33	4.87	0.3	1.98e-6	Serum metabolite levels;
KIRP	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.85	0.4	5.94e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg10547527	chr2:198650123	BOLL	-0.52	-4.88	-0.3	1.9e-6	Ulcerative colitis;
KIRP	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.4	5.7	0.34	3.47e-8	Ovarian reserve;
KIRP	cis	rs1431005	1.000	rs72499925	chr4:188353750	A/G	cg13810101	chr4:188427966	NA	-0.33	-4.86	-0.3	2.13e-6	Response to statin therapy;
KIRP	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg21184320	chr1:21044207	KIF17	-0.36	-5.49	-0.33	9.91e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	trans	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg10756647	chr7:56101905	PSPH	0.98	7.0	0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.13e-62	Parkinson's disease;
KIRP	cis	rs654950	1.000	rs654950	chr1:41987868	G/C	cg06885757	chr1:42089581	HIVEP3	-0.6	-8.75	-0.49	3.35e-16	Airway imaging phenotypes;
KIRP	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg23387468	chr7:139079360	LUC7L2	0.3	5.23	0.32	3.68e-7	Diisocyanate-induced asthma;
KIRP	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.88	0.35	1.34e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.62	-0.34	5.11e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg20701182	chr2:24300061	SF3B14	0.6	4.86	0.3	2.12e-6	Lymphocyte counts;
KIRP	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.82	12.13	0.61	7.59e-27	Blood metabolite ratios;
KIRP	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.5	0.52	1.99e-18	Cognitive test performance;
KIRP	trans	rs927821	0.680	rs11597058	chr10:104201995	A/G	cg06646780	chr6:130182053	C6orf191	-0.64	-6.25	-0.37	1.78e-9	Social autistic-like traits;
KIRP	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.7	-8.64	-0.48	7.05e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.65	-7.84	-0.45	1.35e-13	Calcium levels;
KIRP	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg22676075	chr6:135203613	NA	0.49	7.08	0.41	1.47e-11	Red blood cell count;
KIRP	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.51	6.17	0.37	2.83e-9	Uric acid levels;
KIRP	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.48	0.52	2.33e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	cis	rs9611198	0.755	rs5757719	chr22:39945791	T/C	cg03390717	chr22:39966585	CACNA1I	0.37	6.62	0.39	2.22e-10	Schizophrenia;
KIRP	cis	rs7923609	0.967	rs7085018	chr10:65286667	T/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.66	-0.34	4.17e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.49	-5.99	-0.36	7.31e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.69	8.15	0.46	1.83e-14	Diabetic retinopathy;
KIRP	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-11.56	-0.59	5.8e-25	Cognitive function;
KIRP	cis	rs4664304	0.629	rs3828324	chr2:160834991	C/T	cg03641300	chr2:160917029	PLA2R1	0.39	5.73	0.34	2.98e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.73	8.76	0.49	3.14e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.73	-9.76	-0.53	3.02e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.68	7.03	0.41	1.99e-11	Bipolar disorder;
KIRP	trans	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg13565492	chr6:43139072	SRF	-0.93	-8.53	-0.48	1.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.7	10.55	0.56	1.03e-21	Dupuytren's disease;
KIRP	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg07541023	chr7:19748670	TWISTNB	0.62	5.75	0.34	2.69e-8	Thyroid stimulating hormone;
KIRP	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg18016565	chr1:150552671	MCL1	-0.35	-5.45	-0.33	1.24e-7	Melanoma;
KIRP	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg17294928	chr15:75287854	SCAMP5	0.56	7.48	0.43	1.33e-12	Breast cancer;
KIRP	cis	rs151997	0.924	rs32480	chr5:50208099	G/A	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	7.91	0.45	8.84e-14	Joint mobility (Beighton score);
KIRP	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg26138937	chr11:71823887	C11orf51	1.16	7.55	0.43	8.52e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg07001201	chr5:642380	CEP72	0.7	6.58	0.39	2.86e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07191189	chr2:37193690	STRN	0.52	6.9	0.4	4.46e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs829661	0.762	rs829680	chr2:30709088	G/T	cg10949345	chr2:30726833	LCLAT1	0.72	10.05	0.54	3.97e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg26587870	chr6:27730563	NA	-0.67	-5.27	-0.32	2.94e-7	Breast cancer;
KIRP	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg21926883	chr2:100939477	LONRF2	-0.54	-7.09	-0.41	1.38e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.55	-5.41	-0.33	1.52e-7	Pubertal anthropometrics;
KIRP	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg21775007	chr8:11205619	TDH	-0.45	-5.77	-0.35	2.4e-8	Neuroticism;
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.69	-6.81	-0.4	7.25e-11	Platelet count;
KIRP	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.73	-8.86	-0.49	1.64e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.24	25.98	0.86	1.82e-72	IgG glycosylation;
KIRP	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.09	-0.5	3.45e-17	Mood instability;
KIRP	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.95	-12.61	-0.63	1.89e-28	Vitamin D levels;
KIRP	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.64	-0.39	1.98e-10	Metabolite levels;
KIRP	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg17757837	chr7:157058334	UBE3C	0.82	11.22	0.58	7.06e-24	Body mass index;
KIRP	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.67	8.46	0.47	2.44e-15	Total body bone mineral density;
KIRP	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.87	-7.59	-0.44	6.76e-13	Obesity;Body mass index;
KIRP	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07308232	chr7:1071921	C7orf50	-0.69	-8.95	-0.5	9.06e-17	Longevity;Endometriosis;
KIRP	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.38	4.46e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7084402	0.967	rs2393448	chr10:60333260	T/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.98	-0.57	4.52e-23	Refractive error;
KIRP	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg00579200	chr11:133705235	NA	-0.39	-5.14	-0.31	5.72e-7	Childhood ear infection;
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg21285383	chr16:89894308	SPIRE2	0.34	6.51	0.38	4.1e-10	Vitiligo;
KIRP	cis	rs73193808	0.590	rs9981735	chr21:30567864	G/A	cg03476357	chr21:30257390	N6AMT1	0.45	5.05	0.31	8.5e-7	Coronary artery disease;
KIRP	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.52	-7.24	-0.42	5.87e-12	Menarche (age at onset);
KIRP	cis	rs8027181	0.839	rs8024986	chr15:73024868	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.53	-7.51	-0.43	1.09e-12	Triglyceride levels;
KIRP	cis	rs4956211	0.537	rs12647396	chr4:109707729	G/C	cg07086381	chr4:109682776	AGXT2L1	-0.4	-5.15	-0.31	5.4e-7	Systemic lupus erythematosus;
KIRP	cis	rs76533333	1.000	rs34011672	chr13:113360938	A/G	cg04656015	chr13:113407548	ATP11A	0.61	5.06	0.31	8.34e-7	Red cell distribution width;
KIRP	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg24879335	chr3:133465180	TF	0.47	7.28	0.42	4.45e-12	Iron status biomarkers;
KIRP	trans	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg00405596	chr8:11794950	NA	-0.47	-6.25	-0.37	1.81e-9	Mood instability;
KIRP	cis	rs57561814	1.000	rs6949149	chr7:22749157	G/T	cg26061582	chr7:22766209	IL6	0.71	5.52	0.33	8.52e-8	Tonsillectomy;
KIRP	cis	rs9517320	0.935	rs56294784	chr13:99123198	C/T	cg07423050	chr13:99094983	FARP1	0.32	5.15	0.31	5.3e-7	Longevity;
KIRP	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.66	-6.05	-0.36	5.39e-9	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.55	-6.84	-0.4	6.11e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg24375607	chr4:120327624	NA	0.44	5.22	0.32	3.83e-7	Diastolic blood pressure;
KIRP	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.64	-8.65	-0.48	6.95e-16	Cognitive test performance;
KIRP	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.6	-6.87	-0.4	5.35e-11	Menarche (age at onset);
KIRP	cis	rs12143943	0.966	rs11240762	chr1:204566999	C/T	cg20240347	chr1:204465584	NA	-0.37	-6.94	-0.4	3.5e-11	Cognitive performance;
KIRP	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.72	11.23	0.58	6.94e-24	Breast cancer;
KIRP	trans	rs2472591	0.929	rs73489862	chr13:50511421	G/A	cg04548715	chr7:99598775	NA	0.59	6.43	0.38	6.63e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs12022452	0.630	rs3795346	chr1:40974425	T/C	cg25568243	chr1:40974465	DEM1	0.54	5.87	0.35	1.37e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.85	-0.35	1.56e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs911119	0.818	rs67862677	chr20:23591086	A/C	cg16589663	chr20:23618590	CST3	0.68	6.28	0.37	1.49e-9	Chronic kidney disease;
KIRP	cis	rs61884328	0.852	rs12576831	chr11:47082255	G/T	cg23433285	chr11:47201945	PACSIN3	0.79	6.35	0.38	1.04e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg10047753	chr17:41438598	NA	1.08	17.23	0.74	3.69e-44	Menopause (age at onset);
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11354908	chr19:18255899	MAST3	0.51	6.74	0.39	1.14e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27546670	chr1:147246839	GJA5	0.57	7.47	0.43	1.36e-12	Cognitive performance;
KIRP	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.13	-0.36	3.54e-9	Systolic blood pressure;
KIRP	cis	rs2273156	1.000	rs12893021	chr14:35440680	A/C	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.44	-0.33	1.29e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.55	-7.3	-0.42	3.91e-12	Asthma;
KIRP	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.75	-0.44	2.4e-13	Alcohol dependence;
KIRP	cis	rs10214930	0.723	rs1524529	chr7:27620415	C/G	cg22168087	chr7:27702803	HIBADH	0.52	5.03	0.31	9.5e-7	Hypospadias;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09976282	chr15:31357238	TRPM1;MIR211	1.01	6.22	0.37	2.17e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg01522456	chr1:115632236	TSPAN2	-0.37	-4.99	-0.3	1.12e-6	Autism;
KIRP	cis	rs1485395	0.838	rs11170630	chr12:54040410	C/G	cg16917193	chr12:54089295	NA	0.63	5.9	0.35	1.19e-8	Migraine without aura;
KIRP	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.54	-7.42	-0.43	1.84e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg00122941	chr17:4613640	ARRB2	-0.68	-7.56	-0.43	7.76e-13	Lymphocyte counts;
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg08662619	chr6:150070041	PCMT1	0.34	5.15	0.31	5.3e-7	Lung cancer;
KIRP	cis	rs7546094	1.000	rs10857963	chr1:113091487	C/T	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	5.76	0.34	2.45e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6500550	0.597	rs2285814	chr16:3565123	G/T	cg07396092	chr16:3662230	BTBD12	0.48	5.63	0.34	4.98e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.73	8.26	0.47	9.22e-15	High light scatter reticulocyte count;
KIRP	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.68	-12.41	-0.62	8.99e-28	White blood cell count (basophil);
KIRP	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg00405596	chr8:11794950	NA	0.42	5.29	0.32	2.73e-7	Retinal vascular caliber;
KIRP	cis	rs72829446	0.556	rs12936464	chr17:7403942	A/C	cg02795151	chr17:7402630	POLR2A	-0.86	-9.36	-0.51	5.34e-18	Androgen levels;
KIRP	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.8	11.12	0.58	1.54e-23	Menarche (age at onset);
KIRP	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.05	-0.36	5.48e-9	IgG glycosylation;
KIRP	cis	rs3850699	0.561	rs34058856	chr10:104369323	C/T	cg04362960	chr10:104952993	NT5C2	0.63	5.99	0.36	7.27e-9	Prostate cancer;
KIRP	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg07148914	chr20:33460835	GGT7	-0.54	-7.15	-0.41	9.81e-12	Height;
KIRP	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	cis	rs17125944	0.686	rs7158645	chr14:53332152	C/T	cg00686598	chr14:53173677	PSMC6	-0.66	-5.87	-0.35	1.38e-8	Alzheimer's disease (late onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19504496	chr19:36119917	RBM42	0.57	6.99	0.41	2.54e-11	Smoking initiation;
KIRP	cis	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg03511173	chr18:77590860	NA	0.51	4.88	0.3	1.89e-6	Opioid sensitivity;
KIRP	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg09455208	chr3:40491958	NA	0.3	5.01	0.3	1.03e-6	Renal cell carcinoma;
KIRP	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.46	0.52	2.54e-18	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4594175	0.677	rs7149846	chr14:51739654	A/C	cg23942311	chr14:51606299	NA	0.42	5.67	0.34	3.99e-8	Cancer;
KIRP	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg00173435	chr12:106696525	TCP11L2	0.48	5.43	0.33	1.35e-7	Tourette syndrome;
KIRP	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg17718321	chr1:152188247	HRNR	0.44	5.35	0.32	1.98e-7	Inflammatory skin disease;
KIRP	cis	rs6429082	0.967	rs1305557	chr1:235627837	C/T	cg26050004	chr1:235667680	B3GALNT2	0.55	7.22	0.42	6.54e-12	Adiposity;
KIRP	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.67	-7.48	-0.43	1.31e-12	Gut microbiome composition (summer);
KIRP	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	trans	rs4557101	1.000	rs7635547	chr3:73539192	A/G	cg17641118	chr11:117049889	SIDT2	0.54	6.79	0.4	8.54e-11	QT interval;
KIRP	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.83	-11.76	-0.6	1.21e-25	Height;
KIRP	cis	rs7694379	0.534	rs11732896	chr4:88287993	G/A	cg23841344	chr4:88312519	HSD17B11	0.43	5.03	0.31	9.44e-7	Platelet count;
KIRP	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg00204512	chr16:28754710	NA	0.4	5.15	0.31	5.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4704187	0.687	rs1422698	chr5:74443132	C/T	cg03227963	chr5:74354835	NA	0.41	6.01	0.36	6.64e-9	Response to amphetamines;
KIRP	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg06671706	chr8:8559999	CLDN23	0.59	6.7	0.39	1.44e-10	Obesity-related traits;
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg19030737	chr1:226927988	ITPKB	0.43	6.3	0.37	1.34e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	0.9	7.64	0.44	4.89e-13	Obesity-related traits;
KIRP	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-6.59	-0.39	2.59e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg23920097	chr1:209922102	NA	-0.49	-5.65	-0.34	4.45e-8	Red blood cell count;
KIRP	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg04725166	chr1:7887271	PER3	-0.37	-5.68	-0.34	3.81e-8	Crohn's disease;
KIRP	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.26	0.47	9.21e-15	Lung cancer in ever smokers;
KIRP	cis	rs57590327	0.503	rs9866374	chr3:81615311	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-7.24	-0.42	5.81e-12	Extraversion;
KIRP	cis	rs6473252	0.522	rs1348673	chr8:81825086	A/T	cg08595989	chr8:81827712	NA	0.27	5.12	0.31	6.17e-7	Breast cancer;
KIRP	cis	rs6545883	0.859	rs7561672	chr2:61519094	G/A	cg15711740	chr2:61764176	XPO1	0.61	7.98	0.45	5.48e-14	Tuberculosis;
KIRP	cis	rs7106204	0.620	rs35008727	chr11:24258035	A/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.23	0.32	3.67e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	5.04	0.31	9.02e-7	Schizophrenia;
KIRP	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.95	13.71	0.66	3.62e-32	Cognitive function;
KIRP	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.43	1.36e-12	Body mass index;
KIRP	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.27	-0.32	2.94e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	10.72	0.56	3.04e-22	Coronary artery disease;
KIRP	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.43	-0.62	7.32e-28	Glomerular filtration rate (creatinine);
KIRP	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Hypertriglyceridemia;
KIRP	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.66	7.77	0.44	2.08e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.16.1163115F	chr16:53272647	CHD9	0.5	7.13	0.41	1.14e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7172677	0.711	rs8035588	chr15:75436843	A/C	cg03289416	chr15:75166202	SCAMP2	0.41	5.11	0.31	6.37e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04555837	chr1:173768981	CENPL	0.39	6.31	0.37	1.32e-9	C-reactive protein;
KIRP	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.49	0.65	2.07e-31	Smoking behavior;
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg21063480	chr14:78082891	SPTLC2	0.47	6.14	0.36	3.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.9	12.08	0.61	1.12e-26	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.86	-12.93	-0.64	1.55e-29	Height;
KIRP	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg03433033	chr1:76189801	ACADM	-0.46	-6.48	-0.38	5.09e-10	Daytime sleep phenotypes;
KIRP	cis	rs2481665	0.546	rs2666504	chr1:62635081	T/C	cg18591186	chr1:62594603	INADL	0.35	5.12	0.31	6.11e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg08885076	chr2:99613938	TSGA10	0.58	9.95	0.54	7.9e-20	Chronic sinus infection;
KIRP	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-6.18	-0.37	2.58e-9	Body mass index;
KIRP	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-7.75	-0.44	2.47e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.51	-6.52	-0.38	4.04e-10	White blood cell count;
KIRP	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs3779273	0.776	rs4727631	chr7:77834209	G/A	cg05596911	chr5:118502651	DMXL1	-0.4	-6.52	-0.38	3.85e-10	Body mass index;
KIRP	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg24459738	chr19:57751996	ZNF805	-0.6	-7.51	-0.43	1.11e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg21775007	chr8:11205619	TDH	-0.38	-4.92	-0.3	1.57e-6	Neuroticism;
KIRP	cis	rs7666738	0.546	rs34621463	chr4:98793357	G/C	cg05340658	chr4:99064831	C4orf37	0.66	7.9	0.45	9.2e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-5.83	-0.35	1.77e-8	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg09264619	chr17:80180166	NA	0.37	5.28	0.32	2.77e-7	Life satisfaction;
KIRP	cis	rs78487399	0.808	rs13414140	chr2:43671176	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.89	-0.35	1.26e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10045504	0.502	rs72746051	chr5:38759817	G/A	cg15396434	chr5:38725168	NA	-0.82	-8.24	-0.46	1.06e-14	Night sleep phenotypes;
KIRP	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.73	12.34	0.62	1.54e-27	Anterior chamber depth;
KIRP	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg22676075	chr6:135203613	NA	0.55	6.8	0.4	7.68e-11	High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14431789	chr10:97081759	SORBS1	-0.42	-6.24	-0.37	1.93e-9	Inflammatory biomarkers;
KIRP	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.54	6.51	0.38	4.14e-10	Menopause (age at onset);
KIRP	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg09597638	chr17:3907349	NA	0.53	5.27	0.32	3e-7	Type 2 diabetes;
KIRP	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.06	0.31	8.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg10018233	chr7:150070692	REPIN1	0.57	7.27	0.42	4.84e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg16584676	chr17:46985605	UBE2Z	0.47	5.91	0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15369054	chr17:80825471	TBCD	-0.61	-6.93	-0.4	3.66e-11	Breast cancer;
KIRP	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg05220968	chr6:146057943	EPM2A	0.41	5.37	0.32	1.83e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.17	-0.42	8.81e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg04865290	chr3:52927548	TMEM110	-0.62	-6.84	-0.4	6.08e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6840360	0.642	rs6851814	chr4:152346437	G/A	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.47e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg16989719	chr2:238392110	NA	-0.57	-6.33	-0.37	1.18e-9	Prostate cancer;
KIRP	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.77	9.8	0.53	2.34e-19	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	cis	rs73200209	0.626	rs56178625	chr12:116578048	A/G	cg01776926	chr12:116560359	MED13L	-0.54	-6.03	-0.36	5.82e-9	Total body bone mineral density;
KIRP	cis	rs4776059	1.000	rs10851521	chr15:52942111	G/A	cg25063058	chr15:52860530	ARPP19	0.51	5.67	0.34	4.03e-8	Schizophrenia;
KIRP	trans	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.28	0.37	1.5e-9	Mean corpuscular volume;
KIRP	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg19847130	chr8:10466454	RP1L1	-0.36	-5.29	-0.32	2.76e-7	Neuroticism;
KIRP	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.64	-8.88	-0.49	1.39e-16	Brugada syndrome;
KIRP	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.66	-8.3	-0.47	6.82e-15	Facial morphology (factor 23);
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.16	12.12	0.61	7.82e-27	Platelet count;
KIRP	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg22800045	chr5:56110881	MAP3K1	0.53	5.94	0.35	9.9e-9	Coronary artery disease;
KIRP	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg13206674	chr6:150067644	NUP43	0.51	7.15	0.41	9.7e-12	Testicular germ cell tumor;
KIRP	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg13147721	chr7:65941812	NA	-1.03	-7.08	-0.41	1.51e-11	Gout;
KIRP	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	0.79	9.88	0.53	1.29e-19	Menopause (age at onset);
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg02886878	chr17:53499011	MMD	0.48	6.22	0.37	2.12e-9	Coronary artery disease;
KIRP	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg08283408	chr3:49949060	MON1A	0.44	5.76	0.34	2.44e-8	Body mass index;
KIRP	cis	rs6707387	0.641	rs6435779	chr2:214388312	T/C	cg08319019	chr2:214017104	IKZF2	0.47	5.4	0.33	1.53e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs10073892	1.000	rs10074257	chr5:101697463	A/G	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.96e-11	Cognitive decline (age-related);
KIRP	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg05231480	chr19:49170277	SEC1;NTN5	-0.32	-4.97	-0.3	1.28e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg02336718	chr17:17403227	NA	0.37	5.53	0.33	8.35e-8	Total body bone mineral density;
KIRP	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg07636037	chr3:49044803	WDR6	-0.78	-7.46	-0.43	1.49e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.78	11.51	0.59	8.02e-25	Heart rate;
KIRP	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.19	10.68	0.56	3.92e-22	Alzheimer's disease (late onset);
KIRP	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.9	-10.4	-0.55	3.15e-21	Exhaled nitric oxide output;
KIRP	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg17822266	chr1:2720087	NA	-0.46	-6.3	-0.37	1.33e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg24375607	chr4:120327624	NA	0.58	6.68	0.39	1.57e-10	Corneal astigmatism;
KIRP	cis	rs4395908	0.605	rs11136703	chr8:4027545	A/G	cg01921437	chr8:3974145	CSMD1	-0.44	-5.61	-0.34	5.44e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs9443189	0.813	rs3798439	chr6:76566734	T/G	cg01950844	chr6:76311363	SENP6	-0.59	-5.42	-0.33	1.43e-7	Prostate cancer;
KIRP	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg00405596	chr8:11794950	NA	0.47	6.3	0.37	1.35e-9	Neuroticism;
KIRP	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.85	11.29	0.58	4.34e-24	N-glycan levels;
KIRP	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.43	-5.52	-0.33	8.56e-8	QT interval;
KIRP	cis	rs1562975	0.609	rs60290218	chr4:109409501	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.41	5.12	0.31	6.3e-7	Height;
KIRP	cis	rs4273100	0.512	rs973650	chr17:19291785	A/G	cg18093559	chr17:18951025	GRAP	0.5	5.89	0.35	1.24e-8	Schizophrenia;
KIRP	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.32	7.97	0.45	5.86e-14	Primary biliary cholangitis;
KIRP	cis	rs9826463	0.582	rs73238185	chr3:142141177	T/C	cg20824294	chr3:142316082	PLS1	0.44	6.35	0.38	1.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.6	-7.17	-0.42	8.71e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg16235748	chr6:149772707	ZC3H12D	0.3	5.09	0.31	7.01e-7	Dupuytren's disease;
KIRP	cis	rs9603616	0.719	rs9548876	chr13:40247374	G/A	cg26701198	chr13:40229707	COG6	0.44	5.15	0.31	5.34e-7	Rheumatoid arthritis;
KIRP	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg17470449	chr10:769945	NA	0.7	6.88	0.4	4.89e-11	Uric acid levels;
KIRP	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.67	9.26	0.51	1.03e-17	Obesity-related traits;
KIRP	cis	rs4722166	0.532	rs6461662	chr7:22757089	C/T	cg05472934	chr7:22766657	IL6	0.51	6.61	0.39	2.36e-10	Lung cancer;
KIRP	trans	rs6561151	0.957	rs1373904	chr13:44475398	A/G	cg17145862	chr1:211918768	LPGAT1	0.68	8.37	0.47	4.44e-15	Crohn's disease;
KIRP	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg02344993	chr17:57696989	CLTC	0.61	5.86	0.35	1.46e-8	Hemoglobin concentration;
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.79	-14.73	-0.68	1.28e-35	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01907584	chr1:228604413	TRIM17	0.45	6.33	0.37	1.16e-9	Parkinson's disease;
KIRP	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg03585969	chr10:35415529	CREM	0.76	9.35	0.51	5.55e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07832903	chr10:69644926	SIRT1	0.47	6.27	0.37	1.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.03	0.31	9.46e-7	Menopause (age at onset);
KIRP	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05192639	chr6:26864778	GUSBL1	-0.23	-4.9	-0.3	1.72e-6	Educational attainment;
KIRP	cis	rs6466055	0.616	rs113860003	chr7:104991190	A/G	cg04380332	chr7:105027541	SRPK2	0.36	4.93	0.3	1.52e-6	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg17441377	chr17:3906640	NA	0.58	8.71	0.49	4.49e-16	Type 2 diabetes;
KIRP	cis	rs9603616	0.719	rs4514547	chr13:40238899	C/T	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.62e-7	Rheumatoid arthritis;
KIRP	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.97	0.54	7.01e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9653442	0.545	rs11123814	chr2:100767082	A/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05361709	chr15:75494287	C15orf39	0.47	6.08	0.36	4.61e-9	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg00629928	chr5:358741	AHRR	0.52	5.45	0.33	1.21e-7	Breast cancer;
KIRP	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg14993813	chr1:46806288	NSUN4	-0.6	-7.0	-0.41	2.45e-11	Menopause (age at onset);
KIRP	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.75	-0.34	2.57e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg05082376	chr22:42548792	NA	-0.45	-5.34	-0.32	2.13e-7	Schizophrenia;
KIRP	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.66	10.95	0.57	5.51e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg05207973	chr5:176823642	SLC34A1	0.46	5.03	0.31	9.51e-7	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs6997458	0.716	rs1845253	chr8:86402196	C/T	cg02393479	chr8:86352350	CA3	-0.31	-4.96	-0.3	1.33e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.59	0.73	5.32e-42	Electrocardiographic conduction measures;
KIRP	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.69	-8.97	-0.5	7.78e-17	Huntington's disease progression;
KIRP	cis	rs73526541	0.588	rs79720868	chr8:1066957	C/T	cg01049933	chr8:1047734	NA	0.76	5.77	0.35	2.39e-8	Verbal memory performance (immediate recall change);
KIRP	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-7.43	-0.43	1.8e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.37	7.5	0.43	1.16e-12	Diastolic blood pressure;
KIRP	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.39	-5.47	-0.33	1.12e-7	Endometrial cancer;
KIRP	cis	rs17123764	1.000	rs11169069	chr12:49966534	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs72634258	0.945	rs34124834	chr1:8028930	T/G	cg00042356	chr1:8021962	PARK7	0.93	7.49	0.43	1.25e-12	Inflammatory bowel disease;
KIRP	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg10047753	chr17:41438598	NA	1.13	18.02	0.75	7.6e-47	Menopause (age at onset);
KIRP	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.6	-8.06	-0.46	3.4e-14	Type 2 diabetes;
KIRP	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg14003231	chr6:33640908	ITPR3	0.29	5.17	0.31	4.92e-7	Plateletcrit;
KIRP	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg02487422	chr3:49467188	NICN1	0.36	5.06	0.31	8.08e-7	Parkinson's disease;
KIRP	trans	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg06521331	chr12:34319734	NA	-0.54	-6.76	-0.4	9.91e-11	Bladder cancer;
KIRP	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.81	-11.96	-0.61	2.66e-26	Dental caries;
KIRP	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.53	8.36	0.47	4.73e-15	C-reactive protein levels;
KIRP	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg07052231	chr12:7363540	PEX5	0.38	5.08	0.31	7.34e-7	IgG glycosylation;
KIRP	cis	rs61935443	1.000	rs61935443	chr12:95249764	G/C	cg21533806	chr12:95267307	NA	0.54	5.36	0.32	1.89e-7	Schizophrenia;
KIRP	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg01378222	chr16:28622494	SULT1A1	-0.64	-6.72	-0.39	1.26e-10	Platelet distribution width;
KIRP	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.7	-9.88	-0.53	1.32e-19	Blood protein levels;
KIRP	trans	rs2163503	1.000	rs11209771	chr1:71817309	A/G	cg27386431	chr1:200990482	KIF21B	-0.67	-6.57	-0.39	3.01e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs9596863	0.898	rs9568920	chr13:54352810	A/T	ch.13.53330881F	chr13:54432880	NA	0.6	5.84	0.35	1.63e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.44	5.68	0.34	3.87e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9972944	0.899	rs9972954	chr17:63771050	T/C	cg07283582	chr17:63770753	CCDC46	0.48	7.94	0.45	7.1e-14	Total body bone mineral density;
KIRP	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg14972814	chr11:95582409	MTMR2	0.34	5.46	0.33	1.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg13798912	chr7:905769	UNC84A	0.57	5.29	0.32	2.7e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.57	-8.68	-0.48	5.53e-16	Birth weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21938736	chr18:21083495	C18orf8	0.52	6.41	0.38	7.22e-10	Parkinson's disease;
KIRP	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.63	7.72	0.44	2.93e-13	Vitamin D levels;
KIRP	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-8.13	-0.46	2.15e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.47	-6.18	-0.37	2.64e-9	Body mass index;
KIRP	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	15.2	0.7	3.17e-37	Electrocardiographic conduction measures;
KIRP	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg22437258	chr11:111473054	SIK2	0.6	7.01	0.41	2.29e-11	Primary sclerosing cholangitis;
KIRP	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg00405596	chr8:11794950	NA	-0.55	-7.64	-0.44	4.77e-13	Myopia (pathological);
KIRP	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg23032129	chr1:109941072	SORT1	-0.28	-4.91	-0.3	1.67e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg17385448	chr1:15911702	AGMAT	0.26	5.05	0.31	8.5e-7	Systolic blood pressure;
KIRP	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg26531700	chr6:26746687	NA	0.48	6.87	0.4	5.13e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23947545	chr5:171638072	UBTD2	-0.45	-6.38	-0.38	8.8e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2073300	0.826	rs6048809	chr20:23443788	C/T	cg12480562	chr20:23434244	CST11	0.61	6.2	0.37	2.33e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.64	-7.91	-0.45	8.94e-14	Extraversion;
KIRP	cis	rs7656342	0.599	rs6847858	chr4:9853059	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.89	-0.35	1.24e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.71	0.34	3.31e-8	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.7	0.68	1.59e-35	Platelet count;
KIRP	cis	rs5753618	0.561	rs9606831	chr22:31732512	C/T	cg22777020	chr22:31556080	RNF185	0.48	5.21	0.32	4.08e-7	Colorectal cancer;
KIRP	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.43	5.56	0.33	6.85e-8	Blood metabolite levels;
KIRP	cis	rs77861329	1.000	rs9809254	chr3:52111474	T/C	cg08692210	chr3:52188851	WDR51A	0.93	7.56	0.43	7.98e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10831504	chr12:69005104	RAP1B	0.97	6.51	0.38	4.16e-10	P wave terminal force;
KIRP	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg19847130	chr8:10466454	RP1L1	-0.37	-5.67	-0.34	3.94e-8	Retinal vascular caliber;
KIRP	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.56	10.36	0.55	4.1e-21	Iron status biomarkers (transferrin levels);
KIRP	trans	rs9790314	0.613	rs4679666	chr3:160629025	C/G	cg19274270	chr17:78178856	CARD14	0.34	6.19	0.37	2.52e-9	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.65	-5.7	-0.34	3.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg04865290	chr3:52927548	TMEM110	0.68	7.57	0.43	7.6e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	1.04	14.57	0.68	4.28e-35	Menopause (age at onset);
KIRP	cis	rs6662572	0.906	rs76438782	chr1:46240425	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.31	0.32	2.51e-7	Blood protein levels;
KIRP	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg06815112	chr8:27182871	PTK2B	0.47	6.02	0.36	6.15e-9	Neuroticism;
KIRP	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.52	6.58	0.39	2.86e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs75920871	0.925	rs76523703	chr11:116749509	T/G	cg23684410	chr11:116897558	SIK3	0.53	5.7	0.34	3.44e-8	Subjective well-being;
KIRP	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg07636037	chr3:49044803	WDR6	-0.84	-7.9	-0.45	9.01e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.92	13.34	0.65	6.66e-31	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg00409905	chr10:38381863	ZNF37A	-0.58	-6.8	-0.4	7.8e-11	Obesity (extreme);
KIRP	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	11.86	0.6	6.04e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.82	-0.35	1.85e-8	Fear of minor pain;
KIRP	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg14092571	chr14:90743983	NA	0.4	4.97	0.3	1.26e-6	Mortality in heart failure;
KIRP	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.44	-0.38	6.16e-10	Mood instability;
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs12549025	0.715	rs10503726	chr8:23397266	T/C	cg00472375	chr8:23315376	ENTPD4	0.44	5.17	0.31	4.82e-7	Reticulocyte fraction of red cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18879646	chr1:89990278	LRRC8B	0.46	6.1	0.36	4.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11264213	0.901	rs10796876	chr1:36424985	A/G	cg27506609	chr1:36549197	TEKT2	0.96	10.24	0.55	1.01e-20	Schizophrenia;
KIRP	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.61	-0.52	8.92e-19	Response to antipsychotic treatment;
KIRP	cis	rs2905347	0.696	rs2905319	chr7:22697141	G/C	cg23521230	chr7:22704884	NA	0.41	5.25	0.32	3.35e-7	Major depression and alcohol dependence;
KIRP	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg01631408	chr1:248437212	OR2T33	0.68	8.29	0.47	7.43e-15	Common traits (Other);
KIRP	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg22643751	chr7:855365	UNC84A	0.36	5.05	0.31	8.66e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.06	0.54	3.54e-20	Total body bone mineral density;
KIRP	cis	rs2692947	0.567	rs4243787	chr2:96388762	T/A	cg23100626	chr2:96804247	ASTL	0.39	4.87	0.3	1.96e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg04691961	chr3:161091175	C3orf57	-0.41	-5.89	-0.35	1.23e-8	Educational attainment (years of education);
KIRP	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs6725041	0.547	rs4672645	chr2:213204955	C/T	cg16329650	chr2:213403929	ERBB4	-0.39	-5.13	-0.31	5.96e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.64	5.49	0.33	9.78e-8	Schizophrenia;
KIRP	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.08	0.58	2.02e-23	Exhaled nitric oxide levels;
KIRP	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg13206674	chr6:150067644	NUP43	0.56	8.17	0.46	1.64e-14	Lung cancer;
KIRP	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg05535760	chr7:792225	HEATR2	0.42	4.94	0.3	1.46e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg09904177	chr6:26538194	HMGN4	0.46	5.91	0.35	1.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	5.9	0.35	1.22e-8	Height;
KIRP	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16083429	chr3:49237500	CCDC36	-0.38	-5.0	-0.3	1.08e-6	Menarche (age at onset);
KIRP	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.8	7.34	0.42	3.06e-12	Methadone dose in opioid dependence;
KIRP	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	ch.11.42038R	chr11:967971	AP2A2	0.38	4.9	0.3	1.7e-6	Alzheimer's disease (late onset);
KIRP	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.38	-0.32	1.77e-7	Colorectal cancer;
KIRP	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.57	-6.99	-0.41	2.61e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg01629716	chr15:45996671	NA	0.37	6.54	0.38	3.61e-10	Waist circumference;Weight;
KIRP	cis	rs78487399	0.710	rs72879290	chr2:43633268	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-5.33	-0.32	2.22e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.35	-0.42	3e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.47	-6.49	-0.38	4.74e-10	Testicular germ cell tumor;
KIRP	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg02375832	chr11:62437615	C11orf48	-0.4	-4.92	-0.3	1.6e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11245990	chr11:68621969	NA	0.37	5.01	0.3	1.04e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.59	0.39	2.6200000000000003e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10073892	0.789	rs10044561	chr5:101807713	C/T	cg19774478	chr5:101632501	SLCO4C1	0.67	6.49	0.38	4.62e-10	Cognitive decline (age-related);
KIRP	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	cg12689670	chr1:183009347	LAMC1	-0.46	-6.65	-0.39	1.89e-10	Colorectal cancer;
KIRP	cis	rs9783347	1.000	rs1520884	chr11:18309700	C/T	cg15585147	chr11:18324498	HPS5	-0.45	-6.15	-0.36	3.14e-9	Pancreatic cancer;
KIRP	trans	rs9650657	0.836	rs4841438	chr8:10606756	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.15	-0.37	3.13e-9	Neuroticism;
KIRP	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.62	-8.01	-0.45	4.5e-14	Obesity-related traits;
KIRP	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-6.27	-0.37	1.63e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs931127	0.554	rs34007146	chr11:65477954	G/A	cg11569703	chr11:65557185	OVOL1	-0.33	-4.85	-0.3	2.16e-6	Systemic lupus erythematosus;
KIRP	cis	rs12731740	0.831	rs35029161	chr1:207927153	T/C	cg22525895	chr1:207977042	MIR29B2	-0.63	-4.85	-0.3	2.19e-6	Biomedical quantitative traits;
KIRP	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg08648136	chr8:956695	NA	-0.43	-6.57	-0.39	2.93e-10	Schizophrenia;
KIRP	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12963246	chr6:28129442	ZNF389	0.52	6.36	0.38	9.52e-10	Depression;
KIRP	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg17294928	chr15:75287854	SCAMP5	-0.63	-5.34	-0.32	2.07e-7	Lung cancer;
KIRP	cis	rs28830936	1.000	rs4924570	chr15:41974660	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-5.52	-0.33	8.67e-8	Diastolic blood pressure;
KIRP	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18252515	chr7:66147081	NA	0.46	5.63	0.34	4.8e-8	Aortic root size;
KIRP	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.75	8.16	0.46	1.76e-14	Response to diuretic therapy;
KIRP	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg10932868	chr11:921992	NA	0.54	6.78	0.4	8.86e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg07827796	chr19:33622959	WDR88	0.41	4.91	0.3	1.65e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg09264619	chr17:80180166	NA	-0.35	-4.99	-0.3	1.14e-6	Life satisfaction;
KIRP	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.79	12.82	0.63	3.75e-29	Schizophrenia;
KIRP	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg11833968	chr6:79620685	NA	-0.38	-5.25	-0.32	3.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	1.05	22.23	0.82	8.86e-61	Parkinson's disease;
KIRP	cis	rs9409565	0.793	rs2486632	chr9:97196979	A/G	cg04523069	chr9:97136363	HIATL1	0.47	6.19	0.37	2.56e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg04865290	chr3:52927548	TMEM110	-0.62	-6.84	-0.4	6.08e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.68	8.98	0.5	7.09e-17	Schizophrenia;
KIRP	cis	rs775227	0.574	rs16860849	chr3:113049993	C/T	cg18753928	chr3:113234510	CCDC52	0.55	5.48	0.33	1.04e-7	Dental caries;
KIRP	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg05484376	chr2:27715224	FNDC4	0.41	6.76	0.4	1e-10	Total body bone mineral density;
KIRP	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg09596252	chr17:78655493	RPTOR	0.58	7.62	0.44	5.46e-13	Obesity;
KIRP	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.53	6.81	0.4	7.49e-11	Coronary heart disease;
KIRP	cis	rs4919044	0.641	rs11187225	chr10:94714427	C/G	cg05127821	chr10:94822908	CYP26C1	-1.02	-8.31	-0.47	6.65e-15	Coronary artery disease;
KIRP	cis	rs6504950	0.705	rs9899545	chr17:52986845	T/C	cg26251398	chr17:52985966	TOM1L1	0.43	5.83	0.35	1.71e-8	Breast cancer;
KIRP	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.19	10.48	0.56	1.74e-21	Diabetic kidney disease;
KIRP	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.23	-0.32	3.64e-7	Pulmonary function;
KIRP	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.11	-0.36	3.82e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.61	-6.62	-0.39	2.18e-10	DNA methylation (variation);
KIRP	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg00277334	chr10:82204260	NA	-0.47	-5.44	-0.33	1.28e-7	Post bronchodilator FEV1;
KIRP	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg25182066	chr10:30743637	MAP3K8	-0.67	-8.88	-0.49	1.4e-16	Inflammatory bowel disease;
KIRP	cis	rs714027	0.566	rs4823076	chr22:30519414	G/A	cg01021169	chr22:30184971	ASCC2	0.44	5.59	0.34	6.05e-8	Lymphocyte counts;
KIRP	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg00147788	chr6:125855365	NA	-0.32	-4.98	-0.3	1.18e-6	Brugada syndrome;
KIRP	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs35771425	0.600	rs6667063	chr1:211660746	G/A	cg10512769	chr1:211675356	NA	-0.71	-8.52	-0.48	1.57e-15	Educational attainment (years of education);
KIRP	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.39	-0.33	1.61e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg13147721	chr7:65941812	NA	-1.01	-6.71	-0.39	1.36e-10	Diabetic kidney disease;
KIRP	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	1.07	12.95	0.64	1.31e-29	Exhaled nitric oxide output;
KIRP	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg10189774	chr4:17578691	LAP3	0.55	6.87	0.4	5.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg26149184	chr10:133730230	NA	0.43	5.1	0.31	6.89e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09871261	chr1:162063901	NOS1AP	-0.39	-6.07	-0.36	4.79e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg25019033	chr10:957182	NA	-0.6	-6.01	-0.36	6.65e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg27411982	chr8:10470053	RP1L1	-0.39	-5.01	-0.3	1.06e-6	Neuroticism;
KIRP	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg01843524	chr15:80216276	C15orf37;ST20	0.42	5.17	0.31	4.93e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.87	0.45	1.13e-13	Educational attainment;
KIRP	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.31	-0.42	3.69e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	6.95	0.41	3.27e-11	Menarche (age at onset);
KIRP	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.29	0.62	2.12e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.96	-0.5	8.24e-17	Platelet count;
KIRP	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17554472	chr22:41940697	POLR3H	-0.61	-6.7	-0.39	1.45e-10	Vitiligo;
KIRP	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg00086871	chr4:6988644	TBC1D14	0.77	6.63	0.39	2.15e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg22764044	chr5:178986830	RUFY1	0.44	6.13	0.36	3.47e-9	Lung cancer;
KIRP	cis	rs12681963	0.688	rs10954880	chr8:30008682	T/C	cg04374813	chr8:30012889	DCTN6	0.46	5.13	0.31	5.75e-7	Migraine;
KIRP	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg10446143	chr21:44394730	PKNOX1	-0.48	-6.11	-0.36	3.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg01631408	chr1:248437212	OR2T33	-0.52	-7.2	-0.42	7.26e-12	Common traits (Other);
KIRP	cis	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg07585502	chr8:101912084	NA	-0.63	-7.84	-0.45	1.37e-13	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4656940	0.574	rs508578	chr1:160767060	G/A	cg17331569	chr1:160788135	LY9	0.43	5.1	0.31	6.78e-7	Crohn's disease;
KIRP	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.96	-13.58	-0.65	1.05e-31	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.18	-0.37	2.66e-9	Aortic root size;
KIRP	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.85	12.75	0.63	6.15e-29	Longevity;
KIRP	cis	rs16933812	0.510	rs7850976	chr9:36988851	C/T	cg13738729	chr9:36989127	PAX5	-0.36	-4.92	-0.3	1.59e-6	Obesity-related traits;
KIRP	cis	rs5753618	0.583	rs5749270	chr22:31812853	C/T	cg07713946	chr22:31675144	LIMK2	0.32	5.1	0.31	6.68e-7	Colorectal cancer;
KIRP	trans	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg10756647	chr7:56101905	PSPH	-0.98	-7.03	-0.41	2.01e-11	Diabetic kidney disease;
KIRP	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg27494647	chr7:150038898	RARRES2	0.38	5.67	0.34	3.95e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4594175	0.926	rs10149006	chr14:51615265	A/C	cg23942311	chr14:51606299	NA	0.51	6.75	0.4	1.04e-10	Cancer;
KIRP	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	0.94	12.35	0.62	1.38e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg04310649	chr10:35416472	CREM	0.59	6.98	0.41	2.81e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg26587870	chr6:27730563	NA	-0.64	-4.84	-0.3	2.26e-6	Depression;
KIRP	cis	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg20368463	chr18:77673604	PQLC1	-0.48	-6.09	-0.36	4.41e-9	Schizophrenia;
KIRP	cis	rs7224314	1.000	rs8070689	chr17:65387405	G/T	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.33	-0.42	3.37e-12	Diisocyanate-induced asthma;
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg13092806	chr2:177043255	NA	0.61	7.86	0.45	1.2e-13	IgG glycosylation;
KIRP	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg00405596	chr8:11794950	NA	-0.42	-5.11	-0.31	6.4e-7	Systolic blood pressure;
KIRP	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-6.28	-0.37	1.49e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-11.91	-0.6	4.01e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs9314323	0.592	rs6981737	chr8:26271100	T/G	cg11498726	chr8:26250323	BNIP3L	-0.46	-6.94	-0.4	3.4e-11	Red cell distribution width;
KIRP	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.88	14.72	0.68	1.28e-35	Alcohol dependence (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12726807	chr15:41056075	GCHFR	0.48	6.03	0.36	6.1e-9	Parkinson's disease;
KIRP	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2150410	0.604	rs8131067	chr21:40682542	T/A	cg11890956	chr21:40555474	PSMG1	0.83	5.8	0.35	2.02e-8	Temperament (bipolar disorder);
KIRP	cis	rs7463256	0.966	rs6557643	chr8:23097802	A/G	cg14349055	chr8:23104193	CHMP7	-0.82	-11.09	-0.58	1.99e-23	Attention deficit hyperactivity disorder;
KIRP	cis	rs34286592	1.000	rs13331733	chr16:29848417	A/G	cg08218971	chr16:29826754	C16orf53;PRRT2	0.34	4.93	0.3	1.48e-6	Multiple sclerosis;
KIRP	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg18196295	chr10:418757	DIP2C	0.41	5.09	0.31	7.03e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs10872587	0.555	rs2265470	chr6:146219232	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-5.85	-0.35	1.59e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg06204229	chr3:52865917	ITIH4	0.44	5.11	0.31	6.41e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs11671005	0.735	rs11881000	chr19:58932788	C/T	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg10381502	chr11:71823885	C11orf51	-1.04	-7.3	-0.42	4.09e-12	Severe influenza A (H1N1) infection;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg09002469	chr12:123459295	OGFOD2;ABCB9	0.53	6.74	0.39	1.11e-10	Asthma;
KIRP	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg06243866	chr13:111019493	COL4A2	-0.78	-12.28	-0.62	2.3e-27	White matter hyperintensity burden;
KIRP	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	6.59	0.39	2.72e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg11271282	chr2:238384023	NA	0.44	4.88	0.3	1.94e-6	Prostate cancer;
KIRP	cis	rs1978968	0.731	rs9605466	chr22:18461056	A/T	cg02610425	chr22:18483192	MICAL3	0.38	5.68	0.34	3.78e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs7546094	1.000	rs7554916	chr1:113123734	A/C	cg22162597	chr1:113214053	CAPZA1	0.47	6.61	0.39	2.38e-10	Platelet distribution width;
KIRP	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg26876637	chr1:152193138	HRNR	0.73	9.87	0.53	1.45e-19	Atopic dermatitis;
KIRP	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs9303542	0.559	rs1042822	chr17:46620095	G/T	cg04904318	chr17:46607828	HOXB1	-0.62	-6.76	-0.4	9.88e-11	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.72	10.64	0.56	5.2e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-0.89	-6.66	-0.39	1.74e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	7.25e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2898681	0.581	rs730246	chr4:53680719	T/C	cg00338735	chr4:53728038	RASL11B	0.43	5.34	0.32	2.09e-7	Optic nerve measurement (cup area);
KIRP	cis	rs6545883	0.868	rs6752938	chr2:61841588	C/T	cg15711740	chr2:61764176	XPO1	-0.58	-8.12	-0.46	2.3e-14	Tuberculosis;
KIRP	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Body mass index;
KIRP	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.669	rs10875767	chr12:48599257	A/C	cg20731937	chr12:48336164	NA	0.43	5.69	0.34	3.52e-8	Longevity (90 years and older);
KIRP	trans	rs972578	0.765	rs2267461	chr22:43269547	C/T	cg15321293	chr3:36422198	STAC	-0.48	-6.24	-0.37	1.94e-9	Mean platelet volume;
KIRP	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.43	5.41	0.33	1.47e-7	Aortic root size;
KIRP	cis	rs3736485	0.934	rs8036609	chr15:51861426	C/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.47	-4.95	-0.3	1.35e-6	Smoking behavior;
KIRP	cis	rs10267417	0.603	rs28770193	chr7:19860804	A/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.07	0.31	7.66e-7	Night sleep phenotypes;
KIRP	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg13628971	chr7:2884303	GNA12	0.58	7.25	0.42	5.3e-12	Height;
KIRP	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg10756647	chr7:56101905	PSPH	0.96	6.67	0.39	1.66e-10	Gout;
KIRP	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg23791538	chr6:167370224	RNASET2	-0.44	-5.2	-0.31	4.2e-7	Crohn's disease;
KIRP	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.38	0.38	8.76e-10	Mean platelet volume;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.53	-7.0	-0.41	2.48e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	9.73	0.53	3.84e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs17123764	0.579	rs74089557	chr12:49930366	G/A	cg20471783	chr12:50157085	TMBIM6	0.43	5.09	0.31	7e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.79	-0.63	4.75e-29	Exhaled nitric oxide output;
KIRP	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.29e-9	Obesity-related traits;
KIRP	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	6.85	0.4	5.97e-11	Prudent dietary pattern;
KIRP	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg08648136	chr8:956695	NA	0.51	7.38	0.43	2.4e-12	Schizophrenia;
KIRP	cis	rs981844	0.807	rs56053818	chr4:154638126	T/A	cg14289246	chr4:154710475	SFRP2	0.61	7.05	0.41	1.81e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs367615	1.000	rs58931051	chr5:108907732	A/G	cg17395555	chr5:108820864	NA	0.49	5.12	0.31	6.26e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs8054556	0.647	rs4788211	chr16:30015565	C/T	cg06326092	chr16:30034487	C16orf92	0.43	6.58	0.39	2.87e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.66	9.36	0.51	5.33e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.88	-0.3	1.91e-6	Cervical cancer;
KIRP	cis	rs35883536	0.967	rs2297713	chr1:101092766	T/G	cg06223162	chr1:101003688	GPR88	0.32	6.54	0.38	3.6e-10	Monocyte count;
KIRP	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg02487422	chr3:49467188	NICN1	0.35	4.93	0.3	1.5e-6	Parkinson's disease;
KIRP	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg24972876	chr7:65420302	NA	0.41	5.58	0.34	6.32e-8	Calcium levels;
KIRP	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.54	0.52	1.45e-18	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.4	-5.59	-0.34	6.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.53	7.16	0.42	9.27e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.74	-0.78	1.24e-52	Height;
KIRP	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg17691542	chr6:26056736	HIST1H1C	0.66	8.1	0.46	2.62e-14	Iron status biomarkers;
KIRP	cis	rs6459788	0.630	rs11977865	chr7:157234112	G/A	cg06271696	chr7:157225062	NA	-0.57	-7.56	-0.43	8e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.58	-6.6	-0.39	2.54e-10	Hypospadias;
KIRP	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg03538708	chr1:25844672	NA	-0.38	-4.92	-0.3	1.59e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg23682824	chr7:23144976	KLHL7	0.46	5.55	0.33	7.51e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.42	5.38	0.32	1.76e-7	Blood metabolite levels;
KIRP	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg02404636	chr22:31891804	SFI1	-0.48	-6.33	-0.37	1.15e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-5.13	-0.31	5.83e-7	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01626477	chr2:30454344	LBH	0.46	6.45	0.38	5.94e-10	Parkinson's disease;
KIRP	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-11.59	-0.59	4.46e-25	Triglycerides;
KIRP	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6594713	0.819	rs13180522	chr5:112726022	A/G	cg12552261	chr5:112820674	MCC	0.52	5.23	0.32	3.59e-7	Brain cytoarchitecture;
KIRP	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg06453172	chr10:134556979	INPP5A	-0.6	-7.13	-0.41	1.08e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs494562	0.892	rs618448	chr6:86121324	G/A	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9905704	0.918	rs581903	chr17:56719197	C/T	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	cis	rs8033133	0.602	rs4906699	chr15:25321029	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.54	6.89	0.4	4.78e-11	Blood osmolality (transformed sodium);
KIRP	cis	rs2346160	1.000	rs7753298	chr6:167664193	G/A	cg27333441	chr6:167680455	NA	0.44	5.85	0.35	1.58e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.18	0.51	1.85e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21883621	chr18:43753916	C18orf25	0.51	6.63	0.39	2.17e-10	Parkinson's disease;
KIRP	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg09873164	chr1:152488093	CRCT1	0.53	6.54	0.38	3.57e-10	Hair morphology;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg21515243	chr18:21033072	RIOK3	0.54	6.16	0.37	2.95e-9	Sleep duration;
KIRP	cis	rs12580194	0.593	rs4590978	chr12:55725086	G/T	cg11794356	chr12:55725991	OR6C3	-0.54	-7.13	-0.41	1.11e-11	Cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24933174	chr1:247082741	AHCTF1	0.47	6.71	0.39	1.32e-10	Migraine with aura;
KIRP	cis	rs7327064	0.600	rs9547145	chr13:36871730	G/T	cg13455704	chr13:36871754	C13orf38	0.63	5.54	0.33	7.85e-8	Economic and political preferences;
KIRP	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg19645103	chr12:69753606	YEATS4	-0.48	-4.89	-0.3	1.83e-6	Response to diuretic therapy;
KIRP	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04828587	chr4:174251028	NA	-0.41	-6.24	-0.37	1.93e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg11569703	chr11:65557185	OVOL1	-0.58	-10.51	-0.56	1.4e-21	Systemic lupus erythematosus;
KIRP	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.7	-10.18	-0.54	1.58e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.05	0.41	1.77e-11	Mean corpuscular volume;
KIRP	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.51	-0.73	1.02e-41	Height;
KIRP	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg13679303	chr9:96623674	NA	-0.51	-7.3	-0.42	3.98e-12	DNA methylation (variation);
KIRP	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.38	5.81	0.35	1.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-4.86	-0.3	2.08e-6	Blood metabolite levels;
KIRP	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg24488311	chr11:68621650	NA	0.42	5.33	0.32	2.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg25182066	chr10:30743637	MAP3K8	-0.66	-8.09	-0.46	2.8e-14	Itch intensity from mosquito bite;
KIRP	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg23682824	chr7:23144976	KLHL7	0.48	5.55	0.33	7.28e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7017914	0.902	rs6472542	chr8:71654087	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.4	4.88	0.3	1.91e-6	Bone mineral density;
KIRP	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.61	8.63	0.48	7.86e-16	Endometrial cancer;
KIRP	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-5.41	-0.33	1.48e-7	Aortic root size;
KIRP	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg08888203	chr3:10149979	C3orf24	0.48	4.86	0.3	2.05e-6	Alzheimer's disease;
KIRP	cis	rs13038095	1	rs13038095	chr20:46425576	A/C	cg21798815	chr20:46414765	SULF2	-0.7	-5.24	-0.32	3.45e-7	Atrial fibrillation;
KIRP	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg00806126	chr19:22604979	ZNF98	0.63	6.7	0.39	1.4e-10	Pain;
KIRP	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg23216685	chr1:86174607	ZNHIT6	-0.49	-5.81	-0.35	1.89e-8	Urate levels in overweight individuals;
KIRP	cis	rs2151522	0.563	rs35697500	chr6:127203557	T/A	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.83	9.17	0.5	1.95e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.61	7.93	0.45	7.51e-14	Breast cancer;
KIRP	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	11.26	0.58	5.58e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.87	0.35	1.41e-8	Menopause (age at onset);
KIRP	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg22563815	chr15:78856949	CHRNA5	-0.48	-7.71	-0.44	3.2e-13	Sudden cardiac arrest;
KIRP	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	0.94	10.95	0.57	5.38e-23	Vitiligo;
KIRP	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.17	0.46	1.59e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-7.49	-0.43	1.2e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.74	-8.95	-0.5	8.69e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.42	-5.59	-0.34	6.14e-8	Abdominal aortic aneurysm;
KIRP	cis	rs11671005	0.779	rs35631681	chr19:58999840	C/T	cg13877915	chr19:58951672	ZNF132	0.55	5.02	0.3	1.01e-6	Mean platelet volume;
KIRP	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.72	-7.78	-0.44	1.97e-13	Response to bleomycin (chromatid breaks);
KIRP	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg15488143	chr7:128924101	AHCYL2	0.57	6.04	0.36	5.64e-9	White matter hyperintensity burden;
KIRP	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.67	9.23	0.51	1.29e-17	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.55	-0.39	3.3e-10	Neuroticism;
KIRP	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18125479	chr14:51411049	PYGL	0.53	6.85	0.4	5.77e-11	Smoking initiation;
KIRP	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.73	-10.51	-0.56	1.41e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs897080	0.515	rs1067331	chr2:44627626	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.49	0.38	4.61e-10	Height;
KIRP	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.43	0.38	6.66e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6589219	0.908	rs7103178	chr11:111165009	C/T	cg25129781	chr11:111156908	C11orf53	-0.51	-6.66	-0.39	1.73e-10	Colorectal cancer;
KIRP	cis	rs12049351	0.591	rs10916508	chr1:229659791	A/G	cg11742688	chr1:229674241	ABCB10	-0.35	-5.48	-0.33	1.05e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs67257959	1.000	rs67257959	chr19:17158145	T/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.47	5.43	0.33	1.35e-7	Selective IgA deficiency;
KIRP	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.52	0.43	1e-12	Myopia (pathological);
KIRP	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.8	-0.45	1.77e-13	Gut microbiome composition (summer);
KIRP	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg14169450	chr9:139327907	INPP5E	0.34	4.89	0.3	1.81e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7737355	0.812	rs30735	chr5:130709422	G/A	cg06307176	chr5:131281290	NA	-0.45	-5.43	-0.33	1.38e-7	Life satisfaction;
KIRP	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.56	-6.36	-0.38	9.87e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2014572	0.967	rs10427146	chr19:57755998	T/C	cg24459738	chr19:57751996	ZNF805	-0.56	-7.03	-0.41	2.08e-11	Hyperactive-impulsive symptoms;
KIRP	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.38	0.47	4.16e-15	IgG glycosylation;
KIRP	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg15252951	chr6:33757062	LEMD2	0.44	5.06	0.31	8.37e-7	Crohn's disease;
KIRP	cis	rs7011507	1.000	rs78316926	chr8:49127149	C/G	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.74	0.44	2.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg24531977	chr5:56204891	C5orf35	-0.39	-5.06	-0.31	8.22e-7	Coronary artery disease;
KIRP	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	9.95	0.54	8.04e-20	Lung cancer in ever smokers;
KIRP	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg14851346	chr12:38532713	NA	-0.4	-4.96	-0.3	1.3e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4262150	0.767	rs116745399	chr5:152136262	C/A	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg00343986	chr7:65444356	GUSB	-0.46	-5.52	-0.33	8.76e-8	Aortic root size;
KIRP	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.77	-0.49	3.04e-16	Neuroticism;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.87	-9.09	-0.5	3.49e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	0.73	7.25	0.42	5.31e-12	Type 2 diabetes;
KIRP	cis	rs9815354	0.638	rs73069277	chr3:41967521	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.48	1.5e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7794364	0.658	rs7807677	chr7:117502574	C/T	cg21880328	chr7:117514017	CTTNBP2	-0.36	-5.3	-0.32	2.53e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-1.14	-11.23	-0.58	6.8e-24	Post bronchodilator FEV1;
KIRP	cis	rs4638749	0.501	rs9917181	chr2:108747865	C/T	cg06795125	chr2:108905320	SULT1C2	-0.32	-5.85	-0.35	1.56e-8	Blood pressure;
KIRP	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.57	8.36	0.47	4.75e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg11859384	chr17:80120422	CCDC57	0.45	6.09	0.36	4.42e-9	Life satisfaction;
KIRP	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.51	0.33	9.09e-8	Educational attainment;
KIRP	cis	rs12982744	0.613	rs2238603	chr19:2144471	A/G	cg09261902	chr19:2140048	AP3D1	0.43	5.46	0.33	1.15e-7	Osteoarthritis;Height;
KIRP	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06481639	chr22:41940642	POLR3H	-0.65	-6.84	-0.4	6.39e-11	Vitiligo;
KIRP	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg03060546	chr3:49711283	APEH	0.53	7.02	0.41	2.13e-11	Menarche (age at onset);
KIRP	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.38	-0.38	8.85e-10	Height;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs1345301	0.587	rs10186746	chr2:102866377	G/A	cg12451869	chr2:102867685	NA	0.49	7.18	0.42	8.25e-12	Waist circumference;
KIRP	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.55e-8	Aortic root size;
KIRP	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg23173402	chr1:227635558	NA	0.71	5.67	0.34	4.08e-8	Major depressive disorder;
KIRP	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg04111992	chr7:158790115	NA	-0.42	-5.16	-0.31	5.15e-7	Facial morphology (factor 20);
KIRP	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13198984	chr17:80129470	CCDC57	-0.55	-8.23	-0.46	1.11e-14	Life satisfaction;
KIRP	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg08461772	chr7:95026248	PON3	0.4	5.7	0.34	3.34e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.14	-0.36	3.36e-9	Hemoglobin concentration;
KIRP	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.22	-0.37	2.14e-9	Response to antipsychotic treatment;
KIRP	cis	rs259842	0.764	rs357714	chr2:180670070	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.34	-4.95	-0.3	1.4e-6	Blood protein levels;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs6700559	0.647	rs11801159	chr1:200593102	G/A	cg07804481	chr1:200639085	DDX59	0.39	5.03	0.31	9.51e-7	Coronary artery disease;
KIRP	cis	rs72634258	0.554	rs4908704	chr1:7918904	A/G	cg26816564	chr1:7831052	VAMP3	0.66	5.9	0.35	1.22e-8	Inflammatory bowel disease;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.42	-0.38	7e-10	Height;
KIRP	cis	rs4782151	1.000	rs12596733	chr16:9328879	T/C	ch.16.364290R	chr16:9436357	NA	0.32	4.87	0.3	1.96e-6	Cervical cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17282982	chr1:114355064	RSBN1	0.51	7.15	0.41	9.61e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.37	5.77	0.35	2.33e-8	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21841704	chr3:138327835	FAIM	0.52	6.5	0.38	4.46e-10	Parkinson's disease;
KIRP	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.72	-8.81	-0.49	2.3e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4666002	0.789	rs13023094	chr2:27910706	G/T	cg27432699	chr2:27873401	GPN1	-0.56	-5.5	-0.33	9.69e-8	Phospholipid levels (plasma);
KIRP	cis	rs13095912	0.752	rs13061708	chr3:185339984	T/C	cg11274856	chr3:185301563	NA	0.66	8.4	0.47	3.52e-15	Systolic blood pressure;
KIRP	cis	rs2151522	0.762	rs9375470	chr6:127168044	A/T	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7714584	0.826	rs34005003	chr5:150225199	C/T	cg22134413	chr5:150180641	NA	0.57	5.08	0.31	7.4e-7	Crohn's disease;
KIRP	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg16049864	chr8:95962084	TP53INP1	0.31	4.85	0.3	2.23e-6	Type 2 diabetes;
KIRP	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg13010199	chr12:38710504	ALG10B	0.62	8.4	0.47	3.64e-15	Morning vs. evening chronotype;
KIRP	cis	rs7219021	0.705	rs28635466	chr17:46983820	G/A	cg16584676	chr17:46985605	UBE2Z	-0.42	-4.86	-0.3	2.07e-6	Schizophrenia or bipolar disorder;
KIRP	cis	rs2997447	0.846	rs3008417	chr1:26403470	G/A	cg19633962	chr1:26362018	EXTL1	-0.58	-5.58	-0.34	6.22e-8	QRS complex (12-leadsum);
KIRP	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg10223061	chr2:219282414	VIL1	-0.32	-5.34	-0.32	2.14e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.66	-9.33	-0.51	6.31e-18	QRS duration;
KIRP	cis	rs10858047	0.700	rs7538880	chr1:115194374	G/A	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.52	-0.43	1e-12	Bladder cancer;
KIRP	cis	rs4073416	0.508	rs11844682	chr14:65910844	G/C	cg03016385	chr14:66212404	NA	-0.57	-6.89	-0.4	4.6e-11	N-glycan levels;
KIRP	cis	rs300890	0.536	rs4279157	chr4:144046002	T/A	cg01719995	chr4:144104893	USP38	0.43	5.58	0.34	6.29e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.97	-0.3	1.28e-6	Renal cell carcinoma;
KIRP	cis	rs17209837	1.000	rs59934297	chr7:87116469	T/G	cg00919237	chr7:87102261	ABCB4	-0.66	-6.64	-0.39	1.99e-10	Gallbladder cancer;
KIRP	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.53	6.67	0.39	1.68e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.22	-0.32	3.83e-7	Breast cancer;
KIRP	cis	rs8077577	0.895	rs16960983	chr17:18104568	A/T	cg09161412	chr17:18057145	MYO15A	-0.35	-4.96	-0.3	1.33e-6	Obesity-related traits;
KIRP	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.58	-8.21	-0.46	1.23e-14	Prostate cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01000515	chr17:19265555	B9D1	0.58	6.77	0.4	9.53e-11	Smoking initiation;
KIRP	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.81	-0.53	2.2e-19	Mood instability;
KIRP	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.46	-0.56	1.94e-21	Morning vs. evening chronotype;
KIRP	cis	rs6058796	0.786	rs28789846	chr20:31275545	G/A	cg13636640	chr20:31349939	DNMT3B	0.6	5.69	0.34	3.63e-8	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.74	0.53	3.59e-19	Dupuytren's disease;
KIRP	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11987759	chr7:65425863	GUSB	-0.44	-5.45	-0.33	1.19e-7	Aortic root size;
KIRP	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs4517514	0.509	rs10765252	chr11:89875664	C/T	cg06174606	chr11:89959870	NA	-0.52	-5.25	-0.32	3.33e-7	Trans fatty acid levels;
KIRP	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.34	0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg15128208	chr22:42549153	NA	0.56	6.06	0.36	5.17e-9	Birth weight;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06157335	chr1:53164003	C1orf163	0.48	6.3	0.37	1.38e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7923609	0.818	rs10822159	chr10:65096250	C/T	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.86	-0.3	2.09e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.43	-0.7	4.83e-38	Alzheimer's disease;
KIRP	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs911119	1.000	rs6048956	chr20:23609301	C/T	cg09631192	chr20:23583594	CST9	-0.5	-4.9	-0.3	1.71e-6	Chronic kidney disease;
KIRP	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs1620921	0.505	rs1344729	chr6:161204841	C/T	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.47	-0.33	1.11e-7	Schizophrenia (age at onset);
KIRP	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg10792982	chr14:105748885	BRF1	0.9	14.13	0.67	1.4e-33	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.21	-12.15	-0.61	6.4e-27	Hip circumference adjusted for BMI;
KIRP	cis	rs76662990	0.665	rs10038151	chr5:73917527	A/G	cg03335624	chr5:73934942	ENC1	-0.43	-4.93	-0.3	1.5e-6	Residual cognition;
KIRP	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	trans	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg05926928	chr17:57297772	GDPD1	0.59	6.43	0.38	6.45e-10	Schizophrenia;
KIRP	cis	rs6662572	0.737	rs9429091	chr1:46513088	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.62	0.34	5.18e-8	Blood protein levels;
KIRP	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg19683494	chr5:74908142	NA	-0.43	-5.03	-0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-9.32	-0.51	7.12e-18	Platelet count;
KIRP	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg16068336	chr17:48637367	CACNA1G	-0.41	-5.24	-0.32	3.43e-7	Type 2 diabetes;
KIRP	cis	rs1413885	0.526	rs9728544	chr1:65847105	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.58	6.32	0.37	1.24e-9	Anticoagulant levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17612148	chr17:26898533	PIGS	0.56	6.94	0.4	3.5e-11	Parkinson's disease;
KIRP	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-6.42	-0.38	6.86e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg20965017	chr5:231967	SDHA	-0.52	-5.98	-0.36	7.64e-9	Breast cancer;
KIRP	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22601191	chr20:60968625	CABLES2	0.41	4.95	0.3	1.41e-6	Colorectal cancer;
KIRP	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.82	-9.27	-0.51	9.86e-18	Bipolar disorder and schizophrenia;
KIRP	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.14	0.36	3.33e-9	Putamen volume;
KIRP	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.07e-10	Height;
KIRP	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.38	-0.38	8.95e-10	Axial length;
KIRP	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg19197139	chr17:4613644	ARRB2	0.74	7.6	0.44	6.1e-13	Lymphocyte counts;
KIRP	cis	rs1009181	0.585	rs9379827	chr6:26153335	G/T	cg00631329	chr6:26305371	NA	-0.57	-6.03	-0.36	6.01e-9	Childhood ear infection;
KIRP	cis	rs11779988	0.630	rs17635854	chr8:17895734	A/G	cg01800426	chr8:17659068	MTUS1	-0.47	-5.67	-0.34	3.91e-8	Breast cancer;
KIRP	cis	rs8014252	0.803	rs17108274	chr14:71070401	G/A	cg11204974	chr14:71022665	NA	-0.69	-7.19	-0.42	7.91e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.72	9.7	0.53	4.88e-19	Height;
KIRP	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.59	-5.99	-0.36	7.24e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9986765	1.000	rs9986765	chr7:142835239	C/T	cg11323483	chr7:142828068	PIP	0.6	5.54	0.33	7.73e-8	Cancer;Dermatomyositis;
KIRP	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.61	-6.8	-0.4	7.88e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg03627880	chr6:151815985	C6orf97	-0.43	-4.94	-0.3	1.43e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg23719950	chr11:63933701	MACROD1	0.69	6.4	0.38	7.99e-10	Mean platelet volume;
KIRP	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg16586182	chr3:47516702	SCAP	-0.7	-9.37	-0.51	4.86e-18	Colorectal cancer;
KIRP	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-35.4	-0.91	1.61e-98	Myeloid white cell count;
KIRP	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg15488143	chr7:128924101	AHCYL2	0.6	6.51	0.38	4.28e-10	White matter hyperintensity burden;
KIRP	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg08029281	chr1:67600428	NA	0.48	6.43	0.38	6.74e-10	Psoriasis;
KIRP	trans	rs933360	0.535	rs10248029	chr7:50845703	T/C	cg20003124	chr12:4557277	NA	0.52	6.19	0.37	2.51e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	5.54	0.33	7.72e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.25e-17	Obesity-related traits;
KIRP	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	0.91	13.78	0.66	2.18e-32	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg13010199	chr12:38710504	ALG10B	0.55	6.72	0.39	1.23e-10	Resting heart rate;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00502963	chr1:150488444	NA	-0.57	-6.43	-0.38	6.58e-10	Menopause (age at onset);
KIRP	cis	rs3789045	0.779	rs12043569	chr1:204560004	C/G	cg08641003	chr1:204589008	LRRN2	-0.51	-5.62	-0.34	5.25e-8	Educational attainment (college completion);
KIRP	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.61	-6.6	-0.39	2.56e-10	Corneal astigmatism;
KIRP	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.46	-0.43	1.5e-12	Morning vs. evening chronotype;
KIRP	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg09417038	chr21:47716443	C21orf57	-0.39	-5.32	-0.32	2.38e-7	Testicular germ cell tumor;
KIRP	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg18306943	chr3:40428807	ENTPD3	-0.41	-5.7	-0.34	3.42e-8	Renal cell carcinoma;
KIRP	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg24315340	chr6:146058215	EPM2A	0.42	5.32	0.32	2.32e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.49	-5.88	-0.35	1.36e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.58	7.37	0.43	2.65e-12	Arsenic metabolism;
KIRP	trans	rs7999699	0.902	rs11619382	chr13:48317764	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.34	0.37	1.1e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.72	-8.47	-0.47	2.32e-15	Resting heart rate;
KIRP	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.28	0.42	4.51e-12	Height;
KIRP	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-7.64	-0.44	4.98e-13	Bipolar disorder;
KIRP	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg07169764	chr2:136633963	MCM6	-0.54	-6.28	-0.37	1.52e-9	Mosquito bite size;
KIRP	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.99	-0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs2594989	0.831	rs7620624	chr3:11476270	C/G	cg01796438	chr3:11312864	ATG7	-0.58	-7.32	-0.42	3.48e-12	Circulating chemerin levels;
KIRP	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg20243544	chr17:37824526	PNMT	0.48	6.61	0.39	2.36e-10	Asthma;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.62	9.31	0.51	7.46e-18	Lung cancer;
KIRP	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03605463	chr16:89740564	NA	0.44	5.25	0.32	3.28e-7	Vitiligo;
KIRP	cis	rs4356975	0.563	rs7442453	chr4:69969180	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.38	0.32	1.76e-7	Obesity-related traits;
KIRP	cis	rs8067287	0.688	rs11078356	chr17:16846208	A/G	cg26910001	chr17:16838321	NA	0.47	5.46	0.33	1.16e-7	Diabetic kidney disease;
KIRP	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg06647332	chr5:131281008	NA	0.43	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs138549714	1	rs138549714	chr18:3220755	G/GT	cg14944538	chr18:3220532	MYOM1	-0.76	-5.49	-0.33	1.02e-7	Brain volume in infants (white matter);
KIRP	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg00784671	chr22:46762841	CELSR1	-0.61	-6.12	-0.36	3.6e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg14675211	chr2:100938903	LONRF2	-0.51	-6.53	-0.38	3.66e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg17366294	chr4:99064904	C4orf37	-0.37	-5.17	-0.31	4.77e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.28	15.12	0.69	5.63e-37	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4950322	0.547	rs17355509	chr1:146594721	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-5.07	-0.31	7.85e-7	Protein quantitative trait loci;
KIRP	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.49	6.53	0.38	3.74e-10	Hemoglobin concentration;
KIRP	cis	rs7017914	0.967	rs35207116	chr8:71708971	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs6959887	0.962	rs7795344	chr7:35283453	G/C	cg06685737	chr7:35301730	NA	0.44	6.47	0.38	5.26e-10	Birth weight;
KIRP	trans	rs7939886	0.920	rs17149859	chr11:55795356	G/A	cg15704280	chr7:45808275	SEPT13	0.82	6.03	0.36	5.87e-9	Myopia (pathological);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08188400	chr19:7969347	MAP2K7	0.56	6.51	0.38	4.25e-10	Smoking initiation;
KIRP	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.18	0.42	8.28e-12	Bipolar disorder;
KIRP	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg03217964	chr16:75182191	ZFP1	0.49	6.33	0.37	1.13e-9	Lung adenocarcinoma;
KIRP	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.51	6.46	0.38	5.68e-10	Educational attainment (years of education);
KIRP	cis	rs4474465	0.688	rs7929656	chr11:78276416	T/C	cg27205649	chr11:78285834	NARS2	0.8	11.1	0.58	1.84e-23	Alzheimer's disease (survival time);
KIRP	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg24009623	chr19:33667908	NA	0.49	6.16	0.37	2.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg09597638	chr17:3907349	NA	-0.52	-5.22	-0.32	3.81e-7	Type 2 diabetes;
KIRP	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.47	-6.2	-0.37	2.32e-9	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19223541	chr18:21033234	RIOK3	-0.5	-6.24	-0.37	1.88e-9	Myopia;
KIRP	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Hypertriglyceridemia;
KIRP	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.57	6.87	0.4	5.2e-11	Aortic root size;
KIRP	cis	rs4936894	0.500	rs11219511	chr11:124102839	C/T	cg27160556	chr11:124181099	OR8D1	-0.46	-6.71	-0.39	1.34e-10	Aging (time to death);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14398548	chr9:136836252	VAV2	0.53	6.37	0.38	9.39e-10	Interleukin-4 levels;
KIRP	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg25767906	chr1:53392781	SCP2	-0.35	-4.93	-0.3	1.52e-6	Monocyte count;
KIRP	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.15	-0.5	2.2e-17	Morning vs. evening chronotype;
KIRP	cis	rs10488172	0.842	rs17167240	chr7:133424668	G/A	cg10665199	chr7:133106180	EXOC4	-0.51	-5.38	-0.32	1.75e-7	Tonometry;
KIRP	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.46	5.96	0.36	8.6e-9	Blood protein levels;
KIRP	cis	rs10506328	0.509	rs4759075	chr12:54667285	T/C	cg27478242	chr12:54611928	NA	-0.27	-5.1	-0.31	6.93e-7	Mean platelet volume;
KIRP	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.71	-8.44	-0.47	2.67e-15	Menarche (age at onset);
KIRP	cis	rs7221595	0.825	rs9896963	chr17:3966591	T/C	cg09597638	chr17:3907349	NA	0.59	6.48	0.38	4.96e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10875746	0.729	rs11168355	chr12:48410978	A/G	cg26205652	chr12:48591994	NA	-0.77	-10.01	-0.54	5.13e-20	Longevity (90 years and older);
KIRP	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg26811252	chr16:29126840	RRN3P2	0.66	8.86	0.49	1.67e-16	Menopause (age at onset);
KIRP	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	cg07049167	chr1:166818506	POGK	0.63	7.11	0.41	1.28e-11	Refractive astigmatism;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg27532560	chr4:187881888	NA	0.75	12.35	0.62	1.36e-27	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.07	-14.96	-0.69	1.95e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.79	-12.16	-0.61	6.01e-27	Height;
KIRP	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-11.29	-0.58	4.27e-24	Vitiligo;
KIRP	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-6.81	-0.4	7.65e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.98	-0.41	2.78e-11	Eye color traits;
KIRP	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.03	-13.14	-0.64	2.99e-30	Exhaled nitric oxide output;
KIRP	cis	rs9488822	0.585	rs550480	chr6:116264354	C/A	cg26893134	chr6:116381904	FRK	-0.19	-4.87	-0.3	2.04e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg05484376	chr2:27715224	FNDC4	0.37	6.05	0.36	5.4e-9	Menopause (age at onset);
KIRP	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg08761264	chr16:28874980	SH2B1	-0.43	-5.0	-0.3	1.1e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-6.38	-0.38	8.58e-10	Self-reported allergy;
KIRP	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg21775007	chr8:11205619	TDH	-0.41	-5.3	-0.32	2.63e-7	Monocyte count;
KIRP	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.96	0.54	7.75e-20	Lung cancer;
KIRP	cis	rs3755132	0.929	rs6431721	chr2:15791937	C/T	cg12888861	chr2:15731646	DDX1	0.39	4.93	0.3	1.49e-6	Wilms tumor;
KIRP	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.61	7.61	0.44	5.78e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12744888	chr3:108248186	MYH15	0.47	6.29	0.37	1.45e-9	Interleukin-4 levels;
KIRP	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.48	5.99	0.36	7.37e-9	Mean platelet volume;
KIRP	cis	rs7017914	0.967	rs12675271	chr8:71602009	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.06	-0.31	8.23e-7	Bone mineral density;
KIRP	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	1.19	10.66	0.56	4.63e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.84	-8.27	-0.47	8.37e-15	Obesity;Body mass index;
KIRP	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg12598211	chr12:123634384	NA	-0.41	-4.95	-0.3	1.37e-6	Neutrophil percentage of white cells;
KIRP	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg06637938	chr14:75390232	RPS6KL1	0.46	6.41	0.38	7.5e-10	Coronary artery disease;
KIRP	cis	rs4722166	0.598	rs35658589	chr7:22800435	C/A	cg05472934	chr7:22766657	IL6	0.5	6.85	0.4	5.88e-11	Lung cancer;
KIRP	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.4	-0.38	7.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9309473	1.000	rs1881245	chr2:73649928	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.47	-0.38	5.31e-10	Metabolite levels;
KIRP	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.67	0.39	1.66e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg02527881	chr3:46936655	PTH1R	-0.39	-5.55	-0.33	7.36e-8	Colorectal cancer;
KIRP	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.39	-0.32	1.65e-7	Bladder cancer;
KIRP	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	4.93	0.3	1.54e-6	Educational attainment;
KIRP	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg10223061	chr2:219282414	VIL1	0.32	5.38	0.32	1.77e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.41	6.64	0.39	2.04e-10	Testicular germ cell tumor;
KIRP	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg21184320	chr1:21044207	KIF17	-0.34	-5.14	-0.31	5.69e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	12.64	0.63	1.52e-28	Menopause (age at onset);
KIRP	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg07777115	chr5:623756	CEP72	-0.59	-6.0	-0.36	7.19e-9	Obesity-related traits;
KIRP	cis	rs7119038	0.509	rs10892256	chr11:118578705	G/A	cg19308663	chr11:118741387	NA	0.41	6.4	0.38	7.8e-10	Sjögren's syndrome;
KIRP	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg05304507	chr6:116381966	FRK	0.2	5.32	0.32	2.36e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.61	-7.68	-0.44	3.68e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.83	-0.45	1.49e-13	Platelet count;
KIRP	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.25e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.33	-5.05	-0.31	8.78e-7	Inflammatory bowel disease;
KIRP	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.79	12.34	0.62	1.48e-27	Dental caries;
KIRP	cis	rs17401966	0.522	rs10492969	chr1:10286358	T/C	cg19773385	chr1:10388646	KIF1B	-0.43	-6.2	-0.37	2.41e-9	Hepatocellular carcinoma;
KIRP	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg20240347	chr1:204465584	NA	0.43	8.5	0.48	1.8e-15	Schizophrenia;
KIRP	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.53	-0.43	9.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg08280861	chr8:58055591	NA	0.67	6.15	0.37	3.06e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.47	-4.98	-0.3	1.22e-6	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.8	9.1	0.5	3.07e-17	Post bronchodilator FEV1;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25974586	chr20:32031867	SNTA1	0.49	6.09	0.36	4.38e-9	Smoking initiation;
KIRP	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05776053	chr2:74358815	NA	0.56	5.8	0.35	2.03e-8	Gestational age at birth (maternal effect);
KIRP	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.94	-14.37	-0.68	2.06e-34	Height;
KIRP	cis	rs35000415	0.745	rs117473643	chr7:128698186	G/C	cg19972273	chr7:128594194	NA	0.81	6.17	0.37	2.82e-9	Systemic lupus erythematosus;
KIRP	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.36	-0.51	5.28e-18	Personality dimensions;
KIRP	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg21452805	chr1:244014465	NA	0.72	6.71	0.39	1.3e-10	RR interval (heart rate);
KIRP	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg11859384	chr17:80120422	CCDC57	0.45	5.8	0.35	2.02e-8	Life satisfaction;
KIRP	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg14003231	chr6:33640908	ITPR3	0.28	5.09	0.31	6.96e-7	Plateletcrit;
KIRP	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg21775007	chr8:11205619	TDH	-0.39	-4.99	-0.3	1.17e-6	Neuroticism;
KIRP	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.48	6.16	0.37	2.88e-9	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	0.99	11.81	0.6	8.24e-26	Breast cancer;
KIRP	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	1.12	11.23	0.58	6.61e-24	Psoriasis;
KIRP	cis	rs6540556	0.723	rs12138452	chr1:209886578	T/A	cg23920097	chr1:209922102	NA	-0.5	-5.72	-0.34	3.04e-8	Red blood cell count;
KIRP	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg09788416	chr12:39539408	NA	0.45	5.63	0.34	4.99e-8	Heart rate;
KIRP	cis	rs7737355	1.000	rs2549018	chr5:130698949	C/T	cg25547332	chr5:131281432	NA	-0.47	-5.28	-0.32	2.86e-7	Life satisfaction;
KIRP	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-7.46	-0.43	1.52e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.72	-7.18	-0.42	8.21e-12	Breast cancer;
KIRP	cis	rs7520050	0.966	rs4660910	chr1:46548402	G/T	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg06521331	chr12:34319734	NA	-0.63	-7.51	-0.43	1.11e-12	Morning vs. evening chronotype;
KIRP	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.16	-0.42	9.13e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	12.57	0.63	2.63e-28	Platelet count;
KIRP	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg01559446	chr3:44596178	ZNF167	-0.36	-5.04	-0.31	9.21e-7	Depressive symptoms;
KIRP	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg00241281	chr14:105779794	PACS2	-0.36	-5.0	-0.3	1.11e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.47	-5.97	-0.36	8.23e-9	Blood metabolite levels;
KIRP	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.34	-0.42	3.04e-12	Type 2 diabetes;
KIRP	cis	rs7646881	0.812	rs73015665	chr3:158453934	A/T	cg19483011	chr3:158453295	NA	-0.55	-5.79	-0.35	2.12e-8	Tetralogy of Fallot;
KIRP	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg14835575	chr10:16859367	RSU1	0.59	7.68	0.44	3.68e-13	Platelet distribution width;
KIRP	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.18	0.42	8.11e-12	Rheumatoid arthritis;
KIRP	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.39	-4.99	-0.3	1.15e-6	IgG glycosylation;
KIRP	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	6.72	0.39	1.23e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7712401	0.601	rs246274	chr5:122280803	A/C	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.32	1.68e-7	Mean platelet volume;
KIRP	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg14456004	chr13:21872349	NA	1.09	12.11	0.61	8.99e-27	White matter hyperintensity burden;
KIRP	cis	rs6969780	0.778	rs2465276	chr7:27145717	G/A	cg21001184	chr7:27205262	HOXA9	-0.61	-4.85	-0.3	2.21e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7009516	0.819	rs12682329	chr8:24220798	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.3	-6.21	-0.37	2.23e-9	Hair greying;
KIRP	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg06611532	chr13:114900021	NA	0.23	5.17	0.31	4.81e-7	Schizophrenia;
KIRP	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	1.01	15.72	0.71	5.28e-39	Sudden cardiac arrest;
KIRP	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.77	9.53	0.52	1.57e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02344001	chr7:17831714	SNX13	-0.46	-7.11	-0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.81	-0.35	1.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs28655083	0.636	rs7194836	chr16:77066830	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.58	-5.25	-0.32	3.35e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2073300	1.000	rs6114126	chr20:23452127	A/T	cg12480562	chr20:23434244	CST11	0.62	6.25	0.37	1.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06481639	chr22:41940642	POLR3H	0.58	6.82	0.4	6.96e-11	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18509826	chr3:52017385	ACY1	0.46	6.1	0.36	4.15e-9	Parkinson's disease;
KIRP	cis	rs7640424	0.716	rs35703078	chr3:107859558	A/G	cg09227934	chr3:107805635	CD47	-0.41	-6.75	-0.4	1.07e-10	Body mass index;
KIRP	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.93	12.0	0.61	2.03e-26	Menopause (age at onset);
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg10253484	chr15:75165896	SCAMP2	-0.53	-6.49	-0.38	4.65e-10	Breast cancer;
KIRP	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-6.54	-0.38	3.54e-10	Systemic lupus erythematosus;
KIRP	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg15440763	chr7:158190612	PTPRN2	-0.42	-5.47	-0.33	1.12e-7	Obesity-related traits;
KIRP	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.71	10.31	0.55	6.03e-21	Oral cavity cancer;
KIRP	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12667521	chr19:29218732	NA	0.76	6.83	0.4	6.57e-11	Methadone dose in opioid dependence;
KIRP	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-5.67	-0.34	3.94e-8	Total body bone mineral density;
KIRP	cis	rs9394841	0.692	rs9349202	chr6:41805581	A/C	cg08135965	chr6:41755394	TOMM6	0.5	5.25	0.32	3.29e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs5753618	0.583	rs5753631	chr22:31863022	A/C	cg02404636	chr22:31891804	SFI1	0.53	6.02	0.36	6.28e-9	Colorectal cancer;
KIRP	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg21775007	chr8:11205619	TDH	0.47	6.07	0.36	4.91e-9	Retinal vascular caliber;
KIRP	cis	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg12940923	chr8:10282607	MSRA	-0.36	-4.89	-0.3	1.82e-6	Neuroticism;
KIRP	cis	rs9535307	0.929	rs1581745	chr13:50330957	T/C	cg04663916	chr13:50265991	EBPL	0.67	6.93	0.4	3.69e-11	Obesity-related traits;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.54	-7.05	-0.41	1.83e-11	Longevity;Endometriosis;
KIRP	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.56	-5.07	-0.31	7.74e-7	Blood pressure (smoking interaction);
KIRP	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.5	-0.48	1.83e-15	Mood instability;
KIRP	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.34	0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1830074	1	rs1830074	chr7:6718674	T/C	cg09896999	chr7:6746977	ZNF12	-0.4	-5.27	-0.32	3.02e-7	Body mass index;
KIRP	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17030434	0.906	rs78436201	chr4:154661755	C/A	cg14289246	chr4:154710475	SFRP2	-0.74	-8.76	-0.49	3.16e-16	Electrocardiographic conduction measures;
KIRP	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.78	10.2	0.55	1.28e-20	Aortic root size;
KIRP	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg12560992	chr17:57184187	TRIM37	-0.51	-5.56	-0.33	6.98e-8	Cognitive test performance;
KIRP	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.73	9.7	0.53	4.66e-19	Breast cancer;
KIRP	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.64	7.81	0.45	1.65e-13	Coronary artery disease;
KIRP	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	5.55	0.33	7.51e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.55	-0.33	7.41e-8	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05356662	chr19:3801854	MATK	0.42	6.33	0.37	1.17e-9	Parkinson's disease;
KIRP	cis	rs8018808	1.000	rs12435136	chr14:77856184	G/A	cg20045696	chr14:77926864	AHSA1	-0.45	-5.69	-0.34	3.58e-8	Myeloid white cell count;
KIRP	trans	rs12043259	1.000	rs6680457	chr1:204826464	T/C	cg11485465	chr5:54518469	NA	0.41	6.46	0.38	5.59e-10	Addiction;
KIRP	cis	rs4959799	0.546	rs3813480	chr6:3270840	A/G	cg03657281	chr6:3270030	SLC22A23	0.79	6.02	0.36	6.29e-9	Survival in rectal cancer;
KIRP	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg08761264	chr16:28874980	SH2B1	-0.51	-5.88	-0.35	1.3e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13853450	chr18:64271503	CDH19	-0.45	-6.25	-0.37	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10191772	chr10:103825568	HPS6	0.49	6.13	0.36	3.45e-9	Parkinson's disease;
KIRP	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	0.45	6.3	0.37	1.39e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3135063	0.884	rs3129317	chr4:3287655	A/G	cg08741688	chr4:3415352	RGS12	-0.39	-5.01	-0.3	1.03e-6	Blood protein levels;
KIRP	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.52	-6.44	-0.38	6.1e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.8	12.12	0.61	7.92e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2594989	1.000	rs2606742	chr3:11391717	G/A	cg01796438	chr3:11312864	ATG7	-0.46	-5.74	-0.34	2.79e-8	Circulating chemerin levels;
KIRP	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.61	-8.74	-0.49	3.67e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg03808351	chr9:123631620	PHF19	0.42	5.77	0.35	2.35e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.16	-0.31	5.08e-7	Testicular germ cell tumor;
KIRP	cis	rs7584330	0.626	rs2271809	chr2:238449107	A/G	cg14458575	chr2:238380390	NA	0.56	7.65	0.44	4.41e-13	Prostate cancer;
KIRP	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.88	-0.4	5.07e-11	Joint mobility (Beighton score);
KIRP	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.77	-0.4	9.2e-11	Heart rate;
KIRP	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.74	-10.95	-0.57	5.44e-23	Endometriosis;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.84	-12.5	-0.62	4.36e-28	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-7.94	-0.45	7.15e-14	Body mass index;
KIRP	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.71	11.42	0.59	1.64e-24	Calcium levels;
KIRP	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg05973401	chr12:123451056	ABCB9	-0.63	-7.42	-0.43	1.89e-12	Platelet count;
KIRP	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.37	7.3	0.42	3.92e-12	IgG glycosylation;
KIRP	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.15	-0.41	1e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg24476569	chr13:95954382	ABCC4	-0.51	-8.1	-0.46	2.61e-14	Blood metabolite levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19503731	chr1:244007303	AKT3	0.4	6.24	0.37	1.9e-9	Migraine with aura;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17150246	chr1:161068070	KLHDC9	-0.53	-6.76	-0.4	1.01e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	5.94	0.35	9.74e-9	Mean corpuscular volume;
KIRP	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs4704187	0.687	rs6872475	chr5:74419793	G/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.66	8.44	0.47	2.84e-15	Bladder cancer;
KIRP	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg07395648	chr5:131743802	NA	-0.38	-5.59	-0.34	6.13e-8	Acylcarnitine levels;
KIRP	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.56	6.89	0.4	4.57e-11	Aortic root size;
KIRP	cis	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg03999872	chr20:62272968	STMN3	-0.56	-6.49	-0.38	4.57e-10	Atopic dermatitis;
KIRP	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.36	-0.47	4.71e-15	Blood protein levels;
KIRP	cis	rs1270639	0.778	rs2707942	chr7:157445750	G/C	cg13357408	chr7:157437802	PTPRN2	0.62	6.02	0.36	6.47e-9	Colorectal cancer;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21171335	chr12:122356390	WDR66	0.48	6.53	0.38	3.73e-10	Mean corpuscular volume;
KIRP	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.59	-12.11	-0.61	8.67e-27	Diabetic kidney disease;
KIRP	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg11584989	chr19:19387371	SF4	0.4	5.18	0.31	4.57e-7	Tonsillectomy;
KIRP	cis	rs7534824	0.625	rs12568338	chr1:101500622	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.28	0.32	2.81e-7	Refractive astigmatism;
KIRP	cis	rs9488822	0.585	rs529574	chr6:116268158	T/A	cg15226275	chr6:116381976	FRK	-0.23	-6.03	-0.36	5.87e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.42	4.92	0.3	1.61e-6	Menopause (age at onset);
KIRP	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.18	-0.37	2.65e-9	Breast cancer;
KIRP	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.51	-7.73	-0.44	2.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3026101	0.599	rs1058381	chr17:5288018	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.85	0.35	1.56e-8	Body mass index;
KIRP	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.33	0.42	3.32e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.7	10.55	0.56	1.08e-21	Dupuytren's disease;
KIRP	cis	rs28595532	0.545	rs13101451	chr4:119253427	A/G	cg21605333	chr4:119757512	SEC24D	0.69	5.84	0.35	1.67e-8	Cannabis dependence symptom count;
KIRP	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg06740227	chr12:86229804	RASSF9	0.48	6.31	0.37	1.31e-9	Major depressive disorder;
KIRP	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg05887092	chr17:76393375	PGS1	0.54	7.49	0.43	1.22e-12	HDL cholesterol levels;
KIRP	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.65	-9.31	-0.51	7.64e-18	Retinal vascular caliber;
KIRP	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17554472	chr22:41940697	POLR3H	-0.62	-6.62	-0.39	2.24e-10	Vitiligo;
KIRP	cis	rs10861661	0.963	rs10778511	chr12:107225331	A/T	cg15890332	chr12:107067104	RFX4	0.35	5.16	0.31	5.1e-7	Triglyceride levels;
KIRP	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.13	0.41	1.1e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.59	6.17	0.37	2.85e-9	Gut microbiome composition (summer);
KIRP	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg24631222	chr15:78858424	CHRNA5	0.8	9.7	0.53	4.8e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11877825	0.826	rs4121956	chr18:10569930	C/T	cg25239095	chr18:10589360	NA	0.39	4.87	0.3	1.98e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	1.01	13.09	0.64	4.62e-30	Post bronchodilator FEV1;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg27280396	chr15:61521715	RORA	-0.47	-6.29	-0.37	1.43e-9	Myopia;
KIRP	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.57	6.21	0.37	2.28e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg03465714	chr1:152285911	FLG	0.51	5.43	0.33	1.35e-7	Atopic dermatitis;
KIRP	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg14829360	chr17:73884958	NA	-0.61	-8.62	-0.48	8.2e-16	Psoriasis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03270197	chr6:166796579	BRP44L	0.52	6.95	0.41	3.33e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	6.37	0.38	9e-10	Menopause (age at onset);
KIRP	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.53	-7.21	-0.42	6.93e-12	Heschl's gyrus morphology;
KIRP	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg11663144	chr21:46675770	NA	-0.69	-9.69	-0.53	5.18e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	cg12689670	chr1:183009347	LAMC1	0.43	6.25	0.37	1.77e-9	Colorectal cancer;
KIRP	cis	rs4740619	0.619	rs1328276	chr9:16029036	A/G	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	trans	rs783540	0.835	rs8030185	chr15:83391537	G/A	cg16105309	chr15:79090380	ADAMTS7	-0.44	-6.07	-0.36	4.87e-9	Schizophrenia;
KIRP	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.86	10.05	0.54	3.85e-20	Pulmonary function decline;
KIRP	cis	rs9308731	0.583	rs7567184	chr2:111931072	C/G	cg18646521	chr2:111875858	NA	0.38	5.34	0.32	2.14e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg17764715	chr19:33622953	WDR88	0.68	8.25	0.47	9.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg07972983	chr1:205091412	RBBP5	0.41	4.89	0.3	1.82e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.68	7.51	0.43	1.07e-12	Hair shape;
KIRP	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.15	-15.16	-0.69	4.11e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs13361707	0.959	rs1002424	chr5:40767397	A/G	cg01087697	chr5:40835557	RPL37	-0.47	-5.35	-0.32	2.03e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs9875589	0.747	rs1488378	chr3:14014725	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.45	5.92	0.35	1.09e-8	Ovarian reserve;
KIRP	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg13395646	chr4:1353034	KIAA1530	0.37	4.95	0.3	1.4e-6	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg06074448	chr4:187884817	NA	-0.86	-17.3	-0.74	2.03e-44	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.99	-13.75	-0.66	2.78e-32	Response to antipsychotic treatment;
KIRP	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg01475377	chr6:109611718	NA	-0.38	-5.46	-0.33	1.19e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.54	-6.54	-0.38	3.55e-10	Uric acid levels;
KIRP	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.12	-0.54	2.34e-20	Hemoglobin concentration;
KIRP	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19524238	chr7:2802976	GNA12	-0.38	-5.19	-0.31	4.37e-7	Height;
KIRP	cis	rs12900413	0.564	rs8035800	chr15:90314790	T/C	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.66e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.32	-0.37	1.2e-9	Response to antipsychotic treatment;
KIRP	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.56	6.81	0.4	7.65e-11	Total body bone mineral density;
KIRP	trans	rs1994135	0.565	rs1905240	chr12:33645009	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-7.05	-0.41	1.77e-11	Resting heart rate;
KIRP	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-0.95	-7.23	-0.42	6.01e-12	Mitochondrial DNA levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10561989	chr14:35408569	C14orf19	0.45	6.29	0.37	1.44e-9	Survival in pancreatic cancer;
KIRP	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg04995300	chr3:66848608	NA	-0.77	-9.53	-0.52	1.63e-18	Type 2 diabetes;
KIRP	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	12.29	0.62	2.2e-27	Smoking behavior;
KIRP	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	7.85e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-8.01	-0.45	4.5e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.81	0.53	2.13e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2072732	0.861	rs72629497	chr1:2954123	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg00360474	chr6:37504404	NA	-0.49	-6.78	-0.4	8.89e-11	Cognitive performance;
KIRP	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.72	-0.34	3.03e-8	Bladder cancer;
KIRP	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.35	0.32	2e-7	Heart rate;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.82	0.49	2.17e-16	Life satisfaction;
KIRP	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.64	-6.33	-0.37	1.14e-9	White matter integrity;
KIRP	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.4	0.47	3.49e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg01843524	chr15:80216276	C15orf37;ST20	-0.45	-5.68	-0.34	3.87e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9473924	0.632	rs7768461	chr6:50931807	A/G	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.4	-0.33	1.6e-7	Body mass index;
KIRP	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	0.95	10.68	0.56	3.88e-22	Triglycerides;
KIRP	cis	rs9447004	0.584	rs12215671	chr6:74435607	T/C	cg03006477	chr6:74432658	CD109	0.25	5.19	0.31	4.4e-7	Blood protein levels;Calcium levels;
KIRP	cis	rs9400467	0.528	rs240954	chr6:111659822	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.49	-6.55	-0.39	3.24e-10	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs11783469	0.524	rs13250995	chr8:23329985	G/A	cg00472375	chr8:23315376	ENTPD4	0.57	5.09	0.31	7.18e-7	Reticulocyte count;
KIRP	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg08807101	chr21:30365312	RNF160	-0.55	-5.38	-0.32	1.72e-7	Cognitive test performance;
KIRP	cis	rs7577696	0.539	rs2280972	chr2:32377961	C/T	cg02381751	chr2:32503542	YIPF4	-0.62	-5.92	-0.35	1.08e-8	Inflammatory biomarkers;
KIRP	cis	rs2213920	0.522	rs9284057	chr9:118241947	C/T	cg13918206	chr9:118159781	DEC1	0.56	7.1	0.41	1.31e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.56	7.31	0.42	3.81e-12	Colorectal cancer;
KIRP	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.82	10.26	0.55	8.42e-21	Menarche (age at onset);
KIRP	cis	rs6882076	1.000	rs12517431	chr5:156392248	C/T	cg12943317	chr5:156479607	HAVCR1	-0.65	-7.79	-0.44	1.85e-13	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs7546668	1.000	rs12741552	chr1:15853276	T/C	cg21858823	chr1:15850916	CASP9	0.47	5.19	0.31	4.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	0.620	rs1905241	chr12:33709729	G/A	cg26384229	chr12:38710491	ALG10B	-0.5	-6.08	-0.36	4.56e-9	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9346649	0.606	rs6940383	chr6:168491688	G/A	cg09211372	chr6:168490623	NA	-0.39	-6.87	-0.4	5.16e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.81	11.19	0.58	9.21e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.91	-0.45	8.83e-14	Mood instability;
KIRP	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.44	-5.19	-0.31	4.31e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17554472	chr22:41940697	POLR3H	-0.68	-7.04	-0.41	1.88e-11	Vitiligo;
KIRP	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg03465714	chr1:152285911	FLG	0.47	5.41	0.33	1.46e-7	Atopic dermatitis;
KIRP	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	1.14	12.44	0.62	7.01e-28	Psoriasis;
KIRP	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.77	-9.81	-0.53	2.25e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4262150	0.810	rs4301224	chr5:152060244	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10073892	0.789	rs10063981	chr5:101763870	G/A	cg19774478	chr5:101632501	SLCO4C1	0.67	6.49	0.38	4.62e-10	Cognitive decline (age-related);
KIRP	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.54	5.64	0.34	4.55e-8	Type 2 diabetes;
KIRP	cis	rs2882667	0.690	rs311596	chr5:138072082	A/T	cg04439458	chr5:138467593	SIL1	0.34	4.94	0.3	1.46e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg07511934	chr16:89386912	ANKRD11	0.44	5.53	0.33	8.14e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg25801113	chr15:45476975	SHF	0.42	7.78	0.44	2.04e-13	Uric acid levels;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg20731533	chr19:36631058	CAPNS1	0.5	6.3	0.37	1.35e-9	DNA methylation (variation);
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.48	5.44	0.33	1.26e-7	Longevity;Endometriosis;
KIRP	cis	rs7851660	0.874	rs1955145	chr9:100634751	A/C	cg13688889	chr9:100608707	NA	0.73	8.78	0.49	2.84e-16	Strep throat;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07837717	chr19:2841006	ZNF555	0.47	6.59	0.39	2.66e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg09455208	chr3:40491958	NA	0.32	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13975730	chr9:139329735	INPP5E	-0.48	-6.27	-0.37	1.65e-9	Parkinson's disease;
KIRP	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-0.76	-8.27	-0.47	8.3e-15	Initial pursuit acceleration;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10448954	chr16:89593394	SPG7	0.51	6.74	0.39	1.09e-10	Interleukin-4 levels;
KIRP	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.51	-6.79	-0.4	8.41e-11	Schizophrenia;
KIRP	cis	rs7937682	0.564	rs4938723	chr11:111382565	T/C	cg09085632	chr11:111637200	PPP2R1B	0.54	6.84	0.4	6.21e-11	Primary sclerosing cholangitis;
KIRP	cis	rs10411262	0.746	rs314660	chr19:47172845	T/C	cg13467550	chr19:47212573	PRKD2	0.36	4.88	0.3	1.89e-6	Tonsillectomy;
KIRP	cis	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg06521331	chr12:34319734	NA	-0.57	-7.0	-0.41	2.46e-11	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg02151108	chr14:50098012	C14orf104	-0.55	-7.46	-0.43	1.48e-12	Carotid intima media thickness;
KIRP	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg09597638	chr17:3907349	NA	0.52	5.22	0.32	3.81e-7	Type 2 diabetes;
KIRP	cis	rs13108043	0.605	rs10516787	chr4:87920334	T/C	cg11209507	chr4:87813803	C4orf36	0.46	4.89	0.3	1.8e-6	Red blood cell count;
KIRP	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.34	12.2	0.61	4.31e-27	Diabetic retinopathy;
KIRP	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.61	0.48	9.05e-16	Personality dimensions;
KIRP	cis	rs7005380	0.556	rs35362581	chr8:120933868	G/C	cg21645572	chr8:120931649	DEPDC6	-0.42	-5.02	-0.3	9.81e-7	Interstitial lung disease;
KIRP	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.44	-6.04	-0.36	5.68e-9	Schizophrenia;
KIRP	cis	rs4262150	0.846	rs72799160	chr5:152129523	C/T	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.62	-6.9	-0.4	4.39e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg21452805	chr1:244014465	NA	0.72	6.76	0.4	9.72e-11	RR interval (heart rate);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06468969	chr17:65373914	PITPNC1	-0.51	-6.34	-0.37	1.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11161851	0.901	rs11162075	chr1:75313445	A/G	cg11196437	chr1:75593865	LHX8	0.38	5.64	0.34	4.78e-8	Visceral fat;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22769031	chr20:35580195	SAMHD1	0.6	7.06	0.41	1.73e-11	Smoking initiation;
KIRP	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	6.11	0.36	3.77e-9	Schizophrenia;
KIRP	cis	rs2742234	0.910	rs2505511	chr10:43641029	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.61	-7.54	-0.43	9.21e-13	Hirschsprung disease;
KIRP	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg04539111	chr16:67997858	SLC12A4	0.45	5.31	0.32	2.41e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.49	-7.05	-0.41	1.77e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg00310523	chr12:86230176	RASSF9	0.37	5.7	0.34	3.37e-8	Major depressive disorder;
KIRP	cis	rs6893807	1.000	rs3814424	chr5:87968953	C/T	cg24804195	chr5:87968844	LOC645323	0.59	6.27	0.37	1.57e-9	Body mass index;
KIRP	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	1.2	11.39	0.59	1.97e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7614311	0.639	rs111234932	chr3:63842449	C/T	cg14183384	chr3:63264335	SYNPR	-0.57	-4.89	-0.3	1.85e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.05	0.41	1.83e-11	Attention deficit hyperactivity disorder;
KIRP	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.8	10.92	0.57	6.59e-23	Adiposity;
KIRP	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg27170947	chr2:26402098	FAM59B	0.55	5.33	0.32	2.25e-7	Gut microbiome composition (summer);
KIRP	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg00495681	chr13:53174319	NA	0.37	4.89	0.3	1.86e-6	Lewy body disease;
KIRP	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg11784071	chr10:104629166	AS3MT	-0.36	-4.91	-0.3	1.68e-6	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg00409905	chr10:38381863	ZNF37A	0.54	7.11	0.41	1.23e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.4	6.2	0.37	2.38e-9	Body mass index;
KIRP	cis	rs3126085	0.560	rs3120667	chr1:152318161	A/G	cg26876637	chr1:152193138	HRNR	-0.51	-6.12	-0.36	3.76e-9	Atopic dermatitis;
KIRP	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	5.32	0.32	2.38e-7	Obesity-related traits;
KIRP	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg06636001	chr8:8085503	FLJ10661	0.91	13.25	0.65	1.37e-30	Neuroticism;
KIRP	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg15655495	chr12:38532458	NA	0.26	5.12	0.31	6.21e-7	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.78	10.11	0.54	2.59e-20	Aortic root size;
KIRP	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.59	9.8	0.53	2.31e-19	Total body bone mineral density;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15237820	chr4:78984332	FRAS1	0.41	6.4	0.38	7.6e-10	C-reactive protein;
KIRP	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.97	0.3	1.28e-6	Tonsillectomy;
KIRP	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.91	-6.39	-0.38	8.46e-10	Type 2 diabetes;
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg17294928	chr15:75287854	SCAMP5	0.53	6.91	0.4	4.06e-11	Breast cancer;
KIRP	cis	rs1215050	0.791	rs9993992	chr4:98810851	C/G	cg17366294	chr4:99064904	C4orf37	0.37	5.02	0.3	9.94e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7551222	0.789	rs4951408	chr1:204558984	C/G	cg20240347	chr1:204465584	NA	-0.43	-8.27	-0.47	8.36e-15	Schizophrenia;
KIRP	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg10517650	chr3:113235015	CCDC52	-0.46	-5.94	-0.35	9.78e-9	Dental caries;
KIRP	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-6.98	-0.41	2.68e-11	Monocyte count;
KIRP	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.38	-0.38	8.77e-10	Axial length;
KIRP	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.44	0.43	1.69e-12	Mean corpuscular volume;
KIRP	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg26876637	chr1:152193138	HRNR	-0.88	-8.79	-0.49	2.58e-16	Atopic dermatitis;
KIRP	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg20493526	chr2:3714936	ALLC	0.42	5.01	0.3	1.02e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23161317	chr6:28129485	ZNF389	0.46	5.34	0.32	2.08e-7	Depression;
KIRP	cis	rs17681684	0.565	rs62066044	chr17:9762454	G/A	cg26853458	chr17:9805074	RCVRN	0.54	5.08	0.31	7.47e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.55	-5.55	-0.33	7.45e-8	Type 2 diabetes;
KIRP	cis	rs367943	0.698	rs13167361	chr5:112961789	C/G	cg12552261	chr5:112820674	MCC	0.43	4.87	0.3	2.02e-6	Type 2 diabetes;
KIRP	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.36	-6.09	-0.36	4.3e-9	Fibrinogen levels;
KIRP	cis	rs17065868	1.000	rs9533911	chr13:45138096	C/A	cg10246903	chr13:45222710	NA	0.65	6.9	0.4	4.5e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.78	9.79	0.53	2.45e-19	Gestational age at birth (maternal effect);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17470531	chr2:55646984	CCDC88A	0.49	6.08	0.36	4.54e-9	Inflammatory biomarkers;
KIRP	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-0.97	-14.06	-0.67	2.37e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.89	-10.87	-0.57	9.99e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13132184	0.507	rs68066615	chr4:38094791	G/A	cg19090437	chr4:38080799	TBC1D1	-0.55	-5.38	-0.32	1.78e-7	Verbal declarative memory;
KIRP	cis	rs258892	0.947	rs266444	chr5:72181404	C/T	cg21869765	chr5:72125136	TNPO1	0.55	6.12	0.36	3.65e-9	Small cell lung carcinoma;
KIRP	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.73	-8.76	-0.49	3.13e-16	Breast size;
KIRP	trans	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17183009	chr3:120277827	NA	0.52	6.06	0.36	5.2e-9	Corneal astigmatism;
KIRP	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.48	-6.8	-0.4	7.94e-11	Sitting height ratio;
KIRP	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.65	8.94	0.5	9.53e-17	Mood instability;
KIRP	cis	rs8084125	1.000	rs871830	chr18:74953607	G/C	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.72	9.39	0.51	4.11e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg02696790	chr15:75250997	RPP25	0.31	5.33	0.32	2.19e-7	Breast cancer;
KIRP	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg00319359	chr11:70116639	PPFIA1	0.57	5.88	0.35	1.33e-8	Coronary artery disease;
KIRP	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg20255370	chr15:40268687	EIF2AK4	-0.4	-5.39	-0.32	1.68e-7	Response to haloperidol in psychosis;
KIRP	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.43	5.12	0.31	6.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	trans	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg24644049	chr4:85504048	CDS1	1.08	6.91	0.4	4.19e-11	Skin colour saturation;
KIRP	cis	rs11779988	0.545	rs411531	chr8:17795934	A/G	cg01800426	chr8:17659068	MTUS1	-0.55	-5.38	-0.32	1.75e-7	Breast cancer;
KIRP	cis	rs7572644	0.679	rs9679543	chr2:28050951	C/T	cg27432699	chr2:27873401	GPN1	0.47	5.66	0.34	4.15e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.83	-6.72	-0.39	1.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.46	5.97	0.36	8.17e-9	Gout;
KIRP	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16318349	chr1:154917307	PBXIP1	-0.35	-5.51	-0.33	8.9e-8	Prostate cancer;
KIRP	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg05347473	chr6:146136440	FBXO30	0.56	7.99	0.45	5.27e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-1.19	-11.35	-0.59	2.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg09682330	chr6:28411287	ZSCAN23	-0.42	-5.24	-0.32	3.46e-7	Pubertal anthropometrics;
KIRP	cis	rs11123406	0.501	rs62160380	chr2:111970764	T/G	cg23466623	chr2:111982296	NA	0.59	7.44	0.43	1.66e-12	Type 2 diabetes;
KIRP	cis	rs16828019	0.777	rs35080169	chr1:41454959	G/A	cg18742814	chr1:41828276	NA	0.67	5.65	0.34	4.32e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg00857998	chr1:205179979	DSTYK	0.59	6.79	0.4	8.52e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs12973672	0.812	rs2280745	chr19:35756178	T/C	cg12095397	chr19:35769544	USF2	0.68	6.15	0.37	3.04e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.2	0.37	2.36e-9	Hemoglobin concentration;
KIRP	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.32	-0.37	1.19e-9	Mood instability;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11578784	chr10:105005750	LOC729020	0.54	7.12	0.41	1.19e-11	Interleukin-4 levels;
KIRP	cis	rs72827839	0.802	rs4794321	chr17:46028844	T/C	cg23391107	chr17:45924227	SP6	-0.5	-5.34	-0.32	2.08e-7	Ease of getting up in the morning;
KIRP	cis	rs829883	0.872	rs1641637	chr12:98890564	G/A	cg25150519	chr12:98850993	NA	0.86	12.97	0.64	1.12e-29	Colorectal adenoma (advanced);
KIRP	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg04202892	chr2:111875749	ACOXL	0.46	6.42	0.38	6.98e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.29	0.32	2.77e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11671005	0.735	rs11084543	chr19:58932701	T/C	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.47	-5.28	-0.32	2.88e-7	Neuroticism;
KIRP	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.37	5.42	0.33	1.42e-7	Calcium levels;
KIRP	cis	rs6132905	0.596	rs77117476	chr20:2611493	T/C	cg24848351	chr20:2622020	TMC2	-0.59	-5.19	-0.31	4.32e-7	Mumps;
KIRP	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.54	5.85	0.35	1.57e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs10982256	0.789	rs1535964	chr9:117272439	C/G	cg13636371	chr9:117264095	DFNB31	0.41	5.29	0.32	2.77e-7	Bipolar disorder;
KIRP	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.88	13.17	0.64	2.52e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg23950597	chr19:37808831	NA	-0.67	-5.99	-0.36	7.32e-9	Coronary artery calcification;
KIRP	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.47	7.26	0.42	5.15e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11997175	0.545	rs66789266	chr8:33888156	C/T	cg04338863	chr8:33670619	NA	0.45	5.4	0.33	1.58e-7	Body mass index;
KIRP	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg12560992	chr17:57184187	TRIM37	0.58	5.22	0.32	3.87e-7	Cognitive test performance;
KIRP	cis	rs904092	0.786	rs1497375	chr4:100161833	T/A	cg12011299	chr4:100065546	ADH4	0.55	5.45	0.33	1.23e-7	Alcohol dependence;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	cis	rs4660531	0.890	rs61229336	chr1:41834935	C/T	cg08462924	chr1:41848221	NA	0.43	5.74	0.34	2.79e-8	Bipolar disorder;
KIRP	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.56	-7.17	-0.42	8.58e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg21253087	chr9:139290292	SNAPC4	0.44	6.18	0.37	2.65e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04900915	chr14:73393158	DCAF4	0.47	6.23	0.37	2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg00147788	chr6:125855365	NA	-0.34	-5.22	-0.32	3.88e-7	Brugada syndrome;
KIRP	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.54	7.15	0.41	9.64e-12	Response to temozolomide;
KIRP	cis	rs4700695	0.764	rs36299	chr5:65348120	G/T	cg21114390	chr5:65439923	SFRS12	0.57	6.03	0.36	6.01e-9	Facial morphology (factor 19);
KIRP	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.59	-0.44	6.58e-13	Body mass index;
KIRP	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	6.18	0.37	2.69e-9	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.64	8.5	0.48	1.87e-15	Lung cancer;
KIRP	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg07395648	chr5:131743802	NA	-0.36	-4.94	-0.3	1.41e-6	Blood metabolite levels;
KIRP	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.03e-7	Type 2 diabetes;
KIRP	cis	rs4728302	0.869	rs10255193	chr7:133608911	C/G	cg10665199	chr7:133106180	EXOC4	0.46	5.61	0.34	5.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs10510653	0.522	rs62244401	chr3:32033509	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	6.68	0.39	1.57e-10	Schizophrenia;
KIRP	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.79	10.78	0.57	1.92e-22	Aortic root size;
KIRP	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.58	0.59	4.89e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.39	-5.03	-0.31	9.62e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.45	4.86	0.3	2.1e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg03571507	chr19:53239146	ZNF611	0.24	6.07	0.36	4.82e-9	Response to paliperidone in schizophrenia (PANSS score);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18802601	chr5:34698640	RAI14	0.43	6.15	0.37	3.06e-9	Survival in pancreatic cancer;
KIRP	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.24	-0.37	1.88e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.73	-0.34	2.99e-8	Bipolar disorder;
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg17294928	chr15:75287854	SCAMP5	0.61	8.11	0.46	2.43e-14	Breast cancer;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07308232	chr7:1071921	C7orf50	-0.65	-8.44	-0.47	2.67e-15	Longevity;Endometriosis;
KIRP	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.92	13.45	0.65	2.82e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7523050	0.908	rs72697202	chr1:109398704	A/G	cg08274380	chr1:109419600	GPSM2	0.7	6.49	0.38	4.65e-10	Fat distribution (HIV);
KIRP	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.81	10.74	0.56	2.61e-22	Breast cancer;
KIRP	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg18350739	chr11:68623251	NA	-0.46	-7.24	-0.42	5.63e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.91	14.25	0.67	5.41e-34	Systemic lupus erythematosus;
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg14338887	chr6:42928500	GNMT	-0.46	-6.82	-0.4	7.12e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg17524265	chr8:144659883	NAPRT1	0.83	5.36	0.32	1.88e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.51	-0.38	4.09e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs35123781	0.580	rs355163	chr5:138958078	T/C	cg12205435	chr5:138714322	SLC23A1	-0.39	-5.18	-0.31	4.55e-7	Schizophrenia;
KIRP	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg24044776	chr19:53454761	ZNF816A	-0.36	-4.91	-0.3	1.65e-6	Psoriasis;
KIRP	cis	rs687432	0.924	rs11608016	chr11:57774485	C/T	cg19752551	chr11:57585705	CTNND1	-0.68	-8.88	-0.49	1.44e-16	Parkinson's disease;
KIRP	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs7849270	1.000	rs7849160	chr9:131874552	A/T	cg13538475	chr9:131942899	NA	-0.31	-5.01	-0.3	1.02e-6	Blood metabolite ratios;
KIRP	cis	rs1359582	0.801	rs7068639	chr10:90369699	T/C	cg15661332	chr10:90342814	RNLS	0.57	6.0	0.36	6.85e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.75	-10.33	-0.55	5.23e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg27572855	chr1:25598939	RHD	0.49	8.16	0.46	1.74e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs12220238	0.915	rs10824148	chr10:76078014	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.65	0.39	1.92e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.61	9.19	0.51	1.66e-17	Schizophrenia;
KIRP	trans	rs11718502	0.687	rs11714082	chr3:42524866	G/A	cg01557549	chr3:53168665	NA	-0.49	-6.06	-0.36	5.1e-9	Magnesium levels;
KIRP	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	5.89	0.35	1.26e-8	Longevity;
KIRP	cis	rs1620921	0.902	rs1406890	chr6:161187335	C/T	cg01280913	chr6:161186852	NA	-0.39	-5.12	-0.31	6.08e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.47	6.05	0.36	5.39e-9	Birth weight;
KIRP	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.45	-9.25	-0.51	1.14e-17	Rheumatoid arthritis;
KIRP	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.49	-0.33	9.81e-8	Pulmonary function;
KIRP	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.46	5.87	0.35	1.41e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.56	6.5	0.38	4.5e-10	Pulse pressure;
KIRP	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg22117172	chr7:91764530	CYP51A1	0.39	5.37	0.32	1.83e-7	Breast cancer;
KIRP	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.84	-13.07	-0.64	5.55e-30	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg26816564	chr1:7831052	VAMP3	0.6	5.27	0.32	3.05e-7	Inflammatory bowel disease;
KIRP	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.71	-9.24	-0.51	1.21e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.56	-5.58	-0.34	6.24e-8	Type 2 diabetes;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg19300475	chr17:27230118	DHRS13	-1.12	-6.22	-0.37	2.16e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs3767633	0.764	rs4233381	chr1:161910720	T/C	cg09175582	chr1:161736000	ATF6	0.79	5.04	0.31	9.04e-7	IgG glycosylation;
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.87	15.38	0.7	7.16e-38	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg21573476	chr21:45109991	RRP1B	-0.63	-8.53	-0.48	1.47e-15	Mean corpuscular volume;
KIRP	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg17385448	chr1:15911702	AGMAT	0.25	4.92	0.3	1.57e-6	Systolic blood pressure;
KIRP	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.24	0.37	1.87e-9	Height;
KIRP	cis	rs6001982	0.665	rs17001920	chr22:40849495	T/C	cg07138101	chr22:40742427	ADSL	0.73	5.16	0.31	5.09e-7	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14062745	chr2:65357211	RAB1A	0.5	6.72	0.39	1.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs698833	0.561	rs698808	chr2:44701901	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.69	0.34	3.61e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs2219968	1.000	rs7003597	chr8:78976117	A/G	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7551222	0.716	rs7541589	chr1:204542521	G/A	cg20240347	chr1:204465584	NA	-0.44	-8.36	-0.47	4.75e-15	Schizophrenia;
KIRP	cis	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-5.25	-0.32	3.34e-7	HDL cholesterol;
KIRP	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg23950597	chr19:37808831	NA	0.45	4.98	0.3	1.18e-6	Coronary artery calcification;
KIRP	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg26138937	chr11:71823887	C11orf51	-1.01	-6.94	-0.4	3.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.9	14.25	0.67	5.27e-34	Mean corpuscular volume;
KIRP	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg16988262	chr1:15930761	NA	0.39	5.16	0.31	5.16e-7	Systolic blood pressure;
KIRP	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.95	0.35	9.08e-9	Motion sickness;
KIRP	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.15e-51	Height;
KIRP	cis	rs4523957	0.614	rs7220685	chr17:2059385	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7975161	0.671	rs4475991	chr12:104596756	A/G	cg25273343	chr12:104657179	TXNRD1	0.47	5.43	0.33	1.33e-7	Toenail selenium levels;
KIRP	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-5.92	-0.35	1.06e-8	Personality dimensions;
KIRP	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg00977110	chr5:151150581	G3BP1	0.55	5.67	0.34	4.06e-8	Preschool internalizing problems;
KIRP	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg25287198	chr4:183728479	NA	0.56	4.95	0.3	1.39e-6	Pediatric autoimmune diseases;
KIRP	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-9.86	-0.53	1.52e-19	Coronary artery disease;
KIRP	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.31	-0.32	2.5e-7	Asthma;
KIRP	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-8.77	-0.49	2.94e-16	Body mass index;
KIRP	cis	rs9900972	1.000	rs9900972	chr17:76868614	A/G	cg00961940	chr17:76876995	TIMP2	0.52	6.53	0.38	3.66e-10	Obesity-related traits;
KIRP	cis	rs7937612	1.000	rs7107211	chr11:120262922	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.2	-0.42	7.15e-12	Intraocular pressure;
KIRP	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.83	-0.45	1.46e-13	Arsenic metabolism;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg20656637	chr5:52776630	FST	0.53	6.35	0.38	1.05e-9	DNA methylation (variation);
KIRP	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg10818794	chr15:86012489	AKAP13	-0.48	-6.76	-0.4	1.01e-10	Interstitial lung disease;
KIRP	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2296225	0.722	rs900038	chr1:21057552	C/A	cg14666476	chr1:21112556	HP1BP3	0.68	6.31	0.37	1.28e-9	Eosinophilic esophagitis;
KIRP	cis	rs2904967	0.929	rs626802	chr11:65021612	C/A	cg09225861	chr11:65069680	NA	-0.4	-5.22	-0.32	3.74e-7	Mean corpuscular volume;
KIRP	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	9.61	0.52	9.09e-19	HIV-1 control;
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.55	7.23	0.42	6.15e-12	Aortic root size;
KIRP	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-0.67	-5.53	-0.33	8.22e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.62	-0.56	6.31e-22	Gut microbiome composition (summer);
KIRP	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg23815491	chr16:72088622	HP	0.49	7.22	0.42	6.4e-12	Blood protein levels;
KIRP	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.15	-0.31	5.32e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs876084	0.505	rs7840588	chr8:121108256	G/T	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs13102973	0.682	rs6535054	chr4:135886055	A/C	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg08461772	chr7:95026248	PON3	0.4	5.72	0.34	3.01e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs9393813	0.868	rs4711154	chr6:27446359	A/T	cg18711553	chr6:27366782	ZNF391	-0.38	-5.51	-0.33	9.11e-8	Bipolar disorder;
KIRP	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg11833968	chr6:79620685	NA	-0.37	-5.22	-0.32	3.81e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.73	6.48	0.38	4.92e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4886920	0.862	rs4486846	chr15:78138936	C/T	cg10461261	chr15:78109450	NA	-0.32	-5.18	-0.31	4.59e-7	Neuroticism;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22788606	chr1:167424194	CD247	-0.41	-6.56	-0.39	3.15e-10	Metabolic traits;
KIRP	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.95	12.25	0.62	3.01e-27	Homoarginine levels;
KIRP	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg20701182	chr2:24300061	SF3B14	0.45	5.3	0.32	2.62e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg26207909	chr14:103986467	CKB	-0.46	-5.08	-0.31	7.57e-7	Monocyte count;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18845289	chr12:121124611	MLEC	0.72	6.18	0.37	2.61e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.83	9.89	0.53	1.25e-19	Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-13.79	-0.66	1.93e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs282587	0.597	rs408247	chr13:113405738	C/A	cg04656015	chr13:113407548	ATP11A	0.6	6.54	0.38	3.5e-10	Glycated hemoglobin levels;
KIRP	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg03563238	chr19:33554763	RHPN2	-0.31	-5.39	-0.33	1.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.91	14.4	0.68	1.62e-34	Dental caries;
KIRP	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.43	5.44	0.33	1.27e-7	Crohn's disease;
KIRP	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	0.57	7.68	0.44	3.7e-13	Prostate cancer;
KIRP	cis	rs10518128	1.000	rs7658200	chr4:75712363	G/A	cg20122727	chr4:75719957	BTC	0.49	4.95	0.3	1.36e-6	Electroencephalogram traits;
KIRP	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.74	6.66	0.39	1.78e-10	Diabetic retinopathy;
KIRP	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs501916	0.833	rs10519143	chr15:48055567	T/G	cg16110827	chr15:48056943	SEMA6D	-0.36	-4.95	-0.3	1.36e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.42e-12	Obesity-related traits;
KIRP	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg14689365	chr7:158441557	NCAPG2	-0.41	-5.03	-0.31	9.32e-7	Height;
KIRP	cis	rs62151617	1.000	rs35936451	chr2:70791165	T/C	cg24334149	chr2:71175539	ATP6V1B1	0.51	5.1	0.31	6.65e-7	Hair shape;
KIRP	cis	rs9596863	0.898	rs35646102	chr13:54364897	G/T	ch.13.53330881F	chr13:54432880	NA	0.59	5.77	0.35	2.37e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs11767191	0.846	rs6978160	chr7:48757295	G/A	ch.7.1147807F	chr7:49473528	NA	0.39	4.96	0.3	1.29e-6	Response to amphetamines;
KIRP	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Corneal astigmatism;
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.66	-5.82	-0.35	1.78e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg00405596	chr8:11794950	NA	0.44	5.48	0.33	1.05e-7	Retinal vascular caliber;
KIRP	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg13010199	chr12:38710504	ALG10B	-0.38	-4.9	-0.3	1.76e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.4	4.97	0.3	1.28e-6	Aortic root size;
KIRP	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg02023728	chr11:77925099	USP35	0.3	4.97	0.3	1.23e-6	Alzheimer's disease (survival time);
KIRP	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-5.05	-0.31	8.56e-7	Initial pursuit acceleration;
KIRP	cis	rs13132184	0.507	rs34119528	chr4:38023302	C/G	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.19	-0.31	4.49e-7	Verbal declarative memory;
KIRP	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg18190219	chr22:46762943	CELSR1	0.69	8.15	0.46	1.81e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs77372450	0.636	rs6876128	chr5:156994437	A/G	cg23851860	chr5:157002805	ADAM19	0.44	4.85	0.3	2.18e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.83	-0.35	1.75e-8	Breast cancer;
KIRP	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs6429082	0.509	rs2246554	chr1:235520176	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	4.88	0.3	1.93e-6	Adiposity;
KIRP	cis	rs13006833	0.739	rs291429	chr2:191197941	G/A	cg21644426	chr2:191273491	MFSD6	0.46	5.68	0.34	3.75e-8	Urinary metabolites;
KIRP	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg02297831	chr4:17616191	MED28	0.62	7.88	0.45	1.06e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs60311166	1.000	rs58100002	chr3:52589840	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.9	5.55	0.33	7.28e-8	CTACK levels;
KIRP	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-5.68	-0.34	3.73e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.51	0.33	8.88e-8	Melanoma;
KIRP	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-6.73	-0.39	1.21e-10	Colorectal cancer;
KIRP	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.06	0.54	3.54e-20	Total body bone mineral density;
KIRP	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.42	-5.55	-0.33	7.42e-8	Menarche (age at onset);
KIRP	trans	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19894588	chr14:64061835	NA	-0.62	-7.04	-0.41	1.89e-11	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.11	-0.46	2.42e-14	Retinal vascular caliber;
KIRP	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.83	0.4	6.47e-11	Tonsillectomy;
KIRP	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.44	0.72	1.83e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.04	-0.36	5.54e-9	Lung cancer;
KIRP	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs3105593	0.966	rs2063010	chr15:50941131	A/G	cg05456662	chr15:50716270	USP8	0.41	4.9	0.3	1.75e-6	QT interval;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.76	0.44	2.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.98	-0.36	7.72e-9	Breast cancer;
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg07747251	chr5:1868357	NA	0.42	5.53	0.33	8.19e-8	Cardiovascular disease risk factors;
KIRP	cis	rs2649	0.518	rs6494412	chr15:63856544	C/A	cg22599514	chr15:63798201	USP3	0.46	5.76	0.34	2.51e-8	Aortic root size;
KIRP	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg16989719	chr2:238392110	NA	-0.56	-5.99	-0.36	7.27e-9	Prostate cancer;
KIRP	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	trans	rs79976124	0.797	rs2226266	chr6:66617302	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.47	0.48	2.2e-15	Type 2 diabetes;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg06871246	chr4:1363661	KIAA1530	-0.51	-6.32	-0.37	1.24e-9	Longevity;
KIRP	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg00631329	chr6:26305371	NA	-0.65	-8.68	-0.48	5.72e-16	Educational attainment;
KIRP	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.39	-4.99	-0.3	1.17e-6	Educational attainment (years of education);
KIRP	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.89	13.92	0.66	6.85e-33	Menarche (age at onset);
KIRP	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.79	9.45	0.52	2.81e-18	Corneal astigmatism;
KIRP	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.59	-9.32	-0.51	6.84e-18	C-reactive protein levels;
KIRP	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.61	6.92	0.4	3.96e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg13147721	chr7:65941812	NA	1.03	7.08	0.41	1.49e-11	Diabetic kidney disease;
KIRP	cis	rs59197085	0.636	rs4731517	chr7:128458649	A/C	cg17511168	chr7:128516960	KCP	-0.45	-5.05	-0.31	8.74e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.5	6.57	0.39	3.02e-10	Height;
KIRP	cis	rs9653442	0.564	rs2309753	chr2:100775920	C/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9549367	0.529	rs55946737	chr13:113810014	A/G	cg18105134	chr13:113819100	PROZ	-1.07	-12.14	-0.61	6.72e-27	Platelet distribution width;
KIRP	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08392591	chr16:89556376	ANKRD11	0.51	7.11	0.41	1.28e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.51	-0.33	9.2e-8	Ileal carcinoids;
KIRP	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg21775007	chr8:11205619	TDH	0.44	6.12	0.36	3.62e-9	Neuroticism;
KIRP	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.3	-0.47	6.74e-15	Bipolar disorder;
KIRP	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg16898833	chr6:26189333	HIST1H4D	0.67	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.89	13.43	0.65	3.16e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg23307798	chr14:103986281	CKB	0.76	13.01	0.64	8.7e-30	Body mass index;
KIRP	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs12936587	0.633	rs35851484	chr17:17507905	A/G	cg01246520	chr17:17644344	RAI1	-0.38	-5.75	-0.34	2.65e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs7923609	0.846	rs10761731	chr10:65027610	A/T	cg01631684	chr10:65280961	REEP3	-0.47	-5.4	-0.33	1.56e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg12756093	chr1:115239321	AMPD1	0.56	7.78	0.44	2e-13	Autism;
KIRP	cis	rs9815354	0.812	rs4577439	chr3:41952540	T/A	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg05973401	chr12:123451056	ABCB9	0.59	5.39	0.32	1.65e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6142102	1.000	rs2143230	chr20:32724345	C/T	cg08999081	chr20:33150536	PIGU	0.55	6.93	0.4	3.6e-11	Skin pigmentation;
KIRP	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg08738300	chr3:44038990	NA	0.68	9.56	0.52	1.28e-18	Coronary artery disease;
KIRP	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.19	-0.42	7.59e-12	Neuroticism;
KIRP	cis	rs698833	0.509	rs12987415	chr2:44530423	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	4.93	0.3	1.55e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.53	-6.62	-0.39	2.28e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.76	-0.44	2.27e-13	Alcohol dependence;
KIRP	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.57	7.71	0.44	3.12e-13	Obesity-related traits;
KIRP	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.79	8.19	0.46	1.46e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.69	9.99	0.54	6.16e-20	Lymphocyte counts;
KIRP	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg20991723	chr1:152506922	NA	0.46	5.59	0.34	6.07e-8	Hair morphology;
KIRP	cis	rs1134634	0.520	rs73125606	chr4:15547314	C/A	cg16509355	chr4:15471240	CC2D2A	-0.3	-5.16	-0.31	5.04e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs6749447	0.959	rs6734481	chr2:169041474	C/G	cg10223061	chr2:219282414	VIL1	-0.38	-6.02	-0.36	6.38e-9	Blood pressure;
KIRP	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.49	6.26	0.37	1.73e-9	Prudent dietary pattern;
KIRP	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.98	11.35	0.59	2.67e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.55	0.33	7.37e-8	Educational attainment;
KIRP	cis	rs2411233	1.000	rs11856921	chr15:39278107	A/C	cg19287857	chr15:39890699	NA	-0.37	-5.11	-0.31	6.57e-7	Platelet count;
KIRP	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg26681399	chr22:41777847	TEF	-0.52	-5.08	-0.31	7.48e-7	Vitiligo;
KIRP	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg02297831	chr4:17616191	MED28	-0.49	-6.04	-0.36	5.75e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.68	9.52	0.52	1.74e-18	Blood protein levels;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.49	-6.32	-0.37	1.21e-9	Longevity;Endometriosis;
KIRP	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg07856975	chr6:36356162	ETV7	0.36	5.09	0.31	6.97e-7	Platelet distribution width;
KIRP	cis	rs2410601	0.902	rs7828087	chr8:18911830	A/G	cg19414122	chr8:18896631	NA	0.41	5.09	0.31	7.11e-7	Urinary albumin excretion rate in type 1 diabetes;
KIRP	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.67	-7.27	-0.42	4.74e-12	Gut microbiome composition (summer);
KIRP	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.59	6.25	0.37	1.77e-9	Crohn's disease;
KIRP	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.98	13.0	0.64	9.55e-30	Vitamin D levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13894163	chr9:136932022	BRD3	0.46	6.49	0.38	4.72e-10	Survival in pancreatic cancer;
KIRP	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215748	chr17:6898738	ALOX12	0.38	4.98	0.3	1.2e-6	Tonsillectomy;
KIRP	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.58	-9.39	-0.51	4.12e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	1.02	18.28	0.76	9.53e-48	Heart rate;
KIRP	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.53	0.33	8.3e-8	Lung cancer;
KIRP	cis	rs7582720	0.945	rs72932716	chr2:203642244	T/G	cg08076091	chr2:203926405	NBEAL1	0.83	8.27	0.47	8.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs7523050	0.730	rs34254854	chr1:109419875	C/T	cg08274380	chr1:109419600	GPSM2	1.18	10.28	0.55	7.54e-21	Fat distribution (HIV);
KIRP	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.36	0.38	9.9e-10	Rheumatoid arthritis;
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.27	-0.37	1.65e-9	Lung function (FEV1/FVC);
KIRP	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.07e-11	Bipolar disorder;
KIRP	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg05064044	chr6:292385	DUSP22	-0.56	-6.67	-0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06475006	chr16:89985975	MC1R	-0.69	-4.97	-0.3	1.27e-6	Skin colour saturation;
KIRP	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs7011507	1.000	rs74439937	chr8:49176097	C/T	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg23788917	chr6:8435910	SLC35B3	-0.47	-5.86	-0.35	1.5e-8	Motion sickness;
KIRP	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.98	10.91	0.57	7.13e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.69	7.83	0.45	1.48e-13	Monocyte count;
KIRP	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.96	11.29	0.58	4.45e-24	Corneal astigmatism;
KIRP	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg06064525	chr11:970664	AP2A2	0.28	5.32	0.32	2.29e-7	Alzheimer's disease (late onset);
KIRP	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg20935368	chr5:178288625	ZNF354B	0.42	5.7	0.34	3.49e-8	Sleep duration;
KIRP	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg17764715	chr19:33622953	WDR88	0.68	8.33	0.47	5.65e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.69	8.33	0.47	5.52e-15	Aortic root size;
KIRP	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg18833306	chr6:118973337	C6orf204	0.39	5.0	0.3	1.07e-6	Electrocardiographic conduction measures;
KIRP	cis	rs829883	0.659	rs4762495	chr12:98934105	C/T	cg25150519	chr12:98850993	NA	-0.75	-9.01	-0.5	5.85e-17	Colorectal adenoma (advanced);
KIRP	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg06647332	chr5:131281008	NA	0.43	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.31	-0.32	2.46e-7	Parkinson's disease;
KIRP	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg09571762	chr12:39539558	NA	0.33	4.97	0.3	1.23e-6	Morning vs. evening chronotype;
KIRP	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg22875332	chr1:76189707	ACADM	0.44	6.08	0.36	4.56e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-8.97	-0.5	7.82e-17	Response to antipsychotic treatment;
KIRP	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.56	6.47	0.38	5.16e-10	Osteoporosis;
KIRP	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg20701182	chr2:24300061	SF3B14	1.01	10.82	0.57	1.45e-22	Lymphocyte counts;
KIRP	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg10096100	chr1:26503862	CNKSR1	0.42	5.93	0.35	1.01e-8	Height;
KIRP	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg18595228	chr15:67193261	NA	0.63	5.05	0.31	8.5e-7	Lung cancer (smoking interaction);
KIRP	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.31	-5.11	-0.31	6.39e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	6.29	0.37	1.42e-9	Platelet count;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13546937	chr9:127632120	ARPC5L	-0.56	-6.23	-0.37	2e-9	Menopause (age at onset);
KIRP	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg08603382	chr10:743973	NA	-0.65	-10.12	-0.54	2.38e-20	Psychosis in Alzheimer's disease;
KIRP	cis	rs4356932	0.967	rs10016135	chr4:76974579	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg12573791	chr2:3828286	NA	-0.41	-5.75	-0.34	2.68e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-8.54	-0.48	1.39e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg23625390	chr15:77176239	SCAPER	0.55	7.3	0.42	3.86e-12	Blood metabolite levels;
KIRP	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg14675211	chr2:100938903	LONRF2	0.55	7.45	0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg00999904	chr2:3704751	ALLC	0.52	6.17	0.37	2.79e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs960902	0.935	rs2373109	chr2:37717796	A/T	cg25341268	chr2:37734390	NA	-0.46	-6.29	-0.37	1.42e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg09344028	chr17:70110421	NA	0.44	10.38	0.55	3.51e-21	Thyroid hormone levels;
KIRP	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.46	5.57	0.33	6.72e-8	Tuberculosis;
KIRP	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.78	-11.48	-0.59	1.03e-24	Height;
KIRP	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.69	5.82	0.35	1.8e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.81	-11.86	-0.6	5.92e-26	Systemic lupus erythematosus;
KIRP	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.98	-0.5	7.31e-17	Platelet count;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.73	-0.34	2.86e-8	Lung cancer;
KIRP	cis	rs35883536	0.587	rs2809812	chr1:101032087	G/T	cg06223162	chr1:101003688	GPR88	0.44	9.21	0.51	1.52e-17	Monocyte count;
KIRP	cis	rs4953911	0.893	rs7574239	chr2:135060964	G/A	cg18482303	chr2:135041380	MGAT5	-0.29	-5.37	-0.32	1.83e-7	Multiple sclerosis (severity);
KIRP	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.39	0.32	1.65e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg05802129	chr4:122689817	NA	-0.47	-6.93	-0.4	3.72e-11	Type 2 diabetes;
KIRP	cis	rs7539542	0.529	rs3806346	chr1:202859600	C/T	cg19681188	chr1:202830198	LOC148709	0.47	5.1	0.31	6.68e-7	Mean platelet volume;
KIRP	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05220968	chr6:146057943	EPM2A	-0.41	-5.32	-0.32	2.35e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.45	-6.07	-0.36	4.69e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.79	0.57	1.75e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs13401104	0.796	rs11680754	chr2:237112384	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.18	15.97	0.71	7.39e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7809615	0.748	rs12533251	chr7:99115677	G/A	cg12290671	chr7:99195819	NA	-0.46	-4.99	-0.3	1.17e-6	Blood metabolite ratios;
KIRP	cis	rs6662572	0.737	rs4660330	chr1:46458298	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.35e-8	Blood protein levels;
KIRP	cis	rs897080	0.552	rs1067369	chr2:44652654	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.87	0.35	1.41e-8	Height;
KIRP	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.88	-0.57	8.82e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22022881	chr2:105853494	NA	-0.37	-5.46	-0.33	1.15e-7	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg12692727	chr7:1102344	C7orf50	0.47	5.03	0.31	9.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7630877	0.886	rs1599791	chr3:179595251	A/G	cg18765712	chr3:179670323	PEX5L	0.57	6.72	0.39	1.25e-10	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27294816	chr19:54372713	MYADM	0.46	6.61	0.39	2.33e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23181861	chr19:17970707	RPL18AP3;RPL18A	0.45	6.1	0.36	4.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14065008	chr6:128374435	PTPRK	-0.43	-6.24	-0.37	1.9e-9	Inflammatory biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26366347	chr17:73008860	ICT1	0.5	6.24	0.37	1.91e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01698108	chr3:182880470	LAMP3	0.47	6.19	0.37	2.46e-9	Parkinson's disease;
KIRP	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00585698	chr12:123750864	CDK2AP1	0.5	5.02	0.3	1.01e-6	Neutrophil percentage of white cells;
KIRP	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	5.39	0.32	1.67e-7	Renal cell carcinoma;
KIRP	cis	rs13082711	0.911	rs6775176	chr3:27432475	G/A	cg02860705	chr3:27208620	NA	0.58	8.18	0.46	1.52e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg16434002	chr17:42200994	HDAC5	-0.49	-5.8	-0.35	2.07e-8	Total body bone mineral density;
KIRP	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-1.0	-15.61	-0.71	1.19e-38	Coronary artery disease;
KIRP	cis	rs6693295	0.838	rs2788009	chr1:246238598	A/G	cg11798871	chr1:246315928	SMYD3	-0.4	-5.0	-0.3	1.07e-6	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg05315796	chr3:52349193	DNAH1	0.42	6.76	0.4	1.01e-10	Electroencephalogram traits;
KIRP	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.57	-0.33	6.78e-8	Breast cancer;
KIRP	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.79	-0.35	2.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4356975	0.563	rs7439326	chr4:69964180	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	5.79	0.35	2.17e-8	Iron status biomarkers;
KIRP	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03655016	chr12:49453990	NA	-0.46	-6.32	-0.37	1.24e-9	Metabolic traits;
KIRP	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.79	11.56	0.59	5.69e-25	Heart rate;
KIRP	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.58e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg06585982	chr3:143692056	C3orf58	0.61	7.63	0.44	5.03e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.59	-6.39	-0.38	8.05e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1697139	0.501	rs16896422	chr5:66519431	G/A	cg11553311	chr5:66541588	NA	0.39	5.54	0.33	7.75e-8	Breast cancer;
KIRP	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg20936604	chr3:58311152	NA	-0.7	-5.82	-0.35	1.81e-8	Cholesterol, total;
KIRP	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.96	0.5	8.2e-17	Bipolar disorder;
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.76	12.32	0.62	1.73e-27	Vitiligo;
KIRP	cis	rs4494114	1.000	rs12037982	chr1:39358600	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-5.15	-0.31	5.37e-7	Blood protein levels;
KIRP	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18252515	chr7:66147081	NA	0.44	5.11	0.31	6.59e-7	Aortic root size;
KIRP	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.42	-5.19	-0.31	4.4e-7	Neurofibrillary tangles;
KIRP	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.77	-11.83	-0.6	7.21e-26	Neurofibrillary tangles;
KIRP	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs12912251	0.591	rs4924291	chr15:39000484	A/C	cg10631289	chr15:39006617	NA	0.79	8.75	0.49	3.56e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.42	8.99	0.5	6.96e-17	Vitiligo;
KIRP	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.84	12.86	0.63	2.82e-29	Colorectal cancer;
KIRP	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg00334542	chr7:100209784	MOSPD3	-0.55	-5.34	-0.32	2.16e-7	Other erythrocyte phenotypes;
KIRP	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17886038	chr15:100273718	LYSMD4	0.49	6.22	0.37	2.13e-9	Parkinson's disease;
KIRP	cis	rs981844	0.712	rs1037646	chr4:154738015	C/T	cg14289246	chr4:154710475	SFRP2	-0.54	-7.06	-0.41	1.74e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs17221829	0.764	rs7930024	chr11:89386038	G/C	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.35	-0.32	2.03e-7	Anxiety in major depressive disorder;
KIRP	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.5	0.38	4.37e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09376854	chr10:103535775	FGF8	0.5	7.04	0.41	1.87e-11	Parkinson's disease;
KIRP	cis	rs2274273	0.773	rs8012380	chr14:55735010	T/G	cg04306507	chr14:55594613	LGALS3	0.53	8.17	0.46	1.62e-14	Protein biomarker;
KIRP	trans	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.53	-0.38	3.84e-10	Triglycerides;
KIRP	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.46	7.14	0.41	1.07e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.31	-4.86	-0.3	2.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6001982	0.510	rs73167042	chr22:40840610	G/A	cg07138101	chr22:40742427	ADSL	0.71	4.94	0.3	1.47e-6	Breast cancer;
KIRP	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.86	-0.3	2.05e-6	Schizophrenia;
KIRP	cis	rs712039	0.652	rs866465	chr17:35859404	G/A	cg16670864	chr17:35848621	DUSP14	0.44	5.24	0.32	3.47e-7	Tuberculosis;
KIRP	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.81	0.45	1.66e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg09910967	chr6:139456200	HECA	0.56	6.59	0.39	2.72e-10	Plasma plasminogen activator levels;
KIRP	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.82	11.54	0.59	6.63e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.15	14.46	0.68	1.06e-34	Mitochondrial DNA levels;
KIRP	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg15848620	chr12:58087721	OS9	-0.47	-5.99	-0.36	7.56e-9	Rheumatoid arthritis;
KIRP	cis	rs7666738	0.546	rs11727151	chr4:98837353	A/C	cg05340658	chr4:99064831	C4orf37	0.67	7.79	0.44	1.83e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.62	-0.34	5.2100000000000003e-08	Aortic root size;
KIRP	cis	rs7584330	0.554	rs3751106	chr2:238428418	G/A	cg14458575	chr2:238380390	NA	0.52	6.04	0.36	5.56e-9	Prostate cancer;
KIRP	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.44	5.98	0.36	7.87e-9	Red blood cell count;
KIRP	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	10.34	0.55	4.92e-21	Post bronchodilator FEV1;
KIRP	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.61	6.95	0.4	3.31e-11	Schizophrenia;
KIRP	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg11344533	chr11:111475393	SIK2	-0.3	-5.08	-0.31	7.29e-7	Primary sclerosing cholangitis;
KIRP	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.96	-0.41	3.13e-11	Mood instability;
KIRP	cis	rs12230513	0.732	rs61956327	chr12:55828708	C/T	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs6594713	0.508	rs1838205	chr5:112644100	A/G	cg08939847	chr5:112655559	MCC	0.35	5.28	0.32	2.79e-7	Brain cytoarchitecture;
KIRP	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg22138327	chr13:27999177	GTF3A	0.75	6.77	0.4	9.66e-11	Weight;
KIRP	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	1.09	20.07	0.79	1.01e-53	Gut microbiome composition (winter);
KIRP	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.62	9.09	0.5	3.32e-17	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.57	-0.56	8.85e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.84	13.94	0.66	6.14e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs78545713	0.892	rs11751286	chr6:26241361	C/G	cg01420254	chr6:26195488	NA	0.67	5.28	0.32	2.87e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs5753618	0.583	rs5749279	chr22:31854209	A/G	cg02404636	chr22:31891804	SFI1	0.55	6.98	0.41	2.73e-11	Colorectal cancer;
KIRP	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.89	-15.36	-0.7	8.62e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	5e-23	Prudent dietary pattern;
KIRP	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.17	0.46	1.59e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.64	-10.3	-0.55	6.37e-21	Pulse pressure;
KIRP	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	5.95	0.35	9.28e-9	Menarche (age at onset);
KIRP	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-5.05	-0.31	8.55e-7	Height;
KIRP	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.08	-0.31	7.47e-7	Schizophrenia;
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.53	0.33	8.19e-8	Life satisfaction;
KIRP	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07080220	chr10:102295463	HIF1AN	0.9	9.77	0.53	2.84e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs60871478	0.898	rs67785403	chr7:787201	A/G	cg04727924	chr7:799746	HEATR2	-0.73	-7.38	-0.43	2.4e-12	Cerebrospinal P-tau181p levels;
KIRP	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg17788362	chr6:86352627	SYNCRIP	0.48	6.32	0.37	1.24e-9	Smooth-surface caries;
KIRP	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.46	6.38	0.38	8.85e-10	Testicular germ cell tumor;
KIRP	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.65	-6.83	-0.4	6.77e-11	Schizophrenia;
KIRP	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.84	-11.95	-0.61	2.93e-26	Educational attainment;
KIRP	cis	rs72960926	0.744	rs6941436	chr6:74937191	C/T	cg03266952	chr6:74778945	NA	0.79	5.7	0.34	3.4e-8	Metabolite levels (MHPG);
KIRP	cis	rs9556958	0.708	rs9513435	chr13:99160334	C/G	cg20750642	chr13:99100586	FARP1	0.51	7.25	0.42	5.37e-12	Educational attainment (years of education);
KIRP	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg18306943	chr3:40428807	ENTPD3	-0.39	-5.41	-0.33	1.46e-7	Renal cell carcinoma;
KIRP	cis	rs7084402	0.935	rs12263522	chr10:60343527	C/A	cg05938607	chr10:60274200	BICC1	-0.46	-11.4	-0.59	1.87e-24	Refractive error;
KIRP	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.69	-0.39	1.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.61	-0.39	2.4e-10	Metabolite levels;
KIRP	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-6.01	-0.36	6.51e-9	Response to antipsychotic treatment;
KIRP	cis	rs10982256	0.774	rs998548	chr9:117275182	C/T	cg13636371	chr9:117264095	DFNB31	0.54	7.74	0.44	2.65e-13	Bipolar disorder;
KIRP	cis	rs9513627	0.920	rs16956607	chr13:100120220	A/G	cg25919922	chr13:100150906	NA	-0.64	-5.6	-0.34	5.85e-8	Obesity-related traits;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25019564	chr18:9475492	RALBP1	0.54	6.83	0.4	6.42e-11	Myopia (pathological);
KIRP	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.57	-0.33	6.77e-8	Fear of minor pain;
KIRP	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.62	-0.34	5.11e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg19847866	chr10:1019161	NA	-0.61	-5.59	-0.34	6.17e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06481639	chr22:41940642	POLR3H	0.77	7.84	0.45	1.33e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg21775007	chr8:11205619	TDH	0.45	5.99	0.36	7.53e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18788872	chr11:32605728	EIF3M	0.52	6.03	0.36	6.08e-9	Smoking initiation;
KIRP	cis	rs4791641	0.743	rs2270445	chr17:8219478	A/G	cg25498489	chr17:8230483	NA	-0.38	-5.97	-0.36	8.19e-9	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
KIRP	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg10223061	chr2:219282414	VIL1	0.32	5.19	0.31	4.41e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4363385	0.509	rs11581802	chr1:152936164	G/A	cg25856811	chr1:152973957	SPRR3	-0.4	-5.54	-0.33	7.89e-8	Inflammatory skin disease;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.76	12.42	0.62	8.01e-28	Vitiligo;
KIRP	cis	rs2916247	0.954	rs28707439	chr8:93070202	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.57	-7.21	-0.42	6.96e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	0.95	10.84	0.57	1.2e-22	Corneal structure;
KIRP	cis	rs3736485	0.934	rs1902592	chr15:51881980	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg00310523	chr12:86230176	RASSF9	-0.42	-6.19	-0.37	2.55e-9	Major depressive disorder;
KIRP	cis	rs1215050	0.755	rs9991112	chr4:98651479	A/C	cg05340658	chr4:99064831	C4orf37	-0.44	-5.11	-0.31	6.37e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg05562828	chr17:3906858	NA	0.45	5.87	0.35	1.37e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.41	4.97	0.3	1.24e-6	Body mass index;
KIRP	cis	rs2708977	1.000	rs1011040	chr2:97212755	A/G	cg01950434	chr2:97203154	ARID5A	-0.54	-6.97	-0.41	2.94e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg10760299	chr15:45669010	GATM	0.35	5.11	0.31	6.55e-7	Homoarginine levels;
KIRP	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg22906224	chr7:99728672	NA	-0.65	-7.91	-0.45	9.01e-14	Coronary artery disease;
KIRP	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg07148914	chr20:33460835	GGT7	-0.54	-7.08	-0.41	1.47e-11	Height;
KIRP	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.24	-0.55	9.73e-21	Menopause (age at onset);
KIRP	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18932078	chr1:2524107	MMEL1	-0.47	-6.63	-0.39	2.09e-10	Ulcerative colitis;
KIRP	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg01529538	chr14:23388837	RBM23	0.39	4.96	0.3	1.33e-6	Cognitive ability (multi-trait analysis);
KIRP	cis	rs9921338	0.961	rs72773832	chr16:11413123	G/A	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11081185	chr11:208423	RIC8A;BET1L	0.99	6.6	0.39	2.49e-10	P wave terminal force;
KIRP	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	9.0	0.5	6.24e-17	Educational attainment;
KIRP	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	8.3	0.47	6.97e-15	Neuroticism;
KIRP	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.59	0.44	6.49e-13	Coffee consumption (cups per day);
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02725872	chr8:58115012	NA	-0.74	-7.4	-0.43	2.14e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.85	-7.74	-0.44	2.56e-13	Rheumatoid arthritis;
KIRP	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	1.03	16.04	0.72	4.04e-40	Cognitive function;
KIRP	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg02503808	chr4:7069936	GRPEL1	1.04	11.76	0.6	1.28e-25	Monocyte percentage of white cells;
KIRP	cis	rs6725041	0.627	rs12052282	chr2:213045240	A/C	cg20637307	chr2:213403960	ERBB4	-0.4	-5.38	-0.32	1.74e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg08662619	chr6:150070041	PCMT1	0.36	5.86	0.35	1.48e-8	Lung cancer;
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.66	6.87	0.4	5.31e-11	Lung function (FEV1/FVC);
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg07747251	chr5:1868357	NA	0.42	5.49	0.33	9.81e-8	Cardiovascular disease risk factors;
KIRP	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.22	0.37	2.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21984481	chr17:79567631	NPLOC4	0.54	9.04	0.5	4.83e-17	Eye color traits;
KIRP	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.62	0.39	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.54	0.38	3.62e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13198984	chr17:80129470	CCDC57	-0.49	-7.52	-0.43	1.02e-12	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.76	6.24	0.37	1.92e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs80208956	1.000	rs3862792	chr11:69462856	A/G	cg09520904	chr11:69462943	CCND1	-0.56	-5.29	-0.32	2.75e-7	Major depressive disorder;
KIRP	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-6.71	-0.39	1.29e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2737618	0.680	rs2737686	chr1:200094347	C/T	cg21825944	chr1:200113062	NR5A2	-0.58	-7.91	-0.45	8.57e-14	Uric acid levels;
KIRP	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.84	12.36	0.62	1.25e-27	Eosinophil percentage of white cells;
KIRP	cis	rs6882076	0.884	rs7717984	chr5:156369171	A/G	cg12943317	chr5:156479607	HAVCR1	0.53	6.06	0.36	5.03e-9	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.73	-8.1	-0.46	2.49e-14	Menarche (age at onset);
KIRP	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg27121462	chr16:89883253	FANCA	0.49	6.24	0.37	1.94e-9	Hemoglobin concentration;
KIRP	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.5	-6.25	-0.37	1.79e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs35740288	0.770	rs17635450	chr15:86199049	C/G	cg10818794	chr15:86012489	AKAP13	0.43	4.94	0.3	1.44e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg19610905	chr11:61596333	FADS2	-0.46	-7.32	-0.42	3.51e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs11671005	0.504	rs2305119	chr19:59067623	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.46	-5.65	-0.34	4.42e-8	Mean platelet volume;
KIRP	cis	rs7084402	0.967	rs11006170	chr10:60276369	T/C	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg13147721	chr7:65941812	NA	-0.99	-6.89	-0.4	4.57e-11	Diabetic kidney disease;
KIRP	cis	rs16958440	1.000	rs76594057	chr18:44637272	A/G	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs4363506	0.668	rs10741274	chr10:129278260	G/A	cg07804728	chr10:129284050	NA	0.4	5.45	0.33	1.22e-7	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs6693567	0.565	rs12739706	chr1:150261653	C/G	cg07843065	chr1:150265600	MRPS21	-0.49	-7.0	-0.41	2.4e-11	Migraine;
KIRP	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg12893428	chr3:195717962	SDHAP1	0.44	5.51	0.33	9.1e-8	Pancreatic cancer;
KIRP	trans	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg20528838	chr20:57427730	GNAS	-0.48	-6.41	-0.38	7.39e-10	Height;
KIRP	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.64	8.27	0.47	8.57e-15	Pulse pressure;
KIRP	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg00806126	chr19:22604979	ZNF98	-0.67	-6.84	-0.4	6.19e-11	Pain;
KIRP	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.44	-0.38	6.28e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.67	-10.12	-0.54	2.45e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs4849845	0.889	rs2289172	chr2:121046116	C/G	cg24070213	chr2:121070622	NA	-0.4	-5.55	-0.33	7.51e-8	Mean platelet volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04358685	chr3:12598421	MKRN2	-0.45	-6.28	-0.37	1.52e-9	Metabolic traits;
KIRP	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg20936604	chr3:58311152	NA	-0.67	-5.03	-0.31	9.56e-7	Cholesterol, total;
KIRP	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-5.5	-0.33	9.38e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg12559939	chr2:27858050	GPN1	0.42	5.28	0.32	2.83e-7	Oral cavity cancer;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg27121462	chr16:89883253	FANCA	0.65	9.41	0.51	3.78e-18	Vitiligo;
KIRP	cis	rs3026101	0.624	rs55970234	chr17:5316765	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.83	0.35	1.72e-8	Body mass index;
KIRP	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg13264159	chr8:625131	ERICH1	0.92	6.13	0.36	3.49e-9	IgG glycosylation;
KIRP	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.82	13.71	0.66	3.69e-32	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.95	-0.4	3.31e-11	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14259001	chr14:70510667	NA	0.45	6.07	0.36	4.82e-9	Interleukin-4 levels;
KIRP	cis	rs10861342	0.892	rs11112366	chr12:105486108	G/A	cg23923672	chr12:105501055	KIAA1033	0.83	6.36	0.38	9.66e-10	IgG glycosylation;
KIRP	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg26965718	chr17:79658957	HGS	-0.6	-5.74	-0.34	2.78e-8	Dental caries;
KIRP	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg22875332	chr1:76189707	ACADM	0.34	4.95	0.3	1.35e-6	Daytime sleep phenotypes;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.25	0.32	3.33e-7	Alzheimer's disease;
KIRP	cis	rs3736485	0.932	rs28795073	chr15:51927562	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.15	-0.31	5.28e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs882300	0.967	rs1519528	chr2:136973781	A/G	cg05194412	chr2:137003533	NA	-0.41	-5.46	-0.33	1.19e-7	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg08126542	chr6:37504118	NA	-0.81	-11.63	-0.6	3.32e-25	Cognitive performance;
KIRP	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.59	6.88	0.4	4.96e-11	Sum neutrophil eosinophil counts;
KIRP	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs10484885	0.757	rs72912535	chr6:90159762	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-6.24	-0.37	1.9e-9	QRS interval (sulfonylurea treatment interaction);
KIRP	trans	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.57	6.52	0.38	3.93e-10	Cystic fibrosis severity;
KIRP	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg03788504	chr6:150331562	NA	-0.31	-5.6	-0.34	5.73e-8	Alopecia areata;
KIRP	cis	rs1468333	1.000	rs34927605	chr5:137580418	T/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	5.2	0.31	4.28e-7	Resting heart rate;
KIRP	cis	rs10782582	0.668	rs1250876	chr1:76193232	A/G	cg10523679	chr1:76189770	ACADM	0.38	5.51	0.33	9.2e-8	Daytime sleep phenotypes;
KIRP	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.69	7.95	0.45	6.69e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.5	5.75	0.34	2.59e-8	Platelet distribution width;
KIRP	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.75	-9.87	-0.53	1.42e-19	Inflammatory bowel disease;
KIRP	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.9	-0.4	4.51e-11	Systolic blood pressure;
KIRP	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.41	-0.43	2.08e-12	Triglycerides;
KIRP	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg24579218	chr15:68104479	NA	-0.55	-8.65	-0.48	6.74e-16	Restless legs syndrome;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19712745	chr6:131275789	EPB41L2	-0.4	-6.2	-0.37	2.34e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg15038512	chr6:170123185	PHF10	0.48	5.39	0.33	1.62e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.22e-8	Retinal vascular caliber;
KIRP	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.72	-8.8	-0.49	2.41e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.78	10.62	0.56	6.3e-22	Longevity;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.53	5.2	0.31	4.25e-7	Alzheimer's disease;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.75	8.53	0.48	1.55e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg09408571	chr1:101003634	GPR88	-0.24	-5.53	-0.33	8.1e-8	Monocyte count;
KIRP	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.44	6.74	0.39	1.11e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg24807547	chr6:37504484	NA	0.5	7.68	0.44	3.66e-13	Cognitive performance;
KIRP	trans	rs12043259	0.730	rs4950962	chr1:204791726	A/G	cg11485465	chr5:54518469	NA	-0.39	-6.54	-0.38	3.5e-10	Addiction;
KIRP	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs1958560	0.897	rs7160780	chr14:66052713	G/T	cg03016385	chr14:66212404	NA	-0.45	-5.57	-0.33	6.56e-8	Menarche (age at onset);
KIRP	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6956675	0.874	rs6968344	chr7:62574533	A/G	cg08930214	chr7:62859557	LOC100287834	0.49	5.58	0.34	6.4e-8	Obesity-related traits;
KIRP	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg00079375	chr15:79125835	NA	0.37	5.33	0.32	2.27e-7	Coronary artery disease;
KIRP	cis	rs2979489	0.531	rs3757914	chr8:30415984	G/A	cg26383811	chr8:30366931	RBPMS	0.36	5.07	0.31	7.7e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg10890403	chr12:132336407	NA	0.39	4.92	0.3	1.56e-6	Migraine;
KIRP	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.14e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.54	6.94	0.4	3.42e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg27417294	chr10:81904244	PLAC9	-0.36	-5.09	-0.31	7.04e-7	Sarcoidosis;
KIRP	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17376030	chr22:41985996	PMM1	-0.81	-8.57	-0.48	1.14e-15	Vitiligo;
KIRP	cis	rs4774830	0.744	rs2036739	chr15:56289745	G/T	cg24530489	chr15:56299380	NA	-0.88	-5.28	-0.32	2.9e-7	Delta-5 desaturase activity;
KIRP	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs11126435	0.858	rs2041835	chr2:74927197	C/T	cg08355260	chr2:74729429	LOC151534;LBX2	-0.38	-5.08	-0.31	7.32e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs832187	0.593	rs3774713	chr3:63917692	G/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.43	-4.9	-0.3	1.76e-6	Schizophrenia;
KIRP	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.91	-0.49	1.13e-16	Retinal vascular caliber;
KIRP	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.95	13.23	0.64	1.5e-30	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	6.37	0.38	9.28e-10	Cognitive test performance;
KIRP	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg13611997	chr5:233750	SDHA	-0.44	-5.26	-0.32	3.15e-7	Breast cancer;
KIRP	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg16434002	chr17:42200994	HDAC5	-0.52	-6.47	-0.38	5.12e-10	Total body bone mineral density;
KIRP	cis	rs6681460	0.966	rs1325261	chr1:67110516	G/A	cg13052034	chr1:66999238	SGIP1	0.41	5.51	0.33	9.09e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21708767	chr2:25565514	DNMT3A	-0.42	-6.05	-0.36	5.24e-9	Metabolic traits;
KIRP	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.63	7.6	0.44	6.15e-13	Iron status biomarkers;
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg13453750	chr1:205783389	SLC41A1	0.37	5.5	0.33	9.43e-8	Monocyte percentage of white cells;
KIRP	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.44	-5.04	-0.31	9.19e-7	Resistin levels;
KIRP	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	1.04	9.88	0.53	1.29e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg05669848	chr5:237993	SDHA	-0.48	-5.03	-0.31	9.33e-7	Breast cancer;
KIRP	cis	rs1440410	0.571	rs7673171	chr4:144031098	T/C	cg01719995	chr4:144104893	USP38	0.45	5.95	0.35	9.28e-9	Ischemic stroke;
KIRP	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.55	7.45	0.43	1.53e-12	Breast cancer;
KIRP	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.46	-6.48	-0.38	4.87e-10	Coronary artery disease;
KIRP	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg21695830	chr1:89457462	RBMXL1;CCBL2	0.44	5.89	0.35	1.23e-8	Carotid intima media thickness;
KIRP	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg25019722	chr6:37503610	NA	-0.88	-12.8	-0.63	4.32e-29	Cognitive performance;
KIRP	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg08885076	chr2:99613938	TSGA10	-0.42	-6.42	-0.38	7.06e-10	Bipolar disorder;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg10729496	chr3:10149963	C3orf24	0.54	5.18	0.31	4.62e-7	Alzheimer's disease;
KIRP	cis	rs71277158	0.688	rs2255256	chr3:169785903	G/A	cg04067573	chr3:169899625	PHC3	0.62	5.68	0.34	3.86e-8	Prostate cancer;
KIRP	cis	rs829883	0.622	rs7302630	chr12:98959577	C/A	cg25150519	chr12:98850993	NA	-0.74	-9.06	-0.5	4.07e-17	Colorectal adenoma (advanced);
KIRP	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.78	-0.4	8.77e-11	Heart rate;
KIRP	cis	rs7584330	0.666	rs6760963	chr2:238398268	C/T	cg08992911	chr2:238395768	MLPH	-0.53	-5.62	-0.34	5.13e-8	Prostate cancer;
KIRP	cis	rs12210905	1.000	rs9368492	chr6:27221518	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.67	-5.92	-0.35	1.07e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.43	-5.75	-0.34	2.64e-8	IgG glycosylation;
KIRP	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg09904177	chr6:26538194	HMGN4	-0.53	-6.84	-0.4	6.3e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28489187	0.706	rs233071	chr1:85806005	C/T	cg16011679	chr1:85725395	C1orf52	0.5	6.17	0.37	2.87e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg27462398	chr1:86174642	ZNHIT6	-0.46	-5.59	-0.34	6.1e-8	Urate levels in overweight individuals;
KIRP	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.97	15.22	0.7	2.58e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.57	-7.21	-0.42	6.82e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2708977	0.692	rs17685766	chr2:97319534	G/C	cg01950434	chr2:97203154	ARID5A	0.44	4.96	0.3	1.31e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24110177	chr3:50126178	RBM5	-0.65	-8.78	-0.49	2.86e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.43	0.47	2.96e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-6.99	-0.41	2.51e-11	Menarche (age at onset);
KIRP	cis	rs6722613	0.771	rs7587636	chr2:25518862	C/T	cg10614445	chr2:25526696	DNMT3A	-0.34	-5.91	-0.35	1.16e-8	Ossification of the posterior longitudinal ligament of the spine;
KIRP	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg11569703	chr11:65557185	OVOL1	0.32	4.96	0.3	1.32e-6	Eosinophil percentage of white cells;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08525424	chr20:62439150	NA	0.51	6.31	0.37	1.32e-9	Interleukin-4 levels;
KIRP	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg06060754	chr5:176797920	RGS14	0.75	10.37	0.55	3.89e-21	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.71	-7.81	-0.45	1.61e-13	Gut microbiome composition (summer);
KIRP	cis	rs1823913	1.000	rs6749232	chr2:192115052	C/G	cg12404831	chr2:192114017	MYO1B	-0.49	-6.79	-0.4	8.57e-11	Obesity-related traits;
KIRP	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.79	-0.35	2.17e-8	IgG glycosylation;
KIRP	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg24253500	chr15:84953950	NA	0.53	5.94	0.35	9.68e-9	Schizophrenia;
KIRP	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg19554555	chr3:13937349	NA	-0.46	-6.27	-0.37	1.65e-9	Ovarian reserve;
KIRP	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.86	-0.45	1.23e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.73	-9.96	-0.54	7.37e-20	Ear protrusion;
KIRP	cis	rs1062177	1.000	rs62394155	chr5:151248069	G/A	cg00977110	chr5:151150581	G3BP1	0.62	6.13	0.36	3.54e-9	Preschool internalizing problems;
KIRP	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.5	-7.06	-0.41	1.73e-11	Endometrial cancer;
KIRP	cis	rs4722404	0.502	rs6461817	chr7:3109425	C/T	cg19214707	chr7:3157722	NA	-0.57	-6.89	-0.4	4.72e-11	Atopic dermatitis;
KIRP	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.73	-5.98	-0.36	7.85e-9	IgG glycosylation;
KIRP	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg26893134	chr6:116381904	FRK	-0.19	-5.45	-0.33	1.22e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.8	-0.49	2.47e-16	Coronary artery disease;
KIRP	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.8	-11.26	-0.58	5.42e-24	Bone properties (heel);
KIRP	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg06212747	chr3:49208901	KLHDC8B	0.57	6.37	0.38	9.43e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg04568155	chr16:14724289	PARN	0.47	6.23	0.37	1.96e-9	Asthma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17114847	chr11:47736795	AGBL2	0.48	7.22	0.42	6.32e-12	Survival in pancreatic cancer;
KIRP	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.61	-0.6	3.83e-25	Body mass index;
KIRP	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.61	-0.44	5.67e-13	Morning vs. evening chronotype;
KIRP	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.83	11.0	0.57	3.77e-23	Monocyte count;
KIRP	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.48	11.09	0.58	1.93e-23	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.84	-12.22	-0.61	3.76e-27	Eye color traits;
KIRP	cis	rs244899	0.967	rs244903	chr5:167913510	G/A	cg06604206	chr5:167912465	RARS	-0.5	-6.93	-0.4	3.67e-11	Response to platinum-based chemotherapy (carboplatin);
KIRP	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg17252645	chr8:143867129	LY6D	-0.31	-5.02	-0.3	9.87e-7	Urinary tract infection frequency;
KIRP	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.44	6.55	0.39	3.43e-10	Lung cancer;
KIRP	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.37	0.38	9.09e-10	Protein C levels;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg08132940	chr7:1081526	C7orf50	-0.46	-4.87	-0.3	1.97e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg02297831	chr4:17616191	MED28	0.64	8.1	0.46	2.55e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg20701182	chr2:24300061	SF3B14	-0.49	-5.34	-0.32	2.16e-7	Asthma;
KIRP	cis	rs9912468	0.901	rs17706845	chr17:64310185	A/G	cg19474267	chr17:64306194	PRKCA	0.6	8.28	0.47	7.99e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs4523957	0.651	rs9906705	chr17:2063714	T/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg17554472	chr22:41940697	POLR3H	0.68	6.98	0.41	2.71e-11	Vitiligo;
KIRP	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.25	6.79	0.4	8.5e-11	Crohn's disease;
KIRP	cis	rs3849570	0.555	rs4452351	chr3:82007977	C/T	cg07356753	chr3:81810745	GBE1	-0.54	-6.6	-0.39	2.48e-10	Waist circumference;Body mass index;
KIRP	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.79	0.71	2.92e-39	Bipolar disorder;
KIRP	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.84	-0.53	1.77e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs9640161	0.658	rs57888387	chr7:150004244	G/A	cg21361702	chr7:150065534	REPIN1	0.63	6.1	0.36	4.05e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.8	14.29	0.67	4.04e-34	Height;
KIRP	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg25600027	chr14:23388339	RBM23	-0.52	-6.37	-0.38	9.15e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg09658497	chr7:2847517	GNA12	-0.32	-5.15	-0.31	5.46e-7	Height;
KIRP	cis	rs3736485	0.966	rs7170444	chr15:51890500	G/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.04	-0.31	8.88e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg01631408	chr1:248437212	OR2T33	-0.59	-7.48	-0.43	1.33e-12	Common traits (Other);
KIRP	cis	rs8077577	0.945	rs8069094	chr17:18096528	C/T	cg09161412	chr17:18057145	MYO15A	-0.38	-4.98	-0.3	1.2e-6	Obesity-related traits;
KIRP	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg08885076	chr2:99613938	TSGA10	0.46	7.84	0.45	1.38e-13	Chronic sinus infection;
KIRP	cis	rs959260	0.800	rs9895739	chr17:73399916	C/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.27	-0.37	1.59e-9	Systemic lupus erythematosus;
KIRP	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg06307176	chr5:131281290	NA	-0.53	-5.82	-0.35	1.8e-8	Life satisfaction;
KIRP	cis	rs78487399	0.808	rs12105394	chr2:43676790	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.89	-0.3	1.85e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg22117172	chr7:91764530	CYP51A1	0.47	6.47	0.38	5.26e-10	Breast cancer;
KIRP	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg06637938	chr14:75390232	RPS6KL1	0.49	6.86	0.4	5.43e-11	Height;
KIRP	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.43	5.31	0.32	2.49e-7	Aortic root size;
KIRP	trans	rs263156	0.967	rs263165	chr6:142897803	G/A	cg01789478	chr2:182545485	NEUROD1	-0.35	-6.09	-0.36	4.33e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg26174226	chr8:58114915	NA	-0.58	-6.6	-0.39	2.5e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs2281603	0.951	rs12587136	chr14:64985288	C/T	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.3	-0.32	2.57e-7	Neutrophil percentage of white cells;
KIRP	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg18753928	chr3:113234510	CCDC52	-0.55	-5.52	-0.33	8.57e-8	Dental caries;
KIRP	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.83	0.4	6.47e-11	Tonsillectomy;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.88	0.45	1.07e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.36	0.38	9.99e-10	Morning vs. evening chronotype;
KIRP	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg21919602	chr1:242011447	EXO1	-0.46	-5.93	-0.35	1.04e-8	Menopause (age at onset);
KIRP	trans	rs1864585	0.520	rs7845731	chr8:10675459	A/G	cg26278703	chr11:58910052	FAM111A	0.65	6.34	0.37	1.07e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7941030	0.902	rs12418320	chr11:122528870	C/T	cg20555462	chr11:122535518	UBASH3B	-0.45	-5.46	-0.33	1.19e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.58	-7.28	-0.42	4.48e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.6	-7.44	-0.43	1.7e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9400467	0.506	rs4639374	chr6:111458270	A/G	cg15721981	chr6:111408429	SLC16A10	0.71	6.46	0.38	5.55e-10	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21214613	chr1:16344536	HSPB7	0.34	5.24	0.32	3.5e-7	Dilated cardiomyopathy;
KIRP	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs1629083	0.905	rs17121881	chr11:118081345	A/T	cg18857871	chr11:118064634	AMICA1	0.64	8.53	0.48	1.47e-15	Lung cancer;
KIRP	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.86	-11.07	-0.58	2.29e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7113874	0.511	rs35091649	chr11:8548183	C/G	cg08015107	chr11:8618950	NA	-0.73	-8.88	-0.49	1.38e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg00149659	chr3:10157352	C3orf10	0.66	7.14	0.41	1.02e-11	Alzheimer's disease;
KIRP	cis	rs4762326	1.000	rs7309252	chr12:95687497	A/T	cg07737802	chr12:95537812	FGD6	0.46	6.49	0.38	4.59e-10	Endometriosis;
KIRP	cis	rs7011507	0.891	rs7836185	chr8:49161685	T/C	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg00204512	chr16:28754710	NA	0.41	5.0	0.3	1.08e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg07741184	chr6:167504864	NA	-0.24	-6.4	-0.38	7.85e-10	Crohn's disease;
KIRP	cis	rs9469913	0.799	rs2744955	chr6:34618958	C/G	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.13	-0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg27536791	chr1:183010618	LAMC1	-0.46	-6.11	-0.36	3.84e-9	Inflammatory biomarkers;
KIRP	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg18833306	chr6:118973337	C6orf204	0.4	5.04	0.31	8.85e-7	Electrocardiographic conduction measures;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg27532560	chr4:187881888	NA	-0.75	-12.85	-0.63	2.91e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.72	0.34	3.09e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs8079658	0.904	rs62065066	chr17:63780957	A/T	cg18091269	chr17:63822838	CCDC46	-0.53	-6.56	-0.39	3.18e-10	Post bronchodilator FEV1;
KIRP	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-1.05	-14.59	-0.68	3.66e-35	Platelet distribution width;
KIRP	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.76	-9.25	-0.51	1.14e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg05347473	chr6:146136440	FBXO30	0.56	8.0	0.45	5.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.79	11.28	0.58	4.57e-24	Bladder cancer;
KIRP	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.18	-0.37	2.68e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11038871	0.746	rs10769204	chr11:46676357	C/T	cg16389345	chr11:46697382	NA	0.53	7.16	0.42	9.53e-12	Immunoglobulin A;
KIRP	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.71	-9.0	-0.5	6.25e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg17554472	chr22:41940697	POLR3H	-0.62	-7.0	-0.41	2.42e-11	Vitiligo;
KIRP	cis	rs7084402	0.902	rs1658484	chr10:60288543	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.77e-23	Refractive error;
KIRP	cis	rs7572644	0.640	rs4666024	chr2:28072979	C/G	cg27432699	chr2:27873401	GPN1	-0.47	-5.75	-0.34	2.7e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.6	-0.39	2.51e-10	Neuroticism;
KIRP	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg02980000	chr4:1222292	CTBP1	-0.9	-9.37	-0.51	5.03e-18	Systolic blood pressure;
KIRP	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg16141378	chr3:129829833	LOC729375	0.52	6.85	0.4	5.8e-11	Retinal vascular caliber;
KIRP	cis	rs77861329	0.748	rs4687805	chr3:52123313	A/G	cg08692210	chr3:52188851	WDR51A	0.59	5.72	0.34	3.03e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.92	-8.91	-0.49	1.17e-16	QRS complex (12-leadsum);
KIRP	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.56	7.42	0.43	1.85e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6450176	0.625	rs16881958	chr5:53288201	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.99	-12.7	-0.63	9.33e-29	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg07636037	chr3:49044803	WDR6	-0.72	-6.85	-0.4	5.92e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.4	0.38	7.88e-10	Bipolar disorder;
KIRP	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.52	-6.67	-0.39	1.68e-10	Vitiligo;
KIRP	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg08885076	chr2:99613938	TSGA10	0.38	6.21	0.37	2.29e-9	Chronic sinus infection;
KIRP	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.84	-0.4	6.34e-11	Diastolic blood pressure;
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.94	0.35	9.87e-9	Platelet count;
KIRP	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg05484376	chr2:27715224	FNDC4	-0.4	-6.34	-0.37	1.07e-9	Total body bone mineral density;
KIRP	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.57	-0.39	2.99e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs745080	0.674	rs10162539	chr14:52945364	T/A	cg23333723	chr14:53022898	GPR137C	-0.4	-5.51	-0.33	9.02e-8	Orofacial clefts;
KIRP	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	9.93	0.54	9.14e-20	Homoarginine levels;
KIRP	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg11382394	chr1:2564504	MMEL1	-0.38	-4.87	-0.3	2.02e-6	Ulcerative colitis;
KIRP	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.93	-0.49	1.04e-16	Exhaled nitric oxide output;
KIRP	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.5	-0.48	1.88e-15	Monocyte percentage of white cells;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.76	12.13	0.61	7.35e-27	Menarche (age at onset);
KIRP	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg16386425	chr10:429943	DIP2C	-0.45	-6.25	-0.37	1.82e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.99	11.89	0.6	4.52e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7828089	1.000	rs7837521	chr8:22264151	G/T	cg13512537	chr8:22265999	SLC39A14	-0.45	-6.09	-0.36	4.34e-9	Verbal declarative memory;
KIRP	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.39	6.73	0.39	1.16e-10	QRS complex (12-leadsum);
KIRP	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg00977110	chr5:151150581	G3BP1	0.55	5.67	0.34	4.06e-8	Preschool internalizing problems;
KIRP	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12826209	chr6:26865740	GUSBL1	0.69	6.54	0.38	3.56e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7923609	1.000	rs4595427	chr10:65012944	A/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.67	-0.34	4.04e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10465746	0.905	rs12127266	chr1:84360767	T/G	cg10977910	chr1:84465055	TTLL7	0.45	5.43	0.33	1.34e-7	Obesity-related traits;
KIRP	cis	rs11690256	0.798	rs11678720	chr2:129542628	C/T	cg16353174	chr2:129543148	NA	-0.49	-7.66	-0.44	4.21e-13	Symmetrical dimethylarginine levels;
KIRP	cis	rs8067545	0.667	rs7222403	chr17:19879164	T/C	cg13482628	chr17:19912719	NA	0.57	7.95	0.45	6.6e-14	Schizophrenia;
KIRP	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.6	7.1	0.41	1.32e-11	LDL cholesterol levels;
KIRP	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.69	8.92	0.49	1.09e-16	Blood metabolite levels;
KIRP	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.19e-9	Body mass index;
KIRP	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.02e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.55	0.59	6.26e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4523957	0.547	rs11078856	chr17:2092064	G/A	cg16513277	chr17:2031491	SMG6	-0.72	-10.35	-0.55	4.62e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.55	-0.33	7.23e-8	Coronary artery disease;
KIRP	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-7.16	-0.42	9.32e-12	Vitiligo;
KIRP	cis	rs258892	0.793	rs16900954	chr5:72021191	G/A	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	cis	rs13385	0.769	rs10080146	chr5:139564473	G/A	cg01860693	chr5:139557145	C5orf32	0.5	5.39	0.33	1.62e-7	Atrial fibrillation;
KIRP	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg01304814	chr3:48885189	PRKAR2A	0.57	5.06	0.31	8.34e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.51	-5.67	-0.34	4.05e-8	Schizophrenia;
KIRP	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg08619932	chr19:49200058	FUT2	0.37	5.72	0.34	3.16e-8	Dietary macronutrient intake;
KIRP	cis	rs2380205	0.682	rs7919785	chr10:5926131	G/A	cg27141509	chr10:5886111	NA	-0.34	-4.96	-0.3	1.33e-6	Breast cancer;
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.47	5.94	0.35	9.78e-9	Life satisfaction;
KIRP	trans	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.05	-0.41	1.83e-11	Diabetic kidney disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15553612	chr1:119520934	TBX15	0.45	6.53	0.38	3.74e-10	Survival in pancreatic cancer;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-1.08	-21.17	-0.8	2.5e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.86	-0.35	1.46e-8	Bipolar disorder;
KIRP	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.09	-0.41	1.41e-11	Neuroticism;
KIRP	cis	rs2458413	0.542	rs2514668	chr8:105362656	A/C	cg08657449	chr8:105351661	TM7SF4	0.35	5.76	0.34	2.48e-8	Paget's disease;
KIRP	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg06223162	chr1:101003688	GPR88	0.43	8.88	0.49	1.39e-16	Monocyte count;
KIRP	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg05347473	chr6:146136440	FBXO30	0.48	7.05	0.41	1.76e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06212747	chr3:49208901	KLHDC8B	0.88	13.94	0.66	5.97e-33	Menarche (age at onset);
KIRP	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-8.69	-0.48	5.33e-16	Morning vs. evening chronotype;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06157335	chr1:53164003	C1orf163	-0.51	-6.46	-0.38	5.64e-10	Neuroticism;
KIRP	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.03	-0.31	9.64e-7	Personality dimensions;
KIRP	cis	rs11731606	0.567	rs17377951	chr4:95321099	C/T	cg20625393	chr4:95128694	SMARCAD1	0.62	5.4	0.33	1.54e-7	Mean platelet volume;
KIRP	cis	rs78487399	0.908	rs4339008	chr2:43834352	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.93	-0.3	1.51e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.48	-8.1	-0.46	2.52e-14	Erythrocyte sedimentation rate;
KIRP	trans	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg25042112	chr7:64838748	ZNF92	0.59	6.15	0.37	3.06e-9	Pain;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22188058	chr20:43976933	SDC4	-0.46	-6.05	-0.36	5.41e-9	Myopia;
KIRP	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Hypertriglyceridemia;
KIRP	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.49	6.26	0.37	1.73e-9	Iron status biomarkers;
KIRP	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg25482853	chr8:67687455	SGK3	0.8	7.01	0.41	2.26e-11	Obesity-related traits;
KIRP	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.94	0.35	9.5e-9	Educational attainment;
KIRP	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.77	10.43	0.55	2.52e-21	Bladder cancer;
KIRP	cis	rs883565	0.655	rs7619193	chr3:39044116	T/C	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	trans	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg00343986	chr7:65444356	GUSB	0.43	5.12	0.31	6.05e-7	Aortic root size;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26425730	chr6:153304295	FBXO5	0.51	6.9	0.4	4.29e-11	Survival in pancreatic cancer;
KIRP	cis	rs7903847	0.620	rs954149	chr10:99122936	G/A	cg20016023	chr10:99160130	RRP12	-0.41	-5.55	-0.33	7.31e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02753865	chr7:56119046	CCT6A;PSPH	0.91	6.18	0.37	2.6e-9	P wave terminal force;
KIRP	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	5.32	0.32	2.33e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.69	10.35	0.55	4.54e-21	Dupuytren's disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg19300475	chr17:27230118	DHRS13	-0.62	-6.78	-0.4	8.98e-11	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20317180	chr19:56111252	FIZ1;ZNF524	0.51	6.02	0.36	6.32e-9	Smoking initiation;
KIRP	cis	rs6723108	0.515	rs16831001	chr2:135534794	G/T	cg12500956	chr2:135428796	TMEM163	-0.41	-5.29	-0.32	2.75e-7	Type 2 diabetes;
KIRP	cis	rs1298062	0.756	rs2463241	chr19:50996961	C/T	cg17071417	chr19:50962282	MYBPC2	-0.44	-5.39	-0.33	1.61e-7	Age of smoking initiation;
KIRP	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.37	5.62	0.34	5.16e-8	Mitochondrial DNA levels;
KIRP	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.61	-8.16	-0.46	1.69e-14	Diastolic blood pressure;
KIRP	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg27624424	chr6:160112604	SOD2	0.55	6.52	0.38	3.94e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg16989719	chr2:238392110	NA	-0.55	-6.15	-0.36	3.15e-9	Prostate cancer;
KIRP	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	ch.11.340609R	chr11:12831013	TEAD1	0.4	4.93	0.3	1.55e-6	Educational attainment (years of education);
KIRP	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.12	-0.46	2.22e-14	Joint mobility (Beighton score);
KIRP	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.76	0.49	3.12e-16	Motion sickness;
KIRP	cis	rs9473924	0.542	rs13195969	chr6:50814627	C/A	cg14470998	chr6:50812995	TFAP2B	1.02	9.01	0.5	5.88e-17	Body mass index;
KIRP	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	1.11	13.37	0.65	5.1e-31	IgG glycosylation;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.32	-0.32	2.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.6	-6.78	-0.4	9.1e-11	Initial pursuit acceleration;
KIRP	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg03959625	chr15:84868606	LOC388152	0.62	6.4	0.38	7.94e-10	Schizophrenia;
KIRP	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.67	8.65	0.48	6.81e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10131728	0.892	rs17630746	chr14:81648560	G/A	cg01989461	chr14:81687754	GTF2A1	-0.72	-5.45	-0.33	1.2e-7	IgG glycosylation;
KIRP	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-1.01	-13.05	-0.64	6.18e-30	Platelet distribution width;
KIRP	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.62	-6.75	-0.4	1.07e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg08662619	chr6:150070041	PCMT1	0.37	5.98	0.36	7.78e-9	Lung cancer;
KIRP	trans	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.83	9.8	0.53	2.43e-19	Corneal astigmatism;
KIRP	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg04995300	chr3:66848608	NA	0.81	8.76	0.49	3.13e-16	Type 2 diabetes;
KIRP	cis	rs2916247	1.000	rs7832917	chr8:93036318	A/G	cg10183463	chr8:93005414	RUNX1T1	0.63	8.29	0.47	7.53e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.83	-14.59	-0.68	3.59e-35	Post bronchodilator FEV1;
KIRP	cis	rs11779988	0.598	rs7844114	chr8:17909492	C/T	cg01800426	chr8:17659068	MTUS1	-0.39	-4.89	-0.3	1.81e-6	Breast cancer;
KIRP	cis	rs7011049	0.908	rs11986701	chr8:53833480	G/T	cg26025543	chr8:53854495	NA	0.72	7.58	0.44	6.99e-13	Systolic blood pressure;
KIRP	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.69	0.34	3.64e-8	Personality dimensions;
KIRP	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.98	-0.5	7.38e-17	Total cholesterol levels;
KIRP	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg00919237	chr7:87102261	ABCB4	-0.72	-9.47	-0.52	2.46e-18	Gallbladder cancer;
KIRP	cis	rs77861329	1.000	rs9817653	chr3:52148233	T/G	cg08692210	chr3:52188851	WDR51A	0.95	7.63	0.44	5.21e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs7809615	0.748	rs35183025	chr7:99030782	A/T	cg12290671	chr7:99195819	NA	-0.74	-6.85	-0.4	5.94e-11	Blood metabolite ratios;
KIRP	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg07777115	chr5:623756	CEP72	-0.63	-6.14	-0.36	3.25e-9	Obesity-related traits;
KIRP	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg09526685	chr4:187126073	CYP4V2	-0.59	-5.36	-0.32	1.88e-7	Blood protein levels;
KIRP	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg02487422	chr3:49467188	NICN1	0.4	5.48	0.33	1.08e-7	Parkinson's disease;
KIRP	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs10489202	1.000	rs34192847	chr1:168064317	A/T	cg24449463	chr1:168025552	DCAF6	-0.52	-5.82	-0.35	1.8e-8	Schizophrenia;
KIRP	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg06360820	chr2:242988706	NA	-0.74	-6.54	-0.38	3.6e-10	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08171933	chr1:161860383	ATF6	0.43	6.11	0.36	3.84e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg12218747	chr21:37451666	NA	-0.43	-5.37	-0.32	1.8e-7	Mitral valve prolapse;
KIRP	cis	rs4692589	0.606	rs34752946	chr4:170951738	G/T	cg19918862	chr4:170955249	NA	0.58	6.24	0.37	1.91e-9	Anxiety disorder;
KIRP	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-6.49	-0.38	4.77e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7017914	0.934	rs7009297	chr8:71672366	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg22705602	chr4:152727874	NA	-0.56	-9.87	-0.53	1.43e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.89	13.36	0.65	5.61e-31	Coronary artery disease;
KIRP	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	13.43	0.65	3.25e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs9547692	0.877	rs12020203	chr13:37469287	G/A	cg01493522	chr13:37497338	NA	-0.41	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs13418717	1.000	rs13401458	chr2:127657770	G/T	cg25501666	chr2:127640322	NA	1.07	7.35	0.42	2.95e-12	Heart failure;
KIRP	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs997295	0.554	rs4261477	chr15:68073968	G/T	cg24579218	chr15:68104479	NA	-0.43	-6.78	-0.4	9.1e-11	Motion sickness;
KIRP	cis	rs1440410	0.835	rs9992189	chr4:144060728	G/C	cg01719995	chr4:144104893	USP38	0.43	5.86	0.35	1.47e-8	Ischemic stroke;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.69	-10.34	-0.55	4.97e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg23845249	chr11:68861649	NA	0.57	8.22	0.46	1.18e-14	Blond vs. brown hair color;
KIRP	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg05721485	chr17:44071124	MAPT	0.6	7.75	0.44	2.43e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7011507	1.000	rs56005944	chr8:49165633	G/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.34	-0.32	2.11e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.76	-0.49	3.31e-16	Morning vs. evening chronotype;
KIRP	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg11569703	chr11:65557185	OVOL1	0.44	7.42	0.43	1.94e-12	Systemic lupus erythematosus;
KIRP	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg14458575	chr2:238380390	NA	0.59	8.11	0.46	2.48e-14	Prostate cancer;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg07701084	chr6:150067640	NUP43	0.7	9.39	0.51	4.25e-18	Lung cancer;
KIRP	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.09e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.66	-0.39	1.82e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.34	5.28	0.32	2.86e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.55	-6.15	-0.36	3.2e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg26149184	chr10:133730230	NA	0.42	4.98	0.3	1.2e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs8084125	0.938	rs2097094	chr18:74942422	G/A	cg18461021	chr18:74961002	GALR1	0.62	5.96	0.36	8.82e-9	Obesity-related traits;
KIRP	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg21545522	chr1:205238299	TMCC2	0.38	5.1	0.31	6.74e-7	Red blood cell count;
KIRP	cis	rs580438	0.722	rs354472	chr3:13340809	C/T	cg10657019	chr3:13328039	NA	0.58	7.43	0.43	1.74e-12	Myringotomy;
KIRP	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.62	7.97	0.45	6.1e-14	Pancreatic cancer;
KIRP	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.56	12.12	0.61	7.85e-27	Mean platelet volume;
KIRP	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg13047869	chr3:10149882	C3orf24	0.55	5.46	0.33	1.15e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.89	-0.4	4.76e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg11693508	chr17:37793320	STARD3	-0.68	-7.24	-0.42	5.81e-12	Bipolar disorder;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg17785781	chr5:32174570	GOLPH3	0.53	6.12	0.36	3.67e-9	Plasma plasminogen activator levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10542300	chr15:48442807	MYEF2	-0.45	-6.98	-0.41	2.71e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	0.87	7.59	0.44	6.43e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.62	-7.44	-0.43	1.69e-12	Obesity-related traits;
KIRP	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.63	8.59	0.48	9.85e-16	Depressive symptoms;
KIRP	cis	rs4236601	0.962	rs10258482	chr7:116150095	C/A	cg05166801	chr7:116143459	CAV2	0.48	5.72	0.34	3.09e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.5	-0.33	9.36e-8	Menarche (age at onset);
KIRP	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	1.09	19.36	0.78	2.4e-51	Schizophrenia;
KIRP	cis	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.64	0.34	4.74e-8	Lung cancer;
KIRP	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.82	-8.87	-0.49	1.5e-16	Obesity-related traits;
KIRP	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-0.41	-5.18	-0.31	4.66e-7	Type 2 diabetes;
KIRP	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg24375607	chr4:120327624	NA	0.39	4.85	0.3	2.17e-6	Diastolic blood pressure;
KIRP	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.35	6.63	0.39	2.1e-10	Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg02462569	chr6:150064036	NUP43	-0.37	-5.72	-0.34	3.02e-8	Lung cancer;
KIRP	cis	rs71403859	0.614	rs12935422	chr16:71664225	T/A	cg08717414	chr16:71523259	ZNF19	-0.98	-8.87	-0.49	1.48e-16	Post bronchodilator FEV1;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20530585	chr3:149376036	WWTR1	-0.49	-6.44	-0.38	6.3e-10	Myopia;
KIRP	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg12042659	chr19:58951599	ZNF132	-0.52	-6.42	-0.38	7.08e-10	Uric acid clearance;
KIRP	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24803255	chr13:114807060	RASA3	0.42	6.37	0.38	9.35e-10	Survival in pancreatic cancer;
KIRP	cis	rs6973256	0.897	rs1014442	chr7:133349281	A/T	cg10665199	chr7:133106180	EXOC4	-0.5	-6.31	-0.37	1.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg26585981	chr11:48327164	OR4S1	-0.42	-5.12	-0.31	6.3e-7	Coronary artery disease;
KIRP	cis	rs533123	0.591	rs525672	chr1:29141967	A/G	cg08366446	chr1:29138936	OPRD1	0.83	5.41	0.33	1.51e-7	Schizophrenia;
KIRP	cis	rs12220238	1.000	rs79952914	chr10:75907464	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	6.05	0.36	5.38e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs2522056	1.000	rs2522063	chr5:131805591	G/T	cg07395648	chr5:131743802	NA	0.53	6.38	0.38	8.7e-10	Lymphocyte counts;Fibrinogen;
KIRP	trans	rs7939886	0.920	rs11227854	chr11:56081744	T/C	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02158565	chr7:150788256	AGAP3	0.45	6.34	0.37	1.11e-9	Metabolic traits;
KIRP	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg02836325	chr17:76403955	PGS1	0.41	6.68	0.39	1.55e-10	HDL cholesterol;
KIRP	trans	rs12659622	0.850	rs4510585	chr5:15604921	C/G	cg09887955	chr1:202129854	PTPN7	0.52	6.03	0.36	6.03e-9	Obesity-related traits;
KIRP	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.74	9.45	0.52	2.86e-18	Coronary artery disease;
KIRP	cis	rs3784262	0.669	rs3742959	chr15:58249113	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.16	-0.31	5.04e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.58	7.54	0.43	9.3e-13	Red blood cell count;
KIRP	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg10018233	chr7:150070692	REPIN1	0.53	6.86	0.4	5.51e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8028313	0.504	rs338364	chr15:68173921	A/G	cg24579218	chr15:68104479	NA	-0.47	-6.88	-0.4	4.89e-11	Obesity;
KIRP	cis	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg04607699	chr11:48328132	OR4S1	-0.35	-5.0	-0.3	1.1e-6	HDL cholesterol;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs3764563	0.935	rs10408443	chr19:15715973	C/T	cg20725493	chr19:15740067	CYP4F8	-0.88	-5.89	-0.35	1.28e-8	Inflammatory biomarkers;
KIRP	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.48	7.26	0.42	5.08e-12	Carotid intima media thickness;
KIRP	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs9815354	0.812	rs73071242	chr3:41993011	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.51	0.48	1.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.44	-0.52	2.99e-18	Aortic root size;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02132379	chr7:30031080	SCRN1	-0.44	-6.39	-0.38	8.22e-10	Select biomarker traits;
KIRP	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg13628971	chr7:2884303	GNA12	0.39	4.99	0.3	1.14e-6	Height;
KIRP	cis	rs273218	1.000	rs274366	chr5:53374636	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.69	7.44	0.43	1.66e-12	Migraine;
KIRP	cis	rs1832871	0.521	rs62437411	chr6:158823211	G/A	cg07215822	chr6:158701037	NA	-0.54	-6.33	-0.37	1.18e-9	Height;
KIRP	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.37	-0.38	9.3e-10	Recombination measurement;
KIRP	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg15440763	chr7:158190612	PTPRN2	0.44	5.57	0.33	6.63e-8	Obesity-related traits;
KIRP	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.52	6.9	0.4	4.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs73526541	0.588	rs76536698	chr8:1066059	T/G	cg01049933	chr8:1047734	NA	0.79	5.91	0.35	1.12e-8	Verbal memory performance (immediate recall change);
KIRP	cis	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg09559047	chr8:10916868	XKR6	0.38	5.37	0.32	1.82e-7	Triglycerides;
KIRP	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.81	0.6	8.7e-26	Alzheimer's disease;
KIRP	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg05347473	chr6:146136440	FBXO30	0.57	8.08	0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg15469184	chr8:337539	NA	0.6	6.83	0.4	6.46e-11	Obesity-related traits;
KIRP	cis	rs3825932	0.778	rs11072817	chr15:79236815	G/A	cg25744700	chr15:79237217	CTSH	0.43	5.14	0.31	5.52e-7	Type 1 diabetes;
KIRP	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.73	0.49	4.08e-16	Prudent dietary pattern;
KIRP	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg04310649	chr10:35416472	CREM	-0.57	-7.04	-0.41	1.91e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.72	7.88	0.45	1.04e-13	Corneal astigmatism;
KIRP	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.43	0.43	1.82e-12	Major depressive disorder;
KIRP	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.74	-9.07	-0.5	4.02e-17	Blood metabolite levels;
KIRP	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.31	0.32	2.46e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.12	-0.36	3.76e-9	Dupuytren's disease;
KIRP	cis	rs8027181	0.839	rs2304597	chr15:73052431	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.52	7.65	0.44	4.52e-13	Triglyceride levels;
KIRP	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.3	25.75	0.85	8.84e-72	IgG glycosylation;
KIRP	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg16306078	chr6:126000798	NA	-0.26	-4.88	-0.3	1.93e-6	Endometrial cancer;
KIRP	trans	rs61440199	0.786	rs73818813	chr3:20148085	C/T	cg08354614	chr10:80673607	NA	0.56	6.19	0.37	2.54e-9	Staphylococcus aureus nasal carriage (intermittent);
KIRP	cis	rs6539288	0.677	rs10778518	chr12:107343950	C/T	cg21360079	chr12:107162445	NA	0.44	5.73	0.34	2.91e-8	Total body bone mineral density;
KIRP	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg18709589	chr6:96969512	KIAA0776	0.34	5.15	0.31	5.29e-7	Headache;
KIRP	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.81	10.01	0.54	5.09e-20	Phospholipid levels (plasma);
KIRP	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.2	0.64	1.95e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.68	8.93	0.49	1.01e-16	Cognitive function;
KIRP	cis	rs11710088	0.895	rs13067320	chr3:149199592	T/G	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.43	-0.33	1.36e-7	QRS duration;
KIRP	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	0.82	7.3	0.42	3.89e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.68	-9.08	-0.5	3.69e-17	Huntington's disease progression;
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.59	-8.16	-0.46	1.72e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg19847130	chr8:10466454	RP1L1	0.39	5.87	0.35	1.37e-8	Neuroticism;
KIRP	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg02073558	chr3:44770973	ZNF501	0.47	5.47	0.33	1.1e-7	IgG glycosylation;
KIRP	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.5	-0.38	4.37e-10	Morning vs. evening chronotype;
KIRP	cis	rs981844	0.712	rs1012029	chr4:154749233	C/T	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs12143943	0.902	rs7541449	chr1:204578308	G/T	cg20240347	chr1:204465584	NA	-0.34	-6.29	-0.37	1.44e-9	Cognitive performance;
KIRP	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.34	-0.32	2.13e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.73	-8.82	-0.49	2.22e-16	Coronary artery disease;
KIRP	trans	rs2898857	0.524	rs11652146	chr17:47422363	G/A	cg11430096	chr6:110968061	CDK19	-0.53	-6.52	-0.38	4.01e-10	Cancer;
KIRP	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg18225595	chr11:63971243	STIP1	0.64	5.79	0.35	2.09e-8	Mean platelet volume;
KIRP	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-7.89	-0.45	9.96e-14	Total body bone mineral density;
KIRP	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.22	-5.23	-0.32	3.64e-7	Primary biliary cholangitis;
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-9.63	-0.52	7.68e-19	Longevity;Endometriosis;
KIRP	cis	rs35934224	0.891	rs33997573	chr22:19868951	C/T	cg11182965	chr22:19864308	TXNRD2	-0.45	-6.27	-0.37	1.58e-9	Glaucoma (primary open-angle);
KIRP	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.61	-8.17	-0.46	1.6e-14	Proinsulin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09103073	chr17:39019724	KRT12	0.46	6.56	0.39	3.07e-10	Survival in pancreatic cancer;
KIRP	cis	rs7572644	0.713	rs7560060	chr2:28057524	T/C	cg27432699	chr2:27873401	GPN1	0.45	5.01	0.3	1.06e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs62413470	0.935	rs62411458	chr6:55973866	C/T	cg13327911	chr6:55965977	COL21A1	0.55	5.05	0.31	8.43e-7	Joint mobility (Beighton score);
KIRP	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.72	9.86	0.53	1.49e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.48	6.42	0.38	6.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.5	7.03	0.41	2.01e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6921919	0.583	rs16894021	chr6:28345026	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg11693508	chr17:37793320	STARD3	0.49	6.74	0.39	1.15e-10	Neuroticism;
KIRP	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.44	4.91	0.3	1.68e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs77861329	0.748	rs2334961	chr3:52173625	G/C	cg08692210	chr3:52188851	WDR51A	0.61	6.16	0.37	3.02e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.85	-9.49	-0.52	2.12e-18	Exhaled nitric oxide output;
KIRP	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg21433313	chr16:3507492	NAT15	0.65	7.19	0.42	7.82e-12	Tuberculosis;
KIRP	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg04058563	chr4:185651563	MLF1IP	1.02	10.26	0.55	8.57e-21	Systemic lupus erythematosus;
KIRP	cis	rs7317038	0.653	rs9549754	chr13:114023787	G/A	cg24344662	chr13:114018021	GRTP1	-0.43	-5.32	-0.32	2.37e-7	Mean platelet volume;
KIRP	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg04013166	chr16:89971882	TCF25	0.7	7.33	0.42	3.35e-12	Skin colour saturation;
KIRP	trans	rs3013648	0.777	rs11149323	chr13:85388530	T/C	cg21827674	chr12:133007847	NA	-0.73	-6.55	-0.39	3.36e-10	Huntington's disease progression;
KIRP	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.83	12.1	0.61	9.09e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	8.26	0.47	8.74e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.09	-0.36	4.37e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.81	-10.85	-0.57	1.1e-22	Mean platelet volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13782814	chr10:13390289	SEPHS1	-0.58	-6.51	-0.38	4.19e-10	Menopause (age at onset);
KIRP	cis	rs4908768	0.871	rs4908775	chr1:8794410	G/A	cg25722041	chr1:8623473	RERE	0.71	8.75	0.49	3.52e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg20469991	chr17:27169893	C17orf63	0.54	5.59	0.34	5.93e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7084402	0.967	rs1303968	chr10:60298941	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.87	-0.57	1.02e-22	Refractive error;
KIRP	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg17554472	chr22:41940697	POLR3H	0.54	6.08	0.36	4.45e-9	Vitiligo;
KIRP	cis	rs6693295	0.877	rs12065115	chr1:246296690	A/T	cg11798871	chr1:246315928	SMYD3	0.47	5.68	0.34	3.76e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7192750	0.586	rs2335714	chr16:71897926	A/G	cg22136365	chr16:71611043	TAT	-0.28	-4.88	-0.3	1.91e-6	LDL cholesterol levels;Total cholesterol levels;
KIRP	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.91	-0.45	8.84e-14	Homocysteine levels;
KIRP	cis	rs654384	0.836	rs13224986	chr7:4172109	C/T	cg21882563	chr7:4172065	SDK1	0.43	5.6	0.34	5.71e-8	Positive affect;
KIRP	cis	rs6545883	0.868	rs6748003	chr2:61806700	T/G	cg15711740	chr2:61764176	XPO1	-0.61	-8.39	-0.47	3.85e-15	Tuberculosis;
KIRP	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg00405596	chr8:11794950	NA	0.55	7.62	0.44	5.41e-13	Neuroticism;
KIRP	cis	rs1345301	0.552	rs1558626	chr2:102862070	T/A	cg12451869	chr2:102867685	NA	0.46	6.8	0.4	7.97e-11	Waist circumference;
KIRP	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.56	5.93	0.35	1.03e-8	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg27411982	chr8:10470053	RP1L1	-0.38	-4.86	-0.3	2.11e-6	Neuroticism;
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg10534938	chr5:1868639	NA	0.38	5.12	0.31	6.13e-7	Cardiovascular disease risk factors;
KIRP	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg11707556	chr5:10655725	ANKRD33B	0.51	6.18	0.37	2.59e-9	Coronary artery disease;
KIRP	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.63	9.07	0.5	3.87e-17	Resting heart rate;
KIRP	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg24060327	chr5:131705240	SLC22A5	0.45	5.46	0.33	1.14e-7	Blood metabolite levels;
KIRP	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-12.03	-0.61	1.63e-26	Morning vs. evening chronotype;
KIRP	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg22153407	chr1:230290089	GALNT2	0.35	4.92	0.3	1.58e-6	Coronary artery disease;
KIRP	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17376030	chr22:41985996	PMM1	0.47	5.53	0.33	8.33e-8	Vitiligo;
KIRP	cis	rs6748734	0.625	rs10172404	chr2:241820906	T/C	cg04034577	chr2:241836375	C2orf54	-0.27	-4.99	-0.3	1.14e-6	Urinary metabolites;
KIRP	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg00784671	chr22:46762841	CELSR1	-0.61	-6.15	-0.36	3.14e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.5	-7.87	-0.45	1.12e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6545883	0.868	rs7594191	chr2:61840018	A/G	cg15711740	chr2:61764176	XPO1	0.59	8.29	0.47	7.37e-15	Tuberculosis;
KIRP	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg12218747	chr21:37451666	NA	-0.44	-5.44	-0.33	1.31e-7	Mitral valve prolapse;
KIRP	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg19468946	chr17:37922297	IKZF3	-0.36	-5.14	-0.31	5.59e-7	Asthma;
KIRP	cis	rs7116495	0.609	rs2276396	chr11:71823905	G/C	cg26138937	chr11:71823887	C11orf51	1.15	7.45	0.43	1.57e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.52	0.38	3.91e-10	Neuroticism;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.52	-4.91	-0.3	1.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.57	-6.73	-0.39	1.16e-10	Neuroticism;
KIRP	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs807029	0.577	rs3740490	chr10:102756743	G/C	cg04662943	chr10:102668895	NA	0.46	5.05	0.31	8.51e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2223471	0.624	rs2817372	chr6:50746064	T/C	cg03432817	chr6:50765336	NA	-0.36	-5.44	-0.33	1.3e-7	Subcutaneous adipose tissue;
KIRP	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.6	-7.44	-0.43	1.65e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08311172	chr2:69969004	ANXA4	-0.48	-6.36	-0.38	9.84e-10	Metabolic traits;
KIRP	cis	rs12496230	0.794	rs1867409	chr3:66860178	G/A	cg04995300	chr3:66848608	NA	0.45	6.97	0.41	2.88e-11	Type 2 diabetes;
KIRP	cis	rs9391997	0.568	rs1567900	chr6:433109	T/C	cg13299325	chr6:447777	NA	0.27	5.38	0.32	1.74e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.6	0.68	3.5e-35	Platelet count;
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.23e-8	Life satisfaction;
KIRP	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.52	-5.52	-0.33	8.68e-8	Subjective well-being;
KIRP	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg03959625	chr15:84868606	LOC388152	0.62	6.4	0.38	7.94e-10	Schizophrenia;
KIRP	cis	rs6968419	0.547	rs72603593	chr7:115894376	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.82	-0.35	1.83e-8	Intraocular pressure;
KIRP	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	5.2	0.31	4.21e-7	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	trans	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg03060546	chr3:49711283	APEH	-0.64	-6.73	-0.39	1.16e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.41	0.43	2.01e-12	Neuroticism;
KIRP	cis	rs7116495	1.000	rs2250866	chr11:71804513	A/G	cg18441811	chr11:71824068	C11orf51	-0.61	-4.88	-0.3	1.88e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.6	-6.69	-0.39	1.52e-10	Menarche (age at onset);
KIRP	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.66	-9.95	-0.54	8.13e-20	Educational attainment;
KIRP	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	6.56	0.39	3.15e-10	Schizophrenia;
KIRP	cis	rs12460243	0.938	rs111281472	chr19:8133136	G/A	cg26754826	chr19:8657410	ADAMTS10	0.52	4.97	0.3	1.27e-6	Neurocognitive impairment in HIV-1 infection (continuous);
KIRP	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg10932868	chr11:921992	NA	0.62	8.11	0.46	2.38e-14	Alzheimer's disease (late onset);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg26291519	chr15:76640005	NA	-0.43	-6.06	-0.36	5.1e-9	Inflammatory biomarkers;
KIRP	cis	rs986417	1.000	rs1956549	chr14:60928201	G/A	cg27398547	chr14:60952738	C14orf39	0.74	7.43	0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg02807482	chr3:125708958	NA	-0.52	-4.91	-0.3	1.69e-6	Blood pressure (smoking interaction);
KIRP	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg02187348	chr16:89574699	SPG7	0.42	5.07	0.31	7.99e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.24	26.57	0.86	3.12e-74	IgG glycosylation;
KIRP	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-5.29	-0.32	2.67e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	0.66	5.89	0.35	1.24e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg09904177	chr6:26538194	HMGN4	-0.42	-5.17	-0.31	4.84e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg19116668	chr7:99932089	PMS2L1	-0.51	-5.82	-0.35	1.86e-8	Coronary artery disease;
KIRP	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.59	-0.39	2.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.58	-8.22	-0.46	1.2e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs17123764	0.818	rs4045193	chr12:50003980	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg16606324	chr3:10149918	C3orf24	0.69	5.83	0.35	1.7e-8	Alzheimer's disease;
KIRP	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg09936400	chr10:82049201	MAT1A	-0.3	-4.97	-0.3	1.28e-6	Diabetic kidney disease;
KIRP	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg21573476	chr21:45109991	RRP1B	0.63	8.42	0.47	3.2e-15	Mean corpuscular volume;
KIRP	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg19338460	chr6:170058176	WDR27	-0.8	-8.83	-0.49	1.97e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.95	-0.54	8.19e-20	Mood instability;
KIRP	cis	rs8014252	0.803	rs73283917	chr14:71033156	G/A	cg19730268	chr14:71022823	NA	-0.59	-5.58	-0.34	6.23e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg23307798	chr14:103986281	CKB	0.73	11.35	0.59	2.68e-24	Body mass index;
KIRP	cis	rs12210905	0.688	rs72839474	chr6:27324757	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg20691502	chr1:185688754	NA	0.43	7.34	0.42	3.02e-12	C-reactive protein;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21074015	chr8:23313978	ENTPD4	0.43	6.11	0.36	3.84e-9	Survival in pancreatic cancer;
KIRP	cis	rs7870753	0.838	rs7021496	chr9:99263497	T/C	cg25260653	chr9:99212216	HABP4	0.53	5.77	0.35	2.33e-8	Height;
KIRP	trans	rs62056376	0.736	rs2215185	chr17:32633902	C/T	cg12726354	chr15:28342256	OCA2	0.56	6.38	0.38	8.61e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg26531700	chr6:26746687	NA	0.41	5.58	0.34	6.43e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17592366	0.517	rs4981250	chr14:35254473	A/C	cg09327582	chr14:35236912	BAZ1A	0.48	5.01	0.3	1.05e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs7394190	0.748	rs3088070	chr10:75530013	C/T	cg04833713	chr10:74871078	NUDT13	0.43	4.86	0.3	2.1e-6	Incident atrial fibrillation;
KIRP	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18867708	chr6:26865862	GUSBL1	0.46	5.73	0.34	2.85e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35883536	1.000	rs12566507	chr1:101089679	T/A	cg06223162	chr1:101003688	GPR88	0.32	6.5	0.38	4.41e-10	Monocyte count;
KIRP	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg09754948	chr16:28834200	ATXN2L	0.44	4.88	0.3	1.95e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.66	0.48	6.38e-16	Motion sickness;
KIRP	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg03060546	chr3:49711283	APEH	-0.64	-6.03	-0.36	5.86e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs939574	0.790	rs72955439	chr2:220090804	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	6.12	0.36	3.67e-9	Platelet distribution width;
KIRP	cis	rs2862064	0.745	rs4704733	chr5:156480104	T/G	cg12943317	chr5:156479607	HAVCR1	-0.78	-7.18	-0.42	8.12e-12	Platelet count;
KIRP	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.74	11.81	0.6	8.39e-26	Calcium levels;
KIRP	cis	rs7870753	0.838	rs7858287	chr9:99204516	A/C	cg25260653	chr9:99212216	HABP4	0.57	6.05	0.36	5.37e-9	Height;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06983483	chr5:140998629	DIAPH1	-0.47	-6.2	-0.37	2.42e-9	Myopia;
KIRP	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.14	-0.41	1.03e-11	Joint mobility (Beighton score);
KIRP	cis	rs10875746	0.669	rs11168510	chr12:48685555	A/G	cg26205652	chr12:48591994	NA	0.81	10.25	0.55	9.37e-21	Longevity (90 years and older);
KIRP	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.24	11.89	0.6	4.51e-26	Diabetic retinopathy;
KIRP	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg06204229	chr3:52865917	ITIH4	0.52	5.8	0.35	2.01e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.35	1.11e-8	Triglycerides;
KIRP	cis	rs4704187	0.687	rs6888707	chr5:74442920	A/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs300890	0.643	rs300916	chr4:144273884	G/T	cg19876092	chr4:144208277	NA	0.34	5.03	0.31	9.52e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs12190007	1.000	rs35022800	chr6:169735072	T/G	cg15038512	chr6:170123185	PHF10	-0.38	-5.38	-0.32	1.76e-7	Obesity-related traits;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.6	-8.08	-0.46	2.94e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg14703610	chr5:56206110	C5orf35	-0.48	-6.53	-0.38	3.82e-10	Coronary artery disease;
KIRP	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg02297831	chr4:17616191	MED28	0.61	7.63	0.44	5.26e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.73e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-9.19	-0.51	1.75e-17	Body mass index;
KIRP	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg17376030	chr22:41985996	PMM1	0.41	4.98	0.3	1.2e-6	Vitiligo;
KIRP	trans	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg19274270	chr17:78178856	CARD14	0.36	6.41	0.38	7.33e-10	Morning vs. evening chronotype;
KIRP	trans	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg06521331	chr12:34319734	NA	-0.56	-6.78	-0.4	8.69e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg02023728	chr11:77925099	USP35	-0.29	-4.89	-0.3	1.79e-6	Alzheimer's disease (survival time);
KIRP	cis	rs35955747	0.811	rs9606835	chr22:31766960	A/C	cg02404636	chr22:31891804	SFI1	0.36	4.87	0.3	1.99e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.68	6.05	0.36	5.47e-9	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg18306943	chr3:40428807	ENTPD3	-0.39	-5.26	-0.32	3.12e-7	Renal cell carcinoma;
KIRP	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg21401794	chr1:90099060	LRRC8C	-0.61	-7.7	-0.44	3.29e-13	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg04310649	chr10:35416472	CREM	-0.58	-7.14	-0.41	1.06e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.36	-0.32	1.91e-7	Pulmonary function;
KIRP	cis	rs17401966	0.540	rs58014725	chr1:10474457	T/A	cg19773385	chr1:10388646	KIF1B	-0.45	-6.47	-0.38	5.18e-10	Hepatocellular carcinoma;
KIRP	cis	rs892085	0.681	rs3826803	chr19:10883126	C/G	cg17710535	chr19:10819994	QTRT1	-0.48	-6.18	-0.37	2.58e-9	Psoriasis vulgaris;Psoriasis;
KIRP	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18252515	chr7:66147081	NA	0.46	5.67	0.34	3.9e-8	Aortic root size;
KIRP	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg18305652	chr10:134549665	INPP5A	0.43	6.75	0.4	1.03e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.55	-6.82	-0.4	7.03e-11	Total body bone mineral density;
KIRP	cis	rs7520050	0.933	rs9787208	chr1:46314616	C/A	cg03146154	chr1:46216737	IPP	-0.4	-5.05	-0.31	8.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg01294253	chr9:136912663	BRD3	-0.41	-5.46	-0.33	1.18e-7	Platelet distribution width;
KIRP	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.96	0.35	8.89e-9	Total cholesterol levels;
KIRP	cis	rs259842	0.764	rs165374	chr2:180678258	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.38	-0.32	1.7e-7	Blood protein levels;
KIRP	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg11608241	chr8:8085544	FLJ10661	0.49	6.05	0.36	5.51e-9	Neuroticism;
KIRP	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg23784912	chr18:14132582	ZNF519	1.0	6.8	0.4	7.7e-11	P wave terminal force;
KIRP	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.2e-24	Cognitive test performance;
KIRP	trans	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg13615516	chr5:77269221	NA	0.55	7.31	0.42	3.74e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2017305	0.834	rs12252761	chr10:70780296	C/T	cg01024728	chr10:70782572	NA	0.63	5.17	0.31	4.9e-7	Depression (quantitative trait);
KIRP	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.94	13.51	0.65	1.73e-31	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-11.4	-0.59	1.83e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.89	-0.49	1.31e-16	Blood metabolite levels;
KIRP	cis	rs2070997	0.617	rs3808816	chr9:133746117	C/T	cg03924115	chr9:133768966	QRFP	-0.31	-4.96	-0.3	1.3e-6	Response to amphetamines;
KIRP	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.08	-0.36	4.6e-9	Lung cancer;
KIRP	cis	rs4654899	0.629	rs7515279	chr1:21172774	C/T	cg08890418	chr1:21044141	KIF17	-0.34	-5.14	-0.31	5.67e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg26617929	chr16:1858877	NA	-0.73	-6.16	-0.37	2.96e-9	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.05	-13.26	-0.65	1.24e-30	Exhaled nitric oxide output;
KIRP	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg02073558	chr3:44770973	ZNF501	0.61	8.83	0.49	1.97e-16	Depressive symptoms;
KIRP	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.48	-7.22	-0.42	6.59e-12	Vitamin D levels;
KIRP	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.59	6.88	0.4	4.83e-11	QRS duration;
KIRP	cis	rs687432	0.885	rs7123727	chr11:57799183	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs11225247	0.772	rs11501344	chr11:102228252	A/G	cg06323957	chr11:102217781	BIRC2	0.77	5.0	0.3	1.11e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.45e-19	Colorectal cancer;
KIRP	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg09699651	chr6:150184138	LRP11	0.54	7.28	0.42	4.47e-12	Testicular germ cell tumor;
KIRP	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg14343924	chr8:8086146	FLJ10661	0.43	5.18	0.31	4.66e-7	Systolic blood pressure;
KIRP	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.15	-0.46	1.83e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7116495	0.609	rs73543612	chr11:71820350	C/T	cg26138937	chr11:71823887	C11orf51	1.16	7.55	0.43	8.52e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.45	-5.19	-0.31	4.49e-7	Total body bone mineral density;
KIRP	cis	rs7849270	0.885	rs10760588	chr9:131877474	C/T	cg13538475	chr9:131942899	NA	-0.34	-5.41	-0.33	1.52e-7	Blood metabolite ratios;
KIRP	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg06565975	chr8:143823917	SLURP1	-0.56	-7.8	-0.45	1.78e-13	Urinary tract infection frequency;
KIRP	cis	rs3026101	0.671	rs1544399	chr17:5305887	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg06121193	chr1:90282411	NA	-0.48	-6.94	-0.4	3.55e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4750440	0.702	rs7911259	chr10:14031051	T/C	cg27542038	chr10:14027202	FRMD4A	-0.47	-6.41	-0.38	7.28e-10	Adiponectin levels;
KIRP	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg01631408	chr1:248437212	OR2T33	-0.64	-8.4	-0.47	3.54e-15	Common traits (Other);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17878141	chr5:81521184	ATG10	0.41	6.02	0.36	6.26e-9	Interleukin-4 levels;
KIRP	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg01304814	chr3:48885189	PRKAR2A	0.73	5.57	0.33	6.74e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2637030	0.559	rs2607497	chr5:52995482	A/G	cg06476337	chr5:52856530	NDUFS4	0.55	5.93	0.35	1.01e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00933542	chr6:150070202	PCMT1	0.3	5.91	0.35	1.16e-8	Lung cancer;
KIRP	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00857998	chr1:205179979	DSTYK	-0.67	-8.61	-0.48	8.93e-16	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00585733	chr7:69064884	AUTS2	-0.41	-6.01	-0.36	6.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6499755	0.739	rs31094	chr16:55366819	C/A	cg05099576	chr16:55362342	IRX6	0.27	5.63	0.34	4.9e-8	Hypospadias;
KIRP	trans	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.23	0.37	2.01e-9	Mean corpuscular volume;
KIRP	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg09165964	chr15:75287851	SCAMP5	-1.1	-7.47	-0.43	1.36e-12	Lung cancer;
KIRP	cis	rs7932354	0.710	rs2306032	chr11:46897253	G/C	cg16389345	chr11:46697382	NA	0.44	5.49	0.33	9.96e-8	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.96	13.81	0.66	1.7e-32	Cognitive function;
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg07701084	chr6:150067640	NUP43	0.7	9.33	0.51	6.38e-18	Lung cancer;
KIRP	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.46	5.55	0.33	7.26e-8	Testicular germ cell tumor;
KIRP	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.54	0.38	3.62e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12580194	0.593	rs59136392	chr12:55748204	C/T	cg11794356	chr12:55725991	OR6C3	-0.6	-8.62	-0.48	8.4e-16	Cancer;
KIRP	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-4.99	-0.3	1.13e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.96	-14.5	-0.68	7.68e-35	Schizophrenia;
KIRP	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.29	-0.32	2.7e-7	Gut microbiome composition (summer);
KIRP	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.41	-0.33	1.47e-7	Aortic root size;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg26513180	chr16:89883248	FANCA	0.88	14.66	0.68	2.18e-35	Vitiligo;
KIRP	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.68	-7.01	-0.41	2.31e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs800082	0.668	rs9876975	chr3:144292255	G/A	cg24215973	chr2:240111563	HDAC4	-0.57	-7.76	-0.44	2.29e-13	Smoking behavior;
KIRP	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg18825076	chr15:78729989	IREB2	-0.41	-4.92	-0.3	1.62e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg17652424	chr22:38574118	PLA2G6	-0.28	-5.97	-0.36	8.09e-9	Cutaneous nevi;
KIRP	cis	rs752010	0.902	rs10890152	chr1:42101845	A/T	cg06885757	chr1:42089581	HIVEP3	0.48	6.98	0.41	2.68e-11	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg07402062	chr16:89894098	SPIRE2	0.31	6.48	0.38	4.9e-10	Vitiligo;
KIRP	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-7.12	-0.41	1.18e-11	Tonsillectomy;
KIRP	cis	rs10425738	0.785	rs4090553	chr19:41426757	T/C	cg09508736	chr19:41385865	CYP2A7	-0.48	-5.23	-0.32	3.55e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.63	-7.68	-0.44	3.86e-13	P wave terminal force;
KIRP	cis	rs17095355	1.000	rs56273398	chr10:111708183	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.17	-0.31	4.91e-7	Biliary atresia;
KIRP	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg21643547	chr1:205240462	TMCC2	0.53	7.49	0.43	1.2e-12	Red blood cell count;
KIRP	trans	rs1973993	0.672	rs17367240	chr1:96960057	G/A	cg10631902	chr5:14652156	NA	-0.56	-8.14	-0.46	2.01e-14	Weight;
KIRP	cis	rs7010267	0.935	rs6415470	chr8:119955111	G/A	cg01975934	chr8:119970761	NA	-0.42	-5.32	-0.32	2.28e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs8113308	0.515	rs113082012	chr19:52464233	A/G	cg25782003	chr19:52490127	ZNF350	0.84	6.14	0.36	3.32e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.51	-0.33	9.2e-8	Ileal carcinoids;
KIRP	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg06740227	chr12:86229804	RASSF9	-0.42	-5.4	-0.33	1.54e-7	Major depressive disorder;
KIRP	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.61	-0.39	2.39e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	14.28	0.67	4.27e-34	Platelet count;
KIRP	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11987759	chr7:65425863	GUSB	-0.43	-5.21	-0.32	3.94e-7	Aortic root size;
KIRP	cis	rs3731896	1.000	rs3731896	chr2:220146402	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.55	5.81	0.35	1.89e-8	Educational attainment;
KIRP	cis	rs8045833	0.714	rs749681	chr16:88570675	A/G	cg05152867	chr16:88568237	ZFPM1	0.38	5.58	0.34	6.18e-8	Vascular endothelial growth factor levels;
KIRP	cis	rs72634258	0.554	rs7556518	chr1:7847846	G/A	cg26816564	chr1:7831052	VAMP3	0.83	7.97	0.45	5.88e-14	Inflammatory bowel disease;
KIRP	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg12292205	chr6:26970375	C6orf41	-0.57	-6.78	-0.4	8.77e-11	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.24	-0.37	1.92e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.89	-12.78	-0.63	5.14e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-9.29	-0.51	8.8e-18	Gut microbiome composition (summer);
KIRP	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.6	8.92	0.49	1.08e-16	HDL cholesterol;
KIRP	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.61e-11	Bipolar disorder;
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22618164	chr12:122356400	WDR66	0.65	9.04	0.5	4.72e-17	Mean corpuscular volume;
KIRP	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg25650185	chr19:21324782	ZNF431	0.47	4.89	0.3	1.8e-6	Pain;
KIRP	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg16434002	chr17:42200994	HDAC5	-0.44	-5.01	-0.3	1.04e-6	Total body bone mineral density;
KIRP	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.75e-7	Red blood cell count;
KIRP	cis	rs3105593	1.000	rs3131596	chr15:50877575	T/C	cg05456662	chr15:50716270	USP8	0.45	5.39	0.32	1.68e-7	QT interval;
KIRP	cis	rs3736485	0.934	rs28393906	chr15:51867605	T/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.94	-0.35	9.45e-9	Depression;
KIRP	cis	rs7975161	0.832	rs11111955	chr12:104650735	T/C	cg25273343	chr12:104657179	TXNRD1	-0.62	-5.8	-0.35	2.08e-8	Toenail selenium levels;
KIRP	cis	rs7659604	0.517	rs55989500	chr4:122682155	C/T	cg19748678	chr4:122722346	EXOSC9	0.53	5.39	0.32	1.66e-7	Type 2 diabetes;
KIRP	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.45	9.95	0.54	7.93e-20	Mean corpuscular volume;
KIRP	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.24	-0.37	1.9e-9	Type 2 diabetes;
KIRP	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg10189774	chr4:17578691	LAP3	0.55	6.87	0.4	5.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2299587	0.545	rs13264911	chr8:17759756	C/T	cg01800426	chr8:17659068	MTUS1	-0.43	-5.15	-0.31	5.36e-7	Economic and political preferences;
KIRP	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg00383909	chr3:49044727	WDR6	0.83	6.59	0.39	2.58e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7941030	0.902	rs11605422	chr11:122534190	C/T	cg20555462	chr11:122535518	UBASH3B	-0.47	-5.76	-0.34	2.52e-8	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.46	5.88	0.35	1.32e-8	Recombination rate (males);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18149508	chr1:10532693	DFFA	0.48	6.24	0.37	1.93e-9	Parkinson's disease;
KIRP	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg18964960	chr10:1102726	WDR37	0.64	7.26	0.42	5.12e-12	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.61	-7.02	-0.41	2.19e-11	Mean platelet volume;
KIRP	cis	rs1800469	0.965	rs12983775	chr19:41857439	G/A	cg09537434	chr19:41945824	ATP5SL	-0.53	-5.88	-0.35	1.3e-8	Colorectal cancer;
KIRP	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.9	5.87	0.35	1.39e-8	Putamen volume;
KIRP	cis	rs4638749	0.677	rs17035849	chr2:108842593	G/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-6.85	-0.4	5.77e-11	Blood pressure;
KIRP	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.46	-4.96	-0.3	1.34e-6	Glomerular filtration rate (creatinine);Chronic kidney disease;
KIRP	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	1.1	17.86	0.75	2.61e-46	Cognitive function;
KIRP	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	5.65	0.34	4.51e-8	Renal cell carcinoma;
KIRP	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.43	5.1	0.31	6.65e-7	Height;
KIRP	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.44e-8	Motion sickness;
KIRP	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg12826209	chr6:26865740	GUSBL1	0.76	5.38	0.32	1.72e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.18	0.42	8.36e-12	Retinal vascular caliber;
KIRP	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.73	-0.34	2.87e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.56e-25	Diabetic kidney disease;
KIRP	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.81	-11.96	-0.61	2.66e-26	Dental caries;
KIRP	cis	rs2635047	0.699	rs2247578	chr18:44745056	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.64	0.34	4.7e-8	Educational attainment;
KIRP	cis	rs6901250	0.610	rs9400964	chr6:117144808	G/T	cg05399210	chr6:117082661	FAM162B	-0.39	-5.21	-0.32	3.91e-7	C-reactive protein levels;
KIRP	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs501120	1.000	rs579058	chr10:44755104	A/G	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	1.05	9.3	0.51	7.86e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg23719950	chr11:63933701	MACROD1	-0.69	-6.71	-0.39	1.36e-10	Mean platelet volume;
KIRP	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21545522	chr1:205238299	TMCC2	0.42	5.67	0.34	4e-8	Red blood cell count;
KIRP	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.76	9.36	0.51	5.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02475777	chr4:1388615	CRIPAK	0.41	5.75	0.34	2.68e-8	Longevity;
KIRP	cis	rs3821902	0.646	rs7619741	chr3:64054783	T/A	cg09006292	chr3:64049408	NA	-0.5	-4.94	-0.3	1.42e-6	Breast cancer;
KIRP	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg13147721	chr7:65941812	NA	-1.02	-7.06	-0.41	1.71e-11	Diabetic kidney disease;
KIRP	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.28	-0.37	1.55e-9	Hemoglobin concentration;
KIRP	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.59	-6.64	-0.39	1.96e-10	Menarche (age at onset);
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.25	-0.32	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.55	7.03	0.41	2.03e-11	Coronary heart disease;
KIRP	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg19875535	chr5:140030758	IK	-0.71	-10.03	-0.54	4.61e-20	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.61	7.37	0.43	2.53e-12	Squamous cell carcinoma;
KIRP	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg16141378	chr3:129829833	LOC729375	-0.54	-7.09	-0.41	1.41e-11	Mood instability;
KIRP	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.69	0.34	3.68e-8	Neuroticism;
KIRP	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.77	10.08	0.54	3.09e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs12313068	0.656	rs41436646	chr12:110495171	C/G	cg12870014	chr12:110450643	ANKRD13A	0.54	7.08	0.41	1.51e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4594175	0.886	rs11157802	chr14:51622984	C/T	cg23942311	chr14:51606299	NA	0.53	6.97	0.41	2.97e-11	Cancer;
KIRP	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.75	-0.4	1.08e-10	Triglycerides;
KIRP	cis	rs687432	0.774	rs11604473	chr11:57896527	T/C	cg19752551	chr11:57585705	CTNND1	-0.67	-8.46	-0.47	2.45e-15	Parkinson's disease;
KIRP	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg05082376	chr22:42548792	NA	-0.47	-5.94	-0.35	9.52e-9	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg06792538	chr1:2954250	NA	0.41	4.91	0.3	1.69e-6	Plateletcrit;
KIRP	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg05507819	chr15:63340323	TPM1	0.52	6.43	0.38	6.61e-10	Platelet count;
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.73	10.23	0.55	1.04e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7129556	0.690	rs24356	chr11:77567528	C/T	cg12586386	chr11:77299805	AQP11	0.39	5.27	0.32	3.01e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs9611198	0.755	rs5757719	chr22:39945791	T/C	cg10455938	chr22:40058150	CACNA1I	0.47	6.49	0.38	4.66e-10	Schizophrenia;
KIRP	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg00784671	chr22:46762841	CELSR1	-0.51	-5.71	-0.34	3.19e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.69	-9.64	-0.52	7.36e-19	Menarche (age at onset);
KIRP	cis	rs7551222	0.716	rs11240751	chr1:204462050	A/G	cg20240347	chr1:204465584	NA	-0.42	-7.75	-0.44	2.48e-13	Schizophrenia;
KIRP	cis	rs5753037	0.653	rs131273	chr22:30153721	T/C	cg01021169	chr22:30184971	ASCC2	-0.43	-5.96	-0.36	8.49e-9	Type 1 diabetes;
KIRP	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg19554555	chr3:13937349	NA	-0.46	-6.23	-0.37	1.97e-9	Ovarian reserve;
KIRP	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg00360474	chr6:37504404	NA	-0.5	-7.49	-0.43	1.22e-12	Cognitive performance;
KIRP	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07570687	chr10:102243282	WNT8B	0.49	6.07	0.36	4.7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg01631408	chr1:248437212	OR2T33	-0.67	-9.07	-0.5	4e-17	Common traits (Other);
KIRP	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg17810781	chr1:201082982	CACNA1S	0.47	7.43	0.43	1.8e-12	Permanent tooth development;
KIRP	cis	rs258892	0.895	rs13164198	chr5:72051641	G/T	cg21869765	chr5:72125136	TNPO1	0.52	6.04	0.36	5.63e-9	Small cell lung carcinoma;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25753567	chr19:1420366	DAZAP1	0.46	6.15	0.37	3.05e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg05527609	chr1:210001259	C1orf107	0.45	5.63	0.34	4.98e-8	Red blood cell count;
KIRP	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg06050784	chr16:88016603	BANP	0.4	5.04	0.31	8.92e-7	Menopause (age at onset);
KIRP	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.14	-0.54	2.03e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg12962167	chr3:53033115	SFMBT1	0.83	5.94	0.35	9.45e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-6.42	-0.38	7.07e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs45544231	0.544	rs2193094	chr16:52566454	G/T	cg09051775	chr16:52580266	TOX3	0.36	4.93	0.3	1.5e-6	Restless legs syndrome;
KIRP	cis	rs17023223	0.553	rs72691108	chr1:119762175	G/A	cg05756136	chr1:119680316	WARS2	-0.56	-7.16	-0.42	9.15e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-7.27	-0.42	4.85e-12	Mean corpuscular volume;
KIRP	cis	rs7246657	0.525	rs1667357	chr19:37484352	T/C	cg23950597	chr19:37808831	NA	-0.66	-5.88	-0.35	1.35e-8	Coronary artery calcification;
KIRP	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.99	0.3	1.13e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg11693508	chr17:37793320	STARD3	-0.77	-8.36	-0.47	4.57e-15	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.61	0.34	5.48e-8	Lung cancer;
KIRP	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.1	-0.36	4.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.56	7.52	0.43	1.05e-12	Blood metabolite levels;
KIRP	cis	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg05340658	chr4:99064831	C4orf37	0.66	8.01	0.45	4.63e-14	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg24804195	chr5:87968844	LOC645323	0.47	6.14	0.36	3.27e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.99	-13.59	-0.65	9.48e-32	Ulcerative colitis;
KIRP	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-1.13	-21.08	-0.8	4.6e-57	Monocyte count;
KIRP	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.74	7.64	0.44	4.87e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.36	-0.47	4.67e-15	Total cholesterol levels;
KIRP	cis	rs7536201	1.000	rs7536848	chr1:25294345	A/C	cg23273869	chr1:25296894	NA	-0.36	-5.06	-0.31	8.04e-7	Psoriasis vulgaris;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14121103	chr3:43731973	ABHD5	0.52	6.2	0.37	2.34e-9	Smoking initiation;
KIRP	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-6.92	-0.4	3.82e-11	Lung cancer;
KIRP	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	0.77	7.56	0.43	8.01e-13	Prostate cancer;
KIRP	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg05636881	chr10:105038444	INA	0.7	5.27	0.32	2.97e-7	Arsenic metabolism;
KIRP	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.99	8.17	0.46	1.67e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.6	7.2	0.42	7.47e-12	Aortic root size;
KIRP	cis	rs7113874	0.802	rs10840102	chr11:8676238	C/T	cg08015107	chr11:8618950	NA	-0.43	-5.65	-0.34	4.47e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg06634786	chr22:41940651	POLR3H	-0.48	-5.32	-0.32	2.36e-7	Neuroticism;
KIRP	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.93	12.43	0.62	7.66e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.5	-7.84	-0.45	1.33e-13	Huntington's disease progression;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27451672	chr7:99156362	ZNF655	0.46	6.41	0.38	7.2e-10	Survival in pancreatic cancer;
KIRP	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.54	-0.33	7.69e-8	Aortic root size;
KIRP	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg26513180	chr16:89883248	FANCA	0.86	6.01	0.36	6.62e-9	Skin colour saturation;
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg08901578	chr4:187885870	NA	-0.56	-9.3	-0.51	8.2e-18	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.15	0.41	9.81e-12	Mean corpuscular volume;
KIRP	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg04691961	chr3:161091175	C3orf57	-0.66	-11.15	-0.58	1.2e-23	Morning vs. evening chronotype;
KIRP	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg05991184	chr2:219186017	PNKD	-0.43	-6.26	-0.37	1.74e-9	Colorectal cancer;
KIRP	cis	rs2414059	0.518	rs11070776	chr15:50735488	G/A	cg08437265	chr15:50716283	USP8	0.35	5.0	0.3	1.07e-6	QT interval;
KIRP	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.92	10.64	0.56	5.52e-22	Corneal astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21851530	chr1:120190451	ZNF697	0.49	6.7	0.39	1.4e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1881396	0.947	rs4666010	chr2:27878686	T/C	cg27432699	chr2:27873401	GPN1	0.63	7.0	0.41	2.38e-11	Nonalcoholic fatty liver disease;
KIRP	cis	rs12468557	0.628	rs2371005	chr2:211500887	A/T	cg07063745	chr2:211341572	LANCL1;CPS1	-0.4	-4.85	-0.3	2.15e-6	Body mass index in asthmatics;
KIRP	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg16586182	chr3:47516702	SCAP	-0.43	-5.33	-0.32	2.19e-7	Birth weight;
KIRP	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg20701182	chr2:24300061	SF3B14	0.58	5.17	0.31	4.74e-7	Lymphocyte counts;
KIRP	cis	rs526231	0.543	rs32849	chr5:102470043	C/T	cg23492399	chr5:102201601	PAM	-0.5	-5.47	-0.33	1.1e-7	Primary biliary cholangitis;
KIRP	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.89	-0.35	1.23e-8	Response to antipsychotic treatment;
KIRP	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.82	-0.35	1.85e-8	Educational attainment;
KIRP	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg23306229	chr2:178417860	TTC30B	0.48	5.05	0.31	8.8e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2151522	0.762	rs9401915	chr6:127165656	A/G	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg16141378	chr3:129829833	LOC729375	-0.59	-6.93	-0.4	3.68e-11	Neuroticism;
KIRP	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3741151	0.686	rs1938777	chr11:73122340	A/G	cg17517138	chr11:73019481	ARHGEF17	0.64	5.54	0.33	7.65e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09443479	chr8:108511174	ANGPT1	0.55	8.5	0.48	1.81e-15	Survival in pancreatic cancer;
KIRP	cis	rs7172677	1.000	rs55662404	chr15:75432341	G/A	cg10253484	chr15:75165896	SCAMP2	0.53	5.53	0.33	8.13e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.13	-0.46	2.15e-14	Mean corpuscular volume;
KIRP	cis	rs17401966	0.540	rs4846219	chr1:10463888	C/A	cg17425144	chr1:10567563	PEX14	-0.32	-5.35	-0.32	1.97e-7	Hepatocellular carcinoma;
KIRP	cis	rs12519773	1.000	rs995620	chr5:92452676	A/C	cg18783429	chr5:92414398	NA	0.28	4.98	0.3	1.17e-6	Migraine;
KIRP	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-5.36	-0.32	1.93e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	trans	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg10756647	chr7:56101905	PSPH	0.97	6.98	0.41	2.7e-11	Diabetic kidney disease;
KIRP	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg17736920	chr1:242011382	EXO1	0.45	5.47	0.33	1.13e-7	Menopause (age at onset);
KIRP	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg25019722	chr6:37503610	NA	-0.71	-9.19	-0.51	1.76e-17	Cognitive performance;
KIRP	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.78	10.74	0.56	2.64e-22	Total body bone mineral density;
KIRP	cis	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-5.41	-0.33	1.51e-7	Morning vs. evening chronotype;
KIRP	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.73e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11988203	chr2:198272801	SF3B1	0.46	6.37	0.38	9.13e-10	Interleukin-4 levels;
KIRP	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07570687	chr10:102243282	WNT8B	0.56	7.16	0.42	9.19e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08109568	chr15:31115862	NA	-0.77	-9.38	-0.51	4.53e-18	Huntington's disease progression;
KIRP	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg17376030	chr22:41985996	PMM1	0.58	6.45	0.38	5.77e-10	Vitiligo;
KIRP	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.21	0.32	3.92e-7	Melanoma;
KIRP	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg26531700	chr6:26746687	NA	0.53	7.54	0.43	9.17e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg08313168	chr12:7315531	NA	0.71	6.31	0.37	1.26e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	6.49	0.38	4.62e-10	Breast cancer;
KIRP	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg19610905	chr11:61596333	FADS2	-0.52	-5.82	-0.35	1.83e-8	Neutrophil count;Sum basophil neutrophil counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10832168	chr17:61600389	KCNH6	0.47	6.22	0.37	2.16e-9	Parkinson's disease;
KIRP	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg07936489	chr17:37558343	FBXL20	-0.48	-6.05	-0.36	5.4e-9	Asthma;
KIRP	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg08885076	chr2:99613938	TSGA10	0.48	8.21	0.46	1.27e-14	Chronic sinus infection;
KIRP	trans	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg11693508	chr17:37793320	STARD3	0.57	7.51	0.43	1.12e-12	Neuroticism;
KIRP	cis	rs45544231	0.569	rs11642645	chr16:52558907	C/A	cg09051775	chr16:52580266	TOX3	-0.38	-5.2	-0.31	4.29e-7	Restless legs syndrome;
KIRP	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg23533419	chr12:54090519	NA	-0.33	-5.24	-0.32	3.52e-7	Height;
KIRP	cis	rs4790312	0.668	rs1048483	chr17:1966457	C/T	cg24156229	chr17:1948635	NA	-0.51	-6.6	-0.39	2.57e-10	Left atrial antero-posterior diameter;
KIRP	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	5.48	0.33	1.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg17644776	chr2:200775616	C2orf69	0.64	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs963731	0.737	rs13023273	chr2:39230119	C/G	cg04010122	chr2:39346883	SOS1	-0.82	-5.66	-0.34	4.17e-8	Corticobasal degeneration;
KIRP	cis	rs12580194	0.593	rs61071395	chr12:55721228	G/C	cg19537932	chr12:55886519	OR6C68	-0.48	-6.23	-0.37	1.97e-9	Cancer;
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg14221460	chr8:27183342	PTK2B	0.51	6.62	0.39	2.29e-10	Neuroticism;
KIRP	cis	rs2625529	0.689	rs10851847	chr15:72111760	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-6.53	-0.38	3.81e-10	Red blood cell count;
KIRP	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.12	0.41	1.19e-11	Aortic root size;
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.56	-7.52	-0.43	1.01e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg19765451	chr1:94702724	ARHGAP29	-0.88	-6.4	-0.38	8.01e-10	P wave terminal force;
KIRP	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.43	4.88	0.3	1.87e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg14593290	chr7:50529359	DDC	0.44	5.63	0.34	4.79e-8	Malaria;
KIRP	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.83	9.39	0.51	4.26e-18	High light scatter reticulocyte count;
KIRP	cis	rs882732	0.947	rs10140765	chr14:95023389	C/T	cg08495878	chr14:95027859	SERPINA4	-0.43	-4.93	-0.3	1.48e-6	Blood protein levels;
KIRP	cis	rs2505998	0.957	rs2435359	chr10:43580015	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.52	-5.41	-0.33	1.46e-7	Hirschsprung disease;
KIRP	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.62	7.87	0.45	1.13e-13	Height;
KIRP	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.6	11.37	0.59	2.36e-24	Bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23333220	chr15:64679825	TRIP4	0.55	6.7	0.39	1.39e-10	Smoking initiation;
KIRP	cis	rs9596863	1.000	rs9596855	chr13:54407032	G/A	ch.13.53330881F	chr13:54432880	NA	0.66	6.68	0.39	1.56e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14184786	chr14:94547643	IFI27L1;DDX24	0.55	6.38	0.38	8.91e-10	Smoking initiation;
KIRP	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.53	7.67	0.44	4e-13	Bipolar disorder;
KIRP	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.52	0.43	1.03e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg03894339	chr8:19674705	INTS10	0.59	6.9	0.4	4.48e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.59	-6.62	-0.39	2.27e-10	Coronary artery disease;
KIRP	trans	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.14	-0.41	1.02e-11	Bladder cancer;
KIRP	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg17507749	chr15:85114479	UBE2QP1	0.85	9.44	0.52	2.89e-18	Schizophrenia;
KIRP	cis	rs7119038	0.774	rs7945144	chr11:118608716	A/G	cg19308663	chr11:118741387	NA	0.45	7.24	0.42	5.6e-12	Sjögren's syndrome;
KIRP	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	6.61	0.39	2.36e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.37	-0.32	1.82e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.8	12.09	0.61	1.04e-26	Bladder cancer;
KIRP	cis	rs6684514	1.000	rs12117947	chr1:156244058	A/T	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26314531	chr2:26401878	FAM59B	-0.45	-5.16	-0.31	5.13e-7	Gut microbiome composition (summer);
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.78	12.47	0.62	5.51e-28	Menarche (age at onset);
KIRP	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.35	-5.11	-0.31	6.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs965513	1.000	rs10983700	chr9:100537455	T/C	cg13688889	chr9:100608707	NA	-0.59	-7.51	-0.43	1.08e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-0.51	-7.18	-0.42	8.4e-12	Coronary artery disease;
KIRP	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.98	8.06	0.46	3.34e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.79	10.87	0.57	9.76e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1876905	0.764	rs9398265	chr6:111422602	T/C	cg15721981	chr6:111408429	SLC16A10	0.55	4.91	0.3	1.68e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.96	-10.13	-0.54	2.19e-20	Schizophrenia;
KIRP	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg05370193	chr1:21551575	ECE1	0.42	5.99	0.36	7.26e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg02696742	chr7:106810147	HBP1	-0.78	-7.94	-0.45	7.2e-14	Coronary artery disease;
KIRP	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.94	-10.03	-0.54	4.39e-20	Cognitive test performance;
KIRP	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg06204229	chr3:52865917	ITIH4	-0.42	-5.33	-0.32	2.26e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.09	0.36	4.24e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg22437258	chr11:111473054	SIK2	0.6	7.1	0.41	1.37e-11	Primary sclerosing cholangitis;
KIRP	cis	rs11605924	0.901	rs6485644	chr11:45855998	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.49	-5.89	-0.35	1.23e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.43	-5.31	-0.32	2.51e-7	Aortic root size;
KIRP	cis	rs12049351	0.943	rs6678454	chr1:229717979	C/G	cg11742688	chr1:229674241	ABCB10	0.34	5.54	0.33	7.96e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs867371	1.000	rs1846911	chr15:82468650	G/A	cg00614314	chr15:82944287	LOC80154	0.54	6.46	0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.34	-0.42	3.05e-12	Joint mobility (Beighton score);
KIRP	cis	rs876084	0.505	rs9969584	chr8:121104786	G/A	cg06265175	chr8:121136014	COL14A1	0.49	6.15	0.37	3.04e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg14254433	chr6:34482411	PACSIN1	-0.71	-7.36	-0.42	2.68e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg26585981	chr11:48327164	OR4S1	-0.43	-5.23	-0.32	3.65e-7	HDL cholesterol;
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.25	0.74	3.02e-44	Platelet count;
KIRP	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.15	0.36	3.18e-9	Colorectal cancer;
KIRP	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.7	-8.44	-0.47	2.7e-15	Cognitive function;
KIRP	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.76	-9.0	-0.5	6.24e-17	Coronary artery disease;
KIRP	trans	rs1555543	0.538	rs7416802	chr1:96909292	G/C	cg10631902	chr5:14652156	NA	-0.49	-6.15	-0.37	3.12e-9	Body mass index;
KIRP	cis	rs8014252	0.711	rs58069917	chr14:71043557	C/T	cg11204974	chr14:71022665	NA	-0.73	-7.18	-0.42	8.16e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg07343612	chr16:622815	PIGQ	-0.9	-13.04	-0.64	6.52e-30	Height;
KIRP	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg08717414	chr16:71523259	ZNF19	-0.55	-6.49	-0.38	4.78e-10	Blood protein levels;
KIRP	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	0.95	12.13	0.61	7.65e-27	Blood protein levels;
KIRP	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg02725872	chr8:58115012	NA	0.59	6.46	0.38	5.46e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.79	0.44	1.89e-13	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04892403	chr22:19701827	SEPT5	0.45	6.22	0.37	2.09e-9	Parkinson's disease;
KIRP	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.72	7.88	0.45	1.04e-13	Corneal astigmatism;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg01874867	chr7:94954059	PON1	0.57	8.05	0.46	3.62e-14	Paraoxonase activity;
KIRP	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.82	-11.74	-0.6	1.47e-25	Schizophrenia;
KIRP	cis	rs889398	0.741	rs3790075	chr16:69907811	A/G	cg09409435	chr16:70099608	PDXDC2	0.4	4.96	0.3	1.34e-6	Body mass index;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.72	11.32	0.59	3.33e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.28	-0.32	2.87e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.77	0.35	2.38e-8	Morning vs. evening chronotype;
KIRP	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg21366198	chr4:185655624	MLF1IP	0.38	5.05	0.31	8.59e-7	Kawasaki disease;
KIRP	cis	rs4774830	0.590	rs62045217	chr15:56260773	T/C	cg05129572	chr15:56138634	NEDD4	0.65	4.86	0.3	2.08e-6	Delta-5 desaturase activity;
KIRP	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg23127183	chr11:57508653	C11orf31	0.46	6.25	0.37	1.83e-9	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11271157	chr11:59328467	NA	0.42	6.18	0.37	2.6e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	2.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.61	-9.5	-0.52	2.01e-18	Sense of smell;
KIRP	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.26e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.95	-0.41	3.27e-11	Obesity-related traits;
KIRP	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg21709803	chr11:61594965	FADS2	-0.41	-4.94	-0.3	1.47e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2403221	0.547	rs7115324	chr11:9847307	A/G	cg07197493	chr11:9884649	SBF2	0.34	4.85	0.3	2.21e-6	Smoking initiation;
KIRP	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.07	-0.46	3.05e-14	Coronary artery disease;
KIRP	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg11650704	chr1:154556575	ADAR	-0.42	-5.19	-0.31	4.37e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-5.19	-0.31	4.31e-7	Coronary artery disease;
KIRP	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg02696742	chr7:106810147	HBP1	-0.81	-8.27	-0.47	8.28e-15	Coronary artery disease;
KIRP	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.4	-6.1	-0.36	4.06e-9	Hypertriglyceridemia;
KIRP	cis	rs6125597	0.967	rs6125610	chr20:47904298	C/T	cg03212862	chr20:47662828	CSE1L	-0.41	-5.29	-0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.6	0.39	2.48e-10	Hypertriglyceridemia;
KIRP	cis	rs986417	0.901	rs1955687	chr14:60988606	A/G	cg27398547	chr14:60952738	C14orf39	0.72	7.1	0.41	1.37e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.7	-7.48	-0.43	1.35e-12	DNA methylation (variation);
KIRP	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg19773385	chr1:10388646	KIF1B	-0.61	-7.95	-0.45	6.91e-14	Hepatocellular carcinoma;
KIRP	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg04058563	chr4:185651563	MLF1IP	0.91	9.05	0.5	4.34e-17	Systemic lupus erythematosus;
KIRP	cis	rs7404928	0.718	rs11644103	chr16:23860388	T/A	cg21745164	chr16:23765304	CHP2	-0.65	-7.92	-0.45	7.99e-14	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.23	-0.37	1.97e-9	Dilated cardiomyopathy;
KIRP	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg03959625	chr15:84868606	LOC388152	0.6	7.33	0.42	3.34e-12	Schizophrenia;
KIRP	cis	rs73200209	0.744	rs73198040	chr12:116535736	G/C	cg01776926	chr12:116560359	MED13L	-0.58	-5.94	-0.35	9.91e-9	Total body bone mineral density;
KIRP	cis	rs300890	0.507	rs1397526	chr4:144326409	G/A	cg01719995	chr4:144104893	USP38	-0.44	-5.39	-0.32	1.69e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	1.04	13.47	0.65	2.41e-31	Exhaled nitric oxide output;
KIRP	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs9972944	0.756	rs7207587	chr17:63766307	C/T	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg14851346	chr12:38532713	NA	-0.4	-5.05	-0.31	8.7e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4704187	0.687	rs9654426	chr5:74466737	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.13e-8	Response to amphetamines;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg26327118	chr6:39693366	KIF6	-0.46	-6.22	-0.37	2.17e-9	Myopia;
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg10664184	chr19:17420304	DDA1	0.72	8.46	0.47	2.38e-15	Systemic lupus erythematosus;
KIRP	cis	rs4363385	0.574	rs61813182	chr1:152943868	T/A	cg13444842	chr1:152974279	SPRR3	-0.48	-6.88	-0.4	4.89e-11	Inflammatory skin disease;
KIRP	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03934478	chr11:495069	RNH1	0.8	6.3	0.37	1.39e-9	Body mass index;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10903826	chr4:1242276	CTBP1	-0.57	-6.22	-0.37	2.1e-9	Menopause (age at onset);
KIRP	cis	rs35740288	0.770	rs12898597	chr15:86189919	T/C	cg10818794	chr15:86012489	AKAP13	-0.43	-5.29	-0.32	2.73e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.68	10.03	0.54	4.54e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg04935436	chr20:30431758	NA	0.46	5.92	0.35	1.06e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.09	0.64	4.44e-30	Tonsillectomy;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg24642844	chr7:1081250	C7orf50	-0.36	-4.89	-0.3	1.85e-6	Longevity;Endometriosis;
KIRP	cis	rs72781680	0.611	rs7596060	chr2:24334361	A/G	cg20701182	chr2:24300061	SF3B14	-0.93	-10.16	-0.54	1.77e-20	Lymphocyte counts;
KIRP	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg05926928	chr17:57297772	GDPD1	-0.79	-7.61	-0.44	5.71e-13	Opioid sensitivity;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg07216194	chr8:27182965	PTK2B	-0.46	-5.59	-0.34	5.95e-8	Neuroticism;
KIRP	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.76	-5.45	-0.33	1.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.86	-0.57	1.09e-22	Menopause (age at onset);
KIRP	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.93	15.16	0.69	4.16e-37	Bone mineral density;
KIRP	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17554472	chr22:41940697	POLR3H	0.73	7.35	0.42	2.95e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg07507129	chr1:2371847	NA	-0.44	-5.55	-0.33	7.54e-8	Schizophrenia;
KIRP	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.88	-0.45	1.02e-13	Neuroticism;
KIRP	cis	rs2591576	0.743	rs3849743	chr5:165434873	A/G	cg13976338	chr5:165423657	NA	-0.72	-10.35	-0.55	4.64e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg05527609	chr1:210001259	C1orf107	-0.47	-5.12	-0.31	6.06e-7	Red blood cell count;
KIRP	cis	rs16857609	0.628	rs2618143	chr2:218336686	C/T	cg15335768	chr2:218268053	DIRC3	-0.37	-5.55	-0.33	7.21e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.9	13.2	0.64	1.93e-30	Dupuytren's disease;
KIRP	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.38	-0.47	3.98e-15	Total cholesterol levels;
KIRP	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg13010199	chr12:38710504	ALG10B	0.61	7.7	0.44	3.22e-13	Morning vs. evening chronotype;
KIRP	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.47	5.66	0.34	4.27e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.43	-0.47	3.03e-15	Height;
KIRP	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.34	-0.32	2.1e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-13.18	-0.64	2.36e-30	Alzheimer's disease;
KIRP	cis	rs9962915	1.000	rs1785413	chr18:5596929	A/G	cg12967001	chr18:5544089	EPB41L3	-0.42	-5.13	-0.31	5.77e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg26876637	chr1:152193138	HRNR	-0.7	-8.81	-0.49	2.34e-16	Atopic dermatitis;
KIRP	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.55	6.29	0.37	1.48e-9	Primary sclerosing cholangitis;
KIRP	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg01864069	chr14:103024347	NA	-0.96	-13.28	-0.65	1.08e-30	Platelet count;
KIRP	cis	rs7187994	0.848	rs36008565	chr16:84751046	C/G	cg07647771	chr16:84786436	USP10	-0.39	-5.56	-0.33	7.14e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.26	7.38	0.43	2.5e-12	Type 2 diabetes;
KIRP	cis	rs9815354	0.812	rs61661916	chr3:41921915	T/C	cg03022575	chr3:42003672	ULK4	0.8	8.15	0.46	1.88e-14	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.89	-0.45	9.74e-14	Retinal vascular caliber;
KIRP	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-4.93	-0.3	1.53e-6	Educational attainment;
KIRP	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22022881	chr2:105853494	NA	-0.36	-5.59	-0.34	6.13e-8	Type 2 diabetes;
KIRP	cis	rs4903214	0.895	rs10142706	chr14:74717304	A/G	cg08255017	chr14:74727001	VSX2	-0.41	-5.29	-0.32	2.67e-7	Inflammatory bowel disease;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.71	-8.74	-0.49	3.67e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.91	0.35	1.11e-8	Diabetic retinopathy;
KIRP	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.85	-12.61	-0.63	1.88e-28	Height;
KIRP	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.59	-12.45	-0.62	6.65e-28	Diabetic kidney disease;
KIRP	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg05791153	chr7:19748676	TWISTNB	0.82	6.83	0.4	6.75e-11	Thyroid stimulating hormone;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08678925	chr15:85358595	ALPK3	0.53	7.33	0.42	3.26e-12	Interleukin-4 levels;
KIRP	cis	rs1538970	0.962	rs7544178	chr1:45819069	C/T	cg05343316	chr1:45956843	TESK2	0.63	7.34	0.42	3.06e-12	Platelet count;
KIRP	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	9.14	0.5	2.4e-17	Systemic lupus erythematosus;
KIRP	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.26	-0.47	8.8e-15	Mood instability;
KIRP	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.6	7.66	0.44	4.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg00857998	chr1:205179979	DSTYK	0.62	7.38	0.43	2.41e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.62	-6.38	-0.38	8.62e-10	Tuberculosis;
KIRP	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.48	-7.91	-0.45	8.79e-14	Major depressive disorder;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14230166	chr19:1020974	C19orf6	0.49	6.1	0.36	4.02e-9	Myopia (pathological);
KIRP	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg11833968	chr6:79620685	NA	-0.45	-6.9	-0.4	4.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.25	5.06	0.31	8.03e-7	Coronary artery disease;
KIRP	cis	rs2273156	1.000	rs17102970	chr14:35480569	T/G	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.33	-0.32	2.27e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg01966878	chr4:90757139	SNCA	-0.45	-4.9	-0.3	1.72e-6	Neuroticism;
KIRP	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg04662567	chr6:169592167	NA	-0.75	-6.4	-0.38	7.6e-10	Pulse pressure;
KIRP	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.68	9.37	0.51	4.81e-18	Red blood cell count;
KIRP	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	6.03	0.36	5.82e-9	Type 2 diabetes;
KIRP	cis	rs7709377	0.597	rs11739600	chr5:115474214	C/T	cg23108291	chr5:115420582	COMMD10	0.42	5.02	0.3	9.97e-7	Metabolite levels  (X-11787);
KIRP	cis	rs1570884	0.740	rs12146924	chr13:50134358	T/C	cg03651054	chr13:50194643	NA	0.6	8.45	0.47	2.65e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs10242455	0.571	rs117370443	chr7:98975258	T/C	cg18809830	chr7:99032528	PTCD1	-0.99	-5.73	-0.34	2.95e-8	Blood metabolite levels;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg01763666	chr17:80159506	CCDC57	-0.36	-4.9	-0.3	1.7e-6	Life satisfaction;
KIRP	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-1.12	-8.78	-0.49	2.74e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs7236492	0.935	rs7239086	chr18:77217030	A/C	cg15644404	chr18:77186268	NFATC1	-0.93	-7.35	-0.42	2.9e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7551222	0.752	rs4252725	chr1:204513256	A/G	cg20240347	chr1:204465584	NA	-0.47	-8.88	-0.49	1.42e-16	Schizophrenia;
KIRP	cis	rs7923609	1.000	rs10761723	chr10:64955581	C/T	cg01631684	chr10:65280961	REEP3	-0.48	-5.67	-0.34	4.07e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.4	-0.51	3.82e-18	Chronic sinus infection;
KIRP	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.74	0.44	2.65e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg27411982	chr8:10470053	RP1L1	0.41	4.98	0.3	1.21e-6	Neuroticism;
KIRP	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.91	-11.82	-0.6	8.2e-26	Homoarginine levels;
KIRP	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-4.91	-0.3	1.67e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.59	6.12	0.36	3.65e-9	Axial length;
KIRP	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.61	-0.48	8.88e-16	Neuroticism;
KIRP	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.02	0.36	6.44e-9	Alzheimer's disease (late onset);
KIRP	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg06521331	chr12:34319734	NA	0.51	6.11	0.36	3.89e-9	Morning vs. evening chronotype;
KIRP	cis	rs10484885	0.759	rs56230212	chr6:90234654	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.58	-4.98	-0.3	1.22e-6	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07308232	chr7:1071921	C7orf50	-0.66	-8.59	-0.48	1.04e-15	Longevity;Endometriosis;
KIRP	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg06740227	chr12:86229804	RASSF9	0.47	6.05	0.36	5.44e-9	Major depressive disorder;
KIRP	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg15103426	chr22:29168792	CCDC117	-0.49	-6.7	-0.39	1.42e-10	Red cell distribution width;
KIRP	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.85	12.78	0.63	5.05e-29	Height;
KIRP	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg18306943	chr3:40428807	ENTPD3	-0.45	-6.16	-0.37	3.02e-9	Renal cell carcinoma;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19315081	chr11:10326100	ADM	-0.45	-6.03	-0.36	5.93e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.87	-14.65	-0.68	2.24e-35	Breast cancer;
KIRP	cis	rs2882667	1.000	rs10064201	chr5:138309405	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-6.91	-0.4	4.08e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.76	-9.21	-0.51	1.44e-17	Multiple sclerosis;
KIRP	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.13	-0.61	7.34e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11071200	0.637	rs8025445	chr15:55966642	C/A	cg17396834	chr15:56014697	PRTG	0.42	5.92	0.35	1.1e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	1.1	21.85	0.81	1.46e-59	Height;
KIRP	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.55	0.56	1.02e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg00255919	chr5:131827918	IRF1	0.28	5.83	0.35	1.73e-8	Asthma (sex interaction);
KIRP	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	4.9	0.3	1.78e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.78	-13.99	-0.67	4.12e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg21926883	chr2:100939477	LONRF2	0.58	7.21	0.42	6.66e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg01831904	chr17:28903510	LRRC37B2	0.8	9.26	0.51	1.03e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9972944	0.651	rs12601958	chr17:63820304	A/G	cg07283582	chr17:63770753	CCDC46	-0.5	-7.97	-0.45	6.03e-14	Total body bone mineral density;
KIRP	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.32	-4.85	-0.3	2.19e-6	Life satisfaction;
KIRP	cis	rs17065868	1.000	rs61948033	chr13:45204650	A/G	cg10246903	chr13:45222710	NA	0.72	6.36	0.38	9.83e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs10128251	0.962	rs4748018	chr10:5711507	T/A	cg11519256	chr10:5708881	ASB13	0.47	5.93	0.35	9.94e-9	Childhood ear infection;
KIRP	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg19752551	chr11:57585705	CTNND1	-0.82	-13.6	-0.66	8.79e-32	Schizophrenia;
KIRP	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.53	-7.53	-0.43	9.87e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08905701	chr5:35232164	PRLR	0.51	6.27	0.37	1.59e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6545883	0.929	rs6707830	chr2:61749472	G/A	cg15711740	chr2:61764176	XPO1	-0.58	-7.96	-0.45	6.3e-14	Tuberculosis;
KIRP	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg08501292	chr6:25962987	TRIM38	1.06	8.25	0.47	9.54e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.45	-6.98	-0.41	2.8e-11	Inflammatory bowel disease;
KIRP	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg17366294	chr4:99064904	C4orf37	0.42	5.96	0.36	8.68e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4356932	0.656	rs13111710	chr4:76859705	C/G	cg19388996	chr4:76862389	NAAA	-0.42	-5.36	-0.32	1.96e-7	Blood protein levels;
KIRP	trans	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg13565492	chr6:43139072	SRF	-0.97	-8.92	-0.49	1.1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg06026331	chr20:60912101	LAMA5	-0.48	-6.43	-0.38	6.56e-10	Colorectal cancer;
KIRP	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg05785598	chr3:49045655	WDR6	0.27	4.89	0.3	1.83e-6	Parkinson's disease;
KIRP	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.46	-0.38	5.46e-10	Menopause (age at onset);
KIRP	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg06640241	chr16:89574553	SPG7	0.68	9.29	0.51	8.43e-18	Multiple myeloma (IgH translocation);
KIRP	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.72	10.23	0.55	1.09e-20	Mood instability;
KIRP	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg22633769	chr20:60982531	CABLES2	-0.51	-6.32	-0.37	1.2e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2278796	0.697	rs4951150	chr1:204952849	C/A	cg04862289	chr1:204966208	NFASC	0.39	5.56	0.33	7.15e-8	Mean platelet volume;
KIRP	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.67	-10.1	-0.54	2.67e-20	Hepatocellular carcinoma;
KIRP	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.85	11.29	0.58	4.2e-24	Type 2 diabetes;
KIRP	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05665937	chr4:1216051	CTBP1	0.44	6.15	0.36	3.14e-9	Obesity-related traits;
KIRP	cis	rs10782582	0.609	rs946163	chr1:76383049	A/G	cg10523679	chr1:76189770	ACADM	0.48	6.42	0.38	6.87e-10	Daytime sleep phenotypes;
KIRP	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.42	-5.08	-0.31	7.48e-7	Neuroticism;
KIRP	cis	rs3736594	0.513	rs59876138	chr2:27792323	A/C	cg27432699	chr2:27873401	GPN1	0.55	6.15	0.36	3.14e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg22655038	chr22:31477112	SMTN	0.54	6.68	0.39	1.62e-10	DNA methylation (variation);
KIRP	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.39	-4.99	-0.3	1.15e-6	IgG glycosylation;
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02398342	chr17:80708632	TBCD;FN3K	0.5	6.07	0.36	4.82e-9	Glycated hemoglobin levels;
KIRP	cis	rs593254	0.735	rs735858	chr6:164393134	G/C	cg00040411	chr6:164393165	NA	-0.45	-5.14	-0.31	5.7e-7	Gestational age at birth in labor-initiated deliveries (maternal effect);
KIRP	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.61	5.02	0.3	1.01e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.44	5.57	0.33	6.56e-8	Gout;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg17524854	chr12:67663046	CAND1	0.47	6.06	0.36	5.07e-9	Asthma;
KIRP	cis	rs4141404	0.740	rs9609301	chr22:31895940	C/T	cg02404636	chr22:31891804	SFI1	0.54	5.92	0.35	1.06e-8	Paclitaxel-induced neuropathy;
KIRP	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.95	-0.35	9.35e-9	Breast cancer;
KIRP	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.62	-6.19	-0.37	2.44e-9	Body mass index;
KIRP	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.68	8.94	0.5	9.39e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.46	-0.33	1.14e-7	Schizophrenia (age at onset);
KIRP	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.64	7.46	0.43	1.52e-12	Bone mineral density;
KIRP	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg05552183	chr6:42928497	GNMT	0.54	6.74	0.39	1.15e-10	Blood protein levels;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.83	7.77	0.44	2.11e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.35	-5.49	-0.33	1.02e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg07884673	chr3:53033167	SFMBT1	0.57	5.42	0.33	1.4e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.59e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg04691961	chr3:161091175	C3orf57	-0.39	-5.39	-0.32	1.65e-7	Parkinson's disease;
KIRP	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.03	0.41	2.09e-11	Bipolar disorder;
KIRP	cis	rs6433857	0.536	rs1542035	chr2:181351114	T/C	cg23363182	chr2:181467187	NA	-0.37	-5.25	-0.32	3.32e-7	Body mass index;
KIRP	trans	rs909341	0.909	rs1291207	chr20:62329412	G/A	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.4	-0.43	2.16e-12	Atopic dermatitis;
KIRP	cis	rs16857609	0.564	rs3732009	chr2:218291393	G/A	cg15335768	chr2:218268053	DIRC3	-0.53	-6.95	-0.4	3.34e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs12693043	0.967	rs2358639	chr2:175372957	A/G	cg11778734	chr2:175439522	WIPF1	-0.41	-5.03	-0.31	9.34e-7	Urate levels (BMI interaction);
KIRP	cis	rs6546886	0.957	rs11886928	chr2:74258529	T/G	cg14702570	chr2:74259524	NA	-0.33	-6.74	-0.39	1.1e-10	Dialysis-related mortality;
KIRP	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg16512390	chr1:228756714	NA	0.74	6.08	0.36	4.55e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs76533333	0.646	rs71446623	chr13:113374732	C/T	cg04656015	chr13:113407548	ATP11A	0.6	5.17	0.31	4.78e-7	Red cell distribution width;
KIRP	cis	rs6076065	0.683	rs2424557	chr20:23422159	C/G	cg26790198	chr20:23419120	CSTL1	0.35	5.22	0.32	3.89e-7	Facial morphology (factor 15, philtrum width);
KIRP	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg01721255	chr8:58191610	C8orf71	0.52	5.1	0.31	6.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	1.04	20.21	0.79	3.47e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.82	11.71	0.6	1.87e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.26	-0.37	1.69e-9	Coronary artery disease;
KIRP	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.43	-5.38	-0.32	1.75e-7	Aortic root size;
KIRP	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.27	-5.6	-0.34	5.73e-8	Menarche (age at onset);
KIRP	cis	rs963731	0.649	rs3765058	chr2:39189636	A/G	cg04010122	chr2:39346883	SOS1	0.77	4.99	0.3	1.15e-6	Corticobasal degeneration;
KIRP	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg12163867	chr12:51592794	POU6F1	-0.44	-5.52	-0.33	8.58e-8	Cisplatin-induced ototoxicity;
KIRP	cis	rs7771547	0.607	rs632943	chr6:36469121	A/G	cg04289385	chr6:36355825	ETV7	0.44	6.83	0.4	6.54e-11	Platelet distribution width;
KIRP	cis	rs8084125	0.935	rs7238336	chr18:74953540	A/G	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs9826463	0.582	rs73238158	chr3:142078215	G/A	cg20824294	chr3:142316082	PLS1	0.41	6.08	0.36	4.65e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg08992911	chr2:238395768	MLPH	0.42	5.35	0.32	2e-7	Prostate cancer;
KIRP	cis	rs17321999	1.000	rs1001204	chr2:30478779	A/G	cg05247661	chr2:30472410	LBH	0.65	7.46	0.43	1.52e-12	Systemic lupus erythematosus;
KIRP	cis	rs76793172	0.660	rs3760843	chr19:46288706	A/T	cg00442267	chr19:46317840	RSPH6A	-0.61	-5.44	-0.33	1.26e-7	Eosinophil counts;
KIRP	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	0.78	6.72	0.39	1.25e-10	Breast cancer;
KIRP	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.98	10.44	0.55	2.31e-21	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.54	7.61	0.44	5.84e-13	Dupuytren's disease;
KIRP	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.56	0.39	3.18e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.87	14.86	0.69	4.55e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs787274	1.000	rs4979165	chr9:115609539	T/C	cg13803584	chr9:115635662	SNX30	-0.74	-6.45	-0.38	5.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.87	-0.35	1.42e-8	Body mass index;
KIRP	cis	rs7520050	0.966	rs11211208	chr1:46334256	A/C	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.21e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.44	-0.52	2.91e-18	Gut microbiome composition (summer);
KIRP	cis	rs2712184	0.756	rs2712182	chr2:217647525	T/C	cg05032264	chr2:217675019	NA	-0.47	-6.84	-0.4	6.39e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.67	9.91	0.53	1.09e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.66	9.31	0.51	7.28e-18	Prostate cancer;
KIRP	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg09579323	chr1:150459698	TARS2	0.4	5.04	0.31	9.22e-7	Migraine;
KIRP	cis	rs4356932	1.000	rs7665152	chr4:76960205	T/G	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	6.22	0.37	2.15e-9	Menarche (age at onset);
KIRP	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg00343986	chr7:65444356	GUSB	0.42	5.16	0.31	5.18e-7	Aortic root size;
KIRP	trans	rs2504916	0.784	rs2484241	chr6:160771618	G/A	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	0.59	6.18	0.37	2.71e-9	Response to hepatitis C treatment;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15877295	chr7:138915876	UBN2	0.59	7.16	0.42	9.3e-12	Smoking initiation;
KIRP	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.96	-12.35	-0.62	1.35e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17554472	chr22:41940697	POLR3H	-0.6	-6.42	-0.38	7.04e-10	Vitiligo;
KIRP	cis	rs1950626	0.699	rs12880424	chr14:101459660	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.62	6.36	0.38	9.55e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.5	-6.51	-0.38	4.2e-10	Coronary artery disease;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-8.74	-0.49	3.67e-16	Renal function-related traits (BUN);
KIRP	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	0.73	7.5	0.43	1.14e-12	Prostate cancer;
KIRP	trans	rs7939886	0.920	rs12224086	chr11:55798259	G/T	cg03929089	chr4:120376271	NA	0.95	7.05	0.41	1.75e-11	Myopia (pathological);
KIRP	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.89	13.33	0.65	7.2e-31	Mean platelet volume;
KIRP	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.05	0.75	6.05e-47	Chronic sinus infection;
KIRP	cis	rs4805272	0.962	rs7257609	chr19:29323352	C/T	cg15000279	chr19:29285009	NA	-0.37	-5.36	-0.32	1.89e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.52	6.08	0.36	4.61e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg10305451	chr2:177043427	NA	0.5	6.79	0.4	8.42e-11	IgG glycosylation;
KIRP	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.09	-0.31	7e-7	Blood metabolite levels;
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.35	-5.09	-0.31	7.18e-7	Lymphocyte counts;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg05528293	chr18:74961138	GALR1	0.47	5.1	0.31	6.95e-7	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs12693043	0.764	rs13006261	chr2:175404695	G/A	cg11778734	chr2:175439522	WIPF1	-0.52	-7.19	-0.42	7.58e-12	Urate levels (BMI interaction);
KIRP	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.47	0.7	3.72e-38	Chronic sinus infection;
KIRP	cis	rs12134245	0.874	rs61798047	chr1:92016934	C/T	cg02896835	chr1:92012615	NA	-0.57	-7.4	-0.43	2.12e-12	Breast cancer;
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12697442	chr11:101981167	YAP1	0.46	6.59	0.39	2.64e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17095355	1.000	rs2419313	chr10:111750851	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.63	-0.34	4.85e-8	Biliary atresia;
KIRP	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.38	7.17	0.42	8.82e-12	Monocyte percentage of white cells;
KIRP	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg22089800	chr15:90895588	ZNF774	0.44	5.25	0.32	3.37e-7	Rheumatoid arthritis;
KIRP	cis	rs6952809	1.000	rs6952809	chr7:2448493	T/C	cg06995285	chr7:2418615	EIF3B	0.37	4.95	0.3	1.35e-6	Multiple sclerosis;
KIRP	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	1.99e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg08632701	chr21:37451849	NA	-0.5	-6.19	-0.37	2.46e-9	Mitral valve prolapse;
KIRP	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.48	-0.38	4.93e-10	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13409248	chr3:40428643	ENTPD3	0.39	5.09	0.31	7.13e-7	Renal cell carcinoma;
KIRP	cis	rs4764124	0.571	rs11830399	chr12:14956932	G/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.54	7.68	0.44	3.77e-13	Pubertal anthropometrics;
KIRP	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.26	0.42	5.06e-12	Lung cancer;
KIRP	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg25173405	chr17:45401733	C17orf57	-0.5	-6.55	-0.39	3.3e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg08975724	chr8:8085496	FLJ10661	0.68	8.96	0.5	8.57e-17	Mood instability;
KIRP	cis	rs7546668	1.000	rs4646068	chr1:15828704	T/C	cg21858823	chr1:15850916	CASP9	0.46	5.1	0.31	6.64e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.54	7.36	0.42	2.74e-12	HDL cholesterol;
KIRP	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27087555	chr16:88793112	FAM38A	-1.07	-6.68	-0.39	1.54e-10	Hair color;
KIRP	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.78e-11	Electroencephalogram traits;
KIRP	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.58	6.42	0.38	7.16e-10	Alcohol dependence;
KIRP	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.52	6.29	0.37	1.45e-9	Uric acid levels;
KIRP	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg05347473	chr6:146136440	FBXO30	-0.6	-8.67	-0.48	5.9e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg18154014	chr19:37997991	ZNF793	0.68	6.1	0.36	4.08e-9	Coronary artery calcification;
KIRP	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.32	-0.47	6.28e-15	Mood instability;
KIRP	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	0.93	11.14	0.58	1.32e-23	Corneal structure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09747230	chr5:43613142	NNT	0.56	7.07	0.41	1.55e-11	Interleukin-4 levels;
KIRP	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-5.92	-0.35	1.07e-8	Lung cancer;
KIRP	cis	rs2865126	0.818	rs2865128	chr18:10764029	A/G	cg21165219	chr18:10698044	FAM38B	-0.55	-5.19	-0.31	4.32e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
KIRP	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.75	-0.34	2.65e-8	Neutrophil percentage of white cells;
KIRP	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg00204512	chr16:28754710	NA	0.44	5.81	0.35	1.97e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.85	9.9	0.53	1.13e-19	Corneal structure;
KIRP	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.75	-7.6	-0.44	6.22e-13	Gut microbiome composition (summer);
KIRP	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.71	0.34	3.2e-8	Renal cell carcinoma;
KIRP	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-7.53	-0.43	9.37e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg04310649	chr10:35416472	CREM	0.57	6.63	0.39	2.12e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg09631192	chr20:23583594	CST9	-0.52	-5.2	-0.31	4.27e-7	Chronic kidney disease;
KIRP	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg00933542	chr6:150070202	PCMT1	0.27	5.06	0.31	8.27e-7	Testicular germ cell tumor;
KIRP	cis	rs6593803	0.601	rs10458586	chr1:147288094	C/G	cg27546670	chr1:147246839	GJA5	0.44	5.54	0.33	7.75e-8	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg10047753	chr17:41438598	NA	1.17	19.34	0.78	2.71e-51	Menopause (age at onset);
KIRP	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05347473	chr6:146136440	FBXO30	-0.63	-9.21	-0.51	1.48e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7546094	0.905	rs12046208	chr1:113171589	C/T	cg22162597	chr1:113214053	CAPZA1	-0.42	-5.56	-0.33	7.06e-8	Platelet distribution width;
KIRP	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.98	-0.45	5.66e-14	Bone mineral density;
KIRP	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.73e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	6.04	0.36	5.65e-9	Total body bone mineral density;
KIRP	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.32	0.62	1.76e-27	Platelet count;
KIRP	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.92	-5.66	-0.34	4.26e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.8	9.16	0.5	2.1e-17	Response to diuretic therapy;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg27532560	chr4:187881888	NA	-0.75	-12.68	-0.63	1.13e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg02297831	chr4:17616191	MED28	0.55	6.89	0.4	4.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.05	19.26	0.78	4.97e-51	Testicular germ cell tumor;
KIRP	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.42	5.6	0.34	5.71e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs2692947	0.673	rs4907299	chr2:96780122	G/T	cg23100626	chr2:96804247	ASTL	0.52	7.19	0.42	7.7e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.9	-0.3	1.71e-6	Coronary artery disease;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21016266	chr12:122356598	WDR66	0.61	8.29	0.47	7.38e-15	Mean corpuscular volume;
KIRP	cis	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg08773314	chr2:239334832	ASB1	-0.53	-5.36	-0.32	1.95e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs36715	1.000	rs251386	chr5:127547298	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.86	0.49	1.63e-16	Breast cancer;
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg09455208	chr3:40491958	NA	-0.35	-6.21	-0.37	2.27e-9	Renal cell carcinoma;
KIRP	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.81	0.45	1.7e-13	Iron status biomarkers;
KIRP	cis	rs2970992	0.817	rs2137670	chr2:101330834	G/T	cg01042948	chr2:101319752	NA	0.42	6.03	0.36	5.83e-9	Educational attainment;
KIRP	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs4453791	0.656	rs62242262	chr3:38937383	C/A	cg23654821	chr3:39188656	CSRNP1	0.48	4.89	0.3	1.84e-6	Social communication problems;
KIRP	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg18764771	chr6:116381957	FRK	0.19	5.13	0.31	5.76e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.4	-0.47	3.57e-15	Total cholesterol levels;
KIRP	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.74	-7.84	-0.45	1.37e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs9308433	0.529	rs59864830	chr1:214474889	A/G	cg06198575	chr1:214491504	SMYD2	0.56	7.07	0.41	1.57e-11	IgG glycosylation;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg10207240	chr12:122356781	WDR66	0.58	7.58	0.44	7.1e-13	Mean corpuscular volume;
KIRP	cis	rs7113874	0.578	rs34059271	chr11:8567858	T/C	cg08015107	chr11:8618950	NA	-0.72	-8.78	-0.49	2.81e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.77	9.79	0.53	2.49e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7179456	0.513	rs640704	chr15:59049021	A/G	cg05156742	chr15:59063176	FAM63B	0.55	6.88	0.4	4.91e-11	Asperger disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11766498	chr21:40817540	SH3BGR;LCA5L	0.5	6.52	0.38	3.87e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg14683738	chr19:37701593	ZNF585B	0.5	5.12	0.31	6.23e-7	Coronary artery calcification;
KIRP	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs12580194	0.593	rs61957884	chr12:55720177	A/G	cg19537932	chr12:55886519	OR6C68	-0.47	-6.07	-0.36	4.76e-9	Cancer;
KIRP	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.86	-0.4	5.45e-11	Aortic root size;
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg16590910	chr6:42928470	GNMT	0.42	5.89	0.35	1.27e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg00094735	chr5:1949198	NA	0.48	5.77	0.35	2.43e-8	Gut microbiome composition (winter);
KIRP	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.83	12.55	0.62	2.94e-28	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.72	-5.21	-0.32	4.03e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.11	0.54	2.48e-20	Total body bone mineral density;
KIRP	cis	rs7572644	0.699	rs10175508	chr2:28213424	C/T	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.43	6.29	0.37	1.45e-9	Sense of smell;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg06212747	chr3:49208901	KLHDC8B	0.5	4.99	0.3	1.12e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg20673091	chr1:2541236	MMEL1	0.67	10.05	0.54	3.8e-20	Ulcerative colitis;
KIRP	cis	rs10875746	0.903	rs10875738	chr12:48473739	T/A	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-6.19	-0.37	2.46e-9	Educational attainment (years of education);
KIRP	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.76	11.29	0.58	4.2e-24	Mood instability;
KIRP	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg18944383	chr4:111397179	ENPEP	-0.61	-11.16	-0.58	1.18e-23	Coronary artery disease;
KIRP	cis	rs9962915	1.000	rs1719944	chr18:5596603	A/G	cg12967001	chr18:5544089	EPB41L3	-0.43	-5.21	-0.31	4.09e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg27124370	chr19:33622961	WDR88	0.6	7.43	0.43	1.84e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg04733989	chr22:42467013	NAGA	0.58	7.23	0.42	6.04e-12	Cognitive function;
KIRP	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.28	5.74	0.34	2.83e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7005380	0.556	rs4073559	chr8:120917443	G/C	cg21645572	chr8:120931649	DEPDC6	0.44	5.3	0.32	2.62e-7	Interstitial lung disease;
KIRP	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.59	0.44	6.5e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg09264619	chr17:80180166	NA	-0.52	-6.0	-0.36	6.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18159324	chr12:52463368	C12orf44	0.54	6.13	0.36	3.48e-9	Lung cancer in ever smokers;
KIRP	cis	rs7084402	0.555	rs7069916	chr10:60271824	A/G	cg05938607	chr10:60274200	BICC1	-0.27	-5.61	-0.34	5.44e-8	Refractive error;
KIRP	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	1.11	10.25	0.55	9.48e-21	Lymphocyte percentage of white cells;
KIRP	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.67	-9.26	-0.51	1.03e-17	Huntington's disease progression;
KIRP	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.37	5.11	0.31	6.6e-7	Coronary artery disease;
KIRP	cis	rs11628318	0.906	rs2403064	chr14:103053483	G/A	cg12046867	chr14:103022105	NA	-0.47	-6.44	-0.38	6.29e-10	Platelet count;
KIRP	cis	rs9400467	0.537	rs12213248	chr6:111499394	G/C	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs17030434	0.784	rs6835640	chr4:154650494	C/T	cg14289246	chr4:154710475	SFRP2	-0.6	-7.69	-0.44	3.47e-13	Electrocardiographic conduction measures;
KIRP	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg16558253	chr16:72132732	DHX38	-0.4	-5.43	-0.33	1.36e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs57994353	0.570	rs10870139	chr9:139303269	G/A	cg14169450	chr9:139327907	INPP5E	0.56	6.04	0.36	5.6e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05601917	chr6:125855416	NA	-0.34	-4.95	-0.3	1.38e-6	Brugada syndrome;
KIRP	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg02344993	chr17:57696989	CLTC	0.51	5.1	0.31	6.73e-7	Hemoglobin concentration;
KIRP	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg05315796	chr3:52349193	DNAH1	0.45	6.86	0.4	5.54e-11	Bipolar disorder;
KIRP	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg13880726	chr7:1868755	MAD1L1	0.52	6.13	0.36	3.42e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg23422044	chr7:1970798	MAD1L1	-0.71	-7.1	-0.41	1.33e-11	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18191418	chr3:128336579	NA	0.46	6.75	0.4	1.07e-10	Survival in pancreatic cancer;
KIRP	cis	rs12447804	0.734	rs9926693	chr16:58097357	C/T	cg03859792	chr16:58121049	NA	-0.41	-5.74	-0.34	2.78e-8	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16083429	chr3:49237500	CCDC36	-0.38	-4.94	-0.3	1.44e-6	Menarche (age at onset);
KIRP	cis	rs17221829	0.733	rs12281810	chr11:89409595	C/T	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.46	-0.33	1.18e-7	Anxiety in major depressive disorder;
KIRP	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg25838818	chr2:108905173	SULT1C2	-0.49	-7.07	-0.41	1.55e-11	Blood pressure;
KIRP	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg20887711	chr4:1340912	KIAA1530	-0.45	-5.55	-0.33	7.3900000000000007e-08	Obesity-related traits;
KIRP	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.56	8.23	0.46	1.1e-14	Reticulocyte fraction of red cells;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16917537	chr7:73098262	DNAJC30;WBSCR22	0.56	6.05	0.36	5.29e-9	Lung cancer in ever smokers;
KIRP	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.01	-0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg16497661	chr14:103986332	CKB	0.76	11.35	0.59	2.73e-24	Body mass index;
KIRP	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.26	0.37	1.73e-9	Rheumatoid arthritis;
KIRP	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.66	-8.77	-0.49	3.04e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14159672	chr1:205819179	PM20D1	0.5	5.5	0.33	9.33e-8	Parkinson's disease;
KIRP	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.67	-11.6	-0.59	4.19e-25	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2742417	0.532	rs2742424	chr3:45735218	A/G	cg04037228	chr3:45636386	LIMD1	-0.42	-5.56	-0.33	6.89e-8	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.26	-0.42	4.92e-12	Retinal vascular caliber;
KIRP	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18252515	chr7:66147081	NA	0.46	5.32	0.32	2.3e-7	Aortic root size;
KIRP	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.58	-0.39	2.84e-10	Uric acid levels;
KIRP	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.59	-0.39	2.65e-10	QT interval;
KIRP	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.75	6.87	0.4	5.3e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg02023728	chr11:77925099	USP35	-0.31	-5.52	-0.33	8.62e-8	Alzheimer's disease (survival time);
KIRP	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.05	-0.31	8.43e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg16586182	chr3:47516702	SCAP	0.79	10.09	0.54	2.95e-20	Colorectal cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22995486	chr5:75592299	SV2C	0.48	6.54	0.38	3.47e-10	Interleukin-4 levels;
KIRP	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg00507259	chr4:95128692	SMARCAD1	0.41	5.31	0.32	2.42e-7	QT interval;
KIRP	cis	rs754423	0.582	rs730532	chr14:52518811	G/A	cg10149976	chr14:52535953	NID2	-0.37	-4.88	-0.3	1.89e-6	Craniofacial microsomia;
KIRP	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.22e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2299587	0.762	rs10094922	chr8:17750200	T/C	cg01800426	chr8:17659068	MTUS1	-0.46	-5.21	-0.32	4.03e-7	Economic and political preferences;
KIRP	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	trans	rs6596140	0.620	rs11242172	chr5:133030002	A/G	cg08567913	chr11:114082594	ZBTB16	-0.43	-6.08	-0.36	4.55e-9	Hypertension;
KIRP	cis	rs4664293	0.967	rs1346325	chr2:160542506	C/T	cg08347373	chr2:160653686	CD302	-0.39	-6.05	-0.36	5.4e-9	Monocyte percentage of white cells;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg10254082	chr7:997346	NA	0.48	5.07	0.31	7.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.47	6.44	0.38	6.05e-10	Childhood ear infection;
KIRP	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-7.43	-0.43	1.79e-12	Schizophrenia;
KIRP	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg08499158	chr17:42289980	UBTF	0.67	8.72	0.49	4.19e-16	Total body bone mineral density;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg08132940	chr7:1081526	C7orf50	-0.58	-6.29	-0.37	1.46e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6901004	0.839	rs783086	chr6:111561713	G/A	cg15721981	chr6:111408429	SLC16A10	-0.52	-6.96	-0.41	3.12e-11	Blood metabolite levels;
KIRP	cis	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg16898833	chr6:26189333	HIST1H4D	0.81	5.92	0.35	1.07e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1941687	0.764	rs1493915	chr18:31377582	G/T	cg04226714	chr8:49833948	SNAI2	-0.5	-6.98	-0.41	2.68e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs4776059	1.000	rs4776068	chr15:52947401	G/A	cg25063058	chr15:52860530	ARPP19	0.58	6.35	0.38	1.02e-9	Schizophrenia;
KIRP	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6450176	0.564	rs401449	chr5:53326735	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-8.64	-0.48	7.09e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.1e-11	Obesity-related traits;
KIRP	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg12435725	chr3:58293450	RPP14	-0.46	-5.18	-0.31	4.68e-7	Cholesterol, total;
KIRP	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.44e-9	Mean platelet volume;
KIRP	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg01879757	chr17:41196368	BRCA1	-0.56	-7.52	-0.43	1.04e-12	Menopause (age at onset);
KIRP	cis	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.44	-5.46	-0.33	1.15e-7	Leprosy;
KIRP	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.87	-0.35	1.37e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg24511898	chr2:242576823	ATG4B;THAP4	0.53	6.15	0.37	3.16e-9	Sleep duration;
KIRP	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-5.04	-0.31	8.86e-7	Heart rate;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07395436	chr1:219383604	LYPLAL1	0.42	6.74	0.39	1.14e-10	C-reactive protein;
KIRP	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.8	9.51	0.52	1.86e-18	Red cell distribution width;
KIRP	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.61	8.69	0.48	5.06e-16	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10994681	chr11:31672091	ELP4	-0.39	-6.03	-0.36	6.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg09579323	chr1:150459698	TARS2	0.4	5.07	0.31	7.86e-7	Migraine;
KIRP	cis	rs9381107	0.932	rs16892279	chr6:9483186	A/G	cg14735645	chr6:9486422	NA	-0.55	-6.8	-0.4	7.93e-11	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs514024	0.665	rs3739812	chr9:130495890	A/C	cg13643465	chr9:130375613	STXBP1	0.45	5.93	0.35	1.02e-8	Eating disorders (purging via substances);
KIRP	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.71	9.51	0.52	1.85e-18	Systolic blood pressure;
KIRP	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	7.33	0.42	3.38e-12	Neuroticism;
KIRP	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	1.12	16.01	0.71	5.33e-40	Breast cancer;
KIRP	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.81	6.59	0.39	2.63e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg24874828	chr4:187887005	NA	-0.47	-7.01	-0.41	2.28e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.47	7.17	0.42	8.55e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg22117172	chr7:91764530	CYP51A1	-0.43	-6.13	-0.36	3.38e-9	Breast cancer;
KIRP	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.06	0.36	5.19e-9	Total cholesterol levels;
KIRP	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14169450	chr9:139327907	INPP5E	0.55	6.4	0.38	7.98e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	7.63	0.44	5.09e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg27170947	chr2:26402098	FAM59B	-0.46	-5.47	-0.33	1.11e-7	Gut microbiome composition (summer);
KIRP	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.83	12.5	0.62	4.38e-28	Body mass index;
KIRP	cis	rs11638815	0.626	rs4779039	chr15:83317767	C/G	cg06066596	chr15:83166174	LOC80154	0.41	4.89	0.3	1.8e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
KIRP	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg16672083	chr15:72433130	SENP8	0.42	5.92	0.35	1.09e-8	Red blood cell count;
KIRP	cis	rs787274	1.000	rs787298	chr9:115542206	C/T	cg13803584	chr9:115635662	SNX30	-0.73	-8.28	-0.47	7.7e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-16.01	-0.71	5.21e-40	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.78	-0.35	2.24e-8	Bipolar disorder;
KIRP	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg00405596	chr8:11794950	NA	-0.49	-6.41	-0.38	7.24e-10	Joint mobility (Beighton score);
KIRP	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.57	-6.77	-0.4	9.38e-11	White matter hyperintensity burden;
KIRP	cis	rs17021463	0.807	rs6847989	chr4:95277099	A/C	cg11021082	chr4:95130006	SMARCAD1	0.39	4.95	0.3	1.37e-6	Testicular germ cell tumor;
KIRP	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg13256891	chr4:100009986	ADH5	0.52	6.58	0.39	2.79e-10	Alcohol dependence;
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.39	-0.32	1.69e-7	Obesity-related traits;
KIRP	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15557168	chr22:42548783	NA	-0.42	-5.66	-0.34	4.11e-8	Cognitive function;
KIRP	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23161317	chr6:28129485	ZNF389	0.48	5.77	0.35	2.33e-8	Depression;
KIRP	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.64	8.9	0.49	1.22e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13198984	chr17:80129470	CCDC57	0.56	8.52	0.48	1.65e-15	Life satisfaction;
KIRP	cis	rs7179456	0.517	rs7167872	chr15:59271375	T/C	cg05156742	chr15:59063176	FAM63B	0.42	5.2	0.31	4.23e-7	Asperger disorder;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg05025164	chr4:1340916	KIAA1530	0.47	5.67	0.34	3.93e-8	Obesity-related traits;
KIRP	cis	rs26949	0.526	rs10058456	chr5:60037941	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.35	-0.32	2.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7818345	1.000	rs11204041	chr8:19291371	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.4	5.8	0.35	1.99e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg10254082	chr7:997346	NA	0.48	5.23	0.32	3.71e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.43	5.49	0.33	9.82e-8	Motion sickness;
KIRP	cis	rs58785573	0.513	rs3980	chr4:38593192	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.88	0.3	1.94e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs3744061	0.557	rs4261576	chr17:74648486	G/T	cg27546012	chr17:74684504	MXRA7	0.44	5.33	0.32	2.19e-7	Retinal arteriolar caliber;
KIRP	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.68	6.33	0.37	1.14e-9	Schizophrenia;
KIRP	cis	rs1519814	0.956	rs4871040	chr8:121131611	A/G	cg22335954	chr8:121166405	COL14A1	-0.61	-6.19	-0.37	2.45e-9	Breast cancer;
KIRP	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.13	-0.31	5.92e-7	Breast cancer;
KIRP	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.61	8.68	0.48	5.61e-16	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg10505658	chr17:80084571	CCDC57	-0.26	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-11.25	-0.58	5.76e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg11814155	chr7:99998594	ZCWPW1	0.58	5.41	0.33	1.53e-7	Platelet count;
KIRP	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.46	0.47	2.41e-15	Prudent dietary pattern;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25817788	chr6:21589024	NA	0.54	6.3	0.37	1.37e-9	Smoking initiation;
KIRP	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4843185	0.763	rs9534	chr16:85711502	C/T	cg26571870	chr16:85723150	GINS2	0.41	4.99	0.3	1.12e-6	Platelet distribution width;
KIRP	cis	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg10239186	chr6:166756509	SFT2D1	0.4	5.06	0.31	8.21e-7	Asthma;
KIRP	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.74	11.7	0.6	1.91e-25	Calcium levels;
KIRP	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg12560992	chr17:57184187	TRIM37	0.63	6.74	0.39	1.13e-10	Testicular germ cell tumor;
KIRP	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.74	10.68	0.56	3.87e-22	Hip circumference;
KIRP	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg22852734	chr6:133119734	C6orf192	1.21	11.18	0.58	9.66e-24	Type 2 diabetes nephropathy;
KIRP	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.86	-0.3	2.1e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	0.97	16.23	0.72	9.51e-41	Testicular germ cell tumor;
KIRP	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.47	-5.88	-0.35	1.33e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.45	-11.2	-0.58	8.63e-24	Diabetic kidney disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg26164735	chr4:71768712	MOBKL1A	0.75	6.27	0.37	1.58e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg15556689	chr8:8085844	FLJ10661	0.7	9.17	0.5	1.97e-17	Mood instability;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.79	9.13	0.5	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10654737	chr15:25655057	UBE3A	0.54	7.36	0.42	2.79e-12	Interleukin-4 levels;
KIRP	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-1.05	-7.07	-0.41	1.63e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.39	9.56	0.52	1.29e-18	Corneal astigmatism;
KIRP	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg25902810	chr10:99078978	FRAT1	0.61	7.8	0.45	1.8e-13	Monocyte count;
KIRP	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.6	-0.44	6.36e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.25	-0.32	3.26e-7	Pulmonary function;
KIRP	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg20991723	chr1:152506922	NA	-0.45	-5.34	-0.32	2.07e-7	Hair morphology;
KIRP	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	9.48	0.52	2.23e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.61	7.43	0.43	1.77e-12	Corneal astigmatism;
KIRP	trans	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg02030672	chr11:45687055	CHST1	0.63	8.21	0.46	1.29e-14	Obesity-related traits;
KIRP	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-5.13	-0.31	5.89e-7	Lung cancer;
KIRP	cis	rs16976116	0.901	rs28535372	chr15:55500602	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg00491522	chr10:135256596	NA	0.56	5.98	0.36	7.67e-9	Systemic lupus erythematosus;
KIRP	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg25358565	chr5:93447407	FAM172A	-0.57	-6.47	-0.38	5.33e-10	Diabetic retinopathy;
KIRP	cis	rs17123764	0.786	rs57291131	chr12:50155113	C/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.5	0.33	9.61e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.11	0.31	6.41e-7	Cognitive test performance;
KIRP	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.79	11.28	0.58	4.57e-24	Bladder cancer;
KIRP	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17691542	chr6:26056736	HIST1H1C	0.53	6.63	0.39	2.08e-10	Height;
KIRP	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-8.76	-0.49	3.33e-16	Asthma;
KIRP	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg02336718	chr17:17403227	NA	-0.35	-5.49	-0.33	1.01e-7	Total body bone mineral density;
KIRP	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg20701182	chr2:24300061	SF3B14	0.46	4.92	0.3	1.59e-6	Asthma;
KIRP	cis	rs6466055	0.661	rs66790006	chr7:104882025	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.04	0.31	9.17e-7	Schizophrenia;
KIRP	cis	rs13161895	1.000	rs27012	chr5:179402211	A/C	cg02702477	chr5:179499311	RNF130	0.69	5.28	0.32	2.82e-7	LDL cholesterol;
KIRP	cis	rs4281086	0.544	rs6601476	chr8:10355179	C/G	cg21775007	chr8:11205619	TDH	0.43	5.53	0.33	8.1e-8	Obesity-related traits;
KIRP	cis	rs1978968	1.000	rs5992919	chr22:18443855	A/G	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4141404	0.604	rs2103853	chr22:31855475	T/C	cg02404636	chr22:31891804	SFI1	0.48	6.22	0.37	2.13e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg17294928	chr15:75287854	SCAMP5	-0.66	-5.87	-0.35	1.44e-8	Lung cancer;
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-6.04	-0.36	5.67e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg11569703	chr11:65557185	OVOL1	0.5	7.6	0.44	6.12e-13	Breast cancer;
KIRP	cis	rs13014235	0.532	rs11681592	chr2:202263901	C/G	cg06431681	chr2:202330990	STRADB	0.39	5.27	0.32	2.95e-7	Basal cell carcinoma;
KIRP	cis	rs4006360	0.575	rs6416909	chr17:39235389	A/G	cg15015397	chr17:39261100	KRTAP4-9	0.53	7.59	0.44	6.44e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg02175503	chr12:58329896	NA	0.53	6.04	0.36	5.67e-9	Multiple sclerosis;
KIRP	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.86	-12.21	-0.61	4.14e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg07423050	chr13:99094983	FARP1	0.31	5.1	0.31	6.95e-7	Longevity;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg11317019	chr17:42219250	C17orf53	0.49	6.07	0.36	4.78e-9	Asthma;
KIRP	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.65	-8.82	-0.49	2.16e-16	Aortic root size;
KIRP	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.6	-0.52	1e-18	Neuroticism;
KIRP	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.43	-6.24	-0.37	1.94e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg00614314	chr15:82944287	LOC80154	-0.54	-6.12	-0.36	3.6e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.81	-9.77	-0.53	2.82e-19	Body mass index;
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	16.77	0.73	1.33e-42	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21384718	chr1:21503451	EIF4G3	0.48	6.43	0.38	6.44e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg19913688	chr11:428466	ANO9	-0.76	-5.76	-0.34	2.56e-8	Body mass index;
KIRP	cis	rs2594989	0.943	rs1391903	chr3:11423271	C/G	cg01796438	chr3:11312864	ATG7	0.61	7.6	0.44	6.37e-13	Circulating chemerin levels;
KIRP	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.55	-0.39	3.41e-10	Diastolic blood pressure;
KIRP	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	0.701	rs9618179	chr22:18476909	C/T	cg03078520	chr22:18463400	MICAL3	-0.6	-7.64	-0.44	4.69e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs6466055	0.720	rs7800928	chr7:105007470	T/C	cg04380332	chr7:105027541	SRPK2	-0.63	-9.31	-0.51	7.24e-18	Schizophrenia;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-8.69	-0.48	5.2e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.69	-7.78	-0.44	1.94e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg17845761	chr1:175162550	KIAA0040	0.33	6.55	0.39	3.35e-10	Alcohol dependence;
KIRP	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.88	-13.41	-0.65	3.68e-31	Body mass index;
KIRP	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-5.03	-0.31	9.42e-7	Schizophrenia;
KIRP	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.65	-8.16	-0.46	1.77e-14	Breast cancer;
KIRP	cis	rs4664293	0.801	rs7589771	chr2:160584132	C/T	cg08347373	chr2:160653686	CD302	-0.36	-5.54	-0.33	7.65e-8	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.0	-0.3	1.07e-6	Life satisfaction;
KIRP	cis	rs4666002	0.789	rs13030973	chr2:27928797	T/C	cg05484376	chr2:27715224	FNDC4	-0.48	-5.84	-0.35	1.63e-8	Phospholipid levels (plasma);
KIRP	cis	rs3735025	0.963	rs320704	chr7:137051175	C/T	cg13839563	chr7:136910420	NA	0.39	4.94	0.3	1.47e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg08133631	chr1:26527909	CATSPER4	-0.44	-4.89	-0.3	1.81e-6	Obesity-related traits;
KIRP	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg10326726	chr10:51549505	MSMB	-0.6	-8.92	-0.49	1.06e-16	Prostate-specific antigen levels;
KIRP	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.33	-5.12	-0.31	6.15e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.8	11.75	0.6	1.34e-25	Heart rate;
KIRP	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.19	-0.54	1.38e-20	Hemoglobin concentration;
KIRP	cis	rs10465746	0.933	rs2224990	chr1:84436275	C/A	cg10977910	chr1:84465055	TTLL7	0.49	5.96	0.36	8.52e-9	Obesity-related traits;
KIRP	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.79	9.02	0.5	5.36e-17	Menarche (age at onset);
KIRP	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg18350739	chr11:68623251	NA	-0.52	-7.96	-0.45	6.38e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17123764	0.605	rs7956181	chr12:50056339	T/C	cg02054252	chr12:50078554	FMNL3	0.44	5.01	0.3	1.05e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-6.45	-0.38	5.82e-10	Lung cancer;
KIRP	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-0.95	-7.62	-0.44	5.52e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs34638686	1	rs34638686	chr3:48682658	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-7.06	-0.41	1.72e-11	Educational attainment (years of education);
KIRP	cis	rs13401104	0.587	rs7569760	chr2:237145713	A/C	cg02367144	chr2:237146137	ASB18	0.4	5.25	0.32	3.26e-7	Educational attainment;
KIRP	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.58	7.34	0.42	3.15e-12	Bipolar disorder;
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg15704280	chr7:45808275	SEPT13	0.54	6.21	0.37	2.25e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg15128208	chr22:42549153	NA	0.74	8.01	0.46	4.46e-14	Birth weight;
KIRP	cis	rs55788414	0.932	rs2317123	chr16:81182636	A/T	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs4356932	0.597	rs13125558	chr4:76852585	A/C	cg00809888	chr4:76862425	NAAA	-0.42	-5.78	-0.35	2.29e-8	Blood protein levels;
KIRP	cis	rs9311474	0.596	rs524986	chr3:52228496	T/C	cg05315796	chr3:52349193	DNAH1	0.38	5.32	0.32	2.31e-7	Electroencephalogram traits;
KIRP	trans	rs7084921	0.640	rs12773244	chr10:101865344	G/A	cg13808641	chr9:96006533	WNK2	-0.41	-6.34	-0.37	1.09e-9	Bone mineral density;
KIRP	cis	rs12208915	0.945	rs12214796	chr6:79561068	T/C	cg18132916	chr6:79620363	NA	0.57	5.05	0.31	8.76e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18932078	chr1:2524107	MMEL1	-0.41	-5.5	-0.33	9.63e-8	Ulcerative colitis;
KIRP	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.96	-12.88	-0.63	2.37e-29	Homoarginine levels;
KIRP	cis	rs2554380	1.000	rs2554380	chr15:84315884	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.63	-8.69	-0.48	5.15e-16	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18314121	chr1:225726360	ENAH	0.5	7.39	0.43	2.31e-12	Interleukin-4 levels;
KIRP	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.84	-13.07	-0.64	5.55e-30	Systemic lupus erythematosus;
KIRP	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.55	5.51	0.33	9.23e-8	Pre-treatment pain in head and neck squamous cell carcinoma;
KIRP	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.53	4.91	0.3	1.68e-6	Bipolar disorder;
KIRP	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.65	-10.34	-0.55	4.98e-21	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2802372	0.628	rs1250537	chr10:81038069	T/C	cg18688392	chr10:81059414	ZMIZ1	-0.43	-5.57	-0.33	6.73e-8	Granulocyte count;
KIRP	cis	rs10486003	1.000	rs78940020	chr7:97222560	C/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.62	-4.95	-0.3	1.35e-6	Response to platinum-based agents;
KIRP	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg21775007	chr8:11205619	TDH	0.5	6.7	0.39	1.43e-10	Mood instability;
KIRP	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg15556689	chr8:8085844	FLJ10661	0.55	7.11	0.41	1.28e-11	Retinal vascular caliber;
KIRP	cis	rs7560272	0.501	rs2421675	chr2:73955301	C/A	cg20560298	chr2:73613845	ALMS1	0.44	5.16	0.31	5.1e-7	Schizophrenia;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg23131131	chr22:24373011	LOC391322	0.6	7.12	0.41	1.2e-11	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg19773385	chr1:10388646	KIF1B	-0.45	-6.55	-0.39	3.32e-10	Hepatocellular carcinoma;
KIRP	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg16586182	chr3:47516702	SCAP	-0.81	-11.76	-0.6	1.24e-25	Colorectal cancer;
KIRP	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.44	6.53	0.38	3.65e-10	Bone mineral density;
KIRP	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.15	0.5	2.3e-17	Menopause (age at onset);
KIRP	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.82	-8.6	-0.48	9.31e-16	Hair shape;
KIRP	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.85	13.58	0.65	1.04e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4006360	0.525	rs72625956	chr17:39237517	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	1.03e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg18132916	chr6:79620363	NA	-0.42	-5.73	-0.34	2.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12643440	0.538	rs1522080	chr4:17135354	G/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs45544231	0.544	rs8052175	chr16:52577142	C/T	cg09051775	chr16:52580266	TOX3	-0.39	-5.44	-0.33	1.28e-7	Restless legs syndrome;
KIRP	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg21926883	chr2:100939477	LONRF2	-0.55	-7.44	-0.43	1.66e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13080904	chr7:143534545	LOC154761	0.57	6.89	0.4	4.68e-11	Smoking initiation;
KIRP	cis	rs7221595	0.825	rs2290437	chr17:3923115	G/A	cg21734707	chr17:3908241	ZZEF1	0.58	5.97	0.36	8.09e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs34339938	1	rs34339938	chr12:123678364	GAC/G	cg05973401	chr12:123451056	ABCB9	0.55	6.25	0.37	1.82e-9	Plateletcrit;
KIRP	cis	rs6546886	0.917	rs6546884	chr2:74237898	T/A	cg14702570	chr2:74259524	NA	-0.32	-6.46	-0.38	5.54e-10	Dialysis-related mortality;
KIRP	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-6.0	-0.36	7.17e-9	Gut microbiome composition (summer);
KIRP	cis	rs75920871	0.920	rs4316540	chr11:116819241	C/T	cg23684410	chr11:116897558	SIK3	0.55	6.02	0.36	6.32e-9	Subjective well-being;
KIRP	cis	rs731174	0.802	rs12123842	chr1:38187989	T/C	cg14170840	chr1:38155120	C1orf109	-0.39	-4.93	-0.3	1.49e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg23460707	chr10:133558971	NA	0.36	5.48	0.33	1.05e-7	Survival in rectal cancer;
KIRP	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg18478394	chr8:109455254	TTC35	0.52	6.43	0.38	6.47e-10	Dupuytren's disease;
KIRP	cis	rs2236918	0.932	rs1635501	chr1:242040775	C/T	cg17736920	chr1:242011382	EXO1	0.51	6.69	0.39	1.49e-10	Menopause (age at onset);
KIRP	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.56	0.33	7.17e-8	Breast cancer;
KIRP	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg11130432	chr3:121712080	ILDR1	-0.51	-5.95	-0.35	9.41e-9	Multiple sclerosis;
KIRP	cis	rs67366981	1.000	rs56357623	chr14:77697393	C/A	cg22824376	chr14:77648248	TMEM63C	0.86	6.65	0.39	1.87e-10	Obsessive-compulsive symptoms;
KIRP	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.84	8.39	0.47	3.92e-15	Neuroblastoma;
KIRP	cis	rs4356975	0.563	rs6600887	chr4:69969788	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.48	0.33	1.05e-7	Obesity-related traits;
KIRP	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.73	-0.34	2.99e-8	Bipolar disorder;
KIRP	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.61	7.91	0.45	9.01e-14	Vitiligo;
KIRP	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg20701182	chr2:24300061	SF3B14	0.58	5.16	0.31	5.13e-7	Lymphocyte counts;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg21885897	chr19:44008145	PHLDB3	-0.56	-6.29	-0.37	1.44e-9	Menopause (age at onset);
KIRP	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-1.05	-13.0	-0.64	8.94e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.89	10.47	0.56	1.81e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.02	-0.31	9.7e-7	IgG glycosylation;
KIRP	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs4262150	0.810	rs17565693	chr5:152070764	C/T	cg12297329	chr5:152029980	NA	-0.59	-7.19	-0.42	7.59e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg04733989	chr22:42467013	NAGA	0.42	4.97	0.3	1.27e-6	Cognitive function;
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg09264619	chr17:80180166	NA	-0.4	-5.87	-0.35	1.4e-8	Life satisfaction;
KIRP	cis	rs4849845	0.889	rs4849848	chr2:121043190	A/T	cg24070213	chr2:121070622	NA	0.39	5.4	0.33	1.6e-7	Mean platelet volume;
KIRP	cis	rs6793245	0.960	rs7373779	chr3:38593943	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-6.2	-0.37	2.37e-9	QT interval;
KIRP	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg08992911	chr2:238395768	MLPH	0.42	5.26	0.32	3.18e-7	Prostate cancer;
KIRP	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	8.43	0.47	2.99e-15	Total body bone mineral density;
KIRP	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-8.3	-0.47	7.14e-15	Bipolar disorder;
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg02462569	chr6:150064036	NUP43	-0.43	-6.55	-0.39	3.4e-10	Lung cancer;
KIRP	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg15252951	chr6:33757062	LEMD2	0.46	5.4	0.33	1.59e-7	Crohn's disease;
KIRP	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg19592336	chr6:28129416	ZNF389	0.49	5.61	0.34	5.46e-8	Depression;
KIRP	cis	rs11225247	1.000	rs7104841	chr11:102270051	T/C	cg06323957	chr11:102217781	BIRC2	0.96	6.22	0.37	2.11e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg02151108	chr14:50098012	C14orf104	-0.44	-5.74	-0.34	2.81e-8	Carotid intima media thickness;
KIRP	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg00981070	chr1:2046702	PRKCZ	0.41	5.89	0.35	1.25e-8	Height;
KIRP	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.79	7.2	0.42	7.5e-12	Mean platelet volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02980631	chr6:157008350	NA	-0.52	-6.14	-0.36	3.23e-9	Menopause (age at onset);
KIRP	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.95	-0.5	8.97e-17	Response to antipsychotic treatment;
KIRP	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-11.83	-0.6	7.58e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.12	0.41	1.2e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.69	9.69	0.53	5.08e-19	Blood protein levels;
KIRP	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg13264159	chr8:625131	ERICH1	0.74	4.88	0.3	1.9e-6	IgG glycosylation;
KIRP	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-9.61	-0.52	9.15e-19	Triglycerides;
KIRP	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.75	10.43	0.55	2.56e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	6.39	0.38	8.23e-10	HIV-1 control;
KIRP	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	11.11	0.58	1.62e-23	Mean platelet volume;
KIRP	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23281280	chr6:28129359	ZNF389	0.48	5.21	0.32	3.94e-7	Depression;
KIRP	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.11	15.01	0.69	1.4e-36	Lymphocyte percentage of white cells;
KIRP	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.45	5.0	0.3	1.11e-6	HDL cholesterol;
KIRP	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg14359292	chr7:27170892	HOXA4	-0.34	-5.0	-0.3	1.08e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs8077059	1.000	rs2058104	chr17:55816722	A/G	cg12582317	chr17:55822272	NA	0.41	5.14	0.31	5.52e-7	Sex hormone-binding globulin levels;
KIRP	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg17654217	chr7:100282651	GIGYF1	0.53	4.97	0.3	1.27e-6	Other erythrocyte phenotypes;
KIRP	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11987759	chr7:65425863	GUSB	0.69	9.7	0.53	4.65e-19	Calcium levels;
KIRP	cis	rs16912285	0.688	rs7929701	chr11:24357964	A/C	ch.11.24196551F	chr11:24239977	NA	0.61	5.46	0.33	1.18e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9796	0.774	rs28866311	chr15:41442195	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.31	-0.42	3.62e-12	Menopause (age at onset);
KIRP	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.6	-7.39	-0.43	2.27e-12	Blood metabolite levels;
KIRP	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.54	6.61	0.39	2.31e-10	Systemic lupus erythematosus;
KIRP	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.42	-5.95	-0.35	9.4e-9	Endometrial cancer;
KIRP	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg07810366	chr2:100720526	AFF3	0.33	5.82	0.35	1.8e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.47e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.65	8.74	0.49	3.58e-16	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.86	-10.9	-0.57	8.01e-23	Dupuytren's disease;
KIRP	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.6	6.61	0.39	2.3e-10	Platelet count;
KIRP	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.84	-13.1	-0.64	4.08e-30	Systemic lupus erythematosus;
KIRP	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg13939156	chr17:80058883	NA	-0.49	-5.72	-0.34	3.16e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7849270	0.959	rs7039031	chr9:131899395	A/G	cg13538475	chr9:131942899	NA	-0.32	-5.14	-0.31	5.72e-7	Blood metabolite ratios;
KIRP	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	7.45	0.43	1.58e-12	Neuroticism;
KIRP	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	ch.8.33884649F	chr8:33765107	NA	0.54	6.82	0.4	7.17e-11	Body mass index;
KIRP	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.12	0.41	1.17e-11	Mean platelet volume;
KIRP	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.5e-13	Coffee consumption (cups per day);
KIRP	cis	rs10465746	0.725	rs10127737	chr1:84368642	G/A	cg10977910	chr1:84465055	TTLL7	0.55	7.0	0.41	2.39e-11	Obesity-related traits;
KIRP	cis	rs4273100	0.541	rs973649	chr17:19292068	A/G	cg18093559	chr17:18951025	GRAP	0.5	5.87	0.35	1.42e-8	Schizophrenia;
KIRP	cis	rs6466055	0.661	rs12155351	chr7:104943302	C/T	cg04380332	chr7:105027541	SRPK2	0.36	5.0	0.3	1.08e-6	Schizophrenia;
KIRP	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.74	-9.53	-0.52	1.59e-18	Multiple sclerosis;
KIRP	trans	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.06	-0.36	4.97e-9	Neuroticism;
KIRP	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.67	9.53	0.52	1.56e-18	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg00086871	chr4:6988644	TBC1D14	0.75	6.28	0.37	1.5e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.3	-0.72	5.51e-41	Height;
KIRP	cis	rs240764	0.817	rs239201	chr6:101123993	T/A	cg09795085	chr6:101329169	ASCC3	0.47	5.65	0.34	4.34e-8	Neuroticism;
KIRP	cis	rs2580764	0.678	rs2580765	chr2:55204028	A/C	cg09592903	chr2:55203963	RTN4	0.37	4.99	0.3	1.13e-6	Mean platelet volume;
KIRP	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg00507259	chr4:95128692	SMARCAD1	0.42	5.3	0.32	2.53e-7	QT interval;
KIRP	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.5	-5.82	-0.35	1.81e-8	Tuberculosis;
KIRP	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg19338460	chr6:170058176	WDR27	-0.8	-8.83	-0.49	1.97e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg22223119	chr13:99095684	FARP1	-0.45	-5.34	-0.32	2.12e-7	Obesity-related traits;
KIRP	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg09904177	chr6:26538194	HMGN4	0.46	6.2	0.37	2.41e-9	Schizophrenia;
KIRP	cis	rs6540556	0.608	rs7532324	chr1:209918090	C/T	cg23920097	chr1:209922102	NA	-0.42	-5.4	-0.33	1.57e-7	Red blood cell count;
KIRP	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6832769	1.000	rs11726609	chr4:56400869	A/T	cg09317128	chr4:56265301	TMEM165	0.54	6.74	0.4	1.09e-10	Personality dimensions;
KIRP	cis	rs698833	0.828	rs6745281	chr2:44534472	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.03	0.36	6.04e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg02367723	chr1:46378857	MAST2	0.43	4.96	0.3	1.33e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03315817	chr2:203820169	ALS2CR8	-0.44	-6.79	-0.4	8.33e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-4.97	-0.3	1.28e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg02336718	chr17:17403227	NA	-0.37	-5.66	-0.34	4.26e-8	Total body bone mineral density;
KIRP	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1629083	0.901	rs1793150	chr11:118127314	G/A	cg18857871	chr11:118064634	AMICA1	0.69	10.07	0.54	3.38e-20	Lung cancer;
KIRP	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg19507638	chr5:93509721	C5orf36	-0.58	-5.05	-0.31	8.67e-7	Diabetic retinopathy;
KIRP	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.72	-7.51	-0.43	1.08e-12	Body mass index;
KIRP	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg12140854	chr5:148520817	ABLIM3	-0.56	-6.38	-0.38	8.86e-10	Breast cancer;
KIRP	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.58	7.35	0.42	2.92e-12	Aortic root size;
KIRP	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg02367723	chr1:46378857	MAST2	0.43	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg10434728	chr15:90938212	IQGAP1	0.3	5.07	0.31	7.97e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.32	0.32	2.31e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.64	8.54	0.48	1.46e-15	Lymphocyte counts;
KIRP	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.23	13.01	0.64	8.44e-30	Alzheimer's disease;
KIRP	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg24972876	chr7:65420302	NA	0.41	5.61	0.34	5.38e-8	Calcium levels;
KIRP	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.68	9.65	0.52	6.93e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg05340658	chr4:99064831	C4orf37	0.63	6.59	0.39	2.72e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs357618	1.000	rs357618	chr5:150846612	A/G	cg22672639	chr5:150884813	FAT2	0.36	5.51	0.33	9.05e-8	Basophil percentage of white cells;
KIRP	cis	rs829661	0.793	rs10167083	chr2:30773026	G/A	cg10949345	chr2:30726833	LCLAT1	1.13	14.22	0.67	6.82e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg01796438	chr3:11312864	ATG7	-0.36	-4.95	-0.3	1.35e-6	HDL cholesterol;
KIRP	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.52	-6.07	-0.36	4.91e-9	Inhibitory control;
KIRP	cis	rs9400467	0.506	rs76813116	chr6:111690733	T/G	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2905347	0.560	rs2905312	chr7:22682942	T/C	cg23521230	chr7:22704884	NA	0.39	4.89	0.3	1.83e-6	Major depression and alcohol dependence;
KIRP	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.64	-9.37	-0.51	4.83e-18	Total body bone mineral density;
KIRP	cis	rs11078597	0.731	rs1317708	chr17:1639965	G/A	cg17514665	chr17:1657533	SERPINF2	0.44	5.41	0.33	1.47e-7	Serum albumin level;
KIRP	cis	rs6546324	0.625	rs1023691	chr2:67868794	G/A	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg12454167	chr3:186435060	KNG1	0.53	9.16	0.5	2.15e-17	Blood protein levels;
KIRP	cis	rs1215050	0.755	rs6851840	chr4:98776366	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.52	0.38	3.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg12104764	chr12:110011362	MMAB;MVK	-1.07	-6.08	-0.36	4.47e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs3784262	0.631	rs12903724	chr15:58310387	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.94	-0.3	1.48e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs675026	1.000	rs562859	chr6:154414573	C/T	cg07813322	chr6:154414604	OPRM1	-0.57	-7.35	-0.42	2.88e-12	Hypertension;
KIRP	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.56	-0.33	7.17e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg22604316	chr1:46958801	NA	-0.43	-6.12	-0.36	3.65e-9	Monobrow;
KIRP	cis	rs1978968	1.000	rs2099942	chr22:18438314	A/C	cg02610425	chr22:18483192	MICAL3	0.39	5.88	0.35	1.36e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs78487399	0.808	rs13431070	chr2:43721954	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	5.2	0.31	4.25e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs735539	0.874	rs9579927	chr13:21270201	C/T	cg02792322	chr13:21280448	IL17D	0.32	5.31	0.32	2.51e-7	Dental caries;
KIRP	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.64	-7.03	-0.41	2.02e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg21551340	chr2:1609508	NA	0.5	4.85	0.3	2.19e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg25418670	chr11:30344373	C11orf46	-0.6	-5.02	-0.3	1e-6	Morning vs. evening chronotype;
KIRP	cis	rs1351164	1.000	rs10181989	chr2:218294915	T/C	cg15335768	chr2:218268053	DIRC3	-0.46	-6.23	-0.37	1.99e-9	Height;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24680979	chr2:85788672	GGCX	0.5	6.05	0.36	5.22e-9	Myopia (pathological);
KIRP	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg16497661	chr14:103986332	CKB	0.46	6.32	0.37	1.22e-9	Body mass index;
KIRP	cis	rs67257959	0.739	rs10416982	chr19:17202933	C/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.49	5.6	0.34	5.86e-8	Selective IgA deficiency;
KIRP	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-4.87	-0.3	2e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg05896524	chr21:47604654	C21orf56	0.4	5.07	0.31	7.96e-7	Testicular germ cell tumor;
KIRP	cis	rs2279817	0.863	rs871087	chr1:18017522	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.68	9.03	0.5	5.04e-17	Neuroticism;
KIRP	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg24565620	chr2:194026	NA	-0.7	-5.27	-0.32	3.05e-7	Blood protein levels;
KIRP	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg08462924	chr1:41848221	NA	0.5	7.41	0.43	2.03e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	9.3	0.51	7.89e-18	Total body bone mineral density;
KIRP	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.87	8.56	0.48	1.25e-15	Methadone dose in opioid dependence;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg22935149	chr22:38851884	KCNJ4	-0.57	-6.73	-0.39	1.17e-10	Menopause (age at onset);
KIRP	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg02023728	chr11:77925099	USP35	-0.29	-4.91	-0.3	1.69e-6	Alzheimer's disease (survival time);
KIRP	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg13010199	chr12:38710504	ALG10B	0.5	6.11	0.36	3.92e-9	Morning vs. evening chronotype;
KIRP	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	11.58	0.59	5.03e-25	Breast cancer;
KIRP	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.87	0.53	1.44e-19	Multiple sclerosis;
KIRP	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg26681399	chr22:41777847	TEF	0.52	5.15	0.31	5.46e-7	Vitiligo;
KIRP	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg26876637	chr1:152193138	HRNR	0.71	9.45	0.52	2.8e-18	Atopic dermatitis;
KIRP	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.52	-6.69	-0.39	1.49e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.63	8.04	0.46	3.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg01721255	chr8:58191610	C8orf71	0.6	5.53	0.33	8.12e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg05562828	chr17:3906858	NA	-0.7	-13.58	-0.65	1.02e-31	Type 2 diabetes;
KIRP	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.54	6.56	0.39	3.17e-10	Age at first birth;
KIRP	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs654950	0.875	rs55865698	chr1:41986758	C/T	cg06885757	chr1:42089581	HIVEP3	-0.47	-6.46	-0.38	5.52e-10	Airway imaging phenotypes;
KIRP	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.58	11.9	0.6	4.44e-26	Diabetic kidney disease;
KIRP	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.27	-0.55	7.97e-21	Response to antipsychotic treatment;
KIRP	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg23307798	chr14:103986281	CKB	0.49	7.12	0.41	1.17e-11	Body mass index;
KIRP	cis	rs9815354	0.830	rs1716983	chr3:41964128	G/A	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.62	10.15	0.54	1.93e-20	Cardiovascular disease risk factors;
KIRP	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.48	-7.21	-0.42	6.8e-12	Bipolar disorder;
KIRP	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg16988262	chr1:15930761	NA	0.4	5.29	0.32	2.74e-7	Systolic blood pressure;
KIRP	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.74	10.94	0.57	5.95e-23	Hip circumference;
KIRP	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.68	-6.35	-0.38	1.03e-9	White matter integrity;
KIRP	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg13385521	chr17:29058706	SUZ12P	0.59	5.94	0.35	9.63e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.73	0.34	2.86e-8	Motion sickness;
KIRP	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07843572	chr19:14016952	C19orf57;CC2D1A	-0.45	-6.2	-0.37	2.39e-9	Metabolic traits;
KIRP	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-0.92	-6.75	-0.4	1.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg20631270	chr6:24437470	GPLD1	0.48	5.75	0.34	2.63e-8	Liver enzyme levels;
KIRP	trans	rs2726453	0.562	rs2713834	chr4:106310520	G/T	cg13792596	chr14:64660940	SYNE2	-0.42	-6.05	-0.36	5.28e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.9	15.34	0.7	9.8e-38	Mortality in heart failure;
KIRP	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg04398451	chr17:18023971	MYO15A	0.64	8.42	0.47	3.18e-15	Total body bone mineral density;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg16951854	chr3:49449507	RHOA;TCTA	0.52	6.33	0.37	1.17e-9	Educational attainment;
KIRP	cis	rs7224685	0.569	rs34356467	chr17:3978531	G/T	cg09597638	chr17:3907349	NA	0.55	5.68	0.34	3.84e-8	Type 2 diabetes;
KIRP	cis	rs7106204	1.000	rs6484025	chr11:24214514	C/G	ch.11.24196551F	chr11:24239977	NA	0.84	8.9	0.49	1.28e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg03465714	chr1:152285911	FLG	0.48	4.89	0.3	1.79e-6	Atopic dermatitis;
KIRP	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.55	8.45	0.47	2.57e-15	Bone mineral density;
KIRP	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.52	6.71	0.39	1.3e-10	Crohn's disease;
KIRP	cis	rs2235642	0.582	rs11643891	chr16:1565540	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-5.18	-0.31	4.58e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08790581	chr5:106835992	EFNA5	-0.39	-6.55	-0.39	3.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7116495	0.619	rs7116188	chr11:71841753	A/G	cg11196788	chr11:71737549	NUMA1	-0.55	-4.92	-0.3	1.59e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg15436174	chr10:43711423	RASGEF1A	0.85	9.42	0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg26022315	chr17:47021804	SNF8	0.43	5.76	0.34	2.56e-8	Type 2 diabetes;
KIRP	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.81	10.72	0.56	2.92e-22	Triglycerides;
KIRP	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg05340658	chr4:99064831	C4orf37	0.66	7.68	0.44	3.69e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg07936489	chr17:37558343	FBXL20	-0.5	-6.27	-0.37	1.61e-9	Asthma;
KIRP	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.51	-6.29	-0.37	1.42e-9	Platelet distribution width;
KIRP	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg07862535	chr7:139043722	LUC7L2	0.46	5.16	0.31	4.99e-7	Diisocyanate-induced asthma;
KIRP	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg05362011	chr13:21860987	NA	0.48	5.38	0.32	1.72e-7	White matter hyperintensity burden;
KIRP	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.32	11.8	0.6	9.42e-26	Diabetic retinopathy;
KIRP	cis	rs2929278	0.617	rs524908	chr15:44187991	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.47	-5.92	-0.35	1.06e-8	Schizophrenia;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.53	6.62	0.39	2.19e-10	Resistin levels;
KIRP	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg22437258	chr11:111473054	SIK2	0.6	7.1	0.41	1.37e-11	Primary sclerosing cholangitis;
KIRP	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.92	-0.4	3.8e-11	Total body bone mineral density;
KIRP	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg08923054	chr8:41654455	ANK1	0.74	7.94	0.45	7.11e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg10792982	chr14:105748885	BRF1	0.78	11.8	0.6	8.89e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7870753	0.786	rs3802443	chr9:99263580	A/G	cg25260653	chr9:99212216	HABP4	0.53	5.77	0.35	2.33e-8	Height;
KIRP	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.93	0.45	7.6e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.18	-0.42	8.33e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg00507259	chr4:95128692	SMARCAD1	0.41	5.31	0.32	2.42e-7	QT interval;
KIRP	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-9.07	-0.5	3.83e-17	Total cholesterol levels;
KIRP	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	1.06	13.6	0.66	8.37e-32	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9393777	0.547	rs2893910	chr6:27283254	A/T	cg22548220	chr6:27277996	POM121L2	0.47	5.88	0.35	1.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.39	0.38	8.13e-10	Iron status biomarkers;
KIRP	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs2908668	1.000	rs2908668	chr16:5073773	G/T	cg00849365	chr16:5074999	NAGPA	-0.48	-5.72	-0.34	3.12e-8	Cancer;
KIRP	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Life satisfaction;
KIRP	cis	rs6496044	0.568	rs11632326	chr15:86079834	A/C	cg10818794	chr15:86012489	AKAP13	-0.58	-8.14	-0.46	2.04e-14	Interstitial lung disease;
KIRP	cis	rs1788820	0.917	rs1788819	chr18:21100504	G/A	cg14672496	chr18:21087552	C18orf8	0.41	5.85	0.35	1.55e-8	Body mass index;
KIRP	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.48	-6.0	-0.36	7.13e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.04	-0.46	3.71e-14	Personality dimensions;
KIRP	cis	rs35740288	1.000	rs11637212	chr15:86293097	C/G	cg17133734	chr15:86042851	AKAP13	0.49	5.48	0.33	1.06e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.37	1.59e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg16141378	chr3:129829833	LOC729375	0.54	7.16	0.42	9.14e-12	Triglycerides;
KIRP	cis	rs2976388	0.967	rs2978981	chr8:143759137	C/T	cg17252645	chr8:143867129	LY6D	-0.33	-5.24	-0.32	3.42e-7	Urinary tract infection frequency;
KIRP	cis	rs2916247	1.000	rs9297901	chr8:93036795	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.65	-8.84	-0.49	1.89e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.1	0.36	4.19e-9	Breast cancer;
KIRP	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.72	9.83	0.53	1.86e-19	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg26784012	chr10:32216390	ARHGAP12	0.32	5.18	0.31	4.57e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs9525927	0.570	rs9316074	chr13:44803181	A/G	cg19190762	chr13:44806055	NA	0.5	4.92	0.3	1.58e-6	Dupuytren's disease;
KIRP	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg02725872	chr8:58115012	NA	-0.49	-6.18	-0.37	2.66e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.3	0.55	6.31e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg12692727	chr7:1102344	C7orf50	0.47	5.01	0.3	1.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20999755	chr1:7184726	CAMTA1	0.41	6.2	0.37	2.31e-9	Interleukin-4 levels;
KIRP	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg03289416	chr15:75166202	SCAMP2	-0.43	-6.12	-0.36	3.77e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.92	14.05	0.67	2.64e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg04398451	chr17:18023971	MYO15A	-0.61	-8.37	-0.47	4.46e-15	Total body bone mineral density;
KIRP	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg10360139	chr7:1886902	MAD1L1	0.54	5.99	0.36	7.28e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs11074306	0.541	rs1498520	chr15:28081540	G/T	cg26402630	chr15:28053930	OCA2	0.31	4.99	0.3	1.16e-6	Uveal melanoma;
KIRP	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.13	0.41	1.08e-11	Height;
KIRP	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg20744362	chr22:50050164	C22orf34	0.32	5.09	0.31	7.05e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.85	13.56	0.65	1.17e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21775445	chr20:1373916	FKBP1A	0.59	7.1	0.41	1.3e-11	Smoking initiation;
KIRP	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg24796726	chr7:884288	UNC84A	-0.59	-5.25	-0.32	3.31e-7	Initial pursuit acceleration;
KIRP	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.18	-0.37	2.7e-9	Obesity-related traits;
KIRP	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg17366294	chr4:99064904	C4orf37	-0.37	-5.14	-0.31	5.59e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1172149	0.559	rs17417252	chr1:205216110	A/G	cg21643547	chr1:205240462	TMCC2	0.41	5.19	0.31	4.35e-7	Platelet distribution width;
KIRP	trans	rs12043259	0.730	rs16854508	chr1:204808577	A/G	cg11485465	chr5:54518469	NA	-0.34	-6.31	-0.37	1.29e-9	Addiction;
KIRP	cis	rs17065868	0.881	rs61948037	chr13:45210806	C/T	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.42	5.51	0.33	9.08e-8	Neutrophil percentage of white cells;
KIRP	cis	rs7011507	1.000	rs76940069	chr8:49162265	T/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6746896	0.708	rs994430	chr2:97439001	A/T	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.46	-0.43	1.45e-12	Bipolar disorder;
KIRP	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg13679303	chr9:96623674	NA	-0.46	-6.47	-0.38	5.27e-10	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01529149	chr8:144815967	FAM83H	0.51	6.77	0.4	9.36e-11	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.71	-0.53	4.59e-19	Neuroticism;
KIRP	cis	rs2820315	0.867	rs2819349	chr1:201885026	C/T	cg11586189	chr1:201857591	SHISA4	-0.4	-5.65	-0.34	4.46e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.65	8.4	0.47	3.64e-15	Height;
KIRP	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg07741184	chr6:167504864	NA	-0.2	-5.0	-0.3	1.07e-6	Crohn's disease;
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg22907277	chr7:1156413	C7orf50	0.61	8.18	0.46	1.55e-14	Longevity;Endometriosis;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-6.39	-0.38	8.07e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.58	7.74	0.44	2.5e-13	Schizophrenia;
KIRP	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05601917	chr6:125855416	NA	-0.33	-5.03	-0.31	9.24e-7	Brugada syndrome;
KIRP	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.6	6.66	0.39	1.82e-10	Response to antipsychotic treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24177093	chr5:180650516	TRIM41	0.49	6.62	0.39	2.24e-10	Parkinson's disease;
KIRP	cis	rs4664308	0.618	rs55668231	chr2:160882066	A/G	cg03641300	chr2:160917029	PLA2R1	-0.67	-10.8	-0.57	1.6400000000000001e-22	Idiopathic membranous nephropathy;
KIRP	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.7	5.99	0.36	7.48e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.51	6.57	0.39	2.91e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07570687	chr10:102243282	WNT8B	0.41	4.93	0.3	1.49e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.59	7.48	0.43	1.28e-12	Corneal astigmatism;
KIRP	cis	rs7508	0.512	rs28368325	chr8:17888606	A/G	cg01800426	chr8:17659068	MTUS1	-0.41	-5.11	-0.31	6.61e-7	Atrial fibrillation;
KIRP	cis	rs9463078	0.547	rs9472362	chr6:44751285	C/A	cg25276700	chr6:44698697	NA	0.37	5.35	0.32	2.05e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.55	7.08	0.41	1.54e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9905704	0.633	rs2632518	chr17:56512236	T/C	cg12560992	chr17:57184187	TRIM37	0.55	5.22	0.32	3.75e-7	Testicular germ cell tumor;
KIRP	cis	rs311392	0.554	rs311388	chr8:55101869	T/A	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.51e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg26335602	chr6:28129616	ZNF389	0.43	4.84	0.3	2.26e-6	Depression;
KIRP	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.6	-7.48	-0.43	1.28e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.9	-11.93	-0.61	3.47e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.26	0.32	3.12e-7	Educational attainment;
KIRP	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg08283408	chr3:49949060	MON1A	-0.39	-5.14	-0.31	5.52e-7	Body mass index;
KIRP	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg01849789	chr22:41697279	ZC3H7B	-0.52	-5.57	-0.33	6.75e-8	Neuroticism;
KIRP	cis	rs4654899	0.802	rs115818417	chr1:21200411	C/T	cg05370193	chr1:21551575	ECE1	0.42	5.1	0.31	6.75e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19524238	chr7:2802976	GNA12	-0.37	-4.99	-0.3	1.15e-6	Height;
KIRP	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.66	-0.34	4.1e-8	Yeast infection;
KIRP	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-5.49	-0.33	9.81e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs78545713	0.536	rs116337444	chr6:26208269	G/A	cg01420254	chr6:26195488	NA	1.21	7.59	0.44	6.71e-13	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg27494647	chr7:150038898	RARRES2	0.41	6.34	0.37	1.09e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg07636037	chr3:49044803	WDR6	-0.77	-7.37	-0.43	2.65e-12	Cognitive function;
KIRP	cis	rs7804356	1.000	rs73069533	chr7:26892325	G/A	cg03456212	chr7:26904342	SKAP2	-0.53	-4.98	-0.3	1.22e-6	Type 1 diabetes;
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg07701084	chr6:150067640	NUP43	0.71	10.11	0.54	2.62e-20	Lung cancer;
KIRP	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19717773	chr7:2847554	GNA12	-0.35	-5.13	-0.31	6.01e-7	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg05267623	chr11:64490672	NRXN2	-0.46	-6.16	-0.37	2.9e-9	Metabolic traits;
KIRP	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.49	-5.8	-0.35	2.01e-8	Body mass index;
KIRP	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg04725166	chr1:7887271	PER3	-0.33	-5.19	-0.31	4.48e-7	Crohn's disease;
KIRP	trans	rs4853036	0.904	rs12713683	chr2:70156321	G/A	cg14915290	chr13:42017708	OR7E37P	-0.46	-6.02	-0.36	6.28e-9	Colorectal or endometrial cancer;
KIRP	cis	rs8141529	0.515	rs13056243	chr22:29349306	A/G	cg02153584	chr22:29168773	CCDC117	-0.6	-5.79	-0.35	2.14e-8	Lymphocyte counts;
KIRP	cis	rs73198271	0.960	rs73198287	chr8:8612786	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-5.55	-0.33	7.54e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.76	4.89	0.3	1.83e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05238522	chr4:72323166	SLC4A4	0.38	6.1	0.36	4.1e-9	C-reactive protein;
KIRP	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg10189774	chr4:17578691	LAP3	0.42	5.11	0.31	6.59e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.77	11.19	0.58	9.08e-24	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02172402	chr7:110764536	LRRN3;IMMP2L	-0.45	-6.95	-0.41	3.34e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.18	0.58	9.76e-24	Cognitive test performance;
KIRP	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	1.09	19.89	0.79	3.85e-53	Monocyte count;
KIRP	cis	rs73206853	0.563	rs1973505	chr12:111160003	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.5	-6.07	-0.36	4.82e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg21775007	chr8:11205619	TDH	-0.47	-6.1	-0.36	4.02e-9	Triglycerides;
KIRP	cis	rs4646404	0.509	rs4646356	chr17:17471175	A/G	cg01246520	chr17:17644344	RAI1	0.32	5.42	0.33	1.43e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg07414643	chr4:187882934	NA	0.39	5.01	0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg18234130	chr8:27182889	PTK2B	0.56	7.31	0.42	3.69e-12	Neuroticism;
KIRP	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23248424	chr5:179741104	GFPT2	-0.56	-6.23	-0.37	2.02e-9	Height;
KIRP	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	trans	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg11978873	chr1:226251224	H3F3A;LOC440926	-0.52	-6.08	-0.36	4.51e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	7.31	0.42	3.77e-12	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	7.64	0.44	4.94e-13	Neuroticism;
KIRP	cis	rs6800768	0.633	rs826374	chr3:24163921	A/C	cg10674438	chr3:24145617	LOC152024	-0.48	-6.42	-0.38	7.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg06217071	chr17:408420	NA	0.71	11.58	0.59	4.92e-25	Hip circumference adjusted for BMI;
KIRP	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg21360079	chr12:107162445	NA	-0.71	-10.24	-0.55	9.85e-21	Heart rate;
KIRP	cis	rs7007076	0.710	rs28661804	chr8:124711597	T/G	cg00283535	chr8:124749564	ANXA13	0.47	5.61	0.34	5.32e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7546668	0.652	rs12691551	chr1:15907908	C/G	cg18192808	chr1:15853278	DNAJC16	0.46	5.54	0.33	7.73e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs2979489	0.945	rs11993146	chr8:30319537	G/A	cg26383811	chr8:30366931	RBPMS	-0.39	-5.34	-0.32	2.16e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12391858	chr15:43441510	TMEM62	-0.37	-6.05	-0.36	5.49e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19524238	chr7:2802976	GNA12	-0.39	-5.27	-0.32	2.93e-7	Height;
KIRP	cis	rs888194	0.628	rs10161126	chr12:110042348	C/T	cg05360138	chr12:110035743	NA	-0.46	-5.63	-0.34	4.82e-8	Neuroticism;
KIRP	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.56	0.48	1.23e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-35.4	-0.91	1.61e-98	Myeloid white cell count;
KIRP	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.08	0.31	7.51e-7	Smoking behavior;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg08132940	chr7:1081526	C7orf50	-0.59	-5.93	-0.35	1.02e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg26354017	chr1:205819088	PM20D1	-0.59	-5.43	-0.33	1.36e-7	Menarche (age at onset);
KIRP	cis	rs2658782	0.507	rs11603164	chr11:93016858	T/G	cg15737290	chr11:93063684	CCDC67	-0.7	-8.12	-0.46	2.26e-14	Pulmonary function decline;
KIRP	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.05	15.76	0.71	3.68e-39	Primary sclerosing cholangitis;
KIRP	cis	rs67311347	0.503	rs11719968	chr3:40241600	G/T	cg10755058	chr3:40428713	ENTPD3	0.38	5.48	0.33	1.06e-7	Renal cell carcinoma;
KIRP	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.68	7.81	0.45	1.66e-13	Carotid intima media thickness;
KIRP	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.44	0.47	2.81e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19671926	chr4:122722719	EXOSC9	0.51	6.19	0.37	2.57e-9	Type 2 diabetes;
KIRP	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg19773385	chr1:10388646	KIF1B	-0.7	-9.66	-0.52	6.57e-19	Hepatocellular carcinoma;
KIRP	cis	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.13e-6	IgM levels;
KIRP	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg20169779	chr10:135381914	SYCE1	-0.46	-5.43	-0.33	1.34e-7	Obesity-related traits;
KIRP	cis	rs8060686	0.920	rs56845922	chr16:67770828	T/C	cg04539111	chr16:67997858	SLC12A4	-0.6	-5.89	-0.35	1.27e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.32e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg17330983	chr14:23770641	PPP1R3E	0.5	6.32	0.37	1.2e-9	Asthma;
KIRP	cis	rs9826463	0.877	rs73228788	chr3:142351463	C/T	cg20824294	chr3:142316082	PLS1	0.51	6.86	0.4	5.46e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.58	7.56	0.43	7.76e-13	Retinal vascular caliber;
KIRP	cis	rs12282928	1.000	rs4436574	chr11:48334788	G/A	cg26585981	chr11:48327164	OR4S1	0.52	6.28	0.37	1.54e-9	Migraine - clinic-based;
KIRP	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.32	-5.9	-0.35	1.18e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2594989	0.943	rs2442780	chr3:11510568	A/G	cg01796438	chr3:11312864	ATG7	-0.62	-7.58	-0.43	7.18e-13	Circulating chemerin levels;
KIRP	cis	rs7119167	0.686	rs725103	chr11:73032471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.46	4.91	0.3	1.66e-6	Blood protein levels;
KIRP	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg13010199	chr12:38710504	ALG10B	0.55	6.72	0.39	1.23e-10	Resting heart rate;
KIRP	cis	rs2224391	0.704	rs9504371	chr6:5261608	T/C	cg13962347	chr6:5174647	LYRM4	-0.62	-8.48	-0.48	2.13e-15	Height;
KIRP	cis	rs7709377	0.553	rs7715759	chr5:115471298	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.03	0.31	9.25e-7	Metabolite levels  (X-11787);
KIRP	cis	rs780094	0.500	rs12478841	chr2:27811722	A/G	cg05484376	chr2:27715224	FNDC4	-0.37	-5.48	-0.33	1.06e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.3	-0.32	2.57e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4006360	0.646	rs11868364	chr17:39236968	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.66	-0.48	6.38e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.14	0.54	2.11e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg25730555	chr22:47059586	GRAMD4	0.51	6.14	0.36	3.26e-9	Urate levels in obese individuals;
KIRP	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.42	-0.51	3.49e-18	Triglycerides;
KIRP	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.66	9.68	0.53	5.43e-19	Dupuytren's disease;
KIRP	cis	rs12615966	0.932	rs17030310	chr2:105391647	C/T	cg16465502	chr2:105461796	NA	-0.56	-5.46	-0.33	1.15e-7	Pancreatic cancer;
KIRP	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg02297831	chr4:17616191	MED28	0.43	5.15	0.31	5.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08280861	chr8:58055591	NA	0.81	6.42	0.38	7.03e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.36e-8	Platelet count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01113680	chr13:43842067	ENOX1	0.46	6.34	0.37	1.09e-9	Interleukin-4 levels;
KIRP	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg05785598	chr3:49045655	WDR6	0.29	5.43	0.33	1.34e-7	Parkinson's disease;
KIRP	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.73	9.03	0.5	5.25e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.93	13.7	0.66	3.98e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.33	-0.42	3.25e-12	Morning vs. evening chronotype;
KIRP	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg01843034	chr6:37503916	NA	-1.0	-15.93	-0.71	9.62e-40	Cognitive performance;
KIRP	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-6.39	-0.38	8.46e-10	Bipolar disorder;
KIRP	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg03060546	chr3:49711283	APEH	0.44	5.57	0.33	6.52e-8	Parkinson's disease;
KIRP	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.8	6.48	0.38	5.1e-10	Initial pursuit acceleration;
KIRP	cis	rs7590368	0.673	rs56264212	chr2:10931435	A/C	cg15705551	chr2:10952987	PDIA6	0.65	6.29	0.37	1.44e-9	Educational attainment (years of education);
KIRP	cis	rs10073892	0.633	rs6866041	chr5:101619196	C/T	cg19774478	chr5:101632501	SLCO4C1	0.56	6.05	0.36	5.38e-9	Cognitive decline (age-related);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06899192	chr17:35767064	ACACA;TADA2A	-0.5	-6.31	-0.37	1.31e-9	Myopia;
KIRP	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.23e-9	Breast cancer;
KIRP	cis	rs1832871	0.579	rs828006	chr6:158775014	T/C	cg07215822	chr6:158701037	NA	0.6	8.97	0.5	7.96e-17	Height;
KIRP	cis	rs4805834	0.545	rs12985990	chr19:33216592	G/A	cg07201929	chr19:33182834	NUDT19	-0.58	-5.4	-0.33	1.59e-7	Creatinine levels;
KIRP	cis	rs6466055	0.576	rs4602821	chr7:104611876	C/T	cg04380332	chr7:105027541	SRPK2	-0.41	-5.62	-0.34	5.26e-8	Schizophrenia;
KIRP	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg04607699	chr11:48328132	OR4S1	-0.36	-5.12	-0.31	6.14e-7	HDL cholesterol;
KIRP	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg18477163	chr1:228402036	OBSCN	0.34	6.26	0.37	1.71e-9	Diastolic blood pressure;
KIRP	trans	rs199950	0.910	rs199936	chr1:181594320	G/A	cg04237608	chr1:18659049	IGSF21	0.33	6.05	0.36	5.23e-9	Body mass index (change over time);
KIRP	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg02503808	chr4:7069936	GRPEL1	-0.92	-6.07	-0.36	4.7e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3736485	0.641	rs979259	chr15:51959430	A/G	cg14296394	chr15:51910925	DMXL2	-0.37	-5.63	-0.34	4.79e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18812058	chr8:119630154	SAMD12	-0.47	-6.42	-0.38	6.89e-10	Inflammatory biomarkers;
KIRP	cis	rs4908768	0.871	rs4908508	chr1:8800780	T/C	cg25722041	chr1:8623473	RERE	0.6	7.68	0.44	3.86e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-7.55	-0.43	8.5e-13	Homocysteine levels;
KIRP	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.73	10.89	0.57	8.53e-23	Hip circumference;
KIRP	cis	rs7083	0.935	rs7111678	chr11:117135806	T/C	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.34	0.47	5.5e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg05347473	chr6:146136440	FBXO30	0.56	8.11	0.46	2.48e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.57	7.47	0.43	1.39e-12	Obesity-related traits;
KIRP	trans	rs7999699	0.902	rs11148084	chr13:48322184	C/G	cg23237801	chr1:16476620	EPHA2	0.52	6.52	0.38	3.93e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.77	8.34	0.47	5.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg00982548	chr2:198649783	BOLL	0.56	5.21	0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs3857536	0.679	rs1964856	chr6:66952886	G/A	cg07460842	chr6:66804631	NA	-0.48	-5.77	-0.35	2.38e-8	Blood trace element (Cu levels);
KIRP	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00677455	chr12:58241039	CTDSP2	0.98	12.62	0.63	1.8e-28	Multiple sclerosis;
KIRP	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.86	9.86	0.53	1.49e-19	Gut microbiome composition (summer);
KIRP	cis	rs6568686	0.786	rs6929494	chr6:111857330	T/A	cg22127309	chr6:111907043	TRAF3IP2	-0.57	-5.46	-0.33	1.14e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.34	0.37	1.09e-9	Coronary artery disease;
KIRP	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.85	0.3	2.17e-6	Renal cell carcinoma;
KIRP	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.49	6.82	0.4	7.12e-11	Height;
KIRP	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12893428	chr3:195717962	SDHAP1	0.45	5.95	0.35	9.23e-9	Pancreatic cancer;
KIRP	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg02336718	chr17:17403227	NA	0.37	5.84	0.35	1.68e-8	Total body bone mineral density;
KIRP	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg14228332	chr4:119757509	SEC24D	0.8	4.92	0.3	1.56e-6	Cannabis dependence symptom count;
KIRP	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.41	5.33	0.32	2.22e-7	Longevity;
KIRP	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg13157960	chr19:33183277	NUDT19	0.58	5.01	0.3	1.04e-6	Red blood cell traits;
KIRP	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg00684032	chr4:1343700	KIAA1530	-0.56	-7.35	-0.42	2.86e-12	Obesity-related traits;
KIRP	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.98	0.36	7.63e-9	Schizophrenia;
KIRP	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.75	8.15	0.46	1.89e-14	Corneal astigmatism;
KIRP	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.79	10.55	0.56	1.02e-21	Height;
KIRP	cis	rs4363385	0.588	rs6698361	chr1:153023184	T/G	cg07796016	chr1:152779584	LCE1C	-0.45	-5.82	-0.35	1.86e-8	Inflammatory skin disease;
KIRP	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg12181417	chr19:49337499	HSD17B14	-0.49	-5.48	-0.33	1.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.99	13.45	0.65	2.87e-31	Menopause (age at onset);
KIRP	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	trans	rs7493138	0.967	rs12883958	chr14:28998574	C/G	cg08496086	chr5:2176142	NA	0.45	6.1	0.36	4.14e-9	Longevity;
KIRP	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.52e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg16482183	chr6:26056742	HIST1H1C	0.41	5.16	0.31	5.11e-7	Height;
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg24375607	chr4:120327624	NA	0.6	6.46	0.38	5.47e-10	Corneal astigmatism;
KIRP	cis	rs193541	0.632	rs2910135	chr5:122229790	C/T	cg19412675	chr5:122181750	SNX24	0.58	6.24	0.37	1.9e-9	Glucose homeostasis traits;
KIRP	cis	rs9815354	0.953	rs13088394	chr3:41951715	G/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.27	-0.32	3.04e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg25019033	chr10:957182	NA	-0.58	-5.96	-0.36	8.65e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg08807101	chr21:30365312	RNF160	-0.55	-5.38	-0.32	1.72e-7	Cognitive test performance;
KIRP	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.39	5.35	0.32	1.99e-7	Pulse pressure;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg05562828	chr17:3906858	NA	0.8	17.25	0.74	3.12e-44	Type 2 diabetes;
KIRP	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg23978390	chr7:1156363	C7orf50	0.6	7.14	0.41	1.03e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg17372223	chr3:52568218	NT5DC2	0.3	4.91	0.3	1.64e-6	Bipolar disorder;
KIRP	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.17	-0.37	2.75e-9	Mood instability;
KIRP	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	5.08	0.31	7.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs876084	0.505	rs9969584	chr8:121104786	G/A	cg22335954	chr8:121166405	COL14A1	-0.36	-4.92	-0.3	1.55e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg08603382	chr10:743973	NA	0.45	6.53	0.38	3.75e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg00074818	chr8:8560427	CLDN23	0.4	6.14	0.36	3.27e-9	Obesity-related traits;
KIRP	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.73	9.63	0.52	8.08e-19	Schizophrenia;
KIRP	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.79	-7.61	-0.44	5.71e-13	Opioid sensitivity;
KIRP	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs830124	0.714	rs658957	chr12:122409664	T/C	cg21016266	chr12:122356598	WDR66	0.56	5.73	0.34	2.9e-8	Urinary metabolites;
KIRP	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.97	10.13	0.54	2.17e-20	Alzheimer's disease;
KIRP	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.47	7.18	0.42	8.46e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13520373	chr11:108463818	EXPH5	0.54	7.28	0.42	4.39e-12	Parkinson's disease;
KIRP	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.38	0.51	4.46e-18	Morning vs. evening chronotype;
KIRP	cis	rs1355223	0.844	rs12809046	chr11:34748261	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.31	-0.32	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17539620	0.624	rs56791414	chr6:154849605	A/G	cg20019720	chr6:154832845	CNKSR3	0.44	5.83	0.35	1.73e-8	Lipoprotein (a) levels;
KIRP	cis	rs7428	0.962	rs3637	chr2:85549874	A/G	cg24342717	chr2:85555507	TGOLN2	-0.55	-6.41	-0.38	7.49e-10	Ear protrusion;
KIRP	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.59	-5.44	-0.33	1.28e-7	Body mass index;
KIRP	cis	rs9783347	1.000	rs7947378	chr11:18381327	T/C	cg15585147	chr11:18324498	HPS5	0.44	5.95	0.35	9.04e-9	Pancreatic cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10853637	chr6:1312511	FOXQ1	-0.44	-6.15	-0.37	3.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg19743168	chr1:23544995	NA	-0.47	-6.26	-0.37	1.69e-9	Height;
KIRP	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.51	-6.05	-0.36	5.37e-9	Parkinson's disease;
KIRP	cis	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg19847130	chr8:10466454	RP1L1	0.32	5.06	0.31	8.16e-7	Neuroticism;
KIRP	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg13606994	chr1:44402422	ARTN	-0.26	-5.15	-0.31	5.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	9.81	0.53	2.24e-19	Post bronchodilator FEV1;
KIRP	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.8	-10.49	-0.56	1.61e-21	Body mass index;
KIRP	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.78	10.52	0.56	1.32e-21	Resting heart rate;
KIRP	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg16497661	chr14:103986332	CKB	0.79	12.5	0.62	4.38e-28	Body mass index;
KIRP	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06115741	chr20:33292138	TP53INP2	0.47	6.48	0.38	4.98e-10	Coronary artery disease;
KIRP	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.61	-8.51	-0.48	1.77e-15	Longevity;
KIRP	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg08885076	chr2:99613938	TSGA10	0.46	7.84	0.45	1.38e-13	Chronic sinus infection;
KIRP	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.43	5.38	0.32	1.71e-7	Aortic root size;
KIRP	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.16	0.42	9.12e-12	Bipolar disorder;
KIRP	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.76	0.34	2.51e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.87	13.2	0.64	1.99e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg01631408	chr1:248437212	OR2T33	-0.69	-9.38	-0.51	4.69e-18	Common traits (Other);
KIRP	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.78	11.46	0.59	1.19e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.31	5.73	0.34	2.97e-8	Calcium levels;
KIRP	cis	rs7546668	1.000	rs10803394	chr1:15909480	G/C	cg21858823	chr1:15850916	CASP9	0.47	5.05	0.31	8.54e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs12200782	1.000	rs12200782	chr6:26403036	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.3	-0.37	1.39e-9	Small cell lung carcinoma;
KIRP	cis	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.21	0.37	2.27e-9	Leprosy;
KIRP	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.49	7.96	0.45	6.15e-14	Life satisfaction;
KIRP	trans	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.1	0.41	1.32e-11	Retinal vascular caliber;
KIRP	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg01238044	chr22:24384105	GSTT1	0.64	7.92	0.45	8.28e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs13102973	0.720	rs13137075	chr4:135889366	G/A	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.86	14.51	0.68	6.89e-35	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs584438	0.873	rs584828	chr17:38599230	C/T	cg11961138	chr17:38599366	IGFBP4	-0.26	-4.92	-0.3	1.58e-6	Height;
KIRP	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs1165472	0.755	rs115716306	chr1:56130204	T/A	cg11523071	chr1:56160889	NA	-0.73	-10.89	-0.57	8.65e-23	Paclitaxel-induced neuropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04006554	chr6:46138530	ENPP5	0.51	6.45	0.38	5.73e-10	Parkinson's disease;
KIRP	cis	rs4919044	0.866	rs11187264	chr10:94824024	C/A	cg05127821	chr10:94822908	CYP26C1	-0.92	-6.71	-0.39	1.36e-10	Coronary artery disease;
KIRP	cis	rs6445967	1.000	rs2292673	chr3:58301901	G/A	cg16569813	chr3:58235849	ABHD6	-0.33	-4.89	-0.3	1.83e-6	Platelet count;
KIRP	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.69	-0.39	1.5e-10	Systolic blood pressure;
KIRP	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.7	8.48	0.48	2.12e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00376283	chr12:123451042	ABCB9	0.68	8.15	0.46	1.91e-14	Neutrophil percentage of white cells;
KIRP	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	6.31	0.37	1.3e-9	HDL cholesterol;
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.41	-5.14	-0.31	5.49e-7	Obesity-related traits;
KIRP	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.95	0.35	9.26e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs986417	0.748	rs11158289	chr14:61032390	C/T	cg27398547	chr14:60952738	C14orf39	0.59	5.9	0.35	1.17e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.51	6.17	0.37	2.83e-9	Uric acid levels;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.72	-6.51	-0.38	4.13e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.75	-8.59	-0.48	1.03e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg23625390	chr15:77176239	SCAPER	0.5	6.65	0.39	1.85e-10	Blood metabolite levels;
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.16	11.35	0.59	2.76e-24	Platelet count;
KIRP	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.38	-0.68	1.98e-34	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.62	7.72	0.44	2.94e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-8.62	-0.48	8.21e-16	Platelet count;
KIRP	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.87	0.35	1.42e-8	Tonsillectomy;
KIRP	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.19	0.37	2.46e-9	Intraocular pressure;
KIRP	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.3	-0.47	6.81e-15	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14813603	chr13:103053482	FGF14	-0.46	-6.32	-0.37	1.23e-9	Interleukin-4 levels;
KIRP	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.02	-0.36	6.14e-9	Morning vs. evening chronotype;
KIRP	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.1	-0.31	6.78e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.47	-5.8	-0.35	1.99e-8	Iron status biomarkers;
KIRP	cis	rs60154123	0.730	rs10489391	chr1:210458861	C/T	cg09074223	chr1:210466472	NA	-0.56	-5.63	-0.34	4.86e-8	Coronary artery disease;
KIRP	cis	rs12282928	1.000	rs12282928	chr11:48332028	A/G	cg26585981	chr11:48327164	OR4S1	0.52	6.28	0.37	1.54e-9	Migraine - clinic-based;
KIRP	cis	rs9462846	0.688	rs116255295	chr6:42906241	G/A	cg13397359	chr6:42928475	GNMT	0.55	6.05	0.36	5.27e-9	Blood protein levels;
KIRP	cis	rs1010254	0.510	rs2348648	chr5:151714570	C/T	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.16	-0.37	3e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.71	-9.21	-0.51	1.51e-17	Sudden cardiac arrest;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.15	-0.31	5.45e-7	Electroencephalogram traits;
KIRP	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg26338869	chr17:61819248	STRADA	0.54	6.41	0.38	7.37e-10	Prudent dietary pattern;
KIRP	cis	rs7916697	0.947	rs56238729	chr10:70001640	T/C	cg06988349	chr10:69991859	ATOH7	0.4	5.3	0.32	2.61e-7	Optic disc area;
KIRP	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.61	-0.52	8.95e-19	Hemoglobin concentration;
KIRP	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.03	9.83	0.53	1.85e-19	Lung cancer in ever smokers;
KIRP	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg17279839	chr7:150038598	RARRES2	0.46	6.08	0.36	4.62e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg11641102	chr8:27183873	PTK2B	0.47	6.11	0.36	3.89e-9	Neuroticism;
KIRP	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.54	-0.48	1.44e-15	Retinal vascular caliber;
KIRP	cis	rs9783347	0.890	rs11024634	chr11:18392074	G/A	cg15585147	chr11:18324498	HPS5	0.45	6.06	0.36	4.99e-9	Pancreatic cancer;
KIRP	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg06064525	chr11:970664	AP2A2	-0.37	-7.59	-0.44	6.45e-13	Alzheimer's disease (late onset);
KIRP	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg00204512	chr16:28754710	NA	0.45	6.06	0.36	5.12e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7909074	0.531	rs879343	chr10:45400707	G/T	cg05187965	chr10:45406764	TMEM72	-0.25	-5.52	-0.33	8.59e-8	Mean corpuscular volume;
KIRP	cis	rs6545883	1.000	rs778758	chr2:61782161	T/C	cg15711740	chr2:61764176	XPO1	-0.62	-8.54	-0.48	1.38e-15	Tuberculosis;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.81	-0.35	1.9e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7187994	0.790	rs62048856	chr16:84764491	C/A	cg07647771	chr16:84786436	USP10	-0.48	-5.87	-0.35	1.44e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9473924	0.542	rs66834257	chr6:50809141	G/A	cg14470998	chr6:50812995	TFAP2B	1.01	9.07	0.5	3.83e-17	Body mass index;
KIRP	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.6	-9.33	-0.51	6.46e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs10759243	0.917	rs7871770	chr9:110307465	A/T	cg16281534	chr5:17224860	BASP1	-0.45	-6.05	-0.36	5.22e-9	Breast cancer;
KIRP	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Bladder cancer;
KIRP	cis	rs787274	1.000	rs10124260	chr9:115559341	T/C	cg13803584	chr9:115635662	SNX30	-0.72	-6.55	-0.39	3.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs477692	0.648	rs10829603	chr10:131327351	T/G	cg24747557	chr10:131355152	MGMT	-0.42	-5.65	-0.34	4.38e-8	Response to temozolomide;
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg11204139	chr17:3907470	NA	0.81	14.89	0.69	3.42e-36	Type 2 diabetes;
KIRP	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg22800045	chr5:56110881	MAP3K1	-0.81	-8.61	-0.48	8.74e-16	Initial pursuit acceleration;
KIRP	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg26874164	chr19:58962979	ZNF324B	0.47	5.58	0.33	6.45e-8	Uric acid clearance;
KIRP	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.64	9.93	0.54	9.02e-20	Prostate cancer;
KIRP	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.63	-0.48	7.65e-16	Total cholesterol levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15528519	chr19:36269387	SNX26	0.47	6.06	0.36	4.95e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2119480	0.762	rs376602	chr13:111304944	T/C	cg24331049	chr13:111365604	ING1	-0.45	-5.42	-0.33	1.43e-7	Diastolic blood pressure;
KIRP	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg21475434	chr5:93447410	FAM172A	0.78	6.71	0.39	1.37e-10	Diabetic retinopathy;
KIRP	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg07402800	chr8:145582003	FBXL6;GPR172A	-0.41	-6.01	-0.36	6.48e-9	Interleukin-6 levels;
KIRP	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.62	-6.61	-0.39	2.37e-10	Diastolic blood pressure;
KIRP	cis	rs2733310	0.842	rs4774893	chr15:57106228	T/C	cg13626582	chr15:57592083	LOC283663	-0.23	-5.12	-0.31	6.27e-7	Mean platelet volume;
KIRP	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg02487422	chr3:49467188	NICN1	0.38	4.89	0.3	1.86e-6	Resting heart rate;
KIRP	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.92	-0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.91	-0.35	1.12e-8	Breast cancer;
KIRP	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.51	8.91	0.49	1.16e-16	Vitiligo;
KIRP	cis	rs6882046	0.513	rs447801	chr5:88002653	T/C	cg24804195	chr5:87968844	LOC645323	-0.48	-6.41	-0.38	7.45e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.44	-5.32	-0.32	2.3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg21427119	chr20:30132790	HM13	-0.5	-5.73	-0.34	3e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.42	-5.34	-0.32	2.07e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg20965017	chr5:231967	SDHA	-0.53	-6.11	-0.36	3.91e-9	Breast cancer;
KIRP	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.69	8.76	0.49	3.16e-16	Resting heart rate;
KIRP	cis	rs963731	0.649	rs297135	chr2:39304793	G/A	cg04010122	chr2:39346883	SOS1	-0.91	-6.45	-0.38	5.74e-10	Corticobasal degeneration;
KIRP	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.79	-9.98	-0.54	6.44e-20	Blood trace element (Zn levels);
KIRP	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.45	-0.47	2.5e-15	Calcium levels;
KIRP	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.47	-5.83	-0.35	1.72e-8	Asthma;
KIRP	cis	rs7221595	0.825	rs61442612	chr17:3961019	C/T	cg05562828	chr17:3906858	NA	0.51	5.48	0.33	1.06e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9810890	1.000	rs74602763	chr3:128644612	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg20936604	chr3:58311152	NA	-0.71	-6.13	-0.36	3.51e-9	Cholesterol, total;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.73	6.44	0.38	6.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.66	-6.63	-0.39	2.15e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg26531700	chr6:26746687	NA	0.47	6.83	0.4	6.62e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg21775007	chr8:11205619	TDH	0.51	6.24	0.37	1.95e-9	Mood instability;
KIRP	cis	rs2562456	0.833	rs1781872	chr19:21477403	T/G	cg18461458	chr19:21324796	ZNF431	-0.54	-5.11	-0.31	6.6e-7	Pain;
KIRP	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.66	-9.55	-0.52	1.43e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg19000871	chr14:103996768	TRMT61A	-0.51	-5.66	-0.34	4.26e-8	Reticulocyte count;
KIRP	cis	rs981844	1.000	rs2263434	chr4:154658312	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg21475434	chr5:93447410	FAM172A	-0.43	-4.96	-0.3	1.31e-6	Diabetic retinopathy;
KIRP	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg23533926	chr12:111358616	MYL2	-0.48	-6.33	-0.37	1.18e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.58	0.39	2.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.55	-0.56	1.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg13969321	chr5:6713231	POLS	0.57	6.74	0.39	1.13e-10	Electroencephalogram traits;
KIRP	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg00977110	chr5:151150581	G3BP1	0.57	5.77	0.35	2.4e-8	Preschool internalizing problems;
KIRP	cis	rs7665939	0.790	rs72709294	chr4:190142270	G/C	cg14840187	chr4:190284988	NA	-1.0	-6.53	-0.38	3.83e-10	Amyotrophic lateral sclerosis;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.71	8.94	0.5	9.69e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	trans	rs693249	0.541	rs61901706	chr11:131768231	C/A	cg05184729	chr5:1962311	NA	-0.56	-6.04	-0.36	5.6e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg08126542	chr6:37504118	NA	-0.7	-9.88	-0.53	1.35e-19	Cognitive performance;
KIRP	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.92	13.48	0.65	2.22e-31	Coronary artery disease;
KIRP	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs6662572	0.703	rs17855317	chr1:46500613	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.37	0.32	1.82e-7	Blood protein levels;
KIRP	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg09408571	chr1:101003634	GPR88	-0.24	-5.53	-0.33	8.06e-8	Monocyte count;
KIRP	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.82	-14.77	-0.69	8.91e-36	Body mass index;
KIRP	cis	rs66561647	0.661	rs890442	chr8:128931207	G/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.41	5.24	0.32	3.38e-7	Hemoglobin concentration;
KIRP	cis	rs8067545	0.532	rs12449914	chr17:20003969	T/C	cg04132472	chr17:19861366	AKAP10	0.43	4.99	0.3	1.13e-6	Schizophrenia;
KIRP	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.88	-0.3	1.92e-6	Cervical cancer;
KIRP	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.65	-8.62	-0.48	8.06e-16	Motion sickness;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.93	0.3	1.54e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.52	-7.24	-0.42	5.82e-12	Schizophrenia;
KIRP	cis	rs28489187	0.666	rs233132	chr1:85796545	A/G	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs2131877	0.645	rs4677812	chr3:194863794	C/A	cg21937377	chr3:194868750	C3orf21	0.2	5.05	0.31	8.56e-7	Non-small cell lung cancer;
KIRP	cis	rs6901004	0.605	rs2297939	chr6:111549162	C/T	cg15721981	chr6:111408429	SLC16A10	-0.6	-7.85	-0.45	1.3e-13	Blood metabolite levels;
KIRP	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg24803719	chr17:45855879	NA	-0.4	-5.37	-0.32	1.84e-7	IgG glycosylation;
KIRP	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.57	8.23	0.46	1.08e-14	Carotid intima media thickness;
KIRP	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.73	9.57	0.52	1.19e-18	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35000415	1.000	rs35000415	chr7:128585616	C/T	cg19972273	chr7:128594194	NA	0.85	6.25	0.37	1.81e-9	Systemic lupus erythematosus;
KIRP	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.46	0.33	1.18e-7	Homoarginine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20832448	chr3:36418645	NA	0.43	6.08	0.36	4.51e-9	Interleukin-4 levels;
KIRP	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.73	8.93	0.49	1.04e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3815308	0.530	rs12973409	chr19:2196963	A/G	cg09261902	chr19:2140048	AP3D1	0.58	8.42	0.47	3.16e-15	Breast cancer;
KIRP	cis	rs6662572	0.737	rs12045409	chr1:46358720	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.18	0.31	4.7e-7	Blood protein levels;
KIRP	cis	rs2997447	0.894	rs41311276	chr1:26387625	A/C	cg19633962	chr1:26362018	EXTL1	-0.67	-6.13	-0.36	3.47e-9	QRS complex (12-leadsum);
KIRP	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg20387954	chr3:183756860	HTR3D	0.62	8.89	0.49	1.31e-16	Anterior chamber depth;
KIRP	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-21.7	-0.81	4.73e-59	Height;
KIRP	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-5.67	-0.34	3.99e-8	Endometrial cancer;
KIRP	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	0.88	7.66	0.44	4.32e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.45	-5.61	-0.34	5.54e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs220519	0.811	rs220515	chr20:37283506	A/T	cg24308336	chr20:37270989	C20orf95	-0.23	-5.13	-0.31	5.89e-7	Schizophrenia;
KIRP	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.63	-0.34	4.85e-8	Coronary artery disease;
KIRP	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg18044113	chr7:2236405	MAD1L1	-0.31	-5.12	-0.31	6.3e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9826463	1.000	rs6440095	chr3:142325748	A/T	cg20824294	chr3:142316082	PLS1	0.32	5.59	0.34	5.92e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9584850	0.874	rs3742137	chr13:99102449	C/T	cg20750642	chr13:99100586	FARP1	-0.54	-6.4	-0.38	7.64e-10	Neuroticism;
KIRP	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg08632701	chr21:37451849	NA	-0.47	-5.73	-0.34	2.87e-8	Mitral valve prolapse;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg04371633	chr14:65381025	CHURC1	0.52	6.73	0.39	1.16e-10	Asthma;
KIRP	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg26727032	chr16:67993705	SLC12A4	0.63	5.0	0.3	1.11e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg16479474	chr6:28041457	NA	0.43	4.87	0.3	1.96e-6	Depression;
KIRP	cis	rs11195062	0.521	rs4918485	chr10:111949323	A/T	cg00817464	chr10:111662876	XPNPEP1	0.33	5.19	0.31	4.32e-7	Multiple myeloma;
KIRP	cis	rs9308731	0.583	rs10211562	chr2:111930796	G/T	cg04780086	chr2:111875790	ACOXL	0.44	6.02	0.36	6.19e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg00405596	chr8:11794950	NA	-0.47	-6.12	-0.36	3.64e-9	Retinal vascular caliber;
KIRP	cis	rs11239930	0.560	rs632334	chr1:146551521	C/T	cg16700924	chr1:146552102	NA	-0.44	-4.87	-0.3	2e-6	AIDS progression;
KIRP	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	5.55	0.33	7.53e-8	Renal cell carcinoma;
KIRP	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg05370193	chr1:21551575	ECE1	0.45	6.26	0.37	1.67e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg00405596	chr8:11794950	NA	0.41	5.13	0.31	5.84e-7	Morning vs. evening chronotype;
KIRP	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.1	0.31	6.78e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7215564	0.818	rs34756632	chr17:78618859	C/T	cg06153925	chr17:78755379	RPTOR	0.46	6.07	0.36	4.93e-9	Myopia (pathological);
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg08501292	chr6:25962987	TRIM38	0.85	6.64	0.39	1.97e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11987759	chr7:65425863	GUSB	0.46	5.37	0.32	1.84e-7	Aortic root size;
KIRP	cis	rs13095912	0.962	rs12374077	chr3:185317674	G/C	cg11274856	chr3:185301563	NA	0.53	6.93	0.4	3.65e-11	Systolic blood pressure;
KIRP	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06481639	chr22:41940642	POLR3H	-0.56	-6.36	-0.38	9.65e-10	Vitiligo;
KIRP	trans	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.25	-0.37	1.76e-9	Obesity-related traits;
KIRP	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-9.09	-0.5	3.36e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-6.84	-0.4	6.22e-11	Obesity-related traits;
KIRP	cis	rs10211205	1.000	rs10166654	chr2:236611263	C/T	cg02339850	chr2:236586191	AGAP1	-0.55	-5.59	-0.34	6.06e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2625529	0.824	rs12592044	chr15:72419115	A/G	cg16672083	chr15:72433130	SENP8	-0.5	-6.11	-0.36	3.93e-9	Red blood cell count;
KIRP	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg05973401	chr12:123451056	ABCB9	0.61	7.12	0.41	1.15e-11	Neutrophil percentage of white cells;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg10146807	chr11:43333301	API5	-0.48	-6.41	-0.38	7.47e-10	Obesity-related traits;
KIRP	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.55	-0.39	3.28e-10	Systolic blood pressure;
KIRP	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg12559939	chr2:27858050	GPN1	0.4	4.92	0.3	1.57e-6	Oral cavity cancer;
KIRP	cis	rs4523957	0.651	rs9910413	chr17:2081419	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-11.52	-0.59	7.56e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15179113	chr7:156433342	C7orf13;RNF32	0.49	6.23	0.37	2e-9	Parkinson's disease;
KIRP	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg12218747	chr21:37451666	NA	-0.43	-5.37	-0.32	1.8e-7	Mitral valve prolapse;
KIRP	cis	rs735539	0.645	rs1329518	chr13:21203611	C/G	cg04906043	chr13:21280425	IL17D	-0.49	-5.66	-0.34	4.22e-8	Dental caries;
KIRP	cis	rs6601327	0.665	rs10113155	chr8:9655358	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.0	-0.3	1.09e-6	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg17617930	chr7:31091825	ADCYAP1R1	-0.56	-6.5	-0.38	4.49e-10	Menopause (age at onset);
KIRP	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg10167378	chr1:228756711	NA	-0.42	-5.4	-0.33	1.57e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	ch.11.42038R	chr11:967971	AP2A2	0.46	6.09	0.36	4.3e-9	Alzheimer's disease (late onset);
KIRP	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs554111	0.634	rs7551785	chr1:21524297	C/G	cg21184320	chr1:21044207	KIF17	0.39	5.79	0.35	2.09e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs12986413	1.000	rs11882273	chr19:2173836	T/C	cg09261902	chr19:2140048	AP3D1	0.64	9.85	0.53	1.6e-19	Height;
KIRP	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.49	-0.38	4.73e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.42	0.47	3.18e-15	Electroencephalogram traits;
KIRP	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg02527881	chr3:46936655	PTH1R	-0.5	-6.83	-0.4	6.47e-11	Birth weight;
KIRP	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.7	-0.63	9.44e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4664293	0.836	rs4664300	chr2:160600438	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08931196	chr11:119205177	RNF26	0.47	6.07	0.36	4.8e-9	Parkinson's disease;
KIRP	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg03609598	chr5:56110824	MAP3K1	0.48	5.51	0.33	9.24e-8	Initial pursuit acceleration;
KIRP	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg11833968	chr6:79620685	NA	0.44	6.76	0.4	1.01e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-5.67	-0.34	4e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	6.12	0.36	3.59e-9	Response to antipsychotic treatment;
KIRP	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg07052231	chr12:7363540	PEX5	0.38	5.05	0.31	8.67e-7	IgG glycosylation;
KIRP	cis	rs4563143	0.647	rs61378972	chr19:29218742	C/T	cg12756686	chr19:29218302	NA	0.99	9.86	0.53	1.52e-19	Methadone dose in opioid dependence;
KIRP	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.48	7.4	0.43	2.12e-12	Testicular germ cell tumor;
KIRP	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.43e-13	Corneal astigmatism;
KIRP	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg07741184	chr6:167504864	NA	0.24	6.43	0.38	6.44e-10	Crohn's disease;
KIRP	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg07777115	chr5:623756	CEP72	-0.36	-4.89	-0.3	1.85e-6	Obesity-related traits;
KIRP	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs6743226	0.901	rs7592138	chr2:242218915	G/A	cg10021735	chr2:242295487	FARP2	0.48	5.76	0.34	2.51e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.64e-16	Life satisfaction;
KIRP	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg26513180	chr16:89883248	FANCA	0.82	5.73	0.34	2.91e-8	Skin colour saturation;
KIRP	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg08975724	chr8:8085496	FLJ10661	0.6	7.58	0.44	7.16e-13	Platelet distribution width;
KIRP	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.32	-0.42	3.41e-12	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.22	-0.46	1.16e-14	Mood instability;
KIRP	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg06217071	chr17:408420	NA	0.38	5.03	0.31	9.49e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.62	8.49	0.48	1.99e-15	Platelet count;
KIRP	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.85	-12.42	-0.62	8.2e-28	Leprosy;
KIRP	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.42	-5.52	-0.33	8.57e-8	Body mass index;
KIRP	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.26	7.14	0.41	1.04e-11	Crohn's disease;
KIRP	cis	rs11971779	0.666	rs7786851	chr7:139007020	C/G	cg07862535	chr7:139043722	LUC7L2	-0.62	-6.67	-0.39	1.7e-10	Diisocyanate-induced asthma;
KIRP	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg11845111	chr2:191398756	TMEM194B	-0.74	-7.85	-0.45	1.25e-13	Diastolic blood pressure;
KIRP	cis	rs4805272	1.000	rs2870547	chr19:29324866	G/C	cg15000279	chr19:29285009	NA	-0.36	-5.21	-0.32	3.94e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg22138327	chr13:27999177	GTF3A	0.9	6.73	0.39	1.19e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.72	-10.39	-0.55	3.23e-21	Educational attainment;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg08662619	chr6:150070041	PCMT1	0.38	6.39	0.38	8.4e-10	Lung cancer;
KIRP	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.41	-0.33	1.53e-7	Coronary artery disease;
KIRP	cis	rs9596863	0.898	rs7984502	chr13:54344640	T/C	ch.13.53330881F	chr13:54432880	NA	0.6	5.82	0.35	1.86e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg00383909	chr3:49044727	WDR6	0.44	4.85	0.3	2.19e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-4.85	-0.3	2.22e-6	Platelet distribution width;
KIRP	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg19468946	chr17:37922297	IKZF3	-0.47	-6.48	-0.38	4.99e-10	Self-reported allergy;
KIRP	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-6.81	-0.4	7.3e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg27624424	chr6:160112604	SOD2	0.47	4.95	0.3	1.4e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.18	12.61	0.63	1.83e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs7172677	0.793	rs8029712	chr15:75418170	T/A	cg14664628	chr15:75095509	CSK	-0.51	-5.66	-0.34	4.29e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg10047753	chr17:41438598	NA	1.15	17.6	0.75	2.01e-45	Menopause (age at onset);
KIRP	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.18e-8	Lung cancer;
KIRP	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg21573476	chr21:45109991	RRP1B	-0.56	-7.62	-0.44	5.41e-13	Mean corpuscular volume;
KIRP	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg15147215	chr3:52552868	STAB1	-0.29	-4.97	-0.3	1.26e-6	Electroencephalogram traits;
KIRP	cis	rs981844	0.712	rs6855082	chr4:154754039	A/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs7429990	0.965	rs5016900	chr3:47822877	G/C	cg11946769	chr3:48343235	NME6	0.54	5.42	0.33	1.41e-7	Educational attainment (years of education);
KIRP	cis	rs7851660	0.844	rs4743139	chr9:100638420	A/G	cg13688889	chr9:100608707	NA	-0.69	-8.83	-0.49	1.98e-16	Strep throat;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg01246254	chr10:124134882	PLEKHA1	-0.46	-6.59	-0.39	2.6200000000000003e-10	Serum protein levels (sST2);
KIRP	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg02151108	chr14:50098012	C14orf104	-0.46	-6.02	-0.36	6.39e-9	Carotid intima media thickness;
KIRP	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg09699651	chr6:150184138	LRP11	0.5	6.37	0.38	9.3e-10	Lung cancer;
KIRP	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.81	10.98	0.57	4.24e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg15181151	chr6:150070149	PCMT1	0.3	5.17	0.31	4.78e-7	Lung cancer;
KIRP	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg23307798	chr14:103986281	CKB	0.73	11.44	0.59	1.4e-24	Body mass index;
KIRP	cis	rs7951870	1.000	rs7484002	chr11:46640503	A/G	cg16389345	chr11:46697382	NA	-0.47	-4.87	-0.3	2e-6	Schizophrenia;
KIRP	cis	rs4776059	0.958	rs933860	chr15:52965468	T/C	cg25063058	chr15:52860530	ARPP19	0.54	5.67	0.34	3.93e-8	Schizophrenia;
KIRP	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg05998816	chr21:47859926	PCNT	0.52	6.08	0.36	4.67e-9	Lymphocyte counts;
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.73e-9	Life satisfaction;
KIRP	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg16586182	chr3:47516702	SCAP	0.81	11.56	0.59	5.74e-25	Colorectal cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00399938	chr22:20118646	ZDHHC8	-0.5	-6.53	-0.38	3.67e-10	Metabolic traits;
KIRP	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.64	5.53	0.33	8.18e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.78	8.43	0.47	2.89e-15	Corneal astigmatism;
KIRP	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg20673091	chr1:2541236	MMEL1	0.79	12.91	0.64	1.81e-29	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg12140854	chr5:148520817	ABLIM3	-0.43	-4.95	-0.3	1.37e-6	Breast cancer;
KIRP	cis	rs10073892	0.917	rs1901514	chr5:101711280	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.98	0.41	2.71e-11	Cognitive decline (age-related);
KIRP	cis	rs929596	0.564	rs2741029	chr2:234530160	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-5.28	-0.32	2.87e-7	Total bilirubin levels in HIV-1 infection;
KIRP	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.9	11.73	0.6	1.6e-25	Height;
KIRP	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg27068330	chr11:65405492	SIPA1	0.38	5.18	0.31	4.67e-7	Acne (severe);
KIRP	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-11.36	-0.59	2.63e-24	Total body bone mineral density;
KIRP	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.39	-0.47	3.76e-15	Chronic sinus infection;
KIRP	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg09754948	chr16:28834200	ATXN2L	-0.46	-5.51	-0.33	9.2e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg15282417	chr9:129245246	FAM125B	0.43	7.37	0.43	2.58e-12	Intraocular pressure;
KIRP	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.8	11.0	0.57	3.64e-23	Aortic root size;
KIRP	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.24	-0.51	1.22e-17	Total body bone mineral density;
KIRP	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-6.25	-0.37	1.82e-9	Menarche (age at onset);
KIRP	trans	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg01311341	chr22:25575246	KIAA1671	-0.58	-6.33	-0.37	1.17e-9	Glioblastoma;
KIRP	cis	rs16976116	0.803	rs28590021	chr15:55490993	C/T	cg11288833	chr15:55489084	RSL24D1	0.66	7.46	0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.48	6.16	0.37	2.97e-9	Motion sickness;
KIRP	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.05e-8	Lung cancer;
KIRP	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	8.58	0.48	1.06e-15	Personality dimensions;
KIRP	cis	rs897080	0.515	rs1067332	chr2:44626972	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.39	0.38	8.28e-10	Height;
KIRP	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.55	-6.94	-0.4	3.52e-11	Myeloid white cell count;
KIRP	cis	rs6893807	0.667	rs7733438	chr5:87986284	T/G	cg24804195	chr5:87968844	LOC645323	0.61	5.78	0.35	2.21e-8	Body mass index;
KIRP	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg22604316	chr1:46958801	NA	0.34	4.84	0.3	2.25e-6	Monobrow;
KIRP	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.73	-9.3	-0.51	7.72e-18	Neutrophil percentage of white cells;
KIRP	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg25036284	chr2:26402008	FAM59B	-0.61	-5.93	-0.35	1.04e-8	Gut microbiome composition (summer);
KIRP	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg25650185	chr19:21324782	ZNF431	0.53	5.53	0.33	8.14e-8	Pain;
KIRP	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.15	-21.79	-0.81	2.31e-59	Colorectal cancer;
KIRP	cis	rs4363385	0.510	rs11803710	chr1:153053096	C/G	cg07796016	chr1:152779584	LCE1C	-0.42	-5.12	-0.31	6.13e-7	Inflammatory skin disease;
KIRP	cis	rs7224685	0.569	rs67533014	chr17:3993910	C/T	cg05562828	chr17:3906858	NA	0.55	5.85	0.35	1.57e-8	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg20965017	chr5:231967	SDHA	-0.58	-6.78	-0.4	8.71e-11	Breast cancer;
KIRP	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.28	-0.37	1.56e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs1620921	0.505	rs2115869	chr6:161207892	C/T	cg01280913	chr6:161186852	NA	-0.61	-8.41	-0.47	3.32e-15	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.56	-6.29	-0.37	1.44e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs7113874	0.921	rs34867877	chr11:8677201	G/C	cg08015107	chr11:8618950	NA	0.35	4.95	0.3	1.36e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.64	6.21	0.37	2.28e-9	Mean platelet volume;
KIRP	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg04727924	chr7:799746	HEATR2	-0.79	-8.95	-0.5	8.95e-17	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6662572	1.000	rs6662999	chr1:46119351	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	4.92	0.3	1.56e-6	Blood protein levels;
KIRP	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg02569458	chr12:86230093	RASSF9	-0.35	-5.03	-0.31	9.27e-7	Major depressive disorder;
KIRP	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg24826892	chr11:71159390	DHCR7	0.45	4.93	0.3	1.52e-6	Vitamin D levels;
KIRP	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4262150	0.726	rs67979431	chr5:152012437	G/T	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.96e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg26874229	chr2:105853672	NA	-0.39	-5.35	-0.32	1.99e-7	Type 2 diabetes;
KIRP	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.84	10.18	0.54	1.54e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs4594175	0.707	rs4901102	chr14:51746605	C/T	cg23942311	chr14:51606299	NA	-0.43	-5.83	-0.35	1.75e-8	Cancer;
KIRP	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg02389323	chr16:88786976	FAM38A	1.16	8.14	0.46	1.94e-14	Plateletcrit;
KIRP	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.53	5.29	0.32	2.71e-7	Initial pursuit acceleration;
KIRP	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35740288	0.770	rs4843085	chr15:86158499	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg21926883	chr2:100939477	LONRF2	-0.52	-6.95	-0.41	3.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.44	5.78	0.35	2.23e-8	Hypertriglyceridemia;
KIRP	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.27	0.37	1.6e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2625529	0.590	rs8023703	chr15:72504059	G/A	cg16672083	chr15:72433130	SENP8	0.47	6.12	0.36	3.75e-9	Red blood cell count;
KIRP	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg04058563	chr4:185651563	MLF1IP	-0.49	-6.66	-0.39	1.75e-10	Kawasaki disease;
KIRP	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg00484396	chr16:3507460	NAT15	0.53	5.57	0.33	6.82e-8	Tuberculosis;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.22	-24.51	-0.84	5.66e-68	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg18944383	chr4:111397179	ENPEP	0.71	13.81	0.66	1.64e-32	Height;
KIRP	cis	rs2882667	0.838	rs11958529	chr5:138395068	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-7.61	-0.44	5.74e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg17644776	chr2:200775616	C2orf69	0.56	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.53	-6.26	-0.37	1.67e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	8.25	0.47	9.81e-15	Response to antipsychotic treatment;
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.13	0.36	3.56e-9	Platelet count;
KIRP	cis	rs146671954	1	rs146671954	chr9:136934203	G/A	cg13789015	chr9:136890014	NCRNA00094	0.69	5.89	0.35	1.29e-8	Red cell distribution width;
KIRP	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg15655495	chr12:38532458	NA	-0.3	-5.23	-0.32	3.66e-7	Bladder cancer;
KIRP	cis	rs1971762	0.527	rs4019971	chr12:53978715	A/G	cg16917193	chr12:54089295	NA	0.68	11.06	0.58	2.41e-23	Height;
KIRP	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.46	6.55	0.39	3.31e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs193541	0.632	rs30036	chr5:122278260	A/G	cg19412675	chr5:122181750	SNX24	0.61	6.48	0.38	5.06e-10	Glucose homeostasis traits;
KIRP	cis	rs735539	0.555	rs4608189	chr13:21343209	C/T	cg04906043	chr13:21280425	IL17D	-0.44	-5.08	-0.31	7.56e-7	Dental caries;
KIRP	cis	rs2652822	0.509	rs7163254	chr15:63439403	G/T	cg02713581	chr15:63449717	RPS27L	0.48	5.17	0.31	4.93e-7	Metabolic traits;
KIRP	cis	rs13102973	0.899	rs10213137	chr4:135900543	T/C	cg14419869	chr4:135874104	NA	-0.49	-7.61	-0.44	5.74e-13	Subjective well-being;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.44	5.98	0.36	8.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.18	21.23	0.8	1.54e-57	Cognitive function;
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg14338887	chr6:42928500	GNMT	0.46	6.81	0.4	7.49e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2278796	1.000	rs3892249	chr1:204947489	C/G	cg17449235	chr1:204966235	NFASC	0.55	7.26	0.42	5.07e-12	Mean platelet volume;
KIRP	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs4478858	0.684	rs10798838	chr1:31719450	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.43	-0.33	1.34e-7	Alcohol dependence;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg22907277	chr7:1156413	C7orf50	0.61	7.74	0.44	2.65e-13	Longevity;Endometriosis;
KIRP	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.09	0.54	2.93e-20	Dupuytren's disease;
KIRP	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.32	-0.42	3.54e-12	Uric acid levels;
KIRP	cis	rs2275620	0.526	rs6583963	chr10:96682315	T/A	cg09036531	chr10:96991505	NA	-0.48	-5.68	-0.34	3.82e-8	Gout;
KIRP	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-11.56	-0.59	5.76e-25	Body mass index;
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14159672	chr1:205819179	PM20D1	0.79	11.06	0.58	2.32e-23	Monocyte percentage of white cells;
KIRP	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg09788416	chr12:39539408	NA	0.39	5.26	0.32	3.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs4478037	0.822	rs9863331	chr3:33123235	G/T	cg19404215	chr3:33155277	CRTAP	0.57	5.46	0.33	1.15e-7	Major depressive disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17371621	chr15:61264283	RORA	0.45	6.12	0.36	3.77e-9	Survival in pancreatic cancer;
KIRP	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg08873628	chr1:175162347	KIAA0040	0.4	5.88	0.35	1.32e-8	Alcohol dependence;
KIRP	cis	rs6840360	0.904	rs6813516	chr4:152594407	C/G	cg22705602	chr4:152727874	NA	-0.52	-8.89	-0.49	1.36e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.58	-0.43	7.19e-13	Joint mobility (Beighton score);
KIRP	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.44	-6.51	-0.38	4.14e-10	Sitting height ratio;
KIRP	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.8	7.29	0.42	4.14e-12	Mean platelet volume;
KIRP	cis	rs34779708	0.801	rs12098720	chr10:35538683	G/A	cg03585969	chr10:35415529	CREM	0.64	7.53	0.43	9.49e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10114408	0.959	rs7030088	chr9:96663432	A/C	cg14598338	chr9:96623480	NA	-0.32	-4.91	-0.3	1.7e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs7394190	1.000	rs10824026	chr10:75421208	A/G	cg04833713	chr10:74871078	NUDT13	0.42	5.84	0.35	1.64e-8	Incident atrial fibrillation;
KIRP	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.79	8.41	0.47	3.26e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg04691961	chr3:161091175	C3orf57	-0.63	-10.36	-0.55	4.07e-21	Morning vs. evening chronotype;
KIRP	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg27411982	chr8:10470053	RP1L1	0.42	5.4	0.33	1.54e-7	Triglycerides;
KIRP	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.9	-12.25	-0.62	2.93e-27	Platelet distribution width;
KIRP	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg18190219	chr22:46762943	CELSR1	-0.61	-5.78	-0.35	2.3e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.86	12.13	0.61	7.61e-27	Total body bone mineral density;
KIRP	trans	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg20528838	chr20:57427730	GNAS	-0.44	-6.03	-0.36	5.83e-9	Height;
KIRP	trans	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.21	-0.37	2.29e-9	Endometrial cancer;
KIRP	cis	rs1620921	0.524	rs12214168	chr6:161195801	C/T	cg01280913	chr6:161186852	NA	-0.68	-9.51	-0.52	1.8e-18	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg19875535	chr5:140030758	IK	0.64	8.78	0.49	2.77e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4006360	0.542	rs9900575	chr17:39307675	C/T	cg16985667	chr17:39306289	KRTAP4-5	0.51	6.56	0.39	3.17e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06212747	chr3:49208901	KLHDC8B	0.75	10.38	0.55	3.59e-21	Parkinson's disease;
KIRP	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg18478394	chr8:109455254	TTC35	0.51	6.26	0.37	1.71e-9	Dupuytren's disease;
KIRP	cis	rs259842	0.670	rs4894129	chr2:180707419	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.39	-5.26	-0.32	3.09e-7	Blood protein levels;
KIRP	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.88	10.37	0.55	3.91e-21	Obesity-related traits;
KIRP	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00745463	chr17:30367425	LRRC37B	-0.92	-6.63	-0.39	2.08e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9596863	0.898	rs9591536	chr13:54377682	A/G	ch.13.53330881F	chr13:54432880	NA	0.58	5.87	0.35	1.42e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs448720	0.935	rs431214	chr15:68210593	T/C	cg24579218	chr15:68104479	NA	-0.34	-4.9	-0.3	1.76e-6	Cognitive performance;
KIRP	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg01304814	chr3:48885189	PRKAR2A	0.55	5.06	0.31	8.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.85	11.59	0.59	4.48e-25	Selective IgA deficiency;
KIRP	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.95	11.29	0.58	4.31e-24	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg19308663	chr11:118741387	NA	-0.56	-9.56	-0.52	1.32e-18	Sjögren's syndrome;
KIRP	cis	rs7818345	1.000	rs4392916	chr8:19309355	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.38	5.44	0.33	1.31e-7	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	7.58	0.44	7.1e-13	Height;
KIRP	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg04310649	chr10:35416472	CREM	-0.53	-5.97	-0.36	8.41e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.04	8.02	0.46	4.31e-14	Skin colour saturation;
KIRP	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.69	0.66	4.25e-32	Tonsillectomy;
KIRP	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.94	-13.64	-0.66	6.16e-32	Coronary artery disease;
KIRP	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg20701182	chr2:24300061	SF3B14	0.51	5.03	0.31	9.31e-7	Asthma;
KIRP	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.83	-12.48	-0.62	5.12e-28	Lung cancer in ever smokers;
KIRP	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg21546286	chr11:48923668	NA	-0.45	-5.52	-0.33	8.61e-8	HDL cholesterol;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08043048	chr2:197036688	STK17B	0.5	6.03	0.36	5.89e-9	Lung cancer in ever smokers;
KIRP	cis	rs72960926	0.744	rs11752920	chr6:75000195	C/T	cg03266952	chr6:74778945	NA	-0.76	-5.78	-0.35	2.28e-8	Metabolite levels (MHPG);
KIRP	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.59	7.6	0.44	6.06e-13	Schizophrenia;
KIRP	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-4.88	-0.3	1.9e-6	Multiple sclerosis;
KIRP	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg06386533	chr2:46925753	SOCS5	0.61	8.04	0.46	3.67e-14	Height;
KIRP	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23161317	chr6:28129485	ZNF389	0.42	4.92	0.3	1.57e-6	Depression;
KIRP	cis	rs5771225	0.563	rs5771281	chr22:50693479	A/G	cg16473166	chr22:50639996	SELO	0.74	8.55	0.48	1.35e-15	Late-onset Alzheimer's disease;
KIRP	cis	rs10214930	0.697	rs13242248	chr7:27682871	C/T	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs56146971	0.703	rs79190905	chr14:91848149	C/T	cg10511902	chr14:91842949	CCDC88C	0.5	5.3	0.32	2.54e-7	Alzheimer disease and age of onset;
KIRP	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg22089800	chr15:90895588	ZNF774	0.42	5.04	0.31	8.93e-7	Rheumatoid arthritis;
KIRP	cis	rs4727443	0.899	rs886453	chr7:99588225	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.4	5.37	0.32	1.86e-7	Interstitial lung disease;
KIRP	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg23791538	chr6:167370224	RNASET2	-0.47	-5.66	-0.34	4.2e-8	Crohn's disease;
KIRP	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-7.72	-0.44	2.93e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19346786	chr7:2764209	NA	0.34	6.4	0.38	7.88e-10	Height;
KIRP	cis	rs10940138	0.501	rs6877828	chr5:67249904	A/G	ch.5.1281357F	chr5:67228439	NA	-0.49	-7.25	-0.42	5.29e-12	Menarche (age at onset);
KIRP	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Triglycerides;
KIRP	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.53	-0.33	8.28e-8	Total body bone mineral density;
KIRP	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.54	-7.14	-0.41	1.06e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg00990874	chr7:1149470	C7orf50	-0.41	-4.86	-0.3	2.12e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.49	5.86	0.35	1.46e-8	Metabolite levels;
KIRP	cis	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg13165212	chr22:42675999	NA	0.28	4.99	0.3	1.13e-6	Cognitive function;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg10254082	chr7:997346	NA	0.49	5.04	0.31	9.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12144044	0.784	rs3806443	chr1:113249486	C/G	cg22162597	chr1:113214053	CAPZA1	0.48	5.14	0.31	5.48e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs13064411	0.518	rs9842559	chr3:113252705	A/C	cg18753928	chr3:113234510	CCDC52	-0.47	-5.91	-0.35	1.16e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11987759	chr7:65425863	GUSB	-0.7	-9.8	-0.53	2.33e-19	Calcium levels;
KIRP	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.4	5.71	0.34	3.23e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.68	-9.06	-0.5	4.14e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.81	11.81	0.6	8.47e-26	Menarche (age at onset);
KIRP	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.79	0.4	8.55e-11	Height;
KIRP	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg10189774	chr4:17578691	LAP3	0.54	6.81	0.4	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.63	-9.82	-0.53	2.11e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg09795085	chr6:101329169	ASCC3	0.42	5.14	0.31	5.51e-7	Neuroticism;
KIRP	cis	rs7209700	0.742	rs999323	chr17:45371603	T/C	cg25173405	chr17:45401733	C17orf57	0.4	4.86	0.3	2.07e-6	IgG glycosylation;
KIRP	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg14972814	chr11:95582409	MTMR2	0.34	5.88	0.35	1.33e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4132509	0.779	rs3006939	chr1:243677834	G/A	cg25706552	chr1:244017396	NA	0.45	6.32	0.37	1.23e-9	RR interval (heart rate);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08077726	chr17:74734280	SFRS2;MFSD11	0.54	6.4	0.38	7.75e-10	Smoking initiation;
KIRP	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.26	5.09	0.31	7.25e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs6540555	0.505	rs11806703	chr1:209882906	A/T	cg23920097	chr1:209922102	NA	-0.48	-5.4	-0.33	1.54e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.92	-12.92	-0.64	1.77e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs35995292	0.500	rs6955677	chr7:38933942	C/T	cg19327137	chr7:38886074	VPS41	0.79	12.21	0.61	4.11e-27	Subjective well-being (multi-trait analysis);
KIRP	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.61	0.44	5.67e-13	Prudent dietary pattern;
KIRP	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.81	6.28	0.37	1.54e-9	Arsenic metabolism;
KIRP	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg03235661	chr20:60525775	NA	-0.3	-4.97	-0.3	1.25e-6	Body mass index;
KIRP	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg10932868	chr11:921992	NA	0.46	5.34	0.32	2.12e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg19357178	chr21:45527350	PWP2	0.47	6.02	0.36	6.16e-9	DNA methylation (variation);
KIRP	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg03060546	chr3:49711283	APEH	0.43	5.65	0.34	4.38e-8	Parkinson's disease;
KIRP	cis	rs2230307	0.536	rs11166384	chr1:100439890	C/T	cg24955406	chr1:100503596	HIAT1	0.67	7.68	0.44	3.83e-13	Carotid intima media thickness;
KIRP	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	5.42	0.33	1.42e-7	Vitiligo;
KIRP	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg20019720	chr6:154832845	CNKSR3	0.41	6.2	0.37	2.38e-9	Lipoprotein (a) levels;
KIRP	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.81	12.05	0.61	1.39e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs829661	1.000	rs1447193	chr2:30864980	A/G	cg10949345	chr2:30726833	LCLAT1	0.7	8.66	0.48	6.18e-16	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg27490568	chr2:178487706	NA	0.47	6.28	0.37	1.53e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg00585698	chr12:123750864	CDK2AP1	0.5	6.23	0.37	1.99e-9	Neutrophil percentage of white cells;
KIRP	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Morning vs. evening chronotype;
KIRP	cis	rs7712401	0.584	rs39820	chr5:122299921	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.37	-10.31	-0.55	5.82e-21	Diabetic kidney disease;
KIRP	trans	rs526821	0.595	rs629948	chr11:55356448	G/A	cg15704280	chr7:45808275	SEPT13	-0.51	-6.12	-0.36	3.57e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg18225595	chr11:63971243	STIP1	0.64	5.82	0.35	1.83e-8	Mean platelet volume;
KIRP	cis	rs11997175	0.545	rs59563980	chr8:33665377	C/T	ch.8.33884649F	chr8:33765107	NA	0.5	5.95	0.35	9.24e-9	Body mass index;
KIRP	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-1.12	-18.72	-0.77	3.2e-49	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.42e-11	Schizophrenia;
KIRP	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.65	-8.21	-0.46	1.28e-14	Extraversion;
KIRP	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-11.45	-0.59	1.29e-24	Total body bone mineral density;
KIRP	trans	rs1973993	0.603	rs3912027	chr1:96993603	G/T	cg10631902	chr5:14652156	NA	-0.53	-6.75	-0.4	1.06e-10	Weight;
KIRP	cis	rs6963495	0.649	rs1706888	chr7:105149176	A/G	cg19920283	chr7:105172520	RINT1	0.53	6.27	0.37	1.62e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.55	0.39	3.33e-10	Morning vs. evening chronotype;
KIRP	cis	rs12579753	0.810	rs1343934	chr12:82123112	G/A	cg07988820	chr12:82153109	PPFIA2	-0.74	-8.65	-0.48	6.87e-16	Resting heart rate;
KIRP	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-6.21	-0.37	2.21e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.5	5.96	0.36	8.76e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg06636001	chr8:8085503	FLJ10661	0.66	9.05	0.5	4.48e-17	Retinal vascular caliber;
KIRP	trans	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.89	-0.4	4.68e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.71	11.07	0.58	2.17e-23	Resting heart rate;
KIRP	cis	rs2494938	0.766	rs707973	chr6:40530686	T/G	cg14084896	chr6:40530702	LRFN2	-0.42	-5.37	-0.32	1.83e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs26949	0.526	rs6887637	chr5:60035640	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.42	-5.11	-0.31	6.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7463256	0.966	rs6557643	chr8:23097802	A/G	cg10977890	chr8:23104600	CHMP7	-0.45	-5.12	-0.31	6.31e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.69	0.48	5.24e-16	Prudent dietary pattern;
KIRP	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.28	-0.32	2.81e-7	Morning vs. evening chronotype;
KIRP	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg07075026	chr17:47091521	IGF2BP1	0.35	6.86	0.4	5.46e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.34	-0.32	2.15e-7	Aortic root size;
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg18209359	chr17:80159595	CCDC57	0.42	5.49	0.33	1.02e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.81	11.11	0.58	1.6e-23	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.73	0.39	1.19e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg13165212	chr22:42675999	NA	0.39	6.5	0.38	4.48e-10	Cognitive function;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.67	9.2	0.51	1.55e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4713118	0.869	rs9468214	chr6:27713299	G/C	cg20933634	chr6:27740509	NA	0.36	4.89	0.3	1.79e-6	Parkinson's disease;
KIRP	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg04166393	chr7:2884313	GNA12	0.44	5.71	0.34	3.25e-8	Height;
KIRP	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.78	8.18	0.46	1.53e-14	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.75	9.31	0.51	7.22e-18	Prostate cancer;
KIRP	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-7.76	-0.44	2.2e-13	Cognitive function;
KIRP	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	1.0	18.01	0.75	7.98e-47	Leprosy;
KIRP	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg05347473	chr6:146136440	FBXO30	0.61	8.69	0.48	5.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-1.05	-20.17	-0.79	4.72e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34779708	0.733	rs7087099	chr10:35541982	C/T	cg03585969	chr10:35415529	CREM	0.61	7.1	0.41	1.33e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg09517077	chr6:108880982	FOXO3	0.49	6.36	0.38	9.95e-10	Myopia (pathological);
KIRP	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.34	-0.65	6.77e-31	Schizophrenia;
KIRP	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	6.18	0.37	2.7e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.39	-4.86	-0.3	2.08e-6	Carotid intima media thickness;
KIRP	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	trans	rs7618501	0.699	rs1062633	chr3:49924940	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	8.31	0.47	6.71e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7172677	0.711	rs8035588	chr15:75436843	A/C	cg14664628	chr15:75095509	CSK	-0.45	-5.03	-0.31	9.43e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9815354	0.556	rs60966614	chr3:42005166	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.7	0.49	4.83e-16	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10864791	chr13:22178445	EFHA1	-0.44	-6.25	-0.37	1.83e-9	Metabolic traits;
KIRP	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg06042504	chr8:55087323	NA	-0.61	-7.44	-0.43	1.68e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg21858823	chr1:15850916	CASP9	0.53	5.16	0.31	5.12e-7	Systolic blood pressure;
KIRP	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.72	-11.24	-0.58	6.35e-24	Hepatocellular carcinoma;
KIRP	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.77	9.42	0.51	3.48e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.4	-5.41	-0.33	1.5e-7	Mean corpuscular volume;
KIRP	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-6.38	-0.38	8.58e-10	Self-reported allergy;
KIRP	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg23803603	chr1:2058230	PRKCZ	0.39	5.58	0.34	6.44e-8	Height;
KIRP	cis	rs11955398	0.625	rs6449485	chr5:59995441	C/T	cg02684056	chr5:59996105	DEPDC1B	0.46	5.19	0.31	4.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg03098644	chr7:100410630	EPHB4	0.51	5.33	0.32	2.22e-7	Other erythrocyte phenotypes;
KIRP	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.08	0.64	5e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.75	9.13	0.5	2.65e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.67	-8.37	-0.47	4.36e-15	Extraversion;
KIRP	trans	rs4650994	0.816	rs2209169	chr1:178601492	C/T	cg05059571	chr16:84539110	KIAA1609	0.53	6.91	0.4	4.24e-11	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2625529	0.590	rs2607090	chr15:72496011	C/A	cg16672083	chr15:72433130	SENP8	-0.47	-5.55	-0.33	7.27e-8	Red blood cell count;
KIRP	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg16414030	chr3:133502952	NA	0.51	5.94	0.35	9.81e-9	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-1.05	-12.53	-0.62	3.57e-28	Breast cancer;
KIRP	cis	rs11583732	0.967	rs11265461	chr1:160630143	C/T	cg17720231	chr1:159915374	IGSF9	0.5	4.86	0.3	2.06e-6	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7615316	0.934	rs6440089	chr3:142279796	T/C	cg20824294	chr3:142316082	PLS1	0.22	4.99	0.3	1.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.81	13.27	0.65	1.14e-30	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg13198984	chr17:80129470	CCDC57	0.57	8.66	0.48	6.46e-16	Life satisfaction;
KIRP	cis	rs62355272	0.931	rs990716	chr5:35899264	C/T	cg13894535	chr5:35919491	CAPSL	0.53	6.49	0.38	4.63e-10	Lymphocyte counts;
KIRP	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg23985595	chr17:80112537	CCDC57	-0.34	-4.99	-0.3	1.15e-6	Life satisfaction;
KIRP	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.59	-0.44	6.59e-13	Type 2 diabetes;
KIRP	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.63	-0.34	5.02e-8	Autism;
KIRP	cis	rs2964802	0.505	rs7737359	chr5:10832104	A/G	cg14521931	chr5:10832172	NA	-0.74	-10.8	-0.57	1.61e-22	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.12e-11	Bipolar disorder;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg03289416	chr15:75166202	SCAMP2	0.56	7.61	0.44	5.78e-13	Breast cancer;
KIRP	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9359856	0.529	rs72919922	chr6:90492997	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.92	-0.45	8.37e-14	Bipolar disorder;
KIRP	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg21605333	chr4:119757512	SEC24D	1.35	9.33	0.51	6.6e-18	Cannabis dependence symptom count;
KIRP	cis	rs4720118	0.508	rs4604335	chr7:33389351	G/A	cg22798885	chr7:33102694	NT5C3	-0.41	-5.12	-0.31	6.21e-7	Leprosy;
KIRP	cis	rs6929812	0.605	rs12526495	chr6:27393871	G/A	cg03332623	chr6:27441972	ZNF184	-0.38	-5.28	-0.32	2.81e-7	Neuroticism (multi-trait analysis);
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.81	13.68	0.66	4.54e-32	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg00745463	chr17:30367425	LRRC37B	0.82	6.78	0.4	8.62e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg06307176	chr5:131281290	NA	-0.52	-5.72	-0.34	3.01e-8	Life satisfaction;
KIRP	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.57	7.87	0.45	1.09e-13	Longevity;
KIRP	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	0.72	7.66	0.44	4.28e-13	Pediatric autoimmune diseases;
KIRP	cis	rs1659258	0.568	rs2579026	chr2:88601555	G/A	cg00685853	chr2:88648947	NA	-0.53	-6.42	-0.38	7.13e-10	Visceral fat;
KIRP	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.11	-0.31	6.59e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.51	-7.26	-0.42	5.13e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg23307798	chr14:103986281	CKB	-0.83	-14.87	-0.69	4.04e-36	Body mass index;
KIRP	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11987759	chr7:65425863	GUSB	-0.47	-5.6	-0.34	5.85e-8	Aortic root size;
KIRP	trans	rs1973993	0.537	rs11165664	chr1:97001427	G/T	cg10631902	chr5:14652156	NA	-0.53	-6.66	-0.39	1.81e-10	Weight;
KIRP	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	7.57	0.43	7.38e-13	Lung cancer in ever smokers;
KIRP	cis	rs959260	0.748	rs4789178	chr17:73368242	C/G	cg20590849	chr17:73267439	MIF4GD	-0.61	-6.54	-0.38	3.52e-10	Systemic lupus erythematosus;
KIRP	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-5.83	-0.35	1.71e-8	Self-reported allergy;
KIRP	cis	rs687432	0.924	rs35740149	chr11:57729034	C/T	cg19752551	chr11:57585705	CTNND1	-0.53	-7.36	-0.42	2.69e-12	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg00792783	chr2:198669748	PLCL1	0.48	5.3	0.32	2.63e-7	Dermatomyositis;
KIRP	cis	rs10802346	0.636	rs12047146	chr1:246399981	T/G	cg15962031	chr1:246363574	SMYD3	0.79	5.92	0.35	1.07e-8	Fractional exhaled nitric oxide (childhood);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26828131	chr1:249106207	SH3BP5L	0.48	6.05	0.36	5.38e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	cg04338863	chr8:33670619	NA	0.42	5.41	0.33	1.49e-7	Body mass index;
KIRP	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.84	5.6	0.34	5.61e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.68	8.77	0.49	2.94e-16	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1656402	1.000	rs2950878	chr2:233424954	C/T	cg03852847	chr2:233439513	NA	0.7	11.53	0.59	6.86e-25	Non-small cell lung cancer (survival);
KIRP	cis	rs10924970	0.967	rs2382616	chr1:235454237	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.0	0.3	1.1e-6	Asthma;
KIRP	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg14169450	chr9:139327907	INPP5E	0.34	4.96	0.3	1.33e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs16828019	0.852	rs2300649	chr1:41569203	T/C	cg18742814	chr1:41828276	NA	0.6	5.41	0.33	1.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.73	7.7	0.44	3.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.98	0.3	1.21e-6	Parkinson's disease;
KIRP	trans	rs1344555	0.762	rs16854106	chr3:169284577	G/A	cg17499719	chr20:17588410	DSTN	-0.53	-6.04	-0.36	5.7e-9	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg18190219	chr22:46762943	CELSR1	-0.72	-7.58	-0.44	7.01e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg03060546	chr3:49711283	APEH	0.48	6.4	0.38	7.74e-10	Parkinson's disease;
KIRP	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.55	0.52	1.37e-18	Monocyte percentage of white cells;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14279997	chr9:95476582	BICD2	0.52	6.31	0.37	1.28e-9	Interleukin-4 levels;
KIRP	cis	rs3903072	0.528	rs11227306	chr11:65578672	C/A	cg00576331	chr11:65640516	EFEMP2	-0.43	-5.42	-0.33	1.4e-7	Breast cancer;
KIRP	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg09165964	chr15:75287851	SCAMP5	0.43	5.47	0.33	1.09e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs60871478	1.000	rs62432224	chr7:788284	G/A	cg13798912	chr7:905769	UNC84A	0.57	5.71	0.34	3.18e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13939156	chr17:80058883	NA	-0.49	-7.46	-0.43	1.47e-12	Life satisfaction;
KIRP	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.52	6.43	0.38	6.4e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.03	-0.41	2.03e-11	Systolic blood pressure;
KIRP	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.49	-6.46	-0.38	5.7e-10	Facial morphology (factor 20);
KIRP	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg23594656	chr7:65796392	TPST1	-0.45	-7.11	-0.41	1.28e-11	Aortic root size;
KIRP	cis	rs7011049	0.841	rs66467113	chr8:53873613	C/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg06647332	chr5:131281008	NA	-0.46	-5.02	-0.3	9.79e-7	Life satisfaction;
KIRP	cis	rs35740288	0.770	rs36044792	chr15:86146551	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg21523564	chr15:75251491	NA	0.4	6.4	0.38	7.76e-10	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg15181151	chr6:150070149	PCMT1	0.28	4.85	0.3	2.18e-6	Lung cancer;
KIRP	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg06740227	chr12:86229804	RASSF9	-0.4	-4.93	-0.3	1.52e-6	Major depressive disorder;
KIRP	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg23752985	chr2:85803571	VAMP8	0.45	5.28	0.32	2.87e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.53	8.18	0.46	1.55e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg18586891	chr4:952366	TMEM175	0.62	5.1	0.31	6.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.76	9.5	0.52	1.93e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-1.09	-10.95	-0.57	5.61e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg02487422	chr3:49467188	NICN1	0.39	5.08	0.31	7.4e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.84e-6	Lung cancer;
KIRP	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg20701182	chr2:24300061	SF3B14	0.56	5.14	0.31	5.6e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.58	-7.9	-0.45	9.11e-14	Colorectal cancer;
KIRP	cis	rs1595825	1.000	rs59441945	chr2:198879645	T/A	cg00982548	chr2:198649783	BOLL	-0.5	-4.95	-0.3	1.39e-6	Ulcerative colitis;
KIRP	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.34	-0.42	3.13e-12	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg00784671	chr22:46762841	CELSR1	-0.49	-6.79	-0.4	8.3e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.71	10.39	0.55	3.36e-21	Glycated hemoglobin levels;
KIRP	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.86	-12.31	-0.62	1.88e-27	Height;
KIRP	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg03060546	chr3:49711283	APEH	-0.64	-6.03	-0.36	5.86e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.81	0.4	7.24e-11	Electroencephalogram traits;
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20916646	chr4:852691	GAK	0.51	6.16	0.37	2.93e-9	Sjögren's syndrome;
KIRP	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.58	5.3	0.32	2.59e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06481639	chr22:41940642	POLR3H	0.56	6.02	0.36	6.22e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2151522	0.724	rs115714389	chr6:127173174	G/A	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21640587	chr11:117668038	DSCAML1	0.52	6.64	0.39	1.97e-10	Myopia;
KIRP	cis	rs4566357	1.000	rs6436650	chr2:227925097	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.1	-0.31	6.8e-7	Coronary artery disease;
KIRP	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg05361325	chr10:32636312	EPC1	-0.66	-6.28	-0.37	1.53e-9	Sexual dysfunction (female);
KIRP	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.85	-9.56	-0.52	1.25e-18	Exhaled nitric oxide output;
KIRP	cis	rs7084402	0.967	rs1658432	chr10:60329069	C/G	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08342675	chr2:201676391	BZW1	0.46	6.61	0.39	2.35e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	6.85	0.4	5.9e-11	Height;
KIRP	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg24209194	chr3:40518798	ZNF619	-0.42	-5.39	-0.33	1.65e-7	Renal cell carcinoma;
KIRP	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.19	0.31	4.32e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7113850	0.541	rs75893426	chr11:24210429	T/C	ch.11.24196551F	chr11:24239977	NA	0.9	7.32	0.42	3.45e-12	Bone fracture in osteoporosis;
KIRP	cis	rs6545883	0.894	rs4672423	chr2:61435275	C/T	cg15711740	chr2:61764176	XPO1	0.57	7.47	0.43	1.41e-12	Tuberculosis;
KIRP	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.4	4.98	0.3	1.21e-6	Response to temozolomide;
KIRP	cis	rs10849893	0.595	rs7980819	chr12:121887194	A/G	cg01154721	chr12:121881891	KDM2B	-0.43	-5.56	-0.33	7.15e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18252515	chr7:66147081	NA	0.43	4.94	0.3	1.42e-6	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11668638	chr6:42952412	PPP2R5D	0.56	6.65	0.39	1.9e-10	Smoking initiation;
KIRP	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.7	-0.34	3.47e-8	Endometrial cancer;
KIRP	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.82	-12.44	-0.62	6.8e-28	Extrinsic epigenetic age acceleration;
KIRP	trans	rs353116	0.697	rs353120	chr2:166129524	C/G	cg23361659	chr2:28914775	NA	-0.33	-6.37	-0.38	9.32e-10	Parkinson's disease;
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg21698718	chr17:80085957	CCDC57	0.35	5.11	0.31	6.52e-7	Life satisfaction;
KIRP	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.12	0.58	1.51e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg16989719	chr2:238392110	NA	-0.52	-6.99	-0.41	2.64e-11	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.38e-8	Life satisfaction;
KIRP	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.79	-10.39	-0.55	3.29e-21	Coronary artery disease;
KIRP	trans	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg07211511	chr3:129823064	LOC729375	-0.7	-7.25	-0.42	5.37e-12	Blood pressure (smoking interaction);
KIRP	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.2	0.51	1.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9469913	0.799	rs2814993	chr6:34618893	A/G	cg17674042	chr6:34482479	PACSIN1	0.45	6.03	0.36	5.99e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs4728302	0.607	rs6954207	chr7:133560955	C/T	cg10665199	chr7:133106180	EXOC4	0.42	4.88	0.3	1.88e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg10560079	chr2:191398806	TMEM194B	-0.8	-9.47	-0.52	2.46e-18	Diastolic blood pressure;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg13453750	chr1:205783389	SLC41A1	-0.5	-7.5	-0.43	1.12e-12	Menarche (age at onset);
KIRP	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg24550644	chr17:30846204	MYO1D	0.29	5.41	0.33	1.49e-7	Schizophrenia;
KIRP	cis	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg26585981	chr11:48327164	OR4S1	-0.47	-5.67	-0.34	4.09e-8	HDL cholesterol;
KIRP	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs3857536	0.730	rs7766281	chr6:66988573	T/G	cg07460842	chr6:66804631	NA	-0.45	-5.16	-0.31	5.12e-7	Blood trace element (Cu levels);
KIRP	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-5.61	-0.34	5.43e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.04	0.31	9.16e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8756	0.791	rs76905924	chr12:66361453	A/G	cg06712651	chr12:66351869	HMGA2	-0.72	-12.28	-0.62	2.46e-27	Height;
KIRP	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-5.74	-0.34	2.84e-8	Height;
KIRP	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.3	-5.35	-0.32	1.97e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg15117754	chr3:10150083	C3orf24	0.5	5.05	0.31	8.78e-7	Alzheimer's disease;
KIRP	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-16.39	-0.72	2.71e-41	Height;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02928029	chr8:95835313	INTS8	0.98	6.65	0.39	1.85e-10	P wave terminal force;
KIRP	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg26384229	chr12:38710491	ALG10B	0.66	8.84	0.49	1.91e-16	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg03468072	chr12:39539422	NA	0.41	5.97	0.36	8.09e-9	Morning vs. evening chronotype;
KIRP	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	4.95	0.3	1.37e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.61	5.5	0.33	9.67e-8	Alzheimer's disease;
KIRP	cis	rs9880211	0.660	rs9289514	chr3:136493203	C/T	cg21827317	chr3:136751795	NA	-0.45	-4.87	-0.3	2.04e-6	Body mass index;Height;
KIRP	cis	rs27434	0.607	rs34750	chr5:96142806	G/C	cg16492584	chr5:96139282	ERAP1	-0.43	-5.8	-0.35	2.04e-8	Ankylosing spondylitis;
KIRP	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg16141378	chr3:129829833	LOC729375	-0.5	-6.21	-0.37	2.22e-9	Retinal vascular caliber;
KIRP	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.51	5.02	0.3	9.88e-7	Recombination rate (females);
KIRP	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg04539111	chr16:67997858	SLC12A4	-0.45	-5.21	-0.32	4.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg13010199	chr12:38710504	ALG10B	0.69	8.89	0.49	1.3e-16	Morning vs. evening chronotype;
KIRP	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg23815491	chr16:72088622	HP	0.48	7.05	0.41	1.78e-11	Blood protein levels;
KIRP	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg17108064	chr15:78857060	CHRNA5	0.37	5.25	0.32	3.33e-7	Sudden cardiac arrest;
KIRP	cis	rs28595532	0.641	rs72670220	chr4:119300053	A/G	cg21605333	chr4:119757512	SEC24D	0.87	7.01	0.41	2.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.6	8.47	0.48	2.31e-15	Multiple system atrophy;
KIRP	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11634397	0.513	rs10152983	chr15:80370631	T/C	cg08257866	chr15:80351198	ZFAND6	0.52	5.48	0.33	1.06e-7	Type 2 diabetes;
KIRP	cis	rs9826463	1.000	rs9813377	chr3:142321717	C/T	cg20824294	chr3:142316082	PLS1	0.32	5.4	0.33	1.61e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6987853	0.933	rs6474401	chr8:42367068	T/C	cg09913449	chr8:42400586	C8orf40	-0.4	-5.13	-0.31	5.77e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs5995756	0.761	rs6001638	chr22:40003267	T/C	cg10455938	chr22:40058150	CACNA1I	-0.53	-7.99	-0.45	5.09e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg26615712	chr19:34856250	GPI	-0.56	-6.41	-0.38	7.25e-10	Brain structure;
KIRP	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg04539111	chr16:67997858	SLC12A4	-0.65	-6.71	-0.39	1.33e-10	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2964802	0.505	rs13159419	chr5:10824302	C/A	cg14521931	chr5:10832172	NA	-0.74	-11.29	-0.58	4.16e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.56	-0.52	1.24e-18	Neuroticism;
KIRP	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.75	12.36	0.62	1.31e-27	Prostate cancer;
KIRP	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	0.47	6.11	0.36	3.82e-9	Systemic lupus erythematosus;
KIRP	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg04865290	chr3:52927548	TMEM110	-0.44	-5.4	-0.33	1.55e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg06740227	chr12:86229804	RASSF9	0.43	5.4	0.33	1.61e-7	Major depressive disorder;
KIRP	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	7.57	0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2273669	0.667	rs10457187	chr6:109336051	G/A	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg17133734	chr15:86042851	AKAP13	-0.44	-5.41	-0.33	1.47e-7	Coronary artery disease;
KIRP	cis	rs2224391	0.784	rs35048711	chr6:5262235	G/T	cg13962347	chr6:5174647	LYRM4	-0.62	-8.42	-0.47	3.16e-15	Height;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.61	-7.99	-0.45	5.34e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9653442	0.564	rs7565895	chr2:100774773	G/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg02896835	chr1:92012615	NA	-0.51	-5.21	-0.32	4.02e-7	Eosinophil percentage of white cells;
KIRP	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.33	6.35	0.38	1.02e-9	Alcohol dependence;
KIRP	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.3	-5.43	-0.33	1.36e-7	Monocyte percentage of white cells;
KIRP	cis	rs13424612	1.000	rs4149551	chr2:240921463	C/T	cg01812947	chr2:240904978	NDUFA10	0.41	5.37	0.32	1.87e-7	Odorant perception (isobutyraldehyde);
KIRP	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg26876637	chr1:152193138	HRNR	0.71	9.45	0.52	2.71e-18	Atopic dermatitis;
KIRP	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg19743168	chr1:23544995	NA	-0.56	-7.64	-0.44	4.79e-13	Height;
KIRP	cis	rs939574	0.512	rs55908154	chr2:220145960	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.58	6.22	0.37	2.16e-9	Platelet distribution width;
KIRP	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg24796726	chr7:884288	UNC84A	-0.6	-5.22	-0.32	3.85e-7	Initial pursuit acceleration;
KIRP	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg10617943	chr7:1981403	MAD1L1	-0.39	-5.31	-0.32	2.45e-7	Neuroticism;
KIRP	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg09571762	chr12:39539558	NA	0.37	4.97	0.3	1.26e-6	Heart rate;
KIRP	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.35	-4.99	-0.3	1.12e-6	Monocyte count;
KIRP	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.41	0.47	3.31e-15	Alzheimer's disease;
KIRP	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg00677455	chr12:58241039	CTDSP2	-0.49	-5.51	-0.33	9.14e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06158533	chr10:104221034	TMEM180	0.5	6.15	0.37	3.19e-9	Parkinson's disease;
KIRP	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg18882449	chr10:104885122	NT5C2	-0.52	-6.73	-0.39	1.2e-10	Arsenic metabolism;
KIRP	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg00405596	chr8:11794950	NA	-0.45	-5.88	-0.35	1.32e-8	Retinal vascular caliber;
KIRP	cis	rs6142102	0.923	rs3787230	chr20:32640272	A/G	cg08999081	chr20:33150536	PIGU	0.51	6.7	0.39	1.4e-10	Skin pigmentation;
KIRP	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg23188684	chr11:67383651	NA	-0.42	-5.47	-0.33	1.13e-7	Mean corpuscular volume;
KIRP	cis	rs244899	0.935	rs2432643	chr5:167925030	G/T	cg13011109	chr5:167955758	FBLL1	0.36	4.92	0.3	1.58e-6	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs7923609	0.869	rs9971352	chr10:65265108	A/T	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.9	-0.35	1.17e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg07423050	chr13:99094983	FARP1	0.32	5.21	0.32	4.05e-7	Longevity;
KIRP	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg13289132	chr10:30722225	MAP3K8	-0.42	-5.23	-0.32	3.61e-7	Inflammatory bowel disease;
KIRP	cis	rs12973672	0.812	rs35250673	chr19:35762548	G/A	cg12095397	chr19:35769544	USF2	0.68	6.26	0.37	1.67e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg13271783	chr10:134563150	INPP5A	-0.62	-7.92	-0.45	8.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg10503236	chr1:231470652	EXOC8	-0.54	-7.53	-0.43	9.83e-13	Hemoglobin concentration;
KIRP	cis	rs10073892	0.750	rs13355600	chr5:101702200	T/C	cg19774478	chr5:101632501	SLCO4C1	0.67	6.42	0.38	6.8e-10	Cognitive decline (age-related);
KIRP	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.64	-0.39	2e-10	Blood pressure;
KIRP	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg11972305	chr2:233791962	NGEF	-0.38	-5.18	-0.31	4.6e-7	Schizophrenia;
KIRP	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.56	-0.52	1.25e-18	Lung cancer;
KIRP	cis	rs9517302	0.578	rs2274054	chr13:99098470	C/T	cg22223119	chr13:99095684	FARP1	-0.46	-5.53	-0.33	8.17e-8	Obesity-related traits;
KIRP	cis	rs9309473	0.528	rs11126396	chr2:73565143	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.39	-0.38	8.26e-10	Metabolite levels;
KIRP	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.64	-9.28	-0.51	8.83e-18	Diastolic blood pressure;
KIRP	cis	rs7193541	0.695	rs7199490	chr16:74716026	G/A	cg01733217	chr16:74700730	RFWD3	0.79	11.27	0.58	4.92e-24	Multiple myeloma;
KIRP	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.63	11.35	0.59	2.67e-24	Total body bone mineral density;
KIRP	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.49	5.11	0.31	6.37e-7	Type 2 diabetes;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.72	6.21	0.37	2.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8060686	0.623	rs74024145	chr16:68153382	G/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.62	-0.44	5.48e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.85	8.08	0.46	2.98e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.41	-0.38	7.31e-10	Mood instability;
KIRP	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.43	0.55	2.54e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.21	-0.42	6.67e-12	Retinal vascular caliber;
KIRP	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg06204229	chr3:52865917	ITIH4	0.43	5.07	0.31	7.71e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg10104451	chr8:143696006	ARC	-0.65	-6.93	-0.4	3.75e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.61	6.77	0.4	9.54e-11	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.97	-0.45	5.99e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-4.91	-0.3	1.7e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg18944383	chr4:111397179	ENPEP	0.62	11.38	0.59	2.23e-24	Height;
KIRP	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.82	-8.76	-0.49	3.33e-16	Asthma;
KIRP	cis	rs7105934	1.000	rs6606678	chr11:69239552	T/C	cg24478926	chr11:69237550	NA	-0.59	-5.25	-0.32	3.25e-7	Renal cell carcinoma;
KIRP	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg01879757	chr17:41196368	BRCA1	0.71	9.95	0.54	8.02e-20	Menopause (age at onset);
KIRP	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg00405596	chr8:11794950	NA	0.59	8.39	0.47	3.92e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs17453880	0.963	rs11956179	chr5:151947064	T/G	cg12297329	chr5:152029980	NA	-0.7	-9.95	-0.54	8.27e-20	Subjective well-being;
KIRP	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs2286379	0.933	rs10773998	chr12:1903503	A/G	cg05227549	chr12:1770782	NA	-0.31	-4.99	-0.3	1.12e-6	Blood pressure (smoking interaction);
KIRP	cis	rs300890	0.608	rs3805245	chr4:144308956	T/C	cg01719995	chr4:144104893	USP38	-0.41	-5.13	-0.31	5.93e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.74	-10.69	-0.56	3.81e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg11131117	chr7:1891496	MAD1L1	0.43	5.29	0.32	2.65e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7209700	0.547	rs8078614	chr17:45351505	C/T	cg08085267	chr17:45401833	C17orf57	0.59	5.61	0.34	5.4e-8	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs8060686	0.641	rs7204974	chr16:68033539	G/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.15	-0.41	9.87e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg11941060	chr3:133502564	NA	-0.52	-6.27	-0.37	1.63e-9	Iron status biomarkers;
KIRP	cis	rs28834970	0.675	rs17057051	chr8:27227554	C/T	cg18234130	chr8:27182889	PTK2B	0.54	6.16	0.37	2.92e-9	Alzheimer's disease (late onset);
KIRP	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.65	-9.67	-0.52	5.74e-19	Fibrinogen levels;
KIRP	cis	rs4704187	0.687	rs9918293	chr5:74514828	T/C	cg03227963	chr5:74354835	NA	0.4	5.84	0.35	1.63e-8	Response to amphetamines;
KIRP	cis	rs9921338	0.924	rs7202024	chr16:11440758	A/G	cg00044050	chr16:11439710	C16orf75	-0.55	-5.87	-0.35	1.43e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs2281603	0.570	rs1453007	chr14:64974203	A/G	cg01860774	chr14:64969374	ZBTB25	0.35	5.65	0.34	4.35e-8	Lymphocyte counts;
KIRP	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.9	-11.99	-0.61	2.22e-26	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7084402	0.967	rs7099881	chr10:60316211	A/G	cg05938607	chr10:60274200	BICC1	0.38	9.01	0.5	5.78e-17	Refractive error;
KIRP	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.7	0.8	8.7e-56	Prudent dietary pattern;
KIRP	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg24579218	chr15:68104479	NA	-0.56	-9.05	-0.5	4.6e-17	Restless legs syndrome;
KIRP	cis	rs11169552	0.510	rs11169537	chr12:51126792	G/A	cg12884762	chr12:50931848	DIP2B	-0.44	-4.95	-0.3	1.35e-6	Colorectal cancer;
KIRP	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	12.61	0.63	1.95e-28	Exhaled nitric oxide output;
KIRP	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg16672083	chr15:72433130	SENP8	0.41	5.89	0.35	1.24e-8	Red blood cell count;
KIRP	cis	rs2019216	0.500	rs7359613	chr17:21944028	T/C	cg22648282	chr17:21454238	C17orf51	-0.47	-5.03	-0.31	9.42e-7	Pelvic organ prolapse;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13056247	chr21:45078360	RRP1B;HSF2BP	-0.59	-8.33	-0.47	5.82e-15	Inflammatory biomarkers;
KIRP	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg09873164	chr1:152488093	CRCT1	0.56	7.1	0.41	1.34e-11	Hair morphology;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11970458	chr16:31213481	PYCARD	0.45	6.02	0.36	6.4e-9	Smoking initiation;
KIRP	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.77	9.86	0.53	1.5e-19	Cognitive function;
KIRP	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg14580859	chr9:123691850	NA	0.36	5.15	0.31	5.36e-7	Rheumatoid arthritis;
KIRP	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg04989706	chr14:50066350	PPIL5	-0.46	-5.5	-0.33	9.64e-8	Carotid intima media thickness;
KIRP	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.68	-7.88	-0.45	1.03e-13	Diabetic retinopathy;
KIRP	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg15252951	chr6:33757062	LEMD2	0.42	5.0	0.3	1.09e-6	Crohn's disease;
KIRP	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg05623727	chr3:50126028	RBM5	0.34	4.93	0.3	1.51e-6	Body mass index;
KIRP	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg13271783	chr10:134563150	INPP5A	-0.5	-6.68	-0.39	1.6e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.99	14.26	0.67	4.76e-34	Monocyte count;
KIRP	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg23594656	chr7:65796392	TPST1	0.44	6.0	0.36	6.87e-9	Aortic root size;
KIRP	cis	rs2274273	0.624	rs67386901	chr14:55757364	C/T	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.4e-7	Protein biomarker;
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.11	-0.31	6.38e-7	Lung cancer;
KIRP	trans	rs7246760	1.000	rs67844335	chr19:9898039	G/A	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.46e-20	Pursuit maintenance gain;
KIRP	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg16797656	chr11:68205561	LRP5	0.39	5.11	0.31	6.46e-7	Total body bone mineral density;
KIRP	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg25173405	chr17:45401733	C17orf57	-0.5	-6.55	-0.39	3.3e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs77688320	0.553	rs2080324	chr2:202378812	T/G	cg06431681	chr2:202330990	STRADB	-0.44	-5.23	-0.32	3.65e-7	Breast cancer;
KIRP	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-0.78	-10.98	-0.57	4.27e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs6580649	0.783	rs7969749	chr12:48550755	C/T	cg26205652	chr12:48591994	NA	0.52	6.05	0.36	5.22e-9	Lung cancer;
KIRP	trans	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	7.45	0.43	1.57e-12	Mean corpuscular volume;
KIRP	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg03808351	chr9:123631620	PHF19	0.55	8.23	0.46	1.09e-14	Birth weight;
KIRP	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg23032965	chr3:12705835	RAF1	0.74	8.02	0.46	4.33e-14	Cholesterol, total;
KIRP	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg00732059	chr16:71740210	PHLPP2	-0.59	-5.62	-0.34	5.11e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9940149	1.000	rs6600208	chr16:305268	T/C	cg26484247	chr16:313425	ITFG3	0.46	5.47	0.33	1.12e-7	Type 2 diabetes;
KIRP	cis	rs6585424	1.000	rs35483545	chr10:81939173	T/C	cg27417294	chr10:81904244	PLAC9	0.53	5.04	0.31	8.98e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.18	0.37	2.6e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg08501292	chr6:25962987	TRIM38	0.81	5.5	0.33	9.64e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg04369109	chr6:150039330	LATS1	-0.63	-8.12	-0.46	2.21e-14	Lung cancer;
KIRP	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.58	6.28	0.37	1.53e-9	Menarche (age at onset);
KIRP	cis	rs12496230	0.794	rs1867408	chr3:66860026	C/T	cg04995300	chr3:66848608	NA	0.45	6.97	0.41	2.88e-11	Type 2 diabetes;
KIRP	cis	rs42648	0.837	rs10262472	chr7:89900383	T/C	cg25739043	chr7:89950458	NA	-0.45	-7.18	-0.42	8.1e-12	Homocysteine levels;
KIRP	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.58	6.56	0.39	3.15e-10	Coronary artery disease;
KIRP	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.71	8.9	0.49	1.26e-16	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-9.55	-0.52	1.34e-18	Joint mobility (Beighton score);
KIRP	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.69	10.04	0.54	4.36e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg11031976	chr2:198649780	BOLL	-0.52	-5.03	-0.31	9.29e-7	Ulcerative colitis;
KIRP	cis	rs8030485	0.756	rs1521624	chr15:79412399	C/A	cg17916960	chr15:79447300	NA	0.38	6.81	0.4	7.23e-11	Left ventricle wall thickness;
KIRP	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-1.05	-10.53	-0.56	1.17e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg16577123	chr5:140027231	NDUFA2;IK	0.4	5.13	0.31	5.9e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg22117172	chr7:91764530	CYP51A1	0.47	6.32	0.37	1.19e-9	Breast cancer;
KIRP	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg17595323	chr11:93583763	C11orf90	-0.29	-5.17	-0.31	4.83e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg10402321	chr1:26617780	UBXN11	-0.46	-5.71	-0.34	3.25e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg11569703	chr11:65557185	OVOL1	-0.31	-4.99	-0.3	1.14e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.35	0.62	1.41e-27	Morning vs. evening chronotype;
KIRP	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg01966878	chr4:90757139	SNCA	-0.44	-4.95	-0.3	1.36e-6	Neuroticism;
KIRP	trans	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00938859	chr5:1591904	SDHAP3	0.54	6.28	0.37	1.53e-9	Breast cancer;
KIRP	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.52	4.87	0.3	1.95e-6	Height;
KIRP	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.46	5.38	0.32	1.77e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05025164	chr4:1340916	KIAA1530	0.66	9.09	0.5	3.45e-17	Longevity;
KIRP	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-0.99	-11.59	-0.59	4.61e-25	White matter hyperintensity burden;
KIRP	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.74	7.85	0.45	1.31e-13	Gut microbiome composition (summer);
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg27144592	chr16:783916	NARFL	0.4	5.59	0.34	6.04e-8	Height;
KIRP	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.45e-9	Depression;
KIRP	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-1.33	-10.0	-0.54	5.72e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs860295	0.871	rs6688636	chr1:155478897	T/C	cg02153340	chr1:155202674	NA	0.36	4.86	0.3	2.13e-6	Body mass index;
KIRP	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.89	0.6	4.54e-26	Smoking behavior;
KIRP	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.45	-5.98	-0.36	7.75e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2073300	0.793	rs6048814	chr20:23448411	A/C	cg12062639	chr20:23401060	NAPB	0.79	6.85	0.4	5.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.99	-11.03	-0.58	3.11e-23	Exhaled nitric oxide output;
KIRP	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg27494647	chr7:150038898	RARRES2	-0.4	-6.29	-0.37	1.45e-9	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17482706	chr9:77643371	C9orf41	0.53	6.13	0.36	3.47e-9	Smoking initiation;
KIRP	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21659725	chr3:3221576	CRBN	0.53	6.64	0.39	1.97e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-6.26	-0.37	1.67e-9	Total cholesterol levels;
KIRP	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.37	5.21	0.32	3.97e-7	Coronary artery disease;
KIRP	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs9859260	1.000	rs9990392	chr3:195798522	C/T	cg12923728	chr3:195709715	SDHAP1	-0.43	-5.11	-0.31	6.43e-7	Mean corpuscular volume;
KIRP	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.54	-7.29	-0.42	4.12e-12	Blood protein levels;
KIRP	trans	rs10507349	0.514	rs608886	chr13:26877127	G/T	cg04413680	chr6:71998398	OGFRL1	0.55	6.02	0.36	6.24e-9	Type 2 diabetes;
KIRP	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg08992911	chr2:238395768	MLPH	0.4	4.98	0.3	1.18e-6	Prostate cancer;
KIRP	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg11031976	chr2:198649780	BOLL	-0.54	-5.18	-0.31	4.72e-7	Ulcerative colitis;
KIRP	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs258892	0.895	rs35317818	chr5:72073502	G/C	cg21869765	chr5:72125136	TNPO1	-0.55	-5.99	-0.36	7.27e-9	Small cell lung carcinoma;
KIRP	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	13.03	0.64	7.09e-30	Exhaled nitric oxide output;
KIRP	cis	rs3741151	0.686	rs12276892	chr11:73283990	A/T	cg17517138	chr11:73019481	ARHGEF17	0.59	5.15	0.31	5.29e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.37	-0.51	4.85e-18	Coronary artery disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03952484	chr1:149899818	SF3B4	0.49	6.62	0.39	2.2e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05347473	chr6:146136440	FBXO30	-0.64	-9.36	-0.51	5.14e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.98	0.45	5.49e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07135408	chr1:236908002	ACTN2	-0.43	-6.18	-0.37	2.68e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.54	5.53	0.33	8.2e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg00031303	chr3:195681400	NA	0.67	7.61	0.44	5.77e-13	Pancreatic cancer;
KIRP	cis	rs8054556	0.787	rs12444108	chr16:30027694	G/A	cg06326092	chr16:30034487	C16orf92	0.41	5.87	0.35	1.4e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg11569703	chr11:65557185	OVOL1	0.37	5.72	0.34	3.09e-8	Eosinophil percentage of white cells;
KIRP	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg08885076	chr2:99613938	TSGA10	0.54	7.38	0.43	2.47e-12	Chronic sinus infection;
KIRP	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-5.75	-0.34	2.65e-8	Blood metabolite levels;
KIRP	cis	rs62355272	0.931	rs55654952	chr5:35911179	A/G	cg13894535	chr5:35919491	CAPSL	-0.51	-6.16	-0.37	2.87e-9	Lymphocyte counts;
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.6	-8.7	-0.48	4.92e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg11693508	chr17:37793320	STARD3	-0.7	-7.27	-0.42	4.67e-12	Bipolar disorder;
KIRP	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.64	-6.08	-0.36	4.61e-9	Menarche (age at onset);
KIRP	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.3	-0.55	6.24e-21	Hemoglobin concentration;
KIRP	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg26138937	chr11:71823887	C11orf51	-1.01	-6.88	-0.4	5.04e-11	Severe influenza A (H1N1) infection;
KIRP	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg16141378	chr3:129829833	LOC729375	-0.52	-7.08	-0.41	1.5e-11	Neuroticism;
KIRP	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.73	-0.39	1.18e-10	Obesity (extreme);
KIRP	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg08668510	chr10:1095578	IDI1	0.76	5.21	0.32	4.05e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22794795	chr12:113623087	C12orf52;DDX54	0.44	6.22	0.37	2.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg07701084	chr6:150067640	NUP43	0.63	8.24	0.47	1.03e-14	Lung cancer;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg13198984	chr17:80129470	CCDC57	0.59	9.08	0.5	3.6e-17	Life satisfaction;
KIRP	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.69	-0.44	3.59e-13	Resting heart rate;
KIRP	cis	rs6733011	0.628	rs10188156	chr2:99465875	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.37	-0.32	1.81e-7	Bipolar disorder;
KIRP	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.57	-7.42	-0.43	1.91e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.42	-0.33	1.39e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4750440	0.706	rs11258767	chr10:14016565	C/T	cg27542038	chr10:14027202	FRMD4A	-0.51	-6.8	-0.4	8.03e-11	Adiponectin levels;
KIRP	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg12046867	chr14:103022105	NA	0.53	6.32	0.37	1.22e-9	Platelet count;
KIRP	cis	rs2213920	0.680	rs7863450	chr9:118242611	G/C	cg13918206	chr9:118159781	DEC1	1.01	10.18	0.54	1.51e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-6.32	-0.37	1.23e-9	Neuroticism;
KIRP	cis	rs6568686	0.627	rs174381	chr6:111913479	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.52	5.09	0.31	7.12e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.58	-6.48	-0.38	4.94e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18357526	chr6:26021779	HIST1H4A	0.54	6.99	0.41	2.52e-11	Height;
KIRP	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg00629928	chr5:358741	AHRR	0.51	4.97	0.3	1.27e-6	Breast cancer;
KIRP	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.55	8.59	0.48	1.03e-15	Major depressive disorder;
KIRP	cis	rs4704187	0.553	rs116188801	chr5:74398141	A/G	cg03227963	chr5:74354835	NA	0.41	5.98	0.36	7.91e-9	Response to amphetamines;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg27189623	chr16:705930	WDR90	0.44	6.12	0.36	3.73e-9	Height;
KIRP	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg10326726	chr10:51549505	MSMB	-0.54	-7.88	-0.45	1.09e-13	Prostate-specific antigen levels;
KIRP	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19346786	chr7:2764209	NA	-0.28	-4.89	-0.3	1.84e-6	Height;
KIRP	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg08761264	chr16:28874980	SH2B1	-0.46	-5.31	-0.32	2.42e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg05315796	chr3:52349193	DNAH1	0.4	5.19	0.31	4.35e-7	Schizophrenia;
KIRP	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg27490568	chr2:178487706	NA	0.6	7.99	0.45	5.27e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg04609801	chr16:28609176	SULT1A2	-0.57	-5.61	-0.34	5.57e-8	Platelet distribution width;
KIRP	cis	rs2625529	0.824	rs12902006	chr15:72252996	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-6.2	-0.37	2.37e-9	Red blood cell count;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs9612	0.948	rs12609056	chr19:44258702	G/T	cg08581076	chr19:44259116	C19orf61	0.64	6.92	0.4	3.81e-11	Exhaled nitric oxide output;
KIRP	cis	rs8113308	0.752	rs8113758	chr19:52493307	C/T	cg25782003	chr19:52490127	ZNF350	0.83	8.23	0.46	1.11e-14	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg19847866	chr10:1019161	NA	-0.61	-5.59	-0.34	6.17e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.99	0.67	4.02e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.58	7.69	0.44	3.56e-13	Response to temozolomide;
KIRP	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.4	-0.43	2.09e-12	Myopia (pathological);
KIRP	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg21427119	chr20:30132790	HM13	-0.53	-6.0	-0.36	6.93e-9	Mean corpuscular hemoglobin;
KIRP	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.59	-6.58	-0.39	2.79e-10	Blood pressure (smoking interaction);
KIRP	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.46	5.75	0.34	2.58e-8	Hair shape;
KIRP	cis	rs34779708	0.733	rs3853672	chr10:35549606	A/C	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4400599	0.642	rs10797061	chr1:154206212	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.39	-5.85	-0.35	1.58e-8	Platelet distribution width;
KIRP	cis	rs2671245	0.933	rs2767514	chr1:56159094	C/G	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.82	-8.46	-0.47	2.47e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	1.07	22.86	0.82	8.78e-63	Parkinson's disease;
KIRP	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg05775895	chr3:12838266	CAND2	0.34	5.71	0.34	3.18e-8	QRS complex (12-leadsum);
KIRP	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.05	-0.41	1.76e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.44	-6.29	-0.37	1.43e-9	Vitamin D levels;
KIRP	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg15655495	chr12:38532458	NA	-0.29	-5.23	-0.32	3.55e-7	Bladder cancer;
KIRP	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.66	9.06	0.5	4.09e-17	Colorectal cancer;
KIRP	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.46	0.33	1.15e-7	Breast cancer;
KIRP	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg02070118	chr4:952128	TMEM175	0.61	5.22	0.32	3.82e-7	Parkinson's disease;
KIRP	cis	rs2712184	0.655	rs1003622	chr2:217653608	A/G	cg05032264	chr2:217675019	NA	-0.46	-6.55	-0.39	3.3e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs4778581	0.545	rs11072880	chr15:80398913	A/T	cg08257866	chr15:80351198	ZFAND6	0.45	5.02	0.31	9.75e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.56	-6.84	-0.4	6.24e-11	Aortic root size;
KIRP	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg14517863	chr17:44321492	NA	0.48	5.38	0.32	1.71e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.49	6.08	0.36	4.47e-9	Longevity;Endometriosis;
KIRP	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg16482183	chr6:26056742	HIST1H1C	0.39	5.1	0.31	6.66e-7	Schizophrenia;
KIRP	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.77	13.08	0.64	5.07e-30	Cancer;
KIRP	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg22903471	chr2:27725779	GCKR	0.38	5.24	0.32	3.41e-7	Oral cavity cancer;
KIRP	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7523050	0.730	rs35100394	chr1:109433989	C/G	cg08274380	chr1:109419600	GPSM2	1.16	10.22	0.55	1.14e-20	Fat distribution (HIV);
KIRP	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs2070997	0.702	rs2229070	chr9:133760029	C/G	cg13397898	chr9:133768931	QRFP	0.37	5.02	0.3	9.92e-7	Response to amphetamines;
KIRP	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg06204229	chr3:52865917	ITIH4	0.53	5.93	0.35	1.02e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg10224037	chr5:178157518	ZNF354A	0.78	9.37	0.51	4.87e-18	Neutrophil percentage of white cells;
KIRP	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.39	-6.4	-0.38	7.64e-10	Cystic fibrosis severity;
KIRP	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.72	10.56	0.56	9.93e-22	Colorectal cancer;
KIRP	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.64	8.92	0.49	1.08e-16	Lymphocyte counts;
KIRP	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs889398	0.771	rs4985448	chr16:69899395	A/G	cg09409435	chr16:70099608	PDXDC2	0.44	5.31	0.32	2.4e-7	Body mass index;
KIRP	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg08775375	chr8:10454154	NA	-0.34	-5.11	-0.31	6.48e-7	Neuroticism;
KIRP	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.71	9.39	0.51	4.31e-18	Prudent dietary pattern;
KIRP	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3087591	0.639	rs1048317	chr17:29704002	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.67	0.39	1.69e-10	Hip circumference;
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg08662619	chr6:150070041	PCMT1	0.37	5.96	0.36	8.6e-9	Lung cancer;
KIRP	cis	rs830233	0.504	rs4868761	chr5:165335027	G/A	cg13976338	chr5:165423657	NA	-0.48	-4.86	-0.3	2.09e-6	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.63	7.49	0.43	1.23e-12	Type 2 diabetes;
KIRP	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00585698	chr12:123750864	CDK2AP1	0.5	5.08	0.31	7.61e-7	Neutrophil percentage of white cells;
KIRP	cis	rs13185784	0.709	rs6703	chr5:179660786	A/T	cg23248424	chr5:179741104	GFPT2	-0.46	-5.24	-0.32	3.53e-7	TRAIL levels;
KIRP	cis	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg07460842	chr6:66804631	NA	0.47	5.63	0.34	4.78e-8	Metabolite levels;
KIRP	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.58	-0.65	9.85e-32	Ulcerative colitis;
KIRP	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg07148914	chr20:33460835	GGT7	0.55	7.25	0.42	5.31e-12	Height;
KIRP	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg14851346	chr12:38532713	NA	-0.39	-4.85	-0.3	2.16e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.68	9.47	0.52	2.36e-18	Post bronchodilator FEV1;
KIRP	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.67	8.46	0.47	2.43e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg18367735	chr17:79674897	NA	0.5	6.27	0.37	1.61e-9	Dental caries;
KIRP	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg24807547	chr6:37504484	NA	-0.62	-10.06	-0.54	3.77e-20	Cognitive performance;
KIRP	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg15443732	chr18:74961078	GALR1	0.56	5.5	0.33	9.73e-8	Obesity-related traits;
KIRP	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.49	6.24	0.37	1.85e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs580438	0.529	rs9845966	chr3:13433158	A/C	cg10657019	chr3:13328039	NA	-0.5	-6.53	-0.38	3.68e-10	Myringotomy;
KIRP	cis	rs62380364	0.565	rs13158247	chr5:88030670	C/T	cg22951263	chr5:87985283	NA	-0.47	-6.65	-0.39	1.9e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.8	-11.73	-0.6	1.6e-25	Obesity-related traits;
KIRP	cis	rs13132184	0.586	rs67116068	chr4:38100767	C/T	cg14409701	chr4:38048871	TBC1D1	-0.69	-5.59	-0.34	5.9e-8	Verbal declarative memory;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00526316	chr1:151043472	GABPB2	-0.51	-6.43	-0.38	6.41e-10	Neuroticism;
KIRP	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.03	0.64	7.35e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg10223061	chr2:219282414	VIL1	-0.33	-5.46	-0.33	1.14e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.75	9.5	0.52	1.94e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.92	-0.49	1.1e-16	Resting heart rate;
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg15038512	chr6:170123185	PHF10	-0.56	-8.4	-0.47	3.68e-15	Obesity-related traits;
KIRP	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg00129232	chr17:37814104	STARD3	-0.68	-8.15	-0.46	1.91e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg10932868	chr11:921992	NA	-0.67	-9.12	-0.5	2.82e-17	Alzheimer's disease (late onset);
KIRP	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg26513180	chr16:89883248	FANCA	0.82	5.61	0.34	5.48e-8	Skin colour saturation;
KIRP	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg00784671	chr22:46762841	CELSR1	-0.6	-7.6	-0.44	6.14e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg07460842	chr6:66804631	NA	-0.49	-6.08	-0.36	4.46e-9	Blood trace element (Cu levels);
KIRP	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.3	-0.78	3.67e-51	Schizophrenia;
KIRP	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.66	10.51	0.56	1.36e-21	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07810114	chr1:12018622	PLOD1	0.52	7.07	0.41	1.58e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10178094	0.528	rs62175963	chr2:161339964	T/C	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.58	-0.33	6.47e-8	White blood cell count;
KIRP	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg04865290	chr3:52927548	TMEM110	-0.53	-5.55	-0.33	7.41e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07884270	chr19:13227659	TRMT1;NACC1	0.51	6.46	0.38	5.59e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23372537	chr19:10138480	NA	0.52	6.73	0.39	1.2e-10	Parkinson's disease;
KIRP	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-10.18	-0.54	1.5e-20	Dental caries;
KIRP	cis	rs5753037	0.869	rs5763646	chr22:30359410	T/C	cg27665648	chr22:30112403	NA	0.35	5.03	0.31	9.43e-7	Type 1 diabetes;
KIRP	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.3	13.31	0.65	8.57e-31	Diabetic retinopathy;
KIRP	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7404928	0.794	rs11646426	chr16:23883478	A/G	cg21745164	chr16:23765304	CHP2	-0.55	-6.7	-0.39	1.38e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg08280861	chr8:58055591	NA	0.68	6.25	0.37	1.76e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg12573791	chr2:3828286	NA	0.4	5.62	0.34	5.19e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.51	-0.38	4.29e-10	Coronary artery disease;
KIRP	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg11839771	chr15:80205821	ST20	-0.36	-5.19	-0.31	4.45e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4740619	0.619	rs10738425	chr9:16041576	T/C	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.94	15.3	0.7	1.44e-37	Adiposity;
KIRP	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	9.04	0.5	4.87e-17	Personality dimensions;
KIRP	cis	rs56079296	0.929	rs10069116	chr5:121374825	G/T	cg05256605	chr5:121412184	LOX	-0.52	-5.81	-0.35	1.88e-8	Coronary artery disease;
KIRP	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg23950597	chr19:37808831	NA	-0.68	-7.16	-0.42	9.28e-12	Coronary artery calcification;
KIRP	cis	rs7224314	1.000	rs62084082	chr17:65388046	A/G	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.33	-0.42	3.37e-12	Diisocyanate-induced asthma;
KIRP	cis	rs17123764	0.892	rs11169143	chr12:50147550	C/T	cg20471783	chr12:50157085	TMBIM6	0.41	5.9	0.35	1.19e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-35.4	-0.91	1.61e-98	Myeloid white cell count;
KIRP	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg17554472	chr22:41940697	POLR3H	-0.68	-6.76	-0.4	9.92e-11	Vitiligo;
KIRP	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-7.04	-0.41	1.88e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg04218760	chr10:45406644	TMEM72	-0.25	-6.55	-0.39	3.25e-10	Mean corpuscular volume;
KIRP	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.14	0.46	1.94e-14	Bipolar disorder;
KIRP	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.68	7.88	0.45	1.07e-13	Corneal astigmatism;
KIRP	cis	rs55962025	1.000	rs4690071	chr4:3086753	A/T	cg06533319	chr4:3265114	C4orf44	0.45	5.41	0.33	1.52e-7	Parental longevity (mother's age at death);
KIRP	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.64	8.16	0.46	1.74e-14	Prudent dietary pattern;
KIRP	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.76	10.28	0.55	7.5e-21	Lung cancer;
KIRP	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05347473	chr6:146136440	FBXO30	0.6	8.51	0.48	1.77e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg05343316	chr1:45956843	TESK2	0.72	8.38	0.47	4.23e-15	Platelet count;
KIRP	cis	rs7715806	0.517	rs253392	chr5:74928883	G/T	cg02573091	chr5:74908125	NA	-0.44	-4.98	-0.3	1.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.85	10.56	0.56	9.35e-22	Menopause (age at onset);
KIRP	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-8.99	-0.5	6.76e-17	Resting heart rate;
KIRP	cis	rs4671458	0.626	rs10496102	chr2:63731239	T/C	cg17519650	chr2:63277830	OTX1	-0.49	-4.93	-0.3	1.54e-6	Subjective well-being;
KIRP	cis	rs3767633	0.764	rs2340719	chr1:161832834	G/A	cg09175582	chr1:161736000	ATF6	0.82	5.19	0.31	4.32e-7	IgG glycosylation;
KIRP	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg22824376	chr14:77648248	TMEM63C	0.86	8.13	0.46	2.13e-14	Obsessive-compulsive symptoms;
KIRP	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg02570527	chr1:10970165	NA	-0.41	-4.95	-0.3	1.36e-6	Body mass index;
KIRP	cis	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg06521331	chr12:34319734	NA	-0.39	-4.88	-0.3	1.9e-6	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11987759	chr7:65425863	GUSB	0.45	5.16	0.31	4.98e-7	Aortic root size;
KIRP	cis	rs1448094	0.617	rs952851	chr12:86477341	C/T	cg06740227	chr12:86229804	RASSF9	-0.44	-5.23	-0.32	3.68e-7	Major depressive disorder;
KIRP	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg06671706	chr8:8559999	CLDN23	0.49	6.02	0.36	6.42e-9	Obesity-related traits;
KIRP	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg20578329	chr17:80767326	TBCD	-0.91	-8.23	-0.46	1.09e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs71277158	0.688	rs73879173	chr3:169845604	T/G	cg04067573	chr3:169899625	PHC3	0.65	6.14	0.36	3.29e-9	Prostate cancer;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg19923238	chr8:142232952	SLC45A4	0.45	5.24	0.32	3.45e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg08131204	chr22:41487073	MIR1281	-0.42	-4.92	-0.3	1.61e-6	Neuroticism;
KIRP	cis	rs17065868	1.000	rs9533910	chr13:45137937	G/A	cg10246903	chr13:45222710	NA	0.7	6.66	0.39	1.73e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02018176	chr4:1364513	KIAA1530	0.43	5.57	0.33	6.73e-8	Longevity;
KIRP	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg05623727	chr3:50126028	RBM5	0.34	4.9	0.3	1.7e-6	Body mass index;
KIRP	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.85	9.35	0.51	5.62e-18	Iron status biomarkers;
KIRP	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg27147174	chr7:100797783	AP1S1	-0.7	-9.14	-0.5	2.38e-17	Life satisfaction;
KIRP	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.3e-21	Educational attainment;
KIRP	trans	rs10818894	0.515	rs10818831	chr9:126312791	C/T	cg06112171	chr6:40324498	NA	0.51	6.09	0.36	4.38e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
KIRP	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.48	5.75	0.34	2.58e-8	Diastolic blood pressure;
KIRP	cis	rs13102973	0.646	rs7670551	chr4:135895130	C/T	cg14419869	chr4:135874104	NA	0.39	6.3	0.37	1.35e-9	Subjective well-being;
KIRP	cis	rs9653442	0.564	rs12712071	chr2:100793876	G/A	cg07810366	chr2:100720526	AFF3	-0.33	-5.19	-0.31	4.42e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.73	-8.88	-0.49	1.43e-16	Cognitive function;
KIRP	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg19774624	chr17:42201019	HDAC5	0.43	5.45	0.33	1.22e-7	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg03684893	chr10:554711	DIP2C	0.39	5.62	0.34	5.2e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs1208285	0.530	rs2327428	chr6:134203879	C/T	cg06643013	chr6:134217242	NA	-0.44	-5.11	-0.31	6.54e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.04	12.45	0.62	6.49e-28	Vitiligo;
KIRP	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9649213	0.613	rs10953256	chr7:97951886	G/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs10924970	0.967	rs4659784	chr1:235482463	C/T	cg26050004	chr1:235667680	B3GALNT2	0.4	4.9	0.3	1.7e-6	Asthma;
KIRP	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg23166289	chr1:210001082	C1orf107	0.44	5.29	0.32	2.77e-7	Orofacial clefts;
KIRP	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg12315302	chr6:26189340	HIST1H4D	0.69	5.46	0.33	1.15e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1152591	0.505	rs1152593	chr14:64675895	C/T	cg21174375	chr14:64681225	SYNE2	0.69	9.06	0.5	4.06e-17	Atrial fibrillation;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.86	-11.3	-0.58	4.03e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg04369109	chr6:150039330	LATS1	-0.5	-6.43	-0.38	6.74e-10	Lung cancer;
KIRP	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.72	8.54	0.48	1.39e-15	Cocaine dependence;
KIRP	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.84	-12.82	-0.63	3.72e-29	Asthma;
KIRP	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.59	-8.14	-0.46	1.92e-14	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs4349753	0.904	rs248568	chr5:144183093	T/A	cg16033277	chr17:80885358	TBCD	0.4	6.24	0.37	1.89e-9	Photic sneeze reflex;
KIRP	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.17	0.61	5.34e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg10434728	chr15:90938212	IQGAP1	-0.38	-7.17	-0.42	8.7e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg02002194	chr4:3960332	NA	-0.46	-6.76	-0.4	9.86e-11	Neuroticism;
KIRP	trans	rs2048656	0.524	rs13270518	chr8:9536713	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.05	-0.36	5.31e-9	Schizophrenia;
KIRP	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg10523679	chr1:76189770	ACADM	-0.47	-6.35	-0.38	1.05e-9	Daytime sleep phenotypes;
KIRP	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg22117172	chr7:91764530	CYP51A1	0.46	6.28	0.37	1.49e-9	Breast cancer;
KIRP	cis	rs787274	0.557	rs4979183	chr9:115667355	G/A	cg13803584	chr9:115635662	SNX30	-0.64	-5.61	-0.34	5.54e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.66	-0.52	6.36e-19	Neuranatomic and neurocognitive phenotypes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03338220	chr19:42580251	ZNF574	-0.44	-6.05	-0.36	5.27e-9	Metabolic traits;
KIRP	trans	rs7939886	0.920	rs59168428	chr11:55956018	G/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.56	-5.09	-0.31	7.12e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.54	13.57	0.65	1.08e-31	Airflow obstruction;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.27	5.02	0.3	9.92e-7	Tonsillectomy;
KIRP	cis	rs490234	0.783	rs10986848	chr9:128461889	T/C	cg14078157	chr9:128172775	NA	-0.57	-6.65	-0.39	1.87e-10	Mean arterial pressure;
KIRP	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.34	-0.32	2.09e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11987759	chr7:65425863	GUSB	0.51	6.85	0.4	5.8200000000000003e-11	Aortic root size;
KIRP	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.3	-0.37	1.33e-9	Joint mobility (Beighton score);
KIRP	cis	rs16957091	0.542	rs4994108	chr15:43014674	G/A	cg24196017	chr15:43021976	CDAN1	-0.54	-6.97	-0.41	2.93e-11	MGMT methylation in smokers;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg23522862	chr17:79829415	ARHGDIA	-0.52	-6.37	-0.38	9.3e-10	Type 1 diabetes nephropathy;
KIRP	cis	rs9398803	0.687	rs853986	chr6:127023336	C/G	cg19875578	chr6:126661172	C6orf173	-0.42	-5.44	-0.33	1.26e-7	Male-pattern baldness;
KIRP	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.42	5.39	0.33	1.63e-7	Aortic root size;
KIRP	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.93	0.4	3.59e-11	Retinal vascular caliber;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01110552	chr10:103578627	MGEA5	0.55	6.5	0.38	4.43e-10	Smoking initiation;
KIRP	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg05707623	chr12:122985044	ZCCHC8	0.42	5.07	0.31	7.87e-7	Body mass index;
KIRP	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.39	-0.51	4.2e-18	Hemoglobin concentration;
KIRP	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg15691649	chr6:25882328	NA	-0.42	-5.13	-0.31	5.92e-7	Blood metabolite levels;
KIRP	cis	rs10046574	0.561	rs56014861	chr7:135203027	A/T	cg27474649	chr7:135195673	CNOT4	0.56	5.26	0.32	3.17e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.72	10.08	0.54	3.18e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg11168104	chr5:1857477	NA	-0.38	-4.94	-0.3	1.47e-6	Cardiovascular disease risk factors;
KIRP	cis	rs6568686	0.786	rs7776286	chr6:111810216	A/G	cg15721981	chr6:111408429	SLC16A10	-0.67	-5.81	-0.35	1.96e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.99	-7.82	-0.45	1.6e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg19610905	chr11:61596333	FADS2	-0.46	-7.3	-0.42	3.88e-12	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg03887218	chr1:16534349	ARHGEF19	0.64	8.63	0.48	7.9e-16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9398803	0.678	rs9388500	chr6:126876580	C/G	cg19875578	chr6:126661172	C6orf173	0.45	5.62	0.34	5.23e-8	Male-pattern baldness;
KIRP	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23598886	chr18:12777645	NA	0.73	5.99	0.36	7.46e-9	Inflammatory skin disease;
KIRP	cis	rs7849270	0.879	rs6478866	chr9:131895864	C/G	cg13538475	chr9:131942899	NA	-0.34	-5.39	-0.33	1.64e-7	Blood metabolite ratios;
KIRP	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.64	8.52	0.48	1.66e-15	Motion sickness;
KIRP	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.55	-7.58	-0.44	6.89e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.82	-9.98	-0.54	6.39e-20	Schizophrenia;
KIRP	cis	rs912330	0.500	rs9556966	chr13:99169427	A/C	cg07423050	chr13:99094983	FARP1	0.35	5.36	0.32	1.96e-7	Alzheimer's disease;
KIRP	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.64	-7.28	-0.42	4.6e-12	Menarche (age at onset);
KIRP	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.07	-13.44	-0.65	3.02e-31	White matter hyperintensity burden;
KIRP	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.54	-0.43	9.3e-13	Neuroticism;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.78	-7.89	-0.45	9.76e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg07001201	chr5:642380	CEP72	0.68	6.21	0.37	2.29e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg14893161	chr1:205819251	PM20D1	0.55	5.93	0.35	1.04e-8	Parkinson's disease;
KIRP	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.94	-14.64	-0.68	2.43e-35	Height;
KIRP	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.46	-4.91	-0.3	1.66e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.41	0.38	7.17e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg18932078	chr1:2524107	MMEL1	0.4	5.43	0.33	1.37e-7	Ulcerative colitis;
KIRP	cis	rs8067545	0.532	rs12943904	chr17:20007567	G/C	cg04132472	chr17:19861366	AKAP10	0.45	5.18	0.31	4.63e-7	Schizophrenia;
KIRP	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.91	10.41	0.55	2.8e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs12681963	1.000	rs1355412	chr8:29985683	A/G	cg10449087	chr8:29952694	LEPROTL1	0.51	4.88	0.3	1.87e-6	Migraine;
KIRP	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg09137382	chr11:130731461	NA	0.54	7.91	0.45	8.54e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.53	7.71	0.44	3.05e-13	Pubertal anthropometrics;
KIRP	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.84	12.17	0.61	5.45e-27	Eye color traits;
KIRP	cis	rs7692976	0.868	rs2074390	chr4:110910016	G/A	cg06981781	chr4:110842888	EGF	-0.24	-5.16	-0.31	5.16e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6669919	0.516	rs11577717	chr1:211668920	C/T	cg10512769	chr1:211675356	NA	-0.78	-11.29	-0.58	4.16e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.78	13.01	0.64	8.25e-30	Longevity;Endometriosis;
KIRP	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg14593290	chr7:50529359	DDC	0.7	8.02	0.46	4.23e-14	Malaria;
KIRP	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg21132104	chr15:45694354	SPATA5L1	0.89	10.48	0.56	1.79e-21	Homoarginine levels;
KIRP	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.49	0.33	9.83e-8	Resistin levels;
KIRP	cis	rs4356932	1.000	rs6532163	chr4:76983618	T/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.58	7.03	0.41	1.99e-11	Blood metabolite levels;
KIRP	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.39	0.33	1.63e-7	Total cholesterol levels;
KIRP	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.59	0.76	8.69e-49	Height;
KIRP	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13198984	chr17:80129470	CCDC57	-0.49	-7.52	-0.43	1.03e-12	Life satisfaction;
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg09699651	chr6:150184138	LRP11	0.47	6.26	0.37	1.7e-9	Lung cancer;
KIRP	cis	rs4523957	0.651	rs9898819	chr17:2076352	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-11.26	-0.58	5.35e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.61	8.25	0.47	9.33e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.08e-6	Bladder cancer;
KIRP	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.78	-0.44	1.94e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.88	7.34	0.42	3.12e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg00405596	chr8:11794950	NA	-0.49	-6.58	-0.39	2.89e-10	Monocyte count;
KIRP	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg00094735	chr5:1949198	NA	-0.51	-5.92	-0.35	1.06e-8	Gut microbiome composition (winter);
KIRP	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg24253500	chr15:84953950	NA	0.68	7.67	0.44	4.11e-13	Schizophrenia;
KIRP	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg21466736	chr12:48725269	NA	-0.44	-5.64	-0.34	4.62e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.62	-7.29	-0.42	4.18e-12	Obesity-related traits;
KIRP	trans	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg24644049	chr4:85504048	CDS1	1.02	6.65	0.39	1.88e-10	Skin colour saturation;
KIRP	trans	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.47e-11	Bladder cancer;
KIRP	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg06775570	chr1:201857621	SHISA4	-0.33	-6.03	-0.36	5.82e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg04865290	chr3:52927548	TMEM110	-0.63	-6.42	-0.38	6.99e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.44	5.73	0.34	2.87e-8	Motion sickness;
KIRP	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg09137382	chr11:130731461	NA	0.5	6.79	0.4	8.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg05484376	chr2:27715224	FNDC4	0.4	6.71	0.39	1.34e-10	Total body bone mineral density;
KIRP	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.3	-0.32	2.56e-7	Autism;
KIRP	trans	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.13	-0.36	3.44e-9	Neuroticism;
KIRP	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.26	5.02	0.3	9.98e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	1.11	16.94	0.73	3.42e-43	Monocyte percentage of white cells;
KIRP	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.5	-7.32	-0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	1.06	18.94	0.77	6e-50	Bone mineral density;
KIRP	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.84	10.15	0.54	1.97e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8060686	0.920	rs73591955	chr16:67782568	G/T	cg04539111	chr16:67997858	SLC12A4	-0.58	-5.62	-0.34	5.18e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg05484376	chr2:27715224	FNDC4	-0.31	-5.11	-0.31	6.5e-7	Oral cavity cancer;
KIRP	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.01e-8	Motion sickness;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg01290665	chr5:178018968	COL23A1	0.52	6.05	0.36	5.25e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.63e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs754423	0.703	rs1874569	chr14:52519555	T/C	cg05884192	chr14:52515736	NID2	-0.66	-7.88	-0.45	1.07e-13	Craniofacial microsomia;
KIRP	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg03808351	chr9:123631620	PHF19	0.36	4.91	0.3	1.64e-6	Rheumatoid arthritis;
KIRP	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12480562	chr20:23434244	CST11	-0.64	-5.19	-0.31	4.45e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.54	-7.54	-0.43	8.94e-13	Tuberculosis;
KIRP	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg00204512	chr16:28754710	NA	0.42	5.36	0.32	1.93e-7	Mosquito bite size;
KIRP	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.44	-0.33	1.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg07884673	chr3:53033167	SFMBT1	0.88	7.01	0.41	2.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.35	-0.32	2.05e-7	Morning vs. evening chronotype;
KIRP	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.76	-11.29	-0.58	4.24e-24	Obesity-related traits;
KIRP	cis	rs12200782	1.000	rs12204145	chr6:26600156	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.67	-6.13	-0.36	3.46e-9	Small cell lung carcinoma;
KIRP	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.89	10.22	0.55	1.18e-20	Corneal astigmatism;
KIRP	cis	rs2594989	1.000	rs2606761	chr3:11344427	G/A	cg01796438	chr3:11312864	ATG7	-0.7	-8.09	-0.46	2.82e-14	Circulating chemerin levels;
KIRP	trans	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg16141378	chr3:129829833	LOC729375	0.51	6.51	0.38	4.17e-10	Mood instability;
KIRP	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.43	0.43	1.76e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.58	-6.93	-0.4	3.58e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	5.44	0.33	1.27e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.92	11.35	0.59	2.65e-24	Response to antineoplastic agents;
KIRP	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg11812906	chr14:75593930	NEK9	-0.48	-5.78	-0.35	2.24e-8	Neuroticism;
KIRP	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	11.73	0.6	1.55e-25	Smoking behavior;
KIRP	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs9469913	0.740	rs2814944	chr6:34552797	A/G	cg17674042	chr6:34482479	PACSIN1	0.38	5.17	0.31	4.82e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12292205	chr6:26970375	C6orf41	-0.61	-6.88	-0.4	4.8e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg18882449	chr10:104885122	NT5C2	-0.51	-6.43	-0.38	6.65e-10	Arsenic metabolism;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg16311410	chr22:31892793	SFI1	0.66	6.07	0.36	4.82e-9	Lung function (FEV1);
KIRP	trans	rs12545912	0.691	rs13250951	chr8:9541455	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.46	-0.38	5.5e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg19116668	chr7:99932089	PMS2L1	0.43	4.89	0.3	1.81e-6	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg18132916	chr6:79620363	NA	-0.41	-5.61	-0.34	5.52e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02567719	chr4:83350534	HNRPDL;ENOPH1	0.5	6.4	0.38	7.66e-10	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20314548	chr15:74426273	ISLR2	0.43	6.73	0.39	1.18e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs10073892	0.664	rs12659295	chr5:101908976	C/T	cg19774478	chr5:101632501	SLCO4C1	0.57	5.6	0.34	5.61e-8	Cognitive decline (age-related);
KIRP	cis	rs35740288	0.822	rs17574774	chr15:86233370	C/T	cg10818794	chr15:86012489	AKAP13	0.41	4.95	0.3	1.39e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg13010199	chr12:38710504	ALG10B	0.68	8.82	0.49	2.21e-16	Morning vs. evening chronotype;
KIRP	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.93	-0.35	1e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs3126085	0.560	rs67661262	chr1:152368016	A/C	cg26876637	chr1:152193138	HRNR	-0.71	-7.11	-0.41	1.26e-11	Atopic dermatitis;
KIRP	cis	rs12765878	0.967	rs34887477	chr10:105643436	C/T	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs7635838	0.827	rs4273358	chr3:11415160	T/G	cg00170343	chr3:11313890	ATG7	0.46	5.95	0.35	9.06e-9	HDL cholesterol;
KIRP	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-6.21	-0.37	2.18e-9	Lung cancer;
KIRP	cis	rs514024	0.700	rs553083	chr9:130491483	C/T	cg13643465	chr9:130375613	STXBP1	0.44	5.93	0.35	1e-8	Eating disorders (purging via substances);
KIRP	cis	rs858239	0.539	rs57864591	chr7:23184424	T/A	cg23682824	chr7:23144976	KLHL7	0.54	6.34	0.37	1.1e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.87	0.35	1.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.66	5.64	0.34	4.57e-8	Thyroid stimulating hormone;
KIRP	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg14593290	chr7:50529359	DDC	0.76	9.49	0.52	2.1e-18	Malaria;
KIRP	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.48	0.43	1.33e-12	Lung cancer;
KIRP	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.87	0.6	5.4e-26	Ileal carcinoids;
KIRP	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.45	5.11	0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.58	-8.09	-0.46	2.69e-14	Menarche (age at onset);
KIRP	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg05347473	chr6:146136440	FBXO30	0.61	8.45	0.47	2.64e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs12134040	0.646	rs10925102	chr1:236507727	G/T	cg21399712	chr1:236511386	NA	-0.55	-7.51	-0.43	1.1e-12	Urate levels (BMI interaction);
KIRP	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.6	-0.48	9.25e-16	Blood trace element (Zn levels);
KIRP	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.3	-0.42	4.08e-12	Joint mobility (Beighton score);
KIRP	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg00310523	chr12:86230176	RASSF9	0.43	6.7	0.39	1.45e-10	Major depressive disorder;
KIRP	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.06	20.79	0.8	4.14e-56	Schizophrenia;
KIRP	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg09658497	chr7:2847517	GNA12	-0.37	-5.03	-0.31	9.33e-7	Height;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.79	0.35	2.17e-8	Platelet count;
KIRP	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg19847130	chr8:10466454	RP1L1	0.37	5.33	0.32	2.18e-7	Systolic blood pressure;
KIRP	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26384229	chr12:38710491	ALG10B	0.6	8.31	0.47	6.34e-15	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-1.11	-8.23	-0.46	1.07e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	0.97	15.27	0.7	1.73e-37	Primary sclerosing cholangitis;
KIRP	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg22549504	chr19:17448937	GTPBP3	0.49	5.1	0.31	6.83e-7	Systemic lupus erythematosus;
KIRP	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.83	-12.66	-0.63	1.25e-28	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13038030	chr17:73267041	MIF4GD	0.52	6.76	0.4	9.84e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg27490568	chr2:178487706	NA	0.52	7.07	0.41	1.64e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg07827796	chr19:33622959	WDR88	0.53	6.96	0.41	3.02e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg25759457	chr1:172502420	C1orf9	0.45	6.03	0.36	6.05e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3744061	0.530	rs2079778	chr17:74647097	C/T	cg27546012	chr17:74684504	MXRA7	-0.44	-5.41	-0.33	1.48e-7	Retinal arteriolar caliber;
KIRP	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg07596299	chr11:71824057	C11orf51	-0.84	-5.63	-0.34	5.01e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9815354	1.000	rs6791806	chr3:41889995	C/T	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg21775007	chr8:11205619	TDH	0.45	6.03	0.36	6.11e-9	Neuroticism;
KIRP	cis	rs6960043	1.000	rs6972333	chr7:15051643	G/A	cg19272540	chr7:15055459	NA	-0.21	-5.63	-0.34	4.81e-8	Type 2 diabetes;
KIRP	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg17420885	chr1:87600446	LOC339524	0.51	6.94	0.4	3.44e-11	Smoking behavior;
KIRP	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.79	10.69	0.56	3.71e-22	Body mass index;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.43	7.01	0.41	2.27e-11	Eye color traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04832839	chr3:152879839	RAP2B	0.49	6.66	0.39	1.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg20243544	chr17:37824526	PNMT	0.43	4.91	0.3	1.67e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg12756093	chr1:115239321	AMPD1	0.53	7.07	0.41	1.63e-11	Autism;
KIRP	cis	rs966423	0.527	rs11680689	chr2:218297700	C/G	cg15335768	chr2:218268053	DIRC3	0.41	5.94	0.35	9.64e-9	Thyroid cancer;
KIRP	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	0.54	6.91	0.4	4.15e-11	Myopia;
KIRP	cis	rs17095355	1.000	rs7080576	chr10:111710817	C/T	cg00817464	chr10:111662876	XPNPEP1	0.44	6.42	0.38	6.93e-10	Biliary atresia;
KIRP	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.5	-6.02	-0.36	6.38e-9	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.54	-6.23	-0.37	1.97e-9	Monocyte count;
KIRP	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.53	-6.74	-0.4	1.09e-10	Longevity;
KIRP	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg05639522	chr1:247681581	NA	0.62	5.74	0.34	2.73e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg23479056	chr15:41276147	INO80	-0.36	-4.91	-0.3	1.64e-6	Menopause (age at onset);
KIRP	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.65	-10.03	-0.54	4.55e-20	Menopause (age at onset);
KIRP	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11987759	chr7:65425863	GUSB	-0.52	-6.88	-0.4	5.02e-11	Aortic root size;
KIRP	cis	rs6142102	0.961	rs8119937	chr20:32645551	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.5	0.38	4.37e-10	Skin pigmentation;
KIRP	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg13010199	chr12:38710504	ALG10B	0.41	5.46	0.33	1.16e-7	Heart rate;
KIRP	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.29	0.32	2.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11987759	chr7:65425863	GUSB	0.58	7.63	0.44	4.99e-13	Aortic root size;
KIRP	cis	rs6959887	0.962	rs73099185	chr7:35291313	C/T	cg06685737	chr7:35301730	NA	0.43	6.38	0.38	8.64e-10	Birth weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04296578	chr1:45671659	ZSWIM5	0.55	7.22	0.42	6.34e-12	Parkinson's disease;
KIRP	cis	rs7172677	0.737	rs7178005	chr15:75437420	T/C	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs12517041	1.000	rs10473633	chr5:23310565	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-13.16	-0.64	2.72e-30	Blood metabolite levels;
KIRP	cis	rs10875746	0.551	rs1471998	chr12:48712002	C/T	cg26205652	chr12:48591994	NA	0.8	10.18	0.54	1.58e-20	Longevity (90 years and older);
KIRP	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg23625390	chr15:77176239	SCAPER	-0.45	-5.9	-0.35	1.2e-8	Blood metabolite levels;
KIRP	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.68	-9.06	-0.5	4.18e-17	Male sexual orientation;
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.63	-5.51	-0.33	9.16e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.76	-11.03	-0.58	2.99e-23	Waist circumference;Body mass index;
KIRP	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.12	-0.31	6.18e-7	Bipolar disorder;
KIRP	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.4	-0.43	2.1e-12	Colorectal cancer;
KIRP	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.4	-0.43	2.11e-12	Body mass index;
KIRP	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg21204522	chr6:27730016	NA	-0.71	-5.46	-0.33	1.17e-7	Breast cancer;
KIRP	cis	rs71636778	0.584	rs36042864	chr1:27146944	G/T	cg12203394	chr1:27248618	NUDC	0.68	5.38	0.32	1.7e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.63	-0.34	5.02e-8	Autism;
KIRP	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17554472	chr22:41940697	POLR3H	0.72	7.2	0.42	7.39e-12	Vitiligo;
KIRP	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-7.19	-0.42	7.69e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs6909279	0.522	rs7741872	chr6:151893946	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.51	-6.8	-0.4	7.74e-11	Bone mineral density;
KIRP	cis	rs12580194	0.593	rs12579346	chr12:55786856	A/G	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs4889855	0.505	rs8077626	chr17:78600552	G/C	cg09596252	chr17:78655493	RPTOR	0.51	5.89	0.35	1.23e-8	Fractional excretion of uric acid;
KIRP	cis	rs3126085	0.515	rs6668321	chr1:152353940	C/T	cg26876637	chr1:152193138	HRNR	-0.55	-6.92	-0.4	3.97e-11	Atopic dermatitis;
KIRP	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg08975724	chr8:8085496	FLJ10661	0.7	9.34	0.51	5.89e-18	Neuroticism;
KIRP	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.53	-6.34	-0.37	1.11e-9	Blood metabolite levels;
KIRP	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.62	-0.39	2.17e-10	Initial pursuit acceleration;
KIRP	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.68	0.39	1.59e-10	Educational attainment;
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg13699009	chr12:122356056	WDR66	0.73	11.42	0.59	1.64e-24	Mean corpuscular volume;
KIRP	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02250044	chr14:54976234	CGRRF1	-0.53	-6.38	-0.38	8.91e-10	Interleukin-4 levels;
KIRP	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg14768367	chr16:72042858	DHODH	0.44	5.39	0.32	1.66e-7	Fibrinogen levels;
KIRP	cis	rs6088813	0.677	rs6087707	chr20:34006436	T/C	cg14752227	chr20:34000481	UQCC	0.46	5.15	0.31	5.34e-7	Height;
KIRP	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg17554472	chr22:41940697	POLR3H	-0.59	-6.69	-0.39	1.45e-10	Vitiligo;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg07701084	chr6:150067640	NUP43	0.69	9.46	0.52	2.55e-18	Lung cancer;
KIRP	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg01174859	chr7:128379317	CALU	-0.44	-6.19	-0.37	2.48e-9	Morning vs. evening chronotype;
KIRP	cis	rs9815354	0.556	rs116717051	chr3:42027411	G/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg21237687	chr17:6899380	ALOX12	0.28	4.96	0.3	1.3e-6	Tonsillectomy;
KIRP	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg09075522	chr1:92031145	NA	0.41	5.04	0.31	9.01e-7	Breast cancer;
KIRP	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	0.97	9.55	0.52	1.41e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.38	-0.43	2.39e-12	Type 2 diabetes;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.94	15.58	0.7	1.57e-38	Menarche (age at onset);
KIRP	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg00405596	chr8:11794950	NA	-0.48	-6.35	-0.38	1.05e-9	Retinal vascular caliber;
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg11641102	chr8:27183873	PTK2B	0.45	5.9	0.35	1.2e-8	Neuroticism;
KIRP	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	0.71	7.19	0.42	7.76e-12	Gut microbiome composition (summer);
KIRP	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg17145862	chr1:211918768	LPGAT1	0.89	12.95	0.64	1.35e-29	Leprosy;
KIRP	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.76	8.13	0.46	2.11e-14	Uric acid levels;
KIRP	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.83	15.04	0.69	1.05e-36	Anterior chamber depth;
KIRP	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Migraine;
KIRP	cis	rs3736594	0.513	rs6547735	chr2:27831607	T/C	cg27432699	chr2:27873401	GPN1	0.57	6.71	0.39	1.32e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.79	-12.21	-0.61	4.11e-27	Lung cancer;
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.59	-5.22	-0.32	3.84e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg18132916	chr6:79620363	NA	-0.37	-5.08	-0.31	7.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12620999	0.941	rs10803654	chr2:238036570	C/T	cg15976283	chr2:238042351	NA	0.39	5.39	0.32	1.66e-7	Systemic lupus erythematosus;
KIRP	trans	rs12517041	1.000	rs4701362	chr5:23300849	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.72	-0.44	2.99e-13	Calcium levels;
KIRP	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg07827796	chr19:33622959	WDR88	0.5	6.53	0.38	3.83e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg03929089	chr4:120376271	NA	0.7	6.21	0.37	2.18e-9	Axial length;
KIRP	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.05	0.5	4.46e-17	Lung cancer;
KIRP	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg01629716	chr15:45996671	NA	0.37	6.74	0.39	1.15e-10	Waist circumference;Weight;
KIRP	cis	rs6540559	0.673	rs6698154	chr1:210007777	A/G	cg22029157	chr1:209979665	IRF6	0.46	5.14	0.31	5.62e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs6907629	0.519	rs4710187	chr6:167555092	T/C	cg13805183	chr6:167554790	NA	-0.44	-6.19	-0.37	2.56e-9	Asthma (childhood onset);
KIRP	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	11.78	0.6	1.04e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11434762	chr3:77558000	ROBO2	-0.43	-6.84	-0.4	6.18e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	1.06	20.02	0.79	1.53e-53	Heart rate;
KIRP	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	1.01	14.37	0.68	2.09e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs17221829	0.764	rs7931085	chr11:89386197	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-10.3	-0.55	6.23e-21	Body mass index;
KIRP	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.78	8.2	0.46	1.34e-14	Corneal astigmatism;
KIRP	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg16989719	chr2:238392110	NA	-0.63	-5.96	-0.36	8.52e-9	Prostate cancer;
KIRP	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.52	7.37	0.43	2.54e-12	Systemic lupus erythematosus;
KIRP	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.58	7.61	0.44	5.67e-13	Lymphocyte counts;
KIRP	cis	rs4774899	0.934	rs11858783	chr15:57472751	C/A	cg13626582	chr15:57592083	LOC283663	-0.21	-4.97	-0.3	1.28e-6	Urinary tract infection frequency;
KIRP	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg06015656	chr19:3204771	NCLN	-0.53	-7.48	-0.43	1.34e-12	Bladder cancer;
KIRP	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg06636001	chr8:8085503	FLJ10661	0.7	9.07	0.5	3.79e-17	Retinal vascular caliber;
KIRP	cis	rs7301016	0.948	rs11614822	chr12:62931690	T/G	cg01804193	chr12:63026212	NA	0.54	5.64	0.34	4.68e-8	IgG glycosylation;
KIRP	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.85	12.15	0.61	6.46e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.12	-0.31	6.08e-7	Neuroticism;
KIRP	cis	rs2574704	1.000	rs2574716	chr3:11662122	A/G	cg07643000	chr3:11666825	VGLL4	0.4	5.85	0.35	1.56e-8	Body mass index;
KIRP	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.7	-8.48	-0.48	2.11e-15	Cognitive function;
KIRP	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06634786	chr22:41940651	POLR3H	-0.45	-5.1	-0.31	6.71e-7	Vitiligo;
KIRP	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.66	12.59	0.63	2.27e-28	Bone mineral density;
KIRP	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.47	6.52	0.38	3.95e-10	Gout;
KIRP	trans	rs12517041	1.000	rs6890216	chr5:23299559	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.68	-0.48	5.47e-16	Calcium levels;
KIRP	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.73	5.29	0.32	2.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7534824	0.507	rs7518380	chr1:101451262	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	6.71	0.39	1.36e-10	Refractive astigmatism;
KIRP	cis	rs1030268	0.505	rs77112963	chr7:133259399	G/A	cg10665199	chr7:133106180	EXOC4	0.58	5.73	0.34	2.89e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.53	0.38	3.73e-10	Mean platelet volume;
KIRP	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.49	-6.94	-0.4	3.38e-11	Schizophrenia;
KIRP	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg15247329	chr7:2764246	NA	-0.41	-5.95	-0.35	9.26e-9	Height;
KIRP	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg25019033	chr10:957182	NA	-0.6	-6.09	-0.36	4.36e-9	Eosinophil percentage of granulocytes;
KIRP	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg21775007	chr8:11205619	TDH	0.48	6.55	0.39	3.35e-10	Mood instability;
KIRP	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg06360820	chr2:242988706	NA	-0.77	-6.79	-0.4	8.2e-11	Obesity-related traits;
KIRP	cis	rs11225247	1.000	rs12271900	chr11:102325301	G/A	cg06323957	chr11:102217781	BIRC2	0.75	4.99	0.3	1.14e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	5.82	0.35	1.87e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-5.53	-0.33	8.06e-8	Caffeine consumption;
KIRP	trans	rs35100037	0.803	rs17211886	chr5:128652100	T/C	cg23338408	chr14:31289523	NA	-0.71	-6.04	-0.36	5.73e-9	Ankle injury;
KIRP	trans	rs199950	0.868	rs6691980	chr1:181596223	G/A	cg04237608	chr1:18659049	IGSF21	-0.37	-6.2	-0.37	2.38e-9	Body mass index (change over time);
KIRP	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.95	-16.2	-0.72	1.15e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1629083	0.738	rs590580	chr11:118066104	C/T	cg18857871	chr11:118064634	AMICA1	-0.75	-10.7	-0.56	3.54e-22	Lung cancer;
KIRP	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.99	9.29	0.51	8.45e-18	Cognitive function;
KIRP	cis	rs4345220	0.509	rs7663160	chr4:41641740	A/T	cg15232654	chr4:41643107	LIMCH1	0.46	6.02	0.36	6.21e-9	Migraine with aura;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09962502	chr2:96971189	SNRNP200	-0.56	-6.41	-0.38	7.23e-10	Menopause (age at onset);
KIRP	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.7	0.34	3.4e-8	Depressive symptoms;
KIRP	trans	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg04702396	chr17:15466718	FAM18B2	0.53	6.78	0.4	8.77e-11	Educational attainment (years of education);
KIRP	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	6.04	0.36	5.73e-9	Vitiligo;
KIRP	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg11945507	chr8:142233382	SLC45A4	-0.48	-6.16	-0.37	2.89e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-1.03	-12.18	-0.61	5.14e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8060686	0.858	rs7199443	chr16:67841129	T/G	cg26727032	chr16:67993705	SLC12A4	-0.76	-9.34	-0.51	6.07e-18	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg04725166	chr1:7887271	PER3	-0.35	-5.62	-0.34	5.25e-8	Crohn's disease;
KIRP	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.57	-0.48	1.18e-15	Coronary artery disease;
KIRP	cis	rs7587476	0.906	rs17487792	chr2:215643500	A/G	cg04004882	chr2:215674386	BARD1	-0.77	-6.57	-0.39	2.91e-10	Neuroblastoma;
KIRP	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.41	0.38	7.47e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg06935464	chr4:38784597	TLR10	0.57	5.72	0.34	3.12e-8	Breast cancer;
KIRP	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.67	-5.25	-0.32	3.32e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.59	-0.39	2.73e-10	Renal cell carcinoma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18812198	chr11:68715658	NA	0.49	6.79	0.4	8.16e-11	Interleukin-4 levels;
KIRP	cis	rs56079296	0.925	rs10053942	chr5:121402597	C/T	cg05256605	chr5:121412184	LOX	-0.48	-5.62	-0.34	5.24e-8	Coronary artery disease;
KIRP	cis	rs6132905	0.590	rs76355228	chr20:2605980	C/T	cg24848351	chr20:2622020	TMC2	-0.57	-5.19	-0.31	4.47e-7	Mumps;
KIRP	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg06917634	chr15:78832804	PSMA4	0.47	4.87	0.3	1.99e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg23602478	chr1:26503979	CNKSR1	0.43	6.03	0.36	5.9e-9	Height;
KIRP	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.09	0.5	3.42e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7560272	0.538	rs12233115	chr2:73931891	G/A	cg20560298	chr2:73613845	ALMS1	0.49	5.79	0.35	2.17e-8	Schizophrenia;
KIRP	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-7.64	-0.44	4.91e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.77	0.4	9.12e-11	Lung cancer;
KIRP	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.85	13.6	0.66	8.39e-32	Prostate cancer;
KIRP	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.82	-9.98	-0.54	6.29e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2916247	1.000	rs6986430	chr8:93048104	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.97	-0.45	5.94e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs892085	0.681	rs10417071	chr19:10872431	G/T	cg17710535	chr19:10819994	QTRT1	0.48	6.2	0.37	2.38e-9	Psoriasis vulgaris;Psoriasis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22036694	chr5:132113157	SEPT8	-0.51	-6.17	-0.37	2.79e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3750082	0.621	rs7778110	chr7:32949001	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.47	-5.1	-0.31	6.87e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.61	-7.46	-0.43	1.48e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4919694	0.808	rs112574306	chr10:104971159	C/T	cg04362960	chr10:104952993	NT5C2	1.0	6.85	0.4	5.95e-11	Arsenic metabolism;
KIRP	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03934478	chr11:495069	RNH1	0.79	6.51	0.38	4.18e-10	Body mass index;
KIRP	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.73	-5.54	-0.33	7.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg21523564	chr15:75251491	NA	0.42	6.79	0.4	8.51e-11	Breast cancer;
KIRP	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.78	11.44	0.59	1.35e-24	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24572153	chr13:21047387	CRYL1	0.55	6.99	0.41	2.55e-11	Interleukin-4 levels;
KIRP	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.39	-4.89	-0.3	1.83e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg03060546	chr3:49711283	APEH	0.44	5.76	0.34	2.47e-8	Parkinson's disease;
KIRP	cis	rs9815354	1.000	rs3890604	chr3:41760625	C/T	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.2e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	1.27	10.52	0.56	1.31e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg08657492	chr7:27170832	HOXA4	-0.31	-4.95	-0.3	1.39e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg24060327	chr5:131705240	SLC22A5	-0.47	-5.32	-0.32	2.38e-7	Breast cancer;Mosquito bite size;
KIRP	cis	rs78487399	0.808	rs13416978	chr2:43705265	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.48	4.88	0.3	1.9e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg05347473	chr6:146136440	FBXO30	-0.63	-9.22	-0.51	1.41e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2411233	0.837	rs12906667	chr15:39249829	C/A	cg02291532	chr15:39874776	THBS1	0.43	5.48	0.33	1.05e-7	Platelet count;
KIRP	cis	rs4664304	0.620	rs10929957	chr2:160716508	A/G	cg03641300	chr2:160917029	PLA2R1	0.37	5.5	0.33	9.47e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.74	-9.05	-0.5	4.42e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg00982548	chr2:198649783	BOLL	-0.55	-5.27	-0.32	2.94e-7	Ulcerative colitis;
KIRP	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg23100626	chr2:96804247	ASTL	0.52	7.94	0.45	7.38e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-7.66	-0.44	4.22e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.73	-9.1	-0.5	3.2e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs2882667	0.893	rs10069961	chr5:138294568	A/G	cg04439458	chr5:138467593	SIL1	-0.39	-5.97	-0.36	8.33e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.82	-0.45	1.58e-13	Mean corpuscular volume;
KIRP	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.48	7.74	0.44	2.58e-13	Major depressive disorder;
KIRP	cis	rs7937612	1.000	rs6589812	chr11:120278359	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.27	-0.42	4.73e-12	Intraocular pressure;
KIRP	cis	rs1823913	0.599	rs34262638	chr2:192144168	A/G	cg12404831	chr2:192114017	MYO1B	0.53	7.39	0.43	2.22e-12	Obesity-related traits;
KIRP	cis	rs282587	0.569	rs373653	chr13:113406699	A/G	cg04656015	chr13:113407548	ATP11A	0.66	7.76	0.44	2.21e-13	Glycated hemoglobin levels;
KIRP	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.58	-7.57	-0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg16488304	chr1:151119217	SEMA6C	0.55	6.86	0.4	5.51e-11	Educational attainment;
KIRP	cis	rs4908768	0.906	rs12402539	chr1:8538303	C/A	cg03610117	chr1:8450231	RERE	-0.48	-5.19	-0.31	4.43e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg13819577	chr1:248512075	OR14C36	-0.35	-4.9	-0.3	1.77e-6	Common traits (Other);
KIRP	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg25418670	chr11:30344373	C11orf46	-0.61	-5.09	-0.31	7.27e-7	Morning vs. evening chronotype;
KIRP	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg02931644	chr1:25747376	RHCE	0.35	6.34	0.37	1.11e-9	Erythrocyte sedimentation rate;
KIRP	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.69	-8.24	-0.47	1.06e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg24874828	chr4:187887005	NA	-0.5	-7.41	-0.43	2e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.82	-11.01	-0.57	3.59e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.64	7.16	0.42	9.04e-12	Urate levels in lean individuals;
KIRP	cis	rs4356932	1.000	rs4550961	chr4:76978693	A/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs1413885	0.516	rs4329545	chr1:65861060	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.57	6.13	0.36	3.51e-9	Anticoagulant levels;
KIRP	cis	rs5167	0.533	rs11083755	chr19:45490065	C/T	cg13119609	chr19:45449297	APOC2	0.39	4.86	0.3	2.14e-6	Blood protein levels;
KIRP	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.99	10.28	0.55	7.37e-21	Eosinophilic esophagitis;
KIRP	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg09455208	chr3:40491958	NA	0.29	4.93	0.3	1.52e-6	Renal cell carcinoma;
KIRP	cis	rs8070740	0.786	rs8067738	chr17:5328661	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	7.27	0.42	4.73e-12	Menopause (age at onset);
KIRP	cis	rs812925	0.826	rs2694633	chr2:61540642	A/C	cg15711740	chr2:61764176	XPO1	0.45	4.87	0.3	1.98e-6	Immature fraction of reticulocytes;
KIRP	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg05528293	chr18:74961138	GALR1	0.52	5.78	0.35	2.24e-8	Obesity-related traits;
KIRP	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.65	8.85	0.49	1.81e-16	Alcohol dependence;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg02696790	chr15:75250997	RPP25	0.31	5.51	0.33	8.96e-8	Breast cancer;
KIRP	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.88	-0.6	5.1e-26	Eye color traits;
KIRP	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	1.18	15.99	0.71	5.86e-40	Obesity-related traits;
KIRP	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.34	3.27e-8	Major depressive disorder;
KIRP	cis	rs236907	0.859	rs2181216	chr1:171744655	A/G	cg01410279	chr1:171621941	MYOC	-0.5	-5.13	-0.31	5.81e-7	Mean platelet volume;
KIRP	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.09e-14	Lung cancer;
KIRP	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.71	-9.57	-0.52	1.23e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9581857	0.585	rs9581875	chr13:28099678	A/G	cg22138327	chr13:27999177	GTF3A	0.82	6.34	0.37	1.12e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.44	-6.02	-0.36	6.22e-9	Systemic lupus erythematosus;
KIRP	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27200466	chr3:93747410	STX19;ARL13B	-0.41	-6.39	-0.38	8.45e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-6.92	-0.4	3.94e-11	Asthma;
KIRP	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg24488311	chr11:68621650	NA	0.49	5.52	0.33	8.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7809615	0.901	rs11981478	chr7:99163950	C/T	cg12290671	chr7:99195819	NA	-0.75	-6.99	-0.41	2.57e-11	Blood metabolite ratios;
KIRP	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.98	15.84	0.71	1.92e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg14993813	chr1:46806288	NSUN4	-0.6	-6.81	-0.4	7.38e-11	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09371829	chr7:104654918	MLL5;LOC100216545	0.49	6.97	0.41	2.83e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8756	0.689	rs7959830	chr12:66347368	G/T	cg06712651	chr12:66351869	HMGA2	-0.7	-10.66	-0.56	4.61e-22	Height;
KIRP	cis	rs6466055	0.748	rs1204080	chr7:104988848	A/G	cg04380332	chr7:105027541	SRPK2	0.63	9.35	0.51	5.51e-18	Schizophrenia;
KIRP	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.09	-11.96	-0.61	2.77e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.85	10.63	0.56	5.8e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg00405596	chr8:11794950	NA	-0.45	-5.88	-0.35	1.34e-8	Retinal vascular caliber;
KIRP	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.44	6.76	0.4	9.82e-11	Schizophrenia;
KIRP	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg24804195	chr5:87968844	LOC645323	-0.47	-6.21	-0.37	2.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.1	-0.41	1.3e-11	Monocyte percentage of white cells;
KIRP	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	1.16	8.35	0.47	5.1e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs72820985	1.000	rs74030467	chr16:80844003	T/C	cg04448709	chr16:81349954	GAN	-0.5	-5.07	-0.31	7.99e-7	Breast cancer;
KIRP	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg13978929	chr19:21580086	ZNF493	0.5	4.86	0.3	2.11e-6	Pain;
KIRP	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg11189052	chr15:85197271	WDR73	0.51	5.33	0.32	2.24e-7	Schizophrenia;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05886006	chr1:161359784	NA	0.51	6.23	0.37	2.02e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg16141378	chr3:129829833	LOC729375	0.55	6.78	0.4	8.87e-11	Retinal vascular caliber;
KIRP	cis	rs4132509	0.948	rs7517921	chr1:243856420	T/C	cg21452805	chr1:244014465	NA	0.54	5.51	0.33	8.91e-8	RR interval (heart rate);
KIRP	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.77	0.35	2.43e-8	Aortic root size;
KIRP	cis	rs2072732	0.861	rs56088946	chr1:2961370	T/C	cg11731671	chr1:2995604	PRDM16	-0.55	-6.12	-0.36	3.71e-9	Plateletcrit;
KIRP	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg02367723	chr1:46378857	MAST2	0.46	5.37	0.32	1.83e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7224314	1.000	rs8070284	chr17:65387400	A/G	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.33	-0.42	3.37e-12	Diisocyanate-induced asthma;
KIRP	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.82	-14.75	-0.69	1.08e-35	Body mass index;
KIRP	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.92	11.87	0.6	5.5e-26	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.49	-6.22	-0.37	2.17e-9	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10322361	chr3:155314068	PLCH1	0.48	6.19	0.37	2.55e-9	Interleukin-4 levels;
KIRP	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.37	-4.95	-0.3	1.39e-6	Axial length;
KIRP	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg05484376	chr2:27715224	FNDC4	0.34	5.56	0.33	7.1e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg11846333	chr4:119757529	SEC24D	-1.14	-7.18	-0.42	8.04e-12	Cannabis dependence symptom count;
KIRP	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg20488157	chr14:104394430	TDRD9	-0.72	-9.87	-0.53	1.45e-19	Bipolar disorder;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg27305525	chr1:154955752	FLAD1	0.74	6.19	0.37	2.48e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs699	0.571	rs10864772	chr1:230841003	C/T	cg07390013	chr1:230838294	AGT	0.37	4.85	0.3	2.19e-6	Coronary artery disease;
KIRP	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-5.31	-0.32	2.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg18190219	chr22:46762943	CELSR1	-0.66	-7.49	-0.43	1.24e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg18225595	chr11:63971243	STIP1	0.66	6.06	0.36	5.08e-9	Mean platelet volume;
KIRP	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.53	-5.91	-0.35	1.16e-8	Blood pressure (smoking interaction);
KIRP	cis	rs7083	1.000	rs505045	chr11:117152540	G/T	cg11523350	chr11:117171073	BACE1	-0.28	-5.42	-0.33	1.42e-7	Blood protein levels;
KIRP	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg06742321	chr12:123595122	PITPNM2	0.41	5.02	0.3	9.97e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	12.18	0.61	5.05e-27	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16528272	chr4:3502518	NA	-0.54	-7.09	-0.41	1.39e-11	Parkinson's disease;
KIRP	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-17.26	-0.74	2.9e-44	Coronary artery disease;
KIRP	cis	rs3947	0.789	rs9009	chr8:11702006	A/T	cg00262122	chr8:11665843	FDFT1	0.5	5.58	0.34	6.42e-8	Blood protein levels;
KIRP	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg12405258	chr13:114927641	NA	0.44	6.66	0.39	1.78e-10	Schizophrenia;
KIRP	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.5	5.72	0.34	3.13e-8	Parkinson's disease;
KIRP	trans	rs1106684	1.000	rs61502430	chr7:131465867	G/A	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	trans	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	6.08	0.36	4.49e-9	Metabolite levels;
KIRP	trans	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.08	-0.36	4.59e-9	Triglycerides;
KIRP	trans	rs1962073	0.667	rs11250004	chr8:10270958	T/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.96	-0.45	6.23e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.84	-11.2	-0.58	8.35e-24	Type 2 diabetes;
KIRP	cis	rs7084402	0.529	rs7912116	chr10:60335389	G/C	cg05938607	chr10:60274200	BICC1	-0.37	-8.05	-0.46	3.44e-14	Refractive error;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18173830	chr6:4776623	CDYL	0.64	7.6	0.44	6.26e-13	Smoking initiation;
KIRP	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.6	0.39	2.44e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15813570	chr14:64854563	MTHFD1	0.6	7.24	0.42	5.86e-12	Smoking initiation;
KIRP	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.64	5.77	0.35	2.32e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7534824	0.625	rs12565777	chr1:101485794	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.01	0.41	2.29e-11	Refractive astigmatism;
KIRP	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.48	-6.39	-0.38	8.43e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15740352	chr19:34663535	LSM14A	0.49	6.25	0.37	1.77e-9	Parkinson's disease;
KIRP	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.71	6.9	0.4	4.42e-11	White matter hyperintensity burden;
KIRP	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg01721255	chr8:58191610	C8orf71	0.54	5.56	0.33	7.13e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-0.81	-12.8	-0.63	4.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14466506	chr3:188390968	LPP	0.43	6.29	0.37	1.44e-9	Survival in pancreatic cancer;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg03401519	chr2:177042493	NA	0.36	4.92	0.3	1.57e-6	IgG glycosylation;
KIRP	cis	rs6142102	0.812	rs2377955	chr20:32525370	A/G	cg24642439	chr20:33292090	TP53INP2	0.52	5.7	0.34	3.5e-8	Skin pigmentation;
KIRP	cis	rs10936602	0.527	rs6793160	chr3:169535266	A/C	cg08193579	chr3:169529701	LRRC34	-0.33	-5.01	-0.3	1.04e-6	Renal cell carcinoma;
KIRP	cis	rs6832769	1.000	rs13102385	chr4:56345255	T/C	cg05960024	chr4:56376020	CLOCK	0.63	8.17	0.46	1.65e-14	Personality dimensions;
KIRP	cis	rs236907	0.812	rs17596025	chr1:171746247	T/C	cg01410279	chr1:171621941	MYOC	-0.51	-5.35	-0.32	1.99e-7	Mean platelet volume;
KIRP	cis	rs55788414	0.860	rs1806875	chr16:81184069	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg18196295	chr10:418757	DIP2C	0.43	5.55	0.33	7.47e-8	Psychosis in Alzheimer's disease;
KIRP	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.68	0.44	3.86e-13	Neuroticism;
KIRP	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.42	5.48	0.33	1.05e-7	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.38	-5.39	-0.33	1.63e-7	Monocyte count;
KIRP	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.56	6.25	0.37	1.82e-9	Diisocyanate-induced asthma;
KIRP	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-7.07	-0.41	1.58e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs758324	0.812	rs2159243	chr5:131133900	G/A	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.82e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.92	-0.4	3.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.11e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8179	0.645	rs6954221	chr7:92283262	A/G	cg15732164	chr7:92237376	CDK6	0.49	6.34	0.37	1.08e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg08822215	chr16:89438651	ANKRD11	-0.5	-6.53	-0.38	3.72e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs923375	0.857	rs74251309	chr17:3385379	A/T	cg16505927	chr17:3375209	SPATA22	0.56	5.05	0.31	8.55e-7	Myopia (pathological);
KIRP	trans	rs10851411	1.000	rs10851411	chr15:42859235	T/G	cg24009656	chr6:146759324	NA	0.49	6.4	0.38	7.88e-10	Glucose homeostasis traits;
KIRP	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg19404215	chr3:33155277	CRTAP	0.73	6.44	0.38	6.37e-10	Major depressive disorder;
KIRP	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg26876637	chr1:152193138	HRNR	-0.68	-9.03	-0.5	5e-17	Atopic dermatitis;
KIRP	cis	rs10411936	0.712	rs9305079	chr19:16591464	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.45	4.89	0.3	1.84e-6	White blood cell count;Multiple sclerosis;
KIRP	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs72730918	0.590	rs2607116	chr15:51974433	A/G	cg14296394	chr15:51910925	DMXL2	-0.74	-10.0	-0.54	5.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.83	12.91	0.64	1.87e-29	Dental caries;
KIRP	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg01629716	chr15:45996671	NA	0.37	6.69	0.39	1.49e-10	Waist circumference;Weight;
KIRP	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	1.01	11.28	0.58	4.56e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs654128	0.640	rs173089	chr6:117216666	C/T	cg12892004	chr6:117198278	RFX6	-0.39	-5.15	-0.31	5.27e-7	Telomere length;
KIRP	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg14458575	chr2:238380390	NA	0.5	5.64	0.34	4.65e-8	Prostate cancer;
KIRP	cis	rs2072732	0.808	rs56091202	chr1:2936803	A/G	cg22517653	chr1:2918612	NA	-0.41	-4.87	-0.3	2.03e-6	Plateletcrit;
KIRP	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.92	-11.13	-0.58	1.47e-23	Diastolic blood pressure;
KIRP	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11038871	1.000	rs7949282	chr11:46522306	A/C	cg16389345	chr11:46697382	NA	-0.49	-6.62	-0.39	2.22e-10	Immunoglobulin A;
KIRP	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.61	-9.16	-0.5	2.1e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	12.75	0.63	6.2e-29	Body mass index (adult);
KIRP	cis	rs6585424	1.000	rs11201972	chr10:81932680	C/T	cg27417294	chr10:81904244	PLAC9	0.55	5.41	0.33	1.5e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg16141378	chr3:129829833	LOC729375	-0.51	-6.68	-0.39	1.6e-10	Mood instability;
KIRP	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.26	-6.93	-0.4	3.67e-11	Crohn's disease;
KIRP	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs12900413	0.687	rs28752094	chr15:90311645	G/A	cg24650279	chr15:90327240	NA	-0.41	-5.21	-0.32	4.07e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg08662619	chr6:150070041	PCMT1	0.37	5.9	0.35	1.19e-8	Lung cancer;
KIRP	cis	rs78487399	0.808	rs13405158	chr2:43705286	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.5	5.08	0.31	7.49e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg08533674	chr1:46993347	NA	-0.42	-5.38	-0.32	1.73e-7	Monobrow;
KIRP	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	10.22	0.55	1.13e-20	Ileal carcinoids;
KIRP	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-8.39	-0.47	3.84e-15	Coronary artery disease;
KIRP	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg10189774	chr4:17578691	LAP3	0.52	6.38	0.38	8.57e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	0.75	6.68	0.39	1.55e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.6	-0.48	9.68e-16	Total cholesterol levels;
KIRP	cis	rs9372498	0.536	rs9489467	chr6:118935206	C/T	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.79	6.85	0.4	5.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3752645	1.000	rs7778076	chr7:106723008	A/G	cg02696742	chr7:106810147	HBP1	-0.61	-4.97	-0.3	1.28e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.14	-0.31	5.54e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4132509	0.895	rs12138168	chr1:244009113	A/G	cg25706552	chr1:244017396	NA	0.61	7.4	0.43	2.09e-12	RR interval (heart rate);
KIRP	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.83e-26	Heart rate;
KIRP	cis	rs2692947	0.567	rs4907276	chr2:96391109	G/T	cg23100626	chr2:96804247	ASTL	-0.43	-5.9	-0.35	1.2e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1978968	0.763	rs9605472	chr22:18463216	A/G	cg02610425	chr22:18483192	MICAL3	0.37	5.6	0.34	5.79e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.57	-7.23	-0.42	5.93e-12	Retinal vascular caliber;
KIRP	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg00603274	chr11:61596626	FADS2	-0.57	-5.62	-0.34	5.06e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs2882667	0.931	rs3749665	chr5:138357211	A/G	cg04439458	chr5:138467593	SIL1	-0.42	-6.84	-0.4	6.09e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg18944383	chr4:111397179	ENPEP	0.51	8.48	0.48	2.15e-15	Coronary artery disease;
KIRP	cis	rs526231	0.543	rs34785	chr5:102458103	C/T	cg23492399	chr5:102201601	PAM	-0.49	-5.42	-0.33	1.4e-7	Primary biliary cholangitis;
KIRP	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg11833968	chr6:79620685	NA	-0.44	-6.76	-0.4	9.78e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10207060	0.500	rs4365487	chr2:240706803	T/C	cg20333904	chr2:240724165	NA	-0.41	-4.92	-0.3	1.58e-6	Obesity-related traits;
KIRP	cis	rs3789045	0.819	rs16854023	chr1:204551830	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.2	-0.37	2.37e-9	Educational attainment (college completion);
KIRP	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg24009623	chr19:33667908	NA	0.47	6.09	0.36	4.37e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.5	-0.38	4.55e-10	Blood metabolite levels;
KIRP	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9826463	0.938	rs9847445	chr3:142338536	G/A	cg20824294	chr3:142316082	PLS1	0.33	5.73	0.34	2.93e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg15556689	chr8:8085844	FLJ10661	0.6	8.1	0.46	2.58e-14	Morning vs. evening chronotype;
KIRP	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.75	6.77	0.4	9.66e-11	Weight;
KIRP	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.64	-0.39	1.95e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg10852876	chr4:165953100	TRIM60	-0.46	-4.99	-0.3	1.14e-6	Obesity-related traits;
KIRP	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg23682824	chr7:23144976	KLHL7	0.47	5.69	0.34	3.52e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg10755058	chr3:40428713	ENTPD3	0.34	4.86	0.3	2.1e-6	Renal cell carcinoma;
KIRP	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg05362011	chr13:21860987	NA	-0.46	-5.01	-0.3	1.04e-6	White matter hyperintensity burden;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg17441377	chr17:3906640	NA	-0.51	-7.68	-0.44	3.67e-13	Type 2 diabetes;
KIRP	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.68	8.99	0.5	6.79e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-6.9	-0.4	4.47e-11	Blood metabolite levels;
KIRP	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.3	-0.47	7.05e-15	Coronary artery disease;
KIRP	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.79	8.67	0.48	5.77e-16	Cholesterol, total;
KIRP	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Dermatomyositis;
KIRP	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg08885076	chr2:99613938	TSGA10	-0.37	-5.18	-0.31	4.62e-7	Fear of minor pain;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg04691961	chr3:161091175	C3orf57	-0.64	-10.25	-0.55	9.6e-21	Morning vs. evening chronotype;
KIRP	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg18132916	chr6:79620363	NA	-0.41	-5.69	-0.34	3.56e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs755109	1.000	rs55737216	chr9:100695901	G/A	cg13688889	chr9:100608707	NA	-0.41	-4.9	-0.3	1.77e-6	Quantitative traits;
KIRP	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg25783544	chr11:47291846	MADD	0.43	4.93	0.3	1.48e-6	HDL cholesterol;
KIRP	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.68	-0.39	1.55e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg09699651	chr6:150184138	LRP11	0.48	6.4	0.38	7.67e-10	Lung cancer;
KIRP	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.78	11.51	0.59	8.02e-25	Heart rate;
KIRP	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.72	7.23	0.42	6.22e-12	Bipolar disorder;
KIRP	cis	rs7614311	0.636	rs77639204	chr3:64005452	C/T	cg09006292	chr3:64049408	NA	-0.5	-5.06	-0.31	8.26e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19524238	chr7:2802976	GNA12	-0.39	-5.27	-0.32	2.93e-7	Height;
KIRP	cis	rs7975161	0.882	rs4406890	chr12:104638773	A/C	cg25273343	chr12:104657179	TXNRD1	-0.58	-6.26	-0.37	1.74e-9	Toenail selenium levels;
KIRP	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.85	7.97	0.45	6.12e-14	Methadone dose in opioid dependence;
KIRP	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.97	17.95	0.75	1.25e-46	Breast cancer;
KIRP	cis	rs7572263	0.724	rs11676550	chr2:209053775	T/C	cg23998903	chr2:209048830	C2orf80	-0.36	-5.25	-0.32	3.22e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.65	7.87	0.45	1.15e-13	Bipolar disorder;
KIRP	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.18	-0.31	4.73e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10783624	0.730	rs718150	chr12:39512724	A/G	cg26384229	chr12:38710491	ALG10B	0.36	4.85	0.3	2.24e-6	Schizophrenia;
KIRP	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-12.19	-0.61	4.8400000000000004e-27	Lung function (FEV1);
KIRP	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.51	0.38	4.09e-10	Lung cancer;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg13819577	chr1:248512075	OR14C36	-0.35	-5.03	-0.31	9.59e-7	Common traits (Other);
KIRP	cis	rs2926702	0.810	rs11776287	chr8:71326615	A/G	cg21651000	chr8:71129472	NCOA2	-0.5	-5.04	-0.31	8.92e-7	Non-small cell lung cancer;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg11814155	chr7:99998594	ZCWPW1	0.6	5.64	0.34	4.62e-8	Platelet count;
KIRP	cis	rs13006833	0.739	rs291428	chr2:191197226	G/T	cg27211696	chr2:191398769	TMEM194B	0.36	4.91	0.3	1.68e-6	Urinary metabolites;
KIRP	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.57	7.5	0.43	1.14e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	7.58	0.44	7.17e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	9.21	0.51	1.44e-17	Schizophrenia;
KIRP	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg06606381	chr12:133084897	FBRSL1	-1.09	-6.41	-0.38	7.21e-10	Depression;
KIRP	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.98	0.3	1.18e-6	Renal cell carcinoma;
KIRP	cis	rs9583531	0.760	rs1887200	chr13:111393137	A/C	cg24331049	chr13:111365604	ING1	-0.73	-6.83	-0.4	6.67e-11	Coronary artery disease;
KIRP	cis	rs116979167	0.575	rs67661063	chr7:105187259	T/G	cg19920283	chr7:105172520	RINT1	0.5	5.79	0.35	2.16e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	5.34	0.32	2.13e-7	Renal cell carcinoma;
KIRP	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.61	8.69	0.48	5.35e-16	Schizophrenia;
KIRP	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.59	-0.34	5.97e-8	Triglycerides;
KIRP	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.5	-9.97	-0.54	6.9e-20	Longevity;
KIRP	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg11262906	chr1:85462892	MCOLN2	-0.53	-5.4	-0.33	1.54e-7	Serum sulfate level;
KIRP	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.56	8.09	0.46	2.71e-14	Bone mineral density;
KIRP	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg15976283	chr2:238042351	NA	-0.36	-5.3	-0.32	2.55e-7	Systemic lupus erythematosus;
KIRP	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg07382826	chr16:28625726	SULT1A1	0.5	5.8	0.35	2e-8	Mosquito bite size;
KIRP	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00933542	chr6:150070202	PCMT1	-0.28	-5.33	-0.32	2.26e-7	Lung cancer;
KIRP	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg11972305	chr2:233791962	NGEF	0.39	5.47	0.33	1.09e-7	Schizophrenia;
KIRP	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.73	9.7	0.53	4.9e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.69	-6.87	-0.4	5.33e-11	Obesity-related traits;
KIRP	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25809561	chr17:30822961	MYO1D	0.6	8.15	0.46	1.83e-14	Schizophrenia;
KIRP	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs7011507	0.891	rs76890627	chr8:49178101	C/T	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg08648136	chr8:956695	NA	0.44	6.86	0.4	5.58e-11	Schizophrenia;
KIRP	cis	rs33912345	0.750	rs7155442	chr14:60937844	T/C	cg27398547	chr14:60952738	C14orf39	0.39	5.2	0.31	4.21e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg18350739	chr11:68623251	NA	-0.54	-8.17	-0.46	1.61e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2625529	0.816	rs4777467	chr15:72138478	T/C	cg16672083	chr15:72433130	SENP8	-0.51	-6.21	-0.37	2.29e-9	Red blood cell count;
KIRP	cis	rs1318772	0.623	rs36045988	chr5:112977495	A/T	cg12552261	chr5:112820674	MCC	0.84	4.99	0.3	1.15e-6	F-cell distribution;
KIRP	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg25767906	chr1:53392781	SCP2	-0.34	-4.86	-0.3	2.09e-6	Monocyte count;
KIRP	cis	rs35740288	0.787	rs2291048	chr15:86225658	A/T	cg10818794	chr15:86012489	AKAP13	0.42	5.04	0.31	8.83e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs2048656	0.578	rs7817784	chr8:9682553	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.35	-0.42	2.84e-12	Schizophrenia;
KIRP	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg15660573	chr17:549704	VPS53	-0.82	-12.52	-0.62	3.8e-28	Prostate cancer;
KIRP	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18252515	chr7:66147081	NA	0.47	5.81	0.35	1.97e-8	Aortic root size;
KIRP	cis	rs3857747	0.827	rs7785515	chr7:40477058	T/C	cg00420559	chr7:40367873	C7orf10	0.55	7.4	0.43	2.16e-12	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7172677	1.000	rs7178784	chr15:75425444	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.01	-0.3	1.03e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg19847130	chr8:10466454	RP1L1	0.35	5.09	0.31	7.06e-7	Systolic blood pressure;
KIRP	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.89	-10.0	-0.54	5.48e-20	Gut microbiome composition (summer);
KIRP	cis	rs6005807	0.719	rs9625521	chr22:29039953	T/G	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs580438	0.529	rs6442375	chr3:13409240	C/T	cg10657019	chr3:13328039	NA	-0.52	-6.94	-0.4	3.42e-11	Myringotomy;
KIRP	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg05370193	chr1:21551575	ECE1	0.47	6.33	0.37	1.18e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.34	-0.32	2.11e-7	Cholesterol, total;
KIRP	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg24498760	chr8:49746867	NA	0.39	4.93	0.3	1.54e-6	Blood metabolite ratios;
KIRP	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.63	9.21	0.51	1.53e-17	Total body bone mineral density;
KIRP	trans	rs587242	1.000	rs7543671	chr1:96892268	T/C	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs7577696	0.554	rs35978916	chr2:32400635	T/C	cg02381751	chr2:32503542	YIPF4	-0.57	-5.53	-0.33	7.99e-8	Inflammatory biomarkers;
KIRP	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg13753209	chr17:57696993	CLTC	0.52	5.0	0.3	1.07e-6	Hemoglobin concentration;
KIRP	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg00360474	chr6:37504404	NA	-0.47	-6.68	-0.39	1.58e-10	Cognitive performance;
KIRP	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.48	6.92	0.4	4e-11	Coronary artery disease;
KIRP	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	7.37	0.43	2.55e-12	Height;
KIRP	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.66	10.54	0.56	1.08e-21	Neuroticism;
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs12980942	0.591	rs4591267	chr19:41765407	A/C	cg25627403	chr19:41769009	HNRNPUL1	0.6	4.88	0.3	1.91e-6	Coronary artery disease;
KIRP	cis	rs239198	0.602	rs11755579	chr6:101322469	A/C	cg09795085	chr6:101329169	ASCC3	0.49	5.69	0.34	3.58e-8	Menarche (age at onset);
KIRP	cis	rs3755132	0.929	rs16862838	chr2:15788191	A/G	cg12888861	chr2:15731646	DDX1	-0.38	-5.03	-0.31	9.25e-7	Wilms tumor;
KIRP	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.74	9.07	0.5	3.78e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg23682824	chr7:23144976	KLHL7	0.55	6.58	0.39	2.78e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs501120	0.657	rs589655	chr10:44745315	C/G	cg09554077	chr10:44749378	NA	0.68	7.2	0.42	7.17e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23903597	chr17:61704154	MAP3K3	-0.59	-7.22	-0.42	6.58e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7635838	0.819	rs6776159	chr3:11519324	A/G	cg00170343	chr3:11313890	ATG7	0.5	6.37	0.38	9.45e-10	HDL cholesterol;
KIRP	cis	rs2737618	0.674	rs2821332	chr1:200085714	A/T	cg21825944	chr1:200113062	NR5A2	-0.54	-7.74	-0.44	2.54e-13	Uric acid levels;
KIRP	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg20578329	chr17:80767326	TBCD	-0.48	-5.98	-0.36	7.84e-9	Breast cancer;
KIRP	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg17644776	chr2:200775616	C2orf69	0.62	5.7	0.34	3.5e-8	Schizophrenia;
KIRP	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg20578329	chr17:80767326	TBCD	0.6	7.07	0.41	1.62e-11	Breast cancer;
KIRP	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.72	6.83	0.4	6.52e-11	Pulse pressure;
KIRP	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.6	0.34	5.82e-8	Ovarian reserve;
KIRP	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10982256	0.875	rs10759710	chr9:117252598	C/T	cg13636371	chr9:117264095	DFNB31	0.6	8.37	0.47	4.45e-15	Bipolar disorder;
KIRP	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.6	-7.37	-0.43	2.61e-12	Initial pursuit acceleration;
KIRP	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg03808351	chr9:123631620	PHF19	0.55	8.23	0.46	1.09e-14	Birth weight;
KIRP	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg24154853	chr7:158122151	PTPRN2	-0.38	-5.61	-0.34	5.51e-8	Calcium levels;
KIRP	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.2	0.31	4.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9816226	0.591	rs80080062	chr3:185812169	C/G	cg00760338	chr3:185826511	ETV5	-0.75	-6.6	-0.39	2.55e-10	Obesity;Body mass index;
KIRP	cis	rs6782228	0.675	rs2253151	chr3:128330137	T/C	cg18648031	chr3:128330563	NA	0.24	4.87	0.3	2.04e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg24579218	chr15:68104479	NA	-0.43	-6.1	-0.36	4.1e-9	Obesity;
KIRP	cis	rs10129255	0.500	rs59939897	chr14:107191651	A/G	cg23076370	chr14:107095027	NA	-0.4	-4.87	-0.3	2e-6	Kawasaki disease;
KIRP	cis	rs7119038	0.509	rs11216964	chr11:118581895	G/A	cg19308663	chr11:118741387	NA	0.42	6.43	0.38	6.44e-10	Sjögren's syndrome;
KIRP	cis	rs4073221	0.789	rs13080765	chr3:18211326	A/G	cg07694806	chr3:18168406	NA	0.69	6.06	0.36	5.11e-9	Parkinson's disease;
KIRP	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1345301	0.518	rs17689452	chr2:102864681	A/G	cg12451869	chr2:102867685	NA	0.49	7.0	0.41	2.45e-11	Waist circumference;
KIRP	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.31	-0.32	2.48e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs42648	0.508	rs39201	chr7:89734104	A/G	cg25739043	chr7:89950458	NA	0.37	5.66	0.34	4.3e-8	Homocysteine levels;
KIRP	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg02660097	chr11:68866761	NA	0.37	4.84	0.3	2.25e-6	Blond vs. brown hair color;
KIRP	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-6.98	-0.41	2.76e-11	Gut microbiome composition (summer);
KIRP	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.07	-0.31	7.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21643547	chr1:205240462	TMCC2	-0.73	-11.64	-0.6	3e-25	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg26554054	chr8:600488	NA	0.63	5.19	0.31	4.31e-7	IgG glycosylation;
KIRP	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-6.93	-0.4	3.65e-11	Tonsillectomy;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20540327	chr15:72668275	HEXA;C15orf34	0.46	6.14	0.36	3.24e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg01689657	chr7:91764605	CYP51A1	0.47	7.03	0.41	2.01e-11	Breast cancer;
KIRP	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.51	-7.28	-0.42	4.62e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7870753	0.730	rs1125963	chr9:99133313	T/C	cg25260653	chr9:99212216	HABP4	0.49	5.13	0.31	5.79e-7	Height;
KIRP	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.79	11.73	0.6	1.57e-25	Hip circumference;
KIRP	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.51	-0.43	1.1e-12	Mean corpuscular volume;
KIRP	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-14.56	-0.68	4.7e-35	Primary sclerosing cholangitis;
KIRP	cis	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg21204522	chr6:27730016	NA	-0.61	-5.17	-0.31	4.87e-7	Lung cancer in ever smokers;
KIRP	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.71	0.49	4.42e-16	Motion sickness;
KIRP	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06481639	chr22:41940642	POLR3H	0.7	7.11	0.41	1.24e-11	Vitiligo;
KIRP	cis	rs2380205	0.935	rs4468244	chr10:5898543	A/G	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.22e-8	Breast cancer;
KIRP	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.7	-6.89	-0.4	4.6e-11	Breast cancer;
KIRP	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06481639	chr22:41940642	POLR3H	0.64	6.72	0.39	1.28e-10	Vitiligo;
KIRP	cis	rs6662572	0.703	rs11580953	chr1:46387857	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.64	0.34	4.72e-8	Blood protein levels;
KIRP	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12580194	0.593	rs4448777	chr12:55724981	T/C	cg11794356	chr12:55725991	OR6C3	-0.54	-7.13	-0.41	1.11e-11	Cancer;
KIRP	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg09537434	chr19:41945824	ATP5SL	-0.65	-8.5	-0.48	1.83e-15	Migraine;Coronary artery disease;
KIRP	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg17764715	chr19:33622953	WDR88	0.82	11.92	0.61	3.64e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.46	-0.33	1.16e-7	Parkinson's disease;
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.67	7.89	0.45	9.78e-14	Lung cancer;
KIRP	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.64	6.01	0.36	6.64e-9	Breast cancer;
KIRP	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs6586163	0.527	rs12775501	chr10:90750909	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.61	7.6	0.44	6.3e-13	Chronic lymphocytic leukemia;
KIRP	cis	rs2131877	0.573	rs4266129	chr3:194846933	T/C	cg19775763	chr3:194786989	NA	-0.42	-5.14	-0.31	5.67e-7	Non-small cell lung cancer;
KIRP	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg15117754	chr3:10150083	C3orf24	0.48	4.95	0.3	1.4e-6	Alzheimer's disease;
KIRP	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg13607699	chr17:42295918	UBTF	0.46	5.51	0.33	8.86e-8	Total body bone mineral density;
KIRP	cis	rs60871478	0.898	rs34766380	chr7:786862	G/A	cg04727924	chr7:799746	HEATR2	-0.8	-8.76	-0.49	3.12e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg07636037	chr3:49044803	WDR6	0.61	5.15	0.31	5.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.51e-19	Prudent dietary pattern;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg23046566	chr6:170399029	NA	0.51	6.04	0.36	5.61e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs13385	0.815	rs34386219	chr5:139561906	G/A	cg01860693	chr5:139557145	C5orf32	0.49	5.36	0.32	1.93e-7	Atrial fibrillation;
KIRP	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.49	7.3	0.42	4.01e-12	IgG glycosylation;
KIRP	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.59	7.37	0.43	2.53e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg13409248	chr3:40428643	ENTPD3	0.41	5.34	0.32	2.09e-7	Renal cell carcinoma;
KIRP	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-5.68	-0.34	3.71e-8	Neuroticism;
KIRP	cis	rs16937956	0.626	rs34922792	chr11:8416499	C/T	cg08015107	chr11:8618950	NA	-0.53	-7.11	-0.41	1.22e-11	Body mass index;
KIRP	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14905665	chr2:206661494	NRP2	0.44	6.13	0.36	3.48e-9	Survival in pancreatic cancer;
KIRP	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.87	-14.13	-0.67	1.34e-33	Itch intensity from mosquito bite;
KIRP	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg16989719	chr2:238392110	NA	-0.68	-6.83	-0.4	6.49e-11	Prostate cancer;
KIRP	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg07541023	chr7:19748670	TWISTNB	0.65	5.76	0.34	2.44e-8	Thyroid stimulating hormone;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.68	-0.48	5.55e-16	Life satisfaction;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg23055707	chr2:1681153	PXDN	0.58	6.78	0.4	8.79e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg09873164	chr1:152488093	CRCT1	0.57	7.68	0.44	3.7e-13	Hair morphology;
KIRP	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.27	0.47	8.5e-15	Retinal vascular caliber;
KIRP	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg21775007	chr8:11205619	TDH	0.46	6.21	0.37	2.21e-9	Mood instability;
KIRP	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg08201673	chr17:18167551	SMCR7	0.55	6.53	0.38	3.81e-10	Multiple sclerosis;
KIRP	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.47	5.78	0.35	2.29e-8	Iron status biomarkers;
KIRP	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.82	-0.35	1.81e-8	Pulmonary function;
KIRP	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg02569458	chr12:86230093	RASSF9	0.53	7.78	0.44	2e-13	Major depressive disorder;
KIRP	cis	rs4722404	0.592	rs6461820	chr7:3118246	T/C	cg19214707	chr7:3157722	NA	-0.46	-5.37	-0.32	1.8e-7	Atopic dermatitis;
KIRP	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.32	-0.42	3.47e-12	Fear of minor pain;
KIRP	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg14346243	chr4:90757452	SNCA	-0.43	-5.13	-0.31	6.02e-7	Neuroticism;
KIRP	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.65	-7.26	-0.42	5.18e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.98	-12.64	-0.63	1.54e-28	Neutrophil percentage of white cells;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg11684740	chr22:20109642	RANBP1	-0.46	-6.32	-0.37	1.22e-9	Inflammatory biomarkers;
KIRP	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.48	-0.33	1.05e-7	IgG glycosylation;
KIRP	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.02	0.46	4.18e-14	Coffee consumption (cups per day);
KIRP	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg03834567	chr2:218808745	TNS1	-0.44	-5.28	-0.32	2.87e-7	Ulcerative colitis;
KIRP	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg16898833	chr6:26189333	HIST1H4D	0.79	5.44	0.33	1.32e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg19875535	chr5:140030758	IK	-0.69	-9.9	-0.53	1.15e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11825064	0.725	rs79185239	chr11:134493688	T/C	cg06603561	chr11:134479413	NA	-0.7	-5.61	-0.34	5.53e-8	Seasonality;
KIRP	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-1.0	-11.52	-0.59	7.69e-25	Exhaled nitric oxide output;
KIRP	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.3e-20	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13906749	chr12:120933893	DYNLL1	0.49	6.21	0.37	2.22e-9	Parkinson's disease;
KIRP	cis	rs867371	0.502	rs1846908	chr15:82522526	T/C	cg00614314	chr15:82944287	LOC80154	0.43	5.44	0.33	1.26e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.81	12.53	0.62	3.55e-28	Longevity;Endometriosis;
KIRP	cis	rs2398893	0.883	rs34169833	chr9:96840611	G/A	cg14459158	chr9:96720562	NA	0.31	5.67	0.34	4.06e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-9.41	-0.51	3.79e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg00405596	chr8:11794950	NA	-0.46	-6.05	-0.36	5.32e-9	Triglycerides;
KIRP	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg23752985	chr2:85803571	VAMP8	-0.57	-8.31	-0.47	6.34e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.44	-5.99	-0.36	7.31e-9	IgG glycosylation;
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	15.24	0.7	2.26e-37	Alzheimer's disease;
KIRP	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg05785598	chr3:49045655	WDR6	0.31	5.63	0.34	4.83e-8	Parkinson's disease;
KIRP	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg18154014	chr19:37997991	ZNF793	0.89	9.49	0.52	2.07e-18	Coronary artery calcification;
KIRP	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg09904177	chr6:26538194	HMGN4	0.45	6.04	0.36	5.71e-9	Schizophrenia;
KIRP	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg12435725	chr3:58293450	RPP14	-0.5	-5.43	-0.33	1.36e-7	Cholesterol, total;
KIRP	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.69	-8.89	-0.49	1.29e-16	Personality dimensions;
KIRP	cis	rs714027	0.566	rs5763751	chr22:30460434	G/T	cg27665648	chr22:30112403	NA	-0.43	-5.92	-0.35	1.08e-8	Lymphocyte counts;
KIRP	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.71	-8.32	-0.47	5.93e-15	Obesity-related traits;
KIRP	cis	rs929596	0.564	rs2602364	chr2:234524229	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-5.53	-0.33	8.3e-8	Total bilirubin levels in HIV-1 infection;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.69	6.46	0.38	5.7e-10	Lung function (FEV1);
KIRP	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg16434002	chr17:42200994	HDAC5	0.55	6.68	0.39	1.57e-10	Total body bone mineral density;
KIRP	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg12856521	chr11:46389249	DGKZ	-0.5	-6.81	-0.4	7.53e-11	Crohn's disease;
KIRP	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg14851346	chr12:38532713	NA	-0.4	-4.96	-0.3	1.3e-6	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05662582	chr11:93517353	MED17	-0.51	-6.1	-0.36	4e-9	Interleukin-4 levels;
KIRP	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg00405596	chr8:11794950	NA	-0.44	-5.93	-0.35	1.04e-8	Triglycerides;
KIRP	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg21851534	chr17:3907994	ZZEF1	0.71	11.76	0.6	1.28e-25	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19932227	chr3:119298432	ADPRH	0.46	6.7	0.39	1.4e-10	Parkinson's disease;
KIRP	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-0.75	-7.9	-0.45	9.56e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-5.31	-0.32	2.48e-7	Triglycerides;
KIRP	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg20387954	chr3:183756860	HTR3D	-0.51	-7.04	-0.41	1.93e-11	Anterior chamber depth;
KIRP	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg09873164	chr1:152488093	CRCT1	0.51	6.49	0.38	4.76e-10	Hair morphology;
KIRP	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.13	0.46	2.1e-14	Type 2 diabetes;
KIRP	cis	rs4740619	0.681	rs10738420	chr9:15966656	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.98	-0.3	1.2e-6	Body mass index;
KIRP	cis	rs78487399	0.908	rs75664918	chr2:43839090	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.9	-0.3	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4356975	0.563	rs35402056	chr4:69974267	A/T	cg27372994	chr4:70080453	UGT2B11	0.4	5.23	0.32	3.62e-7	Obesity-related traits;
KIRP	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg06115741	chr20:33292138	TP53INP2	0.4	4.86	0.3	2.13e-6	Height;
KIRP	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg25753631	chr6:25732923	NA	0.27	5.01	0.3	1.04e-6	Iron status biomarkers;
KIRP	cis	rs57561814	0.826	rs116542785	chr7:22747720	G/A	cg01770232	chr7:22766155	IL6	0.65	5.51	0.33	9.17e-8	Tonsillectomy;
KIRP	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.7	8.42	0.47	3.15e-15	Schizophrenia;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg14664628	chr15:75095509	CSK	-0.62	-7.58	-0.44	6.9e-13	Breast cancer;
KIRP	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.74	6.88	0.4	4.92e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg26354017	chr1:205819088	PM20D1	0.45	5.05	0.31	8.52e-7	Parkinson's disease;
KIRP	trans	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg06521331	chr12:34319734	NA	0.48	6.03	0.36	6.09e-9	Heart rate;
KIRP	cis	rs1386478	0.853	rs13087347	chr3:113785818	G/T	cg14431476	chr3:113822413	NA	0.46	5.03	0.31	9.65e-7	Crohn's disease and psoriasis;
KIRP	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg03315344	chr16:75512273	CHST6	0.73	11.39	0.59	2.08e-24	Dupuytren's disease;
KIRP	cis	rs2671245	0.586	rs12407237	chr1:56143773	A/C	cg11523071	chr1:56160889	NA	0.36	4.98	0.3	1.19e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg26220594	chr1:19110978	NA	0.45	4.92	0.3	1.56e-6	Drug-induced liver injury (nitrofurantoin);
KIRP	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.67	9.85	0.53	1.66e-19	Lymphocyte counts;
KIRP	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.23	0.51	1.31e-17	Colorectal cancer;
KIRP	trans	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg21775007	chr8:11205619	TDH	0.46	6.09	0.36	4.42e-9	Mood instability;
KIRP	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	6.26	0.37	1.66e-9	Educational attainment;
KIRP	cis	rs7225151	0.710	rs112809920	chr17:5196610	C/T	cg24500398	chr17:5266808	RABEP1	-0.57	-5.55	-0.33	7.47e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2150410	0.833	rs8127391	chr21:40636060	G/A	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs7587476	0.861	rs17488049	chr2:215651750	G/A	cg04004882	chr2:215674386	BARD1	0.76	6.56	0.39	3.07e-10	Neuroblastoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14843496	chr2:165698108	COBLL1	0.46	6.22	0.37	2.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.59	8.13	0.46	2.11e-14	Motion sickness;
KIRP	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	0.9	14.06	0.67	2.36e-33	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg16506815	chr2:162101123	NA	-0.42	-5.38	-0.32	1.75e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.14	0.61	6.7e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg17470723	chr8:74884337	TCEB1	0.64	8.17	0.46	1.6e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg01798813	chr17:3906674	NA	0.52	7.12	0.41	1.19e-11	Type 2 diabetes;
KIRP	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs1816752	0.776	rs9511268	chr13:25018320	A/G	cg02811702	chr13:24901961	NA	0.41	5.39	0.33	1.62e-7	Obesity-related traits;
KIRP	cis	rs4262150	0.883	rs72802893	chr5:152256185	A/G	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.98e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.59	9.84	0.53	1.72e-19	Migraine;
KIRP	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg03678062	chr6:149772716	ZC3H12D	0.31	5.0	0.3	1.11e-6	Dupuytren's disease;
KIRP	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.64	8.53	0.48	1.51e-15	Eosinophil percentage of white cells;
KIRP	cis	rs877426	0.645	rs2297103	chr13:114775816	G/T	cg00571178	chr13:114841904	RASA3	-0.45	-5.18	-0.31	4.7e-7	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.44	5.08	0.31	7.6e-7	Blood protein levels;
KIRP	cis	rs2554380	0.943	rs2585061	chr15:84347751	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.3	-0.47	6.74e-15	Height;
KIRP	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.51	0.38	4.26e-10	Lung cancer;
KIRP	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.41	5.13	0.31	5.83e-7	Aortic root size;
KIRP	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.05	-0.31	8.7e-7	Coronary artery disease;
KIRP	trans	rs1493916	0.606	rs10432168	chr18:31312106	T/C	cg27147174	chr7:100797783	AP1S1	-0.66	-7.75	-0.44	2.43e-13	Life satisfaction;
KIRP	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26990380	chr4:95469305	PDLIM5	-0.39	-6.65	-0.39	1.91e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg04733989	chr22:42467013	NAGA	0.57	7.94	0.45	7.31e-14	Cognitive function;
KIRP	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.16	-0.37	3e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.64	-0.44	4.74e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg08807101	chr21:30365312	RNF160	-0.55	-6.54	-0.38	3.57e-10	Cognitive test performance;
KIRP	cis	rs6832769	1.000	rs7670225	chr4:56368018	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.04	0.41	1.92e-11	Personality dimensions;
KIRP	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.9	12.87	0.63	2.49e-29	Tonsillectomy;
KIRP	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.53	6.92	0.4	4.01e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8077577	0.689	rs16961133	chr17:18223548	C/T	cg18869244	chr17:18121946	NA	0.44	4.99	0.3	1.15e-6	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18778933	chr5:52760204	NA	0.49	7.21	0.42	6.68e-12	Survival in pancreatic cancer;
KIRP	cis	rs10463316	0.894	rs3846711	chr5:150740749	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.57	-0.39	2.95e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs711830	1.000	rs2249131	chr2:177032095	C/T	cg13092806	chr2:177043255	NA	0.65	6.88	0.4	5.03e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.51	-0.33	9.12e-8	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13939156	chr17:80058883	NA	0.47	7.12	0.41	1.19e-11	Life satisfaction;
KIRP	cis	rs8067287	0.762	rs11649835	chr17:16823541	C/G	cg26910001	chr17:16838321	NA	-0.58	-5.75	-0.34	2.65e-8	Diabetic kidney disease;
KIRP	cis	rs8084125	1.000	rs8084125	chr18:74952758	T/C	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg03128534	chr1:43423976	SLC2A1	-0.62	-7.27	-0.42	4.77e-12	Red cell distribution width;
KIRP	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.21	-0.32	4e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg20415053	chr1:26527928	CATSPER4	-0.43	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs10488172	0.555	rs2001280	chr7:133663292	T/C	cg10665199	chr7:133106180	EXOC4	-0.47	-4.85	-0.3	2.17e-6	Tonometry;
KIRP	cis	rs9815354	0.903	rs11705749	chr3:41947294	C/T	cg03022575	chr3:42003672	ULK4	-0.5	-5.7	-0.34	3.34e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg26354017	chr1:205819088	PM20D1	0.48	5.44	0.33	1.28e-7	Parkinson's disease;
KIRP	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg17470449	chr10:769945	NA	0.48	4.85	0.3	2.24e-6	Uric acid levels;
KIRP	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12667521	chr19:29218732	NA	0.79	7.08	0.41	1.54e-11	Methadone dose in opioid dependence;
KIRP	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.64	-9.26	-0.51	1.02e-17	Retinal vascular caliber;
KIRP	trans	rs112458284	0.557	rs4905135	chr14:94461601	A/G	cg25671374	chr19:10230567	EIF3G	0.66	6.18	0.37	2.71e-9	Chronic obstructive pulmonary disease;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg09491104	chr22:46646882	C22orf40	-0.56	-6.06	-0.36	5.09e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.53	-6.8	-0.4	7.8e-11	Type 2 diabetes;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22811384	chr13:33528605	NA	-0.46	-6.08	-0.36	4.66e-9	Inflammatory biomarkers;
KIRP	cis	rs1147199	0.531	rs1001905	chr9:87272519	A/G	cg22402007	chr9:87282823	NTRK2	-0.4	-4.98	-0.3	1.22e-6	Body mass index;
KIRP	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg17294928	chr15:75287854	SCAMP5	-0.66	-5.48	-0.33	1.03e-7	Lung cancer;
KIRP	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.55	6.47	0.38	5.19e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2273156	1.000	rs12894365	chr14:35435391	C/A	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.65	-0.34	4.31e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22399211	chr4:985076	SLC26A1;IDUA	0.43	6.22	0.37	2.18e-9	Survival in pancreatic cancer;
KIRP	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.18	0.42	8.21e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs490234	0.718	rs2133386	chr9:128173838	C/A	cg14078157	chr9:128172775	NA	-0.41	-5.13	-0.31	5.75e-7	Mean arterial pressure;
KIRP	cis	rs4262150	0.883	rs72799196	chr5:152190622	C/T	cg12297329	chr5:152029980	NA	-0.66	-8.46	-0.47	2.43e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg19596991	chr10:126432951	FAM53B	0.47	6.03	0.36	6.1e-9	Educational attainment;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg12559939	chr2:27858050	GPN1	0.42	5.35	0.32	2.02e-7	Oral cavity cancer;
KIRP	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg00149659	chr3:10157352	C3orf10	0.71	7.49	0.43	1.2e-12	Alzheimer's disease;
KIRP	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg24296786	chr1:45957014	TESK2	0.51	5.68	0.34	3.81e-8	Homocysteine levels;
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg22764044	chr5:178986830	RUFY1	0.41	5.76	0.34	2.53e-8	Lung cancer;
KIRP	cis	rs1823913	0.637	rs2067610	chr2:192163977	C/T	cg12404831	chr2:192114017	MYO1B	0.55	7.62	0.44	5.51e-13	Obesity-related traits;
KIRP	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs897080	0.589	rs1067380	chr2:44646834	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.77	0.35	2.4e-8	Height;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg23156509	chr2:114033830	PAX8;LOC440839	-0.37	-5.74	-0.34	2.72e-8	Lymphocyte counts;
KIRP	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.7	0.44	3.32e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.62	-0.44	5.61e-13	Life satisfaction;
KIRP	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.28	-6.66	-0.39	1.77e-10	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25044635	chr2:25565267	DNMT3A	0.5	6.21	0.37	2.22e-9	Parkinson's disease;
KIRP	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.48	7.83	0.45	1.41e-13	Height;
KIRP	cis	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.04	-0.31	8.94e-7	Neuroticism;
KIRP	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg16586182	chr3:47516702	SCAP	-0.76	-11.03	-0.58	3.06e-23	Colorectal cancer;
KIRP	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg15605315	chr1:45957053	TESK2	-0.47	-5.89	-0.35	1.23e-8	High light scatter reticulocyte count;
KIRP	cis	rs35740288	0.822	rs10520599	chr15:86223097	C/T	cg17133734	chr15:86042851	AKAP13	-0.48	-5.12	-0.31	6.19e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.4	-0.38	7.81e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg04865290	chr3:52927548	TMEM110	-0.44	-5.4	-0.33	1.57e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6832769	0.922	rs819271	chr4:56238847	G/A	cg09317128	chr4:56265301	TMEM165	0.47	5.79	0.35	2.1e-8	Personality dimensions;
KIRP	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg02725872	chr8:58115012	NA	-0.52	-5.92	-0.35	1.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7589728	0.844	rs2363010	chr2:88496399	G/C	cg04511125	chr2:88470314	THNSL2	0.76	5.51	0.33	9.23e-8	Plasma clusterin levels;
KIRP	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg11972305	chr2:233791962	NGEF	-0.38	-5.23	-0.32	3.61e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24537038	chr9:99213506	HABP4	0.59	6.99	0.41	2.56e-11	Smoking initiation;
KIRP	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg18404041	chr3:52824283	ITIH1	-0.46	-5.86	-0.35	1.49e-8	Schizophrenia;
KIRP	cis	rs13385	0.769	rs7704262	chr5:139611043	T/A	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs9653442	0.545	rs11681966	chr2:100759457	A/C	cg07810366	chr2:100720526	AFF3	0.32	5.15	0.31	5.46e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4073221	0.654	rs66790792	chr3:18284981	G/A	cg07694806	chr3:18168406	NA	-0.65	-5.9	-0.35	1.19e-8	Parkinson's disease;
KIRP	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.72	-8.57	-0.48	1.14e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.34	-0.32	2.13e-7	Renal cell carcinoma;
KIRP	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10239600	chr14:103411866	CDC42BPB	0.45	6.02	0.36	6.13e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7507204	0.723	rs12979645	chr19:3414688	A/T	cg08380311	chr19:3435252	NFIC	0.65	5.86	0.35	1.48e-8	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25654957	chr20:36156668	BLCAP	-0.52	-6.04	-0.36	5.75e-9	Interleukin-4 levels;
KIRP	cis	rs7572263	1.000	rs7572263	chr2:209051586	A/G	cg23998903	chr2:209048830	C2orf80	-0.31	-5.39	-0.33	1.63e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs9322193	0.923	rs9322225	chr6:150184882	G/C	cg07701084	chr6:150067640	NUP43	0.59	7.29	0.42	4.15e-12	Lung cancer;
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.92	14.68	0.68	1.81e-35	Menarche (age at onset);
KIRP	cis	rs4835473	0.900	rs10032963	chr4:144654221	G/C	cg08833778	chr4:144622313	FREM3	0.34	4.91	0.3	1.65e-6	Immature fraction of reticulocytes;
KIRP	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.48	6.31	0.37	1.32e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs16828019	0.852	rs71648536	chr1:41632008	T/A	cg03387723	chr1:41708464	SCMH1	-0.81	-6.88	-0.4	4.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.56	-6.29	-0.37	1.41e-9	Menarche (age at onset);
KIRP	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18252515	chr7:66147081	NA	0.46	5.63	0.34	4.8e-8	Aortic root size;
KIRP	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.45	5.74	0.34	2.71e-8	Gout;
KIRP	cis	rs238295	0.881	rs6116869	chr20:5594432	G/T	cg25486615	chr20:5591870	RP5-1022P6.2	0.47	4.85	0.3	2.17e-6	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg06204229	chr3:52865917	ITIH4	0.44	5.11	0.31	6.41e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs9329221	0.585	rs12550717	chr8:10266706	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.35	0.42	2.84e-12	Neuroticism;
KIRP	cis	rs10875746	0.669	rs11168516	chr12:48702065	C/T	cg26205652	chr12:48591994	NA	0.7	9.05	0.5	4.6e-17	Longevity (90 years and older);
KIRP	trans	rs17834760	0.955	rs6933932	chr6:62059718	G/T	cg08476511	chr6:168435923	KIF25	0.51	6.09	0.36	4.25e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.93	-13.06	-0.64	5.87e-30	Cognitive function;
KIRP	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.12e-6	Aortic root size;
KIRP	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg08755490	chr11:65554678	OVOL1	0.42	5.64	0.34	4.69e-8	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
KIRP	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	9.92	0.53	9.81e-20	Parkinson's disease;
KIRP	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.73	-8.47	-0.48	2.24e-15	Diabetic retinopathy;
KIRP	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-11.76	-0.6	1.29e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.88	12.46	0.62	5.98e-28	Monocyte count;
KIRP	cis	rs12982744	0.524	rs2238602	chr19:2144429	A/G	cg09261902	chr19:2140048	AP3D1	0.43	5.46	0.33	1.15e-7	Osteoarthritis;Height;
KIRP	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	6.05	0.36	5.23e-9	Breast cancer;
KIRP	cis	rs1322639	0.657	rs12203887	chr6:169572252	C/T	cg04662567	chr6:169592167	NA	-0.66	-5.54	-0.33	7.67e-8	Pulse pressure;
KIRP	cis	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg21546286	chr11:48923668	NA	0.43	5.38	0.32	1.74e-7	HDL cholesterol;
KIRP	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.51	5.09	0.31	7.12e-7	Alzheimer's disease;
KIRP	cis	rs4262150	0.810	rs17454420	chr5:152014941	A/G	cg12297329	chr5:152029980	NA	0.66	8.15	0.46	1.87e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg11995313	chr8:8860691	ERI1	0.42	5.48	0.33	1.04e-7	Joint mobility (Beighton score);
KIRP	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.73	7.36	0.42	2.76e-12	Bipolar disorder;
KIRP	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg23587288	chr2:27483067	SLC30A3	-0.57	-7.23	-0.42	6.04e-12	Blood metabolite levels;
KIRP	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg06647332	chr5:131281008	NA	0.46	5.01	0.3	1.04e-6	Life satisfaction;
KIRP	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.2	-0.31	4.22e-7	Primary biliary cholangitis;
KIRP	cis	rs834811	0.829	rs6980107	chr7:135900757	C/T	cg01726295	chr7:135938950	NA	-0.37	-5.09	-0.31	7.24e-7	Post-traumatic stress disorder;
KIRP	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg26207909	chr14:103986467	CKB	0.48	6.02	0.36	6.25e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.64	-5.96	-0.36	8.57e-9	Narcolepsy;
KIRP	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg26876637	chr1:152193138	HRNR	0.78	10.34	0.55	4.83e-21	Atopic dermatitis;
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg08662619	chr6:150070041	PCMT1	0.36	5.96	0.36	8.57e-9	Lung cancer;
KIRP	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.87	-12.39	-0.62	9.89e-28	Total body bone mineral density;
KIRP	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.96	11.29	0.58	4.45e-24	Corneal astigmatism;
KIRP	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.94	10.29	0.55	6.77e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg26441486	chr22:50317300	CRELD2	0.41	6.78	0.4	9.04e-11	Schizophrenia;
KIRP	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg23594656	chr7:65796392	TPST1	-0.49	-7.45	-0.43	1.57e-12	Aortic root size;
KIRP	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.6	-0.44	6.26e-13	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.3	-0.37	1.34e-9	Triglycerides;
KIRP	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg01879757	chr17:41196368	BRCA1	-0.76	-10.49	-0.56	1.65e-21	Menopause (age at onset);
KIRP	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.74	5.62	0.34	5.1e-8	Breast cancer;
KIRP	cis	rs6832769	0.961	rs2140077	chr4:56338953	A/G	cg09317128	chr4:56265301	TMEM165	0.52	6.56	0.39	3.13e-10	Personality dimensions;
KIRP	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-9.4	-0.51	3.99e-18	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	5.91	0.35	1.15e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.62	-10.35	-0.55	4.43e-21	Sense of smell;
KIRP	cis	rs7572644	0.640	rs4555299	chr2:28071190	A/G	cg27432699	chr2:27873401	GPN1	0.47	5.71	0.34	3.29e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.39	1.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.49	-5.84	-0.35	1.61e-8	Alzheimer's disease (late onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05090725	chr11:107799287	RAB39	0.6	7.38	0.43	2.36e-12	Smoking initiation;
KIRP	cis	rs2223471	0.624	rs57708642	chr6:50738127	A/T	cg03432817	chr6:50765336	NA	-0.36	-5.49	-0.33	9.84e-8	Subcutaneous adipose tissue;
KIRP	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.79	9.86	0.53	1.58e-19	IgG glycosylation;
KIRP	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg10150615	chr22:24372951	LOC391322	-0.47	-5.4	-0.33	1.59e-7	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg12384639	chr17:618140	VPS53	0.49	5.99	0.36	7.33e-9	Prostate cancer;
KIRP	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02756545	chr1:94884060	ABCD3	0.52	6.15	0.37	3.16e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg04727924	chr7:799746	HEATR2	-0.77	-8.72	-0.49	4.23e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg00277334	chr10:82204260	NA	-0.46	-5.38	-0.32	1.76e-7	Post bronchodilator FEV1;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01089097	chr15:37110495	CSNK1A1P	0.42	6.31	0.37	1.31e-9	Cancer;
KIRP	cis	rs6662572	0.737	rs72677533	chr1:46536558	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.77	0.35	2.44e-8	Blood protein levels;
KIRP	cis	rs10875746	0.903	rs12306451	chr12:48483241	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg10223061	chr2:219282414	VIL1	0.43	7.0	0.41	2.43e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg05562828	chr17:3906858	NA	-0.7	-13.44	-0.65	2.92e-31	Type 2 diabetes;
KIRP	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11987759	chr7:65425863	GUSB	0.51	6.91	0.4	4.05e-11	Aortic root size;
KIRP	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.8	11.03	0.58	3.05e-23	Coronary artery disease;
KIRP	cis	rs14403	0.874	rs3006924	chr1:243650986	G/C	cg21452805	chr1:244014465	NA	0.48	5.1	0.31	6.71e-7	Schizophrenia;
KIRP	cis	rs9843304	0.568	rs11720325	chr3:149216311	A/T	cg08667024	chr3:149219783	TM4SF4	-0.44	-5.98	-0.36	7.98e-9	Gallstone disease;
KIRP	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.12	0.36	3.59e-9	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22561384	chr8:28932160	KIF13B	0.48	6.23	0.37	1.97e-9	Interleukin-4 levels;
KIRP	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg11235152	chr1:67600687	NA	0.75	10.86	0.57	1.1e-22	Psoriasis;
KIRP	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg03235661	chr20:60525775	NA	-0.33	-5.17	-0.31	4.84e-7	Body mass index;
KIRP	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.05	-0.64	6.44e-30	Height;
KIRP	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.64	0.56	5.48e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.64	6.47	0.38	5.19e-10	Protein C levels;
KIRP	cis	rs7215564	0.908	rs34969384	chr17:78678716	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.39e-7	Myopia (pathological);
KIRP	cis	rs745080	0.764	rs6572849	chr14:52977289	C/G	cg23333723	chr14:53022898	GPR137C	-0.42	-5.8	-0.35	2.02e-8	Orofacial clefts;
KIRP	cis	rs4132509	0.625	rs9428966	chr1:243667900	A/C	cg25706552	chr1:244017396	NA	0.33	4.85	0.3	2.17e-6	RR interval (heart rate);
KIRP	trans	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg25288420	chr1:78511713	GIPC2	0.49	6.48	0.38	4.97e-10	Obesity-related traits;
KIRP	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg16865965	chr2:85811662	VAMP5	0.4	6.26	0.37	1.67e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs4356975	0.563	rs6600876	chr4:69956930	T/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.88	10.36	0.55	4.08e-21	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.74	6.66	0.39	1.78e-10	Diabetic retinopathy;
KIRP	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg07596299	chr11:71824057	C11orf51	0.9	5.93	0.35	1.03e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.96	10.41	0.55	2.96e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.54	0.38	3.57e-10	Major depressive disorder;
KIRP	cis	rs9393813	1.000	rs12663650	chr6:27366821	C/A	cg18711553	chr6:27366782	ZNF391	-0.48	-7.06	-0.41	1.66e-11	Bipolar disorder;
KIRP	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.73	-0.44	2.71e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg01238044	chr22:24384105	GSTT1	-0.56	-7.39	-0.43	2.35e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14023874	chr1:168698975	DPT	0.47	6.53	0.38	3.75e-10	Survival in pancreatic cancer;
KIRP	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.46	-9.36	-0.51	5.25e-18	Rheumatoid arthritis;
KIRP	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.68	-9.45	-0.52	2.79e-18	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-5.59	-0.34	6.03e-8	Schizophrenia;
KIRP	cis	rs12476592	0.602	rs1348803	chr2:63895617	C/T	cg17519650	chr2:63277830	OTX1	-0.46	-4.89	-0.3	1.79e-6	Childhood ear infection;
KIRP	cis	rs830383	0.512	rs31723	chr5:165471298	C/T	cg13976338	chr5:165423657	NA	-0.61	-6.1	-0.36	4.06e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg12705353	chr12:122356852	WDR66	0.41	5.53	0.33	8.28e-8	Mean corpuscular volume;
KIRP	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.48	5.95	0.35	9.05e-9	Height;
KIRP	cis	rs7721647	0.853	rs10043890	chr5:90867639	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.41	5.04	0.31	8.88e-7	Breast cancer;
KIRP	cis	rs2371030	0.900	rs2371031	chr2:211570074	A/C	cg18417063	chr2:211583084	NA	-0.53	-7.89	-0.45	1e-13	Non-small cell lung cancer;
KIRP	cis	rs9653442	0.527	rs4850923	chr2:100782256	A/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.21	-0.32	4.02e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.55	-7.33	-0.42	3.31e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-1.07	-17.7	-0.75	9.08e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.72	10.55	0.56	1.06e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.97	15.05	0.69	1.03e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg19875535	chr5:140030758	IK	0.69	9.77	0.53	2.93e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.61	0.6	3.79e-25	Alzheimer's disease;
KIRP	cis	rs12681366	0.663	rs2930970	chr8:95464337	A/G	cg13257157	chr8:95487014	RAD54B	0.41	5.08	0.31	7.57e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs4671458	0.948	rs72815371	chr2:63583236	A/T	cg17519650	chr2:63277830	OTX1	-0.54	-5.39	-0.33	1.62e-7	Subjective well-being;
KIRP	cis	rs603424	0.597	rs574122	chr10:102089174	C/A	cg10365880	chr10:102089681	PKD2L1	0.6	5.03	0.31	9.53e-7	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
KIRP	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg06643013	chr6:134217242	NA	-0.52	-6.8	-0.4	7.9e-11	Coronary artery disease;
KIRP	cis	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.12	-0.36	3.66e-9	Small cell lung carcinoma;
KIRP	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg19592336	chr6:28129416	ZNF389	0.5	5.64	0.34	4.56e-8	Depression;
KIRP	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19524238	chr7:2802976	GNA12	-0.37	-5.01	-0.3	1.05e-6	Height;
KIRP	cis	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg26207909	chr14:103986467	CKB	0.39	4.88	0.3	1.87e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-4.91	-0.3	1.64e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7870753	1.000	rs7024214	chr9:99239173	T/C	cg25260653	chr9:99212216	HABP4	0.54	6.05	0.36	5.3e-9	Height;
KIRP	cis	rs737008	0.922	rs2550475	chr16:11371986	C/T	cg00044050	chr16:11439710	C16orf75	0.59	6.81	0.4	7.24e-11	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18230796	chr4:3294592	NA	0.55	7.4	0.43	2.16e-12	Parkinson's disease;
KIRP	cis	rs804292	0.763	rs8191514	chr8:11627113	C/G	cg26752888	chr8:11627280	NEIL2	1.06	11.15	0.58	1.26e-23	Alcohol dependence;Nicotine use;
KIRP	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.48	5.91	0.35	1.14e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.94	-16.19	-0.72	1.29e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1816752	0.837	rs9318530	chr13:24998557	A/G	cg02811702	chr13:24901961	NA	-0.42	-5.58	-0.34	6.25e-8	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4233802	0.737	rs74749038	chr2:151177761	G/A	cg25300694	chr2:151184358	NA	-0.69	-5.15	-0.31	5.26e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg05347473	chr6:146136440	FBXO30	0.55	7.87	0.45	1.13e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16993249	chr15:75628474	COMMD4	0.49	6.78	0.4	9.09e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-0.76	-8.11	-0.46	2.41e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.85	-13.79	-0.66	1.91e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4006360	0.531	rs4544293	chr17:39241359	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.71	8.56	0.48	1.25e-15	Height;
KIRP	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg22800045	chr5:56110881	MAP3K1	0.81	8.69	0.48	5.27e-16	Initial pursuit acceleration;
KIRP	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg08847533	chr14:75593920	NEK9	-0.51	-6.06	-0.36	4.97e-9	IgG glycosylation;
KIRP	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.03	0.64	7.39e-30	Exhaled nitric oxide output;
KIRP	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.91	14.36	0.68	2.18e-34	Selective IgA deficiency;
KIRP	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs9815354	1.000	rs1717024	chr3:41984888	G/T	cg03022575	chr3:42003672	ULK4	-0.47	-5.41	-0.33	1.46e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs524023	0.874	rs518053	chr11:64456099	C/T	cg09231725	chr11:64357281	SLC22A12	0.58	7.77	0.44	2.16e-13	Urate levels in obese individuals;
KIRP	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg01631408	chr1:248437212	OR2T33	-0.65	-8.81	-0.49	2.27e-16	Common traits (Other);
KIRP	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg17757837	chr7:157058334	UBE3C	0.8	10.79	0.57	1.72e-22	Body mass index;
KIRP	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.63	0.48	7.94e-16	Morning vs. evening chronotype;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.8	-13.67	-0.66	5.13e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg00684032	chr4:1343700	KIAA1530	-0.54	-7.06	-0.41	1.66e-11	Obesity-related traits;
KIRP	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.74	10.6	0.56	7.33e-22	Prostate cancer;
KIRP	cis	rs963731	0.579	rs1454226	chr2:39246862	A/G	cg04010122	chr2:39346883	SOS1	-0.91	-6.14	-0.36	3.23e-9	Corticobasal degeneration;
KIRP	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.45	-0.33	1.23e-7	Schizophrenia;
KIRP	cis	rs614367	1.000	rs614367	chr11:69328764	A/G	cg08353955	chr11:69289746	NA	0.75	6.13	0.36	3.47e-9	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg19875535	chr5:140030758	IK	-0.62	-8.71	-0.49	4.54e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7017914	0.902	rs34882924	chr8:71566308	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.11	-0.31	6.58e-7	Bone mineral density;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg00513467	chr9:21335551	KLHL9	-0.43	-6.2	-0.37	2.35e-9	Serum protein levels (sST2);
KIRP	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg03735888	chr19:58951602	ZNF132	0.44	5.22	0.32	3.83e-7	Uric acid clearance;
KIRP	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.53	6.66	0.39	1.77e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.23	0.37	1.97e-9	Morning vs. evening chronotype;
KIRP	trans	rs74233809	0.901	rs3824754	chr10:104614350	C/T	cg04366687	chr8:145107199	OPLAH	-0.47	-6.05	-0.36	5.29e-9	Birth weight;
KIRP	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg19052272	chr2:3704530	ALLC	-0.61	-7.51	-0.43	1.11e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs13170463	0.579	rs13183365	chr5:8039302	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs6832769	1.000	rs9312662	chr4:56386371	A/G	cg09317128	chr4:56265301	TMEM165	-0.56	-7.1	-0.41	1.31e-11	Personality dimensions;
KIRP	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.4	-5.38	-0.32	1.7e-7	Type 2 diabetes;
KIRP	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	8.33	0.47	5.75e-15	Retinal vascular caliber;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.77	0.35	2.33e-8	Lung cancer;
KIRP	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.53	-6.37	-0.38	9.05e-10	Ulcerative colitis;
KIRP	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.64	8.46	0.47	2.49e-15	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.2	-0.31	4.25e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07472750	chr13:31039592	HMGB1	0.49	6.15	0.37	3.07e-9	Bladder cancer;
KIRP	cis	rs55962025	0.855	rs2024115	chr4:3104568	A/G	cg06533319	chr4:3265114	C4orf44	0.4	5.14	0.31	5.68e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7264396	0.563	rs6060560	chr20:34278890	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.44	-0.38	6.21e-10	Total cholesterol levels;
KIRP	cis	rs287982	1.000	rs287979	chr2:9970967	T/C	cg18436444	chr2:10917754	ATP6V1C2	0.34	5.01	0.3	1.05e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs2504916	1.000	rs2504931	chr6:160835529	A/G	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.57	-6.03	-0.36	5.99e-9	Response to hepatitis C treatment;
KIRP	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg21775007	chr8:11205619	TDH	0.48	6.32	0.37	1.2e-9	Systolic blood pressure;
KIRP	cis	rs3026101	0.534	rs57303034	chr17:5319003	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg01721255	chr8:58191610	C8orf71	0.52	5.1	0.31	6.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18252515	chr7:66147081	NA	0.47	5.43	0.33	1.34e-7	Aortic root size;
KIRP	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.87	-11.78	-0.6	1.09e-25	Cognitive function;
KIRP	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.52	-5.54	-0.33	7.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6142102	0.961	rs4911385	chr20:32558593	C/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.62	0.39	2.21e-10	Skin pigmentation;
KIRP	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.56	-7.02	-0.41	2.21e-11	Schizophrenia;
KIRP	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg08499158	chr17:42289980	UBTF	-0.71	-9.64	-0.52	7.5e-19	Total body bone mineral density;
KIRP	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg19507638	chr5:93509721	C5orf36	-0.61	-5.27	-0.32	2.98e-7	Diabetic retinopathy;
KIRP	cis	rs1891275	0.550	rs4933694	chr10:93499213	C/T	cg07889827	chr10:93443413	NA	-0.42	-7.08	-0.41	1.5e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7015630	0.657	rs62530908	chr8:90847463	C/T	cg18493113	chr8:90847772	NA	-0.55	-5.3	-0.32	2.54e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg19274270	chr17:78178856	CARD14	0.34	6.1	0.36	4.11e-9	Morning vs. evening chronotype;
KIRP	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg07117364	chr1:16154769	NA	-0.43	-5.31	-0.32	2.5e-7	Dilated cardiomyopathy;
KIRP	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-5.44	-0.33	1.32e-7	Colorectal cancer;
KIRP	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-5.16	-0.31	5.2e-7	Bone mineral density;
KIRP	cis	rs7534824	0.860	rs17450841	chr1:101606071	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	5.56	0.33	6.89e-8	Refractive astigmatism;
KIRP	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg16680214	chr1:154839983	KCNN3	-0.41	-6.34	-0.37	1.11e-9	Prostate cancer;
KIRP	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg01559446	chr3:44596178	ZNF167	0.36	5.34	0.32	2.16e-7	Depressive symptoms;
KIRP	cis	rs17592366	0.838	rs74461006	chr14:35348048	C/T	cg09327582	chr14:35236912	BAZ1A	0.71	5.31	0.32	2.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	9.48	0.52	2.23e-18	Hip circumference;
KIRP	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg13256891	chr4:100009986	ADH5	0.56	6.13	0.36	3.51e-9	Alcohol dependence;
KIRP	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg22771759	chr13:24902376	NA	0.42	5.35	0.32	2.01e-7	Obesity-related traits;
KIRP	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00889227	chr1:205173544	DSTYK	-0.36	-5.12	-0.31	6.11e-7	Red blood cell count;
KIRP	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.08	0.36	4.46e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11638352	0.661	rs2706486	chr15:44428982	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.66	-5.96	-0.36	8.79e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	1.09	7.88	0.45	1.04e-13	Skin colour saturation;
KIRP	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg00677455	chr12:58241039	CTDSP2	-0.5	-5.64	-0.34	4.7e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9303542	0.625	rs17703660	chr17:46567134	T/C	cg04904318	chr17:46607828	HOXB1	-0.54	-5.83	-0.35	1.73e-8	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.71	9.56	0.52	1.25e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26928497	chr16:22217548	EEF2K	0.51	6.31	0.37	1.3e-9	Myopia (pathological);
KIRP	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	trans	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.69	7.57	0.43	7.39e-13	Corneal astigmatism;
KIRP	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg17764715	chr19:33622953	WDR88	0.8	11.36	0.59	2.63e-24	Bone properties (heel);
KIRP	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20135002	chr11:47629003	NA	-0.45	-5.07	-0.31	7.94e-7	Subjective well-being;
KIRP	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg10381502	chr11:71823885	C11orf51	1.16	8.09	0.46	2.77e-14	Severe influenza A (H1N1) infection;
KIRP	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.3	-0.47	6.97e-15	Neuroticism;
KIRP	cis	rs8070740	0.898	rs4239056	chr17:5324406	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.36	0.43	2.68e-12	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26786147	chr3:52232021	ALAS1	0.49	6.02	0.36	6.3e-9	Parkinson's disease;
KIRP	cis	rs7903847	0.656	rs11189208	chr10:99169172	C/G	cg20016023	chr10:99160130	RRP12	-0.38	-4.93	-0.3	1.48e-6	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	8.98	0.5	7.02e-17	Alzheimer's disease;
KIRP	cis	rs240764	0.578	rs62422070	chr6:101260827	T/G	cg09795085	chr6:101329169	ASCC3	0.47	5.5	0.33	9.69e-8	Neuroticism;
KIRP	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg16586182	chr3:47516702	SCAP	0.74	9.94	0.54	8.55e-20	Colorectal cancer;
KIRP	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.74	6.66	0.39	1.78e-10	Diabetic retinopathy;
KIRP	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.94	12.34	0.62	1.45e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9311676	0.656	rs62258081	chr3:58367705	A/C	cg06643156	chr3:58380774	PXK	0.36	5.1	0.31	6.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.49	-6.67	-0.39	1.71e-10	Dilated cardiomyopathy;
KIRP	cis	rs901683	0.850	rs75402959	chr10:46092807	C/G	cg27070508	chr10:46193400	NA	-0.72	-4.92	-0.3	1.59e-6	Red blood cell traits;Mean corpuscular volume;
KIRP	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg18825076	chr15:78729989	IREB2	-0.42	-4.96	-0.3	1.34e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20135002	chr11:47629003	NA	-0.47	-5.47	-0.33	1.1e-7	Subjective well-being;
KIRP	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg26681399	chr22:41777847	TEF	0.54	5.33	0.32	2.17e-7	Vitiligo;
KIRP	cis	rs1760803	0.754	rs6657214	chr1:154206538	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.29	-0.32	2.7e-7	Nicotine dependence;
KIRP	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg09788416	chr12:39539408	NA	0.41	5.19	0.31	4.39e-7	Morning vs. evening chronotype;
KIRP	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg10761708	chr20:43804764	PI3	0.5	5.2	0.31	4.22e-7	Blood protein levels;
KIRP	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	11.27	0.58	4.92e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04978709	chr7:75101039	POM121C	0.42	6.16	0.37	2.97e-9	Survival in pancreatic cancer;
KIRP	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg23682824	chr7:23144976	KLHL7	0.47	5.37	0.32	1.79e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1106684	0.929	rs888541	chr7:131454477	A/G	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.46	5.83	0.35	1.71e-8	Iron status biomarkers;
KIRP	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg03060546	chr3:49711283	APEH	-0.57	-5.02	-0.3	1.01e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs17604090	0.887	rs7795109	chr7:29666244	G/A	cg19413766	chr7:29689036	LOC646762	-0.62	-5.92	-0.35	1.1e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
KIRP	cis	rs6832769	1.000	rs13121235	chr4:56311947	A/G	cg05960024	chr4:56376020	CLOCK	0.64	8.16	0.46	1.7e-14	Personality dimensions;
KIRP	cis	rs35740288	0.822	rs11630549	chr15:86275796	C/T	cg17133734	chr15:86042851	AKAP13	-0.49	-5.31	-0.32	2.47e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12580194	0.593	rs60220253	chr12:55717410	A/G	cg19537932	chr12:55886519	OR6C68	-0.46	-6.09	-0.36	4.24e-9	Cancer;
KIRP	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.88	9.92	0.53	1.01e-19	Body mass index;
KIRP	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg05973401	chr12:123451056	ABCB9	0.58	6.63	0.39	2.15e-10	Neutrophil percentage of white cells;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22077528	chr11:33722475	C11orf91	0.39	6.05	0.36	5.41e-9	Cancer;
KIRP	cis	rs3736485	0.934	rs4775956	chr15:51882638	G/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2737618	0.651	rs2248967	chr1:200084893	A/G	cg21825944	chr1:200113062	NR5A2	0.55	7.89	0.45	9.74e-14	Uric acid levels;
KIRP	cis	rs6142102	0.625	rs7263727	chr20:32540939	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.76	0.34	2.51e-8	Skin pigmentation;
KIRP	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg00405596	chr8:11794950	NA	0.47	6.2	0.37	2.41e-9	Triglycerides;
KIRP	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg00495681	chr13:53174319	NA	0.37	4.89	0.3	1.82e-6	Lewy body disease;
KIRP	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg15880211	chr22:50250494	ZBED4	-0.47	-5.75	-0.34	2.58e-8	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21214613	chr1:16344536	HSPB7	0.36	5.17	0.31	4.84e-7	Dilated cardiomyopathy;
KIRP	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.71	8.89	0.49	1.38e-16	Vitiligo;
KIRP	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12560992	chr17:57184187	TRIM37	0.6	6.98	0.41	2.66e-11	Testicular germ cell tumor;
KIRP	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg12454167	chr3:186435060	KNG1	0.52	8.87	0.49	1.52e-16	Blood protein levels;
KIRP	cis	rs889312	0.961	rs961847	chr5:56041064	C/T	cg14703610	chr5:56206110	C5orf35	0.41	5.1	0.31	6.63e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12480562	chr20:23434244	CST11	0.64	5.25	0.32	3.36e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg17644776	chr2:200775616	C2orf69	0.64	7.48	0.43	1.28e-12	Osteoporosis;
KIRP	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg24848339	chr3:12840334	CAND2	0.36	5.55	0.33	7.33e-8	P wave duration;
KIRP	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg15896084	chr13:114927664	NA	0.48	6.41	0.38	7.55e-10	Schizophrenia;
KIRP	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.9	-0.35	1.17e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10465746	0.967	rs11163876	chr1:84440605	T/C	cg10977910	chr1:84465055	TTLL7	0.48	5.81	0.35	1.96e-8	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06695833	chr19:18220682	MAST3	0.51	6.33	0.37	1.18e-9	Parkinson's disease;
KIRP	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.73	10.22	0.55	1.17e-20	Plateletcrit;Platelet count;
KIRP	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg18190219	chr22:46762943	CELSR1	-0.92	-7.39	-0.43	2.32e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.91	0.64	1.83e-29	Platelet count;
KIRP	trans	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg19694781	chr19:47549865	TMEM160	-0.5	-6.07	-0.36	4.69e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg23307798	chr14:103986281	CKB	0.72	11.24	0.58	6.34e-24	Body mass index;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23955675	chr14:37457549	SLC25A21	0.42	6.57	0.39	2.97e-10	C-reactive protein;
KIRP	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg25801113	chr15:45476975	SHF	-0.45	-8.19	-0.46	1.41e-14	Uric acid levels;
KIRP	cis	rs7301016	0.846	rs73126024	chr12:63027764	C/T	cg01804193	chr12:63026212	NA	0.59	6.35	0.38	1.04e-9	IgG glycosylation;
KIRP	cis	rs4936894	0.500	rs12363393	chr11:124117562	A/T	cg27160556	chr11:124181099	OR8D1	-0.45	-6.52	-0.38	3.87e-10	Aging (time to death);
KIRP	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg20628663	chr10:43360327	NA	0.51	6.04	0.36	5.52e-9	Blood protein levels;
KIRP	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10720867	chr6:155537595	TIAM2	0.42	6.04	0.36	5.76e-9	Survival in pancreatic cancer;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09799789	chr1:245836746	KIF26B	0.56	6.49	0.38	4.6e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg09695851	chr17:3907499	NA	0.89	17.43	0.74	7.6e-45	Type 2 diabetes;
KIRP	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.42	7.01	0.41	2.34e-11	Heart rate;
KIRP	cis	rs4704187	0.687	rs1903838	chr5:74479999	G/A	cg03227963	chr5:74354835	NA	0.4	6.0	0.36	7.09e-9	Response to amphetamines;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg21752144	chr2:32288370	SPAST	-0.44	-6.04	-0.36	5.64e-9	Warfarin maintenance dose;
KIRP	cis	rs7923609	0.934	rs10761763	chr10:65188318	T/C	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.12e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs62380364	0.542	rs601499	chr5:88052687	A/C	cg22951263	chr5:87985283	NA	-0.48	-6.79	-0.4	8.41e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.73	10.92	0.57	6.68e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.81	-10.58	-0.56	8.53e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.77	-0.35	2.42e-8	HDL cholesterol;
KIRP	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.81	9.96	0.54	7.61e-20	Corneal astigmatism;
KIRP	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.4	-5.21	-0.32	3.96e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.64	9.65	0.52	6.91e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.62	7.34	0.42	3.17e-12	Menopause (age at onset);
KIRP	cis	rs10504229	0.516	rs7821160	chr8:57986281	C/T	cg02725872	chr8:58115012	NA	0.4	5.5	0.33	9.67e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.56	-9.08	-0.5	3.54e-17	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18076651	chr12:53625605	RARG	0.44	6.22	0.37	2.07e-9	Interleukin-4 levels;
KIRP	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.66	-0.52	6.56e-19	Neuroticism;
KIRP	trans	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg00656387	chr3:40428638	ENTPD3	0.4	5.11	0.31	6.57e-7	Renal cell carcinoma;
KIRP	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg25547332	chr5:131281432	NA	-0.47	-5.31	-0.32	2.5e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg01420254	chr6:26195488	NA	1.27	11.03	0.58	2.91e-23	Gout;Renal underexcretion gout;
KIRP	cis	rs2708977	0.549	rs2678381	chr2:97441266	C/T	cg01950434	chr2:97203154	ARID5A	-0.47	-5.61	-0.34	5.43e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10924970	0.967	rs12731177	chr1:235463173	T/G	cg26050004	chr1:235667680	B3GALNT2	0.4	4.92	0.3	1.57e-6	Asthma;
KIRP	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Smoking initiation;
KIRP	cis	rs10838687	0.825	rs12222581	chr11:47342019	A/T	cg25783544	chr11:47291846	MADD	0.45	4.88	0.3	1.94e-6	Proinsulin levels;
KIRP	cis	rs494562	0.730	rs313204	chr6:86114296	C/A	cg21730993	chr6:86159210	NT5E	0.47	5.13	0.31	5.78e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9467773	0.550	rs4712987	chr6:26399615	A/C	cg09904177	chr6:26538194	HMGN4	-0.45	-5.65	-0.34	4.45e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs514024	0.801	rs522328	chr9:130475011	A/G	cg13643465	chr9:130375613	STXBP1	0.47	6.21	0.37	2.28e-9	Eating disorders (purging via substances);
KIRP	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.89	-10.11	-0.54	2.64e-20	Gut microbiome composition (summer);
KIRP	cis	rs1538970	0.847	rs781230	chr1:45880751	C/T	cg05343316	chr1:45956843	TESK2	-0.66	-7.74	-0.44	2.54e-13	Platelet count;
KIRP	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.49	0.33	1e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7951870	1.000	rs6485682	chr11:46446264	C/A	cg16389345	chr11:46697382	NA	0.51	5.74	0.34	2.74e-8	Schizophrenia;
KIRP	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg00852783	chr1:26633632	UBXN11	0.53	7.66	0.44	4.23e-13	Obesity-related traits;
KIRP	cis	rs7129556	0.702	rs650171	chr11:77498486	T/C	cg12586386	chr11:77299805	AQP11	0.38	5.04	0.31	8.98e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.28	-0.32	2.84e-7	Fear of minor pain;
KIRP	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	5.3	0.32	2.52e-7	Tonsillectomy;
KIRP	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.76	8.37	0.47	4.35e-15	Uric acid levels;
KIRP	cis	rs60871478	0.635	rs4725122	chr7:785318	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.55	5.1	0.31	6.91e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg03258749	chr1:151040405	MLLT11	-0.73	-10.59	-0.56	7.68e-22	Childhood ear infection;
KIRP	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.53	-6.87	-0.4	5.37e-11	Blood metabolite levels;
KIRP	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg17264618	chr3:40429014	ENTPD3	-0.36	-5.54	-0.33	7.65e-8	Renal cell carcinoma;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg02733842	chr7:1102375	C7orf50	0.44	5.08	0.31	7.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg25174290	chr11:3078921	CARS	-0.67	-8.82	-0.49	2.19e-16	Calcium levels;
KIRP	cis	rs11638352	0.661	rs2615268	chr15:44427797	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-5.22	-0.32	3.89e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1816752	0.749	rs77832754	chr13:24990154	G/A	cg02811702	chr13:24901961	NA	0.41	5.47	0.33	1.08e-7	Obesity-related traits;
KIRP	cis	rs6800768	0.593	rs11129139	chr3:24146298	C/G	cg10674438	chr3:24145617	LOC152024	-0.52	-6.83	-0.4	6.57e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg17385448	chr1:15911702	AGMAT	0.24	4.95	0.3	1.39e-6	Systolic blood pressure;
KIRP	cis	rs6707387	0.686	rs2015217	chr2:214536508	C/T	cg08319019	chr2:214017104	IKZF2	0.42	4.86	0.3	2.09e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg08283408	chr3:49949060	MON1A	-0.38	-5.06	-0.31	8.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg24253500	chr15:84953950	NA	0.54	6.1	0.36	4.02e-9	Schizophrenia;
KIRP	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.93	14.63	0.68	2.62e-35	Heart rate;
KIRP	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.1	21.98	0.81	5.77e-60	Platelet distribution width;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7267005	0.661	rs80149515	chr20:34392784	A/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg18657303	chr4:1051139	NA	0.55	5.1	0.31	6.64e-7	Recombination rate (females);
KIRP	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.62	6.7	0.39	1.45e-10	Alcohol dependence;
KIRP	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg02570527	chr1:10970165	NA	-0.4	-5.0	-0.3	1.07e-6	Body mass index;
KIRP	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg07827796	chr19:33622959	WDR88	0.42	4.99	0.3	1.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg24217984	chr15:93633278	RGMA	-0.44	-4.86	-0.3	2.14e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
KIRP	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg26441486	chr22:50317300	CRELD2	0.47	7.75	0.44	2.46e-13	Schizophrenia;
KIRP	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.64	6.3	0.37	1.34e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15369054	chr17:80825471	TBCD	0.68	6.05	0.36	5.47e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs6466055	0.661	rs66912872	chr7:104937147	A/G	cg04380332	chr7:105027541	SRPK2	0.35	4.91	0.3	1.65e-6	Schizophrenia;
KIRP	cis	rs4664304	0.620	rs4665125	chr2:160714314	C/G	cg03641300	chr2:160917029	PLA2R1	0.38	5.68	0.34	3.87e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.8	-13.21	-0.64	1.79e-30	Brugada syndrome;
KIRP	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.5	-5.88	-0.35	1.36e-8	Colorectal cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06960514	chr8:71519778	TRAM1	0.52	6.54	0.38	3.54e-10	C-reactive protein;
KIRP	cis	rs3857067	1.000	rs3857068	chr4:95026494	C/G	cg11021082	chr4:95130006	SMARCAD1	0.39	5.03	0.31	9.37e-7	QT interval;
KIRP	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.25	-0.42	5.37e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2294369	0.906	rs136854	chr22:40058999	C/T	cg21377881	chr22:40064566	CACNA1I	0.44	5.07	0.31	7.66e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs4561483	0.549	rs6498251	chr16:11952290	A/G	cg08843971	chr16:11963173	GSPT1	0.55	7.66	0.44	4.34e-13	Testicular germ cell tumor;
KIRP	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg17724175	chr1:150552817	MCL1	0.35	5.99	0.36	7.34e-9	Melanoma;
KIRP	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg18944383	chr4:111397179	ENPEP	0.51	7.96	0.45	6.21e-14	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.92	15.53	0.7	2.28e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12044355	0.929	rs11122322	chr1:231843962	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-6.3	-0.37	1.34e-9	Alzheimer's disease;
KIRP	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	6.65	0.39	1.92e-10	Lung function (FEV1/FVC);
KIRP	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.58	9.58	0.52	1.15e-18	Total body bone mineral density;
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06028808	chr11:68637592	NA	0.69	8.21	0.46	1.28e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs877282	0.583	rs11253441	chr10:828288	C/T	cg22713356	chr15:30763199	NA	-0.88	-8.74	-0.49	3.81e-16	Uric acid levels;
KIRP	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.87	-13.12	-0.64	3.65e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.45	6.24	0.37	1.91e-9	Red blood cell count;
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg13436085	chr3:183904316	ABCF3	-0.47	-6.28	-0.37	1.56e-9	Platelet-derived growth factor BB levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03424663	chr13:27260005	WASF3	0.49	6.35	0.38	1.04e-9	Interleukin-4 levels;
KIRP	cis	rs2671245	0.933	rs2819478	chr1:56155245	C/G	cg11523071	chr1:56160889	NA	0.41	6.74	0.39	1.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg18357526	chr6:26021779	HIST1H4A	0.39	4.95	0.3	1.38e-6	Height;
KIRP	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg13607699	chr17:42295918	UBTF	0.45	5.47	0.33	1.08e-7	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs9535307	0.929	rs6561550	chr13:50249423	C/T	cg04663916	chr13:50265991	EBPL	0.73	7.66	0.44	4.35e-13	Obesity-related traits;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02795678	chr10:14940698	SUV39H2	0.36	6.06	0.36	4.95e-9	C-reactive protein;
KIRP	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg19773385	chr1:10388646	KIF1B	-0.69	-9.06	-0.5	4.29e-17	Hepatocellular carcinoma;
KIRP	cis	rs4936891	0.577	rs12224791	chr11:123919128	A/G	cg22125253	chr11:123886957	OR10G4	-0.39	-5.02	-0.3	1.01e-6	Male fertility;
KIRP	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.71	-8.11	-0.46	2.34e-14	Adiposity;
KIRP	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg12315302	chr6:26189340	HIST1H4D	0.98	6.85	0.4	5.92e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72960926	0.744	rs56168817	chr6:75043919	A/G	cg03266952	chr6:74778945	NA	-0.7	-5.21	-0.32	4.08e-7	Metabolite levels (MHPG);
KIRP	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg00086871	chr4:6988644	TBC1D14	0.77	6.63	0.39	2.15e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg21698718	chr17:80085957	CCDC57	-0.36	-5.18	-0.31	4.63e-7	Life satisfaction;
KIRP	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg24642439	chr20:33292090	TP53INP2	-0.59	-7.72	-0.44	2.84e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.93	-0.45	7.51e-14	Mean corpuscular volume;
KIRP	cis	rs8067287	0.802	rs62065417	chr17:16820679	T/C	cg26910001	chr17:16838321	NA	-0.56	-5.55	-0.33	7.3900000000000007e-08	Diabetic kidney disease;
KIRP	cis	rs6753739	0.826	rs7599778	chr2:219961660	G/C	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	cis	rs282587	0.530	rs428853	chr13:113387222	T/C	cg04656015	chr13:113407548	ATP11A	0.63	7.36	0.42	2.82e-12	Glycated hemoglobin levels;
KIRP	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg17366294	chr4:99064904	C4orf37	-0.35	-4.92	-0.3	1.57e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	7.43	0.43	1.75e-12	Bipolar disorder;
KIRP	cis	rs9462846	0.725	rs9471969	chr6:42906384	G/T	cg05552183	chr6:42928497	GNMT	0.61	6.97	0.41	2.93e-11	Blood protein levels;
KIRP	cis	rs1558375	0.679	rs31674	chr7:87068464	T/C	cg00919237	chr7:87102261	ABCB4	0.54	6.88	0.4	4.96e-11	Gallbladder cancer;
KIRP	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg12140854	chr5:148520817	ABLIM3	-0.41	-5.31	-0.32	2.41e-7	Breast cancer;
KIRP	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg08992911	chr2:238395768	MLPH	0.47	5.13	0.31	5.86e-7	Prostate cancer;
KIRP	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.76	6.19	0.37	2.5e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.21	0.37	2.28e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.38	5.66	0.34	4.23e-8	Platelet distribution width;
KIRP	cis	rs7246865	0.510	rs6512161	chr19:17171582	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.52	6.59	0.39	2.68e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg10254082	chr7:997346	NA	0.47	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12249377	0.519	rs7087400	chr10:92587180	A/G	cg14313238	chr10:92632228	RPP30	0.45	5.54	0.33	7.86e-8	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs2862064	0.872	rs6555776	chr5:156403505	C/A	cg12943317	chr5:156479607	HAVCR1	-0.85	-6.7	-0.39	1.37e-10	Platelet count;
KIRP	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	1.16	10.04	0.54	4.27e-20	Lymphocyte counts;
KIRP	cis	rs55962025	0.723	rs2269478	chr4:3234828	G/T	cg06533319	chr4:3265114	C4orf44	0.41	5.2	0.31	4.12e-7	Parental longevity (mother's age at death);
KIRP	cis	rs2594989	0.721	rs9860504	chr3:11573615	G/T	cg01796438	chr3:11312864	ATG7	0.6	7.25	0.42	5.31e-12	Circulating chemerin levels;
KIRP	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg25019722	chr6:37503610	NA	-0.78	-10.59	-0.56	7.84e-22	Cognitive performance;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.09	-0.31	7.1e-7	Life satisfaction;
KIRP	cis	rs7523273	0.526	rs2745975	chr1:208013620	C/T	cg22525895	chr1:207977042	MIR29B2	-0.61	-8.36	-0.47	4.6e-15	Schizophrenia;
KIRP	cis	rs2860975	0.542	rs1579029	chr10:96811010	T/C	cg09036531	chr10:96991505	NA	-0.48	-5.87	-0.35	1.4e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.71	-10.56	-0.56	9.91e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18498035	chr18:21166722	NPC1	0.49	6.53	0.38	3.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.52	0.43	1.03e-12	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs259282	0.605	rs8100423	chr19:33109003	C/T	cg02997394	chr19:33096574	ANKRD27	-0.52	-6.16	-0.37	3e-9	Schizophrenia;
KIRP	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg01320579	chr17:75405842	SEPT9	0.47	7.55	0.43	8.75e-13	Airflow obstruction;
KIRP	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.93	15.63	0.71	1.01e-38	Breast cancer;
KIRP	cis	rs631288	0.557	rs2354434	chr1:146679428	A/G	cg25205988	chr1:146714368	CHD1L	0.92	6.02	0.36	6.25e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.7	9.14	0.5	2.47e-17	Morning vs. evening chronotype;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg03762505	chr1:171750926	METTL13	1.02	6.94	0.4	3.52e-11	P wave terminal force;
KIRP	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	7.85	0.45	1.28e-13	Neuroticism;
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.44	-5.19	-0.31	4.5e-7	Longevity;Endometriosis;
KIRP	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg09324608	chr17:30823087	MYO1D	-0.44	-5.41	-0.33	1.51e-7	Schizophrenia;
KIRP	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.51	-9.47	-0.52	2.38e-18	Prostate cancer;
KIRP	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	1.06	19.08	0.77	2.08e-50	Monocyte count;
KIRP	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.86	13.55	0.65	1.28e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.75	-0.34	2.65e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg19899395	chr1:46959349	NA	0.45	5.54	0.33	7.95e-8	Monobrow;
KIRP	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	6.28	0.37	1.49e-9	Cognitive test performance;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19097648	chr5:115177461	ATG12;AP3S1	-0.43	-6.1	-0.36	4.08e-9	Metabolic traits;
KIRP	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.42	-0.51	3.5e-18	Neuroticism;
KIRP	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.89e-8	Glomerular filtration rate;
KIRP	cis	rs7590368	0.715	rs55770944	chr2:10959384	A/G	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs6120849	0.802	rs6087682	chr20:33752897	A/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.09	0.36	4.39e-9	Protein C levels;
KIRP	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	5.59	0.34	5.96e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.42	4.96	0.3	1.32e-6	Height;
KIRP	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.71	10.8	0.57	1.66e-22	Anterior chamber depth;
KIRP	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg27490568	chr2:178487706	NA	0.49	6.55	0.39	3.41e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04287982	chr1:21766521	NBPF3	0.48	6.31	0.37	1.3e-9	Parkinson's disease;
KIRP	cis	rs4523957	0.928	rs8066372	chr17:2180968	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.33	-0.47	5.62e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg17691542	chr6:26056736	HIST1H1C	0.67	7.94	0.45	6.98e-14	Iron status biomarkers;
KIRP	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.98	12.28	0.62	2.44e-27	Response to antineoplastic agents;
KIRP	cis	rs28830936	0.934	rs28401754	chr15:42116903	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.64	-0.39	1.98e-10	Diastolic blood pressure;
KIRP	cis	rs834811	0.871	rs834819	chr7:135895281	G/A	cg01726295	chr7:135938950	NA	0.39	5.52	0.33	8.47e-8	Post-traumatic stress disorder;
KIRP	cis	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-5.19	-0.31	4.31e-7	Morning vs. evening chronotype;
KIRP	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.68	8.9	0.49	1.26e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9928842	1.000	rs9928842	chr16:75242867	T/C	cg09066997	chr16:75300724	BCAR1	0.61	5.1	0.31	6.83e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg00666640	chr1:248458726	OR2T12	0.44	5.13	0.31	5.99e-7	Common traits (Other);
KIRP	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.89	12.81	0.63	3.94e-29	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.43	-5.73	-0.34	2.87e-8	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg06204229	chr3:52865917	ITIH4	0.52	5.81	0.35	1.94e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6723108	0.515	rs1942049	chr2:135574368	G/A	cg25422880	chr2:135218333	TMEM163	-0.44	-6.09	-0.36	4.37e-9	Type 2 diabetes;
KIRP	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-6.63	-0.39	2.17e-10	Total cholesterol levels;
KIRP	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.55	7.08	0.41	1.48e-11	Iron status biomarkers;
KIRP	cis	rs7808935	0.914	rs757136	chr7:27988939	C/T	cg05786569	chr7:27702416	HIBADH	-0.53	-5.17	-0.31	4.89e-7	Prostate cancer;
KIRP	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.9	0.53	1.18e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg18882449	chr10:104885122	NT5C2	-0.5	-6.41	-0.38	7.5e-10	Arsenic metabolism;
KIRP	cis	rs6438504	0.922	rs7622158	chr3:118918444	C/T	cg25372693	chr3:118959985	B4GALT4	0.34	5.62	0.34	5.19e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg24009623	chr19:33667908	NA	0.47	5.79	0.35	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.73	9.34	0.51	5.96e-18	Coronary artery disease;
KIRP	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.65	9.59	0.52	1.07e-18	Retinal vascular caliber;
KIRP	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.86	14.32	0.67	3.19e-34	Prostate cancer;
KIRP	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.51	6.38	0.38	8.67e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.42	5.09	0.31	7.28e-7	Glycated hemoglobin levels;
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.8	-12.88	-0.63	2.32e-29	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-8.05	-0.46	3.65e-14	Response to antipsychotic treatment;
KIRP	cis	rs6960043	1.000	rs12113083	chr7:15051943	G/C	cg19272540	chr7:15055459	NA	-0.21	-5.53	-0.33	8.31e-8	Type 2 diabetes;
KIRP	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg23100626	chr2:96804247	ASTL	-0.52	-7.54	-0.43	8.77e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6504950	0.790	rs8076984	chr17:53035428	T/C	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-9.54	-0.52	1.44e-18	Morning vs. evening chronotype;
KIRP	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.0	-0.3	1.07e-6	Depression;
KIRP	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17507749	chr15:85114479	UBE2QP1	0.78	8.7	0.49	4.68e-16	Schizophrenia;
KIRP	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg14914422	chr1:46958856	NA	0.46	5.81	0.35	1.96e-8	Monobrow;
KIRP	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	7.31	0.42	3.69e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg12756093	chr1:115239321	AMPD1	0.52	7.02	0.41	2.1e-11	Autism;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg20088535	chr4:128802013	PLK4	-0.52	-6.04	-0.36	5.61e-9	Brain structure;
KIRP	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.64	7.71	0.44	3.08e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg11833968	chr6:79620685	NA	-0.45	-6.92	-0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs4849845	0.637	rs13022486	chr2:121038611	C/T	cg24070213	chr2:121070622	NA	0.39	5.94	0.35	9.73e-9	Mean platelet volume;
KIRP	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7224685	0.569	rs8082425	chr17:3991706	C/G	cg09597638	chr17:3907349	NA	0.54	5.36	0.32	1.93e-7	Type 2 diabetes;
KIRP	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.43	-6.04	-0.36	5.68e-9	Height;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07555797	chr14:61788314	PRKCH	-0.49	-6.18	-0.37	2.62e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg08975724	chr8:8085496	FLJ10661	0.69	9.4	0.51	3.91e-18	Mood instability;
KIRP	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg20673091	chr1:2541236	MMEL1	0.68	10.64	0.56	5.22e-22	Ulcerative colitis;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg02696790	chr15:75250997	RPP25	0.32	5.57	0.33	6.74e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	1.01	17.27	0.74	2.7e-44	Bone mineral density;
KIRP	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13621272	chr5:155449909	NA	-0.39	-6.18	-0.37	2.63e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg13010199	chr12:38710504	ALG10B	0.62	7.86	0.45	1.2e-13	Morning vs. evening chronotype;
KIRP	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-7.38	-0.43	2.4e-12	Eye color traits;
KIRP	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg07636037	chr3:49044803	WDR6	-0.73	-5.38	-0.32	1.71e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg19847130	chr8:10466454	RP1L1	-0.32	-4.86	-0.3	2.05e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs883115	0.810	rs7516323	chr1:224785960	C/G	cg01808320	chr1:224927238	CNIH3	-0.37	-5.25	-0.32	3.26e-7	Cancer;
KIRP	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.09e-15	Menarche (age at onset);
KIRP	cis	rs2694528	0.686	rs7723165	chr5:59876715	A/G	cg11474532	chr5:59995715	DEPDC1B	0.85	6.25	0.37	1.79e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.58	8.66	0.48	6.42e-16	Anterior chamber depth;
KIRP	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	4.91	0.3	1.63e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg04455712	chr21:45112962	RRP1B	0.44	5.83	0.35	1.7e-8	Mean corpuscular volume;
KIRP	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	9.38	0.51	4.52e-18	Renal function-related traits (BUN);
KIRP	cis	rs10267417	0.603	rs6966428	chr7:19891587	T/C	cg05791153	chr7:19748676	TWISTNB	0.51	4.96	0.3	1.29e-6	Night sleep phenotypes;
KIRP	cis	rs8077577	0.895	rs10048161	chr17:18082796	C/G	cg09161412	chr17:18057145	MYO15A	-0.4	-5.23	-0.32	3.56e-7	Obesity-related traits;
KIRP	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.97	-0.41	2.95e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21643547	chr1:205240462	TMCC2	-0.7	-10.51	-0.56	1.38e-21	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.5	-0.48	1.91e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg04691961	chr3:161091175	C3orf57	-0.49	-7.3	-0.42	4.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.52	-5.41	-0.33	1.46e-7	Subjective well-being;
KIRP	trans	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg19694781	chr19:47549865	TMEM160	-0.58	-8.1	-0.46	2.51e-14	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.96	12.84	0.63	3.27e-29	Menopause (age at onset);
KIRP	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.45	6.57	0.39	2.91e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.62	-8.99	-0.5	6.53e-17	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg24972876	chr7:65420302	NA	0.41	5.61	0.34	5.38e-8	Aortic root size;
KIRP	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg25319279	chr11:5960081	NA	-0.52	-5.38	-0.32	1.71e-7	DNA methylation (variation);
KIRP	cis	rs2644899	0.859	rs2545757	chr19:41297302	A/G	cg24958765	chr19:41283667	RAB4B	-0.61	-6.61	-0.39	2.37e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs944802	0.929	rs10965266	chr9:22161494	G/T	cg00491127	chr9:22154101	NA	0.46	5.16	0.31	5.13e-7	White blood cell count;
KIRP	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.63	-0.63	1.58e-28	Electrocardiographic conduction measures;
KIRP	cis	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.35	1.11e-8	Triglycerides;
KIRP	cis	rs2820315	1.000	rs2820312	chr1:201869257	G/A	cg11586189	chr1:201857591	SHISA4	-0.4	-5.57	-0.33	6.83e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.43	-5.85	-0.35	1.55e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4332428	1.000	rs4628584	chr10:4972697	G/C	cg19648686	chr10:5044992	AKR1C2	-0.93	-8.17	-0.46	1.68e-14	Height;
KIRP	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg08501292	chr6:25962987	TRIM38	0.77	5.36	0.32	1.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.26	-17.25	-0.74	2.96e-44	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07805029	chr1:92953256	GFI1	-0.41	-6.4	-0.38	7.99e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs858239	0.738	rs13225593	chr7:23260307	A/G	cg23682824	chr7:23144976	KLHL7	0.44	5.14	0.31	5.54e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.55	6.83	0.4	6.76e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-6.05	-0.36	5.36e-9	Coronary artery disease;
KIRP	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.05	-0.31	8.69e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2273156	0.570	rs2010648	chr14:35604892	A/C	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.17	-0.31	4.75e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs1335645	0.655	rs61808584	chr1:111632839	T/C	cg00321911	chr1:111669324	DRAM2	-0.63	-4.98	-0.3	1.18e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg23594656	chr7:65796392	TPST1	0.38	5.6	0.34	5.58e-8	Aortic root size;
KIRP	trans	rs7279771	0.736	rs41315475	chr21:35884633	G/A	cg03797705	chr17:79604227	NPLOC4	-0.56	-6.37	-0.38	9e-10	Cancer;
KIRP	cis	rs1440410	0.835	rs11940580	chr4:144161525	C/G	cg01719995	chr4:144104893	USP38	0.43	5.91	0.35	1.14e-8	Ischemic stroke;
KIRP	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	10.41	0.55	2.87e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11987759	chr7:65425863	GUSB	0.57	7.71	0.44	3.1e-13	Aortic root size;
KIRP	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.82	8.49	0.48	1.93e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs6429082	0.905	rs12405889	chr1:235597252	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.4	-0.38	7.61e-10	Adiposity;
KIRP	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.48	6.51	0.38	4.09e-10	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg10189774	chr4:17578691	LAP3	0.49	5.79	0.35	2.15e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg16141378	chr3:129829833	LOC729375	0.58	7.43	0.43	1.83e-12	Triglycerides;
KIRP	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03934478	chr11:495069	RNH1	0.87	6.74	0.39	1.1e-10	Body mass index;
KIRP	cis	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg19680485	chr15:31195859	MTMR15	-0.53	-4.92	-0.3	1.6e-6	Hypertriglyceridemia;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg17156767	chr19:30364462	NA	-0.42	-6.01	-0.36	6.48e-9	Metabolite levels (MHPG);
KIRP	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.95	16.51	0.72	1.04e-41	Metabolic syndrome;
KIRP	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg21064579	chr19:49206444	FUT2	0.56	8.34	0.47	5.22e-15	Dietary macronutrient intake;
KIRP	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.49	-6.34	-0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs13401104	0.786	rs11677411	chr2:237110028	T/C	cg19324714	chr2:237145437	ASB18	0.47	4.93	0.3	1.51e-6	Educational attainment;
KIRP	cis	rs4400599	0.838	rs2494667	chr1:154109153	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.37	5.28	0.32	2.8e-7	Platelet distribution width;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg06665941	chr21:34602869	IFNAR2	-0.49	-6.06	-0.36	4.99e-9	Type 1 diabetes nephropathy;
KIRP	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg04990556	chr1:26633338	UBXN11	0.65	6.6	0.39	2.54e-10	Obesity-related traits;
KIRP	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.28	-0.32	2.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.33	-0.32	2.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.64	7.42	0.43	1.92e-12	Body mass index;
KIRP	cis	rs754423	0.515	rs768021	chr14:52553563	G/A	cg05884192	chr14:52515736	NID2	-0.44	-5.26	-0.32	3.21e-7	Craniofacial microsomia;
KIRP	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.34	5.02	0.3	9.93e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs66530629	0.834	rs11249171	chr1:25073571	A/C	cg22509179	chr1:25234806	RUNX3	-0.39	-5.11	-0.31	6.59e-7	Plateletcrit;
KIRP	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg15128208	chr22:42549153	NA	0.57	6.2	0.37	2.33e-9	Birth weight;
KIRP	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.69	9.11	0.5	2.87e-17	Response to antipsychotic treatment;
KIRP	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg27398817	chr8:82754497	SNX16	-0.7	-7.55	-0.43	8.37e-13	Diastolic blood pressure;
KIRP	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.36	5.77	0.35	2.35e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14159672	chr1:205819179	PM20D1	0.47	5.46	0.33	1.17e-7	Menarche (age at onset);
KIRP	cis	rs10267417	0.603	rs73267155	chr7:19939513	G/A	cg05791153	chr7:19748676	TWISTNB	0.51	5.05	0.31	8.64e-7	Night sleep phenotypes;
KIRP	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.93	9.62	0.52	8.65e-19	Schizophrenia;
KIRP	cis	rs7084402	0.967	rs1649066	chr10:60305916	G/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs787274	0.764	rs787299	chr9:115542369	A/G	cg13803584	chr9:115635662	SNX30	-0.71	-6.43	-0.38	6.61e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg18944383	chr4:111397179	ENPEP	0.46	7.94	0.45	7.19e-14	Height;
KIRP	cis	rs11710088	1.000	rs11710088	chr3:149193107	G/A	cg08667024	chr3:149219783	TM4SF4	-0.39	-5.6	-0.34	5.8e-8	QRS duration;
KIRP	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg16141378	chr3:129829833	LOC729375	0.51	6.74	0.39	1.15e-10	Retinal vascular caliber;
KIRP	cis	rs330071	0.549	rs11785593	chr8:9256324	A/G	cg12253571	chr8:8283032	NA	-0.39	-4.85	-0.3	2.24e-6	Acne (severe);
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11987759	chr7:65425863	GUSB	0.69	9.85	0.53	1.66e-19	Aortic root size;
KIRP	cis	rs7572644	0.699	rs2337373	chr2:28092922	T/C	cg27432699	chr2:27873401	GPN1	-0.45	-5.39	-0.33	1.61e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.81	11.0	0.57	3.69e-23	Platelet count;
KIRP	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.75	-7.62	-0.44	5.47e-13	Gut microbiome composition (summer);
KIRP	cis	rs72792276	1.000	rs78529289	chr5:127405378	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	6.96	0.41	3.13e-11	Red cell distribution width;
KIRP	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.62	-7.94	-0.45	7.36e-14	Colorectal cancer;
KIRP	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7601312	0.935	rs6436792	chr2:229325965	G/A	cg02542817	chr2:229291442	NA	-0.44	-6.4	-0.38	7.69e-10	Schizophrenia;
KIRP	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg12908607	chr1:44402522	ARTN	-0.35	-5.25	-0.32	3.29e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg25174290	chr11:3078921	CARS	-0.66	-8.53	-0.48	1.55e-15	Calcium levels;
KIRP	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-7.25	-0.42	5.53e-12	Systemic lupus erythematosus;
KIRP	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.67	-7.29	-0.42	4.22e-12	DNA methylation (variation);
KIRP	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg25036284	chr2:26402008	FAM59B	-0.47	-4.94	-0.3	1.42e-6	Gut microbiome composition (summer);
KIRP	cis	rs4704187	0.640	rs7707246	chr5:74354875	G/T	cg03227963	chr5:74354835	NA	0.42	6.26	0.37	1.74e-9	Response to amphetamines;
KIRP	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.86	0.35	1.5e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg11814155	chr7:99998594	ZCWPW1	0.55	5.42	0.33	1.42e-7	Platelet count;
KIRP	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs1355223	0.867	rs7943363	chr11:34691134	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-4.96	-0.3	1.29e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs42648	0.518	rs12535435	chr7:89830817	G/A	cg25739043	chr7:89950458	NA	-0.39	-6.14	-0.36	3.2e-9	Homocysteine levels;
KIRP	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg24807547	chr6:37504484	NA	-0.42	-5.3	-0.32	2.6e-7	Cognitive performance;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.41	-0.33	1.46e-7	Life satisfaction;
KIRP	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.48	-5.71	-0.34	3.18e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg02070118	chr4:952128	TMEM175	0.59	4.94	0.3	1.41e-6	Parkinson's disease;
KIRP	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg16141378	chr3:129829833	LOC729375	-0.61	-8.09	-0.46	2.74e-14	Joint mobility (Beighton score);
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg07216194	chr8:27182965	PTK2B	0.46	5.74	0.34	2.83e-8	Neuroticism;
KIRP	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.46	6.58	0.39	2.75e-10	Coronary artery disease;
KIRP	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-6.71	-0.39	1.3e-10	Menarche (age at onset);
KIRP	cis	rs7737355	0.812	rs2189645	chr5:130804979	A/G	cg06307176	chr5:131281290	NA	-0.42	-5.01	-0.3	1.02e-6	Life satisfaction;
KIRP	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg04315214	chr1:2043799	PRKCZ	0.52	8.33	0.47	5.79e-15	Height;
KIRP	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg17351974	chr5:40835760	RPL37	0.66	5.42	0.33	1.41e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg07701084	chr6:150067640	NUP43	-0.63	-8.16	-0.46	1.69e-14	Lung cancer;
KIRP	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg06212747	chr3:49208901	KLHDC8B	0.66	6.96	0.41	3.02e-11	Menarche (age at onset);
KIRP	cis	rs4566357	0.964	rs4296416	chr2:227921926	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.85	-0.3	2.19e-6	Coronary artery disease;
KIRP	cis	rs7566780	0.575	rs4240228	chr2:16688759	G/T	cg09580478	chr2:16689509	NA	0.48	5.34	0.32	2.1e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg11846333	chr4:119757529	SEC24D	0.94	5.89	0.35	1.25e-8	Cannabis dependence symptom count;
KIRP	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.54	0.48	1.43e-15	Electroencephalogram traits;
KIRP	trans	rs62056376	0.736	rs885691	chr17:32641225	C/T	cg04960603	chr2:119604313	EN1	-0.52	-6.02	-0.36	6.2e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg09137382	chr11:130731461	NA	0.56	8.2	0.46	1.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7017914	0.967	rs34558600	chr8:71586152	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-9.85	-0.53	1.64e-19	Morning vs. evening chronotype;
KIRP	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg07460842	chr6:66804631	NA	0.92	7.76	0.44	2.24e-13	Exhaled nitric oxide output;
KIRP	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.77	-10.68	-0.56	4.05e-22	Blood metabolite levels;
KIRP	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg07395648	chr5:131743802	NA	-0.37	-5.41	-0.33	1.47e-7	Blood metabolite levels;
KIRP	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.62	7.95	0.45	6.73e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs1448094	0.872	rs7300073	chr12:86393513	A/C	cg00310523	chr12:86230176	RASSF9	0.4	6.12	0.36	3.66e-9	Major depressive disorder;
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs6496667	0.779	rs7169914	chr15:90952049	G/T	cg10434728	chr15:90938212	IQGAP1	0.4	5.13	0.31	5.78e-7	Rheumatoid arthritis;
KIRP	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg06307176	chr5:131281290	NA	0.55	5.97	0.36	8.38e-9	Life satisfaction;
KIRP	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg00147788	chr6:125855365	NA	-0.32	-5.08	-0.31	7.41e-7	Brugada syndrome;
KIRP	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg18357526	chr6:26021779	HIST1H4A	0.39	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs12210905	1.000	rs72843615	chr6:27150569	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.73	-0.39	1.16e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs10489525	0.550	rs6659415	chr1:115632211	C/T	cg01522456	chr1:115632236	TSPAN2	0.81	11.26	0.58	5.45e-24	Autism;
KIRP	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg21466736	chr12:48725269	NA	-0.46	-5.84	-0.35	1.67e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10144434	chr1:212209099	INTS7;DTL	0.45	6.37	0.38	9.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.73	-8.0	-0.45	4.94e-14	Gut microbiome composition (summer);
KIRP	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg20312557	chr2:97357134	FER1L5	-0.7	-4.91	-0.3	1.66e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg27205649	chr11:78285834	NARS2	-0.54	-5.0	-0.3	1.07e-6	Testicular germ cell tumor;
KIRP	trans	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg00022858	chr4:55096616	PDGFRA	-0.46	-6.34	-0.37	1.07e-9	Protein C levels;
KIRP	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg10047753	chr17:41438598	NA	0.81	11.09	0.58	1.95e-23	Menopause (age at onset);
KIRP	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.58	5.37	0.32	1.83e-7	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg24644049	chr4:85504048	CDS1	1.09	6.99	0.41	2.59e-11	Skin colour saturation;
KIRP	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12379764	chr21:47803548	PCNT	-0.43	-5.11	-0.31	6.58e-7	Testicular germ cell tumor;
KIRP	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg10503236	chr1:231470652	EXOC8	-0.49	-6.82	-0.4	7.1e-11	Hemoglobin concentration;
KIRP	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.96	0.41	3.04e-11	Schizophrenia;
KIRP	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06505273	chr16:24850292	NA	-0.35	-4.87	-0.3	2.01e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg26384229	chr12:38710491	ALG10B	-0.67	-8.79	-0.49	2.58e-16	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg00800569	chr2:239229395	TRAF3IP1	0.46	4.95	0.3	1.35e-6	Multiple system atrophy;
KIRP	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.29	0.58	4.2e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg21395723	chr22:39101663	GTPBP1	0.44	5.84	0.35	1.63e-8	Menopause (age at onset);
KIRP	cis	rs963731	0.579	rs2060987	chr2:39282079	A/G	cg04010122	chr2:39346883	SOS1	-0.83	-5.59	-0.34	6.01e-8	Corticobasal degeneration;
KIRP	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	1.08	19.25	0.78	5.36e-51	Monocyte count;
KIRP	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.04	0.31	9.03e-7	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.62	9.57	0.52	1.16e-18	Lung cancer;
KIRP	cis	rs1147199	0.585	rs1187368	chr9:87273696	A/G	cg22402007	chr9:87282823	NTRK2	-0.39	-5.03	-0.31	9.63e-7	Body mass index;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02773019	chr3:135684688	PPP2R3A	0.53	6.4	0.38	7.86e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.86	10.6	0.56	7.23e-22	Neutrophil percentage of white cells;
KIRP	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.41	-0.38	7.37e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14169450	chr9:139327907	INPP5E	0.52	7.49	0.43	1.25e-12	Monocyte percentage of white cells;
KIRP	cis	rs3947	0.951	rs1692819	chr8:11705448	G/A	cg21775007	chr8:11205619	TDH	-0.48	-4.89	-0.3	1.84e-6	Blood protein levels;
KIRP	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.68	8.61	0.48	9.09e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-5.95	-0.35	9.32e-9	Aortic root size;
KIRP	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.75	-0.53	3.45e-19	Exhaled nitric oxide output;
KIRP	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-1.0	-11.23	-0.58	6.88e-24	Exhaled nitric oxide output;
KIRP	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	1.04	10.6	0.56	7.38e-22	Blood protein levels;
KIRP	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg16586182	chr3:47516702	SCAP	-0.78	-10.93	-0.57	6.55e-23	Colorectal cancer;
KIRP	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	5.82	0.35	1.81e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-7.45	-0.43	1.54e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6959887	0.962	rs10486660	chr7:35282931	A/C	cg06685737	chr7:35301730	NA	0.44	6.47	0.38	5.26e-10	Birth weight;
KIRP	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg15556689	chr8:8085844	FLJ10661	-0.67	-8.4	-0.47	3.61e-15	Retinal vascular caliber;
KIRP	cis	rs490234	0.841	rs10114882	chr9:128303425	T/C	cg14078157	chr9:128172775	NA	-0.57	-6.79	-0.4	8.37e-11	Mean arterial pressure;
KIRP	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.14	0.36	3.25e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg19402173	chr7:128379420	CALU	-0.69	-9.28	-0.51	9.45e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.57	7.01	0.41	2.35e-11	Iron status biomarkers;
KIRP	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg16558253	chr16:72132732	DHX38	-0.56	-6.03	-0.36	6.08e-9	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24775027	chr2:185459721	NA	-0.46	-7.55	-0.43	8.68e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11997175	0.670	rs34985841	chr8:33661889	C/A	cg04338863	chr8:33670619	NA	0.41	5.33	0.32	2.27e-7	Body mass index;
KIRP	cis	rs2151522	0.724	rs2226176	chr6:127187949	C/G	cg21431617	chr6:127135037	NA	0.28	5.07	0.31	7.94e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.71	9.04	0.5	4.82e-17	Mood instability;
KIRP	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.25	6.76	0.4	9.86e-11	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.61	0.34	5.52e-8	Lung cancer;
KIRP	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg16141378	chr3:129829833	LOC729375	0.53	7.07	0.41	1.55e-11	Triglycerides;
KIRP	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.76	-0.34	2.48e-8	Body mass index;
KIRP	cis	rs2072732	0.861	rs12042403	chr1:2950872	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.82	-0.35	1.85e-8	Plateletcrit;
KIRP	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg04287289	chr16:89883240	FANCA	0.56	7.49	0.43	1.22e-12	Vitiligo;
KIRP	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.56	6.71	0.39	1.34e-10	Hip circumference;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-1.05	-20.83	-0.8	3.11e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg15841412	chr13:111365552	ING1	0.5	5.7	0.34	3.37e-8	Coronary artery disease;
KIRP	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.72	-7.8	-0.45	1.82e-13	DNA methylation (variation);
KIRP	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg15848620	chr12:58087721	OS9	-0.43	-5.0	-0.3	1.1e-6	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs1630500	0.793	rs1218581	chr1:154834696	G/T	cg05687149	chr11:112035945	IL18	0.51	6.44	0.38	6.38e-10	Parkinson's disease;
KIRP	cis	rs12476592	0.571	rs4671505	chr2:63644303	G/T	cg17519650	chr2:63277830	OTX1	-0.44	-4.89	-0.3	1.85e-6	Childhood ear infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21086891	chr3:192635035	C3orf59	0.52	6.07	0.36	4.94e-9	Smoking initiation;
KIRP	cis	rs7601312	1.000	rs11681942	chr2:229312773	G/A	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	cg21523751	chr1:182988639	NA	0.36	5.09	0.31	7.19e-7	Fuchs's corneal dystrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17545146	chr20:62289982	RTEL1	0.52	6.51	0.38	4.19e-10	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg11204139	chr17:3907470	NA	0.82	15.06	0.69	9.54e-37	Type 2 diabetes;
KIRP	trans	rs8001976	0.510	rs9534810	chr13:48331291	A/G	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Aging (time to event);
KIRP	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg05717871	chr11:638507	DRD4	-0.37	-5.17	-0.31	4.74e-7	Systemic lupus erythematosus;
KIRP	cis	rs6593803	0.732	rs1891498	chr1:147226791	C/T	cg27546670	chr1:147246839	GJA5	-0.68	-8.14	-0.46	1.96e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg23067535	chr8:124195133	FAM83A	-0.72	-7.1	-0.41	1.31e-11	Urinary uromodulin levels;
KIRP	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg04995300	chr3:66848608	NA	0.71	8.65	0.48	6.56e-16	Type 2 diabetes;
KIRP	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.66	-0.44	4.16e-13	Height;
KIRP	trans	rs1106684	1.000	rs66717317	chr7:131458445	T/C	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg06740227	chr12:86229804	RASSF9	-0.38	-4.84	-0.3	2.24e-6	Major depressive disorder;
KIRP	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.28	-0.42	4.58e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg14703610	chr5:56206110	C5orf35	0.48	6.57	0.39	2.96e-10	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-6.63	-0.39	2.1e-10	Aortic root size;
KIRP	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.95	-0.54	7.8e-20	Colorectal cancer;
KIRP	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg21573476	chr21:45109991	RRP1B	0.68	10.4	0.55	3.01e-21	Mean corpuscular volume;
KIRP	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	7.96	0.45	6.52e-14	Neuroticism;
KIRP	cis	rs6956675	0.915	rs7795023	chr7:62652291	C/T	cg08930214	chr7:62859557	LOC100287834	0.42	5.17	0.31	4.84e-7	Obesity-related traits;
KIRP	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72653721	0.838	rs3798710	chr6:11002783	C/G	cg13562911	chr6:11044106	ELOVL2	0.53	5.07	0.31	7.75e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.68	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg08999081	chr20:33150536	PIGU	0.44	5.81	0.35	1.88e-8	Height;
KIRP	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.52	6.53	0.38	3.73e-10	Mean platelet volume;
KIRP	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg25753631	chr6:25732923	NA	-0.29	-5.23	-0.32	3.62e-7	Iron status biomarkers;
KIRP	cis	rs4805272	0.925	rs7260432	chr19:29321477	T/C	cg15000279	chr19:29285009	NA	-0.36	-5.14	-0.31	5.53e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg16497661	chr14:103986332	CKB	0.38	4.91	0.3	1.69e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg17595323	chr11:93583763	C11orf90	-0.41	-6.81	-0.4	7.57e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.38	-0.32	1.75e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.06	0.61	1.31e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02972257	chr16:68554789	NA	-0.73	-7.2	-0.42	7.45e-12	Ulcerative colitis;
KIRP	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg22437258	chr11:111473054	SIK2	0.58	7.17	0.42	8.83e-12	Primary sclerosing cholangitis;
KIRP	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7809615	0.901	rs10235235	chr7:99075831	T/C	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite ratios;
KIRP	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	trans	rs77948430	0.867	rs75657039	chr8:13150411	T/C	cg04284319	chr17:77351040	HRNBP3	0.96	6.15	0.37	3.17e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.7	0.34	3.41e-8	Educational attainment;
KIRP	cis	rs7113850	0.541	rs75347910	chr11:24213815	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	7.24	0.42	5.67e-12	Bone fracture in osteoporosis;
KIRP	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-7.57	-0.43	7.46e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg02336718	chr17:17403227	NA	0.33	5.19	0.31	4.3e-7	Total body bone mineral density;
KIRP	cis	rs2901656	0.934	rs9425311	chr1:172388778	G/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.42	5.27	0.32	2.92e-7	Red cell distribution width;Platelet distribution width;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12609243	chr3:54155240	CACNA2D3	0.53	6.34	0.37	1.11e-9	Smoking initiation;
KIRP	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.9	13.12	0.64	3.68e-30	Mean platelet volume;
KIRP	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg02733842	chr7:1102375	C7orf50	-0.61	-5.78	-0.35	2.22e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs7553035	1.000	rs2166104	chr1:211690818	A/T	cg01575408	chr1:211752895	SLC30A1	0.55	4.85	0.3	2.2e-6	Retinopathy in non-diabetics;
KIRP	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg25251562	chr2:3704773	ALLC	-0.51	-6.02	-0.36	6.27e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg00405596	chr8:11794950	NA	0.48	6.21	0.37	2.26e-9	Retinal vascular caliber;
KIRP	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg22777020	chr22:31556080	RNF185	-0.5	-5.31	-0.32	2.5e-7	Colorectal cancer;
KIRP	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.75	-12.31	-0.62	1.94e-27	Prostate cancer;
KIRP	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs876084	0.505	rs9969404	chr8:121107102	A/C	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg21775007	chr8:11205619	TDH	0.5	6.46	0.38	5.42e-10	Systolic blood pressure;
KIRP	cis	rs13385	0.769	rs269780	chr5:139545553	T/G	cg01860693	chr5:139557145	C5orf32	0.49	5.36	0.32	1.95e-7	Atrial fibrillation;
KIRP	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg10932868	chr11:921992	NA	0.55	7.01	0.41	2.25e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7709377	0.621	rs809210	chr5:115616523	A/G	cg23108291	chr5:115420582	COMMD10	-0.44	-5.43	-0.33	1.34e-7	Metabolite levels  (X-11787);
KIRP	cis	rs714027	0.585	rs41173	chr22:30424863	C/G	cg01021169	chr22:30184971	ASCC2	0.41	5.09	0.31	7.02e-7	Lymphocyte counts;
KIRP	cis	rs4930561	0.765	rs7931502	chr11:67959607	A/C	cg16338278	chr11:67432957	ALDH3B2	-0.38	-4.85	-0.3	2.2e-6	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	cis	rs6578185	0.810	rs3935446	chr8:142452954	C/T	cg07762003	chr8:142452454	FLJ43860	-0.63	-9.53	-0.52	1.54e-18	Endometriosis;
KIRP	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00321850	chr1:175162397	KIAA0040	-0.34	-6.17	-0.37	2.77e-9	Alcohol dependence;
KIRP	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg17120908	chr11:65337727	SSSCA1	-0.51	-6.03	-0.36	6.07e-9	Bone mineral density;
KIRP	trans	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg00022858	chr4:55096616	PDGFRA	-0.44	-6.25	-0.37	1.76e-9	Protein C levels;
KIRP	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg05082376	chr22:42548792	NA	-0.44	-5.68	-0.34	3.88e-8	Schizophrenia;
KIRP	trans	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.35	-0.38	1.03e-9	Neuroticism;
KIRP	cis	rs8070740	0.617	rs1058115	chr17:5323269	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	-0.6	-8.08	-0.46	2.92e-14	Menopause (age at onset);
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs7116495	1.000	rs10736786	chr11:71763274	C/T	cg18441811	chr11:71824068	C11orf51	-0.61	-4.93	-0.3	1.51e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.73	10.5	0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg04490037	chr7:50633773	DDC	-0.4	-4.96	-0.3	1.31e-6	Malaria;
KIRP	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg02228329	chr11:64053129	BAD;GPR137	0.65	5.56	0.33	7.03e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.78	-12.68	-0.63	1.1e-28	Breast cancer;
KIRP	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg22903471	chr2:27725779	GCKR	-0.37	-4.98	-0.3	1.2e-6	Oral cavity cancer;
KIRP	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.22e-6	Pulmonary function;
KIRP	cis	rs755109	1.000	rs7030887	chr9:100688511	C/T	cg13688889	chr9:100608707	NA	-0.42	-4.92	-0.3	1.62e-6	Quantitative traits;
KIRP	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-1.06	-7.6	-0.44	6.06e-13	Fat distribution (HIV);
KIRP	cis	rs9309473	0.519	rs1881246	chr2:73650122	T/A	cg20560298	chr2:73613845	ALMS1	0.48	5.92	0.35	1.1e-8	Metabolite levels;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg23978390	chr7:1156363	C7orf50	0.58	7.78	0.44	1.96e-13	Longevity;Endometriosis;
KIRP	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.72	-11.38	-0.59	2.14e-24	Prudent dietary pattern;
KIRP	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.81	-11.25	-0.58	5.99e-24	Joint mobility (Beighton score);
KIRP	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.42	-0.43	1.88e-12	Colorectal cancer;
KIRP	cis	rs35740288	0.822	rs11630179	chr15:86282934	G/A	cg10818794	chr15:86012489	AKAP13	-0.42	-4.91	-0.3	1.68e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg11941060	chr3:133502564	NA	-0.51	-6.18	-0.37	2.65e-9	Iron status biomarkers;
KIRP	cis	rs7903847	0.646	rs10882924	chr10:99159304	T/A	cg20016023	chr10:99160130	RRP12	-0.43	-5.92	-0.35	1.1e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg13699009	chr12:122356056	WDR66	-0.68	-11.05	-0.58	2.56e-23	Mean corpuscular volume;
KIRP	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.96e-9	Breast cancer;
KIRP	cis	rs2692947	0.616	rs2301707	chr2:96931846	T/C	cg23100626	chr2:96804247	ASTL	0.46	5.96	0.36	8.68e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg08992911	chr2:238395768	MLPH	0.47	5.27	0.32	3e-7	Prostate cancer;
KIRP	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.21	0.46	1.24e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg12935359	chr14:103987150	CKB	-0.33	-5.03	-0.31	9.68e-7	Body mass index;
KIRP	cis	rs1978968	0.763	rs9605478	chr22:18464410	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.77	-10.7	-0.56	3.41e-22	Presence of antiphospholipid antibodies;
KIRP	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg19610905	chr11:61596333	FADS2	-0.56	-8.51	-0.48	1.78e-15	Trans fatty acid levels;
KIRP	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg13072238	chr3:49761600	GMPPB	-0.64	-5.57	-0.33	6.76e-8	Menarche (age at onset);
KIRP	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.8	-0.49	2.41e-16	Triglycerides;
KIRP	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.66	-7.17	-0.42	8.49e-12	Vitiligo;
KIRP	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.71	-0.44	3.08e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg17376030	chr22:41985996	PMM1	0.58	6.6	0.39	2.44e-10	Vitiligo;
KIRP	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06771106	chr2:113671356	IL1F7	0.43	5.08	0.31	7.62e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs988913	0.957	rs4141552	chr6:54759929	A/G	cg03513858	chr6:54763001	FAM83B	-0.38	-5.52	-0.33	8.75e-8	Menarche (age at onset);
KIRP	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg19847866	chr10:1019161	NA	-0.64	-5.87	-0.35	1.37e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg21858823	chr1:15850916	CASP9	0.51	5.5	0.33	9.5e-8	Systolic blood pressure;
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.67	0.63	1.17e-28	Platelet count;
KIRP	cis	rs73607972	0.740	rs66961852	chr16:53621388	T/C	cg05113697	chr16:53544098	NA	-0.35	-4.87	-0.3	2.03e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs745080	0.698	rs8003291	chr14:52922654	G/T	cg23333723	chr14:53022898	GPR137C	-0.39	-5.33	-0.32	2.25e-7	Orofacial clefts;
KIRP	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.61	0.48	8.6e-16	Prudent dietary pattern;
KIRP	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg12560992	chr17:57184187	TRIM37	0.55	5.21	0.32	4.03e-7	Cognitive test performance;
KIRP	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg10402321	chr1:26617780	UBXN11	-0.43	-5.61	-0.34	5.3e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.81	-11.14	-0.58	1.31e-23	Menopause (age at onset);
KIRP	trans	rs1106684	1.000	rs35480282	chr7:131463091	A/G	cg13607082	chr12:122652224	LRRC43	-0.65	-6.53	-0.38	3.84e-10	Body mass index;
KIRP	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.6	9.13	0.5	2.55e-17	IgG glycosylation;
KIRP	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.65	-7.09	-0.41	1.38e-11	Corneal astigmatism;
KIRP	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.63	-0.39	2.11e-10	Coronary artery calcification;
KIRP	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg11839771	chr15:80205821	ST20	-0.4	-5.68	-0.34	3.81e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg18198730	chr1:247681584	NA	0.63	5.77	0.35	2.31e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.21	-0.42	6.86e-12	Type 2 diabetes;
KIRP	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg16584676	chr17:46985605	UBE2Z	0.47	5.97	0.36	8.07e-9	Type 2 diabetes;
KIRP	cis	rs778371	0.788	rs2675959	chr2:233791988	T/A	cg11972305	chr2:233791962	NGEF	-0.44	-5.7	-0.34	3.5e-8	Schizophrenia;
KIRP	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.67	-0.52	5.88e-19	Response to antipsychotic treatment;
KIRP	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.9	12.41	0.62	9.06e-28	Schizophrenia;
KIRP	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-12.98	-0.64	1.06e-29	Electrocardiographic conduction measures;
KIRP	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg21361702	chr7:150065534	REPIN1	0.52	5.7	0.34	3.42e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.41	-5.92	-0.35	1.06e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg02733842	chr7:1102375	C7orf50	0.59	6.02	0.36	6.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg00579200	chr11:133705235	NA	-0.43	-5.9	-0.35	1.23e-8	Childhood ear infection;
KIRP	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg08885076	chr2:99613938	TSGA10	0.53	9.26	0.51	1.06e-17	Chronic sinus infection;
KIRP	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg23034840	chr1:205782522	SLC41A1	0.57	6.41	0.38	7.29e-10	Prostate-specific antigen levels;
KIRP	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.41	-0.47	3.35e-15	Neuroticism;
KIRP	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.11	-0.36	3.79e-9	Cutaneous nevi;
KIRP	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.63	3.22e-29	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.04	12.81	0.63	3.89e-29	Vitiligo;
KIRP	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.46	-5.89	-0.35	1.24e-8	Blood metabolite levels;
KIRP	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.52	5.37	0.32	1.81e-7	Tourette syndrome;
KIRP	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg23352942	chr3:46931381	PTH1R	-0.45	-5.93	-0.35	1.04e-8	Birth weight;
KIRP	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg02023728	chr11:77925099	USP35	-0.35	-5.24	-0.32	3.43e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.3	0.51	7.78e-18	Coffee consumption (cups per day);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08204369	chr17:73150733	HN1	0.72	6.76	0.4	1.01e-10	Lung function (FEV1);
KIRP	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg19847130	chr8:10466454	RP1L1	0.38	5.74	0.34	2.71e-8	Retinal vascular caliber;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg10207240	chr12:122356781	WDR66	0.49	6.56	0.39	3.08e-10	Mean corpuscular volume;
KIRP	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.55	6.93	0.4	3.77e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg13147721	chr7:65941812	NA	1.03	7.08	0.41	1.49e-11	Diabetic kidney disease;
KIRP	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7246657	0.639	rs12459015	chr19:38083189	T/A	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23995744	chr1:43824609	CDC20	0.55	6.98	0.41	2.75e-11	Parkinson's disease;
KIRP	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-11.4	-0.59	1.9e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20942339	chr12:51984503	SCN8A	0.59	7.4	0.43	2.15e-12	Parkinson's disease;
KIRP	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg12046867	chr14:103022105	NA	-0.5	-6.05	-0.36	5.42e-9	Platelet count;
KIRP	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.98	14.97	0.69	1.85e-36	Diastolic blood pressure;
KIRP	cis	rs6693567	0.565	rs7544900	chr1:150262333	A/C	cg07843065	chr1:150265600	MRPS21	-0.49	-7.0	-0.41	2.4e-11	Migraine;
KIRP	cis	rs7289126	0.966	rs4820329	chr22:38646063	G/A	cg25457927	chr22:38595422	NA	-0.31	-6.71	-0.39	1.3100000000000001e-10	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-5.7	-0.34	3.49e-8	Self-reported allergy;
KIRP	cis	rs661054	0.956	rs10891705	chr11:114441943	G/A	cg19465033	chr11:114479364	NA	0.42	5.66	0.34	4.1e-8	Ulcerative colitis;
KIRP	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg01620082	chr3:125678407	NA	-1.03	-6.18	-0.37	2.62e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.49	0.43	1.21e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.14e-10	Axial length;
KIRP	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-5.15	-0.31	5.25e-7	Height;
KIRP	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg08975724	chr8:8085496	FLJ10661	0.57	7.41	0.43	2.08e-12	Neuroticism;
KIRP	cis	rs55675132	0.548	rs17476878	chr1:115358056	T/G	cg12756093	chr1:115239321	AMPD1	0.53	5.26	0.32	3.19e-7	Schizophrenia;
KIRP	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.65	-10.07	-0.54	3.35e-20	Hip circumference;Waist circumference;
KIRP	cis	rs4073416	0.502	rs2411823	chr14:65865066	C/T	cg03016385	chr14:66212404	NA	-0.44	-5.71	-0.34	3.17e-8	N-glycan levels;
KIRP	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg12160578	chr15:63334699	TPM1	0.63	6.68	0.39	1.58e-10	Orofacial clefts;
KIRP	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.56	-7.45	-0.43	1.56e-12	Ulcerative colitis;
KIRP	cis	rs4722166	0.599	rs7776857	chr7:22754768	G/T	cg26061582	chr7:22766209	IL6	0.54	5.49	0.33	1.01e-7	Lung cancer;
KIRP	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	1.17	12.6	0.63	2.03e-28	Alzheimer's disease;
KIRP	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg27211696	chr2:191398769	TMEM194B	-0.75	-9.19	-0.51	1.71e-17	Diastolic blood pressure;
KIRP	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.51	6.98	0.41	2.71e-11	Metabolite levels;
KIRP	cis	rs9391997	0.568	rs9328192	chr6:434364	C/T	cg13299325	chr6:447777	NA	-0.25	-5.21	-0.32	4.05e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26207909	chr14:103986467	CKB	0.54	7.13	0.41	1.09e-11	Body mass index;
KIRP	cis	rs4762326	0.584	rs10859853	chr12:95614953	T/C	cg07737802	chr12:95537812	FGD6	0.37	4.89	0.3	1.82e-6	Endometriosis;
KIRP	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.29e-11	Type 2 diabetes;
KIRP	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.39	-5.03	-0.31	9.56e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg26893134	chr6:116381904	FRK	0.21	5.82	0.35	1.84e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg11031976	chr2:198649780	BOLL	-0.55	-5.3	-0.32	2.54e-7	Ulcerative colitis;
KIRP	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-0.96	-14.24	-0.67	5.96e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg19338460	chr6:170058176	WDR27	-0.58	-6.87	-0.4	5.26e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7527798	0.592	rs4097398	chr1:207857760	C/T	cg09232269	chr1:207846808	CR1L	-0.36	-5.27	-0.32	2.93e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg21734707	chr17:3908241	ZZEF1	0.68	10.35	0.55	4.53e-21	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg00343986	chr7:65444356	GUSB	0.48	5.81	0.35	1.89e-8	Calcium levels;
KIRP	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg00857998	chr1:205179979	DSTYK	0.49	6.1	0.36	4.15e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8018808	0.846	rs11624990	chr14:77943616	C/T	cg18872420	chr14:78023429	SPTLC2	0.37	5.52	0.33	8.42e-8	Myeloid white cell count;
KIRP	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg26769984	chr7:1090371	C7orf50	0.73	5.95	0.35	8.95e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg24253500	chr15:84953950	NA	0.55	6.23	0.37	1.97e-9	Schizophrenia;
KIRP	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-6.14	-0.36	3.21e-9	Ulcerative colitis;
KIRP	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg20578329	chr17:80767326	TBCD	0.47	6.19	0.37	2.44e-9	Breast cancer;
KIRP	trans	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg19274270	chr17:78178856	CARD14	0.34	6.1	0.36	4.11e-9	Morning vs. evening chronotype;
KIRP	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-16.25	-0.72	7.66e-41	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg13615516	chr5:77269221	NA	0.52	8.12	0.46	2.28e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.53	0.68	5.82e-35	Alzheimer's disease;
KIRP	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.42	-0.43	1.85e-12	Bipolar disorder;
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg23736307	chr8:27182930	PTK2B	0.53	6.75	0.4	1.05e-10	Neuroticism;
KIRP	cis	rs6060717	0.536	rs6060699	chr20:34523833	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.02	-0.36	6.35e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg08761264	chr16:28874980	SH2B1	-0.46	-5.04	-0.31	9.07e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg13877915	chr19:58951672	ZNF132	0.61	5.99	0.36	7.27e-9	Mean platelet volume;
KIRP	cis	rs2882877	0.735	rs11884632	chr2:190424842	G/C	cg10752008	chr2:190445175	SLC40A1	0.46	5.12	0.31	6.18e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg01028140	chr2:1542097	TPO	-0.5	-5.63	-0.34	4.86e-8	IgG glycosylation;
KIRP	trans	rs1106684	0.925	rs1592696	chr7:131464635	G/C	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs7187994	0.848	rs3764333	chr16:84793261	A/G	cg07647771	chr16:84786436	USP10	-0.4	-5.27	-0.32	2.92e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg15655495	chr12:38532458	NA	0.26	5.08	0.31	7.52e-7	Morning vs. evening chronotype;
KIRP	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.72	10.46	0.55	1.97e-21	Morning vs. evening chronotype;
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.97	0.36	8.42e-9	Platelet count;
KIRP	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg22508957	chr16:3507546	NAT15	0.59	7.18	0.42	8.37e-12	Tuberculosis;
KIRP	cis	rs7923609	0.902	rs10740136	chr10:65329622	A/C	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.19	-0.31	4.39e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg24579218	chr15:68104479	NA	-0.59	-9.29	-0.51	8.76e-18	Restless legs syndrome;
KIRP	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	1.03	11.57	0.59	5.15e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7119	0.717	rs8040702	chr15:77803615	G/A	cg12131826	chr15:77904385	NA	0.52	6.13	0.36	3.54e-9	Type 2 diabetes;
KIRP	cis	rs883565	0.655	rs6599000	chr3:39061512	A/G	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg25482853	chr8:67687455	SGK3	0.8	7.05	0.41	1.76e-11	Obesity-related traits;
KIRP	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.7	-9.3	-0.51	7.74e-18	Systemic lupus erythematosus;
KIRP	cis	rs7084402	0.565	rs7912792	chr10:60335179	C/T	cg05938607	chr10:60274200	BICC1	-0.37	-8.05	-0.46	3.44e-14	Refractive error;
KIRP	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg17757837	chr7:157058334	UBE3C	0.72	9.81	0.53	2.11e-19	Body mass index;
KIRP	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg11382394	chr1:2564504	MMEL1	0.38	4.88	0.3	1.89e-6	Ulcerative colitis;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg12692727	chr7:1102344	C7orf50	0.47	5.01	0.3	1.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.03	0.31	9.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg22676075	chr6:135203613	NA	0.52	7.71	0.44	3.17e-13	Red blood cell count;
KIRP	cis	rs1298062	0.790	rs25668	chr19:50965272	T/C	cg17071417	chr19:50962282	MYBPC2	0.43	4.93	0.3	1.53e-6	Age of smoking initiation;
KIRP	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.11	-0.64	3.87e-30	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00183355	chr21:34100294	SYNJ1	0.52	6.33	0.37	1.13e-9	Parkinson's disease;
KIRP	cis	rs584438	0.803	rs56394376	chr17:38589733	C/T	cg09213124	chr17:38599508	IGFBP4	-0.29	-4.92	-0.3	1.62e-6	Height;
KIRP	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.59	6.37	0.38	9.4e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6132905	0.590	rs79409802	chr20:2606485	C/T	cg24848351	chr20:2622020	TMC2	-0.53	-5.07	-0.31	7.95e-7	Mumps;
KIRP	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-8.43	-0.47	2.85e-15	Colorectal cancer;
KIRP	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs2505998	0.833	rs1864403	chr10:43604950	C/T	cg15436174	chr10:43711423	RASGEF1A	0.53	5.69	0.34	3.63e-8	Hirschsprung disease;
KIRP	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.83e-26	Heart rate;
KIRP	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg09491104	chr22:46646882	C22orf40	-0.52	-5.99	-0.36	7.41e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg07701084	chr6:150067640	NUP43	0.7	9.9	0.53	1.15e-19	Lung cancer;
KIRP	cis	rs2708977	0.965	rs12717781	chr2:97249142	G/A	cg01950434	chr2:97203154	ARID5A	0.54	6.71	0.39	1.32e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1514687	0.534	rs60151917	chr2:1473286	A/T	cg03133821	chr2:1513998	TPO	-0.63	-5.05	-0.31	8.8e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.78	0.35	2.24e-8	Coronary artery disease;
KIRP	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.83	0.45	1.46e-13	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.1	0.31	6.66e-7	Breast cancer;
KIRP	cis	rs9790314	0.582	rs11708813	chr3:160589852	G/A	cg04691961	chr3:161091175	C3orf57	0.44	6.27	0.37	1.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs4740619	0.619	rs4741558	chr9:16038787	G/T	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.07e-7	Body mass index;
KIRP	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.64	-9.34	-0.51	6.14e-18	Resting heart rate;
KIRP	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00376283	chr12:123451042	ABCB9	-0.62	-7.19	-0.42	7.95e-12	Neutrophil percentage of white cells;
KIRP	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.75	0.4	1.06e-10	Breast cancer;
KIRP	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg04025307	chr7:1156635	C7orf50	0.71	5.56	0.33	7.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg02804510	chr19:49199965	FUT2	0.35	5.12	0.31	6.1e-7	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.69	-8.45	-0.47	2.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.55	7.03	0.41	2e-11	Eye color traits;
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs10085978	0.604	rs10099944	chr8:143234817	A/G	cg07766672	chr8:143808440	C8orf55	0.42	4.87	0.3	2.03e-6	Mosquito bite size;
KIRP	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs981844	0.890	rs55850399	chr4:154684906	C/T	cg14289246	chr4:154710475	SFRP2	0.67	7.6	0.44	6.3e-13	Response to statins (LDL cholesterol change);
KIRP	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-7.22	-0.42	6.61e-12	Coronary artery disease;
KIRP	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.07	-0.36	4.93e-9	Obesity-related traits;
KIRP	cis	rs11779988	0.545	rs397096	chr8:17798848	C/G	cg01800426	chr8:17659068	MTUS1	0.6	5.99	0.36	7.42e-9	Breast cancer;
KIRP	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.59	-6.66	-0.39	1.74e-10	LDL cholesterol levels;
KIRP	cis	rs9815354	1.000	rs57479675	chr3:41798038	C/T	cg03022575	chr3:42003672	ULK4	0.54	6.06	0.36	5.02e-9	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08267002	chr2:74741573	TLX2	0.6	6.26	0.37	1.71e-9	Lung function (FEV1);
KIRP	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg12598211	chr12:123634384	NA	-0.44	-5.08	-0.31	7.45e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg07701084	chr6:150067640	NUP43	0.58	7.5	0.43	1.14e-12	Lung cancer;
KIRP	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.67	8.33	0.47	5.73e-15	Red blood cell count;
KIRP	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg17644776	chr2:200775616	C2orf69	0.54	6.31	0.37	1.3e-9	Schizophrenia;
KIRP	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg02336718	chr17:17403227	NA	-0.31	-4.92	-0.3	1.6e-6	Total body bone mineral density;
KIRP	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg00792783	chr2:198669748	PLCL1	0.45	5.07	0.31	7.79e-7	Dermatomyositis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10718078	chr1:201951076	RNPEP	0.48	7.24	0.42	5.64e-12	Survival in pancreatic cancer;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.64	0.44	4.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.46	-0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg16434002	chr17:42200994	HDAC5	0.5	6.05	0.36	5.46e-9	Total body bone mineral density;
KIRP	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.78	10.03	0.54	4.56e-20	Aortic root size;
KIRP	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.35	-7.57	-0.43	7.72e-13	Cutaneous nevi;
KIRP	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.75	-11.42	-0.59	1.62e-24	Educational attainment;
KIRP	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg19676328	chr12:49525230	TUBA1B	-0.6	-6.18	-0.37	2.69e-9	Total cholesterol levels;
KIRP	trans	rs2048656	0.605	rs13249234	chr8:9650401	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.69	0.39	1.53e-10	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.36e-7	Life satisfaction;
KIRP	cis	rs612683	0.931	rs7517704	chr1:100885419	A/G	cg06223162	chr1:101003688	GPR88	0.44	8.0	0.45	5.01e-14	Breast cancer;
KIRP	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.46	5.96	0.36	8.86e-9	Initial pursuit acceleration;
KIRP	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.55	7.44	0.43	1.64e-12	Blood metabolite levels;
KIRP	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.43	-5.05	-0.31	8.61e-7	Reticulocyte count;
KIRP	trans	rs7830939	0.586	rs9918737	chr8:9321543	T/A	cg16141378	chr3:129829833	LOC729375	-0.5	-6.19	-0.37	2.53e-9	Neuroticism;
KIRP	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.85	8.15	0.46	1.88e-14	Systolic blood pressure;
KIRP	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg11266682	chr4:10021025	SLC2A9	0.36	4.99	0.3	1.14e-6	Psychosis and Alzheimer's disease;
KIRP	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.97	11.81	0.6	8.44e-26	Exhaled nitric oxide levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg21864845	chr1:1208426	UBE2J2	-0.48	-6.04	-0.36	5.67e-9	Neuroticism;
KIRP	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg23594656	chr7:65796392	TPST1	0.43	5.92	0.35	1.07e-8	Aortic root size;
KIRP	cis	rs1697139	0.528	rs7725332	chr5:66529458	T/C	cg16691251	chr5:66510806	NA	0.41	5.1	0.31	6.9e-7	Breast cancer;
KIRP	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	9.44	0.52	3.04e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.55	7.43	0.43	1.83e-12	Mean corpuscular volume;
KIRP	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.53e-13	Uric acid levels;
KIRP	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.15	-0.31	5.43e-7	Post bronchodilator FEV1;
KIRP	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg24069376	chr3:38537580	EXOG	0.3	5.02	0.3	9.92e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.5e-21	Bone mineral density;
KIRP	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.94	-0.5	9.22e-17	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16534196	chr19:56089807	ZNF579	0.47	6.1	0.36	4.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13102973	0.899	rs13104539	chr4:135904385	G/A	cg14419869	chr4:135874104	NA	0.48	7.5	0.43	1.13e-12	Subjective well-being;
KIRP	cis	rs4356975	0.563	rs4314345	chr4:69973640	A/G	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs6968419	0.747	rs1004107	chr7:115860783	A/T	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs72730918	0.540	rs2252220	chr15:51934783	G/A	cg14296394	chr15:51910925	DMXL2	-0.78	-10.94	-0.57	6.04e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg16691251	chr5:66510806	NA	0.43	5.75	0.34	2.62e-8	Breast cancer;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00689492	chr4:1303491	MAEA	0.32	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs12210905	1.000	rs12201774	chr6:27058312	A/G	cg11502198	chr6:26597334	ABT1	-0.76	-4.97	-0.3	1.24e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg02811702	chr13:24901961	NA	0.43	5.68	0.34	3.71e-8	Obesity-related traits;
KIRP	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.5	-5.88	-0.35	1.36e-8	Colorectal cancer;
KIRP	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg11846333	chr4:119757529	SEC24D	1.11	5.88	0.35	1.37e-8	Cannabis dependence symptom count;
KIRP	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg12463550	chr7:65579703	CRCP	-0.66	-4.94	-0.3	1.45e-6	Diabetic kidney disease;
KIRP	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.56	-6.47	-0.38	5.27e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.15e-8	HDL cholesterol;
KIRP	cis	rs1355223	0.902	rs4465347	chr11:34727333	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.04	-0.31	8.94e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26094984	chr2:197457425	HECW2	-0.48	-6.65	-0.39	1.83e-10	Metabolic traits;
KIRP	cis	rs77633900	0.502	rs116917406	chr15:76922940	T/C	cg21673338	chr15:77095150	SCAPER	-0.55	-5.31	-0.32	2.51e-7	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-7.16	-0.42	9.04e-12	Response to antipsychotic treatment;
KIRP	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg25251562	chr2:3704773	ALLC	0.62	7.51	0.43	1.12e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.5	0.43	1.17e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.63	6.81	0.4	7.52e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1816752	0.748	rs6490912	chr13:24983079	G/A	cg02811702	chr13:24901961	NA	0.38	4.89	0.3	1.79e-6	Obesity-related traits;
KIRP	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg05973401	chr12:123451056	ABCB9	0.5	5.3	0.32	2.53e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7546668	0.947	rs10803391	chr1:15876578	A/G	cg21858823	chr1:15850916	CASP9	0.48	5.23	0.32	3.69e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs675026	0.926	rs604844	chr6:154454973	C/T	cg07813322	chr6:154414604	OPRM1	0.42	5.48	0.33	1.07e-7	Hypertension;
KIRP	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	7.09	0.41	1.42e-11	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.45	6.45	0.38	5.81e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.52	-5.78	-0.35	2.22e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.24	-0.32	3.45e-7	Bipolar disorder;
KIRP	cis	rs7219021	0.705	rs1962412	chr17:46970259	T/C	cg16584676	chr17:46985605	UBE2Z	0.46	5.54	0.33	7.68e-8	Schizophrenia or bipolar disorder;
KIRP	cis	rs9400467	0.537	rs56272203	chr6:111492436	C/A	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs643506	1.000	rs4936675	chr11:111623088	T/A	cg09085632	chr11:111637200	PPP2R1B	0.53	5.91	0.35	1.13e-8	Breast cancer;
KIRP	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.76	-0.34	2.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.71	-0.39	1.35e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg04607699	chr11:48328132	OR4S1	-0.35	-4.93	-0.3	1.5e-6	HDL cholesterol;
KIRP	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.61	6.97	0.41	2.92e-11	Bipolar disorder;
KIRP	trans	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg01826367	chr1:224180288	NA	-0.88	-6.31	-0.37	1.28e-9	Obesity (early onset extreme);
KIRP	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.71	9.31	0.51	7.35e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg04935436	chr20:30431758	NA	0.56	6.86	0.4	5.47e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.61	5.0	0.3	1.08e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs78487399	0.808	rs116451849	chr2:43662911	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg11707556	chr5:10655725	ANKRD33B	0.54	7.0	0.41	2.37e-11	Coronary artery disease;
KIRP	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.49	-5.87	-0.35	1.4e-8	Menarche (age at onset);
KIRP	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg04691961	chr3:161091175	C3orf57	-0.37	-5.39	-0.33	1.62e-7	Kawasaki disease;
KIRP	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.84	14.07	0.67	2.2e-33	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.0	-0.45	4.74e-14	Coffee consumption (cups per day);
KIRP	cis	rs1190552	0.894	rs2236349	chr14:102963640	G/A	cg10241871	chr14:102965420	TECPR2	-0.5	-5.52	-0.33	8.59e-8	Blood protein levels;
KIRP	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg00405596	chr8:11794950	NA	-0.43	-5.63	-0.34	4.78e-8	Triglycerides;
KIRP	cis	rs5753618	0.561	rs5749265	chr22:31796897	A/C	cg02404636	chr22:31891804	SFI1	0.51	5.79	0.35	2.17e-8	Colorectal cancer;
KIRP	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs7951870	0.891	rs7130141	chr11:46499874	C/T	cg16389345	chr11:46697382	NA	-0.47	-5.31	-0.32	2.46e-7	Schizophrenia;
KIRP	cis	rs904092	0.786	rs2646011	chr4:100161381	A/G	cg12011299	chr4:100065546	ADH4	0.55	5.45	0.33	1.23e-7	Alcohol dependence;
KIRP	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-6.58	-0.39	2.85e-10	Urate levels in overweight individuals;
KIRP	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.46	6.22	0.37	2.13e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
KIRP	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.87	9.79	0.53	2.46e-19	Corneal astigmatism;
KIRP	cis	rs593531	0.571	rs11236088	chr11:74094343	A/G	cg18195628	chr11:73498948	MRPL48	-0.41	-4.85	-0.3	2.23e-6	Neuroticism;
KIRP	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.45	-6.04	-0.36	5.64e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg00310523	chr12:86230176	RASSF9	0.38	5.84	0.35	1.66e-8	Major depressive disorder;
KIRP	cis	rs7590368	0.673	rs72779425	chr2:10940601	C/G	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs4395908	0.529	rs10110433	chr8:4018901	G/C	cg01921437	chr8:3974145	CSMD1	-0.48	-5.86	-0.35	1.48e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs4132509	0.779	rs1538773	chr1:243674682	T/G	cg25706552	chr1:244017396	NA	0.47	6.27	0.37	1.62e-9	RR interval (heart rate);
KIRP	cis	rs3105593	1.000	rs12442787	chr15:50918107	G/T	cg08437265	chr15:50716283	USP8	0.39	4.97	0.3	1.28e-6	QT interval;
KIRP	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	1.16	13.67	0.66	5.04e-32	Red blood cell traits;
KIRP	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg23752985	chr2:85803571	VAMP8	0.49	5.84	0.35	1.68e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs8014204	0.819	rs2003490	chr14:75377555	C/A	cg06637938	chr14:75390232	RPS6KL1	0.84	12.27	0.62	2.61e-27	Caffeine consumption;
KIRP	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.82	9.32	0.51	7.06e-18	Platelet count;
KIRP	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg25486957	chr4:152246857	NA	-0.52	-5.78	-0.35	2.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg18350739	chr11:68623251	NA	-0.48	-7.67	-0.44	3.95e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.28	-0.55	7.67e-21	Menopause (age at onset);
KIRP	cis	rs7225151	0.710	rs78650284	chr17:5243462	A/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.79	-0.35	2.09e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg23625390	chr15:77176239	SCAPER	0.53	7.01	0.41	2.27e-11	Blood metabolite levels;
KIRP	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.35	-5.03	-0.31	9.28e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg00656387	chr3:40428638	ENTPD3	0.41	5.13	0.31	5.79e-7	Renal cell carcinoma;
KIRP	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg26876637	chr1:152193138	HRNR	-0.71	-9.46	-0.52	2.61e-18	Atopic dermatitis;
KIRP	cis	rs2717559	0.541	rs11774054	chr8:143881976	T/C	cg17252645	chr8:143867129	LY6D	-0.39	-6.16	-0.37	3.02e-9	Urinary tract infection frequency;
KIRP	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg15676125	chr6:33679581	C6orf125	0.39	5.17	0.31	4.94e-7	Plateletcrit;
KIRP	cis	rs6005807	0.545	rs12169120	chr22:29005302	A/C	cg12565055	chr22:29076175	TTC28	0.58	4.99	0.3	1.14e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs2131877	0.554	rs2131876	chr3:194854788	C/T	cg13868855	chr3:194833887	C3orf21	-0.44	-5.06	-0.31	8.02e-7	Non-small cell lung cancer;
KIRP	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-5.11	-0.31	6.54e-7	Eosinophil percentage of white cells;
KIRP	cis	rs1950626	0.833	rs12897114	chr14:101395140	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.8	0.4	8.04e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.75	0.44	2.42e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.47	5.52	0.33	8.79e-8	Bone mineral density;
KIRP	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.81	-11.51	-0.59	8.14e-25	Systemic lupus erythematosus;
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg09597638	chr17:3907349	NA	0.81	16.23	0.72	8.88e-41	Type 2 diabetes;
KIRP	cis	rs10858047	0.831	rs7530191	chr1:115183832	T/C	cg12756093	chr1:115239321	AMPD1	-0.71	-6.6	-0.39	2.46e-10	Autism;
KIRP	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-11.59	-0.59	4.56e-25	Alzheimer's disease;
KIRP	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg04310649	chr10:35416472	CREM	-0.58	-7.14	-0.41	1.06e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg21184320	chr1:21044207	KIF17	-0.32	-4.91	-0.3	1.68e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg24253500	chr15:84953950	NA	0.51	5.84	0.35	1.61e-8	Schizophrenia;
KIRP	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg07541023	chr7:19748670	TWISTNB	0.65	5.67	0.34	3.96e-8	Thyroid stimulating hormone;
KIRP	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg26335602	chr6:28129616	ZNF389	-0.44	-4.86	-0.3	2.1e-6	Depression;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg05991184	chr2:219186017	PNKD	-0.43	-6.26	-0.37	1.74e-9	Colorectal cancer;
KIRP	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg00310523	chr12:86230176	RASSF9	0.41	6.43	0.38	6.75e-10	Major depressive disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07051257	chr19:39897430	ZFP36	-0.6	-7.04	-0.41	1.97e-11	Interleukin-4 levels;
KIRP	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.74	9.55	0.52	1.34e-18	Menarche (age at onset);
KIRP	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-5.05	-0.31	8.48e-7	Opioid sensitivity;
KIRP	cis	rs4776970	0.632	rs55993790	chr15:68026522	A/G	cg24579218	chr15:68104479	NA	0.39	5.7	0.34	3.37e-8	Waist circumference;Body mass index;
KIRP	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-6.36	-0.38	9.65e-10	Response to antipsychotic treatment;
KIRP	cis	rs7779181	1.000	rs7779180	chr7:32347202	A/G	cg13207630	chr7:32358064	NA	0.46	5.59	0.34	6.13e-8	Body mass index;
KIRP	cis	rs1656402	0.834	rs11676437	chr2:233453065	A/G	cg03852847	chr2:233439513	NA	-0.7	-11.21	-0.58	7.98e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg03060546	chr3:49711283	APEH	-0.71	-5.48	-0.33	1.05e-7	Cognitive function;
KIRP	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg00405596	chr8:11794950	NA	-0.45	-5.86	-0.35	1.5e-8	Monocyte count;
KIRP	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg05347473	chr6:146136440	FBXO30	-0.56	-8.0	-0.45	5.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.3	0.51	7.98e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg14580859	chr9:123691850	NA	0.39	5.58	0.34	6.29e-8	Rheumatoid arthritis;
KIRP	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg27165867	chr14:105738592	BRF1	-0.41	-4.94	-0.3	1.41e-6	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.37	-0.38	9.1e-10	Lung cancer;
KIRP	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.9	10.18	0.54	1.58e-20	Corneal astigmatism;
KIRP	cis	rs7267005	1.000	rs17093182	chr20:34451540	C/G	cg17201900	chr20:34330562	RBM39	0.92	5.33	0.32	2.17e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg00405596	chr8:11794950	NA	0.47	5.89	0.35	1.24e-8	Monocyte count;
KIRP	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.92	-16.18	-0.72	1.32e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	cis	rs3026101	0.671	rs7502643	chr17:5297009	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	6.73	0.39	1.2e-10	Body mass index;
KIRP	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs6973256	0.828	rs9649046	chr7:133433402	C/T	cg10665199	chr7:133106180	EXOC4	-0.53	-6.32	-0.37	1.21e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.85	0.49	1.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.59	-6.64	-0.39	1.95e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	trans	rs1864585	0.520	rs55637012	chr8:10656739	A/C	cg26278703	chr11:58910052	FAM111A	0.63	6.48	0.38	4.92e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs13170463	0.579	rs4295358	chr5:8051781	C/T	cg03862380	chr20:43029895	HNF4A	-0.45	-6.46	-0.38	5.51e-10	Colorectal cancer;
KIRP	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg18261050	chr1:119551319	NA	0.5	6.43	0.38	6.74e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.48	-7.75	-0.44	2.38e-13	Eye color traits;
KIRP	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg13147721	chr7:65941812	NA	-1.01	-7.18	-0.42	8.25e-12	Diabetic kidney disease;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg23963136	chr19:8372973	CD320	0.52	6.78	0.4	9.08e-11	Educational attainment;
KIRP	cis	rs3739034	0.877	rs13001022	chr2:135520614	G/C	cg15546071	chr2:135691756	CCNT2	-0.53	-4.95	-0.3	1.38e-6	Gut microbiome composition (winter);
KIRP	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.57	-4.97	-0.3	1.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.96	0.57	5.14e-23	Lung cancer in ever smokers;
KIRP	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg09455208	chr3:40491958	NA	0.39	6.53	0.38	3.82e-10	Renal cell carcinoma;
KIRP	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg25801113	chr15:45476975	SHF	-0.45	-8.19	-0.46	1.41e-14	Uric acid levels;
KIRP	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.48	-7.89	-0.45	1.02e-13	Platelet distribution width;
KIRP	cis	rs7923609	1.000	rs7070296	chr10:65070438	T/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.43	-0.33	1.33e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg22004693	chr7:99632812	ZKSCAN1	0.43	5.06	0.31	8.33e-7	Lung function (FEV1/FVC);
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.7	10.35	0.55	4.54e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21643547	chr1:205240462	TMCC2	-0.91	-14.52	-0.68	6.48e-35	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00791764	chr4:53727839	RASL11B	0.34	4.96	0.3	1.33e-6	Optic nerve measurement (cup area);
KIRP	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg00677455	chr12:58241039	CTDSP2	0.99	12.95	0.64	1.38e-29	Multiple sclerosis;
KIRP	cis	rs4908768	0.629	rs12410886	chr1:8878809	A/C	cg03610117	chr1:8450231	RERE	-0.47	-5.22	-0.32	3.86e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-9.22	-0.51	1.42e-17	Colorectal cancer;
KIRP	cis	rs7534824	0.543	rs61780300	chr1:101403601	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.25	0.42	5.24e-12	Refractive astigmatism;
KIRP	cis	rs7017914	0.967	rs7018381	chr8:71670117	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.91	13.06	0.64	5.75e-30	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.65	-9.71	-0.53	4.51e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs9790314	0.589	rs1447618	chr3:160610438	C/T	cg04691961	chr3:161091175	C3orf57	0.44	6.28	0.37	1.52e-9	Morning vs. evening chronotype;
KIRP	cis	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.11	-0.31	6.51e-7	Leprosy;
KIRP	trans	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg10756647	chr7:56101905	PSPH	1.02	7.45	0.43	1.61e-12	Diabetic kidney disease;
KIRP	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg00405596	chr8:11794950	NA	0.45	5.53	0.33	8.34e-8	Neuroticism;
KIRP	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-5.18	-0.31	4.65e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.57	-7.49	-0.43	1.21e-12	Aortic root size;
KIRP	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	0.82	7.19	0.42	7.71e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.45	6.45	0.38	5.81e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.95e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs6442310	0.534	rs1875796	chr3:12443657	C/T	cg15873301	chr3:12045459	SYN2	0.41	5.44	0.33	1.27e-7	Hematocrit;
KIRP	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.69e-16	Motion sickness;
KIRP	cis	rs4356975	0.545	rs4640729	chr4:69949360	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs10781543	0.839	rs1127152	chr9:139335599	A/G	cg14169450	chr9:139327907	INPP5E	0.49	6.77	0.4	9.66e-11	Monocyte percentage of white cells;
KIRP	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.8	-9.26	-0.51	1.05e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.49	6.22	0.37	2.08e-9	Cognitive test performance;
KIRP	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-7.45	-0.43	1.57e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg06521331	chr12:34319734	NA	-0.55	-6.8	-0.4	7.75e-11	Bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24984532	chr10:93872745	CPEB3	0.44	6.23	0.37	1.97e-9	Survival in pancreatic cancer;
KIRP	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.33	-0.32	2.22e-7	Height;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.71	10.77	0.57	2.12e-22	Menarche (age at onset);
KIRP	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.75	9.2	0.51	1.62e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17428704	0.571	rs12109453	chr5:14393511	C/G	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.09	15.12	0.69	5.91e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg21361702	chr7:150065534	REPIN1	0.67	6.73	0.39	1.17e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg23920097	chr1:209922102	NA	-0.47	-5.68	-0.34	3.79e-8	Red blood cell count;
KIRP	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.9	12.89	0.63	2.17e-29	Tonsillectomy;
KIRP	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg21546286	chr11:48923668	NA	-0.48	-6.12	-0.36	3.64e-9	HDL cholesterol;
KIRP	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg27205649	chr11:78285834	NARS2	0.68	9.11	0.5	3.01e-17	Alzheimer's disease (survival time);
KIRP	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg17554472	chr22:41940697	POLR3H	0.43	5.2	0.31	4.17e-7	Vitiligo;
KIRP	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.89	0.45	9.92e-14	Neuroticism;
KIRP	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg15488143	chr7:128924101	AHCYL2	0.57	6.09	0.36	4.31e-9	White matter hyperintensity burden;
KIRP	cis	rs4262150	0.705	rs72804801	chr5:152331031	C/A	cg12297329	chr5:152029980	NA	-0.52	-5.49	-0.33	9.91e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03076246	chr16:67906784	EDC4	0.54	6.57	0.39	3.02e-10	Smoking initiation;
KIRP	cis	rs2625529	0.730	rs7177242	chr15:72184114	A/G	cg16672083	chr15:72433130	SENP8	0.47	6.56	0.39	3.11e-10	Red blood cell count;
KIRP	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24805728	chr15:34630351	SLC12A6	0.54	6.95	0.41	3.25e-11	Parkinson's disease;
KIRP	cis	rs754466	0.561	rs67332822	chr10:79706118	G/A	cg17075019	chr10:79541650	NA	-0.73	-5.78	-0.35	2.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	7.04	0.41	1.89e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2108225	1.000	rs6466190	chr7:107451045	G/T	cg18560240	chr7:107437656	SLC26A3	0.46	5.95	0.35	8.98e-9	Ulcerative colitis;
KIRP	cis	rs6772849	0.775	rs9828414	chr3:128412717	C/T	cg08795948	chr3:128337044	NA	0.41	4.89	0.3	1.85e-6	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg14092571	chr14:90743983	NA	-0.41	-5.38	-0.32	1.75e-7	Mortality in heart failure;
KIRP	trans	rs2032794	1.000	rs2032794	chr5:86432617	T/C	cg14392746	chr11:2721207	KCNQ1;KCNQ1OT1	-0.58	-6.01	-0.36	6.5e-9	Personality dimensions;
KIRP	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	0.88	7.18	0.42	8.12e-12	Fat distribution (HIV);
KIRP	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.8	-6.78	-0.4	8.86e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.63	7.93	0.45	7.69e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.67	-9.63	-0.52	7.64e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg15507776	chr3:136538369	TMEM22	0.4	5.41	0.33	1.47e-7	Neuroticism;
KIRP	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08480307	chr1:100547766	HIAT1	0.38	6.1	0.36	4.08e-9	C-reactive protein;
KIRP	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	0.97	11.45	0.59	1.29e-24	Vitiligo;
KIRP	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.88	11.17	0.58	1.05e-23	Cognitive function;
KIRP	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg21253087	chr9:139290292	SNAPC4	0.4	5.18	0.31	4.54e-7	Monocyte percentage of white cells;
KIRP	cis	rs17407555	0.609	rs10032742	chr4:10278893	A/G	cg11266682	chr4:10021025	SLC2A9	0.32	4.99	0.3	1.17e-6	Schizophrenia (age at onset);
KIRP	cis	rs7560272	0.723	rs6729468	chr2:73765253	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.56	-0.33	7.04e-8	Schizophrenia;
KIRP	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26207909	chr14:103986467	CKB	0.52	6.98	0.41	2.72e-11	Body mass index;
KIRP	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg25457927	chr22:38595422	NA	-0.27	-5.52	-0.33	8.79e-8	Cutaneous nevi;
KIRP	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	6.71	0.39	1.35e-10	Breast cancer;
KIRP	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.75	-11.42	-0.59	1.62e-24	Educational attainment;
KIRP	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg26811252	chr16:29126840	RRN3P2	0.64	8.4	0.47	3.68e-15	Menopause (age at onset);
KIRP	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg06627628	chr2:24431161	ITSN2	-0.56	-5.07	-0.31	7.7300000000000005e-07	Lymphocyte counts;
KIRP	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.06	0.36	5.03e-9	Mean corpuscular volume;
KIRP	cis	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg02972257	chr16:68554789	NA	-0.58	-5.71	-0.34	3.25e-8	Ulcerative colitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07491796	chr11:33037397	DEPDC7	0.42	6.42	0.38	7.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.79	6.91	0.4	4.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs78761021	0.829	rs55789050	chr17:9793417	A/T	cg26853458	chr17:9805074	RCVRN	0.5	4.91	0.3	1.65e-6	Type 2 diabetes;
KIRP	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-0.8	-10.01	-0.54	5.35e-20	Blood trace element (Zn levels);
KIRP	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.13e-6	Aortic root size;
KIRP	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.39	-0.43	2.25e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7851660	0.775	rs7034336	chr9:100661100	C/T	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-5.76	-0.34	2.57e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg25390230	chr3:32612502	DYNC1LI1	0.45	6.05	0.36	5.4e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs13102973	0.720	rs13122251	chr4:135887466	C/T	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.51	-7.24	-0.42	5.56e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.19	-0.42	7.82e-12	Triglycerides;
KIRP	cis	rs17123764	0.710	rs12320556	chr12:49973011	A/G	cg02054252	chr12:50078554	FMNL3	0.43	5.19	0.31	4.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-0.62	-6.88	-0.4	4.86e-11	Initial pursuit acceleration;
KIRP	cis	rs4356975	0.545	rs55757747	chr4:69955637	A/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs6433857	0.536	rs12474658	chr2:181352992	G/T	cg23363182	chr2:181467187	NA	-0.36	-5.0	-0.3	1.1e-6	Body mass index;
KIRP	trans	rs13189969	0.564	rs11949034	chr5:105333676	G/A	cg27050057	chr2:238274488	COL6A3	-0.43	-6.03	-0.36	6.08e-9	Obesity-related traits;
KIRP	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.14	9.07	0.5	3.85e-17	Skin colour saturation;
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.79e-6	Lung cancer;
KIRP	cis	rs7523273	0.586	rs2761425	chr1:207894033	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-5.89	-0.35	1.29e-8	Schizophrenia;
KIRP	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg02495767	chr7:1030999	NA	-0.42	-5.82	-0.35	1.87e-8	Longevity;Endometriosis;
KIRP	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg02807482	chr3:125708958	NA	-0.54	-5.1	-0.31	6.86e-7	Blood pressure (smoking interaction);
KIRP	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	10.21	0.55	1.25e-20	Coffee consumption (cups per day);
KIRP	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg05887092	chr17:76393375	PGS1	0.52	7.09	0.41	1.41e-11	HDL cholesterol levels;
KIRP	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.57	7.19	0.42	7.56e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.66	10.09	0.54	3.04e-20	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs1973993	0.967	rs6679458	chr1:96946253	G/T	cg10631902	chr5:14652156	NA	0.63	9.43	0.52	3.2e-18	Weight;
KIRP	trans	rs7939886	0.764	rs7113688	chr11:55946865	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	trans	rs13170463	0.579	rs13157813	chr5:8051151	A/G	cg03862380	chr20:43029895	HNF4A	-0.42	-6.28	-0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs7602568	1.000	rs10865495	chr2:28585662	T/C	cg27432699	chr2:27873401	GPN1	-0.46	-5.12	-0.31	6.11e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg17145862	chr1:211918768	LPGAT1	0.76	10.56	0.56	9.48e-22	Leprosy;
KIRP	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02187348	chr16:89574699	SPG7	0.45	5.69	0.34	3.63e-8	Multiple myeloma (IgH translocation);
KIRP	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.47	-0.38	5.31e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg20090143	chr19:45452003	APOC2	0.33	5.32	0.32	2.31e-7	Blood protein levels;
KIRP	cis	rs4965006	0.749	rs6598176	chr12:132425448	A/G	cg00588090	chr12:132412438	PUS1	-0.53	-5.86	-0.35	1.52e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg09163369	chr1:210001066	C1orf107	0.49	5.38	0.32	1.7e-7	Orofacial clefts;
KIRP	cis	rs10267417	0.603	rs4275126	chr7:19911030	A/G	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.95	-13.27	-0.65	1.09e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12982744	0.613	rs2240658	chr19:2137870	C/T	cg09261902	chr19:2140048	AP3D1	0.44	5.68	0.34	3.77e-8	Osteoarthritis;Height;
KIRP	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg06060754	chr5:176797920	RGS14	0.46	6.99	0.41	2.54e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	10.35	0.55	4.53e-21	Hip circumference;
KIRP	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.73	-7.34	-0.42	3.18e-12	Bipolar disorder;
KIRP	trans	rs4349753	0.837	rs482011	chr5:144190911	C/T	cg16033277	chr17:80885358	TBCD	0.4	6.28	0.37	1.53e-9	Photic sneeze reflex;
KIRP	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg08499158	chr17:42289980	UBTF	-0.71	-9.64	-0.52	7.5e-19	Total body bone mineral density;
KIRP	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg26065057	chr18:74961000	GALR1	0.62	6.39	0.38	8.3e-10	Obesity-related traits;
KIRP	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.75	-11.46	-0.59	1.19e-24	Rheumatoid arthritis;
KIRP	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.03	-0.36	5.9e-9	Height;
KIRP	cis	rs9815354	1.000	rs9857175	chr3:41822054	T/G	cg03022575	chr3:42003672	ULK4	0.51	5.87	0.35	1.42e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs72843166	0.562	rs10491167	chr17:61426698	C/T	cg19683800	chr17:61518354	CYB561	-0.4	-5.1	-0.31	6.9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.2	16.63	0.73	3.86e-42	Type 1 diabetes nephropathy;
KIRP	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg01864069	chr14:103024347	NA	0.9	9.65	0.52	6.98e-19	Platelet count;
KIRP	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg23307798	chr14:103986281	CKB	-0.46	-6.35	-0.38	1.05e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.71	0.56	3.25e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.77	-8.32	-0.47	6.04e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.23	13.39	0.65	4.39e-31	Corneal structure;
KIRP	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.44	-15.64	-0.71	9.48e-39	Schizophrenia;
KIRP	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg18132916	chr6:79620363	NA	-0.41	-5.72	-0.34	3.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg17764715	chr19:33622953	WDR88	0.64	7.77	0.44	2.08e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	4.89	0.3	1.86e-6	Height;
KIRP	cis	rs1355223	0.533	rs1597960	chr11:34726969	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.13	-0.36	3.42e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.47	-0.33	1.11e-7	HDL cholesterol;
KIRP	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.52e-6	Red blood cell count;
KIRP	cis	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg00405596	chr8:11794950	NA	0.56	7.85	0.45	1.25e-13	Monocyte count;
KIRP	cis	rs988913	0.706	rs74714371	chr6:54959209	A/G	cg03513858	chr6:54763001	FAM83B	-0.36	-5.1	-0.31	6.64e-7	Menarche (age at onset);
KIRP	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg13180566	chr4:1052158	NA	-0.48	-4.89	-0.3	1.81e-6	Recombination rate (females);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14429979	chr11:1009801	AP2A2	0.5	6.1	0.36	4.13e-9	Interleukin-4 levels;
KIRP	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.78	7.78	0.44	1.98e-13	Hip geometry;
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg04369109	chr6:150039330	LATS1	0.5	6.25	0.37	1.84e-9	Lung cancer;
KIRP	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg25566285	chr7:158114605	PTPRN2	0.79	13.2	0.64	1.89e-30	Calcium levels;
KIRP	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-7.53	-0.43	9.35e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs950881	0.867	rs10197862	chr2:102966549	A/G	cg01254707	chr2:102953421	IL1RL1	-0.51	-5.14	-0.31	5.6e-7	Allergy;
KIRP	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.21e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.87	13.57	0.65	1.11e-31	Blood protein levels;
KIRP	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.95	-0.41	3.3e-11	Neuroticism;
KIRP	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	1.1	14.19	0.67	8.4e-34	Obesity-related traits;
KIRP	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.07	0.41	1.63e-11	Rheumatoid arthritis;
KIRP	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.39	-5.27	-0.32	2.92e-7	Blood metabolite levels;
KIRP	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg20607798	chr8:58055168	NA	0.62	4.85	0.3	2.2e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6142102	1.000	rs4911410	chr20:32710974	G/A	cg08999081	chr20:33150536	PIGU	0.55	6.98	0.41	2.78e-11	Skin pigmentation;
KIRP	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05025164	chr4:1340916	KIAA1530	0.45	5.86	0.35	1.51e-8	Obesity-related traits;
KIRP	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.82	-8.12	-0.46	2.19e-14	Coronary artery calcification;
KIRP	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.91	-14.72	-0.68	1.35e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-5.29	-0.32	2.66e-7	Height;
KIRP	cis	rs6753739	0.871	rs1869802	chr2:219977033	A/C	cg01749213	chr2:219906749	CCDC108	0.44	5.46	0.33	1.14e-7	Height;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.03	-0.36	5.96e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg09873164	chr1:152488093	CRCT1	0.51	6.43	0.38	6.44e-10	Hair morphology;
KIRP	cis	rs17221829	0.764	rs11605960	chr11:89418700	C/T	cg02982614	chr11:89391479	FOLH1B	-0.32	-4.97	-0.3	1.25e-6	Anxiety in major depressive disorder;
KIRP	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.72	-0.34	3.07e-8	Bipolar disorder;
KIRP	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.89	0.35	1.29e-8	Motion sickness;
KIRP	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07570687	chr10:102243282	WNT8B	0.54	7.11	0.41	1.25e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg00042356	chr1:8021962	PARK7	0.75	6.24	0.37	1.85e-9	Inflammatory bowel disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25949958	chr11:31833007	PAX6	-0.44	-6.54	-0.38	3.54e-10	Survival in pancreatic cancer;
KIRP	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	1.07	17.06	0.74	1.37e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.28	-0.32	2.85e-7	Life satisfaction;
KIRP	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg04519387	chr11:65556438	OVOL1	0.35	5.41	0.33	1.52e-7	Acne (severe);
KIRP	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.62	9.21	0.51	1.46e-17	Carotid intima media thickness;
KIRP	cis	rs6442310	0.534	rs1151997	chr3:12446004	A/G	cg22839075	chr3:12045461	SYN2	0.39	5.48	0.33	1.07e-7	Hematocrit;
KIRP	cis	rs42648	0.935	rs42629	chr7:89963324	G/T	cg25739043	chr7:89950458	NA	-0.45	-7.1	-0.41	1.32e-11	Homocysteine levels;
KIRP	cis	rs3733418	0.929	rs13134940	chr4:165889612	G/A	cg10852876	chr4:165953100	TRIM60	-0.51	-5.7	-0.34	3.43e-8	Obesity-related traits;
KIRP	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg04662943	chr10:102668895	NA	0.44	4.87	0.3	2.03e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12210905	1.000	rs9348752	chr6:27075483	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.54	-5.28	-0.32	2.81e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg15839431	chr19:19639596	YJEFN3	-0.5	-5.31	-0.32	2.47e-7	Bipolar disorder;
KIRP	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.37	-6.41	-0.38	7.44e-10	Heart rate;
KIRP	cis	rs7945071	0.507	rs7121928	chr11:110304603	A/G	cg04157658	chr11:110243994	NA	0.33	5.21	0.32	4.03e-7	Cognitive function;
KIRP	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg13736514	chr6:26305472	NA	-0.66	-8.7	-0.48	4.96e-16	Educational attainment;
KIRP	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	9.72	0.53	4.06e-19	Post bronchodilator FEV1;
KIRP	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg02073558	chr3:44770973	ZNF501	0.57	8.03	0.46	4.02e-14	Depressive symptoms;
KIRP	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.93	-11.38	-0.59	2.28e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg00484396	chr16:3507460	NAT15	0.61	5.96	0.36	8.47e-9	Tuberculosis;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg24023618	chr6:114292459	HDAC2	-0.49	-6.17	-0.37	2.74e-9	Neuroticism;
KIRP	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.59	7.89	0.45	1.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2820315	1.000	rs2820295	chr1:201800868	G/A	cg11586189	chr1:201857591	SHISA4	-0.4	-5.64	-0.34	4.68e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg04539111	chr16:67997858	SLC12A4	-0.44	-5.03	-0.31	9.26e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20677814	chr7:16656054	ANKMY2	-0.37	-6.07	-0.36	4.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg18132916	chr6:79620363	NA	-0.35	-4.87	-0.3	1.97e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.7e-6	Coronary artery disease;
KIRP	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21747090	chr2:27597821	SNX17	-0.49	-6.8	-0.4	8.03e-11	Total body bone mineral density;
KIRP	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.84	9.24	0.51	1.16e-17	High light scatter reticulocyte count;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-5.19	-0.31	4.45e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22281363	chr8:54899040	TCEA1	0.54	7.45	0.43	1.6e-12	Interleukin-4 levels;
KIRP	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg16672083	chr15:72433130	SENP8	-0.46	-6.34	-0.37	1.08e-9	Red blood cell count;
KIRP	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg08999081	chr20:33150536	PIGU	0.47	6.28	0.37	1.52e-9	Height;
KIRP	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg06012730	chr15:75315579	PPCDC	-0.42	-5.22	-0.32	3.88e-7	Blood trace element (Zn levels);
KIRP	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs6969780	0.778	rs2428434	chr7:27145735	T/A	cg26364809	chr7:27145159	NA	-0.62	-5.71	-0.34	3.22e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.37	6.33	0.37	1.18e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.46	-6.51	-0.38	4.28e-10	Menopause (age at onset);
KIRP	cis	rs588177	0.522	rs34358026	chr11:64015422	T/C	cg18225595	chr11:63971243	STIP1	0.62	5.42	0.33	1.41e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.43	0.38	6.77e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.71	-0.49	4.58e-16	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24641993	chr5:150537046	ANXA6	0.45	6.47	0.38	5.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg16141378	chr3:129829833	LOC729375	0.61	7.77	0.44	2.13e-13	Neuroticism;
KIRP	trans	rs2290402	0.536	rs2279175	chr4:852013	G/A	cg21249729	chr9:138392748	C9orf116;MRPS2	0.61	6.1	0.36	4.19e-9	Type 2 diabetes;
KIRP	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-10.5	-0.56	1.49e-21	Hepatocellular carcinoma;
KIRP	cis	rs1712790	0.639	rs11215194	chr11:114637837	A/T	cg19465033	chr11:114479364	NA	0.39	5.07	0.31	7.83e-7	Urinary albumin excretion;
KIRP	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.73	-9.01	-0.5	5.82e-17	Blood trace element (Zn levels);
KIRP	cis	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg12315302	chr6:26189340	HIST1H4D	0.79	5.51	0.33	8.84e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.8	9.29	0.51	8.59e-18	Smoking behavior;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.52	-6.35	-0.38	1.01e-9	Renal function-related traits (BUN);
KIRP	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.4	4.97	0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.37	-5.61	-0.34	5.47e-8	Mitochondrial DNA levels;
KIRP	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg23172400	chr8:95962367	TP53INP1	-0.28	-5.32	-0.32	2.3e-7	Type 2 diabetes;
KIRP	cis	rs3120667	0.720	rs72698974	chr1:152428847	T/C	cg26876637	chr1:152193138	HRNR	-0.65	-6.0	-0.36	7.07e-9	Eating disorders;
KIRP	cis	rs13185784	0.703	rs55756747	chr5:179675052	C/A	cg02891314	chr5:179741120	GFPT2	0.54	5.24	0.32	3.45e-7	TRAIL levels;
KIRP	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05220968	chr6:146057943	EPM2A	0.39	5.01	0.3	1.06e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.24	-0.42	5.62e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg27490568	chr2:178487706	NA	0.78	8.82	0.49	2.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17125719	chr8:71185581	NCOA2	-0.42	-6.15	-0.37	3.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	5.44	0.33	1.27e-7	Height;
KIRP	cis	rs7808935	0.914	rs11982766	chr7:27983781	C/T	cg05786569	chr7:27702416	HIBADH	0.51	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg23307798	chr14:103986281	CKB	-0.76	-12.97	-0.64	1.15e-29	Body mass index;
KIRP	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg00012203	chr2:219082015	ARPC2	0.66	8.66	0.48	6.27e-16	Colorectal cancer;
KIRP	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.8	8.54	0.48	1.38e-15	Resting heart rate;
KIRP	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.5	-6.19	-0.37	2.56e-9	Red blood cell count;
KIRP	cis	rs11078597	0.731	rs12946666	chr17:1651304	C/G	cg17514665	chr17:1657533	SERPINF2	0.45	5.55	0.33	7.24e-8	Serum albumin level;
KIRP	cis	rs13401104	0.796	rs719544	chr2:237118282	A/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.37	-4.9	-0.3	1.73e-6	Mean platelet volume;
KIRP	cis	rs4006360	0.524	rs4986678	chr17:39225182	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.65	-9.17	-0.5	1.89e-17	Bipolar disorder and schizophrenia;
KIRP	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8038465	0.874	rs12591553	chr15:73993755	G/A	cg15420318	chr15:73925796	NPTN	0.49	6.21	0.37	2.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg12560992	chr17:57184187	TRIM37	-0.55	-5.24	-0.32	3.44e-7	Cognitive test performance;
KIRP	cis	rs2562456	0.833	rs55875743	chr19:21566195	G/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.92	15.82	0.71	2.23e-39	Headache;
KIRP	cis	rs427941	0.632	rs201508	chr7:101764199	T/G	cg06246474	chr7:101738831	CUX1	0.53	6.48	0.38	5e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg00800569	chr2:239229395	TRAF3IP1	0.49	5.45	0.33	1.23e-7	Multiple system atrophy;
KIRP	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.72	0.49	4.09e-16	IgG glycosylation;
KIRP	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg25922239	chr6:33757077	LEMD2	0.63	7.15	0.41	9.64e-12	Crohn's disease;
KIRP	cis	rs4006360	0.601	rs7214364	chr17:39236678	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.66	-0.48	6.38e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg23736307	chr8:27182930	PTK2B	-0.56	-6.89	-0.4	4.67e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg20637307	chr2:213403960	ERBB4	0.5	6.86	0.4	5.55e-11	Symmetrical dimethylarginine levels;
KIRP	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Life satisfaction;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20385461	chr2:161342383	RBMS1	-0.37	-6.18	-0.37	2.68e-9	Inflammatory biomarkers;
KIRP	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg21605333	chr4:119757512	SEC24D	0.76	5.9	0.35	1.17e-8	Cannabis dependence symptom count;
KIRP	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.56	6.19	0.37	2.52e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg13902645	chr11:5959945	NA	-0.58	-6.17	-0.37	2.81e-9	DNA methylation (variation);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09654157	chr20:271184	C20orf96	-0.55	-6.04	-0.36	5.58e-9	Menopause (age at onset);
KIRP	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-5.82	-0.35	1.8e-8	Blood metabolite levels;
KIRP	cis	rs7243821	0.544	rs7232786	chr18:52574116	A/G	cg26630735	chr18:52626848	CCDC68	0.48	5.19	0.31	4.38e-7	Chin dimples;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4765905	1.000	rs2159100	chr12:2346393	C/T	cg10668781	chr12:2307325	CACNA1C	-0.27	-4.92	-0.3	1.59e-6	Schizophrenia;
KIRP	cis	rs16958440	1.000	rs62096469	chr18:44638298	A/G	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.72	0.34	3.11e-8	Personality dimensions;
KIRP	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg15655495	chr12:38532458	NA	-0.28	-5.09	-0.31	6.99e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg06204229	chr3:52865917	ITIH4	0.46	5.32	0.32	2.28e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	1.11	18.29	0.76	9.17e-48	Cognitive function;
KIRP	cis	rs4656940	0.574	rs536015	chr1:160764449	C/G	cg17331569	chr1:160788135	LY9	0.46	5.42	0.33	1.41e-7	Crohn's disease;
KIRP	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.66	6.54	0.38	3.57e-10	Axial length;
KIRP	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.42	-5.98	-0.36	7.72e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	1.04	14.76	0.69	9.78e-36	Cognitive function;
KIRP	cis	rs9549260	0.564	rs9577110	chr13:41271878	T/G	cg21288729	chr13:41239152	FOXO1	0.57	7.53	0.43	9.52e-13	Red blood cell count;
KIRP	cis	rs6445967	1.000	rs35495842	chr3:58310250	T/C	cg16569813	chr3:58235849	ABHD6	-0.35	-5.12	-0.31	6.23e-7	Platelet count;
KIRP	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg11987759	chr7:65425863	GUSB	-0.59	-7.99	-0.45	5.11e-14	Calcium levels;
KIRP	cis	rs4776059	0.761	rs61731670	chr15:52901283	T/C	cg25063058	chr15:52860530	ARPP19	-0.5	-4.88	-0.3	1.91e-6	Schizophrenia;
KIRP	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.87	-11.46	-0.59	1.16e-24	Type 2 diabetes;
KIRP	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-5.91	-0.35	1.15e-8	Personality dimensions;
KIRP	cis	rs7084402	0.967	rs1658485	chr10:60288331	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs4481887	0.573	rs4412629	chr1:248411399	G/T	cg01631408	chr1:248437212	OR2T33	-0.46	-5.84	-0.35	1.61e-8	Common traits (Other);
KIRP	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.55	13.9	0.66	8.45e-33	Airflow obstruction;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18679886	chr7:107531975	DLD	0.59	6.83	0.4	6.77e-11	Smoking initiation;
KIRP	cis	rs4805834	0.668	rs17272183	chr19:33321213	A/G	cg07201929	chr19:33182834	NUDT19	-0.59	-4.95	-0.3	1.4e-6	Creatinine levels;
KIRP	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg03563238	chr19:33554763	RHPN2	-0.32	-5.67	-0.34	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs687432	0.885	rs61904024	chr11:57822755	T/C	cg19752551	chr11:57585705	CTNND1	-0.67	-8.52	-0.48	1.66e-15	Parkinson's disease;
KIRP	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg10189774	chr4:17578691	LAP3	0.48	5.84	0.35	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg00147788	chr6:125855365	NA	-0.32	-5.0	-0.3	1.1e-6	Brugada syndrome;
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.37	0.65	5.21e-31	Platelet count;
KIRP	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.46	0.47	2.46e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs16857609	0.628	rs1478585	chr2:218334784	C/T	cg15335768	chr2:218268053	DIRC3	-0.36	-5.28	-0.32	2.82e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.83	8.66	0.48	6.45e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg00495681	chr13:53174319	NA	0.39	5.38	0.32	1.69e-7	Lewy body disease;
KIRP	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.49e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs62070183	0.882	rs62070164	chr17:31086433	T/C	cg05781649	chr17:31146240	MYO1D	-0.5	-4.98	-0.3	1.18e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2290402	0.536	rs3775127	chr4:886061	G/A	cg14517359	chr4:903473	GAK	-0.59	-5.98	-0.36	7.71e-9	Type 2 diabetes;
KIRP	cis	rs9880211	1.000	rs9809988	chr3:136522221	C/G	cg21827317	chr3:136751795	NA	-0.45	-4.88	-0.3	1.89e-6	Body mass index;Height;
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.8e-8	Lung cancer;
KIRP	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.89	9.88	0.53	1.3e-19	Gut microbiome composition (summer);
KIRP	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg10144569	chr3:42726640	KBTBD5	0.5	5.61	0.34	5.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.47	-6.82	-0.4	7.08e-11	Resting heart rate;
KIRP	cis	rs3120667	0.720	rs11577946	chr1:152412143	T/G	cg26876637	chr1:152193138	HRNR	-0.58	-5.37	-0.32	1.86e-7	Eating disorders;
KIRP	cis	rs7560272	0.723	rs7566315	chr2:73791808	C/T	cg20560298	chr2:73613845	ALMS1	-0.41	-5.03	-0.31	9.25e-7	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07717198	chr8:12521467	NA	-0.46	-7.13	-0.41	1.1e-11	Survival in pancreatic cancer;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg11693508	chr17:37793320	STARD3	0.76	7.93	0.45	7.82e-14	Bipolar disorder;
KIRP	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs6496667	0.821	rs28459968	chr15:90919002	C/G	cg10434728	chr15:90938212	IQGAP1	0.38	4.86	0.3	2.14e-6	Rheumatoid arthritis;
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg18402987	chr7:1209562	NA	0.42	4.84	0.3	2.26e-6	Longevity;Endometriosis;
KIRP	cis	rs780096	1.000	rs780095	chr2:27741105	A/G	cg21747090	chr2:27597821	SNX17	-0.36	-5.01	-0.3	1.04e-6	Total body bone mineral density;
KIRP	cis	rs12431939	1.000	rs12433445	chr14:51666091	G/A	cg23942311	chr14:51606299	NA	-0.6	-5.25	-0.32	3.36e-7	Cancer;
KIRP	cis	rs731174	0.921	rs6686264	chr1:38192337	A/T	cg06917450	chr1:38156652	C1orf109	-0.41	-4.9	-0.3	1.75e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2275565	0.810	rs4659735	chr1:237032925	G/A	cg17297354	chr1:237056641	MTR	-0.53	-5.82	-0.35	1.81e-8	Homocysteine levels;
KIRP	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.12	0.41	1.17e-11	Lung cancer;
KIRP	cis	rs300890	0.590	rs11100788	chr4:144316627	G/A	cg01719995	chr4:144104893	USP38	-0.42	-5.13	-0.31	5.82e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.43e-9	Obesity-related traits;
KIRP	cis	rs7973683	0.541	rs12309481	chr12:124389150	C/A	cg12597309	chr12:124393772	DNAH10	0.43	5.36	0.32	1.94e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	5.96	0.36	8.57e-9	Putamen volume;
KIRP	cis	rs59868192	0.925	rs113877402	chr15:42244923	C/T	cg20935245	chr15:42234343	EHD4	-0.55	-5.4	-0.33	1.58e-7	White blood cell count;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg05665937	chr4:1216051	CTBP1	0.44	5.63	0.34	4.96e-8	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg13409248	chr3:40428643	ENTPD3	0.37	5.14	0.31	5.64e-7	Renal cell carcinoma;
KIRP	cis	rs4791746	0.793	rs12603886	chr17:8651225	A/G	cg03115937	chr17:8649504	CCDC42	0.61	7.54	0.43	9.21e-13	Heroin dependence;
KIRP	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.6	6.99	0.41	2.56e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.4	-5.17	-0.31	4.75e-7	Menarche (age at onset);
KIRP	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.09e-8	Motion sickness;
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27189623	chr16:705930	WDR90	0.45	6.27	0.37	1.58e-9	Height;
KIRP	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg00277334	chr10:82204260	NA	-0.46	-5.43	-0.33	1.35e-7	Post bronchodilator FEV1;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg23736307	chr8:27182930	PTK2B	0.55	7.04	0.41	1.9e-11	Neuroticism;
KIRP	cis	rs4478858	0.698	rs6669381	chr1:31833506	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.41	-0.33	1.5e-7	Alcohol dependence;
KIRP	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	13.23	0.64	1.57e-30	Mean corpuscular hemoglobin;
KIRP	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.1	-0.36	4.15e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg04450003	chr12:50355995	AQP5	0.52	8.31	0.47	6.34e-15	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-6.45	-0.38	5.92e-10	Lung cancer;
KIRP	cis	rs4148087	0.530	rs221953	chr21:43608656	A/G	cg08841829	chr21:43638893	ABCG1	0.48	5.48	0.33	1.05e-7	Eating disorder in bipolar disorder;
KIRP	cis	rs7017914	0.967	rs10448014	chr8:71688165	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.85	9.07	0.5	3.77e-17	Platelet count;
KIRP	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg06121193	chr1:90282411	NA	-0.48	-6.82	-0.4	6.86e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg09491104	chr22:46646882	C22orf40	-0.57	-6.43	-0.38	6.43e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.8	6.94	0.4	3.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.63	8.26	0.47	9.11e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg02158880	chr13:53174818	NA	0.44	5.76	0.34	2.47e-8	Lewy body disease;
KIRP	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11987759	chr7:65425863	GUSB	0.49	6.37	0.38	9.01e-10	Aortic root size;
KIRP	trans	rs12517041	1.000	rs7723641	chr5:23298305	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.96	-0.5	8.24e-17	Calcium levels;
KIRP	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.29	0.58	4.35e-24	Height;
KIRP	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg01877450	chr7:97915802	BRI3	-0.52	-6.77	-0.4	9.18e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg17108064	chr15:78857060	CHRNA5	0.35	5.0	0.3	1.09e-6	Sudden cardiac arrest;
KIRP	cis	rs9311676	0.656	rs3191903	chr3:58382846	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.44	6.08	0.36	4.59e-9	Coronary artery disease;
KIRP	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg05044414	chr3:183734942	ABCC5	0.38	5.8	0.35	2.01e-8	Anterior chamber depth;
KIRP	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs13720	0.722	rs163800	chr20:57578508	C/T	cg23907860	chr20:57583709	CTSZ	0.5	5.48	0.33	1.03e-7	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18743068	chr10:94831650	NA	0.48	6.74	0.39	1.15e-10	Parkinson's disease;
KIRP	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.77	9.77	0.53	2.99e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	8.7	0.48	4.94e-16	Platelet count;
KIRP	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg04691961	chr3:161091175	C3orf57	-0.57	-8.97	-0.5	7.6e-17	Morning vs. evening chronotype;
KIRP	cis	rs7188697	0.922	rs37041	chr16:58579886	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.08	0.31	7.6e-7	QT interval;
KIRP	cis	rs4936894	0.500	rs4935873	chr11:124103523	G/T	cg27160556	chr11:124181099	OR8D1	-0.39	-5.85	-0.35	1.55e-8	Aging (time to death);
KIRP	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	5.19	0.31	4.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23544223	chr18:12777786	NA	0.69	6.08	0.36	4.61e-9	Inflammatory skin disease;
KIRP	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-0.77	-11.67	-0.6	2.41e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-12.17	-0.61	5.65e-27	Dental caries;
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg21698718	chr17:80085957	CCDC57	-0.36	-5.23	-0.32	3.6e-7	Life satisfaction;
KIRP	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.75	9.35	0.51	5.5e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg24881330	chr22:46731750	TRMU	0.73	5.45	0.33	1.24e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.87	12.44	0.62	7.07e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.72	10.24	0.55	9.88e-21	High light scatter reticulocyte count;
KIRP	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg01304814	chr3:48885189	PRKAR2A	0.52	4.85	0.3	2.15e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.87	13.0	0.64	9.24e-30	Eosinophil percentage of white cells;
KIRP	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.92	11.5	0.59	8.6e-25	Response to antineoplastic agents;
KIRP	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23903597	chr17:61704154	MAP3K3	-0.55	-6.62	-0.39	2.24e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs11220082	0.666	rs35203305	chr11:125338883	G/A	cg12585429	chr16:49889252	NA	0.49	6.04	0.36	5.62e-9	Schizophrenia;
KIRP	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.24	0.47	1.01e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.72	-0.34	3.02e-8	Body mass index;
KIRP	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg12549451	chr6:135224345	NA	0.44	5.58	0.34	6.33e-8	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25237056	chr15:91537958	PRC1	0.51	6.18	0.37	2.67e-9	Parkinson's disease;
KIRP	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg18882449	chr10:104885122	NT5C2	-0.41	-5.3	-0.32	2.54e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg23034840	chr1:205782522	SLC41A1	-0.54	-7.17	-0.42	8.53e-12	Menarche (age at onset);
KIRP	cis	rs6723108	0.651	rs6724774	chr2:135407285	C/T	cg25422880	chr2:135218333	TMEM163	0.34	5.04	0.31	8.92e-7	Type 2 diabetes;
KIRP	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg14345882	chr6:26364793	BTN3A2	0.55	4.97	0.3	1.26e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg00800038	chr16:89945340	TCF25	-0.88	-7.15	-0.41	9.67e-12	Skin colour saturation;
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg14338887	chr6:42928500	GNMT	0.47	7.0	0.41	2.35e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg23307798	chr14:103986281	CKB	-0.45	-6.04	-0.36	5.69e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-8.96	-0.5	8.36e-17	Lymphocyte counts;
KIRP	cis	rs2274273	0.615	rs67008693	chr14:55702693	T/C	cg04306507	chr14:55594613	LGALS3	0.42	5.58	0.34	6.4e-8	Protein biomarker;
KIRP	cis	rs6772849	0.930	rs9873888	chr3:128360987	G/A	cg08795948	chr3:128337044	NA	0.5	6.33	0.37	1.13e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.76	-0.63	6.06e-29	Electrocardiographic conduction measures;
KIRP	cis	rs4664304	0.620	rs2729705	chr2:160710922	T/C	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.68	-0.34	3.87e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11339840	chr1:203596058	ATP2B4	0.69	6.52	0.38	3.86e-10	Lung function (FEV1);
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg01763666	chr17:80159506	CCDC57	-0.39	-5.27	-0.32	3.02e-7	Life satisfaction;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03664139	chr6:101329504	ASCC3	0.69	6.34	0.37	1.12e-9	Lung function (FEV1);
KIRP	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg00784671	chr22:46762841	CELSR1	-0.76	-7.79	-0.44	1.87e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.13	-0.41	1.1e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.26	-0.32	3.2e-7	Coronary artery disease;
KIRP	cis	rs5167	0.566	rs60876330	chr19:45488133	C/T	cg13119609	chr19:45449297	APOC2	0.39	4.86	0.3	2.14e-6	Blood protein levels;
KIRP	cis	rs953387	1.000	rs4954567	chr2:136901587	G/T	cg05194412	chr2:137003533	NA	-0.42	-5.55	-0.33	7.31e-8	Arthritis (juvenile idiopathic);
KIRP	cis	rs13424612	0.839	rs4853976	chr2:240906028	T/C	cg19172429	chr2:240878313	NA	0.29	4.94	0.3	1.48e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.18e-13	Life satisfaction;
KIRP	cis	rs13102973	0.899	rs13127569	chr4:135900762	C/A	cg14419869	chr4:135874104	NA	0.48	7.52	0.43	1.02e-12	Subjective well-being;
KIRP	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs7267005	0.661	rs77189140	chr20:34368035	A/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9653442	0.564	rs4851261	chr2:100786717	A/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.27	-0.32	2.99e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg22764044	chr5:178986830	RUFY1	0.43	6.26	0.37	1.71e-9	Lung cancer;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-1.05	-20.37	-0.79	1.02e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	8.26	0.47	9.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4664293	0.836	rs13397597	chr2:160603595	A/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg01677386	chr11:118938358	VPS11	-0.54	-6.56	-0.39	3.16e-10	Coronary artery disease;
KIRP	cis	rs1829883	0.514	rs62375908	chr5:98753389	G/A	cg08333243	chr5:99726346	NA	0.38	5.16	0.31	4.99e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9398803	0.865	rs4565329	chr6:126752798	A/G	cg19875578	chr6:126661172	C6orf173	-0.54	-7.0	-0.41	2.36e-11	Male-pattern baldness;
KIRP	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-7.02	-0.41	2.21e-11	Coronary artery disease;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.16	-21.15	-0.8	2.89e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs16937956	0.657	rs16938063	chr11:8431657	G/T	cg08015107	chr11:8618950	NA	0.55	7.04	0.41	1.92e-11	Body mass index;
KIRP	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.63	7.86	0.45	1.21e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg20965017	chr5:231967	SDHA	0.54	6.18	0.37	2.63e-9	Breast cancer;
KIRP	cis	rs5756931	0.503	rs2012725	chr22:38536861	C/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-5.11	-0.31	6.36e-7	Triglycerides;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12523403	chr19:12779890	MORG1;C19orf56	0.45	6.07	0.36	4.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24564603	chr7:158456404	NCAPG2	0.41	4.95	0.3	1.4e-6	Height;
KIRP	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.42	5.28	0.32	2.83e-7	IgG glycosylation;
KIRP	cis	rs10875746	0.669	rs11168516	chr12:48702065	C/T	cg20731937	chr12:48336164	NA	0.48	6.21	0.37	2.25e-9	Longevity (90 years and older);
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg04369109	chr6:150039330	LATS1	-0.5	-6.39	-0.38	8.26e-10	Lung cancer;
KIRP	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.63	0.48	7.99e-16	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.71	-10.12	-0.54	2.44e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg22189786	chr22:42395067	WBP2NL	0.47	6.05	0.36	5.42e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01624937	chr1:43997446	PTPRF	-0.45	-6.1	-0.36	4.06e-9	Metabolic traits;
KIRP	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg06027949	chr8:82754900	SNX16	-0.61	-6.66	-0.39	1.75e-10	Diastolic blood pressure;
KIRP	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-5.29	-0.32	2.76e-7	Asthma;
KIRP	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg06671706	chr8:8559999	CLDN23	-0.52	-6.25	-0.37	1.78e-9	Obesity-related traits;
KIRP	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.48	6.56	0.39	3.17e-10	Migraine;
KIRP	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg13206674	chr6:150067644	NUP43	0.48	5.59	0.34	6.01e-8	Lung cancer;
KIRP	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.7	-6.9	-0.4	4.45e-11	Breast cancer;
KIRP	cis	rs1978968	0.763	rs9605479	chr22:18464611	T/C	cg02610425	chr22:18483192	MICAL3	0.35	5.24	0.32	3.41e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg02733842	chr7:1102375	C7orf50	0.59	6.02	0.36	6.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.74	-9.3	-0.51	7.89e-18	Aortic root size;
KIRP	cis	rs7551222	0.752	rs4252687	chr1:204497335	G/C	cg20240347	chr1:204465584	NA	-0.45	-8.58	-0.48	1.09e-15	Schizophrenia;
KIRP	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.24	6.75	0.4	1.07e-10	Type 2 diabetes;
KIRP	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.53	-0.38	3.74e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg02975922	chr3:195473998	MUC4	-0.46	-5.62	-0.34	5.04e-8	Pancreatic cancer;
KIRP	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg00361562	chr2:198649771	BOLL	-0.47	-5.0	-0.3	1.07e-6	Ulcerative colitis;
KIRP	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26734620	chr12:56694298	CS	-0.9	-8.33	-0.47	5.52e-15	Psoriasis vulgaris;
KIRP	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-7.04	-0.41	1.89e-11	Hypospadias;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18505103	chr19:3115035	GNA11	-0.54	-6.8	-0.4	8.1e-11	Parkinson's disease;
KIRP	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.72	6.22	0.37	2.14e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.6	0.39	2.45e-10	Educational attainment;
KIRP	cis	rs6539288	0.677	rs1348566	chr12:107325648	C/T	cg26297688	chr12:107349093	C12orf23	-0.38	-4.93	-0.3	1.53e-6	Total body bone mineral density;
KIRP	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs72720396	0.803	rs115552537	chr1:91190856	C/A	cg13456504	chr1:91191583	NA	0.57	6.16	0.37	2.9e-9	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.6	7.89	0.45	9.72e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13791938	chr3:42623511	SEC22C	0.53	6.53	0.38	3.77e-10	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00012992	chr14:61788345	PRKCH	0.43	6.07	0.36	4.7e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs56146971	0.763	rs12587463	chr14:91859967	C/T	cg16433844	chr14:91963127	SMEK1	-0.59	-5.37	-0.32	1.82e-7	Alzheimer disease and age of onset;
KIRP	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.61	7.14	0.41	1.04e-11	Type 2 diabetes;
KIRP	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16524936	chr4:1340807	KIAA1530	-0.47	-5.99	-0.36	7.52e-9	Longevity;
KIRP	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg08999081	chr20:33150536	PIGU	-0.41	-5.28	-0.32	2.88e-7	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15851312	chr15:73076263	ADPGK	0.45	6.35	0.38	1.05e-9	Survival in pancreatic cancer;
KIRP	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg13047869	chr3:10149882	C3orf24	0.49	4.88	0.3	1.88e-6	Alzheimer's disease;
KIRP	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.7	8.92	0.49	1.08e-16	Bladder cancer;
KIRP	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	cis	rs3935685	1.000	rs4886904	chr15:78027178	C/T	cg25212270	chr15:78015279	NA	0.52	5.29	0.32	2.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg19442545	chr10:75533431	FUT11	-0.39	-5.09	-0.31	7.18e-7	Inflammatory bowel disease;
KIRP	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density (age 0-15);
KIRP	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.86	13.53	0.65	1.47e-31	Prostate cancer;
KIRP	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.75	6.97	0.41	2.93e-11	Mean platelet volume;
KIRP	cis	rs13401104	0.796	rs72620806	chr2:237113736	C/T	cg19324714	chr2:237145437	ASB18	0.48	5.18	0.31	4.51e-7	Educational attainment;
KIRP	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.85	8.3	0.47	7.03e-15	Methadone dose in opioid dependence;
KIRP	cis	rs4594175	0.926	rs10138269	chr14:51615360	T/C	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.87	10.92	0.57	6.62e-23	Coronary artery disease;
KIRP	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.72	0.34	3.1e-8	Putamen volume;
KIRP	cis	rs4363385	0.510	rs55959888	chr1:152913490	A/G	cg13444842	chr1:152974279	SPRR3	-0.46	-6.61	-0.39	2.42e-10	Inflammatory skin disease;
KIRP	cis	rs10982256	0.774	rs7046135	chr9:117243809	T/C	cg13636371	chr9:117264095	DFNB31	-0.49	-6.87	-0.4	5.32e-11	Bipolar disorder;
KIRP	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	9.35	0.51	5.47e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs72820985	1.000	rs74030466	chr16:80843922	T/C	cg04448709	chr16:81349954	GAN	-0.49	-5.05	-0.31	8.46e-7	Breast cancer;
KIRP	cis	rs10203711	0.933	rs11695877	chr2:239585797	T/A	cg14580085	chr2:239553406	NA	0.4	5.13	0.31	5.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763512	0.504	rs58201617	chr17:35865451	G/T	cg16670864	chr17:35848621	DUSP14	0.43	5.33	0.32	2.17e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg22117172	chr7:91764530	CYP51A1	-0.44	-6.0	-0.36	6.84e-9	Breast cancer;
KIRP	cis	rs1978968	0.956	rs35089989	chr22:18424298	T/C	cg02610425	chr22:18483192	MICAL3	0.39	5.16	0.31	4.97e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06285648	chr15:57668812	CGNL1	0.6	7.86	0.45	1.21e-13	Parkinson's disease;
KIRP	cis	rs6696239	1.000	rs12140848	chr1:227776942	C/G	cg27395484	chr1:227557617	NA	0.45	4.98	0.3	1.18e-6	Height;
KIRP	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg01967586	chr1:228894546	NA	-0.33	-5.46	-0.33	1.17e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.87	0.35	1.42e-8	Diabetic retinopathy;
KIRP	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.01	-0.45	4.57e-14	Mean corpuscular volume;
KIRP	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg00806126	chr19:22604979	ZNF98	-0.69	-7.28	-0.42	4.61e-12	Pain;
KIRP	cis	rs6500550	0.630	rs8045058	chr16:3691655	C/G	cg07396092	chr16:3662230	BTBD12	-0.42	-5.09	-0.31	7.03e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs2882667	0.690	rs10463975	chr5:138263249	G/A	cg04439458	chr5:138467593	SIL1	-0.35	-4.9	-0.3	1.76e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg00405596	chr8:11794950	NA	-0.39	-4.92	-0.3	1.57e-6	Systolic blood pressure;
KIRP	cis	rs10267417	0.603	rs10216149	chr7:19909093	A/T	cg05791153	chr7:19748676	TWISTNB	0.5	5.13	0.31	6.01e-7	Night sleep phenotypes;
KIRP	cis	rs9913711	0.689	rs8076087	chr17:70136055	C/T	cg09344028	chr17:70110421	NA	-0.31	-6.13	-0.36	3.39e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg27205649	chr11:78285834	NARS2	-0.67	-7.69	-0.44	3.55e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.41	-5.57	-0.33	6.82e-8	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02950623	chr16:14379524	NA	0.5	6.2	0.37	2.31e-9	Parkinson's disease;
KIRP	cis	rs8067354	0.645	rs16943838	chr17:57839604	C/T	cg02344993	chr17:57696989	CLTC	0.56	5.01	0.3	1.06e-6	Hemoglobin concentration;
KIRP	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.99	0.5	6.79e-17	Menopause (age at onset);
KIRP	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	6.54	0.38	3.54e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8177876	0.908	rs80187824	chr16:81118680	T/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.47	7.15	0.41	9.94e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.72	-8.55	-0.48	1.33e-15	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.82e-7	Cognitive function;
KIRP	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg07689907	chr11:61582574	FADS1	0.58	6.78	0.4	8.61e-11	Red cell distribution width;Mean platelet volume;
KIRP	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg26727032	chr16:67993705	SLC12A4	-0.59	-5.41	-0.33	1.49e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.53	0.59	7.26e-25	Alzheimer's disease;
KIRP	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.67	-11.61	-0.59	3.94e-25	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg12315302	chr6:26189340	HIST1H4D	0.96	6.8	0.4	8.09e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs76917914	0.561	rs73492791	chr9:100833925	T/C	cg03040243	chr9:100819229	NANS	0.51	5.63	0.34	4.97e-8	Immature fraction of reticulocytes;
KIRP	cis	rs13161895	0.818	rs116463976	chr5:179484519	G/C	cg02702477	chr5:179499311	RNF130	1.03	7.14	0.41	1.03e-11	LDL cholesterol;
KIRP	cis	rs9403317	0.960	rs9389927	chr6:141839717	T/C	cg15052665	chr6:141804349	NA	0.42	5.12	0.31	6.27e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.4	6.64	0.39	2e-10	Renal cell carcinoma;
KIRP	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg06012730	chr15:75315579	PPCDC	-0.42	-5.22	-0.32	3.88e-7	Blood trace element (Zn levels);
KIRP	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg16306078	chr6:126000798	NA	-0.26	-4.97	-0.3	1.26e-6	Endometrial cancer;
KIRP	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-8.69	-0.48	5.34e-16	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs6688613	0.685	rs6427047	chr1:166914258	A/G	cg07049167	chr1:166818506	POGK	0.46	5.1	0.31	6.63e-7	Refractive astigmatism;
KIRP	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.71	-9.95	-0.54	7.87e-20	Hip circumference;
KIRP	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-5.81	-0.35	1.89e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5762813	0.561	rs73170679	chr22:29271088	G/T	cg02153584	chr22:29168773	CCDC117	0.6	5.3	0.32	2.63e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.73	5.98	0.36	7.76e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4751006	0.543	rs9794336	chr10:128777873	C/T	cg05702161	chr10:128779687	DOCK1	0.88	7.57	0.43	7.39e-13	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04640194	chr12:56754023	STAT2	0.53	6.1	0.36	4.07e-9	Smoking initiation;
KIRP	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.86	-10.29	-0.55	6.73e-21	Gut microbiome composition (winter);
KIRP	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	5.66	0.34	4.3e-8	Menopause (age at onset);
KIRP	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.57	-0.43	7.5e-13	Bipolar disorder;
KIRP	cis	rs7870753	0.838	rs10991352	chr9:99249548	A/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.91	-14.34	-0.67	2.57e-34	Height;
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg16341495	chr8:142228727	SLC45A4	0.41	5.15	0.31	5.43e-7	Immature fraction of reticulocytes;
KIRP	cis	rs914615	0.508	rs7535292	chr1:155127749	T/C	cg02153340	chr1:155202674	NA	-0.48	-7.3	-0.42	4.02e-12	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg26207909	chr14:103986467	CKB	0.39	4.95	0.3	1.37e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02018176	chr4:1364513	KIAA1530	0.45	5.65	0.34	4.33e-8	Longevity;
KIRP	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.79	-11.23	-0.58	6.72e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.54	6.94	0.4	3.41e-11	Longevity;
KIRP	cis	rs17321999	0.516	rs12472981	chr2:30502879	T/C	cg05247661	chr2:30472410	LBH	0.65	5.66	0.34	4.28e-8	Systemic lupus erythematosus;
KIRP	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg09631192	chr20:23583594	CST9	-0.52	-5.17	-0.31	4.9e-7	Chronic kidney disease;
KIRP	cis	rs1881396	0.891	rs62131879	chr2:27755112	T/G	cg27432699	chr2:27873401	GPN1	0.55	6.05	0.36	5.5e-9	Nonalcoholic fatty liver disease;
KIRP	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	9.88	0.53	1.34e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs742614	0.533	rs2103804	chr20:32425403	A/G	cg06304546	chr20:32448765	NA	0.77	11.84	0.6	6.92e-26	Stearic acid (18:0) levels;
KIRP	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg13264159	chr8:625131	ERICH1	-0.81	-6.55	-0.39	3.33e-10	IgG glycosylation;
KIRP	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.72	0.39	1.27e-10	Aortic root size;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.2	-0.37	2.32e-9	Lung cancer;
KIRP	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.62	-8.44	-0.47	2.68e-15	Response to temozolomide;
KIRP	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.56	-8.65	-0.48	6.66e-16	Longevity;
KIRP	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.83	-10.77	-0.57	2.1e-22	Platelet distribution width;
KIRP	cis	rs13095912	0.743	rs13076556	chr3:185339575	A/G	cg11274856	chr3:185301563	NA	0.66	8.4	0.47	3.52e-15	Systolic blood pressure;
KIRP	cis	rs7561273	0.609	rs2339945	chr2:24348096	G/A	cg20701182	chr2:24300061	SF3B14	0.49	6.06	0.36	5.18e-9	Quantitative traits;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.6e-7	Life satisfaction;
KIRP	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.82	12.06	0.61	1.24e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6676180	0.555	rs12060730	chr1:119770702	A/G	cg05756136	chr1:119680316	WARS2	-0.51	-7.23	-0.42	6.23e-12	Monobrow;
KIRP	cis	rs7394190	0.748	rs4746139	chr10:75407649	A/C	cg04833713	chr10:74871078	NUDT13	0.52	5.85	0.35	1.53e-8	Incident atrial fibrillation;
KIRP	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs7134594	0.539	rs7294688	chr12:110054765	C/G	cg05360138	chr12:110035743	NA	-0.5	-6.35	-0.38	1.01e-9	HDL cholesterol;
KIRP	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.9	-0.35	1.22e-8	LDL cholesterol levels;
KIRP	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg06121193	chr1:90282411	NA	-0.48	-6.94	-0.4	3.55e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs806321	0.534	rs1269274	chr13:50895638	A/T	cg10393508	chr13:50950265	NA	-0.45	-6.4	-0.38	7.59e-10	Multiple sclerosis;
KIRP	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.32	-6.1	-0.36	4.15e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.75	-0.49	3.41e-16	Mean corpuscular volume;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg04025307	chr7:1156635	C7orf50	0.81	8.26	0.47	9.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.69	-9.05	-0.5	4.5e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg13180566	chr4:1052158	NA	0.52	5.36	0.32	1.91e-7	Recombination rate (females);
KIRP	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.2	0.42	7.23e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6693295	0.752	rs2787964	chr1:246236017	A/G	cg11798871	chr1:246315928	SMYD3	-0.38	-4.85	-0.3	2.2e-6	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.77	10.02	0.54	4.88e-20	Mood instability;
KIRP	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg19468946	chr17:37922297	IKZF3	-0.38	-5.16	-0.31	5.11e-7	Asthma;
KIRP	cis	rs17655565	0.581	rs7958384	chr12:52767429	T/C	cg07925835	chr12:52762777	KRT85	0.49	5.16	0.31	4.99e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.62	-10.1	-0.54	2.76e-20	Morning vs. evening chronotype;
KIRP	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg25007680	chr1:8021821	PARK7	0.63	8.66	0.48	6.41e-16	Response to antidepressants and depression;
KIRP	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg23594656	chr7:65796392	TPST1	0.5	7.69	0.44	3.45e-13	Aortic root size;
KIRP	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.56	7.35	0.42	2.94e-12	Hip circumference;
KIRP	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg12560992	chr17:57184187	TRIM37	0.52	6.09	0.36	4.22e-9	Cognitive test performance;
KIRP	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg14972814	chr11:95582409	MTMR2	0.33	5.08	0.31	7.46e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	5.66	0.34	4.26e-8	Height;
KIRP	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.24	23.56	0.83	5.08e-65	IgG glycosylation;
KIRP	cis	rs4654899	1.000	rs7554997	chr1:21400139	C/T	cg05370193	chr1:21551575	ECE1	0.44	6.13	0.36	3.5e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.87	11.04	0.58	2.84e-23	Eosinophil percentage of granulocytes;
KIRP	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.83	-0.49	2.01e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg17724175	chr1:150552817	MCL1	0.36	5.72	0.34	3.16e-8	Melanoma;
KIRP	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.5	6.25	0.37	1.84e-9	Breast cancer;
KIRP	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.64	-7.62	-0.44	5.57e-13	Iron status biomarkers;
KIRP	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2057178	0.745	rs12280757	chr11:32353264	G/A	cg07934552	chr11:32355483	NA	0.42	5.09	0.31	7.12e-7	Tuberculosis;
KIRP	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.77	8.68	0.48	5.52e-16	Corneal astigmatism;
KIRP	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg03171003	chr2:111875934	NA	0.41	5.81	0.35	1.93e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg26874164	chr19:58962979	ZNF324B	0.47	5.54	0.33	7.6e-8	Uric acid clearance;
KIRP	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.44	-0.33	1.27e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3126085	0.560	rs1923505	chr1:152359837	T/C	cg26876637	chr1:152193138	HRNR	-0.71	-7.13	-0.41	1.1e-11	Atopic dermatitis;
KIRP	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg08648136	chr8:956695	NA	0.41	5.59	0.34	6.06e-8	Schizophrenia;
KIRP	cis	rs1468333	1.000	rs7735635	chr5:137508336	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.47	-5.21	-0.32	3.9e-7	Resting heart rate;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-5.73	-0.34	2.89e-8	Longevity;Endometriosis;
KIRP	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.53	7.01	0.41	2.31e-11	Aortic root size;
KIRP	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.53	7.6	0.44	6.36e-13	Major depressive disorder;
KIRP	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.32	-0.32	2.32e-7	Chronic sinus infection;
KIRP	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.42	5.21	0.32	4.04e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs11169552	0.510	rs12231309	chr12:51041062	C/T	cg12884762	chr12:50931848	DIP2B	-0.43	-5.1	-0.31	6.73e-7	Colorectal cancer;
KIRP	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2904967	0.810	rs507005	chr11:65045615	T/C	cg09225861	chr11:65069680	NA	0.44	5.77	0.35	2.41e-8	Mean corpuscular volume;
KIRP	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.84	11.37	0.59	2.3e-24	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg21095983	chr6:86352623	SYNCRIP	0.51	6.74	0.39	1.11e-10	Smooth-surface caries;
KIRP	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg04935436	chr20:30431758	NA	0.5	5.88	0.35	1.35e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs4656940	0.574	rs512197	chr1:160766660	G/A	cg17331569	chr1:160788135	LY9	0.44	5.28	0.32	2.8e-7	Crohn's disease;
KIRP	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg25356066	chr3:128598488	ACAD9	0.47	5.43	0.33	1.34e-7	IgG glycosylation;
KIRP	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg08648136	chr8:956695	NA	0.44	5.72	0.34	3.08e-8	Schizophrenia;
KIRP	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-1.0	-11.67	-0.6	2.48e-25	White matter hyperintensity burden;
KIRP	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg07395648	chr5:131743802	NA	0.54	7.79	0.44	1.84e-13	Blood metabolite levels;
KIRP	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.09	-12.09	-0.61	1.04e-26	Vitiligo;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10724490	chr7:6523886	KDELR2	0.52	6.66	0.39	1.8e-10	Myopia (pathological);
KIRP	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.53	6.93	0.4	3.63e-11	Cognitive function;
KIRP	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.64	8.41	0.47	3.29e-15	Aortic root size;
KIRP	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg18753928	chr3:113234510	CCDC52	-0.52	-6.66	-0.39	1.8e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg07843065	chr1:150265600	MRPS21	0.44	5.95	0.35	8.97e-9	Migraine;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23501468	chr14:73606606	PSEN1	0.46	6.85	0.4	6.04e-11	C-reactive protein;
KIRP	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg15534755	chr11:117069859	TAGLN	0.4	4.95	0.3	1.36e-6	Blood protein levels;
KIRP	cis	rs4765905	0.610	rs7133502	chr12:2303486	G/A	cg10668781	chr12:2307325	CACNA1C	-0.35	-6.9	-0.4	4.33e-11	Schizophrenia;
KIRP	cis	rs4006360	0.542	rs9900575	chr17:39307675	C/T	cg25341923	chr17:39239918	KRTAP4-7	0.43	5.74	0.34	2.84e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs829661	0.793	rs2593448	chr2:30828334	A/G	cg10949345	chr2:30726833	LCLAT1	1.14	13.87	0.66	1.03e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.14	-0.31	5.61e-7	Height;
KIRP	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.76	-8.73	-0.49	4.02e-16	Diastolic blood pressure;
KIRP	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.56	-6.56	-0.39	3.23e-10	HDL cholesterol;
KIRP	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg06636001	chr8:8085503	FLJ10661	0.75	10.23	0.55	1.09e-20	Mood instability;
KIRP	cis	rs9426935	0.527	rs7521047	chr1:154076366	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.34	4.91	0.3	1.68e-6	Lentiform nucleus volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06975592	chr1:165796857	UCK2	0.57	6.64	0.39	1.98e-10	Smoking initiation;
KIRP	cis	rs28834970	0.675	rs6557994	chr8:27232018	A/G	cg23736307	chr8:27182930	PTK2B	-0.44	-5.16	-0.31	5.06e-7	Alzheimer's disease (late onset);
KIRP	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg25486957	chr4:152246857	NA	-0.41	-4.88	-0.3	1.9e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	20.06	0.79	1.09e-53	Exhaled nitric oxide output;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24449302	chr15:66679100	MAP2K1	-0.45	-6.63	-0.39	2.06e-10	Metabolic traits;
KIRP	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	11.18	0.58	9.79e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	8.04	0.46	3.83e-14	Systemic lupus erythematosus;
KIRP	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg11735605	chr2:214016230	IKZF2	-0.45	-6.08	-0.36	4.58e-9	Obesity-related traits;
KIRP	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg13010199	chr12:38710504	ALG10B	0.52	6.54	0.38	3.52e-10	Morning vs. evening chronotype;
KIRP	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg26784012	chr10:32216390	ARHGAP12	0.3	4.86	0.3	2.1e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.7	10.79	0.57	1.75e-22	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9962915	1.000	rs1785416	chr18:5599104	T/C	cg12967001	chr18:5544089	EPB41L3	-0.4	-5.0	-0.3	1.09e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs7017914	0.902	rs1373480	chr8:71686967	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg26681399	chr22:41777847	TEF	-0.52	-4.85	-0.3	2.22e-6	Vitiligo;
KIRP	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.42	4.88	0.3	1.87e-6	Menopause (age at onset);
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.48	5.59	0.34	6.09e-8	Glycated hemoglobin levels;
KIRP	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.58	-0.39	2.74e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	6.91	0.4	4.21e-11	Bipolar disorder;
KIRP	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg24304309	chr1:154577895	ADAR	0.34	5.07	0.31	7.72e-7	Blood protein levels;
KIRP	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-1.01	-18.48	-0.76	2.06e-48	Height;
KIRP	cis	rs7005380	0.581	rs6469866	chr8:120911297	G/T	cg21645572	chr8:120931649	DEPDC6	0.48	6.76	0.4	9.7e-11	Interstitial lung disease;
KIRP	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg03959625	chr15:84868606	LOC388152	0.55	6.63	0.39	2.15e-10	Schizophrenia;
KIRP	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.77	12.03	0.61	1.59e-26	Colorectal cancer;
KIRP	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg14952266	chr13:112191215	NA	0.45	6.6	0.39	2.52e-10	Hepatitis;
KIRP	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg05527609	chr1:210001259	C1orf107	-0.43	-5.27	-0.32	3.01e-7	Red blood cell count;
KIRP	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-11.84	-0.6	7e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-11.42	-0.59	1.57e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.45	0.52	2.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg12705353	chr12:122356852	WDR66	0.41	5.51	0.33	9.15e-8	Mean corpuscular volume;
KIRP	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.44	-5.44	-0.33	1.26e-7	Educational attainment (years of education);
KIRP	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg26205652	chr12:48591994	NA	0.47	5.28	0.32	2.85e-7	Lung cancer;
KIRP	cis	rs16936870	0.543	rs71517440	chr8:71204419	C/A	cg14232793	chr8:71155543	NCOA2	0.5	5.68	0.34	3.77e-8	QT interval;
KIRP	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17252645	chr8:143867129	LY6D	-0.54	-9.76	-0.53	3.07e-19	Urinary tract infection frequency;
KIRP	cis	rs918629	0.530	rs3777190	chr5:95247972	A/G	cg16656078	chr5:95278638	ELL2	0.39	5.94	0.35	9.44e-9	IgG glycosylation;
KIRP	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg13978929	chr19:21580086	ZNF493	-0.51	-5.04	-0.31	9e-7	Pain;
KIRP	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.78	8.67	0.48	5.75e-16	Corneal astigmatism;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg10207240	chr12:122356781	WDR66	0.58	7.81	0.45	1.69e-13	Mean corpuscular volume;
KIRP	cis	rs10875746	0.623	rs10875793	chr12:48697430	T/A	cg24011408	chr12:48396354	COL2A1	-0.45	-5.06	-0.31	8.26e-7	Longevity (90 years and older);
KIRP	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.12	-0.31	6.26e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg21775007	chr8:11205619	TDH	0.43	5.42	0.33	1.43e-7	Monocyte count;
KIRP	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg16497661	chr14:103986332	CKB	0.5	6.41	0.38	7.28e-10	Coronary artery disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.73	6.28	0.37	1.49e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg20991723	chr1:152506922	NA	-0.45	-5.29	-0.32	2.7e-7	Hair morphology;
KIRP	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.33	-0.32	2.22e-7	Pulmonary function;
KIRP	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.64	8.96	0.5	8.16e-17	Lymphocyte counts;
KIRP	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.51	7.51	0.43	1.08e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.64	9.51	0.52	1.81e-18	Prostate cancer;
KIRP	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.48	6.35	0.38	1.06e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs282587	0.502	rs393244	chr13:113416977	C/T	cg04656015	chr13:113407548	ATP11A	0.59	6.36	0.38	9.76e-10	Glycated hemoglobin levels;
KIRP	cis	rs6120849	0.754	rs6088678	chr20:33607551	A/G	cg24642439	chr20:33292090	TP53INP2	-0.63	-6.38	-0.38	8.71e-10	Protein C levels;
KIRP	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg01843034	chr6:37503916	NA	-0.96	-15.54	-0.7	2.13e-38	Cognitive performance;
KIRP	cis	rs6001982	0.584	rs1106673	chr22:40825814	G/A	cg07138101	chr22:40742427	ADSL	0.68	5.24	0.32	3.4e-7	Breast cancer;
KIRP	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg19875578	chr6:126661172	C6orf173	0.47	6.08	0.36	4.5e-9	Male-pattern baldness;
KIRP	cis	rs4356932	0.691	rs2242473	chr4:76878956	G/A	cg19388996	chr4:76862389	NAAA	-0.42	-5.37	-0.32	1.8e-7	Blood protein levels;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg14514174	chr9:99181512	ZNF367	-0.47	-6.27	-0.37	1.64e-9	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.71	-9.46	-0.52	2.54e-18	Personality dimensions;
KIRP	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.66	-8.3	-0.47	6.82e-15	Facial morphology (factor 23);
KIRP	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	5.97	0.36	8.34e-9	Personality dimensions;
KIRP	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.63	7.83	0.45	1.45e-13	Alcohol dependence;
KIRP	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.96	-8.0	-0.45	4.86e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1318772	0.577	rs13358293	chr5:112976714	G/C	cg12552261	chr5:112820674	MCC	0.79	5.3	0.32	2.61e-7	F-cell distribution;
KIRP	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.78	0.44	2e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs78487399	0.908	rs72868636	chr2:43838516	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.05	-0.31	8.43e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.77	9.63	0.52	7.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7536201	0.967	rs11249212	chr1:25293201	A/G	cg23273869	chr1:25296894	NA	-0.36	-5.04	-0.31	8.85e-7	Psoriasis vulgaris;
KIRP	cis	rs2859741	0.546	rs3934329	chr1:37504523	C/T	cg09363841	chr1:37513479	NA	-0.37	-5.33	-0.32	2.28e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-6.11	-0.36	3.93e-9	Response to antipsychotic treatment;
KIRP	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.59	-9.46	-0.52	2.68e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.03	-0.31	9.45e-7	Carotid intima media thickness;
KIRP	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg24879335	chr3:133465180	TF	0.5	7.99	0.45	5.16e-14	Iron status biomarkers;
KIRP	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg04166393	chr7:2884313	GNA12	-0.57	-6.85	-0.4	5.78e-11	Height;
KIRP	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.36	5.77	0.35	2.35e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7584330	0.504	rs11884519	chr2:238425283	T/C	cg14458575	chr2:238380390	NA	0.49	5.92	0.35	1.07e-8	Prostate cancer;
KIRP	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs687432	0.924	rs7946468	chr11:57729298	C/T	cg19752551	chr11:57585705	CTNND1	-0.54	-7.43	-0.43	1.82e-12	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02645710	chr12:85430085	TSPAN19;LRRIQ1	0.44	6.5	0.38	4.5e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03041860	chr2:208489911	FAM119A	0.47	6.15	0.37	3.08e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4660306	0.677	rs1691217	chr1:45900190	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.1	0.36	4.16e-9	Homocysteine levels;
KIRP	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg12623918	chr2:306882	NA	0.4	5.01	0.3	1.06e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg27411982	chr8:10470053	RP1L1	-0.43	-5.7	-0.34	3.4e-8	Neuroticism;
KIRP	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.59	7.69	0.44	3.62e-13	Vitiligo;
KIRP	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg25801113	chr15:45476975	SHF	-0.44	-8.11	-0.46	2.41e-14	Uric acid levels;
KIRP	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg14820908	chr5:178986412	RUFY1	0.39	5.42	0.33	1.42e-7	Lung cancer;
KIRP	cis	rs4663866	1.000	rs71426510	chr2:239178909	T/G	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg11262906	chr1:85462892	MCOLN2	0.5	5.64	0.34	4.6e-8	Serum sulfate level;
KIRP	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-5.92	-0.35	1.09e-8	Adiposity;
KIRP	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	1.14	10.8	0.57	1.68e-22	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	10.45	0.55	2.12e-21	Hip circumference;
KIRP	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.55	-6.34	-0.37	1.09e-9	Adiposity;
KIRP	cis	rs10936797	0.775	rs34647670	chr3:174222301	A/T	cg17069914	chr3:174162456	NA	-0.33	-4.96	-0.3	1.3e-6	Obesity-related traits;
KIRP	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg08975724	chr8:8085496	FLJ10661	0.6	7.58	0.44	7.06e-13	Retinal vascular caliber;
KIRP	cis	rs12050794	0.671	rs7179427	chr15:72516821	G/A	cg16672083	chr15:72433130	SENP8	0.39	5.51	0.33	8.97e-8	Metabolite levels (HVA/MHPG ratio);
KIRP	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	1.15	9.37	0.51	4.99e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10073892	1.000	rs62369275	chr5:101699104	G/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.96e-11	Cognitive decline (age-related);
KIRP	cis	rs12220238	0.722	rs4745750	chr10:76394003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.53	6.06	0.36	4.99e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg13482628	chr17:19912719	NA	0.57	7.94	0.45	7.2e-14	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg21546286	chr11:48923668	NA	-0.47	-5.94	-0.35	9.61e-9	HDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09761506	chr2:148815999	NA	-0.41	-6.57	-0.39	2.93e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg27624424	chr6:160112604	SOD2	0.47	4.95	0.3	1.4e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.59	7.32	0.42	3.55e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.45	5.87	0.35	1.4e-8	Height;
KIRP	cis	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg21775007	chr8:11205619	TDH	0.7	9.66	0.52	6.43e-19	Retinal vascular caliber;
KIRP	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg03808351	chr9:123631620	PHF19	0.46	6.49	0.38	4.8e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg25124228	chr12:125621409	AACS	-0.75	-9.06	-0.5	4.17e-17	Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.71	9.34	0.51	5.87e-18	Morning vs. evening chronotype;
KIRP	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg14673194	chr17:80132900	CCDC57	-0.65	-7.06	-0.41	1.65e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg15599146	chr6:157802928	ZDHHC14	0.53	6.69	0.39	1.52e-10	Colorectal cancer;
KIRP	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg13395646	chr4:1353034	KIAA1530	-0.44	-5.89	-0.35	1.28e-8	Longevity;
KIRP	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07685180	chr8:600429	NA	0.7	5.17	0.31	4.83e-7	IgG glycosylation;
KIRP	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.89	-12.07	-0.61	1.17e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.29	0.42	4.15e-12	Coronary artery disease;
KIRP	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg26207909	chr14:103986467	CKB	-0.49	-6.19	-0.37	2.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9547996	0.879	rs2007577	chr13:38191143	T/C	cg13634560	chr13:38173852	POSTN	-0.4	-5.56	-0.33	6.86e-8	Diastolic blood pressure;
KIRP	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-11.06	-0.58	2.42e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.59	6.86	0.4	5.69e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.45e-8	Schizophrenia;
KIRP	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.67	8.96	0.5	8.23e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.65	-9.76	-0.53	3.11e-19	Total body bone mineral density;
KIRP	cis	rs7937612	0.965	rs9633919	chr11:120249493	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.79	-0.4	8.54e-11	Intraocular pressure;
KIRP	cis	rs9921338	0.923	rs6498181	chr16:11427193	C/T	cg00044050	chr16:11439710	C16orf75	-0.52	-5.59	-0.34	5.87e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg11608241	chr8:8085544	FLJ10661	-0.45	-5.55	-0.33	7.47e-8	Joint mobility (Beighton score);
KIRP	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.69	0.48	5.25e-16	Motion sickness;
KIRP	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13047869	chr3:10149882	C3orf24	0.56	5.63	0.34	4.97e-8	Alzheimer's disease;
KIRP	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg23514324	chr3:12329213	PPARG	0.64	6.78	0.4	8.82e-11	LDL cholesterol;
KIRP	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.65	8.82	0.49	2.21e-16	Alcohol dependence;
KIRP	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg19445457	chr11:5799446	OR52N5	-0.42	-5.03	-0.31	9.38e-7	DNA methylation (variation);
KIRP	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.05	20.04	0.79	1.24e-53	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.81	10.6	0.56	7.26e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs829883	0.724	rs11109508	chr12:98905985	T/C	cg25150519	chr12:98850993	NA	-0.76	-9.52	-0.52	1.68e-18	Colorectal adenoma (advanced);
KIRP	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.54	-0.43	9.31e-13	Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.73	-9.18	-0.51	1.78e-17	Aortic root size;
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg10253484	chr15:75165896	SCAMP2	-0.42	-4.91	-0.3	1.65e-6	Breast cancer;
KIRP	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg05791153	chr7:19748676	TWISTNB	0.64	5.72	0.34	3.08e-8	Thyroid stimulating hormone;
KIRP	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg09904177	chr6:26538194	HMGN4	-0.42	-5.17	-0.31	4.84e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8067545	0.512	rs34726000	chr17:19887821	G/T	cg13482628	chr17:19912719	NA	0.44	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06544989	chr22:39130855	UNC84B	0.46	7.99	0.45	5.1e-14	Menopause (age at onset);
KIRP	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.98	8.67	0.48	5.92e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.32	8.4	0.47	3.57e-15	Crohn's disease;
KIRP	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.72	0.34	3.03e-8	Renal cell carcinoma;
KIRP	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-8.74	-0.49	3.75e-16	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.66e-7	Body mass index;
KIRP	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Bladder cancer;
KIRP	cis	rs397969	0.596	rs12450857	chr17:19895248	C/T	cg04132472	chr17:19861366	AKAP10	0.44	5.18	0.31	4.66e-7	Platelet count;
KIRP	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.7	7.51	0.43	1.08e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs631288	0.793	rs894473	chr1:146687789	A/G	cg25205988	chr1:146714368	CHD1L	0.96	5.38	0.32	1.77e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.56	7.31	0.42	3.76e-12	Longevity;
KIRP	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg15556689	chr8:8085844	FLJ10661	0.61	7.66	0.44	4.16e-13	Neuroticism;
KIRP	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.88	-13.81	-0.66	1.63e-32	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15833209	chr5:176778672	LMAN2	0.52	6.55	0.39	3.39e-10	Parkinson's disease;
KIRP	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	0.9	12.62	0.63	1.7e-28	Primary sclerosing cholangitis;
KIRP	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg08017634	chr8:144659831	NAPRT1	0.81	5.27	0.32	2.92e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.74	-0.49	3.58e-16	Mean corpuscular volume;
KIRP	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-5.68	-0.34	3.84e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.9	14.79	0.69	7.77e-36	Breast cancer;
KIRP	cis	rs4073416	0.527	rs1959144	chr14:65946051	T/G	cg03016385	chr14:66212404	NA	-0.55	-6.72	-0.39	1.24e-10	N-glycan levels;
KIRP	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.61	7.41	0.43	2.02e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg26116260	chr4:7069785	GRPEL1	-0.79	-6.71	-0.39	1.29e-10	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg21548813	chr6:291882	DUSP22	-0.59	-6.91	-0.4	4.15e-11	Menopause (age at onset);
KIRP	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.25	-13.49	-0.65	2.09e-31	Hip circumference adjusted for BMI;
KIRP	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.76	6.8	0.4	7.8e-11	Diabetic retinopathy;
KIRP	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg02023728	chr11:77925099	USP35	-0.31	-5.38	-0.32	1.75e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.59	6.04	0.36	5.75e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg27068330	chr11:65405492	SIPA1	-0.41	-4.94	-0.3	1.46e-6	Acne (severe);
KIRP	cis	rs2908197	0.737	rs59755579	chr7:75992444	C/G	cg22830091	chr7:75961684	YWHAG	-0.38	-4.89	-0.3	1.82e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.75	9.4	0.51	4.04e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-6.94	-0.4	3.47e-11	Daytime sleep phenotypes;
KIRP	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg11508081	chr17:41442227	NA	0.37	4.9	0.3	1.77e-6	Menopause (age at onset);
KIRP	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg04691961	chr3:161091175	C3orf57	0.52	8.19	0.46	1.44e-14	Morning vs. evening chronotype;
KIRP	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg13010199	chr12:38710504	ALG10B	-0.38	-4.98	-0.3	1.17e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg16586182	chr3:47516702	SCAP	0.75	9.98	0.54	6.33e-20	Colorectal cancer;
KIRP	cis	rs2733310	0.947	rs1657922	chr15:57178132	C/T	cg13626582	chr15:57592083	LOC283663	-0.23	-5.54	-0.33	7.62e-8	Mean platelet volume;
KIRP	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.15	-0.46	1.87e-14	Body mass index;
KIRP	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg20744362	chr22:50050164	C22orf34	0.33	5.39	0.32	1.67e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg04935436	chr20:30431758	NA	0.48	6.42	0.38	6.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.29	-0.78	4.04e-51	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg13385521	chr17:29058706	SUZ12P	0.77	6.52	0.38	3.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs78487399	0.808	rs1388387	chr2:43736969	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-4.97	-0.3	1.28e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.42	-6.87	-0.4	5.21e-11	Eye color traits;
KIRP	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.48	4.98	0.3	1.22e-6	Diastolic blood pressure;
KIRP	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.7	8.5	0.48	1.89e-15	Blood metabolite levels;
KIRP	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg18944383	chr4:111397179	ENPEP	0.46	7.27	0.42	4.66e-12	Coronary artery disease;
KIRP	trans	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.49	6.57	0.39	3e-10	Brugada syndrome;
KIRP	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	0.94	9.78	0.53	2.74e-19	Height;
KIRP	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.78	9.44	0.52	3.05e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs71277158	0.688	rs73879163	chr3:169770802	T/C	cg04067573	chr3:169899625	PHC3	0.59	5.37	0.32	1.8e-7	Prostate cancer;
KIRP	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27297192	chr10:134578999	INPP5A	0.48	6.09	0.36	4.42e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2387326	0.767	rs12264157	chr10:129943271	G/A	cg16087940	chr10:129947807	NA	-0.36	-4.85	-0.3	2.24e-6	Select biomarker traits;
KIRP	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg06634786	chr22:41940651	POLR3H	-0.49	-5.42	-0.33	1.39e-7	Neuroticism;
KIRP	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-5.98	-0.36	7.88e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.67	9.57	0.52	1.18e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.65	-0.34	4.35e-8	Life satisfaction;
KIRP	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1847202	0.963	rs34317383	chr3:72946652	A/C	cg06781948	chr3:72941472	GXYLT2	0.39	5.21	0.32	4.04e-7	Motion sickness;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg12713142	chr12:57081325	PTGES3	0.66	6.15	0.37	3.07e-9	Lung function (FEV1);
KIRP	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg17356467	chr2:100759845	AFF3	0.55	5.65	0.34	4.5e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg16898833	chr6:26189333	HIST1H4D	0.72	5.02	0.3	9.98e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-0.72	-6.35	-0.38	1.01e-9	Obesity-related traits;
KIRP	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-5.25	-0.32	3.22e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.39	-0.32	1.66e-7	Metabolite levels;
KIRP	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg00405596	chr8:11794950	NA	-0.49	-6.32	-0.37	1.25e-9	Retinal vascular caliber;
KIRP	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.01	-0.46	4.45e-14	Joint mobility (Beighton score);
KIRP	cis	rs12476592	0.602	rs2028887	chr2:63716223	A/G	cg17519650	chr2:63277830	OTX1	-0.4	-5.07	-0.31	7.86e-7	Childhood ear infection;
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.77	0.63	5.54e-29	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17716453	chr19:15619355	CYP4F22	0.47	6.2	0.37	2.4e-9	Parkinson's disease;
KIRP	cis	rs7953704	0.935	rs11060477	chr12:122607063	A/G	cg12414862	chr12:122614630	MLXIP	-0.43	-4.94	-0.3	1.41e-6	Urate levels;
KIRP	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg03128060	chr6:142623767	GPR126	0.34	4.91	0.3	1.69e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	trans	rs12043259	0.730	rs61487427	chr1:204809324	C/T	cg11485465	chr5:54518469	NA	0.35	6.17	0.37	2.72e-9	Addiction;
KIRP	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.38	-5.02	-0.3	1.02e-6	Body mass index;
KIRP	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg19507638	chr5:93509721	C5orf36	-0.55	-5.1	-0.31	6.64e-7	Diabetic retinopathy;
KIRP	cis	rs6580649	0.941	rs7959755	chr12:48446318	T/A	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs7937612	1.000	rs11600703	chr11:120249287	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.79	-0.4	8.54e-11	Intraocular pressure;
KIRP	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg15893493	chr8:124194847	FAM83A	0.87	6.8	0.4	8.01e-11	Urinary uromodulin levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04047827	chr16:24740859	TNRC6A	0.51	6.94	0.4	3.48e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.71	9.58	0.52	1.13e-18	Longevity;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg05564831	chr3:52568323	NT5DC2	0.32	4.88	0.3	1.88e-6	Electroencephalogram traits;
KIRP	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg25706552	chr1:244017396	NA	0.57	7.11	0.41	1.28e-11	RR interval (heart rate);
KIRP	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg11494091	chr17:61959527	GH2	-0.78	-11.67	-0.6	2.55e-25	Prudent dietary pattern;
KIRP	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.45	-6.9	-0.4	4.44e-11	Coronary artery disease;
KIRP	cis	rs7601312	0.967	rs7584169	chr2:229324151	T/A	cg02542817	chr2:229291442	NA	-0.38	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs394563	0.591	rs6570964	chr6:149691859	G/A	cg03678062	chr6:149772716	ZC3H12D	0.32	5.12	0.31	6.25e-7	Dupuytren's disease;
KIRP	cis	rs741951	0.832	rs76496919	chr21:46255802	G/A	cg08823554	chr21:46269191	NA	-0.6	-5.08	-0.31	7.42e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22509189	chr2:225307070	NA	-0.41	-4.98	-0.3	1.22e-6	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.93	9.39	0.51	4.15e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9469913	0.799	rs2744972	chr6:34659054	C/T	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.2	-0.31	4.12e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.76	-8.03	-0.46	4.14e-14	Asthma;
KIRP	trans	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg22358067	chr17:16797159	NA	-0.46	-6.02	-0.36	6.41e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg23024343	chr7:107201750	COG5	0.41	4.86	0.3	2.11e-6	Coronary artery disease;
KIRP	trans	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.14	-0.41	1.06e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	8.89	0.49	1.34e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg05627522	chr15:75251581	NA	0.34	5.04	0.31	9.02e-7	Caffeine consumption;
KIRP	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.78	-9.19	-0.51	1.72e-17	Vitiligo;
KIRP	cis	rs7615316	1.000	rs2177396	chr3:142343401	A/G	cg20824294	chr3:142316082	PLS1	0.22	4.94	0.3	1.42e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.79	12.91	0.64	1.87e-29	Dupuytren's disease;
KIRP	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg02811702	chr13:24901961	NA	0.43	5.68	0.34	3.82e-8	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-5.96	-0.36	8.88e-9	Personality dimensions;
KIRP	cis	rs2124969	0.549	rs56296079	chr2:160941461	C/T	cg03641300	chr2:160917029	PLA2R1	-0.56	-6.27	-0.37	1.6e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.55	-0.39	3.32e-10	Uric acid levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24243429	chr4:148653539	ARHGAP10	0.55	6.41	0.38	7.18e-10	Smoking initiation;
KIRP	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg08885076	chr2:99613938	TSGA10	0.52	8.9	0.49	1.28e-16	Chronic sinus infection;
KIRP	cis	rs4395908	0.559	rs13250579	chr8:4019698	C/A	cg01921437	chr8:3974145	CSMD1	-0.46	-5.73	-0.34	2.86e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs4880487	0.554	rs4880785	chr10:1237920	A/G	cg03183215	chr10:1252341	ADARB2	-0.37	-5.06	-0.31	8.03e-7	Migraine;
KIRP	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg00806126	chr19:22604979	ZNF98	0.69	7.28	0.42	4.38e-12	Pain;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11794814	chr19:40791331	AKT2	-0.47	-6.31	-0.37	1.31e-9	Neuroticism;
KIRP	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg02795151	chr17:7402630	POLR2A	0.78	8.04	0.46	3.8e-14	Androgen levels;
KIRP	cis	rs6723108	0.619	rs1942041	chr2:135515492	T/C	cg25422880	chr2:135218333	TMEM163	-0.48	-6.85	-0.4	5.86e-11	Type 2 diabetes;
KIRP	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.69	9.23	0.51	1.26e-17	Pancreatic cancer;
KIRP	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.4	-0.43	2.14e-12	Bipolar disorder;
KIRP	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg13736514	chr6:26305472	NA	-0.66	-8.71	-0.49	4.4e-16	Educational attainment;
KIRP	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg23307798	chr14:103986281	CKB	0.76	12.82	0.63	3.6e-29	Body mass index;
KIRP	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.61	-0.39	2.41e-10	Neuroticism;
KIRP	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04004882	chr2:215674386	BARD1	0.75	7.27	0.42	4.7e-12	Neuroblastoma;
KIRP	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.5	9.11	0.5	2.86e-17	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16504641	chr6:137143711	PEX7	0.51	6.51	0.38	4.21e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14603973	chr19:45805821	MARK4	-0.46	-6.06	-0.36	5.01e-9	Parkinson's disease;
KIRP	cis	rs6746896	0.639	rs1318597	chr2:97463095	T/C	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.45	-0.43	1.56e-12	Bipolar disorder;
KIRP	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs965513	1.000	rs7027030	chr9:100550455	A/C	cg13688889	chr9:100608707	NA	-0.6	-7.52	-0.43	1.05e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.57	-0.48	1.15e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.65	-0.39	1.9e-10	Mood instability;
KIRP	cis	rs921943	0.881	rs6862283	chr5:78319638	T/C	cg26802063	chr5:78281964	ARSB	0.48	5.91	0.35	1.12e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs9611198	0.765	rs5757721	chr22:39947574	A/G	cg10455938	chr22:40058150	CACNA1I	0.46	6.44	0.38	6.26e-10	Schizophrenia;
KIRP	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg19847130	chr8:10466454	RP1L1	0.33	4.88	0.3	1.89e-6	Retinal vascular caliber;
KIRP	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg01304814	chr3:48885189	PRKAR2A	0.69	5.4	0.33	1.57e-7	Cognitive function;
KIRP	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.05	0.31	8.45e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg21734707	chr17:3908241	ZZEF1	0.66	10.17	0.54	1.59e-20	Type 2 diabetes;
KIRP	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg23231163	chr10:75533350	FUT11	-0.33	-4.98	-0.3	1.2e-6	Inflammatory bowel disease;
KIRP	cis	rs28829049	0.597	rs12740975	chr1:19437923	G/A	cg13387374	chr1:19411106	UBR4	0.42	5.07	0.31	7.89e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4851266	1.000	rs4851264	chr2:100810188	T/C	cg07810366	chr2:100720526	AFF3	-0.32	-4.99	-0.3	1.15e-6	Educational attainment;
KIRP	cis	rs6921919	0.583	rs7773051	chr6:28340316	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.42	-6.03	-0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18376227	chr5:79707092	ZFYVE16	-0.41	-6.34	-0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.61	-6.58	-0.39	2.8e-10	DNA methylation (variation);
KIRP	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg06115741	chr20:33292138	TP53INP2	0.36	4.89	0.3	1.78e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07636037	chr3:49044803	WDR6	0.71	8.31	0.47	6.42e-15	Menarche (age at onset);
KIRP	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.87	-13.19	-0.64	2.04e-30	Longevity;
KIRP	cis	rs42648	0.748	rs12673914	chr7:89943389	C/T	cg25739043	chr7:89950458	NA	-0.43	-6.85	-0.4	5.97e-11	Homocysteine levels;
KIRP	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.67	7.93	0.45	7.88e-14	Corneal astigmatism;
KIRP	cis	rs7870753	0.838	rs10820630	chr9:99207033	C/A	cg25260653	chr9:99212216	HABP4	0.53	5.08	0.31	7.56e-7	Height;
KIRP	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg23995753	chr2:160760732	LY75	-0.42	-5.62	-0.34	5.1e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-7.01	-0.41	2.25e-11	Initial pursuit acceleration;
KIRP	cis	rs9504361	0.838	rs3757114	chr6:559576	A/C	cg13471009	chr6:564609	EXOC2	-0.33	-4.9	-0.3	1.74e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
KIRP	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.68	-5.87	-0.35	1.42e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.67	-8.38	-0.47	4.03e-15	Menopause (age at onset);
KIRP	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg22705602	chr4:152727874	NA	-0.52	-8.94	-0.5	9.31e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg19000871	chr14:103996768	TRMT61A	-0.81	-9.49	-0.52	2.04e-18	Coronary artery disease;
KIRP	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.99	13.8	0.66	1.78e-32	Response to antipsychotic treatment;
KIRP	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	9.25	0.51	1.13e-17	Resting heart rate;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7083	1.000	rs644215	chr11:117145918	T/A	cg11523350	chr11:117171073	BACE1	-0.28	-5.48	-0.33	1.04e-7	Blood protein levels;
KIRP	cis	rs2033732	0.706	rs7833023	chr8:85053241	A/C	cg05716166	chr8:85095498	RALYL	-0.54	-6.11	-0.36	3.92e-9	Body mass index;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14655649	chr8:30769870	NA	-0.57	-6.33	-0.37	1.16e-9	Menopause (age at onset);
KIRP	cis	rs6974574	0.961	rs1717721	chr7:38111340	C/T	cg10754659	chr7:38110151	NA	-0.37	-5.01	-0.3	1.03e-6	Height;
KIRP	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg23601095	chr6:26197514	HIST1H3D	0.77	5.84	0.35	1.63e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.73	9.27	0.51	9.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg12091567	chr17:66097778	LOC651250	-0.82	-8.86	-0.49	1.59e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs10982256	0.782	rs62555200	chr9:117247642	T/C	cg13636371	chr9:117264095	DFNB31	-0.43	-5.5	-0.33	9.32e-8	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.26	-0.32	3.11e-7	Renal cell carcinoma;
KIRP	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.55e-10	Morning vs. evening chronotype;
KIRP	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.44	-6.49	-0.38	4.81e-10	Vitamin D levels;
KIRP	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.25	7.26	0.42	5.16e-12	Type 2 diabetes;
KIRP	cis	rs7113874	0.959	rs12803166	chr11:8646237	G/T	cg08015107	chr11:8618950	NA	0.34	4.9	0.3	1.75e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg15655495	chr12:38532458	NA	-0.28	-5.08	-0.31	7.47e-7	Bladder cancer;
KIRP	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg04132472	chr17:19861366	AKAP10	-0.38	-4.98	-0.3	1.18e-6	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-11.44	-0.59	1.42e-24	Personality dimensions;
KIRP	cis	rs687432	0.774	rs7934149	chr11:57888566	C/T	cg19752551	chr11:57585705	CTNND1	-0.64	-8.23	-0.46	1.09e-14	Parkinson's disease;
KIRP	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg07451762	chr16:28383216	NA	0.43	5.63	0.34	4.98e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6772849	0.796	rs9841521	chr3:128392274	A/G	cg08795948	chr3:128337044	NA	0.5	6.23	0.37	1.98e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs4671458	0.948	rs72815379	chr2:63600430	C/T	cg17519650	chr2:63277830	OTX1	-0.52	-5.13	-0.31	5.93e-7	Subjective well-being;
KIRP	trans	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg10756647	chr7:56101905	PSPH	0.97	6.85	0.4	5.72e-11	Diabetic kidney disease;
KIRP	cis	rs7524258	0.934	rs6689453	chr1:7288384	C/T	cg07173049	chr1:7289937	CAMTA1	0.63	9.57	0.52	1.18e-18	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.58	6.73	0.39	1.15e-10	HDL cholesterol;
KIRP	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg07972983	chr1:205091412	RBBP5	0.41	4.99	0.3	1.16e-6	Red blood cell count;
KIRP	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg24972876	chr7:65420302	NA	0.41	5.61	0.34	5.53e-8	Aortic root size;
KIRP	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg11859384	chr17:80120422	CCDC57	0.46	6.09	0.36	4.39e-9	Life satisfaction;
KIRP	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.64	-7.73	-0.44	2.75e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg13198984	chr17:80129470	CCDC57	0.59	8.88	0.49	1.41e-16	Life satisfaction;
KIRP	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	cg21523751	chr1:182988639	NA	0.34	4.85	0.3	2.23e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg01631408	chr1:248437212	OR2T33	0.61	7.83	0.45	1.43e-13	Common traits (Other);
KIRP	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg04362960	chr10:104952993	NT5C2	-0.46	-4.97	-0.3	1.24e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10214930	0.697	rs7783447	chr7:27626855	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg05082376	chr22:42548792	NA	-0.46	-5.79	-0.35	2.08e-8	Schizophrenia;
KIRP	cis	rs12188164	0.554	rs72711364	chr5:415323	A/G	cg21972741	chr5:435613	AHRR	0.49	6.08	0.36	4.6e-9	Cystic fibrosis severity;
KIRP	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-9.26	-0.51	1.05e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.63	6.91	0.4	4.06e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.46	-6.22	-0.37	2.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.94	-0.4	3.42e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.59	7.42	0.43	1.92e-12	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01185801	chr11:65265397	MALAT1	0.6	7.01	0.41	2.26e-11	Smoking initiation;
KIRP	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg16141378	chr3:129829833	LOC729375	0.55	7.69	0.44	3.48e-13	Triglycerides;
KIRP	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	12.47	0.62	5.56e-28	Bone mineral density;
KIRP	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.33	-0.32	2.17e-7	Skin colour saturation;
KIRP	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.43	0.43	1.8e-12	Aortic root size;
KIRP	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg27432699	chr2:27873401	GPN1	-0.46	-5.98	-0.36	7.63e-9	Total body bone mineral density;
KIRP	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.63	6.97	0.41	2.94e-11	Aortic root size;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04915173	chr10:12292492	CDC123	0.43	6.02	0.36	6.44e-9	Interleukin-4 levels;
KIRP	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg00012203	chr2:219082015	ARPC2	-0.66	-8.37	-0.47	4.27e-15	Colorectal cancer;
KIRP	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.58	-7.43	-0.43	1.84e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-1.07	-21.14	-0.8	3.04e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.88	-10.77	-0.57	2.04e-22	Cisplatin-induced ototoxicity;
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.49	6.38	0.38	8.5e-10	Menarche (age at onset);
KIRP	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.56	8.98	0.5	7e-17	Glomerular filtration rate (creatinine);
KIRP	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.57	-0.43	7.4e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.59	7.27	0.42	4.79e-12	Lung cancer;
KIRP	cis	rs17095355	1.000	rs12569906	chr10:111706856	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.44	-6.42	-0.38	6.93e-10	Biliary atresia;
KIRP	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.69	6.5	0.38	4.39e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7640424	0.691	rs35168062	chr3:107829507	A/G	cg09227934	chr3:107805635	CD47	-0.31	-5.38	-0.32	1.74e-7	Body mass index;
KIRP	cis	rs13185784	0.569	rs6877489	chr5:179677545	C/T	cg02891314	chr5:179741120	GFPT2	-0.52	-5.39	-0.33	1.62e-7	TRAIL levels;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.83	11.39	0.59	2.04e-24	Height;
KIRP	cis	rs3120667	0.790	rs726864	chr1:152400293	C/T	cg26876637	chr1:152193138	HRNR	-0.53	-6.59	-0.39	2.66e-10	Eating disorders;
KIRP	trans	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.89	-0.4	4.72e-11	Morning vs. evening chronotype;
KIRP	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.31	8.15	0.46	1.85e-14	Primary biliary cholangitis;
KIRP	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg17133734	chr15:86042851	AKAP13	-0.46	-5.84	-0.35	1.6e-8	Coronary artery disease;
KIRP	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.66	0.39	1.81e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.52	-11.48	-0.59	9.99e-25	Diabetic kidney disease;
KIRP	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.55	7.54	0.43	8.82e-13	Mean corpuscular volume;
KIRP	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	5.07	0.31	7.79e-7	Menarche (age at onset);
KIRP	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg20673091	chr1:2541236	MMEL1	0.67	10.05	0.54	3.8e-20	Multiple sclerosis;
KIRP	cis	rs13108043	0.541	rs28633398	chr4:87821134	C/A	cg11209507	chr4:87813803	C4orf36	0.5	5.46	0.33	1.18e-7	Red blood cell count;
KIRP	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.66	9.39	0.51	4.3e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.56	6.23	0.37	1.97e-9	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.05	18.94	0.77	5.91e-50	Chronic sinus infection;
KIRP	trans	rs12545912	0.691	rs13250951	chr8:9541455	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.23	-0.37	2.04e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg07212818	chr11:638076	DRD4	-0.44	-5.38	-0.32	1.73e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06212747	chr3:49208901	KLHDC8B	0.75	10.27	0.55	8.25e-21	Parkinson's disease;
KIRP	cis	rs4805834	0.719	rs73035337	chr19:33290433	A/G	cg07201929	chr19:33182834	NUDT19	-0.62	-5.24	-0.32	3.4e-7	Creatinine levels;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13922124	chr7:105221991	EFCAB10	0.55	6.98	0.41	2.67e-11	Smoking initiation;
KIRP	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg15556689	chr8:8085844	FLJ10661	0.68	9.35	0.51	5.41e-18	Mood instability;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.85	-12.12	-0.61	8.34e-27	Longevity;Endometriosis;
KIRP	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.93	10.0	0.54	5.54e-20	Alzheimer's disease;
KIRP	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.92	14.12	0.67	1.48e-33	Bladder cancer;
KIRP	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.74	-11.39	-0.59	1.99e-24	Idiopathic membranous nephropathy;
KIRP	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.57	-7.49	-0.43	1.21e-12	Aortic root size;
KIRP	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.87	-0.35	1.38e-8	IgG glycosylation;
KIRP	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg03711944	chr11:47377212	SPI1	0.33	5.27	0.32	2.92e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg12131826	chr15:77904385	NA	0.42	5.59	0.34	5.9e-8	Type 2 diabetes;
KIRP	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-5.75	-0.34	2.62e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08439880	chr3:133502540	NA	-0.46	-5.34	-0.32	2.15e-7	Iron status biomarkers;
KIRP	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Body mass index;
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.28	-5.89	-0.35	1.24e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg05361325	chr10:32636312	EPC1	-0.65	-6.14	-0.36	3.26e-9	Sexual dysfunction (female);
KIRP	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg03433033	chr1:76189801	ACADM	0.43	6.33	0.37	1.17e-9	Daytime sleep phenotypes;
KIRP	cis	rs12580194	0.593	rs4448777	chr12:55724981	T/C	cg19537932	chr12:55886519	OR6C68	-0.51	-6.55	-0.39	3.35e-10	Cancer;
KIRP	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg25182066	chr10:30743637	MAP3K8	0.6	5.02	0.3	1.01e-6	Itch intensity from mosquito bite;
KIRP	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.94	0.4	3.44e-11	Schizophrenia;
KIRP	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.37	-0.32	1.85e-7	Neuroticism;
KIRP	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg24565620	chr2:194026	NA	0.64	7.51	0.43	1.06e-12	Blood protein levels;
KIRP	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg10503236	chr1:231470652	EXOC8	-0.56	-8.3	-0.47	6.82e-15	Hemoglobin concentration;
KIRP	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.48	8.59	0.48	9.86e-16	Lung cancer;
KIRP	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.51	6.92	0.4	3.91e-11	Mean corpuscular volume;
KIRP	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.77	9.42	0.51	3.4e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg23992470	chr4:843637	GAK	0.63	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-8.63	-0.48	7.71e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.9	-10.35	-0.55	4.46e-21	White matter hyperintensity burden;
KIRP	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.03	-0.31	9.65e-7	Triglycerides;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.45	5.44	0.33	1.3e-7	Longevity;Endometriosis;
KIRP	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.57	-5.3	-0.32	2.58e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.32	10.52	0.56	1.32e-21	Economic and political preferences (immigration/crime);
KIRP	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg20818283	chr2:191399100	TMEM194B	0.54	7.05	0.41	1.8e-11	Pulse pressure;
KIRP	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg00405596	chr8:11794950	NA	0.42	5.29	0.32	2.73e-7	Retinal vascular caliber;
KIRP	cis	rs7116495	1.000	rs73539529	chr11:71815596	T/C	cg11196788	chr11:71737549	NUMA1	-0.54	-4.84	-0.3	2.25e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs4132509	1.000	rs73124169	chr1:243804939	T/C	cg21452805	chr1:244014465	NA	0.53	5.38	0.32	1.7e-7	RR interval (heart rate);
KIRP	cis	rs10992471	0.528	rs1535754	chr9:95201917	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.0	-0.3	1.08e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.83	9.7	0.53	4.82e-19	Platelet count;
KIRP	cis	rs7638995	0.878	rs7644952	chr3:69181064	C/G	cg26574240	chr3:69171822	LMOD3	-0.43	-5.25	-0.32	3.33e-7	Alzheimer's disease (late onset);
KIRP	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg13165212	chr22:42675999	NA	0.28	4.92	0.3	1.56e-6	Cognitive function;
KIRP	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg21919602	chr1:242011447	EXO1	-0.46	-5.93	-0.35	1.04e-8	Menopause (age at onset);
KIRP	cis	rs2441986	0.857	rs7129894	chr11:57986275	G/A	cg19752551	chr11:57585705	CTNND1	-0.44	-5.51	-0.33	8.94e-8	Systolic blood pressure;
KIRP	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.75	10.77	0.57	2.1e-22	Mood instability;
KIRP	cis	rs642803	0.569	rs44205	chr11:65564786	G/A	cg08755490	chr11:65554678	OVOL1	-0.55	-5.99	-0.36	7.29e-9	Urate levels;
KIRP	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg07701084	chr6:150067640	NUP43	0.57	7.35	0.42	3e-12	Lung cancer;
KIRP	cis	rs4638749	0.501	rs2378096	chr2:108765031	A/G	cg06795125	chr2:108905320	SULT1C2	-0.31	-5.68	-0.34	3.82e-8	Blood pressure;
KIRP	cis	rs6693295	0.816	rs12125969	chr1:246341167	C/T	cg11798871	chr1:246315928	SMYD3	-0.58	-6.92	-0.4	3.88e-11	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.95	12.38	0.62	1.07e-27	Vitamin D levels;
KIRP	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs16936870	0.571	rs7017499	chr8:71083453	A/G	cg14232793	chr8:71155543	NCOA2	-0.51	-5.9	-0.35	1.17e-8	QT interval;
KIRP	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-1.12	-17.67	-0.75	1.15e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7804356	0.859	rs2391362	chr7:26907123	T/C	cg03456212	chr7:26904342	SKAP2	-0.59	-5.32	-0.32	2.32e-7	Type 1 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15448726	chr12:53273497	NA	0.45	6.16	0.37	2.92e-9	Smoking initiation;
KIRP	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.69e-59	Prudent dietary pattern;
KIRP	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.1	0.5	3.07e-17	Coronary artery disease;
KIRP	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-7.49	-0.43	1.2e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg07777115	chr5:623756	CEP72	-0.52	-5.67	-0.34	3.89e-8	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14823666	chr10:70166317	RUFY2	0.46	6.22	0.37	2.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2271920	0.626	rs10091396	chr8:27299087	C/A	cg18234130	chr8:27182889	PTK2B	-0.4	-4.87	-0.3	2.04e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs3755605	0.833	rs7635670	chr3:169778625	A/G	cg20137461	chr3:169782135	GPR160	0.39	4.93	0.3	1.54e-6	Testicular germ cell tumor;
KIRP	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg04672837	chr16:48644449	N4BP1	0.5	6.77	0.4	9.65e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg05315796	chr3:52349193	DNAH1	-0.39	-6.3	-0.37	1.39e-9	Electroencephalogram traits;
KIRP	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg03235661	chr20:60525775	NA	-0.3	-4.97	-0.3	1.25e-6	Body mass index;
KIRP	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.67	7.65	0.44	4.65e-13	Gut microbiome composition (summer);
KIRP	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg15556689	chr8:8085844	FLJ10661	0.64	7.96	0.45	6.31e-14	Retinal vascular caliber;
KIRP	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.47	6.1	0.36	4e-9	Mean corpuscular volume;
KIRP	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg15507776	chr3:136538369	TMEM22	0.4	5.4	0.33	1.55e-7	Neuroticism;
KIRP	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.48	0.52	2.27e-18	Bipolar disorder;
KIRP	cis	rs6707387	0.641	rs7596173	chr2:214516231	A/G	cg08319019	chr2:214017104	IKZF2	0.47	5.48	0.33	1.03e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	6.82	0.4	6.86e-11	Cognitive test performance;
KIRP	cis	rs10129255	0.500	rs10142931	chr14:107190525	A/C	cg23076370	chr14:107095027	NA	-0.42	-5.07	-0.31	7.99e-7	Kawasaki disease;
KIRP	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg21204522	chr6:27730016	NA	-0.64	-5.41	-0.33	1.48e-7	Lung cancer in ever smokers;
KIRP	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg26116260	chr4:7069785	GRPEL1	-0.8	-6.39	-0.38	8.05e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.66	-8.38	-0.47	4.09e-15	Tonsillectomy;
KIRP	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.75	-11.12	-0.58	1.53e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.57	-0.33	6.79e-8	Bipolar disorder;
KIRP	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	5.99	0.36	7.52e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10465746	0.935	rs1871925	chr1:84464468	C/G	cg10977910	chr1:84465055	TTLL7	0.48	5.7	0.34	3.45e-8	Obesity-related traits;
KIRP	cis	rs2013441	0.613	rs4925082	chr17:19994673	C/T	cg13482628	chr17:19912719	NA	-0.47	-6.17	-0.37	2.72e-9	Obesity-related traits;
KIRP	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg27494647	chr7:150038898	RARRES2	0.38	5.7	0.34	3.38e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2916247	1.000	rs55701498	chr8:93039932	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.7	-0.44	3.32e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.25	-0.37	1.81e-9	Systolic blood pressure;
KIRP	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.66	8.06	0.46	3.31e-14	Calcium levels;
KIRP	cis	rs67257959	0.708	rs10405158	chr19:17195997	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	5.84	0.35	1.65e-8	Selective IgA deficiency;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg23736307	chr8:27182930	PTK2B	0.52	6.55	0.39	3.36e-10	Neuroticism;
KIRP	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg22676075	chr6:135203613	NA	0.5	7.2	0.42	7.42e-12	Red blood cell count;
KIRP	cis	rs9810890	1.000	rs73198838	chr3:128498292	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs7651736	0.636	rs60985825	chr3:136755496	G/T	cg21827317	chr3:136751795	NA	-0.43	-5.85	-0.35	1.57e-8	Neuroticism;
KIRP	cis	rs981844	0.714	rs6853529	chr4:154706267	C/T	cg14289246	chr4:154710475	SFRP2	0.49	6.35	0.38	1.06e-9	Response to statins (LDL cholesterol change);
KIRP	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.75	-11.2	-0.58	8.71e-24	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg08975724	chr8:8085496	FLJ10661	0.59	7.26	0.42	4.93e-12	Retinal vascular caliber;
KIRP	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05472934	chr7:22766657	IL6	0.81	10.45	0.55	2.1e-21	Lung cancer;
KIRP	trans	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg24644049	chr4:85504048	CDS1	1.08	6.91	0.4	4.19e-11	Skin colour saturation;
KIRP	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.4	-4.88	-0.3	1.93e-6	Longevity;Endometriosis;
KIRP	cis	rs2061333	1.000	rs4508518	chr19:44611420	A/G	cg21636353	chr19:44617292	ZNF225	-0.51	-5.06	-0.31	8.39e-7	Alzheimer's disease;
KIRP	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.43	7.06	0.41	1.69e-11	Testicular germ cell tumor;
KIRP	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg08975724	chr8:8085496	FLJ10661	0.59	8.03	0.46	4.16e-14	Retinal vascular caliber;
KIRP	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg05775895	chr3:12838266	CAND2	-0.31	-4.89	-0.3	1.82e-6	P wave duration;
KIRP	cis	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg19847130	chr8:10466454	RP1L1	0.37	5.33	0.32	2.2e-7	Neuroticism;
KIRP	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg06671706	chr8:8559999	CLDN23	0.56	6.28	0.37	1.55e-9	Obesity-related traits;
KIRP	cis	rs686320	1.000	rs35940245	chr11:65232673	G/A	cg21890820	chr11:65308645	LTBP3	0.6	5.57	0.33	6.69e-8	Hip circumference adjusted for BMI;
KIRP	trans	rs77926410	0.604	rs11053801	chr12:10596117	G/T	cg05279806	chr3:175128616	NAALADL2	-0.38	-6.12	-0.36	3.65e-9	Mean corpuscular volume;
KIRP	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.25	11.86	0.6	6.01e-26	Diabetic retinopathy;
KIRP	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg13852791	chr20:30311386	BCL2L1	0.72	6.69	0.39	1.49e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg13978929	chr19:21580086	ZNF493	-0.52	-5.1	-0.31	6.94e-7	Pain;
KIRP	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg00814883	chr7:100076585	TSC22D4	-0.54	-5.32	-0.32	2.34e-7	Lung function (FEV1/FVC);
KIRP	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg24631222	chr15:78858424	CHRNA5	-0.86	-10.92	-0.57	6.85e-23	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4740619	0.619	rs10810518	chr9:16029175	T/A	cg14451791	chr9:16040625	NA	-0.42	-5.51	-0.33	8.97e-8	Body mass index;
KIRP	cis	rs7903847	0.642	rs12258560	chr10:99137048	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.51	0.59	8.02e-25	Heart rate;
KIRP	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.61	7.11	0.41	1.25e-11	Corneal astigmatism;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23946858	chr19:18779305	KLHL26	0.48	6.09	0.36	4.43e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02725872	chr8:58115012	NA	-0.56	-6.53	-0.38	3.79e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs16936870	0.543	rs2958366	chr8:71158096	T/C	cg14232793	chr8:71155543	NCOA2	-0.59	-7.19	-0.42	7.57e-12	QT interval;
KIRP	trans	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	6.25	0.37	1.75e-9	Ulcerative colitis;
KIRP	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs7646881	0.812	rs113166116	chr3:158460256	C/T	cg19483011	chr3:158453295	NA	-0.49	-5.47	-0.33	1.1e-7	Tetralogy of Fallot;
KIRP	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg16586182	chr3:47516702	SCAP	-0.76	-10.93	-0.57	6.32e-23	Colorectal cancer;
KIRP	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg21858823	chr1:15850916	CASP9	0.52	5.61	0.34	5.38e-8	Systolic blood pressure;
KIRP	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.51	5.44	0.33	1.31e-7	Height;
KIRP	trans	rs76288851	0.799	rs73201796	chr3:126526162	A/G	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.92	-13.94	-0.66	6.29e-33	Monocyte count;
KIRP	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.24	-6.52	-0.38	3.99e-10	Crohn's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24899292	chr19:41798372	HNRNPUL1	0.55	6.65	0.39	1.83e-10	Interleukin-4 levels;
KIRP	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.3	-0.37	1.37e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg23796481	chr11:64053134	BAD;GPR137	-0.56	-5.04	-0.31	9.01e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6977660	0.714	rs12333747	chr7:19814394	G/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.79	0.35	2.09e-8	Thyroid stimulating hormone;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg13906792	chr15:75199810	C15orf17	-0.35	-4.88	-0.3	1.92e-6	Breast cancer;
KIRP	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.81	6.96	0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg16801887	chr16:86541480	NA	-0.5	-6.3	-0.37	1.39e-9	Response to statin therapy;
KIRP	cis	rs71277158	0.630	rs73879159	chr3:169753747	G/T	cg04067573	chr3:169899625	PHC3	0.65	5.78	0.35	2.24e-8	Prostate cancer;
KIRP	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.51	-6.71	-0.39	1.34e-10	Prudent dietary pattern;
KIRP	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg19767477	chr5:127420684	SLC12A2	-0.34	-4.86	-0.3	2.1e-6	Ileal carcinoids;
KIRP	cis	rs2274273	0.624	rs10132453	chr14:55840851	C/T	cg04306507	chr14:55594613	LGALS3	0.38	5.3	0.32	2.54e-7	Protein biomarker;
KIRP	cis	rs2274273	1.000	rs1047556	chr14:55600282	A/T	cg04306507	chr14:55594613	LGALS3	0.49	7.62	0.44	5.63e-13	Protein biomarker;
KIRP	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.01	-14.05	-0.67	2.57e-33	Response to antipsychotic treatment;
KIRP	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.89	0.4	4.64e-11	Blood metabolite levels;
KIRP	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15557168	chr22:42548783	NA	0.42	5.4	0.33	1.53e-7	Cognitive function;
KIRP	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg01566213	chr4:1579287	NA	-0.36	-4.89	-0.3	1.79e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	-0.41	-4.94	-0.3	1.44e-6	Lung cancer;
KIRP	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.64	10.71	0.56	3.1e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs12210905	0.925	rs72838228	chr6:26945920	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.52	-4.87	-0.3	2.01e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg26516362	chr5:178986906	RUFY1	0.47	8.52	0.48	1.66e-15	Lung cancer;
KIRP	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.15	-0.31	5.29e-7	Blood pressure;
KIRP	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11987759	chr7:65425863	GUSB	0.45	5.32	0.32	2.34e-7	Aortic root size;
KIRP	cis	rs10181042	0.565	rs62150982	chr2:61280675	T/C	cg10580144	chr2:61372316	C2orf74	-0.39	-5.42	-0.33	1.41e-7	Crohn's disease;
KIRP	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.56	7.77	0.44	2.11e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.77	-0.35	2.42e-8	Electroencephalogram traits;
KIRP	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-1.05	-12.76	-0.63	6.09e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg23034840	chr1:205782522	SLC41A1	0.58	7.65	0.44	4.66e-13	Menarche (age at onset);
KIRP	cis	rs4356932	0.967	rs28505472	chr4:76972727	C/T	cg19388996	chr4:76862389	NAAA	0.39	5.11	0.31	6.37e-7	Blood protein levels;
KIRP	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg09480190	chr16:85671771	KIAA0182	0.44	5.0	0.3	1.08e-6	Platelet distribution width;
KIRP	cis	rs12580194	0.593	rs12581060	chr12:55797484	A/C	cg11794356	chr12:55725991	OR6C3	-0.53	-6.97	-0.41	2.9e-11	Cancer;
KIRP	cis	rs13108043	0.605	rs33983129	chr4:87939330	C/T	cg11209507	chr4:87813803	C4orf36	0.45	4.87	0.3	2e-6	Red blood cell count;
KIRP	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg05721485	chr17:44071124	MAPT	0.54	7.1	0.41	1.32e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7534824	0.625	rs2391574	chr1:101373298	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	5.64	0.34	4.58e-8	Refractive astigmatism;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg22907277	chr7:1156413	C7orf50	0.87	8.2	0.46	1.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	cg12689670	chr1:183009347	LAMC1	0.56	7.9	0.45	9.36e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.46	0.43	1.5e-12	Myeloid white cell count;
KIRP	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.22	23.81	0.84	8.79e-66	Cognitive function;
KIRP	cis	rs7808935	0.914	rs11971132	chr7:27985867	G/C	cg05786569	chr7:27702416	HIBADH	0.51	4.96	0.3	1.31e-6	Prostate cancer;
KIRP	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.33	4.87	0.3	2.01e-6	Hemoglobin concentration;
KIRP	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.98	10.44	0.55	2.31e-21	Blood protein levels;
KIRP	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg04310649	chr10:35416472	CREM	-0.54	-6.09	-0.36	4.35e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs710913	0.557	rs1180320	chr1:40082002	A/G	cg27567593	chr1:39956653	BMP8A	-0.35	-4.9	-0.3	1.77e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.12	-0.31	6.31e-7	Vitiligo;
KIRP	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14895029	chr7:2775587	GNA12	0.41	5.05	0.31	8.58e-7	Height;
KIRP	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg03060546	chr3:49711283	APEH	-0.62	-6.22	-0.37	2.09e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg04519387	chr11:65556438	OVOL1	0.34	5.24	0.32	3.53e-7	Acne (severe);
KIRP	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg02487422	chr3:49467188	NICN1	0.38	4.97	0.3	1.25e-6	Resting heart rate;
KIRP	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.55	7.85	0.45	1.24e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.85	0.49	1.71e-16	Motion sickness;
KIRP	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.7	-9.49	-0.52	2.13e-18	Breast cancer;
KIRP	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg22906224	chr7:99728672	NA	-0.49	-5.91	-0.35	1.16e-8	Coronary artery disease;
KIRP	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	0.89	10.35	0.55	4.49e-21	Testicular germ cell tumor;
KIRP	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg18825076	chr15:78729989	IREB2	-0.42	-4.96	-0.3	1.34e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.56	7.46	0.43	1.44e-12	Height;
KIRP	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs5753618	0.504	rs8138525	chr22:32011929	T/C	cg02404636	chr22:31891804	SFI1	-0.54	-6.16	-0.37	3.01e-9	Colorectal cancer;
KIRP	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg22138327	chr13:27999177	GTF3A	0.97	10.42	0.55	2.64e-21	Weight;
KIRP	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	0.79	6.95	0.41	3.26e-11	Obesity-related traits;
KIRP	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.43	-0.33	1.36e-7	Aortic root size;
KIRP	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg21573476	chr21:45109991	RRP1B	0.41	5.29	0.32	2.71e-7	Mean corpuscular volume;
KIRP	cis	rs13132184	0.507	rs35266215	chr4:38048878	C/T	cg14409701	chr4:38048871	TBC1D1	-0.79	-7.49	-0.43	1.21e-12	Verbal declarative memory;
KIRP	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg24296786	chr1:45957014	TESK2	-0.66	-8.84	-0.49	1.87e-16	High light scatter reticulocyte count;
KIRP	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg17595323	chr11:93583763	C11orf90	0.3	5.36	0.32	1.91e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg09873164	chr1:152488093	CRCT1	0.56	7.11	0.41	1.24e-11	Hair morphology;
KIRP	cis	rs9314323	0.624	rs117982737	chr8:26241010	C/T	cg11498726	chr8:26250323	BNIP3L	0.53	6.36	0.38	9.92e-10	Red cell distribution width;
KIRP	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg26149184	chr10:133730230	NA	0.42	5.1	0.31	6.86e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-8.41	-0.47	3.33e-15	Alzheimer's disease (survival time);
KIRP	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.54	-7.77	-0.44	2.12e-13	Body mass index;
KIRP	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.58	9.41	0.51	3.62e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg03959625	chr15:84868606	LOC388152	0.51	6.09	0.36	4.39e-9	Schizophrenia;
KIRP	cis	rs5747327	0.874	rs715532	chr22:18159946	A/G	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.04	-0.31	9.17e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs12900413	0.603	rs11629982	chr15:90300272	G/A	cg24650279	chr15:90327240	NA	-0.42	-5.2	-0.31	4.27e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg03808351	chr9:123631620	PHF19	0.42	5.72	0.34	3e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.75	-9.43	-0.52	3.32e-18	Facial morphology (factor 19);
KIRP	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg04727924	chr7:799746	HEATR2	-0.76	-8.6	-0.48	9.51e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-1.0	-12.98	-0.64	1.05e-29	Response to antineoplastic agents;
KIRP	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.45	5.11	0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg27539214	chr16:67997921	SLC12A4	-0.49	-4.86	-0.3	2.06e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg16586182	chr3:47516702	SCAP	-0.67	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-1.05	-10.69	-0.56	3.6e-22	Diabetic retinopathy;
KIRP	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg22852734	chr6:133119734	C6orf192	1.19	11.15	0.58	1.22e-23	Type 2 diabetes nephropathy;
KIRP	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg03060546	chr3:49711283	APEH	0.46	6.22	0.37	2.16e-9	Parkinson's disease;
KIRP	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.66	0.52	6.48e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg18944383	chr4:111397179	ENPEP	-0.71	-13.3	-0.65	9.3e-31	Height;
KIRP	cis	rs9393813	0.529	rs2064093	chr6:27442247	C/T	cg03332623	chr6:27441972	ZNF184	0.38	5.27	0.32	2.97e-7	Bipolar disorder;
KIRP	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.43	6.41	0.38	7.53e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.53	6.3	0.37	1.39e-9	Diastolic blood pressure;
KIRP	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.82	12.42	0.62	7.98e-28	Height;
KIRP	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg21605333	chr4:119757512	SEC24D	1.36	9.38	0.51	4.61e-18	Cannabis dependence symptom count;
KIRP	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg18016565	chr1:150552671	MCL1	0.49	7.35	0.42	2.85e-12	Urate levels;
KIRP	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.37	-5.01	-0.3	1.05e-6	Neuroticism;
KIRP	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.57	9.03	0.5	5.15e-17	C-reactive protein levels;
KIRP	cis	rs6467136	0.754	rs10273920	chr7:127158616	T/C	cg23081781	chr7:127225937	GCC1	-0.36	-4.87	-0.3	1.98e-6	Type 2 diabetes;
KIRP	cis	rs372883	0.530	rs55921835	chr21:30544623	A/G	cg24692254	chr21:30365293	RNF160	-0.45	-5.2	-0.31	4.17e-7	Pancreatic cancer;
KIRP	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg11494091	chr17:61959527	GH2	-0.7	-9.77	-0.53	3e-19	Prudent dietary pattern;
KIRP	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07080220	chr10:102295463	HIF1AN	0.78	7.43	0.43	1.83e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg22431228	chr1:16359049	CLCNKA	0.39	4.88	0.3	1.92e-6	Dilated cardiomyopathy;
KIRP	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg16141378	chr3:129829833	LOC729375	0.47	6.13	0.36	3.39e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.57	8.27	0.47	8.62e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.95e-7	Red blood cell count;
KIRP	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.5	6.77	0.4	9.5e-11	Mean corpuscular volume;
KIRP	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.03	0.41	2e-11	Tonsillectomy;
KIRP	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg21937377	chr3:194868750	C3orf21	0.24	5.06	0.31	8.04e-7	Non-small cell lung cancer;
KIRP	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.51	6.93	0.4	3.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12043259	0.730	rs9658872	chr1:204800718	A/C	cg11485465	chr5:54518469	NA	0.35	6.23	0.37	2.03e-9	Addiction;
KIRP	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg18154014	chr19:37997991	ZNF793	0.91	9.31	0.51	7.22e-18	Coronary artery calcification;
KIRP	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg02138098	chr1:2040968	PRKCZ	0.37	4.86	0.3	2.12e-6	Height;
KIRP	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg26384229	chr12:38710491	ALG10B	0.63	7.98	0.45	5.42e-14	Resting heart rate;
KIRP	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg06871246	chr4:1363661	KIAA1530	0.53	6.3	0.37	1.35e-9	Longevity;
KIRP	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg10434728	chr15:90938212	IQGAP1	0.39	7.26	0.42	5.1e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14447399	chr5:162930290	MAT2B	-0.39	-6.1	-0.36	4.17e-9	C-reactive protein;
KIRP	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26314531	chr2:26401878	FAM59B	-0.48	-5.01	-0.3	1.03e-6	Gut microbiome composition (summer);
KIRP	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.87	-11.76	-0.6	1.2e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg08662619	chr6:150070041	PCMT1	0.36	5.82	0.35	1.78e-8	Lung cancer;
KIRP	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	5.03	0.31	9.42e-7	Height;
KIRP	cis	rs6662572	1.000	rs11587982	chr1:46161868	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.2	0.31	4.16e-7	Blood protein levels;
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg06871246	chr4:1363661	KIAA1530	-0.53	-6.76	-0.4	1.01e-10	Longevity;
KIRP	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg25486957	chr4:152246857	NA	-0.54	-5.81	-0.35	1.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2411233	0.846	rs11632819	chr15:39263049	G/C	cg02291532	chr15:39874776	THBS1	0.42	5.67	0.34	3.89e-8	Platelet count;
KIRP	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-8.08	-0.46	2.97e-14	Personality dimensions;
KIRP	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg26727032	chr16:67993705	SLC12A4	-0.78	-9.01	-0.5	5.96e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.35	-0.42	2.99e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.74	-8.44	-0.47	2.71e-15	Breast cancer;
KIRP	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg04539111	chr16:67997858	SLC12A4	-0.66	-6.79	-0.4	8.16e-11	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.8	11.53	0.59	6.9e-25	Menarche (age at onset);
KIRP	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.57	-0.48	1.13e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.5	-6.8	-0.4	8.01e-11	HDL cholesterol;
KIRP	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg13010199	chr12:38710504	ALG10B	0.57	7.65	0.44	4.48e-13	Bladder cancer;
KIRP	cis	rs440932	0.717	rs330944	chr8:9021293	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	6.94	0.4	3.48e-11	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg05775895	chr3:12838266	CAND2	0.36	6.14	0.36	3.29e-9	QRS complex (12-leadsum);
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-6.25	-0.37	1.8e-9	Lung cancer;
KIRP	cis	rs6466055	0.777	rs2240463	chr7:104844328	C/T	cg04380332	chr7:105027541	SRPK2	-0.62	-9.45	-0.52	2.88e-18	Schizophrenia;
KIRP	cis	rs6693295	0.761	rs7526153	chr1:246296723	C/T	cg11798871	chr1:246315928	SMYD3	-0.43	-5.26	-0.32	3.2e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	4.89	0.3	1.78e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg26876637	chr1:152193138	HRNR	-0.72	-9.53	-0.52	1.61e-18	Atopic dermatitis;
KIRP	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg17691542	chr6:26056736	HIST1H1C	0.47	5.24	0.32	3.5e-7	Iron status biomarkers;
KIRP	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02362017	chr9:131154347	NA	0.46	6.65	0.39	1.84e-10	Gut microbiome composition (summer);
KIRP	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.4	5.26	0.32	3.2e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.58	-12.05	-0.61	1.34e-26	Diabetic kidney disease;
KIRP	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.78	-0.49	2.77e-16	Total cholesterol levels;
KIRP	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.66	-0.39	1.74e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg11812906	chr14:75593930	NEK9	-0.82	-12.3	-0.62	2.1e-27	Height;
KIRP	cis	rs8067287	0.554	rs56092540	chr17:16841417	C/T	cg26910001	chr17:16838321	NA	-0.63	-6.02	-0.36	6.26e-9	Diabetic kidney disease;
KIRP	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.16	-0.61	5.99e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg07395648	chr5:131743802	NA	-0.6	-8.35	-0.47	5.15e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg02600515	chr11:62521696	ZBTB3	0.49	5.13	0.31	6e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.61	6.03	0.36	5.94e-9	Eosinophil percentage of granulocytes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12908665	chr5:114499431	TRIM36	-0.4	-6.16	-0.37	2.9e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.67	-6.22	-0.37	2.09e-9	Menarche (age at onset);
KIRP	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.84	12.39	0.62	9.89e-28	Coronary artery disease;
KIRP	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	4.98	0.3	1.2e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg05072774	chr3:49840536	C3orf54	0.43	5.57	0.33	6.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12367572	0.620	rs2544102	chr12:45420127	A/G	cg04608330	chr12:45269318	NELL2	-0.37	-5.09	-0.31	7.22e-7	Gut microbiome composition (summer);
KIRP	cis	rs259842	0.699	rs56291671	chr2:180728892	A/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.45	-6.3	-0.37	1.38e-9	Blood protein levels;
KIRP	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg00919237	chr7:87102261	ABCB4	-0.75	-9.44	-0.52	3.05e-18	Gallbladder cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15183258	chr15:42061865	MGA	0.43	6.2	0.37	2.37e-9	Interleukin-4 levels;
KIRP	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.83	9.23	0.51	1.31e-17	Corneal astigmatism;
KIRP	cis	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.38	-4.96	-0.3	1.32e-6	Leprosy;
KIRP	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs710987	1.000	rs710987	chr5:3525440	A/G	cg14530963	chr5:3489551	NA	0.41	5.02	0.3	1.01e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs7084402	0.967	rs1658483	chr10:60288933	C/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13939156	chr17:80058883	NA	0.47	7.03	0.41	2.02e-11	Life satisfaction;
KIRP	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg08957091	chr4:120448071	PDE5A	0.37	4.94	0.3	1.43e-6	Corneal astigmatism;
KIRP	cis	rs6908034	0.882	rs6456259	chr6:19761718	A/G	cg02682789	chr6:19804855	NA	0.52	5.3	0.32	2.52e-7	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg03216991	chr17:2415620	METT10D	-0.39	-6.12	-0.36	3.6e-9	Serum protein levels (sST2);
KIRP	cis	rs2916247	0.954	rs11991256	chr8:93077207	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.53	-6.89	-0.4	4.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs17381785	0.718	rs7378221	chr4:14909813	G/T	cg12377275	chr4:15005593	CPEB2	0.43	4.98	0.3	1.18e-6	Urate levels in overweight individuals;
KIRP	cis	rs8067545	0.532	rs3862151	chr17:19957289	A/G	cg13482628	chr17:19912719	NA	0.46	5.16	0.31	5.01e-7	Schizophrenia;
KIRP	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg21045802	chr8:109455806	TTC35	0.53	7.48	0.43	1.28e-12	Dupuytren's disease;
KIRP	cis	rs17123764	0.892	rs11830696	chr12:50151256	T/C	cg20471783	chr12:50157085	TMBIM6	0.42	6.02	0.36	6.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.85	-0.35	1.57e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.47	7.06	0.41	1.67e-11	Lewy body disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05077167	chr2:43453540	ZFP36L2;LOC100129726	0.49	6.08	0.36	4.65e-9	Parkinson's disease;
KIRP	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg06050784	chr16:88016603	BANP	0.4	5.03	0.31	9.36e-7	Menopause (age at onset);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg01995718	chr19:53913889	ZNF765	0.36	6.08	0.36	4.68e-9	Serum protein levels (sST2);
KIRP	cis	rs7651039	0.641	rs2455823	chr3:15666856	T/C	cg16303742	chr3:15540471	COLQ	0.4	4.94	0.3	1.44e-6	Coronary heart disease;
KIRP	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.19	12.35	0.62	1.35e-27	Alzheimer's disease;
KIRP	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	1.06	20.28	0.79	2.1e-54	Height;
KIRP	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.3	-0.55	6.37e-21	Menarche (age at onset);
KIRP	cis	rs7215564	0.908	rs9972968	chr17:78652569	T/C	cg06153925	chr17:78755379	RPTOR	0.31	4.94	0.3	1.46e-6	Myopia (pathological);
KIRP	trans	rs3780486	0.801	rs28517717	chr9:33179451	C/T	cg20290983	chr6:43655470	MRPS18A	0.99	11.09	0.58	1.86e-23	IgG glycosylation;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24044651	chr1:24105262	C1orf128	0.69	6.35	0.38	1.05e-9	Lung function (FEV1);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21224049	chr4:668623	ATP5I	0.68	8.21	0.46	1.23e-14	Smoking initiation;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg04983381	chr16:30798335	ZNF629	0.54	6.85	0.4	5.92e-11	DNA methylation (variation);
KIRP	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg14343924	chr8:8086146	FLJ10661	-0.52	-6.32	-0.37	1.23e-9	Neuroticism;
KIRP	cis	rs8523	0.901	rs7743830	chr6:11014220	A/G	cg13562911	chr6:11044106	ELOVL2	0.38	5.02	0.3	1e-6	Red blood cell fatty acid levels;
KIRP	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.99	15.85	0.71	1.76e-39	Uric acid clearance;
KIRP	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.66	-9.88	-0.53	1.35e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2479106	0.549	rs7855648	chr9:126380439	A/G	cg16191174	chr9:126692580	DENND1A	0.37	4.96	0.3	1.3e-6	Polycystic ovary syndrome;
KIRP	cis	rs6978712	0.591	rs28557454	chr7:127078289	A/G	cg24655706	chr7:127078268	NA	0.68	5.36	0.32	1.88e-7	Medication adherence in chronic diseases;
KIRP	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg12384639	chr17:618140	VPS53	0.47	5.92	0.35	1.05e-8	Prostate cancer;
KIRP	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.27	14.24	0.67	5.85e-34	Uric acid levels;
KIRP	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.55	-0.56	1.08e-21	Height;
KIRP	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg06026331	chr20:60912101	LAMA5	0.46	5.93	0.35	1.02e-8	Colorectal cancer;
KIRP	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg03808351	chr9:123631620	PHF19	0.46	6.35	0.38	1.01e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg15181151	chr6:150070149	PCMT1	0.29	4.9	0.3	1.75e-6	Lung cancer;
KIRP	cis	rs61884328	0.852	rs61897782	chr11:47150177	G/A	cg23433285	chr11:47201945	PACSIN3	0.62	5.16	0.31	5e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.6	6.42	0.38	6.88e-10	Urate levels in lean individuals;
KIRP	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs236907	0.859	rs36080557	chr1:171764003	A/G	cg01410279	chr1:171621941	MYOC	-0.47	-5.46	-0.33	1.14e-7	Mean platelet volume;
KIRP	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg02038168	chr22:39784481	NA	-0.4	-4.99	-0.3	1.16e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg26727032	chr16:67993705	SLC12A4	-0.61	-6.15	-0.36	3.13e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-10.04	-0.54	4.11e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs10861342	1.000	rs11112398	chr12:105572967	A/G	cg23923672	chr12:105501055	KIAA1033	0.81	6.81	0.4	7.55e-11	IgG glycosylation;
KIRP	cis	rs3739034	0.877	rs78877892	chr2:135516504	A/G	cg15546071	chr2:135691756	CCNT2	-0.52	-4.85	-0.3	2.18e-6	Gut microbiome composition (winter);
KIRP	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg02297831	chr4:17616191	MED28	0.59	7.22	0.42	6.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21864845	chr1:1208426	UBE2J2	0.6	7.06	0.41	1.72e-11	Smoking initiation;
KIRP	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg12718519	chr1:2058417	PRKCZ	-0.22	-4.88	-0.3	1.94e-6	Height;
KIRP	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg19025524	chr12:109796872	NA	-0.42	-5.55	-0.33	7.34e-8	Neuroticism;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg18209359	chr17:80159595	CCDC57	-0.42	-5.54	-0.33	7.91e-8	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22517316	chr8:42128500	IKBKB	0.5	7.04	0.41	1.96e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10214930	0.671	rs10951172	chr7:27614111	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.92	0.3	1.59e-6	Hypospadias;
KIRP	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg22089800	chr15:90895588	ZNF774	0.47	5.59	0.34	6.16e-8	Rheumatoid arthritis;
KIRP	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg07777115	chr5:623756	CEP72	-0.59	-6.0	-0.36	7.19e-9	Obesity-related traits;
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg22325292	chr17:80708367	FN3K	0.37	4.86	0.3	2.1e-6	Glycated hemoglobin levels;
KIRP	cis	rs524023	0.914	rs526338	chr11:64418900	G/A	cg09231725	chr11:64357281	SLC22A12	0.59	7.89	0.45	9.83e-14	Urate levels in obese individuals;
KIRP	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.49	6.12	0.36	3.58e-9	Depressive symptoms;
KIRP	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.77	0.63	5.26e-29	Bladder cancer;
KIRP	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	9.63	0.52	7.66e-19	Lung cancer in ever smokers;
KIRP	cis	rs6908034	0.660	rs7746588	chr6:19804640	C/T	cg02682789	chr6:19804855	NA	0.87	6.54	0.38	3.52e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
KIRP	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg04317338	chr11:64019027	PLCB3	0.55	6.47	0.38	5.29e-10	Platelet count;
KIRP	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.79	-5.55	-0.33	7.51e-8	Hippocampal volume;
KIRP	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18932078	chr1:2524107	MMEL1	-0.46	-6.43	-0.38	6.48e-10	Ulcerative colitis;
KIRP	cis	rs7560272	0.588	rs4852959	chr2:73880601	C/A	cg20560298	chr2:73613845	ALMS1	0.49	6.08	0.36	4.65e-9	Schizophrenia;
KIRP	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.56	-8.26	-0.47	9.32e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.74	11.98	0.61	2.39e-26	Mean corpuscular volume;
KIRP	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg23594656	chr7:65796392	TPST1	-0.49	-7.57	-0.43	7.38e-13	Aortic root size;
KIRP	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.9	-12.62	-0.63	1.72e-28	Coronary artery disease;
KIRP	cis	rs6772849	0.930	rs7639400	chr3:128323356	T/C	cg08795948	chr3:128337044	NA	0.52	6.26	0.37	1.68e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.22	-0.32	3.73e-7	Triglycerides;
KIRP	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs11169552	0.510	rs11169507	chr12:51015509	A/G	cg12884762	chr12:50931848	DIP2B	0.44	5.34	0.32	2.14e-7	Colorectal cancer;
KIRP	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg19847130	chr8:10466454	RP1L1	0.37	5.34	0.32	2.1e-7	Retinal vascular caliber;
KIRP	cis	rs17428704	0.571	rs7706484	chr5:14379066	T/G	cg26595256	chr5:14380529	TRIO	-0.85	-6.64	-0.39	1.97e-10	Electroencephalogram traits;
KIRP	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.87	0.4	5.13e-11	Retinal vascular caliber;
KIRP	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg08738300	chr3:44038990	NA	0.7	9.81	0.53	2.24e-19	Coronary artery disease;
KIRP	cis	rs8103278	0.701	rs116959973	chr19:46252333	A/T	cg11657440	chr19:46296263	DMWD	-0.69	-6.97	-0.41	2.83e-11	Coronary artery disease;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.62	0.34	5.11e-8	Lung cancer;
KIRP	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.86	-12.54	-0.62	3.21e-28	Eye color traits;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg11814155	chr7:99998594	ZCWPW1	0.54	5.38	0.32	1.76e-7	Platelet count;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13498382	chr3:101039920	IMPG2	0.41	6.07	0.36	4.73e-9	C-reactive protein;
KIRP	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9914544	0.564	rs11548434	chr17:18761508	G/A	cg26378065	chr17:18585709	ZNF286B	0.38	4.91	0.3	1.64e-6	Educational attainment (years of education);
KIRP	cis	rs10186029	0.509	rs13426230	chr2:213940447	G/A	cg08319019	chr2:214017104	IKZF2	-0.44	-5.23	-0.32	3.67e-7	Systemic sclerosis;
KIRP	cis	rs2371030	0.796	rs2287416	chr2:211580219	A/G	cg18417063	chr2:211583084	NA	-0.45	-6.28	-0.37	1.48e-9	Non-small cell lung cancer;
KIRP	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.98	-0.36	8.01e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.93	0.3	1.49e-6	Menopause (age at onset);
KIRP	cis	rs17428704	0.571	rs62345012	chr5:14379945	G/A	cg26595256	chr5:14380529	TRIO	-0.85	-6.64	-0.39	1.97e-10	Electroencephalogram traits;
KIRP	cis	rs4523957	0.671	rs12103726	chr17:2192839	C/T	cg16513277	chr17:2031491	SMG6	-0.5	-5.94	-0.35	9.74e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg00343986	chr7:65444356	GUSB	0.41	4.93	0.3	1.51e-6	Aortic root size;
KIRP	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	0.95	12.13	0.61	7.65e-27	Blood protein levels;
KIRP	cis	rs922692	0.744	rs4886592	chr15:79082547	T/C	cg04896959	chr15:78267971	NA	0.52	6.87	0.4	5.18e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.43	6.67	0.39	1.63e-10	Lung cancer;
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.64	0.34	4.56e-8	Lung cancer;
KIRP	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.25	0.55	9.26e-21	Hip circumference adjusted for BMI;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08431062	chr19:16607243	C19orf44;CALR3	0.64	6.04	0.36	5.6e-9	Lung function (FEV1);
KIRP	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.64	-7.12	-0.41	1.2e-11	Multiple sclerosis;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03079549	chr15:45879223	PLDN	0.74	6.39	0.38	8.22e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	cg21523751	chr1:182988639	NA	0.41	6.3	0.37	1.37e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.54	5.71	0.34	3.22e-8	Response to diuretic therapy;
KIRP	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	8.36	0.47	4.6e-15	Motion sickness;
KIRP	cis	rs9826463	1.000	rs9868309	chr3:142335332	A/G	cg20824294	chr3:142316082	PLS1	0.31	5.38	0.32	1.7e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg09788416	chr12:39539408	NA	0.37	5.07	0.31	7.96e-7	Morning vs. evening chronotype;
KIRP	cis	rs35740288	0.822	rs2241268	chr15:86278309	G/A	cg17133734	chr15:86042851	AKAP13	-0.49	-5.31	-0.32	2.47e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20314438	chr6:126661369	C6orf173	0.57	7.06	0.41	1.69e-11	Smoking initiation;
KIRP	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.49	5.42	0.33	1.44e-7	Dermatomyositis;
KIRP	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03264133	chr6:25882463	NA	0.41	5.39	0.32	1.67e-7	Height;
KIRP	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs10073892	0.662	rs1376901	chr5:101642861	G/A	cg19774478	chr5:101632501	SLCO4C1	0.62	6.38	0.38	8.78e-10	Cognitive decline (age-related);
KIRP	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.8	9.52	0.52	1.7e-18	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg08591472	chr7:1030197	NA	-0.39	-4.92	-0.3	1.59e-6	Longevity;Endometriosis;
KIRP	cis	rs662064	0.748	rs2506892	chr1:10598216	G/A	cg19773385	chr1:10388646	KIF1B	-0.39	-5.09	-0.31	6.99e-7	Asthma;
KIRP	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg23594656	chr7:65796392	TPST1	0.51	7.89	0.45	9.9e-14	Aortic root size;
KIRP	cis	rs8113308	0.810	rs16983256	chr19:52449481	G/A	cg25782003	chr19:52490127	ZNF350	0.54	5.11	0.31	6.44e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.51	5.97	0.36	8.15e-9	Longevity;Endometriosis;
KIRP	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.38	0.7	7.34e-38	Gut microbiome composition (summer);
KIRP	cis	rs2282032	0.527	rs8004573	chr14:90765743	C/T	cg04374321	chr14:90722782	PSMC1	0.57	6.9	0.4	4.3e-11	Longevity;
KIRP	cis	rs35995292	1.000	rs10266891	chr7:38914805	A/G	cg19327137	chr7:38886074	VPS41	0.52	6.14	0.36	3.32e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11987759	chr7:65425863	GUSB	-0.55	-6.95	-0.4	3.32e-11	Aortic root size;
KIRP	cis	rs9420	0.528	rs34052104	chr11:57384519	A/C	cg23127183	chr11:57508653	C11orf31	-0.46	-5.35	-0.32	1.99e-7	Schizophrenia;
KIRP	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.48	5.77	0.35	2.33e-8	Tuberculosis;
KIRP	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	8.94	0.5	9.68e-17	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs714515	0.934	rs1011731	chr1:172346548	A/G	cg01573306	chr1:172330400	DNM3	-0.4	-4.85	-0.3	2.18e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	5.99	0.36	7.4e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.65	-9.61	-0.52	9.18e-19	Prostate cancer;
KIRP	trans	rs972578	0.765	rs738536	chr22:43260427	C/T	cg15321293	chr3:36422198	STAC	-0.46	-6.07	-0.36	4.71e-9	Mean platelet volume;
KIRP	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs925255	0.743	rs7600164	chr2:28644862	A/T	cg01273330	chr2:28605224	NA	-0.36	-6.28	-0.37	1.5e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.67	-5.98	-0.36	7.63e-9	Menarche (age at onset);
KIRP	cis	rs35740288	0.539	rs4843100	chr15:86339210	G/C	cg20737812	chr15:86336631	KLHL25	-0.5	-5.72	-0.34	3.05e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.6	0.56	7.26e-22	Cognitive test performance;
KIRP	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.56	0.39	3.1e-10	Height;
KIRP	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	0.94	14.54	0.68	5.3e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2573652	1.000	rs2581363	chr15:100513364	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.7	-10.51	-0.56	1.41e-21	Height;
KIRP	cis	rs17209837	1.000	rs45546132	chr7:87086140	C/T	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg05669848	chr5:237993	SDHA	-0.47	-4.96	-0.3	1.31e-6	Breast cancer;
KIRP	cis	rs7572644	0.699	rs1458398	chr2:28219941	A/G	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.61	7.89	0.45	1.01e-13	Vitiligo;
KIRP	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg02151108	chr14:50098012	C14orf104	-0.57	-7.95	-0.45	6.72e-14	Carotid intima media thickness;
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg21851534	chr17:3907994	ZZEF1	-0.62	-9.6	-0.52	9.83e-19	Type 2 diabetes;
KIRP	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.81	-13.79	-0.66	1.97e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1971762	0.527	rs6580950	chr12:53926656	T/A	cg16917193	chr12:54089295	NA	0.66	10.53	0.56	1.24e-21	Height;
KIRP	cis	rs220324	0.683	rs220323	chr21:43586658	C/G	cg08841829	chr21:43638893	ABCG1	-0.43	-5.54	-0.33	7.78e-8	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.79	-11.2	-0.58	8.33e-24	Blood metabolite levels;
KIRP	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.43	8.47	0.48	2.31e-15	Coronary artery disease;
KIRP	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.13	-0.31	5.79e-7	Tonsillectomy;
KIRP	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.25	-0.7	2.03e-37	Headache;
KIRP	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	cg12689670	chr1:183009347	LAMC1	0.47	6.81	0.4	7.36e-11	Hypertriglyceridemia;
KIRP	cis	rs8038465	0.967	rs61012032	chr15:73973978	C/T	cg15420318	chr15:73925796	NPTN	0.57	7.23	0.42	6.25e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs240764	0.658	rs9390681	chr6:101218994	A/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs113084984	0.718	rs1865574	chr2:11681438	A/G	cg07314298	chr2:11723111	GREB1	0.41	5.37	0.32	1.84e-7	Breast cancer;
KIRP	cis	rs16936870	0.543	rs2926701	chr8:71170604	C/T	cg14232793	chr8:71155543	NCOA2	-0.54	-6.24	-0.37	1.89e-9	QT interval;
KIRP	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.75	10.62	0.56	6.06e-22	Neurofibrillary tangles;
KIRP	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.59	-7.15	-0.41	9.73e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.42	5.35	0.32	2.01e-7	Aortic root size;
KIRP	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-6.93	-0.4	3.63e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.52	-0.38	3.87e-10	Lung cancer;
KIRP	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg20140201	chr2:241835670	C2orf54	-0.34	-5.2	-0.31	4.21e-7	Urinary metabolites;
KIRP	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.13	-0.41	1.13e-11	Triglycerides;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20685352	chr3:47823121	SMARCC1	0.48	6.44	0.38	6.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.72	-10.38	-0.55	3.57e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04884046	chr1:97187411	PTBP2	0.5	6.63	0.39	2.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg05562828	chr17:3906858	NA	0.51	5.33	0.32	2.19e-7	Type 2 diabetes;
KIRP	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.72	10.37	0.55	3.81e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	7.85e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg11031976	chr2:198649780	BOLL	0.51	4.95	0.3	1.38e-6	Ulcerative colitis;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.68	10.29	0.55	6.7e-21	Menarche (age at onset);
KIRP	cis	rs11997175	0.603	rs11778978	chr8:33804743	G/T	cg04338863	chr8:33670619	NA	0.38	4.86	0.3	2.05e-6	Body mass index;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15459342	chr1:228296991	MRPL55	0.66	6.18	0.37	2.7e-9	Lung function (FEV1);
KIRP	cis	rs4594175	0.926	rs66625118	chr14:51631062	T/C	cg23942311	chr14:51606299	NA	0.53	7.0	0.41	2.42e-11	Cancer;
KIRP	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg14703610	chr5:56206110	C5orf35	0.49	6.66	0.39	1.75e-10	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg10362475	chr11:70507825	SHANK2	0.37	5.07	0.31	7.9e-7	Renal transplant outcome;
KIRP	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.78	-9.31	-0.51	7.67e-18	Orofacial clefts;
KIRP	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.51	-6.7	-0.39	1.38e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs926938	0.783	rs2144428	chr1:115269211	G/A	cg12756093	chr1:115239321	AMPD1	-0.71	-10.09	-0.54	2.95e-20	Autism;
KIRP	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg03146154	chr1:46216737	IPP	0.46	4.88	0.3	1.95e-6	Platelet count;
KIRP	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.95	-17.88	-0.75	2.2e-46	Dental caries;
KIRP	cis	rs7520050	0.898	rs785502	chr1:46581444	T/C	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs17818399	0.781	rs34449783	chr2:46863555	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.45	0.33	1.25e-7	Height;
KIRP	cis	rs9659323	1.000	rs9659323	chr1:119504361	A/G	cg18261050	chr1:119551319	NA	0.35	4.9	0.3	1.75e-6	Body mass index;
KIRP	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg00814883	chr7:100076585	TSC22D4	-0.51	-5.02	-0.3	1.01e-6	Lung function (FEV1/FVC);
KIRP	cis	rs756777	1.000	rs739451	chr9:136678954	T/C	cg14069709	chr9:136671979	VAV2	-0.5	-5.36	-0.32	1.91e-7	IgG glycosylation;
KIRP	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.59	-7.27	-0.42	4.63e-12	Gastritis;
KIRP	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.37	-4.87	-0.3	1.95e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg14829155	chr15:31115871	NA	-0.77	-9.53	-0.52	1.56e-18	Huntington's disease progression;
KIRP	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg00262122	chr8:11665843	FDFT1	0.44	5.37	0.32	1.85e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-6.77	-0.4	9.14e-11	Menarche (age at onset);
KIRP	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg13010199	chr12:38710504	ALG10B	0.48	6.27	0.37	1.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	9.45	0.52	2.73e-18	Cognitive test performance;
KIRP	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.41	-5.9	-0.35	1.17e-8	Height;
KIRP	cis	rs1270639	0.778	rs2906933	chr7:157450749	T/A	cg13357408	chr7:157437802	PTPRN2	0.67	6.44	0.38	6.21e-10	Colorectal cancer;
KIRP	trans	rs1941687	0.831	rs12954615	chr18:31384449	G/T	cg27147174	chr7:100797783	AP1S1	-0.54	-6.73	-0.39	1.17e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-12.92	-0.64	1.7e-29	Dental caries;
KIRP	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.77	10.16	0.54	1.73e-20	Aortic root size;
KIRP	cis	rs714515	0.934	rs9425591	chr1:172358697	G/T	cg01573306	chr1:172330400	DNM3	0.44	5.79	0.35	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.65	0.52	7.06e-19	Dupuytren's disease;
KIRP	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.26	-0.51	1.06e-17	Personality dimensions;
KIRP	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg19847130	chr8:10466454	RP1L1	0.37	5.46	0.33	1.16e-7	Neuroticism;
KIRP	cis	rs12615966	0.651	rs58796108	chr2:105408088	T/A	cg16465502	chr2:105461796	NA	0.95	7.88	0.45	1.05e-13	Pancreatic cancer;
KIRP	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.46	0.38	5.58e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.48	-6.05	-0.36	5.22e-9	Retinal vascular caliber;
KIRP	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.39	-0.32	1.68e-7	Coronary artery disease;
KIRP	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	0.71	6.44	0.38	6.26e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg05775895	chr3:12838266	CAND2	0.45	7.44	0.43	1.68e-12	QRS complex (12-leadsum);
KIRP	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.77	-11.03	-0.58	2.9e-23	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.64	8.53	0.48	1.54e-15	Lung cancer;
KIRP	cis	rs3026101	0.671	rs8066702	chr17:5310121	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.65	0.39	1.84e-10	Body mass index;
KIRP	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg08648136	chr8:956695	NA	0.48	6.46	0.38	5.57e-10	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24575065	chr7:72972219	BCL7B	0.5	6.24	0.37	1.87e-9	Parkinson's disease;
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.49	-6.25	-0.37	1.79e-9	Testicular germ cell tumor;
KIRP	cis	rs16828019	0.704	rs4996176	chr1:41488168	G/T	cg03387723	chr1:41708464	SCMH1	-0.72	-6.19	-0.37	2.44e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg20637307	chr2:213403960	ERBB4	0.95	17.02	0.74	1.8e-43	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg26876637	chr1:152193138	HRNR	0.78	10.24	0.55	9.91e-21	Atopic dermatitis;
KIRP	cis	rs4006360	0.575	rs67524820	chr17:39318208	T/C	cg16985667	chr17:39306289	KRTAP4-5	0.46	6.29	0.37	1.43e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1011728	0.531	rs10459170	chr12:85756685	C/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	0.41	5.49	0.33	1.01e-7	Bone mineral density (Ward's triangle area);
KIRP	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.74	-0.44	2.64e-13	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4690686	0.500	rs72623908	chr4:177261971	A/G	cg17059388	chr4:177262070	NA	0.86	12.45	0.62	6.18e-28	Essential tremor;
KIRP	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	0.71	7.16	0.42	9.29e-12	Methadone dose in opioid dependence;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10703506	chr12:109576250	ACACB	0.57	6.6	0.39	2.46e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09273779	chr9:35605990	TESK1	0.66	6.19	0.37	2.49e-9	Lung function (FEV1);
KIRP	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg24315340	chr6:146058215	EPM2A	0.42	5.19	0.31	4.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11987759	chr7:65425863	GUSB	0.45	5.16	0.31	4.98e-7	Aortic root size;
KIRP	cis	rs11074306	0.561	rs4778184	chr15:28065033	C/T	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.62e-6	Uveal melanoma;
KIRP	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	11.4	0.59	1.85e-24	Total body bone mineral density;
KIRP	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.79	-10.72	-0.56	3.07e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg01338139	chr15:38987640	C15orf53	-0.56	-6.32	-0.37	1.19e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg06795125	chr2:108905320	SULT1C2	-0.39	-7.18	-0.42	8e-12	Blood pressure;
KIRP	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-11.08	-0.58	2.09e-23	Response to antipsychotic treatment;
KIRP	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.36	-0.38	9.51e-10	Response to antipsychotic treatment;
KIRP	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.8	-9.72	-0.53	4.23e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.58	-6.09	-0.36	4.26e-9	Obesity-related traits;
KIRP	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	10.27	0.55	8.21e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs12044355	0.927	rs16854809	chr1:231839247	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.27	0.32	3.01e-7	Alzheimer's disease;
KIRP	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	5.06	0.31	8.34e-7	Height;
KIRP	cis	rs7005380	0.538	rs1879149	chr8:120931825	C/G	cg21645572	chr8:120931649	DEPDC6	-0.52	-7.24	-0.42	5.77e-12	Interstitial lung disease;
KIRP	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg04935436	chr20:30431758	NA	0.5	6.61	0.39	2.41e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg19875535	chr5:140030758	IK	0.56	7.1	0.41	1.34e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.48	-6.22	-0.37	2.07e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg07636037	chr3:49044803	WDR6	0.64	9.23	0.51	1.33e-17	Resting heart rate;
KIRP	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.47	0.59	1.11e-24	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09032791	chr1:200815860	CAMSAP1L1	-0.41	-6.44	-0.38	6.22e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7656342	0.622	rs10939558	chr4:9844162	T/C	cg11266682	chr4:10021025	SLC2A9	0.32	4.98	0.3	1.17e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg19731401	chr7:2775893	GNA12	0.68	5.97	0.36	8.27e-9	Childhood ear infection;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08163220	chr3:31574309	STT3B	0.48	6.63	0.39	2.15e-10	Survival in pancreatic cancer;
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg09335321	chr1:153940547	CREB3L4;SLC39A1	-0.83	-6.07	-0.36	4.9e-9	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg02378861	chr5:212933	CCDC127	-0.69	-5.49	-0.33	9.88e-8	Fat distribution (HIV);
KIRP	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.4	-5.16	-0.31	5.08e-7	Parkinson's disease;
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22168489	chr12:122356033	WDR66	0.6	8.9	0.49	1.23e-16	Mean corpuscular volume;
KIRP	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg12560992	chr17:57184187	TRIM37	0.54	5.83	0.35	1.74e-8	Cognitive test performance;
KIRP	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg07274523	chr3:49395745	GPX1	0.69	8.37	0.47	4.44e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6723108	0.515	rs2156000	chr2:135546430	C/T	cg25422880	chr2:135218333	TMEM163	-0.45	-6.18	-0.37	2.6e-9	Type 2 diabetes;
KIRP	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-6.35	-0.38	1.03e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2151522	0.603	rs11154374	chr6:127200494	C/A	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	7.2	0.42	7.44e-12	Depressive symptoms;
KIRP	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg03060546	chr3:49711283	APEH	0.43	5.49	0.33	9.81e-8	Parkinson's disease;
KIRP	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.96	15.86	0.71	1.7e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11166927	1.000	rs10435690	chr8:140802093	C/T	cg16909799	chr8:140841666	TRAPPC9	0.65	9.2	0.51	1.62e-17	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg09184832	chr6:79620586	NA	-0.39	-5.02	-0.3	9.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg04865290	chr3:52927548	TMEM110	0.56	6.79	0.4	8.51e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs7939886	0.920	rs11227372	chr11:55919682	C/A	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.64	8.08	0.46	2.84e-14	Coronary artery disease;
KIRP	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18252515	chr7:66147081	NA	0.44	5.11	0.31	6.43e-7	Aortic root size;
KIRP	cis	rs67257959	0.708	rs10412843	chr19:17198287	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	5.79	0.35	2.13e-8	Selective IgA deficiency;
KIRP	cis	rs10982256	0.817	rs10817632	chr9:117270853	T/C	cg13636371	chr9:117264095	DFNB31	-0.4	-5.21	-0.32	4e-7	Bipolar disorder;
KIRP	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.16	0.5	2.16e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.35	-4.89	-0.3	1.85e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.87	12.43	0.62	7.37e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.78	-6.53	-0.38	3.75e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs737693	1.000	rs72981675	chr11:102721251	C/T	cg19620758	chr11:102826565	MMP13	0.71	5.68	0.34	3.79e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs73086581	1.000	rs17214621	chr20:3925924	T/C	cg02187196	chr20:3869020	PANK2	0.5	4.9	0.3	1.7e-6	Response to antidepressants in depression;
KIRP	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	9.15	0.5	2.19e-17	Mean platelet volume;
KIRP	cis	rs734999	0.967	rs6671426	chr1:2504234	C/A	cg20673091	chr1:2541236	MMEL1	0.4	5.55	0.33	7.23e-8	Ulcerative colitis;
KIRP	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg01879757	chr17:41196368	BRCA1	-0.58	-7.84	-0.45	1.4e-13	Menopause (age at onset);
KIRP	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11987759	chr7:65425863	GUSB	-0.54	-7.14	-0.41	1.04e-11	Aortic root size;
KIRP	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-5.96	-0.36	8.8e-9	Obesity (extreme);
KIRP	cis	rs2120243	0.539	rs7618737	chr3:157095621	G/A	cg24825693	chr3:157122686	VEPH1	-0.56	-9.04	-0.5	4.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs7715811	1.000	rs7715552	chr5:13769959	A/T	cg07548982	chr5:13769939	DNAH5	-0.55	-6.91	-0.4	4.07e-11	Subclinical atherosclerosis traits (other);
KIRP	cis	rs7656342	0.653	rs13142238	chr4:9846244	T/C	cg11266682	chr4:10021025	SLC2A9	0.33	5.06	0.31	8.2e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2119480	0.793	rs7317796	chr13:111313674	C/T	cg16216153	chr13:111290848	CARKD	0.37	5.02	0.3	9.92e-7	Diastolic blood pressure;
KIRP	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg03929089	chr4:120376271	NA	0.69	6.11	0.36	3.84e-9	Axial length;
KIRP	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.75	10.48	0.56	1.75e-21	Parkinson's disease;
KIRP	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-5.69	-0.34	3.58e-8	Educational attainment;
KIRP	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.24e-10	Hypertriglyceridemia;
KIRP	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.69	-0.34	3.58e-8	Retinal vascular caliber;
KIRP	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg23752985	chr2:85803571	VAMP8	0.51	6.15	0.36	3.14e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.52	-0.38	3.99e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.86	-0.45	1.2e-13	Bipolar disorder;
KIRP	cis	rs7103648	0.864	rs71475909	chr11:47377283	A/G	cg03711944	chr11:47377212	SPI1	-0.34	-5.39	-0.33	1.62e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.6	-6.76	-0.4	9.75e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8028182	0.636	rs62027209	chr15:75871626	A/G	cg20655648	chr15:75932815	IMP3	0.58	7.23	0.42	6.17e-12	Sudden cardiac arrest;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18881776	chr1:28052146	FAM76A	0.92	6.18	0.37	2.57e-9	P wave terminal force;
KIRP	cis	rs3768716	0.500	rs777329	chr2:215742595	A/G	cg04004882	chr2:215674386	BARD1	-0.59	-5.68	-0.34	3.81e-8	Neuroblastoma;
KIRP	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg23752985	chr2:85803571	VAMP8	0.45	5.28	0.32	2.87e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg12963866	chr19:57752005	ZNF805	-0.48	-6.17	-0.37	2.75e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs7224685	0.569	rs8082425	chr17:3991706	C/G	cg11204139	chr17:3907470	NA	0.57	5.31	0.32	2.4e-7	Type 2 diabetes;
KIRP	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg21108841	chr4:24914750	CCDC149	-0.45	-5.51	-0.33	9.15e-8	Heschl's gyrus morphology;
KIRP	cis	rs989978	0.532	rs10883364	chr10:101287586	A/G	cg07044859	chr10:101282883	NA	-0.34	-5.02	-0.3	1.01e-6	Red blood cell count;
KIRP	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg03970086	chr16:88974840	CBFA2T3	0.42	5.49	0.33	1.02e-7	Social autistic-like traits;
KIRP	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg16141378	chr3:129829833	LOC729375	0.53	6.98	0.41	2.68e-11	Retinal vascular caliber;
KIRP	cis	rs6832769	1.000	rs3736544	chr4:56309992	A/G	cg09317128	chr4:56265301	TMEM165	0.55	7.01	0.41	2.23e-11	Personality dimensions;
KIRP	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg03585969	chr10:35415529	CREM	0.77	9.12	0.5	2.7e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12130219	1.000	rs12733173	chr1:152173972	C/T	cg26879891	chr1:152191343	HRNR	0.5	6.12	0.36	3.71e-9	Inflammatory skin disease;
KIRP	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.39	-0.55	3.23e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01749555	chr17:80709803	TBCD	0.55	6.97	0.41	2.94e-11	Parkinson's disease;
KIRP	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg27205649	chr11:78285834	NARS2	0.62	7.27	0.42	4.83e-12	Alzheimer's disease (survival time);
KIRP	cis	rs2072732	0.821	rs12038530	chr1:2946726	T/A	cg11731671	chr1:2995604	PRDM16	-0.39	-5.13	-0.31	5.97e-7	Plateletcrit;
KIRP	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg19743168	chr1:23544995	NA	0.49	6.81	0.4	7.62e-11	Height;
KIRP	cis	rs9436747	0.874	rs7531110	chr1:65937065	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.43	-5.13	-0.31	5.99e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.4	-5.57	-0.33	6.61e-8	Post-traumatic stress disorder;
KIRP	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg03146154	chr1:46216737	IPP	0.56	5.93	0.35	1.04e-8	Platelet count;
KIRP	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.7	7.14	0.41	1.05e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg04731861	chr2:219085781	ARPC2	-0.26	-6.58	-0.39	2.79e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1134634	0.520	rs11932730	chr4:15565758	C/T	cg16509355	chr4:15471240	CC2D2A	0.31	5.24	0.32	3.51e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7804356	0.906	rs12540388	chr7:26905731	A/T	cg03456212	chr7:26904342	SKAP2	-0.57	-5.18	-0.31	4.55e-7	Type 1 diabetes;
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.23e-8	Life satisfaction;
KIRP	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg06115741	chr20:33292138	TP53INP2	-0.36	-4.94	-0.3	1.46e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg04691961	chr3:161091175	C3orf57	-0.57	-8.97	-0.5	7.6e-17	Morning vs. evening chronotype;
KIRP	cis	rs12780845	0.540	rs2273735	chr10:17216419	T/C	cg01003015	chr10:17271136	VIM	0.41	5.31	0.32	2.46e-7	Homocysteine levels;
KIRP	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.91e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg00204512	chr16:28754710	NA	0.49	6.36	0.38	9.92e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.35e-11	Aortic root size;
KIRP	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.48	-6.88	-0.4	4.89e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg03929089	chr4:120376271	NA	0.72	6.45	0.38	6.04e-10	Axial length;
KIRP	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.44	5.64	0.34	4.55e-8	Height;
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg01324507	chr7:1177794	C7orf50	-0.4	-4.9	-0.3	1.78e-6	Longevity;Endometriosis;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg22800045	chr5:56110881	MAP3K1	-0.6	-6.77	-0.4	9.52e-11	Type 2 diabetes;
KIRP	cis	rs7011049	0.841	rs6473777	chr8:53875544	G/C	cg26025543	chr8:53854495	NA	0.59	6.46	0.38	5.72e-10	Systolic blood pressure;
KIRP	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.13	-0.31	5.8e-7	Systolic blood pressure;
KIRP	trans	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg01311341	chr22:25575246	KIAA1671	-0.61	-7.26	-0.42	5.11e-12	Atopic dermatitis;
KIRP	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg07382826	chr16:28625726	SULT1A1	0.47	5.7	0.34	3.42e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg05665937	chr4:1216051	CTBP1	0.52	7.28	0.42	4.47e-12	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13229058	chr4:118951756	NA	-0.41	-6.45	-0.38	5.96e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7721647	0.853	rs6863217	chr5:90867259	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs7078219	0.523	rs4129134	chr10:101284345	C/G	cg07044859	chr10:101282883	NA	-0.3	-5.2	-0.31	4.15e-7	Dental caries;
KIRP	cis	rs2033732	0.706	rs6473525	chr8:85070206	A/G	cg05716166	chr8:85095498	RALYL	0.52	5.91	0.35	1.12e-8	Body mass index;
KIRP	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.97	9.86	0.53	1.53e-19	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7246657	0.598	rs28660259	chr19:37658681	C/T	cg23950597	chr19:37808831	NA	-0.67	-5.65	-0.34	4.53e-8	Coronary artery calcification;
KIRP	cis	rs7819412	0.582	rs2409685	chr8:10909193	C/A	cg09559047	chr8:10916868	XKR6	0.39	5.48	0.33	1.07e-7	Triglycerides;
KIRP	cis	rs2387326	0.717	rs10829337	chr10:129943548	T/C	cg16087940	chr10:129947807	NA	-0.36	-5.01	-0.3	1.05e-6	Select biomarker traits;
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21211367	chr2:162094118	NA	0.41	5.45	0.33	1.22e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg12315302	chr6:26189340	HIST1H4D	1.08	6.49	0.38	4.71e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg05347473	chr6:146136440	FBXO30	0.48	7.11	0.41	1.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1538970	1.000	rs2050884	chr1:45830824	A/G	cg05343316	chr1:45956843	TESK2	0.63	7.27	0.42	4.91e-12	Platelet count;
KIRP	cis	rs1620921	0.505	rs13203571	chr6:161208765	A/G	cg01280913	chr6:161186852	NA	-0.62	-8.39	-0.47	3.77e-15	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg27124370	chr19:33622961	WDR88	0.68	9.01	0.5	6.01e-17	Colorectal cancer;
KIRP	cis	rs501120	0.584	rs11238937	chr10:44719816	T/A	cg09554077	chr10:44749378	NA	0.69	7.61	0.44	5.93e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1847202	0.859	rs6805260	chr3:72933767	C/T	cg25664220	chr3:72788482	NA	-0.36	-5.2	-0.31	4.19e-7	Motion sickness;
KIRP	cis	rs7851660	0.839	rs7027221	chr9:100662379	T/C	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs17818399	0.815	rs62136873	chr2:46861237	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.44	0.33	1.27e-7	Height;
KIRP	cis	rs6693295	1.000	rs10924477	chr1:246222534	G/A	cg11798871	chr1:246315928	SMYD3	-0.44	-5.21	-0.32	4.02e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7119167	0.540	rs113608693	chr11:73048665	G/A	cg17517138	chr11:73019481	ARHGEF17	0.47	4.91	0.3	1.67e-6	Blood protein levels;
KIRP	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.55	6.14	0.36	3.37e-9	Blood metabolite levels;
KIRP	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-10.96	-0.57	5.05e-23	Coronary artery disease;
KIRP	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg13012494	chr21:47604986	C21orf56	0.4	4.95	0.3	1.36e-6	Testicular germ cell tumor;
KIRP	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg16329650	chr2:213403929	ERBB4	-0.44	-6.1	-0.36	4.01e-9	Symmetrical dimethylarginine levels;
KIRP	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg18944383	chr4:111397179	ENPEP	-0.4	-6.51	-0.38	4.16e-10	Coronary artery disease;
KIRP	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.46	5.38	0.32	1.72e-7	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72843166	0.947	rs72843145	chr17:61052949	T/C	cg19683800	chr17:61518354	CYB561	-0.44	-5.1	-0.31	6.71e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.05	0.36	5.4e-9	Mood instability;
KIRP	cis	rs6992848	0.791	rs35391756	chr8:141167677	C/T	cg13911501	chr8:141220320	TRAPPC9	0.41	4.94	0.3	1.41e-6	Response to amphetamines;
KIRP	cis	rs6577655	0.517	rs4909293	chr8:135587888	G/A	cg17885191	chr8:135476712	NA	0.7	6.65	0.39	1.86e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg19773385	chr1:10388646	KIF1B	-0.72	-10.18	-0.54	1.54e-20	Hepatocellular carcinoma;
KIRP	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.2	21.77	0.81	2.68e-59	Cognitive function;
KIRP	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.31	-0.32	2.42e-7	Gut microbiome composition (summer);
KIRP	cis	rs9581857	0.547	rs9581882	chr13:28110682	C/G	cg22138327	chr13:27999177	GTF3A	0.72	5.75	0.34	2.69e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg14593290	chr7:50529359	DDC	0.67	8.32	0.47	6.13e-15	Malaria;
KIRP	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.78	10.46	0.55	2.06e-21	Aortic root size;
KIRP	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs17221829	0.617	rs1844194	chr11:89389367	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15945016	chr6:26020698	HIST1H4A;HIST1H3A	0.48	6.26	0.37	1.69e-9	Parkinson's disease;
KIRP	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs7903847	0.642	rs7909345	chr10:99150794	T/C	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg08645402	chr16:4508243	NA	0.49	5.96	0.36	8.77e-9	Schizophrenia;
KIRP	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.98	10.27	0.55	8.18e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.8	9.47	0.52	2.4e-18	Response to antipsychotic treatment;
KIRP	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg14952266	chr13:112191215	NA	0.46	6.89	0.4	4.74e-11	Hepatitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12452946	chr4:128886867	MFSD8;C4orf29	0.46	6.49	0.38	4.67e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.24	0.47	1.01e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg08400319	chr2:242004533	SNED1	0.44	6.05	0.36	5.4e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.54	7.26	0.42	5.13e-12	Blood metabolite levels;
KIRP	cis	rs9217	0.776	rs11650977	chr17:7392341	A/G	cg02795151	chr17:7402630	POLR2A	0.56	6.81	0.4	7.57e-11	Height;
KIRP	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.49	0.62	4.56e-28	Ileal carcinoids;
KIRP	cis	rs7551222	0.683	rs898386	chr1:204579697	A/G	cg20240347	chr1:204465584	NA	-0.3	-5.3	-0.32	2.58e-7	Schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03337784	chr13:41768818	KBTBD7	0.44	6.07	0.36	4.8e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg24874828	chr4:187887005	NA	-0.47	-7.05	-0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.39	-5.6	-0.34	5.73e-8	Height;
KIRP	cis	rs11138902	0.673	rs11139279	chr9:72161412	C/T	cg14397918	chr9:72078829	APBA1	0.35	5.61	0.34	5.35e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs75920871	0.925	rs11823918	chr11:116960497	G/C	cg23684410	chr11:116897558	SIK3	0.52	5.21	0.32	3.94e-7	Subjective well-being;
KIRP	cis	rs829661	0.645	rs6759818	chr2:30780707	G/T	cg10949345	chr2:30726833	LCLAT1	0.97	13.9	0.66	8.5e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs73200209	0.703	rs57060349	chr12:116579304	T/C	cg01776926	chr12:116560359	MED13L	-0.53	-6.06	-0.36	5.08e-9	Total body bone mineral density;
KIRP	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs6841333	0.600	rs34740469	chr4:76911752	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.45	-4.96	-0.3	1.3e-6	Monokine induced by gamma interferon levels;
KIRP	cis	rs7017914	0.967	rs6472538	chr8:71586971	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs4704187	0.687	rs4703657	chr5:74461850	T/G	cg03227963	chr5:74354835	NA	0.39	5.67	0.34	3.92e-8	Response to amphetamines;
KIRP	cis	rs1832871	0.599	rs1539312	chr6:158743188	G/A	cg07215822	chr6:158701037	NA	0.59	8.68	0.48	5.48e-16	Height;
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.77	12.81	0.63	3.96e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg22800045	chr5:56110881	MAP3K1	0.78	7.57	0.43	7.46e-13	Type 2 diabetes;
KIRP	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.17	-0.37	2.74e-9	Daytime sleep phenotypes;
KIRP	trans	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	6.25	0.37	1.75e-9	Ulcerative colitis;
KIRP	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23281280	chr6:28129359	ZNF389	0.49	5.32	0.32	2.34e-7	Depression;
KIRP	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	ch.8.33884649F	chr8:33765107	NA	0.59	7.42	0.43	1.9e-12	Body mass index;
KIRP	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.45	-5.14	-0.31	5.47e-7	Neuroticism;
KIRP	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	cis	rs2361701	0.543	rs59252872	chr17:78071247	A/G	cg09238746	chr17:78121135	EIF4A3	-0.46	-5.18	-0.31	4.56e-7	IgG glycosylation;
KIRP	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.94	9.92	0.53	1.01e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-0.88	-11.44	-0.59	1.42e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg17757837	chr7:157058334	UBE3C	-0.92	-14.28	-0.67	4.2e-34	Body mass index;
KIRP	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.82	10.51	0.56	1.35e-21	Mean platelet volume;
KIRP	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	6.84	0.4	6.15e-11	Menarche (age at onset);
KIRP	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	1.08	9.26	0.51	1.03e-17	Blood protein levels;
KIRP	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.78	-7.16	-0.42	9.38e-12	Obesity-related traits;
KIRP	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg23533419	chr12:54090519	NA	-0.33	-5.16	-0.31	5.06e-7	Height;
KIRP	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-0.99	-10.64	-0.56	5.57e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.93e-10	Hypertriglyceridemia;
KIRP	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.84	10.63	0.56	5.94e-22	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs4843185	0.763	rs1974868	chr16:85710983	C/T	cg26571870	chr16:85723150	GINS2	-0.41	-5.0	-0.3	1.09e-6	Platelet distribution width;
KIRP	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg22325292	chr17:80708367	FN3K	-0.37	-5.01	-0.3	1.05e-6	Glycated hemoglobin levels;
KIRP	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.36	0.62	1.28e-27	Smoking behavior;
KIRP	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg00262122	chr8:11665843	FDFT1	0.4	5.07	0.31	7.98e-7	Neuroticism;
KIRP	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.94	-0.35	9.66e-9	Breast cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25152348	chr22:50946712	NCAPH2;LMF2	-0.47	-6.58	-0.39	2.76e-10	Myopia;
KIRP	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09225295	chr7:95405749	DYNC1I1	-0.44	-6.26	-0.37	1.71e-9	Inflammatory biomarkers;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10880834	chr17:55927538	MRPS23	-0.5	-6.79	-0.4	8.23e-11	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21881364	chr11:72438004	ARAP1	0.48	6.48	0.38	4.88e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs830383	0.653	rs31736	chr5:165451462	T/G	cg13976338	chr5:165423657	NA	-0.44	-5.48	-0.33	1.07e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6959887	0.926	rs17606656	chr7:35283049	G/A	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.38e-8	Schizophrenia;
KIRP	cis	rs9473924	0.632	rs9381907	chr6:50832457	A/C	cg03432817	chr6:50765336	NA	-0.35	-5.5	-0.33	9.57e-8	Body mass index;
KIRP	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg15556689	chr8:8085844	FLJ10661	0.71	10.09	0.54	2.97e-20	Triglycerides;
KIRP	cis	rs6585424	1.000	rs61860025	chr10:81925554	G/T	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs28595532	0.545	rs17516582	chr4:119296763	C/G	cg26518628	chr1:97050305	NA	-0.81	-6.13	-0.36	3.42e-9	Cannabis dependence symptom count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27281765	chr8:82358608	PMP2	-0.41	-6.42	-0.38	7.08e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg24804195	chr5:87968844	LOC645323	-0.45	-5.9	-0.35	1.19e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3736485	0.966	rs12592889	chr15:51795172	G/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.1	-0.31	6.83e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7923609	0.967	rs10509186	chr10:65207018	C/T	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.91	10.99	0.57	4.03e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-11.4	-0.59	1.92e-24	Colorectal cancer;
KIRP	cis	rs735539	0.645	rs9552248	chr13:21159200	G/A	cg04906043	chr13:21280425	IL17D	-0.53	-6.51	-0.38	4.2e-10	Dental caries;
KIRP	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.47	0.65	2.47e-31	Bladder cancer;
KIRP	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.44	-6.13	-0.36	3.44e-9	Obesity-related traits;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg01758115	chr16:48357692	LONP2	0.56	6.72	0.39	1.27e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22509189	chr2:225307070	NA	-0.53	-6.26	-0.37	1.67e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs3743772	1.000	rs3743772	chr16:53537423	C/A	cg05113697	chr16:53544098	NA	0.56	5.49	0.33	9.89e-8	Depressive symptoms (SSRI exposure interaction);
KIRP	cis	rs4006360	0.546	rs2874201	chr17:39238382	A/G	cg25341923	chr17:39239918	KRTAP4-7	0.63	9.88	0.53	1.32e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.5	-0.33	9.73e-8	Bipolar disorder;
KIRP	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.96	0.57	5.14e-23	Lung cancer in ever smokers;
KIRP	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs4356932	0.967	rs9999755	chr4:76961802	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.69	8.75	0.49	3.52e-16	Longevity;
KIRP	cis	rs6708331	0.517	rs9989876	chr2:70342710	T/A	cg05298696	chr2:70188691	ASPRV1	-0.48	-6.35	-0.38	1.02e-9	Obesity-related traits;
KIRP	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg24130564	chr14:104152367	KLC1	-0.49	-6.55	-0.39	3.38e-10	Body mass index;
KIRP	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.47	-5.74	-0.34	2.84e-8	Blood protein levels;
KIRP	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg09936142	chr19:10668400	KRI1	-0.42	-4.95	-0.3	1.38e-6	Inflammatory skin disease;
KIRP	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg03714773	chr7:91764589	CYP51A1	0.4	5.81	0.35	1.9e-8	Breast cancer;
KIRP	cis	rs7894407	0.504	rs7089271	chr10:105176914	A/G	cg05636881	chr10:105038444	INA	0.41	5.76	0.34	2.46e-8	White matter hyperintensity burden;
KIRP	trans	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg04702396	chr17:15466718	FAM18B2	-0.56	-7.42	-0.43	1.92e-12	Educational attainment (years of education);
KIRP	cis	rs4132509	1.000	rs6681863	chr1:243982709	C/G	cg25706552	chr1:244017396	NA	0.55	6.76	0.4	1.02e-10	RR interval (heart rate);
KIRP	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.77	-10.85	-0.57	1.18e-22	Height;
KIRP	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	4.86	0.3	2.09e-6	Axial length;
KIRP	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.66	8.39	0.47	3.93e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg09873164	chr1:152488093	CRCT1	0.57	7.6	0.44	6.4e-13	Hair morphology;
KIRP	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18252515	chr7:66147081	NA	0.43	5.27	0.32	2.97e-7	Aortic root size;
KIRP	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.41	-0.38	7.46e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-7.92	-0.45	8.35e-14	Fibrinogen levels;
KIRP	cis	rs7894407	0.856	rs10883855	chr10:105092447	A/G	cg05636881	chr10:105038444	INA	0.4	5.11	0.31	6.45e-7	White matter hyperintensity burden;
KIRP	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.67	8.29	0.47	7.2e-15	Aortic root size;
KIRP	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.82	-5.76	-0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.22	0.7	2.54e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6893300	0.857	rs6860716	chr5:179162840	T/C	cg14593053	chr5:179126677	CANX	-0.57	-6.94	-0.4	3.51e-11	Resting heart rate;
KIRP	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.7	-9.77	-0.53	2.84e-19	Morning vs. evening chronotype;
KIRP	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg05315796	chr3:52349193	DNAH1	0.42	6.6	0.39	2.49e-10	Electroencephalogram traits;
KIRP	cis	rs6746896	0.636	rs7586317	chr2:97447831	T/A	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.45	-0.43	1.6e-12	Bipolar disorder;
KIRP	cis	rs2505998	0.868	rs7092603	chr10:43552931	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.49	-4.9	-0.3	1.76e-6	Hirschsprung disease;
KIRP	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg16497661	chr14:103986332	CKB	-0.46	-6.08	-0.36	4.59e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.6	-0.39	2.46e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	11.26	0.58	5.49e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.55	-6.31	-0.37	1.3e-9	Initial pursuit acceleration;
KIRP	cis	rs1359582	0.757	rs814635	chr10:90412191	C/T	cg15661332	chr10:90342814	RNLS	0.57	5.75	0.34	2.64e-8	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	5.19	0.31	4.44e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.87	7.41	0.43	2.03e-12	Fat distribution (HIV);
KIRP	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg18944383	chr4:111397179	ENPEP	0.52	9.13	0.5	2.54e-17	Height;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02073427	chr10:15252052	NA	0.54	7.02	0.41	2.13e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.97	0.3	1.24e-6	Lymphocyte counts;
KIRP	cis	rs3739034	0.759	rs77422475	chr2:135528787	G/A	cg15546071	chr2:135691756	CCNT2	-0.54	-5.06	-0.31	8.22e-7	Gut microbiome composition (winter);
KIRP	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	cg07049167	chr1:166818506	POGK	0.63	7.16	0.42	9.37e-12	Refractive astigmatism;
KIRP	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14769373	chr6:40998127	UNC5CL	-0.55	-5.33	-0.32	2.24e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg08885076	chr2:99613938	TSGA10	-0.56	-9.67	-0.52	5.76e-19	Chronic sinus infection;
KIRP	cis	rs885389	0.883	rs2280683	chr12:131620738	A/G	cg06374807	chr12:131606857	GPR133	-0.45	-5.82	-0.35	1.84e-8	RR interval (heart rate);
KIRP	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.6	7.0	0.41	2.46e-11	Height;
KIRP	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.82	0.4	7e-11	Morning vs. evening chronotype;
KIRP	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.55	-6.53	-0.38	3.71e-10	Psoriasis;
KIRP	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-16.05	-0.72	3.89e-40	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg25486957	chr4:152246857	NA	-0.42	-5.09	-0.31	7.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.51	-0.43	1.09e-12	Type 2 diabetes;
KIRP	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg15556689	chr8:8085844	FLJ10661	0.57	7.52	0.43	9.95e-13	Retinal vascular caliber;
KIRP	cis	rs7534824	0.625	rs12569251	chr1:101372040	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	5.63	0.34	4.83e-8	Refractive astigmatism;
KIRP	trans	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.13	0.41	1.11e-11	Retinal vascular caliber;
KIRP	cis	rs7584330	0.518	rs78358347	chr2:238413566	C/T	cg14458575	chr2:238380390	NA	0.81	6.66	0.39	1.8e-10	Prostate cancer;
KIRP	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.48	7.38	0.43	2.41e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs13401104	0.796	rs10929167	chr2:237115248	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.44	-5.84	-0.35	1.66e-8	Blood metabolite levels;
KIRP	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26207909	chr14:103986467	CKB	0.74	11.46	0.59	1.23e-24	Body mass index;
KIRP	cis	rs3748682	0.861	rs2291297	chr1:38272660	G/A	cg12658694	chr1:38397304	INPP5B	0.53	5.7	0.34	3.45e-8	Hypothyroidism;
KIRP	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.34	6.55	0.39	3.4e-10	Mean corpuscular volume;
KIRP	cis	rs7172677	0.737	rs6495153	chr15:75437010	C/G	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.36	4.88	0.3	1.87e-6	Coronary artery disease;
KIRP	cis	rs3741151	0.686	rs11828904	chr11:73139116	T/C	cg17517138	chr11:73019481	ARHGEF17	0.69	5.87	0.35	1.39e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg04306507	chr14:55594613	LGALS3	0.52	8.13	0.46	2.09e-14	Protein biomarker;
KIRP	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg01881939	chr17:79480981	ACTG1	0.45	5.15	0.31	5.39e-7	Myopia;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02475777	chr4:1388615	CRIPAK	0.4	5.28	0.32	2.82e-7	Longevity;
KIRP	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.12	0.41	1.17e-11	Lung cancer;
KIRP	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg04733989	chr22:42467013	NAGA	0.55	7.54	0.43	8.95e-13	Cognitive function;
KIRP	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.48	-0.33	1.07e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17747265	chr1:1875780	NA	0.44	6.17	0.37	2.86e-9	Body mass index;
KIRP	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg00982548	chr2:198649783	BOLL	-0.55	-5.16	-0.31	5.18e-7	Ulcerative colitis;
KIRP	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15128208	chr22:42549153	NA	-0.41	-5.08	-0.31	7.42e-7	Cognitive function;
KIRP	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-4.99	-0.3	1.12e-6	Aortic root size;
KIRP	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg05360138	chr12:110035743	NA	0.65	6.99	0.41	2.53e-11	Neuroticism;
KIRP	trans	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.6	0.39	2.49e-10	Resting heart rate;
KIRP	cis	rs3779635	0.844	rs56330356	chr8:27278847	A/G	cg21186296	chr8:27182909	PTK2B	0.44	5.54	0.33	7.78e-8	Neuroticism;
KIRP	cis	rs7534824	0.625	rs17409499	chr1:101504936	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.25	0.42	5.33e-12	Refractive astigmatism;
KIRP	cis	rs17123764	0.710	rs1574326	chr12:50090543	A/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.89	0.3	1.83e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.74	-9.62	-0.52	8.17e-19	Asthma;
KIRP	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg14580859	chr9:123691850	NA	-0.35	-5.06	-0.31	8.37e-7	Rheumatoid arthritis;
KIRP	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.49	0.38	4.56e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.74	10.4	0.55	3.22e-21	Red blood cell count;
KIRP	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	0.94	12.07	0.61	1.19e-26	Corneal structure;
KIRP	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg13147721	chr7:65941812	NA	-1.02	-7.06	-0.41	1.66e-11	Diabetic kidney disease;
KIRP	cis	rs28834970	0.675	rs17057051	chr8:27227554	C/T	cg14221460	chr8:27183342	PTK2B	0.53	6.17	0.37	2.72e-9	Alzheimer's disease (late onset);
KIRP	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	1.0	18.0	0.75	8.84e-47	Bone mineral density;
KIRP	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.6	5.95	0.35	9.03e-9	Platelet distribution width;
KIRP	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.49	-6.04	-0.36	5.57e-9	Red blood cell count;
KIRP	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg17652424	chr22:38574118	PLA2G6	-0.25	-5.14	-0.31	5.48e-7	Cutaneous nevi;
KIRP	cis	rs714027	0.626	rs7287570	chr22:30507358	G/C	cg01021169	chr22:30184971	ASCC2	0.44	5.57	0.33	6.75e-8	Lymphocyte counts;
KIRP	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg26248373	chr2:1572462	NA	-0.63	-5.09	-0.31	7.09e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg04780086	chr2:111875790	ACOXL	0.42	5.89	0.35	1.29e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg17376030	chr22:41985996	PMM1	0.53	5.66	0.34	4.17e-8	Vitiligo;
KIRP	cis	rs7737355	0.812	rs10063264	chr5:130898197	C/G	cg06307176	chr5:131281290	NA	0.42	5.03	0.31	9.64e-7	Life satisfaction;
KIRP	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.13	0.31	5.98e-7	Breast cancer;
KIRP	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg00310523	chr12:86230176	RASSF9	0.42	6.69	0.39	1.49e-10	Major depressive disorder;
KIRP	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11987759	chr7:65425863	GUSB	0.56	7.34	0.42	3.15e-12	Aortic root size;
KIRP	cis	rs34091558	1	rs34091558	chr1:201886769	TA/T	cg11586189	chr1:201857591	SHISA4	-0.4	-5.56	-0.33	7.04e-8	Breast size;
KIRP	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg18806716	chr10:30721971	MAP3K8	0.31	5.0	0.3	1.08e-6	Inflammatory bowel disease;
KIRP	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg06647332	chr5:131281008	NA	-0.45	-5.01	-0.3	1.02e-6	Life satisfaction;
KIRP	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.93	10.35	0.55	4.39e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg25486957	chr4:152246857	NA	-0.45	-5.21	-0.32	4.01e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26262375	chr19:36545698	WDR62;THAP8	0.52	6.47	0.38	5.39e-10	Parkinson's disease;
KIRP	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.48	0.33	1.07e-7	Coronary artery disease;
KIRP	cis	rs4787491	0.729	rs7191849	chr16:30023157	T/C	cg06326092	chr16:30034487	C16orf92	0.46	6.84	0.4	6.32e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.82	8.74	0.49	3.58e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg06640241	chr16:89574553	SPG7	0.66	8.36	0.47	4.73e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.42	-5.06	-0.31	8.22e-7	P wave terminal force;
KIRP	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg25174290	chr11:3078921	CARS	-0.69	-8.96	-0.5	8.26e-17	Calcium levels;
KIRP	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.3	-0.42	4.05e-12	Mood instability;
KIRP	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg03342759	chr3:160939853	NMD3	-0.48	-5.77	-0.35	2.39e-8	Morning vs. evening chronotype;
KIRP	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.35	-0.38	1.04e-9	Alzheimer's disease (late onset);
KIRP	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.66	-7.05	-0.41	1.77e-11	Vitiligo;
KIRP	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.89	0.3	1.85e-6	Tonsillectomy;
KIRP	cis	rs8067545	0.512	rs4925071	chr17:19954499	T/C	cg13482628	chr17:19912719	NA	0.46	5.16	0.31	5.01e-7	Schizophrenia;
KIRP	cis	rs758324	0.947	rs7708140	chr5:131252396	A/G	cg25547332	chr5:131281432	NA	0.49	5.85	0.35	1.56e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg15068132	chr12:102092402	CHPT1	-0.39	-5.09	-0.31	7.05e-7	Blood protein levels;
KIRP	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.8	10.56	0.56	9.99e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg26408565	chr15:76604113	ETFA	-0.44	-5.86	-0.35	1.5e-8	Blood metabolite levels;
KIRP	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg09873164	chr1:152488093	CRCT1	0.57	7.2	0.42	7.42e-12	Hair morphology;
KIRP	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.8	-12.91	-0.64	1.81e-29	Heart rate;
KIRP	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.47	0.33	1.09e-7	Neuroticism;
KIRP	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.91e-25	Vitiligo;
KIRP	cis	rs57561814	1.000	rs57561814	chr7:22753675	G/C	cg01770232	chr7:22766155	IL6	0.73	5.66	0.34	4.23e-8	Tonsillectomy;
KIRP	cis	rs2458413	0.542	rs2514669	chr8:105362842	A/C	cg08657449	chr8:105351661	TM7SF4	-0.35	-5.76	-0.34	2.48e-8	Paget's disease;
KIRP	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg20578329	chr17:80767326	TBCD	-0.96	-9.07	-0.5	3.8e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs2048656	0.569	rs35300296	chr8:9653697	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.56	0.39	3.13e-10	Schizophrenia;
KIRP	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.43	5.5	0.33	9.48e-8	Aortic root size;
KIRP	cis	rs241257	0.643	rs241275	chr1:4627979	C/T	cg11735846	chr1:4770935	AJAP1	0.37	5.64	0.34	4.54e-8	Anxiety disorder;
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg00684032	chr4:1343700	KIAA1530	-0.58	-7.67	-0.44	3.89e-13	Obesity-related traits;
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	5.87	0.35	1.42e-8	Platelet count;
KIRP	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.5	5.99	0.36	7.54e-9	Iron status biomarkers;
KIRP	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	1.07	17.29	0.74	2.23e-44	Cognitive function;
KIRP	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.6	-5.05	-0.31	8.67e-7	Menarche (age at onset);
KIRP	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.43	6.37	0.38	9.13e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg10729496	chr3:10149963	C3orf24	0.55	5.01	0.3	1.04e-6	Alzheimer's disease;
KIRP	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.33	5.45	0.33	1.2e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	0.94	11.19	0.58	9.06e-24	Vitiligo;
KIRP	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-9.18	-0.51	1.81e-17	Morning vs. evening chronotype;
KIRP	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg05370193	chr1:21551575	ECE1	0.42	5.96	0.36	8.5e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.37	5.64	0.34	4.58e-8	QRS complex (12-leadsum);
KIRP	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.21	0.72	1.11e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs12200782	1.000	rs10946822	chr6:26414678	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.54	-5.13	-0.31	5.76e-7	Small cell lung carcinoma;
KIRP	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg19875535	chr5:140030758	IK	-0.65	-9.28	-0.51	9.43e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.41	-4.92	-0.3	1.59e-6	Facial morphology (factor 20);
KIRP	cis	rs939317	0.678	rs843372	chr3:183996213	C/T	cg09405238	chr3:183994500	ECE2	0.56	6.04	0.36	5.58e-9	Menarche (age at onset);
KIRP	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg05784532	chr1:230284198	GALNT2	0.41	6.2	0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.52	0.48	1.58e-15	Personality dimensions;
KIRP	cis	rs259282	0.560	rs4805786	chr19:33120265	T/C	cg02997394	chr19:33096574	ANKRD27	-0.48	-5.62	-0.34	5.16e-8	Schizophrenia;
KIRP	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-7.21	-0.42	6.91e-12	Coronary artery disease;
KIRP	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.34	-4.96	-0.3	1.32e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.15	-0.46	1.8e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1983891	0.742	rs755304	chr6:41552101	T/C	cg20194872	chr6:41519635	FOXP4	0.5	6.54	0.38	3.53e-10	Prostate cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg22928999	chr2:48046329	FBXO11	0.41	6.71	0.39	1.33e-10	C-reactive protein;
KIRP	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-10.87	-0.57	9.82e-23	Morning vs. evening chronotype;
KIRP	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.86	10.61	0.56	6.62e-22	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4975616	0.933	rs13356727	chr5:1312457	G/A	cg07493874	chr5:1342172	CLPTM1L	0.53	7.03	0.41	2.01e-11	Lung cancer;
KIRP	cis	rs7178909	0.933	rs7183156	chr15:90445446	A/G	cg19708238	chr15:90437601	AP3S2	0.46	5.72	0.34	3.12e-8	Common traits (Other);
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg13206674	chr6:150067644	NUP43	0.59	8.51	0.48	1.78e-15	Lung cancer;
KIRP	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg13880726	chr7:1868755	MAD1L1	0.48	5.71	0.34	3.29e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg27087555	chr16:88793112	FAM38A	-1.41	-13.67	-0.66	5.13e-32	Plateletcrit;
KIRP	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	1.09	19.89	0.79	3.85e-53	Monocyte count;
KIRP	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg20701182	chr2:24300061	SF3B14	0.64	5.55	0.33	7.23e-8	Lymphocyte counts;
KIRP	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.04	-0.36	5.63e-9	Height;
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.52	5.21	0.32	4.06e-7	Alzheimer's disease;
KIRP	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	cg04338863	chr8:33670619	NA	0.43	5.05	0.31	8.68e-7	Body mass index;
KIRP	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.03	-0.31	9.46e-7	Bipolar disorder;
KIRP	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs732505	1.000	rs4807789	chr19:5584448	T/C	cg26242866	chr19:5711310	LONP1	0.66	5.01	0.3	1.06e-6	vWF and FVIII levels;
KIRP	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.78	-10.64	-0.56	5.23e-22	Aortic root size;
KIRP	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg23587288	chr2:27483067	SLC30A3	-0.39	-5.03	-0.31	9.63e-7	Total body bone mineral density;
KIRP	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.56	7.98	0.45	5.48e-14	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs6540556	0.834	rs11119337	chr1:209934133	A/G	cg23920097	chr1:209922102	NA	-0.37	-4.89	-0.3	1.81e-6	Red blood cell count;
KIRP	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.7	-9.11	-0.5	3.06e-17	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg13198984	chr17:80129470	CCDC57	0.56	8.54	0.48	1.43e-15	Life satisfaction;
KIRP	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18357526	chr6:26021779	HIST1H4A	0.54	6.96	0.41	3.16e-11	Height;
KIRP	cis	rs12765878	1.000	rs1980653	chr10:105654164	A/G	cg11005552	chr10:105648138	OBFC1	0.4	5.73	0.34	2.95e-8	Coronary artery disease;
KIRP	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.41	-6.31	-0.37	1.27e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04298511	chr7:70159330	AUTS2	-0.49	-6.18	-0.37	2.62e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg05692746	chr2:100937584	LONRF2	-0.43	-5.69	-0.34	3.64e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg23985595	chr17:80112537	CCDC57	0.31	4.86	0.3	2.11e-6	Life satisfaction;
KIRP	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.76	9.36	0.51	5.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs752010	0.630	rs12134174	chr1:42105942	C/T	cg06885757	chr1:42089581	HIVEP3	0.54	8.09	0.46	2.66e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7903847	0.642	rs10882915	chr10:99142184	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.66	-9.4	-0.51	4.06e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13986860	chr13:31338421	ALOX5AP	0.53	7.02	0.41	2.19e-11	Interleukin-4 levels;
KIRP	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg16606324	chr3:10149918	C3orf24	0.69	5.83	0.35	1.7e-8	Alzheimer's disease;
KIRP	cis	rs2594989	1.000	rs346082	chr3:11329216	C/G	cg01796438	chr3:11312864	ATG7	-0.7	-8.03	-0.46	4.02e-14	Circulating chemerin levels;
KIRP	cis	rs11581903	1.000	rs11581903	chr1:53030823	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.58	5.73	0.34	2.86e-8	Joint mobility (Beighton score);
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.57	0.52	1.16e-18	Lung cancer;
KIRP	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg13160058	chr8:26243215	BNIP3L	-0.41	-5.98	-0.36	7.76e-9	Height;
KIRP	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg09579323	chr1:150459698	TARS2	-0.4	-5.09	-0.31	7.25e-7	Migraine;
KIRP	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs1318772	0.932	rs34870059	chr5:112907437	A/C	cg12552261	chr5:112820674	MCC	0.81	5.64	0.34	4.62e-8	F-cell distribution;
KIRP	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs6545883	0.542	rs10177225	chr2:61594498	C/T	cg15711740	chr2:61764176	XPO1	0.45	5.37	0.32	1.85e-7	Tuberculosis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14431266	chr11:67057003	ANKRD13D	0.65	6.06	0.36	5.11e-9	Lung function (FEV1);
KIRP	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.44	0.47	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.88	-14.57	-0.68	4.28e-35	Intelligence (multi-trait analysis);
KIRP	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.39	-5.14	-0.31	5.51e-7	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg14791747	chr16:20752902	THUMPD1	0.65	7.03	0.41	2.05e-11	Cognitive test performance;
KIRP	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg02138098	chr1:2040968	PRKCZ	-0.42	-5.8	-0.35	2.01e-8	Height;
KIRP	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs882300	0.934	rs58085003	chr2:136930556	A/G	cg05194412	chr2:137003533	NA	-0.36	-4.94	-0.3	1.42e-6	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs2281603	0.570	rs12050358	chr14:64966704	C/T	cg01860774	chr14:64969374	ZBTB25	0.33	5.37	0.32	1.8e-7	Lymphocyte counts;
KIRP	trans	rs7246760	1.000	rs7250487	chr19:9886358	T/C	cg02900749	chr2:68251473	NA	-0.96	-8.77	-0.49	3e-16	Pursuit maintenance gain;
KIRP	cis	rs3849570	0.533	rs4440144	chr3:81988359	A/G	cg07356753	chr3:81810745	GBE1	-0.51	-6.61	-0.39	2.36e-10	Waist circumference;Body mass index;
KIRP	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.67	-6.82	-0.4	6.98e-11	Migraine;Coronary artery disease;
KIRP	trans	rs4143844	0.867	rs12915283	chr15:62157579	T/C	cg04814990	chr13:111957387	ARHGEF7	0.94	6.14	0.36	3.28e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	10.36	0.55	4.12e-21	Total body bone mineral density;
KIRP	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.07	-0.41	1.6e-11	Caffeine consumption;
KIRP	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.17	0.46	1.66e-14	Motion sickness;
KIRP	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg00800038	chr16:89945340	TCF25	-0.7	-4.93	-0.3	1.51e-6	Skin colour saturation;
KIRP	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.62	-8.13	-0.46	2.09e-14	Prudent dietary pattern;
KIRP	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.96	-14.89	-0.69	3.45e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.65	7.75	0.44	2.38e-13	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02984159	chr7:1199847	ZFAND2A	0.45	6.28	0.37	1.55e-9	Survival in pancreatic cancer;
KIRP	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.7	7.01	0.41	2.24e-11	Corneal astigmatism;
KIRP	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.81	-0.4	7.37e-11	Monocyte percentage of white cells;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg12705353	chr12:122356852	WDR66	0.53	7.04	0.41	1.87e-11	Mean corpuscular volume;
KIRP	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg04166393	chr7:2884313	GNA12	0.66	7.79	0.44	1.84e-13	Height;
KIRP	cis	rs6959887	0.890	rs2075125	chr7:35301542	C/A	cg06685737	chr7:35301730	NA	0.45	6.58	0.39	2.78e-10	Birth weight;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.39	6.65	0.39	1.88e-10	Heart rate;
KIRP	cis	rs8014252	0.803	rs45523543	chr14:71051088	A/G	cg11204974	chr14:71022665	NA	-0.74	-7.31	-0.42	3.65e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2882877	0.610	rs1123109	chr2:190444392	C/T	cg10752008	chr2:190445175	SLC40A1	-0.52	-5.74	-0.34	2.84e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg10760299	chr15:45669010	GATM	0.32	5.03	0.31	9.43e-7	Homoarginine levels;
KIRP	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg18944383	chr4:111397179	ENPEP	0.39	6.35	0.38	1.05e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.61e-9	Life satisfaction;
KIRP	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg04490037	chr7:50633773	DDC	0.36	4.96	0.3	1.29e-6	Body mass index;
KIRP	cis	rs11168351	0.889	rs12817104	chr12:48382573	G/C	cg21466736	chr12:48725269	NA	-0.41	-5.15	-0.31	5.3e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9896052	0.580	rs8065142	chr17:73441060	G/A	cg25649188	chr17:73499917	CASKIN2	0.47	6.18	0.37	2.69e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	trans	rs702634	1.000	rs4865796	chr5:53272664	G/A	cg02663137	chr19:6745717	TRIP10	-0.54	-6.25	-0.37	1.76e-9	Type 2 diabetes;High light scatter reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg16586182	chr3:47516702	SCAP	0.82	11.64	0.6	3.07e-25	Colorectal cancer;
KIRP	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg13628971	chr7:2884303	GNA12	0.38	5.08	0.31	7.42e-7	Height;
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs12230513	0.732	rs4318592	chr12:55837124	C/A	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.78	-7.6	-0.44	6.26e-13	Prostate cancer;
KIRP	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.32	-0.32	2.36e-7	Colorectal cancer;
KIRP	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	11.19	0.58	9.13e-24	Monocyte percentage of white cells;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21577260	chr17:73285714	SLC25A19	0.45	6.2	0.37	2.32e-9	Survival in pancreatic cancer;
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg05552183	chr6:42928497	GNMT	0.82	13.55	0.65	1.31e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.48	-0.33	1.07e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.7	-8.11	-0.46	2.39e-14	Pancreatic cancer;
KIRP	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg13264159	chr8:625131	ERICH1	0.92	6.13	0.36	3.49e-9	IgG glycosylation;
KIRP	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs16936870	0.543	rs2958367	chr8:71164887	C/T	cg14232793	chr8:71155543	NCOA2	-0.57	-6.48	-0.38	4.85e-10	QT interval;
KIRP	cis	rs731174	0.559	rs10908376	chr1:38196026	G/A	cg12658694	chr1:38397304	INPP5B	-0.47	-5.14	-0.31	5.53e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	5.91	0.35	1.14e-8	Menarche (age at onset);
KIRP	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06544989	chr22:39130855	UNC84B	0.43	6.7	0.39	1.44e-10	Menopause (age at onset);
KIRP	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg07234876	chr8:600039	NA	-1.09	-6.65	-0.39	1.87e-10	IgG glycosylation;
KIRP	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.89	12.81	0.63	3.94e-29	Morning vs. evening chronotype;
KIRP	cis	rs8060686	0.516	rs73612297	chr16:68284754	T/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-7.65	-0.44	4.56e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.43	5.27	0.32	2.97e-7	Eosinophil percentage of white cells;
KIRP	cis	rs4523957	0.671	rs216205	chr17:2196150	C/T	cg16513277	chr17:2031491	SMG6	0.49	5.7	0.34	3.36e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.72	-0.34	3.05e-8	Pulmonary function;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.78	12.65	0.63	1.41e-28	Menarche (age at onset);
KIRP	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.77	-10.29	-0.55	7.1e-21	Adiposity;
KIRP	cis	rs830124	1.000	rs830124	chr12:122395777	C/T	cg01765077	chr12:122356316	WDR66	-0.58	-5.11	-0.31	6.52e-7	Urinary metabolites;
KIRP	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.12	-0.36	3.57e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg04132472	chr17:19861366	AKAP10	0.45	6.31	0.37	1.28e-9	Schizophrenia;
KIRP	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg14675211	chr2:100938903	LONRF2	0.54	6.72	0.39	1.28e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02767759	chr16:30366751	CD2BP2	0.53	6.28	0.37	1.52e-9	Smoking initiation;
KIRP	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	10.06	0.54	3.74e-20	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	trans	rs10129666	0.845	rs7146586	chr14:78687120	G/A	cg01530981	chr1:209756892	CAMK1G	-0.37	-6.13	-0.36	3.5e-9	Electrodermal activity;
KIRP	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.5	-0.59	8.96e-25	Breast cancer;
KIRP	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg20243544	chr17:37824526	PNMT	0.4	4.93	0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02725872	chr8:58115012	NA	-0.66	-6.76	-0.4	9.89e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs11637445	0.858	rs55986190	chr15:67929328	C/T	cg24579218	chr15:68104479	NA	0.4	5.27	0.32	3.06e-7	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.55	8.48	0.48	2.11e-15	Anterior chamber depth;
KIRP	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.04	0.31	8.93e-7	Educational attainment;
KIRP	cis	rs8070740	0.559	rs12600578	chr17:5299950	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.4	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg21253087	chr9:139290292	SNAPC4	0.46	6.39	0.38	8.37e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs1050631	0.564	rs1785925	chr18:33727186	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.67	0.34	3.91e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.93	13.72	0.66	3.48e-32	Tonsillectomy;
KIRP	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg02158880	chr13:53174818	NA	0.39	5.34	0.32	2.12e-7	Lewy body disease;
KIRP	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.79	-9.96	-0.54	7.39e-20	Blood trace element (Zn levels);
KIRP	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg13173536	chr2:3403300	TTC15	-0.38	-5.24	-0.32	3.46e-7	Obesity-related traits;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.5	-7.35	-0.42	2.94e-12	Lymphocyte counts;
KIRP	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.51	-6.74	-0.39	1.14e-10	Schizophrenia;
KIRP	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	6.88	0.4	5.07e-11	Neuroticism;
KIRP	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-5.46	-0.33	1.19e-7	Ulcerative colitis;
KIRP	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg26513180	chr16:89883248	FANCA	0.61	5.56	0.33	7.13e-8	Skin colour saturation;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13734338	chr2:20144847	WDR35	0.4	6.31	0.37	1.3e-9	C-reactive protein;
KIRP	cis	rs72627123	0.656	rs17096208	chr14:74555269	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.91	0.3	1.7e-6	Morning vs. evening chronotype;
KIRP	cis	rs3751972	0.911	rs2079714	chr17:26222520	C/T	cg18091275	chr17:26120155	NOS2	-0.53	-6.27	-0.37	1.64e-9	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-6.44	-0.38	6.08e-10	Response to antipsychotic treatment;
KIRP	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg20573242	chr4:122745356	CCNA2	0.45	5.07	0.31	7.86e-7	Type 2 diabetes;
KIRP	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.43	-0.38	6.74e-10	Metabolite levels (Pyroglutamine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07216656	chr12:29506350	ERGIC2	-0.42	-6.82	-0.4	7.19e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.4	6.47	0.38	5.16e-10	Age at first birth;
KIRP	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.59	-7.76	-0.44	2.26e-13	Total body bone mineral density;
KIRP	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg08501292	chr6:25962987	TRIM38	0.83	5.6	0.34	5.7e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.06	0.36	5e-9	Lung cancer;
KIRP	cis	rs597583	0.664	rs4938395	chr11:117384673	C/T	cg27161313	chr11:117392002	DSCAML1	0.63	6.35	0.38	1.02e-9	Putamen volume;
KIRP	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg14343924	chr8:8086146	FLJ10661	0.5	5.79	0.35	2.19e-8	Mood instability;
KIRP	cis	rs1729407	0.814	rs2542051	chr11:116697738	A/C	cg08985259	chr11:116699649	APOC3	0.31	4.88	0.3	1.88e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg06740227	chr12:86229804	RASSF9	0.44	5.53	0.33	8.37e-8	Major depressive disorder;
KIRP	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05220968	chr6:146057943	EPM2A	-0.4	-5.17	-0.31	4.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7507204	0.906	rs1860323	chr19:3424799	G/C	cg08380311	chr19:3435252	NFIC	0.65	6.93	0.4	3.74e-11	Height;
KIRP	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg02297831	chr4:17616191	MED28	0.51	5.99	0.36	7.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6504950	0.751	rs12937760	chr17:53016130	G/T	cg26251398	chr17:52985966	TOM1L1	0.43	5.23	0.32	3.54e-7	Breast cancer;
KIRP	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09198694	chr6:43738026	VEGFA	-0.63	-7.01	-0.41	2.25e-11	Menopause (age at onset);
KIRP	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg02297831	chr4:17616191	MED28	-0.47	-5.85	-0.35	1.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.5	-6.25	-0.37	1.81e-9	Longevity;Endometriosis;
KIRP	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-6.87	-0.4	5.23e-11	LDL cholesterol levels;LDL cholesterol;
KIRP	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-1.0	-12.92	-0.64	1.65e-29	Platelet distribution width;
KIRP	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.89	-11.91	-0.6	3.87e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.49	-5.47	-0.33	1.09e-7	Neuroticism;
KIRP	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.72	-8.9	-0.49	1.24e-16	Pancreatic cancer;
KIRP	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.19	-0.31	4.32e-7	Height;
KIRP	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.68	-9.19	-0.51	1.75e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3755132	1.000	rs56253741	chr2:15730773	A/G	cg12888861	chr2:15731646	DDX1	0.41	5.34	0.32	2.1e-7	Wilms tumor;
KIRP	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.82	-0.35	1.85e-8	Bipolar disorder;
KIRP	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	5.24	0.32	3.49e-7	Parkinson's disease;
KIRP	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg05791153	chr7:19748676	TWISTNB	0.62	6.31	0.37	1.26e-9	Thyroid stimulating hormone;
KIRP	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.24	0.42	5.57e-12	White blood cell count;
KIRP	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-10.87	-0.57	9.97e-23	Breast cancer;
KIRP	cis	rs11230563	0.501	rs4939488	chr11:60786474	T/C	cg19307003	chr11:60775715	CD6	0.31	5.35	0.32	2.05e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.88	12.69	0.63	1.01e-28	Coronary artery disease;
KIRP	cis	rs72627123	0.656	rs765720	chr14:74541326	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	5.23	0.32	3.65e-7	Morning vs. evening chronotype;
KIRP	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.93	13.79	0.66	2.02e-32	Tonsillectomy;
KIRP	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.74	0.39	1.12e-10	Morning vs. evening chronotype;
KIRP	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg01557791	chr16:72042693	DHODH	-0.7	-7.69	-0.44	3.55e-13	Blood protein levels;
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.85	-0.3	2.16e-6	Longevity;
KIRP	cis	rs3822411	0.518	rs2964785	chr5:10742401	C/T	cg14521931	chr5:10832172	NA	0.52	6.45	0.38	5.81e-10	Sum eosinophil basophil counts;
KIRP	cis	rs882732	0.576	rs2070777	chr14:95034342	T/A	cg05186455	chr14:95027692	SERPINA4	-0.39	-6.14	-0.36	3.27e-9	Blood protein levels;
KIRP	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg10761708	chr20:43804764	PI3	0.49	4.96	0.3	1.33e-6	Blood protein levels;
KIRP	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg13293535	chr8:11597251	GATA4	-0.41	-5.32	-0.32	2.35e-7	Retinal vascular caliber;
KIRP	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg15083037	chr5:83017644	HAPLN1	-0.61	-8.39	-0.47	3.84e-15	Prostate cancer;
KIRP	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-8.72	-0.49	4.34e-16	Morning vs. evening chronotype;
KIRP	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.7	10.49	0.56	1.58e-21	Hip circumference;
KIRP	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg02367723	chr1:46378857	MAST2	0.43	5.04	0.31	9.24e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg16386425	chr10:429943	DIP2C	0.49	7.03	0.41	2.04e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs6132905	0.590	rs74370935	chr20:2625458	G/C	cg24848351	chr20:2622020	TMC2	-0.64	-5.85	-0.35	1.52e-8	Mumps;
KIRP	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg00612595	chr21:47717864	NA	0.4	5.46	0.33	1.17e-7	Testicular germ cell tumor;
KIRP	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.41	8.96	0.5	8.07e-17	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9828933	0.577	rs832194	chr3:63857071	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	1.03	9.86	0.53	1.58e-19	Type 2 diabetes;
KIRP	cis	rs9815354	0.761	rs1851149	chr3:42021708	T/C	cg03022575	chr3:42003672	ULK4	-0.55	-6.03	-0.36	5.92e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.65	-0.52	6.92e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.54	8.17	0.46	1.61e-14	Huntington's disease progression;
KIRP	trans	rs2048656	0.605	rs13273565	chr8:9649146	T/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.21	0.37	2.3e-9	Schizophrenia;
KIRP	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.41	-5.29	-0.32	2.72e-7	Red blood cell count;
KIRP	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg16989719	chr2:238392110	NA	-0.55	-7.32	-0.42	3.54e-12	Prostate cancer;
KIRP	cis	rs13102973	0.965	rs4864244	chr4:135866959	A/G	cg14419869	chr4:135874104	NA	0.61	11.16	0.58	1.16e-23	Subjective well-being;
KIRP	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.11	-0.61	8.57e-27	Alzheimer's disease;
KIRP	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg02146966	chr17:18967117	NA	-0.42	-4.94	-0.3	1.43e-6	Schizophrenia;
KIRP	cis	rs6700559	0.595	rs11581339	chr1:200655233	A/G	cg07804481	chr1:200639085	DDX59	0.48	6.11	0.36	3.96e-9	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg10756647	chr7:56101905	PSPH	0.92	6.69	0.39	1.47e-10	Diabetic kidney disease;
KIRP	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15177315	chr10:102046452	BLOC1S2	0.55	7.6	0.44	6.1e-13	Survival in pancreatic cancer;
KIRP	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.49	6.57	0.39	3.03e-10	Testicular germ cell tumor;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg07216194	chr8:27182965	PTK2B	0.43	5.37	0.32	1.8e-7	Neuroticism;
KIRP	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.46	-7.01	-0.41	2.25e-11	Coronary artery disease;
KIRP	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	trans	rs11834041	0.831	rs7978095	chr12:128233361	C/T	cg02959129	chr3:119217242	C3orf1	0.67	6.35	0.38	1.05e-9	Response to cognitive-behavioural therapy in anxiety disorder;
KIRP	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg21466736	chr12:48725269	NA	-0.44	-5.62	-0.34	5.1e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1629083	0.935	rs1540191	chr11:118090432	G/A	cg18857871	chr11:118064634	AMICA1	0.61	8.03	0.46	3.96e-14	Lung cancer;
KIRP	cis	rs9815354	0.812	rs73073326	chr3:41834195	G/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg18944383	chr4:111397179	ENPEP	0.53	9.3	0.51	7.71e-18	Height;
KIRP	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.34	6.11	0.36	3.77e-9	Renal cell carcinoma;
KIRP	cis	rs10858047	0.883	rs9308267	chr1:115174843	C/T	cg12756093	chr1:115239321	AMPD1	-0.65	-6.27	-0.37	1.63e-9	Autism;
KIRP	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.49	0.38	4.56e-10	Myopia (pathological);
KIRP	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.91	14.89	0.69	3.45e-36	Urate levels in lean individuals;
KIRP	cis	rs77688320	0.553	rs10804114	chr2:202266862	T/G	cg06431681	chr2:202330990	STRADB	0.49	6.18	0.37	2.58e-9	Breast cancer;
KIRP	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.79	0.49	2.58e-16	Motion sickness;
KIRP	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.55	-0.48	1.33e-15	Retinal vascular caliber;
KIRP	cis	rs10875746	0.669	rs11168459	chr12:48596241	A/G	cg26205652	chr12:48591994	NA	0.68	9.11	0.5	3.05e-17	Longevity (90 years and older);
KIRP	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg16342193	chr10:102329863	NA	-0.38	-4.97	-0.3	1.28e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg00982548	chr2:198649783	BOLL	-0.53	-4.88	-0.3	1.86e-6	Ulcerative colitis;
KIRP	cis	rs11997175	0.545	rs59563980	chr8:33665377	C/T	cg04338863	chr8:33670619	NA	0.44	5.53	0.33	8.05e-8	Body mass index;
KIRP	cis	rs2274273	0.624	rs7140628	chr14:55760681	A/C	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.4e-7	Protein biomarker;
KIRP	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs9815354	0.812	rs17219090	chr3:42051952	G/C	cg03022575	chr3:42003672	ULK4	0.69	6.76	0.4	1.02e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08303612	chr6:160770090	SLC22A3	0.4	6.3	0.37	1.38e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs17057718	1.000	rs17057718	chr3:57136585	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-4.99	-0.3	1.13e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.6	7.51	0.43	1.07e-12	Body mass index;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg22753607	chr9:37120306	ZCCHC7	0.63	6.03	0.36	5.98e-9	Lung function (FEV1);
KIRP	cis	rs9328573	1.000	rs12440915	chr15:100509915	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.4	-5.42	-0.33	1.39e-7	Urate levels in lean individuals;
KIRP	cis	rs4654899	0.802	rs12127519	chr1:21247365	C/T	cg05370193	chr1:21551575	ECE1	0.43	5.58	0.33	6.47e-8	Superior frontal gyrus grey matter volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05906350	chr10:86088467	FAM190B	-0.58	-6.32	-0.37	1.22e-9	Menopause (age at onset);
KIRP	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg04080417	chr5:1859792	NA	-0.65	-8.27	-0.47	8.46e-15	Cardiovascular disease risk factors;
KIRP	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.1	-0.31	6.82e-7	Pulmonary function;
KIRP	cis	rs9381107	0.932	rs2223603	chr6:9487956	C/T	cg14735645	chr6:9486422	NA	0.49	6.22	0.37	2.07e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	0.78	10.2	0.55	1.35e-20	Orofacial clefts;
KIRP	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg12140854	chr5:148520817	ABLIM3	-0.45	-4.98	-0.3	1.19e-6	Breast cancer;
KIRP	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.67	-0.52	5.88e-19	Response to antipsychotic treatment;
KIRP	cis	rs12973672	1.000	rs1051995	chr19:35770292	C/T	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9826463	0.759	rs56161530	chr3:142332376	C/A	cg20824294	chr3:142316082	PLS1	0.45	6.46	0.38	5.58e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs78487399	0.808	rs17039131	chr2:43652398	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.27	-0.32	3.05e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	6.53	0.38	3.64e-10	LDL cholesterol;
KIRP	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	17.8	0.75	3.99e-46	Height;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg13092806	chr2:177043255	NA	0.63	8.51	0.48	1.72e-15	IgG glycosylation;
KIRP	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.49	6.55	0.39	3.25e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2594989	0.943	rs2454501	chr3:11500089	A/G	cg01796438	chr3:11312864	ATG7	-0.67	-8.19	-0.46	1.45e-14	Circulating chemerin levels;
KIRP	cis	rs859767	0.501	rs6742638	chr2:135407360	T/G	cg25422880	chr2:135218333	TMEM163	0.34	5.04	0.31	8.92e-7	Neuroticism;
KIRP	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	13.11	0.64	3.91e-30	Personality dimensions;
KIRP	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.87	-8.48	-0.48	2.07e-15	Body mass index;
KIRP	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.76	6.16	0.37	2.88e-9	Diabetic retinopathy;
KIRP	cis	rs9826463	0.582	rs2291363	chr3:142116151	A/G	cg20824294	chr3:142316082	PLS1	0.48	6.68	0.39	1.55e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.74	-10.9	-0.57	8.13e-23	Body mass index;
KIRP	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.5	5.74	0.34	2.73e-8	Platelet distribution width;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04691540	chr1:179198414	ABL2	0.46	6.07	0.36	4.89e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.64	8.64	0.48	7.42e-16	Menarche (age at onset);
KIRP	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.4	5.35	0.32	2.06e-7	Homoarginine levels;
KIRP	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	2.03e-14	Testicular germ cell tumor;
KIRP	cis	rs16957091	0.818	rs7175582	chr15:43039063	A/G	cg24196017	chr15:43021976	CDAN1	0.43	5.47	0.33	1.11e-7	MGMT methylation in smokers;
KIRP	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg11204139	chr17:3907470	NA	0.53	5.04	0.31	8.89e-7	Type 2 diabetes;
KIRP	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.09	-13.17	-0.64	2.49e-30	Alzheimer's disease;
KIRP	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.48	6.49	0.38	4.71e-10	Asthma;
KIRP	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg04727924	chr7:799746	HEATR2	-0.78	-8.86	-0.49	1.63e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.69	0.34	3.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.43	-6.67	-0.39	1.64e-10	Educational attainment;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.53	6.19	0.37	2.45e-9	Smoking initiation;
KIRP	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg01097406	chr16:89675127	NA	0.36	5.78	0.35	2.29e-8	Vitiligo;
KIRP	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.67	10.25	0.55	9.34e-21	Blood metabolite ratios;
KIRP	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg22916017	chr11:64110731	CCDC88B	-0.41	-4.85	-0.3	2.21e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs57590327	0.508	rs4605572	chr3:81965751	A/G	cg07356753	chr3:81810745	GBE1	-0.56	-7.39	-0.43	2.29e-12	Extraversion;
KIRP	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg07775547	chr4:1625484	NA	-0.44	-5.29	-0.32	2.67e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.36	-6.89	-0.4	4.68e-11	Longevity;
KIRP	cis	rs17095355	1.000	rs12267704	chr10:111722008	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.28	-0.32	2.9e-7	Biliary atresia;
KIRP	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg13072238	chr3:49761600	GMPPB	-0.57	-5.29	-0.32	2.66e-7	Menarche (age at onset);
KIRP	cis	rs35740288	0.770	rs11635587	chr15:86173633	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	7.94e-7	Electrocardiographic conduction measures;
KIRP	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	0.99	7.71	0.44	3.02e-13	Arsenic metabolism;
KIRP	cis	rs1524927	1.000	rs12704872	chr7:96334616	T/C	cg03808172	chr7:96339361	SHFM1	0.37	4.9	0.3	1.74e-6	Total body bone mineral density;
KIRP	cis	rs12049351	0.774	rs754025	chr1:229637297	C/T	cg11742688	chr1:229674241	ABCB10	-0.37	-5.52	-0.33	8.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg15226275	chr6:116381976	FRK	0.22	5.9	0.35	1.23e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7715806	0.500	rs2307112	chr5:75003413	A/C	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg10756647	chr7:56101905	PSPH	0.99	6.96	0.41	3.07e-11	Diabetic kidney disease;
KIRP	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.67	-7.26	-0.42	4.99e-12	Corneal structure;
KIRP	trans	rs1106684	1.000	rs11763261	chr7:131462242	C/T	cg13607082	chr12:122652224	LRRC43	-0.65	-6.61	-0.39	2.42e-10	Body mass index;
KIRP	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.76	10.65	0.56	4.91e-22	Facial morphology (factor 23);
KIRP	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04013166	chr16:89971882	TCF25	-0.67	-8.26	-0.47	8.81e-15	Skin colour saturation;
KIRP	cis	rs12282928	0.959	rs2170663	chr11:48319806	A/T	cg26585981	chr11:48327164	OR4S1	-0.42	-4.89	-0.3	1.8e-6	Migraine - clinic-based;
KIRP	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg25811766	chr13:21894605	NA	0.59	5.33	0.32	2.2e-7	White matter hyperintensity burden;
KIRP	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg03714773	chr7:91764589	CYP51A1	0.35	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg08501292	chr6:25962987	TRIM38	1.1	6.16	0.37	2.91e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6693567	0.565	rs1260407	chr1:150306125	T/C	cg07843065	chr1:150265600	MRPS21	0.45	6.26	0.37	1.74e-9	Migraine;
KIRP	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Educational attainment (college completion);
KIRP	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.54	0.43	8.76e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-8.94	-0.5	9.36e-17	Morning vs. evening chronotype;
KIRP	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.48e-11	Diabetic kidney disease;
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs6684514	1.000	rs12022194	chr1:156312331	T/A	cg16558208	chr1:156270281	VHLL	-0.44	-5.9	-0.35	1.19e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	trans	rs974417	0.559	rs12663554	chr6:97389256	A/G	cg00261665	chr3:131101138	NUDT16	-0.5	-6.3	-0.37	1.35e-9	Body mass index;
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.23	0.37	1.99e-9	Lung cancer;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.79	12.01	0.61	1.86e-26	Menarche (age at onset);
KIRP	cis	rs12579753	0.595	rs7398614	chr12:82286339	C/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.48	-0.33	1.07e-7	Resting heart rate;
KIRP	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.52	7.06	0.41	1.74e-11	Mean corpuscular volume;
KIRP	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-11.31	-0.59	3.59e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7712401	0.601	rs193539	chr5:122257617	C/G	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.61	-0.39	2.39e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.88	12.67	0.63	1.21e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg02475777	chr4:1388615	CRIPAK	0.47	6.55	0.39	3.27e-10	Longevity;
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.24	4.96	0.3	1.31e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.61	8.99	0.5	6.78e-17	Lung cancer;
KIRP	cis	rs6466055	0.604	rs1204078	chr7:104986644	A/T	cg04380332	chr7:105027541	SRPK2	0.63	9.41	0.51	3.58e-18	Schizophrenia;
KIRP	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	9.88	0.53	1.32e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9372253	0.564	rs2057151	chr6:110716608	G/C	cg01119278	chr6:110721349	DDO	-0.4	-5.62	-0.34	5.15e-8	Platelet distribution width;
KIRP	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg23706161	chr2:109336669	RANBP2	-0.37	-5.32	-0.32	2.36e-7	Mean platelet volume;
KIRP	cis	rs4494114	1.000	rs12127091	chr1:39339449	C/T	cg25970120	chr1:39325951	RRAGC	-0.4	-5.03	-0.31	9.38e-7	Blood protein levels;
KIRP	cis	rs867371	0.892	rs4344697	chr15:82545214	A/T	cg06066596	chr15:83166174	LOC80154	-0.46	-5.23	-0.32	3.64e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26009944	chr1:52210504	OSBPL9	0.42	6.11	0.36	3.92e-9	Interleukin-4 levels;
KIRP	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg02297831	chr4:17616191	MED28	-0.51	-6.31	-0.37	1.31e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.8	9.04	0.5	4.85e-17	Corneal astigmatism;
KIRP	cis	rs9547996	1.000	rs9547998	chr13:38223134	T/G	cg13634560	chr13:38173852	POSTN	-0.36	-5.02	-0.3	9.79e-7	Diastolic blood pressure;
KIRP	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg01338084	chr22:32026380	PISD	1.13	7.7	0.44	3.34e-13	Age-related hearing impairment;
KIRP	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.59	-7.23	-0.42	6.19e-12	Diastolic blood pressure;
KIRP	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs4356932	1.000	rs4543147	chr4:76976661	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.9	0.3	1.72e-6	Blood protein levels;
KIRP	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.86	10.8	0.57	1.67e-22	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg24110177	chr3:50126178	RBM5	-0.64	-7.56	-0.43	7.88e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs1864585	0.520	rs73200742	chr8:10629356	C/T	cg26278703	chr11:58910052	FAM111A	0.64	6.4	0.38	7.62e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg18657303	chr4:1051139	NA	0.54	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.79	9.18	0.51	1.77e-17	Corneal astigmatism;
KIRP	cis	rs10823500	0.523	rs12774848	chr10:71932436	T/C	cg02100629	chr10:71892760	AIFM2	-0.4	-5.02	-0.3	9.95e-7	Blood protein levels;
KIRP	cis	rs112591243	0.570	rs4819254	chr21:47887462	T/A	cg26904215	chr21:47823096	PCNT	-0.82	-6.08	-0.36	4.47e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.45	-0.43	1.62e-12	Breast cancer;
KIRP	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.66	7.67	0.44	3.93e-13	Dental caries;
KIRP	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.95	11.23	0.58	6.53e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9403521	0.673	rs11155315	chr6:143975157	A/G	cg18240653	chr6:144019428	PHACTR2	-0.51	-6.1	-0.36	4.14e-9	Obesity-related traits;
KIRP	cis	rs6832769	0.961	rs13138697	chr4:56363309	G/A	cg05960024	chr4:56376020	CLOCK	0.7	8.67	0.48	6.06e-16	Personality dimensions;
KIRP	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.84	0.71	2.01e-39	Bipolar disorder;
KIRP	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.7	10.63	0.56	5.67e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10761750	1	rs10761750	chr10:65128619	G/A	cg01631684	chr10:65280961	REEP3	-0.48	-5.63	-0.34	4.98e-8	Vascular endothelial growth factor levels;
KIRP	cis	rs698833	0.886	rs698802	chr2:44697624	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.46	0.38	5.54e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	13.13	0.64	3.33e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2836633	0.929	rs62217519	chr21:40034390	G/A	cg05519781	chr21:40033154	ERG	0.69	9.31	0.51	7.18e-18	Coronary artery disease;
KIRP	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.46	6.52	0.38	4.03e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs6750047	0.546	rs10192788	chr2:38272672	C/T	cg07380506	chr2:38303506	CYP1B1	0.44	5.71	0.34	3.26e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs732505	0.717	rs7260385	chr19:5598357	C/T	cg26242866	chr19:5711310	LONP1	-0.69	-5.39	-0.33	1.62e-7	vWF and FVIII levels;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.34	-0.32	2.08e-7	Life satisfaction;
KIRP	cis	rs6453429	0.720	rs642431	chr5:78364687	C/A	cg06501366	chr5:78365687	BHMT2;DMGDH	-0.33	-5.45	-0.33	1.24e-7	Urinary metabolites;
KIRP	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.63	-8.51	-0.48	1.74e-15	Aortic root size;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.57	-0.33	6.74e-8	Lung cancer;
KIRP	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.92	-9.7	-0.53	4.65e-19	Systolic blood pressure;
KIRP	cis	rs13401104	0.716	rs12185623	chr2:237128932	G/C	cg19324714	chr2:237145437	ASB18	0.51	5.32	0.32	2.31e-7	Educational attainment;
KIRP	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.71	-8.1	-0.46	2.59e-14	QRS complex (12-leadsum);
KIRP	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs12311304	0.901	rs12296735	chr12:15412945	A/G	cg08258403	chr12:15378311	NA	0.38	5.48	0.33	1.03e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs35740288	0.770	rs35447727	chr15:86174399	C/T	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18162120	chr1:224621880	WDR26	-0.42	-6.13	-0.36	3.56e-9	Metabolic traits;
KIRP	cis	rs785830	0.538	rs573071	chr9:256994	A/G	cg14500300	chr9:211689	NA	0.4	5.4	0.33	1.6e-7	Platelet distribution width;
KIRP	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg18350739	chr11:68623251	NA	-0.47	-7.27	-0.42	4.76e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26002218	chr14:103986227	CKB	0.28	5.32	0.32	2.37e-7	Body mass index;
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg05562828	chr17:3906858	NA	0.73	14.85	0.69	4.67e-36	Type 2 diabetes;
KIRP	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg24579218	chr15:68104479	NA	-0.45	-7.1	-0.41	1.35e-11	Restless legs syndrome;
KIRP	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg16141378	chr3:129829833	LOC729375	0.53	6.91	0.4	4.09e-11	Neuroticism;
KIRP	trans	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.48	6.64	0.39	2.01e-10	Endometrial cancer;
KIRP	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.62	-0.34	5.22e-8	Cholesterol, total;
KIRP	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-8.08	-0.46	2.94e-14	Diastolic blood pressure;
KIRP	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.05	-0.31	8.56e-7	Metabolite levels;
KIRP	cis	rs10792830	0.706	rs545592	chr11:85762118	T/C	cg07180834	chr11:85838833	NA	-0.33	-4.87	-0.3	1.98e-6	Psychosis and Alzheimer's disease;
KIRP	cis	rs988913	1.000	rs9370343	chr6:54820676	G/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.56	-0.33	6.84e-8	Menarche (age at onset);
KIRP	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.76	-7.33	-0.42	3.22e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6691722	0.503	rs6667695	chr1:24707669	G/A	cg18323236	chr1:24743029	NIPAL3	0.44	6.31	0.37	1.3e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs2224391	0.628	rs2773314	chr6:5253800	C/T	cg13962347	chr6:5174647	LYRM4	-0.73	-10.18	-0.54	1.54e-20	Height;
KIRP	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg12963866	chr19:57752005	ZNF805	-0.48	-5.99	-0.36	7.56e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.76	-9.77	-0.53	3.01e-19	Facial morphology (factor 19);
KIRP	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.71	9.37	0.51	4.94e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg18154014	chr19:37997991	ZNF793	0.62	5.25	0.32	3.28e-7	Coronary artery calcification;
KIRP	cis	rs1403694	1.000	rs2304451	chr3:186437661	G/C	cg12454167	chr3:186435060	KNG1	0.51	8.85	0.49	1.74e-16	Blood protein levels;
KIRP	trans	rs12043259	1.000	rs12405413	chr1:204825038	G/A	cg11485465	chr5:54518469	NA	0.39	6.28	0.37	1.49e-9	Addiction;
KIRP	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg07395648	chr5:131743802	NA	-0.36	-4.94	-0.3	1.41e-6	Blood metabolite levels;
KIRP	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-12.84	-0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg00931491	chr16:28608288	SULT1A2	-0.25	-5.02	-0.31	9.75e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.64	-10.89	-0.57	8.61e-23	Sense of smell;
KIRP	cis	rs17221829	0.733	rs10830329	chr11:89390612	A/G	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg25173405	chr17:45401733	C17orf57	-0.47	-6.16	-0.37	2.99e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs472402	0.560	rs2288447	chr5:6626091	C/T	cg08700190	chr5:6636046	SRD5A1	-0.42	-5.12	-0.31	6.29e-7	Response to amphetamines;
KIRP	cis	rs4671458	0.948	rs1517403	chr2:63540324	A/G	cg17519650	chr2:63277830	OTX1	-0.53	-5.38	-0.32	1.74e-7	Subjective well-being;
KIRP	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	1.06	7.6	0.44	6.07e-13	Skin colour saturation;
KIRP	trans	rs73191547	0.615	rs10089666	chr8:10083040	A/T	cg08975724	chr8:8085496	FLJ10661	0.53	6.62	0.39	2.29e-10	Schizophrenia;
KIRP	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.81	8.11	0.46	2.47e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.76	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.9	-0.64	2.03e-29	Electrocardiographic conduction measures;
KIRP	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg14541582	chr5:601475	NA	-0.55	-6.14	-0.36	3.3e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-7.44	-0.43	1.7e-12	Gut microbiome composition (summer);
KIRP	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.99	0.41	2.65e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.4	5.43	0.33	1.33e-7	Blood metabolite levels;
KIRP	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg23067535	chr8:124195133	FAM83A	-0.71	-7.16	-0.42	9.25e-12	Urinary uromodulin levels;
KIRP	cis	rs10865541	0.806	rs10187625	chr2:3421168	A/G	cg13173536	chr2:3403300	TTC15	-0.4	-5.33	-0.32	2.24e-7	Obesity-related traits;
KIRP	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg04310649	chr10:35416472	CREM	-0.59	-7.16	-0.42	9.33e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg02600515	chr11:62521696	ZBTB3	0.48	5.04	0.31	8.88e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.97	11.59	0.59	4.56e-25	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17046996	chr20:33999839	UQCC	0.52	6.29	0.37	1.4e-9	Parkinson's disease;
KIRP	cis	rs2882667	0.898	rs11956089	chr5:138394604	G/T	cg04439458	chr5:138467593	SIL1	0.42	7.08	0.41	1.5e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.41	5.44	0.33	1.27e-7	Cardiovascular disease risk factors;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16322655	chr11:31391333	DNAJC24;DCDC1	-0.44	-6.34	-0.37	1.09e-9	Warfarin maintenance dose;
KIRP	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg15038512	chr6:170123185	PHF10	0.48	5.46	0.33	1.14e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg08499158	chr17:42289980	UBTF	0.47	6.06	0.36	5.21e-9	Total body bone mineral density;
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-8.58	-0.48	1.12e-15	Obesity-related traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20720553	chr15:101792477	CHSY1	-0.46	-6.37	-0.38	9.11e-10	Myopia;
KIRP	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs9790314	0.663	rs7632423	chr3:160738728	A/G	cg04691961	chr3:161091175	C3orf57	0.47	7.48	0.43	1.35e-12	Morning vs. evening chronotype;
KIRP	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.75	-10.57	-0.56	9.24e-22	Body mass index;
KIRP	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg13660082	chr14:53194042	PSMC6	-0.73	-7.52	-0.43	1.03e-12	Alzheimer's disease (late onset);
KIRP	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-0.97	-10.4	-0.55	3.15e-21	Blood pressure (smoking interaction);
KIRP	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs78487399	0.710	rs72881068	chr2:43690860	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.69	-0.34	3.61e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.26	0.32	3.15e-7	Cognitive test performance;
KIRP	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.03	0.5	5.24e-17	Bipolar disorder;
KIRP	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.94	15.68	0.71	7.16e-39	Ulcerative colitis;
KIRP	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11987759	chr7:65425863	GUSB	0.5	6.72	0.39	1.27e-10	Aortic root size;
KIRP	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg11621586	chr10:70884670	VPS26A	1.14	14.26	0.67	4.98e-34	Left atrial antero-posterior diameter;
KIRP	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg26874164	chr19:58962979	ZNF324B	0.49	5.67	0.34	3.95e-8	Uric acid clearance;
KIRP	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg16584676	chr17:46985605	UBE2Z	0.47	5.86	0.35	1.48e-8	Type 2 diabetes;
KIRP	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.71	9.66	0.52	6.54e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs4780401	0.642	rs7194145	chr16:11764615	T/G	cg01061890	chr16:11836724	TXNDC11	-0.43	-5.25	-0.32	3.34e-7	Rheumatoid arthritis;
KIRP	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.63	0.34	5.02e-8	Total cholesterol levels;
KIRP	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg01629716	chr15:45996671	NA	0.37	6.6	0.39	2.48e-10	Waist circumference;Weight;
KIRP	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.9	-11.44	-0.59	1.39e-24	Blood protein levels;
KIRP	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05601917	chr6:125855416	NA	-0.38	-5.82	-0.35	1.79e-8	Brugada syndrome;
KIRP	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg06611532	chr13:114900021	NA	0.23	5.51	0.33	9.19e-8	Schizophrenia;
KIRP	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	1.0	15.83	0.71	2.18e-39	Vitamin D levels;
KIRP	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg26681399	chr22:41777847	TEF	-0.54	-5.39	-0.33	1.65e-7	Vitiligo;
KIRP	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.98	-0.5	7.37e-17	Hirschsprung disease;
KIRP	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.55	-7.14	-0.41	1.07e-11	Morning vs. evening chronotype;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg09165964	chr15:75287851	SCAMP5	0.55	7.21	0.42	6.79e-12	Breast cancer;
KIRP	cis	rs7870753	0.838	rs10761035	chr9:99236092	G/A	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg06636001	chr8:8085503	FLJ10661	0.78	10.6	0.56	7.44e-22	Mood instability;
KIRP	cis	rs17767294	0.541	rs72845042	chr6:27568734	A/T	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.42e-7	Parkinson's disease;
KIRP	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg20430773	chr1:16534157	ARHGEF19	0.52	6.45	0.38	5.96e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	1.05	9.85	0.53	1.69e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg10760299	chr15:45669010	GATM	0.37	5.38	0.32	1.69e-7	Homoarginine levels;
KIRP	trans	rs12517041	1.000	rs10072527	chr5:23318246	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.55	-0.43	8.27e-13	Calcium levels;
KIRP	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.98	10.44	0.55	2.31e-21	Blood protein levels;
KIRP	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.65	-0.34	4.32e-8	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13479780	chr6:41909532	CCND3	0.45	6.56	0.39	3.09e-10	Survival in pancreatic cancer;
KIRP	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg20573242	chr4:122745356	CCNA2	0.42	5.11	0.31	6.33e-7	Type 2 diabetes;
KIRP	cis	rs12472274	0.617	rs7568705	chr2:239081808	C/T	cg17459225	chr2:239074497	NA	0.54	6.79	0.4	8.17e-11	Phospholipid levels (plasma);
KIRP	cis	rs10129255	0.536	rs6576223	chr14:107184687	C/T	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.63e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.77	0.49	2.93e-16	Menopause (age at onset);
KIRP	cis	rs27434	0.583	rs151909	chr5:96156888	T/C	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1.01e-7	Ankylosing spondylitis;
KIRP	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.66	9.44	0.52	2.94e-18	Colorectal cancer;
KIRP	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.62	-8.78	-0.49	2.77e-16	Colorectal cancer;
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05665937	chr4:1216051	CTBP1	-0.44	-5.51	-0.33	8.99e-8	Obesity-related traits;
KIRP	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03647317	chr4:187891568	NA	-0.75	-11.9	-0.6	4.38e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs745080	0.635	rs10144819	chr14:52969654	T/A	cg23333723	chr14:53022898	GPR137C	-0.41	-5.68	-0.34	3.84e-8	Orofacial clefts;
KIRP	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.76	-9.56	-0.52	1.28e-18	Pancreatic cancer;
KIRP	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg27205649	chr11:78285834	NARS2	-0.56	-6.31	-0.37	1.3e-9	Testicular germ cell tumor;
KIRP	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.37	0.38	9.03e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg00857998	chr1:205179979	DSTYK	0.56	6.75	0.4	1.03e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05973813	chr11:107992235	ACAT1	0.48	6.35	0.38	1.05e-9	Parkinson's disease;
KIRP	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.24	-24.47	-0.84	7.36e-68	Exhaled nitric oxide output;
KIRP	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26314531	chr2:26401878	FAM59B	-0.49	-5.03	-0.31	9.45e-7	Gut microbiome composition (summer);
KIRP	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs7116495	1.000	rs560777	chr11:71770602	C/T	cg26138937	chr11:71823887	C11orf51	0.69	5.57	0.33	6.7e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs7267005	0.661	rs17093119	chr20:34423392	A/G	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.87	13.57	0.65	1.11e-31	Blood protein levels;
KIRP	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.95	16.78	0.73	1.26e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.69	9.96	0.54	7.7e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.61	-8.22	-0.46	1.16e-14	Colorectal cancer;
KIRP	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.86	16.27	0.72	6.81e-41	Anterior chamber depth;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16639922	chr3:9975056	IL17RC;CRELD1	0.47	6.14	0.36	3.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.54	5.97	0.36	8.39e-9	DNA methylation (variation);
KIRP	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg14250997	chr9:106856677	SMC2	-0.39	-5.03	-0.31	9.28e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	8.27	0.47	8.7e-15	Breast cancer;
KIRP	cis	rs3126085	0.560	rs2282303	chr1:152329435	C/T	cg26876637	chr1:152193138	HRNR	-0.55	-6.29	-0.37	1.43e-9	Atopic dermatitis;
KIRP	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg08700190	chr5:6636046	SRD5A1	-0.49	-6.06	-0.36	5.16e-9	Response to amphetamines;
KIRP	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.76	9.53	0.52	1.61e-18	Monocyte percentage of white cells;
KIRP	cis	rs10488172	0.948	rs17167200	chr7:133333736	G/C	cg10665199	chr7:133106180	EXOC4	-0.52	-5.56	-0.33	7.03e-8	Tonometry;
KIRP	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg14092571	chr14:90743983	NA	-0.38	-4.95	-0.3	1.39e-6	Mortality in heart failure;
KIRP	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	14.73	0.68	1.28e-35	Smoking behavior;
KIRP	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.69	-11.11	-0.58	1.66e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs3812111	0.510	rs1569825	chr6:116590807	T/G	cg18828861	chr6:116576566	TSPYL4	0.43	5.0	0.3	1.07e-6	Age-related macular degeneration;
KIRP	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.59	-7.96	-0.45	6.27e-14	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.73	5.27	0.32	2.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.68	-8.9	-0.49	1.27e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18717490	chr6:34760183	UHRF1BP1	0.53	6.64	0.39	2.04e-10	Parkinson's disease;
KIRP	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.02	-0.54	4.75e-20	Hemoglobin concentration;
KIRP	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg02151108	chr14:50098012	C14orf104	-0.53	-7.18	-0.42	8.22e-12	Carotid intima media thickness;
KIRP	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7011049	1.000	rs10958336	chr8:53841318	G/A	cg26025543	chr8:53854495	NA	0.74	7.56	0.43	7.99e-13	Systolic blood pressure;
KIRP	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12292205	chr6:26970375	C6orf41	-0.58	-6.51	-0.38	4.11e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.9	13.73	0.66	3.1e-32	Testicular germ cell tumor;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2235649	0.667	rs2575372	chr16:1815757	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-5.57	-0.33	6.53e-8	Blood metabolite levels;
KIRP	cis	rs6545883	0.894	rs10177303	chr2:61594459	G/A	cg15711740	chr2:61764176	XPO1	0.6	7.7	0.44	3.29e-13	Tuberculosis;
KIRP	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg18944383	chr4:111397179	ENPEP	0.46	7.4	0.43	2.21e-12	Height;
KIRP	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-7.62	-0.44	5.41e-13	Mean corpuscular volume;
KIRP	cis	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg21546286	chr11:48923668	NA	-0.38	-4.88	-0.3	1.88e-6	HDL cholesterol;
KIRP	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.28	-0.37	1.5e-9	Arsenic metabolism;
KIRP	cis	rs7267005	1.000	rs17093184	chr20:34451602	G/A	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.9	0.88	4.82e-81	Chronic sinus infection;
KIRP	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg05072819	chr3:20081367	KAT2B	0.42	4.99	0.3	1.17e-6	Post-traumatic stress disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22658082	chr5:137368318	FAM13B	0.51	7.11	0.41	1.25e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6442310	0.534	rs709150	chr3:12451337	C/G	cg15873301	chr3:12045459	SYN2	-0.37	-5.03	-0.31	9.31e-7	Hematocrit;
KIRP	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	0.89	11.05	0.58	2.56e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7119	0.717	rs12898370	chr15:77808598	A/T	cg12131826	chr15:77904385	NA	0.49	6.07	0.36	4.8e-9	Type 2 diabetes;
KIRP	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-1.01	-22.1	-0.82	2.35e-60	Multiple myeloma;
KIRP	cis	rs7520050	0.966	rs1085243	chr1:46544768	C/T	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.41	-0.38	7.48e-10	Lung cancer;
KIRP	cis	rs13102973	0.965	rs4864240	chr4:135856737	T/C	cg14419869	chr4:135874104	NA	-0.59	-10.26	-0.55	8.42e-21	Subjective well-being;
KIRP	cis	rs11874712	0.507	rs7239525	chr18:43654033	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.36	-5.19	-0.31	4.3e-7	Migraine - clinic-based;
KIRP	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.0	0.36	7e-9	Menopause (age at onset);
KIRP	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg02376097	chr19:46275166	DMPK	0.46	6.29	0.37	1.46e-9	Coronary artery disease;
KIRP	cis	rs17284969	0.579	rs2371671	chr7:83044481	G/C	cg14519356	chr7:83097669	SEMA3E	0.53	7.54	0.43	8.8e-13	Blood protein levels;
KIRP	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.5	-0.33	9.35e-8	Depression;
KIRP	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.51	-15.23	-0.7	2.36e-37	Plateletcrit;
KIRP	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg18850127	chr7:39170497	POU6F2	0.27	5.3	0.32	2.63e-7	IgG glycosylation;
KIRP	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs1957429	0.522	rs57319601	chr14:65415743	C/T	cg23373153	chr14:65346875	NA	-0.75	-5.25	-0.32	3.37e-7	Pediatric areal bone mineral density (radius);
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg19923238	chr8:142232952	SLC45A4	-0.42	-4.95	-0.3	1.38e-6	Immature fraction of reticulocytes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg05145649	chr17:73127468	NT5C	-0.43	-6.13	-0.36	3.51e-9	Metabolic traits;
KIRP	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg17279839	chr7:150038598	RARRES2	0.54	7.11	0.41	1.26e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05601917	chr6:125855416	NA	-0.34	-5.08	-0.31	7.59e-7	Brugada syndrome;
KIRP	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-7.77	-0.44	2.15e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.9	14.29	0.67	4.03e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg00530320	chr1:46809349	NSUN4	0.45	5.55	0.33	7.3900000000000007e-08	Menopause (age at onset);
KIRP	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg16482183	chr6:26056742	HIST1H1C	0.6	6.88	0.4	4.97e-11	Iron status biomarkers;
KIRP	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.53	-6.92	-0.4	3.91e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg20991723	chr1:152506922	NA	0.43	5.05	0.31	8.46e-7	Hair morphology;
KIRP	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg12940439	chr1:67600707	NA	0.38	5.47	0.33	1.12e-7	Psoriasis;
KIRP	cis	rs7712401	0.715	rs1062350	chr5:122358506	G/A	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg06115741	chr20:33292138	TP53INP2	0.38	5.17	0.31	4.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs12210905	1.000	rs12196889	chr6:27156095	G/C	cg11502198	chr6:26597334	ABT1	-0.74	-4.91	-0.3	1.66e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs1116547	0.543	rs4705553	chr5:112877184	A/G	cg12552261	chr5:112820674	MCC	-0.47	-4.93	-0.3	1.49e-6	Cerebral amyloid angiopathy;
KIRP	cis	rs988913	0.723	rs4715515	chr6:54968444	C/G	cg03513858	chr6:54763001	FAM83B	-0.37	-5.41	-0.33	1.48e-7	Menarche (age at onset);
KIRP	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg16898833	chr6:26189333	HIST1H4D	0.85	5.88	0.35	1.31e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.51	-6.42	-0.38	6.87e-10	Body mass index;
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.7	7.31	0.42	3.66e-12	Bipolar disorder;
KIRP	cis	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg21605333	chr4:119757512	SEC24D	0.59	5.86	0.35	1.48e-8	Cannabis dependence symptom count;
KIRP	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg23280166	chr11:118938394	VPS11	-0.63	-8.02	-0.46	4.19e-14	Coronary artery disease;
KIRP	cis	rs5753037	0.653	rs105311	chr22:30137262	G/A	cg01021169	chr22:30184971	ASCC2	-0.45	-6.32	-0.37	1.22e-9	Type 1 diabetes;
KIRP	cis	rs505401	0.570	rs11879285	chr19:6118289	T/C	cg18109231	chr19:6110877	RFX2	0.81	5.29	0.32	2.73e-7	Mean platelet volume;
KIRP	cis	rs7534824	0.625	rs10493939	chr1:101378026	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	5.63	0.34	4.83e-8	Refractive astigmatism;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg25998860	chr5:126853954	PRRC1	-0.5	-6.25	-0.37	1.82e-9	Neuroticism;
KIRP	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg13010199	chr12:38710504	ALG10B	0.64	7.93	0.45	7.79e-14	Morning vs. evening chronotype;
KIRP	cis	rs11155671	0.530	rs9371505	chr6:150184148	A/C	cg13206674	chr6:150067644	NUP43	0.55	7.79	0.45	1.82e-13	Testicular germ cell tumor;
KIRP	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg12962167	chr3:53033115	SFMBT1	0.66	4.96	0.3	1.32e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs12449568	0.839	rs11079223	chr17:54419016	C/T	cg04456437	chr3:119217424	C3orf1	0.49	6.08	0.36	4.55e-9	Height;
KIRP	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg27124370	chr19:33622961	WDR88	0.56	7.0	0.41	2.42e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg05340658	chr4:99064831	C4orf37	-0.58	-7.08	-0.41	1.51e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs829883	0.659	rs11109520	chr12:98928646	C/T	cg25150519	chr12:98850993	NA	0.75	9.25	0.51	1.12e-17	Colorectal adenoma (advanced);
KIRP	cis	rs1656402	0.953	rs1190446	chr2:233420683	G/C	cg03852847	chr2:233439513	NA	0.66	8.69	0.48	5.06e-16	Non-small cell lung cancer (survival);
KIRP	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.64	7.8	0.45	1.72e-13	Vitiligo;
KIRP	cis	rs4786125	0.555	rs7196838	chr16:6920457	A/G	cg03623568	chr16:6915990	A2BP1	-0.41	-4.99	-0.3	1.16e-6	Heart rate variability traits (SDNN);
KIRP	cis	rs10073892	0.633	rs61335461	chr5:101617245	A/T	cg19774478	chr5:101632501	SLCO4C1	0.56	6.05	0.36	5.38e-9	Cognitive decline (age-related);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12445461	chr9:6681608	NA	0.46	6.09	0.36	4.22e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.45	5.9	0.35	1.17e-8	Mean corpuscular volume;
KIRP	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-7.98	-0.45	5.51e-14	Coronary artery disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11950105	chr17:80050646	FASN	0.51	6.7	0.39	1.44e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.44	0.47	2.74e-15	Motion sickness;
KIRP	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.17	0.37	2.78e-9	Systemic lupus erythematosus;
KIRP	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.53	-5.17	-0.31	4.82e-7	Recombination rate (females);
KIRP	cis	rs66561647	0.634	rs10097497	chr8:128932363	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.42	5.31	0.32	2.44e-7	Hemoglobin concentration;
KIRP	cis	rs9309473	1.000	rs7585004	chr2:73666645	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.33	-0.32	2.27e-7	Metabolite levels;
KIRP	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs6772849	0.931	rs60825080	chr3:128384834	G/T	cg08795948	chr3:128337044	NA	0.51	6.32	0.37	1.22e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs7582720	0.731	rs1971819	chr2:203705787	G/C	cg08076091	chr2:203926405	NBEAL1	-0.48	-5.81	-0.35	1.92e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-8.69	-0.48	5.27e-16	Response to antipsychotic treatment;
KIRP	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.28e-6	Recombination rate (females);
KIRP	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	0.5	8.54	0.48	1.4e-15	QRS complex (12-leadsum);
KIRP	trans	rs9399599	0.899	rs1147846	chr6:147609376	C/T	ch.20.23481851F	chr20:23533851	NA	-0.49	-6.02	-0.36	6.16e-9	Plasma plasminogen activator levels;
KIRP	trans	rs62056376	0.646	rs1024610	chr17:32580231	A/T	cg17635953	chr13:28535085	NA	-0.56	-6.16	-0.37	2.87e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.76	11.47	0.59	1.16e-24	Oral cavity cancer;
KIRP	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg23067535	chr8:124195133	FAM83A	-0.68	-5.8	-0.35	2.08e-8	Urinary uromodulin levels;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg01765077	chr12:122356316	WDR66	0.63	8.74	0.49	3.77e-16	Mean corpuscular volume;
KIRP	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.08	-0.41	1.49e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3790645	1.000	rs364977	chr1:26893836	G/A	cg23229016	chr1:26872525	RPS6KA1	0.25	6.2	0.37	2.37e-9	Glucose homeostasis traits;
KIRP	cis	rs6782228	0.606	rs4857861	chr3:128406767	T/C	cg18648031	chr3:128330563	NA	0.25	5.15	0.31	5.34e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs9815354	0.904	rs73073368	chr3:41843391	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.6	9.05	0.5	4.35e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06481639	chr22:41940642	POLR3H	0.74	7.97	0.45	6.1e-14	Vitiligo;
KIRP	cis	rs10486003	1.000	rs60433176	chr7:97199292	G/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.57	-5.07	-0.31	7.71e-7	Response to platinum-based agents;
KIRP	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg05887092	chr17:76393375	PGS1	0.51	7.11	0.41	1.24e-11	HDL cholesterol levels;
KIRP	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.5	6.64	0.39	2.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs997295	1.000	rs36004835	chr15:67951542	A/C	cg14210607	chr15:68128175	NA	-0.3	-4.91	-0.3	1.65e-6	Motion sickness;
KIRP	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.35	-0.42	2.89e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg24879335	chr3:133465180	TF	0.47	7.29	0.42	4.33e-12	Iron status biomarkers;
KIRP	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg07169764	chr2:136633963	MCM6	0.54	6.29	0.37	1.46e-9	Mosquito bite size;
KIRP	cis	rs3120667	0.720	rs12067942	chr1:152403270	G/C	cg26876637	chr1:152193138	HRNR	-0.51	-5.15	-0.31	5.26e-7	Eating disorders;
KIRP	cis	rs12580194	0.593	rs61957946	chr12:55755778	T/C	cg19537932	chr12:55886519	OR6C68	-0.5	-6.48	-0.38	5.02e-10	Cancer;
KIRP	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.83	13.84	0.66	1.29e-32	Longevity;
KIRP	cis	rs1045714	0.887	rs73033694	chr7:2637139	G/A	cg20813462	chr7:2646259	IQCE	0.65	6.13	0.36	3.49e-9	Urate levels in lean individuals;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-6.83	-0.4	6.68e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.62	8.52	0.48	1.61e-15	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs4356932	0.691	rs2242473	chr4:76878956	G/A	cg00809888	chr4:76862425	NAAA	-0.5	-7.0	-0.41	2.45e-11	Blood protein levels;
KIRP	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.49	6.31	0.37	1.3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.64	-6.47	-0.38	5.2400000000000005e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.73	9.46	0.52	2.56e-18	Crohn's disease;
KIRP	cis	rs2598107	0.601	rs4720265	chr7:37944746	G/A	cg25225232	chr7:37962694	EPDR1	-0.42	-4.97	-0.3	1.27e-6	Dupuytren's disease;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	8.0	0.45	4.85e-14	Aortic root size;
KIRP	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg17644776	chr2:200775616	C2orf69	0.57	5.28	0.32	2.89e-7	Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg05549078	chr18:47807921	MBD1	-0.45	-6.19	-0.37	2.5e-9	Metabolic traits;
KIRP	trans	rs2786098	1.000	rs1337167	chr1:197316435	C/T	cg04370142	chr11:62192342	NA	-0.61	-7.18	-0.42	8.05e-12	Asthma;
KIRP	cis	rs4363506	0.635	rs10830097	chr10:129282756	C/T	cg07804728	chr10:129284050	NA	0.47	5.92	0.35	1.07e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.82	7.74	0.44	2.6e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.8	7.66	0.44	4.33e-13	Lung function (FEV1/FVC);
KIRP	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg16339924	chr4:17578868	LAP3	-0.69	-8.44	-0.47	2.7e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.15	14.72	0.68	1.31e-35	Type 2 diabetes nephropathy;
KIRP	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.03	-0.31	9.54e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg00079169	chr19:2811669	THOP1	0.5	5.51	0.33	9e-8	Total cholesterol levels;
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.87	-12.73	-0.63	7.68e-29	Height;
KIRP	cis	rs2151522	0.762	rs13190766	chr6:127176162	A/G	cg21431617	chr6:127135037	NA	0.29	5.24	0.32	3.4e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.42	5.84	0.35	1.64e-8	Birth weight;
KIRP	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05220968	chr6:146057943	EPM2A	0.39	4.96	0.3	1.32e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	0.34	5.15	0.31	5.33e-7	Renal function-related traits (BUN);
KIRP	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.91	-14.91	-0.69	2.98e-36	Urate levels in lean individuals;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17945282	chr3:142297905	ATR	-0.48	-6.45	-0.38	5.98e-10	Myopia;
KIRP	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg20701182	chr2:24300061	SF3B14	0.48	5.09	0.31	6.98e-7	Asthma;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.79	12.98	0.64	1.08e-29	Longevity;Endometriosis;
KIRP	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.53	0.38	3.8e-10	Rheumatoid arthritis;
KIRP	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.7	-11.74	-0.6	1.5e-25	Gout;
KIRP	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.62	9.24	0.51	1.2e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2241685	0.646	rs1432539	chr2:1919847	C/T	cg22511877	chr2:1942942	MYT1L	0.53	5.55	0.33	7.5e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs9905704	0.918	rs186221	chr17:56695967	C/T	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20887061	chr11:3818910	PGAP2;NUP98	0.51	6.58	0.39	2.74e-10	Parkinson's disease;
KIRP	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg10950524	chr7:2139216	MAD1L1	0.32	5.1	0.31	6.85e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg17333051	chr19:2783644	SGTA	0.43	5.6	0.34	5.66e-8	Total cholesterol levels;
KIRP	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-9.12	-0.5	2.69e-17	Chronic sinus infection;
KIRP	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.86	0.3	2.05e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01381678	chr2:197458093	HECW2	0.52	6.52	0.38	3.97e-10	Parkinson's disease;
KIRP	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.63	-7.32	-0.42	3.52e-12	Dental caries;
KIRP	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.9	13.79	0.66	1.99e-32	Mean corpuscular hemoglobin;
KIRP	trans	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.65	8.29	0.47	7.25e-15	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg11783602	chr8:55087084	NA	-0.48	-5.82	-0.35	1.8e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.37	-5.13	-0.31	5.99e-7	Post-traumatic stress disorder;
KIRP	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg18404041	chr3:52824283	ITIH1	0.36	5.09	0.31	6.99e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg23533926	chr12:111358616	MYL2	-0.48	-6.35	-0.38	1.01e-9	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14655649	chr8:30769870	NA	0.5	6.79	0.4	8.24e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.51	7.07	0.41	1.6e-11	Dupuytren's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19322445	chr10:120801832	EIF3A	-0.46	-6.71	-0.39	1.33e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg04310649	chr10:35416472	CREM	-0.57	-6.7	-0.39	1.38e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.54	-5.46	-0.33	1.14e-7	Platelet distribution width;
KIRP	cis	rs2916247	1.000	rs1814032	chr8:93005447	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.62	-8.75	-0.49	3.48e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg27205649	chr11:78285834	NARS2	-0.54	-5.0	-0.3	1.11e-6	Testicular germ cell tumor;
KIRP	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg23032965	chr3:12705835	RAF1	0.67	7.37	0.43	2.56e-12	Cholesterol, total;
KIRP	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.5	0.48	1.81e-15	IgG glycosylation;
KIRP	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.7e-15	Aortic root size;
KIRP	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.9	15.31	0.7	1.3e-37	Headache;
KIRP	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg21360079	chr12:107162445	NA	-0.67	-9.59	-0.52	1.04e-18	Heart rate;
KIRP	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	1.06	22.67	0.82	3.39e-62	Breast cancer;
KIRP	trans	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg21167628	chr1:45308625	PTCH2	0.41	6.18	0.37	2.6e-9	Facial morphology (factor 20);
KIRP	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.4	0.62	9.37e-28	Monocyte percentage of white cells;
KIRP	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.47	6.09	0.36	4.42e-9	Monocyte count;
KIRP	cis	rs7712401	0.601	rs246275	chr5:122231413	C/T	cg19412675	chr5:122181750	SNX24	0.52	5.64	0.34	4.56e-8	Mean platelet volume;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg24458846	chr11:66512593	C11orf80	0.57	6.84	0.4	6.13e-11	Beard thickness;
KIRP	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg26531700	chr6:26746687	NA	0.41	5.63	0.34	4.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2733954	0.887	rs301163	chr16:85813526	C/T	cg03249995	chr16:85819513	COX4NB	0.46	5.47	0.33	1.12e-7	Leprosy;
KIRP	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	9.63	0.52	7.81e-19	Post bronchodilator FEV1;
KIRP	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg08885076	chr2:99613938	TSGA10	-0.54	-9.28	-0.51	9.11e-18	Chronic sinus infection;
KIRP	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg22960616	chr11:71188716	NADSYN1	0.43	4.94	0.3	1.46e-6	Vitamin D levels;
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg14789911	chr21:47582049	C21orf56	-0.43	-5.43	-0.33	1.36e-7	Testicular germ cell tumor;
KIRP	cis	rs7714584	1.000	rs79780973	chr5:150174810	T/C	cg22134413	chr5:150180641	NA	1.06	7.46	0.43	1.48e-12	Crohn's disease;
KIRP	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.29	-6.0	-0.36	7.18e-9	Asthma (sex interaction);
KIRP	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.2	-0.46	1.34e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.26	-21.72	-0.81	4.03e-59	Breast cancer;
KIRP	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-5.43	-0.33	1.36e-7	Asthma;
KIRP	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	12.28	0.62	2.38e-27	Smoking behavior;
KIRP	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg13010199	chr12:38710504	ALG10B	-0.48	-6.03	-0.36	5.86e-9	Morning vs. evening chronotype;
KIRP	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg24531977	chr5:56204891	C5orf35	-0.38	-4.85	-0.3	2.21e-6	Coronary artery disease;
KIRP	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg21905437	chr5:178450457	ZNF879	0.48	5.8	0.35	2.03e-8	Pubertal anthropometrics;
KIRP	trans	rs263063	0.920	rs263054	chr19:5033337	C/G	cg10466548	chr16:10965217	NA	0.55	6.06	0.36	4.94e-9	Periodontitis (CDC/AAP);
KIRP	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg20701182	chr2:24300061	SF3B14	0.49	5.11	0.31	6.6e-7	Asthma;
KIRP	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg01620082	chr3:125678407	NA	0.82	6.09	0.36	4.24e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg13819577	chr1:248512075	OR14C36	0.37	4.96	0.3	1.32e-6	Common traits (Other);
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.7	9.57	0.52	1.19e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.35	0.38	1.01e-9	Neuroticism;
KIRP	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg18657303	chr4:1051139	NA	0.54	4.96	0.3	1.31e-6	Recombination rate (females);
KIRP	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg25547332	chr5:131281432	NA	0.48	5.25	0.32	3.32e-7	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17315293	chr4:180982754	NA	-0.41	-6.31	-0.37	1.31e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg17294928	chr15:75287854	SCAMP5	0.57	7.67	0.44	3.91e-13	Breast cancer;
KIRP	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.62	-6.91	-0.4	4.25e-11	Type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22377027	chr1:12040208	MFN2	-0.49	-6.02	-0.36	6.45e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.97	-16.44	-0.72	1.71e-41	Breast cancer;
KIRP	cis	rs17321999	0.904	rs72787719	chr2:30474359	G/A	cg05247661	chr2:30472410	LBH	0.75	8.16	0.46	1.74e-14	Systemic lupus erythematosus;
KIRP	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs1832871	0.683	rs11752399	chr6:158711188	G/A	cg07215822	chr6:158701037	NA	-0.65	-7.43	-0.43	1.84e-12	Height;
KIRP	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.8	-0.35	2.06e-8	Parkinson's disease;
KIRP	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.37	8.25	0.47	9.82e-15	Corneal astigmatism;
KIRP	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg07827796	chr19:33622959	WDR88	0.42	4.99	0.3	1.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg14221460	chr8:27183342	PTK2B	0.5	6.54	0.38	3.63e-10	Neuroticism;
KIRP	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.97	-0.36	8.23e-9	Renal cell carcinoma;
KIRP	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-6.42	-0.38	7.04e-10	Asthma;
KIRP	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.7	9.5	0.52	1.91e-18	Schizophrenia;
KIRP	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg13319975	chr6:146136371	FBXO30	0.48	6.34	0.37	1.11e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7852872	0.965	rs7020341	chr9:119247974	C/G	cg13792444	chr9:119245443	ASTN2	0.37	5.44	0.33	1.26e-7	Hippocampal volume;
KIRP	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.6	0.39	2.48e-10	Iron status biomarkers;
KIRP	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg07701084	chr6:150067640	NUP43	0.57	7.23	0.42	6.13e-12	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg08662619	chr6:150070041	PCMT1	0.37	6.2	0.37	2.43e-9	Lung cancer;
KIRP	cis	rs35264875	0.846	rs2924534	chr11:68870516	C/G	cg01403660	chr11:68851641	TPCN2	-0.59	-5.98	-0.36	7.82e-9	Blond vs. brown hair color;
KIRP	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.24	9.73	0.53	3.73e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.85	12.84	0.63	3.14e-29	Height;
KIRP	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg21252483	chr19:49399788	TULP2	-0.48	-6.3	-0.37	1.39e-9	Red cell distribution width;
KIRP	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.23	-0.37	2.03e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.45e-9	Breast cancer;
KIRP	cis	rs7538876	1.000	rs7538876	chr1:17722363	G/A	cg01904812	chr1:17746340	RCC2	0.29	4.9	0.3	1.73e-6	Basal cell carcinoma;
KIRP	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.68	-0.39	1.62e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg06671706	chr8:8559999	CLDN23	-0.57	-6.5	-0.38	4.34e-10	Obesity-related traits;
KIRP	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.42	8.48	0.48	2.12e-15	Mean corpuscular volume;
KIRP	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg16110827	chr15:48056943	SEMA6D	-0.37	-4.99	-0.3	1.13e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.6	-5.79	-0.35	2.15e-8	Schizophrenia;
KIRP	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.63	-8.73	-0.49	3.89e-16	Autism;
KIRP	cis	rs712039	0.617	rs36081240	chr17:35785054	G/A	cg16670864	chr17:35848621	DUSP14	0.47	5.72	0.34	3.05e-8	Tuberculosis;
KIRP	cis	rs68170813	0.523	rs12535093	chr7:107020182	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-8.07	-0.46	3.14e-14	Coronary artery disease;
KIRP	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg24130564	chr14:104152367	KLC1	-0.45	-5.94	-0.35	9.53e-9	Body mass index;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27552081	chr17:25621774	WSB1	-0.52	-6.67	-0.39	1.66e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg19257562	chr1:2043853	PRKCZ	0.42	6.87	0.4	5.16e-11	Height;
KIRP	cis	rs10073892	0.830	rs10072122	chr5:101587931	G/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.39	0.38	8.11e-10	Cognitive decline (age-related);
KIRP	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.36	7.28	0.42	4.42e-12	IgG glycosylation;
KIRP	cis	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg20731937	chr12:48336164	NA	0.43	5.44	0.33	1.29e-7	Longevity (90 years and older);
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.68	5.51	0.33	8.98e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs11622475	1.000	rs2236247	chr14:104378087	C/T	cg20488157	chr14:104394430	TDRD9	0.66	9.14	0.5	2.46e-17	Bipolar disorder;
KIRP	cis	rs12311304	0.965	rs7302643	chr12:15394463	T/C	cg08258403	chr12:15378311	NA	0.38	5.64	0.34	4.6e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.09	-0.36	4.38e-9	Breast cancer;
KIRP	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.95	16.25	0.72	7.82e-41	Breast cancer;
KIRP	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.69	10.27	0.55	7.98e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs6540559	0.673	rs58637469	chr1:209971480	T/A	cg22029157	chr1:209979665	IRF6	0.51	5.74	0.34	2.8e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.85	11.69	0.6	2.1e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9972944	0.902	rs10512504	chr17:63772091	C/T	cg07283582	chr17:63770753	CCDC46	0.52	8.36	0.47	4.56e-15	Total body bone mineral density;
KIRP	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg19507638	chr5:93509721	C5orf36	-0.61	-5.29	-0.32	2.77e-7	Diabetic retinopathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24003273	chr1:46112691	RPS15AP10;GPBP1L1	0.42	6.05	0.36	5.35e-9	Interleukin-4 levels;
KIRP	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg14703610	chr5:56206110	C5orf35	0.51	6.78	0.4	8.83e-11	Coronary artery disease;
KIRP	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18252515	chr7:66147081	NA	0.45	5.46	0.33	1.18e-7	Aortic root size;
KIRP	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg24579218	chr15:68104479	NA	0.38	6.25	0.37	1.82e-9	Restless legs syndrome;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27628854	chr8:121823482	SNTB1	0.48	6.57	0.39	2.94e-10	Cancer;
KIRP	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.88	9.03	0.5	5.15e-17	Hip geometry;
KIRP	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg26528668	chr16:1614120	IFT140	0.4	5.03	0.31	9.52e-7	Coronary artery disease;
KIRP	cis	rs72848980	0.512	rs3781362	chr10:105375601	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.77	9.67	0.52	6.09e-19	White matter hyperintensity burden;
KIRP	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06481639	chr22:41940642	POLR3H	0.7	7.11	0.41	1.24e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.63	-0.34	4.8e-8	Crohn's disease;
KIRP	cis	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.36	-0.42	2.72e-12	Morning vs. evening chronotype;
KIRP	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg04025307	chr7:1156635	C7orf50	0.53	5.8	0.35	2.04e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.46	-0.59	1.22e-24	Chronic sinus infection;
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-5.02	-0.3	9.94e-7	Life satisfaction;
KIRP	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg21775007	chr8:11205619	TDH	0.52	6.42	0.38	7.12e-10	Mood instability;
KIRP	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg21573476	chr21:45109991	RRP1B	-0.66	-8.72	-0.49	4.21e-16	Mean corpuscular volume;
KIRP	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.5	6.64	0.39	2.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.42	5.39	0.33	1.63e-7	Aortic root size;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.43	-0.33	1.33e-7	Obesity-related traits;
KIRP	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.88	-15.25	-0.7	2.1e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg21926883	chr2:100939477	LONRF2	-0.56	-7.42	-0.43	1.9e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg22974920	chr21:40686053	BRWD1	-0.44	-5.15	-0.31	5.23e-7	Cognitive function;
KIRP	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg08992911	chr2:238395768	MLPH	0.49	5.03	0.31	9.49e-7	Prostate cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19313758	chr11:64889193	FAU;MRPL49	0.56	6.32	0.37	1.25e-9	Smoking initiation;
KIRP	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg06636001	chr8:8085503	FLJ10661	0.67	9.04	0.5	4.93e-17	Retinal vascular caliber;
KIRP	cis	rs7903847	0.642	rs10786344	chr10:99165975	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-5.57	-0.33	6.58e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23281280	chr6:28129359	ZNF389	0.44	4.85	0.3	2.16e-6	Depression;
KIRP	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.52	-7.5	-0.43	1.17e-12	Coronary artery disease;
KIRP	cis	rs10426930	0.607	rs858423	chr19:5048374	T/C	cg18473234	chr19:5097819	KDM4B	-0.58	-6.55	-0.39	3.42e-10	Monocyte percentage of white cells;
KIRP	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.61	7.07	0.41	1.63e-11	Obesity-related traits;
KIRP	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.73	7.54	0.43	8.93e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg23477460	chr3:66848765	NA	0.66	7.51	0.43	1.06e-12	Type 2 diabetes;
KIRP	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-12.39	-0.62	1.03e-27	Cognitive function;
KIRP	cis	rs10484885	0.587	rs6941737	chr6:90172981	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.51	-5.43	-0.33	1.35e-7	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.67	7.1	0.41	1.32e-11	Lymphocyte counts;
KIRP	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.88	-14.58	-0.68	3.97e-35	Oral cavity cancer;
KIRP	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg05865280	chr17:75406074	SEPT9	0.52	12.58	0.63	2.39e-28	Airflow obstruction;
KIRP	cis	rs12912251	0.591	rs2643216	chr15:39003809	C/G	cg10631289	chr15:39006617	NA	-0.79	-8.8	-0.49	2.41e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.76	10.87	0.57	9.63e-23	Menarche (age at onset);
KIRP	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.38	-5.55	-0.33	7.49e-8	Tuberculosis;
KIRP	cis	rs60311166	1.000	rs60311166	chr3:52671070	C/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.95	5.8	0.35	1.98e-8	CTACK levels;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg13198984	chr17:80129470	CCDC57	0.57	8.65	0.48	6.63e-16	Life satisfaction;
KIRP	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.69	8.11	0.46	2.46e-14	Body mass index;
KIRP	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg27205649	chr11:78285834	NARS2	0.49	5.5	0.33	9.4e-8	Testicular germ cell tumor;
KIRP	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.76	-9.25	-0.51	1.14e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg04896959	chr15:78267971	NA	0.75	10.3	0.55	6.57e-21	Coronary artery disease or large artery stroke;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg10254082	chr7:997346	NA	0.45	5.06	0.31	8.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6723108	0.651	rs35215000	chr2:135367656	C/A	cg25422880	chr2:135218333	TMEM163	0.38	5.72	0.34	3.05e-8	Type 2 diabetes;
KIRP	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg15443732	chr18:74961078	GALR1	0.55	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg14036092	chr11:66035641	RAB1B	0.44	5.64	0.34	4.64e-8	Gout;
KIRP	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.72	-9.32	-0.51	6.79e-18	N-glycan levels;
KIRP	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-16.59	-0.73	5.36e-42	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05355346	chr8:117777365	UTP23	-0.4	-6.67	-0.39	1.69e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-0.95	-13.26	-0.65	1.23e-30	Blood trace element (Zn levels);
KIRP	cis	rs829661	0.793	rs6731031	chr2:30790557	C/T	cg10949345	chr2:30726833	LCLAT1	1.12	14.05	0.67	2.54e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs3931020	0.566	rs1327086	chr1:75271032	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.57	7.29	0.42	4.25e-12	Resistin levels;
KIRP	trans	rs17079247	0.749	rs7489848	chr13:85808897	C/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27377777	chr17:76849093	TIMP2	0.45	6.65	0.39	1.89e-10	Interleukin-4 levels;
KIRP	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.49	-0.33	9.9e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11209002	0.545	rs2093332	chr1:67531974	G/A	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.81	8.02	0.46	4.31e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.74	0.63	6.93e-29	Platelet count;
KIRP	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.85	-13.86	-0.66	1.16e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.5	-6.31	-0.37	1.28e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg05941025	chr16:89927596	SPIRE2	-0.37	-5.9	-0.35	1.19e-8	Vitiligo;
KIRP	cis	rs758324	0.704	rs40401	chr5:131396478	C/T	cg06307176	chr5:131281290	NA	-0.44	-5.21	-0.32	3.99e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.53	7.28	0.42	4.5e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs72820985	0.604	rs3096280	chr16:80823575	C/T	cg04448709	chr16:81349954	GAN	0.54	5.43	0.33	1.35e-7	Breast cancer;
KIRP	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.7	10.63	0.56	5.67e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg09455208	chr3:40491958	NA	0.32	5.77	0.35	2.43e-8	Renal cell carcinoma;
KIRP	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.83	-10.74	-0.57	2.55e-22	Cognitive function;
KIRP	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg15068132	chr12:102092402	CHPT1	-0.39	-5.09	-0.31	7.05e-7	Blood protein levels;
KIRP	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.98	13.3	0.65	8.9e-31	Vitamin D levels;
KIRP	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.6	-0.39	2.47e-10	Educational attainment;
KIRP	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.91	8.81	0.49	2.26e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.38	-4.89	-0.3	1.84e-6	Mean platelet volume;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20869658	chr2:178481033	TTC30A	0.49	6.01	0.36	6.49e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-0.89	-10.61	-0.56	6.66e-22	Vitiligo;
KIRP	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg17524265	chr8:144659883	NAPRT1	0.79	5.13	0.31	5.8e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.42	-0.33	1.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg07689907	chr11:61582574	FADS1	0.49	6.17	0.37	2.81e-9	Trans fatty acid levels;
KIRP	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg03929089	chr4:120376271	NA	0.69	6.23	0.37	1.97e-9	Axial length;
KIRP	cis	rs2273156	0.706	rs8015622	chr14:35487100	G/A	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.16	-0.31	5.01e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg18944383	chr4:111397179	ENPEP	0.61	11.26	0.58	5.39e-24	Height;
KIRP	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.56	-5.92	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs1421811	0.606	rs981001	chr5:32721545	G/A	cg16267343	chr5:32710456	NPR3	0.97	10.82	0.57	1.42e-22	Blood pressure;
KIRP	cis	rs988913	0.958	rs1503140	chr6:54810766	A/G	cg03513858	chr6:54763001	FAM83B	-0.38	-5.43	-0.33	1.35e-7	Menarche (age at onset);
KIRP	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg02780029	chr10:43622663	RET	-0.35	-5.28	-0.32	2.9e-7	Hirschsprung disease;
KIRP	cis	rs9914544	0.545	rs12451200	chr17:18778493	A/G	cg26378065	chr17:18585709	ZNF286B	0.38	4.84	0.3	2.25e-6	Educational attainment (years of education);
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg17651855	chr11:109920791	NA	0.9	6.11	0.36	3.92e-9	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg16049864	chr8:95962084	TP53INP1	-0.39	-6.29	-0.37	1.47e-9	Type 2 diabetes;
KIRP	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14169450	chr9:139327907	INPP5E	0.54	6.23	0.37	2e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.81	6.64	0.39	1.95e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.25e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.67	-8.5	-0.48	1.83e-15	Body mass index;
KIRP	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.4	6.09	0.36	4.32e-9	Hypertriglyceridemia;
KIRP	cis	rs3026101	0.671	rs57406064	chr17:5300183	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.04	0.36	5.51e-9	Height;
KIRP	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.39	6.6	0.39	2.54e-10	Renal cell carcinoma;
KIRP	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg06042504	chr8:55087323	NA	-0.59	-7.23	-0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg19743168	chr1:23544995	NA	0.51	7.18	0.42	8.1e-12	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15023646	chr10:75880238	AP3M1	0.48	6.49	0.38	4.72e-10	Interleukin-4 levels;
KIRP	cis	rs6968419	0.747	rs3807968	chr7:115863446	G/A	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg11464464	chr5:68513891	MRPS36	0.53	6.65	0.39	1.88e-10	Educational attainment;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.49	-6.21	-0.37	2.22e-9	Longevity;Endometriosis;
KIRP	cis	rs55675132	0.548	rs80326561	chr1:115473713	A/G	cg12756093	chr1:115239321	AMPD1	0.55	5.38	0.32	1.75e-7	Schizophrenia;
KIRP	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.64	-4.93	-0.3	1.53e-6	Schizophrenia;
KIRP	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.24	-0.37	1.95e-9	Height;
KIRP	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02725872	chr8:58115012	NA	-0.73	-7.64	-0.44	4.73e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs6142102	0.961	rs2268089	chr20:32667298	T/C	cg08999081	chr20:33150536	PIGU	0.53	6.94	0.4	3.55e-11	Skin pigmentation;
KIRP	cis	rs2151522	0.724	rs6923072	chr6:127188503	C/A	cg21431617	chr6:127135037	NA	0.29	5.13	0.31	5.85e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.66	7.23	0.42	6.23e-12	Vitiligo;
KIRP	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.33	0.42	3.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.4	5.1	0.31	6.79e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.51	-7.23	-0.42	6.17e-12	Obesity-related traits;
KIRP	cis	rs16854884	1.000	rs35887108	chr3:143780632	C/T	cg06585982	chr3:143692056	C3orf58	0.55	5.76	0.34	2.46e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg27205649	chr11:78285834	NARS2	-0.59	-6.79	-0.4	8.17e-11	Testicular germ cell tumor;
KIRP	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg16586182	chr3:47516702	SCAP	-0.65	-8.67	-0.48	6.01e-16	Colorectal cancer;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg01391022	chr12:122360665	WDR66	-0.39	-5.59	-0.34	6.16e-8	Mean corpuscular volume;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg07648498	chr16:89883185	FANCA	0.42	5.57	0.33	6.53e-8	Vitiligo;
KIRP	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.66	7.64	0.44	4.9e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10982256	0.774	rs4327928	chr9:117246269	G/T	cg13636371	chr9:117264095	DFNB31	-0.51	-7.12	-0.41	1.19e-11	Bipolar disorder;
KIRP	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.21	22.12	0.82	1.97e-60	Cognitive function;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09526975	chr10:13390462	SEPHS1	0.48	6.34	0.37	1.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.8	-12.43	-0.62	7.36e-28	Oral cavity cancer;
KIRP	cis	rs12049351	0.774	rs6662732	chr1:229629245	A/C	cg11742688	chr1:229674241	ABCB10	0.38	5.55	0.33	7.26e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.28	-0.47	8.1e-15	Mean corpuscular volume;
KIRP	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg01950434	chr2:97203154	ARID5A	-0.49	-6.27	-0.37	1.61e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4789452	0.744	rs1105409	chr17:75383940	T/C	cg02320862	chr17:75370284	SEPT9	-0.36	-4.85	-0.3	2.2e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.02	0.75	7.41e-47	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12668415	chr12:133297765	PGAM5	-0.55	-6.91	-0.4	4.02e-11	Parkinson's disease;
KIRP	cis	rs9547996	0.879	rs61957468	chr13:38132914	G/A	cg13634560	chr13:38173852	POSTN	-0.4	-5.54	-0.33	7.83e-8	Diastolic blood pressure;
KIRP	cis	rs4765905	0.549	rs2239025	chr12:2312282	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.51e-11	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg05692746	chr2:100937584	LONRF2	-0.39	-5.06	-0.31	8.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.74e-15	Calcium levels;
KIRP	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.5	5.79	0.35	2.18e-8	Menarche (age at onset);
KIRP	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.22	-0.51	1.35e-17	Response to antipsychotic treatment;
KIRP	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg11667643	chr8:748456	NA	-0.44	-5.22	-0.32	3.89e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg11906718	chr8:101322791	RNF19A	-0.49	-6.5	-0.38	4.48e-10	Atrioventricular conduction;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19300632	chr2:55746645	CCDC104	0.49	6.07	0.36	4.8e-9	Smoking initiation;
KIRP	trans	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg24644049	chr4:85504048	CDS1	0.9	6.64	0.39	2e-10	Skin colour saturation;
KIRP	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.44	5.64	0.34	4.67e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.63	-0.39	2.11e-10	Bipolar disorder;
KIRP	cis	rs1010254	0.510	rs56245652	chr5:151762153	A/G	cg12297329	chr5:152029980	NA	-0.69	-6.92	-0.4	3.89e-11	Optic nerve measurement (cup area);
KIRP	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg16497661	chr14:103986332	CKB	0.47	4.89	0.3	1.84e-6	Coronary artery disease;
KIRP	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg07775547	chr4:1625484	NA	-0.42	-5.14	-0.31	5.61e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06544989	chr22:39130855	UNC84B	0.51	9.04	0.5	4.65e-17	Menopause (age at onset);
KIRP	cis	rs2434422	0.708	rs7249361	chr19:52839396	A/T	cg17271561	chr19:52839334	ZNF610	-0.79	-6.06	-0.36	5.05e-9	Cannabis use (initiation);
KIRP	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.75	-10.39	-0.55	3.28e-21	Hypospadias;
KIRP	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	1.06	17.78	0.75	5.01e-46	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	1.0	13.32	0.65	7.74e-31	Cognitive function;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg15832094	chr12:132266778	SFRS8	0.39	5.4	0.33	1.6e-7	Migraine;
KIRP	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg03465714	chr1:152285911	FLG	0.46	5.13	0.31	5.81e-7	Atopic dermatitis;
KIRP	cis	rs9603616	0.747	rs9548881	chr13:40262760	T/C	cg26701198	chr13:40229707	COG6	0.43	5.17	0.31	4.74e-7	Rheumatoid arthritis;
KIRP	cis	rs876084	0.505	rs11985197	chr8:121107553	G/A	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4132509	0.895	rs6674314	chr1:243920895	A/G	cg21452805	chr1:244014465	NA	0.52	5.09	0.31	7.07e-7	RR interval (heart rate);
KIRP	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02711726	chr17:80685570	FN3KRP	-0.49	-6.78	-0.4	8.81e-11	Glycated hemoglobin levels;
KIRP	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg11752832	chr7:134001865	SLC35B4	0.47	5.71	0.34	3.19e-8	Mean platelet volume;
KIRP	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg23594656	chr7:65796392	TPST1	0.47	7.46	0.43	1.52e-12	Aortic root size;
KIRP	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg19847130	chr8:10466454	RP1L1	0.44	6.58	0.39	2.82e-10	Neuroticism;
KIRP	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg08648136	chr8:956695	NA	0.49	7.68	0.44	3.66e-13	Schizophrenia;
KIRP	cis	rs6142618	0.555	rs3746601	chr20:30662805	A/C	cg09796376	chr20:30640595	HCK	0.42	5.86	0.35	1.5e-8	Inflammatory bowel disease;
KIRP	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.79	9.0	0.5	6.24e-17	White matter hyperintensity burden;
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg07216194	chr8:27182965	PTK2B	0.47	5.88	0.35	1.32e-8	Neuroticism;
KIRP	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	0.95	14.84	0.69	5.01e-36	Breast cancer;
KIRP	trans	rs933360	0.585	rs11238310	chr7:50825283	G/A	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.3e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.76	0.34	2.53e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs911119	0.818	rs56077567	chr20:23591087	T/C	cg09631192	chr20:23583594	CST9	-0.47	-4.87	-0.3	2.03e-6	Chronic kidney disease;
KIRP	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.47	-9.63	-0.52	8.01e-19	Longevity;
KIRP	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9488822	0.662	rs195531	chr6:116252551	A/T	cg15226275	chr6:116381976	FRK	0.2	5.46	0.33	1.18e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-1.14	-13.8	-0.66	1.81e-32	Platelet count;
KIRP	cis	rs9506514	0.722	rs10400670	chr13:21253489	G/A	cg04906043	chr13:21280425	IL17D	-0.4	-5.13	-0.31	5.83e-7	Coronary artery calcification;
KIRP	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.61	8.13	0.46	2.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4660306	0.677	rs1691216	chr1:45899416	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.1	0.36	4.16e-9	Homocysteine levels;
KIRP	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg23950597	chr19:37808831	NA	-0.62	-6.76	-0.4	1.02e-10	Coronary artery calcification;
KIRP	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.39	4.95	0.3	1.36e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.62	-6.91	-0.4	4.23e-11	Neuroticism;
KIRP	cis	rs7712401	0.580	rs185008	chr5:122274734	T/C	cg19412675	chr5:122181750	SNX24	0.47	5.2	0.31	4.22e-7	Mean platelet volume;
KIRP	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.82	11.37	0.59	2.3e-24	Multiple sclerosis;
KIRP	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg04607699	chr11:48328132	OR4S1	0.39	5.64	0.34	4.57e-8	Migraine - clinic-based;
KIRP	cis	rs2219968	1.000	rs4541901	chr8:78971715	G/A	cg00738934	chr8:78996279	NA	0.5	6.93	0.4	3.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg12463550	chr7:65579703	CRCP	-0.43	-4.89	-0.3	1.79e-6	Aortic root size;
KIRP	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg01391022	chr12:122360665	WDR66	0.35	5.23	0.32	3.66e-7	Mean corpuscular volume;
KIRP	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.61	8.72	0.49	4.25e-16	Height;
KIRP	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg18679712	chr3:14989672	NR2C2	0.52	6.56	0.39	3.1e-10	Myopia (pathological);
KIRP	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs2235544	0.588	rs664758	chr1:54461263	C/T	cg25741118	chr1:54482237	LDLRAD1	0.28	5.34	0.32	2.11e-7	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.84	9.95	0.54	7.91e-20	Multiple sclerosis;
KIRP	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.61	8.13	0.46	2.1e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg20673091	chr1:2541236	MMEL1	0.68	10.48	0.56	1.76e-21	Ulcerative colitis;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg12692727	chr7:1102344	C7orf50	0.48	5.13	0.31	5.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.3	-0.32	2.53e-7	Red blood cell count;
KIRP	cis	rs1772578	0.857	rs1772572	chr13:81191176	A/C	cg22417789	chr13:80915465	SPRY2	0.42	5.25	0.32	3.36e-7	Methadone dose in opioid dependence;
KIRP	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs282587	0.569	rs7987238	chr13:113409944	G/A	cg04656015	chr13:113407548	ATP11A	0.62	7.12	0.41	1.15e-11	Glycated hemoglobin levels;
KIRP	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg01872077	chr2:219646372	CYP27A1	-0.37	-4.85	-0.3	2.2e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.86	-0.35	1.45e-8	Breast cancer;
KIRP	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg22961107	chr3:194096808	NA	0.38	5.49	0.33	9.91e-8	Platelet distribution width;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg15147215	chr3:52552868	STAB1	-0.27	-4.89	-0.3	1.86e-6	Bipolar disorder;
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg01798813	chr17:3906674	NA	-0.51	-7.08	-0.41	1.47e-11	Type 2 diabetes;
KIRP	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg04025307	chr7:1156635	C7orf50	0.54	5.92	0.35	1.09e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg04990556	chr1:26633338	UBXN11	0.69	6.74	0.39	1.14e-10	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25449502	chr3:186502039	SNORD2;EIF4A2	0.51	6.59	0.39	2.6e-10	Parkinson's disease;
KIRP	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.88	-12.51	-0.62	4.15e-28	Coronary artery disease;
KIRP	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-19.11	-0.77	1.55e-50	Schizophrenia;
KIRP	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.53	-5.42	-0.33	1.44e-7	Menarche (age at onset);
KIRP	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg10617943	chr7:1981403	MAD1L1	-0.36	-4.97	-0.3	1.28e-6	Neuroticism;
KIRP	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg07274523	chr3:49395745	GPX1	0.69	8.33	0.47	5.52e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.18	-0.42	8.37e-12	Joint mobility (Beighton score);
KIRP	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg02503808	chr4:7069936	GRPEL1	-1.05	-11.03	-0.58	2.91e-23	Monocyte percentage of white cells;
KIRP	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	trans	rs6506900	0.692	rs8091934	chr18:28902197	G/A	cg10906284	chr12:63544430	AVPR1A	0.37	6.03	0.36	5.83e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg10932868	chr11:921992	NA	-0.54	-6.97	-0.41	2.92e-11	Alzheimer's disease (late onset);
KIRP	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg17108064	chr15:78857060	CHRNA5	0.35	5.0	0.3	1.09e-6	Sudden cardiac arrest;
KIRP	trans	rs7404928	0.718	rs11074582	chr16:23864825	G/A	cg06734812	chr19:3223915	BRUNOL5	0.59	6.05	0.36	5.36e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.9	6.8	0.4	8.03e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.71	7.41	0.43	1.97e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.22	-0.37	2.17e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.49	7.95	0.45	6.89e-14	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg07148914	chr20:33460835	GGT7	0.51	7.2	0.42	7.49e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg21775007	chr8:11205619	TDH	-0.38	-4.86	-0.3	2.1e-6	Triglycerides;
KIRP	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg23533926	chr12:111358616	MYL2	-0.47	-6.14	-0.36	3.35e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.02	-14.67	-0.68	1.96e-35	Alzheimer's disease;
KIRP	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.62	8.06	0.46	3.36e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.77	9.45	0.52	2.71e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg02336718	chr17:17403227	NA	0.32	5.15	0.31	5.42e-7	Total body bone mineral density;
KIRP	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg12486944	chr17:80159399	CCDC57	-0.38	-5.09	-0.31	6.98e-7	Life satisfaction;
KIRP	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg01843034	chr6:37503916	NA	-0.95	-15.24	-0.7	2.21e-37	Cognitive performance;
KIRP	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05472934	chr7:22766657	IL6	0.8	10.19	0.54	1.41e-20	Lung cancer;
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.89	-0.49	1.3e-16	Retinal vascular caliber;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03226245	chr19:36486125	SDHAF1	0.54	6.39	0.38	8.38e-10	Smoking initiation;
KIRP	trans	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.88	0.4	4.93e-11	Mean corpuscular volume;
KIRP	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.94	-0.54	8.37e-20	Total body bone mineral density;
KIRP	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.1	0.69	6.82e-37	Platelet count;
KIRP	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.87	10.48	0.56	1.72e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05121388	chr17:60501122	METTL2A	0.48	7.0	0.41	2.43e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg00405596	chr8:11794950	NA	0.46	5.84	0.35	1.68e-8	Retinal vascular caliber;
KIRP	cis	rs2718058	0.630	rs2718045	chr7:37795438	C/G	cg15028436	chr7:37888078	TXNDC3	-0.4	-5.18	-0.31	4.52e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-5.81	-0.35	1.91e-8	Blood metabolite levels;
KIRP	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.53	8.28	0.47	8e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg06212747	chr3:49208901	KLHDC8B	0.84	9.41	0.51	3.81e-18	Menarche (age at onset);
KIRP	cis	rs7246657	0.722	rs10404031	chr19:38035954	A/G	cg18154014	chr19:37997991	ZNF793	0.61	6.66	0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg05527609	chr1:210001259	C1orf107	-0.48	-5.23	-0.32	3.69e-7	Red blood cell count;
KIRP	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg09137382	chr11:130731461	NA	0.57	7.86	0.45	1.18e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12220238	0.722	rs6480743	chr10:76398765	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.53	6.06	0.36	4.99e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4356932	0.967	rs6532154	chr4:76974095	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.61e-9	Blood protein levels;
KIRP	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.49	-11.49	-0.59	9.86e-25	Diabetic kidney disease;
KIRP	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.41	-5.3	-0.32	2.55e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg08662619	chr6:150070041	PCMT1	0.34	5.53	0.33	8.06e-8	Lung cancer;
KIRP	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.44	-0.33	1.28e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg19507638	chr5:93509721	C5orf36	-0.55	-5.02	-0.31	9.73e-7	Diabetic retinopathy;
KIRP	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.77	10.4	0.55	3.12e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.01	0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg22974920	chr21:40686053	BRWD1	0.45	5.1	0.31	6.67e-7	Cognitive function;
KIRP	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg00857998	chr1:205179979	DSTYK	0.59	7.25	0.42	5.51e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2502731	0.583	rs3003579	chr9:130995751	C/G	cg13642260	chr9:130955380	CIZ1	0.42	5.73	0.34	2.85e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs4950322	0.570	rs17356240	chr1:146741537	G/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg23845249	chr11:68861649	NA	0.6	8.76	0.49	3.31e-16	Blond vs. brown hair color;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08887933	chr16:71601037	TAT	0.44	6.27	0.37	1.64e-9	Survival in pancreatic cancer;
KIRP	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.56	7.54	0.43	9.06e-13	Caffeine consumption;
KIRP	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg03474202	chr17:45855739	NA	-0.52	-8.12	-0.46	2.29e-14	IgG glycosylation;
KIRP	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg26875233	chr11:93583750	C11orf90	-0.34	-6.49	-0.38	4.64e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.53	5.65	0.34	4.39e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.84	12.59	0.63	2.24e-28	Eosinophil percentage of white cells;
KIRP	cis	rs17739794	0.557	rs35185084	chr8:808721	C/G	cg01971667	chr8:817044	NA	0.42	5.86	0.35	1.46e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg03684893	chr10:554711	DIP2C	0.36	5.0	0.3	1.09e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.36	6.53	0.38	3.69e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.67	9.34	0.51	6.11e-18	Lymphocyte counts;
KIRP	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.54	6.89	0.4	4.58e-11	Longevity;
KIRP	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg11783602	chr8:55087084	NA	-0.57	-7.07	-0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg10756647	chr7:56101905	PSPH	1.01	7.6	0.44	6.29e-13	Diabetic kidney disease;
KIRP	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg17279839	chr7:150038598	RARRES2	0.53	6.63	0.39	2.05e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs17453880	1.000	rs17453880	chr5:151977841	G/A	cg12297329	chr5:152029980	NA	-0.72	-10.6	-0.56	7.21e-22	Subjective well-being;
KIRP	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.56	6.89	0.4	4.57e-11	Aortic root size;
KIRP	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg23625390	chr15:77176239	SCAPER	0.52	6.99	0.41	2.64e-11	Blood metabolite levels;
KIRP	cis	rs7923609	0.875	rs6479877	chr10:64878118	C/G	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.02	-0.3	9.8e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.77	11.68	0.6	2.36e-25	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg12046867	chr14:103022105	NA	0.45	5.59	0.34	6.03e-8	Platelet count;
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg21851534	chr17:3907994	ZZEF1	-0.62	-9.77	-0.53	2.93e-19	Type 2 diabetes;
KIRP	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg27356188	chr5:637386	CEP72	0.36	4.93	0.3	1.49e-6	Obesity-related traits;
KIRP	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6832769	0.922	rs501679	chr4:56237327	C/T	cg09317128	chr4:56265301	TMEM165	0.48	6.38	0.38	8.7e-10	Personality dimensions;
KIRP	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg03808351	chr9:123631620	PHF19	0.47	6.5	0.38	4.54e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7113874	0.592	rs10500703	chr11:8433864	C/T	cg08015107	chr11:8618950	NA	-0.69	-8.35	-0.47	4.87e-15	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs918629	0.716	rs7700895	chr5:95273410	T/A	cg16656078	chr5:95278638	ELL2	-0.47	-6.7	-0.39	1.4e-10	IgG glycosylation;
KIRP	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg06289844	chr6:126071538	HEY2	-0.44	-6.4	-0.38	7.77e-10	Brugada syndrome;
KIRP	cis	rs7188697	0.922	rs37039	chr16:58578091	C/T	cg21335942	chr16:58549945	SETD6	0.46	5.08	0.31	7.6e-7	QT interval;
KIRP	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg07501729	chr16:846077	CHTF18	0.44	5.71	0.34	3.25e-8	Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg06740227	chr12:86229804	RASSF9	0.5	6.47	0.38	5.27e-10	Major depressive disorder;
KIRP	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg04731861	chr2:219085781	ARPC2	-0.22	-5.25	-0.32	3.32e-7	Colorectal cancer;
KIRP	cis	rs2274273	0.624	rs66551709	chr14:55791022	A/T	cg04306507	chr14:55594613	LGALS3	0.38	5.27	0.32	3.03e-7	Protein biomarker;
KIRP	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-7.22	-0.42	6.35e-12	Interstitial lung disease;
KIRP	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg12062639	chr20:23401060	NAPB	0.84	7.25	0.42	5.29e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03352830	chr11:487213	PTDSS2	0.77	6.38	0.38	8.81e-10	Body mass index;
KIRP	cis	rs2929278	0.736	rs2412823	chr15:44227270	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-5.41	-0.33	1.53e-7	Schizophrenia;
KIRP	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	8.93	0.49	1e-16	Total cholesterol levels;
KIRP	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.75	-9.8	-0.53	2.31e-19	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23167456	chr1:27942186	FGR	0.48	6.07	0.36	4.82e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg26318627	chr11:63887540	MACROD1	0.4	5.5	0.33	9.46e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg26876637	chr1:152193138	HRNR	0.73	9.51	0.52	1.88e-18	Atopic dermatitis;
KIRP	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg08318506	chr11:34938348	PDHX;APIP	-0.41	-5.0	-0.3	1.09e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.71	-0.39	1.35e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.46	-0.47	2.48e-15	Mood instability;
KIRP	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg21605333	chr4:119757512	SEC24D	1.52	11.71	0.6	1.78e-25	Cannabis dependence symptom count;
KIRP	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg15358701	chr1:161410459	NA	-0.64	-5.74	-0.34	2.79e-8	Rheumatoid arthritis;
KIRP	cis	rs55675132	0.548	rs12142149	chr1:115364645	C/T	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs7546094	0.792	rs6537748	chr1:113214381	T/G	cg22162597	chr1:113214053	CAPZA1	-0.43	-5.44	-0.33	1.31e-7	Platelet distribution width;
KIRP	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.45	5.42	0.33	1.42e-7	Asthma (sex interaction);
KIRP	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.73	8.1	0.46	2.49e-14	Menarche (age at onset);
KIRP	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	0.54	6.47	0.38	5.26e-10	Prudent dietary pattern;
KIRP	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg06618935	chr21:46677482	NA	-0.43	-5.21	-0.32	4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	1.08	16.03	0.71	4.36e-40	Menopause (age at onset);
KIRP	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.76	10.92	0.57	7.04e-23	Schizophrenia;
KIRP	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg04374321	chr14:90722782	PSMC1	0.87	13.44	0.65	3.01e-31	Mortality in heart failure;
KIRP	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg21926883	chr2:100939477	LONRF2	-0.57	-7.59	-0.44	6.75e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.72	12.19	0.61	4.9e-27	Weight;
KIRP	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.99	11.51	0.59	8e-25	Vitiligo;
KIRP	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.81	9.92	0.53	1.01e-19	Corneal astigmatism;
KIRP	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg06742321	chr12:123595122	PITPNM2	0.42	5.2	0.31	4.14e-7	Platelet count;
KIRP	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.79	-8.88	-0.49	1.48e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs12360000	0.864	rs9919410	chr10:1902486	A/G	cg26364871	chr10:1889757	NA	0.53	6.57	0.39	2.95e-10	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs4474465	1.000	rs966456	chr11:78168603	T/A	cg27205649	chr11:78285834	NARS2	-0.68	-7.48	-0.43	1.31e-12	Alzheimer's disease (survival time);
KIRP	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.69	-7.98	-0.45	5.44e-14	Pancreatic cancer;
KIRP	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg11970804	chr8:8084126	NA	-0.38	-5.36	-0.32	1.87e-7	Mood instability;
KIRP	cis	rs10932679	0.532	rs2024488	chr2:217662968	G/A	cg05032264	chr2:217675019	NA	-0.42	-5.84	-0.35	1.62e-8	Pulse pressure;
KIRP	cis	rs35000415	0.938	rs17338998	chr7:128618559	C/T	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.69	-9.15	-0.5	2.2e-17	Huntington's disease progression;
KIRP	cis	rs10517025	0.673	rs4324577	chr4:42425852	T/C	cg13587180	chr4:42403248	SHISA3	0.43	4.85	0.3	2.23e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg17007872	chr7:129251834	NRF1	-0.52	-6.12	-0.36	3.62e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg13978929	chr19:21580086	ZNF493	0.52	5.02	0.31	9.78e-7	Pain;
KIRP	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg10223061	chr2:219282414	VIL1	0.29	4.93	0.3	1.53e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg26207909	chr14:103986467	CKB	-0.42	-5.06	-0.31	8.4e-7	Coronary artery disease;
KIRP	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.57	-7.43	-0.43	1.82e-12	Aortic root size;
KIRP	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	1.01	16.51	0.73	9.82e-42	Bone mineral density;
KIRP	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg20636351	chr8:55087400	NA	-0.62	-7.64	-0.44	4.95e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg25036284	chr2:26402008	FAM59B	-0.61	-5.95	-0.35	9.36e-9	Gut microbiome composition (summer);
KIRP	cis	rs6681460	1.000	rs4655648	chr1:67114309	C/T	cg02459107	chr1:67143332	SGIP1	0.48	6.73	0.39	1.17e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.5e-21	Bone mineral density;
KIRP	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.35	-0.47	4.93e-15	Mean corpuscular volume;
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg09597638	chr17:3907349	NA	0.58	8.36	0.47	4.76e-15	Type 2 diabetes;
KIRP	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg05315796	chr3:52349193	DNAH1	0.41	5.81	0.35	1.88e-8	Bipolar disorder;
KIRP	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg26408565	chr15:76604113	ETFA	-0.43	-5.79	-0.35	2.16e-8	Blood metabolite levels;
KIRP	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg17366294	chr4:99064904	C4orf37	0.45	5.38	0.32	1.75e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.69	10.2	0.55	1.33e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6750047	0.566	rs1157185	chr2:38285735	C/T	cg07380506	chr2:38303506	CYP1B1	0.39	5.12	0.31	6.06e-7	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00321850	chr1:175162397	KIAA0040	0.36	6.49	0.38	4.59e-10	Alcohol dependence;
KIRP	cis	rs4704187	0.687	rs6889429	chr5:74482183	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06595275	chr6:35995676	MAPK14	0.56	7.26	0.42	5.1e-12	Parkinson's disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14397941	chr9:125865760	RABGAP1	-0.46	-6.18	-0.37	2.67e-9	Inflammatory biomarkers;
KIRP	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.64	7.65	0.44	4.66e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg26043149	chr18:55253948	FECH	0.5	6.13	0.36	3.54e-9	Bone mineral density;
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.44	5.6	0.34	5.68e-8	Longevity;
KIRP	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg10517650	chr3:113235015	CCDC52	-0.47	-6.14	-0.36	3.29e-9	Dental caries;
KIRP	cis	rs9488822	0.702	rs540981	chr6:116266592	A/G	cg18764771	chr6:116381957	FRK	-0.2	-5.4	-0.33	1.59e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.18	-0.31	4.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.78	6.92	0.4	3.84e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.65	6.93	0.4	3.59e-11	Mammographic density (dense area);
KIRP	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.64	-7.96	-0.45	6.37e-14	Eosinophil percentage of white cells;
KIRP	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.56	-6.24	-0.37	1.85e-9	Iron status biomarkers;
KIRP	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	1.04	15.76	0.71	3.62e-39	Cognitive function;
KIRP	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg14558114	chr2:88469736	THNSL2	0.66	5.37	0.32	1.81e-7	Plasma clusterin levels;
KIRP	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg21174375	chr14:64681225	SYNE2	0.46	5.09	0.31	7.08e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.76	7.68	0.44	3.77e-13	Migraine;Coronary artery disease;
KIRP	cis	rs271674	1.000	rs271674	chr17:47978986	A/G	cg05310240	chr17:47979069	NA	-0.39	-4.87	-0.3	1.96e-6	White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00822591	chr3:16306489	DPH3;OXNAD1	0.47	6.08	0.36	4.66e-9	Parkinson's disease;
KIRP	trans	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg06468920	chr17:61613267	KCNH6	-0.52	-6.42	-0.38	6.96e-10	Body mass index;
KIRP	trans	rs2837828	1.000	rs1888510	chr21:42168974	C/T	cg05777962	chr1:247614860	OR2B11	-0.39	-6.02	-0.36	6.41e-9	Neutrophil count;
KIRP	cis	rs6959887	0.926	rs4723406	chr7:35286471	C/A	cg06685737	chr7:35301730	NA	0.43	6.16	0.37	3e-9	Birth weight;
KIRP	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	cis	rs236907	0.859	rs12753043	chr1:171761821	G/A	cg01410279	chr1:171621941	MYOC	-0.49	-5.57	-0.33	6.83e-8	Mean platelet volume;
KIRP	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg07075026	chr17:47091521	IGF2BP1	-0.4	-7.84	-0.45	1.36e-13	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.93	16.12	0.72	2.12e-40	Metabolic syndrome;
KIRP	cis	rs7289126	1.000	rs7290372	chr22:38628388	T/G	cg25457927	chr22:38595422	NA	-0.31	-7.04	-0.41	1.9e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.09	0.36	4.37e-9	Myopia (pathological);
KIRP	cis	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg13789015	chr9:136890014	NCRNA00094	0.61	5.24	0.32	3.45e-7	Mosquito bite size;
KIRP	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg08738300	chr3:44038990	NA	0.68	9.56	0.52	1.28e-18	Coronary artery disease;
KIRP	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg24289452	chr6:170231220	NA	-0.74	-4.87	-0.3	1.97e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs829661	0.793	rs11127278	chr2:30805028	T/C	cg10949345	chr2:30726833	LCLAT1	1.13	14.39	0.68	1.77e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg14345882	chr6:26364793	BTN3A2	0.34	5.59	0.34	5.93e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.65	8.89	0.49	1.34e-16	Mood instability;
KIRP	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg11632617	chr15:75315747	PPCDC	-0.6	-5.17	-0.31	4.86e-7	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08205230	chr11:67183078	ATPGD1	0.41	6.1	0.36	4.11e-9	Parkinson's disease;
KIRP	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.19	-0.51	1.71e-17	Neuroticism;
KIRP	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.86	10.19	0.54	1.41e-20	Blood protein levels;
KIRP	cis	rs9972944	0.729	rs2024275	chr17:63768913	C/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.16e-13	Total body bone mineral density;
KIRP	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.36	5.03	0.31	9.57e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.6	0.52	9.57e-19	Lung cancer in ever smokers;
KIRP	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.69	-0.39	1.49e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg03060546	chr3:49711283	APEH	0.43	5.66	0.34	4.27e-8	Parkinson's disease;
KIRP	trans	rs9693857	0.520	rs11249927	chr8:9361606	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	6.18	0.37	2.72e-9	Systolic blood pressure;
KIRP	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg10223061	chr2:219282414	VIL1	0.52	7.81	0.45	1.66e-13	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.72	-10.83	-0.57	1.28e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.84	10.15	0.54	1.97e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2120243	0.533	rs62278578	chr3:157055867	C/T	cg24825693	chr3:157122686	VEPH1	-0.37	-5.66	-0.34	4.11e-8	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs17121403	0.661	rs11166404	chr1:100596890	T/C	cg24955406	chr1:100503596	HIAT1	0.78	5.08	0.31	7.35e-7	Pulmonary function decline;
KIRP	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.76	-10.08	-0.54	3.13e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.78	-10.1	-0.54	2.71e-20	Platelet distribution width;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17140208	chr4:146826739	ZNF827	0.43	6.19	0.37	2.47e-9	C-reactive protein;
KIRP	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.44	5.49	0.33	1.01e-7	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00444581	chr8:141856401	PTK2	-0.4	-6.25	-0.37	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26002218	chr14:103986227	CKB	-0.35	-7.14	-0.41	1.03e-11	Body mass index;
KIRP	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.25	-0.32	3.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2790457	0.917	rs2790462	chr10:28873202	C/T	cg05705492	chr10:28955341	NA	-0.54	-8.24	-0.46	1.05e-14	Multiple myeloma;
KIRP	cis	rs6708331	0.517	rs6546570	chr2:70350033	G/C	cg01613454	chr2:70366299	NA	0.39	5.23	0.32	3.68e-7	Obesity-related traits;
KIRP	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.76	-0.34	2.56e-8	Pulmonary function;
KIRP	cis	rs6142102	0.580	rs6142101	chr20:32697845	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	5.74	0.34	2.75e-8	Skin pigmentation;
KIRP	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-7.29	-0.42	4.1e-12	Dental caries;
KIRP	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg11846333	chr4:119757529	SEC24D	1.14	6.8	0.4	7.75e-11	Cannabis dependence symptom count;
KIRP	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg04111992	chr7:158790115	NA	-0.42	-5.16	-0.31	5.15e-7	Facial morphology (factor 20);
KIRP	cis	rs9653442	0.564	rs10185510	chr2:100790581	C/T	cg17356467	chr2:100759845	AFF3	0.44	5.68	0.34	3.85e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs4478137	0.931	rs3967762	chr4:164244976	T/C	cg06758707	chr4:164254230	NPY1R	0.71	9.2	0.51	1.63e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs4262150	0.774	rs56014830	chr5:152028204	T/A	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.05e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg05044414	chr3:183734942	ABCC5	0.38	5.75	0.34	2.65e-8	Anterior chamber depth;
KIRP	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg07701084	chr6:150067640	NUP43	0.58	7.51	0.43	1.06e-12	Testicular germ cell tumor;
KIRP	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.82	9.75	0.53	3.37e-19	Corneal astigmatism;
KIRP	cis	rs4594175	0.707	rs4606635	chr14:51712092	T/C	cg23942311	chr14:51606299	NA	0.41	5.33	0.32	2.25e-7	Cancer;
KIRP	trans	rs9443189	0.806	rs9359139	chr6:76487269	C/G	cg06311355	chr22:24577269	SUSD2	0.31	6.09	0.36	4.31e-9	Prostate cancer;
KIRP	cis	rs471756	0.523	rs2479319	chr9:219528	C/T	cg14500300	chr9:211689	NA	0.4	5.44	0.33	1.26e-7	Mean platelet volume;
KIRP	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14159672	chr1:205819179	PM20D1	0.48	5.33	0.32	2.19e-7	Prostate-specific antigen levels;
KIRP	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.44	-0.43	1.71e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg13289132	chr10:30722225	MAP3K8	0.4	5.1	0.31	6.91e-7	Inflammatory bowel disease;
KIRP	cis	rs7737355	1.000	rs30736	chr5:130724240	A/G	cg06307176	chr5:131281290	NA	-0.54	-5.83	-0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.05	-0.41	1.81e-11	Menopause (age at onset);
KIRP	cis	rs7951870	1.000	rs7108770	chr11:46648432	G/A	cg16389345	chr11:46697382	NA	-0.46	-5.21	-0.31	4.09e-7	Schizophrenia;
KIRP	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg04132472	chr17:19861366	AKAP10	0.41	5.26	0.32	3.07e-7	Schizophrenia;
KIRP	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.63	-0.34	4.84e-8	Aortic root size;
KIRP	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15564488	chr19:3637627	PIP5K1C	-0.54	-6.93	-0.4	3.75e-11	Parkinson's disease;
KIRP	cis	rs1448094	0.605	rs12367761	chr12:86286894	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.47	0.33	1.09e-7	Major depressive disorder;
KIRP	cis	rs12823128	0.904	rs10842784	chr12:26857581	C/T	cg14081884	chr12:26986758	ITPR2	0.41	5.51	0.33	9.05e-8	Birth weight;
KIRP	cis	rs9372498	0.505	rs62422248	chr6:118987610	T/C	cg21191810	chr6:118973309	C6orf204	-0.43	-4.88	-0.3	1.92e-6	Diastolic blood pressure;
KIRP	cis	rs1847505	0.562	rs1606647	chr13:61416304	A/G	cg25164009	chr13:61490935	NA	0.48	5.21	0.32	3.96e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs939574	0.790	rs72955447	chr2:220098287	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	6.12	0.36	3.67e-9	Platelet distribution width;
KIRP	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.66	-7.94	-0.45	7.01e-14	Iron status biomarkers;
KIRP	cis	rs57590327	0.527	rs9845467	chr3:81614473	G/A	cg07356753	chr3:81810745	GBE1	-0.57	-7.24	-0.42	5.81e-12	Extraversion;
KIRP	cis	rs9943753	0.525	rs983307	chr12:109815103	T/G	cg19025524	chr12:109796872	NA	-0.46	-6.32	-0.37	1.25e-9	HDL cholesterol;
KIRP	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg11693508	chr17:37793320	STARD3	0.78	8.5	0.48	1.9e-15	Bipolar disorder;
KIRP	cis	rs4273100	0.834	rs59415593	chr17:19223224	T/G	cg18093559	chr17:18951025	GRAP	-0.57	-5.23	-0.32	3.65e-7	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-1.01	-11.9	-0.6	4.4e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg01966878	chr4:90757139	SNCA	-0.45	-5.07	-0.31	7.78e-7	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02877538	chr11:3013651	NAP1L4	0.49	6.59	0.39	2.7e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.8	0.49	2.46e-16	High light scatter reticulocyte count;
KIRP	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.79	0.66	2.02e-32	Tonsillectomy;
KIRP	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.75	-8.97	-0.5	7.87e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.18	0.51	1.78e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg02002664	chr12:56325736	DGKA	0.5	6.74	0.39	1.1e-10	DNA methylation (variation);
KIRP	cis	rs240764	0.817	rs58266877	chr6:101156284	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.52	-0.33	8.75e-8	Neuroticism;
KIRP	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg14345882	chr6:26364793	BTN3A2	0.56	5.08	0.31	7.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.59	-8.12	-0.46	2.29e-14	Obesity-related traits;
KIRP	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg22903471	chr2:27725779	GCKR	0.41	5.63	0.34	4.85e-8	Oral cavity cancer;
KIRP	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-0.95	-12.11	-0.61	8.89e-27	Blood protein levels;
KIRP	cis	rs1010254	0.559	rs17447016	chr5:151737559	A/C	cg12297329	chr5:152029980	NA	-0.65	-6.67	-0.39	1.67e-10	Optic nerve measurement (cup area);
KIRP	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg02887458	chr19:19495540	GATAD2A	-0.45	-5.42	-0.33	1.42e-7	Bipolar disorder;
KIRP	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.74	-10.53	-0.56	1.22e-21	Menopause (age at onset);
KIRP	trans	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.42	-0.43	1.91e-12	Atopic dermatitis;
KIRP	cis	rs2131877	0.645	rs4677812	chr3:194863794	C/A	cg16306870	chr3:194868790	C3orf21	0.21	5.0	0.3	1.08e-6	Non-small cell lung cancer;
KIRP	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg24807547	chr6:37504484	NA	-0.61	-9.91	-0.53	1.08e-19	Cognitive performance;
KIRP	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg14675211	chr2:100938903	LONRF2	0.51	6.02	0.36	6.16e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7221595	0.825	rs12942967	chr17:3921834	C/T	cg21851534	chr17:3907994	ZZEF1	0.55	5.53	0.33	8.08e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.86	-0.6	5.86e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	6.17	0.37	2.86e-9	Personality dimensions;
KIRP	trans	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg14791747	chr16:20752902	THUMPD1	0.63	6.73	0.39	1.16e-10	Cognitive test performance;
KIRP	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.67	-8.62	-0.48	8.42e-16	Prudent dietary pattern;
KIRP	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.87	0.35	1.41e-8	Depression;
KIRP	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	0.92	13.46	0.65	2.5e-31	Dupuytren's disease;
KIRP	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg05370193	chr1:21551575	ECE1	-0.38	-5.28	-0.32	2.85e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg21204522	chr6:27730016	NA	-0.69	-5.08	-0.31	7.38e-7	Depression;
KIRP	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg10517650	chr3:113235015	CCDC52	-0.47	-6.14	-0.36	3.29e-9	Dental caries;
KIRP	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.58	-5.94	-0.35	9.71e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg09788416	chr12:39539408	NA	0.42	5.35	0.32	2.02e-7	Morning vs. evening chronotype;
KIRP	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg07001201	chr5:642380	CEP72	0.7	6.57	0.39	2.98e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg05784532	chr1:230284198	GALNT2	0.51	7.55	0.43	8.25e-13	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	trans	rs7618501	0.699	rs11713193	chr3:49924424	G/A	cg21659725	chr3:3221576	CRBN	0.62	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6681460	0.898	rs1032635	chr1:67195184	C/G	cg02459107	chr1:67143332	SGIP1	-0.41	-5.83	-0.35	1.74e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg18883852	chr13:45965548	LOC100190939	0.56	6.3	0.37	1.39e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.39	4.98	0.3	1.22e-6	Lung cancer;
KIRP	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs4955124	0.558	rs77566631	chr3:32018805	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	7.44	0.43	1.66e-12	Schizophrenia;
KIRP	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.81	-12.06	-0.61	1.32e-26	Metabolic syndrome;
KIRP	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg17470723	chr8:74884337	TCEB1	0.64	8.25	0.47	9.51e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg04691961	chr3:161091175	C3orf57	0.42	6.15	0.37	3.08e-9	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.89	0.3	1.85e-6	Breast cancer;
KIRP	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg06742321	chr12:123595122	PITPNM2	0.44	5.58	0.34	6.36e-8	Platelet count;
KIRP	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.62	-6.58	-0.39	2.76e-10	Initial pursuit acceleration;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.61	8.64	0.48	7.3e-16	Longevity;Endometriosis;
KIRP	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.36	0.42	2.67e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.71	9.09	0.5	3.42e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-6.41	-0.38	7.51e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.37	-4.89	-0.3	1.8e-6	Vitiligo;
KIRP	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.65	-7.17	-0.42	8.6e-12	Vitiligo;
KIRP	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.82	12.61	0.63	1.83e-28	Height;
KIRP	cis	rs17286411	0.836	rs9925684	chr16:71957753	T/C	cg04254540	chr16:71951199	KIAA0174	-0.38	-5.06	-0.31	8.17e-7	Blood protein levels;
KIRP	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.5	7.57	0.43	7.66e-13	Immature fraction of reticulocytes;
KIRP	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.68	-9.26	-0.51	1.05e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8093481	0.966	rs868526	chr18:10696337	A/G	cg21165219	chr18:10698044	FAM38B	-0.42	-5.24	-0.32	3.44e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs12188164	0.554	rs72711364	chr5:415323	A/G	cg15371732	chr17:78194151	SLC26A11;SGSH	0.54	6.09	0.36	4.21e-9	Cystic fibrosis severity;
KIRP	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.61	-0.44	5.98e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg15704280	chr7:45808275	SEPT13	0.66	6.06	0.36	5.14e-9	Intraocular pressure;
KIRP	cis	rs2151522	0.762	rs7758037	chr6:127205495	G/C	cg21431617	chr6:127135037	NA	0.28	4.92	0.3	1.57e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2554380	0.628	rs963690	chr15:84439820	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.34	-5.05	-0.31	8.51e-7	Height;
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg09597638	chr17:3907349	NA	-0.74	-13.81	-0.66	1.68e-32	Type 2 diabetes;
KIRP	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg15083037	chr5:83017644	HAPLN1	-0.61	-8.83	-0.49	1.95e-16	Prostate cancer;
KIRP	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.31	-0.42	3.74e-12	Bone mineral density;
KIRP	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.63e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg02297831	chr4:17616191	MED28	0.57	7.39	0.43	2.36e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.42	-0.33	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.9	10.92	0.57	6.86e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.5	5.95	0.35	8.94e-9	Metabolite levels;
KIRP	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg07870213	chr5:140052090	DND1	0.63	7.65	0.44	4.51e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	cg21523751	chr1:182988639	NA	0.41	6.32	0.37	1.22e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg04317399	chr7:27170313	HOXA4	0.35	5.22	0.32	3.87e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6838801	0.892	rs7656480	chr4:77574194	A/G	cg17476223	chr4:77663285	SHROOM3	0.55	7.86	0.45	1.21e-13	Cleft lip with or without cleft palate;
KIRP	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg11608241	chr8:8085544	FLJ10661	0.52	6.12	0.36	3.6e-9	Mood instability;
KIRP	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.45	-0.38	5.8e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.53	0.33	8.26e-8	Life satisfaction;
KIRP	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.27	0.42	4.79e-12	Vitiligo;
KIRP	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.58	-11.9	-0.6	4.44e-26	Diabetic kidney disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg23260255	chr3:187871479	LPP	0.51	6.27	0.37	1.62e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	cis	rs6545883	0.899	rs1562309	chr2:61770126	C/A	cg15711740	chr2:61764176	XPO1	-0.63	-8.58	-0.48	1.07e-15	Tuberculosis;
KIRP	cis	rs787274	0.681	rs787270	chr9:115549092	C/T	cg13803584	chr9:115635662	SNX30	-0.73	-7.9	-0.45	9.56e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg16584676	chr17:46985605	UBE2Z	0.49	6.03	0.36	5.82e-9	Type 2 diabetes;
KIRP	cis	rs2625529	1.000	rs2625529	chr15:72118777	C/G	cg16672083	chr15:72433130	SENP8	0.48	6.05	0.36	5.47e-9	Red blood cell count;
KIRP	cis	rs3789045	0.774	rs12029692	chr1:204532323	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.21	-0.37	2.22e-9	Educational attainment (college completion);
KIRP	cis	rs34779708	0.801	rs12242110	chr10:35535695	A/G	cg03585969	chr10:35415529	CREM	0.74	8.33	0.47	5.74e-15	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6662572	0.737	rs6673894	chr1:46301182	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs4262150	0.846	rs4958573	chr5:152091739	G/A	cg12297329	chr5:152029980	NA	-0.67	-8.1	-0.46	2.54e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.83	0.63	3.35e-29	Exhaled nitric oxide output;
KIRP	cis	rs4356975	0.563	rs7438135	chr4:69961339	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.05	0.31	8.47e-7	Obesity-related traits;
KIRP	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.73	7.05	0.41	1.79e-11	Lung function (FEV1/FVC);
KIRP	cis	rs34779708	0.766	rs35308730	chr10:35549796	C/T	cg03585969	chr10:35415529	CREM	0.57	6.59	0.39	2.66e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.45	-0.33	1.25e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.59	-7.15	-0.41	9.72e-12	Mosquito bite size;
KIRP	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs17095355	1.000	rs9988702	chr10:111703389	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.04	-0.36	5.62e-9	Biliary atresia;
KIRP	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.46	0.47	2.36e-15	IgG glycosylation;
KIRP	cis	rs12230513	0.732	rs7980098	chr12:55844694	A/G	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs6684514	1.000	rs2296375	chr1:156309372	G/C	cg16558208	chr1:156270281	VHLL	-0.44	-5.88	-0.35	1.35e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg01475377	chr6:109611718	NA	-0.36	-4.94	-0.3	1.43e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs12200782	1.000	rs12213722	chr6:26473083	A/G	cg11502198	chr6:26597334	ABT1	-0.76	-5.17	-0.31	4.78e-7	Small cell lung carcinoma;
KIRP	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.52	-6.58	-0.39	2.83e-10	Body mass index;
KIRP	cis	rs7083	1.000	rs655023	chr11:117127620	C/T	cg11523350	chr11:117171073	BACE1	-0.28	-5.46	-0.33	1.14e-7	Blood protein levels;
KIRP	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg02820040	chr2:241836501	C2orf54	-0.24	-5.54	-0.33	7.65e-8	Urinary metabolites;
KIRP	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Hypertriglyceridemia;
KIRP	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.1e-9	Cognitive function;
KIRP	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.52	5.15	0.31	5.31e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.39	-6.19	-0.37	2.49e-9	Body mass index;
KIRP	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.09	-0.61	9.94e-27	Exhaled nitric oxide output;
KIRP	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.73	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg07636037	chr3:49044803	WDR6	-0.58	-5.43	-0.33	1.34e-7	Menarche (age at onset);
KIRP	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg20243544	chr17:37824526	PNMT	0.53	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.52	-6.49	-0.38	4.6e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg03714773	chr7:91764589	CYP51A1	0.39	5.6	0.34	5.86e-8	Breast cancer;
KIRP	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.97	-11.65	-0.6	2.91e-25	Exhaled nitric oxide levels;
KIRP	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg13798912	chr7:905769	UNC84A	0.54	5.47	0.33	1.09e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg25173405	chr17:45401733	C17orf57	-0.43	-5.61	-0.34	5.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.27e-12	Prudent dietary pattern;
KIRP	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.77	0.35	2.33e-8	Bipolar disorder;
KIRP	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.75	-10.42	-0.55	2.78e-21	Hypospadias;
KIRP	cis	rs2367563	1.000	rs7315571	chr12:96058277	A/G	cg19013339	chr12:96052514	NTN4	0.34	5.36	0.32	1.95e-7	Allergic dermatitis (nickel);
KIRP	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.41	-7.26	-0.42	5.01e-12	Refractive error;
KIRP	cis	rs4664293	0.867	rs7582124	chr2:160572837	T/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs11779988	0.545	rs398806	chr8:17786226	T/C	cg01800426	chr8:17659068	MTUS1	-0.61	-6.09	-0.36	4.27e-9	Breast cancer;
KIRP	cis	rs11138902	0.636	rs1330326	chr9:72165812	A/G	cg14123607	chr9:72164709	APBA1	-0.43	-5.16	-0.31	5.04e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg01721255	chr8:58191610	C8orf71	0.55	5.43	0.33	1.37e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg13165212	chr22:42675999	NA	0.29	5.32	0.32	2.37e-7	Cognitive function;
KIRP	cis	rs28493229	0.786	rs3815912	chr19:41190726	G/A	cg21869046	chr19:41225005	ITPKC	0.37	4.98	0.3	1.17e-6	Kawasaki disease;
KIRP	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Colorectal cancer;
KIRP	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.5	6.06	0.36	5.04e-9	Blood protein levels;
KIRP	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg03315344	chr16:75512273	CHST6	-0.59	-5.69	-0.34	3.57e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg27205649	chr11:78285834	NARS2	-0.64	-7.26	-0.42	4.97e-12	Alzheimer's disease (survival time);
KIRP	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.95	14.88	0.69	3.66e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg04672837	chr16:48644449	N4BP1	-0.48	-6.66	-0.39	1.76e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.63	-6.66	-0.39	1.82e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.88	8.57	0.48	1.18e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg04132472	chr17:19861366	AKAP10	0.66	10.14	0.54	2e-20	Schizophrenia;
KIRP	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg14413466	chr17:79170920	AZI1	0.34	5.19	0.31	4.33e-7	Frontotemporal dementia;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.2e-8	Life satisfaction;
KIRP	trans	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.6	-6.69	-0.39	1.47e-10	Obesity-related traits;
KIRP	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.46	4.88	0.3	1.91e-6	Obesity (extreme);
KIRP	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.17	-0.54	1.66e-20	Alzheimer's disease (late onset);
KIRP	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.54	6.88	0.4	4.87e-11	Neuroticism;Neuroticism (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.62	0.68	3.03e-35	Alzheimer's disease;
KIRP	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00791764	chr4:53727839	RASL11B	0.37	5.42	0.33	1.45e-7	Optic nerve measurement (cup area);
KIRP	cis	rs2505998	1.000	rs2506006	chr10:43581501	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.19	-0.31	4.31e-7	Hirschsprung disease;
KIRP	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg24747557	chr10:131355152	MGMT	-0.39	-5.21	-0.32	4.03e-7	Response to temozolomide;
KIRP	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg00800038	chr16:89945340	TCF25	-0.79	-5.46	-0.33	1.14e-7	Skin colour saturation;
KIRP	cis	rs4494114	1.000	rs4491033	chr1:39352083	A/C	cg25970120	chr1:39325951	RRAGC	-0.41	-5.31	-0.32	2.41e-7	Blood protein levels;
KIRP	cis	rs28655083	0.956	rs4088757	chr16:77071545	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.49	5.31	0.32	2.48e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.74	10.09	0.54	2.91e-20	Red blood cell count;
KIRP	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.64	-9.9	-0.53	1.19e-19	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-0.84	-11.07	-0.58	2.24e-23	Prostate cancer;
KIRP	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg11764359	chr7:65958608	NA	0.78	5.12	0.31	6.21e-7	Diabetic kidney disease;
KIRP	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.61	5.56	0.33	6.86e-8	Alzheimer's disease;
KIRP	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.51	0.43	1.1e-12	Retinal vascular caliber;
KIRP	cis	rs4956211	0.537	rs62315049	chr4:109704453	C/T	cg07086381	chr4:109682776	AGXT2L1	-0.41	-5.25	-0.32	3.35e-7	Systemic lupus erythematosus;
KIRP	cis	rs11586313	0.507	rs2339385	chr1:152859594	C/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.93	-0.3	1.5e-6	Vitamin D levels;
KIRP	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.44	0.43	1.64e-12	Body mass index;
KIRP	cis	rs787274	1.000	rs1418409	chr9:115573707	T/C	cg13803584	chr9:115635662	SNX30	-0.72	-6.55	-0.39	3.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2303319	0.504	rs62188147	chr2:162286552	G/T	cg19166733	chr15:44192098	FRMD5	1.02	6.17	0.37	2.8e-9	Cognitive function;
KIRP	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg26597838	chr10:835615	NA	-0.4	-5.17	-0.31	4.83e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg06611532	chr13:114900021	NA	0.21	4.93	0.3	1.49e-6	Schizophrenia;
KIRP	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.04	-0.46	3.87e-14	Monocyte percentage of white cells;
KIRP	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.3	0.47	6.82e-15	Eosinophil percentage of white cells;
KIRP	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg11906718	chr8:101322791	RNF19A	0.49	6.51	0.38	4.13e-10	Atrioventricular conduction;
KIRP	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.39	-5.11	-0.31	6.32e-7	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07318110	chr16:82204167	MPHOSPH6	0.49	6.15	0.37	3.08e-9	Parkinson's disease;
KIRP	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.9e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7180079	0.563	rs7403103	chr15:65018526	C/T	cg15337035	chr15:64978493	NA	-0.51	-5.55	-0.33	7.26e-8	Monocyte count;
KIRP	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.75	-0.53	3.28e-19	Hemoglobin concentration;
KIRP	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg19197139	chr17:4613644	ARRB2	-0.49	-5.59	-0.34	5.97e-8	Lymphocyte counts;
KIRP	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.43	-4.94	-0.3	1.47e-6	Resistin levels;
KIRP	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.88	-0.3	1.87e-6	Lung cancer;
KIRP	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg15660573	chr17:549704	VPS53	-0.82	-12.47	-0.62	5.45e-28	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12767885	chr10:134350658	INPP5A	0.51	6.49	0.38	4.79e-10	Parkinson's disease;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.73	11.32	0.59	3.32e-24	Menarche (age at onset);
KIRP	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.85	12.21	0.61	4.12e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.56	-15.13	-0.69	5.4e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs6968419	0.674	rs4730723	chr7:115904052	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.68	-0.34	3.7e-8	Intraocular pressure;
KIRP	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg12131826	chr15:77904385	NA	-0.5	-6.44	-0.38	6.35e-10	Type 2 diabetes;
KIRP	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg06027949	chr8:82754900	SNX16	0.61	6.41	0.38	7.57e-10	Diastolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14293102	chr19:2232170	DOT1L	0.53	6.79	0.4	8.58e-11	Interleukin-4 levels;
KIRP	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg03929089	chr4:120376271	NA	0.76	6.79	0.4	8.56e-11	Intraocular pressure;
KIRP	cis	rs4751006	0.543	rs880761	chr10:128783906	C/T	cg05702161	chr10:128779687	DOCK1	-1.14	-9.47	-0.52	2.34e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs72925845	0.525	rs72907478	chr17:76431015	C/T	cg03830375	chr17:76426088	DNAH17	0.46	4.87	0.3	1.98e-6	Triglycerides;
KIRP	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.7	-9.46	-0.52	2.51e-18	Height;
KIRP	trans	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.9	12.95	0.64	1.4e-29	Bladder cancer;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.59	8.35	0.47	5.13e-15	Longevity;Endometriosis;
KIRP	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.83	9.7	0.53	4.82e-19	Platelet count;
KIRP	cis	rs1364705	1.000	rs1364705	chr8:120224806	C/T	cg09273054	chr8:120220131	MAL2	-0.52	-6.17	-0.37	2.79e-9	Hippocampal atrophy;
KIRP	trans	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.22	-0.37	2.1e-9	Neuroticism;
KIRP	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.51	-6.39	-0.38	8.04e-10	Menarche (age at onset);
KIRP	cis	rs7224685	0.569	rs965515	chr17:4038149	G/A	cg11204139	chr17:3907470	NA	0.54	5.08	0.31	7.57e-7	Type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg06585982	chr3:143692056	C3orf58	0.61	7.65	0.44	4.68e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg10503236	chr1:231470652	EXOC8	-0.55	-7.62	-0.44	5.44e-13	Hemoglobin concentration;
KIRP	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.74	10.18	0.54	1.59e-20	Height;
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg06815112	chr8:27182871	PTK2B	0.53	6.72	0.39	1.22e-10	Neuroticism;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13490827	chr1:46269305	MAST2	-0.47	-6.22	-0.37	2.13e-9	Metabolic traits;
KIRP	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-6.28	-0.37	1.5e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.74	-0.44	2.64e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg03289416	chr15:75166202	SCAMP2	0.41	5.43	0.33	1.36e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.65	-9.35	-0.51	5.55e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7071206	0.898	rs28706743	chr10:79394329	T/G	cg07817648	chr10:79422355	NA	-0.67	-7.62	-0.44	5.37e-13	Bone mineral density;
KIRP	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.73	10.73	0.56	2.84e-22	Total body bone mineral density;
KIRP	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18252515	chr7:66147081	NA	0.42	4.87	0.3	1.96e-6	Calcium levels;
KIRP	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg16988262	chr1:15930761	NA	0.4	5.17	0.31	4.9e-7	Systolic blood pressure;
KIRP	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg19338460	chr6:170058176	WDR27	-0.68	-7.94	-0.45	7.1e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7951870	1.000	rs3802888	chr11:46515902	A/G	cg16389345	chr11:46697382	NA	-0.48	-5.41	-0.33	1.53e-7	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg07884673	chr3:53033167	SFMBT1	0.84	6.52	0.38	3.94e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg18441811	chr11:71824068	C11orf51	-0.78	-5.29	-0.32	2.67e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg05791153	chr7:19748676	TWISTNB	0.68	6.05	0.36	5.43e-9	Thyroid stimulating hormone;
KIRP	cis	rs7572644	0.699	rs1395324	chr2:28276643	C/G	cg27432699	chr2:27873401	GPN1	-0.47	-5.66	-0.34	4.13e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.98	0.36	7.73e-9	Aortic root size;
KIRP	cis	rs113084984	0.718	rs10929754	chr2:11683074	T/G	cg07314298	chr2:11723111	GREB1	0.38	4.96	0.3	1.31e-6	Breast cancer;
KIRP	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-5.47	-0.33	1.11e-7	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07295974	chr16:85045150	ZDHHC7	0.51	6.3	0.37	1.36e-9	Parkinson's disease;
KIRP	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg00310523	chr12:86230176	RASSF9	0.41	6.43	0.38	6.75e-10	Major depressive disorder;
KIRP	cis	rs883565	0.569	rs2949565	chr3:39163425	G/A	cg01426195	chr3:39028469	NA	0.52	8.31	0.47	6.35e-15	Handedness;
KIRP	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs2979489	0.891	rs7822839	chr8:30354453	A/G	cg26383811	chr8:30366931	RBPMS	0.45	6.17	0.37	2.75e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.5	6.87	0.4	5.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7819412	0.521	rs13256092	chr8:11000377	A/T	cg21775007	chr8:11205619	TDH	-0.43	-5.1	-0.31	6.63e-7	Triglycerides;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.87	11.35	0.59	2.7e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg16255804	chr6:135334527	HBS1L	0.33	5.37	0.32	1.86e-7	Red blood cell count;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.34	-6.54	-0.38	3.61e-10	Lymphocyte counts;
KIRP	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.6	0.81	1e-58	Prudent dietary pattern;
KIRP	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	1.02	18.91	0.77	7.65e-50	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.75	9.05	0.5	4.48e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg12756093	chr1:115239321	AMPD1	0.5	6.68	0.39	1.62e-10	Autism;
KIRP	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.48	-4.89	-0.3	1.81e-6	Blood metabolite levels;
KIRP	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs10489525	0.599	rs17033129	chr1:115611539	C/T	cg01522456	chr1:115632236	TSPAN2	0.51	6.17	0.37	2.73e-9	Autism;
KIRP	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg13385521	chr17:29058706	SUZ12P	-0.55	-5.39	-0.32	1.67e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg23442198	chr4:187126114	CYP4V2	0.58	5.46	0.33	1.18e-7	Blood protein levels;
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.19	-0.51	1.69e-17	Platelet count;
KIRP	cis	rs6499755	0.932	rs714507	chr16:55339777	C/T	cg05099576	chr16:55362342	IRX6	0.26	5.6	0.34	5.59e-8	Hypospadias;
KIRP	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg13819577	chr1:248512075	OR14C36	-0.36	-5.0	-0.3	1.06e-6	Common traits (Other);
KIRP	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.86	-0.57	1.06e-22	Colorectal cancer;
KIRP	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	0.66	6.39	0.38	8.22e-10	Skin colour saturation;
KIRP	cis	rs921943	1.000	rs60563713	chr5:78313516	C/G	cg26802063	chr5:78281964	ARSB	0.5	6.19	0.37	2.47e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg27144592	chr16:783916	NARFL	0.38	5.24	0.32	3.5e-7	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14264380	chr17:79651103	ARL16;HGS	0.48	6.58	0.39	2.76e-10	Survival in pancreatic cancer;
KIRP	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg19773385	chr1:10388646	KIF1B	-0.41	-6.0	-0.36	6.88e-9	Hepatocellular carcinoma;
KIRP	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.58	6.48	0.38	4.88e-10	Neutrophil percentage of white cells;
KIRP	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.69	-0.34	3.63e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.17e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1461503	0.934	rs7115679	chr11:122831963	A/G	cg27398637	chr11:122830231	C11orf63	-0.71	-9.68	-0.53	5.36e-19	Menarche (age at onset);
KIRP	cis	rs865483	0.895	rs2522966	chr17:35816616	A/G	cg06716730	chr17:35851459	DUSP14	-0.23	-5.79	-0.35	2.13e-8	Monocyte count;
KIRP	cis	rs11637445	0.627	rs4776988	chr15:68124151	C/T	cg24579218	chr15:68104479	NA	-0.44	-6.73	-0.39	1.15e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4356932	1.000	rs4859595	chr4:76950062	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs259842	0.729	rs12328338	chr2:180712985	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	0.4	5.35	0.32	1.98e-7	Blood protein levels;
KIRP	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.8	-8.11	-0.46	2.43e-14	Fibroblast growth factor basic levels;
KIRP	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.59	8.53	0.48	1.52e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4924997	0.772	rs2018675	chr17:19441531	A/G	cg19949948	chr17:19361230	NA	0.4	5.25	0.32	3.22e-7	Lymphocyte counts;
KIRP	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg23202291	chr11:1979235	NA	0.4	5.48	0.33	1.04e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs4654899	0.802	rs12123910	chr1:21233316	C/T	cg05370193	chr1:21551575	ECE1	0.42	5.1	0.31	6.79e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs3737883	1.000	rs11579055	chr1:203031315	G/T	cg03900565	chr1:203031815	PPFIA4	0.39	5.61	0.34	5.51e-8	Early onset atrial fibrillation;
KIRP	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	5.88	0.35	1.36e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1983891	1.000	rs4714483	chr6:41528214	G/A	cg20194872	chr6:41519635	FOXP4	0.57	7.32	0.42	3.61e-12	Prostate cancer;
KIRP	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg22800045	chr5:56110881	MAP3K1	-0.57	-6.7	-0.39	1.43e-10	Initial pursuit acceleration;
KIRP	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	10.31	0.55	6.17e-21	Cognitive test performance;
KIRP	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	1.04	18.62	0.76	6.96e-49	Heart rate;
KIRP	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.56	-7.24	-0.42	5.65e-12	Iron status biomarkers;
KIRP	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg24807547	chr6:37504484	NA	-0.64	-10.27	-0.55	8.08e-21	Cognitive performance;
KIRP	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.91	9.44	0.52	3.07e-18	Methadone dose in opioid dependence;
KIRP	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg16576597	chr16:28551801	NUPR1	0.36	5.48	0.33	1.06e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.68	8.98	0.5	7.09e-17	Schizophrenia;
KIRP	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg00204512	chr16:28754710	NA	0.46	6.03	0.36	5.88e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.98	9.2	0.51	1.56e-17	Eosinophilic esophagitis;
KIRP	cis	rs1978968	0.763	rs5992943	chr22:18465756	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.68	-8.34	-0.47	5.43e-15	Presence of antiphospholipid antibodies;
KIRP	cis	rs7712401	0.601	rs438196	chr5:122263063	T/G	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.45e-7	Mean platelet volume;
KIRP	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.41	6.04	0.36	5.68e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4233802	0.708	rs7564743	chr2:151133831	A/G	cg25300694	chr2:151184358	NA	0.87	6.81	0.4	7.38e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.4	-0.38	7.75e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4363385	0.510	rs61811902	chr1:153053464	A/G	cg13444842	chr1:152974279	SPRR3	-0.45	-6.15	-0.36	3.15e-9	Inflammatory skin disease;
KIRP	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.96	11.24	0.58	6.38e-24	Corneal astigmatism;
KIRP	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.56	8.83	0.49	2.05e-16	Coronary artery disease;
KIRP	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.61	-6.89	-0.4	4.68e-11	Mean platelet volume;
KIRP	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00585698	chr12:123750864	CDK2AP1	-0.48	-6.11	-0.36	3.95e-9	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12714538	chr1:151372147	PSMB4	0.54	7.04	0.41	1.94e-11	Parkinson's disease;
KIRP	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	1.0	8.94	0.5	9.54e-17	Type 2 diabetes;
KIRP	cis	rs2629540	0.765	rs7097177	chr10:126539839	A/G	cg08799069	chr10:126477246	METTL10	-0.6	-7.67	-0.44	4.03e-13	Cocaine dependence;
KIRP	cis	rs7007076	0.901	rs10089554	chr8:124723379	A/G	cg00283535	chr8:124749564	ANXA13	-0.62	-6.72	-0.39	1.26e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.3	-5.0	-0.3	1.09e-6	Height;
KIRP	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.83	-0.35	1.72e-8	Blood metabolite levels;
KIRP	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-5.28	-0.32	2.88e-7	Height;
KIRP	cis	rs7714584	1.000	rs4958422	chr5:150186734	T/G	cg22134413	chr5:150180641	NA	1.05	7.58	0.44	6.99e-13	Crohn's disease;
KIRP	cis	rs9308731	0.583	rs2165107	chr2:111931350	C/G	cg18646521	chr2:111875858	NA	0.38	5.34	0.32	2.14e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.73	-10.21	-0.55	1.22e-20	Height;
KIRP	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg07636037	chr3:49044803	WDR6	0.5	5.88	0.35	1.33e-8	Resting heart rate;
KIRP	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	1.03	18.9	0.77	7.81e-50	Heart rate;
KIRP	cis	rs9840812	0.645	rs9883916	chr3:136208788	C/T	cg15507776	chr3:136538369	TMEM22	0.44	5.11	0.31	6.47e-7	Fibrinogen levels;
KIRP	cis	rs6956675	0.915	rs7786464	chr7:62615322	C/A	cg27518014	chr7:62859535	LOC100287834	0.46	4.98	0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	1.0	11.25	0.58	6.02e-24	Exhaled nitric oxide output;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16524936	chr4:1340807	KIAA1530	-0.48	-6.09	-0.36	4.36e-9	Longevity;
KIRP	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg17524265	chr8:144659883	NAPRT1	0.83	5.36	0.32	1.94e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.56	-9.53	-0.52	1.6e-18	Bone mineral density;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg23034840	chr1:205782522	SLC41A1	0.54	6.27	0.37	1.65e-9	Menarche (age at onset);
KIRP	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg27411982	chr8:10470053	RP1L1	-0.48	-6.25	-0.37	1.77e-9	Neuroticism;
KIRP	cis	rs3815308	0.530	rs2269880	chr19:2195611	T/C	cg09261902	chr19:2140048	AP3D1	0.6	8.83	0.49	1.98e-16	Breast cancer;
KIRP	cis	rs7712401	0.562	rs364723	chr5:122326464	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg23335576	chr14:104009727	NA	0.34	4.86	0.3	2.08e-6	Body mass index;
KIRP	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21643547	chr1:205240462	TMCC2	-0.86	-14.53	-0.68	5.8e-35	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg09555818	chr19:45449301	APOC2	0.51	7.33	0.42	3.41e-12	Blood protein levels;
KIRP	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.15	-0.41	9.69e-12	Type 2 diabetes;
KIRP	cis	rs6681460	0.866	rs485521	chr1:67209562	T/C	cg02459107	chr1:67143332	SGIP1	-0.4	-5.61	-0.34	5.43e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg04998671	chr14:104000505	TRMT61A	0.72	7.38	0.43	2.47e-12	Coronary artery disease;
KIRP	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs6893300	0.785	rs7704520	chr5:179191054	G/A	cg14593053	chr5:179126677	CANX	-0.58	-7.25	-0.42	5.28e-12	Resting heart rate;
KIRP	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg11382394	chr1:2564504	MMEL1	0.38	4.93	0.3	1.51e-6	Ulcerative colitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09727944	chr6:119390712	FAM184A;MIR548B	0.41	6.25	0.37	1.78e-9	Interleukin-4 levels;
KIRP	cis	rs554111	0.637	rs529162	chr1:21063311	T/A	cg08890418	chr1:21044141	KIF17	0.55	8.53	0.48	1.52e-15	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26249114	chr15:80352055	ZFAND6	0.47	6.22	0.37	2.09e-9	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg24154853	chr7:158122151	PTPRN2	0.37	5.18	0.31	4.66e-7	Calcium levels;
KIRP	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.73	0.39	1.2e-10	Multiple sclerosis;
KIRP	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs4132509	1.000	rs2881275	chr1:243918313	G/C	cg25706552	chr1:244017396	NA	0.58	7.25	0.42	5.42e-12	RR interval (heart rate);
KIRP	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	1.08	11.8	0.6	9.41e-26	Eosinophil percentage of granulocytes;
KIRP	cis	rs6504622	0.818	rs9912794	chr17:45034441	C/T	cg24703533	chr17:45055318	NA	0.38	5.05	0.31	8.72e-7	Orofacial clefts;
KIRP	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.82	12.0	0.61	1.95e-26	Mean platelet volume;
KIRP	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg12549451	chr6:135224345	NA	0.42	5.07	0.31	7.82e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.92	10.47	0.56	1.86e-21	Corneal astigmatism;
KIRP	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg03289416	chr15:75166202	SCAMP2	0.51	6.76	0.4	9.81e-11	Breast cancer;
KIRP	cis	rs3087591	0.683	rs10512434	chr17:29639590	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.62	-9.41	-0.51	3.69e-18	Hip circumference;
KIRP	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.65e-30	Eye color traits;
KIRP	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.87	-8.26	-0.47	8.78e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.96	12.84	0.63	3.27e-29	Menopause (age at onset);
KIRP	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.43	-5.81	-0.35	1.89e-8	Monocyte count;
KIRP	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.24	-0.32	3.46e-7	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.1	0.31	6.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.1	-0.36	4.18e-9	Red blood cell count;
KIRP	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg24747557	chr10:131355152	MGMT	-0.4	-5.52	-0.33	8.53e-8	Response to temozolomide;
KIRP	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg22633769	chr20:60982531	CABLES2	-0.45	-5.69	-0.34	3.54e-8	Colorectal cancer;
KIRP	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.65	-0.34	4.38e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12213875	0.502	rs857467	chr6:14604354	G/A	cg01527307	chr6:14500441	NA	0.39	5.06	0.31	8.13e-7	Ovarian reserve;
KIRP	cis	rs7833787	0.929	rs11995692	chr8:18710869	C/T	cg17701159	chr8:18705777	PSD3	0.37	6.97	0.41	2.9e-11	Obesity-related traits;
KIRP	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.27	0.37	1.6e-9	Neuroticism;
KIRP	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-8.2	-0.46	1.35e-14	Response to antipsychotic treatment;
KIRP	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg12560992	chr17:57184187	TRIM37	-0.48	-5.32	-0.32	2.36e-7	Cognitive test performance;
KIRP	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg18501202	chr6:125855421	NA	-0.35	-5.42	-0.33	1.44e-7	Brugada syndrome;
KIRP	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.58	-8.27	-0.47	8.65e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg07810366	chr2:100720526	AFF3	-0.37	-6.82	-0.4	7.13e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.64	9.42	0.51	3.53e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs13401104	0.796	rs72620803	chr2:237110460	T/C	cg19324714	chr2:237145437	ASB18	0.47	4.94	0.3	1.45e-6	Educational attainment;
KIRP	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.46	-5.72	-0.34	3.14e-8	Depressive symptoms;
KIRP	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs9488822	0.662	rs496311	chr6:116274730	A/G	cg05304507	chr6:116381966	FRK	0.22	5.96	0.36	8.47e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs6832769	1.000	rs1522110	chr4:56380283	C/T	cg09317128	chr4:56265301	TMEM165	0.54	7.18	0.42	8.05e-12	Personality dimensions;
KIRP	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.67	-0.56	4.21e-22	Menopause (age at onset);
KIRP	cis	rs7084402	0.967	rs1649045	chr10:60327047	T/C	cg05938607	chr10:60274200	BICC1	-0.43	-10.39	-0.55	3.38e-21	Refractive error;
KIRP	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-8.99	-0.5	6.91e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.8	0.4	7.65e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.53	6.78	0.4	8.61e-11	Longevity;
KIRP	cis	rs4656940	0.574	rs509219	chr1:160766658	A/G	cg17331569	chr1:160788135	LY9	0.44	5.28	0.32	2.8e-7	Crohn's disease;
KIRP	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.42	0.38	6.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg04733989	chr22:42467013	NAGA	0.53	6.41	0.38	7.41e-10	Cognitive function;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.71	8.54	0.48	1.43e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.51	7.19	0.42	7.71e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs263156	0.934	rs187810	chr6:142885758	A/G	cg01789478	chr2:182545485	NEUROD1	-0.35	-6.02	-0.36	6.25e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg05861140	chr6:150128134	PCMT1	-0.53	-7.61	-0.44	5.89e-13	Lung cancer;
KIRP	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.58	-0.43	7.26e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.52	7.59	0.44	6.68e-13	Sitting height ratio;
KIRP	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.55	-5.8	-0.35	2e-8	Smoking behavior;
KIRP	cis	rs12210905	1.000	rs6902012	chr6:27243767	C/T	cg11502198	chr6:26597334	ABT1	0.76	4.85	0.3	2.17e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs2274273	0.713	rs56725788	chr14:55540101	A/G	cg04306507	chr14:55594613	LGALS3	0.44	6.7	0.39	1.4e-10	Protein biomarker;
KIRP	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.8	0.35	2.07e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg14703610	chr5:56206110	C5orf35	0.39	4.86	0.3	2.08e-6	Coronary artery disease;
KIRP	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.85	0.45	1.3e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg09264619	chr17:80180166	NA	-0.39	-5.33	-0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs55962025	0.765	rs3905238	chr4:3078937	A/G	cg06533319	chr4:3265114	C4orf44	0.4	5.12	0.31	6.31e-7	Parental longevity (mother's age at death);
KIRP	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.76	-8.52	-0.48	1.65e-15	Body mass index;
KIRP	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	trans	rs12517041	1.000	rs4701364	chr5:23301087	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.66	-0.44	4.35e-13	Calcium levels;
KIRP	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.75	9.05	0.5	4.53e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg11608241	chr8:8085544	FLJ10661	-0.48	-6.45	-0.38	6e-10	Triglycerides;
KIRP	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.74	7.58	0.44	6.88e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06544989	chr22:39130855	UNC84B	0.47	8.29	0.47	7.35e-15	Menopause (age at onset);
KIRP	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12379764	chr21:47803548	PCNT	-0.46	-5.49	-0.33	1.02e-7	Testicular germ cell tumor;
KIRP	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg00360474	chr6:37504404	NA	-0.5	-7.49	-0.43	1.22e-12	Cognitive performance;
KIRP	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.17	-0.54	1.6e-20	Coffee consumption (cups per day);
KIRP	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.49	5.26	0.32	3.08e-7	Schizophrenia;
KIRP	cis	rs17818399	0.620	rs3087822	chr2:46852033	C/T	cg02822958	chr2:46747628	ATP6V1E2	-0.45	-6.14	-0.36	3.35e-9	Height;
KIRP	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.59	-7.14	-0.41	1.08e-11	Obesity-related traits;
KIRP	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.83	8.26	0.47	9.3e-15	Fibroblast growth factor basic levels;
KIRP	trans	rs2826891	0.590	rs2826909	chr21:22981476	C/G	cg14528756	chr2:176862893	KIAA1715	-0.41	-6.11	-0.36	3.77e-9	Longevity;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20470467	chr16:30886130	NA	0.46	6.09	0.36	4.22e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1021993	0.587	rs78609792	chr1:209546014	G/A	cg24446417	chr1:209558027	NA	-0.51	-5.7	-0.34	3.37e-8	Gut microbiome composition (winter);
KIRP	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-10.04	-0.54	4.22e-20	Triglycerides;
KIRP	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg01214346	chr17:406501	NA	-0.47	-6.01	-0.36	6.6e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6987853	0.787	rs2974354	chr8:42413943	A/G	cg09913449	chr8:42400586	C8orf40	0.39	5.25	0.32	3.21e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23151374	chr4:164415611	C4orf43	-0.49	-6.27	-0.37	1.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs737693	0.541	rs608194	chr11:102744087	C/T	cg19620758	chr11:102826565	MMP13	0.49	5.31	0.32	2.43e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.53	-0.43	9.63e-13	Cutaneous nevi;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07661923	chr11:6502690	FXC1;ARFIP2	0.55	6.89	0.4	4.6e-11	Parkinson's disease;
KIRP	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	1.02	11.49	0.59	9.35e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs7961894	1.000	rs7961894	chr12:122365583	A/G	cg13699009	chr12:122356056	WDR66	-0.63	-4.92	-0.3	1.61e-6	Platelet count;Mean platelet volume;
KIRP	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.6	7.73	0.44	2.69e-13	Total body bone mineral density;
KIRP	cis	rs7129556	0.690	rs12285765	chr11:77569035	C/T	cg12586386	chr11:77299805	AQP11	0.38	5.08	0.31	7.47e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs6977660	0.714	rs10232870	chr7:19818040	A/G	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19935506	chr2:242626874	DTYMK	0.66	6.07	0.36	4.92e-9	Lung function (FEV1);
KIRP	cis	rs4654899	0.865	rs6693020	chr1:21378057	A/G	cg05370193	chr1:21551575	ECE1	0.45	5.56	0.33	7.03e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.88	14.18	0.67	9.43e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.65	-0.39	1.84e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs300890	0.586	rs300901	chr4:144237547	G/A	cg01719995	chr4:144104893	USP38	0.4	5.03	0.31	9.28e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg18016565	chr1:150552671	MCL1	0.36	5.58	0.34	6.33e-8	Tonsillectomy;
KIRP	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.78	0.4	8.66e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.57	-7.5	-0.43	1.18e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.6	9.32	0.51	6.75e-18	IgA nephropathy;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18811621	chr2:208207188	NA	0.42	6.07	0.36	4.84e-9	Survival in pancreatic cancer;
KIRP	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg05692746	chr2:100937584	LONRF2	-0.4	-5.25	-0.32	3.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.38	-6.84	-0.4	6.15e-11	Renal cell carcinoma;
KIRP	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.62	8.45	0.47	2.65e-15	Total body bone mineral density;
KIRP	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.78	9.94	0.54	8.53e-20	Corneal astigmatism;
KIRP	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg16384552	chr7:74938386	SPDYE8P	0.43	5.16	0.31	5.01e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs6732160	0.549	rs6744529	chr2:73480869	A/G	cg01422370	chr2:73384389	NA	0.43	5.66	0.34	4.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6496044	0.507	rs1471455	chr15:86154727	T/A	cg10818794	chr15:86012489	AKAP13	0.42	5.71	0.34	3.3e-8	Interstitial lung disease;
KIRP	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg02389323	chr16:88786976	FAM38A	1.02	7.76	0.44	2.24e-13	Plateletcrit;
KIRP	cis	rs1823913	0.599	rs17346412	chr2:192150628	G/C	cg12404831	chr2:192114017	MYO1B	0.52	7.27	0.42	4.69e-12	Obesity-related traits;
KIRP	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg05800321	chr8:143867799	LY6D	-0.32	-5.1	-0.31	6.88e-7	Urinary tract infection frequency;
KIRP	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.11	-0.36	3.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.0	-10.74	-0.56	2.67e-22	Alzheimer's disease;
KIRP	cis	rs55986470	0.817	rs66895963	chr2:239403902	A/T	cg18131467	chr2:239335373	ASB1	-0.71	-5.17	-0.31	4.89e-7	Chronotype;
KIRP	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.64	-8.62	-0.48	8.23e-16	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.78	0.66	2.07e-32	Platelet count;
KIRP	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.54	0.38	3.61e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg13819577	chr1:248512075	OR14C36	-0.35	-4.92	-0.3	1.59e-6	Common traits (Other);
KIRP	trans	rs763014	1.000	rs763014	chr16:675680	T/C	cg00950418	chr7:105029125	SRPK2	-0.54	-6.75	-0.4	1.05e-10	Height;
KIRP	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs6973256	0.834	rs10244670	chr7:133323417	A/G	cg10665199	chr7:133106180	EXOC4	-0.51	-6.46	-0.38	5.7e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.9	14.25	0.67	5.4e-34	Coronary artery disease;
KIRP	cis	rs8014252	0.803	rs60120955	chr14:71061733	A/C	cg19730268	chr14:71022823	NA	-0.61	-5.79	-0.35	2.18e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs754423	0.515	rs1956294	chr14:52555811	C/T	cg05884192	chr14:52515736	NID2	0.48	5.42	0.33	1.43e-7	Craniofacial microsomia;
KIRP	cis	rs9603616	0.719	rs7999758	chr13:40236601	G/A	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.52	7.04	0.41	1.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.81	0.45	1.66e-13	Corneal astigmatism;
KIRP	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4664293	0.867	rs7594329	chr2:160572718	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg24296786	chr1:45957014	TESK2	0.48	6.14	0.36	3.22e-9	Red blood cell count;Reticulocyte count;
KIRP	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.38	-0.32	1.75e-7	Aortic root size;
KIRP	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.6	-7.92	-0.45	8.37e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13385	0.769	rs13172695	chr5:139568485	T/C	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs58688157	0.572	rs936472	chr11:593453	T/C	cg15790184	chr11:494944	RNH1	0.35	4.97	0.3	1.26e-6	Systemic lupus erythematosus;
KIRP	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg14580859	chr9:123691850	NA	-0.36	-5.08	-0.31	7.47e-7	Rheumatoid arthritis;
KIRP	cis	rs6832769	0.890	rs564762	chr4:56284631	C/T	cg09317128	chr4:56265301	TMEM165	0.53	7.0	0.41	2.49e-11	Personality dimensions;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11138902	0.673	rs11139228	chr9:72156200	G/A	cg14397918	chr9:72078829	APBA1	0.35	5.51	0.33	9e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs11874712	1.000	rs28504655	chr18:43665348	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.54	7.36	0.42	2.72e-12	HDL cholesterol;
KIRP	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.88	-0.53	1.34e-19	Hemoglobin concentration;
KIRP	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.51	-6.16	-0.37	3.02e-9	Asthma;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg18350739	chr11:68623251	NA	-0.51	-7.75	-0.44	2.4e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg08885076	chr2:99613938	TSGA10	-0.68	-12.14	-0.61	6.97e-27	Chronic sinus infection;
KIRP	cis	rs17221829	0.739	rs7945443	chr11:89372622	T/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.04	-0.31	8.84e-7	Anxiety in major depressive disorder;
KIRP	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.98	-14.54	-0.68	5.46e-35	Coronary artery disease;
KIRP	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.78	-10.46	-0.55	2.06e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg03808351	chr9:123631620	PHF19	0.43	5.85	0.35	1.57e-8	Hip circumference adjusted for BMI;
KIRP	trans	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg24644049	chr4:85504048	CDS1	1.01	6.61	0.39	2.41e-10	Skin colour saturation;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg10305451	chr2:177043427	NA	0.52	7.19	0.42	7.78e-12	IgG glycosylation;
KIRP	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg15226275	chr6:116381976	FRK	0.21	5.92	0.35	1.09e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg25182066	chr10:30743637	MAP3K8	0.63	8.75	0.49	3.5e-16	Inflammatory bowel disease;
KIRP	cis	rs4302748	0.908	rs4723482	chr7:36192249	G/A	cg24442661	chr7:36192818	EEPD1	0.67	7.45	0.43	1.62e-12	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22000472	chr13:54708344	NA	-0.39	-6.18	-0.37	2.71e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg11161011	chr14:65562177	MAX	-0.52	-6.52	-0.38	4.04e-10	Obesity-related traits;
KIRP	trans	rs9914544	0.628	rs4924924	chr17:18677774	C/G	cg04702396	chr17:15466718	FAM18B2	0.64	9.3	0.51	8.14e-18	Educational attainment (years of education);
KIRP	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.89	8.95	0.5	8.69e-17	Methadone dose in opioid dependence;
KIRP	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg21187068	chr8:144659627	NAPRT1	0.74	5.05	0.31	8.49e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.47	-4.96	-0.3	1.34e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.55	-0.48	1.3e-15	Triglycerides;
KIRP	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25623250	chr19:38397745	WDR87;SIPA1L3	0.57	7.17	0.42	8.9e-12	Parkinson's disease;
KIRP	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	1.01	16.87	0.73	5.89e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs13424612	0.839	rs4461287	chr2:240906574	C/T	cg19172429	chr2:240878313	NA	0.29	4.94	0.3	1.48e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.73	-7.98	-0.45	5.56e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg02175503	chr12:58329896	NA	0.83	10.18	0.54	1.51e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.23	0.32	3.68e-7	Tonsillectomy;
KIRP	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg04374321	chr14:90722782	PSMC1	0.92	15.39	0.7	6.94e-38	Mortality in heart failure;
KIRP	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.7	8.14	0.46	1.96e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.81	12.53	0.62	3.55e-28	Longevity;Endometriosis;
KIRP	trans	rs6562760	0.700	rs4885096	chr13:73967507	T/C	cg08147703	chr7:75624098	TMEM120A	0.54	6.16	0.37	2.97e-9	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs9302635	0.688	rs763665	chr16:72078043	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-5.89	-0.35	1.24e-8	Blood protein levels;
KIRP	cis	rs10845606	0.781	rs7972866	chr12:12828320	C/T	cg04607235	chr12:12878440	APOLD1	-0.47	-5.05	-0.31	8.78e-7	Systemic lupus erythematosus;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg08901578	chr4:187885870	NA	-0.48	-7.25	-0.42	5.36e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs4787491	0.729	rs4788212	chr16:30034469	G/T	cg06326092	chr16:30034487	C16orf92	-0.5	-7.89	-0.45	1.01e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg03468072	chr12:39539422	NA	0.44	5.82	0.35	1.86e-8	Morning vs. evening chronotype;
KIRP	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.49	0.59	9.86e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.14	-0.36	3.28e-9	Bladder cancer;
KIRP	cis	rs13082711	0.911	rs2003886	chr3:27527732	G/T	cg02860705	chr3:27208620	NA	0.53	7.16	0.42	9.53e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg26816564	chr1:7831052	VAMP3	0.68	6.13	0.36	3.43e-9	Inflammatory bowel disease;
KIRP	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg25039879	chr17:56429692	SUPT4H1	0.6	5.04	0.31	8.84e-7	Cognitive test performance;
KIRP	cis	rs12823128	0.766	rs7316382	chr12:26924428	T/C	cg14081884	chr12:26986758	ITPR2	0.39	4.9	0.3	1.76e-6	Birth weight;
KIRP	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16414030	chr3:133502952	NA	-0.53	-6.23	-0.37	1.96e-9	Iron status biomarkers;
KIRP	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg26802063	chr5:78281964	ARSB	0.68	8.25	0.47	9.57e-15	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	trans	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Bladder cancer;
KIRP	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.81	-9.64	-0.52	7.45e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-4.93	-0.3	1.54e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.12	0.41	1.19e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.43	-0.52	3.3e-18	Coronary artery disease;
KIRP	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	6.41	0.38	7.39e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.61	-9.03	-0.5	5.26e-17	Systemic lupus erythematosus;
KIRP	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs526231	0.543	rs6880911	chr5:102307471	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.24	-0.32	3.42e-7	Primary biliary cholangitis;
KIRP	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.63	8.93	0.49	1.04e-16	Blood metabolite levels;
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26690034	chr1:75198963	CRYZ;TYW3	0.44	5.49	0.33	9.88e-8	Resistin levels;
KIRP	cis	rs6973256	0.897	rs10808271	chr7:133352318	C/T	cg10665199	chr7:133106180	EXOC4	0.47	5.89	0.35	1.25e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.58	-9.21	-0.51	1.52e-17	Prostate cancer;
KIRP	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg05535760	chr7:792225	HEATR2	-0.88	-8.02	-0.46	4.37e-14	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21643547	chr1:205240462	TMCC2	-0.88	-14.15	-0.67	1.16e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4728302	0.869	rs958404	chr7:133597186	G/T	cg10665199	chr7:133106180	EXOC4	-0.41	-4.99	-0.3	1.15e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1832871	0.711	rs9457300	chr6:158714609	G/C	cg07215822	chr6:158701037	NA	-0.65	-7.43	-0.43	1.84e-12	Height;
KIRP	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.38	0.38	8.67e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs3026101	0.578	rs59605950	chr17:5303493	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg14593290	chr7:50529359	DDC	-0.45	-5.9	-0.35	1.17e-8	Malaria;
KIRP	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.73	-6.66	-0.39	1.8e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2562152	0.530	rs216604	chr16:112513	T/C	cg02949481	chr16:131562	MPG	0.67	5.44	0.33	1.27e-7	Glioblastoma;
KIRP	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.56	5.7	0.34	3.38e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.5	5.7	0.34	3.42e-8	Type 2 diabetes;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11259409	chr11:1331124	LOC255512;TOLLIP	-0.88	-6.37	-0.38	9.47e-10	P wave terminal force;
KIRP	cis	rs2820315	1.000	rs2820313	chr1:201870221	A/G	cg11586189	chr1:201857591	SHISA4	-0.44	-6.38	-0.38	8.55e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.49	-6.2	-0.37	2.4e-9	Neurofibrillary tangles;
KIRP	cis	rs6496667	0.821	rs6496674	chr15:90976340	G/T	cg10434728	chr15:90938212	IQGAP1	0.38	5.05	0.31	8.47e-7	Rheumatoid arthritis;
KIRP	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.63	5.32	0.32	2.32e-7	Putamen volume;
KIRP	cis	rs754423	0.703	rs1540700	chr14:52521773	G/A	cg22881914	chr14:52536147	NID2	-0.37	-5.05	-0.31	8.58e-7	Craniofacial microsomia;
KIRP	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.92	14.91	0.69	2.93e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2274273	0.624	rs8015211	chr14:55841447	A/G	cg04306507	chr14:55594613	LGALS3	0.38	5.28	0.32	2.79e-7	Protein biomarker;
KIRP	cis	rs12135191	0.771	rs12134040	chr1:236490678	A/G	cg21399712	chr1:236511386	NA	-0.47	-6.09	-0.36	4.35e-9	Urate levels (BMI interaction);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01696193	chr6:56819912	BEND6;DST	-0.47	-6.3	-0.37	1.4e-9	Metabolic traits;
KIRP	cis	rs375066	0.592	rs349045	chr19:44299892	A/G	cg11993925	chr19:44307056	LYPD5	-0.37	-5.17	-0.31	4.95e-7	Breast cancer;
KIRP	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-1.11	-9.82	-0.53	2.1e-19	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs1497828	1.000	rs11810416	chr1:217558447	A/G	cg04411442	chr1:217543379	NA	0.31	4.99	0.3	1.12e-6	Dialysis-related mortality;
KIRP	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg18882449	chr10:104885122	NT5C2	-0.49	-6.19	-0.37	2.48e-9	Arsenic metabolism;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.79	14.93	0.69	2.53e-36	Lymphocyte counts;
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19723775	chr5:179050963	HNRNPH1	0.49	5.68	0.34	3.81e-8	Lung cancer;
KIRP	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs10207628	0.698	rs7594230	chr2:127873568	G/A	cg06223080	chr2:127868745	NA	-0.68	-9.02	-0.5	5.58e-17	Psychosis and Alzheimer's disease;
KIRP	cis	rs2905347	0.520	rs2905309	chr7:22648542	C/T	cg23521230	chr7:22704884	NA	0.43	4.99	0.3	1.16e-6	Major depression and alcohol dependence;
KIRP	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.35	4.91	0.3	1.69e-6	Childhood ear infection;
KIRP	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.18e-7	Breast cancer;
KIRP	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.76	-9.11	-0.5	3.02e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18590709	chr17:49122713	SPAG9	-0.44	-6.75	-0.4	1.04e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg25174290	chr11:3078921	CARS	-0.68	-8.99	-0.5	6.95e-17	Calcium levels;
KIRP	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg25173405	chr17:45401733	C17orf57	0.41	5.35	0.32	2.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg14132834	chr19:41945861	ATP5SL	0.59	7.64	0.44	4.88e-13	Height;
KIRP	trans	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-6.88	-0.4	4.82e-11	Obesity-related traits;
KIRP	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg20701182	chr2:24300061	SF3B14	0.59	5.22	0.32	3.83e-7	Lymphocyte counts;
KIRP	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg20295408	chr7:1910781	MAD1L1	0.48	5.1	0.31	6.68e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs656319	0.513	rs17746245	chr8:9981686	A/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.58	0.39	2.84e-10	Myopia (pathological);
KIRP	cis	rs7771547	0.642	rs605684	chr6:36493265	T/C	cg07856975	chr6:36356162	ETV7	0.35	5.06	0.31	8.31e-7	Platelet distribution width;
KIRP	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.3	-0.32	2.57e-7	Bipolar disorder;
KIRP	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg21427119	chr20:30132790	HM13	-0.66	-6.8	-0.4	7.99e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.66	7.61	0.44	5.85e-13	Testicular germ cell tumor;
KIRP	trans	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg10756647	chr7:56101905	PSPH	1.08	8.58	0.48	1.08e-15	Diabetic kidney disease;
KIRP	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg21827317	chr3:136751795	NA	0.36	5.09	0.31	6.95e-7	Neuroticism;
KIRP	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.44	0.47	2.76e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs953387	1.000	rs10803550	chr2:136907790	C/T	cg05194412	chr2:137003533	NA	-0.4	-5.18	-0.31	4.52e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.61	-7.67	-0.44	3.93e-13	Neuroticism;
KIRP	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-1.01	-12.68	-0.63	1.09e-28	Vitiligo;
KIRP	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.85	10.68	0.56	3.98e-22	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs16958440	1.000	rs16958432	chr18:44631773	G/A	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.31	-0.47	6.6e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs76051363	0.500	rs4647934	chr4:1016279	C/T	cg03414932	chr4:1008425	FGFRL1	-0.61	-6.33	-0.37	1.15e-9	Total body bone mineral density;
KIRP	trans	rs6881634	0.501	rs13167053	chr5:77757702	A/T	cg02919814	chr21:37666008	DOPEY2	-0.41	-6.03	-0.36	5.87e-9	Hippocampal atrophy;
KIRP	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg23649088	chr2:200775458	C2orf69	-0.56	-5.47	-0.33	1.08e-7	Schizophrenia;
KIRP	cis	rs73086581	1.000	rs6052218	chr20:3970212	A/G	cg02187196	chr20:3869020	PANK2	0.47	4.9	0.3	1.72e-6	Response to antidepressants in depression;
KIRP	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.32	-0.37	1.2e-9	Aortic root size;
KIRP	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg01338084	chr22:32026380	PISD	0.92	6.99	0.41	2.53e-11	Age-related hearing impairment;
KIRP	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.75	5.61	0.34	5.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	cis	rs2658782	0.704	rs2658766	chr11:93232229	G/A	cg15737290	chr11:93063684	CCDC67	0.7	7.72	0.44	2.86e-13	Pulmonary function decline;
KIRP	cis	rs6977660	0.714	rs28371050	chr7:19816882	C/T	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	trans	rs6601327	0.586	rs6601340	chr8:9461315	A/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.36	-0.38	9.64e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs60311166	1.000	rs56156188	chr3:52730699	T/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.91	5.72	0.34	3.14e-8	CTACK levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07907917	chr19:40949191	SERTAD3	0.55	6.31	0.37	1.26e-9	Lung cancer in ever smokers;
KIRP	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs2117029	0.653	rs1476137	chr12:49523713	A/G	cg24176009	chr12:49580217	TUBA1A	-0.38	-5.16	-0.31	5.21e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg02524346	chr8:600233	NA	0.74	5.78	0.35	2.24e-8	IgG glycosylation;
KIRP	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg07395648	chr5:131743802	NA	0.58	8.09	0.46	2.81e-14	Breast cancer;Mosquito bite size;
KIRP	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	6.32	0.37	1.2e-9	Lung cancer;
KIRP	cis	rs10875746	0.625	rs2898065	chr12:48644619	C/A	cg26205652	chr12:48591994	NA	0.62	8.09	0.46	2.76e-14	Longevity (90 years and older);
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.63	-7.06	-0.41	1.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12643440	0.538	rs12641321	chr4:17141393	G/C	cg22650099	chr4:17144496	NA	-0.7	-8.78	-0.49	2.83e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6495367	1.000	rs1007365	chr15:79379492	T/G	cg17916960	chr15:79447300	NA	0.34	5.88	0.35	1.32e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg10319629	chr12:132285459	NA	-0.33	-4.88	-0.3	1.89e-6	Migraine;
KIRP	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg23791538	chr6:167370224	RNASET2	-0.47	-5.66	-0.34	4.19e-8	Crohn's disease;
KIRP	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg01721255	chr8:58191610	C8orf71	0.54	5.51	0.33	9.08e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg05082376	chr22:42548792	NA	-0.46	-5.89	-0.35	1.27e-8	Schizophrenia;
KIRP	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.65	9.77	0.53	2.82e-19	Dupuytren's disease;
KIRP	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.73	9.34	0.51	5.97e-18	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.42	0.65	3.47e-31	Bladder cancer;
KIRP	cis	rs10901296	0.660	rs2855199	chr9:133765044	T/C	cg13397898	chr9:133768931	QRFP	0.33	5.82	0.35	1.86e-8	Bilirubin levels;
KIRP	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.43	6.57	0.39	2.94e-10	Schizophrenia;
KIRP	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-15.52	-0.7	2.52e-38	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs860295	0.775	rs822508	chr1:155850558	C/T	cg02153340	chr1:155202674	NA	-0.37	-5.05	-0.31	8.53e-7	Body mass index;
KIRP	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg15655495	chr12:38532458	NA	-0.28	-5.37	-0.32	1.85e-7	Bladder cancer;
KIRP	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.82	-10.15	-0.54	1.95e-20	Menarche (age at onset);
KIRP	cis	rs6725041	0.547	rs17419211	chr2:213207921	C/T	cg20637307	chr2:213403960	ERBB4	-0.48	-6.03	-0.36	5.84e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg19847130	chr8:10466454	RP1L1	0.39	5.86	0.35	1.49e-8	Retinal vascular caliber;
KIRP	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.83	-0.35	1.74e-8	Educational attainment;
KIRP	trans	rs12043259	0.730	rs6678477	chr1:204796941	A/G	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg11901034	chr3:128598214	ACAD9	-0.44	-4.85	-0.3	2.18e-6	IgG glycosylation;
KIRP	cis	rs57994353	0.600	rs13295852	chr9:139308426	G/A	cg14169450	chr9:139327907	INPP5E	0.53	5.84	0.35	1.66e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.87	0.45	1.13e-13	Coffee consumption (cups per day);
KIRP	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.86	-10.92	-0.57	7.05e-23	Dupuytren's disease;
KIRP	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.52	6.34	0.37	1.11e-9	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00610348	chr15:37416187	NA	-0.4	-6.18	-0.37	2.58e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12963246	chr6:28129442	ZNF389	-0.48	-5.92	-0.35	1.1e-8	Depression;
KIRP	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg13753209	chr17:57696993	CLTC	0.57	5.52	0.33	8.44e-8	Hemoglobin concentration;
KIRP	cis	rs661054	1.000	rs7117324	chr11:114387956	G/A	cg19465033	chr11:114479364	NA	0.39	5.29	0.32	2.76e-7	Ulcerative colitis;
KIRP	cis	rs258892	1.000	rs185435	chr5:72348272	A/G	cg21869765	chr5:72125136	TNPO1	-0.48	-5.95	-0.35	9.24e-9	Small cell lung carcinoma;
KIRP	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.67	7.99	0.45	5.15e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10207060	0.500	rs10177457	chr2:240708067	G/A	cg20333904	chr2:240724165	NA	-0.41	-4.92	-0.3	1.58e-6	Obesity-related traits;
KIRP	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.73	0.49	3.99e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg17747265	chr1:1875780	NA	-0.7	-13.0	-0.64	9.53e-30	Body mass index;
KIRP	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.6	-8.7	-0.49	4.7e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6546324	0.580	rs6724133	chr2:67858671	A/G	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg25447019	chr17:19030144	GRAPL	0.6	8.44	0.47	2.69e-15	Schizophrenia;
KIRP	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg26898376	chr11:64110657	CCDC88B	0.49	5.5	0.33	9.68e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.37e-10	Aortic root size;
KIRP	trans	rs913655	0.785	rs1844550	chr10:19003430	A/G	cg27106950	chr16:11367916	PRM3	0.57	6.03	0.36	5.91e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16951385	chr10:65029115	JMJD1C	-0.57	-7.48	-0.43	1.33e-12	Interleukin-4 levels;
KIRP	cis	rs9653442	0.527	rs13003982	chr2:100759078	T/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.18	-0.31	4.57e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg02151108	chr14:50098012	C14orf104	-0.53	-7.18	-0.42	8.47e-12	Carotid intima media thickness;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26698781	chr16:30845818	NA	0.47	6.16	0.37	2.87e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.64	-0.34	4.7e-8	Obesity-related traits;
KIRP	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg26513180	chr16:89883248	FANCA	0.81	5.39	0.32	1.67e-7	Skin colour saturation;
KIRP	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.09e-14	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13259357	chr3:191109928	CCDC50	-0.44	-6.72	-0.39	1.27e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7577293	1.000	rs7577293	chr2:85935282	C/T	cg19805943	chr2:85933069	NA	-0.41	-5.1	-0.31	6.82e-7	Blood protein levels;
KIRP	cis	rs9323205	0.765	rs2999387	chr14:51652986	C/G	cg23942311	chr14:51606299	NA	-0.63	-8.85	-0.49	1.72e-16	Cancer;
KIRP	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.66	-0.48	6.41e-16	Neuroticism;
KIRP	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.32	12.04	0.61	1.45e-26	Diabetic retinopathy;
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-9.41	-0.51	3.57e-18	Platelet count;
KIRP	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg17425144	chr1:10567563	PEX14	-0.45	-8.23	-0.46	1.12e-14	Prostate cancer;
KIRP	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.55	-6.89	-0.4	4.52e-11	Arsenic metabolism;
KIRP	cis	rs861020	0.560	rs649275	chr1:209950681	T/C	cg23166289	chr1:210001082	C1orf107	0.39	5.1	0.31	6.85e-7	Orofacial clefts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27228276	chr1:151119210	SEMA6C	0.49	6.89	0.4	4.53e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg13147721	chr7:65941812	NA	-0.96	-6.82	-0.4	6.92e-11	Diabetic kidney disease;
KIRP	cis	rs55962025	0.842	rs362267	chr4:3243218	C/T	cg06533319	chr4:3265114	C4orf44	0.47	5.04	0.31	9.24e-7	Parental longevity (mother's age at death);
KIRP	cis	rs2151522	0.699	rs12661002	chr6:127136061	A/G	cg21431617	chr6:127135037	NA	0.3	5.47	0.33	1.1e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.27	-0.47	8.25e-15	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06478094	chr2:47630251	MSH2	0.47	6.04	0.36	5.58e-9	Parkinson's disease;
KIRP	cis	rs918629	0.567	rs2546191	chr5:95232541	G/A	cg16656078	chr5:95278638	ELL2	-0.35	-5.34	-0.32	2.11e-7	IgG glycosylation;
KIRP	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg04691961	chr3:161091175	C3orf57	-0.4	-6.01	-0.36	6.79e-9	Morning vs. evening chronotype;
KIRP	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.71	-0.44	3.05e-13	Mean corpuscular volume;
KIRP	cis	rs965513	1.000	rs925488	chr9:100546391	C/T	cg13688889	chr9:100608707	NA	-0.59	-7.56	-0.43	7.88e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs12476592	0.602	rs10865338	chr2:63732509	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg21775007	chr8:11205619	TDH	-0.48	-6.28	-0.37	1.5e-9	Neuroticism;
KIRP	cis	rs3789045	0.819	rs16854023	chr1:204551830	A/G	cg18185008	chr1:204589407	LRRN2	-0.6	-6.49	-0.38	4.6e-10	Educational attainment (college completion);
KIRP	cis	rs735539	0.593	rs35584557	chr13:21366557	T/C	cg04906043	chr13:21280425	IL17D	-0.43	-5.12	-0.31	6.05e-7	Dental caries;
KIRP	cis	rs77861329	0.702	rs12496447	chr3:52103787	T/C	cg08692210	chr3:52188851	WDR51A	0.56	5.42	0.33	1.43e-7	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs3733418	0.860	rs13110286	chr4:165956403	G/A	cg10852876	chr4:165953100	TRIM60	-0.52	-5.55	-0.33	7.27e-8	Obesity-related traits;
KIRP	cis	rs6547631	0.622	rs11127	chr2:85924729	C/T	cg24620635	chr2:85921963	GNLY	0.32	5.08	0.31	7.55e-7	Blood protein levels;
KIRP	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	trans	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg18998321	chr18:7038943	LAMA1	-0.32	-6.3	-0.37	1.35e-9	Schizophrenia;
KIRP	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.61	-0.34	5.34e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.13	-0.31	5.92e-7	Pulmonary function;
KIRP	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg08461772	chr7:95026248	PON3	0.41	5.85	0.35	1.53e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	1.34	10.65	0.56	5e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.02	0.31	9.71e-7	Iron status biomarkers;
KIRP	cis	rs76693355	0.512	rs4936518	chr11:120311198	A/T	cg24566217	chr11:120254723	ARHGEF12	-0.43	-5.6	-0.34	5.68e-8	Intraocular pressure;
KIRP	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00852783	chr1:26633632	UBXN11	0.58	7.74	0.44	2.63e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	1.08	19.52	0.78	6.89e-52	Systemic lupus erythematosus;
KIRP	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.9	-13.3	-0.65	8.93e-31	Lung cancer;
KIRP	cis	rs4132509	1.000	rs10927051	chr1:243805936	G/C	cg25706552	chr1:244017396	NA	0.63	8.4	0.47	3.7e-15	RR interval (heart rate);
KIRP	cis	rs8028182	0.549	rs11072542	chr15:75634599	G/A	cg20655648	chr15:75932815	IMP3	-0.55	-6.85	-0.4	5.81e-11	Sudden cardiac arrest;
KIRP	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	1.09	8.9	0.49	1.26e-16	Plasma clusterin levels;
KIRP	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.7	-10.52	-0.56	1.26e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg26174226	chr8:58114915	NA	-0.48	-4.92	-0.3	1.61e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg11764359	chr7:65958608	NA	-0.42	-4.87	-0.3	2.04e-6	Calcium levels;
KIRP	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.47e-13	Bipolar disorder;
KIRP	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg07338119	chr7:157211683	NA	-0.45	-5.35	-0.32	2.06e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs4430311	0.563	rs10927056	chr1:243822570	T/C	cg25706552	chr1:244017396	NA	-0.57	-9.4	-0.51	4.09e-18	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.67	-7.42	-0.43	1.96e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg07741184	chr6:167504864	NA	0.24	6.43	0.38	6.44e-10	Crohn's disease;
KIRP	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.27	27.91	0.87	3.32e-78	IgG glycosylation;
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.95e-8	Life satisfaction;
KIRP	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.68	-8.29	-0.47	7.63e-15	Aortic root size;
KIRP	cis	rs2625529	0.730	rs2929528	chr15:72269337	C/A	cg16672083	chr15:72433130	SENP8	0.46	6.36	0.38	9.7e-10	Red blood cell count;
KIRP	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-5.79	-0.35	2.16e-8	Blood metabolite levels;
KIRP	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.55	7.49	0.43	1.27e-12	Blood protein levels;
KIRP	cis	rs72730918	0.564	rs6493512	chr15:51904611	A/G	cg14296394	chr15:51910925	DMXL2	-0.77	-10.81	-0.57	1.55e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs9290065	0.538	rs898682	chr3:160773133	G/C	cg19274270	chr17:78178856	CARD14	-0.36	-6.18	-0.37	2.59e-9	Kawasaki disease;
KIRP	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg16342193	chr10:102329863	NA	-0.39	-5.11	-0.31	6.46e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.62	-8.27	-0.47	8.71e-15	Bone mineral density;
KIRP	cis	rs9549260	0.577	rs6563841	chr13:41239178	A/C	cg21288729	chr13:41239152	FOXO1	0.74	10.11	0.54	2.58e-20	Red blood cell count;
KIRP	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg04374321	chr14:90722782	PSMC1	-0.84	-11.69	-0.6	2.06e-25	Mortality in heart failure;
KIRP	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-5.82	-0.35	1.8e-8	Asthma;
KIRP	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.98	-0.5	7.4e-17	Retinal vascular caliber;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00499819	chr20:62496386	TPD52L2	0.56	6.15	0.37	3.19e-9	Lung cancer in ever smokers;
KIRP	cis	rs6964587	1.000	rs7781597	chr7:91588194	T/C	cg01689657	chr7:91764605	CYP51A1	0.37	5.14	0.31	5.7e-7	Breast cancer;
KIRP	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.88	9.91	0.53	1.07e-19	Corneal structure;
KIRP	cis	rs16828019	0.704	rs34660906	chr1:41551968	C/T	cg03387723	chr1:41708464	SCMH1	-0.92	-6.32	-0.37	1.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.8	-0.49	2.41e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs258892	0.895	rs6882092	chr5:72086928	G/A	cg21869765	chr5:72125136	TNPO1	-0.54	-5.9	-0.35	1.2e-8	Small cell lung carcinoma;
KIRP	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13047869	chr3:10149882	C3orf24	0.65	5.94	0.35	9.65e-9	Alzheimer's disease;
KIRP	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.55	5.58	0.34	6.23e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.45	-6.82	-0.4	7.01e-11	Coronary artery disease;
KIRP	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg00999904	chr2:3704751	ALLC	0.51	6.07	0.36	4.8e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.76	10.66	0.56	4.65e-22	Body mass index;
KIRP	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.5	0.43	1.15e-12	Obesity-related traits;
KIRP	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg16141378	chr3:129829833	LOC729375	-0.56	-7.07	-0.41	1.62e-11	Neuroticism;
KIRP	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg12315302	chr6:26189340	HIST1H4D	1.05	6.41	0.38	7.21e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg08668510	chr10:1095578	IDI1	0.94	7.0	0.41	2.48e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg06781948	chr3:72941472	GXYLT2	0.48	6.32	0.37	1.23e-9	Motion sickness;
KIRP	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.25e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg00792783	chr2:198669748	PLCL1	-0.46	-5.11	-0.31	6.51e-7	Intracranial aneurysm;
KIRP	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.45e-9	Breast cancer;
KIRP	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.83	9.89	0.53	1.24e-19	Post bronchodilator FEV1;
KIRP	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.5	8.41	0.47	3.39e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs738322	0.901	rs132941	chr22:38545942	T/C	cg17652424	chr22:38574118	PLA2G6	-0.26	-5.18	-0.31	4.55e-7	Cutaneous nevi;
KIRP	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.71	-0.6	1.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg24315340	chr6:146058215	EPM2A	0.43	5.41	0.33	1.5e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.94	13.56	0.65	1.22e-31	Bladder cancer;
KIRP	cis	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.39	5.01	0.3	1.03e-6	Leprosy;
KIRP	cis	rs80130819	0.688	rs7305418	chr12:48586112	A/G	cg26205652	chr12:48591994	NA	0.48	5.39	0.33	1.61e-7	Prostate cancer;
KIRP	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg02297831	chr4:17616191	MED28	0.59	7.57	0.43	7.4e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6693295	0.838	rs1416087	chr1:246237414	A/C	cg11798871	chr1:246315928	SMYD3	-0.41	-5.05	-0.31	8.63e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs10875746	0.669	rs10467101	chr12:48607737	T/C	cg20731937	chr12:48336164	NA	0.45	5.99	0.36	7.51e-9	Longevity (90 years and older);
KIRP	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.75	10.47	0.56	1.91e-21	Hemoglobin concentration;
KIRP	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.64	0.39	2.03e-10	Resting heart rate;
KIRP	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.42	-4.87	-0.3	1.99e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.73	-8.58	-0.48	1.11e-15	Resting heart rate;
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg00933542	chr6:150070202	PCMT1	0.3	5.81	0.35	1.97e-8	Lung cancer;
KIRP	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.39	0.51	4.23e-18	Lung cancer;
KIRP	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg01744552	chr16:1261315	CACNA1H	0.38	4.91	0.3	1.69e-6	Blood protein levels;
KIRP	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg16512390	chr1:228756714	NA	0.76	6.19	0.37	2.48e-9	Chronic lymphocytic leukemia;
KIRP	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.73	0.44	2.75e-13	Myopia (pathological);
KIRP	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.74	-9.94	-0.54	8.72e-20	Personality dimensions;
KIRP	cis	rs6959887	0.962	rs2072434	chr7:35280693	C/T	cg06685737	chr7:35301730	NA	0.43	6.24	0.37	1.85e-9	Birth weight;
KIRP	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.64	-7.51	-0.43	1.08e-12	Schizophrenia;
KIRP	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.83	-0.35	1.75e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2275565	0.810	rs17658475	chr1:237032167	T/G	cg17297354	chr1:237056641	MTR	-0.39	-5.08	-0.31	7.48e-7	Homocysteine levels;
KIRP	cis	rs7267005	1.000	rs78811001	chr20:34465551	G/C	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs258892	0.895	rs13167768	chr5:72034622	A/T	cg21869765	chr5:72125136	TNPO1	-0.52	-5.83	-0.35	1.71e-8	Small cell lung carcinoma;
KIRP	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.46	6.55	0.39	3.38e-10	Sitting height ratio;
KIRP	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.76	-0.34	2.46e-8	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.62	9.2	0.51	1.57e-17	Lung cancer;
KIRP	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.69	-11.03	-0.58	2.98e-23	Educational attainment;
KIRP	trans	rs78049276	0.688	rs73855809	chr4:148380348	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-6.97	-0.41	2.96e-11	Pulse pressure;
KIRP	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.6	-6.75	-0.4	1.06e-10	Response to antineoplastic agents;
KIRP	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.73	12.13	0.61	7.59e-27	Weight;
KIRP	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.52	-0.43	1.05e-12	Height;
KIRP	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg08975724	chr8:8085496	FLJ10661	0.67	9.17	0.5	1.95e-17	Neuroticism;
KIRP	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.22	-0.7	2.59e-37	Chronic sinus infection;
KIRP	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg25173405	chr17:45401733	C17orf57	-0.48	-6.4	-0.38	7.98e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg22705602	chr4:152727874	NA	0.55	9.7	0.53	4.79e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9473924	0.542	rs9473954	chr6:50928547	G/A	cg14470998	chr6:50812995	TFAP2B	0.83	7.7	0.44	3.32e-13	Body mass index;
KIRP	cis	rs12318506	0.826	rs17804612	chr12:75671271	T/C	cg04728562	chr12:75699417	CAPS2	-0.97	-6.78	-0.4	8.69e-11	Coronary artery calcification;
KIRP	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg13010199	chr12:38710504	ALG10B	0.62	7.71	0.44	3.18e-13	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg24315340	chr6:146058215	EPM2A	0.42	5.2	0.31	4.1e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg20703242	chr1:230279135	GALNT2	-0.38	-6.96	-0.41	3.15e-11	Coronary artery disease;
KIRP	cis	rs897080	0.552	rs1085442	chr2:44635454	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.63	0.34	4.88e-8	Height;
KIRP	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.54	-8.27	-0.47	8.33e-15	Huntington's disease progression;
KIRP	cis	rs11997175	0.595	rs6468204	chr8:33774748	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.14	0.31	5.59e-7	Body mass index;
KIRP	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg04539111	chr16:67997858	SLC12A4	-0.47	-5.33	-0.32	2.27e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg04398451	chr17:18023971	MYO15A	0.76	11.17	0.58	1.05e-23	Total body bone mineral density;
KIRP	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg07382826	chr16:28625726	SULT1A1	-0.45	-4.85	-0.3	2.19e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg00484396	chr16:3507460	NAT15	0.53	5.32	0.32	2.3e-7	Tuberculosis;
KIRP	cis	rs42648	0.869	rs42614	chr7:89950363	C/G	cg25739043	chr7:89950458	NA	-0.44	-6.82	-0.4	7.05e-11	Homocysteine levels;
KIRP	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.42	-5.37	-0.32	1.79e-7	Response to temozolomide;
KIRP	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-6.66	-0.39	1.75e-10	HDL cholesterol;
KIRP	cis	rs7709377	0.620	rs12054994	chr5:115477172	A/C	cg23108291	chr5:115420582	COMMD10	0.44	5.34	0.32	2.14e-7	Metabolite levels  (X-11787);
KIRP	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg21100191	chr22:23484243	RTDR1	-0.82	-11.37	-0.59	2.45e-24	Bone mineral density;
KIRP	cis	rs921943	1.000	rs6865893	chr5:78324767	C/A	cg26802063	chr5:78281964	ARSB	0.49	6.08	0.36	4.56e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.84	11.76	0.6	1.28e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.49e-6	Reticulocyte count;High light scatter reticulocyte count;
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg11972305	chr2:233791962	NGEF	-0.38	-5.23	-0.32	3.68e-7	Schizophrenia;
KIRP	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg18306943	chr3:40428807	ENTPD3	-0.38	-5.32	-0.32	2.29e-7	Renal cell carcinoma;
KIRP	cis	rs3760982	0.520	rs425578	chr19:44302256	A/T	cg11993925	chr19:44307056	LYPD5	-0.36	-5.01	-0.3	1.06e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg16586182	chr3:47516702	SCAP	0.81	11.58	0.59	4.94e-25	Colorectal cancer;
KIRP	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.85	10.29	0.55	7.01e-21	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.55	-7.38	-0.43	2.49e-12	Blood metabolite levels;
KIRP	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.14	0.5	2.45e-17	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg07148914	chr20:33460835	GGT7	-0.52	-7.11	-0.41	1.29e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs41005	1.000	rs41003	chr2:8111772	A/C	cg03155496	chr2:8117019	LOC339788	0.57	9.38	0.51	4.43e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.86	10.41	0.55	2.84e-21	Multiple sclerosis;
KIRP	cis	rs4523957	0.748	rs12603592	chr17:2119818	A/T	cg16513277	chr17:2031491	SMG6	-0.64	-9.02	-0.5	5.32e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.07	21.08	0.8	4.82e-57	Schizophrenia;
KIRP	cis	rs1978968	1.000	rs5992921	chr22:18445263	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.6	-0.48	9.35e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs62355272	0.931	rs3822733	chr5:35875134	T/C	cg13894535	chr5:35919491	CAPSL	-0.5	-5.71	-0.34	3.23e-8	Lymphocyte counts;
KIRP	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.07	-0.41	1.63e-11	Obesity-related traits;
KIRP	cis	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg06521331	chr12:34319734	NA	-0.47	-5.75	-0.34	2.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg05717871	chr11:638507	DRD4	-0.38	-5.53	-0.33	8.12e-8	Systemic lupus erythematosus;
KIRP	cis	rs1847505	0.609	rs1606636	chr13:61416080	T/A	cg25164009	chr13:61490935	NA	0.48	5.33	0.32	2.17e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.5	-5.35	-0.32	2.03e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg10017260	chr10:834428	NA	-0.42	-6.3	-0.37	1.35e-9	Survival in rectal cancer;
KIRP	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg20368463	chr18:77673604	PQLC1	0.69	6.43	0.38	6.42e-10	Opioid sensitivity;
KIRP	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.72	11.44	0.59	1.42e-24	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	9.72	0.53	4.26e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	0.8	8.77	0.49	3.04e-16	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-1.02	-17.44	-0.74	6.81e-45	Height;
KIRP	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.53	5.51	0.33	9.17e-8	Recombination rate (females);
KIRP	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.55	7.12	0.41	1.18e-11	Coronary artery disease;
KIRP	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.6	7.21	0.42	6.98e-12	Mosquito bite size;
KIRP	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg07271561	chr3:50359363	HYAL2	0.49	6.26	0.37	1.66e-9	Schizophrenia;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg00371891	chr19:4723959	DPP9	0.84	7.3	0.42	3.97e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg07537917	chr2:241836409	C2orf54	-0.26	-5.54	-0.33	7.69e-8	Urinary metabolites;
KIRP	cis	rs6142102	0.961	rs2268088	chr20:32649064	G/T	cg08999081	chr20:33150536	PIGU	0.51	6.06	0.36	5.16e-9	Skin pigmentation;
KIRP	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.49	5.14	0.31	5.74e-7	Schizophrenia;
KIRP	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	16.15	0.72	1.79e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20753954	chr7:1706809	NA	0.42	6.04	0.36	5.77e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-6.76	-0.4	1e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.03	-0.64	7.39e-30	Height;
KIRP	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	5.02e-11	Blood metabolite levels;
KIRP	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.5	-0.38	4.42e-10	Aortic root size;
KIRP	cis	rs79976124	0.837	rs10498840	chr6:66658513	A/G	cg07460842	chr6:66804631	NA	0.78	9.11	0.5	2.91e-17	Type 2 diabetes;
KIRP	cis	rs12210905	1.000	rs5030955	chr6:27213867	C/T	cg11502198	chr6:26597334	ABT1	-0.85	-5.32	-0.32	2.34e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs13221576	0.569	rs13247984	chr7:93989677	A/T	cg20814616	chr7:94014465	NA	-0.54	-4.88	-0.3	1.91e-6	Intelligence;
KIRP	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.85	16.16	0.72	1.64e-40	Anterior chamber depth;
KIRP	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.76	9.35	0.51	5.61e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9815354	0.669	rs113059632	chr3:41932858	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.9	0.45	9.42e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs5753037	0.809	rs2057882	chr22:30217827	A/T	cg01021169	chr22:30184971	ASCC2	-0.4	-4.89	-0.3	1.79e-6	Type 1 diabetes;
KIRP	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.69	-9.06	-0.5	4.31e-17	Cognitive function;
KIRP	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs8077577	0.689	rs16961114	chr17:18215339	G/C	cg18869244	chr17:18121946	NA	0.45	5.06	0.31	8.19e-7	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16717546	chr7:24474486	NA	0.4	6.34	0.37	1.11e-9	Interleukin-4 levels;
KIRP	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.4	0.33	1.6e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19367626	chr19:6393772	GTF2F1	0.49	6.25	0.37	1.79e-9	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09379601	chr19:12992224	DNASE2	0.59	7.42	0.43	1.9e-12	Smoking initiation;
KIRP	cis	rs6991838	0.557	rs7812390	chr8:66506217	A/G	cg13398993	chr8:66546079	ARMC1	-0.44	-5.05	-0.31	8.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.502	rs9386781	chr6:109584520	G/A	cg21918786	chr6:109611834	NA	-0.38	-5.65	-0.34	4.5e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2299587	0.554	rs3853530	chr8:17748420	C/T	cg01800426	chr8:17659068	MTUS1	-0.44	-5.26	-0.32	3.13e-7	Economic and political preferences;
KIRP	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg10650853	chr12:132676840	NA	0.47	6.71	0.39	1.3100000000000001e-10	Anti-saccade response;
KIRP	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	10.06	0.54	3.68e-20	Ileal carcinoids;
KIRP	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.73	-8.09	-0.46	2.77e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs8084125	1.000	rs72978662	chr18:74951872	G/A	cg05528293	chr18:74961138	GALR1	0.5	4.87	0.3	2.04e-6	Obesity-related traits;
KIRP	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg23845249	chr11:68861649	NA	0.55	8.34	0.47	5.32e-15	Blond vs. brown hair color;
KIRP	cis	rs7615316	0.751	rs9289647	chr3:142032483	G/A	cg20824294	chr3:142316082	PLS1	0.24	5.5	0.33	9.61e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.32	-0.37	1.23e-9	Monocyte count;
KIRP	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-5.58	-0.33	6.46e-8	Colorectal cancer;
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.83	0.63	3.31e-29	Platelet count;
KIRP	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.45	-0.33	1.21e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.5	-5.8	-0.35	2.04e-8	Coronary artery disease;
KIRP	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.45	5.58	0.34	6.31e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs77956314	0.901	rs117425351	chr12:117409752	A/G	cg02017074	chr12:117425053	FBXW8	-0.96	-5.76	-0.34	2.53e-8	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.67	-7.74	-0.44	2.53e-13	Pancreatic cancer;
KIRP	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.99	10.91	0.57	7.53e-23	IgG glycosylation;
KIRP	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.2	0.61	4.33e-27	Morning vs. evening chronotype;
KIRP	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg01629716	chr15:45996671	NA	0.37	6.6	0.39	2.48e-10	Waist circumference;Weight;
KIRP	cis	rs35123781	1.000	rs601336	chr5:139057167	T/C	cg10513866	chr5:139070639	NA	0.35	4.92	0.3	1.6e-6	Schizophrenia;
KIRP	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg06360820	chr2:242988706	NA	-0.83	-8.27	-0.47	8.58e-15	Obesity-related traits;
KIRP	cis	rs7941030	0.902	rs60494825	chr11:122533908	T/C	cg20555462	chr11:122535518	UBASH3B	-0.43	-5.33	-0.32	2.24e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs6546886	0.912	rs7592749	chr2:74299032	G/A	cg14702570	chr2:74259524	NA	-0.31	-5.98	-0.36	7.89e-9	Dialysis-related mortality;
KIRP	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.71	-10.78	-0.57	1.96e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg06647332	chr5:131281008	NA	0.47	5.36	0.32	1.9e-7	Life satisfaction;
KIRP	cis	rs4713675	0.565	rs2274458	chr6:33679596	A/C	cg15676125	chr6:33679581	C6orf125	0.42	5.51	0.33	8.97e-8	Plateletcrit;
KIRP	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg24296786	chr1:45957014	TESK2	0.52	5.73	0.34	2.94e-8	Homocysteine levels;
KIRP	cis	rs11638352	0.661	rs2555376	chr15:44450991	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	5.26	0.32	3.1e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7615316	1.000	rs6775813	chr3:142345623	A/C	cg20824294	chr3:142316082	PLS1	0.24	5.32	0.32	2.39e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs13385	0.769	rs35400561	chr5:139622265	G/A	cg01860693	chr5:139557145	C5orf32	0.46	4.99	0.3	1.16e-6	Atrial fibrillation;
KIRP	cis	rs4302748	0.862	rs12533280	chr7:36171953	C/T	cg24442661	chr7:36192818	EEPD1	0.61	6.62	0.39	2.25e-10	Platelet count;
KIRP	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.54	6.96	0.41	3.16e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs55863869	0.748	rs77841333	chr2:179624788	A/T	cg02880032	chr2:179629472	TTN	0.67	5.49	0.33	9.95e-8	QT interval;
KIRP	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.32	0.47	6e-15	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg09455208	chr3:40491958	NA	0.33	5.64	0.34	4.55e-8	Renal cell carcinoma;
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.91	0.64	1.83e-29	Platelet count;
KIRP	cis	rs2652822	0.525	rs12148434	chr15:63510114	A/G	cg02713581	chr15:63449717	RPS27L	0.47	5.37	0.32	1.82e-7	Metabolic traits;
KIRP	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs2273156	0.570	rs7154306	chr14:35540499	G/T	cg09327582	chr14:35236912	BAZ1A	-0.48	-4.88	-0.3	1.92e-6	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.69	0.39	1.47e-10	Colorectal cancer;
KIRP	cis	rs9535307	0.719	rs9562927	chr13:50363677	A/G	cg04663916	chr13:50265991	EBPL	0.63	6.86	0.4	5.51e-11	Obesity-related traits;
KIRP	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.66	-8.72	-0.49	4.14e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs8070740	0.559	rs58351927	chr17:5297038	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.22	0.32	3.85e-7	Menopause (age at onset);
KIRP	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	11.47	0.59	1.12e-24	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1010254	0.510	rs1363419	chr5:151696411	A/G	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Bladder cancer;
KIRP	cis	rs61884328	0.852	rs61896132	chr11:47113303	C/T	cg23433285	chr11:47201945	PACSIN3	0.69	5.6	0.34	5.68e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs7215564	0.908	rs4969411	chr17:78747982	T/C	cg06153925	chr17:78755379	RPTOR	-0.37	-6.4	-0.38	7.94e-10	Myopia (pathological);
KIRP	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	cg12689670	chr1:183009347	LAMC1	0.45	6.39	0.38	8.41e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg27490568	chr2:178487706	NA	0.53	7.31	0.42	3.7e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25976004	chr4:56815073	CEP135	0.47	6.42	0.38	6.95e-10	Survival in pancreatic cancer;
KIRP	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg25019722	chr6:37503610	NA	-0.99	-15.22	-0.7	2.52e-37	Cognitive performance;
KIRP	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.61	-7.53	-0.43	9.46e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.46	-0.38	5.48e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs921874	0.553	rs2512395	chr11:86786129	C/G	cg22937172	chr2:240168862	HDAC4	0.52	6.7	0.39	1.41e-10	Total body bone mineral density;
KIRP	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.14	0.46	2.03e-14	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25313289	chr16:2264884	PGP	0.51	6.38	0.38	8.88e-10	Parkinson's disease;
KIRP	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.08	0.46	2.93e-14	Menopause (age at onset);
KIRP	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02018176	chr4:1364513	KIAA1530	-0.47	-5.8	-0.35	2.04e-8	Longevity;
KIRP	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg15660573	chr17:549704	VPS53	-0.95	-15.04	-0.69	1.04e-36	Prostate cancer;
KIRP	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg01620082	chr3:125678407	NA	-1.02	-6.59	-0.39	2.65e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg16141378	chr3:129829833	LOC729375	0.6	8.12	0.46	2.28e-14	Retinal vascular caliber;
KIRP	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-7.04	-0.41	1.95e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs501120	0.584	rs11238935	chr10:44714402	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg16141378	chr3:129829833	LOC729375	0.55	7.06	0.41	1.73e-11	Neuroticism;
KIRP	cis	rs2274273	0.638	rs3825614	chr14:55729387	G/A	cg04306507	chr14:55594613	LGALS3	0.43	5.73	0.34	2.97e-8	Protein biomarker;
KIRP	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.59	6.43	0.38	6.62e-10	Aortic root size;
KIRP	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg16584676	chr17:46985605	UBE2Z	0.46	5.88	0.35	1.31e-8	Type 2 diabetes;
KIRP	cis	rs7756236	0.521	rs6907793	chr6:36625206	A/G	cg08179530	chr6:36648295	CDKN1A	0.44	5.73	0.34	2.99e-8	QRS duration;
KIRP	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg24315340	chr6:146058215	EPM2A	0.4	4.94	0.3	1.47e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.36	0.38	9.55e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg13789015	chr9:136890014	NCRNA00094	0.69	5.99	0.36	7.27e-9	Mosquito bite size;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13717333	chr12:122459966	BCL7A	0.46	6.49	0.38	4.77e-10	Survival in pancreatic cancer;
KIRP	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-6.07	-0.36	4.89e-9	Chronic sinus infection;
KIRP	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg26384229	chr12:38710491	ALG10B	-0.64	-8.7	-0.49	4.99e-16	Morning vs. evening chronotype;
KIRP	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.39	4.85	0.3	2.22e-6	Rheumatoid arthritis;
KIRP	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.05	-0.36	5.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg09021430	chr5:549028	NA	-0.48	-4.92	-0.3	1.61e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs524023	0.881	rs544838	chr11:64429059	T/C	cg09231725	chr11:64357281	SLC22A12	0.61	8.03	0.46	3.98e-14	Urate levels in obese individuals;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg22167660	chr19:40885241	HIPK4	0.51	6.43	0.38	6.67e-10	Educational attainment;
KIRP	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.31	0.37	1.28e-9	Vitiligo;
KIRP	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.49	6.47	0.38	5.27e-10	IgG glycosylation;
KIRP	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.45	-4.96	-0.3	1.32e-6	Obesity-related traits;
KIRP	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.67	9.36	0.51	5.18e-18	Post bronchodilator FEV1;
KIRP	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.69	11.15	0.58	1.23e-23	Neuroticism;
KIRP	cis	rs9488822	0.585	rs195517	chr6:116241584	G/A	cg26893134	chr6:116381904	FRK	0.2	5.18	0.31	4.73e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg02297831	chr4:17616191	MED28	0.6	7.66	0.44	4.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2629046	0.817	rs2629043	chr2:225078491	T/C	cg06102602	chr12:96895446	NA	-0.44	-6.09	-0.36	4.41e-9	Height;
KIRP	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.69	9.92	0.53	9.86e-20	Prostate cancer;
KIRP	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.44	0.52	2.91e-18	Bipolar disorder;
KIRP	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	7.91	0.45	8.83e-14	Migraine;Coronary artery disease;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.5	0.33	9.48e-8	Lung cancer;
KIRP	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.59	-0.48	9.8e-16	Total body bone mineral density;
KIRP	cis	rs1971762	0.527	rs6580958	chr12:54073483	A/G	cg23533419	chr12:54090519	NA	-0.34	-5.03	-0.31	9.59e-7	Height;
KIRP	cis	rs7940866	0.809	rs2324317	chr11:130877142	T/C	cg12179176	chr11:130786555	SNX19	0.59	6.81	0.4	7.57e-11	Schizophrenia;
KIRP	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.62	-8.3	-0.47	7.16e-15	Cortisol levels (saliva);
KIRP	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-0.7	-5.57	-0.33	6.62e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.6	-8.3	-0.47	6.8e-15	Asthma;
KIRP	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	0.67	5.82	0.35	1.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2191566	1.000	rs384544	chr19:44505255	A/T	cg18700516	chr19:44507157	ZNF230	0.47	5.25	0.32	3.21e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg26149184	chr10:133730230	NA	0.43	5.1	0.31	6.89e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.27	0.37	1.59e-9	Subjective well-being;
KIRP	cis	rs73198271	0.562	rs55961293	chr8:8675478	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.18	-0.31	4.52e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-16.15	-0.72	1.75e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.38	-0.38	8.56e-10	Monocyte percentage of white cells;
KIRP	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9392653	1.000	rs9378930	chr6:5070042	T/A	cg13207534	chr6:5087447	PPP1R3G	-0.42	-5.14	-0.31	5.56e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg10495392	chr1:46806563	NSUN4	-0.47	-5.46	-0.33	1.17e-7	Menopause (age at onset);
KIRP	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg14541582	chr5:601475	NA	-0.57	-6.5	-0.38	4.44e-10	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.74	7.43	0.43	1.81e-12	Bipolar disorder;
KIRP	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.79	-12.86	-0.63	2.76e-29	Heart rate;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09949816	chr15:34503491	C15orf29	0.42	6.32	0.37	1.22e-9	Survival in pancreatic cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15067350	chr13:66878738	PCDH9	0.38	6.09	0.36	4.4e-9	C-reactive protein;
KIRP	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg06521331	chr12:34319734	NA	-0.61	-7.2	-0.42	7.35e-12	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.87	12.58	0.63	2.35e-28	Morning vs. evening chronotype;
KIRP	cis	rs231513	0.954	rs170766	chr17:41963407	C/G	cg26893861	chr17:41843967	DUSP3	-0.49	-5.09	-0.31	7.06e-7	Cognitive function;
KIRP	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.45	6.26	0.37	1.7e-9	Coronary artery disease;
KIRP	cis	rs2172802	0.693	rs1497919	chr4:62482227	G/A	cg04118610	chr4:62707027	LPHN3	-0.52	-5.91	-0.35	1.11e-8	Partial epilepsies;
KIRP	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg18944383	chr4:111397179	ENPEP	-0.69	-12.79	-0.63	4.57e-29	Coronary artery disease;
KIRP	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.04	17.35	0.74	1.35e-44	Multiple system atrophy;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg27097962	chr14:105780695	PACS2	0.57	6.73	0.39	1.21e-10	Plasma plasminogen activator levels;
KIRP	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg18764771	chr6:116381957	FRK	0.19	5.35	0.32	2.05e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg25251562	chr2:3704773	ALLC	-0.51	-6.02	-0.36	6.27e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21024969	chr6:163994355	QKI	-0.47	-7.25	-0.42	5.3e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4356932	1.000	rs6850760	chr4:76951684	A/T	cg19388996	chr4:76862389	NAAA	0.39	5.03	0.31	9.65e-7	Blood protein levels;
KIRP	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg17691542	chr6:26056736	HIST1H1C	0.67	7.94	0.45	6.98e-14	Iron status biomarkers;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10155725	chr11:86380814	ME3	0.48	6.98	0.41	2.7e-11	Interleukin-4 levels;
KIRP	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-7.6	-0.44	6.12e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg03465714	chr1:152285911	FLG	0.49	5.28	0.32	2.88e-7	Atopic dermatitis;
KIRP	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg26876637	chr1:152193138	HRNR	0.74	10.14	0.54	1.99e-20	Atopic dermatitis;
KIRP	cis	rs7180079	0.620	rs1665897	chr15:64892237	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg25249241	chr11:118125492	MPZL2	-0.32	-5.0	-0.3	1.12e-6	Myopia;
KIRP	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.21	-0.37	2.27e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg22974920	chr21:40686053	BRWD1	0.49	5.86	0.35	1.47e-8	Cognitive function;
KIRP	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.73	7.35	0.42	2.91e-12	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg05861140	chr6:150128134	PCMT1	-0.48	-6.82	-0.4	6.98e-11	Lung cancer;
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22618164	chr12:122356400	WDR66	0.56	7.41	0.43	1.97e-12	Mean corpuscular volume;
KIRP	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.65	-7.74	-0.44	2.64e-13	Iron status biomarkers;
KIRP	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs12134245	0.874	rs61798047	chr1:92016934	C/T	cg25838465	chr1:92012736	NA	-0.61	-7.93	-0.45	7.84e-14	Breast cancer;
KIRP	cis	rs2172802	0.693	rs7660566	chr4:62481231	G/T	cg04118610	chr4:62707027	LPHN3	0.59	7.36	0.42	2.71e-12	Partial epilepsies;
KIRP	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg27121462	chr16:89883253	FANCA	-0.53	-7.25	-0.42	5.4e-12	Vitiligo;
KIRP	cis	rs4791746	1.000	rs7210747	chr17:8627800	T/C	cg03115937	chr17:8649504	CCDC42	-0.52	-5.84	-0.35	1.64e-8	Heroin dependence;
KIRP	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg23479056	chr15:41276147	INO80	-0.36	-4.86	-0.3	2.13e-6	Menopause (age at onset);
KIRP	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	1.15	14.66	0.68	2.19e-35	Response to hepatitis C treatment;
KIRP	cis	rs580438	0.510	rs9310422	chr3:13421942	A/G	cg10657019	chr3:13328039	NA	0.59	7.87	0.45	1.15e-13	Myringotomy;
KIRP	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-0.76	-8.88	-0.49	1.44e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.13	0.31	5.75e-7	Neuroticism;
KIRP	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg19336497	chr11:14380999	RRAS2	0.36	5.1	0.31	6.87e-7	Mitochondrial DNA levels;
KIRP	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.55	-0.56	1.08e-21	Triglycerides;
KIRP	trans	rs4352251	0.543	rs17025378	chr2:101919539	C/G	cg16636104	chr7:104004514	LHFPL3	-0.58	-6.2	-0.37	2.38e-9	Adiponectin levels (BMI-adjusted);Adiponectin levels;
KIRP	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg26513180	chr16:89883248	FANCA	-0.41	-5.08	-0.31	7.57e-7	Vitiligo;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04620418	chr8:65282285	NA	0.47	6.5	0.38	4.43e-10	Smoking initiation;
KIRP	cis	rs7116495	1.000	rs4945426	chr11:71748146	A/C	cg18441811	chr11:71824068	C11orf51	0.61	4.85	0.3	2.18e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg17691542	chr6:26056736	HIST1H1C	0.47	6.2	0.37	2.43e-9	Height;
KIRP	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg08280861	chr8:58055591	NA	0.64	5.86	0.35	1.45e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs34421088	0.531	rs2245232	chr8:11400944	G/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.61	-0.44	5.76e-13	Neuroticism;
KIRP	cis	rs1832871	0.538	rs6924801	chr6:158718805	A/G	cg07215822	chr6:158701037	NA	0.58	8.51	0.48	1.76e-15	Height;
KIRP	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg12560992	chr17:57184187	TRIM37	0.62	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.5	-5.75	-0.34	2.61e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7027203	0.576	rs7862149	chr9:96546778	A/G	cg14598338	chr9:96623480	NA	0.46	7.15	0.41	9.67e-12	DNA methylation (variation);
KIRP	cis	rs9596863	0.851	rs9591532	chr13:54308351	A/G	ch.13.53330881F	chr13:54432880	NA	0.54	5.25	0.32	3.36e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18191664	chr8:37594173	ERLIN2	0.47	6.24	0.37	1.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582720	1.000	rs72932746	chr2:203663498	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.19	10.48	0.56	1.76e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	15.08	0.69	7.91e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.85	10.34	0.55	4.76e-21	Neutrophil percentage of white cells;
KIRP	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.87	13.17	0.64	2.5e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg03894339	chr8:19674705	INTS10	1.21	13.85	0.66	1.23e-32	Lipid metabolism phenotypes;
KIRP	trans	rs17834760	0.955	rs9500731	chr6:62047480	T/C	cg08476511	chr6:168435923	KIF25	0.51	6.09	0.36	4.25e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.48	-6.13	-0.36	3.52e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg22777020	chr22:31556080	RNF185	-0.51	-5.4	-0.33	1.56e-7	Colorectal cancer;
KIRP	trans	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-5.95	-0.35	9.14e-9	Bipolar disorder;
KIRP	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg17554472	chr22:41940697	POLR3H	0.41	4.87	0.3	1.96e-6	Vitiligo;
KIRP	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg14664628	chr15:75095509	CSK	-1.14	-18.91	-0.77	7.5e-50	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2219968	0.701	rs2200015	chr8:78990829	T/C	cg00738934	chr8:78996279	NA	0.44	5.82	0.35	1.82e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	1.16	9.29	0.51	8.59e-18	LDL cholesterol;
KIRP	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg13010199	chr12:38710504	ALG10B	-0.58	-7.72	-0.44	2.85e-13	Morning vs. evening chronotype;
KIRP	cis	rs829661	0.793	rs7583211	chr2:30796361	C/T	cg10949345	chr2:30726833	LCLAT1	1.01	12.98	0.64	1.11e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg12705353	chr12:122356852	WDR66	0.46	6.01	0.36	6.58e-9	Mean corpuscular volume;
KIRP	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg16898833	chr6:26189333	HIST1H4D	0.83	5.9	0.35	1.17e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.62	7.26	0.42	4.96e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs8014252	0.803	rs12587714	chr14:71004376	G/C	cg11204974	chr14:71022665	NA	-0.63	-6.72	-0.39	1.24e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs117787553	1.000	rs1957111	chr14:29781178	C/T	cg16459890	chr11:104916331	CASP1;CARD16	-0.9	-6.02	-0.36	6.19e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs13108043	0.509	rs28533631	chr4:87818090	T/C	cg11209507	chr4:87813803	C4orf36	0.5	5.4	0.33	1.56e-7	Red blood cell count;
KIRP	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg18850127	chr7:39170497	POU6F2	0.28	5.51	0.33	8.95e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01519350	chr3:137906342	ARMC8	-0.47	-6.16	-0.37	2.95e-9	Pancreatic cancer;
KIRP	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.17	-0.37	2.8e-9	Neuroticism;
KIRP	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	7.33	0.42	3.36e-12	Iron status biomarkers;
KIRP	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg18306943	chr3:40428807	ENTPD3	0.4	5.65	0.34	4.34e-8	Renal cell carcinoma;
KIRP	cis	rs1062746	0.544	rs3762182	chr16:87326113	A/G	cg02258303	chr16:87377426	FBXO31	0.43	5.64	0.34	4.72e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs17023223	0.537	rs2361272	chr1:119603417	T/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.21	-0.42	6.83e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.83	-0.6	7.4e-26	Diabetic kidney disease;
KIRP	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg13385521	chr17:29058706	SUZ12P	0.77	6.52	0.38	3.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg22974920	chr21:40686053	BRWD1	0.46	5.4	0.33	1.59e-7	Cognitive function;
KIRP	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.21	0.46	1.26e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13732083	chr21:47605072	C21orf56	-0.38	-4.9	-0.3	1.77e-6	Testicular germ cell tumor;
KIRP	cis	rs7945718	0.840	rs10741601	chr11:12735873	T/C	ch.11.340609R	chr11:12831013	TEAD1	-0.47	-5.89	-0.35	1.25e-8	Educational attainment (years of education);
KIRP	trans	rs9844985	0.630	rs6766837	chr3:116893069	C/G	cg08917664	chr1:147052445	BCL9	-0.4	-6.86	-0.4	5.54e-11	Major depression and alcohol dependence;
KIRP	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	1.12	7.95	0.45	6.73e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7129556	0.737	rs623173	chr11:77529528	C/T	cg12586386	chr11:77299805	AQP11	-0.43	-5.13	-0.31	5.83e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.64	-9.48	-0.52	2.3e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.58	-7.68	-0.44	3.7e-13	Myopia (pathological);
KIRP	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.59	6.96	0.41	2.99e-11	Uric acid levels;
KIRP	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.84	15.02	0.69	1.26e-36	Prostate-specific antigen levels;
KIRP	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.64	-9.06	-0.5	4.13e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg04865290	chr3:52927548	TMEM110	0.38	5.05	0.31	8.54e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.59	0.44	6.52e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg23188430	chr6:125850052	NA	-0.34	-5.28	-0.32	2.86e-7	Brugada syndrome;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-10.13	-0.54	2.23e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01825986	chr20:47804552	STAU1	0.48	6.07	0.36	4.9e-9	Myopia (pathological);
KIRP	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-7.38	-0.43	2.43e-12	Bipolar disorder;
KIRP	cis	rs34526934	0.566	rs35563571	chr2:177044459	T/G	cg14324370	chr2:177042789	NA	-0.68	-8.27	-0.47	8.24e-15	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.67	9.52	0.52	1.76e-18	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.77	11.37	0.59	2.38e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.59	-6.97	-0.41	2.93e-11	Height;
KIRP	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.65	-0.44	4.54e-13	Joint mobility (Beighton score);
KIRP	trans	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.16	-0.37	2.92e-9	Triglycerides;
KIRP	cis	rs10214930	0.625	rs2391453	chr7:27690587	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.66	-6.71	-0.39	1.34e-10	Ulcerative colitis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg19863459	chr19:4639366	TNFAIP8L1	-0.52	-6.07	-0.36	4.9e-9	Menopause (age at onset);
KIRP	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.12	0.31	6.04e-7	Systolic blood pressure;
KIRP	cis	rs4629710	0.562	rs3798252	chr6:131583758	A/T	cg12606694	chr6:131520996	AKAP7	0.51	6.59	0.39	2.64e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.85	-0.3	2.2e-6	Resting heart rate;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05949352	chr11:45202135	PRDM11	0.45	6.1	0.36	4.08e-9	Myopia (pathological);
KIRP	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.56	0.33	7.17e-8	Breast cancer;
KIRP	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg04306507	chr14:55594613	LGALS3	0.52	8.14	0.46	2.04e-14	Protein biomarker;
KIRP	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg22089800	chr15:90895588	ZNF774	0.59	8.07	0.46	3.07e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7700895	0.578	rs147295	chr5:95219261	A/G	cg16656078	chr5:95278638	ELL2	0.34	5.17	0.31	4.73e-7	IgG glycosylation;
KIRP	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.74	-8.61	-0.48	9.15e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg17507749	chr15:85114479	UBE2QP1	0.83	9.27	0.51	1e-17	Schizophrenia;
KIRP	trans	rs4938303	0.633	rs12801136	chr11:116548349	G/A	cg13754915	chr9:140174272	C9orf167	-0.75	-6.6	-0.39	2.44e-10	Triglycerides;
KIRP	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.98	10.33	0.55	5.19e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10940138	0.720	rs2372188	chr5:67233704	T/C	ch.5.1281357F	chr5:67228439	NA	0.7	10.99	0.57	3.9699999999999997e-23	Menarche (age at onset);
KIRP	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg21433313	chr16:3507492	NAT15	-0.45	-5.87	-0.35	1.43e-8	Tuberculosis;
KIRP	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.05e-10	HDL cholesterol levels;
KIRP	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-13.01	-0.64	8.36e-30	Electrocardiographic conduction measures;
KIRP	cis	rs9290877	0.965	rs17671434	chr3:188445439	A/C	cg17392043	chr3:188495102	LPP	0.44	5.7	0.34	3.41e-8	IgE levels;
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg08662619	chr6:150070041	PCMT1	0.38	6.24	0.37	1.9e-9	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11636699	chr19:13044490	FARSA	0.48	6.05	0.36	5.39e-9	Parkinson's disease;
KIRP	cis	rs17209837	1.000	rs4148807	chr7:87105812	G/A	cg00919237	chr7:87102261	ABCB4	-0.68	-7.36	-0.42	2.77e-12	Gallbladder cancer;
KIRP	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg23587288	chr2:27483067	SLC30A3	-0.57	-7.23	-0.42	6.04e-12	Blood metabolite levels;
KIRP	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.57	-6.08	-0.36	4.66e-9	Obesity-related traits;
KIRP	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.51	6.55	0.39	3.38e-10	Asthma (bronchodilator response);
KIRP	cis	rs72730918	0.590	rs716986	chr15:51979813	C/T	cg14296394	chr15:51910925	DMXL2	-0.75	-10.13	-0.54	2.23e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs10982712	0.805	rs1029343	chr9:118121193	C/T	cg23764129	chr11:113846017	HTR3A	0.24	6.03	0.36	5.92e-9	Interleukin-9 levels;
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.49	-6.37	-0.38	8.99e-10	Testicular germ cell tumor;
KIRP	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.75	7.63	0.44	5.25e-13	Bipolar disorder;
KIRP	cis	rs2224391	0.628	rs2753222	chr6:5242075	T/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-5.88	-0.35	1.34e-8	Height;
KIRP	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.45	-6.42	-0.38	6.84e-10	Testicular germ cell tumor;
KIRP	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg12963866	chr19:57752005	ZNF805	-0.47	-6.06	-0.36	5.11e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg24060327	chr5:131705240	SLC22A5	-0.58	-7.8	-0.45	1.71e-13	Acylcarnitine levels;
KIRP	cis	rs13315871	0.929	rs13066351	chr3:58398215	C/T	cg12435725	chr3:58293450	RPP14	-0.52	-5.17	-0.31	4.79e-7	Cholesterol, total;
KIRP	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.47	-6.83	-0.4	6.61e-11	Schizophrenia;
KIRP	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.1	21.84	0.81	1.6e-59	Chronic sinus infection;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg00738919	chr7:1100172	C7orf50	0.43	4.98	0.3	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg00629928	chr5:358741	AHRR	0.52	5.03	0.31	9.34e-7	Breast cancer;
KIRP	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.02	-0.36	6.39e-9	Breast cancer;
KIRP	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.5	6.89	0.4	4.75e-11	Mean corpuscular volume;
KIRP	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg11150807	chr10:43354902	NA	0.57	6.38	0.38	8.72e-10	Blood protein levels;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20568390	chr1:54723340	SSBP3	0.44	6.41	0.38	7.23e-10	Warfarin maintenance dose;
KIRP	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.59e-11	Tonsillectomy;
KIRP	cis	rs7523050	0.643	rs12729998	chr1:109405505	T/C	cg08274380	chr1:109419600	GPSM2	1.08	9.39	0.51	4.36e-18	Fat distribution (HIV);
KIRP	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg13010199	chr12:38710504	ALG10B	0.64	8.06	0.46	3.36e-14	Morning vs. evening chronotype;
KIRP	cis	rs12643440	0.538	rs4280726	chr4:17139547	T/C	cg22650099	chr4:17144496	NA	-0.75	-8.9	-0.49	1.25e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3784262	0.631	rs3742961	chr15:58247977	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.06	-0.31	8.27e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.28	0.37	1.55e-9	Neuroticism;
KIRP	cis	rs7078219	1.000	rs7081330	chr10:101274465	A/G	cg07044859	chr10:101282883	NA	-0.33	-5.66	-0.34	4.15e-8	Dental caries;
KIRP	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.53	7.19	0.42	7.72e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg03060546	chr3:49711283	APEH	0.45	5.78	0.35	2.24e-8	Parkinson's disease;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.02	-0.36	6.39e-9	Longevity;
KIRP	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.47	-0.33	1.12e-7	Height;
KIRP	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.64	-9.05	-0.5	4.47e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.15	0.5	2.21e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg10645314	chr2:3704589	ALLC	-0.64	-7.1	-0.41	1.32e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg12718519	chr1:2058417	PRKCZ	-0.19	-5.5	-0.33	9.66e-8	Height;
KIRP	cis	rs4262150	0.883	rs17489682	chr5:152312444	T/G	cg12297329	chr5:152029980	NA	-0.66	-8.65	-0.48	6.59e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs865483	0.895	rs72828253	chr17:35783416	A/G	cg06716730	chr17:35851459	DUSP14	-0.25	-5.99	-0.36	7.52e-9	Monocyte count;
KIRP	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.56	5.82	0.35	1.78e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-7.29	-0.42	4.11e-12	Platelet count;
KIRP	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.58	7.34	0.42	3.13e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg21698718	chr17:80085957	CCDC57	0.35	5.14	0.31	5.65e-7	Life satisfaction;
KIRP	cis	rs28834970	0.925	rs6987305	chr8:27208126	G/A	cg23736307	chr8:27182930	PTK2B	-0.48	-5.99	-0.36	7.3e-9	Alzheimer's disease (late onset);
KIRP	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg09307838	chr4:120376055	NA	0.63	6.85	0.4	6.04e-11	Educational attainment;
KIRP	cis	rs41563	0.547	rs12668040	chr7:104905057	C/T	cg04380332	chr7:105027541	SRPK2	0.6	6.34	0.37	1.08e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg15270235	chr3:195682595	NA	0.32	4.88	0.3	1.87e-6	Mean corpuscular volume;
KIRP	cis	rs4936894	0.500	rs10790666	chr11:124176977	A/G	cg27160556	chr11:124181099	OR8D1	-0.47	-6.74	-0.39	1.12e-10	Aging (time to death);
KIRP	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg03709012	chr19:19516395	GATAD2A	0.61	6.17	0.37	2.72e-9	Tonsillectomy;
KIRP	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.22	-0.32	3.71e-7	Schizophrenia;
KIRP	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg10503236	chr1:231470652	EXOC8	-0.49	-6.96	-0.41	3.12e-11	Hemoglobin concentration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02287918	chr21:30396957	USP16	0.42	6.02	0.36	6.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs933360	0.535	rs10226937	chr7:50845718	G/A	cg20003124	chr12:4557277	NA	0.52	6.19	0.37	2.51e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.82	10.5	0.56	1.54e-21	Menopause (age at onset);
KIRP	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.93	-8.19	-0.46	1.39e-14	Rheumatoid arthritis;
KIRP	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-0.8	-9.15	-0.5	2.32e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.58	-7.77	-0.44	2.18e-13	Testicular germ cell tumor;
KIRP	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg07148914	chr20:33460835	GGT7	-0.54	-7.07	-0.41	1.62e-11	Height;
KIRP	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.39	4.99	0.3	1.12e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.43	5.36	0.32	1.88e-7	Common traits (Other);
KIRP	cis	rs860295	0.702	rs12041534	chr1:155407096	A/G	cg02153340	chr1:155202674	NA	0.49	6.86	0.4	5.39e-11	Body mass index;
KIRP	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg03834567	chr2:218808745	TNS1	0.44	5.38	0.32	1.76e-7	Ulcerative colitis;
KIRP	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.54	6.35	0.38	1.04e-9	AIDS;
KIRP	cis	rs11209002	0.567	rs2755268	chr1:67539881	T/C	cg02640540	chr1:67518911	SLC35D1	0.54	5.98	0.36	7.71e-9	Crohn's disease;
KIRP	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	8.73	0.49	3.95e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	7.51	0.43	1.08e-12	Longevity;
KIRP	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg23950597	chr19:37808831	NA	-0.65	-6.91	-0.4	4.13e-11	Coronary artery calcification;
KIRP	cis	rs7033996	1.000	rs55845747	chr9:35946420	T/C	cg00918944	chr9:35908117	LOC158376	0.38	5.34	0.32	2.12e-7	Urate levels (BMI interaction);
KIRP	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg18404041	chr3:52824283	ITIH1	0.43	5.37	0.32	1.8e-7	Schizophrenia;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.2	-23.34	-0.83	2.64e-64	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs687432	0.885	rs61904009	chr11:57807613	A/G	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs13161895	1.000	rs34027780	chr5:179478891	C/A	cg02702477	chr5:179499311	RNF130	0.74	5.7	0.34	3.44e-8	LDL cholesterol;
KIRP	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg08662619	chr6:150070041	PCMT1	0.34	5.22	0.32	3.73e-7	Lung cancer;
KIRP	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg22916017	chr11:64110731	CCDC88B	0.48	5.32	0.32	2.29e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.77	-10.87	-0.57	9.69e-23	Morning vs. evening chronotype;
KIRP	cis	rs4663866	1.000	rs13026475	chr2:239178455	T/C	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.24	-5.17	-0.31	4.82e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs7666738	0.546	rs7679681	chr4:98882221	A/G	cg05340658	chr4:99064831	C4orf37	0.67	7.98	0.45	5.53e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg02640540	chr1:67518911	SLC35D1	-0.4	-4.95	-0.3	1.35e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs2916247	1.000	rs2979856	chr8:92980145	A/T	cg10183463	chr8:93005414	RUNX1T1	0.55	7.01	0.41	2.25e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-5.05	-0.31	8.56e-7	Initial pursuit acceleration;
KIRP	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.53	6.84	0.4	6.2e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.57	-7.25	-0.42	5.37e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg09990169	chr2:241835740	C2orf54	0.44	6.07	0.36	4.71e-9	Urinary metabolites;
KIRP	cis	rs7084402	0.967	rs2438182	chr10:60314815	A/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.89	-0.57	8.19e-23	Refractive error;
KIRP	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg25124228	chr12:125621409	AACS	-0.58	-6.55	-0.39	3.35e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	1.0	17.65	0.75	1.34e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8067287	0.724	rs35380019	chr17:16826904	G/A	cg26910001	chr17:16838321	NA	-0.59	-5.78	-0.35	2.27e-8	Diabetic kidney disease;
KIRP	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-9.1	-0.5	3.25e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.9	-0.35	1.22e-8	LDL cholesterol levels;
KIRP	trans	rs10027350	0.704	rs438576	chr4:25235359	A/G	cg09449104	chr2:200935	NA	-0.37	-6.07	-0.36	4.94e-9	Childhood ear infection;
KIRP	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg04166393	chr7:2884313	GNA12	0.5	6.43	0.38	6.41e-10	Height;
KIRP	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.37	-0.38	9.4e-10	Coronary artery disease;
KIRP	cis	rs78487399	0.808	rs7561287	chr2:43689071	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.86	-0.3	2.13e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10421328	0.784	rs8107058	chr19:19759651	T/C	cg03709012	chr19:19516395	GATAD2A	0.44	5.17	0.31	4.93e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12560992	chr17:57184187	TRIM37	0.61	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18252515	chr7:66147081	NA	-0.46	-5.63	-0.34	4.87e-8	Aortic root size;
KIRP	trans	rs12043259	0.730	rs10458595	chr1:204793940	T/C	cg11485465	chr5:54518469	NA	0.38	6.31	0.37	1.26e-9	Addiction;
KIRP	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	8.34	0.47	5.47e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.99	11.59	0.59	4.58e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.34	5.05	0.31	8.45e-7	Eye color traits;
KIRP	cis	rs9323205	0.723	rs12587352	chr14:51739441	T/C	cg23942311	chr14:51606299	NA	-0.52	-5.0	-0.3	1.07e-6	Cancer;
KIRP	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg21466736	chr12:48725269	NA	-0.55	-6.75	-0.4	1.05e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg15556689	chr8:8085844	FLJ10661	0.68	9.23	0.51	1.3e-17	Mood instability;
KIRP	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg10818794	chr15:86012489	AKAP13	-0.52	-7.33	-0.42	3.38e-12	Coronary artery disease;
KIRP	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg16586182	chr3:47516702	SCAP	0.77	9.58	0.52	1.09e-18	Colorectal cancer;
KIRP	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.5e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.84	-12.75	-0.63	6.16e-29	Strep throat;
KIRP	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.45	6.1	0.36	4.06e-9	Testicular germ cell tumor;
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.63	-9.63	-0.52	7.67e-19	Immature fraction of reticulocytes;
KIRP	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.78	-11.71	-0.6	1.81e-25	Diastolic blood pressure;
KIRP	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg08755490	chr11:65554678	OVOL1	0.37	5.27	0.32	3.03e-7	Acne (severe);
KIRP	cis	rs7188697	0.848	rs42947	chr16:58579158	A/C	cg21335942	chr16:58549945	SETD6	0.46	5.08	0.31	7.6e-7	QT interval;
KIRP	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg16524733	chr11:117070046	TAGLN	-0.41	-5.41	-0.33	1.52e-7	Blood protein levels;
KIRP	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.72	-9.07	-0.5	3.89e-17	Coronary artery disease;
KIRP	cis	rs10489525	0.599	rs910622	chr1:115600424	A/G	cg01522456	chr1:115632236	TSPAN2	-0.55	-7.22	-0.42	6.28e-12	Autism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21382232	chr15:59283877	RNF111	-0.41	-6.12	-0.36	3.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg26681399	chr22:41777847	TEF	0.54	5.32	0.32	2.35e-7	Vitiligo;
KIRP	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.27	-0.51	1e-17	Hemoglobin concentration;
KIRP	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.41	-4.87	-0.3	1.99e-6	Tonsillectomy;
KIRP	cis	rs4006360	0.541	rs6503606	chr17:39309901	A/T	cg25341923	chr17:39239918	KRTAP4-7	-0.43	-5.77	-0.35	2.38e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg05562828	chr17:3906858	NA	-0.72	-14.29	-0.67	3.87e-34	Type 2 diabetes;
KIRP	cis	rs4849845	0.598	rs3889223	chr2:121024432	A/G	cg24070213	chr2:121070622	NA	0.4	6.2	0.37	2.4e-9	Mean platelet volume;
KIRP	cis	rs9625935	0.518	rs5752972	chr22:30250312	A/T	cg01021169	chr22:30184971	ASCC2	0.42	5.72	0.34	3.13e-8	Tonsillectomy;
KIRP	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.96	-0.36	8.64e-9	Breast cancer;
KIRP	cis	rs28595532	0.720	rs72670222	chr4:119300095	A/T	cg21605333	chr4:119757512	SEC24D	1.01	6.82	0.4	7e-11	Cannabis dependence symptom count;
KIRP	cis	rs2434422	0.708	rs6509631	chr19:52839474	C/T	cg17271561	chr19:52839334	ZNF610	0.73	6.38	0.38	8.65e-10	Cannabis use (initiation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12393589	chr7:45027643	C7orf40	-0.4	-6.69	-0.39	1.47e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg14458575	chr2:238380390	NA	0.6	8.12	0.46	2.26e-14	Prostate cancer;
KIRP	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.6	-6.85	-0.4	5.72e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg03959625	chr15:84868606	LOC388152	0.65	7.93	0.45	7.78e-14	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg21851534	chr17:3907994	ZZEF1	-0.65	-10.05	-0.54	3.91e-20	Type 2 diabetes;
KIRP	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.62	-8.11	-0.46	2.4e-14	Height;
KIRP	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg24009623	chr19:33667908	NA	0.47	6.3	0.37	1.39e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg20243544	chr17:37824526	PNMT	0.5	7.16	0.42	9.24e-12	Asthma;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg24101359	chr6:42928495	GNMT	0.58	8.05	0.46	3.58e-14	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.49	0.38	4.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg09597638	chr17:3907349	NA	0.49	5.45	0.33	1.22e-7	Type 2 diabetes;
KIRP	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.55	7.28	0.42	4.61e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-7.06	-0.41	1.74e-11	Systemic lupus erythematosus;
KIRP	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg23791538	chr6:167370224	RNASET2	-0.48	-5.56	-0.33	7.11e-8	Crohn's disease;
KIRP	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg07460842	chr6:66804631	NA	0.89	7.62	0.44	5.55e-13	Exhaled nitric oxide output;
KIRP	cis	rs2070433	0.615	rs2073379	chr21:47863025	C/T	cg05998816	chr21:47859926	PCNT	0.56	6.25	0.37	1.75e-9	Lymphocyte counts;
KIRP	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.48	6.78	0.4	8.94e-11	Red blood cell count;
KIRP	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	7.61	0.44	5.92e-13	Rheumatoid arthritis;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-0.85	-16.95	-0.73	3.3e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.56	7.22	0.42	6.63e-12	Schizophrenia;
KIRP	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Smoking initiation;
KIRP	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg11608241	chr8:8085544	FLJ10661	0.48	5.99	0.36	7.59e-9	Neuroticism;
KIRP	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg15234197	chr11:68924956	NA	0.32	4.98	0.3	1.19e-6	Blond vs. brown hair color;
KIRP	cis	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg19847130	chr8:10466454	RP1L1	0.35	5.22	0.32	3.73e-7	Neuroticism;
KIRP	cis	rs687432	0.774	rs1155858	chr11:57889946	A/G	cg19752551	chr11:57585705	CTNND1	-0.64	-8.23	-0.46	1.09e-14	Parkinson's disease;
KIRP	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7.01e-8	Schizophrenia;
KIRP	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.68	8.91	0.49	1.13e-16	Bladder cancer;
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.77	6.37	0.38	9.29e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg24189917	chr7:1970923	MAD1L1	-0.52	-5.07	-0.31	7.78e-7	Bipolar disorder;
KIRP	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.29	-0.55	7.09e-21	Hypospadias;
KIRP	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.58	6.75	0.4	1.08e-10	Mean corpuscular volume;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08280861	chr8:58055591	NA	-0.75	-6.14	-0.36	3.32e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9937943	0.615	rs35495670	chr16:74610422	T/C	cg01733217	chr16:74700730	RFWD3	0.64	5.87	0.35	1.43e-8	Neutrophil percentage of white cells;
KIRP	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.87	-12.71	-0.63	8.94e-29	Height;
KIRP	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.85	-12.17	-0.61	5.37e-27	Height;
KIRP	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.53	-8.83	-0.49	2.01e-16	Eye color traits;
KIRP	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg22875332	chr1:76189707	ACADM	-0.36	-5.28	-0.32	2.88e-7	Daytime sleep phenotypes;
KIRP	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg07395648	chr5:131743802	NA	-0.55	-7.79	-0.44	1.85e-13	Breast cancer;
KIRP	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.7	-7.67	-0.44	4.09e-13	Gut microbiome composition (summer);
KIRP	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg27432699	chr2:27873401	GPN1	-0.54	-6.86	-0.4	5.51e-11	Total body bone mineral density;
KIRP	cis	rs282587	0.569	rs9604421	chr13:113410493	C/G	cg04656015	chr13:113407548	ATP11A	0.6	6.52	0.38	4.04e-10	Glycated hemoglobin levels;
KIRP	cis	rs654950	0.807	rs941970	chr1:41990867	G/A	cg06885757	chr1:42089581	HIVEP3	-0.5	-7.27	-0.42	4.69e-12	Airway imaging phenotypes;
KIRP	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg25036284	chr2:26402008	FAM59B	0.47	5.15	0.31	5.41e-7	Gut microbiome composition (summer);
KIRP	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.59	8.87	0.49	1.58e-16	Airway imaging phenotypes;
KIRP	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	cis	rs1147199	0.585	rs17087470	chr9:87240311	T/C	cg22402007	chr9:87282823	NTRK2	0.4	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.63	-6.91	-0.4	4.09e-11	Initial pursuit acceleration;
KIRP	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.88e-7	Aortic root size;
KIRP	cis	rs9311474	0.713	rs352166	chr3:52238677	C/T	cg05315796	chr3:52349193	DNAH1	0.41	6.16	0.37	2.98e-9	Electroencephalogram traits;
KIRP	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-7.03	-0.41	1.99e-11	Hemoglobin concentration;
KIRP	cis	rs865483	0.895	rs853192	chr17:35821931	C/G	cg06716730	chr17:35851459	DUSP14	0.25	6.05	0.36	5.25e-9	Monocyte count;
KIRP	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	1.0	15.53	0.7	2.27e-38	Vitamin D levels;
KIRP	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg08975724	chr8:8085496	FLJ10661	0.6	7.71	0.44	3.11e-13	Retinal vascular caliber;
KIRP	cis	rs2733201	1.000	rs2706487	chr15:44428885	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.22	0.32	3.89e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	trans	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg25042112	chr7:64838748	ZNF92	0.58	6.25	0.37	1.75e-9	Pain;
KIRP	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.96	-11.54	-0.59	6.38e-25	Dilated cardiomyopathy;
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg27121462	chr16:89883253	FANCA	0.54	7.22	0.42	6.39e-12	Vitiligo;
KIRP	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg02536541	chr18:77568900	NA	-0.72	-10.6	-0.56	7.3e-22	Schizophrenia;
KIRP	trans	rs12043259	0.730	rs12023574	chr1:204802362	A/G	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg14683738	chr19:37701593	ZNF585B	0.46	4.85	0.3	2.21e-6	Coronary artery calcification;
KIRP	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.68	-12.41	-0.62	8.99e-28	White blood cell count (basophil);
KIRP	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg18198730	chr1:247681584	NA	0.82	5.47	0.33	1.11e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg19847130	chr8:10466454	RP1L1	0.33	4.93	0.3	1.48e-6	Neuroticism;
KIRP	cis	rs4774899	1.000	rs11631228	chr15:57256390	A/G	cg13626582	chr15:57592083	LOC283663	-0.2	-5.05	-0.31	8.73e-7	Urinary tract infection frequency;
KIRP	trans	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg19862616	chr7:65841803	NCRNA00174	0.61	7.28	0.42	4.55e-12	Eotaxin levels;
KIRP	cis	rs501120	0.584	rs966161	chr10:44712574	C/T	cg09554077	chr10:44749378	NA	0.69	7.61	0.44	5.93e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg08890418	chr1:21044141	KIF17	-0.7	-9.55	-0.52	1.42e-18	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg20607798	chr8:58055168	NA	0.64	4.88	0.3	1.91e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.63	-0.34	4.87e-8	Bipolar disorder;
KIRP	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg16797656	chr11:68205561	LRP5	0.55	6.69	0.39	1.49e-10	Total body bone mineral density (age 45-60);
KIRP	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.58e-7	Body mass index;
KIRP	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.58	-7.43	-0.43	1.83e-12	Aortic root size;
KIRP	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11888559	0.655	rs4675309	chr2:203879503	A/G	cg24605529	chr2:203879461	NBEAL1	0.83	5.41	0.33	1.52e-7	Height;
KIRP	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-7.99	-0.45	5.34e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg04369109	chr6:150039330	LATS1	-0.5	-6.44	-0.38	6.26e-10	Lung cancer;
KIRP	cis	rs7709377	0.571	rs1669136	chr5:115611183	G/A	cg23108291	chr5:115420582	COMMD10	-0.44	-5.42	-0.33	1.42e-7	Metabolite levels  (X-11787);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18826453	chr4:6540080	NA	0.5	6.3	0.37	1.35e-9	Interleukin-4 levels;
KIRP	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.73	-0.44	2.76e-13	Migraine;Coronary artery disease;
KIRP	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02187348	chr16:89574699	SPG7	0.41	5.03	0.31	9.53e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.58	-7.22	-0.42	6.53e-12	Sudden cardiac arrest;
KIRP	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg00792783	chr2:198669748	PLCL1	0.46	5.4	0.33	1.55e-7	Intracranial aneurysm;
KIRP	cis	rs13401104	0.796	rs72620809	chr2:237116050	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	ch.8.33884649F	chr8:33765107	NA	0.64	8.39	0.47	3.79e-15	Body mass index;
KIRP	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.87	-11.64	-0.6	3.17e-25	Cognitive function;
KIRP	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.49	6.46	0.38	5.61e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-13.76	-0.66	2.49e-32	Alzheimer's disease;
KIRP	cis	rs13319406	0.546	rs6788289	chr3:189832810	G/A	cg03343083	chr3:189718843	LEPREL1	-0.58	-5.49	-0.33	9.91e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs785830	0.521	rs543442	chr9:265491	G/C	cg14500300	chr9:211689	NA	0.39	5.14	0.31	5.6e-7	Platelet distribution width;
KIRP	cis	rs7015630	0.738	rs34642426	chr8:90854846	C/T	cg18493113	chr8:90847772	NA	-0.47	-5.32	-0.32	2.34e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg01877450	chr7:97915802	BRI3	-0.53	-6.97	-0.41	2.92e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	4.9	0.3	1.72e-6	Diisocyanate-induced asthma;
KIRP	cis	rs4646312	0.555	rs5748484	chr22:19922585	C/T	cg07194846	chr22:19930177	COMT;TXNRD2	0.45	4.85	0.3	2.2e-6	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.03e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg19645103	chr12:69753606	YEATS4	-0.48	-5.03	-0.31	9.42e-7	Response to diuretic therapy;
KIRP	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13236679	chr6:37467396	C6orf129	0.57	6.74	0.39	1.09e-10	Smoking initiation;
KIRP	cis	rs67257959	0.708	rs1979260	chr19:17193551	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.49	-5.69	-0.34	3.59e-8	Selective IgA deficiency;
KIRP	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs7852872	0.812	rs7022359	chr9:119251502	T/C	cg13792444	chr9:119245443	ASTN2	0.41	6.39	0.38	8.08e-10	Hippocampal volume;
KIRP	cis	rs4664304	0.620	rs1397717	chr2:160720444	G/T	cg03641300	chr2:160917029	PLA2R1	0.35	5.22	0.32	3.77e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6459788	0.630	rs11977865	chr7:157234112	G/A	cg05333889	chr7:157238977	NA	-0.43	-5.86	-0.35	1.47e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs501120	0.564	rs1704214	chr10:44682729	A/G	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs255758	0.637	rs13180378	chr5:53348730	C/T	cg22592108	chr5:53304441	ARL15	-0.4	-5.2	-0.31	4.26e-7	Rheumatoid arthritis;
KIRP	cis	rs7572263	0.833	rs6710217	chr2:209050352	C/T	cg23998903	chr2:209048830	C2orf80	-0.3	-5.31	-0.32	2.39e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg01631684	chr10:65280961	REEP3	-0.51	-5.94	-0.35	9.49e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg20243544	chr17:37824526	PNMT	0.38	5.06	0.31	8.06e-7	Self-reported allergy;
KIRP	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.35	0.38	1.05e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2274273	0.624	rs8005450	chr14:55799165	A/T	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.4e-7	Protein biomarker;
KIRP	cis	rs62413470	1.000	rs12196860	chr6:55950374	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.14	0.31	5.62e-7	Joint mobility (Beighton score);
KIRP	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.71	-0.6	1.82e-25	Eye color traits;
KIRP	cis	rs258892	0.895	rs4540158	chr5:72038224	A/G	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.63	-8.79	-0.49	2.69e-16	Prudent dietary pattern;
KIRP	cis	rs1950626	0.833	rs67456801	chr14:101399169	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.83	0.4	6.72e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4132509	0.779	rs10737888	chr1:243678483	A/C	cg25706552	chr1:244017396	NA	0.48	6.9	0.4	4.27e-11	RR interval (heart rate);
KIRP	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12826209	chr6:26865740	GUSBL1	0.69	6.54	0.38	3.57e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg23307798	chr14:103986281	CKB	0.48	5.26	0.32	3.21e-7	Coronary artery disease;
KIRP	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.84	-0.45	1.39e-13	Retinal vascular caliber;
KIRP	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.57	6.89	0.4	4.54e-11	Osteoporosis;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.71	10.17	0.54	1.6e-20	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg05072774	chr3:49840536	C3orf54	-0.41	-5.37	-0.32	1.86e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-5.97	-0.36	8.37e-9	Type 2 diabetes;
KIRP	cis	rs62103177	0.733	rs80114941	chr18:77671740	G/A	cg20368463	chr18:77673604	PQLC1	0.82	7.47	0.43	1.37e-12	Opioid sensitivity;
KIRP	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg08131204	chr22:41487073	MIR1281	-0.44	-5.15	-0.31	5.35e-7	Neuroticism;
KIRP	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.82	-0.35	1.8e-8	Pulmonary function;
KIRP	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.34	-0.32	2.15e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.99	0.36	7.39e-9	Total cholesterol levels;
KIRP	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.55	7.57	0.43	7.46e-13	Tuberculosis;
KIRP	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-6.61	-0.39	2.43e-10	Colorectal cancer;
KIRP	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.78	-8.9	-0.49	1.21e-16	Platelet count;
KIRP	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg01097406	chr16:89675127	NA	0.51	9.17	0.5	1.94e-17	Vitiligo;
KIRP	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.66	-9.29	-0.51	8.28e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs909341	0.868	rs6089961	chr20:62349491	G/A	cg11503966	chr20:62272292	STMN3	-0.43	-6.17	-0.37	2.83e-9	Atopic dermatitis;
KIRP	trans	rs2856321	0.874	rs762717	chr12:11868570	G/T	cg10155026	chr12:4553029	FGF6	0.44	6.39	0.38	8.08e-10	Height;
KIRP	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.42	5.08	0.31	7.4e-7	Colorectal cancer;
KIRP	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.8	12.38	0.62	1.1e-27	Testicular germ cell tumor;
KIRP	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.47	-0.33	1.09e-7	Ileal carcinoids;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21620778	chr2:175548020	WIPF1	0.47	7.51	0.43	1.08e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg16141378	chr3:129829833	LOC729375	0.5	6.51	0.38	4.14e-10	Retinal vascular caliber;
KIRP	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-9.15	-0.5	2.21e-17	Total body bone mineral density;
KIRP	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.56	-6.55	-0.39	3.26e-10	Initial pursuit acceleration;
KIRP	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg14391382	chr7:866102	UNC84A	0.54	6.88	0.4	4.8e-11	Subjective well-being;
KIRP	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.34	0.42	3.09e-12	Rheumatoid arthritis;
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.77	-0.44	2.16e-13	Platelet count;
KIRP	cis	rs2150410	0.915	rs68069991	chr21:40516501	T/G	cg11890956	chr21:40555474	PSMG1	-0.77	-5.55	-0.33	7.25e-8	Temperament (bipolar disorder);
KIRP	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.92	0.66	7.08e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg26205652	chr12:48591994	NA	-0.48	-5.25	-0.32	3.26e-7	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08491221	chr17:27717337	TAOK1	0.48	6.09	0.36	4.28e-9	Parkinson's disease;
KIRP	trans	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg08400319	chr2:242004533	SNED1	0.48	6.25	0.37	1.81e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.81	-0.4	7.49e-11	Neuroticism;
KIRP	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.81	0.4	7.36e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-6.99	-0.41	2.65e-11	Systemic lupus erythematosus;
KIRP	cis	rs2290402	0.536	rs2335172	chr4:855282	G/A	cg00846425	chr4:957561	DGKQ	-0.48	-5.28	-0.32	2.87e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.46	5.84	0.35	1.65e-8	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04109349	chr1:245317172	KIF26B	0.51	6.43	0.38	6.64e-10	Smoking initiation;
KIRP	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.22	-6.08	-0.36	4.51e-9	Coronary artery disease;
KIRP	cis	rs17067123	0.614	rs6813463	chr4:180068739	A/T	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	4.96	0.3	1.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6693295	0.536	rs2788013	chr1:246241892	C/T	cg11798871	chr1:246315928	SMYD3	-0.66	-6.99	-0.41	2.59e-11	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg09873164	chr1:152488093	CRCT1	-0.52	-6.53	-0.38	3.72e-10	Hair morphology;
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.45	-5.38	-0.32	1.74e-7	Longevity;Endometriosis;
KIRP	cis	rs11710088	0.931	rs6440617	chr3:149198926	A/C	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.43	-0.33	1.36e-7	QRS duration;
KIRP	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	0.97	10.34	0.55	4.94e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg14768367	chr16:72042858	DHODH	0.5	6.24	0.37	1.88e-9	Fibrinogen levels;
KIRP	cis	rs8032158	1.000	rs11632096	chr15:56210499	A/G	cg02198044	chr15:56286336	NEDD4	-0.45	-5.23	-0.32	3.68e-7	Keloid;
KIRP	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.05	0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72700829	0.593	rs7526955	chr1:150990913	C/G	cg15151059	chr1:150936875	SETDB1	-0.55	-4.93	-0.3	1.49e-6	Schizophrenia;
KIRP	cis	rs3134353	0.829	rs3105460	chr8:101937374	A/G	cg07585502	chr8:101912084	NA	-0.41	-5.13	-0.31	5.82e-7	Body mass index;
KIRP	trans	rs10853057	0.541	rs8076716	chr17:63048009	T/C	cg24886788	chr15:41118060	PPP1R14D	0.43	6.41	0.38	7.19e-10	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	10.7	0.56	3.45e-22	Nonalcoholic fatty liver disease;
KIRP	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.22e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg16898833	chr6:26189333	HIST1H4D	0.92	5.66	0.34	4.26e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7712401	0.601	rs386602	chr5:122321957	T/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.41	-0.33	1.51e-7	Mean platelet volume;
KIRP	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg06212747	chr3:49208901	KLHDC8B	0.59	5.68	0.34	3.84e-8	Menarche (age at onset);
KIRP	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.44	5.96	0.36	8.51e-9	Red blood cell count;
KIRP	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg10756647	chr7:56101905	PSPH	-0.93	-7.05	-0.41	1.82e-11	Gout;
KIRP	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.63	-9.48	-0.52	2.27e-18	Blood trace element (Cu levels);
KIRP	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg06223162	chr1:101003688	GPR88	0.41	8.16	0.46	1.69e-14	Monocyte count;
KIRP	trans	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.18	-0.37	2.7e-9	Bladder cancer;
KIRP	cis	rs6496044	0.568	rs1351196	chr15:86077404	T/C	cg10818794	chr15:86012489	AKAP13	-0.51	-7.14	-0.41	1.03e-11	Interstitial lung disease;
KIRP	cis	rs7236492	0.572	rs78124041	chr18:77181489	G/A	cg15644404	chr18:77186268	NFATC1	-1.01	-6.48	-0.38	4.95e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-7.55	-0.43	8.73e-13	Gut microbiome composition (summer);
KIRP	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg19847130	chr8:10466454	RP1L1	-0.34	-4.87	-0.3	1.96e-6	Retinal vascular caliber;
KIRP	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.86	-9.31	-0.51	7.52e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.59	-6.11	-0.36	3.8e-9	Pancreatic cancer;
KIRP	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.11	0.58	1.6e-23	Smoking behavior;
KIRP	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.24	0.42	5.84e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs62070183	0.938	rs9303654	chr17:31036765	G/A	cg05781649	chr17:31146240	MYO1D	-0.55	-5.68	-0.34	3.81e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg13180566	chr4:1052158	NA	-0.5	-5.07	-0.31	7.96e-7	Recombination rate (females);
KIRP	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.24	13.98	0.67	4.32e-33	Psoriasis vulgaris;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.48	-6.13	-0.36	3.48e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg11707556	chr5:10655725	ANKRD33B	0.67	8.44	0.47	2.8e-15	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.68	5.15	0.31	5.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4926611	0.698	rs10888795	chr1:54061446	A/G	cg08927728	chr1:54059983	GLIS1	-0.27	-6.06	-0.36	4.97e-9	Hand grip strength;
KIRP	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.47	-0.38	5.38e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	0.7	6.02	0.36	6.44e-9	Pediatric areal bone mineral density (radius);
KIRP	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.21	-0.37	2.3e-9	Aortic root size;
KIRP	cis	rs6005807	0.719	rs12168765	chr22:29033308	G/C	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4129585	0.665	rs10098073	chr8:143309504	A/C	cg16886403	chr8:143471632	TSNARE1	0.49	5.31	0.32	2.44e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4262150	0.810	rs72797251	chr5:152010999	G/A	cg12297329	chr5:152029980	NA	-0.67	-8.2	-0.46	1.38e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2279817	0.820	rs11203440	chr1:18026352	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.62	9.05	0.5	4.53e-17	Neuroticism;
KIRP	cis	rs4671458	0.948	rs17474666	chr2:63420517	T/C	cg17519650	chr2:63277830	OTX1	-0.57	-5.81	-0.35	1.88e-8	Subjective well-being;
KIRP	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.67	-7.21	-0.42	7.01e-12	Corneal structure;
KIRP	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.61	8.16	0.46	1.73e-14	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25152368	chr1:2985692	PRDM16;FLJ42875	0.44	6.39	0.38	8.4e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg08198773	chr8:1697536	NA	-0.49	-5.99	-0.36	7.56e-9	Systolic blood pressure;
KIRP	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.5	7.07	0.41	1.64e-11	Red blood cell count;
KIRP	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg25486957	chr4:152246857	NA	-0.45	-5.46	-0.33	1.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-8.73	-0.49	3.94e-16	Mean corpuscular volume;
KIRP	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.83	12.56	0.63	2.73e-28	Mean corpuscular volume;
KIRP	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.0	0.3	1.08e-6	Educational attainment;
KIRP	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg19743168	chr1:23544995	NA	0.5	6.94	0.4	3.39e-11	Height;
KIRP	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg04374321	chr14:90722782	PSMC1	0.92	15.39	0.7	6.94e-38	Mortality in heart failure;
KIRP	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg02820040	chr2:241836501	C2orf54	-0.24	-5.5	-0.33	9.33e-8	Urinary metabolites;
KIRP	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg16586182	chr3:47516702	SCAP	0.85	12.17	0.61	5.32e-27	Colorectal cancer;
KIRP	cis	rs6807915	0.624	rs7610451	chr3:12293739	G/A	cg15873301	chr3:12045459	SYN2	0.39	5.14	0.31	5.51e-7	Leprosy;
KIRP	cis	rs2594989	0.565	rs9848960	chr3:11601360	C/T	cg01796438	chr3:11312864	ATG7	0.39	4.86	0.3	2.14e-6	Circulating chemerin levels;
KIRP	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.46	-0.43	1.48e-12	Retinal vascular caliber;
KIRP	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs13102973	0.640	rs10434069	chr4:135840778	G/A	cg14419869	chr4:135874104	NA	0.5	8.24	0.46	1.06e-14	Subjective well-being;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16120422	chr12:113590924	CCDC42B	0.98	7.29	0.42	4.2e-12	P wave terminal force;
KIRP	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.98	-0.5	7.31e-17	Platelet count;
KIRP	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg04037228	chr3:45636386	LIMD1	-0.35	-5.1	-0.31	6.8e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs2635047	0.542	rs2668772	chr18:44770621	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.66	0.39	1.78e-10	Educational attainment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10652674	chr10:62023665	ANK3	-0.41	-6.21	-0.37	2.21e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.62	-0.56	6.04e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg10326726	chr10:51549505	MSMB	-0.6	-9.06	-0.5	4.08e-17	Prostate-specific antigen levels;
KIRP	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.3	0.58	4.05e-24	Cognitive test performance;
KIRP	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg03733263	chr8:22462867	KIAA1967	-0.8	-11.36	-0.59	2.61e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg13256891	chr4:100009986	ADH5	-0.46	-6.09	-0.36	4.34e-9	Alcohol dependence;
KIRP	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	16.03	0.71	4.6e-40	Colorectal cancer;
KIRP	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg02397686	chr17:73851076	WBP2	0.77	6.19	0.37	2.44e-9	Psoriasis;
KIRP	cis	rs2224391	0.822	rs36055504	chr6:5262230	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.72	-0.39	1.23e-10	Height;
KIRP	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.64	7.88	0.45	1.07e-13	Corneal astigmatism;
KIRP	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-1.06	-13.18	-0.64	2.33e-30	Exhaled nitric oxide output;
KIRP	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00376283	chr12:123451042	ABCB9	-0.63	-7.4	-0.43	2.1e-12	Neutrophil percentage of white cells;
KIRP	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.59	-7.22	-0.42	6.64e-12	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21823995	chr17:40729842	PSMC3IP	0.49	6.33	0.37	1.14e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg23985595	chr17:80112537	CCDC57	-0.34	-5.19	-0.31	4.45e-7	Life satisfaction;
KIRP	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs6504950	0.830	rs1802212	chr17:53038654	A/C	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.97	17.83	0.75	3.26e-46	Electrocardiographic conduction measures;
KIRP	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.2	-0.51	1.55e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.59	5.39	0.32	1.68e-7	Alzheimer's disease;
KIRP	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg07541023	chr7:19748670	TWISTNB	0.66	5.83	0.35	1.71e-8	Thyroid stimulating hormone;
KIRP	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg00500100	chr5:140098250	VTRNA1-2	0.42	5.44	0.33	1.31e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17123764	1.000	rs11169069	chr12:49966534	T/C	cg02054252	chr12:50078554	FMNL3	0.43	5.19	0.31	4.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.26	-0.37	1.69e-9	Cardiac Troponin-T levels;
KIRP	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.82	11.93	0.61	3.43e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg18200150	chr17:30822561	MYO1D	0.48	5.94	0.35	9.86e-9	Schizophrenia;
KIRP	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg05370193	chr1:21551575	ECE1	-0.36	-4.89	-0.3	1.78e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg26924012	chr15:45694286	SPATA5L1	0.85	12.43	0.62	7.78e-28	Homoarginine levels;
KIRP	cis	rs977987	0.872	rs2161648	chr16:75314629	T/G	cg03315344	chr16:75512273	CHST6	0.67	10.11	0.54	2.48e-20	Dupuytren's disease;
KIRP	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs2274273	0.624	rs7150763	chr14:55839801	A/G	cg04306507	chr14:55594613	LGALS3	0.37	5.34	0.32	2.1e-7	Protein biomarker;
KIRP	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.75	8.46	0.47	2.46e-15	Corneal astigmatism;
KIRP	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.97	-0.41	2.89e-11	Neuroticism;
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.45	6.04	0.36	5.66e-9	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.72	10.56	0.56	9.44e-22	Longevity;
KIRP	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.41	-4.92	-0.3	1.56e-6	IgG glycosylation;
KIRP	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.46	5.31	0.32	2.45e-7	Huntington's disease progression;
KIRP	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	1.08	9.24	0.51	1.2e-17	Blood protein levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07772309	chr9:140353475	NELF	-0.5	-6.23	-0.37	2.05e-9	Myopia;
KIRP	cis	rs300774	0.844	rs1810329	chr2:176395	A/T	cg21211680	chr2:198530	NA	0.56	5.9	0.35	1.2e-8	Suicide attempts in bipolar disorder;
KIRP	cis	rs4423214	0.559	rs10898228	chr11:71228358	A/T	cg05163923	chr11:71159392	DHCR7	-0.72	-7.07	-0.41	1.6e-11	Vitamin D levels;
KIRP	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.69	9.56	0.52	1.3e-18	Red blood cell count;
KIRP	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg00405596	chr8:11794950	NA	0.4	5.28	0.32	2.88e-7	Retinal vascular caliber;
KIRP	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.34	-0.37	1.07e-9	Daytime sleep phenotypes;
KIRP	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg07884673	chr3:53033167	SFMBT1	0.88	7.01	0.41	2.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.47	-6.18	-0.37	2.63e-9	Response to antidepressants and depression;
KIRP	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg11663144	chr21:46675770	NA	-0.55	-7.04	-0.41	1.91e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg04990556	chr1:26633338	UBXN11	-0.59	-7.34	-0.42	3.13e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg15448220	chr1:150897856	SETDB1	0.42	5.56	0.33	7.11e-8	Melanoma;
KIRP	trans	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg06521331	chr12:34319734	NA	-0.53	-6.31	-0.37	1.32e-9	Bladder cancer;
KIRP	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.19	0.37	2.46e-9	Mean platelet volume;
KIRP	cis	rs9815354	0.812	rs111277902	chr3:41950312	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg14983838	chr19:29218262	NA	0.73	7.06	0.41	1.66e-11	Methadone dose in opioid dependence;
KIRP	cis	rs1355223	0.573	rs7127169	chr11:34727846	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.13	-0.36	3.42e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.8	-6.87	-0.4	5.2e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.92	-10.15	-0.54	1.95e-20	Gut microbiome composition (summer);
KIRP	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.61	0.39	2.36e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.36	6.29	0.37	1.48e-9	Renal cell carcinoma;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	14.95	0.69	2.17e-36	Platelet count;
KIRP	trans	rs10462065	0.818	rs72750180	chr5:44052617	G/A	cg04689058	chr16:66953825	CDH16	0.6	6.06	0.36	5.01e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg16524936	chr4:1340807	KIAA1530	-0.44	-5.24	-0.32	3.44e-7	Obesity-related traits;
KIRP	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg24375607	chr4:120327624	NA	0.59	6.33	0.37	1.17e-9	Corneal astigmatism;
KIRP	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg02524346	chr8:600233	NA	0.64	4.87	0.3	2.03e-6	IgG glycosylation;
KIRP	cis	rs13102973	0.627	rs4435796	chr4:135883487	T/C	cg14419869	chr4:135874104	NA	0.35	5.02	0.3	9.85e-7	Subjective well-being;
KIRP	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs4654899	0.643	rs589755	chr1:21099846	A/G	cg08890418	chr1:21044141	KIF17	0.34	5.16	0.31	5.06e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.1	-0.36	4.1e-9	Alcohol dependence;
KIRP	cis	rs7577696	0.512	rs212691	chr2:32438075	G/A	cg02381751	chr2:32503542	YIPF4	0.62	6.05	0.36	5.4e-9	Inflammatory biomarkers;
KIRP	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.47	-5.0	-0.3	1.07e-6	Platelet distribution width;
KIRP	cis	rs13064411	0.735	rs2614191	chr3:113269201	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-5.59	-0.34	5.9e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg10701640	chr17:43249399	NA	0.47	9.85	0.53	1.65e-19	Height;
KIRP	cis	rs7116495	0.881	rs7924516	chr11:71667989	T/C	cg26138937	chr11:71823887	C11orf51	-0.71	-5.72	-0.34	3.08e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.62	5.12	0.31	6.07e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9323205	0.954	rs4258524	chr14:51638739	A/T	cg23942311	chr14:51606299	NA	-0.6	-7.4	-0.43	2.13e-12	Cancer;
KIRP	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.76	-12.01	-0.61	1.92e-26	Rheumatoid arthritis;
KIRP	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg25547332	chr5:131281432	NA	-0.47	-5.29	-0.32	2.64e-7	Life satisfaction;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg20274746	chr5:65221372	ERBB2IP	0.71	6.03	0.36	6.1e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg06740227	chr12:86229804	RASSF9	0.47	5.89	0.35	1.26e-8	Major depressive disorder;
KIRP	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg06935464	chr4:38784597	TLR10	0.53	5.27	0.32	2.96e-7	Breast cancer;
KIRP	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.67	-0.44	4.02e-13	Height;
KIRP	cis	rs737008	0.922	rs376374	chr16:11370616	G/A	cg00044050	chr16:11439710	C16orf75	-0.62	-7.48	-0.43	1.27e-12	Obesity-related traits;
KIRP	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-1.15	-14.96	-0.69	2.08e-36	Obesity-related traits;
KIRP	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.93	10.03	0.54	4.62e-20	Alzheimer's disease;
KIRP	cis	rs2224391	0.628	rs2753223	chr6:5244317	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.09	-0.36	4.32e-9	Height;
KIRP	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg16068336	chr17:48637367	CACNA1G	-0.4	-5.12	-0.31	6.28e-7	Type 2 diabetes;
KIRP	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.73	0.6	1.6e-25	Total body bone mineral density;
KIRP	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.24	-0.32	3.38e-7	Mean platelet volume;
KIRP	trans	rs12659622	0.764	rs891195	chr5:15605947	C/A	cg25746134	chr1:202129865	PTPN7	0.48	6.06	0.36	5.1e-9	Obesity-related traits;
KIRP	cis	rs12143943	0.966	rs12135707	chr1:204556223	C/T	cg20240347	chr1:204465584	NA	-0.36	-6.66	-0.39	1.82e-10	Cognitive performance;
KIRP	trans	rs2270927	0.510	rs4566771	chr5:75576522	C/T	cg13563193	chr19:33072644	PDCD5	0.94	6.8	0.4	7.85e-11	Mean corpuscular volume;
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	6.07	0.36	4.9e-9	Lung function (FEV1/FVC);
KIRP	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6684428	1.000	rs4130692	chr1:56345824	C/A	cg11651538	chr1:56320950	NA	-0.83	-10.09	-0.54	2.88e-20	Airflow obstruction;
KIRP	trans	rs12545912	0.710	rs10903317	chr8:9555907	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.26	-0.37	1.71e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-4.93	-0.3	1.54e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.92	-0.35	1.06e-8	Morning vs. evening chronotype;
KIRP	cis	rs6120849	0.901	rs6088738	chr20:33747331	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.04	-0.36	5.59e-9	Protein C levels;
KIRP	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	6.97	0.41	2.97e-11	Coronary artery disease;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.6e-6	Lung cancer;
KIRP	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.09	0.31	7.08e-7	Menopause (age at onset);
KIRP	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg18825076	chr15:78729989	IREB2	-0.42	-4.93	-0.3	1.53e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs6546324	0.625	rs4533457	chr2:67787348	T/G	cg15745817	chr2:67799979	NA	-0.66	-6.92	-0.4	3.95e-11	Endometriosis;
KIRP	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.43	5.4	0.33	1.55e-7	Platelet count;
KIRP	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg00507259	chr4:95128692	SMARCAD1	0.42	5.28	0.32	2.8e-7	QT interval;
KIRP	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg10189774	chr4:17578691	LAP3	0.45	5.55	0.33	7.45e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25328403	chr5:179159884	MAML1	-0.57	-6.17	-0.37	2.78e-9	Menopause (age at onset);
KIRP	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg05484376	chr2:27715224	FNDC4	0.38	6.28	0.37	1.55e-9	Total body bone mineral density;
KIRP	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.4	5.22	0.32	3.88e-7	Systemic lupus erythematosus;
KIRP	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	7.16	0.42	9.34e-12	LDL cholesterol;
KIRP	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg08501292	chr6:25962987	TRIM38	1.07	7.09	0.41	1.44e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg15655495	chr12:38532458	NA	-0.3	-5.2	-0.31	4.15e-7	Bladder cancer;
KIRP	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.73	-7.93	-0.45	7.76e-14	Gut microbiome composition (summer);
KIRP	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.39	7.83	0.45	1.45e-13	Multiple system atrophy;
KIRP	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.42	6.72	0.39	1.23e-10	Age at first birth;
KIRP	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg10253484	chr15:75165896	SCAMP2	0.53	5.72	0.34	3.15e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	10.69	0.56	3.67e-22	Platelet count;
KIRP	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg04837898	chr3:45731254	SACM1L	-0.35	-4.85	-0.3	2.24e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs12230513	0.732	rs61956303	chr12:55818071	C/A	cg19537932	chr12:55886519	OR6C68	-0.57	-7.08	-0.41	1.47e-11	Contrast sensitivity;
KIRP	cis	rs3737883	1.000	rs2270543	chr1:203030685	T/C	cg03900565	chr1:203031815	PPFIA4	0.41	6.1	0.36	4.04e-9	Early onset atrial fibrillation;
KIRP	cis	rs2970992	0.817	rs10176262	chr2:101335019	A/G	cg01042948	chr2:101319752	NA	-0.41	-5.95	-0.35	9.4e-9	Educational attainment;
KIRP	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.55	7.36	0.42	2.69e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.87	13.4	0.65	4.11e-31	Menarche (age at onset);
KIRP	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	6.18	0.37	2.67e-9	Menarche (age at onset);
KIRP	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.63	9.64	0.52	7.36e-19	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg17294928	chr15:75287854	SCAMP5	0.5	6.64	0.39	1.96e-10	Breast cancer;
KIRP	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.61	-8.92	-0.49	1.08e-16	Brugada syndrome;
KIRP	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg04731861	chr2:219085781	ARPC2	-0.27	-6.9	-0.4	4.46e-11	Colorectal cancer;
KIRP	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.76e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.88	-10.28	-0.55	7.29e-21	White matter hyperintensity burden;
KIRP	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.41	6.62	0.39	2.23e-10	Testicular germ cell tumor;
KIRP	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.54	-6.69	-0.39	1.5e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg11814155	chr7:99998594	ZCWPW1	0.59	5.49	0.33	9.86e-8	Lung function (FEV1/FVC);
KIRP	trans	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.23	-0.37	1.99e-9	Neuroticism;
KIRP	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg07068956	chr7:100330872	ZAN	-0.56	-6.11	-0.36	3.93e-9	Other erythrocyte phenotypes;
KIRP	cis	rs12986413	0.967	rs4807211	chr19:2174643	G/A	cg09261902	chr19:2140048	AP3D1	0.64	9.85	0.53	1.6e-19	Height;
KIRP	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg16141378	chr3:129829833	LOC729375	-0.58	-7.9	-0.45	9.31e-14	Mood instability;
KIRP	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.23	-0.32	3.7e-7	Coronary artery disease;
KIRP	cis	rs2273669	0.588	rs114414265	chr6:109306489	C/A	cg05315195	chr6:109294784	ARMC2	-0.63	-6.36	-0.38	1e-9	Prostate cancer;
KIRP	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.38	-0.38	8.75e-10	Retinal vascular caliber;
KIRP	cis	rs7534824	0.860	rs1983968	chr1:101606862	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	5.12	0.31	6.26e-7	Refractive astigmatism;
KIRP	cis	rs6593803	0.622	rs11585427	chr1:147168846	T/G	cg27546670	chr1:147246839	GJA5	-0.56	-5.56	-0.33	6.91e-8	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg25319279	chr11:5960081	NA	-0.62	-6.46	-0.38	5.65e-10	DNA methylation (variation);
KIRP	cis	rs13185784	0.667	rs4454029	chr5:179645325	C/T	cg02891314	chr5:179741120	GFPT2	0.47	4.91	0.3	1.68e-6	TRAIL levels;
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22168489	chr12:122356033	WDR66	0.66	9.77	0.53	2.92e-19	Mean corpuscular volume;
KIRP	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.3	0.47	6.87e-15	Motion sickness;
KIRP	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs17102423	0.929	rs4902363	chr14:65601689	T/G	cg11161011	chr14:65562177	MAX	-0.47	-5.91	-0.35	1.15e-8	Obesity-related traits;
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.78	8.29	0.47	7.59e-15	Lung function (FEV1/FVC);
KIRP	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.54	5.85	0.35	1.57e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.58	8.47	0.48	2.25e-15	Itch intensity from mosquito bite;
KIRP	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.85	-9.58	-0.52	1.13e-18	Cognitive test performance;
KIRP	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.49	-11.34	-0.59	2.9e-24	Diabetic kidney disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02787320	chr17:62103369	NA	0.45	6.04	0.36	5.78e-9	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	0.76	10.96	0.57	4.91e-23	Prudent dietary pattern;
KIRP	cis	rs6840360	0.642	rs1470281	chr4:152431552	A/G	cg25486957	chr4:152246857	NA	-0.42	-4.88	-0.3	1.89e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg01081584	chr15:40268610	EIF2AK4	-0.38	-5.16	-0.31	5.17e-7	Response to haloperidol in psychosis;
KIRP	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-8.46	-0.47	2.47e-15	Homocysteine levels;
KIRP	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg08378932	chr3:149191167	TM4SF4	-0.25	-4.93	-0.3	1.53e-6	Gallstone disease;
KIRP	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.43	5.73	0.34	2.96e-8	Birth weight;
KIRP	cis	rs6725041	0.547	rs59096325	chr2:213203853	C/T	cg16329650	chr2:213403929	ERBB4	-0.38	-4.96	-0.3	1.32e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.75	11.4	0.59	1.89e-24	Metabolite levels;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.57	-9.03	-0.5	5.17e-17	Lymphocyte counts;
KIRP	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg02569458	chr12:86230093	RASSF9	-0.36	-5.01	-0.3	1.05e-6	Major depressive disorder;
KIRP	cis	rs1318772	1.000	rs35451724	chr5:112683992	G/A	cg12552261	chr5:112820674	MCC	0.8	5.06	0.31	8.05e-7	F-cell distribution;
KIRP	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-1.07	-12.28	-0.62	2.4200000000000002e-27	Height;
KIRP	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg03468072	chr12:39539422	NA	0.41	5.95	0.35	9.1e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.42	4.91	0.3	1.68e-6	Aortic root size;
KIRP	cis	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.58	-0.39	2.84e-10	Monocyte percentage of white cells;
KIRP	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg22549504	chr19:17448937	GTPBP3	0.48	5.07	0.31	7.93e-7	Systemic lupus erythematosus;
KIRP	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.18	0.37	2.61e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6001982	0.748	rs10483206	chr22:40901345	C/T	cg07138101	chr22:40742427	ADSL	0.66	5.23	0.32	3.64e-7	Breast cancer;
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.13e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17373728	0.585	rs1912709	chr8:76178563	C/T	cg07016329	chr8:76221503	NA	0.49	5.87	0.35	1.42e-8	Diabetic kidney disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25441200	chr7:156742235	NOM1	0.67	7.98	0.45	5.56e-14	Smoking initiation;
KIRP	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.71	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	11.44	0.59	1.43e-24	Total body bone mineral density;
KIRP	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-7.0	-0.41	2.46e-11	Urinary uromodulin levels;
KIRP	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.88	7.3	0.42	3.93e-12	Obesity-related traits;
KIRP	cis	rs16828019	0.777	rs12047078	chr1:41462986	T/C	cg03387723	chr1:41708464	SCMH1	-0.75	-6.0	-0.36	6.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.64	-0.39	1.97e-10	Morning vs. evening chronotype;
KIRP	trans	rs10488029	0.607	rs6945803	chr7:37074752	G/C	cg22070462	chr2:26395155	FAM59B	0.46	6.03	0.36	6.01e-9	IgG glycosylation;
KIRP	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.74	-10.54	-0.56	1.1e-21	Alcohol dependence;
KIRP	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.54	5.53	0.33	8.27e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg12384639	chr17:618140	VPS53	0.47	5.92	0.35	1.05e-8	Prostate cancer;
KIRP	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.77	-8.01	-0.45	4.52e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4751006	0.543	rs61875505	chr10:128774635	A/G	cg05702161	chr10:128779687	DOCK1	-1.16	-9.47	-0.52	2.4e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.48	-5.66	-0.34	4.13e-8	Carotid intima media thickness;
KIRP	cis	rs6504340	0.739	rs1529334	chr17:46671792	C/T	cg05487507	chr17:46671861	LOC404266;HOXB5	-0.46	-5.78	-0.35	2.31e-8	Primary tooth development (number of teeth);
KIRP	cis	rs1497828	0.956	rs2815224	chr1:217529327	T/C	cg04411442	chr1:217543379	NA	-0.43	-6.58	-0.39	2.73e-10	Dialysis-related mortality;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg21348526	chr15:38647056	SPRED1	0.42	6.1	0.36	4.12e-9	Migraine with aura;
KIRP	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	1.2	6.88	0.4	5.04e-11	LDL cholesterol;
KIRP	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg00241281	chr14:105779794	PACS2	-0.37	-5.15	-0.31	5.41e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-10.59	-0.56	7.76e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg00343986	chr7:65444356	GUSB	-0.4	-4.99	-0.3	1.14e-6	Aortic root size;
KIRP	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg00677455	chr12:58241039	CTDSP2	0.55	6.11	0.36	3.94e-9	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26378593	chr2:128784793	SAP130	-0.55	-6.18	-0.37	2.7e-9	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs73200209	0.744	rs56911341	chr12:116682872	A/C	cg01776926	chr12:116560359	MED13L	-0.55	-6.19	-0.37	2.54e-9	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11057824	chr14:50471938	C14orf182	-0.45	-6.48	-0.38	5.06e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.9	10.58	0.56	8.39e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg26681399	chr22:41777847	TEF	0.54	5.24	0.32	3.49e-7	Vitiligo;
KIRP	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg04362960	chr10:104952993	NT5C2	0.7	7.94	0.45	6.99e-14	Arsenic metabolism;
KIRP	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.02	-0.36	6.18e-9	Response to antipsychotic treatment;
KIRP	cis	rs7561273	0.586	rs6545264	chr2:24310105	A/G	cg20701182	chr2:24300061	SF3B14	0.47	5.81	0.35	1.94e-8	Quantitative traits;
KIRP	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.5	-0.43	1.16e-12	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12973168	chr19:38865653	PSMD8	0.54	6.88	0.4	5e-11	Parkinson's disease;
KIRP	cis	rs2916247	0.954	rs10808644	chr8:93127873	C/T	cg10183463	chr8:93005414	RUNX1T1	0.41	5.05	0.31	8.55e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg17306686	chr7:157230923	NA	0.48	7.06	0.41	1.73e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg05370193	chr1:21551575	ECE1	0.42	5.98	0.36	7.99e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-10.18	-0.54	1.54e-20	Retinal vascular caliber;
KIRP	cis	rs17023223	0.581	rs2765529	chr1:119581900	C/T	cg05756136	chr1:119680316	WARS2	-0.57	-7.72	-0.44	2.85e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg24812749	chr6:127587940	RNF146	0.47	6.09	0.36	4.36e-9	Breast cancer;
KIRP	cis	rs7221595	0.877	rs35321558	chr17:3892909	G/A	cg11204139	chr17:3907470	NA	0.57	5.66	0.34	4.13e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-7.57	-0.43	7.68e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.98e-7	Body mass index;
KIRP	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	13.07	0.64	5.42e-30	Tonsillectomy;
KIRP	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg08885076	chr2:99613938	TSGA10	-0.49	-6.04	-0.36	5.68e-9	Chronic sinus infection;
KIRP	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.21	0.72	1.05e-40	Electrocardiographic conduction measures;
KIRP	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg18944383	chr4:111397179	ENPEP	0.43	7.02	0.41	2.19e-11	Height;
KIRP	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.24	0.37	1.95e-9	Aortic root size;
KIRP	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.64	7.19	0.42	7.9e-12	Vitiligo;
KIRP	trans	rs10242455	0.702	rs28460612	chr7:98993205	C/G	cg09045935	chr12:6379348	NA	0.87	6.11	0.36	3.81e-9	Blood metabolite levels;
KIRP	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.65	-9.5	-0.52	2.02e-18	Dupuytren's disease;
KIRP	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.69	-8.56	-0.48	1.25e-15	Schizophrenia;
KIRP	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	8.7	0.49	4.89e-16	Platelet distribution width;
KIRP	cis	rs13102973	0.682	rs7691622	chr4:135889689	T/C	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	9.76	0.53	3.13e-19	Total body bone mineral density;
KIRP	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs918629	0.761	rs3777175	chr5:95277555	A/G	cg16656078	chr5:95278638	ELL2	-0.51	-7.41	-0.43	2.03e-12	IgG glycosylation;
KIRP	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg22732515	chr19:44031385	ETHE1	0.65	9.26	0.51	1.06e-17	Fractional exhaled nitric oxide (childhood);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00110687	chr17:80989065	B3GNTL1	-0.53	-7.61	-0.44	6.01e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.21	-0.32	4.04e-7	Bladder cancer;
KIRP	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.25	-0.42	5.28e-12	Bone mineral density;
KIRP	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.92	-12.35	-0.62	1.4e-27	Cognitive function;
KIRP	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.6	0.48	9.32e-16	Motion sickness;
KIRP	trans	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	9.05	0.5	4.52e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10642240	chr5:139126512	NA	0.46	6.37	0.38	9.42e-10	Parkinson's disease;
KIRP	cis	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg03511173	chr18:77590860	NA	-0.53	-6.4	-0.38	7.92e-10	Opioid sensitivity;
KIRP	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.48	-0.33	1.07e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.18	0.37	2.69e-9	Neuroticism;
KIRP	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19717773	chr7:2847554	GNA12	-0.38	-5.65	-0.34	4.41e-8	Height;
KIRP	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg26681399	chr22:41777847	TEF	0.51	5.19	0.31	4.41e-7	Vitiligo;
KIRP	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg19847130	chr8:10466454	RP1L1	0.4	5.87	0.35	1.44e-8	Retinal vascular caliber;
KIRP	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.63	6.97	0.41	2.92e-11	Aortic root size;
KIRP	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.92	-0.4	4e-11	Blood pressure;
KIRP	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	4.94	0.3	1.45e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg25486957	chr4:152246857	NA	-0.43	-5.01	-0.3	1.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg07796016	chr1:152779584	LCE1C	-0.44	-5.61	-0.34	5.51e-8	Inflammatory skin disease;
KIRP	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg02023728	chr11:77925099	USP35	0.3	5.13	0.31	5.83e-7	Alzheimer's disease (survival time);
KIRP	cis	rs78761021	0.720	rs55740146	chr17:9796599	G/A	cg26853458	chr17:9805074	RCVRN	0.52	5.05	0.31	8.81e-7	Type 2 diabetes;
KIRP	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg17279839	chr7:150038598	RARRES2	0.43	5.96	0.36	8.84e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.15	10.32	0.55	5.43e-21	Diabetic kidney disease;
KIRP	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.98	-16.75	-0.73	1.5e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg15655495	chr12:38532458	NA	-0.28	-5.09	-0.31	7.19e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12120353	0.529	rs55956326	chr1:4623889	C/T	cg11735846	chr1:4770935	AJAP1	-0.69	-6.13	-0.36	3.48e-9	Anxiety disorder;
KIRP	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18867708	chr6:26865862	GUSBL1	0.46	5.73	0.34	2.85e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg27205649	chr11:78285834	NARS2	0.62	7.38	0.43	2.44e-12	Alzheimer's disease (survival time);
KIRP	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.74	6.88	0.4	4.92e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg13293535	chr8:11597251	GATA4	0.38	4.9	0.3	1.77e-6	Retinal vascular caliber;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.72	6.94	0.4	3.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg18586891	chr4:952366	TMEM175	0.63	5.25	0.32	3.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg15103426	chr22:29168792	CCDC117	0.54	5.71	0.34	3.2e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	trans	rs7863100	0.711	rs13287935	chr9:18650766	G/A	cg13196806	chr10:133996309	JAKMIP3	0.6	6.11	0.36	3.93e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs3784262	0.740	rs12910267	chr15:58374603	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.41	-5.52	-0.33	8.71e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.36	7.09	0.41	1.41e-11	Cisplatin-induced ototoxicity;
KIRP	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.42	-5.11	-0.31	6.45e-7	Resting heart rate;
KIRP	cis	rs12049351	0.774	rs34405887	chr1:229618634	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.57	-0.33	6.58e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.17	-0.37	2.86e-9	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg23479056	chr15:41276147	INO80	-0.39	-5.27	-0.32	2.93e-7	Menopause (age at onset);
KIRP	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg05527609	chr1:210001259	C1orf107	-0.6	-6.66	-0.39	1.82e-10	Red blood cell count;
KIRP	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg17507749	chr15:85114479	UBE2QP1	0.81	8.33	0.47	5.59e-15	Schizophrenia;
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-8.88	-0.49	1.48e-16	Lymphocyte counts;
KIRP	cis	rs35883536	1.000	rs1577504	chr1:101123913	A/T	cg06223162	chr1:101003688	GPR88	0.34	6.97	0.41	2.96e-11	Monocyte count;
KIRP	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.29	0.37	1.47e-9	Homocysteine levels;
KIRP	cis	rs9815354	1.000	rs1615543	chr3:41906404	C/T	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4908768	0.859	rs12131717	chr1:8718085	G/A	cg25722041	chr1:8623473	RERE	0.78	9.18	0.51	1.8e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7224685	0.569	rs12452393	chr17:3985427	G/A	cg09695851	chr17:3907499	NA	0.59	5.66	0.34	4.17e-8	Type 2 diabetes;
KIRP	cis	rs4762326	1.000	rs6538618	chr12:95611185	T/C	cg07737802	chr12:95537812	FGD6	0.47	6.6	0.39	2.49e-10	Endometriosis;
KIRP	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.99	10.52	0.56	1.32e-21	Exhaled nitric oxide output;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19850565	chr19:35168394	ZNF302	0.53	6.57	0.39	3.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.42e-11	Schizophrenia;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.8	-9.76	-0.53	3.21e-19	Longevity;Endometriosis;
KIRP	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs501120	0.564	rs2624682	chr10:44678240	C/T	cg09554077	chr10:44749378	NA	0.51	6.78	0.4	8.66e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg18825076	chr15:78729989	IREB2	-0.45	-5.34	-0.32	2.08e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs7651039	0.641	rs2455916	chr3:15667383	C/T	cg16303742	chr3:15540471	COLQ	0.6	7.96	0.45	6.19e-14	Coronary heart disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12723191	chr1:186429967	PDC;MIR548F1	-0.42	-6.69	-0.39	1.46e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18252515	chr7:66147081	NA	-0.46	-5.45	-0.33	1.2e-7	Aortic root size;
KIRP	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	8.56	0.48	1.28e-15	Response to antipsychotic treatment;
KIRP	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-6.16	-0.37	3.02e-9	Breast cancer;
KIRP	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.62	-0.34	5.11e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs798766	0.953	rs13123646	chr4:1740539	T/C	cg07775547	chr4:1625484	NA	-0.44	-5.19	-0.31	4.34e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21545522	chr1:205238299	TMCC2	0.41	5.54	0.33	7.73e-8	Red blood cell count;
KIRP	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg21253087	chr9:139290292	SNAPC4	0.46	6.54	0.38	3.5e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg16255804	chr6:135334527	HBS1L	0.33	5.14	0.31	5.56e-7	Red blood cell count;
KIRP	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg16141378	chr3:129829833	LOC729375	0.61	8.28	0.47	7.95e-15	Triglycerides;
KIRP	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.45e-7	Alzheimer's disease (survival time);
KIRP	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.48	-0.48	2.11e-15	Coronary artery disease;
KIRP	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg02187348	chr16:89574699	SPG7	0.44	5.56	0.33	7.1e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs73320584	0.518	rs1539719	chr10:92434734	A/G	cg14313238	chr10:92632228	RPP30	0.58	5.07	0.31	8e-7	Alzheimer disease and age of onset;
KIRP	cis	rs3799379	0.550	rs2072804	chr6:26391190	G/A	cg12826209	chr6:26865740	GUSBL1	0.45	5.6	0.34	5.83e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22925553	chr4:141471760	ELMOD2	-0.46	-6.87	-0.4	5.36e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.62	8.3	0.47	6.78e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.19	0.31	4.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.54	7.26	0.42	4.95e-12	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
KIRP	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	9.31	0.51	7.37e-18	Lymphocyte counts;
KIRP	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.06	-9.18	-0.51	1.8e-17	Body mass index;
KIRP	cis	rs12362504	0.532	rs7930281	chr11:9927980	C/G	cg07197493	chr11:9884649	SBF2	0.39	5.13	0.31	6.02e-7	Survival in pancreatic cancer;
KIRP	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg08975724	chr8:8085496	FLJ10661	0.61	7.62	0.44	5.42e-13	Retinal vascular caliber;
KIRP	trans	rs921874	0.586	rs2513233	chr11:86767279	C/T	cg22937172	chr2:240168862	HDAC4	0.5	6.47	0.38	5.31e-10	Total body bone mineral density;
KIRP	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.68	-8.77	-0.49	3.05e-16	Vitiligo;
KIRP	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.11	-0.31	6.56e-7	Mean platelet volume;
KIRP	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.78	10.82	0.57	1.41e-22	Longevity;
KIRP	cis	rs2814331	0.596	rs2814348	chr10:88008094	C/T	cg02632490	chr10:88024529	MIR346;GRID1	-0.4	-5.43	-0.33	1.36e-7	Balding;
KIRP	cis	rs16912285	0.688	rs7109312	chr11:24338974	G/A	ch.11.24196551F	chr11:24239977	NA	0.66	5.89	0.35	1.26e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05733554	chr14:58618292	C14orf37	0.5	6.14	0.36	3.27e-9	Lung cancer in ever smokers;
KIRP	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg16989719	chr2:238392110	NA	-0.55	-7.62	-0.44	5.61e-13	Prostate cancer;
KIRP	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs7072216	0.843	rs2296441	chr10:100144782	C/T	cg19567339	chr10:100142640	NA	0.56	6.1	0.36	4.05e-9	Metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04316673	chr1:52552850	BTF3L4	-0.43	-6.41	-0.38	7.27e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg02336718	chr17:17403227	NA	-0.37	-5.66	-0.34	4.31e-8	Total body bone mineral density;
KIRP	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.92	11.01	0.57	3.41e-23	Menarche (age at onset);
KIRP	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg06042504	chr8:55087323	NA	-0.54	-6.58	-0.39	2.86e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg02297831	chr4:17616191	MED28	-0.52	-5.52	-0.33	8.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.37	-6.67	-0.39	1.68e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	trans	rs6687487	0.929	rs17487259	chr1:23063163	G/A	cg06734993	chr19:41946601	ATP5SL	-0.66	-6.03	-0.36	6.1e-9	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26671050	chr13:94207303	GPC6	0.36	6.1	0.36	4.13e-9	Survival in pancreatic cancer;
KIRP	cis	rs7932354	0.682	rs7118404	chr11:46908730	G/A	cg16389345	chr11:46697382	NA	0.43	5.33	0.32	2.21e-7	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.68	-7.76	-0.44	2.27e-13	Testicular germ cell tumor;
KIRP	cis	rs6539288	0.513	rs7977247	chr12:107259470	T/C	cg21360079	chr12:107162445	NA	-0.57	-8.32	-0.47	6.02e-15	Total body bone mineral density;
KIRP	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg15556689	chr8:8085844	FLJ10661	0.58	7.58	0.44	7.01e-13	Retinal vascular caliber;
KIRP	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.5	5.85	0.35	1.59e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.75	-8.23	-0.46	1.1e-14	Coronary artery disease;
KIRP	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg24315340	chr6:146058215	EPM2A	0.39	4.91	0.3	1.66e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26410557	chr11:18610422	UEVLD	0.42	6.15	0.37	3.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.64e-13	Corneal astigmatism;
KIRP	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.96	0.3	1.29e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg16235748	chr6:149772707	ZC3H12D	0.3	5.0	0.3	1.07e-6	Dupuytren's disease;
KIRP	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16346588	chr10:242978	ZMYND11	0.46	5.57	0.33	6.66e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.83	13.78	0.66	2.15e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs4889855	0.585	rs17848706	chr17:78704618	G/T	cg09596252	chr17:78655493	RPTOR	-0.56	-5.81	-0.35	1.9e-8	Fractional excretion of uric acid;
KIRP	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	IgG glycosylation;
KIRP	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.38	8.0	0.45	4.78e-14	Body mass index;
KIRP	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg02297831	chr4:17616191	MED28	0.54	6.81	0.4	7.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg15655495	chr12:38532458	NA	-0.28	-5.05	-0.31	8.72e-7	Heart rate;
KIRP	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg18694418	chr7:2742484	AMZ1	0.44	4.98	0.3	1.22e-6	Height;
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.48	-8.68	-0.48	5.47e-16	Lung cancer;
KIRP	cis	rs2562456	0.833	rs2650801	chr19:21635355	C/T	cg00806126	chr19:22604979	ZNF98	-0.63	-6.64	-0.39	1.96e-10	Pain;
KIRP	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg11382394	chr1:2564504	MMEL1	-0.38	-4.87	-0.3	2.02e-6	Ulcerative colitis;
KIRP	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.75	9.63	0.52	7.84e-19	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.2	0.46	1.37e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.59	-8.34	-0.47	5.2e-15	Calcium levels;
KIRP	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.5	-7.2	-0.42	7.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs35113840	1	rs35113840	chr2:239101656	G/GA	cg17459225	chr2:239074497	NA	0.77	9.4	0.51	3.86e-18	Red cell distribution width;
KIRP	cis	rs600806	0.850	rs10858086	chr1:109915075	C/A	cg02175308	chr1:109941060	SORT1	-0.26	-4.93	-0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9403317	1.000	rs9403314	chr6:141831351	A/G	cg15052665	chr6:141804349	NA	-0.43	-5.26	-0.32	3.21e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9314323	0.592	rs6981737	chr8:26271100	T/G	cg13160058	chr8:26243215	BNIP3L	-0.45	-6.96	-0.41	3.01e-11	Red cell distribution width;
KIRP	cis	rs4849845	0.889	rs3931840	chr2:121041347	A/C	cg24070213	chr2:121070622	NA	0.38	5.31	0.32	2.46e-7	Mean platelet volume;
KIRP	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg14696996	chr19:15285081	NOTCH3	0.67	7.28	0.42	4.52e-12	Pulse pressure;
KIRP	cis	rs11225247	0.764	rs79028911	chr11:102262449	T/C	cg06323957	chr11:102217781	BIRC2	0.97	6.06	0.36	5.05e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg00376283	chr12:123451042	ABCB9	-0.61	-6.34	-0.37	1.12e-9	Neutrophil percentage of white cells;
KIRP	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.15e-14	Neuroticism;
KIRP	trans	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg10756647	chr7:56101905	PSPH	0.99	6.96	0.41	3.07e-11	Diabetic kidney disease;
KIRP	cis	rs2019216	1.000	rs2019216	chr17:21909650	C/T	cg22648282	chr17:21454238	C17orf51	-0.4	-5.3	-0.32	2.62e-7	Pelvic organ prolapse;
KIRP	cis	rs9653442	0.564	rs4851261	chr2:100786717	A/G	cg17356467	chr2:100759845	AFF3	0.44	5.63	0.34	4.78e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.62	-0.39	2.27e-10	Urinary tract infection frequency;
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg21064579	chr19:49206444	FUT2	0.58	8.69	0.48	5.14e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs72627123	0.867	rs59675549	chr14:74469480	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.97	0.3	1.24e-6	Morning vs. evening chronotype;
KIRP	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg15556689	chr8:8085844	FLJ10661	0.57	6.62	0.39	2.26e-10	Systemic lupus erythematosus;
KIRP	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.88	-0.66	9.89e-33	Chronic sinus infection;
KIRP	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg20991723	chr1:152506922	NA	-0.46	-5.5	-0.33	9.59e-8	Hair morphology;
KIRP	cis	rs7709377	0.597	rs10042177	chr5:115467535	G/A	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.04	8.02	0.46	4.31e-14	Skin colour saturation;
KIRP	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg18595228	chr15:67193261	NA	0.58	6.27	0.37	1.64e-9	Lung cancer (smoking interaction);
KIRP	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.32e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.99	17.53	0.75	3.31e-45	Breast cancer;
KIRP	cis	rs56161922	1.000	rs12567945	chr1:207841934	T/C	cg11752769	chr1:207818423	CR1L	-0.77	-5.03	-0.31	9.67e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.55	-0.39	3.34e-10	Joint mobility (Beighton score);
KIRP	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg08975724	chr8:8085496	FLJ10661	0.8	10.38	0.55	3.58e-21	Mood instability;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09315329	chr13:21141066	IFT88	0.43	6.15	0.37	3.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg23995753	chr2:160760732	LY75	-0.38	-5.04	-0.31	8.83e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs909341	0.680	rs2427534	chr20:62366478	A/G	cg11503966	chr20:62272292	STMN3	-0.42	-5.81	-0.35	1.97e-8	Atopic dermatitis;
KIRP	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21643547	chr1:205240462	TMCC2	-0.68	-10.32	-0.55	5.77e-21	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12931682	chr2:149895553	LYPD6B	0.48	6.84	0.4	6.15e-11	Parkinson's disease;
KIRP	cis	rs9928842	0.882	rs11641896	chr16:75300179	T/C	cg09066997	chr16:75300724	BCAR1	0.63	5.37	0.32	1.78e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.46	-9.35	-0.51	5.55e-18	Longevity;
KIRP	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg24441899	chr7:4244372	SDK1	0.51	7.31	0.42	3.81e-12	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12685995	chr10:126849062	CTBP2	0.48	6.43	0.38	6.63e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.86	8.6	0.48	9.56e-16	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg13414629	chr9:132935646	FREQ	0.52	6.83	0.4	6.76e-11	Alzheimer's disease (cognitive decline);
KIRP	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg20965017	chr5:231967	SDHA	-0.61	-7.08	-0.41	1.52e-11	Breast cancer;
KIRP	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg18225595	chr11:63971243	STIP1	-0.57	-7.25	-0.42	5.25e-12	Platelet count;
KIRP	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg17182837	chr8:41585554	ANK1	0.48	5.14	0.31	5.5e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs55986470	0.670	rs11889825	chr2:239417445	A/G	cg18131467	chr2:239335373	ASB1	0.54	5.19	0.31	4.36e-7	Chronotype;
KIRP	cis	rs2625529	0.761	rs16956444	chr15:72271235	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-6.03	-0.36	6.06e-9	Red blood cell count;
KIRP	cis	rs7948661	1.000	rs7113994	chr11:118382327	A/G	cg06090739	chr11:118230722	UBE4A	0.74	5.11	0.31	6.56e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.73	-0.34	2.91e-8	Life satisfaction;
KIRP	cis	rs2223471	0.602	rs9296637	chr6:50695356	T/C	cg03432817	chr6:50765336	NA	-0.36	-5.44	-0.33	1.27e-7	Subcutaneous adipose tissue;
KIRP	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg18261050	chr1:119551319	NA	0.51	6.7	0.39	1.38e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.5	-0.33	9.71e-8	Pulmonary function;
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	7.84	0.45	1.4e-13	Lung function (FEV1/FVC);
KIRP	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg03711944	chr11:47377212	SPI1	-0.32	-5.17	-0.31	4.9e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs988913	0.619	rs3857606	chr6:54961364	A/G	cg03513858	chr6:54763001	FAM83B	-0.35	-5.0	-0.3	1.1e-6	Menarche (age at onset);
KIRP	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.4	-5.45	-0.33	1.25e-7	HIV-1 susceptibility;
KIRP	cis	rs1440410	0.835	rs4132266	chr4:144086245	G/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.53	0.48	1.55e-15	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg03342759	chr3:160939853	NMD3	-0.47	-5.71	-0.34	3.23e-8	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.76	-10.36	-0.55	4.28e-21	Longevity;Endometriosis;
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg23693289	chr8:27183097	PTK2B	0.55	7.03	0.41	1.97e-11	Neuroticism;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27042000	chr13:114898409	RASA3	-0.48	-6.44	-0.38	6.12e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.47	-0.33	1.12e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.59	-11.51	-0.59	8.26e-25	Diabetic kidney disease;
KIRP	trans	rs909341	0.818	rs67468102	chr20:62344883	G/C	cg01311341	chr22:25575246	KIAA1671	-0.63	-7.64	-0.44	4.95e-13	Atopic dermatitis;
KIRP	cis	rs13034020	0.790	rs72809405	chr2:61173382	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.59	4.91	0.3	1.69e-6	Hodgkin's lymphoma;
KIRP	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	8.18	0.46	1.56e-14	Educational attainment;
KIRP	cis	rs10875746	0.810	rs10875732	chr12:48442105	A/C	cg20731937	chr12:48336164	NA	0.41	5.21	0.31	4.09e-7	Longevity (90 years and older);
KIRP	cis	rs2591576	0.789	rs7700348	chr5:165415631	C/T	cg13976338	chr5:165423657	NA	-0.84	-13.09	-0.64	4.7e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.81	-12.43	-0.62	7.52e-28	Breast cancer;
KIRP	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.53	-6.87	-0.4	5.23e-11	High light scatter reticulocyte count;
KIRP	cis	rs4664293	0.867	rs11681245	chr2:160629393	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg23100626	chr2:96804247	ASTL	0.45	5.77	0.35	2.31e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg08992911	chr2:238395768	MLPH	0.43	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg22307297	chr20:60903441	LAMA5	0.43	4.9	0.3	1.75e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs13170463	0.579	rs35264036	chr5:8046792	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-13.25	-0.65	1.33e-30	Alzheimer's disease;
KIRP	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg14456004	chr13:21872349	NA	-1.09	-13.34	-0.65	6.36e-31	White matter hyperintensity burden;
KIRP	cis	rs981946	0.965	rs11759126	chr6:3369973	C/T	cg18842474	chr6:3356384	SLC22A23	-0.4	-4.99	-0.3	1.12e-6	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
KIRP	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg22029157	chr1:209979665	IRF6	0.5	6.52	0.38	3.86e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs72634258	0.554	rs13306061	chr1:7913445	C/T	cg00042356	chr1:8021962	PARK7	0.57	4.85	0.3	2.23e-6	Inflammatory bowel disease;
KIRP	cis	rs10073892	0.620	rs13355922	chr5:101936104	G/A	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.7	-0.34	3.41e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg18190219	chr22:46762943	CELSR1	-0.77	-7.84	-0.45	1.38e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	11.95	0.61	2.88e-26	Smoking behavior;
KIRP	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.81	11.37	0.59	2.34e-24	Breast cancer;
KIRP	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.22	-0.42	6.31e-12	Rheumatoid arthritis;
KIRP	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-6.22	-0.37	2.15e-9	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg04369109	chr6:150039330	LATS1	-0.52	-6.6	-0.39	2.47e-10	Lung cancer;
KIRP	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.38	-0.51	4.47e-18	Personality dimensions;
KIRP	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg03806693	chr22:41940476	POLR3H	0.45	5.4	0.33	1.53e-7	Neuroticism;
KIRP	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.91	-0.4	4.14e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.72	0.34	3.08e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.53	-8.81	-0.49	2.31e-16	Height;
KIRP	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.52	0.56	1.26e-21	Cognitive test performance;
KIRP	cis	rs9308731	0.583	rs7567184	chr2:111931072	C/G	cg04202892	chr2:111875749	ACOXL	0.48	6.58	0.39	2.82e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs4889855	0.530	rs72856551	chr17:78552267	G/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.4	-0.33	1.55e-7	Fractional excretion of uric acid;
KIRP	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.62	5.93	0.35	1.01e-8	Breast cancer;
KIRP	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.07	-0.31	7.87e-7	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.44	5.6	0.34	5.69e-8	Motion sickness;
KIRP	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.49	0.38	4.56e-10	Myopia (pathological);
KIRP	cis	rs7246967	0.673	rs35061555	chr19:22963766	T/C	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg08662619	chr6:150070041	PCMT1	0.37	6.14	0.36	3.33e-9	Lung cancer;
KIRP	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg19847130	chr8:10466454	RP1L1	0.36	5.4	0.33	1.55e-7	Triglycerides;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20916646	chr4:852691	GAK	0.52	6.27	0.37	1.57e-9	Sjögren's syndrome;
KIRP	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg26384229	chr12:38710491	ALG10B	0.71	9.83	0.53	1.93e-19	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08822215	chr16:89438651	ANKRD11	-0.43	-6.01	-0.36	6.72e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.37	5.46	0.33	1.17e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs42648	0.806	rs6951894	chr7:89893945	A/G	cg25739043	chr7:89950458	NA	-0.38	-5.55	-0.33	7.48e-8	Homocysteine levels;
KIRP	cis	rs490234	0.719	rs13296519	chr9:128471924	G/T	cg14078157	chr9:128172775	NA	-0.55	-6.52	-0.38	3.91e-10	Mean arterial pressure;
KIRP	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.87	10.13	0.54	2.16e-20	Osteoarthritis;
KIRP	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.74	7.43	0.43	1.82e-12	Bipolar disorder;
KIRP	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg16141378	chr3:129829833	LOC729375	-0.49	-6.55	-0.39	3.39e-10	Neuroticism;
KIRP	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg07148914	chr20:33460835	GGT7	0.49	6.0	0.36	7.06e-9	Height;
KIRP	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.49	-5.97	-0.36	8.2e-9	Breast cancer;
KIRP	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.68	10.41	0.55	2.84e-21	Blood metabolite ratios;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02303361	chr19:47354240	AP2S1	0.47	6.15	0.37	3.11e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg24324837	chr19:49891574	CCDC155	0.52	6.51	0.38	4.19e-10	Multiple sclerosis;
KIRP	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	trans	rs2352908	0.678	rs2352921	chr14:49467802	C/T	cg14470332	chr9:69180795	LOC440896	0.61	6.41	0.38	7.21e-10	Social communication problems;
KIRP	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs13034020	0.522	rs13017457	chr2:61248645	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.29	0.37	1.44e-9	Hodgkin's lymphoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08037059	chr1:90460796	LOC492303;ZNF326	0.48	6.22	0.37	2.12e-9	Parkinson's disease;
KIRP	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg24565620	chr2:194026	NA	0.6	6.51	0.38	4.21e-10	Blood protein levels;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.61	-8.32	-0.47	6.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.72	9.49	0.52	2.17e-18	Coronary artery disease;
KIRP	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.62	-6.78	-0.4	8.85e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19475689	chr2:28789802	PLB1	0.44	6.03	0.36	6.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-5.47	-0.33	1.12e-7	Cholesterol, total;
KIRP	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.89	0.4	4.76e-11	Menarche (age at onset);
KIRP	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg03808351	chr9:123631620	PHF19	0.47	6.5	0.38	4.48e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.54	7.61	0.44	5.84e-13	Dupuytren's disease;
KIRP	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg05802129	chr4:122689817	NA	-0.45	-6.05	-0.36	5.43e-9	Type 2 diabetes;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22024508	chr19:16771032	TMEM38A;C19orf42	0.49	6.45	0.38	5.89e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1978968	0.956	rs5992925	chr22:18447697	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.79	-0.4	8.23e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.19	-0.37	2.52e-9	Obesity-related traits;
KIRP	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.6e-10	Morning vs. evening chronotype;
KIRP	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.61	6.93	0.4	3.75e-11	Height;
KIRP	cis	rs62103177	0.683	rs13838	chr18:77663409	C/G	cg20368463	chr18:77673604	PQLC1	0.59	5.69	0.34	3.55e-8	Opioid sensitivity;
KIRP	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.55	-6.15	-0.36	3.2e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg18154014	chr19:37997991	ZNF793	-0.63	-6.84	-0.4	6.4e-11	Coronary artery calcification;
KIRP	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.64	-9.9	-0.53	1.19e-19	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09517106	chr1:198904195	NA	0.51	6.43	0.38	6.68e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs77669868	0.929	rs3782007	chr11:114066438	A/G	cg01914181	chr11:114070210	ZBTB16	-0.55	-5.73	-0.34	2.93e-8	Monocyte percentage of white cells;
KIRP	trans	rs1106684	1.000	rs1477226	chr7:131455364	C/T	cg13607082	chr12:122652224	LRRC43	0.59	6.81	0.4	7.41e-11	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09218510	chr4:25005684	LGI2	0.45	6.33	0.37	1.18e-9	Interleukin-4 levels;
KIRP	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.51	7.34	0.42	3.08e-12	Testicular germ cell tumor;
KIRP	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg23594656	chr7:65796392	TPST1	0.53	8.32	0.47	6.23e-15	Aortic root size;
KIRP	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg18944383	chr4:111397179	ENPEP	-0.69	-12.79	-0.63	4.57e-29	Coronary artery disease;
KIRP	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.72	0.34	3.1e-8	Putamen volume;
KIRP	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.6	8.5	0.48	1.91e-15	Multiple system atrophy;
KIRP	cis	rs9815354	1.000	rs6599179	chr3:41855284	C/T	cg03022575	chr3:42003672	ULK4	0.5	5.83	0.35	1.75e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	cg12689670	chr1:183009347	LAMC1	0.46	6.6	0.39	2.49e-10	Colorectal cancer;
KIRP	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.79	11.29	0.58	4.31e-24	Bladder cancer;
KIRP	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.31	0.55	6.14e-21	Coffee consumption (cups per day);
KIRP	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg09873164	chr1:152488093	CRCT1	0.46	5.28	0.32	2.78e-7	Hair morphology;
KIRP	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-10.08	-0.54	3.14e-20	Body mass index;
KIRP	cis	rs4523957	0.583	rs2760745	chr17:2035591	T/C	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg27494647	chr7:150038898	RARRES2	0.39	5.78	0.35	2.27e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs35955747	0.714	rs4820048	chr22:31854370	A/G	cg02404636	chr22:31891804	SFI1	-0.38	-5.08	-0.31	7.64e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg23594656	chr7:65796392	TPST1	-0.47	-7.53	-0.43	9.42e-13	Aortic root size;
KIRP	cis	rs490234	0.676	rs4838264	chr9:128225561	T/C	cg14078157	chr9:128172775	NA	-0.63	-7.45	-0.43	1.59e-12	Mean arterial pressure;
KIRP	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.76	9.68	0.53	5.56e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17325476	chr1:2201246	SKI	0.56	6.47	0.38	5.31e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg23479056	chr15:41276147	INO80	-0.41	-6.02	-0.36	6.35e-9	Menopause (age at onset);
KIRP	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	10.04	0.54	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03558682	chr13:38928157	UFM1	-0.44	-6.3	-0.37	1.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16576597	chr16:28551801	NUPR1	-0.35	-5.4	-0.33	1.6e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg14250997	chr9:106856677	SMC2	0.43	5.93	0.35	1.03e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	0.96	10.34	0.55	4.86e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.66	-9.01	-0.5	5.86e-17	Longevity;
KIRP	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.66	6.68	0.39	1.62e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.6	-0.34	5.67e-8	HDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10006235	chr11:49226370	FOLH1	-0.39	-6.41	-0.38	7.29e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg12315302	chr6:26189340	HIST1H4D	1.07	6.38	0.38	8.79e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	0.957	rs2053601	chr22:18448605	G/C	cg03078520	chr22:18463400	MICAL3	-0.64	-7.57	-0.43	7.6e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs2839627	0.561	rs2839601	chr21:44317381	A/G	cg03543861	chr21:44258195	NA	0.55	5.97	0.36	8.19e-9	Information processing speed;
KIRP	cis	rs7590368	0.715	rs7587453	chr2:10961390	A/G	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.05	-0.36	5.29e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs763014	0.966	rs15564	chr16:677854	G/T	cg00950418	chr7:105029125	SRPK2	-0.52	-6.61	-0.39	2.43e-10	Height;
KIRP	cis	rs12148477	0.523	rs1808141	chr15:51657431	G/A	cg25905881	chr15:51634250	GLDN	0.4	4.97	0.3	1.24e-6	Follicule stimulating hormone;
KIRP	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg19404215	chr3:33155277	CRTAP	0.65	5.31	0.32	2.46e-7	Major depressive disorder;
KIRP	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.43	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.2e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg13385521	chr17:29058706	SUZ12P	0.58	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs6973256	0.605	rs13237435	chr7:133347570	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.39	-0.38	8.11e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg26207909	chr14:103986467	CKB	-0.44	-5.38	-0.32	1.73e-7	Coronary artery disease;
KIRP	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.9	-0.3	1.74e-6	Resting heart rate;
KIRP	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg06935464	chr4:38784597	TLR10	0.53	5.32	0.32	2.36e-7	Breast cancer;
KIRP	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	5.9	0.35	1.17e-8	Renal cell carcinoma;
KIRP	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg06204229	chr3:52865917	ITIH4	-0.38	-5.7	-0.34	3.47e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.73	10.7	0.56	3.5e-22	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg01877450	chr7:97915802	BRI3	-0.55	-6.98	-0.41	2.68e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.63	7.03	0.41	2.06e-11	Neutrophil percentage of white cells;
KIRP	trans	rs7246760	0.867	rs1115825	chr19:9786121	C/G	cg02900749	chr2:68251473	NA	-1.16	-9.53	-0.52	1.56e-18	Pursuit maintenance gain;
KIRP	cis	rs1847505	0.609	rs717049	chr13:61497129	C/T	cg25164009	chr13:61490935	NA	0.54	5.61	0.34	5.37e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.47	6.41	0.38	7.43e-10	Coronary artery disease;
KIRP	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg00204512	chr16:28754710	NA	0.39	4.86	0.3	2.06e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.61	9.95	0.54	7.82e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11490986	chr7:143599184	FAM115A	0.49	6.16	0.37	2.92e-9	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.09	-0.36	4.29e-9	Menarche (age at onset);
KIRP	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.05	-0.61	1.37e-26	Alzheimer's disease;
KIRP	cis	rs8033133	0.581	rs8042796	chr15:25327396	A/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.5	-6.39	-0.38	8.38e-10	Blood osmolality (transformed sodium);
KIRP	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	1.0	12.81	0.63	4.06e-29	Neutrophil percentage of white cells;
KIRP	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg18016565	chr1:150552671	MCL1	-0.37	-5.72	-0.34	3.13e-8	Tonsillectomy;
KIRP	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.92	-9.98	-0.54	6.51e-20	Schizophrenia;
KIRP	cis	rs2150410	0.915	rs971229	chr21:40652382	G/A	cg11890956	chr21:40555474	PSMG1	0.81	5.66	0.34	4.28e-8	Temperament (bipolar disorder);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04964845	chr14:60761524	PPM1A	0.4	6.41	0.38	7.55e-10	C-reactive protein;
KIRP	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg24565620	chr2:194026	NA	-0.72	-8.17	-0.46	1.63e-14	Blood protein levels;
KIRP	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.01	-7.57	-0.43	7.63e-13	Mitochondrial DNA levels;
KIRP	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg13206674	chr6:150067644	NUP43	0.51	7.18	0.42	8.04e-12	Testicular germ cell tumor;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-8.96	-0.5	8.24e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-0.53	-7.44	-0.43	1.68e-12	Coronary artery disease;
KIRP	cis	rs17095355	1.000	rs921348	chr10:111707498	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.39	-5.41	-0.33	1.47e-7	Biliary atresia;
KIRP	cis	rs7009516	0.669	rs13270982	chr8:24248552	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.32	-6.6	-0.39	2.55e-10	Hair greying;
KIRP	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg02175503	chr12:58329896	NA	0.56	6.04	0.36	5.64e-9	Multiple sclerosis;
KIRP	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg14893161	chr1:205819251	PM20D1	-0.44	-5.51	-0.33	9.07e-8	Menarche (age at onset);
KIRP	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.16	0.37	2.93e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.82	-0.53	2.04e-19	Gut microbiome composition (summer);
KIRP	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.14e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-5.11	-0.31	6.58e-7	Crohn's disease;
KIRP	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00761755	chr17:1531579	SLC43A2	0.6	7.26	0.42	5.12e-12	Smoking initiation;
KIRP	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8028182	0.636	rs8036758	chr15:75817562	G/A	cg20655648	chr15:75932815	IMP3	0.53	6.75	0.4	1.05e-10	Sudden cardiac arrest;
KIRP	cis	rs10267417	0.603	rs10244374	chr7:19863170	C/T	cg05791153	chr7:19748676	TWISTNB	0.56	5.26	0.32	3.17e-7	Night sleep phenotypes;
KIRP	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.88	-7.08	-0.41	1.49e-11	Breast cancer;
KIRP	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg00919237	chr7:87102261	ABCB4	-0.74	-9.19	-0.51	1.69e-17	Gallbladder cancer;
KIRP	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.42	-5.47	-0.33	1.11e-7	IgG glycosylation;
KIRP	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.93	-11.45	-0.59	1.28e-24	Diastolic blood pressure;
KIRP	cis	rs6838801	0.964	rs7686697	chr4:77570354	T/A	cg17476223	chr4:77663285	SHROOM3	0.51	7.31	0.42	3.69e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.53	-5.91	-0.35	1.16e-8	Blood pressure (smoking interaction);
KIRP	cis	rs7106204	0.764	rs4508205	chr11:24218850	C/T	ch.11.24196551F	chr11:24239977	NA	0.82	8.27	0.47	8.57e-15	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.77	0.71	3.57e-39	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17670539	chr10:111986070	MXI1	0.5	6.2	0.37	2.34e-9	Parkinson's disease;
KIRP	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg27068330	chr11:65405492	SIPA1	0.39	5.34	0.32	2.08e-7	Acne (severe);
KIRP	cis	rs7520050	0.966	rs7524495	chr1:46266932	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.53e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.01	-0.36	6.78e-9	Alcohol dependence;
KIRP	cis	rs11145488	1.000	rs11145657	chr9:71815904	G/A	cg14326805	chr9:71737756	TJP2	0.38	4.87	0.3	1.98e-6	Spherical equivalent (joint analysis main effects and education interaction);Myopia;
KIRP	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg00977110	chr5:151150581	G3BP1	-0.63	-6.35	-0.38	1.02e-9	Preschool internalizing problems;
KIRP	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg24972876	chr7:65420302	NA	0.4	5.45	0.33	1.21e-7	Calcium levels;
KIRP	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg00784671	chr22:46762841	CELSR1	-0.85	-8.28	-0.47	7.98e-15	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs714027	0.585	rs9614077	chr22:30244949	C/T	cg01021169	chr22:30184971	ASCC2	-0.47	-5.46	-0.33	1.19e-7	Lymphocyte counts;
KIRP	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	6.84	0.4	6.17e-11	IgG glycosylation;
KIRP	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.64	-0.39	1.95e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg20368463	chr18:77673604	PQLC1	0.68	5.66	0.34	4.15e-8	Opioid sensitivity;
KIRP	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg01557791	chr16:72042693	DHODH	-0.44	-5.3	-0.32	2.62e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.12	-0.41	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20273774	chr5:180671298	GNB2L1;SNORD95	-0.49	-6.97	-0.41	2.87e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.68	-8.37	-0.47	4.3e-15	Iron status biomarkers;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00281152	chr11:124492711	TBRG1	-0.46	-6.4	-0.38	7.77e-10	Metabolic traits;
KIRP	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs1867631	0.565	rs10749764	chr1:67149706	G/C	cg02459107	chr1:67143332	SGIP1	0.43	5.95	0.35	9.19e-9	Menopause (age at onset);
KIRP	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg04132472	chr17:19861366	AKAP10	0.68	10.54	0.56	1.14e-21	Schizophrenia;
KIRP	cis	rs6585424	1.000	rs12268619	chr10:81920660	A/C	cg27417294	chr10:81904244	PLAC9	0.56	5.46	0.33	1.14e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4938534	0.614	rs11213871	chr11:111261112	G/A	cg24049888	chr11:111250129	POU2AF1	0.3	5.1	0.31	6.73e-7	Primary biliary cholangitis;
KIRP	cis	rs2415984	0.622	rs61993305	chr14:46950955	C/T	cg14871534	chr14:47121158	RPL10L	-0.41	-5.07	-0.31	7.83e-7	Number of children ever born;
KIRP	trans	rs2018683	0.711	rs917214	chr7:28968293	T/C	cg19402173	chr7:128379420	CALU	-0.69	-9.06	-0.5	4.04e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs7737355	0.947	rs4706028	chr5:130946227	T/C	cg25547332	chr5:131281432	NA	0.45	5.19	0.31	4.38e-7	Life satisfaction;
KIRP	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	trans	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg00405596	chr8:11794950	NA	-0.47	-6.18	-0.37	2.59e-9	Joint mobility (Beighton score);
KIRP	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12315302	chr6:26189340	HIST1H4D	0.88	6.17	0.37	2.8e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs662064	0.889	rs1188526	chr1:10549848	G/C	cg19773385	chr1:10388646	KIF1B	0.41	5.46	0.33	1.16e-7	Asthma;
KIRP	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17554472	chr22:41940697	POLR3H	0.73	7.47	0.43	1.42e-12	Vitiligo;
KIRP	cis	rs1594829	0.535	rs17055121	chr8:26170975	C/T	cg11498726	chr8:26250323	BNIP3L	-0.31	-4.9	-0.3	1.71e-6	Height;
KIRP	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.56	-7.39	-0.43	2.31e-12	Urate levels in overweight individuals;
KIRP	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg21427119	chr20:30132790	HM13	-0.61	-6.35	-0.38	1.01e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg25600027	chr14:23388339	RBM23	-0.51	-6.22	-0.37	2.16e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7429990	1.000	rs1665982	chr3:47905079	A/G	cg11946769	chr3:48343235	NME6	-0.48	-5.05	-0.31	8.7e-7	Educational attainment (years of education);
KIRP	cis	rs7712401	0.601	rs187405	chr5:122294995	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07570687	chr10:102243282	WNT8B	0.52	6.7	0.39	1.41e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3752645	0.649	rs10241141	chr7:106744514	T/C	cg02696742	chr7:106810147	HBP1	-0.6	-5.2	-0.31	4.19e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.27	12.8	0.63	4.22e-29	Diabetic retinopathy;
KIRP	cis	rs4845459	0.967	rs75567512	chr1:152587933	C/A	cg07796016	chr1:152779584	LCE1C	-0.48	-5.98	-0.36	7.62e-9	Psoriasis;
KIRP	cis	rs72730918	0.564	rs35011964	chr15:51821423	C/T	cg14296394	chr15:51910925	DMXL2	0.76	10.53	0.56	1.23e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg00933542	chr6:150070202	PCMT1	0.29	5.7	0.34	3.35e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10813240	chr12:124422061	CCDC92	-0.43	-6.1	-0.36	4.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7560272	0.538	rs17350056	chr2:73922877	G/A	cg20560298	chr2:73613845	ALMS1	0.49	5.9	0.35	1.17e-8	Schizophrenia;
KIRP	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.64	8.35	0.47	5.1e-15	Coronary artery disease;
KIRP	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.85	-12.56	-0.62	2.82e-28	Strep throat;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15111398	chr1:42504277	NA	0.44	6.13	0.36	3.47e-9	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.75	-7.62	-0.44	5.47e-13	Gut microbiome composition (summer);
KIRP	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	10.43	0.55	2.55e-21	Leprosy;
KIRP	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.58	7.68	0.44	3.81e-13	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15160457	chr18:44676757	HDHD2	0.5	6.45	0.38	5.88e-10	Parkinson's disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg22426944	chr5:88179379	MEF2C	-0.46	-6.7	-0.39	1.45e-10	Migraine with aura;
KIRP	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs6893300	0.961	rs7444006	chr5:179177702	A/T	cg14593053	chr5:179126677	CANX	-0.59	-6.66	-0.39	1.79e-10	Resting heart rate;
KIRP	cis	rs4356932	1.000	rs4257674	chr4:76945685	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-6.26	-0.37	1.74e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.54	6.66	0.39	1.82e-10	Coffee consumption (cups per day);
KIRP	cis	rs2820315	1.000	rs2644119	chr1:201807776	C/T	cg11586189	chr1:201857591	SHISA4	-0.39	-5.45	-0.33	1.24e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.86	-0.3	2.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg24644049	chr4:85504048	CDS1	1.0	6.97	0.41	2.88e-11	Skin colour saturation;
KIRP	cis	rs11605275	1.000	rs76735151	chr11:20026419	G/A	cg14835545	chr11:20032148	NAV2	-0.73	-5.69	-0.34	3.61e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg22138327	chr13:27999177	GTF3A	0.78	8.96	0.5	8.06e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg00204512	chr16:28754710	NA	0.44	5.82	0.35	1.87e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12500976	chr2:233498078	EFHD1	0.52	6.69	0.39	1.53e-10	Parkinson's disease;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg16603669	chr15:48624160	DUT	0.54	6.48	0.38	5.04e-10	Beard thickness;
KIRP	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs15676	0.783	rs2977995	chr9:131584245	A/G	cg00228799	chr9:131580591	ENDOG	0.57	6.38	0.38	8.5e-10	Blood metabolite levels;
KIRP	cis	rs738144	0.687	rs6001225	chr22:39184639	A/C	cg07123855	chr22:39323204	NA	-0.32	-4.86	-0.3	2.11e-6	IgG glycosylation;
KIRP	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg13198984	chr17:80129470	CCDC57	0.6	9.21	0.51	1.45e-17	Life satisfaction;
KIRP	cis	rs72829446	0.530	rs56078345	chr17:7394341	T/C	cg02795151	chr17:7402630	POLR2A	0.75	7.89	0.45	9.98e-14	Androgen levels;
KIRP	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg18944383	chr4:111397179	ENPEP	0.42	6.79	0.4	8.49e-11	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.28	-0.37	1.55e-9	Monocyte percentage of white cells;
KIRP	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.83	-10.76	-0.57	2.15e-22	Cognitive function;
KIRP	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-6.79	-0.4	8.58e-11	Neuroticism;
KIRP	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.62e-7	Life satisfaction;
KIRP	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.35	-4.93	-0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.57	-9.31	-0.51	7.37e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg21775007	chr8:11205619	TDH	-0.47	-6.36	-0.38	9.55e-10	Mood instability;
KIRP	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.76	9.71	0.53	4.54e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12474201	0.814	rs62134772	chr2:47015192	G/A	cg06386533	chr2:46925753	SOCS5	1.06	14.13	0.67	1.37e-33	Height;
KIRP	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg20999797	chr1:1681921	NA	0.51	7.84	0.45	1.41e-13	Body mass index;
KIRP	cis	rs2151522	0.563	rs9388523	chr6:127121564	T/C	cg21431617	chr6:127135037	NA	0.33	6.01	0.36	6.75e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs904251	0.620	rs883372	chr6:37477605	A/C	cg01843034	chr6:37503916	NA	-0.7	-6.98	-0.41	2.8e-11	Cognitive performance;
KIRP	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.85	9.58	0.52	1.09e-18	High light scatter reticulocyte count;
KIRP	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.29e-16	Prudent dietary pattern;
KIRP	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg24633833	chr3:10029261	TMEM111	0.57	5.57	0.33	6.71e-8	Alzheimer's disease;
KIRP	cis	rs2425143	1.000	rs78421482	chr20:34376486	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-5.01	-0.3	1.03e-6	Blood protein levels;
KIRP	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.99	13.95	0.66	5.53e-33	Alcohol dependence;
KIRP	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	12.39	0.62	1e-27	Bone mineral density;
KIRP	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	0.83	7.44	0.43	1.7e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6466055	0.636	rs6466049	chr7:104896929	A/G	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	7.01e-7	Schizophrenia;
KIRP	cis	rs4356932	1.000	rs4859584	chr4:76943137	C/G	cg00809888	chr4:76862425	NAAA	0.44	6.04	0.36	5.77e-9	Blood protein levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23051282	chr17:78940161	RPTOR	0.54	7.23	0.42	5.94e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.57	-7.78	-0.44	1.97e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.68	-12.44	-0.62	6.84e-28	White blood cell count (basophil);
KIRP	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.69	-0.39	1.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs208520	0.909	rs9354410	chr6:67018584	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	7.41	0.43	1.97e-12	Exhaled nitric oxide output;
KIRP	cis	rs79387448	0.655	rs79091585	chr2:102917243	C/T	cg20060108	chr2:102954350	IL1RL1	-0.63	-5.2	-0.31	4.18e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6772849	0.930	rs12630379	chr3:128370204	G/C	cg08795948	chr3:128337044	NA	0.46	5.92	0.35	1.06e-8	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs9473924	0.542	rs9473939	chr6:50877477	T/G	cg14470998	chr6:50812995	TFAP2B	0.81	7.63	0.44	5.28e-13	Body mass index;
KIRP	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.02	0.46	4.37e-14	Heart rate;
KIRP	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09640425	chr7:158790006	NA	0.41	5.05	0.31	8.56e-7	Facial morphology (factor 20);
KIRP	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.14	-0.31	5.72e-7	Morning vs. evening chronotype;
KIRP	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg26876637	chr1:152193138	HRNR	0.75	9.78	0.53	2.65e-19	Atopic dermatitis;
KIRP	cis	rs6545883	0.825	rs4672426	chr2:61457148	G/A	cg15711740	chr2:61764176	XPO1	0.57	7.41	0.43	2.02e-12	Tuberculosis;
KIRP	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-7.5	-0.43	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs61884328	0.561	rs55750336	chr11:46500528	C/T	cg10758369	chr1:48459236	NA	0.5	6.11	0.36	3.84e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg26784012	chr10:32216390	ARHGAP12	0.3	4.86	0.3	2.1e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	trans	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.07	0.36	4.91e-9	Mean corpuscular volume;
KIRP	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	6.68	0.39	1.59e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg17105886	chr17:28927953	LRRC37B2	0.54	5.52	0.33	8.67e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg05082376	chr22:42548792	NA	0.43	5.68	0.34	3.8e-8	Schizophrenia;
KIRP	cis	rs16857609	0.628	rs2568160	chr2:218334463	A/C	cg15335768	chr2:218268053	DIRC3	0.37	5.46	0.33	1.17e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs55788414	0.932	rs9929253	chr16:81181641	C/T	cg06400318	chr16:81190750	PKD1L2	-0.82	-8.08	-0.46	2.93e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.05	0.75	6.05e-47	Chronic sinus infection;
KIRP	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.72	6.42	0.38	6.85e-10	Diabetic retinopathy;
KIRP	cis	rs2017305	0.834	rs12253140	chr10:70780708	G/T	cg01024728	chr10:70782572	NA	0.63	5.17	0.31	4.9e-7	Depression (quantitative trait);
KIRP	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.8	8.96	0.5	8.44e-17	Gestational age at birth (maternal effect);
KIRP	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg19142026	chr7:27170394	HOXA4	-0.46	-5.84	-0.35	1.64e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.99	17.32	0.74	1.75e-44	Breast cancer;
KIRP	cis	rs11673344	0.566	rs7254009	chr19:37918609	C/T	cg14683738	chr19:37701593	ZNF585B	0.44	5.18	0.31	4.53e-7	Obesity-related traits;
KIRP	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04541695	chr4:18023633	LCORL	0.47	6.6	0.39	2.52e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7534824	0.625	rs17448356	chr1:101345093	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.1	0.41	1.3e-11	Refractive astigmatism;
KIRP	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.81	-12.44	-0.62	7.01e-28	Blood metabolite levels;
KIRP	cis	rs1823913	0.599	rs6732976	chr2:192145730	A/G	cg12404831	chr2:192114017	MYO1B	-0.47	-6.5	-0.38	4.34e-10	Obesity-related traits;
KIRP	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.72	9.14	0.5	2.41e-17	Corneal astigmatism;
KIRP	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.39	-0.33	1.62e-7	Colorectal cancer;
KIRP	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.74	10.75	0.57	2.36e-22	Psoriasis;
KIRP	cis	rs2151522	0.724	rs9375463	chr6:127166888	A/C	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.92	-17.04	-0.74	1.6e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1847505	0.609	rs7993826	chr13:61505940	A/G	cg25164009	chr13:61490935	NA	0.57	5.94	0.35	9.62e-9	Polychlorinated biphenyl levels;
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg26174226	chr8:58114915	NA	-0.51	-5.05	-0.31	8.62e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	9.9	0.53	1.14e-19	Total body bone mineral density;
KIRP	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.75	-7.76	-0.44	2.21e-13	Vitiligo;
KIRP	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg00631329	chr6:26305371	NA	-0.65	-8.82	-0.49	2.08e-16	Educational attainment;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12845678	chr7:5388781	TNRC18	0.51	6.1	0.36	4.11e-9	Interleukin-4 levels;
KIRP	cis	rs7215564	0.908	rs35363308	chr17:78687190	A/T	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.4e-7	Myopia (pathological);
KIRP	cis	rs9815354	0.556	rs113213296	chr3:41873097	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg10755058	chr3:40428713	ENTPD3	0.47	6.37	0.38	9.42e-10	Renal cell carcinoma;
KIRP	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	5.89	0.35	1.25e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7077164	1.000	rs1227776	chr10:71580893	G/A	cg20696214	chr10:71583771	COL13A1	-0.47	-6.61	-0.39	2.37e-10	Non-alcoholic fatty liver disease histology (lobular);
KIRP	trans	rs225245	0.817	rs225284	chr17:33933006	A/C	cg19694781	chr19:47549865	TMEM160	-0.53	-6.45	-0.38	6.04e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.61	-7.58	-0.44	6.95e-13	Height;
KIRP	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg00784671	chr22:46762841	CELSR1	-0.67	-8.5	-0.48	1.81e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs238295	0.805	rs6053500	chr20:5542683	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.5	-4.97	-0.3	1.28e-6	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.26	0.65	1.25e-30	Chronic sinus infection;
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-6.32	-0.37	1.22e-9	Lung cancer;
KIRP	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-0.41	-5.11	-0.31	6.43e-7	Type 2 diabetes;
KIRP	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg03929089	chr4:120376271	NA	0.77	6.91	0.4	4.16e-11	Intraocular pressure;
KIRP	cis	rs6120849	0.754	rs752448	chr20:33592248	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	6.37	0.38	9.09e-10	Protein C levels;
KIRP	cis	rs7951870	0.945	rs11038974	chr11:46728954	G/T	cg19486271	chr11:47235900	DDB2	0.49	5.06	0.31	8.04e-7	Schizophrenia;
KIRP	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.56	5.7	0.34	3.38e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs472402	0.540	rs2288445	chr5:6620092	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-5.02	-0.3	9.79e-7	Response to amphetamines;
KIRP	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.5	-5.74	-0.34	2.79e-8	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09642951	chr7:143105970	EPHA1	0.47	6.08	0.36	4.68e-9	Parkinson's disease;
KIRP	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	7.31	0.42	3.84e-12	Lung cancer;
KIRP	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.5	-7.09	-0.41	1.44e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg00656387	chr3:40428638	ENTPD3	-0.37	-4.97	-0.3	1.26e-6	Renal cell carcinoma;
KIRP	cis	rs9653442	0.564	rs7590378	chr2:100789877	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-4.92	-0.3	1.59e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7010267	0.902	rs7006553	chr8:119970779	C/T	cg01975934	chr8:119970761	NA	-0.42	-5.32	-0.32	2.34e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17554472	chr22:41940697	POLR3H	0.67	7.07	0.41	1.61e-11	Vitiligo;
KIRP	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.5	6.52	0.38	3.92e-10	Plateletcrit;Platelet count;
KIRP	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-1.05	-13.98	-0.67	4.37e-33	Response to hepatitis C treatment;
KIRP	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	Neuroticism;
KIRP	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.58	6.72	0.39	1.23e-10	Aortic root size;
KIRP	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs865483	0.895	rs853208	chr17:35826456	C/A	cg06716730	chr17:35851459	DUSP14	0.25	6.06	0.36	5.03e-9	Monocyte count;
KIRP	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg11569703	chr11:65557185	OVOL1	0.5	7.55	0.43	8.38e-13	Breast cancer;
KIRP	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs11209002	0.614	rs10736406	chr1:67573238	A/T	cg02640540	chr1:67518911	SLC35D1	-0.51	-5.66	-0.34	4.19e-8	Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05112574	chr17:76374542	PGS1	0.51	6.5	0.38	4.42e-10	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.43	-7.27	-0.42	4.85e-12	Body mass index;
KIRP	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.6	8.61	0.48	8.84e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1760803	0.754	rs10158820	chr1:154217763	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.49	-0.33	1.02e-7	Nicotine dependence;
KIRP	cis	rs7688540	0.771	rs61792116	chr4:301077	T/C	cg10134910	chr4:1076041	RNF212	-0.25	-5.06	-0.31	8.28e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08130668	chr2:54557891	C2orf73	0.46	6.3	0.37	1.33e-9	Parkinson's disease;
KIRP	trans	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg16141378	chr3:129829833	LOC729375	0.47	6.02	0.36	6.43e-9	Mood instability;
KIRP	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.77	-0.57	2.07e-22	Neuroticism;
KIRP	cis	rs13361707	0.920	rs7702883	chr5:40756681	G/A	cg01087697	chr5:40835557	RPL37	-0.48	-5.48	-0.33	1.07e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.84	0.35	1.66e-8	Schizophrenia;
KIRP	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg08761264	chr16:28874980	SH2B1	-0.52	-5.97	-0.36	8.22e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg05802129	chr4:122689817	NA	-0.69	-9.02	-0.5	5.35e-17	Type 2 diabetes;
KIRP	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.86	11.64	0.6	3e-25	Schizophrenia;
KIRP	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26375259	chr19:3985535	EEF2	0.46	6.39	0.38	8.21e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg15083037	chr5:83017644	HAPLN1	-0.6	-8.58	-0.48	1.07e-15	Prostate cancer;
KIRP	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-9.9	-0.53	1.14e-19	Body mass index;
KIRP	cis	rs6001982	0.584	rs73167041	chr22:40837964	G/T	cg07138101	chr22:40742427	ADSL	0.71	4.94	0.3	1.47e-6	Breast cancer;
KIRP	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-6.0	-0.36	7.02e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1465370	0.750	rs3807136	chr7:130019481	C/T	cg03229158	chr7:130009420	NA	0.34	4.98	0.3	1.22e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.59	-8.06	-0.46	3.38e-14	Menarche (age at onset);
KIRP	cis	rs9896933	1.000	rs9896933	chr17:80898088	T/C	cg20578329	chr17:80767326	TBCD	0.87	8.17	0.46	1.59e-14	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs3739034	0.702	rs17652245	chr2:135533621	T/C	cg15546071	chr2:135691756	CCNT2	-0.52	-4.89	-0.3	1.82e-6	Gut microbiome composition (winter);
KIRP	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg16553119	chr1:165599451	MGST3	-0.44	-5.32	-0.32	2.36e-7	Total ventricular volume;
KIRP	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.67	-7.24	-0.42	5.71e-12	Diastolic blood pressure;
KIRP	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg25036284	chr2:26402008	FAM59B	-0.66	-6.78	-0.4	8.74e-11	Gut microbiome composition (summer);
KIRP	cis	rs1656402	1.000	rs2077975	chr2:233425877	C/A	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.49	4.94e-16	Retinal vascular caliber;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg00802000	chr16:706648	WDR90	-0.4	-5.02	-0.3	1.02e-6	Height;
KIRP	cis	rs2916247	0.954	rs11782927	chr8:93045726	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.65	-0.44	4.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.8	-0.35	2.07e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	9.94	0.54	8.81e-20	Lung cancer in ever smokers;
KIRP	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.34	-0.32	2.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9400467	0.537	rs73530952	chr6:111486242	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.03	0.31	9.56e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-5.28	-0.32	2.82e-7	Aortic root size;
KIRP	cis	rs73200209	0.912	rs17498459	chr12:116541595	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.75	-0.34	2.59e-8	Total body bone mineral density;
KIRP	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg10047753	chr17:41438598	NA	0.9	13.06	0.64	5.79e-30	Menopause (age at onset);
KIRP	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	1.08	11.8	0.6	9.41e-26	Eosinophil percentage of granulocytes;
KIRP	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg17182837	chr8:41585554	ANK1	-0.47	-6.52	-0.38	3.99e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.62	5.85	0.35	1.58e-8	Alzheimer's disease;
KIRP	cis	rs10849893	0.538	rs4980994	chr12:121919295	G/A	cg01154721	chr12:121881891	KDM2B	0.44	5.69	0.34	3.68e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg00677455	chr12:58241039	CTDSP2	-0.55	-6.1	-0.36	4.15e-9	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18143693	chr14:67999927	PLEKHH1	0.51	6.21	0.37	2.23e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.65	-0.39	1.85e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg02591564	chr12:125578355	AACS	-0.51	-5.21	-0.32	3.98e-7	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg08280861	chr8:58055591	NA	0.51	4.98	0.3	1.18e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6693295	0.605	rs4396095	chr1:246213270	A/G	cg11798871	chr1:246315928	SMYD3	-0.42	-5.26	-0.32	3.12e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg25174290	chr11:3078921	CARS	-0.65	-8.41	-0.47	3.44e-15	Calcium levels;
KIRP	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	6.07	0.36	4.82e-9	Height;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.86	0.35	1.51e-8	Lung cancer;
KIRP	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.4	-4.89	-0.3	1.79e-6	Systemic lupus erythematosus;
KIRP	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg00857998	chr1:205179979	DSTYK	0.68	7.99	0.45	5.08e-14	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.7	-9.43	-0.52	3.13e-18	Calcium levels;
KIRP	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.61	8.67	0.48	5.88e-16	Height;
KIRP	trans	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg06521331	chr12:34319734	NA	-0.53	-6.6	-0.39	2.46e-10	Heart rate;
KIRP	cis	rs259842	0.612	rs1480707	chr2:180709478	A/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.42	-5.64	-0.34	4.71e-8	Blood protein levels;
KIRP	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26856583	chr16:87425887	MAP1LC3B;FBXO31	0.54	6.29	0.37	1.42e-9	Smoking initiation;
KIRP	cis	rs12681288	1.000	rs2167505	chr8:1033877	A/C	cg08648136	chr8:956695	NA	0.48	6.98	0.41	2.72e-11	Schizophrenia;
KIRP	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.55	6.72	0.39	1.26e-10	Metabolite levels;
KIRP	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06481639	chr22:41940642	POLR3H	0.5	5.64	0.34	4.59e-8	Vitiligo;
KIRP	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.56	4.89	0.3	1.79e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.91	0.45	8.88e-14	Aortic root size;
KIRP	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12976411	0.575	rs8101983	chr19:32825147	T/G	cg02282382	chr19:32836354	ZNF507	0.62	5.23	0.32	3.7e-7	Coronary artery disease;
KIRP	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-5.57	-0.33	6.83e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18364779	chr6:26104403	HIST1H4C	0.62	8.02	0.46	4.22e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg01097406	chr16:89675127	NA	-0.29	-4.92	-0.3	1.57e-6	Vitiligo;
KIRP	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.44	-5.45	-0.33	1.24e-7	Testicular germ cell tumor;
KIRP	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.21	13.43	0.65	3.35e-31	Alzheimer's disease;
KIRP	cis	rs3784262	0.739	rs1550574	chr15:58213368	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.01	-0.36	6.65e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs6540556	0.859	rs12131636	chr1:209942435	G/C	cg23920097	chr1:209922102	NA	-0.45	-5.19	-0.31	4.46e-7	Red blood cell count;
KIRP	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs921943	0.957	rs1805073	chr5:78326750	G/C	cg26802063	chr5:78281964	ARSB	0.49	6.08	0.36	4.56e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg04310649	chr10:35416472	CREM	0.58	7.11	0.41	1.27e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg02807482	chr3:125708958	NA	-0.54	-5.1	-0.31	6.86e-7	Blood pressure (smoking interaction);
KIRP	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.88	-11.31	-0.58	3.71e-24	Breast cancer;
KIRP	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg00579200	chr11:133705235	NA	-0.42	-5.55	-0.33	7.34e-8	Childhood ear infection;
KIRP	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.29	16.57	0.73	6.38e-42	Corneal structure;
KIRP	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19904058	chr10:135279010	LOC619207	-0.48	-5.18	-0.31	4.51e-7	Systemic lupus erythematosus;
KIRP	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg26205652	chr12:48591994	NA	-0.46	-5.17	-0.31	4.84e-7	Lung cancer;
KIRP	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg05156742	chr15:59063176	FAM63B	0.61	7.72	0.44	2.85e-13	Schizophrenia;
KIRP	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg10326726	chr10:51549505	MSMB	-0.62	-9.28	-0.51	9.11e-18	Prostate-specific antigen levels;
KIRP	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23544223	chr18:12777786	NA	0.75	6.29	0.37	1.48e-9	Inflammatory skin disease;
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.75	10.8	0.57	1.65e-22	Lung cancer;
KIRP	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1359582	1.000	rs1325899	chr10:90317327	G/T	cg15661332	chr10:90342814	RNLS	0.54	5.25	0.32	3.26e-7	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-8.21	-0.46	1.27e-14	Personality dimensions;
KIRP	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.61	-7.29	-0.42	4.11e-12	Blood trace element (Cu levels);
KIRP	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.28	-5.67	-0.34	4.02e-8	Height;
KIRP	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-1.04	-11.77	-0.6	1.2e-25	Platelet distribution width;
KIRP	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.91	-0.64	1.86e-29	Exhaled nitric oxide output;
KIRP	cis	rs9596863	0.799	rs9591531	chr13:54308253	G/A	ch.13.53330881F	chr13:54432880	NA	0.54	5.21	0.32	4.06e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4762326	1.000	rs4762308	chr12:95649013	G/A	cg07737802	chr12:95537812	FGD6	0.46	6.24	0.37	1.85e-9	Endometriosis;
KIRP	cis	rs2290402	0.536	rs73207790	chr4:865430	G/A	cg00846425	chr4:957561	DGKQ	-0.46	-4.88	-0.3	1.87e-6	Type 2 diabetes;
KIRP	cis	rs918629	0.716	rs3756703	chr5:95276063	G/A	cg16656078	chr5:95278638	ELL2	-0.47	-6.89	-0.4	4.77e-11	IgG glycosylation;
KIRP	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.77	8.23	0.46	1.08e-14	Uric acid levels;
KIRP	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.35	-4.96	-0.3	1.33e-6	Menarche (age at onset);
KIRP	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.41	-6.14	-0.36	3.24e-9	Height;
KIRP	cis	rs9534288	0.699	rs7139571	chr13:46662584	G/A	cg15192986	chr13:46630673	CPB2	-0.78	-9.22	-0.51	1.4e-17	Blood protein levels;
KIRP	cis	rs12580194	0.593	rs61956272	chr12:55779559	A/T	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg16141378	chr3:129829833	LOC729375	0.51	6.3	0.37	1.33e-9	Neuroticism;
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg17294928	chr15:75287854	SCAMP5	0.59	7.96	0.45	6.41e-14	Breast cancer;
KIRP	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg25801113	chr15:45476975	SHF	0.42	7.87	0.45	1.11e-13	Uric acid levels;
KIRP	cis	rs7520050	0.931	rs35743647	chr1:46407252	T/C	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg13264159	chr8:625131	ERICH1	-0.84	-7.04	-0.41	1.87e-11	IgG glycosylation;
KIRP	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg13409248	chr3:40428643	ENTPD3	0.39	5.18	0.31	4.65e-7	Renal cell carcinoma;
KIRP	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.94	0.35	9.8e-9	Renal cell carcinoma;
KIRP	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.09	-0.41	1.41e-11	Migraine;Coronary artery disease;
KIRP	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg19847130	chr8:10466454	RP1L1	0.39	5.84	0.35	1.63e-8	Retinal vascular caliber;
KIRP	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.82	-11.9	-0.6	4.15e-26	Longevity;
KIRP	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	1.04	10.59	0.56	7.84e-22	Blood protein levels;
KIRP	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.49	6.88	0.4	4.95e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6541297	0.645	rs4846919	chr1:230301451	A/G	cg05784532	chr1:230284198	GALNT2	0.42	5.63	0.34	4.98e-8	Coronary artery disease;
KIRP	cis	rs34779708	0.931	rs7099593	chr10:35366878	A/C	cg04310649	chr10:35416472	CREM	-0.59	-7.14	-0.41	1.06e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.85	-13.39	-0.65	4.33e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.72	-0.39	1.28e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.71	9.09	0.5	3.45e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.6	6.53	0.38	3.81e-10	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg01763666	chr17:80159506	CCDC57	-0.38	-5.12	-0.31	6.04e-7	Life satisfaction;
KIRP	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg23594656	chr7:65796392	TPST1	0.47	7.48	0.43	1.34e-12	Aortic root size;
KIRP	cis	rs6191	0.935	rs852980	chr5:142700856	G/C	cg08845721	chr5:142780693	NR3C1	-0.39	-5.26	-0.32	3.2e-7	Night sleep phenotypes;
KIRP	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-8.17	-0.46	1.66e-14	Caffeine consumption;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.74	-11.22	-0.58	7.51e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1440410	0.795	rs12506120	chr4:144190448	C/T	cg01719995	chr4:144104893	USP38	0.39	5.08	0.31	7.41e-7	Ischemic stroke;
KIRP	cis	rs3936840	0.686	rs2896439	chr14:102806291	A/G	cg10241871	chr14:102965420	TECPR2	-0.4	-4.89	-0.3	1.85e-6	Plateletcrit;
KIRP	cis	rs1448094	0.967	rs7313443	chr12:86332940	G/A	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg06671706	chr8:8559999	CLDN23	0.56	6.32	0.37	1.21e-9	Obesity-related traits;
KIRP	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg24459738	chr19:57751996	ZNF805	-0.58	-7.17	-0.42	8.82e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs73206853	0.764	rs7311376	chr12:110605559	C/T	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg04935436	chr20:30431758	NA	0.53	6.53	0.38	3.7e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg21186296	chr8:27182909	PTK2B	0.48	6.21	0.37	2.23e-9	Neuroticism;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg00137828	chr10:105881754	C10orf78	0.59	6.85	0.4	5.84e-11	Plasma plasminogen activator levels;
KIRP	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg00646381	chr17:77835854	NA	0.54	7.19	0.42	7.76e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
KIRP	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-1.0	-10.5	-0.56	1.52e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs1620921	0.774	rs812482	chr6:161227652	G/C	cg01280913	chr6:161186852	NA	-0.37	-5.16	-0.31	5.01e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs524023	0.957	rs10792443	chr11:64395252	G/C	cg09231725	chr11:64357281	SLC22A12	0.62	8.09	0.46	2.77e-14	Urate levels in obese individuals;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.77	12.32	0.62	1.71e-27	Menarche (age at onset);
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.01	0.36	6.59e-9	Platelet count;
KIRP	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.72	-9.5	-0.52	1.93e-18	Glaucoma (primary open-angle);
KIRP	cis	rs1712517	0.503	rs72846198	chr10:105098024	G/A	cg04362960	chr10:104952993	NT5C2	-0.6	-7.43	-0.43	1.8e-12	Migraine;
KIRP	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.68	6.35	0.38	1.06e-9	Lung function (FEV1/FVC);
KIRP	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.34	0.32	2.1e-7	Breast cancer;
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg09699651	chr6:150184138	LRP11	0.46	6.26	0.37	1.69e-9	Lung cancer;
KIRP	cis	rs427941	0.632	rs201470	chr7:101744045	G/A	cg06246474	chr7:101738831	CUX1	0.53	6.49	0.38	4.6e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg12131826	chr15:77904385	NA	-0.4	-5.04	-0.31	9.22e-7	Type 2 diabetes;
KIRP	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.66	6.96	0.41	3.12e-11	Eotaxin levels;
KIRP	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.47	7.81	0.45	1.66e-13	Lung cancer;
KIRP	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs6191	0.901	rs853183	chr5:142641502	C/A	cg08845721	chr5:142780693	NR3C1	0.4	5.36	0.32	1.87e-7	Night sleep phenotypes;
KIRP	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.53	13.31	0.65	8.54e-31	Airflow obstruction;
KIRP	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg08975724	chr8:8085496	FLJ10661	0.73	10.37	0.55	3.94e-21	Retinal vascular caliber;
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.8	0.35	2.02e-8	Lung cancer;
KIRP	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.79	9.65	0.52	6.96e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg25600027	chr14:23388339	RBM23	-0.52	-6.43	-0.38	6.42e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs4700695	0.841	rs251294	chr5:65261848	A/G	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs6929812	0.546	rs2393962	chr6:27462824	T/C	cg03332623	chr6:27441972	ZNF184	-0.4	-5.65	-0.34	4.44e-8	Neuroticism (multi-trait analysis);
KIRP	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.64	-9.26	-0.51	1.06e-17	Educational attainment;
KIRP	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg24642439	chr20:33292090	TP53INP2	0.52	6.53	0.38	3.74e-10	Height;
KIRP	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18364779	chr6:26104403	HIST1H4C	0.42	5.5	0.33	9.32e-8	Schizophrenia;
KIRP	cis	rs7923609	0.967	rs7095571	chr10:65150959	T/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.4	-0.33	1.54e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs494562	0.892	rs9353309	chr6:86126145	C/T	cg21730993	chr6:86159210	NT5E	0.49	5.11	0.31	6.5e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.45	5.72	0.34	3e-8	Resistin levels;
KIRP	cis	rs77688320	0.517	rs6717641	chr2:202315207	C/T	cg06431681	chr2:202330990	STRADB	0.55	7.56	0.43	7.91e-13	Breast cancer;
KIRP	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.67	-9.48	-0.52	2.2e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.34	-0.51	6.12e-18	Myopia (pathological);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg17976829	chr10:131934431	GLRX3	0.53	6.16	0.37	2.97e-9	Sleep duration;
KIRP	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg23649088	chr2:200775458	C2orf69	0.54	5.22	0.32	3.89e-7	Schizophrenia;
KIRP	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.44	-0.43	1.73e-12	Breast cancer;
KIRP	cis	rs4908768	1.000	rs12122666	chr1:8741438	A/C	cg25722041	chr1:8623473	RERE	-0.77	-9.31	-0.51	7.33e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.41	-5.05	-0.31	8.47e-7	Carotid intima media thickness;
KIRP	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg07741184	chr6:167504864	NA	0.24	6.43	0.38	6.44e-10	Crohn's disease;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg07511668	chr11:68622177	NA	0.37	5.06	0.31	8.27e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg05360138	chr12:110035743	NA	0.48	5.41	0.33	1.5e-7	Neuroticism;
KIRP	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg18932078	chr1:2524107	MMEL1	-0.41	-5.5	-0.33	9.63e-8	Ulcerative colitis;
KIRP	cis	rs3736485	0.934	rs17609924	chr15:51911592	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17101923	0.853	rs12426889	chr12:66320894	G/A	cg06712651	chr12:66351869	HMGA2	-0.56	-6.05	-0.36	5.41e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg23202291	chr11:1979235	NA	0.44	5.68	0.34	3.77e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-5.06	-0.31	8.37e-7	Triglycerides;
KIRP	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg03929089	chr4:120376271	NA	0.68	6.64	0.39	2.05e-10	Axial length;
KIRP	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.08	0.58	2.02e-23	Exhaled nitric oxide levels;
KIRP	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg07541023	chr7:19748670	TWISTNB	0.64	5.75	0.34	2.62e-8	Thyroid stimulating hormone;
KIRP	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.62	-7.7	-0.44	3.34e-13	Longevity;
KIRP	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.39	-5.55	-0.33	7.38e-8	Alcoholic chronic pancreatitis;
KIRP	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-8.66	-0.48	6.2e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg05220968	chr6:146057943	EPM2A	-0.4	-5.08	-0.31	7.59e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9398803	0.687	rs6911485	chr6:126975115	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14741366	chr20:49571568	DPM1	0.39	6.24	0.37	1.86e-9	C-reactive protein;
KIRP	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00889227	chr1:205173544	DSTYK	-0.38	-5.13	-0.31	5.9e-7	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.66	-0.34	4.29e-8	Mood instability;
KIRP	cis	rs2241685	1.000	rs2241685	chr2:1925993	C/T	cg22511877	chr2:1942942	MYT1L	-0.59	-5.82	-0.35	1.78e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.65	-9.71	-0.53	4.33e-19	Prostate cancer;
KIRP	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg05938607	chr10:60274200	BICC1	0.46	11.3	0.58	4.15e-24	Refractive error;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg03247834	chr17:43212845	ACBD4	-0.49	-6.34	-0.37	1.1e-9	Blood metabolite levels;
KIRP	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.74	-9.67	-0.52	5.89e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9394841	0.667	rs3747749	chr6:41770604	G/A	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs2411233	1.000	rs7166250	chr15:39283101	C/T	cg02291532	chr15:39874776	THBS1	0.4	5.68	0.34	3.71e-8	Platelet count;
KIRP	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg26528668	chr16:1614120	IFT140	0.4	5.06	0.31	8.28e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25908973	chr15:45670865	LOC145663;GATM	0.46	6.27	0.37	1.59e-9	Parkinson's disease;
KIRP	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg01426195	chr3:39028469	NA	-0.41	-6.05	-0.36	5.3e-9	Handedness;
KIRP	trans	rs1962073	0.529	rs13258627	chr8:10274578	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.69	0.39	1.51e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg06634786	chr22:41940651	POLR3H	-0.48	-5.32	-0.32	2.36e-7	Neuroticism;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7527798	0.592	rs12025522	chr1:207854355	A/C	cg09232269	chr1:207846808	CR1L	0.35	4.91	0.3	1.63e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg26408565	chr15:76604113	ETFA	-0.41	-5.55	-0.33	7.54e-8	Blood metabolite levels;
KIRP	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg03929089	chr4:120376271	NA	-0.5	-6.19	-0.37	2.44e-9	Coronary artery disease;
KIRP	cis	rs11779988	0.545	rs404186	chr8:17795496	A/G	cg01800426	chr8:17659068	MTUS1	-0.55	-5.4	-0.33	1.56e-7	Breast cancer;
KIRP	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.9	0.35	1.21e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	trans	rs7037266	0.857	rs7854491	chr9:6970287	G/A	cg09182435	chr1:7579016	CAMTA1	-0.37	-6.31	-0.37	1.3e-9	Menarche (age at onset);
KIRP	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.63	0.34	5.02e-8	Total cholesterol levels;
KIRP	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg26876637	chr1:152193138	HRNR	-0.79	-9.34	-0.51	5.82e-18	Atopic dermatitis;
KIRP	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-6.94	-0.4	3.55e-11	Chronic sinus infection;
KIRP	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.92	-13.03	-0.64	7.15e-30	Coronary artery disease;
KIRP	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg22705602	chr4:152727874	NA	-0.54	-9.4	-0.51	4.04e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.69	-7.74	-0.44	2.57e-13	Alcohol dependence;
KIRP	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg26061582	chr7:22766209	IL6	0.98	7.16	0.42	9.49e-12	Tonsillectomy;
KIRP	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg24130564	chr14:104152367	KLC1	-0.52	-7.03	-0.41	2.02e-11	Body mass index;
KIRP	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19671926	chr4:122722719	EXOSC9	0.51	6.22	0.37	2.12e-9	Type 2 diabetes;
KIRP	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg10932868	chr11:921992	NA	-0.65	-8.77	-0.49	3.07e-16	Alzheimer's disease (late onset);
KIRP	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	7.86	0.45	1.2e-13	Mood instability;
KIRP	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.44	5.61	0.34	5.42e-8	Crohn's disease;
KIRP	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05220968	chr6:146057943	EPM2A	-0.42	-5.15	-0.31	5.25e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs2307121	0.700	rs10940034	chr5:64729075	C/T	cg11190754	chr5:64858552	CENPK;PPWD1	0.43	5.46	0.33	1.19e-7	Corneal structure;
KIRP	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.75	-10.31	-0.55	5.87e-21	Hypospadias;
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.95	-13.52	-0.65	1.61e-31	Longevity;Endometriosis;
KIRP	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg22974920	chr21:40686053	BRWD1	-0.43	-4.98	-0.3	1.21e-6	Cognitive function;
KIRP	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg03929089	chr4:120376271	NA	-0.7	-6.38	-0.38	8.63e-10	D-dimer levels;
KIRP	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg15327641	chr2:3715039	ALLC	0.44	5.36	0.32	1.87e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14169450	chr9:139327907	INPP5E	0.5	7.01	0.41	2.32e-11	Monocyte percentage of white cells;
KIRP	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.33	-0.32	2.17e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg10047753	chr17:41438598	NA	1.13	17.91	0.75	1.78e-46	Menopause (age at onset);
KIRP	cis	rs3931020	0.626	rs277402	chr1:75188321	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.42	-4.94	-0.3	1.44e-6	Resistin levels;
KIRP	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg16736954	chr20:23401023	NAPB	0.63	4.96	0.3	1.3e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2224391	0.628	rs9405260	chr6:5249612	C/T	cg13962347	chr6:5174647	LYRM4	-0.86	-9.97	-0.54	6.76e-20	Height;
KIRP	cis	rs9426935	0.681	rs9427318	chr1:153980904	T/G	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.31	-5.22	-0.32	3.89e-7	Lentiform nucleus volume;
KIRP	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg18709589	chr6:96969512	KIAA0776	0.34	4.99	0.3	1.13e-6	Headache;
KIRP	cis	rs2617583	0.530	rs1478435	chr5:1454612	T/C	cg07151155	chr5:1473589	LPCAT1	-0.42	-5.16	-0.31	5.1e-7	Breast cancer;
KIRP	cis	rs471756	0.523	rs604470	chr9:223979	A/G	cg14500300	chr9:211689	NA	0.42	5.62	0.34	5.17e-8	Mean platelet volume;
KIRP	cis	rs17065868	1.000	rs73190824	chr13:45108587	G/C	cg10246903	chr13:45222710	NA	0.74	6.77	0.4	9.6e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9426935	0.966	rs6668066	chr1:153786182	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	0.28	4.86	0.3	2.07e-6	Lentiform nucleus volume;
KIRP	cis	rs2441986	0.892	rs737701	chr11:57921374	T/G	cg19752551	chr11:57585705	CTNND1	0.4	4.97	0.3	1.24e-6	Systolic blood pressure;
KIRP	cis	rs12693043	0.934	rs1529571	chr2:175388753	C/A	cg11778734	chr2:175439522	WIPF1	-0.4	-5.18	-0.31	4.57e-7	Urate levels (BMI interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15811753	chr2:65454775	ACTR2	0.55	6.88	0.4	4.86e-11	Parkinson's disease;
KIRP	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.97	-0.41	2.87e-11	Neutrophil percentage of white cells;
KIRP	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg14835575	chr10:16859367	RSU1	0.54	6.72	0.39	1.28e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.46	5.95	0.35	9.09e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs1424233	1.000	rs11639714	chr16:79683660	T/C	cg11120865	chr14:21853037	SUPT16H	0.38	6.45	0.38	6.02e-10	Obesity;
KIRP	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg02297831	chr4:17616191	MED28	0.61	7.81	0.45	1.7e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03076246	chr16:67906784	EDC4	0.54	6.18	0.37	2.63e-9	Lung cancer in ever smokers;
KIRP	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg10402321	chr1:26617780	UBXN11	-0.41	-5.31	-0.32	2.5e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3008870	0.628	rs2755257	chr1:67515309	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.09	0.46	2.79e-14	Lymphocyte percentage of white cells;
KIRP	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-8.73	-0.49	3.94e-16	Mean corpuscular volume;
KIRP	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.42e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg01097406	chr16:89675127	NA	0.35	5.61	0.34	5.32e-8	Vitiligo;
KIRP	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-4.9	-0.3	1.72e-6	Aortic root size;
KIRP	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.66	-9.33	-0.51	6.34e-18	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg03060546	chr3:49711283	APEH	-0.6	-6.12	-0.36	3.69e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.65	-9.95	-0.54	8.32e-20	Endometriosis;
KIRP	cis	rs929596	0.564	rs2602373	chr2:234561953	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-5.64	-0.34	4.69e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs6594499	1.000	rs1438673	chr5:110467499	C/T	cg04022379	chr5:110408740	TSLP	0.46	6.87	0.4	5.15e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.84	0.53	1.76e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg19407955	chr1:165599744	MGST3	-0.48	-5.42	-0.33	1.45e-7	Total ventricular volume;
KIRP	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	6.48	0.38	5.06e-10	Height;
KIRP	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	9.95e-11	Bipolar disorder;
KIRP	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.58	-6.94	-0.4	3.48e-11	Monocyte count;
KIRP	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.77	7.91	0.45	8.81e-14	Uric acid levels;
KIRP	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg02696790	chr15:75250997	RPP25	0.29	5.32	0.32	2.32e-7	Breast cancer;
KIRP	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg07169764	chr2:136633963	MCM6	0.53	6.15	0.36	3.18e-9	Mosquito bite size;
KIRP	cis	rs55788414	0.932	rs729265	chr16:81183600	G/A	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg19592336	chr6:28129416	ZNF389	0.48	5.51	0.33	8.85e-8	Depression;
KIRP	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-5.97	-0.36	8.02e-9	Prudent dietary pattern;
KIRP	trans	rs76734026	0.515	rs11158585	chr14:65716650	C/T	cg11517728	chr15:22955872	CYFIP1	0.45	6.02	0.36	6.27e-9	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg03152288	chr2:177042942	NA	0.67	9.42	0.51	3.55e-18	IgG glycosylation;
KIRP	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg26248373	chr2:1572462	NA	-0.65	-6.11	-0.36	3.9e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs697003	1.000	rs697003	chr1:211843076	C/G	cg07170222	chr1:211849252	NEK2	-0.35	-4.95	-0.3	1.38e-6	Red cell distribution width;
KIRP	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg10755058	chr3:40428713	ENTPD3	0.39	5.28	0.32	2.88e-7	Renal cell carcinoma;
KIRP	cis	rs7009516	0.783	rs4872228	chr8:24219671	G/C	cg01759110	chr8:24241694	ADAMDEC1	-0.29	-5.64	-0.34	4.75e-8	Hair greying;
KIRP	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg01338084	chr22:32026380	PISD	1.09	7.61	0.44	5.71e-13	Age-related hearing impairment;
KIRP	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs7590368	0.673	rs17365181	chr2:10937980	T/C	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.56	-6.55	-0.39	3.34e-10	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg01879757	chr17:41196368	BRCA1	-0.79	-10.85	-0.57	1.15e-22	Menopause (age at onset);
KIRP	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg24315340	chr6:146058215	EPM2A	-0.46	-5.87	-0.35	1.37e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.41	-5.75	-0.34	2.65e-8	Blood metabolite levels;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg11204139	chr17:3907470	NA	-0.81	-14.84	-0.69	5.04e-36	Type 2 diabetes;
KIRP	cis	rs9381107	0.505	rs1001384	chr6:9485556	G/A	cg14735645	chr6:9486422	NA	-0.56	-7.73	-0.44	2.72e-13	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs12230513	0.732	rs61957764	chr12:55867916	G/A	cg11794356	chr12:55725991	OR6C3	-0.53	-6.34	-0.37	1.07e-9	Contrast sensitivity;
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-5.16	-0.31	5.19e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg09473613	chr1:24152604	HMGCL	0.45	6.14	0.36	3.34e-9	Immature fraction of reticulocytes;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.89	-13.39	-0.65	4.43e-31	Height;
KIRP	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg16606324	chr3:10149918	C3orf24	0.57	5.31	0.32	2.4e-7	Alzheimer's disease;
KIRP	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg12861170	chr19:19639553	YJEFN3	0.47	4.9	0.3	1.71e-6	Bipolar disorder;
KIRP	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.71	0.39	1.29e-10	Height;
KIRP	cis	rs1983891	0.955	rs2025645	chr6:41519654	A/G	cg20194872	chr6:41519635	FOXP4	0.55	7.11	0.41	1.28e-11	Prostate cancer;
KIRP	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg01689657	chr7:91764605	CYP51A1	0.46	6.83	0.4	6.75e-11	Breast cancer;
KIRP	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.78	7.8	0.45	1.79e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9400467	0.508	rs456871	chr6:111687650	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.92e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg05347473	chr6:146136440	FBXO30	0.61	8.69	0.48	5.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg12826209	chr6:26865740	GUSBL1	0.77	5.4	0.33	1.56e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg21775007	chr8:11205619	TDH	0.43	5.37	0.32	1.8e-7	Neuroticism;
KIRP	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg11382394	chr1:2564504	MMEL1	0.4	5.04	0.31	9.03e-7	Ulcerative colitis;
KIRP	cis	rs8014252	0.803	rs10483830	chr14:71054478	T/C	cg19730268	chr14:71022823	NA	-0.65	-6.04	-0.36	5.54e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.44	0.43	1.65e-12	Aortic root size;
KIRP	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-7.51	-0.43	1.07e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-12.34	-0.62	1.48e-27	Exhaled nitric oxide output;
KIRP	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.52	6.52	0.38	3.91e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs1883415	0.534	rs2760149	chr6:24477848	C/T	cg20631270	chr6:24437470	GPLD1	0.39	4.99	0.3	1.13e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9420	0.528	rs7102271	chr11:57396825	G/T	cg19752551	chr11:57585705	CTNND1	-0.59	-8.37	-0.47	4.36e-15	Schizophrenia;
KIRP	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg04058563	chr4:185651563	MLF1IP	0.49	6.6	0.39	2.57e-10	Kawasaki disease;
KIRP	cis	rs3784262	0.643	rs2453280	chr15:58368379	C/T	cg12031962	chr15:58353849	ALDH1A2	0.38	5.22	0.32	3.9e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1010254	0.510	rs72808303	chr5:151718049	C/T	cg12297329	chr5:152029980	NA	-0.65	-6.6	-0.39	2.56e-10	Optic nerve measurement (cup area);
KIRP	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg19346786	chr7:2764209	NA	0.28	5.06	0.31	8.18e-7	Loneliness (linear analysis);
KIRP	cis	rs16828019	0.704	rs12031277	chr1:41491801	A/G	cg18742814	chr1:41828276	NA	0.67	5.7	0.34	3.48e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.23	-0.32	3.66e-7	Lung cancer;
KIRP	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg05805236	chr11:65401703	PCNXL3	-0.47	-6.14	-0.36	3.31e-9	Acne (severe);
KIRP	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.28	0.67	4.17e-34	Platelet count;
KIRP	cis	rs80130819	0.688	rs4760698	chr12:48592872	C/T	cg26205652	chr12:48591994	NA	0.48	5.39	0.33	1.62e-7	Prostate cancer;
KIRP	cis	rs1440410	0.798	rs9992285	chr4:144060823	G/T	cg01719995	chr4:144104893	USP38	0.44	6.03	0.36	6.05e-9	Ischemic stroke;
KIRP	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg12486944	chr17:80159399	CCDC57	0.36	4.92	0.3	1.59e-6	Life satisfaction;
KIRP	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.17	13.83	0.66	1.4e-32	Sexual dysfunction (female);
KIRP	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg15880211	chr22:50250494	ZBED4	-0.66	-7.43	-0.43	1.74e-12	Schizophrenia;
KIRP	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg18490616	chr2:88469792	THNSL2	-0.66	-5.13	-0.31	5.91e-7	Plasma clusterin levels;
KIRP	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.96	7.87	0.45	1.16e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16570995	chr6:37138163	PIM1	0.49	6.06	0.36	5.13e-9	Parkinson's disease;
KIRP	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.72	5.83	0.35	1.73e-8	IgG glycosylation;
KIRP	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.48	5.01	0.3	1.03e-6	Type 2 diabetes;
KIRP	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs240764	0.621	rs6925316	chr6:101209137	C/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.25	-0.32	3.32e-7	Neuroticism;
KIRP	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.91	10.17	0.54	1.64e-20	HIV-1 control;
KIRP	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11613427	chr3:52932208	TMEM110	-0.3	-5.05	-0.31	8.67e-7	Schizophrenia;
KIRP	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg21452805	chr1:244014465	NA	0.57	5.48	0.33	1.06e-7	RR interval (heart rate);
KIRP	trans	rs72634258	0.519	rs36040967	chr1:7931804	A/G	cg26848524	chr8:55294566	NA	-0.43	-6.08	-0.36	4.47e-9	Inflammatory bowel disease;
KIRP	cis	rs10769945	0.538	rs739906	chr11:1980568	T/C	cg23202291	chr11:1979235	NA	-0.47	-6.08	-0.36	4.61e-9	DNA methylation (variation);
KIRP	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	4.94	0.3	1.43e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.47	-6.55	-0.39	3.42e-10	Systolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03940137	chr1:200708937	CAMSAP1L1	0.54	7.07	0.41	1.64e-11	Parkinson's disease;
KIRP	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.87	-11.59	-0.59	4.54e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs12019361	0.541	rs28381868	chr7:87189184	C/T	cg00919237	chr7:87102261	ABCB4	-0.57	-4.87	-0.3	1.96e-6	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
KIRP	cis	rs8033133	0.560	rs12904560	chr15:25315967	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.49	-5.93	-0.35	1.03e-8	Blood osmolality (transformed sodium);
KIRP	cis	rs10858047	0.883	rs72698008	chr1:115086264	A/G	cg12756093	chr1:115239321	AMPD1	0.64	6.11	0.36	3.87e-9	Autism;
KIRP	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.53	-0.38	3.83e-10	Mood instability;
KIRP	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-1.06	-10.24	-0.55	1.01e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.51	6.06	0.36	5.02e-9	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.52	-0.43	1.03e-12	Aortic root size;
KIRP	cis	rs8077577	0.747	rs2071242	chr17:18154510	T/C	cg18869244	chr17:18121946	NA	0.46	5.24	0.32	3.43e-7	Obesity-related traits;
KIRP	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	9.08	0.5	3.56e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2387326	0.717	rs10829334	chr10:129943402	C/T	cg16087940	chr10:129947807	NA	-0.36	-4.85	-0.3	2.24e-6	Select biomarker traits;
KIRP	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	8.99	0.5	6.9e-17	Resting heart rate;
KIRP	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg02415014	chr8:143852576	LYNX1	0.33	5.14	0.31	5.52e-7	Urinary tract infection frequency;
KIRP	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00376283	chr12:123451042	ABCB9	0.67	8.13	0.46	2.05e-14	Neutrophil percentage of white cells;
KIRP	cis	rs33912345	0.695	rs1254252	chr14:60821209	T/G	cg27398547	chr14:60952738	C14orf39	-0.4	-5.43	-0.33	1.36e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-4.97	-0.3	1.26e-6	Schizophrenia (age at onset);
KIRP	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.52	-7.35	-0.42	2.86e-12	Type 2 diabetes;
KIRP	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	1.19	10.87	0.57	9.65e-23	Lymphocyte counts;
KIRP	cis	rs14403	1.000	rs12134270	chr1:243662668	T/G	cg21452805	chr1:244014465	NA	0.52	5.11	0.31	6.32e-7	Schizophrenia;
KIRP	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.65	-10.04	-0.54	4.22e-20	Pulse pressure;
KIRP	cis	rs963731	0.649	rs212322	chr2:39305928	C/T	cg04010122	chr2:39346883	SOS1	-0.67	-5.14	-0.31	5.72e-7	Corticobasal degeneration;
KIRP	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.55	-6.84	-0.4	6.31e-11	Breast cancer;
KIRP	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg17724175	chr1:150552817	MCL1	0.35	5.93	0.35	9.98e-9	Melanoma;
KIRP	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg08885076	chr2:99613938	TSGA10	-0.38	-5.06	-0.31	8.39e-7	Chronic sinus infection;
KIRP	cis	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg06027949	chr8:82754900	SNX16	0.61	6.38	0.38	8.6e-10	Diastolic blood pressure;
KIRP	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-9.34	-0.51	6.18e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs7760949	0.963	rs9396248	chr6:13906360	A/G	cg27413430	chr6:13925136	RNF182	0.43	5.56	0.33	7.05e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg04438997	chr17:70115868	SOX9	0.38	5.53	0.33	8.04e-8	Thyroid hormone levels;
KIRP	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg16989719	chr2:238392110	NA	-0.63	-6.11	-0.36	3.88e-9	Prostate cancer;
KIRP	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	1.01	17.67	0.75	1.13e-45	Breast cancer;
KIRP	cis	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg13444842	chr1:152974279	SPRR3	-0.38	-5.47	-0.33	1.08e-7	Inflammatory skin disease;
KIRP	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg23978390	chr7:1156363	C7orf50	0.62	8.2	0.46	1.35e-14	Longevity;Endometriosis;
KIRP	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg26248373	chr2:1572462	NA	-0.69	-7.38	-0.43	2.39e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs986417	0.818	rs7153263	chr14:61099261	G/A	cg27398547	chr14:60952738	C14orf39	0.55	5.26	0.32	3.08e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs4740619	0.619	rs1328279	chr9:16030606	A/G	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	cis	rs698833	0.886	rs6721675	chr2:44566027	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.37	0.32	1.78e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg17863274	chr19:49399704	TULP2	-0.4	-5.66	-0.34	4.13e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg02487422	chr3:49467188	NICN1	0.35	4.87	0.3	2.02e-6	Parkinson's disease;
KIRP	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg03959625	chr15:84868606	LOC388152	0.71	8.44	0.47	2.69e-15	Schizophrenia;
KIRP	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg11350586	chr17:70115862	SOX9	-0.37	-5.42	-0.33	1.42e-7	Thyroid hormone levels;
KIRP	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg00204512	chr16:28754710	NA	0.43	5.64	0.34	4.62e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2019216	0.542	rs3829569	chr17:21909222	T/C	cg22648282	chr17:21454238	C17orf51	-0.52	-6.63	-0.39	2.08e-10	Pelvic organ prolapse;
KIRP	cis	rs981844	1.000	rs1371161	chr4:154655171	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.41	0.43	2.08e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs72820985	1.000	rs12444243	chr16:80843513	G/A	cg04448709	chr16:81349954	GAN	-0.49	-5.05	-0.31	8.46e-7	Breast cancer;
KIRP	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg18461458	chr19:21324796	ZNF431	0.48	5.13	0.31	5.96e-7	Pain;
KIRP	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-0.99	-9.34	-0.51	6.06e-18	Post bronchodilator FEV1;
KIRP	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.38	4.87	0.3	1.96e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.02	-0.5	5.67e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.91	0.35	1.11e-8	Diabetic retinopathy;
KIRP	trans	rs17079247	0.841	rs9594007	chr13:85811361	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.07	-0.36	4.77e-9	Bipolar disorder (mania);
KIRP	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.87e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg01428437	chr1:1852164	TMEM52	0.28	4.86	0.3	2.12e-6	Body mass index;
KIRP	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg15269541	chr15:43626905	ADAL	-0.41	-4.93	-0.3	1.51e-6	Lung cancer in ever smokers;
KIRP	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.68	-0.34	3.72e-8	Bipolar disorder;
KIRP	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg15440763	chr7:158190612	PTPRN2	0.49	6.08	0.36	4.49e-9	Obesity-related traits;
KIRP	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg10117171	chr1:25599238	RHD	-0.4	-5.25	-0.32	3.22e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg19773385	chr1:10388646	KIF1B	-0.42	-6.15	-0.36	3.16e-9	Hepatocellular carcinoma;
KIRP	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg24169773	chr3:122142474	KPNA1	-0.57	-6.35	-0.38	1.03e-9	LDL cholesterol levels;
KIRP	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.76	0.4	9.76e-11	Colorectal cancer;
KIRP	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.54	-6.86	-0.4	5.44e-11	Type 2 diabetes;
KIRP	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.57	7.47	0.43	1.43e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.34	-0.32	2.1e-7	Fibrinogen levels;
KIRP	cis	rs6545883	0.965	rs10186325	chr2:61757721	G/T	cg15711740	chr2:61764176	XPO1	-0.56	-7.45	-0.43	1.58e-12	Tuberculosis;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6988985	0.560	rs4736343	chr8:143933200	G/A	cg17812120	chr8:144639478	GSDMD	0.4	4.84	0.3	2.25e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg01843034	chr6:37503916	NA	-0.96	-15.54	-0.7	2.13e-38	Cognitive performance;
KIRP	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.46	6.49	0.38	4.72e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.6	0.39	2.54e-10	Electroencephalogram traits;
KIRP	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11987759	chr7:65425863	GUSB	0.63	9.03	0.5	5.2e-17	Calcium levels;
KIRP	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.49	6.68	0.39	1.56e-10	Red blood cell count;
KIRP	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.84	9.29	0.51	8.79e-18	Iron status biomarkers;
KIRP	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg25251562	chr2:3704773	ALLC	-0.51	-6.0	-0.36	7.07e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.56	8.53	0.48	1.54e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	6.94	0.4	3.55e-11	Tonsillectomy;
KIRP	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg05127821	chr10:94822908	CYP26C1	-1.1	-11.26	-0.58	5.51e-24	Coronary artery disease;
KIRP	cis	rs4478037	1.000	rs59229836	chr3:33162622	T/C	cg19404215	chr3:33155277	CRTAP	0.73	6.78	0.4	8.88e-11	Major depressive disorder;
KIRP	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.67	0.34	4.02e-8	Schizophrenia;
KIRP	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.62	-5.44	-0.33	1.26e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs8077577	1.000	rs2015336	chr17:18073610	A/G	cg04398451	chr17:18023971	MYO15A	-0.47	-4.86	-0.3	2.07e-6	Obesity-related traits;
KIRP	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg04990556	chr1:26633338	UBXN11	0.63	5.87	0.35	1.4e-8	Obesity-related traits;
KIRP	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg08069370	chr15:64387884	SNX1	0.4	5.41	0.33	1.5e-7	Monocyte count;
KIRP	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg01988459	chr11:68622903	NA	-0.37	-5.4	-0.33	1.56e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.79	-0.4	8.41e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg08975724	chr8:8085496	FLJ10661	-0.56	-6.02	-0.36	6.17e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.73	6.99	0.41	2.52e-11	Arsenic metabolism;
KIRP	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	11.98	0.61	2.4e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.39	9.44	0.52	2.9e-18	Corneal astigmatism;
KIRP	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg24315340	chr6:146058215	EPM2A	0.43	5.41	0.33	1.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	0.72	10.27	0.55	7.92e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.75	0.44	2.4e-13	Joint mobility (Beighton score);
KIRP	cis	rs2273669	0.667	rs113477421	chr6:109310268	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-5.77	-0.35	2.36e-8	Prostate cancer;
KIRP	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg23477460	chr3:66848765	NA	0.75	7.69	0.44	3.53e-13	Type 2 diabetes;
KIRP	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg19507638	chr5:93509721	C5orf36	-0.55	-5.19	-0.31	4.39e-7	Diabetic retinopathy;
KIRP	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.83	-0.45	1.49e-13	Platelet count;
KIRP	cis	rs2274273	0.805	rs8012156	chr14:55552500	G/T	cg04306507	chr14:55594613	LGALS3	0.41	6.3	0.37	1.38e-9	Protein biomarker;
KIRP	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.6	-6.85	-0.4	5.72e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-4.86	-0.3	2.1e-6	Neuroticism;
KIRP	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg02811702	chr13:24901961	NA	0.43	5.24	0.32	3.44e-7	Obesity-related traits;
KIRP	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.47	0.38	5.26e-10	Height;
KIRP	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg16989719	chr2:238392110	NA	-0.58	-5.89	-0.35	1.28e-8	Prostate cancer;
KIRP	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg02023728	chr11:77925099	USP35	0.31	5.44	0.33	1.27e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg16414030	chr3:133502952	NA	0.46	5.48	0.33	1.04e-7	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg04438997	chr17:70115868	SOX9	-0.38	-5.59	-0.34	6.09e-8	Thyroid hormone levels;
KIRP	cis	rs8054556	0.787	rs3814877	chr16:30042677	G/T	cg06326092	chr16:30034487	C16orf92	0.46	6.58	0.39	2.78e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs918629	0.761	rs6881872	chr5:95286726	A/C	cg16656078	chr5:95278638	ELL2	-0.51	-7.25	-0.42	5.26e-12	IgG glycosylation;
KIRP	cis	rs6832769	1.000	rs1522108	chr4:56380733	T/C	cg05960024	chr4:56376020	CLOCK	0.7	8.53	0.48	1.54e-15	Personality dimensions;
KIRP	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-5.8	-0.35	2e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg02733842	chr7:1102375	C7orf50	0.56	5.92	0.35	1.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25493687	chr8:27288214	PTK2B	0.54	6.49	0.38	4.81e-10	Interleukin-4 levels;
KIRP	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.41	5.26	0.32	3.07e-7	Aortic root size;
KIRP	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.32	0.32	2.35e-7	Menopause (age at onset);
KIRP	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg12292205	chr6:26970375	C6orf41	0.5	7.29	0.42	4.24e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-7.87	-0.45	1.13e-13	Facial morphology (factor 19);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27338695	chr8:41435702	AGPAT6	0.47	6.63	0.39	2.1e-10	Survival in pancreatic cancer;
KIRP	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg23127183	chr11:57508653	C11orf31	-0.47	-6.31	-0.37	1.31e-9	Schizophrenia;
KIRP	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.75	-0.44	2.42e-13	Retinal vascular caliber;
KIRP	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg00792783	chr2:198669748	PLCL1	0.47	5.28	0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs73058052	0.531	rs3745475	chr19:50100295	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.51	6.19	0.37	2.54e-9	Fibrinogen levels;
KIRP	cis	rs6752107	0.935	rs10929325	chr2:234151031	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.49	6.43	0.38	6.72e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1978968	1.000	rs7291169	chr22:18449038	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.78	-0.4	8.68e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.47	11.64	0.6	3.04e-25	Gout;
KIRP	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg16497661	chr14:103986332	CKB	0.84	14.64	0.68	2.59e-35	Body mass index;
KIRP	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg13010199	chr12:38710504	ALG10B	-0.38	-4.86	-0.3	2.08e-6	Bladder cancer;
KIRP	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg17554472	chr22:41940697	POLR3H	-0.45	-5.44	-0.33	1.3e-7	Neuroticism;
KIRP	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.08	-15.4	-0.7	6.16e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs73206853	0.925	rs12318836	chr12:110642190	A/C	cg12870014	chr12:110450643	ANKRD13A	0.44	4.95	0.3	1.36e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg24579218	chr15:68104479	NA	-0.43	-6.26	-0.37	1.67e-9	Obesity;
KIRP	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.91	0.3	1.65e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4936894	0.500	rs12807551	chr11:124129518	A/G	cg27160556	chr11:124181099	OR8D1	-0.38	-5.59	-0.34	6e-8	Aging (time to death);
KIRP	cis	rs7246967	0.604	rs58653025	chr19:22941617	T/C	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.67	8.35	0.47	5.05e-15	Aortic root size;
KIRP	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.43e-12	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13939156	chr17:80058883	NA	-0.5	-7.62	-0.44	5.4e-13	Life satisfaction;
KIRP	trans	rs2048656	0.523	rs6990300	chr8:9547861	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.25	-0.37	1.81e-9	Schizophrenia;
KIRP	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg01990225	chr2:97406019	LMAN2L	-1.1	-7.34	-0.42	3.1e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	13.16	0.64	2.76e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.79	-11.35	-0.59	2.66e-24	Blood metabolite levels;
KIRP	cis	rs10929159	0.894	rs1349729	chr2:236928217	A/G	cg20128773	chr2:236923534	AGAP1	0.3	5.05	0.31	8.51e-7	Parkinson's disease;
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.52	7.06	0.41	1.67e-11	Menarche (age at onset);
KIRP	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	1.1	11.99	0.61	2.15e-26	Corneal structure;
KIRP	cis	rs6738485	0.930	rs13015630	chr2:106790253	T/C	cg16099169	chr2:106886729	NA	-0.38	-5.48	-0.33	1.04e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-20.9	-0.8	1.83e-56	Height;
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg22903657	chr4:1355424	KIAA1530	-0.39	-5.58	-0.33	6.45e-8	Obesity-related traits;
KIRP	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg02725872	chr8:58115012	NA	-0.45	-5.33	-0.32	2.26e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.84	-0.4	6.14e-11	Monocyte percentage of white cells;
KIRP	cis	rs11209002	0.614	rs7519768	chr1:67555522	C/T	cg02640540	chr1:67518911	SLC35D1	0.59	6.59	0.39	2.63e-10	Crohn's disease;
KIRP	trans	rs12043259	0.730	rs911990	chr1:204810636	A/G	cg11485465	chr5:54518469	NA	0.35	6.26	0.37	1.69e-9	Addiction;
KIRP	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg04672837	chr16:48644449	N4BP1	0.51	7.1	0.41	1.3e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	14.52	0.68	6.58e-35	Cognitive ability;
KIRP	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg23587288	chr2:27483067	SLC30A3	-0.69	-7.86	-0.45	1.22e-13	Blood metabolite levels;
KIRP	trans	rs62103177	0.683	rs13838	chr18:77663409	C/G	cg05926928	chr17:57297772	GDPD1	1.22	13.42	0.65	3.58e-31	Opioid sensitivity;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00607526	chr5:131347278	ACSL6	-0.43	-6.26	-0.37	1.66e-9	Myopia;
KIRP	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.93	15.05	0.69	9.91e-37	Menopause (age at onset);
KIRP	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.51	7.25	0.42	5.22e-12	Testicular germ cell tumor;
KIRP	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg21252483	chr19:49399788	TULP2	-0.42	-8.21	-0.46	1.22e-14	Red cell distribution width;
KIRP	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.45	-5.72	-0.34	3.1e-8	Blood protein levels;
KIRP	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg06223162	chr1:101003688	GPR88	-0.43	-8.89	-0.49	1.31e-16	Monocyte count;
KIRP	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.78	7.52	0.43	1.01e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12431939	0.744	rs12888250	chr14:51669195	C/G	cg23942311	chr14:51606299	NA	0.48	5.71	0.34	3.29e-8	Cancer;
KIRP	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-7.34	-0.42	3.11e-12	Monocyte percentage of white cells;
KIRP	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg17182837	chr8:41585554	ANK1	-0.47	-4.87	-0.3	1.98e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg27170947	chr2:26402098	FAM59B	0.65	6.93	0.4	3.61e-11	Gut microbiome composition (summer);
KIRP	cis	rs11735612	0.624	rs4365774	chr4:138525438	T/A	cg12033966	chr4:138453416	PCDH18	0.36	5.01	0.3	1.04e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg10223061	chr2:219282414	VIL1	-0.33	-5.32	-0.32	2.36e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2224391	0.628	rs2753234	chr6:5251050	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.57	-0.39	3.06e-10	Height;
KIRP	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg05304507	chr6:116381966	FRK	0.21	5.6	0.34	5.64e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.42	-5.57	-0.33	6.55e-8	Educational attainment;
KIRP	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.73	9.7	0.53	4.66e-19	Breast cancer;
KIRP	cis	rs12282928	0.959	rs871248	chr11:48284258	C/A	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.14	0.61	6.89e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.85	0.35	1.6e-8	Renal cell carcinoma;
KIRP	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg08992911	chr2:238395768	MLPH	0.53	5.38	0.32	1.7e-7	Prostate cancer;
KIRP	cis	rs494562	0.730	rs9362209	chr6:86114491	C/T	cg21730993	chr6:86159210	NT5E	0.56	5.49	0.33	1e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.5e-39	Headache;
KIRP	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.77	9.71	0.53	4.6e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.15	-0.37	3.06e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.61	-7.05	-0.41	1.85e-11	Menarche (age at onset);
KIRP	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.35	5.72	0.34	3.03e-8	Monocyte count;
KIRP	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.66	-0.39	1.76e-10	Total body bone mineral density;
KIRP	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg07071690	chr14:105416582	AHNAK2	-0.34	-4.86	-0.3	2.12e-6	Rheumatoid arthritis;
KIRP	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs9400467	0.506	rs12198556	chr6:111662338	C/T	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg08662619	chr6:150070041	PCMT1	-0.34	-5.48	-0.33	1.07e-7	Lung cancer;
KIRP	trans	rs2856321	0.874	rs1009953	chr12:11893128	A/C	cg10155026	chr12:4553029	FGF6	-0.41	-6.14	-0.36	3.24e-9	Height;
KIRP	cis	rs72653721	0.756	rs116642513	chr6:11059211	A/G	cg13562911	chr6:11044106	ELOVL2	0.5	5.13	0.31	5.98e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.97	11.45	0.59	1.33e-24	Corneal astigmatism;
KIRP	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg24253500	chr15:84953950	NA	0.56	6.32	0.37	1.21e-9	Schizophrenia;
KIRP	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.78	10.1	0.54	2.82e-20	Aortic root size;
KIRP	cis	rs909341	0.678	rs2738778	chr20:62291830	C/T	cg11503966	chr20:62272292	STMN3	-0.49	-6.48	-0.38	5.09e-10	Atopic dermatitis;
KIRP	cis	rs1010254	0.510	rs72806363	chr5:151686969	C/G	cg12297329	chr5:152029980	NA	-0.67	-6.71	-0.39	1.32e-10	Optic nerve measurement (cup area);
KIRP	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg18198730	chr1:247681584	NA	0.57	5.37	0.32	1.86e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8018808	0.935	rs6574372	chr14:77906295	T/G	cg20045696	chr14:77926864	AHSA1	0.46	5.47	0.33	1.11e-7	Myeloid white cell count;
KIRP	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4006360	0.575	rs447608	chr17:39308497	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.41	-5.86	-0.35	1.47e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.61	5.24	0.32	3.43e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.79	8.3	0.47	7.03e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs5762813	0.566	rs28360615	chr22:29338656	G/C	cg02153584	chr22:29168773	CCDC117	0.58	5.7	0.34	3.37e-8	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.53	6.4	0.38	7.75e-10	Breast cancer;
KIRP	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.36	0.65	5.76e-31	Personality dimensions;
KIRP	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg20891283	chr12:69753455	YEATS4	0.64	6.71	0.39	1.32e-10	Response to diuretic therapy;
KIRP	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.9e-11	Retinal vascular caliber;
KIRP	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.16	-11.09	-0.58	1.88e-23	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.93	0.35	1.04e-8	Menopause (age at onset);
KIRP	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.81	-11.6	-0.59	4.29e-25	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg17422427	chr2:241507521	RNPEPL1	0.47	6.29	0.37	1.48e-9	Lung adenocarcinoma;
KIRP	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs259842	0.585	rs7607354	chr2:180690942	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.42	-5.77	-0.35	2.36e-8	Blood protein levels;
KIRP	cis	rs3779635	1.000	rs3779635	chr8:27284692	C/T	cg21186296	chr8:27182909	PTK2B	0.43	5.48	0.33	1.06e-7	Neuroticism;
KIRP	cis	rs3105593	1.000	rs28494067	chr15:50908272	A/G	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.51e-7	QT interval;
KIRP	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg27411982	chr8:10470053	RP1L1	0.42	5.61	0.34	5.44e-8	Retinal vascular caliber;
KIRP	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.67	-0.48	5.96e-16	Retinal vascular caliber;
KIRP	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.32	-0.37	1.24e-9	Height;
KIRP	cis	rs55692468	0.883	rs6434068	chr2:153357541	G/C	cg04681845	chr2:153283485	FMNL2	0.49	6.15	0.36	3.14e-9	Intraocular pressure;
KIRP	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg00262122	chr8:11665843	FDFT1	-0.41	-5.06	-0.31	8.33e-7	Neuroticism;
KIRP	cis	rs7508	0.765	rs2898458	chr8:17913813	G/A	cg01800426	chr8:17659068	MTUS1	-0.46	-5.61	-0.34	5.45e-8	Atrial fibrillation;
KIRP	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7536201	0.936	rs4648889	chr1:25293829	G/A	cg23273869	chr1:25296894	NA	-0.37	-5.05	-0.31	8.54e-7	Psoriasis vulgaris;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.45e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.46	-0.33	1.19e-7	Cardiac Troponin-T levels;
KIRP	cis	rs6977660	0.562	rs12112698	chr7:19781431	A/G	cg07541023	chr7:19748670	TWISTNB	0.58	6.01	0.36	6.81e-9	Thyroid stimulating hormone;
KIRP	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.93	-13.32	-0.65	7.63e-31	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs1448094	0.617	rs4842569	chr12:86468609	T/G	cg00310523	chr12:86230176	RASSF9	-0.42	-6.18	-0.37	2.68e-9	Major depressive disorder;
KIRP	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	0.85	14.4	0.68	1.69e-34	Breast cancer;
KIRP	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.04	-0.36	5.69e-9	Height;
KIRP	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.68	9.7	0.53	4.67e-19	Retinal vascular caliber;
KIRP	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	8.57	0.48	1.14e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg18932078	chr1:2524107	MMEL1	0.4	5.46	0.33	1.18e-7	Ulcerative colitis;
KIRP	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg23594656	chr7:65796392	TPST1	0.39	5.9	0.35	1.2e-8	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08020574	chr16:89557182	ANKRD11	0.49	6.19	0.37	2.48e-9	Parkinson's disease;
KIRP	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.58	5.41	0.33	1.48e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.56	0.39	3.08e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06544989	chr22:39130855	UNC84B	-0.47	-8.31	-0.47	6.53e-15	Menopause (age at onset);
KIRP	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.82	10.28	0.55	7.41e-21	Total cholesterol levels;
KIRP	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg23387468	chr7:139079360	LUC7L2	0.3	5.21	0.32	3.92e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2224391	0.590	rs2753235	chr6:5252182	C/T	cg13962347	chr6:5174647	LYRM4	0.68	9.42	0.51	3.41e-18	Height;
KIRP	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	9.47	0.52	2.46e-18	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.46	-6.49	-0.38	4.71e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.84	0.49	1.86e-16	Bipolar disorder;
KIRP	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.29	-0.32	2.65e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg04025307	chr7:1156635	C7orf50	0.71	5.54	0.33	7.72e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg19743168	chr1:23544995	NA	0.52	7.32	0.42	3.45e-12	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19552494	chr11:60674271	PRPF19	0.51	6.08	0.36	4.56e-9	Smoking initiation;
KIRP	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7572644	0.679	rs17006365	chr2:28123374	T/G	cg27432699	chr2:27873401	GPN1	-0.43	-5.28	-0.32	2.86e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg08461772	chr7:95026248	PON3	0.42	6.09	0.36	4.38e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	1.2	6.86	0.4	5.63e-11	LDL cholesterol;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20834587	chr4:170106468	SH3RF1	-0.45	-7.21	-0.42	6.68e-12	Inflammatory biomarkers;
KIRP	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg22117172	chr7:91764530	CYP51A1	0.43	6.1	0.36	3.98e-9	Breast cancer;
KIRP	cis	rs7674212	0.541	rs11727498	chr4:104100987	C/T	cg16532752	chr4:104119610	CENPE	-0.42	-5.01	-0.3	1.05e-6	Type 2 diabetes;
KIRP	cis	rs6558530	0.863	rs4595147	chr8:1703569	G/T	cg08198773	chr8:1697536	NA	0.41	5.16	0.31	5.03e-7	Systolic blood pressure;
KIRP	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs12220238	0.841	rs10824146	chr10:76076779	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.67	0.39	1.67e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.98	15.46	0.7	3.9e-38	Chronic sinus infection;
KIRP	cis	rs6669119	0.668	rs75509607	chr1:19093763	C/T	cg19637330	chr1:19110922	NA	0.62	5.48	0.33	1.07e-7	Percentage gas trapping;
KIRP	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.44	-5.55	-0.33	7.48e-8	Blood metabolite levels;
KIRP	cis	rs1629083	0.967	rs73024606	chr11:118120366	G/C	cg18857871	chr11:118064634	AMICA1	0.63	8.52	0.48	1.65e-15	Lung cancer;
KIRP	cis	rs12200782	0.932	rs12202419	chr6:26465384	G/T	cg23155468	chr6:27110703	HIST1H2BK	0.67	6.13	0.36	3.46e-9	Small cell lung carcinoma;
KIRP	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.35	0.32	2.02e-7	Total cholesterol levels;
KIRP	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.48	7.33	0.42	3.35e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12074154	chr1:181074635	NA	-0.49	-6.39	-0.38	8.09e-10	Myopia;
KIRP	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg00074818	chr8:8560427	CLDN23	0.38	5.74	0.34	2.73e-8	Obesity-related traits;
KIRP	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.29	-0.47	7.47e-15	Coronary artery disease;
KIRP	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.01	-0.45	4.57e-14	Retinal vascular caliber;
KIRP	cis	rs9372498	0.536	rs62422228	chr6:118957276	T/C	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg14703610	chr5:56206110	C5orf35	0.48	6.67	0.39	1.71e-10	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs7084402	0.967	rs1649058	chr10:60317087	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.89	-0.57	8.19e-23	Refractive error;
KIRP	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg00981070	chr1:2046702	PRKCZ	-0.29	-5.17	-0.31	4.9e-7	Height;
KIRP	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.86	13.02	0.64	7.85e-30	Colorectal cancer;
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg02996583	chr8:142237188	SLC45A4	-0.46	-5.63	-0.34	4.83e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs3935996	0.767	rs12058859	chr1:56302126	C/T	cg00761755	chr17:1531579	SLC43A2	0.44	6.02	0.36	6.21e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg22794795	chr12:113623087	C12orf52;DDX54	-0.46	-6.18	-0.37	2.7e-9	Blood metabolite levels;
KIRP	trans	rs7230711	1.000	rs73960375	chr18:48709654	G/T	cg09299053	chr7:57509762	ZNF716	-0.76	-6.05	-0.36	5.47e-9	Immune response to anthrax vaccine;
KIRP	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg12441052	chr11:66313700	ZDHHC24;ACTN3	0.49	5.08	0.31	7.48e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg23965551	chr5:112312497	DCP2	-0.44	-6.3	-0.37	1.38e-9	Blood metabolite levels;
KIRP	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg22676075	chr6:135203613	NA	0.51	7.32	0.42	3.44e-12	Red blood cell count;
KIRP	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.53	6.6	0.39	2.51e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21107223	chr15:75182455	MPI	-0.43	-6.06	-0.36	5.19e-9	Metabolic traits;
KIRP	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.67	0.52	6.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs10875746	0.903	rs12304476	chr12:48482153	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	5.4	0.33	1.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg23387468	chr7:139079360	LUC7L2	0.3	5.23	0.32	3.68e-7	Diisocyanate-induced asthma;
KIRP	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg06766960	chr11:133703094	NA	-0.74	-10.24	-0.55	9.79e-21	Childhood ear infection;
KIRP	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.41	0.33	1.48e-7	Parkinson's disease;
KIRP	cis	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg08501292	chr6:25962987	TRIM38	1.08	6.16	0.37	2.96e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4654899	0.680	rs3890762	chr1:21198265	G/A	cg08890418	chr1:21044141	KIF17	-0.33	-4.9	-0.3	1.73e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.4	-5.21	-0.32	4.02e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg15507776	chr3:136538369	TMEM22	0.41	5.63	0.34	5.03e-8	Neuroticism;
KIRP	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.46	-9.58	-0.52	1.13e-18	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg23693289	chr8:27183097	PTK2B	0.57	7.4	0.43	2.21e-12	Neuroticism;
KIRP	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.0	16.72	0.73	1.96e-42	Schizophrenia;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg12445378	chr8:48741753	PRKDC	-0.57	-6.11	-0.36	3.79e-9	Response to statin therapy;
KIRP	cis	rs4236601	0.720	rs28587043	chr7:116145696	G/A	cg12739419	chr7:116140593	CAV2	0.45	5.6	0.34	5.71e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs7187994	0.732	rs3764281	chr16:84767152	A/G	cg07647771	chr16:84786436	USP10	-0.48	-5.92	-0.35	1.1e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	1.11	13.78	0.66	2.11e-32	Blood trace element (Cu levels);
KIRP	cis	rs6466055	0.639	rs3823752	chr7:104624626	C/T	cg04380332	chr7:105027541	SRPK2	-0.61	-9.15	-0.5	2.17e-17	Schizophrenia;
KIRP	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.67	5.69	0.34	3.6e-8	Diabetic retinopathy;
KIRP	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.59	0.73	5.29e-42	Electrocardiographic conduction measures;
KIRP	cis	rs6540559	0.611	rs61747285	chr1:210004332	G/A	cg22029157	chr1:209979665	IRF6	0.5	5.19	0.31	4.5e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs7221595	0.825	rs4790552	chr17:3923366	G/A	cg05562828	chr17:3906858	NA	0.62	7.51	0.43	1.11e-12	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.53	-7.43	-0.43	1.73e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.74	-9.25	-0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9398803	0.805	rs1591805	chr6:126717064	A/G	cg19875578	chr6:126661172	C6orf173	0.49	6.31	0.37	1.3e-9	Male-pattern baldness;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00822255	chr10:73579668	PSAP	0.55	7.25	0.42	5.37e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8084125	1.000	rs62105183	chr18:74951589	C/T	cg15443732	chr18:74961078	GALR1	0.6	5.48	0.33	1.05e-7	Obesity-related traits;
KIRP	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	1.09	7.76	0.44	2.23e-13	Skin colour saturation;
KIRP	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	1.05	8.95	0.5	8.78e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20443778	chr2:142887886	LRP1B	0.41	6.21	0.37	2.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	0.94	7.22	0.42	6.29e-12	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs12580194	0.593	rs60142559	chr12:55719192	A/G	cg19537932	chr12:55886519	OR6C68	-0.46	-6.09	-0.36	4.28e-9	Cancer;
KIRP	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.45	5.64	0.34	4.59e-8	Asthma;
KIRP	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.4	-0.33	1.57e-7	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.49	6.54	0.38	3.52e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs6991838	0.584	rs7812446	chr8:66505988	G/T	cg13398993	chr8:66546079	ARMC1	-0.44	-5.05	-0.31	8.76e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs13170463	0.579	rs71606018	chr5:8046191	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg13628971	chr7:2884303	GNA12	0.61	7.52	0.43	1.04e-12	Height;
KIRP	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.62	6.46	0.38	5.42e-10	Parkinson's disease;
KIRP	cis	rs7771547	0.642	rs9470309	chr6:36509751	A/G	cg07856975	chr6:36356162	ETV7	0.35	5.13	0.31	5.99e-7	Platelet distribution width;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.77	-14.68	-0.68	1.88e-35	Lymphocyte counts;
KIRP	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	4.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7082209	1.000	rs12265306	chr10:44811617	C/G	cg13191911	chr10:44806660	NA	-0.51	-4.9	-0.3	1.75e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs11605924	0.766	rs12419690	chr11:45858584	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.52	-6.45	-0.38	5.95e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.53	6.38	0.38	8.61e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg11608241	chr8:8085544	FLJ10661	0.45	5.7	0.34	3.37e-8	Neuroticism;
KIRP	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.52	-0.33	8.38e-8	Headache;
KIRP	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.33	0.42	3.4e-12	Aortic root size;
KIRP	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.71	0.39	1.3100000000000001e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.47	5.3	0.32	2.51e-7	Schizophrenia;
KIRP	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg02175308	chr1:109941060	SORT1	-0.26	-5.0	-0.3	1.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.65	8.73	0.49	3.96e-16	Morning vs. evening chronotype;
KIRP	cis	rs10486003	1.000	rs74999287	chr7:97199279	C/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.66	-5.22	-0.32	3.77e-7	Response to platinum-based agents;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	0.84	14.17	0.67	1e-33	Vitiligo;
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.14	0.36	3.33e-9	Putamen volume;
KIRP	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.93	-14.17	-0.67	9.95e-34	Lung cancer;
KIRP	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.21	0.46	1.24e-14	Motion sickness;
KIRP	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.71	-10.12	-0.54	2.45e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg24531977	chr5:56204891	C5orf35	-0.42	-5.42	-0.33	1.41e-7	Coronary artery disease;
KIRP	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.44	-5.22	-0.32	3.75e-7	Acne (severe);
KIRP	cis	rs9308731	0.583	rs4848406	chr2:111933758	G/A	cg04780086	chr2:111875790	ACOXL	0.42	5.72	0.34	3.13e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg11382394	chr1:2564504	MMEL1	0.38	4.93	0.3	1.51e-6	Ulcerative colitis;
KIRP	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.47	-6.59	-0.39	2.63e-10	Systolic blood pressure;
KIRP	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.29e-16	Prudent dietary pattern;
KIRP	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg11815991	chr20:30193098	ID1	-0.45	-4.87	-0.3	2.02e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs7614311	0.689	rs73122704	chr3:63841228	C/T	cg22134162	chr3:63841271	THOC7	-0.46	-5.03	-0.31	9.58e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.69	9.72	0.53	4.18e-19	Caffeine consumption;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	0.82	9.05	0.5	4.52e-17	Gut microbiome composition (summer);
KIRP	cis	rs5746492	0.568	rs73151057	chr22:18397913	T/G	cg00227156	chr22:18463646	MICAL3;MIR648	0.46	6.24	0.37	1.9e-9	Eotaxin levels;
KIRP	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.48	6.01	0.36	6.48e-9	Height;
KIRP	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.33	-0.32	2.26e-7	Pulmonary function;
KIRP	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg21479132	chr6:26055353	NA	0.81	5.67	0.34	4.09e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9914578	0.943	rs3760231	chr17:2014984	T/C	cg16513277	chr17:2031491	SMG6	-0.71	-8.48	-0.48	2.15e-15	Body mass index;
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg18209359	chr17:80159595	CCDC57	-0.44	-5.8	-0.35	2e-8	Life satisfaction;
KIRP	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg27490568	chr2:178487706	NA	0.46	6.01	0.36	6.74e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs34779708	0.931	rs11010083	chr10:35351531	C/G	cg04310649	chr10:35416472	CREM	-0.6	-7.14	-0.41	1.05e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs60871478	0.680	rs34880331	chr7:786833	A/G	cg05535760	chr7:792225	HEATR2	1.06	10.62	0.56	6.11e-22	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg06307176	chr5:131281290	NA	0.53	5.68	0.34	3.74e-8	Life satisfaction;
KIRP	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.66	-0.44	4.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.49	7.57	0.43	7.54e-13	Testicular germ cell tumor;
KIRP	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.89	0.3	1.85e-6	Tonsillectomy;
KIRP	cis	rs2802372	0.528	rs1892497	chr10:81043707	C/T	cg18688392	chr10:81059414	ZMIZ1	-0.63	-7.52	-0.43	1e-12	Granulocyte count;
KIRP	cis	rs4253311	0.547	rs7377304	chr4:187129780	T/G	cg24794857	chr4:187113578	CYP4V2	0.38	5.17	0.31	4.93e-7	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
KIRP	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05220968	chr6:146057943	EPM2A	-0.38	-5.02	-0.31	9.7e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7766436	1.000	rs7766436	chr6:22598259	C/T	cg13666174	chr6:22585274	NA	-0.4	-5.84	-0.35	1.67e-8	Coronary artery disease;
KIRP	trans	rs6601327	0.543	rs11249948	chr8:9648686	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.36	0.42	2.68e-12	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg13010199	chr12:38710504	ALG10B	0.62	7.59	0.44	6.47e-13	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs1862626	0.506	rs11957122	chr5:56048827	C/T	cg14703610	chr5:56206110	C5orf35	0.4	5.03	0.31	9.59e-7	Cancer (pleiotropy);
KIRP	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg00656387	chr3:40428638	ENTPD3	0.4	5.08	0.31	7.53e-7	Renal cell carcinoma;
KIRP	cis	rs10872587	0.555	rs9497426	chr6:146234644	G/A	cg23711669	chr6:146136114	FBXO30	-0.78	-8.48	-0.48	2.1e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.43	0.33	1.37e-7	Total cholesterol levels;
KIRP	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg03171003	chr2:111875934	NA	0.45	6.37	0.38	9e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs4671458	0.656	rs72821632	chr2:63701374	G/A	cg17519650	chr2:63277830	OTX1	-0.49	-4.97	-0.3	1.25e-6	Subjective well-being;
KIRP	trans	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg14791747	chr16:20752902	THUMPD1	0.62	6.69	0.39	1.46e-10	Cognitive test performance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25263167	chr4:177241220	SPCS3	-0.5	-6.07	-0.36	4.91e-9	Interleukin-4 levels;
KIRP	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg02023728	chr11:77925099	USP35	-0.31	-5.46	-0.33	1.14e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.27e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.49	7.62	0.44	5.59e-13	Testicular germ cell tumor;
KIRP	cis	rs4262150	0.883	rs17488630	chr5:152244165	C/T	cg12297329	chr5:152029980	NA	-0.61	-7.69	-0.44	3.58e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.34	-4.86	-0.3	2.11e-6	Erythrocyte sedimentation rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12953095	chr13:21347486	N6AMT2	0.44	6.49	0.38	4.64e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg04202892	chr2:111875749	ACOXL	0.46	6.39	0.38	8.18e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs738322	0.719	rs34066050	chr22:38612604	G/A	cg17652424	chr22:38574118	PLA2G6	0.26	5.06	0.31	8.37e-7	Cutaneous nevi;
KIRP	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.79	-0.35	2.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg02297831	chr4:17616191	MED28	0.54	6.84	0.4	6.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.35	-0.47	4.99e-15	Response to antipsychotic treatment;
KIRP	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.62	-0.52	8.34e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7027203	0.595	rs7846827	chr9:96546525	C/T	cg14598338	chr9:96623480	NA	0.47	7.37	0.43	2.51e-12	DNA methylation (variation);
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg09060608	chr5:178986726	RUFY1	-0.6	-9.88	-0.53	1.34e-19	Lung cancer;
KIRP	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg27490568	chr2:178487706	NA	0.53	7.29	0.42	4.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16857181	chr7:32931955	KBTBD2	0.56	6.66	0.39	1.82e-10	Smoking initiation;
KIRP	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.44	-4.94	-0.3	1.44e-6	Neutrophil percentage of white cells;
KIRP	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.68	7.28	0.42	4.61e-12	Lymphocyte counts;
KIRP	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg23788917	chr6:8435910	SLC35B3	-0.47	-5.86	-0.35	1.52e-8	Motion sickness;
KIRP	cis	rs10140922	0.966	rs28589517	chr14:35820643	G/A	cg07166546	chr14:35805898	NA	-0.24	-6.06	-0.36	5e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23598886	chr18:12777645	NA	-0.65	-5.07	-0.31	7.74e-7	Inflammatory skin disease;
KIRP	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.65	0.44	4.59e-13	Joint mobility (Beighton score);
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg11859384	chr17:80120422	CCDC57	0.44	5.62	0.34	5.12e-8	Life satisfaction;
KIRP	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg10790698	chr19:18539756	SSBP4	-0.34	-7.4	-0.43	2.21e-12	Breast cancer;
KIRP	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg19601865	chr12:132687172	GALNT9	0.53	7.98	0.45	5.45e-14	Anti-saccade response;
KIRP	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg10189774	chr4:17578691	LAP3	0.57	7.19	0.42	7.63e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.13	-0.31	5.85e-7	Leprosy;
KIRP	cis	rs6540559	0.673	rs17317411	chr1:209961314	C/T	cg06375148	chr1:209958343	C1orf74	-0.61	-4.97	-0.3	1.28e-6	Cleft lip with or without cleft palate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15204119	chr19:10613180	KEAP1	0.51	6.49	0.38	4.64e-10	Parkinson's disease;
KIRP	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	1.03	7.82	0.45	1.51e-13	Skin colour saturation;
KIRP	cis	rs4494114	0.967	rs6696437	chr1:39348165	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-5.03	-0.31	9.38e-7	Blood protein levels;
KIRP	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg17145862	chr1:211918768	LPGAT1	0.62	6.44	0.38	6.32e-10	Crohn's disease;
KIRP	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs59868192	0.925	rs72726025	chr15:42240781	T/C	cg20935245	chr15:42234343	EHD4	-0.55	-5.48	-0.33	1.04e-7	White blood cell count;
KIRP	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs11825685	0.790	rs56657264	chr11:134543459	C/T	cg06603561	chr11:134479413	NA	-0.66	-5.64	-0.34	4.64e-8	IgG glycosylation;
KIRP	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg16511985	chr3:153974050	SGEF	0.39	5.49	0.33	1.02e-7	Coronary artery disease;
KIRP	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.44	-5.53	-0.33	7.96e-8	Motion sickness;
KIRP	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.53	0.65	1.49e-31	Bladder cancer;
KIRP	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.67	-9.5	-0.52	1.98e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23209459	chr19:56652545	ZNF444	0.47	6.02	0.36	6.44e-9	Parkinson's disease;
KIRP	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.21	22.34	0.82	4.04e-61	Cognitive function;
KIRP	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg15432903	chr11:17409602	KCNJ11	-0.51	-5.96	-0.36	8.48e-9	Systolic blood pressure;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg01238044	chr22:24384105	GSTT1	0.42	4.86	0.3	2.06e-6	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-0.99	-11.57	-0.59	5.12e-25	White matter hyperintensity burden;
KIRP	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	trans	rs195204	0.628	rs11102897	chr1:115776964	A/G	cg11818615	chr15:98711013	NA	-0.53	-6.16	-0.37	2.91e-9	Alcoholism (heaviness of drinking);
KIRP	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg01620082	chr3:125678407	NA	-0.84	-6.27	-0.37	1.61e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.4e-12	Prudent dietary pattern;
KIRP	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.49	-6.15	-0.37	3.03e-9	Height;
KIRP	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg20651018	chr11:3035856	CARS	-0.4	-5.64	-0.34	4.59e-8	Longevity;
KIRP	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	1.19	6.66	0.39	1.78e-10	LDL cholesterol;
KIRP	cis	rs815815	0.583	rs878665	chr2:47403129	G/T	cg27223769	chr2:47403360	CALM2	-0.68	-8.11	-0.46	2.47e-14	Dialysis-related mortality;
KIRP	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg18833306	chr6:118973337	C6orf204	0.42	5.3	0.32	2.63e-7	Electrocardiographic conduction measures;
KIRP	trans	rs7555006	0.646	rs7553550	chr1:51463450	C/T	cg17804635	chr8:37554071	ZNF703	-0.48	-6.04	-0.36	5.56e-9	Headache;
KIRP	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg10047753	chr17:41438598	NA	0.87	12.74	0.63	6.83e-29	Menopause (age at onset);
KIRP	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.44	0.43	1.66e-12	Height;
KIRP	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.63	-0.39	2.07e-10	Blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15716707	chr11:65585740	NA	0.54	6.86	0.4	5.44e-11	Parkinson's disease;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg10812733	chr19:49014889	LMTK3	0.55	6.45	0.38	5.89e-10	Electroencephalogram traits;
KIRP	cis	rs4356932	1.000	rs1554013	chr4:76933484	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.17	0.37	2.79e-9	Blood protein levels;
KIRP	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.56	-6.47	-0.38	5.16e-10	Osteoporosis;
KIRP	cis	rs6504950	0.705	rs9899602	chr17:52986908	C/T	cg26251398	chr17:52985966	TOM1L1	-0.39	-5.43	-0.33	1.34e-7	Breast cancer;
KIRP	cis	rs4132509	1.000	rs4132509	chr1:243943084	A/C	cg21452805	chr1:244014465	NA	-0.62	-6.01	-0.36	6.79e-9	RR interval (heart rate);
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.6	5.82	0.35	1.79e-8	Alzheimer's disease;
KIRP	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg16497661	chr14:103986332	CKB	0.53	7.19	0.42	7.84e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12900413	0.687	rs28513927	chr15:90304471	T/G	cg24650279	chr15:90327240	NA	-0.43	-5.46	-0.33	1.18e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11584989	chr19:19387371	SF4	0.58	6.31	0.37	1.29e-9	Bipolar disorder;
KIRP	cis	rs3850699	0.926	rs12262998	chr10:104428716	C/T	cg04362960	chr10:104952993	NT5C2	0.53	5.96	0.36	8.47e-9	Prostate cancer;
KIRP	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg11235152	chr1:67600687	NA	0.71	9.99	0.54	5.87e-20	Psoriasis;
KIRP	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg19468946	chr17:37922297	IKZF3	0.51	7.32	0.42	3.46e-12	Self-reported allergy;
KIRP	cis	rs11997175	0.967	rs11993169	chr8:33738004	G/T	cg04338863	chr8:33670619	NA	0.42	5.51	0.33	9.25e-8	Body mass index;
KIRP	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg17554472	chr22:41940697	POLR3H	-0.48	-5.67	-0.34	3.98e-8	Vitiligo;
KIRP	cis	rs28530674	1.000	rs28605607	chr1:19221879	T/C	cg26407146	chr1:19229049	ALDH4A1	1.02	7.42	0.43	1.85e-12	Eosinophilic esophagitis;
KIRP	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.04	-0.58	2.71e-23	Height;
KIRP	cis	rs2273669	0.667	rs76094073	chr6:109288036	C/G	cg05315195	chr6:109294784	ARMC2	-0.63	-6.05	-0.36	5.35e-9	Prostate cancer;
KIRP	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg05340658	chr4:99064831	C4orf37	0.55	6.84	0.4	6.11e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs778371	0.749	rs2675964	chr2:233793676	A/G	cg11972305	chr2:233791962	NGEF	-0.41	-5.29	-0.32	2.76e-7	Schizophrenia;
KIRP	cis	rs4919044	1.000	rs17108043	chr10:94770697	A/G	cg05127821	chr10:94822908	CYP26C1	0.89	6.33	0.37	1.12e-9	Coronary artery disease;
KIRP	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.81	10.88	0.57	9.18e-23	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14032218	chr1:171755066	METTL13	0.53	6.74	0.39	1.14e-10	Interleukin-4 levels;
KIRP	cis	rs9392653	1.000	rs421273	chr6:5073919	C/G	cg13207534	chr6:5087447	PPP1R3G	0.42	5.19	0.31	4.37e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs7215564	0.818	rs4889878	chr17:78662479	G/T	cg06153925	chr17:78755379	RPTOR	0.32	5.21	0.32	3.97e-7	Myopia (pathological);
KIRP	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg18131467	chr2:239335373	ASB1	-0.63	-6.0	-0.36	7.1e-9	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs1018836	0.828	rs7012741	chr8:91536065	A/G	cg16814680	chr8:91681699	NA	-0.52	-6.06	-0.36	4.99e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.43	0.38	6.54e-10	Breast cancer;
KIRP	cis	rs4664293	0.967	rs13020365	chr2:160476404	G/A	cg08347373	chr2:160653686	CD302	-0.4	-6.18	-0.37	2.62e-9	Monocyte percentage of white cells;
KIRP	cis	rs427941	0.632	rs201504	chr7:101759878	C/G	cg06246474	chr7:101738831	CUX1	0.54	6.58	0.39	2.88e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg21890820	chr11:65308645	LTBP3	0.59	5.64	0.34	4.72e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27297192	chr10:134578999	INPP5A	0.62	7.79	0.45	1.82e-13	Migraine;
KIRP	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs240764	0.584	rs11155653	chr6:101217123	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-5.62	-0.34	5.08e-8	Neuroticism;
KIRP	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg21905437	chr5:178450457	ZNF879	0.46	5.18	0.31	4.67e-7	Pubertal anthropometrics;
KIRP	cis	rs3779635	1.000	rs3779635	chr8:27284692	C/T	cg23736307	chr8:27182930	PTK2B	0.46	5.78	0.35	2.31e-8	Neuroticism;
KIRP	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.69	0.6	2.06e-25	Heart rate;
KIRP	cis	rs10421328	0.784	rs28635562	chr19:19769690	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.46	5.22	0.32	3.86e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.31	0.47	6.56e-15	Motion sickness;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	7.03	0.41	2.01e-11	Lymphocyte counts;
KIRP	cis	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg11503966	chr20:62272292	STMN3	-0.41	-5.91	-0.35	1.16e-8	Atopic dermatitis;
KIRP	cis	rs9653442	0.545	rs4850921	chr2:100762699	G/T	cg07810366	chr2:100720526	AFF3	-0.33	-5.23	-0.32	3.7e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.96	16.44	0.72	1.71e-41	Metabolic syndrome;
KIRP	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg06795125	chr2:108905320	SULT1C2	-0.48	-8.37	-0.47	4.43e-15	Blood pressure;
KIRP	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	11.08	0.58	2e-23	Smoking behavior;
KIRP	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06481639	chr22:41940642	POLR3H	0.7	7.14	0.41	1.07e-11	Vitiligo;
KIRP	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.83	12.65	0.63	1.39e-28	Colorectal cancer;
KIRP	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg10326726	chr10:51549505	MSMB	-0.61	-9.0	-0.5	6.33e-17	Prostate-specific antigen levels;
KIRP	cis	rs300890	0.760	rs13118846	chr4:144210162	A/G	cg19876092	chr4:144208277	NA	-0.41	-6.87	-0.4	5.26e-11	Nasopharyngeal carcinoma;
KIRP	cis	rs4654899	0.865	rs12131353	chr1:21321163	C/G	cg05370193	chr1:21551575	ECE1	0.47	6.1	0.36	4.1e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	1.07	12.4	0.62	9.32e-28	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.7	8.92	0.49	1.12e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.49	5.43	0.33	1.36e-7	Psoriasis;
KIRP	cis	rs504918	0.588	rs6779809	chr3:123964485	A/T	cg05766129	chr3:123988013	KALRN	0.41	5.44	0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs3752645	0.764	rs2041525	chr7:106692591	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-5.19	-0.31	4.35e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.72	10.33	0.55	5.23e-21	Hip circumference;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg01798813	chr17:3906674	NA	0.55	7.71	0.44	3.18e-13	Type 2 diabetes;
KIRP	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg22189786	chr22:42395067	WBP2NL	-0.47	-6.0	-0.36	7.13e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.73	-11.48	-0.59	1.04e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16434002	chr17:42200994	HDAC5	-0.53	-6.77	-0.4	9.42e-11	Total body bone mineral density;
KIRP	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17467752	chr17:38218738	THRA	-0.54	-6.6	-0.39	2.45e-10	Myeloid white cell count;
KIRP	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.36	-6.85	-0.4	5.96e-11	Type 2 diabetes;
KIRP	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg10381502	chr11:71823885	C11orf51	-1.09	-7.61	-0.44	5.85e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.06	0.31	8.23e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.7	0.34	3.33e-8	Motion sickness;
KIRP	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.84	-0.45	1.36e-13	Coffee consumption (cups per day);
KIRP	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg21926883	chr2:100939477	LONRF2	-0.52	-6.95	-0.41	3.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11874712	1.000	rs9783887	chr18:43651272	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.4	-5.53	-0.33	8.14e-8	Migraine - clinic-based;
KIRP	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.89	11.17	0.58	1.09e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg14791747	chr16:20752902	THUMPD1	0.59	6.42	0.38	7.14e-10	Cognitive test performance;
KIRP	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-0.93	-8.49	-0.48	1.97e-15	Plateletcrit;
KIRP	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.96	-0.36	8.76e-9	Joint mobility (Beighton score);
KIRP	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.48	-6.5	-0.38	4.41e-10	Asthma;
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.69	-8.67	-0.48	6.06e-16	Longevity;
KIRP	cis	rs7246657	0.722	rs1531549	chr19:38088009	T/C	cg18154014	chr19:37997991	ZNF793	0.62	6.73	0.39	1.21e-10	Coronary artery calcification;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21969190	chr5:94990682	RFESD	-0.42	-6.51	-0.38	4.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg01528321	chr10:82214614	TSPAN14	1.25	19.95	0.79	2.55e-53	Post bronchodilator FEV1;
KIRP	cis	rs7084402	0.967	rs1649028	chr10:60280428	A/G	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	9.97	0.54	7.22e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg12705353	chr12:122356852	WDR66	0.54	7.15	0.41	1.01e-11	Mean corpuscular volume;
KIRP	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg16589663	chr20:23618590	CST3	0.64	6.81	0.4	7.42e-11	Chronic kidney disease;
KIRP	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.55	6.33	0.37	1.16e-9	Aortic root size;
KIRP	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg26338869	chr17:61819248	STRADA	0.54	6.41	0.38	7.37e-10	Prudent dietary pattern;
KIRP	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.56	-0.48	1.28e-15	Joint mobility (Beighton score);
KIRP	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.73	0.39	1.15e-10	Lung cancer;
KIRP	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-6.28	-0.37	1.54e-9	Morning vs. evening chronotype;
KIRP	cis	rs6743226	0.934	rs4234100	chr2:242265273	A/G	cg10021735	chr2:242295487	FARP2	-0.47	-5.65	-0.34	4.39e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg23752985	chr2:85803571	VAMP8	0.47	5.43	0.33	1.32e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.15	-0.31	5.37e-7	Pulmonary function;
KIRP	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs803923	0.545	rs1441747	chr9:119487811	A/G	cg13792444	chr9:119245443	ASTN2	0.35	5.37	0.32	1.78e-7	Lung function (FEV1/FVC);
KIRP	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.89	10.79	0.57	1.75e-22	Platelet distribution width;
KIRP	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg20169779	chr10:135381914	SYCE1	0.7	7.35	0.42	2.94e-12	Gout;
KIRP	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs2671245	0.933	rs2671240	chr1:56155855	T/C	cg11523071	chr1:56160889	NA	0.41	6.74	0.39	1.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg13293535	chr8:11597251	GATA4	-0.42	-5.45	-0.33	1.25e-7	Retinal vascular caliber;
KIRP	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg12315302	chr6:26189340	HIST1H4D	0.93	6.08	0.36	4.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	1.0	8.91	0.49	1.19e-16	Systolic blood pressure;
KIRP	cis	rs4776059	1.000	rs1863512	chr15:52959687	C/T	cg22715398	chr15:52968154	KIAA1370	-0.66	-8.1	-0.46	2.53e-14	Schizophrenia;
KIRP	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.7	7.81	0.45	1.68e-13	Obesity-related traits;
KIRP	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.41	-0.43	2.03e-12	Bipolar disorder;
KIRP	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg15247329	chr7:2764246	NA	-0.35	-5.33	-0.32	2.22e-7	Height;
KIRP	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.29	-6.26	-0.37	1.69e-9	Asthma (sex interaction);
KIRP	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.54	-0.52	1.43e-18	Gut microbiome composition (summer);
KIRP	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg21064579	chr19:49206444	FUT2	0.55	8.1	0.46	2.51e-14	Dietary macronutrient intake;
KIRP	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg03468072	chr12:39539422	NA	0.41	5.83	0.35	1.72e-8	Morning vs. evening chronotype;
KIRP	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.24	-9.67	-0.52	6.1e-19	Diabetic kidney disease;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-1.12	-21.95	-0.81	6.97e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.93	16.12	0.72	2.12e-40	Metabolic syndrome;
KIRP	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.87	-11.13	-0.58	1.38e-23	Parkinson's disease;
KIRP	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg09754948	chr16:28834200	ATXN2L	-0.44	-4.96	-0.3	1.34e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.04	-19.03	-0.77	2.97e-50	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02960663	chr3:184279415	EPHB3	0.45	6.19	0.37	2.51e-9	Parkinson's disease;
KIRP	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	7.55	0.43	8.36e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4073221	0.654	rs34101648	chr3:18259998	A/G	cg07694806	chr3:18168406	NA	-0.68	-6.01	-0.36	6.63e-9	Parkinson's disease;
KIRP	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.67	-0.44	4.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.64	-9.48	-0.52	2.32e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg27490568	chr2:178487706	NA	0.48	6.45	0.38	5.95e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg01988459	chr11:68622903	NA	-0.43	-5.97	-0.36	8.05e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.63	6.7	0.39	1.38e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.52	-6.55	-0.39	3.35e-10	Uric acid levels;
KIRP	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-8.2	-0.46	1.36e-14	Total body bone mineral density;
KIRP	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.77	-0.35	2.36e-8	Neuroticism;
KIRP	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg13939156	chr17:80058883	NA	0.47	5.54	0.33	7.83e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.16	-0.37	2.88e-9	IgG glycosylation;
KIRP	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	trans	rs62056376	0.736	rs62056379	chr17:32672418	C/A	cg09712683	chr2:95692352	MAL	-0.47	-6.06	-0.36	5.21e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.88	13.92	0.66	7.04e-33	IgG glycosylation;
KIRP	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.61	7.6	0.44	6.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg27532560	chr4:187881888	NA	-0.69	-11.08	-0.58	2.06e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.51	-7.17	-0.42	8.91e-12	Height;
KIRP	cis	rs2625529	0.818	rs2246225	chr15:72115230	C/T	cg16672083	chr15:72433130	SENP8	0.54	6.51	0.38	4.12e-10	Red blood cell count;
KIRP	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg16586182	chr3:47516702	SCAP	-0.67	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.91	15.19	0.7	3.37e-37	Menarche (age at onset);
KIRP	cis	rs7621025	0.500	rs4678275	chr3:136653683	C/T	cg15507776	chr3:136538369	TMEM22	0.79	10.7	0.56	3.36e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs9653442	0.527	rs2118280	chr2:100746395	G/A	cg17356467	chr2:100759845	AFF3	0.39	5.47	0.33	1.09e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	4.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.86	12.88	0.63	2.27e-29	Menarche (age at onset);
KIRP	cis	rs7635838	0.892	rs66974661	chr3:11482729	A/G	cg00170343	chr3:11313890	ATG7	0.47	6.15	0.37	3.04e-9	HDL cholesterol;
KIRP	trans	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg00938859	chr5:1591904	SDHAP3	0.59	7.94	0.45	7.23e-14	Breast cancer;
KIRP	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg15691649	chr6:25882328	NA	0.56	6.06	0.36	5.06e-9	Blood metabolite levels;
KIRP	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.31	-5.95	-0.35	9.38e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.58	9.36	0.51	5.16e-18	C-reactive protein levels;
KIRP	trans	rs9329221	0.508	rs6601455	chr8:10273426	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	6.78	0.4	8.79e-11	Neuroticism;
KIRP	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.42	-5.34	-0.32	2.07e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	0.74	10.25	0.55	9.1e-21	Diastolic blood pressure;
KIRP	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs4692589	0.965	rs2291167	chr4:170950887	G/A	cg19918862	chr4:170955249	NA	0.48	5.88	0.35	1.33e-8	Anxiety disorder;
KIRP	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.42	-0.33	1.39e-7	Aortic root size;
KIRP	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.74	6.51	0.38	4.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	1.01	12.65	0.63	1.43e-28	Exhaled nitric oxide output;
KIRP	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02725872	chr8:58115012	NA	-0.75	-7.65	-0.44	4.53e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg09699651	chr6:150184138	LRP11	0.47	6.19	0.37	2.45e-9	Lung cancer;
KIRP	cis	rs41341749	0.831	rs76190126	chr17:34310256	C/A	cg02633371	chr17:35298618	LHX1	-0.4	-5.08	-0.31	7.55e-7	Blood protein levels;
KIRP	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.69	-9.02	-0.5	5.63e-17	Huntington's disease progression;
KIRP	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg17182837	chr8:41585554	ANK1	-0.47	-6.52	-0.38	3.99e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg24585782	chr17:78113791	EIF4A3	-0.55	-6.48	-0.38	5.1e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13279522	0.536	rs4262310	chr8:67000607	T/G	cg04041976	chr8:67085823	TRIM55	-0.44	-5.49	-0.33	9.88e-8	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.62	-8.54	-0.48	1.41e-15	Longevity;Endometriosis;
KIRP	cis	rs2665103	0.610	rs56398167	chr15:82529823	T/C	cg00614314	chr15:82944287	LOC80154	0.39	5.05	0.31	8.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.7	-8.87	-0.49	1.55e-16	Neutrophil percentage of white cells;
KIRP	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12311304	1.000	rs1479405	chr12:15387519	C/T	cg08258403	chr12:15378311	NA	0.38	5.64	0.34	4.6e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg27205649	chr11:78285834	NARS2	-0.65	-7.32	-0.42	3.59e-12	Alzheimer's disease (survival time);
KIRP	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.66	8.55	0.48	1.33e-15	Prudent dietary pattern;
KIRP	cis	rs76693355	0.512	rs11217866	chr11:120300804	T/A	cg24566217	chr11:120254723	ARHGEF12	-0.43	-5.6	-0.34	5.73e-8	Intraocular pressure;
KIRP	cis	rs2224391	0.628	rs2753222	chr6:5242075	T/A	cg13962347	chr6:5174647	LYRM4	-0.77	-10.9	-0.57	7.6e-23	Height;
KIRP	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg09264619	chr17:80180166	NA	0.51	6.02	0.36	6.14e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1413885	0.549	rs1334879	chr1:65846051	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	5.76	0.34	2.47e-8	Anticoagulant levels;
KIRP	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-1.02	-17.32	-0.74	1.81e-44	Height;
KIRP	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg15655495	chr12:38532458	NA	-0.29	-5.4	-0.33	1.6e-7	Bladder cancer;
KIRP	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.51	7.29	0.42	4.31e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3741151	0.686	rs11823913	chr11:73141627	C/G	cg17517138	chr11:73019481	ARHGEF17	0.65	5.64	0.34	4.71e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg04310649	chr10:35416472	CREM	-0.55	-6.24	-0.37	1.93e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.55	-6.39	-0.38	8.47e-10	Initial pursuit acceleration;
KIRP	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg27205649	chr11:78285834	NARS2	-0.54	-5.05	-0.31	8.55e-7	Testicular germ cell tumor;
KIRP	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg21926883	chr2:100939477	LONRF2	-0.53	-6.96	-0.41	3.1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg08885076	chr2:99613938	TSGA10	-0.61	-10.98	-0.57	4.51e-23	Chronic sinus infection;
KIRP	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg08126542	chr6:37504118	NA	-0.73	-10.43	-0.55	2.52e-21	Cognitive performance;
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs2594989	0.887	rs4684071	chr3:11443084	C/G	cg01796438	chr3:11312864	ATG7	-0.74	-8.74	-0.49	3.79e-16	Circulating chemerin levels;
KIRP	cis	rs6708331	0.540	rs11890701	chr2:70360457	T/A	cg05298696	chr2:70188691	ASPRV1	-0.4	-5.33	-0.32	2.21e-7	Obesity-related traits;
KIRP	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.54	6.97	0.41	2.89e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.71	9.04	0.5	4.74e-17	Coronary artery disease;
KIRP	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.83	13.35	0.65	5.86e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs748404	0.697	rs579651	chr15:43558376	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.48	0.38	4.9e-10	Lung cancer;
KIRP	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.88	-11.81	-0.6	8.33e-26	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg21285383	chr16:89894308	SPIRE2	0.3	5.58	0.33	6.46e-8	Vitiligo;
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs17453880	0.750	rs2964237	chr5:151927597	T/C	cg12297329	chr5:152029980	NA	-0.49	-7.03	-0.41	2.07e-11	Subjective well-being;
KIRP	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	0.96	11.79	0.6	1.01e-25	Corneal structure;
KIRP	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.91	0.35	1.15e-8	Breast cancer;
KIRP	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.62	7.11	0.41	1.25e-11	Blood pressure;
KIRP	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.91	-12.5	-0.62	4.25e-28	Gut microbiota (bacterial taxa);
KIRP	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26314531	chr2:26401878	FAM59B	0.47	4.9	0.3	1.75e-6	Gut microbiome composition (summer);
KIRP	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg18190219	chr22:46762943	CELSR1	-0.88	-7.09	-0.41	1.43e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7005380	0.581	rs9987135	chr8:120936895	A/T	cg21645572	chr8:120931649	DEPDC6	-0.49	-6.41	-0.38	7.27e-10	Interstitial lung disease;
KIRP	cis	rs6832769	1.000	rs1522106	chr4:56307214	A/C	cg05960024	chr4:56376020	CLOCK	-0.68	-8.46	-0.47	2.36e-15	Personality dimensions;
KIRP	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.64	-8.44	-0.47	2.67e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	12.18	0.61	5.05e-27	Bipolar disorder;
KIRP	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg20701182	chr2:24300061	SF3B14	0.61	5.37	0.32	1.79e-7	Lymphocyte counts;
KIRP	cis	rs4774899	1.000	rs2111891	chr15:57243872	A/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.08	-0.31	7.64e-7	Urinary tract infection frequency;
KIRP	cis	rs12986413	0.624	rs2159213	chr19:2136102	T/C	cg09261902	chr19:2140048	AP3D1	0.7	11.42	0.59	1.6e-24	Height;
KIRP	cis	rs4566357	0.964	rs6436648	chr2:227923004	C/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.07	-0.31	7.96e-7	Coronary artery disease;
KIRP	cis	rs7011507	1.000	rs76768758	chr8:49177322	T/C	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.64	-6.11	-0.36	3.93e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg02462569	chr6:150064036	NUP43	-0.39	-5.81	-0.35	1.93e-8	Lung cancer;
KIRP	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.45	5.46	0.33	1.18e-7	Obesity-related traits;
KIRP	cis	rs17125944	0.615	rs8019585	chr14:53374843	G/A	cg00686598	chr14:53173677	PSMC6	0.73	6.78	0.4	8.96e-11	Alzheimer's disease (late onset);
KIRP	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.84	-12.09	-0.61	9.86e-27	Height;
KIRP	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.66	-8.55	-0.48	1.35e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.09	0.46	2.69e-14	Response to bleomycin (chromatid breaks);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22440951	chr1:226420174	LIN9	-0.36	-6.31	-0.37	1.28e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17598323	chr1:44440401	ATP6V0B	-0.44	-6.02	-0.36	6.28e-9	Metabolic traits;
KIRP	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-0.91	-8.42	-0.47	3.12e-15	Lung cancer;
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg11859384	chr17:80120422	CCDC57	0.46	5.84	0.35	1.67e-8	Life satisfaction;
KIRP	cis	rs2072732	0.756	rs77415878	chr1:2954047	C/G	cg11731671	chr1:2995604	PRDM16	-0.45	-5.65	-0.34	4.49e-8	Plateletcrit;
KIRP	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.74	-9.25	-0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	11.58	0.59	5.04e-25	Smoking behavior;
KIRP	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-1.01	-13.01	-0.64	8.57e-30	Exhaled nitric oxide output;
KIRP	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.99	14.34	0.67	2.68e-34	Cognitive function;
KIRP	cis	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg27518014	chr7:62859535	LOC100287834	-0.51	-5.52	-0.33	8.45e-8	Obesity-related traits;
KIRP	cis	rs2481665	0.806	rs55725347	chr1:62538252	G/A	cg18591186	chr1:62594603	INADL	-0.66	-9.58	-0.52	1.12e-18	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13198984	chr17:80129470	CCDC57	0.56	8.41	0.47	3.34e-15	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13624320	chr5:134734938	H2AFY	0.47	6.22	0.37	2.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.4	0.51	4.02e-18	Lung cancer;
KIRP	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.45	5.03	0.31	9.26e-7	Schizophrenia;
KIRP	cis	rs12145833	0.538	rs4658547	chr1:243391131	T/G	cg02356786	chr1:243265016	LOC731275	-0.71	-5.53	-0.33	8.19e-8	Obesity (early onset extreme);
KIRP	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg26668828	chr6:292823	DUSP22	-0.56	-6.51	-0.38	4.11e-10	Menopause (age at onset);
KIRP	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg08822215	chr16:89438651	ANKRD11	-0.47	-6.22	-0.37	2.13e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg27124370	chr19:33622961	WDR88	0.57	6.97	0.41	2.86e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00950418	chr7:105029125	SRPK2	-0.51	-6.22	-0.37	2.14e-9	Height;
KIRP	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-6.59	-0.39	2.69e-10	Systemic lupus erythematosus;
KIRP	cis	rs75920871	0.528	rs12274465	chr11:116957189	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.26	-0.32	3.14e-7	Subjective well-being;
KIRP	cis	rs6545883	0.894	rs6734628	chr2:61451260	T/C	cg15711740	chr2:61764176	XPO1	0.56	7.2	0.42	7.13e-12	Tuberculosis;
KIRP	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg21184320	chr1:21044207	KIF17	-0.35	-5.3	-0.32	2.62e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.35	0.32	2.05e-7	Menopause (age at onset);
KIRP	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg24130564	chr14:104152367	KLC1	-0.51	-6.83	-0.4	6.78e-11	Body mass index;
KIRP	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.49	-6.49	-0.38	4.72e-10	Schizophrenia;
KIRP	cis	rs11252926	0.603	rs17293419	chr10:537014	G/A	cg18196295	chr10:418757	DIP2C	-0.39	-5.02	-0.3	1e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg19847130	chr8:10466454	RP1L1	0.36	5.37	0.32	1.86e-7	Neuroticism;
KIRP	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.99	17.44	0.74	7.08e-45	Breast cancer;
KIRP	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg18190219	chr22:46762943	CELSR1	-0.74	-7.48	-0.43	1.3e-12	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-0.97	-10.4	-0.55	3.15e-21	Blood pressure (smoking interaction);
KIRP	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-7.07	-0.41	1.6e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	0.25	5.05	0.31	8.72e-7	Lymphocyte counts;
KIRP	cis	rs12049351	0.719	rs3818237	chr1:229631193	A/G	cg11742688	chr1:229674241	ABCB10	-0.37	-5.7	-0.34	3.46e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.59	11.03	0.58	2.9e-23	Mean platelet volume;
KIRP	cis	rs1978968	1.000	rs1110659	chr22:18444675	T/C	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.2	-0.55	1.32e-20	Alzheimer's disease (late onset);
KIRP	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.51	0.43	1.11e-12	Migraine;
KIRP	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	7.73	0.44	2.75e-13	Total cholesterol levels;
KIRP	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg25834613	chr7:1915315	MAD1L1	-0.38	-4.94	-0.3	1.42e-6	Neuroticism;
KIRP	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.2	-24.31	-0.84	2.36e-67	Exhaled nitric oxide output;
KIRP	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	9.87	0.53	1.44e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.91	-12.99	-0.64	1.03e-29	Monocyte count;
KIRP	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs4908768	1.000	rs11121203	chr1:8648240	T/C	cg25722041	chr1:8623473	RERE	0.82	9.99	0.54	6.01e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg00405596	chr8:11794950	NA	-0.5	-6.09	-0.36	4.29e-9	Triglycerides;
KIRP	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.82	-11.01	-0.57	3.59e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg13512537	chr8:22265999	SLC39A14	-0.41	-5.55	-0.33	7.21e-8	Verbal declarative memory;
KIRP	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.54	13.57	0.65	1.08e-31	Airflow obstruction;
KIRP	cis	rs72960926	0.744	rs72954354	chr6:74949552	C/G	cg03266952	chr6:74778945	NA	-0.61	-5.16	-0.31	5.09e-7	Metabolite levels (MHPG);
KIRP	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.12	14.29	0.67	3.78e-34	Gut microbiome composition (summer);
KIRP	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.48	-5.46	-0.33	1.14e-7	Schizophrenia;
KIRP	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg00277334	chr10:82204260	NA	-0.58	-5.66	-0.34	4.3e-8	Post bronchodilator FEV1;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.78	12.38	0.62	1.1e-27	Schizophrenia;
KIRP	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.58	7.6	0.44	6.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.51	7.5	0.43	1.17e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.43	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg16141378	chr3:129829833	LOC729375	0.61	8.24	0.47	1.05e-14	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18517898	chr19:36435675	LRFN3	-0.55	-6.86	-0.4	5.45e-11	Parkinson's disease;
KIRP	cis	rs2637030	0.559	rs376566	chr5:53005420	G/A	cg06476337	chr5:52856530	NDUFS4	0.55	5.93	0.35	1.01e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.85	8.21	0.46	1.29e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs7870753	0.730	rs2025151	chr9:99161512	C/G	cg25260653	chr9:99212216	HABP4	0.5	5.37	0.32	1.85e-7	Height;
KIRP	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.72	-0.49	4.36e-16	Life satisfaction;
KIRP	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg24375607	chr4:120327624	NA	0.59	6.42	0.38	6.89e-10	Corneal astigmatism;
KIRP	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.42e-7	Alzheimer's disease;
KIRP	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg26412358	chr1:26503933	CNKSR1	-0.4	-5.7	-0.34	3.37e-8	Height;
KIRP	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.45	-9.02	-0.5	5.57e-17	Rheumatoid arthritis;
KIRP	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg02807482	chr3:125708958	NA	-0.49	-5.39	-0.32	1.68e-7	Blood pressure (smoking interaction);
KIRP	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.68	-0.44	3.71e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-1.05	-11.32	-0.59	3.35e-24	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.12	-0.31	6.12e-7	Life satisfaction;
KIRP	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg07068956	chr7:100330872	ZAN	0.4	5.28	0.32	2.85e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs2839627	0.638	rs7281701	chr21:44277296	C/T	cg03543861	chr21:44258195	NA	0.59	6.08	0.36	4.67e-9	Information processing speed;
KIRP	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg15038512	chr6:170123185	PHF10	0.44	5.1	0.31	6.75e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs806794	0.515	rs72834698	chr6:26176517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.7	5.3	0.32	2.55e-7	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	1.06	23.28	0.83	3.94e-64	Breast cancer;
KIRP	cis	rs2223471	0.602	rs2294468	chr6:50723641	T/C	cg03432817	chr6:50765336	NA	-0.36	-5.23	-0.32	3.7e-7	Subcutaneous adipose tissue;
KIRP	cis	rs6466055	0.674	rs6967587	chr7:104744041	C/T	cg04380332	chr7:105027541	SRPK2	-0.66	-9.87	-0.53	1.48e-19	Schizophrenia;
KIRP	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.36	0.38	9.86e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.68	-8.49	-0.48	2.01e-15	Inflammatory bowel disease;
KIRP	cis	rs10982256	0.624	rs1123056	chr9:117236557	T/C	cg13636371	chr9:117264095	DFNB31	0.48	6.46	0.38	5.64e-10	Bipolar disorder;
KIRP	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg13731523	chr4:3047190	NA	-0.37	-5.97	-0.36	8.34e-9	Serum sulfate level;
KIRP	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.75	-10.59	-0.56	8.01e-22	Blood metabolite levels;
KIRP	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg08975724	chr8:8085496	FLJ10661	0.55	7.48	0.43	1.29e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2302729	0.545	rs10161181	chr12:2770730	A/C	cg19945202	chr12:2788847	CACNA1C	-0.75	-10.94	-0.57	5.74e-23	Sleep quality;
KIRP	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	8.17	0.46	1.68e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg24315340	chr6:146058215	EPM2A	0.42	5.28	0.32	2.87e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09778919	chr12:40019907	C12orf40	0.43	6.19	0.37	2.53e-9	Survival in pancreatic cancer;
KIRP	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg23985595	chr17:80112537	CCDC57	0.34	4.98	0.3	1.19e-6	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg01721255	chr8:58191610	C8orf71	0.66	5.64	0.34	4.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.54	-0.33	7.75e-8	Renal cell carcinoma;
KIRP	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg02487422	chr3:49467188	NICN1	0.39	5.29	0.32	2.68e-7	Parkinson's disease;
KIRP	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.19	-0.31	4.46e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.33	5.83	0.35	1.75e-8	Renal cell carcinoma;
KIRP	trans	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg12575136	chr18:32820987	ZNF397	0.75	11.15	0.58	1.27e-23	White blood cell count;
KIRP	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-10.57	-0.56	8.68e-22	Eye color traits;
KIRP	cis	rs4664304	0.764	rs2063440	chr2:160800102	A/C	cg23995753	chr2:160760732	LY75	-0.38	-4.85	-0.3	2.22e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.59	7.85	0.45	1.3e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21643547	chr1:205240462	TMCC2	0.83	14.03	0.67	3.06e-33	Platelet count;
KIRP	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg21775007	chr8:11205619	TDH	-0.5	-6.45	-0.38	5.95e-10	Systolic blood pressure;
KIRP	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.06	-0.31	8.3e-7	Eosinophil percentage of white cells;
KIRP	cis	rs988913	0.957	rs9475098	chr6:54833177	A/G	cg03513858	chr6:54763001	FAM83B	-0.37	-5.17	-0.31	4.87e-7	Menarche (age at onset);
KIRP	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg19507638	chr5:93509721	C5orf36	-0.63	-5.43	-0.33	1.34e-7	Diabetic retinopathy;
KIRP	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-5.7	-0.34	3.47e-8	Homoarginine levels;
KIRP	cis	rs2574704	0.532	rs2616551	chr3:11667123	A/G	cg07643000	chr3:11666825	VGLL4	-0.51	-6.24	-0.37	1.92e-9	Body mass index;
KIRP	cis	rs17253792	0.598	rs35830444	chr14:56017350	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	9.03	0.5	5.11e-17	Bipolar disorder;
KIRP	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg22676075	chr6:135203613	NA	0.52	7.56	0.43	8.09e-13	Red blood cell count;
KIRP	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	13.81	0.66	1.7e-32	Body mass index (adult);
KIRP	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg01872077	chr2:219646372	CYP27A1	0.38	4.91	0.3	1.66e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4901847	0.562	rs11627221	chr14:58617216	G/T	cg15908186	chr14:58618357	C14orf37	0.6	7.73	0.44	2.72e-13	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg18306943	chr3:40428807	ENTPD3	0.44	5.67	0.34	3.92e-8	Renal cell carcinoma;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.27	-5.51	-0.33	8.96e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg01721255	chr8:58191610	C8orf71	0.59	5.42	0.33	1.43e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg10223061	chr2:219282414	VIL1	-0.38	-5.98	-0.36	8.01e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.03	-0.46	3.93e-14	Migraine;Coronary artery disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11674773	chr1:54518492	TMEM59;C1orf83	0.97	6.19	0.37	2.46e-9	P wave terminal force;
KIRP	cis	rs7106204	0.748	rs36092013	chr11:24211987	C/T	ch.11.24196551F	chr11:24239977	NA	0.81	9.6	0.52	9.93e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16484811	chr12:58149022	MARCH9	0.52	6.25	0.37	1.84e-9	Parkinson's disease;
KIRP	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-10.15	-0.54	1.95e-20	Menarche (age at onset);
KIRP	trans	rs10782582	0.758	rs5745559	chr1:76379517	A/C	cg10283277	chr11:111472630	SIK2	-0.31	-6.21	-0.37	2.23e-9	Daytime sleep phenotypes;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg21851534	chr17:3907994	ZZEF1	0.65	10.64	0.56	5.55e-22	Type 2 diabetes;
KIRP	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17554472	chr22:41940697	POLR3H	-0.63	-6.72	-0.39	1.26e-10	Vitiligo;
KIRP	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg24881330	chr22:46731750	TRMU	0.72	5.95	0.35	9.33e-9	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21630651	chr11:62439053	C11orf83;C11orf48	0.56	7.17	0.42	8.5e-12	Parkinson's disease;
KIRP	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.5	0.43	1.19e-12	IgG glycosylation;
KIRP	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.23	-0.37	1.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs11209002	0.567	rs2755269	chr1:67541065	T/C	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs11235843	0.636	rs2140892	chr11:73422879	A/G	cg18195628	chr11:73498948	MRPL48	-0.48	-5.0	-0.3	1.11e-6	Hand grip strength;
KIRP	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.38	-5.33	-0.32	2.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs981844	0.683	rs1037655	chr4:154750408	A/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2901460	0.509	rs10165560	chr2:62059398	A/C	cg02183531	chr2:62113199	CCT4	-0.5	-5.15	-0.31	5.34e-7	Mean corpuscular volume;
KIRP	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	1.05	20.11	0.79	7.2e-54	Height;
KIRP	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.65	7.89	0.45	1.02e-13	Aortic root size;
KIRP	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg25173405	chr17:45401733	C17orf57	0.42	5.39	0.32	1.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2224391	0.628	rs9504364	chr6:5256072	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.52	-0.38	4.06e-10	Height;
KIRP	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-5.57	-0.33	6.63e-8	Coronary artery disease;
KIRP	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg18367735	chr17:79674897	NA	0.77	7.56	0.43	8.15e-13	Dental caries;
KIRP	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.64	10.53	0.56	1.16e-21	Coronary artery disease;
KIRP	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.48	0.72	1.33e-41	Electrocardiographic conduction measures;
KIRP	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.28	-0.78	4.42e-51	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg12692727	chr7:1102344	C7orf50	0.49	5.16	0.31	5.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg14703610	chr5:56206110	C5orf35	0.47	5.94	0.35	9.46e-9	Coronary artery disease;
KIRP	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg12559939	chr2:27858050	GPN1	0.41	5.23	0.32	3.7e-7	Oral cavity cancer;
KIRP	cis	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg27487796	chr7:28973253	NA	-0.21	-4.96	-0.3	1.31e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.74	-9.33	-0.51	6.64e-18	Coronary artery disease;
KIRP	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg07212818	chr11:638076	DRD4	-0.39	-4.91	-0.3	1.68e-6	Systemic lupus erythematosus;
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg21289763	chr17:78868835	RPTOR	0.46	6.12	0.36	3.58e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1018697	0.966	rs6584526	chr10:104566241	G/C	cg04362960	chr10:104952993	NT5C2	0.51	6.18	0.37	2.69e-9	Colorectal adenoma (advanced);
KIRP	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	0.91	13.89	0.66	8.71e-33	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs931812	1.000	rs931812	chr8:101919321	A/G	cg07585502	chr8:101912084	NA	0.65	8.87	0.49	1.53e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4671458	0.948	rs12478442	chr2:63556365	A/G	cg17519650	chr2:63277830	OTX1	0.5	4.99	0.3	1.13e-6	Subjective well-being;
KIRP	cis	rs2574975	0.708	rs2117961	chr10:52130208	A/C	cg10034176	chr10:52120283	SGMS1	-0.54	-7.17	-0.42	8.71e-12	Response to amphetamines;
KIRP	cis	rs684232	0.644	rs2657613	chr17:623902	T/C	cg15660573	chr17:549704	VPS53	-0.82	-12.45	-0.62	6.34e-28	Prostate cancer;
KIRP	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg15880211	chr22:50250494	ZBED4	0.44	5.18	0.31	4.65e-7	Schizophrenia;
KIRP	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	1.26	13.33	0.65	7.24e-31	Eosinophil percentage of granulocytes;
KIRP	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.51	6.33	0.37	1.13e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.53	0.48	1.52e-15	Motion sickness;
KIRP	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.84	-12.73	-0.63	7.28e-29	Height;
KIRP	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.51	0.43	1.06e-12	Educational attainment;
KIRP	cis	rs2587695	0.967	rs2587690	chr2:120282477	A/G	cg07176264	chr2:120281999	SCTR	0.32	5.13	0.31	5.93e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs4740619	0.587	rs2382551	chr9:16033443	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.54	-0.33	7.75e-8	Body mass index;
KIRP	cis	rs73200209	0.744	rs73200226	chr12:116637861	G/A	cg01776926	chr12:116560359	MED13L	-0.58	-6.38	-0.38	8.55e-10	Total body bone mineral density;
KIRP	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs290268	1.000	rs188313	chr9:93548302	C/T	cg02608019	chr9:93564028	SYK	0.78	10.65	0.56	5.16e-22	Platelet count;
KIRP	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.73	-0.39	1.17e-10	Aortic root size;
KIRP	cis	rs3204270	0.759	rs77740144	chr17:79608968	G/A	cg18367735	chr17:79674897	NA	0.66	6.06	0.36	5.06e-9	Dental caries;
KIRP	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.61	8.33	0.47	5.52e-15	Mood instability;
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02359409	chr6:42947317	PEX6	-0.47	-6.24	-0.37	1.86e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13711144	chr7:107218933	BCAP29;DUS4L	0.41	6.21	0.37	2.27e-9	Survival in pancreatic cancer;
KIRP	cis	rs7612445	0.536	rs73043474	chr3:179075060	A/C	cg01750654	chr3:179170617	GNB4	-0.49	-5.46	-0.33	1.18e-7	Resting heart rate;Heart rate;
KIRP	cis	rs10208940	0.920	rs6714976	chr2:68764873	G/T	cg12452813	chr2:68675892	NA	0.47	5.06	0.31	8.07e-7	Urate levels in lean individuals;
KIRP	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg16898833	chr6:26189333	HIST1H4D	0.79	5.41	0.33	1.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.92	15.89	0.71	1.31e-39	Headache;
KIRP	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.72	9.13	0.5	2.66e-17	Coronary artery disease;
KIRP	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg16497661	chr14:103986332	CKB	-0.48	-6.39	-0.38	8.47e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-6.99	-0.41	2.53e-11	Response to antipsychotic treatment;
KIRP	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.73	10.04	0.54	4.17e-20	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg09754948	chr16:28834200	ATXN2L	0.48	5.45	0.33	1.24e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg02569458	chr12:86230093	RASSF9	0.35	5.09	0.31	7.14e-7	Major depressive disorder;
KIRP	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	10.54	0.56	1.11e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-8.98	-0.5	7.2e-17	Mood instability;
KIRP	cis	rs3026101	0.671	rs2407	chr17:5289028	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.91	0.35	1.11e-8	Body mass index;
KIRP	cis	rs7187994	0.895	rs12933276	chr16:84770867	C/T	cg07647771	chr16:84786436	USP10	-0.51	-6.1	-0.36	3.99e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg15028436	chr7:37888078	TXNDC3	-0.67	-8.84	-0.49	1.82e-16	Alzheimer's disease (late onset);
KIRP	cis	rs7224685	0.569	rs965515	chr17:4038149	G/A	cg09695851	chr17:3907499	NA	0.54	5.04	0.31	8.89e-7	Type 2 diabetes;
KIRP	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.95	-13.27	-0.65	1.09e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg16497661	chr14:103986332	CKB	0.77	11.61	0.59	3.86e-25	Body mass index;
KIRP	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-16.83	-0.73	8.37e-43	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-9.18	-0.51	1.78e-17	Chronic sinus infection;
KIRP	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.19	0.37	2.46e-9	Intraocular pressure;
KIRP	cis	rs3105593	0.543	rs28582911	chr15:50729629	G/A	cg05456662	chr15:50716270	USP8	0.41	5.6	0.34	5.69e-8	QT interval;
KIRP	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.97	-0.5	7.67e-17	Mood instability;
KIRP	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.14	-0.31	5.69e-7	Bipolar disorder;
KIRP	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg05639522	chr1:247681581	NA	0.77	5.08	0.31	7.33e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg07884673	chr3:53033167	SFMBT1	0.99	7.42	0.43	1.88e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-5.72	-0.34	3.06e-8	Renal function-related traits (BUN);
KIRP	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.54	-7.92	-0.45	7.99e-14	Huntington's disease progression;
KIRP	cis	rs6723108	0.515	rs2156000	chr2:135546430	C/T	cg12500956	chr2:135428796	TMEM163	0.43	5.38	0.32	1.77e-7	Type 2 diabetes;
KIRP	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.29	0.51	8.32e-18	Cognitive test performance;
KIRP	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs698813	0.604	rs1596010	chr2:44491804	A/C	cg04920474	chr2:44395004	PPM1B	0.38	5.18	0.31	4.52e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg23995753	chr2:160760732	LY75	-0.42	-5.62	-0.34	5.1e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.29e-7	Red blood cell count;
KIRP	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.56	-0.56	9.77e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs7084783	0.538	rs1077016	chr10:105333242	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.41	5.23	0.32	3.64e-7	Fear of pain;
KIRP	cis	rs6732160	0.774	rs11890053	chr2:73373448	G/A	cg01422370	chr2:73384389	NA	0.41	5.51	0.33	8.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.35	-4.9	-0.3	1.77e-6	Metabolite levels;
KIRP	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-6.54	-0.38	3.53e-10	Initial pursuit acceleration;
KIRP	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs731174	0.759	rs591567	chr1:38149847	A/G	cg14170840	chr1:38155120	C1orf109	-0.41	-5.2	-0.31	4.2e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4073221	0.654	rs13063618	chr3:18294897	T/C	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.44	5.12	0.31	6.27e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.73	11.0	0.57	3.86e-23	Blood metabolite ratios;
KIRP	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.65	8.3	0.47	6.97e-15	Mood instability;
KIRP	cis	rs7712401	0.601	rs30054	chr5:122301999	A/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.68	5.11	0.31	6.56e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.36	4.92	0.3	1.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs1459104	0.866	rs28873990	chr11:54812748	G/A	cg26562691	chr16:23850404	PRKCB	0.61	6.04	0.36	5.55e-9	Body mass index;
KIRP	cis	rs8018808	0.935	rs963283	chr14:77901456	C/A	cg20045696	chr14:77926864	AHSA1	0.46	5.53	0.33	8.04e-8	Myeloid white cell count;
KIRP	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.06	-8.69	-0.48	5.14e-16	Mitochondrial DNA levels;
KIRP	cis	rs6973256	0.762	rs11768260	chr7:133430482	T/C	cg10665199	chr7:133106180	EXOC4	-0.5	-5.89	-0.35	1.23e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12208915	0.709	rs12663824	chr6:79483130	A/C	cg18132916	chr6:79620363	NA	0.54	5.23	0.32	3.68e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg06219351	chr7:158114137	PTPRN2	0.61	8.78	0.49	2.8e-16	Calcium levels;
KIRP	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18252515	chr7:66147081	NA	0.43	5.09	0.31	6.97e-7	Aortic root size;
KIRP	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg06481639	chr22:41940642	POLR3H	-0.43	-4.98	-0.3	1.18e-6	Neuroticism;
KIRP	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.97	10.42	0.55	2.69e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.72	-0.34	3.03e-8	Non-small cell lung cancer;
KIRP	cis	rs4926611	0.798	rs4634849	chr1:54043110	C/T	cg08927728	chr1:54059983	GLIS1	-0.24	-5.14	-0.31	5.7e-7	Hand grip strength;
KIRP	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg22431228	chr1:16359049	CLCNKA	0.44	5.36	0.32	1.9e-7	Dilated cardiomyopathy;
KIRP	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26769984	chr7:1090371	C7orf50	-0.66	-6.81	-0.4	7.65e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.58	-6.94	-0.4	3.48e-11	Monocyte count;
KIRP	cis	rs4236601	0.962	rs10262524	chr7:116150952	C/A	cg05166801	chr7:116143459	CAV2	0.48	5.72	0.34	3.1e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.47	6.49	0.38	4.82e-10	Testicular germ cell tumor;
KIRP	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-13.49	-0.65	2.09e-31	Headache;
KIRP	trans	rs13170463	0.579	rs11746322	chr5:8039920	G/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-0.87	-9.19	-0.51	1.72e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.07	-0.31	7.68e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6546324	0.625	rs2861687	chr2:67838184	C/G	cg15745817	chr2:67799979	NA	-0.69	-7.44	-0.43	1.72e-12	Endometriosis;
KIRP	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg13271783	chr10:134563150	INPP5A	-0.55	-6.86	-0.4	5.4e-11	Migraine;
KIRP	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.52	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	9.71	0.53	4.36e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg04037228	chr3:45636386	LIMD1	-0.36	-5.38	-0.32	1.73e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-5.36	-0.32	1.89e-7	Triglycerides;
KIRP	cis	rs4664304	0.620	rs10929956	chr2:160714615	C/T	cg03641300	chr2:160917029	PLA2R1	0.37	5.55	0.33	7.44e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3821902	0.606	rs73119095	chr3:64018177	G/T	cg09006292	chr3:64049408	NA	-0.52	-5.23	-0.32	3.66e-7	Breast cancer;
KIRP	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03934478	chr11:495069	RNH1	0.88	7.15	0.41	9.63e-12	Body mass index;
KIRP	cis	rs6585424	1.000	rs3851055	chr10:81938096	T/C	cg27417294	chr10:81904244	PLAC9	0.52	5.05	0.31	8.49e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg07751222	chr4:102268245	PPP3CA	0.53	6.65	0.39	1.9e-10	Inflammatory biomarkers;
KIRP	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg15896084	chr13:114927664	NA	0.48	6.49	0.38	4.81e-10	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.49	6.6	0.39	2.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg12292205	chr6:26970375	C6orf41	0.33	4.92	0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	14.14	0.67	1.28e-33	Platelet count;
KIRP	cis	rs5743618	0.537	rs4331786	chr4:38769408	C/T	cg06935464	chr4:38784597	TLR10	0.42	5.31	0.32	2.48e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11731606	0.508	rs57403425	chr4:95312411	G/T	cg00507259	chr4:95128692	SMARCAD1	0.7	6.23	0.37	2.02e-9	Mean platelet volume;
KIRP	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.41	0.33	1.47e-7	Lung cancer;
KIRP	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs10463316	0.817	rs7713109	chr5:150789284	A/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.39	-0.38	8.45e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs477895	0.582	rs71456310	chr11:64128494	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	5.18	0.31	4.68e-7	Mean platelet volume;
KIRP	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.62	9.96	0.54	7.66e-20	HDL cholesterol levels;
KIRP	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.27	-5.29	-0.32	2.75e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02991063	chr10:120938274	PRDX3	-0.45	-6.12	-0.36	3.62e-9	Metabolic traits;
KIRP	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.64	7.92	0.45	8.08e-14	Alcohol dependence;
KIRP	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg25838818	chr2:108905173	SULT1C2	0.42	6.84	0.4	6.23e-11	Blood pressure;
KIRP	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg00405596	chr8:11794950	NA	0.5	6.62	0.39	2.21e-10	Mood instability;
KIRP	cis	rs236907	0.859	rs17649609	chr1:171738453	G/A	cg01410279	chr1:171621941	MYOC	-0.53	-5.13	-0.31	5.82e-7	Mean platelet volume;
KIRP	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg20302533	chr7:39170763	POU6F2	0.3	6.54	0.38	3.57e-10	IgG glycosylation;
KIRP	cis	rs17023223	0.537	rs3934789	chr1:119683063	G/A	cg05756136	chr1:119680316	WARS2	-0.6	-7.99	-0.45	5.18e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.49	-5.88	-0.35	1.36e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg14169450	chr9:139327907	INPP5E	0.58	7.19	0.42	7.72e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs904251	0.605	rs4257849	chr6:37410969	T/G	cg01843034	chr6:37503916	NA	-0.6	-6.15	-0.36	3.19e-9	Cognitive performance;
KIRP	cis	rs8077577	0.836	rs58441148	chr17:18106498	T/A	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05025164	chr4:1340916	KIAA1530	0.4	4.94	0.3	1.43e-6	Obesity-related traits;
KIRP	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg21361702	chr7:150065534	REPIN1	-0.6	-6.47	-0.38	5.2400000000000005e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.55	7.61	0.44	5.67e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.47	-0.38	5.37e-10	Coronary artery disease;
KIRP	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.51	7.23	0.42	6.15e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.41	-0.47	3.34e-15	Colorectal cancer;
KIRP	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.61	9.39	0.51	4.39e-18	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.9	13.01	0.64	8.19e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2522056	1.000	rs2522062	chr5:131805416	A/G	cg24060327	chr5:131705240	SLC22A5	0.59	6.11	0.36	3.77e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg00507259	chr4:95128692	SMARCAD1	0.38	4.87	0.3	2.02e-6	QT interval;
KIRP	cis	rs7534824	0.625	rs58234233	chr1:101510440	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.74	6.04	0.36	5.68e-9	Refractive astigmatism;
KIRP	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg18350739	chr11:68623251	NA	-0.51	-7.52	-0.43	1e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs193541	0.530	rs1466371	chr5:122083788	T/C	cg19412675	chr5:122181750	SNX24	0.49	5.32	0.32	2.3e-7	Glucose homeostasis traits;
KIRP	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg11833968	chr6:79620685	NA	-0.47	-7.18	-0.42	8.3e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.3	-5.88	-0.35	1.34e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.92	-0.35	1.08e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg21775007	chr8:11205619	TDH	0.45	5.99	0.36	7.53e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg08514558	chr10:81106712	PPIF	-0.41	-5.7	-0.34	3.49e-8	Height;
KIRP	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg09754948	chr16:28834200	ATXN2L	0.45	5.21	0.32	4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7536201	1.000	rs7545113	chr1:25301477	T/A	cg23273869	chr1:25296894	NA	-0.41	-5.94	-0.35	9.82e-9	Psoriasis vulgaris;
KIRP	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg07068956	chr7:100330872	ZAN	0.41	5.44	0.33	1.28e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg25547332	chr5:131281432	NA	0.47	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg12437481	chr16:420112	MRPL28	-0.57	-7.55	-0.43	8.61e-13	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs6453429	0.720	rs486580	chr5:78367424	A/G	cg08328513	chr5:78365691	BHMT2;DMGDH	-0.28	-5.1	-0.31	6.83e-7	Urinary metabolites;
KIRP	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg20573242	chr4:122745356	CCNA2	0.41	5.11	0.31	6.44e-7	Type 2 diabetes;
KIRP	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.67	-9.89	-0.53	1.26e-19	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Body mass index;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg22120373	chr7:131288554	NA	0.5	6.03	0.36	5.91e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg18944383	chr4:111397179	ENPEP	0.7	13.07	0.64	5.41e-30	Height;
KIRP	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02725872	chr8:58115012	NA	-0.75	-7.74	-0.44	2.65e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.73	-9.97	-0.54	6.85e-20	Personality dimensions;
KIRP	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg05335186	chr13:53173507	NA	0.31	4.86	0.3	2.1e-6	Lewy body disease;
KIRP	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.91	0.53	1.08e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2033732	0.697	rs7017468	chr8:85051853	T/C	cg05716166	chr8:85095498	RALYL	0.59	5.38	0.32	1.75e-7	Body mass index;
KIRP	trans	rs9329221	0.597	rs11776973	chr8:10117411	C/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-9.33	-0.51	6.32e-18	Neuroticism;
KIRP	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.93	-12.78	-0.63	4.86e-29	Cognitive function;
KIRP	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.71	-8.39	-0.47	3.78e-15	Coronary artery disease;
KIRP	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg27490568	chr2:178487706	NA	0.52	6.92	0.4	3.87e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-7.11	-0.41	1.22e-11	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg03714773	chr7:91764589	CYP51A1	0.4	5.9	0.35	1.17e-8	Breast cancer;
KIRP	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.56	5.08	0.31	7.42e-7	Major depressive disorder;
KIRP	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg02931644	chr1:25747376	RHCE	0.51	10.13	0.54	2.22e-20	Erythrocyte sedimentation rate;
KIRP	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.72	-6.84	-0.4	6.23e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg12105361	chr19:10216875	PPAN-P2RY11;SNORD105;PPAN	0.51	6.38	0.38	8.94e-10	Beard thickness;
KIRP	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	12.74	0.63	6.77e-29	Smoking behavior;
KIRP	cis	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23053534	chr4:170679082	C4orf27	0.46	6.1	0.36	4e-9	Parkinson's disease;
KIRP	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.84	-12.31	-0.62	1.88e-27	Eye color traits;
KIRP	cis	rs372883	0.935	rs1153295	chr21:30704080	T/G	cg24692254	chr21:30365293	RNF160	-0.39	-4.99	-0.3	1.15e-6	Pancreatic cancer;
KIRP	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg08761264	chr16:28874980	SH2B1	-0.5	-5.85	-0.35	1.53e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2882667	0.660	rs3088052	chr5:138456815	T/C	cg04439458	chr5:138467593	SIL1	-0.34	-5.38	-0.32	1.73e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs1035491	0.715	rs1912006	chr5:63920084	G/A	cg01791865	chr5:63954708	NA	0.33	5.21	0.32	4.06e-7	Body mass index;
KIRP	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg00094735	chr5:1949198	NA	-0.45	-5.34	-0.32	2.17e-7	Gut microbiome composition (winter);
KIRP	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs17221829	0.733	rs1844199	chr11:89376368	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg09695851	chr17:3907499	NA	0.78	12.01	0.61	1.91e-26	Type 2 diabetes;
KIRP	cis	rs6750047	0.605	rs59501228	chr2:38261972	A/C	cg07380506	chr2:38303506	CYP1B1	-0.45	-5.95	-0.35	9.25e-9	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg18404041	chr3:52824283	ITIH1	0.42	5.35	0.32	1.99e-7	Schizophrenia;
KIRP	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.71	10.19	0.54	1.4e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs7624766	0.555	rs1378654	chr3:160527151	C/T	cg22637730	chr3:160473554	PPM1L	0.44	5.45	0.33	1.22e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg04289385	chr6:36355825	ETV7	-0.48	-7.54	-0.43	9.13e-13	Platelet distribution width;
KIRP	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg02070118	chr4:952128	TMEM175	0.6	4.96	0.3	1.29e-6	Parkinson's disease;
KIRP	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg19468946	chr17:37922297	IKZF3	-0.5	-6.8	-0.4	8.06e-11	Self-reported allergy;
KIRP	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.54	7.23	0.42	6.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.23	11.74	0.6	1.45e-25	Diabetic retinopathy;
KIRP	cis	rs9600832	0.553	rs9544448	chr13:36069426	G/A	cg20704442	chr13:36052768	MIR548F5;NBEA	-0.31	-5.44	-0.33	1.27e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.57	-0.56	8.85e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.38	5.17	0.31	4.78e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.74	-10.08	-0.54	3.25e-20	Childhood ear infection;
KIRP	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg01988459	chr11:68622903	NA	-0.35	-4.84	-0.3	2.26e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg19372772	chr2:264904	ACP1;SH3YL1	-0.47	-6.27	-0.37	1.61e-9	Type 1 diabetes;
KIRP	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.34	5.0	0.3	1.11e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg13147721	chr7:65941812	NA	-0.98	-6.81	-0.4	7.36e-11	Diabetic kidney disease;
KIRP	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.11	0.58	1.6e-23	Smoking behavior;
KIRP	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.53	-7.6	-0.44	6.13e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.63	4.87	0.3	2e-6	Schizophrenia;
KIRP	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.59	-8.46	-0.47	2.44e-15	Diastolic blood pressure;
KIRP	cis	rs986417	1.000	rs10151958	chr14:60977275	T/C	cg27398547	chr14:60952738	C14orf39	0.73	7.31	0.42	3.66e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs4356932	0.967	rs6816898	chr4:76969057	C/A	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg11189052	chr15:85197271	WDR73	0.51	5.2	0.31	4.17e-7	Schizophrenia;
KIRP	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-5.78	-0.35	2.31e-8	Self-reported allergy;
KIRP	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	10.0	0.54	5.61e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg06634786	chr22:41940651	POLR3H	-0.61	-5.12	-0.31	6.14e-7	Vitiligo;
KIRP	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg12560992	chr17:57184187	TRIM37	0.59	5.4	0.33	1.55e-7	Cognitive test performance;
KIRP	cis	rs6546886	0.957	rs12713806	chr2:74258136	T/G	cg14702570	chr2:74259524	NA	-0.31	-6.12	-0.36	3.57e-9	Dialysis-related mortality;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg01238044	chr22:24384105	GSTT1	-0.54	-6.96	-0.41	3.09e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6466055	0.661	rs12532201	chr7:104922944	G/A	cg04380332	chr7:105027541	SRPK2	0.38	5.11	0.31	6.45e-7	Schizophrenia;
KIRP	cis	rs7007076	0.901	rs10105314	chr8:124727321	A/G	cg00283535	chr8:124749564	ANXA13	0.79	8.17	0.46	1.65e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg05861140	chr6:150128134	PCMT1	-0.52	-7.47	-0.43	1.39e-12	Lung cancer;
KIRP	cis	rs467650	0.509	rs27575	chr5:97984911	G/T	cg12450016	chr5:98112437	RGMB	0.4	5.13	0.31	5.99e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg14458575	chr2:238380390	NA	0.51	7.0	0.41	2.45e-11	Prostate cancer;
KIRP	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs9815354	1.000	rs1717006	chr3:41940448	A/C	cg03022575	chr3:42003672	ULK4	0.45	5.11	0.31	6.45e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs12449568	0.839	rs12386059	chr17:54408405	G/A	cg04456437	chr3:119217424	C3orf1	0.48	6.12	0.36	3.66e-9	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15886017	chr9:96278586	FAM120A	0.42	6.4	0.38	7.79e-10	Metabolic traits;
KIRP	cis	rs600806	0.850	rs10745355	chr1:109951711	T/C	cg02175308	chr1:109941060	SORT1	-0.26	-4.92	-0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.99	0.45	5.16e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs988913	1.000	rs9382403	chr6:54825687	A/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.7	-0.34	3.41e-8	Menarche (age at onset);
KIRP	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg03653399	chr8:142233436	SLC45A4	-0.92	-14.01	-0.67	3.5e-33	Immature fraction of reticulocytes;
KIRP	cis	rs10207060	0.500	rs11884577	chr2:240702216	C/G	cg20333904	chr2:240724165	NA	-0.42	-4.99	-0.3	1.14e-6	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.61	0.34	5.54e-8	Lung cancer;
KIRP	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.66	5.13	0.31	6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3120667	0.720	rs1923501	chr1:152411153	C/T	cg26876637	chr1:152193138	HRNR	-0.53	-5.41	-0.33	1.51e-7	Eating disorders;
KIRP	cis	rs6684514	1.000	rs11264462	chr1:156241728	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-5.99	-0.36	7.46e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	7.19e-7	Bladder cancer;
KIRP	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.96	8.06	0.46	3.39e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.72	-8.73	-0.49	3.86e-16	Cognitive function;
KIRP	cis	rs7601312	0.935	rs35927319	chr2:229325107	G/A	cg02542817	chr2:229291442	NA	-0.44	-6.41	-0.38	7.47e-10	Schizophrenia;
KIRP	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg04935436	chr20:30431758	NA	0.47	6.05	0.36	5.37e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.7	-11.68	-0.6	2.23e-25	Calcium levels;
KIRP	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.65	-7.14	-0.41	1.03e-11	HIV-1 control;
KIRP	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.68	8.08	0.46	2.83e-14	Corneal astigmatism;
KIRP	trans	rs3809095	0.521	rs55941903	chr11:16644680	A/C	cg15531249	chr16:85744077	C16orf74	0.43	6.13	0.36	3.45e-9	Total body bone mineral density;
KIRP	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.43	15.01	0.69	1.35e-36	Schizophrenia;
KIRP	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.91	-14.86	-0.69	4.31e-36	Mean corpuscular volume;
KIRP	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg19875535	chr5:140030758	IK	-0.65	-9.25	-0.51	1.11e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg07701084	chr6:150067640	NUP43	0.62	7.99	0.45	5.12e-14	Lung cancer;
KIRP	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg00262122	chr8:11665843	FDFT1	0.41	5.16	0.31	5.06e-7	Neuroticism;
KIRP	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.42	5.49	0.33	1e-7	Melanoma;
KIRP	cis	rs2522056	1.000	rs2522063	chr5:131805591	G/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.11	0.36	3.77e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.91e-8	Life satisfaction;
KIRP	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.03	19.32	0.78	3.22e-51	Schizophrenia;
KIRP	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg27205649	chr11:78285834	NARS2	-0.53	-5.16	-0.31	5.08e-7	Testicular germ cell tumor;
KIRP	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg17143192	chr8:8559678	CLDN23	0.66	7.71	0.44	3.17e-13	Obesity-related traits;
KIRP	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.11	-0.36	3.82e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.62	5.93	0.35	1.01e-8	Breast cancer;
KIRP	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.92e-14	Coffee consumption (cups per day);
KIRP	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05665937	chr4:1216051	CTBP1	0.57	7.91	0.45	8.89e-14	Obesity-related traits;
KIRP	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.38	-5.25	-0.32	3.22e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.6	7.75	0.44	2.45e-13	Colorectal cancer;
KIRP	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.91	-0.35	1.16e-8	Breast cancer;
KIRP	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg22437258	chr11:111473054	SIK2	0.58	6.77	0.4	9.34e-11	Primary sclerosing cholangitis;
KIRP	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.89	12.42	0.62	8.18e-28	Gestational age at birth (maternal effect);
KIRP	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.41	-0.38	7.53e-10	Type 2 diabetes;
KIRP	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-4.95	-0.3	1.37e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	8.02	0.46	4.26e-14	Neuroticism;
KIRP	cis	rs2072732	0.861	rs41334845	chr1:2950370	A/C	cg11731671	chr1:2995604	PRDM16	0.56	6.48	0.38	5.07e-10	Plateletcrit;
KIRP	cis	rs9394841	0.692	rs13193235	chr6:41792659	T/C	cg08135965	chr6:41755394	TOMM6	0.52	5.51	0.33	9.22e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs2594989	0.943	rs2442769	chr3:11491086	A/G	cg01796438	chr3:11312864	ATG7	0.66	6.85	0.4	5.77e-11	Circulating chemerin levels;
KIRP	cis	rs73200209	0.744	rs61937387	chr12:116707971	A/T	cg01776926	chr12:116560359	MED13L	-0.58	-6.33	-0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs4356975	0.563	rs6600895	chr4:69983412	T/C	cg27372994	chr4:70080453	UGT2B11	0.36	4.85	0.3	2.2e-6	Obesity-related traits;
KIRP	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg10223061	chr2:219282414	VIL1	0.38	5.92	0.35	1.05e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02545393	chr11:70244902	CTTN	-0.47	-6.25	-0.37	1.83e-9	Metabolic traits;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20176194	chr2:220173205	PTPRN	0.44	6.09	0.36	4.27e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2736337	0.530	rs11782375	chr8:11294934	C/T	cg21775007	chr8:11205619	TDH	0.52	6.64	0.39	1.94e-10	Rheumatoid arthritis;
KIRP	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.64	-7.49	-0.43	1.22e-12	Menarche (age at onset);
KIRP	cis	rs7771547	0.519	rs6457912	chr6:36373794	C/A	cg07856975	chr6:36356162	ETV7	0.41	5.3	0.32	2.53e-7	Platelet distribution width;
KIRP	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.53	-5.65	-0.34	4.36e-8	Metabolite levels;
KIRP	cis	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03572664	chr14:61544141	NA	-0.47	-6.42	-0.38	6.87e-10	Select biomarker traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18559136	chr18:33767393	MOCOS	-0.47	-6.7	-0.39	1.45e-10	Metabolic traits;
KIRP	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg10760299	chr15:45669010	GATM	0.35	5.13	0.31	5.93e-7	Homoarginine levels;
KIRP	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.82	-9.58	-0.52	1.09e-18	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg26876637	chr1:152193138	HRNR	0.75	9.78	0.53	2.65e-19	Atopic dermatitis;
KIRP	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-1.01	-19.52	-0.78	6.54e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs17221829	0.673	rs4753228	chr11:89369157	G/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs11877825	0.826	rs1893879	chr18:10583247	G/A	cg07277756	chr18:10589357	NA	0.52	6.25	0.37	1.79e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.67	8.62	0.48	8.52e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00689492	chr4:1303491	MAEA	0.32	5.49	0.33	1.01e-7	Obesity-related traits;
KIRP	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs7119038	0.509	rs11216960	chr11:118577873	G/A	cg19308663	chr11:118741387	NA	0.41	6.4	0.38	7.8e-10	Sjögren's syndrome;
KIRP	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg07395648	chr5:131743802	NA	-0.36	-5.0	-0.3	1.08e-6	Blood metabolite levels;
KIRP	cis	rs7091068	0.518	rs4144097	chr10:95432480	A/C	cg20715218	chr10:95462985	C10orf4	0.47	5.76	0.34	2.5e-8	Urinary tract infection frequency;
KIRP	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.44	-7.82	-0.45	1.54e-13	Refractive error;
KIRP	cis	rs4523957	0.928	rs4790071	chr17:2173184	A/G	cg16513277	chr17:2031491	SMG6	-0.59	-8.27	-0.47	8.43e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9473924	0.632	rs9381913	chr6:50874822	T/C	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	12.6	0.63	2.02e-28	Personality dimensions;
KIRP	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg17595323	chr11:93583763	C11orf90	-0.38	-6.43	-0.38	6.67e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg03811519	chr9:134001305	NUP214	-0.54	-6.13	-0.36	3.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4704187	0.687	rs4704176	chr5:74420596	G/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg16497661	chr14:103986332	CKB	0.49	6.61	0.39	2.35e-10	Body mass index;
KIRP	cis	rs867371	0.896	rs8033831	chr15:82513294	C/A	cg06066596	chr15:83166174	LOC80154	-0.45	-5.1	-0.31	6.63e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg25037394	chr1:24152592	HMGCL	0.38	5.09	0.31	7.05e-7	Immature fraction of reticulocytes;
KIRP	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-6.36	-0.38	9.83e-10	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg00442267	chr19:46317840	RSPH6A	0.67	5.88	0.35	1.33e-8	Eosinophil counts;
KIRP	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.24	-0.37	1.91e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg06533319	chr4:3265114	C4orf44	-0.59	-7.72	-0.44	2.87e-13	Parental longevity (mother's age at death);
KIRP	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	7.05	0.41	1.78e-11	Height;
KIRP	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg16797656	chr11:68205561	LRP5	0.64	11.73	0.6	1.61e-25	Total body bone mineral density;
KIRP	cis	rs6942756	0.876	rs7789697	chr7:129060386	T/A	cg02491457	chr7:128862824	NA	-0.54	-6.11	-0.36	3.95e-9	White matter hyperintensity burden;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05451654	chr3:155572045	SLC33A1	-0.5	-6.5	-0.38	4.45e-10	Myopia;
KIRP	cis	rs16828019	0.929	rs111309254	chr1:41736000	A/G	cg18742814	chr1:41828276	NA	0.62	5.65	0.34	4.35e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg20795500	chr2:174970644	OLA1	0.4	6.31	0.37	1.29e-9	C-reactive protein;
KIRP	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.81	-10.26	-0.55	8.78e-21	Menarche (age at onset);
KIRP	cis	rs28655083	1.000	rs8045658	chr16:77056343	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-5.55	-0.33	7.51e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4919044	0.808	rs2478238	chr10:94805531	A/G	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	1.02	12.3	0.62	2.01e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg15660573	chr17:549704	VPS53	-0.85	-12.79	-0.63	4.66e-29	Prostate cancer;
KIRP	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-5.28	-0.32	2.77e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4356932	1.000	rs6814012	chr4:76950778	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs10849605	0.737	rs6489769	chr12:1072965	C/T	cg22243222	chr12:1059299	RAD52	-0.38	-5.2	-0.31	4.2e-7	Lung cancer;
KIRP	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.36	-4.87	-0.3	2.01e-6	Blood metabolite levels;
KIRP	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg18944383	chr4:111397179	ENPEP	-0.54	-9.37	-0.51	4.9e-18	Coronary artery disease;
KIRP	cis	rs9826463	0.702	rs9683274	chr3:142332110	A/G	cg20824294	chr3:142316082	PLS1	0.38	6.23	0.37	2.05e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.58	0.48	1.07e-15	Bipolar disorder;
KIRP	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.46	-6.77	-0.4	9.4e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	7.2	0.42	7.08e-12	Menarche (age at onset);
KIRP	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	6.83	0.4	6.47e-11	Bipolar disorder;
KIRP	cis	rs17102884	0.541	rs8004430	chr14:75171683	C/T	cg08847533	chr14:75593920	NEK9	0.43	4.91	0.3	1.65e-6	Neuroticism;
KIRP	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.8	-0.4	7.74e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1050631	1.000	rs1785916	chr18:33696156	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	6.28	0.37	1.56e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg19025524	chr12:109796872	NA	-0.55	-7.69	-0.44	3.53e-13	Neuroticism;
KIRP	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg05527609	chr1:210001259	C1orf107	-0.44	-5.37	-0.32	1.8e-7	Red blood cell count;
KIRP	cis	rs11605275	1.000	rs74809393	chr11:20031520	C/A	cg14835545	chr11:20032148	NAV2	-0.8	-6.14	-0.36	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.11	-0.31	6.51e-7	IgG glycosylation;
KIRP	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.7	10.45	0.55	2.17e-21	Blood metabolite levels;
KIRP	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg02725872	chr8:58115012	NA	-0.57	-6.51	-0.38	4.27e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	1.0	10.19	0.54	1.48e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg22800045	chr5:56110881	MAP3K1	0.66	7.09	0.41	1.39e-11	Initial pursuit acceleration;
KIRP	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.51	-15.5	-0.7	2.78e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg22800045	chr5:56110881	MAP3K1	0.71	7.43	0.43	1.79e-12	Initial pursuit acceleration;
KIRP	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg01557791	chr16:72042693	DHODH	-0.51	-6.35	-0.38	1.05e-9	Fibrinogen levels;
KIRP	cis	rs2219968	1.000	rs1121552	chr8:78958699	T/G	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs58785573	0.513	rs6531650	chr4:38592376	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.88	0.3	1.95e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs829661	0.739	rs2602798	chr2:30849906	G/A	cg10949345	chr2:30726833	LCLAT1	1.09	13.46	0.65	2.61e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg13072238	chr3:49761600	GMPPB	-0.56	-5.23	-0.32	3.56e-7	Menarche (age at onset);
KIRP	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg01320579	chr17:75405842	SEPT9	0.47	7.54	0.43	9.17e-13	Airflow obstruction;
KIRP	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg23587288	chr2:27483067	SLC30A3	-0.57	-6.85	-0.4	6.01e-11	Blood metabolite levels;
KIRP	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg10017260	chr10:834428	NA	-0.54	-5.5	-0.33	9.59e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg05025164	chr4:1340916	KIAA1530	0.58	8.1	0.46	2.53e-14	Longevity;
KIRP	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg18350739	chr11:68623251	NA	-0.52	-7.96	-0.45	6.38e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17761864	0.579	rs12452074	chr17:2051730	G/T	cg16513277	chr17:2031491	SMG6	0.43	5.37	0.32	1.79e-7	Esophageal cancer (squamous cell);
KIRP	cis	rs370915	1.000	rs9685837	chr4:187818466	C/T	cg19519643	chr4:187840862	NA	-0.5	-6.41	-0.38	7.19e-10	Gout;
KIRP	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.83	-8.78	-0.49	2.84e-16	Exhaled nitric oxide output;
KIRP	cis	rs1440410	0.835	rs11100770	chr4:144053782	C/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg11814155	chr7:99998594	ZCWPW1	0.55	5.27	0.32	2.94e-7	Platelet count;
KIRP	cis	rs2979489	0.580	rs73245347	chr8:30448213	T/G	cg26383811	chr8:30366931	RBPMS	-0.36	-4.88	-0.3	1.94e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.22	-0.32	3.78e-7	Alcohol dependence;
KIRP	cis	rs17065868	1.000	rs9525991	chr13:45183869	T/C	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7945718	0.870	rs3890064	chr11:12758766	C/A	cg25843174	chr11:12811716	TEAD1	0.35	6.48	0.38	4.87e-10	Educational attainment (years of education);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06831919	chr6:3068563	NA	0.44	6.04	0.36	5.76e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg25706552	chr1:244017396	NA	0.58	6.65	0.39	1.85e-10	RR interval (heart rate);
KIRP	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg07212818	chr11:638076	DRD4	-0.42	-5.23	-0.32	3.61e-7	Systemic lupus erythematosus;
KIRP	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.55	7.36	0.43	2.67e-12	White matter hyperintensity burden;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg18209359	chr17:80159595	CCDC57	-0.42	-5.56	-0.33	7.11e-8	Life satisfaction;
KIRP	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	5.26	0.32	3.21e-7	Schizophrenia;
KIRP	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg25019722	chr6:37503610	NA	-0.75	-8.77	-0.49	2.97e-16	Cognitive performance;
KIRP	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.51	-6.25	-0.37	1.85e-9	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs55882075	0.967	rs62404346	chr5:179141391	A/C	cg14593053	chr5:179126677	CANX	0.63	8.17	0.46	1.63e-14	Monocyte percentage of white cells;
KIRP	cis	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg07585502	chr8:101912084	NA	-0.64	-8.35	-0.47	5e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg00204512	chr16:28754710	NA	0.42	5.55	0.33	7.26e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.51	8.9	0.49	1.21e-16	Erythrocyte sedimentation rate;
KIRP	cis	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg26116260	chr4:7069785	GRPEL1	-0.92	-5.08	-0.31	7.38e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.55	-7.89	-0.45	9.78e-14	Gut microbiome composition (summer);
KIRP	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.49	5.28	0.32	2.79e-7	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.65	7.03	0.41	2.07e-11	Gut microbiome composition (summer);
KIRP	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg22117172	chr7:91764530	CYP51A1	0.41	5.57	0.33	6.58e-8	Breast cancer;
KIRP	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	9.21	0.51	1.49e-17	Bipolar disorder;
KIRP	cis	rs687432	0.885	rs34300518	chr11:57815896	T/C	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs939574	0.790	rs79225383	chr2:220093972	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	6.12	0.36	3.67e-9	Platelet distribution width;
KIRP	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg07256732	chr16:621771	PIGQ	-0.46	-6.24	-0.37	1.93e-9	Height;
KIRP	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg09555818	chr19:45449301	APOC2	0.51	7.33	0.42	3.41e-12	Blood protein levels;
KIRP	cis	rs2219968	0.700	rs12541492	chr8:78863766	C/G	cg00738934	chr8:78996279	NA	-0.37	-4.88	-0.3	1.91e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg19507638	chr5:93509721	C5orf36	-0.6	-5.26	-0.32	3.06e-7	Diabetic retinopathy;
KIRP	cis	rs867371	1.000	rs9944197	chr15:82450602	G/A	cg06066596	chr15:83166174	LOC80154	-0.47	-5.53	-0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.97e-8	Motion sickness;
KIRP	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.68	-9.85	-0.53	1.61e-19	Height;
KIRP	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg04490037	chr7:50633773	DDC	-0.39	-5.28	-0.32	2.83e-7	Systemic sclerosis;
KIRP	cis	rs4886920	0.672	rs8040443	chr15:78130915	C/G	cg10461261	chr15:78109450	NA	0.33	5.49	0.33	9.8e-8	Neuroticism;
KIRP	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15664640	chr17:80829946	TBCD	0.66	5.99	0.36	7.49e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.43	-5.74	-0.34	2.84e-8	HDL cholesterol levels;
KIRP	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.7	-9.41	-0.51	3.7e-18	Morning vs. evening chronotype;
KIRP	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.52	-0.38	4.05e-10	Uric acid levels;
KIRP	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg11608241	chr8:8085544	FLJ10661	-0.55	-7.06	-0.41	1.72e-11	Schizophrenia;
KIRP	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.69	8.82	0.49	2.21e-16	Bladder cancer;
KIRP	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	cg12689670	chr1:183009347	LAMC1	-0.46	-6.56	-0.39	3.24e-10	Colorectal cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05362516	chr16:54965089	IRX5	0.46	6.03	0.36	5.85e-9	Smoking initiation;
KIRP	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.79	-6.42	-0.38	7.07e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07830126	chr1:3477690	MEGF6;MIR551A	0.42	6.32	0.37	1.19e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2274273	1.000	rs67098772	chr14:55595242	G/A	cg04306507	chr14:55594613	LGALS3	0.46	7.08	0.41	1.53e-11	Protein biomarker;
KIRP	cis	rs11605924	1.000	rs12794698	chr11:45871861	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.56	-6.88	-0.4	4.86e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg18154014	chr19:37997991	ZNF793	0.68	7.28	0.42	4.54e-12	Coronary artery calcification;
KIRP	cis	rs9815354	0.904	rs73081347	chr3:41903582	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs554111	0.574	rs4060971	chr1:21506930	C/T	cg21184320	chr1:21044207	KIF17	0.37	5.57	0.33	6.51e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg06115741	chr20:33292138	TP53INP2	0.56	7.01	0.41	2.23e-11	Coronary artery disease;
KIRP	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.69	11.68	0.6	2.27e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg04154034	chr17:28927549	LRRC37B2	0.54	5.13	0.31	6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg05861140	chr6:150128134	PCMT1	-0.46	-6.67	-0.39	1.72e-10	Lung cancer;
KIRP	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.06	-0.36	4.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.48	6.8	0.4	7.77e-11	Sitting height ratio;
KIRP	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.44	5.21	0.32	3.93e-7	Cardiac Troponin-T levels;
KIRP	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-5.18	-0.31	4.57e-7	Schizophrenia;
KIRP	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.5	8.3	0.47	7.07e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.75	-8.05	-0.46	3.52e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.71	-0.56	3.17e-22	Gut microbiome composition (summer);
KIRP	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27297192	chr10:134578999	INPP5A	0.64	8.0	0.45	4.93e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg21479132	chr6:26055353	NA	0.77	5.18	0.31	4.6e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg25042112	chr7:64838748	ZNF92	0.58	6.25	0.37	1.75e-9	Pain;
KIRP	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg05347473	chr6:146136440	FBXO30	0.59	8.34	0.47	5.42e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg13770153	chr20:60521292	NA	-0.41	-4.96	-0.3	1.3e-6	Body mass index;
KIRP	cis	rs1468333	1.000	rs2906127	chr5:137539466	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.38	0.32	1.7e-7	Resting heart rate;
KIRP	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.69	-5.09	-0.31	7.15e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg19000871	chr14:103996768	TRMT61A	-0.52	-5.73	-0.34	2.92e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.6	-0.34	5.84e-8	Body mass index;
KIRP	cis	rs7903847	0.620	rs2297988	chr10:99118382	A/G	cg20016023	chr10:99160130	RRP12	-0.39	-5.21	-0.32	3.98e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	5.25	0.32	3.25e-7	Renal cell carcinoma;
KIRP	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.81	0.49	2.34e-16	Bipolar disorder;
KIRP	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	cg21523751	chr1:182988639	NA	0.41	6.21	0.37	2.18e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs1106684	1.000	rs10954329	chr7:131458158	T/C	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg03465714	chr1:152285911	FLG	0.51	5.79	0.35	2.1e-8	Atopic dermatitis;
KIRP	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg23173402	chr1:227635558	NA	0.6	5.02	0.3	1.01e-6	Major depressive disorder;
KIRP	cis	rs1209950	0.536	rs1534827	chr21:40210618	A/C	cg02119577	chr21:40195074	ETS2	0.37	5.23	0.32	3.55e-7	Non-small cell lung cancer (survival);
KIRP	cis	rs16936870	0.543	rs7812666	chr8:71268457	T/C	cg14232793	chr8:71155543	NCOA2	0.56	6.92	0.4	3.91e-11	QT interval;
KIRP	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.97	9.93	0.53	9.44e-20	Bronchopulmonary dysplasia;
KIRP	cis	rs35740288	0.640	rs11632164	chr15:86109539	A/G	cg06993955	chr15:86301167	NA	-0.41	-5.23	-0.32	3.54e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.45	6.54	0.38	3.48e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7601312	1.000	rs2194555	chr2:229323165	T/G	cg02542817	chr2:229291442	NA	-0.38	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg10254082	chr7:997346	NA	0.48	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.82	-11.56	-0.59	5.58e-25	Height;
KIRP	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.72	-9.72	-0.53	4.06e-19	Schizophrenia;
KIRP	cis	rs17023223	0.537	rs2794313	chr1:119587440	T/C	cg18261050	chr1:119551319	NA	0.52	6.98	0.41	2.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.85	-6.93	-0.4	3.58e-11	Arsenic metabolism;
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg21698718	chr17:80085957	CCDC57	0.36	5.28	0.32	2.84e-7	Life satisfaction;
KIRP	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.51	-0.33	9.24e-8	Metabolite levels;
KIRP	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.85	-0.53	1.7e-19	Asthma;
KIRP	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg13319975	chr6:146136371	FBXO30	0.48	6.33	0.37	1.12e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg02336718	chr17:17403227	NA	-0.34	-5.32	-0.32	2.37e-7	Total body bone mineral density;
KIRP	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg22117172	chr7:91764530	CYP51A1	-0.44	-5.92	-0.35	1.08e-8	Breast cancer;
KIRP	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg16672083	chr15:72433130	SENP8	0.45	6.33	0.37	1.16e-9	Red blood cell count;
KIRP	cis	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	5.13	0.31	5.74e-7	Leprosy;
KIRP	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.38e-7	Oral cavity cancer;
KIRP	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	5.95	0.35	9.2e-9	Birth weight;
KIRP	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.79	-9.14	-0.5	2.37e-17	Body mass index;
KIRP	cis	rs2820315	0.964	rs2644109	chr1:201797535	C/T	cg11586189	chr1:201857591	SHISA4	-0.39	-5.37	-0.32	1.8e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7714670	1.000	rs7710068	chr5:73071952	A/G	cg04480106	chr5:72934606	RGNEF	-0.41	-5.44	-0.33	1.31e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.39	-0.47	3.84e-15	Total cholesterol levels;
KIRP	cis	rs12362504	0.504	rs12099354	chr11:9879379	G/A	cg07197493	chr11:9884649	SBF2	-0.44	-6.11	-0.36	3.89e-9	Survival in pancreatic cancer;
KIRP	cis	rs57994353	0.759	rs35873563	chr9:139324029	C/T	cg21253087	chr9:139290292	SNAPC4	0.45	4.89	0.3	1.84e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg06740227	chr12:86229804	RASSF9	0.5	6.52	0.38	3.98e-10	Major depressive disorder;
KIRP	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.6	6.27	0.37	1.61e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.67	-9.06	-0.5	4.1e-17	Huntington's disease progression;
KIRP	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.8	8.95	0.5	8.59e-17	Platelet count;
KIRP	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.16	0.37	2.89e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	trans	rs2856321	0.874	rs2856344	chr12:11890771	G/A	cg10155026	chr12:4553029	FGF6	0.41	6.11	0.36	3.89e-9	Height;
KIRP	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	6.41	0.38	7.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg10756647	chr7:56101905	PSPH	1.07	8.32	0.47	6.01e-15	Diabetic kidney disease;
KIRP	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.64	-9.18	-0.51	1.78e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.64	8.32	0.47	6.22e-15	Pulse pressure;
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.61	9.35	0.51	5.41e-18	Lung cancer;
KIRP	cis	rs10875746	0.903	rs886588	chr12:48477422	A/G	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.85	10.68	0.56	4.04e-22	Coronary artery disease;
KIRP	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.59	7.0	0.41	2.42e-11	Obesity-related traits;
KIRP	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	0.89	10.53	0.56	1.25e-21	Mosquito bite size;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.86	13.06	0.64	5.64e-30	Menarche (age at onset);
KIRP	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17554472	chr22:41940697	POLR3H	-0.58	-6.35	-0.38	1.01e-9	Vitiligo;
KIRP	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.98	15.84	0.71	1.92e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.9	12.61	0.63	1.81e-28	Gestational age at birth (maternal effect);
KIRP	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.92	-0.4	3.9e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.89	9.13	0.5	2.55e-17	Alzheimer's disease;
KIRP	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg14768367	chr16:72042858	DHODH	0.56	7.09	0.41	1.42e-11	Fibrinogen levels;
KIRP	cis	rs9914544	0.545	rs8066636	chr17:18761109	G/A	cg26378065	chr17:18585709	ZNF286B	0.38	4.92	0.3	1.57e-6	Educational attainment (years of education);
KIRP	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg07254608	chr8:41997973	NA	0.53	6.15	0.37	3.03e-9	Sleep duration;
KIRP	cis	rs17023223	0.537	rs2794310	chr1:119561930	C/G	cg18261050	chr1:119551319	NA	0.52	7.05	0.41	1.84e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.98	-13.56	-0.65	1.17e-31	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.7	10.44	0.55	2.32e-21	Hip circumference;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg24642844	chr7:1081250	C7orf50	-0.77	-8.63	-0.48	7.94e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4919044	0.808	rs860669	chr10:94796031	T/C	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.63	7.46	0.43	1.53e-12	Height;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg10355174	chr8:42752513	HOOK3;RNF170	0.51	6.04	0.36	5.56e-9	Plasma plasminogen activator levels;
KIRP	cis	rs6662572	0.737	rs6665193	chr1:46347910	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg03641300	chr2:160917029	PLA2R1	-0.5	-7.6	-0.44	6.09e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2241685	0.850	rs919718	chr2:1952576	A/G	cg22511877	chr2:1942942	MYT1L	0.62	5.94	0.35	9.73e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs7017914	0.967	rs3954897	chr8:71635955	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.6	-6.43	-0.38	6.59e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-5.01	-0.3	1.02e-6	Fear of minor pain;
KIRP	cis	rs28489187	0.706	rs1498375	chr1:85787323	T/A	cg16011679	chr1:85725395	C1orf52	0.53	6.42	0.38	6.91e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19191500	chr13:44361640	ENOX1	0.43	6.22	0.37	2.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.28e-9	Breast cancer;
KIRP	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.28	-0.42	4.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8177876	0.822	rs4889231	chr16:81113715	G/C	cg08591886	chr16:81111003	C16orf46	0.53	5.26	0.32	3.14e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs66569888	0.633	rs11680226	chr2:106745044	A/G	cg16099169	chr2:106886729	NA	0.48	5.99	0.36	7.52e-9	Facial morphology (factor 23);
KIRP	trans	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg13565492	chr6:43139072	SRF	-0.92	-8.73	-0.49	4.08e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.51	6.63	0.39	2.12e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.13	-0.41	1.08e-11	Bladder cancer;
KIRP	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.73	-8.31	-0.47	6.52e-15	Pursuit maintenance gain;
KIRP	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg20415053	chr1:26527928	CATSPER4	-0.43	-4.85	-0.3	2.2e-6	Obesity-related traits;
KIRP	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg07382826	chr16:28625726	SULT1A1	0.51	5.83	0.35	1.72e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2569991	0.588	rs2596909	chr3:12928672	G/C	cg22481960	chr3:13008800	IQSEC1	-0.51	-5.06	-0.31	8.15e-7	Periodontitis (DPAL);
KIRP	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg23594656	chr7:65796392	TPST1	0.51	7.89	0.45	9.9e-14	Aortic root size;
KIRP	cis	rs2289700	0.518	rs77362013	chr15:79167260	T/C	cg04896959	chr15:78267971	NA	-0.74	-5.91	-0.35	1.15e-8	Bipolar disorder;
KIRP	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-7.81	-0.45	1.62e-13	Tonsillectomy;
KIRP	cis	rs6788895	1.000	rs73010967	chr3:150498056	T/C	cg09723797	chr3:150481914	SIAH2	0.87	5.83	0.35	1.75e-8	Breast cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26164735	chr4:71768712	MOBKL1A	0.61	7.18	0.42	8.35e-12	Smoking initiation;
KIRP	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	1.0	14.42	0.68	1.42e-34	Cognitive function;
KIRP	cis	rs7635838	0.573	rs73019547	chr3:11493323	A/C	cg00170343	chr3:11313890	ATG7	0.5	6.57	0.39	3.02e-10	HDL cholesterol;
KIRP	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10073892	0.703	rs9327823	chr5:101638067	G/A	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	trans	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.6	8.33	0.47	5.61e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.71	-8.91	-0.49	1.2e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.59	-0.44	6.48e-13	Bladder cancer;
KIRP	cis	rs965513	1.000	rs4743131	chr9:100554907	C/G	cg13688889	chr9:100608707	NA	-0.59	-7.4	-0.43	2.15e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.5	7.08	0.41	1.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4954585	0.683	rs13004902	chr2:137027680	A/G	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.23e-13	Colorectal cancer;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg11168104	chr5:1857477	NA	-0.39	-5.02	-0.3	9.85e-7	Cardiovascular disease risk factors;
KIRP	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg21518248	chr2:162101506	NA	0.48	5.76	0.34	2.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7719624	0.756	rs2302038	chr5:135397018	A/G	cg16684184	chr5:135415129	NA	0.39	5.86	0.35	1.49e-8	Response to cytidine analogues (gemcitabine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16715194	chr1:233430825	PCNXL2	0.46	6.16	0.37	3.01e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.69	0.44	3.53e-13	IgG glycosylation;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.13	0.41	1.1e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.09	-13.13	-0.64	3.41e-30	Vitiligo;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05596267	chr15:34331198	CHRM5;AVEN	0.51	6.86	0.4	5.71e-11	Myopia (pathological);
KIRP	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg11189052	chr15:85197271	WDR73	0.53	5.38	0.32	1.7e-7	Schizophrenia;
KIRP	cis	rs9886651	0.935	rs4545058	chr8:128799003	A/T	cg24514600	chr8:128805414	PVT1	-0.73	-12.49	-0.62	4.76e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs2067615	0.929	rs752046	chr12:107111560	A/G	cg21360079	chr12:107162445	NA	-0.47	-5.98	-0.36	8.02e-9	Heart rate;
KIRP	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.79	-8.06	-0.46	3.34e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.67	-8.98	-0.5	7.37e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	1.000	rs4851287	chr2:100915772	A/G	cg14675211	chr2:100938903	LONRF2	0.47	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26924012	chr15:45694286	SPATA5L1	0.88	12.13	0.61	7.66e-27	Homoarginine levels;
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.83	13.29	0.65	9.73e-31	Vitiligo;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.7	-0.39	1.43e-10	Longevity;Endometriosis;
KIRP	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg25182066	chr10:30743637	MAP3K8	-0.62	-7.55	-0.43	8.3e-13	Inflammatory bowel disease;
KIRP	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.89	-0.35	1.28e-8	Educational attainment;
KIRP	cis	rs10518128	1.000	rs7692290	chr4:75712720	T/C	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.65e-7	Life satisfaction;
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg24874828	chr4:187887005	NA	0.47	7.09	0.41	1.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17065868	1.000	rs60157962	chr13:45106199	G/A	cg10246903	chr13:45222710	NA	0.7	6.85	0.4	5.96e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6580649	0.882	rs7133249	chr12:48456823	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	6.94	0.4	3.48e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.64	8.72	0.49	4.12e-16	Primary sclerosing cholangitis;
KIRP	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.56	-6.57	-0.39	3.05e-10	Pancreatic cancer;
KIRP	trans	rs17079247	0.841	rs9575843	chr13:85807979	C/T	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg26876637	chr1:152193138	HRNR	-0.77	-8.77	-0.49	3.09e-16	Atopic dermatitis;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg12486944	chr17:80159399	CCDC57	-0.41	-5.52	-0.33	8.46e-8	Life satisfaction;
KIRP	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	7.79	0.44	1.87e-13	Cognitive test performance;
KIRP	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg02527881	chr3:46936655	PTH1R	-0.37	-5.21	-0.32	4.02e-7	Colorectal cancer;
KIRP	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.41	0.33	1.53e-7	Neuroticism;
KIRP	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.84	6.75	0.4	1.07e-10	Fat distribution (HIV);
KIRP	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.98	14.04	0.67	2.83e-33	Platelet distribution width;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07226193	chr11:9685651	SWAP70	0.45	6.04	0.36	5.68e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.94	0.5	9.49e-17	Motion sickness;
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg15181151	chr6:150070149	PCMT1	0.31	5.07	0.31	7.78e-7	Lung cancer;
KIRP	cis	rs35883536	1.000	rs1855798	chr1:101114191	T/C	cg06223162	chr1:101003688	GPR88	0.31	6.25	0.37	1.78e-9	Monocyte count;
KIRP	cis	rs16976116	0.901	rs28564077	chr15:55495151	G/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.62	6.96	0.41	3.03e-11	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs244731	0.920	rs72813185	chr5:176739110	C/A	cg17509989	chr5:176798049	RGS14	0.67	6.7	0.39	1.39e-10	Urate levels in lean individuals;
KIRP	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg17724175	chr1:150552817	MCL1	-0.35	-5.95	-0.35	9.16e-9	Melanoma;
KIRP	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.5	8.41	0.47	3.38e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs830383	0.653	rs31737	chr5:165451047	C/G	cg13976338	chr5:165423657	NA	0.44	5.37	0.32	1.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.01	-0.61	1.85e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg03714773	chr7:91764589	CYP51A1	0.35	5.27	0.32	2.95e-7	Breast cancer;
KIRP	cis	rs4936894	0.500	rs11602188	chr11:124167145	A/G	cg27160556	chr11:124181099	OR8D1	0.46	6.55	0.39	3.29e-10	Aging (time to death);
KIRP	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg04310649	chr10:35416472	CREM	-0.59	-7.08	-0.41	1.47e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.74	9.49	0.52	2.11e-18	Coronary artery disease;
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg07308232	chr7:1071921	C7orf50	-0.48	-4.91	-0.3	1.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg01958934	chr19:45449099	APOC2	-0.39	-5.03	-0.31	9.42e-7	Blood protein levels;
KIRP	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.8	9.64	0.52	7.33e-19	Corneal astigmatism;
KIRP	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.63	-0.48	7.67e-16	Retinal vascular caliber;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18614379	chr15:64388188	SNX1	-0.53	-6.21	-0.37	2.25e-9	Interleukin-4 levels;
KIRP	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	6.22	0.37	2.1e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.47	5.85	0.35	1.53e-8	Coronary artery disease;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg12692727	chr7:1102344	C7orf50	0.47	5.04	0.31	9.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4919044	0.866	rs835265	chr10:94786259	A/G	cg05127821	chr10:94822908	CYP26C1	-1.08	-11.32	-0.59	3.42e-24	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04019098	chr2:232063399	ARMC9	0.51	6.72	0.39	1.28e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12643440	0.585	rs566672	chr4:17167808	C/T	cg22650099	chr4:17144496	NA	0.47	5.74	0.34	2.76e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg07343612	chr16:622815	PIGQ	-0.88	-13.45	-0.65	2.88e-31	Height;
KIRP	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg20312557	chr2:97357134	FER1L5	-0.73	-5.08	-0.31	7.57e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.59	9.68	0.53	5.4e-19	Neuroticism;
KIRP	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.7	7.75	0.44	2.49e-13	Mammographic density (dense area);
KIRP	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.5	-5.5	-0.33	9.42e-8	Total body bone mineral density;
KIRP	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg00585698	chr12:123750864	CDK2AP1	0.53	6.62	0.39	2.27e-10	Neutrophil percentage of white cells;
KIRP	cis	rs812925	0.519	rs2694638	chr2:61635363	G/C	cg15711740	chr2:61764176	XPO1	0.45	5.69	0.34	3.57e-8	Immature fraction of reticulocytes;
KIRP	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.95	-0.45	6.92e-14	Joint mobility (Beighton score);
KIRP	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg12435725	chr3:58293450	RPP14	-0.52	-5.37	-0.32	1.81e-7	Cholesterol, total;
KIRP	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	15.95	0.71	8.61e-40	Menopause (age at onset);
KIRP	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.41	-0.33	1.53e-7	Autism;
KIRP	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.38	7.73	0.44	2.7e-13	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05398773	chr8:71581521	XKR9;LACTB2	0.5	6.37	0.38	9e-10	Parkinson's disease;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg08901578	chr4:187885870	NA	-0.48	-7.17	-0.42	8.94e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.81	8.09	0.46	2.71e-14	Methadone dose in opioid dependence;
KIRP	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg05527609	chr1:210001259	C1orf107	-0.49	-6.28	-0.37	1.52e-9	Monobrow;
KIRP	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.68	7.62	0.44	5.58e-13	Corneal astigmatism;
KIRP	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-1.03	-14.05	-0.67	2.55e-33	Blood pressure (smoking interaction);
KIRP	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg04691961	chr3:161091175	C3orf57	-0.66	-11.15	-0.58	1.2e-23	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg18944383	chr4:111397179	ENPEP	0.52	9.22	0.51	1.34e-17	Height;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg18209359	chr17:80159595	CCDC57	-0.41	-5.27	-0.32	3.02e-7	Life satisfaction;
KIRP	cis	rs11078597	0.767	rs4525526	chr17:1650125	T/C	cg17514665	chr17:1657533	SERPINF2	0.45	5.54	0.33	7.73e-8	Serum albumin level;
KIRP	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.59	-5.79	-0.35	2.12e-8	Lung function (FEV1/FVC);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25006254	chr5:138775137	DNAJC18	0.47	6.7	0.39	1.41e-10	Parkinson's disease;
KIRP	cis	rs28489187	0.643	rs1884139	chr1:85845998	G/T	cg16011679	chr1:85725395	C1orf52	0.52	6.42	0.38	6.84e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs4950322	0.570	rs945742	chr1:146785157	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.41	-0.33	1.52e-7	Protein quantitative trait loci;
KIRP	trans	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg21315798	chr22:50354594	PIM3	-0.48	-6.05	-0.36	5.49e-9	Atopic dermatitis;
KIRP	cis	rs55882075	1.000	rs55882075	chr5:179210115	C/G	cg14593053	chr5:179126677	CANX	0.64	8.56	0.48	1.2e-15	Monocyte percentage of white cells;
KIRP	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.63	0.48	7.67e-16	Colorectal cancer;
KIRP	cis	rs17095355	0.786	rs61624875	chr10:111722489	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.96	-0.36	8.6e-9	Biliary atresia;
KIRP	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg17133734	chr15:86042851	AKAP13	-0.44	-5.53	-0.33	8.29e-8	Coronary artery disease;
KIRP	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	3.92e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs76917914	0.780	rs2417727	chr9:100846475	T/C	cg03040243	chr9:100819229	NANS	0.64	7.01	0.41	2.34e-11	Immature fraction of reticulocytes;
KIRP	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.97	0.5	7.97e-17	Motion sickness;
KIRP	cis	rs12986413	0.624	rs2238599	chr19:2140009	C/T	cg09261902	chr19:2140048	AP3D1	0.71	11.76	0.6	1.23e-25	Height;
KIRP	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.37	5.38	0.32	1.73e-7	Ovarian reserve;
KIRP	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	1.04	8.29	0.47	7.22e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	7.3	0.42	3.93e-12	Eye color traits;
KIRP	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg00800038	chr16:89945340	TCF25	-0.82	-6.01	-0.36	6.72e-9	Skin colour saturation;
KIRP	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.93	14.83	0.69	5.59e-36	Metabolite levels;
KIRP	cis	rs7010267	0.602	rs11995824	chr8:120012700	C/G	cg01975934	chr8:119970761	NA	-0.4	-5.27	-0.32	3.02e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.76	-8.32	-0.47	6.21e-15	Hair shape;
KIRP	cis	rs9581857	0.579	rs75024088	chr13:27970105	G/T	cg22138327	chr13:27999177	GTF3A	1.01	7.32	0.42	3.48e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg19743168	chr1:23544995	NA	0.53	7.36	0.43	2.67e-12	Height;
KIRP	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-0.61	-6.88	-0.4	4.93e-11	Initial pursuit acceleration;
KIRP	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg01251548	chr11:17372745	DKFZp686O24166	-0.4	-5.3	-0.32	2.51e-7	Type 2 diabetes;
KIRP	cis	rs12997796	0.556	rs35129240	chr2:86929217	G/A	cg25203885	chr2:87302643	LOC285074	-0.73	-5.64	-0.34	4.67e-8	Schizophrenia;
KIRP	cis	rs9328573	0.967	rs873843	chr15:100510425	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.44	-6.12	-0.36	3.6e-9	Urate levels in lean individuals;
KIRP	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18971241	chr14:76045025	FLVCR2	-0.47	-6.48	-0.38	5.01e-10	Metabolic traits;
KIRP	cis	rs2574704	0.651	rs2616552	chr3:11666798	G/T	cg07643000	chr3:11666825	VGLL4	-0.65	-9.68	-0.53	5.5e-19	Body mass index;
KIRP	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.43	7.09	0.41	1.38e-11	Testicular germ cell tumor;
KIRP	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25517755	chr10:38738941	LOC399744	-0.52	-7.18	-0.42	8.46e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.5	-0.52	2.02e-18	Mood instability;
KIRP	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg05729581	chr11:3078854	CARS	-0.55	-7.04	-0.41	1.9e-11	Longevity;
KIRP	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.02	-0.54	4.8e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.21	0.46	1.24e-14	Motion sickness;
KIRP	cis	rs12230513	0.732	rs7960126	chr12:55813605	T/G	cg11794356	chr12:55725991	OR6C3	-0.53	-5.35	-0.32	2.03e-7	Contrast sensitivity;
KIRP	cis	rs75920871	1.000	rs4938325	chr11:116898479	G/A	cg23684410	chr11:116897558	SIK3	0.57	6.15	0.37	3.05e-9	Subjective well-being;
KIRP	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.55	7.13	0.41	1.11e-11	Monobrow;
KIRP	cis	rs580438	0.510	rs2280087	chr3:13388084	T/C	cg10657019	chr3:13328039	NA	-0.6	-7.82	-0.45	1.5700000000000001e-13	Myringotomy;
KIRP	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg07169764	chr2:136633963	MCM6	-0.47	-5.41	-0.33	1.49e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.67	-8.9	-0.49	1.21e-16	Longevity;
KIRP	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg04725166	chr1:7887271	PER3	-0.34	-5.37	-0.32	1.87e-7	Crohn's disease;
KIRP	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.56	6.86	0.4	5.45e-11	Total body bone mineral density;
KIRP	cis	rs7084402	0.967	rs1649049	chr10:60324095	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-11.15	-0.58	1.21e-23	Refractive error;
KIRP	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg17376030	chr22:41985996	PMM1	-0.85	-8.92	-0.49	1.05e-16	Cannabis dependence symptom count;
KIRP	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg22117172	chr7:91764530	CYP51A1	-0.46	-6.43	-0.38	6.53e-10	Breast cancer;
KIRP	cis	rs2908197	0.737	rs6978009	chr7:75992234	A/C	cg06959773	chr7:76033795	SRCRB4D;ZP3	0.29	4.96	0.3	1.31e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg22903471	chr2:27725779	GCKR	0.43	5.97	0.36	8.03e-9	Oral cavity cancer;
KIRP	cis	rs4692589	0.581	rs6821231	chr4:170959988	C/T	cg19918862	chr4:170955249	NA	0.61	6.83	0.4	6.79e-11	Anxiety disorder;
KIRP	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.99	9.64	0.52	7.53e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.59	-6.33	-0.37	1.12e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	1.08	12.11	0.61	8.52e-27	Exhaled nitric oxide output;
KIRP	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.18	0.31	4.69e-7	Height;
KIRP	cis	rs10875746	0.669	rs10431526	chr12:48690143	A/G	cg20731937	chr12:48336164	NA	0.45	5.93	0.35	1e-8	Longevity (90 years and older);
KIRP	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.18	12.93	0.64	1.62e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg14703610	chr5:56206110	C5orf35	0.5	6.63	0.39	2.06e-10	Coronary artery disease;
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg18944383	chr4:111397179	ENPEP	0.53	9.66	0.52	6.25e-19	Height;
KIRP	cis	rs9549260	0.753	rs10507486	chr13:41186501	A/G	cg21288729	chr13:41239152	FOXO1	-0.49	-4.85	-0.3	2.17e-6	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04460285	chr2:113522412	CKAP2L	0.5	6.49	0.38	4.58e-10	Parkinson's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23284323	chr21:40685679	BRWD1	0.5	6.26	0.37	1.66e-9	Myopia (pathological);
KIRP	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg08508325	chr11:3079039	CARS	0.32	5.77	0.35	2.34e-8	Calcium levels;
KIRP	cis	rs787274	0.543	rs10759590	chr9:115610567	G/C	cg13803584	chr9:115635662	SNX30	-0.72	-6.69	-0.39	1.53e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9659323	0.539	rs1750331	chr1:119494973	A/G	cg05756136	chr1:119680316	WARS2	-0.41	-5.58	-0.34	6.3e-8	Body mass index;
KIRP	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg25600027	chr14:23388339	RBM23	-0.49	-6.02	-0.36	6.45e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.59	8.65	0.48	6.76e-16	Blood metabolite levels;
KIRP	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg12386194	chr3:101231763	SENP7	0.39	4.98	0.3	1.17e-6	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs7187994	0.848	rs35019923	chr16:84782214	A/C	cg07647771	chr16:84786436	USP10	-0.43	-5.55	-0.33	7.48e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.87e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.9	10.65	0.56	5.17e-22	Exhaled nitric oxide levels;
KIRP	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26207909	chr14:103986467	CKB	-0.75	-11.39	-0.59	1.97e-24	Bone mineral density;
KIRP	cis	rs10214930	0.705	rs12700824	chr7:27661754	T/C	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.93	11.23	0.58	6.66e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs7779181	0.680	rs4723146	chr7:32397448	A/G	cg27532318	chr7:32358331	NA	0.47	5.08	0.31	7.48e-7	Body mass index;
KIRP	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9398235	1.000	rs9398235	chr6:110732116	A/G	cg19196401	chr6:110721138	DDO	-0.44	-5.13	-0.31	5.88e-7	Systemic lupus erythematosus;
KIRP	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.0	-0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	6.98	0.41	2.78e-11	Systemic lupus erythematosus;
KIRP	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs4523957	0.583	rs2984943	chr17:2030135	T/C	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-7.37	-0.43	2.64e-12	Tonsillectomy;
KIRP	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.56	-15.48	-0.7	3.24e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.45e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.77	6.94	0.4	3.5e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs4006360	0.629	rs2132842	chr17:39234214	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.67	-0.48	5.93e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2979489	0.699	rs7840356	chr8:30406251	G/A	cg26383811	chr8:30366931	RBPMS	0.43	5.88	0.35	1.33e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg15083037	chr5:83017644	HAPLN1	-0.57	-8.19	-0.46	1.4e-14	Prostate cancer;
KIRP	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-7.32	-0.42	3.52e-12	Bipolar disorder;
KIRP	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg11833968	chr6:79620685	NA	-0.44	-6.55	-0.39	3.38e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3736485	0.966	rs17609917	chr15:51911487	G/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.86	11.7	0.6	1.95e-25	Longevity;
KIRP	cis	rs4959799	0.557	rs9503516	chr6:3272065	G/A	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.25	-0.32	3.34e-7	Survival in rectal cancer;
KIRP	cis	rs3812111	0.510	rs9372453	chr6:116583872	T/A	cg18828861	chr6:116576566	TSPYL4	0.42	4.87	0.3	1.98e-6	Age-related macular degeneration;
KIRP	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	0.83	10.99	0.57	4e-23	Primary sclerosing cholangitis;
KIRP	cis	rs4356932	1.000	rs6532093	chr4:76948032	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.62	-0.34	5.26e-8	Coronary artery disease;
KIRP	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg06197360	chr20:60970103	CABLES2	-0.51	-5.99	-0.36	7.49e-9	Colorectal cancer;
KIRP	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.64	0.68	2.56e-35	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13530621	chr13:20735337	GJA3	0.43	6.49	0.38	4.79e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg26531700	chr6:26746687	NA	0.45	6.47	0.38	5.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.63	-0.44	5.04e-13	Type 2 diabetes;
KIRP	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg02487422	chr3:49467188	NICN1	0.37	5.18	0.31	4.71e-7	Parkinson's disease;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg07194495	chr7:148958859	ZNF783	0.6	7.37	0.43	2.61e-12	Sleep duration;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg15741583	chr11:6461908	HPX	-0.49	-7.62	-0.44	5.4e-13	Bladder cancer;
KIRP	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg05370193	chr1:21551575	ECE1	-0.36	-5.01	-0.3	1.04e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg07701084	chr6:150067640	NUP43	0.54	6.97	0.41	2.87e-11	Lung cancer;
KIRP	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.7	9.5	0.52	1.97e-18	Systemic lupus erythematosus;
KIRP	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.62	8.97	0.5	7.71e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6662572	0.737	rs11587648	chr1:46585418	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.75	0.34	2.69e-8	Blood protein levels;
KIRP	trans	rs7657257	1.000	rs7657257	chr4:15646941	G/A	cg03228132	chr7:129781429	NA	-0.73	-7.08	-0.41	1.52e-11	Blood protein levels;
KIRP	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6009824	1.000	rs6009824	chr22:50086373	C/T	cg18178197	chr22:50098317	NA	0.59	7.16	0.42	9.1e-12	Natriuretic peptide levels;
KIRP	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg17595323	chr11:93583763	C11orf90	-0.3	-5.15	-0.31	5.31e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.55	7.3	0.42	4.04e-12	Red blood cell count;
KIRP	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00007898	chr1:205180627	DSTYK	-0.56	-6.13	-0.36	3.52e-9	Menopause (age at onset);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23617067	chr1:220292508	IARS2;MIR194-1;MIR215	0.39	6.02	0.36	6.16e-9	C-reactive protein;
KIRP	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg06064525	chr11:970664	AP2A2	-0.37	-7.59	-0.44	6.45e-13	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.05	-0.36	5.39e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1076160	0.846	rs13299768	chr9:135702490	T/C	cg04648087	chr9:135819397	TSC1	-0.39	-4.85	-0.3	2.21e-6	Psoriasis;
KIRP	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg02297831	chr4:17616191	MED28	0.51	5.83	0.35	1.75e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs714515	0.569	rs2032528	chr1:172452087	A/G	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.5	-0.52	1.94e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15703646	chr7:100209939	MOSPD3	0.5	6.17	0.37	2.72e-9	Parkinson's disease;
KIRP	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg11235152	chr1:67600687	NA	0.76	11.48	0.59	1.01e-24	Psoriasis;
KIRP	cis	rs10463316	0.963	rs4958450	chr5:150739932	A/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.63	-0.34	4.95e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2411233	1.000	rs7168645	chr15:39271165	C/T	cg02291532	chr15:39874776	THBS1	0.4	5.42	0.33	1.39e-7	Platelet count;
KIRP	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.46	5.52	0.33	8.73e-8	Blood metabolite levels;
KIRP	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.53	-9.18	-0.51	1.82e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg12480562	chr20:23434244	CST11	0.61	6.06	0.36	4.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs57590327	0.679	rs7639135	chr3:81608976	C/T	cg07356753	chr3:81810745	GBE1	-0.57	-6.17	-0.37	2.73e-9	Extraversion;
KIRP	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.45	6.3	0.37	1.37e-9	Dupuytren's disease;
KIRP	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg21775007	chr8:11205619	TDH	-0.45	-6.33	-0.37	1.18e-9	Neuroticism;
KIRP	cis	rs2625529	0.586	rs7175197	chr15:72461648	G/A	cg16672083	chr15:72433130	SENP8	0.45	6.28	0.37	1.56e-9	Red blood cell count;
KIRP	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-14.7	-0.68	1.58e-35	Coronary artery disease;
KIRP	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg08076091	chr2:203926405	NBEAL1	-0.87	-9.78	-0.53	2.76e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-9.89	-0.53	1.23e-19	Ileal carcinoids;
KIRP	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg07884673	chr3:53033167	SFMBT1	0.93	7.26	0.42	5.22e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.69	-8.04	-0.46	3.66e-14	Glomerular filtration rate;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg04025307	chr7:1156635	C7orf50	0.81	8.3	0.47	6.8e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4728302	0.607	rs12707127	chr7:133586089	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.06	0.31	8.27e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg23933602	chr10:16859644	RSU1	0.54	5.73	0.34	3e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7792596	0.861	rs2374718	chr7:94013502	T/A	cg20814616	chr7:94014465	NA	-0.4	-6.94	-0.4	3.55e-11	Intelligence;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19613905	chr15:56757180	MNS1	0.68	6.32	0.37	1.19e-9	Lung function (FEV1);
KIRP	cis	rs3857747	0.931	rs4360204	chr7:40387459	T/C	cg00420559	chr7:40367873	C7orf10	0.63	8.07	0.46	3.07e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.81	7.96	0.45	6.33e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.71	-10.0	-0.54	5.69e-20	Narcolepsy;
KIRP	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg18478394	chr8:109455254	TTC35	0.48	5.95	0.35	8.93e-9	Dupuytren's disease;
KIRP	cis	rs6142102	0.961	rs1883524	chr20:32626107	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	6.88	0.4	5.04e-11	Skin pigmentation;
KIRP	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.75	-0.4	1.05e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27297192	chr10:134578999	INPP5A	0.63	7.9	0.45	9.59e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs5753618	0.504	rs8142121	chr22:31882785	G/A	cg02404636	chr22:31891804	SFI1	0.56	6.24	0.37	1.92e-9	Colorectal cancer;
KIRP	cis	rs9596863	0.898	rs9568919	chr13:54352229	T/G	ch.13.53330881F	chr13:54432880	NA	0.6	5.84	0.35	1.63e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs10143866	0.588	rs77948181	chr14:52869751	A/G	cg12122340	chr15:59063113	FAM63B	1.07	6.2	0.37	2.39e-9	Smooth-surface caries;
KIRP	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	7.58	0.44	7.03e-13	Height;
KIRP	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	1.21	15.64	0.71	9.55e-39	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18004262	chr3:126076475	KLF15	0.5	6.12	0.36	3.73e-9	Parkinson's disease;
KIRP	cis	rs4704187	0.687	rs10462512	chr5:74387317	C/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs11955398	0.604	rs11951950	chr5:59876940	C/G	cg02684056	chr5:59996105	DEPDC1B	0.46	5.36	0.32	1.93e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-7.65	-0.44	4.67e-13	Alzheimer's disease (survival time);
KIRP	cis	rs1850744	0.826	rs6858644	chr4:9741681	T/G	cg15442990	chr4:9534313	NA	0.82	5.83	0.35	1.77e-8	Economic and political preferences;
KIRP	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.2	0.31	4.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2299587	0.610	rs7001974	chr8:17773295	C/T	cg01800426	chr8:17659068	MTUS1	-0.62	-7.37	-0.43	2.62e-12	Economic and political preferences;
KIRP	cis	rs7527798	0.571	rs11118237	chr1:207818719	G/A	cg09232269	chr1:207846808	CR1L	-0.36	-5.03	-0.31	9.34e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg08132940	chr7:1081526	C7orf50	-0.48	-5.45	-0.33	1.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.98	0.3	1.22e-6	Personality dimensions;
KIRP	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg11846333	chr4:119757529	SEC24D	1.09	7.0	0.41	2.48e-11	Cannabis dependence symptom count;
KIRP	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg04218760	chr10:45406644	TMEM72	-0.25	-6.58	-0.39	2.83e-10	Mean corpuscular volume;
KIRP	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg07936489	chr17:37558343	FBXL20	-0.55	-7.32	-0.42	3.53e-12	Asthma;
KIRP	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.87	13.03	0.64	7.4e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	0.95	18.19	0.76	2e-47	Dental caries;
KIRP	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.7	8.75	0.49	3.47e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11987759	chr7:65425863	GUSB	-0.62	-8.15	-0.46	1.91e-14	Aortic root size;
KIRP	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg19875535	chr5:140030758	IK	-0.71	-10.01	-0.54	5.15e-20	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6783573	0.894	rs939408	chr3:46599079	C/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.53	-7.21	-0.42	7e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10858047	0.883	rs4839384	chr1:115101171	G/A	cg12756093	chr1:115239321	AMPD1	0.64	6.11	0.36	3.87e-9	Autism;
KIRP	cis	rs612683	0.536	rs1855797	chr1:101027126	A/G	cg06223162	chr1:101003688	GPR88	0.5	10.45	0.55	2.22e-21	Breast cancer;
KIRP	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.81	-10.91	-0.57	7.54e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10782582	0.668	rs7516477	chr1:76204502	C/G	cg03433033	chr1:76189801	ACADM	-0.46	-7.26	-0.42	5.2e-12	Daytime sleep phenotypes;
KIRP	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.83	-0.53	1.86e-19	Total body bone mineral density;
KIRP	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.64	7.79	0.44	1.86e-13	Electroencephalographic traits in alcoholism;
KIRP	cis	rs526231	0.575	rs55652053	chr5:102337170	T/A	cg23492399	chr5:102201601	PAM	-0.5	-5.75	-0.34	2.7e-8	Primary biliary cholangitis;
KIRP	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.82	-0.35	1.79e-8	Recombination measurement;
KIRP	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg06064525	chr11:970664	AP2A2	-0.37	-7.61	-0.44	5.99e-13	Alzheimer's disease (late onset);
KIRP	cis	rs151997	0.925	rs26087	chr5:50172911	G/A	cg06027927	chr5:50259733	NA	0.61	7.57	0.43	7.4e-13	Callous-unemotional behaviour;
KIRP	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.08	-13.71	-0.66	3.54e-32	Exhaled nitric oxide output;
KIRP	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs7180079	0.620	rs500641	chr15:64851132	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03934478	chr11:495069	RNH1	0.75	5.98	0.36	7.81e-9	Body mass index;
KIRP	cis	rs6921919	0.583	rs7759191	chr6:28353434	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg17652424	chr22:38574118	PLA2G6	-0.24	-4.94	-0.3	1.42e-6	Cutaneous nevi;
KIRP	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.62	-7.12	-0.41	1.17e-11	DNA methylation (variation);
KIRP	cis	rs7503807	0.664	rs9902390	chr17:78574387	G/A	cg09596252	chr17:78655493	RPTOR	0.5	5.5	0.33	9.45e-8	Obesity;
KIRP	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg26531700	chr6:26746687	NA	0.41	5.58	0.34	6.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs78487399	0.908	rs72868625	chr2:43831186	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.05	-0.31	8.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg03929089	chr4:120376271	NA	-0.53	-6.55	-0.39	3.36e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs7534824	0.625	rs61780332	chr1:101484733	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.01	0.41	2.29e-11	Refractive astigmatism;
KIRP	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg16586182	chr3:47516702	SCAP	0.69	9.3	0.51	7.72e-18	Colorectal cancer;
KIRP	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg00800038	chr16:89945340	TCF25	-0.69	-4.86	-0.3	2.06e-6	Skin colour saturation;
KIRP	cis	rs7721647	0.821	rs1661037	chr5:90838345	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.4	4.91	0.3	1.65e-6	Breast cancer;
KIRP	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.7	-10.07	-0.54	3.47e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.75	-0.63	6.19e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.47	4.89	0.3	1.79e-6	Lymphocyte counts;
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg03188948	chr7:1209495	NA	0.49	5.47	0.33	1.09e-7	Longevity;Endometriosis;
KIRP	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.79	11.22	0.58	7.28e-24	Bladder cancer;
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.51	-0.48	1.75e-15	Life satisfaction;
KIRP	cis	rs3736485	0.934	rs28695624	chr15:51874928	A/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3204270	0.639	rs1126818	chr17:79617830	G/A	cg18367735	chr17:79674897	NA	0.68	6.25	0.37	1.78e-9	Dental caries;
KIRP	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs11605275	1.000	rs78091560	chr11:20032279	G/A	cg14835545	chr11:20032148	NAV2	-0.8	-6.14	-0.36	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.57	7.49	0.43	1.25e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9815354	0.951	rs12492599	chr3:42005734	C/A	cg03022575	chr3:42003672	ULK4	-0.51	-5.85	-0.35	1.52e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.74	11.68	0.6	2.29e-25	Resting heart rate;
KIRP	cis	rs7258015	0.865	rs7250656	chr19:10448566	A/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.48	6.21	0.37	2.22e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.79	-10.64	-0.56	5.36e-22	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01809819	chr1:31192165	MATN1	0.46	6.14	0.36	3.37e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.88	14.94	0.69	2.43e-36	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4400599	0.618	rs9943097	chr1:154205823	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.99	-0.36	7.38e-9	Platelet distribution width;
KIRP	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.45	-8.36	-0.47	4.68e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.75e-13	Life satisfaction;
KIRP	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.47	-4.87	-0.3	1.97e-6	Initial pursuit acceleration;
KIRP	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg24642844	chr7:1081250	C7orf50	-0.73	-6.71	-0.39	1.32e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs927821	0.680	rs11599868	chr10:104201381	C/T	cg06646780	chr6:130182053	C6orf191	0.68	6.51	0.38	4.26e-10	Social autistic-like traits;
KIRP	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg00012203	chr2:219082015	ARPC2	0.81	11.66	0.6	2.75e-25	Colorectal cancer;
KIRP	cis	rs9583531	0.891	rs9521906	chr13:111358000	T/G	cg24331049	chr13:111365604	ING1	-0.79	-6.81	-0.4	7.44e-11	Coronary artery disease;
KIRP	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-10.29	-0.55	7.14e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.64	5.77	0.35	2.32e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs7178375	1.000	rs9806159	chr15:31209654	G/T	cg04373760	chr16:53404718	NA	0.6	6.51	0.38	4.25e-10	Hypertriglyceridemia;
KIRP	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-4.85	-0.3	2.23e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.53	5.2	0.31	4.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12936587	0.935	rs12449964	chr17:17544704	A/G	cg01246520	chr17:17644344	RAI1	0.36	6.06	0.36	5.05e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs3779635	0.844	rs56330356	chr8:27278847	A/G	cg18234130	chr8:27182889	PTK2B	0.45	5.79	0.35	2.18e-8	Neuroticism;
KIRP	cis	rs7719624	0.510	rs955242	chr5:135546166	G/A	cg12897067	chr5:135418308	NA	0.42	4.87	0.3	1.99e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs8053891	1.000	rs8053891	chr16:71997789	A/C	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.04	-0.31	8.87e-7	Coronary artery disease;
KIRP	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.74	11.48	0.59	1.02e-24	Neuroticism;
KIRP	cis	rs2862064	1.000	rs6896499	chr5:156431325	A/G	cg12943317	chr5:156479607	HAVCR1	-0.9	-7.81	-0.45	1.64e-13	Platelet count;
KIRP	cis	rs72730918	0.590	rs9672605	chr15:51990787	T/C	cg14296394	chr15:51910925	DMXL2	0.74	10.35	0.55	4.52e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg05370193	chr1:21551575	ECE1	0.46	6.24	0.37	1.87e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	0.99	15.58	0.7	1.49e-38	Dilated cardiomyopathy;
KIRP	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.2	-0.37	2.34e-9	Chronic sinus infection;
KIRP	cis	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg27411982	chr8:10470053	RP1L1	-0.46	-5.92	-0.35	1.1e-8	Neuroticism;
KIRP	cis	rs2458413	0.500	rs2514665	chr8:105351531	C/T	cg15172053	chr8:105342214	NA	-0.39	-5.05	-0.31	8.64e-7	Paget's disease;
KIRP	cis	rs4664293	0.867	rs6432553	chr2:160577010	A/G	cg08347373	chr2:160653686	CD302	-0.38	-5.81	-0.35	1.88e-8	Monocyte percentage of white cells;
KIRP	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg04374321	chr14:90722782	PSMC1	-0.87	-12.65	-0.63	1.36e-28	Mortality in heart failure;
KIRP	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs8077577	0.708	rs3829589	chr17:18134266	T/C	cg18869244	chr17:18121946	NA	-0.43	-4.95	-0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.16	0.46	1.77e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs73198271	0.603	rs557892	chr8:8596048	A/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.13	-0.31	5.82e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.41	-0.33	1.51e-7	Bipolar disorder;
KIRP	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg09264619	chr17:80180166	NA	0.45	5.16	0.31	5.17e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.85	11.93	0.61	3.36e-26	Breast cancer;
KIRP	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg01872077	chr2:219646372	CYP27A1	-0.43	-5.87	-0.35	1.37e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	9.95	0.54	8.07e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs6881634	0.501	rs13159260	chr5:77690103	T/C	cg02919814	chr21:37666008	DOPEY2	-0.4	-6.03	-0.36	5.94e-9	Hippocampal atrophy;
KIRP	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.41e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04227743	chr2:155711998	KCNJ3	-0.41	-6.65	-0.39	1.84e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg26876637	chr1:152193138	HRNR	-0.7	-8.9	-0.49	1.24e-16	Atopic dermatitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10070431	chr2:232322438	NCL;SNORD20	0.56	7.09	0.41	1.4e-11	Interleukin-4 levels;
KIRP	cis	rs2425143	1.000	rs56904633	chr20:34400757	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.01	-0.3	1.03e-6	Blood protein levels;
KIRP	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg05791153	chr7:19748676	TWISTNB	0.65	5.72	0.34	3.12e-8	Thyroid stimulating hormone;
KIRP	cis	rs4006360	0.525	rs72625956	chr17:39237517	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.66	-0.48	6.38e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.67	6.62	0.39	2.23e-10	Axial length;
KIRP	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.87e-10	Fibrinogen levels;
KIRP	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.35	-5.13	-0.31	5.79e-7	Body mass index;
KIRP	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg08917208	chr2:24149416	ATAD2B	1.17	10.38	0.55	3.69e-21	Lymphocyte counts;
KIRP	cis	rs17121403	0.661	rs12117982	chr1:100535563	G/A	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	trans	rs7923609	0.841	rs10740131	chr10:65271488	A/T	cg22117143	chr9:13251431	MPDZ	-0.44	-6.06	-0.36	4.99e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg10505658	chr17:80084571	CCDC57	-0.26	-4.85	-0.3	2.2e-6	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg07701084	chr6:150067640	NUP43	0.71	10.08	0.54	3.25e-20	Lung cancer;
KIRP	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	7.86	0.45	1.19e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.82	-12.1	-0.61	9.29e-27	Ulcerative colitis;
KIRP	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.59	-6.72	-0.39	1.26e-10	Menarche (age at onset);
KIRP	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs4006360	0.604	rs3914090	chr17:39230058	A/T	cg15015397	chr17:39261100	KRTAP4-9	-0.5	-7.74	-0.44	2.52e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.7	-10.12	-0.54	2.33e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs728478	0.967	rs12452950	chr17:57440353	T/C	cg16535752	chr17:57448097	YPEL2	-0.21	-4.98	-0.3	1.19e-6	QT interval;
KIRP	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.91	-12.14	-0.61	6.99e-27	Bipolar disorder and schizophrenia;
KIRP	cis	rs244293	0.673	rs12944690	chr17:53029614	A/G	cg07707039	chr17:53042137	COX11	-0.4	-5.03	-0.31	9.32e-7	Menarche (age at onset);
KIRP	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.58e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.55	0.75	3.02e-45	Height;
KIRP	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.54	-7.07	-0.41	1.59e-11	Blood metabolite levels;
KIRP	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg25358565	chr5:93447407	FAM172A	-0.58	-6.56	-0.39	3.19e-10	Diabetic retinopathy;
KIRP	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	9.48	0.52	2.27e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9921338	0.923	rs7186455	chr16:11427748	A/G	cg00044050	chr16:11439710	C16orf75	-0.54	-5.77	-0.35	2.33e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg06533319	chr4:3265114	C4orf44	-0.42	-5.07	-0.31	7.92e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.58	-6.17	-0.37	2.81e-9	Obesity-related traits;
KIRP	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25517755	chr10:38738941	LOC399744	-0.37	-5.08	-0.31	7.62e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.95	0.3	1.38e-6	Lung cancer;
KIRP	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.19	-15.85	-0.71	1.85e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.99	13.27	0.65	1.13e-30	Cognitive function;
KIRP	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.89	13.14	0.64	3.19e-30	Psoriasis;
KIRP	cis	rs9596863	0.898	rs9591534	chr13:54363861	C/G	ch.13.53330881F	chr13:54432880	NA	0.61	5.97	0.36	8.43e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs13082711	1.000	rs34234262	chr3:27539188	G/A	cg02860705	chr3:27208620	NA	0.59	7.59	0.44	6.74e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg22916017	chr11:64110731	CCDC88B	0.57	6.68	0.39	1.61e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.64	8.5	0.48	1.87e-15	Calcium levels;
KIRP	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg15655495	chr12:38532458	NA	0.25	4.93	0.3	1.49e-6	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-16.01	-0.71	5.21e-40	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg19468946	chr17:37922297	IKZF3	-0.52	-7.25	-0.42	5.39e-12	Self-reported allergy;
KIRP	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg04025307	chr7:1156635	C7orf50	0.75	7.82	0.45	1.58e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7520050	0.966	rs785488	chr1:46576095	G/A	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.21	-0.42	6.77e-12	Bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05214047	chr5:56112645	MAP3K1	0.57	6.79	0.4	8.52e-11	Smoking initiation;
KIRP	cis	rs56079296	0.929	rs28391435	chr5:121353364	G/A	cg05256605	chr5:121412184	LOX	-0.54	-5.81	-0.35	1.9e-8	Coronary artery disease;
KIRP	cis	rs258892	0.739	rs11952024	chr5:72020195	C/T	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg03999872	chr20:62272968	STMN3	-0.56	-6.52	-0.38	3.89e-10	Atopic dermatitis;
KIRP	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12489547	chr11:15959637	NA	0.48	6.09	0.36	4.23e-9	Interleukin-4 levels;
KIRP	trans	rs225245	0.782	rs178649	chr17:33908197	C/G	cg19694781	chr19:47549865	TMEM160	-0.51	-6.2	-0.37	2.34e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.87	12.12	0.61	8.36e-27	Breast cancer;
KIRP	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.67	-11.02	-0.57	3.35e-23	Urate levels in overweight individuals;
KIRP	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.9e-9	Endometrial cancer;
KIRP	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	0.51	6.21	0.37	2.19e-9	Prudent dietary pattern;
KIRP	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg15744005	chr10:104629667	AS3MT	0.31	6.44	0.38	6.21e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.99	15.12	0.69	5.6e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.94	11.18	0.58	1.01e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.65	8.79	0.49	2.58e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg19847130	chr8:10466454	RP1L1	0.33	4.86	0.3	2.05e-6	Triglycerides;
KIRP	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.33	0.32	2.26e-7	Coronary artery disease;
KIRP	cis	rs4363385	0.747	rs6678107	chr1:152966818	T/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.87	-0.3	1.97e-6	Inflammatory skin disease;
KIRP	cis	rs7927771	0.757	rs1057233	chr11:47376448	G/A	cg20307385	chr11:47447363	PSMC3	0.46	4.96	0.3	1.29e-6	Subjective well-being;
KIRP	cis	rs930036	0.501	rs13006705	chr2:171867153	A/C	cg12801329	chr2:171670795	NA	0.46	5.02	0.3	9.82e-7	Menopause (age at onset);
KIRP	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg08461772	chr7:95026248	PON3	0.41	5.85	0.35	1.53e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg13206674	chr6:150067644	NUP43	0.52	7.41	0.43	1.96e-12	Testicular germ cell tumor;
KIRP	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.72	6.22	0.37	2.14e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.71	9.09	0.5	3.33e-17	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg04132472	chr17:19861366	AKAP10	0.67	10.49	0.56	1.57e-21	Schizophrenia;
KIRP	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.55	5.97	0.36	8.46e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9815354	0.812	rs56290987	chr3:42004882	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.35	0.38	1.04e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg26695010	chr11:65641043	EFEMP2	0.51	5.1	0.31	6.88e-7	Crohn's disease;
KIRP	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg20243544	chr17:37824526	PNMT	0.52	7.5	0.43	1.13e-12	Asthma;
KIRP	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg18944383	chr4:111397179	ENPEP	0.42	6.81	0.4	7.25e-11	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04763192	chr1:111889241	C1orf88	0.51	6.23	0.37	2.04e-9	Smoking initiation;
KIRP	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.7	-7.63	-0.44	5.16e-13	Gut microbiome composition (summer);
KIRP	cis	rs6430538	0.597	rs6731271	chr2:135560072	T/C	cg12500956	chr2:135428796	TMEM163	0.39	5.12	0.31	6.26e-7	Parkinson's disease;
KIRP	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.67	-7.55	-0.43	8.59e-13	Vitiligo;
KIRP	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg03929089	chr4:120376271	NA	0.71	6.51	0.38	4.17e-10	Intraocular pressure;
KIRP	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs4262150	0.764	rs2961760	chr5:151939905	C/T	cg12297329	chr5:152029980	NA	0.52	6.65	0.39	1.85e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg15704280	chr7:45808275	SEPT13	-0.53	-6.44	-0.38	6.15e-10	Pediatric bone mineral density (spine);
KIRP	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg06060754	chr5:176797920	RGS14	-0.61	-7.03	-0.41	1.99e-11	Urate levels in lean individuals;
KIRP	cis	rs2916247	0.909	rs720444	chr8:93098924	G/T	cg10183463	chr8:93005414	RUNX1T1	0.52	6.46	0.38	5.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.03	-0.41	2.08e-11	Response to antipsychotic treatment;
KIRP	cis	rs258892	0.947	rs258895	chr5:72331687	T/C	cg21869765	chr5:72125136	TNPO1	-0.52	-6.26	-0.37	1.74e-9	Small cell lung carcinoma;
KIRP	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg00631329	chr6:26305371	NA	-0.73	-9.5	-0.52	1.99e-18	Educational attainment;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.66	9.68	0.53	5.39e-19	Menarche (age at onset);
KIRP	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg04166393	chr7:2884313	GNA12	0.48	6.43	0.38	6.52e-10	Height;
KIRP	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg07395648	chr5:131743802	NA	-0.47	-6.13	-0.36	3.55e-9	Breast cancer;Mosquito bite size;
KIRP	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03647317	chr4:187891568	NA	-0.77	-13.04	-0.64	7.01e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	7.8	0.45	1.72e-13	Lung function (FEV1/FVC);
KIRP	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.64	-8.2	-0.46	1.35e-14	Motion sickness;
KIRP	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.37	-7.47	-0.43	1.4e-12	Arsenic metabolism;
KIRP	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.53	6.81	0.4	7.49e-11	Coronary heart disease;
KIRP	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.83	-13.07	-0.64	5.34e-30	Dental caries;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01419670	chr5:115696151	NA	-0.46	-7.12	-0.41	1.19e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg01028140	chr2:1542097	TPO	-0.6	-6.03	-0.36	6.11e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs918959	0.793	rs1406251	chr2:181532430	C/T	cg04166432	chr2:181843717	UBE2E3	0.62	4.96	0.3	1.31e-6	Systemic lupus erythematosus;
KIRP	trans	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.77	-0.4	9.14e-11	Obesity-related traits;
KIRP	cis	rs755109	1.000	rs66990486	chr9:100680919	T/C	cg13688889	chr9:100608707	NA	-0.42	-4.89	-0.3	1.81e-6	Quantitative traits;
KIRP	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.9	14.23	0.67	6.26e-34	Coronary artery disease;
KIRP	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.59	0.44	6.61e-13	Aortic root size;
KIRP	cis	rs2859741	0.587	rs510969	chr1:37475061	T/C	cg09363841	chr1:37513479	NA	-0.55	-8.6	-0.48	9.2e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	cg21523751	chr1:182988639	NA	-0.45	-7.25	-0.42	5.46e-12	Colorectal cancer;
KIRP	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.5	6.32	0.37	1.21e-9	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16721845	chr11:68518800	MTL5	0.45	6.23	0.37	1.96e-9	Parkinson's disease;
KIRP	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.77	9.42	0.51	3.4e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg16497661	chr14:103986332	CKB	0.76	11.35	0.59	2.73e-24	Body mass index;
KIRP	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06544989	chr22:39130855	UNC84B	0.45	6.88	0.4	4.98e-11	Menopause (age at onset);
KIRP	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.79	-7.4	-0.43	2.21e-12	Coronary artery calcification;
KIRP	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg01391022	chr12:122360665	WDR66	0.37	5.05	0.31	8.73e-7	Mean corpuscular volume;
KIRP	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg00919237	chr7:87102261	ABCB4	-0.73	-9.18	-0.51	1.82e-17	Gallbladder cancer;
KIRP	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.94	-17.9	-0.75	1.94e-46	Dental caries;
KIRP	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg16362232	chr11:430036	ANO9	0.6	4.89	0.3	1.78e-6	Body mass index;
KIRP	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10073892	0.664	rs56256048	chr5:101894631	G/C	cg19774478	chr5:101632501	SLCO4C1	0.59	5.8	0.35	2e-8	Cognitive decline (age-related);
KIRP	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.4	4.9	0.3	1.71e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg26174226	chr8:58114915	NA	-0.53	-5.22	-0.32	3.76e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.88	8.92	0.49	1.05e-16	Hip geometry;
KIRP	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.48	-6.05	-0.36	5.46e-9	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs6882046	0.513	rs34318	chr5:88027149	G/A	cg22951263	chr5:87985283	NA	-0.45	-6.39	-0.38	8.41e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.91	13.25	0.65	1.36e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg27205649	chr11:78285834	NARS2	-0.56	-5.48	-0.33	1.03e-7	Testicular germ cell tumor;
KIRP	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-1.01	-17.19	-0.74	4.88e-44	Height;
KIRP	cis	rs12580194	0.593	rs115471673	chr12:55766516	A/G	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs6738627	0.766	rs1128249	chr2:165528624	G/T	cg03182029	chr2:165697222	COBLL1	0.38	5.03	0.31	9.3e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.69	-9.2	-0.51	1.63e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg20750642	chr13:99100586	FARP1	0.41	4.96	0.3	1.29e-6	Longevity;
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.24	-4.93	-0.3	1.5e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg22777020	chr22:31556080	RNF185	-0.49	-5.15	-0.31	5.39e-7	Colorectal cancer;
KIRP	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.56	-7.18	-0.42	8.02e-12	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9921338	0.961	rs72773830	chr16:11412823	G/C	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.62	0.34	5.05e-8	Breast cancer;
KIRP	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.43	-5.63	-0.34	4.93e-8	Mean platelet volume;
KIRP	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	4.88	0.3	1.91e-6	Personality dimensions;
KIRP	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.64	0.39	1.94e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.62	9.43	0.52	3.19e-18	Cancer;
KIRP	cis	rs2629540	0.543	rs2559515	chr10:126513925	A/G	cg08799069	chr10:126477246	METTL10	0.77	7.48	0.43	1.29e-12	Cocaine dependence;
KIRP	cis	rs6788895	0.661	rs77431731	chr3:150489911	T/G	cg09723797	chr3:150481914	SIAH2	0.8	5.19	0.31	4.35e-7	Breast cancer;
KIRP	cis	rs4889855	0.530	rs4889865	chr17:78568447	A/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.41	-0.33	1.47e-7	Fractional excretion of uric acid;
KIRP	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg19016782	chr12:123741754	C12orf65	-0.38	-4.89	-0.3	1.82e-6	Neutrophil percentage of white cells;
KIRP	cis	rs12282928	1.000	rs10769339	chr11:48294296	T/A	cg26585981	chr11:48327164	OR4S1	-0.52	-6.32	-0.37	1.25e-9	Migraine - clinic-based;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.53	-0.33	8.24e-8	Lung cancer;
KIRP	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.69	-10.05	-0.54	3.87e-20	Hepatocellular carcinoma;
KIRP	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.4e-15	Lung cancer in ever smokers;
KIRP	cis	rs4700695	0.764	rs37018	chr5:65366645	A/G	cg21114390	chr5:65439923	SFRS12	0.54	5.04	0.31	9.24e-7	Facial morphology (factor 19);
KIRP	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.46	-7.06	-0.41	1.67e-11	Coronary artery disease;
KIRP	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-0.81	-8.19	-0.46	1.42e-14	Lung cancer;
KIRP	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg03647239	chr10:116582469	FAM160B1	0.48	5.27	0.32	3.04e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs504918	0.556	rs56140315	chr3:124013819	C/T	cg05766129	chr3:123988013	KALRN	-0.44	-5.64	-0.34	4.6e-8	Schizophrenia;
KIRP	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.37	0.38	9.41e-10	Mean platelet volume;
KIRP	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg23978390	chr7:1156363	C7orf50	-0.48	-5.06	-0.31	8.24e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-5.63	-0.34	4.8e-8	Morning vs. evening chronotype;
KIRP	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.62	8.72	0.49	4.32e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6466055	0.639	rs11760317	chr7:104711711	T/C	cg04380332	chr7:105027541	SRPK2	-0.63	-9.67	-0.52	6.1e-19	Schizophrenia;
KIRP	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg07541023	chr7:19748670	TWISTNB	-0.43	-4.91	-0.3	1.67e-6	Thyroid stimulating hormone;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-8.58	-0.48	1.09e-15	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.46	5.98	0.36	7.98e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.48	-6.1	-0.36	4.15e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs501916	0.761	rs589889	chr15:48019016	C/G	cg16110827	chr15:48056943	SEMA6D	-0.35	-4.85	-0.3	2.17e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.72	9.76	0.53	3.17e-19	Crohn's disease;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	14.43	0.68	1.33e-34	Lymphocyte counts;
KIRP	cis	rs13108043	0.605	rs34227282	chr4:87932645	C/T	cg11209507	chr4:87813803	C4orf36	0.45	4.87	0.3	2e-6	Red blood cell count;
KIRP	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.19	0.31	4.32e-7	Rheumatoid arthritis;
KIRP	cis	rs13401104	0.796	rs72620811	chr2:237118733	C/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	8.69	0.48	5.3e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.42	-0.59	1.63e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg11062466	chr8:58055876	NA	0.63	4.94	0.3	1.42e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg19507638	chr5:93509721	C5orf36	-0.55	-5.1	-0.31	6.64e-7	Diabetic retinopathy;
KIRP	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.79	10.82	0.57	1.44e-22	Aortic root size;
KIRP	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00321850	chr1:175162397	KIAA0040	0.34	6.19	0.37	2.44e-9	Alcohol dependence;
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	15.44	0.7	4.72e-38	Alzheimer's disease;
KIRP	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.64	5.28	0.32	2.8e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.83	-0.4	6.67e-11	Lung cancer;
KIRP	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.66	9.29	0.51	8.66e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.1	-0.31	6.66e-7	Life satisfaction;
KIRP	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	1.11	8.01	0.45	4.52e-14	Skin colour saturation;
KIRP	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.47	5.38	0.32	1.73e-7	Ulcerative colitis;
KIRP	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.86	11.15	0.58	1.23e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28489187	0.597	rs1001604	chr1:85879524	C/G	cg16011679	chr1:85725395	C1orf52	-0.46	-5.68	-0.34	3.82e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg07741184	chr6:167504864	NA	-0.24	-6.42	-0.38	7.08e-10	Crohn's disease;
KIRP	cis	rs4728302	0.607	rs2288067	chr7:133581102	A/G	cg10665199	chr7:133106180	EXOC4	0.42	4.9	0.3	1.72e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	trans	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg18187862	chr3:45730750	SACM1L	0.57	6.5	0.38	4.53e-10	Primary sclerosing cholangitis;
KIRP	cis	rs2625529	0.590	rs7183196	chr15:72544401	A/G	cg16672083	chr15:72433130	SENP8	-0.39	-5.04	-0.31	9.14e-7	Red blood cell count;
KIRP	cis	rs6466055	0.625	rs7794036	chr7:104870448	T/C	cg04380332	chr7:105027541	SRPK2	0.36	4.88	0.3	1.9e-6	Schizophrenia;
KIRP	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.5	7.0	0.41	2.42e-11	Glioblastoma;Glioma;
KIRP	cis	rs9513593	1.000	rs16956449	chr13:99966605	A/G	cg21788972	chr13:99853209	UBAC2	0.57	6.1	0.36	3.98e-9	Psoriasis;
KIRP	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg04132472	chr17:19861366	AKAP10	0.4	5.2	0.31	4.17e-7	Schizophrenia;
KIRP	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.59	-6.93	-0.4	3.78e-11	Cognitive test performance;
KIRP	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.73	-10.14	-0.54	2.09e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.47	5.51	0.33	8.99e-8	Glycated hemoglobin levels;
KIRP	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.95	-16.76	-0.73	1.41e-42	Height;
KIRP	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg00792783	chr2:198669748	PLCL1	-0.45	-4.88	-0.3	1.95e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-1.06	-12.73	-0.63	7.39e-29	Exhaled nitric oxide output;
KIRP	cis	rs4363385	0.510	rs2339386	chr1:152892307	C/T	cg07796016	chr1:152779584	LCE1C	-0.51	-6.36	-0.38	9.87e-10	Inflammatory skin disease;
KIRP	cis	rs17123764	0.818	rs74089573	chr12:49976074	C/T	cg02054252	chr12:50078554	FMNL3	0.5	4.97	0.3	1.25e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12360000	0.740	rs55679834	chr10:1910856	T/A	cg26364871	chr10:1889757	NA	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	trans	rs629535	1.000	rs629535	chr8:70007938	C/T	cg21567404	chr3:27674614	NA	-0.92	-13.34	-0.65	6.66e-31	Dupuytren's disease;
KIRP	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.51	0.38	4.29e-10	Lung cancer;
KIRP	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg27124370	chr19:33622961	WDR88	0.7	9.68	0.53	5.61e-19	Bone properties (heel);
KIRP	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.31	-6.51	-0.38	4.14e-10	Diastolic blood pressure;
KIRP	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg11131117	chr7:1891496	MAD1L1	0.41	5.14	0.31	5.49e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg06640241	chr16:89574553	SPG7	0.44	5.32	0.32	2.32e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs829661	0.793	rs2609926	chr2:30823556	C/T	cg10949345	chr2:30726833	LCLAT1	1.04	11.8	0.6	8.99e-26	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.88	-13.88	-0.66	9.84e-33	Dental caries;
KIRP	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg20243544	chr17:37824526	PNMT	0.5	7.27	0.42	4.88e-12	Asthma;
KIRP	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg04727924	chr7:799746	HEATR2	-0.76	-8.48	-0.48	2.14e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg04990556	chr1:26633338	UBXN11	-0.59	-7.2	-0.42	7.33e-12	Monocyte percentage of white cells;
KIRP	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs4656940	0.574	rs527766	chr1:160763536	C/T	cg17331569	chr1:160788135	LY9	0.45	5.3	0.32	2.63e-7	Crohn's disease;
KIRP	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18932078	chr1:2524107	MMEL1	-0.41	-5.5	-0.33	9.63e-8	Ulcerative colitis;
KIRP	cis	rs520865	0.786	rs486050	chr5:80344761	C/T	cg17330048	chr5:80257322	RASGRF2	-0.45	-6.56	-0.39	3.08e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.92	12.16	0.61	6.11e-27	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.87	13.9	0.66	8.59e-33	Ulcerative colitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20957382	chr12:105501358	KIAA1033	0.43	6.02	0.36	6.22e-9	Survival in pancreatic cancer;
KIRP	cis	rs62355272	0.760	rs62353742	chr5:35827030	T/C	cg13894535	chr5:35919491	CAPSL	-0.52	-5.41	-0.33	1.48e-7	Lymphocyte counts;
KIRP	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.3	0.47	6.77e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20820438	chr17:655625	ELP2P;GEMIN4	0.46	6.02	0.36	6.16e-9	Parkinson's disease;
KIRP	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.52	-6.11	-0.36	3.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6547631	0.622	rs4240201	chr2:85925667	G/A	cg24620635	chr2:85921963	GNLY	0.32	5.08	0.31	7.32e-7	Blood protein levels;
KIRP	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg18461458	chr19:21324796	ZNF431	-0.48	-4.96	-0.3	1.29e-6	Pain;
KIRP	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg21095983	chr6:86352623	SYNCRIP	0.51	6.73	0.39	1.22e-10	Smooth-surface caries;
KIRP	cis	rs7998202	0.720	rs914020	chr13:113352848	C/G	cg02820901	chr13:113351484	ATP11A	0.59	5.58	0.33	6.45e-8	Glycated hemoglobin levels;
KIRP	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg21775007	chr8:11205619	TDH	0.7	9.65	0.52	6.72e-19	Retinal vascular caliber;
KIRP	cis	rs554111	0.637	rs604659	chr1:21043913	T/C	cg08890418	chr1:21044141	KIF17	0.53	8.17	0.46	1.65e-14	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9948	1.000	rs59244622	chr2:97501632	C/T	cg20312557	chr2:97357134	FER1L5	-0.67	-5.01	-0.3	1.05e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.13	0.31	5.84e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.49	-8.14	-0.46	1.94e-14	Pneumonia;
KIRP	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.74	-7.84	-0.45	1.4e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg03984733	chr9:116139085	HDHD3	0.52	6.3	0.37	1.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7819412	0.582	rs2409685	chr8:10909193	C/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.72	-0.44	2.96e-13	Triglycerides;
KIRP	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg05973401	chr12:123451056	ABCB9	0.51	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg11150807	chr10:43354902	NA	-0.68	-7.41	-0.43	2e-12	Blood protein levels;
KIRP	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	cg21523751	chr1:182988639	NA	0.41	6.48	0.38	5.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg09163369	chr1:210001066	C1orf107	0.53	5.73	0.34	2.87e-8	Orofacial clefts;
KIRP	cis	rs10203711	0.933	rs11693286	chr2:239585278	A/T	cg14580085	chr2:239553406	NA	0.4	5.13	0.31	5.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7178909	0.872	rs3784387	chr15:90437370	G/A	cg19708238	chr15:90437601	AP3S2	0.59	8.2	0.46	1.35e-14	Common traits (Other);
KIRP	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg26207909	chr14:103986467	CKB	-0.43	-5.21	-0.32	3.92e-7	Coronary artery disease;
KIRP	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.88	-14.18	-0.67	8.95e-34	Prostate cancer;
KIRP	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.55	7.58	0.44	6.92e-13	Morning vs. evening chronotype;
KIRP	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00321850	chr1:175162397	KIAA0040	0.36	6.49	0.38	4.66e-10	Alcohol dependence;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09958559	chr16:67064011	CBFB	0.87	6.04	0.36	5.81e-9	P wave terminal force;
KIRP	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.13	0.31	5.78e-7	Bipolar disorder;
KIRP	cis	rs11877825	0.826	rs4121954	chr18:10569713	T/C	cg07277756	chr18:10589357	NA	0.48	6.12	0.36	3.57e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs2425143	1.000	rs74785978	chr20:34373234	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-4.95	-0.3	1.39e-6	Blood protein levels;
KIRP	cis	rs9298506	1.000	rs4552882	chr8:55462324	G/A	cg19005830	chr8:55467175	NA	-0.56	-4.95	-0.3	1.41e-6	Intracranial aneurysm;
KIRP	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-1.0	-16.36	-0.72	3.29e-41	Height;
KIRP	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.46	5.5	0.33	9.65e-8	Airway imaging phenotypes;
KIRP	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.77	-0.4	9.17e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg20469991	chr17:27169893	C17orf63	-0.57	-4.92	-0.3	1.57e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7520050	0.966	rs785489	chr1:46576390	A/G	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg17863274	chr19:49399704	TULP2	-0.41	-5.85	-0.35	1.57e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7106204	0.609	rs75559464	chr11:24285585	C/T	ch.11.24196551F	chr11:24239977	NA	0.75	5.37	0.32	1.86e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2400749	0.830	rs4905857	chr14:100032272	A/G	cg19965031	chr14:100038389	CCDC85C	-0.43	-5.3	-0.32	2.6e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg02353165	chr6:42928485	GNMT	0.75	12.01	0.61	1.79e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17906523	chr1:94883536	ABCD3	0.6	6.66	0.39	1.73e-10	Lung cancer in ever smokers;
KIRP	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg12718519	chr1:2058417	PRKCZ	0.22	4.88	0.3	1.88e-6	Height;
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.75	-0.44	2.36e-13	Platelet count;
KIRP	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.9	11.87	0.6	5.4e-26	Sudden cardiac arrest;
KIRP	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.63	0.66	6.66e-32	Mean platelet volume;
KIRP	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg14324370	chr2:177042789	NA	-0.71	-8.81	-0.49	2.31e-16	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg25753631	chr6:25732923	NA	-0.28	-5.19	-0.31	4.38e-7	Iron status biomarkers;
KIRP	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	1.2	9.42	0.51	3.54e-18	Prostate cancer;
KIRP	cis	rs4689642	0.709	rs13115404	chr4:7226101	T/G	cg21353189	chr4:7228343	SORCS2	0.42	5.61	0.34	5.37e-8	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg26149184	chr10:133730230	NA	0.42	4.91	0.3	1.66e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.42	0.62	8.27e-28	Menopause (age at onset);
KIRP	cis	rs503734	0.502	rs571391	chr3:100963154	C/T	cg27318481	chr3:100970896	IMPG2	-0.44	-5.97	-0.36	8.08e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04501438	chr7:21466669	SP4	0.43	6.13	0.36	3.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	6.82	0.4	6.95e-11	Colorectal cancer;
KIRP	cis	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg13293535	chr8:11597251	GATA4	0.5	6.77	0.4	9.61e-11	Neuroticism;
KIRP	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.57	-0.33	6.79e-8	Neutrophil percentage of white cells;
KIRP	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.62	6.96	0.41	2.98e-11	Smoking initiation;
KIRP	cis	rs72730918	0.618	rs8029731	chr15:51989082	T/C	cg14296394	chr15:51910925	DMXL2	0.68	9.63	0.52	7.85e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.73	9.11	0.5	2.91e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-7.62	-0.44	5.42e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg25706552	chr1:244017396	NA	0.6	6.38	0.38	8.69e-10	RR interval (heart rate);
KIRP	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.7	11.03	0.58	3.02e-23	Intelligence (multi-trait analysis);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13755373	chr14:103059017	RCOR1	0.46	6.04	0.36	5.66e-9	Cancer;
KIRP	cis	rs4363506	0.934	rs949523	chr10:129283431	A/T	cg07804728	chr10:129284050	NA	0.42	5.95	0.35	9.01e-9	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.4	-0.47	3.49e-15	Resting heart rate;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05596149	chr1:169337205	BLZF1;NME7	-0.46	-6.04	-0.36	5.76e-9	Interleukin-4 levels;
KIRP	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg03714773	chr7:91764589	CYP51A1	0.37	5.39	0.33	1.63e-7	Breast cancer;
KIRP	cis	rs7335046	0.708	rs912128	chr13:100074381	A/G	cg25919922	chr13:100150906	NA	0.62	5.84	0.35	1.68e-8	Basal cell carcinoma;
KIRP	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.74	10.85	0.57	1.17e-22	Hip circumference;
KIRP	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg17724175	chr1:150552817	MCL1	0.32	5.39	0.32	1.65e-7	Melanoma;
KIRP	cis	rs986417	0.748	rs10136486	chr14:60946111	C/T	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg16141378	chr3:129829833	LOC729375	0.49	6.38	0.38	8.64e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.36	-0.42	2.75e-12	Morning vs. evening chronotype;
KIRP	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20135002	chr11:47629003	NA	-0.46	-5.39	-0.32	1.69e-7	Subjective well-being;
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.86	-12.74	-0.63	6.65e-29	Height;
KIRP	trans	rs2856321	0.967	rs10743967	chr12:11881529	A/G	cg10155026	chr12:4553029	FGF6	0.41	6.11	0.36	3.97e-9	Height;
KIRP	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	0.86	10.03	0.54	4.54e-20	Pediatric areal bone mineral density (radius);
KIRP	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg13736514	chr6:26305472	NA	0.53	6.63	0.39	2.14e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.79	12.91	0.64	1.87e-29	Dupuytren's disease;
KIRP	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg07827796	chr19:33622959	WDR88	0.53	6.98	0.41	2.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.45	1.59e-13	Morning vs. evening chronotype;
KIRP	trans	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg06521331	chr12:34319734	NA	-0.52	-6.34	-0.37	1.09e-9	Bladder cancer;
KIRP	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.84	0.49	1.91e-16	Bipolar disorder;
KIRP	cis	rs240764	0.817	rs12216304	chr6:101174161	A/G	cg09795085	chr6:101329169	ASCC3	-0.46	-5.43	-0.33	1.32e-7	Neuroticism;
KIRP	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg21427119	chr20:30132790	HM13	-0.42	-4.96	-0.3	1.29e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs17001868	0.568	rs10854729	chr22:40750612	T/C	cg07138101	chr22:40742427	ADSL	0.54	6.08	0.36	4.6e-9	Mammographic density (dense area);
KIRP	cis	rs4664293	0.836	rs13421392	chr2:160658296	G/A	cg08347373	chr2:160653686	CD302	-0.4	-5.94	-0.35	9.73e-9	Monocyte percentage of white cells;
KIRP	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-11.75	-0.6	1.35e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg10241871	chr14:102965420	TECPR2	-0.47	-5.8	-0.35	2.06e-8	Plateletcrit;
KIRP	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.86	11.84	0.6	6.77e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg01966878	chr4:90757139	SNCA	-0.44	-4.89	-0.3	1.82e-6	Neuroticism;
KIRP	cis	rs2671245	0.513	rs9436520	chr1:56137245	A/G	cg11523071	chr1:56160889	NA	0.39	5.9	0.35	1.18e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.18	-4.97	-0.3	1.23e-6	Coronary artery disease;
KIRP	cis	rs6835098	0.646	rs10012395	chr4:174078772	A/G	cg08422745	chr4:174089978	GALNT7	-0.69	-9.31	-0.51	7.65e-18	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs737693	1.000	rs72981698	chr11:102726540	C/T	cg19620758	chr11:102826565	MMP13	0.71	5.65	0.34	4.42e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.84	-12.9	-0.64	1.97e-29	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9788682	0.948	rs905739	chr15:78845110	A/G	cg24631222	chr15:78858424	CHRNA5	0.97	12.95	0.64	1.36e-29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs3924048	0.547	rs72642661	chr1:12612873	C/G	cg00291366	chr1:12616550	NA	0.47	6.65	0.39	1.92e-10	Optic cup area;
KIRP	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg19743168	chr1:23544995	NA	0.48	6.46	0.38	5.5e-10	Height;
KIRP	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg10305451	chr2:177043427	NA	0.54	7.51	0.43	1.1e-12	IgG glycosylation;
KIRP	cis	rs1978968	1.000	rs5992922	chr22:18445287	A/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs10924970	0.870	rs12095886	chr1:235432249	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.33	-6.87	-0.4	5.09e-11	Urinary metabolites;
KIRP	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.58e-6	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg08761264	chr16:28874980	SH2B1	-0.43	-4.9	-0.3	1.76e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.0	-0.3	1.1e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg19257562	chr1:2043853	PRKCZ	-0.37	-5.41	-0.33	1.53e-7	Height;
KIRP	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7630877	0.924	rs73060731	chr3:179634229	G/A	cg18765712	chr3:179670323	PEX5L	0.52	6.21	0.37	2.21e-9	Type 2 diabetes;
KIRP	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg06598544	chr20:61472147	COL9A3	0.72	6.42	0.38	7e-10	Obesity-related traits;
KIRP	cis	rs12476592	0.602	rs187801	chr2:63867446	A/C	cg17519650	chr2:63277830	OTX1	0.45	5.04	0.31	9.19e-7	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04568117	chr19:54695088	MBOAT7;TSEN34	0.5	6.09	0.36	4.4e-9	Parkinson's disease;
KIRP	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	5.96	0.36	8.63e-9	Menarche (age at onset);
KIRP	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.67	6.29	0.37	1.4e-9	Obesity-related traits;
KIRP	cis	rs4356932	1.000	rs6852075	chr4:76952280	T/G	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.64	-11.12	-0.58	1.51e-23	DNA methylation (variation);
KIRP	cis	rs1200821	0.671	rs2226276	chr10:37673052	A/T	cg00409905	chr10:38381863	ZNF37A	0.47	6.12	0.36	3.74e-9	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-1.04	-18.43	-0.76	2.99e-48	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs745080	0.674	rs8004186	chr14:53005169	C/T	cg23333723	chr14:53022898	GPR137C	-0.41	-5.63	-0.34	4.92e-8	Orofacial clefts;
KIRP	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.2	-0.37	2.39e-9	QT interval;
KIRP	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-5.73	-0.34	2.96e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12210905	0.688	rs72845030	chr6:27532643	A/G	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.4e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg09873164	chr1:152488093	CRCT1	0.57	7.6	0.44	6.4e-13	Hair morphology;
KIRP	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21545522	chr1:205238299	TMCC2	-0.5	-6.67	-0.39	1.64e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg12454167	chr3:186435060	KNG1	-0.51	-8.95	-0.5	8.81e-17	Blood protein levels;
KIRP	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.67	-0.34	4.02e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg03146154	chr1:46216737	IPP	0.56	5.93	0.35	1.04e-8	Platelet count;
KIRP	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.72	-0.34	3.08e-8	Alzheimer's disease (late onset);
KIRP	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg05484376	chr2:27715224	FNDC4	0.36	5.71	0.34	3.21e-8	Total body bone mineral density;
KIRP	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.86	8.47	0.48	2.31e-15	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.76	10.0	0.54	5.71e-20	Selective IgA deficiency;
KIRP	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.94	12.34	0.62	1.45e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.86	0.3	2.14e-6	Childhood ear infection;
KIRP	cis	rs2970818	0.831	rs2907494	chr12:4642184	G/A	cg14576962	chr12:4671597	NA	-0.4	-4.92	-0.3	1.59e-6	Phosphorus levels;
KIRP	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.13	-19.59	-0.78	3.88e-52	Triglycerides;
KIRP	trans	rs587242	1.000	rs505066	chr1:96882671	C/A	cg10631902	chr5:14652156	NA	0.54	6.1	0.36	4.17e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg06565975	chr8:143823917	SLURP1	-0.45	-6.76	-0.4	1e-10	Urinary tract infection frequency;
KIRP	cis	rs8113308	0.810	rs8105110	chr19:52452116	C/T	cg25782003	chr19:52490127	ZNF350	0.53	4.97	0.3	1.26e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.65	-8.26	-0.47	9.13e-15	Age at first birth;
KIRP	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.54	-0.33	7.67e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.74	10.89	0.57	8.76e-23	Prostate cancer;
KIRP	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.53	7.8	0.45	1.74e-13	Major depressive disorder;
KIRP	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-11.64	-0.6	3.16e-25	Height;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25484712	chr7:150828561	AGAP3	0.49	6.17	0.37	2.86e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.27	-0.47	8.72e-15	Mean corpuscular volume;
KIRP	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg08741688	chr4:3415352	RGS12	-0.45	-4.85	-0.3	2.22e-6	Serum sulfate level;
KIRP	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.84	11.12	0.58	1.56e-23	Menarche (age at onset);
KIRP	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg19847130	chr8:10466454	RP1L1	0.34	5.21	0.32	4.04e-7	Neuroticism;
KIRP	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg05484376	chr2:27715224	FNDC4	0.33	5.51	0.33	9.21e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.74	-7.49	-0.43	1.23e-12	Lung function (FEV1/FVC);
KIRP	trans	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg10756647	chr7:56101905	PSPH	1.01	7.6	0.44	6.29e-13	Diabetic kidney disease;
KIRP	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg08741688	chr4:3415352	RGS12	-0.44	-4.95	-0.3	1.37e-6	Serum sulfate level;
KIRP	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg14664628	chr15:75095509	CSK	0.54	5.91	0.35	1.11e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.85	-12.25	-0.62	2.91e-27	Homoarginine levels;
KIRP	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	0.91	11.69	0.6	2.18e-25	Cannabis dependence symptom count;
KIRP	cis	rs56146971	0.763	rs12587463	chr14:91859967	C/T	cg10511902	chr14:91842949	CCDC88C	0.48	4.92	0.3	1.58e-6	Alzheimer disease and age of onset;
KIRP	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg18888403	chr1:24152774	HMGCL	-0.36	-5.23	-0.32	3.58e-7	Immature fraction of reticulocytes;
KIRP	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.39	-0.38	8.04e-10	Diastolic blood pressure;
KIRP	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg13010199	chr12:38710504	ALG10B	-0.38	-4.88	-0.3	1.87e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg04731861	chr2:219085781	ARPC2	-0.23	-5.64	-0.34	4.76e-8	Colorectal cancer;
KIRP	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.51	7.08	0.41	1.49e-11	Mean corpuscular volume;
KIRP	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg10047753	chr17:41438598	NA	0.94	13.3	0.65	8.76e-31	Menopause (age at onset);
KIRP	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.82	11.86	0.6	5.82e-26	Eye color traits;
KIRP	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs7215564	0.818	rs756076	chr17:78662918	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg04691961	chr3:161091175	C3orf57	-0.66	-11.15	-0.58	1.2e-23	Morning vs. evening chronotype;
KIRP	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.42	5.36	0.32	1.91e-7	Aortic root size;
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg01798813	chr17:3906674	NA	0.46	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.68	8.77	0.49	2.94e-16	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-7.91	-0.45	8.63e-14	Mean corpuscular volume;
KIRP	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.04	0.36	5.6e-9	Mean platelet volume;
KIRP	cis	rs883115	0.748	rs10799588	chr1:224819109	A/G	cg01808320	chr1:224927238	CNIH3	-0.37	-5.38	-0.32	1.73e-7	Cancer;
KIRP	cis	rs9323205	0.634	rs56043194	chr14:51726066	A/C	cg23942311	chr14:51606299	NA	-0.52	-5.06	-0.31	8.21e-7	Cancer;
KIRP	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.59	7.35	0.42	2.99e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg17788227	chr17:7347145	FGF11;CHRNB1	0.47	4.85	0.3	2.17e-6	Androgen levels;
KIRP	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg06671706	chr8:8559999	CLDN23	-0.59	-6.78	-0.4	9.06e-11	Obesity-related traits;
KIRP	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg14952266	chr13:112191215	NA	0.46	6.67	0.39	1.68e-10	Hepatitis;
KIRP	cis	rs888194	0.677	rs2164743	chr12:109875163	C/T	cg19025524	chr12:109796872	NA	-0.37	-5.08	-0.31	7.37e-7	Neuroticism;
KIRP	cis	rs4849845	0.889	rs17050072	chr2:121048712	T/C	cg24070213	chr2:121070622	NA	0.41	5.66	0.34	4.22e-8	Mean platelet volume;
KIRP	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg02931644	chr1:25747376	RHCE	0.35	6.36	0.38	9.83e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.46	5.69	0.34	3.61e-8	Mean platelet volume;
KIRP	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg20965017	chr5:231967	SDHA	-0.57	-6.75	-0.4	1.04e-10	Breast cancer;
KIRP	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg25797454	chr6:150327115	RAET1K	0.32	5.89	0.35	1.25e-8	Alopecia areata;
KIRP	cis	rs4908768	0.822	rs12122737	chr1:8616404	C/A	cg25722041	chr1:8623473	RERE	0.64	8.48	0.48	2.12e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.72	0.39	1.29e-10	Joint mobility (Beighton score);
KIRP	cis	rs6541297	0.645	rs2103827	chr1:230298285	T/A	cg05784532	chr1:230284198	GALNT2	0.43	5.65	0.34	4.34e-8	Coronary artery disease;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs12713956	0.666	rs11124924	chr2:21206275	C/G	cg03132727	chr1:180967813	STX6	0.62	6.16	0.37	2.96e-9	LDL cholesterol;
KIRP	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg22705602	chr4:152727874	NA	-0.61	-9.29	-0.51	8.33e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs34845616	0.581	rs167915	chr11:133797581	A/T	cg12615165	chr18:19756877	GATA6	0.41	6.05	0.36	5.4e-9	Hand grip strength;
KIRP	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05347473	chr6:146136440	FBXO30	-0.5	-6.92	-0.4	3.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg06637938	chr14:75390232	RPS6KL1	0.52	7.42	0.43	1.92e-12	Height;
KIRP	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg22974920	chr21:40686053	BRWD1	0.51	6.17	0.37	2.78e-9	Cognitive function;
KIRP	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.8	0.49	2.53e-16	Motion sickness;
KIRP	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	1.14	16.25	0.72	7.57e-41	Monocyte percentage of white cells;
KIRP	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg13147721	chr7:65941812	NA	-0.97	-6.86	-0.4	5.62e-11	Diabetic kidney disease;
KIRP	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.45	6.66	0.39	1.83e-10	Major depressive disorder;
KIRP	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.76	-0.34	2.51e-8	Breast cancer;
KIRP	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg22705602	chr4:152727874	NA	-0.43	-6.78	-0.4	9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg08975724	chr8:8085496	FLJ10661	0.67	9.17	0.5	1.95e-17	Systolic blood pressure;
KIRP	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.84	-7.65	-0.44	4.59e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg01528321	chr10:82214614	TSPAN14	0.61	7.84	0.45	1.37e-13	Post bronchodilator FEV1;
KIRP	cis	rs2033732	0.706	rs9298418	chr8:85066831	T/C	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.84	11.92	0.61	3.6e-26	Itch intensity from mosquito bite;
KIRP	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.54	7.45	0.43	1.61e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.58	8.05	0.46	3.57e-14	Prudent dietary pattern;
KIRP	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.46	5.96	0.36	8.86e-9	Initial pursuit acceleration;
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	8.88	0.49	1.43e-16	Lung cancer in ever smokers;
KIRP	cis	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg09559047	chr8:10916868	XKR6	-0.39	-5.61	-0.34	5.34e-8	Triglycerides;
KIRP	cis	rs7129556	0.737	rs72949618	chr11:77464530	G/A	cg12586386	chr11:77299805	AQP11	0.44	5.2	0.31	4.19e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg08603382	chr10:743973	NA	0.44	6.35	0.38	1.05e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg11608241	chr8:8085544	FLJ10661	0.45	5.52	0.33	8.68e-8	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02782622	chr2:69534307	NA	0.43	6.1	0.36	4.01e-9	Parkinson's disease;
KIRP	cis	rs17221829	0.702	rs12360859	chr11:89359887	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.84	-0.3	2.26e-6	Anxiety in major depressive disorder;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs72960926	0.744	rs6926572	chr6:75044118	A/G	cg03266952	chr6:74778945	NA	-0.59	-5.18	-0.31	4.72e-7	Metabolite levels (MHPG);
KIRP	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.48	5.95	0.35	9.1e-9	Initial pursuit acceleration;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.51	6.01	0.36	6.69e-9	Glycated hemoglobin levels;
KIRP	cis	rs9914544	0.545	rs4290526	chr17:18772967	T/C	cg26378065	chr17:18585709	ZNF286B	0.39	5.04	0.31	9.05e-7	Educational attainment (years of education);
KIRP	cis	rs60154123	0.615	rs701943	chr1:210425727	A/G	cg09074223	chr1:210466472	NA	-0.56	-5.51	-0.33	8.89e-8	Coronary artery disease;
KIRP	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.19	0.31	4.4e-7	Menopause (age at onset);
KIRP	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.8	8.32	0.47	5.96e-15	Bipolar disorder;
KIRP	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.45	-0.52	2.82e-18	Rheumatoid arthritis;
KIRP	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.24	0.55	1.02e-20	Bone mineral density;
KIRP	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg00857998	chr1:205179979	DSTYK	0.58	6.8	0.4	8.03e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.51e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg19752551	chr11:57585705	CTNND1	0.67	10.96	0.57	5.06e-23	Schizophrenia;
KIRP	cis	rs10849893	0.595	rs6489811	chr12:121893626	C/T	cg01154721	chr12:121881891	KDM2B	0.39	5.06	0.31	8.22e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.75	-10.89	-0.57	8.75e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg20311770	chr2:25816655	DTNB	-0.45	-6.16	-0.37	3.02e-9	Select biomarker traits;
KIRP	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.65	6.53	0.38	3.84e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-7.07	-0.41	1.59e-11	Response to antipsychotic treatment;
KIRP	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.82	11.66	0.6	2.73e-25	Body mass index;
KIRP	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg05973401	chr12:123451056	ABCB9	-0.59	-5.37	-0.32	1.8e-7	Neutrophil percentage of white cells;
KIRP	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg22284058	chr8:142237359	SLC45A4	-0.44	-5.45	-0.33	1.25e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7113850	0.541	rs7107667	chr11:24224091	T/A	ch.11.24196551F	chr11:24239977	NA	0.94	7.7	0.44	3.28e-13	Bone fracture in osteoporosis;
KIRP	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs4664304	0.537	rs6711770	chr2:160692761	C/T	cg03641300	chr2:160917029	PLA2R1	0.35	5.16	0.31	5.06e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.44	-0.33	1.31e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.42	5.05	0.31	8.54e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6662572	0.774	rs6696284	chr1:46571684	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.82	0.35	1.83e-8	Blood protein levels;
KIRP	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.4	5.15	0.31	5.42e-7	Melanoma;
KIRP	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.49	-6.92	-0.4	3.98e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.75	0.34	2.69e-8	Height;
KIRP	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.45	6.22	0.37	2.08e-9	Red blood cell count;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.22e-7	Life satisfaction;
KIRP	cis	rs9323205	0.953	rs7141012	chr14:51600948	C/G	cg23942311	chr14:51606299	NA	-0.62	-6.41	-0.38	7.37e-10	Cancer;
KIRP	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg00800038	chr16:89945340	TCF25	-0.88	-7.15	-0.41	9.67e-12	Skin colour saturation;
KIRP	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg11784071	chr10:104629166	AS3MT	-0.36	-4.99	-0.3	1.15e-6	Arsenic metabolism;
KIRP	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg10223061	chr2:219282414	VIL1	-0.35	-5.83	-0.35	1.71e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg15733309	chr7:157513707	PTPRN2	-0.48	-7.66	-0.44	4.21e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1619661	0.530	rs1509929	chr10:44682829	A/C	cg09554077	chr10:44749378	NA	0.44	6.5	0.38	4.49e-10	QT interval (ambient particulate matter interaction);
KIRP	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	8.14	0.46	1.99e-14	Total body bone mineral density;
KIRP	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.96	0.57	5.01e-23	Personality dimensions;
KIRP	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg00647317	chr7:50633725	DDC	0.41	6.14	0.36	3.37e-9	Body mass index;
KIRP	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.86	-0.35	1.48e-8	Alzheimer's disease (late onset);
KIRP	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.53	0.56	1.19e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg24296786	chr1:45957014	TESK2	-0.42	-5.3	-0.32	2.58e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs8179	0.700	rs42044	chr7:92250140	T/G	cg15732164	chr7:92237376	CDK6	-0.5	-6.39	-0.38	8.14e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.7	-8.39	-0.47	3.94e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg00677455	chr12:58241039	CTDSP2	0.62	7.44	0.43	1.68e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9381107	0.932	rs2103674	chr6:9451701	G/A	cg14735645	chr6:9486422	NA	-0.44	-5.3	-0.32	2.57e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7771547	0.605	rs659726	chr6:36467791	C/G	cg04289385	chr6:36355825	ETV7	0.44	6.83	0.4	6.54e-11	Platelet distribution width;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-1.09	-21.2	-0.8	1.94e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1823913	0.599	rs17412094	chr2:192148928	C/T	cg12404831	chr2:192114017	MYO1B	0.51	7.13	0.41	1.13e-11	Obesity-related traits;
KIRP	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg08738300	chr3:44038990	NA	0.68	9.55	0.52	1.34e-18	Coronary artery disease;
KIRP	cis	rs9653442	0.510	rs11891046	chr2:100794402	C/G	cg17356467	chr2:100759845	AFF3	0.4	5.54	0.33	7.61e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg00631329	chr6:26305371	NA	-0.66	-8.71	-0.49	4.55e-16	Educational attainment;
KIRP	trans	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.55	-5.77	-0.35	2.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8177876	0.642	rs12445303	chr16:81115573	A/G	cg08591886	chr16:81111003	C16orf46	0.58	5.76	0.34	2.53e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.87	0.45	1.11e-13	Educational attainment;
KIRP	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg02503808	chr4:7069936	GRPEL1	-1.02	-11.13	-0.58	1.46e-23	Monocyte percentage of white cells;
KIRP	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.78	9.55	0.52	1.42e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	1.04	20.17	0.79	4.8e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg26597838	chr10:835615	NA	0.45	5.02	0.3	9.78e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs362272	0.502	rs2798298	chr4:3036602	G/A	cg13731523	chr4:3047190	NA	-0.4	-7.78	-0.44	2.01e-13	Serum sulfate level;
KIRP	cis	rs7656342	0.755	rs13148571	chr4:9873855	C/A	cg11266682	chr4:10021025	SLC2A9	0.32	4.9	0.3	1.77e-6	Gut microbiota (bacterial taxa);
KIRP	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg16141378	chr3:129829833	LOC729375	0.51	6.63	0.39	2.07e-10	Retinal vascular caliber;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07320819	chr13:48877957	RB1	-0.56	-6.74	-0.39	1.11e-10	Interleukin-4 levels;
KIRP	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg17554472	chr22:41940697	POLR3H	0.71	6.6	0.39	2.52e-10	Vitiligo;
KIRP	cis	rs7582720	0.945	rs72932723	chr2:203647646	A/G	cg08076091	chr2:203926405	NBEAL1	0.83	8.27	0.47	8.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs732716	0.785	rs62129354	chr19:4396505	G/A	cg21720385	chr19:4455239	UBXN6	0.72	8.8	0.49	2.54e-16	Mean corpuscular volume;
KIRP	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg08888203	chr3:10149979	C3orf24	0.5	5.36	0.32	1.92e-7	Alzheimer's disease;
KIRP	cis	rs580438	0.510	rs6442369	chr3:13378791	C/T	cg10657019	chr3:13328039	NA	-0.59	-7.76	-0.44	2.32e-13	Myringotomy;
KIRP	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.61	-7.36	-0.42	2.73e-12	Blood metabolite levels;
KIRP	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.01	16.0	0.71	5.64e-40	Bipolar disorder;
KIRP	cis	rs714027	0.605	rs193471	chr22:30447305	A/G	cg01021169	chr22:30184971	ASCC2	0.46	5.52	0.33	8.73e-8	Lymphocyte counts;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09581756	chr1:11906187	NPPA	0.52	7.05	0.41	1.77e-11	Interleukin-4 levels;
KIRP	cis	rs1035491	0.683	rs2366900	chr5:63923337	C/T	cg01791865	chr5:63954708	NA	0.33	5.18	0.31	4.53e-7	Body mass index;
KIRP	cis	rs4594175	0.926	rs12323654	chr14:51630894	G/T	cg23942311	chr14:51606299	NA	0.52	6.83	0.4	6.71e-11	Cancer;
KIRP	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.41	-0.43	1.97e-12	Aortic root size;
KIRP	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.71	9.07	0.5	3.86e-17	Coronary artery disease;
KIRP	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg09904177	chr6:26538194	HMGN4	-0.53	-6.84	-0.4	6.3e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.42	-7.56	-0.43	8.06e-13	Refractive error;
KIRP	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.31	0.37	1.26e-9	Bipolar disorder;
KIRP	cis	rs6960043	0.782	rs1558317	chr7:15065564	T/A	cg19272540	chr7:15055459	NA	-0.23	-6.49	-0.38	4.74e-10	Type 2 diabetes;
KIRP	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs2963155	0.518	rs852978	chr5:142690596	T/C	cg17617527	chr5:142782415	NR3C1	0.77	7.9	0.45	9.51e-14	Breast cancer;
KIRP	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.39	8.29	0.47	7.54e-15	IgG glycosylation;
KIRP	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg23479056	chr15:41276147	INO80	-0.43	-6.31	-0.37	1.28e-9	Menopause (age at onset);
KIRP	cis	rs55882075	0.967	rs59666900	chr5:179147641	C/T	cg14593053	chr5:179126677	CANX	0.65	8.47	0.48	2.19e-15	Monocyte percentage of white cells;
KIRP	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg00484396	chr16:3507460	NAT15	0.54	5.38	0.32	1.7e-7	Tuberculosis;
KIRP	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.69	7.93	0.45	7.67e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg03342759	chr3:160939853	NMD3	-0.56	-7.0	-0.41	2.45e-11	Morning vs. evening chronotype;
KIRP	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.39	-0.43	2.27e-12	Neuroticism;
KIRP	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.31	-0.32	2.43e-7	Longevity;
KIRP	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.87	13.21	0.64	1.86e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.42	-0.38	7e-10	Lung cancer;
KIRP	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.45	-5.67	-0.34	3.98e-8	Asthma;
KIRP	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg00409905	chr10:38381863	ZNF37A	-0.56	-6.27	-0.37	1.65e-9	Obesity (extreme);
KIRP	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg15556689	chr8:8085844	FLJ10661	0.67	8.68	0.48	5.43e-16	Retinal vascular caliber;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03935709	chr16:2125759	TSC2	0.51	6.47	0.38	5.11e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.96	12.95	0.64	1.34e-29	Menopause (age at onset);
KIRP	cis	rs10073892	0.789	rs56268211	chr5:101756244	G/A	cg19774478	chr5:101632501	SLCO4C1	0.67	6.48	0.38	5e-10	Cognitive decline (age-related);
KIRP	cis	rs11638352	0.661	rs2706492	chr15:44423846	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.08	-0.36	4.49e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.96	-0.35	8.92e-9	IgG glycosylation;
KIRP	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg26116260	chr4:7069785	GRPEL1	0.6	7.16	0.42	9.13e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-5.85	-0.35	1.54e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7572644	0.699	rs12470614	chr2:28217327	C/T	cg27432699	chr2:27873401	GPN1	0.44	5.27	0.32	2.93e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10012599	chr11:46744754	F2	0.59	7.3	0.42	4.04e-12	Interleukin-4 levels;
KIRP	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.88	11.91	0.6	4.08e-26	Coronary artery disease;
KIRP	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.7	9.03	0.5	5.23e-17	Morning vs. evening chronotype;
KIRP	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00321850	chr1:175162397	KIAA0040	0.36	6.49	0.38	4.7e-10	Diastolic blood pressure;
KIRP	cis	rs2746347	0.722	rs2746340	chr1:57136597	G/A	cg09935045	chr1:57111199	PRKAA2	0.52	5.36	0.32	1.94e-7	Lymphocyte counts;
KIRP	cis	rs4704187	0.617	rs12656177	chr5:74354422	G/A	cg03227963	chr5:74354835	NA	0.42	6.26	0.37	1.74e-9	Response to amphetamines;
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.44	-0.33	1.26e-7	Lung cancer;
KIRP	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg11783602	chr8:55087084	NA	-0.57	-7.07	-0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs882732	1.000	rs5510	chr14:95033356	A/G	cg05186455	chr14:95027692	SERPINA4	0.4	6.09	0.36	4.4e-9	Blood protein levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04880751	chr1:241695164	KMO	-0.48	-6.5	-0.38	4.33e-10	C-reactive protein;
KIRP	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg25706552	chr1:244017396	NA	0.58	6.65	0.39	1.93e-10	RR interval (heart rate);
KIRP	cis	rs7770227	0.868	rs760610	chr6:114707932	G/A	cg18406000	chr6:114650610	NA	-0.43	-5.69	-0.34	3.68e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	0.76	10.96	0.57	4.91e-23	Prudent dietary pattern;
KIRP	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.84	11.37	0.59	2.3e-24	Morning vs. evening chronotype;
KIRP	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.16	-0.37	2.99e-9	Height;
KIRP	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg13271783	chr10:134563150	INPP5A	-0.55	-7.19	-0.42	7.97e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25251095	chr18:9338365	TWSG1	-0.43	-6.3	-0.37	1.39e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.64	-0.39	2.03e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg09231725	chr11:64357281	SLC22A12	0.61	8.04	0.46	3.67e-14	Urate levels in obese individuals;
KIRP	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg01268866	chr2:3683757	COLEC11	-0.4	-4.88	-0.3	1.87e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs17123764	0.892	rs7971176	chr12:50160080	C/T	cg20471783	chr12:50157085	TMBIM6	0.42	5.9	0.35	1.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-1.0	-12.29	-0.62	2.24e-27	Breast cancer;
KIRP	trans	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg06521331	chr12:34319734	NA	-0.51	-6.27	-0.37	1.57e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11718455	0.767	rs13075535	chr3:43954612	G/A	cg08738300	chr3:44038990	NA	0.65	8.35	0.47	4.89e-15	Coronary artery disease;
KIRP	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.77	11.51	0.59	8.34e-25	Hip circumference;
KIRP	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-1.08	-21.37	-0.81	5.39e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.54	-0.33	7.59e-8	Aortic root size;
KIRP	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.67	-7.4	-0.43	2.1e-12	Diabetic retinopathy;
KIRP	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.37	0.43	2.51e-12	Neuroticism;
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg17960426	chr8:142067321	NA	-0.56	-6.33	-0.37	1.18e-9	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.67	-0.44	4.03e-13	Height;
KIRP	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg26677194	chr12:130822605	PIWIL1	0.43	5.03	0.31	9.52e-7	Menopause (age at onset);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15416064	chr12:49209402	NA	-0.5	-6.28	-0.37	1.54e-9	Myopia;
KIRP	trans	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg19694781	chr19:47549865	TMEM160	-0.57	-7.47	-0.43	1.37e-12	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.47	6.57	0.39	3e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.58	7.58	0.44	7.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-5.52	-0.33	8.56e-8	Cognitive function;
KIRP	cis	rs1318772	0.932	rs17333442	chr5:112947050	A/C	cg12552261	chr5:112820674	MCC	0.75	5.19	0.31	4.35e-7	F-cell distribution;
KIRP	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18252515	chr7:66147081	NA	0.44	5.1	0.31	6.9e-7	Aortic root size;
KIRP	cis	rs7113850	0.541	rs76166238	chr11:24235418	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	8.41	0.47	3.28e-15	Bone fracture in osteoporosis;
KIRP	cis	rs5753618	0.504	rs9609297	chr22:31893731	G/T	cg02404636	chr22:31891804	SFI1	0.57	6.06	0.36	5.13e-9	Colorectal cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14892517	chr2:53898063	LOC100302652;ASB3	0.46	6.03	0.36	5.92e-9	Interleukin-4 levels;
KIRP	cis	rs4523957	0.928	rs11872068	chr17:2176528	G/A	cg16513277	chr17:2031491	SMG6	-0.59	-8.02	-0.46	4.41e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.61	7.59	0.44	6.68e-13	Red cell distribution width;
KIRP	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg08975724	chr8:8085496	FLJ10661	0.61	8.5	0.48	1.82e-15	Neuroticism;
KIRP	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-1.05	-17.41	-0.74	9e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs7215564	0.908	rs4243240	chr17:78660342	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.98	10.46	0.55	1.97e-21	Blood protein levels;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg22159483	chr17:1588198	PRPF8	0.47	6.35	0.38	1.04e-9	Ischemic stroke;
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.52	7.79	0.44	1.91e-13	Lung cancer;
KIRP	cis	rs3784262	0.669	rs12909979	chr15:58241022	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.24	-0.32	3.5e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs10918270	0.838	rs9783050	chr1:161936020	A/G	cg19735514	chr1:161762739	ATF6	-0.35	-4.91	-0.3	1.65e-6	Parkinson's disease (age of onset);
KIRP	trans	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.4e-20	Pursuit maintenance gain;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	9.11e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg18461458	chr19:21324796	ZNF431	-0.48	-4.96	-0.3	1.29e-6	Pain;
KIRP	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-0.63	-6.88	-0.4	5.01e-11	YKL-40 levels;
KIRP	trans	rs7178375	0.678	rs34678577	chr15:31177465	A/C	cg04373760	chr16:53404718	NA	0.69	6.61	0.39	2.4e-10	Hypertriglyceridemia;
KIRP	cis	rs6977660	0.943	rs10227692	chr7:19850199	T/C	cg05791153	chr7:19748676	TWISTNB	0.46	5.04	0.31	9e-7	Thyroid stimulating hormone;
KIRP	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg09596252	chr17:78655493	RPTOR	0.52	5.91	0.35	1.11e-8	Fractional excretion of uric acid;
KIRP	cis	rs2742417	1.000	rs2742406	chr3:45760600	C/T	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	2.97e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg12560992	chr17:57184187	TRIM37	0.68	6.41	0.38	7.43e-10	Cognitive test performance;
KIRP	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.7	8.48	0.48	2.12e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3741151	0.881	rs7951174	chr11:73093135	G/C	cg17517138	chr11:73019481	ARHGEF17	1.06	8.18	0.46	1.52e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs367943	0.666	rs1850412	chr5:112696768	A/G	cg12552261	chr5:112820674	MCC	0.54	6.37	0.38	9.24e-10	Type 2 diabetes;
KIRP	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.46	-6.91	-0.4	4.2e-11	Daytime sleep phenotypes;
KIRP	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg08975724	chr8:8085496	FLJ10661	0.52	6.61	0.39	2.39e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg14972814	chr11:95582409	MTMR2	0.29	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.68	-0.44	3.66e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.65	-7.97	-0.45	5.75e-14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg00990874	chr7:1149470	C7orf50	-0.68	-7.43	-0.43	1.83e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.2	0.42	7.19e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.87	-11.83	-0.6	7.08e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg27205649	chr11:78285834	NARS2	-0.47	-5.07	-0.31	7.67e-7	Testicular germ cell tumor;
KIRP	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.53	-8.02	-0.46	4.25e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.61	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.7	-0.34	3.47e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4363385	0.510	rs6664380	chr1:153030365	G/T	cg07796016	chr1:152779584	LCE1C	-0.48	-6.23	-0.37	2.03e-9	Inflammatory skin disease;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg09033563	chr22:24373618	LOC391322	-0.4	-5.34	-0.32	2.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg18694418	chr7:2742484	AMZ1	0.44	4.99	0.3	1.15e-6	Height;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03647317	chr4:187891568	NA	0.77	12.68	0.63	1.1e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.55	-6.28	-0.37	1.54e-9	Coronary artery disease;
KIRP	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg09163369	chr1:210001066	C1orf107	0.49	6.17	0.37	2.76e-9	Orofacial clefts;
KIRP	cis	rs7113850	0.512	rs11027747	chr11:24197995	A/G	ch.11.24196551F	chr11:24239977	NA	-0.65	-5.67	-0.34	3.98e-8	Bone fracture in osteoporosis;
KIRP	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg12861170	chr19:19639553	YJEFN3	-0.45	-4.86	-0.3	2.06e-6	Bipolar disorder;
KIRP	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	9.75	0.53	3.43e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6696239	1.000	rs12120182	chr1:227814332	G/A	cg27395484	chr1:227557617	NA	0.44	5.0	0.3	1.09e-6	Height;
KIRP	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08045932	chr20:61659980	NA	0.53	6.64	0.39	2.01e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2219968	1.000	rs11783293	chr8:78958925	G/T	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg12405258	chr13:114927641	NA	0.5	7.31	0.42	3.8e-12	Schizophrenia;
KIRP	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg06481639	chr22:41940642	POLR3H	-0.46	-5.46	-0.33	1.14e-7	Vitiligo;
KIRP	cis	rs12476592	0.516	rs6706123	chr2:63801522	G/A	cg17519650	chr2:63277830	OTX1	-0.44	-5.46	-0.33	1.19e-7	Childhood ear infection;
KIRP	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg21546286	chr11:48923668	NA	-0.41	-5.31	-0.32	2.45e-7	HDL cholesterol;
KIRP	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.55	-0.43	8.44e-13	Height;
KIRP	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg27147174	chr7:100797783	AP1S1	-0.74	-9.53	-0.52	1.63e-18	Life satisfaction;
KIRP	trans	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg19274270	chr17:78178856	CARD14	-0.37	-6.62	-0.39	2.24e-10	Morning vs. evening chronotype;
KIRP	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.2	0.51	1.56e-17	Coffee consumption (cups per day);
KIRP	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.17	-0.37	2.83e-9	Breast cancer;
KIRP	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg02319466	chr17:76381040	PGS1	0.45	6.27	0.37	1.65e-9	HDL cholesterol levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18005807	chr22:18506799	MICAL3	0.66	8.15	0.46	1.8e-14	Smoking initiation;
KIRP	cis	rs2278796	0.639	rs4951153	chr1:204970844	C/A	cg04862289	chr1:204966208	NFASC	0.65	8.93	0.49	1.05e-16	Mean platelet volume;
KIRP	cis	rs490234	0.934	rs4837018	chr9:128275991	A/G	cg14078157	chr9:128172775	NA	-0.41	-5.03	-0.31	9.29e-7	Mean arterial pressure;
KIRP	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg18154014	chr19:37997991	ZNF793	0.7	7.84	0.45	1.38e-13	Coronary artery calcification;
KIRP	cis	rs2071426	0.622	rs7899038	chr10:96772412	C/T	cg09036531	chr10:96991505	NA	-0.47	-5.43	-0.33	1.36e-7	Blood metabolite levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00775695	chr9:14693648	ZDHHC21	0.56	6.31	0.37	1.25e-9	Lung cancer in ever smokers;
KIRP	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.02	-0.36	6.22e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6708331	0.517	rs7599072	chr2:70360006	C/T	cg05298696	chr2:70188691	ASPRV1	-0.4	-5.33	-0.32	2.21e-7	Obesity-related traits;
KIRP	cis	rs9815354	0.951	rs9831404	chr3:41871825	T/G	cg03022575	chr3:42003672	ULK4	0.6	6.97	0.41	2.98e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg19847130	chr8:10466454	RP1L1	-0.39	-5.95	-0.35	9.19e-9	Neuroticism;
KIRP	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	0.77	8.18	0.46	1.53e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.63	-6.76	-0.4	9.69e-11	Vitiligo;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.7	9.81	0.53	2.21e-19	Retinal vascular caliber;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09181054	chr1:19232926	IFFO2	-0.44	-6.58	-0.39	2.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.31	0.37	1.29e-9	Ovarian reserve;
KIRP	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg20243544	chr17:37824526	PNMT	0.54	7.89	0.45	1e-13	Asthma;
KIRP	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg23958373	chr8:599963	NA	0.72	6.43	0.38	6.65e-10	IgG glycosylation;
KIRP	cis	rs4700695	0.764	rs27701	chr5:65377526	G/C	cg21114390	chr5:65439923	SFRS12	-0.47	-5.48	-0.33	1.05e-7	Facial morphology (factor 19);
KIRP	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg11522683	chr6:37501428	NA	-0.38	-4.96	-0.3	1.32e-6	Cognitive performance;
KIRP	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg09184832	chr6:79620586	NA	-0.4	-5.1	-0.31	6.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12282928	0.918	rs1503173	chr11:48246297	A/T	cg26585981	chr11:48327164	OR4S1	-0.5	-5.66	-0.34	4.15e-8	Migraine - clinic-based;
KIRP	trans	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg25042112	chr7:64838748	ZNF92	0.58	6.06	0.36	5.19e-9	Pain;
KIRP	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.7	-0.63	9.44e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.26	-0.55	8.54e-21	Menopause (age at onset);
KIRP	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.66	9.07	0.5	3.89e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	1.02	12.55	0.62	3.01e-28	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.71	5.64	0.34	4.73e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1881797	0.527	rs77059530	chr1:247648916	G/A	cg05639522	chr1:247681581	NA	0.77	5.1	0.31	6.82e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2191566	1.000	rs367499	chr19:44504981	G/A	cg18700516	chr19:44507157	ZNF230	0.46	5.2	0.31	4.15e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.86	-11.24	-0.58	6.5e-24	Cognitive function;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.67	-8.67	-0.48	5.78e-16	Longevity;Endometriosis;
KIRP	cis	rs75064307	0.626	rs35672602	chr3:108065574	T/C	cg14703454	chr3:108065259	HHLA2	0.53	6.39	0.38	8.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs45544231	0.593	rs1075367	chr16:52555002	G/A	cg09051775	chr16:52580266	TOX3	-0.38	-5.21	-0.32	4.07e-7	Restless legs syndrome;
KIRP	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.72	-0.39	1.27e-10	Height;
KIRP	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg24268161	chr22:39747459	SYNGR1	-0.24	-5.24	-0.32	3.46e-7	Rheumatoid arthritis;
KIRP	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg15660573	chr17:549704	VPS53	-0.84	-12.8	-0.63	4.16e-29	Prostate cancer;
KIRP	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.56	6.93	0.4	3.75e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.83	8.77	0.49	3.05e-16	Exhaled nitric oxide output;
KIRP	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg26354017	chr1:205819088	PM20D1	0.5	5.81	0.35	1.97e-8	Parkinson's disease;
KIRP	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg03060546	chr3:49711283	APEH	0.54	7.39	0.43	2.31e-12	Menarche (age at onset);
KIRP	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.87	-11.38	-0.59	2.14e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7011049	0.687	rs7815780	chr8:53863922	C/A	cg26025543	chr8:53854495	NA	0.57	6.18	0.37	2.6e-9	Systolic blood pressure;
KIRP	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg23711669	chr6:146136114	FBXO30	0.68	9.47	0.52	2.49e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7763441	0.567	rs2281251	chr6:2434056	A/G	cg18740289	chr6:2437142	NA	-0.43	-5.31	-0.32	2.44e-7	Monobrow;
KIRP	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.65	9.39	0.51	4.25e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.64	-0.39	1.96e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.52	6.87	0.4	5.35e-11	Response to temozolomide;
KIRP	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.81	10.72	0.56	3.07e-22	Breast cancer;
KIRP	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg24375607	chr4:120327624	NA	0.58	6.76	0.4	9.88e-11	Corneal astigmatism;
KIRP	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg02336718	chr17:17403227	NA	-0.35	-5.58	-0.34	6.32e-8	Total body bone mineral density;
KIRP	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.22	-0.32	3.8e-7	Type 2 diabetes;
KIRP	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.21	-0.42	6.77e-12	Vitiligo;
KIRP	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.39	5.23	0.32	3.68e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.46	-5.99	-0.36	7.36e-9	Asthma;
KIRP	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg24375607	chr4:120327624	NA	0.52	6.17	0.37	2.79e-9	Corneal astigmatism;
KIRP	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.03	-0.31	9.57e-7	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22776125	chr6:167041314	RPS6KA2	0.59	7.07	0.41	1.63e-11	Smoking initiation;
KIRP	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26207909	chr14:103986467	CKB	0.52	6.84	0.4	6.06e-11	Body mass index;
KIRP	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg27205649	chr11:78285834	NARS2	0.71	7.89	0.45	9.89e-14	Alzheimer's disease (survival time);
KIRP	cis	rs2151522	0.563	rs35211576	chr6:127116727	A/G	cg21431617	chr6:127135037	NA	0.34	6.19	0.37	2.53e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg11693508	chr17:37793320	STARD3	0.81	8.13	0.46	2.09e-14	Neuroticism;
KIRP	trans	rs1864729	1.000	rs2635161	chr8:98282907	A/C	cg08679828	chr8:102218111	ZNF706	0.75	6.85	0.4	5.74e-11	Estradiol plasma levels (breast cancer);
KIRP	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.75	0.34	2.6e-8	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.8	-8.78	-0.49	2.77e-16	Coronary artery disease;
KIRP	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	0.85	13.22	0.64	1.62e-30	Breast cancer;
KIRP	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	6.45	0.38	5.88e-10	Body mass index;
KIRP	cis	rs4974559	0.739	rs28412861	chr4:1320092	A/G	cg02980000	chr4:1222292	CTBP1	0.98	8.84	0.49	1.94e-16	Systolic blood pressure;
KIRP	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg23032129	chr1:109941072	SORT1	-0.28	-4.91	-0.3	1.67e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg20673091	chr1:2541236	MMEL1	-0.69	-10.69	-0.56	3.7e-22	Ulcerative colitis;
KIRP	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.47	-5.93	-0.35	1.02e-8	Blood metabolite levels;
KIRP	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg06204229	chr3:52865917	ITIH4	0.56	6.49	0.38	4.72e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.81	0.53	2.25e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6496667	0.514	rs62019353	chr15:90933683	T/C	cg10434728	chr15:90938212	IQGAP1	0.37	5.28	0.32	2.84e-7	Rheumatoid arthritis;
KIRP	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.3	-5.08	-0.31	7.45e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg16083429	chr3:49237500	CCDC36	-0.39	-5.12	-0.31	6.26e-7	Menarche (age at onset);
KIRP	trans	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.43	-0.38	6.47e-10	Mood instability;
KIRP	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.45	-5.31	-0.32	2.48e-7	Reticulocyte count;
KIRP	cis	rs2281603	0.951	rs59512674	chr14:64993013	C/T	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11169552	0.510	rs10431486	chr12:50941025	C/T	cg12884762	chr12:50931848	DIP2B	-0.44	-4.96	-0.3	1.3e-6	Colorectal cancer;
KIRP	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg21926883	chr2:100939477	LONRF2	-0.65	-8.85	-0.49	1.76e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.61	7.5	0.43	1.14e-12	Obesity-related traits;
KIRP	trans	rs2048656	0.578	rs2090061	chr8:9680978	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.0	-0.41	2.36e-11	Schizophrenia;
KIRP	cis	rs8010715	0.816	rs6573565	chr14:24594733	A/G	cg23112188	chr14:24563095	PCK2	0.35	5.22	0.32	3.75e-7	IgG glycosylation;
KIRP	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.83	-10.72	-0.56	2.94e-22	Orofacial clefts;
KIRP	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg09873164	chr1:152488093	CRCT1	0.56	7.11	0.41	1.24e-11	Hair morphology;
KIRP	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg01620082	chr3:125678407	NA	-1.09	-6.86	-0.4	5.53e-11	Depression;
KIRP	cis	rs3755132	0.929	rs6708314	chr2:15745211	T/C	cg12888861	chr2:15731646	DDX1	0.4	5.19	0.31	4.42e-7	Wilms tumor;
KIRP	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.93	-11.26	-0.58	5.46e-24	Corneal astigmatism;
KIRP	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01256987	chr12:42539512	GXYLT1	-0.45	-5.9	-0.35	1.21e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg07001201	chr5:642380	CEP72	0.66	6.6	0.39	2.44e-10	Obesity-related traits;
KIRP	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg19442545	chr10:75533431	FUT11	-0.38	-4.94	-0.3	1.45e-6	Inflammatory bowel disease;
KIRP	cis	rs9611519	0.603	rs4821999	chr22:41470001	A/G	cg03806693	chr22:41940476	POLR3H	-0.41	-4.84	-0.3	2.26e-6	Neuroticism;
KIRP	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg02569458	chr12:86230093	RASSF9	0.34	4.9	0.3	1.71e-6	Major depressive disorder;
KIRP	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12893428	chr3:195717962	SDHAP1	0.42	5.21	0.32	4.03e-7	Pancreatic cancer;
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.86	-9.07	-0.5	3.84e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg21890820	chr11:65308645	LTBP3	0.74	5.37	0.32	1.78e-7	Height;
KIRP	cis	rs815815	0.636	rs815817	chr2:47396558	C/T	cg27223769	chr2:47403360	CALM2	-0.7	-8.47	-0.47	2.32e-15	Dialysis-related mortality;
KIRP	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg10517650	chr3:113235015	CCDC52	-0.47	-5.44	-0.33	1.27e-7	Dental caries;
KIRP	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg13010199	chr12:38710504	ALG10B	0.6	7.41	0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg25019722	chr6:37503610	NA	0.75	10.5	0.56	1.46e-21	Cognitive performance;
KIRP	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg05535760	chr7:792225	HEATR2	-0.44	-5.05	-0.31	8.58e-7	Perceived unattractiveness to mosquitoes;
KIRP	trans	rs7710178	0.938	rs12521822	chr5:155965947	T/G	cg23165310	chr3:181422217	SOX2OT	0.74	6.18	0.37	2.71e-9	Airway responsiveness in chronic obstructive pulmonary disease;
KIRP	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg01529538	chr14:23388837	RBM23	0.41	5.14	0.31	5.64e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg09699651	chr6:150184138	LRP11	0.45	6.04	0.36	5.63e-9	Lung cancer;
KIRP	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.56	6.84	0.4	6.3e-11	QRS duration;
KIRP	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	cis	rs6684514	1.000	rs28372828	chr1:156253031	G/C	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	0.76	10.99	0.57	4.04e-23	Prudent dietary pattern;
KIRP	trans	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-6.89	-0.4	4.65e-11	Obesity-related traits;
KIRP	cis	rs151997	0.720	rs152096	chr5:50213850	A/G	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg16141378	chr3:129829833	LOC729375	-0.52	-6.5	-0.38	4.47e-10	Retinal vascular caliber;
KIRP	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.63	-0.52	7.79e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg01657329	chr11:68192670	LRP5	-0.55	-6.7	-0.39	1.41e-10	Total body bone mineral density;
KIRP	cis	rs4262150	0.767	rs10041133	chr5:152328596	A/G	cg12297329	chr5:152029980	NA	0.42	5.61	0.34	5.39e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.68	-7.92	-0.45	7.98e-14	Gut microbiome composition (summer);
KIRP	cis	rs4740619	0.619	rs12379466	chr9:16028394	A/G	cg14451791	chr9:16040625	NA	-0.4	-5.22	-0.32	3.81e-7	Body mass index;
KIRP	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.11	0.58	1.6e-23	Smoking behavior;
KIRP	cis	rs12580194	0.958	rs7974512	chr12:55713606	A/G	cg11794356	chr12:55725991	OR6C3	-0.45	-6.48	-0.38	5.06e-10	Cancer;
KIRP	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg11130432	chr3:121712080	ILDR1	0.42	5.03	0.31	9.38e-7	Multiple sclerosis;
KIRP	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg11738485	chr19:12877000	HOOK2	-0.44	-4.85	-0.3	2.17e-6	Mean corpuscular volume;
KIRP	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-6.27	-0.37	1.57e-9	Response to antipsychotic treatment;
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.42	5.44	0.33	1.28e-7	Longevity;
KIRP	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.99	15.84	0.71	1.95e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs76693355	0.512	rs11217878	chr11:120340383	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.41	-5.23	-0.32	3.68e-7	Intraocular pressure;
KIRP	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg00204512	chr16:28754710	NA	0.47	6.14	0.36	3.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg06740227	chr12:86229804	RASSF9	0.48	6.28	0.37	1.51e-9	Major depressive disorder;
KIRP	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg25486957	chr4:152246857	NA	-0.5	-5.32	-0.32	2.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20974424	chr5:640382	CEP72	-0.47	-6.13	-0.36	3.56e-9	Inflammatory biomarkers;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17421331	chr12:1026102	RAD52	0.51	6.5	0.38	4.5e-10	Interleukin-4 levels;
KIRP	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.59	-9.46	-0.52	2.68e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03452623	chr4:187889614	NA	-1.08	-21.59	-0.81	1.03e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs78487399	0.808	rs7559842	chr2:43673442	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.86	0.35	1.5e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs67756423	0.503	rs4976978	chr8:143314266	A/G	cg24996280	chr8:143481281	TSNARE1	0.42	5.59	0.34	5.99e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg10047753	chr17:41438598	NA	1.16	18.76	0.77	2.33e-49	Menopause (age at onset);
KIRP	cis	rs11264213	0.901	rs794222	chr1:36369024	T/C	cg27506609	chr1:36549197	TEKT2	0.97	10.12	0.54	2.45e-20	Schizophrenia;
KIRP	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs7827545	0.545	rs57219802	chr8:135554231	C/T	cg17885191	chr8:135476712	NA	0.86	7.62	0.44	5.54e-13	Hypertension (SNP x SNP interaction);
KIRP	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-7.86	-0.45	1.19e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg19000871	chr14:103996768	TRMT61A	-0.41	-5.27	-0.32	3.05e-7	Coronary artery disease;
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.46	5.47	0.33	1.1e-7	Glycated hemoglobin levels;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg17294928	chr15:75287854	SCAMP5	0.61	8.11	0.46	2.43e-14	Breast cancer;
KIRP	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11987759	chr7:65425863	GUSB	0.5	6.72	0.39	1.27e-10	Aortic root size;
KIRP	cis	rs6142102	0.812	rs725478	chr20:32518354	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-5.35	-0.32	2.03e-7	Skin pigmentation;
KIRP	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.44	-9.7	-0.53	4.87e-19	Alzheimer's disease (late onset);
KIRP	cis	rs6601327	0.665	rs4841218	chr8:9653902	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-4.94	-0.3	1.43e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg21360079	chr12:107162445	NA	-0.63	-8.8	-0.49	2.48e-16	Heart rate;
KIRP	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	14.84	0.69	5.14e-36	Chronic sinus infection;
KIRP	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06544989	chr22:39130855	UNC84B	0.51	9.08	0.5	3.53e-17	Menopause (age at onset);
KIRP	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.44e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.53	-5.62	-0.34	5.12e-8	Body mass index;
KIRP	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.82	-8.26	-0.47	8.75e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs7615316	0.779	rs6440077	chr3:142017527	A/G	cg20824294	chr3:142316082	PLS1	0.24	5.63	0.34	4.8e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg03289416	chr15:75166202	SCAMP2	0.5	6.73	0.39	1.17e-10	Breast cancer;
KIRP	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	6.86	0.4	5.65e-11	Platelet count;
KIRP	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.9	13.32	0.65	7.41e-31	Mean platelet volume;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25470419	chr5:52907653	NDUFS4	0.41	6.28	0.37	1.54e-9	Migraine with aura;
KIRP	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.68	9.34	0.51	6.01e-18	Prostate cancer;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg26007049	chr14:96000930	GLRX5;SNHG10;SCARNA13	0.5	6.25	0.37	1.84e-9	Colorectal cancer;
KIRP	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.67	-8.87	-0.49	1.53e-16	Breast cancer;
KIRP	cis	rs6743226	0.748	rs12620606	chr2:242154015	A/G	cg10021735	chr2:242295487	FARP2	0.43	5.43	0.33	1.35e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.05	11.93	0.61	3.53e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2219968	0.798	rs9657126	chr8:78942271	T/C	cg00738934	chr8:78996279	NA	-0.37	-5.02	-0.3	1e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.08	0.41	1.48e-11	Bipolar disorder;
KIRP	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.7	9.57	0.52	1.17e-18	Crohn's disease;
KIRP	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13409248	chr3:40428643	ENTPD3	0.39	5.1	0.31	6.94e-7	Renal cell carcinoma;
KIRP	cis	rs16828019	0.777	rs13376450	chr1:41469043	A/G	cg18742814	chr1:41828276	NA	0.67	5.82	0.35	1.85e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.02	0.54	4.8e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2072732	0.861	rs72856440	chr1:2956582	A/G	cg11731671	chr1:2995604	PRDM16	-0.46	-5.81	-0.35	1.96e-8	Plateletcrit;
KIRP	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg11738485	chr19:12877000	HOOK2	0.45	5.64	0.34	4.57e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg23690866	chr17:70118558	SOX9	0.48	6.34	0.37	1.08e-9	Beard thickness;
KIRP	cis	rs77106637	0.530	rs7122044	chr11:72462634	A/G	cg04827223	chr11:72435913	ARAP1	-0.55	-6.58	-0.39	2.87e-10	Type 2 diabetes;
KIRP	cis	rs4594175	0.926	rs4349056	chr14:51625819	A/G	cg23942311	chr14:51606299	NA	0.52	7.02	0.41	2.13e-11	Cancer;
KIRP	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7538876	0.967	rs6695531	chr1:17720088	T/G	cg01904812	chr1:17746340	RCC2	0.29	4.94	0.3	1.43e-6	Basal cell carcinoma;
KIRP	cis	rs4389656	0.857	rs2279657	chr5:6737571	A/G	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg15488143	chr7:128924101	AHCYL2	0.64	6.83	0.4	6.72e-11	White matter hyperintensity burden;
KIRP	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg12573791	chr2:3828286	NA	0.41	5.69	0.34	3.59e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs17123764	0.605	rs6580719	chr12:50071092	C/A	cg20471783	chr12:50157085	TMBIM6	0.35	5.48	0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.54	0.38	3.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7116495	1.000	rs7106748	chr11:71645803	A/C	cg26138937	chr11:71823887	C11orf51	-0.73	-5.91	-0.35	1.13e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00671759	chr17:79479205	ACTG1	-0.54	-6.86	-0.4	5.63e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.62	-9.77	-0.53	2.84e-19	Longevity;
KIRP	cis	rs10761482	0.500	rs2153525	chr10:62269574	G/T	cg01186212	chr10:62110162	ANK3	0.28	4.9	0.3	1.71e-6	Schizophrenia;
KIRP	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.46	8.71	0.49	4.54e-16	Erythrocyte sedimentation rate;
KIRP	cis	rs4954585	0.683	rs4072434	chr2:137014023	C/G	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.14e-13	Colorectal cancer;
KIRP	cis	rs11825064	0.666	rs73596941	chr11:134495285	A/G	cg06603561	chr11:134479413	NA	-0.74	-6.12	-0.36	3.68e-9	Seasonality;
KIRP	cis	rs735539	0.555	rs2253017	chr13:21300909	C/T	cg04906043	chr13:21280425	IL17D	-0.42	-4.87	-0.3	2.03e-6	Dental caries;
KIRP	cis	rs687432	0.847	rs12790525	chr11:57822450	T/C	cg19752551	chr11:57585705	CTNND1	-0.67	-8.52	-0.48	1.66e-15	Parkinson's disease;
KIRP	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	7.28	0.42	4.45e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.78e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.03	-0.31	9.37e-7	Arsenic metabolism;
KIRP	cis	rs3733418	0.929	rs17623445	chr4:165894658	C/T	cg10852876	chr4:165953100	TRIM60	-0.49	-5.51	-0.33	8.96e-8	Obesity-related traits;
KIRP	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.78	7.24	0.42	5.81e-12	Mean platelet volume;
KIRP	trans	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg01620082	chr3:125678407	NA	-1.13	-6.65	-0.39	1.85e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.63	8.45	0.47	2.63e-15	Calcium levels;
KIRP	cis	rs1215050	0.782	rs6532693	chr4:98655815	T/C	cg05340658	chr4:99064831	C4orf37	-0.49	-6.02	-0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs73200209	0.744	rs55643039	chr12:116609355	T/G	cg01776926	chr12:116560359	MED13L	-0.51	-5.82	-0.35	1.81e-8	Total body bone mineral density;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	7.76	0.44	2.29e-13	Bipolar disorder;
KIRP	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.53	6.16	0.37	3.03e-9	Blood metabolite levels;
KIRP	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.81	0.53	2.23e-19	Hip circumference adjusted for BMI;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15777606	chr6:15496615	JARID2	0.61	6.76	0.4	1.02e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.85	12.06	0.61	1.27e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20982606	chr12:109535391	UNG	0.45	6.38	0.38	8.64e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg25019033	chr10:957182	NA	-0.57	-6.06	-0.36	5.18e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs13226913	0.643	rs7780273	chr7:7250449	A/C	cg04827551	chr7:7268805	C1GALT1	-0.4	-5.96	-0.36	8.55e-9	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.77	0.35	2.37e-8	Blood protein levels;
KIRP	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-8.33	-0.47	5.73e-15	Coronary artery disease;
KIRP	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04374321	chr14:90722782	PSMC1	0.93	15.9	0.71	1.27e-39	Mortality in heart failure;
KIRP	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.44	7.23	0.42	5.92e-12	Height;
KIRP	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg01879757	chr17:41196368	BRCA1	-0.52	-6.9	-0.4	4.35e-11	Menopause (age at onset);
KIRP	cis	rs2554380	0.843	rs2098904	chr15:84406255	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.47	-6.56	-0.39	3.21e-10	Height;
KIRP	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg05804037	chr4:1090086	RNF212	0.36	5.19	0.31	4.36e-7	Recombination rate (males);
KIRP	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg16797656	chr11:68205561	LRP5	0.45	6.36	0.38	9.84e-10	Total body bone mineral density;
KIRP	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.6	-6.39	-0.38	8.28e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs11264213	0.818	rs2765012	chr1:36356457	A/G	cg27506609	chr1:36549197	TEKT2	0.96	9.87	0.53	1.47e-19	Schizophrenia;
KIRP	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg19000871	chr14:103996768	TRMT61A	0.44	5.47	0.33	1.13e-7	Coronary artery disease;
KIRP	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9650657	0.836	rs3905581	chr8:10603705	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.29	-0.37	1.44e-9	Neuroticism;
KIRP	cis	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg27487796	chr7:28973253	NA	0.21	5.03	0.31	9.54e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.8	-9.79	-0.53	2.47e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.45	5.82	0.35	1.78e-8	Blood metabolite levels;
KIRP	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg18404041	chr3:52824283	ITIH1	0.45	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs860295	0.702	rs12025532	chr1:155369302	C/T	cg02153340	chr1:155202674	NA	-0.54	-7.17	-0.42	8.97e-12	Body mass index;
KIRP	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.66	-5.17	-0.31	4.77e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.69	-0.44	3.63e-13	Aortic root size;
KIRP	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg15655495	chr12:38532458	NA	0.27	5.29	0.32	2.76e-7	Bladder cancer;
KIRP	cis	rs7582720	1.000	rs72932737	chr2:203654540	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.16	10.03	0.54	4.61e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.52	6.45	0.38	5.76e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.69	-13.11	-0.64	3.83e-30	White blood cell count (basophil);
KIRP	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg17691542	chr6:26056736	HIST1H1C	0.67	7.94	0.45	6.98e-14	Iron status biomarkers;
KIRP	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22117172	chr7:91764530	CYP51A1	0.44	5.99	0.36	7.43e-9	Breast cancer;
KIRP	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.69	0.53	4.95e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	8.35	0.47	4.87e-15	Bipolar disorder;
KIRP	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg18586891	chr4:952366	TMEM175	0.58	5.16	0.31	4.97e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.773	rs4706027	chr5:130932972	T/C	cg06307176	chr5:131281290	NA	0.42	5.02	0.3	9.87e-7	Life satisfaction;
KIRP	cis	rs7116495	0.786	rs678193	chr11:71770273	A/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg24253500	chr15:84953950	NA	-0.69	-7.9	-0.45	9.08e-14	Schizophrenia;
KIRP	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-5.6	-0.34	5.66e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg14972814	chr11:95582409	MTMR2	0.33	5.06	0.31	8.3e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4950322	0.570	rs4950392	chr1:146736548	G/T	cg22381352	chr1:146742008	CHD1L	-0.47	-5.51	-0.33	9.25e-8	Protein quantitative trait loci;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11184237	chr15:75748191	SIN3A	0.49	6.17	0.37	2.83e-9	Parkinson's disease;
KIRP	cis	rs16828019	0.777	rs35496942	chr1:41488904	G/A	cg03387723	chr1:41708464	SCMH1	-0.72	-6.19	-0.37	2.44e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.49	-0.38	4.73e-10	Morning vs. evening chronotype;
KIRP	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg12962167	chr3:53033115	SFMBT1	0.71	5.19	0.31	4.44e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2554380	0.843	rs1365198	chr15:84398903	T/G	cg14598478	chr15:84363061	ADAMTSL3	-0.49	-7.09	-0.41	1.42e-11	Height;
KIRP	cis	rs2071403	0.933	rs938326	chr2:1401781	C/T	cg07083862	chr2:1417248	TPO	0.34	5.42	0.33	1.39e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg05255149	chr17:80675120	FN3KRP	0.48	4.94	0.3	1.44e-6	Glycated hemoglobin levels;
KIRP	cis	rs6723108	0.651	rs6724774	chr2:135407285	C/T	cg12500956	chr2:135428796	TMEM163	-0.42	-5.68	-0.34	3.78e-8	Type 2 diabetes;
KIRP	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs13082711	0.911	rs7625337	chr3:27516853	G/T	cg02860705	chr3:27208620	NA	0.47	6.47	0.38	5.14e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.24	-0.32	3.51e-7	Coronary artery disease;
KIRP	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg18016565	chr1:150552671	MCL1	0.39	5.9	0.35	1.19e-8	Melanoma;
KIRP	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg27624424	chr6:160112604	SOD2	0.48	4.99	0.3	1.16e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg16558253	chr16:72132732	DHX38	-0.6	-8.98	-0.5	7.25e-17	Fibrinogen levels;
KIRP	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg03563238	chr19:33554763	RHPN2	-0.32	-5.67	-0.34	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.4	-0.33	1.55e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg00343986	chr7:65444356	GUSB	0.42	4.94	0.3	1.42e-6	Aortic root size;
KIRP	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-6.62	-0.39	2.18e-10	Axial length;
KIRP	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs3204270	0.639	rs8074225	chr17:79618270	G/A	cg18367735	chr17:79674897	NA	0.68	6.25	0.37	1.78e-9	Dental caries;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02638909	chr8:30888801	PURG	-0.42	-6.07	-0.36	4.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg06636001	chr8:8085503	FLJ10661	0.55	7.28	0.42	4.36e-12	Retinal vascular caliber;
KIRP	cis	rs11955398	0.625	rs6874072	chr5:59987682	C/G	cg02684056	chr5:59996105	DEPDC1B	0.49	5.53	0.33	8.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.64	-0.34	4.65e-8	Coronary artery disease;
KIRP	cis	rs13315871	1.000	rs3196769	chr3:58409361	A/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs501120	0.564	rs10899999	chr10:44690185	A/G	cg09554077	chr10:44749378	NA	0.49	6.69	0.39	1.46e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg10167378	chr1:228756711	NA	0.89	7.34	0.42	3.16e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.08	0.36	4.56e-9	Personality dimensions;
KIRP	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg10047753	chr17:41438598	NA	1.13	17.98	0.75	1.05e-46	Menopause (age at onset);
KIRP	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.65	7.93	0.45	7.91e-14	Vitamin D levels;
KIRP	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23903597	chr17:61704154	MAP3K3	-0.53	-6.58	-0.39	2.86e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg01990225	chr2:97406019	LMAN2L	-1.0	-7.07	-0.41	1.62e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.54	-7.07	-0.41	1.61e-11	Urate levels in overweight individuals;
KIRP	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.4	5.77	0.35	2.35e-8	Cisplatin-induced ototoxicity;
KIRP	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg03887218	chr1:16534349	ARHGEF19	0.61	7.9	0.45	9.26e-14	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs4561483	0.514	rs33639	chr16:11989499	A/C	cg08843971	chr16:11963173	GSPT1	-0.55	-7.72	-0.44	2.91e-13	Testicular germ cell tumor;
KIRP	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg25039879	chr17:56429692	SUPT4H1	0.57	5.06	0.31	8.36e-7	Cognitive test performance;
KIRP	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-5.63	-0.34	4.88e-8	Testicular germ cell tumor;
KIRP	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg17207736	chr8:142237307	SLC45A4	-0.49	-6.17	-0.37	2.81e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg18944383	chr4:111397179	ENPEP	0.51	8.55	0.48	1.35e-15	Coronary artery disease;
KIRP	cis	rs9596863	0.898	rs7983436	chr13:54388598	T/A	ch.13.53330881F	chr13:54432880	NA	0.6	5.81	0.35	1.88e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg17425144	chr1:10567563	PEX14	-0.31	-5.31	-0.32	2.4e-7	Hepatocellular carcinoma;
KIRP	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.6	9.09	0.5	3.3e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-0.79	-6.35	-0.38	1.03e-9	IgG glycosylation;
KIRP	cis	rs7178909	0.902	rs28372736	chr15:90437858	T/C	cg19708238	chr15:90437601	AP3S2	0.59	8.2	0.46	1.35e-14	Common traits (Other);
KIRP	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.26	-0.42	5.22e-12	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.6	7.28	0.42	4.36e-12	Platelet count;
KIRP	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.73	-8.93	-0.49	1.02e-16	Cognitive function;
KIRP	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.83	12.1	0.61	9.05e-27	Bladder cancer;
KIRP	cis	rs9687846	0.877	rs9687832	chr5:55861595	G/A	cg15001016	chr5:55860904	NA	-0.29	-5.29	-0.32	2.69e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg21775007	chr8:11205619	TDH	0.39	5.16	0.31	5.1e-7	Morning vs. evening chronotype;
KIRP	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.41	4.96	0.3	1.3e-6	Tonsillectomy;
KIRP	cis	rs4363506	0.598	rs1931735	chr10:129281800	C/T	cg07804728	chr10:129284050	NA	0.46	5.85	0.35	1.55e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg20966754	chr17:47091339	IGF2BP1	0.29	5.69	0.34	3.54e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.49	-6.07	-0.36	4.79e-9	Iron status biomarkers;
KIRP	cis	rs259842	0.737	rs13411964	chr2:180726526	G/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.46	-6.43	-0.38	6.56e-10	Blood protein levels;
KIRP	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.74	-0.44	2.56e-13	Homocysteine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27577023	chr18:24236500	NA	0.47	6.06	0.36	5.14e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.91e-8	Life satisfaction;
KIRP	cis	rs2230307	0.572	rs17122001	chr1:100628311	A/T	cg24955406	chr1:100503596	HIAT1	0.58	6.12	0.36	3.76e-9	Carotid intima media thickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22833807	chr22:36925177	EIF3D	0.56	6.53	0.38	3.67e-10	Smoking initiation;
KIRP	cis	rs12153243	1.000	rs12153156	chr5:142898251	A/T	cg13907255	chr5:142895549	NA	-0.38	-5.15	-0.31	5.22e-7	Migraine;
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.5	6.46	0.38	5.44e-10	Resistin levels;
KIRP	cis	rs2378353	1	rs2378353	chr20:33970462	A/G	cg14752227	chr20:34000481	UQCC	-0.45	-5.21	-0.32	3.91e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.18	21.1	0.8	4.09e-57	Cognitive function;
KIRP	cis	rs684232	0.931	rs410157	chr17:598240	T/C	cg15660573	chr17:549704	VPS53	-0.46	-5.75	-0.34	2.63e-8	Prostate cancer;
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.74	-0.71	4.49e-39	Immature fraction of reticulocytes;
KIRP	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg10755058	chr3:40428713	ENTPD3	-0.44	-6.36	-0.38	9.98e-10	Renal cell carcinoma;
KIRP	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.25	-0.7	2.03e-37	Alzheimer's disease;
KIRP	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.56	7.12	0.41	1.19e-11	Platelet count;
KIRP	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg02782426	chr3:40428986	ENTPD3	-0.32	-4.88	-0.3	1.88e-6	Renal cell carcinoma;
KIRP	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg08975724	chr8:8085496	FLJ10661	0.69	8.9	0.49	1.23e-16	Systolic blood pressure;
KIRP	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00495681	chr13:53174319	NA	-0.49	-6.95	-0.41	3.21e-11	Lewy body disease;
KIRP	cis	rs2299587	0.582	rs7011029	chr8:17897804	G/A	cg01800426	chr8:17659068	MTUS1	-0.41	-5.19	-0.31	4.41e-7	Economic and political preferences;
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22168489	chr12:122356033	WDR66	0.67	9.73	0.53	3.96e-19	Mean corpuscular volume;
KIRP	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg03806693	chr22:41940476	POLR3H	-0.48	-5.48	-0.33	1.07e-7	Neuroticism;
KIRP	cis	rs34779708	0.931	rs7908573	chr10:35309513	T/C	cg04310649	chr10:35416472	CREM	-0.52	-5.93	-0.35	1.03e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.49	6.93	0.4	3.71e-11	Lewy body disease;
KIRP	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.42	-6.43	-0.38	6.44e-10	Coronary artery disease;
KIRP	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs477895	0.713	rs7944061	chr11:63956839	A/T	cg14078730	chr11:63896557	MACROD1	0.33	4.86	0.3	2.1e-6	Mean platelet volume;
KIRP	cis	rs10875746	0.903	rs58952582	chr12:48458448	T/G	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg00405596	chr8:11794950	NA	0.47	5.85	0.35	1.57e-8	Retinal vascular caliber;
KIRP	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg02795151	chr17:7402630	POLR2A	0.78	8.01	0.45	4.47e-14	Androgen levels;
KIRP	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.11	0.36	3.82e-9	Height;
KIRP	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08439880	chr3:133502540	NA	0.48	6.13	0.36	3.41e-9	Iron status biomarkers;
KIRP	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg18490616	chr2:88469792	THNSL2	0.67	5.4	0.33	1.56e-7	Plasma clusterin levels;
KIRP	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.42	-5.41	-0.33	1.53e-7	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01427869	chr13:113580562	NA	0.47	6.56	0.39	3.1e-10	Survival in pancreatic cancer;
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg23736307	chr8:27182930	PTK2B	0.54	6.9	0.4	4.5e-11	Neuroticism;
KIRP	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg10047753	chr17:41438598	NA	0.83	11.21	0.58	7.65e-24	Menopause (age at onset);
KIRP	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.65	8.06	0.46	3.42e-14	Vitiligo;
KIRP	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg18904891	chr8:8559673	CLDN23	0.69	7.73	0.44	2.68e-13	Obesity-related traits;
KIRP	cis	rs62384625	0.776	rs55865281	chr5:141488807	G/A	cg08523384	chr5:141488047	NDFIP1	-0.36	-4.9	-0.3	1.74e-6	White blood cell count (basophil);
KIRP	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg02023728	chr11:77925099	USP35	-0.29	-4.89	-0.3	1.79e-6	Alzheimer's disease (survival time);
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.58	8.89	0.49	1.36e-16	Lung cancer;
KIRP	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23475963	chr7:128379258	CALU	0.58	6.68	0.39	1.54e-10	Smoking initiation;
KIRP	cis	rs78487399	0.908	rs80144434	chr2:43844640	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.09	-0.31	7.23e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg06935464	chr4:38784597	TLR10	0.52	5.2	0.31	4.1e-7	Breast cancer;
KIRP	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.98	-0.3	1.2e-6	Itch intensity from mosquito bite;
KIRP	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg25356066	chr3:128598488	ACAD9	0.48	5.52	0.33	8.42e-8	IgG glycosylation;
KIRP	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-22.18	-0.82	1.27e-60	Height;
KIRP	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg08662619	chr6:150070041	PCMT1	0.34	5.52	0.33	8.49e-8	Lung cancer;
KIRP	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Retinal vascular caliber;
KIRP	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.69	10.51	0.56	1.39e-21	Height;
KIRP	cis	rs9652601	0.959	rs12919083	chr16:11188930	G/T	cg04616529	chr16:11181986	CLEC16A	-0.38	-4.95	-0.3	1.37e-6	Systemic lupus erythematosus;
KIRP	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg21231944	chr12:82153410	PPFIA2	-0.41	-4.92	-0.3	1.6e-6	Resting heart rate;
KIRP	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.53	-7.18	-0.42	8.34e-12	Dilated cardiomyopathy;
KIRP	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.63	-6.61	-0.39	2.41e-10	Menarche (age at onset);
KIRP	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.61	0.48	9.03e-16	Motion sickness;
KIRP	trans	rs1392502	1.000	rs7200721	chr16:59790623	A/G	cg09837864	chr14:59951053	C14orf149;JKAMP	0.66	6.05	0.36	5.47e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.89	13.27	0.65	1.15e-30	Mean platelet volume;
KIRP	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg21466736	chr12:48725269	NA	-0.39	-4.9	-0.3	1.78e-6	Glycated hemoglobin levels;
KIRP	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19346786	chr7:2764209	NA	-0.4	-6.79	-0.4	8.16e-11	Height;
KIRP	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.05	-0.36	5.42e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs9329221	0.636	rs6999466	chr8:10265712	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.01	0.41	2.31e-11	Neuroticism;
KIRP	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	5.59	0.34	6.01e-8	Renal cell carcinoma;
KIRP	cis	rs7561273	0.586	rs11902756	chr2:24300932	A/G	cg20701182	chr2:24300061	SF3B14	0.5	6.02	0.36	6.21e-9	Quantitative traits;
KIRP	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.5	0.33	9.71e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12230513	0.732	rs61957765	chr12:55868561	T/C	cg11794356	chr12:55725991	OR6C3	-0.5	-6.11	-0.36	3.94e-9	Contrast sensitivity;
KIRP	cis	rs6832769	0.922	rs11133376	chr4:56253033	C/T	cg09317128	chr4:56265301	TMEM165	0.49	6.17	0.37	2.73e-9	Personality dimensions;
KIRP	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-5.3	-0.32	2.55e-7	Schizophrenia;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.57	-7.65	-0.44	4.4e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs11252926	0.673	rs553326	chr10:749238	G/T	cg03684893	chr10:554711	DIP2C	0.39	5.81	0.35	1.97e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs7756236	0.521	rs9470363	chr6:36624713	G/A	cg08179530	chr6:36648295	CDKN1A	0.44	5.73	0.34	2.99e-8	QRS duration;
KIRP	cis	rs7572644	0.665	rs4665393	chr2:28040276	G/A	cg27432699	chr2:27873401	GPN1	0.48	5.49	0.33	1.01e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg18944383	chr4:111397179	ENPEP	0.51	8.45	0.47	2.58e-15	Coronary artery disease;
KIRP	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg05315796	chr3:52349193	DNAH1	-0.47	-7.22	-0.42	6.36e-12	Electroencephalogram traits;
KIRP	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.44	0.43	1.68e-12	Body mass index;
KIRP	cis	rs988913	0.678	rs4490665	chr6:54990817	C/T	cg03513858	chr6:54763001	FAM83B	-0.36	-4.99	-0.3	1.13e-6	Menarche (age at onset);
KIRP	cis	rs73206853	0.764	rs7966591	chr12:110644045	G/A	cg12870014	chr12:110450643	ANKRD13A	0.54	5.69	0.34	3.61e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.4	4.97	0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.31e-34	Breast cancer;
KIRP	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11987759	chr7:65425863	GUSB	-0.54	-7.14	-0.41	1.04e-11	Aortic root size;
KIRP	cis	rs9535307	0.719	rs1570353	chr13:50385967	G/T	cg04663916	chr13:50265991	EBPL	-0.58	-6.2	-0.37	2.38e-9	Obesity-related traits;
KIRP	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg25930673	chr12:123319894	HIP1R	0.68	6.08	0.36	4.66e-9	Schizophrenia;
KIRP	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.59	6.63	0.39	2.1e-10	Aortic root size;
KIRP	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg06640241	chr16:89574553	SPG7	-0.51	-6.23	-0.37	2.04e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs7113874	1.000	rs4256980	chr11:8673939	C/G	cg08015107	chr11:8618950	NA	0.35	4.93	0.3	1.54e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06544989	chr22:39130855	UNC84B	0.51	9.04	0.5	4.65e-17	Menopause (age at onset);
KIRP	cis	rs4789452	1.000	rs7216382	chr17:75374578	T/C	cg05184938	chr17:75369939	SEPT9	-0.36	-4.88	-0.3	1.9e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2411233	0.967	rs11070167	chr15:39288601	A/C	cg05886626	chr15:39873553	THBS1	0.34	5.19	0.31	4.3e-7	Platelet count;
KIRP	cis	rs952623	0.649	rs6952464	chr7:39076327	C/T	cg20302533	chr7:39170763	POU6F2	0.23	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs78487399	0.634	rs6751035	chr2:43752407	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.12	-0.31	6.19e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.84	-15.01	-0.69	1.36e-36	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg24644049	chr4:85504048	CDS1	1.08	6.94	0.4	3.39e-11	Skin colour saturation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02396668	chr19:50528878	VRK3;ZNF473	0.63	7.53	0.43	9.49e-13	Smoking initiation;
KIRP	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg16141378	chr3:129829833	LOC729375	-0.55	-7.26	-0.42	5.01e-12	Systemic lupus erythematosus;
KIRP	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-7.15	-0.42	9.6e-12	Daytime sleep phenotypes;
KIRP	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg07636037	chr3:49044803	WDR6	-0.77	-7.38	-0.43	2.48e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7007076	0.570	rs2116353	chr8:124750228	A/G	cg00283535	chr8:124749564	ANXA13	0.81	11.09	0.58	1.95e-23	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.39	4.98	0.3	1.21e-6	Blood protein levels;
KIRP	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	cg07049167	chr1:166818506	POGK	0.63	7.04	0.41	1.86e-11	Refractive astigmatism;
KIRP	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.71	9.4	0.51	4.03e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg13206674	chr6:150067644	NUP43	0.51	7.23	0.42	6.04e-12	Testicular germ cell tumor;
KIRP	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.39	-0.43	2.22e-12	Type 2 diabetes;
KIRP	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26314531	chr2:26401878	FAM59B	-0.48	-5.07	-0.31	7.87e-7	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg00933542	chr6:150070202	PCMT1	0.31	6.03	0.36	5.83e-9	Lung cancer;
KIRP	cis	rs1891498	0.571	rs11240122	chr1:147235547	T/A	cg27546670	chr1:147246839	GJA5	-0.76	-10.18	-0.54	1.54e-20	Cognitive performance;
KIRP	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-8.21	-0.46	1.27e-14	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg13319975	chr6:146136371	FBXO30	0.46	6.17	0.37	2.78e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg23307798	chr14:103986281	CKB	-0.46	-6.25	-0.37	1.81e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.42	-4.94	-0.3	1.43e-6	Longevity;Endometriosis;
KIRP	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17376030	chr22:41985996	PMM1	0.5	5.79	0.35	2.11e-8	Vitiligo;
KIRP	cis	rs4656940	0.574	rs4656931	chr1:160775632	G/A	cg17331569	chr1:160788135	LY9	-0.42	-4.93	-0.3	1.54e-6	Crohn's disease;
KIRP	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-5.73	-0.34	2.95e-8	Blood metabolite levels;
KIRP	cis	rs7246865	0.510	rs1130222	chr19:17170885	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.5	6.3	0.37	1.37e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.65	-0.34	4.43e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.61	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.7	-10.57	-0.56	9.05e-22	Idiopathic membranous nephropathy;
KIRP	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.76	-9.7	-0.53	4.94e-19	Neutrophil percentage of white cells;
KIRP	cis	rs735539	0.521	rs1348370	chr13:21404658	A/C	cg04906043	chr13:21280425	IL17D	-0.45	-5.4	-0.33	1.55e-7	Dental caries;
KIRP	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.63	-6.57	-0.39	3.02e-10	Gut microbiome composition (summer);
KIRP	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.25	-5.13	-0.31	5.85e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs7520050	0.931	rs11211198	chr1:46282673	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.53e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg19847130	chr8:10466454	RP1L1	0.38	5.74	0.34	2.71e-8	Retinal vascular caliber;
KIRP	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4765905	0.609	rs2239027	chr12:2312301	A/C	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.51e-11	Schizophrenia;
KIRP	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg04080417	chr5:1859792	NA	-0.47	-4.97	-0.3	1.26e-6	Cardiovascular disease risk factors;
KIRP	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.69	-6.4	-0.38	7.65e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.57	7.54	0.43	9.07e-13	HDL cholesterol;
KIRP	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.65	5.21	0.32	3.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg04156418	chr7:157293606	NA	0.38	5.31	0.32	2.45e-7	Inattentive symptoms;
KIRP	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg21775007	chr8:11205619	TDH	-0.52	-6.91	-0.4	4.03e-11	Neuroticism;
KIRP	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.2	-0.31	4.14e-7	Pulmonary function;
KIRP	cis	rs7246657	0.508	rs1628959	chr19:37490376	G/A	cg23950597	chr19:37808831	NA	-0.6	-5.04	-0.31	9.2e-7	Coronary artery calcification;
KIRP	cis	rs6838801	0.789	rs12640320	chr4:77531337	C/A	cg17476223	chr4:77663285	SHROOM3	0.5	6.28	0.37	1.55e-9	Cleft lip with or without cleft palate;
KIRP	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.71	-10.45	-0.55	2.11e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05472934	chr7:22766657	IL6	0.81	10.34	0.55	4.95e-21	Lung cancer;
KIRP	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg20243544	chr17:37824526	PNMT	0.5	6.72	0.39	1.26e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg21775007	chr8:11205619	TDH	-0.38	-4.98	-0.3	1.18e-6	Morning vs. evening chronotype;
KIRP	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg15436174	chr10:43711423	RASGEF1A	0.86	9.43	0.52	3.15e-18	Hirschsprung disease;
KIRP	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg11608241	chr8:8085544	FLJ10661	-0.56	-7.13	-0.41	1.14e-11	Neuroticism;
KIRP	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.99	14.26	0.67	4.95e-34	Height;
KIRP	cis	rs4671458	0.948	rs72813476	chr2:63523174	T/C	cg17519650	chr2:63277830	OTX1	-0.53	-5.38	-0.32	1.74e-7	Subjective well-being;
KIRP	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.55	0.65	1.31e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.89	-0.45	9.74e-14	Retinal vascular caliber;
KIRP	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg26084005	chr2:241760190	KIF1A	-0.48	-5.92	-0.35	1.1e-8	Urinary metabolites;
KIRP	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	1.05	9.16	0.5	2.13e-17	Fat distribution (HIV);
KIRP	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.58	6.78	0.4	8.67e-11	Corneal astigmatism;
KIRP	trans	rs10782582	0.758	rs5745546	chr1:76378038	G/A	cg10283277	chr11:111472630	SIK2	-0.32	-6.3	-0.37	1.36e-9	Daytime sleep phenotypes;
KIRP	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-4.97	-0.3	1.24e-6	Fear of minor pain;
KIRP	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.72	7.67	0.44	4.08e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1448094	0.935	rs10746355	chr12:86330227	A/T	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.96e-7	Major depressive disorder;
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	1.04	11.27	0.58	4.88e-24	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19483861	chr19:7504512	ARHGEF18	-0.47	-6.17	-0.37	2.73e-9	Parkinson's disease;
KIRP	cis	rs13361707	0.685	rs10065570	chr5:40835627	C/T	cg01087697	chr5:40835557	RPL37	-0.42	-5.22	-0.32	3.78e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.65	-10.94	-0.57	5.82e-23	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-15.04	-0.69	1.09e-36	Electrocardiographic conduction measures;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14135272	chr6:166799902	NA	-0.45	-6.15	-0.37	3.08e-9	Inflammatory biomarkers;
KIRP	cis	rs8018808	0.936	rs10140302	chr14:77855693	C/A	cg20045696	chr14:77926864	AHSA1	-0.41	-5.11	-0.31	6.62e-7	Myeloid white cell count;
KIRP	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.34	0.42	3.03e-12	Bipolar disorder;
KIRP	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.75	-9.11	-0.5	2.91e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg00852783	chr1:26633632	UBXN11	0.54	7.52	0.43	1.02e-12	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs2120243	0.533	rs1500921	chr3:157055427	C/T	cg24825693	chr3:157122686	VEPH1	-0.37	-5.66	-0.34	4.11e-8	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.4	-5.15	-0.31	5.25e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.62	-0.66	7.24e-32	Height;
KIRP	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.67	8.95	0.5	8.9e-17	Schizophrenia;
KIRP	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-8.45	-0.47	2.62e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg06815112	chr8:27182871	PTK2B	0.53	6.89	0.4	4.73e-11	Neuroticism;
KIRP	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.69	8.56	0.48	1.24e-15	Multiple sclerosis;
KIRP	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.62	8.28	0.47	8.01e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs56313388	0.793	rs9937815	chr16:56330832	C/T	cg02433656	chr16:56322654	GNAO1	-0.46	-5.53	-0.33	8.36e-8	Pulse pressure;
KIRP	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg24633833	chr3:10029261	TMEM111	0.52	5.33	0.32	2.24e-7	Alzheimer's disease;
KIRP	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.78	-8.37	-0.47	4.24e-15	Coronary artery disease;
KIRP	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg21573476	chr21:45109991	RRP1B	-0.54	-7.31	-0.42	3.76e-12	Mean corpuscular volume;
KIRP	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.47	6.61	0.39	2.37e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs12143943	0.866	rs4252745	chr1:204519187	C/G	cg20240347	chr1:204465584	NA	0.35	6.57	0.39	2.98e-10	Cognitive performance;
KIRP	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.85	0.3	2.14e-6	Menopause (age at onset);
KIRP	cis	rs7721647	0.853	rs1120946	chr5:90859257	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.12	0.31	6.21e-7	Breast cancer;
KIRP	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.65	-6.05	-0.36	5.37e-9	Yeast infection;
KIRP	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg02367723	chr1:46378857	MAST2	0.42	4.86	0.3	2.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	cg12689670	chr1:183009347	LAMC1	0.58	7.96	0.45	6.32e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg18306943	chr3:40428807	ENTPD3	0.36	4.97	0.3	1.23e-6	Renal cell carcinoma;
KIRP	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg00360474	chr6:37504404	NA	-0.36	-4.86	-0.3	2.08e-6	Cognitive performance;
KIRP	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.99	-0.5	6.91e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	9.06	0.5	4.1e-17	Motion sickness;
KIRP	cis	rs12318506	0.623	rs12313311	chr12:75768327	A/T	cg04728562	chr12:75699417	CAPS2	-1.29	-9.04	-0.5	4.78e-17	Coronary artery calcification;
KIRP	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.8	10.95	0.57	5.31e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2591576	0.554	rs11134405	chr5:165433311	A/T	cg13976338	chr5:165423657	NA	-0.8	-12.66	-0.63	1.26e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs4148660	1.000	rs4148656	chr12:22063337	A/G	cg14669847	chr12:22099120	NA	0.36	6.07	0.36	4.69e-9	Gout;
KIRP	trans	rs12049351	0.665	rs1838464	chr1:229616693	T/C	cg00551153	chr21:47333731	PCBP3	-0.49	-6.02	-0.36	6.2e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	0.83	5.85	0.35	1.53e-8	IgG glycosylation;
KIRP	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-16.32	-0.72	4.43e-41	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.61	-7.69	-0.44	3.48e-13	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6546324	0.625	rs6746394	chr2:67845021	A/C	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.84e-13	Endometriosis;
KIRP	cis	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg21546286	chr11:48923668	NA	-0.46	-5.77	-0.35	2.41e-8	HDL cholesterol;
KIRP	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg22437258	chr11:111473054	SIK2	0.48	5.99	0.36	7.38e-9	Primary sclerosing cholangitis;
KIRP	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.6	7.74	0.44	2.52e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg03808351	chr9:123631620	PHF19	0.43	5.92	0.35	1.07e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs737693	0.920	rs17368814	chr11:102748695	C/T	cg19620758	chr11:102826565	MMP13	-0.66	-5.17	-0.31	4.81e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg07511934	chr16:89386912	ANKRD11	0.4	5.11	0.31	6.6e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs4332428	0.730	rs12777893	chr10:4960320	C/G	cg19648686	chr10:5044992	AKR1C2	-0.68	-5.73	-0.34	2.9e-8	Height;
KIRP	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.81	9.2	0.51	1.54e-17	Iron status biomarkers;
KIRP	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.51	0.43	1.07e-12	Body mass index;
KIRP	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7246657	0.551	rs10404069	chr19:37638404	C/T	cg23950597	chr19:37808831	NA	-0.58	-5.31	-0.32	2.44e-7	Coronary artery calcification;
KIRP	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg22437258	chr11:111473054	SIK2	0.63	7.68	0.44	3.81e-13	Primary sclerosing cholangitis;
KIRP	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.47	-0.38	5.27e-10	LDL cholesterol levels;
KIRP	cis	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg21775007	chr8:11205619	TDH	0.4	5.25	0.32	3.37e-7	Monocyte count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14329045	chr2:106694419	C2orf40	0.54	7.32	0.42	3.47e-12	Interleukin-4 levels;
KIRP	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-6.97	-0.41	2.86e-11	Schizophrenia;
KIRP	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.7	0.53	4.62e-19	Corneal astigmatism;
KIRP	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.16	-0.46	1.68e-14	Mood instability;
KIRP	cis	rs4886920	0.894	rs4886932	chr15:78131097	A/G	cg10461261	chr15:78109450	NA	-0.31	-5.09	-0.31	7.2e-7	Neuroticism;
KIRP	cis	rs155346	1.000	rs2560711	chr5:139394941	T/C	cg01090482	chr5:139365336	NRG2	-0.43	-5.29	-0.32	2.7e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg07511668	chr11:68622177	NA	0.39	5.15	0.31	5.38e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6594713	0.643	rs10077431	chr5:112927686	A/C	cg12552261	chr5:112820674	MCC	-0.54	-5.37	-0.32	1.81e-7	Brain cytoarchitecture;
KIRP	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.96	12.93	0.64	1.57e-29	Breast cancer;
KIRP	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg08648136	chr8:956695	NA	0.53	7.6	0.44	6.06e-13	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	8.5	0.48	1.8e-15	Motion sickness;
KIRP	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.07	0.41	1.6e-11	Aortic root size;
KIRP	cis	rs6580649	0.883	rs4075913	chr12:48537624	A/G	cg26205652	chr12:48591994	NA	0.5	5.9	0.35	1.21e-8	Lung cancer;
KIRP	cis	rs10940138	0.830	rs62369638	chr5:67235576	C/G	ch.5.1281357F	chr5:67228439	NA	0.74	10.58	0.56	8.25e-22	Menarche (age at onset);
KIRP	cis	rs6743068	0.541	rs1966423	chr2:202216661	G/C	cg06431681	chr2:202330990	STRADB	0.37	5.03	0.31	9.41e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs10875746	0.669	rs2279464	chr12:48690409	C/T	cg26205652	chr12:48591994	NA	0.81	10.5	0.56	1.49e-21	Longevity (90 years and older);
KIRP	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg12315302	chr6:26189340	HIST1H4D	-0.78	-5.34	-0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg04025307	chr7:1156635	C7orf50	0.74	7.73	0.44	2.73e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3925075	0.531	rs4597342	chr16:31343769	T/C	cg02846316	chr16:31340340	ITGAM	0.46	5.55	0.33	7.5e-8	IgA nephropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13780902	chr11:47869975	NUP160	0.52	6.33	0.37	1.17e-9	Parkinson's disease;
KIRP	cis	rs9603616	0.719	rs4432137	chr13:40245500	G/A	cg26701198	chr13:40229707	COG6	0.44	5.18	0.31	4.57e-7	Rheumatoid arthritis;
KIRP	trans	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg03929089	chr4:120376271	NA	0.89	6.47	0.38	5.16e-10	Axial length;
KIRP	cis	rs1943345	0.556	rs553484	chr11:82921538	C/T	cg07047830	chr11:82868014	PCF11	0.45	5.19	0.31	4.5e-7	Obesity-related traits;
KIRP	cis	rs7172677	0.737	rs8029760	chr15:75435840	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg23698023	chr8:27181813	PTK2B	-0.35	-5.27	-0.32	3.05e-7	Neuroticism;
KIRP	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.31	-5.54	-0.33	7.87e-8	Renal cell carcinoma;
KIRP	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg17507749	chr15:85114479	UBE2QP1	0.86	9.0	0.5	6.46e-17	Schizophrenia;
KIRP	cis	rs4908768	0.911	rs79769442	chr1:8658477	C/T	cg25722041	chr1:8623473	RERE	0.81	9.63	0.52	7.84e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg16141378	chr3:129829833	LOC729375	0.57	7.28	0.42	4.37e-12	Joint mobility (Beighton score);
KIRP	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg15655495	chr12:38532458	NA	0.27	5.0	0.3	1.08e-6	Bladder cancer;
KIRP	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.38	0.43	2.43e-12	Neuroticism;
KIRP	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg10935138	chr17:73851978	WBP2	0.48	5.76	0.34	2.45e-8	White matter hyperintensity burden;
KIRP	cis	rs830383	0.584	rs31769	chr5:165496487	T/C	cg13976338	chr5:165423657	NA	0.6	7.51	0.43	1.08e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs2688608	0.933	rs2688614	chr10:75652876	G/A	cg23231163	chr10:75533350	FUT11	-0.33	-4.95	-0.3	1.41e-6	Inflammatory bowel disease;
KIRP	cis	rs3752645	1.000	rs7786692	chr7:106730033	A/C	cg02696742	chr7:106810147	HBP1	-0.59	-5.07	-0.31	7.65e-7	Bladder cancer (smoking interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27425459	chr2:105697589	MRPS9	0.42	6.08	0.36	4.64e-9	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.38	0.38	8.5e-10	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04080353	chr10:126849780	CTBP2	0.54	6.5	0.38	4.52e-10	Parkinson's disease;
KIRP	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.83	8.39	0.47	3.81e-15	Gastritis;
KIRP	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.65	7.03	0.41	2.07e-11	Gut microbiome composition (summer);
KIRP	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg10504392	chr12:110044639	NA	0.25	5.03	0.31	9.48e-7	Neuroticism;
KIRP	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	0.64	5.75	0.34	2.59e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18084215	chr5:125936716	PHAX	-0.49	-6.29	-0.37	1.45e-9	Myopia;
KIRP	cis	rs1538970	0.884	rs61788261	chr1:45899114	G/A	cg05343316	chr1:45956843	TESK2	0.71	8.03	0.46	4.02e-14	Platelet count;
KIRP	cis	rs3736485	0.932	rs2278989	chr15:51914716	T/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.16	-0.31	5.12e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4262150	0.883	rs4394168	chr5:152264172	T/C	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.93e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg11031976	chr2:198649780	BOLL	-0.52	-5.01	-0.3	1.05e-6	Ulcerative colitis;
KIRP	cis	rs300890	0.698	rs3828512	chr4:144316760	A/G	cg19876092	chr4:144208277	NA	-0.31	-4.98	-0.3	1.18e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.62	-6.71	-0.39	1.3100000000000001e-10	DNA methylation (variation);
KIRP	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	cis	rs4345220	0.585	rs4861124	chr4:41642889	A/G	cg15232654	chr4:41643107	LIMCH1	0.45	5.92	0.35	1.08e-8	Migraine with aura;
KIRP	cis	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg00405596	chr8:11794950	NA	0.56	7.85	0.45	1.25e-13	Monocyte count;
KIRP	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-7.16	-0.42	9.06e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13161895	0.702	rs74507840	chr5:179487430	G/A	cg02702477	chr5:179499311	RNF130	1.09	7.09	0.41	1.38e-11	LDL cholesterol;
KIRP	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.42	8.13	0.46	2.08e-14	Height;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg04025307	chr7:1156635	C7orf50	0.81	8.34	0.47	5.5e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12823128	0.967	rs12579808	chr12:26867000	T/C	cg14081884	chr12:26986758	ITPR2	0.39	4.87	0.3	2e-6	Birth weight;
KIRP	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.5	7.29	0.42	4.31e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.06	0.36	5.19e-9	Total cholesterol levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03485262	chr14:92980031	RIN3	0.43	6.48	0.38	5.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs12043259	0.730	rs59672465	chr1:204809325	A/G	cg11485465	chr5:54518469	NA	0.35	6.17	0.37	2.72e-9	Addiction;
KIRP	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.71	7.79	0.44	1.85e-13	Corneal astigmatism;
KIRP	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.22	-0.37	2.12e-9	Aortic root size;
KIRP	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg19770292	chr5:1868693	NA	0.46	5.38	0.32	1.69e-7	Cardiovascular disease risk factors;
KIRP	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg08761264	chr16:28874980	SH2B1	-0.48	-5.56	-0.33	7.17e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg04780086	chr2:111875790	ACOXL	0.42	5.83	0.35	1.73e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs4938534	0.614	rs11213871	chr11:111261112	G/A	cg11362935	chr11:111250201	POU2AF1	0.3	4.87	0.3	2e-6	Primary biliary cholangitis;
KIRP	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg10047753	chr17:41438598	NA	1.14	17.79	0.75	4.34e-46	Menopause (age at onset);
KIRP	cis	rs6921919	0.583	rs7740351	chr6:28399412	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.37	-0.38	9e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.66	7.6	0.44	6.35e-13	Gut microbiome composition (summer);
KIRP	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.57	-6.55	-0.39	3.26e-10	Pubertal anthropometrics;
KIRP	cis	rs2671245	0.933	rs2671239	chr1:56153246	A/G	cg11523071	chr1:56160889	NA	0.42	6.8	0.4	7.74e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1941687	0.672	rs1026257	chr18:31418131	C/T	cg27147174	chr7:100797783	AP1S1	0.5	6.12	0.36	3.65e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.68	-5.84	-0.35	1.65e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs933360	0.585	rs2074721	chr7:50834583	A/T	cg14240098	chr7:50518052	FIGNL1	0.43	4.92	0.3	1.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9596863	0.847	rs4537884	chr13:54327936	A/G	ch.13.53330881F	chr13:54432880	NA	0.6	5.81	0.35	1.88e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs12780845	0.522	rs17464824	chr10:17210822	A/C	cg01003015	chr10:17271136	VIM	-0.5	-6.46	-0.38	5.45e-10	Homocysteine levels;
KIRP	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.11	-0.46	2.36e-14	Morning vs. evening chronotype;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg03667488	chr10:89733191	NA	0.38	6.03	0.36	5.96e-9	Migraine with aura;
KIRP	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg01950434	chr2:97203154	ARID5A	-0.49	-6.27	-0.37	1.61e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.85	-0.4	6e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.51	-5.51	-0.33	9.09e-8	Total body bone mineral density;
KIRP	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.75	7.51	0.43	1.11e-12	Migraine;Coronary artery disease;
KIRP	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg22875332	chr1:76189707	ACADM	-0.34	-4.99	-0.3	1.16e-6	Daytime sleep phenotypes;
KIRP	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg18225595	chr11:63971243	STIP1	0.65	5.98	0.36	7.85e-9	Mean platelet volume;
KIRP	cis	rs9715521	0.775	rs62301191	chr4:59842587	T/G	cg11281224	chr4:60001000	NA	-0.46	-5.53	-0.33	8.11e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08805041	chr16:621841	PIGQ	-0.38	-5.3	-0.32	2.62e-7	Height;
KIRP	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg24315340	chr6:146058215	EPM2A	-0.4	-4.89	-0.3	1.86e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg23565292	chr14:50234668	KLHDC2	-0.45	-5.36	-0.32	1.87e-7	Carotid intima media thickness;
KIRP	cis	rs17641971	0.684	rs6984804	chr8:49987910	G/A	cg00325661	chr8:49890786	NA	0.44	5.8	0.35	2.04e-8	Blood metabolite levels;
KIRP	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23750338	chr8:142222470	SLC45A4	0.51	6.94	0.4	3.55e-11	Immature fraction of reticulocytes;
KIRP	cis	rs4006360	0.546	rs1846043	chr17:39265300	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.47	-6.32	-0.37	1.22e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg16578609	chr1:2399051	NA	-0.46	-6.05	-0.36	5.38e-9	Non-obstructive azoospermia;
KIRP	cis	rs1850744	0.536	rs2037313	chr4:9724711	T/C	cg15442990	chr4:9534313	NA	0.84	5.74	0.34	2.76e-8	Economic and political preferences;
KIRP	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.65	-0.34	4.36e-8	Morning vs. evening chronotype;
KIRP	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg25588787	chr5:154027256	NA	-0.39	-4.89	-0.3	1.78e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg08890418	chr1:21044141	KIF17	0.33	4.87	0.3	2.02e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	1.04	19.55	0.78	5.19e-52	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.71	-11.09	-0.58	1.92e-23	Hepatocellular carcinoma;
KIRP	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.95	-0.54	8.28e-20	Mood instability;
KIRP	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.79	-0.49	2.64e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.5	7.05	0.41	1.78e-11	Obesity-related traits;
KIRP	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg04310649	chr10:35416472	CREM	-0.51	-5.82	-0.35	1.82e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg18944383	chr4:111397179	ENPEP	-0.43	-7.05	-0.41	1.82e-11	Coronary artery disease;
KIRP	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.68	9.39	0.51	4.29e-18	Mood instability;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09133386	chr6:20404188	E2F3	0.5	6.07	0.36	4.79e-9	Smoking initiation;
KIRP	cis	rs6997458	0.785	rs1389245	chr8:86352388	C/T	cg02393479	chr8:86352350	CA3	0.31	4.89	0.3	1.79e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs2737618	0.722	rs2816978	chr1:200078773	A/G	cg21825944	chr1:200113062	NR5A2	-0.52	-7.3	-0.42	3.91e-12	Uric acid levels;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.76e-8	Life satisfaction;
KIRP	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.82	0.35	1.78e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.42	-0.51	3.36e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg02696790	chr15:75250997	RPP25	-0.31	-5.55	-0.33	7.28e-8	Breast cancer;
KIRP	trans	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17712092	chr4:129076599	LARP1B	0.9	13.23	0.64	1.51e-30	Eosinophil percentage of white cells;
KIRP	cis	rs4563143	0.647	rs61378972	chr19:29218742	C/T	cg14983838	chr19:29218262	NA	0.88	8.75	0.49	3.55e-16	Methadone dose in opioid dependence;
KIRP	cis	rs6545883	0.524	rs12992614	chr2:61593076	C/T	cg15711740	chr2:61764176	XPO1	0.46	5.53	0.33	8.22e-8	Tuberculosis;
KIRP	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	0.82	12.72	0.63	7.93e-29	Breast cancer;
KIRP	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.46	-0.43	1.52e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg08501292	chr6:25962987	TRIM38	1.09	6.47	0.38	5.37e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.67	9.99	0.54	6.2e-20	Retinal vascular caliber;
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.57	7.71	0.44	3.17e-13	Testicular germ cell tumor;
KIRP	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg05082376	chr22:42548792	NA	0.45	5.61	0.34	5.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg19554555	chr3:13937349	NA	-0.46	-6.2	-0.37	2.42e-9	Ovarian reserve;
KIRP	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-5.49	-0.33	1.02e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.48	7.43	0.43	1.84e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg17077180	chr1:38461687	NA	-0.44	-5.93	-0.35	1.01e-8	Coronary artery disease;
KIRP	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg19847130	chr8:10466454	RP1L1	0.39	5.96	0.36	8.71e-9	Retinal vascular caliber;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19853194	chr18:9913725	VAPA	0.69	6.45	0.38	5.94e-10	Lung function (FEV1);
KIRP	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg00086871	chr4:6988644	TBC1D14	0.77	6.63	0.39	2.15e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6681460	0.966	rs4655506	chr1:67150811	C/T	cg02459107	chr1:67143332	SGIP1	0.51	7.13	0.41	1.14e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	0.74	10.75	0.57	2.38e-22	Prudent dietary pattern;
KIRP	cis	rs10824796	0.953	rs2384046	chr10:54535840	T/G	cg27418851	chr10:54531653	MBL2	0.46	5.29	0.32	2.69e-7	Blood protein levels;
KIRP	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.81	-9.16	-0.5	2.12e-17	Blood pressure (smoking interaction);
KIRP	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.54	8.64	0.48	7.37e-16	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15475546	chr14:50329613	NA	0.48	6.5	0.38	4.52e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.72e-11	Aortic root size;
KIRP	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg18032289	chr17:61959525	GH2	-0.38	-4.95	-0.3	1.4e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	0.84	7.49	0.43	1.21e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg09597638	chr17:3907349	NA	0.82	16.53	0.73	9e-42	Type 2 diabetes;
KIRP	cis	rs494562	1.000	rs527670	chr6:86115779	T/C	cg27039625	chr6:86159096	NT5E	0.42	5.31	0.32	2.45e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.97	-0.36	8.23e-9	Renal cell carcinoma;
KIRP	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg20243544	chr17:37824526	PNMT	0.51	7.29	0.42	4.32e-12	Asthma;
KIRP	cis	rs4786125	0.622	rs1492372	chr16:6920965	C/T	cg03623568	chr16:6915990	A2BP1	-0.41	-4.99	-0.3	1.16e-6	Heart rate variability traits (SDNN);
KIRP	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.61	9.33	0.51	6.65e-18	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.63	9.48	0.52	2.23e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.6	-9.34	-0.51	6.1e-18	Coronary artery disease;
KIRP	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-1.03	-16.6	-0.73	5.02e-42	Coronary artery disease;
KIRP	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg21851534	chr17:3907994	ZZEF1	0.5	5.24	0.32	3.42e-7	Type 2 diabetes;
KIRP	cis	rs61332075	0.504	rs7596847	chr2:239321118	T/A	cg18131467	chr2:239335373	ASB1	-0.63	-6.31	-0.37	1.32e-9	Lung function (FEV1/FVC);
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.83	-16.34	-0.72	3.95e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	trans	rs55728055	0.661	rs5753700	chr22:31971258	C/T	cg02791973	chr19:1132256	SBNO2	-0.57	-6.13	-0.36	3.39e-9	Age-related hearing impairment;
KIRP	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.65	-7.61	-0.44	5.8e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6467136	0.715	rs10231675	chr7:127162706	T/G	cg23081781	chr7:127225937	GCC1	-0.38	-5.14	-0.31	5.66e-7	Type 2 diabetes;
KIRP	cis	rs829661	0.793	rs1869424	chr2:30834985	A/G	cg10949345	chr2:30726833	LCLAT1	-1.02	-12.81	-0.63	4.1e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.73	9.32	0.51	7.11e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.64	-9.82	-0.53	1.99e-19	Educational attainment;
KIRP	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg07451762	chr16:28383216	NA	0.38	5.01	0.3	1.05e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg08126542	chr6:37504118	NA	-0.87	-13.58	-0.65	1.04e-31	Cognitive performance;
KIRP	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-6.9	-0.4	4.45e-11	Prudent dietary pattern;
KIRP	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg10223061	chr2:219282414	VIL1	-0.4	-6.37	-0.38	9.28e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.6	-7.43	-0.43	1.83e-12	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00320159	chr20:48429251	SLC9A8	0.52	6.83	0.4	6.5e-11	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14332112	chr6:47277683	TNFRSF21	0.49	6.02	0.36	6.37e-9	Parkinson's disease;
KIRP	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg20965017	chr5:231967	SDHA	-0.56	-6.56	-0.39	3.23e-10	Breast cancer;
KIRP	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg23202291	chr11:1979235	NA	0.43	5.42	0.33	1.41e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.6	8.26	0.47	9.09e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.87	-8.4	-0.47	3.65e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg01988459	chr11:68622903	NA	-0.39	-5.18	-0.31	4.72e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg06740227	chr12:86229804	RASSF9	-0.44	-5.78	-0.35	2.2e-8	Major depressive disorder;
KIRP	cis	rs12210905	1.000	rs72843607	chr6:27110715	C/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg07775547	chr4:1625484	NA	-0.44	-5.29	-0.32	2.67e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.58	0.39	2.78e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs60311166	1.000	rs17052357	chr3:52668638	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.98	6.91	0.4	4.18e-11	CTACK levels;
KIRP	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.93	-14.8	-0.69	6.99e-36	Height;
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg11814155	chr7:99998594	ZCWPW1	0.62	5.61	0.34	5.54e-8	Platelet count;
KIRP	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.96	12.94	0.64	1.45e-29	Menopause (age at onset);
KIRP	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	6.14	0.36	3.26e-9	Response to antipsychotic treatment;
KIRP	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.42	5.7	0.34	3.45e-8	Bipolar disorder;
KIRP	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.67	-10.14	-0.54	2.1e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.54	7.23	0.42	6.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13065560	0.594	rs4234134	chr3:38887970	A/T	cg01426195	chr3:39028469	NA	0.46	7.46	0.43	1.49e-12	Interleukin-18 levels;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg27532560	chr4:187881888	NA	-0.73	-12.12	-0.61	7.87e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.49	5.22	0.32	3.87e-7	Alzheimer's disease;
KIRP	cis	rs1816752	0.792	rs7330956	chr13:24987312	A/G	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20887711	chr4:1340912	KIAA1530	0.5	6.41	0.38	7.37e-10	Obesity-related traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04834749	chr20:43594950	STK4	0.57	6.59	0.39	2.61e-10	Smoking initiation;
KIRP	cis	rs11676855	0.893	rs6721399	chr2:235936607	A/G	cg14917874	chr2:235941519	SH3BP4	0.45	5.5	0.33	9.31e-8	Dialysis-related mortality;
KIRP	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	10.49	0.56	1.66e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	1.03	13.23	0.64	1.55e-30	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11954110	chr11:113644656	ZW10	-0.48	-6.11	-0.36	3.92e-9	Interleukin-4 levels;
KIRP	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	trans	rs587242	1.000	rs661573	chr1:96891371	G/A	cg10631902	chr5:14652156	NA	0.53	6.14	0.36	3.21e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs12311304	0.965	rs11056400	chr12:15365558	A/G	cg08258403	chr12:15378311	NA	-0.33	-4.89	-0.3	1.8e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg10223061	chr2:219282414	VIL1	0.53	7.9	0.45	9.23e-14	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.16	-0.37	2.94e-9	Total cholesterol levels;
KIRP	cis	rs7737355	0.812	rs10515455	chr5:130878789	C/T	cg06307176	chr5:131281290	NA	0.42	5.03	0.31	9.64e-7	Life satisfaction;
KIRP	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg25036284	chr2:26402008	FAM59B	-0.47	-4.98	-0.3	1.19e-6	Gut microbiome composition (summer);
KIRP	cis	rs6681460	0.649	rs1338184	chr1:67005072	C/T	cg13052034	chr1:66999238	SGIP1	-0.42	-5.95	-0.35	9.12e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg02503808	chr4:7069936	GRPEL1	0.93	12.63	0.63	1.59e-28	Monocyte percentage of white cells;
KIRP	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	1.04	20.51	0.79	3.57e-55	Parkinson's disease;
KIRP	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg24324837	chr19:49891574	CCDC155	0.66	8.64	0.48	7.21e-16	Multiple sclerosis;
KIRP	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.69	-9.2	-0.51	1.63e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.54	-5.98	-0.36	8e-9	Vitiligo;
KIRP	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.38	5.02	0.3	9.83e-7	Type 2 diabetes;
KIRP	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.73	10.44	0.55	2.38e-21	Body mass index;
KIRP	cis	rs7246657	0.722	rs2287229	chr19:38188652	G/A	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg00262122	chr8:11665843	FDFT1	0.42	5.14	0.31	5.52e-7	Retinal vascular caliber;
KIRP	cis	rs76533333	0.527	rs34310808	chr13:113422178	G/A	cg04656015	chr13:113407548	ATP11A	0.64	5.72	0.34	3.12e-8	Red cell distribution width;
KIRP	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg05555928	chr11:63887634	MACROD1	0.48	5.28	0.32	2.83e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg20673091	chr1:2541236	MMEL1	0.63	8.96	0.5	8.31e-17	Ulcerative colitis;
KIRP	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.57	6.91	0.4	4.06e-11	Aortic root size;
KIRP	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg24315340	chr6:146058215	EPM2A	-0.37	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.46	7.8	0.45	1.82e-13	Testicular germ cell tumor;
KIRP	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.71	8.02	0.46	4.27e-14	Corneal astigmatism;
KIRP	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg22633769	chr20:60982531	CABLES2	-0.46	-5.91	-0.35	1.13e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.5	-6.83	-0.4	6.46e-11	Obesity-related traits;
KIRP	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.37	-0.47	4.35e-15	Neuroticism;
KIRP	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.77	-0.44	2.15e-13	Mood instability;
KIRP	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.86	8.8	0.49	2.49e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.06	0.36	5.18e-9	Height;
KIRP	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.87	-11.18	-0.58	1.01e-23	Parkinson's disease;
KIRP	cis	rs4794202	0.700	rs11079797	chr17:45912302	C/T	cg10638573	chr17:45915098	SCRN2	0.42	5.33	0.32	2.24e-7	Alzheimer's disease (cognitive decline);
KIRP	cis	rs12995491	1.000	rs12995491	chr2:88527414	C/T	cg04511125	chr2:88470314	THNSL2	0.42	5.21	0.32	3.99e-7	Response to metformin (IC50);
KIRP	cis	rs1440410	0.835	rs6537150	chr4:144067869	T/C	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27333517	chr8:92083018	OTUD6B	-0.56	-7.39	-0.43	2.24e-12	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg06740227	chr12:86229804	RASSF9	0.42	5.37	0.32	1.78e-7	Major depressive disorder;
KIRP	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.18	-0.51	1.84e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs503734	0.502	rs348861	chr3:100955259	G/A	cg27318481	chr3:100970896	IMPG2	-0.53	-7.12	-0.41	1.15e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs5753618	0.509	rs4820951	chr22:31586248	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.3	-0.32	2.54e-7	Colorectal cancer;
KIRP	cis	rs12210905	1.000	rs12201498	chr6:27030084	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.61	-0.39	2.31e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg18806716	chr10:30721971	MAP3K8	0.3	4.98	0.3	1.23e-6	Inflammatory bowel disease;
KIRP	cis	rs7084402	0.905	rs7098329	chr10:60276915	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.3	0.58	3.95e-24	Refractive error;
KIRP	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.73	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3743162	1.000	rs12917429	chr15:85425097	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.52	-4.95	-0.3	1.35e-6	Alzheimer's disease (age of onset);
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg11859384	chr17:80120422	CCDC57	0.43	5.5	0.33	9.37e-8	Life satisfaction;
KIRP	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.8	-10.09	-0.54	3.04e-20	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg04677158	chr5:78279841	ARSB	-0.43	-5.34	-0.32	2.11e-7	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs7607316	0.898	rs11691569	chr2:237523328	A/G	cg25295825	chr2:237489920	CXCR7	-0.55	-6.42	-0.38	6.92e-10	Airflow obstruction;
KIRP	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.9	-12.77	-0.63	5.4e-29	Tonsillectomy;
KIRP	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.59	5.49	0.33	9.94e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.63	8.53	0.48	1.54e-15	Colorectal cancer;
KIRP	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-1.1	-17.62	-0.75	1.67e-45	Cognitive function;
KIRP	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-0.77	-10.21	-0.55	1.26e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs34779708	0.733	rs12243593	chr10:35549045	C/T	cg03585969	chr10:35415529	CREM	0.57	6.62	0.39	2.23e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.34	-6.86	-0.4	5.56e-11	Height;
KIRP	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg00405596	chr8:11794950	NA	-0.4	-5.05	-0.31	8.57e-7	Triglycerides;
KIRP	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.58	7.53	0.43	9.64e-13	Response to antipsychotic treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14604802	chr18:60986766	BCL2	0.48	6.1	0.36	4e-9	Parkinson's disease;
KIRP	cis	rs240764	0.781	rs12212736	chr6:101151410	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.52	-0.33	8.75e-8	Neuroticism;
KIRP	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.74	-10.29	-0.55	7.16e-21	Fibrinogen levels;
KIRP	cis	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg04990556	chr1:26633338	UBXN11	0.64	5.89	0.35	1.29e-8	Obesity-related traits;
KIRP	cis	rs400736	0.729	rs2493215	chr1:8007716	C/T	cg25007680	chr1:8021821	PARK7	0.56	7.49	0.43	1.22e-12	Response to antidepressants and depression;
KIRP	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.75	-10.67	-0.56	4.28e-22	Sudden cardiac arrest;
KIRP	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.28	-0.32	2.83e-7	Bipolar disorder;
KIRP	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg13206674	chr6:150067644	NUP43	0.55	7.54	0.43	8.93e-13	Lung cancer;
KIRP	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg15507776	chr3:136538369	TMEM22	0.38	5.27	0.32	2.96e-7	Neuroticism;
KIRP	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-6.18	-0.37	2.6e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.29	0.47	7.32e-15	Neutrophil percentage of white cells;
KIRP	cis	rs3789045	0.774	rs11801299	chr1:204529084	G/A	cg18185008	chr1:204589407	LRRN2	-0.62	-6.7	-0.39	1.4e-10	Educational attainment (college completion);
KIRP	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.92	-10.62	-0.56	6.37e-22	Diastolic blood pressure;
KIRP	cis	rs72960926	0.744	rs55962148	chr6:74962021	G/T	cg03266952	chr6:74778945	NA	-0.74	-5.3	-0.32	2.57e-7	Metabolite levels (MHPG);
KIRP	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-1.0	-15.03	-0.69	1.2e-36	Coronary artery disease;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg10254082	chr7:997346	NA	0.45	4.98	0.3	1.18e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.14e-21	Alzheimer's disease (late onset);
KIRP	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg27411982	chr8:10470053	RP1L1	-0.4	-4.95	-0.3	1.39e-6	Neuroticism;
KIRP	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg08222618	chr4:941054	TMEM175	-0.57	-4.88	-0.3	1.9e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.55	7.17	0.42	8.56e-12	Obesity-related traits;
KIRP	cis	rs6693295	0.729	rs10802326	chr1:246216665	T/C	cg11798871	chr1:246315928	SMYD3	-0.42	-5.26	-0.32	3.17e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg11608241	chr8:8085544	FLJ10661	0.4	4.97	0.3	1.23e-6	Mood instability;
KIRP	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.94	-0.4	3.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.51	-0.38	4.15e-10	Joint mobility (Beighton score);
KIRP	cis	rs12913538	0.962	rs10851714	chr15:62897029	A/G	cg09983546	chr15:62884068	NA	-0.59	-8.49	-0.48	1.98e-15	Sleep depth;
KIRP	cis	rs2273669	0.915	rs6929070	chr6:109294322	G/T	cg05315195	chr6:109294784	ARMC2	-0.52	-5.81	-0.35	1.93e-8	Prostate cancer;
KIRP	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.16	-0.31	5.2e-7	Dupuytren's disease;
KIRP	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg25019722	chr6:37503610	NA	-0.75	-10.33	-0.55	5.07e-21	Cognitive performance;
KIRP	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.42	-0.33	1.45e-7	Total body bone mineral density;
KIRP	cis	rs2281603	0.521	rs6573559	chr14:64923166	G/T	cg01860774	chr14:64969374	ZBTB25	0.32	5.19	0.31	4.32e-7	Lymphocyte counts;
KIRP	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18364779	chr6:26104403	HIST1H4C	0.38	5.18	0.31	4.58e-7	Schizophrenia;
KIRP	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.88	-16.33	-0.72	4.22e-41	Body mass index;
KIRP	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg08885076	chr2:99613938	TSGA10	0.56	9.77	0.53	2.99e-19	Chronic sinus infection;
KIRP	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg24375607	chr4:120327624	NA	0.48	5.61	0.34	5.47e-8	Corneal astigmatism;
KIRP	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg01028140	chr2:1542097	TPO	-0.5	-5.63	-0.34	4.86e-8	IgG glycosylation;
KIRP	cis	rs7766436	0.885	rs13220769	chr6:22596464	T/A	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs7221595	0.825	rs71366590	chr17:4006685	T/A	cg09597638	chr17:3907349	NA	0.52	5.21	0.32	3.93e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.8	12.87	0.63	2.56e-29	Coronary artery disease;
KIRP	cis	rs10875746	0.551	rs2054903	chr12:48724493	C/T	cg20731937	chr12:48336164	NA	0.44	5.44	0.33	1.28e-7	Longevity (90 years and older);
KIRP	trans	rs13170463	0.579	rs74738574	chr5:8041655	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs8028182	0.636	rs7184046	chr15:75866150	G/C	cg20655648	chr15:75932815	IMP3	0.55	6.81	0.4	7.23e-11	Sudden cardiac arrest;
KIRP	cis	rs2882667	0.931	rs12719518	chr5:138340976	T/C	cg04439458	chr5:138467593	SIL1	-0.43	-7.18	-0.42	8.44e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg11803278	chr7:157951799	PTPRN2	0.44	6.93	0.4	3.69e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg06815112	chr8:27182871	PTK2B	0.53	6.83	0.4	6.57e-11	Neuroticism;
KIRP	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	6.27	0.37	1.6e-9	Depressive symptoms;
KIRP	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg12384639	chr17:618140	VPS53	0.48	5.94	0.35	9.82e-9	Prostate cancer;
KIRP	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.73	9.94	0.54	8.92e-20	Red blood cell count;
KIRP	cis	rs80130819	0.688	rs7313023	chr12:48584179	T/C	cg26205652	chr12:48591994	NA	0.48	5.39	0.33	1.61e-7	Prostate cancer;
KIRP	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg13147721	chr7:65941812	NA	-0.99	-6.89	-0.4	4.57e-11	Diabetic kidney disease;
KIRP	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg04607699	chr11:48328132	OR4S1	0.38	5.54	0.33	7.75e-8	Migraine - clinic-based;
KIRP	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg10617943	chr7:1981403	MAD1L1	-0.37	-5.13	-0.31	5.99e-7	Neuroticism;
KIRP	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.67	8.66	0.48	6.27e-16	Mean platelet volume;
KIRP	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.28	7.49	0.43	1.26e-12	Primary biliary cholangitis;
KIRP	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg24881330	chr22:46731750	TRMU	0.74	6.48	0.38	4.92e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg05709478	chr1:6581295	PLEKHG5	0.58	5.77	0.35	2.4e-8	Body mass index;
KIRP	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-0.77	-7.06	-0.41	1.72e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs1355223	1.000	rs1355222	chr11:34758716	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.48	-0.33	1.07e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg19770292	chr5:1868693	NA	0.41	5.3	0.32	2.63e-7	Cardiovascular disease risk factors;
KIRP	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	ch.8.33884649F	chr8:33765107	NA	0.63	8.02	0.46	4.21e-14	Body mass index;
KIRP	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	9.8	0.53	2.3e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10053473	chr17:62856997	LRRC37A3	0.69	7.21	0.42	6.95e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.19	-0.31	4.33e-7	Bipolar disorder;
KIRP	cis	rs7760949	0.963	rs1330118	chr6:13921016	C/T	cg27413430	chr6:13925136	RNF182	-0.44	-5.41	-0.33	1.49e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.56	-6.34	-0.37	1.11e-9	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.35	5.33	0.32	2.21e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9532580	0.614	rs17446614	chr13:41139877	A/G	cg21288729	chr13:41239152	FOXO1	-0.52	-5.08	-0.31	7.44e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.36	-0.32	1.88e-7	Aortic root size;
KIRP	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.75	-11.46	-0.59	1.17e-24	Lewy body disease;
KIRP	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.5	-0.33	9.73e-8	Renal cell carcinoma;
KIRP	cis	rs584438	1.000	rs584438	chr17:38599172	A/C	cg09213124	chr17:38599508	IGFBP4	0.31	5.45	0.33	1.22e-7	Height;
KIRP	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg00206168	chr11:65308501	LTBP3	0.82	4.9	0.3	1.74e-6	Height;
KIRP	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-4.94	-0.3	1.41e-6	Schizophrenia;
KIRP	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.13	-0.31	5.92e-7	Pulmonary function;
KIRP	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg05347473	chr6:146136440	FBXO30	0.49	7.0	0.41	2.44e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.55	5.9	0.35	1.19e-8	Diisocyanate-induced asthma;
KIRP	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg04310649	chr10:35416472	CREM	-0.57	-6.94	-0.4	3.38e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.53	7.95	0.45	6.79e-14	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.36	0.32	1.89e-7	Lung cancer;
KIRP	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg06060754	chr5:176797920	RGS14	-0.61	-7.06	-0.41	1.74e-11	Urate levels in lean individuals;
KIRP	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02463440	chr8:22132932	PIWIL2	0.42	5.44	0.33	1.32e-7	Hypertriglyceridemia;
KIRP	cis	rs698833	0.780	rs2005203	chr2:44541725	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.34	0.37	1.11e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs4654899	0.865	rs12410467	chr1:21356055	G/A	cg05370193	chr1:21551575	ECE1	0.46	5.8	0.35	1.98e-8	Superior frontal gyrus grey matter volume;
KIRP	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	8.24	0.47	1.02e-14	Systemic lupus erythematosus;
KIRP	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.09	0.54	3.04e-20	Total body bone mineral density;
KIRP	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.91	10.4	0.55	3.1e-21	Corneal astigmatism;
KIRP	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.76	9.62	0.52	8.5e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.5	-0.38	4.42e-10	Coronary artery disease;
KIRP	cis	rs501120	0.584	rs11238929	chr10:44708596	T/A	cg09554077	chr10:44749378	NA	0.65	7.28	0.42	4.54e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg02023728	chr11:77925099	USP35	0.36	5.55	0.33	7.38e-8	Alzheimer's disease (survival time);
KIRP	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.36	-4.88	-0.3	1.88e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.34	5.07e-8	Post bronchodilator FEV1;
KIRP	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.62	8.26	0.47	8.96e-15	Schizophrenia;
KIRP	cis	rs9535307	0.929	rs6561560	chr13:50339507	A/T	cg04663916	chr13:50265991	EBPL	-0.59	-5.05	-0.31	8.6e-7	Obesity-related traits;
KIRP	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	1.03	19.06	0.77	2.28e-50	Heart rate;
KIRP	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	10.99	0.57	4.05e-23	Exhaled nitric oxide levels;
KIRP	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.47	-0.52	2.39e-18	Triglycerides;
KIRP	cis	rs9443189	0.737	rs2842553	chr6:76456632	A/T	cg01950844	chr6:76311363	SENP6	-0.54	-5.69	-0.34	3.52e-8	Prostate cancer;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.8	13.3	0.65	9e-31	Menarche (age at onset);
KIRP	cis	rs829661	0.793	rs2593464	chr2:30872952	C/T	cg10949345	chr2:30726833	LCLAT1	1.09	13.36	0.65	5.56e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.43	5.39	0.33	1.62e-7	Educational attainment (years of education);
KIRP	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	9.5	0.52	1.92e-18	Response to antipsychotic treatment;
KIRP	cis	rs6450176	0.625	rs3776726	chr5:53290052	T/A	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-12.93	-0.64	1.55e-29	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.01	14.16	0.67	1.11e-33	Cognitive ability;
KIRP	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.17	-0.5	1.93e-17	Bladder cancer;
KIRP	cis	rs1417569	1.000	rs1417569	chr10:31101743	C/T	cg10523352	chr10:31093542	NA	-0.52	-6.03	-0.36	5.97e-9	Tuberculosis;
KIRP	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.95	15.06	0.69	8.95e-37	Metabolite levels;
KIRP	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.49	-6.1	-0.36	4.01e-9	Schizophrenia;
KIRP	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.97	-0.5	7.77e-17	Total cholesterol levels;
KIRP	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg21724239	chr8:58056113	NA	0.55	5.06	0.31	8.02e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs10073892	1.000	rs10213798	chr5:101659682	G/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.96e-11	Cognitive decline (age-related);
KIRP	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.92	-15.48	-0.7	3.28e-38	Height;
KIRP	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg14003231	chr6:33640908	ITPR3	0.27	4.89	0.3	1.84e-6	Plateletcrit;
KIRP	cis	rs6688363	0.887	rs6695366	chr1:160097666	G/A	cg01023271	chr1:160068607	IGSF8	0.59	5.36	0.32	1.92e-7	Response to antipsychotic treatment;
KIRP	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.43	-5.83	-0.35	1.73e-8	Monocyte count;
KIRP	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg11498726	chr8:26250323	BNIP3L	-0.53	-7.87	-0.45	1.15e-13	Red cell distribution width;
KIRP	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.55	7.66	0.44	4.33e-13	Mean corpuscular volume;
KIRP	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-6.93	-0.4	3.73e-11	Alcohol dependence;
KIRP	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.49	-0.33	9.99e-8	Colorectal cancer;
KIRP	cis	rs258892	0.895	rs10072874	chr5:72044283	G/C	cg21869765	chr5:72125136	TNPO1	-0.54	-5.82	-0.35	1.83e-8	Small cell lung carcinoma;
KIRP	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.64	-9.63	-0.52	8.08e-19	Educational attainment;
KIRP	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.51	0.59	8.52e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg02002194	chr4:3960332	NA	-0.47	-6.18	-0.37	2.66e-9	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.49	-0.33	9.9e-8	Lung cancer;
KIRP	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.07	-0.31	7.75e-7	IgG glycosylation;
KIRP	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.63	8.61	0.48	8.71e-16	Mood instability;
KIRP	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.64	8.93	0.49	9.9e-17	Total body bone mineral density;
KIRP	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.85	13.29	0.65	9.31e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.58e-23	Primary sclerosing cholangitis;
KIRP	cis	rs2143950	0.621	rs17103226	chr14:35822839	C/T	cg09327582	chr14:35236912	BAZ1A	-0.63	-5.92	-0.35	1.05e-8	Atopic dermatitis;
KIRP	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.7	-6.42	-0.38	7.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.05	0.41	1.78e-11	Height;
KIRP	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.46	5.55	0.33	7.55e-8	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	5.87	0.35	1.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.56	-6.69	-0.39	1.47e-10	Mosquito bite size;
KIRP	cis	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07988820	chr12:82153109	PPFIA2	-0.48	-5.66	-0.34	4.27e-8	Resting heart rate;
KIRP	cis	rs7719624	0.870	rs1990201	chr5:135395203	C/T	cg16684184	chr5:135415129	NA	-0.35	-5.26	-0.32	3.16e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.38	5.14	0.31	5.59e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.31	8.03	0.46	3.96e-14	Crohn's disease;
KIRP	cis	rs9311676	0.656	rs62258140	chr3:58407083	C/T	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg21747090	chr2:27597821	SNX17	-0.49	-6.68	-0.39	1.59e-10	Total body bone mineral density;
KIRP	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	6.45	0.38	5.8e-10	Multiple sclerosis;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-10.04	-0.54	4.09e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.4	5.21	0.32	4.06e-7	Melanoma;
KIRP	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.47	6.48	0.38	4.94e-10	Testicular germ cell tumor;
KIRP	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.59	-7.39	-0.43	2.3e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.35	0.55	4.37e-21	Morning vs. evening chronotype;
KIRP	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg00204512	chr16:28754710	NA	0.49	6.36	0.38	9.92e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg00094735	chr5:1949198	NA	0.46	5.49	0.33	1.02e-7	Gut microbiome composition (winter);
KIRP	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg25319279	chr11:5960081	NA	-0.57	-5.88	-0.35	1.34e-8	DNA methylation (variation);
KIRP	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.28	-0.32	2.85e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg25486957	chr4:152246857	NA	-0.42	-4.91	-0.3	1.68e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs737008	0.960	rs34764020	chr16:11378359	C/T	cg00044050	chr16:11439710	C16orf75	-0.63	-7.54	-0.43	8.94e-13	Obesity-related traits;
KIRP	cis	rs57590327	0.679	rs17018967	chr3:81512209	G/A	cg07356753	chr3:81810745	GBE1	-0.53	-5.72	-0.34	3.16e-8	Extraversion;
KIRP	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6445967	1.000	rs1913716	chr3:58308331	G/A	cg16569813	chr3:58235849	ABHD6	-0.33	-4.91	-0.3	1.63e-6	Platelet count;
KIRP	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	cg21523751	chr1:182988639	NA	0.44	6.66	0.39	1.76e-10	Hypertriglyceridemia;
KIRP	cis	rs78487399	0.808	rs76851696	chr2:43746062	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.02	-0.3	1.01e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11166927	1.000	rs11166929	chr8:140801430	G/A	cg16909799	chr8:140841666	TRAPPC9	0.72	10.46	0.55	1.99e-21	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs1699337	1.000	rs1596667	chr3:12403119	G/T	cg02700894	chr3:12045449	SYN2	0.37	4.93	0.3	1.5e-6	Cholesterol, total;
KIRP	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.59	8.73	0.49	3.85e-16	Brugada syndrome;
KIRP	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.28	-0.37	1.49e-9	Total body bone mineral density;
KIRP	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg16989719	chr2:238392110	NA	-0.56	-6.21	-0.37	2.3e-9	Prostate cancer;
KIRP	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg10326726	chr10:51549505	MSMB	0.55	7.88	0.45	1.04e-13	Prostate-specific antigen levels;
KIRP	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.28	-0.37	1.54e-9	Breast cancer;
KIRP	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg22800045	chr5:56110881	MAP3K1	-0.56	-6.39	-0.38	8.42e-10	Initial pursuit acceleration;
KIRP	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-8.1	-0.46	2.49e-14	Diastolic blood pressure;
KIRP	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.49	6.76	0.4	9.81e-11	Red blood cell count;
KIRP	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs6504950	0.720	rs2877634	chr17:52987545	A/G	cg26251398	chr17:52985966	TOM1L1	0.43	6.03	0.36	5.88e-9	Breast cancer;
KIRP	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.93	16.12	0.72	2.12e-40	Metabolic syndrome;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-6.99	-0.41	2.5e-11	Bipolar disorder;
KIRP	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	8.36	0.47	4.53e-15	Motion sickness;
KIRP	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.75	-10.52	-0.56	1.3e-21	Prostate cancer;
KIRP	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg14675211	chr2:100938903	LONRF2	0.54	7.32	0.42	3.59e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	14.32	0.67	3.08e-34	Tonsillectomy;
KIRP	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.59	9.01	0.5	5.92e-17	Personality dimensions;
KIRP	cis	rs9653442	0.564	rs2164711	chr2:100775422	G/T	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg04317338	chr11:64019027	PLCB3	0.85	7.0	0.41	2.49e-11	Mean platelet volume;
KIRP	cis	rs234043	1.000	rs234051	chr3:172311712	C/T	cg01059398	chr3:172235808	TNFSF10	0.4	6.02	0.36	6.47e-9	Renal cell carcinoma;
KIRP	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	0.71	7.32	0.42	3.5e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.06	0.61	1.27e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6496667	0.779	rs8039288	chr15:91000445	A/T	cg10434728	chr15:90938212	IQGAP1	0.35	4.9	0.3	1.74e-6	Rheumatoid arthritis;
KIRP	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg05484376	chr2:27715224	FNDC4	-0.3	-4.89	-0.3	1.86e-6	Total body bone mineral density;
KIRP	cis	rs12049351	0.774	rs12125978	chr1:229627722	T/C	cg11742688	chr1:229674241	ABCB10	-0.38	-5.58	-0.34	6.24e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs1355223	0.833	rs286885	chr11:34687346	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.42	5.02	0.31	9.78e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.93	-9.13	-0.5	2.55e-17	Lung cancer;
KIRP	cis	rs6725041	0.663	rs1949653	chr2:213104624	G/A	cg20637307	chr2:213403960	ERBB4	-0.41	-5.39	-0.32	1.67e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-6.54	-0.38	3.56e-10	Menarche (age at onset);
KIRP	cis	rs7508	1.000	rs7508	chr8:17913970	G/A	cg01800426	chr8:17659068	MTUS1	-0.47	-4.85	-0.3	2.17e-6	Atrial fibrillation;
KIRP	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-6.54	-0.38	3.46e-10	Primary sclerosing cholangitis;
KIRP	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.83	-14.96	-0.69	2.08e-36	Body mass index;
KIRP	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg23752985	chr2:85803571	VAMP8	0.47	5.59	0.34	5.98e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg23594656	chr7:65796392	TPST1	0.52	8.28	0.47	8.07e-15	Aortic root size;
KIRP	cis	rs73086581	0.787	rs73084505	chr20:3856874	C/T	cg02187196	chr20:3869020	PANK2	0.6	5.48	0.33	1.04e-7	Response to antidepressants in depression;
KIRP	trans	rs7939886	0.920	rs10792448	chr11:55804542	C/G	cg15704280	chr7:45808275	SEPT13	0.82	6.03	0.36	5.87e-9	Myopia (pathological);
KIRP	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.91	0.45	8.88e-14	Aortic root size;
KIRP	trans	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg06521331	chr12:34319734	NA	-0.58	-6.97	-0.41	2.88e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg24044776	chr19:53454761	ZNF816A	-0.48	-7.12	-0.41	1.17e-11	Psoriasis;
KIRP	cis	rs2562456	0.833	rs57250002	chr19:21526850	T/C	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg03563238	chr19:33554763	RHPN2	-0.33	-5.98	-0.36	7.68e-9	Bone properties (heel);
KIRP	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.55	0.62	2.88e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17507749	chr15:85114479	UBE2QP1	0.7	7.49	0.43	1.21e-12	Schizophrenia;
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21957399	chr18:11980981	IMPA2	0.44	5.96	0.36	8.83e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06475006	chr16:89985975	MC1R	-0.69	-4.96	-0.3	1.31e-6	Skin colour saturation;
KIRP	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.66	0.44	4.14e-13	Calcium levels;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg07859478	chr19:808116	PTBP1	1.31	7.62	0.44	5.49e-13	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.18	-0.42	8.27e-12	Bone mineral density;
KIRP	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	11.29	0.58	4.38e-24	Blood protein levels;
KIRP	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.5	-7.3	-0.42	3.92e-12	Bipolar disorder;
KIRP	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.2	0.42	7.27e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.86	-0.53	1.56e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7011049	0.778	rs7822512	chr8:53874273	A/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs6722613	0.900	rs749130	chr2:25530028	C/T	cg10614445	chr2:25526696	DNMT3A	0.32	5.37	0.32	1.83e-7	Ossification of the posterior longitudinal ligament of the spine;
KIRP	cis	rs959260	1.000	rs7216423	chr17:73365671	T/C	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.9	13.1	0.64	4.33e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg24633833	chr3:10029261	TMEM111	0.53	5.11	0.31	6.38e-7	Alzheimer's disease;
KIRP	cis	rs2742417	0.967	rs1609553	chr3:45735142	T/C	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs804280	0.535	rs10435719	chr8:11776904	C/T	cg00405596	chr8:11794950	NA	0.57	7.71	0.44	3.1e-13	Myopia (pathological);
KIRP	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg00405596	chr8:11794950	NA	-0.39	-4.95	-0.3	1.37e-6	Triglycerides;
KIRP	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.32	0.37	1.22e-9	Mean platelet volume;
KIRP	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.21e-7	Breast cancer;
KIRP	cis	rs72792276	1.000	rs17164395	chr5:127395526	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	7.1	0.41	1.37e-11	Red cell distribution width;
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg14664628	chr15:75095509	CSK	-0.61	-7.42	-0.43	1.9e-12	Breast cancer;
KIRP	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg26207909	chr14:103986467	CKB	-0.47	-6.09	-0.36	4.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	1.02	13.9	0.66	8.12e-33	Neutrophil percentage of white cells;
KIRP	cis	rs2688419	0.545	rs1849478	chr3:23067010	C/G	cg00327796	chr3:23032191	NA	-0.46	-6.24	-0.37	1.89e-9	Type 2 diabetes;
KIRP	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.76	9.65	0.52	6.9e-19	Neutrophil percentage of white cells;
KIRP	cis	rs1925690	1.000	rs2182182	chr6:87911780	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-4.99	-0.3	1.16e-6	Entorhinal cortical volume (Alzheimer's disease interaction);
KIRP	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-7.74	-0.44	2.65e-13	Bipolar disorder;
KIRP	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg00262122	chr8:11665843	FDFT1	0.43	5.41	0.33	1.52e-7	Myopia (pathological);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23501467	chr19:20011770	ZNF93	0.46	6.14	0.36	3.2e-9	Parkinson's disease;
KIRP	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.64	0.39	2.01e-10	Multiple sclerosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04650786	chr6:108395545	OSTM1	0.57	6.75	0.4	1.05e-10	Smoking initiation;
KIRP	cis	rs2625529	0.530	rs2959930	chr15:72598614	A/G	cg16672083	chr15:72433130	SENP8	-0.39	-5.19	-0.31	4.35e-7	Red blood cell count;
KIRP	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg21775007	chr8:11205619	TDH	0.46	6.11	0.36	3.9e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.44	-0.43	1.73e-12	Breast cancer;
KIRP	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.59	7.32	0.42	3.49e-12	Arsenic metabolism;
KIRP	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.43	-0.62	7.29e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.51	-5.37	-0.32	1.79e-7	Corneal structure;
KIRP	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg11833968	chr6:79620685	NA	-0.38	-5.56	-0.33	7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.71	9.94	0.54	8.55e-20	Mean corpuscular volume;
KIRP	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs11209002	0.592	rs7551197	chr1:67588090	A/T	cg02640540	chr1:67518911	SLC35D1	0.6	6.73	0.39	1.22e-10	Crohn's disease;
KIRP	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs7520050	0.966	rs6661910	chr1:46290632	A/T	cg03146154	chr1:46216737	IPP	-0.42	-5.22	-0.32	3.87e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.43	-5.71	-0.34	3.28e-8	Body mass index;
KIRP	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg21427119	chr20:30132790	HM13	-0.58	-5.49	-0.33	1e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.84	-0.35	1.65e-8	IgG glycosylation;
KIRP	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg22138327	chr13:27999177	GTF3A	0.89	7.04	0.41	1.88e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.24	0.32	3.48e-7	Smoking behavior;
KIRP	cis	rs3857067	1.000	rs1588382	chr4:95017589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.03	-0.31	9.37e-7	QT interval;
KIRP	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg24375607	chr4:120327624	NA	0.39	4.95	0.3	1.39e-6	Diastolic blood pressure;
KIRP	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg14458575	chr2:238380390	NA	0.57	5.6	0.34	5.63e-8	Prostate cancer;
KIRP	cis	rs1958560	0.829	rs2268955	chr14:66090009	T/A	cg03016385	chr14:66212404	NA	-0.4	-5.16	-0.31	4.97e-7	Menarche (age at onset);
KIRP	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.77	-9.32	-0.51	7.01e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs12517041	0.938	rs1428616	chr5:23260829	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-6.38	-0.38	8.8e-10	Calcium levels;
KIRP	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg11211951	chr8:145729740	GPT	-0.33	-5.38	-0.32	1.71e-7	Age at first birth;
KIRP	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.4	5.52	0.33	8.69e-8	Homoarginine levels;
KIRP	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs58785573	0.513	rs10011814	chr4:38591799	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.86	0.3	2.09e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg07460842	chr6:66804631	NA	-0.48	-5.9	-0.35	1.2e-8	Blood trace element (Cu levels);
KIRP	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg25182066	chr10:30743637	MAP3K8	-0.65	-8.87	-0.49	1.58e-16	Inflammatory bowel disease;
KIRP	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg22307297	chr20:60903441	LAMA5	0.41	4.92	0.3	1.59e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7075426	0.512	rs9633738	chr10:88183796	T/A	cg07322936	chr10:88137208	NA	-0.51	-4.89	-0.3	1.81e-6	Migraine without aura;
KIRP	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.48e-11	Diabetic kidney disease;
KIRP	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg12962167	chr3:53033115	SFMBT1	0.72	5.26	0.32	3.15e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6991838	0.584	rs7835313	chr8:66546126	C/G	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg13736514	chr6:26305472	NA	-0.72	-9.27	-0.51	9.65e-18	Educational attainment;
KIRP	cis	rs4664293	0.867	rs6761145	chr2:160582184	A/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.58	-6.53	-0.38	3.77e-10	Menarche (age at onset);
KIRP	cis	rs4654899	0.865	rs10916927	chr1:21385795	T/C	cg05370193	chr1:21551575	ECE1	0.46	6.02	0.36	6.18e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27229823	chr2:105858015	GPR45	0.45	6.08	0.36	4.53e-9	Interleukin-4 levels;
KIRP	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12311304	0.965	rs7303854	chr12:15359241	A/T	cg08258403	chr12:15378311	NA	0.32	4.93	0.3	1.51e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9815354	0.909	rs1716975	chr3:41960006	T/C	cg03022575	chr3:42003672	ULK4	-0.5	-5.76	-0.34	2.5e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs714027	0.585	rs737911	chr22:30399417	A/G	cg01021169	chr22:30184971	ASCC2	0.44	5.33	0.32	2.24e-7	Lymphocyte counts;
KIRP	cis	rs4006360	0.646	rs917635	chr17:39302683	A/G	cg15015397	chr17:39261100	KRTAP4-9	0.56	7.81	0.45	1.68e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg24315340	chr6:146058215	EPM2A	0.45	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.58	-6.96	-0.41	3.15e-11	Bone mineral density;
KIRP	cis	rs9653442	0.545	rs4851257	chr2:100775297	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.48	-0.33	1.08e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.75	-11.2	-0.58	8.16e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13626624	chr20:656518	SCRT2	0.44	6.05	0.36	5.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg01765077	chr12:122356316	WDR66	-0.59	-8.41	-0.47	3.42e-15	Mean corpuscular volume;
KIRP	cis	rs3857067	0.967	rs1472984	chr4:95036553	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-5.04	-0.31	9.22e-7	QT interval;
KIRP	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.43	-0.43	1.79e-12	Triglycerides;
KIRP	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs4302748	0.862	rs57651006	chr7:36184211	T/C	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg00677455	chr12:58241039	CTDSP2	-0.5	-5.62	-0.34	5.09e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.91	-0.49	1.19e-16	Total cholesterol levels;
KIRP	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg22437258	chr11:111473054	SIK2	-0.54	-6.11	-0.36	3.92e-9	Primary sclerosing cholangitis;
KIRP	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.45	-5.73	-0.34	2.99e-8	Schizophrenia;
KIRP	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.5	-0.38	4.55e-10	Blood metabolite levels;
KIRP	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.49	-5.87	-0.35	1.4e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05220968	chr6:146057943	EPM2A	-0.43	-5.56	-0.33	7.04e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04374321	chr14:90722782	PSMC1	0.9	14.55	0.68	5.12e-35	Mortality in heart failure;
KIRP	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	0.7	6.5	0.38	4.39e-10	Obesity-related traits;
KIRP	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-9.28	-0.51	9.13e-18	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17945282	chr3:142297905	ATR	0.49	6.49	0.38	4.61e-10	Parkinson's disease;
KIRP	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.84	-7.37	-0.43	2.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg03060546	chr3:49711283	APEH	-0.72	-5.48	-0.33	1.04e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00585698	chr12:123750864	CDK2AP1	0.49	6.21	0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs7849270	0.760	rs419636	chr9:131931277	T/C	cg13538475	chr9:131942899	NA	0.37	5.31	0.32	2.44e-7	Blood metabolite ratios;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16465768	chr2:136287945	R3HDM1;ZRANB3	0.91	6.13	0.36	3.44e-9	P wave terminal force;
KIRP	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg12599982	chr1:44399894	ARTN	0.41	5.1	0.31	6.66e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg06871246	chr4:1363661	KIAA1530	0.47	5.9	0.35	1.22e-8	Obesity-related traits;
KIRP	cis	rs838147	0.537	rs485073	chr19:49207255	A/G	cg02804510	chr19:49199965	FUT2	0.34	4.91	0.3	1.65e-6	Dietary macronutrient intake;
KIRP	cis	rs7180079	0.544	rs4777601	chr15:65100154	G/T	cg15337035	chr15:64978493	NA	-0.49	-5.39	-0.32	1.68e-7	Monocyte count;
KIRP	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg06453172	chr10:134556979	INPP5A	-0.56	-6.3	-0.37	1.36e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.68	-0.34	3.88e-8	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14765337	chr11:45931715	PEX16	0.55	6.9	0.4	4.32e-11	Interleukin-4 levels;
KIRP	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.32	0.37	1.19e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg09990169	chr2:241835740	C2orf54	-0.38	-5.85	-0.35	1.58e-8	Urinary metabolites;
KIRP	cis	rs757081	0.667	rs17560341	chr11:17107163	C/T	cg15432903	chr11:17409602	KCNJ11	-0.53	-6.3	-0.37	1.36e-9	Systolic blood pressure;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13939156	chr17:80058883	NA	-0.5	-7.53	-0.43	9.75e-13	Life satisfaction;
KIRP	cis	rs55788414	0.932	rs34444956	chr16:81185412	C/T	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.32	-0.47	5.89e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg00012203	chr2:219082015	ARPC2	-0.41	-5.13	-0.31	5.89e-7	Ulcerative colitis;
KIRP	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg15103426	chr22:29168792	CCDC117	0.53	5.37	0.32	1.83e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg04607699	chr11:48328132	OR4S1	-0.37	-5.18	-0.31	4.56e-7	HDL cholesterol;
KIRP	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg23649088	chr2:200775458	C2orf69	0.59	6.33	0.37	1.15e-9	Schizophrenia;
KIRP	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.91	11.63	0.6	3.43e-25	Menopause (age at onset);
KIRP	trans	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg25042112	chr7:64838748	ZNF92	0.57	6.09	0.36	4.23e-9	Pain;
KIRP	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.12	0.41	1.2e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg21184320	chr1:21044207	KIF17	-0.37	-5.48	-0.33	1.03e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6969780	0.915	rs12666926	chr7:27189561	A/G	cg17457637	chr7:27170717	HOXA4	-0.37	-4.87	-0.3	1.96e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg07001201	chr5:642380	CEP72	0.65	6.54	0.38	3.59e-10	Obesity-related traits;
KIRP	trans	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg00938859	chr5:1591904	SDHAP3	0.6	8.0	0.45	5.04e-14	Breast cancer;
KIRP	cis	rs6120849	0.901	rs11696967	chr20:33743609	A/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.62	0.39	2.22e-10	Protein C levels;
KIRP	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg08126542	chr6:37504118	NA	-0.83	-13.29	-0.65	9.68e-31	Cognitive performance;
KIRP	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.87	13.49	0.65	2.05e-31	Menarche (age at onset);
KIRP	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg21775007	chr8:11205619	TDH	-0.41	-5.33	-0.32	2.25e-7	Triglycerides;
KIRP	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	1.99e-8	Motion sickness;
KIRP	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg20542592	chr8:11973495	FAM66D	0.39	4.88	0.3	1.89e-6	Triglycerides;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23052386	chr13:111553101	ANKRD10	0.44	6.4	0.38	7.86e-10	Survival in pancreatic cancer;
KIRP	cis	rs13065560	0.594	rs9858516	chr3:38891548	C/T	cg01426195	chr3:39028469	NA	-0.45	-7.21	-0.42	6.67e-12	Interleukin-18 levels;
KIRP	cis	rs4356975	0.563	rs6422324	chr4:69953103	A/T	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg01657329	chr11:68192670	LRP5	-0.51	-5.53	-0.33	8.19e-8	Total body bone mineral density;
KIRP	trans	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.4e-20	Pursuit maintenance gain;
KIRP	cis	rs6539288	0.563	rs11113122	chr12:107211325	T/C	cg21360079	chr12:107162445	NA	-0.56	-7.98	-0.45	5.42e-14	Total body bone mineral density;
KIRP	cis	rs7572644	0.640	rs9678336	chr2:28065404	A/G	cg27432699	chr2:27873401	GPN1	0.46	5.66	0.34	4.29e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg23625390	chr15:77176239	SCAPER	0.52	6.8	0.4	7.82e-11	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25800082	chr19:57702803	ZNF264	0.46	6.3	0.37	1.33e-9	Parkinson's disease;
KIRP	cis	rs17286411	0.867	rs952160	chr16:71965725	T/C	cg04254540	chr16:71951199	KIAA0174	-0.37	-4.99	-0.3	1.15e-6	Blood protein levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg01628954	chr18:60190696	ZCCHC2	-0.51	-6.32	-0.37	1.24e-9	Neuroticism;
KIRP	cis	rs300890	0.717	rs300947	chr4:144209789	G/A	cg01719995	chr4:144104893	USP38	0.38	4.86	0.3	2.09e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.15	14.79	0.69	7.6e-36	Type 2 diabetes nephropathy;
KIRP	cis	rs7666738	0.515	rs13131874	chr4:98779183	A/G	cg17366294	chr4:99064904	C4orf37	0.38	4.86	0.3	2.14e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg13147721	chr7:65941812	NA	-0.89	-6.37	-0.38	9.24e-10	Diabetic kidney disease;
KIRP	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg08992911	chr2:238395768	MLPH	0.42	5.35	0.32	2e-7	Prostate cancer;
KIRP	cis	rs4713118	0.824	rs9366702	chr6:27734470	T/C	cg20933634	chr6:27740509	NA	0.4	5.36	0.32	1.93e-7	Parkinson's disease;
KIRP	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	0.9	7.48	0.43	1.31e-12	Thyroid stimulating hormone;
KIRP	cis	rs11651000	0.625	rs4794067	chr17:45808828	T/C	cg03474202	chr17:45855739	NA	-0.41	-5.9	-0.35	1.18e-8	IgG glycosylation;
KIRP	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.51	-5.77	-0.35	2.38e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg03959625	chr15:84868606	LOC388152	0.4	5.03	0.31	9.26e-7	Schizophrenia;
KIRP	cis	rs228437	0.913	rs7763821	chr6:134939618	A/G	cg24504307	chr6:134963096	NA	0.41	6.4	0.38	8e-10	Melanoma;
KIRP	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.59	-7.8	-0.45	1.81e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg01311341	chr22:25575246	KIAA1671	0.65	7.52	0.43	1.02e-12	Atopic dermatitis;
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg09699651	chr6:150184138	LRP11	0.47	6.12	0.36	3.75e-9	Lung cancer;
KIRP	cis	rs17092148	0.887	rs2068474	chr20:33231079	A/G	cg16810054	chr20:33298113	TP53INP2	-0.41	-4.85	-0.3	2.24e-6	Neuroticism;
KIRP	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.64	5.19	0.31	4.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs40363	0.594	rs250626	chr16:3511892	G/A	cg00484396	chr16:3507460	NAT15	0.54	7.11	0.41	1.26e-11	Tuberculosis;
KIRP	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.58	0.34	6.3e-8	Educational attainment;
KIRP	cis	rs10214930	0.624	rs4719902	chr7:27588342	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg01097406	chr16:89675127	NA	0.51	8.94	0.5	9.57e-17	Vitiligo;
KIRP	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.71	7.94	0.45	7.08e-14	Obesity-related traits;
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.41	-5.3	-0.32	2.63e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.97	0.36	8.07e-9	Type 2 diabetes;
KIRP	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg21573476	chr21:45109991	RRP1B	-0.78	-10.7	-0.56	3.44e-22	Mean corpuscular volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16119372	chr1:202321656	PPP1R12B	0.46	6.23	0.37	2e-9	Interleukin-4 levels;
KIRP	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.96	-0.36	8.61e-9	IgG glycosylation;
KIRP	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.74	-11.28	-0.58	4.76e-24	Lung cancer;
KIRP	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg05130518	chr13:21295590	IL17D	0.41	5.25	0.32	3.23e-7	Dental caries;
KIRP	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.65	8.18	0.46	1.49e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.91	-9.89	-0.53	1.28e-19	Corneal astigmatism;
KIRP	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg22777020	chr22:31556080	RNF185	-0.49	-5.14	-0.31	5.63e-7	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26406571	chr11:2422425	TSSC4	0.52	6.66	0.39	1.73e-10	Parkinson's disease;
KIRP	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.75	10.89	0.57	8.61e-23	Schizophrenia;
KIRP	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18364779	chr6:26104403	HIST1H4C	0.63	8.13	0.46	2.14e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs8010715	0.636	rs2277480	chr14:24587515	G/A	cg23112188	chr14:24563095	PCK2	-0.34	-4.96	-0.3	1.29e-6	IgG glycosylation;
KIRP	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg06217071	chr17:408420	NA	0.68	11.1	0.58	1.81e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs2594989	0.943	rs2454512	chr3:11487506	A/G	cg01796438	chr3:11312864	ATG7	-0.61	-7.62	-0.44	5.6e-13	Circulating chemerin levels;
KIRP	cis	rs2150410	0.915	rs6517530	chr21:40597825	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04875987	chr17:79981264	STRA13;LRRC45	0.47	6.6	0.39	2.55e-10	Survival in pancreatic cancer;
KIRP	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-5.88	-0.35	1.33e-8	Chronic sinus infection;
KIRP	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.63	-7.93	-0.45	7.58e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	1.1	22.11	0.82	2.24e-60	Parkinson's disease;
KIRP	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	0.97	12.77	0.63	5.65e-29	Breast cancer;
KIRP	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.55	7.33	0.42	3.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg16926213	chr1:1841314	NA	0.33	5.59	0.34	5.94e-8	Body mass index;
KIRP	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21926750	chr11:77300530	AQP11	0.51	7.13	0.41	1.14e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg04369109	chr6:150039330	LATS1	-0.5	-6.42	-0.38	6.84e-10	Lung cancer;
KIRP	trans	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg13565492	chr6:43139072	SRF	-0.93	-8.61	-0.48	8.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-0.75	-5.92	-0.35	1.09e-8	IgG glycosylation;
KIRP	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.67	8.62	0.48	8.38e-16	Height;
KIRP	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.53	7.58	0.43	7.19e-13	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01811064	chr11:118972945	DPAGT1	0.57	7.54	0.43	9.15e-13	Parkinson's disease;
KIRP	cis	rs73198271	1.000	rs11784958	chr8:8607781	C/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.94	-0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg03929089	chr4:120376271	NA	-0.52	-6.06	-0.36	5.13e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.78	8.62	0.48	8.47e-16	Type 2 diabetes;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg11641102	chr8:27183873	PTK2B	0.44	5.79	0.35	2.12e-8	Neuroticism;
KIRP	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg21360079	chr12:107162445	NA	-0.69	-9.63	-0.52	7.81e-19	Heart rate;
KIRP	cis	rs9304742	1.000	rs9304742	chr19:53451291	A/G	cg24044776	chr19:53454761	ZNF816A	-0.4	-5.99	-0.36	7.5e-9	Psoriasis;
KIRP	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg18306943	chr3:40428807	ENTPD3	0.44	5.83	0.35	1.75e-8	Renal cell carcinoma;
KIRP	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.69	8.91	0.49	1.14e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.58	9.44	0.52	3.08e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.95	-0.45	6.86e-14	Neuroticism;
KIRP	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg04013166	chr16:89971882	TCF25	0.56	4.96	0.3	1.34e-6	Skin colour saturation;
KIRP	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg11266682	chr4:10021025	SLC2A9	0.42	5.24	0.32	3.53e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-1.08	-21.33	-0.81	7.38e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg04990556	chr1:26633338	UBXN11	0.69	6.74	0.39	1.14e-10	Obesity-related traits;
KIRP	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.99	-0.73	2.29e-43	Height;
KIRP	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18867708	chr6:26865862	GUSBL1	0.47	5.92	0.35	1.07e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	5.11	0.31	6.34e-7	Childhood ear infection;
KIRP	cis	rs4400599	0.618	rs1194603	chr1:154228287	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.41	5.99	0.36	7.38e-9	Platelet distribution width;
KIRP	cis	rs6545883	0.894	rs2167566	chr2:61519408	G/T	cg15711740	chr2:61764176	XPO1	-0.58	-7.71	-0.44	3.1400000000000003e-13	Tuberculosis;
KIRP	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	1.05	23.51	0.83	7.38e-65	Breast cancer;
KIRP	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg21395723	chr22:39101663	GTPBP1	0.38	4.99	0.3	1.17e-6	Menopause (age at onset);
KIRP	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg09555818	chr19:45449301	APOC2	0.52	7.56	0.43	7.83e-13	Blood protein levels;
KIRP	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.63	8.21	0.46	1.26e-14	Height;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.78	12.24	0.62	3.32e-27	Menarche (age at onset);
KIRP	cis	rs7570971	0.792	rs56369224	chr2:136328890	A/T	cg05194412	chr2:137003533	NA	-0.39	-4.87	-0.3	2.02e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs12540874	0.524	rs7804365	chr7:50637148	A/C	cg04490037	chr7:50633773	DDC	0.39	5.17	0.31	4.76e-7	Systemic sclerosis;
KIRP	cis	rs6545883	0.965	rs2305155	chr2:61729258	A/G	cg15711740	chr2:61764176	XPO1	-0.58	-7.87	-0.45	1.16e-13	Tuberculosis;
KIRP	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.69	-0.63	1.02e-28	Breast cancer;
KIRP	trans	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg25214090	chr10:38739885	LOC399744	0.51	6.62	0.39	2.18e-10	Diastolic blood pressure;
KIRP	cis	rs16858210	0.529	rs10937154	chr3:183569489	C/T	cg25686905	chr3:183603175	PARL	-0.44	-4.92	-0.3	1.6e-6	Menopause (age at onset);
KIRP	cis	rs2033732	0.706	rs1437509	chr8:85065342	G/T	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg18944383	chr4:111397179	ENPEP	0.46	7.17	0.42	8.74e-12	Coronary artery disease;
KIRP	cis	rs4950322	0.570	rs17356219	chr1:146737343	A/C	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg02175308	chr1:109941060	SORT1	-0.26	-4.94	-0.3	1.41e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.43	-5.27	-0.32	2.98e-7	Neuroticism;
KIRP	cis	rs4690686	0.731	rs11941845	chr4:177276526	G/A	cg17059388	chr4:177262070	NA	0.55	7.66	0.44	4.16e-13	Essential tremor;
KIRP	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-7.03	-0.41	2e-11	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.43	0.33	1.34e-7	Personality dimensions;
KIRP	cis	rs8113308	0.810	rs73582180	chr19:52446537	G/A	cg25782003	chr19:52490127	ZNF350	0.53	4.97	0.3	1.23e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.02	0.36	6.17e-9	Diabetic retinopathy;
KIRP	cis	rs918629	0.530	rs2042340	chr5:95235193	T/C	cg16656078	chr5:95278638	ELL2	-0.38	-5.79	-0.35	2.19e-8	IgG glycosylation;
KIRP	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg14673194	chr17:80132900	CCDC57	-0.74	-8.02	-0.46	4.22e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg22022881	chr2:105853494	NA	-0.38	-5.56	-0.33	6.92e-8	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg13939156	chr17:80058883	NA	-0.5	-7.51	-0.43	1.06e-12	Life satisfaction;
KIRP	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg13736514	chr6:26305472	NA	0.53	6.6	0.39	2.56e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6504622	0.557	rs1867237	chr17:45003829	A/G	cg16759221	chr17:45003025	GOSR2	-0.32	-4.87	-0.3	1.99e-6	Orofacial clefts;
KIRP	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg16606324	chr3:10149918	C3orf24	0.54	5.06	0.31	8.1e-7	Alzheimer's disease;
KIRP	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg09408571	chr1:101003634	GPR88	0.23	5.16	0.31	5.2e-7	Monocyte count;
KIRP	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.63	-5.05	-0.31	8.53e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.69	6.89	0.4	4.76e-11	Uric acid levels;
KIRP	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.41	5.34	0.32	2.08e-7	Verbal declarative memory;
KIRP	cis	rs4356932	1.000	rs6826163	chr4:76973445	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.68	5.51	0.33	8.98e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg01378222	chr16:28622494	SULT1A1	-0.68	-6.24	-0.37	1.88e-9	Platelet distribution width;
KIRP	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.88	12.2	0.61	4.27e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.7	8.53	0.48	1.47e-15	Late-onset Alzheimer's disease;
KIRP	cis	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-7.11	-0.41	1.24e-11	Neuroticism;
KIRP	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	1.08	14.24	0.67	5.78e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8453	0.579	rs3121508	chr1:115348875	G/T	cg12756093	chr1:115239321	AMPD1	0.52	5.59	0.34	5.97e-8	Autism;
KIRP	cis	rs4780401	0.755	rs8191297	chr16:11766986	T/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.06	-0.31	8.32e-7	Rheumatoid arthritis;
KIRP	cis	rs2235573	0.836	rs132932	chr22:38488616	A/T	cg19171272	chr22:38449367	NA	0.59	8.38	0.47	4.11e-15	Glioblastoma;Glioma;
KIRP	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.42	-8.24	-0.47	1.04e-14	Longevity;
KIRP	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg23752985	chr2:85803571	VAMP8	0.59	8.47	0.48	2.2e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg04727924	chr7:799746	HEATR2	0.5	4.94	0.3	1.44e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg04989706	chr14:50066350	PPIL5	-0.49	-5.81	-0.35	1.93e-8	Carotid intima media thickness;
KIRP	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.29	27.51	0.87	5.11e-77	IgG glycosylation;
KIRP	cis	rs12476592	0.602	rs6546018	chr2:63817422	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.04	-0.31	9.19e-7	Childhood ear infection;
KIRP	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg09165964	chr15:75287851	SCAMP5	-0.79	-7.47	-0.43	1.41e-12	Lung cancer;
KIRP	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg25801113	chr15:45476975	SHF	0.49	9.56	0.52	1.31e-18	Uric acid levels;
KIRP	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-8.14	-0.46	1.93e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg05973401	chr12:123451056	ABCB9	-0.56	-6.43	-0.38	6.68e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg21926883	chr2:100939477	LONRF2	-0.57	-7.88	-0.45	1.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	0.948	rs7566385	chr2:73756817	G/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.19	-0.31	4.36e-7	Metabolite levels;
KIRP	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg02336718	chr17:17403227	NA	-0.35	-5.39	-0.32	1.66e-7	Total body bone mineral density;
KIRP	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11987759	chr7:65425863	GUSB	-0.67	-9.46	-0.52	2.67e-18	Aortic root size;
KIRP	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.21	-0.32	4.01e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6542826	0.870	rs11688086	chr2:110063267	G/A	cg05232118	chr2:216660598	NA	0.5	6.05	0.36	5.45e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg19901468	chr14:105411992	AHNAK2	0.74	11.52	0.59	7.45e-25	Rheumatoid arthritis;
KIRP	cis	rs490234	0.702	rs4838279	chr9:128411726	G/A	cg14078157	chr9:128172775	NA	-0.66	-7.65	-0.44	4.58e-13	Mean arterial pressure;
KIRP	cis	rs12282928	1.000	rs7106648	chr11:48283292	A/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10769251	chr19:10679905	CDKN2D	0.51	6.29	0.37	1.42e-9	Parkinson's disease;
KIRP	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Systemic lupus erythematosus;
KIRP	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.66	-0.44	4.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.73	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2387326	0.629	rs12261739	chr10:129945520	A/G	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	5.45	0.33	1.24e-7	Schizophrenia;
KIRP	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-6.87	-0.4	5.16e-11	Mood instability;
KIRP	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.44	-0.33	1.27e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg12560992	chr17:57184187	TRIM37	0.61	5.52	0.33	8.6e-8	Cognitive test performance;
KIRP	cis	rs11790388	0.505	rs7026947	chr9:129746239	A/G	cg13970942	chr9:129673409	NA	-0.4	-5.24	-0.32	3.53e-7	Schizophrenia;
KIRP	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06505273	chr16:24850292	NA	0.4	5.34	0.32	2.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg10377582	chr12:51612794	POU6F1	-0.31	-5.26	-0.32	3.18e-7	Cisplatin-induced ototoxicity;
KIRP	trans	rs9944715	1.000	rs9963153	chr18:43840064	A/G	cg01718231	chr17:29326311	RNF135	-0.51	-6.18	-0.37	2.7e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg11641102	chr8:27183873	PTK2B	0.38	4.9	0.3	1.76e-6	Neuroticism;
KIRP	cis	rs6681460	0.901	rs1373911	chr1:67041065	T/C	cg13052034	chr1:66999238	SGIP1	0.41	5.73	0.34	2.91e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.07e-9	Schizophrenia;
KIRP	cis	rs501120	0.584	rs11238912	chr10:44695909	T/C	cg09554077	chr10:44749378	NA	0.52	5.56	0.33	7.14e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg11783602	chr8:55087084	NA	-0.55	-6.63	-0.39	2.14e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.66	-6.05	-0.36	5.48e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg07701084	chr6:150067640	NUP43	0.58	7.44	0.43	1.68e-12	Testicular germ cell tumor;
KIRP	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.8	9.11	0.5	2.92e-17	Corneal astigmatism;
KIRP	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	1.05	14.92	0.69	2.81e-36	Cognitive function;
KIRP	cis	rs2278796	0.528	rs4951151	chr1:204970302	T/C	cg04862289	chr1:204966208	NFASC	0.67	8.95	0.5	8.95e-17	Mean platelet volume;
KIRP	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.52	-6.52	-0.38	3.9e-10	Alzheimer's disease (late onset);
KIRP	cis	rs829661	0.843	rs2609945	chr2:30864326	A/G	cg10949345	chr2:30726833	LCLAT1	0.96	11.67	0.6	2.52e-25	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs1864585	0.520	rs73208785	chr8:10678120	T/C	cg26278703	chr11:58910052	FAM111A	0.64	6.24	0.37	1.94e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.5e-10	Coronary artery disease;
KIRP	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.37	5.28	0.32	2.79e-7	Plateletcrit;
KIRP	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.82	11.16	0.58	1.11e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10761482	0.861	rs4948410	chr10:62116047	G/A	cg01186212	chr10:62110162	ANK3	-0.29	-4.96	-0.3	1.32e-6	Schizophrenia;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.66	-7.68	-0.44	3.68e-13	Menopause (age at onset);
KIRP	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.48	-0.33	1.08e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.95	-0.57	5.27e-23	Triglycerides;
KIRP	cis	rs3825932	0.744	rs11072818	chr15:79236933	A/G	cg25744700	chr15:79237217	CTSH	0.42	5.23	0.32	3.57e-7	Type 1 diabetes;
KIRP	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14169450	chr9:139327907	INPP5E	0.55	6.51	0.38	4.3e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.74	-8.62	-0.48	8.2e-16	Body mass index;
KIRP	cis	rs4950322	0.570	rs11800580	chr1:146732707	A/G	cg22381352	chr1:146742008	CHD1L	0.47	5.51	0.33	8.9e-8	Protein quantitative trait loci;
KIRP	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg18932078	chr1:2524107	MMEL1	0.47	6.5	0.38	4.51e-10	Ulcerative colitis;
KIRP	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.89	13.77	0.66	2.36e-32	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.45	-0.43	1.56e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	1.01	19.81	0.78	7.6e-53	Height;
KIRP	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg12046867	chr14:103022105	NA	-0.51	-6.15	-0.37	3.09e-9	Platelet count;
KIRP	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg27494647	chr7:150038898	RARRES2	0.44	6.22	0.37	2.13e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs735539	0.645	rs6490600	chr13:21208189	G/T	cg04906043	chr13:21280425	IL17D	-0.48	-5.57	-0.33	6.71e-8	Dental caries;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.78	6.79	0.4	8.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.38	-0.51	4.53e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg06212747	chr3:49208901	KLHDC8B	0.71	8.53	0.48	1.5e-15	Menarche (age at onset);
KIRP	cis	rs8018808	0.905	rs11622359	chr14:77939449	C/T	cg20045696	chr14:77926864	AHSA1	-0.46	-5.55	-0.33	7.24e-8	Myeloid white cell count;
KIRP	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.35	-5.15	-0.31	5.33e-7	Monocyte count;
KIRP	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg15676125	chr6:33679581	C6orf125	0.39	5.15	0.31	5.25e-7	Plateletcrit;
KIRP	cis	rs9296736	0.890	rs9382280	chr6:53912613	C/T	cg04374786	chr6:53939321	C6orf142	0.39	5.22	0.32	3.79e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7523273	0.565	rs2796251	chr1:207903688	C/G	cg22525895	chr1:207977042	MIR29B2	-0.47	-5.99	-0.36	7.26e-9	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15907819	chr5:27119093	NA	0.42	6.18	0.37	2.65e-9	Interleukin-4 levels;
KIRP	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg02807482	chr3:125708958	NA	-0.49	-5.41	-0.33	1.48e-7	Blood pressure (smoking interaction);
KIRP	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.34	-0.37	1.07e-9	Daytime sleep phenotypes;
KIRP	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	6.02	0.36	6.2e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12360000	0.510	rs4880946	chr10:1914321	A/G	cg26364871	chr10:1889757	NA	-0.48	-6.1	-0.36	4.13e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.56	-7.24	-0.42	5.77e-12	Height;
KIRP	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.54	-0.33	7.61e-8	Menarche (age at onset);
KIRP	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-7.89	-0.45	9.67e-14	Common traits (Other);
KIRP	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.85	0.53	1.6e-19	Ileal carcinoids;
KIRP	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.46	5.94	0.35	9.89e-9	Type 2 diabetes;
KIRP	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.07	21.08	0.8	4.82e-57	Schizophrenia;
KIRP	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg16141378	chr3:129829833	LOC729375	0.54	7.17	0.42	8.54e-12	Morning vs. evening chronotype;
KIRP	cis	rs3824347	0.872	rs2376271	chr9:77581337	C/T	cg01251476	chr9:77566080	C9orf40	-0.35	-5.07	-0.31	7.92e-7	Urinary magnesium-to-creatinine ratio;
KIRP	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.51	6.57	0.39	3.01e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg02336718	chr17:17403227	NA	-0.3	-4.98	-0.3	1.21e-6	Total body bone mineral density;
KIRP	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.31	-0.37	1.28e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10513788	0.951	rs72622597	chr3:182073321	T/C	cg01449425	chr3:181957089	NA	-0.47	-6.33	-0.37	1.12e-9	Cognitive function;
KIRP	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	1.08	23.78	0.83	1.06e-65	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-7.21	-0.42	7.01e-12	Dental caries;
KIRP	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg06565975	chr8:143823917	SLURP1	-0.57	-7.74	-0.44	2.64e-13	Urinary tract infection frequency;
KIRP	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.01	0.3	1.03e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.49	0.62	4.56e-28	Ileal carcinoids;
KIRP	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.47	-0.78	9.99e-52	Height;
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-5.94	-0.35	9.77e-9	Lung cancer;
KIRP	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06481639	chr22:41940642	POLR3H	0.64	6.72	0.39	1.28e-10	Vitiligo;
KIRP	trans	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-7.32	-0.42	3.62e-12	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.0	-15.36	-0.7	8.64e-38	Primary sclerosing cholangitis;
KIRP	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.72	8.71	0.49	4.41e-16	Alcohol dependence;
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13047869	chr3:10149882	C3orf24	0.62	5.67	0.34	3.89e-8	Alzheimer's disease;
KIRP	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.66	7.54	0.43	9.16e-13	Corneal astigmatism;
KIRP	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg18306943	chr3:40428807	ENTPD3	0.47	6.33	0.37	1.16e-9	Renal cell carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20768298	chr1:10458896	PGD	0.5	6.69	0.39	1.5e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.8	-0.35	2e-8	IgG glycosylation;
KIRP	cis	rs4666002	0.956	rs10169065	chr2:27778560	A/G	cg05484376	chr2:27715224	FNDC4	-0.37	-5.51	-0.33	8.99e-8	Phospholipid levels (plasma);
KIRP	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg13592947	chr5:1111049	SLC12A7	0.29	4.94	0.3	1.42e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.91	0.3	1.69e-6	Coronary artery calcification;
KIRP	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.85	12.86	0.63	2.63e-29	Height;
KIRP	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg19743168	chr1:23544995	NA	0.48	6.44	0.38	6.35e-10	Height;
KIRP	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2415984	0.600	rs61990993	chr14:46850479	C/G	cg14871534	chr14:47121158	RPL10L	-0.43	-5.16	-0.31	5.13e-7	Number of children ever born;
KIRP	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.6	6.88	0.4	5.04e-11	Response to antipsychotic treatment;
KIRP	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.69	10.36	0.55	4.11e-21	Retinal vascular caliber;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg27189623	chr16:705930	WDR90	0.44	6.08	0.36	4.58e-9	Height;
KIRP	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-6.99	-0.41	2.6e-11	Vitiligo;
KIRP	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.72	-10.61	-0.56	6.67e-22	Hip circumference;
KIRP	trans	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.73	-0.39	1.22e-10	Myopia (pathological);
KIRP	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg08975724	chr8:8085496	FLJ10661	0.65	8.14	0.46	1.94e-14	Neuroticism;
KIRP	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg11995313	chr8:8860691	ERI1	0.39	5.2	0.31	4.1e-7	Joint mobility (Beighton score);
KIRP	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-5.56	-0.33	7.17e-8	Rheumatoid arthritis;
KIRP	cis	rs2302045	1.000	rs740393	chr2:242065498	A/G	cg01305291	chr2:242003078	SNED1	0.5	5.3	0.32	2.61e-7	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio);
KIRP	trans	rs457352	0.614	rs469481	chr21:31229321	G/A	cg11059873	chr5:155794596	SGCD	0.5	6.22	0.37	2.07e-9	Periodontitis (DPAL);
KIRP	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs273218	1.000	rs156442	chr5:53373029	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.68	7.74	0.44	2.63e-13	Migraine;
KIRP	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07509240	chr7:65420297	NA	0.34	4.87	0.3	2e-6	Calcium levels;
KIRP	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05220968	chr6:146057943	EPM2A	-0.37	-5.03	-0.31	9.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.75	-9.43	-0.52	3.32e-18	Facial morphology (factor 19);
KIRP	cis	rs73198271	0.628	rs11781258	chr8:8589758	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg23127183	chr11:57508653	C11orf31	-0.55	-7.19	-0.42	7.64e-12	Schizophrenia;
KIRP	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.37	-5.16	-0.31	5.09e-7	Height;
KIRP	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.41	5.27	0.32	2.94e-7	Aortic root size;
KIRP	cis	rs10465746	0.935	rs12406984	chr1:84416215	C/G	cg10977910	chr1:84465055	TTLL7	0.47	5.77	0.35	2.37e-8	Obesity-related traits;
KIRP	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.85	-0.4	5.91e-11	Systemic lupus erythematosus;
KIRP	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg22508957	chr16:3507546	NAT15	0.43	6.02	0.36	6.45e-9	Body mass index (adult);
KIRP	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.45	-5.26	-0.32	3.21e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.53e-7	Tonsillectomy;
KIRP	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-1.18	-9.85	-0.53	1.64e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.65	10.15	0.54	1.97e-20	Heart rate;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	6.23	0.37	2.05e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg08461772	chr7:95026248	PON3	0.34	4.93	0.3	1.49e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.55	6.16	0.37	3.02e-9	Bone mineral density (spine);
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.2e-8	Life satisfaction;
KIRP	cis	rs6991838	0.584	rs14213	chr8:66514954	C/T	cg13398993	chr8:66546079	ARMC1	0.43	4.97	0.3	1.28e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4950322	0.580	rs4950371	chr1:146585825	C/T	cg22381352	chr1:146742008	CHD1L	-0.43	-4.97	-0.3	1.24e-6	Protein quantitative trait loci;
KIRP	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.98	12.35	0.62	1.39e-27	Response to antineoplastic agents;
KIRP	trans	rs4742903	0.509	rs1507506	chr9:106956123	A/G	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.09	-0.36	4.22e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.53	-0.33	8.24e-8	Headache;
KIRP	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs9488822	0.585	rs569201	chr6:116265861	C/T	cg15226275	chr6:116381976	FRK	-0.23	-6.05	-0.36	5.43e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.87	0.3	1.96e-6	Menarche (age at onset);
KIRP	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.36	0.32	1.89e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.94	-8.86	-0.49	1.7e-16	Lung cancer in ever smokers;
KIRP	cis	rs12042938	1.000	rs11122319	chr1:231808282	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-5.87	-0.35	1.37e-8	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.31	-0.32	2.48e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2346160	0.899	rs206980	chr6:167691798	A/G	cg27333441	chr6:167680455	NA	0.42	5.49	0.33	9.86e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg06647332	chr5:131281008	NA	0.46	5.15	0.31	5.27e-7	Life satisfaction;
KIRP	cis	rs11638352	1.000	rs4924731	chr15:44296724	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.83	-5.72	-0.34	3.12e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg21856205	chr7:94953877	PON1	0.66	10.52	0.56	1.33e-21	Paraoxonase activity;
KIRP	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg15128208	chr22:42549153	NA	0.4	5.23	0.32	3.55e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.57	-7.53	-0.43	9.41e-13	Iron status biomarkers;
KIRP	cis	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	cg12689670	chr1:183009347	LAMC1	0.58	8.07	0.46	3.21e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-1.06	-19.56	-0.78	4.84e-52	Migraine;
KIRP	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg16917193	chr12:54089295	NA	-0.56	-6.82	-0.4	6.87e-11	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg18306943	chr3:40428807	ENTPD3	-0.42	-5.92	-0.35	1.07e-8	Renal cell carcinoma;
KIRP	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.41	-0.38	7.47e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg02931644	chr1:25747376	RHCE	-0.35	-6.35	-0.38	1.05e-9	Erythrocyte sedimentation rate;
KIRP	cis	rs13102973	0.682	rs13107817	chr4:135885535	C/T	cg14419869	chr4:135874104	NA	0.38	6.02	0.36	6.18e-9	Subjective well-being;
KIRP	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.48	-0.52	2.31e-18	Response to antipsychotic treatment;
KIRP	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg16797656	chr11:68205561	LRP5	0.62	10.79	0.57	1.76e-22	Total body bone mineral density;
KIRP	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.29	-0.42	4.29e-12	Neuroticism;
KIRP	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs6674970	0.777	rs12087892	chr1:151118500	T/C	cg11822372	chr1:151115635	SEMA6C	-0.57	-6.22	-0.37	2.14e-9	Childhood ear infection;
KIRP	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg00800038	chr16:89945340	TCF25	-0.72	-5.08	-0.31	7.46e-7	Skin colour saturation;
KIRP	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg24324837	chr19:49891574	CCDC155	0.66	8.48	0.48	2.11e-15	Multiple sclerosis;
KIRP	cis	rs76793172	0.660	rs4803852	chr19:46238926	G/T	cg11657440	chr19:46296263	DMWD	0.76	5.4	0.33	1.57e-7	Eosinophil counts;
KIRP	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg22654517	chr2:96458247	NA	0.34	5.25	0.32	3.3e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26231529	chr11:67033704	ADRBK1	0.5	6.48	0.38	5.01e-10	Parkinson's disease;
KIRP	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.5	-6.38	-0.38	8.54e-10	Type 2 diabetes;
KIRP	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.51	-6.87	-0.4	5.16e-11	Migraine;
KIRP	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.7	7.83	0.45	1.5e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg13206674	chr6:150067644	NUP43	0.63	9.28	0.51	8.93e-18	Lung cancer;
KIRP	cis	rs7224685	0.569	rs7212168	chr17:4024640	G/A	cg09597638	chr17:3907349	NA	0.53	5.26	0.32	3.16e-7	Type 2 diabetes;
KIRP	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.62	6.32	0.37	1.24e-9	Axial length;
KIRP	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.57	6.92	0.4	3.87e-11	Aortic root size;
KIRP	cis	rs3755132	0.778	rs4668455	chr2:15740177	G/A	cg12888861	chr2:15731646	DDX1	0.41	5.39	0.33	1.62e-7	Wilms tumor;
KIRP	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.72	0.39	1.26e-10	Cannabis dependence symptom count;
KIRP	cis	rs7523273	0.565	rs12733108	chr1:207887210	C/T	cg22525895	chr1:207977042	MIR29B2	0.45	5.79	0.35	2.14e-8	Schizophrenia;
KIRP	cis	rs6001982	0.667	rs56135013	chr22:40887074	C/T	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08343347	chr4:36076000	ARAP2	0.41	6.31	0.37	1.27e-9	Migraine with aura;
KIRP	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.86	-13.64	-0.66	6.46e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.73	5.97	0.36	8.24e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6939532	0.522	rs9366652	chr6:26354219	C/G	cg12826209	chr6:26865740	GUSBL1	0.43	5.0	0.3	1.09e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.35	-0.38	1.05e-9	Fibrinogen levels;
KIRP	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg24315340	chr6:146058215	EPM2A	0.44	5.54	0.33	7.91e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg08999081	chr20:33150536	PIGU	0.46	6.15	0.37	3.04e-9	Height;
KIRP	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	trans	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg16141378	chr3:129829833	LOC729375	0.62	8.23	0.46	1.1e-14	Triglycerides;
KIRP	cis	rs10073892	0.511	rs7708617	chr5:101880288	G/T	cg19774478	chr5:101632501	SLCO4C1	0.6	6.49	0.38	4.75e-10	Cognitive decline (age-related);
KIRP	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg01721255	chr8:58191610	C8orf71	0.67	5.7	0.34	3.4e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6545883	0.965	rs3771261	chr2:61762161	A/G	cg15711740	chr2:61764176	XPO1	-0.59	-7.97	-0.45	6e-14	Tuberculosis;
KIRP	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg05484376	chr2:27715224	FNDC4	0.34	5.44	0.33	1.26e-7	Total body bone mineral density;
KIRP	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-0.8	-10.01	-0.54	5.35e-20	Blood trace element (Zn levels);
KIRP	cis	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg07460842	chr6:66804631	NA	-0.49	-6.08	-0.36	4.46e-9	Blood trace element (Cu levels);
KIRP	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg16606324	chr3:10149918	C3orf24	0.58	5.37	0.32	1.81e-7	Alzheimer's disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg24341944	chr3:157827791	RSRC1	0.95	6.43	0.38	6.46e-10	P wave terminal force;
KIRP	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.93	-11.13	-0.58	1.44e-23	White matter hyperintensity burden;
KIRP	cis	rs9834373	0.811	rs9837213	chr3:78481884	A/G	cg06138941	chr3:78371609	NA	-0.38	-5.06	-0.31	8.14e-7	Protein quantitative trait loci;
KIRP	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	6.6	0.39	2.47e-10	Mean platelet volume;
KIRP	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg10756647	chr7:56101905	PSPH	0.96	6.91	0.4	4.19e-11	Diabetic kidney disease;
KIRP	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.82	12.98	0.64	1.07e-29	Multiple myeloma (IgH translocation);
KIRP	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.45	5.22	0.32	3.79e-7	Schizophrenia;
KIRP	cis	rs728616	0.681	rs3862518	chr10:81917957	A/G	cg27417294	chr10:81904244	PLAC9	0.56	5.04	0.31	9.13e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	9.14	0.5	2.41e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.73	-0.34	2.94e-8	Electroencephalogram traits;
KIRP	cis	rs7084402	0.967	rs1658460	chr10:60299151	T/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.87	-0.57	1.02e-22	Refractive error;
KIRP	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg08890418	chr1:21044141	KIF17	-0.43	-6.55	-0.39	3.37e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6832769	0.961	rs11133379	chr4:56306111	G/A	cg05960024	chr4:56376020	CLOCK	0.63	8.05	0.46	3.46e-14	Personality dimensions;
KIRP	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.69	9.24	0.51	1.18e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19717773	chr7:2847554	GNA12	0.36	5.63	0.34	5.03e-8	Height;
KIRP	cis	rs35740288	0.694	rs17618909	chr15:86095462	A/C	cg10818794	chr15:86012489	AKAP13	-0.42	-5.13	-0.31	6e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg00800038	chr16:89945340	TCF25	-0.83	-6.22	-0.37	2.14e-9	Skin colour saturation;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15776560	chr3:25916362	NA	-0.47	-6.17	-0.37	2.84e-9	Inflammatory biomarkers;
KIRP	cis	rs6429082	0.508	rs4233473	chr1:235488052	C/G	cg26050004	chr1:235667680	B3GALNT2	0.4	4.96	0.3	1.32e-6	Adiposity;
KIRP	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg21775007	chr8:11205619	TDH	0.5	6.73	0.39	1.21e-10	Mood instability;
KIRP	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.67	-0.34	4.02e-8	Aortic root size;
KIRP	cis	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.23e-12	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg12826209	chr6:26865740	GUSBL1	0.74	4.95	0.3	1.41e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.87	10.9	0.57	8.12e-23	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	8.97	0.5	7.91e-17	Colorectal cancer;
KIRP	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg13319975	chr6:146136371	FBXO30	0.44	5.95	0.35	9.08e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8077577	0.945	rs62073608	chr17:18071448	T/C	cg09161412	chr17:18057145	MYO15A	-0.39	-5.17	-0.31	4.75e-7	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.95	12.32	0.62	1.8e-27	Homoarginine levels;
KIRP	cis	rs1620921	0.505	rs1549741	chr6:161204783	G/T	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.15e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.7	-10.73	-0.56	2.72e-22	Height;
KIRP	cis	rs654950	0.875	rs2810550	chr1:41995339	T/C	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.47	-0.38	5.23e-10	Airway imaging phenotypes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08697244	chr7:6487510	DAGLB	0.46	6.03	0.36	5.96e-9	Parkinson's disease;
KIRP	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	0.81	11.39	0.59	2.05e-24	Breast cancer;
KIRP	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg11608241	chr8:8085544	FLJ10661	-0.41	-5.26	-0.32	3.11e-7	Mood instability;
KIRP	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.35	5.02	0.3	1e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg10434728	chr15:90938212	IQGAP1	0.42	7.94	0.45	7.02e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg16797656	chr11:68205561	LRP5	0.37	4.87	0.3	2.01e-6	Total body bone mineral density;
KIRP	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg01631408	chr1:248437212	OR2T33	-0.65	-8.45	-0.47	2.6e-15	Common traits (Other);
KIRP	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg07689907	chr11:61582574	FADS1	0.47	5.97	0.36	8.45e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20753954	chr7:1706809	NA	-0.54	-6.46	-0.38	5.56e-10	Menopause (age at onset);
KIRP	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg12362517	chr11:133800685	IGSF9B	0.42	4.86	0.3	2.12e-6	Parkinson's disease;
KIRP	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.69	8.87	0.49	1.52e-16	Prudent dietary pattern;
KIRP	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.08	-15.4	-0.7	6.16e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10207628	0.601	rs6743470	chr2:127868435	G/T	cg06223080	chr2:127868745	NA	-0.68	-9.09	-0.5	3.35e-17	Psychosis and Alzheimer's disease;
KIRP	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.79	-0.44	1.87e-13	Aortic root size;
KIRP	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg01631408	chr1:248437212	OR2T33	-0.37	-5.17	-0.31	4.92e-7	Common traits (Other);
KIRP	cis	rs8070740	0.503	rs10792	chr17:5288179	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.44	5.02	0.3	1.01e-6	Menopause (age at onset);
KIRP	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg23477460	chr3:66848765	NA	-0.67	-7.67	-0.44	4.12e-13	Type 2 diabetes;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg03146073	chr3:44519063	ZNF445	0.57	6.92	0.4	3.83e-11	DNA methylation (variation);
KIRP	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-20.44	-0.79	6.07e-55	Myeloid white cell count;
KIRP	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-8.18	-0.46	1.56e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.57	7.02	0.41	2.13e-11	Total body bone mineral density;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.78	5.79	0.35	2.17e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7082209	1.000	rs4491167	chr10:44810820	T/A	cg09554077	chr10:44749378	NA	0.44	5.33	0.32	2.23e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs7335046	0.614	rs72651404	chr13:100081653	A/G	cg25919922	chr13:100150906	NA	-0.6	-5.27	-0.32	2.94e-7	Basal cell carcinoma;
KIRP	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.53	7.33	0.42	3.3e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.92	13.06	0.64	5.77e-30	Menopause (age at onset);
KIRP	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.53	-4.91	-0.3	1.63e-6	Body mass index (adult);
KIRP	cis	rs9462846	0.652	rs115953673	chr6:42906243	T/A	cg05552183	chr6:42928497	GNMT	0.61	6.98	0.41	2.71e-11	Blood protein levels;
KIRP	cis	rs8028313	0.529	rs380803	chr15:68161273	T/C	cg24579218	chr15:68104479	NA	0.45	6.41	0.38	7.43e-10	Obesity;
KIRP	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg16141378	chr3:129829833	LOC729375	0.51	6.39	0.38	8.13e-10	Joint mobility (Beighton score);
KIRP	cis	rs12145833	0.538	rs61833885	chr1:243397188	C/A	cg02356786	chr1:243265016	LOC731275	0.9	6.46	0.38	5.43e-10	Obesity (early onset extreme);
KIRP	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg22117172	chr7:91764530	CYP51A1	0.41	5.72	0.34	3.04e-8	Breast cancer;
KIRP	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg02023728	chr11:77925099	USP35	-0.33	-5.33	-0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	trans	rs1864585	0.520	rs73208775	chr8:10668281	A/G	cg26278703	chr11:58910052	FAM111A	0.63	6.53	0.38	3.78e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg12140854	chr5:148520817	ABLIM3	-0.57	-6.36	-0.38	1e-9	Breast cancer;
KIRP	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg07777115	chr5:623756	CEP72	-0.51	-5.03	-0.31	9.28e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.64	9.57	0.52	1.19e-18	Vitiligo;
KIRP	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg15507776	chr3:136538369	TMEM22	0.39	5.29	0.32	2.69e-7	Neuroticism;
KIRP	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.58	7.59	0.44	6.61e-13	Height;
KIRP	cis	rs2348418	0.647	rs10843210	chr12:28728733	T/C	cg13890972	chr12:28721907	NA	-0.34	-4.91	-0.3	1.69e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg19636519	chr7:99541626	NA	0.3	5.39	0.33	1.65e-7	Coronary artery disease;
KIRP	cis	rs4356932	1.000	rs13130221	chr4:76955617	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	1.04	13.47	0.65	2.41e-31	Exhaled nitric oxide output;
KIRP	cis	rs28834970	0.925	rs2322599	chr8:27211910	G/A	cg14221460	chr8:27183342	PTK2B	-0.47	-6.12	-0.36	3.71e-9	Alzheimer's disease (late onset);
KIRP	cis	rs2410601	0.520	rs1426916	chr8:18882501	C/G	cg03215416	chr8:18823341	PSD3	-0.4	-5.21	-0.32	4.02e-7	Urinary albumin excretion rate in type 1 diabetes;
KIRP	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.53	8.1	0.46	2.52e-14	Itch intensity from mosquito bite;
KIRP	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.83	11.87	0.6	5.27e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg02487422	chr3:49467188	NICN1	0.42	5.69	0.34	3.63e-8	Parkinson's disease;
KIRP	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg08501292	chr6:25962987	TRIM38	1.0	7.48	0.43	1.32e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg05304507	chr6:116381966	FRK	0.2	5.45	0.33	1.19e-7	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17433772	chr4:151501739	MAB21L2;LRBA	-0.41	-6.2	-0.37	2.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.76	-12.45	-0.62	6.31e-28	Prostate cancer;
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	4.9	0.3	1.77e-6	Electroencephalogram traits;
KIRP	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.69	-0.66	4.32e-32	Primary sclerosing cholangitis;
KIRP	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-1.01	-16.86	-0.73	6.45e-43	Height;
KIRP	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg17724175	chr1:150552817	MCL1	0.37	5.92	0.35	1.05e-8	Melanoma;
KIRP	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.43	0.33	1.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4656940	0.574	rs560681	chr1:160786670	C/T	cg17331569	chr1:160788135	LY9	-0.41	-4.99	-0.3	1.12e-6	Crohn's disease;
KIRP	trans	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19633487	chr1:2522370	MMEL1;C1orf93	0.44	6.2	0.37	2.42e-9	Electrocardiographic conduction measures;
KIRP	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg10790698	chr19:18539756	SSBP4	-0.33	-7.28	-0.42	4.38e-12	Breast cancer;
KIRP	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.51	6.79	0.4	8.29e-11	Plateletcrit;
KIRP	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	1.04	13.47	0.65	2.41e-31	Exhaled nitric oxide output;
KIRP	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg27205649	chr11:78285834	NARS2	0.67	8.93	0.49	1.04e-16	Alzheimer's disease (survival time);
KIRP	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	1.1	11.81	0.6	8.4e-26	Corneal structure;
KIRP	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg25418670	chr11:30344373	C11orf46	0.6	5.07	0.31	7.92e-7	Morning vs. evening chronotype;
KIRP	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.57	-7.7	-0.44	3.25e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.6e-25	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-0.76	-9.01	-0.5	5.76e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg03653399	chr8:142233436	SLC45A4	-0.54	-6.63	-0.39	2.1e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg00405596	chr8:11794950	NA	-0.43	-5.47	-0.33	1.1e-7	Retinal vascular caliber;
KIRP	cis	rs4766646	0.524	rs6606743	chr12:110279179	A/G	cg10794374	chr12:110278745	NA	-0.28	-5.11	-0.31	6.49e-7	Metabolite levels (MHPG);
KIRP	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.52	-6.29	-0.37	1.44e-9	Homocysteine levels;
KIRP	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.23	-0.58	6.86e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs4789693	0.938	rs12952655	chr17:80421139	C/T	cg04308225	chr17:80449738	NA	-0.56	-5.94	-0.35	9.43e-9	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.7	-7.95	-0.45	6.92e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.98	15.84	0.71	1.92e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-12.37	-0.62	1.2100000000000001e-27	Vitiligo;
KIRP	trans	rs2562456	0.833	rs2650801	chr19:21635355	C/T	cg25042112	chr7:64838748	ZNF92	-0.61	-6.61	-0.39	2.41e-10	Pain;
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-7.4	-0.43	2.12e-12	Lung cancer;
KIRP	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.5	-6.33	-0.37	1.17e-9	Prudent dietary pattern;
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.46	5.9	0.35	1.21e-8	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.56	0.52	1.25e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4780401	0.703	rs8191295	chr16:11766905	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.06	-0.31	8.32e-7	Rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.18	-0.37	2.58e-9	Lung cancer;
KIRP	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.6	-7.22	-0.42	6.54e-12	Aortic root size;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08640168	chr5:138273197	NA	-0.45	-6.3	-0.37	1.33e-9	Survival in pancreatic cancer;
KIRP	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg05775895	chr3:12838266	CAND2	0.45	7.44	0.43	1.68e-12	QRS complex (12-leadsum);
KIRP	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.8	9.84	0.53	1.73e-19	Pulse pressure;
KIRP	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs6546324	0.625	rs2861695	chr2:67846727	A/G	cg15745817	chr2:67799979	NA	-0.7	-7.52	-0.43	1.01e-12	Endometriosis;
KIRP	cis	rs6466055	0.661	rs6963624	chr7:104923811	T/C	cg04380332	chr7:105027541	SRPK2	0.38	5.11	0.31	6.45e-7	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.96	12.68	0.63	1.12e-28	Homoarginine levels;
KIRP	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.84	0.45	1.4e-13	Rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.11	-0.31	6.56e-7	Lung cancer;
KIRP	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg22117172	chr7:91764530	CYP51A1	0.44	6.05	0.36	5.23e-9	Breast cancer;
KIRP	cis	rs2151522	0.762	rs6915704	chr6:127194137	A/G	cg21431617	chr6:127135037	NA	0.28	4.9	0.3	1.72e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg19148410	chr11:111250352	POU2AF1	0.42	6.29	0.37	1.4e-9	Primary biliary cholangitis;
KIRP	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.67	-0.44	3.96e-13	Eye color traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07803864	chr10:5446998	TUBAL3	-0.41	-6.17	-0.37	2.83e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs732716	0.785	rs62129354	chr19:4396505	G/A	cg03719555	chr19:4455413	UBXN6	0.51	7.74	0.44	2.5e-13	Mean corpuscular volume;
KIRP	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.98	8.68	0.48	5.68e-16	Type 2 diabetes;
KIRP	cis	rs2315504	0.509	rs2240076	chr17:39035615	C/T	cg26086101	chr17:38992251	TMEM99	-0.31	-5.0	-0.3	1.11e-6	Height;
KIRP	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg08280861	chr8:58055591	NA	0.51	4.92	0.3	1.62e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.5	-6.02	-0.36	6.19e-9	P wave terminal force;
KIRP	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	4.8e-11	Aortic root size;
KIRP	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-6.82	-0.4	7.21e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14820908	chr5:178986412	RUFY1	0.43	6.14	0.36	3.26e-9	Lung cancer;
KIRP	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.53	0.52	1.59e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs829661	0.793	rs829664	chr2:30725733	A/G	cg10949345	chr2:30726833	LCLAT1	1.11	15.88	0.71	1.5e-39	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg00376283	chr12:123451042	ABCB9	0.81	10.68	0.56	4.14e-22	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.62	-0.34	5.17e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9399135	0.773	rs1331308	chr6:135405122	G/T	cg24558204	chr6:135376177	HBS1L	-0.42	-5.37	-0.32	1.81e-7	Red blood cell count;
KIRP	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-1.07	-20.33	-0.79	1.35e-54	Monocyte count;
KIRP	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.56	-7.28	-0.42	4.39e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19717773	chr7:2847554	GNA12	-0.43	-6.31	-0.37	1.26e-9	Height;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg02733842	chr7:1102375	C7orf50	0.41	4.89	0.3	1.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06237353	chr15:82554820	EFTUD1;FAM154B	0.47	6.82	0.4	7.18e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.5	-0.43	1.16e-12	Type 2 diabetes;
KIRP	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.69	-0.39	1.49e-10	Obesity-related traits;
KIRP	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.31	0.32	2.41e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	1.05	9.14	0.5	2.47e-17	Type 2 diabetes;
KIRP	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.89	10.66	0.56	4.78e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg10189774	chr4:17578691	LAP3	0.47	5.65	0.34	4.43e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-8.81	-0.49	2.35e-16	Mitochondrial DNA levels;
KIRP	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-1.0	-11.23	-0.58	6.88e-24	Exhaled nitric oxide output;
KIRP	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.94	-0.45	7.19e-14	Coffee consumption (cups per day);
KIRP	cis	rs2230307	0.656	rs12146139	chr1:100458417	G/A	cg24955406	chr1:100503596	HIAT1	0.53	5.24	0.32	3.38e-7	Carotid intima media thickness;
KIRP	cis	rs6545883	0.894	rs6739427	chr2:61452879	T/C	cg15711740	chr2:61764176	XPO1	0.57	7.46	0.43	1.51e-12	Tuberculosis;
KIRP	trans	rs6601327	0.670	rs9987266	chr8:9659346	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.46	-0.38	5.42e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.69	6.6	0.39	2.45e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6578185	0.782	rs6578184	chr8:142453003	A/G	cg15142913	chr8:142440250	PTP4A3	0.37	4.98	0.3	1.2e-6	Endometriosis;
KIRP	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg04944784	chr2:26401820	FAM59B	-0.56	-6.24	-0.37	1.93e-9	Gut microbiome composition (summer);
KIRP	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.54	-6.38	-0.38	8.84e-10	Macular telangiectasia type 2;
KIRP	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs7010267	0.773	rs10101385	chr8:119923850	A/G	cg01975934	chr8:119970761	NA	0.41	5.26	0.32	3.18e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.64	-10.66	-0.56	4.7e-22	Lung cancer;
KIRP	cis	rs478607	0.915	rs61884449	chr11:64485193	C/T	cg09231725	chr11:64357281	SLC22A12	-0.58	-4.97	-0.3	1.25e-6	Urate levels;
KIRP	cis	rs1210638	0.545	rs6518507	chr22:18976479	C/G	cg12798833	chr22:18958832	DGCR5	-0.48	-6.39	-0.38	8.03e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.27	10.79	0.57	1.84e-22	Atopic dermatitis;
KIRP	trans	rs909341	0.859	rs3208008	chr20:62326110	A/C	cg01311341	chr22:25575246	KIAA1671	0.62	7.4	0.43	2.16e-12	Atopic dermatitis;
KIRP	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs3767633	0.858	rs7532448	chr1:161862745	C/T	cg09175582	chr1:161736000	ATF6	0.74	6.03	0.36	5.88e-9	IgG glycosylation;
KIRP	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg05526886	chr2:227700861	RHBDD1	0.43	5.19	0.31	4.5e-7	Pulmonary function;
KIRP	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	6.56	0.39	3.2e-10	Coronary heart disease;
KIRP	cis	rs1823874	0.710	rs2902472	chr15:100364462	A/G	cg13132497	chr15:100469152	NA	-0.4	-4.87	-0.3	2.01e-6	IgG glycosylation;
KIRP	cis	rs4646404	0.582	rs4924999	chr17:17492002	A/G	cg01246520	chr17:17644344	RAI1	-0.32	-5.25	-0.32	3.34e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg03929089	chr4:120376271	NA	0.7	6.26	0.37	1.72e-9	Axial length;
KIRP	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26314531	chr2:26401878	FAM59B	-0.53	-5.92	-0.35	1.1e-8	Gut microbiome composition (summer);
KIRP	cis	rs7709377	0.570	rs1396478	chr5:115454608	A/T	cg23108291	chr5:115420582	COMMD10	0.41	4.95	0.3	1.4e-6	Metabolite levels  (X-11787);
KIRP	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.78	-0.35	2.22e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25517755	chr10:38738941	LOC399744	-0.36	-5.03	-0.31	9.43e-7	Extrinsic epigenetic age acceleration;
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.58	-6.76	-0.4	1e-10	Menopause (age at onset);
KIRP	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg17757837	chr7:157058334	UBE3C	-0.79	-10.7	-0.56	3.35e-22	Body mass index;
KIRP	cis	rs7737355	0.773	rs7720194	chr5:130837077	T/C	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.85e-6	Life satisfaction;
KIRP	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.29	0.37	1.4e-9	Major depressive disorder;
KIRP	cis	rs714027	0.605	rs1989870	chr22:30472254	A/G	cg27665648	chr22:30112403	NA	0.45	6.35	0.38	1.03e-9	Lymphocyte counts;
KIRP	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-6.82	-0.4	7.21e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg21479132	chr6:26055353	NA	0.78	5.26	0.32	3.15e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.6	9.41	0.51	3.69e-18	Coronary artery disease;
KIRP	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg09231725	chr11:64357281	SLC22A12	-0.51	-5.79	-0.35	2.12e-8	Body mass index;Urate levels;
KIRP	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-7.08	-0.41	1.51e-11	Initial pursuit acceleration;
KIRP	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02034447	chr16:89574710	SPG7	0.41	5.29	0.32	2.77e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs16986825	0.570	rs5752822	chr22:29266025	A/G	cg15103426	chr22:29168792	CCDC117	0.5	5.67	0.34	3.96e-8	Pancreatic cancer;
KIRP	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg16141378	chr3:129829833	LOC729375	0.62	8.06	0.46	3.23e-14	Neuroticism;
KIRP	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.64	-0.39	1.96e-10	Axial length;
KIRP	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg23533926	chr12:111358616	MYL2	-0.54	-7.16	-0.42	9.43e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg26876637	chr1:152193138	HRNR	0.71	9.19	0.51	1.71e-17	Atopic dermatitis;
KIRP	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg04719120	chr6:96025338	MANEA	-0.6	-5.73	-0.34	2.9e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg27189623	chr16:705930	WDR90	0.46	6.3	0.37	1.34e-9	Height;
KIRP	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg18162783	chr1:1795891	GNB1	0.36	5.71	0.34	3.16e-8	Body mass index;
KIRP	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg06781948	chr3:72941472	GXYLT2	0.5	6.74	0.39	1.14e-10	Motion sickness;
KIRP	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg05973401	chr12:123451056	ABCB9	0.62	7.27	0.42	4.73e-12	Platelet count;
KIRP	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.08	-0.36	4.66e-9	Height;
KIRP	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	8.36	0.47	4.8e-15	Response to antipsychotic treatment;
KIRP	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-0.98	-17.85	-0.75	2.9e-46	Heart rate;
KIRP	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.44	4.94	0.3	1.46e-6	Schizophrenia;
KIRP	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.47	0.47	2.32e-15	Colorectal cancer;
KIRP	cis	rs35740288	0.770	rs1382538	chr15:86165896	G/C	cg10818794	chr15:86012489	AKAP13	-0.44	-4.99	-0.3	1.14e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.61	8.81	0.49	2.34e-16	Colorectal cancer;
KIRP	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.16	15.51	0.7	2.57e-38	Platelet count;
KIRP	trans	rs7084921	0.608	rs11598979	chr10:101833720	C/T	cg13808641	chr9:96006533	WNK2	-0.4	-6.06	-0.36	5.06e-9	Bone mineral density;
KIRP	cis	rs742071	0.586	rs17352079	chr1:18941887	C/T	cg22389438	chr1:18926496	NA	-0.41	-5.76	-0.34	2.5e-8	Nonsyndromic cleft lip with cleft palate;Orofacial clefts;
KIRP	cis	rs80282103	0.618	rs11250264	chr10:1151723	A/C	cg08668510	chr10:1095578	IDI1	0.96	6.43	0.38	6.5e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.81	10.65	0.56	4.97e-22	Acylcarnitine levels;
KIRP	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.87	-0.4	5.3e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2950163	0.842	rs1918040	chr2:6188658	A/G	cg26659079	chr2:5836181	SOX11	0.38	4.96	0.3	1.33e-6	Response to metformin (IC50);
KIRP	trans	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg19274270	chr17:78178856	CARD14	-0.39	-7.09	-0.41	1.43e-11	Kawasaki disease;
KIRP	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg16672083	chr15:72433130	SENP8	0.45	6.28	0.37	1.56e-9	Red blood cell count;
KIRP	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4791746	0.948	rs4791748	chr17:8632297	A/G	cg03115937	chr17:8649504	CCDC42	-0.54	-6.0	-0.36	6.84e-9	Heroin dependence;
KIRP	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-0.94	-11.7	-0.6	1.95e-25	Blood protein levels;
KIRP	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	cis	rs7809950	0.817	rs2712230	chr7:107294151	G/A	cg23024343	chr7:107201750	COG5	0.54	7.75	0.44	2.45e-13	Coronary artery disease;
KIRP	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.45	-0.33	1.2e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.01	0.3	1.02e-6	Menopause (age at onset);
KIRP	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs2191566	0.576	rs436790	chr19:44491927	A/G	cg18700516	chr19:44507157	ZNF230	-0.42	-4.9	-0.3	1.77e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg19197139	chr17:4613644	ARRB2	0.74	7.71	0.44	3.07e-13	Lymphocyte counts;
KIRP	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg08807101	chr21:30365312	RNF160	-0.55	-5.34	-0.32	2.09e-7	Cognitive test performance;
KIRP	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg17376030	chr22:41985996	PMM1	-0.54	-5.73	-0.34	2.93e-8	Vitiligo;
KIRP	cis	rs1468333	1.000	rs4835669	chr5:137473391	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	5.18	0.31	4.53e-7	Resting heart rate;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.29	4.94	0.3	1.45e-6	Renal function-related traits (BUN);
KIRP	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg12317470	chr15:67143691	NA	0.59	5.36	0.32	1.93e-7	Lung cancer (smoking interaction);
KIRP	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg22974920	chr21:40686053	BRWD1	0.5	5.93	0.35	1.02e-8	Cognitive function;
KIRP	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg11584989	chr19:19387371	SF4	0.41	5.27	0.32	2.99e-7	Tonsillectomy;
KIRP	cis	rs9815354	1.000	rs1716644	chr3:41968028	A/G	cg03022575	chr3:42003672	ULK4	-0.56	-6.6	-0.39	2.52e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.72	-0.34	3.04e-8	Glomerular filtration rate;
KIRP	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	7.96	0.45	6.2e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg00360474	chr6:37504404	NA	0.46	6.68	0.39	1.61e-10	Cognitive performance;
KIRP	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.04	-0.31	8.93e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg25036284	chr2:26402008	FAM59B	-0.47	-4.94	-0.3	1.42e-6	Gut microbiome composition (summer);
KIRP	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.42	6.0	0.36	7.1e-9	Tuberculosis;
KIRP	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	0.55	6.57	0.39	3.04e-10	Prudent dietary pattern;
KIRP	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-10.24	-0.55	9.89e-21	Mood instability;
KIRP	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.48	-6.27	-0.37	1.57e-9	Body mass index;
KIRP	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.55	0.39	3.33e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.88	9.79	0.53	2.58e-19	Pulmonary function decline;
KIRP	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs3096299	0.809	rs3096325	chr16:89421678	A/G	cg08392591	chr16:89556376	ANKRD11	0.41	5.21	0.32	4.05e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-7.71	-0.44	3.09e-13	Neuroticism;
KIRP	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.6	-0.48	9.25e-16	Blood trace element (Zn levels);
KIRP	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.37	0.47	4.38e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2273156	1.000	rs12050267	chr14:35411428	C/G	cg09327582	chr14:35236912	BAZ1A	-0.53	-5.88	-0.35	1.36e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs501120	0.564	rs11598314	chr10:44685795	A/G	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.31	-6.09	-0.36	4.26e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.77	-10.38	-0.55	3.66e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.26	0.7	1.9e-37	Headache;
KIRP	cis	rs1577917	0.545	rs1832070	chr6:86483172	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.53	6.47	0.38	5.18e-10	Response to antipsychotic treatment;
KIRP	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.66	-11.94	-0.61	3.16e-26	White blood cell count (basophil);
KIRP	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.44	-6.58	-0.39	2.79e-10	Schizophrenia;
KIRP	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg14851346	chr12:38532713	NA	-0.41	-5.11	-0.31	6.46e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg24631222	chr15:78858424	CHRNA5	0.86	9.9	0.53	1.12e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg08901578	chr4:187885870	NA	-0.45	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg20578329	chr17:80767326	TBCD	-0.63	-7.28	-0.42	4.57e-12	Breast cancer;
KIRP	cis	rs7267005	0.661	rs41293084	chr20:34192340	C/G	cg17201900	chr20:34330562	RBM39	1.17	6.97	0.41	2.92e-11	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg00800038	chr16:89945340	TCF25	-0.7	-4.93	-0.3	1.51e-6	Skin colour saturation;
KIRP	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg12892004	chr6:117198278	RFX6	-0.42	-7.14	-0.41	1.04e-11	C-reactive protein levels;
KIRP	cis	rs883565	0.528	rs9311200	chr3:38953896	C/T	cg01426195	chr3:39028469	NA	-0.47	-7.26	-0.42	5.04e-12	Handedness;
KIRP	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.73	9.39	0.51	4.37e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg10304824	chr2:177028804	HOXD3	0.25	5.15	0.31	5.29e-7	IgG glycosylation;
KIRP	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg07972983	chr1:205091412	RBBP5	-0.42	-4.95	-0.3	1.36e-6	Red blood cell count;
KIRP	cis	rs290268	0.585	rs290992	chr9:93561309	C/T	cg02608019	chr9:93564028	SYK	-0.66	-8.69	-0.48	5.08e-16	Platelet count;
KIRP	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.67	10.18	0.54	1.57e-20	Coronary artery disease;
KIRP	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.61	-9.13	-0.5	2.63e-17	Educational attainment;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14880282	chr13:19412250	LOC284232	0.45	6.84	0.4	6.12e-11	Cancer;
KIRP	cis	rs11731606	0.567	rs17377951	chr4:95321099	C/T	cg00507259	chr4:95128692	SMARCAD1	0.66	5.94	0.35	9.71e-9	Mean platelet volume;
KIRP	cis	rs1847202	0.859	rs6771288	chr3:72939471	A/G	cg06781948	chr3:72941472	GXYLT2	0.39	5.14	0.31	5.52e-7	Motion sickness;
KIRP	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg16797656	chr11:68205561	LRP5	0.38	4.98	0.3	1.2e-6	Total body bone mineral density;
KIRP	cis	rs4006360	0.604	rs1976318	chr17:39250906	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs4356932	1.000	rs13130018	chr4:76955519	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg14580859	chr9:123691850	NA	0.36	5.05	0.31	8.62e-7	Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20739904	chr5:6629638	NSUN2	-0.49	-6.45	-0.38	5.86e-10	Parkinson's disease;
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14893161	chr1:205819251	PM20D1	0.83	12.07	0.61	1.18e-26	Monocyte percentage of white cells;
KIRP	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-5.02	-0.3	9.81e-7	Morning vs. evening chronotype;
KIRP	trans	rs12517041	1.000	rs1428630	chr5:23321186	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.48	-0.43	1.3e-12	Calcium levels;
KIRP	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	0.78	8.41	0.47	3.41e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg13615516	chr5:77269221	NA	0.52	8.24	0.47	1.03e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.58	-7.08	-0.41	1.55e-11	Aortic root size;
KIRP	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.01	-0.5	5.93e-17	Retinal vascular caliber;
KIRP	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg01088410	chr5:170739179	NA	-0.43	-6.07	-0.36	4.92e-9	Vertical cup-disc ratio;
KIRP	cis	rs6976053	0.518	rs314357	chr7:100410069	A/G	cg03098644	chr7:100410630	EPHB4	-0.56	-7.62	-0.44	5.52e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
KIRP	cis	rs12476592	0.602	rs2166497	chr2:63800159	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19671926	chr4:122722719	EXOSC9	0.52	6.37	0.38	9.38e-10	Type 2 diabetes;
KIRP	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08439880	chr3:133502540	NA	-0.5	-6.5	-0.38	4.4e-10	Iron status biomarkers;
KIRP	cis	rs526231	0.511	rs10434793	chr5:102389815	A/T	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.71	8.98	0.5	7.45e-17	Bladder cancer;
KIRP	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19671926	chr4:122722719	EXOSC9	0.51	6.19	0.37	2.57e-9	Type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg18132916	chr6:79620363	NA	-0.42	-5.7	-0.34	3.43e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.84	-11.72	-0.6	1.7e-25	Height;
KIRP	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.88	14.18	0.67	9.43e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4262150	0.667	rs4509081	chr5:152257172	A/G	cg12297329	chr5:152029980	NA	0.46	6.52	0.38	4.02e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.74e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	5.96	0.36	8.63e-9	Menarche (age at onset);
KIRP	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg02725872	chr8:58115012	NA	-0.53	-6.02	-0.36	6.19e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.62	-0.56	6.31e-22	Gut microbiome composition (summer);
KIRP	trans	rs1106684	1.000	rs35842177	chr7:131463170	A/G	cg13607082	chr12:122652224	LRRC43	-0.65	-6.65	-0.39	1.85e-10	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13976753	chr1:24681532	GRHL3	-0.44	-6.18	-0.37	2.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg26668828	chr6:292823	DUSP22	-0.62	-7.26	-0.42	5.14e-12	Menopause (age at onset);
KIRP	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	6.77	0.4	9.3e-11	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9810890	0.702	rs73210621	chr3:128655147	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.45e-7	Dental caries;
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16524936	chr4:1340807	KIAA1530	-0.53	-6.95	-0.41	3.25e-11	Longevity;
KIRP	cis	rs4356932	1.000	rs6850760	chr4:76951684	A/T	cg00809888	chr4:76862425	NAAA	0.44	6.24	0.37	1.88e-9	Blood protein levels;
KIRP	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.49	4.49e-16	Neutrophil percentage of white cells;
KIRP	cis	rs7172677	1.000	rs7172205	chr15:75424335	A/G	cg14664628	chr15:75095509	CSK	-0.45	-4.94	-0.3	1.45e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg16497661	chr14:103986332	CKB	-0.53	-6.98	-0.41	2.71e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs4356975	0.509	rs6600884	chr4:69968066	A/C	cg23411876	chr7:140396886	LOC100134713;NDUFB2	-0.46	-6.03	-0.36	5.88e-9	Obesity-related traits;
KIRP	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg00631329	chr6:26305371	NA	-0.67	-8.25	-0.47	9.41e-15	Educational attainment;
KIRP	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg02725872	chr8:58115012	NA	-0.55	-6.18	-0.37	2.66e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.62	6.99	0.41	2.54e-11	Aortic root size;
KIRP	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.75	-10.28	-0.55	7.2e-21	Gut microbiota (bacterial taxa);
KIRP	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	cg21523751	chr1:182988639	NA	0.45	7.2	0.42	7.14e-12	Colorectal cancer;
KIRP	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg23974023	chr2:113544294	IL1A	-0.36	-5.12	-0.31	6.18e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	1.1	8.4	0.47	3.6e-15	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg04025307	chr7:1156635	C7orf50	0.77	7.99	0.45	5.22e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg10130564	chr11:117069849	TAGLN	-0.41	-5.1	-0.31	6.65e-7	Blood protein levels;
KIRP	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11622362	chr11:34938112	PDHX;APIP	-0.44	-5.38	-0.32	1.76e-7	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01144693	chr1:85359106	LPAR3	0.44	6.08	0.36	4.54e-9	Smoking initiation;
KIRP	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.88	13.65	0.66	5.73e-32	Mean corpuscular volume;
KIRP	cis	rs6800768	0.633	rs12498129	chr3:24120454	A/G	cg10674438	chr3:24145617	LOC152024	-0.52	-6.73	-0.39	1.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg15848620	chr12:58087721	OS9	0.44	4.94	0.3	1.47e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05347473	chr6:146136440	FBXO30	0.57	8.12	0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2671245	0.586	rs9436525	chr1:56139752	A/G	cg11523071	chr1:56160889	NA	0.43	6.6	0.39	2.53e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26207909	chr14:103986467	CKB	0.47	6.36	0.38	9.6e-10	Body mass index;
KIRP	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg09596252	chr17:78655493	RPTOR	0.47	5.44	0.33	1.26e-7	Fractional excretion of uric acid;
KIRP	cis	rs7246657	0.722	rs954504	chr19:38045394	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	1.09	17.81	0.75	3.82e-46	Cognitive function;
KIRP	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg05692746	chr2:100937584	LONRF2	-0.39	-5.05	-0.31	8.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg26138937	chr11:71823887	C11orf51	-1.11	-7.13	-0.41	1.1e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-8.04	-0.46	3.86e-14	Response to antipsychotic treatment;
KIRP	cis	rs714027	1.000	rs714027	chr22:30577771	A/G	cg27665648	chr22:30112403	NA	0.4	5.84	0.35	1.61e-8	Lymphocyte counts;
KIRP	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg12253828	chr6:101329408	ASCC3	0.98	7.74	0.44	2.62e-13	Economic and political preferences (immigration/crime);
KIRP	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.86	12.58	0.63	2.32e-28	Personality dimensions;
KIRP	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg04727924	chr7:799746	HEATR2	-0.69	-6.57	-0.39	2.92e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg04025307	chr7:1156635	C7orf50	0.5	6.34	0.37	1.12e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg08917208	chr2:24149416	ATAD2B	0.62	5.34	0.32	2.14e-7	Lymphocyte counts;
KIRP	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.31	17.35	0.74	1.41e-44	Corneal structure;
KIRP	cis	rs11696739	0.536	rs3761268	chr20:1601167	C/T	cg11295724	chr20:1538353	SIRPD	-0.5	-4.9	-0.3	1.7e-6	Mean platelet volume;
KIRP	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.4	5.11	0.31	6.51e-7	IgG glycosylation;
KIRP	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	1.04	15.9	0.71	1.22e-39	Homoarginine levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23486345	chr6:99797485	C6orf168	-0.46	-6.57	-0.39	2.97e-10	Myopia;
KIRP	cis	rs13102973	0.965	rs10434072	chr4:135867883	C/T	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	trans	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg16141378	chr3:129829833	LOC729375	0.62	8.27	0.47	8.34e-15	Neuroticism;
KIRP	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg23625390	chr15:77176239	SCAPER	0.52	6.85	0.4	5.97e-11	Blood metabolite levels;
KIRP	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.38	-0.47	4.18e-15	Retinal vascular caliber;
KIRP	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.1	13.54	0.65	1.34e-31	IgG glycosylation;
KIRP	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.25	25.72	0.85	1.14e-71	IgG glycosylation;
KIRP	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg01320579	chr17:75405842	SEPT9	0.47	7.63	0.44	5.29e-13	Airflow obstruction;
KIRP	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs7849270	1.000	rs3739843	chr9:131882961	G/A	cg13538475	chr9:131942899	NA	-0.31	-5.02	-0.3	9.84e-7	Blood metabolite ratios;
KIRP	cis	rs4774830	0.744	rs2414455	chr15:56290399	C/A	cg24530489	chr15:56299380	NA	-0.86	-5.06	-0.31	8.14e-7	Delta-5 desaturase activity;
KIRP	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg08807101	chr21:30365312	RNF160	-0.58	-7.08	-0.41	1.51e-11	Pancreatic cancer;
KIRP	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.71	0.71	5.4e-39	Menarche (age at onset);
KIRP	cis	rs12586317	0.557	rs72664863	chr14:35643588	C/T	cg07166546	chr14:35805898	NA	-0.28	-6.53	-0.38	3.67e-10	Psoriasis;
KIRP	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg20503657	chr10:835505	NA	0.52	6.13	0.36	3.47e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs244899	0.935	rs590784	chr5:167917504	G/T	cg13011109	chr5:167955758	FBLL1	0.36	5.05	0.31	8.61e-7	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg18154014	chr19:37997991	ZNF793	0.94	9.68	0.53	5.45e-19	Coronary artery calcification;
KIRP	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.76	-0.34	2.49e-8	Educational attainment;
KIRP	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg22437258	chr11:111473054	SIK2	0.55	6.59	0.39	2.73e-10	Primary sclerosing cholangitis;
KIRP	cis	rs2223471	0.776	rs10948570	chr6:50646175	C/T	cg03432817	chr6:50765336	NA	0.41	6.53	0.38	3.65e-10	Subcutaneous adipose tissue;
KIRP	cis	rs4805272	0.632	rs7249919	chr19:29335362	C/A	cg15000279	chr19:29285009	NA	0.39	5.94	0.35	9.53e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg20636351	chr8:55087400	NA	-0.53	-6.42	-0.38	6.85e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.99	-13.26	-0.65	1.25e-30	Homoarginine levels;
KIRP	cis	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.93	0.3	1.49e-6	Leprosy;
KIRP	cis	rs7923609	0.967	rs3740331	chr10:65192288	G/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg00543991	chr22:32367038	NA	0.53	4.85	0.3	2.17e-6	Childhood ear infection;
KIRP	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.34	0.55	4.65e-21	Cognitive test performance;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-6.21	-0.37	2.3e-9	Breast cancer;
KIRP	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg04609801	chr16:28609176	SULT1A2	-0.47	-5.39	-0.33	1.62e-7	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06134546	chr15:64753130	NA	0.49	6.06	0.36	5.09e-9	Parkinson's disease;
KIRP	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.51	7.64	0.44	4.98e-13	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09119654	chr2:61293073	KIAA1841	-0.5	-6.52	-0.38	4.04e-10	Myopia;
KIRP	cis	rs4481887	0.830	rs4364913	chr1:248515635	C/A	cg01631408	chr1:248437212	OR2T33	-0.46	-6.09	-0.36	4.21e-9	Common traits (Other);
KIRP	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.49	-0.52	2.12e-18	Chronic sinus infection;
KIRP	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.75	-12.02	-0.61	1.71e-26	Rheumatoid arthritis;
KIRP	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.59	8.15	0.46	1.88e-14	Myopia (pathological);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14377739	chr9:139699037	KIAA1984;LOC100131193	-0.43	-6.12	-0.36	3.68e-9	Parkinson's disease;
KIRP	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.83	12.9	0.64	1.97e-29	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09240267	chr20:31437287	MAPRE1	0.43	6.03	0.36	5.97e-9	Survival in pancreatic cancer;
KIRP	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.83	-11.52	-0.59	7.85e-25	Height;
KIRP	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg16584676	chr17:46985605	UBE2Z	0.5	6.17	0.37	2.75e-9	Type 2 diabetes;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16315668	chr3:123676816	CCDC14	0.39	6.41	0.38	7.54e-10	C-reactive protein;
KIRP	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-9.14	-0.5	2.42e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs5747327	0.838	rs35945753	chr22:18156644	A/G	cg19898043	chr22:18121309	BCL2L13	-0.41	-4.92	-0.3	1.61e-6	Myeloid white cell count;Granulocyte count;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg01426354	chr20:33999881	UQCC	0.51	6.03	0.36	6e-9	Plasma plasminogen activator levels;
KIRP	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs1555895	0.521	rs1057303	chr10:853155	T/C	cg10017260	chr10:834428	NA	-0.43	-6.41	-0.38	7.43e-10	Survival in rectal cancer;
KIRP	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg02002194	chr4:3960332	NA	-0.45	-6.83	-0.4	6.5e-11	Mood instability;
KIRP	cis	rs1620921	1.000	rs1621801	chr6:161196966	A/C	cg01280913	chr6:161186852	NA	-0.38	-5.25	-0.32	3.24e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.54	8.47	0.48	2.31e-15	Schizophrenia;
KIRP	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg21077578	chr7:1022970	CYP2W1	0.36	4.96	0.3	1.31e-6	Longevity;Endometriosis;
KIRP	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg13010199	chr12:38710504	ALG10B	0.39	5.07	0.31	7.91e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6001982	0.667	rs113409089	chr22:40885600	G/A	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.68	7.94	0.45	7.15e-14	Diabetic retinopathy;
KIRP	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg17644776	chr2:200775616	C2orf69	-0.57	-4.93	-0.3	1.5e-6	Schizophrenia;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg17704177	chr6:36562212	SFRS3	0.92	6.1	0.36	4.18e-9	P wave terminal force;
KIRP	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.69	7.81	0.45	1.7e-13	Corneal astigmatism;
KIRP	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg00129232	chr17:37814104	STARD3	-0.81	-11.95	-0.61	2.88e-26	Asthma;
KIRP	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg07451762	chr16:28383216	NA	-0.43	-5.84	-0.35	1.63e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.54	0.52	1.45e-18	Cognitive test performance;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20850894	chr4:73013819	NPFFR2	-0.41	-6.87	-0.4	5.29e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7254192	0.625	rs736625	chr19:41265201	C/T	cg24958765	chr19:41283667	RAB4B	-0.48	-5.83	-0.35	1.73e-8	Post bronchodilator FEV1;
KIRP	cis	rs1021993	0.545	rs58017268	chr1:209540074	C/T	cg24446417	chr1:209558027	NA	-0.52	-5.16	-0.31	5.19e-7	Gut microbiome composition (winter);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27261837	chr1:146714163	CHD1L	0.65	7.87	0.45	1.14e-13	Smoking initiation;
KIRP	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg14893161	chr1:205819251	PM20D1	-0.55	-5.02	-0.3	1e-6	Menarche (age at onset);
KIRP	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.71	-9.16	-0.5	2.16e-17	Alzheimer's disease;
KIRP	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.64	-7.95	-0.45	6.61e-14	Longevity;
KIRP	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg23594656	chr7:65796392	TPST1	0.51	7.85	0.45	1.32e-13	Aortic root size;
KIRP	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.55	-8.83	-0.49	2.04e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg06212747	chr3:49208901	KLHDC8B	0.56	6.27	0.37	1.64e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs2882667	0.964	rs67296915	chr5:138301599	C/T	cg04439458	chr5:138467593	SIL1	-0.39	-6.21	-0.37	2.28e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg09555818	chr19:45449301	APOC2	0.41	5.33	0.32	2.25e-7	Blood protein levels;
KIRP	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.41	5.85	0.35	1.52e-8	Endometrial cancer;
KIRP	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.64	-7.75	-0.44	2.37e-13	Facial morphology (factor 19);
KIRP	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.87	-9.73	-0.53	3.77e-19	Pulmonary function decline;
KIRP	cis	rs830233	0.654	rs26442	chr5:165373210	C/G	cg13976338	chr5:165423657	NA	0.53	6.26	0.37	1.69e-9	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs10981012	0.504	rs10981092	chr9:114584031	A/G	cg14428669	chr9:114659192	UGCG	0.45	4.94	0.3	1.44e-6	Coronary artery disease;
KIRP	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-5.23	-0.32	3.59e-7	Cognitive function;
KIRP	cis	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg19171272	chr22:38449367	NA	-0.62	-9.12	-0.5	2.7e-17	Glioblastoma;Glioma;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs6967385	0.560	rs12673036	chr7:12343463	A/G	cg20607287	chr7:12443886	VWDE	0.37	5.02	0.31	9.7e-7	Response to taxane treatment (placlitaxel);
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg06815112	chr8:27182871	PTK2B	0.49	6.4	0.38	7.84e-10	Neuroticism;
KIRP	cis	rs911119	0.913	rs6048922	chr20:23578116	G/C	cg09631192	chr20:23583594	CST9	-0.48	-5.1	-0.31	6.68e-7	Chronic kidney disease;
KIRP	cis	rs72730918	0.564	rs17524906	chr15:51829812	G/A	cg14296394	chr15:51910925	DMXL2	0.76	10.53	0.56	1.23e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	1.0	17.09	0.74	1.06e-43	Menopause (age at onset);
KIRP	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.93	-0.35	1.03e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg07843065	chr1:150265600	MRPS21	0.41	5.7	0.34	3.49e-8	Migraine;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14579362	chr19:39926682	RPS16	0.46	6.38	0.38	8.67e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg06212747	chr3:49208901	KLHDC8B	0.57	6.39	0.38	8.08e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg15247329	chr7:2764246	NA	-0.36	-4.97	-0.3	1.27e-6	Height;
KIRP	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg20295408	chr7:1910781	MAD1L1	-0.44	-4.89	-0.3	1.81e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg24110177	chr3:50126178	RBM5	-0.66	-7.38	-0.43	2.43e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13939156	chr17:80058883	NA	-0.5	-7.43	-0.43	1.83e-12	Life satisfaction;
KIRP	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.2	0.31	4.11e-7	Parkinson's disease;
KIRP	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg21775007	chr8:11205619	TDH	-0.52	-6.96	-0.41	3e-11	Triglycerides;
KIRP	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	0.98	11.31	0.59	3.61e-24	Iron status biomarkers;
KIRP	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.63	8.83	0.49	2.04e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg23985595	chr17:80112537	CCDC57	-0.34	-5.19	-0.31	4.45e-7	Life satisfaction;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg20431676	chr16:88815953	FAM38A	0.43	6.65	0.39	1.88e-10	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs4654899	0.865	rs960564	chr1:21416435	G/T	cg05370193	chr1:21551575	ECE1	0.46	6.2	0.37	2.43e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.36	-0.38	9.63e-10	Breast cancer;
KIRP	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	6.53	0.38	3.64e-10	LDL cholesterol;
KIRP	cis	rs1971256	0.500	rs1971255	chr6:151816094	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.53	-4.94	-0.3	1.41e-6	Endometriosis;
KIRP	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	4.9	0.3	1.71e-6	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs6500395	0.588	rs2354580	chr16:48637178	C/T	cg04672837	chr16:48644449	N4BP1	0.43	5.97	0.36	8.15e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.67	8.6	0.48	9.36e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.08	0.46	3.01e-14	Menopause (age at onset);
KIRP	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg20560906	chr3:47459876	SCAP	0.46	6.54	0.38	3.61e-10	Serum protein levels (sST2);
KIRP	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.73	7.37	0.43	2.62e-12	Bipolar disorder;
KIRP	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.47	6.84	0.4	6.37e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.55	7.62	0.44	5.57e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.43	0.33	1.33e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg23307798	chr14:103986281	CKB	-0.44	-5.87	-0.35	1.41e-8	Coronary artery disease;
KIRP	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg25173405	chr17:45401733	C17orf57	0.42	5.37	0.32	1.79e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.75	9.58	0.52	1.12e-18	Renal function-related traits (BUN);
KIRP	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg20991723	chr1:152506922	NA	-0.46	-5.49	-0.33	1.01e-7	Hair morphology;
KIRP	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg13731523	chr4:3047190	NA	-0.38	-6.4	-0.38	7.86e-10	Serum sulfate level;
KIRP	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.64	8.14	0.46	1.96e-14	Tonsillectomy;
KIRP	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-8.33	-0.47	5.66e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs6064045	0.510	rs462703	chr20:52679179	A/T	cg23682609	chr20:52687365	BCAS1	0.38	6.12	0.36	3.76e-9	IgG glycosylation;
KIRP	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.29	-0.37	1.47e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11955398	0.501	rs4235480	chr5:60032371	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.01	-0.3	1.06e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.68	-7.85	-0.45	1.28e-13	Height;
KIRP	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	7.57	0.43	7.7e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg11266682	chr4:10021025	SLC2A9	0.38	4.86	0.3	2.07e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9323205	0.765	rs2999389	chr14:51654510	G/A	cg23942311	chr14:51606299	NA	0.65	9.09	0.5	3.32e-17	Cancer;
KIRP	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.39	-4.96	-0.3	1.29e-6	Neuroticism;
KIRP	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg22654517	chr2:96458247	NA	0.34	5.25	0.32	3.3e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg17279839	chr7:150038598	RARRES2	0.55	6.91	0.4	4.09e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.33	-0.32	2.2e-7	Bipolar disorder;
KIRP	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg22541963	chr20:60982533	CABLES2	0.47	5.75	0.34	2.58e-8	Colorectal cancer;
KIRP	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.56	9.73	0.53	3.97e-19	Bone mineral density;
KIRP	cis	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.92	-0.35	1.06e-8	HDL cholesterol;
KIRP	cis	rs9361491	0.508	rs9343787	chr6:79415606	A/C	cg09184832	chr6:79620586	NA	-0.38	-4.89	-0.3	1.86e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.67	0.39	1.66e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg21775007	chr8:11205619	TDH	0.49	6.41	0.38	7.4e-10	Mood instability;
KIRP	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg03468072	chr12:39539422	NA	0.41	5.88	0.35	1.31e-8	Morning vs. evening chronotype;
KIRP	cis	rs1010254	0.510	rs17543712	chr5:151715526	C/G	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.51	0.48	1.76e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.14	0.46	2.01e-14	Smoking initiation;
KIRP	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.44	5.69	0.34	3.65e-8	Height;
KIRP	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23598886	chr18:12777645	NA	-0.62	-4.91	-0.3	1.67e-6	Inflammatory skin disease;
KIRP	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg03468072	chr12:39539422	NA	0.39	5.76	0.34	2.53e-8	Morning vs. evening chronotype;
KIRP	cis	rs12220238	0.722	rs6480742	chr10:76398466	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.54	6.09	0.36	4.25e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7010876	0.568	rs13439559	chr8:89244402	G/A	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg12573674	chr2:1569213	NA	-0.57	-5.03	-0.31	9.32e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7527798	0.592	rs6657161	chr1:207847128	C/T	cg09232269	chr1:207846808	CR1L	-0.39	-5.66	-0.34	4.24e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs3857747	0.827	rs4364550	chr7:40458304	A/G	cg00420559	chr7:40367873	C7orf10	-0.57	-7.54	-0.43	9.31e-13	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.09	-0.41	1.42e-11	Fear of minor pain;
KIRP	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.49	-6.1	-0.36	4.01e-9	Alzheimer's disease (late onset);
KIRP	cis	rs448720	1.000	rs392452	chr15:68207015	C/T	cg24579218	chr15:68104479	NA	-0.35	-5.0	-0.3	1.11e-6	Cognitive performance;
KIRP	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.6	-8.37	-0.47	4.35e-15	Coronary artery disease;
KIRP	cis	rs4804368	0.591	rs1035940	chr19:7199978	C/G	cg09377704	chr19:7936683	NA	0.44	4.91	0.3	1.67e-6	Renal cell carcinoma;
KIRP	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg03146154	chr1:46216737	IPP	-0.41	-5.25	-0.32	3.22e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.68	8.23	0.46	1.11e-14	Post bronchodilator FEV1;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09234543	chr2:240090592	HDAC4	-0.51	-6.61	-0.39	2.3e-10	Parkinson's disease;
KIRP	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg10189774	chr4:17578691	LAP3	0.47	5.74	0.34	2.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11987759	chr7:65425863	GUSB	-0.56	-7.52	-0.43	1.01e-12	Aortic root size;
KIRP	cis	rs4302748	0.862	rs11971718	chr7:36184620	T/C	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	trans	rs752590	0.623	rs67776659	chr2:113984594	T/C	cg10779423	chr3:50604763	C3orf18	0.49	6.08	0.36	4.49e-9	Mucinous ovarian carcinoma;
KIRP	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.84	11.75	0.6	1.37e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg21475434	chr5:93447410	FAM172A	-0.44	-5.18	-0.31	4.56e-7	Diabetic retinopathy;
KIRP	cis	rs6545883	0.929	rs778155	chr2:61647901	A/G	cg15711740	chr2:61764176	XPO1	0.62	7.95	0.45	6.67e-14	Tuberculosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27557143	chr19:19754301	GMIP	0.45	6.08	0.36	4.52e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.55	-6.41	-0.38	7.21e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg04727924	chr7:799746	HEATR2	-0.68	-7.7	-0.44	3.23e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	cg12689670	chr1:183009347	LAMC1	0.42	6.1	0.36	4.17e-9	Colorectal cancer;
KIRP	cis	rs2457480	0.866	rs11238940	chr10:44721459	G/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;
KIRP	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	7.89	0.45	9.64e-14	Height;
KIRP	trans	rs9409565	1.000	rs9409565	chr9:97251034	C/T	cg05679027	chr9:99775184	HIATL2	-0.51	-6.18	-0.37	2.62e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08037420	chr3:172428855	NCEH1	0.61	7.35	0.42	3.01e-12	Smoking initiation;
KIRP	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg13736514	chr6:26305472	NA	-0.6	-7.69	-0.44	3.53e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs16857609	0.600	rs10932715	chr2:218259783	A/G	cg15335768	chr2:218268053	DIRC3	-0.53	-7.05	-0.41	1.83e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	1.09	20.11	0.79	7.2e-54	Gut microbiome composition (winter);
KIRP	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg00646200	chr1:148855367	NA	0.52	6.28	0.37	1.51e-9	Hip geometry;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.56	6.98	0.41	2.8e-11	Longevity;Endometriosis;
KIRP	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.03	-0.31	9.66e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg15507776	chr3:136538369	TMEM22	0.39	5.39	0.33	1.65e-7	Neuroticism;
KIRP	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.5	-7.83	-0.45	1.46e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg06671706	chr8:8559999	CLDN23	0.58	6.54	0.38	3.61e-10	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.41	-5.58	-0.34	6.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg24375607	chr4:120327624	NA	0.55	5.69	0.34	3.62e-8	Corneal astigmatism;
KIRP	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.46	5.54	0.33	7.61e-8	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.45	5.44	0.33	1.26e-7	HDL cholesterol;
KIRP	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.62	-0.48	8.09e-16	Coronary artery disease;
KIRP	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg24699146	chr1:24152579	HMGCL	0.42	5.45	0.33	1.22e-7	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
KIRP	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.76	-9.2	-0.51	1.63e-17	Longevity;Endometriosis;
KIRP	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	1.24	8.67	0.48	5.92e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg27529930	chr15:40697959	IVD	0.52	6.42	0.38	6.81e-10	Educational attainment;
KIRP	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.29	-0.32	2.7e-7	Gut microbiome composition (summer);
KIRP	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.45	-5.2	-0.31	4.22e-7	Non-obstructive azoospermia;
KIRP	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-0.9	-10.25	-0.55	9.01e-21	Triglycerides;
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.79	13.09	0.64	4.61e-30	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg20490199	chr8:104033148	ATP6V1C1	-0.55	-6.17	-0.37	2.77e-9	Corneal astigmatism;
KIRP	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.45	0.38	6e-10	Height;
KIRP	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	1.0	15.83	0.71	2.18e-39	Vitamin D levels;
KIRP	cis	rs4262150	0.810	rs17566146	chr5:152088959	C/G	cg12297329	chr5:152029980	NA	-0.61	-7.36	-0.42	2.73e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13198984	chr17:80129470	CCDC57	-0.55	-8.37	-0.47	4.36e-15	Life satisfaction;
KIRP	cis	rs981844	0.712	rs11099914	chr4:154743519	C/T	cg14289246	chr4:154710475	SFRP2	-0.54	-7.04	-0.41	1.94e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.71	8.49	0.48	1.93e-15	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg06521331	chr12:34319734	NA	-0.57	-6.9	-0.4	4.38e-11	Morning vs. evening chronotype;
KIRP	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.59	-0.44	6.53e-13	Response to antipsychotic treatment;
KIRP	cis	rs4631830	0.568	rs12781411	chr10:51491589	C/T	cg10326726	chr10:51549505	MSMB	0.62	8.41	0.47	3.37e-15	Prostate-specific antigen levels;
KIRP	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.26	0.51	1.03e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.53	-6.21	-0.37	2.25e-9	Ulcerative colitis;
KIRP	trans	rs526231	0.644	rs35797	chr5:102614327	A/G	cg20610017	chr1:173991134	NA	0.46	6.08	0.36	4.61e-9	Primary biliary cholangitis;
KIRP	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg03714773	chr7:91764589	CYP51A1	0.33	4.92	0.3	1.6e-6	Breast cancer;
KIRP	cis	rs7503807	0.664	rs35524093	chr17:78574246	A/G	cg09596252	chr17:78655493	RPTOR	0.51	5.65	0.34	4.39e-8	Obesity;
KIRP	cis	rs7640424	0.649	rs35595234	chr3:107922116	C/T	cg09227934	chr3:107805635	CD47	-0.36	-6.11	-0.36	3.85e-9	Body mass index;
KIRP	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg24253500	chr15:84953950	NA	0.54	6.18	0.37	2.62e-9	Schizophrenia;
KIRP	cis	rs66696671	0.559	rs2420637	chr10:121356658	G/A	cg06765389	chr10:121379685	NA	-0.4	-5.49	-0.33	9.84e-8	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg04990556	chr1:26633338	UBXN11	-0.6	-7.51	-0.43	1.11e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-9.59	-0.52	1.01e-18	Lymphocyte counts;
KIRP	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.46	7.62	0.44	5.41e-13	Fibrinogen levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23238603	chr1:31867686	NA	0.44	6.02	0.36	6.45e-9	Survival in pancreatic cancer;
KIRP	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg00784671	chr22:46762841	CELSR1	-0.6	-7.31	-0.42	3.76e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg21523564	chr15:75251491	NA	0.37	6.07	0.36	4.75e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	trans	rs564343	0.688	rs539046	chr11:65843778	A/T	cg26701943	chr11:108369231	KDELC2	-0.49	-6.17	-0.37	2.83e-9	Obesity (early onset extreme);
KIRP	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-0.74	-7.4	-0.43	2.16e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg12292205	chr6:26970375	C6orf41	-0.68	-7.46	-0.43	1.45e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg11859384	chr17:80120422	CCDC57	0.43	5.63	0.34	4.95e-8	Life satisfaction;
KIRP	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.71	10.34	0.55	4.65e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	6.08	0.36	4.45e-9	Total body bone mineral density;
KIRP	cis	rs7011507	1.000	rs55816658	chr8:49138165	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs16828019	0.852	rs3766324	chr1:41588653	A/G	cg24596898	chr1:41849189	NA	0.62	4.96	0.3	1.32e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.55	6.59	0.39	2.73e-10	Height;
KIRP	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21972741	chr5:435613	AHRR	0.53	7.0	0.41	2.45e-11	Cystic fibrosis severity;
KIRP	cis	rs9826463	0.582	rs11720007	chr3:142134712	T/G	cg20824294	chr3:142316082	PLS1	0.4	5.95	0.35	9.41e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07256732	chr16:621771	PIGQ	-0.46	-6.54	-0.38	3.52e-10	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23396286	chr10:99258505	UBTD1;MMS19	0.5	6.64	0.39	2.01e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs2411233	0.868	rs11853815	chr15:39257395	A/C	cg19287857	chr15:39890699	NA	0.45	6.19	0.37	2.44e-9	Platelet count;
KIRP	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.54	-0.48	1.42e-15	Common traits (Other);
KIRP	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.78	10.28	0.55	7.59e-21	Orofacial clefts;
KIRP	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg19507638	chr5:93509721	C5orf36	-0.58	-5.39	-0.32	1.68e-7	Diabetic retinopathy;
KIRP	cis	rs16828019	0.852	rs12045171	chr1:41528805	G/A	cg03387723	chr1:41708464	SCMH1	-0.63	-5.68	-0.34	3.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2172802	0.570	rs4860423	chr4:62537297	C/T	cg04118610	chr4:62707027	LPHN3	-0.45	-5.54	-0.33	7.95e-8	Partial epilepsies;
KIRP	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	8.34	0.47	5.47e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11731606	0.583	rs7670371	chr4:95339036	C/T	cg00507259	chr4:95128692	SMARCAD1	0.56	4.98	0.3	1.17e-6	Mean platelet volume;
KIRP	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg18016565	chr1:150552671	MCL1	-0.39	-6.02	-0.36	6.36e-9	Melanoma;
KIRP	cis	rs2625529	0.775	rs35673773	chr15:72399886	C/A	cg16672083	chr15:72433130	SENP8	-0.5	-6.11	-0.36	3.93e-9	Red blood cell count;
KIRP	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg21856205	chr7:94953877	PON1	0.44	5.39	0.32	1.65e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.14	0.31	5.69e-7	Melanoma;
KIRP	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.37	0.38	9.31e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg13482628	chr17:19912719	NA	0.6	8.38	0.47	4.08e-15	Schizophrenia;
KIRP	cis	rs4262150	0.883	rs72799189	chr5:152186600	T/C	cg12297329	chr5:152029980	NA	-0.66	-8.52	-0.48	1.61e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00338735	chr4:53728038	RASL11B	0.46	5.59	0.34	5.9e-8	Optic nerve measurement (cup area);
KIRP	cis	rs7184046	0.797	rs13737	chr15:75932129	G/T	cg20655648	chr15:75932815	IMP3	0.6	7.54	0.43	8.91e-13	Height;
KIRP	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.76e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg00857998	chr1:205179979	DSTYK	0.59	6.75	0.4	1.03e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7178572	0.789	rs4886869	chr15:77799657	A/G	cg22256960	chr15:77711686	NA	-0.37	-4.99	-0.3	1.15e-6	Type 2 diabetes;
KIRP	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11987759	chr7:65425863	GUSB	0.51	6.86	0.4	5.44e-11	Aortic root size;
KIRP	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.83	8.3	0.47	6.85e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.84	-10.71	-0.56	3.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs1408799	0.815	rs13297008	chr9:12677471	G/A	cg05274944	chr9:12693694	TYRP1	0.35	4.98	0.3	1.22e-6	Eye color;Blue vs. green eyes;
KIRP	cis	rs2224391	0.540	rs1570085	chr6:5253063	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.56	-0.39	3.08e-10	Height;
KIRP	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg25650185	chr19:21324782	ZNF431	-0.49	-5.16	-0.31	4.97e-7	Pain;
KIRP	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg11204139	chr17:3907470	NA	-0.54	-5.18	-0.31	4.72e-7	Type 2 diabetes;
KIRP	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.49	-7.0	-0.41	2.49e-11	Height;
KIRP	cis	rs11673344	0.566	rs185368	chr19:37872729	T/C	cg14683738	chr19:37701593	ZNF585B	0.47	5.48	0.33	1.07e-7	Obesity-related traits;
KIRP	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.23	0.42	5.99e-12	Arsenic metabolism;
KIRP	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.31	-0.37	1.28e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.58	7.36	0.42	2.71e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.82	-12.91	-0.64	1.85e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.19	-0.54	1.43e-20	Total body bone mineral density;
KIRP	cis	rs427941	0.632	rs201507	chr7:101764141	T/C	cg06246474	chr7:101738831	CUX1	0.54	6.64	0.39	1.96e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs490234	0.676	rs13293034	chr9:128256951	C/T	cg14078157	chr9:128172775	NA	-0.65	-7.72	-0.44	2.92e-13	Mean arterial pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20250077	chr2:198380995	MOBKL3	0.47	6.03	0.36	5.81e-9	Parkinson's disease;
KIRP	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17507749	chr15:85114479	UBE2QP1	0.7	7.86	0.45	1.23e-13	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs9309473	0.519	rs4852951	chr2:73869796	C/G	cg20560298	chr2:73613845	ALMS1	0.44	5.43	0.33	1.38e-7	Metabolite levels;
KIRP	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.89	13.51	0.65	1.72e-31	Height;
KIRP	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.52	-6.91	-0.4	4.03e-11	Lung cancer;
KIRP	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.7	9.62	0.52	8.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs72960926	0.744	rs11754468	chr6:74932522	C/T	cg03266952	chr6:74778945	NA	-0.6	-5.12	-0.31	6.2e-7	Metabolite levels (MHPG);
KIRP	cis	rs2458413	0.500	rs2514666	chr8:105351943	C/T	cg08657449	chr8:105351661	TM7SF4	-0.37	-5.88	-0.35	1.35e-8	Paget's disease;
KIRP	trans	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg10756647	chr7:56101905	PSPH	0.99	7.0	0.41	2.41e-11	Diabetic kidney disease;
KIRP	cis	rs7712401	0.601	rs397731	chr5:122322959	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs7215564	0.908	rs35878324	chr17:78677530	C/T	cg06153925	chr17:78755379	RPTOR	0.49	6.42	0.38	6.96e-10	Myopia (pathological);
KIRP	cis	rs9826463	0.527	rs112722008	chr3:142053561	A/G	cg20824294	chr3:142316082	PLS1	0.44	6.38	0.38	8.91e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	7.87	0.45	1.09e-13	Tonsillectomy;
KIRP	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg25457927	chr22:38595422	NA	-0.34	-7.44	-0.43	1.67e-12	Cutaneous nevi;
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg21186296	chr8:27182909	PTK2B	0.48	6.19	0.37	2.53e-9	Neuroticism;
KIRP	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg10223061	chr2:219282414	VIL1	-0.37	-6.13	-0.36	3.39e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	11.32	0.59	3.38e-24	Bone mineral density;
KIRP	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg25797454	chr6:150327115	RAET1K	0.33	6.18	0.37	2.63e-9	Alopecia areata;
KIRP	cis	rs1497828	1.000	rs2815237	chr1:217543239	T/C	cg04411442	chr1:217543379	NA	0.31	4.94	0.3	1.46e-6	Dialysis-related mortality;
KIRP	trans	rs6601327	0.665	rs10107992	chr8:9653287	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.55	-0.43	8.54e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg27490568	chr2:178487706	NA	0.5	6.83	0.4	6.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15235185	chr1:193028809	TROVE2;UCHL5	0.6	7.17	0.42	8.85e-12	Smoking initiation;
KIRP	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	0.91	11.68	0.6	2.23e-25	Vitiligo;
KIRP	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg04306507	chr14:55594613	LGALS3	0.52	8.14	0.46	2.04e-14	Protein biomarker;
KIRP	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg11608241	chr8:8085544	FLJ10661	0.41	5.03	0.31	9.41e-7	Platelet distribution width;
KIRP	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6901250	0.523	rs641338	chr6:117086265	C/A	cg12892004	chr6:117198278	RFX6	0.38	6.35	0.38	1.05e-9	C-reactive protein levels;
KIRP	cis	rs4356932	0.715	rs9992952	chr4:76898174	A/C	cg19388996	chr4:76862389	NAAA	0.43	5.39	0.33	1.63e-7	Blood protein levels;
KIRP	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	0.93	14.63	0.68	2.62e-35	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.48	-4.91	-0.3	1.65e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.92	11.73	0.6	1.59e-25	Menopause (age at onset);
KIRP	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.9	-12.41	-0.62	9.06e-28	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg01620082	chr3:125678407	NA	-1.15	-7.09	-0.41	1.39e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.62	8.22	0.46	1.17e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs10214930	0.697	rs2110526	chr7:27635680	T/C	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.58	-7.35	-0.42	2.96e-12	Autism;
KIRP	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	0.75	11.0	0.57	3.65e-23	Prudent dietary pattern;
KIRP	trans	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg25214090	chr10:38739885	LOC399744	-0.51	-6.45	-0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg19338460	chr6:170058176	WDR27	-0.68	-7.94	-0.45	7.1e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg04374321	chr14:90722782	PSMC1	0.81	12.41	0.62	8.7300000000000009e-28	Mortality in heart failure;
KIRP	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg26338869	chr17:61819248	STRADA	-0.5	-6.09	-0.36	4.41e-9	Prudent dietary pattern;
KIRP	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.16	0.5	2.16e-17	Colorectal cancer;
KIRP	cis	rs6466055	0.612	rs68113831	chr7:104860104	G/C	cg04380332	chr7:105027541	SRPK2	0.39	5.38	0.32	1.76e-7	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg03714773	chr7:91764589	CYP51A1	0.42	6.27	0.37	1.61e-9	Breast cancer;
KIRP	cis	rs2278796	0.789	rs1078719	chr1:204962405	A/G	cg04862289	chr1:204966208	NFASC	0.73	10.39	0.55	3.46e-21	Mean platelet volume;
KIRP	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.68	8.87	0.49	1.51e-16	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11522767	chr6:157342961	ARID1B	0.58	6.7	0.39	1.37e-10	Smoking initiation;
KIRP	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg13482628	chr17:19912719	NA	0.57	8.08	0.46	2.95e-14	Schizophrenia;
KIRP	trans	rs564343	0.560	rs4930170	chr11:65811208	G/T	cg26701943	chr11:108369231	KDELC2	-0.48	-6.24	-0.37	1.89e-9	Obesity (early onset extreme);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg00908822	chr10:133728813	NA	0.46	6.3	0.37	1.38e-9	Migraine with aura;
KIRP	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.87	0.3	2.04e-6	Coronary artery disease;
KIRP	trans	rs10864302	0.525	rs7528931	chr1:7429606	T/G	cg03833273	chr5:72863980	UTP15	0.43	6.18	0.37	2.62e-9	Photic sneeze reflex;
KIRP	trans	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg10756647	chr7:56101905	PSPH	0.99	7.09	0.41	1.4e-11	Diabetic kidney disease;
KIRP	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.28	-0.37	1.49e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2273669	0.667	rs12154092	chr6:109313303	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.27	-0.37	1.64e-9	Prostate cancer;
KIRP	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.42e-13	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg26875233	chr11:93583750	C11orf90	-0.34	-6.49	-0.38	4.64e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4006360	0.579	rs1510075	chr17:39236452	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.92	-0.53	9.86e-20	Bipolar disorder and schizophrenia;
KIRP	trans	rs2048656	0.578	rs10095236	chr8:9684925	C/T	cg16141378	chr3:129829833	LOC729375	0.51	6.7	0.39	1.39e-10	Schizophrenia;
KIRP	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg21782813	chr7:2030301	MAD1L1	0.38	4.84	0.3	2.27e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs12042938	0.622	rs61707606	chr1:231813446	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	5.4	0.33	1.58e-7	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.93	-15.8	-0.71	2.71e-39	Breast cancer;
KIRP	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg08822215	chr16:89438651	ANKRD11	-0.4	-5.18	-0.31	4.62e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22433210	chr17:43662623	NA	0.67	8.13	0.46	2.08e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg00079169	chr19:2811669	THOP1	0.5	5.31	0.32	2.45e-7	Total cholesterol levels;
KIRP	cis	rs2591576	0.604	rs6880888	chr5:165424767	A/G	cg13976338	chr5:165423657	NA	0.86	13.71	0.66	3.54e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.93	0.3	1.48e-6	Renal cell carcinoma;
KIRP	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg14768367	chr16:72042858	DHODH	0.44	5.35	0.32	2.05e-7	Fibrinogen levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03358980	chr10:102770406	NA	0.5	6.28	0.37	1.51e-9	Interleukin-4 levels;
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg03160526	chr17:80928410	B3GNTL1	0.4	4.94	0.3	1.42e-6	Glycated hemoglobin levels;
KIRP	cis	rs7561273	0.586	rs4149372	chr2:24305512	T/G	cg20701182	chr2:24300061	SF3B14	0.49	5.89	0.35	1.28e-8	Quantitative traits;
KIRP	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg24642439	chr20:33292090	TP53INP2	-0.58	-7.59	-0.44	6.58e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg07810366	chr2:100720526	AFF3	0.36	6.48	0.38	5.05e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs12595433	0.522	rs4775590	chr15:63288121	A/C	cg03196360	chr15:63270641	NA	-0.3	-5.64	-0.34	4.64e-8	Obesity-related traits;
KIRP	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg04310649	chr10:35416472	CREM	-0.55	-6.24	-0.37	1.93e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.19	0.37	2.53e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg07395648	chr5:131743802	NA	0.36	5.09	0.31	7.22e-7	Blood metabolite levels;
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg09699651	chr6:150184138	LRP11	0.47	6.45	0.38	5.76e-10	Lung cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05491852	chr1:3663832	KIAA0495	0.46	6.54	0.38	3.46e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg21395723	chr22:39101663	GTPBP1	0.39	5.26	0.32	3.12e-7	Menopause (age at onset);
KIRP	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.36	-0.76	5.44e-48	Schizophrenia;
KIRP	cis	rs526231	0.543	rs246900	chr5:102534629	T/A	cg23492399	chr5:102201601	PAM	-0.51	-5.61	-0.34	5.34e-8	Primary biliary cholangitis;
KIRP	cis	rs7560272	0.501	rs12713793	chr2:73956114	T/C	cg20560298	chr2:73613845	ALMS1	0.45	5.42	0.33	1.41e-7	Schizophrenia;
KIRP	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04418585	chr11:84735349	DLG2	-0.4	-6.47	-0.38	5.27e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06850241	chr22:41845214	NA	-0.46	-5.61	-0.34	5.37e-8	Vitiligo;
KIRP	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg05791153	chr7:19748676	TWISTNB	0.64	5.69	0.34	3.54e-8	Thyroid stimulating hormone;
KIRP	cis	rs9815354	1.000	rs73071329	chr3:41810539	G/A	cg03022575	chr3:42003672	ULK4	0.49	5.55	0.33	7.22e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg24375607	chr4:120327624	NA	0.73	8.0	0.45	4.76e-14	Corneal astigmatism;
KIRP	cis	rs2380205	0.967	rs2380208	chr10:5900032	C/G	cg27141509	chr10:5886111	NA	0.36	5.28	0.32	2.89e-7	Breast cancer;
KIRP	cis	rs4073221	0.585	rs7429106	chr3:18321125	A/G	cg07694806	chr3:18168406	NA	-0.68	-5.96	-0.36	8.55e-9	Parkinson's disease;
KIRP	cis	rs12210905	0.688	rs12209905	chr6:27404592	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.74	-0.34	2.75e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.52	-0.38	4.04e-10	Bipolar disorder;
KIRP	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg16434002	chr17:42200994	HDAC5	-0.58	-7.1	-0.41	1.37e-11	Total body bone mineral density;
KIRP	cis	rs12208915	0.848	rs77415956	chr6:79514757	G/A	cg18132916	chr6:79620363	NA	0.54	5.06	0.31	8.38e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.81	-10.58	-0.56	8.66e-22	Parkinson's disease;
KIRP	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg15655495	chr12:38532458	NA	0.28	5.14	0.31	5.69e-7	Bladder cancer;
KIRP	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg23029597	chr12:123009494	RSRC2	-0.47	-5.96	-0.35	8.93e-9	Body mass index;
KIRP	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg20243544	chr17:37824526	PNMT	0.52	7.38	0.43	2.39e-12	Asthma;
KIRP	cis	rs7005380	0.581	rs16893299	chr8:120940652	C/T	cg21645572	chr8:120931649	DEPDC6	-0.43	-5.55	-0.33	7.3900000000000007e-08	Interstitial lung disease;
KIRP	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.81	11.17	0.58	1.06e-23	Aortic root size;
KIRP	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.45	0.43	1.59e-12	Aortic root size;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26151740	chr19:54641525	CNOT3	-0.5	-6.91	-0.4	4.14e-11	Metabolic traits;
KIRP	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.56	-6.64	-0.39	1.96e-10	Initial pursuit acceleration;
KIRP	cis	rs13067260	0.557	rs9819083	chr3:123721123	A/G	cg19918027	chr3:123987645	KALRN	-0.64	-5.69	-0.34	3.6e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	13.88	0.66	9.79e-33	Alzheimer's disease;
KIRP	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.77	-9.81	-0.53	2.24e-19	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg20302533	chr7:39170763	POU6F2	0.27	5.66	0.34	4.12e-8	IgG glycosylation;
KIRP	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs6005807	0.719	rs2881496	chr22:28921265	C/G	cg12565055	chr22:29076175	TTC28	-0.58	-5.07	-0.31	7.91e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.8	15.09	0.69	7.29e-37	Lymphocyte counts;
KIRP	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.39	-6.17	-0.37	2.72e-9	Body mass index;
KIRP	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.79	-9.49	-0.52	2.05e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg01529538	chr14:23388837	RBM23	0.42	5.29	0.32	2.68e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg23845249	chr11:68861649	NA	0.56	8.01	0.45	4.71e-14	Blond vs. brown hair color;
KIRP	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg24826892	chr11:71159390	DHCR7	0.45	4.93	0.3	1.52e-6	Vitamin D levels;
KIRP	cis	rs10128264	0.934	rs1250590	chr10:80983786	A/C	cg20744163	chr10:80999841	ZMIZ1	0.34	5.72	0.34	3.11e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg09699651	chr6:150184138	LRP11	0.48	6.48	0.38	4.95e-10	Lung cancer;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.49	0.38	4.69e-10	Lung cancer;
KIRP	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2290159	0.706	rs11923427	chr3:12663835	C/G	cg23032965	chr3:12705835	RAF1	0.73	7.34	0.42	3.17e-12	Cholesterol, total;
KIRP	cis	rs970821	0.667	rs6470183	chr8:124752408	C/T	cg00283535	chr8:124749564	ANXA13	-0.36	-6.09	-0.36	4.27e-9	Breast cancer;
KIRP	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9469913	0.740	rs2744977	chr6:34563060	A/G	cg14254433	chr6:34482411	PACSIN1	-0.44	-5.35	-0.32	2.03e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.45	6.7	0.39	1.43e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.65	-8.42	-0.47	3.2e-15	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00050590	chr18:61637441	SERPINB8	0.53	6.74	0.39	1.11e-10	Parkinson's disease;
KIRP	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.87	9.69	0.53	4.96e-19	Corneal astigmatism;
KIRP	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg23982607	chr1:1823379	GNB1	-0.83	-14.6	-0.68	3.3e-35	Body mass index;
KIRP	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg27490568	chr2:178487706	NA	0.76	10.22	0.55	1.14e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.87	-13.44	-0.65	3.06e-31	Height;
KIRP	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.97	8.99	0.5	6.69e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg27068330	chr11:65405492	SIPA1	0.38	5.18	0.31	4.67e-7	Acne (severe);
KIRP	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg25486957	chr4:152246857	NA	-0.43	-5.2	-0.31	4.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.5	-6.37	-0.38	9.35e-10	White blood cell count;
KIRP	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs11605924	1.000	rs11605924	chr11:45873091	A/C	cg23097878	chr11:45879730	CRY2	0.32	6.54	0.38	3.55e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.52	6.57	0.39	2.98e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10706293	chr17:20920717	USP22	0.49	6.6	0.39	2.47e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.58	-4.99	-0.3	1.17e-6	Narcolepsy;
KIRP	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg08645402	chr16:4508243	NA	0.39	4.95	0.3	1.4e-6	Schizophrenia;
KIRP	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.66	6.56	0.39	3.21e-10	Eotaxin levels;
KIRP	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg08501292	chr6:25962987	TRIM38	0.64	4.85	0.3	2.15e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11987759	chr7:65425863	GUSB	0.49	6.25	0.37	1.84e-9	Aortic root size;
KIRP	cis	rs34018670	1	rs34018670	chr16:80843234	C/CAG	cg04448709	chr16:81349954	GAN	-0.49	-5.05	-0.31	8.46e-7	Monocyte count;
KIRP	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg18944383	chr4:111397179	ENPEP	0.53	9.64	0.52	7.56e-19	Height;
KIRP	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.68	9.71	0.53	4.31e-19	Lymphocyte counts;
KIRP	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	0.95	10.16	0.54	1.76e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2067663	0.680	rs636631	chr5:88055975	C/A	cg18498987	chr5:88179539	MEF2C	-0.42	-5.45	-0.33	1.21e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.56	7.09	0.41	1.4e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10486227	chr15:75249876	RPP25	0.41	6.12	0.36	3.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2591576	0.775	rs11957418	chr5:165419044	G/A	cg13976338	chr5:165423657	NA	-0.81	-12.9	-0.64	2.03e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08439880	chr3:133502540	NA	-0.52	-6.35	-0.38	1.03e-9	Iron status biomarkers;
KIRP	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg15068132	chr12:102092402	CHPT1	-0.38	-4.97	-0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.96	-13.76	-0.66	2.39e-32	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.66	-9.97	-0.54	6.99e-20	Total body bone mineral density;
KIRP	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.67	-0.34	3.91e-8	Huntington's disease progression;
KIRP	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	1.04	19.55	0.78	5.19e-52	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-6.51	-0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.63	-8.38	-0.47	4.06e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07576517	chr1:243419299	SDCCAG8;CEP170	-0.46	-6.21	-0.37	2.22e-9	Migraine with aura;
KIRP	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.25	-0.58	5.76e-24	Vitamin D levels;
KIRP	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg23505145	chr19:12996616	KLF1	0.58	8.55	0.48	1.32e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.4	-5.13	-0.31	5.92e-7	IgG glycosylation;
KIRP	cis	rs9513627	0.915	rs73556177	chr13:100121840	G/A	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs35661897	0.920	rs34550030	chr2:227339970	C/T	cg03426602	chr2:227312417	NA	-0.57	-6.97	-0.41	2.82e-11	Urinary tract infection frequency;
KIRP	trans	rs2786098	1.000	rs1337167	chr1:197316435	C/T	cg07944278	chr6:35699425	LOC285847	-0.56	-6.13	-0.36	3.52e-9	Asthma;
KIRP	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.78	9.85	0.53	1.69e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.82	12.2	0.61	4.28e-27	IgG glycosylation;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg02367723	chr1:46378857	MAST2	0.42	4.88	0.3	1.94e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg07701084	chr6:150067640	NUP43	0.68	9.48	0.52	2.26e-18	Lung cancer;
KIRP	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.6	6.7	0.39	1.38e-10	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00337957	chr19:8547807	HNRNPM	-0.45	-6.14	-0.36	3.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg10756647	chr7:56101905	PSPH	0.91	6.61	0.39	2.37e-10	Diabetic kidney disease;
KIRP	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg06212747	chr3:49208901	KLHDC8B	0.63	8.86	0.49	1.6e-16	Resting heart rate;
KIRP	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg09473613	chr1:24152604	HMGCL	0.47	6.4	0.38	7.74e-10	Immature fraction of reticulocytes;
KIRP	cis	rs7766436	0.885	rs5010014	chr6:22587299	A/G	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs7590368	0.961	rs13432104	chr2:10960661	T/C	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.95e-15	Aortic root size;
KIRP	cis	rs6466055	0.564	rs7809464	chr7:105035389	G/A	cg04380332	chr7:105027541	SRPK2	0.38	5.1	0.31	6.9e-7	Schizophrenia;
KIRP	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg05709478	chr1:6581295	PLEKHG5	0.65	6.52	0.38	3.9e-10	Body mass index;
KIRP	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg10547527	chr2:198650123	BOLL	0.55	5.04	0.31	8.83e-7	Ulcerative colitis;
KIRP	cis	rs11603020	0.950	rs78364821	chr11:57370742	C/T	cg23127183	chr11:57508653	C11orf31	-0.46	-5.49	-0.33	9.75e-8	Blood protein levels;
KIRP	trans	rs2048656	0.578	rs2090061	chr8:9680978	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.44	-0.43	1.66e-12	Schizophrenia;
KIRP	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-7.98	-0.45	5.63e-14	Mean corpuscular volume;
KIRP	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg06953865	chr19:18549723	ISYNA1	-0.42	-6.33	-0.37	1.17e-9	Breast cancer;
KIRP	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg26727032	chr16:67993705	SLC12A4	-0.76	-8.92	-0.49	1.11e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17065868	1.000	rs61949809	chr13:45060945	C/A	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg00933542	chr6:150070202	PCMT1	-0.29	-5.52	-0.33	8.75e-8	Lung cancer;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.75	10.65	0.56	4.85e-22	Lung cancer;
KIRP	cis	rs7919006	0.793	rs72803464	chr10:76795131	C/G	cg01390419	chr10:76803856	DUPD1	0.52	6.1	0.36	4.18e-9	Weight;
KIRP	cis	rs6738627	0.895	rs10179126	chr2:165511794	C/G	cg03182029	chr2:165697222	COBLL1	0.38	4.93	0.3	1.53e-6	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.43	-0.43	1.81e-12	Monocyte percentage of white cells;
KIRP	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg00647317	chr7:50633725	DDC	-0.45	-5.84	-0.35	1.66e-8	Malaria;
KIRP	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg23920097	chr1:209922102	NA	-0.47	-5.58	-0.34	6.41e-8	Red blood cell count;
KIRP	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12480562	chr20:23434244	CST11	0.64	5.09	0.31	7.02e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.62	8.58	0.48	1.12e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs459571	0.796	rs10993894	chr9:136884511	C/T	cg01294253	chr9:136912663	BRD3	0.41	5.34	0.32	2.11e-7	Platelet distribution width;
KIRP	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.95	7.8	0.45	1.79e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg13198984	chr17:80129470	CCDC57	0.53	7.94	0.45	7.12e-14	Life satisfaction;
KIRP	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	0.97	11.51	0.59	8.25e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs57561814	0.655	rs58879058	chr7:22741822	T/C	cg26061582	chr7:22766209	IL6	0.78	6.17	0.37	2.79e-9	Tonsillectomy;
KIRP	cis	rs6772849	0.804	rs4857920	chr3:128407623	C/T	cg08795948	chr3:128337044	NA	0.41	4.96	0.3	1.33e-6	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg24315340	chr6:146058215	EPM2A	0.44	5.6	0.34	5.86e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6594713	0.717	rs10056194	chr5:112857862	T/G	cg12552261	chr5:112820674	MCC	0.6	6.08	0.36	4.49e-9	Brain cytoarchitecture;
KIRP	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg03808351	chr9:123631620	PHF19	0.4	5.39	0.33	1.62e-7	Rheumatoid arthritis;
KIRP	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.59	8.03	0.46	4.1e-14	Mood instability;
KIRP	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.58	7.72	0.44	2.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.72	-7.48	-0.43	1.33e-12	Iron status biomarkers;
KIRP	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.69	10.62	0.56	6.31e-22	Retinal vascular caliber;
KIRP	cis	rs77861329	1.000	rs13319566	chr3:52095555	C/G	cg08692210	chr3:52188851	WDR51A	0.81	5.51	0.33	8.87e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.58	5.3	0.32	2.59e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7508	0.535	rs11779988	chr8:17784414	T/C	cg01800426	chr8:17659068	MTUS1	-0.43	-5.45	-0.33	1.2e-7	Atrial fibrillation;
KIRP	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg17554472	chr22:41940697	POLR3H	-0.7	-6.98	-0.41	2.79e-11	Vitiligo;
KIRP	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.81	-11.03	-0.58	3.03e-23	Longevity;
KIRP	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg00405596	chr8:11794950	NA	0.51	6.52	0.38	4e-10	Neuroticism;
KIRP	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.56	7.41	0.43	2.08e-12	Breast cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg21761045	chr8:87354805	WWP1	-0.57	-6.1	-0.36	4.06e-9	Menopause (age at onset);
KIRP	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg13271783	chr10:134563150	INPP5A	-0.63	-7.91	-0.45	8.75e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg17294928	chr15:75287854	SCAMP5	-0.76	-4.85	-0.3	2.21e-6	Lung cancer;
KIRP	cis	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg00405596	chr8:11794950	NA	-0.5	-6.22	-0.37	2.09e-9	Triglycerides;
KIRP	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg00106254	chr7:1943704	MAD1L1	-0.57	-6.17	-0.37	2.85e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1883415	0.530	rs3765311	chr6:24503862	G/T	cg20631270	chr6:24437470	GPLD1	-0.38	-4.88	-0.3	1.93e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9400467	0.506	rs77097930	chr6:111615479	G/A	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-8.98	-0.5	7.44e-17	Schizophrenia;
KIRP	cis	rs1629083	0.967	rs61900882	chr11:118130199	T/C	cg18857871	chr11:118064634	AMICA1	0.62	8.24	0.47	1.03e-14	Lung cancer;
KIRP	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg24579218	chr15:68104479	NA	-0.43	-6.1	-0.36	4.1e-9	Obesity;
KIRP	cis	rs7011507	1.000	rs76247795	chr8:49133461	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg24060327	chr5:131705240	SLC22A5	-0.55	-7.39	-0.43	2.23e-12	Blood metabolite levels;
KIRP	cis	rs17095355	0.539	rs3890722	chr10:111925233	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.46	-6.9	-0.4	4.5e-11	Biliary atresia;
KIRP	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-8.47	-0.48	2.3e-15	Brugada syndrome;
KIRP	cis	rs1318772	1.000	rs458055	chr5:112799883	C/T	cg12552261	chr5:112820674	MCC	-0.8	-5.11	-0.31	6.49e-7	F-cell distribution;
KIRP	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg07827796	chr19:33622959	WDR88	0.48	6.23	0.37	2.05e-9	Bone properties (heel);
KIRP	trans	rs2048656	0.605	rs13248108	chr8:9651273	G/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.42	0.38	7.13e-10	Schizophrenia;
KIRP	cis	rs2273669	0.667	rs76249006	chr6:109366740	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-6.21	-0.37	2.2e-9	Prostate cancer;
KIRP	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.69	0.44	3.58e-13	Tonsillectomy;
KIRP	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.44	6.04	0.36	5.62e-9	Schizophrenia;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.7	-0.49	4.81e-16	Obesity-related traits;
KIRP	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg03684893	chr10:554711	DIP2C	0.39	5.46	0.33	1.19e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs4774899	0.966	rs12908760	chr15:57505217	G/T	cg13626582	chr15:57592083	LOC283663	-0.21	-5.03	-0.31	9.42e-7	Urinary tract infection frequency;
KIRP	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg00129232	chr17:37814104	STARD3	-0.63	-8.07	-0.46	3.04e-14	Self-reported allergy;
KIRP	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg21926883	chr2:100939477	LONRF2	-0.51	-6.89	-0.4	4.59e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg15660573	chr17:549704	VPS53	-0.95	-15.04	-0.69	1.04e-36	Prostate cancer;
KIRP	cis	rs1209950	0.901	rs1209953	chr21:40180383	T/A	cg02119577	chr21:40195074	ETS2	-0.35	-5.3	-0.32	2.58e-7	Non-small cell lung cancer (survival);
KIRP	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	1.0	10.19	0.54	1.48e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.58	7.32	0.42	3.53e-12	Tonsillectomy;
KIRP	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	IgG glycosylation;
KIRP	trans	rs10152811	0.675	rs55882120	chr15:86818162	A/G	cg09774649	chr4:8476536	C4orf23	-0.53	-6.07	-0.36	4.7e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.32	0.47	6e-15	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg10189774	chr4:17578691	LAP3	0.5	6.06	0.36	5.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	1.0	16.77	0.73	1.31e-42	Bone mineral density;
KIRP	cis	rs7188697	0.769	rs9932944	chr16:58616165	C/T	cg21335942	chr16:58549945	SETD6	-0.47	-5.04	-0.31	8.83e-7	QT interval;
KIRP	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.36	6.0	0.36	7.06e-9	Heart rate;
KIRP	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs10924970	0.967	rs10925074	chr1:235365869	A/T	cg26050004	chr1:235667680	B3GALNT2	0.41	4.86	0.3	2.11e-6	Asthma;
KIRP	cis	rs9403317	0.960	rs9389929	chr6:141840934	T/A	cg15052665	chr6:141804349	NA	0.42	5.12	0.31	6.27e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg16989719	chr2:238392110	NA	-0.57	-6.33	-0.37	1.18e-9	Prostate cancer;
KIRP	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.4	-0.43	2.12e-12	Triglycerides;
KIRP	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg10664184	chr19:17420304	DDA1	-0.72	-8.49	-0.48	2.02e-15	Systemic lupus erythematosus;
KIRP	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.71	10.91	0.57	7.41e-23	Blood metabolite ratios;
KIRP	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.55	-5.39	-0.32	1.67e-7	Platelet distribution width;
KIRP	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-7.08	-0.41	1.52e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.45	5.87	0.35	1.43e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-5.7	-0.34	3.41e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7560272	0.538	rs12619258	chr2:73935915	G/T	cg20560298	chr2:73613845	ALMS1	0.5	6.12	0.36	3.74e-9	Schizophrenia;
KIRP	cis	rs13065560	0.659	rs6776510	chr3:38887253	C/T	cg01426195	chr3:39028469	NA	-0.4	-6.08	-0.36	4.61e-9	Interleukin-18 levels;
KIRP	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.65	-6.49	-0.38	4.7e-10	Blood trace element (Zn levels);
KIRP	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	8.58	0.48	1.09e-15	Motion sickness;
KIRP	cis	rs889398	0.900	rs4783722	chr16:69581912	A/G	cg09409435	chr16:70099608	PDXDC2	-0.42	-5.03	-0.31	9.43e-7	Body mass index;
KIRP	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	8.16	0.46	1.72e-14	Retinal vascular caliber;
KIRP	cis	rs71597109	0.639	rs17266552	chr4:102726519	G/A	cg14855874	chr4:102712397	BANK1	0.39	4.89	0.3	1.86e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	7.58	0.44	7.03e-13	Menarche (age at onset);
KIRP	cis	rs10073892	0.667	rs62372160	chr5:101612357	G/A	cg19774478	chr5:101632501	SLCO4C1	0.62	5.95	0.35	9.15e-9	Cognitive decline (age-related);
KIRP	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg24060327	chr5:131705240	SLC22A5	-0.47	-6.14	-0.36	3.23e-9	Breast cancer;
KIRP	cis	rs9581857	0.547	rs9581881	chr13:28106637	A/G	cg22138327	chr13:27999177	GTF3A	0.75	5.95	0.35	9.35e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1440410	0.571	rs10471101	chr4:144031928	T/C	cg01719995	chr4:144104893	USP38	0.46	6.06	0.36	5.14e-9	Ischemic stroke;
KIRP	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.66	6.55	0.39	3.34e-10	Axial length;
KIRP	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.47	-6.33	-0.37	1.16e-9	Systolic blood pressure;
KIRP	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.27	-0.78	4.5e-51	Schizophrenia;
KIRP	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.96	11.16	0.58	1.1e-23	Corneal astigmatism;
KIRP	cis	rs9807841	0.670	rs8107719	chr19:10804389	T/C	cg09936142	chr19:10668400	KRI1	-0.43	-4.88	-0.3	1.92e-6	Inflammatory skin disease;
KIRP	cis	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.22e-12	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.69	7.94	0.45	7.02e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.18	-0.31	4.64e-7	Life satisfaction;
KIRP	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg27121462	chr16:89883253	FANCA	0.4	4.95	0.3	1.35e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs11644362	1.000	rs35972357	chr16:12987664	C/T	cg06890432	chr16:12997467	SHISA9	-0.39	-6.01	-0.36	6.78e-9	Positive affect;Subjective well-being;
KIRP	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.6	-7.96	-0.45	6.31e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.84	-11.16	-0.58	1.13e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg01877450	chr7:97915802	BRI3	-0.6	-7.67	-0.44	3.92e-13	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2472476	0.872	rs2472474	chr9:107534787	T/C	cg18011916	chr7:35295120	TBX20	0.42	6.02	0.36	6.35e-9	Obesity-related traits;
KIRP	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	1.01	17.66	0.75	1.2e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.45	-6.32	-0.37	1.19e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7187994	0.848	rs12448489	chr16:84774022	G/A	cg07647771	chr16:84786436	USP10	-0.5	-6.08	-0.36	4.59e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs28595532	0.800	rs111626798	chr4:119352517	C/T	cg21605333	chr4:119757512	SEC24D	1.1	8.23	0.46	1.06e-14	Cannabis dependence symptom count;
KIRP	cis	rs9682041	0.627	rs10936625	chr3:170094908	G/T	cg11886554	chr3:170076028	SKIL	-0.45	-4.91	-0.3	1.66e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.71	0.66	3.59e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.32	-0.32	2.32e-7	Subjective well-being;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.7	-0.53	4.76e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg04780086	chr2:111875790	ACOXL	0.44	6.15	0.37	3.05e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-5.45	-0.33	1.24e-7	Testicular germ cell tumor;
KIRP	cis	rs2072732	0.706	rs112690788	chr1:2954055	A/G	cg11731671	chr1:2995604	PRDM16	-0.44	-5.63	-0.34	4.87e-8	Plateletcrit;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg02894226	chr20:3190561	ITPA	0.74	6.38	0.38	8.66e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg17764715	chr19:33622953	WDR88	0.66	8.39	0.47	3.73e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.29	-0.32	2.68e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	12.15	0.61	6.43e-27	Platelet count;
KIRP	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg18190219	chr22:46762943	CELSR1	-0.55	-5.14	-0.31	5.56e-7	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15692086	chr6:89340909	RNGTT	0.42	6.21	0.37	2.28e-9	Interleukin-4 levels;
KIRP	cis	rs15676	1.000	rs10988125	chr9:131572903	A/G	cg00228799	chr9:131580591	ENDOG	0.56	6.26	0.37	1.66e-9	Blood metabolite levels;
KIRP	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg20387954	chr3:183756860	HTR3D	0.64	9.26	0.51	1.04e-17	Anterior chamber depth;
KIRP	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12210905	0.920	rs9393802	chr6:27243105	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.57	-5.03	-0.31	9.33e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg23649088	chr2:200775458	C2orf69	-0.67	-5.83	-0.35	1.7e-8	Schizophrenia;
KIRP	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.51	6.19	0.37	2.45e-9	Lung cancer;
KIRP	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-6.08	-0.36	4.56e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg13198984	chr17:80129470	CCDC57	0.57	8.48	0.48	2.18e-15	Life satisfaction;
KIRP	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg06618935	chr21:46677482	NA	-0.42	-5.07	-0.31	7.96e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs975752	0.717	rs2281949	chr10:102006402	C/T	cg13817732	chr10:102046368	BLOC1S2	0.71	5.98	0.36	7.69e-9	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg26769984	chr7:1090371	C7orf50	0.65	6.2	0.37	2.31e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs6545883	0.868	rs7608483	chr2:61836235	A/C	cg15711740	chr2:61764176	XPO1	-0.63	-8.59	-0.48	1.04e-15	Tuberculosis;
KIRP	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.63	9.62	0.52	8.47e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg07384080	chr1:156148190	NA	0.29	4.88	0.3	1.93e-6	Testicular germ cell tumor;
KIRP	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.44	5.64	0.34	4.65e-8	Crohn's disease;
KIRP	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs2219968	1.000	rs6982487	chr8:78972260	C/A	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg08890418	chr1:21044141	KIF17	-0.4	-6.13	-0.36	3.52e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg00631329	chr6:26305371	NA	-0.66	-8.74	-0.49	3.82e-16	Educational attainment;
KIRP	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg07884673	chr3:53033167	SFMBT1	0.92	6.96	0.41	3.13e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4936894	0.500	rs12272169	chr11:124088753	G/T	cg27160556	chr11:124181099	OR8D1	-0.39	-5.88	-0.35	1.33e-8	Aging (time to death);
KIRP	cis	rs735539	0.521	rs1570672	chr13:21408818	C/T	cg04906043	chr13:21280425	IL17D	-0.45	-5.42	-0.33	1.44e-7	Dental caries;
KIRP	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.65	12.1	0.61	9.51e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg19142026	chr7:27170394	HOXA4	-0.44	-6.07	-0.36	4.89e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1408799	0.521	rs2733833	chr9:12705095	T/G	cg05274944	chr9:12693694	TYRP1	0.43	6.63	0.39	2.15e-10	Eye color;Blue vs. green eyes;
KIRP	cis	rs244899	0.967	rs184957	chr5:167919623	T/A	cg06604206	chr5:167912465	RARS	-0.54	-7.56	-0.43	7.74e-13	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs6728642	1.000	rs59178801	chr2:97604455	C/T	cg26665480	chr2:98280029	ACTR1B	-0.49	-5.05	-0.31	8.79e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg18709589	chr6:96969512	KIAA0776	0.38	5.07	0.31	7.95e-7	Migraine;Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg24209194	chr3:40518798	ZNF619	-0.4	-5.09	-0.31	7.08e-7	Renal cell carcinoma;
KIRP	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6988985	0.728	rs3753121	chr8:143926380	C/T	cg17812120	chr8:144639478	GSDMD	-0.4	-4.84	-0.3	2.25e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	5.43	0.33	1.33e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg16141378	chr3:129829833	LOC729375	-0.56	-6.62	-0.39	2.22e-10	Neuroticism;
KIRP	cis	rs17445240	1.000	rs77719803	chr2:3701076	G/C	cg19825600	chr2:3704501	ALLC	0.58	4.91	0.3	1.69e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg01763666	chr17:80159506	CCDC57	0.37	5.12	0.31	6.26e-7	Life satisfaction;
KIRP	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg18478394	chr8:109455254	TTC35	0.49	5.99	0.36	7.59e-9	Dupuytren's disease;
KIRP	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg11635098	chr7:100497156	NA	-0.66	-7.03	-0.41	2.05e-11	Resting heart rate;
KIRP	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg20003494	chr4:90757398	SNCA	-0.4	-5.39	-0.33	1.64e-7	Neuroticism;
KIRP	cis	rs17373728	1.000	rs17373728	chr8:76225516	C/T	cg07016329	chr8:76221503	NA	0.56	7.17	0.42	8.62e-12	Diabetic kidney disease;
KIRP	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.66	9.02	0.5	5.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.43	7.55	0.43	8.43e-13	Renal cell carcinoma;
KIRP	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	9.33	0.51	6.36e-18	Obesity-related traits;
KIRP	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19651192	chr13:88323266	NA	0.45	6.55	0.39	3.4e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.75	-7.92	-0.45	8e-14	Asthma;
KIRP	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg19025524	chr12:109796872	NA	-0.37	-4.91	-0.3	1.68e-6	Neuroticism;
KIRP	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg06212747	chr3:49208901	KLHDC8B	0.69	8.13	0.46	2.15e-14	Menarche (age at onset);
KIRP	trans	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.39	-0.38	8.16e-10	Neuroticism;
KIRP	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg12599982	chr1:44399894	ARTN	0.43	5.19	0.31	4.36e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06770877	chr13:31897247	B3GALTL	0.52	6.62	0.39	2.23e-10	Interleukin-4 levels;
KIRP	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.58	-9.66	-0.52	6.5e-19	Schizophrenia;
KIRP	cis	rs10929159	0.928	rs1349731	chr2:236924047	C/T	cg20128773	chr2:236923534	AGAP1	-0.3	-5.23	-0.32	3.54e-7	Parkinson's disease;
KIRP	cis	rs42648	0.536	rs2158747	chr7:89798421	G/T	cg25739043	chr7:89950458	NA	-0.38	-5.95	-0.35	9.17e-9	Homocysteine levels;
KIRP	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	9.55	0.52	1.36e-18	Mood instability;
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg12705353	chr12:122356852	WDR66	-0.51	-7.01	-0.41	2.32e-11	Mean corpuscular volume;
KIRP	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg24375607	chr4:120327624	NA	0.59	6.85	0.4	5.84e-11	Corneal astigmatism;
KIRP	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Bladder cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01951671	chr13:70681017	KLHL1;ATXN8OS	-0.41	-6.03	-0.36	6.02e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg14541582	chr5:601475	NA	-0.58	-6.64	-0.39	2.04e-10	Obesity-related traits;
KIRP	cis	rs17453880	0.929	rs4473762	chr5:152065361	T/C	cg12297329	chr5:152029980	NA	-0.68	-10.07	-0.54	3.47e-20	Subjective well-being;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg24874828	chr4:187887005	NA	-0.48	-7.26	-0.42	5.16e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17067123	0.539	rs11735192	chr4:180065076	A/C	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.69	-8.81	-0.49	2.34e-16	Iron status biomarkers;
KIRP	cis	rs2274273	0.870	rs67514154	chr14:55767382	T/C	cg04306507	chr14:55594613	LGALS3	0.41	6.29	0.37	1.44e-9	Protein biomarker;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.19	0.42	7.66e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg04854107	chr15:38544003	SPRED1	0.94	6.45	0.38	5.93e-10	P wave terminal force;
KIRP	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.06	-0.5	4.24e-17	Rheumatoid arthritis;
KIRP	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.68	-8.5	-0.48	1.83e-15	Recalcitrant atopic dermatitis;
KIRP	cis	rs6725041	0.819	rs11677095	chr2:213092080	A/G	cg20637307	chr2:213403960	ERBB4	-0.39	-5.12	-0.31	6.15e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs1476679	0.962	rs34995835	chr7:99990364	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.48	-5.2	-0.31	4.13e-7	Alzheimer's disease (late onset);
KIRP	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg18129178	chr5:148520854	ABLIM3	0.5	5.27	0.32	3.05e-7	Breast cancer;
KIRP	trans	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg19894588	chr14:64061835	NA	-0.62	-7.29	-0.42	4.13e-12	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs10267417	0.603	rs114520435	chr7:19944551	A/G	cg05791153	chr7:19748676	TWISTNB	0.51	5.12	0.31	6.3e-7	Night sleep phenotypes;
KIRP	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.92	10.48	0.56	1.77e-21	Breast cancer;
KIRP	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.4	4.92	0.3	1.56e-6	Diabetic retinopathy;
KIRP	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg22138327	chr13:27999177	GTF3A	-0.98	-7.76	-0.44	2.31e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs10465746	0.780	rs1871924	chr1:84398466	T/A	cg10977910	chr1:84465055	TTLL7	0.55	7.03	0.41	2.01e-11	Obesity-related traits;
KIRP	cis	rs6545883	0.929	rs2121660	chr2:61653058	T/C	cg15711740	chr2:61764176	XPO1	0.62	8.05	0.46	3.63e-14	Tuberculosis;
KIRP	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg04111992	chr7:158790115	NA	0.4	4.99	0.3	1.13e-6	Facial morphology (factor 20);
KIRP	cis	rs6693567	0.874	rs698915	chr1:150388318	C/T	cg17724175	chr1:150552817	MCL1	0.38	5.42	0.33	1.43e-7	Migraine;
KIRP	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1359582	1.000	rs1359582	chr10:90330483	A/C	cg15661332	chr10:90342814	RNLS	0.52	5.09	0.31	7.07e-7	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.36	0.32	1.94e-7	Coronary artery disease;
KIRP	trans	rs9944715	0.734	rs9967220	chr18:43780059	C/T	cg01718231	chr17:29326311	RNF135	-0.52	-6.22	-0.37	2.1e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs7212590	0.618	rs7219051	chr17:58032710	G/A	cg10252138	chr17:58120427	NA	-0.67	-5.48	-0.33	1.05e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.03	-0.36	5.9e-9	Height;
KIRP	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.53	-6.75	-0.4	1.06e-10	Lung cancer;
KIRP	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg09264619	chr17:80180166	NA	0.48	5.59	0.34	5.96e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-5.82	-0.35	1.8e-8	Morning vs. evening chronotype;
KIRP	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.64	-6.07	-0.36	4.71e-9	Breast cancer;
KIRP	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	11.18	0.58	1e-23	Platelet count;
KIRP	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.4	5.01	0.3	1.06e-6	Blood protein levels;
KIRP	cis	rs16912285	0.688	rs59246618	chr11:24315201	G/T	ch.11.24196551F	chr11:24239977	NA	0.82	9.53	0.52	1.57e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.81	12.28	0.62	2.43e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-1.01	-16.92	-0.73	3.99e-43	Height;
KIRP	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.52	5.16	0.31	4.99e-7	Diastolic blood pressure;
KIRP	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg04202892	chr2:111875749	ACOXL	0.44	6.12	0.36	3.75e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg05621596	chr22:47072043	GRAMD4	-0.52	-7.54	-0.43	8.8e-13	Urate levels in obese individuals;
KIRP	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg06565975	chr8:143823917	SLURP1	0.46	7.0	0.41	2.42e-11	Urinary tract infection frequency;
KIRP	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.74	6.8	0.4	8e-11	Fat distribution (HIV);
KIRP	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg25486957	chr4:152246857	NA	-0.52	-5.73	-0.34	2.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.19	-0.31	4.48e-7	Myopia (pathological);
KIRP	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.65	0.56	4.92e-22	Cognitive test performance;
KIRP	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.79	-0.66	2.03e-32	Height;
KIRP	cis	rs981844	0.740	rs10009844	chr4:154681576	C/T	cg14289246	chr4:154710475	SFRP2	-0.49	-6.51	-0.38	4.14e-10	Response to statins (LDL cholesterol change);
KIRP	cis	rs12210905	1.000	rs72843629	chr6:27175215	G/T	cg11502198	chr6:26597334	ABT1	-0.73	-4.9	-0.3	1.78e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.73	-7.92	-0.45	8.02e-14	Schizophrenia;
KIRP	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.43	5.5	0.33	9.41e-8	Menopause (age at onset);
KIRP	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.35	-0.38	1.04e-9	Joint mobility (Beighton score);
KIRP	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg01631408	chr1:248437212	OR2T33	-0.63	-8.38	-0.47	4.12e-15	Common traits (Other);
KIRP	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.41	6.71	0.39	1.3e-10	Myeloid white cell count;
KIRP	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.66	8.0	0.45	4.83e-14	Calcium levels;
KIRP	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17507749	chr15:85114479	UBE2QP1	0.69	7.72	0.44	2.85e-13	Schizophrenia;
KIRP	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.73	11.51	0.59	8.42e-25	Calcium levels;
KIRP	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.6	7.81	0.45	1.66e-13	Resting heart rate;
KIRP	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.15	15.72	0.71	5.01e-39	Lymphocyte percentage of white cells;
KIRP	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.8	-0.53	2.34e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg11608241	chr8:8085544	FLJ10661	0.45	5.68	0.34	3.85e-8	Neuroticism;
KIRP	cis	rs6832769	1.000	rs28463765	chr4:56412434	C/T	cg09317128	chr4:56265301	TMEM165	-0.52	-6.52	-0.38	3.89e-10	Personality dimensions;
KIRP	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.59e-8	Aortic root size;
KIRP	cis	rs738321	0.756	rs4821740	chr22:38514423	C/G	cg25457927	chr22:38595422	NA	-0.28	-5.67	-0.34	4.07e-8	Breast cancer;
KIRP	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.27	-0.37	1.6e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.55	0.48	1.32e-15	Prudent dietary pattern;
KIRP	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.9	14.46	0.68	9.93e-35	Ewing sarcoma;
KIRP	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.32	0.32	2.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2239815	0.515	rs5762849	chr22:29238086	G/A	cg02153584	chr22:29168773	CCDC117	0.59	5.73	0.34	2.93e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg21854759	chr1:92012499	NA	-0.47	-6.05	-0.36	5.32e-9	Breast cancer;
KIRP	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs7904985	0.924	rs2217223	chr10:88111630	A/G	cg07322936	chr10:88137208	NA	0.51	5.45	0.33	1.21e-7	Barrett's esophagus;
KIRP	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.71	-9.67	-0.52	5.77e-19	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg24375607	chr4:120327624	NA	0.59	6.42	0.38	6.89e-10	Corneal astigmatism;
KIRP	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11987759	chr7:65425863	GUSB	-0.53	-6.94	-0.4	3.55e-11	Aortic root size;
KIRP	cis	rs10186029	0.657	rs11689895	chr2:213938553	G/T	cg08319019	chr2:214017104	IKZF2	0.41	4.89	0.3	1.78e-6	Systemic sclerosis;
KIRP	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.44	-0.43	1.73e-12	Response to antipsychotic treatment;
KIRP	cis	rs59197085	0.636	rs2307036	chr7:128454537	C/A	cg17511168	chr7:128516960	KCP	0.44	5.01	0.3	1.05e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07188220	chr14:67981637	TMEM229B	0.53	6.49	0.38	4.69e-10	Parkinson's disease;
KIRP	cis	rs10216189	1.000	rs7799665	chr7:5527501	G/A	cg05318486	chr7:5553423	FBXL18	-0.47	-5.89	-0.35	1.29e-8	Relative hand skill in reading disability;
KIRP	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.31	4.9	0.3	1.77e-6	Testicular germ cell tumor;
KIRP	cis	rs3752645	0.764	rs9641372	chr7:106691486	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-5.19	-0.31	4.35e-7	Bladder cancer (smoking interaction);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03056682	chr16:57023329	NLRC5	-0.54	-6.02	-0.36	6.29e-9	Menopause (age at onset);
KIRP	cis	rs9394841	0.692	rs9369312	chr6:41841535	A/T	cg08135965	chr6:41755394	TOMM6	0.52	5.55	0.33	7.36e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	5.01	0.3	1.02e-6	Educational attainment;
KIRP	cis	rs13161895	1.000	rs35592104	chr5:179447661	A/T	cg02702477	chr5:179499311	RNF130	0.69	5.39	0.33	1.62e-7	LDL cholesterol;
KIRP	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg23307798	chr14:103986281	CKB	0.78	13.92	0.66	7.09e-33	Body mass index;
KIRP	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.56	-15.56	-0.7	1.74e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.42	-0.33	1.45e-7	Leprosy;
KIRP	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.71	9.87	0.53	1.48e-19	Pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27556913	chr4:1341059	KIAA1530	0.45	6.14	0.36	3.28e-9	Parkinson's disease;
KIRP	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.42	4.89e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.84	0.35	1.67e-8	Coronary artery disease;
KIRP	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.86	0.35	1.48e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4664304	0.629	rs955388	chr2:160837921	A/G	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.64	-0.34	4.75e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs13108043	0.605	rs62306505	chr4:87936842	A/G	cg11209507	chr4:87813803	C4orf36	0.45	4.87	0.3	2e-6	Red blood cell count;
KIRP	cis	rs7623687	0.786	rs73088161	chr3:49465162	C/T	cg19401529	chr3:49056140	DALRD3	0.98	6.2	0.37	2.41e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs10486003	1.000	rs6948859	chr7:97239206	G/C	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.64	-5.08	-0.31	7.63e-7	Response to platinum-based agents;
KIRP	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg00106254	chr7:1943704	MAD1L1	-0.53	-5.87	-0.35	1.39e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7572644	0.662	rs9309658	chr2:28256831	A/G	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg10935138	chr17:73851978	WBP2	0.58	7.49	0.43	1.24e-12	Psoriasis;
KIRP	cis	rs77688320	0.535	rs13022344	chr2:202264156	C/T	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.77	10.62	0.56	6.25e-22	Blood protein levels;
KIRP	cis	rs10073892	0.621	rs10070402	chr5:101641602	G/A	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs73198271	0.562	rs17631052	chr8:8663787	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.18	-0.31	4.53e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg17595323	chr11:93583763	C11orf90	0.3	5.15	0.31	5.41e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9462846	0.959	rs10456518	chr6:42830484	G/A	cg05552183	chr6:42928497	GNMT	0.44	5.21	0.32	4.05e-7	Blood protein levels;
KIRP	cis	rs300890	0.513	rs72719182	chr4:144068805	A/G	cg01719995	chr4:144104893	USP38	-0.43	-5.51	-0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg17764715	chr19:33622953	WDR88	0.66	7.81	0.45	1.63e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1978968	1.000	rs11704059	chr22:18449543	A/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.57	-0.43	7.35e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg11833968	chr6:79620685	NA	-0.49	-7.46	-0.43	1.49e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg07395648	chr5:131743802	NA	0.56	7.95	0.45	6.75e-14	Blood metabolite levels;
KIRP	cis	rs33912345	0.643	rs1254306	chr14:60887900	C/T	cg27398547	chr14:60952738	C14orf39	-0.4	-5.4	-0.33	1.56e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1805008	0.568	rs76888998	chr16:89884310	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.18	-8.11	-0.46	2.39e-14	Skin colour saturation;
KIRP	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg02527881	chr3:46936655	PTH1R	-0.39	-5.55	-0.33	7.36e-8	Colorectal cancer;
KIRP	cis	rs6832769	1.000	rs13102385	chr4:56345255	T/C	cg09317128	chr4:56265301	TMEM165	0.55	7.44	0.43	1.63e-12	Personality dimensions;
KIRP	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.4	-5.11	-0.31	6.6e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg06565975	chr8:143823917	SLURP1	-0.49	-7.2	-0.42	7.29e-12	Urinary tract infection frequency;
KIRP	cis	rs11877825	0.826	rs8088257	chr18:10579953	T/G	cg07277756	chr18:10589357	NA	0.49	5.97	0.36	8.16e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs71636778	0.584	rs17162316	chr1:27177907	C/G	cg12203394	chr1:27248618	NUDC	0.61	4.87	0.3	2.02e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg17441377	chr17:3906640	NA	-0.52	-7.98	-0.45	5.55e-14	Type 2 diabetes;
KIRP	cis	rs918629	0.798	rs2546199	chr5:95282091	A/C	cg16656078	chr5:95278638	ELL2	-0.47	-6.78	-0.4	8.68e-11	IgG glycosylation;
KIRP	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.43	-5.43	-0.33	1.32e-7	Blood metabolite levels;
KIRP	cis	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg13293535	chr8:11597251	GATA4	-0.5	-6.47	-0.38	5.31e-10	Neuroticism;
KIRP	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.78	0.44	2.06e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.13	0.31	5.85e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6504950	0.888	rs2628315	chr17:53226622	C/T	cg26251398	chr17:52985966	TOM1L1	0.37	5.03	0.31	9.48e-7	Breast cancer;
KIRP	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.88	0.35	1.3e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	9.31	0.51	7.55e-18	Lung cancer in ever smokers;
KIRP	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.39	-0.38	8.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.63	-7.5	-0.43	1.19e-12	Metabolic traits;
KIRP	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.07	-0.36	4.85e-9	Ulcerative colitis;
KIRP	cis	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.31	-0.37	1.29e-9	Joint mobility (Beighton score);
KIRP	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	8.87	0.49	1.54e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16551220	chr14:53103238	GPR137C	0.38	6.29	0.37	1.45e-9	C-reactive protein;
KIRP	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg05527609	chr1:210001259	C1orf107	-0.43	-5.28	-0.32	2.85e-7	Red blood cell count;
KIRP	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg03684893	chr10:554711	DIP2C	-0.37	-5.29	-0.32	2.74e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3099143	0.901	rs28551558	chr15:77234637	C/T	cg21673338	chr15:77095150	SCAPER	-0.52	-5.42	-0.33	1.4e-7	Recalcitrant atopic dermatitis;
KIRP	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17384381	0.953	rs3768223	chr1:85809183	T/C	cg16011679	chr1:85725395	C1orf52	0.86	8.54	0.48	1.43e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-7.69	-0.44	3.62e-13	Total body bone mineral density;
KIRP	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg21360079	chr12:107162445	NA	-0.67	-9.39	-0.51	4.32e-18	Heart rate;
KIRP	cis	rs13385	0.769	rs7715649	chr5:139605517	G/A	cg01860693	chr5:139557145	C5orf32	0.46	4.92	0.3	1.57e-6	Atrial fibrillation;
KIRP	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg17724175	chr1:150552817	MCL1	-0.44	-7.44	-0.43	1.68e-12	Urate levels;
KIRP	cis	rs1923539	0.822	rs1923536	chr10:81709809	C/T	cg17004975	chr10:81743287	NA	0.41	5.16	0.31	4.98e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs16912285	0.892	rs80332091	chr11:24255248	T/A	ch.11.24196551F	chr11:24239977	NA	0.84	6.94	0.4	3.5e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.7	10.55	0.56	1.03e-21	Dupuytren's disease;
KIRP	cis	rs12044355	0.929	rs11122323	chr1:231848933	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	4.99	0.3	1.13e-6	Alzheimer's disease;
KIRP	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.6	7.56	0.43	8.11e-13	Resistin levels;
KIRP	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.65	-9.14	-0.5	2.36e-17	Retinal vascular caliber;
KIRP	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg18753928	chr3:113234510	CCDC52	-0.52	-6.66	-0.39	1.8e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs537626	0.848	rs624797	chr11:69308575	G/T	cg15442037	chr11:69286293	NA	0.43	6.16	0.37	3e-9	Breast cancer (early onset);
KIRP	cis	rs7119167	0.901	rs880317	chr11:73108276	A/G	cg17517138	chr11:73019481	ARHGEF17	0.51	5.36	0.32	1.91e-7	Blood protein levels;
KIRP	cis	rs778371	0.749	rs2592120	chr2:233793664	C/T	cg08000102	chr2:233561755	GIGYF2	-0.45	-4.97	-0.3	1.24e-6	Schizophrenia;
KIRP	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.48	0.33	1.04e-7	Menopause (age at onset);
KIRP	cis	rs2143950	0.834	rs78426265	chr14:35762991	A/T	cg09327582	chr14:35236912	BAZ1A	-0.56	-5.24	-0.32	3.47e-7	Atopic dermatitis;
KIRP	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg17644776	chr2:200775616	C2orf69	-0.56	-5.32	-0.32	2.38e-7	Schizophrenia;
KIRP	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg16586182	chr3:47516702	SCAP	0.83	11.88	0.6	5.15e-26	Colorectal cancer;
KIRP	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27297192	chr10:134578999	INPP5A	0.63	7.73	0.44	2.82e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.15	-0.46	1.86e-14	Response to antipsychotic treatment;
KIRP	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.58	7.78	0.44	2.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4148660	1.000	rs34413975	chr12:22071073	C/T	cg14669847	chr12:22099120	NA	-0.35	-5.91	-0.35	1.14e-8	Gout;
KIRP	cis	rs7595037	0.512	rs12621489	chr2:68597779	A/G	cg07594636	chr2:68547088	CNRIP1	0.39	4.86	0.3	2.09e-6	Multiple sclerosis;
KIRP	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.94	-0.61	3.15e-26	Eye color traits;
KIRP	cis	rs4638749	0.501	rs2220261	chr2:108758885	G/A	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.94	-0.3	1.43e-6	Blood pressure;
KIRP	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.57	7.46	0.43	1.47e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4262150	0.726	rs4958318	chr5:151943054	C/T	cg12297329	chr5:152029980	NA	-0.63	-7.76	-0.44	2.32e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.77	11.78	0.6	1.06e-25	Breast cancer;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.86	14.15	0.67	1.17e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs10853057	0.541	rs77675516	chr17:63046808	C/T	cg24886788	chr15:41118060	PPP1R14D	0.43	6.44	0.38	6.2e-10	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs7975161	0.640	rs10778323	chr12:104746075	A/G	cg25273343	chr12:104657179	TXNRD1	0.59	5.44	0.33	1.3e-7	Toenail selenium levels;
KIRP	cis	rs330048	0.510	rs11784654	chr8:8969611	T/A	cg06636001	chr8:8085503	FLJ10661	-0.41	-5.13	-0.31	5.82e-7	Systemic lupus erythematosus;
KIRP	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.66	8.44	0.47	2.84e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.59	-6.75	-0.4	1.06e-10	Urate levels;
KIRP	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg07395648	chr5:131743802	NA	-0.38	-5.59	-0.34	6.13e-8	Acylcarnitine levels;
KIRP	cis	rs7951870	1.000	rs11038914	chr11:46561301	A/G	cg16389345	chr11:46697382	NA	0.43	5.04	0.31	8.94e-7	Schizophrenia;
KIRP	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg09873164	chr1:152488093	CRCT1	0.55	7.17	0.42	8.63e-12	Hair morphology;
KIRP	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.73	0.39	1.17e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg07382826	chr16:28625726	SULT1A1	0.48	5.35	0.32	2.06e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.13	0.31	5.79e-7	Neuroticism;
KIRP	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-7.09	-0.41	1.4e-11	Systemic lupus erythematosus;
KIRP	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg12131826	chr15:77904385	NA	-0.41	-5.49	-0.33	9.8e-8	Type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.8	0.4	7.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-6.56	-0.39	3.09e-10	Colorectal cancer;
KIRP	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.82	-11.5	-0.59	8.59e-25	Total body bone mineral density;
KIRP	cis	rs45544231	0.569	rs3095605	chr16:52583847	A/G	cg09051775	chr16:52580266	TOX3	-0.4	-5.5	-0.33	9.68e-8	Restless legs syndrome;
KIRP	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg12962167	chr3:53033115	SFMBT1	0.71	5.15	0.31	5.38e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.73	-10.48	-0.56	1.8e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg15083037	chr5:83017644	HAPLN1	-0.62	-8.73	-0.49	4.01e-16	Prostate cancer;
KIRP	cis	rs2904967	0.703	rs2904982	chr11:65004301	G/T	cg12562828	chr11:65076843	NA	-0.86	-11.61	-0.6	3.75e-25	Mean corpuscular volume;
KIRP	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.49	7.64	0.44	4.95e-13	Testicular germ cell tumor;
KIRP	cis	rs4262150	0.883	rs55752608	chr5:152138775	T/A	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg11189052	chr15:85197271	WDR73	-0.54	-5.16	-0.31	5.03e-7	Schizophrenia;
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.71	-9.64	-0.52	7.29e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.75	10.36	0.55	4.16e-21	Bone properties (heel);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07047920	chr16:2802315	SRRM2;LOC100128788	0.51	6.82	0.4	6.95e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17429842	chr1:179202149	NA	0.5	6.06	0.36	5.07e-9	Interleukin-4 levels;
KIRP	trans	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg24644049	chr4:85504048	CDS1	0.93	6.87	0.4	5.21e-11	Skin colour saturation;
KIRP	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg23533926	chr12:111358616	MYL2	-0.48	-6.35	-0.38	1.01e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg26875233	chr11:93583750	C11orf90	0.44	7.88	0.45	1.05e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs4900538	0.963	rs942023	chr14:102972170	T/C	cg18135206	chr14:102964638	TECPR2	0.93	14.53	0.68	6.06e-35	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.54	7.09	0.41	1.41e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.51	7.25	0.42	5.29e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.45	6.02	0.36	6.4e-9	Ulcerative colitis;
KIRP	cis	rs57590327	0.645	rs62265395	chr3:81531932	C/T	cg07356753	chr3:81810745	GBE1	-0.54	-5.64	-0.34	4.67e-8	Extraversion;
KIRP	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs4006360	0.574	rs6503592	chr17:39253010	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.43	-0.47	2.97e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg07001201	chr5:642380	CEP72	0.65	6.56	0.39	3.18e-10	Obesity-related traits;
KIRP	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-0.95	-11.59	-0.59	4.48e-25	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg01872077	chr2:219646372	CYP27A1	-0.38	-4.85	-0.3	2.22e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17123764	0.892	rs12321169	chr12:50115917	G/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.87	0.3	1.97e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.18	10.55	0.56	1.01e-21	Atopic dermatitis;
KIRP	cis	rs10129255	0.500	rs9324092	chr14:107139823	A/G	cg23076370	chr14:107095027	NA	0.43	5.25	0.32	3.28e-7	Kawasaki disease;
KIRP	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.04	0.69	1.11e-36	Platelet count;
KIRP	cis	rs6969780	1.000	rs929249	chr7:27167537	T/C	cg19142026	chr7:27170394	HOXA4	0.43	4.95	0.3	1.39e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7017914	0.967	rs7014012	chr8:71672743	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.38e-7	Bone mineral density;
KIRP	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.21	0.32	4.06e-7	Melanoma;
KIRP	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg15655495	chr12:38532458	NA	-0.25	-4.85	-0.3	2.18e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg12598211	chr12:123634384	NA	-0.45	-5.19	-0.31	4.34e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2315504	0.509	rs2051806	chr17:39031451	C/T	cg26086101	chr17:38992251	TMEM99	-0.3	-4.9	-0.3	1.73e-6	Height;
KIRP	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.77	8.45	0.47	2.51e-15	Bipolar disorder;
KIRP	cis	rs9783347	1.000	rs4150564	chr11:18355308	G/A	cg15585147	chr11:18324498	HPS5	0.44	5.95	0.35	9.4e-9	Pancreatic cancer;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08052428	chr9:135996421	RALGDS	-0.47	-6.25	-0.37	1.84e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg10950524	chr7:2139216	MAD1L1	0.29	4.98	0.3	1.2e-6	Schizophrenia;
KIRP	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg18764771	chr6:116381957	FRK	0.19	5.23	0.32	3.7e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	10.27	0.55	8.1e-21	Menopause (age at onset);
KIRP	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg00852783	chr1:26633632	UBXN11	-0.5	-4.93	-0.3	1.51e-6	Obesity-related traits;
KIRP	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.56	0.39	3.09e-10	Height;
KIRP	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.25	-0.37	1.75e-9	Total body bone mineral density;
KIRP	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg12315302	chr6:26189340	HIST1H4D	0.78	5.35	0.32	1.97e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7572644	0.760	rs10190494	chr2:28131243	A/G	cg27432699	chr2:27873401	GPN1	-0.45	-5.39	-0.32	1.68e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.43	-6.2	-0.37	2.33e-9	Vitamin D levels;
KIRP	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg00094735	chr5:1949198	NA	0.47	5.67	0.34	3.92e-8	Gut microbiome composition (winter);
KIRP	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg07541023	chr7:19748670	TWISTNB	0.68	6.09	0.36	4.25e-9	Thyroid stimulating hormone;
KIRP	cis	rs8060686	0.546	rs8047343	chr16:68143745	G/A	cg26727032	chr16:67993705	SLC12A4	-0.74	-8.94	-0.5	9.24e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	1.05	18.91	0.77	7.21e-50	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.43	-0.55	2.45e-21	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-5.24	-0.32	3.46e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.44	5.72	0.34	3.09e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6662572	1.000	rs72688452	chr1:46092365	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.81	0.35	1.93e-8	Blood protein levels;
KIRP	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.7	-12.78	-0.63	5.12e-29	Body mass index;
KIRP	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs4654899	0.865	rs6658526	chr1:21391314	A/G	cg05370193	chr1:21551575	ECE1	-0.48	-5.77	-0.35	2.34e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.64	6.06	0.36	5.18e-9	Height;
KIRP	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14159672	chr1:205819179	PM20D1	-0.5	-5.83	-0.35	1.72e-8	Parkinson's disease;
KIRP	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.77	-0.4	9.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7809950	0.834	rs2712199	chr7:107140239	A/G	cg23024343	chr7:107201750	COG5	-0.46	-7.12	-0.41	1.16e-11	Coronary artery disease;
KIRP	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.9	-0.35	1.17e-8	Breast cancer;
KIRP	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07256732	chr16:621771	PIGQ	-0.46	-6.41	-0.38	7.24e-10	Height;
KIRP	cis	rs6968419	0.755	rs4730719	chr7:115895010	A/C	cg02561103	chr7:115862891	TES	0.42	5.98	0.36	7.99e-9	Intraocular pressure;
KIRP	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg00933542	chr6:150070202	PCMT1	0.27	5.17	0.31	4.84e-7	Lung cancer;
KIRP	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs72960926	0.744	rs1931272	chr6:74950681	C/T	cg03266952	chr6:74778945	NA	-0.74	-5.3	-0.32	2.57e-7	Metabolite levels (MHPG);
KIRP	cis	rs9810890	0.850	rs73196977	chr3:128450224	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg16512390	chr1:228756714	NA	0.45	5.04	0.31	8.95e-7	Diastolic blood pressure;
KIRP	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.56	7.01	0.41	2.26e-11	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7560272	0.538	rs7599453	chr2:73937901	T/G	cg20560298	chr2:73613845	ALMS1	0.49	5.96	0.36	8.72e-9	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.76	-11.25	-0.58	6.01e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4728302	0.838	rs2042453	chr7:133580730	G/A	cg10665199	chr7:133106180	EXOC4	0.48	5.73	0.34	2.94e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	trans	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-6.86	-0.4	5.53e-11	Obesity-related traits;
KIRP	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26002218	chr14:103986227	CKB	-0.35	-7.19	-0.42	7.65e-12	Body mass index;
KIRP	cis	rs4805272	1.000	rs7246224	chr19:29323438	T/C	cg04546413	chr19:29218101	NA	0.43	4.86	0.3	2.05e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6499129	0.558	rs7191281	chr16:67655133	T/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.66	-0.34	4.17e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6832769	1.000	rs6554286	chr4:56400304	T/G	cg09317128	chr4:56265301	TMEM165	-0.55	-7.05	-0.41	1.78e-11	Personality dimensions;
KIRP	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg15436174	chr10:43711423	RASGEF1A	0.79	8.46	0.47	2.45e-15	Hirschsprung disease;
KIRP	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg10047753	chr17:41438598	NA	1.17	19.27	0.78	4.52e-51	Menopause (age at onset);
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14678666	chr6:46520136	CYP39A1	0.38	6.12	0.36	3.57e-9	C-reactive protein;
KIRP	cis	rs2505998	0.796	rs2505537	chr10:43592158	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.8	-0.35	1.98e-8	Hirschsprung disease;
KIRP	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg11518657	chr1:67396239	MIER1	-0.6	-5.91	-0.35	1.17e-8	Lymphocyte percentage of white cells;
KIRP	trans	rs1973993	0.689	rs17375929	chr1:96962246	A/T	cg10631902	chr5:14652156	NA	-0.59	-8.37	-0.47	4.24e-15	Weight;
KIRP	cis	rs9790314	0.613	rs6799160	chr3:160634889	A/G	cg04691961	chr3:161091175	C3orf57	0.45	6.47	0.38	5.29e-10	Morning vs. evening chronotype;
KIRP	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.87	-15.4	-0.7	6.41e-38	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.45	-0.33	1.24e-7	Bipolar disorder;
KIRP	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	10.16	0.54	1.78e-20	Cognitive test performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15064304	chr1:153895398	GATAD2B	0.48	6.11	0.36	3.92e-9	Parkinson's disease;
KIRP	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg16141378	chr3:129829833	LOC729375	0.52	6.93	0.4	3.72e-11	Triglycerides;
KIRP	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg15247329	chr7:2764246	NA	-0.41	-5.96	-0.36	8.56e-9	Height;
KIRP	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.45	-5.87	-0.35	1.4e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	9.21	0.51	1.51e-17	Bone mineral density;
KIRP	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg09408571	chr1:101003634	GPR88	-0.23	-5.22	-0.32	3.75e-7	Monocyte count;
KIRP	cis	rs12780845	0.931	rs17466418	chr10:17244307	G/T	cg01003015	chr10:17271136	VIM	0.47	5.26	0.32	3.08e-7	Homocysteine levels;
KIRP	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg26531700	chr6:26746687	NA	0.5	7.18	0.42	8.28e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.29	-0.32	2.65e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27548644	chr19:11473142	LPPR2	-0.48	-6.64	-0.39	1.95e-10	Parkinson's disease;
KIRP	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.85	11.59	0.59	4.56e-25	Selective IgA deficiency;
KIRP	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg05044414	chr3:183734942	ABCC5	0.37	5.6	0.34	5.77e-8	Anterior chamber depth;
KIRP	cis	rs2224391	0.628	rs2753230	chr6:5248538	C/G	cg13962347	chr6:5174647	LYRM4	0.7	9.62	0.52	8.38e-19	Height;
KIRP	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.92	-14.62	-0.68	3.02e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15176678	chr19:10230499	EIF3G	0.47	6.29	0.37	1.47e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs861318	0.838	rs855866	chr1:159052720	A/G	cg22583711	chr7:154795321	PAXIP1;LOC202781	-0.57	-6.02	-0.36	6.41e-9	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23249133	chr14:55450934	WDHD1	-0.46	-7.12	-0.41	1.2e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-0.75	-9.28	-0.51	9.43e-18	Blood trace element (Zn levels);
KIRP	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg00629928	chr5:358741	AHRR	0.51	4.97	0.3	1.27e-6	Breast cancer;
KIRP	cis	rs9309473	0.950	rs10189885	chr2:73877055	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.04	-0.36	5.52e-9	Metabolite levels;
KIRP	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.5	-5.71	-0.34	3.29e-8	Colorectal cancer;
KIRP	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.32	-0.37	1.19e-9	Alcohol dependence;
KIRP	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.07	-0.46	3.18e-14	Body mass index;
KIRP	cis	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg19847130	chr8:10466454	RP1L1	0.37	5.26	0.32	3.1e-7	Triglycerides;
KIRP	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	1.04	20.83	0.8	3.1e-56	Breast cancer;
KIRP	cis	rs2213920	0.679	rs7047851	chr9:118220718	A/G	cg13918206	chr9:118159781	DEC1	-0.98	-10.14	-0.54	2.11e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs8022179	0.566	rs62006258	chr14:103838909	A/C	cg16497661	chr14:103986332	CKB	-0.53	-6.04	-0.36	5.63e-9	Monocyte count;
KIRP	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.41	-5.31	-0.32	2.44e-7	Type 2 diabetes;
KIRP	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.43	5.9	0.35	1.21e-8	Bone mineral density (hip);Bone mineral density;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15389440	chr4:129730137	PHF17	-0.45	-6.07	-0.36	4.86e-9	Inflammatory biomarkers;
KIRP	cis	rs2235642	0.621	rs2667665	chr16:1569524	A/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.63	-0.34	4.91e-8	Coronary artery disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00589864	chr2:68478328	PPP3R1	-0.46	-6.87	-0.4	5.36e-11	C-reactive protein;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02037518	chr11:57283212	SLC43A1	-0.51	-7.2	-0.42	7.46e-12	Survival in pancreatic cancer;
KIRP	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.58	7.74	0.44	2.55e-13	Blood protein levels;
KIRP	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg27532560	chr4:187881888	NA	-0.73	-12.39	-0.62	9.92e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11603020	0.904	rs4926	chr11:57381989	G/A	cg23127183	chr11:57508653	C11orf31	-0.46	-5.33	-0.32	2.18e-7	Blood protein levels;
KIRP	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg01620082	chr3:125678407	NA	-0.94	-6.45	-0.38	5.99e-10	Lung cancer;Intelligence (multi-trait analysis);
KIRP	cis	rs4280164	0.945	rs4366641	chr14:24771101	C/T	cg18688254	chr14:24701745	GMPR2;NEDD8	-0.49	-4.84	-0.3	2.25e-6	Parent of origin effect on language impairment (paternal);
KIRP	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19368394	chr1:61843430	NFIA	-0.44	-6.57	-0.39	3.02e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.49	0.38	4.73e-10	Height;
KIRP	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg16989719	chr2:238392110	NA	-0.52	-5.85	-0.35	1.57e-8	Prostate cancer;
KIRP	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.53	-5.65	-0.34	4.36e-8	Body mass index;
KIRP	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.69	-9.38	-0.51	4.64e-18	Childhood ear infection;
KIRP	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg09184832	chr6:79620586	NA	-0.38	-4.97	-0.3	1.25e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs8070740	0.898	rs8078914	chr17:5323924	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.36	0.43	2.68e-12	Menopause (age at onset);
KIRP	cis	rs7538876	0.967	rs6678552	chr1:17720391	G/A	cg07394400	chr1:17752023	RCC2	-0.37	-5.29	-0.32	2.77e-7	Basal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.22e-7	Life satisfaction;
KIRP	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.73	-7.76	-0.44	2.33e-13	Blood pressure (smoking interaction);
KIRP	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-5.0	-0.3	1.1e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.91	0.3	1.65e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs7999699	0.967	rs9526396	chr13:48335090	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	6.82e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-7.15	-0.41	9.63e-12	Gut microbiome composition (summer);
KIRP	cis	rs1712790	0.702	rs12289022	chr11:114627848	A/C	cg19465033	chr11:114479364	NA	0.39	5.17	0.31	4.82e-7	Urinary albumin excretion;
KIRP	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.3	-7.11	-0.41	1.22e-11	Mean corpuscular volume;
KIRP	cis	rs4671458	0.572	rs17617855	chr2:63719887	T/C	cg17519650	chr2:63277830	OTX1	-0.49	-4.93	-0.3	1.54e-6	Subjective well-being;
KIRP	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.46	-5.7	-0.34	3.34e-8	Crohn's disease;
KIRP	cis	rs17209837	1.000	rs4148815	chr7:87087834	A/T	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.37	0.65	5.32e-31	Personality dimensions;
KIRP	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg23067535	chr8:124195133	FAM83A	-0.71	-7.0	-0.41	2.46e-11	Urinary uromodulin levels;
KIRP	cis	rs2562456	0.520	rs660063	chr19:21453905	T/G	cg18461458	chr19:21324796	ZNF431	0.52	4.87	0.3	1.96e-6	Pain;
KIRP	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.17	-0.46	1.58e-14	Total cholesterol levels;
KIRP	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	6.51	0.38	4.31e-10	Height;
KIRP	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.52	7.06	0.41	1.73e-11	Gout;
KIRP	cis	rs4129585	0.928	rs13262595	chr8:143316970	A/G	cg16886403	chr8:143471632	TSNARE1	0.45	4.88	0.3	1.92e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg20731937	chr12:48336164	NA	0.41	5.23	0.32	3.61e-7	Longevity (90 years and older);
KIRP	cis	rs4237845	0.591	rs10877041	chr12:58328500	G/A	cg00677455	chr12:58241039	CTDSP2	0.69	7.81	0.45	1.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg23479056	chr15:41276147	INO80	-0.38	-5.16	-0.31	5.17e-7	Menopause (age at onset);
KIRP	cis	rs12476592	0.602	rs262483	chr2:63877246	G/C	cg17519650	chr2:63277830	OTX1	-0.44	-5.05	-0.31	8.6e-7	Childhood ear infection;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16364152	chr20:5591818	RP5-1022P6.2	0.43	6.06	0.36	5.2e-9	Survival in pancreatic cancer;
KIRP	cis	rs559928	0.502	rs11231787	chr11:64179813	T/C	cg05555928	chr11:63887634	MACROD1	-0.43	-5.26	-0.32	3.14e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.69	9.64	0.52	7.5e-19	Blood protein levels;
KIRP	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.42	-0.33	1.44e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.63	-8.05	-0.46	3.58e-14	Colorectal cancer;
KIRP	cis	rs1978968	0.763	rs5992136	chr22:18453103	G/C	cg03078520	chr22:18463400	MICAL3	-0.77	-10.55	-0.56	1.02e-21	Presence of antiphospholipid antibodies;
KIRP	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg23594656	chr7:65796392	TPST1	-0.41	-5.84	-0.35	1.67e-8	Aortic root size;
KIRP	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg05834625	chr6:170176447	C6orf70	0.51	4.93	0.3	1.54e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1837494	0.566	rs12694587	chr2:223892312	T/C	cg02552189	chr2:223891284	NA	-0.56	-7.94	-0.45	7.09e-14	Oropharynx cancer;
KIRP	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.22	0.61	3.78e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.61	7.97	0.45	5.89e-14	Breast cancer;
KIRP	cis	rs7534824	0.860	rs80278569	chr1:101605316	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	5.49	0.33	1.01e-7	Refractive astigmatism;
KIRP	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00585698	chr12:123750864	CDK2AP1	0.38	4.99	0.3	1.17e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg10223061	chr2:219282414	VIL1	0.31	5.11	0.31	6.34e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg01864069	chr14:103024347	NA	-0.9	-10.11	-0.54	2.55e-20	Platelet count;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg07256732	chr16:621771	PIGQ	-0.47	-6.53	-0.38	3.64e-10	Height;
KIRP	cis	rs2072732	0.861	rs12039132	chr1:2949355	C/T	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.52e-7	Plateletcrit;
KIRP	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.59	7.23	0.42	5.95e-12	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27492874	chr19:5680956	HSD11B1L;C19orf70	0.46	6.33	0.37	1.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06634786	chr22:41940651	POLR3H	-0.44	-5.09	-0.31	7.29e-7	Vitiligo;
KIRP	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.24	23.72	0.83	1.6e-65	Cognitive function;
KIRP	cis	rs4262150	0.726	rs6884556	chr5:152013316	G/C	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.18e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6840360	0.617	rs2724563	chr4:152349959	G/C	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6545883	0.894	rs6760075	chr2:61612881	C/A	cg15711740	chr2:61764176	XPO1	0.61	7.98	0.45	5.59e-14	Tuberculosis;
KIRP	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	5.75	0.34	2.62e-8	Monocyte percentage of white cells;
KIRP	cis	rs4722166	0.597	rs2002792	chr7:22763845	C/G	cg05472934	chr7:22766657	IL6	0.43	5.49	0.33	9.96e-8	Lung cancer;
KIRP	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg05639522	chr1:247681581	NA	0.58	5.52	0.33	8.67e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.59	5.9	0.35	1.21e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.42	0.43	1.95e-12	Joint mobility (Beighton score);
KIRP	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.28	-0.42	4.5e-12	Menopause (age at onset);
KIRP	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.39	3.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg04691961	chr3:161091175	C3orf57	0.48	7.19	0.42	7.59e-12	Morning vs. evening chronotype;
KIRP	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg15038512	chr6:170123185	PHF10	0.48	5.39	0.33	1.62e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16318349	chr1:154917307	PBXIP1	0.28	4.94	0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs7539542	0.569	rs72752764	chr1:202851592	G/T	cg19681188	chr1:202830198	LOC148709	-0.47	-5.1	-0.31	6.7e-7	Mean platelet volume;
KIRP	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg05552183	chr6:42928497	GNMT	0.45	5.15	0.31	5.43e-7	Blood protein levels;
KIRP	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.73	-0.34	2.95e-8	Height;
KIRP	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00290607	chr11:67383545	NA	0.35	4.89	0.3	1.82e-6	Mean corpuscular volume;
KIRP	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg23958373	chr8:599963	NA	-0.97	-6.3	-0.37	1.35e-9	IgG glycosylation;
KIRP	cis	rs7760535	0.794	rs3851225	chr6:111825132	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.45	-5.68	-0.34	3.7e-8	Metabolic traits;
KIRP	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-5.32	-0.32	2.39e-7	Total body bone mineral density;
KIRP	cis	rs1805008	0.608	rs34019730	chr16:89812930	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.2	-8.02	-0.46	4.19e-14	Skin colour saturation;
KIRP	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.44	0.33	1.3e-7	Cognitive test performance;
KIRP	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.69	-0.39	1.48e-10	Coronary artery disease;
KIRP	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01616529	chr11:638424	DRD4	-0.42	-5.66	-0.34	4.28e-8	Systemic lupus erythematosus;
KIRP	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.45	6.19	0.37	2.52e-9	Testicular germ cell tumor;
KIRP	cis	rs9815354	0.857	rs6796078	chr3:42017820	A/T	cg03022575	chr3:42003672	ULK4	-0.54	-6.11	-0.36	3.82e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	5.38	0.32	1.7e-7	Myopia (pathological);
KIRP	cis	rs4638749	0.501	rs9917181	chr2:108747865	C/T	cg25838818	chr2:108905173	SULT1C2	-0.37	-5.75	-0.34	2.68e-8	Blood pressure;
KIRP	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg17595323	chr11:93583763	C11orf90	-0.31	-5.23	-0.32	3.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs34779708	0.931	rs11597483	chr10:35285117	A/G	cg04310649	chr10:35416472	CREM	-0.53	-5.97	-0.36	8.41e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.56	6.7	0.39	1.39e-10	Multiple sclerosis;
KIRP	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.3e-7	Bipolar disorder;
KIRP	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg10189774	chr4:17578691	LAP3	0.48	5.48	0.33	1.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.8	-0.63	4.23e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-5.47	-0.33	1.11e-7	Morning vs. evening chronotype;
KIRP	cis	rs1829883	0.626	rs2548089	chr5:98910440	A/C	cg08333243	chr5:99726346	NA	0.4	5.23	0.32	3.59e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.73	11.14	0.58	1.3e-23	Menarche (age at onset);
KIRP	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.42	0.38	7.02e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg07648498	chr16:89883185	FANCA	0.41	5.39	0.32	1.67e-7	Vitiligo;
KIRP	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg18932078	chr1:2524107	MMEL1	0.4	5.45	0.33	1.23e-7	Ulcerative colitis;
KIRP	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	4.86	0.3	2.07e-6	Total cholesterol levels;
KIRP	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs2415984	0.622	rs28487986	chr14:46924435	T/G	cg14871534	chr14:47121158	RPL10L	-0.46	-5.42	-0.33	1.41e-7	Number of children ever born;
KIRP	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg26207909	chr14:103986467	CKB	-0.44	-5.39	-0.32	1.65e-7	Coronary artery disease;
KIRP	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.04	-0.36	5.81e-9	IgG glycosylation;
KIRP	cis	rs397969	0.596	rs9901294	chr17:19888501	G/A	cg13482628	chr17:19912719	NA	0.49	5.8	0.35	1.99e-8	Platelet count;
KIRP	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.08	-0.36	4.63e-9	Bladder cancer;
KIRP	cis	rs2274273	1.000	rs2274273	chr14:55614636	A/G	cg04306507	chr14:55594613	LGALS3	-0.46	-7.18	-0.42	8.29e-12	Protein biomarker;
KIRP	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.2	-0.46	1.29e-14	Response to antipsychotic treatment;
KIRP	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg15556689	chr8:8085844	FLJ10661	0.58	7.21	0.42	6.72e-12	Neuroticism;
KIRP	cis	rs2220004	0.614	rs10895984	chr11:55830265	C/T	cg01505312	chr11:56258856	OR5M8;OR8U8	-0.53	-5.91	-0.35	1.13e-8	Odorant perception (&beta-damascenone);
KIRP	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16434002	chr17:42200994	HDAC5	-0.55	-6.91	-0.4	4.21e-11	Total body bone mineral density;
KIRP	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg23594656	chr7:65796392	TPST1	0.5	7.89	0.45	9.85e-14	Aortic root size;
KIRP	cis	rs9359856	0.529	rs1328017	chr6:90297603	T/C	cg13799429	chr6:90582589	CASP8AP2	0.76	7.32	0.42	3.55e-12	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13407422	chr20:25371439	ABHD12	0.51	6.37	0.38	9.02e-10	Parkinson's disease;
KIRP	trans	rs12043259	0.730	rs7529113	chr1:204819761	T/C	cg11485465	chr5:54518469	NA	0.38	6.61	0.39	2.41e-10	Addiction;
KIRP	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.06	11.81	0.6	8.3e-26	Cannabis dependence symptom count;
KIRP	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.0	-0.3	1.09e-6	Cervical cancer;
KIRP	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg10223061	chr2:219282414	VIL1	-0.37	-6.1	-0.36	4.06e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg24955955	chr5:415729	AHRR	0.73	5.87	0.35	1.41e-8	Fat distribution (HIV);
KIRP	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.71	-10.58	-0.56	8.12e-22	Eosinophilic esophagitis;
KIRP	trans	rs540254	0.619	rs4656932	chr1:160779495	C/T	cg24082677	chr5:38105272	NA	0.49	6.03	0.36	6.12e-9	Blood protein levels;
KIRP	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg24110177	chr3:50126178	RBM5	-0.62	-7.58	-0.44	7.09e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs2055729	0.710	rs13257396	chr8:9736383	A/C	cg06636001	chr8:8085503	FLJ10661	0.56	6.16	0.37	2.96e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-7.22	-0.42	6.48e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23516759	chr2:201153734	NA	-0.64	-6.19	-0.37	2.52e-9	Chickenpox;
KIRP	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-0.59	-8.96	-0.5	8.43e-17	Trans fatty acid levels;
KIRP	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg13010199	chr12:38710504	ALG10B	-0.38	-4.85	-0.3	2.18e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6032067	0.929	rs17424668	chr20:43809647	C/T	cg10761708	chr20:43804764	PI3	-0.53	-5.55	-0.33	7.35e-8	Blood protein levels;
KIRP	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg20140201	chr2:241835670	C2orf54	-0.34	-5.2	-0.31	4.21e-7	Urinary metabolites;
KIRP	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.42	-11.69	-0.6	2.16e-25	Plateletcrit;
KIRP	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg21132104	chr15:45694354	SPATA5L1	0.62	7.53	0.43	9.32e-13	Glomerular filtration rate;
KIRP	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.49	5.98	0.36	7.99e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12044355	0.858	rs12040259	chr1:231826253	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.35	0.38	1.02e-9	Alzheimer's disease;
KIRP	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.69	-0.44	3.57e-13	Lung cancer;
KIRP	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.4	-0.51	3.82e-18	Chronic sinus infection;
KIRP	cis	rs6840360	0.593	rs4696103	chr4:152564611	A/G	cg25486957	chr4:152246857	NA	-0.48	-5.28	-0.32	2.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1829883	0.898	rs2461990	chr5:98793519	G/A	cg08333243	chr5:99726346	NA	-0.41	-5.46	-0.33	1.19e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg12501888	chr15:85177176	SCAND2	-0.41	-5.12	-0.31	6.06e-7	P wave terminal force;
KIRP	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg16988262	chr1:15930761	NA	0.41	5.12	0.31	6.29e-7	Systolic blood pressure;
KIRP	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg17279839	chr7:150038598	RARRES2	0.43	5.24	0.32	3.39e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg07061783	chr6:25882402	NA	-0.5	-5.37	-0.32	1.81e-7	Urate levels;
KIRP	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.32	-4.97	-0.3	1.27e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg26205652	chr12:48591994	NA	0.46	4.87	0.3	2.03e-6	Lung cancer;
KIRP	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.82	12.82	0.63	3.81e-29	Asthma;
KIRP	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg15556689	chr8:8085844	FLJ10661	0.63	8.32	0.47	6.11e-15	Retinal vascular caliber;
KIRP	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg12288994	chr5:1860383	NA	0.54	7.34	0.42	3.11e-12	Cardiovascular disease risk factors;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23511851	chr13:108087589	FAM155A	0.43	6.05	0.36	5.3300000000000004e-09	Interleukin-4 levels;
KIRP	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.64	-5.95	-0.35	9.25e-9	Breast cancer;
KIRP	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg02073558	chr3:44770973	ZNF501	0.68	10.63	0.56	5.92e-22	Depressive symptoms;
KIRP	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg26149184	chr10:133730230	NA	0.41	4.88	0.3	1.91e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs17123764	0.710	rs4563	chr12:50152193	G/A	cg20471783	chr12:50157085	TMBIM6	0.31	4.93	0.3	1.48e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4765905	0.580	rs10848631	chr12:2314825	G/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.75	-0.4	1.06e-10	Schizophrenia;
KIRP	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.74	8.93	0.49	1.04e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.06	-0.31	8.18e-7	Schizophrenia;
KIRP	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.54	-7.0	-0.41	2.39e-11	Extraversion;
KIRP	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2637030	0.559	rs2637024	chr5:52993453	A/G	cg06476337	chr5:52856530	NDUFS4	0.56	6.3	0.37	1.34e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.71	-7.19	-0.42	7.88e-12	Vitiligo;
KIRP	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg18016565	chr1:150552671	MCL1	0.39	5.85	0.35	1.54e-8	Tonsillectomy;
KIRP	trans	rs57602752	0.793	rs112825709	chr10:120622014	C/A	cg02768671	chr6:169470822	NA	0.57	7.28	0.42	4.38e-12	Cannabis dependence;
KIRP	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg03678062	chr6:149772716	ZC3H12D	-0.33	-4.94	-0.3	1.42e-6	Dupuytren's disease;
KIRP	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.8	9.07	0.5	4e-17	Diastolic blood pressure;
KIRP	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.57	11.85	0.6	6.39e-26	Diabetic kidney disease;
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg21734707	chr17:3908241	ZZEF1	-0.59	-8.63	-0.48	7.77e-16	Type 2 diabetes;
KIRP	trans	rs13170463	0.579	rs34824474	chr5:8034562	A/G	cg03862380	chr20:43029895	HNF4A	0.39	6.03	0.36	6.1e-9	Colorectal cancer;
KIRP	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.63	-7.85	-0.45	1.3e-13	Iron status biomarkers;
KIRP	cis	rs4006360	0.575	rs6503607	chr17:39315344	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.42	-5.59	-0.34	6.14e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	4.06e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg07005513	chr11:61595956	FADS2	-0.61	-5.08	-0.31	7.53e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-9.27	-0.51	9.66e-18	Bipolar disorder;
KIRP	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg20701182	chr2:24300061	SF3B14	0.51	5.27	0.32	3.02e-7	Asthma;
KIRP	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg27284194	chr4:1044797	NA	0.58	5.67	0.34	3.97e-8	Recombination rate (females);
KIRP	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.56e-25	Diabetic kidney disease;
KIRP	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	10.43	0.55	2.55e-21	Personality dimensions;
KIRP	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg11494091	chr17:61959527	GH2	0.49	6.12	0.36	3.63e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14094447	chr9:74383399	TMEM2	0.49	6.32	0.37	1.25e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.97	9.84	0.53	1.76e-19	Eosinophilic esophagitis;
KIRP	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg14703610	chr5:56206110	C5orf35	0.51	6.68	0.39	1.6e-10	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.51	-0.33	9.05e-8	Breast cancer;
KIRP	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg17724175	chr1:150552817	MCL1	0.3	5.15	0.31	5.23e-7	Tonsillectomy;
KIRP	cis	rs4006360	0.504	rs7502045	chr17:39252972	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.41	-0.47	3.36e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg27147174	chr7:100797783	AP1S1	-0.69	-9.01	-0.5	5.77e-17	Life satisfaction;
KIRP	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.63	-9.11	-0.5	2.92e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.44	-5.7	-0.34	3.36e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.61	-0.34	5.39e-8	Aortic root size;
KIRP	cis	rs9354308	0.677	rs2814136	chr6:66560775	A/G	cg07460842	chr6:66804631	NA	0.4	4.94	0.3	1.44e-6	Metabolite levels;
KIRP	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.64	-0.39	1.95e-10	Total body bone mineral density;
KIRP	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs927821	0.618	rs1572531	chr10:104193733	T/C	cg06646780	chr6:130182053	C6orf191	0.68	6.4	0.38	7.76e-10	Social autistic-like traits;
KIRP	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4073221	0.520	rs13065273	chr3:18194852	T/C	cg07694806	chr3:18168406	NA	-0.82	-7.09	-0.41	1.44e-11	Parkinson's disease;
KIRP	cis	rs1978968	0.654	rs13056749	chr22:18402924	G/A	cg03078520	chr22:18463400	MICAL3	-0.52	-6.31	-0.37	1.29e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg17691542	chr6:26056736	HIST1H1C	0.44	5.81	0.35	1.9e-8	Height;
KIRP	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.73	-9.27	-0.51	9.91e-18	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.05	0.41	1.83e-11	Mean platelet volume;
KIRP	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg08501292	chr6:25962987	TRIM38	0.79	5.43	0.33	1.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.52	-5.95	-0.35	9.26e-9	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs12517041	1.000	rs16892316	chr5:23282819	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg00310523	chr12:86230176	RASSF9	0.43	6.64	0.39	1.95e-10	Major depressive disorder;
KIRP	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05601917	chr6:125855416	NA	0.34	4.96	0.3	1.34e-6	Endometrial cancer;
KIRP	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg01988459	chr11:68622903	NA	-0.43	-5.89	-0.35	1.24e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs62380364	0.542	rs2457979	chr5:88039660	T/A	cg22951263	chr5:87985283	NA	-0.48	-6.82	-0.4	6.93e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7615316	0.934	rs6782400	chr3:142295368	C/A	cg20824294	chr3:142316082	PLS1	0.22	4.99	0.3	1.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg25486957	chr4:152246857	NA	-0.47	-5.25	-0.32	3.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg10617943	chr7:1981403	MAD1L1	-0.35	-4.9	-0.3	1.72e-6	Neuroticism;
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg00684032	chr4:1343700	KIAA1530	0.52	6.77	0.4	9.64e-11	Obesity-related traits;
KIRP	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs41005	1.000	rs13402078	chr2:8113107	C/T	cg03155496	chr2:8117019	LOC339788	-0.58	-9.34	-0.51	6.2e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.8	-10.88	-0.57	9.33e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg11801959	chr13:50123613	RCBTB1	-0.37	-5.15	-0.31	5.41e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg00334542	chr7:100209784	MOSPD3	-0.79	-6.73	-0.39	1.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	14.41	0.68	1.47e-34	Alzheimer's disease;
KIRP	cis	rs3755132	0.929	rs6743036	chr2:15767761	G/A	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05782078	chr7:140179173	MKRN1	-0.42	-6.12	-0.36	3.59e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.76e-9	Breast cancer;
KIRP	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	cg21523751	chr1:182988639	NA	0.35	4.94	0.3	1.46e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg24253500	chr15:84953950	NA	0.51	5.84	0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs654128	0.686	rs339349	chr6:117220647	A/G	cg12892004	chr6:117198278	RFX6	-0.53	-5.11	-0.31	6.46e-7	Telomere length;
KIRP	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.73	11.07	0.58	2.23e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg16341495	chr8:142228727	SLC45A4	-0.4	-4.96	-0.3	1.33e-6	Immature fraction of reticulocytes;
KIRP	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.85	10.33	0.55	5.32e-21	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.42	-5.11	-0.31	6.49e-7	Glycated hemoglobin levels;
KIRP	cis	rs17095355	1.000	rs734164	chr10:111698160	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.52	-0.38	3.89e-10	Biliary atresia;
KIRP	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.48	4.97	0.3	1.23e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg16917193	chr12:54089295	NA	0.85	16.34	0.72	3.89e-41	Height;
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg01798813	chr17:3906674	NA	0.52	7.21	0.42	6.97e-12	Type 2 diabetes;
KIRP	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	0.77	8.42	0.47	3.06e-15	Initial pursuit acceleration;
KIRP	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.53	13.12	0.64	3.56e-30	Airflow obstruction;
KIRP	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.92	-11.5	-0.59	8.6e-25	Response to antineoplastic agents;
KIRP	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg01689657	chr7:91764605	CYP51A1	0.45	6.58	0.39	2.76e-10	Breast cancer;
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs4748857	0.947	rs9888000	chr10:23606391	A/G	cg12804278	chr10:23633326	C10orf67	0.43	5.24	0.32	3.47e-7	Systemic lupus erythematosus;
KIRP	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-1.02	-9.32	-0.51	6.86e-18	Left atrial antero-posterior diameter;
KIRP	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.49	-6.59	-0.39	2.68e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg18882449	chr10:104885122	NT5C2	-0.47	-6.08	-0.36	4.53e-9	Arsenic metabolism;
KIRP	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.42e-13	Morning vs. evening chronotype;
KIRP	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.49	6.6	0.39	2.49e-10	Mean corpuscular volume;
KIRP	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	1.11	21.12	0.8	3.55e-57	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg19445457	chr11:5799446	OR52N5	-0.45	-5.43	-0.33	1.36e-7	DNA methylation (variation);
KIRP	cis	rs7178909	0.902	rs3853640	chr15:90443720	A/C	cg19708238	chr15:90437601	AP3S2	0.56	7.7	0.44	3.27e-13	Common traits (Other);
KIRP	cis	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg21546286	chr11:48923668	NA	-0.47	-6.01	-0.36	6.59e-9	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03699079	chr1:47082129	MOBKL2C	0.53	6.71	0.39	1.33e-10	Parkinson's disease;
KIRP	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.73	-8.63	-0.48	8.01e-16	Diastolic blood pressure;
KIRP	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg06935464	chr4:38784597	TLR10	0.53	5.32	0.32	2.36e-7	Breast cancer;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.79	14.8	0.69	7.33e-36	Lymphocyte counts;
KIRP	cis	rs5753037	0.809	rs2079338	chr22:30203842	G/A	cg27665648	chr22:30112403	NA	0.45	6.1	0.36	4.18e-9	Type 1 diabetes;
KIRP	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg00310523	chr12:86230176	RASSF9	-0.47	-7.52	-0.43	1e-12	Major depressive disorder;
KIRP	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg04310649	chr10:35416472	CREM	-0.59	-7.08	-0.41	1.47e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg17507749	chr15:85114479	UBE2QP1	0.89	9.87	0.53	1.44e-19	Schizophrenia;
KIRP	cis	rs812925	0.537	rs2463097	chr2:61614301	G/C	cg15711740	chr2:61764176	XPO1	0.47	5.9	0.35	1.19e-8	Immature fraction of reticulocytes;
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11987759	chr7:65425863	GUSB	0.69	9.64	0.52	7.53e-19	Aortic root size;
KIRP	cis	rs2051211	0.947	rs60479981	chr3:38568611	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-8.64	-0.48	7.26e-16	QRS duration;
KIRP	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.84	8.78	0.49	2.81e-16	Methadone dose in opioid dependence;
KIRP	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	7.95	0.45	6.91e-14	Joint mobility (Beighton score);
KIRP	cis	rs8018808	0.935	rs2091916	chr14:77914752	A/G	cg18872420	chr14:78023429	SPTLC2	0.37	5.41	0.33	1.49e-7	Myeloid white cell count;
KIRP	cis	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg09559047	chr8:10916868	XKR6	-0.39	-5.39	-0.32	1.66e-7	Triglycerides;
KIRP	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.61	6.63	0.39	2.06e-10	Alcohol dependence;
KIRP	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.46	5.81	0.35	1.92e-8	Height;
KIRP	cis	rs882300	0.900	rs12691875	chr2:136915698	C/A	cg05194412	chr2:137003533	NA	0.42	5.24	0.32	3.51e-7	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs7562790	0.610	rs3770895	chr2:36656471	G/A	cg09467607	chr2:36825704	FEZ2	0.41	5.04	0.31	8.89e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs11955175	1.000	rs11953942	chr5:40674713	C/A	cg17351974	chr5:40835760	RPL37	0.54	4.9	0.3	1.73e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.26	0.42	4.92e-12	Testicular germ cell tumor;
KIRP	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.44	5.64	0.34	4.55e-8	Height;
KIRP	cis	rs4971059	0.629	rs12904	chr1:155106697	G/A	cg02153340	chr1:155202674	NA	-0.41	-5.81	-0.35	1.93e-8	Breast cancer;
KIRP	cis	rs9986765	1.000	rs76467433	chr7:142824852	C/T	cg11323483	chr7:142828068	PIP	-0.66	-5.72	-0.34	3.05e-8	Cancer;Dermatomyositis;
KIRP	cis	rs4936894	0.519	rs11219530	chr11:124118080	C/T	cg27160556	chr11:124181099	OR8D1	-0.39	-5.81	-0.35	1.89e-8	Aging (time to death);
KIRP	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.6	-8.03	-0.46	4.13e-14	Pulse pressure;
KIRP	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs220519	0.811	rs220516	chr20:37283372	T/C	cg24308336	chr20:37270989	C20orf95	0.23	5.11	0.31	6.33e-7	Schizophrenia;
KIRP	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg02807482	chr3:125708958	NA	-0.48	-4.98	-0.3	1.18e-6	Blood pressure (smoking interaction);
KIRP	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.77	-0.35	2.36e-8	Breast cancer;
KIRP	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg18016565	chr1:150552671	MCL1	0.39	6.0	0.36	6.96e-9	Melanoma;
KIRP	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.76	9.38	0.51	4.71e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07234876	chr8:600039	NA	1.0	7.53	0.43	9.73e-13	IgG glycosylation;
KIRP	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg05315796	chr3:52349193	DNAH1	0.55	8.49	0.48	1.96e-15	Bipolar disorder;
KIRP	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg04673462	chr1:38461896	NA	0.37	5.01	0.3	1.06e-6	Coronary artery disease;
KIRP	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.58	7.6	0.44	6.06e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs8077577	0.895	rs735960	chr17:18057301	G/A	cg18869244	chr17:18121946	NA	0.46	4.92	0.3	1.57e-6	Obesity-related traits;
KIRP	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-9.47	-0.52	2.48e-18	Response to antipsychotic treatment;
KIRP	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	1.09	8.34	0.47	5.2e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.53	-6.41	-0.38	7.21e-10	Renal function-related traits (BUN);
KIRP	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.29	-0.32	2.75e-7	Mean platelet volume;
KIRP	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs7129556	0.701	rs4945220	chr11:77528161	C/G	cg12586386	chr11:77299805	AQP11	-0.41	-5.47	-0.33	1.09e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs1978968	0.763	rs9605474	chr22:18463297	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.78	-11.07	-0.58	2.19e-23	Presence of antiphospholipid antibodies;
KIRP	trans	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg16141378	chr3:129829833	LOC729375	0.53	6.74	0.39	1.09e-10	Systolic blood pressure;
KIRP	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-7.35	-0.42	2.95e-12	Gut microbiome composition (summer);
KIRP	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg16068336	chr17:48637367	CACNA1G	-0.41	-5.24	-0.32	3.43e-7	Type 2 diabetes;
KIRP	cis	rs514024	0.700	rs10118731	chr9:130418652	G/A	cg13643465	chr9:130375613	STXBP1	0.45	5.57	0.33	6.73e-8	Eating disorders (purging via substances);
KIRP	cis	rs728616	0.681	rs17100316	chr10:81913337	A/G	cg27417294	chr10:81904244	PLAC9	0.56	5.02	0.3	1.01e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg25547332	chr5:131281432	NA	0.47	5.25	0.32	3.35e-7	Life satisfaction;
KIRP	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.69	0.39	1.5e-10	Height;
KIRP	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.5e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.43	-5.94	-0.35	9.76e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-4.96	-0.3	1.33e-6	Coronary artery disease;
KIRP	cis	rs1420338	0.839	rs918036	chr7:34181859	A/G	cg01275685	chr7:34179230	BMPER	-0.63	-9.65	-0.52	7.02e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.41	-7.3	-0.42	4.05e-12	Refractive error;
KIRP	cis	rs7246657	0.598	rs28660259	chr19:37658681	C/T	cg18154014	chr19:37997991	ZNF793	0.71	5.98	0.36	7.95e-9	Coronary artery calcification;
KIRP	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11987759	chr7:65425863	GUSB	0.46	5.83	0.35	1.7e-8	Aortic root size;
KIRP	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg00262122	chr8:11665843	FDFT1	0.4	4.9	0.3	1.78e-6	Neuroticism;
KIRP	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07080220	chr10:102295463	HIF1AN	0.72	6.68	0.39	1.56e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.43	5.92	0.35	1.06e-8	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24069935	chr14:74226554	C14orf43	0.48	6.3	0.37	1.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg13206674	chr6:150067644	NUP43	0.47	5.5	0.33	9.51e-8	Lung cancer;
KIRP	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.05	0.41	1.85e-11	Aortic root size;
KIRP	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.17	0.37	2.77e-9	Personality dimensions;
KIRP	cis	rs17253792	0.545	rs35294669	chr14:56017438	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.88	12.69	0.63	1.01e-28	Coronary artery disease;
KIRP	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.89	-13.94	-0.66	6.28e-33	Breast cancer;
KIRP	cis	rs9596863	0.821	rs4884722	chr13:54429821	C/A	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.64	-0.34	4.68e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.89	-0.4	4.78e-11	Total body bone mineral density;
KIRP	cis	rs55675132	0.510	rs17544384	chr1:115295160	T/C	cg12756093	chr1:115239321	AMPD1	0.65	6.41	0.38	7.5e-10	Schizophrenia;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.85	-12.72	-0.63	8.27e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg22906224	chr7:99728672	NA	0.5	5.86	0.35	1.52e-8	Coronary artery disease;
KIRP	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.94	14.9	0.69	3.34e-36	Metabolite levels;
KIRP	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg16497661	chr14:103986332	CKB	0.77	11.61	0.59	3.86e-25	Body mass index;
KIRP	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg11845111	chr2:191398756	TMEM194B	-0.7	-7.73	-0.44	2.69e-13	Diastolic blood pressure;
KIRP	cis	rs9469913	0.668	rs76967117	chr6:34603691	G/A	cg14254433	chr6:34482411	PACSIN1	-0.56	-5.43	-0.33	1.35e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04541695	chr4:18023633	LCORL	0.5	6.4	0.38	7.61e-10	Parkinson's disease;
KIRP	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs7188697	0.845	rs1981960	chr16:58597289	C/G	cg21335942	chr16:58549945	SETD6	-0.47	-5.09	-0.31	7.14e-7	QT interval;
KIRP	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg27494647	chr7:150038898	RARRES2	0.43	6.07	0.36	4.87e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg17376030	chr22:41985996	PMM1	-0.85	-8.89	-0.49	1.3e-16	Vitiligo;
KIRP	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg10729496	chr3:10149963	C3orf24	0.55	5.0	0.3	1.07e-6	Alzheimer's disease;
KIRP	cis	rs13315871	1.000	rs78248959	chr3:58455068	G/A	cg12435725	chr3:58293450	RPP14	-0.54	-5.29	-0.32	2.65e-7	Cholesterol, total;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05718146	chr15:80544652	NA	0.43	6.29	0.37	1.45e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs62413470	1.000	rs12211223	chr6:55959848	T/C	cg13327911	chr6:55965977	COL21A1	0.55	5.03	0.31	9.6e-7	Joint mobility (Beighton score);
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.44	5.1	0.31	6.75e-7	Longevity;Endometriosis;
KIRP	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg00405596	chr8:11794950	NA	0.51	6.2	0.37	2.31e-9	Retinal vascular caliber;
KIRP	trans	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	6.1	0.36	4.19e-9	Ulcerative colitis;
KIRP	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg07511934	chr16:89386912	ANKRD11	0.42	5.3	0.32	2.57e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14169450	chr9:139327907	INPP5E	0.51	7.44	0.43	1.69e-12	Monocyte percentage of white cells;
KIRP	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	8.82	0.49	2.11e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs61990749	0.571	rs4448861	chr14:78307735	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.72	5.97	0.36	8.24e-9	Fibroblast growth factor basic levels;
KIRP	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg08847533	chr14:75593920	NEK9	0.52	6.23	0.37	2.04e-9	IgG glycosylation;
KIRP	cis	rs4845875	0.514	rs198406	chr1:11897592	A/G	cg24844545	chr1:11908347	NPPA	-0.36	-5.06	-0.31	8.4e-7	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.96	9.82	0.53	1.98e-19	Cerebrospinal P-tau181p levels;
KIRP	cis	rs490234	0.812	rs4838286	chr9:128460057	G/A	cg14078157	chr9:128172775	NA	-0.57	-6.7	-0.39	1.37e-10	Mean arterial pressure;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.51e-6	Life satisfaction;
KIRP	cis	rs13401104	0.796	rs10929174	chr2:237116829	A/G	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	1.11	8.08	0.46	2.97e-14	Skin colour saturation;
KIRP	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-1.07	-9.74	-0.53	3.66e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15541049	chr10:5931975	ANKRD16;FBXO18	0.5	6.21	0.37	2.25e-9	Myopia (pathological);
KIRP	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04127303	chr1:78148262	ZZZ3	0.55	6.29	0.37	1.43e-9	Lung cancer in ever smokers;
KIRP	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.74	0.44	2.53e-13	Educational attainment;
KIRP	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.8	0.4	7.74e-11	Colorectal cancer;
KIRP	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg25173405	chr17:45401733	C17orf57	0.47	6.21	0.37	2.21e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11203032	0.831	rs4399251	chr10:90943634	A/C	cg16672925	chr10:90967113	CH25H	0.76	8.01	0.45	4.68e-14	Heart failure;
KIRP	cis	rs7107174	1.000	rs2510044	chr11:77909014	G/A	cg02023728	chr11:77925099	USP35	0.43	5.42	0.33	1.41e-7	Testicular germ cell tumor;
KIRP	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg19636519	chr7:99541626	NA	-0.38	-7.01	-0.41	2.29e-11	Coronary artery disease;
KIRP	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg21926883	chr2:100939477	LONRF2	0.43	5.05	0.31	8.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs883565	0.916	rs12636980	chr3:39124132	C/T	cg01426195	chr3:39028469	NA	0.51	7.14	0.41	1.03e-11	Handedness;
KIRP	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs1050631	0.657	rs1789551	chr18:33716092	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.48	0.33	1.05e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.77	11.61	0.59	3.92e-25	Breast cancer;
KIRP	cis	rs300890	0.730	rs300919	chr4:144264722	T/C	cg01601573	chr4:144256835	GAB1	0.35	4.88	0.3	1.91e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs240764	0.817	rs12214151	chr6:101159516	G/T	cg09795085	chr6:101329169	ASCC3	-0.47	-5.45	-0.33	1.21e-7	Neuroticism;
KIRP	cis	rs8177876	0.749	rs2278024	chr16:81079233	C/G	cg08591886	chr16:81111003	C16orf46	-0.61	-5.44	-0.33	1.29e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg20965017	chr5:231967	SDHA	-0.6	-6.99	-0.41	2.59e-11	Breast cancer;
KIRP	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg05768032	chr16:30646687	NA	0.53	6.59	0.39	2.63e-10	Multiple myeloma;
KIRP	cis	rs62247992	0.698	rs737351	chr3:43129337	T/C	cg12239580	chr3:43073058	FAM198A	0.37	5.14	0.31	5.51e-7	Facial morphology (factor 15, philtrum width);
KIRP	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-11.44	-0.59	1.42e-24	Personality dimensions;
KIRP	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg04370829	chr17:406249	NA	0.4	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs939317	0.635	rs865809	chr3:183997735	C/T	cg09405238	chr3:183994500	ECE2	-0.55	-6.14	-0.36	3.23e-9	Menarche (age at onset);
KIRP	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.47	-0.33	1.11e-7	Aortic root size;
KIRP	cis	rs2742417	0.967	rs1883096	chr3:45750015	C/T	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.4	5.86	0.35	1.46e-8	Myeloid white cell count;
KIRP	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.76	9.38	0.51	4.54e-18	Response to diuretic therapy;
KIRP	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.88	11.44	0.59	1.4e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.53	-6.5	-0.38	4.53e-10	Total body bone mineral density;
KIRP	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	5.49	0.33	1.01e-7	Mean platelet volume;
KIRP	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.69	9.3	0.51	7.73e-18	Monocyte count;
KIRP	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg02100629	chr10:71892760	AIFM2	-0.4	-5.15	-0.31	5.31e-7	Blood protein levels;
KIRP	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-13.33	-0.65	7.02e-31	Alzheimer's disease;
KIRP	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs1816752	0.819	rs1981276	chr13:24983499	C/A	cg22771759	chr13:24902376	NA	0.38	4.89	0.3	1.83e-6	Obesity-related traits;
KIRP	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11987759	chr7:65425863	GUSB	-0.52	-7.11	-0.41	1.27e-11	Aortic root size;
KIRP	cis	rs7561273	0.561	rs35268318	chr2:24352824	A/T	cg20701182	chr2:24300061	SF3B14	0.49	6.0	0.36	6.89e-9	Quantitative traits;
KIRP	cis	rs240764	0.717	rs6904959	chr6:101157916	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.17	-0.31	4.74e-7	Neuroticism;
KIRP	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg18944383	chr4:111397179	ENPEP	0.54	9.58	0.52	1.1e-18	Height;
KIRP	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg15147215	chr3:52552868	STAB1	-0.29	-4.9	-0.3	1.72e-6	Electroencephalogram traits;
KIRP	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06481639	chr22:41940642	POLR3H	0.73	7.11	0.41	1.23e-11	Vitiligo;
KIRP	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg10503236	chr1:231470652	EXOC8	0.49	6.59	0.39	2.69e-10	Hemoglobin concentration;
KIRP	cis	rs1577917	0.545	rs7755958	chr6:86488511	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.41	4.92	0.3	1.61e-6	Response to antipsychotic treatment;
KIRP	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg24253500	chr15:84953950	NA	0.52	5.99	0.36	7.33e-9	Schizophrenia;
KIRP	cis	rs7638995	0.878	rs3968927	chr3:69183404	C/T	cg26574240	chr3:69171822	LMOD3	-0.68	-7.75	-0.44	2.35e-13	Alzheimer's disease (late onset);
KIRP	trans	rs12517041	1.000	rs2081950	chr5:23287505	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.68	-0.48	5.57e-16	Calcium levels;
KIRP	cis	rs7129556	0.645	rs684813	chr11:77494754	G/A	cg12586386	chr11:77299805	AQP11	0.49	5.72	0.34	3.11e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	trans	rs7999699	0.967	rs2406515	chr13:48333772	A/G	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	6.82e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg10434728	chr15:90938212	IQGAP1	-0.3	-5.07	-0.31	7.86e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.67	8.13	0.46	2.14e-14	Blood protein levels;
KIRP	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13732083	chr21:47605072	C21orf56	0.48	6.39	0.38	8.23e-10	Testicular germ cell tumor;
KIRP	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.31	-0.32	2.46e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7923609	0.967	rs10740126	chr10:65210935	A/G	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg23649088	chr2:200775458	C2orf69	-0.52	-5.46	-0.33	1.17e-7	Schizophrenia;
KIRP	cis	rs687432	0.650	rs10896701	chr11:57873135	T/C	cg19752551	chr11:57585705	CTNND1	0.38	5.39	0.33	1.63e-7	Parkinson's disease;
KIRP	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.42	-6.47	-0.38	5.19e-10	Refractive error;
KIRP	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg06795125	chr2:108905320	SULT1C2	-0.39	-7.18	-0.42	8e-12	Blood pressure;
KIRP	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.08e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg05528293	chr18:74961138	GALR1	0.55	6.02	0.36	6.34e-9	Obesity-related traits;
KIRP	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg25457927	chr22:38595422	NA	-0.27	-5.52	-0.33	8.74e-8	Cutaneous nevi;
KIRP	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.39	1.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg27129171	chr3:47204927	SETD2	0.66	9.13	0.5	2.58e-17	Colorectal cancer;
KIRP	cis	rs6088813	0.677	rs6088832	chr20:34006176	C/T	cg14752227	chr20:34000481	UQCC	0.46	5.17	0.31	4.97e-7	Height;
KIRP	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg09788416	chr12:39539408	NA	0.37	5.07	0.31	7.96e-7	Morning vs. evening chronotype;
KIRP	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	1.14	14.45	0.68	1.14e-34	Monocyte percentage of white cells;
KIRP	cis	rs4006360	0.511	rs7503699	chr17:39258027	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.53	-7.58	-0.44	7e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2342371	0.641	rs4916427	chr3:196094213	C/T	cg09821211	chr3:195954098	OSTalpha	0.46	5.01	0.3	1.06e-6	Fat distribution (HIV);
KIRP	cis	rs8018808	0.870	rs11159264	chr14:77937017	T/C	cg20045696	chr14:77926864	AHSA1	0.46	5.6	0.34	5.83e-8	Myeloid white cell count;
KIRP	cis	rs2425143	0.915	rs2378408	chr20:34367732	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	6.0	0.36	7.1e-9	Blood protein levels;
KIRP	trans	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
KIRP	cis	rs7180079	0.620	rs12916779	chr15:64739630	C/A	cg15337035	chr15:64978493	NA	-0.49	-5.35	-0.32	2e-7	Monocyte count;
KIRP	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg10117171	chr1:25599238	RHD	-0.38	-5.14	-0.31	5.55e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9311676	0.632	rs11714389	chr3:58447299	C/T	cg06643156	chr3:58380774	PXK	0.34	4.87	0.3	1.97e-6	Systemic lupus erythematosus;
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21016266	chr12:122356598	WDR66	-0.49	-6.56	-0.39	3.18e-10	Mean corpuscular volume;
KIRP	cis	rs4363385	0.747	rs7529110	chr1:152966247	A/C	cg13444842	chr1:152974279	SPRR3	-0.35	-4.86	-0.3	2.07e-6	Inflammatory skin disease;
KIRP	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.2	-0.37	2.39e-9	QT interval;
KIRP	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.93	0.35	1.04e-8	Type 2 diabetes;
KIRP	cis	rs73206853	0.841	rs73194013	chr12:111100677	T/C	cg12870014	chr12:110450643	ANKRD13A	0.52	4.88	0.3	1.89e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.88	-10.87	-0.57	9.75e-23	Gut microbiome composition (summer);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13049961	chr5:139498384	NA	-0.47	-7.41	-0.43	2.03e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs6601327	0.641	rs10096462	chr8:9614993	C/A	cg15556689	chr8:8085844	FLJ10661	0.58	7.65	0.44	4.56e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg09165964	chr15:75287851	SCAMP5	0.44	5.52	0.33	8.6e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17322444	chr19:33572249	GPATCH1	0.66	7.92	0.45	8.16e-14	Smoking initiation;
KIRP	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	9.63	0.52	7.81e-19	Post bronchodilator FEV1;
KIRP	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.36	-0.38	9.8e-10	Response to antipsychotic treatment;
KIRP	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.59	-5.0	-0.3	1.11e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg27422857	chr2:105853526	NA	-0.44	-5.86	-0.35	1.49e-8	Type 2 diabetes;
KIRP	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	7.12	0.41	1.21e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8177876	0.642	rs76909932	chr16:81119054	A/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg11945507	chr8:142233382	SLC45A4	0.91	15.24	0.7	2.17e-37	Immature fraction of reticulocytes;
KIRP	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg15226275	chr6:116381976	FRK	0.21	5.77	0.35	2.37e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.29	-0.62	2.21e-27	Eye color traits;
KIRP	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.79	8.79	0.49	2.62e-16	Bipolar disorder;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01453694	chr22:39746048	SYNGR1	-0.54	-5.82	-0.35	1.79e-8	Menopause (age at onset);
KIRP	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.91	-11.48	-0.59	1.04e-24	Homoarginine levels;
KIRP	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg16497661	chr14:103986332	CKB	-0.51	-6.69	-0.39	1.46e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg13976219	chr19:7197166	INSR	0.49	6.03	0.36	5.93e-9	Plasma plasminogen activator levels;
KIRP	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg23280166	chr11:118938394	VPS11	-0.62	-7.4	-0.43	2.18e-12	Coronary artery disease;
KIRP	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg20701182	chr2:24300061	SF3B14	0.6	5.2	0.31	4.18e-7	Lymphocyte counts;
KIRP	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.92	-0.4	3.86e-11	Menopause (age at onset);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg11183000	chr6:122720825	HSF2	0.56	6.47	0.38	5.22e-10	Plasma plasminogen activator levels;
KIRP	cis	rs981844	0.583	rs62325060	chr4:154630501	G/A	cg14289246	chr4:154710475	SFRP2	0.58	5.5	0.33	9.65e-8	Response to statins (LDL cholesterol change);
KIRP	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg16586182	chr3:47516702	SCAP	0.84	11.73	0.6	1.62e-25	Colorectal cancer;
KIRP	cis	rs9469913	0.799	rs6936177	chr6:34783717	C/G	cg17674042	chr6:34482479	PACSIN1	-0.39	-5.28	-0.32	2.81e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs830124	0.714	rs1177589	chr12:122403933	A/G	cg01765077	chr12:122356316	WDR66	0.57	5.94	0.35	9.83e-9	Urinary metabolites;
KIRP	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.35	0.38	1.05e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg00204512	chr16:28754710	NA	0.48	6.25	0.37	1.77e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.49	-6.48	-0.38	4.95e-10	Body mass index;
KIRP	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.5	5.89	0.35	1.25e-8	Metabolite levels;
KIRP	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.36	-4.88	-0.3	1.93e-6	Type 2 diabetes;
KIRP	trans	rs11165623	0.602	rs12120893	chr1:97007132	C/T	cg10631902	chr5:14652156	NA	-0.5	-6.51	-0.38	4.27e-10	Hip circumference;Waist circumference;
KIRP	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	7.91	0.45	8.96e-14	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12268958	chr18:21166718	NPC1	0.51	6.22	0.37	2.1e-9	Parkinson's disease;
KIRP	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg01864069	chr14:103024347	NA	0.88	9.84	0.53	1.72e-19	Platelet count;
KIRP	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.27	17.01	0.74	1.93e-43	Corneal structure;
KIRP	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.62	0.39	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.45	-4.88	-0.3	1.92e-6	Obesity (extreme);
KIRP	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs1823913	0.599	rs12989203	chr2:192141343	G/A	cg12404831	chr2:192114017	MYO1B	0.53	7.39	0.43	2.22e-12	Obesity-related traits;
KIRP	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.42	-5.3	-0.32	2.55e-7	Crohn's disease;
KIRP	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg15704280	chr7:45808275	SEPT13	0.69	6.25	0.37	1.84e-9	Intraocular pressure;
KIRP	cis	rs71277158	0.688	rs2287478	chr3:169788105	A/C	cg04067573	chr3:169899625	PHC3	0.62	5.65	0.34	4.33e-8	Prostate cancer;
KIRP	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.71	7.12	0.41	1.2e-11	Menarche (age at onset);
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-0.83	-14.77	-0.69	9.24e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg13319975	chr6:146136371	FBXO30	0.44	5.17	0.31	4.75e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9921338	0.886	rs4780363	chr16:11415891	C/T	cg00044050	chr16:11439710	C16orf75	0.48	5.22	0.32	3.89e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs963731	0.649	rs297141	chr2:39319382	T/C	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15644539	chr6:139802112	NA	0.56	6.49	0.38	4.59e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg11608241	chr8:8085544	FLJ10661	0.58	7.32	0.42	3.57e-12	Neuroticism;
KIRP	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg11235152	chr1:67600687	NA	0.68	10.42	0.55	2.64e-21	Psoriasis;
KIRP	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.46	-6.01	-0.36	6.66e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12090413	chr18:47807928	MBD1	0.54	6.89	0.4	4.77e-11	Parkinson's disease;
KIRP	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.81	0.35	1.92e-8	Aortic root size;
KIRP	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.24	-0.32	3.37e-7	Coronary artery disease;
KIRP	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg05896524	chr21:47604654	C21orf56	0.43	5.35	0.32	2.01e-7	Testicular germ cell tumor;
KIRP	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.92	10.92	0.57	6.67e-23	Corneal astigmatism;
KIRP	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	1.11	8.08	0.46	2.97e-14	Skin colour saturation;
KIRP	cis	rs6750047	0.567	rs336039	chr2:38258827	C/T	cg07380506	chr2:38303506	CYP1B1	-0.42	-5.7	-0.34	3.48e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	1.06	19.04	0.77	2.75e-50	Bone mineral density;
KIRP	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.79	9.89	0.53	1.27e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg26043149	chr18:55253948	FECH	0.51	6.19	0.37	2.5e-9	Bone mineral density;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17453250	chr15:75870836	PTPN9	0.45	6.35	0.38	1.03e-9	Cancer;
KIRP	cis	rs13102973	0.863	rs13103492	chr4:135907685	A/C	cg14419869	chr4:135874104	NA	0.48	7.44	0.43	1.67e-12	Subjective well-being;
KIRP	cis	rs4789693	1.000	rs4789693	chr17:80421870	A/C	cg04308225	chr17:80449738	NA	0.53	6.08	0.36	4.59e-9	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs300890	0.544	rs13136521	chr4:144205564	A/G	cg19876092	chr4:144208277	NA	-0.41	-6.26	-0.37	1.72e-9	Nasopharyngeal carcinoma;
KIRP	cis	rs785830	0.506	rs477109	chr9:239865	G/C	cg14500300	chr9:211689	NA	0.41	5.54	0.33	7.71e-8	Platelet distribution width;
KIRP	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg19468946	chr17:37922297	IKZF3	-0.49	-6.64	-0.39	2.04e-10	Self-reported allergy;
KIRP	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.93	12.03	0.61	1.55e-26	Platelet distribution width;
KIRP	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.99	-13.88	-0.66	9.5e-33	Response to antipsychotic treatment;
KIRP	cis	rs4742903	0.904	rs7048676	chr9:106998349	G/A	cg14250997	chr9:106856677	SMC2	0.39	5.26	0.32	3.06e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg27124370	chr19:33622961	WDR88	0.56	6.98	0.41	2.77e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg27532560	chr4:187881888	NA	-0.74	-12.71	-0.63	8.46e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7106204	0.748	rs6484032	chr11:24237153	C/A	ch.11.24196551F	chr11:24239977	NA	0.79	9.48	0.52	2.31e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg17145862	chr1:211918768	LPGAT1	-0.9	-13.12	-0.64	3.65e-30	Leprosy;
KIRP	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.71e-36	Prostate cancer;
KIRP	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.85	13.12	0.64	3.64e-30	Mean corpuscular volume;
KIRP	cis	rs2273669	0.667	rs11757168	chr6:109301091	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-6.36	-0.38	9.81e-10	Prostate cancer;
KIRP	cis	rs6585424	1.000	rs2228427	chr10:81926718	A/G	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg00631329	chr6:26305371	NA	-0.65	-8.82	-0.49	2.08e-16	Educational attainment;
KIRP	cis	rs16828019	0.852	rs71648536	chr1:41632008	T/A	cg18742814	chr1:41828276	NA	0.65	5.73	0.34	2.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg08999081	chr20:33150536	PIGU	0.42	5.08	0.31	7.56e-7	Height;
KIRP	cis	rs4132509	0.696	rs10927062	chr1:243889364	A/G	cg25706552	chr1:244017396	NA	0.52	6.75	0.4	1.08e-10	RR interval (heart rate);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00533811	chr22:51021411	CHKB-CPT1B;CHKB;LOC100144603	0.54	7.58	0.44	6.96e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.61	-8.75	-0.49	3.57e-16	Diastolic blood pressure;
KIRP	cis	rs1829883	0.835	rs2511900	chr5:98775156	G/A	cg08333243	chr5:99726346	NA	-0.41	-5.31	-0.32	2.47e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg09455208	chr3:40491958	NA	-0.34	-6.05	-0.36	5.49e-9	Renal cell carcinoma;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg07511668	chr11:68622177	NA	0.39	5.2	0.31	4.14e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10982256	0.870	rs10982247	chr9:117250792	C/T	cg13636371	chr9:117264095	DFNB31	-0.51	-7.43	-0.43	1.78e-12	Bipolar disorder;
KIRP	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.54	-0.48	1.45e-15	Coronary artery disease;
KIRP	cis	rs6977660	0.714	rs12536561	chr7:19816659	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs6725041	0.819	rs10048819	chr2:213090681	T/G	cg20637307	chr2:213403960	ERBB4	-0.4	-5.19	-0.31	4.34e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.46	-5.82	-0.35	1.81e-8	IgG glycosylation;
KIRP	cis	rs2380205	0.967	rs11255555	chr10:5895361	G/A	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.52e-8	Breast cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10117884	chr1:166955898	NA	0.38	6.25	0.37	1.79e-9	C-reactive protein;
KIRP	trans	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.52	-6.98	-0.41	2.73e-11	Mean corpuscular volume;
KIRP	cis	rs7106204	0.514	rs12291514	chr11:24360203	T/C	ch.11.24196551F	chr11:24239977	NA	0.68	6.41	0.38	7.21e-10	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg19507638	chr5:93509721	C5orf36	-0.59	-5.45	-0.33	1.22e-7	Diabetic retinopathy;
KIRP	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.57	-6.1	-0.36	4.04e-9	Obesity-related traits;
KIRP	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.86e-8	Depression;
KIRP	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg07775547	chr4:1625484	NA	-0.44	-5.51	-0.33	8.87e-8	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg15252951	chr6:33757062	LEMD2	0.45	5.36	0.32	1.95e-7	Crohn's disease;
KIRP	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.9	-12.62	-0.63	1.72e-28	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23957911	chr4:2758084	TNIP2	0.5	6.19	0.37	2.52e-9	Parkinson's disease;
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg01391022	chr12:122360665	WDR66	-0.4	-5.73	-0.34	2.98e-8	Mean corpuscular volume;
KIRP	cis	rs7551222	0.716	rs12041075	chr1:204492153	C/G	cg20240347	chr1:204465584	NA	-0.46	-8.74	-0.49	3.79e-16	Schizophrenia;
KIRP	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg18225595	chr11:63971243	STIP1	0.55	5.02	0.3	1.01e-6	Mean platelet volume;
KIRP	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.96	0.57	5.14e-23	Lung cancer in ever smokers;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg08850400	chr17:18231786	SHMT1	-0.5	-6.44	-0.38	6.37e-10	Inflammatory biomarkers;
KIRP	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17376030	chr22:41985996	PMM1	0.8	8.22	0.46	1.2e-14	Vitiligo;
KIRP	cis	rs6545883	0.894	rs9677047	chr2:61585295	C/G	cg15711740	chr2:61764176	XPO1	0.58	7.36	0.42	2.79e-12	Tuberculosis;
KIRP	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg00241281	chr14:105779794	PACS2	-0.35	-4.85	-0.3	2.23e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg00405596	chr8:11794950	NA	0.39	5.0	0.3	1.09e-6	Systolic blood pressure;
KIRP	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg24488311	chr11:68621650	NA	0.47	5.4	0.33	1.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12643440	0.887	rs601566	chr4:17204780	C/A	cg22650099	chr4:17144496	NA	0.45	5.56	0.33	7.15e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9815354	0.812	rs17284472	chr3:41996304	A/G	cg03022575	chr3:42003672	ULK4	-0.82	-8.43	-0.47	2.98e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg07308232	chr7:1071921	C7orf50	-0.65	-8.1	-0.46	2.53e-14	Longevity;Endometriosis;
KIRP	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	1.01	7.4	0.43	2.1e-12	Skin colour saturation;
KIRP	cis	rs17065868	1.000	rs73188772	chr13:45062476	C/A	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg05527609	chr1:210001259	C1orf107	-0.37	-4.94	-0.3	1.47e-6	Monobrow;
KIRP	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg25866889	chr13:114914595	NA	-0.4	-5.55	-0.33	7.42e-8	Schizophrenia;
KIRP	cis	rs7374004	0.601	rs13062931	chr3:38637160	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.43	5.09	0.31	6.99e-7	PR interval;
KIRP	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg26876637	chr1:152193138	HRNR	0.75	9.78	0.53	2.65e-19	Atopic dermatitis;
KIRP	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.72	10.41	0.55	2.9e-21	Hip circumference;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13604008	chr9:135906154	GTF3C5	0.53	7.1	0.41	1.36e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2998286	0.822	rs2095901	chr10:28803719	A/G	cg10174683	chr16:85619974	NA	-0.67	-6.08	-0.36	4.67e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg08600765	chr20:34638493	LOC647979	-0.7	-6.62	-0.39	2.18e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.63	-9.55	-0.52	1.4e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs35771425	0.626	rs11119744	chr1:211644575	C/T	cg10512769	chr1:211675356	NA	-0.73	-9.24	-0.51	1.17e-17	Educational attainment (years of education);
KIRP	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg17863274	chr19:49399704	TULP2	-0.33	-4.85	-0.3	2.22e-6	Red cell distribution width;
KIRP	cis	rs9303542	0.694	rs8071207	chr17:46584016	T/C	cg04904318	chr17:46607828	HOXB1	0.45	5.7	0.34	3.36e-8	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.49	7.4	0.43	2.09e-12	Resting heart rate;
KIRP	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.84	7.58	0.44	7.07e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2742417	1.000	rs2673037	chr3:45749094	A/T	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.7	-9.07	-0.5	4.03e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05025164	chr4:1340916	KIAA1530	0.38	4.92	0.3	1.6e-6	Obesity-related traits;
KIRP	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg26924012	chr15:45694286	SPATA5L1	0.67	8.85	0.49	1.81e-16	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs11074306	0.561	rs2311467	chr15:28069026	T/C	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.59e-6	Uveal melanoma;
KIRP	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	1.18	8.75	0.49	3.54e-16	Economic and political preferences (immigration/crime);
KIRP	cis	rs13102973	0.965	rs55967588	chr4:135860189	G/A	cg14419869	chr4:135874104	NA	0.53	8.8	0.49	2.5e-16	Subjective well-being;
KIRP	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.73	7.58	0.44	6.93e-13	Vitiligo;
KIRP	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg00262122	chr8:11665843	FDFT1	0.54	6.44	0.38	6.13e-10	Myopia (pathological);
KIRP	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.67	-8.91	-0.49	1.2e-16	Schizophrenia;
KIRP	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.51	7.22	0.42	6.39e-12	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.54	6.39	0.38	8.25e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-1.04	-6.94	-0.4	3.55e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg12598211	chr12:123634384	NA	-0.44	-5.45	-0.33	1.22e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.16	-0.5	2.03e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.32	-0.47	6.17e-15	Common traits (Other);
KIRP	cis	rs11410354	1	rs11410354	chr11:442472	C/CT	cg03576123	chr11:487126	PTDSS2	0.88	8.1	0.46	2.5e-14	Breast cancer;
KIRP	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.74	-8.54	-0.48	1.41e-15	Obesity-related traits;
KIRP	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.85	0.4	5.93e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2055729	0.645	rs12544019	chr8:9742578	T/C	cg06636001	chr8:8085503	FLJ10661	0.56	6.26	0.37	1.74e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.17	25.87	0.86	3.98e-72	Schizophrenia;
KIRP	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-7.89	-0.45	9.93e-14	Mitochondrial DNA levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09827037	chr3:5028674	NA	0.54	6.59	0.39	2.65e-10	Parkinson's disease;
KIRP	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg03808351	chr9:123631620	PHF19	0.43	5.88	0.35	1.3e-8	Hip circumference adjusted for BMI;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14769792	chr4:89629747	FAM13AOS	0.47	6.58	0.39	2.88e-10	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11393479	chr19:11529564	RGL3	0.52	7.08	0.41	1.51e-11	Parkinson's disease;
KIRP	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.95	15.22	0.7	2.6e-37	Menopause (age at onset);
KIRP	cis	rs17065868	1.000	rs9533895	chr13:45103407	T/C	cg10246903	chr13:45222710	NA	0.7	6.85	0.4	5.96e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12402495	chr1:154192844	C1orf43;UBAP2L	0.56	6.35	0.38	1.06e-9	Lung cancer in ever smokers;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22112476	chr4:1714772	SLBP	-0.45	-6.2	-0.37	2.34e-9	Metabolic traits;
KIRP	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg06740227	chr12:86229804	RASSF9	0.51	6.7	0.39	1.44e-10	Major depressive disorder;
KIRP	cis	rs4132509	0.793	rs10927046	chr1:243801190	T/C	cg21452805	chr1:244014465	NA	0.66	5.61	0.34	5.39e-8	RR interval (heart rate);
KIRP	cis	rs11018874	0.735	rs4307680	chr11:89900630	A/C	cg06174606	chr11:89959870	NA	-0.57	-5.91	-0.35	1.11e-8	White blood cell types;
KIRP	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.47	7.19	0.42	7.98e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg05714579	chr10:131428358	MGMT	0.52	6.79	0.4	8.33e-11	Response to temozolomide;
KIRP	cis	rs4702718	0.574	rs5745281	chr5:10684841	C/T	cg14521931	chr5:10832172	NA	0.51	5.19	0.31	4.48e-7	Obesity-related traits;
KIRP	cis	rs787274	1.000	rs787303	chr9:115491795	C/T	cg13803584	chr9:115635662	SNX30	0.78	7.1	0.41	1.36e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg07117364	chr1:16154769	NA	-0.4	-4.86	-0.3	2.08e-6	Dilated cardiomyopathy;
KIRP	cis	rs2882667	0.858	rs11957633	chr5:138364394	T/C	cg04439458	chr5:138467593	SIL1	-0.5	-7.53	-0.43	9.84e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.11	0.31	6.61e-7	Lung cancer;
KIRP	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21545522	chr1:205238299	TMCC2	0.42	5.72	0.34	3.12e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.95	8.19	0.46	1.46e-14	Arsenic metabolism;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10155725	chr11:86380814	ME3	0.51	6.51	0.38	4.12e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-7.46	-0.43	1.48e-12	Glomerular filtration rate (creatinine);
KIRP	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.53	7.41	0.43	2.05e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg03465714	chr1:152285911	FLG	0.49	5.29	0.32	2.69e-7	Atopic dermatitis;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.7	11.26	0.58	5.5e-24	Lung cancer;
KIRP	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.16	0.46	1.77e-14	IgG glycosylation;
KIRP	trans	rs4026608	0.931	rs1871675	chr12:66411692	C/T	cg07316577	chr5:122181443	SNX24	0.5	6.09	0.36	4.24e-9	Aortic root size;
KIRP	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.62	8.45	0.47	2.63e-15	Response to temozolomide;
KIRP	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.66	-0.48	6.39e-16	Coronary artery disease;
KIRP	trans	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg00938859	chr5:1591904	SDHAP3	0.54	6.28	0.37	1.53e-9	Breast cancer;
KIRP	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg18225595	chr11:63971243	STIP1	0.65	5.98	0.36	7.85e-9	Mean platelet volume;
KIRP	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.55	-0.33	7.51e-8	Schizophrenia (age at onset);
KIRP	cis	rs2625529	0.617	rs62023343	chr15:72174963	C/A	cg16672083	chr15:72433130	SENP8	0.43	6.19	0.37	2.49e-9	Red blood cell count;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg08163220	chr3:31574309	STT3B	0.57	6.67	0.39	1.63e-10	Electroencephalogram traits;
KIRP	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg25486957	chr4:152246857	NA	-0.48	-5.39	-0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18252515	chr7:66147081	NA	0.44	5.1	0.31	6.9e-7	Aortic root size;
KIRP	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.96	-0.41	3.06e-11	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.64	0.34	4.56e-8	Lung cancer;
KIRP	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg23594656	chr7:65796392	TPST1	0.43	5.71	0.34	3.17e-8	Aortic root size;
KIRP	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.48	-5.93	-0.35	1.03e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg10729496	chr3:10149963	C3orf24	-0.54	-5.02	-0.31	9.71e-7	Alzheimer's disease;
KIRP	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg26681399	chr22:41777847	TEF	-0.53	-5.3	-0.32	2.62e-7	Vitiligo;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.93	14.98	0.69	1.73e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs136211	0.577	rs9607339	chr22:36768932	G/T	cg16924664	chr22:36878180	TXN2	0.41	4.99	0.3	1.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9535307	0.858	rs2025263	chr13:50308847	C/T	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg08888203	chr3:10149979	C3orf24	0.5	5.27	0.32	2.96e-7	Alzheimer's disease;
KIRP	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.71	7.51	0.43	1.07e-12	Vitiligo;
KIRP	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	9.32	0.51	7.06e-18	Mood instability;
KIRP	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.17	0.42	8.89e-12	Coronary artery disease;
KIRP	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.92	14.02	0.67	3.18e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg25039879	chr17:56429692	SUPT4H1	0.6	5.23	0.32	3.61e-7	Cognitive test performance;
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	8.96	0.5	8.54e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg27490568	chr2:178487706	NA	0.46	6.3	0.37	1.34e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2224391	0.628	rs9504364	chr6:5256072	C/T	cg13962347	chr6:5174647	LYRM4	-0.73	-10.27	-0.55	8e-21	Height;
KIRP	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.38	-0.47	4.08e-15	Monocyte percentage of white cells;
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg05315796	chr3:52349193	DNAH1	-0.44	-6.78	-0.4	8.98e-11	Electroencephalogram traits;
KIRP	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.56	7.03	0.41	2.04e-11	Uric acid clearance;
KIRP	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg08283408	chr3:49949060	MON1A	0.36	4.91	0.3	1.67e-6	Body mass index;
KIRP	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	cg04338863	chr8:33670619	NA	0.4	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs10979	1.000	rs9403507	chr6:143887821	C/G	cg25407410	chr6:143891975	LOC285740	0.46	5.74	0.34	2.74e-8	Hypospadias;
KIRP	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9393777	0.668	rs16897515	chr6:27278020	A/C	cg22548220	chr6:27277996	POM121L2	-0.49	-6.15	-0.36	3.17e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12692119	0.614	rs4616428	chr2:127620861	A/C	cg25501666	chr2:127640322	NA	-0.44	-5.12	-0.31	6.1e-7	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	7.8	0.45	1.71e-13	Mean corpuscular hemoglobin;
KIRP	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.45	0.52	2.7e-18	Corneal astigmatism;
KIRP	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.94	12.64	0.63	1.48e-28	Cognitive function;
KIRP	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07395648	chr5:131743802	NA	0.59	8.31	0.47	6.39e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs231513	1.000	rs231519	chr17:41961051	C/T	cg26893861	chr17:41843967	DUSP3	0.65	6.74	0.4	1.09e-10	Cognitive function;
KIRP	cis	rs734999	0.588	rs3748817	chr1:2525665	T/C	cg20673091	chr1:2541236	MMEL1	0.78	12.61	0.63	1.94e-28	Ulcerative colitis;
KIRP	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg23920097	chr1:209922102	NA	-0.42	-5.57	-0.33	6.76e-8	Red blood cell count;
KIRP	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.73	-0.63	7.41e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg19875535	chr5:140030758	IK	0.65	9.21	0.51	1.53e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.94	16.26	0.72	7.21e-41	Mortality in heart failure;
KIRP	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.82	11.33	0.59	3.19e-24	Mean platelet volume;
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.35	-0.32	2.04e-7	Renal cell carcinoma;
KIRP	cis	rs13190036	1.000	rs34832871	chr5:176655929	A/G	cg04708888	chr5:176739561	MXD3	0.64	5.01	0.3	1.05e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs9393813	0.626	rs12664996	chr6:27363644	A/C	cg03332623	chr6:27441972	ZNF184	-0.37	-5.09	-0.31	7.02e-7	Bipolar disorder;
KIRP	cis	rs2271404	1.000	rs2271404	chr2:112003867	T/C	cg23466623	chr2:111982296	NA	-0.61	-5.23	-0.32	3.55e-7	Atopic dermatitis;
KIRP	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.73	9.99	0.54	5.88e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-9.88	-0.53	1.28e-19	Gut microbiome composition (summer);
KIRP	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.71	6.81	0.4	7.65e-11	Gut microbiome composition (summer);
KIRP	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.36	-5.64	-0.34	4.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.31	-0.32	2.51e-7	Neuroticism;
KIRP	cis	rs7688540	0.771	rs11722197	chr4:281707	A/G	cg10134910	chr4:1076041	RNF212	-0.24	-4.85	-0.3	2.19e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.53	-6.6	-0.39	2.48e-10	Platelet distribution width;
KIRP	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.76	-9.78	-0.53	2.67e-19	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.64	-9.34	-0.51	5.99e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg08975724	chr8:8085496	FLJ10661	-0.74	-10.08	-0.54	3.22e-20	Triglycerides;
KIRP	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19524238	chr7:2802976	GNA12	-0.37	-5.04	-0.31	9.04e-7	Height;
KIRP	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs58649573	0.552	rs10760307	chr9:126786733	C/G	cg14112217	chr9:126806003	NA	-0.33	-4.88	-0.3	1.88e-6	Post-traumatic stress disorder;
KIRP	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.35	-0.32	2.04e-7	Depression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09779392	chr19:11094753	SMARCA4	0.55	6.54	0.38	3.58e-10	Interleukin-4 levels;
KIRP	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg00149659	chr3:10157352	C3orf10	0.59	7.05	0.41	1.79e-11	Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20261243	chr20:44718728	NCOA5	0.59	7.0	0.41	2.37e-11	Smoking initiation;
KIRP	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.51	-0.33	8.85e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25565998	chr19:56166418	U2AF2	0.45	6.03	0.36	5.82e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg05220968	chr6:146057943	EPM2A	-0.42	-5.32	-0.32	2.36e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7818345	0.967	rs17479099	chr8:19277144	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.38	0.38	8.95e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg21905437	chr5:178450457	ZNF879	0.58	6.68	0.39	1.56e-10	Pubertal anthropometrics;
KIRP	cis	rs1144	0.508	rs2430484	chr7:104581962	G/T	cg04380332	chr7:105027541	SRPK2	-0.52	-7.51	-0.43	1.11e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg17366294	chr4:99064904	C4orf37	0.39	5.34	0.32	2.07e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.85	-11.28	-0.58	4.58e-24	Type 2 diabetes;
KIRP	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.24e-6	Recombination rate (females);
KIRP	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.14	-0.41	1.05e-11	Migraine;Coronary artery disease;
KIRP	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg23479056	chr15:41276147	INO80	-0.38	-5.16	-0.31	5.04e-7	Menopause (age at onset);
KIRP	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.78	-10.58	-0.56	8.56e-22	Aortic root size;
KIRP	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg17077180	chr1:38461687	NA	0.4	5.56	0.33	6.99e-8	Coronary artery disease;
KIRP	cis	rs2594989	0.790	rs2454491	chr3:11514290	A/G	cg01796438	chr3:11312864	ATG7	-0.41	-5.46	-0.33	1.14e-7	Circulating chemerin levels;
KIRP	cis	rs9584850	0.874	rs3742136	chr13:99102607	C/T	cg20750642	chr13:99100586	FARP1	-0.54	-6.51	-0.38	4.16e-10	Neuroticism;
KIRP	cis	rs2562456	0.520	rs279793	chr19:21455774	C/T	cg18461458	chr19:21324796	ZNF431	-0.53	-4.97	-0.3	1.27e-6	Pain;
KIRP	cis	rs10107145	0.509	rs73209954	chr8:10760667	G/C	cg21625330	chr8:9911636	MSRA	0.44	5.17	0.31	4.95e-7	Systolic blood pressure;
KIRP	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	15.33	0.7	1.11e-37	Post bronchodilator FEV1;
KIRP	cis	rs71597109	0.650	rs34261083	chr4:102717797	C/T	cg14855874	chr4:102712397	BANK1	0.38	4.97	0.3	1.28e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg16736954	chr20:23401023	NAPB	0.63	4.96	0.3	1.3e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7243821	0.639	rs8090635	chr18:52665858	A/G	cg26630735	chr18:52626848	CCDC68	0.48	5.29	0.32	2.7e-7	Chin dimples;
KIRP	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.51	-0.33	9.24e-8	Metabolite levels;
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs2120243	0.791	rs7615621	chr3:157152600	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.58	7.86	0.45	1.18e-13	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09311052	chr1:154531418	UBE2Q1	0.7	6.51	0.38	4.27e-10	Lung function (FEV1);
KIRP	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-6.36	-0.38	9.65e-10	Response to antipsychotic treatment;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09638001	chr20:44520063	CTSA;NEURL2	-0.51	-6.54	-0.38	3.54e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7246657	0.598	rs10417545	chr19:37654263	C/G	cg23950597	chr19:37808831	NA	-0.67	-5.61	-0.34	5.49e-8	Coronary artery calcification;
KIRP	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.9	7.42	0.43	1.9e-12	Alzheimer's disease (late onset);
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg05861140	chr6:150128134	PCMT1	-0.45	-6.17	-0.37	2.83e-9	Lung cancer;
KIRP	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg08885076	chr2:99613938	TSGA10	-0.43	-6.36	-0.38	9.52e-10	Bipolar disorder;
KIRP	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-1.07	-11.68	-0.6	2.25e-25	Corneal structure;
KIRP	cis	rs2859741	0.565	rs12023397	chr1:37507739	G/A	cg09363841	chr1:37513479	NA	-0.41	-5.92	-0.35	1.07e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs7945718	0.810	rs10831910	chr11:12830974	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.46	5.82	0.35	1.78e-8	Educational attainment (years of education);
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg20578329	chr17:80767326	TBCD	0.45	5.67	0.34	3.93e-8	Glycated hemoglobin levels;
KIRP	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.64	-7.37	-0.43	2.59e-12	Systemic lupus erythematosus;
KIRP	cis	rs16937956	0.597	rs12788149	chr11:8406930	C/G	cg08015107	chr11:8618950	NA	-0.53	-6.93	-0.4	3.73e-11	Body mass index;
KIRP	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg12598211	chr12:123634384	NA	-0.45	-5.44	-0.33	1.27e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg14324370	chr2:177042789	NA	0.7	9.61	0.52	8.73e-19	IgG glycosylation;
KIRP	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.35	-0.38	1.05e-9	Fibrinogen levels;
KIRP	cis	rs7224685	0.548	rs17710668	chr17:3880546	C/G	cg09597638	chr17:3907349	NA	0.58	6.56	0.39	3.24e-10	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01335204	chr3:44552057	NA	0.48	6.41	0.38	7.58e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.18	-0.42	8.3e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02962892	chr19:16989384	SIN3B	-0.47	-6.08	-0.36	4.6e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs631288	0.793	rs1530337	chr1:146683319	C/A	cg25205988	chr1:146714368	CHD1L	0.92	6.02	0.36	6.25e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg13798912	chr7:905769	UNC84A	0.53	5.38	0.32	1.76e-7	Cerebrospinal P-tau181p levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27309920	chr12:6798957	ZNF384	-0.52	-6.98	-0.41	2.78e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-8.92	-0.49	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-7.78	-0.44	1.99e-13	Neuroticism;
KIRP	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.61	0.39	2.35e-10	Colorectal cancer;
KIRP	cis	rs832187	0.813	rs704369	chr3:63868271	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.45	5.23	0.32	3.71e-7	Schizophrenia;
KIRP	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	cg21523751	chr1:182988639	NA	0.41	6.48	0.38	5.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6681460	0.966	rs7524851	chr1:67093018	T/C	cg13052034	chr1:66999238	SGIP1	0.4	5.41	0.33	1.51e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg00656387	chr3:40428638	ENTPD3	0.36	4.86	0.3	2.12e-6	Renal cell carcinoma;
KIRP	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	12.23	0.61	3.48e-27	Smoking behavior;
KIRP	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.03e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs4073416	0.534	rs7147002	chr14:66032546	T/C	cg03016385	chr14:66212404	NA	-0.51	-6.08	-0.36	4.46e-9	N-glycan levels;
KIRP	cis	rs580438	0.568	rs6442370	chr3:13378930	G/A	cg10657019	chr3:13328039	NA	-0.48	-6.33	-0.37	1.13e-9	Myringotomy;
KIRP	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.32	-6.55	-0.39	3.42e-10	Breast cancer;
KIRP	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg13147721	chr7:65941812	NA	0.92	6.86	0.4	5.46e-11	Diabetic kidney disease;
KIRP	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.7	-0.53	4.73e-19	Morning vs. evening chronotype;
KIRP	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg16141378	chr3:129829833	LOC729375	0.57	7.73	0.44	2.73e-13	Neuroticism;
KIRP	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26207909	chr14:103986467	CKB	0.75	10.94	0.57	5.66e-23	Body mass index;
KIRP	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.87	-0.57	1.01e-22	Breast cancer;
KIRP	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.35	0.62	1.34e-27	Ileal carcinoids;
KIRP	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.5	-5.98	-0.36	7.86e-9	Iron status biomarkers;
KIRP	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg04455712	chr21:45112962	RRP1B	0.5	6.79	0.4	8.32e-11	Mean corpuscular volume;
KIRP	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.54	7.44	0.43	1.71e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg11789530	chr4:8429930	ACOX3	-0.57	-6.6	-0.39	2.57e-10	Response to antineoplastic agents;
KIRP	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.11	-0.46	2.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10861342	0.892	rs3829297	chr12:105592823	G/C	cg23923672	chr12:105501055	KIAA1033	0.81	6.81	0.4	7.55e-11	IgG glycosylation;
KIRP	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg26681399	chr22:41777847	TEF	-0.42	-4.97	-0.3	1.23e-6	Neuroticism;
KIRP	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs13014235	0.532	rs10497867	chr2:202284867	T/C	cg06431681	chr2:202330990	STRADB	0.35	4.87	0.3	2.02e-6	Basal cell carcinoma;
KIRP	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.76	11.07	0.58	2.24e-23	Schizophrenia;
KIRP	cis	rs2694528	0.686	rs6885703	chr5:59862790	T/C	cg11474532	chr5:59995715	DEPDC1B	0.86	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	cis	rs12050794	0.636	rs4506844	chr15:72509138	C/T	cg16672083	chr15:72433130	SENP8	0.4	5.63	0.34	4.94e-8	Metabolite levels (HVA/MHPG ratio);
KIRP	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.76	11.37	0.59	2.32e-24	Blood metabolite levels;
KIRP	cis	rs8070740	1.000	rs8066928	chr17:5328155	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.38	0.43	2.45e-12	Menopause (age at onset);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12807293	chr14:59656816	DAAM1	-0.5	-6.75	-0.4	1.08e-10	Warfarin maintenance dose;
KIRP	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.84	10.79	0.57	1.8e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs6445967	1.000	rs2292674	chr3:58302404	A/T	cg16569813	chr3:58235849	ABHD6	-0.33	-4.89	-0.3	1.83e-6	Platelet count;
KIRP	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg01475377	chr6:109611718	NA	-0.42	-5.89	-0.35	1.26e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg07856975	chr6:36356162	ETV7	0.37	5.48	0.33	1.05e-7	Platelet distribution width;
KIRP	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.29	-0.51	8.3e-18	Asthma;
KIRP	cis	rs6516091	0.850	rs11699483	chr20:6048460	G/A	cg25325723	chr20:6104886	FERMT1	-0.6	-5.9	-0.35	1.19e-8	Abdominal aortic aneurysm;
KIRP	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg04656015	chr13:113407548	ATP11A	-0.49	-5.01	-0.3	1.04e-6	Glycated hemoglobin levels;
KIRP	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.56	5.4	0.33	1.54e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
KIRP	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.37	6.79	0.4	8.56e-11	Refractive error;
KIRP	cis	rs10875746	0.903	rs12301339	chr12:48475233	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	6.84	0.4	6.15e-11	Menarche (age at onset);
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.81	-10.9	-0.57	7.88e-23	Longevity;Endometriosis;
KIRP	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02807482	chr3:125708958	NA	-0.55	-5.19	-0.31	4.5e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg02918577	chr15:93633145	RGMA	-0.46	-5.7	-0.34	3.41e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.41	-5.42	-0.33	1.43e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg26335602	chr6:28129616	ZNF389	0.47	4.95	0.3	1.37e-6	Depression;
KIRP	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg22676075	chr6:135203613	NA	0.48	6.74	0.39	1.13e-10	Red blood cell count;
KIRP	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	10.32	0.55	5.58e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg12501888	chr15:85177176	SCAND2	-0.41	-5.1	-0.31	6.89e-7	P wave terminal force;
KIRP	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.77	8.86	0.49	1.59e-16	Triglycerides;
KIRP	cis	rs981844	0.712	rs1037654	chr4:154750300	C/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.56	8.19	0.46	1.46e-14	Blood protein levels;
KIRP	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg26035817	chr1:114414802	PTPN22	0.61	7.92	0.45	8.15e-14	Bacteremia;
KIRP	cis	rs2862064	1.000	rs1354163	chr5:156420703	C/T	cg12943317	chr5:156479607	HAVCR1	-0.93	-7.12	-0.41	1.16e-11	Platelet count;
KIRP	cis	rs7005380	0.581	rs9987297	chr8:120933689	G/A	cg21645572	chr8:120931649	DEPDC6	-0.52	-7.24	-0.42	5.77e-12	Interstitial lung disease;
KIRP	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg16141378	chr3:129829833	LOC729375	0.62	8.25	0.47	9.33e-15	Neuroticism;
KIRP	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.42	4.89	0.3	1.84e-6	Depression;
KIRP	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.66	7.99	0.45	5.2e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.85	6.74	0.39	1.1e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00864171	chr11:67383662	NA	-0.41	-4.91	-0.3	1.68e-6	Mean corpuscular volume;
KIRP	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg10189774	chr4:17578691	LAP3	0.48	5.66	0.34	4.13e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.57	-0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.56	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs3857747	0.578	rs11772069	chr7:40386317	G/A	cg00420559	chr7:40367873	C7orf10	-0.45	-6.48	-0.38	4.85e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg06611532	chr13:114900021	NA	0.21	4.89	0.3	1.83e-6	Schizophrenia;
KIRP	cis	rs10029851	0.645	rs1436504	chr4:109625184	A/G	cg16525761	chr4:109541525	LOC285456;RPL34	-0.45	-5.0	-0.3	1.09e-6	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.85	12.21	0.61	4.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg22676075	chr6:135203613	NA	0.51	7.41	0.43	1.97e-12	Red blood cell count;
KIRP	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.91	14.06	0.67	2.41e-33	Selective IgA deficiency;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26302994	chr2:44395983	PPM1B	0.52	6.67	0.39	1.7e-10	Parkinson's disease;
KIRP	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.76	-0.63	5.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg06307176	chr5:131281290	NA	0.55	5.97	0.36	8.38e-9	Life satisfaction;
KIRP	cis	rs4919044	0.808	rs12416051	chr10:94788835	C/T	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.42	0.62	8.08e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2219968	1.000	rs35551201	chr8:78963968	G/A	cg00738934	chr8:78996279	NA	0.4	4.97	0.3	1.26e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg27411982	chr8:10470053	RP1L1	-0.4	-5.06	-0.31	8.08e-7	Neuroticism;
KIRP	cis	rs2562456	0.833	rs62107547	chr19:21524047	A/C	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.02	14.84	0.69	5.02e-36	Primary sclerosing cholangitis;
KIRP	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg08999081	chr20:33150536	PIGU	0.47	6.44	0.38	6.2e-10	Height;
KIRP	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.72	-9.99	-0.54	6.08e-20	Ear protrusion;
KIRP	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.89	0.6	4.48e-26	Smoking behavior;
KIRP	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.37	0.47	4.39e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.01	0.5	5.87e-17	Colorectal cancer;
KIRP	cis	rs9611198	0.846	rs4820383	chr22:39961286	C/A	cg10455938	chr22:40058150	CACNA1I	0.54	7.36	0.42	2.78e-12	Schizophrenia;
KIRP	cis	rs10875746	0.669	rs2279464	chr12:48690409	C/T	cg20731937	chr12:48336164	NA	0.47	5.91	0.35	1.13e-8	Longevity (90 years and older);
KIRP	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg14541582	chr5:601475	NA	-0.58	-6.64	-0.39	2.04e-10	Obesity-related traits;
KIRP	trans	rs2072153	0.715	rs12948327	chr17:47333478	C/T	cg11430096	chr6:110968061	CDK19	0.58	7.41	0.43	2.01e-12	Height;
KIRP	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg13256891	chr4:100009986	ADH5	0.51	6.59	0.39	2.73e-10	Alcohol dependence;
KIRP	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-5.23	-0.32	3.56e-7	Height;
KIRP	cis	rs2970992	0.817	rs10165648	chr2:101335235	A/G	cg01042948	chr2:101319752	NA	0.41	5.95	0.35	9.4e-9	Educational attainment;
KIRP	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.06	-0.54	3.69e-20	Hemoglobin concentration;
KIRP	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.52	6.78	0.4	8.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg21361702	chr7:150065534	REPIN1	0.56	5.93	0.35	1.02e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18201393	chr15:75135266	ULK3	-0.51	-6.75	-0.4	1.07e-10	Metabolic traits;
KIRP	trans	rs11165623	0.602	rs7521690	chr1:97015761	A/C	cg10631902	chr5:14652156	NA	-0.47	-6.38	-0.38	8.52e-10	Hip circumference;Waist circumference;
KIRP	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.18	0.31	4.58e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.34	-4.85	-0.3	2.24e-6	Monocyte count;
KIRP	cis	rs17453880	0.929	rs6868043	chr5:152031752	T/C	cg12297329	chr5:152029980	NA	-0.72	-11.2	-0.58	8.35e-24	Subjective well-being;
KIRP	cis	rs737008	0.922	rs2070923	chr16:11369855	G/T	cg00044050	chr16:11439710	C16orf75	0.56	6.43	0.38	6.43e-10	Obesity-related traits;
KIRP	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg12559939	chr2:27858050	GPN1	0.42	5.28	0.32	2.83e-7	Oral cavity cancer;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.1	-0.36	4.01e-9	Lung cancer;
KIRP	cis	rs2223471	0.875	rs2235497	chr6:50703074	G/A	cg03432817	chr6:50765336	NA	-0.52	-8.3	-0.47	6.98e-15	Subcutaneous adipose tissue;
KIRP	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.28	-0.47	7.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	trans	rs11603020	0.904	rs11606677	chr11:57383377	G/A	cg16592121	chr10:133794558	BNIP3	-0.32	-6.05	-0.36	5.5e-9	Blood protein levels;
KIRP	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.56	6.98	0.41	2.77e-11	Total body bone mineral density;
KIRP	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.08	14.7	0.68	1.57e-35	Corneal structure;
KIRP	cis	rs8077577	0.747	rs12449313	chr17:18221010	A/G	cg18869244	chr17:18121946	NA	0.44	4.99	0.3	1.15e-6	Obesity-related traits;
KIRP	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	13.41	0.65	3.83e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg25753631	chr6:25732923	NA	-0.27	-5.05	-0.31	8.71e-7	Iron status biomarkers;
KIRP	cis	rs6546886	1.000	rs6743073	chr2:74241037	A/G	cg14702570	chr2:74259524	NA	-0.32	-6.47	-0.38	5.12e-10	Dialysis-related mortality;
KIRP	cis	rs986417	0.748	rs10145546	chr14:61100892	A/G	cg27398547	chr14:60952738	C14orf39	0.55	5.26	0.32	3.07e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-7.55	-0.43	8.6e-13	Body mass index;
KIRP	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs287982	0.935	rs287978	chr2:9970534	T/C	cg18436444	chr2:10917754	ATP6V1C2	0.34	4.92	0.3	1.58e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg06050784	chr16:88016603	BANP	0.45	5.43	0.33	1.33e-7	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24777315	chr12:66135734	NA	0.4	6.12	0.36	3.62e-9	Survival in pancreatic cancer;
KIRP	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	6.93	0.4	3.74e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12153243	0.714	rs6580286	chr5:142905354	T/C	cg13907255	chr5:142895549	NA	-0.38	-4.94	-0.3	1.46e-6	Migraine;
KIRP	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg08992911	chr2:238395768	MLPH	0.56	5.43	0.33	1.35e-7	Prostate cancer;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-9.57	-0.52	1.2e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3126085	0.515	rs7515448	chr1:152372035	A/G	cg26876637	chr1:152193138	HRNR	-0.52	-6.48	-0.38	5.05e-10	Atopic dermatitis;
KIRP	cis	rs17621444	0.522	rs4752371	chr10:121792095	G/A	cg02041677	chr10:121771263	NA	-0.35	-4.9	-0.3	1.75e-6	IgG glycosylation;
KIRP	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.05	0.31	8.49e-7	Parkinson's disease;
KIRP	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	1.03	10.9	0.57	7.7e-23	Monocyte percentage of white cells;
KIRP	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg22349387	chr12:9600060	DDX12	-0.36	-5.18	-0.31	4.61e-7	Breast size;
KIRP	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.47	6.45	0.38	5.98e-10	Birth weight;
KIRP	cis	rs7107770	1.000	rs4936997	chr11:125090227	C/T	cg04164023	chr11:125106101	PKNOX2	-0.55	-4.85	-0.3	2.18e-6	Photic sneeze reflex;
KIRP	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg17366294	chr4:99064904	C4orf37	0.36	4.97	0.3	1.28e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg23594656	chr7:65796392	TPST1	0.51	7.97	0.45	5.76e-14	Aortic root size;
KIRP	trans	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg01311341	chr22:25575246	KIAA1671	0.64	7.45	0.43	1.6e-12	Atopic dermatitis;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.41e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg15605315	chr1:45957053	TESK2	-0.4	-5.0	-0.3	1.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.75	8.74	0.49	3.66e-16	High light scatter reticulocyte count;
KIRP	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14672709	chr17:48133110	ITGA3	0.51	6.75	0.4	1.05e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.43	-0.43	1.82e-12	Breast cancer;
KIRP	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12412942	0.965	rs7073929	chr10:2358482	A/G	cg23939236	chr10:2357224	NA	-0.38	-5.84	-0.35	1.67e-8	Schizophrenia;
KIRP	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.4e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.06	-0.31	8.1e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg15226275	chr6:116381976	FRK	-0.21	-5.89	-0.35	1.29e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-4.98	-0.3	1.22e-6	Electroencephalogram traits;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-7.39	-0.43	2.34e-12	Longevity;Endometriosis;
KIRP	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.51	-0.33	9.23e-8	Pulmonary function;
KIRP	cis	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.36	-0.42	2.8e-12	Morning vs. evening chronotype;
KIRP	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-6.35	-0.38	1.01e-9	Chronic sinus infection;
KIRP	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs1440410	0.835	rs10004598	chr4:144062417	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs7546668	1.000	rs10803388	chr1:15850097	G/A	cg21858823	chr1:15850916	CASP9	0.47	5.19	0.31	4.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17401966	0.522	rs4845930	chr1:10319049	G/A	cg19773385	chr1:10388646	KIF1B	-0.44	-6.5	-0.38	4.5e-10	Hepatocellular carcinoma;
KIRP	cis	rs12049351	0.774	rs1065675	chr1:229622162	A/G	cg11742688	chr1:229674241	ABCB10	-0.39	-6.37	-0.38	9.43e-10	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg06731904	chr7:6075438	EIF2AK1	-0.43	-6.02	-0.36	6.28e-9	Inflammatory biomarkers;
KIRP	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg21747090	chr2:27597821	SNX17	-0.46	-6.13	-0.36	3.45e-9	Total body bone mineral density;
KIRP	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg18944383	chr4:111397179	ENPEP	0.48	7.71	0.44	3.16e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.74	9.25	0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg21734707	chr17:3908241	ZZEF1	0.68	10.44	0.55	2.33e-21	Type 2 diabetes;
KIRP	cis	rs1341267	1.000	rs6492725	chr13:95285580	A/C	cg09582042	chr13:95253676	GPR180	-0.29	-4.98	-0.3	1.19e-6	Triglyceride levels;
KIRP	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg08461772	chr7:95026248	PON3	0.41	5.85	0.35	1.53e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.47	6.39	0.38	8.07e-10	Age-related hearing impairment;
KIRP	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg11005552	chr10:105648138	OBFC1	0.41	5.9	0.35	1.2e-8	Coronary artery disease;
KIRP	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg12046867	chr14:103022105	NA	0.53	6.01	0.36	6.77e-9	Platelet count;
KIRP	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg02996583	chr8:142237188	SLC45A4	-0.44	-5.25	-0.32	3.24e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg06917634	chr15:78832804	PSMA4	0.47	4.9	0.3	1.78e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg11764359	chr7:65958608	NA	0.78	5.12	0.31	6.21e-7	Diabetic kidney disease;
KIRP	cis	rs12731740	1.000	rs6701558	chr1:207997813	A/G	cg22525895	chr1:207977042	MIR29B2	-0.64	-4.9	-0.3	1.74e-6	Biomedical quantitative traits;
KIRP	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06850241	chr22:41845214	NA	-0.45	-5.12	-0.31	6.15e-7	Vitiligo;
KIRP	cis	rs7572644	0.699	rs13400398	chr2:28162109	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-5.35	-0.32	2.01e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs2151522	0.563	rs2022476	chr6:127136222	C/G	cg21431617	chr6:127135037	NA	-0.32	-5.87	-0.35	1.42e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg20184165	chr4:140222646	NAA15	-0.56	-6.04	-0.36	5.77e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.4	0.55	3.22e-21	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg06636001	chr8:8085503	FLJ10661	0.68	8.76	0.49	3.24e-16	Retinal vascular caliber;
KIRP	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.98	0.5	7.01e-17	Colorectal cancer;
KIRP	cis	rs7224685	0.569	rs8066378	chr17:3996334	T/C	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.55e-7	Type 2 diabetes;
KIRP	cis	rs3733418	0.929	rs7656863	chr4:165883244	T/G	cg10852876	chr4:165953100	TRIM60	-0.46	-5.21	-0.32	4.07e-7	Obesity-related traits;
KIRP	cis	rs4356932	1.000	rs7683657	chr4:76962643	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01008117	chr12:4399358	CCND2	-0.39	-6.18	-0.37	2.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.11	-0.36	3.78e-9	Lung cancer;
KIRP	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg07052231	chr12:7363540	PEX5	0.38	5.08	0.31	7.34e-7	IgG glycosylation;
KIRP	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.41	5.64	0.34	4.7e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.62	0.48	8.24e-16	Personality dimensions;
KIRP	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.76	-0.34	2.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.51	6.71	0.39	1.36e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg13939156	chr17:80058883	NA	-0.48	-7.28	-0.42	4.58e-12	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00696023	chr3:155588382	GMPS	0.5	6.21	0.37	2.27e-9	Parkinson's disease;
KIRP	cis	rs4356932	1.000	rs7689664	chr4:76963351	T/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs7714584	1.000	rs76548544	chr5:150223515	T/A	cg22134413	chr5:150180641	NA	0.57	5.1	0.31	6.85e-7	Crohn's disease;
KIRP	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.07	0.36	4.93e-9	Educational attainment;
KIRP	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.82	-0.49	2.21e-16	Total cholesterol levels;
KIRP	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.55	0.39	3.33e-10	Prudent dietary pattern;
KIRP	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg02487422	chr3:49467188	NICN1	0.4	5.52	0.33	8.44e-8	Parkinson's disease;
KIRP	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.99	-0.5	6.69e-17	Common traits (Other);
KIRP	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.87	11.0	0.57	3.68e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1497828	0.956	rs1007737	chr1:217547872	G/C	cg04411442	chr1:217543379	NA	0.41	6.21	0.37	2.22e-9	Dialysis-related mortality;
KIRP	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.78	10.64	0.56	5.33e-22	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12134040	0.514	rs55915504	chr1:236528424	G/T	cg21399712	chr1:236511386	NA	-0.5	-6.65	-0.39	1.83e-10	Urate levels (BMI interaction);
KIRP	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg08999081	chr20:33150536	PIGU	0.45	6.13	0.36	3.4e-9	Height;
KIRP	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg00343986	chr7:65444356	GUSB	0.41	5.01	0.3	1.02e-6	Aortic root size;
KIRP	cis	rs11997175	0.603	rs7462153	chr8:33814607	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.45	0.33	1.23e-7	Body mass index;
KIRP	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg23958373	chr8:599963	NA	0.96	7.12	0.41	1.19e-11	IgG glycosylation;
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-5.18	-0.31	4.72e-7	Obesity-related traits;
KIRP	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg21926883	chr2:100939477	LONRF2	-0.63	-8.82	-0.49	2.2e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg26587870	chr6:27730563	NA	-0.64	-4.94	-0.3	1.47e-6	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18661731	chr18:59854239	PIGN;KIAA1468	0.57	8.5	0.48	1.83e-15	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.69	0.39	1.53e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg27121462	chr16:89883253	FANCA	0.64	9.29	0.51	8.63e-18	Vitiligo;
KIRP	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.83	9.97	0.54	6.87e-20	Corneal astigmatism;
KIRP	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.62	5.91	0.35	1.14e-8	Breast cancer;
KIRP	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.11	-0.36	3.79e-9	Response to antipsychotic treatment;
KIRP	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.45	-0.43	1.57e-12	Menopause (age at onset);
KIRP	cis	rs8756	0.689	rs1979440	chr12:66346624	A/G	cg06712651	chr12:66351869	HMGA2	-0.67	-10.11	-0.54	2.61e-20	Height;
KIRP	cis	rs4664293	0.867	rs13415025	chr2:160586310	C/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs2288884	0.559	rs8104890	chr19:52519608	C/T	cg05974498	chr19:52599256	ZNF841	0.34	4.88	0.3	1.88e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
KIRP	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15664640	chr17:80829946	TBCD	-0.9	-11.56	-0.59	5.81e-25	Breast cancer;
KIRP	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.68	-12.52	-0.62	3.62e-28	White blood cell count (basophil);
KIRP	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg05721485	chr17:44071124	MAPT	0.6	7.77	0.44	2.08e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.56	-15.98	-0.71	6.51e-40	Hip circumference adjusted for BMI;
KIRP	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.75	-11.3	-0.58	4.1e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs501120	0.810	rs541483	chr10:44746395	A/G	cg09554077	chr10:44749378	NA	0.68	9.76	0.53	3.1400000000000002e-19	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17376030	chr22:41985996	PMM1	-0.71	-7.5	-0.43	1.13e-12	Vitiligo;
KIRP	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.77	0.49	2.92e-16	IgG glycosylation;
KIRP	cis	rs7980687	0.527	rs1626703	chr12:123710835	A/C	cg00376283	chr12:123451042	ABCB9	0.77	9.6	0.52	9.39e-19	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-0.84	-9.41	-0.51	3.71e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg02389323	chr16:88786976	FAM38A	0.77	6.59	0.39	2.64e-10	Plateletcrit;
KIRP	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg02367723	chr1:46378857	MAST2	0.44	5.04	0.31	9.18e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8014252	0.803	rs58777530	chr14:71001222	C/T	cg11204974	chr14:71022665	NA	-0.64	-6.71	-0.39	1.3100000000000001e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg19468946	chr17:37922297	IKZF3	0.51	7.32	0.42	3.46e-12	Self-reported allergy;
KIRP	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.17	0.37	2.86e-9	Menopause (age at onset);
KIRP	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03934478	chr11:495069	RNH1	0.95	7.66	0.44	4.28e-13	Body mass index;
KIRP	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg13264159	chr8:625131	ERICH1	-0.61	-5.81	-0.35	1.96e-8	IgG glycosylation;
KIRP	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg02574844	chr11:5959923	NA	-0.57	-5.88	-0.35	1.33e-8	DNA methylation (variation);
KIRP	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg17595323	chr11:93583763	C11orf90	0.3	5.2	0.31	4.19e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-7.95	-0.45	6.57e-14	Response to antipsychotic treatment;
KIRP	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11987759	chr7:65425863	GUSB	0.52	6.96	0.41	3.1e-11	Aortic root size;
KIRP	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.89	-0.4	4.58e-11	Aortic root size;
KIRP	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.98	-14.78	-0.69	8.19e-36	Coronary artery disease;
KIRP	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.91	10.41	0.55	2.94e-21	Corneal astigmatism;
KIRP	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg02461776	chr11:598696	PHRF1	0.48	5.06	0.31	8.02e-7	Systemic lupus erythematosus;
KIRP	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg02319466	chr17:76381040	PGS1	0.47	6.53	0.38	3.84e-10	HDL cholesterol levels;
KIRP	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.61	6.31	0.37	1.26e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.48	7.34	0.42	3.17e-12	Tumor biomarkers;
KIRP	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg12435725	chr3:58293450	RPP14	-0.45	-5.11	-0.31	6.35e-7	Cholesterol, total;
KIRP	cis	rs12195424	0.730	rs77627159	chr6:56308904	G/T	cg20782286	chr6:56298173	NA	-0.65	-4.88	-0.3	1.89e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs9309473	0.539	rs6745560	chr2:73827117	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.83	-0.35	1.75e-8	Metabolite levels;
KIRP	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.78	12.44	0.62	7.07e-28	Heart rate;
KIRP	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg02297831	chr4:17616191	MED28	-0.5	-6.01	-0.36	6.52e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg22168489	chr12:122356033	WDR66	-0.57	-7.74	-0.44	2.59e-13	Mean corpuscular volume;
KIRP	cis	rs13102973	0.899	rs11735890	chr4:135902143	A/G	cg14419869	chr4:135874104	NA	0.48	7.52	0.43	1.02e-12	Subjective well-being;
KIRP	cis	rs4363385	0.509	rs11581802	chr1:152936164	G/A	cg13444842	chr1:152974279	SPRR3	-0.45	-6.56	-0.39	3.18e-10	Inflammatory skin disease;
KIRP	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	8.74	0.49	3.57e-16	Type 2 diabetes;
KIRP	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg04662567	chr6:169592167	NA	-0.73	-6.26	-0.37	1.69e-9	Pulse pressure;
KIRP	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg04013166	chr16:89971882	TCF25	0.67	5.63	0.34	4.83e-8	Skin colour saturation;
KIRP	cis	rs17030434	1.000	rs78249279	chr4:154718783	C/T	cg14289246	chr4:154710475	SFRP2	-0.8	-9.61	-0.52	8.78e-19	Electrocardiographic conduction measures;
KIRP	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.85	10.62	0.56	6.23e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.85	-0.4	5.99e-11	Hemoglobin concentration;
KIRP	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg05368731	chr17:41323189	NBR1	0.71	9.02	0.5	5.68e-17	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.85	12.87	0.63	2.49e-29	Height;
KIRP	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.82	-8.25	-0.47	9.95e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs13190036	0.901	rs28715668	chr5:176699268	T/C	cg04708888	chr5:176739561	MXD3	-0.61	-5.06	-0.31	8.09e-7	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg14458575	chr2:238380390	NA	0.44	5.25	0.32	3.22e-7	Prostate cancer;
KIRP	cis	rs2012796	0.956	rs10450940	chr14:81825326	C/A	cg02996355	chr14:81879375	NA	0.4	5.48	0.33	1.08e-7	Night sleep phenotypes;
KIRP	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg03808351	chr9:123631620	PHF19	0.41	5.53	0.33	8.24e-8	Rheumatoid arthritis;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg20887711	chr4:1340912	KIAA1530	0.5	6.3	0.37	1.4e-9	Longevity;
KIRP	cis	rs829661	0.645	rs55674232	chr2:30824544	T/G	cg10949345	chr2:30726833	LCLAT1	1.07	13.43	0.65	3.16e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg11833968	chr6:79620685	NA	-0.37	-5.12	-0.31	6.06e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.52	-0.33	8.54e-8	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00741700	chr12:110338011	TCHP	0.49	6.12	0.36	3.7e-9	Parkinson's disease;
KIRP	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg08131204	chr22:41487073	MIR1281	-0.44	-5.19	-0.31	4.4e-7	Neuroticism;
KIRP	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	8.26	0.47	8.92e-15	Mean corpuscular volume;
KIRP	cis	rs2625529	0.824	rs2279283	chr15:72243666	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.43e-9	Red blood cell count;
KIRP	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.89	-12.93	-0.64	1.63e-29	Tonsillectomy;
KIRP	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.43	-4.94	-0.3	1.43e-6	Menarche (age at onset);
KIRP	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.47	5.96	0.36	8.62e-9	Osteoporosis;
KIRP	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg20965017	chr5:231967	SDHA	-0.61	-7.07	-0.41	1.57e-11	Breast cancer;
KIRP	cis	rs6708331	0.517	rs12617812	chr2:70359471	A/G	cg05298696	chr2:70188691	ASPRV1	-0.4	-5.33	-0.32	2.21e-7	Obesity-related traits;
KIRP	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg00684032	chr4:1343700	KIAA1530	0.5	6.67	0.39	1.65e-10	Obesity-related traits;
KIRP	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-6.01	-0.36	6.64e-9	Height;
KIRP	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.9	0.66	8.08e-33	Smoking behavior;
KIRP	cis	rs62380364	0.602	rs610217	chr5:88065263	G/A	cg24804195	chr5:87968844	LOC645323	-0.43	-5.53	-0.33	8.19e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg22676075	chr6:135203613	NA	0.47	6.84	0.4	6.37e-11	Red blood cell count;
KIRP	cis	rs12049351	0.774	rs1065674	chr1:229623338	C/T	cg11742688	chr1:229674241	ABCB10	0.39	6.29	0.37	1.44e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg01677386	chr11:118938358	VPS11	-0.54	-6.57	-0.39	3.02e-10	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.78	-10.43	-0.55	2.46e-21	Aortic root size;
KIRP	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg12292205	chr6:26970375	C6orf41	-0.63	-7.64	-0.44	4.96e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7680126	0.644	rs4697703	chr4:10107431	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-4.88	-0.3	1.94e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs7630877	0.889	rs59453720	chr3:179586414	T/C	cg18765712	chr3:179670323	PEX5L	0.57	6.53	0.38	3.74e-10	Type 2 diabetes;
KIRP	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg21856205	chr7:94953877	PON1	-0.46	-5.58	-0.34	6.39e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.4	-0.55	3.23e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg15252951	chr6:33757062	LEMD2	0.48	5.74	0.34	2.76e-8	Crohn's disease;
KIRP	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.73e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8038465	0.874	rs11574495	chr15:74003936	C/T	cg15420318	chr15:73925796	NPTN	0.47	5.78	0.35	2.24e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs889398	0.802	rs12921407	chr16:69860933	T/C	cg09409435	chr16:70099608	PDXDC2	-0.44	-5.24	-0.32	3.41e-7	Body mass index;
KIRP	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.61	6.64	0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs2273669	0.667	rs11755471	chr6:109342169	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.56	-0.39	3.14e-10	Prostate cancer;
KIRP	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.27	0.37	1.62e-9	Homocysteine levels;
KIRP	cis	rs17221829	0.769	rs11018674	chr11:89357113	G/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.99	-0.3	1.14e-6	Anxiety in major depressive disorder;
KIRP	cis	rs8018808	0.905	rs4903586	chr14:77938633	C/G	cg20045696	chr14:77926864	AHSA1	-0.45	-5.38	-0.32	1.75e-7	Myeloid white cell count;
KIRP	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.66	9.07	0.5	3.89e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.49	-6.84	-0.4	6.17e-11	Motion sickness;
KIRP	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.86	10.53	0.56	1.22e-21	Neutrophil percentage of white cells;
KIRP	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-0.95	-10.45	-0.55	2.11e-21	Blood protein levels;
KIRP	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.17	0.31	4.74e-7	Height;
KIRP	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.14e-11	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20513950	chr11:72463673	ARAP1	0.44	6.26	0.37	1.69e-9	Parkinson's disease;
KIRP	cis	rs494562	1.000	rs495472	chr6:86117021	C/T	cg21730993	chr6:86159210	NT5E	0.49	4.95	0.3	1.36e-6	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.3	-0.58	4.08e-24	Chronic sinus infection;
KIRP	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.73	9.44	0.52	3.08e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.79	8.69	0.48	5.22e-16	High light scatter reticulocyte count;
KIRP	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg15848620	chr12:58087721	OS9	-0.51	-6.0	-0.36	7.16e-9	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21627865	chr13:73632885	KLF5	0.45	6.16	0.37	2.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4740619	0.619	rs943789	chr9:16031951	G/A	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs2041895	0.509	rs10861674	chr12:107304037	A/G	cg15890332	chr12:107067104	RFX4	0.35	4.95	0.3	1.35e-6	Glaucoma (low intraocular pressure);
KIRP	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg17143192	chr8:8559678	CLDN23	0.59	6.84	0.4	6.38e-11	Obesity-related traits;
KIRP	cis	rs7147624	0.572	rs72714491	chr14:66024580	T/A	cg03016385	chr14:66212404	NA	0.98	5.83	0.35	1.78e-8	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs55894533	0.597	rs2645408	chr8:11746358	A/G	cg21281001	chr8:11725306	CTSB	0.45	5.17	0.31	4.9e-7	Leprosy;
KIRP	cis	rs7520050	0.931	rs6698247	chr1:46371486	C/T	cg03146154	chr1:46216737	IPP	-0.42	-5.26	-0.32	3.2e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.2	-0.37	2.32e-9	Neuroticism;
KIRP	cis	rs13315871	0.654	rs11711261	chr3:58343696	C/A	cg12435725	chr3:58293450	RPP14	-0.38	-5.44	-0.33	1.28e-7	Cholesterol, total;
KIRP	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg07701084	chr6:150067640	NUP43	0.57	7.23	0.42	6.13e-12	Testicular germ cell tumor;
KIRP	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	5.04	0.31	9.07e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	1.11	15.87	0.71	1.58e-39	Breast cancer;
KIRP	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg16989719	chr2:238392110	NA	-0.58	-5.89	-0.35	1.28e-8	Prostate cancer;
KIRP	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-1.07	-14.85	-0.69	4.91e-36	Orofacial clefts;
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg10755058	chr3:40428713	ENTPD3	-0.42	-5.95	-0.35	9.14e-9	Renal cell carcinoma;
KIRP	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg25482853	chr8:67687455	SGK3	0.68	6.06	0.36	4.99e-9	Obesity-related traits;
KIRP	cis	rs7849270	0.879	rs2229419	chr9:131857630	C/T	cg13538475	chr9:131942899	NA	0.36	5.42	0.33	1.4e-7	Blood metabolite ratios;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13620490	chr9:100561868	NA	0.42	6.45	0.38	5.76e-10	C-reactive protein;
KIRP	cis	rs3540	0.960	rs11853271	chr15:91025830	C/T	cg10434728	chr15:90938212	IQGAP1	0.28	4.86	0.3	2.09e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg13628971	chr7:2884303	GNA12	0.66	7.93	0.45	7.8500000000000006e-14	Height;
KIRP	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.65	7.72	0.44	2.96e-13	Total cholesterol levels;
KIRP	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.81	9.41	0.51	3.58e-18	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.35	0.42	2.93e-12	Diabetic kidney disease;
KIRP	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.44	7.79	0.45	1.82e-13	Lipoprotein (a) levels;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg24874828	chr4:187887005	NA	-0.55	-8.81	-0.49	2.36e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs35740288	0.929	rs11636821	chr15:86306005	T/G	cg17133734	chr15:86042851	AKAP13	-0.49	-5.3	-0.32	2.54e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.84	7.7	0.44	3.31e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.46	-6.09	-0.36	4.27e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.9	14.73	0.68	1.19e-35	Breast cancer;
KIRP	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg06871246	chr4:1363661	KIAA1530	0.43	5.33	0.32	2.17e-7	Obesity-related traits;
KIRP	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.32	18.83	0.77	1.38e-49	Corneal structure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23308293	chr11:74660156	XRRA1;SPCS2	-0.46	-6.1	-0.36	4.03e-9	Metabolic traits;
KIRP	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg16235748	chr6:149772707	ZC3H12D	0.3	4.93	0.3	1.54e-6	Dupuytren's disease;
KIRP	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg03711944	chr11:47377212	SPI1	-0.32	-5.5	-0.33	9.49e-8	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	6.91	0.4	4.13e-11	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs7546094	1.000	rs902289	chr1:113236087	C/T	cg22162597	chr1:113214053	CAPZA1	-0.51	-7.42	-0.43	1.95e-12	Platelet distribution width;
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg00599163	chr2:162100495	NA	0.63	8.23	0.46	1.1e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg07636037	chr3:49044803	WDR6	0.46	5.54	0.33	7.83e-8	Resting heart rate;
KIRP	cis	rs9400467	0.506	rs77549436	chr6:111690730	T/G	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.86	-10.49	-0.56	1.6e-21	Schizophrenia;
KIRP	cis	rs754423	0.532	rs941625	chr14:52547735	A/G	cg16066272	chr14:52535949	NID2	-0.38	-5.74	-0.34	2.75e-8	Craniofacial microsomia;
KIRP	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	5.67	0.34	4.09e-8	Renal cell carcinoma;
KIRP	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.59	-7.19	-0.42	7.53e-12	Aortic root size;
KIRP	cis	rs7580658	0.545	rs13006847	chr2:127952263	C/T	cg16751203	chr2:127950803	CYP27C1	-0.41	-5.73	-0.34	2.99e-8	Protein C levels;
KIRP	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg10755058	chr3:40428713	ENTPD3	0.44	6.22	0.37	2.16e-9	Renal cell carcinoma;
KIRP	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.06e-10	Prudent dietary pattern;
KIRP	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg08533674	chr1:46993347	NA	-0.47	-5.86	-0.35	1.46e-8	Monobrow;
KIRP	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg13010199	chr12:38710504	ALG10B	0.49	6.21	0.37	2.2e-9	Morning vs. evening chronotype;
KIRP	cis	rs4972539	0.784	rs6731949	chr2:174087309	G/A	cg04505972	chr2:173508040	NA	-0.44	-5.79	-0.35	2.08e-8	Parental longevity (mother's age at death);
KIRP	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-5.77	-0.35	2.43e-8	Eosinophil percentage of white cells;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19881999	chr2:100038008	REV1	0.42	6.27	0.37	1.65e-9	C-reactive protein;
KIRP	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.45	-0.47	2.55e-15	Joint mobility (Beighton score);
KIRP	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.12	0.36	3.76e-9	Total cholesterol levels;
KIRP	cis	rs4363506	0.649	rs34623735	chr10:129281256	C/T	cg07804728	chr10:129284050	NA	0.47	5.85	0.35	1.53e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs12911832	0.727	rs682619	chr15:59098773	T/C	cg05156742	chr15:59063176	FAM63B	0.57	7.36	0.42	2.71e-12	Schizophrenia;
KIRP	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg16576597	chr16:28551801	NUPR1	0.36	5.49	0.33	9.98e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.44	5.83	0.35	1.73e-8	Melanoma;
KIRP	cis	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg00405596	chr8:11794950	NA	-0.53	-6.82	-0.4	6.91e-11	Triglycerides;
KIRP	cis	rs10924309	0.597	rs12143468	chr1:245854465	C/T	cg00036263	chr1:245852353	KIF26B	-0.53	-7.42	-0.43	1.95e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.87	14.08	0.67	2e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.95	13.11	0.64	3.97e-30	Breast cancer;
KIRP	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs501120	0.584	rs2804031	chr10:44702928	T/G	cg09554077	chr10:44749378	NA	0.56	5.95	0.35	9.34e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9596863	0.898	rs9568914	chr13:54341107	T/C	ch.13.53330881F	chr13:54432880	NA	0.49	4.95	0.3	1.39e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs838147	0.733	rs12975781	chr19:49249698	A/G	cg08619932	chr19:49200058	FUT2	0.32	4.94	0.3	1.46e-6	Dietary macronutrient intake;
KIRP	cis	rs7188697	0.646	rs7184114	chr16:58585369	C/A	cg21335942	chr16:58549945	SETD6	-0.51	-5.85	-0.35	1.55e-8	QT interval;
KIRP	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	6.75	0.4	1.06e-10	Monocyte count;
KIRP	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.48	-0.33	1.03e-7	Obesity-related traits;
KIRP	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.67	0.48	5.84e-16	Morning vs. evening chronotype;
KIRP	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.89	11.89	0.6	4.62e-26	Bipolar disorder;
KIRP	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.43	-5.56	-0.33	7e-8	Aortic root size;
KIRP	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.88	0.63	2.36e-29	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14091799	chr17:34891389	PIGW;MYO19	0.52	6.38	0.38	8.94e-10	Parkinson's disease;
KIRP	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.05	-18.88	-0.77	9.24e-50	Height;
KIRP	cis	rs2411233	0.967	rs6492849	chr15:39271087	T/C	cg02291532	chr15:39874776	THBS1	0.4	5.42	0.33	1.39e-7	Platelet count;
KIRP	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-1.07	-14.63	-0.68	2.62e-35	Alopecia areata;
KIRP	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.45	-5.36	-0.32	1.87e-7	Schizophrenia;
KIRP	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.52	7.03	0.41	2.04e-11	Mean corpuscular volume;
KIRP	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.89	14.29	0.67	3.87e-34	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.55	7.67	0.44	4.11e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.34	-5.51	-0.33	8.96e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-4.86	-0.3	2.07e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.66	-8.18	-0.46	1.56e-14	Height;
KIRP	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.29	7.95	0.45	6.9e-14	Crohn's disease;
KIRP	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.05	0.36	5.29e-9	Bipolar disorder;
KIRP	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.19	0.31	4.4e-7	Menopause (age at onset);
KIRP	cis	rs6893300	0.961	rs4700838	chr5:179185121	A/G	cg14593053	chr5:179126677	CANX	-0.56	-6.36	-0.38	9.95e-10	Resting heart rate;
KIRP	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg18920559	chr5:173846557	NA	-0.51	-6.63	-0.39	2.14e-10	Vertical cup-disc ratio;
KIRP	cis	rs9473924	0.632	rs1547211	chr6:50930598	C/T	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg16898833	chr6:26189333	HIST1H4D	0.68	5.04	0.31	9.2e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg09555818	chr19:45449301	APOC2	0.5	7.26	0.42	4.94e-12	Blood protein levels;
KIRP	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	0.83	10.18	0.54	1.53e-20	Prostate cancer;
KIRP	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03385944	chr11:798041	NA	0.52	6.76	0.4	1.01e-10	Parkinson's disease;
KIRP	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.75	9.34	0.51	5.84e-18	Corneal astigmatism;
KIRP	cis	rs12620999	0.878	rs59725626	chr2:237970010	G/A	cg23555395	chr2:238036564	NA	0.45	5.14	0.31	5.52e-7	Systemic lupus erythematosus;
KIRP	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-8.69	-0.48	5.19e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.64	-9.23	-0.51	1.29e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7909791	0.543	rs11191842	chr10:105639808	C/T	cg11005552	chr10:105648138	OBFC1	0.45	4.98	0.3	1.18e-6	White matter hyperintensity burden;
KIRP	cis	rs4363385	0.776	rs1890284	chr1:152942190	G/A	cg07796016	chr1:152779584	LCE1C	-0.45	-5.02	-0.31	9.78e-7	Inflammatory skin disease;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.82	10.28	0.55	7.44e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg06521331	chr12:34319734	NA	-0.5	-6.22	-0.37	2.17e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12479064	0.694	rs75263609	chr2:100133193	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.55	-5.53	-0.33	8.37e-8	Chronic sinus infection;
KIRP	cis	rs4332428	0.892	rs5011019	chr10:4967128	G/C	cg19648686	chr10:5044992	AKR1C2	-0.89	-7.93	-0.45	7.9e-14	Height;
KIRP	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.1	0.36	4.1e-9	Breast cancer;
KIRP	cis	rs7715811	1.000	rs6554812	chr5:13762972	T/C	cg07548982	chr5:13769939	DNAH5	-0.52	-6.4	-0.38	7.59e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg23788917	chr6:8435910	SLC35B3	-0.62	-8.01	-0.45	4.48e-14	Motion sickness;
KIRP	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	5.39	0.33	1.62e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg00405596	chr8:11794950	NA	0.47	5.82	0.35	1.8e-8	Morning vs. evening chronotype;
KIRP	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19671926	chr4:122722719	EXOSC9	0.49	5.86	0.35	1.5e-8	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.47	-5.76	-0.34	2.53e-8	Reticulocyte count;
KIRP	cis	rs240764	0.658	rs7746961	chr6:101215244	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.26	-0.32	3.14e-7	Neuroticism;
KIRP	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.49	6.74	0.39	1.13e-10	Kawasaki disease;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.77	6.77	0.4	9.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12249377	0.519	rs7906960	chr10:92586205	A/G	cg14313238	chr10:92632228	RPP30	0.45	5.54	0.33	7.86e-8	White matter microstructure (global fractional anisotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03044069	chr11:46299550	CREB3L1	0.44	6.42	0.38	6.83e-10	Parkinson's disease;
KIRP	cis	rs7665939	0.932	rs56397407	chr4:190122308	G/A	cg14840187	chr4:190284988	NA	-0.74	-5.91	-0.35	1.14e-8	Amyotrophic lateral sclerosis;
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg23693289	chr8:27183097	PTK2B	0.54	6.98	0.41	2.72e-11	Neuroticism;
KIRP	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09289335	chr20:42144161	L3MBTL	0.57	6.6	0.39	2.45e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs75064307	0.734	rs1902523	chr3:108102084	C/T	cg14703454	chr3:108065259	HHLA2	0.5	5.54	0.33	7.87e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.94	14.26	0.67	4.93e-34	Dupuytren's disease;
KIRP	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.62	8.21	0.46	1.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21211866	chr9:35111727	KIAA1539	0.56	6.18	0.37	2.57e-9	Lung cancer in ever smokers;
KIRP	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.61	-7.08	-0.41	1.49e-11	Menarche (age at onset);
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.48	5.54	0.33	7.85e-8	Glycated hemoglobin levels;
KIRP	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg15147215	chr3:52552868	STAB1	-0.29	-4.93	-0.3	1.48e-6	Electroencephalogram traits;
KIRP	cis	rs2625529	0.730	rs1481861	chr15:72240129	A/G	cg16672083	chr15:72433130	SENP8	0.47	6.56	0.39	3.12e-10	Red blood cell count;
KIRP	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.86	-0.49	1.61e-16	Resting heart rate;
KIRP	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.57	9.12	0.5	2.79e-17	C-reactive protein levels;
KIRP	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.77	9.06	0.5	4.11e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4356932	0.871	rs4859606	chr4:76965879	C/T	cg00809888	chr4:76862425	NAAA	0.43	5.93	0.35	1.02e-8	Blood protein levels;
KIRP	cis	rs3087591	0.659	rs757377	chr17:29720426	G/A	cg24425628	chr17:29625626	OMG;NF1	0.61	8.74	0.49	3.65e-16	Hip circumference;
KIRP	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.61	0.39	2.35e-10	Retinal vascular caliber;
KIRP	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg06521331	chr12:34319734	NA	-0.63	-7.44	-0.43	1.68e-12	Morning vs. evening chronotype;
KIRP	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.79	-0.4	8.27e-11	Menopause (age at onset);
KIRP	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.41	7.98	0.45	5.44e-14	Height;
KIRP	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg09307838	chr4:120376055	NA	-0.42	-5.21	-0.32	4.04e-7	Diastolic blood pressure;
KIRP	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg05666200	chr11:89790683	NA	-0.47	-4.86	-0.3	2.06e-6	White blood cell types;
KIRP	cis	rs12615966	1.000	rs17030292	chr2:105383596	C/G	cg16465502	chr2:105461796	NA	0.55	5.38	0.32	1.77e-7	Pancreatic cancer;
KIRP	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05025164	chr4:1340916	KIAA1530	-0.43	-5.45	-0.33	1.25e-7	Obesity-related traits;
KIRP	cis	rs17209837	0.915	rs7805184	chr7:87118601	G/A	cg00919237	chr7:87102261	ABCB4	-0.66	-6.68	-0.39	1.54e-10	Gallbladder cancer;
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg21734707	chr17:3908241	ZZEF1	0.66	10.17	0.54	1.59e-20	Type 2 diabetes;
KIRP	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg15247329	chr7:2764246	NA	-0.36	-5.02	-0.3	9.97e-7	Height;
KIRP	cis	rs10203711	1.000	rs907099	chr2:239559769	G/C	cg14580085	chr2:239553406	NA	0.39	5.2	0.31	4.28e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg04906043	chr13:21280425	IL17D	0.65	9.15	0.5	2.31e-17	Dental caries;
KIRP	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	trans	rs6076960	0.564	rs3852935	chr20:6143180	C/G	cg17788362	chr6:86352627	SYNCRIP	0.47	6.49	0.38	4.69e-10	Smooth-surface caries;
KIRP	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	5.8	0.35	2.02e-8	Lymphocyte counts;
KIRP	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.12	0.58	1.56e-23	Cognitive test performance;
KIRP	cis	rs9394841	0.692	rs3806113	chr6:41876335	C/T	cg08135965	chr6:41755394	TOMM6	0.49	5.32	0.32	2.34e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.38	-0.43	2.4e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7577696	0.512	rs212736	chr2:32473126	T/C	cg02381751	chr2:32503542	YIPF4	0.59	5.73	0.34	2.99e-8	Inflammatory biomarkers;
KIRP	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.2	-0.31	4.25e-7	Ulcerative colitis;
KIRP	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.82	-0.35	1.82e-8	Pulmonary function;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.47	5.65	0.34	4.45e-8	Longevity;Endometriosis;
KIRP	cis	rs950173	1.000	rs6716901	chr2:172673453	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.72	-5.53	-0.33	8.18e-8	Hippocampal volume;
KIRP	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.22	0.37	2.09e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg04727924	chr7:799746	HEATR2	0.61	5.7	0.34	3.43e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2910162	0.865	rs5010836	chr5:159919166	G/T	cg03306240	chr5:159912455	MIR146A	0.45	6.74	0.39	1.11e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg11995313	chr8:8860691	ERI1	0.39	5.33	0.32	2.19e-7	Joint mobility (Beighton score);
KIRP	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.57	-0.33	6.5e-8	Personality dimensions;
KIRP	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.18	-0.31	4.57e-7	IgG glycosylation;
KIRP	cis	rs7919006	0.793	rs74146273	chr10:76799137	G/A	cg01390419	chr10:76803856	DUPD1	0.55	5.24	0.32	3.38e-7	Weight;
KIRP	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg03098644	chr7:100410630	EPHB4	0.51	5.21	0.32	4.04e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.47	-6.11	-0.36	3.9e-9	Schizophrenia;
KIRP	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg08283408	chr3:49949060	MON1A	0.39	5.11	0.31	6.43e-7	Body mass index;
KIRP	cis	rs7729447	0.813	rs1031648	chr5:32692105	T/A	cg16267343	chr5:32710456	NPR3	0.54	6.16	0.37	2.9e-9	Blood pressure;
KIRP	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg15848620	chr12:58087721	OS9	-0.47	-5.41	-0.33	1.47e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.78	0.44	2.01e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	8.89	0.49	1.35e-16	Neuroticism;
KIRP	trans	rs2288327	0.557	rs60488846	chr2:179357842	C/T	cg14011486	chr1:26737247	LIN28	0.69	6.84	0.4	6.36e-11	Atrial fibrillation;
KIRP	trans	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg24644049	chr4:85504048	CDS1	1.07	6.91	0.4	4.17e-11	Skin colour saturation;
KIRP	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg26681399	chr22:41777847	TEF	0.5	5.02	0.3	1.01e-6	Vitiligo;
KIRP	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.48	6.64	0.39	1.96e-10	Lewy body disease;
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg01763666	chr17:80159506	CCDC57	0.36	5.08	0.31	7.59e-7	Life satisfaction;
KIRP	cis	rs78487399	0.908	rs10186307	chr2:43839896	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.9	-0.3	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.44	4.99	0.3	1.16e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs9469913	0.799	rs2814994	chr6:34620153	T/A	cg17674042	chr6:34482479	PACSIN1	-0.49	-6.63	-0.39	2.12e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-16.76	-0.73	1.48e-42	Height;
KIRP	trans	rs7404843	0.925	rs12600043	chr16:15539952	A/G	cg02716450	chr16:28638775	NA	0.99	10.2	0.55	1.35e-20	Testicular germ cell tumor;
KIRP	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.44	5.88	0.35	1.32e-8	Homoarginine levels;
KIRP	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-4.88	-0.3	1.89e-6	Ileal carcinoids;
KIRP	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.18	0.31	4.54e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2273669	0.667	rs76201299	chr6:109344975	T/G	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3857067	1.000	rs115969971	chr4:95023550	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg12598211	chr12:123634384	NA	-0.44	-5.37	-0.32	1.8e-7	Neutrophil percentage of white cells;
KIRP	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.22	-0.32	3.83e-7	Breast cancer;
KIRP	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.6	-5.84	-0.35	1.63e-8	Body mass index;
KIRP	cis	rs12519773	0.526	rs4242241	chr5:92518370	C/T	cg18783429	chr5:92414398	NA	0.28	4.87	0.3	1.98e-6	Migraine;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26512142	chr11:2554198	KCNQ1	0.66	7.91	0.45	8.64e-14	Smoking initiation;
KIRP	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg18357645	chr12:58087776	OS9	-0.54	-5.27	-0.32	2.95e-7	Multiple sclerosis;
KIRP	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25517755	chr10:38738941	LOC399744	0.34	4.86	0.3	2.09e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.68	9.05	0.5	4.33e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs66561647	0.661	rs35851359	chr8:128935626	G/C	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	4.96	0.3	1.34e-6	Hemoglobin concentration;
KIRP	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02972257	chr16:68554789	NA	-0.72	-7.14	-0.41	1.07e-11	Ulcerative colitis;
KIRP	cis	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg26585981	chr11:48327164	OR4S1	-0.47	-5.66	-0.34	4.12e-8	HDL cholesterol;
KIRP	cis	rs6991838	0.584	rs34226237	chr8:66513165	A/C	cg13398993	chr8:66546079	ARMC1	-0.45	-5.19	-0.31	4.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg18279126	chr7:2041391	MAD1L1	0.49	5.2	0.31	4.2e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.31	-5.22	-0.32	3.83e-7	Dupuytren's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18045575	chr2:27341901	CGREF1	0.41	6.04	0.36	5.69e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg12435725	chr3:58293450	RPP14	-0.49	-4.85	-0.3	2.15e-6	Cholesterol, total;
KIRP	cis	rs6893807	0.778	rs1501672	chr5:87963761	A/G	cg24804195	chr5:87968844	LOC645323	0.5	5.02	0.3	9.91e-7	Body mass index;
KIRP	cis	rs1949733	0.675	rs2010758	chr4:8475623	G/A	cg11789530	chr4:8429930	ACOX3	0.75	8.98	0.5	7.25e-17	Response to antineoplastic agents;
KIRP	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02725872	chr8:58115012	NA	-0.66	-6.51	-0.38	4.09e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg16077055	chr2:106428750	NCK2	0.31	6.19	0.37	2.44e-9	Addiction;
KIRP	cis	rs11225247	1.000	rs1058606	chr11:102267098	A/T	cg06323957	chr11:102217781	BIRC2	0.98	6.08	0.36	4.57e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.61	-0.52	9.32e-19	Asthma;
KIRP	cis	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg19847130	chr8:10466454	RP1L1	0.42	5.9	0.35	1.17e-8	Retinal vascular caliber;
KIRP	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg27529037	chr20:44575021	PCIF1	-0.41	-5.01	-0.3	1.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11074306	0.522	rs2311470	chr15:28082022	G/C	cg26402630	chr15:28053930	OCA2	0.31	5.06	0.31	8.36e-7	Uveal melanoma;
KIRP	cis	rs56161922	1.000	rs74401244	chr1:207844799	T/C	cg09557387	chr1:207818395	CR1L	1.08	6.5	0.38	4.51e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg03808351	chr9:123631620	PHF19	0.39	5.26	0.32	3.15e-7	Rheumatoid arthritis;
KIRP	trans	rs12043259	0.730	rs59436169	chr1:204797992	G/C	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs11776767	0.538	rs12546026	chr8:10710715	G/T	cg12568669	chr8:11666485	FDFT1	-0.26	-5.45	-0.33	1.21e-7	Triglycerides;
KIRP	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.56	6.85	0.4	6.02e-11	Cognitive test performance;
KIRP	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg04025307	chr7:1156635	C7orf50	0.54	5.81	0.35	1.97e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.96	11.76	0.6	1.27e-25	Corneal astigmatism;
KIRP	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg23594656	chr7:65796392	TPST1	0.39	5.62	0.34	5.16e-8	Aortic root size;
KIRP	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	6.56	0.39	3.11e-10	Total body bone mineral density;
KIRP	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.4	5.95	0.35	9.32e-9	Diastolic blood pressure;
KIRP	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.41	5.5	0.33	9.32e-8	Blood metabolite levels;
KIRP	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.77	9.11	0.5	2.94e-17	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs12200782	0.769	rs10456329	chr6:26436399	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.52	-4.98	-0.3	1.22e-6	Small cell lung carcinoma;
KIRP	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.77	0.44	2.17e-13	Morning vs. evening chronotype;
KIRP	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg18461021	chr18:74961002	GALR1	0.52	5.33	0.32	2.19e-7	Obesity-related traits;
KIRP	cis	rs6499755	0.896	rs8058278	chr16:55344508	G/A	cg05099576	chr16:55362342	IRX6	0.28	5.83	0.35	1.78e-8	Hypospadias;
KIRP	cis	rs6782228	0.606	rs6775270	chr3:128403498	A/G	cg18648031	chr3:128330563	NA	0.26	5.42	0.33	1.41e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs3820928	0.904	rs2195487	chr2:227759720	G/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.92	-0.3	1.59e-6	Pulmonary function;
KIRP	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs7010267	0.935	rs10955915	chr8:119963547	A/G	cg01975934	chr8:119970761	NA	-0.42	-5.33	-0.32	2.17e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.86	-0.45	1.18e-13	Height;
KIRP	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.99	-0.45	5.21e-14	Retinal vascular caliber;
KIRP	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg00405596	chr8:11794950	NA	-0.45	-5.52	-0.33	8.43e-8	Neuroticism;
KIRP	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-4.96	-0.3	1.29e-6	Schizophrenia;
KIRP	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.39e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg11189052	chr15:85197271	WDR73	0.49	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg00977110	chr5:151150581	G3BP1	-0.61	-5.99	-0.36	7.22e-9	Preschool internalizing problems;
KIRP	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.63	-6.66	-0.39	1.74e-10	Axial length;
KIRP	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg24807547	chr6:37504484	NA	-0.63	-10.13	-0.54	2.2e-20	Cognitive performance;
KIRP	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs8067354	0.645	rs72838857	chr17:57836767	A/G	cg02344993	chr17:57696989	CLTC	0.56	5.01	0.3	1.06e-6	Hemoglobin concentration;
KIRP	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg01843034	chr6:37503916	NA	-0.81	-11.54	-0.59	6.48e-25	Cognitive performance;
KIRP	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg10503236	chr1:231470652	EXOC8	-0.54	-7.44	-0.43	1.69e-12	Hemoglobin concentration;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02295678	chr17:7123415	DLG4;ACADVL	-0.51	-6.09	-0.36	4.27e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07402800	chr8:145582003	FBXL6;GPR172A	0.84	6.25	0.37	1.77e-9	P wave terminal force;
KIRP	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs3109167	0.631	rs57351637	chr7:83105843	C/G	cg14519356	chr7:83097669	SEMA3E	-0.45	-6.17	-0.37	2.76e-9	Blood protein levels;
KIRP	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.46	5.5	0.33	9.61e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs9309473	0.950	rs13408433	chr2:73883072	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.4	-0.33	1.57e-7	Metabolite levels;
KIRP	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg16989719	chr2:238392110	NA	-0.52	-6.92	-0.4	3.94e-11	Prostate cancer;
KIRP	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.58	7.45	0.43	1.6e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs2975734	0.709	rs6988826	chr8:10109625	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.84	-0.4	6.35e-11	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs7246967	0.673	rs34671960	chr19:22948693	G/A	cg03230154	chr19:22817176	ZNF492	0.51	4.99	0.3	1.13e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs7395581	0.918	rs11039166	chr11:47316691	A/C	cg26139080	chr11:47293733	MADD	-0.42	-5.27	-0.32	3e-7	HDL cholesterol;
KIRP	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg18709589	chr6:96969512	KIAA0776	-0.34	-5.13	-0.31	6.01e-7	Headache;
KIRP	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.62	-9.12	-0.5	2.73e-17	Menopause (age at onset);
KIRP	cis	rs11230563	0.501	rs4939488	chr11:60786474	T/C	cg10158843	chr11:60776172	CD6	0.35	5.55	0.33	7.2e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-6.65	-0.39	1.93e-10	Ulcerative colitis;
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg23978390	chr7:1156363	C7orf50	0.42	5.5	0.33	9.52e-8	Longevity;Endometriosis;
KIRP	cis	rs6585424	1.000	rs34749786	chr10:81924390	C/A	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs13190036	0.551	rs28932178	chr5:176637576	T/C	cg04708888	chr5:176739561	MXD3	0.63	5.09	0.31	7.1e-7	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-8.31	-0.47	6.35e-15	Homocysteine levels;
KIRP	cis	rs7635838	0.687	rs9849485	chr3:11395741	G/A	cg00170343	chr3:11313890	ATG7	0.49	6.7	0.39	1.4e-10	HDL cholesterol;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22618164	chr12:122356400	WDR66	0.66	9.23	0.51	1.29e-17	Mean corpuscular volume;
KIRP	cis	rs9603616	0.648	rs7998582	chr13:40239618	A/G	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs1062746	0.544	rs17770933	chr16:87325729	C/T	cg02258303	chr16:87377426	FBXO31	-0.42	-5.06	-0.31	8.08e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09861318	chr3:149530987	RNF13	0.44	6.18	0.37	2.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1656402	1.000	rs1190444	chr2:233421679	G/A	cg03852847	chr2:233439513	NA	0.66	8.66	0.48	6.2e-16	Non-small cell lung cancer (survival);
KIRP	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg01324507	chr7:1177794	C7orf50	0.51	5.44	0.33	1.31e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.47	5.58	0.34	6.27e-8	Diastolic blood pressure;
KIRP	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.73e-9	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.07	-0.41	1.58e-11	Initial pursuit acceleration;
KIRP	cis	rs2483058	0.767	rs11809494	chr1:206623866	C/T	cg19452316	chr1:206680966	RASSF5	0.4	5.48	0.33	1.06e-7	Cholesterol and Triglycerides;
KIRP	cis	rs6939532	0.517	rs733528	chr6:26374903	A/G	cg12826209	chr6:26865740	GUSBL1	0.47	5.5	0.33	9.29e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	1.1	17.06	0.74	1.39e-43	Homoarginine levels;
KIRP	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.48	-0.43	1.27e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9790314	0.613	rs2121718	chr3:160603511	C/T	cg04691961	chr3:161091175	C3orf57	0.44	6.25	0.37	1.82e-9	Morning vs. evening chronotype;
KIRP	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.66	-8.19	-0.46	1.41e-14	Multiple sclerosis;
KIRP	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	1.0	16.17	0.72	1.49e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs3748682	0.516	rs111956467	chr1:38215917	C/T	cg16341373	chr1:38157962	CDCA8	-0.55	-5.01	-0.3	1.03e-6	Hypothyroidism;
KIRP	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg14972814	chr11:95582409	MTMR2	0.35	5.73	0.34	2.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg01181863	chr3:195395398	SDHAP2	-0.82	-9.45	-0.52	2.87e-18	Pancreatic cancer;
KIRP	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-7.03	-0.41	2.02e-11	Chronic sinus infection;
KIRP	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-5.19	-0.31	4.38e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21016266	chr12:122356598	WDR66	-0.62	-8.63	-0.48	7.99e-16	Mean corpuscular volume;
KIRP	trans	rs6601327	0.603	rs10095171	chr8:9669885	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.75	-0.4	1.08e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.57	-7.47	-0.43	1.4e-12	Height;
KIRP	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.56	-7.45	-0.43	1.57e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.4	-0.51	3.82e-18	Chronic sinus infection;
KIRP	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.78	9.95	0.54	8.15e-20	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.73	9.39	0.51	4.24e-18	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.68	5.15	0.31	5.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10489525	0.599	rs7526323	chr1:115604241	G/A	cg01522456	chr1:115632236	TSPAN2	0.51	6.92	0.4	3.98e-11	Autism;
KIRP	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.73	10.02	0.54	4.82e-20	Red blood cell count;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.733	rs60616028	chr10:35543802	G/A	cg03585969	chr10:35415529	CREM	0.61	6.93	0.4	3.67e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-1.28	-12.57	-0.63	2.53e-28	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs28834970	0.571	rs17447007	chr8:27230637	A/G	cg18234130	chr8:27182889	PTK2B	-0.44	-5.22	-0.32	3.89e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg15556689	chr8:8085844	FLJ10661	0.68	9.39	0.51	4.29e-18	Systolic blood pressure;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg13147721	chr7:65941812	NA	1.02	7.05	0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg00343986	chr7:65444356	GUSB	0.43	5.01	0.3	1.06e-6	Aortic root size;
KIRP	cis	rs10214930	0.752	rs12540063	chr7:27661545	T/C	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09477006	chr4:6711267	MRFAP1L1	0.5	6.63	0.39	2.1e-10	Parkinson's disease;
KIRP	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.81	-7.12	-0.41	1.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg08499158	chr17:42289980	UBTF	-0.7	-9.34	-0.51	5.95e-18	Total body bone mineral density;
KIRP	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.52	-6.2	-0.37	2.31e-9	Ulcerative colitis;
KIRP	cis	rs698833	0.828	rs1067341	chr2:44623687	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	4.88	0.3	1.89e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs719152	0.836	rs11042929	chr11:10723689	C/T	cg07356130	chr11:10772521	CTR9	0.45	4.85	0.3	2.17e-6	Mean platelet volume;
KIRP	cis	rs507080	0.769	rs570952	chr11:118500193	T/C	cg04173919	chr11:118528438	PHLDB1	0.35	4.99	0.3	1.14e-6	Serum metabolite levels;
KIRP	cis	rs7173743	0.525	rs4401016	chr15:79134791	G/A	cg00079375	chr15:79125835	NA	0.45	6.32	0.37	1.19e-9	Coronary artery disease;
KIRP	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.63	7.79	0.44	1.84e-13	Body mass index;
KIRP	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg10255544	chr17:80519551	FOXK2	-0.56	-8.25	-0.47	9.71e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs11644362	1.000	rs4781349	chr16:12987249	T/C	cg06890432	chr16:12997467	SHISA9	-0.39	-6.02	-0.36	6.3e-9	Positive affect;Subjective well-being;
KIRP	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.5	5.04	0.31	9.15e-7	Initial pursuit acceleration;
KIRP	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg07167872	chr1:205819463	PM20D1	0.46	5.2	0.31	4.2e-7	Parkinson's disease;
KIRP	cis	rs4356932	0.597	rs13125558	chr4:76852585	A/C	cg19388996	chr4:76862389	NAAA	-0.4	-5.18	-0.31	4.68e-7	Blood protein levels;
KIRP	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.42	-0.47	3.1e-15	Morning vs. evening chronotype;
KIRP	cis	rs7683537	0.692	rs56317358	chr4:185659470	G/A	cg04058563	chr4:185651563	MLF1IP	1.06	10.29	0.55	7.12e-21	Systemic lupus erythematosus;
KIRP	cis	rs4692589	1.000	rs17546378	chr4:170935854	G/A	cg19918862	chr4:170955249	NA	0.42	5.11	0.31	6.49e-7	Anxiety disorder;
KIRP	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg07414643	chr4:187882934	NA	0.42	5.59	0.34	5.9e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	1.2	11.16	0.58	1.11e-23	Lymphocyte counts;
KIRP	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg02336718	chr17:17403227	NA	0.33	5.25	0.32	3.33e-7	Total body bone mineral density;
KIRP	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.28	0.42	4.45e-12	Neuroticism;
KIRP	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg13397359	chr6:42928475	GNMT	0.46	5.1	0.31	6.83e-7	Blood protein levels;
KIRP	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.02	18.27	0.76	1.05e-47	Testicular germ cell tumor;
KIRP	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	8.51	0.48	1.72e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg18350739	chr11:68623251	NA	-0.48	-7.47	-0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.34	-7.45	-0.43	1.6e-12	Cutaneous nevi;
KIRP	cis	rs4805272	0.962	rs2870545	chr19:29324761	C/G	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg05861140	chr6:150128134	PCMT1	-0.47	-6.53	-0.38	3.68e-10	Lung cancer;
KIRP	cis	rs6449957	0.832	rs7715780	chr5:67453288	A/G	cg09038926	chr5:67483109	NA	-0.38	-5.03	-0.31	9.47e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.75	9.94	0.54	8.78e-20	Morning vs. evening chronotype;
KIRP	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg01280390	chr8:19363452	CSGALNACT1	-0.4	-5.31	-0.32	2.45e-7	Oropharynx cancer;
KIRP	cis	rs4950322	0.570	rs79810882	chr1:146707223	G/T	cg22381352	chr1:146742008	CHD1L	-0.42	-5.02	-0.3	9.83e-7	Protein quantitative trait loci;
KIRP	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-4.95	-0.3	1.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7107174	0.579	rs1981405	chr11:77976208	C/T	cg02023728	chr11:77925099	USP35	0.46	5.2	0.31	4.23e-7	Testicular germ cell tumor;
KIRP	cis	rs4845459	0.967	rs4845454	chr1:152592184	C/T	cg07796016	chr1:152779584	LCE1C	-0.49	-5.95	-0.35	9.1e-9	Psoriasis;
KIRP	cis	rs6788895	1.000	rs34348847	chr3:150501389	C/G	cg09723797	chr3:150481914	SIAH2	0.68	5.15	0.31	5.39e-7	Breast cancer;
KIRP	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.46	6.72	0.39	1.27e-10	Sitting height ratio;
KIRP	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17507749	chr15:85114479	UBE2QP1	0.69	7.63	0.44	5.11e-13	Schizophrenia;
KIRP	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg21926883	chr2:100939477	LONRF2	-0.52	-7.05	-0.41	1.79e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.86	9.68	0.53	5.7e-19	Mosquito bite size;
KIRP	cis	rs17023223	0.537	rs2361271	chr1:119603405	A/G	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	2.94e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4886920	0.672	rs12437900	chr15:78134138	G/T	cg10461261	chr15:78109450	NA	0.32	5.15	0.31	5.3e-7	Neuroticism;
KIRP	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.58	-0.44	6.92e-13	Initial pursuit acceleration;
KIRP	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-1.01	-16.92	-0.73	3.99e-43	Height;
KIRP	trans	rs11165623	0.602	rs4127309	chr1:97006892	T/C	cg10631902	chr5:14652156	NA	-0.46	-6.14	-0.36	3.37e-9	Hip circumference;Waist circumference;
KIRP	cis	rs7551222	0.752	rs10793767	chr1:204549564	A/C	cg20240347	chr1:204465584	NA	-0.41	-7.93	-0.45	7.83e-14	Schizophrenia;
KIRP	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.19	-0.37	2.47e-9	Aortic root size;
KIRP	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.96	15.26	0.7	1.94e-37	Intelligence (multi-trait analysis);
KIRP	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg17145862	chr1:211918768	LPGAT1	-0.91	-13.38	-0.65	4.63e-31	Leprosy;
KIRP	cis	rs601339	1.000	rs1798219	chr12:123180061	A/C	cg18578876	chr12:123200353	GPR109B	0.49	4.85	0.3	2.19e-6	Adiponectin levels;
KIRP	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg18190219	chr22:46762943	CELSR1	-0.66	-5.74	-0.34	2.71e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg21174375	chr14:64681225	SYNE2	0.43	4.89	0.3	1.83e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg26531700	chr6:26746687	NA	0.39	5.0	0.3	1.11e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg24692254	chr21:30365293	RNF160	-0.49	-4.98	-0.3	1.21e-6	Cognitive test performance;
KIRP	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg04731861	chr2:219085781	ARPC2	0.28	7.35	0.42	2.94e-12	Colorectal cancer;
KIRP	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.57	0.39	2.99e-10	Lung cancer;
KIRP	cis	rs6466055	0.661	rs67529088	chr7:104907066	G/C	cg04380332	chr7:105027541	SRPK2	0.37	5.05	0.31	8.67e-7	Schizophrenia;
KIRP	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.54	-6.8	-0.4	7.86e-11	Type 2 diabetes;
KIRP	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg26898376	chr11:64110657	CCDC88B	0.58	5.26	0.32	3.1e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg08382946	chr5:1082689	SLC12A7	0.48	6.16	0.37	2.93e-9	QT interval;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17312092	chr12:75057893	NA	-0.46	-6.96	-0.41	3.11e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs7129556	0.954	rs2032395	chr11:77314503	A/G	cg12586386	chr11:77299805	AQP11	0.45	5.99	0.36	7.48e-9	Weight loss (gastric bypass surgery);
KIRP	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg10845886	chr2:3471009	TTC15	-0.59	-8.21	-0.46	1.25e-14	Neurofibrillary tangles;
KIRP	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg01877450	chr7:97915802	BRI3	0.56	7.08	0.41	1.46e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg05315796	chr3:52349193	DNAH1	0.4	6.3	0.37	1.33e-9	Electroencephalogram traits;
KIRP	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.83	10.05	0.54	3.87e-20	Response to antipsychotic treatment;
KIRP	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg13010199	chr12:38710504	ALG10B	0.68	8.82	0.49	2.21e-16	Morning vs. evening chronotype;
KIRP	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.13	0.31	5.91e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7923609	0.934	rs10761771	chr10:65230164	T/C	cg01631684	chr10:65280961	REEP3	-0.51	-6.0	-0.36	7.17e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg21360079	chr12:107162445	NA	-0.67	-9.86	-0.53	1.53e-19	Heart rate;
KIRP	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg27426351	chr10:43362370	NA	0.44	6.32	0.37	1.24e-9	Blood protein levels;
KIRP	cis	rs735539	0.645	rs9552252	chr13:21192905	C/T	cg04906043	chr13:21280425	IL17D	-0.48	-5.42	-0.33	1.43e-7	Dental caries;
KIRP	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.62	-0.39	2.23e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04026044	chr4:74452103	RASSF6	-0.44	-7.02	-0.41	2.13e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02839544	chr19:1354667	MUM1	0.45	6.35	0.38	1.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.59	-6.94	-0.4	3.56e-11	Corneal astigmatism;
KIRP	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.43	5.66	0.34	4.19e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg01616529	chr11:638424	DRD4	-0.36	-4.85	-0.3	2.22e-6	Systemic lupus erythematosus;
KIRP	trans	rs1941687	0.764	rs4799357	chr18:31366442	T/C	cg27147174	chr7:100797783	AP1S1	-0.7	-9.19	-0.51	1.72e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.44	-5.94	-0.35	9.7e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.31	-0.32	2.41e-7	Breast cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg14024356	chr1:154934173	PYGO2	0.54	6.81	0.4	7.3e-11	Asthma;
KIRP	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.79	-11.64	-0.6	3.02e-25	Heart rate;
KIRP	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.59	7.32	0.42	3.55e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg12435725	chr3:58293450	RPP14	-0.5	-5.43	-0.33	1.36e-7	Cholesterol, total;
KIRP	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.58	7.16	0.42	9.31e-12	Breast cancer;
KIRP	cis	rs7809615	0.901	rs6947826	chr7:99156520	C/T	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite ratios;
KIRP	cis	rs4654899	0.680	rs4233274	chr1:21121678	C/T	cg05370193	chr1:21551575	ECE1	0.36	5.08	0.31	7.36e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.51	-7.54	-0.43	9.13e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg12560992	chr17:57184187	TRIM37	0.61	5.52	0.33	8.6e-8	Cognitive test performance;
KIRP	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg04117972	chr1:227635322	NA	0.67	5.22	0.32	3.75e-7	Major depressive disorder;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01546919	chr14:75522151	ACYP1	0.42	6.21	0.37	2.2e-9	C-reactive protein;
KIRP	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg19507638	chr5:93509721	C5orf36	-0.59	-5.31	-0.32	2.47e-7	Diabetic retinopathy;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg09355771	chr2:177043147	NA	0.5	6.46	0.38	5.53e-10	IgG glycosylation;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg04477202	chr2:32289458	SPAST	0.5	6.09	0.36	4.27e-9	Educational attainment;
KIRP	cis	rs3736485	0.966	rs4774596	chr15:51910975	C/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg17724175	chr1:150552817	MCL1	0.35	5.92	0.35	1.05e-8	Melanoma;
KIRP	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.69	8.92	0.49	1.12e-16	Blood metabolite levels;
KIRP	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-4.97	-0.3	1.27e-6	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs867371	0.929	rs7173852	chr15:82461853	A/G	cg06066596	chr15:83166174	LOC80154	-0.42	-4.95	-0.3	1.35e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg00129232	chr17:37814104	STARD3	-0.69	-8.72	-0.49	4.11e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs4356975	0.563	rs7698846	chr4:69971996	T/C	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg18864164	chr10:115934049	MIR2110;C10orf118	0.49	6.29	0.37	1.45e-9	Asthma;
KIRP	cis	rs13418717	1.000	rs13394375	chr2:127677701	C/T	cg25501666	chr2:127640322	NA	0.97	6.17	0.37	2.78e-9	Heart failure;
KIRP	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.36	5.88	0.35	1.31e-8	Skin aging (microtopography measurement);
KIRP	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg11833968	chr6:79620685	NA	-0.37	-5.14	-0.31	5.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.53	-7.28	-0.42	4.61e-12	Type 2 diabetes;
KIRP	cis	rs6973256	0.897	rs10231829	chr7:133348338	T/A	cg10665199	chr7:133106180	EXOC4	-0.5	-6.3	-0.37	1.36e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg20701182	chr2:24300061	SF3B14	0.56	5.04	0.31	9.03e-7	Lymphocyte counts;
KIRP	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.45	-6.8	-0.4	8.01e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs13185784	0.703	rs55756747	chr5:179675052	C/A	cg13944838	chr5:179740914	GFPT2	0.53	5.16	0.31	5.17e-7	TRAIL levels;
KIRP	cis	rs2071403	0.933	rs1567920	chr2:1413226	A/G	cg07083862	chr2:1417248	TPO	0.33	5.27	0.32	2.93e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg21523564	chr15:75251491	NA	-0.35	-5.94	-0.35	9.57e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4903604	0.581	rs11159278	chr14:78034001	C/G	cg18872420	chr14:78023429	SPTLC2	0.37	5.69	0.34	3.51e-8	Gut microbiome composition (winter);
KIRP	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.74	10.45	0.55	2.19e-21	Body mass index;
KIRP	cis	rs7903847	0.642	rs10882911	chr10:99138064	A/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.85	14.23	0.67	6.15e-34	Intelligence (multi-trait analysis);
KIRP	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg08712631	chr7:1960676	MAD1L1	-0.45	-5.92	-0.35	1.06e-8	Neuroticism;
KIRP	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-13.01	-0.64	8.73e-30	Exhaled nitric oxide output;
KIRP	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.4	-6.43	-0.38	6.44e-10	Body mass index;
KIRP	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg26059219	chr3:4508837	SUMF1	0.68	6.34	0.37	1.07e-9	Lung function (FEV1);
KIRP	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.67	-0.48	5.93e-16	Morning vs. evening chronotype;
KIRP	cis	rs11716531	0.574	rs7624067	chr3:27267853	G/A	cg02860705	chr3:27208620	NA	0.56	7.38	0.43	2.41e-12	Diastolic blood pressure;
KIRP	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.49e-6	Red blood cell count;
KIRP	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg00310523	chr12:86230176	RASSF9	-0.47	-7.52	-0.43	1e-12	Major depressive disorder;
KIRP	cis	rs1816752	0.819	rs7400583	chr13:24990054	C/T	cg02811702	chr13:24901961	NA	0.38	5.04	0.31	9.08e-7	Obesity-related traits;
KIRP	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.66	8.73	0.49	4.01e-16	Morning vs. evening chronotype;
KIRP	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.97	0.67	4.71e-33	Electrocardiographic conduction measures;
KIRP	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.49	-6.48	-0.38	5.07e-10	Lung cancer;
KIRP	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-5.65	-0.34	4.45e-8	Alzheimer's disease (late onset);
KIRP	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.72	-9.09	-0.5	3.51e-17	Ulcerative colitis;
KIRP	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.11e-7	Breast cancer;
KIRP	cis	rs8054556	0.730	rs4788190	chr16:29948401	G/A	cg06326092	chr16:30034487	C16orf92	0.35	5.04	0.31	9.02e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.06	-0.31	8.17e-7	Red blood cell count;
KIRP	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg16988262	chr1:15930761	NA	0.39	5.01	0.3	1.06e-6	Systolic blood pressure;
KIRP	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg23815491	chr16:72088622	HP	-0.37	-5.33	-0.32	2.26e-7	Blood protein levels;
KIRP	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.7	8.2	0.46	1.35e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.89	14.69	0.68	1.62e-35	Ulcerative colitis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23628684	chr21:30446052	CCT8	0.53	7.39	0.43	2.31e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7737355	1.000	rs12517604	chr5:130748500	T/C	cg25547332	chr5:131281432	NA	-0.47	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg02375832	chr11:62437615	C11orf48	-0.43	-5.48	-0.33	1.07e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.77	11.45	0.59	1.26e-24	Hip circumference;
KIRP	cis	rs290268	0.838	rs1333635	chr9:93566406	A/G	cg02608019	chr9:93564028	SYK	0.82	11.59	0.59	4.36e-25	Platelet count;
KIRP	cis	rs970548	0.688	rs2082109	chr10:45931102	T/C	cg15590007	chr10:45870220	ALOX5	0.54	5.71	0.34	3.22e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.44	9.74	0.53	3.56e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4148087	1.000	rs4148100	chr21:43640169	T/C	cg08841829	chr21:43638893	ABCG1	-0.58	-4.92	-0.3	1.58e-6	Eating disorder in bipolar disorder;
KIRP	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.82	6.89	0.4	4.67e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2273669	0.504	rs112211350	chr6:109457989	T/C	cg05315195	chr6:109294784	ARMC2	-0.53	-5.12	-0.31	6.11e-7	Prostate cancer;
KIRP	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.79	-0.35	2.13e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.41	-5.31	-0.32	2.4e-7	Renal cell carcinoma;
KIRP	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs13102973	1.000	rs11722746	chr4:135850567	A/T	cg14419869	chr4:135874104	NA	0.52	8.63	0.48	7.65e-16	Subjective well-being;
KIRP	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	1.05	13.5	0.65	1.89e-31	Exhaled nitric oxide output;
KIRP	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.41	6.25	0.37	1.75e-9	Information processing speed;
KIRP	cis	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-4.85	-0.3	2.15e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4689642	0.709	rs4689657	chr4:7225818	G/C	cg21353189	chr4:7228343	SORCS2	0.41	5.5	0.33	9.62e-8	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.78	9.77	0.53	2.84e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12786942	0.628	rs11224763	chr11:101309387	G/A	cg03942599	chr11:101341554	TRPC6	0.48	5.5	0.33	9.65e-8	Facial depth;
KIRP	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.66	-12.27	-0.62	2.47e-27	Intelligence (multi-trait analysis);
KIRP	trans	rs10877945	0.522	rs7297754	chr12:63443521	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.49	-6.44	-0.38	6.37e-10	Obesity-related traits;
KIRP	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg21775007	chr8:11205619	TDH	-0.48	-6.22	-0.37	2.06e-9	Systolic blood pressure;
KIRP	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg17646820	chr3:66848679	NA	0.75	9.96	0.54	7.42e-20	Type 2 diabetes;
KIRP	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.37	1.34e-9	Bladder cancer;
KIRP	cis	rs4835473	0.900	rs58106929	chr4:144654319	A/G	cg08833778	chr4:144622313	FREM3	0.35	4.91	0.3	1.67e-6	Immature fraction of reticulocytes;
KIRP	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg06995285	chr7:2418615	EIF3B	0.82	8.52	0.48	1.6e-15	Multiple sclerosis;
KIRP	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg09873164	chr1:152488093	CRCT1	0.5	5.86	0.35	1.46e-8	Hair morphology;
KIRP	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.45	-5.71	-0.34	3.29e-8	Ulcerative colitis;
KIRP	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg03585969	chr10:35415529	CREM	0.77	9.5	0.52	2.02e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2380205	1.000	rs12253826	chr10:5886381	T/C	cg27141509	chr10:5886111	NA	-0.39	-5.6	-0.34	5.78e-8	Breast cancer;
KIRP	cis	rs9513627	0.833	rs73556146	chr13:100116920	A/G	cg25919922	chr13:100150906	NA	-0.74	-5.87	-0.35	1.4e-8	Obesity-related traits;
KIRP	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg22705602	chr4:152727874	NA	-0.52	-8.98	-0.5	7.23e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2997447	0.894	rs55722280	chr1:26412684	T/C	cg19633962	chr1:26362018	EXTL1	-0.52	-5.05	-0.31	8.77e-7	QRS complex (12-leadsum);
KIRP	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-5.45	-0.33	1.24e-7	Endometrial cancer;
KIRP	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg03351412	chr1:154909251	PMVK	0.59	7.05	0.41	1.83e-11	Prostate cancer;
KIRP	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.98	14.54	0.68	5.43e-35	Heart rate;
KIRP	cis	rs4389656	0.857	rs274699	chr5:6730332	A/C	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg13939156	chr17:80058883	NA	-0.49	-7.4	-0.43	2.2e-12	Life satisfaction;
KIRP	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	trans	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg25214090	chr10:38739885	LOC399744	0.63	7.51	0.43	1.12e-12	Corneal astigmatism;
KIRP	cis	rs6662572	0.737	rs72677518	chr1:46511118	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.63	0.34	4.91e-8	Blood protein levels;
KIRP	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17507749	chr15:85114479	UBE2QP1	0.77	8.61	0.48	8.76e-16	Schizophrenia;
KIRP	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg27205649	chr11:78285834	NARS2	-0.55	-5.4	-0.33	1.55e-7	Testicular germ cell tumor;
KIRP	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.46	-5.83	-0.35	1.76e-8	IgG glycosylation;
KIRP	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.98	10.66	0.56	4.58e-22	HIV-1 control;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg12337011	chr2:28002424	MRPL33	0.52	6.38	0.38	8.87e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.03	0.41	2.08e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	18.65	0.77	5.45e-49	Exhaled nitric oxide output;
KIRP	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.87	13.61	0.66	8.1e-32	Blood protein levels;
KIRP	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.85	-9.97	-0.54	7.2e-20	Cognitive ability;
KIRP	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg01304814	chr3:48885189	PRKAR2A	0.51	4.9	0.3	1.77e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4789452	1.000	rs7216382	chr17:75374578	T/C	cg12985929	chr17:75370611	SEPT9	-0.38	-5.2	-0.31	4.29e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg24315340	chr6:146058215	EPM2A	0.43	5.49	0.33	1.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.79	-11.65	-0.6	2.8e-25	Menarche (age at onset);
KIRP	cis	rs986417	1.000	rs1254322	chr14:60906976	G/A	cg27398547	chr14:60952738	C14orf39	-0.67	-5.77	-0.35	2.42e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6901004	0.803	rs168522	chr6:111506628	A/G	cg15721981	chr6:111408429	SLC16A10	-0.56	-7.75	-0.44	2.39e-13	Blood metabolite levels;
KIRP	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.27	-22.16	-0.82	1.54e-60	Breast cancer;
KIRP	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg15557168	chr22:42548783	NA	-0.39	-5.48	-0.33	1.07e-7	Cognitive function;
KIRP	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.72	-9.1	-0.5	3.2e-17	Height;
KIRP	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg21918786	chr6:109611834	NA	-0.42	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs6504622	0.537	rs1662597	chr17:44994855	T/C	cg16759221	chr17:45003025	GOSR2	-0.39	-5.85	-0.35	1.54e-8	Orofacial clefts;
KIRP	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg19847130	chr8:10466454	RP1L1	0.4	5.87	0.35	1.42e-8	Retinal vascular caliber;
KIRP	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg09455208	chr3:40491958	NA	-0.35	-6.17	-0.37	2.85e-9	Renal cell carcinoma;
KIRP	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.68	9.79	0.53	2.52e-19	Dupuytren's disease;
KIRP	cis	rs80282103	1.000	rs80282103	chr10:899071	A/T	cg08668510	chr10:1095578	IDI1	0.7	4.91	0.3	1.64e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.09	-0.5	3.36e-17	Mean corpuscular volume;
KIRP	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.38	-0.38	8.92e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg24315340	chr6:146058215	EPM2A	0.43	5.48	0.33	1.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.75	10.83	0.57	1.34e-22	Lung cancer;
KIRP	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.4	-6.3	-0.37	1.33e-9	Body mass index;
KIRP	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg13010199	chr12:38710504	ALG10B	0.55	6.7	0.39	1.43e-10	Resting heart rate;
KIRP	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	6.94	0.4	3.54e-11	Height;
KIRP	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg26248373	chr2:1572462	NA	0.66	6.33	0.37	1.13e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg23533419	chr12:54090519	NA	-0.33	-5.16	-0.31	5.07e-7	Height;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg00990874	chr7:1149470	C7orf50	-0.87	-9.04	-0.5	4.77e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	1.06	19.97	0.79	2.13e-53	Heart rate;
KIRP	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.81	9.47	0.52	2.34e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.95	0.5	8.93e-17	Bladder cancer;
KIRP	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg15839431	chr19:19639596	YJEFN3	-0.53	-5.41	-0.33	1.48e-7	Bipolar disorder;
KIRP	cis	rs745080	0.519	rs1006237	chr14:53001304	C/T	cg23333723	chr14:53022898	GPR137C	-0.42	-5.5	-0.33	9.3e-8	Orofacial clefts;
KIRP	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05209770	chr6:89827644	SFRS13B	-0.57	-6.15	-0.37	3.06e-9	Menopause (age at onset);
KIRP	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg21132104	chr15:45694354	SPATA5L1	0.58	7.07	0.41	1.57e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.49	-5.82	-0.35	1.81e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9652601	0.919	rs12924729	chr16:11187783	C/T	cg04616529	chr16:11181986	CLEC16A	0.37	4.86	0.3	2.06e-6	Systemic lupus erythematosus;
KIRP	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.63	-8.63	-0.48	7.79e-16	Response to antidepressants and depression;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25348504	chr12:111180878	PPP1CC	0.48	6.63	0.39	2.13e-10	Survival in pancreatic cancer;
KIRP	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs963731	0.579	rs4670269	chr2:39198036	C/T	cg04010122	chr2:39346883	SOS1	0.63	4.94	0.3	1.46e-6	Corticobasal degeneration;
KIRP	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg21926883	chr2:100939477	LONRF2	-0.51	-6.89	-0.4	4.59e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	0.71	6.44	0.38	6.26e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.75	7.59	0.44	6.6e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.87	-0.4	5.29e-11	Hemoglobin concentration;
KIRP	cis	rs6142102	0.625	rs6141436	chr20:32554571	T/A	cg24642439	chr20:33292090	TP53INP2	0.49	5.75	0.34	2.67e-8	Skin pigmentation;
KIRP	cis	rs7180079	0.514	rs574205	chr15:64775834	C/A	cg15337035	chr15:64978493	NA	-0.47	-5.19	-0.31	4.34e-7	Monocyte count;
KIRP	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.45	-5.81	-0.35	1.92e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.83	11.76	0.6	1.29e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.23	-0.42	6.02e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg03959625	chr15:84868606	LOC388152	0.49	5.81	0.35	1.91e-8	Schizophrenia;
KIRP	cis	rs11997175	0.545	rs4733458	chr8:33661542	G/T	ch.8.33884649F	chr8:33765107	NA	0.5	5.89	0.35	1.24e-8	Body mass index;
KIRP	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17507749	chr15:85114479	UBE2QP1	0.78	8.52	0.48	1.64e-15	Schizophrenia;
KIRP	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	0.95	8.19	0.46	1.46e-14	Arsenic metabolism;
KIRP	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg01872077	chr2:219646372	CYP27A1	0.4	5.27	0.32	2.97e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg25319279	chr11:5960081	NA	-0.62	-6.46	-0.38	5.65e-10	DNA methylation (variation);
KIRP	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.67	9.22	0.51	1.42e-17	Caffeine consumption;
KIRP	cis	rs7674212	0.865	rs1481279	chr4:103977938	A/T	cg16532752	chr4:104119610	CENPE	0.43	5.34	0.32	2.13e-7	Type 2 diabetes;
KIRP	cis	rs6088813	1.000	rs6088812	chr20:33974163	T/A	cg14752227	chr20:34000481	UQCC	-0.52	-6.86	-0.4	5.42e-11	Height;
KIRP	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	7.81	0.45	1.7e-13	Systemic lupus erythematosus;
KIRP	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.97	-10.26	-0.55	8.46e-21	Schizophrenia;
KIRP	cis	rs526231	0.511	rs2288389	chr5:102353808	C/G	cg23492399	chr5:102201601	PAM	-0.45	-5.04	-0.31	9.02e-7	Primary biliary cholangitis;
KIRP	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.62	0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.89	0.53	1.22e-19	Lung cancer in ever smokers;
KIRP	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	1.01	20.02	0.79	1.42e-53	Parkinson's disease;
KIRP	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg09184832	chr6:79620586	NA	-0.5	-7.13	-0.41	1.13e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs394563	0.591	rs237012	chr6:149729198	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.33	-5.3	-0.32	2.59e-7	Dupuytren's disease;
KIRP	cis	rs11997175	0.603	rs7008747	chr8:33834886	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.2	0.31	4.13e-7	Body mass index;
KIRP	trans	rs6601327	0.603	rs28634186	chr8:9669335	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.26	-0.37	1.74e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11790388	0.505	rs665249	chr9:129729403	C/T	cg13970942	chr9:129673409	NA	0.39	5.21	0.32	4.06e-7	Schizophrenia;
KIRP	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.85	-10.84	-0.57	1.24e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.5	7.59	0.44	6.67e-13	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg07636037	chr3:49044803	WDR6	-0.73	-7.4	-0.43	2.15e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1858037	0.867	rs55945621	chr2:65615354	G/A	cg08085232	chr2:65598271	SPRED2	-0.54	-6.43	-0.38	6.55e-10	Rheumatoid arthritis;
KIRP	cis	rs8113308	0.810	rs7254930	chr19:52451527	G/T	cg24732339	chr19:52471368	ZNF350	-0.45	-5.02	-0.3	9.83e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	trans	rs76288851	0.799	rs73205615	chr3:126588618	T/C	cg13821433	chr2:26726535	OTOF	0.58	6.49	0.38	4.61e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.43	0.52	3.23e-18	Colorectal cancer;
KIRP	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.65	-7.89	-0.45	1.01e-13	Facial morphology (factor 19);
KIRP	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg18882449	chr10:104885122	NT5C2	0.5	6.26	0.37	1.68e-9	Arsenic metabolism;
KIRP	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	5.96	0.36	8.57e-9	Putamen volume;
KIRP	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg16306078	chr6:126000798	NA	0.26	4.91	0.3	1.69e-6	Endometrial cancer;
KIRP	cis	rs7116495	1.000	rs2298456	chr11:71730715	A/T	cg18441811	chr11:71824068	C11orf51	0.61	4.89	0.3	1.85e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9400467	0.528	rs456569	chr6:111674801	T/G	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21313137	chr20:44462302	SNX21	0.5	6.47	0.38	5.11e-10	Parkinson's disease;
KIRP	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.73	-8.78	-0.49	2.86e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs7903847	0.642	rs1537646	chr10:99149922	T/C	cg20016023	chr10:99160130	RRP12	-0.44	-6.06	-0.36	5.2e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.88	10.43	0.55	2.47e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg22138327	chr13:27999177	GTF3A	0.85	6.53	0.38	3.64e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.29	5.53	0.33	8.07e-8	Monocyte percentage of white cells;
KIRP	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs7404095	0.695	rs10852256	chr16:23869517	A/G	cg21745164	chr16:23765304	CHP2	0.33	4.86	0.3	2.05e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.28	-4.85	-0.3	2.24e-6	Renal function-related traits (BUN);
KIRP	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.65	7.77	0.44	2.11e-13	Corneal astigmatism;
KIRP	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.74	-0.49	3.75e-16	Resting heart rate;
KIRP	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg17554472	chr22:41940697	POLR3H	0.65	6.72	0.39	1.28e-10	Vitiligo;
KIRP	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.18	15.9	0.71	1.19e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-8.21	-0.46	1.24e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.38	0.32	1.76e-7	Homoarginine levels;
KIRP	cis	rs897080	0.552	rs1067388	chr2:44642482	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.94	0.35	9.82e-9	Height;
KIRP	cis	rs6960043	0.652	rs6461149	chr7:15044103	C/T	cg19272540	chr7:15055459	NA	0.23	6.48	0.38	5.04e-10	Type 2 diabetes;
KIRP	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg00684032	chr4:1343700	KIAA1530	0.46	5.89	0.35	1.26e-8	Longevity;
KIRP	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.21	-0.42	6.67e-12	Bladder cancer;
KIRP	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.45	5.75	0.34	2.62e-8	Red blood cell count;
KIRP	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg03342759	chr3:160939853	NMD3	-0.43	-5.18	-0.31	4.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-1.0	-12.96	-0.64	1.28e-29	Dilated cardiomyopathy;
KIRP	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.47	5.62	0.34	5.2100000000000003e-08	Glycated hemoglobin levels;
KIRP	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.7	5.37	0.32	1.84e-7	Breast cancer;
KIRP	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21659725	chr3:3221576	CRBN	-0.49	-6.13	-0.36	3.4e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.59	-7.97	-0.45	5.86e-14	Breast cancer;
KIRP	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.54	-5.42	-0.33	1.44e-7	Schizophrenia;
KIRP	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg20542592	chr8:11973495	FAM66D	0.4	5.08	0.31	7.42e-7	Triglycerides;
KIRP	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-6.08	-0.36	4.53e-9	Body mass index;
KIRP	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg06815112	chr8:27182871	PTK2B	0.53	6.8	0.4	8.1e-11	Neuroticism;
KIRP	cis	rs7551222	0.714	rs4951404	chr1:204541342	G/C	cg20240347	chr1:204465584	NA	-0.38	-6.26	-0.37	1.67e-9	Schizophrenia;
KIRP	cis	rs1448094	0.605	rs12367761	chr12:86286894	T/C	cg00310523	chr12:86230176	RASSF9	0.44	6.87	0.4	5.27e-11	Major depressive disorder;
KIRP	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.28	-0.37	1.56e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg04111992	chr7:158790115	NA	-0.4	-4.86	-0.3	2.13e-6	Facial morphology (factor 20);
KIRP	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	7.47	0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-6.52	-0.38	3.9e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4950322	0.515	rs17160050	chr1:146727213	T/C	cg22381352	chr1:146742008	CHD1L	-0.39	-4.87	-0.3	2.02e-6	Protein quantitative trait loci;
KIRP	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.71	-0.39	1.32e-10	QT interval;
KIRP	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg16606324	chr3:10149918	C3orf24	-0.57	-5.2	-0.31	4.23e-7	Alzheimer's disease;
KIRP	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg00204512	chr16:28754710	NA	0.39	5.01	0.3	1.04e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.74	-10.94	-0.57	5.82e-23	Retinal vascular caliber;
KIRP	cis	rs349045	0.560	rs11083725	chr19:44300576	C/T	cg11993925	chr19:44307056	LYPD5	-0.4	-5.44	-0.33	1.26e-7	Reading or mathematical ability;
KIRP	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2274273	0.870	rs3783652	chr14:55854208	A/G	cg04306507	chr14:55594613	LGALS3	0.45	7.09	0.41	1.41e-11	Protein biomarker;
KIRP	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg13482628	chr17:19912719	NA	0.61	8.68	0.48	5.61e-16	Schizophrenia;
KIRP	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg27247782	chr7:158767135	NA	0.4	4.94	0.3	1.46e-6	Facial morphology (factor 20);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11467732	chr10:65225196	JMJD1C;LOC84989	-0.49	-6.24	-0.37	1.95e-9	Migraine with aura;
KIRP	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.4	-0.51	4.06e-18	Mean corpuscular volume;
KIRP	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00889227	chr1:205173544	DSTYK	-0.41	-5.86	-0.35	1.46e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.23	6.11	0.36	3.95e-9	Crohn's disease;
KIRP	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg12692727	chr7:1102344	C7orf50	0.47	5.09	0.31	6.96e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.43	-5.24	-0.32	3.38e-7	Aortic root size;
KIRP	trans	rs4742903	0.935	rs10991165	chr9:106973498	A/G	cg12952552	chr14:68283333	ZFYVE26	0.48	6.24	0.37	1.94e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg08392591	chr16:89556376	ANKRD11	0.44	5.89	0.35	1.26e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs9921338	0.961	rs7193278	chr16:11445831	A/C	cg00044050	chr16:11439710	C16orf75	-0.54	-5.83	-0.35	1.76e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg10760299	chr15:45669010	GATM	0.35	5.11	0.31	6.47e-7	Homoarginine levels;
KIRP	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg00103785	chr1:155043322	NA	-0.3	-5.29	-0.32	2.76e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg24315340	chr6:146058215	EPM2A	0.41	5.28	0.32	2.87e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg20991723	chr1:152506922	NA	-0.45	-5.48	-0.33	1.04e-7	Hair morphology;
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24859484	chr2:174830050	SP3	-0.46	-6.16	-0.37	2.91e-9	Survival in pancreatic cancer;
KIRP	cis	rs806321	0.641	rs806334	chr13:50852240	G/T	cg10393508	chr13:50950265	NA	-0.42	-6.05	-0.36	5.24e-9	Multiple sclerosis;
KIRP	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.88	12.22	0.61	3.7e-27	Schizophrenia;
KIRP	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg00784671	chr22:46762841	CELSR1	-0.59	-6.44	-0.38	6.11e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.59	-5.44	-0.33	1.28e-7	Body mass index;
KIRP	cis	rs10046574	0.519	rs10265128	chr7:135211446	A/G	cg27474649	chr7:135195673	CNOT4	0.55	5.18	0.31	4.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6584283	0.656	rs7080361	chr10:101277772	T/C	cg07044859	chr10:101282883	NA	-0.32	-5.87	-0.35	1.39e-8	Ulcerative colitis;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.71	10.3	0.55	6.24e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg23307798	chr14:103986281	CKB	-0.51	-6.91	-0.4	4.21e-11	Coronary artery disease;
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg12705353	chr12:122356852	WDR66	0.54	7.09	0.41	1.38e-11	Mean corpuscular volume;
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg03653399	chr8:142233436	SLC45A4	-0.93	-14.46	-0.68	1e-34	Immature fraction of reticulocytes;
KIRP	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs6921919	0.551	rs13201753	chr6:28331128	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.39	-5.49	-0.33	9.92e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg04362960	chr10:104952993	NT5C2	-0.53	-6.36	-0.38	9.75e-10	Waist circumference;Hip circumference;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21026553	chr17:21279874	KCNJ12	-0.41	-6.03	-0.36	5.84e-9	Metabolic traits;
KIRP	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.81	10.46	0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs921943	1.000	rs1862228	chr5:78314051	T/C	cg26802063	chr5:78281964	ARSB	0.49	6.11	0.36	3.78e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25939213	chr14:23340606	LRP10	0.52	6.2	0.37	2.42e-9	Smoking initiation;
KIRP	cis	rs6142102	0.961	rs8123521	chr20:32668885	A/C	cg08999081	chr20:33150536	PIGU	0.53	6.29	0.37	1.48e-9	Skin pigmentation;
KIRP	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.66	9.4	0.51	4.03e-18	Retinal vascular caliber;
KIRP	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	7.79	0.44	1.84e-13	Mean corpuscular hemoglobin;
KIRP	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.78	11.32	0.59	3.35e-24	Total body bone mineral density;
KIRP	cis	rs9876781	0.559	rs13073692	chr3:48403302	C/T	cg11946769	chr3:48343235	NME6	0.41	5.12	0.31	6.22e-7	Longevity;
KIRP	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg02491457	chr7:128862824	NA	0.47	5.87	0.35	1.37e-8	White matter hyperintensity burden;
KIRP	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg13198984	chr17:80129470	CCDC57	0.58	8.84	0.49	1.94e-16	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16082166	chr14:89259075	EML5	0.54	6.96	0.41	3.04e-11	Parkinson's disease;
KIRP	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg21419209	chr3:44054225	NA	-0.76	-9.41	-0.51	3.75e-18	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09606734	chr11:47511307	CUGBP1	0.5	6.34	0.37	1.06e-9	Interleukin-4 levels;
KIRP	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.87	-0.45	1.1e-13	Neuroticism;
KIRP	cis	rs4774899	0.966	rs12917247	chr15:57363575	G/C	cg13626582	chr15:57592083	LOC283663	-0.2	-4.91	-0.3	1.68e-6	Urinary tract infection frequency;
KIRP	trans	rs8083850	0.666	rs4278818	chr18:50692978	C/T	cg06213626	chr1:153586168	S100A16	-0.48	-6.45	-0.38	5.84e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg18932078	chr1:2524107	MMEL1	-0.44	-6.02	-0.36	6.38e-9	Ulcerative colitis;
KIRP	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg10295955	chr4:187884368	NA	-1.14	-20.32	-0.79	1.48e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35740288	0.770	rs11631660	chr15:86215412	G/T	cg17133734	chr15:86042851	AKAP13	0.47	5.16	0.31	5.21e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg14664628	chr15:75095509	CSK	-0.56	-6.12	-0.36	3.59e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg13180566	chr4:1052158	NA	-0.47	-5.03	-0.31	9.29e-7	Recombination rate (females);
KIRP	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.29	5.53	0.33	8.07e-8	Monocyte percentage of white cells;
KIRP	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg10503236	chr1:231470652	EXOC8	-0.52	-7.5	-0.43	1.14e-12	Hemoglobin concentration;
KIRP	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.51	5.95	0.35	9.41e-9	Diastolic blood pressure;
KIRP	cis	rs35740288	0.822	rs17637142	chr15:86240503	T/C	cg17133734	chr15:86042851	AKAP13	-0.49	-5.38	-0.32	1.78e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg27490568	chr2:178487706	NA	0.48	6.74	0.39	1.14e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg00656387	chr3:40428638	ENTPD3	0.4	5.15	0.31	5.35e-7	Renal cell carcinoma;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg23985595	chr17:80112537	CCDC57	0.37	5.6	0.34	5.58e-8	Life satisfaction;
KIRP	cis	rs4494114	1.000	rs9438984	chr1:39361615	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-5.14	-0.31	5.64e-7	Blood protein levels;
KIRP	cis	rs1712517	0.838	rs6584543	chr10:104997014	G/A	cg05636881	chr10:105038444	INA	-0.39	-5.86	-0.35	1.45e-8	Migraine;
KIRP	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.94	-13.72	-0.66	3.46e-32	Blood protein levels;
KIRP	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.08	-0.36	4.46e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs6430538	0.671	rs11884708	chr2:135545282	A/C	cg12500956	chr2:135428796	TMEM163	0.43	5.38	0.32	1.76e-7	Parkinson's disease;
KIRP	cis	rs10874312	0.760	rs10782784	chr1:82954830	G/C	cg09892671	chr1:82951578	NA	-0.36	-5.18	-0.31	4.51e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	7.75	0.44	2.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2562456	0.833	rs62109218	chr19:21528861	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg01304814	chr3:48885189	PRKAR2A	0.73	5.61	0.34	5.33e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.61	-6.89	-0.4	4.59e-11	Schizophrenia;
KIRP	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg20387954	chr3:183756860	HTR3D	0.49	6.7	0.39	1.43e-10	Anterior chamber depth;
KIRP	cis	rs829661	0.690	rs10183928	chr2:30798541	G/A	cg10949345	chr2:30726833	LCLAT1	1.13	14.31	0.67	3.43e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs16936870	0.543	rs7015784	chr8:71214283	C/T	cg14232793	chr8:71155543	NCOA2	0.56	6.48	0.38	5.07e-10	QT interval;
KIRP	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.51	6.65	0.39	1.84e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.83	0.45	1.49e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.26	15.58	0.7	1.51e-38	Corneal structure;
KIRP	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.99	17.56	0.75	2.75e-45	Breast cancer;
KIRP	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.62	7.31	0.42	3.76e-12	Bipolar disorder;
KIRP	trans	rs4349753	0.904	rs248578	chr5:144200943	A/G	cg16033277	chr17:80885358	TBCD	0.39	6.1	0.36	4.13e-9	Photic sneeze reflex;
KIRP	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.75	-0.4	1.04e-10	Bipolar disorder;
KIRP	cis	rs6956675	0.958	rs7779974	chr7:62576724	T/C	cg08930214	chr7:62859557	LOC100287834	0.47	5.35	0.32	2.02e-7	Obesity-related traits;
KIRP	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg00012203	chr2:219082015	ARPC2	-0.44	-5.49	-0.33	9.76e-8	Ulcerative colitis;
KIRP	cis	rs11586313	0.571	rs11583382	chr1:152874096	G/A	cg07796016	chr1:152779584	LCE1C	-0.45	-5.52	-0.33	8.67e-8	Vitamin D levels;
KIRP	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.49	5.77	0.35	2.4e-8	Uric acid levels;
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg09597638	chr17:3907349	NA	0.8	16.01	0.71	5.05e-40	Type 2 diabetes;
KIRP	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg05370193	chr1:21551575	ECE1	0.45	5.8	0.35	2.08e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg06212747	chr3:49208901	KLHDC8B	0.58	6.46	0.38	5.63e-10	Menarche (age at onset);
KIRP	trans	rs34112283	0.592	rs13024145	chr2:144251789	T/A	cg18711535	chr15:64736348	TRIP4	0.36	6.03	0.36	6.07e-9	Neuroticism;
KIRP	cis	rs12823128	0.967	rs34963777	chr12:26895351	T/C	cg14081884	chr12:26986758	ITPR2	0.39	4.95	0.3	1.39e-6	Birth weight;
KIRP	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.23	0.37	1.97e-9	Tonsillectomy;
KIRP	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg10434728	chr15:90938212	IQGAP1	0.45	8.66	0.48	6.54e-16	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.38	-0.32	1.75e-7	Colorectal cancer;
KIRP	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg11494091	chr17:61959527	GH2	0.47	5.87	0.35	1.42e-8	Height;
KIRP	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg10326726	chr10:51549505	MSMB	0.65	9.37	0.51	4.95e-18	Prostate-specific antigen levels;
KIRP	cis	rs4474465	0.833	rs6592792	chr11:78271614	A/C	cg27205649	chr11:78285834	NARS2	0.68	6.75	0.4	1.05e-10	Alzheimer's disease (survival time);
KIRP	cis	rs4901847	0.967	rs4901846	chr14:58553582	G/C	cg15908186	chr14:58618357	C14orf37	0.43	5.5	0.33	9.39e-8	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs58649573	0.509	rs4836956	chr9:126788836	C/T	cg14112217	chr9:126806003	NA	0.35	5.07	0.31	7.79e-7	Post-traumatic stress disorder;
KIRP	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg21775007	chr8:11205619	TDH	0.7	9.66	0.52	6.43e-19	Retinal vascular caliber;
KIRP	cis	rs3750082	0.582	rs3750079	chr7:32969419	G/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.46	-5.21	-0.31	4.09e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs7737355	1.000	rs40396	chr5:130708044	C/G	cg06307176	chr5:131281290	NA	-0.53	-5.75	-0.34	2.57e-8	Life satisfaction;
KIRP	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg16141378	chr3:129829833	LOC729375	0.53	6.7	0.39	1.42e-10	Retinal vascular caliber;
KIRP	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	cg04338863	chr8:33670619	NA	0.42	5.45	0.33	1.22e-7	Body mass index;
KIRP	trans	rs6847149	0.789	rs62324954	chr4:110751691	G/A	cg06992324	chr2:122322947	CLASP1	0.53	6.02	0.36	6.3e-9	Exercise treadmill test traits;
KIRP	cis	rs7849270	1.000	rs10760589	chr9:131906293	T/C	cg13538475	chr9:131942899	NA	-0.34	-5.45	-0.33	1.2e-7	Blood metabolite ratios;
KIRP	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.9	-14.21	-0.67	7.08e-34	Systemic lupus erythematosus;
KIRP	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.72	-0.49	4.24e-16	Morning vs. evening chronotype;
KIRP	cis	rs4713675	0.565	rs4713671	chr6:33699899	A/G	cg15676125	chr6:33679581	C6orf125	0.4	5.37	0.32	1.87e-7	Plateletcrit;
KIRP	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9810890	1.000	rs73196979	chr3:128450276	T/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs911119	1.000	rs13038305	chr20:23610262	C/T	cg16589663	chr20:23618590	CST3	0.63	6.14	0.36	3.25e-9	Chronic kidney disease;
KIRP	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.68	8.23	0.46	1.12e-14	Aortic root size;
KIRP	cis	rs867371	1.000	rs11855089	chr15:82447265	T/C	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.79	13.78	0.66	2.08e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg24154853	chr7:158122151	PTPRN2	0.38	5.44	0.33	1.29e-7	Calcium levels;
KIRP	cis	rs11960470	1.000	rs11960470	chr5:50328257	A/C	cg06027927	chr5:50259733	NA	0.54	6.85	0.4	5.75e-11	Breast cancer;
KIRP	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg10756647	chr7:56101905	PSPH	0.98	7.0	0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.76	-5.41	-0.33	1.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2416257	1.000	rs17551370	chr5:110404185	G/A	cg04022379	chr5:110408740	TSLP	-0.53	-4.85	-0.3	2.17e-6	Eosinophil counts;
KIRP	trans	rs7939886	0.920	rs1842675	chr11:56080824	G/C	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg08920773	chr3:38207524	OXSR1	-0.45	-6.6	-0.39	2.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs2120243	0.539	rs2168431	chr3:157120029	A/T	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs10073892	0.789	rs11745781	chr5:101743263	T/C	cg19774478	chr5:101632501	SLCO4C1	0.67	6.48	0.38	5.1e-10	Cognitive decline (age-related);
KIRP	cis	rs41005	1.000	rs42357	chr2:8110896	C/T	cg03155496	chr2:8117019	LOC339788	0.59	9.79	0.53	2.55e-19	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11172967	chr5:122847744	CSNK1G3	-0.46	-6.15	-0.37	3.09e-9	Migraine with aura;
KIRP	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.36	-0.42	2.75e-12	Morning vs. evening chronotype;
KIRP	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg19636519	chr7:99541626	NA	-0.32	-6.08	-0.36	4.56e-9	Coronary artery disease;
KIRP	cis	rs1408799	0.830	rs10960749	chr9:12671566	G/A	cg05274944	chr9:12693694	TYRP1	0.37	5.35	0.32	1.99e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.7	-7.8	-0.45	1.78e-13	Corneal astigmatism;
KIRP	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg21698718	chr17:80085957	CCDC57	0.36	5.36	0.32	1.93e-7	Life satisfaction;
KIRP	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17125944	0.686	rs11157933	chr14:53349798	G/A	cg00686598	chr14:53173677	PSMC6	-0.72	-6.73	-0.39	1.22e-10	Alzheimer's disease (late onset);
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.81	-11.19	-0.58	9.33e-24	Longevity;
KIRP	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg17182837	chr8:41585554	ANK1	-0.48	-6.76	-0.4	1.02e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg13334819	chr7:99746414	C7orf59	-0.52	-5.86	-0.35	1.48e-8	Coronary artery disease;
KIRP	cis	rs7188697	0.922	rs37034	chr16:58551360	C/G	cg21335942	chr16:58549945	SETD6	0.47	5.15	0.31	5.3e-7	QT interval;
KIRP	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg22777020	chr22:31556080	RNF185	-0.5	-5.32	-0.32	2.37e-7	Colorectal cancer;
KIRP	cis	rs7246657	0.551	rs12978093	chr19:37584416	C/T	cg23950597	chr19:37808831	NA	-0.7	-6.07	-0.36	4.73e-9	Coronary artery calcification;
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg17294928	chr15:75287854	SCAMP5	0.57	7.36	0.42	2.71e-12	Caffeine consumption;
KIRP	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.5	-0.33	9.58e-8	Metabolite levels;
KIRP	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.46	-0.43	1.52e-12	Alzheimer's disease (late onset);
KIRP	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg07701084	chr6:150067640	NUP43	0.67	8.54	0.48	1.44e-15	Lung cancer;
KIRP	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.54	0.33	7.96e-8	Educational attainment;
KIRP	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg07382826	chr16:28625726	SULT1A1	0.52	6.23	0.37	2.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg24253500	chr15:84953950	NA	0.66	7.65	0.44	4.67e-13	Schizophrenia;
KIRP	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.61	-0.39	2.31e-10	Recombination measurement;
KIRP	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.52	6.59	0.39	2.64e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.61	-7.22	-0.42	6.36e-12	Mosquito bite size;
KIRP	cis	rs12282928	1.000	rs10838860	chr11:48307374	T/C	cg26585981	chr11:48327164	OR4S1	0.51	6.24	0.37	1.9e-9	Migraine - clinic-based;
KIRP	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.59e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg21851534	chr17:3907994	ZZEF1	0.68	11.04	0.58	2.88e-23	Type 2 diabetes;
KIRP	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs755109	1.000	rs1475696	chr9:100691397	C/T	cg13688889	chr9:100608707	NA	-0.42	-4.92	-0.3	1.62e-6	Quantitative traits;
KIRP	cis	rs7077164	1.000	rs1227769	chr10:71586296	C/T	cg20696214	chr10:71583771	COL13A1	-0.47	-6.64	-0.39	1.96e-10	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.19	-0.37	2.45e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.95	0.41	3.27e-11	Lung cancer;
KIRP	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.17	0.42	8.86e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2274273	0.624	rs8003279	chr14:55864130	A/G	cg04306507	chr14:55594613	LGALS3	0.4	5.35	0.32	2.05e-7	Protein biomarker;
KIRP	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.16	-0.42	9.3e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs231513	0.911	rs124722	chr17:41956002	T/G	cg26893861	chr17:41843967	DUSP3	-0.48	-4.92	-0.3	1.56e-6	Cognitive function;
KIRP	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg13180566	chr4:1052158	NA	-0.51	-5.13	-0.31	5.75e-7	Recombination rate (females);
KIRP	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg08501292	chr6:25962987	TRIM38	1.03	8.19	0.46	1.42e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg02297831	chr4:17616191	MED28	0.52	6.38	0.38	8.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1847505	0.562	rs78216531	chr13:61463118	T/C	cg25164009	chr13:61490935	NA	0.52	5.57	0.33	6.65e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg10223061	chr2:219282414	VIL1	0.31	5.27	0.32	2.93e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs281408	0.559	rs281381	chr19:49214748	C/T	cg13540341	chr19:49222985	MAMSTR	-0.34	-5.7	-0.34	3.42e-8	Urinary metabolites (H-NMR features);
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.4	-0.33	1.59e-7	Bipolar disorder;
KIRP	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg20488157	chr14:104394430	TDRD9	0.77	9.8	0.53	2.35e-19	Bipolar disorder;
KIRP	cis	rs7116495	1.000	rs1939242	chr11:71753582	C/T	cg26138937	chr11:71823887	C11orf51	-0.65	-5.2	-0.31	4.18e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-9.12	-0.5	2.73e-17	Brugada syndrome;
KIRP	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23831021	chr20:57607762	ATP5E	-0.53	-6.7	-0.39	1.39e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-12.62	-0.63	1.68e-28	Alzheimer's disease;
KIRP	cis	rs4523957	0.928	rs403553	chr17:2191260	C/T	cg16513277	chr17:2031491	SMG6	0.6	8.31	0.47	6.59e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg00800038	chr16:89945340	TCF25	-0.69	-5.05	-0.31	8.53e-7	Skin colour saturation;
KIRP	cis	rs8018808	0.905	rs11159259	chr14:77892393	C/T	cg20045696	chr14:77926864	AHSA1	0.45	5.47	0.33	1.12e-7	Myeloid white cell count;
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.69	7.22	0.42	6.28e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3736485	0.966	rs4775961	chr15:51892959	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.15	-0.31	5.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.52	9.03	0.5	5.16e-17	Bone mineral density;
KIRP	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg00343986	chr7:65444356	GUSB	0.5	6.09	0.36	4.43e-9	Aortic root size;
KIRP	cis	rs4740619	0.619	rs10756741	chr9:16041911	A/G	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg21546286	chr11:48923668	NA	0.41	5.04	0.31	8.83e-7	HDL cholesterol;
KIRP	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.87	-11.08	-0.58	2.09e-23	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg21775007	chr8:11205619	TDH	-0.4	-5.07	-0.31	7.72e-7	Neuroticism;
KIRP	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.96	-13.77	-0.66	2.35e-32	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3821902	0.646	rs17344716	chr3:64019744	T/A	cg09006292	chr3:64049408	NA	-0.52	-5.45	-0.33	1.22e-7	Breast cancer;
KIRP	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg21427119	chr20:30132790	HM13	-0.43	-5.14	-0.31	5.63e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.51	-6.69	-0.39	1.51e-10	Multiple sclerosis;
KIRP	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.25	0.32	3.21e-7	Retinal vascular caliber;
KIRP	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.77	-11.02	-0.58	3.15e-23	Height;
KIRP	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	0.86	7.87	0.45	1.11e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.39	0.32	1.65e-7	Breast cancer;
KIRP	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.83	11.79	0.6	9.66e-26	Platelet distribution width;
KIRP	cis	rs6977660	0.507	rs4719580	chr7:19784847	G/T	cg05791153	chr7:19748676	TWISTNB	0.59	6.08	0.36	4.58e-9	Thyroid stimulating hormone;
KIRP	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.29	0.32	2.77e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.6	-6.85	-0.4	5.97e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.2	-0.51	1.57e-17	Morning vs. evening chronotype;
KIRP	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.88	-0.57	8.98e-23	Exhaled nitric oxide output;
KIRP	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	1.05	16.65	0.73	3.48e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10521094	chr7:107262441	BCAP29	-0.49	-6.39	-0.38	8.32e-10	Inflammatory biomarkers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24290546	chr3:150134309	TSC22D2	-0.44	-6.52	-0.38	4e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.95	-0.35	9.4e-9	Glomerular filtration rate;
KIRP	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	10.2	0.55	1.32e-20	Schizophrenia;
KIRP	cis	rs35883536	0.506	rs2809814	chr1:101031829	C/T	cg06223162	chr1:101003688	GPR88	0.45	9.41	0.51	3.73e-18	Monocyte count;
KIRP	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg19847130	chr8:10466454	RP1L1	-0.42	-6.15	-0.37	3.13e-9	Retinal vascular caliber;
KIRP	cis	rs6832769	1.000	rs6853192	chr4:56409254	T/A	cg09317128	chr4:56265301	TMEM165	-0.54	-7.28	-0.42	4.58e-12	Personality dimensions;
KIRP	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg00599163	chr2:162100495	NA	0.44	5.12	0.31	6.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.26	0.32	3.12e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg26876637	chr1:152193138	HRNR	-0.72	-9.53	-0.52	1.61e-18	Atopic dermatitis;
KIRP	cis	rs787274	0.850	rs10739378	chr9:115639631	C/T	cg13803584	chr9:115635662	SNX30	-0.77	-8.23	-0.46	1.07e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg25281562	chr12:121454272	C12orf43	-0.57	-6.39	-0.38	8.2e-10	N-glycan levels;
KIRP	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.55	-0.33	7.51e-8	Pulmonary function;
KIRP	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.66	8.21	0.46	1.23e-14	Iron status biomarkers;
KIRP	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.98e-7	Schizophrenia;
KIRP	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg00262122	chr8:11665843	FDFT1	0.4	4.9	0.3	1.78e-6	Neuroticism;
KIRP	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.72	-11.78	-0.6	1.08e-25	Itch intensity from mosquito bite;
KIRP	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg11906718	chr8:101322791	RNF19A	-0.56	-7.24	-0.42	5.57e-12	Atrioventricular conduction;
KIRP	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-5.25	-0.32	3.21e-7	Skin colour saturation;
KIRP	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	1.01	18.24	0.76	1.34e-47	Heart rate;
KIRP	cis	rs698813	0.604	rs768007	chr2:44487486	G/A	cg04920474	chr2:44395004	PPM1B	0.38	5.16	0.31	5.01e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	trans	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg01620082	chr3:125678407	NA	0.84	6.14	0.36	3.26e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.72	-9.73	-0.53	3.81e-19	Blood metabolite levels;
KIRP	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg21918786	chr6:109611834	NA	-0.39	-5.41	-0.33	1.46e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg11970804	chr8:8084126	NA	0.39	5.11	0.31	6.37e-7	Neuroticism;
KIRP	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.63	6.04	0.36	5.64e-9	Breast cancer;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-0.83	-14.36	-0.68	2.22e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.49	0.52	2.13e-18	Cognitive test performance;
KIRP	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.95	-8.67	-0.48	6.11e-16	Rheumatoid arthritis;
KIRP	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.45	-5.99	-0.36	7.27e-9	Refractive error;
KIRP	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.36	7.04	0.41	1.88e-11	Educational attainment (years of education);
KIRP	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.79	6.69	0.39	1.48e-10	Alzheimer's disease;
KIRP	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.78	0.4	9.11e-11	Menarche (age at onset);
KIRP	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.47	-0.38	5.35e-10	Retinal vascular caliber;
KIRP	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.54	7.39	0.43	2.25e-12	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13782814	chr10:13390289	SEPHS1	0.52	6.6	0.39	2.49e-10	Parkinson's disease;
KIRP	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.63	5.65	0.34	4.51e-8	Menarche (age at onset);
KIRP	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.74	-10.78	-0.57	1.87e-22	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg04374321	chr14:90722782	PSMC1	0.85	13.51	0.65	1.72e-31	Mortality in heart failure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22041590	chr2:158747855	NA	0.47	6.34	0.37	1.09e-9	Interleukin-4 levels;
KIRP	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg03433033	chr1:76189801	ACADM	-0.43	-6.4	-0.38	7.65e-10	Daytime sleep phenotypes;
KIRP	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg06050784	chr16:88016603	BANP	0.4	4.93	0.3	1.53e-6	Menopause (age at onset);
KIRP	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg00806126	chr19:22604979	ZNF98	-0.69	-7.28	-0.42	4.61e-12	Pain;
KIRP	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.6	-7.84	-0.45	1.35e-13	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs8042680	1.000	rs6496743	chr15:91528358	G/A	cg07236925	chr15:91498269	RCCD1	-0.41	-4.93	-0.3	1.55e-6	Type 2 diabetes;
KIRP	cis	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg07460842	chr6:66804631	NA	-0.49	-6.0	-0.36	6.94e-9	Blood trace element (Cu levels);
KIRP	trans	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	9.11	0.5	2.87e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.11	-0.31	6.54e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	0.72	9.65	0.52	6.87e-19	Red blood cell count;
KIRP	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.87	-0.45	1.15e-13	Obesity-related traits;
KIRP	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg09264619	chr17:80180166	NA	-0.52	-5.98	-0.36	7.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	5.39	0.32	1.66e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.03e-9	Depression;
KIRP	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg18694418	chr7:2742484	AMZ1	0.44	4.99	0.3	1.15e-6	Height;
KIRP	cis	rs1413885	0.516	rs3818449	chr1:65844963	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.59	6.52	0.38	3.85e-10	Anticoagulant levels;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.64	-0.39	1.96e-10	Lung cancer;
KIRP	cis	rs12049351	0.722	rs6703347	chr1:229626166	A/T	cg11742688	chr1:229674241	ABCB10	-0.39	-5.8	-0.35	2.04e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.76	-0.44	2.23e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.4	-0.38	7.74e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6681460	0.899	rs502690	chr1:67182403	A/T	cg13052034	chr1:66999238	SGIP1	0.38	5.35	0.32	1.98e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.52	-5.54	-0.33	7.87e-8	Obesity-related traits;
KIRP	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	11.2	0.58	8.69e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11252926	0.603	rs17293419	chr10:537014	G/A	cg08603382	chr10:743973	NA	-0.51	-7.81	-0.45	1.62e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs11225247	0.649	rs11605087	chr11:102225219	C/T	cg06323957	chr11:102217781	BIRC2	0.78	5.02	0.3	1e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg25902810	chr10:99078978	FRAT1	-0.59	-7.11	-0.41	1.28e-11	Monocyte count;
KIRP	cis	rs501120	0.925	rs1657344	chr10:44781234	C/T	cg09554077	chr10:44749378	NA	0.64	7.3	0.42	3.93e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24229701	chr12:130821962	PIWIL1	0.41	5.46	0.33	1.15e-7	Menopause (age at onset);
KIRP	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.92	11.66	0.6	2.7e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg08885076	chr2:99613938	TSGA10	-0.53	-8.97	-0.5	7.61e-17	Chronic sinus infection;
KIRP	cis	rs4356932	0.967	rs9999755	chr4:76961802	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg06521331	chr12:34319734	NA	-0.46	-5.24	-0.32	3.52e-7	Resting heart rate;
KIRP	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg25482853	chr8:67687455	SGK3	0.79	6.99	0.41	2.64e-11	Obesity-related traits;
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg16590910	chr6:42928470	GNMT	0.44	6.1	0.36	4.05e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18023558	chr4:10118459	WDR1	0.44	6.25	0.37	1.83e-9	Survival in pancreatic cancer;
KIRP	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.46	-0.38	5.43e-10	LDL cholesterol levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22920873	chr7:139025153	C7orf55	0.48	6.4	0.38	7.69e-10	Survival in pancreatic cancer;
KIRP	cis	rs1359582	0.836	rs10736360	chr10:90366262	C/G	cg15661332	chr10:90342814	RNLS	0.58	5.97	0.36	8.27e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs9815354	0.951	rs1716674	chr3:41902972	G/C	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.34	-0.37	1.07e-9	Lung cancer;
KIRP	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg05692746	chr2:100937584	LONRF2	-0.39	-4.97	-0.3	1.23e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.36	0.32	1.93e-7	Menopause (age at onset);
KIRP	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs17453880	0.929	rs6860209	chr5:152049547	A/G	cg12297329	chr5:152029980	NA	-0.71	-10.56	-0.56	9.55e-22	Subjective well-being;
KIRP	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.66	8.95	0.5	8.89e-17	Morning vs. evening chronotype;
KIRP	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	6.18	0.37	2.66e-9	Initial pursuit acceleration;
KIRP	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.83	-0.4	6.5500000000000006e-11	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.58	-7.04	-0.41	1.92e-11	Menopause (age at onset);
KIRP	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg05785598	chr3:49045655	WDR6	0.29	5.25	0.32	3.3e-7	Parkinson's disease;
KIRP	cis	rs4663866	0.803	rs71426511	chr2:239180200	G/A	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03570498	chr10:131566727	NA	-0.46	-6.23	-0.37	1.99e-9	Parkinson's disease;
KIRP	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg04657146	chr19:12876947	HOOK2	-0.48	-5.72	-0.34	3.04e-8	Mean corpuscular volume;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg22560979	chr5:10565263	ANKRD33B	0.48	6.28	0.37	1.49e-9	Asthma;
KIRP	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.7	9.02	0.5	5.65e-17	Blood metabolite levels;
KIRP	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.36	-0.32	1.93e-7	Coronary artery disease;
KIRP	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	0.83	6.13	0.36	3.41e-9	IgG glycosylation;
KIRP	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg26248373	chr2:1572462	NA	-0.67	-6.42	-0.38	7.09e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs78487399	0.808	rs75321787	chr2:43843071	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.13	-0.31	5.87e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.6	-5.27	-0.32	2.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9584850	0.540	rs17574536	chr13:99171040	G/A	cg20750642	chr13:99100586	FARP1	-0.53	-5.68	-0.34	3.86e-8	Neuroticism;
KIRP	cis	rs8103278	0.507	rs10415988	chr19:46246704	C/T	cg14061069	chr19:46274453	DMPK	0.68	11.55	0.59	6.08e-25	Coronary artery disease;
KIRP	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg12315302	chr6:26189340	HIST1H4D	0.78	5.35	0.32	1.97e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg24972876	chr7:65420302	NA	0.45	6.39	0.38	8.4e-10	Calcium levels;
KIRP	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.7	5.27	0.32	2.96e-7	Schizophrenia;
KIRP	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.92	12.75	0.63	6.22e-29	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.45	6.42	0.38	6.94e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07147218	chr11:65769464	EIF1AD;BANF1	0.56	6.14	0.36	3.28e-9	Lung cancer in ever smokers;
KIRP	cis	rs1620921	0.505	rs11756434	chr6:161201356	T/C	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.6	8.76	0.49	3.24e-16	Immature fraction of reticulocytes;
KIRP	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg15147215	chr3:52552868	STAB1	-0.31	-5.55	-0.33	7.44e-8	Hemoglobin concentration;
KIRP	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.73	0.34	2.85e-8	Total cholesterol levels;
KIRP	trans	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg16141378	chr3:129829833	LOC729375	0.58	7.87	0.45	1.13e-13	Mood instability;
KIRP	cis	rs3857536	0.704	rs7753493	chr6:66963871	A/G	cg07460842	chr6:66804631	NA	-0.46	-5.48	-0.33	1.07e-7	Blood trace element (Cu levels);
KIRP	cis	rs6732160	0.588	rs11126392	chr2:73374454	A/G	cg01422370	chr2:73384389	NA	0.51	6.92	0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-5.64	-0.34	4.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26462239	chr17:45608823	NPEPPS	-0.45	-6.17	-0.37	2.72e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.84	-8.44	-0.47	2.82e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.65	-10.58	-0.56	8.65e-22	Morning vs. evening chronotype;
KIRP	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg06671706	chr8:8559999	CLDN23	0.52	6.28	0.37	1.55e-9	Obesity-related traits;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.8	-0.4	7.89e-11	Aortic root size;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09672890	chr17:70536484	NA	-0.49	-6.22	-0.37	2.17e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	5.96	0.36	8.85e-9	Menarche (age at onset);
KIRP	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.4	0.33	1.58e-7	Blood protein levels;
KIRP	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.59	7.93	0.45	7.62e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg08662619	chr6:150070041	PCMT1	0.36	6.09	0.36	4.33e-9	Lung cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27505472	chr2:121036705	RALB	0.39	6.08	0.36	4.48e-9	Survival in pancreatic cancer;
KIRP	cis	rs7116495	1.000	rs3886589	chr11:71669487	G/T	cg26138937	chr11:71823887	C11orf51	-0.72	-5.85	-0.35	1.53e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2574975	0.509	rs1210065	chr10:52212789	A/G	cg10034176	chr10:52120283	SGMS1	-0.39	-5.55	-0.33	7.2e-8	Response to amphetamines;
KIRP	cis	rs9653442	1.000	rs1160542	chr2:100832155	A/G	cg07810366	chr2:100720526	AFF3	0.31	5.66	0.34	4.13e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19273316	chr1:228353364	C1orf69	0.46	6.35	0.38	1.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg05692746	chr2:100937584	LONRF2	-0.39	-5.03	-0.31	9.61e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	9.67	0.52	5.8e-19	Cognitive test performance;
KIRP	cis	rs300032	0.570	rs72802568	chr16:86647042	G/C	cg00440195	chr16:86652360	NA	-0.56	-5.5	-0.33	9.74e-8	IgG glycosylation;
KIRP	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg11266682	chr4:10021025	SLC2A9	0.37	5.54	0.33	7.64e-8	Blood metabolite levels;
KIRP	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-4.89	-0.3	1.84e-6	Mean platelet volume;
KIRP	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00653609	chr6:39082964	C6orf64	0.58	6.86	0.4	5.48e-11	Smoking initiation;
KIRP	cis	rs865483	0.764	rs113593735	chr17:35755546	A/G	cg06716730	chr17:35851459	DUSP14	-0.24	-5.52	-0.33	8.4e-8	Monocyte count;
KIRP	cis	rs6725041	0.846	rs10153695	chr2:213067231	G/A	cg20637307	chr2:213403960	ERBB4	-0.41	-5.38	-0.32	1.76e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg14593290	chr7:50529359	DDC	-0.76	-9.42	-0.52	3.34e-18	Malaria;
KIRP	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg08603382	chr10:743973	NA	0.43	6.17	0.37	2.83e-9	Psychosis in Alzheimer's disease;
KIRP	trans	rs7493138	0.967	rs4384536	chr14:28997083	C/A	cg08496086	chr5:2176142	NA	0.45	6.1	0.36	4.14e-9	Longevity;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07898887	chr1:62512893	INADL	0.4	6.23	0.37	1.97e-9	C-reactive protein;
KIRP	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.56	4.87	0.3	2.01e-6	Bipolar disorder;
KIRP	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.41	6.83	0.4	6.77e-11	Huntington's disease progression;
KIRP	cis	rs35883536	1.000	rs11583008	chr1:101085094	A/G	cg06223162	chr1:101003688	GPR88	0.31	6.29	0.37	1.47e-9	Monocyte count;
KIRP	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg13072238	chr3:49761600	GMPPB	-0.6	-5.73	-0.34	2.86e-8	Menarche (age at onset);
KIRP	cis	rs7520050	0.966	rs12021587	chr1:46472759	G/T	cg03146154	chr1:46216737	IPP	-0.42	-5.26	-0.32	3.06e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg12288994	chr5:1860383	NA	0.55	7.57	0.43	7.34e-13	Cardiovascular disease risk factors;
KIRP	cis	rs12311304	1.000	rs12307658	chr12:15388131	A/C	cg08258403	chr12:15378311	NA	0.39	5.77	0.35	2.43e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10517025	0.673	rs73235563	chr4:42431280	G/A	cg13587180	chr4:42403248	SHISA3	0.44	4.99	0.3	1.13e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs72960926	0.744	rs72967284	chr6:75024375	C/T	cg03266952	chr6:74778945	NA	-0.69	-4.96	-0.3	1.33e-6	Metabolite levels (MHPG);
KIRP	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	1.11	15.87	0.71	1.58e-39	Breast cancer;
KIRP	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.48	5.56	0.33	6.95e-8	Glycated hemoglobin levels;
KIRP	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg12140854	chr5:148520817	ABLIM3	0.44	4.87	0.3	1.97e-6	Breast cancer;
KIRP	trans	rs12659622	0.764	rs1582998	chr5:15611504	C/T	cg09887955	chr1:202129854	PTPN7	0.52	6.08	0.36	4.51e-9	Obesity-related traits;
KIRP	cis	rs12643440	0.718	rs515956	chr4:17142835	C/T	cg22650099	chr4:17144496	NA	0.51	7.08	0.41	1.54e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg27205649	chr11:78285834	NARS2	-0.52	-5.9	-0.35	1.2e-8	Testicular germ cell tumor;
KIRP	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg04935436	chr20:30431758	NA	0.53	6.52	0.38	4.05e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4664293	0.836	rs7567818	chr2:160602697	C/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.92	10.68	0.56	4.13e-22	Neuroticism;
KIRP	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.8	-9.03	-0.5	5.01e-17	Hirschsprung disease;
KIRP	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	5.0	0.3	1.1e-6	Menarche (age at onset);
KIRP	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.66	9.09	0.5	3.29e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25951256	chr10:38645740	HSD17B7P2	-0.41	-4.92	-0.3	1.6e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12071656	chr20:44642570	MMP9	0.46	6.9	0.4	4.4e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg04310649	chr10:35416472	CREM	-0.5	-5.86	-0.35	1.46e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg22764044	chr5:178986830	RUFY1	0.46	6.63	0.39	2.16e-10	Lung cancer;
KIRP	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg24747557	chr10:131355152	MGMT	-0.42	-5.65	-0.34	4.47e-8	Response to temozolomide;
KIRP	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg03714773	chr7:91764589	CYP51A1	-0.34	-5.13	-0.31	5.85e-7	Breast cancer;
KIRP	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg24488311	chr11:68621650	NA	0.41	5.08	0.31	7.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-11.97	-0.61	2.57e-26	Total body bone mineral density;
KIRP	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.51	-6.68	-0.39	1.61e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg07701084	chr6:150067640	NUP43	0.62	8.18	0.46	1.49e-14	Lung cancer;
KIRP	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-6.06	-0.36	5.21e-9	Colorectal cancer;
KIRP	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg01236616	chr12:121019343	POP5	-1.27	-15.31	-0.7	1.24e-37	Type 1 diabetes nephropathy;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14146148	chr9:131302123	GLE1	0.46	6.62	0.39	2.3e-10	Survival in pancreatic cancer;
KIRP	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.71	9.81	0.53	2.14e-19	Caffeine consumption;
KIRP	trans	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg10756647	chr7:56101905	PSPH	-0.96	-6.72	-0.39	1.25e-10	Diabetic kidney disease;
KIRP	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg15660573	chr17:549704	VPS53	0.5	6.41	0.38	7.37e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.33	5.81	0.35	1.93e-8	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.54	0.59	6.69e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.53	-0.33	8.3e-8	Total body bone mineral density;
KIRP	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg05340658	chr4:99064831	C4orf37	0.49	5.52	0.33	8.45e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7939886	0.920	rs11227670	chr11:56026737	A/C	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.42	5.41	0.33	1.47e-7	Aortic root size;
KIRP	cis	rs10875746	0.551	rs10875799	chr12:48740879	C/A	cg26205652	chr12:48591994	NA	0.79	10.08	0.54	3.07e-20	Longevity (90 years and older);
KIRP	cis	rs3784262	0.669	rs7178598	chr15:58309016	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.87	-0.3	2.04e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.59	7.85	0.45	1.3e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20470467	chr16:30886130	NA	0.54	6.3	0.37	1.33e-9	Smoking initiation;
KIRP	cis	rs1134634	0.520	rs4280723	chr4:15575718	C/G	cg16509355	chr4:15471240	CC2D2A	0.31	5.38	0.32	1.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	0.88	7.26	0.42	4.97e-12	Thyroid stimulating hormone;
KIRP	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	0.82	8.09	0.46	2.65e-14	Mitochondrial DNA levels;
KIRP	cis	rs7923609	1.000	rs1935	chr10:64927823	C/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.67	-0.34	4.07e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2908197	0.663	rs7802264	chr7:75985782	T/C	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.29	-4.88	-0.3	1.94e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.4	-0.38	7.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg00405596	chr8:11794950	NA	-0.44	-5.82	-0.35	1.79e-8	Triglycerides;
KIRP	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg25173405	chr17:45401733	C17orf57	-0.38	-4.91	-0.3	1.68e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.5	-6.47	-0.38	5.4e-10	Corneal astigmatism;
KIRP	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg17524265	chr8:144659883	NAPRT1	0.83	5.36	0.32	1.88e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-8.68	-0.48	5.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg14664628	chr15:75095509	CSK	-0.56	-6.25	-0.37	1.78e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg01411142	chr8:19674711	INTS10	0.45	4.94	0.3	1.43e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10818894	0.611	rs10117455	chr9:126692599	G/T	cg16191174	chr9:126692580	DENND1A	0.71	8.9	0.49	1.25e-16	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
KIRP	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	0.49	5.54	0.33	7.73e-8	Monocyte percentage of white cells;
KIRP	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08448040	chr3:13521693	HDAC11	0.55	6.54	0.38	3.45e-10	Smoking initiation;
KIRP	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.4	-4.96	-0.3	1.31e-6	Blood protein levels;
KIRP	cis	rs629922	0.533	rs643123	chr11:114065457	C/T	cg01914181	chr11:114070210	ZBTB16	-0.55	-5.55	-0.33	7.33e-8	Paneth cell defects in Crohn's disease;
KIRP	cis	rs7760535	0.811	rs7764591	chr6:111783414	G/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.56	-0.33	7.03e-8	Metabolic traits;
KIRP	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	6.1	0.36	4.04e-9	Menopause (age at onset);
KIRP	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.48	-0.33	1.05e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg24315340	chr6:146058215	EPM2A	-0.43	-5.45	-0.33	1.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4761097	0.620	rs1947350	chr12:85228470	A/G	cg00765312	chr12:85674694	ALX1	0.51	6.0	0.36	7.11e-9	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.65	-8.78	-0.49	2.9e-16	Paraoxonase activity;
KIRP	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg00631329	chr6:26305371	NA	-0.54	-6.89	-0.4	4.52e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg17385448	chr1:15911702	AGMAT	0.25	4.85	0.3	2.24e-6	Systolic blood pressure;
KIRP	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.92	9.13	0.5	2.52e-17	Lymphocyte counts;
KIRP	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	0.45	6.15	0.37	3.04e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg18882449	chr10:104885122	NT5C2	-0.4	-5.08	-0.31	7.45e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg14703610	chr5:56206110	C5orf35	-0.48	-6.29	-0.37	1.46e-9	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	0.83	9.05	0.5	4.46e-17	Gut microbiome composition (summer);
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.18	-22.08	-0.82	2.69e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg05044414	chr3:183734942	ABCC5	0.38	5.8	0.35	2.07e-8	Anterior chamber depth;
KIRP	cis	rs9290877	0.637	rs9290879	chr3:188450208	A/G	cg17392043	chr3:188495102	LPP	-0.51	-6.2	-0.37	2.37e-9	IgE levels;
KIRP	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg07862535	chr7:139043722	LUC7L2	0.48	5.41	0.33	1.46e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg07414643	chr4:187882934	NA	-0.4	-5.24	-0.32	3.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.02	0.36	6.24e-9	Height;
KIRP	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg10326726	chr10:51549505	MSMB	0.56	7.96	0.45	6.4e-14	Prostate-specific antigen levels;
KIRP	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg03060546	chr3:49711283	APEH	-0.66	-6.99	-0.41	2.52e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14387428	chr11:118023538	SCN4B	0.56	7.53	0.43	9.52e-13	Parkinson's disease;
KIRP	cis	rs2708977	0.965	rs13019986	chr2:97243058	C/T	cg01950434	chr2:97203154	ARID5A	0.54	6.71	0.39	1.37e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.46	6.37	0.38	9.14e-10	Childhood ear infection;
KIRP	cis	rs240764	0.555	rs11967951	chr6:101231905	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.22	0.32	3.85e-7	Neuroticism;
KIRP	trans	rs12709013	0.591	rs4784986	chr16:58836911	A/G	cg12115882	chr11:133449267	NA	-0.46	-6.56	-0.39	3.12e-10	Blood metabolite ratios;
KIRP	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.87	-0.57	9.52e-23	Height;
KIRP	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.77	9.47	0.52	2.4e-18	Migraine;Coronary artery disease;
KIRP	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.64	-8.89	-0.49	1.32e-16	Breast cancer;
KIRP	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	0.67	5.72	0.34	3.02e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.97	0.54	6.75e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg09165964	chr15:75287851	SCAMP5	0.5	6.65	0.39	1.89e-10	Breast cancer;
KIRP	cis	rs28669119	0.555	rs17485836	chr5:88065130	C/T	cg24804195	chr5:87968844	LOC645323	0.74	5.26	0.32	3.14e-7	Schizophrenia;
KIRP	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.63	7.28	0.42	4.42e-12	Subjective well-being;
KIRP	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.84	9.13	0.5	2.51e-17	Chronic sinus infection;
KIRP	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.0	-0.36	6.88e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.77	9.79	0.53	2.61e-19	Coronary artery disease;
KIRP	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg18305652	chr10:134549665	INPP5A	0.46	7.14	0.41	1.06e-11	Migraine;
KIRP	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.55	7.37	0.43	2.56e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.59	-8.44	-0.47	2.76e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.54	0.56	1.11e-21	Morning vs. evening chronotype;
KIRP	cis	rs12049351	0.719	rs34804247	chr1:229620685	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.57	-0.33	6.58e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg00074818	chr8:8560427	CLDN23	-0.28	-4.97	-0.3	1.25e-6	Neuroticism;
KIRP	cis	rs7127900	0.583	rs67186729	chr11:2233549	T/C	cg25635251	chr11:2234043	NA	0.44	6.97	0.41	2.85e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.72	-12.98	-0.64	1.09e-29	Body mass index;
KIRP	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05220968	chr6:146057943	EPM2A	-0.39	-5.0	-0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.25	-0.55	9.2e-21	Schizophrenia;
KIRP	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.58	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09251477	chr11:126173810	DCPS	0.44	6.05	0.36	5.4e-9	Survival in pancreatic cancer;
KIRP	cis	rs79881201	0.825	rs12186767	chr5:110471218	A/G	cg04022379	chr5:110408740	TSLP	-0.5	-6.03	-0.36	5.84e-9	Sum eosinophil basophil counts;
KIRP	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg09795085	chr6:101329169	ASCC3	0.49	5.78	0.35	2.3e-8	Neuroticism;
KIRP	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg16898833	chr6:26189333	HIST1H4D	0.73	5.08	0.31	7.59e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7267005	0.661	rs2425135	chr20:34341654	A/G	cg17201900	chr20:34330562	RBM39	0.95	5.54	0.33	7.71e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-8.8	-0.49	2.42e-16	Coronary artery disease;
KIRP	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18364779	chr6:26104403	HIST1H4C	0.41	5.32	0.32	2.34e-7	Schizophrenia;
KIRP	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg18016565	chr1:150552671	MCL1	0.42	6.11	0.36	3.77e-9	Melanoma;
KIRP	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg15660573	chr17:549704	VPS53	0.56	7.09	0.41	1.38e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.55	7.33	0.42	3.37e-12	Mean corpuscular volume;
KIRP	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.94	0.54	8.79e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6772849	0.930	rs9813197	chr3:128369104	G/A	cg08795948	chr3:128337044	NA	0.47	6.02	0.36	6.26e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg24807547	chr6:37504484	NA	-0.53	-7.53	-0.43	9.67e-13	Cognitive performance;
KIRP	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.58	-8.41	-0.47	3.42e-15	Blood metabolite levels;
KIRP	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	1.03	19.67	0.78	2.19e-52	Birth weight;
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg23736307	chr8:27182930	PTK2B	0.55	7.04	0.41	1.9e-11	Neuroticism;
KIRP	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.83	0.66	1.46e-32	Electrocardiographic conduction measures;
KIRP	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	7.69	0.44	3.44e-13	Multiple sclerosis;
KIRP	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg20387954	chr3:183756860	HTR3D	0.47	6.61	0.39	2.39e-10	Anterior chamber depth;
KIRP	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.91	-14.03	-0.67	3.02e-33	Height;
KIRP	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs7671900	0.625	rs12643799	chr4:88260263	A/G	cg23841344	chr4:88312519	HSD17B11	-0.43	-5.56	-0.33	7.18e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs4253772	0.688	rs113928699	chr22:46649344	G/A	cg00784671	chr22:46762841	CELSR1	-0.64	-6.68	-0.39	1.56e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.39	5.01	0.3	1.05e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03045067	chr16:72819254	ZFHX3	-0.42	-6.44	-0.38	6.3e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.38	-0.32	1.77e-7	Life satisfaction;
KIRP	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.83	9.01	0.5	6.01e-17	Prostate cancer;
KIRP	cis	rs9788682	0.948	rs28498264	chr15:78837673	C/T	cg06917634	chr15:78832804	PSMA4	-0.62	-6.58	-0.39	2.8e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23690785	chr4:130030465	C4orf33	-0.44	-6.76	-0.4	1.02e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.84e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg18586891	chr4:952366	TMEM175	0.58	4.97	0.3	1.24e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1847202	1.000	rs11918615	chr3:72942407	T/C	cg06781948	chr3:72941472	GXYLT2	0.4	5.39	0.32	1.68e-7	Motion sickness;
KIRP	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs10486003	1.000	rs10486003	chr7:97229778	A/G	cg05663341	chr7:96634660	DLX6AS;DLX6	0.62	4.99	0.3	1.16e-6	Response to platinum-based agents;
KIRP	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg07596299	chr11:71824057	C11orf51	-0.84	-5.63	-0.34	5.01e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg09571762	chr12:39539558	NA	0.33	4.87	0.3	1.98e-6	Morning vs. evening chronotype;
KIRP	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22117172	chr7:91764530	CYP51A1	0.45	6.18	0.37	2.63e-9	Breast cancer;
KIRP	trans	rs1941687	0.831	rs12957087	chr18:31328519	C/T	cg27147174	chr7:100797783	AP1S1	-0.58	-7.16	-0.42	9.06e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs11997175	0.545	rs66584807	chr8:33667609	A/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.01	0.36	6.81e-9	Body mass index;
KIRP	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg04935436	chr20:30431758	NA	0.45	4.84	0.3	2.25e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs62012628	0.527	rs6495329	chr15:79092603	G/A	cg22753661	chr15:79092743	ADAMTS7	-0.48	-5.41	-0.33	1.46e-7	Diastolic blood pressure;
KIRP	cis	rs8070740	0.947	rs3809842	chr17:5329199	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.38	0.43	2.45e-12	Menopause (age at onset);
KIRP	cis	rs4722166	0.532	rs4719713	chr7:22758811	G/A	cg05472934	chr7:22766657	IL6	0.53	6.71	0.39	1.34e-10	Lung cancer;
KIRP	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.7	9.78	0.53	2.7e-19	Schizophrenia;
KIRP	cis	rs675026	0.927	rs548646	chr6:154418147	A/G	cg07813322	chr6:154414604	OPRM1	-0.52	-6.83	-0.4	6.72e-11	Hypertension;
KIRP	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg08847533	chr14:75593920	NEK9	0.52	6.22	0.37	2.14e-9	IgG glycosylation;
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.62	8.41	0.47	3.31e-15	Mean corpuscular volume;
KIRP	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.65	-9.14	-0.5	2.41e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2688608	0.698	rs2633323	chr10:75694826	G/A	cg23231163	chr10:75533350	FUT11	-0.34	-4.98	-0.3	1.22e-6	Inflammatory bowel disease;
KIRP	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg05082376	chr22:42548792	NA	-0.45	-5.84	-0.35	1.68e-8	Schizophrenia;
KIRP	cis	rs3762637	0.943	rs9289199	chr3:122277172	G/A	cg24169773	chr3:122142474	KPNA1	-0.58	-5.98	-0.36	7.92e-9	LDL cholesterol levels;
KIRP	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.62	-7.19	-0.42	7.95e-12	Neutrophil percentage of white cells;
KIRP	cis	rs787274	1.000	rs7868830	chr9:115577125	G/A	cg13803584	chr9:115635662	SNX30	-0.73	-8.23	-0.46	1.1e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg08755490	chr11:65554678	OVOL1	0.37	5.26	0.32	3.11e-7	Acne (severe);
KIRP	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	17.01	0.74	1.96e-43	Height;
KIRP	trans	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.33e-11	Morning vs. evening chronotype;
KIRP	cis	rs2273669	0.667	rs6918331	chr6:109317394	C/G	cg05315195	chr6:109294784	ARMC2	-0.62	-6.19	-0.37	2.5e-9	Prostate cancer;
KIRP	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg23100626	chr2:96804247	ASTL	-0.48	-6.57	-0.39	3.02e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.82	-9.25	-0.51	1.1e-17	Parkinson's disease;
KIRP	cis	rs7546668	1.000	rs2295626	chr1:15874961	T/A	cg21858823	chr1:15850916	CASP9	0.48	5.33	0.32	2.24e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.86	0.4	5.41e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-8.59	-0.48	1.01e-15	Triglycerides;
KIRP	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.83	-8.0	-0.45	4.95e-14	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg08873628	chr1:175162347	KIAA0040	-0.39	-5.77	-0.35	2.43e-8	Alcohol dependence;
KIRP	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg22223119	chr13:99095684	FARP1	-0.52	-6.0	-0.36	7.18e-9	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-6.41	-0.38	7.24e-10	Personality dimensions;
KIRP	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.5	6.54	0.38	3.5e-10	Blood protein levels;
KIRP	cis	rs1816752	0.777	rs6490915	chr13:24987862	G/C	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg13160058	chr8:26243215	BNIP3L	-0.41	-5.81	-0.35	1.91e-8	Red cell distribution width;
KIRP	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.94	11.08	0.58	2.1e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.58	-7.43	-0.43	1.84e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.35	5.28	0.32	2.87e-7	Headache;
KIRP	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg04025307	chr7:1156635	C7orf50	0.57	5.69	0.34	3.51e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-5.97	-0.36	8.4e-9	Response to antipsychotic treatment;
KIRP	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.83	11.18	0.58	9.56e-24	Morning vs. evening chronotype;
KIRP	cis	rs7674212	0.541	rs2720460	chr4:104054686	C/T	cg16532752	chr4:104119610	CENPE	0.43	5.28	0.32	2.91e-7	Type 2 diabetes;
KIRP	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21385522	chr1:16154831	NA	0.45	5.58	0.33	6.49e-8	Systolic blood pressure;
KIRP	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg21427119	chr20:30132790	HM13	-0.56	-6.46	-0.38	5.58e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg15147215	chr3:52552868	STAB1	-0.35	-6.26	-0.37	1.7e-9	Electroencephalogram traits;
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.46	0.7	3.94e-38	Platelet count;
KIRP	cis	rs6691722	0.503	rs3765431	chr1:24706410	T/C	cg18323236	chr1:24743029	NIPAL3	0.46	6.57	0.39	3e-10	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg07636037	chr3:49044803	WDR6	-0.77	-7.33	-0.42	3.35e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-1.04	-18.81	-0.77	1.66e-49	Systemic lupus erythematosus;
KIRP	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.5	-0.33	9.34e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7173743	0.525	rs7403438	chr15:79136048	C/T	cg00079375	chr15:79125835	NA	0.4	5.61	0.34	5.33e-8	Coronary artery disease;
KIRP	cis	rs7209700	0.788	rs12949936	chr17:45372422	A/G	cg25173405	chr17:45401733	C17orf57	0.42	4.93	0.3	1.53e-6	IgG glycosylation;
KIRP	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg26205652	chr12:48591994	NA	0.77	10.4	0.55	3.07e-21	Longevity (90 years and older);
KIRP	trans	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg10756647	chr7:56101905	PSPH	0.96	6.72	0.39	1.25e-10	Diabetic kidney disease;
KIRP	trans	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs14057	0.965	rs2294526	chr1:6735702	C/A	cg27299712	chr1:6550532	PLEKHG5	0.4	5.07	0.31	7.7e-7	Systolic blood pressure;
KIRP	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg04374321	chr14:90722782	PSMC1	0.5	5.45	0.33	1.24e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07308232	chr7:1071921	C7orf50	-0.72	-8.97	-0.5	7.97e-17	Longevity;Endometriosis;
KIRP	cis	rs7640424	0.649	rs11917909	chr3:107864673	G/A	cg09227934	chr3:107805635	CD47	-0.34	-5.97	-0.36	8.12e-9	Body mass index;
KIRP	cis	rs35000415	0.872	rs2070197	chr7:128589000	T/C	cg19972273	chr7:128594194	NA	0.85	6.25	0.37	1.81e-9	Systemic lupus erythematosus;
KIRP	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.94	16.06	0.72	3.55e-40	Bone mineral density;
KIRP	cis	rs17123764	0.710	rs1470906	chr12:50146055	G/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.93	0.3	1.48e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.45	5.74	0.34	2.73e-8	HDL cholesterol;
KIRP	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.03	0.46	4.12e-14	Morning vs. evening chronotype;
KIRP	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25597177	chr13:22239929	NA	-0.4	-6.03	-0.36	5.88e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.68	9.38	0.51	4.59e-18	Coronary artery disease;
KIRP	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs6504622	0.875	rs3851786	chr17:45046932	A/G	cg24703533	chr17:45055318	NA	0.39	5.45	0.33	1.23e-7	Orofacial clefts;
KIRP	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg06259664	chr16:537672	RAB11FIP3	0.73	11.13	0.58	1.42e-23	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-0.62	-6.81	-0.4	7.24e-11	Initial pursuit acceleration;
KIRP	cis	rs9359856	0.636	rs9344946	chr6:90298371	T/G	cg13799429	chr6:90582589	CASP8AP2	0.57	6.15	0.36	3.16e-9	Bipolar disorder;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg02733842	chr7:1102375	C7orf50	0.43	5.09	0.31	7.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg05347473	chr6:146136440	FBXO30	0.65	9.53	0.52	1.59e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg06289844	chr6:126071538	HEY2	0.34	4.91	0.3	1.69e-6	Brugada syndrome;
KIRP	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg22705602	chr4:152727874	NA	-0.61	-9.06	-0.5	4.31e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg06871246	chr4:1363661	KIAA1530	0.56	7.01	0.41	2.33e-11	Longevity;
KIRP	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg01620082	chr3:125678407	NA	-1.18	-7.43	-0.43	1.79e-12	Depression;
KIRP	cis	rs16854884	0.657	rs35796781	chr3:143731662	T/C	cg06585982	chr3:143692056	C3orf58	0.58	7.53	0.43	9.84e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs9409565	0.826	rs9409778	chr9:97242839	G/A	cg04523069	chr9:97136363	HIATL1	0.5	6.7	0.39	1.37e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21972741	chr5:435613	AHRR	0.53	7.04	0.41	1.88e-11	Cystic fibrosis severity;
KIRP	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.68	-8.07	-0.46	3.17e-14	Blood protein levels;
KIRP	trans	rs3800131	0.723	rs1570536	chr6:1962493	T/C	cg17165055	chr3:192584827	C3orf59	0.47	6.46	0.38	5.51e-10	Obesity-related traits;
KIRP	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.55	5.76	0.34	2.5e-8	Type 2 diabetes;
KIRP	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.43	5.91	0.35	1.11e-8	Monocyte count;
KIRP	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.95	0.57	5.5e-23	Personality dimensions;
KIRP	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg00933542	chr6:150070202	PCMT1	0.26	4.98	0.3	1.2e-6	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.71	0.34	3.26e-8	Lung cancer;
KIRP	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.15e-7	Aortic root size;
KIRP	cis	rs33912345	0.695	rs1254315	chr14:60896779	C/T	cg27398547	chr14:60952738	C14orf39	-0.42	-5.59	-0.34	5.96e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.81	-11.39	-0.59	1.99e-24	Eye color traits;
KIRP	cis	rs9547996	0.879	rs17258466	chr13:38194065	A/G	cg13634560	chr13:38173852	POSTN	-0.39	-5.47	-0.33	1.08e-7	Diastolic blood pressure;
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.43	9.25	0.51	1.09e-17	Vitiligo;
KIRP	cis	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg06066596	chr15:83166174	LOC80154	-0.44	-6.02	-0.36	6.24e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05902997	chr5:65440515	SFRS12	0.51	6.54	0.38	3.6e-10	Parkinson's disease;
KIRP	cis	rs16936870	0.516	rs4236984	chr8:71139352	G/A	cg14232793	chr8:71155543	NCOA2	-0.58	-6.82	-0.4	7.07e-11	QT interval;
KIRP	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.31	-0.32	2.49e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7894051	1.000	rs7894051	chr10:135184421	C/G	cg20534287	chr10:135191450	PAOX	-0.51	-6.51	-0.38	4.08e-10	Lifespan;
KIRP	cis	rs13095912	1.000	rs13340181	chr3:185325612	T/C	cg11274856	chr3:185301563	NA	0.53	6.89	0.4	4.61e-11	Systolic blood pressure;
KIRP	cis	rs1832871	0.672	rs11751081	chr6:158761505	G/A	cg07215822	chr6:158701037	NA	-0.64	-7.4	-0.43	2.13e-12	Height;
KIRP	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-9.64	-0.52	7.49e-19	Primary sclerosing cholangitis;
KIRP	cis	rs11138902	0.673	rs11139228	chr9:72156200	G/A	cg14123607	chr9:72164709	APBA1	-0.41	-5.0	-0.3	1.11e-6	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.37	-7.71	-0.44	3.1400000000000003e-13	IgG glycosylation;
KIRP	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.91	13.71	0.66	3.79e-32	Mean platelet volume;
KIRP	cis	rs877426	0.681	rs113130895	chr13:114806184	C/T	cg00571178	chr13:114841904	RASA3	-0.52	-5.52	-0.33	8.62e-8	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs2274273	0.901	rs7147136	chr14:55826688	G/C	cg04306507	chr14:55594613	LGALS3	0.4	5.89	0.35	1.23e-8	Protein biomarker;
KIRP	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg16325326	chr1:53192061	ZYG11B	0.74	8.82	0.49	2.09e-16	Monocyte count;
KIRP	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg19468946	chr17:37922297	IKZF3	-0.39	-5.35	-0.32	2.05e-7	Asthma;
KIRP	cis	rs16958440	0.581	rs11875768	chr18:44689360	T/G	cg17192377	chr18:44677553	HDHD2	0.65	6.32	0.37	1.22e-9	Sitting height ratio;
KIRP	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.08e-6	Bladder cancer;
KIRP	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.44	5.43	0.33	1.38e-7	Kawasaki disease;
KIRP	trans	rs10936632	0.565	rs9865021	chr3:170146881	C/T	cg25378003	chr6:41472488	NA	0.41	6.31	0.37	1.26e-9	Prostate cancer;
KIRP	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	1.03	19.21	0.77	7.12e-51	Height;
KIRP	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg16141378	chr3:129829833	LOC729375	0.48	6.23	0.37	2.01e-9	Retinal vascular caliber;
KIRP	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.67	-10.03	-0.54	4.66e-20	Pulse pressure;
KIRP	cis	rs2441986	0.929	rs2867031	chr11:57921577	G/C	cg19752551	chr11:57585705	CTNND1	-0.44	-5.31	-0.32	2.49e-7	Systolic blood pressure;
KIRP	cis	rs7809615	0.901	rs13243267	chr7:99053314	C/G	cg24024660	chr7:99195788	NA	0.58	5.42	0.33	1.39e-7	Blood metabolite ratios;
KIRP	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	0.69	9.64	0.52	7.11e-19	Cognitive test performance;
KIRP	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.01e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.44	-5.7	-0.34	3.46e-8	Body mass index;
KIRP	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.74	-8.83	-0.49	2e-16	Platelet distribution width;
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.77	10.43	0.55	2.45e-21	Longevity;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg23736307	chr8:27182930	PTK2B	0.55	7.07	0.41	1.58e-11	Neuroticism;
KIRP	cis	rs4523957	0.690	rs11867782	chr17:2090507	T/G	cg16513277	chr17:2031491	SMG6	-0.78	-11.41	-0.59	1.7e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg21775007	chr8:11205619	TDH	0.41	5.02	0.3	1.01e-6	Neuroticism;
KIRP	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.97	-0.5	7.57e-17	Hirschsprung disease;
KIRP	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26769984	chr7:1090371	C7orf50	0.68	6.97	0.41	2.92e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg17595323	chr11:93583763	C11orf90	-0.33	-5.41	-0.33	1.52e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg16497661	chr14:103986332	CKB	0.77	11.61	0.59	3.86e-25	Body mass index;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.52	-0.33	8.43e-8	Life satisfaction;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02233558	chr5:127418922	SLC12A2;FLJ33630	0.55	6.4	0.38	7.83e-10	Smoking initiation;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg27532560	chr4:187881888	NA	0.75	12.97	0.64	1.13e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.01	0.67	3.42e-33	Chronic sinus infection;
KIRP	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.89	0.57	8.39e-23	Lung cancer in ever smokers;
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21171335	chr12:122356390	WDR66	0.5	6.59	0.39	2.6e-10	Mean corpuscular volume;
KIRP	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.73	-0.39	1.19e-10	Type 2 diabetes;
KIRP	cis	rs7929679	0.571	rs11032860	chr11:34799345	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.36e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs36715	1.000	rs181850	chr5:127547487	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.86	0.49	1.63e-16	Breast cancer;
KIRP	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.71	10.07	0.54	3.29e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04824469	chr14:41469306	NA	-0.51	-7.6	-0.44	6.33e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs600806	0.778	rs4970765	chr1:110009171	C/T	cg02175308	chr1:109941060	SORT1	-0.26	-4.87	-0.3	2.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	0.950	rs6756885	chr2:73805172	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.71	-0.34	3.33e-8	Metabolite levels;
KIRP	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.57	-7.53	-0.43	9.74e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00321850	chr1:175162397	KIAA0040	-0.34	-6.25	-0.37	1.76e-9	Alcohol dependence;
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg26516362	chr5:178986906	RUFY1	0.48	8.53	0.48	1.56e-15	Lung cancer;
KIRP	cis	rs4699052	0.963	rs56144793	chr4:104150653	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-5.19	-0.31	4.3e-7	Testicular germ cell tumor;
KIRP	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg00864860	chr1:7907996	UTS2	-0.51	-6.03	-0.36	6.11e-9	Crohn's disease;
KIRP	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.91	14.89	0.69	3.59e-36	Breast cancer;
KIRP	cis	rs1045902	0.967	rs1469530	chr2:73464948	C/T	cg01422370	chr2:73384389	NA	0.43	5.68	0.34	3.77e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs965513	1.000	rs10739496	chr9:100552559	C/T	cg13688889	chr9:100608707	NA	-0.59	-7.44	-0.43	1.67e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19500275	chr17:80737654	TBCD	0.46	5.5	0.33	9.43e-8	Glycated hemoglobin levels;
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg00656387	chr3:40428638	ENTPD3	-0.36	-4.92	-0.3	1.59e-6	Renal cell carcinoma;
KIRP	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.65	-8.41	-0.47	3.31e-15	Prudent dietary pattern;
KIRP	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.13	23.66	0.83	2.55e-65	Testicular germ cell tumor;
KIRP	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.15	-0.41	9.87e-12	Monocyte count;
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-5.98	-0.36	7.69e-9	Lung cancer;
KIRP	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.86	0.57	1.06e-22	Lung cancer in ever smokers;
KIRP	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	7.89	0.45	9.64e-14	Height;
KIRP	cis	rs78487399	0.808	rs13419380	chr2:43739184	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.86	-0.3	2.11e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg14972814	chr11:95582409	MTMR2	0.3	5.16	0.31	5e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7582180	0.629	rs11895772	chr2:100938917	G/C	cg14675211	chr2:100938903	LONRF2	0.61	8.25	0.47	9.39e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs1318772	0.932	rs7703186	chr5:112907867	C/A	cg12552261	chr5:112820674	MCC	0.81	5.64	0.34	4.62e-8	F-cell distribution;
KIRP	cis	rs7463659	0.512	rs62524716	chr8:135450378	A/G	cg09855544	chr8:135498122	ZFAT	-0.42	-4.98	-0.3	1.18e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.63	7.26	0.42	5.03e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.51	7.24	0.42	5.71e-12	Schizophrenia;
KIRP	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.72	8.26	0.47	9.22e-15	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.82	9.56	0.52	1.24e-18	Gestational age at birth (maternal effect);
KIRP	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.52	-6.89	-0.4	4.68e-11	Blood metabolite levels;
KIRP	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08439880	chr3:133502540	NA	-0.51	-6.31	-0.37	1.28e-9	Iron status biomarkers;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg22325292	chr17:80708367	FN3K	0.4	5.29	0.32	2.66e-7	Glycated hemoglobin levels;
KIRP	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.43	-0.38	6.7e-10	LDL cholesterol levels;
KIRP	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg12480562	chr20:23434244	CST11	0.58	5.68	0.34	3.77e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14870128	chr10:70931312	VPS26A	0.53	7.61	0.44	5.97e-13	Interleukin-4 levels;
KIRP	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.5	6.18	0.37	2.68e-9	Radiation response;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.49	6.08	0.36	4.47e-9	Longevity;Endometriosis;
KIRP	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-1.07	-19.83	-0.78	6.26e-53	Height;
KIRP	trans	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg27490568	chr2:178487706	NA	0.85	11.3	0.58	3.88e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg19507638	chr5:93509721	C5orf36	-0.63	-5.41	-0.33	1.47e-7	Diabetic retinopathy;
KIRP	cis	rs290268	0.874	rs290994	chr9:93559515	T/A	cg02608019	chr9:93564028	SYK	0.82	11.52	0.59	7.58e-25	Platelet count;
KIRP	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	cg21523751	chr1:182988639	NA	0.44	6.66	0.39	1.76e-10	Hypertriglyceridemia;
KIRP	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs4956211	0.507	rs12651572	chr4:109712409	G/A	cg07086381	chr4:109682776	AGXT2L1	-0.43	-5.61	-0.34	5.32e-8	Systemic lupus erythematosus;
KIRP	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg01777586	chr17:80163174	CCDC57	0.46	4.9	0.3	1.76e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.6	6.38	0.38	8.51e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.41	-5.03	-0.31	9.64e-7	Neurofibrillary tangles;
KIRP	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg02404636	chr22:31891804	SFI1	0.48	5.43	0.33	1.38e-7	Colorectal cancer;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.37	-0.32	1.78e-7	Life satisfaction;
KIRP	cis	rs13382275	0.632	rs13384065	chr2:940126	T/G	cg10902693	chr2:875509	NA	0.58	6.46	0.38	5.62e-10	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs4356932	1.000	rs7655350	chr4:76977073	A/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.64	-5.3	-0.32	2.61e-7	Yeast infection;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.41e-13	Life satisfaction;
KIRP	cis	rs11605275	1.000	rs16937347	chr11:20026717	A/G	cg14835545	chr11:20032148	NAV2	-0.62	-5.42	-0.33	1.41e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg21285383	chr16:89894308	SPIRE2	0.29	5.5	0.33	9.27e-8	Vitiligo;
KIRP	cis	rs7572644	0.699	rs898034	chr2:28090820	T/C	cg27432699	chr2:27873401	GPN1	-0.44	-5.2	-0.31	4.13e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07308232	chr7:1071921	C7orf50	-0.71	-9.75	-0.53	3.46e-19	Longevity;Endometriosis;
KIRP	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1359582	0.767	rs2861428	chr10:90371332	T/C	cg15661332	chr10:90342814	RNLS	0.58	6.29	0.37	1.44e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.6	5.8	0.35	2.05e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.71	-8.36	-0.47	4.78e-15	Resting heart rate;
KIRP	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg11901034	chr3:128598214	ACAD9	0.42	5.32	0.32	2.39e-7	IgG glycosylation;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg27532560	chr4:187881888	NA	-0.75	-12.97	-0.64	1.19e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.16	0.31	5.17e-7	Educational attainment;
KIRP	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.23	-0.32	3.55e-7	Bladder cancer;
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg00814883	chr7:100076585	TSC22D4	-0.57	-6.01	-0.36	6.71e-9	Lung function (FEV1/FVC);
KIRP	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg23693289	chr8:27183097	PTK2B	0.49	6.18	0.37	2.65e-9	Neuroticism;
KIRP	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.66	-0.48	6.29e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9914578	0.943	rs9904872	chr17:2005241	T/A	cg16513277	chr17:2031491	SMG6	-0.71	-8.48	-0.48	2.07e-15	Body mass index;
KIRP	cis	rs17057718	1.000	rs80095764	chr3:57149793	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.36	-4.88	-0.3	1.87e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4664304	0.620	rs1039932	chr2:160712772	G/A	cg03641300	chr2:160917029	PLA2R1	0.37	5.61	0.34	5.38e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.16	-0.31	5.18e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.76	11.12	0.58	1.49e-23	Heart rate;
KIRP	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.44	5.62	0.34	5.14e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.99	14.17	0.67	1.02e-33	Cognitive function;
KIRP	cis	rs3105593	0.605	rs3131562	chr15:50772479	C/T	cg08437265	chr15:50716283	USP8	0.42	5.62	0.34	5.09e-8	QT interval;
KIRP	cis	rs6142102	0.961	rs6120487	chr20:32622608	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	6.77	0.4	9.61e-11	Skin pigmentation;
KIRP	cis	rs6580649	0.941	rs4589362	chr12:48478664	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg26695010	chr11:65641043	EFEMP2	0.76	9.73	0.53	4e-19	Eosinophil percentage of white cells;
KIRP	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg17385448	chr1:15911702	AGMAT	0.25	4.92	0.3	1.57e-6	Systolic blood pressure;
KIRP	cis	rs986417	1.000	rs6573313	chr14:60961299	A/G	cg27398547	chr14:60952738	C14orf39	0.64	5.82	0.35	1.82e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs16912285	0.688	rs7126291	chr11:24312936	A/C	ch.11.24196551F	chr11:24239977	NA	0.82	9.53	0.52	1.57e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.63	-0.34	4.86e-8	Breast cancer;
KIRP	cis	rs4704187	0.687	rs13359143	chr5:74433360	T/C	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	cis	rs6681460	0.966	rs2025595	chr1:67152499	G/A	cg02459107	chr1:67143332	SGIP1	0.48	6.56	0.39	3.21e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	1.12	17.37	0.74	1.2e-44	Homoarginine levels;
KIRP	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg11995313	chr8:8860691	ERI1	0.4	5.2	0.31	4.13e-7	Joint mobility (Beighton score);
KIRP	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-28.03	-0.87	1.51e-78	Myeloid white cell count;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg24874828	chr4:187887005	NA	-0.49	-7.06	-0.41	1.65e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.48	-0.33	1.08e-7	Pulmonary function;
KIRP	cis	rs258892	0.895	rs7722344	chr5:72023608	A/G	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg02980000	chr4:1222292	CTBP1	0.89	8.23	0.46	1.08e-14	Systolic blood pressure;
KIRP	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.23	-0.51	1.3e-17	Personality dimensions;
KIRP	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs2457480	0.850	rs61855743	chr10:44681729	A/G	cg09554077	chr10:44749378	NA	0.59	6.17	0.37	2.8e-9	Coronary artery disease;
KIRP	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg06289844	chr6:126071538	HEY2	0.4	5.87	0.35	1.43e-8	Brugada syndrome;
KIRP	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.78	-9.95	-0.54	8.12e-20	Blood trace element (Zn levels);
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg09695851	chr17:3907499	NA	0.64	8.75	0.49	3.5e-16	Type 2 diabetes;
KIRP	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.44e-11	Schizophrenia;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09857708	chr16:66586376	CKLF	-0.47	-6.07	-0.36	4.72e-9	Neuroticism;
KIRP	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg21775007	chr8:11205619	TDH	0.44	5.97	0.36	8.37e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.87	6.95	0.4	3.33e-11	Inflammatory bowel disease;
KIRP	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-5.47	-0.33	1.12e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs28489187	0.617	rs233124	chr1:85791658	A/G	cg16011679	chr1:85725395	C1orf52	0.44	5.5	0.33	9.49e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.45	9.68	0.53	5.53e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs918629	0.530	rs9314162	chr5:95252594	C/A	cg16656078	chr5:95278638	ELL2	-0.36	-5.4	-0.33	1.58e-7	IgG glycosylation;
KIRP	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg26207909	chr14:103986467	CKB	-0.44	-5.39	-0.32	1.66e-7	Coronary artery disease;
KIRP	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-0.84	-9.36	-0.51	5.22e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.81	10.56	0.56	9.99e-22	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	trans	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg24644049	chr4:85504048	CDS1	0.99	6.58	0.39	2.83e-10	Skin colour saturation;
KIRP	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.53	-0.43	9.46e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2802372	0.781	rs1250552	chr10:81058027	C/T	cg18688392	chr10:81059414	ZMIZ1	0.41	5.23	0.32	3.58e-7	Granulocyte count;
KIRP	cis	rs3741151	0.892	rs2027763	chr11:73035799	A/G	cg17517138	chr11:73019481	ARHGEF17	0.66	5.38	0.32	1.76e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.53	6.82	0.4	7.02e-11	Tonsillectomy;
KIRP	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.31	-0.51	7.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9596863	0.950	rs6561749	chr13:54435195	G/C	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.64	-0.34	4.68e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs151997	0.925	rs27847	chr5:50176197	G/T	cg06027927	chr5:50259733	NA	0.61	7.57	0.43	7.4e-13	Callous-unemotional behaviour;
KIRP	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg12046867	chr14:103022105	NA	0.52	6.12	0.36	3.77e-9	Platelet count;
KIRP	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg14703610	chr5:56206110	C5orf35	0.47	6.2	0.37	2.31e-9	Coronary artery disease;
KIRP	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg02733842	chr7:1102375	C7orf50	0.56	5.71	0.34	3.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25517755	chr10:38738941	LOC399744	-0.53	-7.29	-0.42	4.15e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4919694	0.808	rs77521106	chr10:104980726	G/T	cg04362960	chr10:104952993	NT5C2	0.96	7.1	0.41	1.34e-11	Arsenic metabolism;
KIRP	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.5	0.48	1.8e-15	Bipolar disorder;
KIRP	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg06064525	chr11:970664	AP2A2	-0.37	-7.4	-0.43	2.15e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.29	-0.37	1.44e-9	Breast cancer;
KIRP	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.33	0.42	3.21e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7937612	1.000	rs7948928	chr11:120273224	C/G	cg24566217	chr11:120254723	ARHGEF12	0.48	6.97	0.41	2.85e-11	Intraocular pressure;
KIRP	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	4.94	0.3	1.45e-6	Tonsillectomy;
KIRP	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.38	4.93	0.3	1.51e-6	Melanoma;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13198984	chr17:80129470	CCDC57	-0.54	-8.03	-0.46	4.14e-14	Life satisfaction;
KIRP	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.69	12.8	0.63	4.32e-29	White blood cell count (basophil);
KIRP	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.72	9.75	0.53	3.42e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.71	11.21	0.58	7.94e-24	Resting heart rate;
KIRP	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	1.07	15.45	0.7	4.42e-38	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17139369	chr19:8478169	MARCH2	0.57	7.63	0.44	5.22e-13	Parkinson's disease;
KIRP	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.71	-8.42	-0.47	3.18e-15	Diabetic retinopathy;
KIRP	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	9.55	0.52	1.33e-18	Renal function-related traits (BUN);
KIRP	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.53	0.38	3.73e-10	Mean platelet volume;
KIRP	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg23682824	chr7:23144976	KLHL7	0.52	6.09	0.36	4.38e-9	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg15934090	chr1:100435551	SLC35A3	0.52	6.42	0.38	7e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.88	10.96	0.57	5.1e-23	Obesity-related traits;
KIRP	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.45	5.64	0.34	4.59e-8	Asthma;
KIRP	cis	rs2651899	0.867	rs207200	chr1:3073555	T/C	cg01413848	chr1:3081226	PRDM16	0.43	5.61	0.34	5.55e-8	Migraine;
KIRP	cis	rs77972916	0.519	rs13411327	chr2:43515483	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-7.96	-0.45	6.38e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	6.85	0.4	6.03e-11	Myopia (pathological);
KIRP	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs447921	0.861	rs56154175	chr17:74419086	C/T	cg17201438	chr17:74438067	UBE2O	0.47	5.22	0.32	3.82e-7	Mitochondrial DNA levels;
KIRP	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.75	9.87	0.53	1.38e-19	Lung cancer;
KIRP	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg20936604	chr3:58311152	NA	-0.65	-5.03	-0.31	9.58e-7	Cholesterol, total;
KIRP	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.76	-8.42	-0.47	3.06e-15	Parkinson's disease;
KIRP	cis	rs4702718	0.616	rs267978	chr5:10719804	A/G	cg14521931	chr5:10832172	NA	-0.43	-5.83	-0.35	1.72e-8	Obesity-related traits;
KIRP	cis	rs13102973	0.835	rs4280795	chr4:135857246	T/A	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	8.99e-16	Subjective well-being;
KIRP	cis	rs17592366	0.517	rs7156153	chr14:35308074	G/A	cg09327582	chr14:35236912	BAZ1A	0.56	5.95	0.35	9.24e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05220968	chr6:146057943	EPM2A	-0.44	-5.46	-0.33	1.18e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2554380	0.891	rs1426164	chr15:84301836	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-8.35	-0.47	5.06e-15	Height;
KIRP	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg00898013	chr13:113819073	PROZ	-0.58	-5.56	-0.33	6.94e-8	Platelet distribution width;
KIRP	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg03563238	chr19:33554763	RHPN2	-0.32	-5.74	-0.34	2.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs77669868	0.929	rs76761091	chr11:114067058	A/G	cg01914181	chr11:114070210	ZBTB16	0.57	5.83	0.35	1.73e-8	Monocyte percentage of white cells;
KIRP	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg00647317	chr7:50633725	DDC	0.45	6.93	0.4	3.67e-11	Body mass index;
KIRP	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-6.96	-0.41	3.06e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.81	0.4	7.23e-11	Monocyte percentage of white cells;
KIRP	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.73	9.24	0.51	1.18e-17	Coronary artery disease;
KIRP	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg24459738	chr19:57751996	ZNF805	-0.52	-6.28	-0.37	1.54e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.49	0.38	4.65e-10	Educational attainment;
KIRP	cis	rs239198	0.521	rs13198473	chr6:101337779	C/T	cg09795085	chr6:101329169	ASCC3	0.49	5.62	0.34	5.26e-8	Menarche (age at onset);
KIRP	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.56	-11.14	-0.58	1.29e-23	Prostate cancer;
KIRP	cis	rs9309473	0.950	rs7567585	chr2:73751966	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.42	-0.33	1.4e-7	Metabolite levels;
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.57	7.68	0.44	3.65e-13	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20400622	chr8:76477653	HNF4G	-0.43	-7.05	-0.41	1.83e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg21573476	chr21:45109991	RRP1B	0.6	8.52	0.48	1.59e-15	Mean corpuscular volume;
KIRP	trans	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.67	0.39	1.71e-10	Mean corpuscular volume;
KIRP	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg08822215	chr16:89438651	ANKRD11	-0.5	-6.51	-0.38	4.11e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs2172802	0.570	rs4860422	chr4:62524423	A/C	cg04118610	chr4:62707027	LPHN3	0.43	5.38	0.32	1.71e-7	Partial epilepsies;
KIRP	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.58	8.92	0.49	1.05e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4262150	0.764	rs4958561	chr5:151930231	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.0	-0.45	4.94e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.58	6.52	0.38	3.91e-10	Diisocyanate-induced asthma;
KIRP	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06028808	chr11:68637592	NA	-0.69	-8.54	-0.48	1.41e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg26893134	chr6:116381904	FRK	-0.2	-5.34	-0.32	2.11e-7	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25463822	chr1:193028375	TROVE2;UCHL5	0.47	7.08	0.41	1.52e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10875746	0.669	rs61940962	chr12:48595477	A/C	cg26205652	chr12:48591994	NA	0.72	9.53	0.52	1.61e-18	Longevity (90 years and older);
KIRP	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.96	11.16	0.58	1.1e-23	Corneal astigmatism;
KIRP	trans	rs12449568	0.874	rs2159967	chr17:54420786	T/C	cg04456437	chr3:119217424	C3orf1	0.48	6.06	0.36	5.07e-9	Height;
KIRP	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-7.62	-0.44	5.41e-13	Mean corpuscular volume;
KIRP	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg06636001	chr8:8085503	FLJ10661	0.92	13.07	0.64	5.34e-30	Neuroticism;
KIRP	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.17e-15	Obesity-related traits;
KIRP	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg01872077	chr2:219646372	CYP27A1	0.41	5.44	0.33	1.32e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg06026331	chr20:60912101	LAMA5	0.48	5.25	0.32	3.27e-7	Colorectal cancer;
KIRP	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg24296786	chr1:45957014	TESK2	0.54	6.41	0.38	7.17e-10	Homocysteine levels;
KIRP	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.0	10.65	0.56	5.16e-22	HIV-1 control;
KIRP	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.71	9.8	0.53	2.41e-19	Mood instability;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08286599	chr2:191208694	INPP1	0.53	6.2	0.37	2.35e-9	Smoking initiation;
KIRP	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.7	0.34	3.39e-8	Aortic root size;
KIRP	cis	rs7119167	0.805	rs56801796	chr11:73090265	A/G	cg17517138	chr11:73019481	ARHGEF17	0.53	5.54	0.33	7.7e-8	Blood protein levels;
KIRP	cis	rs13315871	1.000	rs71311865	chr3:58372423	G/A	cg12435725	chr3:58293450	RPP14	-0.5	-5.29	-0.32	2.7e-7	Cholesterol, total;
KIRP	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg03806693	chr22:41940476	POLR3H	-0.45	-5.33	-0.32	2.18e-7	Neuroticism;
KIRP	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	7.97	0.45	5.77e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg01620082	chr3:125678407	NA	-0.86	-6.2	-0.37	2.38e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg10617943	chr7:1981403	MAD1L1	-0.4	-5.13	-0.31	5.75e-7	Bipolar disorder;
KIRP	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.71	-8.43	-0.47	2.87e-15	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.49	-0.38	4.82e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.86	12.49	0.62	4.62e-28	Blood metabolite ratios;
KIRP	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg23920097	chr1:209922102	NA	-0.45	-5.39	-0.33	1.62e-7	Red blood cell count;
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.46	-5.75	-0.34	2.7e-8	Iron status biomarkers;
KIRP	cis	rs4363385	0.509	rs11576882	chr1:152918785	T/G	cg25856811	chr1:152973957	SPRR3	-0.39	-5.36	-0.32	1.94e-7	Inflammatory skin disease;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.69	11.52	0.59	7.85e-25	Cardiovascular disease risk factors;
KIRP	cis	rs6088813	0.961	rs6060371	chr20:33913322	G/T	cg14752227	chr20:34000481	UQCC	0.47	6.0	0.36	7.15e-9	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01353569	chr7:106810328	HBP1	0.52	6.94	0.4	3.42e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	6.46	0.38	5.71e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg07741184	chr6:167504864	NA	-0.2	-4.89	-0.3	1.82e-6	Rheumatoid arthritis;
KIRP	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg06204229	chr3:52865917	ITIH4	0.53	5.94	0.35	9.49e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs78545713	1.000	rs3734534	chr6:26240649	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	0.57	5.06	0.31	8.22e-7	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15389440	chr4:129730137	PHF17	0.5	6.61	0.39	2.33e-10	Interleukin-4 levels;
KIRP	cis	rs9302690	1.000	rs75700677	chr16:57480315	G/A	cg27017172	chr16:57497170	POLR2C	0.98	7.89	0.45	9.98e-14	Blood protein levels;
KIRP	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg21720385	chr19:4455239	UBXN6	0.4	5.41	0.33	1.47e-7	Mean corpuscular volume;
KIRP	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.97	0.88	2.9e-81	Chronic sinus infection;
KIRP	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg23533419	chr12:54090519	NA	-0.31	-4.85	-0.3	2.16e-6	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23274123	chr1:229478617	C1orf96	-0.53	-6.52	-0.38	3.97e-10	Interleukin-4 levels;
KIRP	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.81	-0.45	1.62e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2395528	0.514	rs1513393	chr10:80124387	G/A	cg08356028	chr10:80217969	NA	-0.32	-4.87	-0.3	1.98e-6	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs1511802	0.591	rs6810892	chr4:187123941	C/T	cg24794857	chr4:187113578	CYP4V2	0.38	5.26	0.32	3.18e-7	Blood protein levels;
KIRP	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7937612	1.000	rs7101415	chr11:120239088	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.19	-0.42	7.96e-12	Intraocular pressure;
KIRP	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.97	0.71	7.13e-40	Bipolar disorder;
KIRP	cis	rs1823913	0.637	rs4853465	chr2:192159494	A/G	cg12404831	chr2:192114017	MYO1B	-0.45	-6.06	-0.36	5.16e-9	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg15655495	chr12:38532458	NA	-0.28	-5.03	-0.31	9.3e-7	Bladder cancer;
KIRP	cis	rs11161851	0.868	rs12562135	chr1:75313199	G/A	cg11196437	chr1:75593865	LHX8	-0.37	-5.49	-0.33	1e-7	Visceral fat;
KIRP	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.91	0.45	8.89e-14	Obesity-related traits;
KIRP	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg02375832	chr11:62437615	C11orf48	-0.41	-5.1	-0.31	6.68e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.69	-7.27	-0.42	4.73e-12	Urate levels in lean individuals;
KIRP	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.43	-0.38	6.74e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg22284058	chr8:142237359	SLC45A4	-0.41	-5.1	-0.31	6.82e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg04166393	chr7:2884313	GNA12	-0.58	-7.03	-0.41	1.98e-11	Height;
KIRP	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.72	0.44	2.91e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg15128208	chr22:42549153	NA	0.55	6.05	0.36	5.24e-9	Birth weight;
KIRP	cis	rs9535307	0.719	rs1198315	chr13:50370168	C/T	cg04663916	chr13:50265991	EBPL	-0.56	-6.05	-0.36	5.39e-9	Obesity-related traits;
KIRP	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.7	9.33	0.51	6.27e-18	Total cholesterol levels;
KIRP	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.87	-0.45	1.12e-13	Homocysteine levels;
KIRP	cis	rs1050631	0.592	rs1785932	chr18:33719434	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.46	5.74	0.34	2.71e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.96	8.3	0.47	6.98e-15	Eosinophilic esophagitis;
KIRP	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs8018808	0.935	rs11159263	chr14:77930188	G/C	cg18872420	chr14:78023429	SPTLC2	0.36	5.24	0.32	3.52e-7	Myeloid white cell count;
KIRP	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13047869	chr3:10149882	C3orf24	0.57	5.4	0.33	1.57e-7	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12181797	chr4:4292013	ZNF509;LYAR	0.53	6.81	0.4	7.57e-11	Parkinson's disease;
KIRP	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg21890820	chr11:65308645	LTBP3	-0.41	-4.9	-0.3	1.7e-6	Plateletcrit;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22929010	chr22:50900096	SBF1	0.46	6.38	0.38	8.57e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	6.02	0.36	6.22e-9	Mean platelet volume;
KIRP	cis	rs4713118	0.513	rs1225591	chr6:28148752	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.23	-0.37	1.99e-9	Parkinson's disease;
KIRP	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.81	-0.4	7.58e-11	Menopause (age at onset);
KIRP	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	1.07	19.17	0.77	1.04e-50	Bone mineral density;
KIRP	cis	rs11169552	0.510	rs12231317	chr12:51041005	G/A	cg12884762	chr12:50931848	DIP2B	-0.43	-5.1	-0.31	6.73e-7	Colorectal cancer;
KIRP	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.34	0.32	2.12e-7	Coronary artery disease;
KIRP	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg14541582	chr5:601475	NA	-0.54	-6.18	-0.37	2.65e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.62	8.14	0.46	1.95e-14	Pancreatic cancer;
KIRP	cis	rs7721647	0.853	rs10058587	chr5:90872543	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.4	4.92	0.3	1.61e-6	Breast cancer;
KIRP	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.55	-6.68	-0.39	1.55e-10	Corneal astigmatism;
KIRP	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.41	-6.4	-0.38	7.69e-10	Colorectal cancer;
KIRP	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg03161606	chr19:29218774	NA	0.69	5.61	0.34	5.42e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg18694418	chr7:2742484	AMZ1	0.45	4.98	0.3	1.19e-6	Height;
KIRP	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.83	-11.54	-0.59	6.69e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-6.69	-0.39	1.5e-10	Schizophrenia;
KIRP	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.57	6.91	0.4	4.22e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.46	7.79	0.44	1.89e-13	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs6546324	0.615	rs7598280	chr2:67815313	A/T	cg15745817	chr2:67799979	NA	-0.66	-7.21	-0.42	6.9e-12	Endometriosis;
KIRP	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.67	-6.14	-0.36	3.28e-9	Schizophrenia;
KIRP	cis	rs981844	0.816	rs74549610	chr4:154710464	C/G	cg14289246	chr4:154710475	SFRP2	0.69	7.88	0.45	1.03e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.69	0.39	1.5e-10	Height;
KIRP	cis	rs9473924	0.542	rs2857501	chr6:50797286	A/G	cg14470998	chr6:50812995	TFAP2B	0.99	8.93	0.49	1.01e-16	Body mass index;
KIRP	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.01	12.55	0.62	2.91e-28	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.79	9.68	0.53	5.56e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg24951754	chr12:132676717	NA	0.46	6.3	0.37	1.37e-9	Anti-saccade response;
KIRP	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.57	7.41	0.43	2.01e-12	Alzheimer's disease;
KIRP	cis	rs8084125	0.938	rs2097094	chr18:74942422	G/A	cg15443732	chr18:74961078	GALR1	0.54	4.88	0.3	1.95e-6	Obesity-related traits;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-5.46	-0.33	1.14e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg04990556	chr1:26633338	UBXN11	-0.61	-7.48	-0.43	1.34e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg25036284	chr2:26402008	FAM59B	-0.67	-6.98	-0.41	2.76e-11	Gut microbiome composition (summer);
KIRP	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-7.5	-0.43	1.14e-12	Electroencephalogram traits;
KIRP	cis	rs7929679	0.521	rs10768094	chr11:34792189	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg10223061	chr2:219282414	VIL1	0.44	6.95	0.4	3.34e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs714027	0.605	rs193475	chr22:30450492	T/C	cg01021169	chr22:30184971	ASCC2	0.43	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs13095912	1.000	rs2034343	chr3:185337854	A/T	cg11274856	chr3:185301563	NA	0.55	7.09	0.41	1.42e-11	Systolic blood pressure;
KIRP	cis	rs7395581	0.918	rs1449627	chr11:47290984	T/G	cg26139080	chr11:47293733	MADD	-0.42	-5.32	-0.32	2.35e-7	HDL cholesterol;
KIRP	cis	rs7011049	0.841	rs6473776	chr8:53875125	C/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.62	5.84	0.35	1.65e-8	Alzheimer's disease;
KIRP	cis	rs12765878	0.580	rs11191822	chr10:105599770	T/G	cg11005552	chr10:105648138	OBFC1	-0.39	-4.93	-0.3	1.49e-6	Coronary artery disease;
KIRP	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg04865290	chr3:52927548	TMEM110	-0.65	-6.82	-0.4	7.2e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg08822215	chr16:89438651	ANKRD11	-0.51	-6.56	-0.39	3.2e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6429082	1.000	rs6429082	chr1:235600129	C/T	cg26050004	chr1:235667680	B3GALNT2	0.43	5.45	0.33	1.25e-7	Adiposity;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg08662619	chr6:150070041	PCMT1	0.38	6.38	0.38	8.7e-10	Lung cancer;
KIRP	trans	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg17470723	chr8:74884337	TCEB1	0.6	6.41	0.38	7.19e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.84	11.2	0.58	8.35e-24	Type 2 diabetes;
KIRP	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg13444842	chr1:152974279	SPRR3	-0.41	-5.92	-0.35	1.1e-8	Inflammatory skin disease;
KIRP	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.93	-12.24	-0.62	3.17e-27	Platelet distribution width;
KIRP	cis	rs494562	0.892	rs7767626	chr6:86124394	G/A	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.7	10.7	0.56	3.33e-22	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.25	16.39	0.72	2.71e-41	Atopic dermatitis;
KIRP	cis	rs829883	0.966	rs249815	chr12:98893709	A/G	cg25150519	chr12:98850993	NA	0.86	12.97	0.64	1.12e-29	Colorectal adenoma (advanced);
KIRP	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg07636037	chr3:49044803	WDR6	-0.66	-6.72	-0.39	1.27e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg15282417	chr9:129245246	FAM125B	0.47	8.2	0.46	1.31e-14	Intraocular pressure;
KIRP	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg12856521	chr11:46389249	DGKZ	0.43	6.22	0.37	2.14e-9	Leprosy;
KIRP	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg05347473	chr6:146136440	FBXO30	0.55	7.72	0.44	2.87e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06282189	chr18:67735875	RTTN	-0.44	-6.23	-0.37	2e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9815354	0.812	rs73073364	chr3:41843058	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg23205692	chr1:25664452	TMEM50A	-0.36	-4.98	-0.3	1.22e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg05896524	chr21:47604654	C21orf56	0.43	5.31	0.32	2.4e-7	Testicular germ cell tumor;
KIRP	cis	rs10904887	0.846	rs1885396	chr10:17243351	C/T	cg01003015	chr10:17271136	VIM	-0.47	-5.96	-0.36	8.62e-9	Telomere length;
KIRP	cis	rs2916247	1.000	rs1899666	chr8:93006087	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.56	-7.34	-0.42	3.11e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.615	rs2137288	chr18:44752041	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.46	7.03	0.41	2.04e-11	Educational attainment;
KIRP	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.66	-0.34	4.18e-8	Metabolite levels;
KIRP	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg17470449	chr10:769945	NA	0.6	6.51	0.38	4.19e-10	Uric acid levels;
KIRP	trans	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.82	0.4	6.92e-11	Mean corpuscular volume;
KIRP	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.59	-6.25	-0.37	1.76e-9	Pancreatic cancer;
KIRP	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg24189917	chr7:1970923	MAD1L1	-0.54	-4.87	-0.3	1.96e-6	Bipolar disorder;
KIRP	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg08992911	chr2:238395768	MLPH	0.4	4.96	0.3	1.3e-6	Prostate cancer;
KIRP	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.44	5.51	0.33	8.98e-8	Testicular germ cell tumor;
KIRP	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.83	8.65	0.48	6.75e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.62	-8.91	-0.49	1.2e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg25281562	chr12:121454272	C12orf43	-0.51	-5.73	-0.34	2.98e-8	N-glycan levels;
KIRP	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg20469991	chr17:27169893	C17orf63	0.54	5.64	0.34	4.55e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg12560992	chr17:57184187	TRIM37	-0.53	-6.25	-0.37	1.77e-9	Cognitive test performance;
KIRP	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.65	-9.82	-0.53	2e-19	Fibrinogen levels;
KIRP	cis	rs9488822	0.662	rs495565	chr6:116262976	G/A	cg26893134	chr6:116381904	FRK	-0.19	-5.16	-0.31	5.01e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1867631	0.585	rs11208922	chr1:67080226	T/C	cg02459107	chr1:67143332	SGIP1	0.39	5.81	0.35	1.93e-8	Menopause (age at onset);
KIRP	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg25281562	chr12:121454272	C12orf43	0.56	6.2	0.37	2.38e-9	N-glycan levels;
KIRP	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg06637938	chr14:75390232	RPS6KL1	0.51	7.19	0.42	7.91e-12	Height;
KIRP	trans	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg23594656	chr7:65796392	TPST1	-0.46	-6.32	-0.37	1.2e-9	Aortic root size;
KIRP	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.18	-0.46	1.56e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1035491	0.715	rs2002628	chr5:63919470	C/T	cg01791865	chr5:63954708	NA	-0.34	-5.42	-0.33	1.43e-7	Body mass index;
KIRP	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.07	12.87	0.63	2.44e-29	Vitiligo;
KIRP	cis	rs1711745	0.702	rs2995805	chr9:115454618	T/C	cg13803584	chr9:115635662	SNX30	0.61	6.97	0.41	2.93e-11	Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.63	-8.81	-0.49	2.31e-16	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg18306943	chr3:40428807	ENTPD3	-0.47	-6.56	-0.39	3.15e-10	Renal cell carcinoma;
KIRP	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg24633833	chr3:10029261	TMEM111	0.53	5.11	0.31	6.38e-7	Alzheimer's disease;
KIRP	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.09	-0.46	2.83e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7225151	0.710	rs79346409	chr17:5246039	A/T	cg24500398	chr17:5266808	RABEP1	-0.58	-5.79	-0.35	2.09e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg21775007	chr8:11205619	TDH	-0.47	-6.12	-0.36	3.72e-9	Neuroticism;
KIRP	cis	rs988913	1.000	rs7765236	chr6:54835567	G/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.67	-0.34	3.97e-8	Menarche (age at onset);
KIRP	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.33	4.88	0.3	1.87e-6	Carotid intima media thickness;
KIRP	trans	rs61931739	0.592	rs61927750	chr12:33696070	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.12	-0.36	3.67e-9	Morning vs. evening chronotype;
KIRP	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	1.05	6.65	0.39	1.89e-10	Type 2 diabetes nephropathy;
KIRP	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.52	-7.0	-0.41	2.47e-11	Subjective well-being;Cardiovascular disease risk factors;
KIRP	cis	rs12580194	0.593	rs7487419	chr12:55769801	C/G	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs11690462	0.926	rs11689086	chr2:26549127	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.42	5.13	0.31	5.85e-7	Coronary artery disease;
KIRP	cis	rs11574514	1.000	rs8049622	chr16:67800927	G/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-5.58	-0.34	6.22e-8	Crohn's disease;
KIRP	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg05347473	chr6:146136440	FBXO30	0.5	6.96	0.41	3.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg06064525	chr11:970664	AP2A2	-0.29	-5.31	-0.32	2.43e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg12131826	chr15:77904385	NA	0.48	5.65	0.34	4.4e-8	Type 2 diabetes;
KIRP	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg08807101	chr21:30365312	RNF160	-0.51	-5.89	-0.35	1.23e-8	Cognitive test performance;
KIRP	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	1.02	11.12	0.58	1.52e-23	IgG glycosylation;
KIRP	cis	rs9815354	1.000	rs9854833	chr3:41775577	C/T	cg03022575	chr3:42003672	ULK4	0.64	6.58	0.39	2.89e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7937612	0.895	rs4936517	chr11:120228286	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.02	-0.41	2.2e-11	Intraocular pressure;
KIRP	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg26262840	chr14:90767686	C14orf102	0.35	5.35	0.32	2.04e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg05235143	chr10:124713794	C10orf88	-0.45	-6.05	-0.36	5.36e-9	Metabolic traits;
KIRP	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.56	6.6	0.39	2.53e-10	Dialysis-related mortality;
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.59	-8.28	-0.47	7.77e-15	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2859741	0.647	rs548661	chr1:37479392	T/G	cg09363841	chr1:37513479	NA	-0.57	-9.26	-0.51	1.07e-17	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs9603616	0.719	rs9548873	chr13:40238492	C/T	cg26701198	chr13:40229707	COG6	0.45	5.35	0.32	1.98e-7	Rheumatoid arthritis;
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02359409	chr6:42947317	PEX6	-0.51	-7.04	-0.41	1.88e-11	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg03468072	chr12:39539422	NA	0.42	5.75	0.34	2.62e-8	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.73	-0.49	3.83e-16	Personality dimensions;
KIRP	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	0.91	10.63	0.56	5.68e-22	Corneal structure;
KIRP	trans	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg19694781	chr19:47549865	TMEM160	-0.58	-7.73	-0.44	2.82e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7560272	0.501	rs2272178	chr2:73977609	C/T	cg20560298	chr2:73613845	ALMS1	0.45	5.41	0.33	1.46e-7	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.58	7.76	0.44	2.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg18190219	chr22:46762943	CELSR1	-0.74	-7.53	-0.43	9.32e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-7.43	-0.43	1.74e-12	Gut microbiome composition (summer);
KIRP	cis	rs6546324	0.625	rs2861700	chr2:67855441	A/G	cg15745817	chr2:67799979	NA	0.69	7.48	0.43	1.35e-12	Endometriosis;
KIRP	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6968419	0.747	rs3757730	chr7:115882323	G/A	cg02561103	chr7:115862891	TES	-0.43	-6.15	-0.36	3.16e-9	Intraocular pressure;
KIRP	cis	rs7116495	1.000	rs4944232	chr11:71642258	A/G	cg26138937	chr11:71823887	C11orf51	0.72	5.85	0.35	1.53e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6504950	0.800	rs12952253	chr17:53005716	A/G	cg26251398	chr17:52985966	TOM1L1	0.45	5.67	0.34	4.04e-8	Breast cancer;
KIRP	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.55	6.55	0.39	3.26e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg04025307	chr7:1156635	C7orf50	0.84	9.05	0.5	4.59e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.85	12.07	0.61	1.21e-26	Total body bone mineral density;
KIRP	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.01	-0.3	1.04e-6	Inflammatory skin disease;
KIRP	cis	rs4805272	1.000	rs4805275	chr19:29322264	T/C	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs10267417	0.603	rs34087364	chr7:19860293	A/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.06	0.31	8.32e-7	Night sleep phenotypes;
KIRP	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-1.01	-10.18	-0.54	1.49e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg17077180	chr1:38461687	NA	-0.4	-4.95	-0.3	1.41e-6	Coronary artery disease;
KIRP	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.49	-7.34	-0.42	3.12e-12	Electroencephalogram traits;
KIRP	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.23	-0.32	3.61e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.82	-10.75	-0.57	2.35e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4006360	0.575	rs67524820	chr17:39318208	T/C	cg15015397	chr17:39261100	KRTAP4-9	0.35	4.95	0.3	1.35e-6	Bipolar disorder and schizophrenia;
KIRP	trans	rs7404843	0.733	rs153003	chr16:15491400	G/T	cg02716450	chr16:28638775	NA	0.73	8.44	0.47	2.81e-15	Testicular germ cell tumor;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.75	-11.05	-0.58	2.51e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.7	7.32	0.42	3.54e-12	Bipolar disorder;
KIRP	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg12826209	chr6:26865740	GUSBL1	0.78	5.45	0.33	1.24e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.53	-7.04	-0.41	1.88e-11	Breast cancer;
KIRP	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg10326726	chr10:51549505	MSMB	-0.6	-9.0	-0.5	6.31e-17	Prostate-specific antigen levels;
KIRP	cis	rs6558530	0.932	rs4370560	chr8:1708194	G/A	cg08198773	chr8:1697536	NA	0.38	4.85	0.3	2.19e-6	Systolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08496016	chr9:99181722	ZNF367	0.6	7.18	0.42	8.29e-12	Smoking initiation;
KIRP	cis	rs6700896	0.931	rs12021623	chr1:66153586	A/C	cg04111102	chr1:66153794	NA	0.34	5.05	0.31	8.53e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.77	9.98	0.54	6.68e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.85	-11.94	-0.61	3.22e-26	Total body bone mineral density;
KIRP	cis	rs986417	1.000	rs1268621	chr14:60921571	G/A	cg27398547	chr14:60952738	C14orf39	-0.74	-7.43	-0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg02175308	chr1:109941060	SORT1	-0.29	-5.54	-0.33	7.78e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26526719	chr5:1949144	NA	0.4	4.89	0.3	1.86e-6	Gut microbiome composition (winter);
KIRP	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.73	9.11	0.5	2.91e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	17.02	0.74	1.92e-43	Platelet count;
KIRP	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg13206674	chr6:150067644	NUP43	0.55	7.89	0.45	1.02e-13	Lung cancer;
KIRP	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.45	5.3	0.32	2.53e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.44e-7	Morning vs. evening chronotype;
KIRP	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.56	-0.33	7.06e-8	Metabolite levels;
KIRP	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.82	-13.28	-0.65	1.06e-30	Prostate cancer;
KIRP	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.8	-13.44	-0.65	3.11e-31	Itch intensity from mosquito bite;
KIRP	cis	rs885389	0.883	rs2280683	chr12:131620738	A/G	cg00260028	chr12:131606990	GPR133	-0.44	-5.28	-0.32	2.77e-7	RR interval (heart rate);
KIRP	cis	rs494562	1.000	rs495469	chr6:86117025	C/T	cg27039625	chr6:86159096	NT5E	0.45	5.78	0.35	2.28e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6495367	1.000	rs1007366	chr15:79379541	G/A	cg17916960	chr15:79447300	NA	0.34	5.79	0.35	2.11e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs1023500	1.000	rs6002548	chr22:42337040	T/G	cg04733989	chr22:42467013	NAGA	-0.53	-5.69	-0.34	3.57e-8	Schizophrenia;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg12475106	chr4:503275	PIGG	0.44	6.02	0.36	6.28e-9	Pancreatic cancer;
KIRP	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.49e-6	Red blood cell count;
KIRP	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg10223061	chr2:219282414	VIL1	-0.37	-6.09	-0.36	4.34e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.36	-0.32	1.88e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4006360	0.545	rs365738	chr17:39279082	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.52	-7.48	-0.43	1.29e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25772365	chr6:140762224	NA	0.49	7.14	0.41	1.05e-11	Interleukin-4 levels;
KIRP	cis	rs2950163	0.898	rs2693931	chr2:6186881	C/T	cg26659079	chr2:5836181	SOX11	0.38	4.91	0.3	1.62e-6	Response to metformin (IC50);
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg26134248	chr17:3907702	NA	-0.54	-7.86	-0.45	1.17e-13	Type 2 diabetes;
KIRP	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	10.02	0.54	4.72e-20	Bone mineral density;
KIRP	cis	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg19171272	chr22:38449367	NA	-0.66	-10.11	-0.54	2.57e-20	Glioblastoma;Glioma;
KIRP	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.74	-6.38	-0.38	8.69e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg15128208	chr22:42549153	NA	0.7	7.61	0.44	5.97e-13	Birth weight;
KIRP	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.32	-0.42	3.45e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg04865290	chr3:52927548	TMEM110	-0.6	-6.86	-0.4	5.4e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg08775375	chr8:10454154	NA	-0.35	-4.85	-0.3	2.23e-6	Neuroticism;
KIRP	cis	rs11264213	0.792	rs12562583	chr1:36178868	G/T	cg27506609	chr1:36549197	TEKT2	0.76	6.7	0.39	1.45e-10	Schizophrenia;
KIRP	cis	rs12714314	0.602	rs10199754	chr2:1938028	G/A	cg20846728	chr2:1843184	MYT1L	-0.37	-6.2	-0.37	2.31e-9	Type 2 diabetes (age of onset);
KIRP	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg17554472	chr22:41940697	POLR3H	0.62	6.08	0.36	4.51e-9	Vitiligo;
KIRP	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.82	-9.25	-0.51	1.13e-17	Coronary artery disease;
KIRP	cis	rs73242632	1.000	rs114513553	chr4:57858458	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	4.89	0.3	1.8e-6	Congenital heart disease (maternal effect);
KIRP	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.68	-9.42	-0.51	3.49e-18	Colorectal cancer;
KIRP	cis	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg12315302	chr6:26189340	HIST1H4D	1.31	7.66	0.44	4.19e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.82	-0.35	1.8e-8	Crohn's disease;
KIRP	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg22777020	chr22:31556080	RNF185	-0.5	-5.32	-0.32	2.37e-7	Colorectal cancer;
KIRP	cis	rs7712401	0.601	rs13185741	chr5:122338010	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.92	15.62	0.71	1.11e-38	Mortality in heart failure;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22468065	chr3:51533482	VPRBP	-0.47	-6.03	-0.36	6.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14706107	chr11:94801827	SFRS2B	0.45	6.16	0.37	3e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07673023	chr2:27434729	C2orf28;SLC5A6	0.5	6.44	0.38	6.27e-10	Parkinson's disease;
KIRP	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.47	0.43	1.36e-12	Obesity-related traits;
KIRP	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg05022225	chr19:49866942	DKKL1;TEAD2	0.47	5.68	0.34	3.71e-8	Multiple sclerosis;
KIRP	cis	rs787274	0.850	rs2025544	chr9:115632969	C/T	cg13803584	chr9:115635662	SNX30	0.74	6.04	0.36	5.81e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg27189623	chr16:705930	WDR90	0.46	6.3	0.37	1.34e-9	Height;
KIRP	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07570687	chr10:102243282	WNT8B	-0.53	-7.27	-0.42	4.68e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg16386425	chr10:429943	DIP2C	0.39	4.87	0.3	1.97e-6	Psychosis in Alzheimer's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17602885	chr1:9804627	CLSTN1	0.47	6.17	0.37	2.84e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.63	8.95	0.5	8.59e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07706812	chr16:71746357	PHLPP2	0.41	6.41	0.38	7.56e-10	C-reactive protein;
KIRP	cis	rs2970992	0.764	rs3112258	chr2:101328375	T/C	cg01042948	chr2:101319752	NA	0.42	5.93	0.35	1.02e-8	Educational attainment;
KIRP	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.49	-6.61	-0.39	2.39e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-1.06	-23.39	-0.83	1.79e-64	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.97	8.54	0.48	1.38e-15	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25764131	chr19:24311037	ZNF254	-0.39	-6.22	-0.37	2.07e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg27124370	chr19:33622961	WDR88	-0.57	-7.0	-0.41	2.46e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg00343986	chr7:65444356	GUSB	0.43	5.1	0.31	6.87e-7	Aortic root size;
KIRP	cis	rs1729407	0.774	rs2849167	chr11:116684744	A/G	cg26566898	chr11:117069891	TAGLN	-0.4	-5.44	-0.33	1.32e-7	Apolipoprotein A-IV levels;
KIRP	cis	rs4728302	0.838	rs10225605	chr7:133591676	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg21253087	chr9:139290292	SNAPC4	0.46	6.43	0.38	6.63e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.06	-0.41	1.74e-11	Eye color traits;
KIRP	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg18357526	chr6:26021779	HIST1H4A	0.38	4.88	0.3	1.93e-6	Height;
KIRP	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg19671926	chr4:122722719	EXOSC9	0.48	5.78	0.35	2.27e-8	Type 2 diabetes;
KIRP	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs9443189	0.806	rs9359139	chr6:76487269	C/G	cg01950844	chr6:76311363	SENP6	0.54	5.42	0.33	1.41e-7	Prostate cancer;
KIRP	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.73	-0.56	2.84e-22	Breast cancer;
KIRP	cis	rs1712517	0.873	rs7903004	chr10:105004101	G/A	cg05636881	chr10:105038444	INA	-0.39	-5.83	-0.35	1.76e-8	Migraine;
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.41	5.27	0.32	2.97e-7	Aortic root size;
KIRP	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-6.9	-0.4	4.31e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs501120	0.584	rs677465	chr10:44732917	G/A	cg09554077	chr10:44749378	NA	0.68	7.59	0.44	6.43e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs757081	0.671	rs214072	chr11:17305270	C/T	cg15432903	chr11:17409602	KCNJ11	-0.64	-7.46	-0.43	1.48e-12	Systolic blood pressure;
KIRP	cis	rs4835473	0.932	rs7356305	chr4:144659003	A/G	cg08833778	chr4:144622313	FREM3	0.35	5.0	0.3	1.09e-6	Immature fraction of reticulocytes;
KIRP	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg23980314	chr2:23750035	KLHL29	0.41	6.23	0.37	2.03e-9	Serum protein levels (sST2);
KIRP	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.73	-0.39	1.17e-10	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.41	5.28	0.32	2.79e-7	Aortic root size;
KIRP	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-1.07	-20.28	-0.79	2.1e-54	Height;
KIRP	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.27	0.37	1.64e-9	Height;
KIRP	cis	rs2151522	0.762	rs9388535	chr6:127168448	C/T	cg21431617	chr6:127135037	NA	0.29	5.24	0.32	3.4e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.73	9.27	0.51	9.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.35	6.35	0.38	1.05e-9	Erythrocyte sedimentation rate;
KIRP	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.86	13.49	0.65	2.02e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2979489	0.891	rs6982511	chr8:30355513	G/T	cg26383811	chr8:30366931	RBPMS	-0.45	-6.15	-0.37	3.06e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.62e-7	Depression;
KIRP	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg23995753	chr2:160760732	LY75	-0.44	-5.83	-0.35	1.75e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg13731523	chr4:3047190	NA	-0.36	-5.96	-0.36	8.64e-9	Serum sulfate level;
KIRP	cis	rs7027203	0.595	rs2398876	chr9:96536853	T/C	cg14598338	chr9:96623480	NA	0.45	6.98	0.41	2.72e-11	DNA methylation (variation);
KIRP	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.4	-6.3	-0.37	1.35e-9	Body mass index;
KIRP	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg07636037	chr3:49044803	WDR6	0.43	4.99	0.3	1.14e-6	Resting heart rate;
KIRP	cis	rs10982256	0.817	rs2297814	chr9:117267172	G/A	cg13636371	chr9:117264095	DFNB31	-0.4	-5.21	-0.32	4e-7	Bipolar disorder;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.1	-0.31	6.73e-7	Colorectal cancer;
KIRP	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg17736920	chr1:242011382	EXO1	0.42	5.13	0.31	5.86e-7	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg08888203	chr3:10149979	C3orf24	0.49	5.13	0.31	5.78e-7	Alzheimer's disease;
KIRP	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg11815991	chr20:30193098	ID1	-0.45	-4.87	-0.3	2.02e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.54	7.13	0.41	1.11e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.11	-0.31	6.6e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg10584100	chr8:62604144	ASPH	-0.44	-6.02	-0.36	6.37e-9	Select biomarker traits;
KIRP	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.04	0.36	5.52e-9	Height;
KIRP	cis	rs9393813	0.805	rs2205829	chr6:27480227	A/G	cg03332623	chr6:27441972	ZNF184	0.32	4.89	0.3	1.82e-6	Bipolar disorder;
KIRP	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18252515	chr7:66147081	NA	0.46	5.38	0.32	1.7e-7	Aortic root size;
KIRP	cis	rs959260	1.000	rs4788892	chr17:73391277	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.09	-0.36	4.32e-9	Systemic lupus erythematosus;
KIRP	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg06565975	chr8:143823917	SLURP1	0.48	7.36	0.42	2.81e-12	Urinary tract infection frequency;
KIRP	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.29	0.37	1.48e-9	Menopause (age at onset);
KIRP	cis	rs7565981	1.000	rs72627410	chr2:101427758	G/A	cg02232089	chr2:101440696	NPAS2	-0.58	-5.27	-0.32	2.94e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg06453172	chr10:134556979	INPP5A	-0.57	-6.46	-0.38	5.46e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.57	-7.76	-0.44	2.29e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.55	6.82	0.4	6.81e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2367563	1.000	rs8699	chr12:96051883	A/G	cg19013339	chr12:96052514	NTN4	0.33	5.08	0.31	7.31e-7	Allergic dermatitis (nickel);
KIRP	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg11833968	chr6:79620685	NA	-0.44	-6.76	-0.4	9.78e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	0.519	rs7598901	chr2:73675844	C/T	cg20560298	chr2:73613845	ALMS1	0.47	5.83	0.35	1.77e-8	Metabolite levels;
KIRP	cis	rs1620921	0.505	rs11758404	chr6:161210455	A/G	cg01280913	chr6:161186852	NA	-0.58	-7.69	-0.44	3.56e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1862626	0.506	rs7716644	chr5:56043426	C/T	cg14703610	chr5:56206110	C5orf35	0.41	5.24	0.32	3.45e-7	Cancer (pleiotropy);
KIRP	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.69	9.0	0.5	6.12e-17	Cognitive function;
KIRP	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.33	-5.26	-0.32	3.15e-7	Asthma;
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs2280630	0.529	rs1274957	chr3:39185077	G/A	cg01426195	chr3:39028469	NA	0.6	9.42	0.51	3.55e-18	Verbal declarative memory;
KIRP	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg25801113	chr15:45476975	SHF	0.44	7.98	0.45	5.46e-14	Uric acid levels;
KIRP	cis	rs12704876	0.509	rs1608741	chr7:96354206	G/A	cg03808172	chr7:96339361	SHFM1	0.57	7.56	0.43	7.85e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg08169901	chr6:163834872	QKI	0.45	6.06	0.36	5.09e-9	Colorectal cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13106476	chr6:11542732	TMEM170B	0.45	6.06	0.36	5.17e-9	Interleukin-4 levels;
KIRP	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.49	-0.43	1.2e-12	Gut microbiome composition (summer);
KIRP	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.48	0.33	1.03e-7	Total cholesterol levels;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg00137828	chr10:105881754	C10orf78	0.5	6.2	0.37	2.42e-9	DNA methylation (variation);
KIRP	cis	rs9394841	0.667	rs10807268	chr6:41777591	A/T	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs1816752	0.652	rs2902356	chr13:24988471	C/T	cg02811702	chr13:24901961	NA	0.41	5.38	0.32	1.77e-7	Obesity-related traits;
KIRP	cis	rs2302729	0.625	rs10848693	chr12:2833013	A/T	cg19945202	chr12:2788847	CACNA1C	0.59	5.37	0.32	1.83e-7	Sleep quality;
KIRP	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.63	-7.39	-0.43	2.25e-12	Type 2 diabetes;
KIRP	cis	rs4356932	1.000	rs6828596	chr4:76961373	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.9	0.3	1.75e-6	Blood protein levels;
KIRP	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	0.6	5.05	0.31	8.68e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.86	-13.52	-0.65	1.62e-31	Height;
KIRP	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg17554472	chr22:41940697	POLR3H	0.68	6.94	0.4	3.5e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg05347473	chr6:146136440	FBXO30	0.5	7.18	0.42	8.29e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg24375607	chr4:120327624	NA	0.59	6.42	0.38	6.89e-10	Corneal astigmatism;
KIRP	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg23307798	chr14:103986281	CKB	-0.51	-6.88	-0.4	4.81e-11	Coronary artery disease;
KIRP	trans	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg11693508	chr17:37793320	STARD3	0.5	6.76	0.4	9.81e-11	Neuroticism;
KIRP	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg07621104	chr11:117668040	DSCAML1	0.46	5.81	0.35	1.91e-8	Myopia;
KIRP	trans	rs6734238	0.966	rs7587033	chr2:113850262	C/G	cg11332951	chr1:2396472	NA	-0.41	-6.04	-0.36	5.75e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	trans	rs1459104	0.866	rs12804916	chr11:54831763	G/A	cg26562691	chr16:23850404	PRKCB	0.61	6.04	0.36	5.55e-9	Body mass index;
KIRP	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.83	12.06	0.61	1.3e-26	Blood metabolite ratios;
KIRP	cis	rs12318506	0.826	rs11180438	chr12:75668035	T/G	cg04728562	chr12:75699417	CAPS2	-0.99	-7.34	-0.42	3.08e-12	Coronary artery calcification;
KIRP	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg02534363	chr3:47050950	NBEAL2	-0.29	-4.93	-0.3	1.48e-6	Colorectal cancer;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03647317	chr4:187891568	NA	-0.78	-13.12	-0.64	3.72e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17067123	0.539	rs79352031	chr4:180066810	C/T	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.47	-0.33	1.09e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg26338869	chr17:61819248	STRADA	0.56	6.71	0.39	1.3100000000000001e-10	Prudent dietary pattern;
KIRP	cis	rs9400467	0.506	rs12192147	chr6:111648057	G/C	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.21	0.32	3.96e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	1.11	7.87	0.45	1.11e-13	Skin colour saturation;
KIRP	trans	rs6555855	0.672	rs4242184	chr5:168726086	C/T	cg04970847	chr16:1351306	NA	-0.37	-6.11	-0.36	3.84e-9	Menarche (age at onset);
KIRP	cis	rs3026101	0.671	rs3026134	chr17:5309690	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg02527881	chr3:46936655	PTH1R	-0.49	-6.32	-0.37	1.25e-9	Birth weight;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25634484	chr8:8559074	CLDN23	-0.42	-6.25	-0.37	1.81e-9	Myopia;
KIRP	cis	rs7903847	0.642	rs11189200	chr10:99156273	C/G	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2908197	0.699	rs2860469	chr7:75960506	A/C	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.3	-5.01	-0.3	1.03e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2380205	0.935	rs907689	chr10:5900973	A/G	cg27141509	chr10:5886111	NA	-0.36	-5.3	-0.32	2.53e-7	Breast cancer;
KIRP	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.78	-10.13	-0.54	2.16e-20	Coronary artery disease;
KIRP	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg09904177	chr6:26538194	HMGN4	0.4	4.95	0.3	1.4e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23542449	chr12:22602447	KIAA0528	-0.42	-6.48	-0.38	4.84e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg05304507	chr6:116381966	FRK	0.21	5.73	0.34	3e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg06742321	chr12:123595122	PITPNM2	-0.44	-5.44	-0.33	1.3e-7	Platelet count;
KIRP	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-7.77	-0.44	2.13e-13	Tonsillectomy;
KIRP	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg08499158	chr17:42289980	UBTF	0.59	7.86	0.45	1.22e-13	Total body bone mineral density;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-10.59	-0.56	7.76e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg15655495	chr12:38532458	NA	0.26	5.05	0.31	8.43e-7	Bladder cancer;
KIRP	cis	rs7404928	0.526	rs11645239	chr16:23847062	C/G	cg05497750	chr16:23765381	CHP2	-0.48	-5.69	-0.34	3.65e-8	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.43	5.7	0.34	3.5e-8	Hypertriglyceridemia;
KIRP	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-1.0	-9.66	-0.52	6.56e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs136211	0.640	rs9306310	chr22:36758258	G/A	cg16924664	chr22:36878180	TXN2	0.47	5.59	0.34	6e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8177876	0.822	rs59685942	chr16:81115139	A/G	cg08591886	chr16:81111003	C16orf46	-0.59	-5.76	-0.34	2.45e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10671167	chr7:39988923	CDK13	0.52	6.02	0.36	6.16e-9	Smoking initiation;
KIRP	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07562458	chr1:224622430	WDR26	0.52	7.02	0.41	2.17e-11	Parkinson's disease;
KIRP	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.34	-6.6	-0.39	2.45e-10	Urinary metabolites;
KIRP	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg07936489	chr17:37558343	FBXL20	-0.51	-6.53	-0.38	3.7e-10	Asthma;
KIRP	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg26681399	chr22:41777847	TEF	0.54	5.26	0.32	3.19e-7	Vitiligo;
KIRP	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg08888203	chr3:10149979	C3orf24	0.5	5.28	0.32	2.83e-7	Alzheimer's disease;
KIRP	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.54	-6.85	-0.4	6.01e-11	Type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21819024	chr1:52344978	NRD1	0.52	6.14	0.36	3.35e-9	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25719132	chr2:70520671	SNRPG	0.51	6.32	0.37	1.23e-9	Parkinson's disease;
KIRP	cis	rs6504950	0.720	rs9914836	chr17:52997875	C/G	cg26251398	chr17:52985966	TOM1L1	0.43	5.71	0.34	3.16e-8	Breast cancer;
KIRP	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.07	0.61	1.14e-26	Blood protein levels;
KIRP	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg14324370	chr2:177042789	NA	0.74	10.08	0.54	3.21e-20	IgG glycosylation;
KIRP	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg10503236	chr1:231470652	EXOC8	-0.51	-7.28	-0.42	4.53e-12	Hemoglobin concentration;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14565903	chr19:14260591	LPHN1	0.29	6.43	0.38	6.75e-10	Survival in pancreatic cancer;
KIRP	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.63	10.41	0.55	2.95e-21	Coronary artery disease;
KIRP	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6433857	0.536	rs1971134	chr2:181351532	G/A	cg23363182	chr2:181467187	NA	-0.36	-4.9	-0.3	1.75e-6	Body mass index;
KIRP	cis	rs4389656	0.625	rs7712516	chr5:6745571	A/T	cg10857441	chr5:6722123	POLS	-0.45	-6.36	-0.38	9.58e-10	Coronary artery disease;
KIRP	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.96	-15.26	-0.7	1.94e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg11131117	chr7:1891496	MAD1L1	0.4	4.85	0.3	2.19e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.5	-6.32	-0.37	1.24e-9	Breast cancer;
KIRP	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.56	-6.6	-0.39	2.45e-10	Facial morphology (factor 23);
KIRP	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.08	0.31	7.56e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg14664628	chr15:75095509	CSK	-0.61	-7.42	-0.43	1.9e-12	Breast cancer;
KIRP	cis	rs7188697	0.922	rs6499962	chr16:58610750	A/C	cg21335942	chr16:58549945	SETD6	-0.46	-5.12	-0.31	6.31e-7	QT interval;
KIRP	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.23	-0.55	1.03e-20	Hypospadias;
KIRP	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg15026998	chr2:160761622	LY75	-0.35	-5.1	-0.31	6.71e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.59	7.52	0.43	1.01e-12	Aortic root size;
KIRP	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg10760299	chr15:45669010	GATM	0.35	5.11	0.31	6.55e-7	Homoarginine levels;
KIRP	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs4919044	0.808	rs1339820	chr10:94818382	A/C	cg05127821	chr10:94822908	CYP26C1	1.06	10.5	0.56	1.45e-21	Coronary artery disease;
KIRP	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg22117172	chr7:91764530	CYP51A1	0.51	7.34	0.42	3.04e-12	Breast cancer;
KIRP	cis	rs6445967	1.000	rs6786088	chr3:58315075	T/C	cg16569813	chr3:58235849	ABHD6	-0.33	-4.89	-0.3	1.81e-6	Platelet count;
KIRP	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg16388071	chr6:169726476	NA	-0.38	-5.16	-0.31	4.99e-7	Obesity-related traits;
KIRP	cis	rs7011507	1.000	rs79060284	chr8:49147932	G/C	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.67e-19	Prudent dietary pattern;
KIRP	cis	rs2071426	0.959	rs36084004	chr10:96826028	C/T	cg09036531	chr10:96991505	NA	-0.67	-7.37	-0.43	2.66e-12	Blood metabolite levels;
KIRP	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.25	0.55	8.96e-21	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03468541	chr14:89029199	ZC3H14	-0.48	-6.48	-0.38	4.86e-10	Myopia;
KIRP	cis	rs7116495	1.000	rs4944258	chr11:71743393	T/A	cg18441811	chr11:71824068	C11orf51	-0.61	-4.9	-0.3	1.78e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.42	4.9	0.3	1.74e-6	Aortic root size;
KIRP	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.78	6.41	0.38	7.4e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs4356975	0.563	rs12512526	chr4:69966418	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg27347728	chr4:17578864	LAP3	0.41	4.85	0.3	2.15e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3736594	0.959	rs10201247	chr2:27974971	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-7.32	-0.42	3.46e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg06871246	chr4:1363661	KIAA1530	-0.58	-7.21	-0.42	6.77e-12	Longevity;
KIRP	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.72	9.21	0.51	1.44e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17554472	chr22:41940697	POLR3H	-0.64	-6.79	-0.4	8.18e-11	Vitiligo;
KIRP	cis	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.35e-7	Oral cavity cancer;
KIRP	cis	rs6859018	0.951	rs3181217	chr5:158752270	C/T	cg26646896	chr5:158686746	NA	-0.34	-4.95	-0.3	1.36e-6	Serum sulfate level;
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	14.67	0.68	1.99e-35	Alzheimer's disease;
KIRP	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.43	5.25	0.32	3.33e-7	Iron status biomarkers;
KIRP	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg05360138	chr12:110035743	NA	0.49	5.54	0.33	7.95e-8	Neuroticism;
KIRP	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg05335186	chr13:53173507	NA	0.43	6.5	0.38	4.41e-10	Lewy body disease;
KIRP	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.46	-6.15	-0.36	3.13e-9	Schizophrenia;
KIRP	cis	rs9311676	0.632	rs4130877	chr3:58374893	T/C	cg06643156	chr3:58380774	PXK	0.35	4.97	0.3	1.27e-6	Systemic lupus erythematosus;
KIRP	cis	rs1440410	0.795	rs13119330	chr4:144185569	C/T	cg01719995	chr4:144104893	USP38	0.4	5.27	0.32	3.02e-7	Ischemic stroke;
KIRP	cis	rs787274	1.000	rs947609	chr9:115516562	A/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.34	-0.37	1.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs73200209	0.912	rs7969182	chr12:116612079	T/C	cg01776926	chr12:116560359	MED13L	-0.44	-5.31	-0.32	2.45e-7	Total body bone mineral density;
KIRP	cis	rs5753618	0.509	rs5997902	chr22:31583007	A/G	cg22777020	chr22:31556080	RNF185	-0.47	-4.96	-0.3	1.33e-6	Colorectal cancer;
KIRP	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.6	9.07	0.5	3.93e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11955175	0.717	rs112304996	chr5:40867592	A/T	cg04002187	chr5:40835754	RPL37	0.79	5.29	0.32	2.67e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg23322996	chr12:94312405	NA	0.59	6.32	0.37	1.19e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg00310523	chr12:86230176	RASSF9	-0.57	-8.93	-0.49	9.94e-17	Major depressive disorder;
KIRP	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.72	10.52	0.56	1.34e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg14329673	chr8:95732141	DPY19L4	-0.57	-6.04	-0.36	5.8e-9	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs3755132	0.929	rs4668949	chr2:15771615	C/T	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.67	8.98	0.5	7.43e-17	Longevity;
KIRP	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg01877450	chr7:97915802	BRI3	-0.52	-6.59	-0.39	2.6e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.34	0.47	5.3e-15	Mood instability;
KIRP	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6594499	0.872	rs6594498	chr5:110458351	G/A	cg04022379	chr5:110408740	TSLP	0.47	7.07	0.41	1.59e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.64	7.87	0.45	1.16e-13	Aortic root size;
KIRP	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg01843524	chr15:80216276	C15orf37;ST20	0.48	5.85	0.35	1.56e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs238295	0.805	rs1056244	chr20:5551034	G/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.5	-5.08	-0.31	7.56e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg22974920	chr21:40686053	BRWD1	0.46	5.53	0.33	8.11e-8	Cognitive function;
KIRP	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg19678392	chr7:94953810	PON1	0.41	4.89	0.3	1.82e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18357526	chr6:26021779	HIST1H4A	0.51	6.64	0.39	1.95e-10	Height;
KIRP	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.27	-0.37	1.59e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4713118	0.869	rs9283883	chr6:27715470	T/A	cg20933634	chr6:27740509	NA	0.36	4.88	0.3	1.87e-6	Parkinson's disease;
KIRP	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg02336718	chr17:17403227	NA	0.34	5.14	0.31	5.49e-7	Total body bone mineral density;
KIRP	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.92	-13.68	-0.66	4.64e-32	Lung cancer;
KIRP	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.92	-0.4	3.9e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.54	6.97	0.41	2.89e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg26149184	chr10:133730230	NA	0.41	4.93	0.3	1.52e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-0.99	-15.27	-0.7	1.73e-37	Dilated cardiomyopathy;
KIRP	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.48	5.33	0.32	2.21e-7	Schizophrenia;
KIRP	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	cis	rs963731	0.649	rs2123881	chr2:39247742	G/A	cg04010122	chr2:39346883	SOS1	-0.95	-6.6	-0.39	2.52e-10	Corticobasal degeneration;
KIRP	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg14593290	chr7:50529359	DDC	-0.43	-5.44	-0.33	1.31e-7	Malaria;
KIRP	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.57	7.71	0.44	3.07e-13	Obesity-related traits;
KIRP	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-9.09	-0.5	3.37e-17	Resting heart rate;
KIRP	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.22e-13	Coronary artery calcification;
KIRP	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.1	0.41	1.31e-11	Retinal vascular caliber;
KIRP	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.69	0.48	5.22e-16	Motion sickness;
KIRP	cis	rs10128264	0.902	rs1250582	chr10:80973447	G/T	cg18737081	chr10:80999807	ZMIZ1	-0.27	-5.05	-0.31	8.73e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.57	-0.43	7.48e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg12591125	chr7:1885375	MAD1L1	0.58	5.55	0.33	7.48e-8	Bipolar disorder;
KIRP	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05220968	chr6:146057943	EPM2A	0.38	4.9	0.3	1.72e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg21775007	chr8:11205619	TDH	-0.39	-5.03	-0.31	9.63e-7	Neuroticism;
KIRP	cis	rs4389656	0.857	rs274715	chr5:6723429	C/T	cg10857441	chr5:6722123	POLS	0.47	6.69	0.39	1.49e-10	Coronary artery disease;
KIRP	cis	rs526231	0.578	rs6867392	chr5:102281887	C/G	cg23492399	chr5:102201601	PAM	-0.46	-5.14	-0.31	5.67e-7	Primary biliary cholangitis;
KIRP	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg07701084	chr6:150067640	NUP43	0.59	7.65	0.44	4.68e-13	Lung cancer;
KIRP	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg02297831	chr4:17616191	MED28	0.59	7.18	0.42	8.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02115904	chr11:82997380	CCDC90B	0.98	6.54	0.38	3.52e-10	P wave terminal force;
KIRP	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.2	-0.55	1.31e-20	Coffee consumption (cups per day);
KIRP	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	1.01	17.62	0.75	1.64e-45	Breast cancer;
KIRP	trans	rs7246760	0.737	rs73501268	chr19:9803081	G/A	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.4e-20	Pursuit maintenance gain;
KIRP	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg26513180	chr16:89883248	FANCA	0.57	6.98	0.41	2.72e-11	Vitiligo;
KIRP	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg04455712	chr21:45112962	RRP1B	0.44	5.83	0.35	1.7e-8	Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs9815354	0.767	rs73071238	chr3:41992243	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.51	0.48	1.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.58	-7.71	-0.44	3.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.84	12.82	0.63	3.76e-29	Orofacial clefts;
KIRP	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg09936400	chr10:82049201	MAT1A	0.3	4.94	0.3	1.45e-6	Diabetic kidney disease;
KIRP	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.37	-7.45	-0.43	1.6e-12	Arsenic metabolism;
KIRP	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.79	12.24	0.62	3.25e-27	Multiple myeloma (IgH translocation);
KIRP	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7011507	1.000	rs76590780	chr8:49132921	A/G	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	0.89	6.77	0.4	9.3e-11	Mitochondrial DNA levels;
KIRP	cis	rs12220238	0.558	rs11000915	chr10:75952970	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.8	5.67	0.34	3.92e-8	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.64	7.66	0.44	4.17e-13	Eosinophil percentage of white cells;
KIRP	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.78	-9.76	-0.53	3.01e-19	Menarche (age at onset);
KIRP	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg06042504	chr8:55087323	NA	-0.61	-7.56	-0.43	7.79e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.93	14.65	0.68	2.37e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13893634	chr17:48229117	PPP1R9B	-0.46	-5.7	-0.34	3.5e-8	Temporomandibular joint disorder;
KIRP	cis	rs2457480	0.852	rs61857485	chr10:44719292	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;
KIRP	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.67	7.64	0.44	4.98e-13	Carotid intima media thickness;
KIRP	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.63	-8.98	-0.5	7.28e-17	Brugada syndrome;
KIRP	cis	rs7187994	0.848	rs12920732	chr16:84780613	C/T	cg07647771	chr16:84786436	USP10	-0.42	-5.42	-0.33	1.42e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-0.84	-8.24	-0.46	1.06e-14	Developmental language disorder (linguistic errors);
KIRP	trans	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg16141378	chr3:129829833	LOC729375	0.48	6.34	0.37	1.1e-9	Mood instability;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26366830	chr5:173043172	BOD1	0.43	6.05	0.36	5.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	1.12	21.43	0.81	3.36e-58	Monocyte count;
KIRP	cis	rs10207060	0.500	rs62183161	chr2:240699856	C/T	cg20333904	chr2:240724165	NA	-0.46	-5.17	-0.31	4.85e-7	Obesity-related traits;
KIRP	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.91	11.58	0.59	4.95e-25	Menopause (age at onset);
KIRP	cis	rs4903604	0.581	rs11850485	chr14:78033863	A/G	cg18872420	chr14:78023429	SPTLC2	0.37	5.69	0.34	3.51e-8	Gut microbiome composition (winter);
KIRP	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.56	7.78	0.44	1.99e-13	Mean corpuscular volume;
KIRP	cis	rs714027	1.000	rs4823075	chr22:30519152	T/C	cg27665648	chr22:30112403	NA	-0.41	-5.96	-0.35	8.91e-9	Lymphocyte counts;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg05025164	chr4:1340916	KIAA1530	0.46	5.6	0.34	5.78e-8	Obesity-related traits;
KIRP	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg00405596	chr8:11794950	NA	-0.46	-6.21	-0.37	2.25e-9	Mood instability;
KIRP	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg25319279	chr11:5960081	NA	-0.62	-6.46	-0.38	5.65e-10	DNA methylation (variation);
KIRP	cis	rs7180079	0.620	rs498806	chr15:64850939	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.01	-0.3	1.05e-6	Monocyte count;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-1.03	-12.18	-0.61	5.14e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.85	12.21	0.61	4.05e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg10326726	chr10:51549505	MSMB	-0.6	-8.92	-0.49	1.09e-16	Prostate-specific antigen levels;
KIRP	cis	rs62355272	0.897	rs6871116	chr5:35924748	G/C	cg13894535	chr5:35919491	CAPSL	-0.54	-6.28	-0.37	1.51e-9	Lymphocyte counts;
KIRP	cis	rs6561750	1.000	rs6561750	chr13:54435237	C/T	ch.13.53330881F	chr13:54432880	NA	-0.37	-5.0	-0.3	1.09e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg13852791	chr20:30311386	BCL2L1	0.64	7.0	0.41	2.43e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs2071403	0.901	rs938325	chr2:1401447	A/G	cg06500727	chr2:1417164	TPO	0.37	5.71	0.34	3.25e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg22563815	chr15:78856949	CHRNA5	0.5	7.8	0.45	1.8e-13	Sudden cardiac arrest;
KIRP	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.9	11.77	0.6	1.19e-25	Homoarginine levels;
KIRP	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg05342945	chr12:48394962	COL2A1	-0.45	-4.97	-0.3	1.27e-6	Lung cancer;
KIRP	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.53	-0.33	8.35e-8	Bipolar disorder;
KIRP	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11987759	chr7:65425863	GUSB	0.41	4.87	0.3	2.03e-6	Aortic root size;
KIRP	cis	rs3755132	0.929	rs3213793	chr2:15744123	T/G	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs41264869	0.628	rs7529665	chr1:205124871	G/A	cg21214746	chr1:205091277	RBBP5	0.53	6.88	0.4	4.91e-11	Blood protein levels;
KIRP	cis	rs13217239	0.511	rs4546474	chr6:27224633	C/T	cg12292205	chr6:26970375	C6orf41	0.37	5.39	0.33	1.62e-7	Schizophrenia;
KIRP	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg14664628	chr15:75095509	CSK	0.45	5.63	0.34	4.8e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.49	6.0	0.36	7.15e-9	Glycated hemoglobin levels;
KIRP	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs7215564	0.908	rs4889884	chr17:78664465	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs2548003	1.000	rs1593020	chr5:28733106	T/C	cg22863700	chr5:28928346	NA	0.42	4.91	0.3	1.69e-6	Hip geometry;
KIRP	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg25039879	chr17:56429692	SUPT4H1	0.59	5.06	0.31	8.1e-7	Cognitive test performance;
KIRP	cis	rs2294693	0.891	rs4714420	chr6:40992799	T/C	cg14769373	chr6:40998127	UNC5CL	-0.54	-5.96	-0.36	8.89e-9	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16821385	chr11:46467232	AMBRA1	0.45	6.63	0.39	2.11e-10	Survival in pancreatic cancer;
KIRP	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.14	0.46	1.95e-14	Neutrophil percentage of white cells;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg04371633	chr14:65381025	CHURC1	-0.48	-6.13	-0.36	3.43e-9	Neuroticism;
KIRP	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.38	-4.98	-0.3	1.19e-6	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07007148	chr14:33399915	NA	-0.45	-7.07	-0.41	1.63e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg00204512	chr16:28754710	NA	0.48	6.39	0.38	8.06e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7688540	0.723	rs17521834	chr4:225449	C/T	cg17891759	chr4:299121	NA	0.47	4.87	0.3	2.04e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.78	-11.21	-0.58	8.02e-24	Dental caries;
KIRP	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg01843034	chr6:37503916	NA	0.81	11.86	0.6	6.06e-26	Cognitive performance;
KIRP	cis	rs1215050	0.791	rs13114823	chr4:98671119	G/A	cg05340658	chr4:99064831	C4orf37	-0.49	-6.02	-0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg25922239	chr6:33757077	LEMD2	0.63	7.15	0.41	9.64e-12	Crohn's disease;
KIRP	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg23594656	chr7:65796392	TPST1	0.47	7.51	0.43	1.1e-12	Aortic root size;
KIRP	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24110177	chr3:50126178	RBM5	-0.67	-7.57	-0.43	7.5e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.87	8.93	0.49	1.03e-16	Hip geometry;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg07918776	chr15:49170303	SHC4;EID1	0.49	6.25	0.37	1.8e-9	DNA methylation (variation);
KIRP	cis	rs897080	0.552	rs1067389	chr2:44642290	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.94	0.35	9.82e-9	Height;
KIRP	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.7	-9.96	-0.54	7.66e-20	Brugada syndrome;
KIRP	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg12940439	chr1:67600707	NA	0.32	4.89	0.3	1.8e-6	Psoriasis;
KIRP	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg17764715	chr19:33622953	WDR88	0.67	8.41	0.47	3.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7221595	0.825	rs8081260	chr17:3981937	T/C	cg05562828	chr17:3906858	NA	0.56	6.19	0.37	2.5e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.04	-12.48	-0.62	5.1e-28	Vitiligo;
KIRP	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg08992911	chr2:238395768	MLPH	0.39	5.04	0.31	8.89e-7	Prostate cancer;
KIRP	cis	rs2671245	1.000	rs2671231	chr1:56157486	C/T	cg11523071	chr1:56160889	NA	0.4	6.16	0.37	2.91e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs199950	0.823	rs199946	chr1:181598815	C/A	cg04237608	chr1:18659049	IGSF21	0.39	6.56	0.39	3.22e-10	Body mass index (change over time);
KIRP	cis	rs10875746	0.669	rs11168487	chr12:48640709	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-5.03	-0.31	9.32e-7	Longevity (90 years and older);
KIRP	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg13385521	chr17:29058706	SUZ12P	0.85	6.87	0.4	5.32e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11987759	chr7:65425863	GUSB	0.49	6.37	0.38	9.01e-10	Aortic root size;
KIRP	cis	rs3755132	0.929	rs61446904	chr2:15748873	A/C	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.91	15.09	0.69	7.49e-37	Breast cancer;
KIRP	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.5	0.33	9.72e-8	Diisocyanate-induced asthma;
KIRP	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12893428	chr3:195717962	SDHAP1	0.48	6.43	0.38	6.57e-10	Pancreatic cancer;
KIRP	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.64	-0.34	4.76e-8	Height;
KIRP	cis	rs9879311	0.966	rs4684685	chr3:10411553	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.39	5.26	0.32	3.08e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs3762637	0.941	rs9810996	chr3:122074387	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.7	-0.34	3.39e-8	LDL cholesterol levels;
KIRP	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.92	-14.68	-0.68	1.78e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.5	-0.33	9.69e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18364779	chr6:26104403	HIST1H4C	0.42	5.5	0.33	9.47e-8	Schizophrenia;
KIRP	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.46	-5.66	-0.34	4.18e-8	Ulcerative colitis;
KIRP	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg00334542	chr7:100209784	MOSPD3	-0.77	-6.2	-0.37	2.42e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4926611	1.000	rs10888801	chr1:54108777	C/T	cg08927728	chr1:54059983	GLIS1	-0.24	-5.2	-0.31	4.1e-7	Hand grip strength;
KIRP	cis	rs873917	0.577	rs784611	chr1:40125988	T/A	cg18438793	chr1:40149837	HPCAL4	0.46	6.19	0.37	2.54e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg11783602	chr8:55087084	NA	-0.58	-6.88	-0.4	4.83e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.65	7.89	0.45	1e-13	Aortic root size;
KIRP	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg14703610	chr5:56206110	C5orf35	0.52	5.96	0.36	8.73e-9	Initial pursuit acceleration;
KIRP	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg16306078	chr6:126000798	NA	0.26	4.86	0.3	2.12e-6	Endometrial cancer;
KIRP	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.61	-10.01	-0.54	5.35e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs6466055	0.739	rs7806591	chr7:104927776	C/T	cg04380332	chr7:105027541	SRPK2	0.64	9.7	0.53	4.91e-19	Schizophrenia;
KIRP	cis	rs12210905	1.000	rs9368492	chr6:27221518	A/G	cg11502198	chr6:26597334	ABT1	-0.73	-5.02	-0.3	9.94e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg03959625	chr15:84868606	LOC388152	0.47	5.59	0.34	6.05e-8	Schizophrenia;
KIRP	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	cis	rs883565	0.569	rs1274972	chr3:39161456	G/A	cg01426195	chr3:39028469	NA	-0.52	-8.32	-0.47	5.98e-15	Handedness;
KIRP	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg05669848	chr5:237993	SDHA	-0.51	-5.37	-0.32	1.84e-7	Breast cancer;
KIRP	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.49	-7.89	-0.45	9.78e-14	Longevity;
KIRP	cis	rs78487399	0.710	rs74469180	chr2:43603367	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.04	-0.31	9.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg08992911	chr2:238395768	MLPH	0.41	5.16	0.31	5.18e-7	Prostate cancer;
KIRP	cis	rs7818345	0.967	rs4481612	chr8:19285336	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.4	0.38	7.59e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg21518248	chr2:162101506	NA	0.48	5.76	0.34	2.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg17340268	chr14:105411764	AHNAK2	-0.38	-4.96	-0.3	1.29e-6	Rheumatoid arthritis;
KIRP	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.42	5.97	0.36	8.39e-9	Dupuytren's disease;
KIRP	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.31	-0.42	3.69e-12	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.38	-5.14	-0.31	5.67e-7	Bipolar disorder;
KIRP	cis	rs2862064	0.818	rs1979870	chr5:156481383	T/C	cg12943317	chr5:156479607	HAVCR1	-0.94	-8.21	-0.46	1.26e-14	Platelet count;
KIRP	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.2	-0.31	4.19e-7	Coronary artery disease;
KIRP	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.7	-9.54	-0.52	1.46e-18	Cocaine dependence;
KIRP	cis	rs2904967	0.929	rs2904981	chr11:65003026	C/T	cg12562828	chr11:65076843	NA	-0.46	-6.71	-0.39	1.29e-10	Mean corpuscular volume;
KIRP	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.14	0.31	5.62e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2151522	0.603	rs1343220	chr6:127193036	G/A	cg21431617	chr6:127135037	NA	0.3	5.14	0.31	5.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.48	6.42	0.38	6.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg00677455	chr12:58241039	CTDSP2	-0.53	-6.56	-0.39	3.21e-10	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.78	0.49	2.79e-16	Life satisfaction;
KIRP	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.46e-8	Life satisfaction;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg07216194	chr8:27182965	PTK2B	0.47	5.88	0.35	1.32e-8	Neuroticism;
KIRP	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg18461458	chr19:21324796	ZNF431	0.47	4.88	0.3	1.94e-6	Pain;
KIRP	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	11.78	0.6	1.07e-25	Menarche (age at onset);
KIRP	trans	rs2867695	0.651	rs72656552	chr4:81135658	C/T	cg01441113	chr4:186560403	SORBS2	0.53	6.2	0.37	2.35e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs11800820	0.647	rs73136166	chr1:246673834	C/G	cg16700716	chr1:246684329	NA	0.61	5.9	0.35	1.19e-8	Obesity-related traits;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.57	-5.93	-0.35	1.01e-8	Lung function (FEV1/FVC);
KIRP	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg03585969	chr10:35415529	CREM	0.77	9.43	0.52	3.29e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg02002194	chr4:3960332	NA	-0.45	-6.08	-0.36	4.51e-9	Mood instability;
KIRP	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.44	5.89	0.35	1.3e-8	Body mass index;
KIRP	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.5	5.83	0.35	1.73e-8	Uric acid levels;
KIRP	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.8	-10.63	-0.56	5.77e-22	Menopause (age at onset);
KIRP	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03891929	chr10:89623341	PTEN;KILLIN	0.5	6.02	0.36	6.46e-9	Parkinson's disease;
KIRP	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg04804543	chr8:142233427	SLC45A4	0.48	5.28	0.32	2.86e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg05526886	chr2:227700861	RHBDD1	0.43	5.04	0.31	9.15e-7	Pulmonary function;
KIRP	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg06307176	chr5:131281290	NA	-0.55	-6.4	-0.38	7.71e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7809799	0.571	rs17161687	chr7:98941909	A/G	cg12290671	chr7:99195819	NA	0.64	4.91	0.3	1.67e-6	Ulcerative colitis;
KIRP	cis	rs72634258	0.786	rs9434992	chr1:8179392	G/T	cg00042356	chr1:8021962	PARK7	0.5	4.97	0.3	1.23e-6	Inflammatory bowel disease;
KIRP	cis	rs9513627	0.920	rs73556201	chr13:100128753	C/G	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-9.32	-0.51	6.79e-18	Developmental language disorder (linguistic errors);
KIRP	cis	rs2574704	0.961	rs2616557	chr3:11658291	G/A	cg07643000	chr3:11666825	VGLL4	-0.41	-6.0	-0.36	6.95e-9	Body mass index;
KIRP	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.72	9.85	0.53	1.7e-19	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7119038	0.818	rs11217033	chr11:118673706	T/C	cg19308663	chr11:118741387	NA	0.59	9.86	0.53	1.53e-19	Sjögren's syndrome;
KIRP	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg12756093	chr1:115239321	AMPD1	0.53	6.95	0.4	3.34e-11	Autism;
KIRP	cis	rs687432	0.774	rs56016266	chr11:57897131	G/A	cg19752551	chr11:57585705	CTNND1	-0.67	-8.46	-0.47	2.39e-15	Parkinson's disease;
KIRP	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs597583	0.951	rs579239	chr11:117425009	T/C	cg27161313	chr11:117392002	DSCAML1	-0.43	-4.94	-0.3	1.45e-6	Putamen volume;
KIRP	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg12560992	chr17:57184187	TRIM37	0.59	6.24	0.37	1.95e-9	Testicular germ cell tumor;
KIRP	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	9.14	0.5	2.37e-17	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs427941	0.667	rs201436	chr7:101733576	T/C	cg06246474	chr7:101738831	CUX1	0.55	6.87	0.4	5.13e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.29	0.32	2.73e-7	Educational attainment;
KIRP	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg02160872	chr5:212506	CCDC127	-0.46	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs8010715	0.816	rs8015168	chr14:24599872	A/T	cg23112188	chr14:24563095	PCK2	-0.34	-5.04	-0.31	9.06e-7	IgG glycosylation;
KIRP	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg22800045	chr5:56110881	MAP3K1	-0.7	-7.5	-0.43	1.13e-12	Initial pursuit acceleration;
KIRP	cis	rs7870753	0.838	rs10761086	chr9:99259251	C/T	cg25260653	chr9:99212216	HABP4	0.52	4.92	0.3	1.6e-6	Height;
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg02696790	chr15:75250997	RPP25	-0.3	-5.11	-0.31	6.49e-7	Breast cancer;
KIRP	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg01631408	chr1:248437212	OR2T33	-0.59	-7.62	-0.44	5.54e-13	Common traits (Other);
KIRP	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	0.86	12.12	0.61	8.17e-27	Homoarginine levels;
KIRP	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.89	-0.3	1.86e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.73	-9.7	-0.53	4.7e-19	Prudent dietary pattern;
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg21186296	chr8:27182909	PTK2B	0.48	6.12	0.36	3.77e-9	Neuroticism;
KIRP	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg11608241	chr8:8085544	FLJ10661	0.43	5.5	0.33	9.71e-8	Systolic blood pressure;
KIRP	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg14092571	chr14:90743983	NA	0.41	4.98	0.3	1.18e-6	Mortality in heart failure;
KIRP	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.62e-7	Depression;
KIRP	cis	rs711830	1.000	rs1549334	chr2:177039197	G/A	cg13092806	chr2:177043255	NA	0.65	6.84	0.4	6.33e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg03788504	chr6:150331562	NA	-0.37	-6.9	-0.4	4.4e-11	Alopecia areata;
KIRP	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg10932868	chr11:921992	NA	0.55	7.01	0.41	2.25e-11	Alzheimer's disease (late onset);
KIRP	cis	rs959260	1.000	rs7226070	chr17:73372811	T/C	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg18461458	chr19:21324796	ZNF431	0.47	4.9	0.3	1.76e-6	Pain;
KIRP	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.53e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.56	-7.51	-0.43	1.1e-12	Lung cancer;
KIRP	cis	rs7147624	1.000	rs10083363	chr14:66200768	G/A	cg03016385	chr14:66212404	NA	-0.95	-9.44	-0.52	3e-18	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg11738485	chr19:12877000	HOOK2	0.44	4.91	0.3	1.63e-6	Mean corpuscular volume;
KIRP	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg08975724	chr8:8085496	FLJ10661	0.67	8.56	0.48	1.24e-15	Neuroticism;
KIRP	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.62	-6.6	-0.39	2.54e-10	Response to diuretic therapy;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg27552081	chr17:25621774	WSB1	0.49	6.44	0.38	6.19e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg24692254	chr21:30365293	RNF160	0.46	5.98	0.36	7.68e-9	Pancreatic cancer;
KIRP	cis	rs1021993	0.672	rs1395752	chr1:209490435	G/C	cg06155620	chr1:209527581	NA	0.36	4.96	0.3	1.29e-6	Gut microbiome composition (winter);
KIRP	cis	rs17020663	0.713	rs753475	chr2:101647866	A/C	cg17494863	chr2:101638916	TBC1D8	-0.51	-5.44	-0.33	1.28e-7	Pulse pressure;
KIRP	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg08662619	chr6:150070041	PCMT1	-0.34	-5.42	-0.33	1.44e-7	Lung cancer;
KIRP	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.79	-12.19	-0.61	4.71e-27	Idiopathic membranous nephropathy;
KIRP	trans	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg10756647	chr7:56101905	PSPH	1.01	7.6	0.44	6.29e-13	Diabetic kidney disease;
KIRP	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25540579	chr19:1653193	TCF3	0.49	6.89	0.4	4.65e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs6545883	0.507	rs12617371	chr2:61569134	A/G	cg15711740	chr2:61764176	XPO1	0.43	5.18	0.31	4.65e-7	Tuberculosis;
KIRP	cis	rs6545883	0.826	rs777593	chr2:61419103	C/A	cg15711740	chr2:61764176	XPO1	-0.55	-6.92	-0.4	3.8e-11	Tuberculosis;
KIRP	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.7	-0.34	3.37e-8	Menarche (age at onset);
KIRP	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg23387468	chr7:139079360	LUC7L2	0.3	5.16	0.31	5.15e-7	Diisocyanate-induced asthma;
KIRP	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg00629928	chr5:358741	AHRR	0.51	4.96	0.3	1.34e-6	Breast cancer;
KIRP	cis	rs10208940	0.502	rs10203846	chr2:68670921	G/A	cg12452813	chr2:68675892	NA	-0.64	-7.88	-0.45	1.04e-13	Urate levels in lean individuals;
KIRP	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.76	10.94	0.57	5.71e-23	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05387457	chr10:21785997	C10orf114;MIR1915	0.47	6.03	0.36	6.03e-9	Parkinson's disease;
KIRP	cis	rs11997175	0.692	rs6468202	chr8:33747720	C/A	ch.8.33884649F	chr8:33765107	NA	0.63	7.94	0.45	7.26e-14	Body mass index;
KIRP	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg18850127	chr7:39170497	POU6F2	0.29	5.64	0.34	4.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.14	-0.41	1.08e-11	Gut microbiome composition (summer);
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg27532560	chr4:187881888	NA	-0.77	-12.87	-0.63	2.48e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7404843	0.925	rs72774861	chr16:15509634	C/A	cg02716450	chr16:28638775	NA	1.04	11.1	0.58	1.81e-23	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg10223061	chr2:219282414	VIL1	0.42	6.74	0.4	1.09e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7119	0.689	rs11630926	chr15:77819582	T/C	cg12131826	chr15:77904385	NA	0.47	5.43	0.33	1.33e-7	Type 2 diabetes;
KIRP	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.35	-5.25	-0.32	3.37e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg08648136	chr8:956695	NA	0.43	6.53	0.38	3.7e-10	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18760194	chr8:35186363	UNC5D	0.52	7.28	0.42	4.47e-12	Interleukin-4 levels;
KIRP	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg01422370	chr2:73384389	NA	0.42	5.55	0.33	7.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.1	-0.31	6.69e-7	Metabolite levels;
KIRP	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg16405210	chr4:1374714	KIAA1530	0.46	6.03	0.36	6e-9	Obesity-related traits;
KIRP	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.72	-8.57	-0.48	1.14e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2635047	0.638	rs55730206	chr18:44608230	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.84	-0.35	1.65e-8	Educational attainment;
KIRP	cis	rs13161895	1.000	rs6873781	chr5:179436734	A/C	cg02702477	chr5:179499311	RNF130	-0.69	-5.36	-0.32	1.95e-7	LDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21583226	chr2:31360693	GALNT14	0.51	6.51	0.38	4.19e-10	Parkinson's disease;
KIRP	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.98	-9.74	-0.53	3.65e-19	Multiple sclerosis;
KIRP	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.78	-11.2	-0.58	8.32e-24	Bladder cancer;
KIRP	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	1.22	12.22	0.61	3.81e-27	Alzheimer's disease;
KIRP	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.12	-0.31	6.28e-7	Blood pressure;
KIRP	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg24826892	chr11:71159390	DHCR7	-0.44	-4.95	-0.3	1.39e-6	Vitamin D levels;
KIRP	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.49e-6	Tonsillectomy;
KIRP	cis	rs9488822	0.650	rs195523	chr6:116246964	G/A	cg15226275	chr6:116381976	FRK	0.2	5.17	0.31	4.96e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3790645	0.958	rs2290589	chr1:26880288	C/T	cg23229016	chr1:26872525	RPS6KA1	0.24	6.12	0.36	3.74e-9	Glucose homeostasis traits;
KIRP	cis	rs12476592	0.602	rs262523	chr2:63892684	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-4.85	-0.3	2.21e-6	Childhood ear infection;
KIRP	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	cg12689670	chr1:183009347	LAMC1	0.44	6.32	0.37	1.25e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	1.07	17.19	0.74	5.02e-44	Cognitive function;
KIRP	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.51	-7.38	-0.43	2.45e-12	IgG glycosylation;
KIRP	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.06	-0.36	5.02e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.71	8.34	0.47	5.37e-15	Corneal astigmatism;
KIRP	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.53	-6.83	-0.4	6.58e-11	Mean corpuscular volume;
KIRP	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-23.51	-0.83	7.61e-65	Exhaled nitric oxide output;
KIRP	cis	rs6545883	0.831	rs9309336	chr2:61763165	T/C	cg15711740	chr2:61764176	XPO1	-0.62	-8.5	-0.48	1.87e-15	Tuberculosis;
KIRP	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.54	-0.38	3.49e-10	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-1.04	-15.92	-0.71	1.09e-39	Homoarginine levels;
KIRP	cis	rs2916247	1.000	rs6982094	chr8:93047827	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.97	-0.45	5.94e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs687432	0.812	rs7935428	chr11:57876436	C/A	cg19752551	chr11:57585705	CTNND1	-0.68	-8.75	-0.49	3.43e-16	Parkinson's disease;
KIRP	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg22705602	chr4:152727874	NA	-0.51	-8.61	-0.48	8.89e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg22356347	chr1:167427500	CD247	-0.43	-5.82	-0.35	1.84e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg19828298	chr1:3713105	LRRC47	0.56	6.55	0.39	3.38e-10	Sleep duration;
KIRP	cis	rs12155623	0.578	rs13277226	chr8:49883029	G/T	cg22283653	chr8:49824208	NA	-0.4	-5.45	-0.33	1.23e-7	Sudden cardiac arrest;
KIRP	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.25	6.69	0.39	1.52e-10	Crohn's disease;
KIRP	cis	rs921943	0.957	rs16876363	chr5:78327759	A/C	cg26802063	chr5:78281964	ARSB	-0.48	-5.97	-0.36	8.1e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18364779	chr6:26104403	HIST1H4C	0.61	8.02	0.46	4.2e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg23307798	chr14:103986281	CKB	-0.38	-5.09	-0.31	6.97e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg17590657	chr6:29973669	HLA-J;NCRNA00171	0.43	5.1	0.31	6.9e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.69	9.36	0.51	5.34e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.59	-8.14	-0.46	1.93e-14	Breast cancer;
KIRP	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.54	8.57	0.48	1.17e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.66	8.85	0.49	1.81e-16	Red blood cell count;
KIRP	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg13939156	chr17:80058883	NA	-0.48	-5.48	-0.33	1.06e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6601327	0.665	rs10107992	chr8:9653287	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-4.94	-0.3	1.43e-6	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11285937	chr4:39979757	PDS5A	0.67	6.09	0.36	4.39e-9	Lung function (FEV1);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04620418	chr8:65282285	NA	0.44	6.28	0.37	1.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.46	-0.43	1.44e-12	Triglycerides;
KIRP	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg15655495	chr12:38532458	NA	0.27	5.0	0.3	1.1e-6	Bladder cancer;
KIRP	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg04539111	chr16:67997858	SLC12A4	-0.66	-6.79	-0.4	8.16e-11	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7715811	0.913	rs1910091	chr5:13781535	G/A	cg07548982	chr5:13769939	DNAH5	-0.54	-6.46	-0.38	5.71e-10	Subclinical atherosclerosis traits (other);
KIRP	trans	rs2048656	0.524	rs12543959	chr8:9539000	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.22	-0.37	2.13e-9	Schizophrenia;
KIRP	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg04920474	chr2:44395004	PPM1B	0.36	4.94	0.3	1.43e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg00405596	chr8:11794950	NA	0.59	8.42	0.47	3.18e-15	Neuroticism;
KIRP	cis	rs5753037	0.809	rs2057882	chr22:30217827	A/T	cg27665648	chr22:30112403	NA	0.47	6.64	0.39	2.03e-10	Type 1 diabetes;
KIRP	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.24	-0.47	9.98e-15	Mood instability;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03122372	chr12:56651912	ANKRD52	-0.57	-6.1	-0.36	4.05e-9	Menopause (age at onset);
KIRP	cis	rs6546886	0.912	rs10168410	chr2:74294110	A/T	cg14702570	chr2:74259524	NA	-0.27	-5.22	-0.32	3.85e-7	Dialysis-related mortality;
KIRP	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg06365898	chr1:16533907	ARHGEF19	0.48	6.83	0.4	6.62e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.96	16.55	0.73	7.41e-42	Metabolic syndrome;
KIRP	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.6	-9.75	-0.53	3.38e-19	Itch intensity from mosquito bite;
KIRP	cis	rs12210905	1.000	rs114337870	chr6:27254937	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.8	-5.91	-0.35	1.13e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.5	-6.13	-0.36	3.56e-9	Alzheimer's disease (late onset);
KIRP	cis	rs17030434	0.654	rs1530105	chr4:154646994	C/T	cg14289246	chr4:154710475	SFRP2	0.62	7.4	0.43	2.14e-12	Electrocardiographic conduction measures;
KIRP	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs5753618	0.555	rs5749291	chr22:31907523	C/G	cg02404636	chr22:31891804	SFI1	0.56	6.55	0.39	3.35e-10	Colorectal cancer;
KIRP	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg02993010	chr8:124780839	FAM91A1	-0.57	-5.96	-0.36	8.74e-9	Pancreatic cancer;
KIRP	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.86	13.13	0.64	3.29e-30	Longevity;
KIRP	trans	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.59	-7.17	-0.42	8.81e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.38	7.63	0.44	5.09e-13	Diastolic blood pressure;
KIRP	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.88	-9.89	-0.53	1.24e-19	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17214676	chr8:92260467	SLC26A7	0.41	6.07	0.36	4.81e-9	Interleukin-4 levels;
KIRP	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.51	7.83	0.45	1.41e-13	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg10189774	chr4:17578691	LAP3	0.44	5.3	0.32	2.61e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.65	12.4	0.62	9.6e-28	Bone mineral density;
KIRP	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.53	-7.3	-0.42	3.93e-12	Pulmonary function;
KIRP	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.77	0.6	1.13e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7520050	0.897	rs4440807	chr1:46470878	T/C	cg03146154	chr1:46216737	IPP	-0.42	-5.26	-0.32	3.06e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.53	-7.64	-0.44	4.81e-13	Height;
KIRP	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg05520288	chr5:34929958	DNAJC21	0.58	7.25	0.42	5.48e-12	Educational attainment;
KIRP	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7481311	0.956	rs7125904	chr11:27543003	A/C	cg18117895	chr11:27722066	BDNF	0.47	5.06	0.31	8.21e-7	Body mass index;Weight;
KIRP	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg17376030	chr22:41985996	PMM1	0.62	6.84	0.4	6.27e-11	Vitiligo;
KIRP	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg05335186	chr13:53173507	NA	0.34	5.4	0.33	1.56e-7	Lewy body disease;
KIRP	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg17757837	chr7:157058334	UBE3C	0.8	10.77	0.57	2.01e-22	Body mass index;
KIRP	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.61	-7.34	-0.42	3.12e-12	Mosquito bite size;
KIRP	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.83	-13.8	-0.66	1.82e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.77	-11.9	-0.6	4.41e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.49	5.76	0.34	2.48e-8	Longevity;Endometriosis;
KIRP	cis	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs3750082	0.817	rs4723221	chr7:32954207	C/T	cg08946731	chr7:32981826	RP9P	-0.35	-5.19	-0.31	4.4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6504950	0.830	rs17745231	chr17:53036529	C/G	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.6	8.36	0.47	4.52e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs732716	0.853	rs1127888	chr19:4454083	C/T	cg19820705	chr19:4455316	UBXN6	0.67	8.34	0.47	5.5e-15	Mean corpuscular volume;
KIRP	cis	rs17453880	0.929	rs4612055	chr5:151963332	C/T	cg12297329	chr5:152029980	NA	0.66	9.9	0.53	1.15e-19	Subjective well-being;
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.79	11.48	0.59	1.04e-24	Obesity-related traits;
KIRP	cis	rs7562790	0.697	rs2023549	chr2:36679795	G/A	cg09467607	chr2:36825704	FEZ2	0.45	5.68	0.34	3.88e-8	QRS duration;QRS complex (Cornell);
KIRP	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.78	6.03	0.36	6.03e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg03684893	chr10:554711	DIP2C	-0.44	-6.43	-0.38	6.44e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs2738048	1.000	rs2702909	chr8:6824225	T/C	cg02787689	chr8:6828103	DEFA10P	-0.32	-6.26	-0.37	1.72e-9	IgA nephropathy;
KIRP	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg10351095	chr21:47802916	PCNT	0.44	5.7	0.34	3.34e-8	Testicular germ cell tumor;
KIRP	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18252515	chr7:66147081	NA	0.44	5.17	0.31	4.94e-7	Aortic root size;
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg06871246	chr4:1363661	KIAA1530	-0.52	-6.62	-0.39	2.24e-10	Longevity;
KIRP	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg08999081	chr20:33150536	PIGU	0.41	5.25	0.32	3.37e-7	Height;
KIRP	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	1.03	14.38	0.68	1.89e-34	Menopause (age at onset);
KIRP	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg12591125	chr7:1885375	MAD1L1	0.63	6.1	0.36	4.08e-9	Bipolar disorder;
KIRP	cis	rs6670533	0.571	rs72884445	chr1:24868592	C/T	cg07475527	chr1:24864545	NA	-0.99	-7.86	-0.45	1.18e-13	Fasting blood insulin (BMI interaction);
KIRP	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg04672837	chr16:48644449	N4BP1	0.48	6.48	0.38	4.88e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs10517025	0.673	rs17630357	chr4:42425114	A/T	cg13587180	chr4:42403248	SHISA3	0.43	4.85	0.3	2.23e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg13256891	chr4:100009986	ADH5	0.51	6.55	0.39	3.29e-10	Alcohol dependence;
KIRP	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.53	-7.46	-0.43	1.5e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs6539288	0.674	rs4964494	chr12:107284460	A/G	cg15890332	chr12:107067104	RFX4	0.31	5.38	0.32	1.74e-7	Total body bone mineral density;
KIRP	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.72	-9.63	-0.52	7.99e-19	Joint mobility (Beighton score);
KIRP	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg23649088	chr2:200775458	C2orf69	0.68	5.91	0.35	1.15e-8	Schizophrenia;
KIRP	cis	rs7224685	0.569	rs8066580	chr17:3996494	T/C	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.55e-7	Type 2 diabetes;
KIRP	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg00405596	chr8:11794950	NA	-0.42	-5.36	-0.32	1.91e-7	Neuroticism;
KIRP	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg04731861	chr2:219085781	ARPC2	0.31	7.96	0.45	6.19e-14	Colorectal cancer;
KIRP	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg20933634	chr6:27740509	NA	0.36	4.88	0.3	1.87e-6	Parkinson's disease;
KIRP	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-0.55	-6.68	-0.39	1.62e-10	Acne (severe);
KIRP	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.86	9.66	0.52	6.17e-19	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.45	6.47	0.38	5.32e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.6	-6.72	-0.39	1.25e-10	Aortic root size;
KIRP	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg20936604	chr3:58311152	NA	-0.7	-5.19	-0.31	4.51e-7	Cholesterol, total;
KIRP	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-12.1	-0.61	9.3e-27	Mortality in heart failure;
KIRP	cis	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg27636011	chr10:102746998	C10orf2;MRPL43	0.43	5.08	0.31	7.6e-7	Educational attainment;
KIRP	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.08	-0.31	7.31e-7	Bipolar disorder;
KIRP	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.09	-0.31	7.19e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg23594656	chr7:65796392	TPST1	-0.47	-7.31	-0.42	3.79e-12	Aortic root size;
KIRP	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg05220968	chr6:146057943	EPM2A	-0.42	-5.57	-0.33	6.53e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.68	8.88	0.49	1.47e-16	Breast cancer;
KIRP	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.75	9.32	0.51	6.82e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs231513	0.954	rs231510	chr17:41966470	T/C	cg26893861	chr17:41843967	DUSP3	-0.48	-5.02	-0.3	9.95e-7	Cognitive function;
KIRP	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	0.94	8.25	0.47	9.43e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs55675132	0.548	rs75587174	chr1:115373507	G/A	cg12756093	chr1:115239321	AMPD1	0.51	5.1	0.31	6.86e-7	Schizophrenia;
KIRP	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg25203885	chr2:87302643	LOC285074	-0.78	-6.28	-0.37	1.5e-9	Schizophrenia;
KIRP	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.65	0.48	6.58e-16	Motion sickness;
KIRP	cis	rs6969780	0.915	rs12666919	chr7:27189498	A/T	cg11410718	chr7:27170412	HOXA4	-0.42	-5.35	-0.32	2.01e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.64	-8.97	-0.5	7.91e-17	Multiple myeloma (IgH translocation);
KIRP	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-15.57	-0.7	1.66e-38	Height;
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg04369109	chr6:150039330	LATS1	-0.47	-5.74	-0.34	2.77e-8	Lung cancer;
KIRP	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.5	-5.71	-0.34	3.32e-8	Total cholesterol levels;
KIRP	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg02228329	chr11:64053129	BAD;GPR137	0.67	5.72	0.34	3.01e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.62	-6.4	-0.38	7.94e-10	DNA methylation (variation);
KIRP	cis	rs7119167	0.686	rs58364325	chr11:73054469	C/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.17	0.31	4.78e-7	Blood protein levels;
KIRP	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.75	8.58	0.48	1.08e-15	Corneal astigmatism;
KIRP	trans	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg03060546	chr3:49711283	APEH	-0.63	-6.64	-0.39	2.01e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.57	7.51	0.43	1.09e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.91	-14.97	-0.69	1.81e-36	Urate levels in lean individuals;
KIRP	cis	rs2281603	0.951	rs12385918	chr14:64999945	G/A	cg25009451	chr14:65006716	HSPA2	0.48	5.26	0.32	3.2e-7	Lymphocyte counts;
KIRP	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg13160058	chr8:26243215	BNIP3L	-0.47	-7.02	-0.41	2.15e-11	Red cell distribution width;
KIRP	cis	rs6496667	0.779	rs28516870	chr15:91037754	G/A	cg10434728	chr15:90938212	IQGAP1	0.36	4.87	0.3	2.03e-6	Rheumatoid arthritis;
KIRP	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg21775007	chr8:11205619	TDH	0.44	5.85	0.35	1.57e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.79	0.57	1.82e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs911119	0.866	rs6048925	chr20:23579056	C/A	cg16589663	chr20:23618590	CST3	0.49	4.91	0.3	1.64e-6	Chronic kidney disease;
KIRP	cis	rs13385	0.769	rs10060203	chr5:139599319	T/G	cg01860693	chr5:139557145	C5orf32	0.48	5.25	0.32	3.33e-7	Atrial fibrillation;
KIRP	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.88	6.99	0.41	2.52e-11	Fat distribution (HIV);
KIRP	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg16898833	chr6:26189333	HIST1H4D	0.62	5.03	0.31	9.48e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	1.03	10.51	0.56	1.43e-21	Height;
KIRP	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.4	-5.37	-0.32	1.78e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11605924	0.901	rs11607883	chr11:45839709	G/A	cg23097878	chr11:45879730	CRY2	0.33	6.54	0.38	3.53e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs4704187	0.687	rs10462513	chr5:74422607	C/T	cg03227963	chr5:74354835	NA	0.41	5.94	0.35	9.57e-9	Response to amphetamines;
KIRP	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	cg21523751	chr1:182988639	NA	0.35	5.26	0.32	3.21e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs3126085	1.000	rs3126098	chr1:152311923	T/C	cg26876637	chr1:152193138	HRNR	-0.68	-8.37	-0.47	4.29e-15	Atopic dermatitis;
KIRP	cis	rs11225247	0.772	rs35623064	chr11:102237391	T/C	cg06323957	chr11:102217781	BIRC2	0.75	4.95	0.3	1.36e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.75	10.68	0.56	3.97e-22	Height;
KIRP	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg01943577	chr7:158741284	NA	-0.37	-5.07	-0.31	7.68e-7	Height;
KIRP	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.43	-0.38	6.55e-10	Neuroticism;
KIRP	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg22974920	chr21:40686053	BRWD1	-0.46	-5.46	-0.33	1.13e-7	Cognitive function;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg00689492	chr4:1303491	MAEA	0.3	5.45	0.33	1.23e-7	Longevity;
KIRP	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-11.22	-0.58	7.11e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg18190219	chr22:46762943	CELSR1	-0.7	-5.94	-0.35	9.52e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.6	-6.87	-0.4	5.38e-11	Diabetic retinopathy;
KIRP	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.88	-0.4	4.95e-11	Triglycerides;
KIRP	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg23307798	chr14:103986281	CKB	-0.5	-6.73	-0.39	1.2e-10	Coronary artery disease;
KIRP	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.74	6.88	0.4	4.92e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs981844	0.890	rs62325113	chr4:154692555	A/G	cg14289246	chr4:154710475	SFRP2	0.69	7.85	0.45	1.27e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.5	-6.48	-0.38	5.05e-10	Coronary artery disease;
KIRP	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg17554472	chr22:41940697	POLR3H	0.67	7.11	0.41	1.22e-11	Vitiligo;
KIRP	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.54	-6.43	-0.38	6.61e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.34	5.19	0.31	4.46e-7	Type 2 diabetes;
KIRP	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg02187348	chr16:89574699	SPG7	0.47	5.76	0.34	2.53e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs4849845	0.637	rs62168279	chr2:121026771	T/C	cg24070213	chr2:121070622	NA	0.38	5.67	0.34	3.97e-8	Mean platelet volume;
KIRP	cis	rs2071403	0.933	rs1567920	chr2:1413226	A/G	cg06500727	chr2:1417164	TPO	0.47	7.45	0.43	1.6e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg01721255	chr8:58191610	C8orf71	0.61	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.37	-4.99	-0.3	1.15e-6	Blood metabolite levels;
KIRP	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.49	6.36	0.38	1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs882732	1.000	rs10146582	chr14:95037778	G/A	cg05186455	chr14:95027692	SERPINA4	-0.39	-5.3	-0.32	2.63e-7	Blood protein levels;
KIRP	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg12315302	chr6:26189340	HIST1H4D	0.73	5.11	0.31	6.41e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.45	-5.76	-0.34	2.46e-8	Initial pursuit acceleration;
KIRP	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg17366294	chr4:99064904	C4orf37	-0.35	-4.93	-0.3	1.52e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22307297	chr20:60903441	LAMA5	0.41	4.92	0.3	1.61e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.58	-0.8	2.03e-55	Height;
KIRP	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.63	-7.24	-0.42	5.59e-12	Vitiligo;
KIRP	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg26138937	chr11:71823887	C11orf51	-1.01	-6.88	-0.4	5.04e-11	Severe influenza A (H1N1) infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17544639	chr10:102289693	NDUFB8	0.51	6.79	0.4	8.58e-11	Parkinson's disease;
KIRP	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg04132472	chr17:19861366	AKAP10	0.46	6.43	0.38	6.57e-10	Schizophrenia;
KIRP	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.45	-15.77	-0.71	3.52e-39	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg06953865	chr19:18549723	ISYNA1	-0.39	-6.05	-0.36	5.31e-9	Breast cancer;
KIRP	cis	rs62012628	0.527	rs6495329	chr15:79092603	G/A	cg04896959	chr15:78267971	NA	-0.82	-10.82	-0.57	1.46e-22	Diastolic blood pressure;
KIRP	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg15556689	chr8:8085844	FLJ10661	0.54	7.12	0.41	1.15e-11	Joint mobility (Beighton score);
KIRP	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-1.05	-12.99	-0.64	9.96e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs757081	0.671	rs214090	chr11:17297161	C/T	cg15432903	chr11:17409602	KCNJ11	-0.62	-7.24	-0.42	5.88e-12	Systolic blood pressure;
KIRP	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.85	13.03	0.64	7.5e-30	Ulcerative colitis;
KIRP	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05220968	chr6:146057943	EPM2A	0.39	4.94	0.3	1.44e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.59	-0.52	1.04e-18	Morning vs. evening chronotype;
KIRP	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.51	6.34	0.37	1.08e-9	Radiation response;
KIRP	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg24315340	chr6:146058215	EPM2A	0.44	5.45	0.33	1.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00522555	chr19:10602587	KEAP1	0.46	6.53	0.38	3.73e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg20701182	chr2:24300061	SF3B14	0.62	5.29	0.32	2.68e-7	Lymphocyte counts;
KIRP	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg08283408	chr3:49949060	MON1A	0.44	5.85	0.35	1.52e-8	Body mass index;
KIRP	cis	rs7737355	0.812	rs181738	chr5:130820451	T/C	cg06307176	chr5:131281290	NA	0.41	4.96	0.3	1.33e-6	Life satisfaction;
KIRP	cis	rs9323205	0.861	rs55763867	chr14:51608567	G/A	cg23942311	chr14:51606299	NA	-0.59	-6.51	-0.38	4.27e-10	Cancer;
KIRP	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-0.78	-8.12	-0.46	2.3e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.59	5.54	0.33	7.59e-8	Eosinophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14654948	chr6:36164803	BRPF3	0.56	7.24	0.42	5.68e-12	Parkinson's disease;
KIRP	cis	rs10818894	0.571	rs4838069	chr9:126316511	C/T	cg16191174	chr9:126692580	DENND1A	0.5	5.44	0.33	1.31e-7	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
KIRP	cis	rs12367572	0.663	rs4561266	chr12:45415763	C/T	cg04608330	chr12:45269318	NELL2	-0.37	-5.09	-0.31	6.96e-7	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-18.85	-0.77	1.15e-49	Height;
KIRP	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.92	5.2	0.31	4.23e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg16586182	chr3:47516702	SCAP	-0.74	-10.5	-0.56	1.49e-21	Colorectal cancer;
KIRP	cis	rs7106204	0.620	rs16912295	chr11:24260162	T/C	ch.11.24196551F	chr11:24239977	NA	0.67	5.23	0.32	3.67e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg06815112	chr8:27182871	PTK2B	0.53	6.89	0.4	4.73e-11	Neuroticism;
KIRP	cis	rs6689305	0.674	rs6670361	chr1:100200184	C/T	cg09408571	chr1:101003634	GPR88	0.29	4.85	0.3	2.17e-6	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs6732160	0.741	rs10203600	chr2:73361398	G/C	cg01422370	chr2:73384389	NA	0.41	5.3	0.32	2.57e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.35	-0.51	5.65e-18	Morning vs. evening chronotype;
KIRP	cis	rs4262150	0.667	rs7444191	chr5:152251433	G/A	cg12297329	chr5:152029980	NA	0.47	6.61	0.39	2.37e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2930047	0.535	rs267949	chr5:10743929	T/C	cg14521931	chr5:10832172	NA	-0.53	-6.79	-0.4	8.17e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg21573476	chr21:45109991	RRP1B	-0.77	-10.85	-0.57	1.18e-22	Mean corpuscular volume;
KIRP	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.31e-11	Aortic root size;
KIRP	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg08499158	chr17:42289980	UBTF	0.47	6.2	0.37	2.36e-9	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg01304814	chr3:48885189	PRKAR2A	0.7	5.44	0.33	1.27e-7	Cognitive function;
KIRP	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg20750642	chr13:99100586	FARP1	0.39	5.39	0.33	1.61e-7	Alzheimer's disease;
KIRP	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.52	-13.79	-0.66	1.95e-32	Hip circumference adjusted for BMI;
KIRP	cis	rs34779708	0.931	rs4934711	chr10:35360310	G/A	cg04310649	chr10:35416472	CREM	-0.6	-7.14	-0.41	1.05e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	8.86	0.49	1.67e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs13067260	0.655	rs2332722	chr3:123725200	A/G	cg19918027	chr3:123987645	KALRN	-0.62	-5.46	-0.33	1.14e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7084402	0.934	rs1658441	chr10:60323021	G/C	cg05938607	chr10:60274200	BICC1	-0.45	-11.15	-0.58	1.21e-23	Refractive error;
KIRP	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg10224037	chr5:178157518	ZNF354A	0.87	10.34	0.55	4.85e-21	Neutrophil percentage of white cells;
KIRP	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg08992911	chr2:238395768	MLPH	0.56	5.43	0.33	1.38e-7	Prostate cancer;
KIRP	trans	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.64	5.29	0.32	2.74e-7	Putamen volume;
KIRP	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg04691961	chr3:161091175	C3orf57	-0.42	-5.68	-0.34	3.87e-8	Parkinson's disease;
KIRP	cis	rs12580194	0.593	rs61957933	chr12:55744710	T/G	cg11794356	chr12:55725991	OR6C3	-0.6	-8.62	-0.48	8.4e-16	Cancer;
KIRP	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg04519387	chr11:65556438	OVOL1	-0.35	-5.44	-0.33	1.29e-7	Acne (severe);
KIRP	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.49	6.34	0.37	1.08e-9	Testicular germ cell tumor;
KIRP	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg00491522	chr10:135256596	NA	0.68	10.08	0.54	3.23e-20	Systemic lupus erythematosus;
KIRP	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.63	7.8	0.45	1.79e-13	Multiple sclerosis;
KIRP	trans	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg19274270	chr17:78178856	CARD14	-0.36	-6.47	-0.38	5.25e-10	Kawasaki disease;
KIRP	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.43	-0.33	1.34e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg06042504	chr8:55087323	NA	-0.53	-6.5	-0.38	4.46e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18364779	chr6:26104403	HIST1H4C	0.37	4.98	0.3	1.21e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07544984	chr3:42845911	HIGD1A	0.5	6.21	0.37	2.23e-9	Parkinson's disease;
KIRP	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.54	7.1	0.41	1.37e-11	Response to temozolomide;
KIRP	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	1.35	10.84	0.57	1.19e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10609068	chr12:45609265	ANO6;PLEKHA9	0.44	6.26	0.37	1.74e-9	Survival in pancreatic cancer;
KIRP	cis	rs13168506	0.538	rs12515040	chr5:135441559	A/G	cg16684184	chr5:135415129	NA	-0.33	-4.9	-0.3	1.72e-6	Stroke;
KIRP	cis	rs7221595	0.778	rs62072386	chr17:3896168	T/C	cg09597638	chr17:3907349	NA	0.53	6.03	0.36	6.12e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26617929	chr16:1858877	NA	-0.56	-5.0	-0.3	1.08e-6	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg00360474	chr6:37504404	NA	-0.5	-7.42	-0.43	1.87e-12	Cognitive performance;
KIRP	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg08501292	chr6:25962987	TRIM38	1.15	6.48	0.38	5.04e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg05714579	chr10:131428358	MGMT	0.48	6.0	0.36	7.08e-9	Response to temozolomide;
KIRP	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.22e-9	Breast cancer;
KIRP	cis	rs17023223	0.537	rs2765533	chr1:119597395	T/C	cg18261050	chr1:119551319	NA	0.49	6.56	0.39	3.12e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg03157738	chr19:11308118	KANK2	0.56	6.53	0.38	3.79e-10	Sleep duration;
KIRP	cis	rs6088813	1.000	rs6060402	chr20:34005240	T/C	cg14752227	chr20:34000481	UQCC	-0.49	-6.28	-0.37	1.49e-9	Height;
KIRP	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg23920097	chr1:209922102	NA	0.43	5.67	0.34	3.93e-8	Red blood cell count;
KIRP	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	1.04	12.49	0.62	4.79e-28	Response to antineoplastic agents;
KIRP	trans	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.03	-0.41	1.99e-11	Triglycerides;
KIRP	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg08501292	chr6:25962987	TRIM38	0.7	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	5.27	0.32	2.93e-7	Menopause (age at onset);
KIRP	cis	rs4356932	1.000	rs10017657	chr4:76985178	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-7.17	-0.42	8.73e-12	Morning vs. evening chronotype;
KIRP	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.98	14.12	0.67	1.47e-33	Cognitive function;
KIRP	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.81e-8	Body mass index;
KIRP	cis	rs17818399	0.781	rs6746598	chr2:46865773	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.44	0.33	1.28e-7	Height;
KIRP	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-6.0	-0.36	6.87e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4132509	1.000	rs28869008	chr1:243986344	C/A	cg21452805	chr1:244014465	NA	0.57	5.42	0.33	1.41e-7	RR interval (heart rate);
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-0.7	-7.13	-0.41	1.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.25	0.32	3.23e-7	Lung cancer;
KIRP	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.61	-0.34	5.47e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-4.95	-0.3	1.35e-6	Ulcerative colitis;
KIRP	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-1.19	-15.72	-0.71	5.08e-39	Platelet distribution width;
KIRP	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.56	6.83	0.4	6.5e-11	Aortic root size;
KIRP	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.92	-0.4	3.79e-11	Mood instability;
KIRP	cis	rs1165472	1.000	rs6659204	chr1:56111170	T/C	cg11523071	chr1:56160889	NA	0.39	5.12	0.31	6.26e-7	Paclitaxel-induced neuropathy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23797439	chr20:8113355	PLCB1	0.5	6.14	0.36	3.37e-9	Smoking initiation;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02475777	chr4:1388615	CRIPAK	0.36	4.87	0.3	2.03e-6	Obesity-related traits;
KIRP	cis	rs13065560	0.534	rs4318494	chr3:38886804	A/G	cg01426195	chr3:39028469	NA	-0.38	-6.02	-0.36	6.44e-9	Interleukin-18 levels;
KIRP	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg21775007	chr8:11205619	TDH	-0.46	-6.31	-0.37	1.3e-9	Neuroticism;
KIRP	cis	rs6088619	1.000	rs6088619	chr20:33411871	A/G	cg24642439	chr20:33292090	TP53INP2	0.72	5.39	0.33	1.64e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs76693355	0.512	rs12270397	chr11:120248342	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.44	-5.63	-0.34	4.78e-8	Intraocular pressure;
KIRP	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg01849466	chr14:104193079	ZFYVE21	0.42	5.17	0.31	4.79e-7	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.2	-0.51	1.63e-17	Morning vs. evening chronotype;
KIRP	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.88	-0.4	4.84e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg15764593	chr10:829463	NA	0.83	9.01	0.5	5.94e-17	Uric acid levels;
KIRP	cis	rs6545883	0.965	rs7421663	chr2:61753786	C/T	cg15711740	chr2:61764176	XPO1	-0.61	-8.27	-0.47	8.41e-15	Tuberculosis;
KIRP	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg13206674	chr6:150067644	NUP43	-0.52	-7.38	-0.43	2.39e-12	Testicular germ cell tumor;
KIRP	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.82	-8.97	-0.5	7.94e-17	Gastritis;
KIRP	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg05082376	chr22:42548792	NA	0.46	5.84	0.35	1.62e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.05	-0.31	8.64e-7	Schizophrenia;
KIRP	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg09754948	chr16:28834200	ATXN2L	0.44	4.96	0.3	1.31e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg23587288	chr2:27483067	SLC30A3	-0.38	-4.85	-0.3	2.23e-6	Total body bone mineral density;
KIRP	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	16.07	0.72	3.23e-40	Colorectal cancer;
KIRP	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.53	6.84	0.4	6.23e-11	IgG glycosylation;
KIRP	cis	rs7621025	0.505	rs61789643	chr3:136109752	G/T	cg15507776	chr3:136538369	TMEM22	-0.69	-5.92	-0.35	1.07e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg13736514	chr6:26305472	NA	-0.48	-5.2	-0.31	4.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg11845111	chr2:191398756	TMEM194B	-0.72	-7.89	-0.45	1.02e-13	Diastolic blood pressure;
KIRP	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg21905437	chr5:178450457	ZNF879	0.58	6.86	0.4	5.63e-11	Pubertal anthropometrics;
KIRP	cis	rs2071403	0.933	rs1972113	chr2:1407046	T/C	cg06500727	chr2:1417164	TPO	0.46	7.02	0.41	2.1e-11	Thyroid peroxidase antibody positivity;
KIRP	cis	rs10128251	0.962	rs10752281	chr10:5711220	C/T	cg11519256	chr10:5708881	ASB13	-0.48	-5.9	-0.35	1.22e-8	Childhood ear infection;
KIRP	cis	rs918629	0.567	rs1458018	chr5:95253295	G/T	cg16656078	chr5:95278638	ELL2	-0.35	-5.32	-0.32	2.35e-7	IgG glycosylation;
KIRP	cis	rs13082711	0.911	rs17019809	chr3:27509080	A/G	cg02860705	chr3:27208620	NA	0.47	6.61	0.39	2.37e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24447438	chr18:21718979	CABYR	0.41	6.45	0.38	5.85e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.42	5.37	0.32	1.81e-7	Response to temozolomide;
KIRP	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg26068271	chr17:76253126	NA	-0.44	-6.47	-0.38	5.14e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.01	15.65	0.71	8.82e-39	Chronic sinus infection;
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	12.59	0.63	2.24e-28	Platelet count;
KIRP	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg18944383	chr4:111397179	ENPEP	-0.71	-13.29	-0.65	9.53e-31	Coronary artery disease;
KIRP	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg26816564	chr1:7831052	VAMP3	0.64	5.97	0.36	8.27e-9	Inflammatory bowel disease;
KIRP	cis	rs10073892	0.664	rs12657044	chr5:101890779	A/T	cg19774478	chr5:101632501	SLCO4C1	0.59	5.85	0.35	1.53e-8	Cognitive decline (age-related);
KIRP	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.73	-0.39	1.17e-10	Alcohol dependence;
KIRP	trans	rs2548003	0.518	rs2554904	chr5:28726189	T/A	cg23224356	chr2:98206733	ANKRD36B	0.62	6.08	0.36	4.48e-9	Hip geometry;
KIRP	cis	rs2425143	1.000	rs11699044	chr20:34312713	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.57	5.96	0.35	8.92e-9	Blood protein levels;
KIRP	cis	rs220324	0.683	rs467917	chr21:43593352	G/C	cg08841829	chr21:43638893	ABCG1	0.45	5.35	0.32	2.02e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.5	-0.33	9.69e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6838801	0.752	rs6817407	chr4:77616338	C/G	cg17476223	chr4:77663285	SHROOM3	-0.52	-7.19	-0.42	7.56e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg26875233	chr11:93583750	C11orf90	0.36	6.94	0.4	3.43e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16828019	0.852	rs12729586	chr1:41522377	C/A	cg03387723	chr1:41708464	SCMH1	-0.78	-6.48	-0.38	5.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.92	-0.69	2.74e-36	Alzheimer's disease;
KIRP	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.05	12.04	0.61	1.48e-26	Vitiligo;
KIRP	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-8.12	-0.46	2.24e-14	Personality dimensions;
KIRP	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs7463659	0.512	rs6992045	chr8:135448749	T/C	cg09855544	chr8:135498122	ZFAT	-0.42	-4.98	-0.3	1.18e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg04733989	chr22:42467013	NAGA	0.58	7.56	0.43	7.79e-13	Cognitive function;
KIRP	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	1.06	20.03	0.79	1.42e-53	Heart rate;
KIRP	cis	rs7976059	0.895	rs12367434	chr12:52247915	C/T	cg27042523	chr12:52245356	NA	0.75	11.4	0.59	1.83e-24	Urate levels;
KIRP	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.76	-8.65	-0.48	6.77e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg16989719	chr2:238392110	NA	-0.55	-5.87	-0.35	1.38e-8	Prostate cancer;
KIRP	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.21	0.37	2.21e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05347473	chr6:146136440	FBXO30	-0.6	-8.82	-0.49	2.16e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60154123	0.730	rs587203	chr1:210463786	C/T	cg09074223	chr1:210466472	NA	0.59	6.1	0.36	4.14e-9	Coronary artery disease;
KIRP	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.85	12.92	0.64	1.65e-29	Ulcerative colitis;
KIRP	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.79	-14.75	-0.68	1.08e-35	Obesity-related traits;
KIRP	trans	rs5760842	0.517	rs5760857	chr22:25501854	T/C	cg16733866	chr21:42792609	MX1	0.69	8.91	0.49	1.15e-16	Recurrent major depressive disorder;
KIRP	cis	rs16958440	1.000	rs62096474	chr18:44647504	G/A	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg06742321	chr12:123595122	PITPNM2	0.44	5.44	0.33	1.29e-7	Neutrophil percentage of white cells;
KIRP	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-1.03	-18.82	-0.77	1.49e-49	Height;
KIRP	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.98	-15.87	-0.71	1.54e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs11603020	0.950	rs11229066	chr11:57374871	C/G	cg23127183	chr11:57508653	C11orf31	-0.46	-5.33	-0.32	2.17e-7	Blood protein levels;
KIRP	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.5	7.56	0.43	8.02e-13	Resting heart rate;
KIRP	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.45	6.28	0.37	1.49e-9	Sitting height ratio;
KIRP	cis	rs1440410	0.798	rs10001113	chr4:144136405	T/C	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.87	5.84	0.35	1.66e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg00405596	chr8:11794950	NA	-0.48	-6.27	-0.37	1.63e-9	Retinal vascular caliber;
KIRP	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg06042504	chr8:55087323	NA	-0.61	-7.41	-0.43	2e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12963246	chr6:28129442	ZNF389	-0.51	-6.23	-0.37	2.02e-9	Depression;
KIRP	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.81	11.0	0.57	3.8e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-6.8	-0.4	7.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.0	0.36	6.96e-9	Lung cancer;
KIRP	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg26874164	chr19:58962979	ZNF324B	0.46	5.34	0.32	2.13e-7	Uric acid clearance;
KIRP	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.57	7.52	0.43	9.96e-13	Morning vs. evening chronotype;
KIRP	cis	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.45	5.75	0.34	2.62e-8	Leprosy;
KIRP	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg09408571	chr1:101003634	GPR88	-0.24	-5.4	-0.33	1.54e-7	Monocyte count;
KIRP	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	6.12	0.36	3.7e-9	Schizophrenia;
KIRP	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.72	-10.08	-0.54	3.09e-20	Caffeine consumption;
KIRP	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.77	-10.27	-0.55	8.15e-21	Aortic root size;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg17133734	chr15:86042851	AKAP13	-0.44	-5.43	-0.33	1.33e-7	Interstitial lung disease;
KIRP	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.46	-5.9	-0.35	1.21e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.67	-8.93	-0.49	1.01e-16	Sudden cardiac arrest;
KIRP	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	cis	rs9815354	0.812	rs73081372	chr3:41917993	C/T	cg03022575	chr3:42003672	ULK4	0.8	8.0	0.45	4.8e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs447921	0.861	rs4789301	chr17:74454212	A/C	cg16776035	chr17:74542680	NA	0.56	5.23	0.32	3.68e-7	Mitochondrial DNA levels;
KIRP	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg02297831	chr4:17616191	MED28	0.59	7.6	0.44	6.25e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.94	0.35	9.83e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg21775007	chr8:11205619	TDH	0.46	6.17	0.37	2.74e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11874712	0.965	rs28694780	chr18:43665338	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.17	-0.31	4.86e-7	Bipolar disorder;
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05665937	chr4:1216051	CTBP1	0.46	6.31	0.37	1.32e-9	Obesity-related traits;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.51	-0.33	8.89e-8	Lung cancer;
KIRP	cis	rs13033859	0.758	rs6708206	chr2:167187	A/C	cg10118717	chr2:203439	NA	-0.42	-6.67	-0.39	1.72e-10	Mitochondrial DNA levels;
KIRP	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg14416269	chr4:6271139	WFS1	0.34	5.18	0.31	4.71e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs1422110	0.626	rs2080881	chr5:85516859	T/G	cg01787110	chr1:109008453	NBPF6	0.66	7.77	0.44	2.18e-13	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08280861	chr8:58055591	NA	0.62	5.16	0.31	5.06e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.52	6.03	0.36	6.04e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg27087555	chr16:88793112	FAM38A	-0.89	-6.02	-0.36	6.27e-9	Plateletcrit;
KIRP	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.82	-10.04	-0.54	4.12e-20	Blood protein levels;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07147234	chr12:56522077	ESYT1	0.69	6.42	0.38	6.81e-10	Lung function (FEV1);
KIRP	cis	rs829661	0.793	rs860487	chr2:30703971	G/A	cg10949345	chr2:30726833	LCLAT1	1.13	15.93	0.71	9.72e-40	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg11845111	chr2:191398756	TMEM194B	0.95	10.09	0.54	3e-20	Diastolic blood pressure;
KIRP	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg10755058	chr3:40428713	ENTPD3	0.47	6.55	0.39	3.42e-10	Renal cell carcinoma;
KIRP	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.93	14.79	0.69	7.52e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg00800038	chr16:89945340	TCF25	-0.62	-5.99	-0.36	7.36e-9	Skin colour saturation;
KIRP	cis	rs7551222	0.646	rs2926536	chr1:204456983	T/G	cg20240347	chr1:204465584	NA	0.36	5.71	0.34	3.27e-8	Schizophrenia;
KIRP	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.5	6.74	0.39	1.14e-10	Coronary artery disease;
KIRP	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.57	-7.55	-0.43	8.35e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.99	13.06	0.64	5.65e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2494938	0.730	rs6915503	chr6:40523269	T/G	cg14084896	chr6:40530702	LRFN2	-0.46	-5.82	-0.35	1.78e-8	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.38	-15.16	-0.7	4.02e-37	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg03060546	chr3:49711283	APEH	0.46	6.17	0.37	2.85e-9	Parkinson's disease;
KIRP	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg26752003	chr8:145688521	CYHR1	0.74	10.08	0.54	3.11e-20	Age at first birth;
KIRP	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg07068956	chr7:100330872	ZAN	-0.57	-6.24	-0.37	1.87e-9	Other erythrocyte phenotypes;
KIRP	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.83	11.2	0.58	8.63e-24	Morning vs. evening chronotype;
KIRP	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.84	-0.45	1.4e-13	Neuroticism;
KIRP	cis	rs9914544	0.545	rs9912713	chr17:18771145	G/A	cg26378065	chr17:18585709	ZNF286B	0.38	4.93	0.3	1.49e-6	Educational attainment (years of education);
KIRP	cis	rs1165472	0.760	rs13374534	chr1:56125890	G/A	cg11523071	chr1:56160889	NA	-0.61	-7.74	-0.44	2.62e-13	Paclitaxel-induced neuropathy;
KIRP	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05046026	chr11:61559981	C11orf10;FEN1;MIR611	0.49	6.21	0.37	2.27e-9	Parkinson's disease;
KIRP	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.47	6.36	0.38	9.84e-10	Red blood cell count;
KIRP	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.37	-0.38	8.99e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs17266357	0.625	rs75088535	chr4:102725320	A/C	cg14855874	chr4:102712397	BANK1	0.39	5.2	0.31	4.11e-7	Blood protein levels;
KIRP	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-0.76	-11.0	-0.57	3.62e-23	Prudent dietary pattern;
KIRP	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs4919044	0.808	rs835271	chr10:94791678	C/T	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.56	7.76	0.44	2.22e-13	Schizophrenia;
KIRP	cis	rs10045504	0.502	rs72746043	chr5:38757226	T/C	cg15396434	chr5:38725168	NA	-0.88	-8.66	-0.48	6.33e-16	Night sleep phenotypes;
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.71	8.9	0.49	1.23e-16	Longevity;
KIRP	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.31	-0.32	2.41e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7546668	1.000	rs10803389	chr1:15861287	C/T	cg21858823	chr1:15850916	CASP9	0.47	5.21	0.31	4.08e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4702718	0.616	rs267973	chr5:10726281	A/G	cg14521931	chr5:10832172	NA	-0.44	-5.92	-0.35	1.1e-8	Obesity-related traits;
KIRP	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg07843065	chr1:150265600	MRPS21	0.43	5.89	0.35	1.28e-8	Migraine;
KIRP	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg26769984	chr7:1090371	C7orf50	0.8	7.58	0.44	6.85e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg11846333	chr4:119757529	SEC24D	1.05	5.8	0.35	2e-8	Cannabis dependence symptom count;
KIRP	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-13.01	-0.64	8.73e-30	Exhaled nitric oxide output;
KIRP	cis	rs7635838	0.929	rs7638724	chr3:11413387	T/G	cg00170343	chr3:11313890	ATG7	0.39	4.94	0.3	1.47e-6	HDL cholesterol;
KIRP	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.57	7.69	0.44	3.46e-13	Mean corpuscular volume;
KIRP	cis	rs7555523	0.887	rs10918274	chr1:165714416	T/C	cg24409356	chr1:165738333	TMCO1	0.7	5.75	0.34	2.65e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.65	-6.86	-0.4	5.65e-11	Lung cancer in ever smokers;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	16.0	0.71	5.54e-40	Platelet count;
KIRP	cis	rs2880765	0.525	rs2062234	chr15:86054490	A/G	cg17133734	chr15:86042851	AKAP13	-0.53	-6.51	-0.38	4.29e-10	Coronary artery disease;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.76	11.61	0.6	3.79e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg26874229	chr2:105853672	NA	0.35	4.89	0.3	1.85e-6	Type 2 diabetes;
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.54	-7.25	-0.42	5.51e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.74	7.84	0.45	1.38e-13	Corneal astigmatism;
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.64	-7.55	-0.43	8.65e-13	Menopause (age at onset);
KIRP	cis	rs13315871	0.615	rs6793358	chr3:58356454	C/G	cg12435725	chr3:58293450	RPP14	-0.36	-5.18	-0.31	4.52e-7	Cholesterol, total;
KIRP	cis	rs6009824	0.836	rs6009821	chr22:50085697	C/T	cg27029450	chr22:50098074	NA	0.58	5.99	0.36	7.6e-9	Natriuretic peptide levels;
KIRP	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg00531865	chr16:30841666	NA	-0.44	-4.95	-0.3	1.36e-6	Diastolic blood pressure;
KIRP	cis	rs17101923	1.000	rs17101923	chr12:66338202	G/T	cg06712651	chr12:66351869	HMGA2	-0.58	-6.44	-0.38	6.05e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg05025164	chr4:1340916	KIAA1530	0.54	7.06	0.41	1.66e-11	Longevity;
KIRP	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.71	0.34	3.17e-8	Depressive symptoms;
KIRP	cis	rs1538970	0.781	rs11211139	chr1:46015751	G/T	cg03146154	chr1:46216737	IPP	0.56	5.61	0.34	5.36e-8	Platelet count;
KIRP	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.9	0.35	1.22e-8	Motion sickness;
KIRP	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg25019722	chr6:37503610	NA	-0.8	-10.64	-0.56	5.19e-22	Cognitive performance;
KIRP	cis	rs5747327	0.874	rs2401164	chr22:18131226	C/T	cg19898043	chr22:18121309	BCL2L13	-0.41	-4.92	-0.3	1.55e-6	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.69	-9.03	-0.5	5.31e-17	Total body bone mineral density;
KIRP	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4849845	0.925	rs1370379	chr2:121014589	C/T	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg00129232	chr17:37814104	STARD3	-0.68	-7.38	-0.43	2.5e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg18806716	chr10:30721971	MAP3K8	0.31	4.98	0.3	1.22e-6	Inflammatory bowel disease;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.97	17.34	0.74	1.52e-44	Menarche (age at onset);
KIRP	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-5.06	-0.31	8.36e-7	Neuroticism;
KIRP	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg23307798	chr14:103986281	CKB	-0.79	-13.83	-0.66	1.44e-32	Body mass index;
KIRP	cis	rs7221595	0.756	rs9900661	chr17:3962450	A/G	cg05562828	chr17:3906858	NA	0.56	6.38	0.38	8.55e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6438504	0.922	rs12637159	chr3:118919833	A/T	cg25372693	chr3:118959985	B4GALT4	0.33	5.48	0.33	1.03e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.45	-5.31	-0.32	2.43e-7	P wave terminal force;
KIRP	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg12598211	chr12:123634384	NA	-0.45	-5.22	-0.32	3.74e-7	Neutrophil percentage of white cells;
KIRP	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg06671706	chr8:8559999	CLDN23	0.56	6.33	0.37	1.18e-9	Obesity-related traits;
KIRP	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.64	-9.26	-0.51	1.04e-17	Educational attainment;
KIRP	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.28	-22.66	-0.82	3.82e-62	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10775050	chr11:129765220	NFRKB	0.48	6.71	0.39	1.34e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7129556	0.728	rs628668	chr11:77577494	C/T	cg12586386	chr11:77299805	AQP11	0.39	5.14	0.31	5.53e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg06212747	chr3:49208901	KLHDC8B	0.64	5.48	0.33	1.04e-7	Menarche (age at onset);
KIRP	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	0.97	10.6	0.56	7.12e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.3	-0.32	2.61e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs17030434	0.906	rs11099901	chr4:154671468	T/A	cg14289246	chr4:154710475	SFRP2	-0.75	-8.87	-0.49	1.55e-16	Electrocardiographic conduction measures;
KIRP	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg08885076	chr2:99613938	TSGA10	-0.63	-11.29	-0.58	4.23e-24	Chronic sinus infection;
KIRP	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-0.39	-4.99	-0.3	1.12e-6	Type 2 diabetes;
KIRP	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.67	-9.14	-0.5	2.44e-17	Huntington's disease progression;
KIRP	cis	rs1050631	1.000	rs11873168	chr18:33707581	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.54	6.54	0.38	3.55e-10	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.51	-7.14	-0.41	1.04e-11	Mosquito bite size;
KIRP	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs4664293	0.867	rs6740910	chr2:160649220	G/A	cg08347373	chr2:160653686	CD302	-0.45	-6.68	-0.39	1.57e-10	Monocyte percentage of white cells;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg27060240	chr2:62412324	NA	-0.47	-6.78	-0.4	8.83e-11	Inflammatory biomarkers;
KIRP	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg13409248	chr3:40428643	ENTPD3	0.39	5.28	0.32	2.8e-7	Renal cell carcinoma;
KIRP	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	6.14	0.36	3.26e-9	Schizophrenia;
KIRP	cis	rs12367572	0.501	rs8181757	chr12:45486220	G/A	cg04608330	chr12:45269318	NELL2	-0.4	-5.07	-0.31	7.93e-7	Gut microbiome composition (summer);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg22811384	chr13:33528605	NA	0.55	6.27	0.37	1.6e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg03060546	chr3:49711283	APEH	0.53	7.05	0.41	1.75e-11	Menarche (age at onset);
KIRP	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.91	-14.88	-0.69	3.93e-36	Urate levels in lean individuals;
KIRP	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.68	-9.73	-0.53	3.96e-19	Lymphocyte counts;
KIRP	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.83	-0.53	1.92e-19	Neuroticism;
KIRP	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.12	-0.31	6.03e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7033996	1.000	rs16932784	chr9:35937718	G/A	cg00918944	chr9:35908117	LOC158376	0.36	5.08	0.31	7.29e-7	Urate levels (BMI interaction);
KIRP	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg02807482	chr3:125708958	NA	-0.5	-4.86	-0.3	2.08e-6	Blood pressure (smoking interaction);
KIRP	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg08632701	chr21:37451849	NA	-0.43	-5.37	-0.32	1.8e-7	Mitral valve prolapse;
KIRP	cis	rs7017914	0.967	rs13274381	chr8:71765094	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.03	-0.31	9.44e-7	Bone mineral density;
KIRP	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.7	-0.34	3.36e-8	Depression;
KIRP	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.41	7.05	0.41	1.75e-11	Heart rate;
KIRP	cis	rs959260	0.800	rs8081778	chr17:73312272	T/C	cg20590849	chr17:73267439	MIF4GD	-0.49	-4.99	-0.3	1.13e-6	Systemic lupus erythematosus;
KIRP	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg11354908	chr19:18255899	MAST3	0.48	6.05	0.36	5.32e-9	Pancreatic cancer;
KIRP	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7941030	0.902	rs7118212	chr11:122534804	T/A	cg20555462	chr11:122535518	UBASH3B	-0.43	-5.39	-0.33	1.63e-7	HDL cholesterol;Cholesterol, total;
KIRP	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs687432	0.586	rs2245676	chr11:57912693	T/G	cg19752551	chr11:57585705	CTNND1	-0.36	-4.99	-0.3	1.14e-6	Parkinson's disease;
KIRP	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	0.92	10.39	0.55	3.46e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-0.84	-9.18	-0.51	1.79e-17	Gut microbiome composition (summer);
KIRP	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg00343986	chr7:65444356	GUSB	-0.4	-4.89	-0.3	1.8e-6	Aortic root size;
KIRP	trans	rs7939886	0.920	rs12226441	chr11:55867822	G/A	cg03929089	chr4:120376271	NA	0.93	6.82	0.4	7.22e-11	Myopia (pathological);
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.56	-6.16	-0.37	2.94e-9	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.62	9.57	0.52	1.19e-18	Lung cancer;
KIRP	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-6.09	-0.36	4.25e-9	Monocyte percentage of white cells;
KIRP	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg26876637	chr1:152193138	HRNR	-0.71	-9.45	-0.52	2.83e-18	Atopic dermatitis;
KIRP	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg02807482	chr3:125708958	NA	-0.52	-5.03	-0.31	9.42e-7	Blood pressure (smoking interaction);
KIRP	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	trans	rs17079247	0.722	rs9594006	chr13:85807422	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg02297831	chr4:17616191	MED28	-0.6	-7.01	-0.41	2.29e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07234876	chr8:600039	NA	0.89	6.45	0.38	5.86e-10	IgG glycosylation;
KIRP	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.99	10.26	0.55	8.48e-21	HIV-1 control;
KIRP	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg21419209	chr3:44054225	NA	-0.74	-8.97	-0.5	7.69e-17	Coronary artery disease;
KIRP	cis	rs17001868	0.541	rs2092163	chr22:40810231	C/T	cg07138101	chr22:40742427	ADSL	0.76	6.12	0.36	3.57e-9	Mammographic density (dense area);
KIRP	cis	rs2220004	0.614	rs34123169	chr11:55973965	C/T	cg01505312	chr11:56258856	OR5M8;OR8U8	0.49	5.4	0.33	1.59e-7	Odorant perception (&beta-damascenone);
KIRP	cis	rs6788895	1.000	rs56840421	chr3:150496200	C/A	cg09723797	chr3:150481914	SIAH2	0.82	5.18	0.31	4.69e-7	Breast cancer;
KIRP	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.4	-5.41	-0.33	1.47e-7	IgG glycosylation;
KIRP	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg05315796	chr3:52349193	DNAH1	-0.44	-6.71	-0.39	1.3e-10	Bipolar disorder;
KIRP	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.25	0.47	9.67e-15	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01592108	chr2:175830522	CHN1	-0.41	-6.3	-0.37	1.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	1.1	15.72	0.71	5.01e-39	Breast cancer;
KIRP	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.02	-0.36	6.19e-9	IgG glycosylation;
KIRP	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs7106204	0.609	rs12788920	chr11:24284514	C/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.39	0.33	1.64e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg25251562	chr2:3704773	ALLC	0.4	5.42	0.33	1.41e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.98	12.35	0.62	1.39e-27	Response to antineoplastic agents;
KIRP	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg23307798	chr14:103986281	CKB	0.48	6.92	0.4	3.88e-11	Body mass index;
KIRP	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-11.52	-0.59	7.46e-25	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.67	8.16	0.46	1.75e-14	Blood metabolite levels;
KIRP	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.93	10.76	0.57	2.25e-22	Menarche (age at onset);
KIRP	cis	rs7045138	1	rs7045138	chr9:100591463	C/T	cg13688889	chr9:100608707	NA	-0.73	-10.13	-0.54	2.13e-20	Thyroid hormone levels;
KIRP	cis	rs2274459	0.841	rs10456075	chr6:33681603	G/A	cg06253072	chr6:33679850	C6orf125	0.53	5.59	0.34	5.97e-8	Obesity (extreme);
KIRP	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.92	-0.3	1.59e-6	Resting heart rate;
KIRP	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.36	-0.51	5.11e-18	Bone mineral density;
KIRP	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg07384165	chr1:10488281	NA	0.44	5.7	0.34	3.4e-8	Prostate cancer;
KIRP	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg01557791	chr16:72042693	DHODH	-0.69	-7.71	-0.44	3.09e-13	Blood protein levels;
KIRP	cis	rs10861342	0.786	rs17036781	chr12:105597284	A/G	cg23923672	chr12:105501055	KIAA1033	-0.86	-5.06	-0.31	8.14e-7	IgG glycosylation;
KIRP	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-0.93	-8.32	-0.47	6.1e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.0	-0.36	7.09e-9	Total body bone mineral density;
KIRP	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.74	10.57	0.56	9.16e-22	Crohn's disease;
KIRP	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.9	13.63	0.66	6.64e-32	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12586317	0.557	rs4488360	chr14:35656211	G/C	cg07166546	chr14:35805898	NA	-0.28	-6.59	-0.39	2.72e-10	Psoriasis;
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-6.52	-0.38	3.93e-10	Lung cancer;
KIRP	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Colorectal cancer;
KIRP	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.43	7.68	0.44	3.86e-13	Superior crus of antihelix expression;
KIRP	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg00405596	chr8:11794950	NA	0.6	8.2	0.46	1.3e-14	Myopia (pathological);
KIRP	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.64	0.34	4.72e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.16	-0.31	5.09e-7	Major depressive disorder;
KIRP	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg18451016	chr1:38461880	NA	-0.44	-5.86	-0.35	1.46e-8	Coronary artery disease;
KIRP	cis	rs9659323	0.689	rs7545737	chr1:119533823	C/T	cg05756136	chr1:119680316	WARS2	0.39	4.92	0.3	1.56e-6	Body mass index;
KIRP	trans	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg16141378	chr3:129829833	LOC729375	-0.56	-7.3	-0.42	4e-12	Joint mobility (Beighton score);
KIRP	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.44	-4.87	-0.3	1.97e-6	Longevity;Endometriosis;
KIRP	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg18279126	chr7:2041391	MAD1L1	0.48	5.13	0.31	5.85e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.06	0.36	5.13e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs889398	0.771	rs11075732	chr16:69766038	A/G	cg09409435	chr16:70099608	PDXDC2	-0.42	-4.97	-0.3	1.23e-6	Body mass index;
KIRP	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg07511668	chr11:68622177	NA	0.39	4.86	0.3	2.1e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.8	10.81	0.57	1.49e-22	Aortic root size;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.48e-6	Life satisfaction;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13048209	chr3:176745490	TBL1XR1	0.41	6.04	0.36	5.61e-9	Survival in pancreatic cancer;
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.59	5.33	0.32	2.22e-7	Alzheimer's disease;
KIRP	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg17554472	chr22:41940697	POLR3H	-0.58	-6.63	-0.39	2.08e-10	Vitiligo;
KIRP	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35995292	0.963	rs7803397	chr7:38905686	C/T	cg19327137	chr7:38886074	VPS41	-0.49	-6.13	-0.36	3.4e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-0.78	-12.35	-0.62	1.36e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.22	0.58	7.06e-24	Morning vs. evening chronotype;
KIRP	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg18944383	chr4:111397179	ENPEP	0.44	6.63	0.39	2.16e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-5.89	-0.35	1.25e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg07423050	chr13:99094983	FARP1	0.31	5.18	0.31	4.66e-7	Longevity;
KIRP	cis	rs35995292	0.553	rs2392605	chr7:38924670	T/C	cg19327137	chr7:38886074	VPS41	0.83	12.86	0.63	2.81e-29	Subjective well-being (multi-trait analysis);
KIRP	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg08873628	chr1:175162347	KIAA0040	0.41	6.0	0.36	7.2e-9	Alcohol dependence;
KIRP	cis	rs6901250	0.610	rs9400964	chr6:117144808	G/T	cg12892004	chr6:117198278	RFX6	0.41	6.7	0.39	1.4e-10	C-reactive protein levels;
KIRP	cis	rs10875746	0.903	rs2158516	chr12:48490834	T/A	cg26205652	chr12:48591994	NA	0.78	10.5	0.56	1.49e-21	Longevity (90 years and older);
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg04055847	chr7:100487800	UFSP1;ACHE	0.48	6.02	0.36	6.44e-9	Beard thickness;
KIRP	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06357691	chr11:64072954	ESRRA	-0.56	-6.06	-0.36	5.04e-9	Menopause (age at onset);
KIRP	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-5.09	-0.31	6.97e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.67	8.02	0.46	4.31e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2151522	0.563	rs35772466	chr6:127141068	C/T	cg21431617	chr6:127135037	NA	0.33	5.9	0.35	1.18e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg27490568	chr2:178487706	NA	0.49	6.61	0.39	2.35e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00361562	chr2:198649771	BOLL	-0.5	-5.3	-0.32	2.51e-7	Ulcerative colitis;
KIRP	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg11584989	chr19:19387371	SF4	-0.4	-5.06	-0.31	8.31e-7	Tonsillectomy;
KIRP	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	9.12	0.5	2.84e-17	Resting heart rate;
KIRP	cis	rs3736485	0.934	rs4775952	chr15:51869056	T/C	cg14296394	chr15:51910925	DMXL2	-0.36	-5.29	-0.32	2.68e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02972257	chr16:68554789	NA	-0.72	-7.26	-0.42	5.11e-12	Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.56	8.04	0.46	3.68e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12976411	0.575	rs7252058	chr19:32827391	G/A	cg18253629	chr19:32836317	ZNF507	0.66	5.1	0.31	6.75e-7	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20513448	chr7:104837830	SRPK2	0.45	6.63	0.39	2.07e-10	Survival in pancreatic cancer;
KIRP	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-6.81	-0.4	7.24e-11	Total body bone mineral density;
KIRP	trans	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	7.14	0.41	1.03e-11	Lung function (FEV1/FVC);
KIRP	cis	rs526231	0.511	rs17155009	chr5:102374144	C/T	cg23492399	chr5:102201601	PAM	-0.48	-5.35	-0.32	2.03e-7	Primary biliary cholangitis;
KIRP	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.61	-6.85	-0.4	5.92e-11	Schizophrenia;
KIRP	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.37	5.56	0.33	7.07e-8	Mitochondrial DNA levels;
KIRP	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.91	-0.35	1.12e-8	Breast cancer;
KIRP	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.52	-6.35	-0.38	1.01e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.83	-0.49	2.01e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.56	-7.28	-0.42	4.41e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-8.82	-0.49	2.14e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg02367723	chr1:46378857	MAST2	0.43	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14439950	chr11:64901879	SYVN1	-0.48	-6.21	-0.37	2.2e-9	Metabolic traits;
KIRP	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.26	0.42	4.99e-12	Height;
KIRP	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.76	-9.32	-0.51	6.74e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10778556	chr1:24113913	C1orf128	0.52	6.37	0.38	9.13e-10	Interleukin-4 levels;
KIRP	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.77	-7.04	-0.41	1.87e-11	Mean platelet volume;
KIRP	cis	rs883565	0.740	rs7624734	chr3:39108503	G/A	cg01426195	chr3:39028469	NA	-0.67	-11.18	-0.58	9.53e-24	Handedness;
KIRP	cis	rs7777754	1.000	rs7778258	chr7:50666378	G/A	cg14593290	chr7:50529359	DDC	0.42	5.07	0.31	7.83e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.32	0.51	6.98e-18	Parkinson's disease;
KIRP	cis	rs921943	1.000	rs7709472	chr5:78315151	A/T	cg26802063	chr5:78281964	ARSB	0.48	5.93	0.35	1.02e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs2151522	0.511	rs2022478	chr6:127111947	C/T	cg21431617	chr6:127135037	NA	0.33	5.98	0.36	7.81e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7221595	0.825	rs8069643	chr17:3971237	C/T	cg05562828	chr17:3906858	NA	0.54	6.34	0.37	1.08e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg00802000	chr16:706648	WDR90	-0.4	-5.02	-0.3	1.02e-6	Height;
KIRP	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg07827796	chr19:33622959	WDR88	-0.54	-7.08	-0.41	1.54e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.73	11.29	0.58	4.2e-24	Neuroticism;
KIRP	cis	rs8067354	0.645	rs2645487	chr17:57886125	T/G	cg13753209	chr17:57696993	CLTC	0.57	5.52	0.33	8.44e-8	Hemoglobin concentration;
KIRP	cis	rs6005807	0.719	rs12169071	chr22:29033210	C/G	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	trans	rs1517426	0.637	rs1361461	chr1:102925321	A/G	cg00910715	chr2:132218639	NA	0.35	6.24	0.37	1.92e-9	Gut microbiome composition (summer and winter);
KIRP	cis	rs16976116	0.901	rs2899581	chr15:55491643	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg05315796	chr3:52349193	DNAH1	0.39	6.35	0.38	1.02e-9	Bipolar disorder;
KIRP	cis	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg02254774	chr11:50257496	LOC441601	0.47	5.78	0.35	2.28e-8	Height;
KIRP	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg08975724	chr8:8085496	FLJ10661	-0.69	-8.92	-0.49	1.09e-16	Joint mobility (Beighton score);
KIRP	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg16586182	chr3:47516702	SCAP	0.67	8.37	0.47	4.32e-15	QT interval;
KIRP	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.53	-6.56	-0.39	3.18e-10	Total body bone mineral density;
KIRP	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.7	0.49	4.78e-16	Motion sickness;
KIRP	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg02151108	chr14:50098012	C14orf104	-0.51	-7.07	-0.41	1.64e-11	Carotid intima media thickness;
KIRP	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg20991723	chr1:152506922	NA	-0.46	-5.54	-0.33	7.68e-8	Hair morphology;
KIRP	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.74	0.44	2.53e-13	Educational attainment;
KIRP	cis	rs9400467	0.506	rs12199233	chr6:111592317	G/A	cg15721981	chr6:111408429	SLC16A10	0.75	6.87	0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs3789045	0.826	rs55979051	chr1:204567041	A/G	cg08641003	chr1:204589008	LRRN2	-0.52	-5.29	-0.32	2.76e-7	Educational attainment (college completion);
KIRP	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg11833968	chr6:79620685	NA	-0.45	-6.8	-0.4	8.09e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.09	-0.41	1.41e-11	Longevity;
KIRP	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg26513180	chr16:89883248	FANCA	0.57	5.47	0.33	1.08e-7	Skin colour saturation;
KIRP	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6430538	0.550	rs11902999	chr2:135567151	T/C	cg25422880	chr2:135218333	TMEM163	-0.36	-5.09	-0.31	7.28e-7	Parkinson's disease;
KIRP	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.37e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg06026331	chr20:60912101	LAMA5	-0.49	-6.49	-0.38	4.75e-10	Colorectal cancer;
KIRP	cis	rs12714314	0.535	rs62650072	chr2:1960042	G/A	cg20846728	chr2:1843184	MYT1L	-0.36	-5.89	-0.35	1.24e-8	Type 2 diabetes (age of onset);
KIRP	cis	rs1983891	0.742	rs9369295	chr6:41564026	G/C	cg20194872	chr6:41519635	FOXP4	0.5	6.54	0.38	3.49e-10	Prostate cancer;
KIRP	cis	rs9658691	0.920	rs2234768	chr10:90749943	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.8	-4.89	-0.3	1.78e-6	Mosquito bite size;
KIRP	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs12313068	0.709	rs73404675	chr12:110504102	G/A	cg12870014	chr12:110450643	ANKRD13A	0.56	7.38	0.43	2.48e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg06115741	chr20:33292138	TP53INP2	0.41	5.49	0.33	1.01e-7	Coronary artery disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14265254	chr17:17495025	PEMT	-0.43	-6.13	-0.36	3.39e-9	Metabolic traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07379344	chr16:70147964	PDPR	0.49	6.07	0.36	4.88e-9	Parkinson's disease;
KIRP	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.86	12.72	0.63	8.07e-29	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.9	13.09	0.64	4.5e-30	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11656663	chr1:202976539	TMEM183A;TMEM183B	0.57	7.34	0.42	3.07e-12	Parkinson's disease;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13939156	chr17:80058883	NA	-0.49	-7.18	-0.42	8.13e-12	Life satisfaction;
KIRP	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg03929089	chr4:120376271	NA	0.62	6.23	0.37	2.02e-9	Axial length;
KIRP	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.19	0.31	4.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.73	11.11	0.58	1.6e-23	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-8.45	-0.47	2.62e-15	Gut microbiome composition (summer);
KIRP	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	4.93	0.3	1.5e-6	Renal cell carcinoma;
KIRP	cis	rs710913	0.618	rs2310799	chr1:40066622	G/A	cg27567593	chr1:39956653	BMP8A	-0.35	-4.93	-0.3	1.55e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.48	-5.95	-0.35	9.04e-9	Inflammatory skin disease;
KIRP	cis	rs9547996	0.879	rs9547953	chr13:38138863	C/T	cg13634560	chr13:38173852	POSTN	-0.41	-5.62	-0.34	5.23e-8	Diastolic blood pressure;
KIRP	trans	rs1801239	0.786	rs62619939	chr10:16967586	C/G	cg10880177	chr5:1729256	NA	-0.61	-6.54	-0.38	3.55e-10	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
KIRP	cis	rs35740288	0.822	rs4843090	chr15:86220629	T/C	cg17133734	chr15:86042851	AKAP13	-0.5	-5.31	-0.32	2.46e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	0.71	6.43	0.38	6.63e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.8	-12.12	-0.61	7.93e-27	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25338766	chr19:36500444	ALKBH6;C19orf46	0.42	6.28	0.37	1.51e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.81	-0.4	7.55e-11	Menopause (age at onset);
KIRP	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.18	0.37	2.58e-9	Colorectal cancer;
KIRP	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg23231163	chr10:75533350	FUT11	-0.33	-5.08	-0.31	7.59e-7	Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03465782	chr14:74485822	ENTPD5;C14orf45	0.5	6.39	0.38	8.21e-10	Parkinson's disease;
KIRP	cis	rs988913	0.706	rs13208701	chr6:54880468	T/A	cg03513858	chr6:54763001	FAM83B	-0.37	-5.03	-0.31	9.25e-7	Menarche (age at onset);
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg11859384	chr17:80120422	CCDC57	0.44	5.62	0.34	5.05e-8	Life satisfaction;
KIRP	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg11707556	chr5:10655725	ANKRD33B	0.54	6.6	0.39	2.48e-10	Coronary artery disease;
KIRP	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg23899408	chr19:12877188	HOOK2	0.44	5.05	0.31	8.78e-7	Mean corpuscular volume;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	6.61	0.39	2.39e-10	Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.54	-0.33	7.93e-8	Life satisfaction;
KIRP	cis	rs9469913	0.740	rs2744939	chr6:34548206	T/A	cg17674042	chr6:34482479	PACSIN1	-0.53	-6.6	-0.39	2.54e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg00310523	chr12:86230176	RASSF9	-0.57	-8.93	-0.49	9.94e-17	Major depressive disorder;
KIRP	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	1.04	18.03	0.75	7e-47	Eosinophil percentage of white cells;
KIRP	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg23335576	chr14:104009727	NA	0.38	5.16	0.31	5.17e-7	Body mass index;
KIRP	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg05973401	chr12:123451056	ABCB9	-0.53	-5.52	-0.33	8.53e-8	Neutrophil percentage of white cells;
KIRP	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg19849509	chr2:175204996	NA	-0.57	-6.68	-0.39	1.59e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	8.76	0.49	3.14e-16	Platelet count;
KIRP	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14240646	chr10:27532245	ACBD5	-0.72	-7.68	-0.44	3.69e-13	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05746795	chr8:48100410	NA	0.47	6.47	0.38	5.13e-10	Parkinson's disease;
KIRP	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg26531700	chr6:26746687	NA	0.39	5.32	0.32	2.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12579753	0.667	rs7959589	chr12:82304439	A/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.56	-0.33	6.93e-8	Resting heart rate;
KIRP	cis	rs2562456	0.834	rs13346641	chr19:21592283	C/T	cg18461458	chr19:21324796	ZNF431	-0.53	-5.11	-0.31	6.62e-7	Pain;
KIRP	cis	rs4748857	0.947	rs7084042	chr10:23509719	T/C	cg12804278	chr10:23633326	C10orf67	0.43	5.34	0.32	2.1e-7	Systemic lupus erythematosus;
KIRP	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.66	-7.34	-0.42	3.15e-12	Chronic sinus infection;
KIRP	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.92	0.57	6.88e-23	Cognitive test performance;
KIRP	trans	rs933360	0.553	rs734422	chr7:50823430	C/T	cg20003124	chr12:4557277	NA	0.55	6.75	0.4	1.08e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18932078	chr1:2524107	MMEL1	0.47	6.5	0.38	4.51e-10	Ulcerative colitis;
KIRP	trans	rs6601327	0.540	rs4841225	chr8:9669164	T/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.68	-0.39	1.59e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg25174290	chr11:3078921	CARS	-0.56	-6.04	-0.36	5.52e-9	Calcium levels;
KIRP	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.4	-7.37	-0.43	2.59e-12	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs4974559	0.739	rs59810282	chr4:1320968	A/G	cg02980000	chr4:1222292	CTBP1	0.89	8.61	0.48	9.04e-16	Systolic blood pressure;
KIRP	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.61	-7.79	-0.44	1.85e-13	Extraversion;
KIRP	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.4	-0.33	1.54e-7	Alzheimer's disease (late onset);
KIRP	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-8.12	-0.46	2.19e-14	Colorectal cancer;
KIRP	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg04374321	chr14:90722782	PSMC1	0.91	15.78	0.71	3.2e-39	Mortality in heart failure;
KIRP	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	5.03	0.31	9.32e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs3784262	0.669	rs12594082	chr15:58267779	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.87	-0.3	1.95e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs28489187	0.706	rs4949890	chr1:85830632	T/C	cg16011679	chr1:85725395	C1orf52	0.54	6.47	0.38	5.36e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs17381785	0.812	rs7692906	chr4:14912353	T/C	cg12377275	chr4:15005593	CPEB2	0.49	5.53	0.33	8.33e-8	Urate levels in overweight individuals;
KIRP	cis	rs259282	0.605	rs8101920	chr19:33109270	A/C	cg02997394	chr19:33096574	ANKRD27	-0.52	-6.15	-0.37	3.09e-9	Schizophrenia;
KIRP	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg26205652	chr12:48591994	NA	0.78	10.5	0.56	1.45e-21	Longevity (90 years and older);
KIRP	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg05272587	chr13:111038400	COL4A2	-0.37	-5.42	-0.33	1.42e-7	White matter hyperintensity burden;
KIRP	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.04	8.02	0.46	4.31e-14	Skin colour saturation;
KIRP	cis	rs4702718	0.651	rs2930047	chr5:10695526	A/G	cg14521931	chr5:10832172	NA	0.38	5.07	0.31	7.78e-7	Obesity-related traits;
KIRP	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg06217071	chr17:408420	NA	0.72	11.29	0.58	4.3e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg01620082	chr3:125678407	NA	-0.87	-6.45	-0.38	5.79e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs66569888	0.538	rs56291108	chr2:106757143	G/A	cg16099169	chr2:106886729	NA	-0.39	-4.95	-0.3	1.39e-6	Facial morphology (factor 23);
KIRP	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.82	9.87	0.53	1.46e-19	Corneal astigmatism;
KIRP	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.56	8.06	0.46	3.34e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6939532	0.544	rs10946816	chr6:26361946	C/G	cg14345882	chr6:26364793	BTN3A2	0.32	5.0	0.3	1.1e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg15147215	chr3:52552868	STAB1	-0.35	-6.09	-0.36	4.28e-9	Electroencephalogram traits;
KIRP	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.12	-0.41	1.18e-11	Height;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.88	8.45	0.47	2.54e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10114408	0.959	rs7863704	chr9:96638610	C/T	cg14598338	chr9:96623480	NA	-0.34	-5.17	-0.31	4.92e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.43	5.47	0.33	1.1e-7	Aortic root size;
KIRP	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg08198773	chr8:1697536	NA	0.52	6.33	0.37	1.12e-9	Systolic blood pressure;
KIRP	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.93	14.87	0.69	4.23e-36	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06728437	chr2:208031766	KLF7	-0.42	-6.18	-0.37	2.65e-9	Metabolic traits;
KIRP	cis	rs2594989	0.837	rs2922348	chr3:11309784	T/C	cg01796438	chr3:11312864	ATG7	-0.63	-7.29	-0.42	4.17e-12	Circulating chemerin levels;
KIRP	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg08807101	chr21:30365312	RNF160	0.6	7.26	0.42	5.01e-12	Pancreatic cancer;
KIRP	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg10523679	chr1:76189770	ACADM	-0.44	-6.13	-0.36	3.41e-9	Daytime sleep phenotypes;
KIRP	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg21573476	chr21:45109991	RRP1B	-0.85	-13.45	-0.65	2.77e-31	Coronary artery disease;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg23736307	chr8:27182930	PTK2B	0.56	7.06	0.41	1.73e-11	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08678000	chr8:89047821	NA	-0.42	-6.13	-0.36	3.45e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17221829	0.644	rs12420632	chr11:89366231	G/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-4.86	-0.3	2.09e-6	Anxiety in major depressive disorder;
KIRP	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg01620082	chr3:125678407	NA	-1.23	-7.87	-0.45	1.11e-13	Depression;
KIRP	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg06740227	chr12:86229804	RASSF9	0.5	6.32	0.37	1.22e-9	Major depressive disorder;
KIRP	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg01566213	chr4:1579287	NA	-0.35	-4.88	-0.3	1.87e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs9467160	0.734	rs9467170	chr6:24452754	G/A	cg20631270	chr6:24437470	GPLD1	0.46	5.31	0.32	2.49e-7	Liver enzyme levels;
KIRP	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	5.02	0.3	9.79e-7	Obesity-related traits;
KIRP	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	cis	rs9938149	0.706	rs7498700	chr16:88320620	T/C	cg05435882	chr16:88311214	NA	-0.5	-5.95	-0.35	9.38e-9	Corneal structure;Central corneal thickness;
KIRP	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg08499158	chr17:42289980	UBTF	0.7	8.86	0.49	1.66e-16	Total body bone mineral density;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07138452	chr17:17141020	FLCN	-0.45	-6.24	-0.37	1.91e-9	Myopia;
KIRP	cis	rs1727638	0.603	rs852953	chr6:72143093	C/T	cg16255583	chr6:72220122	NA	-0.36	-4.88	-0.3	1.88e-6	Cerebrospinal fluid AB1-42 levels;
KIRP	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg27494647	chr7:150038898	RARRES2	0.35	5.29	0.32	2.75e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	7.27	0.42	4.88e-12	Mean corpuscular hemoglobin;
KIRP	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.47	5.96	0.36	8.48e-9	Resistin levels;
KIRP	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs55962025	0.711	rs7691627	chr4:3111410	G/A	cg06533319	chr4:3265114	C4orf44	0.41	5.3	0.32	2.56e-7	Parental longevity (mother's age at death);
KIRP	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.59	8.07	0.46	3.18e-14	Depressive symptoms;
KIRP	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.74	-9.47	-0.52	2.38e-18	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17555499	chr10:75542150	CHCHD1	0.42	6.22	0.37	2.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg05692746	chr2:100937584	LONRF2	-0.39	-4.97	-0.3	1.23e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.83	-6.85	-0.4	5.74e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.97	-15.19	-0.7	3.32e-37	Height;
KIRP	cis	rs77633900	0.772	rs2957613	chr15:76700589	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-5.56	-0.33	7.01e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.32	12.04	0.61	1.45e-26	Diabetic retinopathy;
KIRP	cis	rs7246657	0.551	rs12978093	chr19:37584416	C/T	cg18154014	chr19:37997991	ZNF793	0.6	5.07	0.31	7.67e-7	Coronary artery calcification;
KIRP	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg01097406	chr16:89675127	NA	-0.43	-7.75	-0.44	2.39e-13	Vitiligo;
KIRP	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.71	9.1	0.5	3.11e-17	Coronary artery disease;
KIRP	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.25	-0.47	9.93e-15	Triglycerides;
KIRP	trans	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg24644049	chr4:85504048	CDS1	1.0	6.97	0.41	2.88e-11	Skin colour saturation;
KIRP	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.49	-6.15	-0.37	3.03e-9	Neurofibrillary tangles;
KIRP	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.43	-7.52	-0.43	9.92e-13	Refractive error;
KIRP	trans	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg01311341	chr22:25575246	KIAA1671	-0.61	-6.57	-0.39	2.96e-10	Glioblastoma;
KIRP	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg02725872	chr8:58115012	NA	-0.61	-4.97	-0.3	1.23e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.76	9.48	0.52	2.3e-18	Coronary artery disease;
KIRP	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.06	-0.67	2.44e-33	Primary sclerosing cholangitis;
KIRP	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg11707556	chr5:10655725	ANKRD33B	0.56	6.47	0.38	5.34e-10	Coronary artery disease;
KIRP	cis	rs12973672	0.812	rs13345192	chr19:35756155	A/C	cg12095397	chr19:35769544	USF2	-0.68	-6.27	-0.37	1.57e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg07402062	chr16:89894098	SPIRE2	0.33	6.87	0.4	5.29e-11	Vitiligo;
KIRP	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg12292205	chr6:26970375	C6orf41	0.33	4.92	0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.84	-0.4	6.15e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7011507	1.000	rs78220207	chr8:49182195	T/C	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.59	-5.05	-0.31	8.81e-7	Schizophrenia;
KIRP	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.36	-4.97	-0.3	1.25e-6	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12253830	chr12:22487668	ST8SIA1	0.45	6.27	0.37	1.64e-9	Parkinson's disease;
KIRP	cis	rs6743068	0.521	rs2349074	chr2:202222507	G/T	cg06431681	chr2:202330990	STRADB	0.37	5.03	0.31	9.41e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg26441486	chr22:50317300	CRELD2	0.4	6.43	0.38	6.6e-10	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.86	12.89	0.64	2.09e-29	Longevity;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.48	-0.38	4.93e-10	Lung cancer;
KIRP	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg21573476	chr21:45109991	RRP1B	-0.57	-7.88	-0.45	1.05e-13	Mean corpuscular volume;
KIRP	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.45	5.41	0.33	1.52e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg11621586	chr10:70884670	VPS26A	1.17	15.09	0.69	7.5e-37	Left atrial antero-posterior diameter;
KIRP	cis	rs6546886	0.912	rs7606491	chr2:74298958	T/C	cg14702570	chr2:74259524	NA	-0.3	-5.85	-0.35	1.56e-8	Dialysis-related mortality;
KIRP	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.47	-5.26	-0.32	3.2e-7	White matter hyperintensity burden;
KIRP	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.65	-9.27	-0.51	9.96e-18	Retinal vascular caliber;
KIRP	cis	rs714027	0.545	rs41161	chr22:30407652	T/C	cg27665648	chr22:30112403	NA	-0.42	-5.81	-0.35	1.89e-8	Lymphocyte counts;
KIRP	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg13877915	chr19:58951672	ZNF132	0.61	5.87	0.35	1.43e-8	Mean platelet volume;
KIRP	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	1.07	8.78	0.49	2.89e-16	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs11216435	0.512	rs2276343	chr11:117375596	G/A	cg27161313	chr11:117392002	DSCAML1	-0.54	-5.23	-0.32	3.58e-7	Menarche (age at onset);
KIRP	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg24088639	chr11:34937564	PDHX;APIP	0.43	5.08	0.31	7.39e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs7072216	0.666	rs11598689	chr10:100156027	G/T	cg19567339	chr10:100142640	NA	0.5	5.17	0.31	4.77e-7	Metabolite levels;
KIRP	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg03315344	chr16:75512273	CHST6	0.72	11.3	0.58	4.08e-24	Dupuytren's disease;
KIRP	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.67	-7.78	-0.44	1.98e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.39	-5.23	-0.32	3.69e-7	Leprosy;
KIRP	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg11846333	chr4:119757529	SEC24D	1.05	5.8	0.35	2e-8	Cannabis dependence symptom count;
KIRP	cis	rs2554380	0.843	rs1019667	chr15:84380849	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.5	-7.2	-0.42	7.09e-12	Height;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-6.4	-0.38	7.63e-10	Lung cancer;
KIRP	cis	rs9513627	0.831	rs2031423	chr13:100174766	G/A	cg25919922	chr13:100150906	NA	0.74	5.17	0.31	4.86e-7	Obesity-related traits;
KIRP	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.46	6.96	0.41	3.07e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg14675211	chr2:100938903	LONRF2	0.55	7.45	0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	0.775	rs72938351	chr2:204151503	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.02	7.13	0.41	1.14e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-10.36	-0.55	4.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26313152	chr19:7598793	PNPLA6;MCOLN1	0.44	6.5	0.38	4.53e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.73	7.6	0.44	6.11e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.83	-0.35	1.78e-8	Obesity-related traits;
KIRP	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.84	10.1	0.54	2.76e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.38e-6	Depression;
KIRP	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg08992911	chr2:238395768	MLPH	0.5	4.93	0.3	1.49e-6	Prostate cancer;
KIRP	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.44	0.43	1.71e-12	Multiple sclerosis;
KIRP	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg22117172	chr7:91764530	CYP51A1	0.42	5.75	0.34	2.68e-8	Breast cancer;
KIRP	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.82	-12.23	-0.62	3.4e-27	Asthma;
KIRP	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.43	8.11	0.46	2.46e-14	Educational attainment (years of education);
KIRP	cis	rs4812048	0.649	rs6070702	chr20:57621562	G/C	cg14073986	chr20:57617431	SLMO2	0.65	5.77	0.35	2.32e-8	Mean platelet volume;
KIRP	cis	rs7246657	0.891	rs2279149	chr19:38024367	T/C	cg18154014	chr19:37997991	ZNF793	0.83	8.9	0.49	1.28e-16	Coronary artery calcification;
KIRP	cis	rs4332428	1.000	rs4397735	chr10:4965543	G/A	cg19648686	chr10:5044992	AKR1C2	-0.93	-7.63	-0.44	5.2e-13	Height;
KIRP	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.63	-6.85	-0.4	5.78e-11	Hair shape;
KIRP	trans	rs11165623	0.602	rs4619021	chr1:97025910	T/C	cg10631902	chr5:14652156	NA	-0.49	-6.69	-0.39	1.48e-10	Hip circumference;Waist circumference;
KIRP	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg21573476	chr21:45109991	RRP1B	-0.65	-8.57	-0.48	1.18e-15	Mean corpuscular volume;
KIRP	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	0.49	6.39	0.38	8.4e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs883565	0.543	rs35628459	chr3:39174437	T/A	cg01426195	chr3:39028469	NA	0.5	8.04	0.46	3.83e-14	Handedness;
KIRP	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.16	-0.37	2.94e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09735905	chr1:70820197	HHLA3;ANKRD13C	0.59	6.94	0.4	3.54e-11	Smoking initiation;
KIRP	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.3	-0.47	6.77e-15	Retinal vascular caliber;
KIRP	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg02187348	chr16:89574699	SPG7	0.52	6.84	0.4	6.3e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs2299587	0.642	rs2073570	chr8:17782627	C/G	cg01800426	chr8:17659068	MTUS1	-0.54	-6.53	-0.38	3.76e-10	Economic and political preferences;
KIRP	cis	rs7027203	0.576	rs11790754	chr9:96535709	T/G	cg14598338	chr9:96623480	NA	0.45	6.92	0.4	3.97e-11	DNA methylation (variation);
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg15837992	chr6:3724407	C6orf145	-0.51	-6.05	-0.36	5.27e-9	Response to statin therapy;
KIRP	cis	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs2635047	0.638	rs9961383	chr18:44604001	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	6.32	0.37	1.21e-9	Educational attainment;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.74	0.66	2.88e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg07117364	chr1:16154769	NA	-0.43	-5.16	-0.31	5.13e-7	Dilated cardiomyopathy;
KIRP	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.58	-7.1	-0.41	1.31e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-5.49	-0.33	1e-7	Parkinson's disease;
KIRP	cis	rs9318086	0.512	rs4769290	chr13:24373443	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.41	-4.95	-0.3	1.4e-6	Myopia (pathological);
KIRP	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11622362	chr11:34938112	PDHX;APIP	-0.5	-6.19	-0.37	2.47e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg21605333	chr4:119757512	SEC24D	1.67	11.88	0.6	5.17e-26	Cannabis dependence symptom count;
KIRP	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.42	4.93	0.3	1.53e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg26769984	chr7:1090371	C7orf50	0.66	6.11	0.36	3.78e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21747090	chr2:27597821	SNX17	0.43	6.05	0.36	5.46e-9	Total body bone mineral density;
KIRP	trans	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg06521331	chr12:34319734	NA	0.47	6.04	0.36	5.52e-9	Bladder cancer;
KIRP	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg00864860	chr1:7907996	UTS2	-0.51	-6.03	-0.36	6.11e-9	Crohn's disease;
KIRP	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg22437258	chr11:111473054	SIK2	0.48	5.99	0.36	7.37e-9	Primary sclerosing cholangitis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14976964	chr5:134240766	PCBD2	-0.54	-6.03	-0.36	5.92e-9	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23348161	chr2:240964931	NDUFA10	0.47	6.42	0.38	7.03e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17358127	chr4:118005533	TRAM1L1	0.46	6.99	0.41	2.61e-11	Survival in pancreatic cancer;
KIRP	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	13.39	0.65	4.31e-31	Personality dimensions;
KIRP	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.84	10.03	0.54	4.52e-20	Multiple sclerosis;
KIRP	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg14675211	chr2:100938903	LONRF2	0.55	7.17	0.42	8.49e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg13010199	chr12:38710504	ALG10B	0.61	7.63	0.44	5.05e-13	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg08975724	chr8:8085496	FLJ10661	0.5	6.52	0.38	4.02e-10	Retinal vascular caliber;
KIRP	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.8	10.26	0.55	8.79e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7826238	0.526	rs876955	chr8:8310884	C/G	cg08975724	chr8:8085496	FLJ10661	0.6	7.14	0.41	1.08e-11	Systolic blood pressure;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9361491	0.508	rs9343787	chr6:79415606	A/C	cg11833968	chr6:79620685	NA	-0.35	-4.92	-0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg23594656	chr7:65796392	TPST1	-0.47	-7.24	-0.42	5.76e-12	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20707008	chr6:160210612	MRPL18;TCP1	0.51	6.1	0.36	4.11e-9	Smoking initiation;
KIRP	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg19847866	chr10:1019161	NA	-0.62	-5.72	-0.34	3.03e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg19847866	chr10:1019161	NA	0.46	5.34	0.32	2.13e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13412395	chr9:102583693	NR4A3	0.48	6.32	0.37	1.21e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1484642	0.582	rs28710334	chr8:9943487	G/C	cg15537082	chr8:9762300	MIR124-1;LOC157627	0.53	5.03	0.31	9.46e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg11161011	chr14:65562177	MAX	-0.59	-6.93	-0.4	3.58e-11	Obesity-related traits;
KIRP	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg19445457	chr11:5799446	OR52N5	-0.47	-5.61	-0.34	5.3e-8	DNA methylation (variation);
KIRP	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.76	-9.13	-0.5	2.62e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-16.59	-0.73	5.24e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs501120	1.000	rs607760	chr10:44756236	A/G	cg09554077	chr10:44749378	NA	0.74	12.04	0.61	1.45e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs12042938	0.507	rs1655302	chr1:231731528	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.0	-0.54	5.71e-20	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg18306943	chr3:40428807	ENTPD3	0.41	5.58	0.34	6.19e-8	Renal cell carcinoma;
KIRP	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.56	-7.43	-0.43	1.83e-12	Mean corpuscular volume;
KIRP	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-8.98	-0.5	7.19e-17	Lymphocyte counts;
KIRP	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg17644776	chr2:200775616	C2orf69	0.47	5.26	0.32	3.19e-7	Osteoporosis;
KIRP	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg01294253	chr9:136912663	BRD3	0.42	5.44	0.33	1.29e-7	Platelet distribution width;
KIRP	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.86	-0.4	5.6e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg07636037	chr3:49044803	WDR6	0.51	6.04	0.36	5.69e-9	Resting heart rate;
KIRP	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18364779	chr6:26104403	HIST1H4C	0.37	4.99	0.3	1.16e-6	Schizophrenia;
KIRP	cis	rs7122257	0.524	rs7110449	chr11:11151111	A/T	cg16931664	chr11:11169707	NA	0.43	6.11	0.36	3.82e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs539514	0.587	rs668008	chr13:76369746	C/T	cg04757411	chr13:76259545	LMO7	-0.36	-5.02	-0.3	9.8e-7	Type 1 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20725539	chr19:9695373	ZNF121	0.52	6.6	0.39	2.45e-10	Parkinson's disease;
KIRP	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.57	-6.97	-0.41	2.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.49	5.39	0.33	1.64e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs4356932	0.905	rs6532086	chr4:76937278	G/A	cg00809888	chr4:76862425	NAAA	0.45	6.34	0.37	1.07e-9	Blood protein levels;
KIRP	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.7	9.97	0.54	6.97e-20	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.16	0.54	1.76e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.63	-6.14	-0.36	3.23e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.04	0.31	9.09e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg22907277	chr7:1156413	C7orf50	0.63	7.43	0.43	1.77e-12	Longevity;Endometriosis;
KIRP	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg26207909	chr14:103986467	CKB	-0.47	-5.94	-0.35	9.74e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg02733842	chr7:1102375	C7orf50	0.59	6.02	0.36	6.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-5.03	-0.31	9.62e-7	Lung cancer;
KIRP	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs7614311	0.689	rs2276863	chr3:63849043	C/A	cg22134162	chr3:63841271	THOC7	-0.46	-5.43	-0.33	1.38e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.93	0.57	6.37e-23	Cognitive test performance;
KIRP	cis	rs7555523	0.887	rs4269750	chr1:165711510	C/T	cg24409356	chr1:165738333	TMCO1	0.7	5.75	0.34	2.65e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs1978968	0.956	rs7290762	chr22:18449130	C/G	cg02610425	chr22:18483192	MICAL3	0.36	5.04	0.31	8.99e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs8014252	0.803	rs56922268	chr14:71052171	A/C	cg11204974	chr14:71022665	NA	-0.74	-7.31	-0.42	3.65e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-0.94	-13.48	-0.65	2.28e-31	Blood trace element (Zn levels);
KIRP	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg08619932	chr19:49200058	FUT2	0.37	5.62	0.34	5.27e-8	Dietary macronutrient intake;
KIRP	cis	rs1050631	0.556	rs4267398	chr18:33767749	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.05	0.31	8.45e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg16486109	chr11:613632	IRF7	0.43	5.08	0.31	7.44e-7	Systemic lupus erythematosus;
KIRP	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.44	-6.17	-0.37	2.72e-9	Ovarian reserve;
KIRP	cis	rs12220238	0.722	rs11001096	chr10:76413103	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.89	0.35	1.29e-8	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05124756	chr4:2263820	MXD4	0.47	6.11	0.36	3.92e-9	Parkinson's disease;
KIRP	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg08807101	chr21:30365312	RNF160	-0.58	-5.68	-0.34	3.83e-8	Cognitive test performance;
KIRP	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.74	-9.76	-0.53	3.03e-19	Blood metabolite levels;
KIRP	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.82	-0.4	6.9e-11	Hemoglobin concentration;
KIRP	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.55e-23	Primary sclerosing cholangitis;
KIRP	trans	rs1223583	0.743	rs1223580	chr10:95771829	C/G	cg20595745	chr1:63249763	ATG4C	-0.5	-6.69	-0.39	1.51e-10	Coronary artery disease;
KIRP	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11987759	chr7:65425863	GUSB	0.61	8.16	0.46	1.69e-14	Aortic root size;
KIRP	cis	rs7520050	0.966	rs6656992	chr1:46333068	C/G	cg03146154	chr1:46216737	IPP	-0.42	-5.24	-0.32	3.48e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg13271783	chr10:134563150	INPP5A	-0.59	-7.64	-0.44	4.93e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.63	8.96	0.5	8.55e-17	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.73	0.49	3.98e-16	Morning vs. evening chronotype;
KIRP	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	1.06	18.45	0.76	2.73e-48	Gut microbiome composition (winter);
KIRP	cis	rs778371	0.671	rs13008436	chr2:233719948	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.72	-0.53	4.01e-19	Schizophrenia;
KIRP	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06028808	chr11:68637592	NA	0.71	8.81	0.49	2.26e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6442310	0.534	rs2921190	chr3:12419475	T/C	cg02700894	chr3:12045449	SYN2	0.36	5.01	0.3	1.03e-6	Hematocrit;
KIRP	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-7.58	-0.44	6.82e-13	Coronary artery disease;
KIRP	cis	rs6684428	0.518	rs7553701	chr1:56367159	G/T	cg11651538	chr1:56320950	NA	-0.55	-7.24	-0.42	5.63e-12	Airflow obstruction;
KIRP	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg15128208	chr22:42549153	NA	0.37	4.89	0.3	1.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs2904967	1.000	rs2904967	chr11:65091609	G/A	cg12562828	chr11:65076843	NA	0.62	9.11	0.5	3.06e-17	Mean corpuscular volume;
KIRP	cis	rs6859018	0.812	rs11135056	chr5:158687281	C/T	cg26646896	chr5:158686746	NA	-0.37	-5.33	-0.32	2.18e-7	Serum sulfate level;
KIRP	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg15327641	chr2:3715039	ALLC	0.41	5.08	0.31	7.53e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs367943	0.634	rs6594701	chr5:112685743	C/T	cg12552261	chr5:112820674	MCC	0.5	5.71	0.34	3.24e-8	Type 2 diabetes;
KIRP	cis	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg08773314	chr2:239334832	ASB1	-0.55	-5.71	-0.34	3.29e-8	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.59	-7.26	-0.42	5.05e-12	Coronary artery disease;
KIRP	cis	rs10211205	1.000	rs10211205	chr2:236617466	C/T	cg02339850	chr2:236586191	AGAP1	-0.44	-4.92	-0.3	1.55e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2562456	0.833	rs62107540	chr19:21518495	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.23	-13.58	-0.65	1.02e-31	Alzheimer's disease;
KIRP	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg15841412	chr13:111365552	ING1	0.49	5.65	0.34	4.34e-8	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.6	-0.39	2.45e-10	Gut microbiome composition (summer);
KIRP	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg05085585	chr16:30420623	ZNF771	-0.35	-4.92	-0.3	1.56e-6	Tonsillectomy;
KIRP	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.24	-0.32	3.51e-7	Triglycerides;
KIRP	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.81	-12.43	-0.62	7.52e-28	Breast cancer;
KIRP	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.22	-0.37	2.09e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs357618	0.931	rs394736	chr5:150847509	A/G	cg22672639	chr5:150884813	FAT2	0.35	5.34	0.32	2.15e-7	Basophil percentage of white cells;
KIRP	cis	rs1891275	0.515	rs6583784	chr10:93491576	A/G	cg07889827	chr10:93443413	NA	0.43	7.25	0.42	5.52e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7577293	1.000	rs12151752	chr2:85934652	T/C	cg19805943	chr2:85933069	NA	-0.41	-4.86	-0.3	2.1e-6	Blood protein levels;
KIRP	cis	rs539514	0.614	rs658746	chr13:76373413	A/T	cg04757411	chr13:76259545	LMO7	-0.36	-4.99	-0.3	1.12e-6	Type 1 diabetes;
KIRP	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg07645718	chr20:61493192	TCFL5	0.8	6.24	0.37	1.86e-9	Obesity-related traits;
KIRP	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	cg12689670	chr1:183009347	LAMC1	0.56	7.85	0.45	1.32e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.52	5.16	0.31	5.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2411233	1.000	rs1824493	chr15:39284663	A/T	cg02291532	chr15:39874776	THBS1	0.38	5.17	0.31	4.92e-7	Platelet count;
KIRP	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.44	5.96	0.36	8.51e-9	Red blood cell count;
KIRP	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.77	-0.35	2.43e-8	Subjective well-being;
KIRP	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg05625103	chr10:2543513	NA	-0.55	-6.71	-0.39	1.32e-10	Age-related hearing impairment;
KIRP	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg12591125	chr7:1885375	MAD1L1	0.66	6.12	0.36	3.69e-9	Bipolar disorder;
KIRP	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.57	6.16	0.37	2.91e-9	Type 2 diabetes;
KIRP	cis	rs1519814	0.956	rs4133251	chr8:121166993	A/G	cg22335954	chr8:121166405	COL14A1	-0.66	-6.41	-0.38	7.38e-10	Breast cancer;
KIRP	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg13798912	chr7:905769	UNC84A	0.62	6.05	0.36	5.29e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	5.64	0.34	4.66e-8	Diastolic blood pressure;
KIRP	cis	rs7737355	0.812	rs2042252	chr5:130980027	A/G	cg25547332	chr5:131281432	NA	-0.39	-4.89	-0.3	1.82e-6	Life satisfaction;
KIRP	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.42	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.42	-6.13	-0.36	3.43e-9	Bipolar disorder;
KIRP	cis	rs2011503	0.509	rs10403579	chr19:19770329	T/C	cg11584989	chr19:19387371	SF4	0.52	5.11	0.31	6.34e-7	Bipolar disorder;
KIRP	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.59	7.94	0.45	7.14e-14	Retinal vascular caliber;
KIRP	cis	rs6901004	0.592	rs14399	chr6:111543944	C/A	cg15721981	chr6:111408429	SLC16A10	-0.63	-8.28	-0.47	8.12e-15	Blood metabolite levels;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07402062	chr16:89894098	SPIRE2	0.33	6.95	0.41	3.27e-11	Vitiligo;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04261408	chr8:97506675	SDC2	0.49	6.16	0.37	2.9e-9	C-reactive protein;
KIRP	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.03	-13.4	-0.65	4.21e-31	Exhaled nitric oxide output;
KIRP	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.49	0.38	4.69e-10	Height;
KIRP	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-7.38	-0.43	2.38e-12	Chronic sinus infection;
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.31e-13	Life satisfaction;
KIRP	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.35	5.4	0.33	1.6e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.54	-5.53	-0.33	8.12e-8	Schizophrenia;
KIRP	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg13409248	chr3:40428643	ENTPD3	0.39	5.25	0.32	3.24e-7	Renal cell carcinoma;
KIRP	cis	rs4523957	0.579	rs903162	chr17:2092200	C/T	cg16513277	chr17:2031491	SMG6	-0.72	-10.38	-0.55	3.61e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.1e-9	Morning vs. evening chronotype;
KIRP	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg21854759	chr1:92012499	NA	0.48	6.23	0.37	2.03e-9	Breast cancer;
KIRP	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.89	11.23	0.58	6.81e-24	Schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17331738	chr1:156647236	NES	0.44	6.16	0.37	2.96e-9	Myopia (pathological);
KIRP	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg08847533	chr14:75593920	NEK9	0.53	6.19	0.37	2.51e-9	IgG glycosylation;
KIRP	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg22906224	chr7:99728672	NA	0.47	5.63	0.34	5.02e-8	Coronary artery disease;
KIRP	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.49	0.38	4.56e-10	Myopia (pathological);
KIRP	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg24972876	chr7:65420302	NA	0.41	5.58	0.34	6.38e-8	Calcium levels;
KIRP	cis	rs10463316	0.784	rs906678	chr5:150779040	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.26	-0.37	1.72e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs1829883	0.737	rs2845977	chr5:98922589	A/G	cg08333243	chr5:99726346	NA	0.43	5.53	0.33	8.08e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg01763666	chr17:80159506	CCDC57	-0.38	-5.15	-0.31	5.43e-7	Life satisfaction;
KIRP	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.53	6.16	0.37	3.03e-9	Blood metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09024808	chr16:24764225	TNRC6A	-0.43	-6.47	-0.38	5.15e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.12	9.25	0.51	1.09e-17	Cognitive function;
KIRP	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg23950597	chr19:37808831	NA	-0.64	-6.78	-0.4	8.94e-11	Coronary artery calcification;
KIRP	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-6.21	-0.37	2.2e-9	Personality dimensions;
KIRP	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.03e-7	Schizophrenia;
KIRP	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.83	12.81	0.63	3.96e-29	IgG glycosylation;
KIRP	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.73	10.78	0.57	1.87e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.67	9.39	0.51	4.26e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20333067	chr17:30676942	ZNF207;MIR632	-0.49	-6.32	-0.37	1.24e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.85	0.45	1.24e-13	Obesity-related traits;
KIRP	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.8	9.79	0.53	2.53e-19	Corneal astigmatism;
KIRP	cis	rs400736	0.562	rs12129505	chr1:8171734	T/C	cg25007680	chr1:8021821	PARK7	-0.47	-5.81	-0.35	1.91e-8	Response to antidepressants and depression;
KIRP	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21643547	chr1:205240462	TMCC2	-0.85	-13.15	-0.64	2.95e-30	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg08501292	chr6:25962987	TRIM38	1.09	8.31	0.47	6.59e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.31	-0.47	6.3e-15	Morning vs. evening chronotype;
KIRP	cis	rs76693355	0.512	rs12807097	chr11:120242348	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.42	-5.34	-0.32	2.08e-7	Intraocular pressure;
KIRP	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.63	-7.09	-0.41	1.38e-11	Neuroticism;
KIRP	cis	rs7633770	0.786	rs6442012	chr3:46686346	A/G	cg11219411	chr3:46661640	NA	0.53	7.52	0.43	1.04e-12	Coronary artery disease;
KIRP	cis	rs1823913	1.000	rs1454749	chr2:192105635	C/T	cg12404831	chr2:192114017	MYO1B	0.5	6.78	0.4	8.68e-11	Obesity-related traits;
KIRP	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	9.43	0.52	3.25e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6800768	0.633	rs826375	chr3:24163964	A/G	cg10674438	chr3:24145617	LOC152024	-0.5	-6.88	-0.4	4.99e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12976411	0.575	rs55679515	chr19:32823044	G/A	cg02282382	chr19:32836354	ZNF507	0.62	5.17	0.31	4.93e-7	Coronary artery disease;
KIRP	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg00310523	chr12:86230176	RASSF9	0.46	7.27	0.42	4.62e-12	Major depressive disorder;
KIRP	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.3	13.31	0.65	8.57e-31	Diabetic retinopathy;
KIRP	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.64	8.3	0.47	7.09e-15	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.47	6.93	0.4	3.65e-11	Lewy body disease;
KIRP	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.66	9.24	0.51	1.19e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	7.41	0.43	2.02e-12	Alzheimer's disease;
KIRP	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.78e-11	Bipolar disorder;
KIRP	cis	rs3857067	0.967	rs1904096	chr4:95012684	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.85	-0.3	2.16e-6	QT interval;
KIRP	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg20520273	chr2:109403139	CCDC138	-0.39	-5.1	-0.31	6.85e-7	Mean platelet volume;
KIRP	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg04238871	chr10:126431886	FAM53B	0.58	7.49	0.43	1.24e-12	Sleep duration;
KIRP	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.14	-0.31	5.55e-7	Prion diseases;
KIRP	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg04731861	chr2:219085781	ARPC2	-0.28	-7.01	-0.41	2.32e-11	Colorectal cancer;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg04025307	chr7:1156635	C7orf50	0.75	7.94	0.45	7.15e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2271404	1.000	rs72837860	chr2:112007572	G/A	cg23466623	chr2:111982296	NA	-0.64	-5.26	-0.32	3.1e-7	Atopic dermatitis;
KIRP	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.24	0.55	1.01e-20	Cognitive test performance;
KIRP	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg03887218	chr1:16534349	ARHGEF19	0.49	6.42	0.38	6.95e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg08975724	chr8:8085496	FLJ10661	0.61	8.08	0.46	2.92e-14	Retinal vascular caliber;
KIRP	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.84	13.38	0.65	4.78e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg15691649	chr6:25882328	NA	0.43	5.33	0.32	2.19e-7	Blood metabolite levels;
KIRP	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg23335576	chr14:104009727	NA	-0.35	-4.97	-0.3	1.25e-6	Body mass index;
KIRP	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17376030	chr22:41985996	PMM1	-0.78	-7.95	-0.45	6.85e-14	Vitiligo;
KIRP	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg19554555	chr3:13937349	NA	-0.45	-6.15	-0.36	3.17e-9	Ovarian reserve;
KIRP	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg04990556	chr1:26633338	UBXN11	0.64	6.07	0.36	4.77e-9	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03666506	chr17:15635376	TBC1D26	-0.42	-6.24	-0.37	1.9e-9	Survival in pancreatic cancer;
KIRP	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.5	6.45	0.38	5.8e-10	Blood metabolite levels;
KIRP	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg14768367	chr16:72042858	DHODH	-0.83	-7.32	-0.42	3.46e-12	Blood protein levels;
KIRP	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg04804543	chr8:142233427	SLC45A4	-0.58	-7.38	-0.43	2.37e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.02	0.69	1.23e-36	Platelet count;
KIRP	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs7766436	1.000	rs13217022	chr6:22612757	T/C	cg13666174	chr6:22585274	NA	-0.39	-5.63	-0.34	4.84e-8	Coronary artery disease;
KIRP	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs960902	0.818	rs58694726	chr2:37718696	G/A	cg25341268	chr2:37734390	NA	0.61	7.96	0.45	6.34e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg23100626	chr2:96804247	ASTL	0.52	7.25	0.42	5.54e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24663984	chr11:118230199	UBE4A	0.47	6.32	0.37	1.25e-9	Survival in pancreatic cancer;
KIRP	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.13	0.36	3.45e-9	Lung cancer;
KIRP	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.64	-5.96	-0.36	8.57e-9	Narcolepsy;
KIRP	cis	rs3824344	0.531	rs7870336	chr9:37007769	C/G	cg14294708	chr9:37120828	ZCCHC7	-0.43	-5.25	-0.32	3.28e-7	Intelligence;
KIRP	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13693582	chr14:69441902	ACTN1	0.44	6.12	0.36	3.63e-9	Gut microbiome composition (summer);
KIRP	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg05340658	chr4:99064831	C4orf37	0.67	7.77	0.44	2.14e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.64	5.54	0.33	7.84e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.31	0.51	7.33e-18	Lymphocyte counts;
KIRP	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.75	0.4	1.06e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1864585	0.520	rs7827270	chr8:10590553	C/T	cg26278703	chr11:58910052	FAM111A	0.58	6.03	0.36	6.01e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg26876637	chr1:152193138	HRNR	-0.82	-8.34	-0.47	5.26e-15	Atopic dermatitis;
KIRP	cis	rs11711311	0.712	rs4682139	chr3:113331859	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.3	0.42	3.94e-12	IgG glycosylation;
KIRP	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.02	14.94	0.69	2.38e-36	Bipolar disorder;
KIRP	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.82	-12.06	-0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60871478	0.898	rs34766380	chr7:786862	G/A	cg05535760	chr7:792225	HEATR2	0.83	8.33	0.47	5.6e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs931127	0.836	rs523029	chr11:65476487	T/G	cg11569703	chr11:65557185	OVOL1	0.43	7.12	0.41	1.17e-11	Systemic lupus erythematosus;
KIRP	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.68	-0.34	3.7e-8	Aortic root size;
KIRP	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.13	0.36	3.52e-9	Neuroticism;
KIRP	cis	rs9308731	0.614	rs6755484	chr2:111949096	T/C	cg04202892	chr2:111875749	ACOXL	0.41	5.62	0.34	5.11e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg23422044	chr7:1970798	MAD1L1	-0.51	-6.43	-0.38	6.42e-10	Neuroticism;
KIRP	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	10.72	0.56	2.98e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22864355	chr14:105225861	SIVA1	0.53	7.09	0.41	1.38e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28595532	0.641	rs116674223	chr4:119371479	G/C	cg21605333	chr4:119757512	SEC24D	1.08	7.63	0.44	5.17e-13	Cannabis dependence symptom count;
KIRP	cis	rs7923609	0.875	rs6479877	chr10:64878118	C/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.44	-0.33	1.27e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.7e-13	Life satisfaction;
KIRP	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.56	-0.43	8.02e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg06156847	chr2:113672199	IL1F7	-0.43	-6.07	-0.36	4.92e-9	Pulmonary function;
KIRP	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26847753	chr15:44119241	WDR76	0.47	6.2	0.37	2.41e-9	Parkinson's disease;
KIRP	cis	rs6738627	1.000	rs6738627	chr2:165544450	G/A	cg03182029	chr2:165697222	COBLL1	0.38	4.97	0.3	1.26e-6	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.21	0.37	2.27e-9	Morning vs. evening chronotype;
KIRP	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.41	-4.99	-0.3	1.15e-6	Diastolic blood pressure;
KIRP	cis	rs258892	0.895	rs34066594	chr5:72030627	T/C	cg21869765	chr5:72125136	TNPO1	-0.52	-5.83	-0.35	1.71e-8	Small cell lung carcinoma;
KIRP	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.5	0.43	1.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg09890400	chr1:26503858	CNKSR1	0.42	5.81	0.35	1.94e-8	Height;
KIRP	cis	rs7677751	1.000	rs7677751	chr4:55124460	C/T	cg17187183	chr4:55093834	PDGFRA	0.68	6.4	0.38	7.91e-10	Corneal astigmatism;
KIRP	cis	rs745821	0.701	rs17718537	chr18:48099345	G/T	cg18923635	chr18:48083994	NA	0.43	4.97	0.3	1.27e-6	Diastolic blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05572930	chr6:125404126	RNF217	-0.4	-6.38	-0.38	8.7e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	1.26	14.24	0.67	5.78e-34	Eosinophil percentage of granulocytes;
KIRP	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg19773385	chr1:10388646	KIF1B	-0.75	-11.21	-0.58	7.68e-24	Hepatocellular carcinoma;
KIRP	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7570971	0.617	rs935613	chr2:136022798	C/T	cg07169764	chr2:136633963	MCM6	0.5	5.82	0.35	1.79e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs6142102	0.923	rs4911394	chr20:32577327	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.69	0.39	1.46e-10	Skin pigmentation;
KIRP	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-7.82	-0.45	1.51e-13	Migraine;
KIRP	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg16512390	chr1:228756714	NA	0.46	5.16	0.31	5.18e-7	Diastolic blood pressure;
KIRP	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.73	10.94	0.57	5.84e-23	Orofacial clefts;
KIRP	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg18527119	chr7:66119851	NA	0.45	4.93	0.3	1.51e-6	Aortic root size;
KIRP	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.78	9.99	0.54	6.01e-20	Corneal astigmatism;
KIRP	cis	rs4389656	0.857	rs453536	chr5:6736458	T/G	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg23533419	chr12:54090519	NA	-0.33	-5.18	-0.31	4.52e-7	Height;
KIRP	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.37	-9.1	-0.5	3.23e-17	Asthma (sex interaction);
KIRP	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg13319975	chr6:146136371	FBXO30	-0.45	-6.31	-0.37	1.28e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.49	6.59	0.39	2.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg08999081	chr20:33150536	PIGU	0.45	5.92	0.35	1.05e-8	Height;
KIRP	cis	rs6988636	0.818	rs73339658	chr8:124173007	A/G	cg15893493	chr8:124194847	FAM83A	0.92	6.64	0.39	2.02e-10	Urinary uromodulin levels;
KIRP	cis	rs11225247	0.881	rs79796684	chr11:102257170	T/C	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg04310649	chr10:35416472	CREM	-0.59	-7.07	-0.41	1.6e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.65	-6.83	-0.4	6.64e-11	Gut microbiome composition (summer);
KIRP	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-0.84	-9.36	-0.51	5.22e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03224364	chr1:235667348	B3GALNT2	0.54	6.77	0.4	9.54e-11	Parkinson's disease;
KIRP	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg27279351	chr12:120934652	DYNLL1	0.62	5.93	0.35	1.01e-8	High light scatter reticulocyte count;
KIRP	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.59	-9.4	-0.51	4.05e-18	Neuroticism;
KIRP	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg17845761	chr1:175162550	KIAA0040	-0.34	-6.43	-0.38	6.54e-10	Alcohol dependence;
KIRP	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg10255544	chr17:80519551	FOXK2	0.56	8.2	0.46	1.37e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg00409905	chr10:38381863	ZNF37A	-0.57	-6.26	-0.37	1.72e-9	Obesity (extreme);
KIRP	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.15	-20.42	-0.79	7.09e-55	Ulcerative colitis;
KIRP	cis	rs78487399	0.710	rs13408002	chr2:43610027	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.3	-0.32	2.55e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4728302	0.607	rs6954999	chr7:133588927	G/A	cg10665199	chr7:133106180	EXOC4	0.42	4.92	0.3	1.58e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs838147	0.844	rs11672046	chr19:49247601	C/T	cg13540341	chr19:49222985	MAMSTR	0.35	5.62	0.34	5.06e-8	Dietary macronutrient intake;
KIRP	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.74	11.86	0.6	5.91e-26	Monocyte percentage of white cells;
KIRP	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg23202291	chr11:1979235	NA	0.41	5.22	0.32	3.9e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12768767	chr1:47779966	STIL	-0.46	-6.05	-0.36	5.47e-9	Metabolic traits;
KIRP	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.64	-0.34	4.68e-8	Common traits (Other);
KIRP	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.08	-0.31	7.45e-7	Neuroticism;
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02359409	chr6:42947317	PEX6	-0.47	-6.31	-0.37	1.32e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1847505	0.957	rs6562145	chr13:61525919	G/A	cg25164009	chr13:61490935	NA	-0.58	-6.35	-0.38	1.02e-9	Polychlorinated biphenyl levels;
KIRP	cis	rs4740619	0.619	rs1328277	chr9:16029126	G/C	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg10495392	chr1:46806563	NSUN4	0.46	5.01	0.3	1.02e-6	Menopause (age at onset);
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg09104050	chr16:68563912	NA	-0.45	-6.42	-0.38	6.97e-10	Metabolite levels (MHPG);
KIRP	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7566780	0.575	rs4383328	chr2:16693124	A/T	cg09580478	chr2:16689509	NA	0.46	5.28	0.32	2.83e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.79	10.53	0.56	1.21e-21	Pancreatic cancer;
KIRP	cis	rs17221829	0.733	rs10830326	chr11:89389110	T/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs6696846	0.936	rs12134724	chr1:205039288	T/C	cg00857998	chr1:205179979	DSTYK	0.58	6.99	0.41	2.53e-11	Red blood cell count;
KIRP	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.68	9.77	0.53	2.97e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.73	10.77	0.57	2.06e-22	Platelet distribution width;
KIRP	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.43	-0.38	6.73e-10	Mood instability;
KIRP	cis	rs1413885	0.516	rs10158872	chr1:65836230	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.61	0.34	5.54e-8	Anticoagulant levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04691540	chr1:179198414	ABL2	0.59	7.04	0.41	1.87e-11	Smoking initiation;
KIRP	cis	rs35661897	0.688	rs7566840	chr2:227345743	G/A	cg03426602	chr2:227312417	NA	-0.33	-4.85	-0.3	2.18e-6	Urinary tract infection frequency;
KIRP	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg08994789	chr17:28903642	LRRC37B2	0.75	8.84	0.49	1.86e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg24296786	chr1:45957014	TESK2	0.63	8.44	0.47	2.76e-15	High light scatter reticulocyte count;
KIRP	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	cis	rs7424096	0.555	rs75219072	chr2:37225706	C/T	cg14987922	chr2:37194071	STRN	0.58	5.99	0.36	7.35e-9	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.59	7.92	0.45	8.24e-14	Iron status biomarkers;
KIRP	cis	rs8070740	1.000	rs8076900	chr17:5327927	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.38	0.43	2.49e-12	Menopause (age at onset);
KIRP	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg15282417	chr9:129245246	FAM125B	0.45	7.69	0.44	3.62e-13	Intraocular pressure;
KIRP	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.37	5.43	0.33	1.33e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.73	-10.5	-0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg18187862	chr3:45730750	SACM1L	0.54	6.15	0.37	3.15e-9	Primary sclerosing cholangitis;
KIRP	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-5.61	-0.34	5.49e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.83	8.93	0.49	1.05e-16	Alzheimer's disease;
KIRP	cis	rs12230513	0.732	rs61956358	chr12:55852286	G/T	cg19537932	chr12:55886519	OR6C68	-0.6	-7.41	-0.43	1.98e-12	Contrast sensitivity;
KIRP	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg11833968	chr6:79620685	NA	-0.38	-5.25	-0.32	3.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.25	6.54	0.38	3.55e-10	Crohn's disease;
KIRP	cis	rs6499129	0.558	rs28711261	chr16:67617186	A/G	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.54	-0.33	7.61e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4478037	0.822	rs3924696	chr3:33122013	T/C	cg19404215	chr3:33155277	CRTAP	0.56	5.3	0.32	2.55e-7	Major depressive disorder;
KIRP	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg05868516	chr6:26286170	HIST1H4H	0.39	5.01	0.3	1.05e-6	Educational attainment;
KIRP	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg25767906	chr1:53392781	SCP2	-0.35	-4.84	-0.3	2.27e-6	Monocyte count;
KIRP	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs5756391	0.523	rs2049908	chr22:37311089	A/G	cg16356956	chr22:37317934	CSF2RB	0.42	5.74	0.34	2.72e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg11189052	chr15:85197271	WDR73	0.56	5.9	0.35	1.18e-8	Schizophrenia;
KIRP	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.81	-0.35	1.89e-8	Reticulocyte count;
KIRP	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.5	-0.38	4.44e-10	Schizophrenia;
KIRP	cis	rs4919087	0.781	rs7901853	chr10:99082360	T/C	cg25902810	chr10:99078978	FRAT1	0.56	6.61	0.39	2.38e-10	Monocyte count;
KIRP	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7084402	0.967	rs1623568	chr10:60320446	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.77	-0.57	2.01e-22	Refractive error;
KIRP	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	0.7	6.61	0.39	2.41e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.65	8.97	0.5	7.89e-17	Longevity;
KIRP	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.48	-0.33	1.04e-7	Aortic root size;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19236395	chr7:44122272	POLM	-0.55	-7.2	-0.42	7.19e-12	Myopia;
KIRP	cis	rs524023	0.914	rs2277311	chr11:64387932	G/A	cg09231725	chr11:64357281	SLC22A12	0.59	7.89	0.45	9.83e-14	Urate levels in obese individuals;
KIRP	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.44	5.5	0.33	9.28e-8	Aortic root size;
KIRP	cis	rs6959887	0.548	rs33916666	chr7:35306718	C/T	cg06685737	chr7:35301730	NA	-0.59	-9.63	-0.52	7.97e-19	Birth weight;
KIRP	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.5	-6.38	-0.38	8.54e-10	Type 2 diabetes;
KIRP	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg02725872	chr8:58115012	NA	-0.62	-5.12	-0.31	6.21e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.74	11.2	0.58	8.47e-24	Type 2 diabetes;
KIRP	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg01689657	chr7:91764605	CYP51A1	0.4	5.77	0.35	2.4e-8	Breast cancer;
KIRP	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	12.61	0.63	1.94e-28	Smoking behavior;
KIRP	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.82	9.84	0.53	1.73e-19	Corneal astigmatism;
KIRP	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg21360079	chr12:107162445	NA	-0.67	-9.59	-0.52	1.06e-18	Heart rate;
KIRP	cis	rs11710088	0.740	rs4408826	chr3:149186625	T/A	cg08667024	chr3:149219783	TM4SF4	-0.46	-5.82	-0.35	1.84e-8	QRS duration;
KIRP	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.64	9.3	0.51	8.07e-18	Hip circumference;
KIRP	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs2916247	0.954	rs13273012	chr8:93092337	G/A	cg10183463	chr8:93005414	RUNX1T1	0.53	6.93	0.4	3.64e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg15327641	chr2:3715039	ALLC	0.5	6.53	0.38	3.82e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.07	-0.31	7.86e-7	Obesity-related traits;
KIRP	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg10523679	chr1:76189770	ACADM	-0.51	-7.11	-0.41	1.24e-11	Daytime sleep phenotypes;
KIRP	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.63e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4233802	1.000	rs10165225	chr2:151121736	C/T	cg25300694	chr2:151184358	NA	0.87	6.81	0.4	7.38e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-6.55	-0.39	3.31e-10	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.21	0.32	4.02e-7	Lung cancer;
KIRP	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg17376030	chr22:41985996	PMM1	-0.52	-6.46	-0.38	5.42e-10	Vitiligo;
KIRP	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	7.74	0.44	2.51e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg21427119	chr20:30132790	HM13	-0.42	-4.98	-0.3	1.18e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg15676125	chr6:33679581	C6orf125	0.43	5.42	0.33	1.45e-7	Plateletcrit;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25878872	chr4:159593506	ETFDH;C4orf46	0.46	6.05	0.36	5.29e-9	Parkinson's disease;
KIRP	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg04998671	chr14:104000505	TRMT61A	0.58	6.7	0.39	1.37e-10	Coronary artery disease;
KIRP	cis	rs11593576	0.550	rs7895110	chr10:80994117	T/A	cg18737081	chr10:80999807	ZMIZ1	-0.31	-5.51	-0.33	8.97e-8	Vitiligo;
KIRP	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg18944383	chr4:111397179	ENPEP	0.61	11.18	0.58	1.02e-23	Height;
KIRP	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg03711944	chr11:47377212	SPI1	-0.3	-5.05	-0.31	8.69e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg13453750	chr1:205783389	SLC41A1	-0.51	-7.44	-0.43	1.67e-12	Menarche (age at onset);
KIRP	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg04727924	chr7:799746	HEATR2	-0.78	-8.73	-0.49	3.88e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-0.72	-7.65	-0.44	4.41e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg22176566	chr1:43424700	SLC2A1	0.5	4.88	0.3	1.89e-6	Red cell distribution width;
KIRP	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.56	-5.32	-0.32	2.36e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs412658	0.776	rs8113700	chr19:22319421	G/A	cg17074339	chr11:11642133	GALNTL4	-0.54	-6.37	-0.38	9.24e-10	Telomere length;
KIRP	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg24253500	chr15:84953950	NA	0.52	5.84	0.35	1.66e-8	Schizophrenia;
KIRP	cis	rs6959887	0.926	rs2240994	chr7:35280947	C/T	cg06685737	chr7:35301730	NA	0.43	6.29	0.37	1.46e-9	Birth weight;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18076360	chr19:44515398	ZNF230	0.43	6.12	0.36	3.65e-9	Migraine with aura;
KIRP	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.28	7.47	0.43	1.42e-12	Primary biliary cholangitis;
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.61	8.94	0.5	9.34e-17	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26480413	chr15:90233593	WDR93;PEX11A	0.44	6.04	0.36	5.63e-9	Parkinson's disease;
KIRP	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg13482628	chr17:19912719	NA	0.53	6.86	0.4	5.45e-11	Schizophrenia;
KIRP	cis	rs6466055	0.661	rs55671517	chr7:104827528	A/G	cg04380332	chr7:105027541	SRPK2	0.37	4.98	0.3	1.23e-6	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs10073892	0.743	rs62372217	chr5:101650918	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.51e-21	Bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17879352	chr4:1319092	MAEA	0.53	6.81	0.4	7.46e-11	Interleukin-4 levels;
KIRP	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg06618935	chr21:46677482	NA	-0.47	-5.45	-0.33	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs258892	0.895	rs3846643	chr5:72023038	T/A	cg21869765	chr5:72125136	TNPO1	-0.52	-5.9	-0.35	1.19e-8	Small cell lung carcinoma;
KIRP	cis	rs2562456	0.839	rs2562411	chr19:21601983	T/G	cg18461458	chr19:21324796	ZNF431	-0.54	-5.15	-0.31	5.22e-7	Pain;
KIRP	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.95	-13.1	-0.64	4.36e-30	Schizophrenia;
KIRP	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg13660082	chr14:53194042	PSMC6	-0.69	-7.1	-0.41	1.35e-11	Alzheimer's disease (late onset);
KIRP	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg27205649	chr11:78285834	NARS2	0.63	7.38	0.43	2.47e-12	Alzheimer's disease (survival time);
KIRP	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg09873164	chr1:152488093	CRCT1	0.56	6.62	0.39	2.23e-10	Hair morphology;
KIRP	cis	rs2151522	0.603	rs13213649	chr6:127204067	A/G	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.4e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.74	-9.25	-0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg22676075	chr6:135203613	NA	0.48	6.84	0.4	6.4e-11	Red blood cell count;
KIRP	cis	rs2573652	1.000	rs2573650	chr15:100514097	A/G	cg09918751	chr15:100517450	ADAMTS17	0.68	9.73	0.53	3.82e-19	Height;
KIRP	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.85	-0.35	1.56e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4956211	0.518	rs2344628	chr4:109708455	C/G	cg07086381	chr4:109682776	AGXT2L1	-0.4	-5.25	-0.32	3.25e-7	Systemic lupus erythematosus;
KIRP	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg16482183	chr6:26056742	HIST1H1C	0.38	5.02	0.31	9.72e-7	Schizophrenia;
KIRP	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.62	5.11	0.31	6.56e-7	Schizophrenia;
KIRP	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.47	-5.65	-0.34	4.33e-8	Neuroticism;
KIRP	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.75	6.04	0.36	5.77e-9	Inflammatory bowel disease;
KIRP	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.46	0.59	1.22e-24	Alzheimer's disease;
KIRP	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg05370193	chr1:21551575	ECE1	0.42	5.93	0.35	1.04e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs78487399	0.614	rs10166376	chr2:43622472	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.35	-0.32	2e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.41	5.71	0.34	3.19e-8	Endometrial cancer;
KIRP	cis	rs61863818	0.557	rs7898743	chr10:99153540	T/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.91	-0.35	1.12e-8	Monocyte percentage of white cells;
KIRP	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.36	5.01	0.3	1.03e-6	Coronary artery disease;
KIRP	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.24	-0.62	3.21e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.57	-4.94	-0.3	1.47e-6	Narcolepsy;
KIRP	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	0.84	12.62	0.63	1.72e-28	Body mass index;
KIRP	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.73	8.26	0.47	9.29e-15	Corneal astigmatism;
KIRP	cis	rs17065868	0.803	rs10220075	chr13:45197421	A/G	cg10246903	chr13:45222710	NA	0.55	5.89	0.35	1.25e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1887596	0.629	rs1625599	chr13:27257688	C/T	cg01312412	chr13:27282625	NA	-0.42	-4.95	-0.3	1.35e-6	Facial morphology (factor 3, length of philtrum);
KIRP	cis	rs6832769	1.000	rs9997288	chr4:56347227	A/G	cg05960024	chr4:56376020	CLOCK	0.69	8.55	0.48	1.31e-15	Personality dimensions;
KIRP	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg04369109	chr6:150039330	LATS1	-0.52	-6.6	-0.39	2.47e-10	Lung cancer;
KIRP	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg00800038	chr16:89945340	TCF25	-0.89	-7.26	-0.42	4.94e-12	Skin colour saturation;
KIRP	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.92	-14.85	-0.69	4.8e-36	Breast cancer;
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg13206674	chr6:150067644	NUP43	0.64	9.69	0.53	5.17e-19	Lung cancer;
KIRP	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.68	9.21	0.51	1.51e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9659323	0.622	rs6689568	chr1:119502961	A/G	cg18261050	chr1:119551319	NA	0.37	4.89	0.3	1.78e-6	Body mass index;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-6.15	-0.37	3.05e-9	Longevity;
KIRP	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.97	0.3	1.27e-6	Menopause (age at onset);
KIRP	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.59	7.95	0.45	6.72e-14	Height;
KIRP	cis	rs11997175	0.583	rs7009719	chr8:33834824	C/G	cg04338863	chr8:33670619	NA	0.49	6.62	0.39	2.26e-10	Body mass index;
KIRP	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs494562	0.892	rs573892	chr6:86118189	A/C	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-6.25	-0.37	1.79e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg05315796	chr3:52349193	DNAH1	0.46	7.04	0.41	1.86e-11	Electroencephalogram traits;
KIRP	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg22800045	chr5:56110881	MAP3K1	0.71	7.43	0.43	1.79e-12	Initial pursuit acceleration;
KIRP	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.6	7.12	0.41	1.18e-11	Coronary artery disease;
KIRP	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg07423050	chr13:99094983	FARP1	-0.58	-9.11	-0.5	3.06e-17	Neuroticism;
KIRP	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.74	0.39	1.15e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.07e-10	Height;
KIRP	trans	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg24644049	chr4:85504048	CDS1	1.09	6.99	0.41	2.61e-11	Skin colour saturation;
KIRP	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	cg21523751	chr1:182988639	NA	0.35	4.94	0.3	1.42e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.65	8.21	0.46	1.25e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs35740288	0.770	rs4843085	chr15:86158499	A/G	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg04181038	chr4:183730758	NA	0.72	7.64	0.44	4.7e-13	Pediatric autoimmune diseases;
KIRP	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.15	-0.36	3.16e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2820315	0.867	rs2820317	chr1:201878537	G/C	cg11586189	chr1:201857591	SHISA4	-0.44	-6.43	-0.38	6.5e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg00631329	chr6:26305371	NA	0.55	6.94	0.4	3.36e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3736485	0.966	rs2414114	chr15:51905781	T/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.16e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.57	-6.39	-0.38	8.47e-10	Coronary artery disease;
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.75	0.34	2.6e-8	Platelet count;
KIRP	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg03929089	chr4:120376271	NA	-0.68	-6.83	-0.4	6.61e-11	Axial length;
KIRP	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-6.33	-0.37	1.17e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.73	9.46	0.52	2.52e-18	Coronary artery disease;
KIRP	cis	rs12049351	0.774	rs1020353	chr1:229697318	C/A	cg11742688	chr1:229674241	ABCB10	-0.41	-5.75	-0.34	2.62e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.49	6.93	0.4	3.73e-11	Immature fraction of reticulocytes;
KIRP	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg19507638	chr5:93509721	C5orf36	-0.61	-5.62	-0.34	5.27e-8	Diabetic retinopathy;
KIRP	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg03929089	chr4:120376271	NA	-0.53	-6.54	-0.38	3.44e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg05022688	chr3:170137633	CLDN11	-0.41	-5.03	-0.31	9.55e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs4908768	0.579	rs56280806	chr1:8875542	G/A	cg25722041	chr1:8623473	RERE	0.59	7.68	0.44	3.68e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg09990169	chr2:241835740	C2orf54	-0.45	-6.67	-0.39	1.64e-10	Urinary metabolites;
KIRP	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-18.22	-0.76	1.54e-47	Ulcerative colitis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13952948	chr9:111881453	C9orf5	0.52	6.28	0.37	1.51e-9	C-reactive protein;
KIRP	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-15.55	-0.7	1.99e-38	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.47	-6.88	-0.4	4.93e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs6005807	0.719	rs9625509	chr22:28989246	G/C	cg12565055	chr22:29076175	TTC28	0.57	4.9	0.3	1.76e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.46	6.53	0.38	3.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.7	-7.34	-0.42	3.18e-12	Initial pursuit acceleration;
KIRP	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.95	-0.5	9.09e-17	Coronary artery disease;
KIRP	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg07001201	chr5:642380	CEP72	0.7	6.53	0.38	3.76e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-1.04	-17.33	-0.74	1.68e-44	Coronary artery disease;
KIRP	cis	rs6060960	0.502	rs6089110	chr20:30486907	A/T	cg13852791	chr20:30311386	BCL2L1	0.65	5.91	0.35	1.14e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19717773	chr7:2847554	GNA12	0.3	5.11	0.31	6.41e-7	Height;
KIRP	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.77	10.17	0.54	1.66e-20	Aortic root size;
KIRP	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.84	10.14	0.54	2e-20	Gestational age at birth (maternal effect);
KIRP	cis	rs6102059	0.548	rs4812441	chr20:39187925	G/A	cg06665391	chr20:39312290	NA	0.41	5.24	0.32	3.48e-7	LDL cholesterol;
KIRP	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26526719	chr5:1949144	NA	0.44	5.37	0.32	1.81e-7	Gut microbiome composition (winter);
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.28	0.32	2.84e-7	Life satisfaction;
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg05627522	chr15:75251581	NA	0.32	4.95	0.3	1.37e-6	Breast cancer;
KIRP	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg05527609	chr1:210001259	C1orf107	-0.47	-5.17	-0.31	4.81e-7	Red blood cell count;
KIRP	trans	rs1973993	0.603	rs1967769	chr1:96993449	C/T	cg10631902	chr5:14652156	NA	0.52	6.51	0.38	4.08e-10	Weight;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20749212	chr11:31262762	NA	-0.44	-7.01	-0.41	2.32e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg26065057	chr18:74961000	GALR1	0.6	6.27	0.37	1.58e-9	Obesity-related traits;
KIRP	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.44	5.04	0.31	9.03e-7	Lung cancer;
KIRP	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg17347335	chr11:93583973	C11orf90	0.31	5.06	0.31	8.07e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg18964960	chr10:1102726	WDR37	0.59	5.03	0.31	9.58e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.36e-8	Platelet count;
KIRP	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg27205649	chr11:78285834	NARS2	-0.57	-5.88	-0.35	1.35e-8	Testicular germ cell tumor;
KIRP	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.97	-0.41	2.84e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg19116668	chr7:99932089	PMS2L1	0.45	5.17	0.31	4.92e-7	Coronary artery disease;
KIRP	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.73	-0.78	1.35e-52	Height;
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.19	-0.51	1.69e-17	Platelet count;
KIRP	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	0.61	6.74	0.39	1.1e-10	Initial pursuit acceleration;
KIRP	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.69	-0.44	3.59e-13	Resting heart rate;
KIRP	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.4	4.99	0.3	1.12e-6	Total body bone mineral density;
KIRP	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.71	7.79	0.44	1.85e-13	Corneal astigmatism;
KIRP	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	1.03	15.1	0.69	6.53e-37	Total cholesterol levels;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg25861327	chr15:41625136	NUSAP1;OIP5	-0.49	-6.79	-0.4	8.45e-11	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.81	9.81	0.53	2.22e-19	Corneal astigmatism;
KIRP	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.8	-8.23	-0.46	1.11e-14	Bronchopulmonary dysplasia;
KIRP	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-16.66	-0.73	3.11e-42	Height;
KIRP	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg04025307	chr7:1156635	C7orf50	0.54	5.89	0.35	1.25e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg24315340	chr6:146058215	EPM2A	0.44	5.44	0.33	1.3e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.81	-12.15	-0.61	6.26e-27	Response to temozolomide;
KIRP	cis	rs11710088	0.931	rs4577407	chr3:149195749	A/G	cg08667024	chr3:149219783	TM4SF4	0.4	5.64	0.34	4.74e-8	QRS duration;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg08662619	chr6:150070041	PCMT1	0.37	6.16	0.37	2.9e-9	Lung cancer;
KIRP	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.45	6.25	0.37	1.82e-9	Lewy body disease;
KIRP	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.74	-11.01	-0.57	3.52e-23	Prostate cancer;
KIRP	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.76	12.18	0.61	5.12e-27	Hepatocellular carcinoma;
KIRP	cis	rs72653721	0.838	rs17764592	chr6:11003144	G/T	cg13562911	chr6:11044106	ELOVL2	-0.51	-5.05	-0.31	8.69e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-5.63	-0.34	4.88e-8	Testicular germ cell tumor;
KIRP	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.93	-12.81	-0.63	3.99e-29	Gut microbiota (bacterial taxa);
KIRP	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	1.06	19.04	0.77	2.75e-50	Bone mineral density;
KIRP	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg00784671	chr22:46762841	CELSR1	-0.59	-7.57	-0.43	7.28e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg12756093	chr1:115239321	AMPD1	0.52	7.01	0.41	2.34e-11	Autism;
KIRP	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.06e-7	Coronary artery disease;
KIRP	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg04691961	chr3:161091175	C3orf57	-0.49	-7.35	-0.42	2.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg06871246	chr4:1363661	KIAA1530	0.55	6.68	0.39	1.57e-10	Longevity;
KIRP	cis	rs7923609	0.967	rs10761762	chr10:65184717	T/C	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg01843524	chr15:80216276	C15orf37;ST20	0.42	5.22	0.32	3.79e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9318086	0.776	rs1326130	chr13:24447664	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	7.55	0.43	8.37e-13	Myopia (pathological);
KIRP	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.68	-0.39	1.55e-10	Morning vs. evening chronotype;
KIRP	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg25338242	chr13:114786047	RASA3	0.41	4.91	0.3	1.66e-6	Schizophrenia;
KIRP	cis	rs4722404	0.739	rs10951044	chr7:3141147	C/T	cg19214707	chr7:3157722	NA	-0.46	-5.86	-0.35	1.45e-8	Atopic dermatitis;
KIRP	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg05709478	chr1:6581295	PLEKHG5	0.6	5.39	0.32	1.66e-7	Body mass index;
KIRP	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.01	0.41	2.22e-11	Bipolar disorder;
KIRP	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.53	7.14	0.41	1.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.63	-7.08	-0.41	1.53e-11	Breast cancer;
KIRP	cis	rs732716	0.785	rs11667543	chr19:4374850	C/T	cg03719555	chr19:4455413	UBXN6	0.49	7.28	0.42	4.4e-12	Mean corpuscular volume;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg13453750	chr1:205783389	SLC41A1	-0.38	-5.73	-0.34	2.91e-8	Monocyte percentage of white cells;
KIRP	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.58	-6.67	-0.39	1.69e-10	Blood pressure (smoking interaction);
KIRP	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.58	7.24	0.42	5.79e-12	Arsenic metabolism;
KIRP	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg15485101	chr11:133734466	NA	0.41	5.57	0.33	6.5e-8	Childhood ear infection;
KIRP	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg19077165	chr18:44547161	KATNAL2	0.52	6.5	0.38	4.51e-10	Personality dimensions;
KIRP	cis	rs10861342	1.000	rs10861353	chr12:105515290	T/C	cg23923672	chr12:105501055	KIAA1033	0.85	6.54	0.39	3.44e-10	IgG glycosylation;
KIRP	cis	rs1538970	0.924	rs7531253	chr1:45890183	T/C	cg05343316	chr1:45956843	TESK2	0.71	8.03	0.46	4.02e-14	Platelet count;
KIRP	cis	rs4692589	1.000	rs4519759	chr4:170933919	T/C	cg19918862	chr4:170955249	NA	0.42	5.11	0.31	6.49e-7	Anxiety disorder;
KIRP	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.31e-14	Obesity-related traits;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg01238044	chr22:24384105	GSTT1	-0.53	-6.97	-0.41	2.82e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg16717723	chr8:2172215	NA	0.55	6.5	0.38	4.54e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	1.0	18.18	0.76	2.06e-47	Leprosy;
KIRP	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg26513180	chr16:89883248	FANCA	0.59	7.67	0.44	3.89e-13	Vitiligo;
KIRP	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.42	0.38	6.85e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.38	-0.43	2.41e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg11189052	chr15:85197271	WDR73	-0.53	-4.99	-0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs7560272	0.501	rs7210	chr2:73957124	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.53	0.33	8.02e-8	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06006512	chr3:89221147	EPHA3	-0.39	-6.32	-0.37	1.24e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.87e-32	Mean platelet volume;
KIRP	cis	rs6457821	1.000	rs7765510	chr6:35261407	C/T	cg06087101	chr6:35551932	FKBP5	0.58	5.17	0.31	4.93e-7	Height;
KIRP	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg00405596	chr8:11794950	NA	-0.45	-5.76	-0.34	2.48e-8	Retinal vascular caliber;
KIRP	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.73	8.77	0.49	3.08e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.62	-7.27	-0.42	4.72e-12	Dental caries;
KIRP	trans	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.61	6.12	0.36	3.57e-9	Ulcerative colitis;
KIRP	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg08603382	chr10:743973	NA	0.52	7.88	0.45	1.05e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg01557791	chr16:72042693	DHODH	-0.48	-5.98	-0.36	7.72e-9	Fibrinogen levels;
KIRP	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg26811252	chr16:29126840	RRN3P2	0.66	8.77	0.49	3.04e-16	Menopause (age at onset);
KIRP	cis	rs7760949	0.888	rs1966191	chr6:13911961	A/C	cg27413430	chr6:13925136	RNF182	0.39	4.9	0.3	1.75e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10518128	1.000	rs28416221	chr4:75710773	A/G	cg20122727	chr4:75719957	BTC	0.55	5.61	0.34	5.31e-8	Electroencephalogram traits;
KIRP	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	14.95	0.69	2.11e-36	Electrocardiographic conduction measures;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26483359	chr8:146012773	ZNF34	0.48	6.82	0.4	7.01e-11	Survival in pancreatic cancer;
KIRP	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.92	-13.16	-0.64	2.6e-30	Coronary artery disease;
KIRP	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg23307798	chr14:103986281	CKB	0.72	11.23	0.58	6.81e-24	Body mass index;
KIRP	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.29	4.97	0.3	1.28e-6	Electrocardiographic conduction measures;
KIRP	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.55	-8.58	-0.48	1.07e-15	Longevity;
KIRP	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.79	-7.05	-0.41	1.77e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4919044	0.808	rs12354891	chr10:94818438	T/A	cg05127821	chr10:94822908	CYP26C1	-0.88	-5.74	-0.34	2.78e-8	Coronary artery disease;
KIRP	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14769373	chr6:40998127	UNC5CL	-0.63	-6.76	-0.4	9.77e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25517755	chr10:38738941	LOC399744	-0.52	-7.16	-0.42	9.35e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17221829	0.673	rs11018676	chr11:89362728	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.18	-0.42	8.23e-12	Joint mobility (Beighton score);
KIRP	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg02487422	chr3:49467188	NICN1	0.38	5.09	0.31	7.14e-7	Parkinson's disease;
KIRP	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	1.08	10.93	0.57	6.3e-23	Psoriasis;
KIRP	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.33	0.42	3.29e-12	Bipolar disorder;
KIRP	cis	rs787274	0.557	rs2147646	chr9:115669173	C/G	cg13803584	chr9:115635662	SNX30	-0.64	-5.24	-0.32	3.47e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-0.89	-6.23	-0.37	2.06e-9	Inflammatory biomarkers;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17322444	chr19:33572249	GPATCH1	0.68	6.33	0.37	1.16e-9	Lung function (FEV1);
KIRP	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.66	6.65	0.39	1.85e-10	Axial length;
KIRP	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.43	-5.1	-0.31	6.71e-7	Airway imaging phenotypes;
KIRP	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg10434728	chr15:90938212	IQGAP1	0.3	5.07	0.31	7.68e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg03152288	chr2:177042942	NA	-0.5	-5.99	-0.36	7.38e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg09699651	chr6:150184138	LRP11	0.46	6.0	0.36	7.15e-9	Lung cancer;
KIRP	cis	rs6088813	1.000	rs224333	chr20:34023962	G/A	cg14752227	chr20:34000481	UQCC	0.44	5.22	0.32	3.82e-7	Height;
KIRP	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg00405596	chr8:11794950	NA	0.4	5.05	0.31	8.54e-7	Retinal vascular caliber;
KIRP	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.82	-11.38	-0.59	2.25e-24	Colorectal cancer;
KIRP	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg13010199	chr12:38710504	ALG10B	-0.46	-6.02	-0.36	6.47e-9	Morning vs. evening chronotype;
KIRP	cis	rs10464366	0.597	rs10951590	chr7:39091043	C/T	cg18850127	chr7:39170497	POU6F2	0.25	4.94	0.3	1.42e-6	IgG glycosylation;
KIRP	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg09455208	chr3:40491958	NA	0.3	4.98	0.3	1.19e-6	Renal cell carcinoma;
KIRP	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.66	-9.44	-0.52	2.92e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.59	7.85	0.45	1.26e-13	Blood protein levels;
KIRP	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.1	-0.36	4.14e-9	Daytime sleep phenotypes;
KIRP	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.58	-7.21	-0.42	6.79e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.18	0.61	5.01e-27	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.42	-0.43	1.91e-12	Atopic dermatitis;
KIRP	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.63	-6.98	-0.41	2.7e-11	Sum neutrophil eosinophil counts;
KIRP	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	5.39	0.32	1.69e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.73	-10.17	-0.54	1.65e-20	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15495463	chr18:74729151	MBP	0.46	6.44	0.38	6.22e-10	Survival in pancreatic cancer;
KIRP	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.56	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.64	9.34	0.51	5.85e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06434972	chr7:44122219	POLM	-0.47	-6.16	-0.37	2.94e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs400736	0.602	rs10864330	chr1:8168564	C/T	cg25007680	chr1:8021821	PARK7	-0.41	-5.37	-0.32	1.83e-7	Response to antidepressants and depression;
KIRP	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg16141378	chr3:129829833	LOC729375	0.48	6.32	0.37	1.23e-9	Triglycerides;
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.76	-9.43	-0.52	3.3e-18	Longevity;Endometriosis;
KIRP	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.33	0.47	5.66e-15	Motion sickness;
KIRP	trans	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.19	0.46	1.41e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs12541635	0.677	rs2029880	chr8:107024649	T/C	cg10147462	chr8:107024639	NA	0.33	4.89	0.3	1.79e-6	Age of smoking initiation;
KIRP	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.53	-0.43	9.69e-13	Body mass index;
KIRP	cis	rs7562790	0.651	rs3770901	chr2:36650012	T/C	cg09467607	chr2:36825704	FEZ2	0.43	5.27	0.32	3.05e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs9488822	0.585	rs7756746	chr6:116239881	C/T	cg18764771	chr6:116381957	FRK	-0.22	-5.3	-0.32	2.54e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7508	0.511	rs208025	chr8:17878170	A/G	cg01800426	chr8:17659068	MTUS1	-0.49	-5.02	-0.31	9.76e-7	Atrial fibrillation;
KIRP	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.91	-12.45	-0.62	6.33e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.59	10.27	0.55	8.01e-21	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.38	5.2	0.31	4.19e-7	Bipolar disorder;
KIRP	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	0.79	8.38	0.47	4.23e-15	Pediatric areal bone mineral density (radius);
KIRP	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg21775007	chr8:11205619	TDH	-0.42	-5.2	-0.31	4.18e-7	Triglycerides;
KIRP	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg11161011	chr14:65562177	MAX	-0.84	-10.7	-0.56	3.45e-22	Obesity-related traits;
KIRP	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.39	5.46	0.33	1.17e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.69	-7.7	-0.44	3.25e-13	Menarche (age at onset);
KIRP	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.6e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.61	-0.34	5.41e-8	Height;
KIRP	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg11130432	chr3:121712080	ILDR1	-0.43	-5.09	-0.31	7.24e-7	Multiple sclerosis;
KIRP	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.66	5.54	0.33	7.79e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-1.16	-11.96	-0.61	2.7e-26	Post bronchodilator FEV1;
KIRP	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg11764359	chr7:65958608	NA	0.45	5.26	0.32	3.19e-7	Calcium levels;
KIRP	cis	rs12580194	0.593	rs60220253	chr12:55717410	A/G	cg11794356	chr12:55725991	OR6C3	-0.6	-8.55	-0.48	1.29e-15	Cancer;
KIRP	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11987759	chr7:65425863	GUSB	0.5	6.39	0.38	8.4e-10	Aortic root size;
KIRP	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg18932078	chr1:2524107	MMEL1	0.4	5.43	0.33	1.37e-7	Ulcerative colitis;
KIRP	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.15	-0.31	5.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.65	-10.41	-0.55	2.86e-21	Lung function (FVC);
KIRP	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.92	-14.76	-0.69	1e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.59	-6.86	-0.4	5.64e-11	Schizophrenia;
KIRP	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-0.99	-7.33	-0.42	3.4e-12	Mitochondrial DNA levels;
KIRP	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.42	0.43	1.92e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.74	-8.17	-0.46	1.63e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs2273669	0.667	rs114481082	chr6:109280932	G/A	cg05315195	chr6:109294784	ARMC2	-0.58	-6.18	-0.37	2.67e-9	Prostate cancer;
KIRP	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.82	7.74	0.44	2.6e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.21	-0.37	2.2e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg03806693	chr22:41940476	POLR3H	-0.48	-5.48	-0.33	1.05e-7	Neuroticism;
KIRP	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.24	-0.47	9.98e-15	Mood instability;
KIRP	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg10144569	chr3:42726640	KBTBD5	-0.48	-5.0	-0.3	1.11e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg03465714	chr1:152285911	FLG	0.52	5.67	0.34	4.01e-8	Atopic dermatitis;
KIRP	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	cis	rs4363385	0.510	rs10494282	chr1:152923762	G/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.06	-0.36	5.18e-9	Inflammatory skin disease;
KIRP	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg23533419	chr12:54090519	NA	-0.33	-5.24	-0.32	3.52e-7	Height;
KIRP	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.48	-6.35	-0.38	1.02e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.68	-0.53	5.64e-19	Response to antipsychotic treatment;
KIRP	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.09	0.31	7.08e-7	Menopause (age at onset);
KIRP	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.67	0.39	1.67e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg06565975	chr8:143823917	SLURP1	-0.51	-7.42	-0.43	1.88e-12	Urinary tract infection frequency;
KIRP	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs17095355	1.000	rs11194926	chr10:111700922	A/G	cg00817464	chr10:111662876	XPNPEP1	0.42	5.73	0.34	2.99e-8	Biliary atresia;
KIRP	cis	rs4765905	0.610	rs4765902	chr12:2312965	C/T	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg10189774	chr4:17578691	LAP3	0.55	6.89	0.4	4.64e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg09455208	chr3:40491958	NA	0.41	7.02	0.41	2.18e-11	Renal cell carcinoma;
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg14359292	chr7:27170892	HOXA4	-0.34	-4.87	-0.3	2.01e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.51	-6.67	-0.39	1.66e-10	Blood metabolite levels;
KIRP	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	-0.54	-6.45	-0.38	5.8e-10	Prudent dietary pattern;
KIRP	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg02158880	chr13:53174818	NA	0.45	5.85	0.35	1.59e-8	Lewy body disease;
KIRP	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06544989	chr22:39130855	UNC84B	0.47	7.28	0.42	4.42e-12	Menopause (age at onset);
KIRP	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08280861	chr8:58055591	NA	0.73	5.84	0.35	1.62e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg05484376	chr2:27715224	FNDC4	-0.31	-5.11	-0.31	6.5e-7	Oral cavity cancer;
KIRP	cis	rs9815354	1.000	rs1628874	chr3:41955714	G/A	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	12.26	0.62	2.75e-27	Tonsillectomy;
KIRP	cis	rs13418717	1.000	rs79581146	chr2:127644428	C/T	cg25501666	chr2:127640322	NA	1.09	7.44	0.43	1.68e-12	Heart failure;
KIRP	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg11569703	chr11:65557185	OVOL1	0.62	11.07	0.58	2.27e-23	Acne (severe);
KIRP	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.18	-0.51	1.86e-17	Personality dimensions;
KIRP	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11987759	chr7:65425863	GUSB	-0.44	-6.03	-0.36	5.84e-9	Aortic root size;
KIRP	cis	rs28595532	0.546	rs13102483	chr4:119246396	G/A	cg21605333	chr4:119757512	SEC24D	0.77	5.62	0.34	5.09e-8	Cannabis dependence symptom count;
KIRP	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.81	9.87	0.53	1.4e-19	Corneal astigmatism;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02214595	chr16:67143798	C16orf70	-0.47	-6.57	-0.39	2.91e-10	Myopia;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22168489	chr12:122356033	WDR66	0.67	10.26	0.55	8.37e-21	Mean corpuscular volume;
KIRP	cis	rs5743618	0.537	rs4470638	chr4:38768068	C/T	cg06935464	chr4:38784597	TLR10	0.38	4.89	0.3	1.8e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	5.75	0.34	2.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.58	-6.86	-0.4	5.45e-11	DNA methylation (variation);
KIRP	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg12855166	chr17:30846586	MYO1D	0.36	4.85	0.3	2.18e-6	Schizophrenia;
KIRP	cis	rs77688320	0.535	rs6732993	chr2:202264316	C/T	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg13906792	chr15:75199810	C15orf17	-0.36	-5.24	-0.32	3.37e-7	Breast cancer;
KIRP	cis	rs9972944	0.756	rs6416949	chr17:63767219	A/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.78	-0.44	2.03e-13	Total body bone mineral density;
KIRP	cis	rs8033133	0.957	rs7162559	chr15:25352341	C/T	cg14481604	chr15:25334117	SNORD116-22	0.56	6.51	0.38	4.31e-10	Blood osmolality (transformed sodium);
KIRP	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.57	-6.62	-0.39	2.18e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.92	15.01	0.69	1.33e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.47	6.2	0.37	2.42e-9	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg03714773	chr7:91764589	CYP51A1	0.41	6.13	0.36	3.39e-9	Breast cancer;
KIRP	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.73	-0.39	1.17e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7953249	0.542	rs1169284	chr12:121419926	T/C	cg02403541	chr12:121454288	C12orf43	0.66	8.33	0.47	5.85e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7923609	1.000	rs10761723	chr10:64955581	C/T	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.61	-0.34	5.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1958560	0.897	rs4899178	chr14:65862987	C/T	cg03016385	chr14:66212404	NA	-0.43	-5.55	-0.33	7.5e-8	Menarche (age at onset);
KIRP	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.3	-6.04	-0.36	5.56e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg18306943	chr3:40428807	ENTPD3	0.45	5.87	0.35	1.4e-8	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10388316	chr1:1710208	NADK	0.53	6.56	0.39	3.12e-10	Parkinson's disease;
KIRP	trans	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg19274270	chr17:78178856	CARD14	0.37	6.71	0.39	1.33e-10	Morning vs. evening chronotype;
KIRP	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.43	-5.1	-0.31	6.69e-7	Facial morphology (factor 20);
KIRP	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs7072216	0.666	rs17109597	chr10:100142154	G/A	cg19567339	chr10:100142640	NA	0.51	5.2	0.31	4.28e-7	Metabolite levels;
KIRP	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-6.64	-0.39	2e-10	Mean platelet volume;
KIRP	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.28	0.37	1.48e-9	Total body bone mineral density;
KIRP	trans	rs13170463	0.579	rs11742299	chr5:8038583	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7607369	0.500	rs6712856	chr2:219658617	A/T	cg10223061	chr2:219282414	VIL1	0.31	5.15	0.31	5.45e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.73	-8.4	-0.47	3.47e-15	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	10.7	0.56	3.4e-22	Cognitive test performance;
KIRP	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.49	-0.43	1.26e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05596911	chr5:118502651	DMXL1	-0.45	-6.61	-0.39	2.38e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.79	0.44	1.88e-13	Coffee consumption (cups per day);
KIRP	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.71	-10.44	-0.55	2.35e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg24069376	chr3:38537580	EXOG	-0.3	-4.92	-0.3	1.58e-6	Electrocardiographic conduction measures;
KIRP	cis	rs10858047	0.883	rs12037358	chr1:115089279	T/C	cg12756093	chr1:115239321	AMPD1	0.64	6.11	0.36	3.87e-9	Autism;
KIRP	trans	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg06521331	chr12:34319734	NA	-0.58	-7.11	-0.41	1.24e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7760535	0.930	rs7742244	chr6:111852662	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.46	-6.08	-0.36	4.61e-9	Metabolic traits;
KIRP	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg23982607	chr1:1823379	GNB1	-0.83	-14.6	-0.68	3.3e-35	Body mass index;
KIRP	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	9.94	0.54	8.94e-20	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6466055	0.566	rs10252714	chr7:104694071	T/G	cg04380332	chr7:105027541	SRPK2	-0.4	-5.48	-0.33	1.03e-7	Schizophrenia;
KIRP	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg13514129	chr1:39547527	MACF1	0.54	7.95	0.45	6.58e-14	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs12210905	1.000	rs3531	chr6:27095313	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs10267417	0.603	rs4721835	chr7:19910273	C/T	cg05791153	chr7:19748676	TWISTNB	0.48	4.92	0.3	1.58e-6	Night sleep phenotypes;
KIRP	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.77	8.85	0.49	1.72e-16	Corneal astigmatism;
KIRP	cis	rs4728302	0.607	rs4517044	chr7:133607014	T/A	cg10665199	chr7:133106180	EXOC4	0.42	4.95	0.3	1.39e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.49	-0.59	9.48e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3752645	0.649	rs112171645	chr7:106739665	A/T	cg02696742	chr7:106810147	HBP1	-0.58	-4.95	-0.3	1.36e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs4950322	0.542	rs4950382	chr1:146648224	C/T	cg22381352	chr1:146742008	CHD1L	-0.37	-5.12	-0.31	6.19e-7	Protein quantitative trait loci;
KIRP	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.87	-0.4	5.32e-11	Longevity;Endometriosis;
KIRP	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-6.58	-0.39	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg07068956	chr7:100330872	ZAN	-0.57	-6.26	-0.37	1.72e-9	Other erythrocyte phenotypes;
KIRP	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg21775007	chr8:11205619	TDH	-0.45	-5.77	-0.35	2.33e-8	Neuroticism;
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg23693289	chr8:27183097	PTK2B	0.58	7.47	0.43	1.42e-12	Neuroticism;
KIRP	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.03	-16.67	-0.73	2.92e-42	Dilated cardiomyopathy;
KIRP	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg27147174	chr7:100797783	AP1S1	-0.72	-9.23	-0.51	1.25e-17	Life satisfaction;
KIRP	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.75	10.23	0.55	1.07e-20	Red blood cell count;
KIRP	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.79	-11.91	-0.6	3.96e-26	Asthma;
KIRP	cis	rs4950322	0.543	rs115392281	chr1:146790018	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-7.97	-0.45	5.75e-14	Schizophrenia;
KIRP	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.77	11.09	0.58	1.9e-23	Prostate cancer;
KIRP	cis	rs2073300	1.000	rs6048811	chr20:23446719	G/C	cg12480562	chr20:23434244	CST11	0.6	5.98	0.36	7.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11593576	0.550	rs1250594	chr10:80997021	G/A	cg18737081	chr10:80999807	ZMIZ1	-0.29	-5.04	-0.31	8.88e-7	Vitiligo;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.73	-0.39	1.19e-10	Immature fraction of reticulocytes;
KIRP	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2000999	0.514	rs12928056	chr16:72225574	C/A	cg04254540	chr16:71951199	KIAA0174	-0.71	-4.88	-0.3	1.93e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.3	-0.32	2.59e-7	Life satisfaction;
KIRP	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.7	8.46	0.47	2.38e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.68	-8.07	-0.46	3.17e-14	Blood protein levels;
KIRP	trans	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.22	-0.37	2.09e-9	Endometrial cancer;
KIRP	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg16497661	chr14:103986332	CKB	0.82	13.61	0.66	7.81e-32	Body mass index;
KIRP	trans	rs12517041	1.000	rs1593967	chr5:23313900	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.72	-6.31	-0.37	1.3e-9	Calcium levels;
KIRP	trans	rs12690897	0.704	rs4534077	chr7:85337215	C/A	cg25658385	chr6:35265341	DEF6	-0.35	-6.02	-0.36	6.34e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	0.93	12.47	0.62	5.58e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg19636519	chr7:99541626	NA	0.38	6.98	0.41	2.7e-11	Coronary artery disease;
KIRP	cis	rs28595532	0.545	rs13144171	chr4:119257458	G/A	cg21605333	chr4:119757512	SEC24D	0.69	5.84	0.35	1.67e-8	Cannabis dependence symptom count;
KIRP	cis	rs13082711	0.522	rs594466	chr3:27362069	A/G	cg02860705	chr3:27208620	NA	-0.41	-6.26	-0.37	1.71e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.82	-8.6	-0.48	9.31e-16	Hair shape;
KIRP	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.21	-0.42	6.77e-12	Vitiligo;
KIRP	cis	rs1800469	0.965	rs12983775	chr19:41857439	G/A	cg08477640	chr19:41863820	B9D2	0.61	7.12	0.41	1.22e-11	Colorectal cancer;
KIRP	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg01028140	chr2:1542097	TPO	-0.52	-5.91	-0.35	1.16e-8	IgG glycosylation;
KIRP	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg11839771	chr15:80205821	ST20	-0.43	-6.48	-0.38	5.11e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs10214930	0.624	rs6959126	chr7:27604250	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.89	0.3	1.79e-6	Hypospadias;
KIRP	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg04132472	chr17:19861366	AKAP10	0.38	4.85	0.3	2.22e-6	Schizophrenia;
KIRP	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.86	14.71	0.68	1.43e-35	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg11815991	chr20:30193098	ID1	-0.5	-5.07	-0.31	7.7e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg11972305	chr2:233791962	NGEF	0.38	5.12	0.31	6.22e-7	Schizophrenia;
KIRP	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.21	-0.32	3.94e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1485395	0.836	rs10444558	chr12:54055485	A/T	cg16917193	chr12:54089295	NA	0.64	6.0	0.36	7.14e-9	Migraine without aura;
KIRP	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.18	10.57	0.56	8.72e-22	Atopic dermatitis;
KIRP	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg22676075	chr6:135203613	NA	0.5	7.18	0.42	8.21e-12	Red blood cell count;
KIRP	cis	rs7246967	0.551	rs7248993	chr19:22849152	G/C	cg24889512	chr19:22816950	ZNF492	0.5	4.86	0.3	2.08e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs10904908	1.000	rs10795465	chr10:17260525	C/T	cg01003015	chr10:17271136	VIM	-0.4	-4.91	-0.3	1.67e-6	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs4356932	1.000	rs11097223	chr4:76987496	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.2	0.37	2.43e-9	Blood protein levels;
KIRP	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg02023728	chr11:77925099	USP35	0.31	5.35	0.32	2.04e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7849270	0.879	rs7046990	chr9:131856138	G/C	cg13538475	chr9:131942899	NA	-0.37	-5.67	-0.34	3.97e-8	Blood metabolite ratios;
KIRP	trans	rs1429107	0.618	rs9993943	chr4:148354114	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-6.02	-0.36	6.38e-9	Obesity-related traits;
KIRP	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg25174290	chr11:3078921	CARS	0.87	12.58	0.63	2.44e-28	Longevity;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg00099393	chr7:157361621	PTPRN2	0.42	6.03	0.36	5.89e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg00204512	chr16:28754710	NA	0.4	5.15	0.31	5.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg22437258	chr11:111473054	SIK2	0.57	6.55	0.39	3.25e-10	Primary sclerosing cholangitis;
KIRP	cis	rs2290419	0.730	rs77157858	chr11:68944928	A/G	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg24060327	chr5:131705240	SLC22A5	-0.51	-6.63	-0.39	2.06e-10	Blood metabolite levels;
KIRP	cis	rs6504340	0.739	rs872760	chr17:46668951	A/G	cg05487507	chr17:46671861	LOC404266;HOXB5	0.56	6.51	0.38	4.3e-10	Primary tooth development (number of teeth);
KIRP	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.14	-0.36	3.33e-9	Lung cancer;
KIRP	cis	rs9303542	0.559	rs2326012	chr17:46618581	C/T	cg04904318	chr17:46607828	HOXB1	-0.57	-6.31	-0.37	1.27e-9	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs17123764	0.605	rs73305085	chr12:50056233	G/A	cg02054252	chr12:50078554	FMNL3	0.48	5.33	0.32	2.23e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg11693508	chr17:37793320	STARD3	0.75	7.91	0.45	8.75e-14	Bipolar disorder;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg10137463	chr15:23085908	NIPA1	0.6	6.33	0.37	1.18e-9	Response to statin therapy;
KIRP	cis	rs1635	0.655	rs73742541	chr6:28310615	T/C	cg15743358	chr6:28303923	ZNF323	-0.88	-6.46	-0.38	5.65e-10	Schizophrenia;
KIRP	cis	rs9583531	0.660	rs61971610	chr13:111330476	T/C	cg07595035	chr13:111291582	CARKD	0.68	5.03	0.31	9.34e-7	Coronary artery disease;
KIRP	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	0.99	17.93	0.75	1.5e-46	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09672890	chr17:70536484	NA	0.55	6.37	0.38	9.13e-10	Smoking initiation;
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.18	21.46	0.81	2.71e-58	Cognitive function;
KIRP	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.87e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.0	-0.3	1.11e-6	Triglycerides;
KIRP	cis	rs539514	0.690	rs4885345	chr13:76318453	C/T	cg04757411	chr13:76259545	LMO7	0.34	4.9	0.3	1.73e-6	Type 1 diabetes;
KIRP	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-15.28	-0.7	1.61e-37	Primary sclerosing cholangitis;
KIRP	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg04804543	chr8:142233427	SLC45A4	-1.01	-17.1	-0.74	1.02e-43	Immature fraction of reticulocytes;
KIRP	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.77	-10.04	-0.54	4.15e-20	Height;
KIRP	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg13606994	chr1:44402422	ARTN	0.31	6.09	0.36	4.27e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg26513180	chr16:89883248	FANCA	-0.53	-6.75	-0.4	1.05e-10	Vitiligo;
KIRP	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.73	-7.28	-0.42	4.39e-12	Vitiligo;
KIRP	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg18944383	chr4:111397179	ENPEP	0.53	9.27	0.51	9.51e-18	Height;
KIRP	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.74	10.99	0.57	3.99e-23	Hip circumference;
KIRP	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg22903471	chr2:27725779	GCKR	0.4	5.5	0.33	9.59e-8	Oral cavity cancer;
KIRP	cis	rs9400467	0.537	rs56272203	chr6:111492436	C/A	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1468333	1.000	rs10479179	chr5:137564115	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.39	0.33	1.63e-7	Resting heart rate;
KIRP	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg20703242	chr1:230279135	GALNT2	0.41	7.54	0.43	9.19e-13	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.97	-0.41	2.96e-11	Joint mobility (Beighton score);
KIRP	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.93	12.81	0.63	4.04e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.47	-6.65	-0.39	1.87e-10	Endometrial cancer;
KIRP	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs7635838	0.892	rs9310383	chr3:11491305	A/G	cg00170343	chr3:11313890	ATG7	-0.46	-6.07	-0.36	4.84e-9	HDL cholesterol;
KIRP	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.52	-7.46	-0.43	1.49e-12	Daytime sleep phenotypes;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg05477027	chr19:46295590	DMWD	0.55	6.39	0.38	8.16e-10	Sleep duration;
KIRP	cis	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.15e-6	Androgen levels;
KIRP	cis	rs6973256	0.605	rs7794168	chr7:133357606	T/C	cg10665199	chr7:133106180	EXOC4	0.48	5.88	0.35	1.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg23978390	chr7:1156363	C7orf50	-0.4	-5.16	-0.31	5.12e-7	Longevity;Endometriosis;
KIRP	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12826209	chr6:26865740	GUSBL1	0.76	5.38	0.32	1.72e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6681460	0.800	rs481681	chr1:67194378	G/A	cg13052034	chr1:66999238	SGIP1	-0.35	-4.91	-0.3	1.65e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs4791746	0.948	rs4791326	chr17:8631788	G/A	cg03115937	chr17:8649504	CCDC42	-0.51	-6.26	-0.37	1.68e-9	Heroin dependence;
KIRP	cis	rs11195062	0.693	rs1573042	chr10:111983060	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.32	-5.17	-0.31	4.79e-7	Multiple myeloma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22135063	chr6:158589436	GTF2H5;SERAC1	0.52	6.74	0.39	1.13e-10	Parkinson's disease;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg09672890	chr17:70536484	NA	0.49	6.14	0.36	3.24e-9	Asthma;
KIRP	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15664640	chr17:80829946	TBCD	-0.72	-6.3	-0.37	1.34e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg16141378	chr3:129829833	LOC729375	0.48	6.34	0.37	1.1e-9	Mood instability;
KIRP	cis	rs687432	0.924	rs7926878	chr11:57733759	T/C	cg19752551	chr11:57585705	CTNND1	-0.54	-7.43	-0.43	1.82e-12	Parkinson's disease;
KIRP	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.11	-0.31	6.32e-7	Bladder cancer;
KIRP	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-7.57	-0.43	7.46e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	0.98	15.8	0.71	2.75e-39	Multiple system atrophy;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg10519082	chr1:245026741	HNRNPU	-0.45	-6.13	-0.36	3.47e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg01804193	chr12:63026212	NA	0.58	6.28	0.37	1.52e-9	IgG glycosylation;
KIRP	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg08313168	chr12:7315531	NA	0.71	6.31	0.37	1.26e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.23	-0.55	1.04e-20	Hemoglobin concentration;
KIRP	cis	rs687432	0.774	rs7120442	chr11:57899255	G/A	cg19752551	chr11:57585705	CTNND1	-0.67	-8.58	-0.48	1.06e-15	Parkinson's disease;
KIRP	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.78	-6.37	-0.38	9.14e-10	Schizophrenia;
KIRP	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg00677455	chr12:58241039	CTDSP2	-0.62	-6.78	-0.4	8.74e-11	Multiple sclerosis;
KIRP	cis	rs708547	0.766	rs781545	chr4:57732025	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.69	-7.84	-0.45	1.37e-13	Response to bleomycin (chromatid breaks);
KIRP	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.85e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.96	11.18	0.58	1.01e-23	Corneal astigmatism;
KIRP	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg12046867	chr14:103022105	NA	0.52	6.12	0.36	3.77e-9	Platelet count;
KIRP	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg17410650	chr12:54324560	NA	-0.45	-6.06	-0.36	5.1e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
KIRP	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg00977110	chr5:151150581	G3BP1	0.62	6.21	0.37	2.2e-9	Preschool internalizing problems;
KIRP	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg07424592	chr7:64974309	NA	0.75	4.93	0.3	1.51e-6	Diabetic kidney disease;
KIRP	cis	rs7560272	0.723	rs6722867	chr2:73816285	A/G	cg20560298	chr2:73613845	ALMS1	-0.41	-5.06	-0.31	8.14e-7	Schizophrenia;
KIRP	cis	rs501120	0.584	rs7082177	chr10:44698630	G/A	cg09554077	chr10:44749378	NA	0.51	5.54	0.33	7.93e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-1.02	-11.31	-0.58	3.73e-24	Alzheimer's disease;
KIRP	cis	rs2151522	0.750	rs9388518	chr6:127103785	A/C	cg21431617	chr6:127135037	NA	-0.3	-5.59	-0.34	6.01e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.6	5.46	0.33	1.18e-7	Alzheimer's disease;
KIRP	cis	rs876084	0.505	rs10955953	chr8:121106381	C/T	cg06265175	chr8:121136014	COL14A1	-0.51	-6.35	-0.38	1.05e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg20243544	chr17:37824526	PNMT	0.4	5.31	0.32	2.46e-7	Self-reported allergy;
KIRP	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.42	-5.44	-0.33	1.26e-7	Blood metabolite levels;
KIRP	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-1.0	-8.05	-0.46	3.49e-14	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-6.27	-0.37	1.57e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4666002	0.789	rs13023094	chr2:27910706	G/T	cg05484376	chr2:27715224	FNDC4	0.43	5.33	0.32	2.19e-7	Phospholipid levels (plasma);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02696274	chr8:101572050	ANKRD46	-0.52	-6.18	-0.37	2.68e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	trans	rs7084921	0.608	rs12780510	chr10:101865881	T/C	cg13808641	chr9:96006533	WNK2	-0.41	-6.28	-0.37	1.53e-9	Bone mineral density;
KIRP	cis	rs7191439	0.522	rs4597303	chr16:88763561	T/C	cg02389323	chr16:88786976	FAM38A	0.92	5.07	0.31	7.81e-7	Plateletcrit;
KIRP	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg02336718	chr17:17403227	NA	-0.32	-4.91	-0.3	1.69e-6	Total body bone mineral density;
KIRP	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	1.94e-14	Testicular germ cell tumor;
KIRP	cis	rs6496667	0.865	rs8043146	chr15:90850373	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	5.09	0.31	7.04e-7	Rheumatoid arthritis;
KIRP	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg00982548	chr2:198649783	BOLL	-0.52	-4.89	-0.3	1.84e-6	Ulcerative colitis;
KIRP	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg17724175	chr1:150552817	MCL1	0.37	6.23	0.37	2.05e-9	Tonsillectomy;
KIRP	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.42	5.41	0.33	1.47e-7	Aortic root size;
KIRP	cis	rs11955175	1.000	rs79575541	chr5:40672422	C/G	cg05478818	chr5:40835740	RPL37	0.7	5.44	0.33	1.32e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs745080	0.674	rs3742533	chr14:52981401	G/T	cg23333723	chr14:53022898	GPR137C	-0.41	-5.72	-0.34	3.07e-8	Orofacial clefts;
KIRP	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	trans	rs225245	0.610	rs321607	chr17:33880584	A/G	cg19694781	chr19:47549865	TMEM160	-0.5	-6.15	-0.37	3.1e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.28	5.43	0.33	1.35e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9815354	1.000	rs1716696	chr3:41935811	C/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.11e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-4.92	-0.3	1.62e-6	Lung cancer;
KIRP	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg01620082	chr3:125678407	NA	-1.07	-7.07	-0.41	1.62e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2997447	0.761	rs60404932	chr1:26454881	C/T	cg19633962	chr1:26362018	EXTL1	-0.52	-4.86	-0.3	2.13e-6	QRS complex (12-leadsum);
KIRP	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.42	4.89e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg26531700	chr6:26746687	NA	0.47	6.71	0.39	1.36e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	14.31	0.67	3.33e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg01872077	chr2:219646372	CYP27A1	0.4	5.19	0.31	4.4e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9654415	0.560	rs13155213	chr5:72551337	A/C	cg14879418	chr5:72571312	NA	-0.46	-5.64	-0.34	4.56e-8	Eyebrow thickness;
KIRP	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.46	-0.33	1.19e-7	Breast cancer;
KIRP	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07570687	chr10:102243282	WNT8B	0.54	7.11	0.41	1.25e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.6	-6.57	-0.39	2.92e-10	Aortic root size;
KIRP	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	6.04	0.36	5.74e-9	Personality dimensions;
KIRP	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg00405596	chr8:11794950	NA	0.39	5.04	0.31	8.91e-7	Retinal vascular caliber;
KIRP	cis	rs1079204	0.793	rs76394798	chr2:219178595	A/T	cg05728596	chr2:219128475	GPBAR1	0.75	5.31	0.32	2.4e-7	Smooth-surface caries;
KIRP	trans	rs877282	0.583	rs12358255	chr10:828626	C/T	cg22713356	chr15:30763199	NA	0.81	7.93	0.45	7.88e-14	Uric acid levels;
KIRP	cis	rs7945718	0.535	rs7114698	chr11:12707876	C/T	cg25843174	chr11:12811716	TEAD1	0.31	5.39	0.33	1.64e-7	Educational attainment (years of education);
KIRP	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.43	-5.38	-0.32	1.75e-7	Metabolite levels (Pyroglutamine);
KIRP	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	1.02	12.91	0.64	1.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.47	-6.08	-0.36	4.61e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.67	9.78	0.53	2.66e-19	Dupuytren's disease;
KIRP	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg04731861	chr2:219085781	ARPC2	-0.28	-7.01	-0.41	2.32e-11	Colorectal cancer;
KIRP	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05220968	chr6:146057943	EPM2A	-0.41	-5.3	-0.32	2.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6539288	0.803	rs4479083	chr12:107321245	G/C	cg21360079	chr12:107162445	NA	-0.38	-5.01	-0.3	1.02e-6	Total body bone mineral density;
KIRP	cis	rs6723108	0.627	rs2166480	chr2:135637338	A/G	cg12500956	chr2:135428796	TMEM163	-0.37	-4.86	-0.3	2.12e-6	Type 2 diabetes;
KIRP	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg24189917	chr7:1970923	MAD1L1	-0.45	-5.04	-0.31	9.02e-7	Neuroticism;
KIRP	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg03128945	chr5:622914	CEP72	-0.48	-6.86	-0.4	5.4e-11	Obesity-related traits;
KIRP	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.25	17.47	0.74	5.64e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg22974920	chr21:40686053	BRWD1	0.48	5.46	0.33	1.19e-7	Cognitive function;
KIRP	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg23565292	chr14:50234668	KLHDC2	-0.47	-5.5	-0.33	9.41e-8	Carotid intima media thickness;
KIRP	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	6.23	0.37	1.99e-9	Total body bone mineral density;
KIRP	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	0.71	9.59	0.52	1.03e-18	Prostate cancer;
KIRP	cis	rs7553864	0.605	rs7531038	chr1:87605049	C/G	cg17420885	chr1:87600446	LOC339524	-0.58	-7.48	-0.43	1.31e-12	Smoking behavior;
KIRP	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg18944383	chr4:111397179	ENPEP	0.55	9.77	0.53	2.88e-19	Height;
KIRP	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg04013166	chr16:89971882	TCF25	0.64	5.08	0.31	7.53e-7	Skin colour saturation;
KIRP	cis	rs9900972	0.959	rs4789941	chr17:76877500	G/C	cg00961940	chr17:76876995	TIMP2	0.55	7.18	0.42	8.07e-12	Obesity-related traits;
KIRP	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.82	11.12	0.58	1.59e-23	Morning vs. evening chronotype;
KIRP	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.55	-8.23	-0.46	1.13e-14	Inflammatory skin disease;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00127545	chr3:51705085	TEX264	-0.47	-6.34	-0.37	1.09e-9	Morning vs. evening chronotype;
KIRP	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg20936604	chr3:58311152	NA	-0.7	-6.1	-0.36	4.15e-9	Cholesterol, total;
KIRP	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.76	9.98	0.54	6.47e-20	Schizophrenia;
KIRP	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.49	0.43	1.22e-12	HDL cholesterol levels;
KIRP	cis	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.44	-7.19	-0.42	7.93e-12	Inflammatory bowel disease;
KIRP	cis	rs7638909	0.512	rs7645178	chr3:38597558	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.45	-5.68	-0.34	3.84e-8	Electrocardiographic conduction measures;
KIRP	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.46	-10.43	-0.55	2.5e-21	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3789045	0.866	rs11584700	chr1:204576983	C/T	cg17419461	chr1:204415978	PIK3C2B	0.53	5.4	0.33	1.58e-7	Educational attainment (college completion);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23371655	chr17:4225165	UBE2G1	0.41	6.03	0.36	5.93e-9	Interleukin-4 levels;
KIRP	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.06e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg20636351	chr8:55087400	NA	-0.54	-6.62	-0.39	2.2e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg22681709	chr2:178499509	PDE11A	-0.61	-8.94	-0.5	9.36e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7404928	0.794	rs11074584	chr16:23875929	G/A	cg21745164	chr16:23765304	CHP2	-0.55	-6.57	-0.39	3e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs2016266	0.819	rs6580942	chr12:53662624	C/A	cg16917193	chr12:54089295	NA	0.49	5.94	0.35	9.54e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs2281603	0.570	rs2045024	chr14:64937352	A/G	cg01860774	chr14:64969374	ZBTB25	0.34	5.42	0.33	1.44e-7	Lymphocyte counts;
KIRP	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.45	6.85	0.4	5.95e-11	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.23	-24.7	-0.84	1.49e-68	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25948154	chr15:40763247	CHST14	0.49	6.56	0.39	3.24e-10	Parkinson's disease;
KIRP	cis	rs2294693	0.680	rs4714423	chr6:41012483	C/A	cg14769373	chr6:40998127	UNC5CL	-0.42	-5.03	-0.31	9.35e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-9.9	-0.53	1.14e-19	Body mass index;
KIRP	trans	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg06521331	chr12:34319734	NA	-0.54	-6.76	-0.4	9.91e-11	Bladder cancer;
KIRP	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg21064579	chr19:49206444	FUT2	0.55	8.19	0.46	1.41e-14	Dietary macronutrient intake;
KIRP	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.63	-9.83	-0.53	1.9e-19	Educational attainment;
KIRP	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg19847866	chr10:1019161	NA	0.4	5.01	0.3	1.03e-6	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.62	8.53	0.48	1.56e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.33	-0.32	2.21e-7	Life satisfaction;
KIRP	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.54	-6.58	-0.39	2.8e-10	Cognitive test performance;
KIRP	cis	rs9815354	0.767	rs73073342	chr3:41839455	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs9322225	chr6:150184882	G/C	cg19673125	chr6:150240577	RAET1G	0.21	4.95	0.3	1.35e-6	Lung cancer;
KIRP	cis	rs364477	0.904	rs279904	chr9:960479	A/G	cg13952963	chr9:998547	NA	0.59	4.93	0.3	1.49e-6	Major depressive disorder;
KIRP	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.58	7.87	0.45	1.12e-13	HDL cholesterol;
KIRP	cis	rs516946	1.000	rs515071	chr8:41519462	C/T	cg19441908	chr8:41529140	ANK1	0.47	6.61	0.39	2.32e-10	Type 2 diabetes;
KIRP	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.41	0.33	1.46e-7	Coronary artery disease;
KIRP	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.01e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.81	-9.28	-0.51	8.95e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12850832	chr2:27309063	KHK;EMILIN1	0.42	6.15	0.37	3.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1973993	0.967	rs10875017	chr1:96949526	C/T	cg10631902	chr5:14652156	NA	0.65	9.87	0.53	1.47e-19	Weight;
KIRP	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.73	8.09	0.46	2.77e-14	Corneal astigmatism;
KIRP	cis	rs3789045	0.779	rs12043569	chr1:204560004	C/G	cg18185008	chr1:204589407	LRRN2	-0.6	-7.01	-0.41	2.29e-11	Educational attainment (college completion);
KIRP	cis	rs6732160	0.613	rs6546804	chr2:73385919	G/A	cg01422370	chr2:73384389	NA	0.52	7.05	0.41	1.82e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.53	5.2	0.31	4.25e-7	Alzheimer's disease;
KIRP	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg06212747	chr3:49208901	KLHDC8B	0.65	7.21	0.42	6.94e-12	Menarche (age at onset);
KIRP	cis	rs8113308	0.688	rs7259507	chr19:52445728	A/G	cg24732339	chr19:52471368	ZNF350	-0.44	-4.92	-0.3	1.57e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg03160526	chr17:80928410	B3GNTL1	0.42	5.24	0.32	3.42e-7	Glycated hemoglobin levels;
KIRP	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg00684032	chr4:1343700	KIAA1530	0.44	5.02	0.31	9.77e-7	Longevity;
KIRP	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-0.9	-7.96	-0.45	6.22e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.13	-9.57	-0.52	1.2e-18	Body mass index;
KIRP	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.75	0.34	2.7e-8	Birth weight;
KIRP	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg09344028	chr17:70110421	NA	0.4	7.85	0.45	1.24e-13	Thyroid hormone levels;
KIRP	cis	rs7009516	0.653	rs4442155	chr8:24220787	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.26	5.29	0.32	2.66e-7	Hair greying;
KIRP	cis	rs2151522	0.603	rs6921132	chr6:127194720	C/T	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.35	-0.38	1e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg18944383	chr4:111397179	ENPEP	0.54	9.58	0.52	1.1e-18	Height;
KIRP	cis	rs2411233	1.000	rs11637063	chr15:39266308	G/A	cg02291532	chr15:39874776	THBS1	0.37	5.09	0.31	7.23e-7	Platelet count;
KIRP	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg22974920	chr21:40686053	BRWD1	0.51	6.18	0.37	2.62e-9	Cognitive function;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18500431	chr7:1709489	NA	0.66	6.65	0.39	1.89e-10	Lung function (FEV1);
KIRP	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.82	11.69	0.6	2.16e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.71	9.66	0.52	6.54e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs7539409	0.651	rs6696140	chr1:84317468	C/T	cg10977910	chr1:84465055	TTLL7	-0.61	-5.61	-0.34	5.48e-8	Alzheimer's disease;
KIRP	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg05874882	chr4:1763078	NA	-0.38	-5.01	-0.3	1.02e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs73200209	0.912	rs57109552	chr12:116657460	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.66	-0.34	4.12e-8	Total body bone mineral density;
KIRP	cis	rs981844	0.712	rs4434231	chr4:154746293	G/T	cg14289246	chr4:154710475	SFRP2	-0.55	-7.05	-0.41	1.83e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs35934224	0.891	rs13054713	chr22:19867914	C/A	cg11182965	chr22:19864308	TXNRD2	-0.47	-6.48	-0.38	5.1e-10	Glaucoma (primary open-angle);
KIRP	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16346588	chr10:242978	ZMYND11	0.47	5.86	0.35	1.45e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.42	4.98	0.3	1.17e-6	Resistin levels;
KIRP	cis	rs2671245	0.933	rs1514141	chr1:56161478	T/C	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	0.83	12.51	0.62	3.92e-28	Body mass index;
KIRP	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2591576	0.789	rs830236	chr5:165404875	C/G	cg13976338	chr5:165423657	NA	-0.74	-10.85	-0.57	1.15e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.26	0.32	3.07e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-5.23	-0.32	3.68e-7	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.26	-16.91	-0.73	4.36e-43	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg08662619	chr6:150070041	PCMT1	0.36	6.04	0.36	5.76e-9	Lung cancer;
KIRP	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.46	6.78	0.4	8.82e-11	Lung cancer;
KIRP	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	1.0	11.25	0.58	5.81e-24	Iron status biomarkers;
KIRP	cis	rs12476592	0.602	rs10469945	chr2:63816776	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-5.04	-0.31	9.19e-7	Childhood ear infection;
KIRP	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-4.96	-0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs367615	1.000	rs367615	chr5:108948937	C/T	cg17395555	chr5:108820864	NA	-0.46	-5.04	-0.31	9.09e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	7.16	0.42	9.09e-12	Iron status biomarkers;
KIRP	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	10.43	0.55	2.55e-21	Leprosy;
KIRP	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.96	0.3	1.3e-6	Coronary artery calcification;
KIRP	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.58	-0.39	2.79e-10	Diastolic blood pressure;
KIRP	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18252515	chr7:66147081	NA	0.52	5.73	0.34	2.94e-8	Aortic root size;
KIRP	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-12.75	-0.63	6.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg08890418	chr1:21044141	KIF17	-0.33	-5.01	-0.3	1.06e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg06204229	chr3:52865917	ITIH4	0.47	4.99	0.3	1.16e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03136486	chr8:89048264	NA	0.37	6.07	0.36	4.84e-9	C-reactive protein;
KIRP	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg06481639	chr22:41940642	POLR3H	-0.45	-4.93	-0.3	1.53e-6	Neuroticism;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg19770292	chr5:1868693	NA	0.41	5.32	0.32	2.32e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9984896	0.541	rs12626551	chr21:37912042	G/A	cg16719517	chr21:37442385	CBR1	-0.44	-4.9	-0.3	1.7e-6	QT interval;
KIRP	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg23024343	chr7:107201750	COG5	0.44	4.9	0.3	1.71e-6	Coronary artery disease;
KIRP	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.68	8.62	0.48	8.42e-16	Multiple sclerosis;
KIRP	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg22654517	chr2:96458247	NA	0.34	5.2	0.31	4.26e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg02297831	chr4:17616191	MED28	0.54	6.42	0.38	7.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg05340658	chr4:99064831	C4orf37	-0.54	-6.7	-0.39	1.41e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04246880	chr10:135150497	CALY	-0.47	-6.35	-0.38	1.03e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1859156	0.716	rs4455423	chr4:95737843	C/T	cg22708944	chr15:74164906	TBC1D21	-0.23	-6.29	-0.37	1.44e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs10875746	0.859	rs12305647	chr12:48582961	T/C	cg26205652	chr12:48591994	NA	0.8	10.98	0.57	4.38e-23	Longevity (90 years and older);
KIRP	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg06495924	chr8:145149574	CYC1	-0.57	-5.07	-0.31	7.76e-7	Blood metabolite levels;
KIRP	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	5.48	0.33	1.03e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.72	9.06	0.5	4.23e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.47	-7.84	-0.45	1.39e-13	Height;
KIRP	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg18190219	chr22:46762943	CELSR1	-0.87	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4926298	1.000	rs931068	chr19:13158678	A/G	cg06417478	chr19:12876846	HOOK2	-0.39	-5.0	-0.3	1.08e-6	Bipolar disorder;
KIRP	cis	rs7534824	0.625	rs12561853	chr1:101457863	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.82	-7.17	-0.42	8.74e-12	Refractive astigmatism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23142935	chr16:22385308	CDR2	0.56	6.5	0.38	4.41e-10	Smoking initiation;
KIRP	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg19847130	chr8:10466454	RP1L1	0.37	5.45	0.33	1.22e-7	Neuroticism;
KIRP	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.64	-9.9	-0.53	1.19e-19	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.84	-0.53	1.77e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg23587288	chr2:27483067	SLC30A3	-0.7	-7.39	-0.43	2.33e-12	Blood metabolite levels;
KIRP	cis	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg06307176	chr5:131281290	NA	0.52	5.68	0.34	3.79e-8	Life satisfaction;
KIRP	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg17595323	chr11:93583763	C11orf90	0.37	6.29	0.37	1.47e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.58	-6.67	-0.39	1.72e-10	Menopause (age at onset);
KIRP	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg01557791	chr16:72042693	DHODH	-0.51	-6.35	-0.38	1.05e-9	Fibrinogen levels;
KIRP	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	12.2	0.61	4.47e-27	Bipolar disorder;
KIRP	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg16235748	chr6:149772707	ZC3H12D	0.35	5.63	0.34	4.95e-8	Dupuytren's disease;
KIRP	cis	rs9513593	1.000	rs1927724	chr13:99992312	A/C	cg21788972	chr13:99853209	UBAC2	0.57	6.04	0.36	5.77e-9	Psoriasis;
KIRP	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.65	9.01	0.5	5.75e-17	Prostate cancer;
KIRP	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg16898833	chr6:26189333	HIST1H4D	0.75	5.29	0.32	2.73e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.7	10.93	0.57	6.27e-23	Coronary artery disease;
KIRP	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.54	-6.98	-0.41	2.8e-11	Retinal vascular caliber;
KIRP	cis	rs1823913	0.599	rs4146103	chr2:192136726	T/A	cg12404831	chr2:192114017	MYO1B	0.47	6.57	0.39	2.97e-10	Obesity-related traits;
KIRP	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12826209	chr6:26865740	GUSBL1	0.47	5.88	0.35	1.32e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg14703610	chr5:56206110	C5orf35	0.47	6.26	0.37	1.69e-9	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs282587	0.569	rs282601	chr13:113392619	A/G	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.82e-12	Glycated hemoglobin levels;
KIRP	cis	rs6430538	0.621	rs6753223	chr2:135576472	A/G	cg12500956	chr2:135428796	TMEM163	0.43	5.43	0.33	1.36e-7	Parkinson's disease;
KIRP	cis	rs5753037	0.838	rs140145	chr22:30178305	C/T	cg01021169	chr22:30184971	ASCC2	-0.42	-5.34	-0.32	2.14e-7	Type 1 diabetes;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03797768	chr13:24040813	NA	0.47	6.73	0.39	1.16e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05837253	chr5:42424075	GHR	0.56	7.27	0.42	4.81e-12	Parkinson's disease;
KIRP	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.26	-0.37	1.67e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.68	11.95	0.61	2.97e-26	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg14228332	chr4:119757509	SEC24D	0.79	4.86	0.3	2.08e-6	Cannabis dependence symptom count;
KIRP	cis	rs10207628	1.000	rs76168490	chr2:127850618	C/G	cg06223080	chr2:127868745	NA	-0.59	-7.95	-0.45	6.96e-14	Psychosis and Alzheimer's disease;
KIRP	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.5	7.09	0.41	1.44e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg05692746	chr2:100937584	LONRF2	-0.38	-4.99	-0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2071403	0.901	rs9711204	chr2:1406012	C/T	cg06500727	chr2:1417164	TPO	0.38	5.7	0.34	3.34e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg15128208	chr22:42549153	NA	0.74	8.01	0.46	4.46e-14	Birth weight;
KIRP	cis	rs2790457	0.917	rs1265831	chr10:28912850	C/G	cg05705492	chr10:28955341	NA	-0.55	-8.54	-0.48	1.45e-15	Multiple myeloma;
KIRP	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25833597	chr17:30823145	MYO1D	0.4	5.15	0.31	5.39e-7	Schizophrenia;
KIRP	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	7.02	0.41	2.15e-11	Rheumatoid arthritis;
KIRP	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.23	-0.67	6.18e-34	Primary sclerosing cholangitis;
KIRP	cis	rs7809615	0.901	rs28862110	chr7:99183531	T/C	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite ratios;
KIRP	cis	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg19183248	chr4:152364959	FAM160A1	0.4	4.97	0.3	1.24e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.65	-8.66	-0.48	6.53e-16	Breast cancer;
KIRP	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.48	6.67	0.39	1.72e-10	Red blood cell count;
KIRP	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.76	7.95	0.45	6.95e-14	Schizophrenia;
KIRP	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg27124370	chr19:33622961	WDR88	0.6	5.27	0.32	2.97e-7	Bone properties (heel);
KIRP	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	trans	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.12	-0.36	3.59e-9	Neuroticism;
KIRP	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.98	-15.13	-0.69	5.09e-37	Personality dimensions;
KIRP	cis	rs1867631	0.585	rs6670827	chr1:67127006	C/T	cg13052034	chr1:66999238	SGIP1	0.45	6.92	0.4	3.84e-11	Menopause (age at onset);
KIRP	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02924347	chr16:2390352	ABCA17P;ABCA3	-0.48	-6.03	-0.36	6.02e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.74	-8.17	-0.46	1.63e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg14456004	chr13:21872349	NA	-1.03	-12.98	-0.64	1.08e-29	White matter hyperintensity burden;
KIRP	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-5.63	-0.34	4.88e-8	Fear of minor pain;
KIRP	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.99	0.45	5.33e-14	Retinal vascular caliber;
KIRP	cis	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg06521331	chr12:34319734	NA	-0.47	-5.75	-0.34	2.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.45	0.65	2.74e-31	Bladder cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02951971	chr14:50698663	SOS2	0.47	6.18	0.37	2.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.68	10.53	0.56	1.24e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.38	0.47	4.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4713118	1.000	rs1139226	chr6:27675290	A/T	cg20933634	chr6:27740509	NA	0.39	4.91	0.3	1.64e-6	Parkinson's disease;
KIRP	cis	rs757081	0.667	rs3950680	chr11:17138666	G/A	cg15432903	chr11:17409602	KCNJ11	-0.51	-5.97	-0.36	8.26e-9	Systolic blood pressure;
KIRP	cis	rs13095912	0.785	rs6444076	chr3:185321405	T/C	cg11274856	chr3:185301563	NA	0.65	8.37	0.47	4.25e-15	Systolic blood pressure;
KIRP	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.56	-7.54	-0.43	9.01e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg07856975	chr6:36356162	ETV7	0.39	5.71	0.34	3.18e-8	Platelet distribution width;
KIRP	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11987759	chr7:65425863	GUSB	-0.53	-6.84	-0.4	6.1e-11	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13749939	chr11:796434	SLC25A22	0.59	7.42	0.43	1.95e-12	Smoking initiation;
KIRP	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.99	-0.36	7.41e-9	Type 2 diabetes;
KIRP	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.25	6.69	0.39	1.52e-10	Crohn's disease;
KIRP	cis	rs41563	0.607	rs6955349	chr7:104601236	G/A	cg04380332	chr7:105027541	SRPK2	-0.63	-9.33	-0.51	6.34e-18	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1957429	0.520	rs230715	chr14:65320549	G/C	cg23373153	chr14:65346875	NA	-0.58	-4.92	-0.3	1.61e-6	Pediatric areal bone mineral density (radius);
KIRP	cis	rs42648	0.777	rs4728878	chr7:89924232	T/G	cg25739043	chr7:89950458	NA	-0.45	-6.99	-0.41	2.62e-11	Homocysteine levels;
KIRP	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05220968	chr6:146057943	EPM2A	-0.38	-4.98	-0.3	1.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs981844	0.890	rs55917677	chr4:154701051	C/T	cg14289246	chr4:154710475	SFRP2	0.69	7.85	0.45	1.27e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.86	13.33	0.65	6.97e-31	Longevity;Endometriosis;
KIRP	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg02660097	chr11:68866761	NA	-0.31	-4.86	-0.3	2.05e-6	Blond vs. brown hair color;
KIRP	cis	rs13401104	0.796	rs12468256	chr2:237111995	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.16	-0.46	1.7e-14	Response to antipsychotic treatment;
KIRP	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	1.07	18.94	0.77	5.98e-50	Bone mineral density;
KIRP	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg13206674	chr6:150067644	NUP43	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg05255149	chr17:80675120	FN3KRP	-0.45	-4.86	-0.3	2.08e-6	Glycated hemoglobin levels;
KIRP	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10211518	chr19:633735	POLRMT	0.54	6.28	0.37	1.51e-9	Smoking initiation;
KIRP	trans	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg19274270	chr17:78178856	CARD14	-0.36	-6.53	-0.38	3.78e-10	Morning vs. evening chronotype;
KIRP	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg09408571	chr1:101003634	GPR88	-0.23	-5.28	-0.32	2.85e-7	Monocyte count;
KIRP	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.72	0.34	3.07e-8	Schizophrenia;
KIRP	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.41	-5.16	-0.31	5.2e-7	Aortic root size;
KIRP	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg25173405	chr17:45401733	C17orf57	0.46	6.19	0.37	2.52e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.43	10.46	0.55	2.08e-21	Cutaneous nevi;
KIRP	cis	rs13082711	0.911	rs57317249	chr3:27515854	A/C	cg02860705	chr3:27208620	NA	0.47	6.62	0.39	2.2e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.62	6.96	0.41	3.16e-11	Caffeine consumption;
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	13.65	0.66	5.67e-32	Platelet count;
KIRP	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.41	-11.61	-0.6	3.75e-25	Diabetic kidney disease;
KIRP	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.59	7.81	0.45	1.67e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg19507638	chr5:93509721	C5orf36	0.63	5.43	0.33	1.34e-7	Diabetic retinopathy;
KIRP	cis	rs7945071	0.851	rs34034333	chr11:110264987	A/G	cg04157658	chr11:110243994	NA	0.39	5.0	0.3	1.09e-6	Cognitive function;
KIRP	cis	rs17321999	0.904	rs13386353	chr2:30480756	A/G	cg05247661	chr2:30472410	LBH	0.7	7.72	0.44	2.88e-13	Systemic lupus erythematosus;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg00684032	chr4:1343700	KIAA1530	0.53	6.96	0.41	3.05e-11	Longevity;
KIRP	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg00310523	chr12:86230176	RASSF9	-0.57	-8.93	-0.49	9.94e-17	Major depressive disorder;
KIRP	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.68	-0.34	3.72e-8	Bipolar disorder;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17322444	chr19:33572249	GPATCH1	0.73	6.18	0.37	2.71e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.28	27.93	0.87	2.91e-78	IgG glycosylation;
KIRP	cis	rs1847202	0.793	rs11918132	chr3:72952144	C/T	cg06781948	chr3:72941472	GXYLT2	0.43	5.83	0.35	1.77e-8	Motion sickness;
KIRP	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg23100626	chr2:96804247	ASTL	0.5	6.89	0.4	4.65e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.16e-7	Life satisfaction;
KIRP	cis	rs4664304	0.620	rs10929958	chr2:160720538	A/G	cg03641300	chr2:160917029	PLA2R1	0.35	5.22	0.32	3.77e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4006360	0.646	rs4890158	chr17:39295805	A/T	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-8.68	-0.48	5.54e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.77	0.66	2.37e-32	Platelet count;
KIRP	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.35	-4.85	-0.3	2.15e-6	Depressive symptoms;
KIRP	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.68	9.63	0.52	8.06e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.76	10.35	0.55	4.48e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg00405596	chr8:11794950	NA	0.49	6.75	0.4	1.08e-10	Monocyte count;
KIRP	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.88	13.81	0.66	1.71e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62413470	0.935	rs12216538	chr6:55941034	C/G	cg13327911	chr6:55965977	COL21A1	0.56	4.93	0.3	1.48e-6	Joint mobility (Beighton score);
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.61	-10.54	-0.56	1.14e-21	Lung cancer;
KIRP	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.46	-0.33	1.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-5.12	-0.31	6.17e-7	Testicular germ cell tumor;
KIRP	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.51	-11.28	-0.58	4.73e-24	Diabetic kidney disease;
KIRP	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-7.76	-0.44	2.25e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17554472	chr22:41940697	POLR3H	-0.64	-6.69	-0.39	1.51e-10	Vitiligo;
KIRP	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	11.0	0.57	3.62e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9653442	0.900	rs10194635	chr2:100834217	T/A	cg07810366	chr2:100720526	AFF3	-0.29	-4.94	-0.3	1.48e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs6001982	0.584	rs61675795	chr22:40839696	C/T	cg07138101	chr22:40742427	ADSL	0.69	5.32	0.32	2.3e-7	Breast cancer;
KIRP	cis	rs6499755	0.712	rs31109	chr16:55378226	G/C	cg05099576	chr16:55362342	IRX6	0.24	5.01	0.3	1.03e-6	Hypospadias;
KIRP	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg07636037	chr3:49044803	WDR6	-0.59	-4.91	-0.3	1.66e-6	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	1.02	18.91	0.77	7.65e-50	Parkinson's disease;
KIRP	cis	rs4786125	0.542	rs2345826	chr16:6916235	G/T	cg03623568	chr16:6915990	A2BP1	-0.42	-5.19	-0.31	4.46e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs1978968	0.763	rs9605481	chr22:18465677	C/T	cg02610425	chr22:18483192	MICAL3	0.42	5.84	0.35	1.69e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.38	-0.47	4.02e-15	Neuroticism;
KIRP	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-15.77	-0.71	3.44e-39	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6859018	1.000	rs2288831	chr5:158750013	T/C	cg26646896	chr5:158686746	NA	-0.34	-4.95	-0.3	1.36e-6	Serum sulfate level;
KIRP	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.02	0.31	9.74e-7	Diisocyanate-induced asthma;
KIRP	cis	rs78487399	0.908	rs12475503	chr2:43831319	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.06	-0.31	8.11e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg16141378	chr3:129829833	LOC729375	0.51	6.48	0.38	4.89e-10	Retinal vascular caliber;
KIRP	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	1.05	19.32	0.78	3.05e-51	Bone mineral density;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09762612	chr19:56109078	FIZ1	-0.51	-6.16	-0.37	2.97e-9	Inflammatory biomarkers;
KIRP	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.9	6.89	0.4	4.54e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg13256891	chr4:100009986	ADH5	0.5	6.13	0.36	3.5e-9	Alcohol dependence;
KIRP	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.34e-8	Platelet count;
KIRP	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg13611997	chr5:233750	SDHA	-0.48	-5.62	-0.34	5.29e-8	Breast cancer;
KIRP	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08048268	chr3:133502702	NA	-0.41	-4.99	-0.3	1.12e-6	Iron status biomarkers;
KIRP	cis	rs4006360	0.503	rs1848808	chr17:39249321	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.49	5.48	0.33	1.08e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs654128	0.640	rs339330	chr6:117209490	T/G	cg12892004	chr6:117198278	RFX6	-0.39	-5.29	-0.32	2.72e-7	Telomere length;
KIRP	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.56	-8.91	-0.49	1.16e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.3	-0.37	1.38e-9	Diastolic blood pressure;
KIRP	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.52	-0.38	4e-10	Retinal vascular caliber;
KIRP	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.41	4.89	0.3	1.83e-6	Body mass index;
KIRP	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.75	-10.69	-0.56	3.73e-22	Waist circumference;Body mass index;
KIRP	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.75	0.4	1.03e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg06740227	chr12:86229804	RASSF9	0.45	5.71	0.34	3.33e-8	Major depressive disorder;
KIRP	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	9.49	0.52	2.13e-18	Smoking behavior;
KIRP	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	6.4	0.38	7.84e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg25486957	chr4:152246857	NA	-0.42	-5.06	-0.31	8.26e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs853308	1.000	rs864091	chr8:133933290	C/A	cg06478102	chr15:73992274	CD276	-0.49	-6.08	-0.36	4.54e-9	Vitiligo;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12738264	chr7:148725795	PDIA4	0.57	7.7	0.44	3.31e-13	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4430311	0.756	rs2953329	chr1:244025999	A/G	cg25706552	chr1:244017396	NA	0.62	9.94	0.54	8.95e-20	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.88	6.62	0.39	2.25e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg27411982	chr8:10470053	RP1L1	0.43	5.49	0.33	9.94e-8	Neuroticism;
KIRP	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.81	-13.46	-0.65	2.65e-31	Corneal structure;
KIRP	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.58	0.34	6.3e-8	Educational attainment;
KIRP	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.71	10.04	0.54	4.29e-20	Caffeine consumption;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-6.19	-0.37	2.49e-9	Longevity;
KIRP	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.87e-11	Retinal vascular caliber;
KIRP	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06544989	chr22:39130855	UNC84B	0.49	8.1	0.46	2.55e-14	Menopause (age at onset);
KIRP	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	6.8	0.4	8.01e-11	Cognitive test performance;
KIRP	cis	rs12282928	0.959	rs2101185	chr11:48319573	G/T	cg26585981	chr11:48327164	OR4S1	0.5	6.04	0.36	5.75e-9	Migraine - clinic-based;
KIRP	cis	rs7011049	1.000	rs72640848	chr8:53836225	A/G	cg26025543	chr8:53854495	NA	0.72	7.64	0.44	4.89e-13	Systolic blood pressure;
KIRP	cis	rs55692468	0.771	rs6744391	chr2:153334614	T/C	cg04681845	chr2:153283485	FMNL2	-0.53	-6.64	-0.39	1.97e-10	Intraocular pressure;
KIRP	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.12	0.36	3.59e-9	Neuroticism;
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg00507259	chr4:95128692	SMARCAD1	0.41	5.1	0.31	6.78e-7	Testicular germ cell tumor;
KIRP	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg08873628	chr1:175162347	KIAA0040	0.44	6.53	0.38	3.75e-10	Alcohol dependence;
KIRP	cis	rs5753037	0.838	rs140147	chr22:30184599	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-5.45	-0.33	1.22e-7	Type 1 diabetes;
KIRP	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg05991184	chr2:219186017	PNKD	-0.37	-5.48	-0.33	1.05e-7	Colorectal cancer;
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg01798813	chr17:3906674	NA	0.48	6.48	0.38	5.03e-10	Type 2 diabetes;
KIRP	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg00405596	chr8:11794950	NA	-0.51	-6.67	-0.39	1.68e-10	Retinal vascular caliber;
KIRP	cis	rs9815354	1.000	rs73069394	chr3:41787233	G/A	cg03022575	chr3:42003672	ULK4	0.51	5.72	0.34	3.16e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.96	12.85	0.63	2.83e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.91	-0.35	1.12e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg02158880	chr13:53174818	NA	0.37	4.99	0.3	1.15e-6	Lewy body disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17192681	chr2:10953115	PDIA6	0.47	6.27	0.37	1.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.79	9.98	0.54	6.68e-20	Phospholipid levels (plasma);
KIRP	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.63	0.34	4.97e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	7.94	0.45	7.35e-14	Height;
KIRP	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.18	-0.51	1.85e-17	Mood instability;
KIRP	cis	rs580438	0.510	rs6442377	chr3:13418086	C/A	cg10657019	chr3:13328039	NA	-0.51	-6.59	-0.39	2.66e-10	Myringotomy;
KIRP	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	8.85	0.49	1.8e-16	Schizophrenia;
KIRP	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs12135062	0.538	rs2651929	chr1:3101353	C/T	cg20253172	chr1:3107290	PRDM16	0.42	5.62	0.34	5.17e-8	Migraine;
KIRP	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg08975724	chr8:8085496	FLJ10661	0.53	6.81	0.4	7.46e-11	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06923622	chr16:54964737	IRX5	0.52	6.6	0.39	2.57e-10	Parkinson's disease;
KIRP	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg10818794	chr15:86012489	AKAP13	-0.49	-7.0	-0.41	2.48e-11	Coronary artery disease;
KIRP	cis	rs12949688	1.000	rs886925	chr17:55817649	G/C	cg12582317	chr17:55822272	NA	0.61	9.99	0.54	6.01e-20	Schizophrenia;
KIRP	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.73	8.81	0.49	2.33e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg13010199	chr12:38710504	ALG10B	0.51	6.49	0.38	4.74e-10	Morning vs. evening chronotype;
KIRP	cis	rs7562790	0.610	rs4670556	chr2:36650878	G/A	cg09467607	chr2:36825704	FEZ2	0.41	5.08	0.31	7.44e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg18190219	chr22:46762943	CELSR1	-0.64	-6.93	-0.4	3.77e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6450176	0.633	rs391448	chr5:53332323	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-9.15	-0.5	2.21e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs1215050	0.791	rs649866	chr4:98738826	T/C	cg05340658	chr4:99064831	C4orf37	0.58	6.99	0.41	2.55e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.43	0.43	1.83e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4356932	0.967	rs10856873	chr4:76972924	T/G	cg00809888	chr4:76862425	NAAA	0.43	6.05	0.36	5.46e-9	Blood protein levels;
KIRP	trans	rs17079247	0.841	rs9566053	chr13:85810454	C/T	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg07645718	chr20:61493192	TCFL5	0.75	6.44	0.38	6.33e-10	Obesity-related traits;
KIRP	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.42	-6.08	-0.36	4.5e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg07827796	chr19:33622959	WDR88	0.44	5.24	0.32	3.47e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs3858145	0.500	rs4633337	chr10:70045727	G/T	cg04882175	chr6:131122610	NA	0.55	6.43	0.38	6.6e-10	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs244899	1.000	rs244899	chr5:167911040	C/T	cg06604206	chr5:167912465	RARS	-0.52	-7.2	-0.42	7.13e-12	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.96	0.41	3.04e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs77688320	0.535	rs12468504	chr2:202258469	A/C	cg06431681	chr2:202330990	STRADB	-0.51	-6.9	-0.4	4.35e-11	Breast cancer;
KIRP	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.63	8.99	0.5	6.86e-17	Resting heart rate;
KIRP	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.55	5.44	0.33	1.29e-7	Initial pursuit acceleration;
KIRP	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg06521331	chr12:34319734	NA	-0.55	-6.8	-0.4	7.8e-11	Heart rate;
KIRP	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg09184832	chr6:79620586	NA	-0.4	-5.02	-0.3	9.86e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.5	-0.52	2.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9612	1.000	rs346534	chr19:44250831	A/G	cg08581076	chr19:44259116	C19orf61	0.6	6.46	0.38	5.65e-10	Exhaled nitric oxide output;
KIRP	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.11	0.36	3.78e-9	Body mass index;
KIRP	cis	rs17641971	0.645	rs341805	chr8:50034658	T/G	cg00325661	chr8:49890786	NA	0.46	5.75	0.34	2.7e-8	Blood metabolite levels;
KIRP	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	5.92	0.35	1.1e-8	Sudden cardiac arrest;
KIRP	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.4	-5.05	-0.31	8.47e-7	Platelet count;
KIRP	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.06	0.31	8.06e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2241685	0.621	rs7579818	chr2:1899145	G/T	cg22511877	chr2:1942942	MYT1L	-0.58	-5.37	-0.32	1.86e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.84	-13.35	-0.65	5.91e-31	Breast cancer;
KIRP	trans	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg21775007	chr8:11205619	TDH	0.52	6.54	0.38	3.63e-10	Neuroticism;
KIRP	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.7	10.63	0.56	5.67e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg25801113	chr15:45476975	SHF	-0.44	-8.11	-0.46	2.41e-14	Uric acid levels;
KIRP	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-0.97	-15.73	-0.71	4.61e-39	Height;
KIRP	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.18	0.51	1.78e-17	Bladder cancer;
KIRP	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24229701	chr12:130821962	PIWIL1	0.41	5.18	0.31	4.7e-7	Menopause (age at onset);
KIRP	trans	rs11165623	0.792	rs6671371	chr1:96977039	A/G	cg10631902	chr5:14652156	NA	-0.62	-9.41	-0.51	3.8e-18	Hip circumference;Waist circumference;
KIRP	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg07701084	chr6:150067640	NUP43	0.55	6.33	0.37	1.12e-9	Lung cancer;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg12705353	chr12:122356852	WDR66	0.39	5.23	0.32	3.57e-7	Mean corpuscular volume;
KIRP	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg03468072	chr12:39539422	NA	0.41	5.96	0.36	8.79e-9	Morning vs. evening chronotype;
KIRP	cis	rs4780401	0.567	rs34340800	chr16:11779318	G/A	cg01061890	chr16:11836724	TXNDC11	-0.44	-5.01	-0.3	1.04e-6	Rheumatoid arthritis;
KIRP	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.42	-7.37	-0.43	2.56e-12	Refractive error;
KIRP	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.61	-7.71	-0.44	3.09e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17768439	chr3:50273700	GNAI2	0.52	6.45	0.38	5.74e-10	Parkinson's disease;
KIRP	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg11271282	chr2:238384023	NA	0.51	5.8	0.35	2.05e-8	Prostate cancer;
KIRP	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-1.06	-19.18	-0.77	8.96e-51	Leprosy;
KIRP	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs76693355	0.541	rs2276035	chr11:120346360	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.41	-5.23	-0.32	3.68e-7	Intraocular pressure;
KIRP	cis	rs1014246	0.848	rs11197798	chr10:118457277	C/T	cg14919929	chr10:118506882	NA	0.68	9.07	0.5	3.84e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg11906718	chr8:101322791	RNF19A	0.64	8.21	0.46	1.26e-14	Atrioventricular conduction;
KIRP	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg27124370	chr19:33622961	WDR88	0.55	6.85	0.4	5.81e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.41	5.13	0.31	5.83e-7	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03697856	chr19:2096672	C19orf36;MOBKL2A	0.55	6.86	0.4	5.7e-11	Parkinson's disease;
KIRP	cis	rs7129556	0.701	rs10899399	chr11:77409832	C/T	cg12586386	chr11:77299805	AQP11	0.43	5.68	0.34	3.89e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.57	8.02	0.46	4.35e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	trans	rs1559088	0.512	rs36085438	chr19:33562145	G/A	cg25386676	chr5:172175721	NA	-0.49	-6.3	-0.37	1.34e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.03	11.52	0.59	7.83e-25	Vitiligo;
KIRP	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.58	-6.62	-0.39	2.19e-10	Menarche (age at onset);
KIRP	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs4713675	0.604	rs791902	chr6:33702617	G/A	cg15676125	chr6:33679581	C6orf125	-0.39	-4.92	-0.3	1.6e-6	Plateletcrit;
KIRP	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg05315796	chr3:52349193	DNAH1	0.44	6.78	0.4	9.07e-11	Bipolar disorder;
KIRP	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.75	-11.07	-0.58	2.3e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	5.08	0.31	7.58e-7	Height;
KIRP	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.83	9.86	0.53	1.55e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg26585981	chr11:48327164	OR4S1	-0.43	-5.19	-0.31	4.45e-7	HDL cholesterol;
KIRP	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.24	-0.37	1.91e-9	Neuroticism;
KIRP	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	1.05	6.67	0.39	1.66e-10	Type 2 diabetes nephropathy;
KIRP	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-0.77	-11.61	-0.6	3.83e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4805272	1.000	rs1363323	chr19:29326952	C/G	cg15000279	chr19:29285009	NA	-0.36	-5.17	-0.31	4.74e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13198984	chr17:80129470	CCDC57	0.44	6.47	0.38	5.34e-10	Life satisfaction;
KIRP	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs1122900	1.000	rs1122900	chr5:36689181	A/C	cg24186104	chr5:36689192	NA	-0.51	-8.46	-0.47	2.4e-15	Aggressive periodontitis;
KIRP	cis	rs10267417	0.603	rs12666448	chr7:19859119	G/A	cg05791153	chr7:19748676	TWISTNB	0.5	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.97	15.55	0.7	1.92e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.46	-5.19	-0.31	4.46e-7	Educational attainment (years of education);
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.34	5.56	0.33	7.05e-8	Lymphocyte counts;
KIRP	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg12131826	chr15:77904385	NA	0.4	5.28	0.32	2.91e-7	Type 2 diabetes;
KIRP	cis	rs860295	0.665	rs12028416	chr1:155401161	G/T	cg02153340	chr1:155202674	NA	-0.56	-7.62	-0.44	5.37e-13	Body mass index;
KIRP	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg04727924	chr7:799746	HEATR2	0.64	5.86	0.35	1.49e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg22437258	chr11:111473054	SIK2	-0.56	-6.11	-0.36	3.97e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg06307176	chr5:131281290	NA	0.52	5.68	0.34	3.79e-8	Life satisfaction;
KIRP	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg08501292	chr6:25962987	TRIM38	1.0	7.63	0.44	5.22e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.86	-11.65	-0.6	2.86e-25	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14053500	chr19:29703769	UQCRFS1	0.47	6.04	0.36	5.76e-9	Parkinson's disease;
KIRP	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.7	0.44	3.25e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg01990225	chr2:97406019	LMAN2L	-1.05	-6.94	-0.4	3.4e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.37	0.43	2.66e-12	Lung cancer;
KIRP	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.73	8.69	0.48	5.21e-16	Corneal astigmatism;
KIRP	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	10.22	0.55	1.17e-20	Lymphocyte counts;
KIRP	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.7	7.13	0.41	1.12e-11	Protein C levels;
KIRP	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.02	0.46	4.26e-14	Neuroticism;
KIRP	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg12435725	chr3:58293450	RPP14	-0.45	-5.22	-0.32	3.76e-7	Cholesterol, total;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg09699651	chr6:150184138	LRP11	0.47	6.26	0.37	1.68e-9	Lung cancer;
KIRP	cis	rs4389656	0.784	rs274723	chr5:6718563	A/G	cg10857441	chr5:6722123	POLS	-0.47	-6.67	-0.39	1.65e-10	Coronary artery disease;
KIRP	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.5	-7.21	-0.42	6.77e-12	Coronary artery disease;
KIRP	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.07	-0.36	4.77e-9	Longevity;
KIRP	cis	rs7923609	0.846	rs10761731	chr10:65027610	A/T	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.1	-0.31	6.68e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09960727	chr20:39765952	PLCG1	0.51	6.45	0.38	5.89e-10	Parkinson's disease;
KIRP	cis	rs2120243	0.539	rs12486427	chr3:157113276	A/C	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.75e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs12973672	1.000	rs28365136	chr19:35769561	T/G	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg06740227	chr12:86229804	RASSF9	0.4	5.07	0.31	7.83e-7	Major depressive disorder;
KIRP	cis	rs6772849	0.708	rs12491942	chr3:128421469	C/G	cg08795948	chr3:128337044	NA	0.46	5.22	0.32	3.86e-7	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.37	0.47	4.38e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg05784532	chr1:230284198	GALNT2	0.42	6.84	0.4	6.21e-11	Coronary artery disease;
KIRP	trans	rs1995809	0.793	rs12508180	chr4:147966649	C/T	cg23682866	chr10:43858278	NA	0.61	6.32	0.37	1.24e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.65	-0.8	1.2e-55	Height;
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg07648498	chr16:89883185	FANCA	0.48	5.94	0.35	9.8e-9	Vitiligo;
KIRP	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.77	0.4	9.34e-11	Bipolar disorder;
KIRP	cis	rs56161922	1.000	rs17045979	chr1:207842704	T/C	cg11752769	chr1:207818423	CR1L	-0.77	-5.03	-0.31	9.67e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	1.01	19.99	0.79	1.89e-53	Parkinson's disease;
KIRP	cis	rs2275565	1.000	rs2275565	chr1:237048676	A/C	cg17297354	chr1:237056641	MTR	0.35	4.87	0.3	2.02e-6	Homocysteine levels;
KIRP	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.61	-7.49	-0.43	1.25e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.18	-0.51	1.8e-17	Urate levels in overweight individuals;
KIRP	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg07884673	chr3:53033167	SFMBT1	1.0	7.75	0.44	2.48e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs9788721	1.000	rs55781567	chr15:78857986	C/G	cg18825076	chr15:78729989	IREB2	-0.42	-5.05	-0.31	8.74e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg15038512	chr6:170123185	PHF10	0.46	5.31	0.32	2.45e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.74	6.79	0.4	8.5e-11	Mean platelet volume;
KIRP	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg14829360	chr17:73884958	NA	-0.61	-8.71	-0.49	4.65e-16	Psoriasis;
KIRP	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.62	-7.24	-0.42	5.88e-12	Bone mineral density;
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.48	-5.64	-0.34	4.75e-8	Lung cancer;
KIRP	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.71	8.46	0.47	2.45e-15	Obesity-related traits;
KIRP	trans	rs2048656	0.523	rs13270801	chr8:9543651	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.32	-0.37	1.21e-9	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20892287	chr11:128893851	RICS	-0.42	-6.38	-0.38	8.58e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7243821	0.579	rs4801109	chr18:52571434	A/G	cg26630735	chr18:52626848	CCDC68	-0.41	-4.86	-0.3	2.07e-6	Chin dimples;
KIRP	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs73200209	0.744	rs11612443	chr12:116518839	A/G	cg01776926	chr12:116560359	MED13L	-0.57	-6.29	-0.37	1.4e-9	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14466896	chr22:45705870	FAM118A	0.49	6.06	0.36	5e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg24315340	chr6:146058215	EPM2A	-0.47	-6.15	-0.36	3.17e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg01324507	chr7:1177794	C7orf50	0.54	4.92	0.3	1.58e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.59	6.6	0.39	2.51e-10	Height;
KIRP	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.48	0.38	5.07e-10	Platelet count;
KIRP	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.68	-7.56	-0.43	8.07e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-0.89	-12.89	-0.63	2.18e-29	Dupuytren's disease;
KIRP	cis	rs889312	0.500	rs832552	chr5:56113850	A/C	cg12311346	chr5:56204834	C5orf35	0.39	5.25	0.32	3.22e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg15068132	chr12:102092402	CHPT1	-0.38	-4.97	-0.3	1.28e-6	Blood protein levels;
KIRP	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00321850	chr1:175162397	KIAA0040	0.34	6.0	0.36	7.01e-9	Alcohol dependence;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.79	6.89	0.4	4.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg27205649	chr11:78285834	NARS2	-0.53	-5.89	-0.35	1.28e-8	Testicular germ cell tumor;
KIRP	trans	rs12517041	1.000	rs995215	chr5:23285366	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.65	-0.48	6.64e-16	Calcium levels;
KIRP	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12463199	chr20:49126897	PTPN1	0.55	6.5	0.38	4.4e-10	Smoking initiation;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23138817	chr14:105864896	NA	-0.45	-6.07	-0.36	4.73e-9	Metabolic traits;
KIRP	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg05784532	chr1:230284198	GALNT2	0.47	7.37	0.43	2.63e-12	Coronary artery disease;
KIRP	cis	rs16828019	0.852	rs10489520	chr1:41511755	C/A	cg18742814	chr1:41828276	NA	0.69	5.91	0.35	1.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.66	-0.34	4.16e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7188697	0.922	rs9924805	chr16:58615659	T/C	cg21335942	chr16:58549945	SETD6	-0.46	-5.12	-0.31	6.31e-7	QT interval;
KIRP	cis	rs963731	0.579	rs12712630	chr2:39284582	A/G	cg04010122	chr2:39346883	SOS1	-0.78	-5.22	-0.32	3.75e-7	Corticobasal degeneration;
KIRP	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.85	-10.16	-0.54	1.83e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.72	10.56	0.56	9.66e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.43	-5.25	-0.32	3.32e-7	Leprosy;
KIRP	cis	rs1215050	0.791	rs6813619	chr4:98830768	C/T	cg05340658	chr4:99064831	C4orf37	-0.53	-6.4	-0.38	7.8e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.64	0.6	3.08e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.87	0.35	1.37e-8	Personality dimensions;
KIRP	cis	rs1318772	1.000	rs34539248	chr5:112697365	T/C	cg12552261	chr5:112820674	MCC	0.84	5.49	0.33	1e-7	F-cell distribution;
KIRP	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg05315796	chr3:52349193	DNAH1	0.37	5.67	0.34	3.97e-8	Bipolar disorder;
KIRP	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg14465207	chr2:10951250	PDIA6	0.42	5.58	0.34	6.37e-8	Cardiac Troponin-T levels;
KIRP	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.23e-8	Life satisfaction;
KIRP	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.99	0.45	5.35e-14	Corneal astigmatism;
KIRP	cis	rs4728302	0.607	rs6974386	chr7:133588738	T/C	cg10665199	chr7:133106180	EXOC4	0.43	5.04	0.31	9.21e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg17644776	chr2:200775616	C2orf69	-0.49	-5.13	-0.31	5.79e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.81	11.02	0.58	3.14e-23	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.58	-7.93	-0.45	7.52e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.76	8.89	0.49	1.32e-16	White matter hyperintensity burden;
KIRP	cis	rs12693043	1.000	rs12693043	chr2:175377565	C/T	cg11778734	chr2:175439522	WIPF1	0.4	4.94	0.3	1.42e-6	Urate levels (BMI interaction);
KIRP	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg16255804	chr6:135334527	HBS1L	-0.34	-5.53	-0.33	8.17e-8	Red blood cell count;
KIRP	cis	rs897080	0.515	rs1085450	chr2:44650698	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.75	0.34	2.69e-8	Height;
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.51	-0.38	4.24e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.79	0.57	1.84e-22	Cognitive test performance;
KIRP	cis	rs1050631	0.592	rs1785900	chr18:33710170	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.47	0.33	1.13e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.79	10.94	0.57	5.66e-23	Aortic root size;
KIRP	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.11	-13.56	-0.65	1.16e-31	Vitiligo;
KIRP	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.74	9.48	0.52	2.23e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17608500	chr1:154955711	FLAD1	0.68	8.32	0.47	6.19e-15	Smoking initiation;
KIRP	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg18944383	chr4:111397179	ENPEP	0.43	7.01	0.41	2.3e-11	Height;
KIRP	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.51	0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.86	-12.46	-0.62	5.84e-28	Calcium levels;
KIRP	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs7671900	0.634	rs10028866	chr4:88189869	C/G	cg23841344	chr4:88312519	HSD17B11	-0.46	-5.69	-0.34	3.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg22676075	chr6:135203613	NA	0.46	6.6	0.39	2.49e-10	Red blood cell count;
KIRP	cis	rs4409675	1.000	rs61789695	chr1:28255693	G/A	cg23691781	chr1:28212827	C1orf38	0.34	5.93	0.35	1.04e-8	Corneal astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08949862	chr2:63277672	OTX1	0.43	6.82	0.4	7.07e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.53	7.22	0.42	6.46e-12	Kawasaki disease;
KIRP	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-1.07	-19.63	-0.78	2.89e-52	Height;
KIRP	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg11382394	chr1:2564504	MMEL1	-0.38	-4.87	-0.3	2.02e-6	Ulcerative colitis;
KIRP	cis	rs11783469	0.522	rs4872125	chr8:23268270	G/A	cg00472375	chr8:23315376	ENTPD4	0.55	5.34	0.32	2.14e-7	Reticulocyte count;
KIRP	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.5	-5.69	-0.34	3.53e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg01765077	chr12:122356316	WDR66	0.64	8.8	0.49	2.53e-16	Mean corpuscular volume;
KIRP	cis	rs11955175	1.000	rs79132719	chr5:40668525	T/C	cg05478818	chr5:40835740	RPL37	0.69	5.36	0.32	1.88e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg10756647	chr7:56101905	PSPH	-0.98	-7.0	-0.41	2.39e-11	Diabetic kidney disease;
KIRP	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg03959625	chr15:84868606	LOC388152	-0.63	-7.04	-0.41	1.86e-11	Schizophrenia;
KIRP	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.76	8.8	0.49	2.46e-16	High light scatter reticulocyte count;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23708337	chr7:1209742	NA	0.41	5.2	0.31	4.23e-7	Longevity;Endometriosis;
KIRP	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	trans	rs1973993	0.561	rs61334931	chr1:96988776	T/A	cg10631902	chr5:14652156	NA	-0.55	-6.76	-0.4	1.02e-10	Weight;
KIRP	cis	rs13065560	0.534	rs6789111	chr3:38904222	G/A	cg01426195	chr3:39028469	NA	-0.37	-6.06	-0.36	5.02e-9	Interleukin-18 levels;
KIRP	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.02	-0.36	6.23e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg23335576	chr14:104009727	NA	0.4	5.47	0.33	1.11e-7	Body mass index;
KIRP	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.14	-0.36	3.35e-9	Bladder cancer;
KIRP	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.17	12.83	0.63	3.51e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs34375054	0.573	rs12831151	chr12:125656263	C/T	cg25124228	chr12:125621409	AACS	-0.57	-5.91	-0.35	1.14e-8	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06481639	chr22:41940642	POLR3H	0.43	5.06	0.31	8.35e-7	Vitiligo;
KIRP	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.67	-10.04	-0.54	4.28e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2151522	0.563	rs1343224	chr6:127136405	G/C	cg21431617	chr6:127135037	NA	0.33	5.87	0.35	1.38e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1978968	0.751	rs5992138	chr22:18458621	A/C	cg02610425	chr22:18483192	MICAL3	0.38	5.32	0.32	2.38e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg23594656	chr7:65796392	TPST1	-0.44	-6.17	-0.37	2.75e-9	Aortic root size;
KIRP	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.36	-0.32	1.91e-7	Bipolar disorder;
KIRP	cis	rs9815354	0.951	rs55835726	chr3:41763049	C/T	cg03022575	chr3:42003672	ULK4	0.64	6.56	0.39	3.09e-10	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	8.88	0.49	1.42e-16	Neuroticism;
KIRP	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg24253500	chr15:84953950	NA	0.54	6.17	0.37	2.75e-9	Schizophrenia;
KIRP	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg11635098	chr7:100497156	NA	-0.67	-7.23	-0.42	6.1e-12	Resting heart rate;
KIRP	trans	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg00405596	chr8:11794950	NA	0.54	6.55	0.39	3.36e-10	Neuroticism;
KIRP	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05220968	chr6:146057943	EPM2A	-0.43	-5.5	-0.33	9.28e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg15848620	chr12:58087721	OS9	-0.43	-4.93	-0.3	1.51e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg25547332	chr5:131281432	NA	-0.49	-5.52	-0.33	8.62e-8	Life satisfaction;
KIRP	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg17294928	chr15:75287854	SCAMP5	0.66	6.04	0.36	5.74e-9	Lung cancer;
KIRP	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.74	-7.88	-0.45	1.03e-13	Diastolic blood pressure;
KIRP	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg01843034	chr6:37503916	NA	-0.82	-11.5	-0.59	9.23e-25	Cognitive performance;
KIRP	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	0.71	9.07	0.5	3.79e-17	Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11596498	chr19:41221028	ADCK4	0.48	6.02	0.36	6.16e-9	Parkinson's disease;
KIRP	cis	rs7523050	0.643	rs35665867	chr1:109395436	G/A	cg08274380	chr1:109419600	GPSM2	1.22	9.94	0.54	8.37e-20	Fat distribution (HIV);
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg22535103	chr8:58192502	C8orf71	-0.46	-4.9	-0.3	1.72e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg10818794	chr15:86012489	AKAP13	-0.52	-7.33	-0.42	3.38e-12	Coronary artery disease;
KIRP	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg20140201	chr2:241835670	C2orf54	-0.34	-5.08	-0.31	7.32e-7	Urinary metabolites;
KIRP	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	4.91	0.3	1.65e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg08126542	chr6:37504118	NA	-0.68	-9.68	-0.53	5.69e-19	Cognitive performance;
KIRP	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.73	-8.68	-0.48	5.39e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.22e-13	Coronary artery calcification;
KIRP	cis	rs9612	0.950	rs7256472	chr19:44246970	C/T	cg08581076	chr19:44259116	C19orf61	0.64	6.91	0.4	4.07e-11	Exhaled nitric oxide output;
KIRP	cis	rs9896052	0.534	rs8065160	chr17:73441090	A/G	cg25649188	chr17:73499917	CASKIN2	-0.47	-6.23	-0.37	1.97e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg21573476	chr21:45109991	RRP1B	-0.57	-7.69	-0.44	3.62e-13	Mean corpuscular volume;
KIRP	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.59	-6.6	-0.39	2.46e-10	Bipolar disorder;
KIRP	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg07001201	chr5:642380	CEP72	0.67	6.2	0.37	2.42e-9	Obesity-related traits;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg14078059	chr12:65174660	NA	0.95	6.43	0.38	6.63e-10	P wave terminal force;
KIRP	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-5.69	-0.34	3.63e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13185784	0.569	rs6877489	chr5:179677545	C/T	cg23221052	chr5:179740743	GFPT2	-0.48	-5.03	-0.31	9.44e-7	TRAIL levels;
KIRP	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg24416660	chr17:73865998	NA	-0.43	-5.8	-0.35	2.08e-8	Psoriasis;
KIRP	cis	rs11264213	0.786	rs72659692	chr1:36292258	A/G	cg27506609	chr1:36549197	TEKT2	0.96	5.34	0.32	2.13e-7	Schizophrenia;
KIRP	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg12560992	chr17:57184187	TRIM37	0.6	5.22	0.32	3.73e-7	Cognitive test performance;
KIRP	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-5.07	-0.31	7.85e-7	Primary biliary cholangitis;
KIRP	cis	rs654128	0.640	rs170951	chr6:117220071	T/C	cg12892004	chr6:117198278	RFX6	-0.39	-5.15	-0.31	5.27e-7	Telomere length;
KIRP	trans	rs6866721	0.870	rs13161380	chr5:116218596	T/C	cg12737536	chr10:5227162	AKR1CL1	0.44	6.15	0.37	3.05e-9	Body mass index;
KIRP	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.41	-5.36	-0.32	1.94e-7	Hypertriglyceridemia;
KIRP	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.44	5.46	0.33	1.17e-7	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14554871	chr9:131486327	ZDHHC12	0.49	6.37	0.38	9.38e-10	Parkinson's disease;
KIRP	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg18478394	chr8:109455254	TTC35	0.49	5.91	0.35	1.16e-8	Dupuytren's disease;
KIRP	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg13180566	chr4:1052158	NA	0.5	5.16	0.31	5.07e-7	Recombination rate (females);
KIRP	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg26681399	chr22:41777847	TEF	0.54	5.22	0.32	3.74e-7	Vitiligo;
KIRP	cis	rs4926611	0.730	rs2950252	chr1:54048719	C/G	cg08927728	chr1:54059983	GLIS1	-0.25	-5.61	-0.34	5.44e-8	Hand grip strength;
KIRP	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.89	0.4	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg08132940	chr7:1081526	C7orf50	-0.7	-7.18	-0.42	8.2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.02	0.61	1.76e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.47e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2384207	0.584	rs66480871	chr12:113766464	A/G	cg13296563	chr12:112847257	RPL6	-0.6	-4.92	-0.3	1.61e-6	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg15655495	chr12:38532458	NA	-0.28	-4.93	-0.3	1.51e-6	Bladder cancer;
KIRP	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg10018233	chr7:150070692	REPIN1	0.55	7.12	0.41	1.19e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6684428	0.706	rs61774839	chr1:56336609	G/A	cg11651538	chr1:56320950	NA	-0.91	-11.79	-0.6	9.84e-26	Airflow obstruction;
KIRP	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.62	-0.34	5.17e-8	Aortic root size;
KIRP	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg24633833	chr3:10029261	TMEM111	0.54	5.21	0.32	3.94e-7	Alzheimer's disease;
KIRP	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg14541582	chr5:601475	NA	0.55	6.12	0.36	3.63e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg21775007	chr8:11205619	TDH	0.43	5.81	0.35	1.88e-8	Myopia (pathological);
KIRP	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.85	-0.3	2.17e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.69	-7.92	-0.45	8.3e-14	Monocyte count;
KIRP	cis	rs1978968	0.912	rs13057016	chr22:18466779	G/A	cg03078520	chr22:18463400	MICAL3	-0.73	-8.97	-0.5	7.89e-17	Presence of antiphospholipid antibodies;
KIRP	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.66	12.59	0.63	2.27e-28	Bone mineral density;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg23978390	chr7:1156363	C7orf50	0.42	5.5	0.33	9.6e-8	Longevity;Endometriosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22227582	chr18:66694317	CCDC102B	-0.4	-6.35	-0.38	1.03e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg09175582	chr1:161736000	ATF6	0.73	5.85	0.35	1.58e-8	IgG glycosylation;
KIRP	cis	rs7503807	0.651	rs901065	chr17:78599655	G/T	cg09596252	chr17:78655493	RPTOR	0.48	5.28	0.32	2.77e-7	Obesity;
KIRP	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.57	-6.1	-0.36	4.04e-9	Obesity-related traits;
KIRP	cis	rs7180079	0.514	rs7403751	chr15:64979291	G/C	cg15337035	chr15:64978493	NA	-0.45	-5.3	-0.32	2.52e-7	Monocyte count;
KIRP	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.22	0.7	2.54e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582720	0.731	rs1971819	chr2:203705787	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.69	-7.14	-0.41	1.07e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg08885076	chr2:99613938	TSGA10	0.53	9.26	0.51	1.06e-17	Chronic sinus infection;
KIRP	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.76	11.75	0.6	1.35e-25	Heart rate;
KIRP	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.82	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg20255370	chr15:40268687	EIF2AK4	-0.36	-5.01	-0.3	1.04e-6	Response to haloperidol in psychosis;
KIRP	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.85	11.97	0.61	2.48e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg19761014	chr17:28927070	LRRC37B2	0.67	4.92	0.3	1.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg00686598	chr14:53173677	PSMC6	-0.7	-6.74	-0.39	1.12e-10	Alzheimer's disease (late onset);
KIRP	cis	rs12780845	0.928	rs11813029	chr10:17244915	T/C	cg01003015	chr10:17271136	VIM	0.47	5.25	0.32	3.23e-7	Homocysteine levels;
KIRP	trans	rs9845942	0.821	rs11129637	chr3:3566264	G/C	cg18403361	chr14:38725750	CLEC14A	-0.48	-6.61	-0.39	2.37e-10	Eating disorder in bipolar disorder;
KIRP	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.5	5.57	0.33	6.78e-8	Coronary artery disease;
KIRP	cis	rs2997447	0.846	rs12067677	chr1:26411971	C/T	cg19633962	chr1:26362018	EXTL1	-0.5	-4.85	-0.3	2.16e-6	QRS complex (12-leadsum);
KIRP	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.38	-0.51	4.51e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.05e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7523273	0.565	rs2796234	chr1:207900695	T/A	cg22525895	chr1:207977042	MIR29B2	-0.46	-5.9	-0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs6058796	0.681	rs28529295	chr20:31274668	C/G	cg13636640	chr20:31349939	DNMT3B	0.62	5.47	0.33	1.12e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs7119167	0.901	rs73542998	chr11:73148498	A/G	cg17517138	chr11:73019481	ARHGEF17	0.48	5.05	0.31	8.52e-7	Blood protein levels;
KIRP	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.39	5.42	0.33	1.42e-7	Platelet count;
KIRP	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.43	4.89	0.3	1.79e-6	Schizophrenia;
KIRP	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg13010199	chr12:38710504	ALG10B	0.38	5.02	0.3	1.01e-6	Morning vs. evening chronotype;
KIRP	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg27211696	chr2:191398769	TMEM194B	-0.74	-8.8	-0.49	2.41e-16	Diastolic blood pressure;
KIRP	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.84	-10.78	-0.57	1.97e-22	Chronic sinus infection;
KIRP	cis	rs13102973	1.000	rs13112665	chr4:135898581	C/A	cg14419869	chr4:135874104	NA	0.49	8.0	0.45	4.79e-14	Subjective well-being;
KIRP	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.31	5.13	0.31	5.81e-7	Iron status biomarkers (transferrin levels);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05295494	chr6:69345425	BAI3	-0.47	-6.08	-0.36	4.51e-9	Interleukin-4 levels;
KIRP	cis	rs4728302	0.869	rs13228262	chr7:133598288	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.37	7.34	0.42	3.14e-12	IgG glycosylation;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01283332	chr5:1856932	NA	-0.5	-6.55	-0.39	3.26e-10	Cardiovascular disease risk factors;
KIRP	cis	rs56804039	0.524	rs66989459	chr8:8367911	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-4.86	-0.3	2.11e-6	Cervical cancer;
KIRP	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Bladder cancer;
KIRP	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-5.9	-0.35	1.19e-8	Renal cell carcinoma;
KIRP	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.25e-10	Hepatitis;
KIRP	cis	rs9816226	0.793	rs869400	chr3:185826740	T/G	cg00760338	chr3:185826511	ETV5	0.78	7.39	0.43	2.27e-12	Obesity;Body mass index;
KIRP	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-1.07	-21.8	-0.81	2.11e-59	Height;
KIRP	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.14e-11	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-8.36	-0.47	4.6e-15	Response to antipsychotic treatment;
KIRP	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg07382826	chr16:28625726	SULT1A1	0.46	5.19	0.31	4.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.78	-7.78	-0.44	1.99e-13	Bipolar disorder;
KIRP	cis	rs2400749	0.830	rs10873506	chr14:100033222	T/C	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.44	-0.33	1.32e-7	Alzheimer's disease (survival time);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14128708	chr11:2176433	INS-IGF2	0.51	6.21	0.37	2.23e-9	Interleukin-4 levels;
KIRP	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.65	-7.6	-0.44	6.31e-13	Height;
KIRP	cis	rs6504950	0.760	rs17745189	chr17:53013980	A/G	cg26251398	chr17:52985966	TOM1L1	0.42	5.13	0.31	5.78e-7	Breast cancer;
KIRP	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.55	7.09	0.41	1.42e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25117505	chr11:66313529	ZDHHC24;ACTN3	0.49	6.24	0.37	1.86e-9	Parkinson's disease;
KIRP	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06647332	chr5:131281008	NA	-0.45	-4.92	-0.3	1.58e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.84	11.46	0.59	1.18e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-6.3	-0.37	1.39e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg00745463	chr17:30367425	LRRC37B	-0.66	-6.55	-0.39	3.27e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg09165964	chr15:75287851	SCAMP5	-0.68	-6.86	-0.4	5.42e-11	Blood trace element (Zn levels);
KIRP	cis	rs1505368	0.505	rs12694279	chr2:213253406	C/A	cg20637307	chr2:213403960	ERBB4	0.51	6.92	0.4	3.81e-11	Symmetrical dimethylarginine levels;
KIRP	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg17328964	chr8:145687451	CYHR1	0.42	5.29	0.32	2.74e-7	Age at first birth;
KIRP	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.45	5.33	0.32	2.21e-7	Total body bone mineral density;
KIRP	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.52	-0.48	1.63e-15	Mean corpuscular volume;
KIRP	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.35	-0.62	1.38e-27	Exhaled nitric oxide output;
KIRP	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.28	7.49	0.43	1.26e-12	Primary biliary cholangitis;
KIRP	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg00376283	chr12:123451042	ABCB9	-0.62	-7.22	-0.42	6.35e-12	Neutrophil percentage of white cells;
KIRP	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.12	0.41	1.19e-11	Aortic root size;
KIRP	trans	rs9813712	0.595	rs1453240	chr3:130001692	C/T	cg19009305	chr15:89181732	ISG20	0.39	6.12	0.36	3.59e-9	Response to amphetamines;
KIRP	cis	rs6442310	1.000	rs6442310	chr3:12358230	T/A	cg15873301	chr3:12045459	SYN2	-0.41	-5.02	-0.31	9.7e-7	Hematocrit;
KIRP	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7129556	0.954	rs6592738	chr11:77323126	C/T	cg12586386	chr11:77299805	AQP11	0.46	6.1	0.36	4.05e-9	Weight loss (gastric bypass surgery);
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23708337	chr7:1209742	NA	0.41	5.14	0.31	5.72e-7	Longevity;Endometriosis;
KIRP	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg09201719	chr10:104596890	CYP17A1	0.37	5.32	0.32	2.28e-7	Arsenic metabolism;
KIRP	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.4	-0.38	7.93e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs4006360	0.657	rs6503588	chr17:39235453	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.58	-8.24	-0.47	1.03e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg08807101	chr21:30365312	RNF160	0.46	5.57	0.33	6.57e-8	Pancreatic cancer;
KIRP	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.71	9.97	0.54	6.92e-20	Narcolepsy;
KIRP	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg24169773	chr3:122142474	KPNA1	-0.58	-6.44	-0.38	6.31e-10	LDL cholesterol levels;
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg15181151	chr6:150070149	PCMT1	0.29	4.87	0.3	1.97e-6	Lung cancer;
KIRP	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.36	-5.49	-0.33	1e-7	Body mass index;
KIRP	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.81e-31	Diabetic retinopathy;
KIRP	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.77	-10.27	-0.55	8.15e-21	Aortic root size;
KIRP	cis	rs4356932	1.000	rs10014049	chr4:76953532	C/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg06210147	chr17:40428290	STAT5B	-0.48	-6.38	-0.38	8.77e-10	Morning vs. evening chronotype;
KIRP	cis	rs273573	0.643	rs7930606	chr11:30996872	C/T	cg14844989	chr11:31128820	NA	0.34	4.9	0.3	1.77e-6	Total body bone mineral density;
KIRP	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.06	0.36	5.13e-9	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg19040474	chr17:151914	RPH3AL	-0.38	-6.27	-0.37	1.58e-9	Bladder cancer;
KIRP	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.98	15.84	0.71	1.92e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-8.04	-0.46	3.77e-14	Schizophrenia;
KIRP	cis	rs7712401	0.601	rs30060	chr5:122296700	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	7.81	0.45	1.67e-13	Mean corpuscular hemoglobin;
KIRP	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg06042504	chr8:55087323	NA	-0.59	-7.22	-0.42	6.49e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg05340658	chr4:99064831	C4orf37	0.46	5.15	0.31	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.46	6.16	0.37	2.94e-9	Height;
KIRP	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg05370193	chr1:21551575	ECE1	0.45	6.28	0.37	1.5e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7084402	0.967	rs1621227	chr10:60327734	C/G	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	-0.73	-9.44	-0.52	2.91e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.43	-0.38	6.64e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-1.0	-17.06	-0.74	1.39e-43	Height;
KIRP	trans	rs7999699	0.870	rs12585259	chr13:48317304	C/T	cg23237801	chr1:16476620	EPHA2	0.5	6.3	0.37	1.33e-9	Colorectal cancer (diet interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01103911	chr2:29044463	SPDYA	0.49	6.97	0.41	2.89e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	2.03e-10	Coronary artery calcification;
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.47	6.49	0.38	4.58e-10	Testicular germ cell tumor;
KIRP	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg15117754	chr3:10150083	C3orf24	0.5	5.05	0.31	8.66e-7	Alzheimer's disease;
KIRP	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.37	5.03	0.31	9.61e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6681460	0.932	rs2146904	chr1:67160336	C/T	cg02459107	chr1:67143332	SGIP1	-0.39	-5.7	-0.34	3.42e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs8027181	0.959	rs11631352	chr15:73086473	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.41	-5.91	-0.35	1.15e-8	Triglyceride levels;
KIRP	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.64	-0.34	4.7e-8	Obesity-related traits;
KIRP	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.45e-9	Type 2 diabetes;
KIRP	cis	rs787274	0.850	rs2645985	chr9:115510812	A/G	cg13803584	chr9:115635662	SNX30	0.73	6.6	0.39	2.57e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.4	-0.38	7.87e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4356975	0.563	rs4273534	chr4:69950645	A/C	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18802706	chr17:78902434	RPTOR	0.47	6.09	0.36	4.27e-9	Interleukin-4 levels;
KIRP	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg18441811	chr11:71824068	C11orf51	0.89	5.52	0.33	8.44e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg18306943	chr3:40428807	ENTPD3	0.46	5.86	0.35	1.46e-8	Renal cell carcinoma;
KIRP	cis	rs9324022	0.722	rs72698709	chr14:101165747	C/T	cg18089426	chr14:101175970	NA	0.67	5.68	0.34	3.79e-8	Plateletcrit;
KIRP	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09273012	chr2:45675674	SRBD1	-0.41	-6.26	-0.37	1.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.89	-0.3	1.83e-6	Life satisfaction;
KIRP	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.8	-13.81	-0.66	1.74e-32	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg25319279	chr11:5960081	NA	0.55	5.5	0.33	9.4e-8	DNA methylation (variation);
KIRP	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16318349	chr1:154917307	PBXIP1	0.32	5.38	0.32	1.71e-7	Prostate cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04383352	chr3:88188026	ZNF654	-0.45	-6.54	-0.38	3.5e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg15848620	chr12:58087721	OS9	0.42	5.23	0.32	3.6e-7	Multiple sclerosis;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg11646757	chr7:128095699	C7orf68	0.45	6.22	0.37	2.13e-9	Ischemic stroke;
KIRP	cis	rs12210905	0.764	rs72835248	chr6:26931817	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.79	-0.4	8.28e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs4716602	0.596	rs34977094	chr7:156160864	C/T	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.72	9.94	0.54	8.49e-20	Blood protein levels;
KIRP	cis	rs9914544	0.628	rs9908821	chr17:18679404	A/G	cg26306683	chr17:18585705	ZNF286B	0.4	4.95	0.3	1.39e-6	Educational attainment (years of education);
KIRP	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg09408571	chr1:101003634	GPR88	0.24	5.33	0.32	2.27e-7	Monocyte count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06837842	chr10:27059746	ABI1	-0.41	-6.05	-0.36	5.24e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7808935	0.768	rs757138	chr7:27989403	T/G	cg05786569	chr7:27702416	HIBADH	0.45	5.23	0.32	3.61e-7	Prostate cancer;
KIRP	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.74	-10.08	-0.54	3.25e-20	Childhood ear infection;
KIRP	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.45	-0.38	5.8e-10	Bladder cancer;
KIRP	cis	rs9914578	1.000	rs9914577	chr17:2005130	C/T	cg16513277	chr17:2031491	SMG6	-0.72	-8.68	-0.48	5.64e-16	Body mass index;
KIRP	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.87	0.53	1.43e-19	Prudent dietary pattern;
KIRP	cis	rs2151522	0.724	rs13209747	chr6:127115454	A/G	cg21431617	chr6:127135037	NA	-0.31	-5.75	-0.34	2.67e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs362272	0.502	rs2798298	chr4:3036602	G/A	cg14003022	chr4:3043019	NA	-0.37	-5.01	-0.3	1.05e-6	Serum sulfate level;
KIRP	cis	rs8014252	0.614	rs28612538	chr14:71025206	G/A	cg11204974	chr14:71022665	NA	-0.56	-6.05	-0.36	5.46e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg18165381	chr3:44552316	NA	-0.4	-5.04	-0.31	8.89e-7	Depressive symptoms;
KIRP	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	5.43	0.33	1.35e-7	Schizophrenia;
KIRP	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.25	-0.78	5.4e-51	Height;
KIRP	cis	rs7565981	1.000	rs72627413	chr2:101429037	C/A	cg02232089	chr2:101440696	NPAS2	-0.57	-5.23	-0.32	3.63e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.81	-12.43	-0.62	7.52e-28	Breast cancer;
KIRP	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.18	-16.24	-0.72	8.32e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16318349	chr1:154917307	PBXIP1	-0.3	-5.11	-0.31	6.54e-7	Prostate cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20621256	chr9:140118465	C9orf169	0.6	7.34	0.42	3.08e-12	Smoking initiation;
KIRP	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.25	-0.32	3.36e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.94	-12.27	-0.62	2.56e-27	Platelet distribution width;
KIRP	cis	rs2380220	0.935	rs7748857	chr6:96001887	A/G	cg15832292	chr6:96025679	MANEA	0.65	5.4	0.33	1.55e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.88	-0.3	1.88e-6	Inflammatory bowel disease;
KIRP	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg25654697	chr7:7680075	RPA3	0.48	6.48	0.38	4.95e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.92	15.99	0.71	5.9e-40	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg06212747	chr3:49208901	KLHDC8B	0.61	6.62	0.39	2.28e-10	Menarche (age at onset);
KIRP	cis	rs16828019	0.777	rs12047078	chr1:41462986	T/C	cg18742814	chr1:41828276	NA	0.68	5.73	0.34	2.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.44	0.7	4.73e-38	Bipolar disorder;
KIRP	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7119167	0.673	rs61131329	chr11:73029269	C/G	cg17517138	chr11:73019481	ARHGEF17	0.47	5.03	0.31	9.41e-7	Blood protein levels;
KIRP	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.67	-9.15	-0.5	2.21e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs2548003	0.541	rs2014310	chr5:28723589	T/C	cg12623145	chr2:97778927	ANKRD36	0.62	6.16	0.37	2.99e-9	Hip geometry;
KIRP	cis	rs7084402	0.967	rs1658424	chr10:60331588	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.63	7.97	0.45	6.07e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs42648	0.564	rs11763820	chr7:89818945	T/G	cg25739043	chr7:89950458	NA	-0.37	-5.73	-0.34	2.95e-8	Homocysteine levels;
KIRP	cis	rs12049351	0.774	rs1053512	chr1:229652698	G/T	cg11742688	chr1:229674241	ABCB10	-0.4	-5.5	-0.33	9.52e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg22863700	chr5:28928346	NA	-0.6	-6.2	-0.37	2.41e-9	Hip geometry;
KIRP	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.84	9.78	0.53	2.71e-19	Neutrophil percentage of white cells;
KIRP	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs11078597	0.731	rs2287322	chr17:1641035	A/G	cg17514665	chr17:1657533	SERPINF2	0.43	5.4	0.33	1.59e-7	Serum albumin level;
KIRP	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	5.18	0.31	4.73e-7	Bipolar disorder;
KIRP	cis	rs6142102	0.961	rs6088361	chr20:32557326	G/A	cg08999081	chr20:33150536	PIGU	0.47	5.73	0.34	2.96e-8	Skin pigmentation;
KIRP	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.99	8.47	0.47	2.33e-15	Systolic blood pressure;
KIRP	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.82	10.18	0.54	1.56e-20	Menarche (age at onset);
KIRP	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.74	0.44	2.56e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg00319359	chr11:70116639	PPFIA1	0.64	6.28	0.37	1.52e-9	Coronary artery disease;
KIRP	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.24e-6	Menopause (age at onset);
KIRP	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.12	0.67	1.53e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg03396347	chr1:1875803	NA	-0.62	-9.14	-0.5	2.41e-17	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26240433	chr14:94547826	DDX24;IFI27L1	-0.47	-6.17	-0.37	2.85e-9	Interleukin-4 levels;
KIRP	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg03060546	chr3:49711283	APEH	-0.59	-5.04	-0.31	9.03e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.29	-0.32	2.64e-7	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07569756	chr17:48474564	LRRC59	0.66	7.93	0.45	7.88e-14	Smoking initiation;
KIRP	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.38	8.0	0.45	4.78e-14	Body mass index;
KIRP	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.34	0.37	1.11e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.59	0.34	6.07e-8	Lung cancer;
KIRP	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.97	-0.3	1.26e-6	Prostate cancer;
KIRP	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	7.59	0.44	6.43e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.63	9.59	0.52	1.01e-18	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg10932868	chr11:921992	NA	0.57	7.18	0.42	8.44e-12	Alzheimer's disease (late onset);
KIRP	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.04	0.36	5.71e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4006360	0.531	rs7502102	chr17:39307041	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.39	-5.3	-0.32	2.53e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.16	-0.37	2.87e-9	Breast cancer;
KIRP	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg06386533	chr2:46925753	SOCS5	0.47	4.97	0.3	1.24e-6	Height;
KIRP	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg05315796	chr3:52349193	DNAH1	-0.44	-6.78	-0.4	8.64e-11	Bipolar disorder;
KIRP	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.27	-0.32	2.99e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4950322	0.517	rs116479391	chr1:146792659	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs41005	0.967	rs13430914	chr2:8114648	A/G	cg03155496	chr2:8117019	LOC339788	0.56	8.94	0.5	9.34e-17	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.48	5.87	0.35	1.37e-8	Menopause (age at onset);
KIRP	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.91	10.32	0.55	5.71e-21	Corneal astigmatism;
KIRP	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.86	-0.35	1.44e-8	Colorectal cancer;
KIRP	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg13271783	chr10:134563150	INPP5A	-0.56	-7.12	-0.41	1.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	9.26	0.51	1.08e-17	Resting heart rate;
KIRP	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06634786	chr22:41940651	POLR3H	-0.41	-4.99	-0.3	1.12e-6	Vitiligo;
KIRP	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg05370193	chr1:21551575	ECE1	0.38	5.37	0.32	1.78e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.93	13.77	0.66	2.26e-32	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.76	-12.08	-0.61	1.08e-26	Hepatocellular carcinoma;
KIRP	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.86	-11.01	-0.57	3.42e-23	Breast cancer;
KIRP	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg27490568	chr2:178487706	NA	0.49	6.58	0.39	2.85e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	0.71	6.79	0.4	8.36e-11	Breast cancer;
KIRP	cis	rs4356932	0.715	rs9992952	chr4:76898174	A/C	cg00809888	chr4:76862425	NAAA	0.5	6.94	0.4	3.48e-11	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25928521	chr11:14893339	PDE3B	-0.42	-6.27	-0.37	1.62e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg24488311	chr11:68621650	NA	0.48	5.85	0.35	1.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg26924012	chr15:45694286	SPATA5L1	0.58	7.45	0.43	1.53e-12	Glomerular filtration rate;
KIRP	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.73	0.49	3.94e-16	Electroencephalogram traits;
KIRP	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs17092148	1.000	rs62211617	chr20:33400355	C/G	cg16810054	chr20:33298113	TP53INP2	0.47	5.71	0.34	3.17e-8	Neuroticism;
KIRP	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg16141378	chr3:129829833	LOC729375	0.51	6.46	0.38	5.55e-10	Neuroticism;
KIRP	cis	rs11874712	1.000	rs1800636	chr18:43670420	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg00101154	chr16:420108	MRPL28	-0.45	-5.34	-0.32	2.15e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.77	-0.4	9.6e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.88	-10.3	-0.55	6.28e-21	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.95	-13.47	-0.65	2.44e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.75	10.66	0.56	4.79e-22	Waist circumference;Body mass index;
KIRP	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg20673091	chr1:2541236	MMEL1	0.66	10.03	0.54	4.47e-20	Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.28	-0.32	2.85e-7	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11948456	chr2:179278332	MIR548N	0.4	6.27	0.37	1.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12900413	0.687	rs35060998	chr15:90310294	A/G	cg24650279	chr15:90327240	NA	-0.41	-5.23	-0.32	3.7e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs509477	1.000	rs7245165	chr18:32567007	C/A	cg23791764	chr18:32556832	MAPRE2	0.53	6.71	0.39	1.35e-10	Cerebrospinal fluid AB1-42 levels;
KIRP	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.64	-6.71	-0.39	1.29e-10	DNA methylation (variation);
KIRP	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg18404041	chr3:52824283	ITIH1	0.42	5.22	0.32	3.84e-7	Schizophrenia;
KIRP	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.61	7.53	0.43	9.9e-13	Chronic lymphocytic leukemia;
KIRP	cis	rs6882046	0.513	rs34320	chr5:88021527	T/G	cg24804195	chr5:87968844	LOC645323	-0.46	-6.03	-0.36	6.1e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	cg04338863	chr8:33670619	NA	0.47	6.22	0.37	2.17e-9	Body mass index;
KIRP	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg22974920	chr21:40686053	BRWD1	0.46	5.46	0.33	1.18e-7	Cognitive function;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg27570636	chr1:214454189	SMYD2	0.65	6.05	0.36	5.3300000000000004e-09	Lung function (FEV1);
KIRP	cis	rs4704846	0.614	rs6555828	chr5:156493740	C/T	cg12943317	chr5:156479607	HAVCR1	-0.55	-5.31	-0.32	2.44e-7	Blood protein levels;
KIRP	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.59	8.69	0.48	5.34e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg21605333	chr4:119757512	SEC24D	-1.61	-10.76	-0.57	2.29e-22	Cannabis dependence symptom count;
KIRP	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg06156847	chr2:113672199	IL1F7	0.37	5.1	0.31	6.73e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.34e-15	Bone mineral density;
KIRP	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.78	12.17	0.61	5.41e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs42648	0.566	rs13247629	chr7:89889585	A/G	cg25739043	chr7:89950458	NA	-0.38	-5.78	-0.35	2.3e-8	Homocysteine levels;
KIRP	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.49	-0.43	1.21e-12	Height;
KIRP	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.22	-0.46	1.16e-14	Monocyte percentage of white cells;
KIRP	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg25706552	chr1:244017396	NA	0.54	6.68	0.39	1.56e-10	RR interval (heart rate);
KIRP	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg20045696	chr14:77926864	AHSA1	0.5	6.19	0.37	2.52e-9	Myeloid white cell count;
KIRP	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.71	0.34	3.17e-8	Melanoma;
KIRP	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg03653399	chr8:142233436	SLC45A4	0.48	6.18	0.37	2.62e-9	Birth weight;
KIRP	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-5.05	-0.31	8.44e-7	Response to bleomycin (chromatid breaks);
KIRP	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg04731861	chr2:219085781	ARPC2	0.23	5.74	0.34	2.71e-8	Colorectal cancer;
KIRP	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg14324370	chr2:177042789	NA	-0.72	-8.77	-0.49	2.94e-16	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.53	7.4	0.43	2.12e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35740288	0.770	rs11633893	chr15:86148438	A/G	cg17133734	chr15:86042851	AKAP13	0.5	5.48	0.33	1.08e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs4851551	0.543	rs1997503	chr2:102809235	C/T	cg21292012	chr2:91715690	NA	0.78	6.35	0.38	1.03e-9	Blood protein levels;
KIRP	cis	rs6901250	0.655	rs9384990	chr6:117126941	A/G	cg12892004	chr6:117198278	RFX6	0.42	6.93	0.4	3.64e-11	C-reactive protein levels;
KIRP	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.37	0.32	1.85e-7	Menarche (age at onset);
KIRP	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.63	-7.14	-0.41	1.06e-11	Neuroticism;
KIRP	trans	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.66	-9.29	-0.51	8.3e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs3741151	0.686	rs7114009	chr11:73115314	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.65	-5.88	-0.35	1.35e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg11262906	chr1:85462892	MCOLN2	-0.56	-6.0	-0.36	6.94e-9	Serum sulfate level;
KIRP	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg18904891	chr8:8559673	CLDN23	0.63	7.38	0.43	2.36e-12	Obesity-related traits;
KIRP	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.58	-6.86	-0.4	5.41e-11	Monocyte count;
KIRP	cis	rs11628318	1.000	rs11628318	chr14:103040087	T/A	cg01864069	chr14:103024347	NA	-0.74	-9.58	-0.52	1.1e-18	Platelet count;
KIRP	cis	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg06521331	chr12:34319734	NA	-0.5	-6.05	-0.36	5.43e-9	Morning vs. evening chronotype;
KIRP	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.17	-0.37	2.79e-9	Parkinson's disease;
KIRP	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.92	0.3	1.58e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg05043794	chr9:111880884	C9orf5	-0.27	-5.65	-0.34	4.52e-8	Menarche (age at onset);
KIRP	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg21827317	chr3:136751795	NA	0.38	5.21	0.32	4.03e-7	Neuroticism;
KIRP	cis	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg06585982	chr3:143692056	C3orf58	0.6	7.61	0.44	5.87e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg17646820	chr3:66848679	NA	0.74	9.63	0.52	7.69e-19	Type 2 diabetes;
KIRP	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg07382826	chr16:28625726	SULT1A1	0.52	6.23	0.37	2.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7224685	0.569	rs8066580	chr17:3996494	T/C	cg05562828	chr17:3906858	NA	0.54	5.68	0.34	3.72e-8	Type 2 diabetes;
KIRP	cis	rs228437	0.802	rs228441	chr6:134899931	C/T	cg24504307	chr6:134963096	NA	-0.42	-6.09	-0.36	4.39e-9	Melanoma;
KIRP	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.75	11.58	0.59	4.99e-25	Multiple myeloma;
KIRP	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.75	-0.34	2.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.89	-0.45	1.01e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs8070740	1.000	rs4790772	chr17:5330959	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.43	0.43	1.79e-12	Menopause (age at onset);
KIRP	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.81	7.19	0.42	7.6e-12	Obesity-related traits;
KIRP	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg04132472	chr17:19861366	AKAP10	0.52	7.5	0.43	1.14e-12	Schizophrenia;
KIRP	cis	rs7539542	0.622	rs10920529	chr1:202902597	G/A	cg08940984	chr1:202857613	RABIF	0.46	5.38	0.32	1.73e-7	Mean platelet volume;
KIRP	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.37	0.38	9.48e-10	Morning vs. evening chronotype;
KIRP	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg03711944	chr11:47377212	SPI1	-0.34	-5.48	-0.33	1.06e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2236918	1.000	rs2526699	chr1:242022130	T/C	cg17736920	chr1:242011382	EXO1	0.75	9.88	0.53	1.32e-19	Menopause (age at onset);
KIRP	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	8e-7	Electrocardiographic conduction measures;
KIRP	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg12140854	chr5:148520817	ABLIM3	-0.51	-6.12	-0.36	3.69e-9	Breast cancer;
KIRP	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.18	0.31	4.51e-7	Cognitive test performance;
KIRP	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs259842	0.612	rs13399189	chr2:180668212	T/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.05	-0.31	8.69e-7	Blood protein levels;
KIRP	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.71	-0.34	3.19e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg12463550	chr7:65579703	CRCP	0.59	7.29	0.42	4.14e-12	Aortic root size;
KIRP	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.53	7.05	0.41	1.83e-11	HDL cholesterol;
KIRP	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.19	0.51	1.75e-17	Colorectal cancer;
KIRP	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs6684514	1.000	rs11264468	chr1:156274585	C/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.94	-0.35	9.46e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-7.59	-0.44	6.5e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.35	1.28e-8	Mean platelet volume;
KIRP	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	0.76	9.2	0.51	1.6e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg24796726	chr7:884288	UNC84A	-0.53	-5.18	-0.31	4.61e-7	Initial pursuit acceleration;
KIRP	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.1	0.41	1.32e-11	Height;
KIRP	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg23594656	chr7:65796392	TPST1	-0.52	-8.14	-0.46	2e-14	Aortic root size;
KIRP	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.96	15.39	0.7	7.03e-38	Uric acid clearance;
KIRP	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.86	-0.4	5.67e-11	Myopia;Myopia (pathological);
KIRP	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	7.11	0.41	1.27e-11	Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25303599	chr11:61595807	FADS2	0.46	6.4	0.38	7.64e-10	Parkinson's disease;
KIRP	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-7.24	-0.42	5.85e-12	Neuroticism;
KIRP	cis	rs616147	0.627	rs9871799	chr3:39484320	G/A	cg17944282	chr3:39448217	RPSA	0.43	5.27	0.32	3.05e-7	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6544713	1.000	rs6544713	chr2:44073881	T/C	cg21783355	chr2:44066198	ABCG5;ABCG8	0.4	5.47	0.33	1.1e-7	Coronary artery disease;LDL cholesterol;
KIRP	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg15556689	chr8:8085844	FLJ10661	-0.66	-9.16	-0.5	2.1e-17	Retinal vascular caliber;
KIRP	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.91	-0.35	1.15e-8	Obesity-related traits;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14257396	chr1:107603778	NA	0.43	6.07	0.36	4.94e-9	Migraine with aura;
KIRP	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-7.9	-0.45	9.42e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.64	-7.15	-0.41	9.9e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.79	10.62	0.56	6.18e-22	Platelet count;
KIRP	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Corneal astigmatism;
KIRP	cis	rs911119	0.866	rs4815223	chr20:23577112	C/A	cg16589663	chr20:23618590	CST3	0.49	4.96	0.3	1.3e-6	Chronic kidney disease;
KIRP	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.84	-13.04	-0.64	6.83e-30	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-7.23	-0.42	6e-12	Corneal structure;
KIRP	cis	rs72827839	0.793	rs72823527	chr17:46098810	G/T	cg03171361	chr17:47075758	IGF2BP1	-0.49	-4.95	-0.3	1.38e-6	Ease of getting up in the morning;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21108767	chr7:99933721	PILRB;PMS2L1	1.0	6.55	0.39	3.28e-10	P wave terminal force;
KIRP	cis	rs11825064	0.832	rs74442558	chr11:134482794	G/A	cg06603561	chr11:134479413	NA	-0.64	-5.15	-0.31	5.36e-7	Seasonality;
KIRP	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg08822215	chr16:89438651	ANKRD11	-0.52	-6.86	-0.4	5.63e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs17253792	0.598	rs12880362	chr14:56017929	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.74	-9.9	-0.53	1.15e-19	Sudden cardiac arrest;
KIRP	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg05669848	chr5:237993	SDHA	-0.51	-5.32	-0.32	2.39e-7	Breast cancer;
KIRP	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16524936	chr4:1340807	KIAA1530	-0.46	-5.85	-0.35	1.57e-8	Longevity;
KIRP	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.74	11.32	0.59	3.53e-24	Type 2 diabetes;
KIRP	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	11.85	0.6	6.25e-26	Menarche (age at onset);
KIRP	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.48	0.33	1.06e-7	Breast cancer;
KIRP	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08822215	chr16:89438651	ANKRD11	0.61	8.28	0.47	7.7e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23630158	chr17:74722648	C17orf95;JMJD6	0.45	6.15	0.37	3.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.1	-0.41	1.3e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7258015	1.000	rs3176767	chr19:10449751	A/C	cg25279553	chr19:10444815	RAVER1;ICAM3	0.47	6.26	0.37	1.67e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs2150410	0.915	rs9978953	chr21:40664399	G/T	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs17023223	0.537	rs12092807	chr1:119750644	A/G	cg05756136	chr1:119680316	WARS2	0.49	5.72	0.34	3.04e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06157335	chr1:53164003	C1orf163	0.56	6.53	0.38	3.82e-10	Smoking initiation;
KIRP	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18876405	chr7:65276391	NA	0.41	5.01	0.3	1.05e-6	Aortic root size;
KIRP	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.48	-5.72	-0.34	3.08e-8	P wave terminal force;
KIRP	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg04166393	chr7:2884313	GNA12	0.65	7.84	0.45	1.33e-13	Height;
KIRP	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg24060327	chr5:131705240	SLC22A5	0.45	5.44	0.33	1.3e-7	Blood metabolite levels;
KIRP	trans	rs9970896	0.579	rs2385029	chr1:236044714	C/T	cg02281038	chr19:14139137	RLN3	-0.66	-6.21	-0.37	2.3e-9	Monocyte percentage of white cells;
KIRP	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05220968	chr6:146057943	EPM2A	-0.42	-5.24	-0.32	3.5e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	12.87	0.63	2.61e-29	Exhaled nitric oxide output;
KIRP	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg00684032	chr4:1343700	KIAA1530	0.45	5.79	0.35	2.15e-8	Longevity;
KIRP	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.77	0.4	9.57e-11	Electroencephalogram traits;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	6.18	0.37	2.67e-9	Bipolar disorder;
KIRP	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.53	6.84	0.4	6.2e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg15488143	chr7:128924101	AHCYL2	0.57	6.23	0.37	2.05e-9	White matter hyperintensity burden;
KIRP	cis	rs894344	0.650	rs11166592	chr8:135577008	A/C	cg09855544	chr8:135498122	ZFAT	0.38	4.93	0.3	1.49e-6	Systolic blood pressure;
KIRP	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.57	-6.9	-0.4	4.32e-11	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13561592	chr9:118916976	PAPPA	0.48	6.58	0.39	2.81e-10	Parkinson's disease;
KIRP	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.4	-4.89	-0.3	1.82e-6	Body mass index;
KIRP	cis	rs4849845	0.925	rs4849844	chr2:121013056	T/C	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.87	-10.36	-0.55	4.06e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs259842	0.612	rs966440	chr2:180703608	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.42	-5.63	-0.34	4.81e-8	Blood protein levels;
KIRP	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.5	5.36	0.32	1.95e-7	Smoking behavior;
KIRP	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg19468946	chr17:37922297	IKZF3	-0.48	-6.55	-0.39	3.34e-10	Self-reported allergy;
KIRP	cis	rs9309473	1.000	rs6546835	chr2:73664715	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.68	-0.34	3.85e-8	Metabolite levels;
KIRP	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06850241	chr22:41845214	NA	-0.41	-5.47	-0.33	1.11e-7	Vitiligo;
KIRP	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05220968	chr6:146057943	EPM2A	-0.36	-4.9	-0.3	1.72e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.06	0.54	3.68e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.74	-9.57	-0.52	1.24e-18	Breast size;
KIRP	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.86	-0.4	5.67e-11	Joint mobility (Beighton score);
KIRP	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.62	-0.34	5.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11834862	0.770	rs10444603	chr12:132694910	C/G	cg19601865	chr12:132687172	GALNT9	-0.46	-5.12	-0.31	6.26e-7	Anti-saccade response;
KIRP	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg19197139	chr17:4613644	ARRB2	0.75	7.8	0.45	1.72e-13	Lymphocyte counts;
KIRP	cis	rs8038465	0.874	rs3816661	chr15:74005600	C/T	cg15420318	chr15:73925796	NPTN	0.48	6.13	0.36	3.5e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.76	-10.23	-0.55	1.03e-20	Mosquito bite size;
KIRP	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs10517025	0.636	rs7660559	chr4:42431888	A/G	cg13587180	chr4:42403248	SHISA3	0.44	4.99	0.3	1.13e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.58	-7.87	-0.45	1.16e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs6539288	0.563	rs11113122	chr12:107211325	T/C	cg15890332	chr12:107067104	RFX4	0.36	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00290607	chr11:67383545	NA	0.35	4.89	0.3	1.82e-6	Mean corpuscular volume;
KIRP	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.75	-9.04	-0.5	4.77e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	7.63	0.44	5.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.79	-7.61	-0.44	5.71e-13	Opioid sensitivity;
KIRP	cis	rs7903847	0.642	rs11189191	chr10:99148796	T/C	cg20016023	chr10:99160130	RRP12	-0.44	-5.76	-0.34	2.55e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11342046	chr2:242641489	ING5	0.83	7.05	0.41	1.81e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs711830	0.587	rs10188827	chr2:177007664	C/T	cg13092806	chr2:177043255	NA	0.56	5.26	0.32	3.1e-7	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg21395723	chr22:39101663	GTPBP1	-0.43	-5.19	-0.31	4.33e-7	Menopause (age at onset);
KIRP	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-5.66	-0.34	4.23e-8	Colorectal cancer;
KIRP	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.6	7.91	0.45	8.51e-14	Tuberculosis;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08673532	chr16:87422913	FBXO31	0.56	6.48	0.38	4.84e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.52	-7.67	-0.44	4.11e-13	Daytime sleep phenotypes;
KIRP	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.58	-12.05	-0.61	1.34e-26	Diabetic kidney disease;
KIRP	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.79	-9.56	-0.52	1.26e-18	Body mass index;
KIRP	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.51	-7.28	-0.42	4.57e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg01843034	chr6:37503916	NA	-0.96	-15.54	-0.7	2.13e-38	Cognitive performance;
KIRP	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg07869135	chr8:123794843	ZHX2	-0.41	-5.01	-0.3	1.06e-6	Type 1 diabetes nephropathy;
KIRP	cis	rs7614311	0.681	rs57766205	chr3:63895303	G/C	cg22134162	chr3:63841271	THOC7	-0.42	-5.88	-0.35	1.35e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg13289132	chr10:30722225	MAP3K8	0.42	5.45	0.33	1.23e-7	Inflammatory bowel disease;
KIRP	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg00319359	chr11:70116639	PPFIA1	0.55	5.72	0.34	3.12e-8	Coronary artery disease;
KIRP	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg08738300	chr3:44038990	NA	0.67	9.39	0.51	4.36e-18	Coronary artery disease;
KIRP	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg05315796	chr3:52349193	DNAH1	0.33	4.98	0.3	1.22e-6	Body mass index;
KIRP	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg22676075	chr6:135203613	NA	0.51	7.28	0.42	4.47e-12	Red blood cell count;
KIRP	cis	rs427941	0.703	rs201456	chr7:101741059	C/G	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.27e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7582720	1.000	rs72932753	chr2:203670122	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.59e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg10818794	chr15:86012489	AKAP13	-0.53	-7.48	-0.43	1.29e-12	Coronary artery disease;
KIRP	cis	rs1538970	1.000	rs7417107	chr1:45831915	G/C	cg05343316	chr1:45956843	TESK2	0.63	7.27	0.42	4.91e-12	Platelet count;
KIRP	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.62	8.76	0.49	3.2e-16	Schizophrenia;
KIRP	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.33	0.37	1.17e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg14228332	chr4:119757509	SEC24D	0.79	4.86	0.3	2.08e-6	Cannabis dependence symptom count;
KIRP	cis	rs11877825	0.826	rs3748426	chr18:10581732	G/A	cg25239095	chr18:10589360	NA	0.41	4.88	0.3	1.87e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.92	14.13	0.67	1.36e-33	Selective IgA deficiency;
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs3105593	0.933	rs3098202	chr15:50838236	C/G	cg05456662	chr15:50716270	USP8	0.37	4.96	0.3	1.32e-6	QT interval;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00984694	chr16:58498151	NDRG4	-0.52	-6.23	-0.37	1.99e-9	Interleukin-4 levels;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg23962380	chr3:101443264	CEP97	-0.54	-6.7	-0.39	1.44e-10	Obesity-related traits;
KIRP	cis	rs2865126	0.818	rs2178100	chr18:10765352	A/G	cg21165219	chr18:10698044	FAM38B	-0.54	-5.17	-0.31	4.87e-7	Metabolite levels (5-HIAA/ MHPG Ratio);
KIRP	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4523957	0.583	rs7503141	chr17:2044645	T/C	cg16513277	chr17:2031491	SMG6	-0.86	-12.82	-0.63	3.79e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.84	-11.76	-0.6	1.26e-25	Total body bone mineral density;
KIRP	cis	rs68170813	0.917	rs13234124	chr7:107225043	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-6.19	-0.37	2.53e-9	Coronary artery disease;
KIRP	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg01988459	chr11:68622903	NA	-0.36	-5.0	-0.3	1.09e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.83	-10.75	-0.57	2.46e-22	Coronary artery disease;
KIRP	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.49	-5.71	-0.34	3.24e-8	Body mass index;
KIRP	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.83	12.52	0.62	3.78e-28	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04882341	chr4:170679129	C4orf27	0.45	6.02	0.36	6.32e-9	Parkinson's disease;
KIRP	cis	rs10924970	1.000	rs10157739	chr1:235354555	C/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.1	0.31	6.89e-7	Asthma;
KIRP	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.23	-0.42	6.19e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.59	-6.65	-0.39	1.84e-10	Blood pressure (smoking interaction);
KIRP	cis	rs7577696	0.606	rs212747	chr2:32414704	A/G	cg02381751	chr2:32503542	YIPF4	0.55	5.53	0.33	8.12e-8	Inflammatory biomarkers;
KIRP	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	12.1	0.61	9.23e-27	Smoking behavior;
KIRP	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.93	-13.17	-0.64	2.52e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.4	-6.79	-0.4	8.53e-11	Refractive error;
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.15	0.64	2.78e-30	Platelet count;
KIRP	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.63	-0.52	7.62e-19	Neuroticism;
KIRP	cis	rs9843304	0.529	rs4681512	chr3:149203441	C/T	cg08667024	chr3:149219783	TM4SF4	-0.41	-6.16	-0.37	2.96e-9	Gallstone disease;
KIRP	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.66	9.3	0.51	8.01e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.93	-12.63	-0.63	1.56e-28	Cognitive function;
KIRP	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg18367735	chr17:79674897	NA	0.74	7.38	0.43	2.48e-12	Dental caries;
KIRP	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4750440	0.736	rs4748070	chr10:14031388	G/A	cg27542038	chr10:14027202	FRMD4A	-0.47	-6.39	-0.38	8.26e-10	Adiponectin levels;
KIRP	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.34	-0.47	5.48e-15	Mood instability;
KIRP	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.56	7.64	0.44	4.95e-13	Colorectal cancer;
KIRP	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.34	-0.32	2.09e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.8	-8.47	-0.48	2.3e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.35	-5.07	-0.31	7.91e-7	Body mass index;
KIRP	cis	rs13315871	1.000	rs9850717	chr3:58351875	C/T	cg12435725	chr3:58293450	RPP14	-0.49	-5.33	-0.32	2.25e-7	Cholesterol, total;
KIRP	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs12096438	1.000	rs3856240	chr1:25892525	T/C	cg21452808	chr1:25900135	NA	0.39	6.33	0.37	1.15e-9	Platelet count;Mean platelet volume;
KIRP	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.51	-6.14	-0.36	3.23e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.53	7.18	0.42	8.16e-12	Kawasaki disease;
KIRP	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.63	-8.49	-0.48	2e-15	Pancreatic cancer;
KIRP	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.61	-7.45	-0.43	1.61e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.89	-13.26	-0.65	1.24e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs8079658	0.904	rs17622316	chr17:63776591	T/C	cg18091269	chr17:63822838	CCDC46	-0.52	-6.46	-0.38	5.71e-10	Post bronchodilator FEV1;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.76	11.52	0.59	7.59e-25	Menarche (age at onset);
KIRP	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg00491522	chr10:135256596	NA	0.51	5.54	0.33	7.9e-8	Systemic lupus erythematosus;
KIRP	cis	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg26585981	chr11:48327164	OR4S1	-0.44	-5.46	-0.33	1.16e-7	Height;
KIRP	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.83	8.77	0.49	2.92e-16	Systolic blood pressure;
KIRP	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg02023728	chr11:77925099	USP35	-0.3	-5.15	-0.31	5.3e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg13072238	chr3:49761600	GMPPB	-0.58	-5.38	-0.32	1.73e-7	Menarche (age at onset);
KIRP	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.71	5.88	0.35	1.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22168489	chr12:122356033	WDR66	0.6	8.86	0.49	1.6e-16	Mean corpuscular volume;
KIRP	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-0.67	-7.71	-0.44	3.12e-13	Initial pursuit acceleration;
KIRP	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Bipolar disorder;
KIRP	cis	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg03342759	chr3:160939853	NMD3	0.41	4.84	0.3	2.26e-6	Morning vs. evening chronotype;
KIRP	cis	rs13720	0.722	rs163795	chr20:57577505	C/G	cg23907860	chr20:57583709	CTSZ	-0.46	-5.23	-0.32	3.7e-7	Platelet distribution width;
KIRP	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg26752003	chr8:145688521	CYHR1	-0.68	-8.63	-0.48	7.99e-16	Age at first birth;
KIRP	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.94	9.62	0.52	8.63e-19	Methadone dose in opioid dependence;
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21171335	chr12:122356390	WDR66	0.64	8.62	0.48	8.2e-16	Mean corpuscular volume;
KIRP	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.77	-11.12	-0.58	1.49e-23	Hip circumference;
KIRP	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg27411982	chr8:10470053	RP1L1	0.42	5.2	0.31	4.21e-7	Retinal vascular caliber;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg01363902	chr12:121022439	NA	0.46	6.09	0.36	4.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg20003494	chr4:90757398	SNCA	-0.37	-4.87	-0.3	2.01e-6	Neuroticism;
KIRP	cis	rs9652601	0.959	rs12708715	chr16:11177824	C/T	cg04616529	chr16:11181986	CLEC16A	0.37	4.91	0.3	1.63e-6	Systemic lupus erythematosus;
KIRP	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg16524733	chr11:117070046	TAGLN	0.44	5.78	0.35	2.29e-8	Blood protein levels;
KIRP	cis	rs13343954	0.825	rs7254716	chr19:33532128	T/C	cg27124370	chr19:33622961	WDR88	0.61	6.66	0.39	1.75e-10	Colorectal cancer;
KIRP	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg16586182	chr3:47516702	SCAP	-0.73	-10.27	-0.55	8.22e-21	Colorectal cancer;
KIRP	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-7.76	-0.44	2.31e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2150410	0.915	rs8131263	chr21:40605218	C/T	cg11890956	chr21:40555474	PSMG1	0.76	5.61	0.34	5.32e-8	Temperament (bipolar disorder);
KIRP	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg13319975	chr6:146136371	FBXO30	0.48	6.73	0.39	1.2e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.84	-12.49	-0.62	4.66e-28	Strep throat;
KIRP	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg05784532	chr1:230284198	GALNT2	0.42	6.33	0.37	1.18e-9	Coronary artery disease;
KIRP	cis	rs7172677	1.000	rs7172677	chr15:75424593	G/T	cg14664628	chr15:75095509	CSK	0.45	5.01	0.3	1.04e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00855626	chr19:5690231	RPL36	0.45	6.3	0.37	1.39e-9	Survival in pancreatic cancer;
KIRP	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.81	-9.73	-0.53	3.97e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs10046574	0.561	rs9656457	chr7:135202254	T/A	cg27474649	chr7:135195673	CNOT4	0.56	5.28	0.32	2.82e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.59	8.76	0.49	3.33e-16	Blood metabolite levels;
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-7.91	-0.45	8.58e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg18882449	chr10:104885122	NT5C2	-0.51	-6.51	-0.38	4.12e-10	Arsenic metabolism;
KIRP	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs10875746	0.859	rs4760680	chr12:48466697	G/T	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg12384639	chr17:618140	VPS53	0.48	6.09	0.36	4.33e-9	Prostate cancer;
KIRP	cis	rs7615316	0.872	rs9879995	chr3:142307799	A/C	cg20824294	chr3:142316082	PLS1	0.24	5.39	0.32	1.66e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs10484885	0.757	rs12215741	chr6:90154845	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.68	-6.24	-0.37	1.9e-9	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.63	-10.24	-0.55	1.01e-20	Morning vs. evening chronotype;
KIRP	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg05082376	chr22:42548792	NA	0.44	5.53	0.33	8.12e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg26831259	chr4:1366826	KIAA1530	0.37	4.88	0.3	1.93e-6	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-1.1	-24.41	-0.84	1.18e-67	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11997175	1.000	rs6468200	chr8:33745191	A/T	ch.8.33884649F	chr8:33765107	NA	0.53	6.64	0.39	1.99e-10	Body mass index;
KIRP	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	8.4	0.47	3.71e-15	Personality dimensions;
KIRP	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg00343986	chr7:65444356	GUSB	-0.42	-4.96	-0.3	1.3e-6	Aortic root size;
KIRP	cis	rs2131877	0.555	rs4677818	chr3:194874624	A/G	cg13868855	chr3:194833887	C3orf21	-0.42	-4.91	-0.3	1.65e-6	Non-small cell lung cancer;
KIRP	cis	rs73200209	0.744	rs56869346	chr12:116514538	T/C	cg01776926	chr12:116560359	MED13L	-0.57	-6.29	-0.37	1.45e-9	Total body bone mineral density;
KIRP	cis	rs2441986	0.894	rs1031357	chr11:57954110	A/G	cg19752551	chr11:57585705	CTNND1	-0.42	-5.08	-0.31	7.29e-7	Systolic blood pressure;
KIRP	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg03474202	chr17:45855739	NA	-0.52	-8.27	-0.47	8.65e-15	IgG glycosylation;
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg16341495	chr8:142228727	SLC45A4	-0.39	-4.86	-0.3	2.14e-6	Immature fraction of reticulocytes;
KIRP	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs829661	0.843	rs829632	chr2:30733617	G/A	cg10949345	chr2:30726833	LCLAT1	0.96	12.64	0.63	1.52e-28	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.92	0.35	1.06e-8	Educational attainment;
KIRP	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg04362960	chr10:104952993	NT5C2	-0.44	-4.98	-0.3	1.2e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04213235	chr1:145826932	GPR89A	0.51	6.11	0.36	3.91e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg21231944	chr12:82153410	PPFIA2	0.39	5.31	0.32	2.45e-7	Resting heart rate;
KIRP	cis	rs7009516	0.819	rs11997686	chr8:24221608	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.29	-6.03	-0.36	5.99e-9	Hair greying;
KIRP	cis	rs7709377	0.570	rs10059455	chr5:115434739	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7937612	1.000	rs7924963	chr11:120233536	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.06	-0.41	1.67e-11	Intraocular pressure;
KIRP	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02187348	chr16:89574699	SPG7	0.38	4.89	0.3	1.8e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg11502198	chr6:26597334	ABT1	-0.48	-6.03	-0.36	5.93e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.07	0.41	1.55e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13361707	0.700	rs28540420	chr5:40687463	C/T	cg01087697	chr5:40835557	RPL37	-0.49	-5.41	-0.33	1.48e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg00701064	chr4:6280414	WFS1	0.35	7.01	0.41	2.32e-11	Cisplatin-induced ototoxicity;
KIRP	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.56	-7.01	-0.41	2.29e-11	Hip circumference;
KIRP	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.05	-19.07	-0.77	2.17e-50	Height;
KIRP	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.84	11.59	0.59	4.64e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12963246	chr6:28129442	ZNF389	0.48	5.91	0.35	1.15e-8	Depression;
KIRP	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	1.01	17.0	0.73	2.16e-43	Bone mineral density;
KIRP	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg07701084	chr6:150067640	NUP43	0.7	9.7	0.53	4.85e-19	Lung cancer;
KIRP	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg13165212	chr22:42675999	NA	0.41	7.03	0.41	2.02e-11	Cognitive function;
KIRP	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg16482183	chr6:26056742	HIST1H1C	0.42	5.37	0.32	1.84e-7	Schizophrenia;
KIRP	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.23	-0.37	2.04e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg13206674	chr6:150067644	NUP43	0.52	7.4	0.43	2.22e-12	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25873214	chr11:47587499	PTPMT1	0.51	6.11	0.36	3.84e-9	Parkinson's disease;
KIRP	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg08975724	chr8:8085496	FLJ10661	0.61	7.54	0.43	8.87e-13	Retinal vascular caliber;
KIRP	cis	rs1847505	0.609	rs7327556	chr13:61487578	C/A	cg25164009	chr13:61490935	NA	0.54	5.58	0.34	6.37e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs72960926	0.744	rs11752717	chr6:74954435	G/A	cg03266952	chr6:74778945	NA	-0.74	-5.3	-0.32	2.57e-7	Metabolite levels (MHPG);
KIRP	cis	rs2652822	1.000	rs1126309	chr15:63429062	A/G	cg02713581	chr15:63449717	RPS27L	0.62	7.25	0.42	5.34e-12	Metabolic traits;
KIRP	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.48	6.09	0.36	4.42e-9	Height;
KIRP	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg15103426	chr22:29168792	CCDC117	0.52	5.81	0.35	1.92e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.85	13.94	0.66	6.14e-33	Vitiligo;
KIRP	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.18e-11	Blood metabolite levels;
KIRP	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.13	-0.31	5.83e-7	Inflammatory skin disease;
KIRP	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg05340658	chr4:99064831	C4orf37	0.63	6.84	0.4	6.12e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.44	-6.49	-0.38	4.68e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-5.74	-0.34	2.74e-8	Response to antipsychotic treatment;
KIRP	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg02903104	chr8:1507517	DLGAP2	0.37	5.53	0.33	8.22e-8	Lung cancer;
KIRP	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.89	-12.91	-0.64	1.82e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg12598211	chr12:123634384	NA	-0.45	-5.44	-0.33	1.27e-7	Neutrophil percentage of white cells;
KIRP	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	1.04	9.28	0.51	9.24e-18	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05364211	chr1:213188787	ANGEL2	0.59	7.93	0.45	7.44e-14	Parkinson's disease;
KIRP	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17169566	chr4:150999923	DCLK2	0.46	6.11	0.36	3.84e-9	Parkinson's disease;
KIRP	cis	rs829661	0.947	rs829641	chr2:30700235	C/T	cg10949345	chr2:30726833	LCLAT1	0.73	10.36	0.55	4.19e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.66	-8.5	-0.48	1.9e-15	Motion sickness;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14845736	chr1:213189048	ANGEL2	0.42	6.15	0.37	3.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg15655495	chr12:38532458	NA	-0.3	-5.16	-0.31	5.06e-7	Bladder cancer;
KIRP	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg04865290	chr3:52927548	TMEM110	0.6	7.27	0.42	4.82e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-15.85	-0.71	1.85e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg25482853	chr8:67687455	SGK3	0.84	7.1	0.41	1.37e-11	Obesity-related traits;
KIRP	cis	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg04607699	chr11:48328132	OR4S1	-0.36	-5.12	-0.31	6.12e-7	HDL cholesterol;
KIRP	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.71	-0.34	3.17e-8	Type 2 diabetes;
KIRP	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg16482183	chr6:26056742	HIST1H1C	0.46	5.18	0.31	4.73e-7	Iron status biomarkers;
KIRP	cis	rs13161895	1.000	rs12656814	chr5:179471556	G/A	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.97	-0.45	6.11e-14	Coffee consumption (cups per day);
KIRP	cis	rs8038465	0.624	rs2127015	chr15:73985223	T/C	cg15420318	chr15:73925796	NPTN	0.49	6.21	0.37	2.19e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs16958440	1.000	rs62096463	chr18:44628928	A/G	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.69	-10.74	-0.57	2.56e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs12752838	0.777	rs10864368	chr1:8918313	A/G	cg06972019	chr1:8937448	ENO1	-0.34	-4.96	-0.3	1.33e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	trans	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg05926928	chr17:57297772	GDPD1	0.63	6.13	0.36	3.39e-9	Opioid sensitivity;
KIRP	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	1.11	9.26	0.51	1.04e-17	Corneal curvature;
KIRP	cis	rs12200782	1.000	rs12211201	chr6:26461461	A/G	cg11502198	chr6:26597334	ABT1	-0.78	-5.36	-0.32	1.87e-7	Small cell lung carcinoma;
KIRP	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.93	0.3	1.5e-6	Menopause (age at onset);
KIRP	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg22705602	chr4:152727874	NA	-0.55	-9.7	-0.53	4.68e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10426930	0.607	rs2613755	chr19:5059941	A/G	cg18473234	chr19:5097819	KDM4B	-0.45	-5.17	-0.31	4.89e-7	Monocyte percentage of white cells;
KIRP	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2904967	1.000	rs487989	chr11:65064690	G/A	cg12562828	chr11:65076843	NA	0.62	9.18	0.51	1.87e-17	Mean corpuscular volume;
KIRP	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.7	-0.39	1.42e-10	Obesity-related traits;
KIRP	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.49	6.35	0.38	1.01e-9	Recombination rate (males);
KIRP	cis	rs1215050	0.740	rs11097580	chr4:98767255	C/A	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.77	-8.56	-0.48	1.22e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.36	5.33	0.32	2.22e-7	Lymphocyte counts;
KIRP	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16524936	chr4:1340807	KIAA1530	-0.47	-5.95	-0.35	9.36e-9	Longevity;
KIRP	cis	rs2273669	0.667	rs7759680	chr6:109310649	C/T	cg05315195	chr6:109294784	ARMC2	-0.48	-5.48	-0.33	1.06e-7	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs7224685	0.515	rs7207986	chr17:3979949	G/A	cg09695851	chr17:3907499	NA	0.6	5.78	0.35	2.23e-8	Type 2 diabetes;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22081084	chr1:89990230	LRRC8B	0.55	7.3	0.42	3.97e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg19773385	chr1:10388646	KIF1B	-0.72	-11.24	-0.58	6.24e-24	Hepatocellular carcinoma;
KIRP	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg26681399	chr22:41777847	TEF	-0.49	-5.12	-0.31	6.14e-7	Vitiligo;
KIRP	cis	rs7635838	0.859	rs34621655	chr3:11530121	T/C	cg00170343	chr3:11313890	ATG7	0.48	5.98	0.36	7.65e-9	HDL cholesterol;
KIRP	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg27490568	chr2:178487706	NA	0.45	5.85	0.35	1.56e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-6.59	-0.39	2.61e-10	Morning vs. evening chronotype;
KIRP	cis	rs77688320	0.553	rs7582946	chr2:202288692	C/T	cg06431681	chr2:202330990	STRADB	0.47	5.46	0.33	1.18e-7	Breast cancer;
KIRP	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg00800038	chr16:89945340	TCF25	-0.6	-5.33	-0.32	2.23e-7	Skin colour saturation;
KIRP	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.58	6.8	0.4	7.67e-11	Educational attainment;
KIRP	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.58	7.99	0.45	5.14e-14	Height;
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.69	10.96	0.57	4.9e-23	Lung cancer;
KIRP	cis	rs7202877	0.706	rs1540	chr16:75481185	G/C	cg03315344	chr16:75512273	CHST6	-0.59	-5.3	-0.32	2.56e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs42648	0.564	rs7777282	chr7:89822305	A/G	cg25739043	chr7:89950458	NA	-0.37	-5.87	-0.35	1.42e-8	Homocysteine levels;
KIRP	cis	rs8084125	0.832	rs62105166	chr18:74944518	A/G	cg15443732	chr18:74961078	GALR1	0.51	4.91	0.3	1.65e-6	Obesity-related traits;
KIRP	trans	rs9561428	1.000	rs76257876	chr13:94415066	C/T	cg26695444	chr10:42970351	LOC84856	-0.81	-6.25	-0.37	1.81e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9859260	0.961	rs9846149	chr3:195787308	C/G	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.54	8.78	0.49	2.75e-16	Testicular germ cell tumor;
KIRP	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg00343986	chr7:65444356	GUSB	-0.44	-5.28	-0.32	2.82e-7	Aortic root size;
KIRP	cis	rs9304742	0.962	rs12459008	chr19:53454789	A/T	cg24044776	chr19:53454761	ZNF816A	0.48	7.12	0.41	1.22e-11	Psoriasis;
KIRP	cis	rs7078219	0.965	rs7081858	chr10:101274565	G/A	cg07044859	chr10:101282883	NA	-0.33	-5.62	-0.34	5.15e-8	Dental caries;
KIRP	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg14689365	chr7:158441557	NCAPG2	0.41	5.13	0.31	5.83e-7	Height;
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.77	11.67	0.6	2.47e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg14675211	chr2:100938903	LONRF2	0.54	7.32	0.42	3.58e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22085380	chr3:120174428	NA	-0.43	-6.04	-0.36	5.76e-9	Inflammatory biomarkers;
KIRP	trans	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs35607894	0.500	rs73293246	chr14:72462263	G/A	cg09954251	chr8:1278972	NA	0.54	6.09	0.36	4.24e-9	Schizophrenia;
KIRP	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.25	17.47	0.74	5.64e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg00666640	chr1:248458726	OR2T12	0.46	5.52	0.33	8.71e-8	Common traits (Other);
KIRP	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.95	-0.41	3.29e-11	Morning vs. evening chronotype;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06056004	chr5:44809616	MRPS30	0.64	6.09	0.36	4.37e-9	Lung function (FEV1);
KIRP	cis	rs6142102	0.602	rs10485503	chr20:32557842	A/G	cg08999081	chr20:33150536	PIGU	0.38	4.88	0.3	1.88e-6	Skin pigmentation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23093116	chr1:117489843	PTGFRN	0.51	7.59	0.44	6.43e-13	Survival in pancreatic cancer;
KIRP	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.4	-5.84	-0.35	1.63e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg05272587	chr13:111038400	COL4A2	0.4	6.24	0.37	1.86e-9	White matter hyperintensity burden;
KIRP	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg02336718	chr17:17403227	NA	-0.33	-5.31	-0.32	2.45e-7	Total body bone mineral density;
KIRP	cis	rs6882076	1.000	rs6874202	chr5:156391628	T/C	cg12943317	chr5:156479607	HAVCR1	-0.6	-7.45	-0.43	1.54e-12	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.56	-5.98	-0.36	7.86e-9	Body mass index;
KIRP	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg05805236	chr11:65401703	PCNXL3	0.54	7.53	0.43	9.49e-13	Systemic lupus erythematosus;
KIRP	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg02160872	chr5:212506	CCDC127	-0.46	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg15507776	chr3:136538369	TMEM22	0.39	5.39	0.33	1.65e-7	Neuroticism;
KIRP	cis	rs6088813	0.925	rs1540928	chr20:33961845	C/A	cg14752227	chr20:34000481	UQCC	-0.52	-6.88	-0.4	4.97e-11	Height;
KIRP	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.74	9.84	0.53	1.79e-19	Crohn's disease;
KIRP	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg21775007	chr8:11205619	TDH	-0.48	-6.08	-0.36	4.44e-9	Systolic blood pressure;
KIRP	cis	rs7408868	0.611	rs11669982	chr19:15292366	C/T	cg14696996	chr19:15285081	NOTCH3	0.61	6.59	0.39	2.63e-10	Pulse pressure;
KIRP	cis	rs4631830	0.965	rs4306255	chr10:51542444	A/G	cg10326726	chr10:51549505	MSMB	-0.59	-8.57	-0.48	1.15e-15	Prostate-specific antigen levels;
KIRP	cis	rs9653442	0.564	rs13013594	chr2:100784190	A/G	cg17356467	chr2:100759845	AFF3	0.44	5.63	0.34	4.78e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.48	-0.33	1.04e-7	Life satisfaction;
KIRP	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.2	13.91	0.66	7.79e-33	Sexual dysfunction (female);
KIRP	cis	rs504918	0.506	rs73188196	chr3:124028519	A/T	cg05766129	chr3:123988013	KALRN	-0.45	-5.74	-0.34	2.85e-8	Schizophrenia;
KIRP	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg05342945	chr12:48394962	COL2A1	-0.45	-4.97	-0.3	1.28e-6	Lung cancer;
KIRP	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg08662619	chr6:150070041	PCMT1	0.36	5.76	0.34	2.55e-8	Lung cancer;
KIRP	cis	rs600806	0.778	rs12145677	chr1:110023610	G/A	cg02175308	chr1:109941060	SORT1	0.31	5.85	0.35	1.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.42	-5.47	-0.33	1.09e-7	Breast cancer;
KIRP	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.26	0.37	1.74e-9	Joint mobility (Beighton score);
KIRP	cis	rs12496230	0.794	rs12635603	chr3:66858921	C/T	cg17646820	chr3:66848679	NA	0.4	6.55	0.39	3.37e-10	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09994117	chr8:75231860	JPH1	0.42	6.04	0.36	5.6e-9	Survival in pancreatic cancer;
KIRP	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.43	0.47	2.96e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6960043	0.818	rs1974619	chr7:15065300	C/T	cg19272540	chr7:15055459	NA	-0.24	-7.06	-0.41	1.7e-11	Type 2 diabetes;
KIRP	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.27	-0.32	3.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00261534	chr10:3826854	KLF6	0.55	7.22	0.42	6.44e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.55	-7.1	-0.41	1.3e-11	Hip circumference adjusted for BMI;
KIRP	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg18944383	chr4:111397179	ENPEP	0.51	8.32	0.47	6.11e-15	Coronary artery disease;
KIRP	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.14	9.53	0.52	1.59e-18	Cognitive function;
KIRP	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2120243	0.539	rs1563420	chr3:157119326	A/G	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs7999699	0.869	rs56693380	chr13:48323475	T/C	cg23237801	chr1:16476620	EPHA2	0.54	6.76	0.4	1e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-10.12	-0.54	2.38e-20	Heart rate;
KIRP	cis	rs981844	0.712	rs4292309	chr4:154745178	C/A	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.09	7.8	0.45	1.81e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.74	-0.49	3.58e-16	Mean corpuscular volume;
KIRP	cis	rs4664293	0.632	rs7588230	chr2:160653720	C/T	cg08347373	chr2:160653686	CD302	0.38	5.97	0.36	8.06e-9	Monocyte percentage of white cells;
KIRP	cis	rs9393813	0.901	rs12529756	chr6:27471448	C/T	cg18711553	chr6:27366782	ZNF391	-0.42	-6.26	-0.37	1.71e-9	Bipolar disorder;
KIRP	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.43	-0.52	3.15e-18	Mood instability;
KIRP	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.39	8.21	0.46	1.23e-14	Body mass index;
KIRP	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg18404041	chr3:52824283	ITIH1	-0.42	-4.89	-0.3	1.83e-6	Schizophrenia;
KIRP	cis	rs42648	0.869	rs10234301	chr7:89918278	T/C	cg25739043	chr7:89950458	NA	-0.44	-6.81	-0.4	7.49e-11	Homocysteine levels;
KIRP	cis	rs741677	0.963	rs441821	chr17:474394	A/G	cg06217071	chr17:408420	NA	0.51	7.42	0.43	1.94e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12580194	0.593	rs55659159	chr12:55747754	C/T	cg11794356	chr12:55725991	OR6C3	-0.6	-8.62	-0.48	8.4e-16	Cancer;
KIRP	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg27624424	chr6:160112604	SOD2	0.47	4.92	0.3	1.56e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-8.84	-0.49	1.86e-16	Hemoglobin concentration;
KIRP	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.38	12.45	0.62	6.49e-28	Alzheimer's disease (late onset);
KIRP	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg26677194	chr12:130822605	PIWIL1	-0.43	-5.53	-0.33	8.36e-8	Menopause (age at onset);
KIRP	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.78	-9.88	-0.53	1.34e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.39	-0.32	1.67e-7	Aortic root size;
KIRP	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.46	5.29	0.32	2.73e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.67	-0.44	4.02e-13	Height;
KIRP	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg26513180	chr16:89883248	FANCA	0.74	5.19	0.31	4.34e-7	Skin colour saturation;
KIRP	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.78	0.4	8.86e-11	Mean corpuscular volume;
KIRP	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg05044414	chr3:183734942	ABCC5	0.38	5.75	0.34	2.62e-8	Anterior chamber depth;
KIRP	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg08603382	chr10:743973	NA	0.48	7.01	0.41	2.3e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.46	6.21	0.37	2.27e-9	Coronary artery disease;
KIRP	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg02012338	chr4:187126139	CYP4V2	0.59	5.35	0.32	2.03e-7	Blood protein levels;
KIRP	cis	rs7542091	0.704	rs2142907	chr1:210039505	T/C	cg05527609	chr1:210001259	C1orf107	-0.37	-4.92	-0.3	1.57e-6	Monobrow;
KIRP	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	13.89	0.66	8.76e-33	IgG glycosylation;
KIRP	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.89	13.27	0.65	1.15e-30	Mean platelet volume;
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg24874828	chr4:187887005	NA	-0.49	-7.3	-0.42	3.94e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17065868	1.000	rs67898828	chr13:45129347	T/C	cg10246903	chr13:45222710	NA	0.69	6.47	0.38	5.38e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4690686	0.538	rs10520346	chr4:177259088	C/G	cg17059388	chr4:177262070	NA	0.81	10.69	0.56	3.71e-22	Essential tremor;
KIRP	cis	rs12580194	0.556	rs73119000	chr12:55736662	G/A	cg11794356	chr12:55725991	OR6C3	-0.61	-8.76	-0.49	3.28e-16	Cancer;
KIRP	cis	rs4560672	0.938	rs1358940	chr6:158526581	C/T	cg14029994	chr6:158589857	SERAC1;GTF2H5	0.52	4.98	0.3	1.2e-6	Smoking quantity;
KIRP	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg10117171	chr1:25599238	RHD	-0.4	-5.25	-0.32	3.22e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg26875233	chr11:93583750	C11orf90	-0.42	-7.77	-0.44	2.14e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	17.57	0.75	2.51e-45	Homoarginine levels;
KIRP	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg10790698	chr19:18539756	SSBP4	-0.33	-7.1	-0.41	1.35e-11	Breast cancer;
KIRP	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.6	-7.54	-0.43	8.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27566521	chr1:9970633	CTNNBIP1	0.49	6.51	0.38	4.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-8.6	-0.48	9.47e-16	Colorectal cancer;
KIRP	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg10253484	chr15:75165896	SCAMP2	0.52	5.57	0.33	6.54e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	9.28	0.51	9.25e-18	Hemoglobin concentration;
KIRP	cis	rs9921338	0.961	rs12934968	chr16:11414066	C/A	cg00044050	chr16:11439710	C16orf75	0.44	4.85	0.3	2.23e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg14011486	chr1:26737247	LIN28	-0.68	-7.4	-0.43	2.11e-12	Atrial fibrillation;
KIRP	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05601917	chr6:125855416	NA	-0.36	-5.33	-0.32	2.24e-7	Brugada syndrome;
KIRP	cis	rs7503807	0.688	rs901060	chr17:78594990	G/A	cg09596252	chr17:78655493	RPTOR	0.52	5.87	0.35	1.43e-8	Obesity;
KIRP	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg26876637	chr1:152193138	HRNR	-0.87	-8.57	-0.48	1.13e-15	Atopic dermatitis;
KIRP	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg08923054	chr8:41654455	ANK1	0.66	7.88	0.45	1.03e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.59	7.75	0.44	2.45e-13	Pulse pressure;
KIRP	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.29e-16	Prudent dietary pattern;
KIRP	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.97	12.65	0.63	1.34e-28	Menopause (age at onset);
KIRP	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg21064579	chr19:49206444	FUT2	0.59	8.87	0.49	1.56e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs897080	0.515	rs1067402	chr2:44676226	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.57	-5.77	-0.35	2.33e-8	Height;
KIRP	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg05315796	chr3:52349193	DNAH1	0.45	6.95	0.41	3.3e-11	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23487303	chr19:59086729	MGC2752	0.51	6.44	0.38	6.14e-10	Parkinson's disease;
KIRP	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg23531748	chr20:60969906	CABLES2	0.39	5.46	0.33	1.16e-7	Colorectal cancer;
KIRP	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.52	-5.72	-0.34	3.09e-8	DNA methylation (variation);
KIRP	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21643547	chr1:205240462	TMCC2	-0.7	-10.58	-0.56	8.5e-22	Red blood cell count;
KIRP	cis	rs501120	0.584	rs11517251	chr10:44724052	A/G	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.9	-10.55	-0.56	1.07e-21	White matter hyperintensity burden;
KIRP	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	1.19	12.9	0.64	2.02e-29	Monocyte percentage of white cells;
KIRP	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg05255149	chr17:80675120	FN3KRP	0.49	5.3	0.32	2.54e-7	Glycated hemoglobin levels;
KIRP	cis	rs2224391	0.704	rs17139985	chr6:5261603	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.94	-0.4	3.55e-11	Height;
KIRP	cis	rs8103278	1.000	rs62109854	chr19:46350375	A/C	cg11657440	chr19:46296263	DMWD	-0.71	-9.05	-0.5	4.43e-17	Coronary artery disease;
KIRP	trans	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17183009	chr3:120277827	NA	0.54	6.44	0.38	6.37e-10	Corneal astigmatism;
KIRP	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.48	6.27	0.37	1.63e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.64	-7.55	-0.43	8.65e-13	Menopause (age at onset);
KIRP	cis	rs9420	0.754	rs631791	chr11:57675410	A/G	cg19752551	chr11:57585705	CTNND1	0.66	8.72	0.49	4.11e-16	Schizophrenia;
KIRP	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.37	7.09	0.41	1.46e-11	Educational attainment (years of education);
KIRP	cis	rs10995505	0.589	rs4601646	chr10:64880280	G/A	cg25356468	chr10:64875536	NA	-0.43	-5.01	-0.3	1.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.54	6.31	0.37	1.28e-9	Aortic root size;
KIRP	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg19847130	chr8:10466454	RP1L1	0.35	5.25	0.32	3.23e-7	Retinal vascular caliber;
KIRP	cis	rs9399401	0.677	rs6925979	chr6:142651052	G/A	cg03128060	chr6:142623767	GPR126	0.36	5.08	0.31	7.58e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.11e-7	Breast cancer;
KIRP	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.57	6.57	0.39	2.98e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.58	7.83	0.45	1.47e-13	Total body bone mineral density;
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.65	-8.24	-0.47	1e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs6882046	0.513	rs34316	chr5:88015545	A/C	cg24804195	chr5:87968844	LOC645323	-0.47	-6.11	-0.36	3.88e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs7870753	0.782	rs10991346	chr9:99247758	C/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs1062177	0.756	rs2915815	chr5:151115883	G/C	cg00977110	chr5:151150581	G3BP1	-0.6	-6.08	-0.36	4.65e-9	Preschool internalizing problems;
KIRP	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg24253500	chr15:84953950	NA	0.64	6.84	0.4	6.22e-11	Schizophrenia;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21871465	chr11:3013656	NAP1L4	0.44	6.12	0.36	3.62e-9	Cancer;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Blood metabolite levels;
KIRP	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.58	7.45	0.43	1.62e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	1.32	9.84	0.53	1.73e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	5.66	0.34	4.13e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.79	13.5	0.65	1.89e-31	Height;
KIRP	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg10189774	chr4:17578691	LAP3	0.48	5.75	0.34	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs74233809	0.901	rs3824754	chr10:104614350	C/T	cg26256223	chr8:145106582	OPLAH	-0.5	-6.06	-0.36	5.1e-9	Birth weight;
KIRP	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg05457628	chr5:178986728	RUFY1	0.52	7.77	0.44	2.06e-13	Lung cancer;
KIRP	cis	rs929596	0.564	rs2741024	chr2:234517745	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.69	-0.34	3.62e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.48	7.58	0.44	6.83e-13	Lymphocyte counts;
KIRP	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-5.7	-0.34	3.41e-8	Blood metabolite levels;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.88	-0.45	1.09e-13	Myopia (pathological);
KIRP	cis	rs2802372	0.620	rs1250538	chr10:81037800	G/T	cg18688392	chr10:81059414	ZMIZ1	-0.42	-5.45	-0.33	1.22e-7	Granulocyte count;
KIRP	cis	rs5995756	0.736	rs5995755	chr22:39999013	A/G	cg10455938	chr22:40058150	CACNA1I	-0.54	-7.91	-0.45	8.92e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg21573476	chr21:45109991	RRP1B	-0.63	-8.54	-0.48	1.41e-15	Mean corpuscular volume;
KIRP	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.83	11.37	0.59	2.33e-24	Morning vs. evening chronotype;
KIRP	cis	rs882732	1.000	rs10147337	chr14:95025560	A/T	cg05186455	chr14:95027692	SERPINA4	-0.4	-5.29	-0.32	2.72e-7	Blood protein levels;
KIRP	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-12.08	-0.61	1.11e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs11605924	0.819	rs12805422	chr11:45839889	G/A	cg23097878	chr11:45879730	CRY2	0.3	6.08	0.36	4.67e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	1.14	15.59	0.7	1.36e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.53	0.33	8.19e-8	Life satisfaction;
KIRP	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg09408571	chr1:101003634	GPR88	-0.22	-5.02	-0.3	1e-6	Monocyte count;
KIRP	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs8018808	0.905	rs7142380	chr14:77931231	T/C	cg20045696	chr14:77926864	AHSA1	0.46	5.47	0.33	1.08e-7	Myeloid white cell count;
KIRP	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.07	8.1	0.46	2.49e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23279887	chr19:19249481	TMEM161A	0.48	6.73	0.39	1.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.84	11.99	0.61	2.24e-26	Total body bone mineral density;
KIRP	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Life satisfaction;
KIRP	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.16	0.46	1.73e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg02297831	chr4:17616191	MED28	0.6	7.53	0.43	9.62e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-0.99	-11.75	-0.6	1.3e-25	Breast cancer;
KIRP	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.58	6.74	0.39	1.13e-10	Schizophrenia;
KIRP	cis	rs2120243	0.539	rs1585080	chr3:157106982	A/G	cg24825693	chr3:157122686	VEPH1	-0.57	-8.98	-0.5	7.36e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs28655083	0.826	rs2134335	chr16:77079272	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.62	-5.48	-0.33	1.03e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.76	10.44	0.55	2.32e-21	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-0.96	-11.67	-0.6	2.43e-25	Vitiligo;
KIRP	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.7	-8.4	-0.47	3.48e-15	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2119480	0.559	rs381835	chr13:111300957	A/T	cg24331049	chr13:111365604	ING1	-0.47	-5.51	-0.33	9.14e-8	Diastolic blood pressure;
KIRP	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg19850565	chr19:35168394	ZNF302	0.45	6.02	0.36	6.42e-9	Lung adenocarcinoma;
KIRP	cis	rs11910985	0.546	rs113970410	chr21:48080896	C/G	cg23283320	chr21:48055893	PRMT2	1.45	9.12	0.5	2.82e-17	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.54	13.6	0.66	8.49e-32	Airflow obstruction;
KIRP	cis	rs7945071	0.507	rs11213397	chr11:110296813	A/G	cg04157658	chr11:110243994	NA	0.31	4.85	0.3	2.24e-6	Cognitive function;
KIRP	cis	rs7119167	0.686	rs1894076	chr11:73035296	C/T	cg17517138	chr11:73019481	ARHGEF17	0.46	4.89	0.3	1.84e-6	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17187705	chr13:35735300	NBEA	0.49	7.1	0.41	1.32e-11	Survival in pancreatic cancer;
KIRP	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.0	-0.3	1.09e-6	Cervical cancer;
KIRP	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03651054	chr13:50194643	NA	0.74	11.43	0.59	1.46e-24	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg04374321	chr14:90722782	PSMC1	-0.88	-12.8	-0.63	4.43e-29	Mortality in heart failure;
KIRP	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg09788416	chr12:39539408	NA	0.43	5.25	0.32	3.22e-7	Morning vs. evening chronotype;
KIRP	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg02487422	chr3:49467188	NICN1	0.35	5.0	0.3	1.08e-6	Parkinson's disease;
KIRP	cis	rs240764	0.817	rs239246	chr6:101089134	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs74181299	0.620	rs6546123	chr2:65303582	T/C	cg05010058	chr2:65284262	CEP68	-0.45	-6.36	-0.38	9.56e-10	Pulse pressure;
KIRP	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.96	-0.3	1.33e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.71	-10.12	-0.54	2.34e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg01422370	chr2:73384389	NA	0.43	5.58	0.34	6.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3105593	1.000	rs28718130	chr15:50909489	G/A	cg08437265	chr15:50716283	USP8	0.39	4.93	0.3	1.48e-6	QT interval;
KIRP	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.76	8.13	0.46	2.11e-14	Uric acid levels;
KIRP	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg03959625	chr15:84868606	LOC388152	0.69	8.46	0.47	2.38e-15	Schizophrenia;
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg22105103	chr4:187893119	NA	0.72	10.44	0.55	2.4e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg11845111	chr2:191398756	TMEM194B	-0.77	-8.39	-0.47	3.8e-15	Diastolic blood pressure;
KIRP	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	6.86	0.4	5.5e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg11845111	chr2:191398756	TMEM194B	-0.93	-10.11	-0.54	2.59e-20	Diastolic blood pressure;
KIRP	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.25	-0.37	1.81e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9962915	0.935	rs1719985	chr18:5598554	A/G	cg12967001	chr18:5544089	EPB41L3	0.41	5.06	0.31	8.02e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs228437	1.000	rs6928242	chr6:134936389	T/G	cg24504307	chr6:134963096	NA	-0.54	-7.79	-0.45	1.82e-13	Melanoma;
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg15147215	chr3:52552868	STAB1	-0.28	-5.04	-0.31	8.86e-7	Bipolar disorder;
KIRP	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.67	-12.52	-0.62	3.81e-28	White blood cell count (basophil);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14026747	chr4:135865398	NA	-0.4	-6.55	-0.39	3.41e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.44	-5.69	-0.34	3.65e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs981844	0.775	rs10517580	chr4:154744128	T/G	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg05784532	chr1:230284198	GALNT2	-0.43	-5.84	-0.35	1.68e-8	Coronary artery disease;
KIRP	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-5.71	-0.34	3.24e-8	Crohn's disease;
KIRP	cis	rs4262150	0.508	rs55696164	chr5:151890623	G/A	cg12297329	chr5:152029980	NA	-0.74	-9.14	-0.5	2.48e-17	Bipolar disorder and schizophrenia;
KIRP	cis	rs7937612	0.897	rs11217821	chr11:120202099	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.12	-0.41	1.17e-11	Intraocular pressure;
KIRP	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.85	0.35	1.54e-8	Tonsillectomy;
KIRP	cis	rs6696846	0.936	rs12134724	chr1:205039288	T/C	cg21643547	chr1:205240462	TMCC2	-0.61	-8.63	-0.48	7.68e-16	Red blood cell count;
KIRP	cis	rs9311676	0.656	rs6445977	chr3:58379560	T/C	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs78579285	0.584	rs9930994	chr16:88800693	C/T	cg09054528	chr16:88821542	FAM38A	-0.65	-5.38	-0.32	1.77e-7	Joint mobility (Beighton score);
KIRP	cis	rs3736594	0.513	rs2384627	chr2:27774449	G/A	cg27432699	chr2:27873401	GPN1	0.58	6.35	0.38	1.06e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs3007168	1.000	rs3007076	chr14:51605352	G/T	cg23942311	chr14:51606299	NA	0.53	5.54	0.33	7.84e-8	Cancer;
KIRP	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg21252483	chr19:49399788	TULP2	-0.3	-5.4	-0.33	1.58e-7	Red cell distribution width;
KIRP	cis	rs7534824	0.625	rs6686202	chr1:101493078	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.51	0.33	9.04e-8	Refractive astigmatism;
KIRP	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	7.05	0.41	1.79e-11	Menarche (age at onset);
KIRP	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg23950597	chr19:37808831	NA	-0.63	-6.75	-0.4	1.07e-10	Coronary artery calcification;
KIRP	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-5.71	-0.34	3.23e-8	Asthma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12828867	chr5:61708427	IPO11	0.54	6.25	0.37	1.83e-9	Smoking initiation;
KIRP	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	4.1e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg18882449	chr10:104885122	NT5C2	-0.49	-6.35	-0.38	1.01e-9	Arsenic metabolism;
KIRP	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg01304814	chr3:48885189	PRKAR2A	0.56	5.16	0.31	4.98e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.58	-6.98	-0.41	2.74e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.14	-0.31	5.56e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs7011507	0.891	rs111975935	chr8:49136167	T/G	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.75	9.89	0.53	1.27e-19	Morning vs. evening chronotype;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11032070	chr20:31172387	NA	0.68	6.33	0.37	1.18e-9	Lung function (FEV1);
KIRP	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg13482628	chr17:19912719	NA	0.53	6.85	0.4	5.99e-11	Schizophrenia;
KIRP	cis	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.44	-5.55	-0.33	7.53e-8	Leprosy;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg24874828	chr4:187887005	NA	-0.47	-7.01	-0.41	2.33e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.88	11.36	0.59	2.57e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.64	-6.33	-0.37	1.16e-9	Body mass index;
KIRP	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-7.65	-0.44	4.56e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.86	-10.98	-0.57	4.48e-23	Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs11718455	0.585	rs1491708	chr3:43911578	C/T	cg08738300	chr3:44038990	NA	0.56	7.28	0.42	4.37e-12	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg23594656	chr7:65796392	TPST1	-0.49	-7.41	-0.43	2e-12	Aortic root size;
KIRP	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4728302	0.607	rs10263851	chr7:133611256	C/T	cg10665199	chr7:133106180	EXOC4	0.43	4.96	0.3	1.31e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs728616	0.867	rs7080405	chr10:81901943	G/C	cg04850286	chr10:81895943	PLAC9	0.51	4.85	0.3	2.24e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.31	0.51	7.44e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg02023728	chr11:77925099	USP35	0.33	5.03	0.31	9.51e-7	Testicular germ cell tumor;
KIRP	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.86	-12.2	-0.61	4.49e-27	Coronary artery disease;
KIRP	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.76	-9.8	-0.53	2.28e-19	Aortic root size;
KIRP	cis	rs11997175	0.543	rs115681590	chr8:33761157	G/T	ch.8.33884649F	chr8:33765107	NA	0.59	7.12	0.41	1.16e-11	Body mass index;
KIRP	cis	rs73198271	0.960	rs11778970	chr8:8609334	G/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.23	-0.32	3.67e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.07e-11	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21547190	chr19:33793141	CEBPA;LOC80054	0.53	7.15	0.41	9.9e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg12315302	chr6:26189340	HIST1H4D	0.86	6.07	0.36	4.77e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4363385	0.567	rs7551791	chr1:153024267	A/T	cg13444842	chr1:152974279	SPRR3	-0.43	-6.12	-0.36	3.72e-9	Inflammatory skin disease;
KIRP	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.53	0.48	1.56e-15	Prudent dietary pattern;
KIRP	cis	rs75229567	0.618	rs35394896	chr12:70188346	T/A	cg10114359	chr12:70132523	RAB3IP	0.57	4.88	0.3	1.87e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.69	-10.23	-0.55	1.11e-20	Prudent dietary pattern;
KIRP	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.42	4.93	0.3	1.5e-6	Menopause (age at onset);
KIRP	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.84	12.84	0.63	3.2e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.51	-0.38	4.25e-10	Joint mobility (Beighton score);
KIRP	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.25	0.47	9.92e-15	Breast cancer;
KIRP	cis	rs889398	0.769	rs12927052	chr16:69857043	A/G	cg09409435	chr16:70099608	PDXDC2	-0.41	-5.0	-0.3	1.1e-6	Body mass index;
KIRP	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg17517138	chr11:73019481	ARHGEF17	0.78	6.87	0.4	5.23e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg18306943	chr3:40428807	ENTPD3	0.46	5.87	0.35	1.4e-8	Renal cell carcinoma;
KIRP	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.88	12.2	0.61	4.27e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1981331	0.609	rs3088287	chr21:48079669	G/A	cg23283320	chr21:48055893	PRMT2	1.08	8.27	0.47	8.47e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg21775007	chr8:11205619	TDH	-0.46	-6.25	-0.37	1.83e-9	Neuroticism;
KIRP	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg08975724	chr8:8085496	FLJ10661	0.7	9.19	0.51	1.76e-17	Mood instability;
KIRP	cis	rs16936870	0.543	rs7841047	chr8:71265978	G/A	cg14232793	chr8:71155543	NCOA2	0.56	6.72	0.39	1.26e-10	QT interval;
KIRP	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.45	-0.43	1.55e-12	Breast cancer;
KIRP	cis	rs6589219	0.788	rs1987128	chr11:111152496	C/G	cg25129781	chr11:111156908	C11orf53	-0.42	-5.35	-0.32	1.97e-7	Colorectal cancer;
KIRP	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg25407064	chr15:40226267	EIF2AK4	-0.63	-6.54	-0.38	3.62e-10	Response to haloperidol in psychosis;
KIRP	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	6.74	0.39	1.1e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.68	-8.63	-0.48	7.5e-16	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03647317	chr4:187891568	NA	-0.76	-12.73	-0.63	7.32e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.07e-11	Blood metabolite levels;
KIRP	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	5.86	0.35	1.51e-8	Thyroid stimulating hormone;
KIRP	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15477738	chr2:174824642	SP3	0.47	6.07	0.36	4.86e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg05692746	chr2:100937584	LONRF2	-0.41	-5.47	-0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.7	0.39	1.37e-10	Colorectal cancer;
KIRP	cis	rs17065868	1.000	rs9525983	chr13:45148257	G/A	cg10246903	chr13:45222710	NA	0.75	6.72	0.39	1.26e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs8067287	0.688	rs8081126	chr17:16845362	T/C	cg26910001	chr17:16838321	NA	-0.42	-5.01	-0.3	1.02e-6	Diabetic kidney disease;
KIRP	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2425143	1.000	rs117010355	chr20:34343442	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.05	-0.31	8.46e-7	Blood protein levels;
KIRP	cis	rs10849605	0.737	rs7300039	chr12:1068178	A/T	cg22243222	chr12:1059299	RAD52	-0.38	-4.87	-0.3	2.02e-6	Lung cancer;
KIRP	cis	rs10838634	1.000	rs7120113	chr11:46934369	C/T	cg25873214	chr11:47587499	PTPMT1	-0.59	-4.86	-0.3	2.07e-6	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.6	-7.63	-0.44	5.19e-13	Personality dimensions;
KIRP	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg01097406	chr16:89675127	NA	0.35	5.58	0.33	6.5e-8	Vitiligo;
KIRP	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg08603382	chr10:743973	NA	-0.68	-11.05	-0.58	2.64e-23	Psychosis in Alzheimer's disease;
KIRP	cis	rs4728302	0.838	rs10224828	chr7:133591071	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13198984	chr17:80129470	CCDC57	-0.55	-8.25	-0.47	9.88e-15	Life satisfaction;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.27	-0.37	1.63e-9	Longevity;Endometriosis;
KIRP	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.69	-9.21	-0.51	1.51e-17	Huntington's disease progression;
KIRP	cis	rs8077577	0.747	rs3817992	chr17:18194011	C/A	cg18869244	chr17:18121946	NA	0.46	5.16	0.31	5.07e-7	Obesity-related traits;
KIRP	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7766436	0.885	rs4711020	chr6:22582920	A/G	cg13666174	chr6:22585274	NA	-0.44	-6.1	-0.36	4.02e-9	Coronary artery disease;
KIRP	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.7	9.24	0.51	1.21e-17	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7084402	0.905	rs1896244	chr10:60276182	A/G	cg05938607	chr10:60274200	BICC1	0.45	10.84	0.57	1.22e-22	Refractive error;
KIRP	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.45	-5.64	-0.34	4.71e-8	Educational attainment (years of education);
KIRP	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg02002194	chr4:3960332	NA	-0.43	-6.14	-0.36	3.24e-9	Morning vs. evening chronotype;
KIRP	cis	rs77633900	0.614	rs157757	chr15:76855927	G/C	cg21673338	chr15:77095150	SCAPER	-0.58	-5.54	-0.33	7.82e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg05665937	chr4:1216051	CTBP1	0.43	5.47	0.33	1.08e-7	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.67	9.19	0.51	1.73e-17	Lymphocyte counts;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08260549	chr8:21777063	XPO7	0.48	6.1	0.36	4.06e-9	Myopia (pathological);
KIRP	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.79	10.43	0.55	2.53e-21	Monocyte count;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg15270235	chr3:195682595	NA	0.32	4.88	0.3	1.87e-6	Mean corpuscular volume;
KIRP	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg14784868	chr12:69753453	YEATS4	0.51	5.22	0.32	3.82e-7	Response to diuretic therapy;
KIRP	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg15848620	chr12:58087721	OS9	-0.51	-6.17	-0.37	2.77e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs16973500	0.808	rs61523290	chr16:71943556	A/G	cg00732059	chr16:71740210	PHLPP2	-0.56	-5.51	-0.33	9.02e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs11264213	0.901	rs645123	chr1:36458075	T/C	cg27506609	chr1:36549197	TEKT2	0.98	7.88	0.45	1.05e-13	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.83	11.71	0.6	1.8e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.8	-0.45	1.71e-13	Gut microbiome composition (summer);
KIRP	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg15655495	chr12:38532458	NA	0.27	5.34	0.32	2.1e-7	Bladder cancer;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02475777	chr4:1388615	CRIPAK	0.4	5.37	0.32	1.79e-7	Longevity;
KIRP	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.96	-0.45	6.38e-14	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9393813	0.626	rs12664996	chr6:27363644	A/C	cg18711553	chr6:27366782	ZNF391	-0.42	-5.63	-0.34	4.98e-8	Bipolar disorder;
KIRP	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.91	-0.49	1.17e-16	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg00576331	chr11:65640516	EFEMP2	0.57	7.52	0.43	1.03e-12	DNA methylation (variation);
KIRP	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg25019033	chr10:957182	NA	-0.63	-7.58	-0.44	6.98e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg08975724	chr8:8085496	FLJ10661	0.72	8.35	0.47	4.96e-15	Red cell distribution width;
KIRP	cis	rs9653442	0.545	rs4851252	chr2:100757280	C/T	cg22139774	chr2:100720529	AFF3	-0.31	-5.03	-0.31	9.49e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg09264619	chr17:80180166	NA	0.51	6.09	0.36	4.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18077032	chr15:51235757	LOC100132724;AP4E1	0.39	6.19	0.37	2.54e-9	C-reactive protein;
KIRP	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.8	-0.45	1.74e-13	Monocyte percentage of white cells;
KIRP	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.87	-0.49	1.49e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg06115741	chr20:33292138	TP53INP2	-0.36	-4.9	-0.3	1.74e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26306683	chr17:18585705	ZNF286B	0.61	7.59	0.44	6.79e-13	Educational attainment (years of education);
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg16497661	chr14:103986332	CKB	0.52	7.22	0.42	6.38e-12	Body mass index;
KIRP	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg17757837	chr7:157058334	UBE3C	0.78	10.53	0.56	1.21e-21	Body mass index;
KIRP	trans	rs12431410	0.536	rs1013822	chr14:60149910	G/A	cg20601314	chr10:104179541	FBXL15;PSD	-0.56	-6.21	-0.37	2.25e-9	Schizophrenia;
KIRP	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	1.11	8.53	0.48	1.51e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.54	-8.24	-0.47	1.04e-14	Huntington's disease progression;
KIRP	cis	rs7615316	0.872	rs7635146	chr3:142350079	A/G	cg20824294	chr3:142316082	PLS1	0.25	5.41	0.33	1.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.93	15.2	0.7	3.07e-37	Breast cancer;
KIRP	trans	rs7863100	0.711	rs34498930	chr9:18650755	A/G	cg13196806	chr10:133996309	JAKMIP3	0.6	6.03	0.36	5.92e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg04865290	chr3:52927548	TMEM110	-0.41	-5.24	-0.32	3.4e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs17123764	0.818	rs11169082	chr12:49985408	G/A	cg02054252	chr12:50078554	FMNL3	0.44	5.29	0.32	2.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.4	-0.43	2.1e-12	Colorectal cancer;
KIRP	cis	rs5752326	0.510	rs739289	chr22:26862153	A/C	cg20819150	chr22:26891497	TFIP11	-0.53	-4.98	-0.3	1.18e-6	Ischemic stroke;
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg23985595	chr17:80112537	CCDC57	-0.35	-5.36	-0.32	1.92e-7	Life satisfaction;
KIRP	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.77	-11.54	-0.59	6.58e-25	Obesity-related traits;
KIRP	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg15128208	chr22:42549153	NA	0.69	7.61	0.44	5.99e-13	Birth weight;
KIRP	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg01721255	chr8:58191610	C8orf71	0.54	5.56	0.33	7.13e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs55788414	0.505	rs7190543	chr16:81189320	T/C	cg06400318	chr16:81190750	PKD1L2	-0.77	-9.69	-0.53	5.26e-19	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.01	0.36	6.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg02733842	chr7:1102375	C7orf50	0.46	5.41	0.33	1.48e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21016266	chr12:122356598	WDR66	0.67	9.12	0.5	2.71e-17	Mean corpuscular volume;
KIRP	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg24112000	chr20:60950667	NA	0.64	7.9	0.45	9.22e-14	Colorectal cancer;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg04777052	chr13:73355909	DIS3;PIBF1	0.56	6.19	0.37	2.53e-9	Plasma plasminogen activator levels;
KIRP	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.44	5.44	0.33	1.27e-7	Aortic root size;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-6.14	-0.36	3.3e-9	Lung cancer;
KIRP	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.72	-0.34	3.02e-8	Aortic root size;
KIRP	trans	rs12043259	0.685	rs12407417	chr1:204812698	C/T	cg11485465	chr5:54518469	NA	0.39	6.66	0.39	1.81e-10	Addiction;
KIRP	cis	rs6142102	1.000	rs6059673	chr20:32705561	T/C	cg24642439	chr20:33292090	TP53INP2	0.55	5.99	0.36	7.54e-9	Skin pigmentation;
KIRP	cis	rs7534801	0.603	rs12134861	chr1:244915937	A/T	cg20597013	chr1:244894274	NA	-0.34	-5.58	-0.34	6.28e-8	Longitudinal change in brain amyloid plaque burden;
KIRP	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg18016565	chr1:150552671	MCL1	-0.37	-5.46	-0.33	1.14e-7	Lymphocyte counts;
KIRP	cis	rs8032158	1.000	rs8038646	chr15:56263346	T/C	cg02198044	chr15:56286336	NEDD4	-0.45	-5.12	-0.31	6.25e-7	Keloid;
KIRP	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.46	-0.38	5.47e-10	Blood pressure;
KIRP	cis	rs6005807	0.719	rs9620810	chr22:29053727	T/C	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	0.71	6.44	0.38	6.26e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg08499158	chr17:42289980	UBTF	0.5	6.26	0.37	1.71e-9	Total body bone mineral density;
KIRP	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.1	12.35	0.62	1.41e-27	Vitiligo;
KIRP	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg17340268	chr14:105411764	AHNAK2	-0.38	-4.96	-0.3	1.29e-6	Rheumatoid arthritis;
KIRP	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26097210	chr10:70092729	PBLD;HNRNPH3	0.48	6.07	0.36	4.75e-9	Parkinson's disease;
KIRP	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs78487399	0.908	rs74501107	chr2:43806012	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.44	-0.33	1.29e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10861342	1.000	rs12320123	chr12:105492167	C/T	cg23923672	chr12:105501055	KIAA1033	0.9	9.11	0.5	2.88e-17	IgG glycosylation;
KIRP	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.51	7.18	0.42	8.34e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs9914544	0.628	rs4630608	chr17:18678548	C/T	cg04702396	chr17:15466718	FAM18B2	0.68	9.97	0.54	7.11e-20	Educational attainment (years of education);
KIRP	cis	rs9372498	0.536	rs9489477	chr6:118946192	T/G	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-0.89	-6.23	-0.37	2.06e-9	Inflammatory biomarkers;
KIRP	cis	rs62158211	0.565	rs2121243	chr2:114099346	C/T	cg17784749	chr2:114082611	LOC440839	0.44	5.12	0.31	6.05e-7	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg04132472	chr17:19861366	AKAP10	-0.4	-5.2	-0.31	4.17e-7	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.56e-25	Diabetic kidney disease;
KIRP	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg13264159	chr8:625131	ERICH1	-0.77	-6.81	-0.4	7.42e-11	IgG glycosylation;
KIRP	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs830233	0.609	rs62383305	chr5:165444279	C/T	cg13976338	chr5:165423657	NA	-0.63	-6.09	-0.36	4.23e-9	QT interval (sulfonylurea treatment interaction);
KIRP	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.49	0.38	4.56e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9938149	0.736	rs6540223	chr16:88321436	A/G	cg05435882	chr16:88311214	NA	0.45	5.39	0.32	1.65e-7	Corneal structure;Central corneal thickness;
KIRP	cis	rs2448490	0.642	rs573589	chr11:65483981	C/T	cg11569703	chr11:65557185	OVOL1	-0.36	-5.65	-0.34	4.46e-8	Platelet count;
KIRP	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg07395648	chr5:131743802	NA	-0.54	-7.65	-0.44	4.46e-13	Acylcarnitine levels;
KIRP	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg23791538	chr6:167370224	RNASET2	-0.46	-5.71	-0.34	3.24e-8	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg09699651	chr6:150184138	LRP11	0.5	6.74	0.39	1.13e-10	Lung cancer;
KIRP	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	8.73	0.49	3.89e-16	Initial pursuit acceleration;
KIRP	trans	rs4349753	0.870	rs118783	chr5:144158536	G/C	cg16033277	chr17:80885358	TBCD	0.39	6.04	0.36	5.74e-9	Photic sneeze reflex;
KIRP	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg04990556	chr1:26633338	UBXN11	-0.6	-7.42	-0.43	1.95e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.0	-0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg05156742	chr15:59063176	FAM63B	0.61	7.72	0.44	2.85e-13	Schizophrenia;
KIRP	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.67	-8.23	-0.46	1.08e-14	Age at first birth;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04214090	chr14:21110582	OR6S1	0.46	6.16	0.37	2.97e-9	Interleukin-4 levels;
KIRP	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.79	-0.35	2.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1712517	0.771	rs10883857	chr10:105127587	A/C	cg05636881	chr10:105038444	INA	-0.43	-6.12	-0.36	3.59e-9	Migraine;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15661415	chr7:54825247	SEC61G	0.48	6.96	0.41	3.1e-11	Interleukin-4 levels;
KIRP	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg22244940	chr12:132335942	MMP17	0.52	6.4	0.38	7.88e-10	Migraine;
KIRP	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg26138937	chr11:71823887	C11orf51	-1.11	-7.13	-0.41	1.1e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs986417	1.000	rs6573312	chr14:60952536	G/T	cg27398547	chr14:60952738	C14orf39	0.73	7.28	0.42	4.38e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-9.99	-0.54	6.23e-20	Hemoglobin concentration;
KIRP	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg09526685	chr4:187126073	CYP4V2	0.99	7.89	0.45	1.01e-13	Blood protein levels;
KIRP	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg23587288	chr2:27483067	SLC30A3	-0.4	-5.02	-0.3	9.96e-7	Total body bone mineral density;
KIRP	cis	rs12318506	0.826	rs11180433	chr12:75661470	T/C	cg04728562	chr12:75699417	CAPS2	-0.92	-6.4	-0.38	7.72e-10	Coronary artery calcification;
KIRP	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg16141378	chr3:129829833	LOC729375	0.56	7.39	0.43	2.27e-12	Systolic blood pressure;
KIRP	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-6.34	-0.37	1.07e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg15764593	chr10:829463	NA	-0.82	-8.79	-0.49	2.61e-16	Uric acid levels;
KIRP	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.8	7.06	0.41	1.72e-11	Menopause (age at onset);
KIRP	cis	rs6580649	0.941	rs11609399	chr12:48501161	A/T	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.97	0.3	1.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05756848	chr4:84457469	AGPAT9	0.49	6.13	0.36	3.54e-9	Parkinson's disease;
KIRP	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg08645402	chr16:4508243	NA	0.47	6.58	0.39	2.77e-10	Schizophrenia;
KIRP	cis	rs6669919	0.553	rs11587632	chr1:211668437	T/C	cg10512769	chr1:211675356	NA	-0.78	-11.29	-0.58	4.16e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.45	-6.58	-0.39	2.75e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg19913688	chr11:428466	ANO9	-0.74	-5.43	-0.33	1.36e-7	Body mass index;
KIRP	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.75	-0.57	2.33e-22	Retinal vascular caliber;
KIRP	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg05527609	chr1:210001259	C1orf107	-0.37	-4.96	-0.3	1.33e-6	Monobrow;
KIRP	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.71	-10.67	-0.56	4.21e-22	Hepatocellular carcinoma;
KIRP	cis	rs6563943	0.857	rs1833965	chr16:83636801	A/C	cg01935413	chr16:83636749	CDH13	-0.48	-7.14	-0.41	1.04e-11	Height;
KIRP	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg10189774	chr4:17578691	LAP3	-0.42	-5.09	-0.31	7.26e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg04111992	chr7:158790115	NA	-0.43	-5.6	-0.34	5.84e-8	Facial morphology (factor 20);
KIRP	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.31	-6.13	-0.36	3.42e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.83e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.44	6.59	0.39	2.67e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg07653901	chr22:50250238	ZBED4	-0.6	-6.53	-0.38	3.78e-10	Schizophrenia;
KIRP	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.71	9.64	0.52	7.18e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.5	6.26	0.37	1.66e-9	Birth weight;
KIRP	cis	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.36	-0.32	1.93e-7	Leprosy;
KIRP	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg23625390	chr15:77176239	SCAPER	0.45	6.13	0.36	3.4e-9	Blood metabolite levels;
KIRP	cis	rs3789045	1.000	rs3789044	chr1:204589101	C/T	cg18185008	chr1:204589407	LRRN2	-0.72	-8.21	-0.46	1.24e-14	Educational attainment (college completion);
KIRP	cis	rs6910061	1.000	rs10080950	chr6:11116467	T/G	cg27233058	chr6:11094804	LOC221710	0.56	5.76	0.34	2.49e-8	Diabetic kidney disease;
KIRP	cis	rs1519814	1.000	rs4871037	chr8:121124042	A/G	cg22335954	chr8:121166405	COL14A1	-0.59	-5.99	-0.36	7.34e-9	Breast cancer;
KIRP	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg06640241	chr16:89574553	SPG7	0.65	8.56	0.48	1.26e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.96	11.36	0.59	2.48e-24	Exhaled nitric oxide levels;
KIRP	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.78e-7	Aortic root size;
KIRP	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.65	9.44	0.52	3.04e-18	Schizophrenia;
KIRP	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.92	0.49	1.07e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg01304814	chr3:48885189	PRKAR2A	0.51	4.9	0.3	1.77e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-0.9	-12.04	-0.61	1.47e-26	Blood protein levels;
KIRP	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg17279839	chr7:150038598	RARRES2	0.42	5.2	0.31	4.12e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.57	-0.52	1.19e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-9.87	-0.53	1.44e-19	Total body bone mineral density;
KIRP	cis	rs2279817	0.818	rs71644062	chr1:17980530	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.85	-0.45	1.32e-13	Neuroticism;
KIRP	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg13877915	chr19:58951672	ZNF132	0.61	5.91	0.35	1.15e-8	Mean platelet volume;
KIRP	cis	rs11264213	0.901	rs72661641	chr1:36448130	A/G	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg02487422	chr3:49467188	NICN1	0.47	6.69	0.39	1.48e-10	Parkinson's disease;
KIRP	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg17652424	chr22:38574118	PLA2G6	-0.24	-4.87	-0.3	1.96e-6	Cutaneous nevi;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24455383	chr1:243736307	AKT3	-0.47	-7.0	-0.41	2.42e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.71	8.96	0.5	8.12e-17	Coronary artery disease;
KIRP	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.26	0.37	1.68e-9	Height;
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07256732	chr16:621771	PIGQ	-0.43	-5.98	-0.36	7.7e-9	Height;
KIRP	trans	rs62056376	0.736	rs1233651	chr17:32639361	C/T	cg17635953	chr13:28535085	NA	0.65	6.72	0.39	1.25e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs6543140	0.572	rs17027173	chr2:103057043	G/A	cg09003973	chr2:102972529	NA	0.49	5.03	0.31	9.46e-7	Blood protein levels;
KIRP	cis	rs7246865	0.510	rs2305752	chr19:17186127	A/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.4	0.38	7.71e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.46	-0.65	2.5e-31	Monocyte count;
KIRP	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.55	6.38	0.38	8.86e-10	Axial length;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.74e-8	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg25019033	chr10:957182	NA	-0.61	-7.29	-0.42	4.31e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.54	-12.08	-0.61	1.06e-26	Diabetic kidney disease;
KIRP	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg06223162	chr1:101003688	GPR88	-0.43	-8.73	-0.49	3.97e-16	Monocyte count;
KIRP	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg07928363	chr10:1254425	ADARB2	0.37	5.2	0.31	4.12e-7	Migraine;
KIRP	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18932078	chr1:2524107	MMEL1	0.43	5.98	0.36	7.76e-9	Ulcerative colitis;
KIRP	trans	rs613872	0.573	rs618869	chr18:53248151	C/T	cg20474425	chr12:54746067	NA	-0.44	-6.29	-0.37	1.45e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.66	8.26	0.47	9.27e-15	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.44	15.65	0.71	8.59e-39	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg11130432	chr3:121712080	ILDR1	-0.48	-5.54	-0.33	7.79e-8	Multiple sclerosis;
KIRP	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.87	10.14	0.54	2.12e-20	Response to bleomycin (chromatid breaks);
KIRP	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-8.84	-0.49	1.85e-16	Platelet distribution width;
KIRP	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.8e-7	Life satisfaction;
KIRP	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Melanoma;
KIRP	cis	rs7923609	0.967	rs10761729	chr10:64995604	G/C	cg01631684	chr10:65280961	REEP3	-0.48	-5.67	-0.34	4.07e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27304813	chr3:120068385	LRRC58	-0.47	-6.11	-0.36	3.97e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.59	7.58	0.44	6.86e-13	Height;
KIRP	cis	rs1978968	0.717	rs34740481	chr22:18401620	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-5.92	-0.35	1.08e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.73	-10.16	-0.54	1.75e-20	Hypospadias;
KIRP	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.81	0.45	1.66e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-7.35	-0.42	2.85e-12	Common traits (Other);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10843715	chr11:111636955	PPP2R1B	0.51	6.99	0.41	2.53e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg01304814	chr3:48885189	PRKAR2A	-0.53	-5.63	-0.34	5.01e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	1.01	14.02	0.67	3.33e-33	Cognitive function;
KIRP	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.12	0.41	1.15e-11	Aortic root size;
KIRP	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.93	-11.41	-0.59	1.75e-24	Diastolic blood pressure;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg14915620	chr3:47887956	DHX30	-0.5	-6.63	-0.39	2.08e-10	Colorectal cancer;
KIRP	cis	rs2281603	0.951	rs73267744	chr14:64978179	A/C	cg25009451	chr14:65006716	HSPA2	0.48	5.17	0.31	4.78e-7	Lymphocyte counts;
KIRP	cis	rs75804782	0.521	rs55915157	chr2:239424273	T/C	cg08773314	chr2:239334832	ASB1	-0.44	-4.97	-0.3	1.28e-6	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg18279126	chr7:2041391	MAD1L1	0.49	5.08	0.31	7.43e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs741677	0.963	rs7214033	chr17:472173	C/T	cg06217071	chr17:408420	NA	0.52	7.44	0.43	1.71e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.42	-0.33	1.42e-7	Colorectal cancer;
KIRP	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs675026	0.927	rs584709	chr6:154419539	C/T	cg07813322	chr6:154414604	OPRM1	-0.46	-5.77	-0.35	2.37e-8	Hypertension;
KIRP	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-6.55	-0.39	3.42e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg08999081	chr20:33150536	PIGU	-0.47	-6.28	-0.37	1.52e-9	Height;
KIRP	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05220968	chr6:146057943	EPM2A	0.39	5.04	0.31	9.14e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg21775007	chr8:11205619	TDH	-0.5	-6.34	-0.37	1.07e-9	Joint mobility (Beighton score);
KIRP	cis	rs6445967	1.000	rs1913715	chr3:58308214	G/A	cg16569813	chr3:58235849	ABHD6	-0.33	-4.89	-0.3	1.82e-6	Platelet count;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg23034840	chr1:205782522	SLC41A1	0.58	7.65	0.44	4.46e-13	Menarche (age at onset);
KIRP	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.18	-17.05	-0.74	1.48e-43	Lymphocyte percentage of white cells;
KIRP	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg12560992	chr17:57184187	TRIM37	0.57	6.42	0.38	7.09e-10	Testicular germ cell tumor;
KIRP	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.08e-11	Blood metabolite levels;
KIRP	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	13.8	0.66	1.79e-32	Smoking behavior;
KIRP	cis	rs6832769	1.000	rs11133399	chr4:56413831	A/G	cg09317128	chr4:56265301	TMEM165	-0.52	-6.45	-0.38	5.81e-10	Personality dimensions;
KIRP	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg03808351	chr9:123631620	PHF19	0.55	8.22	0.46	1.16e-14	Birth weight;
KIRP	trans	rs6561151	0.957	rs1373904	chr13:44475398	A/G	cg12856521	chr11:46389249	DGKZ	0.49	6.8	0.4	7.71e-11	Crohn's disease;
KIRP	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.47	-6.97	-0.41	2.85e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-0.88	-9.23	-0.51	1.26e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26207909	chr14:103986467	CKB	0.57	7.8	0.45	1.73e-13	Body mass index;
KIRP	cis	rs1448094	0.605	rs12367761	chr12:86286894	T/C	cg06740227	chr12:86229804	RASSF9	0.48	6.18	0.37	2.66e-9	Major depressive disorder;
KIRP	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.62	0.6	3.48e-25	Ileal carcinoids;
KIRP	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.54	-7.8	-0.45	1.76e-13	Metabolite levels;
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.76	10.84	0.57	1.21e-22	Longevity;
KIRP	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-10.23	-0.55	1.06e-20	Total body bone mineral density;
KIRP	cis	rs11731606	0.508	rs56943028	chr4:95285813	T/C	cg00507259	chr4:95128692	SMARCAD1	0.6	5.96	0.36	8.75e-9	Mean platelet volume;
KIRP	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.51	-6.65	-0.39	1.86e-10	Schizophrenia;
KIRP	cis	rs11710088	0.931	rs34659397	chr3:149200362	G/T	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.55	-0.33	7.3900000000000007e-08	QRS duration;
KIRP	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	5.06	0.31	8.33e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg06219351	chr7:158114137	PTPRN2	0.58	8.37	0.47	4.5e-15	Calcium levels;
KIRP	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs76917914	0.780	rs16912622	chr9:100843660	A/C	cg03040243	chr9:100819229	NANS	-0.6	-6.62	-0.39	2.22e-10	Immature fraction of reticulocytes;
KIRP	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.36	-0.51	5.08e-18	Morning vs. evening chronotype;
KIRP	trans	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg06311355	chr22:24577269	SUSD2	-0.3	-6.23	-0.37	1.99e-9	Prostate cancer;
KIRP	cis	rs1934955	0.537	rs7097433	chr10:96776966	C/T	cg09036531	chr10:96991505	NA	-0.46	-5.34	-0.32	2.09e-7	Blood metabolite levels;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg01238044	chr22:24384105	GSTT1	-0.59	-7.61	-0.44	5.97e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1978968	0.763	rs8140977	chr22:18463608	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.78	-11.07	-0.58	2.19e-23	Presence of antiphospholipid antibodies;
KIRP	cis	rs2625529	0.824	rs7182776	chr15:72462831	A/G	cg16672083	chr15:72433130	SENP8	0.5	6.74	0.39	1.13e-10	Red blood cell count;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.69	5.49	0.33	1.01e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.41e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	13.69	0.66	4.36e-32	Platelet count;
KIRP	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg03999872	chr20:62272968	STMN3	0.63	7.18	0.42	8.23e-12	Atopic dermatitis;
KIRP	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs524023	0.957	rs893007	chr11:64365668	C/A	cg09231725	chr11:64357281	SLC22A12	0.6	8.02	0.46	4.39e-14	Urate levels in obese individuals;
KIRP	cis	rs997295	0.554	rs28568344	chr15:68096527	A/G	cg24579218	chr15:68104479	NA	-0.41	-6.41	-0.38	7.43e-10	Motion sickness;
KIRP	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.18	0.61	4.96e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.13	-0.31	5.85e-7	Life satisfaction;
KIRP	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.19	0.51	1.75e-17	Colorectal cancer;
KIRP	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.18	-0.42	8.45e-12	Aortic root size;
KIRP	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.61e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-5.6	-0.34	5.58e-8	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.87	0.35	1.44e-8	Menopause (age at onset);
KIRP	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg06740227	chr12:86229804	RASSF9	-0.44	-5.27	-0.32	2.95e-7	Major depressive disorder;
KIRP	cis	rs72634258	0.520	rs4908485	chr1:7907984	A/G	cg26816564	chr1:7831052	VAMP3	0.8	7.33	0.42	3.24e-12	Inflammatory bowel disease;
KIRP	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25925833	chr15:69113196	ANP32A	0.5	6.53	0.38	3.68e-10	Parkinson's disease;
KIRP	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.6	-7.37	-0.43	2.62e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg05775895	chr3:12838266	CAND2	-0.31	-5.09	-0.31	7.11e-7	QRS complex (12-leadsum);
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg01798813	chr17:3906674	NA	0.47	6.29	0.37	1.42e-9	Type 2 diabetes;
KIRP	cis	rs7700895	0.554	rs154460	chr5:95217430	A/T	cg16656078	chr5:95278638	ELL2	0.34	5.06	0.31	8.28e-7	IgG glycosylation;
KIRP	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg11189052	chr15:85197271	WDR73	0.49	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.96	11.29	0.58	4.45e-24	Corneal astigmatism;
KIRP	cis	rs745821	0.879	rs11082833	chr18:48140734	C/T	cg18923635	chr18:48083994	NA	0.43	5.04	0.31	9.08e-7	Diastolic blood pressure;
KIRP	cis	rs13401104	0.796	rs1466207	chr2:237121350	C/T	cg19324714	chr2:237145437	ASB18	0.48	4.99	0.3	1.13e-6	Educational attainment;
KIRP	cis	rs7119	0.636	rs34020536	chr15:77819586	G/A	cg12131826	chr15:77904385	NA	0.47	5.43	0.33	1.33e-7	Type 2 diabetes;
KIRP	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18357526	chr6:26021779	HIST1H4A	0.53	6.94	0.4	3.42e-11	Height;
KIRP	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-5.9	-0.35	1.22e-8	Aortic root size;
KIRP	cis	rs7116495	1.000	rs947932	chr11:71656705	A/G	cg11196788	chr11:71737549	NUMA1	0.56	4.99	0.3	1.14e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg21523564	chr15:75251491	NA	0.36	6.06	0.36	4.98e-9	Breast cancer;
KIRP	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.24	-0.32	3.42e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.59e-16	Motion sickness;
KIRP	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.33	-0.37	1.13e-9	IgG glycosylation;
KIRP	trans	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.49	-0.38	4.61e-10	Neuroticism;
KIRP	cis	rs6815814	0.950	rs73236633	chr4:38839319	T/C	cg06935464	chr4:38784597	TLR10	0.53	5.39	0.32	1.67e-7	Breast cancer;
KIRP	cis	rs6088813	0.890	rs6088817	chr20:33984976	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-6.83	-0.4	6.58e-11	Height;
KIRP	cis	rs17253792	0.545	rs35466279	chr14:56017022	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.56	7.8	0.45	1.77e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg21214613	chr1:16344536	HSPB7	0.33	5.04	0.31	8.96e-7	Systolic blood pressure;
KIRP	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg06935464	chr4:38784597	TLR10	0.49	5.04	0.31	9.1e-7	Breast cancer;
KIRP	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg06521331	chr12:34319734	NA	-0.47	-5.75	-0.34	2.63e-8	Morning vs. evening chronotype;
KIRP	cis	rs62247992	0.698	rs7619872	chr3:43116170	C/T	cg12239580	chr3:43073058	FAM198A	0.38	5.33	0.32	2.25e-7	Facial morphology (factor 15, philtrum width);
KIRP	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.78	-11.3	-0.58	4.04e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg18438793	chr1:40149837	HPCAL4	0.44	6.21	0.37	2.24e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.42	-5.26	-0.32	3.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg25797454	chr6:150327115	RAET1K	0.36	6.53	0.38	3.81e-10	Alopecia areata;
KIRP	cis	rs1858037	0.867	rs67453645	chr2:65586042	C/T	cg08085232	chr2:65598271	SPRED2	-0.54	-6.48	-0.38	4.98e-10	Rheumatoid arthritis;
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg07701084	chr6:150067640	NUP43	0.66	8.54	0.48	1.4e-15	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13546937	chr9:127632120	ARPC5L	0.52	6.58	0.39	2.78e-10	Parkinson's disease;
KIRP	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs804292	0.800	rs8191589	chr8:11634194	T/A	cg26752888	chr8:11627280	NEIL2	1.02	10.78	0.57	1.91e-22	Alcohol dependence;Nicotine use;
KIRP	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-0.78	-9.26	-0.51	1.08e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg00360474	chr6:37504404	NA	-0.48	-6.81	-0.4	7.41e-11	Cognitive performance;
KIRP	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.63	0.44	5.07e-13	Colorectal cancer;
KIRP	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.14e-21	Alzheimer's disease (late onset);
KIRP	cis	rs714027	0.511	rs131274	chr22:30153864	G/A	cg01021169	chr22:30184971	ASCC2	-0.44	-5.54	-0.33	7.68e-8	Lymphocyte counts;
KIRP	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.66	7.59	0.44	6.69e-13	Arsenic metabolism;
KIRP	cis	rs9468199	1.000	rs9468199	chr6:27681215	G/A	cg18711553	chr6:27366782	ZNF391	0.46	4.9	0.3	1.73e-6	Parkinson's disease;
KIRP	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.83	9.78	0.53	2.8e-19	Post bronchodilator FEV1;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12126991	chr10:45455245	RASSF4	0.48	6.05	0.36	5.37e-9	Parkinson's disease;
KIRP	trans	rs7618501	0.521	rs11712056	chr3:49914397	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	6.1	0.36	4.16e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.855	rs17122620	chr12:48464475	A/G	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.04	-0.54	4.26e-20	Total body bone mineral density;
KIRP	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	1.04	11.22	0.58	7.18e-24	Eosinophil percentage of granulocytes;
KIRP	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.38e-7	Bipolar disorder;
KIRP	cis	rs2929278	0.589	rs2411284	chr15:44038899	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.29	-0.37	1.42e-9	Schizophrenia;
KIRP	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7301016	1.000	rs7962519	chr12:62868885	T/G	cg01804193	chr12:63026212	NA	0.53	5.36	0.32	1.91e-7	IgG glycosylation;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21700582	chr7:93474119	NA	0.43	6.48	0.38	4.99e-10	Cancer;
KIRP	cis	rs2279817	1.000	rs10788680	chr1:18019454	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.65	9.94	0.54	8.48e-20	Neuroticism;
KIRP	cis	rs7737355	1.000	rs257390	chr5:130740617	C/T	cg06647332	chr5:131281008	NA	-0.45	-4.98	-0.3	1.19e-6	Life satisfaction;
KIRP	cis	rs9400467	0.509	rs11153287	chr6:111704537	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.45	-5.82	-0.35	1.79e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1147199	0.585	rs72737613	chr9:87239918	T/C	cg22402007	chr9:87282823	NTRK2	0.4	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.56	6.89	0.4	4.57e-11	Aortic root size;
KIRP	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg20965017	chr5:231967	SDHA	-0.57	-6.54	-0.38	3.54e-10	Breast cancer;
KIRP	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg15655495	chr12:38532458	NA	-0.27	-5.38	-0.32	1.71e-7	Bladder cancer;
KIRP	cis	rs72772090	0.710	rs1559085	chr5:96078702	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-5.77	-0.35	2.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.75	10.14	0.54	2.01e-20	Red blood cell count;
KIRP	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.64	7.77	0.44	2.14e-13	Coronary artery disease;
KIRP	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg26876637	chr1:152193138	HRNR	-0.79	-8.59	-0.48	1.02e-15	Atopic dermatitis;
KIRP	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg21573476	chr21:45109991	RRP1B	-0.72	-10.26	-0.55	8.93e-21	Mean corpuscular volume;
KIRP	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.83	10.8	0.57	1.69e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09779392	chr19:11094753	SMARCA4	0.6	6.23	0.37	1.96e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.53	7.5	0.43	1.19e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6901250	0.655	rs9384990	chr6:117126941	A/G	cg05399210	chr6:117082661	FAM162B	-0.38	-5.14	-0.31	5.72e-7	C-reactive protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14227687	chr7:100303735	POP7	0.44	6.07	0.36	4.81e-9	Survival in pancreatic cancer;
KIRP	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.68	-9.04	-0.5	4.71e-17	Blood metabolite levels;
KIRP	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.89	-12.0	-0.61	1.96e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.9	0.45	9.22e-14	Coffee consumption (cups per day);
KIRP	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.51	-5.06	-0.31	8.26e-7	Initial pursuit acceleration;
KIRP	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.88	0.4	4.85e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg18501202	chr6:125855421	NA	-0.34	-5.07	-0.31	7.87e-7	Brugada syndrome;
KIRP	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.86	13.78	0.66	2.09e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.44	5.64	0.34	4.67e-8	Motion sickness;
KIRP	cis	rs56161922	0.818	rs111340461	chr1:207870682	A/C	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	8.24	0.47	1.01e-14	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4865169	0.967	rs10023088	chr4:57884435	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	5.76	0.34	2.51e-8	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06241380	chr16:67595954	CTCF	-0.5	-6.13	-0.36	3.51e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.35	-7.9	-0.45	9.06e-14	Cutaneous nevi;
KIRP	cis	rs17407555	0.683	rs4697999	chr4:10274934	C/G	cg11266682	chr4:10021025	SLC2A9	0.33	5.07	0.31	7.65e-7	Schizophrenia (age at onset);
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	0.79	7.39	0.43	2.29e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-15.16	-0.7	4.13e-37	Alzheimer's disease;
KIRP	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg04289385	chr6:36355825	ETV7	0.37	4.85	0.3	2.15e-6	Platelet distribution width;
KIRP	cis	rs17065868	1.000	rs61947968	chr13:45090314	G/T	cg10246903	chr13:45222710	NA	0.67	6.34	0.37	1.11e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs35883536	1.000	rs2065784	chr1:101096056	A/G	cg06223162	chr1:101003688	GPR88	-0.3	-6.11	-0.36	3.89e-9	Monocyte count;
KIRP	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.48	7.16	0.42	9.42e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7582720	1.000	rs80087860	chr2:203673072	A/C	cg08076091	chr2:203926405	NBEAL1	0.83	8.63	0.48	7.67e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4356932	1.000	rs7655350	chr4:76977073	A/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs4919087	0.748	rs11189131	chr10:99085835	G/A	cg25902810	chr10:99078978	FRAT1	-0.55	-6.13	-0.36	3.49e-9	Monocyte count;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02737830	chr12:64616354	C12orf66	0.71	6.62	0.39	2.29e-10	Lung function (FEV1);
KIRP	cis	rs282587	0.502	rs408476	chr13:113400056	A/C	cg04656015	chr13:113407548	ATP11A	0.65	7.73	0.44	2.75e-13	Glycated hemoglobin levels;
KIRP	cis	rs7560272	0.501	rs12713790	chr2:73945611	C/T	cg20560298	chr2:73613845	ALMS1	0.46	5.49	0.33	1.02e-7	Schizophrenia;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg06074448	chr4:187884817	NA	-0.8	-13.91	-0.66	7.67e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg20469991	chr17:27169893	C17orf63	0.53	5.55	0.33	7.38e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs9859260	0.961	rs2300780	chr3:195790291	T/C	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.47	-6.66	-0.39	1.73e-10	Endometrial cancer;
KIRP	cis	rs3026101	0.671	rs57774467	chr17:5300205	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.46	-0.38	5.51e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg02733842	chr7:1102375	C7orf50	0.45	5.01	0.3	1.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.92	0.3	1.6e-6	Menopause (age at onset);
KIRP	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-5.77	-0.35	2.38e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	7.42	0.43	1.92e-12	Neuroticism;
KIRP	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.71	-10.06	-0.54	3.66e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4332428	0.764	rs34420413	chr10:4978600	C/T	cg19648686	chr10:5044992	AKR1C2	-1.02	-8.33	-0.47	5.85e-15	Height;
KIRP	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.75	9.62	0.52	8.21e-19	Coronary artery disease;
KIRP	cis	rs2916247	0.954	rs72671436	chr8:93077986	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.52	-6.42	-0.38	7.11e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.510	rs2068678	chr1:152906956	G/A	cg13444842	chr1:152974279	SPRR3	-0.46	-6.6	-0.39	2.44e-10	Inflammatory skin disease;
KIRP	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-1.07	-22.39	-0.82	2.63e-61	Parkinson's disease;
KIRP	cis	rs8014252	0.803	rs74062769	chr14:71070576	A/C	cg19730268	chr14:71022823	NA	-0.61	-5.79	-0.35	2.18e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.45	-5.9	-0.35	1.2e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg11861562	chr11:117069780	TAGLN	0.42	5.41	0.33	1.47e-7	Blood protein levels;
KIRP	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg01280390	chr8:19363452	CSGALNACT1	-0.44	-5.93	-0.35	9.98e-9	Oropharynx cancer;
KIRP	trans	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	6.08	0.36	4.63e-9	Retinal vascular caliber;
KIRP	cis	rs4704187	0.687	rs4360021	chr5:74421962	A/G	cg03227963	chr5:74354835	NA	0.41	5.94	0.35	9.57e-9	Response to amphetamines;
KIRP	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg00204512	chr16:28754710	NA	0.43	5.33	0.32	2.22e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.75	12.06	0.61	1.27e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.65	-9.83	-0.53	1.91e-19	Total body bone mineral density;
KIRP	cis	rs236907	0.859	rs2232824	chr1:171761458	T/C	cg01410279	chr1:171621941	MYOC	-0.49	-5.57	-0.33	6.83e-8	Mean platelet volume;
KIRP	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.52	-6.75	-0.4	1.03e-10	Blood metabolite levels;
KIRP	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg11508081	chr17:41442227	NA	0.37	5.0	0.3	1.1e-6	Menopause (age at onset);
KIRP	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg05340658	chr4:99064831	C4orf37	-0.49	-5.64	-0.34	4.56e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00399938	chr22:20118646	ZDHHC8	-0.56	-6.04	-0.36	5.74e-9	Menopause (age at onset);
KIRP	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg11859384	chr17:80120422	CCDC57	0.46	6.09	0.36	4.39e-9	Life satisfaction;
KIRP	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg12856521	chr11:46389249	DGKZ	0.63	7.45	0.43	1.54e-12	Crohn's disease;
KIRP	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg16797656	chr11:68205561	LRP5	0.39	5.11	0.31	6.53e-7	Total body bone mineral density;
KIRP	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.81	-0.35	1.9e-8	Retinal vascular caliber;
KIRP	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg20673091	chr1:2541236	MMEL1	-0.69	-10.69	-0.56	3.7e-22	Ulcerative colitis;
KIRP	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.03	0.61	1.57e-26	Blood protein levels;
KIRP	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.16	0.31	5.12e-7	Schizophrenia;
KIRP	cis	rs838721	0.574	rs11676156	chr2:234259001	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	5.04	0.31	8.94e-7	Total body bone mineral density;
KIRP	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs17533156	0.612	rs12603478	chr17:75128651	A/G	cg11416367	chr17:75137675	SEC14L1	0.54	5.39	0.33	1.62e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg07169764	chr2:136633963	MCM6	0.53	6.29	0.37	1.42e-9	Corneal structure;
KIRP	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg24110177	chr3:50126178	RBM5	0.62	8.08	0.46	2.94e-14	Menarche (age at onset);
KIRP	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.39	0.55	3.29e-21	Dupuytren's disease;
KIRP	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.77	7.77	0.44	2.13e-13	Uric acid levels;
KIRP	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.82	12.17	0.61	5.41e-27	Orofacial clefts;
KIRP	cis	rs4237845	0.591	rs2372309	chr12:58329820	G/A	cg00677455	chr12:58241039	CTDSP2	0.69	7.81	0.45	1.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.49	-5.9	-0.35	1.19e-8	Breast cancer;
KIRP	cis	rs7539542	0.600	rs9943282	chr1:202895140	C/T	cg08940984	chr1:202857613	RABIF	0.45	5.35	0.32	2.05e-7	Mean platelet volume;
KIRP	cis	rs11677416	1.000	rs4848303	chr2:113552698	A/G	cg23974023	chr2:113544294	IL1A	-0.35	-5.38	-0.32	1.7e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg19743168	chr1:23544995	NA	-0.48	-6.59	-0.39	2.61e-10	Height;
KIRP	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg26513180	chr16:89883248	FANCA	0.79	5.27	0.32	2.98e-7	Skin colour saturation;
KIRP	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.46	5.05	0.31	8.44e-7	Alzheimer's disease (late onset);
KIRP	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg18944383	chr4:111397179	ENPEP	0.45	7.27	0.42	4.64e-12	Height;
KIRP	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	8.7	0.48	4.94e-16	Platelet count;
KIRP	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.5	6.48	0.38	5e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg13206674	chr6:150067644	NUP43	0.44	4.99	0.3	1.16e-6	Lung cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08843538	chr2:210288784	MAP2	-0.42	-6.19	-0.37	2.54e-9	Metabolic traits;
KIRP	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.25	17.28	0.74	2.45e-44	Type 1 diabetes nephropathy;
KIRP	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.74	-9.87	-0.53	1.46e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.8	-11.72	-0.6	1.71e-25	Blood metabolite levels;
KIRP	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg00319359	chr11:70116639	PPFIA1	0.55	5.67	0.34	3.93e-8	Coronary artery disease;
KIRP	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.85	-0.49	1.72e-16	Retinal vascular caliber;
KIRP	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.69	-7.68	-0.44	3.83e-13	QRS complex (12-leadsum);
KIRP	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.54	6.64	0.39	2e-10	Arsenic metabolism;
KIRP	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.59	-9.33	-0.51	6.51e-18	C-reactive protein levels;
KIRP	trans	rs1106684	1.000	rs10954330	chr7:131459600	C/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs8114671	0.740	rs3761141	chr20:33737824	A/C	cg24642439	chr20:33292090	TP53INP2	0.48	5.67	0.34	3.99e-8	Height;
KIRP	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.96	0.57	4.96e-23	Cognitive test performance;
KIRP	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.51	-7.93	-0.45	7.5e-14	Platelet distribution width;
KIRP	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg18944383	chr4:111397179	ENPEP	0.52	9.22	0.51	1.34e-17	Height;
KIRP	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.59	7.86	0.45	1.21e-13	Mean corpuscular volume;
KIRP	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.64	0.39	2.01e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6125597	0.901	rs6125612	chr20:47906558	A/G	cg03212862	chr20:47662828	CSE1L	-0.41	-5.29	-0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.54e-13	Life satisfaction;
KIRP	cis	rs2412208	0.545	rs7414485	chr1:7121397	G/A	cg20434152	chr1:7120926	CAMTA1	-0.46	-6.63	-0.39	2.12e-10	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg25174290	chr11:3078921	CARS	-0.66	-8.37	-0.47	4.5e-15	Calcium levels;
KIRP	cis	rs4356975	0.563	rs7685151	chr4:69979773	C/T	cg27372994	chr4:70080453	UGT2B11	0.36	4.85	0.3	2.18e-6	Obesity-related traits;
KIRP	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	8.17	0.46	1.68e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22010774	chr19:38956915	RYR1	-0.48	-6.62	-0.39	2.19e-10	Parkinson's disease;
KIRP	cis	rs12615966	1.000	rs9941579	chr2:105384506	C/T	cg16465502	chr2:105461796	NA	0.63	5.73	0.34	2.86e-8	Pancreatic cancer;
KIRP	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg05340658	chr4:99064831	C4orf37	0.46	5.16	0.31	5.15e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg25338242	chr13:114786047	RASA3	0.42	4.98	0.3	1.22e-6	Schizophrenia;
KIRP	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg17764715	chr19:33622953	WDR88	0.81	11.49	0.59	9.7e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.0	-0.45	4.83e-14	Mean corpuscular volume;
KIRP	cis	rs4780401	0.728	rs4781136	chr16:11767978	G/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-5.06	-0.31	8.25e-7	Rheumatoid arthritis;
KIRP	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.93	-0.53	9.46e-20	Retinal vascular caliber;
KIRP	trans	rs3013648	0.777	rs11149330	chr13:85393293	T/C	cg21827674	chr12:133007847	NA	-0.73	-6.59	-0.39	2.7e-10	Huntington's disease progression;
KIRP	cis	rs12476592	0.516	rs7558796	chr2:63597108	T/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.3	-0.32	2.57e-7	Childhood ear infection;
KIRP	cis	rs4308124	1.000	rs115444904	chr2:112013373	C/A	cg23466623	chr2:111982296	NA	0.41	5.68	0.34	3.86e-8	Vitiligo;
KIRP	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.12	-0.31	6.16e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs1298062	0.689	rs12985344	chr19:50954750	T/C	cg17071417	chr19:50962282	MYBPC2	0.5	5.9	0.35	1.22e-8	Age of smoking initiation;
KIRP	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.8	-11.37	-0.59	2.39e-24	Blood metabolite levels;
KIRP	cis	rs6662572	0.703	rs7548617	chr1:46365489	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.35e-8	Blood protein levels;
KIRP	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.42	-0.59	1.63e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg14835575	chr10:16859367	RSU1	0.61	7.98	0.45	5.51e-14	Platelet distribution width;
KIRP	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.69	-0.56	3.73e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg12140854	chr5:148520817	ABLIM3	0.48	5.63	0.34	4.81e-8	Breast cancer;
KIRP	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg15655495	chr12:38532458	NA	-0.3	-5.21	-0.32	3.96e-7	Bladder cancer;
KIRP	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg26207909	chr14:103986467	CKB	0.43	5.33	0.32	2.2e-7	Coronary artery disease;
KIRP	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.81	7.8	0.45	1.72e-13	Iron status biomarkers;
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05665937	chr4:1216051	CTBP1	-0.44	-5.47	-0.33	1.13e-7	Obesity-related traits;
KIRP	cis	rs2051773	0.567	rs7130826	chr11:17037793	T/G	cg15432903	chr11:17409602	KCNJ11	-0.51	-6.12	-0.36	3.57e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg00631329	chr6:26305371	NA	-0.64	-8.28	-0.47	7.95e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.13	0.72	1.96e-40	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.68	-7.49	-0.43	1.24e-12	DNA methylation (variation);
KIRP	cis	rs11877825	0.826	rs8088116	chr18:10579879	T/A	cg07277756	chr18:10589357	NA	0.49	6.0	0.36	6.92e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg11318054	chr7:157361692	PTPRN2	-0.4	-6.03	-0.36	6.13e-9	Erectile dysfunction in type 1 diabetes;
KIRP	trans	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg06521331	chr12:34319734	NA	-0.57	-6.96	-0.41	3.04e-11	Bladder cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21157115	chr9:33001303	APTX	0.96	6.29	0.37	1.41e-9	P wave terminal force;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.69	-9.9	-0.53	1.13e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs10904908	0.733	rs7080366	chr10:17254832	C/T	cg01003015	chr10:17271136	VIM	-0.43	-5.12	-0.31	6.13e-7	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.69	-6.8	-0.4	7.99e-11	Breast cancer;
KIRP	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg21285383	chr16:89894308	SPIRE2	0.34	6.38	0.38	8.83e-10	Vitiligo;
KIRP	cis	rs11676348	0.703	rs6737563	chr2:218945674	T/C	cg03834567	chr2:218808745	TNS1	0.49	5.65	0.34	4.48e-8	Ulcerative colitis;
KIRP	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg23845249	chr11:68861649	NA	0.6	8.76	0.49	3.31e-16	Blond vs. brown hair color;
KIRP	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.4	-4.91	-0.3	1.68e-6	Obesity-related traits;
KIRP	cis	rs7267005	0.661	rs78094716	chr20:34432958	A/G	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4746818	0.643	rs2855020	chr10:70856510	C/T	cg11621586	chr10:70884670	VPS26A	0.72	6.69	0.39	1.45e-10	Left atrial antero-posterior diameter;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg00444019	chr10:14646244	FAM107B	-0.52	-6.12	-0.36	3.75e-9	Brain structure;
KIRP	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.56	7.46	0.43	1.49e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.38	-0.32	1.7e-7	Joint mobility (Beighton score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26284901	chr15:73925319	NPTN	0.51	6.24	0.37	1.89e-9	Parkinson's disease;
KIRP	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg07936489	chr17:37558343	FBXL20	-0.46	-5.71	-0.34	3.29e-8	Asthma;
KIRP	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.86	-9.39	-0.51	4.33e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg09597638	chr17:3907349	NA	0.56	5.89	0.35	1.29e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.47	6.84	0.4	6.17e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg21100191	chr22:23484243	RTDR1	1.04	17.71	0.75	8.57e-46	Bone mineral density;
KIRP	cis	rs4242434	0.892	rs4872527	chr8:22496048	G/A	cg03733263	chr8:22462867	KIAA1967	1.1	15.55	0.7	1.94e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg24344221	chr1:35658281	SFPQ	0.54	6.37	0.38	9.01e-10	Educational attainment;
KIRP	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg06671706	chr8:8559999	CLDN23	0.56	6.48	0.38	4.86e-10	Obesity-related traits;
KIRP	cis	rs258892	0.895	rs10059897	chr5:72080538	C/T	cg21869765	chr5:72125136	TNPO1	-0.56	-6.06	-0.36	5.1e-9	Small cell lung carcinoma;
KIRP	cis	rs7951870	0.945	rs57739486	chr11:46723516	C/T	cg19486271	chr11:47235900	DDB2	0.53	5.0	0.3	1.09e-6	Schizophrenia;
KIRP	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg02524346	chr8:600233	NA	0.88	6.52	0.38	4e-10	IgG glycosylation;
KIRP	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg00825309	chr19:58991885	ZNF446	-0.56	-6.88	-0.4	5.05e-11	Uric acid clearance;
KIRP	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.67	8.35	0.47	5.08e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.75	0.53	3.38e-19	Post bronchodilator FEV1;
KIRP	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11584989	chr19:19387371	SF4	0.57	6.09	0.36	4.34e-9	Bipolar disorder;
KIRP	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.63	8.61	0.48	8.68e-16	Mean corpuscular volume;
KIRP	cis	rs1497828	0.956	rs2646839	chr1:217553421	G/A	cg04411442	chr1:217543379	NA	0.41	6.19	0.37	2.53e-9	Dialysis-related mortality;
KIRP	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg18867708	chr6:26865862	GUSBL1	0.46	5.76	0.34	2.54e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.87	7.47	0.43	1.4e-12	Fat distribution (HIV);
KIRP	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.39	0.33	1.64e-7	Menopause (age at onset);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg22975147	chr17:8021903	ALOXE3	0.51	6.02	0.36	6.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7267005	0.661	rs113226660	chr20:34368629	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.14	-0.46	2.04e-14	Body mass index;
KIRP	cis	rs6009824	0.579	rs34296882	chr22:50098333	C/T	cg22070880	chr22:50098194	NA	0.93	10.06	0.54	3.67e-20	Natriuretic peptide levels;
KIRP	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.12	0.36	3.65e-9	Depression;
KIRP	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg24881330	chr22:46731750	TRMU	0.79	5.41	0.33	1.51e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg25507518	chr7:2405875	EIF3B	0.42	5.03	0.31	9.53e-7	Multiple sclerosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13743387	chr4:54280858	FIP1L1	-0.41	-6.38	-0.38	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.24	-0.32	3.39e-7	Alcohol dependence;
KIRP	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg05973401	chr12:123451056	ABCB9	0.55	6.26	0.37	1.69e-9	Neutrophil percentage of white cells;
KIRP	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg09231725	chr11:64357281	SLC22A12	-0.65	-8.74	-0.49	3.6e-16	Urate levels in obese individuals;
KIRP	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18252515	chr7:66147081	NA	0.43	5.26	0.32	3.17e-7	Aortic root size;
KIRP	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.72	0.39	1.24e-10	Morning vs. evening chronotype;
KIRP	cis	rs10131728	1.000	rs12895990	chr14:81676282	T/C	cg01989461	chr14:81687754	GTF2A1	-0.81	-6.17	-0.37	2.76e-9	IgG glycosylation;
KIRP	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.82	12.6	0.63	2.06e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg19610905	chr11:61596333	FADS2	-0.52	-7.86	-0.45	1.18e-13	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
KIRP	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.58	8.48	0.48	2.04e-15	Ovarian reserve;
KIRP	trans	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.21	-0.55	1.24e-20	Neuroticism;
KIRP	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg13047869	chr3:10149882	C3orf24	0.54	5.27	0.32	3.01e-7	Alzheimer's disease;
KIRP	cis	rs15676	0.947	rs2280842	chr9:131585808	C/G	cg00228799	chr9:131580591	ENDOG	0.58	6.58	0.39	2.89e-10	Blood metabolite levels;
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.52	-0.33	8.66e-8	Life satisfaction;
KIRP	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg08885076	chr2:99613938	TSGA10	-0.62	-11.09	-0.58	1.96e-23	Chronic sinus infection;
KIRP	trans	rs10496166	0.565	rs11897459	chr2:69044629	G/T	cg10096454	chr10:103880868	LDB1	-0.53	-6.12	-0.36	3.62e-9	RR interval (heart rate);
KIRP	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg23594656	chr7:65796392	TPST1	-0.47	-7.53	-0.43	9.42e-13	Aortic root size;
KIRP	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs798766	0.909	rs744658	chr4:1755074	C/T	cg07775547	chr4:1625484	NA	-0.46	-5.41	-0.33	1.52e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.8	11.01	0.57	3.45e-23	Aortic root size;
KIRP	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.36	-0.38	1e-9	Aortic root size;
KIRP	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25361117	chr19:11750727	NA	0.56	7.12	0.41	1.21e-11	Parkinson's disease;
KIRP	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-0.91	-9.09	-0.5	3.5e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg06453172	chr10:134556979	INPP5A	-0.52	-5.77	-0.35	2.41e-8	Migraine;
KIRP	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.62	8.31	0.47	6.33e-15	Prostate cancer;
KIRP	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.5	6.57	0.39	2.9e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg03877680	chr5:178157825	ZNF354A	0.72	8.2	0.46	1.3e-14	Neutrophil percentage of white cells;
KIRP	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24549020	chr5:56110836	MAP3K1	-0.52	-5.04	-0.31	8.97e-7	Initial pursuit acceleration;
KIRP	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.73	-9.98	-0.54	6.28e-20	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16895486	chr8:26614263	ADRA1A	-0.41	-6.75	-0.4	1.06e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg04935436	chr20:30431758	NA	0.49	5.77	0.35	2.36e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs867371	0.929	rs1501371	chr15:82460440	A/C	cg06066596	chr15:83166174	LOC80154	-0.42	-4.92	-0.3	1.57e-6	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.93e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg22117172	chr7:91764530	CYP51A1	0.4	5.52	0.33	8.7e-8	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg07701084	chr6:150067640	NUP43	0.65	8.65	0.48	6.85e-16	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27601182	chr16:2673800	LOC652276	0.48	6.36	0.38	1e-9	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19268579	chr10:43904406	HNRNPF	0.57	7.26	0.42	4.96e-12	Parkinson's disease;
KIRP	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg00631329	chr6:26305371	NA	-0.64	-9.38	-0.51	4.52e-18	Educational attainment;
KIRP	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg27205649	chr11:78285834	NARS2	-0.55	-6.24	-0.37	1.86e-9	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20785715	chr8:144718023	ZNF623	0.5	6.02	0.36	6.15e-9	Parkinson's disease;
KIRP	cis	rs12760731	0.720	rs12755909	chr1:178305298	G/A	cg00404053	chr1:178313656	RASAL2	0.65	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs6681460	0.674	rs4134135	chr1:67012728	A/G	cg02459107	chr1:67143332	SGIP1	0.38	5.22	0.32	3.89e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg23024343	chr7:107201750	COG5	0.43	4.96	0.3	1.31e-6	Coronary artery disease;
KIRP	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.16	-0.31	5.07e-7	Bladder cancer;
KIRP	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.58	8.37	0.47	4.26e-15	Carotid intima media thickness;
KIRP	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg23166289	chr1:210001082	C1orf107	0.45	5.72	0.34	3.1e-8	Monobrow;
KIRP	cis	rs889398	0.802	rs2291959	chr16:69873992	T/G	cg09409435	chr16:70099608	PDXDC2	0.43	5.15	0.31	5.41e-7	Body mass index;
KIRP	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg20362242	chr5:692897	TPPP	0.56	4.86	0.3	2.06e-6	Obesity-related traits;
KIRP	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.64	-9.01	-0.5	5.96e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4787491	0.729	rs11150584	chr16:30039678	C/A	cg06326092	chr16:30034487	C16orf92	0.48	7.36	0.43	2.67e-12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	5.26	0.32	3.17e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg00507259	chr4:95128692	SMARCAD1	0.41	5.24	0.32	3.37e-7	QT interval;
KIRP	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.26	-0.32	3.07e-7	Pulmonary function;
KIRP	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg03808351	chr9:123631620	PHF19	0.4	5.46	0.33	1.17e-7	Rheumatoid arthritis;
KIRP	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg16586182	chr3:47516702	SCAP	0.56	6.72	0.39	1.23e-10	Birth weight;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg21285383	chr16:89894308	SPIRE2	0.33	6.18	0.37	2.69e-9	Vitiligo;
KIRP	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.45	-8.44	-0.47	2.78e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.84	-12.63	-0.63	1.64e-28	Height;
KIRP	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.46	6.14	0.36	3.34e-9	Hypertriglyceridemia;
KIRP	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.43	4.86	0.3	2.05e-6	Schizophrenia;
KIRP	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.65	6.38	0.38	8.7e-10	Eotaxin levels;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg08989290	chr16:615782	NHLRC4	0.4	5.99	0.36	7.39e-9	Height;
KIRP	trans	rs12431410	0.536	rs1957993	chr14:60144313	C/T	cg20601314	chr10:104179541	FBXL15;PSD	-0.56	-6.06	-0.36	5.07e-9	Schizophrenia;
KIRP	cis	rs2574975	0.531	rs1203406	chr10:52198016	A/G	cg10034176	chr10:52120283	SGMS1	0.4	5.74	0.34	2.71e-8	Response to amphetamines;
KIRP	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg22617819	chr1:44378782	ST3GAL3	-0.4	-6.44	-0.38	6.3e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14159672	chr1:205819179	PM20D1	-0.6	-5.79	-0.35	2.13e-8	Menarche (age at onset);
KIRP	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg12559939	chr2:27858050	GPN1	0.42	5.22	0.32	3.81e-7	Oral cavity cancer;
KIRP	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg06223162	chr1:101003688	GPR88	0.4	7.85	0.45	1.3e-13	Monocyte count;
KIRP	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg25547332	chr5:131281432	NA	-0.5	-6.12	-0.36	3.6e-9	Life satisfaction;
KIRP	cis	rs7010267	0.935	rs7463176	chr8:119957625	A/G	cg01975934	chr8:119970761	NA	-0.42	-5.33	-0.32	2.17e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs427941	0.632	rs382228	chr7:101786064	A/C	cg06246474	chr7:101738831	CUX1	0.52	6.36	0.38	9.78e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2591576	0.623	rs1096227	chr5:165398171	G/A	cg13976338	chr5:165423657	NA	-0.71	-10.32	-0.55	5.46e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg20999797	chr1:1681921	NA	0.53	8.22	0.46	1.15e-14	Body mass index;
KIRP	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.4	0.51	3.88e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg23533926	chr12:111358616	MYL2	0.48	6.29	0.37	1.43e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs56161922	0.818	rs4437879	chr1:207875977	G/A	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg02975922	chr3:195473998	MUC4	-0.44	-5.2	-0.31	4.22e-7	Pancreatic cancer;
KIRP	cis	rs10782582	0.668	rs814897	chr1:76154273	G/A	cg10523679	chr1:76189770	ACADM	0.42	6.32	0.37	1.23e-9	Daytime sleep phenotypes;
KIRP	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.66	7.07	0.41	1.59e-11	Vitiligo;
KIRP	trans	rs6733379	0.588	rs2193790	chr2:34445953	A/G	cg23570261	chr2:128284252	IWS1	0.45	6.06	0.36	5.02e-9	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs8014252	0.803	rs60555424	chr14:71041502	T/C	cg19730268	chr14:71022823	NA	-0.62	-5.87	-0.35	1.37e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg09408571	chr1:101003634	GPR88	0.39	10.01	0.54	5.07e-20	Breast cancer;
KIRP	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg08533674	chr1:46993347	NA	-0.42	-5.47	-0.33	1.13e-7	Monobrow;
KIRP	cis	rs9584850	0.794	rs9630321	chr13:99106979	C/G	cg20750642	chr13:99100586	FARP1	-0.55	-6.56	-0.39	3.11e-10	Neuroticism;
KIRP	cis	rs4664293	0.867	rs7606046	chr2:160576158	A/G	cg08347373	chr2:160653686	CD302	-0.42	-6.48	-0.38	4.86e-10	Monocyte percentage of white cells;
KIRP	cis	rs504918	0.584	rs4420813	chr3:123990232	A/G	cg05766129	chr3:123988013	KALRN	-0.48	-7.11	-0.41	1.25e-11	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09235788	chr1:111220207	NA	0.46	6.49	0.38	4.82e-10	Interleukin-4 levels;
KIRP	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.44	0.33	1.3e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg06637938	chr14:75390232	RPS6KL1	0.47	6.46	0.38	5.47e-10	Caffeine consumption;
KIRP	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.5	-5.73	-0.34	2.93e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg09788416	chr12:39539408	NA	0.41	5.55	0.33	7.5e-8	Morning vs. evening chronotype;
KIRP	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-21.84	-0.81	1.65e-59	Height;
KIRP	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.67	-9.09	-0.5	3.32e-17	Colorectal cancer;
KIRP	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15128208	chr22:42549153	NA	-0.41	-5.08	-0.31	7.58e-7	Cognitive function;
KIRP	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.52	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.33	0.42	3.34e-12	Prudent dietary pattern;
KIRP	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg07701084	chr6:150067640	NUP43	0.7	9.84	0.53	1.82e-19	Lung cancer;
KIRP	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg05315796	chr3:52349193	DNAH1	0.59	8.89	0.49	1.33e-16	Bipolar disorder;
KIRP	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg23594656	chr7:65796392	TPST1	-0.52	-8.1	-0.46	2.51e-14	Aortic root size;
KIRP	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.84	12.1	0.61	9.37e-27	Morning vs. evening chronotype;
KIRP	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.29	0.37	1.45e-9	Neuroticism;
KIRP	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.83	-0.49	1.97e-16	Blood metabolite levels;
KIRP	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg07843065	chr1:150265600	MRPS21	-0.44	-6.15	-0.37	3.13e-9	Migraine;
KIRP	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.46	0.68	1.07e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg24253500	chr15:84953950	NA	-0.41	-5.21	-0.32	3.99e-7	Schizophrenia;
KIRP	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.48	0.38	4.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg00106254	chr7:1943704	MAD1L1	-0.62	-6.73	-0.39	1.21e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg23845249	chr11:68861649	NA	0.61	8.64	0.48	7.34e-16	Blond vs. brown hair color;
KIRP	cis	rs7712401	0.601	rs35157167	chr5:122318201	G/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.67	9.21	0.51	1.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6466055	0.661	rs6967753	chr7:104787971	T/C	cg04380332	chr7:105027541	SRPK2	0.41	5.51	0.33	8.81e-8	Schizophrenia;
KIRP	trans	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19894588	chr14:64061835	NA	0.5	6.87	0.4	5.25e-11	Glioblastoma;Glioma;
KIRP	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg26174226	chr8:58114915	NA	-0.51	-5.79	-0.35	2.11e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.38	-5.15	-0.31	5.34e-7	Menarche (age at onset);
KIRP	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg26248373	chr2:1572462	NA	-0.61	-5.98	-0.36	7.66e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg10790698	chr19:18539756	SSBP4	-0.34	-7.34	-0.42	3.11e-12	Breast cancer;
KIRP	cis	rs933688	0.689	rs12697808	chr5:90605389	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.5	-4.88	-0.3	1.88e-6	Smoking behavior;
KIRP	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg08992911	chr2:238395768	MLPH	0.55	5.31	0.32	2.44e-7	Prostate cancer;
KIRP	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.97	-0.3	1.23e-6	Blood metabolite levels;
KIRP	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg11987759	chr7:65425863	GUSB	-0.58	-8.0	-0.45	5.02e-14	Calcium levels;
KIRP	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.85	0.66	1.24e-32	Electrocardiographic conduction measures;
KIRP	cis	rs13343954	0.825	rs7259371	chr19:33534641	G/A	cg17764715	chr19:33622953	WDR88	0.73	8.13	0.46	2.09e-14	Colorectal cancer;
KIRP	cis	rs7674212	1.000	rs7674212	chr4:103988899	G/T	cg16532752	chr4:104119610	CENPE	-0.4	-4.93	-0.3	1.55e-6	Type 2 diabetes;
KIRP	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.33	-0.37	1.16e-9	Neuroticism;
KIRP	cis	rs7727544	0.526	rs17516457	chr5:131590387	T/C	cg07395648	chr5:131743802	NA	-0.46	-6.18	-0.37	2.58e-9	Blood metabolite levels;
KIRP	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-4.93	-0.3	1.52e-6	Testicular germ cell tumor;
KIRP	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.87	-0.45	1.16e-13	Breast cancer;
KIRP	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-6.83	-0.4	6.66e-11	Gut microbiome composition (summer);
KIRP	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.63	-8.2	-0.46	1.35e-14	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19864851	chr10:75503847	SEC24C	0.53	6.28	0.37	1.52e-9	Smoking initiation;
KIRP	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.22	-0.32	3.81e-7	Alcohol dependence;
KIRP	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg04539111	chr16:67997858	SLC12A4	-0.42	-4.85	-0.3	2.21e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg04804543	chr8:142233427	SLC45A4	-0.58	-7.2	-0.42	7.46e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06856480	chr19:34850338	NA	-0.46	-6.26	-0.37	1.74e-9	Metabolic traits;
KIRP	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg17133734	chr15:86042851	AKAP13	-0.44	-5.4	-0.33	1.57e-7	Coronary artery disease;
KIRP	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg10755058	chr3:40428713	ENTPD3	0.44	6.21	0.37	2.29e-9	Renal cell carcinoma;
KIRP	cis	rs4880487	0.505	rs883660	chr10:1206834	A/G	cg03183215	chr10:1252341	ADARB2	-0.4	-4.84	-0.3	2.25e-6	Migraine;
KIRP	trans	rs9650657	0.525	rs7819602	chr8:10726842	C/G	cg16141378	chr3:129829833	LOC729375	0.47	6.15	0.37	3.07e-9	Neuroticism;
KIRP	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg16339924	chr4:17578868	LAP3	-0.53	-6.93	-0.4	3.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08740862	chr11:62314417	AHNAK	0.55	7.24	0.42	5.56e-12	Parkinson's disease;
KIRP	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg02569458	chr12:86230093	RASSF9	-0.37	-5.37	-0.32	1.82e-7	Major depressive disorder;
KIRP	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg09184832	chr6:79620586	NA	-0.53	-7.41	-0.43	2.04e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs13170463	0.579	rs76292996	chr5:8036124	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.48	0.38	4.99e-10	Breast cancer;
KIRP	cis	rs2718812	0.792	rs1006098	chr3:133411605	G/T	cg11941060	chr3:133502564	NA	0.38	4.85	0.3	2.18e-6	Iron status biomarkers;
KIRP	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg12560992	chr17:57184187	TRIM37	0.55	4.87	0.3	1.99e-6	Cognitive test performance;
KIRP	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.58	-0.39	2.81e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs714515	0.569	rs2032529	chr1:172451999	T/G	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	10.57	0.56	9.11e-22	Coffee consumption (cups per day);
KIRP	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg10189774	chr4:17578691	LAP3	0.47	5.68	0.34	3.87e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg26875233	chr11:93583750	C11orf90	-0.36	-6.75	-0.4	1.08e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.81	-13.99	-0.67	4.1e-33	Post bronchodilator FEV1;
KIRP	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.98	15.57	0.7	1.63e-38	Uric acid clearance;
KIRP	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.48	7.26	0.42	5.06e-12	Resting heart rate;
KIRP	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.97	-0.3	1.27e-6	Metabolite levels;
KIRP	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg25486957	chr4:152246857	NA	0.45	5.15	0.31	5.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg02640540	chr1:67518911	SLC35D1	0.43	5.25	0.32	3.35e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg04166393	chr7:2884313	GNA12	0.43	5.57	0.33	6.76e-8	Height;
KIRP	cis	rs9815354	1.000	rs1716693	chr3:41985600	C/T	cg03022575	chr3:42003672	ULK4	-0.49	-5.58	-0.34	6.24e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs258892	0.895	rs34653	chr5:72146480	A/G	cg21869765	chr5:72125136	TNPO1	0.57	6.31	0.37	1.27e-9	Small cell lung carcinoma;
KIRP	cis	rs193541	0.593	rs154499	chr5:122219666	A/C	cg19412675	chr5:122181750	SNX24	0.59	6.29	0.37	1.4e-9	Glucose homeostasis traits;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg17441377	chr17:3906640	NA	-0.53	-7.98	-0.45	5.73e-14	Type 2 diabetes;
KIRP	cis	rs679087	0.612	rs7970465	chr12:29905251	C/T	cg14258853	chr12:29935411	TMTC1	-0.52	-5.67	-0.34	4.08e-8	Schizophrenia;
KIRP	cis	rs867371	1.000	rs8042464	chr15:82465536	A/G	cg00614314	chr15:82944287	LOC80154	0.51	6.09	0.36	4.28e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs4737010	0.501	rs2032736	chr8:41639266	C/A	cg08923054	chr8:41654455	ANK1	-0.62	-6.35	-0.38	1.02e-9	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.58	-6.24	-0.37	1.94e-9	Initial pursuit acceleration;
KIRP	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg21395723	chr22:39101663	GTPBP1	0.4	5.16	0.31	5e-7	Menopause (age at onset);
KIRP	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.73	9.59	0.52	1.06e-18	Schizophrenia;
KIRP	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg11895451	chr1:16533891	ARHGEF19	0.42	5.83	0.35	1.75e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.78	6.25	0.37	1.75e-9	Initial pursuit acceleration;
KIRP	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.86	10.93	0.57	6.39e-23	Hemoglobin concentration;Hematocrit;
KIRP	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.53	-6.63	-0.39	2.14e-10	Coronary artery disease;
KIRP	cis	rs10463316	0.817	rs11167545	chr5:150778076	C/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.03	-0.36	5.97e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.22e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.44	0.33	1.27e-7	Menopause (age at onset);
KIRP	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2230307	0.536	rs11166385	chr1:100443462	A/G	cg24955406	chr1:100503596	HIAT1	0.67	7.68	0.44	3.83e-13	Carotid intima media thickness;
KIRP	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-5.35	-0.32	2.05e-7	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06481639	chr22:41940642	POLR3H	0.71	7.27	0.42	4.79e-12	Vitiligo;
KIRP	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-6.25	-0.37	1.83e-9	Glomerular filtration rate (creatinine);
KIRP	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	6.67	0.39	1.68e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-0.97	-14.04	-0.67	2.83e-33	Blood trace element (Zn levels);
KIRP	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.66	6.54	0.38	3.57e-10	Axial length;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs13272623	0.502	rs268627	chr8:71561041	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.58	-7.58	-0.44	6.9e-13	IgG glycosylation;
KIRP	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg11906718	chr8:101322791	RNF19A	-0.67	-7.55	-0.43	8.62e-13	Atrioventricular conduction;
KIRP	cis	rs9790314	0.663	rs7632423	chr3:160738728	A/G	cg03342759	chr3:160939853	NMD3	0.46	5.93	0.35	9.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.569	rs8066378	chr17:3996334	T/C	cg09695851	chr17:3907499	NA	0.54	5.15	0.31	5.3e-7	Type 2 diabetes;
KIRP	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.69	8.53	0.48	1.53e-15	Multiple sclerosis;
KIRP	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.51	7.36	0.42	2.71e-12	Daytime sleep phenotypes;
KIRP	cis	rs548987	0.529	rs6456703	chr6:25826119	C/T	cg12310025	chr6:25882481	NA	-0.43	-5.04	-0.31	8.84e-7	Homocysteine levels;
KIRP	cis	rs11605924	0.766	rs12419690	chr11:45858584	G/A	cg23097878	chr11:45879730	CRY2	0.3	6.22	0.37	2.07e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg14768367	chr16:72042858	DHODH	0.45	5.51	0.33	9.16e-8	Fibrinogen levels;
KIRP	cis	rs12476592	0.602	rs262488	chr2:63882179	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-4.85	-0.3	2.21e-6	Childhood ear infection;
KIRP	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg17376030	chr22:41985996	PMM1	0.48	5.24	0.32	3.54e-7	Vitiligo;
KIRP	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-5.04	-0.31	8.87e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4765905	0.671	rs1108075	chr12:2333671	G/A	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.71	-0.34	3.28e-8	Schizophrenia;
KIRP	cis	rs654128	0.545	rs339325	chr6:117205393	T/C	cg12892004	chr6:117198278	RFX6	-0.42	-5.73	-0.34	2.87e-8	Telomere length;
KIRP	cis	rs8033133	0.647	rs1124767	chr15:25326173	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.56	-7.02	-0.41	2.12e-11	Blood osmolality (transformed sodium);
KIRP	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.68	8.89	0.49	1.33e-16	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg13147721	chr7:65941812	NA	-0.92	-6.64	-0.39	2.04e-10	Diabetic kidney disease;
KIRP	cis	rs365132	0.934	rs183686	chr5:176494102	A/G	cg16309518	chr5:176445507	NA	-0.87	-13.1	-0.64	4.25e-30	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.3	-5.0	-0.3	1.1e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.56	7.76	0.44	2.3e-13	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg23693289	chr8:27183097	PTK2B	0.58	7.46	0.43	1.49e-12	Neuroticism;
KIRP	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.74	-9.02	-0.5	5.36e-17	Personality dimensions;
KIRP	cis	rs6516091	0.850	rs62199228	chr20:6047655	G/A	cg25325723	chr20:6104886	FERMT1	-0.6	-5.9	-0.35	1.19e-8	Abdominal aortic aneurysm;
KIRP	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.37	-0.43	2.53e-12	Type 2 diabetes;
KIRP	cis	rs17301259	0.587	rs7808887	chr7:88441125	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.3	-4.93	-0.3	1.5e-6	Heschl's gyrus morphology;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01934787	chr3:37152029	LRRFIP2	0.39	6.17	0.37	2.85e-9	C-reactive protein;
KIRP	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg06115741	chr20:33292138	TP53INP2	0.4	4.86	0.3	2.13e-6	Height;
KIRP	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.38	7.44e-10	Height;
KIRP	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.73	9.96	0.54	7.49e-20	Red blood cell count;
KIRP	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg07001201	chr5:642380	CEP72	0.68	6.4	0.38	7.71e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1832871	0.672	rs9457362	chr6:158772052	C/T	cg07215822	chr6:158701037	NA	-0.63	-7.32	-0.42	3.45e-12	Height;
KIRP	cis	rs722599	0.683	rs10144860	chr14:75286426	T/C	cg08847533	chr14:75593920	NEK9	0.52	6.21	0.37	2.3e-9	IgG glycosylation;
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs12712073	0.845	rs1370353	chr2:100764824	G/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10046574	0.561	rs10226494	chr7:135214412	C/G	cg27474649	chr7:135195673	CNOT4	0.56	5.36	0.32	1.94e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg13819577	chr1:248512075	OR14C36	-0.38	-5.05	-0.31	8.57e-7	Common traits (Other);
KIRP	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg21466736	chr12:48725269	NA	-0.45	-5.83	-0.35	1.72e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03647317	chr4:187891568	NA	-0.82	-13.82	-0.66	1.54e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.57	7.64	0.44	4.75e-13	Joint mobility (Beighton score);
KIRP	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.21	-0.42	6.85e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.61	-8.38	-0.47	4.15e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs8018808	0.935	rs176772	chr14:77881808	A/G	cg20045696	chr14:77926864	AHSA1	0.48	6.11	0.36	3.9e-9	Myeloid white cell count;
KIRP	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg02023728	chr11:77925099	USP35	-0.33	-5.33	-0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.67	-0.34	4.06e-8	Endometrial cancer;
KIRP	cis	rs986417	0.688	rs8018111	chr14:60964347	A/G	cg27398547	chr14:60952738	C14orf39	0.66	6.66	0.39	1.82e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg22903471	chr2:27725779	GCKR	-0.37	-5.16	-0.31	5.2e-7	Oral cavity cancer;
KIRP	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.61	9.95	0.54	7.82e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7709909	0.755	rs32950	chr5:80018244	A/G	cg24059623	chr5:79951536	MSH3;DHFR	0.36	4.96	0.3	1.33e-6	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9633740	0.685	rs4934284	chr10:82277297	C/G	cg01528321	chr10:82214614	TSPAN14	-0.93	-6.05	-0.36	5.42e-9	Post bronchodilator FEV1;
KIRP	cis	rs6466055	0.661	rs17640623	chr7:104913312	G/C	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs1864585	0.520	rs73208785	chr8:10678120	T/C	cg21775007	chr8:11205619	TDH	-0.49	-4.88	-0.3	1.95e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04705907	chr1:169764193	C1orf112;C1orf156	-0.57	-6.77	-0.4	9.39e-11	Interleukin-4 levels;
KIRP	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.78	0.4	8.73e-11	Diabetic retinopathy;
KIRP	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.6	-8.05	-0.46	3.48e-14	Schizophrenia;
KIRP	cis	rs7011049	1.000	rs72643599	chr8:53854434	A/G	cg26025543	chr8:53854495	NA	0.75	7.78	0.44	2.06e-13	Systolic blood pressure;
KIRP	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.32	18.72	0.77	3.28e-49	Corneal structure;
KIRP	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.31	-7.27	-0.42	4.63e-12	Mean corpuscular volume;
KIRP	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.26	-0.47	8.92e-15	Triglycerides;
KIRP	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.58	8.83	0.49	1.95e-16	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg24826892	chr11:71159390	DHCR7	0.43	5.15	0.31	5.26e-7	Vitamin D levels;
KIRP	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	1.1	12.19	0.61	4.72e-27	Post bronchodilator FEV1;
KIRP	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg07511934	chr16:89386912	ANKRD11	0.39	4.97	0.3	1.27e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-9.82	-0.53	2.06e-19	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-0.79	-7.7	-0.44	3.32e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.6	-7.0	-0.41	2.37e-11	Menarche (age at onset);
KIRP	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	9.4	0.51	3.91e-18	Obesity-related traits;
KIRP	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg21775007	chr8:11205619	TDH	0.73	11.32	0.59	3.39e-24	Retinal vascular caliber;
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg02462569	chr6:150064036	NUP43	0.35	5.27	0.32	3.04e-7	Lung cancer;
KIRP	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	7.27	0.42	4.84e-12	Glomerular filtration rate;
KIRP	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.62	-0.44	5.62e-13	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.84e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs8049040	0.524	rs35326792	chr16:71427061	G/A	cg08717414	chr16:71523259	ZNF19	-0.59	-6.8	-0.4	7.72e-11	Blood protein levels;
KIRP	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg04727924	chr7:799746	HEATR2	-0.69	-7.21	-0.42	7.05e-12	Cerebrospinal P-tau181p levels;
KIRP	trans	rs12709013	0.591	rs6499980	chr16:58821876	C/T	cg12115882	chr11:133449267	NA	-0.45	-6.19	-0.37	2.52e-9	Blood metabolite ratios;
KIRP	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.77	0.4	9.43e-11	Morning vs. evening chronotype;
KIRP	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg23307798	chr14:103986281	CKB	-0.51	-6.86	-0.4	5.7e-11	Coronary artery disease;
KIRP	cis	rs4664304	0.754	rs67504285	chr2:160821211	C/T	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.15	-0.31	5.21e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.6	6.74	0.4	1.09e-10	Subjective well-being;
KIRP	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs13095912	0.719	rs7625483	chr3:185297113	T/C	cg11274856	chr3:185301563	NA	0.6	7.5	0.43	1.13e-12	Systolic blood pressure;
KIRP	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.86	-11.52	-0.59	7.45e-25	Primary sclerosing cholangitis;
KIRP	cis	rs113123495	0.609	rs2485275	chr19:5636672	A/T	cg26242866	chr19:5711310	LONP1	0.73	4.93	0.3	1.53e-6	Obsessive-compulsive symptoms;
KIRP	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.65	-8.5	-0.48	1.8e-15	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg13753209	chr17:57696993	CLTC	0.56	5.48	0.33	1.04e-7	Hemoglobin concentration;
KIRP	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.54	6.97	0.41	2.89e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.0	-0.41	2.41e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7246967	0.611	rs2194113	chr19:22958075	C/T	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs6547631	0.808	rs13011848	chr2:85907694	G/A	cg07313956	chr2:85895360	SFTPB	0.33	5.01	0.3	1.04e-6	Blood protein levels;
KIRP	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg07856975	chr6:36356162	ETV7	0.45	5.67	0.34	3.98e-8	Platelet distribution width;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10633746	chr17:18164442	SMCR7	0.6	7.07	0.41	1.58e-11	Smoking initiation;
KIRP	cis	rs7766436	0.848	rs13211568	chr6:22573180	A/T	cg13666174	chr6:22585274	NA	-0.46	-6.03	-0.36	5.82e-9	Coronary artery disease;
KIRP	cis	rs9715521	0.775	rs11931812	chr4:59844473	T/C	cg11281224	chr4:60001000	NA	-0.42	-5.15	-0.31	5.39e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg05088513	chr18:12329191	AFG3L2	0.47	6.32	0.37	1.2e-9	Obesity-related traits;
KIRP	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17507749	chr15:85114479	UBE2QP1	0.72	7.93	0.45	7.76e-14	Schizophrenia;
KIRP	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs9311676	0.656	rs11712213	chr3:58384995	G/A	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg26681399	chr22:41777847	TEF	0.5	5.14	0.31	5.68e-7	Vitiligo;
KIRP	cis	rs253959	0.576	rs785370	chr5:115646886	T/G	cg23108291	chr5:115420582	COMMD10	-0.45	-5.09	-0.31	6.97e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	cis	rs7017914	0.935	rs35564237	chr8:71600474	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.79	10.6	0.56	7.47e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.88	13.84	0.66	1.3e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg17554472	chr22:41940697	POLR3H	-0.66	-7.38	-0.43	2.45e-12	Vitiligo;
KIRP	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg07606381	chr6:8435919	SLC35B3	-0.65	-8.49	-0.48	2.04e-15	Motion sickness;
KIRP	cis	rs17121403	0.661	rs11166414	chr1:100660826	G/A	cg24955406	chr1:100503596	HIAT1	0.75	5.05	0.31	8.68e-7	Pulmonary function decline;
KIRP	cis	rs6457821	1.000	rs6934583	chr6:35297390	G/A	cg06087101	chr6:35551932	FKBP5	0.55	5.04	0.31	9.12e-7	Height;
KIRP	cis	rs4654899	0.680	rs2305463	chr1:21180181	C/T	cg08890418	chr1:21044141	KIF17	-0.35	-5.3	-0.32	2.55e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2860975	0.620	rs7898759	chr10:96800354	T/C	cg09036531	chr10:96991505	NA	-0.48	-5.87	-0.35	1.4e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18357526	chr6:26021779	HIST1H4A	0.52	6.72	0.39	1.24e-10	Height;
KIRP	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs7178909	0.872	rs7179633	chr15:90434877	T/C	cg19708238	chr15:90437601	AP3S2	0.57	7.9	0.45	9.08e-14	Common traits (Other);
KIRP	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.6	-8.67	-0.48	5.88e-16	Brugada syndrome;
KIRP	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.53	-7.03	-0.41	1.99e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.61	-0.34	5.52e-8	Total body bone mineral density;
KIRP	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Colorectal cancer;
KIRP	cis	rs11123406	0.723	rs4849463	chr2:111958854	C/G	cg23466623	chr2:111982296	NA	0.51	6.89	0.4	4.64e-11	Type 2 diabetes;
KIRP	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.79	7.11	0.41	1.22e-11	Obesity-related traits;
KIRP	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.55	7.13	0.41	1.1e-11	Menopause (age at onset);
KIRP	trans	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.02	-0.41	2.17e-11	Diabetic kidney disease;
KIRP	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	11.77	0.6	1.18e-25	Bipolar disorder;
KIRP	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg17736920	chr1:242011382	EXO1	0.71	9.19	0.51	1.72e-17	Menopause (age at onset);
KIRP	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg16586182	chr3:47516702	SCAP	0.45	5.45	0.33	1.23e-7	Birth weight;
KIRP	cis	rs11628318	0.853	rs4906224	chr14:103025040	C/T	cg12046867	chr14:103022105	NA	-0.55	-6.84	-0.4	6.18e-11	Platelet count;
KIRP	cis	rs9826463	0.757	rs60001529	chr3:142282717	G/A	cg20824294	chr3:142316082	PLS1	0.41	6.47	0.38	5.22e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.52	-0.33	8.38e-8	Obesity-related traits;
KIRP	cis	rs698833	0.886	rs2053454	chr2:44550290	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.84	0.35	1.62e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg25590640	chr22:38005350	GGA1	0.49	6.21	0.37	2.28e-9	Educational attainment;
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.21	-0.32	4.05e-7	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs2668423	0.922	rs2668418	chr19:1366422	C/G	cg02639931	chr19:1387894	NDUFS7	-0.75	-9.76	-0.53	3.06e-19	Nonalcoholic fatty liver disease;
KIRP	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.15	-0.41	1.01e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	trans	rs225245	0.782	rs161183	chr17:33919475	G/C	cg19694781	chr19:47549865	TMEM160	-0.53	-6.49	-0.38	4.73e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18574725	chr17:34900600	GGNBP2	0.57	7.41	0.43	2e-12	Parkinson's disease;
KIRP	cis	rs4308124	1.000	rs4308124	chr2:112010486	T/C	cg23466623	chr2:111982296	NA	0.4	5.61	0.34	5.56e-8	Vitiligo;
KIRP	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg11235152	chr1:67600687	NA	0.74	11.14	0.58	1.33e-23	Psoriasis;
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg17207736	chr8:142237307	SLC45A4	-0.5	-6.33	-0.37	1.17e-9	Immature fraction of reticulocytes;
KIRP	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg23748340	chr12:48592721	NA	-0.43	-4.91	-0.3	1.7e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19894588	chr14:64061835	NA	-0.49	-6.84	-0.4	6.39e-11	Glioblastoma;Glioma;
KIRP	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.4	6.61	0.39	2.37e-10	Testicular germ cell tumor;
KIRP	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs10465746	0.935	rs2389647	chr1:84403041	C/T	cg10977910	chr1:84465055	TTLL7	0.49	5.92	0.35	1.1e-8	Obesity-related traits;
KIRP	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg18501202	chr6:125855421	NA	-0.32	-4.88	-0.3	1.93e-6	Brugada syndrome;
KIRP	cis	rs7523273	0.565	rs34355011	chr1:207887322	T/G	cg22525895	chr1:207977042	MIR29B2	0.46	5.74	0.34	2.82e-8	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7173743	0.967	rs28694044	chr15:79134718	A/T	cg00079375	chr15:79125835	NA	-0.41	-5.83	-0.35	1.7e-8	Coronary artery disease;
KIRP	cis	rs7923609	1.000	rs12355784	chr10:65121565	G/T	cg01631684	chr10:65280961	REEP3	-0.5	-5.88	-0.35	1.33e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.19	0.51	1.75e-17	Colorectal cancer;
KIRP	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.72	8.9	0.49	1.28e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg21174375	chr14:64681225	SYNE2	0.44	4.93	0.3	1.52e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10011647	chr11:58892585	FAM111B	0.54	7.26	0.42	4.99e-12	Interleukin-4 levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18151703	chr5:115418530	NA	-0.41	-6.45	-0.38	6.02e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.65	7.37	0.43	2.55e-12	Body mass index;
KIRP	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.63	-0.39	2.05e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg06035437	chr8:1398411	NA	-0.6	-7.14	-0.41	1.07e-11	Triglycerides;
KIRP	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg02725872	chr8:58115012	NA	-0.45	-5.09	-0.31	7.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs61884328	0.852	rs55968738	chr11:47037104	C/T	cg23433285	chr11:47201945	PACSIN3	0.75	6.06	0.36	5.16e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.44	5.96	0.36	8.51e-9	Red blood cell count;
KIRP	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.45	6.39	0.38	8.33e-10	Sitting height ratio;
KIRP	cis	rs2839627	0.598	rs2246573	chr21:44253016	C/T	cg03543861	chr21:44258195	NA	-0.53	-6.12	-0.36	3.64e-9	Information processing speed;
KIRP	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg25019033	chr10:957182	NA	0.66	7.98	0.45	5.44e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs4849845	0.889	rs6542576	chr2:121013781	G/A	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg23815491	chr16:72088622	HP	-0.36	-6.03	-0.36	5.9e-9	Prostate cancer;
KIRP	cis	rs4704187	0.687	rs1422699	chr5:74442410	G/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.55	6.59	0.39	2.67e-10	Blood metabolite levels;
KIRP	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg05370193	chr1:21551575	ECE1	-0.36	-4.96	-0.3	1.33e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-8.1	-0.46	2.49e-14	Diastolic blood pressure;
KIRP	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.83	0.49	1.99e-16	Motion sickness;
KIRP	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg00122941	chr17:4613640	ARRB2	0.78	8.33	0.47	5.86e-15	Lymphocyte counts;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02145411	chr1:110528025	AHCYL1	-0.48	-6.21	-0.37	2.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.65	7.53	0.43	9.79e-13	Neutrophil percentage of white cells;
KIRP	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	12.42	0.62	8.27e-28	Menopause (age at onset);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24786176	chr4:113153431	AP1AR	0.7	6.5	0.38	4.53e-10	Lung function (FEV1);
KIRP	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg00405596	chr8:11794950	NA	-0.42	-5.44	-0.33	1.28e-7	Triglycerides;
KIRP	cis	rs7395581	0.918	rs4752824	chr11:47324666	A/T	cg26139080	chr11:47293733	MADD	-0.4	-5.0	-0.3	1.11e-6	HDL cholesterol;
KIRP	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	6.51	0.38	4.14e-10	Neuroticism;
KIRP	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg16497661	chr14:103986332	CKB	-0.51	-6.43	-0.38	6.42e-10	Coronary artery disease;
KIRP	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg27205649	chr11:78285834	NARS2	-0.65	-8.75	-0.49	3.45e-16	Alzheimer's disease (survival time);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04412200	chr7:148680425	NA	0.44	6.13	0.36	3.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg21427119	chr20:30132790	HM13	-0.66	-6.44	-0.38	6.07e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.67	8.83	0.49	1.95e-16	Schizophrenia;
KIRP	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg12218747	chr21:37451666	NA	-0.54	-7.61	-0.44	6.01e-13	Mitral valve prolapse;
KIRP	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.48	-6.22	-0.37	2.08e-9	Height;
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg00684032	chr4:1343700	KIAA1530	0.53	7.23	0.42	6.16e-12	Longevity;
KIRP	cis	rs7078012	0.504	rs17879395	chr10:81691125	A/G	cg24613050	chr10:81743128	NA	-0.53	-4.96	-0.3	1.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.27	-0.32	3e-7	Breast cancer;
KIRP	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg25486957	chr4:152246857	NA	-0.5	-5.34	-0.32	2.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg02023728	chr11:77925099	USP35	0.35	5.38	0.32	1.71e-7	Alzheimer's disease (survival time);
KIRP	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.19	0.58	9.33e-24	Morning vs. evening chronotype;
KIRP	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg22705602	chr4:152727874	NA	-0.55	-9.78	-0.53	2.67e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg17372223	chr3:52568218	NT5DC2	0.36	5.75	0.34	2.59e-8	Electroencephalogram traits;
KIRP	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.49	-7.49	-0.43	1.22e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg00938859	chr5:1591904	SDHAP3	0.55	6.74	0.39	1.14e-10	Breast cancer;
KIRP	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg19847866	chr10:1019161	NA	-0.61	-5.67	-0.34	4.08e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7429990	0.932	rs12493348	chr3:48143538	A/T	cg11946769	chr3:48343235	NME6	-0.43	-5.16	-0.31	4.97e-7	Educational attainment (years of education);
KIRP	cis	rs10488172	0.948	rs10954423	chr7:133331279	T/C	cg10665199	chr7:133106180	EXOC4	-0.52	-5.55	-0.33	7.51e-8	Tonometry;
KIRP	trans	rs1973993	0.745	rs6686016	chr1:96948002	G/A	cg10631902	chr5:14652156	NA	-0.64	-9.47	-0.52	2.38e-18	Weight;
KIRP	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg07636037	chr3:49044803	WDR6	-0.8	-7.04	-0.41	1.93e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg09006292	chr3:64049408	NA	-0.56	-5.33	-0.32	2.21e-7	Lung function (FVC);Lung function (FEV1);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16267784	chr13:24449046	MIPEP	-0.41	-6.07	-0.36	4.81e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9400467	0.537	rs73528998	chr6:111445630	C/T	cg15721981	chr6:111408429	SLC16A10	0.7	6.3	0.37	1.33e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08704250	chr15:31115839	NA	-0.46	-7.17	-0.42	9e-12	Huntington's disease progression;
KIRP	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg08499158	chr17:42289980	UBTF	-0.74	-9.7	-0.53	4.63e-19	Total body bone mineral density;
KIRP	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg00319359	chr11:70116639	PPFIA1	0.73	5.75	0.34	2.61e-8	Coronary artery disease;
KIRP	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-1.01	-12.24	-0.62	3.34e-27	Vitiligo;
KIRP	cis	rs2073300	1.000	rs2207988	chr20:23446000	C/A	cg12480562	chr20:23434244	CST11	0.6	5.99	0.36	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3105593	0.933	rs3101850	chr15:50844314	A/G	cg08437265	chr15:50716283	USP8	0.36	4.93	0.3	1.53e-6	QT interval;
KIRP	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg06935464	chr4:38784597	TLR10	0.52	5.2	0.31	4.1e-7	Breast cancer;
KIRP	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg02475777	chr4:1388615	CRIPAK	0.55	5.18	0.31	4.64e-7	Recombination rate (females);
KIRP	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg19847130	chr8:10466454	RP1L1	0.37	5.59	0.34	5.89e-8	Neuroticism;
KIRP	cis	rs838721	0.574	rs11679046	chr2:234258101	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	5.03	0.31	9.66e-7	Total body bone mineral density;
KIRP	trans	rs10027350	0.704	rs382650	chr4:25235360	G/C	cg09449104	chr2:200935	NA	-0.37	-6.07	-0.36	4.94e-9	Childhood ear infection;
KIRP	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.59	-8.19	-0.46	1.38e-14	Breast size;
KIRP	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.7	-9.09	-0.5	3.36e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg14092571	chr14:90743983	NA	0.41	4.98	0.3	1.18e-6	Mortality in heart failure;
KIRP	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.52	7.46	0.43	1.44e-12	Schizophrenia;
KIRP	cis	rs8062405	0.690	rs4787458	chr16:28531287	A/G	cg07382826	chr16:28625726	SULT1A1	0.53	5.77	0.35	2.39e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12210905	1.000	rs9368498	chr6:27254006	G/A	cg11502198	chr6:26597334	ABT1	-0.85	-4.86	-0.3	2.09e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.75	10.64	0.56	5.29e-22	Schizophrenia;
KIRP	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg15934090	chr1:100435551	SLC35A3	-0.47	-6.03	-0.36	6e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3760982	0.813	rs10426528	chr19:44299298	A/G	cg11993925	chr19:44307056	LYPD5	0.37	5.24	0.32	3.5e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	trans	rs12517041	1.000	rs6891825	chr5:23299740	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.55	-0.48	1.33e-15	Calcium levels;
KIRP	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs889512	0.642	rs28595463	chr16:75281235	C/T	cg03315344	chr16:75512273	CHST6	-0.63	-5.08	-0.31	7.31e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.71	9.01	0.5	5.88e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-0.85	-9.15	-0.5	2.21e-17	Gut microbiome composition (summer);
KIRP	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.96	12.45	0.62	6.32e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.22	14.16	0.67	1.12e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs7945718	0.781	rs11022505	chr11:12822366	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.45	5.57	0.33	6.51e-8	Educational attainment (years of education);
KIRP	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.49	-5.46	-0.33	1.17e-7	Iron status biomarkers;
KIRP	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.83	-0.4	6.52e-11	Coronary artery disease;
KIRP	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.86	10.37	0.55	3.75e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs6450176	0.953	rs3776724	chr5:53292270	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-10.96	-0.57	5.05e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-7.86	-0.45	1.17e-13	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg12623145	chr2:97778927	ANKRD36	-0.63	-6.36	-0.38	9.78e-10	Hip geometry;
KIRP	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.71	7.11	0.41	1.22e-11	Chronic kidney disease;
KIRP	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-9.98	-0.54	6.52e-20	Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg24315340	chr6:146058215	EPM2A	-0.39	-4.9	-0.3	1.77e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs253959	0.607	rs254152	chr5:115641827	C/G	cg23108291	chr5:115420582	COMMD10	0.45	5.14	0.31	5.52e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg05834845	chr3:195489306	MUC4	0.75	6.67	0.39	1.72e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9394841	0.667	rs3827633	chr6:41759846	A/C	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.03	-0.41	2.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	5.79	0.35	2.16e-8	Longevity;
KIRP	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg08603382	chr10:743973	NA	0.45	6.47	0.38	5.23e-10	Psychosis in Alzheimer's disease;
KIRP	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg00405596	chr8:11794950	NA	0.49	6.48	0.38	4.96e-10	Mood instability;
KIRP	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg14914422	chr1:46958856	NA	-0.44	-5.42	-0.33	1.43e-7	Monobrow;
KIRP	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.03	-0.31	9.38e-7	Depression;
KIRP	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.16e-51	Leprosy;
KIRP	cis	rs7828089	1.000	rs34542820	chr8:22264079	C/T	cg13512537	chr8:22265999	SLC39A14	-0.44	-5.91	-0.35	1.11e-8	Verbal declarative memory;
KIRP	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	17.26	0.74	2.9e-44	Homoarginine levels;
KIRP	trans	rs2048656	0.578	rs925610	chr8:9681836	G/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.84e-9	Schizophrenia;
KIRP	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.37	-0.32	1.79e-7	Schizophrenia;
KIRP	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg24747557	chr10:131355152	MGMT	-0.42	-5.59	-0.34	6.05e-8	Response to temozolomide;
KIRP	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg17554472	chr22:41940697	POLR3H	-0.44	-5.47	-0.33	1.11e-7	Vitiligo;
KIRP	cis	rs661054	0.955	rs661946	chr11:114430609	C/T	cg19465033	chr11:114479364	NA	0.35	4.85	0.3	2.23e-6	Ulcerative colitis;
KIRP	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.71	9.4	0.51	3.89e-18	Morning vs. evening chronotype;
KIRP	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg16797656	chr11:68205561	LRP5	0.37	4.86	0.3	2.06e-6	Total body bone mineral density;
KIRP	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg21132104	chr15:45694354	SPATA5L1	0.59	7.28	0.42	4.51e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs3096299	0.809	rs3096325	chr16:89421678	A/G	cg07511934	chr16:89386912	ANKRD11	0.46	6.0	0.36	6.83e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg08392591	chr16:89556376	ANKRD11	0.42	5.14	0.31	5.5e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg05220968	chr6:146057943	EPM2A	-0.41	-5.3	-0.32	2.63e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg15655495	chr12:38532458	NA	-0.29	-5.23	-0.32	3.54e-7	Bladder cancer;
KIRP	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.2	-0.37	2.35e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg17764715	chr19:33622953	WDR88	0.68	8.32	0.47	5.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg12963246	chr6:28129442	ZNF389	0.53	6.47	0.38	5.28e-10	Depression;
KIRP	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg26898376	chr11:64110657	CCDC88B	0.49	5.67	0.34	4.09e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.44	-0.33	1.26e-7	Lung cancer;
KIRP	cis	rs9815354	1.000	rs9876960	chr3:41985812	C/T	cg03022575	chr3:42003672	ULK4	-0.49	-5.58	-0.34	6.24e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.73	7.06	0.41	1.74e-11	Psoriasis vulgaris;
KIRP	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg11189052	chr15:85197271	WDR73	0.5	5.2	0.31	4.27e-7	Schizophrenia;
KIRP	cis	rs2625529	0.938	rs4238447	chr15:72131880	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-6.2	-0.37	2.4e-9	Red blood cell count;
KIRP	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.58	7.88	0.45	1.03e-13	Height;
KIRP	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11645453	chr3:52864694	ITIH4	-0.34	-5.39	-0.33	1.61e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.83	9.97	0.54	7.02e-20	Corneal astigmatism;
KIRP	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.7	7.41	0.43	2.04e-12	Small cell lung carcinoma;
KIRP	cis	rs9604529	0.759	rs111556560	chr13:114623063	G/A	cg13259177	chr13:114761607	RASA3	-0.62	-5.33	-0.32	2.17e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7582720	1.000	rs72932772	chr2:203682304	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.5	0.56	1.49e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.38	0.47	4.23e-15	IgG glycosylation;
KIRP	cis	rs6882046	0.513	rs446219	chr5:88005827	T/C	cg24804195	chr5:87968844	LOC645323	-0.46	-6.08	-0.36	4.44e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg17332573	chr6:26250934	HIST1H2BH;HIST1H3F	-0.66	-5.0	-0.3	1.09e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs4141404	0.851	rs5749248	chr22:31683711	C/A	cg22777020	chr22:31556080	RNF185	-0.55	-5.55	-0.33	7.52e-8	Paclitaxel-induced neuropathy;
KIRP	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg25486957	chr4:152246857	NA	-0.46	-5.39	-0.33	1.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg00405596	chr8:11794950	NA	0.57	7.93	0.45	7.59e-14	Neuroticism;
KIRP	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg16141378	chr3:129829833	LOC729375	-0.45	-6.05	-0.36	5.3e-9	Schizophrenia;
KIRP	cis	rs42648	0.535	rs10952994	chr7:89753859	G/C	cg25739043	chr7:89950458	NA	0.36	5.58	0.34	6.37e-8	Homocysteine levels;
KIRP	cis	rs1505368	0.533	rs4369808	chr2:213261279	G/C	cg16329650	chr2:213403929	ERBB4	0.42	5.71	0.34	3.3e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg11584989	chr19:19387371	SF4	0.4	5.09	0.31	7.06e-7	Tonsillectomy;
KIRP	cis	rs4253772	0.872	rs79700435	chr22:46638211	G/A	cg18190219	chr22:46762943	CELSR1	-0.63	-5.94	-0.35	9.5e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4132509	1.000	rs3766673	chr1:243720473	T/C	cg25706552	chr1:244017396	NA	0.51	6.55	0.39	3.31e-10	RR interval (heart rate);
KIRP	cis	rs12913538	1.000	rs4265758	chr15:62896297	T/G	cg09983546	chr15:62884068	NA	0.58	8.15	0.46	1.8e-14	Sleep depth;
KIRP	cis	rs6968419	0.642	rs67251819	chr7:115905586	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.77	-0.35	2.43e-8	Intraocular pressure;
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg10534938	chr5:1868639	NA	0.37	5.02	0.3	9.94e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg10189261	chr14:101176105	NA	-0.5	-5.0	-0.3	1.11e-6	Plateletcrit;
KIRP	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.72	-11.04	-0.58	2.74e-23	Hepatocellular carcinoma;
KIRP	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.05	11.8	0.6	9.21e-26	Vitiligo;
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13198984	chr17:80129470	CCDC57	0.59	8.79	0.49	2.58e-16	Life satisfaction;
KIRP	trans	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg10756647	chr7:56101905	PSPH	1.02	7.45	0.43	1.61e-12	Diabetic kidney disease;
KIRP	cis	rs6545883	0.931	rs11125885	chr2:61755728	G/C	cg15711740	chr2:61764176	XPO1	-0.61	-8.27	-0.47	8.41e-15	Tuberculosis;
KIRP	cis	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg00405596	chr8:11794950	NA	0.55	7.79	0.44	1.91e-13	Monocyte count;
KIRP	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.45e-24	Cognitive test performance;
KIRP	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg17145862	chr1:211918768	LPGAT1	-0.6	-6.35	-0.38	1.05e-9	Crohn's disease;
KIRP	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.59	0.73	5.57e-42	Chronic sinus infection;
KIRP	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg09699651	chr6:150184138	LRP11	0.45	5.91	0.35	1.13e-8	Lung cancer;
KIRP	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.64	8.24	0.46	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.64	6.99	0.41	2.51e-11	Gut microbiome composition (summer);
KIRP	cis	rs9900972	0.877	rs8064344	chr17:76876974	C/T	cg00961940	chr17:76876995	TIMP2	0.54	6.99	0.41	2.54e-11	Obesity-related traits;
KIRP	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg23625390	chr15:77176239	SCAPER	0.54	7.33	0.42	3.33e-12	Blood metabolite levels;
KIRP	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg22676075	chr6:135203613	NA	0.5	7.2	0.42	7.42e-12	Red blood cell count;
KIRP	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.55	-6.81	-0.4	7.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg24631222	chr15:78858424	CHRNA5	0.76	9.08	0.5	3.67e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.16	0.54	1.73e-20	Cognitive test performance;
KIRP	cis	rs7312774	1.000	rs7312774	chr12:107305728	G/A	cg16260113	chr12:107380972	MTERFD3	0.71	6.44	0.38	6.26e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.1	0.31	6.74e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	6.0	0.36	7.03e-9	Bipolar disorder;
KIRP	cis	rs1712517	0.771	rs61350103	chr10:105069120	A/C	cg05636881	chr10:105038444	INA	0.43	6.19	0.37	2.45e-9	Migraine;
KIRP	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-6.61	-0.39	2.39e-10	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18505879	chr18:60382658	PHLPP1	0.47	6.22	0.37	2.07e-9	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17431079	chr1:39607710	MACF1	0.44	6.06	0.36	5.12e-9	Interleukin-4 levels;
KIRP	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg07382826	chr16:28625726	SULT1A1	0.48	5.29	0.32	2.65e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg12598211	chr12:123634384	NA	-0.45	-5.52	-0.33	8.75e-8	Neutrophil percentage of white cells;
KIRP	cis	rs7849270	1.000	rs7855278	chr9:131921365	A/C	cg13538475	chr9:131942899	NA	0.32	5.04	0.31	9.16e-7	Blood metabolite ratios;
KIRP	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg07843065	chr1:150265600	MRPS21	-0.51	-7.36	-0.42	2.76e-12	Migraine;
KIRP	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg16141378	chr3:129829833	LOC729375	0.65	8.92	0.49	1.12e-16	Neuroticism;
KIRP	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.36	-4.85	-0.3	2.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13401104	0.587	rs62190973	chr2:237145231	T/A	cg26422059	chr2:237146110	ASB18	0.46	5.27	0.32	3.03e-7	Educational attainment;
KIRP	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs6430538	0.597	rs4300887	chr2:135572810	C/A	cg12500956	chr2:135428796	TMEM163	0.39	5.11	0.31	6.44e-7	Parkinson's disease;
KIRP	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.59	-8.74	-0.49	3.59e-16	Neurofibrillary tangles;
KIRP	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.47	-6.93	-0.4	3.75e-11	Vitamin D levels;
KIRP	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.67	8.45	0.47	2.66e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg24375607	chr4:120327624	NA	0.55	6.08	0.36	4.63e-9	Educational attainment;
KIRP	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.77	8.76	0.49	3.14e-16	Corneal astigmatism;
KIRP	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg00360474	chr6:37504404	NA	-0.47	-6.61	-0.39	2.36e-10	Cognitive performance;
KIRP	cis	rs6988636	0.710	rs62521805	chr8:124159200	C/T	cg15893493	chr8:124194847	FAM83A	0.88	7.15	0.41	9.92e-12	Urinary uromodulin levels;
KIRP	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	1.0	18.01	0.75	7.98e-47	Leprosy;
KIRP	cis	rs2346177	0.875	rs6726089	chr2:46645480	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-5.76	-0.34	2.5e-8	HDL cholesterol;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09564133	chr5:176738847	MXD3	0.58	6.85	0.4	5.87e-11	Smoking initiation;
KIRP	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg27494647	chr7:150038898	RARRES2	0.44	6.01	0.36	6.72e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg22138327	chr13:27999177	GTF3A	0.89	6.78	0.4	8.96e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.96	-11.2	-0.58	8.53e-24	Colorectal cancer;
KIRP	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.47	6.45	0.38	5.98e-10	Birth weight;
KIRP	cis	rs7712401	0.601	rs246282	chr5:122225605	G/T	cg19412675	chr5:122181750	SNX24	0.51	5.58	0.34	6.28e-8	Mean platelet volume;
KIRP	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10053473	chr17:62856997	LRRC37A3	0.72	7.75	0.44	2.37e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg26441486	chr22:50317300	CRELD2	-0.44	-7.17	-0.42	8.62e-12	Schizophrenia;
KIRP	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-8.53	-0.48	1.51e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg12591125	chr7:1885375	MAD1L1	0.59	5.68	0.34	3.81e-8	Bipolar disorder;
KIRP	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg26681399	chr22:41777847	TEF	-0.46	-5.07	-0.31	7.84e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8113308	0.515	rs56343029	chr19:52463437	C/A	cg25782003	chr19:52490127	ZNF350	0.81	6.16	0.37	2.87e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg17554472	chr22:41940697	POLR3H	-0.43	-5.06	-0.31	8.37e-7	Neuroticism;
KIRP	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.84	9.82	0.53	2.1e-19	Neutrophil percentage of white cells;
KIRP	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.2	0.37	2.36e-9	Breast cancer;
KIRP	cis	rs16958440	0.708	rs1434528	chr18:44632323	G/A	cg17192377	chr18:44677553	HDHD2	0.48	5.21	0.32	4.04e-7	Sitting height ratio;
KIRP	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-8.56	-0.48	1.24e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg21186296	chr8:27182909	PTK2B	-0.48	-6.11	-0.36	3.96e-9	Neuroticism;
KIRP	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.78	-0.35	2.27e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg27398637	chr11:122830231	C11orf63	-0.76	-10.23	-0.55	1.08e-20	Menarche (age at onset);
KIRP	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg27147174	chr7:100797783	AP1S1	-0.56	-7.12	-0.41	1.16e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs12949688	0.600	rs10083861	chr17:55838072	C/T	cg12582317	chr17:55822272	NA	0.45	6.43	0.38	6.71e-10	Schizophrenia;
KIRP	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.81	-9.79	-0.53	2.61e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-9.16	-0.5	2.04e-17	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.04	-0.31	9.2e-7	Life satisfaction;
KIRP	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg21361702	chr7:150065534	REPIN1	0.53	5.27	0.32	2.94e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg00846425	chr4:957561	DGKQ	-0.51	-5.23	-0.32	3.57e-7	Type 2 diabetes;
KIRP	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg22689280	chr22:47017522	NA	0.44	4.9	0.3	1.77e-6	Urate levels in obese individuals;
KIRP	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg16512390	chr1:228756714	NA	0.77	6.07	0.36	4.89e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.55	6.92	0.4	3.88e-11	Total body bone mineral density;
KIRP	cis	rs803923	0.545	rs12376144	chr9:119488641	A/C	cg13792444	chr9:119245443	ASTN2	0.36	5.62	0.34	5.23e-8	Lung function (FEV1/FVC);
KIRP	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.53	6.17	0.37	2.78e-9	Dialysis-related mortality;
KIRP	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.25e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35123781	1.000	rs673632	chr5:139057237	G/T	cg10513866	chr5:139070639	NA	0.35	4.87	0.3	2e-6	Schizophrenia;
KIRP	cis	rs6142102	0.961	rs1319363	chr20:32541876	T/A	cg08999081	chr20:33150536	PIGU	0.5	6.04	0.36	5.58e-9	Skin pigmentation;
KIRP	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00321850	chr1:175162397	KIAA0040	0.36	6.4	0.38	8.01e-10	Alcohol dependence;
KIRP	trans	rs7999699	0.902	rs9534772	chr13:48309677	C/G	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.56	-7.33	-0.42	3.35e-12	Aortic root size;
KIRP	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg24315340	chr6:146058215	EPM2A	0.43	5.41	0.33	1.5e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg04727924	chr7:799746	HEATR2	-0.79	-8.74	-0.49	3.78e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7635838	0.819	rs904474	chr3:11524648	C/G	cg00170343	chr3:11313890	ATG7	0.48	6.17	0.37	2.8e-9	HDL cholesterol;
KIRP	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.33	0.55	5.23e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg11859384	chr17:80120422	CCDC57	0.43	5.6	0.34	5.86e-8	Life satisfaction;
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.18	0.37	2.65e-9	Platelet count;
KIRP	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg05527609	chr1:210001259	C1orf107	0.48	5.3	0.32	2.62e-7	Red blood cell count;
KIRP	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	11.98	0.61	2.34e-26	Menopause (age at onset);
KIRP	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.77	0.4	9.42e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.77	11.67	0.6	2.47e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2120243	0.653	rs3816527	chr3:157155314	C/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.49	6.2	0.37	2.31e-9	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.62	7.51	0.43	1.06e-12	Testicular germ cell tumor;
KIRP	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg16898833	chr6:26189333	HIST1H4D	1.0	5.7	0.34	3.42e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg06742321	chr12:123595122	PITPNM2	0.41	5.06	0.31	8.07e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.52	-6.25	-0.37	1.78e-9	Prudent dietary pattern;
KIRP	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg17145862	chr1:211918768	LPGAT1	0.9	12.73	0.63	7.28e-29	Leprosy;
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg10207240	chr12:122356781	WDR66	0.53	7.01	0.41	2.32e-11	Mean corpuscular volume;
KIRP	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg02187348	chr16:89574699	SPG7	0.46	5.79	0.35	2.1e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	13.93	0.66	6.54e-33	Platelet count;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Blood metabolite levels;
KIRP	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	4.87	0.3	2.03e-6	Schizophrenia;
KIRP	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.68	-8.16	-0.46	1.72e-14	Blood protein levels;
KIRP	cis	rs2625529	0.652	rs2957740	chr15:72307691	A/G	cg16672083	chr15:72433130	SENP8	0.44	6.22	0.37	2.12e-9	Red blood cell count;
KIRP	trans	rs13170463	0.579	rs13184257	chr5:8043403	G/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9815354	0.638	rs17284933	chr3:42029835	T/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-7.33	-0.42	3.28e-12	Lung cancer;
KIRP	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.33	-0.32	2.18e-7	Personality dimensions;
KIRP	cis	rs17065868	1.000	rs61947998	chr13:45166114	G/A	cg10246903	chr13:45222710	NA	0.75	6.75	0.4	1.09e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.19	0.31	4.3e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.17	0.31	4.79e-7	Lung cancer;
KIRP	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.44	5.11	0.31	6.54e-7	Schizophrenia;
KIRP	cis	rs7681423	0.951	rs35147053	chr4:155517842	A/G	cg20735720	chr4:155535218	FGG	-0.61	-8.01	-0.45	4.73e-14	Fibrinogen;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26351027	chr8:86157501	CA13	0.39	6.17	0.37	2.81e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.74	-0.63	6.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	0.87	12.46	0.62	5.92e-28	Homoarginine levels;
KIRP	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.45	0.55	2.19e-21	Hip circumference;
KIRP	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.7	-0.34	3.38e-8	Coronary artery disease;
KIRP	cis	rs9638182	0.725	rs35173225	chr7:73001021	C/T	cg14087351	chr7:73037990	MLXIPL	-0.52	-4.88	-0.3	1.95e-6	Triglycerides;
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg07216194	chr8:27182965	PTK2B	-0.5	-6.01	-0.36	6.76e-9	Alzheimer's disease (late onset);
KIRP	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.41	5.3	0.32	2.58e-7	Dilated cardiomyopathy;
KIRP	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.57	-0.33	6.77e-8	Aortic root size;
KIRP	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9859260	1.000	rs2300777	chr3:195790811	A/C	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	cis	rs14168	1.000	rs10998976	chr10:53460490	A/T	cg18823846	chr10:53459691	PRKG1;CSTF2T	0.62	5.46	0.33	1.14e-7	Mammographic density (non-dense area);
KIRP	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	6.64	0.39	1.97e-10	Rheumatoid arthritis;
KIRP	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg13798912	chr7:905769	UNC84A	0.51	5.24	0.32	3.44e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9905704	0.633	rs2531727	chr17:56502264	C/T	cg12560992	chr17:57184187	TRIM37	0.54	5.12	0.31	6.06e-7	Testicular germ cell tumor;
KIRP	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg01181863	chr3:195395398	SDHAP2	-0.71	-8.11	-0.46	2.35e-14	Pancreatic cancer;
KIRP	cis	rs2652822	0.686	rs4774476	chr15:63407390	A/G	cg02713581	chr15:63449717	RPS27L	-0.57	-6.83	-0.4	6.63e-11	Metabolic traits;
KIRP	cis	rs33912345	0.656	rs1269027	chr14:60902298	T/A	cg27398547	chr14:60952738	C14orf39	-0.4	-5.42	-0.33	1.41e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg15674680	chr20:60982522	CABLES2	0.46	5.51	0.33	8.94e-8	Colorectal cancer;
KIRP	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.93	10.0	0.54	5.44e-20	Alzheimer's disease;
KIRP	cis	rs7116495	0.881	rs7930544	chr11:71737354	C/T	cg26138937	chr11:71823887	C11orf51	-0.7	-5.65	-0.34	4.46e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.11	-0.36	3.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2548003	0.518	rs2554904	chr5:28726189	T/A	cg12623145	chr2:97778927	ANKRD36	0.62	6.16	0.37	2.99e-9	Hip geometry;
KIRP	cis	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.8	-0.4	8.05e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.65	7.99	0.45	5.23e-14	Aortic root size;
KIRP	cis	rs6546324	0.625	rs11900280	chr2:67840401	T/C	cg15745817	chr2:67799979	NA	-0.69	-7.44	-0.43	1.72e-12	Endometriosis;
KIRP	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg13147721	chr7:65941812	NA	-0.93	-6.69	-0.39	1.53e-10	Diabetic kidney disease;
KIRP	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg09455208	chr3:40491958	NA	-0.37	-6.64	-0.39	2.04e-10	Renal cell carcinoma;
KIRP	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.36	-0.38	1e-9	Aortic root size;
KIRP	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	12.59	0.63	2.27e-28	Bone mineral density;
KIRP	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.88	0.3	1.95e-6	Coronary artery calcification;
KIRP	cis	rs601339	0.878	rs7956284	chr12:123183017	G/A	cg18578876	chr12:123200353	GPR109B	0.5	4.92	0.3	1.59e-6	Adiponectin levels;
KIRP	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg01097406	chr16:89675127	NA	-0.35	-5.41	-0.33	1.52e-7	Vitiligo;
KIRP	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg23958373	chr8:599963	NA	0.88	6.96	0.41	3.06e-11	IgG glycosylation;
KIRP	cis	rs6546324	1.000	rs1430787	chr2:67868498	A/T	cg15745817	chr2:67799979	NA	-0.45	-5.96	-0.36	8.58e-9	Endometriosis;
KIRP	cis	rs58649573	0.509	rs2055029	chr9:126789678	T/C	cg14112217	chr9:126806003	NA	0.35	5.13	0.31	5.87e-7	Post-traumatic stress disorder;
KIRP	cis	rs2594989	0.778	rs6801721	chr3:11470267	T/C	cg01796438	chr3:11312864	ATG7	-0.72	-8.29	-0.47	7.47e-15	Circulating chemerin levels;
KIRP	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg22027985	chr11:4115532	RRM1	-0.43	-4.95	-0.3	1.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg01843034	chr6:37503916	NA	-0.98	-15.64	-0.71	9.77e-39	Cognitive performance;
KIRP	cis	rs6838801	0.892	rs10518153	chr4:77573615	C/T	cg17476223	chr4:77663285	SHROOM3	0.52	7.07	0.41	1.56e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs2916247	1.000	rs2920466	chr8:92998096	A/T	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.61	-0.48	8.66e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.09	0.46	2.69e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs4356975	0.563	rs12642938	chr4:69976217	T/C	cg27372994	chr4:70080453	UGT2B11	0.4	5.23	0.32	3.62e-7	Obesity-related traits;
KIRP	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg08873628	chr1:175162347	KIAA0040	-0.4	-5.8	-0.35	1.98e-8	Alcohol dependence;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22619810	chr11:63679637	RCOR2	-0.41	-6.02	-0.36	6.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg02725872	chr8:58115012	NA	-0.53	-6.05	-0.36	5.35e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.7	10.94	0.57	5.89e-23	Educational attainment;
KIRP	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.79	-0.4	8.21e-11	Daytime sleep phenotypes;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.41	9.03	0.5	5.16e-17	Vitiligo;
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.86	0.35	1.45e-8	Lung cancer;
KIRP	cis	rs6541297	0.699	rs4846916	chr1:230296492	G/A	cg05784532	chr1:230284198	GALNT2	0.46	5.77	0.35	2.35e-8	Coronary artery disease;
KIRP	cis	rs6725041	0.547	rs4672645	chr2:213204955	C/T	cg20637307	chr2:213403960	ERBB4	-0.49	-6.33	-0.37	1.12e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs4356932	0.632	rs2292533	chr4:76861859	C/T	cg00809888	chr4:76862425	NAAA	-0.5	-7.15	-0.41	9.77e-12	Blood protein levels;
KIRP	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.76	11.47	0.59	1.16e-24	Oral cavity cancer;
KIRP	cis	rs12973672	0.812	rs12979058	chr19:35750684	G/A	cg12095397	chr19:35769544	USF2	0.67	6.2	0.37	2.33e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12752838	0.777	rs11590606	chr1:8917669	C/T	cg06972019	chr1:8937448	ENO1	-0.34	-4.99	-0.3	1.14e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4006360	0.628	rs439075	chr17:39239467	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.55	-8.42	-0.47	3.23e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs3857536	0.869	rs7771991	chr6:66876021	C/G	cg07460842	chr6:66804631	NA	-0.37	-4.95	-0.3	1.35e-6	Blood trace element (Cu levels);
KIRP	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs73058052	1.000	rs2288920	chr19:50091798	G/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.64	7.18	0.42	8.43e-12	Fibrinogen levels;
KIRP	cis	rs2742417	1.000	rs1877934	chr3:45753295	G/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg25838818	chr2:108905173	SULT1C2	-0.66	-9.99	-0.54	6.09e-20	Lobe size;
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.46	6.4	0.38	7.84e-10	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10783584	chr11:3686892	CHRNA10	-0.4	-6.22	-0.37	2.16e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13334819	chr7:99746414	C7orf59	0.6	6.62	0.39	2.29e-10	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg12559939	chr2:27858050	GPN1	0.43	5.55	0.33	7.51e-8	Oral cavity cancer;
KIRP	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg10503236	chr1:231470652	EXOC8	-0.53	-7.35	-0.42	2.94e-12	Hemoglobin concentration;
KIRP	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg12598211	chr12:123634384	NA	-0.4	-4.97	-0.3	1.25e-6	Platelet count;
KIRP	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.84	-12.77	-0.63	5.31e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs2411233	0.967	rs11070167	chr15:39288601	A/C	cg19287857	chr15:39890699	NA	0.37	5.22	0.32	3.73e-7	Platelet count;
KIRP	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.66	-8.97	-0.5	7.69e-17	Lymphocyte percentage of white cells;
KIRP	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-1.01	-18.55	-0.76	1.2e-48	Height;
KIRP	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	5.41	0.33	1.53e-7	Personality dimensions;
KIRP	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.83	11.71	0.6	1.77e-25	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg02996583	chr8:142237188	SLC45A4	0.48	5.68	0.34	3.86e-8	Immature fraction of reticulocytes;
KIRP	cis	rs1165472	0.755	rs12743424	chr1:56161993	A/T	cg11523071	chr1:56160889	NA	-0.59	-7.61	-0.44	5.8e-13	Paclitaxel-induced neuropathy;
KIRP	cis	rs4262150	0.960	rs9324737	chr5:152279610	C/G	cg12297329	chr5:152029980	NA	0.42	5.87	0.35	1.39e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg06307176	chr5:131281290	NA	-0.55	-6.0	-0.36	7.07e-9	Life satisfaction;
KIRP	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.77	-10.64	-0.56	5.23e-22	Waist circumference;Body mass index;
KIRP	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.59	8.11	0.46	2.43e-14	Mood instability;
KIRP	cis	rs7078219	1.000	rs7078219	chr10:101274365	A/G	cg07044859	chr10:101282883	NA	0.32	5.52	0.33	8.65e-8	Dental caries;
KIRP	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05220968	chr6:146057943	EPM2A	0.39	5.01	0.3	1.06e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg06565975	chr8:143823917	SLURP1	-0.35	-5.02	-0.3	9.89e-7	Urinary tract infection frequency;
KIRP	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.23	0.7	2.45e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.65	10.25	0.55	9.36e-21	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	8.89	0.49	1.37e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.8	0.45	1.71e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.82	11.64	0.6	3.02e-25	Neuroticism;
KIRP	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-1.01	-16.87	-0.73	5.9e-43	Height;
KIRP	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.67	-10.37	-0.55	3.92e-21	Total body bone mineral density;
KIRP	cis	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg03511173	chr18:77590860	NA	0.51	4.95	0.3	1.38e-6	Opioid sensitivity;
KIRP	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-6.81	-0.4	7.38e-11	Menopause (age at onset);
KIRP	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.71	-7.67	-0.44	3.97e-13	Iron status biomarkers;
KIRP	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.76	-0.34	2.51e-8	Breast cancer;
KIRP	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17574911	chr8:145726688	PPP1R16A	0.26	5.05	0.31	8.53e-7	Age at first birth;
KIRP	cis	rs6464929	0.956	rs4727005	chr7:148704869	C/T	cg05518778	chr7:148730143	NA	-0.42	-5.27	-0.32	2.99e-7	Pediatric bone mineral content (hip);
KIRP	trans	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg13565492	chr6:43139072	SRF	-0.92	-8.34	-0.47	5.43e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg18944383	chr4:111397179	ENPEP	0.52	9.14	0.5	2.35e-17	Height;
KIRP	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24110177	chr3:50126178	RBM5	-0.66	-7.66	-0.44	4.15e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7945705	0.870	rs4910156	chr11:8941197	T/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	6.9	0.4	4.31e-11	Hemoglobin concentration;
KIRP	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.59	-0.48	1.02e-15	Triglycerides;
KIRP	cis	rs4474465	0.850	rs7942371	chr11:78219975	A/G	cg27205649	chr11:78285834	NARS2	0.62	7.85	0.45	1.24e-13	Alzheimer's disease (survival time);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05843339	chr6:143268816	NA	0.46	6.34	0.37	1.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg00784671	chr22:46762841	CELSR1	-0.82	-8.14	-0.46	2.02e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3736485	0.934	rs4775953	chr15:51873173	G/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.02	-0.31	9.75e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg05361325	chr10:32636312	EPC1	-0.66	-6.3	-0.37	1.4e-9	Sexual dysfunction (female);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07494646	chr22:37415349	MPST;TST	-0.5	-6.49	-0.38	4.61e-10	Myopia;
KIRP	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.37	-4.84	-0.3	2.25e-6	Blood protein levels;
KIRP	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg06226150	chr20:62369956	SLC2A4RG;LIME1	-0.36	-5.35	-0.32	1.99e-7	Prostate cancer;
KIRP	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg12560992	chr17:57184187	TRIM37	0.63	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-12.39	-0.62	1.01e-27	Longevity;
KIRP	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg09408571	chr1:101003634	GPR88	-0.22	-4.98	-0.3	1.22e-6	Monocyte count;
KIRP	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-6.12	-0.36	3.74e-9	Eosinophil percentage of white cells;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16277706	chr1:90287101	LRRC8D	-0.45	-6.13	-0.36	3.51e-9	Warfarin maintenance dose;
KIRP	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.29	0.37	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.51	-6.99	-0.41	2.56e-11	Coronary artery disease;
KIRP	cis	rs7553864	1.000	rs4551571	chr1:87614244	C/G	cg17420885	chr1:87600446	LOC339524	-0.49	-6.61	-0.39	2.38e-10	Smoking behavior;
KIRP	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.87	-13.91	-0.66	7.79e-33	Height;
KIRP	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	1.04	10.44	0.55	2.37e-21	Psoriasis;
KIRP	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.26	0.32	3.14e-7	Smoking behavior;
KIRP	cis	rs3736485	1.000	rs11631408	chr15:51746236	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.17	-0.31	4.91e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.94	-0.35	9.75e-9	Glomerular filtration rate;
KIRP	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-9.01	-0.5	5.84e-17	Brugada syndrome;
KIRP	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.82	-0.35	1.81e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.4e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-1.01	-13.15	-0.64	2.9e-30	Dilated cardiomyopathy;
KIRP	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg14580859	chr9:123691850	NA	0.35	5.07	0.31	7.84e-7	Rheumatoid arthritis;
KIRP	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	9.69	0.53	5.1e-19	Chronic sinus infection;
KIRP	cis	rs3120667	0.790	rs1923493	chr1:152384203	A/C	cg26876637	chr1:152193138	HRNR	-0.54	-6.01	-0.36	6.74e-9	Eating disorders;
KIRP	cis	rs236907	0.859	rs6675708	chr1:171732363	G/A	cg01410279	chr1:171621941	MYOC	-0.52	-5.28	-0.32	2.83e-7	Mean platelet volume;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg24296786	chr1:45957014	TESK2	-0.64	-8.52	-0.48	1.63e-15	High light scatter reticulocyte count;
KIRP	cis	rs9886651	0.935	rs4404878	chr8:128798394	T/C	cg24514600	chr8:128805414	PVT1	-0.73	-12.48	-0.62	5.25e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.06	-14.23	-0.67	6.25e-34	Body mass index;
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg09695851	chr17:3907499	NA	-0.87	-16.87	-0.73	6.09e-43	Type 2 diabetes;
KIRP	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	15.39	0.7	6.8e-38	Alzheimer's disease;
KIRP	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.64	0.44	4.79e-13	Depressive symptoms;
KIRP	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.38	7.65	0.44	4.55e-13	Diastolic blood pressure;
KIRP	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.74	9.45	0.52	2.83e-18	Urate levels in obese individuals;
KIRP	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg14416269	chr4:6271139	WFS1	0.34	5.1	0.31	6.73e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.91	-0.4	4.03e-11	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10550160	chr7:139044797	LUC7L2	0.47	6.17	0.37	2.76e-9	Parkinson's disease;
KIRP	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg20607798	chr8:58055168	NA	0.77	5.98	0.36	7.94e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.32	-5.33	-0.32	2.17e-7	Dupuytren's disease;
KIRP	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg08885800	chr1:201084119	NA	-0.35	-4.84	-0.3	2.24e-6	Permanent tooth development;
KIRP	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.96	0.54	7.54e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.18	0.51	1.83e-17	Prudent dietary pattern;
KIRP	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg03465714	chr1:152285911	FLG	0.47	5.1	0.31	6.87e-7	Atopic dermatitis;
KIRP	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg16141378	chr3:129829833	LOC729375	0.62	7.76	0.44	2.34e-13	Neuroticism;
KIRP	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-9.14	-0.5	2.42e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.7	8.15	0.46	1.88e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.34	-0.32	2.16e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10510057	0.637	rs4752328	chr10:121315856	A/G	cg06765389	chr10:121379685	NA	-0.43	-6.75	-0.4	1.03e-10	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.94	14.73	0.68	1.27e-35	Metabolite levels;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05776053	chr2:74358815	NA	0.54	5.56	0.33	6.91e-8	Gestational age at birth (maternal effect);
KIRP	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg26876637	chr1:152193138	HRNR	0.75	9.78	0.53	2.65e-19	Atopic dermatitis;
KIRP	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.51	-0.33	9.19e-8	Breast cancer;
KIRP	cis	rs4664308	0.740	rs877635	chr2:160902847	A/C	cg03641300	chr2:160917029	PLA2R1	-0.56	-8.78	-0.49	2.83e-16	Idiopathic membranous nephropathy;
KIRP	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg23127183	chr11:57508653	C11orf31	0.45	6.17	0.37	2.84e-9	Schizophrenia;
KIRP	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.87	-11.04	-0.58	2.87e-23	Coronary artery disease;
KIRP	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg17996757	chr7:131013207	MKLN1	0.47	6.69	0.39	1.49e-10	Ischemic stroke;
KIRP	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.41	0.55	2.98e-21	Cognitive test performance;
KIRP	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg09890400	chr1:26503858	CNKSR1	0.42	5.79	0.35	2.13e-8	Height;
KIRP	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg17356467	chr2:100759845	AFF3	0.43	5.68	0.34	3.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	1.05	19.84	0.78	5.77e-53	Breast cancer;
KIRP	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg19847866	chr10:1019161	NA	-0.6	-5.4	-0.33	1.59e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.37	-0.43	2.54e-12	Exhaled nitric oxide output;
KIRP	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg26207909	chr14:103986467	CKB	0.56	7.67	0.44	3.95e-13	Body mass index;
KIRP	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg23992470	chr4:843637	GAK	0.63	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	5.27	0.32	2.94e-7	Schizophrenia;
KIRP	cis	rs6893300	1.000	rs6893300	chr5:179135815	C/A	cg14593053	chr5:179126677	CANX	-0.56	-6.19	-0.37	2.56e-9	Resting heart rate;
KIRP	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-1.03	-10.4	-0.55	3.03e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.57	7.72	0.44	2.98e-13	Caffeine consumption;
KIRP	cis	rs4073416	0.568	rs12885842	chr14:65918652	C/T	cg03016385	chr14:66212404	NA	-0.51	-6.42	-0.38	6.98e-10	N-glycan levels;
KIRP	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs1832871	0.683	rs56197409	chr6:158684338	A/G	cg07215822	chr6:158701037	NA	-0.64	-7.45	-0.43	1.55e-12	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14163061	chr2:44223239	LRPPRC	-0.46	-6.04	-0.36	5.57e-9	Survival in pancreatic cancer;
KIRP	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.81	0.49	2.37e-16	Morning vs. evening chronotype;
KIRP	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg00360474	chr6:37504404	NA	-0.49	-7.25	-0.42	5.3e-12	Cognitive performance;
KIRP	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.47	-6.67	-0.39	1.63e-10	Schizophrenia;
KIRP	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.65	-7.53	-0.43	9.33e-13	Bone mineral density;
KIRP	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg08755490	chr11:65554678	OVOL1	0.38	5.4	0.33	1.58e-7	Acne (severe);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10698419	chr4:72897317	NPFFR2	0.37	6.34	0.37	1.08e-9	C-reactive protein;
KIRP	cis	rs926938	0.543	rs360600	chr1:115388116	T/C	cg12756093	chr1:115239321	AMPD1	0.63	8.36	0.47	4.79e-15	Autism;
KIRP	cis	rs4132509	0.948	rs12136624	chr1:243981611	C/A	cg21452805	chr1:244014465	NA	0.57	5.46	0.33	1.15e-7	RR interval (heart rate);
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.15	-0.36	3.19e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs785830	0.655	rs588412	chr9:249391	A/C	cg14500300	chr9:211689	NA	-0.5	-6.65	-0.39	1.84e-10	Platelet distribution width;
KIRP	cis	rs9815354	0.812	rs59873855	chr3:41929538	T/C	cg03022575	chr3:42003672	ULK4	0.62	6.57	0.39	2.99e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs17030434	0.784	rs67664355	chr4:154660229	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-6.88	-0.4	5.06e-11	Electrocardiographic conduction measures;
KIRP	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.56	7.64	0.44	4.95e-13	Colorectal cancer;
KIRP	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg04226714	chr8:49833948	SNAI2	0.49	6.61	0.39	2.36e-10	Life satisfaction;
KIRP	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg04865290	chr3:52927548	TMEM110	-0.58	-6.78	-0.4	8.84e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.43	5.62	0.34	5.03e-8	Schizophrenia;
KIRP	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs138491296	1	rs138491296	chr17:27961561	GATTATT/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-8.17	-0.46	1.61e-14	White blood cell count;
KIRP	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs6988636	0.792	rs62521803	chr8:124152970	A/C	cg15893493	chr8:124194847	FAM83A	0.89	6.61	0.39	2.34e-10	Urinary uromodulin levels;
KIRP	cis	rs240764	0.817	rs239229	chr6:101105975	T/C	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11987759	chr7:65425863	GUSB	0.47	6.2	0.37	2.41e-9	Aortic root size;
KIRP	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	9.32	0.51	6.68e-18	Bone mineral density;
KIRP	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.8	-10.83	-0.57	1.29e-22	Aortic root size;
KIRP	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg15655495	chr12:38532458	NA	0.25	4.84	0.3	2.26e-6	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18451529	chr2:15698011	NBAS	0.41	6.51	0.38	4.27e-10	Survival in pancreatic cancer;
KIRP	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-5.0	-0.3	1.1e-6	Initial pursuit acceleration;
KIRP	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	1.05	13.54	0.65	1.4e-31	Exhaled nitric oxide output;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.43	-5.73	-0.34	2.89e-8	Testicular germ cell tumor;
KIRP	cis	rs9815354	1.000	rs9865780	chr3:41895802	A/G	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-8.04	-0.46	3.79e-14	Personality dimensions;
KIRP	cis	rs4950322	0.543	rs114302864	chr1:146789849	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.74	5.68	0.34	3.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.61	-6.51	-0.38	4.25e-10	DNA methylation (variation);
KIRP	trans	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg15469184	chr8:337539	NA	0.59	6.7	0.39	1.41e-10	Obesity-related traits;
KIRP	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.49	-5.95	-0.35	9.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.63	7.53	0.43	9.63e-13	Type 2 diabetes;
KIRP	cis	rs2281603	0.570	rs1966865	chr14:64975861	G/A	cg01860774	chr14:64969374	ZBTB25	0.35	5.61	0.34	5.52e-8	Lymphocyte counts;
KIRP	cis	rs2281603	0.570	rs11848179	chr14:64977053	A/G	cg01860774	chr14:64969374	ZBTB25	0.35	5.62	0.34	5.03e-8	Lymphocyte counts;
KIRP	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	5.95	0.35	9.41e-9	Menarche (age at onset);
KIRP	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05472934	chr7:22766657	IL6	0.81	10.7	0.56	3.36e-22	Lung cancer;
KIRP	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.87	-12.6	-0.63	2.02e-28	Total body bone mineral density;
KIRP	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.5	-5.76	-0.34	2.49e-8	Iron status biomarkers;
KIRP	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.09	0.41	1.39e-11	Height;
KIRP	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg04306507	chr14:55594613	LGALS3	0.52	8.14	0.46	2.04e-14	Protein biomarker;
KIRP	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.2	-0.46	1.33e-14	Fibrinogen levels;
KIRP	cis	rs573521	1.000	rs617819	chr11:102714716	C/G	cg19620758	chr11:102826565	MMP13	0.36	4.96	0.3	1.3e-6	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;
KIRP	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.52	-7.24	-0.42	5.87e-12	Menarche (age at onset);
KIRP	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.03	11.84	0.6	7.05e-26	Vitiligo;
KIRP	cis	rs7590368	0.926	rs12623588	chr2:10957612	C/G	cg15705551	chr2:10952987	PDIA6	-0.49	-5.51	-0.33	9.12e-8	Educational attainment (years of education);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03746065	chr20:3827354	MAVS	-0.49	-6.26	-0.37	1.67e-9	Myopia;
KIRP	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.4	3.46e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12208915	0.720	rs9352655	chr6:79503423	T/A	cg18132916	chr6:79620363	NA	0.56	4.99	0.3	1.17e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg21479132	chr6:26055353	NA	0.79	5.39	0.32	1.67e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.11	-0.46	2.47e-14	Monocyte percentage of white cells;
KIRP	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.68	10.52	0.56	1.28e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg18657303	chr4:1051139	NA	0.54	4.94	0.3	1.43e-6	Recombination rate (females);
KIRP	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg18501202	chr6:125855421	NA	-0.35	-5.39	-0.32	1.67e-7	Brugada syndrome;
KIRP	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.68	-8.07	-0.46	3.17e-14	Blood protein levels;
KIRP	cis	rs17221829	0.733	rs12421374	chr11:89381067	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.23e-6	Anxiety in major depressive disorder;
KIRP	cis	rs4722404	0.502	rs13223548	chr7:3110446	T/C	cg19214707	chr7:3157722	NA	-0.53	-6.32	-0.37	1.19e-9	Atopic dermatitis;
KIRP	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.71	10.53	0.56	1.17e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg00094735	chr5:1949198	NA	0.5	5.84	0.35	1.65e-8	Gut microbiome composition (winter);
KIRP	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.5	5.89	0.35	1.25e-8	Metabolite levels;
KIRP	cis	rs4302748	0.862	rs57133121	chr7:36182859	G/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs12780845	0.540	rs10904894	chr10:17219656	T/C	cg01003015	chr10:17271136	VIM	-0.4	-4.87	-0.3	1.99e-6	Homocysteine levels;
KIRP	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg24375607	chr4:120327624	NA	0.58	6.67	0.39	1.69e-10	Corneal astigmatism;
KIRP	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg27121462	chr16:89883253	FANCA	-0.51	-6.56	-0.39	3.06e-10	Vitiligo;
KIRP	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.58	5.97	0.36	8.04e-9	Height;
KIRP	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg00376283	chr12:123451042	ABCB9	0.82	11.0	0.57	3.86e-23	Platelet count;
KIRP	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg05370193	chr1:21551575	ECE1	0.48	6.43	0.38	6.43e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.59	-5.44	-0.33	1.28e-7	Body mass index;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg00024416	chr22:24240387	NA	0.41	5.65	0.34	4.48e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.55	-5.94	-0.35	9.43e-9	Lung function (FEV1/FVC);
KIRP	cis	rs2273669	0.667	rs4527738	chr6:109309150	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.46e-9	Obesity-related traits;
KIRP	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs35661897	0.920	rs4423582	chr2:227294535	G/T	cg03426602	chr2:227312417	NA	0.53	6.75	0.4	1.05e-10	Urinary tract infection frequency;
KIRP	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg09201719	chr10:104596890	CYP17A1	0.38	5.53	0.33	8.18e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs7646881	0.812	rs74618709	chr3:158455281	G/C	cg19483011	chr3:158453295	NA	-0.49	-5.49	-0.33	1.01e-7	Tetralogy of Fallot;
KIRP	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.55	7.09	0.41	1.45e-11	Coronary heart disease;
KIRP	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.35	0.42	3e-12	Aortic root size;
KIRP	cis	rs4523957	0.548	rs7225623	chr17:2089548	T/C	cg16513277	chr17:2031491	SMG6	-0.72	-10.18	-0.54	1.54e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg26784012	chr10:32216390	ARHGAP12	0.32	5.11	0.31	6.39e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	1.05	15.06	0.69	9.04e-37	Menopause (age at onset);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg01786151	chr1:41347977	NA	-0.52	-7.08	-0.41	1.49e-11	Inflammatory biomarkers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21434563	chr6:161413126	MAP3K4	0.52	6.87	0.4	5.15e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21697561	chr17:73974931	C17orf106;ACOX1	0.54	6.63	0.39	2.08e-10	Parkinson's disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg24572153	chr13:21047387	CRYL1	0.57	6.46	0.38	5.63e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.88	-12.51	-0.62	4.17e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.88	11.6	0.59	4.18e-25	Primary sclerosing cholangitis;
KIRP	cis	rs6001982	0.667	rs6001913	chr22:40836753	C/A	cg07138101	chr22:40742427	ADSL	0.65	5.03	0.31	9.65e-7	Breast cancer;
KIRP	cis	rs2736337	0.530	rs11782375	chr8:11294934	C/T	cg08224773	chr8:11311868	FAM167A	0.39	6.94	0.4	3.48e-11	Rheumatoid arthritis;
KIRP	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.09	-0.31	7.22e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg22797968	chr5:138629998	MATR3	0.46	5.32	0.32	2.37e-7	Esophageal squamous cell carcinoma;
KIRP	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg21191810	chr6:118973309	C6orf204	0.36	4.87	0.3	1.98e-6	Electrocardiographic conduction measures;
KIRP	cis	rs7033996	0.908	rs57364197	chr9:35946380	T/C	cg00918944	chr9:35908117	LOC158376	0.38	5.34	0.32	2.12e-7	Urate levels (BMI interaction);
KIRP	cis	rs27434	0.583	rs40091	chr5:96154919	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1.01e-7	Ankylosing spondylitis;
KIRP	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.53	-6.32	-0.37	1.22e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.72	-9.01	-0.5	5.96e-17	Height;
KIRP	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg06565975	chr8:143823917	SLURP1	0.48	7.6	0.44	6.33e-13	Urinary tract infection frequency;
KIRP	cis	rs7113850	0.541	rs7101719	chr11:24234947	T/C	ch.11.24196551F	chr11:24239977	NA	0.88	8.1	0.46	2.56e-14	Bone fracture in osteoporosis;
KIRP	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs273573	0.557	rs10835717	chr11:30895245	A/G	cg14844989	chr11:31128820	NA	0.34	4.98	0.3	1.18e-6	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.31e-9	Depression;
KIRP	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg26373071	chr5:1325741	CLPTM1L	-0.53	-6.75	-0.4	1.06e-10	Lung cancer;
KIRP	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg24315340	chr6:146058215	EPM2A	0.4	5.01	0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs2712184	0.756	rs715049	chr2:217657102	C/T	cg05032264	chr2:217675019	NA	-0.47	-6.75	-0.4	1.07e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs6457821	1.000	rs73407643	chr6:35169123	T/C	cg06087101	chr6:35551932	FKBP5	0.55	4.91	0.3	1.68e-6	Height;
KIRP	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg08742575	chr21:47604166	C21orf56	-0.47	-5.01	-0.3	1.03e-6	Lymphocyte counts;
KIRP	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.53e-7	Plateletcrit;
KIRP	cis	rs3026101	0.578	rs1806238	chr17:5295502	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	5.92	0.35	1.06e-8	Response to antipsychotic treatment;
KIRP	cis	rs9488822	0.585	rs390255	chr6:116237680	A/G	cg05304507	chr6:116381966	FRK	0.21	5.39	0.32	1.67e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6893300	1.000	rs55975622	chr5:179167705	T/C	cg14593053	chr5:179126677	CANX	-0.57	-6.28	-0.37	1.5e-9	Resting heart rate;
KIRP	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	5.38	0.32	1.72e-7	Renal cell carcinoma;
KIRP	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.69	-0.39	1.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg02023728	chr11:77925099	USP35	0.32	5.44	0.33	1.3e-7	Alzheimer's disease (survival time);
KIRP	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.64	-9.09	-0.5	3.42e-17	Schizophrenia;
KIRP	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.12	-0.41	1.18e-11	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs12545912	0.770	rs7003791	chr8:9545368	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.66	-0.39	1.81e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6032067	0.929	rs36032462	chr20:43873088	T/C	cg10761708	chr20:43804764	PI3	0.53	5.42	0.33	1.45e-7	Blood protein levels;
KIRP	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11987759	chr7:65425863	GUSB	0.47	5.94	0.35	9.76e-9	Aortic root size;
KIRP	cis	rs7714584	1.000	rs59980321	chr5:150241813	A/T	cg22134413	chr5:150180641	NA	0.75	6.67	0.39	1.7e-10	Crohn's disease;
KIRP	cis	rs2494938	0.730	rs846505	chr6:40527634	A/C	cg14084896	chr6:40530702	LRFN2	-0.44	-5.74	-0.34	2.81e-8	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg13198984	chr17:80129470	CCDC57	0.59	8.9	0.49	1.22e-16	Life satisfaction;
KIRP	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.47	-0.52	2.49e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg19847130	chr8:10466454	RP1L1	0.38	5.83	0.35	1.78e-8	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.62	-6.75	-0.4	1.08e-10	DNA methylation (variation);
KIRP	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	ch.11.340609R	chr11:12831013	TEAD1	-0.49	-6.05	-0.36	5.31e-9	Educational attainment (years of education);
KIRP	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg02002194	chr4:3960332	NA	-0.45	-6.15	-0.37	3.11e-9	Neuroticism;
KIRP	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.42	-5.16	-0.31	5.01e-7	Iron status biomarkers;
KIRP	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg26138937	chr11:71823887	C11orf51	-1.01	-6.94	-0.4	3.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs4664308	0.505	rs1037694	chr2:161028992	A/G	cg03641300	chr2:160917029	PLA2R1	-0.5	-7.97	-0.45	5.87e-14	Idiopathic membranous nephropathy;
KIRP	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg14675211	chr2:100938903	LONRF2	0.48	6.26	0.37	1.74e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14893161	chr1:205819251	PM20D1	0.49	5.52	0.33	8.55e-8	Parkinson's disease;
KIRP	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg19913688	chr11:428466	ANO9	0.95	8.4	0.47	3.48e-15	Body mass index;
KIRP	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs6977940	0.512	rs6461600	chr7:2816537	C/T	cg19731401	chr7:2775893	GNA12	0.56	6.15	0.36	3.17e-9	White matter integrity;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg26466970	chr3:59035943	C3orf67	0.46	6.55	0.39	3.32e-10	Neuroticism;
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs1134634	0.520	rs75099653	chr4:15628020	A/G	cg16509355	chr4:15471240	CC2D2A	-0.35	-5.81	-0.35	1.92e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-1.06	-18.82	-0.77	1.53e-49	Height;
KIRP	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg05347473	chr6:146136440	FBXO30	-0.46	-6.26	-0.37	1.72e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.65	9.62	0.52	8.24e-19	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12713142	chr12:57081325	PTGES3	0.52	6.09	0.36	4.33e-9	Smoking initiation;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05329982	chr11:62359210	TUT1	-0.51	-6.74	-0.39	1.11e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08949428	chr13:98451284	NA	0.5	6.46	0.38	5.44e-10	Interleukin-4 levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11109621	chr5:26881128	CDH9	-0.45	-6.83	-0.4	6.77e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.47	-6.54	-0.39	3.45e-10	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg06636001	chr8:8085503	FLJ10661	0.89	12.4	0.62	9.4e-28	Mood instability;
KIRP	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14305942	chr9:132572700	TOR1B	0.5	6.15	0.37	3.09e-9	Interleukin-4 levels;
KIRP	cis	rs77972916	0.536	rs11679731	chr2:43589064	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.39	-0.32	1.68e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.53	0.33	8.2e-8	Lung cancer;
KIRP	cis	rs1440410	0.835	rs7685461	chr4:144054883	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11371933	chr10:53459365	PRKG1;CSTF2T	-0.51	-6.3	-0.37	1.37e-9	Migraine with aura;
KIRP	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg18736775	chr8:18248649	NAT2	-0.51	-5.01	-0.3	1.04e-6	Blood metabolite levels;
KIRP	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.7	-9.85	-0.53	1.69e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs11914070	0.860	rs62229144	chr22:18963205	C/T	cg12798833	chr22:18958832	DGCR5	-0.4	-4.89	-0.3	1.81e-6	Gait variability;
KIRP	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg21918786	chr6:109611834	NA	0.38	5.61	0.34	5.54e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg18440316	chr19:18077727	KCNN1	-0.42	-5.9	-0.35	1.17e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs997295	0.554	rs7180312	chr15:68105256	G/A	cg24579218	chr15:68104479	NA	-0.41	-6.41	-0.38	7.43e-10	Motion sickness;
KIRP	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.43	5.97	0.36	8.29e-9	Lewy body disease;
KIRP	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.71	9.18	0.5	1.88e-17	Bladder cancer;
KIRP	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.9	14.26	0.67	5.04e-34	Height;
KIRP	cis	rs2671245	1.000	rs1165484	chr1:56185826	T/A	cg11523071	chr1:56160889	NA	0.37	5.78	0.35	2.2e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg07382826	chr16:28625726	SULT1A1	0.44	5.21	0.32	4.06e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12711979	0.875	rs11686157	chr2:3855020	C/G	cg17052675	chr2:3827356	NA	-0.36	-5.38	-0.32	1.77e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.6	7.67	0.44	3.98e-13	Body mass index;
KIRP	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.75	-7.09	-0.41	1.42e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.59	-0.34	5.88e-8	Height;
KIRP	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg17554472	chr22:41940697	POLR3H	0.65	6.61	0.39	2.39e-10	Vitiligo;
KIRP	cis	rs12900413	0.687	rs12908468	chr15:90304236	T/G	cg24650279	chr15:90327240	NA	-0.41	-5.17	-0.31	4.79e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg07843065	chr1:150265600	MRPS21	0.42	5.71	0.34	3.21e-8	Migraine;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02321289	chr15:63450340	RPS27L	-0.46	-6.3	-0.37	1.39e-9	C-reactive protein;
KIRP	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-1.16	-21.02	-0.8	7.65e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Alcohol dependence;
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	1.95e-6	Lung cancer;
KIRP	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg02462569	chr6:150064036	NUP43	-0.33	-4.97	-0.3	1.28e-6	Lung cancer;
KIRP	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg04374321	chr14:90722782	PSMC1	0.91	15.42	0.7	5.42e-38	Mortality in heart failure;
KIRP	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg13147721	chr7:65941812	NA	-0.91	-6.56	-0.39	3.19e-10	Diabetic kidney disease;
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-5.98	-0.36	7.61e-9	Lung function (FEV1/FVC);
KIRP	cis	rs12900413	0.645	rs28407340	chr15:90311864	C/T	cg24650279	chr15:90327240	NA	-0.4	-5.11	-0.31	6.44e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	-0.47	-5.5	-0.33	9.55e-8	Glycated hemoglobin levels;
KIRP	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs4791746	0.846	rs9895426	chr17:8647127	C/T	cg22573359	chr17:8645026	CCDC42	-0.31	-5.0	-0.3	1.09e-6	Heroin dependence;
KIRP	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	trans	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg11608241	chr8:8085544	FLJ10661	-0.53	-6.76	-0.4	9.74e-11	Triglycerides;
KIRP	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg16898833	chr6:26189333	HIST1H4D	0.74	5.31	0.32	2.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs228437	0.586	rs2207421	chr6:134913417	A/C	cg24504307	chr6:134963096	NA	-0.3	-5.02	-0.3	1e-6	Melanoma;
KIRP	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.0	-0.41	2.49e-11	Type 2 diabetes;
KIRP	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs35740288	0.770	rs34058174	chr15:86174462	G/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10296688	chr13:52598408	UTP14C;ALG11	-0.5	-6.39	-0.38	8.18e-10	Inflammatory biomarkers;
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg10304824	chr2:177028804	HOXD3	0.24	4.93	0.3	1.53e-6	IgG glycosylation;
KIRP	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg10189774	chr4:17578691	LAP3	-0.44	-5.07	-0.31	7.85e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.49	6.75	0.4	1.03e-10	Height;
KIRP	cis	rs1978968	0.869	rs35035092	chr22:18463274	G/T	cg02610425	chr22:18483192	MICAL3	0.42	5.4	0.33	1.57e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4787491	0.704	rs67218159	chr16:30050505	C/T	cg06326092	chr16:30034487	C16orf92	0.5	7.83	0.45	1.48e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg07701084	chr6:150067640	NUP43	0.61	7.95	0.45	6.88e-14	Lung cancer;
KIRP	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.47	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs7112043	0.778	rs1472975	chr11:34776643	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.49	5.85	0.35	1.57e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.75	7.47	0.43	1.38e-12	Breast cancer;
KIRP	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.49	7.02	0.41	2.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.55	6.44	0.38	6.24e-10	Aortic root size;
KIRP	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.18	0.37	2.68e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.44	5.09	0.31	7.27e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.79	8.99	0.5	6.85e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg12935359	chr14:103987150	CKB	0.42	6.3	0.37	1.37e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg24476569	chr13:95954382	ABCC4	-0.6	-9.23	-0.51	1.26e-17	Blood metabolite levels;
KIRP	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg03959625	chr15:84868606	LOC388152	0.69	8.46	0.47	2.38e-15	Schizophrenia;
KIRP	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.07	0.54	3.52e-20	Total body bone mineral density;
KIRP	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-7.02	-0.41	2.19e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26378065	chr17:18585709	ZNF286B	0.54	6.78	0.4	9e-11	Educational attainment (years of education);
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg09264619	chr17:80180166	NA	-0.37	-5.42	-0.33	1.45e-7	Life satisfaction;
KIRP	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg07274523	chr3:49395745	GPX1	0.72	8.71	0.49	4.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg10189261	chr14:101176105	NA	-0.47	-5.06	-0.31	8.03e-7	Plateletcrit;
KIRP	trans	rs8054556	0.760	rs11642740	chr16:30060655	C/T	cg13500354	chr6:168617491	NA	-0.33	-6.02	-0.36	6.39e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg23172400	chr8:95962367	TP53INP1	0.27	5.21	0.32	3.99e-7	Type 2 diabetes;
KIRP	cis	rs2625529	0.652	rs2957728	chr15:72236432	G/T	cg16672083	chr15:72433130	SENP8	0.45	6.34	0.37	1.08e-9	Red blood cell count;
KIRP	cis	rs7656342	0.636	rs4697902	chr4:9863936	T/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-5.8	-0.35	2.03e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs17057718	0.950	rs74999629	chr3:57117542	G/A	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-4.98	-0.3	1.21e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs77372450	0.636	rs28712355	chr5:157023508	A/G	cg23851860	chr5:157002805	ADAM19	0.47	5.22	0.32	3.73e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.15	-0.5	2.17e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg08501292	chr6:25962987	TRIM38	0.96	6.58	0.39	2.85e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg26353844	chr1:95133907	NA	0.38	6.8	0.4	7.74e-11	Serum protein levels (sST2);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26879696	chr10:114206778	VTI1A;ZDHHC6	0.51	7.15	0.41	9.71e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.61	9.07	0.5	3.78e-17	Immature fraction of reticulocytes;
KIRP	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg04733989	chr22:42467013	NAGA	0.55	7.49	0.43	1.25e-12	Cognitive function;
KIRP	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg22089800	chr15:90895588	ZNF774	0.43	5.0	0.3	1.09e-6	Rheumatoid arthritis;
KIRP	cis	rs6753739	0.745	rs1455839	chr2:219912509	A/C	cg01749213	chr2:219906749	CCDC108	0.41	4.97	0.3	1.25e-6	Height;
KIRP	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.61	-0.34	5.39e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg06640241	chr16:89574553	SPG7	0.62	7.28	0.42	4.36e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs16828019	0.852	rs35190461	chr1:41543135	T/C	cg03387723	chr1:41708464	SCMH1	-0.75	-6.67	-0.39	1.68e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.58	7.52	0.43	1.01e-12	Aortic root size;
KIRP	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg26248373	chr2:1572462	NA	-0.67	-7.26	-0.42	5.16e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9394841	0.667	rs12661667	chr6:41792545	C/T	cg08135965	chr6:41755394	TOMM6	0.52	5.54	0.33	7.95e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.39	-5.03	-0.31	9.37e-7	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.72	-10.21	-0.55	1.2e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.43	7.07	0.41	1.64e-11	Superior crus of antihelix expression;
KIRP	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	cis	rs2224391	0.590	rs9405813	chr6:5251850	G/C	cg13962347	chr6:5174647	LYRM4	-0.86	-10.14	-0.54	2.04e-20	Height;
KIRP	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.21	0.58	7.81e-24	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.44	0.47	2.81e-15	Type 2 diabetes;
KIRP	cis	rs7688540	0.771	rs7674560	chr4:263319	G/C	cg17891759	chr4:299121	NA	-0.44	-5.11	-0.31	6.42e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-0.99	-16.59	-0.73	5.21e-42	Height;
KIRP	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	7.67	0.44	4.09e-13	IgG glycosylation;
KIRP	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg21775007	chr8:11205619	TDH	-0.47	-6.41	-0.38	7.5e-10	Neuroticism;
KIRP	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.45	-5.48	-0.33	1.07e-7	Iron status biomarkers;
KIRP	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg22117172	chr7:91764530	CYP51A1	0.41	5.6	0.34	5.82e-8	Breast cancer;
KIRP	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.5e-10	Coronary artery disease;
KIRP	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg01631408	chr1:248437212	OR2T33	-0.47	-6.37	-0.38	9.37e-10	Common traits (Other);
KIRP	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg27205649	chr11:78285834	NARS2	-0.5	-5.19	-0.31	4.31e-7	Testicular germ cell tumor;
KIRP	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.72	6.96	0.41	3.15e-11	Breast cancer;
KIRP	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.62	7.98	0.45	5.42e-14	Longevity;Endometriosis;
KIRP	cis	rs9309473	1.000	rs10496191	chr2:73673798	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.72	-0.34	3.04e-8	Metabolite levels;
KIRP	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-16.86	-0.73	6.75e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.12	-0.31	6.3e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.26	26.34	0.86	1.52e-73	IgG glycosylation;
KIRP	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.71	10.45	0.55	2.17e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.7	0.68	1.62e-35	Electrocardiographic conduction measures;
KIRP	cis	rs838147	0.844	rs12982115	chr19:49248640	A/G	cg08619932	chr19:49200058	FUT2	-0.36	-5.5	-0.33	9.58e-8	Dietary macronutrient intake;
KIRP	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.99	-0.3	1.14e-6	Psoriasis;
KIRP	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.93	15.79	0.71	2.92e-39	Ulcerative colitis;
KIRP	cis	rs7106204	0.668	rs7119362	chr11:24218132	G/T	ch.11.24196551F	chr11:24239977	NA	0.81	9.61	0.52	9.01e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.44	-10.58	-0.56	8.1e-22	Diastolic blood pressure;
KIRP	trans	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.35	-0.38	1.03e-9	Neuroticism;
KIRP	cis	rs7945718	0.870	rs3890064	chr11:12758766	C/A	ch.11.340609R	chr11:12831013	TEAD1	-0.4	-5.05	-0.31	8.79e-7	Educational attainment (years of education);
KIRP	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.97	14.08	0.67	2.09e-33	Cognitive function;
KIRP	trans	rs9944715	0.954	rs6507677	chr18:43762557	T/C	cg01718231	chr17:29326311	RNF135	0.51	6.02	0.36	6.25e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	trans	rs7660760	0.763	rs1449744	chr4:177498192	T/C	cg11970806	chr17:56066485	VEZF1	-0.4	-6.07	-0.36	4.78e-9	Left ventricle wall thickness;
KIRP	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	0.8	8.87	0.49	1.55e-16	Testicular germ cell tumor;
KIRP	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.53	-6.67	-0.39	1.7e-10	Platelet distribution width;
KIRP	cis	rs9513627	0.915	rs73556182	chr13:100122107	A/G	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-8.08	-0.46	2.97e-14	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07342512	chr1:65886002	LEPROT;LEPR	0.47	6.49	0.38	4.6e-10	Survival in pancreatic cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21636400	chr19:46196737	QPCTL;SNRPD2	0.45	6.23	0.37	1.99e-9	Survival in pancreatic cancer;
KIRP	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.21	0.55	1.22e-20	Dupuytren's disease;
KIRP	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	5.33	0.32	2.23e-7	Renal cell carcinoma;
KIRP	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg17595323	chr11:93583763	C11orf90	-0.38	-6.42	-0.38	7e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg04226714	chr8:49833948	SNAI2	-0.51	-6.79	-0.4	8.51e-11	Life satisfaction;
KIRP	trans	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg24644049	chr4:85504048	CDS1	1.09	6.99	0.41	2.59e-11	Skin colour saturation;
KIRP	cis	rs997295	1.000	rs8035675	chr15:67965581	C/T	cg14210607	chr15:68128175	NA	-0.3	-4.91	-0.3	1.66e-6	Motion sickness;
KIRP	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg26248373	chr2:1572462	NA	-0.62	-6.01	-0.36	6.48e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs3748682	0.861	rs28420383	chr1:38346405	T/C	cg12658694	chr1:38397304	INPP5B	0.56	6.04	0.36	5.52e-9	Hypothyroidism;
KIRP	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.44	0.38	6.14e-10	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13073409	chr1:197099113	ASPM	-0.47	-7.46	-0.43	1.51e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11987759	chr7:65425863	GUSB	0.51	6.85	0.4	5.8200000000000003e-11	Aortic root size;
KIRP	cis	rs5756391	0.524	rs2413436	chr22:37312561	A/G	cg16356956	chr22:37317934	CSF2RB	0.41	5.57	0.33	6.62e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.87	-0.78	4.7e-53	Height;
KIRP	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.4	-5.2	-0.31	4.15e-7	Obesity;
KIRP	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.91	-15.44	-0.7	4.63e-38	Oral cavity cancer;
KIRP	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.27	5.73	0.34	2.88e-8	Pursuit maintenance gain;
KIRP	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.28	4.87	0.3	2.01e-6	Monocyte count;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.28	5.08	0.31	7.41e-7	Tonsillectomy;
KIRP	cis	rs16828019	0.852	rs2300649	chr1:41569203	T/C	cg08144172	chr1:41849203	NA	0.63	5.17	0.31	4.96e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg05941025	chr16:89927596	SPIRE2	0.35	5.5	0.33	9.46e-8	Schizophrenia;
KIRP	trans	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs787274	1.000	rs4979150	chr9:115553502	T/A	cg13803584	chr9:115635662	SNX30	-0.74	-8.38	-0.47	4e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7267005	0.661	rs75792504	chr20:34425383	G/T	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.39	0.38	8.07e-10	Colorectal cancer;
KIRP	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.94e-7	Red blood cell count;
KIRP	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.83	-0.49	2.01e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.66	-11.73	-0.6	1.54e-25	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg23985595	chr17:80112537	CCDC57	0.34	5.22	0.32	3.89e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg25650185	chr19:21324782	ZNF431	-0.48	-5.13	-0.31	5.95e-7	Pain;
KIRP	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg10818794	chr15:86012489	AKAP13	-0.5	-7.11	-0.41	1.27e-11	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.75	-9.7	-0.53	4.8e-19	Aortic root size;
KIRP	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.24	0.62	3.23e-27	Ileal carcinoids;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4711336	0.935	rs754404	chr6:33664730	T/C	cg15676125	chr6:33679581	C6orf125	0.41	5.59	0.34	6.12e-8	Height;
KIRP	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.44	0.47	2.81e-15	Type 2 diabetes;
KIRP	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.67	-7.46	-0.43	1.49e-12	Menarche (age at onset);
KIRP	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.52	-0.43	1.05e-12	Mood instability;
KIRP	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.48	14.02	0.67	3.17e-33	Opioid sensitivity;
KIRP	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.2	-0.31	4.12e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg18225595	chr11:63971243	STIP1	0.64	5.79	0.35	2.09e-8	Mean platelet volume;
KIRP	cis	rs904251	0.714	rs2776910	chr6:37436284	A/G	cg01843034	chr6:37503916	NA	-0.56	-5.74	-0.34	2.75e-8	Cognitive performance;
KIRP	cis	rs1832871	0.541	rs17581620	chr6:158880590	A/G	cg07215822	chr6:158701037	NA	-0.54	-5.71	-0.34	3.32e-8	Height;
KIRP	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.72	10.6	0.56	7.25e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.8	11.66	0.6	2.75e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg04310649	chr10:35416472	CREM	-0.54	-6.09	-0.36	4.37e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.48	7.36	0.42	2.83e-12	Resting heart rate;
KIRP	trans	rs12043259	0.730	rs12041010	chr1:204785812	T/A	cg11485465	chr5:54518469	NA	0.35	6.34	0.37	1.1e-9	Addiction;
KIRP	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.57e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.38	-5.04	-0.31	9.17e-7	Multiple myeloma;
KIRP	cis	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.88	-0.3	1.92e-6	Cervical cancer;
KIRP	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.65	8.39	0.47	3.91e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	cis	rs2505998	0.833	rs752977	chr10:43588381	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.82	-0.35	1.84e-8	Hirschsprung disease;
KIRP	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg11859384	chr17:80120422	CCDC57	-0.4	-5.05	-0.31	8.5e-7	Life satisfaction;
KIRP	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.87	0.45	1.14e-13	Educational attainment;
KIRP	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg07741184	chr6:167504864	NA	-0.23	-6.12	-0.36	3.63e-9	Crohn's disease;
KIRP	cis	rs6832769	1.000	rs6819660	chr4:56374577	T/G	cg09317128	chr4:56265301	TMEM165	0.55	7.35	0.42	2.97e-12	Personality dimensions;
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.8	7.78	0.44	2e-13	Lung function (FEV1/FVC);
KIRP	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg04374321	chr14:90722782	PSMC1	0.5	5.38	0.32	1.69e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Bladder cancer;
KIRP	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.41	5.06	0.31	8.32e-7	Blood protein levels;
KIRP	cis	rs1978968	0.731	rs9605467	chr22:18461166	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.79	-11.2	-0.58	8.59e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.15	0.37	3.12e-9	Menopause (age at onset);
KIRP	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg24375607	chr4:120327624	NA	0.48	5.67	0.34	3.96e-8	Corneal astigmatism;
KIRP	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.23	-16.15	-0.72	1.68e-40	Type 1 diabetes nephropathy;
KIRP	cis	rs524023	0.629	rs480617	chr11:64478320	C/T	cg09231725	chr11:64357281	SLC22A12	0.5	6.46	0.38	5.62e-10	Urate levels in obese individuals;
KIRP	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.35	-0.42	2.96e-12	Red cell distribution width;
KIRP	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg24375607	chr4:120327624	NA	-0.47	-5.16	-0.31	5.13e-7	Corneal astigmatism;
KIRP	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg05669848	chr5:237993	SDHA	-0.48	-5.04	-0.31	8.88e-7	Breast cancer;
KIRP	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg04398451	chr17:18023971	MYO15A	-0.66	-9.16	-0.5	2.14e-17	Total body bone mineral density;
KIRP	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg08648136	chr8:956695	NA	0.53	8.58	0.48	1.09e-15	Schizophrenia;
KIRP	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-8.04	-0.46	3.77e-14	Schizophrenia;
KIRP	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.73	-0.39	1.18e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	9.65	0.52	6.93e-19	Coronary artery disease;
KIRP	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg01849466	chr14:104193079	ZFYVE21	0.48	6.04	0.36	5.79e-9	Schizophrenia;
KIRP	cis	rs9427116	0.702	rs9427109	chr1:154609009	A/G	cg11650704	chr1:154556575	ADAR	-0.4	-4.91	-0.3	1.65e-6	Blood protein levels;
KIRP	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg20935368	chr5:178288625	ZNF354B	0.42	5.7	0.34	3.49e-8	Sleep duration;
KIRP	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.6	-7.92	-0.45	8.34e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.35	-0.42	2.96e-12	Red cell distribution width;
KIRP	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg21184320	chr1:21044207	KIF17	-0.37	-5.57	-0.33	6.74e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg14851346	chr12:38532713	NA	-0.4	-4.95	-0.3	1.36e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg01988459	chr11:68622903	NA	-0.44	-6.03	-0.36	6e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.78	6.83	0.4	6.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg22676075	chr6:135203613	NA	0.5	7.21	0.42	7.07e-12	Red blood cell count;
KIRP	cis	rs78487399	0.808	rs998768	chr2:43711523	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.86	-0.35	1.51e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg11498726	chr8:26250323	BNIP3L	-0.55	-8.03	-0.46	4.16e-14	Red cell distribution width;
KIRP	cis	rs2905347	1.000	rs2905347	chr7:22620319	C/T	cg23521230	chr7:22704884	NA	-0.39	-5.2	-0.31	4.27e-7	Major depression and alcohol dependence;
KIRP	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg13482628	chr17:19912719	NA	0.57	8.11	0.46	2.42e-14	Schizophrenia;
KIRP	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.69	10.68	0.56	4.1e-22	Blood metabolite ratios;
KIRP	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	1.0	17.43	0.74	7.3e-45	Breast cancer;
KIRP	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.23	0.51	1.31e-17	Colorectal cancer;
KIRP	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	5.27	0.32	2.91e-7	Schizophrenia;
KIRP	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.41	5.15	0.31	5.44e-7	High light scatter reticulocyte count;
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.93	0.3	1.51e-6	Lung cancer;
KIRP	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-7.58	-0.43	7.22e-13	Total bilirubin levels in HIV-1 infection;
KIRP	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg22334962	chr1:44435615	DPH2	-0.61	-6.31	-0.37	1.3e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg07884673	chr3:53033167	SFMBT1	0.84	7.15	0.41	9.8e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.06	-0.5	4.21e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.42	-5.31	-0.32	2.44e-7	Blood metabolite levels;
KIRP	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg08885076	chr2:99613938	TSGA10	0.56	9.88	0.53	1.31e-19	Chronic sinus infection;
KIRP	cis	rs7534824	0.543	rs6577221	chr1:101420406	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	7.87	0.45	1.11e-13	Refractive astigmatism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26869604	chr10:72142636	LRRC20	0.51	6.21	0.37	2.23e-9	Smoking initiation;
KIRP	cis	rs2013441	0.613	rs7215803	chr17:19998377	C/T	cg13482628	chr17:19912719	NA	0.47	6.19	0.37	2.49e-9	Obesity-related traits;
KIRP	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.73	-0.34	2.95e-8	Parkinson's disease;
KIRP	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.4	-5.6	-0.34	5.68e-8	Endometrial cancer;
KIRP	cis	rs6952809	1.000	rs2023968	chr7:2451461	A/G	cg06995285	chr7:2418615	EIF3B	-0.36	-4.9	-0.3	1.7e-6	Multiple sclerosis;
KIRP	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg13319975	chr6:146136371	FBXO30	0.43	5.73	0.34	2.92e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.42	-0.51	3.4e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg05785598	chr3:49045655	WDR6	0.3	5.37	0.32	1.8e-7	Parkinson's disease;
KIRP	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.5	7.14	0.41	1.04e-11	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7665939	0.860	rs61745583	chr4:190125993	A/G	cg01790032	chr4:190285510	NA	-0.73	-5.02	-0.3	9.89e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.72	10.54	0.56	1.15e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg07382826	chr16:28625726	SULT1A1	0.53	5.88	0.35	1.3e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.71	-9.94	-0.54	8.5e-20	Body mass index;
KIRP	cis	rs600806	0.813	rs4970760	chr1:109985439	A/G	cg02175308	chr1:109941060	SORT1	-0.26	-4.99	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7129556	0.859	rs11605638	chr11:77239334	C/T	cg12586386	chr11:77299805	AQP11	0.47	5.57	0.33	6.83e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg05562828	chr17:3906858	NA	0.82	17.56	0.75	2.8e-45	Type 2 diabetes;
KIRP	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg23719950	chr11:63933701	MACROD1	-0.66	-6.44	-0.38	6.21e-10	Mean platelet volume;
KIRP	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg18709589	chr6:96969512	KIAA0776	0.34	5.04	0.31	8.89e-7	Headache;
KIRP	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.93e-10	Hypertriglyceridemia;
KIRP	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg26174226	chr8:58114915	NA	-0.51	-5.06	-0.31	8.02e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.32	0.47	6.18e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg05044414	chr3:183734942	ABCC5	0.38	5.63	0.34	4.87e-8	Anterior chamber depth;
KIRP	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	9.11	0.5	2.9e-17	Resting heart rate;
KIRP	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg04733989	chr22:42467013	NAGA	-0.54	-6.59	-0.39	2.68e-10	Cognitive function;
KIRP	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-0.93	-9.31	-0.51	7.37e-18	Developmental language disorder (linguistic errors);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01078248	chr7:123197661	NDUFA5	0.7	6.7	0.39	1.43e-10	Lung function (FEV1);
KIRP	cis	rs4765905	0.610	rs61909095	chr12:2301189	T/C	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.86	-0.4	5.63e-11	Schizophrenia;
KIRP	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	1.01	15.24	0.7	2.27e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.54	-6.71	-0.39	1.34e-10	Schizophrenia;
KIRP	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg14456004	chr13:21872349	NA	-1.14	-14.21	-0.67	7.06e-34	White matter hyperintensity burden;
KIRP	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.06	-0.72	3.55e-40	Height;
KIRP	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.42	6.42	0.38	6.97e-10	Lipoprotein (a) levels;
KIRP	cis	rs367943	0.712	rs10042223	chr5:112712832	C/T	cg12552261	chr5:112820674	MCC	0.56	6.61	0.39	2.32e-10	Type 2 diabetes;
KIRP	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg17133734	chr15:86042851	AKAP13	-0.46	-5.8	-0.35	2.03e-8	Coronary artery disease;
KIRP	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-6.11	-0.36	3.81e-9	Eosinophil percentage of white cells;
KIRP	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.57	-7.69	-0.44	3.59e-13	Testicular germ cell tumor;
KIRP	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	4.91	0.3	1.66e-6	Schizophrenia;
KIRP	cis	rs9308731	0.583	rs10211562	chr2:111930796	G/T	cg03171003	chr2:111875934	NA	0.42	5.75	0.34	2.57e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg10756647	chr7:56101905	PSPH	0.94	7.09	0.41	1.45e-11	Diabetic kidney disease;
KIRP	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg05579598	chr16:88989069	CBFA2T3	0.25	5.1	0.31	6.85e-7	Social autistic-like traits;
KIRP	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-8.12	-0.46	2.24e-14	Personality dimensions;
KIRP	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.55	-0.39	3.29e-10	Obesity-related traits;
KIRP	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg05692746	chr2:100937584	LONRF2	-0.4	-5.25	-0.32	3.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.52	0.52	1.7e-18	Bipolar disorder;
KIRP	cis	rs4936891	0.504	rs11219389	chr11:123852381	C/T	cg22125253	chr11:123886957	OR10G4	-0.37	-5.02	-0.3	9.96e-7	Male fertility;
KIRP	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg00125455	chr20:44574271	PCIF1	0.44	8.65	0.48	6.68e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.78	14.45	0.68	1.11e-34	Lymphocyte counts;
KIRP	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg02896835	chr1:92012615	NA	0.53	5.41	0.33	1.48e-7	Eosinophil percentage of white cells;
KIRP	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg18154014	chr19:37997991	ZNF793	0.73	7.82	0.45	1.58e-13	Coronary artery calcification;
KIRP	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg12559939	chr2:27858050	GPN1	-0.4	-4.87	-0.3	1.99e-6	Total body bone mineral density;
KIRP	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.87	13.21	0.64	1.81e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.43	-6.2	-0.37	2.33e-9	Vitamin D levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15188491	chr1:146644106	PRKAB2	0.63	7.73	0.44	2.8e-13	Smoking initiation;
KIRP	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg15871215	chr5:81402204	ATG10	-0.49	-6.45	-0.38	5.74e-10	Breast cancer;
KIRP	cis	rs4356975	0.563	rs56217918	chr4:69955643	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg10207240	chr12:122356781	WDR66	0.61	8.08	0.46	2.84e-14	Mean corpuscular volume;
KIRP	cis	rs904092	0.786	rs62305755	chr4:100150020	G/A	cg12011299	chr4:100065546	ADH4	0.55	5.45	0.33	1.23e-7	Alcohol dependence;
KIRP	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg03060546	chr3:49711283	APEH	0.52	6.87	0.4	5.09e-11	Menarche (age at onset);
KIRP	cis	rs4660306	0.744	rs11583290	chr1:45926363	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.37	0.38	9.27e-10	Homocysteine levels;
KIRP	cis	rs7729447	0.776	rs58529247	chr5:32693889	C/T	cg16267343	chr5:32710456	NPR3	0.53	6.0	0.36	6.86e-9	Blood pressure;
KIRP	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.17	-0.42	8.85e-12	Glomerular filtration rate;
KIRP	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.29	0.42	4.1e-12	Rheumatoid arthritis;
KIRP	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.9	-9.11	-0.5	2.89e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg13611997	chr5:233750	SDHA	-0.46	-5.47	-0.33	1.11e-7	Breast cancer;
KIRP	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.12	-0.31	6.31e-7	Fear of minor pain;
KIRP	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg02073558	chr3:44770973	ZNF501	0.57	8.06	0.46	3.4e-14	Depressive symptoms;
KIRP	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.71	6.96	0.41	3.11e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg04673462	chr1:38461896	NA	0.48	6.54	0.38	3.51e-10	Coronary artery disease;
KIRP	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20135002	chr11:47629003	NA	-0.47	-5.7	-0.34	3.37e-8	Subjective well-being;
KIRP	cis	rs11866815	0.857	rs2361988	chr16:398151	T/C	cg26913058	chr16:419975	MRPL28	-0.5	-5.7	-0.34	3.47e-8	Body mass index;
KIRP	cis	rs9403521	0.673	rs7748882	chr6:143991712	T/C	cg18240653	chr6:144019428	PHACTR2	-0.46	-5.81	-0.35	1.95e-8	Obesity-related traits;
KIRP	cis	rs9807841	0.643	rs4435370	chr19:10774623	G/A	cg09936142	chr19:10668400	KRI1	-0.44	-4.87	-0.3	2.02e-6	Inflammatory skin disease;
KIRP	cis	rs754423	0.622	rs730531	chr14:52518683	A/G	cg10149976	chr14:52535953	NID2	-0.39	-4.9	-0.3	1.74e-6	Craniofacial microsomia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20144576	chr6:44225102	SLC35B2	-0.63	-6.84	-0.4	6.19e-11	Menopause (age at onset);
KIRP	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg18461458	chr19:21324796	ZNF431	0.48	5.08	0.31	7.57e-7	Pain;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11065262	chr2:191878861	STAT1	0.49	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs1903068	1.000	rs4516787	chr4:56010165	C/T	cg20092376	chr4:56023423	NA	-0.4	-5.03	-0.31	9.41e-7	Endometriosis;
KIRP	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.72	5.96	0.36	8.51e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.46	9.47	0.52	2.44e-18	Ewing sarcoma;
KIRP	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg11569703	chr11:65557185	OVOL1	0.48	8.3	0.47	6.88e-15	Acne (severe);
KIRP	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.46	-0.33	1.16e-7	Joint mobility (Beighton score);
KIRP	cis	rs17023223	0.537	rs2645295	chr1:119582448	C/T	cg05756136	chr1:119680316	WARS2	-0.57	-7.73	-0.44	2.79e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	1.03	18.03	0.75	6.97e-47	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.64	8.52	0.48	1.66e-15	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg11569703	chr11:65557185	OVOL1	-0.48	-8.57	-0.48	1.18e-15	Acne (severe);
KIRP	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg03468072	chr12:39539422	NA	0.41	5.96	0.36	8.47e-9	Morning vs. evening chronotype;
KIRP	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.88	-0.4	4.92e-11	Daytime sleep phenotypes;
KIRP	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-11.0	-0.57	3.74e-23	Menarche (age at onset);
KIRP	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.45	5.99	0.36	7.27e-9	Lipoprotein (a) levels;
KIRP	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.86	12.88	0.63	2.34e-29	Longevity;
KIRP	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.42	-6.69	-0.39	1.51e-10	Eye color traits;
KIRP	cis	rs6545883	0.929	rs1186711	chr2:61688505	T/C	cg15711740	chr2:61764176	XPO1	-0.62	-7.92	-0.45	8.31e-14	Tuberculosis;
KIRP	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	0.91	11.68	0.6	2.23e-25	Vitiligo;
KIRP	cis	rs897080	0.515	rs2616449	chr2:44597262	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.38	0.32	1.74e-7	Height;
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg17471677	chr22:42094896	MEI1	-0.42	-6.02	-0.36	6.25e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg11161011	chr14:65562177	MAX	-0.62	-8.01	-0.45	4.64e-14	Obesity-related traits;
KIRP	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg26597838	chr10:835615	NA	-0.43	-5.01	-0.3	1.04e-6	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17376030	chr22:41985996	PMM1	-0.71	-7.45	-0.43	1.61e-12	Vitiligo;
KIRP	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg13010199	chr12:38710504	ALG10B	0.69	8.89	0.49	1.3e-16	Morning vs. evening chronotype;
KIRP	cis	rs829661	0.739	rs2593465	chr2:30873188	C/G	cg10949345	chr2:30726833	LCLAT1	1.09	13.36	0.65	5.56e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs400736	0.896	rs225126	chr1:8090615	A/G	cg25007680	chr1:8021821	PARK7	0.63	8.28	0.47	8.09e-15	Response to antidepressants and depression;
KIRP	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.61	6.63	0.39	2.11e-10	Corneal astigmatism;
KIRP	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg26061582	chr7:22766209	IL6	0.41	4.85	0.3	2.17e-6	Lung cancer;
KIRP	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.47	-6.69	-0.39	1.51e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg23601095	chr6:26197514	HIST1H3D	0.91	7.48	0.43	1.33e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg25547332	chr5:131281432	NA	0.46	5.03	0.31	9.47e-7	Life satisfaction;
KIRP	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg26384229	chr12:38710491	ALG10B	-0.67	-8.97	-0.5	7.5e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg16867584	chr19:49200180	FUT2	0.33	5.42	0.33	1.39e-7	Dietary macronutrient intake;
KIRP	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg18016565	chr1:150552671	MCL1	0.38	5.79	0.35	2.14e-8	Melanoma;
KIRP	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg19752551	chr11:57585705	CTNND1	-0.8	-13.34	-0.65	6.31e-31	Schizophrenia;
KIRP	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.95	12.81	0.63	4.05e-29	Coronary artery disease;
KIRP	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17376030	chr22:41985996	PMM1	0.7	7.6	0.44	6.12e-13	Vitiligo;
KIRP	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.47	-0.33	1.13e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2151522	0.603	rs9398821	chr6:127168663	G/T	cg21431617	chr6:127135037	NA	0.31	5.52	0.33	8.52e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.86	13.39	0.65	4.41e-31	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17212008	chr17:80209339	CSNK1D	0.53	6.97	0.41	2.92e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-13.01	-0.64	8.44e-30	Vitiligo;
KIRP	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.92	-0.4	4.01e-11	Mood instability;
KIRP	cis	rs7119	0.634	rs55883527	chr15:77854352	G/T	cg12131826	chr15:77904385	NA	0.44	5.17	0.31	4.88e-7	Type 2 diabetes;
KIRP	cis	rs3120667	0.720	rs72698960	chr1:152413579	T/C	cg26876637	chr1:152193138	HRNR	-0.6	-5.59	-0.34	6.13e-8	Eating disorders;
KIRP	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.72	-0.34	3.11e-8	Height;
KIRP	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.3	-6.04	-0.36	5.79e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.67	-9.3	-0.51	7.91e-18	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg24687543	chr11:63912206	MACROD1	0.52	4.94	0.3	1.42e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg19171272	chr22:38449367	NA	-0.66	-9.97	-0.54	6.74e-20	Glioblastoma;Glioma;
KIRP	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.5	7.86	0.45	1.2e-13	Testicular germ cell tumor;
KIRP	cis	rs7951870	0.945	rs58147945	chr11:46500654	C/G	cg16389345	chr11:46697382	NA	-0.48	-5.1	-0.31	6.78e-7	Schizophrenia;
KIRP	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.22	-0.37	2.13e-9	Bladder cancer;
KIRP	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg09699651	chr6:150184138	LRP11	0.59	8.17	0.46	1.6e-14	Testicular germ cell tumor;
KIRP	cis	rs6088813	1.000	rs62211529	chr20:33959315	T/C	cg14752227	chr20:34000481	UQCC	-0.54	-7.1	-0.41	1.35e-11	Height;
KIRP	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg17757837	chr7:157058334	UBE3C	0.82	11.22	0.58	7.06e-24	Body mass index;
KIRP	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14169450	chr9:139327907	INPP5E	0.61	7.12	0.41	1.21e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.83	0.4	6.53e-11	Axial length;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10835230	chr19:2457145	LMNB2	0.51	6.6	0.39	2.51e-10	Parkinson's disease;
KIRP	cis	rs472402	0.623	rs8192131	chr5:6636465	C/T	cg08700190	chr5:6636046	SRD5A1	-0.48	-6.08	-0.36	4.56e-9	Response to amphetamines;
KIRP	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg21132104	chr15:45694354	SPATA5L1	0.77	9.72	0.53	4.09e-19	Homoarginine levels;
KIRP	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.61	-9.78	-0.53	2.8e-19	Itch intensity from mosquito bite;
KIRP	cis	rs259842	0.612	rs10185471	chr2:180709606	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.54	-0.33	7.88e-8	Blood protein levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07592830	chr1:198259669	NEK7	0.37	6.22	0.37	2.17e-9	C-reactive protein;
KIRP	cis	rs2591576	0.682	rs6865847	chr5:165430938	T/C	cg13976338	chr5:165423657	NA	-0.71	-9.61	-0.52	9.04e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	10.11	0.54	2.6e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.3	6.07	0.36	4.82e-9	Schizophrenia;
KIRP	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-12.85	-0.63	2.93e-29	Vitiligo;
KIRP	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg08888203	chr3:10149979	C3orf24	0.5	5.3	0.32	2.64e-7	Alzheimer's disease;
KIRP	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg00666640	chr1:248458726	OR2T12	0.47	5.76	0.34	2.48e-8	Common traits (Other);
KIRP	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	cis	rs8084125	1.000	rs62105169	chr18:74945193	A/G	cg18461021	chr18:74961002	GALR1	0.62	5.9	0.35	1.19e-8	Obesity-related traits;
KIRP	cis	rs4955124	0.558	rs60434847	chr3:32017702	T/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.81	7.14	0.41	1.03e-11	Schizophrenia;
KIRP	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg19468946	chr17:37922297	IKZF3	-0.48	-6.55	-0.39	3.34e-10	Self-reported allergy;
KIRP	cis	rs6142102	0.961	rs1007090	chr20:32582871	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.69	0.39	1.46e-10	Skin pigmentation;
KIRP	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.57	-0.56	9.31e-22	Menopause (age at onset);
KIRP	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11987759	chr7:65425863	GUSB	0.44	5.28	0.32	2.85e-7	Aortic root size;
KIRP	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg23533926	chr12:111358616	MYL2	-0.49	-6.43	-0.38	6.65e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg16434002	chr17:42200994	HDAC5	-0.57	-6.95	-0.41	3.24e-11	Total body bone mineral density;
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg08662619	chr6:150070041	PCMT1	0.38	6.29	0.37	1.42e-9	Lung cancer;
KIRP	cis	rs4148660	0.697	rs704217	chr12:22047174	A/G	cg14669847	chr12:22099120	NA	-0.38	-6.36	-0.38	9.59e-10	Gout;
KIRP	cis	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-5.36	-0.32	1.96e-7	Systemic lupus erythematosus;
KIRP	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.74	-12.06	-0.61	1.25e-26	Prostate cancer;
KIRP	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg26384229	chr12:38710491	ALG10B	0.68	9.32	0.51	6.99e-18	Morning vs. evening chronotype;
KIRP	cis	rs1978968	1.000	rs7286607	chr22:18444657	T/C	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg10223061	chr2:219282414	VIL1	-0.36	-5.98	-0.36	7.88e-9	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs13170463	0.579	rs13162612	chr5:8043021	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-5.45	-0.33	1.25e-7	Testicular germ cell tumor;
KIRP	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg13482628	chr17:19912719	NA	0.66	9.75	0.53	3.37e-19	Schizophrenia;
KIRP	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg21095983	chr6:86352623	SYNCRIP	0.5	6.92	0.4	3.92e-11	Smooth-surface caries;
KIRP	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.11	-0.36	3.81e-9	Cutaneous nevi;
KIRP	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26207909	chr14:103986467	CKB	0.74	10.53	0.56	1.19e-21	Body mass index;
KIRP	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.66	-7.07	-0.41	1.6e-11	Gout;
KIRP	cis	rs6499755	0.712	rs31087	chr16:55363238	G/A	cg05099576	chr16:55362342	IRX6	0.3	6.35	0.38	1.03e-9	Hypospadias;
KIRP	cis	rs7017914	0.934	rs6998024	chr8:71660840	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.71	-6.96	-0.41	3.07e-11	Body mass index;
KIRP	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.44	7.79	0.45	1.82e-13	Lipoprotein (a) levels;
KIRP	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-1.2	-12.89	-0.63	2.19e-29	Monocyte percentage of white cells;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23164327	chr5:40755670	TTC33	-0.48	-6.08	-0.36	4.59e-9	Myopia;
KIRP	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg24826892	chr11:71159390	DHCR7	0.44	4.87	0.3	1.99e-6	Vitamin D levels;
KIRP	cis	rs975752	0.717	rs7082753	chr10:102008483	A/G	cg13817732	chr10:102046368	BLOC1S2	0.74	6.25	0.37	1.78e-9	Schizophrenia;
KIRP	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.54	8.08	0.46	3e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs240764	0.687	rs7754085	chr6:101220806	T/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.77	0.66	2.37e-32	Platelet count;
KIRP	cis	rs2904967	0.852	rs488289	chr11:65039264	T/C	cg09225861	chr11:65069680	NA	0.43	5.62	0.34	5.1e-8	Mean corpuscular volume;
KIRP	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	9.13	0.5	2.54e-17	Educational attainment;
KIRP	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg21573476	chr21:45109991	RRP1B	-0.78	-10.83	-0.57	1.34e-22	Mean corpuscular volume;
KIRP	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg00083206	chr6:110721305	DDO	-0.44	-6.74	-0.39	1.14e-10	Platelet distribution width;
KIRP	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.48	6.44	0.38	6.18e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2151522	0.544	rs4618551	chr6:127120816	G/C	cg21431617	chr6:127135037	NA	0.33	6.01	0.36	6.75e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.65	0.39	1.87e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	cis	rs7546094	1.000	rs6691932	chr1:113144263	T/C	cg22162597	chr1:113214053	CAPZA1	0.47	6.59	0.39	2.59e-10	Platelet distribution width;
KIRP	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg00360474	chr6:37504404	NA	-0.51	-7.28	-0.42	4.58e-12	Cognitive performance;
KIRP	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00889227	chr1:205173544	DSTYK	-0.41	-5.86	-0.35	1.46e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg00074818	chr8:8560427	CLDN23	0.43	6.45	0.38	6.04e-10	Obesity-related traits;
KIRP	cis	rs11874712	0.712	rs2578183	chr18:43676720	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.38	-5.66	-0.34	4.18e-8	Migraine - clinic-based;
KIRP	cis	rs10267417	0.603	rs6969717	chr7:19908081	T/C	cg05791153	chr7:19748676	TWISTNB	0.5	5.15	0.31	5.43e-7	Night sleep phenotypes;
KIRP	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg07741184	chr6:167504864	NA	0.24	6.45	0.38	5.8e-10	Crohn's disease;
KIRP	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg12549451	chr6:135224345	NA	0.45	5.89	0.35	1.24e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg24558204	chr6:135376177	HBS1L	-0.63	-8.17	-0.46	1.66e-14	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.53	8.02	0.46	4.21e-14	Lung cancer;
KIRP	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.9	-13.18	-0.64	2.32e-30	Mortality in heart failure;
KIRP	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.97	13.76	0.66	2.51e-32	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.33	-0.74	1.68e-44	Coronary artery disease;
KIRP	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.48	-6.48	-0.38	5.06e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16346588	chr10:242978	ZMYND11	0.42	4.99	0.3	1.12e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.83e-16	Immature fraction of reticulocytes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19267910	chr2:142948816	NA	-0.4	-6.22	-0.37	2.17e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7572644	0.665	rs4420671	chr2:28039300	G/C	cg27432699	chr2:27873401	GPN1	0.49	5.54	0.33	7.71e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg10167378	chr1:228756711	NA	0.45	5.57	0.33	6.65e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7221595	0.825	rs8078629	chr17:3983964	A/C	cg05562828	chr17:3906858	NA	0.56	6.19	0.37	2.5e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.4	5.35	0.32	1.98e-7	Bipolar disorder;
KIRP	trans	rs1106684	1.000	rs58699753	chr7:131461137	G/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs10208940	0.920	rs6742045	chr2:68811850	G/A	cg12452813	chr2:68675892	NA	0.45	4.91	0.3	1.64e-6	Urate levels in lean individuals;
KIRP	cis	rs9788721	0.835	rs17487223	chr15:78923987	A/G	cg21642963	chr15:78858002	CHRNA5	-0.51	-5.73	-0.34	2.87e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	8.8	0.49	2.5e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg18306943	chr3:40428807	ENTPD3	0.41	5.38	0.32	1.76e-7	Renal cell carcinoma;
KIRP	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg05973401	chr12:123451056	ABCB9	0.6	7.03	0.41	2.09e-11	Platelet count;
KIRP	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.73	9.33	0.51	6.36e-18	Coronary artery disease;
KIRP	cis	rs2034088	1.000	rs2034088	chr17:423051	T/C	cg06217071	chr17:408420	NA	0.74	11.18	0.58	1e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs9311676	0.618	rs12152337	chr3:58365271	T/C	cg06643156	chr3:58380774	PXK	0.36	5.1	0.31	6.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg06521331	chr12:34319734	NA	0.62	7.41	0.43	1.99e-12	Morning vs. evening chronotype;
KIRP	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.57	-0.48	1.17e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.86	-0.49	1.65e-16	Height;
KIRP	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	10.19	0.54	1.46e-20	Smoking behavior;
KIRP	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg05361325	chr10:32636312	EPC1	-0.66	-6.28	-0.37	1.54e-9	Sexual dysfunction (female);
KIRP	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.65	9.55	0.52	1.35e-18	Dupuytren's disease;
KIRP	cis	rs925255	0.747	rs6547851	chr2:28629367	G/C	cg01273330	chr2:28605224	NA	0.36	6.28	0.37	1.52e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs7712401	0.562	rs30062	chr5:122296376	C/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg23736307	chr8:27182930	PTK2B	0.51	6.52	0.38	3.87e-10	Neuroticism;
KIRP	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg24060327	chr5:131705240	SLC22A5	-0.75	-9.27	-0.51	9.65e-18	Acylcarnitine levels;
KIRP	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	0.96	14.94	0.69	2.31e-36	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg01973587	chr1:228161476	NA	-0.39	-4.87	-0.3	1.99e-6	Diastolic blood pressure;
KIRP	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg08283408	chr3:49949060	MON1A	0.42	5.54	0.33	7.78e-8	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11112791	chr14:58619036	C14orf37	0.5	6.12	0.36	3.65e-9	Parkinson's disease;
KIRP	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.57	9.56	0.52	1.33e-18	Schizophrenia;
KIRP	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2880765	0.527	rs35184622	chr15:86073035	A/G	cg10818794	chr15:86012489	AKAP13	-0.52	-7.0	-0.41	2.48e-11	Coronary artery disease;
KIRP	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	4.86	0.3	2.07e-6	Total cholesterol levels;
KIRP	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24110177	chr3:50126178	RBM5	0.44	5.6	0.34	5.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg23100626	chr2:96804247	ASTL	0.44	6.22	0.37	2.08e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.53	-6.63	-0.39	2.1e-10	Longevity;
KIRP	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg17385448	chr1:15911702	AGMAT	0.27	5.3	0.32	2.51e-7	Systolic blood pressure;
KIRP	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.84	13.06	0.64	5.72e-30	Dental caries;
KIRP	trans	rs12545912	0.770	rs4841196	chr8:9555092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.53	-0.38	3.8e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4742903	0.904	rs1333941	chr9:106996386	C/G	cg14250997	chr9:106856677	SMC2	0.39	5.36	0.32	1.89e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg10223061	chr2:219282414	VIL1	0.44	7.03	0.41	1.97e-11	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg01428437	chr1:1852164	TMEM52	0.29	4.98	0.3	1.19e-6	Body mass index;
KIRP	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.69	0.44	3.46e-13	Obesity-related traits;
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg07701084	chr6:150067640	NUP43	0.75	10.59	0.56	8.01e-22	Lung cancer;
KIRP	cis	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg05779272	chr9:33168018	B4GALT1	0.37	4.89	0.3	1.83e-6	IgG glycosylation;
KIRP	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.72	10.1	0.54	2.68e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6988636	0.710	rs73339626	chr8:124142757	A/G	cg22384356	chr8:124195192	FAM83A	-0.54	-4.89	-0.3	1.82e-6	Urinary uromodulin levels;
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg00080972	chr5:178986291	RUFY1	-0.38	-5.81	-0.35	1.9e-8	Lung cancer;
KIRP	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.48	0.62	5.02e-28	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg01311341	chr22:25575246	KIAA1671	-0.64	-7.53	-0.43	9.43e-13	Atopic dermatitis;
KIRP	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.15	-0.31	5.22e-7	Bladder cancer;
KIRP	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg09165964	chr15:75287851	SCAMP5	-0.94	-9.11	-0.5	2.99e-17	Lung cancer;
KIRP	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.5	5.91	0.35	1.11e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg11846333	chr4:119757529	SEC24D	1.1	6.4	0.38	7.97e-10	Cannabis dependence symptom count;
KIRP	cis	rs2671245	0.901	rs1877716	chr1:56162228	C/G	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-1.05	-20.37	-0.79	1.02e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.29e-11	Type 2 diabetes;
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.5	-6.49	-0.38	4.82e-10	Testicular germ cell tumor;
KIRP	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.22	-0.37	2.09e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs67385638	0.925	rs12417960	chr11:5265106	C/A	cg12559170	chr11:5275217	HBG2	0.48	7.01	0.41	2.24e-11	Hemoglobin levels;
KIRP	cis	rs16828019	0.777	rs10489521	chr1:41508490	C/T	cg18742814	chr1:41828276	NA	0.7	5.98	0.36	7.69e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs72820985	1.000	rs74030464	chr16:80841711	C/T	cg04448709	chr16:81349954	GAN	-0.49	-5.01	-0.3	1.04e-6	Breast cancer;
KIRP	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	cis	rs7794364	0.681	rs10242758	chr7:117522956	G/T	cg21880328	chr7:117514017	CTTNBP2	-0.37	-5.54	-0.33	7.68e-8	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg04691961	chr3:161091175	C3orf57	0.44	6.31	0.37	1.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.78	11.58	0.59	4.77e-25	Heart rate;
KIRP	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.55	6.18	0.37	2.71e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg13902645	chr11:5959945	NA	-0.59	-6.26	-0.37	1.69e-9	DNA methylation (variation);
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.56	-0.33	6.85e-8	Life satisfaction;
KIRP	cis	rs2223471	0.624	rs2817374	chr6:50746213	G/A	cg03432817	chr6:50765336	NA	-0.36	-5.44	-0.33	1.3e-7	Subcutaneous adipose tissue;
KIRP	cis	rs7809799	0.571	rs67934834	chr7:98899464	C/T	cg12290671	chr7:99195819	NA	-0.69	-5.27	-0.32	2.97e-7	Ulcerative colitis;
KIRP	cis	rs16957091	0.954	rs112968809	chr15:43030403	C/A	cg24196017	chr15:43021976	CDAN1	-0.42	-5.3	-0.32	2.61e-7	MGMT methylation in smokers;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg10207240	chr12:122356781	WDR66	-0.57	-7.73	-0.44	2.81e-13	Mean corpuscular volume;
KIRP	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.79	0.4	8.44e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7852872	1.000	rs7852872	chr9:119249339	C/G	cg13792444	chr9:119245443	ASTN2	0.39	5.75	0.34	2.7e-8	Hippocampal volume;
KIRP	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.93	0.35	1.04e-8	Morning vs. evening chronotype;
KIRP	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg12598211	chr12:123634384	NA	-0.4	-5.03	-0.31	9.29e-7	Platelet count;
KIRP	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg19847130	chr8:10466454	RP1L1	-0.33	-5.06	-0.31	8.39e-7	Morning vs. evening chronotype;
KIRP	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg17654217	chr7:100282651	GIGYF1	0.53	5.08	0.31	7.31e-7	Other erythrocyte phenotypes;
KIRP	cis	rs17030434	1.000	rs952211	chr4:154717816	A/G	cg14289246	chr4:154710475	SFRP2	-0.82	-9.35	-0.51	5.71e-18	Electrocardiographic conduction measures;
KIRP	cis	rs6499755	0.712	rs31090	chr16:55363628	A/G	cg05099576	chr16:55362342	IRX6	0.3	6.26	0.37	1.72e-9	Hypospadias;
KIRP	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.38	-0.38	8.61e-10	Response to antipsychotic treatment;
KIRP	cis	rs4594175	0.926	rs72688717	chr14:51614493	C/T	cg23942311	chr14:51606299	NA	0.44	5.28	0.32	2.86e-7	Cancer;
KIRP	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.74	6.71	0.39	1.35e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.4	-5.37	-0.32	1.82e-7	Childhood ear infection;
KIRP	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.71	8.95	0.5	8.6e-17	Morning vs. evening chronotype;
KIRP	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.65	-9.74	-0.53	3.7e-19	Menopause (age at onset);
KIRP	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg04362960	chr10:104952993	NT5C2	0.64	7.48	0.43	1.3e-12	Arsenic metabolism;
KIRP	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13939156	chr17:80058883	NA	-0.47	-7.53	-0.43	9.91e-13	Life satisfaction;
KIRP	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.23	-0.32	3.62e-7	Lung cancer;
KIRP	cis	rs367943	0.712	rs6896650	chr5:112681048	T/C	cg12552261	chr5:112820674	MCC	0.49	5.73	0.34	2.91e-8	Type 2 diabetes;
KIRP	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	cis	rs16828019	0.777	rs34502739	chr1:41459146	A/G	cg18742814	chr1:41828276	NA	0.67	5.69	0.34	3.62e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg00310523	chr12:86230176	RASSF9	-0.42	-6.61	-0.39	2.32e-10	Major depressive disorder;
KIRP	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.79	7.12	0.41	1.21e-11	Inflammatory bowel disease;
KIRP	cis	rs1448094	0.967	rs1374995	chr12:86341764	A/G	cg06740227	chr12:86229804	RASSF9	0.4	5.08	0.31	7.47e-7	Major depressive disorder;
KIRP	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg09904177	chr6:26538194	HMGN4	-0.47	-5.71	-0.34	3.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg24315340	chr6:146058215	EPM2A	0.39	4.93	0.3	1.54e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg16141378	chr3:129829833	LOC729375	-0.55	-6.84	-0.4	6.06e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg26174226	chr8:58114915	NA	-0.55	-6.12	-0.36	3.68e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-1.07	-12.74	-0.63	6.86e-29	Exhaled nitric oxide output;
KIRP	cis	rs1847505	0.593	rs3127045	chr13:61401233	C/T	cg25164009	chr13:61490935	NA	-0.43	-4.87	-0.3	1.99e-6	Polychlorinated biphenyl levels;
KIRP	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.58	-7.17	-0.42	8.68e-12	Cognitive test performance;
KIRP	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg10664184	chr19:17420304	DDA1	0.72	8.39	0.47	3.72e-15	Systemic lupus erythematosus;
KIRP	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.85	11.24	0.58	6.32e-24	Primary sclerosing cholangitis;
KIRP	cis	rs12049351	0.665	rs4148761	chr1:229662344	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.52	-0.33	8.56e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7116495	1.000	rs7930721	chr11:71737481	C/A	cg26138937	chr11:71823887	C11orf51	-0.7	-5.65	-0.34	4.46e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg13731523	chr4:3047190	NA	-0.36	-5.93	-0.35	1.04e-8	Serum sulfate level;
KIRP	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.86	12.52	0.62	3.88e-28	Glomerular filtration rate (creatinine);
KIRP	cis	rs8014252	0.803	rs61388426	chr14:71045002	G/A	cg11204974	chr14:71022665	NA	-0.73	-7.13	-0.41	1.09e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg05255149	chr17:80675120	FN3KRP	0.54	6.4	0.38	7.98e-10	Glycated hemoglobin levels;
KIRP	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg15556689	chr8:8085844	FLJ10661	0.65	8.16	0.46	1.7e-14	Retinal vascular caliber;
KIRP	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.01	12.56	0.63	2.79e-28	Testicular germ cell tumor;
KIRP	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12049351	0.774	rs12138965	chr1:229655720	T/C	cg11742688	chr1:229674241	ABCB10	-0.38	-5.52	-0.33	8.56e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg06307176	chr5:131281290	NA	0.56	6.37	0.38	9.09e-10	Life satisfaction;
KIRP	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.75	-10.41	-0.55	2.93e-21	Plateletcrit;Platelet count;
KIRP	cis	rs7172677	1.000	rs2029520	chr15:75415768	A/G	cg14664628	chr15:75095509	CSK	-0.56	-6.09	-0.36	4.38e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg03468072	chr12:39539422	NA	0.44	5.82	0.35	1.86e-8	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.48	0.52	2.29e-18	Bladder cancer;
KIRP	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg15556689	chr8:8085844	FLJ10661	0.68	9.23	0.51	1.3e-17	Mood instability;
KIRP	cis	rs9905704	0.718	rs72826360	chr17:56664395	T/G	cg12560992	chr17:57184187	TRIM37	0.53	4.93	0.3	1.54e-6	Testicular germ cell tumor;
KIRP	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg17845761	chr1:175162550	KIAA0040	0.26	4.96	0.3	1.31e-6	Alcohol dependence;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23674647	chr1:92001147	NA	-0.45	-6.51	-0.38	4.2e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg19468946	chr17:37922297	IKZF3	-0.48	-6.8	-0.4	7.78e-11	Asthma;
KIRP	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.51	6.41	0.38	7.33e-10	HDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26191710	chr1:193251763	NA	-0.43	-6.82	-0.4	6.93e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs75920871	0.925	rs4938333	chr11:116930888	A/G	cg23684410	chr11:116897558	SIK3	0.56	6.11	0.36	3.78e-9	Subjective well-being;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22752506	chr17:79895093	PYCR1	-0.49	-6.69	-0.39	1.47e-10	Metabolic traits;
KIRP	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.35	-4.98	-0.3	1.18e-6	Body mass index;
KIRP	cis	rs3857747	0.827	rs7782097	chr7:40473004	C/G	cg00420559	chr7:40367873	C7orf10	0.55	7.42	0.43	1.9e-12	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs11827555	0.614	rs11222808	chr11:131697390	T/A	cg26224223	chr19:31840737	TSHZ3	-0.58	-6.19	-0.37	2.53e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.86	0.4	5.5e-11	Menarche (age at onset);
KIRP	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	1.12	12.0	0.61	2.05e-26	Psoriasis;
KIRP	cis	rs7224685	0.548	rs17710668	chr17:3880546	C/G	cg21851534	chr17:3907994	ZZEF1	0.62	6.65	0.39	1.92e-10	Type 2 diabetes;
KIRP	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.64	-4.88	-0.3	1.89e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9443189	0.813	rs2842556	chr6:76447204	T/C	cg01950844	chr6:76311363	SENP6	-0.57	-6.21	-0.37	2.2e-9	Prostate cancer;
KIRP	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg21204522	chr6:27730016	NA	-0.71	-5.39	-0.33	1.63e-7	Breast cancer;
KIRP	cis	rs9513627	0.915	rs80270035	chr13:100121784	C/T	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg16077055	chr2:106428750	NCK2	0.31	6.06	0.36	4.96e-9	Addiction;
KIRP	cis	rs73200209	0.912	rs57703342	chr12:116677337	C/G	cg01776926	chr12:116560359	MED13L	-0.47	-5.57	-0.33	6.51e-8	Total body bone mineral density;
KIRP	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.59	7.79	0.45	1.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6707387	0.641	rs7572369	chr2:214491910	G/A	cg08319019	chr2:214017104	IKZF2	0.47	5.38	0.32	1.72e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-7.09	-0.41	1.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4638749	0.501	rs12624041	chr2:108763547	C/A	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.05	-0.31	8.5e-7	Blood pressure;
KIRP	trans	rs2048656	0.550	rs7825012	chr8:9671885	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.39	-0.38	8.19e-10	Schizophrenia;
KIRP	cis	rs8053891	0.507	rs10852510	chr16:72026041	G/A	cg01557791	chr16:72042693	DHODH	-0.46	-4.88	-0.3	1.88e-6	Coronary artery disease;
KIRP	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.6	7.57	0.43	7.5e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.66	-9.14	-0.5	2.45e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23089673	chr5:53245594	ARL15	0.47	6.37	0.38	9.25e-10	Interleukin-4 levels;
KIRP	cis	rs56079296	0.501	rs2913409	chr5:121326028	G/A	cg05256605	chr5:121412184	LOX	0.53	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg12962167	chr3:53033115	SFMBT1	0.71	5.19	0.31	4.44e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs17095355	1.000	rs55781439	chr10:111670220	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.75	-0.34	2.67e-8	Biliary atresia;
KIRP	cis	rs830383	0.554	rs194057	chr5:165410782	G/A	cg13976338	chr5:165423657	NA	-0.49	-5.51	-0.33	8.88e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17756712	0.527	rs1193742	chr6:635629	T/C	cg14374089	chr6:596013	EXOC2	0.45	5.09	0.31	7.14e-7	Vertical cup-disc ratio;
KIRP	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.84	10.06	0.54	3.7e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs16958440	1.000	rs2289132	chr18:44602292	G/A	cg17192377	chr18:44677553	HDHD2	0.75	6.98	0.41	2.8e-11	Sitting height ratio;
KIRP	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg24565620	chr2:194026	NA	-0.73	-8.67	-0.48	5.97e-16	Blood protein levels;
KIRP	cis	rs9346649	0.967	rs6920748	chr6:168490047	T/G	cg09211372	chr6:168490623	NA	0.32	5.78	0.35	2.22e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.11	-0.31	6.33e-7	Pulmonary function;
KIRP	cis	rs838147	0.844	rs8111208	chr19:49248022	A/C	cg13540341	chr19:49222985	MAMSTR	0.35	5.62	0.34	5.06e-8	Dietary macronutrient intake;
KIRP	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg05044414	chr3:183734942	ABCC5	0.38	5.75	0.34	2.69e-8	Anterior chamber depth;
KIRP	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.72	8.66	0.48	6.42e-16	Alcohol dependence;
KIRP	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.43	6.02	0.36	6.34e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.69	-6.45	-0.38	5.81e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9372498	0.505	rs9489462	chr6:118927855	C/T	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg20673091	chr1:2541236	MMEL1	-0.67	-10.18	-0.54	1.53e-20	Ulcerative colitis;
KIRP	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.29	-0.51	8.48e-18	Mean corpuscular volume;
KIRP	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg24296786	chr1:45957014	TESK2	0.52	5.76	0.34	2.48e-8	Homocysteine levels;
KIRP	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg23682824	chr7:23144976	KLHL7	0.51	5.97	0.36	8.4e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2562456	0.833	rs4429400	chr19:21520965	T/C	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.52	-6.59	-0.39	2.69e-10	Longevity;
KIRP	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.26	-0.42	5.12e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2742417	1.000	rs2742418	chr3:45731920	C/T	cg04037228	chr3:45636386	LIMD1	0.37	5.44	0.33	1.27e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg07395648	chr5:131743802	NA	0.58	8.09	0.46	2.81e-14	Breast cancer;Mosquito bite size;
KIRP	cis	rs6669119	0.668	rs17354622	chr1:19087996	G/T	cg26220594	chr1:19110978	NA	0.67	6.16	0.37	3.02e-9	Percentage gas trapping;
KIRP	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs2281603	0.951	rs10149286	chr14:64995236	G/T	cg25009451	chr14:65006716	HSPA2	0.48	5.2	0.31	4.12e-7	Lymphocyte counts;
KIRP	cis	rs911119	0.955	rs12625716	chr20:23606845	A/G	cg16589663	chr20:23618590	CST3	-0.53	-5.09	-0.31	7.29e-7	Chronic kidney disease;
KIRP	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg10818794	chr15:86012489	AKAP13	-0.53	-7.47	-0.43	1.39e-12	Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg13010199	chr12:38710504	ALG10B	0.68	8.9	0.49	1.22e-16	Morning vs. evening chronotype;
KIRP	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	5.19e-9	Depression;
KIRP	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.56	8.03	0.46	3.93e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.12	0.41	1.17e-11	Bipolar disorder;
KIRP	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg02038168	chr22:39784481	NA	-0.41	-4.99	-0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg11783602	chr8:55087084	NA	-0.58	-7.02	-0.41	2.09e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg18932078	chr1:2524107	MMEL1	0.4	5.43	0.33	1.38e-7	Ulcerative colitis;
KIRP	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.62e-8	Motion sickness;
KIRP	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg23033748	chr14:75592666	NEK9	-0.33	-4.94	-0.3	1.46e-6	Height;
KIRP	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg03468072	chr12:39539422	NA	0.42	5.68	0.34	3.85e-8	Morning vs. evening chronotype;
KIRP	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00889227	chr1:205173544	DSTYK	-0.37	-5.23	-0.32	3.66e-7	Red blood cell count;
KIRP	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg21775007	chr8:11205619	TDH	-0.54	-6.85	-0.4	5.84e-11	Neuroticism;
KIRP	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs787274	0.718	rs4979171	chr9:115627262	T/C	cg13803584	chr9:115635662	SNX30	-0.71	-5.99	-0.36	7.27e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.29	0.37	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9938149	0.706	rs12711488	chr16:88319421	C/G	cg05435882	chr16:88311214	NA	-0.49	-5.81	-0.35	1.97e-8	Corneal structure;Central corneal thickness;
KIRP	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg04990556	chr1:26633338	UBXN11	0.64	6.02	0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg11814155	chr7:99998594	ZCWPW1	0.72	6.19	0.37	2.55e-9	Platelet count;
KIRP	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2151522	0.762	rs11154376	chr6:127200643	A/G	cg21431617	chr6:127135037	NA	0.29	4.97	0.3	1.23e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs12362504	0.532	rs12796169	chr11:9930529	C/T	cg07197493	chr11:9884649	SBF2	-0.38	-4.98	-0.3	1.2e-6	Survival in pancreatic cancer;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg12692727	chr7:1102344	C7orf50	0.47	5.08	0.31	7.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9843304	0.721	rs4681176	chr3:149201954	A/G	cg08667024	chr3:149219783	TM4SF4	-0.34	-4.89	-0.3	1.8e-6	Gallstone disease;
KIRP	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.92	14.03	0.67	3.01e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.57	7.52	0.43	1e-12	White matter hyperintensity burden;
KIRP	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.6	7.81	0.45	1.69e-13	Mean corpuscular volume;
KIRP	cis	rs12044355	0.929	rs12045248	chr1:231850748	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	4.96	0.3	1.33e-6	Alzheimer's disease;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.81	-10.65	-0.56	5.13e-22	Longevity;Endometriosis;
KIRP	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg02344993	chr17:57696989	CLTC	0.56	5.41	0.33	1.53e-7	Hemoglobin concentration;
KIRP	cis	rs7539542	0.556	rs6427979	chr1:202869503	T/C	cg08940984	chr1:202857613	RABIF	0.46	5.7	0.34	3.4e-8	Mean platelet volume;
KIRP	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg01475377	chr6:109611718	NA	-0.36	-5.26	-0.32	3.08e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs41005	0.597	rs62104919	chr2:8101999	C/T	cg03155496	chr2:8117019	LOC339788	-0.47	-6.7	-0.39	1.42e-10	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg05973401	chr12:123451056	ABCB9	-0.53	-5.31	-0.32	2.43e-7	Neutrophil percentage of white cells;
KIRP	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg14458575	chr2:238380390	NA	0.75	7.51	0.43	1.12e-12	Prostate cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07031542	chr1:214567074	PTPN14	-0.39	-6.16	-0.37	2.89e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	5.16	0.31	5.2e-7	Schizophrenia;
KIRP	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	1.0	8.16	0.46	1.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs75920871	0.748	rs7946399	chr11:116962753	G/C	cg04087571	chr11:116723030	SIK3	-0.28	-5.55	-0.33	7.48e-8	Subjective well-being;
KIRP	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.88	12.37	0.62	1.19e-27	Monocyte count;
KIRP	cis	rs2172802	0.924	rs11941524	chr4:62446484	A/G	cg02936451	chr4:62066211	NA	0.41	4.99	0.3	1.16e-6	Partial epilepsies;
KIRP	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.9	-14.57	-0.68	4.18e-35	Dental caries;
KIRP	cis	rs7584330	0.504	rs7598417	chr2:238435265	C/G	cg14458575	chr2:238380390	NA	0.49	6.19	0.37	2.48e-9	Prostate cancer;
KIRP	cis	rs4363385	0.510	rs11588463	chr1:152901984	T/C	cg13444842	chr1:152974279	SPRR3	-0.44	-6.31	-0.37	1.32e-9	Inflammatory skin disease;
KIRP	cis	rs4845875	0.513	rs198397	chr1:11883332	A/G	cg24844545	chr1:11908347	NPPA	-0.36	-5.11	-0.31	6.48e-7	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg07843065	chr1:150265600	MRPS21	0.43	5.89	0.35	1.28e-8	Migraine;
KIRP	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4650994	0.509	rs7519794	chr1:178542390	G/T	cg12486710	chr1:178512616	C1orf220	-0.26	-5.5	-0.33	9.6e-8	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs80207740	0.838	rs17581959	chr8:21807757	A/G	cg17168535	chr8:21777572	XPO7	0.67	6.42	0.38	7.16e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.4	-6.25	-0.37	1.83e-9	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05401447	chr7:100728731	TRIM56	0.49	6.75	0.4	1.09e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4664304	0.714	rs66496937	chr2:160738509	A/G	cg03641300	chr2:160917029	PLA2R1	-0.43	-6.4	-0.38	7.7e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs2562456	0.833	rs62107531	chr19:21509065	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg00784671	chr22:46762841	CELSR1	-0.65	-7.63	-0.44	5.11e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg22916017	chr11:64110731	CCDC88B	-0.55	-6.45	-0.38	5.82e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.56	0.39	3.1e-10	Height;
KIRP	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	0.99	7.51	0.43	1.08e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.8	10.94	0.57	5.98e-23	Adiposity;
KIRP	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.02	-0.36	6.17e-9	Personality dimensions;
KIRP	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Bladder cancer;
KIRP	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	6.87	0.4	5.23e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9815354	1.000	rs2683695	chr3:41914928	C/T	cg03022575	chr3:42003672	ULK4	0.5	5.79	0.35	2.18e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs867371	1.000	rs7166570	chr15:82466221	C/T	cg06066596	chr15:83166174	LOC80154	-0.47	-5.53	-0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22590775	chr19:49891494	CCDC155	0.66	8.95	0.5	8.72e-17	Multiple sclerosis;
KIRP	cis	rs9596863	0.950	rs9568935	chr13:54397928	C/T	ch.13.53330881F	chr13:54432880	NA	0.62	6.35	0.38	1.02e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg01988459	chr11:68622903	NA	-0.44	-6.11	-0.36	3.83e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	5.31	0.32	2.44e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2979489	0.533	rs62505279	chr8:30447069	C/T	cg26383811	chr8:30366931	RBPMS	-0.36	-4.88	-0.3	1.87e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs2904967	0.929	rs503277	chr11:65078626	G/A	cg12562828	chr11:65076843	NA	0.48	7.3	0.42	4.04e-12	Mean corpuscular volume;
KIRP	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-5.89	-0.35	1.25e-8	Response to antipsychotic treatment;
KIRP	cis	rs4664293	0.867	rs13415100	chr2:160586227	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05601917	chr6:125855416	NA	-0.34	-5.07	-0.31	7.7e-7	Brugada syndrome;
KIRP	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg25801113	chr15:45476975	SHF	0.46	9.2	0.51	1.55e-17	Uric acid levels;
KIRP	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.54	7.87	0.45	1.13e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2635047	0.615	rs1512238	chr18:44748467	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.98	0.36	7.69e-9	Educational attainment;
KIRP	cis	rs6733011	0.604	rs12712035	chr2:99461298	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.38	-0.32	1.75e-7	Bipolar disorder;
KIRP	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg24296786	chr1:45957014	TESK2	-0.59	-7.4	-0.43	2.2e-12	High light scatter reticulocyte count;
KIRP	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Bladder cancer;
KIRP	cis	rs78487399	0.808	rs6717636	chr2:43703684	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.98	-0.3	1.18e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg10950524	chr7:2139216	MAD1L1	0.31	5.09	0.31	7.05e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg09264619	chr17:80180166	NA	-0.52	-6.2	-0.37	2.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg19022780	chr9:134378720	POMT1	0.51	6.07	0.36	4.94e-9	Beard thickness;
KIRP	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11987759	chr7:65425863	GUSB	0.48	6.28	0.37	1.52e-9	Aortic root size;
KIRP	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.59	7.74	0.44	2.58e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.7	6.71	0.39	1.33e-10	Ulcerative colitis;
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13198984	chr17:80129470	CCDC57	-0.55	-8.25	-0.47	9.88e-15	Life satisfaction;
KIRP	cis	rs1209950	0.536	rs2015748	chr21:40202969	A/G	cg02119577	chr21:40195074	ETS2	0.4	5.43	0.33	1.34e-7	Non-small cell lung cancer (survival);
KIRP	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-8.95	-0.5	9.07e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.56	7.06	0.41	1.66e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs13361707	0.801	rs10038769	chr5:40720128	A/C	cg01087697	chr5:40835557	RPL37	-0.48	-5.43	-0.33	1.37e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.22	-0.61	3.62e-27	Blood trace element (Zn levels);
KIRP	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg01304814	chr3:48885189	PRKAR2A	0.78	5.75	0.34	2.58e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg12315302	chr6:26189340	HIST1H4D	0.96	6.8	0.4	8.09e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08704250	chr15:31115839	NA	-0.58	-8.18	-0.46	1.52e-14	Huntington's disease progression;
KIRP	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg16141378	chr3:129829833	LOC729375	0.49	6.33	0.37	1.16e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11866815	0.901	rs758033	chr16:397044	G/T	cg26913058	chr16:419975	MRPL28	-0.51	-5.73	-0.34	2.98e-8	Body mass index;
KIRP	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg27490568	chr2:178487706	NA	0.46	6.34	0.37	1.09e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	6.75	0.4	1.05e-10	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.73	-10.5	-0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs597583	0.715	rs4938400	chr11:117399604	C/A	cg27161313	chr11:117392002	DSCAML1	-0.73	-7.29	-0.42	4.31e-12	Putamen volume;
KIRP	trans	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	9.14	0.5	2.45e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg03808351	chr9:123631620	PHF19	0.46	6.36	0.38	9.75e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7011507	1.000	rs7011507	chr8:49129242	G/A	cg15325961	chr8:49183143	NA	0.61	5.22	0.32	3.76e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs3748682	0.731	rs3891572	chr1:38298876	C/T	cg12658694	chr1:38397304	INPP5B	0.54	5.94	0.35	9.48e-9	Hypothyroidism;
KIRP	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg00806126	chr19:22604979	ZNF98	0.68	7.09	0.41	1.41e-11	Pain;
KIRP	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg23594656	chr7:65796392	TPST1	0.4	5.99	0.36	7.24e-9	Aortic root size;
KIRP	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.63	7.03	0.41	2.06e-11	Neutrophil percentage of white cells;
KIRP	cis	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg21775007	chr8:11205619	TDH	0.41	5.0	0.3	1.1e-6	Monocyte count;
KIRP	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg18306943	chr3:40428807	ENTPD3	0.4	5.65	0.34	4.34e-8	Renal cell carcinoma;
KIRP	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg22928002	chr5:148929784	CSNK1A1	-0.49	-7.03	-0.41	2.06e-11	Obesity-related traits;
KIRP	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg21905437	chr5:178450457	ZNF879	0.59	6.87	0.4	5.22e-11	Pubertal anthropometrics;
KIRP	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9488822	0.662	rs195532	chr6:116253765	T/G	cg15226275	chr6:116381976	FRK	0.2	5.4	0.33	1.56e-7	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25953536	chr17:26684567	POLDIP2;TMEM199	0.48	6.09	0.36	4.42e-9	Parkinson's disease;
KIRP	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg00012203	chr2:219082015	ARPC2	0.66	8.66	0.48	6.27e-16	Colorectal cancer;
KIRP	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.43	-6.39	-0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.94	11.05	0.58	2.5e-23	Corneal astigmatism;
KIRP	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg21253087	chr9:139290292	SNAPC4	0.47	6.51	0.38	4.21e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg23894439	chr1:183413866	NA	0.42	5.52	0.33	8.5e-8	Systemic lupus erythematosus;
KIRP	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg09788416	chr12:39539408	NA	-0.39	-5.36	-0.32	1.88e-7	Morning vs. evening chronotype;
KIRP	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-4.91	-0.3	1.62e-6	Extrinsic epigenetic age acceleration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08308934	chr14:91976742	SMEK1	0.53	6.64	0.39	2e-10	Parkinson's disease;
KIRP	trans	rs412658	0.776	rs7257051	chr19:22319292	A/G	cg17074339	chr11:11642133	GALNTL4	-0.54	-6.37	-0.38	9.24e-10	Telomere length;
KIRP	cis	rs1635	0.826	rs4711167	chr6:28294888	C/T	cg15743358	chr6:28303923	ZNF323	0.83	6.31	0.37	1.29e-9	Schizophrenia;
KIRP	cis	rs1519814	1.000	rs4588897	chr8:121139142	A/G	cg22335954	chr8:121166405	COL14A1	-0.62	-6.35	-0.38	1.03e-9	Breast cancer;
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.85	11.41	0.59	1.69e-24	Longevity;
KIRP	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.15	-0.41	9.72e-12	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.96	15.0	0.69	1.49e-36	Triglycerides;
KIRP	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.51	0.43	1.08e-12	Retinal vascular caliber;
KIRP	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg07382826	chr16:28625726	SULT1A1	0.42	4.94	0.3	1.43e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg26354017	chr1:205819088	PM20D1	0.48	5.56	0.33	7.12e-8	Menarche (age at onset);
KIRP	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg22549504	chr19:17448937	GTPBP3	0.48	5.07	0.31	7.93e-7	Systemic lupus erythematosus;
KIRP	cis	rs2219968	0.828	rs12543027	chr8:78887060	T/A	cg00738934	chr8:78996279	NA	-0.39	-5.24	-0.32	3.4e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs11924390	0.749	rs822364	chr3:186452716	A/G	cg12454167	chr3:186435060	KNG1	0.5	8.49	0.48	2.03e-15	Adiponectin levels;
KIRP	cis	rs9815354	0.812	rs73828283	chr3:41835099	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	15.41	0.7	5.96e-38	Platelet count;
KIRP	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg22974920	chr21:40686053	BRWD1	-0.44	-5.14	-0.31	5.55e-7	Cognitive function;
KIRP	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg24848339	chr3:12840334	CAND2	0.36	5.39	0.33	1.64e-7	QRS complex (12-leadsum);
KIRP	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.69	-0.34	3.69e-8	Breast cancer;
KIRP	cis	rs732716	0.785	rs9973266	chr19:4392715	G/A	cg19820705	chr19:4455316	UBXN6	0.67	8.25	0.47	9.87e-15	Mean corpuscular volume;
KIRP	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg06640241	chr16:89574553	SPG7	0.79	12.24	0.62	3.2e-27	Multiple myeloma (IgH translocation);
KIRP	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.22	-0.37	2.14e-9	Hemoglobin concentration;
KIRP	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg12369402	chr1:90227771	NA	0.37	5.27	0.32	2.97e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg00079169	chr19:2811669	THOP1	0.53	5.46	0.33	1.16e-7	Total cholesterol levels;
KIRP	cis	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.21	0.37	2.27e-9	Leprosy;
KIRP	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg24650279	chr15:90327240	NA	-0.4	-5.16	-0.31	5.06e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05058121	chr16:23569099	EARS2;UBFD1	0.43	6.05	0.36	5.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg01763666	chr17:80159506	CCDC57	-0.4	-5.21	-0.32	4.04e-7	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25548984	chr4:118007342	TRAM1L1	0.45	7.06	0.41	1.7e-11	Interleukin-4 levels;
KIRP	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.51	6.2	0.37	2.43e-9	Chronic sinus infection;
KIRP	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg15252951	chr6:33757062	LEMD2	0.5	5.77	0.35	2.33e-8	Crohn's disease;
KIRP	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg20503657	chr10:835505	NA	1.24	11.45	0.59	1.3e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.93	12.33	0.62	1.66e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	1.06	14.5	0.68	7.56e-35	Menopause (age at onset);
KIRP	cis	rs4889855	0.614	rs7209676	chr17:78500751	T/C	cg00066239	chr17:78472159	NA	-0.27	-4.85	-0.3	2.18e-6	Fractional excretion of uric acid;
KIRP	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg21427119	chr20:30132790	HM13	-0.54	-6.19	-0.37	2.53e-9	Mean corpuscular volume;
KIRP	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2278729	0.514	rs9223	chr2:101609827	C/T	cg15506514	chr2:101638852	TBC1D8	0.46	5.07	0.31	7.86e-7	Osteoporosis-related phenotypes;
KIRP	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-0.86	-6.27	-0.37	1.57e-9	IgG glycosylation;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08949428	chr13:98451284	NA	0.55	6.42	0.38	7.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.17	20.95	0.8	1.27e-56	Cognitive function;
KIRP	cis	rs4776059	0.798	rs7167494	chr15:52928453	C/G	cg25063058	chr15:52860530	ARPP19	-0.58	-5.54	-0.33	7.86e-8	Schizophrenia;
KIRP	trans	rs7403037	0.550	rs61993572	chr15:24640152	T/A	cg00996262	chr17:7554930	ATP1B2	0.61	6.21	0.37	2.28e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.79	11.93	0.61	3.38e-26	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg23594656	chr7:65796392	TPST1	-0.44	-6.16	-0.37	2.93e-9	Aortic root size;
KIRP	cis	rs1505368	0.505	rs2135156	chr2:213259226	C/T	cg20637307	chr2:213403960	ERBB4	0.5	6.72	0.39	1.23e-10	Symmetrical dimethylarginine levels;
KIRP	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg00204512	chr16:28754710	NA	0.43	5.37	0.32	1.83e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.44	6.02	0.36	6.28e-9	Total body bone mineral density;
KIRP	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	6.44	0.38	6.07e-10	Educational attainment;
KIRP	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg04310649	chr10:35416472	CREM	-0.57	-6.95	-0.41	3.31e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg16482183	chr6:26056742	HIST1H1C	0.65	7.25	0.42	5.45e-12	Height;
KIRP	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.58	8.21	0.46	1.22e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-6.96	-0.41	3.02e-11	Monocyte count;
KIRP	cis	rs838147	0.733	rs12978499	chr19:49237552	A/C	cg08619932	chr19:49200058	FUT2	-0.37	-5.5	-0.33	9.5e-8	Dietary macronutrient intake;
KIRP	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.44	6.1	0.36	4.11e-9	Sitting height ratio;
KIRP	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.04	-0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg17691542	chr6:26056736	HIST1H1C	0.48	6.26	0.37	1.65e-9	Height;
KIRP	cis	rs1208285	0.591	rs2876235	chr6:134203960	C/T	cg06643013	chr6:134217242	NA	-0.44	-5.11	-0.31	6.54e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs4664293	0.867	rs1834761	chr2:160601789	A/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs4430311	0.964	rs2953331	chr1:244024268	A/G	cg25706552	chr1:244017396	NA	-0.53	-8.42	-0.47	3.19e-15	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.39	0.38	8.39e-10	Menarche (age at onset);
KIRP	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-7.56	-0.43	8.08e-13	Tonsillectomy;
KIRP	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.02	-0.46	4.43e-14	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09240793	chr17:79465311	NA	-0.4	-6.15	-0.37	3.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg06521331	chr12:34319734	NA	-0.59	-7.25	-0.42	5.45e-12	Morning vs. evening chronotype;
KIRP	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.14e-10	Axial length;
KIRP	cis	rs11955398	0.585	rs716345	chr5:60012944	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.25	-0.32	3.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-6.29	-0.37	1.47e-9	Fibrinogen levels;
KIRP	cis	rs12643440	0.574	rs1581400	chr4:17139504	A/G	cg22650099	chr4:17144496	NA	-0.7	-8.78	-0.49	2.83e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg03806693	chr22:41940476	POLR3H	-0.46	-5.17	-0.31	4.86e-7	Neuroticism;
KIRP	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg22906224	chr7:99728672	NA	-0.58	-7.27	-0.42	4.8e-12	Coronary artery disease;
KIRP	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.71	0.39	1.32e-10	Menarche (age at onset);
KIRP	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg18944383	chr4:111397179	ENPEP	0.53	9.27	0.51	1.01e-17	Height;
KIRP	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.83e-16	Immature fraction of reticulocytes;
KIRP	cis	rs4765905	0.610	rs2239022	chr12:2310551	G/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.91	-0.4	4.22e-11	Schizophrenia;
KIRP	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	1.0	17.48	0.74	4.9e-45	Parkinson's disease;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-1.06	-22.68	-0.82	3.21e-62	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9400467	0.537	rs17606481	chr6:111542388	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.57	5.32	0.32	2.37e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.78	-10.61	-0.56	6.76e-22	Aortic root size;
KIRP	cis	rs35740288	0.742	rs4843087	chr15:86172855	A/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.96	-0.36	8.77e-9	Breast cancer;
KIRP	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	4.95	0.3	1.35e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.77	-0.44	2.19e-13	Eye color traits;
KIRP	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg03235661	chr20:60525775	NA	-0.37	-5.64	-0.34	4.68e-8	Body mass index;
KIRP	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg08873628	chr1:175162347	KIAA0040	-0.37	-5.5	-0.33	9.62e-8	Alcohol dependence;
KIRP	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-6.45	-0.38	5.93e-10	Blood metabolite levels;
KIRP	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.51	-6.03	-0.36	5.82e-9	Parkinson's disease;
KIRP	cis	rs12580194	0.593	rs12579346	chr12:55786856	A/G	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.71	10.2	0.55	1.35e-20	Oral cavity cancer;
KIRP	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.53	-6.8	-0.4	7.9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg01950434	chr2:97203154	ARID5A	-0.5	-6.59	-0.39	2.7e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.58	7.86	0.45	1.21e-13	Mean corpuscular volume;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg09755102	chr1:33283495	S100PBP;YARS	0.73	6.23	0.37	2.02e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg23815491	chr16:72088622	HP	0.52	7.43	0.43	1.74e-12	Blood protein levels;
KIRP	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.72	8.97	0.5	7.89e-17	Aortic root size;
KIRP	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg23649088	chr2:200775458	C2orf69	0.53	4.89	0.3	1.81e-6	Schizophrenia;
KIRP	cis	rs220324	0.657	rs468357	chr21:43589902	C/G	cg08841829	chr21:43638893	ABCG1	0.46	5.39	0.32	1.67e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg05393297	chr12:53359155	NA	-0.26	-4.89	-0.3	1.86e-6	Cancer (pleiotropy);
KIRP	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.82	9.47	0.52	2.37e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.72	-8.87	-0.49	1.52e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.69	0.34	3.61e-8	Depression;
KIRP	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	10.01	0.54	5.32e-20	Lung cancer in ever smokers;
KIRP	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.74	-0.44	2.56e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs8067545	0.532	rs17759041	chr17:19959966	A/G	cg13482628	chr17:19912719	NA	0.46	5.16	0.31	5.01e-7	Schizophrenia;
KIRP	cis	rs7737355	0.947	rs11750739	chr5:130911743	C/T	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.36	0.65	5.42e-31	Platelet count;
KIRP	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg18132916	chr6:79620363	NA	-0.4	-5.6	-0.34	5.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg09699651	chr6:150184138	LRP11	0.45	5.78	0.35	2.26e-8	Lung cancer;
KIRP	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg01864069	chr14:103024347	NA	0.9	10.03	0.54	4.6e-20	Platelet count;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg12463550	chr7:65579703	CRCP	-0.44	-4.95	-0.3	1.41e-6	Aortic root size;
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg01765077	chr12:122356316	WDR66	0.55	7.44	0.43	1.67e-12	Mean corpuscular volume;
KIRP	cis	rs10121009	0.565	rs10972468	chr9:35431471	T/C	cg15271616	chr9:35490515	RUSC2	0.38	5.2	0.31	4.21e-7	Parkinson's disease;
KIRP	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.2	-0.42	7.34e-12	Alzheimer's disease (late onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05930186	chr1:224024803	TP53BP2	-0.45	-7.12	-0.41	1.21e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs12544026	0.857	rs13251735	chr8:102830075	C/T	cg11282936	chr19:17007648	CPAMD8	-0.46	-6.16	-0.37	2.96e-9	Major depression and alcohol dependence;
KIRP	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs12311304	1.000	rs1479406	chr12:15387543	C/T	cg08258403	chr12:15378311	NA	0.38	5.52	0.33	8.74e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.37	5.12	0.31	6.2e-7	Monocyte count;
KIRP	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg18944383	chr4:111397179	ENPEP	0.54	9.49	0.52	2.08e-18	Height;
KIRP	cis	rs4654899	0.758	rs10218584	chr1:21474480	C/G	cg08890418	chr1:21044141	KIF17	-0.33	-5.01	-0.3	1.02e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg25173405	chr17:45401733	C17orf57	-0.46	-6.1	-0.36	4.01e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	7.08	0.41	1.47e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.76	-10.5	-0.56	1.5e-21	Mean platelet volume;
KIRP	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg25019033	chr10:957182	NA	-0.61	-6.79	-0.4	8.3e-11	Eosinophil percentage of granulocytes;
KIRP	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg21775007	chr8:11205619	TDH	-0.46	-6.28	-0.37	1.51e-9	Neuroticism;
KIRP	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.44	-5.1	-0.31	6.66e-7	Exhaled nitric oxide output;
KIRP	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg21775007	chr8:11205619	TDH	-0.39	-4.96	-0.3	1.32e-6	Morning vs. evening chronotype;
KIRP	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-4.93	-0.3	1.51e-6	Lung cancer;
KIRP	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.07e-11	Blood metabolite levels;
KIRP	cis	rs6032067	0.866	rs2233901	chr20:43851094	A/G	cg10761708	chr20:43804764	PI3	-0.49	-5.17	-0.31	4.77e-7	Blood protein levels;
KIRP	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-1.05	-14.62	-0.68	2.89e-35	Platelet distribution width;
KIRP	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.57	7.62	0.44	5.39e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	1.99e-8	Lung cancer;
KIRP	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg15655495	chr12:38532458	NA	-0.25	-5.09	-0.31	7.09e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs859767	0.501	rs10193171	chr2:135403199	C/T	cg25422880	chr2:135218333	TMEM163	-0.37	-5.59	-0.34	5.99e-8	Neuroticism;
KIRP	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.7	-0.39	1.43e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs258892	0.895	rs34252662	chr5:72054308	G/C	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg05163923	chr11:71159392	DHCR7	0.99	13.65	0.66	5.83e-32	Vitamin D levels;
KIRP	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.66	8.34	0.47	5.36e-15	Coronary artery disease;
KIRP	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.57	7.0	0.41	2.44e-11	Monocyte count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17422427	chr2:241507521	RNPEPL1	0.59	6.96	0.41	3.04e-11	Smoking initiation;
KIRP	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.65	8.78	0.49	2.89e-16	Multiple sclerosis;
KIRP	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.03	-0.31	9.58e-7	Pulmonary function;
KIRP	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	1.07	20.34	0.79	1.28e-54	Heart rate;
KIRP	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.9	16.33	0.72	4.06e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg04438997	chr17:70115868	SOX9	0.36	4.93	0.3	1.49e-6	Thyroid hormone levels;
KIRP	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.07	0.41	1.63e-11	Cannabis dependence symptom count;
KIRP	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.91	-0.4	4.04e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg07653901	chr22:50250238	ZBED4	0.44	5.06	0.31	8.08e-7	Schizophrenia;
KIRP	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.4	5.77	0.35	2.32e-8	Bone mineral density;
KIRP	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg13444842	chr1:152974279	SPRR3	-0.38	-5.49	-0.33	9.83e-8	Inflammatory skin disease;
KIRP	cis	rs6997458	0.785	rs713489	chr8:86342573	G/A	cg02393479	chr8:86352350	CA3	-0.32	-4.95	-0.3	1.36e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	1.16	16.01	0.71	5.03e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.85e-7	Neuroticism;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg11859384	chr17:80120422	CCDC57	-0.47	-5.94	-0.35	9.59e-9	Life satisfaction;
KIRP	cis	rs7221595	0.778	rs2727072	chr17:3918585	C/G	cg09597638	chr17:3907349	NA	0.65	8.6	0.48	9.62e-16	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.66	12.59	0.63	2.27e-28	Bone mineral density;
KIRP	cis	rs375066	0.592	rs349047	chr19:44300884	G/A	cg11993925	chr19:44307056	LYPD5	-0.35	-5.0	-0.3	1.08e-6	Breast cancer;
KIRP	cis	rs4073221	0.520	rs2002965	chr3:18201026	A/G	cg07694806	chr3:18168406	NA	-0.72	-6.35	-0.38	1.05e-9	Parkinson's disease;
KIRP	cis	rs929596	0.531	rs2741022	chr2:234514273	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-5.42	-0.33	1.41e-7	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.9	9.67	0.52	6.08e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg14675211	chr2:100938903	LONRF2	0.49	6.53	0.38	3.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.16	0.58	1.16e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.41	5.09	0.31	7.02e-7	Aortic root size;
KIRP	cis	rs7011507	1.000	rs75702219	chr8:49171749	A/G	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs11710088	0.931	rs4320033	chr3:149199255	A/C	cg08667024	chr3:149219783	TM4SF4	-0.37	-5.37	-0.32	1.8e-7	QRS duration;
KIRP	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg20243544	chr17:37824526	PNMT	0.4	4.98	0.3	1.22e-6	Urinary metabolites;
KIRP	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	5.25	0.32	3.32e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.62	-8.17	-0.46	1.58e-14	Age at first birth;
KIRP	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.24e-6	Menopause (age at onset);
KIRP	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg10523679	chr1:76189770	ACADM	-0.6	-7.78	-0.44	2.02e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg23224356	chr2:98206733	ANKRD36B	0.63	6.21	0.37	2.18e-9	Hip geometry;
KIRP	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05665937	chr4:1216051	CTBP1	0.57	7.91	0.45	8.6e-14	Obesity-related traits;
KIRP	cis	rs6681460	0.674	rs4134135	chr1:67012728	A/G	cg13052034	chr1:66999238	SGIP1	0.43	5.8	0.35	2.02e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg17764715	chr19:33622953	WDR88	-0.69	-8.5	-0.48	1.8e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11442381	chr3:52312806	WDR82	0.51	7.15	0.41	9.74e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.95e-7	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.19	0.37	2.57e-9	Mean corpuscular volume;
KIRP	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.09	-0.46	2.76e-14	Mood instability;
KIRP	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg00507259	chr4:95128692	SMARCAD1	0.41	5.32	0.32	2.38e-7	QT interval;
KIRP	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg11031976	chr2:198649780	BOLL	0.51	5.03	0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.48	-5.82	-0.35	1.79e-8	Monocyte count;
KIRP	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.58	-7.47	-0.43	1.4e-12	Resting heart rate;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14237958	chr9:74674159	C9orf57	0.54	7.53	0.43	9.71e-13	Interleukin-4 levels;
KIRP	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.61	7.61	0.44	5.78e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4262150	0.672	rs72797254	chr5:152012507	T/C	cg12297329	chr5:152029980	NA	-0.67	-8.2	-0.46	1.38e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.87	12.09	0.61	1e-26	Platelet distribution width;
KIRP	cis	rs7929679	0.551	rs11032849	chr11:34785740	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.56	5.69	0.34	3.51e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.77	0.44	2.08e-13	Rheumatoid arthritis;
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg27532560	chr4:187881888	NA	-0.73	-12.39	-0.62	9.92e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	1.1	6.83	0.4	6.66e-11	LDL cholesterol;
KIRP	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg14921437	chr20:32255988	NECAB3;C20orf134	-0.39	-4.86	-0.3	2.07e-6	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13363640	chr11:2985302	SNORA54;NAP1L4	0.48	6.79	0.4	8.54e-11	Survival in pancreatic cancer;
KIRP	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.61	8.83	0.49	2e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs16828019	0.852	rs16827876	chr1:41539536	T/G	cg24596898	chr1:41849189	NA	0.62	5.14	0.31	5.5e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg01620082	chr3:125678407	NA	-1.15	-7.44	-0.43	1.65e-12	Depression;
KIRP	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.64	9.15	0.5	2.17e-17	Colorectal cancer;
KIRP	cis	rs10875746	0.951	rs2286021	chr12:48528220	C/T	cg20731937	chr12:48336164	NA	0.4	5.15	0.31	5.24e-7	Longevity (90 years and older);
KIRP	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.84	-10.21	-0.55	1.23e-20	Homoarginine levels;
KIRP	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.77	11.46	0.59	1.22e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.49	-0.48	2.01e-15	Morning vs. evening chronotype;
KIRP	trans	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg16141378	chr3:129829833	LOC729375	-0.52	-6.59	-0.39	2.58e-10	Mood instability;
KIRP	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg14580859	chr9:123691850	NA	0.37	5.28	0.32	2.84e-7	Rheumatoid arthritis;
KIRP	cis	rs4886920	0.862	rs34549121	chr15:78123986	T/C	cg10461261	chr15:78109450	NA	-0.36	-5.84	-0.35	1.68e-8	Neuroticism;
KIRP	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.6	0.34	5.71e-8	Menarche (age at onset);
KIRP	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.93	0.4	3.67e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg03772063	chr4:175440325	HPGD	0.38	6.09	0.36	4.42e-9	Migraine with aura;
KIRP	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-5.57	-0.33	6.69e-8	Dental caries;
KIRP	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg08126542	chr6:37504118	NA	-0.81	-11.8	-0.6	8.87e-26	Cognitive performance;
KIRP	cis	rs9488822	0.662	rs195532	chr6:116253765	T/G	cg05304507	chr6:116381966	FRK	0.2	5.38	0.32	1.75e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.96	8.08	0.46	2.93e-14	Body mass index;
KIRP	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.03	-18.31	-0.76	7.81e-48	Height;
KIRP	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg05729581	chr11:3078854	CARS	-0.55	-6.99	-0.41	2.53e-11	Longevity;
KIRP	cis	rs7209700	0.547	rs7217214	chr17:45355227	T/C	cg25173405	chr17:45401733	C17orf57	0.53	5.12	0.31	6.29e-7	IgG glycosylation;
KIRP	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg27211696	chr2:191398769	TMEM194B	-0.76	-9.08	-0.5	3.57e-17	Diastolic blood pressure;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg22396663	chr7:2107835	MAD1L1	-0.47	-6.25	-0.37	1.77e-9	Bladder cancer;
KIRP	cis	rs883115	0.810	rs1932991	chr1:224783293	T/C	cg01808320	chr1:224927238	CNIH3	-0.36	-5.14	-0.31	5.56e-7	Cancer;
KIRP	cis	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg26585981	chr11:48327164	OR4S1	-0.42	-5.2	-0.31	4.27e-7	Height;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.83	14.05	0.67	2.58e-33	Menarche (age at onset);
KIRP	cis	rs412050	0.696	rs113366054	chr22:22267184	A/C	cg17089214	chr22:22089827	YPEL1	0.57	5.43	0.33	1.37e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.62	0.39	2.28e-10	Rheumatoid arthritis;
KIRP	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.73	0.49	3.98e-16	Morning vs. evening chronotype;
KIRP	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.69	-9.48	-0.52	2.25e-18	Morning vs. evening chronotype;
KIRP	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.92	15.2	0.7	3.14e-37	Metabolic syndrome;
KIRP	cis	rs7851660	0.809	rs3824495	chr9:100663700	A/C	cg13688889	chr9:100608707	NA	0.67	8.56	0.48	1.24e-15	Strep throat;
KIRP	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.46e-19	Colorectal cancer;
KIRP	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg27068330	chr11:65405492	SIPA1	0.38	5.18	0.31	4.67e-7	Acne (severe);
KIRP	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg02002194	chr4:3960332	NA	-0.46	-6.94	-0.4	3.5e-11	Mood instability;
KIRP	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg27624424	chr6:160112604	SOD2	0.51	5.69	0.34	3.59e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.59	-0.39	2.67e-10	Height;
KIRP	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.19	21.37	0.81	5.31e-58	Cognitive function;
KIRP	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.33e-11	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01834010	chr13:111365570	ING1	0.43	6.35	0.38	1.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4805272	1.000	rs10427034	chr19:29324019	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23197559	chr2:232573080	PTMA	0.5	7.08	0.41	1.5e-11	Survival in pancreatic cancer;
KIRP	cis	rs9393813	0.967	rs764284	chr6:27312078	C/T	cg18711553	chr6:27366782	ZNF391	0.33	4.9	0.3	1.72e-6	Bipolar disorder;
KIRP	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.66	10.97	0.57	4.52e-23	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs675026	0.853	rs618207	chr6:154424670	A/G	cg07813322	chr6:154414604	OPRM1	-0.45	-5.75	-0.34	2.65e-8	Hypertension;
KIRP	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.75	-10.79	-0.57	1.82e-22	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs74181299	0.892	rs2540945	chr2:65289825	A/G	cg05010058	chr2:65284262	CEP68	0.49	7.05	0.41	1.78e-11	Pulse pressure;
KIRP	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.23	-17.36	-0.74	1.34e-44	Breast cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00476814	chr22:19974536	ARVCF	-0.43	-6.16	-0.37	2.92e-9	Metabolic traits;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg21734707	chr17:3908241	ZZEF1	0.63	9.53	0.52	1.64e-18	Type 2 diabetes;
KIRP	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.82	0.4	6.85e-11	Joint mobility (Beighton score);
KIRP	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.49	5.22	0.32	3.87e-7	Alzheimer's disease;
KIRP	cis	rs9309473	0.519	rs6746971	chr2:73669462	A/G	cg20560298	chr2:73613845	ALMS1	-0.4	-4.92	-0.3	1.59e-6	Metabolite levels;
KIRP	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	1.1	13.9	0.66	8.48e-33	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.7	-9.15	-0.5	2.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.1	0.5	3.11e-17	Menopause (age at onset);
KIRP	cis	rs7005380	0.581	rs9987140	chr8:120936874	G/A	cg21645572	chr8:120931649	DEPDC6	-0.49	-6.41	-0.38	7.27e-10	Interstitial lung disease;
KIRP	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26526719	chr5:1949144	NA	-0.45	-5.22	-0.32	3.82e-7	Gut microbiome composition (winter);
KIRP	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg17644776	chr2:200775616	C2orf69	-0.56	-5.32	-0.32	2.38e-7	Schizophrenia;
KIRP	cis	rs806321	0.510	rs1262867	chr13:50891047	A/C	cg10393508	chr13:50950265	NA	-0.45	-6.38	-0.38	8.55e-10	Multiple sclerosis;
KIRP	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg01689657	chr7:91764605	CYP51A1	0.37	5.17	0.31	4.95e-7	Breast cancer;
KIRP	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.85	-13.36	-0.65	5.44e-31	Blood metabolite levels;
KIRP	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg24315340	chr6:146058215	EPM2A	0.41	5.12	0.31	6.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.3	0.42	3.99e-12	Prudent dietary pattern;
KIRP	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-5.46	-0.33	1.18e-7	Testicular germ cell tumor;
KIRP	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg20243544	chr17:37824526	PNMT	0.37	5.03	0.31	9.52e-7	Self-reported allergy;
KIRP	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg18306943	chr3:40428807	ENTPD3	0.47	6.42	0.38	6.91e-10	Renal cell carcinoma;
KIRP	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.5	-0.33	9.66e-8	Autism;
KIRP	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.25	0.37	1.8e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.03	-17.56	-0.75	2.6e-45	Dilated cardiomyopathy;
KIRP	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-1.0	-10.54	-0.56	1.13e-21	Cognitive test performance;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21037018	chr7:35840485	SEPT7	0.46	6.39	0.38	8.34e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg09904177	chr6:26538194	HMGN4	-0.53	-7.2	-0.42	7.45e-12	Schizophrenia;
KIRP	cis	rs921916	0.746	rs2366293	chr7:50227828	G/C	cg02697348	chr7:50199187	C7orf72	-0.55	-5.14	-0.31	5.69e-7	Systemic lupus erythematosus;
KIRP	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg19077165	chr18:44547161	KATNAL2	0.47	5.9	0.35	1.21e-8	Personality dimensions;
KIRP	cis	rs290268	1.000	rs290271	chr9:93551619	G/A	cg02608019	chr9:93564028	SYK	0.8	11.03	0.58	2.92e-23	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04570518	chr19:925787	ARID3A	0.59	7.5	0.43	1.18e-12	Parkinson's disease;
KIRP	cis	rs2494663	0.610	rs6427457	chr1:154079291	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.95	-0.3	1.41e-6	Mean platelet volume;
KIRP	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg03315344	chr16:75512273	CHST6	0.55	5.51	0.33	9.13e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg03959625	chr15:84868606	LOC388152	0.71	8.47	0.48	2.22e-15	Schizophrenia;
KIRP	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg19025524	chr12:109796872	NA	0.4	5.29	0.32	2.66e-7	Neuroticism;
KIRP	cis	rs6539288	0.641	rs12318060	chr12:107340612	T/C	cg21360079	chr12:107162445	NA	-0.45	-5.64	-0.34	4.71e-8	Total body bone mineral density;
KIRP	cis	rs42648	0.693	rs2106274	chr7:89880548	C/T	cg25739043	chr7:89950458	NA	-0.41	-6.47	-0.38	5.14e-10	Homocysteine levels;
KIRP	cis	rs662064	0.963	rs10864460	chr1:10563671	C/G	cg07384165	chr1:10488281	NA	-0.45	-5.46	-0.33	1.15e-7	Asthma;
KIRP	trans	rs10519937	0.935	rs17839693	chr5:126735871	T/C	cg21063282	chr14:95235402	GSC	0.45	6.08	0.36	4.66e-9	IgG glycosylation;
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg19294448	chr17:6900799	ALOX12	-0.37	-4.86	-0.3	2.06e-6	Tonsillectomy;
KIRP	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.77	11.94	0.61	3.23e-26	Multiple myeloma;
KIRP	cis	rs2219968	0.756	rs10283381	chr8:78922806	G/A	cg00738934	chr8:78996279	NA	-0.39	-5.23	-0.32	3.62e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs12900413	0.687	rs28650972	chr15:90311941	C/T	cg24650279	chr15:90327240	NA	-0.42	-5.29	-0.32	2.65e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.46	0.47	2.47e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg16497661	chr14:103986332	CKB	-0.51	-6.75	-0.4	1.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.59	6.3	0.37	1.37e-9	Gut microbiome composition (summer);
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.47	-0.33	1.1e-7	Bipolar disorder;
KIRP	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg23587288	chr2:27483067	SLC30A3	-0.66	-7.48	-0.43	1.32e-12	Blood metabolite levels;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24993194	chr6:25963187	TRIM38	0.61	6.1	0.36	4.01e-9	Lung function (FEV1);
KIRP	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.22	-20.64	-0.8	1.37e-55	Breast cancer;
KIRP	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.64	7.47	0.43	1.43e-12	Schizophrenia;
KIRP	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-8.46	-0.47	2.47e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.44	-6.64	-0.39	1.98e-10	Bipolar disorder;
KIRP	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10248619	0.505	rs977791	chr7:50759158	G/T	cg11521274	chr1:198131619	NEK7	0.42	6.09	0.36	4.27e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	1.14	14.6	0.68	3.32e-35	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1106684	1.000	rs10954327	chr7:131458006	A/G	cg13607082	chr12:122652224	LRRC43	-0.61	-6.7	-0.39	1.43e-10	Body mass index;
KIRP	cis	rs6723108	0.713	rs6728095	chr2:135376072	T/A	cg12500956	chr2:135428796	TMEM163	-0.41	-5.67	-0.34	4e-8	Type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg21252483	chr19:49399788	TULP2	-0.49	-6.39	-0.38	8.12e-10	Red cell distribution width;
KIRP	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.6	8.11	0.46	2.41e-14	Mood instability;
KIRP	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg04132472	chr17:19861366	AKAP10	0.47	6.74	0.39	1.11e-10	Schizophrenia;
KIRP	cis	rs6433857	0.536	rs1901750	chr2:181350739	C/T	cg23363182	chr2:181467187	NA	-0.37	-5.25	-0.32	3.32e-7	Body mass index;
KIRP	cis	rs888194	0.589	rs874170	chr12:110004960	C/T	cg05360138	chr12:110035743	NA	0.4	4.87	0.3	1.96e-6	Neuroticism;
KIRP	cis	rs9488822	0.585	rs550480	chr6:116264354	C/A	cg05304507	chr6:116381966	FRK	-0.21	-5.27	-0.32	2.99e-7	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24866706	chr3:96338474	NA	-0.43	-6.13	-0.36	3.56e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	1.02	15.96	0.71	7.68e-40	Vitamin D levels;
KIRP	cis	rs909341	0.909	rs1291207	chr20:62329412	G/A	cg11503966	chr20:62272292	STMN3	-0.41	-5.88	-0.35	1.35e-8	Atopic dermatitis;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.1	-0.36	4.01e-9	Lung cancer;
KIRP	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg22117172	chr7:91764530	CYP51A1	-0.41	-5.59	-0.34	5.91e-8	Breast cancer;
KIRP	cis	rs1978968	0.913	rs34272636	chr22:18433603	A/C	cg02610425	chr22:18483192	MICAL3	0.39	4.97	0.3	1.26e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs9790314	0.613	rs1447620	chr3:160616211	T/C	cg04691961	chr3:161091175	C3orf57	0.42	6.18	0.37	2.65e-9	Morning vs. evening chronotype;
KIRP	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.55	-6.05	-0.36	5.39e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg08125733	chr17:73851984	WBP2	-0.47	-5.91	-0.35	1.13e-8	White matter hyperintensity burden;
KIRP	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.54	7.5	0.43	1.14e-12	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.12	-0.31	6.21e-7	Leprosy;
KIRP	cis	rs77669868	0.929	rs3782004	chr11:114070250	T/C	cg01914181	chr11:114070210	ZBTB16	0.56	6.16	0.37	2.87e-9	Monocyte percentage of white cells;
KIRP	cis	rs8038465	0.638	rs62004615	chr15:73957799	C/A	cg15420318	chr15:73925796	NPTN	0.63	9.21	0.51	1.45e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	1.15	9.16	0.5	2.05e-17	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00938859	chr5:1591904	SDHAP3	0.59	8.0	0.45	5.05e-14	Breast cancer;
KIRP	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg24972876	chr7:65420302	NA	0.36	4.93	0.3	1.52e-6	Calcium levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17960347	chr12:2457373	CACNA1C	-0.48	-7.4	-0.43	2.11e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.84	-12.58	-0.63	2.42e-28	Caffeine consumption;
KIRP	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23161317	chr6:28129485	ZNF389	0.46	5.4	0.33	1.59e-7	Depression;
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.43	8.97	0.5	7.66e-17	Vitiligo;
KIRP	cis	rs6681460	0.674	rs2121051	chr1:67017177	G/A	cg13052034	chr1:66999238	SGIP1	0.45	6.21	0.37	2.26e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13672975	chr18:11908811	MPPE1	0.48	6.16	0.37	3.02e-9	Parkinson's disease;
KIRP	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.85	12.21	0.61	4.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs10861342	1.000	rs34705618	chr12:105518611	C/G	cg23923672	chr12:105501055	KIAA1033	0.85	6.54	0.39	3.44e-10	IgG glycosylation;
KIRP	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg19875535	chr5:140030758	IK	0.64	8.88	0.49	1.42e-16	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22183057	chr5:162883763	NUDCD2	-0.43	-6.43	-0.38	6.69e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg02297831	chr4:17616191	MED28	0.61	7.81	0.45	1.7e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-6.01	-0.36	6.6e-9	Neuroticism;
KIRP	cis	rs7523273	0.565	rs2025374	chr1:207887536	A/G	cg22525895	chr1:207977042	MIR29B2	-0.45	-5.79	-0.35	2.14e-8	Schizophrenia;
KIRP	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg04865290	chr3:52927548	TMEM110	-0.43	-5.31	-0.32	2.4e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10871290	0.507	rs3851731	chr16:74485788	C/T	cg01733217	chr16:74700730	RFWD3	0.57	7.05	0.41	1.81e-11	Breast cancer;
KIRP	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.87	-11.95	-0.61	3.04e-26	Personality dimensions;
KIRP	cis	rs7943358	0.758	rs747783	chr11:15713556	G/A	cg11966998	chr11:15692519	NA	-0.27	-4.94	-0.3	1.43e-6	Gut microbiome composition (summer);
KIRP	cis	rs1359582	0.793	rs860949	chr10:90414939	A/G	cg15661332	chr10:90342814	RNLS	0.56	5.67	0.34	3.96e-8	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs1555895	0.576	rs4881536	chr10:848058	A/G	cg10017260	chr10:834428	NA	-0.39	-5.45	-0.33	1.2e-7	Survival in rectal cancer;
KIRP	cis	rs6882046	0.513	rs34316	chr5:88015545	A/C	cg22951263	chr5:87985283	NA	-0.44	-6.06	-0.36	5.05e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.97	16.57	0.73	6.18e-42	Breast cancer;
KIRP	cis	rs4974559	0.744	rs10024529	chr4:1363886	G/A	cg02980000	chr4:1222292	CTBP1	0.96	8.63	0.48	7.92e-16	Systolic blood pressure;
KIRP	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-1.0	-12.92	-0.64	1.65e-29	Platelet distribution width;
KIRP	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg05802129	chr4:122689817	NA	-0.48	-6.94	-0.4	3.55e-11	Type 2 diabetes;
KIRP	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.7	-13.15	-0.64	2.79e-30	White blood cell count (basophil);
KIRP	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.75	10.88	0.57	9.17e-23	Body mass index;
KIRP	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg19847130	chr8:10466454	RP1L1	-0.36	-5.41	-0.33	1.5e-7	Retinal vascular caliber;
KIRP	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.59	-8.14	-0.46	1.93e-14	Breast cancer;
KIRP	cis	rs4666002	0.957	rs1919128	chr2:27801759	A/G	cg05484376	chr2:27715224	FNDC4	-0.38	-5.27	-0.32	2.96e-7	Phospholipid levels (plasma);
KIRP	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.55	-5.15	-0.31	5.42e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs6832769	0.961	rs1011095	chr4:56264941	C/G	cg05960024	chr4:56376020	CLOCK	0.61	7.95	0.45	6.64e-14	Personality dimensions;
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg16060761	chr17:80687452	NA	-0.54	-6.79	-0.4	8.16e-11	Glycated hemoglobin levels;
KIRP	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.94	15.52	0.7	2.43e-38	Menopause (age at onset);
KIRP	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27423433	chr19:808699	PTBP1	-0.49	-6.29	-0.37	1.45e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg08501292	chr6:25962987	TRIM38	0.77	5.36	0.32	1.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs7408868	0.656	rs1043997	chr19:15292437	T/C	cg14696996	chr19:15285081	NOTCH3	0.61	6.59	0.39	2.63e-10	Pulse pressure;
KIRP	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.4	5.33	0.32	2.25e-7	Homoarginine levels;
KIRP	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs11166927	0.548	rs2100803	chr8:140839371	A/C	cg16909799	chr8:140841666	TRAPPC9	-0.94	-15.46	-0.7	4.01e-38	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg27451672	chr7:99156362	ZNF655	0.52	6.12	0.36	3.7e-9	Plasma plasminogen activator levels;
KIRP	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg12463550	chr7:65579703	CRCP	-0.6	-7.22	-0.42	6.54e-12	Aortic root size;
KIRP	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.25	11.78	0.6	1.09e-25	Diabetic retinopathy;
KIRP	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.54	-6.8	-0.4	7.75e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	0.81	6.27	0.37	1.63e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg13611997	chr5:233750	SDHA	-0.42	-5.01	-0.3	1.06e-6	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.64	9.7	0.53	4.82e-19	Lung cancer;
KIRP	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.59	-9.37	-0.51	4.78e-18	Pulse pressure;
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg21285383	chr16:89894308	SPIRE2	0.32	6.1	0.36	4.07e-9	Vitiligo;
KIRP	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg03209412	chr4:183728196	NA	0.45	6.04	0.36	5.8e-9	Pediatric autoimmune diseases;
KIRP	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.92	14.91	0.69	2.93e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.55	-7.46	-0.43	1.51e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10021731	0.597	rs11098263	chr4:115607637	A/G	cg22609233	chr4:115518992	UGT8	0.37	4.91	0.3	1.65e-6	Optic disc area;
KIRP	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.43	-6.83	-0.4	6.59e-11	Refractive error;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.73	0.53	3.76e-19	Lung cancer;
KIRP	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg01657329	chr11:68192670	LRP5	-0.51	-5.56	-0.33	6.93e-8	Total body bone mineral density;
KIRP	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.3	-11.51	-0.59	8.5e-25	Diabetic retinopathy;
KIRP	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg07395648	chr5:131743802	NA	-0.49	-6.77	-0.4	9.48e-11	Blood metabolite levels;
KIRP	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-8.18	-0.46	1.57e-14	Total body bone mineral density;
KIRP	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg13160058	chr8:26243215	BNIP3L	-0.51	-6.82	-0.4	7.09e-11	Red cell distribution width;
KIRP	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg19847866	chr10:1019161	NA	-0.45	-5.21	-0.32	4.06e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg04310649	chr10:35416472	CREM	-0.59	-6.95	-0.4	3.35e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9815354	0.812	rs73077365	chr3:41851559	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.37	0.47	4.35e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.48	6.26	0.37	1.69e-9	Liver enzyme levels;
KIRP	cis	rs7527798	0.592	rs11118337	chr1:207852693	G/C	cg09232269	chr1:207846808	CR1L	-0.37	-5.46	-0.33	1.17e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6450176	1.000	rs67473746	chr5:53296730	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.33	-0.59	3.2e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.2	-0.46	1.36e-14	Personality dimensions;
KIRP	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.84	-0.35	1.63e-8	Schizophrenia;
KIRP	trans	rs972578	0.715	rs2273142	chr22:43230140	C/G	cg15321293	chr3:36422198	STAC	-0.47	-6.07	-0.36	4.81e-9	Mean platelet volume;
KIRP	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.67	10.55	0.56	1.06e-21	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.15	0.31	5.23e-7	Schizophrenia;
KIRP	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.63	8.55	0.48	1.31e-15	Morning vs. evening chronotype;
KIRP	cis	rs41264869	0.628	rs3795556	chr1:205112911	T/C	cg21214746	chr1:205091277	RBBP5	0.51	6.66	0.39	1.77e-10	Blood protein levels;
KIRP	cis	rs12580194	0.593	rs67934812	chr12:55785591	T/G	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg21573476	chr21:45109991	RRP1B	-0.77	-10.89	-0.57	8.67e-23	Mean corpuscular volume;
KIRP	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18364779	chr6:26104403	HIST1H4C	0.38	5.18	0.31	4.58e-7	Schizophrenia;
KIRP	cis	rs16958440	1.000	rs60854219	chr18:44646664	G/A	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-9.29	-0.51	8.62e-18	Total body bone mineral density;
KIRP	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg04731861	chr2:219085781	ARPC2	-0.21	-5.13	-0.31	5.83e-7	Colorectal cancer;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg14121103	chr3:43731973	ABHD5	0.51	6.04	0.36	5.69e-9	Sleep duration;
KIRP	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.48	6.03	0.36	5.88e-9	Motion sickness;
KIRP	cis	rs2594989	1.000	rs2606752	chr3:11360170	A/G	cg01796438	chr3:11312864	ATG7	-0.69	-7.83	-0.45	1.47e-13	Circulating chemerin levels;
KIRP	cis	rs10861342	1.000	rs11112380	chr12:105526695	C/T	cg23923672	chr12:105501055	KIAA1033	0.83	6.26	0.37	1.69e-9	IgG glycosylation;
KIRP	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.41	-0.33	1.51e-7	Depression;
KIRP	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7429990	0.932	rs936428	chr3:48167281	A/G	cg11946769	chr3:48343235	NME6	-0.44	-5.35	-0.32	2.01e-7	Educational attainment (years of education);
KIRP	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.6	-7.19	-0.42	7.77e-12	Initial pursuit acceleration;
KIRP	trans	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19894588	chr14:64061835	NA	0.49	6.72	0.39	1.27e-10	Glioblastoma;Glioma;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19524810	chr5:1112228	SLC12A7	-0.46	-6.15	-0.37	3.2e-9	Myopia;
KIRP	cis	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg06647332	chr5:131281008	NA	0.48	5.2	0.31	4.2e-7	Life satisfaction;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg02668984	chr17:48172022	PDK2	0.79	6.92	0.4	3.8e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg10756647	chr7:56101905	PSPH	1.06	8.29	0.47	7.36e-15	Diabetic kidney disease;
KIRP	cis	rs72634258	0.554	rs4908699	chr1:7905274	G/A	cg26816564	chr1:7831052	VAMP3	0.83	8.03	0.46	4.15e-14	Inflammatory bowel disease;
KIRP	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg01320579	chr17:75405842	SEPT9	0.48	7.83	0.45	1.48e-13	Airflow obstruction;
KIRP	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-6.92	-0.4	3.98e-11	Tonsillectomy;
KIRP	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.21	-0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	trans	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.54	6.1	0.36	4.04e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.75	9.2	0.51	1.54e-17	Monocyte percentage of white cells;
KIRP	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.75	0.34	2.59e-8	Menopause (age at onset);
KIRP	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.73	-9.74	-0.53	3.71e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	5.84	0.35	1.67e-8	Longevity;
KIRP	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.87	12.83	0.63	3.5e-29	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg05991184	chr2:219186017	PNKD	0.35	5.03	0.31	9.51e-7	Colorectal cancer;
KIRP	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg04287289	chr16:89883240	FANCA	0.58	7.45	0.43	1.61e-12	Vitiligo;
KIRP	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg04865290	chr3:52927548	TMEM110	-0.61	-6.77	-0.4	9.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.55	-6.57	-0.39	3.01e-10	Iron status biomarkers;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.16	0.42	9.31e-12	Lymphocyte counts;
KIRP	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg17554472	chr22:41940697	POLR3H	0.67	6.96	0.41	3.16e-11	Vitiligo;
KIRP	cis	rs13221576	0.569	rs71562852	chr7:94014251	C/T	cg20814616	chr7:94014465	NA	-0.52	-4.85	-0.3	2.21e-6	Intelligence;
KIRP	cis	rs2274273	0.624	rs7151754	chr14:55788501	C/T	cg04306507	chr14:55594613	LGALS3	0.38	5.23	0.32	3.58e-7	Protein biomarker;
KIRP	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.87	-13.51	-0.65	1.69e-31	Height;
KIRP	cis	rs10073892	0.549	rs13179639	chr5:101976958	A/G	cg19774478	chr5:101632501	SLCO4C1	0.52	5.39	0.32	1.65e-7	Cognitive decline (age-related);
KIRP	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25809561	chr17:30822961	MYO1D	0.59	8.18	0.46	1.53e-14	Schizophrenia;
KIRP	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg17764715	chr19:33622953	WDR88	0.68	8.45	0.47	2.5e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.54	7.47	0.43	1.41e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17902989	chr19:3985501	EEF2	0.53	6.68	0.39	1.58e-10	Parkinson's disease;
KIRP	cis	rs981844	0.712	rs1037649	chr4:154737796	G/A	cg14289246	chr4:154710475	SFRP2	-0.54	-7.06	-0.41	1.74e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.04	-0.46	3.74e-14	Morning vs. evening chronotype;
KIRP	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg23649088	chr2:200775458	C2orf69	0.39	5.08	0.31	7.51e-7	QT interval;
KIRP	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.12e-8	Skin colour saturation;
KIRP	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg06740227	chr12:86229804	RASSF9	0.51	6.7	0.39	1.44e-10	Major depressive disorder;
KIRP	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg02975922	chr3:195473998	MUC4	-0.55	-6.06	-0.36	5.1e-9	Pancreatic cancer;
KIRP	cis	rs6733011	0.581	rs4851162	chr2:99466659	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.37	-0.32	1.81e-7	Bipolar disorder;
KIRP	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.7	-9.67	-0.52	5.87e-19	Schizophrenia;
KIRP	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg07395648	chr5:131743802	NA	-0.58	-8.36	-0.47	4.56e-15	Blood metabolite levels;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg05073845	chr13:41240516	FOXO1	0.54	6.3	0.37	1.35e-9	Plasma plasminogen activator levels;
KIRP	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	9.72	0.53	4.16e-19	Coffee consumption (cups per day);
KIRP	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.61	-6.48	-0.38	4.96e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.82	-11.42	-0.59	1.58e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg07309820	chr7:148901717	ZNF282	-0.39	-4.91	-0.3	1.68e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.37	-5.09	-0.31	7.23e-7	Vitiligo;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03443922	chr7:107384711	CBLL1	0.52	6.07	0.36	4.91e-9	Smoking initiation;
KIRP	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.26	-0.32	3.09e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.82	-8.7	-0.49	4.87e-16	Bipolar disorder;
KIRP	cis	rs6733011	0.559	rs6711022	chr2:99449536	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.29	-0.32	2.76e-7	Bipolar disorder;
KIRP	cis	rs10982256	0.774	rs10759712	chr9:117253434	G/A	cg13636371	chr9:117264095	DFNB31	-0.49	-7.12	-0.41	1.18e-11	Bipolar disorder;
KIRP	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg21827317	chr3:136751795	NA	0.37	5.21	0.32	4.05e-7	Neuroticism;
KIRP	cis	rs1981331	0.609	rs76937225	chr21:48069682	C/T	cg23283320	chr21:48055893	PRMT2	1.45	9.12	0.5	2.82e-17	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.43	0.33	1.35e-7	Height;
KIRP	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-10.0	-0.54	5.43e-20	Eye color traits;
KIRP	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg19912559	chr1:40204330	PPIE	0.41	5.11	0.31	6.45e-7	Blood protein levels;
KIRP	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg21253087	chr9:139290292	SNAPC4	-0.38	-5.17	-0.31	4.86e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.73	9.51	0.52	1.86e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.75	-0.34	2.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6684428	0.572	rs4926699	chr1:56341880	C/A	cg11651538	chr1:56320950	NA	-0.54	-7.54	-0.43	8.98e-13	Airflow obstruction;
KIRP	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-0.96	-13.61	-0.66	8.03e-32	Blood trace element (Zn levels);
KIRP	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.51	5.54	0.33	7.63e-8	Lung cancer;
KIRP	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.88	8.11	0.46	2.41e-14	Alzheimer's disease;
KIRP	cis	rs7944584	0.588	rs11988	chr11:47261260	G/A	cg20307385	chr11:47447363	PSMC3	0.58	6.98	0.41	2.72e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.5	-6.33	-0.37	1.15e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13440296	chr4:106067738	TET2	0.53	6.61	0.39	2.42e-10	Parkinson's disease;
KIRP	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.94	-10.45	-0.55	2.09e-21	Blood protein levels;
KIRP	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.6	-7.9	-0.45	9.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12976411	0.575	rs16966906	chr19:32823374	A/G	cg02282382	chr19:32836354	ZNF507	0.62	5.17	0.31	4.93e-7	Coronary artery disease;
KIRP	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.68	8.65	0.48	6.73e-16	Blood metabolite levels;
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg09177884	chr7:1199841	ZFAND2A	-0.55	-5.12	-0.31	6.07e-7	Bronchopulmonary dysplasia;
KIRP	trans	rs1864585	0.520	rs73208791	chr8:10680338	T/C	cg26278703	chr11:58910052	FAM111A	0.64	6.41	0.38	7.25e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.45	-5.83	-0.35	1.72e-8	Aortic root size;
KIRP	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.61	0.34	5.46e-8	Lung cancer;
KIRP	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg12962167	chr3:53033115	SFMBT1	0.64	4.94	0.3	1.42e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.19	-16.18	-0.72	1.4e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.25	6.79	0.4	8.5e-11	Crohn's disease;
KIRP	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.55	-5.54	-0.33	7.84e-8	Subjective well-being;
KIRP	cis	rs55882075	0.537	rs62406698	chr5:179110429	C/T	cg14593053	chr5:179126677	CANX	0.6	7.41	0.43	2.01e-12	Monocyte percentage of white cells;
KIRP	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.63	-9.57	-0.52	1.23e-18	Obesity-related traits;
KIRP	cis	rs35883536	1.000	rs1610387	chr1:101123943	T/G	cg06223162	chr1:101003688	GPR88	0.34	6.97	0.41	2.96e-11	Monocyte count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25201980	chr8:146127417	ZNF250	0.55	6.45	0.38	5.97e-10	Smoking initiation;
KIRP	cis	rs6137287	0.643	rs6047261	chr20:21103910	T/G	cg04219410	chr20:21106687	PLK1S1	0.42	5.07	0.31	7.9e-7	Height;
KIRP	cis	rs1978968	0.869	rs5992931	chr22:18455914	G/A	cg03078520	chr22:18463400	MICAL3	-0.69	-7.9	-0.45	9.52e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.51	-0.33	9.24e-8	Pulmonary function;
KIRP	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.66	-7.05	-0.41	1.79e-11	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.03	-0.31	9.64e-7	Personality dimensions;
KIRP	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.68	-0.66	4.52e-32	Response to antipsychotic treatment;
KIRP	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.17	0.31	4.75e-7	Cognitive test performance;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.43	6.05	0.36	5.37e-9	Coronary artery disease;
KIRP	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.07	-0.36	4.72e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6577655	0.517	rs6999469	chr8:135577530	G/A	cg17885191	chr8:135476712	NA	0.71	6.73	0.39	1.22e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.73	-10.77	-0.57	2.04e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6545883	0.525	rs2049747	chr2:61364154	G/A	cg15711740	chr2:61764176	XPO1	0.58	7.48	0.43	1.29e-12	Tuberculosis;
KIRP	cis	rs6788895	1.000	rs2014279	chr3:150487945	G/T	cg09723797	chr3:150481914	SIAH2	0.78	5.84	0.35	1.66e-8	Breast cancer;
KIRP	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.68	-7.89	-0.45	1.01e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.45	-0.33	1.25e-7	Life satisfaction;
KIRP	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.07	0.36	4.69e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6910061	1.000	rs9468412	chr6:11095876	C/T	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg07884673	chr3:53033167	SFMBT1	0.8	6.41	0.38	7.38e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19346786	chr7:2764209	NA	-0.38	-6.49	-0.38	4.79e-10	Height;
KIRP	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.74	11.04	0.58	2.81e-23	Blood metabolite ratios;
KIRP	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.41	-5.58	-0.34	6.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg04733989	chr22:42467013	NAGA	0.57	7.72	0.44	2.89e-13	Cognitive function;
KIRP	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg18944383	chr4:111397179	ENPEP	-0.53	-9.27	-0.51	9.73e-18	Coronary artery disease;
KIRP	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.45	0.33	1.21e-7	Educational attainment;
KIRP	cis	rs17321999	1.000	rs72787721	chr2:30489411	C/T	cg05247661	chr2:30472410	LBH	0.79	7.99	0.45	5.31e-14	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.68	-0.39	1.56e-10	Lung cancer;
KIRP	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-7.26	-0.42	5.19e-12	Monocyte percentage of white cells;
KIRP	cis	rs15676	0.783	rs3829057	chr9:131567982	A/G	cg00228799	chr9:131580591	ENDOG	0.48	4.93	0.3	1.5e-6	Blood metabolite levels;
KIRP	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.1	8.16	0.46	1.71e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.63	-7.01	-0.41	2.25e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3857747	0.537	rs17171704	chr7:40421488	T/G	cg00420559	chr7:40367873	C7orf10	-0.41	-5.79	-0.35	2.18e-8	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2281603	0.520	rs61985663	chr14:64937704	C/T	cg01860774	chr14:64969374	ZBTB25	0.33	5.26	0.32	3.13e-7	Lymphocyte counts;
KIRP	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg27124370	chr19:33622961	WDR88	0.58	7.15	0.41	9.82e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg02336718	chr17:17403227	NA	0.39	5.9	0.35	1.22e-8	Total body bone mineral density;
KIRP	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.63	7.49	0.43	1.23e-12	Type 2 diabetes;
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.67	-11.03	-0.58	3.11e-23	Mean corpuscular volume;
KIRP	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.6	6.96	0.41	3.11e-11	Height;
KIRP	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	6.49	0.38	4.82e-10	Response to antipsychotic treatment;
KIRP	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7551222	0.752	rs4245736	chr1:204486205	G/C	cg20240347	chr1:204465584	NA	-0.46	-8.75	-0.49	3.42e-16	Schizophrenia;
KIRP	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.41	-0.38	7.28e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.54	7.4	0.43	2.11e-12	Colorectal cancer;
KIRP	cis	rs6901250	0.632	rs688961	chr6:117089080	A/T	cg12892004	chr6:117198278	RFX6	0.36	5.93	0.35	1.01e-8	C-reactive protein levels;
KIRP	cis	rs7110373	1	rs7110373	chr11:122813224	C/T	cg27398637	chr11:122830231	C11orf63	-0.61	-8.18	-0.46	1.55e-14	Age at voice drop;
KIRP	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg10223061	chr2:219282414	VIL1	-0.32	-5.17	-0.31	4.79e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11671005	0.735	rs11671591	chr19:58918337	A/G	cg13877915	chr19:58951672	ZNF132	-0.56	-5.47	-0.33	1.12e-7	Mean platelet volume;
KIRP	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-8.05	-0.46	3.65e-14	Response to antipsychotic treatment;
KIRP	cis	rs13272623	0.713	rs7813558	chr8:71997727	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	0.46	4.98	0.3	1.2e-6	IgG glycosylation;
KIRP	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.89	-0.49	1.33e-16	Triglycerides;
KIRP	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg23752985	chr2:85803571	VAMP8	-0.45	-5.28	-0.32	2.87e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs494562	0.892	rs575477	chr6:86118064	A/G	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs4979906	1.000	rs4325263	chr10:79444236	A/G	cg07817648	chr10:79422355	NA	-0.45	-4.93	-0.3	1.48e-6	Mortality in heart failure;
KIRP	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg14835575	chr10:16859367	RSU1	0.53	6.91	0.4	4.24e-11	Platelet distribution width;
KIRP	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.87	11.47	0.59	1.09e-24	Type 2 diabetes;
KIRP	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.63	4.87	0.3	2e-6	Schizophrenia;
KIRP	trans	rs12517041	1.000	rs2081954	chr5:23295705	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg27624424	chr6:160112604	SOD2	-0.51	-5.09	-0.31	7.14e-7	Iron status biomarkers;
KIRP	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg14952266	chr13:112191215	NA	0.46	6.67	0.39	1.68e-10	Hepatitis;
KIRP	cis	rs1620921	0.505	rs1344730	chr6:161204995	G/A	cg01280913	chr6:161186852	NA	-0.69	-9.38	-0.51	4.41e-18	Lipoprotein (a) - cholesterol levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05902531	chr12:58239324	CTDSP2	0.51	6.23	0.37	2.02e-9	Myopia (pathological);
KIRP	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.19	15.12	0.69	5.79e-37	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.46	-0.33	1.15e-7	Menarche (age at onset);
KIRP	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg08975724	chr8:8085496	FLJ10661	0.68	9.25	0.51	1.13e-17	Mood instability;
KIRP	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.43	-0.47	3e-15	Retinal vascular caliber;
KIRP	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.4	-4.96	-0.3	1.31e-6	Blood protein levels;
KIRP	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.59	-8.1	-0.46	2.5e-14	Schizophrenia;
KIRP	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg21573476	chr21:45109991	RRP1B	-0.6	-8.15	-0.46	1.84e-14	Mean corpuscular volume;
KIRP	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.69	-5.38	-0.32	1.78e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.37	-0.38	9.04e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9311676	0.632	rs6774357	chr3:58361530	A/C	cg06643156	chr3:58380774	PXK	0.36	5.14	0.31	5.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs4363385	0.667	rs2066004	chr1:152922896	A/G	cg07796016	chr1:152779584	LCE1C	-0.41	-4.89	-0.3	1.8e-6	Inflammatory skin disease;
KIRP	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.91	-0.64	1.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs60871478	0.680	rs34880331	chr7:786833	A/G	cg04727924	chr7:799746	HEATR2	-0.68	-6.65	-0.39	1.83e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.63	-8.18	-0.46	1.54e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25768103	chr19:19174831	SLC25A42	-0.47	-6.05	-0.36	5.42e-9	Myopia;
KIRP	trans	rs6601327	0.641	rs10096462	chr8:9614993	C/A	cg08975724	chr8:8085496	FLJ10661	0.53	6.72	0.39	1.25e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.97	10.44	0.55	2.25e-21	IgG glycosylation;
KIRP	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg06289844	chr6:126071538	HEY2	0.35	4.91	0.3	1.62e-6	Brugada syndrome;
KIRP	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.31	7.38	0.43	2.47e-12	IgG glycosylation;
KIRP	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg21605333	chr4:119757512	SEC24D	1.56	11.04	0.58	2.74e-23	Cannabis dependence symptom count;
KIRP	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.91	-11.7	-0.6	1.96e-25	Breast cancer;
KIRP	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.88	-9.85	-0.53	1.68e-19	Lymphocyte counts;Red cell distribution width;
KIRP	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	8.55	0.48	1.32e-15	Retinal vascular caliber;
KIRP	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.59	-6.57	-0.39	3.06e-10	Platelet count;
KIRP	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.08	0.31	7.6e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.75	-6.83	-0.4	6.44e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.55	-6.08	-0.36	4.56e-9	Menopause (age at onset);
KIRP	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg24972876	chr7:65420302	NA	-0.46	-6.53	-0.38	3.78e-10	Calcium levels;
KIRP	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.57	7.45	0.43	1.57e-12	Hip circumference;
KIRP	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.5	-9.32	-0.51	6.7e-18	Cystic fibrosis severity;
KIRP	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.41	0.51	3.69e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27205938	chr3:184053933	FAM131A	0.55	6.71	0.39	1.35e-10	Parkinson's disease;
KIRP	cis	rs11877825	0.826	rs8098954	chr18:10578697	A/G	cg07277756	chr18:10589357	NA	0.51	6.1	0.36	4.12e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.45	-0.52	2.86e-18	Chronic sinus infection;
KIRP	cis	rs1978968	0.956	rs5992925	chr22:18447697	G/A	cg02610425	chr22:18483192	MICAL3	0.36	5.07	0.31	7.93e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs7011507	1.000	rs7017974	chr8:49164057	T/C	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.58	-7.58	-0.44	7.15e-13	Pulse pressure;
KIRP	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.89	15.56	0.7	1.78e-38	Coronary artery disease;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg11317019	chr17:42219250	C17orf53	-0.5	-6.01	-0.36	6.49e-9	Type 1 diabetes nephropathy;
KIRP	cis	rs228437	0.529	rs12528767	chr6:135005886	C/T	cg24504307	chr6:134963096	NA	0.44	5.03	0.31	9.35e-7	Melanoma;
KIRP	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.8	11.91	0.6	3.89e-26	Height;
KIRP	cis	rs1629083	0.875	rs1805	chr11:118076069	A/C	cg18857871	chr11:118064634	AMICA1	0.65	8.76	0.49	3.23e-16	Lung cancer;
KIRP	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23598886	chr18:12777645	NA	0.73	6.0	0.36	6.89e-9	Inflammatory skin disease;
KIRP	cis	rs944802	0.929	rs10965269	chr9:22162061	A/G	cg00491127	chr9:22154101	NA	-0.47	-5.11	-0.31	6.48e-7	White blood cell count;
KIRP	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.89	11.88	0.6	5.2e-26	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.34	0.37	1.08e-9	Mean platelet volume;
KIRP	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.77	0.4	9.47e-11	Bipolar disorder;
KIRP	cis	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	5.13	0.31	5.74e-7	Leprosy;
KIRP	cis	rs6545883	0.965	rs778752	chr2:61776902	C/G	cg15711740	chr2:61764176	XPO1	-0.61	-8.4	-0.47	3.5e-15	Tuberculosis;
KIRP	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.89	-12.76	-0.63	5.9e-29	Cocaine dependence;
KIRP	cis	rs4281086	0.541	rs10094938	chr8:10395326	A/C	cg21775007	chr8:11205619	TDH	0.43	5.7	0.34	3.42e-8	Obesity-related traits;
KIRP	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7.01e-8	Schizophrenia;
KIRP	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg18646521	chr2:111875858	NA	0.4	5.75	0.34	2.66e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.69	-12.53	-0.62	3.58e-28	White blood cell count (basophil);
KIRP	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg06365898	chr1:16533907	ARHGEF19	-0.47	-6.34	-0.37	1.08e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-22.18	-0.82	1.27e-60	Height;
KIRP	cis	rs787274	1.000	rs787280	chr9:115539085	C/T	cg13803584	chr9:115635662	SNX30	-0.74	-8.4	-0.47	3.67e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9400467	0.528	rs4276544	chr6:111759699	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.42	-5.44	-0.33	1.29e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.58	-8.21	-0.46	1.24e-14	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12386437	chr3:39438558	SLC25A38	0.41	6.24	0.37	1.93e-9	Survival in pancreatic cancer;
KIRP	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-10.56	-0.56	9.53e-22	Colorectal cancer;
KIRP	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg23422044	chr7:1970798	MAD1L1	-0.68	-6.41	-0.38	7.28e-10	Neuroticism;
KIRP	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg23920097	chr1:209922102	NA	-0.47	-5.57	-0.33	6.67e-8	Red blood cell count;
KIRP	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg02951883	chr7:2050386	MAD1L1	-0.52	-5.97	-0.36	8.17e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.04	0.54	4.37e-20	Total body bone mineral density;
KIRP	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.4	9.48e-11	Red blood cell count;
KIRP	cis	rs2733310	0.895	rs1820994	chr15:57297779	A/G	cg13626582	chr15:57592083	LOC283663	-0.25	-6.03	-0.36	5.86e-9	Mean platelet volume;
KIRP	cis	rs13315871	1.000	rs71311857	chr3:58323377	A/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.14	-0.31	5.49e-7	Cholesterol, total;
KIRP	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs80130819	0.748	rs2409001	chr12:48594490	T/C	cg26205652	chr12:48591994	NA	0.48	5.01	0.3	1.05e-6	Prostate cancer;
KIRP	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.4	5.16	0.31	5.07e-7	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-6.93	-0.4	3.76e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg00982548	chr2:198649783	BOLL	-0.57	-5.23	-0.32	3.57e-7	Ulcerative colitis;
KIRP	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg01028140	chr2:1542097	TPO	-0.51	-5.97	-0.36	8.03e-9	IgG glycosylation;
KIRP	cis	rs11169552	0.510	rs10876047	chr12:50925285	C/G	cg12884762	chr12:50931848	DIP2B	-0.43	-5.05	-0.31	8.79e-7	Colorectal cancer;
KIRP	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg23958373	chr8:599963	NA	0.77	5.75	0.34	2.66e-8	IgG glycosylation;
KIRP	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.36	-5.8	-0.35	2.06e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs867371	1.000	rs1174543	chr15:82448073	C/T	cg00614314	chr15:82944287	LOC80154	-0.54	-6.37	-0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11987759	chr7:65425863	GUSB	-0.62	-8.44	-0.47	2.69e-15	Aortic root size;
KIRP	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.89	11.21	0.58	8.07e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7714584	1.000	rs10051924	chr5:150226639	T/C	cg22134413	chr5:150180641	NA	0.58	5.21	0.32	3.98e-7	Crohn's disease;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg14128259	chr12:27848523	REP15	0.4	6.07	0.36	4.7e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.59	6.73	0.39	1.15e-10	Lung cancer;
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.36	-5.24	-0.32	3.4e-7	Lymphocyte counts;
KIRP	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.58	7.25	0.42	5.41e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.85	12.64	0.63	1.43e-28	Eosinophil percentage of white cells;
KIRP	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.18	0.42	8.11e-12	Myopia (pathological);
KIRP	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.44	5.98	0.36	7.9e-9	Red blood cell count;
KIRP	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.49	-0.33	9.78e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg21734707	chr17:3908241	ZZEF1	-0.49	-6.52	-0.38	3.9e-10	Type 2 diabetes;
KIRP	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.71	-12.25	-0.62	2.99e-27	Urate levels in overweight individuals;
KIRP	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.43	5.14	0.31	5.5e-7	Aortic root size;
KIRP	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-5.82	-0.35	1.85e-8	Aortic root size;
KIRP	cis	rs12230513	0.732	rs61957760	chr12:55859957	G/T	cg19537932	chr12:55886519	OR6C68	-0.62	-7.6	-0.44	6.32e-13	Contrast sensitivity;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15812903	chr14:100912065	WDR25	0.51	6.43	0.38	6.73e-10	Interleukin-4 levels;
KIRP	cis	rs12913538	0.619	rs12908357	chr15:62899904	A/G	cg09983546	chr15:62884068	NA	0.47	5.43	0.33	1.38e-7	Sleep depth;
KIRP	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.93	13.45	0.65	2.79e-31	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2274273	0.638	rs58269011	chr14:55684388	A/G	cg04306507	chr14:55594613	LGALS3	0.43	5.65	0.34	4.38e-8	Protein biomarker;
KIRP	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.75	-0.34	2.6e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-0.94	-14.54	-0.68	5.43e-35	Gut microbiome composition (winter);
KIRP	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.58	7.88	0.45	1.03e-13	Height;
KIRP	cis	rs9290877	0.667	rs6774775	chr3:188455874	A/G	cg17392043	chr3:188495102	LPP	-0.49	-6.45	-0.38	5.99e-10	IgE levels;
KIRP	cis	rs2625529	0.504	rs11072349	chr15:72464471	T/C	cg16672083	chr15:72433130	SENP8	0.39	5.38	0.32	1.71e-7	Red blood cell count;
KIRP	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.29	0.47	7.23e-15	IgG glycosylation;
KIRP	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.84	8.92	0.49	1.07e-16	Educational attainment;
KIRP	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17376030	chr22:41985996	PMM1	-0.69	-7.61	-0.44	5.93e-13	Vitiligo;
KIRP	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg23594656	chr7:65796392	TPST1	0.49	7.62	0.44	5.37e-13	Aortic root size;
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	8.92e-8	Life satisfaction;
KIRP	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.18	0.42	8.26e-12	Acne (severe);
KIRP	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs6539288	0.677	rs10735418	chr12:107343376	T/C	cg21360079	chr12:107162445	NA	-0.46	-5.72	-0.34	3.1e-8	Total body bone mineral density;
KIRP	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg00981070	chr1:2046702	PRKCZ	0.42	6.9	0.4	4.46e-11	Height;
KIRP	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.95	12.34	0.62	1.5e-27	Menopause (age at onset);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09400194	chr10:81107848	PPIF	0.74	7.0	0.41	2.41e-11	Lung function (FEV1);
KIRP	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.11	-0.36	3.82e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg02461776	chr11:598696	PHRF1	0.74	7.7	0.44	3.38e-13	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.59	8.16	0.46	1.76e-14	Migraine;
KIRP	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg15445000	chr17:37608096	MED1	0.47	5.59	0.34	6.01e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.45	-6.02	-0.36	6.4e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12900413	0.687	rs12902809	chr15:90305617	C/G	cg24650279	chr15:90327240	NA	-0.42	-5.35	-0.32	2.04e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs12780845	0.505	rs10795462	chr10:17245119	A/C	cg01003015	chr10:17271136	VIM	-0.49	-6.27	-0.37	1.63e-9	Homocysteine levels;
KIRP	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.43	5.94	0.35	9.53e-9	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01682615	chr4:2845235	ADD1	0.53	6.61	0.39	2.31e-10	Parkinson's disease;
KIRP	cis	rs6577655	0.547	rs7841171	chr8:135591699	G/A	cg17885191	chr8:135476712	NA	0.66	6.45	0.38	5.91e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg08600765	chr20:34638493	LOC647979	-0.79	-8.35	-0.47	4.95e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.6	-6.65	-0.39	1.91e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs6838801	0.964	rs4859456	chr4:77562958	T/C	cg17476223	chr4:77663285	SHROOM3	-0.43	-5.92	-0.35	1.1e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.61	8.89	0.49	1.3e-16	Resting heart rate;
KIRP	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.1	0.36	4e-9	Lung cancer;
KIRP	cis	rs17209837	0.915	rs17149660	chr7:87089524	T/C	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs2219968	0.961	rs4460363	chr8:78962903	G/A	cg00738934	chr8:78996279	NA	0.5	7.0	0.41	2.49e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg14972814	chr11:95582409	MTMR2	0.37	6.01	0.36	6.82e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2072732	0.861	rs67289919	chr1:2954208	G/A	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13370280	chr6:137539688	IFNGR1	0.64	6.12	0.36	3.76e-9	Lung function (FEV1);
KIRP	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg18586891	chr4:952366	TMEM175	0.64	5.16	0.31	5.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.75	-0.53	3.44e-19	Response to antipsychotic treatment;
KIRP	cis	rs9488822	0.585	rs390255	chr6:116237680	A/G	cg26893134	chr6:116381904	FRK	0.2	5.25	0.32	3.35e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.61	7.71	0.44	3.08e-13	Type 2 diabetes;
KIRP	cis	rs28489187	0.617	rs233112	chr1:85785751	C/T	cg16011679	chr1:85725395	C1orf52	-0.45	-5.54	-0.33	7.63e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg05340658	chr4:99064831	C4orf37	-0.63	-8.11	-0.46	2.39e-14	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	7.77	0.44	2.07e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9962915	0.967	rs1785410	chr18:5594917	C/T	cg06550462	chr18:5544208	EPB41L3	-0.4	-4.93	-0.3	1.52e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg02415014	chr8:143852576	LYNX1	0.32	5.17	0.31	4.82e-7	Urinary tract infection frequency;
KIRP	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg02297831	chr4:17616191	MED28	-0.51	-5.83	-0.35	1.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4363385	0.647	rs7548977	chr1:152987365	T/G	cg07796016	chr1:152779584	LCE1C	-0.49	-6.29	-0.37	1.46e-9	Inflammatory skin disease;
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg10304824	chr2:177028804	HOXD3	0.25	5.11	0.31	6.33e-7	IgG glycosylation;
KIRP	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg03342759	chr3:160939853	NMD3	-0.49	-6.36	-0.38	9.92e-10	Morning vs. evening chronotype;
KIRP	cis	rs7707921	0.767	rs6894520	chr5:81594748	C/T	cg07807695	chr5:81608485	ATP6AP1L	0.43	5.67	0.34	4e-8	Breast cancer;
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.5	-6.54	-0.38	3.5e-10	Testicular germ cell tumor;
KIRP	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.74	9.38	0.51	4.57e-18	Aortic root size;
KIRP	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	1.04	13.4	0.65	4.17e-31	Exhaled nitric oxide output;
KIRP	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.25	0.51	1.13e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.87	-0.53	1.44e-19	Colorectal cancer;
KIRP	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg03474202	chr17:45855739	NA	-0.52	-8.12	-0.46	2.29e-14	IgG glycosylation;
KIRP	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg24579218	chr15:68104479	NA	-0.45	-7.42	-0.43	1.95e-12	Restless legs syndrome;
KIRP	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg00784671	chr22:46762841	CELSR1	-0.64	-6.68	-0.39	1.56e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg27411982	chr8:10470053	RP1L1	-0.37	-4.89	-0.3	1.85e-6	Neuroticism;
KIRP	cis	rs17453880	0.890	rs60862272	chr5:152009347	A/G	cg12297329	chr5:152029980	NA	-0.7	-10.54	-0.56	1.1e-21	Subjective well-being;
KIRP	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	6.94	0.4	3.53e-11	Platelet count;
KIRP	cis	rs2273669	0.667	rs76267985	chr6:109326183	A/T	cg05315195	chr6:109294784	ARMC2	-0.59	-6.26	-0.37	1.67e-9	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-7.29	-0.42	4.3e-12	Platelet count;
KIRP	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.92	12.57	0.63	2.54e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs3750965	1.000	rs7950657	chr11:68834831	G/A	cg06818126	chr11:68850279	TPCN2	-0.46	-5.24	-0.32	3.48e-7	Hair color;
KIRP	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.58	6.99	0.41	2.63e-11	Mean corpuscular volume;
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.72	-10.74	-0.57	2.49e-22	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg02030672	chr11:45687055	CHST1	-0.52	-6.52	-0.38	3.92e-10	Obesity-related traits;
KIRP	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.68	8.86	0.49	1.69e-16	Prudent dietary pattern;
KIRP	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.59	8.65	0.48	6.55e-16	Systemic lupus erythematosus;
KIRP	cis	rs7224685	0.569	rs35977026	chr17:4036528	G/A	cg09597638	chr17:3907349	NA	0.52	5.13	0.31	5.9e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.41	5.06	0.31	8.14e-7	Aortic root size;
KIRP	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.78	10.19	0.54	1.48e-20	Systemic lupus erythematosus;
KIRP	cis	rs7215564	0.908	rs77750710	chr17:78717117	C/T	cg06153925	chr17:78755379	RPTOR	0.43	6.35	0.38	1.02e-9	Myopia (pathological);
KIRP	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg11995313	chr8:8860691	ERI1	0.42	5.48	0.33	1.04e-7	Joint mobility (Beighton score);
KIRP	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg27347728	chr4:17578864	LAP3	0.41	4.85	0.3	2.15e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.76	11.41	0.59	1.73e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2278796	0.918	rs11240326	chr1:204955416	G/A	cg17947172	chr1:204966197	NFASC	0.57	7.66	0.44	4.2e-13	Mean platelet volume;
KIRP	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg21918786	chr6:109611834	NA	-0.37	-5.39	-0.33	1.63e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.85	12.97	0.64	1.18e-29	Prostate cancer;
KIRP	cis	rs11997175	0.583	rs17781020	chr8:33850858	C/G	ch.8.33884649F	chr8:33765107	NA	0.48	5.14	0.31	5.73e-7	Body mass index;
KIRP	cis	rs6968419	0.755	rs10500059	chr7:115900394	C/T	cg02561103	chr7:115862891	TES	-0.4	-5.66	-0.34	4.23e-8	Intraocular pressure;
KIRP	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.22	-20.64	-0.8	1.37e-55	Breast cancer;
KIRP	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.68	5.61	0.34	5.57e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.51	-7.8	-0.45	1.77e-13	Huntington's disease progression;
KIRP	cis	rs4006360	0.545	rs365738	chr17:39279082	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.46	-6.71	-0.39	1.3e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-8.44	-0.47	2.76e-15	Retinal vascular caliber;
KIRP	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.68	5.73	0.34	2.95e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs12210905	0.688	rs12215878	chr6:27336844	G/C	cg08851530	chr6:28072375	NA	0.89	5.14	0.31	5.55e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg27205649	chr11:78285834	NARS2	0.52	5.57	0.33	6.56e-8	Testicular germ cell tumor;
KIRP	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.45	-9.43	-0.52	3.18e-18	Mean corpuscular volume;
KIRP	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	7.14e-8	Breast cancer;
KIRP	cis	rs6733011	0.582	rs6757099	chr2:99415235	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.13	-0.31	5.85e-7	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13263057	chr2:68357899	WDR92	0.5	6.48	0.38	5.02e-10	Interleukin-4 levels;
KIRP	cis	rs9783347	1.000	rs4150622	chr11:18365710	A/G	cg15585147	chr11:18324498	HPS5	0.46	6.38	0.38	8.53e-10	Pancreatic cancer;
KIRP	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.41	-5.87	-0.35	1.39e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg07216194	chr8:27182965	PTK2B	0.46	5.75	0.34	2.6e-8	Neuroticism;
KIRP	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.71	10.58	0.56	8.32e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.73	-0.34	2.89e-8	Body mass index;
KIRP	cis	rs4684776	0.676	rs11714563	chr3:11313214	A/G	cg00170343	chr3:11313890	ATG7	-0.5	-4.88	-0.3	1.93e-6	Small vessel stroke;
KIRP	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.58	9.38	0.51	4.62e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg10664184	chr19:17420304	DDA1	0.72	8.39	0.47	3.72e-15	Systemic lupus erythematosus;
KIRP	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-5.07	-0.31	7.67e-7	Chronic sinus infection;
KIRP	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	5.02	0.3	9.96e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10568689	chr11:73591256	PAAF1	0.57	6.16	0.37	2.9e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg22117172	chr7:91764530	CYP51A1	-0.38	-5.18	-0.31	4.61e-7	Breast cancer;
KIRP	cis	rs5753037	0.653	rs140123	chr22:30143206	A/G	cg01021169	chr22:30184971	ASCC2	0.48	6.68	0.39	1.61e-10	Type 1 diabetes;
KIRP	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1034435	0.575	rs6007864	chr22:48883081	C/T	cg05992904	chr22:48892994	FAM19A5	0.49	4.98	0.3	1.18e-6	Late-onset Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25594980	chr1:179198508	ABL2	0.47	6.13	0.36	3.52e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9400467	0.537	rs17606672	chr6:111546833	G/C	cg22127309	chr6:111907043	TRAF3IP2	0.57	5.32	0.32	2.37e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6545883	0.899	rs12473030	chr2:61720497	T/A	cg15711740	chr2:61764176	XPO1	-0.6	-8.11	-0.46	2.37e-14	Tuberculosis;
KIRP	cis	rs494562	0.892	rs1322403	chr6:86127162	A/G	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs10214930	0.813	rs6415252	chr7:27668860	C/T	cg22168087	chr7:27702803	HIBADH	0.51	5.07	0.31	7.97e-7	Hypospadias;
KIRP	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19717773	chr7:2847554	GNA12	0.35	5.32	0.32	2.33e-7	Height;
KIRP	cis	rs9840812	0.623	rs4678433	chr3:136265682	C/T	cg15507776	chr3:136538369	TMEM22	0.42	5.46	0.33	1.19e-7	Fibrinogen levels;
KIRP	cis	rs4523957	0.651	rs9895342	chr17:2081647	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.52	-0.59	7.56e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9463078	0.506	rs4714820	chr6:44736737	T/A	cg25276700	chr6:44698697	NA	0.35	5.06	0.31	8.28e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-6.75	-0.4	1.03e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.75	7.7	0.44	3.33e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg04398451	chr17:18023971	MYO15A	0.78	11.17	0.58	1.09e-23	Total body bone mineral density;
KIRP	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.57	7.14	0.41	1.07e-11	Blood protein levels;
KIRP	cis	rs8014252	0.803	rs73282126	chr14:70986041	T/C	cg11204974	chr14:71022665	NA	-0.62	-6.59	-0.39	2.66e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.57	0.52	1.21e-18	Coffee consumption (cups per day);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22481606	chr17:56429567	SUPT4H1	0.69	8.23	0.46	1.07e-14	Smoking initiation;
KIRP	cis	rs12725198	1.000	rs12725198	chr1:16080171	A/G	cg26036626	chr1:16085597	FBLIM1	0.35	4.89	0.3	1.83e-6	Cardiac Troponin-T levels;
KIRP	cis	rs71597109	0.681	rs11938245	chr4:102721078	C/T	cg14855874	chr4:102712397	BANK1	0.41	5.37	0.32	1.86e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.42	0.33	1.41e-7	Putamen volume;
KIRP	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg19770292	chr5:1868693	NA	0.46	5.39	0.33	1.65e-7	Cardiovascular disease risk factors;
KIRP	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.48	0.62	5.09e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.58	7.08	0.41	1.52e-11	Aortic root size;
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg19770292	chr5:1868693	NA	0.41	5.26	0.32	3.2e-7	Cardiovascular disease risk factors;
KIRP	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-6.23	-0.37	2.03e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.45	4.86	0.3	2.08e-6	Obesity (extreme);
KIRP	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg03653399	chr8:142233436	SLC45A4	0.52	6.37	0.38	9.05e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.17	-0.37	2.79e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12153243	0.802	rs12153151	chr5:142897834	T/A	cg13907255	chr5:142895549	NA	-0.37	-5.06	-0.31	8.08e-7	Migraine;
KIRP	cis	rs2070997	1.000	rs2070997	chr9:133748083	A/G	cg13397898	chr9:133768931	QRFP	0.33	5.01	0.3	1.05e-6	Response to amphetamines;
KIRP	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs17761864	0.762	rs11658881	chr17:2072949	A/G	cg16513277	chr17:2031491	SMG6	0.43	5.17	0.31	4.9e-7	Esophageal cancer (squamous cell);
KIRP	cis	rs6909279	0.678	rs11155795	chr6:151851339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.55	6.8	0.4	7.73e-11	Bone mineral density;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04968835	chr1:143913847	FAM72D	-0.49	-6.26	-0.37	1.7e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs6561151	0.957	rs9316058	chr13:44485076	G/C	cg17145862	chr1:211918768	LPGAT1	0.68	8.29	0.47	7.48e-15	Crohn's disease;
KIRP	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.52	-6.71	-0.39	1.33e-10	Body mass index;
KIRP	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg05709478	chr1:6581295	PLEKHG5	-0.59	-5.42	-0.33	1.44e-7	Body mass index;
KIRP	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.6	-7.88	-0.45	1.06e-13	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg12486944	chr17:80159399	CCDC57	-0.39	-4.98	-0.3	1.18e-6	Life satisfaction;
KIRP	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.57	7.41	0.43	2.04e-12	Breast cancer;
KIRP	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.78	-0.35	2.26e-8	Educational attainment;
KIRP	cis	rs7590368	0.673	rs55648622	chr2:10932765	C/T	cg15705551	chr2:10952987	PDIA6	0.65	6.29	0.37	1.44e-9	Educational attainment (years of education);
KIRP	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg00800038	chr16:89945340	TCF25	-0.67	-5.57	-0.33	6.72e-8	Interleukin-17 levels;
KIRP	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.94e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7127900	0.784	rs7114836	chr11:2229012	G/A	cg25635251	chr11:2234043	NA	0.53	8.0	0.45	4.9e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs6546886	0.957	rs11885172	chr2:74257094	T/C	cg14702570	chr2:74259524	NA	-0.31	-6.31	-0.37	1.31e-9	Dialysis-related mortality;
KIRP	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.46	-4.84	-0.3	2.26e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg17644776	chr2:200775616	C2orf69	0.57	5.29	0.32	2.71e-7	Schizophrenia;
KIRP	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.45	7.4	0.43	2.18e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-11.69	-0.6	2.19e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.62	-8.64	-0.48	7.43e-16	Lymphocyte counts;
KIRP	cis	rs17213078	0.505	rs6735859	chr2:106744603	T/C	cg16099169	chr2:106886729	NA	0.37	5.17	0.31	4.78e-7	Facial morphology (factor 23);
KIRP	cis	rs4356932	1.000	rs4356932	chr4:76955194	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.79	11.61	0.59	3.92e-25	Bladder cancer;
KIRP	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.98	8.31	0.47	6.7e-15	Body mass index;
KIRP	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.14	-10.14	-0.54	2.12e-20	Body mass index;
KIRP	cis	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg16099169	chr2:106886729	NA	-0.47	-7.03	-0.41	2e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.01	-0.3	1.04e-6	Neutrophil percentage of white cells;
KIRP	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.41	-0.33	1.51e-7	Aortic root size;
KIRP	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.7	-9.27	-0.51	9.81e-18	Colorectal cancer;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg10880834	chr17:55927538	MRPS23	0.53	6.63	0.39	2.1e-10	DNA methylation (variation);
KIRP	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.21	-0.32	3.99e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12476592	0.543	rs4671510	chr2:63742880	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs6516091	0.850	rs62199232	chr20:6050137	T/G	cg25325723	chr20:6104886	FERMT1	-0.64	-6.41	-0.38	7.27e-10	Abdominal aortic aneurysm;
KIRP	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-7.04	-0.41	1.96e-11	Systemic lupus erythematosus;
KIRP	cis	rs4845459	1.000	rs6702463	chr1:152598711	A/T	cg07796016	chr1:152779584	LCE1C	-0.43	-5.01	-0.3	1.04e-6	Psoriasis;
KIRP	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	5.32	0.32	2.36e-7	Menopause (age at onset);
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-8.98	-0.5	7.06e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15828085	chr19:30302476	CCNE1	0.47	6.24	0.37	1.87e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3774854	1.000	rs3774854	chr4:5711368	C/T	cg09558315	chr4:5711301	EVC2	0.35	5.23	0.32	3.7e-7	Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease;
KIRP	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg05340658	chr4:99064831	C4orf37	0.67	8.12	0.46	2.18e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg04369109	chr6:150039330	LATS1	-0.59	-7.6	-0.44	6.39e-13	Lung cancer;
KIRP	cis	rs143000161	1	rs143000161	chr2:165710540	A/T	cg03182029	chr2:165697222	COBLL1	0.92	8.2	0.46	1.3e-14	Heschl's gyrus morphology;
KIRP	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.97	0.45	5.98e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.4	-0.38	7.77e-10	Alcohol dependence;
KIRP	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg04691961	chr3:161091175	C3orf57	-0.46	-7.17	-0.42	8.73e-12	Morning vs. evening chronotype;
KIRP	cis	rs7180079	0.620	rs7162324	chr15:64736287	A/G	cg15337035	chr15:64978493	NA	-0.48	-5.25	-0.32	3.24e-7	Monocyte count;
KIRP	cis	rs7122257	0.507	rs7110986	chr11:11161248	A/G	cg16931664	chr11:11169707	NA	-0.42	-5.89	-0.35	1.26e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg11906718	chr8:101322791	RNF19A	0.53	7.21	0.42	7.02e-12	Atrioventricular conduction;
KIRP	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg00579200	chr11:133705235	NA	-0.43	-5.73	-0.34	2.86e-8	Childhood ear infection;
KIRP	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.77	-12.19	-0.61	4.54e-27	Prostate cancer;
KIRP	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.27	0.32	3.01e-7	Educational attainment;
KIRP	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg04731861	chr2:219085781	ARPC2	-0.21	-5.05	-0.31	8.55e-7	Colorectal cancer;
KIRP	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.29	-0.32	2.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg24296786	chr1:45957014	TESK2	0.51	5.59	0.34	5.92e-8	Homocysteine levels;
KIRP	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11987759	chr7:65425863	GUSB	-0.45	-5.43	-0.33	1.33e-7	Aortic root size;
KIRP	cis	rs8077577	0.562	rs8081042	chr17:18199067	C/G	cg18869244	chr17:18121946	NA	0.46	5.16	0.31	5.07e-7	Obesity-related traits;
KIRP	cis	rs258892	0.895	rs9293442	chr5:72055595	T/C	cg21869765	chr5:72125136	TNPO1	-0.52	-5.66	-0.34	4.17e-8	Small cell lung carcinoma;
KIRP	cis	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.3	-0.37	1.39e-9	Migraine - clinic-based;
KIRP	cis	rs2306032	0.669	rs10838622	chr11:46856536	T/C	cg16389345	chr11:46697382	NA	0.41	5.05	0.31	8.61e-7	Total body bone mineral density;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg15249211	chr10:126303581	NA	0.57	6.08	0.36	4.68e-9	Response to statin therapy;
KIRP	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.83	-0.45	1.46e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.11	-0.31	6.55e-7	Type 2 diabetes;
KIRP	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.53	-0.43	9.5e-13	Neuroticism;
KIRP	cis	rs4262150	0.883	rs12659715	chr5:152310058	A/G	cg12297329	chr5:152029980	NA	-0.64	-8.3	-0.47	6.76e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18798572	chr1:52116301	OSBPL9	0.51	7.53	0.43	9.7e-13	Interleukin-4 levels;
KIRP	cis	rs3736485	0.934	rs2414106	chr15:51868741	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.53e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg19694781	chr19:47549865	TMEM160	0.58	7.73	0.44	2.82e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.66	0.39	1.79e-10	Aortic root size;
KIRP	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg12140854	chr5:148520817	ABLIM3	0.54	6.14	0.36	3.34e-9	Breast cancer;
KIRP	cis	rs4356203	0.875	rs11024136	chr11:17064397	T/C	cg01251548	chr11:17372745	DKFZp686O24166	0.39	5.05	0.31	8.43e-7	Schizophrenia;Schizophrenia or bipolar disorder;
KIRP	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg00405596	chr8:11794950	NA	-0.49	-6.58	-0.39	2.89e-10	Monocyte count;
KIRP	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg07775547	chr4:1625484	NA	0.42	5.32	0.32	2.3e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs13102973	0.682	rs11938038	chr4:135894258	T/C	cg14419869	chr4:135874104	NA	0.39	6.3	0.37	1.35e-9	Subjective well-being;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05151811	chr10:17270250	VIM	-0.46	-6.21	-0.37	2.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.94	12.34	0.62	1.46e-27	Bipolar disorder;
KIRP	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg02570527	chr1:10970165	NA	-0.44	-5.3	-0.32	2.6e-7	Body mass index;
KIRP	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.43	-5.74	-0.34	2.85e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg03468072	chr12:39539422	NA	0.44	5.82	0.35	1.86e-8	Morning vs. evening chronotype;
KIRP	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg12940439	chr1:67600707	NA	0.34	5.27	0.32	2.92e-7	Psoriasis;
KIRP	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	0.9	13.07	0.64	5.42e-30	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.29	0.51	8.32e-18	Cognitive test performance;
KIRP	cis	rs2296225	0.722	rs6668854	chr1:21045508	C/A	cg14666476	chr1:21112556	HP1BP3	0.67	5.89	0.35	1.29e-8	Eosinophilic esophagitis;
KIRP	cis	rs742071	0.586	rs2185203	chr1:18942715	G/T	cg22389438	chr1:18926496	NA	-0.4	-5.61	-0.34	5.45e-8	Nonsyndromic cleft lip with cleft palate;Orofacial clefts;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21092551	chr15:29993498	TJP1	0.45	6.59	0.39	2.64e-10	Survival in pancreatic cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13328485	chr2:170806154	UBR3	-0.42	-6.55	-0.39	3.33e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-5.84	-0.35	1.6e-8	Monocyte count;
KIRP	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.52	0.38	4.01e-10	Atrioventricular conduction;
KIRP	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.76	8.75	0.49	3.5e-16	Corneal astigmatism;
KIRP	cis	rs6707387	0.686	rs1304727	chr2:214475387	A/G	cg08319019	chr2:214017104	IKZF2	0.44	4.85	0.3	2.16e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.46	-6.02	-0.36	6.16e-9	Leprosy;
KIRP	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.32	-5.12	-0.31	6.1e-7	Asthma;
KIRP	cis	rs6732160	0.691	rs13432787	chr2:73430234	T/C	cg01422370	chr2:73384389	NA	0.4	5.33	0.32	2.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg07796016	chr1:152779584	LCE1C	-0.54	-6.61	-0.39	2.42e-10	Inflammatory skin disease;
KIRP	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg18190219	chr22:46762943	CELSR1	-0.88	-7.1	-0.41	1.34e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.33	-0.37	1.15e-9	Obesity-related traits;
KIRP	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg13798912	chr7:905769	UNC84A	0.55	5.53	0.33	8.11e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.2	0.46	1.37e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg15880211	chr22:50250494	ZBED4	0.45	5.29	0.32	2.73e-7	Schizophrenia;
KIRP	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg24459738	chr19:57751996	ZNF805	-0.55	-6.9	-0.4	4.41e-11	Hyperactive-impulsive symptoms;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg16727006	chr16:87470545	ZCCHC14	0.51	6.04	0.36	5.8e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg11693508	chr17:37793320	STARD3	0.81	8.42	0.47	3.25e-15	Bipolar disorder;
KIRP	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg16486109	chr11:613632	IRF7	0.43	5.28	0.32	2.81e-7	Systemic lupus erythematosus;
KIRP	trans	rs12043259	0.730	rs10458596	chr1:204793981	G/A	cg11485465	chr5:54518469	NA	0.38	6.31	0.37	1.26e-9	Addiction;
KIRP	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6102059	0.525	rs6093368	chr20:39197871	A/C	cg22477343	chr20:39312069	NA	0.5	6.38	0.38	8.83e-10	LDL cholesterol;
KIRP	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.46	6.18	0.37	2.66e-9	Menopause (age at onset);
KIRP	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.4	5.08	0.31	7.32e-7	Lung cancer;
KIRP	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg14675211	chr2:100938903	LONRF2	0.52	6.35	0.38	1.03e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg07169764	chr2:136633963	MCM6	-0.44	-4.94	-0.3	1.44e-6	Mosquito bite size;
KIRP	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.63	6.38	0.38	8.52e-10	Axial length;
KIRP	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg21858823	chr1:15850916	CASP9	0.52	5.47	0.33	1.12e-7	Systolic blood pressure;
KIRP	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.98	15.3	0.7	1.41e-37	Diastolic blood pressure;
KIRP	trans	rs2048656	0.523	rs7825286	chr8:9648541	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.19	0.37	2.49e-9	Schizophrenia;
KIRP	cis	rs2013441	0.613	rs12451841	chr17:20004875	G/A	cg13482628	chr17:19912719	NA	0.46	6.05	0.36	5.42e-9	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10256686	chr10:60027792	IPMK;CISD1	0.48	6.1	0.36	4.04e-9	Parkinson's disease;
KIRP	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs10131728	0.892	rs12888290	chr14:81715688	C/T	cg01989461	chr14:81687754	GTF2A1	-0.75	-5.73	-0.34	2.89e-8	IgG glycosylation;
KIRP	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg00409905	chr10:38381863	ZNF37A	-0.59	-7.71	-0.44	3.07e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg12661370	chr5:149340060	SLC26A2	0.45	5.52	0.33	8.52e-8	HIV-1 control;
KIRP	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	1.12	13.11	0.64	3.86e-30	Eosinophil percentage of granulocytes;
KIRP	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg12591125	chr7:1885375	MAD1L1	0.63	6.25	0.37	1.76e-9	Neuroticism;
KIRP	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.68	-6.31	-0.37	1.29e-9	Menarche (age at onset);
KIRP	cis	rs300774	0.841	rs453447	chr2:205446	G/T	cg21211680	chr2:198530	NA	0.48	5.33	0.32	2.17e-7	Suicide attempts in bipolar disorder;
KIRP	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.96	13.89	0.66	9.03e-33	Gestational age at birth (maternal effect);
KIRP	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.7	-0.44	3.34e-13	Height;
KIRP	cis	rs7654585	1.000	rs7654585	chr4:25942751	A/G	cg10409131	chr4:25915609	C4orf52	0.54	6.14	0.36	3.25e-9	Obesity-related traits;
KIRP	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg06060754	chr5:176797920	RGS14	0.59	6.6	0.39	2.45e-10	Urate levels in lean individuals;
KIRP	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.76	6.66	0.39	1.78e-10	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08575972	chr19:58454374	ZNF256	-0.41	-6.12	-0.36	3.74e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg05562828	chr17:3906858	NA	0.72	14.33	0.67	2.85e-34	Type 2 diabetes;
KIRP	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.59	-7.19	-0.42	7.52e-12	Metabolite levels;
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg14221460	chr8:27183342	PTK2B	0.53	6.98	0.41	2.7e-11	Neuroticism;
KIRP	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs28595532	0.660	rs11933762	chr4:119307126	A/G	cg21605333	chr4:119757512	SEC24D	0.55	5.66	0.34	4.22e-8	Cannabis dependence symptom count;
KIRP	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg03060546	chr3:49711283	APEH	0.49	6.33	0.37	1.14e-9	Parkinson's disease;
KIRP	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	0.84	7.68	0.44	3.65e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.82	-9.96	-0.54	7.49e-20	Parkinson's disease;
KIRP	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg16141378	chr3:129829833	LOC729375	0.52	6.63	0.39	2.11e-10	Retinal vascular caliber;
KIRP	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs7395581	0.918	rs10501321	chr11:47294626	A/G	cg26139080	chr11:47293733	MADD	-0.42	-5.26	-0.32	3.2e-7	HDL cholesterol;
KIRP	cis	rs11955175	1.000	rs11953977	chr5:40674690	G/C	cg04002187	chr5:40835754	RPL37	0.67	5.41	0.33	1.5e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.25	-0.42	5.38e-12	Type 2 diabetes;
KIRP	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg05315796	chr3:52349193	DNAH1	0.43	6.55	0.39	3.37e-10	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.37	-0.32	1.81e-7	Renal cell carcinoma;
KIRP	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg17425144	chr1:10567563	PEX14	0.44	7.46	0.43	1.49e-12	Hand grip strength;
KIRP	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg24009623	chr19:33667908	NA	0.49	6.58	0.39	2.78e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17401966	0.522	rs2027330	chr1:10275592	C/T	cg19773385	chr1:10388646	KIF1B	-0.44	-6.5	-0.38	4.32e-10	Hepatocellular carcinoma;
KIRP	cis	rs7837860	0.588	rs17729482	chr8:89304297	T/A	cg08624180	chr8:89339080	MMP16	-0.63	-5.33	-0.32	2.21e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7546094	0.935	rs6700673	chr1:113157054	C/T	cg22162597	chr1:113214053	CAPZA1	0.47	6.72	0.39	1.25e-10	Platelet distribution width;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	-0.48	-6.15	-0.37	3.15e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg16606324	chr3:10149918	C3orf24	0.69	5.83	0.35	1.7e-8	Alzheimer's disease;
KIRP	cis	rs9513627	1.000	rs3928271	chr13:100186958	G/A	cg25919922	chr13:100150906	NA	0.67	4.87	0.3	1.99e-6	Obesity-related traits;
KIRP	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg23791538	chr6:167370224	RNASET2	-0.47	-5.71	-0.34	3.2e-8	Crohn's disease;
KIRP	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs490234	0.746	rs1266009	chr9:128192316	A/G	cg14078157	chr9:128172775	NA	-0.41	-5.16	-0.31	4.97e-7	Mean arterial pressure;
KIRP	cis	rs7009516	0.749	rs7012863	chr8:24218225	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.28	5.66	0.34	4.14e-8	Hair greying;
KIRP	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.79	-11.23	-0.58	6.86e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19524238	chr7:2802976	GNA12	-0.33	-5.12	-0.31	6.28e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg04865290	chr3:52927548	TMEM110	-0.66	-6.64	-0.39	2.03e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.76	8.32	0.47	5.98e-15	Uric acid levels;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg17439770	chr10:1383257	ADARB2	0.43	6.28	0.37	1.53e-9	Ischemic stroke;
KIRP	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg07541023	chr7:19748670	TWISTNB	0.66	5.83	0.35	1.71e-8	Thyroid stimulating hormone;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.56	-0.39	3.23e-10	Height;
KIRP	cis	rs7394190	0.748	rs11000777	chr10:75545063	G/C	cg04833713	chr10:74871078	NUDT13	0.43	4.86	0.3	2.1e-6	Incident atrial fibrillation;
KIRP	cis	rs13185784	0.667	rs6882940	chr5:179648989	A/G	cg23248424	chr5:179741104	GFPT2	-0.49	-5.17	-0.31	4.94e-7	TRAIL levels;
KIRP	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg26876637	chr1:152193138	HRNR	-0.73	-9.9	-0.53	1.13e-19	Atopic dermatitis;
KIRP	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18252515	chr7:66147081	NA	0.47	5.43	0.33	1.34e-7	Aortic root size;
KIRP	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.79	0.71	2.98e-39	Bipolar disorder;
KIRP	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg05072774	chr3:49840536	C3orf54	0.43	5.57	0.33	6.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg00122941	chr17:4613640	ARRB2	0.8	8.6	0.48	9.59e-16	Lymphocyte counts;
KIRP	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.36	-5.7	-0.34	3.39e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.74	11.1	0.58	1.81e-23	Blood metabolite ratios;
KIRP	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.89	-11.81	-0.6	8.68e-26	Blood protein levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02836487	chr3:128206457	GATA2	0.49	6.87	0.4	5.38e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.17	-0.31	4.94e-7	Life satisfaction;
KIRP	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.64	7.75	0.44	2.35e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3206736	0.663	rs329571	chr7:35095787	C/G	cg06685737	chr7:35301730	NA	0.41	5.91	0.35	1.15e-8	Diastolic blood pressure;
KIRP	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg02336718	chr17:17403227	NA	0.35	5.39	0.33	1.61e-7	Total body bone mineral density;
KIRP	cis	rs3752645	1.000	rs11772245	chr7:106748078	C/G	cg02696742	chr7:106810147	HBP1	-0.59	-5.11	-0.31	6.61e-7	Bladder cancer (smoking interaction);
KIRP	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.76	-0.63	5.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.23	-0.32	3.67e-7	Blood pressure;
KIRP	cis	rs6960043	1.000	rs62448644	chr7:15053485	C/T	cg19272540	chr7:15055459	NA	-0.22	-5.85	-0.35	1.57e-8	Type 2 diabetes;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.22	-22.7	-0.82	2.81e-62	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7621025	0.690	rs11715257	chr3:136182053	C/T	cg15507776	chr3:136538369	TMEM22	0.46	5.42	0.33	1.41e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06544989	chr22:39130855	UNC84B	0.51	8.37	0.47	4.3e-15	Menopause (age at onset);
KIRP	cis	rs7766436	0.524	rs66992531	chr6:22511065	T/C	cg13666174	chr6:22585274	NA	-0.43	-5.45	-0.33	1.21e-7	Coronary artery disease;
KIRP	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-7.84	-0.45	1.41e-13	Pancreatic cancer;
KIRP	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.46	5.6	0.34	5.57e-8	Diastolic blood pressure;
KIRP	cis	rs76793172	0.623	rs10775546	chr19:46267534	C/T	cg11657440	chr19:46296263	DMWD	0.71	5.08	0.31	7.42e-7	Eosinophil counts;
KIRP	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg21100191	chr22:23484243	RTDR1	1.03	17.54	0.75	3.27e-45	Bone mineral density;
KIRP	cis	rs597583	0.806	rs10892135	chr11:117392826	G/A	cg27161313	chr11:117392002	DSCAML1	-0.49	-5.51	-0.33	9.13e-8	Putamen volume;
KIRP	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.5	6.32	0.37	1.22e-9	Mean platelet volume;
KIRP	cis	rs2865126	0.761	rs1881089	chr18:10765806	A/C	cg21165219	chr18:10698044	FAM38B	-0.51	-4.86	-0.3	2.09e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
KIRP	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg17133734	chr15:86042851	AKAP13	0.48	5.99	0.36	7.27e-9	Coronary artery disease;
KIRP	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg05315796	chr3:52349193	DNAH1	0.45	6.78	0.4	8.86e-11	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	trans	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg01311341	chr22:25575246	KIAA1671	-0.63	-7.67	-0.44	3.94e-13	Atopic dermatitis;
KIRP	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.14	0.31	5.59e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.48	-5.16	-0.31	5.11e-7	Initial pursuit acceleration;
KIRP	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg02534363	chr3:47050950	NBEAL2	-0.33	-5.63	-0.34	4.88e-8	Colorectal cancer;
KIRP	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.48	5.88	0.35	1.36e-8	Common traits (Other);
KIRP	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	1.05	11.28	0.58	4.7e-24	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.66	-8.38	-0.47	4.09e-15	Tonsillectomy;
KIRP	cis	rs7546668	1.000	rs7546668	chr1:15855123	G/C	cg21858823	chr1:15850916	CASP9	0.47	5.17	0.31	4.92e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg21775007	chr8:11205619	TDH	0.45	6.21	0.37	2.25e-9	Myopia (pathological);
KIRP	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.76	8.93	0.49	1.01e-16	Diastolic blood pressure;
KIRP	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.97	18.24	0.76	1.3e-47	Colorectal adenoma (advanced);
KIRP	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.89e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.41	-0.43	2.07e-12	Morning vs. evening chronotype;
KIRP	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26207909	chr14:103986467	CKB	0.74	10.52	0.56	1.27e-21	Body mass index;
KIRP	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.31	4.89	0.3	1.81e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.95	-14.2	-0.67	7.7e-34	Coronary artery disease;
KIRP	cis	rs918629	0.761	rs57243277	chr5:95288165	G/A	cg16656078	chr5:95278638	ELL2	-0.51	-7.25	-0.42	5.26e-12	IgG glycosylation;
KIRP	cis	rs3790645	0.958	rs12723936	chr1:26872554	A/G	cg23229016	chr1:26872525	RPS6KA1	0.24	6.18	0.37	2.61e-9	Glucose homeostasis traits;
KIRP	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg09238746	chr17:78121135	EIF4A3	0.69	8.05	0.46	3.66e-14	Yeast infection;
KIRP	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg24375607	chr4:120327624	NA	0.58	6.62	0.39	2.21e-10	Corneal astigmatism;
KIRP	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg24747557	chr10:131355152	MGMT	0.42	5.67	0.34	3.94e-8	Response to temozolomide;
KIRP	cis	rs612683	0.536	rs1335753	chr1:101027157	G/T	cg06223162	chr1:101003688	GPR88	0.51	10.55	0.56	1.07e-21	Breast cancer;
KIRP	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg09699651	chr6:150184138	LRP11	0.43	5.62	0.34	5.11e-8	Lung cancer;
KIRP	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg26681399	chr22:41777847	TEF	-0.48	-4.98	-0.3	1.18e-6	Vitiligo;
KIRP	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.07	-0.31	7.86e-7	Obesity-related traits;
KIRP	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	8.65	0.48	6.84e-16	Mood instability;
KIRP	cis	rs4262150	0.689	rs11167584	chr5:152004727	A/C	cg12297329	chr5:152029980	NA	-0.62	-8.04	-0.46	3.69e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg13882414	chr3:39194867	CSRNP1	0.55	7.1	0.41	1.37e-11	Asthma;
KIRP	cis	rs4704187	0.687	rs9293643	chr5:74365053	C/T	cg03227963	chr5:74354835	NA	-0.4	-5.91	-0.35	1.16e-8	Response to amphetamines;
KIRP	trans	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg16141378	chr3:129829833	LOC729375	0.48	6.32	0.37	1.2e-9	Mood instability;
KIRP	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg26149184	chr10:133730230	NA	0.42	4.88	0.3	1.94e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	1.07	15.78	0.71	3.12e-39	Menopause (age at onset);
KIRP	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	1.09	20.68	0.8	1e-55	Height;
KIRP	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.83	13.18	0.64	2.25e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs7851660	0.809	rs10984235	chr9:100660896	C/T	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg27205649	chr11:78285834	NARS2	-0.66	-8.36	-0.47	4.59e-15	Alzheimer's disease (survival time);
KIRP	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.56	-5.64	-0.34	4.55e-8	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12123154	chr19:3198856	NCLN	-0.45	-6.05	-0.36	5.39e-9	Parkinson's disease;
KIRP	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.85	8.3	0.47	7.08e-15	Large artery stroke;
KIRP	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.28	0.37	1.51e-9	Aortic root size;
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg09597638	chr17:3907349	NA	-0.8	-16.18	-0.72	1.35e-40	Type 2 diabetes;
KIRP	cis	rs11997175	0.902	rs7009022	chr8:33700404	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.76	0.34	2.55e-8	Body mass index;
KIRP	cis	rs2457480	0.850	rs11238902	chr10:44681091	C/T	cg09554077	chr10:44749378	NA	0.57	5.93	0.35	1.02e-8	Coronary artery disease;
KIRP	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.61	7.35	0.42	2.87e-12	Sum neutrophil eosinophil counts;
KIRP	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg26441486	chr22:50317300	CRELD2	0.45	7.18	0.42	8.25e-12	Schizophrenia;
KIRP	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg11663144	chr21:46675770	NA	-0.55	-6.84	-0.4	6.06e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00873937	chr10:69991564	ATOH7	0.55	7.18	0.42	8.35e-12	Smoking initiation;
KIRP	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	15.21	0.7	2.88e-37	Platelet count;
KIRP	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg05887092	chr17:76393375	PGS1	0.5	7.01	0.41	2.3e-11	HDL cholesterol levels;
KIRP	cis	rs9584850	0.834	rs4294654	chr13:99119607	G/A	cg20750642	chr13:99100586	FARP1	-0.5	-5.93	-0.35	1.04e-8	Neuroticism;
KIRP	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg17443007	chr1:101659419	NA	0.4	5.69	0.34	3.68e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01294023	chr19:41816151	CCDC97	0.48	6.3	0.37	1.37e-9	Parkinson's disease;
KIRP	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg06742321	chr12:123595122	PITPNM2	0.42	5.13	0.31	5.86e-7	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04207741	chr12:57482553	NAB2	0.46	6.29	0.37	1.48e-9	Parkinson's disease;
KIRP	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg26384229	chr12:38710491	ALG10B	0.68	8.79	0.49	2.55e-16	Morning vs. evening chronotype;
KIRP	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg19554555	chr3:13937349	NA	-0.45	-6.24	-0.37	1.86e-9	Ovarian reserve;
KIRP	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.38	4.89	0.3	1.8e-6	Oropharynx cancer;
KIRP	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.74	9.32	0.51	6.76e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.78	9.94	0.54	8.53e-20	Corneal astigmatism;
KIRP	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg21475434	chr5:93447410	FAM172A	0.77	5.99	0.36	7.4e-9	Diabetic retinopathy;
KIRP	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg19875535	chr5:140030758	IK	0.63	8.77	0.49	2.93e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.63	9.33	0.51	6.32e-18	Endometriosis;
KIRP	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.78e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4791746	0.947	rs8078371	chr17:8623208	C/T	cg03115937	chr17:8649504	CCDC42	-0.54	-5.94	-0.35	9.77e-9	Heroin dependence;
KIRP	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg13319975	chr6:146136371	FBXO30	-0.44	-6.4	-0.38	7.91e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	3.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-0.84	-9.25	-0.51	1.13e-17	Blood pressure (smoking interaction);
KIRP	cis	rs7615316	1.000	rs6802774	chr3:142351466	G/C	cg20824294	chr3:142316082	PLS1	0.25	5.41	0.33	1.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.45	-5.28	-0.32	2.8e-7	Total body bone mineral density;
KIRP	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6142102	0.961	rs6120519	chr20:32688113	A/G	cg08999081	chr20:33150536	PIGU	0.51	6.75	0.4	1.07e-10	Skin pigmentation;
KIRP	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.21	0.37	2.19e-9	Retinal vascular caliber;
KIRP	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg09029085	chr17:47094198	IGF2BP1	0.25	5.74	0.34	2.72e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.7	-9.51	-0.52	1.86e-18	Waist circumference;Body mass index;
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg09033563	chr22:24373618	LOC391322	-0.39	-5.06	-0.31	8.34e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.75	-0.49	3.36e-16	Migraine;Coronary artery disease;
KIRP	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg23750338	chr8:142222470	SLC45A4	-0.42	-6.04	-0.36	5.76e-9	Immature fraction of reticulocytes;
KIRP	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg19650706	chr5:140594406	PCDHB13	-0.45	-4.99	-0.3	1.16e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg09408571	chr1:101003634	GPR88	0.24	5.41	0.33	1.51e-7	Monocyte count;
KIRP	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.51e-10	Aortic root size;
KIRP	cis	rs13359291	0.841	rs10044090	chr5:122475727	C/T	cg16368670	chr5:122501738	PRDM6	0.49	6.12	0.36	3.61e-9	Systolic blood pressure;
KIRP	cis	rs1983891	0.706	rs9381084	chr6:41570350	C/T	cg20194872	chr6:41519635	FOXP4	0.5	6.53	0.38	3.71e-10	Prostate cancer;
KIRP	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg06740227	chr12:86229804	RASSF9	0.45	5.72	0.34	3.03e-8	Major depressive disorder;
KIRP	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.02	0.46	4.37e-14	Heart rate;
KIRP	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg26876637	chr1:152193138	HRNR	-0.82	-8.34	-0.47	5.26e-15	Atopic dermatitis;
KIRP	cis	rs7011049	0.778	rs72648429	chr8:53872390	C/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs17095355	0.901	rs6584964	chr10:111759160	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.89	-0.35	1.27e-8	Biliary atresia;
KIRP	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.56	9.54	0.52	1.47e-18	White blood cell count (basophil);
KIRP	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg13978929	chr19:21580086	ZNF493	0.51	4.93	0.3	1.53e-6	Pain;
KIRP	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg26084005	chr2:241760190	KIF1A	-0.5	-6.71	-0.39	1.35e-10	Urinary metabolites;
KIRP	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg14768367	chr16:72042858	DHODH	0.45	5.5	0.33	9.51e-8	Fibrinogen levels;
KIRP	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.66	-8.88	-0.49	1.44e-16	Colorectal cancer;
KIRP	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs684232	0.644	rs870183	chr17:599811	A/G	cg12384639	chr17:618140	VPS53	0.45	5.86	0.35	1.5e-8	Prostate cancer;
KIRP	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg12131826	chr15:77904385	NA	0.49	5.7	0.34	3.41e-8	Type 2 diabetes;
KIRP	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.37	-0.74	1.19e-44	Schizophrenia;
KIRP	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg26207909	chr14:103986467	CKB	-0.44	-5.3	-0.32	2.56e-7	Coronary artery disease;
KIRP	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.43	-5.04	-0.31	8.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg26174226	chr8:58114915	NA	-0.63	-7.42	-0.43	1.96e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2016266	0.502	rs7137242	chr12:53638882	C/T	cg04065151	chr12:53682969	ESPL1	-0.43	-5.38	-0.32	1.73e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs2242194	0.515	rs10908453	chr1:155006091	A/G	cg24250549	chr1:154909240	PMVK	0.42	4.92	0.3	1.61e-6	Schizophrenia;
KIRP	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.53e-7	Plateletcrit;
KIRP	cis	rs7011507	1.000	rs79378568	chr8:49177554	C/T	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6504622	0.818	rs9303532	chr17:45034002	C/T	cg24703533	chr17:45055318	NA	-0.38	-5.05	-0.31	8.62e-7	Orofacial clefts;
KIRP	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg26513180	chr16:89883248	FANCA	0.59	5.49	0.33	1.01e-7	Skin colour saturation;
KIRP	cis	rs9584850	0.834	rs12869627	chr13:99120452	G/A	cg20750642	chr13:99100586	FARP1	-0.51	-5.93	-0.35	1e-8	Neuroticism;
KIRP	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg06521331	chr12:34319734	NA	-0.48	-5.99	-0.36	7.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.44	-9.66	-0.52	6.52e-19	Alzheimer's disease (late onset);
KIRP	cis	rs986417	1.000	rs1254332	chr14:60916587	T/C	cg27398547	chr14:60952738	C14orf39	-0.74	-7.44	-0.43	1.69e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg08888203	chr3:10149979	C3orf24	0.5	5.27	0.32	2.96e-7	Alzheimer's disease;
KIRP	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg03474202	chr17:45855739	NA	-0.47	-7.4	-0.43	2.13e-12	IgG glycosylation;
KIRP	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg24375607	chr4:120327624	NA	0.58	6.73	0.39	1.15e-10	Corneal astigmatism;
KIRP	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.79	-12.67	-0.63	1.16e-28	Prostate cancer;
KIRP	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg05340658	chr4:99064831	C4orf37	0.66	7.3	0.42	3.94e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs61884328	0.733	rs77654484	chr11:47206594	C/A	cg23433285	chr11:47201945	PACSIN3	0.68	5.27	0.32	2.99e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.38	4.92	0.3	1.56e-6	Melanoma;
KIRP	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	10.93	0.57	6.17e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2415984	0.622	rs61993294	chr14:46932466	C/G	cg14871534	chr14:47121158	RPL10L	-0.45	-5.35	-0.32	2.02e-7	Number of children ever born;
KIRP	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg12480562	chr20:23434244	CST11	0.62	6.29	0.37	1.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.0	-0.3	1.1e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.73	8.26	0.47	8.9e-15	Corneal astigmatism;
KIRP	cis	rs4523957	0.671	rs4790070	chr17:2158094	C/G	cg16513277	chr17:2031491	SMG6	0.49	5.8	0.35	2.04e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs1978968	0.707	rs13058527	chr22:18412929	G/A	cg03078520	chr22:18463400	MICAL3	-0.6	-7.51	-0.43	1.09e-12	Presence of antiphospholipid antibodies;
KIRP	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.75	-10.14	-0.54	2.11e-20	Gestational age at birth (maternal effect);
KIRP	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.42	-5.04	-0.31	9.1e-7	Aortic root size;
KIRP	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.07	-0.46	3.18e-14	Body mass index;
KIRP	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7221595	0.825	rs8074860	chr17:3986657	C/G	cg05562828	chr17:3906858	NA	0.55	6.01	0.36	6.71e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg22903471	chr2:27725779	GCKR	0.37	4.99	0.3	1.12e-6	Total body bone mineral density;
KIRP	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg06671706	chr8:8559999	CLDN23	0.56	6.32	0.37	1.21e-9	Obesity-related traits;
KIRP	cis	rs6669919	0.570	rs34293509	chr1:211690673	C/A	cg10512769	chr1:211675356	NA	-0.46	-5.81	-0.35	1.88e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg24633833	chr3:10029261	TMEM111	0.52	4.98	0.3	1.17e-6	Alzheimer's disease;
KIRP	cis	rs4281086	0.582	rs4543507	chr8:10354324	T/C	cg21775007	chr8:11205619	TDH	0.42	5.43	0.33	1.32e-7	Obesity-related traits;
KIRP	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.9	-0.45	9.34e-14	Type 2 diabetes;
KIRP	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.42	-0.43	1.91e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs2172802	0.638	rs7675385	chr4:62502229	A/G	cg04118610	chr4:62707027	LPHN3	-0.44	-5.53	-0.33	8.3e-8	Partial epilepsies;
KIRP	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.24e-8	Lung cancer;
KIRP	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg03929089	chr4:120376271	NA	0.77	6.91	0.4	4.16e-11	Axial length;
KIRP	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg17356467	chr2:100759845	AFF3	0.55	5.63	0.34	4.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.64	-7.61	-0.44	5.94e-13	Iron status biomarkers;
KIRP	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg07701084	chr6:150067640	NUP43	0.61	7.87	0.45	1.11e-13	Lung cancer;
KIRP	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.86	-10.8	-0.57	1.61e-22	Vitamin D levels;
KIRP	cis	rs7601312	0.869	rs7579057	chr2:229284145	A/T	cg02542817	chr2:229291442	NA	-0.56	-8.62	-0.48	8.52e-16	Schizophrenia;
KIRP	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.06	-0.41	1.65e-11	Mean corpuscular volume;
KIRP	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	1.04	13.37	0.65	5.14e-31	Exhaled nitric oxide output;
KIRP	cis	rs4332428	1.000	rs36000835	chr10:4979788	G/A	cg19648686	chr10:5044992	AKR1C2	-1.02	-8.33	-0.47	5.69e-15	Height;
KIRP	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg18944383	chr4:111397179	ENPEP	-0.52	-8.38	-0.47	4.08e-15	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.2	-0.42	7.26e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.9	-14.7	-0.68	1.54e-35	Breast cancer;
KIRP	cis	rs4302748	0.862	rs59125899	chr7:36182857	G/A	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.63	7.84	0.45	1.41e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.56	-15.56	-0.7	1.74e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.78	0.4	8.73e-11	Bipolar disorder;
KIRP	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.74	-8.88	-0.49	1.45e-16	Alcohol dependence;
KIRP	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.53	-6.83	-0.4	6.68e-11	Body mass index;
KIRP	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg04317338	chr11:64019027	PLCB3	0.79	7.26	0.42	5.05e-12	Mean platelet volume;
KIRP	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.43	-6.77	-0.4	9.52e-11	Platelet distribution width;
KIRP	cis	rs858239	0.539	rs6975852	chr7:23186654	T/C	cg23682824	chr7:23144976	KLHL7	0.49	5.63	0.34	5.03e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	7.43	0.43	1.83e-12	Rheumatoid arthritis;
KIRP	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg06634786	chr22:41940651	POLR3H	-0.46	-5.34	-0.32	2.14e-7	Neuroticism;
KIRP	cis	rs2591576	0.546	rs7734499	chr5:165432611	A/C	cg13976338	chr5:165423657	NA	-0.8	-12.55	-0.62	2.87e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.58	-7.22	-0.42	6.41e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.43	5.63	0.34	4.92e-8	Height;
KIRP	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-1.07	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	cis	rs7084402	0.967	rs1820542	chr10:60315643	T/C	cg05938607	chr10:60274200	BICC1	-0.38	-9.13	-0.5	2.57e-17	Refractive error;
KIRP	trans	rs2071199	0.515	rs2425638	chr20:43026629	C/T	cg19644018	chr1:36549719	TEKT2	0.55	6.06	0.36	5.16e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-10.07	-0.54	3.3e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4594175	0.926	rs10873044	chr14:51615856	T/C	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.54	6.71	0.39	1.3100000000000001e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11997175	0.935	rs6990082	chr8:33708034	C/A	cg04338863	chr8:33670619	NA	0.39	5.08	0.31	7.41e-7	Body mass index;
KIRP	cis	rs501120	1.000	rs665855	chr10:44757751	T/C	cg09554077	chr10:44749378	NA	0.7	10.63	0.56	5.74e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.59	8.2	0.46	1.34e-14	Mean corpuscular volume;
KIRP	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg10223061	chr2:219282414	VIL1	0.41	6.47	0.38	5.38e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg04731861	chr2:219085781	ARPC2	0.27	6.93	0.4	3.61e-11	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.76	-10.22	-0.55	1.18e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7224685	0.569	rs8082227	chr17:3991563	C/T	cg11204139	chr17:3907470	NA	0.57	5.26	0.32	3.13e-7	Type 2 diabetes;
KIRP	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4516970	0.655	rs73781666	chr6:160206106	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	-0.73	-4.9	-0.3	1.73e-6	Iron status biomarkers;
KIRP	cis	rs17123764	0.818	rs2005195	chr12:49983479	A/G	cg20471783	chr12:50157085	TMBIM6	0.33	5.05	0.31	8.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg26531700	chr6:26746687	NA	0.45	6.44	0.38	6.24e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg09408571	chr1:101003634	GPR88	0.24	5.47	0.33	1.12e-7	Monocyte count;
KIRP	cis	rs12620999	0.941	rs10929213	chr2:238020637	A/G	cg15976283	chr2:238042351	NA	0.38	5.1	0.31	6.77e-7	Systemic lupus erythematosus;
KIRP	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.46	-6.87	-0.4	5.37e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6968419	0.747	rs9969224	chr7:115861660	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg00277334	chr10:82204260	NA	-0.44	-4.9	-0.3	1.76e-6	Post bronchodilator FEV1;
KIRP	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.65	0.34	4.39e-8	Aortic root size;
KIRP	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.46	-6.42	-0.38	6.97e-10	Coronary artery disease;
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg21064579	chr19:49206444	FUT2	0.59	8.84	0.49	1.93e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27428660	chr1:54519174	C1orf83;TMEM59	0.45	6.07	0.36	4.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.64	-8.89	-0.49	1.33e-16	Breast cancer;
KIRP	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	0.99	7.71	0.44	3.02e-13	Arsenic metabolism;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16524936	chr4:1340807	KIAA1530	-0.5	-6.31	-0.37	1.27e-9	Longevity;
KIRP	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.59	6.3	0.37	1.4e-9	Alcohol dependence;
KIRP	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs35740288	0.721	rs4843093	chr15:86237433	G/A	cg17133734	chr15:86042851	AKAP13	-0.48	-5.27	-0.32	2.93e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22509189	chr2:225307070	NA	-0.53	-6.16	-0.37	2.97e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs1165472	0.588	rs7540786	chr1:56119747	G/T	cg11523071	chr1:56160889	NA	0.42	6.06	0.36	5.17e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.08	-0.41	1.48e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg13145017	chr7:150757087	SLC4A2	0.48	6.03	0.36	6e-9	DNA methylation (variation);
KIRP	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg00334542	chr7:100209784	MOSPD3	-0.59	-5.3	-0.32	2.57e-7	Other erythrocyte phenotypes;
KIRP	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs9469913	0.740	rs2814977	chr6:34576433	G/A	cg14254433	chr6:34482411	PACSIN1	-0.44	-5.33	-0.32	2.25e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs34286592	1.000	rs3815824	chr16:29852860	C/T	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	4.94	0.3	1.45e-6	Multiple sclerosis;
KIRP	cis	rs4936894	0.500	rs4935875	chr11:124130019	G/C	cg27160556	chr11:124181099	OR8D1	-0.38	-5.6	-0.34	5.85e-8	Aging (time to death);
KIRP	cis	rs3736594	1.000	rs13013484	chr2:27988821	G/A	cg27432699	chr2:27873401	GPN1	-0.55	-7.19	-0.42	7.53e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.74	-0.39	1.14e-10	Morning vs. evening chronotype;
KIRP	cis	rs13315871	0.746	rs35674270	chr3:58209954	A/G	cg20936604	chr3:58311152	NA	-0.61	-4.93	-0.3	1.5e-6	Cholesterol, total;
KIRP	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.26	26.19	0.86	4.3e-73	IgG glycosylation;
KIRP	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.7	-8.97	-0.5	7.82e-17	Blood metabolite levels;
KIRP	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg00405596	chr8:11794950	NA	-0.48	-6.11	-0.36	3.83e-9	Retinal vascular caliber;
KIRP	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg21535247	chr6:8435926	SLC35B3	-0.51	-6.63	-0.39	2.13e-10	Motion sickness;
KIRP	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.62e-12	Menopause (age at onset);
KIRP	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.53	-7.34	-0.42	3.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6681460	0.966	rs10789215	chr1:67151185	C/T	cg13052034	chr1:66999238	SGIP1	-0.44	-5.93	-0.35	1.02e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg12131826	chr15:77904385	NA	0.42	5.67	0.34	3.97e-8	Type 2 diabetes;
KIRP	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	8.29	0.47	7.41e-15	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-16.57	-0.73	6.43e-42	Height;
KIRP	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.5	-0.33	9.61e-8	Morning vs. evening chronotype;
KIRP	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	1.05	10.98	0.57	4.26e-23	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.76	-0.34	2.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.7	-0.49	4.81e-16	Obesity-related traits;
KIRP	cis	rs2224391	0.628	rs2773310	chr6:5250828	C/T	cg13962347	chr6:5174647	LYRM4	-0.72	-9.98	-0.54	6.29e-20	Height;
KIRP	cis	rs11997175	0.603	rs1603197	chr8:33966328	C/T	ch.8.33884649F	chr8:33765107	NA	0.5	5.4	0.33	1.57e-7	Body mass index;
KIRP	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.65	9.04	0.5	4.94e-17	Dental caries;
KIRP	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.7	6.9	0.4	4.48e-11	Prostate cancer;
KIRP	cis	rs12476592	0.571	rs1446565	chr2:63731575	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg09695851	chr17:3907499	NA	-0.82	-15.02	-0.69	1.27e-36	Type 2 diabetes;
KIRP	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.37	5.0	0.3	1.11e-6	Total body bone mineral density;
KIRP	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg14675211	chr2:100938903	LONRF2	0.5	6.76	0.4	9.83e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6921919	0.583	rs6922169	chr6:28382932	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.38	-0.38	8.49e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6681460	0.649	rs1338184	chr1:67005072	C/T	cg02459107	chr1:67143332	SGIP1	-0.38	-5.43	-0.33	1.36e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs140839642	1	rs140839642	chr11:102728812	T/A	cg19620758	chr11:102826565	MMP13	0.69	6.19	0.37	2.55e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs13102973	0.720	rs67429820	chr4:135888003	G/A	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs10832963	0.626	rs4757674	chr11:18619119	T/C	cg09201001	chr11:18656081	SPTY2D1	0.63	8.41	0.47	3.44e-15	Breast cancer;
KIRP	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg07382826	chr16:28625726	SULT1A1	0.45	4.97	0.3	1.24e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.62	7.6	0.44	6.4e-13	Alzheimer's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12698834	chr17:18128735	LLGL1	0.47	6.04	0.36	5.57e-9	Myopia (pathological);
KIRP	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.59	-0.48	9.83e-16	Neuroticism;
KIRP	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.47	-0.52	2.36e-18	Personality dimensions;
KIRP	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.74	0.44	2.61e-13	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg24826892	chr11:71159390	DHCR7	-0.46	-5.04	-0.31	9.15e-7	Vitamin D levels;
KIRP	cis	rs311392	0.902	rs438437	chr8:55094187	G/C	cg11783602	chr8:55087084	NA	-0.58	-7.24	-0.42	5.82e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25951580	chr19:58962937	ZNF324B	-0.51	-6.85	-0.4	5.88e-11	Electrocardiographic conduction measures;
KIRP	cis	rs9826463	0.757	rs66597875	chr3:142264782	T/C	cg20824294	chr3:142316082	PLS1	0.38	6.17	0.37	2.73e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.14	-0.41	1.03e-11	Vitiligo;
KIRP	trans	rs9944715	0.954	rs4890319	chr18:43812644	T/A	cg01718231	chr17:29326311	RNF135	-0.5	-6.05	-0.36	5.24e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	7.0	0.41	2.44e-11	Monocyte count;
KIRP	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.56e-25	Diabetic kidney disease;
KIRP	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.49	4.88	0.3	1.91e-6	Recombination rate (females);
KIRP	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.8	0.4	7.69e-11	Bipolar disorder;
KIRP	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg09904177	chr6:26538194	HMGN4	-0.47	-5.64	-0.34	4.77e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-1.22	-12.46	-0.62	5.86e-28	Post bronchodilator FEV1;
KIRP	cis	rs656319	0.580	rs13279701	chr8:9969450	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-5.08	-0.31	7.58e-7	Myopia (pathological);
KIRP	cis	rs8077577	0.895	rs3088233	chr17:18112675	C/T	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18884271	chr12:65641969	LEMD3	-0.48	-7.03	-0.41	2e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.67	-0.34	4.07e-8	Depression;
KIRP	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.44	7.25	0.42	5.41e-12	Testicular germ cell tumor;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.25	0.32	3.33e-7	Alzheimer's disease;
KIRP	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	1e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.11	0.41	1.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg18190219	chr22:46762943	CELSR1	-0.72	-6.09	-0.36	4.35e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7327064	0.666	rs9547079	chr13:36863336	T/C	cg13455704	chr13:36871754	C13orf38	0.63	5.59	0.34	6.01e-8	Economic and political preferences;
KIRP	cis	rs7520050	0.966	rs1707340	chr1:46514942	T/C	cg03146154	chr1:46216737	IPP	-0.42	-5.48	-0.33	1.05e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	6.37	0.38	9.29e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-1.06	-10.24	-0.55	1.01e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.2	22.31	0.82	4.98e-61	Schizophrenia;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09464028	chr2:128744380	SAP130	1.15	6.68	0.39	1.56e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	10.4	0.55	3.11e-21	Monocyte percentage of white cells;
KIRP	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.17	-0.42	8.51e-12	Bone mineral density;
KIRP	cis	rs7096127	0.966	rs2366907	chr10:24499924	A/G	cg04122385	chr10:24535410	KIAA1217;PRINS	0.41	5.04	0.31	9.02e-7	Lobe attachment (rater scored);
KIRP	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg12856521	chr11:46389249	DGKZ	0.54	6.9	0.4	4.3e-11	Crohn's disease;
KIRP	cis	rs78487399	0.808	rs10203174	chr2:43690030	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.83	-0.35	1.74e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Colorectal cancer;
KIRP	cis	rs11955175	1.000	rs77394428	chr5:40743517	A/G	cg05478818	chr5:40835740	RPL37	0.71	5.02	0.3	1.01e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.59	8.47	0.48	2.23e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg25288420	chr1:78511713	GIPC2	0.47	6.43	0.38	6.56e-10	Obesity-related traits;
KIRP	cis	rs7617480	0.756	rs990211	chr3:48721040	A/G	cg07636037	chr3:49044803	WDR6	0.68	6.31	0.37	1.3e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs6732160	0.525	rs2303907	chr2:73470497	T/C	cg01422370	chr2:73384389	NA	0.43	5.78	0.35	2.29e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.91	0.45	8.92e-14	Height;
KIRP	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.52	-0.33	8.69e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7116495	1.000	rs6592455	chr11:71689541	C/T	cg26138937	chr11:71823887	C11orf51	0.73	5.8	0.35	1.98e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7849270	1.000	rs1009242	chr9:131916832	A/G	cg13538475	chr9:131942899	NA	-0.35	-5.63	-0.34	4.89e-8	Blood metabolite ratios;
KIRP	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.38	-0.38	8.92e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.7	9.97	0.54	7.02e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7221595	0.825	rs12951359	chr17:3921731	T/A	cg21851534	chr17:3907994	ZZEF1	0.55	5.53	0.33	8.08e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	9.66	0.52	6.29e-19	Ileal carcinoids;
KIRP	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	6.07	0.36	4.69e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17065868	1.000	rs9525987	chr13:45171831	A/G	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	1.01	17.67	0.75	1.13e-45	Breast cancer;
KIRP	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	6.96	0.41	3.01e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.57	-0.68	4.3e-35	Primary sclerosing cholangitis;
KIRP	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg06212747	chr3:49208901	KLHDC8B	0.47	5.57	0.33	6.57e-8	Resting heart rate;
KIRP	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.56	-7.24	-0.42	5.88e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg04310649	chr10:35416472	CREM	0.52	6.22	0.37	2.17e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-6.18	-0.37	2.65e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg24687543	chr11:63912206	MACROD1	0.52	4.94	0.3	1.42e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.83	-13.21	-0.64	1.83e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.46	-6.06	-0.36	4.95e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.45	0.38	5.83e-10	Mean corpuscular volume;
KIRP	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.69	7.93	0.45	7.78e-14	Carotid intima media thickness;
KIRP	cis	rs72653721	0.627	rs12662634	chr6:11074191	G/A	cg13562911	chr6:11044106	ELOVL2	0.51	4.85	0.3	2.23e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs2625529	0.652	rs8023788	chr15:72459847	A/G	cg16672083	chr15:72433130	SENP8	0.45	6.19	0.37	2.52e-9	Red blood cell count;
KIRP	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.48	-6.14	-0.36	3.35e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs997295	1.000	rs11630417	chr15:68012609	T/C	cg14210607	chr15:68128175	NA	-0.31	-5.06	-0.31	8.37e-7	Motion sickness;
KIRP	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.51	-0.38	4.07e-10	Coronary artery disease;
KIRP	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg03585969	chr10:35415529	CREM	0.75	9.28	0.51	9.02e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.16	-0.5	2.13e-17	Colorectal cancer;
KIRP	cis	rs72829446	0.530	rs8075007	chr17:7374507	A/T	cg02795151	chr17:7402630	POLR2A	0.75	7.43	0.43	1.83e-12	Androgen levels;
KIRP	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.88e-18	Height;
KIRP	cis	rs10924970	0.967	rs3845566	chr1:235449757	T/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.73e-7	Asthma;
KIRP	cis	rs1629083	0.967	rs4936425	chr11:118126904	C/T	cg18857871	chr11:118064634	AMICA1	0.62	8.29	0.47	7.39e-15	Lung cancer;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-6.02	-0.36	6.16e-9	Lung cancer;
KIRP	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg09873164	chr1:152488093	CRCT1	0.51	6.46	0.38	5.44e-10	Hair morphology;
KIRP	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.37	-0.32	1.79e-7	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	7.09	0.41	1.39e-11	Platelet count;
KIRP	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg07810366	chr2:100720526	AFF3	-0.33	-5.73	-0.34	2.89e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.61	0.48	8.71e-16	Electroencephalogram traits;
KIRP	cis	rs7523050	0.730	rs67008022	chr1:109487904	G/A	cg08274380	chr1:109419600	GPSM2	0.71	6.01	0.36	6.52e-9	Fat distribution (HIV);
KIRP	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg06204229	chr3:52865917	ITIH4	0.57	6.65	0.39	1.93e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.45	6.21	0.37	2.3e-9	Sitting height ratio;
KIRP	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.78	0.4	8.89e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.38	6.36	0.38	9.91e-10	Heart rate;
KIRP	cis	rs2625529	0.824	rs2415121	chr15:72134018	C/T	cg16672083	chr15:72433130	SENP8	-0.46	-6.42	-0.38	6.92e-10	Red blood cell count;
KIRP	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.6	5.84	0.35	1.67e-8	Plateletcrit;
KIRP	trans	rs656319	0.513	rs688541	chr8:9818000	T/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-7.29	-0.42	4.11e-12	Myopia (pathological);
KIRP	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.96	-14.99	-0.69	1.65e-36	Height;
KIRP	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-6.02	-0.36	6.29e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.75	-9.87	-0.53	1.38e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs5753618	0.561	rs2283881	chr22:31638932	G/A	cg22777020	chr22:31556080	RNF185	-0.51	-5.4	-0.33	1.56e-7	Colorectal cancer;
KIRP	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.85	11.88	0.6	5.09e-26	Monocyte count;
KIRP	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg05973401	chr12:123451056	ABCB9	0.51	4.86	0.3	2.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.57	0.33	6.66e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg21546286	chr11:48923668	NA	-0.47	-6.15	-0.36	3.17e-9	HDL cholesterol;
KIRP	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg18016565	chr1:150552671	MCL1	-0.35	-5.28	-0.32	2.78e-7	Tonsillectomy;
KIRP	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	1.11	16.31	0.72	4.73e-41	Breast cancer;
KIRP	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg13978929	chr19:21580086	ZNF493	0.52	5.02	0.3	9.85e-7	Pain;
KIRP	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg18305652	chr10:134549665	INPP5A	0.49	7.5	0.43	1.13e-12	Migraine;
KIRP	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.14e-20	Alzheimer's disease;
KIRP	cis	rs71597109	0.681	rs4699261	chr4:102725474	A/G	cg14855874	chr4:102712397	BANK1	-0.41	-5.38	-0.32	1.77e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-7.58	-0.44	6.89e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00149659	chr3:10157352	C3orf10	0.83	8.87	0.49	1.55e-16	Alzheimer's disease;
KIRP	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.23	20.46	0.79	5.11e-55	Cognitive function;
KIRP	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.62	-6.76	-0.4	1.01e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.46	6.46	0.38	5.67e-10	Coronary artery disease;
KIRP	cis	rs4783244	0.897	rs4783242	chr16:82651428	C/A	cg09415485	chr16:82663111	CDH13	-0.28	-5.25	-0.32	3.24e-7	Adiponectin levels;
KIRP	cis	rs13401104	0.686	rs72620812	chr2:237118765	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-4.87	-0.3	1.97e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg02569458	chr12:86230093	RASSF9	0.38	5.52	0.33	8.68e-8	Major depressive disorder;
KIRP	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg16141378	chr3:129829833	LOC729375	0.52	6.53	0.38	3.67e-10	Retinal vascular caliber;
KIRP	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg19761014	chr17:28927070	LRRC37B2	0.64	4.88	0.3	1.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.6	-7.25	-0.42	5.34e-12	Body mass index;
KIRP	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.48	-5.89	-0.35	1.25e-8	Initial pursuit acceleration;
KIRP	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg16672083	chr15:72433130	SENP8	0.41	5.89	0.35	1.24e-8	Red blood cell count;
KIRP	cis	rs2281603	0.570	rs28469649	chr14:64972249	G/C	cg01860774	chr14:64969374	ZBTB25	0.35	5.65	0.34	4.35e-8	Lymphocyte counts;
KIRP	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg01411142	chr8:19674711	INTS10	-0.52	-5.86	-0.35	1.49e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7116495	1.000	rs4945434	chr11:71759087	A/G	cg11196788	chr11:71737549	NUMA1	-0.57	-5.11	-0.31	6.34e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs66561647	0.719	rs7821928	chr8:128939295	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.53	6.53	0.38	3.83e-10	Hemoglobin concentration;
KIRP	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.7	8.47	0.47	2.32e-15	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.38	-0.32	1.74e-7	Coronary artery disease;
KIRP	cis	rs35771425	1.000	rs11579557	chr1:211619703	A/G	cg10512769	chr1:211675356	NA	0.51	4.99	0.3	1.15e-6	Educational attainment (years of education);
KIRP	cis	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg26876637	chr1:152193138	HRNR	0.59	8.15	0.46	1.91e-14	Atopic dermatitis;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21745110	chr11:19798742	NAV2	0.42	6.12	0.36	3.76e-9	Cancer;
KIRP	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg18944383	chr4:111397179	ENPEP	0.53	9.27	0.51	1.01e-17	Height;
KIRP	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg20312557	chr2:97357134	FER1L5	-0.79	-5.51	-0.33	9.19e-8	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.84	13.17	0.64	2.41e-30	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10403048	chr19:15490832	AKAP8	0.52	6.1	0.36	4.15e-9	Smoking initiation;
KIRP	cis	rs3947	1.000	rs1736084	chr8:11703657	C/T	cg21775007	chr8:11205619	TDH	-0.48	-4.89	-0.3	1.79e-6	Blood protein levels;
KIRP	cis	rs151997	0.853	rs3846498	chr5:50253625	A/C	cg06027927	chr5:50259733	NA	-0.6	-8.04	-0.46	3.74e-14	Callous-unemotional behaviour;
KIRP	trans	rs7084921	0.608	rs12779818	chr10:101866118	G/A	cg13808641	chr9:96006533	WNK2	-0.41	-6.28	-0.37	1.53e-9	Bone mineral density;
KIRP	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.81	-0.45	1.62e-13	Total cholesterol levels;
KIRP	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.66	-0.39	1.77e-10	Systolic blood pressure;
KIRP	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg24498760	chr8:49746867	NA	0.4	4.95	0.3	1.38e-6	Blood metabolite ratios;
KIRP	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.57	-6.38	-0.38	8.82e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6568686	0.730	rs6936935	chr6:111845774	T/C	cg15721981	chr6:111408429	SLC16A10	-0.69	-6.27	-0.37	1.57e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg04455712	chr21:45112962	RRP1B	-0.41	-5.57	-0.33	6.74e-8	Mean corpuscular volume;
KIRP	cis	rs72627509	0.951	rs72627508	chr4:57831564	C/G	cg26694713	chr4:57773883	REST	0.54	4.98	0.3	1.2e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7172677	0.737	rs11072528	chr15:75436455	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.06	-0.31	8.13e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14562915	chr15:71055704	UACA	0.53	6.74	0.39	1.13e-10	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg13978929	chr19:21580086	ZNF493	0.49	4.86	0.3	2.06e-6	Pain;
KIRP	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11225247	0.655	rs112276332	chr11:102226953	A/G	cg06323957	chr11:102217781	BIRC2	0.77	5.0	0.3	1.11e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg10254082	chr7:997346	NA	0.47	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.55	-6.33	-0.37	1.15e-9	Breast cancer;
KIRP	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.68	9.41	0.51	3.63e-18	Lung cancer;
KIRP	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.62	0.44	5.34e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.17	-0.31	4.92e-7	Metabolite levels;
KIRP	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.56	-7.13	-0.41	1.11e-11	Blood protein levels;
KIRP	cis	rs4356932	0.691	rs6827617	chr4:76916146	G/A	cg00809888	chr4:76862425	NAAA	0.49	6.94	0.4	3.44e-11	Blood protein levels;
KIRP	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs77861329	0.670	rs9828327	chr3:52120209	T/C	cg08692210	chr3:52188851	WDR51A	0.6	5.92	0.35	1.05e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.48	-8.99	-0.5	6.82e-17	Plateletcrit;Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15214092	chr17:79670496	MRPL12	0.5	6.18	0.37	2.67e-9	Parkinson's disease;
KIRP	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.77	8.34	0.47	5.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	8.86	0.49	1.66e-16	Resting heart rate;
KIRP	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg05340658	chr4:99064831	C4orf37	-0.54	-6.7	-0.39	1.41e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.29	6.19	0.37	2.54e-9	Body mass index;
KIRP	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	1.04	13.47	0.65	2.41e-31	Exhaled nitric oxide output;
KIRP	cis	rs4740619	0.619	rs943788	chr9:16031886	G/A	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs858239	0.539	rs2178140	chr7:23191625	G/C	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs249153	1.000	rs249153	chr12:95324389	A/G	cg15837333	chr12:64519179	SRGAP1	-0.55	-6.19	-0.37	2.54e-9	Alzheimer's disease;
KIRP	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg26965718	chr17:79658957	HGS	-0.63	-6.02	-0.36	6.39e-9	Dental caries;
KIRP	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.63	6.19	0.37	2.56e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg17294928	chr15:75287854	SCAMP5	-0.58	-5.67	-0.34	4.07e-8	Blood trace element (Zn levels);
KIRP	cis	rs16828019	0.929	rs2363805	chr1:41719434	G/T	cg03387723	chr1:41708464	SCMH1	-0.77	-6.79	-0.4	8.12e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-6.07	-0.36	4.84e-9	Blood metabolite levels;
KIRP	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.66	-0.39	1.74e-10	Aortic root size;
KIRP	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.57	-0.48	1.15e-15	Mean corpuscular volume;
KIRP	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	0.95	18.19	0.76	2e-47	Dental caries;
KIRP	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg10047753	chr17:41438598	NA	1.14	17.91	0.75	1.73e-46	Menopause (age at onset);
KIRP	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.09	-0.5	3.39e-17	Neuroticism;
KIRP	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.11	0.41	1.23e-11	Resting heart rate;
KIRP	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg12435725	chr3:58293450	RPP14	-0.47	-5.07	-0.31	7.85e-7	Cholesterol, total;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg15085390	chr1:25573930	C1orf63	-0.58	-6.27	-0.37	1.58e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-8.3	-0.47	6.75e-15	Platelet distribution width;
KIRP	cis	rs193541	0.632	rs1460040	chr5:122105232	A/G	cg19412675	chr5:122181750	SNX24	0.52	5.54	0.33	7.95e-8	Glucose homeostasis traits;
KIRP	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg05692746	chr2:100937584	LONRF2	-0.37	-4.87	-0.3	2.01e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	1.05	11.58	0.59	4.72e-25	Height;
KIRP	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.45	-0.38	5.89e-10	Type 2 diabetes;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.43	4.9	0.3	1.72e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11955398	0.521	rs6449489	chr5:60026236	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.12	-0.31	6.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.59	8.83	0.49	1.98e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.14e-21	Alzheimer's disease (late onset);
KIRP	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.14e-7	Aortic root size;
KIRP	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg09990169	chr2:241835740	C2orf54	-0.47	-6.92	-0.4	3.84e-11	Urinary metabolites;
KIRP	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg04374321	chr14:90722782	PSMC1	0.57	6.93	0.4	3.7e-11	Longevity;
KIRP	cis	rs2594989	0.943	rs2454493	chr3:11506458	A/G	cg01796438	chr3:11312864	ATG7	-0.6	-7.79	-0.44	1.87e-13	Circulating chemerin levels;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-9.23	-0.51	1.28e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs785830	0.558	rs573860	chr9:257034	A/G	cg14500300	chr9:211689	NA	0.37	4.87	0.3	1.97e-6	Platelet distribution width;
KIRP	cis	rs1190552	0.846	rs11160683	chr14:102933347	A/G	cg10241871	chr14:102965420	TECPR2	-0.5	-5.6	-0.34	5.58e-8	Blood protein levels;
KIRP	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg22676075	chr6:135203613	NA	0.52	7.67	0.44	3.9e-13	Red blood cell count;
KIRP	cis	rs7116495	1.000	rs3018302	chr11:71790942	A/C	cg07596299	chr11:71824057	C11orf51	-0.62	-4.93	-0.3	1.49e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg10402321	chr1:26617780	UBXN11	-0.42	-5.33	-0.32	2.2e-7	Monocyte percentage of white cells;
KIRP	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.53	-6.22	-0.37	2.11e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	6.7	0.39	1.41e-10	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24782169	chr11:62554862	TMEM179B	0.52	6.75	0.4	1.08e-10	Parkinson's disease;
KIRP	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.57	7.66	0.44	4.38e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg07636037	chr3:49044803	WDR6	0.53	5.34	0.32	2.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04025307	chr7:1156635	C7orf50	0.57	5.67	0.34	3.98e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg08461772	chr7:95026248	PON3	0.4	5.72	0.34	3.01e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7737355	0.812	rs10059807	chr5:130877684	T/C	cg06307176	chr5:131281290	NA	0.42	5.02	0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg11168104	chr5:1857477	NA	-0.4	-5.13	-0.31	5.93e-7	Cardiovascular disease risk factors;
KIRP	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg17366294	chr4:99064904	C4orf37	0.37	5.0	0.3	1.07e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.13e-12	Uric acid levels;
KIRP	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg22705602	chr4:152727874	NA	-0.51	-8.33	-0.47	5.54e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg15181151	chr6:150070149	PCMT1	0.31	5.28	0.32	2.82e-7	Lung cancer;
KIRP	cis	rs7808935	0.628	rs9791862	chr7:27950760	G/A	cg22168087	chr7:27702803	HIBADH	0.72	7.39	0.43	2.36e-12	Prostate cancer;
KIRP	cis	rs7123876	0.553	rs12099027	chr11:72433920	A/G	cg04827223	chr11:72435913	ARAP1	-0.4	-5.39	-0.32	1.68e-7	Body mass index;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-1.0	-15.83	-0.71	2.18e-39	Gut microbiome composition (winter);
KIRP	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs17401966	0.540	rs4846199	chr1:10283961	A/G	cg19773385	chr1:10388646	KIF1B	-0.44	-6.51	-0.38	4.28e-10	Hepatocellular carcinoma;
KIRP	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg24955955	chr5:415729	AHRR	0.77	6.34	0.37	1.12e-9	Fat distribution (HIV);
KIRP	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg11812906	chr14:75593930	NEK9	0.72	8.83	0.49	1.95e-16	Height;
KIRP	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg17554472	chr22:41940697	POLR3H	-0.61	-6.5	-0.38	4.5e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg10117171	chr1:25599238	RHD	-0.41	-5.52	-0.33	8.78e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05220968	chr6:146057943	EPM2A	0.39	4.98	0.3	1.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg23024343	chr7:107201750	COG5	0.4	4.89	0.3	1.83e-6	Coronary artery disease;
KIRP	cis	rs960902	0.544	rs12151799	chr2:37767862	G/A	cg25341268	chr2:37734390	NA	0.5	6.13	0.36	3.51e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.82	-10.01	-0.54	5.29e-20	Schizophrenia;
KIRP	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg15605315	chr1:45957053	TESK2	0.38	4.88	0.3	1.87e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg21523564	chr15:75251491	NA	0.39	6.08	0.36	4.6e-9	Breast cancer;
KIRP	trans	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	1.06	20.02	0.79	1.53e-53	Heart rate;
KIRP	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg27519958	chr1:161735129	ATF6	-0.68	-8.25	-0.47	9.68e-15	IgG glycosylation;
KIRP	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.84	14.07	0.67	2.2e-33	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.44	5.61	0.34	5.42e-8	Crohn's disease;
KIRP	cis	rs8177876	0.658	rs11150337	chr16:81069317	G/A	cg08591886	chr16:81111003	C16orf46	-0.55	-5.07	-0.31	7.74e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.62	-8.75	-0.49	3.47e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.47	-0.38	5.11e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs17121403	0.661	rs11166402	chr1:100563249	G/A	cg24955406	chr1:100503596	HIAT1	0.76	5.0	0.3	1.09e-6	Pulmonary function decline;
KIRP	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg05347473	chr6:146136440	FBXO30	0.62	8.83	0.49	2.01e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.47	0.43	1.37e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg26754761	chr2:177040938	NA	0.32	5.5	0.33	9.64e-8	IgG glycosylation;
KIRP	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.45	-0.33	1.23e-7	Neuroticism;
KIRP	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02034447	chr16:89574710	SPG7	0.39	4.92	0.3	1.57e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.68	8.5	0.48	1.83e-15	Recalcitrant atopic dermatitis;
KIRP	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.87	9.78	0.53	2.71e-19	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.95	16.65	0.73	3.3e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg03711944	chr11:47377212	SPI1	-0.3	-5.01	-0.3	1.02e-6	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg19906672	chr4:6918868	TBC1D14	0.51	5.33	0.32	2.22e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4776059	0.958	rs35505902	chr15:52888493	A/G	cg22715398	chr15:52968154	KIAA1370	-0.68	-8.15	-0.46	1.88e-14	Schizophrenia;
KIRP	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg23791538	chr6:167370224	RNASET2	-0.47	-5.68	-0.34	3.77e-8	Crohn's disease;
KIRP	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg21775007	chr8:11205619	TDH	0.52	6.43	0.38	6.63e-10	Mood instability;
KIRP	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg01620082	chr3:125678407	NA	-1.04	-6.81	-0.4	7.58e-11	Lung cancer in ever smokers;
KIRP	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg03146154	chr1:46216737	IPP	0.45	5.54	0.33	7.69e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.44	4.96	0.3	1.29e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-0.73	-8.07	-0.46	3.16e-14	Initial pursuit acceleration;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg24742219	chr4:926315	TMEM175;GAK	0.52	6.51	0.38	4.16e-10	DNA methylation (variation);
KIRP	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.52	-4.93	-0.3	1.51e-6	IFN-related cytopenia;
KIRP	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg03808351	chr9:123631620	PHF19	0.46	6.42	0.38	6.99e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs35000415	0.938	rs34381587	chr7:128666825	A/G	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg05272587	chr13:111038400	COL4A2	-0.34	-5.0	-0.3	1.08e-6	White matter hyperintensity burden;
KIRP	cis	rs10513788	0.540	rs1542694	chr3:181982899	C/T	cg01449425	chr3:181957089	NA	0.5	6.92	0.4	3.96e-11	Cognitive function;
KIRP	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg00405596	chr8:11794950	NA	-0.48	-6.43	-0.38	6.42e-10	Mood instability;
KIRP	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-6.11	-0.36	3.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11779988	0.543	rs410445	chr8:17882304	C/T	cg01800426	chr8:17659068	MTUS1	-0.63	-6.3	-0.37	1.36e-9	Breast cancer;
KIRP	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg08461772	chr7:95026248	PON3	0.4	5.76	0.34	2.51e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg11995313	chr8:8860691	ERI1	0.4	5.36	0.32	1.88e-7	Joint mobility (Beighton score);
KIRP	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-7.22	-0.42	6.61e-12	Coronary artery disease;
KIRP	cis	rs4776059	1.000	rs11070907	chr15:52924231	G/T	cg22715398	chr15:52968154	KIAA1370	-0.58	-7.13	-0.41	1.1e-11	Schizophrenia;
KIRP	cis	rs2274273	0.662	rs67215571	chr14:55673723	G/A	cg04306507	chr14:55594613	LGALS3	0.41	5.41	0.33	1.51e-7	Protein biomarker;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11245990	chr11:68621969	NA	0.38	5.17	0.31	4.89e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg10254082	chr7:997346	NA	0.46	4.88	0.3	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.32	-0.59	3.48e-24	Alzheimer's disease;
KIRP	cis	rs7572644	0.665	rs4666017	chr2:28040525	C/A	cg27432699	chr2:27873401	GPN1	0.48	5.49	0.33	1.01e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs4750440	0.642	rs1574583	chr10:14026870	C/G	cg27542038	chr10:14027202	FRMD4A	-0.59	-7.45	-0.43	1.56e-12	Adiponectin levels;
KIRP	cis	rs17373728	0.526	rs9886508	chr8:76152991	C/T	cg07016329	chr8:76221503	NA	0.45	6.03	0.36	6.09e-9	Diabetic kidney disease;
KIRP	trans	rs2698530	0.791	rs2698526	chr2:64499523	C/T	cg04647370	chr7:44613073	DDX56	-0.52	-6.3	-0.37	1.38e-9	Iron status biomarkers;
KIRP	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg10434728	chr15:90938212	IQGAP1	-0.42	-8.01	-0.45	4.61e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19638349	chr2:18741870	RDH14	0.47	6.1	0.36	4.02e-9	Parkinson's disease;
KIRP	cis	rs12360000	0.800	rs11250869	chr10:1917721	T/C	cg26364871	chr10:1889757	NA	-0.52	-6.08	-0.36	4.44e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.22	-0.32	3.8e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg23587288	chr2:27483067	SLC30A3	-0.67	-7.57	-0.43	7.72e-13	Blood metabolite levels;
KIRP	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg17145862	chr1:211918768	LPGAT1	-0.91	-12.97	-0.64	1.12e-29	Leprosy;
KIRP	cis	rs7236492	0.532	rs8090536	chr18:77195553	C/T	cg15644404	chr18:77186268	NFATC1	-0.56	-6.03	-0.36	6.11e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6723226	0.503	rs4952262	chr2:32597234	G/A	cg02381751	chr2:32503542	YIPF4	-0.48	-5.8	-0.35	2e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.67	9.49	0.52	2.17e-18	Colorectal cancer;
KIRP	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.83	9.65	0.52	6.73e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.52	0.38	4.04e-10	Morning vs. evening chronotype;
KIRP	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg02319466	chr17:76381040	PGS1	0.46	6.4	0.38	7.86e-10	HDL cholesterol levels;
KIRP	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.52	0.38	3.87e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.96	0.45	6.5e-14	Height;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg05255149	chr17:80675120	FN3KRP	0.47	5.13	0.31	5.77e-7	Glycated hemoglobin levels;
KIRP	cis	rs4722404	0.800	rs6943609	chr7:3141596	G/A	cg19214707	chr7:3157722	NA	0.45	5.42	0.33	1.44e-7	Atopic dermatitis;
KIRP	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.55	-0.39	3.4e-10	Joint mobility (Beighton score);
KIRP	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg23587288	chr2:27483067	SLC30A3	-0.67	-7.77	-0.44	2.11e-13	Blood metabolite levels;
KIRP	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg02297831	chr4:17616191	MED28	-0.55	-6.48	-0.38	5.02e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg21827317	chr3:136751795	NA	0.37	5.18	0.31	4.61e-7	Neuroticism;
KIRP	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.95	0.5	8.75e-17	Colorectal cancer;
KIRP	cis	rs11628318	0.515	rs7152144	chr14:103126101	C/T	cg01864069	chr14:103024347	NA	0.43	5.26	0.32	3.11e-7	Platelet count;
KIRP	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg11584989	chr19:19387371	SF4	0.41	5.23	0.32	3.59e-7	Tonsillectomy;
KIRP	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.33	-4.86	-0.3	2.14e-6	Monocyte count;
KIRP	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.88	-12.18	-0.61	5.08e-27	Platelet distribution width;
KIRP	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18932078	chr1:2524107	MMEL1	-0.48	-6.76	-0.4	1.02e-10	Ulcerative colitis;
KIRP	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg23202291	chr11:1979235	NA	0.42	5.41	0.33	1.51e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs580438	0.529	rs2062851	chr3:13434264	G/A	cg10657019	chr3:13328039	NA	-0.48	-6.16	-0.37	2.97e-9	Myringotomy;
KIRP	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg02462569	chr6:150064036	NUP43	-0.48	-6.94	-0.4	3.48e-11	Lung cancer;
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg11945507	chr8:142233382	SLC45A4	-0.47	-6.23	-0.37	2e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4523957	0.579	rs2270478	chr17:2089848	G/A	cg16513277	chr17:2031491	SMG6	-0.71	-10.28	-0.55	7.57e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg03653399	chr8:142233436	SLC45A4	-0.95	-14.83	-0.69	5.6e-36	Immature fraction of reticulocytes;
KIRP	cis	rs58785573	0.513	rs7678668	chr4:38592819	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.88	0.3	1.95e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs4805272	0.962	rs1363328	chr19:29325563	A/T	cg15000279	chr19:29285009	NA	-0.36	-5.06	-0.31	8.1e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6442310	0.534	rs2028759	chr3:12418612	C/T	cg15873301	chr3:12045459	SYN2	0.42	5.69	0.34	3.65e-8	Hematocrit;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14155567	chr7:5540534	FBXL18	0.47	6.05	0.36	5.3300000000000004e-09	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg13385521	chr17:29058706	SUZ12P	-0.53	-5.16	-0.31	5.04e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.8	10.22	0.55	1.19e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs13170463	0.579	rs17268712	chr5:8035843	A/C	cg03862380	chr20:43029895	HNF4A	-0.41	-6.42	-0.38	7.07e-10	Colorectal cancer;
KIRP	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-9.01	-0.5	6.07e-17	Neuroticism;
KIRP	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.8	7.73	0.44	2.74e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.38	-5.14	-0.31	5.73e-7	Blood metabolite levels;
KIRP	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg01721255	chr8:58191610	C8orf71	0.5	4.89	0.3	1.85e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.38	0.51	4.52e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg26134248	chr17:3907702	NA	0.44	6.13	0.36	3.48e-9	Type 2 diabetes;
KIRP	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.55	7.58	0.43	7.25e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg13047869	chr3:10149882	C3orf24	0.51	5.05	0.31	8.54e-7	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08452348	chr5:134303703	CATSPER3	-0.45	-6.71	-0.39	1.35e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.76	-0.63	5.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg20742385	chr13:113633654	MCF2L	-0.33	-5.24	-0.32	3.52e-7	Systolic blood pressure;
KIRP	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.56	0.48	1.21e-15	Motion sickness;
KIRP	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.56	-6.76	-0.4	1e-10	Aortic root size;
KIRP	cis	rs1524927	1.000	rs12704872	chr7:96334616	T/C	cg00227355	chr7:96336147	SHFM1	-0.32	-4.86	-0.3	2.12e-6	Total body bone mineral density;
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.77	12.2	0.61	4.53e-27	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg18461458	chr19:21324796	ZNF431	0.48	5.08	0.31	7.57e-7	Pain;
KIRP	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg17340268	chr14:105411764	AHNAK2	-0.39	-4.97	-0.3	1.26e-6	Rheumatoid arthritis;
KIRP	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg05973401	chr12:123451056	ABCB9	-0.61	-5.55	-0.33	7.41e-8	Neutrophil percentage of white cells;
KIRP	trans	rs12517041	0.935	rs4701359	chr5:23284257	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.25	-0.47	9.63e-15	Calcium levels;
KIRP	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.57	7.32	0.42	3.53e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg00083206	chr6:110721305	DDO	-0.44	-6.74	-0.39	1.14e-10	Platelet distribution width;
KIRP	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07308232	chr7:1071921	C7orf50	-0.72	-9.87	-0.53	1.4e-19	Longevity;Endometriosis;
KIRP	cis	rs17641971	0.684	rs10957363	chr8:49999175	T/A	cg00325661	chr8:49890786	NA	0.44	5.72	0.34	3.04e-8	Blood metabolite levels;
KIRP	cis	rs12704876	0.530	rs2177675	chr7:96342253	A/T	cg03808172	chr7:96339361	SHFM1	0.62	8.5	0.48	1.9e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-5.72	-0.34	3.03e-8	Coronary artery disease;
KIRP	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	cis	rs12096438	0.903	rs4418583	chr1:25893242	T/C	cg21452808	chr1:25900135	NA	0.4	6.36	0.38	9.74e-10	Platelet count;Mean platelet volume;
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg11168104	chr5:1857477	NA	-0.4	-5.07	-0.31	7.87e-7	Cardiovascular disease risk factors;
KIRP	cis	rs34779708	0.733	rs59287215	chr10:35543994	C/T	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.7	9.1	0.5	3.19e-17	Height;
KIRP	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg20651018	chr11:3035856	CARS	-0.38	-5.33	-0.32	2.25e-7	Longevity;
KIRP	cis	rs4356932	1.000	rs8878	chr4:76942300	C/T	cg19388996	chr4:76862389	NAAA	-0.39	-5.03	-0.31	9.27e-7	Blood protein levels;
KIRP	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg09201719	chr10:104596890	CYP17A1	0.37	5.25	0.32	3.24e-7	Arsenic metabolism;
KIRP	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-7.04	-0.41	1.95e-11	Morning vs. evening chronotype;
KIRP	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg04727924	chr7:799746	HEATR2	-0.76	-8.57	-0.48	1.14e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.6	-6.77	-0.4	9.54e-11	Response to antineoplastic agents;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22901337	chr14:23790498	PABPN1	-0.55	-6.45	-0.38	5.97e-10	Interleukin-4 levels;
KIRP	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs848512	0.533	rs4141686	chr2:36712597	G/A	cg09467607	chr2:36825704	FEZ2	0.38	5.35	0.32	2.02e-7	IgE levels in asthmatics;
KIRP	cis	rs17123764	0.710	rs7952734	chr12:50062681	A/C	cg02054252	chr12:50078554	FMNL3	0.47	5.39	0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.76	10.62	0.56	6.01e-22	Schizophrenia;
KIRP	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.57	7.04	0.41	1.94e-11	Platelet count;
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.29	-0.37	1.45e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.6	11.61	0.6	3.84e-25	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.91	-0.4	4.07e-11	Response to antipsychotic treatment;
KIRP	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.86	-11.93	-0.61	3.52e-26	Post bronchodilator FEV1;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg23101091	chr17:38296248	CASC3	0.48	6.08	0.36	4.54e-9	Asthma;
KIRP	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg06935464	chr4:38784597	TLR10	0.5	4.86	0.3	2.12e-6	Breast cancer;
KIRP	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.72	9.75	0.53	3.45e-19	Breast cancer;
KIRP	cis	rs3735025	0.963	rs320705	chr7:137051382	G/T	cg13839563	chr7:136910420	NA	0.39	4.94	0.3	1.47e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09730820	chr16:15736852	NDE1;MIR484;KIAA0430	0.5	6.75	0.4	1.06e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3812111	0.510	rs9387390	chr6:116584080	T/C	cg18828861	chr6:116576566	TSPYL4	0.42	4.87	0.3	1.98e-6	Age-related macular degeneration;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06558372	chr1:65990448	LEPR	0.49	6.04	0.36	5.53e-9	Interleukin-4 levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22246187	chr4:2471515	RNF4	0.5	7.07	0.41	1.56e-11	Survival in pancreatic cancer;
KIRP	cis	rs4654899	1.000	rs6663452	chr1:21423154	T/C	cg05370193	chr1:21551575	ECE1	0.43	5.93	0.35	1.01e-8	Superior frontal gyrus grey matter volume;
KIRP	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.5	-0.78	7.71e-52	Height;
KIRP	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg26566898	chr11:117069891	TAGLN	-0.38	-4.91	-0.3	1.64e-6	Blood protein levels;
KIRP	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg05719877	chr11:114271629	C11orf71;RBM7	-0.47	-6.31	-0.37	1.3e-9	Platelet-derived growth factor BB levels;
KIRP	cis	rs6579956	0.517	rs6579952	chr5:152024757	C/T	cg12297329	chr5:152029980	NA	0.44	5.79	0.35	2.13e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg16127683	chr15:40268777	EIF2AK4	-0.53	-6.07	-0.36	4.86e-9	Corneal curvature;
KIRP	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg03702533	chr15:77830579	NA	0.33	5.0	0.3	1.12e-6	Type 2 diabetes;
KIRP	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg03647239	chr10:116582469	FAM160B1	0.52	5.95	0.35	9.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.45	-9.09	-0.5	3.46e-17	Rheumatoid arthritis;
KIRP	cis	rs10488172	0.857	rs17167135	chr7:133223017	A/G	cg10665199	chr7:133106180	EXOC4	0.49	5.24	0.32	3.5e-7	Tonometry;
KIRP	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.53	0.38	3.74e-10	Morning vs. evening chronotype;
KIRP	cis	rs12145833	0.596	rs12026068	chr1:243440352	A/G	cg02356786	chr1:243265016	LOC731275	0.86	6.02	0.36	6.25e-9	Obesity (early onset extreme);
KIRP	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.68	-8.34	-0.47	5.26e-15	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.52	7.31	0.42	3.84e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3120667	0.790	rs10888486	chr1:152382062	C/T	cg26876637	chr1:152193138	HRNR	-0.65	-6.26	-0.37	1.72e-9	Eating disorders;
KIRP	cis	rs7539542	0.556	rs6662413	chr1:202888496	C/T	cg08940984	chr1:202857613	RABIF	-0.47	-5.93	-0.35	1.04e-8	Mean platelet volume;
KIRP	cis	rs12780845	1.000	rs34434809	chr10:17187634	G/C	cg01003015	chr10:17271136	VIM	0.45	4.89	0.3	1.83e-6	Homocysteine levels;
KIRP	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-10.33	-0.55	5.02e-21	Morning vs. evening chronotype;
KIRP	cis	rs258892	0.947	rs258894	chr5:72332060	A/T	cg21869765	chr5:72125136	TNPO1	-0.57	-6.35	-0.38	1.03e-9	Small cell lung carcinoma;
KIRP	cis	rs2150410	0.915	rs7276559	chr21:40657021	A/G	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg07212818	chr11:638076	DRD4	-0.38	-4.99	-0.3	1.13e-6	Systemic lupus erythematosus;
KIRP	cis	rs11209002	0.614	rs6670381	chr1:67562106	G/T	cg02640540	chr1:67518911	SLC35D1	0.58	6.47	0.38	5.19e-10	Crohn's disease;
KIRP	cis	rs2916247	1.000	rs894754	chr8:93012369	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.66	-9.18	-0.51	1.86e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg19913688	chr11:428466	ANO9	-0.76	-6.1	-0.36	4.09e-9	Body mass index;
KIRP	trans	rs6601327	0.665	rs11249949	chr8:9655612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.66	-0.44	4.39e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12540874	0.518	rs12718674	chr7:50627130	T/C	cg00647317	chr7:50633725	DDC	0.46	6.72	0.39	1.23e-10	Systemic sclerosis;
KIRP	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.79	7.35	0.42	2.86e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.84	0.49	1.89e-16	Motion sickness;
KIRP	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.17	-0.46	1.62e-14	Calcium levels;
KIRP	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.35	-5.78	-0.35	2.28e-8	Prostate cancer;
KIRP	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05347473	chr6:146136440	FBXO30	0.57	8.14	0.46	1.94e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.43	-6.28	-0.37	1.5e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11987759	chr7:65425863	GUSB	-0.63	-8.38	-0.47	4.07e-15	Aortic root size;
KIRP	cis	rs17001868	0.527	rs9611324	chr22:40781162	T/C	cg07138101	chr22:40742427	ADSL	0.58	7.03	0.41	2.06e-11	Mammographic density (dense area);
KIRP	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg04310649	chr10:35416472	CREM	-0.53	-6.08	-0.36	4.45e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.12	-0.36	3.74e-9	Lung cancer;
KIRP	cis	rs7656342	0.653	rs11726221	chr4:9853863	C/A	cg11266682	chr4:10021025	SLC2A9	0.32	4.98	0.3	1.22e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs867371	0.892	rs4344697	chr15:82545214	A/T	cg00614314	chr15:82944287	LOC80154	0.54	6.21	0.37	2.3e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.74	-0.34	2.71e-8	Educational attainment;
KIRP	cis	rs2573652	1.000	rs2727199	chr15:100514417	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.72	-11.51	-0.59	8.08e-25	Height;
KIRP	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-1.05	-10.81	-0.57	1.57e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.69	-0.44	3.45e-13	Neuroticism;
KIRP	cis	rs6684428	0.611	rs72904468	chr1:56366209	T/C	cg11651538	chr1:56320950	NA	-0.6	-7.86	-0.45	1.17e-13	Airflow obstruction;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11997175	0.550	rs7464954	chr8:33832202	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	6.87	0.4	5.27e-11	Body mass index;
KIRP	cis	rs2916247	0.788	rs1973258	chr8:93121262	A/G	cg10183463	chr8:93005414	RUNX1T1	0.43	5.03	0.31	9.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.51	6.54	0.38	3.57e-10	HDL cholesterol levels;
KIRP	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.48	7.44	0.43	1.64e-12	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg08126542	chr6:37504118	NA	-0.55	-6.36	-0.38	9.96e-10	Cognitive performance;
KIRP	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg15247329	chr7:2764246	NA	-0.35	-4.92	-0.3	1.61e-6	Height;
KIRP	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.73	8.3	0.47	6.84e-15	Gestational age at birth (maternal effect);
KIRP	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.63	-8.12	-0.46	2.29e-14	Colorectal cancer;
KIRP	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.58	7.76	0.44	2.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs17384381	1.000	rs12135333	chr1:85890494	C/A	cg16011679	chr1:85725395	C1orf52	0.82	8.05	0.46	3.56e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9400467	0.506	rs10485124	chr6:111631907	C/G	cg15721981	chr6:111408429	SLC16A10	0.77	7.11	0.41	1.29e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7009516	0.819	rs12542012	chr8:24223031	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.3	6.11	0.36	3.9e-9	Hair greying;
KIRP	cis	rs7404928	0.794	rs72777933	chr16:23871398	C/T	cg21745164	chr16:23765304	CHP2	-0.55	-6.46	-0.38	5.68e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs7106204	1.000	rs7925633	chr11:24214815	A/G	ch.11.24196551F	chr11:24239977	NA	0.84	8.9	0.49	1.28e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	7.02	0.41	2.21e-11	Mean platelet volume;
KIRP	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.71	10.98	0.57	4.21e-23	Noise-induced hearing loss;
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.42	-0.33	1.44e-7	Lung cancer;
KIRP	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.76	9.13	0.5	2.53e-17	Blood trace element (Zn levels);
KIRP	cis	rs6585424	1.000	rs61860024	chr10:81925363	G/A	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs1829883	0.862	rs2460655	chr5:98797742	C/T	cg08333243	chr5:99726346	NA	-0.41	-5.46	-0.33	1.19e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.01	0.57	3.61e-23	Monocyte percentage of white cells;
KIRP	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.33	-0.32	2.22e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08427575	chr7:75988356	YWHAG	-0.45	-6.09	-0.36	4.23e-9	Metabolic traits;
KIRP	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.99	-0.3	1.16e-6	Type 2 diabetes;
KIRP	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg05998816	chr21:47859926	PCNT	0.54	6.07	0.36	4.85e-9	Lymphocyte counts;
KIRP	cis	rs7017914	0.934	rs56043721	chr8:71630427	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.41	-0.47	3.41e-15	Total cholesterol levels;
KIRP	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-4.96	-0.3	1.34e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.44	-5.71	-0.34	3.2e-8	Aortic root size;
KIRP	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	0.79	8.38	0.47	4.23e-15	Pediatric areal bone mineral density (radius);
KIRP	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.26	-0.42	5.01e-12	Type 2 diabetes;
KIRP	cis	rs662064	0.962	rs660725	chr1:10557544	A/G	cg17425144	chr1:10567563	PEX14	0.34	5.8	0.35	2e-8	Asthma;
KIRP	cis	rs7812879	0.516	rs12543308	chr8:11308793	C/G	cg08224773	chr8:11311868	FAM167A	0.39	5.41	0.33	1.49e-7	Systemic lupus erythematosus;
KIRP	cis	rs7771547	0.607	rs584196	chr6:36456243	G/C	cg07856975	chr6:36356162	ETV7	0.35	5.12	0.31	6.07e-7	Platelet distribution width;
KIRP	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.27	-0.37	1.6e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg05340658	chr4:99064831	C4orf37	-0.54	-6.7	-0.39	1.41e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2625529	0.824	rs4238449	chr15:72421603	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg00405596	chr8:11794950	NA	-0.44	-5.63	-0.34	5e-8	Retinal vascular caliber;
KIRP	cis	rs11955175	1.000	rs73080591	chr5:40634687	T/C	cg04002187	chr5:40835754	RPL37	0.68	5.52	0.33	8.57e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-1.09	-20.38	-0.79	9.75e-55	Bone mineral density;
KIRP	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.62	-7.71	-0.44	3.21e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg05991184	chr2:219186017	PNKD	-0.34	-4.86	-0.3	2.07e-6	Colorectal cancer;
KIRP	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.47	-6.81	-0.4	7.34e-11	Schizophrenia;
KIRP	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg03465714	chr1:152285911	FLG	-0.46	-4.86	-0.3	2.12e-6	Atopic dermatitis;
KIRP	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg14593290	chr7:50529359	DDC	0.47	6.01	0.36	6.54e-9	Malaria;
KIRP	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs10492096	0.898	rs12426815	chr12:6580314	A/G	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.5	-5.17	-0.31	4.8e-7	Hip geometry;
KIRP	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg26084005	chr2:241760190	KIF1A	-0.47	-6.19	-0.37	2.53e-9	Urinary metabolites;
KIRP	cis	rs7017914	0.967	rs35295900	chr8:71642061	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs1062746	0.520	rs17770965	chr16:87328597	G/A	cg02258303	chr16:87377426	FBXO31	-0.42	-5.11	-0.31	6.44e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.61	-6.99	-0.41	2.5e-11	Menopause (age at onset);
KIRP	cis	rs8027181	0.839	rs7176235	chr15:72999104	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.52	7.59	0.44	6.5e-13	Triglyceride levels;
KIRP	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.68	-0.44	3.84e-13	Triglycerides;
KIRP	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.53	8.74	0.49	3.73e-16	Rheumatoid arthritis;
KIRP	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg16558253	chr16:72132732	DHX38	0.47	7.04	0.41	1.89e-11	Fibrinogen levels;
KIRP	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	0.89	11.98	0.61	2.34e-26	Monocyte percentage of white cells;
KIRP	cis	rs2120243	0.653	rs3816527	chr3:157155314	C/A	cg24825693	chr3:157122686	VEPH1	-0.39	-5.24	-0.32	3.4e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg00684032	chr4:1343700	KIAA1530	0.52	7.13	0.41	1.09e-11	Longevity;
KIRP	cis	rs10782582	0.609	rs6656501	chr1:76266126	A/C	cg10523679	chr1:76189770	ACADM	-0.44	-6.13	-0.36	3.43e-9	Daytime sleep phenotypes;
KIRP	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg23479056	chr15:41276147	INO80	-0.43	-6.39	-0.38	8.05e-10	Menopause (age at onset);
KIRP	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg07511934	chr16:89386912	ANKRD11	0.47	5.96	0.36	8.56e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs7837860	0.588	rs7821897	chr8:89330431	C/G	cg08624180	chr8:89339080	MMP16	0.58	5.01	0.3	1.04e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17057718	1.000	rs1488123	chr3:57151812	G/A	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-4.99	-0.3	1.15e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2289681	0.525	rs2277617	chr17:42977073	T/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.59	-6.54	-0.38	3.63e-10	Cognitive function;
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.72	-8.81	-0.49	2.34e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg04362960	chr10:104952993	NT5C2	0.43	5.09	0.31	7.27e-7	Colorectal cancer;
KIRP	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23111772	chr20:62338704	ARFRP1;ZGPAT	0.49	7.13	0.41	1.13e-11	Survival in pancreatic cancer;
KIRP	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.41	-7.39	-0.43	2.29e-12	Refractive error;
KIRP	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg00507259	chr4:95128692	SMARCAD1	-0.43	-5.31	-0.32	2.42e-7	QT interval;
KIRP	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.85	13.07	0.64	5.5e-30	Prostate cancer;
KIRP	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.68	-7.11	-0.41	1.28e-11	Vitiligo;
KIRP	cis	rs7903847	0.642	rs9887991	chr10:99159634	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.82	-0.35	1.78e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg08501292	chr6:25962987	TRIM38	0.82	5.29	0.32	2.71e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-10.96	-0.57	4.93e-23	Triglycerides;
KIRP	cis	rs7224685	0.722	rs12945048	chr17:4159244	C/A	cg09597638	chr17:3907349	NA	0.55	6.28	0.37	1.52e-9	Type 2 diabetes;
KIRP	cis	rs72960926	0.744	rs72954314	chr6:74939737	A/G	cg03266952	chr6:74778945	NA	-0.73	-5.27	-0.32	3e-7	Metabolite levels (MHPG);
KIRP	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-6.88	-0.4	4.96e-11	Morning vs. evening chronotype;
KIRP	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.67	-8.85	-0.49	1.72e-16	Aortic root size;
KIRP	cis	rs13401104	0.754	rs11687335	chr2:237117233	A/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04004882	chr2:215674386	BARD1	0.82	7.83	0.45	1.45e-13	Neuroblastoma;
KIRP	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg14768367	chr16:72042858	DHODH	0.45	5.5	0.33	9.51e-8	Fibrinogen levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09400194	chr10:81107848	PPIF	0.51	6.85	0.4	6.01e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs34779708	0.733	rs4244997	chr10:35547254	T/C	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg15117754	chr3:10150083	C3orf24	0.48	4.92	0.3	1.62e-6	Alzheimer's disease;
KIRP	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.82	-0.4	7.01e-11	Aortic root size;
KIRP	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.58	-7.88	-0.45	1.08e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.02	0.31	9.71e-7	Iron status biomarkers;
KIRP	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.85	8.15	0.46	1.88e-14	Systolic blood pressure;
KIRP	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg14683738	chr19:37701593	ZNF585B	-0.52	-5.08	-0.31	7.29e-7	Coronary artery calcification;
KIRP	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg21360079	chr12:107162445	NA	-0.66	-8.99	-0.5	6.59e-17	Heart rate;
KIRP	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.49	6.28	0.37	1.5e-9	Blood metabolite levels;
KIRP	cis	rs6882716	0.591	rs10044607	chr5:10806058	G/A	cg14521931	chr5:10832172	NA	-0.85	-10.33	-0.55	5.11e-21	Alcohol consumption (maxi-drinks);
KIRP	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	6.26	0.37	1.68e-9	Height;
KIRP	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg02187348	chr16:89574699	SPG7	0.49	5.95	0.35	9.35e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg18165381	chr3:44552316	NA	-0.39	-4.9	-0.3	1.73e-6	Depressive symptoms;
KIRP	cis	rs1620921	0.505	rs66496533	chr6:161210741	T/C	cg01280913	chr6:161186852	NA	-0.58	-7.69	-0.44	3.56e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg16584676	chr17:46985605	UBE2Z	0.47	5.87	0.35	1.43e-8	Type 2 diabetes;
KIRP	cis	rs9584850	0.834	rs9584855	chr13:99119000	G/T	cg20750642	chr13:99100586	FARP1	0.44	5.25	0.32	3.23e-7	Neuroticism;
KIRP	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.55	6.84	0.4	6.07e-11	Total body bone mineral density;
KIRP	cis	rs4478037	1.000	rs4076086	chr3:33161898	C/T	cg19404215	chr3:33155277	CRTAP	0.71	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	cis	rs7224685	0.569	rs7212168	chr17:4024640	G/A	cg11204139	chr17:3907470	NA	0.55	5.17	0.31	4.95e-7	Type 2 diabetes;
KIRP	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.31	-0.62	1.85e-27	Primary sclerosing cholangitis;
KIRP	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-0.62	-6.92	-0.4	3.91e-11	Initial pursuit acceleration;
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.77	12.26	0.62	2.73e-27	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18606460	chr4:123082094	NA	-0.4	-6.15	-0.37	3.18e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg22089800	chr15:90895588	ZNF774	0.45	5.35	0.32	1.99e-7	Rheumatoid arthritis;
KIRP	cis	rs5743618	0.537	rs10017482	chr4:38765335	A/C	cg06935464	chr4:38784597	TLR10	0.4	4.96	0.3	1.34e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21747090	chr2:27597821	SNX17	-0.5	-6.96	-0.41	3.1e-11	Menopause (age at onset);
KIRP	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg21573476	chr21:45109991	RRP1B	-0.55	-7.53	-0.43	9.81e-13	Mean corpuscular volume;
KIRP	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.9	10.44	0.55	2.25e-21	Blood protein levels;
KIRP	cis	rs1318772	1.000	rs26965	chr5:112739017	A/G	cg12552261	chr5:112820674	MCC	-0.66	-4.97	-0.3	1.24e-6	F-cell distribution;
KIRP	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.67	-9.11	-0.5	3.06e-17	Personality dimensions;
KIRP	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.65	-6.99	-0.41	2.64e-11	DNA methylation (variation);
KIRP	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.46	-0.33	1.19e-7	Body mass index;
KIRP	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.48	-4.92	-0.3	1.6e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg08975724	chr8:8085496	FLJ10661	0.64	8.12	0.46	2.21e-14	Mood instability;
KIRP	cis	rs17020663	0.771	rs2278722	chr2:101620136	A/G	cg17494863	chr2:101638916	TBC1D8	-0.5	-5.3	-0.32	2.59e-7	Pulse pressure;
KIRP	cis	rs273573	0.556	rs10742253	chr11:30908020	T/C	cg14844989	chr11:31128820	NA	0.34	4.84	0.3	2.26e-6	Total body bone mineral density;
KIRP	cis	rs11574514	1.000	rs9938862	chr16:67723801	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-5.5	-0.33	9.37e-8	Crohn's disease;
KIRP	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg05343316	chr1:45956843	TESK2	0.77	8.88	0.49	1.48e-16	Platelet count;
KIRP	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.42	-0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.69	10.4	0.55	3.2e-21	Eosinophilic esophagitis;
KIRP	cis	rs7404928	0.672	rs2106375	chr16:23865532	A/C	cg21745164	chr16:23765304	CHP2	-0.55	-7.18	-0.42	8.08e-12	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08080008	chr16:2009616	NDUFB10	0.5	6.4	0.38	7.8e-10	Parkinson's disease;
KIRP	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.74e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs216345	0.966	rs1971430	chr9:33782375	G/A	cg14607208	chr9:38546089	NA	0.54	6.77	0.4	9.13e-11	Bipolar disorder;
KIRP	cis	rs9488822	0.662	rs195534	chr6:116254834	T/C	cg05304507	chr6:116381966	FRK	0.21	5.36	0.32	1.95e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg00738919	chr7:1100172	C7orf50	0.43	5.06	0.31	8.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15977278	chr12:104234975	NT5DC3	0.53	6.93	0.4	3.59e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.84	10.22	0.55	1.18e-20	Post bronchodilator FEV1;
KIRP	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.94	12.74	0.63	7.06e-29	Breast cancer;
KIRP	cis	rs7267005	0.661	rs17093129	chr20:34427797	A/T	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.86	9.35	0.51	5.58e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg18538332	chr22:24372958	LOC391322	0.55	6.6	0.39	2.47e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.95	12.76	0.63	5.83e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09326324	chr1:161123937	UFC1	0.51	6.05	0.36	5.34e-9	Smoking initiation;
KIRP	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.5	-6.51	-0.38	4.26e-10	Schizophrenia;
KIRP	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg12292205	chr6:26970375	C6orf41	0.44	5.15	0.31	5.43e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.83	-0.4	6.5500000000000006e-11	Heart rate;
KIRP	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs4953911	1.000	rs55816735	chr2:135069791	C/T	cg18482303	chr2:135041380	MGAT5	-0.27	-5.2	-0.31	4.27e-7	Multiple sclerosis (severity);
KIRP	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg08975724	chr8:8085496	FLJ10661	0.64	8.71	0.49	4.66e-16	Mood instability;
KIRP	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08392591	chr16:89556376	ANKRD11	0.44	5.75	0.34	2.67e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.87	0.35	1.43e-8	Renal cell carcinoma;
KIRP	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.74	10.49	0.56	1.65e-21	Psoriasis;
KIRP	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg04935436	chr20:30431758	NA	0.48	6.35	0.38	1.04e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs11986414	1	rs11986414	chr8:1746950	A/G	cg22756942	chr8:1746360	NA	0.55	6.39	0.38	8.06e-10	Gaucher disease severity;
KIRP	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.34	0.47	5.42e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4671458	0.626	rs72821628	chr2:63695036	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-4.91	-0.3	1.68e-6	Subjective well-being;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15773890	chr6:17259549	NA	0.35	6.26	0.37	1.7e-9	Survival in pancreatic cancer;
KIRP	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.3	-0.72	5.51e-41	Height;
KIRP	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg23387468	chr7:139079360	LUC7L2	0.3	5.04	0.31	9.16e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.57	6.34	0.37	1.06e-9	Bipolar disorder;
KIRP	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs244899	0.967	rs2445785	chr5:167924928	A/G	cg13011109	chr5:167955758	FBLL1	-0.39	-5.46	-0.33	1.17e-7	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs6137287	1.000	rs3827959	chr20:21179145	G/A	cg04219410	chr20:21106687	PLK1S1	-0.45	-5.0	-0.3	1.08e-6	Height;
KIRP	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg16898833	chr6:26189333	HIST1H4D	0.73	4.98	0.3	1.18e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.33	0.79	1.39e-54	Chronic sinus infection;
KIRP	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg13611997	chr5:233750	SDHA	-0.41	-4.92	-0.3	1.58e-6	Breast cancer;
KIRP	cis	rs7520050	0.931	rs6697557	chr1:46307809	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-4.98	-0.3	1.18e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg16691251	chr5:66510806	NA	0.52	7.33	0.42	3.22e-12	Breast cancer;
KIRP	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg26874229	chr2:105853672	NA	-0.4	-5.49	-0.33	1.01e-7	Type 2 diabetes;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13198984	chr17:80129470	CCDC57	-0.55	-8.25	-0.47	9.67e-15	Life satisfaction;
KIRP	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg17764715	chr19:33622953	WDR88	0.67	8.41	0.47	3.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs62056376	0.736	rs62056379	chr17:32672418	C/A	cg17635953	chr13:28535085	NA	-0.68	-6.77	-0.4	9.19e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg07701084	chr6:150067640	NUP43	0.69	9.14	0.5	2.47e-17	Lung cancer;
KIRP	cis	rs372883	0.901	rs733610	chr21:30656199	G/A	cg08807101	chr21:30365312	RNF160	-0.43	-5.17	-0.31	4.94e-7	Pancreatic cancer;
KIRP	cis	rs2274273	0.840	rs10142448	chr14:55838108	G/T	cg04306507	chr14:55594613	LGALS3	-0.4	-6.32	-0.37	1.24e-9	Protein biomarker;
KIRP	cis	rs597583	0.715	rs2276340	chr11:117391966	G/A	cg27161313	chr11:117392002	DSCAML1	-0.71	-7.37	-0.43	2.56e-12	Putamen volume;
KIRP	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg03714773	chr7:91764589	CYP51A1	0.37	5.27	0.32	2.99e-7	Breast cancer;
KIRP	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg01843034	chr6:37503916	NA	0.66	7.91	0.45	8.97e-14	Cognitive performance;
KIRP	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	1.07	19.61	0.78	3.35e-52	Bone mineral density;
KIRP	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg05347473	chr6:146136440	FBXO30	0.62	8.8	0.49	2.52e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.76	10.7	0.56	3.42e-22	Dental caries;
KIRP	cis	rs6693295	0.752	rs2787998	chr1:246233492	G/C	cg11798871	chr1:246315928	SMYD3	-0.38	-4.85	-0.3	2.2e-6	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg02475777	chr4:1388615	CRIPAK	0.53	4.93	0.3	1.5e-6	Recombination rate (females);
KIRP	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.39	-0.38	8.45e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.53	-7.73	-0.44	2.75e-13	Daytime sleep phenotypes;
KIRP	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.92	14.72	0.68	1.32e-35	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.02e-8	Motion sickness;
KIRP	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.66	9.59	0.52	1.03e-18	Dupuytren's disease;
KIRP	cis	rs7463659	0.512	rs62524716	chr8:135450378	A/G	cg13434034	chr8:135477110	NA	0.45	5.86	0.35	1.5e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3762637	0.882	rs9818537	chr3:122086457	G/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.68	-0.34	3.73e-8	LDL cholesterol levels;
KIRP	cis	rs2839619	1.000	rs2839619	chr21:44436177	C/T	cg20154816	chr21:44412511	PKNOX1	-0.34	-5.78	-0.35	2.3e-8	Biochemical measures;
KIRP	cis	rs11605924	0.792	rs10838524	chr11:45870177	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.59	-7.5	-0.43	1.13e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-5.2	-0.31	4.2e-7	Psoriasis;
KIRP	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg08029281	chr1:67600428	NA	0.35	5.0	0.3	1.08e-6	Psoriasis;
KIRP	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.67	8.16	0.46	1.75e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.77	-11.32	-0.59	3.39e-24	Heart rate;
KIRP	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.2	0.46	1.33e-14	Motion sickness;
KIRP	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.77	10.93	0.57	6.2e-23	Schizophrenia;
KIRP	cis	rs12476592	0.571	rs112194	chr2:63876872	T/G	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs66530629	0.874	rs4648876	chr1:25097392	A/G	cg22509179	chr1:25234806	RUNX3	-0.38	-5.05	-0.31	8.71e-7	Plateletcrit;
KIRP	cis	rs1468333	0.964	rs2967785	chr5:137543713	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	5.29	0.32	2.71e-7	Resting heart rate;
KIRP	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg06766960	chr11:133703094	NA	-0.57	-7.11	-0.41	1.25e-11	Childhood ear infection;
KIRP	cis	rs28395178	1	rs28395178	chr15:78850558	G/A	cg06917634	chr15:78832804	PSMA4	-0.67	-6.67	-0.39	1.64e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00592244	chr3:66392474	SLC25A26	0.41	6.06	0.36	5.11e-9	Interleukin-4 levels;
KIRP	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.35	0.7	9.06e-38	Chronic sinus infection;
KIRP	cis	rs13102973	0.932	rs4130840	chr4:135869598	T/G	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.2	0.42	7.15e-12	Neuroticism;
KIRP	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-1.0	-15.57	-0.7	1.71e-38	Height;
KIRP	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg01280390	chr8:19363452	CSGALNACT1	-0.4	-5.39	-0.32	1.66e-7	Oropharynx cancer;
KIRP	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.5	5.94	0.35	9.64e-9	Metabolite levels;
KIRP	cis	rs2742417	1.000	rs1969626	chr3:45746836	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2733310	0.744	rs16977153	chr15:57222686	A/C	cg13626582	chr15:57592083	LOC283663	0.26	6.03	0.36	5.84e-9	Mean platelet volume;
KIRP	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg06026331	chr20:60912101	LAMA5	0.79	9.71	0.53	4.45e-19	Colorectal cancer;
KIRP	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.66	9.32	0.51	6.91e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs61931739	0.620	rs7297316	chr12:33702261	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-6.09	-0.36	4.24e-9	Morning vs. evening chronotype;
KIRP	cis	rs1943345	0.830	rs571055	chr11:82898829	G/C	cg07047830	chr11:82868014	PCF11	0.58	6.06	0.36	4.95e-9	Obesity-related traits;
KIRP	cis	rs10864907	0.967	rs2723151	chr2:113645117	A/G	cg03712744	chr2:113669835	IL1F7	-0.34	-5.11	-0.31	6.5e-7	Pulmonary function;
KIRP	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg23594656	chr7:65796392	TPST1	0.55	8.57	0.48	1.15e-15	Aortic root size;
KIRP	cis	rs9581857	0.547	rs9581868	chr13:28070682	C/T	cg22138327	chr13:27999177	GTF3A	0.85	6.58	0.39	2.87e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.54	-0.39	3.45e-10	Lung cancer;
KIRP	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg18187862	chr3:45730750	SACM1L	-0.58	-6.4	-0.38	7.63e-10	Primary sclerosing cholangitis;
KIRP	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg07541023	chr7:19748670	TWISTNB	0.61	5.57	0.33	6.59e-8	Thyroid stimulating hormone;
KIRP	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg26876637	chr1:152193138	HRNR	0.77	10.13	0.54	2.27e-20	Atopic dermatitis;
KIRP	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.81	-9.22	-0.51	1.39e-17	Blood pressure (smoking interaction);
KIRP	cis	rs2120243	0.572	rs3816528	chr3:157127290	C/T	cg24825693	chr3:157122686	VEPH1	0.54	8.87	0.49	1.57e-16	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	13.23	0.64	1.5e-30	Platelet count;
KIRP	cis	rs4262150	0.693	rs4501386	chr5:152310278	G/T	cg12297329	chr5:152029980	NA	0.47	6.66	0.39	1.82e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs4819143	0.504	rs6518259	chr21:47317886	C/G	cg11214348	chr21:47283868	PCBP3	0.48	5.29	0.32	2.76e-7	Insulin resistance/response;
KIRP	trans	rs1106684	1.000	rs11765324	chr7:131464481	C/T	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs4849845	0.637	rs11688038	chr2:121026582	A/G	cg24070213	chr2:121070622	NA	0.4	6.2	0.37	2.4e-9	Mean platelet volume;
KIRP	cis	rs10203711	1.000	rs4994753	chr2:239567253	T/C	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7017914	0.902	rs13269513	chr8:71578079	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs7005380	0.531	rs68097758	chr8:120960511	G/A	cg21645572	chr8:120931649	DEPDC6	-0.44	-6.08	-0.36	4.47e-9	Interstitial lung disease;
KIRP	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg20302533	chr7:39170763	POU6F2	0.27	5.38	0.32	1.71e-7	IgG glycosylation;
KIRP	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg21775007	chr8:11205619	TDH	0.42	5.22	0.32	3.73e-7	Neuroticism;
KIRP	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-16.15	-0.72	1.79e-40	Electrocardiographic conduction measures;
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg23985595	chr17:80112537	CCDC57	0.34	5.1	0.31	6.8e-7	Life satisfaction;
KIRP	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg04289385	chr6:36355825	ETV7	-0.46	-7.27	-0.42	4.71e-12	Platelet distribution width;
KIRP	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.35	0.55	4.48e-21	Ileal carcinoids;
KIRP	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg16898833	chr6:26189333	HIST1H4D	0.75	5.43	0.33	1.36e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11638352	0.661	rs2706488	chr15:44389897	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-6.31	-0.37	1.26e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg10360139	chr7:1886902	MAD1L1	-0.47	-5.08	-0.31	7.52e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-8.09	-0.46	2.73e-14	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs3767633	0.925	rs6427633	chr1:161849569	C/T	cg09175582	chr1:161736000	ATF6	0.72	5.88	0.35	1.35e-8	IgG glycosylation;
KIRP	cis	rs17407555	0.632	rs12510726	chr4:10271067	T/A	cg11266682	chr4:10021025	SLC2A9	0.35	5.28	0.32	2.79e-7	Schizophrenia (age at onset);
KIRP	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.91	-10.58	-0.56	8.06e-22	Cognitive ability;
KIRP	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-5.59	-0.34	6.16e-8	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg19694781	chr19:47549865	TMEM160	-0.58	-7.45	-0.43	1.56e-12	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs72634258	0.519	rs4908487	chr1:7937437	C/T	cg26816564	chr1:7831052	VAMP3	0.61	5.28	0.32	2.87e-7	Inflammatory bowel disease;
KIRP	cis	rs7106204	0.764	rs7933686	chr11:24246790	G/C	ch.11.24196551F	chr11:24239977	NA	0.92	7.47	0.43	1.39e-12	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.89	12.29	0.62	2.17e-27	Coronary artery disease;
KIRP	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	0.94	7.61	0.44	5.88e-13	Thyroid stimulating hormone;
KIRP	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26207909	chr14:103986467	CKB	0.52	6.84	0.4	6.06e-11	Body mass index;
KIRP	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg22920501	chr2:26401640	FAM59B	-0.63	-7.22	-0.42	6.59e-12	Gut microbiome composition (summer);
KIRP	cis	rs4654899	0.680	rs6704421	chr1:21220674	A/C	cg08890418	chr1:21044141	KIF17	-0.34	-5.02	-0.3	1e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4742903	0.509	rs4451366	chr9:106959666	G/A	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	2.04e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-7.11	-0.41	1.26e-11	Menarche (age at onset);
KIRP	cis	rs9962915	0.967	rs1719943	chr18:5594667	C/T	cg12967001	chr18:5544089	EPB41L3	-0.39	-4.98	-0.3	1.2e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs2976388	0.935	rs2978978	chr8:143756530	T/C	cg17252645	chr8:143867129	LY6D	-0.3	-4.86	-0.3	2.08e-6	Urinary tract infection frequency;
KIRP	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.63	10.13	0.54	2.19e-20	Cardiovascular disease risk factors;
KIRP	cis	rs3026101	0.671	rs9789002	chr17:5298792	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.48	6.08	0.36	4.45e-9	Body mass index;
KIRP	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.44	-7.53	-0.43	9.54e-13	Lymphocyte counts;
KIRP	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	9.07	0.5	3.79e-17	Retinal vascular caliber;
KIRP	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7534824	0.625	rs61780286	chr1:101359898	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.84	7.07	0.41	1.59e-11	Refractive astigmatism;
KIRP	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.41e-7	Morning vs. evening chronotype;
KIRP	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.43	5.48	0.33	1.03e-7	Melanoma;
KIRP	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg05315796	chr3:52349193	DNAH1	0.44	6.83	0.4	6.43e-11	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.95	12.44	0.62	6.68e-28	Menopause (age at onset);
KIRP	cis	rs11587400	0.679	rs12090305	chr1:115109441	G/A	cg12756093	chr1:115239321	AMPD1	0.43	5.34	0.32	2.07e-7	Autism;
KIRP	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg04804543	chr8:142233427	SLC45A4	-0.75	-10.8	-0.57	1.65e-22	Immature fraction of reticulocytes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03790745	chr11:63679432	RCOR2	-0.43	-6.09	-0.36	4.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg00405596	chr8:11794950	NA	0.47	6.0	0.36	7.11e-9	Monocyte count;
KIRP	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.44	6.19	0.37	2.55e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.0	0.3	1.08e-6	Protein C levels;
KIRP	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.38	7.44e-10	Height;
KIRP	cis	rs9488822	0.662	rs580396	chr6:116263181	T/C	cg18764771	chr6:116381957	FRK	-0.18	-5.08	-0.31	7.52e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10189230	0.546	rs6436266	chr2:222357235	T/C	cg14652038	chr2:222343519	EPHA4	0.4	5.57	0.33	6.5e-8	Urate levels in lean individuals;
KIRP	cis	rs894344	0.650	rs55675081	chr8:135582032	C/A	cg09855544	chr8:135498122	ZFAT	0.4	5.24	0.32	3.38e-7	Systolic blood pressure;
KIRP	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22590775	chr19:49891494	CCDC155	0.65	6.08	0.36	4.45e-9	Multiple sclerosis;
KIRP	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg19636519	chr7:99541626	NA	0.32	5.95	0.35	9.33e-9	Coronary artery disease;
KIRP	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.64	-0.34	4.68e-8	Type 2 diabetes;
KIRP	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-0.87	-6.7	-0.39	1.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.98	-0.5	7.37e-17	Hirschsprung disease;
KIRP	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.76	6.77	0.4	9.4e-11	Diabetic retinopathy;
KIRP	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg02807482	chr3:125708958	NA	-0.53	-4.98	-0.3	1.19e-6	Blood pressure (smoking interaction);
KIRP	cis	rs2594989	0.943	rs4580536	chr3:11422319	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-7.55	-0.43	8.33e-13	Circulating chemerin levels;
KIRP	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.41	-0.43	2.03e-12	Bipolar disorder;
KIRP	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.37	5.05	0.31	8.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-1.01	-15.85	-0.71	1.84e-39	Personality dimensions;
KIRP	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.44e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2224391	0.534	rs2753228	chr6:5246623	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.17	-0.37	2.75e-9	Height;
KIRP	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg25547332	chr5:131281432	NA	-0.45	-5.12	-0.31	6.04e-7	Life satisfaction;
KIRP	cis	rs7692976	0.549	rs4444903	chr4:110834110	A/G	cg06981781	chr4:110842888	EGF	-0.23	-5.24	-0.32	3.41e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.53	5.73	0.34	2.95e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs4006360	0.685	rs2320221	chr17:39251266	A/C	cg15015397	chr17:39261100	KRTAP4-9	0.45	6.53	0.38	3.75e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.71	9.56	0.52	1.28e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.52	-6.38	-0.38	8.86e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg18944383	chr4:111397179	ENPEP	0.55	9.74	0.53	3.66e-19	Height;
KIRP	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg27490568	chr2:178487706	NA	-0.72	-9.75	-0.53	3.39e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.14	-10.14	-0.54	2.12e-20	Body mass index;
KIRP	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg20936604	chr3:58311152	NA	-0.6	-5.07	-0.31	7.92e-7	Cholesterol, total;
KIRP	cis	rs79220007	1.000	rs79220007	chr6:26098474	T/C	cg17691542	chr6:26056736	HIST1H1C	0.92	5.66	0.34	4.2e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11987759	chr7:65425863	GUSB	-0.56	-7.07	-0.41	1.61e-11	Aortic root size;
KIRP	cis	rs7572263	0.724	rs10497896	chr2:209049899	G/C	cg23998903	chr2:209048830	C2orf80	-0.37	-5.41	-0.33	1.5e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs10102274	1.000	rs16905310	chr8:91777808	A/G	cg16814680	chr8:91681699	NA	-0.8	-4.9	-0.3	1.73e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.65	-0.66	5.97e-32	Monocyte count;
KIRP	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.26	5.04	0.31	8.86e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs6466055	0.720	rs10227302	chr7:105021829	C/G	cg04380332	chr7:105027541	SRPK2	-0.65	-9.7	-0.53	4.9e-19	Schizophrenia;
KIRP	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg19743168	chr1:23544995	NA	0.52	7.25	0.42	5.51e-12	Height;
KIRP	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.55	-6.74	-0.39	1.11e-10	Iron status biomarkers;
KIRP	cis	rs12210905	0.920	rs72839451	chr6:27265437	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.71	-0.39	1.35e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs17209837	1.000	rs17149647	chr7:87086931	T/C	cg00919237	chr7:87102261	ABCB4	-0.75	-8.0	-0.45	4.77e-14	Gallbladder cancer;
KIRP	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.42	-0.43	1.91e-12	Mood instability;
KIRP	cis	rs7737355	0.898	rs6864413	chr5:130637868	G/T	cg25547332	chr5:131281432	NA	0.5	5.58	0.34	6.36e-8	Life satisfaction;
KIRP	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg03563238	chr19:33554763	RHPN2	-0.33	-5.62	-0.34	5.2e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.75	-0.63	6.19e-29	Extrinsic epigenetic age acceleration;
KIRP	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-22.57	-0.82	7.09e-62	Exhaled nitric oxide output;
KIRP	cis	rs13359291	0.841	rs10041191	chr5:122475830	C/T	cg16368670	chr5:122501738	PRDM6	-0.48	-5.85	-0.35	1.55e-8	Systolic blood pressure;
KIRP	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg24881330	chr22:46731750	TRMU	0.65	4.93	0.3	1.48e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1050631	0.564	rs1785931	chr18:33722107	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.7	9.3	0.51	8.09e-18	Eye color traits;
KIRP	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg08975724	chr8:8085496	FLJ10661	0.61	8.1	0.46	2.58e-14	Retinal vascular caliber;
KIRP	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.85e-7	Diabetic retinopathy;
KIRP	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg18404041	chr3:52824283	ITIH1	0.36	5.23	0.32	3.6e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs3736485	0.934	rs28648597	chr15:51856066	T/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.52	-7.13	-0.41	1.09e-11	Obesity-related traits;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	7.76	0.44	2.32e-13	Lymphocyte counts;
KIRP	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.68	-8.29	-0.47	7.3e-15	Aortic root size;
KIRP	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg09545109	chr3:50388910	TUSC4;CYB561D2	-0.46	-5.0	-0.3	1.09e-6	Diastolic blood pressure;
KIRP	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.4	0.38	7.62e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9362426	1.000	rs9294377	chr6:88084839	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	5.61	0.34	5.51e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg06585982	chr3:143692056	C3orf58	0.58	7.33	0.42	3.24e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg16589663	chr20:23618590	CST3	0.71	7.14	0.41	1.04e-11	Chronic kidney disease;
KIRP	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.69	-0.39	1.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg04719120	chr6:96025338	MANEA	0.59	5.07	0.31	7.76e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-8.91	-0.49	1.14e-16	Resting heart rate;
KIRP	cis	rs13082711	0.911	rs7640929	chr3:27513944	C/A	cg02860705	chr3:27208620	NA	0.47	6.6	0.39	2.55e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	7.56	0.43	8.12e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.52	7.27	0.42	4.73e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg24881330	chr22:46731750	TRMU	0.6	5.15	0.31	5.4e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4711350	0.765	rs756139	chr6:33755541	G/A	cg25922239	chr6:33757077	LEMD2	0.58	6.17	0.37	2.87e-9	Schizophrenia;
KIRP	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg11204139	chr17:3907470	NA	0.49	5.31	0.32	2.42e-7	Type 2 diabetes;
KIRP	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg10818794	chr15:86012489	AKAP13	0.49	7.08	0.41	1.53e-11	Coronary artery disease;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg10534938	chr5:1868639	NA	0.37	5.02	0.3	9.94e-7	Cardiovascular disease risk factors;
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg12262378	chr17:6899522	ALOX12	0.32	5.7	0.34	3.49e-8	Tonsillectomy;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs7947761	0.715	rs61910505	chr11:100612604	A/G	cg20593887	chr7:2106784	MAD1L1	-0.45	-6.08	-0.36	4.53e-9	Coronary artery disease;
KIRP	trans	rs301901	0.796	rs1829292	chr5:37505646	G/T	cg01568846	chr3:179281462	ACTL6A	0.48	6.03	0.36	5.85e-9	Height;
KIRP	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg05304507	chr6:116381966	FRK	0.21	5.73	0.34	3e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.08	0.31	7.3e-7	Breast cancer;
KIRP	cis	rs75920871	0.925	rs11826651	chr11:116920693	T/A	cg23684410	chr11:116897558	SIK3	0.57	6.16	0.37	2.93e-9	Subjective well-being;
KIRP	cis	rs3825932	0.778	rs1369324	chr15:79239719	C/T	cg25744700	chr15:79237217	CTSH	-0.43	-5.13	-0.31	5.84e-7	Type 1 diabetes;
KIRP	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.58	-7.15	-0.41	9.95e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs988913	0.513	rs2134538	chr6:54858157	G/A	cg03513858	chr6:54763001	FAM83B	-0.34	-4.9	-0.3	1.76e-6	Menarche (age at onset);
KIRP	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.69	-8.23	-0.46	1.08e-14	Resting heart rate;
KIRP	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.25	0.47	9.95e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg21775007	chr8:11205619	TDH	-0.41	-5.08	-0.31	7.39e-7	Neuroticism;
KIRP	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.75	10.6	0.56	7.36e-22	Diastolic blood pressure;
KIRP	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.48	-7.13	-0.41	1.09e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.71	8.22	0.46	1.17e-14	Corneal astigmatism;
KIRP	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg07741184	chr6:167504864	NA	-0.23	-5.64	-0.34	4.56e-8	Rheumatoid arthritis;
KIRP	cis	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.38	-0.32	1.74e-7	Leprosy;
KIRP	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.12	-0.31	6.3e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09695851	chr17:3907499	NA	0.7	11.16	0.58	1.18e-23	Type 2 diabetes;
KIRP	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.76	-10.38	-0.55	3.54e-21	Fibrinogen levels;
KIRP	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.49	-0.33	1e-7	Height;
KIRP	cis	rs1978968	0.956	rs8135939	chr22:18434284	A/G	cg02610425	chr22:18483192	MICAL3	0.39	5.48	0.33	1.06e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.66	-9.03	-0.5	4.99e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7833787	0.832	rs7827258	chr8:18698295	G/C	cg17701159	chr8:18705777	PSD3	-0.34	-5.98	-0.36	7.77e-9	Obesity-related traits;
KIRP	cis	rs2057178	0.860	rs7123725	chr11:32355336	G/T	cg07934552	chr11:32355483	NA	0.44	5.31	0.32	2.45e-7	Tuberculosis;
KIRP	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg16339924	chr4:17578868	LAP3	-0.6	-7.66	-0.44	4.16e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14159672	chr1:205819179	PM20D1	-0.43	-5.34	-0.32	2.09e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.59	-7.03	-0.41	2.09e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg18944383	chr4:111397179	ENPEP	0.6	11.0	0.57	3.69e-23	Height;
KIRP	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.55	6.04	0.36	5.56e-9	Platelet distribution width;
KIRP	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.18e-7	Red blood cell count;
KIRP	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.4	-0.33	1.56e-7	Pulmonary function;
KIRP	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg05340658	chr4:99064831	C4orf37	0.57	6.84	0.4	6.26e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35176054	0.730	rs7093473	chr10:105535331	C/T	cg00730670	chr10:105510713	SH3PXD2A	0.46	4.97	0.3	1.27e-6	Atrial fibrillation;
KIRP	cis	rs732716	0.785	rs62130979	chr19:4432444	T/C	cg03719555	chr19:4455413	UBXN6	0.53	7.97	0.45	5.79e-14	Mean corpuscular volume;
KIRP	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg06640241	chr16:89574553	SPG7	0.78	11.6	0.59	4.32e-25	Multiple myeloma (IgH translocation);
KIRP	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg26138937	chr11:71823887	C11orf51	1.16	8.04	0.46	3.69e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs17221829	0.673	rs10830335	chr11:89403934	T/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.14	-0.31	5.61e-7	Anxiety in major depressive disorder;
KIRP	cis	rs10982256	0.774	rs12551529	chr9:117256896	A/G	cg13636371	chr9:117264095	DFNB31	-0.49	-6.94	-0.4	3.5e-11	Bipolar disorder;
KIRP	cis	rs748404	0.697	rs546722	chr15:43580819	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.33	0.42	3.21e-12	Lung cancer;
KIRP	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.48	-6.25	-0.37	1.79e-9	Body mass index;
KIRP	cis	rs3540	0.960	rs7167704	chr15:90956801	G/T	cg10434728	chr15:90938212	IQGAP1	0.3	4.93	0.3	1.53e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.9	-0.3	1.78e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10267417	0.603	rs10081258	chr7:19934237	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	5.11	0.31	6.44e-7	Night sleep phenotypes;
KIRP	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.46	5.64	0.34	4.7e-8	HDL cholesterol;
KIRP	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg18657303	chr4:1051139	NA	0.53	4.96	0.3	1.31e-6	Recombination rate (females);
KIRP	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg13147721	chr7:65941812	NA	-0.94	-6.7	-0.39	1.4e-10	Diabetic kidney disease;
KIRP	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg13962347	chr6:5174647	LYRM4	-0.81	-11.54	-0.59	6.65e-25	Height;
KIRP	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg18367735	chr17:79674897	NA	0.7	8.0	0.45	4.75e-14	Dental caries;
KIRP	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11987759	chr7:65425863	GUSB	0.52	6.87	0.4	5.14e-11	Aortic root size;
KIRP	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.06	-0.41	1.66e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg02487422	chr3:49467188	NICN1	0.37	5.08	0.31	7.32e-7	Parkinson's disease;
KIRP	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.79	-8.12	-0.46	2.22e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg17724175	chr1:150552817	MCL1	0.32	4.97	0.3	1.24e-6	Melanoma;
KIRP	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Educational attainment;
KIRP	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg17759274	chr19:39260954	NA	0.26	5.08	0.31	7.44e-7	Heart rate;
KIRP	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.58	6.96	0.41	3.06e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs3818717	0.538	rs4925108	chr17:17649423	C/T	cg04398451	chr17:18023971	MYO15A	0.43	5.44	0.33	1.27e-7	Lymphocyte counts;
KIRP	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.45	5.62	0.34	5.06e-8	Osteoporosis;
KIRP	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.69	-0.39	1.47e-10	Alcohol dependence;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13748552	chr7:150929513	CHPF2	-0.47	-6.31	-0.37	1.27e-9	Myopia;
KIRP	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.59e-12	Obesity-related traits;
KIRP	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.67	10.12	0.54	2.42e-20	Retinal vascular caliber;
KIRP	cis	rs8018808	0.967	rs176766	chr14:77865367	G/A	cg20045696	chr14:77926864	AHSA1	0.41	5.11	0.31	6.62e-7	Myeloid white cell count;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg19902122	chr11:1087601	MUC2	-0.45	-6.14	-0.36	3.37e-9	Bladder cancer;
KIRP	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.58	-9.4	-0.51	4.02e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg19899395	chr1:46959349	NA	0.43	5.52	0.33	8.43e-8	Monobrow;
KIRP	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17554472	chr22:41940697	POLR3H	-0.66	-6.79	-0.4	8.54e-11	Vitiligo;
KIRP	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.96	11.32	0.59	3.51e-24	Corneal astigmatism;
KIRP	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	0.92	13.94	0.66	5.97e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg26207909	chr14:103986467	CKB	-0.44	-5.3	-0.32	2.52e-7	Coronary artery disease;
KIRP	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.87	-9.88	-0.53	1.35e-19	Gut microbiome composition (summer);
KIRP	cis	rs1050631	0.592	rs1785903	chr18:33711642	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.47	0.33	1.12e-7	Esophageal squamous cell cancer (length of survival);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15894192	chr7:66205482	RABGEF1	-0.96	-6.46	-0.38	5.58e-10	P wave terminal force;
KIRP	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.43	5.06	0.31	8.05e-7	Systemic lupus erythematosus;
KIRP	trans	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg18393722	chr15:85113863	UBE2QP1	0.44	6.39	0.38	8.27e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg26513180	chr16:89883248	FANCA	0.52	5.3	0.32	2.61e-7	Skin colour saturation;
KIRP	cis	rs17253792	0.545	rs12894368	chr14:56025178	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.75	5.16	0.31	5.02e-7	Putamen volume;
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.61	5.5	0.33	9.67e-8	Alzheimer's disease;
KIRP	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.73	9.29	0.51	8.51e-18	Corneal astigmatism;
KIRP	cis	rs7113850	0.541	rs80031332	chr11:24211553	A/G	ch.11.24196551F	chr11:24239977	NA	0.92	7.45	0.43	1.61e-12	Bone fracture in osteoporosis;
KIRP	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg18872420	chr14:78023429	SPTLC2	0.33	4.88	0.3	1.95e-6	Myeloid white cell count;
KIRP	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg14851346	chr12:38532713	NA	-0.39	-4.85	-0.3	2.19e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4704187	0.687	rs10051572	chr5:74502797	G/A	cg03227963	chr5:74354835	NA	0.4	5.79	0.35	2.13e-8	Response to amphetamines;
KIRP	cis	rs7127900	1.000	rs10840584	chr11:2228618	T/C	cg25635251	chr11:2234043	NA	0.54	8.04	0.46	3.69e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-8.66	-0.48	6.27e-16	Alzheimer's disease;
KIRP	trans	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg06521331	chr12:34319734	NA	-0.55	-6.83	-0.4	6.5500000000000006e-11	Heart rate;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20573562	chr11:18034664	SERGEF	-0.45	-6.08	-0.36	4.46e-9	Metabolic traits;
KIRP	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-0.84	-9.36	-0.51	5.22e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.54	-6.56	-0.39	3.2e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00229245	chr4:150999547	DCLK2	0.48	6.15	0.37	3.14e-9	Parkinson's disease;
KIRP	cis	rs7737355	0.853	rs1468453	chr5:130587459	A/C	cg06307176	chr5:131281290	NA	0.51	5.47	0.33	1.11e-7	Life satisfaction;
KIRP	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	10.24	0.55	1.02e-20	Nonalcoholic fatty liver disease;
KIRP	cis	rs7904985	0.889	rs1078789	chr10:88110247	C/T	cg07322936	chr10:88137208	NA	-0.52	-5.58	-0.34	6.35e-8	Barrett's esophagus;
KIRP	cis	rs830383	0.515	rs2591580	chr5:165406607	G/A	cg13976338	chr5:165423657	NA	-0.59	-6.14	-0.36	3.23e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.84	8.15	0.46	1.88e-14	Inflammatory bowel disease;
KIRP	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.62	6.7	0.39	1.43e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.2	-0.37	2.39e-9	Diastolic blood pressure;
KIRP	cis	rs6832769	0.961	rs28790098	chr4:56398109	C/T	cg09317128	chr4:56265301	TMEM165	-0.55	-7.0	-0.41	2.46e-11	Personality dimensions;
KIRP	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.7	-6.97	-0.41	2.83e-11	Lung function (FEV1/FVC);
KIRP	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-9.41	-0.51	3.65e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg15507776	chr3:136538369	TMEM22	0.53	7.47	0.43	1.42e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	8.19	0.46	1.46e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Bladder cancer;
KIRP	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-7.06	-0.41	1.66e-11	Morning vs. evening chronotype;
KIRP	cis	rs10465746	0.935	rs35946036	chr1:84438991	A/G	cg10977910	chr1:84465055	TTLL7	0.48	5.82	0.35	1.82e-8	Obesity-related traits;
KIRP	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg05370193	chr1:21551575	ECE1	-0.36	-4.94	-0.3	1.48e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	1.04	10.47	0.56	1.84e-21	Psoriasis;
KIRP	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.67	8.62	0.48	8.49e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	5.8	0.35	2.08e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs829661	0.512	rs7608857	chr2:30808843	C/T	cg10949345	chr2:30726833	LCLAT1	0.49	7.21	0.42	7.04e-12	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg23565292	chr14:50234668	KLHDC2	-0.41	-4.87	-0.3	2.04e-6	Carotid intima media thickness;
KIRP	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.9	0.88	4.82e-81	Chronic sinus infection;
KIRP	cis	rs17065868	1.000	rs9595149	chr13:45124858	C/A	cg10246903	chr13:45222710	NA	0.7	6.56	0.39	3.23e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.43	5.13	0.31	5.93e-7	Melanoma;
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.66	-8.01	-0.45	4.73e-14	Aortic root size;
KIRP	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg20243544	chr17:37824526	PNMT	0.47	6.35	0.38	1e-9	Asthma;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg14227687	chr7:100303735	POP7	0.53	6.32	0.37	1.19e-9	Plasma plasminogen activator levels;
KIRP	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.89	0.3	1.85e-6	Tonsillectomy;
KIRP	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06481639	chr22:41940642	POLR3H	0.68	6.71	0.39	1.34e-10	Cannabis dependence symptom count;
KIRP	cis	rs698833	0.828	rs4952710	chr2:44524575	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.42	0.38	7.08e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.81	-0.78	7.56e-53	Schizophrenia;
KIRP	cis	rs4389656	0.826	rs395939	chr5:6734245	T/C	cg10857441	chr5:6722123	POLS	-0.47	-6.61	-0.39	2.37e-10	Coronary artery disease;
KIRP	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg16497661	chr14:103986332	CKB	0.76	11.28	0.58	4.56e-24	Body mass index;
KIRP	cis	rs7712401	0.601	rs2910140	chr5:122264395	T/A	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.52e-7	Mean platelet volume;
KIRP	cis	rs4849845	0.889	rs2289174	chr2:121045884	G/A	cg24070213	chr2:121070622	NA	0.4	5.57	0.33	6.55e-8	Mean platelet volume;
KIRP	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs914615	0.552	rs4971088	chr1:155142883	T/A	cg02153340	chr1:155202674	NA	-0.48	-7.21	-0.42	6.92e-12	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs988913	1.000	rs6922186	chr6:54811092	A/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.57	-0.33	6.59e-8	Menarche (age at onset);
KIRP	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00938859	chr5:1591904	SDHAP3	0.62	8.37	0.47	4.32e-15	Breast cancer;
KIRP	cis	rs78487399	0.808	rs17030835	chr2:43686245	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.13	-0.31	5.89e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1923539	0.822	rs1923536	chr10:81709809	C/T	cg24613050	chr10:81743128	NA	0.36	5.03	0.31	9.4e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.72	0.66	3.43e-32	Mean corpuscular hemoglobin;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24243429	chr4:148653539	ARHGAP10	0.66	6.07	0.36	4.92e-9	Lung function (FEV1);
KIRP	cis	rs1413885	0.516	rs3818449	chr1:65844963	A/G	cg13202122	chr1:65886182	LEPROT;LEPR	0.44	5.16	0.31	5e-7	Anticoagulant levels;
KIRP	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26002218	chr14:103986227	CKB	0.29	5.91	0.35	1.12e-8	Body mass index;
KIRP	cis	rs2131877	0.645	rs11721261	chr3:194876993	C/T	cg19775763	chr3:194786989	NA	-0.47	-5.37	-0.32	1.83e-7	Non-small cell lung cancer;
KIRP	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.71	9.4	0.51	3.91e-18	Obesity-related traits;
KIRP	cis	rs73200209	0.744	rs57085207	chr12:116579289	T/C	cg01776926	chr12:116560359	MED13L	-0.54	-6.03	-0.36	5.82e-9	Total body bone mineral density;
KIRP	cis	rs7255436	0.965	rs62117510	chr19:8452613	T/G	cg10174797	chr19:8464628	RAB11B	0.51	6.38	0.38	8.56e-10	HDL cholesterol;
KIRP	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg18700516	chr19:44507157	ZNF230	0.47	5.36	0.32	1.96e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-1.03	-16.12	-0.72	2.26e-40	Menopause (age at onset);
KIRP	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg26531700	chr6:26746687	NA	0.45	6.44	0.38	6.24e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.56	7.2	0.42	7.14e-12	Tuberculosis;
KIRP	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.84	12.22	0.61	3.72e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs732765	0.734	rs28470774	chr14:75186907	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.86	-0.3	2.08e-6	Non-small cell lung cancer;
KIRP	cis	rs860295	0.557	rs10796941	chr1:155284261	C/T	cg02153340	chr1:155202674	NA	-0.58	-7.67	-0.44	3.91e-13	Body mass index;
KIRP	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.27	-0.51	9.9e-18	Retinal vascular caliber;
KIRP	cis	rs921943	1.000	rs933683	chr5:78324003	G/T	cg26802063	chr5:78281964	ARSB	0.45	5.56	0.33	7.19e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs7561273	0.565	rs6545275	chr2:24331860	A/G	cg20701182	chr2:24300061	SF3B14	0.49	6.0	0.36	7.17e-9	Quantitative traits;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs654128	0.640	rs339338	chr6:117214706	T/C	cg12892004	chr6:117198278	RFX6	-0.39	-5.1	-0.31	6.89e-7	Telomere length;
KIRP	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	0.71	6.44	0.38	6.26e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.19	21.88	0.81	1.2e-59	Cognitive function;
KIRP	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg04111992	chr7:158790115	NA	-0.4	-5.25	-0.32	3.3e-7	Facial morphology (factor 20);
KIRP	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg23693289	chr8:27183097	PTK2B	0.58	7.47	0.43	1.42e-12	Neuroticism;
KIRP	cis	rs4704187	0.624	rs35719345	chr5:74551962	T/C	cg03227963	chr5:74354835	NA	0.41	5.96	0.35	8.9e-9	Response to amphetamines;
KIRP	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9296095	0.554	rs12214883	chr6:33513968	A/G	cg14003231	chr6:33640908	ITPR3	0.33	4.93	0.3	1.49e-6	Platelet count;
KIRP	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.67	-9.2	-0.51	1.64e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.9	-9.8	-0.53	2.34e-19	Alzheimer's disease;
KIRP	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg18833306	chr6:118973337	C6orf204	0.42	5.32	0.32	2.39e-7	Electrocardiographic conduction measures;
KIRP	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2041895	0.509	rs10861676	chr12:107311235	G/A	cg15890332	chr12:107067104	RFX4	0.35	4.95	0.3	1.35e-6	Glaucoma (low intraocular pressure);
KIRP	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg22974920	chr21:40686053	BRWD1	0.51	6.12	0.36	3.58e-9	Cognitive function;
KIRP	cis	rs17592366	0.762	rs4982227	chr14:35346607	C/T	cg09327582	chr14:35236912	BAZ1A	0.71	5.31	0.32	2.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.15	0.31	5.37e-7	Body mass index;
KIRP	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.62	6.86	0.4	5.5e-11	Aortic root size;
KIRP	cis	rs9815354	1.000	rs9882329	chr3:41767154	T/C	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.33	8.71e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7712401	0.601	rs246315	chr5:122266438	C/T	cg19412675	chr5:122181750	SNX24	0.48	5.28	0.32	2.78e-7	Mean platelet volume;
KIRP	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	7.84	0.45	1.39e-13	Neuroticism;
KIRP	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg17595323	chr11:93583763	C11orf90	0.38	6.41	0.38	7.22e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2380205	1.000	rs7098372	chr10:5886149	T/C	cg27141509	chr10:5886111	NA	-0.39	-5.62	-0.34	5.2100000000000003e-08	Breast cancer;
KIRP	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.57	7.38	0.43	2.42e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.67	-8.99	-0.5	6.67e-17	Colorectal cancer;
KIRP	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg04896959	chr15:78267971	NA	-0.66	-6.28	-0.37	1.51e-9	Coronary artery disease or large artery stroke;
KIRP	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg17724175	chr1:150552817	MCL1	-0.34	-5.46	-0.33	1.16e-7	Melanoma;
KIRP	cis	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.44	5.78	0.35	2.23e-8	QT interval;
KIRP	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg18944383	chr4:111397179	ENPEP	0.44	6.59	0.39	2.64e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-5.34	-0.32	2.07e-7	Neuroticism;
KIRP	cis	rs67766926	0.537	rs17539345	chr2:61250101	A/C	cg15711740	chr2:61764176	XPO1	-0.46	-4.92	-0.3	1.61e-6	Inflammatory skin disease;
KIRP	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.78	-9.19	-0.51	1.72e-17	Vitiligo;
KIRP	trans	rs6810798	0.780	rs1583003	chr4:148296025	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.52	-6.12	-0.36	3.71e-9	Coronary artery disease;
KIRP	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg08807101	chr21:30365312	RNF160	-0.56	-6.74	-0.39	1.11e-10	Pancreatic cancer;
KIRP	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg27494647	chr7:150038898	RARRES2	0.45	6.48	0.38	4.93e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.61	-7.55	-0.43	8.51e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs12913547	0.617	rs12441344	chr15:67447895	A/G	cg26430287	chr15:67439567	SMAD3	0.33	5.12	0.31	6.29e-7	Corneal structure;
KIRP	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg14003231	chr6:33640908	ITPR3	0.28	4.95	0.3	1.4e-6	Plateletcrit;
KIRP	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs4704187	0.574	rs4704184	chr5:74471677	A/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg08901578	chr4:187885870	NA	-0.5	-7.79	-0.44	1.93e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.06	0.31	8.07e-7	Cognitive test performance;
KIRP	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg04362960	chr10:104952993	NT5C2	0.56	6.82	0.4	7.12e-11	Arsenic metabolism;
KIRP	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg19847130	chr8:10466454	RP1L1	-0.42	-6.14	-0.36	3.26e-9	Retinal vascular caliber;
KIRP	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg13731523	chr4:3047190	NA	-0.35	-5.81	-0.35	1.95e-8	Serum sulfate level;
KIRP	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.45e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.6	6.37	0.38	9.4e-10	Diisocyanate-induced asthma;
KIRP	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.25	-0.47	9.74e-15	Retinal vascular caliber;
KIRP	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.76	-0.4	9.84e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg06212747	chr3:49208901	KLHDC8B	0.69	8.26	0.47	8.86e-15	Menarche (age at onset);
KIRP	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.43	5.84	0.35	1.64e-8	Retinal vascular caliber;
KIRP	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg11189052	chr15:85197271	WDR73	0.58	5.53	0.33	8.12e-8	Schizophrenia;
KIRP	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18932078	chr1:2524107	MMEL1	0.43	5.99	0.36	7.39e-9	Ulcerative colitis;
KIRP	cis	rs7113874	0.921	rs4929923	chr11:8639200	A/G	cg08015107	chr11:8618950	NA	0.34	4.91	0.3	1.67e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1298908	1.000	rs1298908	chr10:82013134	A/G	cg09936400	chr10:82049201	MAT1A	-0.31	-5.21	-0.32	4.07e-7	Diabetic kidney disease;
KIRP	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.87	-0.49	1.56e-16	Neuroticism;
KIRP	cis	rs12367572	0.641	rs4285943	chr12:45404768	A/C	cg04608330	chr12:45269318	NELL2	0.38	5.1	0.31	6.76e-7	Gut microbiome composition (summer);
KIRP	cis	rs2224391	0.628	rs2753231	chr6:5248915	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.66	-0.39	1.77e-10	Height;
KIRP	cis	rs3741798	1.000	rs28372890	chr12:12503519	C/A	cg08615371	chr12:12503544	MANSC1	1.01	8.87	0.49	1.48e-16	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	1.03	14.27	0.67	4.59e-34	Blood pressure (smoking interaction);
KIRP	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.75	-0.49	3.43e-16	Neuroticism;
KIRP	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg18306943	chr3:40428807	ENTPD3	0.46	5.9	0.35	1.19e-8	Renal cell carcinoma;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.53	-0.33	8.38e-8	Life satisfaction;
KIRP	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg23682824	chr7:23144976	KLHL7	0.59	7.3	0.42	4e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7809799	0.571	rs66568021	chr7:98942989	C/T	cg12290671	chr7:99195819	NA	-0.71	-5.37	-0.32	1.84e-7	Ulcerative colitis;
KIRP	cis	rs2286379	0.933	rs10773999	chr12:1903507	G/C	cg05227549	chr12:1770782	NA	-0.31	-4.99	-0.3	1.12e-6	Blood pressure (smoking interaction);
KIRP	cis	rs883565	0.569	rs1274968	chr3:39170090	A/G	cg01426195	chr3:39028469	NA	-0.52	-8.29	-0.47	7.58e-15	Handedness;
KIRP	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg27205649	chr11:78285834	NARS2	0.65	8.09	0.46	2.75e-14	Alzheimer's disease (survival time);
KIRP	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs6959887	0.962	rs7790713	chr7:35299841	A/G	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.69	8.38	0.47	4.11e-15	Monocyte count;
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg23978390	chr7:1156363	C7orf50	0.55	5.34	0.32	2.07e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.45e-9	Type 2 diabetes;
KIRP	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.45	6.29	0.37	1.42e-9	Dupuytren's disease;
KIRP	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg21174375	chr14:64681225	SYNE2	0.68	9.23	0.51	1.27e-17	Atrial fibrillation;
KIRP	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.95	-0.5	8.97e-17	Response to antipsychotic treatment;
KIRP	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.66	9.44	0.52	3.07e-18	Colorectal cancer;
KIRP	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg07884673	chr3:53033167	SFMBT1	0.98	7.6	0.44	6.35e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg18350739	chr11:68623251	NA	0.51	7.92	0.45	8.19e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.86	15.07	0.69	8.65e-37	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs13315871	1.000	rs75828026	chr3:58346736	C/T	cg12435725	chr3:58293450	RPP14	-0.52	-5.68	-0.34	3.75e-8	Cholesterol, total;
KIRP	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.57	0.33	6.71e-8	Ovarian reserve;
KIRP	cis	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg11502198	chr6:26597334	ABT1	-0.8	-5.42	-0.33	1.39e-7	Small cell lung carcinoma;
KIRP	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg18154014	chr19:37997991	ZNF793	0.62	6.77	0.4	9.55e-11	Coronary artery calcification;
KIRP	cis	rs662064	0.603	rs12065251	chr1:10522289	C/T	cg19773385	chr1:10388646	KIF1B	-0.45	-5.65	-0.34	4.47e-8	Asthma;
KIRP	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg11859384	chr17:80120422	CCDC57	-0.41	-5.19	-0.31	4.3e-7	Life satisfaction;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg08901578	chr4:187885870	NA	-0.49	-7.35	-0.42	3.01e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs758324	0.947	rs559971	chr5:131316164	A/G	cg06307176	chr5:131281290	NA	0.48	5.07	0.31	7.67e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg15655495	chr12:38532458	NA	-0.28	-5.01	-0.3	1.06e-6	Bladder cancer;
KIRP	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.64	-0.44	4.74e-13	Joint mobility (Beighton score);
KIRP	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.85	-7.1	-0.41	1.37e-11	Obesity-related traits;
KIRP	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7221595	0.778	rs57625058	chr17:3914513	T/G	cg05562828	chr17:3906858	NA	0.62	6.75	0.4	1.05e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	6.72	0.39	1.23e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs735860	0.763	rs1346603	chr6:53149262	C/T	cg10236188	chr6:53219634	NA	0.4	5.3	0.32	2.6e-7	Glaucoma;
KIRP	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg08807101	chr21:30365312	RNF160	-0.59	-5.9	-0.35	1.23e-8	Cognitive test performance;
KIRP	cis	rs1420338	0.967	rs4720151	chr7:34160523	G/A	cg01275685	chr7:34179230	BMPER	-0.51	-7.12	-0.41	1.17e-11	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs2481665	0.904	rs2481677	chr1:62632571	G/A	cg18591186	chr1:62594603	INADL	-0.66	-10.07	-0.54	3.48e-20	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23544223	chr18:12777786	NA	0.68	5.77	0.35	2.42e-8	Inflammatory skin disease;
KIRP	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg18944383	chr4:111397179	ENPEP	0.51	8.51	0.48	1.7e-15	Coronary artery disease;
KIRP	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	5.64	0.34	4.76e-8	Response to antipsychotic treatment;
KIRP	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-8.84	-0.49	1.82e-16	Response to antipsychotic treatment;
KIRP	cis	rs494562	0.892	rs1322404	chr6:86126912	T/A	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg21546286	chr11:48923668	NA	-0.38	-4.92	-0.3	1.56e-6	HDL cholesterol;
KIRP	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-7.72	-0.44	3e-13	Bipolar disorder;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg14789911	chr21:47582049	C21orf56	0.45	5.62	0.34	5.18e-8	Testicular germ cell tumor;
KIRP	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.59	7.81	0.45	1.6e-13	Height;
KIRP	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg26116260	chr4:7069785	GRPEL1	-0.74	-5.09	-0.31	7.05e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.81	-0.4	7.62e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg10503236	chr1:231470652	EXOC8	-0.56	-8.24	-0.47	1e-14	Hemoglobin concentration;
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.55	7.25	0.42	5.54e-12	Menarche (age at onset);
KIRP	cis	rs6001982	0.667	rs17001915	chr22:40842466	G/T	cg07138101	chr22:40742427	ADSL	0.67	5.58	0.34	6.33e-8	Breast cancer;
KIRP	trans	rs2726453	0.562	rs2713834	chr4:106310520	G/T	cg12201110	chr5:95321963	NA	-0.38	-6.17	-0.37	2.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.37	5.48	0.33	1.03e-7	Survival in rectal cancer;
KIRP	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.84	12.19	0.61	4.65e-27	Colorectal cancer;
KIRP	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg07884673	chr3:53033167	SFMBT1	1.0	7.75	0.44	2.48e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg13615516	chr5:77269221	NA	0.52	8.22	0.46	1.15e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.58	-6.77	-0.4	9.32e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.14	-0.41	1.06e-11	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17675882	chr20:35374068	NDRG3	0.59	7.09	0.41	1.44e-11	Smoking initiation;
KIRP	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.42	-0.33	1.45e-7	Menarche (age at onset);
KIRP	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.41	10.42	0.55	2.68e-21	Prostate cancer;
KIRP	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-1.01	-16.87	-0.73	5.9e-43	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05076971	chr7:117824189	NAA38	0.45	6.09	0.36	4.36e-9	Survival in pancreatic cancer;
KIRP	cis	rs4664304	0.739	rs2162500	chr2:160708645	C/G	cg03641300	chr2:160917029	PLA2R1	0.38	5.8	0.35	2.06e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg10495392	chr1:46806563	NSUN4	0.46	5.26	0.32	3.11e-7	Menopause (age at onset);
KIRP	cis	rs6959887	0.603	rs2392359	chr7:35277216	T/C	cg06685737	chr7:35301730	NA	0.44	6.34	0.37	1.07e-9	Birth weight;
KIRP	cis	rs6832769	0.961	rs2177127	chr4:56379959	A/C	cg09317128	chr4:56265301	TMEM165	0.56	7.13	0.41	1.11e-11	Personality dimensions;
KIRP	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.56	6.27	0.37	1.63e-9	Gestational age at birth (maternal effect);
KIRP	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.49	0.65	2.07e-31	Smoking behavior;
KIRP	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.49	6.4	0.38	7.77e-10	Menopause (age at onset);
KIRP	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17376030	chr22:41985996	PMM1	-0.52	-5.6	-0.34	5.82e-8	Vitiligo;
KIRP	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.59	6.77	0.4	9.27e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg21775007	chr8:11205619	TDH	0.54	7.03	0.41	2.01e-11	Neuroticism;
KIRP	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-17.28	-0.74	2.49e-44	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs62056376	0.736	rs885691	chr17:32641225	C/T	cg21513437	chr17:39678107	NA	-0.49	-6.24	-0.37	1.9e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs16828019	0.852	rs3766324	chr1:41588653	A/G	cg08144172	chr1:41849203	NA	0.62	4.91	0.3	1.65e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4919087	0.851	rs3781373	chr10:99080585	C/T	cg25902810	chr10:99078978	FRAT1	0.56	6.62	0.39	2.22e-10	Monocyte count;
KIRP	cis	rs7224685	0.569	rs35578550	chr17:3996470	A/G	cg09597638	chr17:3907349	NA	0.52	5.18	0.31	4.62e-7	Type 2 diabetes;
KIRP	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.38	-9.49	-0.52	2.16e-18	Asthma (sex interaction);
KIRP	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11987759	chr7:65425863	GUSB	0.61	8.16	0.46	1.69e-14	Aortic root size;
KIRP	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.42	5.99	0.36	7.49e-9	Testicular germ cell tumor;
KIRP	cis	rs7246865	0.768	rs8106184	chr19:17159779	A/C	cg18440316	chr19:18077727	KCNN1	-0.39	-5.36	-0.32	1.93e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.67	-11.09	-0.58	1.92e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	-0.43	-5.07	-0.31	7.72e-7	Glycated hemoglobin levels;
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg14324370	chr2:177042789	NA	0.73	10.22	0.55	1.18e-20	IgG glycosylation;
KIRP	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg05315796	chr3:52349193	DNAH1	0.43	6.09	0.36	4.31e-9	Bipolar disorder;
KIRP	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg03146154	chr1:46216737	IPP	0.55	5.78	0.35	2.27e-8	Platelet count;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.34	-0.32	2.16e-7	Lung cancer;
KIRP	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.94	16.39	0.72	2.55e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.61e-9	Life satisfaction;
KIRP	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg06345736	chr22:50966936	TYMP	0.68	7.23	0.42	5.97e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg09915433	chr19:53449742	NA	-0.35	-4.92	-0.3	1.6e-6	Psoriasis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16465559	chr8:105502059	LRP12	-0.42	-6.52	-0.38	3.85e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7213347	0.780	rs170041	chr17:2170216	C/T	cg15816464	chr17:2026533	SMG6	-0.36	-5.28	-0.32	2.77e-7	Total body bone mineral density;
KIRP	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg24796726	chr7:884288	UNC84A	-0.6	-5.22	-0.32	3.85e-7	Initial pursuit acceleration;
KIRP	cis	rs7224314	1.000	rs62084081	chr17:65387148	G/C	cg01507342	chr17:65387096	PITPNC1	-0.53	-7.66	-0.44	4.17e-13	Diisocyanate-induced asthma;
KIRP	cis	rs712039	0.652	rs1616371	chr17:35773799	A/G	cg16670864	chr17:35848621	DUSP14	0.4	5.06	0.31	8.25e-7	Tuberculosis;
KIRP	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-0.97	-9.41	-0.51	3.72e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs9420	0.784	rs12790660	chr11:57667222	T/C	cg23127183	chr11:57508653	C11orf31	-0.5	-5.85	-0.35	1.58e-8	Schizophrenia;
KIRP	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.34	0.37	1.08e-9	Major depressive disorder;
KIRP	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.48	6.67	0.39	1.68e-10	Testicular germ cell tumor;
KIRP	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-8.84	-0.49	1.87e-16	Myopia (pathological);
KIRP	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.03e-7	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg10047753	chr17:41438598	NA	1.14	17.79	0.75	4.34e-46	Menopause (age at onset);
KIRP	cis	rs72960926	0.744	rs56020332	chr6:75030022	C/G	cg03266952	chr6:74778945	NA	-0.73	-5.39	-0.33	1.63e-7	Metabolite levels (MHPG);
KIRP	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	5.96	0.36	8.7e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg21573476	chr21:45109991	RRP1B	-0.57	-7.8	-0.45	1.75e-13	Mean corpuscular volume;
KIRP	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg27426351	chr10:43362370	NA	0.45	6.33	0.37	1.14e-9	Blood protein levels;
KIRP	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.83	11.5	0.59	8.72e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-0.99	-12.12	-0.61	8.36e-27	Breast cancer;
KIRP	cis	rs3812049	0.611	rs251393	chr5:127533085	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	7.62	0.44	5.36e-13	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs8067545	1.000	rs4925067	chr17:19921222	C/G	cg04132472	chr17:19861366	AKAP10	0.51	7.52	0.43	1.04e-12	Schizophrenia;
KIRP	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg12560992	chr17:57184187	TRIM37	0.7	6.76	0.4	9.88e-11	Cognitive test performance;
KIRP	cis	rs2559856	0.967	rs2559863	chr12:102087108	C/T	cg15068132	chr12:102092402	CHPT1	-0.4	-5.19	-0.31	4.45e-7	Blood protein levels;
KIRP	cis	rs12976411	0.575	rs35367178	chr19:32825503	G/A	cg02282382	chr19:32836354	ZNF507	0.62	5.23	0.32	3.7e-7	Coronary artery disease;
KIRP	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.82	0.4	7.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.7e-8	Mortality in heart failure;
KIRP	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.73	7.47	0.43	1.43e-12	Prostate cancer;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00802000	chr16:706648	WDR90	-0.4	-5.08	-0.31	7.34e-7	Height;
KIRP	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg19847130	chr8:10466454	RP1L1	0.37	5.53	0.33	8.2e-8	Neuroticism;
KIRP	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg03808351	chr9:123631620	PHF19	0.43	5.98	0.36	7.62e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg24642439	chr20:33292090	TP53INP2	0.79	11.1	0.58	1.74e-23	Coronary artery disease;
KIRP	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.84	-11.21	-0.58	7.92e-24	Adiposity;
KIRP	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg08076091	chr2:203926405	NBEAL1	0.89	9.25	0.51	1.1e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03903647	chr4:40058344	N4BP2;LOC344967	0.49	6.85	0.4	5.75e-11	Survival in pancreatic cancer;
KIRP	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg04289385	chr6:36355825	ETV7	-0.36	-4.9	-0.3	1.7e-6	Platelet distribution width;
KIRP	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg04691961	chr3:161091175	C3orf57	-0.35	-4.88	-0.3	1.9e-6	Educational attainment (years of education);
KIRP	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg12573674	chr2:1569213	NA	-0.59	-5.29	-0.32	2.64e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg21523564	chr15:75251491	NA	0.39	6.23	0.37	1.98e-9	Breast cancer;
KIRP	cis	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13185784	0.667	rs4454029	chr5:179645325	C/T	cg23248424	chr5:179741104	GFPT2	0.51	5.41	0.33	1.5e-7	TRAIL levels;
KIRP	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.74	8.7	0.48	4.92e-16	Gestational age at birth (maternal effect);
KIRP	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-1.0	-14.59	-0.68	3.66e-35	Monocyte count;
KIRP	cis	rs7707921	0.767	rs226196	chr5:81576965	C/A	cg07807695	chr5:81608485	ATP6AP1L	-0.44	-5.63	-0.34	4.79e-8	Breast cancer;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg00024416	chr22:24240387	NA	-0.35	-5.03	-0.31	9.32e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.16	-0.46	1.75e-14	Myopia (pathological);
KIRP	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg04539111	chr16:67997858	SLC12A4	-0.58	-5.12	-0.31	6.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg14440974	chr22:39074834	NA	0.38	5.03	0.31	9.59e-7	Menopause (age at onset);
KIRP	cis	rs9886651	0.935	rs13248719	chr8:128802751	T/C	cg24514600	chr8:128805414	PVT1	-0.73	-12.58	-0.63	2.31e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8014252	0.803	rs17108201	chr14:70988931	A/G	cg19730268	chr14:71022823	NA	-0.72	-6.48	-0.38	4.91e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg25036284	chr2:26402008	FAM59B	-0.6	-6.0	-0.36	7.17e-9	Gut microbiome composition (summer);
KIRP	cis	rs2273669	0.667	rs2003315	chr6:109367169	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.41	-0.38	7.27e-10	Prostate cancer;
KIRP	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg04727924	chr7:799746	HEATR2	0.64	5.89	0.35	1.29e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1476670	0.683	rs813642	chr1:44506420	A/C	cg09470012	chr1:44509516	NA	0.35	5.56	0.33	7.16e-8	Eotaxin levels;
KIRP	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.7	-9.07	-0.5	4.03e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs57994353	0.540	rs12379380	chr9:139279981	C/T	cg21253087	chr9:139290292	SNAPC4	0.47	5.61	0.34	5.35e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	1.0	13.49	0.65	2.08e-31	Vitamin D levels;
KIRP	cis	rs9310709	0.517	rs616006	chr3:23037791	T/C	cg00327796	chr3:23032191	NA	-0.53	-7.26	-0.42	4.95e-12	Chronic kidney disease and serum creatinine levels;
KIRP	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	0.87	9.92	0.53	1.03e-19	Pediatric areal bone mineral density (radius);
KIRP	trans	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.88	0.4	5.08e-11	Mean corpuscular volume;
KIRP	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg16988262	chr1:15930761	NA	0.39	4.99	0.3	1.12e-6	Systolic blood pressure;
KIRP	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg17366294	chr4:99064904	C4orf37	0.35	4.93	0.3	1.54e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10924970	0.934	rs56681442	chr1:235466800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.67e-7	Asthma;
KIRP	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg26248373	chr2:1572462	NA	-0.57	-5.31	-0.32	2.48e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	0.7	5.56	0.33	7.1e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.47	5.26	0.32	3.19e-7	Osteoporosis;
KIRP	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg13482628	chr17:19912719	NA	0.53	6.91	0.4	4.08e-11	Schizophrenia;
KIRP	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg14345882	chr6:26364793	BTN3A2	-0.54	-4.99	-0.3	1.13e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10073892	0.516	rs35075848	chr5:101976881	T/A	cg19774478	chr5:101632501	SLCO4C1	0.53	5.47	0.33	1.09e-7	Cognitive decline (age-related);
KIRP	cis	rs72730918	0.590	rs2622769	chr15:51976230	A/C	cg14296394	chr15:51910925	DMXL2	0.76	10.31	0.55	6.03e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	0.44	5.33	0.32	2.18e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg11584989	chr19:19387371	SF4	0.41	5.27	0.32	2.99e-7	Tonsillectomy;
KIRP	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.73	-0.78	1.35e-52	Height;
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg01763666	chr17:80159506	CCDC57	0.36	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg12288994	chr5:1860383	NA	0.55	7.44	0.43	1.72e-12	Cardiovascular disease risk factors;
KIRP	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.47	6.09	0.36	4.32e-9	Blood metabolite levels;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.74	10.44	0.55	2.27e-21	Menarche (age at onset);
KIRP	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.47	7.96	0.45	6.28e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.82	0.49	2.15e-16	Morning vs. evening chronotype;
KIRP	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg01872077	chr2:219646372	CYP27A1	0.42	5.9	0.35	1.21e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.55e-13	Life satisfaction;
KIRP	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.64	8.58	0.48	1.1e-15	Alcohol dependence;
KIRP	cis	rs7172677	0.737	rs8029760	chr15:75435840	A/G	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs427941	0.668	rs201459	chr7:101741502	G/A	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.27e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7246967	0.673	rs6511383	chr19:22956900	C/T	cg03230154	chr19:22817176	ZNF492	0.5	4.89	0.3	1.83e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs1978968	1.000	rs5992919	chr22:18443855	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg03289416	chr15:75166202	SCAMP2	0.58	7.82	0.45	1.5e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Hypertriglyceridemia;
KIRP	cis	rs2411233	0.837	rs11638429	chr15:39260109	C/T	cg02291532	chr15:39874776	THBS1	0.42	5.5	0.33	9.54e-8	Platelet count;
KIRP	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg11189052	chr15:85197271	WDR73	0.52	4.93	0.3	1.5e-6	Schizophrenia;
KIRP	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.68	9.37	0.51	4.74e-18	Asperger disorder;
KIRP	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.6	7.34	0.42	3.13e-12	Obesity-related traits;
KIRP	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.68	9.38	0.51	4.68e-18	Obesity-related traits;
KIRP	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg19847130	chr8:10466454	RP1L1	0.35	5.14	0.31	5.5e-7	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04880732	chr14:92789193	SLC24A4	0.54	6.95	0.41	3.31e-11	Parkinson's disease;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.62	-0.34	5.26e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.71	-0.44	3.21e-13	Response to antipsychotic treatment;
KIRP	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg10503236	chr1:231470652	EXOC8	-0.52	-7.32	-0.42	3.41e-12	Hemoglobin concentration;
KIRP	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.88	13.16	0.64	2.59e-30	Eosinophil percentage of white cells;
KIRP	cis	rs7709377	0.570	rs6896479	chr5:115425582	A/C	cg23108291	chr5:115420582	COMMD10	-0.41	-4.96	-0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg16405210	chr4:1374714	KIAA1530	-0.84	-10.89	-0.57	8.35e-23	Longevity;
KIRP	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg04369109	chr6:150039330	LATS1	-0.45	-5.54	-0.33	7.95e-8	Lung cancer;
KIRP	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.64	-7.24	-0.42	5.84e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.65	-7.35	-0.42	2.84e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg00083206	chr6:110721305	DDO	-0.41	-5.99	-0.36	7.28e-9	Platelet distribution width;
KIRP	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-0.59	-7.97	-0.45	5.98e-14	Morning vs. evening chronotype;
KIRP	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg16482183	chr6:26056742	HIST1H1C	0.62	7.1	0.41	1.32e-11	Iron status biomarkers;
KIRP	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg18357526	chr6:26021779	HIST1H4A	0.45	6.11	0.36	3.82e-9	Height;
KIRP	cis	rs1816752	0.837	rs57052031	chr13:24983868	T/A	cg02811702	chr13:24901961	NA	0.38	4.89	0.3	1.79e-6	Obesity-related traits;
KIRP	cis	rs11078597	0.731	rs12944946	chr17:1649486	C/G	cg17514665	chr17:1657533	SERPINF2	0.45	5.66	0.34	4.22e-8	Serum albumin level;
KIRP	cis	rs9634489	0.620	rs1927792	chr13:96921313	A/T	cg02571835	chr13:96230311	CLDN10	-0.39	-5.7	-0.34	3.36e-8	Body mass index;
KIRP	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.08	0.31	7.5e-7	Axial length;
KIRP	cis	rs6430538	0.621	rs6757855	chr2:135574163	A/G	cg12500956	chr2:135428796	TMEM163	-0.39	-5.17	-0.31	4.82e-7	Parkinson's disease;
KIRP	cis	rs12765878	0.812	rs2984132	chr10:105657892	T/C	cg11005552	chr10:105648138	OBFC1	-0.42	-5.76	-0.34	2.54e-8	Coronary artery disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg08448040	chr3:13521693	HDAC11	-0.5	-6.42	-0.38	7.07e-10	Neuroticism;
KIRP	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.96	0.57	5.14e-23	Lung cancer in ever smokers;
KIRP	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-1.44	-9.97	-0.54	6.73e-20	Plateletcrit;
KIRP	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg07777115	chr5:623756	CEP72	-0.61	-6.17	-0.37	2.77e-9	Obesity-related traits;
KIRP	cis	rs1823913	0.614	rs1973067	chr2:192166747	T/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs2179367	0.887	rs6570965	chr6:149717476	C/A	cg16235748	chr6:149772707	ZC3H12D	-0.3	-4.94	-0.3	1.44e-6	Dupuytren's disease;
KIRP	cis	rs1570884	0.767	rs3751384	chr13:50123622	G/C	cg03651054	chr13:50194643	NA	0.59	8.42	0.47	3.25e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg22604316	chr1:46958801	NA	0.45	6.33	0.37	1.13e-9	Monobrow;
KIRP	cis	rs17030434	0.954	rs79908936	chr4:154749305	C/T	cg14289246	chr4:154710475	SFRP2	-0.77	-9.34	-0.51	5.92e-18	Electrocardiographic conduction measures;
KIRP	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.52	-5.75	-0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-5.54	-0.33	7.95e-8	Total body bone mineral density;
KIRP	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	5.42	0.33	1.42e-7	Schizophrenia;
KIRP	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.42	-5.45	-0.33	1.22e-7	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.7	-10.14	-0.54	2e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.88	9.85	0.53	1.64e-19	Gut microbiome composition (summer);
KIRP	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.58e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.93	14.95	0.69	2.18e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	22.38	0.82	2.87e-61	Chronic sinus infection;
KIRP	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	6.11	0.36	3.95e-9	Eotaxin levels;
KIRP	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.13	0.46	2.1e-14	Type 2 diabetes;
KIRP	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg10189774	chr4:17578691	LAP3	0.49	5.68	0.34	3.88e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	1.02	18.87	0.77	9.88e-50	Bone mineral density;
KIRP	cis	rs885389	1.000	rs885389	chr12:131621762	C/T	cg00260028	chr12:131606990	GPR133	0.47	5.7	0.34	3.34e-8	RR interval (heart rate);
KIRP	cis	rs7665939	1.000	rs72709219	chr4:190115517	A/G	cg09826759	chr4:190284978	NA	-0.77	-5.15	-0.31	5.23e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.69	-7.24	-0.42	5.82e-12	Vitiligo;
KIRP	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	7.4	0.43	2.13e-12	Height;
KIRP	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.68	5.0	0.3	1.11e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	0.89	6.53	0.38	3.72e-10	IgG glycosylation;
KIRP	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg07541023	chr7:19748670	TWISTNB	-0.63	-5.9	-0.35	1.19e-8	Thyroid stimulating hormone;
KIRP	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.72	-9.59	-0.52	1.02e-18	Breast cancer;
KIRP	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg26248373	chr2:1572462	NA	-0.63	-5.73	-0.34	2.88e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg06521331	chr12:34319734	NA	-0.47	-5.93	-0.35	1.03e-8	Morning vs. evening chronotype;
KIRP	cis	rs78487399	0.808	rs6732766	chr2:43712785	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-5.05	-0.31	8.72e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7116495	0.609	rs949323	chr11:71714528	T/G	cg10381502	chr11:71823885	C11orf51	-1.06	-7.44	-0.43	1.67e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	1.04	17.62	0.75	1.73e-45	Bone mineral density;
KIRP	cis	rs4791746	1.000	rs7223367	chr17:8618791	G/A	cg03115937	chr17:8649504	CCDC42	-0.53	-6.33	-0.37	1.14e-9	Heroin dependence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07163991	chr2:128381835	MYO7B	-0.39	-6.08	-0.36	4.49e-9	Parkinson's disease;
KIRP	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.49	6.75	0.4	1.07e-10	Mean corpuscular volume;
KIRP	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.75	-11.7	-0.6	1.93e-25	Birth weight;
KIRP	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg05926928	chr17:57297772	GDPD1	-0.68	-6.95	-0.41	3.17e-11	Opioid sensitivity;
KIRP	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs4849845	0.812	rs7593660	chr2:121026652	T/A	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21605986	chr5:175788725	KIAA1191	0.95	6.41	0.38	7.24e-10	P wave terminal force;
KIRP	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg24807547	chr6:37504484	NA	-0.64	-10.1	-0.54	2.79e-20	Cognitive performance;
KIRP	cis	rs4936894	0.500	rs4936912	chr11:124140466	T/G	cg27160556	chr11:124181099	OR8D1	-0.45	-6.43	-0.38	6.48e-10	Aging (time to death);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25650390	chr19:34895271	PDCD2L	0.5	6.16	0.37	2.94e-9	Parkinson's disease;
KIRP	cis	rs7096127	0.966	rs11013972	chr10:24500832	A/G	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.88	0.3	1.91e-6	Lobe attachment (rater scored);
KIRP	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-6.88	-0.4	4.9e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg02487422	chr3:49467188	NICN1	0.36	5.05	0.31	8.43e-7	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs4728302	0.838	rs7798804	chr7:133584085	C/T	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.74e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg07216194	chr8:27182965	PTK2B	0.47	5.88	0.35	1.32e-8	Neuroticism;
KIRP	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.52	-6.9	-0.4	4.28e-11	Schizophrenia;
KIRP	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg16512390	chr1:228756714	NA	0.77	6.25	0.37	1.83e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.37	-0.55	3.75e-21	Hypospadias;
KIRP	cis	rs9810890	0.850	rs79042456	chr3:128517917	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05220968	chr6:146057943	EPM2A	-0.42	-5.61	-0.34	5.45e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.53e-45	Cognitive function;
KIRP	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	1.12	13.29	0.65	9.34e-31	Iron status biomarkers;
KIRP	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.73	10.57	0.56	8.84e-22	Anterior chamber depth;
KIRP	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13047869	chr3:10149882	C3orf24	0.57	5.31	0.32	2.48e-7	Alzheimer's disease;
KIRP	cis	rs526231	0.511	rs73179850	chr5:102348577	T/A	cg23492399	chr5:102201601	PAM	-0.51	-5.7	-0.34	3.41e-8	Primary biliary cholangitis;
KIRP	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg26384229	chr12:38710491	ALG10B	0.62	7.89	0.45	9.65e-14	Resting heart rate;
KIRP	cis	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg02972257	chr16:68554789	NA	-0.51	-4.99	-0.3	1.14e-6	Ulcerative colitis;
KIRP	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.73	-8.4	-0.47	3.64e-15	Adiposity;
KIRP	cis	rs865483	0.861	rs1063215	chr17:35874936	A/G	cg06716730	chr17:35851459	DUSP14	0.22	5.13	0.31	5.99e-7	Monocyte count;
KIRP	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg06565975	chr8:143823917	SLURP1	-0.56	-7.88	-0.45	1.03e-13	Urinary tract infection frequency;
KIRP	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.37	-0.32	1.79e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg17554472	chr22:41940697	POLR3H	-0.4	-4.93	-0.3	1.5e-6	Vitiligo;
KIRP	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg19875535	chr5:140030758	IK	0.53	6.59	0.39	2.59e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7527798	0.592	rs11118359	chr1:207858546	T/C	cg09232269	chr1:207846808	CR1L	-0.37	-5.35	-0.32	1.98e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs4751006	0.649	rs76125285	chr10:128779647	C/T	cg05702161	chr10:128779687	DOCK1	-1.12	-8.23	-0.46	1.11e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg01324507	chr7:1177794	C7orf50	0.41	5.13	0.31	6.01e-7	Longevity;Endometriosis;
KIRP	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg17145862	chr1:211918768	LPGAT1	0.76	10.56	0.56	9.48e-22	Leprosy;
KIRP	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg02804510	chr19:49199965	FUT2	0.34	4.94	0.3	1.41e-6	Dietary macronutrient intake;
KIRP	cis	rs6541297	0.699	rs4846915	chr1:230296470	C/A	cg20703242	chr1:230279135	GALNT2	0.33	4.9	0.3	1.76e-6	Coronary artery disease;
KIRP	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg00361562	chr2:198649771	BOLL	-0.53	-5.19	-0.31	4.41e-7	Ulcerative colitis;
KIRP	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.7	10.7	0.56	3.56e-22	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs7847231	0.504	rs2157664	chr9:118209542	C/T	cg13918206	chr9:118159781	DEC1	-0.33	-4.89	-0.3	1.79e-6	Educational attainment;
KIRP	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg07930552	chr6:133119739	C6orf192	0.82	5.79	0.35	2.13e-8	Type 2 diabetes nephropathy;
KIRP	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.39	-0.55	3.23e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	7.1	0.41	1.34e-11	Coffee consumption (cups per day);
KIRP	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.88	-14.69	-0.68	1.69e-35	Oral cavity cancer;
KIRP	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg21174375	chr14:64681225	SYNE2	0.44	4.93	0.3	1.52e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12924262	chr12:102091054	CHPT1	0.49	6.32	0.37	1.23e-9	Blood protein levels;
KIRP	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.95	15.04	0.69	1.09e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.76	6.41	0.38	7.52e-10	Initial pursuit acceleration;
KIRP	trans	rs13170463	0.579	rs13180823	chr5:8042899	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09775785	chr19:1863133	KLF16	-0.57	-6.17	-0.37	2.84e-9	Menopause (age at onset);
KIRP	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-7.25	-0.42	5.27e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg26531700	chr6:26746687	NA	-0.4	-5.43	-0.33	1.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg02070118	chr4:952128	TMEM175	0.62	5.03	0.31	9.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.36	-4.99	-0.3	1.12e-6	Neuroticism;
KIRP	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.9	11.68	0.6	2.3e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg23682824	chr7:23144976	KLHL7	0.56	6.77	0.4	9.38e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg18190219	chr22:46762943	CELSR1	-0.81	-6.71	-0.39	1.33e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg21698718	chr17:80085957	CCDC57	0.34	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg07636037	chr3:49044803	WDR6	0.57	5.4	0.33	1.6e-7	Menarche (age at onset);
KIRP	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg10523679	chr1:76189770	ACADM	-0.46	-6.38	-0.38	8.52e-10	Daytime sleep phenotypes;
KIRP	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.2	16.09	0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg19274270	chr17:78178856	CARD14	-0.36	-6.44	-0.38	6.06e-10	Educational attainment (years of education);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27305525	chr1:154955752	FLAD1	0.62	7.35	0.42	2.88e-12	Smoking initiation;
KIRP	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.62	8.42	0.47	3.18e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15128208	chr22:42549153	NA	-0.44	-5.55	-0.33	7.4e-8	Cognitive function;
KIRP	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.74	-8.54	-0.48	1.37e-15	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.39e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06850241	chr22:41845214	NA	-0.44	-5.07	-0.31	7.83e-7	Vitiligo;
KIRP	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.69	8.19	0.46	1.39e-14	Breast cancer;
KIRP	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg22800045	chr5:56110881	MAP3K1	0.61	7.03	0.41	2.06e-11	Initial pursuit acceleration;
KIRP	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.24	-0.42	5.66e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg11168104	chr5:1857477	NA	-0.39	-5.04	-0.31	9.21e-7	Cardiovascular disease risk factors;
KIRP	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg00852783	chr1:26633632	UBXN11	0.56	7.94	0.45	7.2e-14	Obesity-related traits;
KIRP	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg13256891	chr4:100009986	ADH5	0.47	5.88	0.35	1.33e-8	Alcohol dependence;
KIRP	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.77	9.95	0.54	8.22e-20	Coronary artery disease;
KIRP	cis	rs918629	0.798	rs6894651	chr5:95292267	C/T	cg16656078	chr5:95278638	ELL2	-0.47	-6.75	-0.4	1.09e-10	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.25	-0.37	1.82e-9	Lung cancer;
KIRP	cis	rs1076160	1.000	rs883838	chr9:135815474	T/G	cg04648087	chr9:135819397	TSC1	-0.4	-5.22	-0.32	3.76e-7	Psoriasis;
KIRP	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.8	-13.27	-0.65	1.09e-30	Prostate cancer;
KIRP	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11225247	0.536	rs12277853	chr11:102257853	A/G	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs17023223	0.581	rs10923750	chr1:119650795	T/G	cg05756136	chr1:119680316	WARS2	-0.61	-8.2	-0.46	1.37e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.98	-9.71	-0.53	4.49e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.62	5.24	0.32	3.44e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg10253484	chr15:75165896	SCAMP2	-0.6	-6.91	-0.4	4.15e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.46	5.75	0.34	2.64e-8	Height;
KIRP	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg11189052	chr15:85197271	WDR73	-0.49	-5.91	-0.35	1.15e-8	P wave terminal force;
KIRP	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg05973401	chr12:123451056	ABCB9	0.54	6.1	0.36	4.12e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.68e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15004949	chr19:8578767	ZNF414	0.5	6.28	0.37	1.56e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.4	0.7	6.37e-38	Gut microbiome composition (summer);
KIRP	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg19875535	chr5:140030758	IK	0.62	8.62	0.48	8.53e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg18154014	chr19:37997991	ZNF793	0.65	5.41	0.33	1.53e-7	Coronary artery calcification;
KIRP	trans	rs6601327	0.613	rs12677507	chr8:9481687	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.99	-0.41	2.63e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.55	-5.57	-0.33	6.69e-8	Dental caries;
KIRP	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.59	-7.26	-0.42	5.15e-12	Aortic root size;
KIRP	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg09264619	chr17:80180166	NA	0.39	5.53	0.33	8.11e-8	Life satisfaction;
KIRP	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg10755058	chr3:40428713	ENTPD3	0.39	5.63	0.34	5.02e-8	Renal cell carcinoma;
KIRP	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.23	25.81	0.85	5.97e-72	IgG glycosylation;
KIRP	cis	rs61501627	1.000	rs1368801	chr15:39227595	C/G	cg20597477	chr15:40211272	GPR176	0.88	5.13	0.31	5.77e-7	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);
KIRP	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg17366294	chr4:99064904	C4orf37	0.44	6.38	0.38	8.94e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.42	-6.69	-0.39	1.48e-10	Eye color traits;
KIRP	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.65	8.68	0.48	5.39e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs758324	0.947	rs7708140	chr5:131252396	A/G	cg06307176	chr5:131281290	NA	0.47	5.23	0.32	3.54e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg23335576	chr14:104009727	NA	0.4	5.77	0.35	2.36e-8	Body mass index;
KIRP	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	-0.44	-4.95	-0.3	1.39e-6	Resistin levels;
KIRP	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	1.09	16.21	0.72	1.08e-40	Eosinophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg08712631	chr7:1960676	MAD1L1	-0.41	-5.37	-0.32	1.83e-7	Neuroticism;
KIRP	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05523653	chr17:900031	TIMM22	0.49	6.58	0.39	2.76e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11599998	chr3:160283537	KPNA4	-0.49	-6.79	-0.4	8.54e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.42e-10	Hypertriglyceridemia;
KIRP	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg03289416	chr15:75166202	SCAMP2	-0.44	-6.19	-0.37	2.48e-9	Caffeine consumption;
KIRP	cis	rs6539267	0.885	rs34762209	chr12:106722466	T/C	cg00173435	chr12:106696525	TCP11L2	0.63	6.32	0.37	1.19e-9	Tourette syndrome;
KIRP	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-5.4	-0.33	1.56e-7	Lung cancer;
KIRP	cis	rs2274273	0.662	rs66476033	chr14:55660863	C/A	cg04306507	chr14:55594613	LGALS3	0.42	5.58	0.34	6.18e-8	Protein biomarker;
KIRP	cis	rs6832769	1.000	rs11733864	chr4:56321530	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.51	-8.55	-0.48	1.29e-15	Height;
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.18	-0.31	4.67e-7	Breast cancer;
KIRP	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs6466055	0.748	rs41563	chr7:104852654	G/A	cg04380332	chr7:105027541	SRPK2	-0.63	-9.63	-0.52	7.86e-19	Schizophrenia;
KIRP	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.91	14.33	0.67	2.89e-34	Triglycerides;
KIRP	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg02570527	chr1:10970165	NA	-0.4	-4.9	-0.3	1.74e-6	Body mass index;
KIRP	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.48	-5.88	-0.35	1.32e-8	Coronary artery disease;
KIRP	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.72	-9.1	-0.5	3.12e-17	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs6973256	0.865	rs763646	chr7:133343353	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.38	-0.38	8.55e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1322639	0.614	rs6940913	chr6:169563666	G/A	cg04662567	chr6:169592167	NA	-0.64	-5.39	-0.33	1.64e-7	Pulse pressure;
KIRP	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg24503407	chr1:205819492	PM20D1	0.46	5.04	0.31	9.1e-7	Parkinson's disease;
KIRP	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.58	-6.95	-0.41	3.17e-11	Vitiligo;
KIRP	cis	rs6466055	0.661	rs2299305	chr7:104791075	A/G	cg04380332	chr7:105027541	SRPK2	0.36	4.9	0.3	1.7e-6	Schizophrenia;
KIRP	cis	rs10073892	0.750	rs10072167	chr5:101642257	G/T	cg19774478	chr5:101632501	SLCO4C1	0.66	6.46	0.38	5.58e-10	Cognitive decline (age-related);
KIRP	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.86	10.44	0.55	2.38e-21	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg20312557	chr2:97357134	FER1L5	-0.79	-5.51	-0.33	9.19e-8	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs10492096	0.947	rs12371184	chr12:6632925	A/G	cg13857086	chr12:6580257	VAMP1	0.62	6.33	0.37	1.13e-9	Hip geometry;
KIRP	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg14345882	chr6:26364793	BTN3A2	0.34	5.73	0.34	2.99e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.69	8.06	0.46	3.32e-14	Cocaine dependence;
KIRP	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg14703610	chr5:56206110	C5orf35	-0.48	-6.68	-0.39	1.59e-10	Coronary artery disease;
KIRP	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.59	-9.1	-0.5	3.17e-17	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00629928	chr5:358741	AHRR	0.5	4.86	0.3	2.09e-6	Breast cancer;
KIRP	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.74	-0.44	2.5e-13	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17221829	0.733	rs10830337	chr11:89407049	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.13	-0.31	5.82e-7	Anxiety in major depressive disorder;
KIRP	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.07	0.36	4.82e-9	Height;
KIRP	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg01028140	chr2:1542097	TPO	-0.51	-5.82	-0.35	1.81e-8	IgG glycosylation;
KIRP	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-1.0	-15.73	-0.71	4.78e-39	Coronary artery disease;
KIRP	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.54	7.11	0.41	1.24e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1816752	0.819	rs6490917	chr13:24997257	G/T	cg02811702	chr13:24901961	NA	0.42	5.53	0.33	8.04e-8	Obesity-related traits;
KIRP	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.75	-0.34	2.58e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg01721255	chr8:58191610	C8orf71	0.53	5.14	0.31	5.64e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12448860	chr6:106959601	AIM1	0.46	6.48	0.38	5.07e-10	Parkinson's disease;
KIRP	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg04132472	chr17:19861366	AKAP10	0.64	9.49	0.52	2.14e-18	Schizophrenia;
KIRP	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg02336718	chr17:17403227	NA	0.37	5.54	0.33	7.83e-8	Total body bone mineral density;
KIRP	cis	rs11169552	0.510	rs4238106	chr12:50997591	A/C	cg12884762	chr12:50931848	DIP2B	-0.42	-4.88	-0.3	1.87e-6	Colorectal cancer;
KIRP	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg14972814	chr11:95582409	MTMR2	-0.35	-5.93	-0.35	1.04e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	6.56	0.39	3.15e-10	Schizophrenia;
KIRP	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.51	-6.72	-0.39	1.27e-10	Aortic root size;
KIRP	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg15655495	chr12:38532458	NA	0.26	5.01	0.3	1.05e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9815354	0.680	rs112310714	chr3:42024797	A/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2882667	0.867	rs11749045	chr5:138420960	C/T	cg04439458	chr5:138467593	SIL1	-0.41	-6.94	-0.4	3.5e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-4.89	-0.3	1.84e-6	Mean platelet volume;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg05861140	chr6:150128134	PCMT1	0.45	6.39	0.38	8.26e-10	Lung cancer;
KIRP	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg05555928	chr11:63887634	MACROD1	-0.39	-5.27	-0.32	2.96e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1873147	1.000	rs12440411	chr15:63313581	T/G	cg12160578	chr15:63334699	TPM1	-0.47	-5.77	-0.35	2.39e-8	Orofacial clefts;
KIRP	cis	rs7560272	0.538	rs17434634	chr2:73922926	T/A	cg20560298	chr2:73613845	ALMS1	0.51	6.22	0.37	2.06e-9	Schizophrenia;
KIRP	cis	rs35883536	0.647	rs2809795	chr1:101038345	A/G	cg09408571	chr1:101003634	GPR88	0.23	5.14	0.31	5.55e-7	Monocyte count;
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg23985595	chr17:80112537	CCDC57	-0.33	-4.86	-0.3	2.09e-6	Life satisfaction;
KIRP	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs10811516	0.520	rs4568676	chr9:21184475	C/G	cg23029519	chr9:21187344	IFNA4	0.52	6.29	0.37	1.47e-9	Response to mepolizumab in severe asthma;
KIRP	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg23601095	chr6:26197514	HIST1H3D	0.91	7.48	0.43	1.33e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg18646521	chr2:111875858	NA	0.41	5.85	0.35	1.59e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg19468946	chr17:37922297	IKZF3	-0.49	-6.9	-0.4	4.42e-11	Self-reported allergy;
KIRP	cis	rs11723261	0.582	rs11732336	chr4:140512	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.49	5.09	0.31	6.96e-7	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.75	-9.52	-0.52	1.71e-18	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg06636001	chr8:8085503	FLJ10661	0.71	9.24	0.51	1.19e-17	Neuroticism;
KIRP	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13047869	chr3:10149882	C3orf24	0.52	4.89	0.3	1.81e-6	Alzheimer's disease;
KIRP	cis	rs1062177	0.724	rs2915828	chr5:151118121	G/A	cg00977110	chr5:151150581	G3BP1	-0.61	-6.2	-0.37	2.4e-9	Preschool internalizing problems;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.85	0.35	1.56e-8	Lung cancer;
KIRP	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg11764359	chr7:65958608	NA	0.74	5.02	0.3	1.01e-6	Diabetic kidney disease;
KIRP	cis	rs3857747	0.827	rs12234882	chr7:40451643	A/G	cg00420559	chr7:40367873	C7orf10	-0.57	-7.78	-0.44	1.98e-13	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2070997	0.702	rs1056209	chr9:133762590	G/A	cg13397898	chr9:133768931	QRFP	0.36	4.9	0.3	1.75e-6	Response to amphetamines;
KIRP	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg01475377	chr6:109611718	NA	-0.36	-4.92	-0.3	1.6e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg09904177	chr6:26538194	HMGN4	-0.42	-5.17	-0.31	4.84e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg24579218	chr15:68104479	NA	-0.55	-7.81	-0.45	1.6e-13	Restless legs syndrome;
KIRP	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.7	9.77	0.53	2.82e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg07701084	chr6:150067640	NUP43	0.65	8.35	0.47	4.97e-15	Lung cancer;
KIRP	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.77	-0.35	2.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg11783602	chr8:55087084	NA	-0.57	-7.02	-0.41	2.13e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.69	-10.21	-0.55	1.21e-20	Idiopathic membranous nephropathy;
KIRP	trans	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.24e-10	Diabetic kidney disease;
KIRP	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg16586182	chr3:47516702	SCAP	0.74	9.93	0.53	9.29e-20	Colorectal cancer;
KIRP	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs55962025	0.711	rs2298971	chr4:3200079	A/G	cg06533319	chr4:3265114	C4orf44	0.39	4.96	0.3	1.35e-6	Parental longevity (mother's age at death);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11735308	chr3:107941242	IFT57	-0.5	-6.28	-0.37	1.5e-9	Interleukin-4 levels;
KIRP	cis	rs3026101	0.671	rs56300366	chr17:5297839	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.88	0.35	1.34e-8	Body mass index;
KIRP	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.38	-0.38	8.49e-10	Neuroticism;
KIRP	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg10223061	chr2:219282414	VIL1	0.28	4.89	0.3	1.85e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.08e-11	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg02811702	chr13:24901961	NA	0.41	5.15	0.31	5.34e-7	Obesity-related traits;
KIRP	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.66	11.54	0.59	6.6e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	0.731	rs10207567	chr2:203714973	C/G	cg08076091	chr2:203926405	NBEAL1	0.49	5.91	0.35	1.14e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs10027350	0.734	rs313551	chr4:25242141	G/T	cg09449104	chr2:200935	NA	-0.38	-6.14	-0.36	3.31e-9	Childhood ear infection;
KIRP	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.41	-7.35	-0.42	2.96e-12	Refractive error;
KIRP	cis	rs1210638	0.756	rs2518800	chr22:18973471	C/T	cg06148736	chr22:18985691	NA	-0.31	-5.19	-0.31	4.44e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.78	7.73	0.44	2.71e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.44	7.01	0.41	2.3e-11	Eye color traits;
KIRP	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg06212747	chr3:49208901	KLHDC8B	0.71	8.35	0.47	4.98e-15	Menarche (age at onset);
KIRP	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs712039	0.652	rs853232	chr17:35841181	G/A	cg16670864	chr17:35848621	DUSP14	0.38	5.17	0.31	4.75e-7	Tuberculosis;
KIRP	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.86	0.4	5.7e-11	Bipolar disorder;
KIRP	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-8.94	-0.5	9.22e-17	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	0.92	12.02	0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg07701084	chr6:150067640	NUP43	0.66	8.49	0.48	2.02e-15	Lung cancer;
KIRP	cis	rs7932354	0.528	rs6485739	chr11:47145072	G/A	cg16389345	chr11:46697382	NA	0.39	5.16	0.31	5.06e-7	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.7	-8.34	-0.47	5.34e-15	Obesity-related traits;
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg16590910	chr6:42928470	GNMT	0.47	6.7	0.39	1.42e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.35	-4.9	-0.3	1.74e-6	Monocyte count;
KIRP	cis	rs12200782	1.000	rs10456330	chr6:26436692	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.72	-6.27	-0.37	1.63e-9	Small cell lung carcinoma;
KIRP	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.36	-0.38	9.97e-10	Daytime sleep phenotypes;
KIRP	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07570687	chr10:102243282	WNT8B	0.4	5.01	0.3	1.03e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.87	-0.4	5.17e-11	Alzheimer's disease (late onset);
KIRP	cis	rs62388641	0.539	rs56304710	chr6:1542576	C/T	cg01806741	chr6:1527072	NA	-0.38	-5.88	-0.35	1.33e-8	Daytime sleep phenotypes;
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.78	11.96	0.61	2.65e-26	Menarche (age at onset);
KIRP	trans	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg06521331	chr12:34319734	NA	0.55	6.81	0.4	7.43e-11	Bladder cancer;
KIRP	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.44	-6.06	-0.36	5.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg14349672	chr11:133703707	NA	-0.43	-4.96	-0.3	1.33e-6	Childhood ear infection;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.55e-7	Life satisfaction;
KIRP	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-0.77	-7.06	-0.41	1.72e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.99	12.57	0.63	2.6e-28	Alzheimer's disease;
KIRP	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.47	6.82	0.4	6.84e-11	Blood metabolite levels;
KIRP	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	8.29	0.47	7.37e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4132509	1.000	rs12049228	chr1:243995271	C/A	cg25706552	chr1:244017396	NA	0.59	7.16	0.42	9.44e-12	RR interval (heart rate);
KIRP	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.62	-7.69	-0.44	3.49e-13	Glomerular filtration rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16583330	chr1:36916012	OSCP1	0.49	7.12	0.41	1.16e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.6	8.74	0.49	3.82e-16	Dupuytren's disease;
KIRP	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.72	9.11	0.5	2.94e-17	Coronary artery disease;
KIRP	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs735860	0.763	rs1429146	chr6:53130285	C/T	cg10236188	chr6:53219634	NA	-0.39	-5.28	-0.32	2.82e-7	Glaucoma;
KIRP	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg16141378	chr3:129829833	LOC729375	0.52	6.77	0.4	9.39e-11	Retinal vascular caliber;
KIRP	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg20628663	chr10:43360327	NA	0.54	6.34	0.37	1.07e-9	Blood protein levels;
KIRP	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.99	13.06	0.64	5.65e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.51	-0.38	4.24e-10	Lung cancer;
KIRP	cis	rs34286592	0.929	rs8058824	chr16:29828710	C/G	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	5.1	0.31	6.78e-7	Multiple sclerosis;
KIRP	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07623839	chr16:767530	NA	0.69	8.49	0.48	1.92e-15	Height;
KIRP	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.5	0.38	4.37e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10875746	0.551	rs1471997	chr12:48723595	G/A	cg20731937	chr12:48336164	NA	0.45	5.57	0.33	6.61e-8	Longevity (90 years and older);
KIRP	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	5.66	0.34	4.24e-8	Menarche (age at onset);
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19872317	chr14:65346686	NA	0.48	6.05	0.36	5.41e-9	Smoking initiation;
KIRP	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-5.0	-0.3	1.1e-6	Initial pursuit acceleration;
KIRP	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.45e-21	Diabetic kidney disease;
KIRP	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg17376030	chr22:41985996	PMM1	-0.58	-6.84	-0.4	6.13e-11	Vitiligo;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09976981	chr22:43564007	TTLL12	-0.45	-6.16	-0.37	2.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.78	-10.71	-0.56	3.22e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg00919237	chr7:87102261	ABCB4	-0.74	-9.23	-0.51	1.29e-17	Gallbladder cancer;
KIRP	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.79	11.1	0.58	1.82e-23	Menarche (age at onset);
KIRP	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.67	-7.65	-0.44	4.65e-13	Gut microbiome composition (summer);
KIRP	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.75	0.49	3.51e-16	Bipolar disorder;
KIRP	cis	rs447921	0.861	rs36119142	chr17:74454336	T/G	cg16776035	chr17:74542680	NA	-0.6	-4.93	-0.3	1.52e-6	Mitochondrial DNA levels;
KIRP	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.78	11.36	0.59	2.52e-24	Schizophrenia;
KIRP	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg19913688	chr11:428466	ANO9	0.94	8.35	0.47	4.85e-15	Body mass index;
KIRP	cis	rs7404928	0.651	rs56350292	chr16:23947611	C/A	cg21745164	chr16:23765304	CHP2	-0.36	-5.1	-0.31	6.64e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.51e-9	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06899192	chr17:35767064	ACACA;TADA2A	0.54	6.63	0.39	2.1e-10	Parkinson's disease;
KIRP	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	1.32	9.84	0.53	1.73e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs2472591	0.929	rs2475837	chr13:50535863	C/T	cg04548715	chr7:99598775	NA	0.57	6.38	0.38	8.72e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg04691961	chr3:161091175	C3orf57	-0.48	-7.21	-0.42	6.97e-12	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg09699651	chr6:150184138	LRP11	-0.48	-6.24	-0.37	1.9e-9	Lung cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg16868751	chr10:96162146	TBC1D12	0.52	6.53	0.38	3.74e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.74	8.82	0.49	2.17e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs12210905	1.000	rs72843613	chr6:27138467	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.77	-6.49	-0.38	4.74e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg25730555	chr22:47059586	GRAMD4	0.49	5.85	0.35	1.56e-8	Urate levels in obese individuals;
KIRP	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.63	-0.56	5.81e-22	Refractive error;
KIRP	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg07395648	chr5:131743802	NA	-0.39	-5.49	-0.33	9.97e-8	Blood metabolite levels;
KIRP	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.39	9.44	0.52	2.95e-18	Corneal astigmatism;
KIRP	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	5.96	0.36	8.85e-9	Menarche (age at onset);
KIRP	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg04374321	chr14:90722782	PSMC1	-0.84	-11.75	-0.6	1.35e-25	Mortality in heart failure;
KIRP	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.95	-11.41	-0.59	1.78e-24	Exhaled nitric oxide levels;
KIRP	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.59	0.34	6.17e-8	Schizophrenia;
KIRP	trans	rs7999699	0.967	rs9534811	chr13:48335221	T/C	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Colorectal cancer (diet interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04902049	chr1:36622448	MAP7D1	0.77	6.55	0.39	3.39e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs829883	0.724	rs1439774	chr12:98907692	C/T	cg25150519	chr12:98850993	NA	-0.76	-9.33	-0.51	6.45e-18	Colorectal adenoma (advanced);
KIRP	trans	rs9217	1.000	rs9217	chr17:7363088	T/C	cg08566640	chr11:64091735	NA	-0.54	-6.72	-0.39	1.26e-10	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03672602	chr19:19754555	GMIP	0.52	6.15	0.37	3.13e-9	Smoking initiation;
KIRP	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-20.03	-0.79	1.4e-53	Height;
KIRP	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.53	0.75	3.3e-45	Chronic sinus infection;
KIRP	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.57	7.41	0.43	1.97e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg12315302	chr6:26189340	HIST1H4D	0.71	5.47	0.33	1.09e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs745821	0.701	rs3853681	chr18:48100771	G/A	cg18923635	chr18:48083994	NA	0.43	5.12	0.31	6.19e-7	Diastolic blood pressure;
KIRP	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-10.98	-0.57	4.29e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs10861342	1.000	rs10861350	chr12:105484913	G/A	cg23923672	chr12:105501055	KIAA1033	0.83	6.36	0.38	9.66e-10	IgG glycosylation;
KIRP	cis	rs6662572	0.737	rs11584814	chr1:46504389	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.63	0.34	4.91e-8	Blood protein levels;
KIRP	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.83	12.94	0.64	1.47e-29	Metabolic syndrome;
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.61	8.26	0.47	9.17e-15	Vitiligo;
KIRP	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.56	6.94	0.4	3.44e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg00204512	chr16:28754710	NA	0.43	5.3	0.32	2.53e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.69	5.57	0.33	6.83e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg07395648	chr5:131743802	NA	-0.62	-7.08	-0.41	1.48e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.88	6.62	0.39	2.25e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg05805236	chr11:65401703	PCNXL3	-0.37	-5.1	-0.31	6.86e-7	Systemic lupus erythematosus;
KIRP	cis	rs4663866	1.000	rs13026475	chr2:239178455	T/C	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.68	-0.34	3.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.87	8.72	0.49	4.23e-16	Chronic sinus infection;
KIRP	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.9	-0.45	9.01e-14	Neuroticism;
KIRP	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg05370193	chr1:21551575	ECE1	0.43	6.08	0.36	4.45e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.65	9.58	0.52	1.09e-18	Menarche (age at onset);
KIRP	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.58	5.3	0.32	2.59e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg08975724	chr8:8085496	FLJ10661	0.56	7.36	0.42	2.67e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1440410	0.835	rs11100780	chr4:144104906	G/A	cg01719995	chr4:144104893	USP38	0.45	6.25	0.37	1.81e-9	Ischemic stroke;
KIRP	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg02725872	chr8:58115012	NA	-0.53	-6.22	-0.37	2.11e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-0.83	-9.23	-0.51	1.28e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.41	5.09	0.31	7.21e-7	Longevity;Endometriosis;
KIRP	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.57	8.04	0.46	3.78e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7221595	0.778	rs12946045	chr17:3904307	G/C	cg09695851	chr17:3907499	NA	0.62	6.76	0.4	1.01e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7374004	1.000	rs7374004	chr3:38625709	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-5.54	-0.33	7.79e-8	PR interval;
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs4523957	0.671	rs7223161	chr17:2176181	G/A	cg16513277	chr17:2031491	SMG6	-0.49	-5.89	-0.35	1.23e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4664293	0.899	rs7588710	chr2:160529522	T/A	cg08347373	chr2:160653686	CD302	-0.43	-6.17	-0.37	2.75e-9	Monocyte percentage of white cells;
KIRP	cis	rs3779635	1.000	rs725788	chr8:27265371	T/C	cg23736307	chr8:27182930	PTK2B	0.45	5.81	0.35	1.92e-8	Neuroticism;
KIRP	cis	rs2273669	0.915	rs6568554	chr6:109290319	C/A	cg05315195	chr6:109294784	ARMC2	-0.5	-5.66	-0.34	4.22e-8	Prostate cancer;
KIRP	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.52	5.16	0.31	5.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.28e-7	Bipolar disorder;
KIRP	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.61	-6.75	-0.4	1.08e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14608422	chr10:75634225	CAMK2G	0.45	6.08	0.36	4.52e-9	Cancer;
KIRP	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.83	-10.88	-0.57	9.02e-23	Parkinson's disease;
KIRP	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg12384639	chr17:618140	VPS53	0.47	5.99	0.36	7.26e-9	Prostate cancer;
KIRP	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22878388	chr2:105853796	NA	-0.42	-7.03	-0.41	2.06e-11	Type 2 diabetes;
KIRP	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	cg12689670	chr1:183009347	LAMC1	0.45	6.53	0.38	3.81e-10	Colorectal cancer;
KIRP	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.66	9.09	0.5	3.43e-17	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.64	-0.34	4.55e-8	Life satisfaction;
KIRP	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg08773314	chr2:239334832	ASB1	0.41	7.3	0.42	4e-12	Multiple system atrophy;
KIRP	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00376283	chr12:123451042	ABCB9	-0.67	-6.35	-0.38	1.04e-9	Neutrophil percentage of white cells;
KIRP	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.63	6.3	0.37	1.35e-9	Axial length;
KIRP	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg09571762	chr12:39539558	NA	0.37	5.19	0.31	4.51e-7	Morning vs. evening chronotype;
KIRP	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.85	11.95	0.61	2.99e-26	Platelet distribution width;
KIRP	trans	rs1941687	0.797	rs12967889	chr18:31399371	G/A	cg04226714	chr8:49833948	SNAI2	-0.45	-6.08	-0.36	4.5e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg16586182	chr3:47516702	SCAP	0.61	8.47	0.48	2.24e-15	Colorectal cancer;
KIRP	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.65	-0.52	6.83e-19	Total body bone mineral density;
KIRP	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg24747557	chr10:131355152	MGMT	-0.44	-5.95	-0.35	9.09e-9	Response to temozolomide;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.6	-8.43	-0.47	2.88e-15	Mean corpuscular volume;
KIRP	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.08	-0.5	3.69e-17	Retinal vascular caliber;
KIRP	cis	rs2274273	0.934	rs17740741	chr14:55762712	G/C	cg04306507	chr14:55594613	LGALS3	0.41	6.02	0.36	6.24e-9	Protein biomarker;
KIRP	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg09904177	chr6:26538194	HMGN4	-0.54	-7.01	-0.41	2.23e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.62	-6.6	-0.39	2.49e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg11234688	chr2:1609660	NA	0.53	4.97	0.3	1.24e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg19752551	chr11:57585705	CTNND1	-0.68	-11.35	-0.59	2.76e-24	Schizophrenia;
KIRP	cis	rs11967485	0.686	rs72996913	chr6:157135778	G/A	cg23222435	chr6:157204239	ARID1B	-0.74	-4.98	-0.3	1.19e-6	Calcium levels;
KIRP	trans	rs921874	0.553	rs2512357	chr11:86775119	A/G	cg20852851	chr2:240168848	HDAC4	0.45	6.15	0.37	3.16e-9	Total body bone mineral density;
KIRP	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.47	-6.02	-0.36	6.43e-9	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.95	16.25	0.72	7.82e-41	Breast cancer;
KIRP	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.56e-13	Corneal astigmatism;
KIRP	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.61	5.99	0.36	7.58e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.69	0.44	3.53e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17401966	0.502	rs6541080	chr1:10236039	A/G	cg19773385	chr1:10388646	KIF1B	0.38	5.2	0.31	4.15e-7	Hepatocellular carcinoma;
KIRP	cis	rs12096438	1.000	rs3924236	chr1:25895406	C/T	cg21452808	chr1:25900135	NA	0.36	5.72	0.34	3.05e-8	Platelet count;Mean platelet volume;
KIRP	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg23920097	chr1:209922102	NA	-0.43	-5.77	-0.35	2.34e-8	Red blood cell count;
KIRP	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg00677455	chr12:58241039	CTDSP2	-0.52	-5.8	-0.35	2.02e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.92	-0.4	3.93e-11	Neuroticism;
KIRP	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-7.85	-0.45	1.32e-13	Coronary artery disease;
KIRP	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.71	9.33	0.51	6.29e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.64	0.73	3.78e-42	Chronic sinus infection;
KIRP	trans	rs9329221	0.502	rs11777364	chr8:10288546	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.39	0.38	8.02e-10	Neuroticism;
KIRP	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-5.06	-0.31	8.1e-7	Aortic root size;
KIRP	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg12131826	chr15:77904385	NA	0.48	5.75	0.34	2.67e-8	Type 2 diabetes;
KIRP	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	0.8	9.42	0.51	3.54e-18	Testicular germ cell tumor;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20321375	chr12:8185526	FOXJ2	0.56	6.51	0.38	4.3e-10	Smoking initiation;
KIRP	trans	rs6601327	0.600	rs10103925	chr8:9652211	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.14	-0.41	1.06e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	10.11	0.54	2.59e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg01677386	chr11:118938358	VPS11	-0.52	-6.25	-0.37	1.83e-9	Coronary artery disease;
KIRP	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.84	0.35	1.68e-8	Cognitive test performance;
KIRP	cis	rs6500395	0.609	rs8057605	chr16:48565569	T/C	cg04672837	chr16:48644449	N4BP1	0.44	6.09	0.36	4.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.57	-9.24	-0.51	1.18e-17	Prostate cancer;
KIRP	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-7.32	-0.42	3.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.51	-7.73	-0.44	2.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.97	-0.3	1.25e-6	Blood metabolite levels;
KIRP	cis	rs2249694	1.000	rs2249694	chr10:135352153	A/G	cg20169779	chr10:135381914	SYCE1	0.45	5.16	0.31	5.11e-7	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg23985595	chr17:80112537	CCDC57	-0.35	-5.22	-0.32	3.74e-7	Life satisfaction;
KIRP	cis	rs3857747	0.931	rs4723951	chr7:40363735	C/T	cg00420559	chr7:40367873	C7orf10	-0.62	-8.4	-0.47	3.65e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.56	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs6832769	1.000	rs12646078	chr4:56368204	T/C	cg09317128	chr4:56265301	TMEM165	0.53	6.58	0.39	2.84e-10	Personality dimensions;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25137155	chr5:110888191	NA	-0.39	-6.12	-0.36	3.68e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11718455	0.767	rs13075535	chr3:43954612	G/A	cg21419209	chr3:44054225	NA	-0.71	-8.08	-0.46	2.94e-14	Coronary artery disease;
KIRP	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.48	-5.98	-0.36	7.64e-9	Monocyte count;
KIRP	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg26876637	chr1:152193138	HRNR	-0.75	-9.82	-0.53	1.99e-19	Atopic dermatitis;
KIRP	cis	rs6120849	0.802	rs6087681	chr20:33752896	G/C	cg24642439	chr20:33292090	TP53INP2	0.55	6.09	0.36	4.39e-9	Protein C levels;
KIRP	cis	rs7572644	0.699	rs12466717	chr2:28096792	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-5.19	-0.31	4.44e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.24	23.72	0.83	1.59e-65	Schizophrenia;
KIRP	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	1.19	14.49	0.68	7.97e-35	Night sleep phenotypes;
KIRP	cis	rs6142102	0.961	rs2284388	chr20:32655741	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	6.78	0.4	8.7e-11	Skin pigmentation;
KIRP	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg25319279	chr11:5960081	NA	-0.62	-6.46	-0.38	5.65e-10	DNA methylation (variation);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00850756	chr6:41909180	CCND3	-0.56	-6.14	-0.36	3.2e-9	Menopause (age at onset);
KIRP	cis	rs7692976	0.578	rs3796948	chr4:110854431	G/A	cg06981781	chr4:110842888	EGF	-0.24	-5.25	-0.32	3.31e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.99	8.86	0.49	1.65e-16	Exhaled nitric oxide output;
KIRP	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.59	9.33	0.51	6.49e-18	Urate levels in obese individuals;
KIRP	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg06027949	chr8:82754900	SNX16	0.54	5.79	0.35	2.19e-8	Diastolic blood pressure;
KIRP	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg17356467	chr2:100759845	AFF3	0.55	5.63	0.34	4.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.37	0.43	2.58e-12	Prudent dietary pattern;
KIRP	cis	rs959260	1.000	rs7211915	chr17:73379872	A/G	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.68	9.14	0.5	2.42e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3087591	0.666	rs2953016	chr17:29494693	C/G	cg24425628	chr17:29625626	OMG;NF1	0.71	8.94	0.5	9.77e-17	Hip circumference;
KIRP	cis	rs6459788	0.630	rs11977865	chr7:157234112	G/A	cg03453431	chr7:157225567	NA	-0.38	-4.97	-0.3	1.27e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.4	0.33	1.6e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11825064	0.832	rs11820355	chr11:134477985	A/G	cg06603561	chr11:134479413	NA	-0.54	-5.14	-0.31	5.57e-7	Seasonality;
KIRP	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.55	-0.52	1.42e-18	Triglycerides;
KIRP	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg25019033	chr10:957182	NA	-0.49	-5.23	-0.32	3.64e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs4305714	0.645	rs6923261	chr6:22933362	A/G	cg16403932	chr12:57881247	MARS	0.5	6.1	0.36	4.17e-9	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer;
KIRP	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.85	0.35	1.59e-8	Motion sickness;
KIRP	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	9.09	0.5	3.28e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3126085	0.560	rs2525	chr1:152339064	A/G	cg26876637	chr1:152193138	HRNR	-0.57	-6.22	-0.37	2.11e-9	Atopic dermatitis;
KIRP	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.45	5.61	0.34	5.57e-8	Eosinophil percentage of white cells;
KIRP	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg00495681	chr13:53174319	NA	0.44	5.98	0.36	7.78e-9	Lewy body disease;
KIRP	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.2	-0.31	4.14e-7	Pulmonary function;
KIRP	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	0.76	7.1	0.41	1.31e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs728478	0.935	rs8073731	chr17:57463982	A/G	cg16535752	chr17:57448097	YPEL2	-0.21	-4.99	-0.3	1.13e-6	QT interval;
KIRP	cis	rs3026101	0.624	rs1058383	chr17:5288203	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.52	-7.08	-0.41	1.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.89	0.45	9.71e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg23479056	chr15:41276147	INO80	0.36	4.94	0.3	1.47e-6	Menopause (age at onset);
KIRP	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.4	-0.43	2.21e-12	Triglycerides;
KIRP	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg22800045	chr5:56110881	MAP3K1	0.61	7.03	0.41	2.06e-11	Initial pursuit acceleration;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17342834	chr11:535396	HRAS	0.46	6.26	0.37	1.68e-9	Cancer;
KIRP	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.97	-0.45	5.87e-14	Gut microbiome composition (summer);
KIRP	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg21184320	chr1:21044207	KIF17	-0.38	-5.74	-0.34	2.76e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1359582	0.801	rs1555839	chr10:90382820	C/T	cg15661332	chr10:90342814	RNLS	0.57	6.18	0.37	2.67e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg27624424	chr6:160112604	SOD2	-0.56	-6.59	-0.39	2.73e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg06521331	chr12:34319734	NA	0.47	5.95	0.35	9.2e-9	Morning vs. evening chronotype;
KIRP	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg07862535	chr7:139043722	LUC7L2	0.48	5.3	0.32	2.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg00405596	chr8:11794950	NA	-0.41	-5.36	-0.32	1.95e-7	Triglycerides;
KIRP	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	1.0	9.86	0.53	1.58e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06734429	chr19:39926689	RPS16	0.5	6.84	0.4	6.26e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2916247	0.954	rs7007307	chr8:93063802	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg06766960	chr11:133703094	NA	0.71	9.8	0.53	2.4e-19	Childhood ear infection;
KIRP	cis	rs1843834	0.721	rs1434057	chr2:225606389	T/G	cg22509189	chr2:225307070	NA	-0.44	-5.38	-0.32	1.72e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.92	-0.35	1.07e-8	IgG glycosylation;
KIRP	cis	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg07585502	chr8:101912084	NA	-0.62	-8.87	-0.49	1.51e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg03854865	chr6:26224070	HIST1H3E	0.62	4.85	0.3	2.16e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.84	0.35	1.63e-8	Total cholesterol levels;
KIRP	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.24	0.37	1.89e-9	Neuroticism;
KIRP	cis	rs580438	0.510	rs2009190	chr3:13431430	T/C	cg10657019	chr3:13328039	NA	-0.47	-6.07	-0.36	4.81e-9	Myringotomy;
KIRP	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.9	14.74	0.68	1.13e-35	Dental caries;
KIRP	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.56	5.96	0.36	8.67e-9	Type 2 diabetes;
KIRP	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.62	8.37	0.47	4.52e-15	Testicular germ cell tumor;
KIRP	cis	rs11690462	0.534	rs13432533	chr2:26571411	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.39	-4.96	-0.3	1.29e-6	Coronary artery disease;
KIRP	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg14675211	chr2:100938903	LONRF2	0.48	6.26	0.37	1.74e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6681460	0.800	rs485543	chr1:67194372	C/T	cg02459107	chr1:67143332	SGIP1	-0.39	-5.56	-0.33	6.92e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6585424	1.000	rs61860045	chr10:81947397	C/T	cg27417294	chr10:81904244	PLAC9	0.53	5.04	0.31	8.98e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4319547	0.688	rs10847242	chr12:123079020	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.56	-7.17	-0.42	8.88e-12	Body mass index;
KIRP	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.33	-5.25	-0.32	3.34e-7	Testicular germ cell tumor;
KIRP	cis	rs12101261	0.580	rs8003515	chr14:81446242	G/C	cg06600135	chr14:81408086	NA	0.41	5.14	0.31	5.5e-7	Graves' disease;
KIRP	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7116495	0.609	rs73543612	chr11:71820350	C/T	cg10381502	chr11:71823885	C11orf51	1.15	7.55	0.43	8.26e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs10865541	0.967	rs6755448	chr2:3397359	T/C	cg11642891	chr2:3452563	TTC15	-0.5	-6.34	-0.37	1.08e-9	Obesity-related traits;
KIRP	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg20673841	chr7:107026890	COG5	0.39	4.87	0.3	1.99e-6	Coronary artery disease;
KIRP	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.61	-0.44	5.82e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs747782	0.646	rs61914719	chr11:48059091	C/T	cg03929089	chr4:120376271	NA	0.71	6.18	0.37	2.6e-9	Intraocular pressure;
KIRP	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.09	0.46	2.71e-14	Hip circumference adjusted for BMI;
KIRP	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg13010199	chr12:38710504	ALG10B	0.69	9.16	0.5	2.03e-17	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.03	-0.36	6.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.42	-7.6	-0.44	6.06e-13	Refractive error;
KIRP	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg01420254	chr6:26195488	NA	-1.25	-11.04	-0.58	2.79e-23	Gout;Renal underexcretion gout;
KIRP	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.92	12.02	0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.46	-6.87	-0.4	5.37e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-1.07	-20.51	-0.79	3.66e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg06640241	chr16:89574553	SPG7	0.64	7.63	0.44	5.09e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg23958373	chr8:599963	NA	-1.02	-6.25	-0.37	1.8e-9	IgG glycosylation;
KIRP	cis	rs77633900	0.772	rs157775	chr15:76755641	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-5.66	-0.34	4.14e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs4474465	0.607	rs7930161	chr11:78268878	C/A	cg27205649	chr11:78285834	NARS2	0.74	8.21	0.46	1.27e-14	Alzheimer's disease (survival time);
KIRP	cis	rs2997447	0.846	rs55912918	chr1:26409801	C/T	cg19633962	chr1:26362018	EXTL1	-0.69	-5.8	-0.35	2.04e-8	QRS complex (12-leadsum);
KIRP	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.75	-9.27	-0.51	9.99e-18	Response to antipsychotic treatment;
KIRP	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	1.0	15.37	0.7	7.85e-38	Vitamin D levels;
KIRP	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.74	10.77	0.57	2.02e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg10117171	chr1:25599238	RHD	-0.43	-5.79	-0.35	2.15e-8	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs12049351	0.774	rs6670553	chr1:229635867	A/G	cg11742688	chr1:229674241	ABCB10	-0.37	-5.52	-0.33	8.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.8	-8.62	-0.48	8.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg15655495	chr12:38532458	NA	-0.31	-5.33	-0.32	2.21e-7	Bladder cancer;
KIRP	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	9.69	0.53	5.1e-19	Obesity-related traits;
KIRP	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg02175503	chr12:58329896	NA	0.55	5.97	0.36	8.38e-9	Multiple sclerosis;
KIRP	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg06204229	chr3:52865917	ITIH4	-0.45	-5.58	-0.34	6.24e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg02836325	chr17:76403955	PGS1	0.4	6.83	0.4	6.48e-11	HDL cholesterol levels;
KIRP	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg15764593	chr10:829463	NA	-0.83	-8.98	-0.5	7.11e-17	Uric acid levels;
KIRP	cis	rs12823128	0.870	rs895964	chr12:26858066	G/A	cg14081884	chr12:26986758	ITPR2	0.4	5.53	0.33	8.21e-8	Birth weight;
KIRP	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.55	5.56	0.33	7.02e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs9394169	0.533	rs4713675	chr6:33718418	C/T	cg25922239	chr6:33757077	LEMD2	0.45	5.25	0.32	3.22e-7	Essential tremor;
KIRP	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg17644776	chr2:200775616	C2orf69	0.62	5.64	0.34	4.77e-8	Schizophrenia;
KIRP	cis	rs7432375	0.578	rs17366234	chr3:136577085	C/T	cg15507776	chr3:136538369	TMEM22	0.43	5.53	0.33	7.99e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg26138937	chr11:71823887	C11orf51	1.12	6.64	0.39	1.94e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.66	7.83	0.45	1.47e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs933360	0.681	rs6943153	chr7:50791579	T/C	cg10285873	chr2:243031394	LOC728323	0.5	6.02	0.36	6.19e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg14345882	chr6:26364793	BTN3A2	0.53	5.04	0.31	8.9e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.63	8.06	0.46	3.28e-14	Prudent dietary pattern;
KIRP	cis	rs11264213	0.901	rs716925	chr1:36424517	A/G	cg27506609	chr1:36549197	TEKT2	0.95	10.16	0.54	1.83e-20	Schizophrenia;
KIRP	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg13072238	chr3:49761600	GMPPB	-0.59	-5.64	-0.34	4.58e-8	Menarche (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03720416	chr4:13486103	RAB28	0.42	6.06	0.36	5.14e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.17	0.58	1.04e-23	Smoking behavior;
KIRP	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.7	-0.39	1.44e-10	Retinal vascular caliber;
KIRP	cis	rs282587	0.569	rs415552	chr13:113407564	A/C	cg04656015	chr13:113407548	ATP11A	0.66	7.84	0.45	1.35e-13	Glycated hemoglobin levels;
KIRP	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg04804543	chr8:142233427	SLC45A4	-0.61	-7.77	-0.44	2.15e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7560272	0.501	rs12624267	chr2:73986931	C/T	cg20560298	chr2:73613845	ALMS1	0.44	5.2	0.31	4.13e-7	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.79e-15	Prudent dietary pattern;
KIRP	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.8	-8.42	-0.47	3.24e-15	Hair shape;
KIRP	cis	rs6753739	0.871	rs9784128	chr2:219978638	C/T	cg01749213	chr2:219906749	CCDC108	-0.42	-5.17	-0.31	4.94e-7	Height;
KIRP	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg17145862	chr1:211918768	LPGAT1	0.74	10.07	0.54	3.51e-20	Leprosy;
KIRP	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.83	12.1	0.61	9.4e-27	Bladder cancer;
KIRP	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	8.34	0.47	5.4e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.23	-0.42	6.24e-12	Migraine;Coronary artery disease;
KIRP	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.74	-0.49	3.77e-16	Mean corpuscular volume;
KIRP	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.13	0.41	1.1e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-7.76	-0.44	2.33e-13	Colorectal cancer;
KIRP	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.68	-9.42	-0.51	3.49e-18	Colorectal cancer;
KIRP	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg04374321	chr14:90722782	PSMC1	-0.9	-13.35	-0.65	6.05e-31	Mortality in heart failure;
KIRP	cis	rs1355223	0.902	rs11607035	chr11:34718911	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-5.43	-0.33	1.37e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12681366	0.734	rs16916788	chr8:95399618	C/T	cg13257157	chr8:95487014	RAD54B	0.4	4.93	0.3	1.52e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6750047	0.546	rs1367696	chr2:38286914	C/T	cg07380506	chr2:38303506	CYP1B1	0.44	5.81	0.35	1.95e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.42	5.62	0.34	5.13e-8	Birth weight;
KIRP	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg25797454	chr6:150327115	RAET1K	-0.31	-5.73	-0.34	2.97e-8	Alopecia areata;
KIRP	cis	rs1359582	0.836	rs2576155	chr10:90339593	C/T	cg15661332	chr10:90342814	RNLS	0.59	5.98	0.36	7.8e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.64	9.71	0.53	4.59e-19	Lung cancer;
KIRP	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.58	6.85	0.4	5.72e-11	Mosquito bite size;
KIRP	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg07274523	chr3:49395745	GPX1	0.71	8.53	0.48	1.47e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6102059	0.548	rs6016382	chr20:39181246	T/A	cg06665391	chr20:39312290	NA	0.4	4.98	0.3	1.22e-6	LDL cholesterol;
KIRP	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg18306943	chr3:40428807	ENTPD3	0.45	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	cis	rs6752107	0.503	rs2304774	chr2:234235749	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.61	7.2	0.42	7.2e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.49	-0.38	4.6e-10	Type 2 diabetes;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16944159	chr2:62132759	COMMD1	-0.5	-6.41	-0.38	7.18e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg01843034	chr6:37503916	NA	-0.7	-7.84	-0.45	1.39e-13	Cognitive performance;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.15	-0.36	3.17e-9	Lung cancer;
KIRP	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg02600515	chr11:62521696	ZBTB3	0.49	5.05	0.31	8.48e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.43	-0.43	1.79e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08555924	chr18:29026301	DSG3	0.4	6.14	0.36	3.21e-9	C-reactive protein;
KIRP	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg23625390	chr15:77176239	SCAPER	-0.56	-7.53	-0.43	9.9e-13	Blood metabolite levels;
KIRP	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.3	0.67	3.61e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.89	13.27	0.65	1.15e-30	Mean platelet volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09000178	chr16:67063319	CBFB	1.12	7.54	0.43	9.26e-13	P wave terminal force;
KIRP	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20135002	chr11:47629003	NA	0.45	5.33	0.32	2.17e-7	Subjective well-being;
KIRP	cis	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg09559047	chr8:10916868	XKR6	0.4	5.78	0.35	2.31e-8	Triglycerides;
KIRP	cis	rs4073221	0.929	rs66479003	chr3:18280276	G/T	cg07694806	chr3:18168406	NA	-0.83	-7.08	-0.41	1.52e-11	Parkinson's disease;
KIRP	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7945071	0.507	rs1596295	chr11:110253214	G/A	cg04157658	chr11:110243994	NA	0.37	5.76	0.34	2.45e-8	Cognitive function;
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.84	14.28	0.67	4.22e-34	Vitiligo;
KIRP	cis	rs883565	0.740	rs6780772	chr3:39087764	A/G	cg01426195	chr3:39028469	NA	-0.67	-11.15	-0.58	1.24e-23	Handedness;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24991452	chr6:35996059	MAPK14	0.58	6.26	0.37	1.75e-9	Lung cancer in ever smokers;
KIRP	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-1.03	-17.25	-0.74	3.14e-44	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg19592336	chr6:28129416	ZNF389	0.53	5.95	0.35	9.17e-9	Depression;
KIRP	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg05887092	chr17:76393375	PGS1	0.54	7.49	0.43	1.22e-12	HDL cholesterol levels;
KIRP	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.62	-9.41	-0.51	3.77e-18	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.05	0.31	8.43e-7	Height;
KIRP	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.59	7.91	0.45	8.58e-14	Prudent dietary pattern;
KIRP	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg03959625	chr15:84868606	LOC388152	0.5	5.94	0.35	9.84e-9	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg12598211	chr12:123634384	NA	-0.45	-5.49	-0.33	1e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.86	14.32	0.67	3.19e-34	Prostate cancer;
KIRP	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg22189786	chr22:42395067	WBP2NL	0.44	5.59	0.34	5.91e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6438504	0.922	rs6778091	chr3:118945159	T/C	cg25372693	chr3:118959985	B4GALT4	-0.31	-5.35	-0.32	2.06e-7	Clozapine-induced cytotoxicity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24821941	chr4:71457332	AMBN	-0.4	-6.19	-0.37	2.5e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg02795151	chr17:7402630	POLR2A	0.78	8.0	0.45	4.88e-14	Androgen levels;
KIRP	cis	rs6504622	0.537	rs189899	chr17:45000529	G/C	cg16759221	chr17:45003025	GOSR2	-0.4	-5.86	-0.35	1.45e-8	Orofacial clefts;
KIRP	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.55	14.1	0.67	1.78e-33	Airflow obstruction;
KIRP	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.92	14.3	0.67	3.61e-34	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg22676075	chr6:135203613	NA	0.49	7.17	0.42	8.81e-12	Red blood cell count;
KIRP	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg20573242	chr4:122745356	CCNA2	0.43	5.32	0.32	2.37e-7	Type 2 diabetes;
KIRP	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.62	-7.0	-0.41	2.47e-11	Coronary artery disease;
KIRP	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg11189052	chr15:85197271	WDR73	0.5	5.15	0.31	5.43e-7	Schizophrenia;
KIRP	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	0.4	4.92	0.3	1.55e-6	Large artery stroke;
KIRP	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	8.04	0.46	3.81e-14	Eosinophil percentage of white cells;
KIRP	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg06742321	chr12:123595122	PITPNM2	0.44	5.55	0.33	7.31e-8	Platelet count;
KIRP	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.48	-0.65	2.16e-31	Tonsillectomy;
KIRP	cis	rs4704187	0.617	rs4704185	chr5:74471690	G/A	cg03227963	chr5:74354835	NA	0.4	6.0	0.36	7.09e-9	Response to amphetamines;
KIRP	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.55	7.61	0.44	5.78e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg22732515	chr19:44031385	ETHE1	0.65	9.64	0.52	7.1e-19	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.47	-0.33	1.12e-7	Obesity-related traits;
KIRP	cis	rs12712073	0.845	rs1370353	chr2:100764824	G/C	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs137699	0.652	rs137706	chr22:39751400	T/G	cg24399712	chr22:39784796	NA	-0.62	-7.36	-0.42	2.77e-12	IgG glycosylation;
KIRP	cis	rs10875595	0.836	rs12187725	chr5:140662912	A/G	cg24830062	chr5:140700576	TAF7	-0.62	-5.84	-0.35	1.66e-8	Pulmonary function decline;
KIRP	cis	rs712039	0.652	rs8069062	chr17:35829306	C/T	cg16670864	chr17:35848621	DUSP14	0.41	4.91	0.3	1.67e-6	Tuberculosis;
KIRP	cis	rs7688540	0.800	rs12506277	chr4:287649	T/C	cg17891759	chr4:299121	NA	-0.39	-4.98	-0.3	1.18e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.88	-0.35	1.3e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7009516	0.625	rs3765124	chr8:24261526	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.32	-6.72	-0.39	1.26e-10	Hair greying;
KIRP	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg22643751	chr7:855365	UNC84A	0.36	5.11	0.31	6.34e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg05627522	chr15:75251581	NA	0.38	6.12	0.36	3.61e-9	Breast cancer;
KIRP	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg07382826	chr16:28625726	SULT1A1	0.51	6.06	0.36	4.95e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs675026	0.963	rs612512	chr6:154449695	T/G	cg07813322	chr6:154414604	OPRM1	-0.44	-5.74	-0.34	2.83e-8	Hypertension;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03160445	chr3:100120349	LNP1;TOMM70A	0.49	6.41	0.38	7.56e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-6.99	-0.41	2.58e-11	Bipolar disorder;
KIRP	cis	rs7326068	0.610	rs2477165	chr13:21445435	A/G	cg04906043	chr13:21280425	IL17D	-0.42	-4.87	-0.3	2.03e-6	Schizophrenia, bipolar disorder and depression (combined);
KIRP	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18357526	chr6:26021779	HIST1H4A	0.55	7.52	0.43	1.01e-12	Height;
KIRP	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-0.78	-10.38	-0.55	3.58e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.28	0.55	7.7e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.68	9.87	0.53	1.48e-19	Dupuytren's disease;
KIRP	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.82	10.68	0.56	3.86e-22	Total cholesterol levels;
KIRP	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.41	9.78	0.53	2.74e-19	Diastolic blood pressure;
KIRP	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg13072238	chr3:49761600	GMPPB	0.55	5.01	0.3	1.04e-6	Menarche (age at onset);
KIRP	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	cg12689670	chr1:183009347	LAMC1	0.58	7.96	0.45	6.32e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.65	7.58	0.43	7.22e-13	DNA methylation (variation);
KIRP	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg15691649	chr6:25882328	NA	-0.46	-5.53	-0.33	7.98e-8	Blood metabolite levels;
KIRP	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-1.16	-14.97	-0.69	1.92e-36	Platelet distribution width;
KIRP	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg13256891	chr4:100009986	ADH5	0.5	6.13	0.36	3.5e-9	Alcohol dependence;
KIRP	cis	rs6973256	0.543	rs13243553	chr7:133506955	A/G	cg10665199	chr7:133106180	EXOC4	-0.44	-5.59	-0.34	6.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17554472	chr22:41940697	POLR3H	-0.65	-6.98	-0.41	2.69e-11	Vitiligo;
KIRP	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.73	-7.35	-0.42	2.89e-12	Bipolar disorder;
KIRP	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg12573674	chr2:1569213	NA	-0.59	-5.29	-0.32	2.64e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg21698718	chr17:80085957	CCDC57	0.36	5.21	0.32	3.98e-7	Life satisfaction;
KIRP	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.82	9.47	0.52	2.45e-18	Corneal astigmatism;
KIRP	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	1.07	17.19	0.74	5.02e-44	Cognitive function;
KIRP	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.41	5.32	0.32	2.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.81	11.12	0.58	1.54e-23	Coronary artery disease;
KIRP	cis	rs2219968	0.828	rs12545997	chr8:78910679	C/A	cg00738934	chr8:78996279	NA	-0.38	-5.14	-0.31	5.72e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg16989719	chr2:238392110	NA	-0.55	-5.7	-0.34	3.4e-8	Prostate cancer;
KIRP	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg00310523	chr12:86230176	RASSF9	0.39	6.02	0.36	6.18e-9	Major depressive disorder;
KIRP	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg23995753	chr2:160760732	LY75	-0.42	-5.66	-0.34	4.09e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs35123781	0.696	rs10067965	chr5:139071353	T/C	cg10513866	chr5:139070639	NA	0.54	7.6	0.44	6.15e-13	Schizophrenia;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg04804543	chr8:142233427	SLC45A4	-1.02	-17.66	-0.75	1.2e-45	Immature fraction of reticulocytes;
KIRP	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.66	6.09	0.36	4.33e-9	Neutrophil percentage of white cells;
KIRP	cis	rs8038465	1.000	rs8038465	chr15:73978337	A/G	cg15420318	chr15:73925796	NPTN	-0.53	-6.76	-0.4	1e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	1.0	10.6	0.56	7.27e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-5.32	-0.32	2.35e-7	Schizophrenia;
KIRP	cis	rs780094	0.500	rs7570476	chr2:27784658	C/T	cg05484376	chr2:27715224	FNDC4	-0.37	-5.51	-0.33	9.26e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs4148660	1.000	rs1517276	chr12:22066180	C/T	cg14669847	chr12:22099120	NA	0.33	5.76	0.34	2.47e-8	Gout;
KIRP	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg19292749	chr17:79650816	ARL16;HGS	0.54	4.97	0.3	1.23e-6	Dental caries;
KIRP	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.55	7.08	0.41	1.54e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-5.0	-0.3	1.07e-6	Testicular germ cell tumor;
KIRP	cis	rs3806933	0.522	rs13157863	chr5:110470505	G/A	cg04022379	chr5:110408740	TSLP	0.7	10.09	0.54	2.99e-20	Eosinophilic esophagitis;
KIRP	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.26	-5.45	-0.33	1.22e-7	Menarche (age at onset);
KIRP	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg20636351	chr8:55087400	NA	-0.62	-7.64	-0.44	4.95e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-7.98	-0.45	5.59e-14	Homocysteine levels;
KIRP	cis	rs1440410	0.835	rs10011709	chr4:144080500	A/G	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg18586891	chr4:952366	TMEM175	0.62	5.11	0.31	6.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.633	rs917016	chr17:56454156	C/T	cg12560992	chr17:57184187	TRIM37	-0.55	-4.96	-0.3	1.31e-6	Testicular germ cell tumor;
KIRP	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.5	-6.39	-0.38	8.15e-10	Post bronchodilator FEV1;
KIRP	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg19500275	chr17:80737654	TBCD	0.46	5.41	0.33	1.53e-7	Glycated hemoglobin levels;
KIRP	trans	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg19694781	chr19:47549865	TMEM160	0.61	8.24	0.47	1.03e-14	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.47	-5.09	-0.31	7.1e-7	Obesity (extreme);
KIRP	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.51	-5.72	-0.34	3.06e-8	Schizophrenia;
KIRP	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg27124370	chr19:33622961	WDR88	0.56	6.98	0.41	2.77e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg13444842	chr1:152974279	SPRR3	0.35	4.93	0.3	1.5e-6	Inflammatory skin disease;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	7.63	0.44	5.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6462411	0.938	rs10243770	chr7:3915753	A/G	cg27348223	chr5:1445354	SLC6A3	0.48	6.11	0.36	3.92e-9	Quantitative traits;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg17294928	chr15:75287854	SCAMP5	0.56	7.43	0.43	1.76e-12	Breast cancer;
KIRP	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg09596252	chr17:78655493	RPTOR	0.57	7.54	0.43	9.17e-13	Obesity;
KIRP	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg19866673	chr12:132237789	SFRS8	-0.39	-5.55	-0.33	7.22e-8	Migraine;
KIRP	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.15	-0.46	1.88e-14	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.42	0.62	8.27e-28	Menopause (age at onset);
KIRP	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05654049	chr3:23852499	UBE2E1	-0.43	-6.14	-0.36	3.23e-9	Electrocardiographic conduction measures;
KIRP	cis	rs4132509	0.947	rs10927039	chr1:243721726	C/T	cg21452805	chr1:244014465	NA	-0.55	-5.71	-0.34	3.22e-8	RR interval (heart rate);
KIRP	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg21605333	chr4:119757512	SEC24D	1.48	9.55	0.52	1.36e-18	Cannabis dependence symptom count;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg09033563	chr22:24373618	LOC391322	-0.4	-5.35	-0.32	1.96e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.32	0.37	1.23e-9	Major depressive disorder;
KIRP	cis	rs2929278	0.561	rs62018952	chr15:44080737	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.48	-5.82	-0.35	1.86e-8	Schizophrenia;
KIRP	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg12599982	chr1:44399894	ARTN	0.42	5.13	0.31	6.01e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg03653399	chr8:142233436	SLC45A4	-0.46	-5.56	-0.33	6.92e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg21775007	chr8:11205619	TDH	-0.43	-5.74	-0.34	2.73e-8	Neuroticism;
KIRP	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.1	0.36	4.1e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.45	6.36	0.38	9.93e-10	Obesity-related traits;
KIRP	cis	rs7766436	0.885	rs7742025	chr6:22575798	A/T	cg13666174	chr6:22585274	NA	-0.47	-6.15	-0.37	3.03e-9	Coronary artery disease;
KIRP	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg27462398	chr1:86174642	ZNHIT6	-0.59	-8.79	-0.49	2.62e-16	Urate levels in overweight individuals;
KIRP	cis	rs2130392	0.961	rs2696035	chr4:185612953	A/G	cg04058563	chr4:185651563	MLF1IP	0.4	5.04	0.31	8.89e-7	Kawasaki disease;
KIRP	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.68	-0.34	3.76e-8	Bipolar disorder;
KIRP	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	trans	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg19274270	chr17:78178856	CARD14	-0.35	-6.33	-0.37	1.12e-9	Morning vs. evening chronotype;
KIRP	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.89	-0.66	8.74e-33	Ulcerative colitis;
KIRP	cis	rs258892	0.895	rs34155124	chr5:72060249	C/T	cg21869765	chr5:72125136	TNPO1	-0.54	-5.83	-0.35	1.74e-8	Small cell lung carcinoma;
KIRP	cis	rs10214930	0.624	rs13244903	chr7:27688911	A/G	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg01763666	chr17:80159506	CCDC57	-0.38	-5.34	-0.32	2.09e-7	Life satisfaction;
KIRP	cis	rs6120849	1.000	rs6120849	chr20:33730387	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	7.49	0.43	1.21e-12	Protein C levels;
KIRP	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg15083037	chr5:83017644	HAPLN1	-0.5	-7.84	-0.45	1.38e-13	Prostate cancer;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17885579	chr8:59572218	NSMAF	0.52	6.87	0.4	5.17e-11	Myopia (pathological);
KIRP	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.86	-13.53	-0.65	1.45e-31	Menopause (age at onset);
KIRP	cis	rs3857536	0.730	rs4710585	chr6:66967579	C/T	cg07460842	chr6:66804631	NA	-0.46	-5.48	-0.33	1.07e-7	Blood trace element (Cu levels);
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.28	0.37	1.52e-9	Lung cancer;
KIRP	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.09	0.54	2.89e-20	Coffee consumption (cups per day);
KIRP	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.4	-0.47	3.57e-15	Total cholesterol levels;
KIRP	cis	rs4356975	0.522	rs56388229	chr4:69966658	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.13	0.31	5.97e-7	Obesity-related traits;
KIRP	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.7	8.59	0.48	1.03e-15	Aortic root size;
KIRP	cis	rs7674212	0.541	rs2720448	chr4:104030589	C/T	cg16532752	chr4:104119610	CENPE	-0.43	-5.31	-0.32	2.5e-7	Type 2 diabetes;
KIRP	cis	rs9547996	0.879	rs61957470	chr13:38133049	G/A	cg13634560	chr13:38173852	POSTN	-0.41	-5.66	-0.34	4.15e-8	Diastolic blood pressure;
KIRP	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.45	6.45	0.38	5.91e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg08668510	chr10:1095578	IDI1	0.92	6.73	0.39	1.21e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs1891498	0.571	rs791273	chr1:147234618	A/G	cg27546670	chr1:147246839	GJA5	-0.61	-8.28	-0.47	8.15e-15	Cognitive performance;
KIRP	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.8	0.4	7.66e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.11	-0.8	3.83e-57	Ulcerative colitis;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.59	8.64	0.48	7.49e-16	Menarche (age at onset);
KIRP	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs4356932	0.691	rs4859581	chr4:76906974	A/G	cg19388996	chr4:76862389	NAAA	0.44	5.61	0.34	5.39e-8	Blood protein levels;
KIRP	trans	rs1559473	0.512	rs10932940	chr2:222898997	C/T	cg14426312	chr9:71395063	FAM122A;PIP5K1B	0.49	6.03	0.36	6.09e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.81	0.66	1.62e-32	Alzheimer's disease;
KIRP	cis	rs12973672	0.812	rs28365133	chr19:35761519	A/G	cg12095397	chr19:35769544	USF2	0.67	6.2	0.37	2.39e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.49	-6.23	-0.37	2.02e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.88	13.6	0.66	8.49e-32	Coronary artery disease;
KIRP	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.57	-4.95	-0.3	1.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02333649	chr22:19471093	CDC45L	0.49	6.44	0.38	6.23e-10	Interleukin-4 levels;
KIRP	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	0.6	5.85	0.35	1.53e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.82	10.63	0.56	5.89e-22	Primary sclerosing cholangitis;
KIRP	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.92	-0.35	1.06e-8	Joint mobility (Beighton score);
KIRP	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg18350739	chr11:68623251	NA	-0.52	-7.76	-0.44	2.2e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg20493526	chr2:3714936	ALLC	0.41	5.16	0.31	5.06e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	0.85	9.12	0.5	2.75e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.55	-7.22	-0.42	6.3e-12	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13939156	chr17:80058883	NA	0.5	7.52	0.43	1.02e-12	Life satisfaction;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.36	-5.09	-0.31	7.01e-7	Lymphocyte counts;
KIRP	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.74	11.2	0.58	8.47e-24	Type 2 diabetes;
KIRP	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg12560992	chr17:57184187	TRIM37	0.54	5.83	0.35	1.74e-8	Cognitive test performance;
KIRP	cis	rs997295	1.000	rs11637027	chr15:67937755	G/T	cg24579218	chr15:68104479	NA	0.37	5.56	0.33	6.94e-8	Motion sickness;
KIRP	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg26875233	chr11:93583750	C11orf90	-0.36	-6.61	-0.39	2.4e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.49	0.38	4.65e-10	Educational attainment;
KIRP	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-4.99	-0.3	1.17e-6	Schizophrenia;
KIRP	trans	rs12517041	1.000	rs34069672	chr5:23281789	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.39	-5.05	-0.31	8.44e-7	Breast cancer;
KIRP	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-4.9	-0.3	1.71e-6	Skin colour saturation;
KIRP	cis	rs77633900	0.772	rs4886492	chr15:76672817	T/A	cg21673338	chr15:77095150	SCAPER	0.51	5.19	0.31	4.35e-7	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.45	9.27	0.51	9.61e-18	Ewing sarcoma;
KIRP	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.81	13.04	0.64	6.72e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg03452623	chr4:187889614	NA	-1.06	-19.25	-0.78	5.23e-51	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.53	-4.97	-0.3	1.26e-6	Hip geometry;
KIRP	cis	rs6743226	0.840	rs6747036	chr2:242227054	T/C	cg10021735	chr2:242295487	FARP2	0.46	5.78	0.35	2.25e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.27	-5.57	-0.33	6.53e-8	Menarche (age at onset);
KIRP	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.44	5.61	0.34	5.42e-8	Crohn's disease;
KIRP	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg16584676	chr17:46985605	UBE2Z	0.47	5.8	0.35	2.06e-8	Type 2 diabetes;
KIRP	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg23815491	chr16:72088622	HP	0.39	6.43	0.38	6.41e-10	Fibrinogen levels;
KIRP	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg13180566	chr4:1052158	NA	-0.51	-5.34	-0.32	2.14e-7	Recombination rate (females);
KIRP	cis	rs2223471	0.624	rs2294469	chr6:50723625	T/G	cg03432817	chr6:50765336	NA	-0.36	-5.23	-0.32	3.7e-7	Subcutaneous adipose tissue;
KIRP	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	8.84	0.49	1.82e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2274273	0.600	rs10134317	chr14:55793448	C/T	cg04306507	chr14:55594613	LGALS3	0.39	5.44	0.33	1.27e-7	Protein biomarker;
KIRP	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.84	8.67	0.48	5.83e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs16828019	0.852	rs11209576	chr1:41586029	T/C	cg03387723	chr1:41708464	SCMH1	-0.8	-6.73	-0.39	1.18e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-8.11	-0.46	2.34e-14	Morning vs. evening chronotype;
KIRP	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg11608241	chr8:8085544	FLJ10661	-0.47	-6.03	-0.36	5.95e-9	Neuroticism;
KIRP	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	6.51	0.38	4.18e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10267417	0.603	rs6976553	chr7:19869113	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	5.5	0.33	9.27e-8	Night sleep phenotypes;
KIRP	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.51	-6.81	-0.4	7.55e-11	Facial morphology (factor 20);
KIRP	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg25547332	chr5:131281432	NA	0.47	5.15	0.31	5.31e-7	Life satisfaction;
KIRP	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.38	5.09	0.31	7.15e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg18944383	chr4:111397179	ENPEP	0.48	8.01	0.45	4.67e-14	Height;
KIRP	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.24	0.37	1.89e-9	Major depressive disorder;
KIRP	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.54	-0.43	9.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.64	8.51	0.48	1.71e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.82	11.71	0.6	1.87e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs10924309	0.855	rs2008766	chr1:245860205	C/A	cg00036263	chr1:245852353	KIF26B	-0.49	-6.4	-0.38	7.78e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg19531713	chr17:41277059	BRCA1;NBR2	0.71	6.23	0.37	1.97e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs867371	1.000	rs13380319	chr15:82506867	G/T	cg00614314	chr15:82944287	LOC80154	0.54	6.45	0.38	6.04e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg24488311	chr11:68621650	NA	0.44	5.59	0.34	5.91e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-5.45	-0.33	1.24e-7	Total body bone mineral density;
KIRP	trans	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg10756647	chr7:56101905	PSPH	1.01	7.6	0.44	6.29e-13	Diabetic kidney disease;
KIRP	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4073221	0.860	rs13071572	chr3:18259222	G/T	cg07694806	chr3:18168406	NA	-0.84	-7.06	-0.41	1.69e-11	Parkinson's disease;
KIRP	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg00361562	chr2:198649771	BOLL	0.49	4.84	0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg20430773	chr1:16534157	ARHGEF19	0.52	6.46	0.38	5.42e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg18404041	chr3:52824283	ITIH1	0.35	4.99	0.3	1.16e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg02336718	chr17:17403227	NA	0.38	5.88	0.35	1.32e-8	Total body bone mineral density;
KIRP	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.5	-6.51	-0.38	4.2e-10	Coronary artery disease;
KIRP	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg01280390	chr8:19363452	CSGALNACT1	-0.39	-5.13	-0.31	5.96e-7	Oropharynx cancer;
KIRP	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg05756136	chr1:119680316	WARS2	-0.61	-8.19	-0.46	1.47e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs3092073	1.000	rs3092073	chr20:44595649	G/A	cg00125455	chr20:44574271	PCIF1	-0.3	-5.5	-0.33	9.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.2	-0.37	2.38e-9	Colorectal cancer;
KIRP	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg15117754	chr3:10150083	C3orf24	0.49	4.89	0.3	1.82e-6	Alzheimer's disease;
KIRP	cis	rs6968419	0.609	rs73716710	chr7:115905744	G/A	cg02561103	chr7:115862891	TES	-0.42	-6.01	-0.36	6.7e-9	Intraocular pressure;
KIRP	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg19077165	chr18:44547161	KATNAL2	0.49	6.1	0.36	4.15e-9	Personality dimensions;
KIRP	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.64	0.34	4.58e-8	Breast cancer;
KIRP	cis	rs17065868	0.764	rs17065818	chr13:45022180	T/C	cg10246903	chr13:45222710	NA	0.52	5.0	0.3	1.09e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.62	5.85	0.35	1.58e-8	Alzheimer's disease;
KIRP	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.02	-0.36	6.14e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.38	7.67	0.44	3.98e-13	Multiple system atrophy;
KIRP	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg22916017	chr11:64110731	CCDC88B	0.53	6.49	0.38	4.78e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.52	6.34	0.37	1.08e-9	Arsenic metabolism;
KIRP	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.07e-12	Blood protein levels;
KIRP	trans	rs7521492	0.647	rs2760214	chr1:163675984	G/A	cg21988461	chr4:88008667	AFF1	-0.39	-6.18	-0.37	2.64e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.33e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg24488311	chr11:68621650	NA	0.44	5.2	0.31	4.15e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19236395	chr7:44122272	POLM	0.45	6.1	0.36	4.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg00784671	chr22:46762841	CELSR1	-0.82	-8.14	-0.46	2.02e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.39	9.57	0.52	1.19e-18	Corneal astigmatism;
KIRP	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.02	-0.3	9.97e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	8.67	0.48	5.98e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg13072238	chr3:49761600	GMPPB	-0.59	-5.64	-0.34	4.58e-8	Menarche (age at onset);
KIRP	trans	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.44	-0.38	6.21e-10	Neuroticism;
KIRP	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.12	-14.25	-0.67	5.41e-34	Lymphocyte percentage of white cells;
KIRP	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.4	5.33	0.32	2.2e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.42	-5.96	-0.36	8.48e-9	Height;
KIRP	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	1.2	14.63	0.68	2.81e-35	Type 2 diabetes nephropathy;
KIRP	cis	rs61863818	0.842	rs11189214	chr10:99181008	A/G	cg07052063	chr10:99255236	MMS19	-0.49	-5.42	-0.33	1.39e-7	Monocyte percentage of white cells;
KIRP	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	1.15	12.62	0.63	1.7e-28	Psoriasis;
KIRP	cis	rs59197085	0.515	rs17165121	chr7:128442479	A/G	cg17511168	chr7:128516960	KCP	0.41	4.85	0.3	2.15e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00303672	chr20:31171386	NA	0.5	6.32	0.37	1.23e-9	Obesity-related traits;
KIRP	cis	rs6882046	0.513	rs681446	chr5:88054292	C/T	cg24804195	chr5:87968844	LOC645323	0.46	6.09	0.36	4.39e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.63	6.97	0.41	2.94e-11	Aortic root size;
KIRP	cis	rs910873	0.505	rs7261964	chr20:33205011	C/T	cg16810054	chr20:33298113	TP53INP2	-0.42	-4.85	-0.3	2.21e-6	Melanoma;
KIRP	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.78	10.83	0.57	1.31e-22	Coronary artery disease;
KIRP	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg14458575	chr2:238380390	NA	0.56	5.88	0.35	1.35e-8	Prostate cancer;
KIRP	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg09507567	chr10:124027408	NA	0.31	5.6	0.34	5.68e-8	Total body bone mineral density;
KIRP	cis	rs741702	0.928	rs2293683	chr19:13039284	A/G	cg11738485	chr19:12877000	HOOK2	0.44	5.48	0.33	1.07e-7	Red blood cell traits;
KIRP	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg12591125	chr7:1885375	MAD1L1	0.59	5.69	0.34	3.51e-8	Bipolar disorder;
KIRP	cis	rs3829109	0.564	rs11145891	chr9:139293912	T/C	cg14169450	chr9:139327907	INPP5E	0.47	5.76	0.34	2.48e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs2278796	0.789	rs1078719	chr1:204962405	A/G	cg17947172	chr1:204966197	NFASC	0.75	10.14	0.54	2.08e-20	Mean platelet volume;
KIRP	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.75	5.73	0.34	2.89e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.58	-7.39	-0.43	2.35e-12	Aortic root size;
KIRP	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10214930	0.697	rs12665991	chr7:27659771	A/G	cg22168087	chr7:27702803	HIBADH	0.47	5.0	0.3	1.09e-6	Hypospadias;
KIRP	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs7590368	0.962	rs13431633	chr2:10960225	T/C	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs1209950	0.866	rs1734588	chr21:40180889	A/G	cg02119577	chr21:40195074	ETS2	-0.35	-5.33	-0.32	2.24e-7	Non-small cell lung cancer (survival);
KIRP	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.57	8.05	0.46	3.52e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19346786	chr7:2764209	NA	-0.47	-7.9	-0.45	9.09e-14	Height;
KIRP	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.4	5.85	0.35	1.6e-8	Colorectal cancer;
KIRP	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.8	0.71	2.77e-39	Bipolar disorder;
KIRP	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.49	5.4	0.33	1.59e-7	Vitiligo;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg09699651	chr6:150184138	LRP11	0.45	5.81	0.35	1.89e-8	Lung cancer;
KIRP	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.76	-9.48	-0.52	2.3e-18	Coronary artery disease;
KIRP	cis	rs2904967	0.852	rs560097	chr11:65042530	A/C	cg09225861	chr11:65069680	NA	0.41	4.91	0.3	1.67e-6	Mean corpuscular volume;
KIRP	cis	rs4363385	0.510	rs17627288	chr1:152923848	C/T	cg07796016	chr1:152779584	LCE1C	-0.47	-5.83	-0.35	1.74e-8	Inflammatory skin disease;
KIRP	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs73105738	0.590	rs58647958	chr5:73280092	A/G	cg26653990	chr5:72510846	NA	-0.49	-5.67	-0.34	3.96e-8	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.21	19.88	0.79	4.44e-53	Cognitive function;
KIRP	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.86	-13.36	-0.65	5.53e-31	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.27	-0.42	4.74e-12	Daytime sleep phenotypes;
KIRP	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.68	-8.59	-0.48	9.94e-16	Coronary artery disease;
KIRP	cis	rs2224391	0.628	rs9392666	chr6:5249888	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-6.9	-0.4	4.3e-11	Height;
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg03289416	chr15:75166202	SCAMP2	0.56	7.48	0.43	1.3e-12	Caffeine consumption;
KIRP	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.48	-6.33	-0.37	1.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2230307	0.536	rs11166409	chr1:100641411	T/C	cg24955406	chr1:100503596	HIAT1	-0.58	-6.1	-0.36	4.04e-9	Carotid intima media thickness;
KIRP	cis	rs255758	0.637	rs156836	chr5:53347280	A/C	cg22592108	chr5:53304441	ARL15	-0.4	-5.26	-0.32	3.2e-7	Rheumatoid arthritis;
KIRP	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg04166393	chr7:2884313	GNA12	0.66	8.03	0.46	3.94e-14	Height;
KIRP	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.4	-0.38	7.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6882046	0.513	rs587490	chr5:88032522	C/T	cg24804195	chr5:87968844	LOC645323	-0.45	-5.94	-0.35	9.67e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs17655565	0.581	rs1622677	chr12:52762444	A/G	cg07925835	chr12:52762777	KRT85	-0.49	-5.53	-0.33	8.12e-8	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.49	5.88	0.35	1.32e-8	Glycated hemoglobin levels;
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg23978390	chr7:1156363	C7orf50	0.53	7.31	0.42	3.72e-12	Longevity;Endometriosis;
KIRP	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-8.76	-0.49	3.33e-16	Asthma;
KIRP	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.4	0.55	3.19e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.11	-0.41	1.24e-11	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.12	-0.41	1.2e-11	Vitiligo;
KIRP	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.57	-0.33	6.69e-8	Life satisfaction;
KIRP	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.72	9.08	0.5	3.62e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg06636001	chr8:8085503	FLJ10661	0.59	7.46	0.43	1.46e-12	Retinal vascular caliber;
KIRP	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg03115019	chr17:80708279	FN3K	0.41	4.89	0.3	1.82e-6	Glycated hemoglobin levels;
KIRP	cis	rs11955175	1.000	rs11951044	chr5:40671189	G/A	cg04002187	chr5:40835754	RPL37	0.66	5.32	0.32	2.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6921919	0.583	rs3734563	chr6:28349725	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.35	-0.38	1.05e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.67	-8.26	-0.47	9.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.97	11.63	0.6	3.41e-25	Exhaled nitric oxide levels;
KIRP	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg01420254	chr6:26195488	NA	1.16	10.2	0.55	1.31e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-1.1	-10.16	-0.54	1.73e-20	Post bronchodilator FEV1;
KIRP	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.78	7.85	0.45	1.28e-13	Hip geometry;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14932796	chr17:55038330	COIL	0.63	7.43	0.43	1.83e-12	Smoking initiation;
KIRP	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.86	-0.4	5.39e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs236907	0.859	rs12742601	chr1:171762125	T/C	cg01410279	chr1:171621941	MYOC	-0.48	-5.53	-0.33	8.28e-8	Mean platelet volume;
KIRP	cis	rs599083	0.502	rs113307519	chr11:68212641	C/T	cg16797656	chr11:68205561	LRP5	0.45	5.54	0.33	7.77e-8	Bone mineral density (spine);
KIRP	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.78	6.55	0.39	3.3e-10	Fat distribution (HIV);
KIRP	cis	rs1485395	0.945	rs2365344	chr12:54009977	A/T	cg16917193	chr12:54089295	NA	0.6	5.92	0.35	1.09e-8	Migraine without aura;
KIRP	trans	rs10895140	0.756	rs4312036	chr11:101519352	C/T	ch.1.69949640R	chr1:70177052	NA	-0.53	-6.09	-0.36	4.4e-9	Menarche (age at onset);
KIRP	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg07395648	chr5:131743802	NA	-0.57	-8.37	-0.47	4.45e-15	Blood metabolite levels;
KIRP	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.66	9.11	0.5	2.88e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11766298	0.702	rs6467239	chr7:128969888	G/T	cg06809055	chr7:129142284	NA	0.68	4.84	0.3	2.26e-6	Response to fenofibrate;
KIRP	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg11693508	chr17:37793320	STARD3	0.69	7.26	0.42	5.19e-12	Bipolar disorder;
KIRP	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-7.74	-0.44	2.57e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs3736485	0.934	rs2414105	chr15:51868373	A/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.29	-0.32	2.68e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.27	0.32	3.03e-7	Coronary artery disease;
KIRP	cis	rs838721	0.574	rs13003198	chr2:234257105	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	5.08	0.31	7.38e-7	Total body bone mineral density;
KIRP	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.59	-7.04	-0.41	1.87e-11	Coronary artery disease;
KIRP	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg02527881	chr3:46936655	PTH1R	-0.42	-6.08	-0.36	4.64e-9	Colorectal cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18802048	chr17:55948689	CUEDC1	0.45	6.09	0.36	4.25e-9	Survival in pancreatic cancer;
KIRP	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.88	-15.25	-0.7	2.1e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.55	-5.8	-0.35	2.04e-8	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg04369109	chr6:150039330	LATS1	-0.53	-6.73	-0.39	1.17e-10	Lung cancer;
KIRP	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg11584989	chr19:19387371	SF4	-0.41	-5.23	-0.32	3.59e-7	Tonsillectomy;
KIRP	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.2	0.51	1.55e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg25288420	chr1:78511713	GIPC2	0.48	6.43	0.38	6.42e-10	Obesity-related traits;
KIRP	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-15.62	-0.71	1.08e-38	Lymphocyte percentage of white cells;
KIRP	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg27411982	chr8:10470053	RP1L1	0.41	5.26	0.32	3.13e-7	Neuroticism;
KIRP	cis	rs6959887	0.962	rs10254475	chr7:35283584	G/T	cg06685737	chr7:35301730	NA	0.43	6.24	0.37	1.88e-9	Birth weight;
KIRP	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.32	5.21	0.32	3.92e-7	Asthma;
KIRP	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg14851346	chr12:38532713	NA	-0.4	-5.01	-0.3	1.03e-6	Morning vs. evening chronotype;
KIRP	cis	rs6421571	0.565	rs10892263	chr11:118587319	T/C	cg19308663	chr11:118741387	NA	0.48	7.37	0.43	2.64e-12	Primary biliary cholangitis;
KIRP	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg21775007	chr8:11205619	TDH	0.43	5.86	0.35	1.48e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.51	6.9	0.4	4.43e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg16586182	chr3:47516702	SCAP	-0.67	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.4	-5.6	-0.34	5.68e-8	Endometrial cancer;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg13495574	chr1:173793781	CENPL;DARS2	-0.43	-6.12	-0.36	3.61e-9	Metabolite levels (MHPG);
KIRP	cis	rs6541297	0.699	rs4846915	chr1:230296470	C/A	cg05784532	chr1:230284198	GALNT2	0.46	5.77	0.35	2.35e-8	Coronary artery disease;
KIRP	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg22138327	chr13:27999177	GTF3A	0.98	7.36	0.42	2.82e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1971762	0.545	rs7297461	chr12:54047178	A/T	cg23533419	chr12:54090519	NA	-0.33	-5.08	-0.31	7.44e-7	Height;
KIRP	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.57	7.11	0.41	1.28e-11	QRS duration;
KIRP	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-7.04	-0.41	1.93e-11	Aortic root size;
KIRP	cis	rs6693567	0.565	rs1776273	chr1:150270209	C/T	cg07843065	chr1:150265600	MRPS21	0.51	7.36	0.42	2.76e-12	Migraine;
KIRP	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.74	-8.62	-0.48	8.41e-16	Tonsillectomy;
KIRP	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.3	0.32	2.63e-7	Alzheimer's disease;
KIRP	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.5	6.62	0.39	2.22e-10	High light scatter reticulocyte count;
KIRP	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg27490568	chr2:178487706	NA	0.5	6.82	0.4	7.21e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg24250549	chr1:154909240	PMVK	0.42	5.23	0.32	3.61e-7	Schizophrenia;
KIRP	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.86	-11.6	-0.59	4.1e-25	Cognitive function;
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg12599982	chr1:44399894	ARTN	0.43	5.19	0.31	4.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2762049	0.524	rs806344	chr13:50857421	A/G	cg10393508	chr13:50950265	NA	-0.4	-5.51	-0.33	9.03e-8	Aortic root size;
KIRP	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs7225151	0.710	rs112421661	chr17:5241850	C/T	cg24500398	chr17:5266808	RABEP1	-0.58	-5.81	-0.35	1.88e-8	Alzheimer's disease (late onset);
KIRP	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.47	-4.84	-0.3	2.24e-6	Platelet distribution width;
KIRP	cis	rs7078219	0.505	rs10883362	chr10:101286984	C/T	cg07044859	chr10:101282883	NA	-0.27	-4.86	-0.3	2.06e-6	Dental caries;
KIRP	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.21	-0.32	4.07e-7	Metabolite levels;
KIRP	cis	rs883565	0.502	rs4496420	chr3:38942716	A/C	cg01426195	chr3:39028469	NA	0.49	7.37	0.43	2.56e-12	Handedness;
KIRP	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs4356975	0.522	rs59415892	chr4:69958909	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.61	-8.69	-0.48	5.11e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg18404041	chr3:52824283	ITIH1	-0.48	-5.59	-0.34	6.1e-8	Schizophrenia;
KIRP	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.56	-7.05	-0.41	1.83e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg11005552	chr10:105648138	OBFC1	0.41	5.9	0.35	1.2e-8	Coronary artery disease;
KIRP	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.91	-0.35	1.11e-8	Height;
KIRP	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg23307798	chr14:103986281	CKB	-0.48	-6.28	-0.37	1.55e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg00933542	chr6:150070202	PCMT1	0.27	5.0	0.3	1.09e-6	Lung cancer;
KIRP	cis	rs674424	1.000	rs674424	chr11:119030752	C/T	cg16724696	chr11:118992527	HINFP	-0.5	-5.99	-0.36	7.59e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg11886554	chr3:170076028	SKIL	-0.55	-5.82	-0.35	1.82e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs2278796	0.639	rs6702469	chr1:204968787	A/G	cg04862289	chr1:204966208	NFASC	0.7	9.75	0.53	3.3e-19	Mean platelet volume;
KIRP	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs6832769	1.000	rs9312662	chr4:56386371	A/G	cg05960024	chr4:56376020	CLOCK	-0.72	-9.2	-0.51	1.58e-17	Personality dimensions;
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg08662619	chr6:150070041	PCMT1	0.36	5.74	0.34	2.75e-8	Lung cancer;
KIRP	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg23601095	chr6:26197514	HIST1H3D	1.02	8.6	0.48	9.47e-16	Gout;Renal underexcretion gout;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg25029022	chr1:185126088	C1orf25;C1orf26	0.5	6.26	0.37	1.72e-9	Inflammatory biomarkers;
KIRP	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.58	-8.52	-0.48	1.65e-15	Urate levels in overweight individuals;
KIRP	cis	rs1978968	0.763	rs8140977	chr22:18463608	C/T	cg03078520	chr22:18463400	MICAL3	-0.84	-12.0	-0.61	2.05e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.51	6.82	0.4	7.15e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1057510	0.858	rs7303399	chr12:6708813	A/T	cg13857086	chr12:6580257	VAMP1	0.62	5.01	0.3	1.02e-6	Myopia (pathological);
KIRP	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg06212747	chr3:49208901	KLHDC8B	0.64	9.04	0.5	4.85e-17	Resting heart rate;
KIRP	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	14.9	0.69	3.13e-36	Chronic sinus infection;
KIRP	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02187348	chr16:89574699	SPG7	0.51	6.52	0.38	3.89e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs28669119	0.778	rs622803	chr5:88069593	G/T	cg18498987	chr5:88179539	MEF2C	-0.5	-6.28	-0.37	1.55e-9	Schizophrenia;
KIRP	cis	rs2415984	0.570	rs28674745	chr14:46924415	G/C	cg14871534	chr14:47121158	RPL10L	-0.45	-5.37	-0.32	1.82e-7	Number of children ever born;
KIRP	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26327118	chr6:39693366	KIF6	0.46	6.45	0.38	5.75e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1161397	0.708	rs280284	chr6:50568262	A/G	cg03432817	chr6:50765336	NA	-0.45	-4.99	-0.3	1.15e-6	Overweight status;
KIRP	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg17366294	chr4:99064904	C4orf37	-0.39	-5.29	-0.32	2.72e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13229655	chr1:10532570	DFFA	0.47	6.35	0.38	1.06e-9	Survival in pancreatic cancer;
KIRP	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs9815354	0.670	rs73073238	chr3:42014325	G/C	cg03022575	chr3:42003672	ULK4	0.78	7.87	0.45	1.16e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	1.05	10.71	0.56	3.23e-22	Type 2 diabetes nephropathy;
KIRP	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.07	-12.86	-0.63	2.63e-29	Vitiligo;
KIRP	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.75	-0.34	2.61e-8	Educational attainment;
KIRP	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs11203032	0.831	rs12217507	chr10:90922828	G/A	cg16672925	chr10:90967113	CH25H	0.78	7.68	0.44	3.81e-13	Heart failure;
KIRP	cis	rs4073416	0.504	rs6573612	chr14:65912829	G/A	cg03016385	chr14:66212404	NA	-0.57	-6.89	-0.4	4.6e-11	N-glycan levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg25722142	chr6:139695762	CITED2	0.49	6.37	0.38	9.16e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	trans	rs9790314	0.613	rs6809177	chr3:160630477	G/T	cg19274270	chr17:78178856	CARD14	0.35	6.3	0.37	1.4e-9	Morning vs. evening chronotype;
KIRP	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg02733842	chr7:1102375	C7orf50	-0.48	-5.01	-0.3	1.02e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs2916247	1.000	rs10089969	chr8:93060896	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg00504896	chr12:9437009	LOC642846	-0.51	-6.33	-0.37	1.18e-9	Breast size;
KIRP	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-5.84	-0.35	1.69e-8	HDL cholesterol;
KIRP	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.77	11.37	0.59	2.41e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg10189774	chr4:17578691	LAP3	0.52	6.39	0.38	8.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.66	-8.22	-0.46	1.17e-14	Body mass index;
KIRP	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.46	5.48	0.33	1.03e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg12573674	chr2:1569213	NA	-0.56	-5.05	-0.31	8.42e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21255605	chr3:14989131	NR2C2	-0.51	-6.07	-0.36	4.86e-9	Interleukin-4 levels;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	7.94	0.45	7.15e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg10223061	chr2:219282414	VIL1	-0.35	-5.52	-0.33	8.54e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.78	0.35	2.28e-8	Motion sickness;
KIRP	cis	rs3885907	1.000	rs9508832	chr13:31314264	G/A	cg19953038	chr13:31306303	NA	-0.44	-5.11	-0.31	6.48e-7	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
KIRP	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.66	0.39	1.78e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1265507	0.666	rs1248061	chr12:114862959	A/T	cg12437821	chr12:114852027	NA	0.37	4.95	0.3	1.4e-6	Percent mammographic density;
KIRP	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.65	-7.89	-0.45	9.79e-14	Blood metabolite levels;
KIRP	cis	rs526231	0.575	rs62362524	chr5:102314227	G/T	cg23492399	chr5:102201601	PAM	-0.49	-5.56	-0.33	7.01e-8	Primary biliary cholangitis;
KIRP	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.64	0.34	4.78e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg05347473	chr6:146136440	FBXO30	0.61	8.67	0.48	5.98e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg10755058	chr3:40428713	ENTPD3	-0.37	-5.14	-0.31	5.53e-7	Renal cell carcinoma;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg11598736	chr3:195384522	SDHAP2	0.6	5.47	0.33	1.09e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.47	-4.87	-0.3	2.01e-6	Psoriasis;
KIRP	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.43	0.33	1.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	1.000	rs1717000	chr3:41930219	A/C	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.11e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.99	-15.29	-0.7	1.5e-37	Sudden cardiac arrest;
KIRP	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.45	-6.02	-0.36	6.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9467773	0.609	rs12663780	chr6:26397573	T/C	cg09904177	chr6:26538194	HMGN4	-0.42	-5.21	-0.32	4.01e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.1	-0.31	6.77e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2625529	0.590	rs713048	chr15:72543084	G/A	cg16672083	chr15:72433130	SENP8	-0.47	-5.68	-0.34	3.72e-8	Red blood cell count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16978263	chr3:160118452	SMC4;IFT80	0.54	6.68	0.39	1.61e-10	Smoking initiation;
KIRP	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1629083	0.905	rs17121882	chr11:118081468	C/T	cg18857871	chr11:118064634	AMICA1	0.64	8.53	0.48	1.47e-15	Lung cancer;
KIRP	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg07541023	chr7:19748670	TWISTNB	0.67	6.18	0.37	2.58e-9	Thyroid stimulating hormone;
KIRP	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.23	-18.08	-0.76	4.55e-47	Type 1 diabetes nephropathy;
KIRP	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg13256891	chr4:100009986	ADH5	0.47	5.85	0.35	1.59e-8	Alcohol dependence;
KIRP	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12667521	chr19:29218732	NA	0.93	9.2	0.51	1.59e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg10434728	chr15:90938212	IQGAP1	0.4	7.04	0.41	1.87e-11	Rheumatoid arthritis;
KIRP	cis	rs2904967	0.852	rs1858783	chr11:65042941	A/G	cg12562828	chr11:65076843	NA	0.47	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.44	-5.77	-0.35	2.34e-8	Facial morphology (factor 20);
KIRP	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.37	6.6	0.39	2.49e-10	Left ventricle wall thickness;
KIRP	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg02023728	chr11:77925099	USP35	0.33	5.29	0.32	2.7e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.53	6.62	0.39	2.3e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09238106	chr11:64242796	NA	0.53	6.46	0.38	5.71e-10	Interleukin-4 levels;
KIRP	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg11952622	chr19:58962976	ZNF324B	0.42	4.93	0.3	1.51e-6	Uric acid clearance;
KIRP	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.75	10.65	0.56	4.98e-22	Prudent dietary pattern;
KIRP	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.72	-0.34	3.13e-8	Bipolar disorder;
KIRP	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg23127183	chr11:57508653	C11orf31	-0.55	-7.04	-0.41	1.91e-11	Schizophrenia;
KIRP	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.22	-20.64	-0.8	1.37e-55	Breast cancer;
KIRP	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg17757837	chr7:157058334	UBE3C	-0.68	-8.6	-0.48	9.27e-16	Body mass index;
KIRP	cis	rs981844	0.601	rs62323856	chr4:154623149	T/C	cg14289246	chr4:154710475	SFRP2	0.59	5.79	0.35	2.15e-8	Response to statins (LDL cholesterol change);
KIRP	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.6	6.5	0.38	4.49e-10	Gut microbiome composition (summer);
KIRP	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg25008857	chr14:105974488	NA	0.43	4.89	0.3	1.79e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-6.87	-0.4	5.1e-11	Axial length;
KIRP	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.48	6.58	0.39	2.74e-10	Lewy body disease;
KIRP	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.3	5.96	0.36	8.55e-9	Schizophrenia;
KIRP	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.24	0.42	5.83e-12	Mean platelet volume;
KIRP	cis	rs10214930	0.697	rs6980382	chr7:27637662	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.27	-0.37	1.65e-9	Monocyte percentage of white cells;
KIRP	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs584438	0.873	rs584828	chr17:38599230	C/T	cg09213124	chr17:38599508	IGFBP4	-0.29	-4.99	-0.3	1.14e-6	Height;
KIRP	cis	rs4716602	0.550	rs12672151	chr7:156159053	A/G	cg16983916	chr7:156159713	NA	-0.44	-5.54	-0.33	7.93e-8	Anti-saccade response;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg08989290	chr16:615782	NHLRC4	0.4	5.77	0.35	2.33e-8	Height;
KIRP	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg25418670	chr11:30344373	C11orf46	-0.6	-5.19	-0.31	4.33e-7	Morning vs. evening chronotype;
KIRP	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg09873164	chr1:152488093	CRCT1	0.55	6.97	0.41	2.88e-11	Hair morphology;
KIRP	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.36	-5.26	-0.32	3.12e-7	Eye color traits;
KIRP	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg19636519	chr7:99541626	NA	0.29	4.91	0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs1461503	0.534	rs7944405	chr11:122816099	A/G	cg27398637	chr11:122830231	C11orf63	-0.71	-9.45	-0.52	2.74e-18	Menarche (age at onset);
KIRP	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg17279839	chr7:150038598	RARRES2	0.41	5.46	0.33	1.18e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs698833	0.892	rs698801	chr2:44691662	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.65	0.39	1.84e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.32	-0.42	3.55e-12	Morning vs. evening chronotype;
KIRP	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.43	5.62	0.34	5.24e-8	Blood metabolite levels;
KIRP	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3849570	0.643	rs9870954	chr3:81978850	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-7.32	-0.42	3.43e-12	Waist circumference;Body mass index;
KIRP	cis	rs981844	0.735	rs17371573	chr4:154765216	G/A	cg14289246	chr4:154710475	SFRP2	0.66	7.66	0.44	4.13e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.15	-0.37	3.12e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.53	-6.0	-0.36	6.85e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg06634786	chr22:41940651	POLR3H	-0.45	-4.87	-0.3	1.96e-6	Neuroticism;
KIRP	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.69	9.6	0.52	9.97e-19	Hemoglobin concentration;
KIRP	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.56	7.88	0.45	1.08e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	6.3	0.37	1.34e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg23736307	chr8:27182930	PTK2B	0.53	6.59	0.39	2.67e-10	Neuroticism;
KIRP	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	4.85	0.3	2.19e-6	Height;
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	0.86	14.67	0.68	1.95e-35	Vitiligo;
KIRP	cis	rs6568686	0.786	rs9387014	chr6:111850541	G/A	cg15721981	chr6:111408429	SLC16A10	-0.67	-5.95	-0.35	9.05e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.34	5.82	0.35	1.85e-8	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7737355	0.741	rs6875363	chr5:130581195	A/G	cg06307176	chr5:131281290	NA	-0.57	-5.38	-0.32	1.77e-7	Life satisfaction;
KIRP	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.52	7.35	0.42	2.92e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg21401794	chr1:90099060	LRRC8C	0.7	9.86	0.53	1.51e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.93	-14.09	-0.67	1.85e-33	Chronic sinus infection;
KIRP	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg01721255	chr8:58191610	C8orf71	0.5	4.89	0.3	1.85e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg19554555	chr3:13937349	NA	-0.47	-6.49	-0.38	4.64e-10	Ovarian reserve;
KIRP	trans	rs12043259	0.730	rs4951136	chr1:204815729	G/T	cg11485465	chr5:54518469	NA	0.39	6.76	0.4	9.86e-11	Addiction;
KIRP	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	8.0	0.45	4.77e-14	Iron status biomarkers;
KIRP	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-0.78	-9.17	-0.5	2e-17	Gut microbiome composition (summer);
KIRP	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23598886	chr18:12777645	NA	0.67	5.81	0.35	1.89e-8	Inflammatory skin disease;
KIRP	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.5e-21	Bone mineral density;
KIRP	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg10326726	chr10:51549505	MSMB	-0.59	-8.94	-0.5	9.47e-17	Prostate-specific antigen levels;
KIRP	cis	rs4791746	0.901	rs4458042	chr17:8618608	A/G	cg03115937	chr17:8649504	CCDC42	-0.52	-6.29	-0.37	1.43e-9	Heroin dependence;
KIRP	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.65	8.29	0.47	7.54e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-1.1	-24.58	-0.84	3.51e-68	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.64	0.34	4.56e-8	Lung cancer;
KIRP	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.45	-5.91	-0.35	1.15e-8	Schizophrenia;
KIRP	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.14	-0.41	1.05e-11	Migraine;Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg15117754	chr3:10150083	C3orf24	0.54	5.15	0.31	5.25e-7	Alzheimer's disease;
KIRP	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.72	7.88	0.45	1.04e-13	Corneal astigmatism;
KIRP	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.63	8.18	0.46	1.54e-14	Age at first birth;
KIRP	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-5.43	-0.33	1.38e-7	Parkinson's disease;
KIRP	cis	rs882732	1.000	rs10133253	chr14:95033681	A/G	cg08495878	chr14:95027859	SERPINA4	-0.41	-5.09	-0.31	7.07e-7	Blood protein levels;
KIRP	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg26138937	chr11:71823887	C11orf51	0.93	6.02	0.36	6.39e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.03	0.41	1.98e-11	Aortic root size;
KIRP	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs514024	0.672	rs482095	chr9:130493513	A/G	cg13643465	chr9:130375613	STXBP1	0.44	5.92	0.35	1.08e-8	Eating disorders (purging via substances);
KIRP	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg12661370	chr5:149340060	SLC26A2	0.47	5.69	0.34	3.53e-8	HIV-1 control;
KIRP	cis	rs7007076	0.901	rs1367825	chr8:124728107	G/A	cg00283535	chr8:124749564	ANXA13	0.79	8.06	0.46	3.39e-14	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18350866	chr20:39766189	PLCG1	0.53	6.95	0.41	3.35e-11	Parkinson's disease;
KIRP	cis	rs858239	0.539	rs4295546	chr7:23191021	C/T	cg23682824	chr7:23144976	KLHL7	0.52	6.09	0.36	4.23e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.3	-6.04	-0.36	5.56e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg22654517	chr2:96458247	NA	0.34	5.14	0.31	5.69e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg13271783	chr10:134563150	INPP5A	-0.61	-7.75	-0.44	2.36e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4262150	0.883	rs72802882	chr5:152242673	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg26727032	chr16:67993705	SLC12A4	-0.55	-4.93	-0.3	1.49e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2117029	0.586	rs10783307	chr12:49529605	A/T	cg24176009	chr12:49580217	TUBA1A	-0.37	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.52	6.9	0.4	4.45e-11	Blood metabolite levels;
KIRP	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg00800038	chr16:89945340	TCF25	-0.78	-5.27	-0.32	3.04e-7	Skin colour saturation;
KIRP	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.59	6.3	0.37	1.36e-9	Diisocyanate-induced asthma;
KIRP	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.04	16.27	0.72	6.88e-41	Subjective well-being;
KIRP	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.65	8.37	0.47	4.31e-15	Height;
KIRP	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg11941060	chr3:133502564	NA	-0.48	-5.93	-0.35	1.05e-8	Iron status biomarkers;
KIRP	cis	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg04733911	chr16:78082701	NA	-0.45	-5.07	-0.31	7.72e-7	Systolic blood pressure (alcohol consumption interaction);
KIRP	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.69	5.73	0.34	3e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.95	-16.29	-0.72	5.87e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs10129255	0.518	rs11847766	chr14:107187425	T/C	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.31	5.09e-7	Kawasaki disease;
KIRP	cis	rs6832769	0.961	rs1873092	chr4:56444300	T/C	cg05960024	chr4:56376020	CLOCK	-0.7	-8.78	-0.49	2.78e-16	Personality dimensions;
KIRP	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.62	7.25	0.42	5.43e-12	Height;
KIRP	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.6	-0.39	2.48e-10	Coronary artery disease;
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	14.45	0.68	1.1e-34	Platelet count;
KIRP	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-5.93	-0.35	1.01e-8	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg12315302	chr6:26189340	HIST1H4D	-0.94	-6.51	-0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.61	0.44	5.89e-13	Tonsillectomy;
KIRP	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.64	-10.75	-0.57	2.35e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs7147624	0.938	rs7151148	chr14:65936665	G/C	cg03016385	chr14:66212404	NA	-0.98	-10.51	-0.56	1.42e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg09788416	chr12:39539408	NA	0.41	5.29	0.32	2.74e-7	Morning vs. evening chronotype;
KIRP	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg19847130	chr8:10466454	RP1L1	-0.34	-5.02	-0.3	1e-6	Retinal vascular caliber;
KIRP	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg16691251	chr5:66510806	NA	0.42	5.44	0.33	1.25e-7	Breast cancer;
KIRP	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg13266496	chr6:110720918	DDO	0.35	5.66	0.34	4.24e-8	Platelet distribution width;
KIRP	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.89	-13.87	-0.66	1.05e-32	Height;
KIRP	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg24375607	chr4:120327624	NA	0.61	6.64	0.39	1.96e-10	Corneal astigmatism;
KIRP	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg18709589	chr6:96969512	KIAA0776	0.34	5.04	0.31	8.89e-7	Headache;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-1.07	-23.51	-0.83	7.55e-65	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.58	6.38	0.38	8.69e-10	Alcohol dependence;
KIRP	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.93	-0.3	1.52e-6	Schizophrenia;
KIRP	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.22	-0.37	2.14e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.71	7.14	0.41	1.04e-11	Chronic kidney disease;
KIRP	cis	rs4908768	0.906	rs6656249	chr1:8581015	A/C	cg03610117	chr1:8450231	RERE	-0.45	-5.22	-0.32	3.85e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg11235152	chr1:67600687	NA	0.63	9.51	0.52	1.86e-18	Psoriasis;
KIRP	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	0.6	6.55	0.39	3.28e-10	Crohn's disease;
KIRP	cis	rs6738627	0.861	rs3923113	chr2:165501849	A/C	cg03182029	chr2:165697222	COBLL1	0.4	5.21	0.32	3.92e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23903597	chr17:61704154	MAP3K3	-0.55	-6.68	-0.39	1.59e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	1.04	20.17	0.79	4.8e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.5	-6.62	-0.39	2.28e-10	Immature fraction of reticulocytes;
KIRP	cis	rs4664293	0.867	rs2357532	chr2:160597427	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02291224	chr15:69591187	PAQR5	0.52	7.01	0.41	2.32e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.42	9.01	0.5	5.8e-17	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg07921184	chr16:71880281	ATXN1L	0.55	6.33	0.37	1.18e-9	Electroencephalogram traits;
KIRP	cis	rs16958440	0.581	rs11082564	chr18:44659149	C/G	cg17192377	chr18:44677553	HDHD2	0.5	5.21	0.32	3.91e-7	Sitting height ratio;
KIRP	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.49	6.82	0.4	6.86e-11	Testicular germ cell tumor;
KIRP	cis	rs859767	0.501	rs10210052	chr2:135417350	C/T	cg12500956	chr2:135428796	TMEM163	-0.42	-5.68	-0.34	3.75e-8	Neuroticism;
KIRP	cis	rs6457821	1.000	rs11961212	chr6:35330150	T/C	cg06087101	chr6:35551932	FKBP5	0.55	5.04	0.31	9.12e-7	Height;
KIRP	cis	rs60871478	0.898	rs67785403	chr7:787201	A/G	cg05535760	chr7:792225	HEATR2	0.96	9.5	0.52	1.93e-18	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20135002	chr11:47629003	NA	-0.42	-5.01	-0.3	1.06e-6	Subjective well-being;
KIRP	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.26	0.32	3.2e-7	Educational attainment;
KIRP	cis	rs12496230	0.794	rs4856964	chr3:66858561	C/T	cg17646820	chr3:66848679	NA	0.4	6.7	0.39	1.4e-10	Type 2 diabetes;
KIRP	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.14	0.72	1.87e-40	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.69	9.78	0.53	2.7e-19	Metabolic syndrome;
KIRP	cis	rs4362	0.902	rs4351	chr17:61569732	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.39	-5.19	-0.31	4.5e-7	Blood metabolite levels;
KIRP	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs12445022	0.571	rs4843625	chr16:87576996	G/C	cg08031982	chr16:87577539	NA	0.41	6.77	0.4	9.25e-11	Small vessel stroke;Systemic juvenile idiopathic arthritis;
KIRP	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.36	-4.88	-0.3	1.89e-6	Renal function-related traits (BUN);
KIRP	cis	rs13279522	0.711	rs59792335	chr8:66970455	A/T	cg04041976	chr8:67085823	TRIM55	-0.57	-5.82	-0.35	1.82e-8	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	7.98	0.45	5.63e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs1859156	0.767	rs17429308	chr4:95831071	C/G	cg24204951	chr2:239172084	PER2	0.28	6.42	0.38	6.95e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs9815354	0.638	rs73073302	chr3:42029879	T/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg27211696	chr2:191398769	TMEM194B	-0.77	-9.41	-0.51	3.69e-18	Diastolic blood pressure;
KIRP	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg05347473	chr6:146136440	FBXO30	-0.62	-7.36	-0.42	2.79e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg06307176	chr5:131281290	NA	-0.55	-6.43	-0.38	6.68e-10	Life satisfaction;
KIRP	cis	rs4006360	0.629	rs72625995	chr17:39253835	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.58	-7.99	-0.45	5.39e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.17	-0.54	1.66e-20	Alzheimer's disease (late onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25683012	chr12:57030113	BAZ2A	0.58	6.86	0.4	5.48e-11	Smoking initiation;
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg00080972	chr5:178986291	RUFY1	0.38	5.72	0.34	3.1e-8	Lung cancer;
KIRP	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-8.78	-0.49	2.84e-16	Hemoglobin concentration;
KIRP	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.8	-10.53	-0.56	1.22e-21	Platelet count;
KIRP	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg02811702	chr13:24901961	NA	0.43	5.73	0.34	2.89e-8	Obesity-related traits;
KIRP	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.44	-0.65	3.06e-31	Height;
KIRP	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.06	-0.46	3.29e-14	Mood instability;
KIRP	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	0.95	8.19	0.46	1.46e-14	Arsenic metabolism;
KIRP	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.98	-15.05	-0.69	1.01e-36	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg16141378	chr3:129829833	LOC729375	0.51	6.87	0.4	5.2e-11	Triglycerides;
KIRP	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.96	-0.5	8.41e-17	Platelet count;
KIRP	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-7.63	-0.44	5.28e-13	Morning vs. evening chronotype;
KIRP	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.65	-0.56	4.85e-22	Menopause (age at onset);
KIRP	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	1.09	10.82	0.57	1.4e-22	Psoriasis;
KIRP	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Alcohol dependence;
KIRP	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-9.08	-0.5	3.69e-17	Neuroticism;
KIRP	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.66	6.53	0.38	3.7e-10	Eotaxin levels;
KIRP	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26314531	chr2:26401878	FAM59B	-0.48	-5.05	-0.31	8.55e-7	Gut microbiome composition (summer);
KIRP	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.56	7.11	0.41	1.22e-11	QRS duration;
KIRP	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.98	-0.45	5.53e-14	Retinal vascular caliber;
KIRP	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.52	-8.72	-0.49	4.13e-16	Alzheimer's disease;
KIRP	cis	rs7601312	1.000	rs7573382	chr2:229324680	C/T	cg02542817	chr2:229291442	NA	-0.38	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.6	-9.15	-0.5	2.23e-17	Hip circumference;Waist circumference;
KIRP	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg21014159	chr11:117668035	DSCAML1	0.42	5.77	0.35	2.38e-8	Myopia;
KIRP	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg17554472	chr22:41940697	POLR3H	-0.44	-5.05	-0.31	8.62e-7	Neuroticism;
KIRP	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.94	-17.83	-0.75	3.36e-46	Dental caries;
KIRP	cis	rs7539409	0.604	rs6689821	chr1:84316605	A/G	cg10977910	chr1:84465055	TTLL7	0.6	5.44	0.33	1.28e-7	Alzheimer's disease;
KIRP	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg22356347	chr1:167427500	CD247	-0.5	-6.81	-0.4	7.39e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg02336718	chr17:17403227	NA	-0.37	-5.68	-0.34	3.87e-8	Total body bone mineral density;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12999362	chr7:75947528	NA	0.48	6.09	0.36	4.3e-9	Myopia (pathological);
KIRP	cis	rs12200560	0.505	rs9386691	chr6:97081076	A/G	cg06623918	chr6:96969491	KIAA0776	-0.49	-6.09	-0.36	4.26e-9	Coronary heart disease;
KIRP	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.32	18.83	0.77	1.38e-49	Corneal structure;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05108160	chr13:110790284	NA	0.52	6.02	0.36	6.35e-9	Lung cancer in ever smokers;
KIRP	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.38	-0.51	4.61e-18	Brugada syndrome;
KIRP	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg25650185	chr19:21324782	ZNF431	0.48	5.1	0.31	6.75e-7	Pain;
KIRP	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.73	-10.15	-0.54	1.9e-20	Male sexual orientation;
KIRP	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.78	9.56	0.52	1.29e-18	Multiple system atrophy;
KIRP	cis	rs448720	0.554	rs7171219	chr15:68113771	C/A	cg24579218	chr15:68104479	NA	-0.47	-7.59	-0.44	6.74e-13	Cognitive performance;
KIRP	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.9	10.88	0.57	9.44e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg08847533	chr14:75593920	NEK9	0.54	6.27	0.37	1.57e-9	IgG glycosylation;
KIRP	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	4.95	0.3	1.37e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03647317	chr4:187891568	NA	-0.77	-12.86	-0.63	2.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg26248373	chr2:1572462	NA	-0.63	-5.88	-0.35	1.32e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-1.08	-9.43	-0.52	3.28e-18	Mitochondrial DNA levels;
KIRP	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg21095983	chr6:86352623	SYNCRIP	0.54	6.97	0.41	2.94e-11	Smooth-surface caries;
KIRP	cis	rs1021993	0.645	rs11586524	chr1:209496533	A/T	cg06155620	chr1:209527581	NA	0.35	4.93	0.3	1.5e-6	Gut microbiome composition (winter);
KIRP	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg05347473	chr6:146136440	FBXO30	0.61	8.69	0.48	5.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.48	-5.01	-0.3	1.04e-6	Platelet distribution width;
KIRP	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.89	-0.45	9.73e-14	Mood instability;
KIRP	trans	rs10432169	1	rs10432169	chr18:31347098	C/G	cg27147174	chr7:100797783	AP1S1	-0.58	-7.23	-0.42	6.18e-12	Subjective well-being;
KIRP	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg13165212	chr22:42675999	NA	-0.29	-4.94	-0.3	1.44e-6	Cognitive function;
KIRP	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.89	0.45	9.98e-14	Lung cancer in ever smokers;
KIRP	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-5.32	-0.32	2.39e-7	Height;
KIRP	cis	rs1867631	1.000	rs11208928	chr1:67089562	G/T	cg13052034	chr1:66999238	SGIP1	0.5	7.03	0.41	1.97e-11	Menopause (age at onset);
KIRP	cis	rs834811	0.797	rs2633365	chr7:135879797	A/G	cg01726295	chr7:135938950	NA	0.35	4.86	0.3	2.09e-6	Post-traumatic stress disorder;
KIRP	cis	rs2963155	0.518	rs10482614	chr5:142782402	C/T	cg17617527	chr5:142782415	NR3C1	0.77	7.84	0.45	1.39e-13	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18800042	chr5:141238690	PCDH1	0.54	6.72	0.39	1.26e-10	Interleukin-4 levels;
KIRP	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg09873164	chr1:152488093	CRCT1	0.57	7.45	0.43	1.59e-12	Hair morphology;
KIRP	cis	rs4690686	0.836	rs10027831	chr4:177256699	T/C	cg17059388	chr4:177262070	NA	0.56	7.89	0.45	1.01e-13	Essential tremor;
KIRP	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg06818126	chr11:68850279	TPCN2	-0.49	-5.62	-0.34	5.06e-8	Hair color;
KIRP	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.93	13.17	0.64	2.54e-30	Cognitive function;
KIRP	cis	rs12765878	1.000	rs4918068	chr10:105644736	T/G	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.28	14.61	0.68	3.17e-35	Uric acid levels;
KIRP	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.12	-0.5	2.68e-17	Hirschsprung disease;
KIRP	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.76	8.88	0.49	1.4e-16	Adiposity;
KIRP	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.53	7.08	0.41	1.47e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs34421088	0.560	rs11780851	chr8:11401116	G/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-7.79	-0.44	1.83e-13	Neuroticism;
KIRP	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg15147215	chr3:52552868	STAB1	-0.29	-4.9	-0.3	1.75e-6	Electroencephalogram traits;
KIRP	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.72	-9.91	-0.53	1.05e-19	Eye color traits;
KIRP	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.55	-7.27	-0.42	4.84e-12	Brugada syndrome;
KIRP	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.25	-0.42	5.35e-12	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg05340658	chr4:99064831	C4orf37	-0.52	-6.19	-0.37	2.45e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg13256891	chr4:100009986	ADH5	0.54	6.85	0.4	6.05e-11	Alcohol dependence;
KIRP	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.99	15.83	0.71	2.17e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg26262840	chr14:90767686	C14orf102	0.35	5.31	0.32	2.51e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs7215564	0.908	rs2316061	chr17:78663660	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs8070740	0.898	rs4493114	chr17:5324207	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.29	0.42	4.3e-12	Menopause (age at onset);
KIRP	cis	rs447921	0.861	rs67873924	chr17:74429992	C/G	cg17201438	chr17:74438067	UBE2O	0.44	4.93	0.3	1.52e-6	Mitochondrial DNA levels;
KIRP	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.87	10.52	0.56	1.28e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg17691542	chr6:26056736	HIST1H1C	0.64	7.37	0.43	2.63e-12	Iron status biomarkers;
KIRP	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg24699146	chr1:24152579	HMGCL	0.42	5.49	0.33	1e-7	Immature fraction of reticulocytes;
KIRP	cis	rs11622475	0.953	rs59776579	chr14:104370035	T/G	cg20488157	chr14:104394430	TDRD9	0.72	10.04	0.54	4.19e-20	Bipolar disorder;
KIRP	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.75	9.89	0.53	1.2e-19	Multiple sclerosis;
KIRP	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg01557791	chr16:72042693	DHODH	-0.7	-8.06	-0.46	3.42e-14	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.5	-0.33	9.5e-8	Aortic root size;
KIRP	cis	rs981844	0.848	rs17279789	chr4:154643245	T/C	cg14289246	chr4:154710475	SFRP2	0.69	7.37	0.43	2.52e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg25930673	chr12:123319894	HIP1R	-0.62	-5.73	-0.34	2.91e-8	Schizophrenia;
KIRP	trans	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg10756647	chr7:56101905	PSPH	1.09	8.55	0.48	1.29e-15	Diabetic kidney disease;
KIRP	cis	rs116726256	0.744	rs6741451	chr2:1842787	C/T	cg07855242	chr2:1841068	MYT1L	0.61	5.83	0.35	1.69e-8	Interleukin-8 levels;
KIRP	cis	rs1978968	0.957	rs34486385	chr22:18444290	C/T	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.14	18.98	0.77	4.32e-50	Cognitive function;
KIRP	cis	rs1440410	0.571	rs10034934	chr4:144033521	A/G	cg01719995	chr4:144104893	USP38	0.46	6.07	0.36	4.76e-9	Ischemic stroke;
KIRP	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.44	5.25	0.32	3.34e-7	Metabolite levels (MHPG);
KIRP	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg24579218	chr15:68104479	NA	0.38	6.25	0.37	1.78e-9	Restless legs syndrome;
KIRP	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	6.92	0.4	3.79e-11	Menarche (age at onset);
KIRP	cis	rs501120	0.810	rs684666	chr10:44745847	T/C	cg09554077	chr10:44749378	NA	0.74	12.39	0.62	1.01e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs17539620	0.808	rs17539432	chr6:154876414	G/C	cg20019720	chr6:154832845	CNKSR3	0.34	5.18	0.31	4.53e-7	Lipoprotein (a) levels;
KIRP	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg06740227	chr12:86229804	RASSF9	0.4	5.01	0.3	1.04e-6	Major depressive disorder;
KIRP	cis	rs4664293	0.632	rs2059697	chr2:160655590	A/G	cg08347373	chr2:160653686	CD302	0.36	5.55	0.33	7.36e-8	Monocyte percentage of white cells;
KIRP	cis	rs975210	0.556	rs2291986	chr15:70368432	C/T	cg01666796	chr15:70364327	TLE3	0.41	5.08	0.31	7.64e-7	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg13319975	chr6:146136371	FBXO30	0.45	6.18	0.37	2.67e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2213920	0.920	rs9408871	chr9:118263618	C/T	cg13918206	chr9:118159781	DEC1	0.87	8.53	0.48	1.52e-15	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.83	-0.49	1.97e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9810890	1.000	rs115225846	chr3:128619237	C/T	cg15033153	chr3:128514015	RAB7A	0.73	5.07	0.31	7.93e-7	Dental caries;
KIRP	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg10210624	chr19:58662595	ZNF329	0.6	5.6	0.34	5.81e-8	Cholesterol, total;
KIRP	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.66	-8.72	-0.49	4.14e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4716602	0.596	rs10253193	chr7:156157801	C/T	cg16983916	chr7:156159713	NA	-0.42	-5.4	-0.33	1.56e-7	Anti-saccade response;
KIRP	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.48	-5.1	-0.31	6.94e-7	Psoriasis;
KIRP	cis	rs11608355	0.538	rs11611957	chr12:109801803	A/G	cg19025524	chr12:109796872	NA	-0.48	-6.54	-0.38	3.56e-10	Neuroticism;
KIRP	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg07701084	chr6:150067640	NUP43	0.59	7.58	0.44	7.04e-13	Lung cancer;
KIRP	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.96	11.34	0.59	2.87e-24	Corneal astigmatism;
KIRP	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.73	7.74	0.44	2.62e-13	Vitiligo;
KIRP	cis	rs10214930	0.697	rs2080245	chr7:27569530	C/G	cg22168087	chr7:27702803	HIBADH	0.47	4.89	0.3	1.79e-6	Hypospadias;
KIRP	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg22138327	chr13:27999177	GTF3A	0.95	7.3	0.42	4e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg19468946	chr17:37922297	IKZF3	0.53	7.26	0.42	5.01e-12	Self-reported allergy;
KIRP	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.94	15.5	0.7	2.98e-38	Mean corpuscular volume;
KIRP	cis	rs1832871	0.683	rs9459852	chr6:158687250	T/G	cg07215822	chr6:158701037	NA	-0.64	-7.51	-0.43	1.1e-12	Height;
KIRP	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22618164	chr12:122356400	WDR66	0.61	8.39	0.47	3.76e-15	Mean corpuscular volume;
KIRP	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs6662572	0.737	rs9429187	chr1:46558927	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.82	0.35	1.86e-8	Blood protein levels;
KIRP	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	6.91	0.4	4.19e-11	Lymphocyte counts;
KIRP	cis	rs17655565	0.581	rs949384	chr12:52767548	T/C	cg07925835	chr12:52762777	KRT85	0.49	5.47	0.33	1.1e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg26084005	chr2:241760190	KIF1A	0.49	6.46	0.38	5.65e-10	Urinary metabolites;
KIRP	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-7.22	-0.42	6.59e-12	Vitamin D levels;
KIRP	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.77	9.17	0.5	1.95e-17	Adiposity;
KIRP	cis	rs7792596	0.539	rs13221476	chr7:94006920	A/G	cg20814616	chr7:94014465	NA	0.45	5.29	0.32	2.65e-7	Intelligence;
KIRP	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg00977110	chr5:151150581	G3BP1	0.54	5.68	0.34	3.7e-8	Preschool internalizing problems;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg24874828	chr4:187887005	NA	-0.47	-7.01	-0.41	2.33e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs75920871	0.720	rs4938340	chr11:116980622	G/A	cg23684410	chr11:116897558	SIK3	0.55	5.16	0.31	5.04e-7	Subjective well-being;
KIRP	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.38	-6.32	-0.37	1.24e-9	Height;
KIRP	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg00656387	chr3:40428638	ENTPD3	0.38	4.85	0.3	2.14e-6	Renal cell carcinoma;
KIRP	cis	rs7172677	0.961	rs34511319	chr15:75429717	A/C	cg14664628	chr15:75095509	CSK	-0.49	-5.27	-0.32	3e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4751006	0.543	rs2890130	chr10:128783848	T/C	cg05702161	chr10:128779687	DOCK1	-1.15	-9.42	-0.51	3.41e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg00982548	chr2:198649783	BOLL	-0.56	-5.46	-0.33	1.19e-7	Ulcerative colitis;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09256448	chr16:638327	NA	0.35	4.98	0.3	1.18e-6	Height;
KIRP	cis	rs193541	0.530	rs2125857	chr5:122083156	G/A	cg19412675	chr5:122181750	SNX24	0.51	5.42	0.33	1.4e-7	Glucose homeostasis traits;
KIRP	trans	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg24644049	chr4:85504048	CDS1	1.0	6.54	0.38	3.47e-10	Skin colour saturation;
KIRP	cis	rs1514687	0.534	rs2138020	chr2:1482093	T/A	cg03133821	chr2:1513998	TPO	-0.62	-5.29	-0.32	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-7.98	-0.45	5.66e-14	Response to antipsychotic treatment;
KIRP	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg13628971	chr7:2884303	GNA12	0.44	5.74	0.34	2.83e-8	Height;
KIRP	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg01620082	chr3:125678407	NA	-0.84	-6.27	-0.37	1.61e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.48	-5.98	-0.36	7.71e-9	Monocyte count;
KIRP	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.71	-10.18	-0.54	1.57e-20	Brugada syndrome;
KIRP	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg14972814	chr11:95582409	MTMR2	0.36	6.1	0.36	4.14e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15079326	chr1:110882112	RBM15	0.45	6.24	0.37	1.95e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7172677	0.737	rs12910348	chr15:75437642	A/G	cg14082893	chr15:75400931	NA	0.34	5.02	0.31	9.7e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs661054	0.956	rs511590	chr11:114441248	A/G	cg19465033	chr11:114479364	NA	-0.4	-5.59	-0.34	5.93e-8	Ulcerative colitis;
KIRP	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.34	-10.73	-0.56	2.72e-22	Economic and political preferences (immigration/crime);
KIRP	cis	rs11168936	0.637	rs3858587	chr12:49670433	A/G	cg21300561	chr12:49525534	TUBA1B	-0.41	-4.87	-0.3	2.02e-6	Cancer (pleiotropy);
KIRP	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.39	0.38	8.24e-10	Menarche (age at onset);
KIRP	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.54	-6.78	-0.4	8.89e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.81	9.85	0.53	1.67e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.16e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08704250	chr15:31115839	NA	-0.56	-8.08	-0.46	2.95e-14	Huntington's disease progression;
KIRP	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg17554472	chr22:41940697	POLR3H	0.67	7.11	0.41	1.22e-11	Vitiligo;
KIRP	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg18367735	chr17:79674897	NA	0.57	6.73	0.39	1.16e-10	Dental caries;
KIRP	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg25482853	chr8:67687455	SGK3	0.69	6.27	0.37	1.57e-9	Obesity-related traits;
KIRP	cis	rs714515	0.934	rs12405515	chr1:172357441	G/T	cg01573306	chr1:172330400	DNM3	0.45	5.92	0.35	1.1e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs6450176	1.000	rs3776717	chr5:53298762	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.33	0.47	5.81e-15	Lung cancer in ever smokers;
KIRP	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.4e-11	Response to antipsychotic treatment;
KIRP	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg09571762	chr12:39539558	NA	0.37	5.16	0.31	5.05e-7	Morning vs. evening chronotype;
KIRP	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.35	-5.31	-0.32	2.5e-7	Body mass index;
KIRP	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-6.63	-0.39	2.09e-10	Chronic sinus infection;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01743110	chr15:65294293	MTFMT	0.49	7.41	0.43	2.04e-12	C-reactive protein;
KIRP	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.19	0.37	2.44e-9	Menopause (age at onset);
KIRP	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs4824093	0.610	rs28473584	chr22:50315413	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-4.89	-0.3	1.84e-6	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.38	-5.02	-0.3	1.01e-6	Educational attainment (years of education);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15351736	chr11:111808104	DIXDC1	0.68	6.81	0.4	7.3e-11	Lung function (FEV1);
KIRP	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.5	-5.85	-0.35	1.6e-8	Common traits (Other);
KIRP	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.08	0.36	4.49e-9	Breast cancer;
KIRP	cis	rs282587	0.569	rs428270	chr13:113411956	T/G	cg04656015	chr13:113407548	ATP11A	0.67	7.85	0.45	1.25e-13	Glycated hemoglobin levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23814388	chr20:48770442	TMEM189;TMEM189-UBE2V1	-0.5	-6.58	-0.39	2.78e-10	Myopia;
KIRP	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg26248373	chr2:1572462	NA	-0.48	-5.39	-0.33	1.61e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.4	0.38	7.64e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07832834	chr1:2457954	PANK4	0.47	6.63	0.39	2.06e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7301016	0.895	rs11174514	chr12:62895074	G/C	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg25486957	chr4:152246857	NA	-0.53	-5.69	-0.34	3.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg07636037	chr3:49044803	WDR6	0.57	5.4	0.33	1.6e-7	Menarche (age at onset);
KIRP	cis	rs924840	0.634	rs2869030	chr15:78711803	A/C	cg24631222	chr15:78858424	CHRNA5	0.51	6.22	0.37	2.1e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	trans	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.98e-12	Bladder cancer;
KIRP	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg26784012	chr10:32216390	ARHGAP12	0.3	4.86	0.3	2.12e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg07701084	chr6:150067640	NUP43	0.7	9.75	0.53	3.47e-19	Lung cancer;
KIRP	cis	rs11997175	0.603	rs4739382	chr8:33807012	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.45	0.33	1.23e-7	Body mass index;
KIRP	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg00405596	chr8:11794950	NA	-0.48	-6.31	-0.37	1.26e-9	Retinal vascular caliber;
KIRP	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.58	-12.09	-0.61	9.99e-27	Diabetic kidney disease;
KIRP	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg08885076	chr2:99613938	TSGA10	0.46	7.84	0.45	1.38e-13	Chronic sinus infection;
KIRP	cis	rs12096438	0.934	rs6688931	chr1:25889672	G/A	cg21452808	chr1:25900135	NA	-0.4	-6.36	-0.38	1e-9	Platelet count;Mean platelet volume;
KIRP	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.42	5.15	0.31	5.37e-7	Free thyroxine concentration;
KIRP	cis	rs17057718	1.000	rs747089	chr3:57153869	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.4	-5.44	-0.33	1.26e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2279817	0.863	rs35871295	chr1:17984468	A/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.12	-0.46	2.27e-14	Neuroticism;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg10994292	chr5:110074295	SLC25A46	-0.48	-6.1	-0.36	4.11e-9	Obesity-related traits;
KIRP	cis	rs1116547	0.714	rs4705820	chr5:112766498	T/A	cg12552261	chr5:112820674	MCC	-0.47	-5.08	-0.31	7.52e-7	Cerebral amyloid angiopathy;
KIRP	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.54	-0.43	9.14e-13	Migraine;Coronary artery disease;
KIRP	trans	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.35	0.42	2.93e-12	Diabetic kidney disease;
KIRP	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.69	7.49	0.43	1.2e-12	Gut microbiome composition (summer);
KIRP	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.92	8.74	0.49	3.65e-16	Neuroticism;
KIRP	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg26335602	chr6:28129616	ZNF389	0.43	4.86	0.3	2.08e-6	Depression;
KIRP	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.8	12.32	0.62	1.75e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.56	7.95	0.45	6.75e-14	Breast cancer;
KIRP	cis	rs2274273	0.638	rs3759667	chr14:55658421	A/G	cg04306507	chr14:55594613	LGALS3	0.41	5.28	0.32	2.82e-7	Protein biomarker;
KIRP	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.77	10.84	0.57	1.2e-22	Height;
KIRP	cis	rs1144	0.505	rs2252074	chr7:104594253	T/G	cg04380332	chr7:105027541	SRPK2	-0.46	-6.86	-0.4	5.4e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg23127183	chr11:57508653	C11orf31	-0.45	-6.2	-0.37	2.41e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Bladder cancer;
KIRP	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	1.09	20.48	0.79	4.43e-55	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04241308	chr4:183838090	DCTD	0.48	6.38	0.38	8.56e-10	Parkinson's disease;
KIRP	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	1.16	13.69	0.66	4.38e-32	Red blood cell traits;
KIRP	cis	rs7592578	0.603	rs12476782	chr2:191472880	G/A	cg11845111	chr2:191398756	TMEM194B	-0.86	-9.44	-0.52	3.04e-18	Diastolic blood pressure;
KIRP	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg18944383	chr4:111397179	ENPEP	0.53	9.29	0.51	8.76e-18	Height;
KIRP	cis	rs526231	0.543	rs34766	chr5:102510923	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.37e-8	Primary biliary cholangitis;
KIRP	cis	rs5753037	0.585	rs7954	chr22:30184950	A/G	cg01021169	chr22:30184971	ASCC2	-0.51	-7.27	-0.42	4.64e-12	Type 1 diabetes;
KIRP	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.56	-0.39	3.19e-10	Response to antipsychotic treatment;
KIRP	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.27	0.32	2.93e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg21214613	chr1:16344536	HSPB7	0.34	5.24	0.32	3.43e-7	Dilated cardiomyopathy;
KIRP	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.35	5.47	0.33	1.09e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.49	8.71	0.49	4.58e-16	Vitiligo;
KIRP	cis	rs785830	0.871	rs494637	chr9:267606	G/A	cg14500300	chr9:211689	NA	0.47	6.15	0.36	3.17e-9	Platelet distribution width;
KIRP	cis	rs4774899	1.000	rs12916478	chr15:57502856	C/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.5	-0.33	9.31e-8	Urinary tract infection frequency;
KIRP	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.35	-0.32	2.03e-7	Atopic dermatitis;
KIRP	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.89	14.66	0.68	2.12e-35	Metabolic syndrome;
KIRP	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg07952391	chr2:88470173	THNSL2	0.91	7.5	0.43	1.13e-12	Plasma clusterin levels;
KIRP	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.13	-0.36	3.5e-9	Schizophrenia;
KIRP	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.72	9.75	0.53	3.45e-19	Pancreatic cancer;
KIRP	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.83	-14.46	-0.68	1.02e-34	Post bronchodilator FEV1;
KIRP	cis	rs73200209	0.744	rs7133286	chr12:116483965	A/C	cg01776926	chr12:116560359	MED13L	-0.55	-6.09	-0.36	4.27e-9	Total body bone mineral density;
KIRP	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01973587	chr1:228161476	NA	0.39	5.04	0.31	8.83e-7	Diastolic blood pressure;
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg13453750	chr1:205783389	SLC41A1	-0.49	-7.67	-0.44	4.08e-13	Menarche (age at onset);
KIRP	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.06	0.36	5.08e-9	Melanoma;
KIRP	cis	rs16828019	0.777	rs115916606	chr1:41642700	C/G	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg00405596	chr8:11794950	NA	-0.43	-5.58	-0.34	6.36e-8	Triglycerides;
KIRP	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg15488143	chr7:128924101	AHCYL2	-0.54	-5.98	-0.36	7.8e-9	White matter hyperintensity burden;
KIRP	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.25	0.32	3.23e-7	Retinal vascular caliber;
KIRP	cis	rs7794364	0.658	rs6965740	chr7:117514840	A/C	cg21880328	chr7:117514017	CTTNBP2	-0.35	-5.28	-0.32	2.8e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg13482628	chr17:19912719	NA	0.58	8.22	0.46	1.15e-14	Schizophrenia;
KIRP	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.53	-0.33	8.35e-8	Bipolar disorder;
KIRP	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.55	0.48	1.3e-15	Electroencephalogram traits;
KIRP	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	4.87	0.3	2.02e-6	Height;
KIRP	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg27432699	chr2:27873401	GPN1	-0.52	-6.77	-0.4	9.59e-11	Total body bone mineral density;
KIRP	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg05315796	chr3:52349193	DNAH1	0.41	6.46	0.38	5.5e-10	Electroencephalogram traits;
KIRP	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg09631192	chr20:23583594	CST9	-0.55	-5.29	-0.32	2.71e-7	Chronic kidney disease;
KIRP	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg16384552	chr7:74938386	SPDYE8P	-0.55	-6.71	-0.39	1.36e-10	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg11235152	chr1:67600687	NA	0.76	11.26	0.58	5.55e-24	Psoriasis;
KIRP	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08917092	chr7:16566261	NA	0.55	6.31	0.37	1.31e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.54	-0.52	1.47e-18	Coronary artery disease;
KIRP	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.18	-15.97	-0.71	7.39e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs12580194	1.000	rs61539173	chr12:55703206	C/T	cg11794356	chr12:55725991	OR6C3	-0.46	-6.64	-0.39	1.99e-10	Cancer;
KIRP	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.79	11.21	0.58	8.11e-24	Mean corpuscular hemoglobin;
KIRP	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg20243544	chr17:37824526	PNMT	0.49	6.95	0.41	3.31e-11	Asthma;
KIRP	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg04546413	chr19:29218101	NA	-0.58	-5.22	-0.32	3.74e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg13165212	chr22:42675999	NA	0.39	6.58	0.39	2.78e-10	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18316234	chr18:77748485	TXNL4A	0.51	6.47	0.38	5.19e-10	Parkinson's disease;
KIRP	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs3857536	0.904	rs10806525	chr6:66900488	A/C	cg07460842	chr6:66804631	NA	-0.4	-5.26	-0.32	3.11e-7	Blood trace element (Cu levels);
KIRP	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	1.0	14.74	0.68	1.15e-35	Cognitive function;
KIRP	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.19	0.42	7.76e-12	Aortic root size;
KIRP	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg00405596	chr8:11794950	NA	-0.5	-6.44	-0.38	6.17e-10	Retinal vascular caliber;
KIRP	cis	rs838147	0.844	rs12611203	chr19:49248295	G/A	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.3e-7	Dietary macronutrient intake;
KIRP	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg18944383	chr4:111397179	ENPEP	0.52	9.09	0.5	3.28e-17	Height;
KIRP	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.6	7.56	0.43	8.11e-13	Resistin levels;
KIRP	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.9	-11.89	-0.6	4.78e-26	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7213347	0.678	rs11658797	chr17:2088969	T/G	cg15816464	chr17:2026533	SMG6	0.36	5.23	0.32	3.6e-7	Total body bone mineral density;
KIRP	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg24253500	chr15:84953950	NA	-0.62	-6.61	-0.39	2.35e-10	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04740166	chr11:76652096	ACER3	-0.45	-7.11	-0.41	1.27e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.73	0.34	2.95e-8	Bipolar disorder;
KIRP	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.79	7.22	0.42	6.5e-12	Mean platelet volume;
KIRP	cis	rs7106204	0.513	rs2165784	chr11:24249360	C/A	ch.11.24196551F	chr11:24239977	NA	0.84	10.41	0.55	2.88e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.06e-11	Blood metabolite levels;
KIRP	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.64	-8.73	-0.49	3.89e-16	Colorectal cancer;
KIRP	cis	rs2738048	1.000	rs2702908	chr8:6824614	G/A	cg02787689	chr8:6828103	DEFA10P	-0.32	-6.23	-0.37	1.97e-9	IgA nephropathy;
KIRP	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.77	-8.5	-0.48	1.81e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.76	-9.18	-0.51	1.88e-17	Coronary artery disease;
KIRP	cis	rs2718058	0.630	rs2722359	chr7:37839764	T/C	cg15028436	chr7:37888078	TXNDC3	0.51	5.42	0.33	1.42e-7	Alzheimer's disease (late onset);
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02359409	chr6:42947317	PEX6	-0.52	-7.06	-0.41	1.68e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg07701084	chr6:150067640	NUP43	0.7	9.91	0.53	1.11e-19	Lung cancer;
KIRP	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.31	0.37	1.31e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.18	-0.31	4.61e-7	Metabolite levels;
KIRP	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Hypertriglyceridemia;
KIRP	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.86	-10.04	-0.54	4.33e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg03585969	chr10:35415529	CREM	0.83	9.93	0.53	9.6e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.62	8.77	0.49	3.02e-16	Endometrial cancer;
KIRP	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.31e-34	Breast cancer;
KIRP	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg21926883	chr2:100939477	LONRF2	-0.57	-7.89	-0.45	9.97e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.94	11.08	0.58	2.1e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-5.79	-0.35	2.13e-8	Inflammatory skin disease;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg18261144	chr6:167370276	RNASET2	0.55	6.33	0.37	1.18e-9	Electroencephalogram traits;
KIRP	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg00504896	chr12:9437009	LOC642846	-0.6	-8.24	-0.47	1.03e-14	Breast size;
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22618164	chr12:122356400	WDR66	-0.6	-8.21	-0.46	1.22e-14	Mean corpuscular volume;
KIRP	cis	rs2858942	0.818	rs2685123	chr16:248418	T/C	cg08400316	chr16:204221	HBZ	0.52	6.15	0.36	3.19e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs1823913	0.599	rs35892286	chr2:192133736	C/T	cg12404831	chr2:192114017	MYO1B	0.54	7.52	0.43	1.02e-12	Obesity-related traits;
KIRP	cis	rs2274459	1.000	rs12199132	chr6:33708250	G/A	cg06253072	chr6:33679850	C6orf125	0.5	5.03	0.31	9.25e-7	Obesity (extreme);
KIRP	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03934478	chr11:495069	RNH1	0.87	6.74	0.39	1.1e-10	Body mass index;
KIRP	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg02297831	chr4:17616191	MED28	0.54	6.84	0.4	6.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.75	-11.0	-0.57	3.62e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.15	0.37	3.11e-9	Mean platelet volume;
KIRP	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg13798912	chr7:905769	UNC84A	0.55	5.53	0.33	8.11e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.37	-0.43	2.63e-12	Morning vs. evening chronotype;
KIRP	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.44	-8.63	-0.48	7.65e-16	Longevity;
KIRP	cis	rs6772849	0.830	rs4857917	chr3:128376178	C/T	cg08795948	chr3:128337044	NA	0.51	6.38	0.38	8.81e-10	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	cis	rs4704187	0.687	rs115403098	chr5:74397384	A/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17559031	chr17:79673092	MRPL12	0.48	6.46	0.38	5.58e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg02462569	chr6:150064036	NUP43	-0.34	-5.11	-0.31	6.38e-7	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01803704	chr14:101453206	SNORD114-26;SNORD114-27	-0.46	-6.53	-0.38	3.82e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	1.01	13.26	0.65	1.18e-30	Exhaled nitric oxide output;
KIRP	cis	rs780096	0.967	rs1260333	chr2:27748624	A/G	cg22903471	chr2:27725779	GCKR	-0.46	-6.74	-0.39	1.14e-10	Total body bone mineral density;
KIRP	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg16141378	chr3:129829833	LOC729375	0.47	6.27	0.37	1.59e-9	Triglycerides;
KIRP	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg10223061	chr2:219282414	VIL1	0.43	6.79	0.4	8.47e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg20060108	chr2:102954350	IL1RL1	-0.61	-4.88	-0.3	1.94e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs7870753	0.838	rs10512239	chr9:99247012	G/A	cg25260653	chr9:99212216	HABP4	0.49	4.85	0.3	2.18e-6	Height;
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg11814155	chr7:99998594	ZCWPW1	0.61	5.7	0.34	3.36e-8	Platelet count;
KIRP	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.47	0.48	2.22e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg15664640	chr17:80829946	TBCD	-0.52	-5.22	-0.32	3.78e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.83	-12.02	-0.61	1.77e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg16989719	chr2:238392110	NA	-0.63	-6.11	-0.36	3.88e-9	Prostate cancer;
KIRP	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg04804543	chr8:142233427	SLC45A4	0.6	7.5	0.43	1.16e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.68	-0.39	1.62e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg05973401	chr12:123451056	ABCB9	-0.61	-7.16	-0.42	9.5e-12	Neutrophil percentage of white cells;
KIRP	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.5	-10.71	-0.56	3.17e-22	Longevity;
KIRP	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.96	12.93	0.64	1.57e-29	Breast cancer;
KIRP	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg17304646	chr3:125932534	NA	0.29	4.89	0.3	1.8e-6	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg18586891	chr4:952366	TMEM175	0.58	4.92	0.3	1.59e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg18944383	chr4:111397179	ENPEP	0.68	11.55	0.59	6.09e-25	Coronary artery disease;
KIRP	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	8.58	0.48	1.11e-15	Total body bone mineral density;
KIRP	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17376030	chr22:41985996	PMM1	-0.78	-8.02	-0.46	4.18e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	7.43	0.43	1.74e-12	Schizophrenia;
KIRP	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg06481639	chr22:41940642	POLR3H	-0.44	-4.87	-0.3	2.03e-6	Neuroticism;
KIRP	cis	rs1497828	1.000	rs2646846	chr1:217564117	G/A	cg04411442	chr1:217543379	NA	0.31	5.01	0.3	1.03e-6	Dialysis-related mortality;
KIRP	cis	rs8523	0.838	rs17675322	chr6:11059185	T/A	cg13562911	chr6:11044106	ELOVL2	0.41	5.43	0.33	1.32e-7	Red blood cell fatty acid levels;
KIRP	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	7.19e-7	Bladder cancer;
KIRP	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.69	-6.8	-0.4	7.99e-11	Breast cancer;
KIRP	cis	rs9311676	0.632	rs11923181	chr3:58380569	A/C	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.6	7.06	0.41	1.73e-11	Testicular germ cell tumor;
KIRP	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	0.57	8.16	0.46	1.71e-14	Coronary artery disease;
KIRP	cis	rs6442310	0.534	rs2921193	chr3:12441507	G/A	cg22839075	chr3:12045461	SYN2	0.34	4.94	0.3	1.45e-6	Hematocrit;
KIRP	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg01403660	chr11:68851641	TPCN2	0.69	6.8	0.4	8.02e-11	Blond vs. brown hair color;
KIRP	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg21573476	chr21:45109991	RRP1B	-0.67	-10.02	-0.54	4.74e-20	Mean corpuscular volume;
KIRP	cis	rs8060686	0.844	rs7196076	chr16:67887494	T/A	cg04539111	chr16:67997858	SLC12A4	-0.61	-5.82	-0.35	1.87e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18252515	chr7:66147081	NA	0.46	5.66	0.34	4.23e-8	Aortic root size;
KIRP	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg23594656	chr7:65796392	TPST1	0.39	6.04	0.36	5.75e-9	Aortic root size;
KIRP	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.77	-0.35	2.41e-8	Reticulocyte count;
KIRP	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.71	-9.2	-0.51	1.61e-17	Breast cancer;
KIRP	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.82	-11.84	-0.6	6.82e-26	Dental caries;
KIRP	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.76	-0.44	2.29e-13	Total cholesterol levels;
KIRP	cis	rs1829883	0.636	rs2968351	chr5:98728753	G/A	cg08333243	chr5:99726346	NA	0.39	5.15	0.31	5.44e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg08648136	chr8:956695	NA	0.43	6.67	0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs12282928	0.918	rs1503186	chr11:48244307	A/G	cg26585981	chr11:48327164	OR4S1	-0.51	-5.76	-0.34	2.54e-8	Migraine - clinic-based;
KIRP	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg03808351	chr9:123631620	PHF19	0.45	6.3	0.37	1.36e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.68	-7.93	-0.45	7.47e-14	IgG glycosylation;
KIRP	cis	rs6662572	0.737	rs7555458	chr1:46554142	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.51	0.33	8.96e-8	Blood protein levels;
KIRP	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.45	6.62	0.39	2.21e-10	Urate levels in lean individuals;
KIRP	cis	rs13095912	0.962	rs34505819	chr3:185340721	C/T	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.1e-11	Systolic blood pressure;
KIRP	cis	rs56775891	0.537	rs7236339	chr18:77579773	C/T	cg02536541	chr18:77568900	NA	-0.69	-8.57	-0.48	1.13e-15	Schizophrenia;
KIRP	cis	rs7714584	1.000	rs79442859	chr5:150171210	T/C	cg22134413	chr5:150180641	NA	1.06	7.56	0.43	8.2e-13	Crohn's disease;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg24874828	chr4:187887005	NA	-0.47	-7.01	-0.41	2.33e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24069221	chr6:149721844	SUMO4;MAP3K7IP2	-0.42	-6.45	-0.38	5.89e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4700695	0.841	rs27132	chr5:65288791	A/G	cg21114390	chr5:65439923	SFRS12	0.58	6.29	0.37	1.43e-9	Facial morphology (factor 19);
KIRP	cis	rs7116495	0.881	rs6592449	chr11:71670222	C/T	cg11196788	chr11:71737549	NUMA1	0.56	5.01	0.3	1.03e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg03235661	chr20:60525775	NA	-0.35	-5.36	-0.32	1.87e-7	Body mass index;
KIRP	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11987759	chr7:65425863	GUSB	-0.56	-7.22	-0.42	6.55e-12	Aortic root size;
KIRP	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.13	0.58	1.4e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12823128	0.766	rs7134992	chr12:26934133	G/A	cg14081884	chr12:26986758	ITPR2	0.4	5.0	0.3	1.1e-6	Birth weight;
KIRP	trans	rs12517041	1.000	rs7734577	chr5:23290864	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg25039879	chr17:56429692	SUPT4H1	-0.56	-4.9	-0.3	1.75e-6	Cognitive test performance;
KIRP	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg16141378	chr3:129829833	LOC729375	-0.6	-7.96	-0.45	6.51e-14	Joint mobility (Beighton score);
KIRP	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11987759	chr7:65425863	GUSB	0.45	5.24	0.32	3.52e-7	Aortic root size;
KIRP	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg00981070	chr1:2046702	PRKCZ	0.41	5.94	0.35	9.62e-9	Height;
KIRP	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.33	-5.37	-0.32	1.86e-7	Dupuytren's disease;
KIRP	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg09137382	chr11:130731461	NA	0.59	8.58	0.48	1.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs58688157	0.960	rs112006329	chr11:617228	G/A	cg16486109	chr11:613632	IRF7	0.41	4.96	0.3	1.33e-6	Systemic lupus erythematosus;
KIRP	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg24060327	chr5:131705240	SLC22A5	-0.43	-4.84	-0.3	2.26e-6	Breast cancer;Mosquito bite size;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19570596	chr22:29977162	NIPSNAP1	-0.47	-6.63	-0.39	2.12e-10	Myopia;
KIRP	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.6	8.79	0.49	2.55e-16	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
KIRP	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.01	-0.3	1.06e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.4	5.0	0.3	1.1e-6	Neutrophil percentage of white cells;
KIRP	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.44	6.71	0.39	1.3e-10	Tuberculosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02002494	chr3:119013045	CDGAP	0.54	6.43	0.38	6.41e-10	Smoking initiation;
KIRP	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg12962167	chr3:53033115	SFMBT1	0.64	4.94	0.3	1.42e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs698833	0.828	rs6705951	chr2:44534012	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	5.06	0.31	8.3e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg21775007	chr8:11205619	TDH	-0.45	-6.19	-0.37	2.44e-9	Neuroticism;
KIRP	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	9.36	0.51	5.35e-18	Cognitive test performance;
KIRP	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.19	-23.05	-0.83	2.2e-63	Exhaled nitric oxide output;
KIRP	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg01420254	chr6:26195488	NA	1.14	10.18	0.54	1.59e-20	Gout;Renal underexcretion gout;
KIRP	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg12571920	chr5:176541067	NA	-0.55	-6.13	-0.36	3.46e-9	Subjective well-being;
KIRP	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.24	-0.32	3.45e-7	Headache;
KIRP	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.93	0.45	7.61e-14	Coffee consumption (cups per day);
KIRP	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg00784671	chr22:46762841	CELSR1	-0.82	-8.14	-0.46	2.02e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.46	5.97	0.36	8.17e-9	Gout;
KIRP	cis	rs4722166	0.532	rs1880242	chr7:22759607	A/C	cg05472934	chr7:22766657	IL6	-0.53	-6.75	-0.4	1.08e-10	Lung cancer;
KIRP	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg13962347	chr6:5174647	LYRM4	-0.6	-8.3	-0.47	6.89e-15	Height;
KIRP	trans	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17183009	chr3:120277827	NA	0.56	6.38	0.38	8.81e-10	Corneal astigmatism;
KIRP	cis	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg08773314	chr2:239334832	ASB1	-0.56	-5.79	-0.35	2.14e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.56	7.75	0.44	2.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.76	-9.26	-0.51	1.04e-17	Response to antipsychotic treatment;
KIRP	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg17143192	chr8:8559678	CLDN23	0.72	8.3	0.47	6.94e-15	Obesity-related traits;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17088814	chr2:12856702	TRIB2	0.52	6.73	0.39	1.22e-10	Myopia (pathological);
KIRP	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.43	0.52	3.11e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg01765077	chr12:122356316	WDR66	0.49	6.69	0.39	1.46e-10	Mean corpuscular volume;
KIRP	cis	rs4919044	0.808	rs2486680	chr10:94805529	C/T	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg04672837	chr16:48644449	N4BP1	0.53	7.7	0.44	3.3e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.88	12.02	0.61	1.68e-26	Coronary artery disease;
KIRP	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.69	-6.92	-0.4	3.86e-11	Migraine;Coronary artery disease;
KIRP	cis	rs7187994	0.790	rs16974508	chr16:84781075	G/A	cg07647771	chr16:84786436	USP10	-0.43	-5.54	-0.33	7.74e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.28	-0.37	1.52e-9	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23973123	chr4:81207949	FGF5	-0.42	-6.36	-0.38	9.89e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13939156	chr17:80058883	NA	0.53	8.22	0.46	1.17e-14	Life satisfaction;
KIRP	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.25	-0.62	2.92e-27	Alzheimer's disease;
KIRP	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.13e-6	Aortic root size;
KIRP	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.63	8.32	0.47	5.94e-15	Iron status biomarkers;
KIRP	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.86	11.17	0.58	1.07e-23	Monocyte count;
KIRP	cis	rs1891498	0.602	rs10793704	chr1:147239987	A/T	cg27546670	chr1:147246839	GJA5	0.71	9.95	0.54	7.89e-20	Cognitive performance;
KIRP	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.91	0.3	1.69e-6	Coronary artery calcification;
KIRP	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22783747	chr14:69614817	DCAF5	0.44	6.28	0.37	1.51e-9	Interleukin-4 levels;
KIRP	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.75	-0.4	1.07e-10	Retinal vascular caliber;
KIRP	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00889227	chr1:205173544	DSTYK	-0.41	-5.86	-0.35	1.46e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6585424	1.000	rs61860035	chr10:81932453	C/G	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.75	10.01	0.54	5.08e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg12315302	chr6:26189340	HIST1H4D	1.23	7.32	0.42	3.52e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.79	0.71	2.98e-39	Bipolar disorder;
KIRP	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg05347473	chr6:146136440	FBXO30	0.61	8.69	0.48	5.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.58	7.57	0.43	7.6e-13	Alcohol dependence;
KIRP	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg02725872	chr8:58115012	NA	-0.55	-6.05	-0.36	5.4e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg05552183	chr6:42928497	GNMT	0.68	10.7	0.56	3.42e-22	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg09655341	chr17:79618100	PDE6G	-0.34	-5.44	-0.33	1.3e-7	Eye color traits;
KIRP	cis	rs16857609	0.628	rs6754268	chr2:218356797	A/G	cg15335768	chr2:218268053	DIRC3	-0.34	-4.97	-0.3	1.24e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.71	-10.18	-0.54	1.49e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	0.86	11.85	0.6	6.29e-26	Homoarginine levels;
KIRP	cis	rs714515	0.934	rs12404665	chr1:172357433	T/C	cg01573306	chr1:172330400	DNM3	0.44	5.72	0.34	3.14e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	5.39	0.33	1.62e-7	Bipolar disorder;
KIRP	cis	rs7814319	0.674	rs2643339	chr8:97246978	C/A	cg20787634	chr8:97240163	UQCRB	-0.57	-7.96	-0.45	6.47e-14	Lung function (FVC);
KIRP	cis	rs16857609	0.564	rs1478581	chr2:218292652	C/T	cg15335768	chr2:218268053	DIRC3	-0.54	-7.12	-0.41	1.22e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs9914544	0.545	rs4393623	chr17:18775900	A/G	cg26306683	chr17:18585705	ZNF286B	0.38	4.97	0.3	1.24e-6	Educational attainment (years of education);
KIRP	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg17554472	chr22:41940697	POLR3H	0.68	7.1	0.41	1.32e-11	Vitiligo;
KIRP	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	5.06	0.31	8.15e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	12.82	0.63	3.75e-29	Personality dimensions;
KIRP	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg07701084	chr6:150067640	NUP43	0.54	5.58	0.34	6.37e-8	Lung cancer;
KIRP	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg09904177	chr6:26538194	HMGN4	0.54	7.48	0.43	1.28e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs831571	0.955	rs35837	chr3:64013249	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.56	-5.25	-0.32	3.29e-7	Type 2 diabetes;
KIRP	cis	rs13082711	0.871	rs35701251	chr3:27529753	T/A	cg02860705	chr3:27208620	NA	0.53	6.93	0.4	3.58e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg17376030	chr22:41985996	PMM1	-0.75	-7.64	-0.44	4.85e-13	Vitiligo;
KIRP	cis	rs6973256	0.865	rs10954424	chr7:133335479	G/A	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.26	13.43	0.65	3.21e-31	Eosinophil percentage of granulocytes;
KIRP	cis	rs9914988	0.613	rs12941884	chr17:27284443	A/G	cg10538030	chr17:27276405	PHF12	-0.6	-5.14	-0.31	5.72e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs12681288	0.640	rs6985741	chr8:962858	C/T	cg08648136	chr8:956695	NA	0.39	5.56	0.33	7.08e-8	Schizophrenia;
KIRP	cis	rs11756659	0.653	rs199738	chr6:25963456	A/G	cg21844956	chr6:25963442	TRIM38	0.51	5.37	0.32	1.78e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg04935436	chr20:30431758	NA	0.49	6.5	0.38	4.32e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00864171	chr11:67383662	NA	0.39	5.2	0.31	4.27e-7	Mean corpuscular volume;
KIRP	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg08662619	chr6:150070041	PCMT1	0.34	5.46	0.33	1.15e-7	Lung cancer;
KIRP	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.77	10.16	0.54	1.73e-20	Aortic root size;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.88	-9.88	-0.53	1.29e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.63	7.69	0.44	3.44e-13	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.94	15.31	0.7	1.25e-37	Menarche (age at onset);
KIRP	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg14664628	chr15:75095509	CSK	0.5	5.92	0.35	1.07e-8	Systemic lupus erythematosus;
KIRP	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.76	6.4	0.38	7.84e-10	Diabetic retinopathy;
KIRP	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.77	-7.21	-0.42	6.77e-12	Lymphocyte percentage of white cells;
KIRP	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	1.01	14.37	0.68	2.09e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.49	6.02	0.36	6.15e-9	Asthma;
KIRP	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.53	-7.15	-0.41	1.01e-11	Schizophrenia;
KIRP	cis	rs8044868	0.530	rs7201866	chr16:72086534	A/T	cg16558253	chr16:72132732	DHX38	-0.41	-5.56	-0.33	6.96e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs8077889	0.750	rs72836564	chr17:41935064	G/A	cg26893861	chr17:41843967	DUSP3	0.86	9.03	0.5	5.06e-17	Triglycerides;
KIRP	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.75	-10.73	-0.56	2.87e-22	Height;
KIRP	cis	rs661054	1.000	rs580705	chr11:114430047	C/G	cg19465033	chr11:114479364	NA	0.35	4.85	0.3	2.23e-6	Ulcerative colitis;
KIRP	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-4.89	-0.3	1.84e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-0.76	-6.66	-0.39	1.81e-10	Obesity-related traits;
KIRP	cis	rs4664304	0.620	rs2136977	chr2:160722850	C/T	cg03641300	chr2:160917029	PLA2R1	0.35	5.21	0.32	4.02e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg23594656	chr7:65796392	TPST1	0.46	7.16	0.42	9.28e-12	Aortic root size;
KIRP	cis	rs6504340	0.739	rs4793943	chr17:46666937	C/G	cg05487507	chr17:46671861	LOC404266;HOXB5	0.56	6.51	0.38	4.3e-10	Primary tooth development (number of teeth);
KIRP	cis	rs7851660	0.844	rs993501	chr9:100623377	A/G	cg13688889	chr9:100608707	NA	0.67	8.53	0.48	1.47e-15	Strep throat;
KIRP	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.49e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.57	8.34	0.47	5.51e-15	Prudent dietary pattern;
KIRP	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg09695851	chr17:3907499	NA	-0.82	-14.77	-0.69	8.8e-36	Type 2 diabetes;
KIRP	cis	rs240764	0.658	rs10223467	chr6:101207589	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.25	-0.32	3.32e-7	Neuroticism;
KIRP	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04022379	chr5:110408740	TSLP	0.72	11.4	0.59	1.91e-24	Eosinophilic esophagitis;
KIRP	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	trans	rs933360	0.585	rs886700	chr7:50824933	T/C	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg01864069	chr14:103024347	NA	-0.86	-10.04	-0.54	4.11e-20	Platelet count;
KIRP	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg26587870	chr6:27730563	NA	-0.65	-4.92	-0.3	1.56e-6	Breast cancer;
KIRP	cis	rs220324	0.688	rs9974977	chr21:43563496	G/A	cg09727148	chr21:43560719	UMODL1	0.42	4.9	0.3	1.75e-6	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs914615	0.552	rs11264337	chr1:155138450	C/T	cg02153340	chr1:155202674	NA	-0.48	-7.29	-0.42	4.18e-12	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg21419209	chr3:44054225	NA	-0.73	-9.07	-0.5	3.77e-17	Coronary artery disease;
KIRP	cis	rs4356932	1.000	rs4512021	chr4:76954407	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.22	0.37	2.1e-9	Blood protein levels;
KIRP	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16318349	chr1:154917307	PBXIP1	-0.35	-5.51	-0.33	8.9e-8	Prostate cancer;
KIRP	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.69	6.26	0.37	1.69e-9	Menarche (age at onset);
KIRP	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.69	8.92	0.49	1.1e-16	Resting heart rate;
KIRP	cis	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-4.94	-0.3	1.47e-6	Neuroticism;
KIRP	cis	rs6669919	0.647	rs10863900	chr1:211675597	A/G	cg10512769	chr1:211675356	NA	-0.43	-6.25	-0.37	1.8e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-6.53	-0.38	3.69e-10	Gut microbiome composition (summer);
KIRP	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-7.26	-0.42	5.13e-12	Gut microbiome composition (summer);
KIRP	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg11569703	chr11:65557185	OVOL1	0.33	4.96	0.3	1.35e-6	Eosinophil percentage of white cells;
KIRP	cis	rs9443189	0.813	rs2842561	chr6:76434273	A/C	cg01950844	chr6:76311363	SENP6	-0.57	-6.11	-0.36	3.82e-9	Prostate cancer;
KIRP	cis	rs10129255	0.536	rs10142951	chr14:107190574	A/G	cg23076370	chr14:107095027	NA	-0.4	-4.97	-0.3	1.27e-6	Kawasaki disease;
KIRP	cis	rs12140703	0.510	rs1572993	chr1:205045087	G/A	cg21643547	chr1:205240462	TMCC2	0.44	6.43	0.38	6.69e-10	Reticulocyte count;
KIRP	cis	rs2150410	0.915	rs4818004	chr21:40587049	A/G	cg11890956	chr21:40555474	PSMG1	0.8	5.66	0.34	4.1e-8	Temperament (bipolar disorder);
KIRP	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	9.21	0.51	1.44e-17	Post bronchodilator FEV1;
KIRP	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	0.89	6.89	0.4	4.7e-11	Age-related hearing impairment;
KIRP	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.76	-0.4	9.7e-11	Body mass index;
KIRP	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.38	-0.51	4.51e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg25486957	chr4:152246857	NA	-0.55	-5.96	-0.36	8.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.62	-6.67	-0.39	1.64e-10	Body mass index;
KIRP	cis	rs7998202	0.567	rs7982570	chr13:113370892	T/C	cg02820901	chr13:113351484	ATP11A	0.65	5.88	0.35	1.31e-8	Glycated hemoglobin levels;
KIRP	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg05315796	chr3:52349193	DNAH1	0.52	7.28	0.42	4.42e-12	Bipolar disorder;
KIRP	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs68170813	1.000	rs35024078	chr7:107245468	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-6.15	-0.36	3.16e-9	Coronary artery disease;
KIRP	cis	rs4654899	0.571	rs34530426	chr1:21085204	C/T	cg05370193	chr1:21551575	ECE1	0.37	5.17	0.31	4.79e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg16141378	chr3:129829833	LOC729375	0.46	6.09	0.36	4.32e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.55	-6.79	-0.4	8.6e-11	Type 2 diabetes;
KIRP	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.62	7.82	0.45	1.5700000000000001e-13	Tonsillectomy;
KIRP	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs6787782	0.541	rs1561646	chr3:18646668	A/G	cg10921334	chr6:119529888	MAN1A1	0.71	6.05	0.36	5.44e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs2625529	0.775	rs16956273	chr15:72117102	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-6.52	-0.38	4e-10	Red blood cell count;
KIRP	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-7.58	-0.44	6.88e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11078597	0.731	rs12937244	chr17:1646317	T/C	cg17514665	chr17:1657533	SERPINF2	0.46	5.69	0.34	3.64e-8	Serum albumin level;
KIRP	cis	rs151997	0.962	rs28090	chr5:50177509	T/C	cg06027927	chr5:50259733	NA	0.61	7.57	0.43	7.4e-13	Callous-unemotional behaviour;
KIRP	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.26	0.37	1.72e-9	Aortic root size;
KIRP	trans	rs7939886	0.920	rs7940563	chr11:55875133	C/T	cg03929089	chr4:120376271	NA	0.93	6.82	0.4	7.22e-11	Myopia (pathological);
KIRP	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.12	-0.36	3.58e-9	Coronary artery disease;
KIRP	cis	rs7712401	0.601	rs2910136	chr5:122254017	C/T	cg19412675	chr5:122181750	SNX24	-0.48	-5.24	-0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs7546668	1.000	rs10803392	chr1:15876758	C/T	cg21858823	chr1:15850916	CASP9	0.47	5.07	0.31	7.69e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg14664628	chr15:75095509	CSK	0.44	5.51	0.33	8.99e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07869135	chr8:123794843	ZHX2	0.49	6.63	0.39	2.1e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.4	6.24	0.37	1.93e-9	Body mass index;
KIRP	cis	rs6681460	0.649	rs6691033	chr1:67007429	C/T	cg13052034	chr1:66999238	SGIP1	0.44	6.03	0.36	5.85e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs9947295	0.649	rs1477484	chr18:11781076	G/T	cg14735704	chr18:11749182	GNAL	-0.47	-4.88	-0.3	1.89e-6	QT interval (drug interaction);
KIRP	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.57	-6.46	-0.38	5.54e-10	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02050903	chr11:44117243	EXT2	0.56	7.36	0.42	2.77e-12	Parkinson's disease;
KIRP	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.57	9.3	0.51	8.08e-18	Lung cancer;
KIRP	cis	rs7666738	0.515	rs13118898	chr4:98792893	T/A	cg05340658	chr4:99064831	C4orf37	0.66	7.9	0.45	9.2e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03576530	chr14:105167973	INF2	0.57	7.25	0.42	5.37e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	5.51	0.33	9.24e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs57338032	0.891	rs3817092	chr15:78764285	A/G	cg06917634	chr15:78832804	PSMA4	0.55	4.86	0.3	2.1e-6	CTACK levels;
KIRP	cis	rs877426	0.634	rs7329801	chr13:114824560	G/A	cg00571178	chr13:114841904	RASA3	-0.47	-5.09	-0.31	7.22e-7	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg25486957	chr4:152246857	NA	-0.48	-5.39	-0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg23815491	chr16:72088622	HP	0.5	7.15	0.42	9.58e-12	Blood protein levels;
KIRP	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg05315796	chr3:52349193	DNAH1	0.45	6.78	0.4	8.74e-11	Bipolar disorder;
KIRP	trans	rs488628	0.518	rs7632701	chr3:118184249	A/C	cg26312998	chr6:43337775	ZNF318	-0.47	-6.28	-0.37	1.5e-9	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.85	-13.19	-0.64	2.16e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.58	0.39	2.87e-10	Joint mobility (Beighton score);
KIRP	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.07	0.31	7.76e-7	Personality dimensions;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24475545	chr6:25153422	NA	0.53	6.37	0.38	9.11e-10	Interleukin-4 levels;
KIRP	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.74e-7	Schizophrenia;
KIRP	cis	rs13361707	0.726	rs11956047	chr5:40812377	G/A	cg01087697	chr5:40835557	RPL37	-0.42	-4.91	-0.3	1.65e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-9.08	-0.5	3.59e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	2.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg17422427	chr2:241507521	RNPEPL1	0.55	6.43	0.38	6.42e-10	Sleep duration;
KIRP	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-5.76	-0.34	2.56e-8	Aortic root size;
KIRP	cis	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg07460842	chr6:66804631	NA	-0.48	-5.9	-0.35	1.2e-8	Blood trace element (Cu levels);
KIRP	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.95	-9.55	-0.52	1.41e-18	Developmental language disorder (linguistic errors);
KIRP	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.57	6.13	0.36	3.41e-9	Type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg23587288	chr2:27483067	SLC30A3	0.56	7.06	0.41	1.65e-11	Blood metabolite levels;
KIRP	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.65	9.28	0.51	9.23e-18	Height;
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg07959982	chr6:153324114	MTRF1L	-0.49	-6.27	-0.37	1.61e-9	Platelet-derived growth factor BB levels;
KIRP	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.87	-11.92	-0.61	3.6e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs40363	0.645	rs37838	chr16:3509754	G/A	cg00484396	chr16:3507460	NAT15	0.52	6.59	0.39	2.65e-10	Tuberculosis;
KIRP	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-0.6	-6.71	-0.39	1.35e-10	Initial pursuit acceleration;
KIRP	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg27124370	chr19:33622961	WDR88	0.72	10.41	0.55	2.97e-21	Bone properties (heel);
KIRP	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.2	-0.31	4.21e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg24296786	chr1:45957014	TESK2	0.64	8.63	0.48	7.72e-16	High light scatter reticulocyte count;
KIRP	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	0.93	14.58	0.68	3.99e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	5.64	0.34	4.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.51	-6.22	-0.37	2.13e-9	Iron status biomarkers;
KIRP	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg21204522	chr6:27730016	NA	-0.71	-5.31	-0.32	2.48e-7	Depression;
KIRP	cis	rs7751419	0.527	rs4714216	chr6:39106207	G/A	cg08089693	chr6:39098871	NA	-0.77	-12.85	-0.63	2.83e-29	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg22604316	chr1:46958801	NA	-0.43	-6.1	-0.36	4.06e-9	Monobrow;
KIRP	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.46	5.91	0.35	1.15e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.61	-8.45	-0.47	2.5e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg21360079	chr12:107162445	NA	-0.69	-9.92	-0.53	9.98e-20	Heart rate;
KIRP	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg17724175	chr1:150552817	MCL1	0.34	5.72	0.34	3.13e-8	Melanoma;
KIRP	cis	rs7674212	0.507	rs223322	chr4:103800194	G/A	cg16532752	chr4:104119610	CENPE	-0.41	-4.91	-0.3	1.7e-6	Type 2 diabetes;
KIRP	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg06223162	chr1:101003688	GPR88	-0.42	-8.48	-0.48	2.1e-15	Monocyte count;
KIRP	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.52	0.33	8.79e-8	Body mass index;
KIRP	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6120849	0.754	rs36003887	chr20:33589107	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.37	0.38	9.09e-10	Protein C levels;
KIRP	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg22974920	chr21:40686053	BRWD1	0.51	6.17	0.37	2.78e-9	Cognitive function;
KIRP	cis	rs2380205	0.967	rs12255077	chr10:5897986	T/C	cg27141509	chr10:5886111	NA	-0.38	-5.54	-0.33	7.7e-8	Breast cancer;
KIRP	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg23594656	chr7:65796392	TPST1	0.46	7.16	0.42	9.28e-12	Aortic root size;
KIRP	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg09571762	chr12:39539558	NA	0.36	5.04	0.31	9e-7	Morning vs. evening chronotype;
KIRP	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22590775	chr19:49891494	CCDC155	-0.54	-6.43	-0.38	6.57e-10	Multiple sclerosis;
KIRP	cis	rs6668108	1	rs6668108	chr1:165691320	A/G	cg24409356	chr1:165738333	TMCO1	0.71	6.05	0.36	5.47e-9	Intraocular pressure;
KIRP	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg25706552	chr1:244017396	NA	0.58	6.13	0.36	3.42e-9	RR interval (heart rate);
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.74	-0.44	2.56e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs13401104	0.796	rs10929170	chr2:237115591	A/G	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.89	0.45	9.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00950418	chr7:105029125	SRPK2	-0.54	-6.58	-0.39	2.79e-10	Height;
KIRP	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13939156	chr17:80058883	NA	-0.5	-7.2	-0.42	7.32e-12	Life satisfaction;
KIRP	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg04935436	chr20:30431758	NA	0.48	5.81	0.35	1.95e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.44	-5.89	-0.35	1.24e-8	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs4356932	0.691	rs2242471	chr4:76878716	G/C	cg19388996	chr4:76862389	NAAA	-0.42	-5.37	-0.32	1.8e-7	Blood protein levels;
KIRP	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg16584676	chr17:46985605	UBE2Z	-0.45	-5.57	-0.33	6.6e-8	Type 2 diabetes;
KIRP	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.71	-6.32	-0.37	1.23e-9	Thyroid stimulating hormone;
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg18183042	chr17:80733038	TBCD	-0.37	-4.93	-0.3	1.54e-6	Glycated hemoglobin levels;
KIRP	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg23920097	chr1:209922102	NA	-0.44	-5.3	-0.32	2.59e-7	Red blood cell count;
KIRP	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	1.2	13.0	0.64	9.23e-30	Corneal structure;
KIRP	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs56079296	0.929	rs11241627	chr5:121273302	C/T	cg05256605	chr5:121412184	LOX	0.52	5.61	0.34	5.32e-8	Coronary artery disease;
KIRP	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	1.15	15.13	0.69	5.46e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7555523	0.887	rs4657475	chr1:165687175	T/C	cg24409356	chr1:165738333	TMCO1	0.52	4.95	0.3	1.39e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.78	9.46	0.52	2.57e-18	Neutrophil percentage of white cells;
KIRP	cis	rs1978968	1.000	rs2099944	chr22:18438578	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.62	-7.95	-0.45	6.62e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.83	-12.02	-0.61	1.68e-26	Dental caries;
KIRP	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg18357526	chr6:26021779	HIST1H4A	0.49	6.53	0.38	3.82e-10	Height;
KIRP	cis	rs4356932	1.000	rs4371639	chr4:76946569	G/T	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs6585424	0.929	rs12256429	chr10:81938632	A/G	cg27417294	chr10:81904244	PLAC9	0.52	5.17	0.31	4.91e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.59	-5.94	-0.35	9.63e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1448094	0.935	rs4919775	chr12:86339985	T/C	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.12e-6	Atopic dermatitis;
KIRP	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.78	-0.44	2.01e-13	Myopia (pathological);
KIRP	cis	rs7635838	0.819	rs4684072	chr3:11514860	A/G	cg00170343	chr3:11313890	ATG7	0.49	6.35	0.38	1.04e-9	HDL cholesterol;
KIRP	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg06307176	chr5:131281290	NA	0.55	6.03	0.36	6.12e-9	Life satisfaction;
KIRP	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-5.03	-0.31	9.46e-7	Cognitive function;
KIRP	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg16497661	chr14:103986332	CKB	0.52	7.08	0.41	1.47e-11	Body mass index;
KIRP	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.8	11.69	0.6	2.09e-25	Heart rate;
KIRP	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.66	-6.15	-0.36	3.17e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.44	-0.62	6.71e-28	Headache;
KIRP	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.78	8.48	0.48	2.17e-15	Cholesterol, total;
KIRP	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.58	-6.12	-0.36	3.68e-9	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.79	6.85	0.4	5.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.39	5.46	0.33	1.17e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7089973	0.934	rs12771956	chr10:116576228	C/G	cg03647239	chr10:116582469	FAM160B1	0.5	5.53	0.33	8.2e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs357618	1.000	rs357620	chr5:150847121	A/T	cg22672639	chr5:150884813	FAT2	0.35	5.33	0.32	2.17e-7	Basophil percentage of white cells;
KIRP	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs4631830	0.540	rs10825187	chr10:51491927	G/T	cg10326726	chr10:51549505	MSMB	0.54	7.34	0.42	3.03e-12	Prostate-specific antigen levels;
KIRP	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.69	10.73	0.56	2.72e-22	Blood metabolite ratios;
KIRP	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.52	-6.98	-0.41	2.65e-11	Urate levels in overweight individuals;
KIRP	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.74	9.45	0.52	2.86e-18	Coronary artery disease;
KIRP	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.39	5.73	0.34	2.94e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	1.0	14.35	0.67	2.53e-34	Alcohol dependence;
KIRP	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.65	-10.51	-0.56	1.35e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs580438	0.510	rs3796321	chr3:13418331	A/T	cg10657019	chr3:13328039	NA	-0.61	-8.11	-0.46	2.41e-14	Myringotomy;
KIRP	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.49	6.58	0.39	2.89e-10	Migraine;
KIRP	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	5.58	0.34	6.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	1.05	19.04	0.77	2.67e-50	Diastolic blood pressure;
KIRP	trans	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg06521331	chr12:34319734	NA	-0.55	-6.83	-0.4	6.5500000000000006e-11	Heart rate;
KIRP	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.56	-8.94	-0.5	9.8e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.8	10.69	0.56	3.62e-22	Response to antipsychotic treatment;
KIRP	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05347473	chr6:146136440	FBXO30	0.57	8.14	0.46	1.94e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs9311676	0.656	rs4399910	chr3:58389809	A/G	cg06643156	chr3:58380774	PXK	0.35	4.94	0.3	1.47e-6	Systemic lupus erythematosus;
KIRP	trans	rs7944735	0.567	rs77684932	chr11:48024893	A/G	cg03929089	chr4:120376271	NA	0.82	6.09	0.36	4.34e-9	Intraocular pressure;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.39	-0.32	1.67e-7	Lung cancer;
KIRP	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.64	8.06	0.46	3.37e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg20936604	chr3:58311152	NA	-0.62	-4.86	-0.3	2.14e-6	Cholesterol, total;
KIRP	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg20493526	chr2:3714936	ALLC	0.49	5.02	0.3	9.99e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.74	11.19	0.58	9.09e-24	Oral cavity cancer;
KIRP	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	0.99	18.45	0.76	2.6e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.57	7.69	0.44	3.46e-13	Prostate cancer;
KIRP	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg03894339	chr8:19674705	INTS10	0.56	6.33	0.37	1.17e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs13401104	0.796	rs7584847	chr2:237119457	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.51	-8.01	-0.45	4.51e-14	IgG glycosylation;
KIRP	cis	rs4950322	0.542	rs12046706	chr1:146661337	G/T	cg22381352	chr1:146742008	CHD1L	-0.37	-5.15	-0.31	5.24e-7	Protein quantitative trait loci;
KIRP	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.52	7.25	0.42	5.38e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.35	-4.94	-0.3	1.41e-6	Monocyte count;
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11987759	chr7:65425863	GUSB	0.69	9.62	0.52	8.21e-19	Aortic root size;
KIRP	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg21475434	chr5:93447410	FAM172A	-0.43	-4.99	-0.3	1.14e-6	Diabetic retinopathy;
KIRP	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.63	9.22	0.51	1.43e-17	Vitiligo;
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg18209359	chr17:80159595	CCDC57	0.42	5.53	0.33	8.26e-8	Life satisfaction;
KIRP	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12292205	chr6:26970375	C6orf41	-0.5	-6.37	-0.38	9.4e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg02353165	chr6:42928485	GNMT	0.57	6.87	0.4	5.31e-11	Blood protein levels;
KIRP	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.64	8.27	0.47	8.57e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg12623918	chr2:306882	NA	0.46	5.83	0.35	1.77e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1903068	0.853	rs12498317	chr4:56007093	G/A	cg20092376	chr4:56023423	NA	0.42	5.05	0.31	8.61e-7	Endometriosis;
KIRP	cis	rs1215050	0.791	rs700738	chr4:98907909	C/A	cg17366294	chr4:99064904	C4orf37	-0.38	-5.03	-0.31	9.4e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.24	-21.83	-0.81	1.72e-59	Breast cancer;
KIRP	cis	rs4704187	0.687	rs6864485	chr5:74497984	T/C	cg03227963	chr5:74354835	NA	0.4	5.79	0.35	2.13e-8	Response to amphetamines;
KIRP	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg13072238	chr3:49761600	GMPPB	-0.5	-4.95	-0.3	1.37e-6	Menarche (age at onset);
KIRP	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21643547	chr1:205240462	TMCC2	-0.69	-10.44	-0.55	2.37e-21	Red blood cell count;
KIRP	cis	rs7520050	0.966	rs785494	chr1:46586626	C/A	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11987759	chr7:65425863	GUSB	0.52	6.96	0.41	3.15e-11	Aortic root size;
KIRP	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg15445000	chr17:37608096	MED1	0.46	5.46	0.33	1.18e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.51	0.48	1.77e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21211367	chr2:162094118	NA	0.41	5.47	0.33	1.11e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	cg12689670	chr1:183009347	LAMC1	0.52	7.05	0.41	1.85e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.59	-5.61	-0.34	5.53e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27286337	chr10:134555280	INPP5A	0.85	10.59	0.56	7.78e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.09	0.31	7.1e-7	Parkinson's disease;
KIRP	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.39	-6.19	-0.37	2.49e-9	Body mass index;
KIRP	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.87	-0.45	1.11e-13	Depression;
KIRP	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	5.99	0.36	7.42e-9	Total body bone mineral density;
KIRP	cis	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.41	5.24	0.32	3.4e-7	Leprosy;
KIRP	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.4	-0.68	1.69e-34	Primary sclerosing cholangitis;
KIRP	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.19	-0.31	4.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg16497661	chr14:103986332	CKB	0.85	14.87	0.69	4.13e-36	Body mass index;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg09597638	chr17:3907349	NA	-0.75	-14.25	-0.67	5.14e-34	Type 2 diabetes;
KIRP	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.77	9.71	0.53	4.49e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg09117114	chr16:67998030	SLC12A4	-0.49	-5.17	-0.31	4.87e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14937543	chr3:20081518	KAT2B	0.56	6.87	0.4	5.36e-11	Parkinson's disease;
KIRP	cis	rs17655565	0.581	rs12424634	chr12:52769186	C/T	cg07925835	chr12:52762777	KRT85	0.48	5.02	0.3	9.93e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs3924048	0.559	rs4580	chr1:12628188	T/C	cg00291366	chr1:12616550	NA	0.41	5.74	0.34	2.82e-8	Optic cup area;
KIRP	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.85	0.66	1.27e-32	Cognitive function;
KIRP	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.64	-0.34	4.64e-8	Life satisfaction;
KIRP	cis	rs735539	0.521	rs1966190	chr13:21409137	A/C	cg04906043	chr13:21280425	IL17D	-0.46	-5.51	-0.33	9.24e-8	Dental caries;
KIRP	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-0.99	-13.82	-0.66	1.6e-32	Blood protein levels;
KIRP	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg21573476	chr21:45109991	RRP1B	-0.81	-10.79	-0.57	1.83e-22	Mean corpuscular volume;
KIRP	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg06197360	chr20:60970103	CABLES2	-0.48	-5.61	-0.34	5.51e-8	Colorectal cancer;
KIRP	cis	rs4073221	0.654	rs7373213	chr3:18298889	C/T	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.55	-6.52	-0.38	3.88e-10	Metabolite levels;
KIRP	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg07274523	chr3:49395745	GPX1	-0.73	-8.61	-0.48	9.12e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg24101359	chr6:42928495	GNMT	0.45	6.32	0.37	1.19e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg02002194	chr4:3960332	NA	0.42	6.05	0.36	5.3300000000000004e-09	Retinal vascular caliber;
KIRP	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg21427119	chr20:30132790	HM13	-0.42	-5.04	-0.31	8.89e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.67	9.52	0.52	1.71e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.79	-11.35	-0.59	2.66e-24	Blood metabolite levels;
KIRP	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg17376030	chr22:41985996	PMM1	0.48	5.54	0.33	7.96e-8	Vitiligo;
KIRP	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.63	-8.23	-0.46	1.12e-14	Obesity-related traits;
KIRP	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.16	-0.79	5.05e-54	Height;
KIRP	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11987759	chr7:65425863	GUSB	0.53	6.79	0.4	8.27e-11	Aortic root size;
KIRP	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.48	6.48	0.38	4.99e-10	Personality dimensions;
KIRP	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.97	-0.3	1.23e-6	Obesity-related traits;
KIRP	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg23594656	chr7:65796392	TPST1	-0.47	-6.48	-0.38	5.08e-10	Aortic root size;
KIRP	cis	rs62070183	0.808	rs76373015	chr17:31142041	C/A	cg05781649	chr17:31146240	MYO1D	-0.5	-4.9	-0.3	1.71e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4356932	0.967	rs28433437	chr4:76972653	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs12360000	0.522	rs11250865	chr10:1913841	T/C	cg26364871	chr10:1889757	NA	-0.49	-6.25	-0.37	1.79e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08439880	chr3:133502540	NA	-0.58	-7.21	-0.42	6.72e-12	Iron status biomarkers;
KIRP	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.59	5.51	0.33	8.86e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.46	6.37	0.38	9.17e-10	Dupuytren's disease;
KIRP	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.67	-0.34	3.89e-8	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.22	-0.37	2.11e-9	Lung cancer;
KIRP	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg04025307	chr7:1156635	C7orf50	0.49	5.03	0.31	9.33e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.39	-0.38	8.45e-10	Height;
KIRP	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	7.07	0.41	1.58e-11	Neuroticism;
KIRP	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.75	11.45	0.59	1.33e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg11846333	chr4:119757529	SEC24D	1.1	6.27	0.37	1.63e-9	Cannabis dependence symptom count;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg17150246	chr1:161068070	KLHDC9	0.53	6.05	0.36	5.3e-9	Sleep duration;
KIRP	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.49	-0.48	2.03e-15	Retinal vascular caliber;
KIRP	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.48	0.48	2.07e-15	Motion sickness;
KIRP	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	5.55	0.33	7.27e-8	Monocyte percentage of white cells;
KIRP	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg04519387	chr11:65556438	OVOL1	0.34	5.15	0.31	5.47e-7	Acne (severe);
KIRP	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.93	14.0	0.67	3.87e-33	Mean platelet volume;
KIRP	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.28	0.37	1.53e-9	Thyroid stimulating hormone;
KIRP	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg08600765	chr20:34638493	LOC647979	-0.68	-6.58	-0.39	2.78e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22317537	chr8:144099822	LY6E;LOC100133669	-0.45	-6.09	-0.36	4.28e-9	Myopia;
KIRP	trans	rs459571	0.796	rs10993894	chr9:136884511	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.73	-8.54	-0.48	1.45e-15	Platelet distribution width;
KIRP	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg08499158	chr17:42289980	UBTF	0.5	6.32	0.37	1.22e-9	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg04865290	chr3:52927548	TMEM110	0.62	7.16	0.42	9.49e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7849270	0.959	rs713218	chr9:131900770	G/C	cg13538475	chr9:131942899	NA	-0.32	-5.14	-0.31	5.72e-7	Blood metabolite ratios;
KIRP	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg06815112	chr8:27182871	PTK2B	0.47	6.02	0.36	6.15e-9	Neuroticism;
KIRP	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.95	-16.66	-0.73	3.13e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg04733989	chr22:42467013	NAGA	0.54	7.42	0.43	1.9e-12	Cognitive function;
KIRP	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.26	-0.32	3.07e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.49	-5.99	-0.36	7.59e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.7	8.78	0.49	2.89e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08473924	chr5:55115187	NA	-0.39	-6.32	-0.37	1.23e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.54	-0.43	9.27e-13	Bipolar disorder;
KIRP	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg23283495	chr1:209979779	IRF6	-0.33	-5.31	-0.32	2.4e-7	Monobrow;
KIRP	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.06	-0.31	8.16e-7	Neutrophil percentage of white cells;
KIRP	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.72	9.24	0.51	1.21e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.57	-5.01	-0.3	1.03e-6	Other erythrocyte phenotypes;
KIRP	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.59	-6.56	-0.39	3.17e-10	Chronic sinus infection;
KIRP	cis	rs236907	0.814	rs6695933	chr1:171774239	A/C	cg01410279	chr1:171621941	MYOC	-0.5	-4.93	-0.3	1.5e-6	Mean platelet volume;
KIRP	cis	rs7560272	0.695	rs10190002	chr2:73794054	C/T	cg20560298	chr2:73613845	ALMS1	-0.4	-4.94	-0.3	1.43e-6	Schizophrenia;
KIRP	cis	rs4478858	0.735	rs12563669	chr1:31858067	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.4	-0.33	1.56e-7	Alcohol dependence;
KIRP	cis	rs34779708	0.931	rs7920095	chr10:35303334	G/A	cg03585969	chr10:35415529	CREM	0.83	9.93	0.53	9.33e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg12661370	chr5:149340060	SLC26A2	0.52	6.73	0.39	1.21e-10	HIV-1 control;
KIRP	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs1468333	0.894	rs435570	chr5:137468635	T/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.34	0.32	2.16e-7	Resting heart rate;
KIRP	cis	rs13102973	0.965	rs28799927	chr4:135867094	A/G	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.79	11.06	0.58	2.45e-23	Menarche (age at onset);
KIRP	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg11031976	chr2:198649780	BOLL	-0.54	-5.09	-0.31	7.17e-7	Ulcerative colitis;
KIRP	cis	rs10267417	0.603	rs10233354	chr7:19895372	C/T	cg05791153	chr7:19748676	TWISTNB	0.56	5.16	0.31	5.07e-7	Night sleep phenotypes;
KIRP	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg06636001	chr8:8085503	FLJ10661	0.61	7.99	0.45	5.24e-14	Retinal vascular caliber;
KIRP	cis	rs7116495	1.000	rs4121395	chr11:71669242	C/T	cg11196788	chr11:71737549	NUMA1	0.55	4.94	0.3	1.45e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7709377	0.574	rs11241366	chr5:115469128	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.03	0.31	9.34e-7	Metabolite levels  (X-11787);
KIRP	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-5.45	-0.33	1.25e-7	Colorectal cancer;
KIRP	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.05	-0.41	1.77e-11	Neuroticism;
KIRP	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.77	0.35	2.4e-8	Lung cancer;
KIRP	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.93	-12.24	-0.62	3.17e-27	Platelet distribution width;
KIRP	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.56	-7.46	-0.43	1.46e-12	Schizophrenia;
KIRP	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-1.0	-11.67	-0.6	2.48e-25	White matter hyperintensity burden;
KIRP	cis	rs1208285	0.564	rs9402540	chr6:134200030	G/A	cg06643013	chr6:134217242	NA	-0.42	-5.07	-0.31	7.83e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg26207909	chr14:103986467	CKB	-0.51	-6.53	-0.38	3.68e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg17595323	chr11:93583763	C11orf90	0.34	5.64	0.34	4.68e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	11.0	0.57	3.79e-23	Smoking behavior;
KIRP	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.47	5.81	0.35	1.95e-8	Multiple myeloma (IgH translocation);
KIRP	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg16141378	chr3:129829833	LOC729375	0.51	6.61	0.39	2.33e-10	Neuroticism;
KIRP	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.32	0.32	2.32e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9921338	0.961	rs7198849	chr16:11373301	C/T	cg00044050	chr16:11439710	C16orf75	-0.48	-5.09	-0.31	7.24e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.76	8.37	0.47	4.35e-15	Uric acid levels;
KIRP	cis	rs4789452	1.000	rs11659109	chr17:75375859	C/T	cg02320862	chr17:75370284	SEPT9	-0.36	-4.91	-0.3	1.66e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg10818794	chr15:86012489	AKAP13	-0.49	-7.0	-0.41	2.48e-11	Coronary artery disease;
KIRP	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg26876637	chr1:152193138	HRNR	0.71	9.45	0.52	2.8e-18	Atopic dermatitis;
KIRP	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.94	13.54	0.65	1.43e-31	Height;
KIRP	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.54	-7.3	-0.42	3.87e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg16497661	chr14:103986332	CKB	0.69	8.02	0.46	4.22e-14	Body mass index;
KIRP	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg02187348	chr16:89574699	SPG7	0.43	4.93	0.3	1.55e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.09	17.89	0.75	2.13e-46	Primary sclerosing cholangitis;
KIRP	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.64	8.09	0.46	2.79e-14	QT interval;
KIRP	cis	rs11169552	0.510	rs10876056	chr12:50948517	G/A	cg12884762	chr12:50931848	DIP2B	-0.42	-4.87	-0.3	1.98e-6	Colorectal cancer;
KIRP	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.85	-13.48	-0.65	2.2e-31	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01809819	chr1:31192165	MATN1	0.55	6.62	0.39	2.27e-10	Smoking initiation;
KIRP	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.4	5.59	0.34	6.15e-8	Coronary artery disease;
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-6.74	-0.39	1.11e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-6.55	-0.39	3.4e-10	Sjögren's syndrome;Systemic lupus erythematosus;
KIRP	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.19	-0.37	2.49e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9630089	0.622	rs4919083	chr10:98958738	T/C	cg25902810	chr10:99078978	FRAT1	0.43	5.22	0.32	3.87e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.77	-8.63	-0.48	7.69e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs151997	0.962	rs27273	chr5:50181074	G/A	cg06027927	chr5:50259733	NA	0.59	7.41	0.43	2.02e-12	Callous-unemotional behaviour;
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.02	0.69	1.23e-36	Platelet count;
KIRP	cis	rs6684428	1.000	rs17113073	chr1:56355353	A/T	cg11651538	chr1:56320950	NA	-0.86	-8.88	-0.49	1.39e-16	Airflow obstruction;
KIRP	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18364779	chr6:26104403	HIST1H4C	0.38	5.13	0.31	5.85e-7	Schizophrenia;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.85	7.82	0.45	1.52e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.31	0.58	3.64e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-0.66	-7.74	-0.44	2.65e-13	Initial pursuit acceleration;
KIRP	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg18132916	chr6:79620363	NA	-0.43	-5.83	-0.35	1.72e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.42	-5.23	-0.32	3.59e-7	Educational attainment;
KIRP	cis	rs3126085	0.515	rs10788837	chr1:152351487	A/G	cg26876637	chr1:152193138	HRNR	-0.55	-6.91	-0.4	4.18e-11	Atopic dermatitis;
KIRP	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.04	-0.36	5.7e-9	Obesity-related traits;
KIRP	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.47	0.43	1.4e-12	Coronary artery disease;
KIRP	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.17	-0.37	2.81e-9	Obesity-related traits;
KIRP	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg23719950	chr11:63933701	MACROD1	0.67	6.52	0.38	3.91e-10	Mean platelet volume;
KIRP	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.4	-5.28	-0.32	2.84e-7	Body mass index;
KIRP	cis	rs2150410	0.915	rs67649754	chr21:40551055	C/A	cg11890956	chr21:40555474	PSMG1	-0.76	-5.5	-0.33	9.59e-8	Temperament (bipolar disorder);
KIRP	cis	rs9616064	0.889	rs5767287	chr22:46996179	G/A	cg25730555	chr22:47059586	GRAMD4	0.47	5.57	0.33	6.53e-8	Urate levels in obese individuals;
KIRP	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.56	-0.56	9.77e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg14703610	chr5:56206110	C5orf35	0.5	6.84	0.4	6.16e-11	Coronary artery disease;
KIRP	cis	rs1816854	0.572	rs11182282	chr12:44214899	C/A	cg20956634	chr12:44200518	TWF1	0.59	5.21	0.32	4.08e-7	Inflammatory bowel disease;
KIRP	cis	rs17095355	0.748	rs2501577	chr10:111846687	C/T	cg00817464	chr10:111662876	XPNPEP1	0.49	7.74	0.44	2.65e-13	Biliary atresia;
KIRP	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg19633962	chr1:26362018	EXTL1	-0.56	-5.03	-0.31	9.26e-7	Height;
KIRP	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.88e-7	Schizophrenia;
KIRP	cis	rs883565	0.569	rs1274970	chr3:39163252	A/G	cg01426195	chr3:39028469	NA	0.52	8.32	0.47	6.03e-15	Handedness;
KIRP	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.77	13.46	0.65	2.49e-31	Weight;
KIRP	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.59	0.39	2.67e-10	Educational attainment;
KIRP	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg05340658	chr4:99064831	C4orf37	0.67	8.15	0.46	1.86e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg02660097	chr11:68866761	NA	0.4	5.16	0.31	5.17e-7	Blond vs. brown hair color;
KIRP	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05836184	chr7:114686942	NA	-0.42	-6.37	-0.38	9.02e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs793571	0.568	rs6494029	chr15:58923206	T/C	cg05156742	chr15:59063176	FAM63B	0.6	7.71	0.44	3.15e-13	Schizophrenia;
KIRP	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg00852783	chr1:26633632	UBXN11	-0.48	-5.55	-0.33	7.3900000000000007e-08	Obesity-related traits;
KIRP	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg20243544	chr17:37824526	PNMT	0.51	7.2	0.42	7.43e-12	Asthma;
KIRP	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	1.09	17.26	0.74	2.9e-44	Homoarginine levels;
KIRP	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.85	-0.35	1.58e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.69	9.23	0.51	1.29e-17	Total body bone mineral density;
KIRP	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg12559939	chr2:27858050	GPN1	0.41	4.91	0.3	1.63e-6	Total body bone mineral density;
KIRP	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19171272	chr22:38449367	NA	-0.55	-8.04	-0.46	3.66e-14	Glioblastoma;Glioma;
KIRP	cis	rs7989336	0.605	rs7324999	chr13:96929528	C/T	cg02571835	chr13:96230311	CLDN10	0.4	5.36	0.32	1.87e-7	Obesity;
KIRP	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.97	-15.8	-0.71	2.75e-39	Prudent dietary pattern;
KIRP	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg13409248	chr3:40428643	ENTPD3	0.38	5.31	0.32	2.41e-7	Renal cell carcinoma;
KIRP	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.36	6.52	0.38	4.04e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.9	0.53	1.14e-19	Total body bone mineral density;
KIRP	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg13514129	chr1:39547527	MACF1	0.53	7.79	0.44	1.82e-13	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg05234568	chr11:5960015	NA	-0.59	-6.05	-0.36	5.44e-9	DNA methylation (variation);
KIRP	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	0.89	13.15	0.64	2.79e-30	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg09695851	chr17:3907499	NA	-0.54	-5.14	-0.31	5.72e-7	Type 2 diabetes;
KIRP	cis	rs1012068	0.624	rs4820997	chr22:32324140	C/T	cg15333674	chr22:32435499	NA	-0.42	-5.03	-0.31	9.55e-7	Chronic hepatitis C infection;
KIRP	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg23173402	chr1:227635558	NA	0.89	6.1	0.36	4.05e-9	Major depressive disorder;
KIRP	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.8	12.48	0.62	5.09e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg25356066	chr3:128598488	ACAD9	0.46	5.37	0.32	1.85e-7	IgG glycosylation;
KIRP	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	5.96	0.36	8.85e-9	Menarche (age at onset);
KIRP	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg15676125	chr6:33679581	C6orf125	0.42	5.72	0.34	3.07e-8	Height;
KIRP	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12292205	chr6:26970375	C6orf41	-0.58	-6.34	-0.37	1.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12200782	0.722	rs12216155	chr6:26373943	A/G	cg00631329	chr6:26305371	NA	-0.89	-5.25	-0.32	3.24e-7	Small cell lung carcinoma;
KIRP	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs7374004	0.628	rs7374289	chr3:38633071	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.45	5.3	0.32	2.61e-7	PR interval;
KIRP	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	cis	rs735539	0.645	rs9550663	chr13:21174053	C/T	cg27499820	chr13:21296301	IL17D	0.35	5.06	0.31	8.12e-7	Dental caries;
KIRP	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.03	0.64	7.35e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg21643547	chr1:205240462	TMCC2	-0.68	-9.87	-0.53	1.43e-19	Red blood cell count;
KIRP	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.51	7.04	0.41	1.87e-11	Lewy body disease;
KIRP	cis	rs35740288	0.742	rs4843087	chr15:86172855	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.62	11.88	0.6	4.88e-26	Bone mineral density;
KIRP	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.66	-11.1	-0.58	1.72e-23	Neuroticism;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg04553410	chr7:150864885	GBX1	0.88	6.41	0.38	7.3e-10	P wave terminal force;
KIRP	trans	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg26043149	chr18:55253948	FECH	-0.5	-6.19	-0.37	2.55e-9	Bone mineral density;
KIRP	cis	rs4774899	0.934	rs12898356	chr15:57497722	C/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.47	-0.33	1.08e-7	Urinary tract infection frequency;
KIRP	cis	rs735539	0.517	rs9552240	chr13:21126497	T/C	cg04906043	chr13:21280425	IL17D	-0.5	-5.87	-0.35	1.38e-8	Dental caries;
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg23985595	chr17:80112537	CCDC57	0.37	5.62	0.34	5.12e-8	Life satisfaction;
KIRP	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-0.7	-9.42	-0.52	3.34e-18	Prostate cancer;
KIRP	trans	rs933360	0.557	rs1978208	chr7:50785448	A/G	cg20003124	chr12:4557277	NA	-0.54	-6.14	-0.36	3.35e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.47	-0.43	1.35e-12	Joint mobility (Beighton score);
KIRP	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.78	10.11	0.54	2.48e-20	Systemic lupus erythematosus;
KIRP	cis	rs7560272	0.501	rs2421676	chr2:73966087	G/A	cg20560298	chr2:73613845	ALMS1	0.43	5.01	0.3	1.03e-6	Schizophrenia;
KIRP	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg13010199	chr12:38710504	ALG10B	-0.42	-5.6	-0.34	5.6e-8	Heart rate;
KIRP	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	1.0	13.12	0.64	3.6e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg15896084	chr13:114927664	NA	0.49	6.57	0.39	2.98e-10	Schizophrenia;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.05	-0.31	8.51e-7	Life satisfaction;
KIRP	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.62	8.21	0.46	1.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg15507776	chr3:136538369	TMEM22	0.4	5.42	0.33	1.39e-7	Neuroticism;
KIRP	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg06027949	chr8:82754900	SNX16	-0.61	-6.41	-0.38	7.57e-10	Diastolic blood pressure;
KIRP	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg22705602	chr4:152727874	NA	-0.52	-8.54	-0.48	1.39e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7615316	0.844	rs13075471	chr3:142191659	T/C	cg20824294	chr3:142316082	PLS1	0.22	4.87	0.3	2.03e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6594499	0.872	rs2112541	chr5:110449346	T/C	cg04022379	chr5:110408740	TSLP	0.49	7.37	0.43	2.52e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.78	11.61	0.6	3.82e-25	Height;
KIRP	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg10017260	chr10:834428	NA	-0.55	-5.43	-0.33	1.33e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs4920343	0.698	rs578988	chr1:19077291	T/C	cg19637330	chr1:19110922	NA	0.39	4.94	0.3	1.43e-6	Knee osteoarthritis;
KIRP	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.5	6.57	0.39	2.94e-10	Testicular germ cell tumor;
KIRP	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg04287289	chr16:89883240	FANCA	-0.39	-5.11	-0.31	6.55e-7	Vitiligo;
KIRP	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-4.85	-0.3	2.15e-6	Large artery stroke;
KIRP	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.16e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6681460	1.000	rs4655648	chr1:67114309	C/T	cg13052034	chr1:66999238	SGIP1	0.43	5.89	0.35	1.28e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs7481584	0.962	rs12805915	chr11:2969771	G/A	cg25174290	chr11:3078921	CARS	-0.57	-6.3	-0.37	1.34e-9	Calcium levels;
KIRP	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.48	0.43	1.29e-12	Myopia (pathological);
KIRP	cis	rs17065868	1.000	rs55684354	chr13:45067534	G/A	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs7999699	0.935	rs10507560	chr13:48330418	A/T	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.56	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	8.29	0.47	7.55e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs4494114	0.967	rs1925677	chr1:39346905	T/G	cg25970120	chr1:39325951	RRAGC	-0.38	-4.98	-0.3	1.22e-6	Blood protein levels;
KIRP	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.82	0.4	6.88e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg06026331	chr20:60912101	LAMA5	-0.47	-6.28	-0.37	1.5e-9	Colorectal cancer;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.48	6.09	0.36	4.25e-9	Resistin levels;
KIRP	cis	rs9302690	1.000	rs62037100	chr16:57430934	T/G	cg27017172	chr16:57497170	POLR2C	0.82	5.46	0.33	1.17e-7	Blood protein levels;
KIRP	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.67	-12.32	-0.62	1.77e-27	White blood cell count (basophil);
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02523424	chr22:39548724	CBX7	-0.53	-5.76	-0.34	2.47e-8	Menopause (age at onset);
KIRP	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg06634786	chr22:41940651	POLR3H	-0.49	-5.31	-0.32	2.5e-7	Neuroticism;
KIRP	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg07234876	chr8:600039	NA	0.8	5.52	0.33	8.51e-8	IgG glycosylation;
KIRP	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg25930673	chr12:123319894	HIP1R	-0.65	-5.99	-0.36	7.43e-9	Schizophrenia;
KIRP	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-10.94	-0.57	5.78e-23	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.11	-0.46	2.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12102151	chr20:57617922	SLMO2	-0.51	-6.54	-0.38	3.44e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.59	-7.39	-0.43	2.34e-12	Fibrinogen levels;
KIRP	cis	rs787274	0.764	rs1693411	chr9:115452665	G/C	cg13803584	chr9:115635662	SNX30	0.6	5.96	0.36	8.47e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-10.06	-0.54	3.58e-20	Coffee consumption (cups per day);
KIRP	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg03060546	chr3:49711283	APEH	0.53	7.02	0.41	2.19e-11	Menarche (age at onset);
KIRP	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg01864069	chr14:103024347	NA	-0.86	-10.11	-0.54	2.48e-20	Platelet count;
KIRP	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.12	-0.41	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11710088	0.740	rs34394409	chr3:149195226	C/T	cg08667024	chr3:149219783	TM4SF4	-0.42	-5.04	-0.31	8.86e-7	QRS duration;
KIRP	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg02461776	chr11:598696	PHRF1	0.48	5.17	0.31	4.81e-7	Systemic lupus erythematosus;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg13193676	chr8:80942319	MRPS28	0.95	6.43	0.38	6.66e-10	P wave terminal force;
KIRP	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.58	6.94	0.4	3.46e-11	Eosinophil percentage of white cells;
KIRP	cis	rs17057718	1.000	rs79932559	chr3:57145726	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.37	-4.95	-0.3	1.36e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.61	7.86	0.45	1.22e-13	Coronary artery disease;
KIRP	cis	rs6910061	0.913	rs28712814	chr6:11108745	T/G	cg27233058	chr6:11094804	LOC221710	0.57	5.76	0.34	2.46e-8	Diabetic kidney disease;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg17194243	chr13:37633605	FAM48A	0.53	6.58	0.39	2.81e-10	Plasma plasminogen activator levels;
KIRP	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.45	5.78	0.35	2.27e-8	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.4	-0.38	7.74e-10	Longevity;
KIRP	cis	rs17020663	0.713	rs73943418	chr2:101640637	T/C	cg17494863	chr2:101638916	TBC1D8	-0.52	-5.47	-0.33	1.12e-7	Pulse pressure;
KIRP	cis	rs55871839	0.619	rs6471756	chr8:59802159	A/G	cg07426533	chr8:59803705	TOX	-0.51	-8.77	-0.49	3.1e-16	Pneumonia;
KIRP	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.83	15.72	0.71	5.13e-39	Anterior chamber depth;
KIRP	cis	rs8077577	0.708	rs9913139	chr17:18153815	T/C	cg18869244	chr17:18121946	NA	0.43	5.07	0.31	7.77e-7	Obesity-related traits;
KIRP	cis	rs7075426	0.669	rs3858279	chr10:88257602	A/G	cg07322936	chr10:88137208	NA	0.5	5.44	0.33	1.28e-7	Migraine without aura;
KIRP	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg13798912	chr7:905769	UNC84A	0.65	6.4	0.38	7.87e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1829883	0.717	rs2682165	chr5:98888092	C/T	cg08333243	chr5:99726346	NA	-0.42	-5.32	-0.32	2.39e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6732160	0.588	rs13407363	chr2:73372558	T/C	cg01422370	chr2:73384389	NA	0.51	6.94	0.4	3.4e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.48	-6.28	-0.37	1.49e-9	Schizophrenia;
KIRP	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24229701	chr12:130821962	PIWIL1	0.42	5.27	0.32	3.04e-7	Menopause (age at onset);
KIRP	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg18888403	chr1:24152774	HMGCL	0.37	5.36	0.32	1.96e-7	Immature fraction of reticulocytes;
KIRP	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	cg12689670	chr1:183009347	LAMC1	-0.55	-7.6	-0.44	6.2800000000000005e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.42	0.33	1.41e-7	Lung cancer;
KIRP	cis	rs75804782	0.521	rs55973123	chr2:239416264	G/A	cg18131467	chr2:239335373	ASB1	-0.74	-5.36	-0.32	1.93e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.96	8.06	0.46	3.34e-14	Body mass index;
KIRP	cis	rs4262150	0.544	rs56346646	chr5:151915603	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.85	-0.49	1.73e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg15147215	chr3:52552868	STAB1	-0.34	-5.97	-0.36	8.08e-9	Electroencephalogram traits;
KIRP	cis	rs11250464	0.517	rs2892335	chr10:1432136	T/G	cg08668359	chr10:1443807	ADARB2	0.43	5.4	0.33	1.57e-7	Radiation response;
KIRP	cis	rs7712401	0.569	rs7709836	chr5:122352833	T/C	cg19328475	chr5:122430277	PRDM6	0.36	5.08	0.31	7.36e-7	Mean platelet volume;
KIRP	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg16141378	chr3:129829833	LOC729375	0.48	6.31	0.37	1.27e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9381040	0.692	rs4714430	chr6:41157054	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-5.19	-0.31	4.43e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2179367	0.887	rs2143076	chr6:149746451	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.31	-5.09	-0.31	7.19e-7	Dupuytren's disease;
KIRP	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.56e-17	Retinal vascular caliber;
KIRP	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.46	6.29	0.37	1.41e-9	Red blood cell count;
KIRP	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.31	0.32	2.43e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs9494145	0.567	rs35786788	chr6:135419042	G/A	cg22676075	chr6:135203613	NA	0.42	4.89	0.3	1.79e-6	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
KIRP	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg24520871	chr10:73074265	NA	-0.56	-6.05	-0.36	5.5e-9	Immature fraction of reticulocytes;
KIRP	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg14675211	chr2:100938903	LONRF2	0.52	7.01	0.41	2.33e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg15655495	chr12:38532458	NA	-0.28	-5.24	-0.32	3.49e-7	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.62	-6.68	-0.39	1.58e-10	Gut microbiome composition (summer);
KIRP	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg02951883	chr7:2050386	MAD1L1	-0.49	-5.91	-0.35	1.11e-8	Schizophrenia;
KIRP	cis	rs4704187	0.687	rs58067979	chr5:74523555	C/T	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.73e-8	Response to amphetamines;
KIRP	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.58	7.15	0.41	1.01e-11	Arsenic metabolism;
KIRP	cis	rs258892	0.895	rs34670	chr5:72162863	T/C	cg21869765	chr5:72125136	TNPO1	0.57	6.26	0.37	1.7e-9	Small cell lung carcinoma;
KIRP	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.69	7.29	0.42	4.09e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6690583	0.623	rs75918067	chr1:85453413	T/C	cg22153463	chr1:85462885	MCOLN2	0.59	5.33	0.32	2.19e-7	Serum sulfate level;
KIRP	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.92	-0.49	1.07e-16	Retinal vascular caliber;
KIRP	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.44	-6.77	-0.4	9.39e-11	Tonsillectomy;
KIRP	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg07606381	chr6:8435919	SLC35B3	-0.41	-5.13	-0.31	5.92e-7	Motion sickness;
KIRP	cis	rs42648	0.564	rs10224488	chr7:89810261	A/G	cg25739043	chr7:89950458	NA	-0.33	-5.2	-0.31	4.28e-7	Homocysteine levels;
KIRP	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg12384639	chr17:618140	VPS53	0.48	6.07	0.36	4.69e-9	Prostate cancer;
KIRP	cis	rs9443189	0.762	rs2748944	chr6:76436106	A/G	cg01950844	chr6:76311363	SENP6	0.61	6.72	0.39	1.23e-10	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07462328	chr16:18573511	NOMO2	0.47	6.06	0.36	5.1e-9	Parkinson's disease;
KIRP	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg21573476	chr21:45109991	RRP1B	-0.68	-9.51	-0.52	1.87e-18	Mean corpuscular volume;
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg01798813	chr17:3906674	NA	0.61	8.62	0.48	8.44e-16	Type 2 diabetes;
KIRP	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg23188430	chr6:125850052	NA	-0.36	-5.52	-0.33	8.76e-8	High light scatter reticulocyte count;
KIRP	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.92	14.66	0.68	2.1e-35	Testicular germ cell tumor;
KIRP	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.64	7.67	0.44	4.05e-13	Obesity-related traits;
KIRP	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	10.81	0.57	1.54e-22	Hip circumference adjusted for BMI;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01778974	chr15:57387422	TCF12	-0.42	-6.65	-0.39	1.88e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg08662619	chr6:150070041	PCMT1	0.38	6.39	0.38	8.35e-10	Lung cancer;
KIRP	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.64	-7.28	-0.42	4.6e-12	Menarche (age at onset);
KIRP	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	10.4	0.55	3.04e-21	Total body bone mineral density;
KIRP	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.82e-10	Bipolar disorder;
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg06815112	chr8:27182871	PTK2B	0.54	6.93	0.4	3.72e-11	Neuroticism;
KIRP	cis	rs9381040	0.692	rs3088370	chr6:41157670	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-5.19	-0.31	4.43e-7	Alzheimer's disease (late onset);
KIRP	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18823784	chr15:79103221	ADAMTS7	0.49	6.52	0.38	3.94e-10	Smoking initiation;
KIRP	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06481639	chr22:41940642	POLR3H	-0.47	-5.45	-0.33	1.24e-7	Vitiligo;
KIRP	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.93	7.43	0.43	1.73e-12	Obesity-related traits;
KIRP	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg01191920	chr7:158217561	PTPRN2	-0.66	-11.15	-0.58	1.26e-23	Obesity-related traits;
KIRP	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	9.56	0.52	1.3e-18	Lung cancer in ever smokers;
KIRP	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.92	0.4	3.81e-11	Rheumatoid arthritis;
KIRP	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg18357526	chr6:26021779	HIST1H4A	0.42	4.91	0.3	1.7e-6	Blood metabolite levels;
KIRP	cis	rs78487399	0.808	rs6737882	chr2:43731908	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.06	-0.31	8.28e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg17652424	chr22:38574118	PLA2G6	-0.25	-5.33	-0.32	2.27e-7	Cutaneous nevi;
KIRP	cis	rs12681288	0.748	rs2123054	chr8:1028227	C/G	cg08648136	chr8:956695	NA	0.45	5.84	0.35	1.68e-8	Schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14915620	chr3:47887956	DHX30	0.61	6.66	0.39	1.79e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	1.01	19.03	0.77	3.04e-50	Breast cancer;
KIRP	cis	rs963731	0.649	rs6544187	chr2:39232275	G/C	cg04010122	chr2:39346883	SOS1	-0.86	-5.4	-0.33	1.58e-7	Corticobasal degeneration;
KIRP	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.17	-0.37	2.83e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg11965913	chr1:205819406	PM20D1	0.45	4.98	0.3	1.21e-6	Parkinson's disease;
KIRP	trans	rs1941687	0.702	rs4392137	chr18:31316708	T/C	cg27147174	chr7:100797783	AP1S1	-0.57	-7.22	-0.42	6.53e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg00034003	chr16:88779146	CTU2	-0.42	-5.21	-0.32	4.07e-7	Autism spectrum disorder-related traits;
KIRP	cis	rs4236601	0.720	rs7811851	chr7:116156731	A/T	cg05166801	chr7:116143459	CAV2	0.48	5.87	0.35	1.37e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg20542592	chr8:11973495	FAM66D	-0.38	-4.92	-0.3	1.56e-6	Retinal vascular caliber;
KIRP	cis	rs10267417	0.603	rs4275127	chr7:19911062	A/G	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.23e-10	Major depressive disorder;
KIRP	cis	rs2950163	0.898	rs2693814	chr2:6191624	A/G	cg26659079	chr2:5836181	SOX11	-0.39	-4.96	-0.3	1.34e-6	Response to metformin (IC50);
KIRP	cis	rs55788414	0.932	rs2873367	chr16:81184380	T/A	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs11264213	0.681	rs116324086	chr1:36287771	A/G	cg27506609	chr1:36549197	TEKT2	0.96	5.34	0.32	2.13e-7	Schizophrenia;
KIRP	cis	rs9308731	0.583	rs2165107	chr2:111931350	C/G	cg03171003	chr2:111875934	NA	0.42	5.75	0.34	2.57e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs16858210	0.520	rs12636861	chr3:183549788	T/C	cg03417191	chr3:183542750	MAP6D1	-0.61	-5.4	-0.33	1.57e-7	Menopause (age at onset);
KIRP	cis	rs4690686	0.500	rs3921993	chr4:177263284	A/G	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs10463316	0.817	rs58892766	chr5:150776115	T/C	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.76	-0.34	2.5e-8	Metabolite levels (Pyroglutamine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13432900	chr19:49999314	RPS11	0.46	6.09	0.36	4.24e-9	Parkinson's disease;
KIRP	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg15226275	chr6:116381976	FRK	0.21	5.77	0.35	2.39e-8	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs76288851	0.543	rs9857890	chr3:126684607	C/T	cg13821433	chr2:26726535	OTOF	0.54	6.1	0.36	4.01e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.72	10.11	0.54	2.61e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg24879335	chr3:133465180	TF	0.45	6.97	0.41	2.82e-11	Iron status biomarkers;
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs4006360	0.531	rs4544293	chr17:39241359	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs10875746	0.669	rs4760701	chr12:48698518	A/G	cg26205652	chr12:48591994	NA	0.62	8.21	0.46	1.27e-14	Longevity (90 years and older);
KIRP	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg02297831	chr4:17616191	MED28	0.6	7.69	0.44	3.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs754423	0.515	rs1956291	chr14:52555673	C/T	cg05884192	chr14:52515736	NID2	0.47	5.21	0.32	4.05e-7	Craniofacial microsomia;
KIRP	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.89	14.52	0.68	6.38e-35	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg22681709	chr2:178499509	PDE11A	-0.62	-8.7	-0.49	4.88e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.67	8.45	0.47	2.62e-15	Bipolar disorder;
KIRP	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.56	-7.27	-0.42	4.69e-12	Aortic root size;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07281959	chr15:91421381	FURIN	0.4	6.03	0.36	6.02e-9	Cancer;
KIRP	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.46	8.71	0.49	4.54e-16	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.09e-14	Lung cancer;
KIRP	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg22617819	chr1:44378782	ST3GAL3	0.38	6.2	0.37	2.35e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2219968	1.000	rs6473086	chr8:78974646	T/C	cg00738934	chr8:78996279	NA	0.49	6.85	0.4	6.04e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4955124	0.558	rs12485651	chr3:32018536	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.78	7.2	0.42	7.49e-12	Schizophrenia;
KIRP	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.93	12.82	0.63	3.81e-29	Monocyte count;
KIRP	cis	rs2057149	0.776	rs1980531	chr6:110724518	C/T	cg18783796	chr6:110012478	AKD1;FIG4	-0.47	-5.73	-0.34	2.99e-8	Platelet distribution width;Mean platelet volume;
KIRP	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.11	-0.31	6.33e-7	IgG glycosylation;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22618164	chr12:122356400	WDR66	0.66	9.1	0.5	3.2e-17	Mean corpuscular volume;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-0.83	-14.92	-0.69	2.79e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg20542592	chr8:11973495	FAM66D	0.38	5.09	0.31	6.99e-7	Morning vs. evening chronotype;
KIRP	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12311346	chr5:56204834	C5orf35	-0.35	-4.91	-0.3	1.68e-6	Coronary artery disease;
KIRP	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.73	10.82	0.57	1.4e-22	Prostate cancer;
KIRP	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.72	7.99	0.45	5.21e-14	Initial pursuit acceleration;
KIRP	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.27	12.8	0.63	4.22e-29	Diabetic retinopathy;
KIRP	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg17376030	chr22:41985996	PMM1	-0.83	-8.87	-0.49	1.57e-16	Vitiligo;
KIRP	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs4704187	0.687	rs6898116	chr5:74486778	T/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.58	6.9	0.4	4.35e-11	Aortic root size;
KIRP	cis	rs698813	0.851	rs698812	chr2:44703714	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.42	0.33	1.42e-7	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14169450	chr9:139327907	INPP5E	0.56	6.56	0.39	3.14e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2279817	0.735	rs12067869	chr1:17989765	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-8.38	-0.47	3.97e-15	Neuroticism;
KIRP	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg26876637	chr1:152193138	HRNR	-0.68	-9.03	-0.5	5e-17	Atopic dermatitis;
KIRP	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg18154014	chr19:37997991	ZNF793	0.59	5.0	0.3	1.07e-6	Coronary artery calcification;
KIRP	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg00656387	chr3:40428638	ENTPD3	0.4	5.1	0.31	6.79e-7	Renal cell carcinoma;
KIRP	cis	rs151997	0.962	rs56170692	chr5:50247928	G/A	cg06027927	chr5:50259733	NA	0.58	7.33	0.42	3.3e-12	Callous-unemotional behaviour;
KIRP	cis	rs7523273	0.565	rs2761420	chr1:207889368	G/T	cg22525895	chr1:207977042	MIR29B2	-0.47	-5.84	-0.35	1.63e-8	Schizophrenia;
KIRP	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg16141378	chr3:129829833	LOC729375	0.53	7.13	0.41	1.08e-11	Neuroticism;
KIRP	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg12742826	chr1:26365331	SLC30A2	-0.46	-5.11	-0.31	6.47e-7	QRS complex (12-leadsum);
KIRP	cis	rs4819052	0.851	rs2256000	chr21:46685909	T/C	cg11663144	chr21:46675770	NA	-0.65	-9.24	-0.51	1.16e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.23	0.32	3.64e-7	Lung cancer;
KIRP	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.42	-5.46	-0.33	1.16e-7	Body mass index;
KIRP	cis	rs8028182	0.636	rs7175852	chr15:75694535	C/T	cg20655648	chr15:75932815	IMP3	0.53	6.62	0.39	2.19e-10	Sudden cardiac arrest;
KIRP	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.84	0.57	1.23e-22	Cognitive test performance;
KIRP	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.96	-10.83	-0.57	1.37e-22	Cognitive test performance;
KIRP	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg23307798	chr14:103986281	CKB	-0.52	-6.95	-0.4	3.35e-11	Coronary artery disease;
KIRP	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-7.74	-0.44	2.53e-13	Bone mineral density;
KIRP	cis	rs6449957	0.741	rs6882730	chr5:67464205	C/T	cg09038926	chr5:67483109	NA	-0.39	-5.16	-0.31	5.04e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg16590910	chr6:42928470	GNMT	0.43	5.91	0.35	1.12e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.86	8.87	0.49	1.53e-16	Bipolar disorder;
KIRP	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs3743266	0.634	rs7165874	chr15:60784609	A/T	cg27554954	chr15:60691595	ANXA2	-0.32	-4.86	-0.3	2.09e-6	Menarche (age at onset);
KIRP	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.6	-0.39	2.55e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.87	-0.63	2.55e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg23307798	chr14:103986281	CKB	0.48	6.7	0.39	1.44e-10	Body mass index;
KIRP	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	0.79	8.68	0.48	5.59e-16	Gut microbiome composition (summer);
KIRP	cis	rs35160687	0.814	rs7563887	chr2:86516121	C/T	cg06002975	chr2:86422967	IMMT	0.39	5.07	0.31	7.84e-7	Night sleep phenotypes;
KIRP	cis	rs12643440	0.538	rs16894433	chr4:17143112	A/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.47	-6.22	-0.37	2.1e-9	Crohn's disease;
KIRP	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg18944383	chr4:111397179	ENPEP	0.6	11.1	0.58	1.77e-23	Height;
KIRP	cis	rs11138902	0.649	rs1330331	chr9:72159507	C/T	cg14123607	chr9:72164709	APBA1	-0.41	-4.92	-0.3	1.62e-6	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.67	-7.32	-0.42	3.51e-12	QRS complex (12-leadsum);
KIRP	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06481639	chr22:41940642	POLR3H	0.75	7.72	0.44	2.84e-13	Vitiligo;
KIRP	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg11650704	chr1:154556575	ADAR	0.41	5.09	0.31	7.04e-7	Blood protein levels;
KIRP	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg06740227	chr12:86229804	RASSF9	0.49	6.27	0.37	1.59e-9	Major depressive disorder;
KIRP	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	9.87	0.53	1.44e-19	Alzheimer's disease;
KIRP	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.39	5.9	0.35	1.17e-8	Hypertriglyceridemia;
KIRP	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.42	-0.47	3.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.38	0.38	8.64e-10	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.99	0.45	5.12e-14	Iron status biomarkers;
KIRP	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg09455208	chr3:40491958	NA	0.37	6.54	0.38	3.61e-10	Renal cell carcinoma;
KIRP	cis	rs2019216	0.967	rs1606426	chr17:21927959	A/G	cg22648282	chr17:21454238	C17orf51	-0.38	-5.15	-0.31	5.36e-7	Pelvic organ prolapse;
KIRP	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg22138327	chr13:27999177	GTF3A	0.89	6.79	0.4	8.18e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.43	-6.08	-0.36	4.68e-9	Dementia with Lewy bodies;
KIRP	cis	rs1034435	0.547	rs5768686	chr22:48899214	G/A	cg05992904	chr22:48892994	FAM19A5	-0.66	-7.9	-0.45	9.43e-14	Late-onset Alzheimer's disease;
KIRP	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.45	-8.44	-0.47	2.78e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Bladder cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23063740	chr3:55182246	NA	0.53	7.98	0.45	5.64e-14	Interleukin-4 levels;
KIRP	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.75	-8.52	-0.48	1.59e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs4700695	0.841	rs251306	chr5:65252453	C/T	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	cg04338863	chr8:33670619	NA	0.48	6.3	0.37	1.36e-9	Body mass index;
KIRP	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.56	-6.79	-0.4	8.33e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg00361562	chr2:198649771	BOLL	-0.49	-5.2	-0.31	4.1e-7	Ulcerative colitis;
KIRP	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.64	5.2	0.31	4.21e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg17376030	chr22:41985996	PMM1	-0.54	-6.67	-0.39	1.68e-10	Vitiligo;
KIRP	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg22880770	chr2:97166341	NEURL3	0.32	4.86	0.3	2.13e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.66	-8.01	-0.45	4.7e-14	Aortic root size;
KIRP	cis	rs1538970	0.962	rs9429077	chr1:45820667	C/A	cg05343316	chr1:45956843	TESK2	0.64	7.35	0.42	3e-12	Platelet count;
KIRP	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg05072774	chr3:49840536	C3orf54	0.43	5.46	0.33	1.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.44	5.99	0.36	7.25e-9	Optic nerve measurement (cup area);
KIRP	cis	rs28655083	0.529	rs1847161	chr16:77097796	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	5.18	0.31	4.57e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34779708	0.771	rs3867218	chr10:35527543	T/C	cg03585969	chr10:35415529	CREM	0.77	9.16	0.5	2.13e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-1.02	-9.51	-0.52	1.8e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	trans	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.0	-0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs9399135	0.627	rs6930223	chr6:135424203	G/T	cg24558204	chr6:135376177	HBS1L	0.44	5.63	0.34	4.8e-8	Red blood cell count;
KIRP	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg04731861	chr2:219085781	ARPC2	-0.22	-5.25	-0.32	3.23e-7	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg18306943	chr3:40428807	ENTPD3	0.44	5.82	0.35	1.85e-8	Renal cell carcinoma;
KIRP	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg04990556	chr1:26633338	UBXN11	0.63	5.87	0.35	1.4e-8	Obesity-related traits;
KIRP	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg05315796	chr3:52349193	DNAH1	0.42	6.45	0.38	5.77e-10	Bipolar disorder;
KIRP	cis	rs953387	1.000	rs1401687	chr2:136908062	G/C	cg05194412	chr2:137003533	NA	-0.41	-5.44	-0.33	1.26e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Colorectal cancer;
KIRP	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg23995753	chr2:160760732	LY75	-0.38	-5.21	-0.32	3.99e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10465746	0.780	rs11163867	chr1:84384847	C/T	cg10977910	chr1:84465055	TTLL7	0.54	6.65	0.39	1.86e-10	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.22	0.42	6.6e-12	Retinal vascular caliber;
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg15181151	chr6:150070149	PCMT1	0.29	4.85	0.3	2.18e-6	Lung cancer;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-6.82	-0.4	7.08e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.83	-14.17	-0.67	9.73e-34	Heart rate;
KIRP	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22117172	chr7:91764530	CYP51A1	0.45	6.16	0.37	2.94e-9	Breast cancer;
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg00343986	chr7:65444356	GUSB	0.43	5.27	0.32	2.93e-7	Aortic root size;
KIRP	cis	rs7246865	0.510	rs11086051	chr19:17168590	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.33	0.37	1.16e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.38	-5.29	-0.32	2.69e-7	Bipolar disorder;
KIRP	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg23307798	chr14:103986281	CKB	-0.4	-5.33	-0.32	2.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.55	8.99	0.5	6.55e-17	Total body bone mineral density;
KIRP	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.53e-7	Tonsillectomy;
KIRP	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.27	11.92	0.61	3.72e-26	Alzheimer's disease (late onset);
KIRP	cis	rs2916247	1.000	rs1838181	chr8:92993679	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.65	-0.48	6.91e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4919044	0.674	rs9419766	chr10:94800788	G/A	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.65	8.34	0.47	5.41e-15	Height;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.65	9.86	0.53	1.48e-19	Lung cancer;
KIRP	cis	rs2151522	0.563	rs1592288	chr6:127121340	C/G	cg21431617	chr6:127135037	NA	0.33	6.01	0.36	6.75e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	1.03	14.23	0.67	6.44e-34	Menopause (age at onset);
KIRP	cis	rs9318086	0.901	rs7336730	chr13:24452104	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-8.06	-0.46	3.25e-14	Myopia (pathological);
KIRP	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg00656387	chr3:40428638	ENTPD3	0.4	5.08	0.31	7.53e-7	Renal cell carcinoma;
KIRP	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg06050784	chr16:88016603	BANP	0.4	5.03	0.31	9.36e-7	Menopause (age at onset);
KIRP	cis	rs2219968	0.962	rs9643734	chr8:78950552	C/T	cg00738934	chr8:78996279	NA	0.4	5.15	0.31	5.25e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3821902	0.597	rs73119079	chr3:64015399	G/A	cg09006292	chr3:64049408	NA	-0.51	-5.17	-0.31	4.75e-7	Breast cancer;
KIRP	cis	rs12519773	1.000	rs6880789	chr5:92451777	A/G	cg18783429	chr5:92414398	NA	0.28	4.98	0.3	1.17e-6	Migraine;
KIRP	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.12	-0.36	3.68e-9	Morning vs. evening chronotype;
KIRP	trans	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg19274270	chr17:78178856	CARD14	-0.36	-6.5	-0.38	4.33e-10	Educational attainment (years of education);
KIRP	trans	rs2504916	0.784	rs2504957	chr6:160752092	C/A	cg11980410	chr1:145397667	NA	0.61	6.02	0.36	6.32e-9	Response to hepatitis C treatment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25544073	chr8:98656304	MTDH	0.46	6.2	0.37	2.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg22676075	chr6:135203613	NA	0.5	7.21	0.42	6.78e-12	Red blood cell count;
KIRP	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs830124	0.714	rs1177589	chr12:122403933	A/G	cg21171335	chr12:122356390	WDR66	0.54	5.55	0.33	7.27e-8	Urinary metabolites;
KIRP	cis	rs2882667	0.824	rs1560656	chr5:138470789	A/G	cg04439458	chr5:138467593	SIL1	0.49	7.47	0.43	1.37e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.62	-0.34	5.09e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9488822	0.585	rs7768026	chr6:116274313	A/G	cg05304507	chr6:116381966	FRK	-0.21	-5.48	-0.33	1.03e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg00409905	chr10:38381863	ZNF37A	0.5	6.57	0.39	3.03e-10	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg15534755	chr11:117069859	TAGLN	0.4	5.02	0.31	9.74e-7	Blood protein levels;
KIRP	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg18016565	chr1:150552671	MCL1	-0.49	-7.73	-0.44	2.68e-13	Tonsillectomy;
KIRP	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg02574844	chr11:5959923	NA	-0.55	-5.55	-0.33	7.49e-8	DNA methylation (variation);
KIRP	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	5.38	0.32	1.72e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg05484376	chr2:27715224	FNDC4	0.38	6.36	0.38	9.91e-10	Total body bone mineral density;
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.51	6.42	0.38	7e-10	Obesity-related traits;
KIRP	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.64	-8.15	-0.46	1.89e-14	Iron status biomarkers;
KIRP	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg11801959	chr13:50123613	RCBTB1	-0.36	-5.03	-0.31	9.48e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	trans	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00938859	chr5:1591904	SDHAP3	0.58	7.76	0.44	2.2e-13	Breast cancer;
KIRP	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	6.86	0.4	5.4e-11	Lymphocyte counts;
KIRP	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.74	-9.44	-0.52	2.91e-18	Height;
KIRP	cis	rs6001982	0.584	rs6001911	chr22:40825193	C/T	cg07138101	chr22:40742427	ADSL	-0.66	-5.18	-0.31	4.69e-7	Breast cancer;
KIRP	cis	rs2274273	0.837	rs11625968	chr14:55801004	G/C	cg04306507	chr14:55594613	LGALS3	0.45	7.07	0.41	1.63e-11	Protein biomarker;
KIRP	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23598886	chr18:12777645	NA	0.74	6.09	0.36	4.28e-9	Inflammatory skin disease;
KIRP	cis	rs2718058	0.601	rs2709104	chr7:37762810	A/G	cg15028436	chr7:37888078	TXNDC3	-0.49	-5.55	-0.33	7.26e-8	Alzheimer's disease (late onset);
KIRP	trans	rs4513299	0.540	rs13000279	chr2:115018653	G/A	cg11402503	chr1:24514013	IL28RA	0.53	6.15	0.37	3.12e-9	Inflammatory biomarkers;
KIRP	trans	rs1478898	0.569	rs2264306	chr8:11388449	G/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-6.27	-0.37	1.64e-9	Morning vs. evening chronotype;
KIRP	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg00129232	chr17:37814104	STARD3	0.41	5.06	0.31	8.17e-7	Asthma;
KIRP	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs838147	0.844	rs8111208	chr19:49248022	A/C	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.27e-7	Dietary macronutrient intake;
KIRP	cis	rs11603020	0.950	rs28362947	chr11:57369008	C/G	cg23127183	chr11:57508653	C11orf31	-0.46	-5.42	-0.33	1.41e-7	Blood protein levels;
KIRP	cis	rs9815354	0.812	rs73071304	chr3:41797504	G/C	cg03022575	chr3:42003672	ULK4	0.78	7.73	0.44	2.76e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs930036	0.547	rs13015226	chr2:171763638	T/A	cg12801329	chr2:171670795	NA	0.46	5.2	0.31	4.2e-7	Menopause (age at onset);
KIRP	cis	rs34779708	0.931	rs58159560	chr10:35351249	C/T	cg03585969	chr10:35415529	CREM	0.83	9.93	0.53	9.6e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs13170463	0.579	rs13174739	chr5:8041517	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.74	10.89	0.57	8.48e-23	Prostate cancer;
KIRP	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg10760299	chr15:45669010	GATM	0.32	5.1	0.31	6.66e-7	Homoarginine levels;
KIRP	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg18586891	chr4:952366	TMEM175	0.53	4.91	0.3	1.64e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.93	10.88	0.57	9.44e-23	Cognitive ability;
KIRP	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg05527609	chr1:210001259	C1orf107	-0.49	-5.21	-0.32	4.07e-7	Red blood cell count;
KIRP	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.69	7.95	0.45	6.86e-14	Obesity-related traits;
KIRP	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.59	-0.39	2.66e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg05991184	chr2:219186017	PNKD	-0.34	-4.94	-0.3	1.46e-6	Colorectal cancer;
KIRP	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.82	-8.11	-0.46	2.39e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-18.58	-0.76	9.79e-49	Height;
KIRP	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7.07e-10	Crohn's disease;
KIRP	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg07636037	chr3:49044803	WDR6	-0.56	-5.55	-0.33	7.22e-8	Menarche (age at onset);
KIRP	cis	rs2191566	0.506	rs396116	chr19:44494583	A/G	cg18700516	chr19:44507157	ZNF230	0.42	4.93	0.3	1.54e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.94	-13.68	-0.66	4.69e-32	Sudden cardiac arrest;
KIRP	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg23842812	chr7:76127459	DTX2	0.53	4.86	0.3	2.13e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-5.81	-0.35	1.9e-8	Aortic root size;
KIRP	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg13852791	chr20:30311386	BCL2L1	0.83	7.23	0.42	6.12e-12	Mean corpuscular hemoglobin;
KIRP	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	2.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4478037	1.000	rs58864038	chr3:33161355	G/A	cg19404215	chr3:33155277	CRTAP	0.71	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.6	-0.52	9.45e-19	Schizophrenia;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.88	-13.29	-0.65	9.56e-31	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.1	0.5	3.2e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	11.26	0.58	5.49e-24	Platelet count;
KIRP	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.79	10.87	0.57	9.76e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg21775007	chr8:11205619	TDH	-0.41	-5.45	-0.33	1.19e-7	Triglycerides;
KIRP	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.72	-10.06	-0.54	3.71e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22117172	chr7:91764530	CYP51A1	0.45	6.18	0.37	2.68e-9	Breast cancer;
KIRP	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	0.9	14.42	0.68	1.39e-34	Ewing sarcoma;
KIRP	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs240764	0.781	rs239227	chr6:101107089	C/G	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs7792596	1.000	rs6465411	chr7:94003260	T/C	cg20814616	chr7:94014465	NA	-0.33	-5.61	-0.34	5.33e-8	Intelligence;
KIRP	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.55	-0.39	3.42e-10	Response to antipsychotic treatment;
KIRP	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.77	-0.35	2.41e-8	Reticulocyte count;
KIRP	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.58	7.21	0.42	6.8e-12	Aortic root size;
KIRP	trans	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg01620082	chr3:125678407	NA	-1.0	-6.11	-0.36	3.9e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.59	6.67	0.39	1.7e-10	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.7	-7.56	-0.43	7.8e-13	Blood trace element (Cu levels);
KIRP	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.39	-4.92	-0.3	1.6e-6	Educational attainment (years of education);
KIRP	cis	rs4720750	0.510	rs2348557	chr7:7766950	C/T	cg12383621	chr7:7735611	RPA3	-0.4	-4.94	-0.3	1.42e-6	Neuroticism;
KIRP	cis	rs12995491	0.843	rs1878809	chr2:88518315	C/T	cg04511125	chr2:88470314	THNSL2	-0.4	-5.24	-0.32	3.46e-7	Response to metformin (IC50);
KIRP	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.64	-8.25	-0.47	9.4e-15	Iron status biomarkers;
KIRP	cis	rs11638352	1.000	rs8038096	chr15:44367290	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.65	-5.41	-0.33	1.47e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18867708	chr6:26865862	GUSBL1	0.48	6.1	0.36	4e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.75	-10.95	-0.57	5.25e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-5.55	-0.33	7.25e-8	Myopia (pathological);
KIRP	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.46	-5.74	-0.34	2.78e-8	IgG glycosylation;
KIRP	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg26335602	chr6:28129616	ZNF389	-0.45	-5.01	-0.3	1.05e-6	Depression;
KIRP	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.38	-4.97	-0.3	1.27e-6	Testicular germ cell tumor;
KIRP	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg02696742	chr7:106810147	HBP1	-0.8	-7.99	-0.45	5.19e-14	Coronary artery disease;
KIRP	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.71	10.84	0.57	1.23e-22	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00542384	chr5:68868293	GTF2H2C;GTF2H2D	-0.39	-6.11	-0.36	3.88e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9309473	1.000	rs6724782	chr2:73679990	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.52	-0.33	8.5e-8	Metabolite levels;
KIRP	cis	rs6738485	0.895	rs13030981	chr2:106816021	A/C	cg16099169	chr2:106886729	NA	-0.37	-5.3	-0.32	2.55e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs1697139	0.967	rs1705396	chr5:66510876	T/C	cg16691251	chr5:66510806	NA	0.56	7.38	0.43	2.37e-12	Breast cancer;
KIRP	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg03161606	chr19:29218774	NA	0.62	5.45	0.33	1.2e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7127900	1.000	rs4077457	chr11:2230354	T/C	cg25635251	chr11:2234043	NA	0.53	8.01	0.46	4.45e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22117172	chr7:91764530	CYP51A1	0.53	7.55	0.43	8.69e-13	Breast cancer;
KIRP	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.53	-7.26	-0.42	5.11e-12	Height;
KIRP	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg26207909	chr14:103986467	CKB	0.41	5.22	0.32	3.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17428704	0.649	rs6883134	chr5:14415590	A/G	cg26595256	chr5:14380529	TRIO	-0.7	-6.03	-0.36	6.13e-9	Electroencephalogram traits;
KIRP	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.67	9.06	0.5	4.07e-17	Schizophrenia;
KIRP	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg15128208	chr22:42549153	NA	0.54	6.07	0.36	4.77e-9	Birth weight;
KIRP	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg05484376	chr2:27715224	FNDC4	0.4	6.71	0.39	1.34e-10	Total body bone mineral density;
KIRP	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.73	-10.14	-0.54	2.06e-20	Ear protrusion;
KIRP	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.68	-8.21	-0.46	1.23e-14	Height;
KIRP	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.47	-0.33	1.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.37	0.59	2.33e-24	Morning vs. evening chronotype;
KIRP	cis	rs4919044	0.808	rs9419763	chr10:94788965	G/A	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs1978968	1.000	rs2099945	chr22:18438642	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.53	-6.61	-0.39	2.35e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg05754148	chr16:3507555	NAT15	0.5	4.94	0.3	1.43e-6	Tuberculosis;
KIRP	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg16586182	chr3:47516702	SCAP	-0.51	-6.26	-0.37	1.68e-9	Birth weight;
KIRP	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs13102973	0.932	rs13112852	chr4:135838470	C/T	cg14419869	chr4:135874104	NA	0.52	8.65	0.48	6.59e-16	Subjective well-being;
KIRP	cis	rs3849570	0.533	rs6809792	chr3:81990084	C/T	cg07356753	chr3:81810745	GBE1	-0.52	-6.77	-0.4	9.65e-11	Waist circumference;Body mass index;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02047359	chr10:75174015	ANXA7	-0.5	-6.47	-0.38	5.36e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.35	5.01	0.3	1.06e-6	Menarche (age at onset);
KIRP	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Colorectal cancer;
KIRP	cis	rs883565	0.528	rs4676584	chr3:38965907	C/A	cg01426195	chr3:39028469	NA	0.55	8.84	0.49	1.92e-16	Handedness;
KIRP	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg24375607	chr4:120327624	NA	0.58	6.76	0.4	1.02e-10	Corneal astigmatism;
KIRP	cis	rs4704187	0.617	rs1477936	chr5:74448502	T/A	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs909341	0.868	rs2315009	chr20:62344140	C/G	cg11503966	chr20:62272292	STMN3	-0.43	-6.1	-0.36	4.03e-9	Atopic dermatitis;
KIRP	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg20814179	chr4:940893	TMEM175	-0.4	-6.41	-0.38	7.56e-10	Systemic sclerosis;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.91e-8	Life satisfaction;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19531713	chr17:41277059	BRCA1;NBR2	0.56	6.98	0.41	2.75e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	0.73	7.82	0.45	1.53e-13	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg16434002	chr17:42200994	HDAC5	-0.51	-6.12	-0.36	3.71e-9	Total body bone mineral density;
KIRP	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.58	11.9	0.6	4.44e-26	Diabetic kidney disease;
KIRP	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg18306943	chr3:40428807	ENTPD3	-0.45	-6.23	-0.37	2.02e-9	Renal cell carcinoma;
KIRP	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.21	0.51	1.47e-17	Lung cancer in ever smokers;
KIRP	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.84	-13.27	-0.65	1.15e-30	Asthma;
KIRP	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.6	-7.42	-0.43	1.9e-12	Arsenic metabolism;
KIRP	cis	rs7178909	0.835	rs12437459	chr15:90420773	A/C	cg19708238	chr15:90437601	AP3S2	0.52	7.05	0.41	1.76e-11	Common traits (Other);
KIRP	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.68	-0.39	1.62e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg04691540	chr1:179198414	ABL2	0.49	6.22	0.37	2.09e-9	Asthma;
KIRP	cis	rs10426930	0.621	rs72990138	chr19:5018217	T/A	cg18473234	chr19:5097819	KDM4B	0.51	5.16	0.31	5.1e-7	Monocyte percentage of white cells;
KIRP	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.78	-10.67	-0.56	4.42e-22	Height;
KIRP	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.62	-6.76	-0.4	1.01e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.15	-0.31	5.43e-7	Post bronchodilator FEV1;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.89	-0.45	9.89e-14	Breast cancer;
KIRP	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.63	-7.08	-0.41	1.5e-11	Neuroticism;
KIRP	cis	rs8179	1.000	rs8179	chr7:92236164	T/C	cg15732164	chr7:92237376	CDK6	0.68	8.15	0.46	1.81e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg18501202	chr6:125855421	NA	-0.33	-5.02	-0.3	9.98e-7	Brugada syndrome;
KIRP	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.4	-4.89	-0.3	1.85e-6	Diabetic retinopathy;
KIRP	cis	rs9309473	0.519	rs2421574	chr2:73908767	C/G	cg20560298	chr2:73613845	ALMS1	0.53	6.8	0.4	7.83e-11	Metabolite levels;
KIRP	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.51	7.62	0.44	5.46e-13	IgG glycosylation;
KIRP	cis	rs4908768	0.906	rs12403339	chr1:8558292	G/A	cg25722041	chr1:8623473	RERE	0.79	10.01	0.54	5.12e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9761603	0.812	rs13112145	chr4:138413244	C/T	cg12033966	chr4:138453416	PCDH18	-0.44	-5.99	-0.36	7.24e-9	Diastolic blood pressure;
KIRP	cis	rs684232	0.666	rs2254134	chr17:628664	A/G	cg12384639	chr17:618140	VPS53	0.48	6.23	0.37	1.96e-9	Prostate cancer;
KIRP	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.07	-0.41	1.61e-11	Neuroticism;
KIRP	cis	rs17453880	0.929	rs4958572	chr5:152031109	C/T	cg12297329	chr5:152029980	NA	-0.72	-11.2	-0.58	8.35e-24	Subjective well-being;
KIRP	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.7	10.17	0.54	1.66e-20	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	cg21523751	chr1:182988639	NA	0.44	6.87	0.4	5.26e-11	Hypertriglyceridemia;
KIRP	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.22	-0.32	3.78e-7	Skin colour saturation;
KIRP	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg00908189	chr16:619842	PIGQ	0.89	11.88	0.6	4.97e-26	Height;
KIRP	cis	rs7106204	0.609	rs11824883	chr11:24284952	G/A	ch.11.24196551F	chr11:24239977	NA	0.73	5.87	0.35	1.39e-8	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg02725872	chr8:58115012	NA	-0.59	-7.35	-0.42	2.92e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs904251	0.647	rs2776908	chr6:37434857	T/C	cg08126542	chr6:37504118	NA	-0.52	-5.5	-0.33	9.3e-8	Cognitive performance;
KIRP	cis	rs11018874	0.808	rs71471032	chr11:89888921	A/T	cg06174606	chr11:89959870	NA	-0.54	-5.68	-0.34	3.86e-8	White blood cell types;
KIRP	cis	rs2016266	0.819	rs10747662	chr12:53669821	A/T	cg16917193	chr12:54089295	NA	0.45	5.65	0.34	4.52e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.16	0.42	9.11e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.65	8.87	0.49	1.57e-16	Colorectal cancer;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg23131131	chr22:24373011	LOC391322	-0.75	-10.01	-0.54	5.37e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.59	-7.61	-0.44	5.66e-13	Diastolic blood pressure;
KIRP	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg11965913	chr1:205819406	PM20D1	-0.41	-4.84	-0.3	2.26e-6	Prostate-specific antigen levels;
KIRP	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	trans	rs643955	0.637	rs4841271	chr8:9870137	T/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs73200209	0.912	rs17427053	chr12:116695895	A/G	cg01776926	chr12:116560359	MED13L	0.47	5.51	0.33	9.02e-8	Total body bone mineral density;
KIRP	cis	rs8060686	0.545	rs8056649	chr16:68260083	A/G	cg26727032	chr16:67993705	SLC12A4	0.51	5.01	0.3	1.05e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg00484396	chr16:3507460	NAT15	0.53	5.41	0.33	1.49e-7	Tuberculosis;
KIRP	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg08283408	chr3:49949060	MON1A	-0.42	-5.7	-0.34	3.33e-8	Body mass index;
KIRP	cis	rs16912285	0.591	rs12796137	chr11:24364459	T/G	ch.11.24196551F	chr11:24239977	NA	0.65	6.14	0.36	3.28e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg01200585	chr1:228362443	C1orf69	0.4	5.06	0.31	8.12e-7	Diastolic blood pressure;
KIRP	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg24296786	chr1:45957014	TESK2	-0.5	-5.43	-0.33	1.35e-7	Homocysteine levels;
KIRP	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg09455208	chr3:40491958	NA	0.3	4.97	0.3	1.26e-6	Renal cell carcinoma;
KIRP	cis	rs58649573	0.509	rs4836955	chr9:126788469	G/A	cg14112217	chr9:126806003	NA	0.37	5.26	0.32	3.18e-7	Post-traumatic stress disorder;
KIRP	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.44	-7.34	-0.42	3.2e-12	Refractive error;
KIRP	cis	rs9318086	0.935	rs9652081	chr13:24435510	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.6	-8.0	-0.45	4.81e-14	Myopia (pathological);
KIRP	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg04132472	chr17:19861366	AKAP10	0.46	6.43	0.38	6.57e-10	Schizophrenia;
KIRP	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs4671458	0.948	rs1829526	chr2:63464879	A/G	cg17519650	chr2:63277830	OTX1	-0.51	-5.23	-0.32	3.67e-7	Subjective well-being;
KIRP	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-9.33	-0.51	6.29e-18	Morning vs. evening chronotype;
KIRP	cis	rs6782228	0.606	rs2712404	chr3:128332679	C/T	cg18648031	chr3:128330563	NA	-0.27	-5.71	-0.34	3.26e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg26769984	chr7:1090371	C7orf50	0.65	7.06	0.41	1.73e-11	Bronchopulmonary dysplasia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13195218	chr1:223900468	CAPN2	0.48	6.12	0.36	3.7e-9	Parkinson's disease;
KIRP	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg07701084	chr6:150067640	NUP43	0.58	6.69	0.39	1.45e-10	Testicular germ cell tumor;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg21607453	chr9:98783545	NCRNA00092	0.61	6.23	0.37	2.03e-9	Lung function (FEV1);
KIRP	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.44	6.4	0.38	7.87e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs12210905	0.622	rs116198502	chr6:26915015	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.52	-4.87	-0.3	2.01e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg05887092	chr17:76393375	PGS1	0.5	6.86	0.4	5.48e-11	HDL cholesterol levels;
KIRP	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.73	8.77	0.49	2.95e-16	Mammographic density (dense area);
KIRP	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.82	11.61	0.59	4.01e-25	Breast cancer;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs12214131	0.569	rs1355021	chr6:106253535	C/G	cg09763439	chr6:3473380	NA	0.43	6.08	0.36	4.64e-9	Male-pattern baldness;
KIRP	cis	rs7010876	0.568	rs7821734	chr8:89205162	G/A	cg08624180	chr8:89339080	MMP16	-0.53	-4.94	-0.3	1.44e-6	Schizophrenia;
KIRP	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.49	-6.99	-0.41	2.52e-11	Daytime sleep phenotypes;
KIRP	cis	rs10875746	0.669	rs10875779	chr12:48629869	G/A	cg20731937	chr12:48336164	NA	0.48	5.99	0.36	7.55e-9	Longevity (90 years and older);
KIRP	cis	rs42648	0.596	rs194520	chr7:89854446	T/G	cg25739043	chr7:89950458	NA	-0.43	-6.91	-0.4	4.22e-11	Homocysteine levels;
KIRP	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg20578329	chr17:80767326	TBCD	-0.79	-8.44	-0.47	2.77e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.6	6.56	0.39	3.21e-10	Gut microbiome composition (summer);
KIRP	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg22117172	chr7:91764530	CYP51A1	0.44	5.88	0.35	1.31e-8	Breast cancer;
KIRP	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.75	-7.62	-0.44	5.4e-13	Gut microbiome composition (summer);
KIRP	cis	rs7546094	1.000	rs6537743	chr1:113092527	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	cg07049167	chr1:166818506	POGK	0.56	6.09	0.36	4.26e-9	Refractive astigmatism;
KIRP	cis	rs7011507	1.000	rs55828804	chr8:49174731	A/G	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg21851534	chr17:3907994	ZZEF1	-0.64	-10.21	-0.55	1.26e-20	Type 2 diabetes;
KIRP	cis	rs11866815	0.901	rs9938786	chr16:399054	C/T	cg26913058	chr16:419975	MRPL28	-0.56	-6.5	-0.38	4.33e-10	Body mass index;
KIRP	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg04362960	chr10:104952993	NT5C2	0.44	5.16	0.31	4.98e-7	Colorectal cancer;
KIRP	trans	rs13170463	0.579	rs35619107	chr5:8038060	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg26354017	chr1:205819088	PM20D1	-0.61	-6.08	-0.36	4.51e-9	Menarche (age at onset);
KIRP	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg09873164	chr1:152488093	CRCT1	0.56	7.11	0.41	1.24e-11	Hair morphology;
KIRP	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.74	0.34	2.84e-8	Height;
KIRP	cis	rs7923609	0.812	rs10822184	chr10:65337153	C/T	cg01631684	chr10:65280961	REEP3	0.49	5.77	0.35	2.33e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2273669	0.667	rs11751295	chr6:109334458	C/G	cg05315195	chr6:109294784	ARMC2	-0.64	-6.37	-0.38	9.03e-10	Prostate cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21749200	chr2:179328668	FKBP7;MIR548N	0.4	6.49	0.38	4.77e-10	C-reactive protein;
KIRP	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.97	8.36	0.47	4.59e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1950626	0.750	rs34144313	chr14:101431216	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.82	0.4	7.2e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.19	-21.57	-0.81	1.24e-58	Ulcerative colitis;
KIRP	cis	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.37	-0.43	2.63e-12	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-0.82	-9.2	-0.51	1.6e-17	Gut microbiome composition (summer);
KIRP	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg04369109	chr6:150039330	LATS1	-0.63	-8.12	-0.46	2.27e-14	Lung cancer;
KIRP	cis	rs8077577	0.731	rs11869952	chr17:18221713	T/C	cg18869244	chr17:18121946	NA	0.44	4.99	0.3	1.15e-6	Obesity-related traits;
KIRP	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg11608241	chr8:8085544	FLJ10661	-0.41	-5.07	-0.31	8.01e-7	Mood instability;
KIRP	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg03468072	chr12:39539422	NA	0.44	5.9	0.35	1.17e-8	Morning vs. evening chronotype;
KIRP	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.69	-8.41	-0.47	3.25e-15	Cognitive function;
KIRP	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.11	0.41	1.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5753037	0.838	rs131293	chr22:30171031	T/G	cg01021169	chr22:30184971	ASCC2	-0.43	-5.44	-0.33	1.31e-7	Type 1 diabetes;
KIRP	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg22777020	chr22:31556080	RNF185	-0.51	-5.45	-0.33	1.24e-7	Colorectal cancer;
KIRP	cis	rs1629083	0.902	rs10892226	chr11:118096618	G/A	cg18857871	chr11:118064634	AMICA1	0.61	8.0	0.45	4.91e-14	Lung cancer;
KIRP	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01288350	chr16:2136783	TSC2	0.51	6.52	0.38	3.89e-10	Pancreatic cancer;
KIRP	cis	rs7221595	0.756	rs35852805	chr17:3892563	C/T	cg21851534	chr17:3907994	ZZEF1	0.56	5.57	0.33	6.62e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.44e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1403694	0.515	rs5030058	chr3:186452415	T/G	cg12454167	chr3:186435060	KNG1	0.5	8.49	0.48	2.03e-15	Blood protein levels;
KIRP	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg00310523	chr12:86230176	RASSF9	0.39	6.07	0.36	4.92e-9	Major depressive disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.53	6.15	0.37	3.2e-9	Smoking initiation;
KIRP	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.55	4.85	0.3	2.15e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs329122	0.782	rs329123	chr5:133865435	A/T	cg21975834	chr5:133847811	NA	-0.19	-5.02	-0.3	1.01e-6	Body mass index;Type 2 diabetes;
KIRP	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg03808351	chr9:123631620	PHF19	0.43	6.01	0.36	6.64e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg25486957	chr4:152246857	NA	-0.51	-5.72	-0.34	3.04e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02539984	chr15:58960059	ADAM10	-0.42	-6.27	-0.37	1.58e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	1.03	11.14	0.58	1.31e-23	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6466055	0.661	rs17640599	chr7:104911576	T/C	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.42	-5.94	-0.35	9.64e-9	Monocyte count;
KIRP	trans	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg08700190	chr5:6636046	SRD5A1	-0.48	-5.99	-0.36	7.33e-9	Response to amphetamines;
KIRP	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg18016565	chr1:150552671	MCL1	0.37	5.58	0.34	6.26e-8	Blood protein levels;
KIRP	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg23335576	chr14:104009727	NA	0.39	5.53	0.33	8.32e-8	Body mass index;
KIRP	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.61	9.38	0.51	4.63e-18	Lung cancer;
KIRP	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.46	-6.2	-0.37	2.38e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs4728302	0.869	rs12707128	chr7:133589796	A/G	cg10665199	chr7:133106180	EXOC4	0.44	5.45	0.33	1.19e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12496230	0.794	rs6549424	chr3:66866748	T/C	cg04995300	chr3:66848608	NA	0.43	6.5	0.38	4.49e-10	Type 2 diabetes;
KIRP	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.11	-0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg18132916	chr6:79620363	NA	-0.37	-4.89	-0.3	1.84e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3206736	0.729	rs1052355	chr7:35119776	A/T	cg06685737	chr7:35301730	NA	0.4	5.54	0.33	7.66e-8	Diastolic blood pressure;
KIRP	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg05802129	chr4:122689817	NA	-0.73	-10.08	-0.54	3.23e-20	Type 2 diabetes;
KIRP	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg07274523	chr3:49395745	GPX1	0.69	8.43	0.47	3.04e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-8.83	-0.49	1.97e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg07936489	chr17:37558343	FBXL20	-0.57	-7.5	-0.43	1.17e-12	Asthma;
KIRP	cis	rs684232	0.901	rs450289	chr17:629896	G/T	cg15660573	chr17:549704	VPS53	-0.47	-6.07	-0.36	4.87e-9	Prostate cancer;
KIRP	trans	rs17094273	1.000	rs17094217	chr14:97092164	T/C	cg27186851	chr7:2566750	LFNG	0.6	6.05	0.36	5.4e-9	Tanning;
KIRP	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.25	-0.32	3.36e-7	Parkinson's disease;
KIRP	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg26876637	chr1:152193138	HRNR	0.72	9.65	0.52	6.81e-19	Atopic dermatitis;
KIRP	cis	rs9584850	0.874	rs4584	chr13:99101869	G/C	cg20750642	chr13:99100586	FARP1	-0.54	-6.53	-0.38	3.83e-10	Neuroticism;
KIRP	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.85	-0.4	5.97e-11	Monocyte percentage of white cells;
KIRP	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs7084402	0.967	rs1658423	chr10:60331627	T/G	cg05938607	chr10:60274200	BICC1	-0.37	-8.68	-0.48	5.51e-16	Refractive error;
KIRP	trans	rs2048656	0.507	rs7813718	chr8:9676094	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.78	-0.4	8.85e-11	Schizophrenia;
KIRP	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg15655495	chr12:38532458	NA	0.29	5.5	0.33	9.72e-8	Bladder cancer;
KIRP	cis	rs1140227	0.502	rs10789304	chr1:41587412	A/T	cg03387723	chr1:41708464	SCMH1	-0.46	-5.35	-0.32	1.96e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.82	-13.07	-0.64	5.47e-30	Prostate cancer;
KIRP	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	-0.47	-5.5	-0.33	9.55e-8	Glycated hemoglobin levels;
KIRP	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg02376097	chr19:46275166	DMPK	0.49	6.7	0.39	1.43e-10	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.07	0.31	7.7300000000000005e-07	Menopause (age at onset);
KIRP	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.25	-0.32	3.36e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg06995285	chr7:2418615	EIF3B	0.75	7.81	0.45	1.63e-13	Multiple sclerosis;
KIRP	cis	rs7202877	0.706	rs42472	chr16:75473320	T/A	cg03315344	chr16:75512273	CHST6	-0.59	-5.46	-0.33	1.14e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg16989719	chr2:238392110	NA	-0.57	-6.33	-0.37	1.18e-9	Prostate cancer;
KIRP	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	cg04338863	chr8:33670619	NA	0.4	5.28	0.32	2.86e-7	Body mass index;
KIRP	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg03714773	chr7:91764589	CYP51A1	0.36	5.21	0.32	3.93e-7	Breast cancer;
KIRP	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.16	13.04	0.64	6.71e-30	Uric acid levels;
KIRP	cis	rs8177876	0.749	rs76892049	chr16:81089341	T/C	cg08591886	chr16:81111003	C16orf46	-0.65	-5.36	-0.32	1.94e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.54	-5.43	-0.33	1.33e-7	DNA methylation (variation);
KIRP	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg23307798	chr14:103986281	CKB	0.67	8.23	0.46	1.1e-14	Body mass index;
KIRP	cis	rs10186029	0.582	rs1992395	chr2:214003871	G/T	cg08319019	chr2:214017104	IKZF2	-0.41	-4.87	-0.3	2e-6	Systemic sclerosis;
KIRP	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg17218026	chr1:154582156	ADAR	-0.33	-5.03	-0.31	9.44e-7	Blood protein levels;
KIRP	cis	rs1659258	0.667	rs1713943	chr2:88599766	G/A	cg00685853	chr2:88648947	NA	-0.54	-6.47	-0.38	5.29e-10	Visceral fat;
KIRP	cis	rs3813567	0.759	rs12594247	chr15:78946633	C/T	cg05914723	chr15:78953907	NA	0.6	5.36	0.32	1.95e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs13102973	0.931	rs4561977	chr4:135848936	T/C	cg14419869	chr4:135874104	NA	0.52	8.63	0.48	7.65e-16	Subjective well-being;
KIRP	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.32	-5.55	-0.33	7.56e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.41	-6.02	-0.36	6.32e-9	Reticulocyte fraction of red cells;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13049961	chr5:139498384	NA	0.38	6.17	0.37	2.73e-9	C-reactive protein;
KIRP	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	7.3	0.42	3.92e-12	Retinal vascular caliber;
KIRP	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	6.95	0.41	3.35e-11	Neuroticism;
KIRP	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs7715811	0.956	rs5023693	chr5:13767129	T/C	cg07548982	chr5:13769939	DNAH5	-0.52	-6.32	-0.37	1.2e-9	Subclinical atherosclerosis traits (other);
KIRP	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.8	10.66	0.56	4.63e-22	Multiple sclerosis;
KIRP	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.67e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.35	0.38	1.04e-9	Mood instability;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05978187	chr14:69864930	ERH;SLC39A9	0.45	6.51	0.38	4.28e-10	Survival in pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08352032	chr19:45805935	MARK4	-0.46	-6.02	-0.36	6.28e-9	Parkinson's disease;
KIRP	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.77	0.4	9.16e-11	Bipolar disorder;
KIRP	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.25	0.32	3.23e-7	Menarche (age at onset);
KIRP	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg01721255	chr8:58191610	C8orf71	0.49	4.85	0.3	2.16e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.35	-0.38	1.02e-9	Lung cancer;
KIRP	cis	rs13343954	0.778	rs10401503	chr19:33543547	C/T	cg17764715	chr19:33622953	WDR88	0.68	7.38	0.43	2.42e-12	Colorectal cancer;
KIRP	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.68	-9.28	-0.51	9.42e-18	Schizophrenia;
KIRP	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg05085585	chr16:30420623	ZNF771	0.35	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.94	-0.4	3.46e-11	Acne (severe);
KIRP	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg22617819	chr1:44378782	ST3GAL3	0.35	5.27	0.32	2.93e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6466055	0.777	rs66599006	chr7:104934271	A/G	cg04380332	chr7:105027541	SRPK2	0.64	9.69	0.53	5.05e-19	Schizophrenia;
KIRP	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.42	-4.91	-0.3	1.69e-6	Monocyte count;
KIRP	cis	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.23e-12	Morning vs. evening chronotype;
KIRP	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26526719	chr5:1949144	NA	-0.45	-5.18	-0.31	4.66e-7	Gut microbiome composition (winter);
KIRP	cis	rs7656342	0.653	rs1401439	chr4:9832622	G/C	cg00071950	chr4:10020882	SLC2A9	0.36	4.97	0.3	1.27e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.59	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg12486944	chr17:80159399	CCDC57	0.38	5.11	0.31	6.4e-7	Life satisfaction;
KIRP	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.65	8.65	0.48	6.77e-16	Schizophrenia;
KIRP	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	8.61	0.48	9.02e-16	Neuroticism;
KIRP	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.24	-0.62	3.12e-27	Ulcerative colitis;
KIRP	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg04374321	chr14:90722782	PSMC1	0.98	17.27	0.74	2.57e-44	Mortality in heart failure;
KIRP	cis	rs7116495	0.881	rs676721	chr11:71770638	G/A	cg18441811	chr11:71824068	C11orf51	-0.64	-5.22	-0.32	3.79e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.47	6.08	0.36	4.53e-9	Menopause (age at onset);
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg19770292	chr5:1868693	NA	0.4	5.23	0.32	3.62e-7	Cardiovascular disease risk factors;
KIRP	cis	rs4523957	0.651	rs4790316	chr17:2074977	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.26	-0.58	5.35e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.52	-6.39	-0.38	8.39e-10	Breast cancer;
KIRP	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.5	6.32	0.37	1.22e-9	HDL cholesterol;
KIRP	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg22138327	chr13:27999177	GTF3A	0.81	7.26	0.42	5e-12	Weight;
KIRP	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.33	-0.37	1.15e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	7.9	0.45	9.07e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26314531	chr2:26401878	FAM59B	-0.51	-5.61	-0.34	5.31e-8	Gut microbiome composition (summer);
KIRP	cis	rs17221829	0.733	rs7945304	chr11:89372524	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.66	9.53	0.52	1.54e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.07e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs9826463	0.582	rs6440076	chr3:142015067	T/A	cg20824294	chr3:142316082	PLS1	0.31	5.41	0.33	1.49e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	16.09	0.72	2.77e-40	Colorectal cancer;
KIRP	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.0	-0.36	7.15e-9	Mood instability;
KIRP	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	1.0	17.65	0.75	1.34e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5753037	0.809	rs140150	chr22:30185719	C/G	cg27665648	chr22:30112403	NA	0.46	6.54	0.38	3.5e-10	Type 1 diabetes;
KIRP	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.78	-9.19	-0.51	1.72e-17	Vitiligo;
KIRP	cis	rs580438	0.529	rs2046189	chr3:13404717	T/C	cg10657019	chr3:13328039	NA	-0.49	-6.42	-0.38	7.12e-10	Myringotomy;
KIRP	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.73	-0.34	2.85e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.71	-0.56	3.17e-22	Gut microbiome composition (summer);
KIRP	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg23601095	chr6:26197514	HIST1H3D	0.98	8.29	0.47	7.23e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07308232	chr7:1071921	C7orf50	-0.66	-8.53	-0.48	1.52e-15	Longevity;Endometriosis;
KIRP	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg05082376	chr22:42548792	NA	-0.4	-5.23	-0.32	3.59e-7	Schizophrenia;
KIRP	cis	rs4689642	0.666	rs4689659	chr4:7228214	C/T	cg21353189	chr4:7228343	SORCS2	0.37	4.97	0.3	1.24e-6	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs13095912	1.000	rs9714158	chr3:185328780	C/T	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.09e-11	Systolic blood pressure;
KIRP	trans	rs13170463	0.579	rs13161816	chr5:8051298	C/G	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg14972814	chr11:95582409	MTMR2	0.36	6.07	0.36	4.87e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg03571507	chr19:53239146	ZNF611	0.22	5.57	0.33	6.53e-8	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.66	8.37	0.47	4.42e-15	Prudent dietary pattern;
KIRP	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg03235661	chr20:60525775	NA	-0.31	-5.18	-0.31	4.71e-7	Body mass index;
KIRP	cis	rs9584850	0.562	rs17471066	chr13:99164699	A/G	cg20750642	chr13:99100586	FARP1	-0.57	-6.0	-0.36	6.96e-9	Neuroticism;
KIRP	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg14847009	chr1:175162515	KIAA0040	-0.25	-5.21	-0.32	4.06e-7	Alcohol dependence;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.37	5.02	0.3	9.92e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6681460	1.000	rs4655636	chr1:67068537	A/G	cg13052034	chr1:66999238	SGIP1	0.37	5.03	0.31	9.34e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4132509	0.603	rs12408951	chr1:243679364	A/G	cg21452805	chr1:244014465	NA	0.6	5.64	0.34	4.77e-8	RR interval (heart rate);
KIRP	cis	rs300890	0.513	rs10007896	chr4:144043961	A/T	cg01719995	chr4:144104893	USP38	0.43	5.6	0.34	5.7e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.98	-0.41	2.75e-11	Daytime sleep phenotypes;
KIRP	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	10.14	0.54	2.08e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.36	0.38	9.55e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg24851858	chr13:114927579	NA	0.41	5.01	0.3	1.02e-6	Schizophrenia;
KIRP	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.48	8.81	0.49	2.33e-16	Lung cancer;
KIRP	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-8.25	-0.47	9.75e-15	Response to antipsychotic treatment;
KIRP	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-1.05	-12.9	-0.64	1.93e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.46	-0.38	5.61e-10	Hemoglobin concentration;
KIRP	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05347473	chr6:146136440	FBXO30	0.53	7.43	0.43	1.82e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3126085	0.935	rs11586114	chr1:152299767	G/A	cg26876637	chr1:152193138	HRNR	-0.82	-8.03	-0.46	4.1e-14	Atopic dermatitis;
KIRP	cis	rs9488822	0.662	rs195524	chr6:116247480	G/C	cg15226275	chr6:116381976	FRK	0.2	5.17	0.31	4.96e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.8	-0.35	2.07e-8	Prudent dietary pattern;
KIRP	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-5.45	-0.33	1.25e-7	Testicular germ cell tumor;
KIRP	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.99	9.14	0.5	2.43e-17	Systolic blood pressure;
KIRP	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	trans	rs225245	0.531	rs321609	chr17:33880676	G/T	cg19694781	chr19:47549865	TMEM160	-0.65	-8.15	-0.46	1.82e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2051773	0.567	rs11024113	chr11:17042444	G/A	cg15432903	chr11:17409602	KCNJ11	-0.46	-5.48	-0.33	1.04e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs7656342	0.599	rs6812007	chr4:9850220	A/C	cg11266682	chr4:10021025	SLC2A9	0.36	5.67	0.34	4.07e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.74	9.52	0.52	1.67e-18	Body mass index;
KIRP	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.79	-7.66	-0.44	4.19e-13	Lung cancer in ever smokers;
KIRP	cis	rs16957091	0.865	rs67391479	chr15:43004351	G/A	cg24196017	chr15:43021976	CDAN1	-0.45	-6.07	-0.36	4.73e-9	MGMT methylation in smokers;
KIRP	cis	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg26816564	chr1:7831052	VAMP3	0.56	5.16	0.31	5.13e-7	Inflammatory bowel disease;
KIRP	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg00262122	chr8:11665843	FDFT1	0.41	4.99	0.3	1.16e-6	Myopia (pathological);
KIRP	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg20312557	chr2:97357134	FER1L5	-0.67	-4.86	-0.3	2.07e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.64	-9.83	-0.53	1.92e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-5.64	-0.34	4.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.51	7.15	0.41	9.79e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg04990556	chr1:26633338	UBXN11	-0.59	-6.84	-0.4	6.19e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7007076	0.609	rs4006384	chr8:124743796	A/G	cg00283535	chr8:124749564	ANXA13	0.64	7.94	0.45	7.05e-14	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.02	-0.57	3.22e-23	Height;
KIRP	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.19	21.62	0.81	8.42e-59	Cognitive function;
KIRP	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.2	-0.37	2.36e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs897080	0.552	rs1067365	chr2:44655398	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.76	0.34	2.54e-8	Height;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-1.16	-21.01	-0.8	7.81e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg05973401	chr12:123451056	ABCB9	0.59	5.39	0.32	1.65e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4356932	1.000	rs4859416	chr4:76986499	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.26	-5.61	-0.34	5.37e-8	Social autistic-like traits;
KIRP	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.98	0.36	7.62e-9	Menopause (age at onset);
KIRP	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg00334542	chr7:100209784	MOSPD3	-0.73	-6.08	-0.36	4.54e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs258892	0.895	rs2338793	chr5:72073172	T/G	cg21869765	chr5:72125136	TNPO1	-0.45	-5.4	-0.33	1.58e-7	Small cell lung carcinoma;
KIRP	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg23625390	chr15:77176239	SCAPER	0.54	7.01	0.41	2.26e-11	Blood metabolite levels;
KIRP	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg02146966	chr17:18967117	NA	0.43	4.94	0.3	1.43e-6	Schizophrenia;
KIRP	cis	rs11874712	1.000	rs9783884	chr18:43651133	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.51	-0.33	9.06e-8	Migraine - clinic-based;
KIRP	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16386425	chr10:429943	DIP2C	-0.47	-6.4	-0.38	7.7e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.12	12.67	0.63	1.18e-28	Smoking behavior;
KIRP	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg20636351	chr8:55087400	NA	-0.53	-6.6	-0.39	2.54e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.52	-7.61	-0.44	5.66e-13	Daytime sleep phenotypes;
KIRP	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.31	-5.34	-0.32	2.15e-7	Refractive error;
KIRP	cis	rs7546094	1.000	rs7546094	chr1:113154400	C/T	cg22162597	chr1:113214053	CAPZA1	0.47	6.72	0.39	1.25e-10	Platelet distribution width;
KIRP	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-1.56	-11.78	-0.6	1.06e-25	Cannabis dependence symptom count;
KIRP	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.17	0.67	1.01e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.97	10.41	0.55	2.81e-21	Blood protein levels;
KIRP	cis	rs2625529	0.824	rs2306488	chr15:72292115	A/G	cg16672083	chr15:72433130	SENP8	-0.48	-5.91	-0.35	1.11e-8	Red blood cell count;
KIRP	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg26384229	chr12:38710491	ALG10B	0.68	8.94	0.5	9.7e-17	Resting heart rate;
KIRP	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg05347473	chr6:146136440	FBXO30	0.46	6.47	0.38	5.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.47	-6.25	-0.37	1.82e-9	Childhood ear infection;
KIRP	cis	rs71520386	0.632	rs10224419	chr7:22870016	A/G	cg15401507	chr7:22894281	NA	-0.39	-4.97	-0.3	1.23e-6	Fibrinogen levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19421484	chr11:64052187	BAD;GPR137	0.51	6.26	0.37	1.66e-9	Parkinson's disease;
KIRP	cis	rs6585424	1.000	rs12779955	chr10:81940864	C/T	cg27417294	chr10:81904244	PLAC9	-0.56	-5.3	-0.32	2.62e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg16482183	chr6:26056742	HIST1H1C	0.64	7.23	0.42	6.1e-12	Iron status biomarkers;
KIRP	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.49	-0.43	1.23e-12	Bone mineral density;
KIRP	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg05335186	chr13:53173507	NA	0.45	6.7	0.39	1.43e-10	Lewy body disease;
KIRP	cis	rs9900972	0.851	rs62077283	chr17:76868135	T/C	cg00961940	chr17:76876995	TIMP2	0.52	6.53	0.38	3.66e-10	Obesity-related traits;
KIRP	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.97	0.71	7.36e-40	Bipolar disorder;
KIRP	cis	rs860295	0.702	rs12239100	chr1:155428476	C/A	cg02153340	chr1:155202674	NA	-0.54	-7.16	-0.42	9.52e-12	Body mass index;
KIRP	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg05347473	chr6:146136440	FBXO30	-0.6	-8.66	-0.48	6.16e-16	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12107699	chr21:46238210	SUMO3	0.46	6.23	0.37	1.96e-9	Parkinson's disease;
KIRP	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	6.02	0.36	6.43e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	12.52	0.62	3.75e-28	Eye color traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18211447	chr14:102771717	RAGE	0.53	6.32	0.37	1.19e-9	Smoking initiation;
KIRP	cis	rs6977660	0.714	rs6976854	chr7:19818311	A/G	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg06521331	chr12:34319734	NA	-0.45	-5.41	-0.33	1.52e-7	Morning vs. evening chronotype;
KIRP	trans	rs800082	0.501	rs9844730	chr3:144216886	T/G	cg24215973	chr2:240111563	HDAC4	0.5	6.5	0.38	4.35e-10	Smoking behavior;
KIRP	cis	rs9398803	0.865	rs2184968	chr6:126760994	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.54	0.33	7.77e-8	Male-pattern baldness;
KIRP	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.93	-0.4	3.69e-11	Neuroticism;
KIRP	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.42	0.38	6.88e-10	Morning vs. evening chronotype;
KIRP	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.33	-0.47	5.65e-15	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11987759	chr7:65425863	GUSB	0.46	5.48	0.33	1.05e-7	Aortic root size;
KIRP	cis	rs7429990	0.896	rs7427648	chr3:48158239	C/T	cg11946769	chr3:48343235	NME6	-0.43	-5.22	-0.32	3.83e-7	Educational attainment (years of education);
KIRP	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.59	-5.0	-0.3	1.11e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	7.26	0.42	5.02e-12	Eosinophil percentage of white cells;
KIRP	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.28	17.56	0.75	2.69e-45	Corneal structure;
KIRP	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-20.05	-0.79	1.21e-53	Chronic sinus infection;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg23693289	chr8:27183097	PTK2B	0.58	7.48	0.43	1.35e-12	Neuroticism;
KIRP	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.73	9.42	0.51	3.43e-18	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12780845	0.931	rs17381591	chr10:17244048	C/T	cg01003015	chr10:17271136	VIM	-0.46	-5.02	-0.3	9.86e-7	Homocysteine levels;
KIRP	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg15556689	chr8:8085844	FLJ10661	0.69	9.36	0.51	5.22e-18	Systolic blood pressure;
KIRP	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.7	9.81	0.53	2.21e-19	Retinal vascular caliber;
KIRP	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg21851534	chr17:3907994	ZZEF1	0.65	10.49	0.56	1.59e-21	Type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg22654517	chr2:96458247	NA	0.32	4.99	0.3	1.15e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg02336718	chr17:17403227	NA	-0.33	-5.24	-0.32	3.51e-7	Total body bone mineral density;
KIRP	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg11846333	chr4:119757529	SEC24D	1.17	7.16	0.42	9.33e-12	Cannabis dependence symptom count;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.22	-25.0	-0.85	1.77e-69	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16828019	0.852	rs71648540	chr1:41722295	G/A	cg18742814	chr1:41828276	NA	0.62	5.65	0.34	4.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs7116495	1.000	rs3750908	chr11:71822401	A/G	cg18441811	chr11:71824068	C11orf51	0.61	4.9	0.3	1.73e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg13206674	chr6:150067644	NUP43	0.47	6.01	0.36	6.71e-9	Lung cancer;
KIRP	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg04132472	chr17:19861366	AKAP10	0.39	5.0	0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs7737355	1.000	rs2551036	chr5:130648994	G/A	cg06307176	chr5:131281290	NA	0.53	5.73	0.34	2.95e-8	Life satisfaction;
KIRP	cis	rs41464348	0.534	rs2123769	chr2:33525407	C/T	cg16572410	chr2:33467199	LTBP1	0.51	5.89	0.35	1.25e-8	Height;
KIRP	cis	rs654128	0.640	rs339333	chr6:117211809	T/G	cg12892004	chr6:117198278	RFX6	-0.45	-5.79	-0.35	2.1e-8	Telomere length;
KIRP	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.79	-0.4	8.21e-11	Daytime sleep phenotypes;
KIRP	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg00074818	chr8:8560427	CLDN23	0.4	6.34	0.37	1.09e-9	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg19847130	chr8:10466454	RP1L1	-0.33	-5.18	-0.31	4.56e-7	Myopia (pathological);
KIRP	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.53	7.34	0.42	3.13e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.19	-0.31	4.48e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg25063058	chr15:52860530	ARPP19	0.6	6.57	0.39	2.92e-10	Schizophrenia;
KIRP	cis	rs1978968	0.957	rs2053601	chr22:18448605	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.78	-0.4	8.68e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-12.12	-0.61	7.96e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg01631408	chr1:248437212	OR2T33	-0.67	-8.66	-0.48	6.15e-16	Common traits (Other);
KIRP	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg23173402	chr1:227635558	NA	0.6	5.02	0.3	1.01e-6	Major depressive disorder;
KIRP	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22117172	chr7:91764530	CYP51A1	0.49	6.8	0.4	7.75e-11	Breast cancer;
KIRP	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg26531700	chr6:26746687	NA	0.47	6.83	0.4	6.62e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4700695	0.841	rs251612	chr5:65275023	G/A	cg21114390	chr5:65439923	SFRS12	0.59	5.56	0.33	7.19e-8	Facial morphology (factor 19);
KIRP	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.76	8.85	0.49	1.71e-16	Adiposity;
KIRP	cis	rs6832769	1.000	rs12643926	chr4:56310621	C/T	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.28	0.37	1.52e-9	Lung cancer;
KIRP	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg24315340	chr6:146058215	EPM2A	-0.39	-4.92	-0.3	1.6e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Schizophrenia;
KIRP	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.97	-0.45	6.11e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs12579753	0.526	rs73359948	chr12:82322986	A/G	cg07988820	chr12:82153109	PPFIA2	-0.44	-5.22	-0.32	3.88e-7	Resting heart rate;
KIRP	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs1018836	0.700	rs7824511	chr8:91521545	T/C	cg16814680	chr8:91681699	NA	-0.62	-7.13	-0.41	1.14e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.56	-8.06	-0.46	3.31e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7814319	0.677	rs2319599	chr8:97305907	T/C	cg20787634	chr8:97240163	UQCRB	-0.54	-8.14	-0.46	1.93e-14	Lung function (FVC);
KIRP	cis	rs6663390	0.510	rs3754170	chr1:208087296	A/G	cg00387621	chr1:208086895	NA	0.62	4.94	0.3	1.43e-6	Facial morphology (factor 18);
KIRP	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.45e-8	Lung cancer;
KIRP	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.65	-8.21	-0.46	1.28e-14	Extraversion;
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg21851534	chr17:3907994	ZZEF1	0.63	9.96	0.54	7.41e-20	Type 2 diabetes;
KIRP	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.87	-11.65	-0.6	2.91e-25	Cognitive function;
KIRP	cis	rs12580194	0.593	rs79104523	chr12:55749220	T/C	cg11794356	chr12:55725991	OR6C3	-0.55	-7.81	-0.45	1.67e-13	Cancer;
KIRP	trans	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg01126162	chr10:5734985	C10orf18	0.41	6.06	0.36	5.22e-9	Lung cancer in ever smokers;
KIRP	cis	rs520865	1.000	rs520865	chr5:80337457	C/T	cg17330048	chr5:80257322	RASGRF2	-0.41	-6.18	-0.37	2.69e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.63	8.29	0.47	7.56e-15	Breast size;
KIRP	cis	rs6991838	0.557	rs67046768	chr8:66489721	A/G	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.43	0.33	1.38e-7	Melanoma;
KIRP	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.78	7.85	0.45	1.28e-13	Hip geometry;
KIRP	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.09	0.54	2.93e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs300890	0.729	rs1027851	chr4:144298152	G/A	cg19876092	chr4:144208277	NA	-0.31	-4.94	-0.3	1.44e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg05072774	chr3:49840536	C3orf54	0.43	5.47	0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.37	0.38	9.07e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs981844	1.000	rs2606341	chr4:154658702	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.32	-0.32	2.33e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg11815991	chr20:30193098	ID1	-0.5	-5.07	-0.31	7.7e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg01777586	chr17:80163174	CCDC57	-0.45	-4.84	-0.3	2.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg16584676	chr17:46985605	UBE2Z	0.47	5.91	0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs712039	0.652	rs829161	chr17:35763863	C/T	cg16670864	chr17:35848621	DUSP14	-0.41	-4.91	-0.3	1.68e-6	Tuberculosis;
KIRP	trans	rs12517041	1.000	rs7722738	chr5:23288074	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs4908768	0.657	rs10492963	chr1:8810341	A/G	cg03610117	chr1:8450231	RERE	0.43	4.85	0.3	2.17e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg25174290	chr11:3078921	CARS	-0.69	-8.53	-0.48	1.47e-15	Calcium levels;
KIRP	cis	rs71403859	1.000	rs71403859	chr16:71640207	C/T	cg08717414	chr16:71523259	ZNF19	-1.11	-9.86	-0.53	1.55e-19	Post bronchodilator FEV1;
KIRP	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.94	-0.61	3.07e-26	Eye color traits;
KIRP	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.64	0.39	1.99e-10	Neuroticism;
KIRP	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	0.66	6.91	0.4	4.21e-11	Bipolar disorder;
KIRP	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.61	-0.48	8.87e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg09165964	chr15:75287851	SCAMP5	-0.64	-6.42	-0.38	6.77e-10	Blood trace element (Zn levels);
KIRP	cis	rs7909074	0.509	rs2026427	chr10:45389704	T/C	cg05187965	chr10:45406764	TMEM72	-0.24	-5.44	-0.33	1.31e-7	Mean corpuscular volume;
KIRP	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg20312557	chr2:97357134	FER1L5	-0.7	-4.91	-0.3	1.66e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-6.44	-0.38	6.23e-10	Educational attainment;
KIRP	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs12043259	0.730	rs7529301	chr1:204819957	T/C	cg11485465	chr5:54518469	NA	0.37	6.28	0.37	1.56e-9	Addiction;
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg00684032	chr4:1343700	KIAA1530	-0.46	-5.55	-0.33	7.4e-8	Longevity;
KIRP	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.48	-0.38	5.03e-10	HDL cholesterol;
KIRP	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16318349	chr1:154917307	PBXIP1	-0.29	-5.17	-0.31	4.75e-7	Prostate cancer;
KIRP	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg11518657	chr1:67396239	MIER1	0.48	4.95	0.3	1.39e-6	Lymphocyte percentage of white cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23258033	chr12:72071095	THAP2	-0.42	-6.28	-0.37	1.5e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.58	-7.04	-0.41	1.89e-11	Aortic root size;
KIRP	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.62	9.45	0.52	2.7e-18	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18987026	chr7:107297715	LOC286002	-0.45	-6.46	-0.38	5.47e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.45	6.83	0.4	6.57e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg09911534	chr15:67153556	NA	-0.54	-4.86	-0.3	2.09e-6	Lung cancer (smoking interaction);
KIRP	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.0	0.36	6.88e-9	Height;
KIRP	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg02187348	chr16:89574699	SPG7	0.45	5.05	0.31	8.68e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-0.93	-12.71	-0.63	8.53e-29	Blood trace element (Zn levels);
KIRP	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg17644776	chr2:200775616	C2orf69	-0.59	-6.06	-0.36	5.14e-9	Schizophrenia;
KIRP	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	13.41	0.65	3.93e-31	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.65e-7	Life satisfaction;
KIRP	cis	rs16936870	0.571	rs2977988	chr8:71146050	C/G	cg14232793	chr8:71155543	NCOA2	-0.57	-6.96	-0.41	3.05e-11	QT interval;
KIRP	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg06115741	chr20:33292138	TP53INP2	0.39	5.03	0.31	9.42e-7	Coronary artery disease;
KIRP	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	1.09	9.73	0.53	3.88e-19	Pulse pressure;
KIRP	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs3857747	0.827	rs8180744	chr7:40452861	T/A	cg00420559	chr7:40367873	C7orf10	-0.57	-7.98	-0.45	5.5e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.56e-13	Coffee consumption (cups per day);
KIRP	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-7.02	-0.41	2.13e-11	Monocyte percentage of white cells;
KIRP	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg24699146	chr1:24152579	HMGCL	0.46	6.48	0.38	5.05e-10	Immature fraction of reticulocytes;
KIRP	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.65	7.84	0.45	1.37e-13	Obesity-related traits;
KIRP	cis	rs4664293	0.836	rs4665118	chr2:160659449	G/T	cg08347373	chr2:160653686	CD302	-0.42	-6.19	-0.37	2.46e-9	Monocyte percentage of white cells;
KIRP	cis	rs300890	0.513	rs11100781	chr4:144132622	A/G	cg01719995	chr4:144104893	USP38	0.39	5.05	0.31	8.71e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.6	-0.34	5.66e-8	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25053907	chr4:492859	ZNF721;PIGG	0.47	6.09	0.36	4.37e-9	Parkinson's disease;
KIRP	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.46	0.47	2.38e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg14683738	chr19:37701593	ZNF585B	-0.48	-4.94	-0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs9302635	0.745	rs35549608	chr16:72227398	T/C	cg01557791	chr16:72042693	DHODH	-0.74	-6.14	-0.36	3.34e-9	Blood protein levels;
KIRP	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.59	7.01	0.41	2.3e-11	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.88	6.62	0.39	2.25e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	6.64	0.39	2.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4713118	0.662	rs149948	chr6:27974817	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.45	-4.99	-0.3	1.12e-6	Parkinson's disease;
KIRP	cis	rs7246657	0.663	rs4803276	chr19:38072330	C/A	cg18154014	chr19:37997991	ZNF793	0.62	6.72	0.39	1.28e-10	Coronary artery calcification;
KIRP	cis	rs981844	0.826	rs1545604	chr4:154682733	C/T	cg14289246	chr4:154710475	SFRP2	0.58	7.11	0.41	1.26e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.87	12.83	0.63	3.51e-29	Coronary artery disease;
KIRP	trans	rs12517041	1.000	rs16892325	chr5:23283742	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.35	-0.47	5.07e-15	Calcium levels;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25860425	chr11:64684671	ATG2A	0.58	7.19	0.42	7.67e-12	Parkinson's disease;
KIRP	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	11.52	0.59	7.82e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.55	-6.57	-0.39	3.01e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg22117172	chr7:91764530	CYP51A1	-0.41	-5.65	-0.34	4.32e-8	Breast cancer;
KIRP	cis	rs11637445	1.000	rs11637445	chr15:67991606	G/T	cg24579218	chr15:68104479	NA	0.39	4.96	0.3	1.33e-6	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg08603382	chr10:743973	NA	0.57	8.42	0.47	3.17e-15	Psychosis in Alzheimer's disease;
KIRP	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.63	-6.66	-0.39	1.82e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10355708	chr8:145618298	ADCK5	0.48	6.42	0.38	6.81e-10	Survival in pancreatic cancer;
KIRP	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg05552183	chr6:42928497	GNMT	0.43	4.97	0.3	1.23e-6	Blood protein levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17627617	chr3:142682682	PAQR9	-0.46	-6.55	-0.39	3.36e-10	Metabolic traits;
KIRP	cis	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.93	0.3	1.49e-6	Leprosy;
KIRP	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	trans	rs7740797	0.967	rs3757291	chr6:155124583	G/T	cg20598190	chr2:240866924	NA	0.41	6.04	0.36	5.75e-9	Colorectal or endometrial cancer;
KIRP	cis	rs77861329	1.000	rs9847092	chr3:52199453	T/C	cg08692210	chr3:52188851	WDR51A	0.96	7.5	0.43	1.15e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.39	-5.02	-0.3	1.01e-6	Mean platelet volume;
KIRP	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs9371601	0.859	rs473101	chr6:152717198	T/C	cg05529123	chr2:66910386	NA	-0.46	-6.2	-0.37	2.37e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg06636001	chr8:8085503	FLJ10661	0.65	8.95	0.5	9.02e-17	Retinal vascular caliber;
KIRP	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7084402	0.967	rs7078900	chr10:60273430	G/A	cg05938607	chr10:60274200	BICC1	0.41	10.01	0.54	5.2e-20	Refractive error;
KIRP	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg17691542	chr6:26056736	HIST1H1C	0.44	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.94	-0.54	8.61e-20	Response to antipsychotic treatment;
KIRP	cis	rs2115536	0.630	rs12102032	chr15:80233399	A/C	cg01843524	chr15:80216276	C15orf37;ST20	0.48	6.02	0.36	6.34e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7692976	0.578	rs12503113	chr4:110845707	T/C	cg06981781	chr4:110842888	EGF	-0.23	-5.09	-0.31	7.05e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg05669848	chr5:237993	SDHA	-0.5	-5.18	-0.31	4.64e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15201400	chr5:141392656	GNPDA1	0.49	6.2	0.37	2.33e-9	Parkinson's disease;
KIRP	cis	rs4660531	1.000	rs4660531	chr1:41839822	G/T	cg08462924	chr1:41848221	NA	0.41	5.77	0.35	2.43e-8	Bipolar disorder;
KIRP	cis	rs714027	0.605	rs1468176	chr22:30544516	G/A	cg01021169	chr22:30184971	ASCC2	0.44	5.59	0.34	6.05e-8	Lymphocyte counts;
KIRP	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg03959625	chr15:84868606	LOC388152	0.48	5.63	0.34	4.88e-8	Schizophrenia;
KIRP	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-7.2	-0.42	7.27e-12	Coronary artery disease;
KIRP	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-6.61	-0.39	2.43e-10	Cardiac Troponin-T levels;
KIRP	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.34	-0.32	2.09e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.28	0.76	1.02e-47	Chronic sinus infection;
KIRP	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg10130564	chr11:117069849	TAGLN	-0.4	-5.0	-0.3	1.07e-6	Blood protein levels;
KIRP	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.76	11.55	0.59	5.99e-25	Blood metabolite ratios;
KIRP	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	1.03	19.06	0.77	2.28e-50	Heart rate;
KIRP	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.48	5.66	0.34	4.17e-8	Menarche (age at onset);
KIRP	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.67	-8.07	-0.46	3.08e-14	Iron status biomarkers;
KIRP	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.95e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.52	-6.4	-0.38	7.96e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9398803	0.589	rs853965	chr6:127036174	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-5.49	-0.33	9.85e-8	Male-pattern baldness;
KIRP	cis	rs6500395	0.963	rs12444902	chr16:48667126	G/T	cg04672837	chr16:48644449	N4BP1	0.45	6.35	0.38	1.05e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02445972	chr17:7166593	CLDN7	0.42	6.12	0.36	3.72e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.71	7.43	0.43	1.76e-12	Corneal astigmatism;
KIRP	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg07395648	chr5:131743802	NA	-0.35	-4.88	-0.3	1.89e-6	Blood metabolite levels;
KIRP	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2223471	1.000	rs6928000	chr6:50742161	G/A	cg03432817	chr6:50765336	NA	-0.51	-8.27	-0.47	8.33e-15	Subcutaneous adipose tissue;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03767155	chr2:8822052	ID2	0.45	6.04	0.36	5.67e-9	Survival in pancreatic cancer;
KIRP	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg23682824	chr7:23144976	KLHL7	0.58	6.98	0.41	2.76e-11	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg09496464	chr2:208904568	NA	-0.46	-6.46	-0.38	5.52e-10	Select biomarker traits;
KIRP	cis	rs9815354	0.812	rs73830532	chr3:41898814	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.74	7.09	0.41	1.45e-11	Bipolar disorder;
KIRP	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg02487422	chr3:49467188	NICN1	0.4	5.37	0.32	1.79e-7	Parkinson's disease;
KIRP	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.63	-0.39	2.07e-10	Aortic root size;
KIRP	cis	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24203851	chr6:111136481	CDK19	-0.37	-4.87	-0.3	2.04e-6	Metabolic traits;
KIRP	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg17366294	chr4:99064904	C4orf37	0.39	5.47	0.33	1.1e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17376030	chr22:41985996	PMM1	-0.81	-8.5	-0.48	1.85e-15	Vitiligo;
KIRP	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg22777020	chr22:31556080	RNF185	0.48	5.21	0.32	4.08e-7	Colorectal cancer;
KIRP	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.55	7.94	0.45	7.03e-14	Carotid intima media thickness;
KIRP	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	1.02	21.59	0.81	1.01e-58	Multiple myeloma;
KIRP	cis	rs2034650	0.563	rs11070270	chr15:40708422	C/T	cg08996748	chr15:40651036	DISP2	0.37	5.4	0.33	1.59e-7	Interstitial lung disease;
KIRP	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.45	-0.38	5.8e-10	Breast cancer;
KIRP	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg14825094	chr17:61818420	STRADA	-0.42	-4.85	-0.3	2.23e-6	Height;
KIRP	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.99	-15.41	-0.7	6.07e-38	Ulcerative colitis;
KIRP	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-10.52	-0.56	1.3e-21	Chronic sinus infection;
KIRP	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.82	9.85	0.53	1.69e-19	Post bronchodilator FEV1;
KIRP	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.81	-12.07	-0.61	1.15e-26	Headache;
KIRP	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg04310649	chr10:35416472	CREM	-0.59	-6.99	-0.41	2.51e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.82	11.82	0.6	7.75e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg16898833	chr6:26189333	HIST1H4D	0.72	5.13	0.31	5.76e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.25	-0.37	1.81e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs918629	0.716	rs12055262	chr5:95274632	T/C	cg16656078	chr5:95278638	ELL2	-0.46	-6.7	-0.39	1.38e-10	IgG glycosylation;
KIRP	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg22974920	chr21:40686053	BRWD1	0.47	5.74	0.34	2.73e-8	Cognitive function;
KIRP	trans	rs4143844	0.867	rs1052306	chr15:62149045	T/C	cg04814990	chr13:111957387	ARHGEF7	0.96	6.22	0.37	2.08e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25833597	chr17:30823145	MYO1D	0.4	5.23	0.32	3.57e-7	Schizophrenia;
KIRP	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.32	5.08	0.31	7.51e-7	Testicular germ cell tumor;
KIRP	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.87	9.45	0.52	2.73e-18	Pulmonary function decline;
KIRP	cis	rs2742234	0.794	rs17153156	chr10:43704637	C/G	cg15436174	chr10:43711423	RASGEF1A	0.42	5.3	0.32	2.58e-7	Hirschsprung disease;
KIRP	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.71	9.65	0.52	7.03e-19	Schizophrenia;
KIRP	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.32e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg10223061	chr2:219282414	VIL1	-0.32	-5.28	-0.32	2.84e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.04	-0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.38	0.59	2.24e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.55	6.54	0.38	3.48e-10	Lung cancer;
KIRP	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg17595323	chr11:93583763	C11orf90	-0.37	-6.29	-0.37	1.47e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs876084	0.505	rs7840588	chr8:121108256	G/T	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg22903471	chr2:27725779	GCKR	0.39	5.33	0.32	2.2e-7	Oral cavity cancer;
KIRP	trans	rs7404843	0.850	rs6498553	chr16:15539902	T/C	cg02716450	chr16:28638775	NA	-0.8	-8.29	-0.47	7.21e-15	Testicular germ cell tumor;
KIRP	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg22906224	chr7:99728672	NA	0.46	5.55	0.33	7.53e-8	Coronary artery disease;
KIRP	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.6	6.84	0.4	6.26e-11	Aortic root size;
KIRP	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg20362242	chr5:692897	TPPP	0.57	4.95	0.3	1.39e-6	Obesity-related traits;
KIRP	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg25174290	chr11:3078921	CARS	-0.57	-6.11	-0.36	3.92e-9	Calcium levels;
KIRP	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg14003231	chr6:33640908	ITPR3	0.28	4.95	0.3	1.37e-6	Plateletcrit;
KIRP	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg17182837	chr8:41585554	ANK1	-0.5	-5.33	-0.32	2.23e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23836814	chr11:47681300	AGBL2	0.38	6.02	0.36	6.45e-9	C-reactive protein;
KIRP	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg10223061	chr2:219282414	VIL1	-0.35	-5.83	-0.35	1.71e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02018176	chr4:1364513	KIAA1530	-0.38	-4.87	-0.3	2.01e-6	Obesity-related traits;
KIRP	cis	rs4713118	0.597	rs172166	chr6:28020820	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-4.88	-0.3	1.92e-6	Parkinson's disease;
KIRP	cis	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13461710	chr1:160287986	COPA;SUMO1P3	0.33	4.89	0.3	1.83e-6	C-reactive protein;
KIRP	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.97	16.03	0.71	4.44e-40	Bone mineral density;
KIRP	cis	rs5752326	0.558	rs1023494	chr22:26865040	T/C	cg20819150	chr22:26891497	TFIP11	0.53	5.0	0.3	1.11e-6	Ischemic stroke;
KIRP	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.12	12.67	0.63	1.22e-28	Smoking behavior;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg09699651	chr6:150184138	LRP11	0.46	5.96	0.36	8.71e-9	Lung cancer;
KIRP	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	1.23	13.96	0.66	5.34e-33	Monocyte percentage of white cells;
KIRP	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg18357526	chr6:26021779	HIST1H4A	0.42	4.86	0.3	2.13e-6	Blood metabolite levels;
KIRP	cis	rs963731	0.649	rs77498284	chr2:39349726	C/A	cg04010122	chr2:39346883	SOS1	0.93	6.39	0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.75	8.73	0.49	4.06e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg00504896	chr12:9437009	LOC642846	-0.51	-6.33	-0.37	1.18e-9	Breast size;
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.27	-0.32	2.92e-7	Life satisfaction;
KIRP	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg19847866	chr10:1019161	NA	-0.61	-5.52	-0.33	8.64e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7560272	0.502	rs4513320	chr2:73920741	T/C	cg20560298	chr2:73613845	ALMS1	0.51	6.24	0.37	1.95e-9	Schizophrenia;
KIRP	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.44	5.72	0.34	3.06e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg07395648	chr5:131743802	NA	-0.58	-8.65	-0.48	6.7e-16	Blood metabolite levels;
KIRP	trans	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.22	-0.37	2.07e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg05370193	chr1:21551575	ECE1	0.42	5.99	0.36	7.3e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07308232	chr7:1071921	C7orf50	-0.7	-8.7	-0.48	4.93e-16	Longevity;Endometriosis;
KIRP	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg22437258	chr11:111473054	SIK2	0.62	7.51	0.43	1.08e-12	Primary sclerosing cholangitis;
KIRP	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	1.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg06042504	chr8:55087323	NA	-0.61	-7.12	-0.41	1.17e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7395581	0.918	rs12575456	chr11:47326073	G/A	cg26139080	chr11:47293733	MADD	-0.42	-5.27	-0.32	2.98e-7	HDL cholesterol;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10681804	chr20:33433114	GGT7	0.61	7.67	0.44	4.11e-13	Interleukin-4 levels;
KIRP	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.93	-14.08	-0.67	2.1e-33	Primary sclerosing cholangitis;
KIRP	cis	rs7712401	0.601	rs404442	chr5:122344931	C/T	cg19412675	chr5:122181750	SNX24	-0.49	-5.31	-0.32	2.49e-7	Mean platelet volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00948275	chr1:228645512	HIST3H2BB;HIST3H2A	-0.55	-6.34	-0.37	1.07e-9	Interleukin-4 levels;
KIRP	cis	rs4731207	0.698	rs2040926	chr7:124457295	C/G	cg05630886	chr7:124431682	NA	-0.29	-4.94	-0.3	1.43e-6	Cutaneous malignant melanoma;
KIRP	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.49	0.62	4.56e-28	Ileal carcinoids;
KIRP	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.34	5.06	0.31	8.32e-7	Eye color traits;
KIRP	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.67	-7.46	-0.43	1.49e-12	Menarche (age at onset);
KIRP	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.75	-7.68	-0.44	3.78e-13	Hair shape;
KIRP	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs4845875	0.600	rs6696752	chr1:11835935	T/C	cg24844545	chr1:11908347	NPPA	0.37	4.9	0.3	1.73e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg17470449	chr10:769945	NA	0.68	7.38	0.43	2.41e-12	Uric acid levels;
KIRP	cis	rs9859260	1.000	rs11718657	chr3:195797553	C/A	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.89	-0.3	1.79e-6	Mean corpuscular volume;
KIRP	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.63	7.09	0.41	1.41e-11	Schizophrenia;
KIRP	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.98	0.36	7.84e-9	Menopause (age at onset);
KIRP	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.5	6.81	0.4	7.41e-11	Migraine;
KIRP	cis	rs10905065	0.804	rs2380203	chr10:5810897	A/G	cg25171089	chr10:5708825	ASB13	0.39	4.9	0.3	1.73e-6	Menopause (age at onset);
KIRP	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg12560992	chr17:57184187	TRIM37	0.58	5.35	0.32	2.01e-7	Cognitive test performance;
KIRP	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.47	-0.38	5.19e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-1.16	-9.51	-0.52	1.87e-18	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
KIRP	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.5	0.52	2e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.52	-0.48	1.62e-15	Blood trace element (Zn levels);
KIRP	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.77	-0.35	2.42e-8	Electroencephalogram traits;
KIRP	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	1.01	18.29	0.76	8.97e-48	Heart rate;
KIRP	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-8.1	-0.46	2.62e-14	Retinal vascular caliber;
KIRP	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.65	-9.56	-0.52	1.29e-18	Body mass index;
KIRP	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg26138937	chr11:71823887	C11orf51	-1.15	-8.03	-0.46	3.95e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.7	-12.8	-0.63	4.44e-29	White blood cell count (basophil);
KIRP	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.49	-6.15	-0.37	3.09e-9	Post bronchodilator FEV1;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02537268	chr17:79659547	HGS	0.51	6.59	0.39	2.69e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg10818794	chr15:86012489	AKAP13	-0.58	-8.24	-0.47	1.03e-14	Interstitial lung disease;
KIRP	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.54	-6.69	-0.39	1.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2151522	0.762	rs34443655	chr6:127177958	A/G	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg12266841	chr11:45687263	CHST1	0.49	6.33	0.37	1.15e-9	DNA methylation (variation);
KIRP	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.16	0.37	2.95e-9	Morning vs. evening chronotype;
KIRP	cis	rs9644630	0.841	rs4922035	chr8:19328174	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.4	-5.25	-0.32	3.29e-7	Oropharynx cancer;
KIRP	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.68	-0.6	2.25e-25	Caffeine consumption;
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg14789911	chr21:47582049	C21orf56	-0.4	-5.01	-0.3	1.04e-6	Testicular germ cell tumor;
KIRP	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Colorectal cancer;
KIRP	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.75	11.31	0.58	3.62e-24	Metabolite levels;
KIRP	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.77	10.32	0.55	5.53e-21	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.65	-6.51	-0.38	4.15e-10	DNA methylation (variation);
KIRP	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.84	-13.03	-0.64	7.51e-30	Blood metabolite levels;
KIRP	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Bladder cancer;
KIRP	cis	rs4704187	0.687	rs7735937	chr5:74441700	G/A	cg03227963	chr5:74354835	NA	0.42	6.08	0.36	4.44e-9	Response to amphetamines;
KIRP	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg16388071	chr6:169726476	NA	-0.4	-5.62	-0.34	5.13e-8	Obesity-related traits;
KIRP	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.68	9.79	0.53	2.56e-19	Lymphocyte counts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10698984	chr13:30424281	UBL3	0.47	6.18	0.37	2.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21545522	chr1:205238299	TMCC2	0.55	7.31	0.42	3.76e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2301888	0.962	rs2240339	chr1:17674108	C/T	cg01790353	chr1:17674483	PADI4	0.41	5.3	0.32	2.59e-7	Rheumatoid arthritis;
KIRP	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg18806716	chr10:30721971	MAP3K8	-0.31	-5.1	-0.31	6.66e-7	Inflammatory bowel disease;
KIRP	cis	rs7923609	0.740	rs10761784	chr10:65308750	A/T	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.11	-0.31	6.45e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.46	-10.98	-0.57	4.41e-23	Diabetic kidney disease;
KIRP	cis	rs11731606	0.508	rs17376943	chr4:95277117	G/A	cg20625393	chr4:95128694	SMARCAD1	0.67	5.72	0.34	3.15e-8	Mean platelet volume;
KIRP	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.56	7.5	0.43	1.14e-12	Height;
KIRP	cis	rs4789452	0.573	rs312872	chr17:75367327	A/C	cg05865280	chr17:75406074	SEPT9	-0.23	-4.99	-0.3	1.17e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs687432	0.885	rs12803905	chr11:57733997	T/C	cg19752551	chr11:57585705	CTNND1	-0.69	-9.18	-0.5	1.89e-17	Parkinson's disease;
KIRP	cis	rs36715	1.000	rs40527	chr5:127550252	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	8.19	0.46	1.42e-14	Breast cancer;
KIRP	cis	rs17030434	0.728	rs16998891	chr4:154646419	T/G	cg14289246	chr4:154710475	SFRP2	-0.77	-8.95	-0.5	8.99e-17	Electrocardiographic conduction measures;
KIRP	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg26149184	chr10:133730230	NA	0.43	5.1	0.31	6.89e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs12943633	0.530	rs75397452	chr17:37807707	T/C	cg22243000	chr17:37813369	STARD3	0.9	5.8	0.35	2.01e-8	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7075426	0.716	rs11598718	chr10:88294484	G/A	cg07322936	chr10:88137208	NA	0.49	5.3	0.32	2.54e-7	Migraine without aura;
KIRP	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg07701084	chr6:150067640	NUP43	0.71	9.27	0.51	9.98e-18	Lung cancer;
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg22907277	chr7:1156413	C7orf50	0.83	8.12	0.46	2.2e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg25036284	chr2:26402008	FAM59B	-0.51	-5.37	-0.32	1.85e-7	Gut microbiome composition (summer);
KIRP	cis	rs4959799	0.655	rs6919570	chr6:3277017	A/G	cg03657281	chr6:3270030	SLC22A23	0.74	5.28	0.32	2.87e-7	Survival in rectal cancer;
KIRP	cis	rs7520050	0.931	rs1707333	chr1:46547035	C/G	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2594989	0.943	rs62245869	chr3:11439820	G/A	cg01796438	chr3:11312864	ATG7	-0.73	-8.81	-0.49	2.28e-16	Circulating chemerin levels;
KIRP	cis	rs9653442	0.628	rs12474386	chr2:100857017	G/A	cg07810366	chr2:100720526	AFF3	-0.3	-4.95	-0.3	1.4e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6504950	0.615	rs66898273	chr17:52993956	C/T	cg26251398	chr17:52985966	TOM1L1	0.4	5.47	0.33	1.12e-7	Breast cancer;
KIRP	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.35	-0.32	2.03e-7	Renal cell carcinoma;
KIRP	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg18944383	chr4:111397179	ENPEP	0.52	9.21	0.51	1.47e-17	Height;
KIRP	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg14972814	chr11:95582409	MTMR2	0.32	5.46	0.33	1.14e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg00677901	chr16:88017247	BANP	0.42	4.96	0.3	1.31e-6	Menopause (age at onset);
KIRP	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.45	-0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.86	14.35	0.68	2.42e-34	Multiple myeloma;
KIRP	cis	rs2692947	0.644	rs772175	chr2:96944553	G/A	cg23100626	chr2:96804247	ASTL	0.51	6.92	0.4	3.82e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs1978968	1.000	rs5992917	chr22:18443699	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.59	-6.97	-0.41	2.9100000000000002e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg10223061	chr2:219282414	VIL1	0.54	7.97	0.45	6.02e-14	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs2273669	0.667	rs9688896	chr6:109364698	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.41	-0.38	7.27e-10	Prostate cancer;
KIRP	cis	rs5753618	0.504	rs9606846	chr22:31897571	C/T	cg02404636	chr22:31891804	SFI1	0.54	5.92	0.35	1.06e-8	Colorectal cancer;
KIRP	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.07	19.08	0.77	1.99e-50	Triglycerides;
KIRP	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg08873628	chr1:175162347	KIAA0040	0.44	6.53	0.38	3.78e-10	Alcohol dependence;
KIRP	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	1.09	8.04	0.46	3.69e-14	Skin colour saturation;
KIRP	cis	rs2858942	0.780	rs2858014	chr16:248357	T/C	cg08400316	chr16:204221	HBZ	0.52	6.15	0.36	3.19e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg24315340	chr6:146058215	EPM2A	-0.43	-5.54	-0.33	7.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.62	7.88	0.45	1.08e-13	Mood instability;
KIRP	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg10729496	chr3:10149963	C3orf24	0.53	4.99	0.3	1.13e-6	Alzheimer's disease;
KIRP	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg21523564	chr15:75251491	NA	-0.36	-6.05	-0.36	5.46e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	1.04	13.37	0.65	5.14e-31	Exhaled nitric oxide output;
KIRP	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.12	-0.36	3.64e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg09264619	chr17:80180166	NA	-0.5	-5.93	-0.35	1.02e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.46	-6.98	-0.41	2.8e-11	Coronary artery disease;
KIRP	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.49	-8.76	-0.49	3.14e-16	Height;
KIRP	cis	rs3824347	0.771	rs10869477	chr9:77652604	A/G	cg01251476	chr9:77566080	C9orf40	0.31	4.92	0.3	1.57e-6	Urinary magnesium-to-creatinine ratio;
KIRP	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-12.93	-0.64	1.58e-29	Dental caries;
KIRP	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg20701182	chr2:24300061	SF3B14	0.95	10.22	0.55	1.16e-20	Lymphocyte counts;
KIRP	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.55	6.25	0.37	1.84e-9	Primary sclerosing cholangitis;
KIRP	cis	rs9475752	0.793	rs71564870	chr6:56818846	G/C	cg22880620	chr6:56820808	BEND6;DST	0.48	5.02	0.3	1e-6	Menarche (age at onset);
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg09597638	chr17:3907349	NA	0.71	11.35	0.59	2.76e-24	Type 2 diabetes;
KIRP	cis	rs9393813	0.529	rs7761966	chr6:27445703	C/T	cg03332623	chr6:27441972	ZNF184	-0.39	-5.37	-0.32	1.81e-7	Bipolar disorder;
KIRP	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.82	8.53	0.48	1.56e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs4356975	0.563	rs4131317	chr4:69948998	A/T	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	1.05	10.53	0.56	1.17e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.54	-0.43	8.78e-13	Morning vs. evening chronotype;
KIRP	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-0.84	-9.41	-0.51	3.71e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs5753618	0.561	rs737684	chr22:31659827	C/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.36	-0.32	1.96e-7	Colorectal cancer;
KIRP	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg13072238	chr3:49761600	GMPPB	-0.59	-5.64	-0.34	4.58e-8	Menarche (age at onset);
KIRP	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg06223162	chr1:101003688	GPR88	-0.42	-8.41	-0.47	3.28e-15	Monocyte count;
KIRP	cis	rs2219968	0.828	rs4077569	chr8:78918381	C/A	cg00738934	chr8:78996279	NA	-0.38	-5.11	-0.31	6.62e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs75920871	0.541	rs76690043	chr11:116801529	C/G	cg23684410	chr11:116897558	SIK3	0.5	5.21	0.32	3.95e-7	Subjective well-being;
KIRP	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.64	-9.38	-0.51	4.62e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.29e-7	Red blood cell count;
KIRP	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg22681709	chr2:178499509	PDE11A	-0.61	-8.9	-0.49	1.24e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg16083429	chr3:49237500	CCDC36	-0.4	-5.24	-0.32	3.4e-7	Menarche (age at onset);
KIRP	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-5.67	-0.34	3.96e-8	Metabolite levels;
KIRP	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg24009623	chr19:33667908	NA	0.47	5.71	0.34	3.27e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04106633	chr4:1044584	NA	0.47	5.68	0.34	3.72e-8	Recombination rate (males);
KIRP	cis	rs9323205	0.798	rs11157805	chr14:51658390	C/G	cg23942311	chr14:51606299	NA	0.63	8.34	0.47	5.35e-15	Cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25297425	chr7:6144127	USP42	-0.51	-6.23	-0.37	2.04e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4654899	0.965	rs17418249	chr1:21390582	C/T	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.87e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.62	8.2	0.46	1.3e-14	Prostate cancer;
KIRP	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.57	-7.01	-0.41	2.24e-11	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.31	-0.32	2.44e-7	Life satisfaction;
KIRP	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg19445457	chr11:5799446	OR52N5	-0.45	-4.94	-0.3	1.42e-6	DNA methylation (variation);
KIRP	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.39	-0.47	3.81e-15	Triglycerides;
KIRP	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	1.02	17.27	0.74	2.59e-44	Bone mineral density;
KIRP	cis	rs7849270	1.000	rs9697030	chr9:131920181	T/C	cg13538475	chr9:131942899	NA	-0.33	-5.02	-0.3	9.9e-7	Blood metabolite ratios;
KIRP	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.01	-0.3	1.05e-6	Neuroticism;
KIRP	cis	rs13185784	0.662	rs730688	chr5:179704903	A/G	cg23248424	chr5:179741104	GFPT2	-0.51	-5.34	-0.32	2.06e-7	TRAIL levels;
KIRP	cis	rs4356975	0.563	rs7439152	chr4:69969006	G/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.44	0.33	1.27e-7	Obesity-related traits;
KIRP	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.13	-0.41	1.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1413885	0.549	rs9436726	chr1:65853196	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.75	0.34	2.59e-8	Anticoagulant levels;
KIRP	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	0.75	6.58	0.39	2.82e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.08	20.37	0.79	9.97e-55	Prudent dietary pattern;
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg11814155	chr7:99998594	ZCWPW1	0.57	5.32	0.32	2.34e-7	Platelet count;
KIRP	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg00981070	chr1:2046702	PRKCZ	0.41	5.86	0.35	1.5e-8	Height;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.76	13.31	0.65	7.99e-31	Height;
KIRP	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.81	-15.52	-0.7	2.54e-38	Obesity-related traits;
KIRP	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg06917634	chr15:78832804	PSMA4	0.47	4.89	0.3	1.81e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	0.92	9.61	0.52	9.26e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	1.08	9.79	0.53	2.5e-19	Pulse pressure;
KIRP	cis	rs921943	1.000	rs7735031	chr5:78325380	T/A	cg26802063	chr5:78281964	ARSB	0.49	6.08	0.36	4.56e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs11138902	0.673	rs2777864	chr9:72091413	T/C	cg14397918	chr9:72078829	APBA1	-0.34	-5.5	-0.33	9.4e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg20469991	chr17:27169893	C17orf63	0.54	5.64	0.34	4.55e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7258015	1.000	rs7257871	chr19:10449252	T/C	cg25279553	chr19:10444815	RAVER1;ICAM3	0.48	6.21	0.37	2.28e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.03	-0.5	5.2e-17	Mood instability;
KIRP	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg03433033	chr1:76189801	ACADM	0.65	8.18	0.46	1.48e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs644148	0.836	rs2686776	chr19:45000366	T/C	cg15540054	chr19:45004280	ZNF180	-0.75	-9.26	-0.51	1.07e-17	Personality dimensions;
KIRP	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.3	7.29	0.42	4.22e-12	IgG glycosylation;
KIRP	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg18135206	chr14:102964638	TECPR2	0.47	5.32	0.32	2.29e-7	Blood protein levels;
KIRP	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.4	-5.5	-0.33	9.72e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22868319	chr20:33265117	PIGU	0.51	6.22	0.37	2.17e-9	Parkinson's disease;
KIRP	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.8	-0.49	2.41e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg10189774	chr4:17578691	LAP3	0.52	6.32	0.37	1.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg18200150	chr17:30822561	MYO1D	0.48	5.76	0.34	2.51e-8	Schizophrenia;
KIRP	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	14.07	0.67	2.19e-33	Gut microbiome composition (summer);
KIRP	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.37	6.63	0.39	2.16e-10	Renal cell carcinoma;
KIRP	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg15871215	chr5:81402204	ATG10	0.49	6.46	0.38	5.44e-10	Breast cancer;
KIRP	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.59	8.27	0.47	8.42e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs712039	0.652	rs2946340	chr17:35749716	C/T	cg16670864	chr17:35848621	DUSP14	0.42	4.98	0.3	1.2e-6	Tuberculosis;
KIRP	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg22771759	chr13:24902376	NA	0.42	5.37	0.32	1.81e-7	Obesity-related traits;
KIRP	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.45	6.28	0.37	1.52e-9	Red blood cell count;
KIRP	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.36	0.32	1.92e-7	Ovarian reserve;
KIRP	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.55	-0.39	3.34e-10	Joint mobility (Beighton score);
KIRP	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.53	6.51	0.38	4.22e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg12658694	chr1:38397304	INPP5B	0.74	10.01	0.54	5.15e-20	Coronary artery disease;
KIRP	cis	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.44	5.68	0.34	3.75e-8	Leprosy;
KIRP	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.82	-11.01	-0.57	3.59e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10208940	0.920	rs13400155	chr2:68723636	G/A	cg12452813	chr2:68675892	NA	0.47	5.07	0.31	7.97e-7	Urate levels in lean individuals;
KIRP	cis	rs7534824	0.543	rs61780295	chr1:101400264	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.18	0.42	8.47e-12	Refractive astigmatism;
KIRP	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.39	-5.91	-0.35	1.15e-8	Platelet distribution width;
KIRP	cis	rs2289328	0.943	rs3803359	chr15:40662748	A/G	cg08996748	chr15:40651036	DISP2	0.44	4.89	0.3	1.8e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs6601327	0.665	rs11249949	chr8:9655612	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.07	-0.41	1.57e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.88	10.23	0.55	1.04e-20	Pulmonary function decline;
KIRP	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs282587	0.569	rs426765	chr13:113414798	A/T	cg04656015	chr13:113407548	ATP11A	0.58	6.36	0.38	9.68e-10	Glycated hemoglobin levels;
KIRP	cis	rs1659258	0.527	rs1258404	chr2:88620216	C/T	cg00685853	chr2:88648947	NA	-0.51	-5.8	-0.35	2.03e-8	Visceral fat;
KIRP	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg24565620	chr2:194026	NA	-0.72	-5.07	-0.31	7.81e-7	Blood protein levels;
KIRP	cis	rs8177876	0.749	rs78707250	chr16:81080362	G/A	cg08591886	chr16:81111003	C16orf46	-0.68	-5.33	-0.32	2.22e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13648088	chr10:124768538	ACADSB;IKZF5	-0.45	-6.36	-0.38	9.52e-10	Metabolic traits;
KIRP	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg00066239	chr17:78472159	NA	-0.28	-5.11	-0.31	6.37e-7	Fractional excretion of uric acid;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09965499	chr8:110563678	EBAG9	-0.49	-7.97	-0.45	5.79e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.55	-8.27	-0.47	8.57e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg19052272	chr2:3704530	ALLC	-0.37	-4.97	-0.3	1.24e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg16989719	chr2:238392110	NA	-0.63	-6.11	-0.36	3.88e-9	Prostate cancer;
KIRP	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg04896959	chr15:78267971	NA	-0.55	-4.91	-0.3	1.63e-6	Post bronchodilator FEV1;
KIRP	cis	rs12282928	0.959	rs1158897	chr11:48273340	T/C	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg20135002	chr11:47629003	NA	-0.41	-4.87	-0.3	2.02e-6	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg24747557	chr10:131355152	MGMT	-0.39	-5.25	-0.32	3.36e-7	Response to temozolomide;
KIRP	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg17376030	chr22:41985996	PMM1	-0.52	-6.46	-0.38	5.42e-10	Vitiligo;
KIRP	cis	rs7395581	0.775	rs2269434	chr11:47360412	T/C	cg26139080	chr11:47293733	MADD	-0.43	-5.29	-0.32	2.71e-7	HDL cholesterol;
KIRP	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg06634786	chr22:41940651	POLR3H	-0.52	-5.6	-0.34	5.82e-8	Neuroticism;
KIRP	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg00074818	chr8:8560427	CLDN23	0.4	6.33	0.37	1.16e-9	Obesity-related traits;
KIRP	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.57	0.43	7.71e-13	Mean corpuscular volume;
KIRP	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg05714579	chr10:131428358	MGMT	0.4	5.21	0.32	3.98e-7	Response to temozolomide;
KIRP	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg23950597	chr19:37808831	NA	-0.76	-6.6	-0.39	2.54e-10	Coronary artery calcification;
KIRP	trans	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg06521331	chr12:34319734	NA	-0.5	-6.2	-0.37	2.38e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12096438	1.000	rs12096438	chr1:25889422	C/T	cg21452808	chr1:25900135	NA	-0.39	-6.28	-0.37	1.51e-9	Platelet count;Mean platelet volume;
KIRP	cis	rs9815354	0.680	rs73073263	chr3:42018666	C/A	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.38	-6.05	-0.36	5.45e-9	Age at first birth;
KIRP	cis	rs17023223	0.537	rs2361272	chr1:119603417	T/C	cg18261050	chr1:119551319	NA	0.49	6.56	0.39	3.12e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	1.05	14.72	0.68	1.29e-35	Menopause (age at onset);
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.44	-5.55	-0.33	7.2e-8	Longevity;
KIRP	cis	rs2273669	0.667	rs76367548	chr6:109356589	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.83	-10.99	-0.57	4.12e-23	N-glycan levels;
KIRP	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-7.62	-0.44	5.58e-13	Morning vs. evening chronotype;
KIRP	cis	rs4646404	0.509	rs746900	chr17:17426127	T/A	cg01246520	chr17:17644344	RAI1	-0.3	-4.91	-0.3	1.64e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs11696739	0.536	rs11696842	chr20:1600794	C/T	cg11295724	chr20:1538353	SIRPD	-0.5	-4.88	-0.3	1.91e-6	Mean platelet volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18806033	chr2:134182001	NCKAP5	0.45	6.23	0.37	1.96e-9	Interleukin-4 levels;
KIRP	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11628318	0.853	rs11626063	chr14:103024706	G/C	cg12046867	chr14:103022105	NA	-0.55	-6.91	-0.4	4.04e-11	Platelet count;
KIRP	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-5.67	-0.34	3.92e-8	Triglycerides;
KIRP	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.51	7.51	0.43	1.06e-12	Schizophrenia;
KIRP	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg06223162	chr1:101003688	GPR88	0.48	10.03	0.54	4.43e-20	Monocyte count;
KIRP	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	cis	rs13108043	0.605	rs17702203	chr4:87961503	A/C	cg11209507	chr4:87813803	C4orf36	0.47	4.97	0.3	1.27e-6	Red blood cell count;
KIRP	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.45	-5.97	-0.36	8.14e-9	Blood metabolite levels;
KIRP	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.79	-8.71	-0.49	4.41e-16	Hirschsprung disease;
KIRP	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg06204229	chr3:52865917	ITIH4	-0.43	-5.1	-0.31	6.73e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg08888203	chr3:10149979	C3orf24	0.46	4.91	0.3	1.62e-6	Alzheimer's disease;
KIRP	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg24315340	chr6:146058215	EPM2A	0.45	5.65	0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22683308	chr4:1340831	KIAA1530	0.4	4.94	0.3	1.47e-6	Longevity;
KIRP	cis	rs7709377	0.595	rs11241360	chr5:115448187	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.64e-7	Metabolite levels  (X-11787);
KIRP	cis	rs4908768	0.534	rs11586056	chr1:8845199	G/T	cg25722041	chr1:8623473	RERE	0.78	8.23	0.46	1.1e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9403521	0.898	rs12198291	chr6:143975600	G/A	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.1	-0.31	6.93e-7	Obesity-related traits;
KIRP	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.45	-0.78	1.14e-51	Height;
KIRP	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.48	-5.83	-0.35	1.75e-8	Carotid intima media thickness;
KIRP	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg24881330	chr22:46731750	TRMU	0.61	5.98	0.36	7.91e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18364779	chr6:26104403	HIST1H4C	0.41	5.32	0.32	2.33e-7	Schizophrenia;
KIRP	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.35	0.42	2.95e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg01420254	chr6:26195488	NA	1.24	11.27	0.58	4.85e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg19407955	chr1:165599744	MGST3	-0.44	-5.2	-0.31	4.26e-7	Total ventricular volume;
KIRP	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg16725984	chr16:89735184	C16orf55	0.2	5.4	0.33	1.57e-7	Vitiligo;
KIRP	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.45	0.62	6.38e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg14221460	chr8:27183342	PTK2B	0.52	6.81	0.4	7.31e-11	Neuroticism;
KIRP	trans	rs7999699	0.902	rs115625847	chr13:48311724	A/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg05775895	chr3:12838266	CAND2	0.33	5.54	0.33	7.84e-8	P wave duration;
KIRP	cis	rs3762637	0.941	rs7653592	chr3:122218371	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-6.4	-0.38	7.87e-10	LDL cholesterol levels;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.51	-6.67	-0.39	1.72e-10	Mean corpuscular volume;
KIRP	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12756686	chr19:29218302	NA	0.87	8.56	0.48	1.25e-15	Methadone dose in opioid dependence;
KIRP	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg08999081	chr20:33150536	PIGU	0.48	5.0	0.3	1.08e-6	Protein C levels;
KIRP	cis	rs27434	0.561	rs151910	chr5:96156956	C/A	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1.01e-7	Ankylosing spondylitis;
KIRP	cis	rs11586313	0.507	rs2339385	chr1:152859594	C/G	cg07796016	chr1:152779584	LCE1C	-0.48	-6.11	-0.36	3.94e-9	Vitamin D levels;
KIRP	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	1.02	18.71	0.77	3.45e-49	Parkinson's disease;
KIRP	cis	rs4262150	0.508	rs72795352	chr5:151911070	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.85	-0.49	1.73e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00857998	chr1:205179979	DSTYK	0.65	8.35	0.47	5.02e-15	Red blood cell count;
KIRP	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.45	6.3	0.37	1.37e-9	Dupuytren's disease;
KIRP	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.16	-0.42	9.06e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs6959887	0.962	rs73099187	chr7:35291491	G/A	cg06685737	chr7:35301730	NA	0.43	6.24	0.37	1.86e-9	Birth weight;
KIRP	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.92	-10.19	-0.54	1.39e-20	Gut microbiome composition (summer);
KIRP	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.27	0.32	2.98e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs16857609	0.564	rs13388148	chr2:218281500	T/G	cg15335768	chr2:218268053	DIRC3	-0.47	-6.17	-0.37	2.77e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs1635	0.655	rs60568488	chr6:28309511	T/C	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg14703610	chr5:56206110	C5orf35	0.47	6.19	0.37	2.5e-9	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.54	-8.57	-0.48	1.17e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs2964802	0.505	rs10513058	chr5:10804383	C/T	cg14521931	chr5:10832172	NA	-0.7	-10.42	-0.55	2.61e-21	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.44	9.81	0.53	2.17e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs12049351	0.774	rs754023	chr1:229637503	A/T	cg11742688	chr1:229674241	ABCB10	-0.4	-6.53	-0.38	3.81e-10	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.44	4.04e-13	Bladder cancer;
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18252515	chr7:66147081	NA	0.46	5.48	0.33	1.04e-7	Aortic root size;
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.61	-8.45	-0.47	2.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03585549	chr3:16926335	PLCL2	0.5	6.31	0.37	1.3e-9	Parkinson's disease;
KIRP	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg23958373	chr8:599963	NA	1.01	7.2	0.42	7.17e-12	IgG glycosylation;
KIRP	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	20.97	0.8	1.11e-56	Colorectal cancer;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg01798813	chr17:3906674	NA	-0.51	-6.98	-0.41	2.78e-11	Type 2 diabetes;
KIRP	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.74	0.34	2.77e-8	Melanoma;
KIRP	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg07689907	chr11:61582574	FADS1	0.48	6.04	0.36	5.58e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg22800045	chr5:56110881	MAP3K1	0.73	7.81	0.45	1.66e-13	Initial pursuit acceleration;
KIRP	cis	rs7082209	0.941	rs67379075	chr10:44811968	A/C	cg09554077	chr10:44749378	NA	0.47	6.01	0.36	6.64e-9	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.76	11.07	0.58	2.26e-23	Heart rate;
KIRP	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.97	-13.19	-0.64	2.13e-30	Response to antipsychotic treatment;
KIRP	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.91	-0.4	4.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg21361702	chr7:150065534	REPIN1	0.47	5.52	0.33	8.55e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg19893067	chr17:80732956	TBCD	-0.36	-4.9	-0.3	1.75e-6	Glycated hemoglobin levels;
KIRP	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg09231725	chr11:64357281	SLC22A12	-0.67	-9.08	-0.5	3.76e-17	Urate levels in obese individuals;
KIRP	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg11635098	chr7:100497156	NA	-0.66	-7.16	-0.42	9.24e-12	Resting heart rate;
KIRP	cis	rs2151522	0.788	rs13216524	chr6:127151914	G/A	cg21431617	chr6:127135037	NA	0.3	5.41	0.33	1.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.82	11.12	0.58	1.53e-23	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg01338084	chr22:32026380	PISD	0.99	7.39	0.43	2.23e-12	Age-related hearing impairment;
KIRP	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10214930	0.671	rs28416309	chr7:27633742	T/G	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.28	25.03	0.85	1.39e-69	IgG glycosylation;
KIRP	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.31	-0.47	6.69e-15	Monocyte percentage of white cells;
KIRP	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.69	10.41	0.55	2.99e-21	Lewy body disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12180372	chr14:94547582	DDX24;IFI27L1	0.5	6.86	0.4	5.46e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7709377	0.620	rs7729396	chr5:115461826	C/T	cg23108291	chr5:115420582	COMMD10	0.41	4.94	0.3	1.43e-6	Metabolite levels  (X-11787);
KIRP	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg04998671	chr14:104000505	TRMT61A	-0.66	-6.19	-0.37	2.5e-9	Coronary artery disease;
KIRP	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg11130432	chr3:121712080	ILDR1	-0.43	-5.09	-0.31	7.24e-7	Multiple sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15040075	chr2:232379222	C2orf52	0.48	6.3	0.37	1.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg17885191	chr8:135476712	NA	0.52	6.04	0.36	5.81e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.53	-5.68	-0.34	3.89e-8	Body mass index;
KIRP	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.65	-10.52	-0.56	1.27e-21	Morning vs. evening chronotype;
KIRP	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.41	-6.28	-0.37	1.53e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.72	10.24	0.55	1e-20	High light scatter reticulocyte count;
KIRP	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg07988820	chr12:82153109	PPFIA2	0.56	6.97	0.41	2.92e-11	Resting heart rate;
KIRP	cis	rs228437	0.529	rs112095449	chr6:135003315	C/T	cg24504307	chr6:134963096	NA	0.45	5.15	0.31	5.36e-7	Melanoma;
KIRP	cis	rs754423	0.558	rs10498441	chr14:52544224	C/T	cg16066272	chr14:52535949	NID2	-0.37	-5.6	-0.34	5.75e-8	Craniofacial microsomia;
KIRP	cis	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg21625330	chr8:9911636	MSRA	0.4	4.95	0.3	1.38e-6	Neuroticism;
KIRP	cis	rs77956314	0.792	rs117924143	chr12:117440958	T/C	cg02017074	chr12:117425053	FBXW8	-0.95	-5.84	-0.35	1.66e-8	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs16828019	0.704	rs34660906	chr1:41551968	C/T	cg18742814	chr1:41828276	NA	0.83	5.96	0.36	8.52e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.9	0.71	1.19e-39	Metabolic syndrome;
KIRP	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21643547	chr1:205240462	TMCC2	-0.7	-10.31	-0.55	5.81e-21	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08267614	chr19:11485407	C19orf39	0.55	6.89	0.4	4.64e-11	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20161774	chr10:126490235	FAM175B	0.51	6.37	0.38	9.44e-10	Parkinson's disease;
KIRP	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.41	-5.17	-0.31	4.81e-7	Menarche (age at onset);
KIRP	cis	rs58688157	0.921	rs35600572	chr11:617214	A/G	cg16486109	chr11:613632	IRF7	0.41	4.96	0.3	1.33e-6	Systemic lupus erythematosus;
KIRP	cis	rs10465746	0.780	rs11163872	chr1:84421969	G/T	cg10977910	chr1:84465055	TTLL7	0.57	7.21	0.42	6.82e-12	Obesity-related traits;
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg17294928	chr15:75287854	SCAMP5	0.39	5.28	0.32	2.79e-7	Breast cancer;
KIRP	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.21e-6	Morning vs. evening chronotype;
KIRP	cis	rs17041941	1.000	rs17041941	chr2:111993364	G/A	cg23466623	chr2:111982296	NA	0.54	5.7	0.34	3.35e-8	Cognitive function;
KIRP	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.49	-6.77	-0.4	9.2e-11	Birth weight;
KIRP	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.65	-8.31	-0.47	6.71e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs580438	0.529	rs4684130	chr3:13409528	C/T	cg10657019	chr3:13328039	NA	-0.52	-6.79	-0.4	8.22e-11	Myringotomy;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13198984	chr17:80129470	CCDC57	-0.58	-8.78	-0.49	2.83e-16	Life satisfaction;
KIRP	cis	rs7572263	0.874	rs9646836	chr2:209055610	C/A	cg23998903	chr2:209048830	C2orf80	0.31	5.36	0.32	1.89e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg11382394	chr1:2564504	MMEL1	0.4	5.08	0.31	7.6e-7	Ulcerative colitis;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.84	-10.48	-0.56	1.78e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16936870	0.602	rs2958365	chr8:71155500	T/G	cg14232793	chr8:71155543	NCOA2	-0.58	-6.82	-0.4	6.86e-11	QT interval;
KIRP	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.72	8.87	0.49	1.49e-16	Cognitive function;
KIRP	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.74	9.52	0.52	1.74e-18	Coronary artery disease;
KIRP	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg12560992	chr17:57184187	TRIM37	0.44	5.26	0.32	3.17e-7	Cognitive test performance;
KIRP	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg16751203	chr2:127950803	CYP27C1	0.38	5.02	0.31	9.74e-7	Protein C levels;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-5.97	-0.36	8.37e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.48e-20	Dupuytren's disease;
KIRP	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-21.95	-0.81	7.26e-60	Exhaled nitric oxide output;
KIRP	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg01620082	chr3:125678407	NA	1.13	7.31	0.42	3.7e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	0.93	12.23	0.61	3.47e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7395581	0.918	rs10838692	chr11:47345100	T/C	cg26139080	chr11:47293733	MADD	-0.42	-5.12	-0.31	6.13e-7	HDL cholesterol;
KIRP	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg21918786	chr6:109611834	NA	0.42	5.95	0.35	9.14e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7289126	0.966	rs2284072	chr22:38633666	A/C	cg25457927	chr22:38595422	NA	-0.31	-6.87	-0.4	5.2e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs7084402	0.902	rs1649017	chr10:60288531	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.77e-23	Refractive error;
KIRP	cis	rs7119	0.637	rs11636231	chr15:77854876	A/C	cg12131826	chr15:77904385	NA	0.45	5.24	0.32	3.53e-7	Type 2 diabetes;
KIRP	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.81	-0.35	1.89e-8	Diastolic blood pressure;
KIRP	cis	rs6453429	0.753	rs6453427	chr5:78361789	A/G	cg06501366	chr5:78365687	BHMT2;DMGDH	-0.32	-5.05	-0.31	8.73e-7	Urinary metabolites;
KIRP	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.49	0.48	2.01e-15	Lung cancer in ever smokers;
KIRP	cis	rs4363385	0.510	rs6693927	chr1:153044009	G/A	cg07796016	chr1:152779584	LCE1C	-0.46	-5.89	-0.35	1.3e-8	Inflammatory skin disease;
KIRP	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.32	5.19	0.31	4.49e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg13978929	chr19:21580086	ZNF493	-0.51	-5.05	-0.31	8.53e-7	Pain;
KIRP	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.66	7.89	0.45	9.72e-14	Platelet count;
KIRP	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg00405596	chr8:11794950	NA	0.59	8.37	0.47	4.5e-15	Neuroticism;
KIRP	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs7760949	0.852	rs9349847	chr6:13927711	T/C	cg27413430	chr6:13925136	RNF182	0.42	5.22	0.32	3.85e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs888194	0.651	rs6606734	chr12:110013639	T/G	cg05360138	chr12:110035743	NA	0.41	5.05	0.31	8.45e-7	Neuroticism;
KIRP	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.87	-0.6	5.58e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs662064	0.692	rs12129512	chr1:10572967	G/T	cg19773385	chr1:10388646	KIF1B	-0.5	-5.83	-0.35	1.74e-8	Asthma;
KIRP	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12311346	chr5:56204834	C5orf35	-0.49	-6.69	-0.39	1.48e-10	Coronary artery disease;
KIRP	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg07212818	chr11:638076	DRD4	-0.42	-5.25	-0.32	3.33e-7	Systemic lupus erythematosus;
KIRP	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.77	-10.97	-0.57	4.61e-23	Plateletcrit;Platelet count;
KIRP	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg05347473	chr6:146136440	FBXO30	0.45	6.39	0.38	8.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg00814883	chr7:100076585	TSC22D4	-0.56	-5.94	-0.35	9.78e-9	Lung function (FEV1/FVC);
KIRP	cis	rs6132905	0.590	rs113594194	chr20:2626876	G/A	cg24848351	chr20:2622020	TMC2	-0.64	-5.85	-0.35	1.52e-8	Mumps;
KIRP	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.29	-0.32	2.74e-7	Colorectal cancer;
KIRP	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg09904177	chr6:26538194	HMGN4	-0.42	-5.17	-0.31	4.93e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs71277158	0.688	rs2287483	chr3:169756846	C/T	cg04067573	chr3:169899625	PHC3	0.65	5.76	0.34	2.55e-8	Prostate cancer;
KIRP	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg10932868	chr11:921992	NA	0.51	5.8	0.35	2.03e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg01877450	chr7:97915802	BRI3	-0.55	-7.11	-0.41	1.23e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11967485	0.609	rs62435822	chr6:157164199	G/A	cg23222435	chr6:157204239	ARID1B	-0.69	-5.13	-0.31	5.92e-7	Calcium levels;
KIRP	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.95e-8	Type 2 diabetes;
KIRP	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg12623918	chr2:306882	NA	0.46	5.8	0.35	2.07e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9826463	0.702	rs28365824	chr3:142315114	C/A	cg20824294	chr3:142316082	PLS1	0.42	6.55	0.39	3.3e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs26949	0.511	rs1562235	chr5:59877538	T/G	cg02684056	chr5:59996105	DEPDC1B	0.43	5.17	0.31	4.92e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs4938303	0.633	rs61906081	chr11:116537059	G/A	cg13754915	chr9:140174272	C9orf167	-0.73	-6.14	-0.36	3.23e-9	Triglycerides;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.79	9.94	0.54	8.68e-20	Longevity;
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.2	0.51	1.58e-17	Lung cancer;
KIRP	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.05	0.31	8.68e-7	Colorectal cancer;
KIRP	cis	rs14403	0.874	rs2994327	chr1:243650858	C/T	cg21452805	chr1:244014465	NA	0.5	5.38	0.32	1.69e-7	Schizophrenia;
KIRP	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.68	-7.81	-0.45	1.64e-13	Alcohol dependence;
KIRP	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg08923054	chr8:41654455	ANK1	0.72	7.91	0.45	8.6e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09570585	chr7:138916241	UBN2	0.44	6.14	0.36	3.35e-9	Survival in pancreatic cancer;
KIRP	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.38	-5.85	-0.35	1.56e-8	Body mass index;
KIRP	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-8.21	-0.46	1.29e-14	Personality dimensions;
KIRP	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.43	5.98	0.36	7.85e-9	Childhood ear infection;
KIRP	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg13010199	chr12:38710504	ALG10B	0.58	7.25	0.42	5.48e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.64	-0.34	4.7e-8	Obesity-related traits;
KIRP	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.54	5.65	0.34	4.49e-8	Response to diuretic therapy;
KIRP	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.58	11.9	0.6	4.44e-26	Diabetic kidney disease;
KIRP	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg22676075	chr6:135203613	NA	0.5	6.52	0.38	4.03e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg15436174	chr10:43711423	RASGEF1A	0.8	8.25	0.47	9.76e-15	Hirschsprung disease;
KIRP	cis	rs17102884	0.600	rs9671386	chr14:75151047	G/A	cg08847533	chr14:75593920	NEK9	0.44	4.9	0.3	1.77e-6	Neuroticism;
KIRP	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg16105309	chr15:79090380	ADAMTS7	0.61	7.93	0.45	7.45e-14	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10321119	chr14:76450724	C14orf179	0.53	6.74	0.39	1.09e-10	Interleukin-4 levels;
KIRP	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.23	-0.37	1.96e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma (childhood onset);
KIRP	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg15841412	chr13:111365552	ING1	0.49	5.47	0.33	1.12e-7	Coronary artery disease;
KIRP	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.61	-6.97	-0.41	2.81e-11	Platelet distribution width;
KIRP	cis	rs427941	0.632	rs201478	chr7:101746964	G/C	cg06246474	chr7:101738831	CUX1	0.53	6.49	0.38	4.6e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4700695	0.764	rs152993	chr5:65262968	A/T	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg06521331	chr12:34319734	NA	-0.5	-6.14	-0.36	3.36e-9	Morning vs. evening chronotype;
KIRP	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg01378222	chr16:28622494	SULT1A1	-0.67	-6.34	-0.37	1.09e-9	Platelet distribution width;
KIRP	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg26681399	chr22:41777847	TEF	0.51	5.19	0.31	4.41e-7	Vitiligo;
KIRP	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.46	5.83	0.35	1.75e-8	Recombination rate (males);
KIRP	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg00982548	chr2:198649783	BOLL	-0.58	-5.12	-0.31	6.15e-7	Ulcerative colitis;
KIRP	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg07148914	chr20:33460835	GGT7	-0.53	-7.3	-0.42	3.88e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs4389656	0.743	rs34681760	chr5:6712834	T/C	cg10857441	chr5:6722123	POLS	-0.46	-6.46	-0.38	5.67e-10	Coronary artery disease;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.56	-5.49	-0.33	9.97e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	1.05	17.44	0.74	6.65e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg22676075	chr6:135203613	NA	0.52	7.71	0.44	3.17e-13	Red blood cell count;
KIRP	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.71	0.49	4.44e-16	Lymphocyte counts;
KIRP	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg13012494	chr21:47604986	C21orf56	-0.38	-4.88	-0.3	1.89e-6	Testicular germ cell tumor;
KIRP	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.56	8.54	0.48	1.43e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7737355	0.945	rs245801	chr5:130666955	T/C	cg06647332	chr5:131281008	NA	-0.46	-5.05	-0.31	8.66e-7	Life satisfaction;
KIRP	cis	rs42235	0.683	rs2282983	chr7:92279363	A/G	cg15732164	chr7:92237376	CDK6	-0.35	-4.93	-0.3	1.49e-6	Hip circumference adjusted for BMI;Height;
KIRP	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg02160872	chr5:212506	CCDC127	-0.47	-5.15	-0.31	5.43e-7	Breast cancer;
KIRP	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg06766960	chr11:133703094	NA	-0.74	-10.28	-0.55	7.2e-21	Childhood ear infection;
KIRP	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.69	9.56	0.52	1.24e-18	Temperament;
KIRP	trans	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg25042112	chr7:64838748	ZNF92	-0.6	-6.34	-0.37	1.1e-9	Pain;
KIRP	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	1.1	16.11	0.72	2.38e-40	Multiple sclerosis;
KIRP	cis	rs4523957	0.928	rs10852932	chr17:2143460	G/T	cg16513277	chr17:2031491	SMG6	-0.58	-7.96	-0.45	6.51e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16047223	chr3:195610084	TNK2	0.49	6.1	0.36	4.13e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs78761021	0.720	rs7220089	chr17:9796985	G/A	cg26853458	chr17:9805074	RCVRN	0.52	5.05	0.31	8.81e-7	Type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.82	0.4	7.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs526231	0.543	rs34789	chr5:102460739	A/T	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg00677455	chr12:58241039	CTDSP2	-0.52	-5.8	-0.35	2.02e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs72730918	0.590	rs2606146	chr15:51985564	T/C	cg14296394	chr15:51910925	DMXL2	-0.71	-10.0	-0.54	5.76e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2400749	0.739	rs4268691	chr14:100034907	G/A	cg19965031	chr14:100038389	CCDC85C	-0.42	-5.07	-0.31	7.65e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2411233	0.811	rs3910264	chr15:39262124	A/G	cg19287857	chr15:39890699	NA	0.45	6.33	0.37	1.18e-9	Platelet count;
KIRP	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg23649088	chr2:200775458	C2orf69	0.69	5.99	0.36	7.51e-9	Schizophrenia;
KIRP	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-6.24	-0.37	1.89e-9	Bladder cancer;
KIRP	cis	rs10083777	0.551	rs79623059	chr16:81007245	G/A	cg08591886	chr16:81111003	C16orf46	-0.7	-5.11	-0.31	6.62e-7	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.55	6.92	0.4	3.87e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg14784868	chr12:69753453	YEATS4	0.51	5.25	0.32	3.33e-7	Response to diuretic therapy;
KIRP	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg27205649	chr11:78285834	NARS2	-0.59	-6.87	-0.4	5.23e-11	Testicular germ cell tumor;
KIRP	cis	rs9399401	0.634	rs984932	chr6:142803037	C/T	cg09547025	chr6:142721804	GPR126	-0.37	-4.87	-0.3	1.99e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	cg04338863	chr8:33670619	NA	0.4	5.42	0.33	1.43e-7	Body mass index;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg10254082	chr7:997346	NA	0.47	4.9	0.3	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.75	-0.63	6.4e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs118105804	1.000	rs10765621	chr11:93402693	A/G	cg10353388	chr11:93474820	C11orf54;TAF1D	-1.32	-7.18	-0.42	8.09e-12	Scarlet fever;
KIRP	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg26681399	chr22:41777847	TEF	0.5	5.26	0.32	3.19e-7	Vitiligo;
KIRP	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-8.1	-0.46	2.52e-14	Chronic sinus infection;
KIRP	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	7.48	0.43	1.3e-12	Iron status biomarkers;
KIRP	cis	rs4073416	0.542	rs11158604	chr14:66094450	G/A	cg03016385	chr14:66212404	NA	-0.54	-6.58	-0.39	2.73e-10	N-glycan levels;
KIRP	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg26690034	chr1:75198963	CRYZ;TYW3	0.41	4.98	0.3	1.22e-6	Resistin levels;
KIRP	cis	rs7923609	0.870	rs10822156	chr10:65080727	T/C	cg08743896	chr10:65200160	JMJD1C	-0.36	-5.24	-0.32	3.4e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.69	-10.1	-0.54	2.76e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3736485	0.966	rs7174435	chr15:51895065	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.15	-0.31	5.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6496667	0.642	rs12148876	chr15:91065208	G/A	cg10434728	chr15:90938212	IQGAP1	0.33	4.88	0.3	1.91e-6	Rheumatoid arthritis;
KIRP	cis	rs3774830	0.846	rs11731730	chr4:5454545	C/T	cg26943120	chr4:5472116	STK32B	0.24	6.05	0.36	5.4e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7999699	0.967	rs66463258	chr13:48326728	C/T	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.65	-8.04	-0.46	3.89e-14	Aortic root size;
KIRP	cis	rs11673344	0.864	rs8107192	chr19:37499627	G/A	cg14683738	chr19:37701593	ZNF585B	-0.44	-5.06	-0.31	8.4e-7	Obesity-related traits;
KIRP	cis	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.45e-9	HDL cholesterol;
KIRP	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.56e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg13010199	chr12:38710504	ALG10B	0.51	6.09	0.36	4.25e-9	Morning vs. evening chronotype;
KIRP	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg08645402	chr16:4508243	NA	0.49	6.42	0.38	7.12e-10	Schizophrenia;
KIRP	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg01872077	chr2:219646372	CYP27A1	0.41	5.44	0.33	1.32e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg11993925	chr19:44307056	LYPD5	0.42	5.64	0.34	4.71e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg12963866	chr19:57752005	ZNF805	0.44	5.59	0.34	6.08e-8	Hyperactive-impulsive symptoms;
KIRP	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-4.99	-0.3	1.14e-6	Personality dimensions;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg02733842	chr7:1102375	C7orf50	0.45	4.92	0.3	1.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg04607699	chr11:48328132	OR4S1	-0.35	-4.94	-0.3	1.46e-6	HDL cholesterol;
KIRP	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9473924	0.542	rs2817378	chr6:50789197	G/A	cg14470998	chr6:50812995	TFAP2B	0.99	8.91	0.49	1.14e-16	Body mass index;
KIRP	cis	rs12643440	0.538	rs2314599	chr4:17139624	A/G	cg22650099	chr4:17144496	NA	-0.71	-8.86	-0.49	1.64e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	1.03	18.99	0.77	4.16e-50	Heart rate;
KIRP	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7084402	0.934	rs1658428	chr10:60330917	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg09658497	chr7:2847517	GNA12	-0.35	-4.9	-0.3	1.74e-6	Height;
KIRP	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg10818794	chr15:86012489	AKAP13	-0.52	-7.33	-0.42	3.38e-12	Coronary artery disease;
KIRP	cis	rs6438504	0.922	rs4528932	chr3:118941441	C/T	cg25372693	chr3:118959985	B4GALT4	0.32	5.53	0.33	8.31e-8	Clozapine-induced cytotoxicity;
KIRP	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg17788362	chr6:86352627	SYNCRIP	-0.45	-6.08	-0.36	4.53e-9	Smooth-surface caries;
KIRP	cis	rs7246967	0.673	rs59621958	chr19:22940659	C/T	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg05342945	chr12:48394962	COL2A1	-0.46	-4.93	-0.3	1.53e-6	Lung cancer;
KIRP	cis	rs62229266	1.000	rs62229266	chr21:37460271	A/T	cg08632701	chr21:37451849	NA	-0.43	-5.29	-0.32	2.66e-7	Mitral valve prolapse;
KIRP	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg22951263	chr5:87985283	NA	-0.47	-6.65	-0.39	1.89e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.83	-11.85	-0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.27e-11	Diabetic kidney disease;
KIRP	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.1	-0.36	4.13e-9	Systolic blood pressure;
KIRP	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg22676075	chr6:135203613	NA	0.47	6.59	0.39	2.69e-10	Red blood cell count;
KIRP	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00149659	chr3:10157352	C3orf10	0.96	10.41	0.55	2.85e-21	Alzheimer's disease;
KIRP	cis	rs1620921	0.505	rs12526591	chr6:161204311	T/A	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.64	8.55	0.48	1.35e-15	Height;
KIRP	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg13266496	chr6:110720918	DDO	-0.34	-5.41	-0.33	1.46e-7	Platelet distribution width;
KIRP	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.62	7.05	0.41	1.78e-11	Aortic root size;
KIRP	cis	rs7078219	0.505	rs10883371	chr10:101292455	G/T	cg07044859	chr10:101282883	NA	-0.29	-5.24	-0.32	3.38e-7	Dental caries;
KIRP	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03576123	chr11:487126	PTDSS2	-1.13	-9.71	-0.53	4.45e-19	Body mass index;
KIRP	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg23250157	chr14:64679961	SYNE2	-0.47	-5.2	-0.31	4.21e-7	Atrial fibrillation;
KIRP	trans	rs2998286	0.723	rs332168	chr10:28896417	C/T	cg10174683	chr16:85619974	NA	-0.64	-6.06	-0.36	5.1e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.52	-4.89	-0.3	1.84e-6	Alzheimer's disease;
KIRP	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.5	-4.99	-0.3	1.16e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12476592	0.571	rs10865341	chr2:63824050	A/T	cg17519650	chr2:63277830	OTX1	-0.46	-5.06	-0.31	8.15e-7	Childhood ear infection;
KIRP	cis	rs151997	0.925	rs27287	chr5:50195567	C/A	cg06027927	chr5:50259733	NA	0.61	7.6	0.44	6.21e-13	Callous-unemotional behaviour;
KIRP	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.7	10.62	0.56	6.1e-22	Dupuytren's disease;
KIRP	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.5	-0.38	4.37e-10	Triglycerides;
KIRP	cis	rs2411233	0.837	rs12907480	chr15:39250334	C/T	cg02291532	chr15:39874776	THBS1	0.49	6.5	0.38	4.47e-10	Platelet count;
KIRP	trans	rs12517041	1.000	rs7734125	chr5:23300072	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.87	-7.96	-0.45	6.4e-14	Calcium levels;
KIRP	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.89	14.03	0.67	3.05e-33	Breast cancer;
KIRP	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg18402987	chr7:1209562	NA	0.74	5.22	0.32	3.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg04539111	chr16:67997858	SLC12A4	-0.68	-6.9	-0.4	4.27e-11	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.59	-0.34	5.99e-8	Life satisfaction;
KIRP	cis	rs397969	0.596	rs9901294	chr17:19888501	G/A	cg04132472	chr17:19861366	AKAP10	0.55	6.91	0.4	4.21e-11	Platelet count;
KIRP	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg04691961	chr3:161091175	C3orf57	0.45	6.67	0.39	1.63e-10	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-10.86	-0.57	1.06e-22	Colorectal cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04044983	chr16:67280079	FHOD1	0.49	6.07	0.36	4.74e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg02527881	chr3:46936655	PTH1R	-0.49	-7.05	-0.41	1.78e-11	Birth weight;
KIRP	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg05342945	chr12:48394962	COL2A1	-0.48	-5.35	-0.32	1.97e-7	Lung cancer;
KIRP	cis	rs687432	0.924	rs7123570	chr11:57705948	G/A	cg19752551	chr11:57585705	CTNND1	-0.54	-7.49	-0.43	1.2e-12	Parkinson's disease;
KIRP	cis	rs4666002	0.750	rs13021208	chr2:27901728	C/T	cg27432699	chr2:27873401	GPN1	0.58	5.59	0.34	5.9e-8	Phospholipid levels (plasma);
KIRP	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.67	-9.48	-0.52	2.25e-18	QRS duration;
KIRP	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg03563238	chr19:33554763	RHPN2	-0.33	-5.65	-0.34	4.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.8	0.4	7.82e-11	Aortic root size;
KIRP	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.02	-0.36	6.33e-9	Personality dimensions;
KIRP	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg18944383	chr4:111397179	ENPEP	0.4	6.41	0.38	7.31e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1659258	0.568	rs1258436	chr2:88608962	G/T	cg00685853	chr2:88648947	NA	-0.54	-6.47	-0.38	5.29e-10	Visceral fat;
KIRP	cis	rs6500395	0.588	rs1011666	chr16:48704293	T/C	cg04672837	chr16:48644449	N4BP1	-0.38	-5.24	-0.32	3.53e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.06	-13.14	-0.64	3.11e-30	Vitiligo;
KIRP	cis	rs10073892	0.511	rs6864567	chr5:101867396	C/T	cg19774478	chr5:101632501	SLCO4C1	0.53	5.69	0.34	3.63e-8	Cognitive decline (age-related);
KIRP	cis	rs963731	0.649	rs4670272	chr2:39260468	A/C	cg04010122	chr2:39346883	SOS1	-1.02	-6.82	-0.4	7.09e-11	Corticobasal degeneration;
KIRP	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05220968	chr6:146057943	EPM2A	0.39	4.85	0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-4.9	-0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.08	-0.31	7.59e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg14675211	chr2:100938903	LONRF2	0.56	7.17	0.42	8.92e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.79	-7.32	-0.42	3.58e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs13102973	1.000	rs7439938	chr4:135897696	G/A	cg14419869	chr4:135874104	NA	-0.5	-8.17	-0.46	1.68e-14	Subjective well-being;
KIRP	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.58	7.0	0.41	2.49e-11	Osteoporosis;
KIRP	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg17863274	chr19:49399704	TULP2	-0.4	-5.72	-0.34	3.12e-8	Red cell distribution width;
KIRP	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg02836325	chr17:76403955	PGS1	0.37	6.06	0.36	4.94e-9	HDL cholesterol levels;
KIRP	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg00310523	chr12:86230176	RASSF9	-0.4	-6.15	-0.36	3.16e-9	Major depressive disorder;
KIRP	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg04117972	chr1:227635322	NA	0.64	4.97	0.3	1.26e-6	Major depressive disorder;
KIRP	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24110177	chr3:50126178	RBM5	0.64	8.22	0.46	1.19e-14	Menarche (age at onset);
KIRP	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.59	5.54	0.33	7.59e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg02725872	chr8:58115012	NA	-0.53	-6.15	-0.37	3.1e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.92	9.91	0.53	1.08e-19	Body mass index;
KIRP	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	11.01	0.57	3.45e-23	Nonalcoholic fatty liver disease;
KIRP	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.56	7.11	0.41	1.22e-11	Coronary artery disease;
KIRP	trans	rs7939886	0.688	rs11227290	chr11:55896577	A/G	cg03929089	chr4:120376271	NA	0.93	6.78	0.4	8.74e-11	Myopia (pathological);
KIRP	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.68	-12.25	-0.62	3.05e-27	Body mass index;
KIRP	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.5	0.33	9.44e-8	Body mass index;
KIRP	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.08e-6	Calcium levels;
KIRP	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg26205652	chr12:48591994	NA	0.79	10.69	0.56	3.79e-22	Longevity (90 years and older);
KIRP	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.58e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.8	10.78	0.57	1.97e-22	Morning vs. evening chronotype;
KIRP	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg19849509	chr2:175204996	NA	-0.53	-6.34	-0.37	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.99	-0.3	1.14e-6	Cognitive function;
KIRP	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-5.85	-0.35	1.58e-8	Chronic sinus infection;
KIRP	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.71	11.1	0.58	1.75e-23	Resting heart rate;
KIRP	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg26531700	chr6:26746687	NA	0.41	5.48	0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg07382826	chr16:28625726	SULT1A1	0.47	5.42	0.33	1.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.79	14.72	0.68	1.31e-35	Lymphocyte counts;
KIRP	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg19539972	chr4:7069911	GRPEL1	0.4	5.17	0.31	4.91e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg18882449	chr10:104885122	NT5C2	-0.51	-6.47	-0.38	5.23e-10	Arsenic metabolism;
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg21851534	chr17:3907994	ZZEF1	0.65	10.62	0.56	6.25e-22	Type 2 diabetes;
KIRP	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg13010199	chr12:38710504	ALG10B	0.67	8.68	0.48	5.57e-16	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg13180566	chr4:1052158	NA	-0.54	-5.47	-0.33	1.09e-7	Recombination rate (females);
KIRP	cis	rs1568889	0.592	rs17652117	chr11:28483645	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.74	-7.75	-0.44	2.37e-13	Bipolar disorder;
KIRP	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs4908768	0.594	rs11121228	chr1:8830642	T/C	cg25722041	chr1:8623473	RERE	0.57	7.39	0.43	2.3e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.57	7.17	0.42	8.94e-12	Arsenic metabolism;
KIRP	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	0.84	7.95	0.45	6.67e-14	Methadone dose in opioid dependence;
KIRP	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg05220968	chr6:146057943	EPM2A	-0.4	-5.08	-0.31	7.59e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7188697	0.809	rs4784956	chr16:58596291	A/C	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.69	8.45	0.47	2.54e-15	Neutrophil percentage of white cells;
KIRP	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-0.87	-12.51	-0.62	3.93e-28	Dupuytren's disease;
KIRP	cis	rs9378357	0.614	rs4076221	chr6:3290726	A/G	cg03657281	chr6:3270030	SLC22A23	0.51	5.89	0.35	1.25e-8	Obesity-related traits;
KIRP	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg03465714	chr1:152285911	FLG	-0.41	-4.94	-0.3	1.46e-6	Atopic dermatitis;
KIRP	cis	rs4262150	0.883	rs72799198	chr5:152190705	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.46	-0.47	2.43e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg15848620	chr12:58087721	OS9	-0.44	-5.08	-0.31	7.39e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21659725	chr3:3221576	CRBN	0.51	6.16	0.37	2.95e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg27147174	chr7:100797783	AP1S1	-0.73	-9.34	-0.51	6.12e-18	Life satisfaction;
KIRP	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.6	-8.66	-0.48	6.25e-16	Blood metabolite levels;
KIRP	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05665937	chr4:1216051	CTBP1	0.51	7.02	0.41	2.21e-11	Obesity-related traits;
KIRP	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg25182066	chr10:30743637	MAP3K8	-0.64	-8.67	-0.48	6.01e-16	Inflammatory bowel disease;
KIRP	cis	rs9443189	1.000	rs9443189	chr6:76495882	A/G	cg01950844	chr6:76311363	SENP6	0.54	5.42	0.33	1.41e-7	Prostate cancer;
KIRP	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.81	0.53	2.22e-19	Dupuytren's disease;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	14.83	0.69	5.56e-36	Platelet count;
KIRP	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg13147721	chr7:65941812	NA	-0.96	-7.07	-0.41	1.56e-11	Gout;
KIRP	cis	rs1009181	0.585	rs72834696	chr6:26161399	G/A	cg00631329	chr6:26305371	NA	-0.55	-5.75	-0.34	2.66e-8	Childhood ear infection;
KIRP	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.57	8.31	0.47	6.44e-15	Metabolite levels;
KIRP	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg09163369	chr1:210001066	C1orf107	0.47	5.23	0.32	3.65e-7	Orofacial clefts;
KIRP	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg17294928	chr15:75287854	SCAMP5	-0.57	-5.52	-0.33	8.7e-8	Blood trace element (Zn levels);
KIRP	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	0.82	7.19	0.42	7.71e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg20701182	chr2:24300061	SF3B14	0.6	5.29	0.32	2.66e-7	Lymphocyte counts;
KIRP	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg23188430	chr6:125850052	NA	-0.34	-5.39	-0.33	1.65e-7	Brugada syndrome;
KIRP	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.18	21.23	0.8	1.54e-57	Cognitive function;
KIRP	cis	rs17030434	0.815	rs78638854	chr4:154648804	C/T	cg14289246	chr4:154710475	SFRP2	-0.73	-8.41	-0.47	3.32e-15	Electrocardiographic conduction measures;
KIRP	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.33	0.47	5.55e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01114163	chr5:1856713	NA	-0.45	-5.48	-0.33	1.03e-7	Cardiovascular disease risk factors;
KIRP	cis	rs4654899	0.865	rs61779065	chr1:21356474	A/T	cg05370193	chr1:21551575	ECE1	0.47	5.91	0.35	1.16e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10754283	0.934	rs6661282	chr1:90119992	C/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.72	0.53	4.19e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.83	10.95	0.57	5.27e-23	Primary sclerosing cholangitis;
KIRP	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7106204	0.764	rs7949823	chr11:24213668	C/G	ch.11.24196551F	chr11:24239977	NA	0.84	8.4	0.47	3.64e-15	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12988725	chr2:47142883	MCFD2	0.52	6.7	0.39	1.44e-10	Parkinson's disease;
KIRP	trans	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	6.12	0.36	3.74e-9	Ulcerative colitis;
KIRP	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.64	8.26	0.47	9.09e-15	Alcohol dependence;
KIRP	cis	rs282587	0.569	rs192530	chr13:113388303	A/G	cg04656015	chr13:113407548	ATP11A	0.63	7.35	0.42	2.95e-12	Glycated hemoglobin levels;
KIRP	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-6.41	-0.38	7.38e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6662572	0.578	rs6662307	chr1:46287287	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.55	0.33	7.57e-8	Blood protein levels;
KIRP	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg23594656	chr7:65796392	TPST1	0.51	7.9	0.45	9.44e-14	Aortic root size;
KIRP	cis	rs6499755	0.768	rs79085284	chr16:55362377	C/T	cg05099576	chr16:55362342	IRX6	0.35	7.02	0.41	2.1e-11	Hypospadias;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg01391022	chr12:122360665	WDR66	-0.35	-5.19	-0.31	4.37e-7	Mean corpuscular volume;
KIRP	cis	rs9535307	0.929	rs7984061	chr13:50337340	G/A	cg04663916	chr13:50265991	EBPL	0.66	6.85	0.4	5.97e-11	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13082711	1.000	rs6791212	chr3:27507179	C/A	cg02860705	chr3:27208620	NA	0.56	7.7	0.44	3.24e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg08890418	chr1:21044141	KIF17	0.34	4.98	0.3	1.2e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10073892	0.662	rs2123132	chr5:101640251	A/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.76	8.23	0.46	1.08e-14	Uric acid levels;
KIRP	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.76	-0.44	2.29e-13	Height;
KIRP	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.72	9.18	0.51	1.78e-17	Bladder cancer;
KIRP	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-5.66	-0.34	4.22e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.55	-7.81	-0.45	1.62e-13	Coronary artery disease;
KIRP	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.62	7.23	0.42	5.93e-12	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20624538	chr11:118662171	DDX6	0.46	6.04	0.36	5.53e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00338735	chr4:53728038	RASL11B	0.49	5.79	0.35	2.13e-8	Optic nerve measurement (cup area);
KIRP	trans	rs6464816	0.668	rs2074712	chr7:147259728	C/T	cg04662649	chr15:41191689	VPS18	0.54	6.08	0.36	4.44e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg02462569	chr6:150064036	NUP43	-0.33	-4.88	-0.3	1.87e-6	Lung cancer;
KIRP	cis	rs240764	0.746	rs240153	chr6:101067135	A/C	cg09795085	chr6:101329169	ASCC3	0.44	5.29	0.32	2.71e-7	Neuroticism;
KIRP	cis	rs3789045	0.774	rs4252733	chr1:204516918	C/T	cg18185008	chr1:204589407	LRRN2	-0.62	-6.7	-0.39	1.4e-10	Educational attainment (college completion);
KIRP	cis	rs1903068	1.000	rs9312658	chr4:56005526	C/A	cg01777861	chr4:56023843	NA	0.38	4.85	0.3	2.23e-6	Endometriosis;
KIRP	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.76	11.35	0.59	2.66e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg04673462	chr1:38461896	NA	-0.37	-4.89	-0.3	1.82e-6	Coronary artery disease;
KIRP	cis	rs2224391	0.656	rs17140096	chr6:5287255	G/A	cg13962347	chr6:5174647	LYRM4	-0.46	-4.97	-0.3	1.23e-6	Height;
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-6.4	-0.38	7.91e-10	Longevity;Endometriosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14797887	chr15:56757312	MNS1	0.47	6.53	0.38	3.64e-10	Survival in pancreatic cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12714793	chr17:74303886	QRICH2	-0.45	-6.05	-0.36	5.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg09631192	chr20:23583594	CST9	-0.52	-5.2	-0.31	4.27e-7	Chronic kidney disease;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.79	8.87	0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg01689657	chr7:91764605	CYP51A1	-0.36	-5.38	-0.32	1.72e-7	Breast cancer;
KIRP	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.67	0.44	3.94e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.47	-5.72	-0.34	3.11e-8	Longevity;
KIRP	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg17654217	chr7:100282651	GIGYF1	0.51	4.89	0.3	1.82e-6	Other erythrocyte phenotypes;
KIRP	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-7.04	-0.41	1.95e-11	Daytime sleep phenotypes;
KIRP	cis	rs7937612	0.965	rs7932037	chr11:120259430	T/A	cg24566217	chr11:120254723	ARHGEF12	-0.45	-6.53	-0.38	3.74e-10	Intraocular pressure;
KIRP	cis	rs6662572	0.950	rs11579176	chr1:46050561	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.3	0.32	2.58e-7	Blood protein levels;
KIRP	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg09788416	chr12:39539408	NA	0.43	5.43	0.33	1.33e-7	Morning vs. evening chronotype;
KIRP	cis	rs7215564	0.730	rs34484282	chr17:78684663	G/A	cg06153925	chr17:78755379	RPTOR	0.31	5.07	0.31	7.65e-7	Myopia (pathological);
KIRP	cis	rs2400749	0.739	rs8019472	chr14:100025857	T/A	cg19965031	chr14:100038389	CCDC85C	-0.44	-5.3	-0.32	2.6e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2120243	0.539	rs1840673	chr3:157117977	A/G	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs385076	0.536	rs13017027	chr2:32291903	C/T	cg02381751	chr2:32503542	YIPF4	-0.55	-5.01	-0.3	1.03e-6	Interleukin-18 levels;
KIRP	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.64	-9.74	-0.53	3.64e-19	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg21475434	chr5:93447410	FAM172A	-0.46	-5.3	-0.32	2.52e-7	Diabetic retinopathy;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg21851534	chr17:3907994	ZZEF1	0.66	10.71	0.56	3.14e-22	Type 2 diabetes;
KIRP	cis	rs2882667	0.931	rs10044736	chr5:138320809	A/G	cg04439458	chr5:138467593	SIL1	0.41	6.88	0.4	4.81e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg20362242	chr5:692897	TPPP	0.57	4.94	0.3	1.45e-6	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	4.83e-8	Lung cancer;
KIRP	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.39	-0.47	3.84e-15	Total cholesterol levels;
KIRP	cis	rs77861329	0.748	rs747343	chr3:52109407	T/C	cg08692210	chr3:52188851	WDR51A	0.59	5.89	0.35	1.24e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs7709377	0.521	rs2416426	chr5:115437470	T/C	cg23108291	chr5:115420582	COMMD10	0.43	5.15	0.31	5.21e-7	Metabolite levels  (X-11787);
KIRP	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs7005380	0.531	rs7837823	chr8:120910779	T/C	cg21645572	chr8:120931649	DEPDC6	0.42	4.93	0.3	1.48e-6	Interstitial lung disease;
KIRP	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.64	11.8	0.6	9.15e-26	Blood protein levels;
KIRP	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg27124370	chr19:33622961	WDR88	0.56	6.98	0.41	2.77e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	1.1	13.24	0.65	1.4e-30	Type 2 diabetes nephropathy;
KIRP	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.77	8.56	0.48	1.21e-15	Corneal astigmatism;
KIRP	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.35	-5.3	-0.32	2.63e-7	Headache;
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.5	6.64	0.39	1.98e-10	Resistin levels;
KIRP	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg24812749	chr6:127587940	RNF146	0.47	6.09	0.36	4.36e-9	Breast cancer;
KIRP	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.32	0.37	1.21e-9	Obesity-related traits;
KIRP	cis	rs7707921	0.522	rs10065463	chr5:81500280	A/G	cg15871215	chr5:81402204	ATG10	-0.48	-6.39	-0.38	8.23e-10	Breast cancer;
KIRP	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.48	-7.79	-0.44	1.91e-13	Eye color traits;
KIRP	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg03894339	chr8:19674705	INTS10	0.61	7.06	0.41	1.69e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg00262122	chr8:11665843	FDFT1	0.4	4.9	0.3	1.78e-6	Neuroticism;
KIRP	cis	rs2249694	1.000	rs2249695	chr10:135352168	T/C	cg20169779	chr10:135381914	SYCE1	0.45	5.16	0.31	5.11e-7	Obesity-related traits;
KIRP	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	ch.11.42038R	chr11:967971	AP2A2	0.4	5.33	0.32	2.18e-7	Alzheimer's disease (late onset);
KIRP	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-8.23	-0.46	1.09e-14	Coronary artery disease;
KIRP	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg04842962	chr6:43655489	MRPS18A	1.06	12.17	0.61	5.54e-27	IgG glycosylation;
KIRP	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.53	6.9	0.4	4.37e-11	HDL cholesterol;
KIRP	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg26531700	chr6:26746687	NA	0.46	6.23	0.37	2.03e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22117172	chr7:91764530	CYP51A1	0.45	6.14	0.36	3.3e-9	Breast cancer;
KIRP	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.55	-7.61	-0.44	5.82e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2671245	0.509	rs114690596	chr1:56130147	T/A	cg11523071	chr1:56160889	NA	0.42	6.4	0.38	7.71e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg07796016	chr1:152779584	LCE1C	-0.42	-5.33	-0.32	2.19e-7	Inflammatory skin disease;
KIRP	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.77	-10.41	-0.55	2.84e-21	Aortic root size;
KIRP	cis	rs977987	0.843	rs28558946	chr16:75489322	G/T	cg03315344	chr16:75512273	CHST6	0.69	10.65	0.56	4.93e-22	Dupuytren's disease;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.84	-0.71	1.96e-39	Immature fraction of reticulocytes;
KIRP	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg13334819	chr7:99746414	C7orf59	0.53	6.01	0.36	6.53e-9	Coronary artery disease;
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg25703541	chr22:24373054	LOC391322	-0.76	-11.55	-0.59	6.17e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.37	-5.06	-0.31	8.26e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.57	6.11	0.36	3.82e-9	Bipolar disorder;
KIRP	cis	rs1018697	1.000	rs7080587	chr10:104545274	C/T	cg04362960	chr10:104952993	NT5C2	0.47	5.63	0.34	4.81e-8	Colorectal adenoma (advanced);
KIRP	cis	rs9400467	0.506	rs76110409	chr6:111603132	C/A	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.08e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg13160058	chr8:26243215	BNIP3L	0.47	6.97	0.41	2.81e-11	Red cell distribution width;
KIRP	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs2692947	0.589	rs810057	chr2:97015073	T/C	cg23100626	chr2:96804247	ASTL	0.5	6.65	0.39	1.88e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg07741184	chr6:167504864	NA	-0.23	-6.11	-0.36	3.89e-9	Crohn's disease;
KIRP	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg23307798	chr14:103986281	CKB	-0.46	-6.22	-0.37	2.17e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10426930	0.639	rs1136405	chr19:5062814	T/C	cg18473234	chr19:5097819	KDM4B	-0.46	-5.29	-0.32	2.75e-7	Monocyte percentage of white cells;
KIRP	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg11663144	chr21:46675770	NA	-0.56	-7.89	-0.45	9.77e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1829883	0.637	rs2963595	chr5:98734713	C/T	cg08333243	chr5:99726346	NA	0.37	4.91	0.3	1.69e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg07075026	chr17:47091521	IGF2BP1	0.4	7.59	0.44	6.59e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.47	-5.79	-0.35	2.17e-8	Iron status biomarkers;
KIRP	cis	rs12210905	1.000	rs12213361	chr6:27138387	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.76	-6.37	-0.38	9.47e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	9.26	0.51	1.02e-17	Bipolar disorder;
KIRP	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg23920097	chr1:209922102	NA	-0.4	-5.28	-0.32	2.78e-7	Red blood cell count;
KIRP	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-9.37	-0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04004882	chr2:215674386	BARD1	0.71	6.69	0.39	1.47e-10	Neuroblastoma;
KIRP	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.52	0.38	3.99e-10	Educational attainment;
KIRP	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg05361325	chr10:32636312	EPC1	-0.64	-6.08	-0.36	4.62e-9	Sexual dysfunction (female);
KIRP	trans	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg06521331	chr12:34319734	NA	-0.5	-6.22	-0.37	2.17e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.42	4.84	0.3	2.24e-6	Height;
KIRP	cis	rs6568686	0.627	rs174374	chr6:111906055	A/G	cg15721981	chr6:111408429	SLC16A10	0.53	4.91	0.3	1.68e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-1.04	-18.83	-0.77	1.37e-49	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-5.67	-0.34	4.03e-8	Chronic sinus infection;
KIRP	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg04727924	chr7:799746	HEATR2	-0.64	-6.51	-0.38	4.25e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg26441486	chr22:50317300	CRELD2	0.48	5.53	0.33	8.22e-8	Mean platelet volume;
KIRP	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.98	-15.69	-0.71	6.25e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.34	5.35	0.32	2.06e-7	Asthma (childhood onset);
KIRP	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg06115741	chr20:33292138	TP53INP2	-0.36	-4.92	-0.3	1.6e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.54e-10	Fibrinogen levels;
KIRP	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg00361562	chr2:198649771	BOLL	-0.49	-5.04	-0.31	9.11e-7	Ulcerative colitis;
KIRP	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.87e-32	Mean platelet volume;
KIRP	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs231513	0.911	rs124720	chr17:41960141	A/G	cg26893861	chr17:41843967	DUSP3	-0.58	-5.06	-0.31	8.04e-7	Cognitive function;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.6	9.04	0.5	4.72e-17	Menarche (age at onset);
KIRP	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	5.16	0.31	5.14e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs75064307	0.705	rs9868805	chr3:108101619	A/T	cg14703454	chr3:108065259	HHLA2	-0.57	-6.18	-0.37	2.66e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-7.04	-0.41	1.92e-11	Mean corpuscular volume;
KIRP	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.09	-0.36	4.21e-9	Neuroticism;
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.63	9.44	0.52	2.93e-18	Immature fraction of reticulocytes;
KIRP	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-7.77	-0.44	2.15e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs600806	0.683	rs10857788	chr1:110012289	G/A	cg02175308	chr1:109941060	SORT1	-0.27	-4.98	-0.3	1.22e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.41	-4.88	-0.3	1.89e-6	Blood metabolite levels;
KIRP	cis	rs10875746	1.000	rs10875746	chr12:48518264	A/C	cg20731937	chr12:48336164	NA	0.37	4.97	0.3	1.24e-6	Longevity (90 years and older);
KIRP	trans	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg19694781	chr19:47549865	TMEM160	-0.58	-7.63	-0.44	5.21e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs981844	1.000	rs2606324	chr4:154652447	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.02	0.41	2.09e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.85	-0.35	1.57e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	1.19	11.07	0.58	2.17e-23	Lymphocyte counts;
KIRP	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.74	-10.38	-0.55	3.65e-21	White blood cell count;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg13010199	chr12:38710504	ALG10B	-0.46	-5.56	-0.33	6.98e-8	Morning vs. evening chronotype;
KIRP	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.94	-0.35	9.76e-9	Alzheimer's disease (late onset);
KIRP	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	7.92	0.45	8.02e-14	Lung cancer;
KIRP	cis	rs6545883	0.655	rs11893880	chr2:61422019	C/T	cg15711740	chr2:61764176	XPO1	-0.61	-8.03	-0.46	4.06e-14	Tuberculosis;
KIRP	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg10845886	chr2:3471009	TTC15	-0.54	-7.82	-0.45	1.56e-13	Neurofibrillary tangles;
KIRP	cis	rs9535307	0.584	rs61961506	chr13:50401701	C/A	cg04663916	chr13:50265991	EBPL	-0.65	-6.3	-0.37	1.37e-9	Obesity-related traits;
KIRP	cis	rs74181299	0.750	rs58342673	chr2:65347584	T/C	cg05010058	chr2:65284262	CEP68	-0.51	-7.1	-0.41	1.34e-11	Pulse pressure;
KIRP	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg25173405	chr17:45401733	C17orf57	-0.48	-6.4	-0.38	7.99e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg20302533	chr7:39170763	POU6F2	0.25	5.32	0.32	2.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg00666640	chr1:248458726	OR2T12	-0.5	-5.96	-0.36	8.61e-9	Common traits (Other);
KIRP	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.64	7.92	0.45	8.39e-14	Body mass index;
KIRP	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg23601095	chr6:26197514	HIST1H3D	1.06	8.54	0.48	1.38e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg23752985	chr2:85803571	VAMP8	0.61	9.17	0.5	1.97e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs4886920	0.862	rs7179211	chr15:78135931	G/C	cg10461261	chr15:78109450	NA	-0.33	-5.35	-0.32	1.97e-7	Neuroticism;
KIRP	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs7011507	1.000	rs79343834	chr8:49178909	A/C	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7149242	0.961	rs7142683	chr14:101158882	A/G	cg18089426	chr14:101175970	NA	-0.53	-7.13	-0.41	1.14e-11	Platelet count;
KIRP	cis	rs4805834	0.719	rs10853922	chr19:33268425	A/T	cg07201929	chr19:33182834	NUDT19	0.61	4.97	0.3	1.27e-6	Creatinine levels;
KIRP	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.53	5.74	0.34	2.81e-8	Schizophrenia;
KIRP	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.83	-8.91	-0.49	1.18e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.56	7.61	0.44	5.78e-13	Gout;
KIRP	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17376030	chr22:41985996	PMM1	0.61	6.41	0.38	7.28e-10	Vitiligo;
KIRP	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.59	-0.34	5.9e-8	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs2383024	0.645	rs4961567	chr9:17486683	A/C	cg14825633	chr11:69704700	NA	0.43	6.06	0.36	5.18e-9	Pulmonary function decline;
KIRP	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-6.99	-0.41	2.51e-11	Menarche (age at onset);
KIRP	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg00666640	chr1:248458726	OR2T12	0.4	4.98	0.3	1.2e-6	Common traits (Other);
KIRP	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg06121193	chr1:90282411	NA	-0.49	-7.01	-0.41	2.34e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.78	12.17	0.61	5.41e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg06026331	chr20:60912101	LAMA5	-0.47	-6.26	-0.37	1.73e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.89	-0.4	4.56e-11	Type 2 diabetes;
KIRP	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15679981	chr2:45616428	SRBD1	-0.42	-6.38	-0.38	8.82e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs397969	0.646	rs203467	chr17:19809749	C/T	cg04132472	chr17:19861366	AKAP10	0.57	6.6	0.39	2.5e-10	Platelet count;
KIRP	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.12e-22	Coronary artery disease;
KIRP	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.08	-0.36	4.5e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs830383	0.515	rs830233	chr5:165403746	C/T	cg13976338	chr5:165423657	NA	-0.6	-6.43	-0.38	6.56e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.55	7.46	0.43	1.51e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9381107	0.932	rs9394529	chr6:9436737	G/A	cg14735645	chr6:9486422	NA	-0.47	-5.62	-0.34	5.15e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg14593290	chr7:50529359	DDC	-0.77	-9.64	-0.52	7.37e-19	Malaria;
KIRP	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.13	-0.31	5.76e-7	Lung cancer;
KIRP	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.85	0.4	5.96e-11	Tonsillectomy;
KIRP	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.99	-0.5	6.91e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.77	-0.4	9.48e-11	Neuroticism;
KIRP	cis	rs9296736	0.890	rs1359561	chr6:53899341	C/T	cg04374786	chr6:53939321	C6orf142	0.4	5.0	0.3	1.08e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg02002194	chr4:3960332	NA	0.48	6.97	0.41	2.82e-11	Mood instability;
KIRP	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.61	-0.44	5.71e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg20578329	chr17:80767326	TBCD	-0.49	-6.44	-0.38	6.06e-10	Breast cancer;
KIRP	cis	rs62070183	0.882	rs17183600	chr17:31175079	T/C	cg05781649	chr17:31146240	MYO1D	-0.51	-5.13	-0.31	5.78e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.82	-12.23	-0.62	3.4e-27	Asthma;
KIRP	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.73	6.09	0.36	4.39e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.03	15.53	0.7	2.19e-38	Subjective well-being;
KIRP	cis	rs865483	0.860	rs862490	chr17:35850275	T/C	cg06716730	chr17:35851459	DUSP14	0.24	5.8	0.35	2.06e-8	Monocyte count;
KIRP	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.09	-0.31	7.28e-7	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.6	0.34	5.66e-8	Life satisfaction;
KIRP	trans	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg13565492	chr6:43139072	SRF	-0.94	-8.66	-0.48	6.42e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7582180	0.900	rs2309823	chr2:100901557	A/G	cg14675211	chr2:100938903	LONRF2	-0.54	-6.42	-0.38	7.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.63	8.38	0.47	4.22e-15	Lung cancer;
KIRP	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.61	-9.89	-0.53	1.21e-19	Prostate cancer;
KIRP	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.92	-13.94	-0.66	6.29e-33	Monocyte count;
KIRP	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.63	0.39	2.15e-10	Breast cancer;
KIRP	cis	rs4782151	1.000	rs7501294	chr16:9328774	G/A	ch.16.364290R	chr16:9436357	NA	0.32	4.94	0.3	1.44e-6	Cervical cancer;
KIRP	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-4.93	-0.3	1.5e-6	Parkinson's disease;
KIRP	cis	rs2997447	0.600	rs1335759	chr1:26471743	G/T	cg20415053	chr1:26527928	CATSPER4	-0.33	-4.85	-0.3	2.15e-6	QRS complex (12-leadsum);
KIRP	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.35e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs829883	1.000	rs829883	chr12:98879606	G/A	cg25150519	chr12:98850993	NA	0.87	13.14	0.64	3.09e-30	Colorectal adenoma (advanced);
KIRP	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs75216060	0.861	rs9657228	chr8:13819637	A/C	cg12665059	chr8:13787749	NA	0.31	4.89	0.3	1.82e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs12042938	0.600	rs4658880	chr1:231764621	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	6.41	0.38	7.41e-10	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-0.83	-9.6	-0.52	9.95e-19	Gut microbiome composition (summer);
KIRP	cis	rs9815354	0.680	rs10510730	chr3:41849013	C/G	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.6	8.39	0.47	3.82e-15	Menarche (age at onset);
KIRP	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg26516362	chr5:178986906	RUFY1	-0.37	-6.58	-0.39	2.82e-10	Lung cancer;
KIRP	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.12	-0.31	6.07e-7	Obesity-related traits;
KIRP	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.45	5.84	0.35	1.62e-8	Recombination rate (males);
KIRP	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg17133734	chr15:86042851	AKAP13	-0.45	-5.67	-0.34	4.07e-8	Interstitial lung disease;
KIRP	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg05362011	chr13:21860987	NA	-0.46	-4.93	-0.3	1.51e-6	White matter hyperintensity burden;
KIRP	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.38	0.38	8.82e-10	Colorectal cancer;
KIRP	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.48	0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.48	-9.88	-0.53	1.28e-19	Longevity;
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg24101359	chr6:42928495	GNMT	0.62	9.32	0.51	6.75e-18	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.21	0.55	1.22e-20	Dupuytren's disease;
KIRP	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.68e-6	Depression;
KIRP	cis	rs78487399	0.808	rs7586101	chr2:43669851	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.6	5.36	0.32	1.88e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	1.1	12.0	0.61	1.94e-26	Corneal structure;
KIRP	cis	rs9815354	0.857	rs73830583	chr3:41996948	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.47	0.48	2.26e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3087591	0.690	rs12103621	chr17:29607235	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.6	-7.96	-0.45	6.46e-14	Hip circumference;
KIRP	cis	rs79149102	0.579	rs78434425	chr15:75304754	C/T	cg09165964	chr15:75287851	SCAMP5	-1.08	-7.21	-0.42	6.83e-12	Lung cancer;
KIRP	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	6.95	0.4	3.33e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.51	6.66	0.39	1.77e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.56	7.15	0.42	9.58e-12	Platelet count;
KIRP	cis	rs12519773	1.000	rs4869412	chr5:92455655	A/G	cg18783429	chr5:92414398	NA	0.29	5.2	0.31	4.18e-7	Migraine;
KIRP	cis	rs8027181	0.839	rs11072385	chr15:73020839	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.55	0.43	8.32e-13	Triglyceride levels;
KIRP	cis	rs4474465	1.000	rs2063728	chr11:78185636	G/C	cg02023728	chr11:77925099	USP35	0.37	5.73	0.34	2.92e-8	Alzheimer's disease (survival time);
KIRP	cis	rs4888378	0.576	rs8050367	chr16:75313258	A/G	cg07303275	chr16:75499416	TMEM170A	-0.46	-5.45	-0.33	1.25e-7	Coronary artery disease;
KIRP	cis	rs9604529	0.759	rs113489856	chr13:114617056	C/T	cg13259177	chr13:114761607	RASA3	-0.71	-5.83	-0.35	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg16141378	chr3:129829833	LOC729375	-0.57	-7.4	-0.43	2.17e-12	Mood instability;
KIRP	cis	rs6977660	0.660	rs10269891	chr7:19816063	T/C	cg05791153	chr7:19748676	TWISTNB	0.6	5.98	0.36	8e-9	Thyroid stimulating hormone;
KIRP	cis	rs838147	0.760	rs281408	chr19:49233406	A/C	cg13540341	chr19:49222985	MAMSTR	-0.35	-5.68	-0.34	3.79e-8	Dietary macronutrient intake;
KIRP	cis	rs10214930	0.697	rs12539707	chr7:27626165	T/C	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.78	-0.4	8.9e-11	Hemoglobin concentration;
KIRP	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.55	-7.49	-0.43	1.23e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.54	6.31	0.37	1.27e-9	Body mass index (adult);
KIRP	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg23335576	chr14:104009727	NA	0.37	5.13	0.31	5.79e-7	Body mass index;
KIRP	cis	rs7404928	0.718	rs12447916	chr16:23858915	G/A	cg05497750	chr16:23765381	CHP2	-0.45	-5.21	-0.32	4.02e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.88	10.72	0.56	3.04e-22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs6142102	0.625	rs9753690	chr20:32540801	C/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.76	0.34	2.51e-8	Skin pigmentation;
KIRP	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs6842047	0.611	rs4253421	chr4:187204937	C/T	cg09526685	chr4:187126073	CYP4V2	-0.71	-5.53	-0.33	8.01e-8	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.89	0.35	1.29e-8	Motion sickness;
KIRP	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.6	0.39	2.5e-10	Morning vs. evening chronotype;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.86	-0.53	1.56e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10465746	0.905	rs12738214	chr1:84359050	C/A	cg10977910	chr1:84465055	TTLL7	0.45	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	trans	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg04702396	chr17:15466718	FAM18B2	0.49	6.34	0.37	1.08e-9	Educational attainment (years of education);
KIRP	cis	rs6952809	1.000	rs7350030	chr7:2449157	G/A	cg25507518	chr7:2405875	EIF3B	0.36	5.05	0.31	8.49e-7	Multiple sclerosis;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg08280861	chr8:58055591	NA	0.53	5.02	0.3	9.82e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	cg04338863	chr8:33670619	NA	0.42	5.41	0.33	1.49e-7	Body mass index;
KIRP	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.73	8.08	0.46	2.9e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs3857067	1.000	rs1397026	chr4:95013729	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg26893134	chr6:116381904	FRK	0.21	5.6	0.34	5.8e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3829109	0.564	rs11145889	chr9:139293843	A/G	cg21253087	chr9:139290292	SNAPC4	0.47	5.4	0.33	1.59e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.76	8.47	0.48	2.27e-15	Corneal astigmatism;
KIRP	trans	rs7246760	1.000	rs67359088	chr19:9863668	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.09	-0.54	3.04e-20	Pursuit maintenance gain;
KIRP	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg18367735	chr17:79674897	NA	0.7	7.94	0.45	7.03e-14	Dental caries;
KIRP	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg06212747	chr3:49208901	KLHDC8B	0.57	5.51	0.33	8.98e-8	Menarche (age at onset);
KIRP	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg03714773	chr7:91764589	CYP51A1	0.4	5.78	0.35	2.31e-8	Breast cancer;
KIRP	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-21.56	-0.81	1.32e-58	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00891242	chr3:157828165	RSRC1	0.46	6.28	0.37	1.55e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.91	0.35	1.15e-8	Menopause (age at onset);
KIRP	cis	rs698813	0.763	rs786614	chr2:44590567	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.52	0.38	3.9e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs7011049	0.915	rs113906680	chr8:53868320	T/C	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.71	0.49	4.43e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg24154853	chr7:158122151	PTPRN2	0.4	5.7	0.34	3.36e-8	Calcium levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19586645	chr17:73266642	MIF4GD	0.47	6.28	0.37	1.54e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg05072774	chr3:49840536	C3orf54	0.43	5.57	0.33	6.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.69	-13.08	-0.64	4.81e-30	White blood cell count (basophil);
KIRP	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.85	11.2	0.58	8.63e-24	Menarche (age at onset);
KIRP	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.16	15.52	0.7	2.44e-38	Lymphocyte percentage of white cells;
KIRP	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.21	-0.32	3.93e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.38	5.36	0.32	1.89e-7	Monocyte count;
KIRP	trans	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg12623145	chr2:97778927	ANKRD36	0.63	6.31	0.37	1.27e-9	Hip geometry;
KIRP	trans	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.06	-0.41	1.65e-11	Bladder cancer;
KIRP	cis	rs9488822	0.702	rs540981	chr6:116266592	A/G	cg26893134	chr6:116381904	FRK	-0.2	-5.3	-0.32	2.61e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs77633900	0.772	rs2956873	chr15:76695305	G/A	cg21673338	chr15:77095150	SCAPER	-0.65	-6.19	-0.37	2.56e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7083	1.000	rs678837	chr11:117109270	G/T	cg11523350	chr11:117171073	BACE1	-0.26	-5.02	-0.3	9.9e-7	Blood protein levels;
KIRP	cis	rs12479064	0.694	rs75263609	chr2:100133193	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-4.85	-0.3	2.18e-6	Chronic sinus infection;
KIRP	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.45e-22	Chronic sinus infection;
KIRP	cis	rs75920871	0.925	rs4936360	chr11:116893769	C/G	cg23684410	chr11:116897558	SIK3	-0.57	-5.96	-0.36	8.71e-9	Subjective well-being;
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg03289416	chr15:75166202	SCAMP2	0.51	6.88	0.4	4.93e-11	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01637870	chr14:69261986	C14orf181	-0.53	-6.27	-0.37	1.64e-9	Interleukin-4 levels;
KIRP	cis	rs4356975	0.563	rs4694177	chr4:69975859	C/T	cg27372994	chr4:70080453	UGT2B11	0.4	5.23	0.32	3.62e-7	Obesity-related traits;
KIRP	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.86	-0.35	1.45e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg00745463	chr17:30367425	LRRC37B	-0.65	-6.4	-0.38	7.74e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg05361325	chr10:32636312	EPC1	-0.66	-6.3	-0.37	1.37e-9	Sexual dysfunction (female);
KIRP	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	6.1	0.36	4.07e-9	Breast cancer;
KIRP	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4689642	0.666	rs4689658	chr4:7228171	A/G	cg21353189	chr4:7228343	SORCS2	-0.39	-5.44	-0.33	1.27e-7	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.65	9.23	0.51	1.27e-17	Multiple system atrophy;
KIRP	cis	rs6442310	0.534	rs2938392	chr3:12434608	G/A	cg02700894	chr3:12045449	SYN2	0.42	5.89	0.35	1.27e-8	Hematocrit;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg09699651	chr6:150184138	LRP11	0.47	6.21	0.37	2.24e-9	Lung cancer;
KIRP	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg03808351	chr9:123631620	PHF19	0.54	8.02	0.46	4.44e-14	Birth weight;
KIRP	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	21.04	0.8	6.59e-57	Colorectal cancer;
KIRP	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.6	8.01	0.45	4.57e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs7246760	0.867	rs57999229	chr19:9817357	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.02	-0.54	4.82e-20	Pursuit maintenance gain;
KIRP	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.8	-11.79	-0.6	9.69e-26	Asthma;
KIRP	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.6	-8.07	-0.46	3.04e-14	Motion sickness;
KIRP	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.39	5.08	0.31	7.3e-7	Hypertriglyceridemia;
KIRP	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg20999797	chr1:1681921	NA	0.53	8.22	0.46	1.15e-14	Body mass index;
KIRP	trans	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs55788414	1.000	rs67345347	chr16:81185125	G/C	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.31	-0.47	6.41e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-7.65	-0.44	4.6e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11638352	0.661	rs2706491	chr15:44423829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.08	-0.36	4.49e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs311392	0.525	rs311391	chr8:55103542	T/G	cg06042504	chr8:55087323	NA	-0.54	-6.68	-0.39	1.6e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.61	0.48	8.89e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg08807892	chr2:162101083	NA	0.64	8.94	0.5	9.44e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	0.95	9.46	0.52	2.55e-18	Blood protein levels;
KIRP	cis	rs7546094	1.000	rs7415820	chr1:113169449	G/A	cg22162597	chr1:113214053	CAPZA1	-0.5	-7.05	-0.41	1.78e-11	Platelet distribution width;
KIRP	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.57	-7.78	-0.44	2.01e-13	Lung cancer;
KIRP	cis	rs6969780	0.630	rs10238095	chr7:27196643	A/G	cg08657492	chr7:27170832	HOXA4	-0.29	-4.85	-0.3	2.16e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg09184832	chr6:79620586	NA	-0.52	-7.28	-0.42	4.54e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	7.89	0.45	9.64e-14	Height;
KIRP	cis	rs12044355	0.789	rs11589082	chr1:231824656	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	6.17	0.37	2.75e-9	Alzheimer's disease;
KIRP	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.16	-0.37	2.93e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg02297831	chr4:17616191	MED28	-0.49	-5.32	-0.32	2.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg02487422	chr3:49467188	NICN1	0.35	4.93	0.3	1.5e-6	Parkinson's disease;
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg01238044	chr22:24384105	GSTT1	-0.52	-6.72	-0.39	1.27e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg03684893	chr10:554711	DIP2C	-0.37	-5.57	-0.33	6.79e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.83	-0.45	1.43e-13	Gut microbiome composition (summer);
KIRP	cis	rs787274	0.867	rs10739374	chr9:115602703	G/C	cg13803584	chr9:115635662	SNX30	-0.71	-6.23	-0.37	2.01e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.09	11.66	0.6	2.73e-25	Lung cancer in ever smokers;
KIRP	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.51	-6.41	-0.38	7.44e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs2377585	0.653	rs7976729	chr12:8848685	A/G	cg03761649	chr12:8850719	RIMKLB	0.52	4.9	0.3	1.72e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7709377	0.597	rs10478280	chr5:115481662	A/C	cg23108291	chr5:115420582	COMMD10	0.4	4.87	0.3	2.02e-6	Metabolite levels  (X-11787);
KIRP	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg27539214	chr16:67997921	SLC12A4	-0.52	-4.96	-0.3	1.31e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs357618	1.000	rs357624	chr5:150848701	A/G	cg22672639	chr5:150884813	FAT2	0.35	5.34	0.32	2.15e-7	Basophil percentage of white cells;
KIRP	cis	rs4262150	0.883	rs55880278	chr5:152167864	G/A	cg12297329	chr5:152029980	NA	-0.66	-8.3	-0.47	7.1e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.35	5.14	0.31	5.48e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs8084125	0.938	rs62105163	chr18:74943673	C/T	cg18461021	chr18:74961002	GALR1	0.62	5.93	0.35	1.02e-8	Obesity-related traits;
KIRP	cis	rs10779751	0.887	rs2300095	chr1:11265717	A/G	cg08854313	chr1:11322531	MTOR	0.67	9.11	0.5	2.99e-17	Body mass index;
KIRP	cis	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg21545522	chr1:205238299	TMCC2	0.43	5.81	0.35	1.91e-8	Red blood cell count;
KIRP	cis	rs17123764	0.818	rs12321819	chr12:49941997	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.88	0.3	1.92e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.64	-7.26	-0.42	4.97e-12	Longevity;Endometriosis;
KIRP	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09959495	chr2:237029385	AGAP1	0.55	6.93	0.4	3.59e-11	Interleukin-4 levels;
KIRP	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.32	-5.76	-0.34	2.44e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg16584676	chr17:46985605	UBE2Z	0.43	5.23	0.32	3.6e-7	Coronary heart disease;
KIRP	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg26681399	chr22:41777847	TEF	0.43	4.9	0.3	1.73e-6	Vitiligo;
KIRP	cis	rs4728302	0.869	rs6978170	chr7:133603838	C/T	cg10665199	chr7:133106180	EXOC4	0.46	5.61	0.34	5.51e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	6.14	0.36	3.35e-9	Total body bone mineral density;
KIRP	cis	rs8014252	0.803	rs7145530	chr14:71036510	T/C	cg19730268	chr14:71022823	NA	-0.59	-5.58	-0.34	6.23e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg04132472	chr17:19861366	AKAP10	0.67	10.41	0.55	2.83e-21	Schizophrenia;
KIRP	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.44	-5.84	-0.35	1.65e-8	Blood metabolite levels;
KIRP	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs9972944	0.756	rs2024273	chr17:63768972	A/G	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.16e-13	Total body bone mineral density;
KIRP	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-7.33	-0.42	3.37e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs16936870	0.543	rs2926713	chr8:71155513	A/C	cg14232793	chr8:71155543	NCOA2	-0.58	-6.82	-0.4	6.86e-11	QT interval;
KIRP	cis	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg11266682	chr4:10021025	SLC2A9	0.42	5.26	0.32	3.16e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg05562828	chr17:3906858	NA	0.7	11.78	0.6	1.06e-25	Type 2 diabetes;
KIRP	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.73	10.28	0.55	7.33e-21	Caffeine consumption;
KIRP	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg00361562	chr2:198649771	BOLL	-0.53	-5.2	-0.31	4.28e-7	Ulcerative colitis;
KIRP	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.64	-5.88	-0.35	1.33e-8	Schizophrenia;
KIRP	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg26384229	chr12:38710491	ALG10B	0.71	9.74	0.53	3.69e-19	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg00852783	chr1:26633632	UBXN11	-0.53	-5.03	-0.31	9.39e-7	Obesity-related traits;
KIRP	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.49	-6.58	-0.39	2.75e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.97	9.26	0.51	1.02e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-8.51	-0.48	1.71e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.26	0.47	9.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.7	8.1	0.46	2.61e-14	Diabetic retinopathy;
KIRP	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg06671706	chr8:8559999	CLDN23	0.52	6.07	0.36	4.72e-9	Obesity-related traits;
KIRP	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg05717871	chr11:638507	DRD4	-0.37	-5.11	-0.31	6.38e-7	Systemic lupus erythematosus;
KIRP	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.63	-7.27	-0.42	4.88e-12	Menarche (age at onset);
KIRP	cis	rs7849270	0.851	rs7861663	chr9:131880946	G/A	cg13538475	chr9:131942899	NA	-0.31	-4.98	-0.3	1.21e-6	Blood metabolite ratios;
KIRP	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg02023728	chr11:77925099	USP35	-0.29	-4.99	-0.3	1.13e-6	Alzheimer's disease (survival time);
KIRP	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.43	-5.61	-0.34	5.56e-8	Aortic root size;
KIRP	trans	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.59	7.86	0.45	1.22e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg03808351	chr9:123631620	PHF19	0.43	5.79	0.35	2.17e-8	Birth weight;
KIRP	cis	rs26232	0.583	rs26434	chr5:102363402	C/T	cg23492399	chr5:102201601	PAM	0.45	5.07	0.31	7.99e-7	Rheumatoid arthritis;
KIRP	cis	rs3736594	0.513	rs6704596	chr2:27796927	A/G	cg27432699	chr2:27873401	GPN1	0.55	6.15	0.36	3.14e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg09596252	chr17:78655493	RPTOR	0.59	7.74	0.44	2.61e-13	Obesity;
KIRP	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.89	-0.35	1.29e-8	Pulmonary function;
KIRP	cis	rs4478858	0.654	rs113490486	chr1:31712863	C/G	cg00250761	chr1:31883323	NA	-0.32	-5.56	-0.33	6.93e-8	Alcohol dependence;
KIRP	cis	rs4919087	0.748	rs1687369	chr10:98976923	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-4.88	-0.3	1.87e-6	Monocyte count;
KIRP	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg07827796	chr19:33622959	WDR88	0.47	6.05	0.36	5.42e-9	Bone properties (heel);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg03399598	chr4:174091002	GALNT7	-0.49	-6.15	-0.37	3.04e-9	Neuroticism;
KIRP	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg14458575	chr2:238380390	NA	0.46	5.23	0.32	3.55e-7	Prostate cancer;
KIRP	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-1.16	-16.61	-0.73	4.61e-42	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12249207	chr21:19191835	C21orf91	0.51	6.57	0.39	3.03e-10	Parkinson's disease;
KIRP	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.6	8.08	0.46	2.84e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.73	-10.16	-0.54	1.75e-20	Hypospadias;
KIRP	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.38	-5.69	-0.34	3.62e-8	Body mass index;
KIRP	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.54	14.86	0.69	4.38e-36	Systolic blood pressure;
KIRP	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg04374321	chr14:90722782	PSMC1	-0.84	-11.73	-0.6	1.52e-25	Mortality in heart failure;
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07343612	chr16:622815	PIGQ	-0.89	-13.51	-0.65	1.74e-31	Height;
KIRP	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.39	5.6	0.34	5.61e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg00343986	chr7:65444356	GUSB	0.43	5.01	0.3	1.03e-6	Aortic root size;
KIRP	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.14	-0.31	5.51e-7	Colorectal cancer;
KIRP	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg03734594	chr13:111297400	CARS2	0.38	5.77	0.35	2.43e-8	Coronary artery disease;
KIRP	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.6	0.52	9.42e-19	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg15181151	chr6:150070149	PCMT1	0.3	4.97	0.3	1.25e-6	Lung cancer;
KIRP	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.77	11.23	0.58	7.01e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs939574	0.790	rs72955444	chr2:220094673	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	6.12	0.36	3.67e-9	Platelet distribution width;
KIRP	cis	rs12210905	1.000	rs72843640	chr6:27202093	T/A	cg11502198	chr6:26597334	ABT1	-0.83	-5.28	-0.32	2.87e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2882667	0.898	rs11952020	chr5:138395156	A/T	cg04439458	chr5:138467593	SIL1	-0.44	-7.49	-0.43	1.24e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg02151108	chr14:50098012	C14orf104	-0.54	-7.17	-0.42	8.82e-12	Carotid intima media thickness;
KIRP	cis	rs5753037	0.838	rs140147	chr22:30184599	C/T	cg27665648	chr22:30112403	NA	0.45	6.1	0.36	4.12e-9	Type 1 diabetes;
KIRP	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.43	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.56	7.57	0.43	7.64e-13	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.4e-8	Life satisfaction;
KIRP	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg02487422	chr3:49467188	NICN1	0.37	5.25	0.32	3.3e-7	Parkinson's disease;
KIRP	cis	rs7113874	0.578	rs12787407	chr11:8554152	G/C	cg08015107	chr11:8618950	NA	-0.72	-8.78	-0.49	2.81e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs7867456	0.546	rs10757178	chr9:21046674	A/G	cg25477576	chr5:167696167	NA	0.37	6.14	0.36	3.3e-9	Axial length;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.89	-0.53	1.28e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg05585630	chr7:157510462	PTPRN2	-0.36	-4.89	-0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.92	14.02	0.67	3.18e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg21523564	chr15:75251491	NA	0.43	6.63	0.39	2.16e-10	Caffeine consumption;
KIRP	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg02487422	chr3:49467188	NICN1	0.44	5.77	0.35	2.35e-8	Resting heart rate;
KIRP	cis	rs526231	0.543	rs34801	chr5:102426513	T/A	cg23492399	chr5:102201601	PAM	-0.49	-5.38	-0.32	1.72e-7	Primary biliary cholangitis;
KIRP	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg05347473	chr6:146136440	FBXO30	0.49	6.93	0.4	3.74e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg21573476	chr21:45109991	RRP1B	-0.62	-8.44	-0.47	2.72e-15	Mean corpuscular volume;
KIRP	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg18882449	chr10:104885122	NT5C2	-0.52	-6.73	-0.39	1.2e-10	Arsenic metabolism;
KIRP	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg11945507	chr8:142233382	SLC45A4	-0.5	-6.67	-0.39	1.69e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.56	-0.48	1.23e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12480562	chr20:23434244	CST11	0.66	5.11	0.31	6.53e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.75	-0.4	1.08e-10	Alcohol dependence;
KIRP	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg14972814	chr11:95582409	MTMR2	0.33	5.73	0.34	3e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.78	-9.57	-0.52	1.23e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1568657	0.779	rs2167602	chr15:83649292	C/T	cg18543993	chr8:88886320	DCAF4L2	-0.41	-6.14	-0.36	3.36e-9	Kawasaki disease;
KIRP	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	5.86	0.35	1.47e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.72	5.96	0.36	8.51e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-4.92	-0.3	1.62e-6	Schizophrenia;
KIRP	cis	rs28595532	0.720	rs72670233	chr4:119316237	C/G	cg21605333	chr4:119757512	SEC24D	0.99	6.69	0.39	1.46e-10	Cannabis dependence symptom count;
KIRP	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg21361702	chr7:150065534	REPIN1	0.64	6.27	0.37	1.59e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6831352	0.569	rs4148883	chr4:100066332	T/C	cg12011299	chr4:100065546	ADH4	0.48	6.53	0.38	3.82e-10	Alcohol dependence;
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.66	-8.16	-0.46	1.76e-14	Obesity-related traits;
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg05562828	chr17:3906858	NA	0.72	14.35	0.68	2.41e-34	Type 2 diabetes;
KIRP	cis	rs1345301	0.518	rs1035131	chr2:102862641	A/C	cg12451869	chr2:102867685	NA	0.47	6.81	0.4	7.39e-11	Waist circumference;
KIRP	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.77	10.33	0.55	5.35e-21	Hemoglobin concentration;
KIRP	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg22771759	chr13:24902376	NA	0.42	5.31	0.32	2.4e-7	Obesity-related traits;
KIRP	cis	rs11671005	0.735	rs11667591	chr19:58937637	G/A	cg13877915	chr19:58951672	ZNF132	0.6	5.91	0.35	1.12e-8	Mean platelet volume;
KIRP	cis	rs1950626	0.577	rs35097045	chr14:101454403	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.53	6.1	0.36	4.05e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg26876637	chr1:152193138	HRNR	-0.7	-8.81	-0.49	2.34e-16	Atopic dermatitis;
KIRP	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.84e-11	Hypertriglyceridemia;
KIRP	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.59	0.52	1.04e-18	Post bronchodilator FEV1;
KIRP	trans	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg09872104	chr7:134855509	C7orf49	-0.88	-6.41	-0.38	7.38e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2733201	1.000	rs11635948	chr15:44286094	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-5.99	-0.36	7.6e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06634786	chr22:41940651	POLR3H	0.42	4.94	0.3	1.45e-6	Vitiligo;
KIRP	cis	rs73198271	0.562	rs73519953	chr8:8660278	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-4.88	-0.3	1.9e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs8064024	0.680	rs8056320	chr16:4918017	T/C	cg21293562	chr15:96901651	NA	-0.48	-6.13	-0.36	3.57e-9	Cancer;
KIRP	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-7.78	-0.44	1.95e-13	Blood protein levels;
KIRP	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.71	9.08	0.5	3.61e-17	Bladder cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20774722	chr17:19551893	ALDH3A2	-0.42	-6.05	-0.36	5.5e-9	Metabolic traits;
KIRP	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.02	-0.36	6.16e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05220968	chr6:146057943	EPM2A	-0.41	-5.14	-0.31	5.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1823913	0.637	rs4853584	chr2:192175322	T/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.14	-0.36	3.27e-9	Obesity-related traits;
KIRP	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.13	0.41	1.14e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.86	-0.3	2.05e-6	Pulmonary function;
KIRP	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs2554380	0.628	rs11853983	chr15:84462810	A/G	cg14598478	chr15:84363061	ADAMTSL3	0.32	5.33	0.32	2.26e-7	Height;
KIRP	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.37	-0.51	4.96e-18	Platelet count;
KIRP	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.72	0.34	3.13e-8	Birth weight;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16299590	chr13:49282944	CYSLTR2	0.45	6.34	0.37	1.11e-9	Interleukin-4 levels;
KIRP	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.74	0.53	3.48e-19	Colorectal cancer;
KIRP	cis	rs867371	1.000	rs2867579	chr15:82475384	G/C	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs732716	0.785	rs56033249	chr19:4369447	C/T	cg21720385	chr19:4455239	UBXN6	0.69	8.1	0.46	2.53e-14	Mean corpuscular volume;
KIRP	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	1.01	18.22	0.76	1.61e-47	Heart rate;
KIRP	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg13660082	chr14:53194042	PSMC6	-0.71	-7.3	-0.42	3.88e-12	Alzheimer's disease (late onset);
KIRP	trans	rs6601327	0.632	rs4841220	chr8:9656059	T/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.07	-0.41	1.57e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg17849569	chr6:28058911	ZSCAN12L1	0.41	5.16	0.31	4.99e-7	Cardiac Troponin-T levels;
KIRP	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.66	-7.27	-0.42	4.72e-12	Initial pursuit acceleration;
KIRP	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg19610905	chr11:61596333	FADS2	-0.58	-8.27	-0.47	8.61e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-5.23	-0.32	3.55e-7	Fear of minor pain;
KIRP	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg17554472	chr22:41940697	POLR3H	0.67	6.73	0.39	1.16e-10	Vitiligo;
KIRP	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.63	5.65	0.34	4.51e-8	Menarche (age at onset);
KIRP	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.87	-11.4	-0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.2	16.09	0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-7.98	-0.45	5.69e-14	Alzheimer's disease;
KIRP	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg18888403	chr1:24152774	HMGCL	0.36	5.16	0.31	5.06e-7	Immature fraction of reticulocytes;
KIRP	trans	rs1630500	0.793	rs1218583	chr1:154833978	T/G	cg05687149	chr11:112035945	IL18	0.51	6.44	0.38	6.38e-10	Parkinson's disease;
KIRP	cis	rs829661	0.793	rs1975555	chr2:30817685	A/T	cg10949345	chr2:30726833	LCLAT1	1.13	14.33	0.67	2.92e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg02002194	chr4:3960332	NA	0.43	6.23	0.37	1.96e-9	Neuroticism;
KIRP	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg16506815	chr2:162101123	NA	0.51	6.05	0.36	5.31e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.55	-7.19	-0.42	7.52e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.24	0.32	3.45e-7	Height;
KIRP	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg19196401	chr6:110721138	DDO	-0.44	-6.58	-0.39	2.79e-10	Platelet distribution width;
KIRP	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.82	11.54	0.59	6.63e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg26248373	chr2:1572462	NA	-0.69	-8.95	-0.5	8.7e-17	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.48	-0.33	1.06e-7	Height;
KIRP	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.21e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg04132472	chr17:19861366	AKAP10	0.42	5.53	0.33	8.14e-8	Schizophrenia;
KIRP	cis	rs74181299	0.717	rs11893423	chr2:65350949	G/A	cg05010058	chr2:65284262	CEP68	-0.4	-5.35	-0.32	1.98e-7	Pulse pressure;
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg24488311	chr11:68621650	NA	-0.42	-5.08	-0.31	7.53e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.66	-7.81	-0.45	1.66e-13	Birth weight;
KIRP	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg04691961	chr3:161091175	C3orf57	0.67	11.31	0.58	3.79e-24	Morning vs. evening chronotype;
KIRP	cis	rs17030434	0.906	rs12643219	chr4:154670798	T/C	cg14289246	chr4:154710475	SFRP2	-0.76	-8.89	-0.49	1.33e-16	Electrocardiographic conduction measures;
KIRP	cis	rs743757	1.000	rs6446206	chr3:50455470	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.49	5.19	0.31	4.47e-7	Diastolic blood pressure;
KIRP	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg13334819	chr7:99746414	C7orf59	-0.45	-5.0	-0.3	1.08e-6	Coronary artery disease;
KIRP	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg17470723	chr8:74884337	TCEB1	0.64	8.25	0.47	9.51e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4954585	0.708	rs6430612	chr2:137006198	C/T	cg05194412	chr2:137003533	NA	0.49	6.53	0.38	3.71e-10	Colorectal cancer;
KIRP	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg09184832	chr6:79620586	NA	-0.52	-7.24	-0.42	5.67e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.46	6.9	0.4	4.35e-11	Tuberculosis;
KIRP	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg27490568	chr2:178487706	NA	0.56	7.69	0.44	3.62e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg02012338	chr4:187126139	CYP4V2	0.91	8.2	0.46	1.35e-14	Blood protein levels;
KIRP	cis	rs7903847	0.596	rs869967	chr10:99147975	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7688540	0.771	rs12505835	chr4:297525	G/C	cg10134910	chr4:1076041	RNF212	-0.25	-4.95	-0.3	1.37e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11026330	chr4:18023101	LCORL	0.54	6.54	0.38	3.46e-10	Parkinson's disease;
KIRP	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg23587288	chr2:27483067	SLC30A3	-0.75	-9.19	-0.51	1.75e-17	Blood metabolite levels;
KIRP	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.52	6.01	0.36	6.52e-9	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg01689657	chr7:91764605	CYP51A1	0.41	5.93	0.35	1.01e-8	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20459407	chr7:100895581	NA	0.49	6.03	0.36	5.99e-9	Parkinson's disease;
KIRP	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.07	0.46	3.09e-14	Eosinophil percentage of white cells;
KIRP	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs8028182	0.636	rs8029112	chr15:75808972	T/C	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg01566213	chr4:1579287	NA	0.37	5.03	0.31	9.36e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg24315340	chr6:146058215	EPM2A	0.42	5.25	0.32	3.22e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.39	-0.47	3.96e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.19	24.0	0.84	2.19e-66	Exhaled nitric oxide output;
KIRP	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg13206674	chr6:150067644	NUP43	0.59	8.4	0.47	3.62e-15	Lung cancer;
KIRP	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.53	6.62	0.39	2.21e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6120849	0.662	rs6060300	chr20:33780970	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	5.86	0.35	1.46e-8	Protein C levels;
KIRP	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg25251562	chr2:3704773	ALLC	0.46	5.36	0.32	1.96e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg08847533	chr14:75593920	NEK9	0.5	6.06	0.36	5.12e-9	IgG glycosylation;
KIRP	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	0.95	14.03	0.67	2.91e-33	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.48	-7.89	-0.45	1.02e-13	Platelet distribution width;
KIRP	cis	rs2033732	0.706	rs6473526	chr8:85070305	T/C	cg05716166	chr8:85095498	RALYL	0.52	5.96	0.36	8.53e-9	Body mass index;
KIRP	trans	rs10777332	0.675	rs11106294	chr12:92207940	A/G	cg04275566	chr13:113512395	ATP11A	-0.63	-6.03	-0.36	6.11e-9	Biochemical measures;
KIRP	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.61	0.44	5.95e-13	Aortic root size;
KIRP	trans	rs225245	0.782	rs321601	chr17:33892087	A/C	cg19694781	chr19:47549865	TMEM160	0.51	6.51	0.38	4.09e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg22508957	chr16:3507546	NAT15	0.44	6.76	0.4	1.02e-10	Tuberculosis;
KIRP	cis	rs3136516	0.503	rs17787966	chr11:47070425	C/G	cg16389345	chr11:46697382	NA	-0.43	-5.49	-0.33	9.88e-8	Venous thromboembolism;
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg02696790	chr15:75250997	RPP25	0.32	5.59	0.34	6.06e-8	Breast cancer;
KIRP	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg20701182	chr2:24300061	SF3B14	1.0	11.04	0.58	2.89e-23	Lymphocyte counts;
KIRP	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg26384229	chr12:38710491	ALG10B	-0.67	-9.11	-0.5	2.94e-17	Morning vs. evening chronotype;
KIRP	cis	rs7225151	0.710	rs112065650	chr17:5196409	C/T	cg24500398	chr17:5266808	RABEP1	-0.58	-5.61	-0.34	5.57e-8	Alzheimer's disease (late onset);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg04207741	chr12:57482553	NAB2	-0.44	-6.07	-0.36	4.94e-9	Blood metabolite levels;
KIRP	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg17764715	chr19:33622953	WDR88	0.82	11.95	0.61	2.96e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.35	-0.51	5.7e-18	Response to antipsychotic treatment;
KIRP	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	15.12	0.69	5.79e-37	Alzheimer's disease;
KIRP	cis	rs7258465	0.931	rs875396	chr19:18611147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.08	-0.36	4.64e-9	Breast cancer;
KIRP	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	trans	rs1459104	0.641	rs4454742	chr11:54840592	A/T	cg26562691	chr16:23850404	PRKCB	0.62	6.1	0.36	4.01e-9	Body mass index;
KIRP	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.78	6.59	0.39	2.69e-10	Bipolar disorder;
KIRP	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.9	13.91	0.66	7.44e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg03060546	chr3:49711283	APEH	0.45	5.74	0.34	2.84e-8	Parkinson's disease;
KIRP	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg06671706	chr8:8559999	CLDN23	0.52	6.07	0.36	4.72e-9	Obesity-related traits;
KIRP	cis	rs6457821	1.000	rs73407660	chr6:35194205	A/G	cg06087101	chr6:35551932	FKBP5	0.6	5.32	0.32	2.37e-7	Height;
KIRP	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23281280	chr6:28129359	ZNF389	0.47	5.06	0.31	8.21e-7	Depression;
KIRP	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.71	8.29	0.47	7.55e-15	Breast cancer;
KIRP	cis	rs9547996	1.000	rs9547994	chr13:38219448	A/C	cg13634560	chr13:38173852	POSTN	-0.38	-5.07	-0.31	7.72e-7	Diastolic blood pressure;
KIRP	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg00262122	chr8:11665843	FDFT1	0.44	5.42	0.33	1.42e-7	Myopia (pathological);
KIRP	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.42	5.34	0.32	2.16e-7	Melanoma;
KIRP	cis	rs687432	1.000	rs687432	chr11:57694260	A/C	cg19752551	chr11:57585705	CTNND1	0.49	6.92	0.4	3.98e-11	Parkinson's disease;
KIRP	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.61	7.87	0.45	1.16e-13	Inflammatory bowel disease;
KIRP	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.6	6.22	0.37	2.18e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-5.95	-0.35	9.15e-9	Joint mobility (Beighton score);
KIRP	cis	rs10875746	0.624	rs11168498	chr12:48655088	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-5.19	-0.31	4.45e-7	Longevity (90 years and older);
KIRP	cis	rs9826463	0.646	rs11711434	chr3:142336362	G/A	cg20824294	chr3:142316082	PLS1	0.45	6.46	0.38	5.51e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.32	0.32	2.31e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2885056	0.739	rs4363951	chr19:10649473	G/A	cg04833646	chr19:10679720	CDKN2D	0.98	12.36	0.62	1.25e-27	Red cell distribution width;
KIRP	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg23307798	chr14:103986281	CKB	-0.49	-5.29	-0.32	2.76e-7	Coronary artery disease;
KIRP	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg11569703	chr11:65557185	OVOL1	0.6	10.84	0.57	1.23e-22	Acne (severe);
KIRP	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg11204139	chr17:3907470	NA	0.53	6.04	0.36	5.61e-9	Type 2 diabetes;
KIRP	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.5	6.87	0.4	5.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.28	-0.37	1.48e-9	Lung cancer;
KIRP	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.81	9.34	0.51	5.89e-18	Platelet count;
KIRP	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.98	-12.57	-0.63	2.62e-28	Response to antineoplastic agents;
KIRP	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-4.97	-0.3	1.24e-6	Menarche (age at onset);
KIRP	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00321850	chr1:175162397	KIAA0040	0.36	6.49	0.38	4.7e-10	Alcohol dependence;
KIRP	cis	rs11225247	0.772	rs12270109	chr11:102229310	G/C	cg06323957	chr11:102217781	BIRC2	0.77	5.2	0.31	4.18e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.06	0.41	1.68e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.21	21.79	0.81	2.4e-59	Cognitive function;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03156389	chr20:23330637	NXT1	0.53	6.14	0.36	3.29e-9	Smoking initiation;
KIRP	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg17554472	chr22:41940697	POLR3H	-0.64	-5.55	-0.33	7.41e-8	Vitiligo;
KIRP	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.71	10.68	0.56	3.9e-22	Height;
KIRP	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg01843034	chr6:37503916	NA	-0.7	-9.21	-0.51	1.5e-17	Cognitive performance;
KIRP	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.62	9.51	0.52	1.82e-18	Bone mineral density;
KIRP	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg11635098	chr7:100497156	NA	-0.67	-7.23	-0.42	6.1e-12	Resting heart rate;
KIRP	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.45	-0.43	1.57e-12	Mood instability;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg16139199	chr18:19180362	ESCO1	0.5	6.32	0.37	1.23e-9	Asthma;
KIRP	cis	rs7011507	1.000	rs55878633	chr8:49168452	T/A	cg15325961	chr8:49183143	NA	0.6	5.05	0.31	8.57e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Hypertriglyceridemia;
KIRP	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.88	-11.67	-0.6	2.5e-25	Prostate cancer;
KIRP	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.32	-0.42	3.45e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.73	0.53	3.85e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.57	-7.38	-0.43	2.48e-12	Aortic root size;
KIRP	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.69	-5.87	-0.35	1.38e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.74	-6.3	-0.37	1.37e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18932078	chr1:2524107	MMEL1	0.4	5.46	0.33	1.18e-7	Ulcerative colitis;
KIRP	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg14092988	chr3:52407081	DNAH1	0.32	5.75	0.34	2.59e-8	Bipolar disorder;
KIRP	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.3	1.01e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10214930	0.697	rs12670771	chr7:27656590	T/C	cg22168087	chr7:27702803	HIBADH	0.48	5.09	0.31	6.96e-7	Hypospadias;
KIRP	cis	rs12693043	0.845	rs4972677	chr2:175378634	G/C	cg11778734	chr2:175439522	WIPF1	-0.43	-5.86	-0.35	1.46e-8	Urate levels (BMI interaction);
KIRP	cis	rs12986413	1.000	rs12983458	chr19:2168612	A/G	cg09261902	chr19:2140048	AP3D1	0.64	9.98	0.54	6.36e-20	Height;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg16268157	chr7:99778414	STAG3	-0.52	-6.0	-0.36	6.85e-9	Lung function (FEV1/FVC);
KIRP	cis	rs1832871	0.965	rs705953	chr6:158775332	A/G	cg07215822	chr6:158701037	NA	0.51	6.52	0.38	4.01e-10	Height;
KIRP	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.56	7.52	0.43	1.05e-12	Blood metabolite levels;
KIRP	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.95	12.83	0.63	3.5e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs4716602	0.596	rs10261230	chr7:156159632	C/T	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	cis	rs7814319	0.933	rs7827095	chr8:97239126	C/T	cg20787634	chr8:97240163	UQCRB	0.58	9.29	0.51	8.28e-18	Lung function (FVC);
KIRP	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08508325	chr11:3079039	CARS	0.31	5.74	0.34	2.72e-8	Calcium levels;
KIRP	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg24459738	chr19:57751996	ZNF805	0.54	6.71	0.39	1.3100000000000001e-10	Hyperactive-impulsive symptoms;
KIRP	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg10790698	chr19:18539756	SSBP4	-0.34	-7.42	-0.43	1.96e-12	Breast cancer;
KIRP	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg14458575	chr2:238380390	NA	0.57	7.24	0.42	5.77e-12	Prostate cancer;
KIRP	cis	rs8060686	0.920	rs60990105	chr16:67680956	T/A	cg04539111	chr16:67997858	SLC12A4	-0.48	-4.87	-0.3	2.03e-6	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs918629	0.679	rs72656689	chr5:95270872	A/G	cg16656078	chr5:95278638	ELL2	-0.47	-6.9	-0.4	4.39e-11	IgG glycosylation;
KIRP	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.51	-5.34	-0.32	2.07e-7	Corneal structure;
KIRP	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.6	0.39	2.56e-10	Renal cell carcinoma;
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.34	5.56	0.33	7.05e-8	Lymphocyte counts;
KIRP	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.42	-5.06	-0.31	8.08e-7	Educational attainment;
KIRP	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.68	9.18	0.51	1.77e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.34	-0.42	3.04e-12	Type 2 diabetes;
KIRP	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg21573476	chr21:45109991	RRP1B	-0.62	-8.31	-0.47	6.49e-15	Mean corpuscular volume;
KIRP	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg17340268	chr14:105411764	AHNAK2	0.4	5.18	0.31	4.58e-7	Rheumatoid arthritis;
KIRP	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.22	-0.42	6.31e-12	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14693521	chr3:28502257	ZCWPW2	0.39	6.21	0.37	2.27e-9	Interleukin-4 levels;
KIRP	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.78	-11.07	-0.58	2.26e-23	Blood metabolite levels;
KIRP	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.69	7.73	0.44	2.74e-13	Corneal astigmatism;
KIRP	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.4	-0.43	2.12e-12	Response to antipsychotic treatment;
KIRP	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	0.55	8.3	0.47	6.75e-15	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.67	7.6	0.44	6.02e-13	Neutrophil percentage of white cells;
KIRP	cis	rs4141404	0.757	rs5749272	chr22:31830351	C/T	cg20742981	chr22:31644190	LIMK2	0.31	5.1	0.31	6.86e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg15128208	chr22:42549153	NA	0.72	8.23	0.46	1.09e-14	Birth weight;
KIRP	cis	rs7084402	0.967	rs1896243	chr10:60276291	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.13	0.58	1.42e-23	Refractive error;
KIRP	cis	rs12976411	0.575	rs8113450	chr19:32820551	G/T	cg02282382	chr19:32836354	ZNF507	0.68	5.62	0.34	5.13e-8	Coronary artery disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01398415	chr1:226309536	NA	0.67	6.54	0.38	3.47e-10	Lung function (FEV1);
KIRP	cis	rs17373728	0.739	rs6472896	chr8:76190315	A/C	cg07016329	chr8:76221503	NA	-0.54	-7.29	-0.42	4.1e-12	Diabetic kidney disease;
KIRP	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg17724175	chr1:150552817	MCL1	0.34	5.86	0.35	1.49e-8	Urate levels;
KIRP	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.93	-13.43	-0.65	3.32e-31	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19346786	chr7:2764209	NA	-0.44	-6.85	-0.4	6e-11	Height;
KIRP	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg10932289	chr17:55038442	COIL	0.48	6.2	0.37	2.35e-9	Bladder cancer;
KIRP	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.36	0.38	9.98e-10	Height;
KIRP	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg00262122	chr8:11665843	FDFT1	-0.42	-5.08	-0.31	7.43e-7	Retinal vascular caliber;
KIRP	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.61	-9.26	-0.51	1.06e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg14343924	chr8:8086146	FLJ10661	0.44	5.21	0.32	3.94e-7	Neuroticism;
KIRP	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-12.5	-0.62	4.45e-28	Primary sclerosing cholangitis;
KIRP	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.32	-4.97	-0.3	1.27e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.45	6.13	0.36	3.44e-9	Sitting height ratio;
KIRP	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	1.01	18.45	0.76	2.57e-48	Platelet distribution width;
KIRP	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg06197360	chr20:60970103	CABLES2	-0.49	-5.5	-0.33	9.42e-8	Colorectal cancer;
KIRP	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg09264619	chr17:80180166	NA	-0.41	-6.02	-0.36	6.15e-9	Life satisfaction;
KIRP	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.63	8.98	0.5	7.12e-17	Resting heart rate;
KIRP	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg08917208	chr2:24149416	ATAD2B	0.99	8.51	0.48	1.78e-15	Lymphocyte counts;
KIRP	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg22189786	chr22:42395067	WBP2NL	0.45	5.8	0.35	2.04e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs687432	0.774	rs7934184	chr11:57904552	A/C	cg19752551	chr11:57585705	CTNND1	0.59	7.3	0.42	3.87e-12	Parkinson's disease;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg07216194	chr8:27182965	PTK2B	0.46	5.59	0.34	6.14e-8	Neuroticism;
KIRP	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg08501292	chr6:25962987	TRIM38	1.12	7.24	0.42	5.66e-12	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00471768	chr20:14319125	FLRT3;MACROD2	-0.4	-6.08	-0.36	4.68e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg23594656	chr7:65796392	TPST1	0.47	7.48	0.43	1.34e-12	Aortic root size;
KIRP	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.14	-0.46	2.04e-14	Neuroticism;
KIRP	cis	rs73198271	0.603	rs571130	chr8:8593691	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.18	-0.31	4.58e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3829109	0.564	rs11789379	chr9:139285260	T/C	cg21253087	chr9:139290292	SNAPC4	0.47	4.84	0.3	2.25e-6	Peak insulin response;Acute insulin response;
KIRP	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg07701084	chr6:150067640	NUP43	0.64	8.24	0.46	1.06e-14	Lung cancer;
KIRP	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.67	-7.41	-0.43	1.97e-12	Blood pressure (smoking interaction);
KIRP	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.57	8.17	0.46	1.66e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.5	6.54	0.38	3.5e-10	Blood protein levels;
KIRP	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg13819577	chr1:248512075	OR14C36	-0.39	-5.12	-0.31	6.07e-7	Common traits (Other);
KIRP	cis	rs8113308	0.752	rs113374423	chr19:52490952	G/A	cg25782003	chr19:52490127	ZNF350	0.99	9.43	0.52	3.23e-18	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20930514	chr14:77499758	NA	0.52	6.96	0.41	3.07e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.68	0.39	1.54e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7534824	0.625	rs61780321	chr1:101428304	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.0	0.41	2.49e-11	Refractive astigmatism;
KIRP	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.45	0.38	5.83e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg22357984	chr1:109982423	NA	0.4	6.23	0.37	1.96e-9	Warfarin maintenance dose;
KIRP	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.61	8.32	0.47	5.96e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg09455208	chr3:40491958	NA	0.29	4.9	0.3	1.7e-6	Renal cell carcinoma;
KIRP	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.05	-0.36	5.39e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18252515	chr7:66147081	NA	0.46	5.72	0.34	3.13e-8	Aortic root size;
KIRP	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.38	7.97	0.45	5.76e-14	Body mass index;
KIRP	cis	rs240764	0.645	rs454747	chr6:101055566	T/C	cg09795085	chr6:101329169	ASCC3	0.42	4.86	0.3	2.05e-6	Neuroticism;
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	5.64	0.34	4.62e-8	Platelet count;
KIRP	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.94	-0.3	1.41e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.68	10.43	0.55	2.42e-21	Resting heart rate;
KIRP	cis	rs1783925	1.000	rs1783925	chr11:125304009	C/T	cg03464685	chr11:125439445	EI24	0.44	4.85	0.3	2.2e-6	Formal thought disorder in schizophrenia;
KIRP	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18367020	chr2:73461259	CCT7;C2orf7	0.53	7.22	0.42	6.64e-12	Parkinson's disease;
KIRP	cis	rs1978968	1.000	rs2099942	chr22:18438314	A/C	cg03078520	chr22:18463400	MICAL3	-0.68	-8.77	-0.49	3.04e-16	Presence of antiphospholipid antibodies;
KIRP	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	0.98	10.5	0.56	1.48e-21	Opioid sensitivity;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.72	-0.34	3.12e-8	Breast cancer;
KIRP	cis	rs1318772	0.800	rs34158516	chr5:112919000	G/A	cg12552261	chr5:112820674	MCC	0.78	5.42	0.33	1.41e-7	F-cell distribution;
KIRP	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg02297831	chr4:17616191	MED28	0.52	6.58	0.39	2.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg15691649	chr6:25882328	NA	0.44	5.38	0.32	1.76e-7	Blood metabolite levels;
KIRP	cis	rs6684428	0.901	rs7516605	chr1:56343290	A/C	cg11651538	chr1:56320950	NA	-0.89	-10.74	-0.56	2.66e-22	Airflow obstruction;
KIRP	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg18478394	chr8:109455254	TTC35	0.5	6.27	0.37	1.64e-9	Dupuytren's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06697094	chr17:54911185	DGKE	0.53	7.02	0.41	2.21e-11	Parkinson's disease;
KIRP	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.61	8.68	0.48	5.56e-16	Colorectal cancer;
KIRP	cis	rs212524	0.807	rs212540	chr1:21593117	A/G	cg08890418	chr1:21044141	KIF17	-0.42	-5.7	-0.34	3.33e-8	Height;
KIRP	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.51e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6725041	0.717	rs12185587	chr2:213101298	T/C	cg16329650	chr2:213403929	ERBB4	-0.36	-5.03	-0.31	9.28e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs9400467	0.537	rs12214550	chr6:111505499	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg10047753	chr17:41438598	NA	1.14	17.99	0.75	9.7e-47	Menopause (age at onset);
KIRP	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.96	0.3	1.3e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg00852783	chr1:26633632	UBXN11	-0.5	-4.93	-0.3	1.51e-6	Obesity-related traits;
KIRP	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-12.94	-0.64	1.44e-29	Dental caries;
KIRP	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	8.14	0.46	2.04e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.85	-9.24	-0.51	1.23e-17	Osteoarthritis;
KIRP	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-0.63	-5.98	-0.36	7.63e-9	Breast cancer;
KIRP	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg15128208	chr22:42549153	NA	-0.55	-6.0	-0.36	7.11e-9	Birth weight;
KIRP	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05347473	chr6:146136440	FBXO30	-0.64	-9.39	-0.51	4.19e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17376030	chr22:41985996	PMM1	0.7	7.71	0.44	3.04e-13	Vitiligo;
KIRP	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.13	-0.36	3.56e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs1864585	0.520	rs57348261	chr8:10669089	G/A	cg26278703	chr11:58910052	FAM111A	0.63	6.34	0.37	1.1e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.56e-13	Coffee consumption (cups per day);
KIRP	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.14	0.31	5.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.72e-15	Prudent dietary pattern;
KIRP	cis	rs5753618	0.504	rs5753661	chr22:31899797	C/A	cg02404636	chr22:31891804	SFI1	0.57	6.68	0.39	1.6e-10	Colorectal cancer;
KIRP	cis	rs11225247	0.772	rs12275349	chr11:102237720	C/T	cg06323957	chr11:102217781	BIRC2	0.75	4.95	0.3	1.36e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.72	-0.39	1.26e-10	Response to antipsychotic treatment;
KIRP	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg23307798	chr14:103986281	CKB	-0.44	-5.89	-0.35	1.27e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.69	8.89	0.49	1.31e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.07	12.26	0.62	2.69e-27	Uric acid levels;
KIRP	cis	rs5995756	1.000	rs5995756	chr22:40000313	A/G	cg10455938	chr22:40058150	CACNA1I	-0.46	-6.68	-0.39	1.56e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00124160	chr7:142490954	NA	0.45	6.43	0.38	6.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg12718519	chr1:2058417	PRKCZ	0.22	4.88	0.3	1.88e-6	Height;
KIRP	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.01	14.1	0.67	1.74e-33	Corneal structure;
KIRP	cis	rs4950322	0.570	rs72692971	chr1:146804820	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg01950434	chr2:97203154	ARID5A	-0.49	-6.24	-0.37	1.87e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg03340356	chr1:67600835	NA	0.53	6.06	0.36	5.01e-9	Psoriasis;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04371633	chr14:65381025	CHURC1	-0.49	-6.38	-0.38	8.69e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.02	-0.3	1.01e-6	Major depressive disorder;
KIRP	cis	rs2120243	0.539	rs988588	chr3:157054016	C/G	cg24825693	chr3:157122686	VEPH1	-0.53	-8.16	-0.46	1.74e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-1.07	-7.75	-0.44	2.41e-13	Obesity-related traits;
KIRP	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.39	0.47	3.93e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg05347473	chr6:146136440	FBXO30	0.58	8.12	0.46	2.19e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.37	-0.43	2.52e-12	Neuroticism;
KIRP	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.71	-7.37	-0.43	2.61e-12	Putamen volume;
KIRP	cis	rs8049040	0.586	rs16972663	chr16:71460564	C/T	cg08717414	chr16:71523259	ZNF19	-0.58	-6.49	-0.38	4.79e-10	Blood protein levels;
KIRP	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	cg21523751	chr1:182988639	NA	0.35	4.92	0.3	1.57e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg23649088	chr2:200775458	C2orf69	-0.4	-5.13	-0.31	5.78e-7	QT interval;
KIRP	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg11642891	chr2:3452563	TTC15	-0.52	-6.65	-0.39	1.93e-10	Obesity-related traits;
KIRP	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg10932868	chr11:921992	NA	0.49	5.8	0.35	1.98e-8	Alzheimer's disease (late onset);
KIRP	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.68	-7.2	-0.42	7.25e-12	DNA methylation (variation);
KIRP	cis	rs1832871	0.683	rs6908487	chr6:158713047	G/T	cg07215822	chr6:158701037	NA	-0.65	-7.43	-0.43	1.84e-12	Height;
KIRP	cis	rs4234798	0.567	rs4689635	chr4:7211039	T/C	cg18431297	chr4:7219810	SORCS2	0.47	5.42	0.33	1.43e-7	Insulin-like growth factors;
KIRP	cis	rs3820881	0.516	rs17531743	chr2:201245404	G/A	cg23516759	chr2:201153734	NA	-0.79	-7.25	-0.42	5.28e-12	Chickenpox;
KIRP	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.6	6.24	0.37	1.85e-9	Crohn's disease;
KIRP	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg00495681	chr13:53174319	NA	0.38	5.18	0.31	4.58e-7	Lewy body disease;
KIRP	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg17764715	chr19:33622953	WDR88	0.66	8.29	0.47	7.25e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2594989	0.943	rs2454509	chr3:11489653	C/T	cg01796438	chr3:11312864	ATG7	0.6	7.38	0.43	2.38e-12	Circulating chemerin levels;
KIRP	cis	rs6832769	1.000	rs7677526	chr4:56349908	A/T	cg05960024	chr4:56376020	CLOCK	0.62	8.04	0.46	3.88e-14	Personality dimensions;
KIRP	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	7.66	0.44	4.27e-13	Post bronchodilator FEV1;
KIRP	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.77	8.58	0.48	1.1e-15	Corneal astigmatism;
KIRP	cis	rs28493229	0.748	rs10426415	chr19:41183590	A/G	cg21869046	chr19:41225005	ITPKC	0.42	5.49	0.33	1e-7	Kawasaki disease;
KIRP	cis	rs712039	0.652	rs853206	chr17:35824796	T/C	cg16670864	chr17:35848621	DUSP14	0.41	5.14	0.31	5.58e-7	Tuberculosis;
KIRP	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.64	-0.39	1.97e-10	Bipolar disorder;
KIRP	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg00784671	chr22:46762841	CELSR1	-0.76	-7.73	-0.44	2.73e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg05526886	chr2:227700861	RHBDD1	-0.4	-4.92	-0.3	1.6e-6	Coronary artery disease;
KIRP	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg07843065	chr1:150265600	MRPS21	0.44	6.19	0.37	2.56e-9	Migraine;
KIRP	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg13385521	chr17:29058706	SUZ12P	0.86	6.44	0.38	6.21e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.58	-7.26	-0.42	4.95e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.62	-0.56	6.31e-22	Gut microbiome composition (summer);
KIRP	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.52	-0.33	8.4e-8	Triglycerides;
KIRP	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11645453	chr3:52864694	ITIH4	0.45	6.22	0.37	2.09e-9	Bipolar disorder;
KIRP	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg26513180	chr16:89883248	FANCA	0.79	5.63	0.34	4.9e-8	Skin colour saturation;
KIRP	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.88	10.67	0.56	4.39e-22	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16458523	chr8:144329134	ZFP41	0.49	6.5	0.38	4.5e-10	Parkinson's disease;
KIRP	cis	rs7084783	0.622	rs61606504	chr10:105348767	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.5	6.71	0.39	1.3100000000000001e-10	Fear of pain;
KIRP	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-5.59	-0.34	6.1e-8	Total body bone mineral density;
KIRP	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-6.39	-0.38	8.41e-10	Axial length;
KIRP	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.65	-0.48	6.59e-16	Retinal vascular caliber;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg21523564	chr15:75251491	NA	0.43	6.82	0.4	6.97e-11	Breast cancer;
KIRP	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.52	6.71	0.39	1.32e-10	Mean corpuscular volume;
KIRP	cis	rs1559088	0.512	rs34266236	chr19:33564874	C/A	cg27124370	chr19:33622961	WDR88	0.51	4.97	0.3	1.25e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs687432	0.688	rs12788387	chr11:57893347	A/C	cg19752551	chr11:57585705	CTNND1	-0.56	-7.58	-0.44	6.83e-13	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21736089	chr19:3110171	GNA11	0.48	6.14	0.36	3.37e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs5753618	0.504	rs5749295	chr22:31932895	A/T	cg02404636	chr22:31891804	SFI1	0.53	6.66	0.39	1.77e-10	Colorectal cancer;
KIRP	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.78	0.35	2.2e-8	Educational attainment;
KIRP	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.55	-6.93	-0.4	3.77e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-1.13	-9.82	-0.53	2.07e-19	Body mass index;
KIRP	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg23032965	chr3:12705835	RAF1	0.71	7.85	0.45	1.28e-13	Cholesterol, total;
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs10073892	0.789	rs72779917	chr5:101692601	G/C	cg19774478	chr5:101632501	SLCO4C1	0.67	6.48	0.38	4.83e-10	Cognitive decline (age-related);
KIRP	cis	rs4789693	0.938	rs4789694	chr17:80428099	A/C	cg04308225	chr17:80449738	NA	-0.55	-5.6	-0.34	5.81e-8	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs667920	0.573	rs9682783	chr3:136539689	T/C	cg15507776	chr3:136538369	TMEM22	0.8	11.17	0.58	1.05e-23	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12484590	chr1:156475177	NA	0.55	6.77	0.4	9.25e-11	Smoking initiation;
KIRP	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg25019722	chr6:37503610	NA	-0.98	-15.2	-0.7	3.04e-37	Cognitive performance;
KIRP	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.9	-0.49	1.27e-16	Triglycerides;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11877270	chr2:65658583	SPRED2	0.9	6.01	0.36	6.49e-9	P wave terminal force;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.74	-10.42	-0.55	2.72e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04205664	chr7:139209511	CLEC2L	0.46	6.02	0.36	6.39e-9	Interleukin-4 levels;
KIRP	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7015630	0.657	rs16900888	chr8:90837747	A/G	cg18493113	chr8:90847772	NA	0.54	5.73	0.34	2.88e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	trans	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.08	0.36	4.67e-9	Retinal vascular caliber;
KIRP	cis	rs10858047	0.883	rs4543788	chr1:115179501	C/T	cg12756093	chr1:115239321	AMPD1	-0.67	-6.46	-0.38	5.42e-10	Autism;
KIRP	cis	rs3741151	0.686	rs61516411	chr11:73302768	T/C	cg17517138	chr11:73019481	ARHGEF17	0.66	5.63	0.34	4.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27431596	chr1:120190588	ZNF697	0.53	6.89	0.4	4.52e-11	Parkinson's disease;
KIRP	cis	rs494562	0.892	rs521005	chr6:86116542	A/G	cg27039625	chr6:86159096	NT5E	0.49	5.82	0.35	1.79e-8	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27606288	chr2:96783070	ADRA2B	0.64	7.2	0.42	7.11e-12	Lung cancer in ever smokers;
KIRP	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg13010199	chr12:38710504	ALG10B	0.59	7.39	0.43	2.31e-12	Morning vs. evening chronotype;
KIRP	cis	rs4308124	0.708	rs6747657	chr2:112003163	C/T	cg04571233	chr2:111982156	NA	-0.57	-6.58	-0.39	2.75e-10	Vitiligo;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00783759	chr4:128983441	LARP1B	-0.47	-6.19	-0.37	2.56e-9	Morning vs. evening chronotype;
KIRP	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.78	-0.44	1.95e-13	Systolic blood pressure;
KIRP	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.72	5.87	0.35	1.4e-8	Body mass index;
KIRP	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.42	-5.16	-0.31	4.97e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs838147	0.844	rs8108468	chr19:49247786	G/A	cg13540341	chr19:49222985	MAMSTR	0.35	5.62	0.34	5.06e-8	Dietary macronutrient intake;
KIRP	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.85	-13.37	-0.65	5.05e-31	Coronary artery disease;
KIRP	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.98	13.11	0.64	4.01e-30	Cognitive function;
KIRP	cis	rs4356932	0.632	rs2292533	chr4:76861859	C/T	cg19388996	chr4:76862389	NAAA	-0.42	-5.38	-0.32	1.72e-7	Blood protein levels;
KIRP	cis	rs6499755	0.768	rs31095	chr16:55367230	C/T	cg05099576	chr16:55362342	IRX6	0.33	6.7	0.39	1.4e-10	Hypospadias;
KIRP	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.56	-7.92	-0.45	8.3e-14	Calcium levels;
KIRP	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg04317338	chr11:64019027	PLCB3	0.8	6.04	0.36	5.51e-9	Mean platelet volume;
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07256732	chr16:621771	PIGQ	-0.46	-6.57	-0.39	2.95e-10	Height;
KIRP	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-1.02	-16.79	-0.73	1.11e-42	Gut microbiome composition (winter);
KIRP	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.79	9.09	0.5	3.44e-17	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.11e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg09911534	chr15:67153556	NA	-0.37	-5.42	-0.33	1.44e-7	Lung cancer (smoking interaction);
KIRP	cis	rs12549025	0.836	rs11778179	chr8:23415655	A/G	cg00892891	chr8:23423734	SLC25A37	-0.47	-4.91	-0.3	1.63e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg00484396	chr16:3507460	NAT15	0.53	5.32	0.32	2.3e-7	Tuberculosis;
KIRP	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.47	-5.83	-0.35	1.7e-8	Asthma;
KIRP	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg01320579	chr17:75405842	SEPT9	0.47	7.69	0.44	3.56e-13	Airflow obstruction;
KIRP	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg03808351	chr9:123631620	PHF19	0.37	4.96	0.3	1.33e-6	Rheumatoid arthritis;
KIRP	cis	rs7551222	0.714	rs4951401	chr1:204537648	G/A	cg20240347	chr1:204465584	NA	-0.37	-6.07	-0.36	4.69e-9	Schizophrenia;
KIRP	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg15443732	chr18:74961078	GALR1	0.52	5.14	0.31	5.49e-7	Obesity-related traits;
KIRP	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg08885076	chr2:99613938	TSGA10	-0.36	-5.13	-0.31	5.81e-7	Fear of minor pain;
KIRP	cis	rs7615316	0.779	rs9871402	chr3:142024351	A/C	cg20824294	chr3:142316082	PLS1	0.22	5.17	0.31	4.85e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg16434002	chr17:42200994	HDAC5	-0.51	-6.27	-0.37	1.59e-9	Total body bone mineral density;
KIRP	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.51	5.93	0.35	1.05e-8	Platelet distribution width;
KIRP	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg06289844	chr6:126071538	HEY2	0.34	4.93	0.3	1.5e-6	Brugada syndrome;
KIRP	cis	rs8060686	0.668	rs8048034	chr16:68210604	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-7.5	-0.43	1.15e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17121403	0.661	rs115625519	chr1:100628211	A/T	cg24955406	chr1:100503596	HIAT1	0.78	5.11	0.31	6.5e-7	Pulmonary function decline;
KIRP	cis	rs11625487	0.609	rs45493395	chr14:77976468	T/C	cg20045696	chr14:77926864	AHSA1	-0.68	-5.72	-0.34	3.14e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg05709478	chr1:6581295	PLEKHG5	0.66	5.81	0.35	1.95e-8	Body mass index;
KIRP	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	8.01e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8028182	0.636	rs4462560	chr15:75647964	G/C	cg20655648	chr15:75932815	IMP3	-0.54	-6.85	-0.4	5.73e-11	Sudden cardiac arrest;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18514344	chr10:95242156	MYOF	0.49	7.21	0.42	6.8e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg07001201	chr5:642380	CEP72	0.67	6.07	0.36	4.73e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1823913	0.599	rs67342262	chr2:192160338	G/A	cg12404831	chr2:192114017	MYO1B	0.54	7.48	0.43	1.29e-12	Obesity-related traits;
KIRP	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg27494647	chr7:150038898	RARRES2	0.39	5.78	0.35	2.27e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10875746	0.729	rs1990028	chr12:48408013	A/G	cg20731937	chr12:48336164	NA	0.48	5.97	0.36	8.13e-9	Longevity (90 years and older);
KIRP	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg10223061	chr2:219282414	VIL1	0.33	5.48	0.33	1.06e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	1.05	18.13	0.76	3.07e-47	Bone mineral density;
KIRP	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11987759	chr7:65425863	GUSB	0.53	7.0	0.41	2.44e-11	Aortic root size;
KIRP	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg11846333	chr4:119757529	SEC24D	0.96	5.72	0.34	3.04e-8	Cannabis dependence symptom count;
KIRP	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg07882059	chr11:68924751	NA	0.3	5.19	0.31	4.36e-7	Blond vs. brown hair color;
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg26402253	chr7:87849886	SRI	-0.48	-6.39	-0.38	8.42e-10	Breast cancer;
KIRP	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg00405596	chr8:11794950	NA	-0.49	-6.45	-0.38	5.73e-10	Retinal vascular caliber;
KIRP	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.82	11.18	0.58	9.48e-24	Essential tremor;
KIRP	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.53	-6.75	-0.4	1.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.35	5.18	0.31	4.53e-7	Calcium levels;
KIRP	cis	rs6540556	0.608	rs2884090	chr1:209884059	C/T	cg23920097	chr1:209922102	NA	-0.42	-5.66	-0.34	4.31e-8	Red blood cell count;
KIRP	cis	rs3743266	0.507	rs34092508	chr15:60722979	C/T	cg22293140	chr15:60689852	ANXA2	-0.64	-5.76	-0.34	2.57e-8	Menarche (age at onset);
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg21698718	chr17:80085957	CCDC57	-0.36	-5.12	-0.31	6.13e-7	Life satisfaction;
KIRP	cis	rs11593576	0.550	rs7909784	chr10:80993925	G/T	cg18737081	chr10:80999807	ZMIZ1	-0.3	-5.24	-0.32	3.45e-7	Vitiligo;
KIRP	cis	rs7523273	0.597	rs56075814	chr1:207975949	T/C	cg22525895	chr1:207977042	MIR29B2	-0.6	-5.72	-0.34	3.15e-8	Schizophrenia;
KIRP	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	1.1	15.91	0.71	1.16e-39	Multiple sclerosis;
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.8e-8	Lung cancer;
KIRP	cis	rs7721647	0.821	rs332523	chr5:90830449	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.19	0.31	4.51e-7	Breast cancer;
KIRP	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.37	-0.32	1.8e-7	Colorectal cancer;
KIRP	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	8.83	0.49	2.05e-16	Resting heart rate;
KIRP	cis	rs2033732	0.601	rs1866083	chr8:85040188	C/T	cg05716166	chr8:85095498	RALYL	0.54	5.04	0.31	9.16e-7	Body mass index;
KIRP	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.62	-7.22	-0.42	6.47e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg21395723	chr22:39101663	GTPBP1	0.41	4.85	0.3	2.15e-6	Menopause (age at onset);
KIRP	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.69	7.66	0.44	4.29e-13	Corneal astigmatism;
KIRP	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.39	-0.33	1.64e-7	Pulmonary function;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg13079154	chr12:111180884	PPP1CC	-1.13	-6.31	-0.37	1.29e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.83	-13.02	-0.64	8.19e-30	Breast cancer;
KIRP	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg07636037	chr3:49044803	WDR6	0.53	4.89	0.3	1.81e-6	Menarche (age at onset);
KIRP	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg11522683	chr6:37501428	NA	-0.4	-5.33	-0.32	2.2e-7	Cognitive performance;
KIRP	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	1.09	12.24	0.62	3.1e-27	Post bronchodilator FEV1;
KIRP	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.47	5.29	0.32	2.69e-7	Osteoporosis;
KIRP	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs372883	0.901	rs733610	chr21:30656199	G/A	cg24692254	chr21:30365293	RNF160	-0.45	-5.8	-0.35	2.02e-8	Pancreatic cancer;
KIRP	cis	rs787274	1.000	rs787275	chr9:115550523	C/G	cg13803584	chr9:115635662	SNX30	-0.73	-7.94	-0.45	7.34e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.95	16.17	0.72	1.49e-40	Bone mineral density;
KIRP	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	8.97	0.5	7.69e-17	Bipolar disorder;
KIRP	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg23950597	chr19:37808831	NA	-0.61	-6.63	-0.39	2.17e-10	Coronary artery calcification;
KIRP	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg06565975	chr8:143823917	SLURP1	0.55	7.69	0.44	3.59e-13	Urinary tract infection frequency;
KIRP	cis	rs10465746	0.725	rs1359331	chr1:84360301	C/A	cg10977910	chr1:84465055	TTLL7	0.55	7.0	0.41	2.39e-11	Obesity-related traits;
KIRP	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg01028140	chr2:1542097	TPO	-0.66	-6.65	-0.39	1.84e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg21211680	chr2:198530	NA	-0.94	-11.5	-0.59	9.02e-25	Blood protein levels;
KIRP	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.42	8.52	0.48	1.65e-15	Mean corpuscular volume;
KIRP	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.95	0.3	1.35e-6	Educational attainment;
KIRP	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24110177	chr3:50126178	RBM5	0.44	5.66	0.34	4.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25517755	chr10:38738941	LOC399744	-0.52	-7.1	-0.41	1.36e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.45	-12.06	-0.61	1.28e-26	Diabetic kidney disease;
KIRP	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.49	8.1	0.46	2.57e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg22437258	chr11:111473054	SIK2	-0.55	-6.4	-0.38	7.61e-10	Primary sclerosing cholangitis;
KIRP	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg10591111	chr5:226296	SDHA	-0.48	-4.94	-0.3	1.41e-6	Breast cancer;
KIRP	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.74	-10.32	-0.55	5.45e-21	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13556604	chr1:203274688	BTG2	0.52	6.79	0.4	8.56e-11	Parkinson's disease;
KIRP	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg06953865	chr19:18549723	ISYNA1	-0.4	-6.22	-0.37	2.18e-9	Breast cancer;
KIRP	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.41	-0.51	3.57e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.79	10.9	0.57	7.84e-23	N-glycan levels;
KIRP	cis	rs4901847	0.967	rs12433262	chr14:58552899	T/C	cg15908186	chr14:58618357	C14orf37	0.43	5.47	0.33	1.08e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg00784671	chr22:46762841	CELSR1	-0.67	-7.22	-0.42	6.61e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.42	0.47	3.14e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.12	-0.31	6.17e-7	Testicular germ cell tumor;
KIRP	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg11569703	chr11:65557185	OVOL1	0.37	5.69	0.34	3.54e-8	Eosinophil percentage of white cells;
KIRP	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.85	-0.35	1.56e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs367943	0.712	rs26968	chr5:112742429	A/G	cg12552261	chr5:112820674	MCC	0.56	6.69	0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.51	7.08	0.41	1.53e-11	Coronary artery disease;
KIRP	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.67	10.68	0.56	4.02e-22	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs10510057	0.592	rs3009877	chr10:121328495	C/T	cg06765389	chr10:121379685	NA	-0.47	-7.27	-0.42	4.78e-12	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.75	10.96	0.57	5.16e-23	Mood instability;
KIRP	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.27	17.58	0.75	2.36e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg00792783	chr2:198669748	PLCL1	0.47	5.25	0.32	3.3e-7	Dermatomyositis;
KIRP	cis	rs904251	0.507	rs11756941	chr6:37416219	C/G	cg01843034	chr6:37503916	NA	-0.54	-4.95	-0.3	1.36e-6	Cognitive performance;
KIRP	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg22800045	chr5:56110881	MAP3K1	0.73	7.81	0.45	1.66e-13	Initial pursuit acceleration;
KIRP	cis	rs1978968	1.000	rs5992928	chr22:18451438	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.55	-6.55	-0.39	3.34e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	trans	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg06521331	chr12:34319734	NA	-0.63	-7.65	-0.44	4.42e-13	Bladder cancer;
KIRP	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.39	-0.43	2.22e-12	Triglycerides;
KIRP	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.74	9.85	0.53	1.61e-19	Eye color traits;
KIRP	cis	rs12693043	0.727	rs6748959	chr2:175424127	C/T	cg11778734	chr2:175439522	WIPF1	-0.59	-8.28	-0.47	8.01e-15	Urate levels (BMI interaction);
KIRP	cis	rs6496667	0.779	rs7170480	chr15:90951639	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	5.13	0.31	5.78e-7	Rheumatoid arthritis;
KIRP	cis	rs113084984	0.718	rs7558961	chr2:11683450	T/C	cg07314298	chr2:11723111	GREB1	0.39	5.12	0.31	6.04e-7	Breast cancer;
KIRP	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.63	7.34	0.42	3.08e-12	Mammographic density (dense area);
KIRP	cis	rs923375	0.857	rs12601330	chr17:3382791	G/A	cg16505927	chr17:3375209	SPATA22	0.57	5.06	0.31	8.06e-7	Myopia (pathological);
KIRP	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs12986413	0.967	rs1015670	chr19:2171490	G/A	cg09261902	chr19:2140048	AP3D1	0.64	10.0	0.54	5.7e-20	Height;
KIRP	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.64	-9.37	-0.51	4.96e-18	Body mass index;
KIRP	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-1.0	-10.57	-0.56	9.15e-22	HIV-1 control;
KIRP	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.92	15.71	0.71	5.62e-39	Headache;
KIRP	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.39	-0.47	3.84e-15	Total cholesterol levels;
KIRP	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.73	-7.98	-0.45	5.56e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1569175	0.655	rs4673650	chr2:200896267	G/C	cg17644776	chr2:200775616	C2orf69	-0.69	-4.92	-0.3	1.61e-6	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19524238	chr7:2802976	GNA12	-0.37	-5.48	-0.33	1.04e-7	Height;
KIRP	cis	rs4750440	0.702	rs4748068	chr10:14030692	T/A	cg27542038	chr10:14027202	FRMD4A	-0.47	-6.44	-0.38	6.38e-10	Adiponectin levels;
KIRP	cis	rs698813	0.851	rs2592199	chr2:44710169	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.53	0.33	8.16e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg25772418	chr12:131519998	GPR133	-0.41	-5.81	-0.35	1.91e-8	Longevity;
KIRP	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	5.0	0.3	1.1e-6	Rheumatoid arthritis;
KIRP	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg09231725	chr11:64357281	SLC22A12	-0.52	-5.91	-0.35	1.13e-8	Body mass index;Urate levels;
KIRP	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.83	8.64	0.48	7.13e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.81	-10.65	-0.56	4.83e-22	Menopause (age at onset);
KIRP	cis	rs1978968	0.913	rs12158823	chr22:18439420	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.89	-0.4	4.64e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.37	0.65	5.21e-31	Platelet count;
KIRP	cis	rs9420	0.784	rs10896656	chr11:57668941	C/G	cg19752551	chr11:57585705	CTNND1	-0.75	-10.41	-0.55	2.91e-21	Schizophrenia;
KIRP	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.83	0.45	1.41e-13	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18905155	chr10:54577662	NA	0.5	6.33	0.37	1.13e-9	Interleukin-4 levels;
KIRP	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-6.31	-0.37	1.32e-9	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11645898	0.513	rs55741258	chr16:72112480	C/T	cg14768367	chr16:72042858	DHODH	-0.64	-7.04	-0.41	1.92e-11	Blood protein levels;
KIRP	cis	rs6545883	0.524	rs2694619	chr2:61536901	C/T	cg15711740	chr2:61764176	XPO1	0.45	5.58	0.34	6.23e-8	Tuberculosis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12057946	chr11:120195905	TMEM136	-0.47	-6.21	-0.37	2.22e-9	Myopia;
KIRP	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.77	-0.69	9.15e-36	Height;
KIRP	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	trans	rs2048656	0.605	rs13249234	chr8:9650401	T/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.24	0.37	1.95e-9	Schizophrenia;
KIRP	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14169450	chr9:139327907	INPP5E	0.59	6.7	0.39	1.41e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.77	-10.95	-0.57	5.49e-23	Neurofibrillary tangles;
KIRP	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.54	-6.99	-0.41	2.51e-11	Iron status biomarkers;
KIRP	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17554472	chr22:41940697	POLR3H	-0.61	-6.56	-0.39	3.09e-10	Vitiligo;
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg14221460	chr8:27183342	PTK2B	0.5	6.39	0.38	8.3e-10	Neuroticism;
KIRP	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	1.07	15.28	0.7	1.67e-37	Menopause (age at onset);
KIRP	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	8.59	0.48	1.04e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg27432699	chr2:27873401	GPN1	-0.48	-6.34	-0.37	1.1e-9	Total body bone mineral density;
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00933542	chr6:150070202	PCMT1	0.3	5.67	0.34	3.97e-8	Lung cancer;
KIRP	cis	rs7534824	0.625	rs17409499	chr1:101504936	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	5.79	0.35	2.18e-8	Refractive astigmatism;
KIRP	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg09571762	chr12:39539558	NA	0.33	4.9	0.3	1.74e-6	Morning vs. evening chronotype;
KIRP	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg18154014	chr19:37997991	ZNF793	0.91	9.33	0.51	6.56e-18	Coronary artery calcification;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10116456	chr1:231838098	TSNAX-DISC1;DISC1	0.41	6.02	0.36	6.23e-9	Survival in pancreatic cancer;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg08975724	chr8:8085496	FLJ10661	0.67	9.22	0.51	1.4e-17	Systolic blood pressure;
KIRP	cis	rs6504950	0.745	rs1962045	chr17:52996150	C/T	cg26251398	chr17:52985966	TOM1L1	0.4	5.47	0.33	1.12e-7	Breast cancer;
KIRP	cis	rs965513	1.000	rs7850258	chr9:100549013	C/T	cg13688889	chr9:100608707	NA	0.6	7.68	0.44	3.75e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.55	0.75	3.02e-45	Height;
KIRP	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.49	-7.5	-0.43	1.15e-12	Coronary artery disease;
KIRP	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-7.5	-0.43	1.16e-12	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs6859018	1.000	rs28409559	chr5:158723294	G/A	cg26646896	chr5:158686746	NA	-0.37	-5.44	-0.33	1.27e-7	Serum sulfate level;
KIRP	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg19680485	chr15:31195859	MTMR15	-0.45	-5.38	-0.32	1.76e-7	Huntington's disease progression;
KIRP	cis	rs7190997	0.544	rs4889649	chr16:31362263	T/G	cg02846316	chr16:31340340	ITGAM	0.46	5.75	0.34	2.63e-8	IgA nephropathy;
KIRP	cis	rs7078219	0.714	rs11190136	chr10:101287681	A/G	cg07044859	chr10:101282883	NA	-0.34	-5.02	-0.3	1.01e-6	Dental caries;
KIRP	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.86	-11.66	-0.6	2.7e-25	Cognitive function;
KIRP	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.42	6.16	0.37	2.87e-9	Electroencephalogram traits;
KIRP	cis	rs1816752	0.905	rs4769348	chr13:24975113	G/A	cg22771759	chr13:24902376	NA	0.4	5.18	0.31	4.71e-7	Obesity-related traits;
KIRP	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.53	-0.38	3.75e-10	Morning vs. evening chronotype;
KIRP	cis	rs10982256	0.846	rs10817622	chr9:117242575	T/C	cg13636371	chr9:117264095	DFNB31	0.55	7.61	0.44	5.9e-13	Bipolar disorder;
KIRP	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg10223061	chr2:219282414	VIL1	0.44	6.96	0.41	3.1e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1978968	0.731	rs9605462	chr22:18459859	C/T	cg02610425	chr22:18483192	MICAL3	0.38	5.68	0.34	3.78e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs698833	0.962	rs1067386	chr2:44644257	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.27	0.32	2.97e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.31	5.59	0.34	6.07e-8	Calcium levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09417640	chr7:99723162	MBLAC1	0.48	6.2	0.37	2.36e-9	Interleukin-4 levels;
KIRP	cis	rs8054556	1.000	rs3814884	chr16:29994736	T/A	cg06326092	chr16:30034487	C16orf92	0.35	4.87	0.3	1.96e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7709377	0.595	rs10463676	chr5:115455536	C/G	cg23108291	chr5:115420582	COMMD10	0.41	4.95	0.3	1.39e-6	Metabolite levels  (X-11787);
KIRP	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg24296786	chr1:45957014	TESK2	0.51	5.71	0.34	3.29e-8	Homocysteine levels;
KIRP	cis	rs12615966	1.000	rs12620555	chr2:105379115	T/C	cg16465502	chr2:105461796	NA	0.64	5.68	0.34	3.76e-8	Pancreatic cancer;
KIRP	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.46	0.38	5.47e-10	Obesity-related traits;
KIRP	cis	rs7219021	0.669	rs35584414	chr17:47022727	C/G	cg16584676	chr17:46985605	UBE2Z	-0.43	-4.87	-0.3	2e-6	Schizophrenia or bipolar disorder;
KIRP	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-5.68	-0.34	3.79e-8	Colorectal cancer;
KIRP	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.86	13.68	0.66	4.72e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13082711	0.911	rs13097178	chr3:27527920	T/C	cg02860705	chr3:27208620	NA	0.53	7.16	0.42	9.47e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg08822215	chr16:89438651	ANKRD11	0.54	6.8	0.4	7.72e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg03115019	chr17:80708279	FN3K	0.42	4.9	0.3	1.71e-6	Glycated hemoglobin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03586029	chr4:128886849	MFSD8;C4orf29	0.56	7.07	0.41	1.61e-11	Parkinson's disease;
KIRP	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg15443732	chr18:74961078	GALR1	0.56	5.5	0.33	9.73e-8	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.69	6.86	0.4	5.6e-11	Axial length;
KIRP	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.81	0.66	1.62e-32	Alzheimer's disease;
KIRP	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	1.05	21.7	0.81	4.49e-59	Multiple myeloma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07866179	chr16:23652650	PALB2;DCTN5	0.5	6.16	0.37	2.98e-9	Parkinson's disease;
KIRP	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg08648136	chr8:956695	NA	0.38	5.49	0.33	1.02e-7	Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20746096	chr12:64238043	SRGAP1	-0.57	-6.27	-0.37	1.6e-9	Menopause (age at onset);
KIRP	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.08	12.84	0.63	3.24e-29	Vitiligo;
KIRP	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.59	7.67	0.44	4.12e-13	Longevity;Endometriosis;
KIRP	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-7.87	-0.45	1.14e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs78487399	0.808	rs17406646	chr2:43678617	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.14	-0.31	5.69e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.72	-7.8	-0.45	1.82e-13	DNA methylation (variation);
KIRP	cis	rs75920871	1.000	rs11216221	chr11:116868137	A/C	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs16828019	0.852	rs12406620	chr1:41512664	A/T	cg18742814	chr1:41828276	NA	0.69	5.91	0.35	1.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs12693043	0.727	rs7562798	chr2:175434640	C/T	cg11778734	chr2:175439522	WIPF1	-0.6	-8.81	-0.49	2.35e-16	Urate levels (BMI interaction);
KIRP	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.54	-0.52	1.51e-18	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-1.0	-12.29	-0.62	2.24e-27	Breast cancer;
KIRP	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.65	6.21	0.37	2.22e-9	Schizophrenia;
KIRP	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg13880726	chr7:1868755	MAD1L1	0.49	5.49	0.33	1.01e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.01	-0.3	1.06e-6	Coronary artery disease;
KIRP	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.47	-6.97	-0.41	2.85e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.81	-10.63	-0.56	5.76e-22	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13456812	chr6:167369504	RNASET2	0.72	6.7	0.39	1.41e-10	Lung function (FEV1);
KIRP	trans	rs7939886	0.920	rs11227729	chr11:56039901	G/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.71	8.93	0.49	1.02e-16	Morning vs. evening chronotype;
KIRP	cis	rs795484	0.610	rs2936839	chr12:118580315	T/C	cg16572268	chr12:118583242	PEBP1	-0.37	-5.26	-0.32	3.19e-7	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
KIRP	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg10167378	chr1:228756711	NA	0.51	5.8	0.35	2.07e-8	Diastolic blood pressure;
KIRP	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	15.2	0.7	3.17e-37	Electrocardiographic conduction measures;
KIRP	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.49	0.38	4.78e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs925255	0.711	rs12478126	chr2:28645948	C/T	cg01273330	chr2:28605224	NA	-0.32	-5.47	-0.33	1.11e-7	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg23522862	chr17:79829415	ARHGDIA	0.52	6.45	0.38	6.02e-10	Asthma;
KIRP	cis	rs9400467	0.506	rs12196873	chr6:111598058	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.52	-4.86	-0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs986417	1.000	rs1254298	chr14:60883842	C/T	cg27398547	chr14:60952738	C14orf39	-0.64	-5.49	-0.33	1e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.59	4.91	0.3	1.64e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg22903471	chr2:27725779	GCKR	-0.53	-7.69	-0.44	3.55e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg26875233	chr11:93583750	C11orf90	-0.44	-7.81	-0.45	1.65e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.62	7.27	0.42	4.91e-12	Height;
KIRP	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg12131826	chr15:77904385	NA	0.5	5.91	0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.3	-0.42	3.99e-12	Menopause (age at onset);
KIRP	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	11.88	0.6	5.12e-26	Systemic lupus erythematosus;
KIRP	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg08313168	chr12:7315531	NA	0.68	6.18	0.37	2.61e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.6	9.75	0.53	3.35e-19	Neuroticism;
KIRP	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.57	0.48	1.15e-15	Morning vs. evening chronotype;
KIRP	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.84	12.14	0.61	6.8e-27	Eye color traits;
KIRP	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg11569703	chr11:65557185	OVOL1	-0.59	-10.55	-0.56	1.04e-21	Acne (severe);
KIRP	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.4	-5.65	-0.34	4.46e-8	Headache;
KIRP	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.7	0.56	3.42e-22	Cognitive test performance;
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg10189774	chr4:17578691	LAP3	0.48	5.75	0.34	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15045943	chr5:171614719	STK10	0.46	6.12	0.36	3.71e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs412050	0.502	rs8136405	chr22:22148021	A/C	cg17089214	chr22:22089827	YPEL1	0.6	5.08	0.31	7.35e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.17	-0.46	1.59e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg21452805	chr1:244014465	NA	0.57	5.58	0.34	6.33e-8	RR interval (heart rate);
KIRP	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg00122941	chr17:4613640	ARRB2	0.81	8.59	0.48	1.03e-15	Lymphocyte counts;
KIRP	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.77	10.92	0.57	6.78e-23	Colorectal cancer;
KIRP	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.54	7.17	0.42	8.64e-12	Primary sclerosing cholangitis;
KIRP	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg22676075	chr6:135203613	NA	0.52	7.54	0.43	8.95e-13	Red blood cell count;
KIRP	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.84	0.53	1.78e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg03060546	chr3:49711283	APEH	0.43	5.47	0.33	1.1e-7	Parkinson's disease;
KIRP	cis	rs4908768	0.579	rs12142911	chr1:8857245	C/G	cg25722041	chr1:8623473	RERE	0.66	8.27	0.47	8.56e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.83	11.81	0.6	8.49e-26	Body mass index;
KIRP	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.8	-0.4	7.66e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6832769	1.000	rs1522110	chr4:56380283	C/T	cg05960024	chr4:56376020	CLOCK	0.64	8.26	0.47	9.23e-15	Personality dimensions;
KIRP	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.64	5.36	0.32	1.87e-7	Diabetic retinopathy;
KIRP	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	20.24	0.79	2.77e-54	Prudent dietary pattern;
KIRP	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg11522683	chr6:37501428	NA	-0.38	-4.98	-0.3	1.19e-6	Cognitive performance;
KIRP	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg08992911	chr2:238395768	MLPH	0.5	4.93	0.3	1.49e-6	Prostate cancer;
KIRP	cis	rs8038465	0.762	rs35149321	chr15:73962728	G/A	cg15420318	chr15:73925796	NPTN	0.58	7.91	0.45	9e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.71	-0.39	1.34e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg03160526	chr17:80928410	B3GNTL1	0.4	4.99	0.3	1.17e-6	Glycated hemoglobin levels;
KIRP	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg12573674	chr2:1569213	NA	-0.52	-5.05	-0.31	8.41e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.6	10.53	0.56	1.22e-21	Neuroticism;
KIRP	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18252515	chr7:66147081	NA	0.44	5.1	0.31	6.9e-7	Aortic root size;
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.78	9.97	0.54	6.77e-20	Developmental language disorder (linguistic errors);
KIRP	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.83	9.19	0.51	1.7e-17	Type 2 diabetes;
KIRP	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	9.29	0.51	8.31e-18	Total body bone mineral density;
KIRP	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg22396632	chr1:3079212	PRDM16	-0.37	-4.95	-0.3	1.36e-6	Migraine;
KIRP	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-7.48	-0.43	1.31e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.36	0.38	9.75e-10	Coronary artery disease;
KIRP	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg02478829	chr6:26598070	ABT1	0.36	5.21	0.32	4.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg24631222	chr15:78858424	CHRNA5	0.76	9.08	0.5	3.74e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11651000	0.625	rs2074190	chr17:45811210	A/G	cg03474202	chr17:45855739	NA	-0.37	-5.48	-0.33	1.05e-7	IgG glycosylation;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12756521	chr8:131028985	NA	-0.57	-6.41	-0.38	7.45e-10	Menopause (age at onset);
KIRP	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg18833306	chr6:118973337	C6orf204	-0.48	-4.86	-0.3	2.13e-6	Diastolic blood pressure;
KIRP	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.24	11.64	0.6	3.02e-25	Diabetic retinopathy;
KIRP	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.92	14.72	0.68	1.36e-35	Blood protein levels;
KIRP	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg18132916	chr6:79620363	NA	-0.41	-5.61	-0.34	5.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.66	9.02	0.5	5.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs9290065	0.686	rs1839021	chr3:160623669	T/G	cg04691961	chr3:161091175	C3orf57	0.43	6.21	0.37	2.24e-9	Kawasaki disease;
KIRP	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg12598211	chr12:123634384	NA	-0.45	-5.39	-0.32	1.66e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.6	8.22	0.46	1.18e-14	Homocysteine levels;
KIRP	trans	rs3779273	0.748	rs4236580	chr7:77835256	T/C	cg05596911	chr5:118502651	DMXL1	-0.44	-7.22	-0.42	6.63e-12	Body mass index;
KIRP	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.7	-7.53	-0.43	9.87e-13	DNA methylation (variation);
KIRP	cis	rs9914544	0.564	rs12451220	chr17:18778421	C/T	cg26378065	chr17:18585709	ZNF286B	0.38	4.84	0.3	2.25e-6	Educational attainment (years of education);
KIRP	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.72	9.96	0.54	7.6e-20	Lung cancer;
KIRP	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg11266682	chr4:10021025	SLC2A9	0.34	4.95	0.3	1.35e-6	Blood metabolite levels;
KIRP	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.2	-0.37	2.41e-9	Triglycerides;
KIRP	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-5.09	-0.31	7.06e-7	IgG glycosylation;
KIRP	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.08	-0.31	7.52e-7	Breast cancer;
KIRP	trans	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg16141378	chr3:129829833	LOC729375	-0.59	-6.98	-0.41	2.75e-11	Neuroticism;
KIRP	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23969309	chr17:38278604	MSL1	-0.54	-6.02	-0.36	6.41e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg04369109	chr6:150039330	LATS1	-0.44	-5.33	-0.32	2.24e-7	Lung cancer;
KIRP	cis	rs231513	0.954	rs231501	chr17:41972303	C/T	cg26893861	chr17:41843967	DUSP3	-0.49	-5.09	-0.31	7.26e-7	Cognitive function;
KIRP	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg23307798	chr14:103986281	CKB	0.5	7.09	0.41	1.41e-11	Body mass index;
KIRP	cis	rs9398803	0.687	rs1826189	chr6:126922214	C/T	cg19875578	chr6:126661172	C6orf173	0.43	5.48	0.33	1.04e-7	Male-pattern baldness;
KIRP	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-9.82	-0.53	2.06e-19	Chronic sinus infection;
KIRP	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11987759	chr7:65425863	GUSB	0.47	6.04	0.36	5.68e-9	Aortic root size;
KIRP	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.63	-6.98	-0.41	2.79e-11	Asthma;
KIRP	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.52	-6.49	-0.38	4.6e-10	Type 2 diabetes;
KIRP	cis	rs1298062	0.790	rs25668	chr19:50965272	T/C	cg11430371	chr19:50961752	MYBPC2	0.39	5.29	0.32	2.71e-7	Age of smoking initiation;
KIRP	cis	rs453301	0.579	rs10096850	chr8:8798222	A/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.43	-0.38	6.63e-10	Joint mobility (Beighton score);
KIRP	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg08501292	chr6:25962987	TRIM38	0.91	6.27	0.37	1.65e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	cg04338863	chr8:33670619	NA	0.45	5.95	0.35	9.07e-9	Body mass index;
KIRP	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.46	-6.48	-0.38	4.95e-10	Birth weight;
KIRP	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg10018233	chr7:150070692	REPIN1	0.62	7.6	0.44	6.09e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7143963	0.609	rs3783386	chr14:103367708	C/T	cg24154132	chr14:103367632	TRAF3	0.29	5.5	0.33	9.59e-8	Body mass index;
KIRP	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.12	-0.31	6.16e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7221595	0.778	rs2290439	chr17:3924306	A/G	cg21734707	chr17:3908241	ZZEF1	0.5	5.48	0.33	1.07e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg04725166	chr1:7887271	PER3	-0.32	-5.06	-0.31	8.12e-7	Crohn's disease;
KIRP	cis	rs10802346	0.588	rs12027835	chr1:246363094	G/C	cg15962031	chr1:246363574	SMYD3	0.79	5.91	0.35	1.15e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.27	-0.42	4.63e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13793178	chr1:26232731	STMN1	0.46	6.27	0.37	1.57e-9	Myopia (pathological);
KIRP	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.81	-11.86	-0.6	5.65e-26	Asthma;
KIRP	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	9.21	0.51	1.51e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg17764715	chr19:33622953	WDR88	0.68	8.32	0.47	5.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04978709	chr7:75101039	POM121C	-0.46	-6.25	-0.37	1.85e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.41	-4.92	-0.3	1.58e-6	Coronary artery disease;
KIRP	cis	rs60311166	1.000	rs60770874	chr3:52750199	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	1.0	7.06	0.41	1.65e-11	CTACK levels;
KIRP	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg13180566	chr4:1052158	NA	0.55	5.56	0.33	6.94e-8	Recombination rate (females);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg05619116	chr3:27754569	NA	0.98	7.54	0.43	9.17e-13	P wave terminal force;
KIRP	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.93	-0.3	1.49e-6	Pulmonary function;
KIRP	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.89	0.3	1.85e-6	Tonsillectomy;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03952484	chr1:149899818	SF3B4	0.5	6.29	0.37	1.45e-9	Asthma;
KIRP	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.57	-0.39	3.01e-10	Type 2 diabetes;
KIRP	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg17279839	chr7:150038598	RARRES2	0.47	6.44	0.38	6.28e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01120514	chr4:25314414	ZCCHC4	0.56	7.37	0.43	2.55e-12	Parkinson's disease;
KIRP	cis	rs11997175	0.935	rs3903385	chr8:33687399	T/G	ch.8.33884649F	chr8:33765107	NA	0.43	5.12	0.31	6.31e-7	Body mass index;
KIRP	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg19507638	chr5:93509721	C5orf36	-0.59	-5.29	-0.32	2.71e-7	Diabetic retinopathy;
KIRP	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.5	-4.96	-0.3	1.34e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs7221595	0.825	rs61442612	chr17:3961019	C/T	cg09597638	chr17:3907349	NA	0.49	5.02	0.3	1.01e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4805272	0.962	rs888830	chr19:29324621	A/C	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg18225595	chr11:63971243	STIP1	0.67	6.1	0.36	4.2e-9	Mean platelet volume;
KIRP	cis	rs624899	0.655	rs1671825	chr19:11588405	A/G	cg08877591	chr19:11648452	CNN1	-0.67	-5.99	-0.36	7.22e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.34	5.38	0.32	1.72e-7	QRS complex (12-leadsum);
KIRP	cis	rs72772090	0.710	rs11745122	chr5:96060738	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-5.81	-0.35	1.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-6.16	-0.37	2.87e-9	Bipolar disorder;
KIRP	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.33e-11	Aortic root size;
KIRP	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.72	-8.86	-0.49	1.59e-16	Cognitive function;
KIRP	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg18882449	chr10:104885122	NT5C2	-0.5	-6.37	-0.38	9.06e-10	Arsenic metabolism;
KIRP	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.93	-13.38	-0.65	4.87e-31	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.58	-7.1	-0.41	1.33e-11	Obesity-related traits;
KIRP	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg27624424	chr6:160112604	SOD2	0.54	6.47	0.38	5.2400000000000005e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg16797656	chr11:68205561	LRP5	0.38	4.99	0.3	1.16e-6	Total body bone mineral density;
KIRP	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.82	8.53	0.48	1.56e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-1.01	-16.76	-0.73	1.41e-42	Height;
KIRP	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg24375607	chr4:120327624	NA	0.44	5.29	0.32	2.68e-7	Diastolic blood pressure;
KIRP	cis	rs6968419	0.755	rs2896181	chr7:115897884	A/G	cg02561103	chr7:115862891	TES	0.41	5.75	0.34	2.58e-8	Intraocular pressure;
KIRP	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.68	-9.46	-0.52	2.61e-18	Height;
KIRP	cis	rs2299587	0.830	rs28655174	chr8:17804665	G/A	cg01800426	chr8:17659068	MTUS1	-0.4	-4.89	-0.3	1.81e-6	Economic and political preferences;
KIRP	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg24747557	chr10:131355152	MGMT	0.49	6.75	0.4	1.05e-10	Response to temozolomide;
KIRP	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg02836325	chr17:76403955	PGS1	0.39	6.62	0.39	2.24e-10	HDL cholesterol levels;
KIRP	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.81e-7	Cognitive function;
KIRP	cis	rs11074306	0.508	rs12911001	chr15:28044435	T/C	cg26402630	chr15:28053930	OCA2	0.29	4.86	0.3	2.05e-6	Uveal melanoma;
KIRP	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.23	0.58	6.61e-24	Bladder cancer;
KIRP	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	1.2	11.24	0.58	6.22e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08109568	chr15:31115862	NA	-0.71	-8.86	-0.49	1.6e-16	Huntington's disease progression;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2072732	0.808	rs67908307	chr1:2954297	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg15282417	chr9:129245246	FAM125B	0.45	8.01	0.45	4.66e-14	Intraocular pressure;
KIRP	cis	rs9400467	0.508	rs11756643	chr6:111726146	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.67	-0.34	4.06e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6973256	0.705	rs2551023	chr7:133472662	A/C	cg10665199	chr7:133106180	EXOC4	-0.42	-4.91	-0.3	1.64e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.73	9.1	0.5	3.17e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg09699651	chr6:150184138	LRP11	0.47	6.26	0.37	1.68e-9	Lung cancer;
KIRP	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.48	-7.62	-0.44	5.56e-13	Platelet distribution width;
KIRP	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg21191810	chr6:118973309	C6orf204	-0.42	-4.89	-0.3	1.86e-6	Diastolic blood pressure;
KIRP	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg18209359	chr17:80159595	CCDC57	-0.38	-4.87	-0.3	1.99e-6	Life satisfaction;
KIRP	cis	rs71277158	0.688	rs77248289	chr3:169905625	C/T	cg04067573	chr3:169899625	PHC3	0.69	6.49	0.38	4.7e-10	Prostate cancer;
KIRP	cis	rs17592366	0.838	rs12437059	chr14:35326831	A/G	cg09327582	chr14:35236912	BAZ1A	0.69	5.25	0.32	3.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.37	-0.32	1.79e-7	Chronic sinus infection;
KIRP	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.33	0.47	5.86e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7027203	0.521	rs2265567	chr9:96515243	C/G	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.98e-10	DNA methylation (variation);
KIRP	cis	rs2916247	1.000	rs6995893	chr8:93034861	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.94	-0.45	7.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9972944	0.729	rs7211481	chr17:63766434	A/C	cg07283582	chr17:63770753	CCDC46	-0.5	-8.19	-0.46	1.46e-14	Total body bone mineral density;
KIRP	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg05082376	chr22:42548792	NA	-0.4	-5.36	-0.32	1.95e-7	Schizophrenia;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg13453750	chr1:205783389	SLC41A1	0.46	6.65	0.39	1.84e-10	Menarche (age at onset);
KIRP	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.44	-0.52	3e-18	Coronary artery disease;
KIRP	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.41	6.86	0.4	5.56e-11	Heart rate;
KIRP	cis	rs7923609	0.967	rs6479896	chr10:65126832	T/C	cg01631684	chr10:65280961	REEP3	-0.48	-5.66	-0.34	4.15e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.89	-0.45	9.75e-14	Retinal vascular caliber;
KIRP	cis	rs75229567	0.717	rs74527680	chr12:70235392	A/G	cg10114359	chr12:70132523	RAB3IP	1.32	8.96	0.5	8.15e-17	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg02725872	chr8:58115012	NA	-0.52	-5.86	-0.35	1.51e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.16e-51	Leprosy;
KIRP	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg18585693	chr11:117668161	DSCAML1	0.31	5.27	0.32	3.04e-7	Myopia;
KIRP	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg02733842	chr7:1102375	C7orf50	-0.5	-5.37	-0.32	1.8e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs4656940	0.574	rs7555286	chr1:160767249	C/T	cg17331569	chr1:160788135	LY9	-0.5	-6.07	-0.36	4.94e-9	Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08283932	chr20:43280707	ADA	0.46	6.45	0.38	5.95e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg15655495	chr12:38532458	NA	0.25	4.89	0.3	1.81e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg05721485	chr17:44071124	MAPT	0.58	7.75	0.44	2.44e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.05	0.41	1.84e-11	Height;
KIRP	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg03929089	chr4:120376271	NA	0.68	6.64	0.39	2.05e-10	Axial length;
KIRP	cis	rs9905704	0.681	rs887206	chr17:56575084	G/C	cg12560992	chr17:57184187	TRIM37	-0.52	-4.85	-0.3	2.23e-6	Testicular germ cell tumor;
KIRP	cis	rs9815354	0.597	rs80066790	chr3:42000843	A/G	cg03022575	chr3:42003672	ULK4	0.79	8.37	0.47	4.39e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	cg21523751	chr1:182988639	NA	0.36	4.86	0.3	2.14e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs3925075	1.000	rs12923297	chr16:31360944	T/C	cg02846316	chr16:31340340	ITGAM	0.63	9.79	0.53	2.57e-19	IgA nephropathy;
KIRP	cis	rs2635047	0.542	rs11082567	chr18:44769820	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.87	0.4	5.29e-11	Educational attainment;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4638749	0.501	rs1003018	chr2:108760922	G/T	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.14	-0.31	5.57e-7	Blood pressure;
KIRP	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.52	-6.75	-0.4	1.03e-10	Blood metabolite levels;
KIRP	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.82	13.48	0.65	2.16e-31	Height;
KIRP	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.53	0.48	1.5e-15	Prudent dietary pattern;
KIRP	cis	rs6516091	1.000	rs6516091	chr20:6050622	G/A	cg25325723	chr20:6104886	FERMT1	-0.48	-5.41	-0.33	1.47e-7	Abdominal aortic aneurysm;
KIRP	cis	rs1440410	0.835	rs9790396	chr4:144051519	G/A	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg03254818	chr6:169586852	NA	-0.47	-7.15	-0.41	1.01e-11	Pulse pressure;
KIRP	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg01631408	chr1:248437212	OR2T33	-0.67	-8.66	-0.48	6.15e-16	Common traits (Other);
KIRP	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg02461776	chr11:598696	PHRF1	0.49	5.23	0.32	3.65e-7	Systemic lupus erythematosus;
KIRP	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.54	-7.41	-0.43	2.05e-12	Ulcerative colitis;
KIRP	trans	rs7619833	1.000	rs2087758	chr3:27456579	T/A	cg22620680	chr3:122920514	SEC22A	-0.46	-6.25	-0.37	1.8e-9	Breast cancer;
KIRP	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.56	-5.92	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.13e-8	Life satisfaction;
KIRP	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg26784012	chr10:32216390	ARHGAP12	0.32	5.1	0.31	6.74e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg20578329	chr17:80767326	TBCD	-0.65	-7.46	-0.43	1.48e-12	Breast cancer;
KIRP	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg10636391	chr1:45672074	ZSWIM5	-0.46	-6.15	-0.37	3.19e-9	Pancreatic cancer;
KIRP	cis	rs7551222	0.634	rs11801289	chr1:204528969	G/C	cg20240347	chr1:204465584	NA	-0.44	-8.58	-0.48	1.09e-15	Schizophrenia;
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.5	6.3	0.37	1.38e-9	Longevity;
KIRP	cis	rs9400467	0.537	rs3218591	chr6:111696129	T/A	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg01631408	chr1:248437212	OR2T33	-0.71	-9.59	-0.52	1.04e-18	Common traits (Other);
KIRP	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg18944383	chr4:111397179	ENPEP	0.7	13.18	0.64	2.33e-30	Coronary artery disease;
KIRP	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.94	-0.5	9.66e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.01	0.3	1.03e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8060686	0.516	rs8048364	chr16:68253324	T/G	cg26727032	chr16:67993705	SLC12A4	-0.75	-8.93	-0.49	1.02e-16	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs244899	0.967	rs2432642	chr5:167921047	C/G	cg06604206	chr5:167912465	RARS	-0.53	-7.5	-0.43	1.12e-12	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.85	9.94	0.54	8.61e-20	Neutrophil percentage of white cells;
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg05562828	chr17:3906858	NA	0.77	16.28	0.72	6.18e-41	Type 2 diabetes;
KIRP	trans	rs12545912	0.739	rs12541617	chr8:9539099	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.22	-0.37	2.13e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs812925	0.964	rs11125883	chr2:61710573	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-4.96	-0.3	1.33e-6	Immature fraction of reticulocytes;
KIRP	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.18	12.93	0.64	1.62e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.79	7.59	0.44	6.77e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg21395723	chr22:39101663	GTPBP1	0.4	5.46	0.33	1.17e-7	Menopause (age at onset);
KIRP	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg18461021	chr18:74961002	GALR1	0.51	5.3	0.32	2.55e-7	Obesity-related traits;
KIRP	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.39	0.38	8.39e-10	Menarche (age at onset);
KIRP	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg13319975	chr6:146136371	FBXO30	0.47	6.27	0.37	1.6e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg14082893	chr15:75400931	NA	0.35	5.18	0.31	4.72e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.56	6.44	0.38	6.07e-10	Coronary artery disease;
KIRP	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.33e-20	Hemoglobin concentration;
KIRP	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg01849789	chr22:41697279	ZC3H7B	-0.5	-5.56	-0.33	7e-8	Neuroticism;
KIRP	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.53	7.03	0.41	2.08e-11	Mean corpuscular volume;
KIRP	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.89	-12.13	-0.61	7.52e-27	Platelet distribution width;
KIRP	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	1.04	13.46	0.65	2.55e-31	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10861342	0.786	rs12303948	chr12:105591569	G/A	cg23923672	chr12:105501055	KIAA1033	0.96	7.25	0.42	5.29e-12	IgG glycosylation;
KIRP	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg12257156	chr7:158823799	VIPR2	0.32	5.26	0.32	3.08e-7	Facial morphology (factor 20);
KIRP	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.93	5.16	0.31	5.04e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.36	-0.32	1.92e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7712401	0.601	rs62377430	chr5:122334688	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs9905704	0.645	rs17175543	chr17:56803598	G/T	cg12560992	chr17:57184187	TRIM37	0.57	5.19	0.31	4.46e-7	Testicular germ cell tumor;
KIRP	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06850241	chr22:41845214	NA	-0.49	-5.49	-0.33	1.02e-7	Vitiligo;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.31	6.18	0.37	2.69e-9	Tonsillectomy;
KIRP	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.45	0.52	2.72e-18	Bipolar disorder;
KIRP	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg00277334	chr10:82204260	NA	-0.45	-5.14	-0.31	5.54e-7	Post bronchodilator FEV1;
KIRP	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.47	-0.33	1.11e-7	Life satisfaction;
KIRP	cis	rs834603	0.546	rs1534138	chr7:47482750	T/C	cg09696706	chr7:47479511	TNS3	0.42	4.86	0.3	2.08e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg22563815	chr15:78856949	CHRNA5	-0.44	-7.05	-0.41	1.78e-11	Sudden cardiac arrest;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08648041	chr20:2633689	NOP56;SNORD110	-0.49	-6.4	-0.38	7.86e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs78487399	0.808	rs114563746	chr2:43760880	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.04	-0.31	8.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4566357	1.000	rs1317770	chr2:227911725	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.32	-0.32	2.3e-7	Coronary artery disease;
KIRP	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.21	-5.18	-0.31	4.71e-7	Coronary artery disease;
KIRP	cis	rs4389656	0.778	rs2290616	chr5:6747104	C/T	cg10857441	chr5:6722123	POLS	0.45	5.45	0.33	1.25e-7	Coronary artery disease;
KIRP	cis	rs4664293	0.867	rs13389662	chr2:160586437	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs2290419	0.614	rs115322032	chr11:68943863	T/C	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.32	-5.22	-0.32	3.72e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28669119	0.778	rs80043958	chr5:88179575	A/G	cg18498987	chr5:88179539	MEF2C	0.52	6.4	0.38	7.97e-10	Schizophrenia;
KIRP	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.99	-0.3	1.15e-6	Schizophrenia;
KIRP	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.57	-0.43	7.4e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.28	-0.32	2.82e-7	Aortic root size;
KIRP	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg19292749	chr17:79650816	ARL16;HGS	0.53	5.58	0.34	6.38e-8	Dental caries;
KIRP	cis	rs55788414	0.932	rs59201365	chr16:81185681	C/G	cg06400318	chr16:81190750	PKD1L2	-0.89	-8.3	-0.47	7.01e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg05926928	chr17:57297772	GDPD1	0.97	10.36	0.55	4.29e-21	Opioid sensitivity;
KIRP	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg03714773	chr7:91764589	CYP51A1	0.4	5.81	0.35	1.9e-8	Breast cancer;
KIRP	cis	rs11593576	0.861	rs10824732	chr10:81009788	G/A	cg20744163	chr10:80999841	ZMIZ1	-0.4	-5.81	-0.35	1.88e-8	Vitiligo;
KIRP	trans	rs61839660	0.850	rs61839672	chr10:6111993	G/A	cg05165990	chr12:10365908	GABARAPL1	0.92	6.13	0.36	3.49e-9	Lymphocyte percentage of white cells;Type 1 diabetes;Crohn's disease;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg02896835	chr1:92012615	NA	-0.5	-5.13	-0.31	5.85e-7	Eosinophil percentage of white cells;
KIRP	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg00666640	chr1:248458726	OR2T12	0.46	6.14	0.36	3.22e-9	Common traits (Other);
KIRP	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.64	-7.71	-0.44	3.11e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.19	-0.46	1.39e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.78	7.95	0.45	6.61e-14	Uric acid levels;
KIRP	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18252515	chr7:66147081	NA	-0.48	-5.55	-0.33	7.44e-8	Aortic root size;
KIRP	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	0.78	6.97	0.41	2.82e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.0	13.88	0.66	9.64e-33	Response to antipsychotic treatment;
KIRP	cis	rs394563	0.839	rs584916	chr6:149790319	A/C	cg07828024	chr6:149772892	ZC3H12D	-0.31	-5.29	-0.32	2.7e-7	Dupuytren's disease;
KIRP	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	1.17	9.91	0.53	1.08e-19	Corneal curvature;
KIRP	cis	rs4683142	0.518	rs6802312	chr3:46025941	T/C	cg08033130	chr3:45983597	CXCR6;FYCO1	0.34	4.91	0.3	1.67e-6	Methadone dose in opioid dependence;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11200358	chr6:24719988	C6orf62	-0.56	-6.93	-0.4	3.76e-11	Interleukin-4 levels;
KIRP	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.71	0.44	3.07e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2594989	0.943	rs9878389	chr3:11457099	T/G	cg01796438	chr3:11312864	ATG7	-0.59	-7.59	-0.44	6.52e-13	Circulating chemerin levels;
KIRP	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg18154014	chr19:37997991	ZNF793	0.92	9.77	0.53	2.98e-19	Coronary artery calcification;
KIRP	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.47	7.08	0.41	1.53e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs73206853	0.698	rs1018133	chr12:111121302	G/C	cg12870014	chr12:110450643	ANKRD13A	0.5	4.86	0.3	2.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-1.0	-10.48	-0.56	1.77e-21	Post bronchodilator FEV1;
KIRP	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26240231	chr7:1148101	C7orf50	0.35	5.07	0.31	7.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17691542	chr6:26056736	HIST1H1C	0.49	6.26	0.37	1.67e-9	Iron status biomarkers;
KIRP	cis	rs17453880	0.963	rs6869968	chr5:151945837	A/G	cg12297329	chr5:152029980	NA	-0.69	-9.69	-0.53	5.01e-19	Subjective well-being;
KIRP	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.55	7.33	0.42	3.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs76693355	0.512	rs4938803	chr11:120268022	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.43	-5.5	-0.33	9.53e-8	Intraocular pressure;
KIRP	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.46	-7.1	-0.41	1.32e-11	Coronary artery disease;
KIRP	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Bladder cancer;
KIRP	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.97	-0.3	1.24e-6	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg11814155	chr7:99998594	ZCWPW1	0.57	5.43	0.33	1.38e-7	Platelet count;
KIRP	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.36	7.15	0.41	1.01e-11	Mean corpuscular volume;
KIRP	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.1	-0.31	6.73e-7	Colorectal cancer;
KIRP	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.02	-0.54	4.79e-20	Coffee consumption (cups per day);
KIRP	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-5.79	-0.35	2.16e-8	Schizophrenia;
KIRP	cis	rs1440410	0.965	rs57168887	chr4:144114195	C/T	cg01719995	chr4:144104893	USP38	0.45	6.02	0.36	6.47e-9	Ischemic stroke;
KIRP	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg16511985	chr3:153974050	SGEF	0.39	5.43	0.33	1.34e-7	Coronary artery disease;
KIRP	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg00507259	chr4:95128692	SMARCAD1	0.42	5.36	0.32	1.96e-7	QT interval;
KIRP	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg18825076	chr15:78729989	IREB2	-0.42	-4.96	-0.3	1.34e-6	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.57	-0.56	8.87e-22	Chronic sinus infection;
KIRP	trans	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg13565492	chr6:43139072	SRF	-0.7	-6.4	-0.38	7.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg04310649	chr10:35416472	CREM	-0.51	-6.01	-0.36	6.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg15556689	chr8:8085844	FLJ10661	0.5	6.49	0.38	4.56e-10	Myopia (pathological);
KIRP	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.55	7.05	0.41	1.81e-11	Longevity;
KIRP	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg22117172	chr7:91764530	CYP51A1	0.5	7.21	0.42	6.98e-12	Breast cancer;
KIRP	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.79	9.5	0.52	1.98e-18	Corneal astigmatism;
KIRP	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.07	0.8	5.15e-57	Prudent dietary pattern;
KIRP	cis	rs16828019	0.929	rs35813191	chr1:41742800	T/C	cg18742814	chr1:41828276	NA	0.62	5.65	0.34	4.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg09344028	chr17:70110421	NA	0.4	8.49	0.48	1.96e-15	Thyroid hormone levels;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.87	-9.09	-0.5	3.49e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg08885076	chr2:99613938	TSGA10	-0.38	-5.46	-0.33	1.17e-7	Bipolar disorder;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg09906747	chr21:34914446	SON;GART	0.53	6.42	0.38	6.94e-10	Plasma plasminogen activator levels;
KIRP	cis	rs4006360	0.505	rs8067313	chr17:39290306	G/T	cg25341923	chr17:39239918	KRTAP4-7	-0.6	-8.0	-0.45	4.85e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26913058	chr16:419975	MRPL28	-0.39	-4.94	-0.3	1.41e-6	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23207985	chr11:67034251	ADRBK1	0.52	6.02	0.36	6.2e-9	Smoking initiation;
KIRP	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg15605315	chr1:45957053	TESK2	-0.52	-6.73	-0.39	1.19e-10	High light scatter reticulocyte count;
KIRP	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.69e-59	Prudent dietary pattern;
KIRP	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg20387954	chr3:183756860	HTR3D	0.59	8.68	0.48	5.7e-16	Anterior chamber depth;
KIRP	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.62	6.88	0.4	4.82e-11	Crohn's disease;
KIRP	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-7.85	-0.45	1.3e-13	Gut microbiome composition (summer);
KIRP	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.47	7.83	0.45	1.45e-13	Testicular germ cell tumor;
KIRP	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.36	-5.23	-0.32	3.64e-7	Obesity-related traits;
KIRP	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17376030	chr22:41985996	PMM1	0.66	6.19	0.37	2.52e-9	Vitiligo;
KIRP	cis	rs600806	0.778	rs518697	chr1:110014778	G/A	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.620	rs61927734	chr12:33691977	A/T	cg26384229	chr12:38710491	ALG10B	-0.52	-6.17	-0.37	2.78e-9	Morning vs. evening chronotype;
KIRP	cis	rs236907	0.859	rs34320898	chr1:171759139	G/C	cg01410279	chr1:171621941	MYOC	-0.49	-4.86	-0.3	2.05e-6	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.62e-9	Lung cancer;
KIRP	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.73	9.7	0.53	4.75e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00701992	chr19:7621749	PNPLA6	-0.46	-6.41	-0.38	7.48e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4523957	0.890	rs216217	chr17:2145090	G/A	cg16513277	chr17:2031491	SMG6	0.59	8.06	0.46	3.36e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.54	-8.27	-0.47	8.33e-15	Huntington's disease progression;
KIRP	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.75	10.43	0.55	2.42e-21	Diastolic blood pressure;
KIRP	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	cg21523751	chr1:182988639	NA	0.42	6.43	0.38	6.48e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg22189786	chr22:42395067	WBP2NL	0.44	5.67	0.34	3.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg05592363	chr5:78908495	PAPD4	0.56	6.21	0.37	2.21e-9	Response to statin therapy;
KIRP	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-7.67	-0.44	4.02e-13	Pulmonary function;
KIRP	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.47	5.4	0.33	1.53e-7	Osteoporosis;
KIRP	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02725872	chr8:58115012	NA	-0.7	-8.38	-0.47	4.18e-15	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02369015	chr19:2702924	GNG7	0.48	6.3	0.37	1.33e-9	Parkinson's disease;
KIRP	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg08700190	chr5:6636046	SRD5A1	-0.48	-5.94	-0.35	9.51e-9	Response to amphetamines;
KIRP	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.58	7.88	0.45	1.08e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-0.8	-8.86	-0.49	1.63e-16	Cannabis dependence symptom count;
KIRP	cis	rs7551222	0.752	rs4252677	chr1:204495253	G/A	cg20240347	chr1:204465584	NA	-0.46	-8.73	-0.49	4.06e-16	Schizophrenia;
KIRP	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg20735989	chr4:730612	PCGF3	-0.48	-6.06	-0.36	5e-9	White blood cell count;
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg08989290	chr16:615782	NHLRC4	0.46	6.91	0.4	4.03e-11	Height;
KIRP	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg07395648	chr5:131743802	NA	0.55	6.6	0.39	2.44e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	6.08	0.36	4.55e-9	Response to antipsychotic treatment;
KIRP	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg18441811	chr11:71824068	C11orf51	-0.78	-5.29	-0.32	2.67e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.56	9.41	0.51	3.69e-18	Lung cancer;
KIRP	cis	rs10207628	0.738	rs7575209	chr2:127884123	A/C	cg06223080	chr2:127868745	NA	-0.64	-8.29	-0.47	7.54e-15	Psychosis and Alzheimer's disease;
KIRP	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg15226275	chr6:116381976	FRK	-0.21	-5.59	-0.34	6.17e-8	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	9.54	0.52	1.46e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3736594	0.759	rs6753736	chr2:27958855	C/G	cg27432699	chr2:27873401	GPN1	-0.63	-8.04	-0.46	3.87e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.86	0.35	1.5e-8	Diabetic retinopathy;
KIRP	cis	rs447	0.945	rs4141151	chr7:83737361	A/G	cg22846510	chr7:83753280	SEMA3A	-0.43	-5.02	-0.3	9.97e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs988913	1.000	rs7744592	chr6:54826345	A/G	cg03513858	chr6:54763001	FAM83B	-0.38	-5.7	-0.34	3.41e-8	Menarche (age at onset);
KIRP	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	1.12	22.06	0.81	3.18e-60	Gut microbiome composition (winter);
KIRP	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.46	6.38	0.38	8.48e-10	Red blood cell count;
KIRP	cis	rs10875746	0.855	rs73102065	chr12:48492607	T/C	cg20731937	chr12:48336164	NA	0.42	5.29	0.32	2.73e-7	Longevity (90 years and older);
KIRP	cis	rs3126085	1.000	rs72697000	chr1:152276772	C/A	cg26876637	chr1:152193138	HRNR	-0.83	-8.38	-0.47	4.04e-15	Atopic dermatitis;
KIRP	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.55	7.1	0.41	1.35e-11	Monobrow;
KIRP	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg07068956	chr7:100330872	ZAN	-0.53	-5.52	-0.33	8.77e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg05304507	chr6:116381966	FRK	0.2	5.28	0.32	2.86e-7	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22152521	chr13:46543137	ZC3H13	-0.45	-6.62	-0.39	2.24e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.26e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.69	5.57	0.33	6.83e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7243821	0.705	rs62094098	chr18:52643654	C/G	cg26630735	chr18:52626848	CCDC68	0.65	6.63	0.39	2.16e-10	Chin dimples;
KIRP	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg05973401	chr12:123451056	ABCB9	0.51	5.45	0.33	1.2e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg15691649	chr6:25882328	NA	0.53	5.94	0.35	9.79e-9	Blood metabolite levels;
KIRP	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg00262122	chr8:11665843	FDFT1	-0.42	-5.09	-0.31	7.12e-7	Retinal vascular caliber;
KIRP	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.73	10.93	0.57	6.27e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg06212747	chr3:49208901	KLHDC8B	0.69	8.26	0.47	8.86e-15	Menarche (age at onset);
KIRP	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.4	-4.91	-0.3	1.68e-6	Obesity-related traits;
KIRP	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg03128945	chr5:622914	CEP72	-0.48	-6.86	-0.4	5.4e-11	Obesity-related traits;
KIRP	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg14580859	chr9:123691850	NA	0.37	5.14	0.31	5.58e-7	Prostate-specific antigen levels;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.87	12.12	0.61	8.36e-27	Breast cancer;
KIRP	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg12623918	chr2:306882	NA	0.4	5.05	0.31	8.63e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.64	6.73	0.39	1.19e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.5.92182126F	chr5:92156370	NA	0.46	6.77	0.4	9.2e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7714584	1.000	rs10078968	chr5:150244273	C/A	cg22134413	chr5:150180641	NA	0.56	5.12	0.31	6.24e-7	Crohn's disease;
KIRP	cis	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg00405596	chr8:11794950	NA	-0.4	-5.32	-0.32	2.39e-7	Triglycerides;
KIRP	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.21	-0.46	1.27e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.49	-5.31	-0.32	2.48e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.91	14.15	0.67	1.17e-33	Testicular germ cell tumor;
KIRP	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg08668510	chr10:1095578	IDI1	0.76	5.21	0.32	4.05e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs55962025	0.662	rs362309	chr4:3240915	G/C	cg06533319	chr4:3265114	C4orf44	0.42	5.28	0.32	2.83e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7084402	0.967	rs10826199	chr10:60274213	T/C	cg05938607	chr10:60274200	BICC1	0.42	10.22	0.55	1.15e-20	Refractive error;
KIRP	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg21775007	chr8:11205619	TDH	0.52	7.04	0.41	1.87e-11	Mood instability;
KIRP	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.61	6.98	0.41	2.71e-11	Height;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.63	6.76	0.4	9.69e-11	Gut microbiome composition (summer);
KIRP	cis	rs4478137	0.501	rs7657483	chr4:164232102	T/C	cg06758707	chr4:164254230	NPY1R	-0.48	-5.39	-0.32	1.67e-7	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg02725872	chr8:58115012	NA	-0.54	-6.12	-0.36	3.73e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg16898833	chr6:26189333	HIST1H4D	0.83	5.9	0.35	1.17e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.28	-0.37	1.5e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	6.98	0.41	2.79e-11	Aortic root size;
KIRP	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.25	0.47	9.85e-15	Motion sickness;
KIRP	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.11	-0.36	3.86e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.6	-0.44	6.03e-13	Mean corpuscular volume;
KIRP	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18252515	chr7:66147081	NA	0.48	5.61	0.34	5.46e-8	Aortic root size;
KIRP	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg07541023	chr7:19748670	TWISTNB	-0.69	-7.16	-0.42	9.5e-12	Thyroid stimulating hormone;
KIRP	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.64	-7.73	-0.44	2.81e-13	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg09256448	chr16:638327	NA	0.35	4.91	0.3	1.66e-6	Height;
KIRP	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs17067123	0.614	rs11727059	chr4:180065225	G/A	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg23719950	chr11:63933701	MACROD1	-0.69	-6.73	-0.39	1.2e-10	Mean platelet volume;
KIRP	cis	rs56399783	0.708	rs55868372	chr7:2758563	G/C	cg19731401	chr7:2775893	GNA12	0.75	6.84	0.4	6.37e-11	Childhood ear infection;
KIRP	cis	rs2151522	0.563	rs4424110	chr6:127120646	C/G	cg21431617	chr6:127135037	NA	-0.31	-5.5	-0.33	9.42e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2591576	0.753	rs62383279	chr5:165419031	G/A	cg13976338	chr5:165423657	NA	-0.78	-12.34	-0.62	1.55e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs3026101	0.671	rs3026144	chr17:5316680	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.48e-8	Body mass index;
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-0.96	-9.46	-0.52	2.63e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.68	7.28	0.42	4.61e-12	Lymphocyte counts;
KIRP	cis	rs6438504	0.883	rs7612846	chr3:118915168	G/C	cg25372693	chr3:118959985	B4GALT4	0.36	6.06	0.36	5.02e-9	Clozapine-induced cytotoxicity;
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.76e-7	Life satisfaction;
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg15117754	chr3:10150083	C3orf24	0.56	5.3	0.32	2.52e-7	Alzheimer's disease;
KIRP	cis	rs714027	0.534	rs140124	chr22:30143693	G/C	cg27665648	chr22:30112403	NA	0.47	6.67	0.39	1.72e-10	Lymphocyte counts;
KIRP	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.9	14.12	0.67	1.47e-33	Ulcerative colitis;
KIRP	cis	rs7523273	0.597	rs4844392	chr1:207991209	C/G	cg22525895	chr1:207977042	MIR29B2	-0.58	-5.46	-0.33	1.19e-7	Schizophrenia;
KIRP	cis	rs12900413	0.603	rs12907030	chr15:90301439	C/T	cg24650279	chr15:90327240	NA	-0.41	-5.08	-0.31	7.51e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg27205649	chr11:78285834	NARS2	0.64	8.01	0.46	4.45e-14	Alzheimer's disease (survival time);
KIRP	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-5.49	-0.33	1e-7	Height;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00734512	chr14:105106484	NA	-0.46	-6.26	-0.37	1.72e-9	Morning vs. evening chronotype;
KIRP	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.59	10.4	0.55	3.16e-21	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.47	5.7	0.34	3.38e-8	Body mass index;
KIRP	cis	rs6500395	0.588	rs4479221	chr16:48680835	G/C	cg04672837	chr16:48644449	N4BP1	0.38	5.26	0.32	3.15e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg00576331	chr11:65640516	EFEMP2	0.51	5.65	0.34	4.46e-8	Crohn's disease;
KIRP	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.11	-0.46	2.44e-14	Retinal vascular caliber;
KIRP	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.11	0.41	1.23e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.55	-6.31	-0.37	1.31e-9	Schizophrenia;
KIRP	cis	rs8016982	0.632	rs4899786	chr14:81643800	G/T	cg01989461	chr14:81687754	GTF2A1	-0.5	-5.15	-0.31	5.35e-7	Schizophrenia;
KIRP	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.47	6.15	0.37	3.07e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg00814883	chr7:100076585	TSC22D4	-0.51	-5.05	-0.31	8.63e-7	Lung function (FEV1/FVC);
KIRP	cis	rs16937	0.518	rs1172149	chr1:205224758	A/G	cg21643547	chr1:205240462	TMCC2	-0.46	-6.38	-0.38	8.95e-10	Schizophrenia;
KIRP	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.29	-0.51	8.76e-18	Aortic root size;
KIRP	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.95	-15.72	-0.71	5.21e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.56	0.39	3.18e-10	Major depressive disorder;
KIRP	cis	rs992157	0.932	rs10203039	chr2:219187367	T/C	cg04731861	chr2:219085781	ARPC2	-0.22	-5.23	-0.32	3.66e-7	Colorectal cancer;
KIRP	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.13	-0.31	5.83e-7	Inflammatory skin disease;
KIRP	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg05721485	chr17:44071124	MAPT	-0.55	-7.49	-0.43	1.26e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg27205649	chr11:78285834	NARS2	-0.54	-5.16	-0.31	5.15e-7	Testicular germ cell tumor;
KIRP	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.16	-0.31	5.2e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.49	-5.96	-0.36	8.67e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22878388	chr2:105853796	NA	-0.45	-7.27	-0.42	4.64e-12	Type 2 diabetes;
KIRP	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.38	7.94	0.45	7.13e-14	Body mass index;
KIRP	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.86	11.52	0.59	7.73e-25	Cognitive function;
KIRP	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-6.82	-0.4	6.83e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs13172324	0.649	rs10512919	chr5:7402004	A/G	cg18545596	chr22:40322629	GRAP2	-0.72	-6.41	-0.38	7.58e-10	Myopia (pathological);
KIRP	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs76917914	0.820	rs3739670	chr9:100819192	C/T	cg03040243	chr9:100819229	NANS	0.63	6.64	0.39	1.95e-10	Immature fraction of reticulocytes;
KIRP	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.86	0.4	5.64e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.81	-0.4	7.44e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg24881330	chr22:46731750	TRMU	0.75	4.88	0.3	1.88e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.99	0.45	5.09e-14	Height;
KIRP	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg23803603	chr1:2058230	PRKCZ	0.37	5.77	0.35	2.36e-8	Height;
KIRP	cis	rs7312774	0.618	rs4964518	chr12:107466217	C/T	cg16260113	chr12:107380972	MTERFD3	0.66	5.58	0.34	6.24e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg12718519	chr1:2058417	PRKCZ	-0.18	-5.22	-0.32	3.75e-7	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23063740	chr3:55182246	NA	-0.39	-6.59	-0.39	2.64e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6753739	0.745	rs4672911	chr2:219912538	C/T	cg01749213	chr2:219906749	CCDC108	0.41	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.76	-0.34	2.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.73	9.78	0.53	2.75e-19	Eye color traits;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg07701084	chr6:150067640	NUP43	0.7	9.88	0.53	1.34e-19	Lung cancer;
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.77	12.75	0.63	6.18e-29	Vitiligo;
KIRP	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.52e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.3	0.37	1.35e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg04935436	chr20:30431758	NA	0.48	6.38	0.38	8.85e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg14532426	chr21:33245908	HUNK	0.46	6.09	0.36	4.33e-9	Bladder cancer;
KIRP	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.0	-0.3	1.11e-6	Bipolar disorder;
KIRP	cis	rs7084402	0.935	rs1427195	chr10:60278967	T/C	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	7.19e-7	Bladder cancer;
KIRP	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.61	7.9	0.45	9.17e-14	Recalcitrant atopic dermatitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05274056	chr14:75451109	NA	0.47	6.08	0.36	4.47e-9	Interleukin-4 levels;
KIRP	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg06598544	chr20:61472147	COL9A3	0.65	5.51	0.33	9.17e-8	Obesity-related traits;
KIRP	cis	rs4594175	1.000	rs4594175	chr14:51606541	C/A	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg17182837	chr8:41585554	ANK1	-0.45	-6.32	-0.37	1.24e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.09	0.74	1.08e-43	Chronic sinus infection;
KIRP	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg07001201	chr5:642380	CEP72	0.52	6.12	0.36	3.69e-9	Obesity-related traits;
KIRP	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg21231944	chr12:82153410	PPFIA2	-0.41	-5.08	-0.31	7.64e-7	Resting heart rate;
KIRP	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg26531700	chr6:26746687	NA	0.41	5.58	0.33	6.47e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	1.000	rs4925067	chr17:19921222	C/G	cg13482628	chr17:19912719	NA	0.69	10.75	0.57	2.43e-22	Schizophrenia;
KIRP	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg21419209	chr3:44054225	NA	-0.75	-9.18	-0.5	1.88e-17	Coronary artery disease;
KIRP	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg26876637	chr1:152193138	HRNR	0.73	9.79	0.53	2.44e-19	Atopic dermatitis;
KIRP	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg03929089	chr4:120376271	NA	0.93	6.78	0.4	8.74e-11	Myopia (pathological);
KIRP	trans	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.78	-0.4	8.76e-11	Heart rate;
KIRP	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg24488311	chr11:68621650	NA	0.48	5.85	0.35	1.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18570751	chr11:61735315	FTH1	0.53	6.62	0.39	2.19e-10	Parkinson's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14195915	chr1:29507864	SFRS4	-0.46	-6.04	-0.36	5.79e-9	Metabolic traits;
KIRP	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg21546286	chr11:48923668	NA	-0.48	-6.12	-0.36	3.74e-9	HDL cholesterol;
KIRP	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.35	6.71	0.39	1.33e-10	Educational attainment (years of education);
KIRP	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg04226714	chr8:49833948	SNAI2	0.45	6.3	0.37	1.34e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22871610	chr4:56464927	NMU	-0.42	-7.23	-0.42	6.02e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg08888203	chr3:10149979	C3orf24	0.5	5.19	0.31	4.33e-7	Alzheimer's disease;
KIRP	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.64	8.78	0.49	2.8e-16	Autism;
KIRP	cis	rs7615316	0.902	rs9825207	chr3:142304543	T/C	cg20824294	chr3:142316082	PLS1	0.23	5.13	0.31	6.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.64	7.61	0.44	5.8e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg00928795	chr16:75261098	NA	-0.55	-5.02	-0.3	9.91e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	1.0	8.25	0.47	9.35e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg17736920	chr1:242011382	EXO1	0.43	5.18	0.31	4.58e-7	Menopause (age at onset);
KIRP	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg23705113	chr11:77774867	THRSP	-0.41	-5.02	-0.31	9.7e-7	Pelvic organ prolapse;
KIRP	cis	rs6142102	1.000	rs6059672	chr20:32705468	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	5.93	0.35	1.05e-8	Skin pigmentation;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.68	0.48	5.38e-16	Life satisfaction;
KIRP	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.47	7.72	0.44	2.88e-13	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.53	5.6	0.34	5.64e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg14187409	chr7:56174376	CHCHD2	0.67	6.35	0.38	1.01e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg02390115	chr1:21767211	NBPF3	0.63	8.94	0.5	9.23e-17	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg26207909	chr14:103986467	CKB	0.51	6.78	0.4	9.11e-11	Body mass index;
KIRP	cis	rs7666738	0.576	rs7660951	chr4:98651581	T/A	cg05340658	chr4:99064831	C4orf37	0.65	7.69	0.44	3.55e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2839627	0.598	rs9975526	chr21:44266573	T/A	cg03543861	chr21:44258195	NA	0.53	6.09	0.36	4.29e-9	Information processing speed;
KIRP	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg04624458	chr1:1913527	KIAA1751	0.51	7.28	0.42	4.39e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg04315214	chr1:2043799	PRKCZ	-0.39	-5.88	-0.35	1.31e-8	Height;
KIRP	cis	rs6973256	0.583	rs2430768	chr7:133340287	T/C	cg10665199	chr7:133106180	EXOC4	-0.51	-6.5	-0.38	4.42e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.79	12.7	0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.8	9.08	0.5	3.55e-17	Corneal astigmatism;
KIRP	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.64	-8.48	-0.48	2.05e-15	Calcium levels;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.82	7.69	0.44	3.47e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9660180	0.967	rs66701417	chr1:1698092	A/G	cg17747265	chr1:1875780	NA	-0.72	-12.81	-0.63	3.87e-29	Body mass index;
KIRP	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg04362960	chr10:104952993	NT5C2	0.42	5.05	0.31	8.68e-7	Colorectal cancer;
KIRP	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.16	-0.46	1.7e-14	Response to antipsychotic treatment;
KIRP	cis	rs60843830	0.517	rs58416198	chr2:175580	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	5.74	0.34	2.81e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.85	12.87	0.63	2.61e-29	Height;
KIRP	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.8	-0.35	2.07e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3922844	0.609	rs9311192	chr3:38634611	C/T	cg22884020	chr3:38081186	DLEC1	-0.39	-4.91	-0.3	1.69e-6	P wave duration;PR interval;QT interval;QRS duration;
KIRP	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	trans	rs7618501	0.699	rs9862795	chr3:49915506	A/T	cg21659725	chr3:3221576	CRBN	0.62	8.11	0.46	2.46e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs10861661	0.963	rs10778511	chr12:107225331	A/T	cg21360079	chr12:107162445	NA	-0.62	-7.61	-0.44	5.96e-13	Triglyceride levels;
KIRP	cis	rs1971762	0.527	rs7300936	chr12:54030586	C/T	cg23533419	chr12:54090519	NA	-0.35	-5.33	-0.32	2.2e-7	Height;
KIRP	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19700328	chr14:106028568	NA	-0.65	-6.73	-0.39	1.17e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.76	11.54	0.59	6.64e-25	Blood metabolite ratios;
KIRP	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg02725872	chr8:58115012	NA	-0.56	-6.43	-0.38	6.51e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-0.81	-7.37	-0.43	2.62e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	0.97	11.15	0.58	1.27e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.83	-11.21	-0.58	7.81e-24	Menopause (age at onset);
KIRP	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.94	8.93	0.49	9.85e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg21427119	chr20:30132790	HM13	-0.65	-6.78	-0.4	8.96e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs8033133	0.560	rs1549478	chr15:25332200	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.49	-6.11	-0.36	3.81e-9	Blood osmolality (transformed sodium);
KIRP	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg21775007	chr8:11205619	TDH	0.46	6.15	0.37	3.05e-9	Mood instability;
KIRP	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.56	8.15	0.46	1.87e-14	Fat distribution (HIV);
KIRP	cis	rs4523957	0.788	rs11078865	chr17:2109109	T/A	cg16513277	chr17:2031491	SMG6	-0.64	-8.73	-0.49	4.07e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg00631329	chr6:26305371	NA	-0.7	-8.9	-0.49	1.27e-16	Educational attainment;
KIRP	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs4805272	1.000	rs4805276	chr19:29327894	C/T	cg15000279	chr19:29285009	NA	-0.36	-5.07	-0.31	7.79e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.81	0.53	2.21e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26682649	chr17:3571907	TMEM93;TAX1BP3	-0.56	-6.48	-0.38	5.01e-10	Menopause (age at onset);
KIRP	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg24375607	chr4:120327624	NA	0.59	6.25	0.37	1.79e-9	Corneal astigmatism;
KIRP	cis	rs2301573	1.000	rs746210	chr3:129294568	G/A	cg15504747	chr3:129312979	PLXND1	-0.47	-5.02	-0.3	9.89e-7	Hip circumference;
KIRP	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg18132916	chr6:79620363	NA	-0.42	-5.73	-0.34	2.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7122257	0.601	rs11043111	chr11:11150534	A/G	cg16931664	chr11:11169707	NA	-0.45	-6.3	-0.37	1.36e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-10.33	-0.55	5.28e-21	Parkinson's disease;
KIRP	cis	rs2859741	0.587	rs580029	chr1:37471609	C/A	cg09363841	chr1:37513479	NA	-0.54	-8.41	-0.47	3.27e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg25110126	chr1:46999211	NA	0.45	5.66	0.34	4.22e-8	Monobrow;
KIRP	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.78e-9	Total body bone mineral density;
KIRP	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg18753928	chr3:113234510	CCDC52	-0.53	-6.71	-0.39	1.32e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs8126001	0.573	rs7271530	chr20:62727915	A/G	cg13277040	chr20:62716332	OPRL1;C20orf201	-0.3	-5.56	-0.33	7.11e-8	Pulse pressure;Mean corpuscular volume;
KIRP	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.51	-0.43	1.07e-12	Joint mobility (Beighton score);
KIRP	cis	rs17221829	0.644	rs7943100	chr11:89382037	C/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.1	-0.31	6.92e-7	Anxiety in major depressive disorder;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.0	0.3	1.08e-6	Menopause (age at onset);
KIRP	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.6	9.23	0.51	1.33e-17	Personality dimensions;
KIRP	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.68	8.68	0.48	5.72e-16	Facial morphology (factor 19);
KIRP	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.43	0.38	6.57e-10	Retinal vascular caliber;
KIRP	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg09231725	chr11:64357281	SLC22A12	0.61	8.03	0.46	3.95e-14	Urate levels in obese individuals;
KIRP	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg27572855	chr1:25598939	RHD	0.59	10.48	0.56	1.74e-21	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg23307798	chr14:103986281	CKB	0.79	13.84	0.66	1.28e-32	Body mass index;
KIRP	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg02158880	chr13:53174818	NA	0.37	5.05	0.31	8.41e-7	Lewy body disease;
KIRP	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.91	12.72	0.63	8.26e-29	Cognitive function;
KIRP	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg07741184	chr6:167504864	NA	-0.24	-6.42	-0.38	7.08e-10	Crohn's disease;
KIRP	cis	rs8103278	0.706	rs3810333	chr19:46318691	T/C	cg11657440	chr19:46296263	DMWD	-0.49	-5.94	-0.35	9.45e-9	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.06	0.61	1.27e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg24009623	chr19:33667908	NA	0.47	6.09	0.36	4.37e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.59	-7.33	-0.42	3.24e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);
KIRP	cis	rs1971762	0.527	rs6580953	chr12:54021138	T/C	cg16917193	chr12:54089295	NA	0.86	14.98	0.69	1.75e-36	Height;
KIRP	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg16141378	chr3:129829833	LOC729375	-0.46	-6.08	-0.36	4.66e-9	Retinal vascular caliber;
KIRP	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.51	0.43	1.1e-12	Lung cancer;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg21285383	chr16:89894308	SPIRE2	0.33	6.2	0.37	2.38e-9	Vitiligo;
KIRP	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg11054631	chr12:72667493	LOC283392;TRHDE	-0.5	-6.18	-0.37	2.7e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.23	-0.37	2.03e-9	Obesity-related traits;
KIRP	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.42	-4.97	-0.3	1.27e-6	Educational attainment;
KIRP	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-6.54	-0.38	3.54e-10	Systemic lupus erythematosus;
KIRP	cis	rs2791713	0.563	rs4844559	chr1:207162827	A/G	cg24040043	chr1:207224982	YOD1	0.28	4.88	0.3	1.88e-6	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg03929089	chr4:120376271	NA	-0.58	-6.72	-0.39	1.28e-10	Coronary artery disease;
KIRP	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.81	10.04	0.54	4.18e-20	Corneal astigmatism;
KIRP	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.57	-7.37	-0.43	2.53e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3120667	0.720	rs2146117	chr1:152416909	A/T	cg26876637	chr1:152193138	HRNR	0.64	6.04	0.36	5.74e-9	Eating disorders;
KIRP	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg16255804	chr6:135334527	HBS1L	-0.33	-5.37	-0.32	1.85e-7	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12813709	chr11:576467	PHRF1;LOC143666	0.46	6.17	0.37	2.85e-9	Parkinson's disease;
KIRP	cis	rs4849845	0.812	rs3931842	chr2:121039392	G/C	cg24070213	chr2:121070622	NA	0.38	5.19	0.31	4.36e-7	Mean platelet volume;
KIRP	cis	rs12476592	0.602	rs262495	chr2:63848607	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-4.95	-0.3	1.38e-6	Childhood ear infection;
KIRP	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.75	8.2	0.46	1.36e-14	Gut microbiome composition (summer);
KIRP	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.61	0.39	2.35e-10	Colorectal cancer;
KIRP	cis	rs7941600	0.708	rs10840202	chr11:9320346	G/T	cg19415743	chr11:9336845	TMEM41B	0.67	6.21	0.37	2.29e-9	Coronary artery disease;
KIRP	cis	rs17123764	0.818	rs11169081	chr12:49985210	G/A	cg02054252	chr12:50078554	FMNL3	0.42	4.96	0.3	1.35e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs35740288	1.000	rs17577449	chr15:86297185	G/A	cg17133734	chr15:86042851	AKAP13	-0.43	-4.88	-0.3	1.95e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg01689657	chr7:91764605	CYP51A1	0.38	5.65	0.34	4.52e-8	Breast cancer;
KIRP	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.77	-0.57	2.09e-22	Colorectal cancer;
KIRP	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg17168535	chr8:21777572	XPO7	0.89	14.06	0.67	2.32e-33	Mean corpuscular volume;
KIRP	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg03959625	chr15:84868606	LOC388152	0.45	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	0.87	9.87	0.53	1.47e-19	Pediatric areal bone mineral density (radius);
KIRP	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg16898833	chr6:26189333	HIST1H4D	0.95	5.79	0.35	2.15e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.1	0.31	6.93e-7	Breast cancer;
KIRP	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.28	14.54	0.68	5.29e-35	Uric acid levels;
KIRP	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.92e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.36	6.61	0.39	2.35e-10	Refractive error;
KIRP	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg11667643	chr8:748456	NA	-0.5	-5.87	-0.35	1.39e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs2904967	1.000	rs630055	chr11:65087533	G/T	cg09225861	chr11:65069680	NA	-0.47	-6.29	-0.37	1.41e-9	Mean corpuscular volume;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02711726	chr17:80685570	FN3KRP	-0.64	-8.91	-0.49	1.18e-16	Glycated hemoglobin levels;
KIRP	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg24807547	chr6:37504484	NA	-0.53	-8.11	-0.46	2.36e-14	Cognitive performance;
KIRP	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.74e-11	Vitiligo;
KIRP	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg15117754	chr3:10150083	C3orf24	0.51	5.14	0.31	5.51e-7	Alzheimer's disease;
KIRP	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	0.95	8.09	0.46	2.79e-14	Arsenic metabolism;
KIRP	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg09873164	chr1:152488093	CRCT1	0.57	7.68	0.44	3.7e-13	Hair morphology;
KIRP	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg20503657	chr10:835505	NA	-0.5	-5.86	-0.35	1.5e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.59	7.89	0.45	9.91e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg09695851	chr17:3907499	NA	0.86	16.66	0.73	3.21e-42	Type 2 diabetes;
KIRP	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg11344533	chr11:111475393	SIK2	-0.3	-5.16	-0.31	5.02e-7	Primary sclerosing cholangitis;
KIRP	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.49	5.98	0.36	7.76e-9	Height;
KIRP	cis	rs2635047	0.542	rs1512236	chr18:44768493	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.46	-0.38	5.44e-10	Educational attainment;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs925255	0.747	rs6547850	chr2:28629343	G/T	cg01273330	chr2:28605224	NA	0.36	6.31	0.37	1.29e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00765710	chr1:249200642	PGBD2	0.44	6.2	0.37	2.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.88	7.39	0.43	2.22e-12	Chronic lymphocytic leukemia;
KIRP	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.91	-0.4	4.08e-11	Neuroticism;
KIRP	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Hypertriglyceridemia;
KIRP	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg16926213	chr1:1841314	NA	0.32	5.43	0.33	1.34e-7	Body mass index;
KIRP	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	8.16	0.46	1.76e-14	IgG glycosylation;
KIRP	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.59	0.34	6.01e-8	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4262150	0.739	rs72799176	chr5:152154526	T/C	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	1.03	14.06	0.67	2.45e-33	Menopause (age at onset);
KIRP	cis	rs8113308	0.810	rs7258701	chr19:52445069	C/T	cg25782003	chr19:52490127	ZNF350	0.53	4.94	0.3	1.47e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg03959625	chr15:84868606	LOC388152	0.5	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg25486957	chr4:152246857	NA	-0.5	-5.47	-0.33	1.11e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.97	-15.05	-0.69	1.02e-36	Height;
KIRP	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg10167378	chr1:228756711	NA	0.52	5.93	0.35	1.01e-8	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25161114	chr18:61089948	VPS4B	0.51	6.37	0.38	9.45e-10	Parkinson's disease;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg08662619	chr6:150070041	PCMT1	0.38	6.21	0.37	2.25e-9	Lung cancer;
KIRP	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg09408571	chr1:101003634	GPR88	0.24	5.47	0.33	1.12e-7	Monocyte count;
KIRP	cis	rs2236918	0.932	rs1635517	chr1:242012033	A/G	cg17736920	chr1:242011382	EXO1	-0.75	-9.81	-0.53	2.12e-19	Menopause (age at onset);
KIRP	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.85	-0.3	2.16e-6	Dupuytren's disease;
KIRP	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.46	6.57	0.39	3.02e-10	Airway imaging phenotypes;
KIRP	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.53	-0.43	9.9e-13	Resting heart rate;
KIRP	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg23791538	chr6:167370224	RNASET2	-0.47	-5.71	-0.34	3.2e-8	Crohn's disease;
KIRP	cis	rs17453880	0.963	rs4304072	chr5:151953465	G/C	cg12297329	chr5:152029980	NA	-0.68	-10.25	-0.55	9.53e-21	Subjective well-being;
KIRP	cis	rs7546668	0.744	rs1800615	chr1:15832281	C/T	cg21858823	chr1:15850916	CASP9	0.46	5.13	0.31	5.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.62	-6.53	-0.38	3.82e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg08975724	chr8:8085496	FLJ10661	0.57	7.68	0.44	3.84e-13	Neuroticism;
KIRP	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.2e-8	Aortic root size;
KIRP	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.7	-7.62	-0.44	5.63e-13	Blood pressure (smoking interaction);
KIRP	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg13271783	chr10:134563150	INPP5A	-0.52	-6.8	-0.4	7.94e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4664293	0.833	rs3764969	chr2:160620848	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.28	-0.37	1.55e-9	Monocyte percentage of white cells;
KIRP	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-5.24	-0.32	3.5e-7	Aortic root size;
KIRP	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.28	-22.66	-0.82	3.82e-62	Breast cancer;
KIRP	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg18154014	chr19:37997991	ZNF793	-0.61	-6.68	-0.39	1.57e-10	Coronary artery calcification;
KIRP	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg09455208	chr3:40491958	NA	0.34	5.87	0.35	1.43e-8	Renal cell carcinoma;
KIRP	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.5	6.36	0.38	9.69e-10	Total body bone mineral density;
KIRP	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg20368463	chr18:77673604	PQLC1	0.66	5.48	0.33	1.05e-7	Opioid sensitivity;
KIRP	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.91	14.93	0.69	2.55e-36	Breast cancer;
KIRP	cis	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg07256732	chr16:621771	PIGQ	-0.47	-6.53	-0.38	3.64e-10	Height;
KIRP	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.49	-0.52	2.13e-18	Personality dimensions;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20284440	chr14:52118688	FRMD6	0.53	7.0	0.41	2.42e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05665937	chr4:1216051	CTBP1	0.57	8.0	0.45	5.01e-14	Obesity-related traits;
KIRP	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.68	-8.47	-0.48	2.21e-15	Tonsillectomy;
KIRP	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.88	-0.4	4.95e-11	Joint mobility (Beighton score);
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	1.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10489525	0.583	rs6691374	chr1:115642818	T/C	cg01522456	chr1:115632236	TSPAN2	0.76	10.53	0.56	1.23e-21	Autism;
KIRP	cis	rs4728302	0.869	rs13233690	chr7:133587328	C/T	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.74e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2172802	0.629	rs62304005	chr4:62494219	C/T	cg04118610	chr4:62707027	LPHN3	0.58	7.23	0.42	6.21e-12	Partial epilepsies;
KIRP	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.61	6.44	0.38	6.18e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.82	0.4	6.82e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	0.85	7.07	0.41	1.55e-11	Mean corpuscular volume;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg08662619	chr6:150070041	PCMT1	0.38	6.32	0.37	1.21e-9	Lung cancer;
KIRP	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs712039	0.652	rs853222	chr17:35790022	G/T	cg16670864	chr17:35848621	DUSP14	0.41	4.9	0.3	1.7e-6	Tuberculosis;
KIRP	cis	rs9361491	0.508	rs9352611	chr6:79396968	T/C	cg09184832	chr6:79620586	NA	-0.38	-4.92	-0.3	1.62e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.71e-36	Prostate cancer;
KIRP	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-7.35	-0.42	2.86e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6009824	0.891	rs6009820	chr22:50085456	C/T	cg22070880	chr22:50098194	NA	0.76	7.98	0.45	5.47e-14	Natriuretic peptide levels;
KIRP	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg23032965	chr3:12705835	RAF1	0.73	7.98	0.45	5.52e-14	Cholesterol, total;
KIRP	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg07870213	chr5:140052090	DND1	-0.63	-8.15	-0.46	1.86e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.99	-13.11	-0.64	4.04e-30	Homoarginine levels;
KIRP	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs8523	0.671	rs60376022	chr6:11027949	A/C	cg13562911	chr6:11044106	ELOVL2	0.41	5.31	0.32	2.51e-7	Red blood cell fatty acid levels;
KIRP	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg20965017	chr5:231967	SDHA	-0.58	-6.76	-0.4	9.71e-11	Breast cancer;
KIRP	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.21	-0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4389656	0.629	rs274669	chr5:6711947	T/A	cg10857441	chr5:6722123	POLS	-0.37	-5.22	-0.32	3.84e-7	Coronary artery disease;
KIRP	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg03929089	chr4:120376271	NA	0.63	6.33	0.37	1.16e-9	Axial length;
KIRP	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-5.43	-0.33	1.34e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg09137382	chr11:130731461	NA	-0.49	-6.51	-0.38	4.18e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg19847130	chr8:10466454	RP1L1	0.43	6.23	0.37	1.96e-9	Joint mobility (Beighton score);
KIRP	cis	rs7301016	1.000	rs11174495	chr12:62864931	A/G	cg01804193	chr12:63026212	NA	0.54	5.55	0.33	7.43e-8	IgG glycosylation;
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg07339812	chr16:25268887	ZKSCAN2	-0.44	-6.36	-0.38	1e-9	Type 1 diabetes;
KIRP	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	1.17	8.95	0.5	8.89e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.07	9.5	0.52	1.95e-18	Plateletcrit;
KIRP	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg17554472	chr22:41940697	POLR3H	-0.7	-6.98	-0.41	2.79e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.19	0.31	4.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	1.08	8.65	0.48	6.67e-16	Blood protein levels;
KIRP	cis	rs988913	0.581	rs3125267	chr6:54857921	A/G	cg03513858	chr6:54763001	FAM83B	-0.34	-4.9	-0.3	1.76e-6	Menarche (age at onset);
KIRP	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-0.71	-9.63	-0.52	8.01e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	16.99	0.73	2.26e-43	Platelet count;
KIRP	cis	rs6499255	1.000	rs4985523	chr16:69797192	T/A	cg15192750	chr16:69999425	NA	0.48	4.89	0.3	1.78e-6	IgE levels;
KIRP	cis	rs4700695	0.764	rs251593	chr5:65313889	G/A	cg21114390	chr5:65439923	SFRS12	0.58	6.28	0.37	1.5e-9	Facial morphology (factor 19);
KIRP	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg15534755	chr11:117069859	TAGLN	0.42	5.19	0.31	4.43e-7	Blood protein levels;
KIRP	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.46	5.87	0.35	1.4e-8	Initial pursuit acceleration;
KIRP	cis	rs829661	0.793	rs1525062	chr2:30768213	A/G	cg10949345	chr2:30726833	LCLAT1	-1.0	-13.38	-0.65	4.79e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.47e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg25174290	chr11:3078921	CARS	-0.66	-8.35	-0.47	4.84e-15	Calcium levels;
KIRP	cis	rs10782582	0.617	rs1146587	chr1:76229326	T/C	cg10523679	chr1:76189770	ACADM	0.39	5.76	0.34	2.55e-8	Daytime sleep phenotypes;
KIRP	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg02151108	chr14:50098012	C14orf104	-0.51	-6.78	-0.4	8.93e-11	Carotid intima media thickness;
KIRP	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg15691649	chr6:25882328	NA	-0.42	-5.03	-0.31	9.62e-7	Blood metabolite levels;
KIRP	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg21361702	chr7:150065534	REPIN1	0.51	5.02	0.31	9.72e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4936891	1.000	rs7119122	chr11:123917281	A/C	cg22125253	chr11:123886957	OR10G4	0.39	5.72	0.34	3.03e-8	Male fertility;
KIRP	cis	rs10178094	0.669	rs7595982	chr2:161332385	T/G	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.62	-0.34	5.1e-8	White blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09778919	chr12:40019907	C12orf40	0.55	7.36	0.42	2.73e-12	Interleukin-4 levels;
KIRP	cis	rs12496230	0.794	rs4856967	chr3:66864887	T/C	cg04995300	chr3:66848608	NA	0.43	6.53	0.38	3.78e-10	Type 2 diabetes;
KIRP	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-7.77	-0.44	2.19e-13	Arsenic metabolism;
KIRP	cis	rs7662987	1.000	rs7683704	chr4:100004226	C/T	cg13256891	chr4:100009986	ADH5	-0.66	-5.24	-0.32	3.44e-7	Smoking initiation;
KIRP	cis	rs981844	1.000	rs2606332	chr4:154655372	G/A	cg14289246	chr4:154710475	SFRP2	0.66	7.41	0.43	2.08e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs728616	0.681	rs35420115	chr10:81908188	A/G	cg27417294	chr10:81904244	PLAC9	0.56	5.05	0.31	8.68e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	11.27	0.58	4.86e-24	Calcium levels;
KIRP	cis	rs9311676	0.618	rs11130639	chr3:58406004	G/T	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg07645718	chr20:61493192	TCFL5	0.78	5.75	0.34	2.59e-8	Obesity-related traits;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg09597638	chr17:3907349	NA	-0.75	-14.16	-0.67	1.12e-33	Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.43	-5.04	-0.31	8.98e-7	Aortic root size;
KIRP	cis	rs9473924	0.505	rs7768747	chr6:50931762	G/A	cg14470998	chr6:50812995	TFAP2B	0.83	7.7	0.44	3.32e-13	Body mass index;
KIRP	cis	rs490234	0.702	rs13302549	chr9:128284775	T/C	cg14078157	chr9:128172775	NA	-0.65	-7.84	-0.45	1.36e-13	Mean arterial pressure;
KIRP	trans	rs3809095	0.521	rs7481887	chr11:16669707	A/C	cg15531249	chr16:85744077	C16orf74	0.43	6.05	0.36	5.3300000000000004e-09	Total body bone mineral density;
KIRP	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.61	-9.0	-0.5	6.44e-17	Menopause (age at onset);
KIRP	cis	rs4728302	0.869	rs7805864	chr7:133610390	G/A	cg10665199	chr7:133106180	EXOC4	0.44	5.45	0.33	1.19e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	4.87	0.3	2.03e-6	Schizophrenia;
KIRP	trans	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs6568686	0.786	rs3851227	chr6:111826301	C/G	cg15721981	chr6:111408429	SLC16A10	-0.71	-6.57	-0.39	2.95e-10	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg00383909	chr3:49044727	WDR6	0.44	4.86	0.3	2.05e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.6	6.99	0.41	2.51e-11	Iron status biomarkers;
KIRP	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.65	8.84	0.49	1.82e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs936229	0.906	rs9210	chr15:75128501	T/C	cg10253484	chr15:75165896	SCAMP2	-0.62	-7.15	-0.41	9.63e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2712184	0.683	rs2541406	chr2:217635847	C/G	cg05032264	chr2:217675019	NA	-0.39	-5.44	-0.33	1.3e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-5.89	-0.35	1.27e-8	Schizophrenia;
KIRP	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.72	-0.34	3.02e-8	Ulcerative colitis;
KIRP	trans	rs17685	0.849	rs3815455	chr7:75611756	C/T	cg19862616	chr7:65841803	NCRNA00174	0.62	7.22	0.42	6.58e-12	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7646881	0.904	rs112493023	chr3:158448276	A/G	cg19483011	chr3:158453295	NA	-0.5	-5.6	-0.34	5.67e-8	Tetralogy of Fallot;
KIRP	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.48	-7.08	-0.41	1.49e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7084402	0.967	rs1427197	chr10:60275150	A/G	cg05938607	chr10:60274200	BICC1	0.42	10.22	0.55	1.15e-20	Refractive error;
KIRP	cis	rs7119	0.635	rs2667764	chr15:77881239	C/T	cg12131826	chr15:77904385	NA	-0.45	-5.72	-0.34	3.02e-8	Type 2 diabetes;
KIRP	cis	rs7404928	1.000	rs3785397	chr16:23903132	A/G	cg21745164	chr16:23765304	CHP2	-0.36	-5.16	-0.31	4.99e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.49	-5.78	-0.35	2.3e-8	P wave terminal force;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05378295	chr18:19284987	ABHD3	0.54	6.7	0.39	1.37e-10	Parkinson's disease;
KIRP	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	1.38	9.77	0.53	2.99e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	9.37	0.51	4.71e-18	Response to bleomycin (chromatid breaks);
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg01283332	chr5:1856932	NA	-0.52	-6.54	-0.38	3.63e-10	Cardiovascular disease risk factors;
KIRP	cis	rs11997175	0.510	rs34465523	chr8:33796849	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.61	0.34	5.3e-8	Body mass index;
KIRP	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg00405596	chr8:11794950	NA	-0.46	-5.56	-0.33	7.13e-8	Neuroticism;
KIRP	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.68	-9.13	-0.5	2.59e-17	Huntington's disease progression;
KIRP	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.66	-0.63	1.27e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	14.28	0.67	4.35e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg01798813	chr17:3906674	NA	0.56	7.94	0.45	7e-14	Type 2 diabetes;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21893314	chr15:40453133	BUB1B	0.97	6.44	0.38	6.18e-10	P wave terminal force;
KIRP	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	8.19	0.46	1.45e-14	Migraine;Coronary artery disease;
KIRP	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.56	-6.04	-0.36	5.79e-9	DNA methylation (variation);
KIRP	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg22138327	chr13:27999177	GTF3A	0.68	6.38	0.38	8.49e-10	Weight;
KIRP	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-1.07	-20.96	-0.8	1.16e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg13819577	chr1:248512075	OR14C36	-0.38	-5.09	-0.31	7.21e-7	Common traits (Other);
KIRP	cis	rs60154123	0.730	rs608791	chr1:210464638	C/T	cg09074223	chr1:210466472	NA	0.53	5.63	0.34	4.99e-8	Coronary artery disease;
KIRP	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.58	0.39	2.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg07653901	chr22:50250238	ZBED4	0.42	5.05	0.31	8.62e-7	Schizophrenia;
KIRP	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg16141378	chr3:129829833	LOC729375	0.56	7.74	0.44	2.53e-13	Morning vs. evening chronotype;
KIRP	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg23100626	chr2:96804247	ASTL	-0.5	-7.06	-0.41	1.72e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1023500	1.000	rs6002554	chr22:42339095	T/C	cg04733989	chr22:42467013	NAGA	-0.53	-5.69	-0.34	3.54e-8	Schizophrenia;
KIRP	cis	rs4523957	0.928	rs170044	chr17:2197502	C/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.11	-0.46	2.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs16858210	0.874	rs1879256	chr3:183609061	A/G	cg01324343	chr3:183735012	ABCC5	0.39	5.23	0.32	3.64e-7	Menopause (age at onset);
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg17132465	chr8:120868177	DSCC1	0.46	6.09	0.36	4.32e-9	Coronary artery disease;
KIRP	cis	rs13102973	0.538	rs4626266	chr4:135914123	A/G	cg14419869	chr4:135874104	NA	0.38	5.71	0.34	3.26e-8	Subjective well-being;
KIRP	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.66	7.78	0.44	2.04e-13	Schizophrenia;
KIRP	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.28e-7	Schizophrenia;
KIRP	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg09904177	chr6:26538194	HMGN4	0.55	7.59	0.44	6.69e-13	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg02415014	chr8:143852576	LYNX1	-0.31	-4.88	-0.3	1.91e-6	Urinary tract infection frequency;
KIRP	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg09571762	chr12:39539558	NA	0.33	4.92	0.3	1.62e-6	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.77	12.03	0.61	1.59e-26	Colorectal cancer;
KIRP	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4919044	0.808	rs9419765	chr10:94798171	C/T	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.5	6.45	0.38	5.8e-10	Blood metabolite levels;
KIRP	cis	rs1978968	1.000	rs4410378	chr22:18451391	G/A	cg02610425	chr22:18483192	MICAL3	0.35	4.89	0.3	1.78e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs4132509	1.000	rs6660534	chr1:243791642	A/C	cg25706552	chr1:244017396	NA	0.53	6.88	0.4	4.91e-11	RR interval (heart rate);
KIRP	cis	rs9653442	0.545	rs13415465	chr2:100764004	T/G	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.66	-8.17	-0.46	1.6e-14	Aortic root size;
KIRP	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.66	-0.39	1.82e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs4716602	1.000	rs4716602	chr7:156166549	G/A	cg04090468	chr7:156181990	NA	0.5	6.1	0.36	4.1e-9	Anti-saccade response;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03813443	chr1:232765924	NA	0.49	6.58	0.39	2.82e-10	Parkinson's disease;
KIRP	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg25922239	chr6:33757077	LEMD2	0.57	7.22	0.42	6.64e-12	Crohn's disease;
KIRP	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg07777115	chr5:623756	CEP72	-0.55	-5.77	-0.35	2.38e-8	Obesity-related traits;
KIRP	cis	rs7011049	0.660	rs112735381	chr8:53867352	T/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.45	5.79	0.35	2.17e-8	Height;
KIRP	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.45	-5.25	-0.32	3.3e-7	Reticulocyte count;
KIRP	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.54	7.76	0.44	2.21e-13	Lewy body disease;
KIRP	cis	rs9549260	0.632	rs7323267	chr13:41204015	A/G	cg21288729	chr13:41239152	FOXO1	0.52	4.92	0.3	1.61e-6	Red blood cell count;
KIRP	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.03e-7	Type 2 diabetes;
KIRP	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.58	-6.75	-0.4	1.04e-10	Corneal astigmatism;
KIRP	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.07	0.41	1.63e-11	Rheumatoid arthritis;
KIRP	cis	rs12976411	0.575	rs6510240	chr19:32820082	A/G	cg02282382	chr19:32836354	ZNF507	0.6	5.06	0.31	8.11e-7	Coronary artery disease;
KIRP	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-1.06	-19.25	-0.78	5.21e-51	Height;
KIRP	trans	rs61931739	0.620	rs61927753	chr12:33699277	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-6.09	-0.36	4.24e-9	Morning vs. evening chronotype;
KIRP	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.04	-20.35	-0.79	1.19e-54	Platelet distribution width;
KIRP	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg17014757	chr1:203156097	CHI3L1	-0.64	-6.92	-0.4	3.99e-11	YKL-40 levels;
KIRP	cis	rs28719689	0.730	rs62483952	chr8:1259343	G/A	cg22761795	chr8:1265118	NA	0.96	7.26	0.42	5e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.6	7.92	0.45	8.1e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.75	-8.31	-0.47	6.37e-15	Parkinson's disease;
KIRP	cis	rs4845459	0.967	rs4845453	chr1:152591953	C/G	cg07796016	chr1:152779584	LCE1C	-0.46	-5.54	-0.33	7.86e-8	Psoriasis;
KIRP	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg16434002	chr17:42200994	HDAC5	-0.56	-6.7	-0.39	1.38e-10	Total body bone mineral density;
KIRP	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.69	-9.81	-0.53	2.19e-19	Lymphocyte counts;
KIRP	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg14458575	chr2:238380390	NA	0.6	8.12	0.46	2.25e-14	Prostate cancer;
KIRP	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05665937	chr4:1216051	CTBP1	0.49	6.77	0.4	9.47e-11	Obesity-related traits;
KIRP	cis	rs2224391	0.628	rs2753237	chr6:5252675	A/G	cg13962347	chr6:5174647	LYRM4	-0.71	-9.56	-0.52	1.28e-18	Height;
KIRP	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg03894339	chr8:19674705	INTS10	0.59	6.9	0.4	4.48e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-10.57	-0.56	8.97e-22	Schizophrenia;
KIRP	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.58	7.64	0.44	4.94e-13	Bladder cancer;
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg17441377	chr17:3906640	NA	-0.5	-7.27	-0.42	4.73e-12	Type 2 diabetes;
KIRP	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.65	-9.51	-0.52	1.85e-18	Retinal vascular caliber;
KIRP	cis	rs13161895	0.941	rs12519642	chr5:179438626	T/G	cg02702477	chr5:179499311	RNF130	-0.69	-5.36	-0.32	1.95e-7	LDL cholesterol;
KIRP	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.43	5.71	0.34	3.29e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.38	-4.92	-0.3	1.58e-6	Mean platelet volume;
KIRP	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg03714773	chr7:91764589	CYP51A1	0.39	5.86	0.35	1.48e-8	Breast cancer;
KIRP	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg15832292	chr6:96025679	MANEA	0.71	5.7	0.34	3.38e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg08975724	chr8:8085496	FLJ10661	0.75	10.3	0.55	6.61e-21	Neuroticism;
KIRP	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.25	-0.42	5.38e-12	Type 2 diabetes;
KIRP	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.26	-0.32	3.07e-7	Pulmonary function;
KIRP	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg02569458	chr12:86230093	RASSF9	0.38	5.51	0.33	9.24e-8	Major depressive disorder;
KIRP	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-5.75	-0.34	2.59e-8	Subjective well-being;
KIRP	trans	rs6601327	0.602	rs35431433	chr8:9660621	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.7	-0.39	1.41e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2150410	0.833	rs9982122	chr21:40547310	G/A	cg11890956	chr21:40555474	PSMG1	-0.76	-5.53	-0.33	8e-8	Temperament (bipolar disorder);
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg17441377	chr17:3906640	NA	0.51	7.63	0.44	5.05e-13	Type 2 diabetes;
KIRP	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg23950597	chr19:37808831	NA	-0.67	-5.66	-0.34	4.18e-8	Coronary artery calcification;
KIRP	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg08992911	chr2:238395768	MLPH	0.45	5.54	0.33	7.9e-8	Prostate cancer;
KIRP	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.64	7.96	0.45	6.22e-14	Corneal astigmatism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10724491	chr3:112738377	C3orf17	0.49	6.17	0.37	2.79e-9	Myopia (pathological);
KIRP	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.38	0.51	4.48e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.89	-17.4	-0.74	9.76e-45	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.51	5.27	0.32	3.02e-7	Height;
KIRP	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.52	6.17	0.37	2.79e-9	Breast cancer;
KIRP	cis	rs6691722	0.503	rs3765427	chr1:24705567	G/A	cg18323236	chr1:24743029	NIPAL3	0.45	6.41	0.38	7.22e-10	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs10463316	0.894	rs7709994	chr5:150753597	A/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-7.03	-0.41	2.06e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2862064	0.872	rs4704734	chr5:156480406	G/A	cg12943317	chr5:156479607	HAVCR1	-0.79	-7.22	-0.42	6.56e-12	Platelet count;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22168489	chr12:122356033	WDR66	0.59	8.87	0.49	1.49e-16	Mean corpuscular volume;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-1.0	-17.93	-0.75	1.5e-46	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.07	-13.44	-0.65	2.92e-31	Alzheimer's disease;
KIRP	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.61	-0.34	5.53e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg06640241	chr16:89574553	SPG7	0.65	8.56	0.48	1.24e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs7107770	0.825	rs4935911	chr11:125084742	G/A	cg04164023	chr11:125106101	PKNOX2	-0.61	-5.16	-0.31	5.13e-7	Photic sneeze reflex;
KIRP	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-14.23	-0.67	6.09e-34	Gut microbiome composition (summer);
KIRP	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg23531748	chr20:60969906	CABLES2	0.35	4.85	0.3	2.22e-6	Colorectal cancer;
KIRP	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg21638338	chr7:157276278	NA	0.42	5.15	0.31	5.45e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs11628318	0.563	rs4906234	chr14:103076928	G/C	cg01864069	chr14:103024347	NA	-0.54	-6.29	-0.37	1.48e-9	Platelet count;
KIRP	cis	rs1456297	0.806	rs11857716	chr15:51759152	T/C	cg14296394	chr15:51910925	DMXL2	0.72	9.7	0.53	4.85e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	7.16	0.42	9.09e-12	Iron status biomarkers;
KIRP	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12311346	chr5:56204834	C5orf35	-0.39	-5.38	-0.32	1.71e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg15038512	chr6:170123185	PHF10	0.48	5.39	0.33	1.62e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg22029157	chr1:209979665	IRF6	-0.44	-6.62	-0.39	2.2e-10	Monobrow;
KIRP	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg22437258	chr11:111473054	SIK2	-0.42	-4.93	-0.3	1.5e-6	Primary sclerosing cholangitis;
KIRP	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg11518657	chr1:67396239	MIER1	0.61	6.01	0.36	6.56e-9	Lymphocyte percentage of white cells;
KIRP	cis	rs1359582	0.793	rs861507	chr10:90410363	C/T	cg15661332	chr10:90342814	RNLS	0.57	5.75	0.34	2.64e-8	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg07117364	chr1:16154769	NA	-0.42	-5.08	-0.31	7.62e-7	Dilated cardiomyopathy;
KIRP	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg21775007	chr8:11205619	TDH	-0.45	-5.86	-0.35	1.51e-8	Neuroticism;
KIRP	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.59	7.87	0.45	1.1e-13	Lymphocyte counts;
KIRP	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.38	-0.51	4.47e-18	Personality dimensions;
KIRP	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.5	-0.48	1.85e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7560272	0.538	rs1806683	chr2:73939812	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.51	-0.33	8.81e-8	Schizophrenia;
KIRP	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.94	14.99	0.69	1.57e-36	Mean corpuscular volume;
KIRP	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.84	0.49	1.86e-16	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.18	0.42	8.22e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg19197139	chr17:4613644	ARRB2	0.74	7.6	0.44	6.1e-13	Lymphocyte counts;
KIRP	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg18306943	chr3:40428807	ENTPD3	0.47	6.05	0.36	5.41e-9	Renal cell carcinoma;
KIRP	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.29	-0.37	1.47e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg18306943	chr3:40428807	ENTPD3	-0.42	-5.78	-0.35	2.3e-8	Renal cell carcinoma;
KIRP	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-6.29	-0.37	1.41e-9	Obesity (extreme);
KIRP	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.73	0.44	2.71e-13	Coffee consumption (cups per day);
KIRP	cis	rs1408799	0.630	rs2762457	chr9:12689313	G/T	cg05274944	chr9:12693694	TYRP1	0.37	5.27	0.32	2.92e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.57	-0.33	6.51e-8	IgG glycosylation;
KIRP	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.51	-6.2	-0.37	2.37e-9	Body mass index;
KIRP	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-7.84	-0.45	1.4e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs3784262	0.874	rs11852835	chr15:58228599	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.5	-6.8	-0.4	7.73e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7601312	1.000	rs13010444	chr2:229318429	G/A	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs12282928	0.700	rs2047815	chr11:48199897	C/T	cg26585981	chr11:48327164	OR4S1	0.48	5.82	0.35	1.84e-8	Migraine - clinic-based;
KIRP	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg09029085	chr17:47094198	IGF2BP1	0.25	5.65	0.34	4.49e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs10465746	0.967	rs11163868	chr1:84397013	T/G	cg10977910	chr1:84465055	TTLL7	0.47	5.77	0.35	2.38e-8	Obesity-related traits;
KIRP	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg24375607	chr4:120327624	NA	0.58	6.73	0.39	1.15e-10	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11410731	chr4:24586118	DHX15	0.54	6.98	0.41	2.72e-11	Parkinson's disease;
KIRP	cis	rs4148087	0.929	rs4148098	chr21:43639553	T/A	cg08841829	chr21:43638893	ABCG1	-0.58	-4.92	-0.3	1.58e-6	Eating disorder in bipolar disorder;
KIRP	cis	rs73200209	0.869	rs55862915	chr12:116695932	G/A	cg01776926	chr12:116560359	MED13L	-0.46	-5.46	-0.33	1.18e-7	Total body bone mineral density;
KIRP	cis	rs6001982	0.748	rs73167067	chr22:40875199	C/G	cg07138101	chr22:40742427	ADSL	0.7	5.67	0.34	3.95e-8	Breast cancer;
KIRP	cis	rs4253772	1.000	rs4253772	chr22:46627603	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-6.17	-0.37	2.79e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.48	0.65	2.14e-31	Electrocardiographic conduction measures;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00001245	chr3:15106710	MRPS25	0.51	6.66	0.39	1.78e-10	Parkinson's disease;
KIRP	cis	rs6088813	1.000	rs4911178	chr20:33952620	C/T	cg14752227	chr20:34000481	UQCC	-0.5	-6.68	-0.39	1.61e-10	Height;
KIRP	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg25486957	chr4:152246857	NA	-0.42	-4.9	-0.3	1.7e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg23188430	chr6:125850052	NA	-0.32	-5.19	-0.31	4.47e-7	Brugada syndrome;
KIRP	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.69	-6.36	-0.38	9.56e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	10.06	0.54	3.76e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-5.72	-0.34	3.1e-8	Alzheimer's disease (late onset);
KIRP	cis	rs240764	0.817	rs240143	chr6:101080621	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg03808351	chr9:123631620	PHF19	-0.41	-5.61	-0.34	5.36e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	9.0	0.5	6.43e-17	Prudent dietary pattern;
KIRP	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg09029085	chr17:47094198	IGF2BP1	0.24	5.6	0.34	5.63e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.46	5.84	0.35	1.68e-8	HDL cholesterol;
KIRP	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.55	5.93	0.35	9.96e-9	Type 2 diabetes;
KIRP	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg10434728	chr15:90938212	IQGAP1	0.41	7.23	0.42	5.91e-12	Rheumatoid arthritis;
KIRP	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	7.44	0.43	1.66e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg24631222	chr15:78858424	CHRNA5	0.76	9.03	0.5	5.24e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg25914931	chr10:94352760	KIF11	-0.58	-6.02	-0.36	6.41e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.85	-0.63	2.87e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg19731401	chr7:2775893	GNA12	0.68	6.55	0.39	3.38e-10	Childhood ear infection;
KIRP	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.62	-8.68	-0.48	5.48e-16	Schizophrenia;
KIRP	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg00343986	chr7:65444356	GUSB	-0.4	-4.95	-0.3	1.37e-6	Aortic root size;
KIRP	cis	rs35883536	0.900	rs7520474	chr1:101091376	T/C	cg06223162	chr1:101003688	GPR88	-0.34	-6.84	-0.4	6.27e-11	Monocyte count;
KIRP	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.67	-10.45	-0.55	2.16e-21	Hepatocellular carcinoma;
KIRP	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg10189774	chr4:17578691	LAP3	0.44	5.39	0.32	1.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12780845	0.540	rs7096079	chr10:17180675	A/C	cg01003015	chr10:17271136	VIM	-0.51	-6.76	-0.4	1.02e-10	Homocysteine levels;
KIRP	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.06	-0.54	3.7799999999999997e-20	Hemoglobin concentration;
KIRP	cis	rs11874712	1.000	rs11082509	chr18:43655010	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.4	-5.68	-0.34	3.76e-8	Migraine - clinic-based;
KIRP	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.81	11.04	0.58	2.79e-23	Breast cancer;
KIRP	cis	rs240764	0.817	rs12199888	chr6:101154419	T/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.47	-0.33	1.11e-7	Neuroticism;
KIRP	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.76	0.81	2.97e-59	Prudent dietary pattern;
KIRP	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg21573476	chr21:45109991	RRP1B	0.78	10.45	0.55	2.16e-21	Mean corpuscular volume;
KIRP	trans	rs4650994	0.816	rs2761470	chr1:178596033	G/C	cg05059571	chr16:84539110	KIAA1609	0.56	7.35	0.42	2.84e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs6601327	0.571	rs35874762	chr8:9565392	C/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.41	-0.43	1.98e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13129231	0.806	rs17676882	chr4:114373068	C/T	cg21323720	chr4:114357601	NA	0.4	4.92	0.3	1.56e-6	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
KIRP	cis	rs2916247	0.862	rs7012347	chr8:93116149	T/C	cg10183463	chr8:93005414	RUNX1T1	0.46	5.37	0.32	1.85e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-8.75	-0.49	3.39e-16	Platelet distribution width;
KIRP	cis	rs35883536	0.740	rs4604711	chr1:101089492	A/C	cg06223162	chr1:101003688	GPR88	0.32	6.5	0.38	4.55e-10	Monocyte count;
KIRP	cis	rs2548003	0.518	rs2014316	chr5:28723711	T/C	cg22863700	chr5:28928346	NA	0.64	6.63	0.39	2.05e-10	Hip geometry;
KIRP	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.32	0.62	1.76e-27	Platelet count;
KIRP	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg12165864	chr7:66369176	NA	-0.48	-4.88	-0.3	1.92e-6	Corneal structure;
KIRP	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg01444801	chr10:135216882	MTG1	-0.56	-6.37	-0.38	9.18e-10	Systemic lupus erythematosus;
KIRP	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg03999872	chr20:62272968	STMN3	0.63	7.18	0.42	8.23e-12	Atopic dermatitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09739850	chr5:175545977	NA	0.43	6.02	0.36	6.38e-9	Interleukin-4 levels;
KIRP	cis	rs10875746	0.669	rs61941006	chr12:48631133	G/A	cg20731937	chr12:48336164	NA	0.42	5.59	0.34	6.17e-8	Longevity (90 years and older);
KIRP	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg17849569	chr6:28058911	ZSCAN12L1	0.42	5.28	0.32	2.91e-7	Cardiac Troponin-T levels;
KIRP	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.61	8.3	0.47	6.97e-15	Lymphocyte counts;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27189623	chr16:705930	WDR90	0.45	6.32	0.37	1.25e-9	Height;
KIRP	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg16574807	chr4:6945745	TBC1D14	0.66	5.7	0.34	3.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-1.05	-12.8	-0.63	4.33e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg13334819	chr7:99746414	C7orf59	0.53	6.01	0.36	6.53e-9	Coronary artery disease;
KIRP	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg00343986	chr7:65444356	GUSB	-0.45	-5.43	-0.33	1.36e-7	Aortic root size;
KIRP	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg06781948	chr3:72941472	GXYLT2	0.46	6.21	0.37	2.21e-9	Motion sickness;
KIRP	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04374321	chr14:90722782	PSMC1	0.9	14.55	0.68	5.12e-35	Mortality in heart failure;
KIRP	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.63	7.73	0.44	2.72e-13	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.78	9.37	0.51	4.83e-18	Corneal astigmatism;
KIRP	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg25319279	chr11:5960081	NA	-0.58	-5.84	-0.35	1.65e-8	DNA methylation (variation);
KIRP	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg09990169	chr2:241835740	C2orf54	-0.45	-6.68	-0.39	1.6e-10	Urinary metabolites;
KIRP	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg12940439	chr1:67600707	NA	-0.36	-5.44	-0.33	1.26e-7	Psoriasis;
KIRP	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.71	-0.34	3.22e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.51	4.94	0.3	1.44e-6	Recombination rate (females);
KIRP	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.75	-10.2	-0.55	1.36e-20	Blood metabolite levels;
KIRP	cis	rs6500395	0.962	rs9972682	chr16:48686644	T/G	cg04672837	chr16:48644449	N4BP1	0.47	6.16	0.37	2.89e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg12560992	chr17:57184187	TRIM37	0.63	6.74	0.39	1.13e-10	Testicular germ cell tumor;
KIRP	cis	rs4889855	0.556	rs4508465	chr17:78543368	G/A	cg09596252	chr17:78655493	RPTOR	-0.49	-5.58	-0.34	6.36e-8	Fractional excretion of uric acid;
KIRP	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.9	13.28	0.65	1.01e-30	Triglycerides;
KIRP	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.55	0.68	5.14e-35	Electrocardiographic conduction measures;
KIRP	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.63	7.07	0.41	1.57e-11	Aortic root size;
KIRP	cis	rs471756	0.523	rs574399	chr9:219875	T/A	cg14500300	chr9:211689	NA	0.4	5.55	0.33	7.3900000000000007e-08	Mean platelet volume;
KIRP	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.7	-12.71	-0.63	8.92e-29	White blood cell count (basophil);
KIRP	cis	rs6662572	0.737	rs4660315	chr1:46270942	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.4e-8	Blood protein levels;
KIRP	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.19	-0.37	2.46e-9	Morning vs. evening chronotype;
KIRP	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.11	-0.41	1.24e-11	Type 2 diabetes;
KIRP	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.59	-7.44	-0.43	1.7e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6594713	0.921	rs6887482	chr5:112741433	G/T	cg12552261	chr5:112820674	MCC	-0.49	-4.85	-0.3	2.21e-6	Brain cytoarchitecture;
KIRP	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg16141378	chr3:129829833	LOC729375	0.59	8.2	0.46	1.35e-14	Neuroticism;
KIRP	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	0.91	6.98	0.41	2.76e-11	IgG glycosylation;
KIRP	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg26039829	chr8:22132926	PIWIL2	0.43	5.55	0.33	7.36e-8	Hypertriglyceridemia;
KIRP	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.38	0.51	4.48e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.65	8.59	0.48	9.96e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.68	10.07	0.54	3.3e-20	Dupuytren's disease;
KIRP	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg05775895	chr3:12838266	CAND2	0.39	6.4	0.38	7.83e-10	QRS complex (12-leadsum);
KIRP	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.92	-14.77	-0.69	9.17e-36	Height;
KIRP	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-6.18	-0.37	2.68e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12653917	chr2:220222978	NA	0.39	6.33	0.37	1.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	0.85	7.65	0.44	4.68e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4776059	1.000	rs2288271	chr15:52886466	A/G	cg25063058	chr15:52860530	ARPP19	0.62	6.75	0.4	1.08e-10	Schizophrenia;
KIRP	cis	rs9815354	1.000	rs9830064	chr3:41881801	T/C	cg03022575	chr3:42003672	ULK4	0.51	5.91	0.35	1.15e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	1.06	11.99	0.61	2.16e-26	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.84	0.4	6.27e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg02073558	chr3:44770973	ZNF501	0.7	11.18	0.58	9.55e-24	Depressive symptoms;
KIRP	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26002218	chr14:103986227	CKB	0.29	5.78	0.35	2.21e-8	Body mass index;
KIRP	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg04539111	chr16:67997858	SLC12A4	-0.56	-4.93	-0.3	1.53e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.49	6.75	0.4	1.05e-10	Height;
KIRP	cis	rs4865875	0.579	rs58637533	chr5:54184239	T/G	cg08820104	chr5:54183619	NA	-0.7	-5.09	-0.31	6.97e-7	Sense of smell;
KIRP	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.77	-11.35	-0.59	2.85e-24	Hip circumference;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg07216194	chr8:27182965	PTK2B	0.46	5.73	0.34	2.98e-8	Neuroticism;
KIRP	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.35	12.29	0.62	2.19e-27	Diabetic retinopathy;
KIRP	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg25319279	chr11:5960081	NA	-0.58	-5.75	-0.34	2.63e-8	DNA methylation (variation);
KIRP	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.75	0.4	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg03684893	chr10:554711	DIP2C	0.36	4.91	0.3	1.67e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg02570527	chr1:10970165	NA	-0.4	-4.92	-0.3	1.59e-6	Body mass index;
KIRP	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg10017260	chr10:834428	NA	-0.55	-5.42	-0.33	1.44e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.74	0.53	3.7e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-8.25	-0.47	9.61e-15	Brugada syndrome;
KIRP	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.64	-0.52	7.43e-19	Neuroticism;
KIRP	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg07382826	chr16:28625726	SULT1A1	0.53	5.88	0.35	1.3e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg21775007	chr8:11205619	TDH	-0.39	-5.02	-0.3	1e-6	Monocyte count;
KIRP	cis	rs7712401	0.623	rs30044	chr5:122272080	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.23	0.32	3.58e-7	Mean platelet volume;
KIRP	cis	rs9584850	0.574	rs61969454	chr13:99170232	T/C	cg20750642	chr13:99100586	FARP1	-0.51	-5.56	-0.33	7.12e-8	Neuroticism;
KIRP	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.69	-9.23	-0.51	1.25e-17	Glomerular filtration rate;
KIRP	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.6	-6.61	-0.39	2.41e-10	Pancreatic cancer;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.74	-10.75	-0.57	2.44e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs710216	0.912	rs11537640	chr1:43424519	T/G	cg03128534	chr1:43423976	SLC2A1	0.5	4.93	0.3	1.5e-6	Red cell distribution width;
KIRP	cis	rs4805834	0.719	rs73035338	chr19:33292012	C/T	cg07201929	chr19:33182834	NUDT19	-0.62	-5.24	-0.32	3.4e-7	Creatinine levels;
KIRP	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.51	-11.6	-0.59	4.35e-25	Diabetic kidney disease;
KIRP	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.51	6.73	0.39	1.21e-10	Schizophrenia;
KIRP	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.32	5.63	0.34	4.97e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2223471	0.602	rs9367409	chr6:50704228	T/C	cg03432817	chr6:50765336	NA	-0.34	-4.94	-0.3	1.45e-6	Subcutaneous adipose tissue;
KIRP	cis	rs9815354	0.812	rs4547673	chr3:41952303	A/C	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg19847866	chr10:1019161	NA	-0.54	-4.86	-0.3	2.06e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg12940439	chr1:67600707	NA	0.35	5.31	0.32	2.44e-7	Psoriasis;
KIRP	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.36	4.9	0.3	1.73e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.55	6.95	0.41	3.19e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg26513180	chr16:89883248	FANCA	0.82	5.6	0.34	5.62e-8	Skin colour saturation;
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg26134248	chr17:3907702	NA	0.57	8.44	0.47	2.71e-15	Type 2 diabetes;
KIRP	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg10326726	chr10:51549505	MSMB	0.56	7.96	0.45	6.4e-14	Prostate-specific antigen levels;
KIRP	cis	rs4699052	1.000	rs6533059	chr4:104133376	T/G	cg16532752	chr4:104119610	CENPE	-0.44	-5.59	-0.34	5.94e-8	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27304047	chr2:97001659	NCAPH	0.49	6.12	0.36	3.6e-9	Parkinson's disease;
KIRP	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	cg04338863	chr8:33670619	NA	-0.39	-5.19	-0.31	4.46e-7	Body mass index;
KIRP	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.62	-7.91	-0.45	8.51e-14	Iron status biomarkers;
KIRP	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.52e-15	Skin colour saturation;
KIRP	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg18478394	chr8:109455254	TTC35	0.62	7.78	0.44	1.97e-13	Dupuytren's disease;
KIRP	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-5.43	-0.33	1.37e-7	Metabolite levels;
KIRP	cis	rs6088813	0.961	rs2425063	chr20:33924273	C/A	cg14752227	chr20:34000481	UQCC	0.47	6.02	0.36	6.19e-9	Height;
KIRP	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg18016565	chr1:150552671	MCL1	-0.46	-7.25	-0.42	5.41e-12	Tonsillectomy;
KIRP	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.7	-9.94	-0.54	8.37e-20	Obesity-related traits;
KIRP	cis	rs1215050	0.791	rs1605259	chr4:98799732	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.4	0.38	7.89e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.71	-0.44	3.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.07	0.46	3.05e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10900048	chr4:73935377	COX18	-0.45	-6.39	-0.38	8.45e-10	Metabolic traits;
KIRP	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg04511125	chr2:88470314	THNSL2	0.92	6.94	0.4	3.48e-11	Plasma clusterin levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg20261243	chr20:44718728	NCOA5	0.75	6.47	0.38	5.13e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg03563238	chr19:33554763	RHPN2	-0.33	-6.09	-0.36	4.22e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.84e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg10790698	chr19:18539756	SSBP4	-0.33	-7.26	-0.42	5.11e-12	Breast cancer;
KIRP	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg06740227	chr12:86229804	RASSF9	0.43	5.44	0.33	1.26e-7	Major depressive disorder;
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg07648498	chr16:89883185	FANCA	0.39	4.9	0.3	1.75e-6	Vitiligo;
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-7.78	-0.44	1.94e-13	Longevity;Endometriosis;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	6.76	0.4	9.8e-11	Lymphocyte counts;
KIRP	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.31	0.37	1.31e-9	Educational attainment;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.45	6.06	0.36	5.14e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg23533926	chr12:111358616	MYL2	0.49	6.45	0.38	5.74e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.58	8.07	0.46	3.07e-14	Longevity;Endometriosis;
KIRP	cis	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.08e-11	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg14343924	chr8:8086146	FLJ10661	0.51	5.8	0.35	2.06e-8	Mood instability;
KIRP	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg03188948	chr7:1209495	NA	0.82	5.68	0.34	3.72e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg05729581	chr11:3078854	CARS	-0.5	-6.21	-0.37	2.26e-9	Type 2 diabetes;
KIRP	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg26554054	chr8:600488	NA	0.72	5.17	0.31	4.92e-7	IgG glycosylation;
KIRP	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg25173405	chr17:45401733	C17orf57	0.51	6.66	0.39	1.79e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg05692746	chr2:100937584	LONRF2	-0.39	-5.03	-0.31	9.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.73	9.82	0.53	2.03e-19	Pancreatic cancer;
KIRP	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.46	-6.08	-0.36	4.5e-9	Schizophrenia;
KIRP	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.72	7.64	0.44	4.9e-13	Lymphocyte counts;
KIRP	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.65	0.34	4.43e-8	Homoarginine levels;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.7	10.18	0.54	1.56e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.15	-0.46	1.88e-14	Coronary artery disease;
KIRP	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-5.11	-0.31	6.62e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05315796	chr3:52349193	DNAH1	0.4	6.18	0.37	2.66e-9	Electroencephalogram traits;
KIRP	cis	rs9494145	0.652	rs9399137	chr6:135419018	T/C	cg22676075	chr6:135203613	NA	0.42	4.89	0.3	1.79e-6	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
KIRP	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.68	-0.34	3.75e-8	Cholesterol, total;
KIRP	cis	rs2281603	0.521	rs35115595	chr14:64949924	C/T	cg01860774	chr14:64969374	ZBTB25	0.34	5.41	0.33	1.46e-7	Lymphocyte counts;
KIRP	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.84	-8.71	-0.49	4.57e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg08533674	chr1:46993347	NA	-0.45	-5.64	-0.34	4.74e-8	Monobrow;
KIRP	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.93	10.46	0.55	2e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg12661370	chr5:149340060	SLC26A2	0.47	5.75	0.34	2.7e-8	HIV-1 control;
KIRP	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg21360079	chr12:107162445	NA	-0.73	-10.32	-0.55	5.58e-21	Heart rate;
KIRP	cis	rs58688157	0.572	rs936472	chr11:593453	T/C	cg01616529	chr11:638424	DRD4	-0.34	-4.97	-0.3	1.27e-6	Systemic lupus erythematosus;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07769121	chr16:86543519	FOXF1	0.52	6.52	0.38	3.94e-10	Parkinson's disease;
KIRP	trans	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs7709377	0.595	rs253952	chr5:115633670	A/G	cg23108291	chr5:115420582	COMMD10	-0.41	-4.9	-0.3	1.72e-6	Metabolite levels  (X-11787);
KIRP	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.83	6.9	0.4	4.42e-11	Initial pursuit acceleration;
KIRP	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.37	-0.43	2.66e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7463659	0.845	rs35797542	chr8:135464721	T/C	cg09855544	chr8:135498122	ZFAT	-0.45	-5.68	-0.34	3.84e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7116495	1.000	rs2511075	chr11:71780257	T/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.47	0.38	5.34e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.32	-5.38	-0.32	1.72e-7	Lymphocyte counts;
KIRP	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg24110177	chr3:50126178	RBM5	-0.67	-7.56	-0.43	8.07e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs61867294	0.794	rs12246611	chr10:106674031	A/G	cg08495770	chr10:106400824	SORCS3	0.38	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs7565981	1.000	rs11886530	chr2:101426084	T/C	cg02232089	chr2:101440696	NPAS2	-0.61	-5.52	-0.33	8.55e-8	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.63	8.23	0.46	1.13e-14	Inhibitory control;
KIRP	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.52	-6.36	-0.38	9.9e-10	Metabolite levels;
KIRP	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg19338460	chr6:170058176	WDR27	-0.66	-7.71	-0.44	3.16e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1185460	0.546	rs17075	chr11:118959331	A/G	cg23280166	chr11:118938394	VPS11	-0.52	-6.18	-0.37	2.67e-9	Coronary artery disease;
KIRP	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg15282417	chr9:129245246	FAM125B	0.44	7.45	0.43	1.57e-12	Intraocular pressure;
KIRP	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.41	-0.43	1.97e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.68	-9.81	-0.53	2.22e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs13424612	0.896	rs12467120	chr2:240894275	A/G	cg01812947	chr2:240904978	NDUFA10	-0.38	-4.88	-0.3	1.92e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-6.51	-0.38	4.21e-10	Initial pursuit acceleration;
KIRP	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	6.94	0.4	3.52e-11	Platelet count;
KIRP	cis	rs1858037	0.867	rs57913336	chr2:65587619	G/A	cg08085232	chr2:65598271	SPRED2	-0.54	-6.48	-0.38	4.98e-10	Rheumatoid arthritis;
KIRP	cis	rs4443100	0.958	rs5996459	chr22:23391131	G/A	cg14186256	chr22:23484241	RTDR1	0.46	5.02	0.3	1e-6	Serum parathyroid hormone levels;
KIRP	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs4566357	1.000	rs2396444	chr2:227921314	T/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.06	-0.31	8.14e-7	Coronary artery disease;
KIRP	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.67	9.64	0.52	7.37e-19	Lymphocyte counts;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03518179	chr1:156470915	MEF2D	-0.54	-7.75	-0.44	2.48e-13	Metabolic traits;
KIRP	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg02023728	chr11:77925099	USP35	-0.32	-5.6	-0.34	5.66e-8	Alzheimer's disease (survival time);
KIRP	cis	rs2479106	0.591	rs4836937	chr9:126360328	A/G	cg16191174	chr9:126692580	DENND1A	0.38	5.09	0.31	6.99e-7	Polycystic ovary syndrome;
KIRP	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.64	8.82	0.49	2.18e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.53	-7.57	-0.43	7.64e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-6.2	-0.37	2.4e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg15557168	chr22:42548783	NA	-0.4	-5.61	-0.34	5.32e-8	Cognitive function;
KIRP	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.79	-0.4	8.55e-11	Monocyte percentage of white cells;
KIRP	cis	rs4950322	0.518	rs4950306	chr1:146589420	C/G	cg22381352	chr1:146742008	CHD1L	-0.42	-4.86	-0.3	2.12e-6	Protein quantitative trait loci;
KIRP	cis	rs2150410	0.833	rs7283439	chr21:40645737	G/A	cg11890956	chr21:40555474	PSMG1	0.85	5.97	0.36	8.14e-9	Temperament (bipolar disorder);
KIRP	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.72	-11.37	-0.59	2.4e-24	Hepatocellular carcinoma;
KIRP	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05315796	chr3:52349193	DNAH1	-0.36	-5.59	-0.34	6.14e-8	Bipolar disorder;
KIRP	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15781525	chr6:564561	EXOC2	0.46	6.65	0.39	1.89e-10	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.73	-9.18	-0.51	1.78e-17	Aortic root size;
KIRP	cis	rs17221829	0.525	rs9804670	chr11:89375801	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.01	-0.36	6.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg00990874	chr7:1149470	C7orf50	-0.71	-7.57	-0.43	7.36e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs10518128	1.000	rs28529552	chr4:75705581	C/T	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27286337	chr10:134555280	INPP5A	0.89	10.73	0.56	2.75e-22	Migraine;
KIRP	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.54	6.39	0.38	8.13e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.53	-6.6	-0.39	2.58e-10	Coronary artery disease;
KIRP	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.71	7.43	0.43	1.76e-12	Corneal astigmatism;
KIRP	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg03711944	chr11:47377212	SPI1	-0.3	-5.06	-0.31	8.12e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg04539111	chr16:67997858	SLC12A4	-0.66	-6.79	-0.4	8.16e-11	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.83	9.97	0.54	6.87e-20	Corneal astigmatism;
KIRP	cis	rs55863869	0.748	rs2291311	chr2:179629461	C/T	cg02880032	chr2:179629472	TTN	-0.69	-6.27	-0.37	1.59e-9	QT interval;
KIRP	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.39	-5.12	-0.31	6.23e-7	Parkinson's disease;
KIRP	cis	rs7534824	0.625	rs61780331	chr1:101480610	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.38	0.32	1.71e-7	Refractive astigmatism;
KIRP	cis	rs6102059	0.692	rs2206689	chr20:39209518	A/G	cg06665391	chr20:39312290	NA	0.41	5.13	0.31	5.89e-7	LDL cholesterol;
KIRP	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.41	5.19	0.31	4.45e-7	Aortic root size;
KIRP	trans	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.34	0.37	1.08e-9	Retinal vascular caliber;
KIRP	trans	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs2151522	0.603	rs1543706	chr6:127197404	C/T	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg13180566	chr4:1052158	NA	-0.53	-5.36	-0.32	1.95e-7	Recombination rate (females);
KIRP	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.68	9.26	0.51	1.08e-17	Post bronchodilator FEV1;
KIRP	cis	rs1981331	0.609	rs73907584	chr21:48079678	A/G	cg17243659	chr21:48055224	PRMT2	0.97	6.83	0.4	6.43e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg05342945	chr12:48394962	COL2A1	-0.5	-5.18	-0.31	4.53e-7	Lung cancer;
KIRP	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg13628971	chr7:2884303	GNA12	0.6	6.94	0.4	3.44e-11	Height;
KIRP	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.69	-8.79	-0.49	2.65e-16	Schizophrenia;
KIRP	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.53	6.27	0.37	1.61e-9	Blood metabolite levels;
KIRP	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-6.98	-0.41	2.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10208940	0.920	rs7576303	chr2:68838019	G/A	cg12452813	chr2:68675892	NA	0.45	4.91	0.3	1.64e-6	Urate levels in lean individuals;
KIRP	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.74	11.48	0.59	1.02e-24	Neuroticism;
KIRP	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg22437258	chr11:111473054	SIK2	0.63	7.48	0.43	1.34e-12	Primary sclerosing cholangitis;
KIRP	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.22	-0.32	3.77e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-5.07	-0.31	7.97e-7	Life satisfaction;
KIRP	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.7	-6.69	-0.39	1.47e-10	Ulcerative colitis;
KIRP	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.67	-9.14	-0.5	2.43e-17	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.64	8.13	0.46	2.11e-14	Glomerular filtration rate;
KIRP	cis	rs9513627	1.000	rs73556181	chr13:100122092	G/A	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg15068132	chr12:102092402	CHPT1	0.4	5.3	0.32	2.56e-7	Blood protein levels;
KIRP	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg12756093	chr1:115239321	AMPD1	0.56	7.66	0.44	4.21e-13	Autism;
KIRP	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15369054	chr17:80825471	TBCD	-0.51	-5.06	-0.31	8.1e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.63	-7.17	-0.42	8.77e-12	Type 2 diabetes;
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-8.76	-0.49	3.3e-16	Platelet count;
KIRP	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.15	-28.11	-0.87	9.22e-79	Myeloid white cell count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10769393	chr19:2819754	ZNF554	0.48	6.45	0.38	5.76e-10	Survival in pancreatic cancer;
KIRP	cis	rs12780845	0.540	rs11254431	chr10:17222673	T/C	cg01003015	chr10:17271136	VIM	-0.4	-4.87	-0.3	1.99e-6	Homocysteine levels;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.1	-0.31	6.73e-7	Life satisfaction;
KIRP	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.55	7.6	0.44	6.19e-13	Blood metabolite levels;
KIRP	cis	rs2274273	0.967	rs67756714	chr14:55589823	G/A	cg04306507	chr14:55594613	LGALS3	0.46	7.0	0.41	2.37e-11	Protein biomarker;
KIRP	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg26205652	chr12:48591994	NA	0.46	5.19	0.31	4.38e-7	Lung cancer;
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg10295955	chr4:187884368	NA	-1.09	-17.77	-0.75	5.17e-46	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7011049	0.915	rs7823407	chr8:53870460	C/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg02972257	chr16:68554789	NA	0.62	6.23	0.37	2.05e-9	Ulcerative colitis;
KIRP	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.46	-7.06	-0.41	1.69e-11	Coronary artery disease;
KIRP	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg22681709	chr2:178499509	PDE11A	-0.64	-9.1	-0.5	3.12e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4389656	0.857	rs274677	chr5:6754402	T/C	cg10857441	chr5:6722123	POLS	-0.44	-6.21	-0.37	2.26e-9	Coronary artery disease;
KIRP	cis	rs10858047	1.000	rs10858047	chr1:115073876	C/T	cg12756093	chr1:115239321	AMPD1	-0.62	-6.15	-0.37	3.03e-9	Autism;
KIRP	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg16049864	chr8:95962084	TP53INP1	-0.39	-6.14	-0.36	3.38e-9	Type 2 diabetes;
KIRP	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg08392591	chr16:89556376	ANKRD11	-0.42	-5.1	-0.31	6.91e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg10756647	chr7:56101905	PSPH	0.97	7.01	0.41	2.23e-11	Diabetic kidney disease;
KIRP	cis	rs6681460	1.000	rs6680944	chr1:67122565	A/T	cg02459107	chr1:67143332	SGIP1	0.5	7.21	0.42	6.67e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs6840360	0.642	rs4235219	chr4:152346103	T/G	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg27490568	chr2:178487706	NA	0.68	9.37	0.51	4.83e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg06212747	chr3:49208901	KLHDC8B	0.5	5.75	0.34	2.68e-8	Resting heart rate;
KIRP	cis	rs290268	0.874	rs290988	chr9:93562955	C/G	cg02608019	chr9:93564028	SYK	0.82	11.76	0.6	1.24e-25	Platelet count;
KIRP	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-5.91	-0.35	1.12e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.79	0.4	8.49e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.46	-5.46	-0.33	1.19e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17836842	chr2:28319151	BRE	-0.39	-6.59	-0.39	2.65e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.63	0.44	5.23e-13	Lung cancer in ever smokers;
KIRP	cis	rs17092148	1.000	rs6058112	chr20:33322006	G/C	cg16810054	chr20:33298113	TP53INP2	-0.47	-5.71	-0.34	3.17e-8	Neuroticism;
KIRP	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg09990169	chr2:241835740	C2orf54	-0.45	-6.8	-0.4	7.86e-11	Urinary metabolites;
KIRP	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg13047869	chr3:10149882	C3orf24	0.54	5.1	0.31	6.67e-7	Alzheimer's disease;
KIRP	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg12560992	chr17:57184187	TRIM37	0.61	5.4	0.33	1.6e-7	Cognitive test performance;
KIRP	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.43	0.62	7.37e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg23307798	chr14:103986281	CKB	-0.44	-5.84	-0.35	1.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg14673194	chr17:80132900	CCDC57	-0.77	-8.68	-0.48	5.51e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.54e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.41	-5.81	-0.35	1.93e-8	Plateletcrit;
KIRP	cis	rs11644362	0.966	rs1433747	chr16:12992147	C/A	cg06890432	chr16:12997467	SHISA9	-0.42	-6.59	-0.39	2.71e-10	Positive affect;Subjective well-being;
KIRP	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.47	5.61	0.34	5.39e-8	Glomerular filtration rate (creatinine);
KIRP	trans	rs2472591	0.852	rs2472599	chr13:50530502	G/T	cg04548715	chr7:99598775	NA	0.57	6.38	0.38	8.72e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.88	-0.49	1.48e-16	Total cholesterol levels;
KIRP	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg10017260	chr10:834428	NA	-0.45	-6.39	-0.38	8.02e-10	Survival in rectal cancer;
KIRP	cis	rs4740619	0.619	rs10738427	chr9:16041822	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg25319279	chr11:5960081	NA	-0.52	-5.14	-0.31	5.72e-7	DNA methylation (variation);
KIRP	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.92	12.96	0.64	1.22e-29	Bladder cancer;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02594940	chr19:35759230	USF2	0.45	6.07	0.36	4.73e-9	Cancer;
KIRP	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.9	0.4	4.26e-11	Bipolar disorder;
KIRP	cis	rs7808935	0.958	rs17156041	chr7:27975745	C/T	cg22168087	chr7:27702803	HIBADH	0.81	7.98	0.45	5.62e-14	Prostate cancer;
KIRP	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	6.98e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg03060546	chr3:49711283	APEH	0.43	5.66	0.34	4.27e-8	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg17764715	chr19:33622953	WDR88	0.68	8.36	0.47	4.57e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg03235661	chr20:60525775	NA	-0.29	-4.95	-0.3	1.36e-6	Body mass index;
KIRP	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg18132916	chr6:79620363	NA	-0.42	-5.76	-0.34	2.48e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7614311	0.681	rs73119022	chr3:63979834	T/C	cg22134162	chr3:63841271	THOC7	-0.41	-4.98	-0.3	1.18e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.83	-15.06	-0.69	8.88e-37	Body mass index;
KIRP	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg15128208	chr22:42549153	NA	-0.39	-5.16	-0.31	5.08e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.42	-6.57	-0.39	2.91e-10	Coronary artery disease;
KIRP	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22117172	chr7:91764530	CYP51A1	0.53	7.59	0.44	6.52e-13	Breast cancer;
KIRP	cis	rs11605924	0.901	rs11038672	chr11:45846498	C/G	cg23097878	chr11:45879730	CRY2	0.33	6.78	0.4	8.94e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg19468946	chr17:37922297	IKZF3	-0.46	-6.54	-0.38	3.6e-10	Asthma;
KIRP	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.47	-0.48	2.2e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg22117172	chr7:91764530	CYP51A1	0.42	5.94	0.35	9.56e-9	Breast cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg20654260	chr6:44238905	TMEM151B	-0.8	-6.03	-0.36	6.09e-9	P wave terminal force;
KIRP	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.48	0.38	4.99e-10	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05045933	chr11:66627577	PC;LRFN4	0.49	6.3	0.37	1.38e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.66	-8.48	-0.48	2.15e-15	Colorectal cancer;
KIRP	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg00990874	chr7:1149470	C7orf50	-0.39	-4.95	-0.3	1.37e-6	Longevity;Endometriosis;
KIRP	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg09904177	chr6:26538194	HMGN4	-0.45	-5.16	-0.31	5.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7766436	0.961	rs6900627	chr6:22570245	G/A	cg13666174	chr6:22585274	NA	-0.41	-5.6	-0.34	5.68e-8	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.66	-0.63	1.28e-28	Breast cancer;
KIRP	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg17652424	chr22:38574118	PLA2G6	-0.25	-4.94	-0.3	1.46e-6	Cutaneous nevi;
KIRP	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.82	9.3	0.51	7.76e-18	Vitamin D levels;
KIRP	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg03959625	chr15:84868606	LOC388152	0.46	5.92	0.35	1.08e-8	Schizophrenia;
KIRP	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg03808351	chr9:123631620	PHF19	0.45	6.23	0.37	2.04e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs10073892	0.789	rs111400704	chr5:101756600	C/T	cg19774478	chr5:101632501	SLCO4C1	0.67	6.48	0.38	5e-10	Cognitive decline (age-related);
KIRP	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg00376283	chr12:123451042	ABCB9	-0.64	-7.38	-0.43	2.36e-12	Neutrophil percentage of white cells;
KIRP	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg05370193	chr1:21551575	ECE1	0.45	6.24	0.37	1.87e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs932287	0.545	rs1960181	chr11:9046767	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.5	6.05	0.36	5.34e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.45	-5.75	-0.34	2.61e-8	Initial pursuit acceleration;
KIRP	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg18964960	chr10:1102726	WDR37	0.6	5.04	0.31	8.87e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.67	-7.75	-0.44	2.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-13.04	-0.64	7e-30	Vitiligo;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.68	10.62	0.56	6.43e-22	Menarche (age at onset);
KIRP	cis	rs490234	0.841	rs490333	chr9:128354569	T/C	cg14078157	chr9:128172775	NA	0.4	4.92	0.3	1.61e-6	Mean arterial pressure;
KIRP	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.56	5.41	0.33	1.46e-7	Skin colour saturation;
KIRP	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.86	-0.4	5.61e-11	Neuroticism;
KIRP	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.43	-0.47	2.92e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg08662619	chr6:150070041	PCMT1	0.36	5.84	0.35	1.67e-8	Lung cancer;
KIRP	cis	rs5995756	0.761	rs1534883	chr22:40005425	T/C	cg10455938	chr22:40058150	CACNA1I	-0.52	-7.85	-0.45	1.3e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg21479132	chr6:26055353	NA	0.76	4.88	0.3	1.95e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg24565620	chr2:194026	NA	0.72	8.52	0.48	1.61e-15	Blood protein levels;
KIRP	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.44	-5.67	-0.34	3.96e-8	Aortic root size;
KIRP	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg02151108	chr14:50098012	C14orf104	0.46	6.05	0.36	5.22e-9	Carotid intima media thickness;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03627295	chr13:46756439	LCP1	0.4	6.72	0.39	1.25e-10	Survival in pancreatic cancer;
KIRP	cis	rs10102274	1.000	rs73311068	chr8:91788964	A/G	cg16814680	chr8:91681699	NA	-0.8	-4.9	-0.3	1.73e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs9400467	0.537	rs12197886	chr6:111491405	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs501120	0.584	rs1615053	chr10:44677935	T/C	cg09554077	chr10:44749378	NA	0.59	6.19	0.37	2.52e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.7	7.44	0.43	1.69e-12	Lymphocyte counts;
KIRP	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.62	-8.06	-0.46	3.32e-14	Response to temozolomide;
KIRP	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.47e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7534824	0.625	rs6692186	chr1:101470217	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.37	0.32	1.85e-7	Refractive astigmatism;
KIRP	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.65	7.5	0.43	1.13e-12	Corneal astigmatism;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg01114163	chr5:1856713	NA	-0.42	-5.1	-0.31	6.7e-7	Cardiovascular disease risk factors;
KIRP	cis	rs5753037	0.676	rs737945	chr22:30202774	G/C	cg01021169	chr22:30184971	ASCC2	-0.49	-6.35	-0.38	1.01e-9	Type 1 diabetes;
KIRP	cis	rs6939532	0.522	rs6933583	chr6:26355283	A/C	cg12826209	chr6:26865740	GUSBL1	0.44	5.14	0.31	5.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6977660	0.714	rs6945533	chr7:19813913	G/C	cg05791153	chr7:19748676	TWISTNB	0.61	5.79	0.35	2.13e-8	Thyroid stimulating hormone;
KIRP	cis	rs17453880	0.890	rs6869035	chr5:152028258	C/T	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs4472734	0.813	rs4394613	chr1:214622818	A/G	cg00063699	chr1:214624242	PTPN14	-0.45	-6.36	-0.38	9.6e-10	Height;
KIRP	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg21191810	chr6:118973309	C6orf204	-0.42	-4.89	-0.3	1.86e-6	Diastolic blood pressure;
KIRP	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg17420585	chr12:42539391	GXYLT1	-0.4	-5.4	-0.33	1.55e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.49	-0.38	4.72e-10	Neuroticism;
KIRP	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg09473613	chr1:24152604	HMGCL	-0.43	-5.32	-0.32	2.37e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.43	6.32	0.37	1.25e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg03260781	chr1:16346299	HSPB7	0.32	5.11	0.31	6.38e-7	Dilated cardiomyopathy;
KIRP	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.2	-0.31	4.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	1.12	7.95	0.45	6.73e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg11856688	chr1:200708343	CAMSAP1L1	0.55	6.45	0.38	5.78e-10	Plasma plasminogen activator levels;
KIRP	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-1.12	-18.41	-0.76	3.5e-48	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.67	10.01	0.54	5.39e-20	Pulse pressure;
KIRP	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg04035386	chr16:68564532	NA	-0.4	-4.87	-0.3	1.96e-6	Ulcerative colitis;
KIRP	cis	rs7536201	1.000	rs4265380	chr1:25293356	C/T	cg23273869	chr1:25296894	NA	-0.36	-4.98	-0.3	1.18e-6	Psoriasis vulgaris;
KIRP	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg27205649	chr11:78285834	NARS2	-0.64	-7.75	-0.44	2.47e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg11833968	chr6:79620685	NA	-0.45	-7.05	-0.41	1.81e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.13	-0.36	3.5e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs732716	0.785	rs55660045	chr19:4425305	T/G	cg19820705	chr19:4455316	UBXN6	0.67	8.34	0.47	5.38e-15	Mean corpuscular volume;
KIRP	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26002218	chr14:103986227	CKB	0.26	4.95	0.3	1.36e-6	Body mass index;
KIRP	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.72e-6	Systolic blood pressure;
KIRP	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.68	-10.9	-0.57	7.9e-23	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg24972876	chr7:65420302	NA	-0.4	-5.58	-0.34	6.24e-8	Aortic root size;
KIRP	cis	rs3733418	0.527	rs3733420	chr4:165878162	T/C	cg10852876	chr4:165953100	TRIM60	-0.53	-4.97	-0.3	1.28e-6	Obesity-related traits;
KIRP	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.79	0.63	4.59e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg10144569	chr3:42726640	KBTBD5	-0.48	-5.0	-0.3	1.11e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.7	-8.48	-0.48	2.05e-15	Mammographic density (dense area);
KIRP	cis	rs10214930	0.671	rs1005128	chr7:27608676	T/C	cg22168087	chr7:27702803	HIBADH	0.47	4.94	0.3	1.43e-6	Hypospadias;
KIRP	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	0.95	17.6	0.75	2e-45	Dental caries;
KIRP	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	cg04338863	chr8:33670619	NA	0.45	5.93	0.35	1.01e-8	Body mass index;
KIRP	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.4	0.62	9.26e-28	Diabetic retinopathy;
KIRP	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.54	7.07	0.41	1.58e-11	Aortic root size;
KIRP	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-6.91	-0.4	4.12e-11	Fear of minor pain;
KIRP	cis	rs8060686	0.516	rs7184821	chr16:68270229	T/C	cg26727032	chr16:67993705	SLC12A4	-0.74	-8.77	-0.49	3.02e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.65	-7.64	-0.44	4.94e-13	Smoking initiation;
KIRP	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg20387954	chr3:183756860	HTR3D	0.64	9.42	0.51	3.55e-18	Anterior chamber depth;
KIRP	cis	rs4849845	0.925	rs10180465	chr2:121011770	A/G	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs4389656	0.857	rs274713	chr5:6723560	A/C	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg23682824	chr7:23144976	KLHL7	0.52	6.14	0.36	3.29e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	1.1	10.18	0.54	1.57e-20	Lymphocyte counts;
KIRP	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.37	0.51	4.98e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg07810366	chr2:100720526	AFF3	-0.32	-4.92	-0.3	1.62e-6	Educational attainment;
KIRP	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.49	-0.33	9.78e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg00277334	chr10:82204260	NA	-0.45	-5.12	-0.31	6.18e-7	Post bronchodilator FEV1;
KIRP	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.56	7.61	0.44	5.75e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	0.68	6.8	0.4	8.11e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg00846425	chr4:957561	DGKQ	-0.51	-5.3	-0.32	2.59e-7	Type 2 diabetes;
KIRP	cis	rs4702718	0.633	rs3822412	chr5:10689768	A/G	cg14521931	chr5:10832172	NA	0.41	5.51	0.33	8.93e-8	Obesity-related traits;
KIRP	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg00405596	chr8:11794950	NA	-0.46	-6.25	-0.37	1.75e-9	Neuroticism;
KIRP	cis	rs7681423	0.951	rs13130318	chr4:155538470	T/G	cg20735720	chr4:155535218	FGG	-0.67	-8.73	-0.49	3.93e-16	Fibrinogen;
KIRP	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg06115741	chr20:33292138	TP53INP2	0.4	5.44	0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs7941030	0.902	rs7117842	chr11:122534504	T/C	cg20555462	chr11:122535518	UBASH3B	-0.41	-5.01	-0.3	1.02e-6	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs7188697	0.922	rs246258	chr16:58579274	A/G	cg21335942	chr16:58549945	SETD6	-0.46	-5.08	-0.31	7.6e-7	QT interval;
KIRP	cis	rs3540	0.960	rs8025842	chr15:90995471	C/T	cg22089800	chr15:90895588	ZNF774	0.44	5.47	0.33	1.11e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg06360820	chr2:242988706	NA	-0.74	-6.49	-0.38	4.59e-10	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.97	0.41	2.92e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg02367723	chr1:46378857	MAST2	0.42	4.89	0.3	1.86e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.34	-4.85	-0.3	2.18e-6	Lymphocyte counts;
KIRP	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.97	-14.59	-0.68	3.63e-35	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04694492	chr16:4387567	GLIS2	-0.47	-6.79	-0.4	8.48e-11	Parkinson's disease;
KIRP	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.79	9.91	0.53	1.07e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg15841412	chr13:111365552	ING1	-0.49	-5.48	-0.33	1.06e-7	Coronary artery disease;
KIRP	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.63	0.52	8.08e-19	Bipolar disorder;
KIRP	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08045932	chr20:61659980	NA	0.54	6.78	0.4	8.92e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs61884328	0.852	rs57964319	chr11:47146599	C/T	cg23433285	chr11:47201945	PACSIN3	0.69	5.6	0.34	5.68e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg01721255	chr8:58191610	C8orf71	0.56	5.75	0.34	2.67e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg17863274	chr19:49399704	TULP2	-0.33	-4.85	-0.3	2.22e-6	Red cell distribution width;
KIRP	cis	rs1620921	0.563	rs2489936	chr6:161280325	C/T	cg01280913	chr6:161186852	NA	-0.43	-5.57	-0.33	6.58e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs4969178	0.965	rs8071884	chr17:76398058	C/G	cg20026190	chr17:76395443	PGS1	0.51	6.54	0.38	3.48e-10	HDL cholesterol levels;
KIRP	cis	rs62413470	1.000	rs12210402	chr6:55943418	C/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.06	0.54	3.68e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs2219968	1.000	rs4639505	chr8:78971658	A/G	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs59698941	0.550	rs12652469	chr5:132182765	A/G	cg14825688	chr5:132208181	LEAP2	-0.37	-4.93	-0.3	1.52e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	8.79	0.49	2.69e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	1.0	11.02	0.57	3.21e-23	Blood protein levels;
KIRP	cis	rs4711350	0.765	rs6921772	chr6:33749686	A/G	cg25922239	chr6:33757077	LEMD2	0.55	5.85	0.35	1.58e-8	Schizophrenia;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg11593111	chr5:139493674	PURA	-0.51	-6.72	-0.39	1.24e-10	Blood metabolite levels;
KIRP	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.85	11.75	0.6	1.32e-25	Breast cancer;
KIRP	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg13482628	chr17:19912719	NA	0.53	6.82	0.4	6.89e-11	Schizophrenia;
KIRP	cis	rs7113874	0.613	rs35225809	chr11:8533585	C/T	cg08015107	chr11:8618950	NA	-0.72	-8.72	-0.49	4.22e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.81	-0.49	2.38e-16	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.48	6.77	0.4	9.29e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.13	-0.36	3.48e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.49	5.11	0.31	6.38e-7	Schizophrenia;
KIRP	cis	rs6662572	0.737	rs6429592	chr1:46472153	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.35e-8	Blood protein levels;
KIRP	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.63	0.34	4.83e-8	Lung cancer;
KIRP	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg07701084	chr6:150067640	NUP43	0.61	7.79	0.45	1.82e-13	Lung cancer;
KIRP	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg02297831	chr4:17616191	MED28	0.55	6.89	0.4	4.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4742903	1.000	rs3818625	chr9:106856452	G/A	cg14250997	chr9:106856677	SMC2	0.4	5.18	0.31	4.7e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6088813	0.922	rs4911493	chr20:33960799	A/G	cg14752227	chr20:34000481	UQCC	-0.52	-6.88	-0.4	5.07e-11	Height;
KIRP	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg26384229	chr12:38710491	ALG10B	0.72	9.92	0.53	9.72e-20	Morning vs. evening chronotype;
KIRP	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21214613	chr1:16344536	HSPB7	0.35	5.31	0.32	2.44e-7	Systolic blood pressure;
KIRP	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.28	-0.47	8.18e-15	Mood instability;
KIRP	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.53	6.86	0.4	5.51e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Bipolar disorder;
KIRP	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg08603382	chr10:743973	NA	-0.59	-9.75	-0.53	3.34e-19	Psychosis in Alzheimer's disease;
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.53	-7.6	-0.44	6.29e-13	Obesity-related traits;
KIRP	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.93	-12.95	-0.64	1.35e-29	Cognitive function;
KIRP	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.79	0.35	2.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.68	9.33	0.51	6.55e-18	Menarche (age at onset);
KIRP	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.8	10.38	0.55	3.48e-21	Cisplatin-induced ototoxicity;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.71	-9.91	-0.53	1.09e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs10940138	0.774	rs57209938	chr5:67234233	A/G	ch.5.1281357F	chr5:67228439	NA	0.7	10.99	0.57	3.9699999999999997e-23	Menarche (age at onset);
KIRP	cis	rs11779988	0.571	rs208052	chr8:17825559	G/C	cg01800426	chr8:17659068	MTUS1	-0.61	-6.1	-0.36	4.12e-9	Breast cancer;
KIRP	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-12.76	-0.63	6.02e-29	Exhaled nitric oxide output;
KIRP	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg16586182	chr3:47516702	SCAP	0.68	9.25	0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs13065560	0.766	rs12634131	chr3:38866591	A/G	cg01426195	chr3:39028469	NA	-0.42	-6.18	-0.37	2.71e-9	Interleukin-18 levels;
KIRP	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg20493526	chr2:3714936	ALLC	0.44	5.57	0.33	6.83e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs10924970	0.625	rs10925482	chr1:235499263	C/T	cg26050004	chr1:235667680	B3GALNT2	0.44	4.87	0.3	1.96e-6	Asthma;
KIRP	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17376030	chr22:41985996	PMM1	-0.73	-8.24	-0.47	1e-14	Vitiligo;
KIRP	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.41	-6.59	-0.39	2.65e-10	Body mass index;
KIRP	cis	rs4561483	0.667	rs3743590	chr16:11930337	A/C	cg08843971	chr16:11963173	GSPT1	-0.41	-5.73	-0.34	2.92e-8	Testicular germ cell tumor;
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg23698023	chr8:27181813	PTK2B	0.34	5.15	0.31	5.25e-7	Neuroticism;
KIRP	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.99	18.52	0.76	1.47e-48	Colorectal adenoma (advanced);
KIRP	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.58	7.68	0.44	3.86e-13	Migraine;
KIRP	cis	rs4566357	0.787	rs6748048	chr2:227822440	T/C	cg11843606	chr2:227700838	RHBDD1	-0.52	-6.37	-0.38	9.32e-10	Coronary artery disease;
KIRP	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	11.8	0.6	9.08e-26	Monocyte count;
KIRP	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.68	9.7	0.53	4.79e-19	Retinal vascular caliber;
KIRP	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg00405596	chr8:11794950	NA	0.47	5.76	0.34	2.47e-8	Retinal vascular caliber;
KIRP	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg02038168	chr22:39784481	NA	-0.43	-5.44	-0.33	1.27e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.8	8.04	0.46	3.77e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg03394422	chr14:75389280	RPS6KL1	0.39	4.97	0.3	1.23e-6	Caffeine consumption;
KIRP	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg20673091	chr1:2541236	MMEL1	0.67	10.05	0.54	3.8e-20	Ulcerative colitis;
KIRP	cis	rs9972944	0.902	rs9972883	chr17:63771316	C/A	cg07283582	chr17:63770753	CCDC46	0.48	8.03	0.46	3.95e-14	Total body bone mineral density;
KIRP	cis	rs7301016	0.947	rs10877862	chr12:62888647	T/C	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.57	-7.26	-0.42	5.13e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.64	-9.18	-0.51	1.77e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.49	6.0	0.36	7.05e-9	Glycated hemoglobin levels;
KIRP	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg05791153	chr7:19748676	TWISTNB	0.87	7.23	0.42	5.92e-12	Thyroid stimulating hormone;
KIRP	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg17252645	chr8:143867129	LY6D	-0.5	-9.39	-0.51	4.26e-18	Urinary tract infection frequency;
KIRP	cis	rs2070433	0.904	rs11701571	chr21:47963149	A/G	cg07608496	chr21:47649218	MCM3APAS;LSS	-0.46	-5.08	-0.31	7.63e-7	Lymphocyte counts;
KIRP	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.58	11.9	0.6	4.44e-26	Diabetic kidney disease;
KIRP	cis	rs1440410	0.835	rs4234887	chr4:144134277	C/T	cg01719995	chr4:144104893	USP38	0.39	5.25	0.32	3.32e-7	Ischemic stroke;
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.12	-20.38	-0.79	9.82e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	13.19	0.64	2.11e-30	Platelet count;
KIRP	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg18132916	chr6:79620363	NA	-0.41	-5.72	-0.34	3.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.84	9.74	0.53	3.62e-19	Blood pressure (smoking interaction);
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg23693289	chr8:27183097	PTK2B	-0.5	-5.99	-0.36	7.26e-9	Alzheimer's disease (late onset);
KIRP	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.33	-0.32	2.2e-7	Colorectal cancer;
KIRP	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.58	-9.07	-0.5	3.94e-17	Coronary artery disease;
KIRP	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg06223162	chr1:101003688	GPR88	0.35	7.34	0.42	3.11e-12	Monocyte count;
KIRP	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.74	-9.14	-0.5	2.38e-17	Blood metabolite levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15422644	chr12:52116112	SCN8A	0.51	6.63	0.39	2.1e-10	Interleukin-4 levels;
KIRP	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.84	8.66	0.48	6.19e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg23978390	chr7:1156363	C7orf50	0.5	5.35	0.32	2.06e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07080220	chr10:102295463	HIF1AN	0.88	7.27	0.42	4.75e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg16479474	chr6:28041457	NA	0.52	5.83	0.35	1.76e-8	Parkinson's disease;
KIRP	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.53	-0.38	3.74e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.13	-0.36	3.42e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.55	7.0	0.41	2.5e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs960902	0.713	rs7557408	chr2:37742301	C/T	cg25341268	chr2:37734390	NA	-0.65	-8.95	-0.5	8.87e-17	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg06792538	chr1:2954250	NA	0.41	4.91	0.3	1.69e-6	Plateletcrit;
KIRP	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg13736514	chr6:26305472	NA	-0.65	-9.13	-0.5	2.53e-17	Educational attainment;
KIRP	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-15.65	-0.71	9e-39	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-6.94	-0.4	3.52e-11	Vitiligo;
KIRP	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg16141378	chr3:129829833	LOC729375	0.52	6.57	0.39	2.94e-10	Retinal vascular caliber;
KIRP	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.79	-11.35	-0.59	2.66e-24	Blood metabolite levels;
KIRP	cis	rs193541	0.545	rs112390044	chr5:122312002	A/C	cg19412675	chr5:122181750	SNX24	-0.57	-6.08	-0.36	4.5e-9	Glucose homeostasis traits;
KIRP	cis	rs17655565	0.581	rs17657609	chr12:52763601	C/T	cg07925835	chr12:52762777	KRT85	0.48	5.23	0.32	3.55e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.56	6.12	0.36	3.64e-9	Pubertal anthropometrics;
KIRP	cis	rs7569084	0.566	rs7584295	chr2:65581074	T/C	cg08085232	chr2:65598271	SPRED2	-0.52	-6.56	-0.39	3.11e-10	Sum eosinophil basophil counts;
KIRP	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.68	8.61	0.48	9.09e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.79	11.43	0.59	1.45e-24	Dental caries;
KIRP	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.6	-6.8	-0.4	7.73e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7503807	0.664	rs11150736	chr17:78613507	C/T	cg09596252	chr17:78655493	RPTOR	0.52	6.17	0.37	2.79e-9	Obesity;
KIRP	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg06307176	chr5:131281290	NA	0.54	5.98	0.36	7.72e-9	Life satisfaction;
KIRP	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.95	15.54	0.7	2.14e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.91	0.49	1.14e-16	Resting heart rate;
KIRP	trans	rs4652676	0.954	rs199931	chr1:181742767	G/T	cg01133215	chr6:45399681	RUNX2	-0.36	-6.1	-0.36	4.05e-9	Neuroticism;
KIRP	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg17340268	chr14:105411764	AHNAK2	-0.4	-5.13	-0.31	5.9e-7	Rheumatoid arthritis;
KIRP	cis	rs2625529	0.526	rs8031386	chr15:72508799	C/A	cg16672083	chr15:72433130	SENP8	-0.38	-4.96	-0.3	1.31e-6	Red blood cell count;
KIRP	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.99	15.19	0.7	3.19e-37	Sudden cardiac arrest;
KIRP	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	9.29	0.51	8.29e-18	LDL cholesterol;
KIRP	cis	rs7011507	1.000	rs74438906	chr8:49166956	C/T	cg15325961	chr8:49183143	NA	0.6	5.05	0.31	8.57e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg01763666	chr17:80159506	CCDC57	-0.38	-5.34	-0.32	2.09e-7	Life satisfaction;
KIRP	cis	rs4936894	0.500	rs4936918	chr11:124179835	C/T	cg27160556	chr11:124181099	OR8D1	-0.44	-6.18	-0.37	2.67e-9	Aging (time to death);
KIRP	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.09	-0.31	7.17e-7	Pulmonary function;
KIRP	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.59	7.04	0.41	1.93e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7539542	0.536	rs12091234	chr1:202855508	C/T	cg08940984	chr1:202857613	RABIF	0.46	5.67	0.34	4.01e-8	Mean platelet volume;
KIRP	cis	rs3789045	0.774	rs12031912	chr1:204476113	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.27	-0.37	1.59e-9	Educational attainment (college completion);
KIRP	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.63	7.42	0.43	1.93e-12	Neutrophil percentage of white cells;
KIRP	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.54	6.71	0.39	1.3100000000000001e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg18764771	chr6:116381957	FRK	0.19	5.32	0.32	2.37e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.84	12.3	0.62	2.01e-27	Monocyte count;
KIRP	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.5	7.41	0.43	2.04e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs12714314	0.602	rs13400823	chr2:1918360	A/G	cg20846728	chr2:1843184	MYT1L	-0.36	-6.03	-0.36	5.96e-9	Type 2 diabetes (age of onset);
KIRP	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.78e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9469913	0.799	rs2744955	chr6:34618958	C/G	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.28	-0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg04058563	chr4:185651563	MLF1IP	-0.53	-7.5	-0.43	1.19e-12	Kawasaki disease;
KIRP	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	1.0	10.19	0.54	1.48e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg17554472	chr22:41940697	POLR3H	-0.57	-6.28	-0.37	1.5e-9	Vitiligo;
KIRP	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.54	7.4	0.43	2.11e-12	Colorectal cancer;
KIRP	cis	rs7106204	0.609	rs11827033	chr11:24305935	A/G	ch.11.24196551F	chr11:24239977	NA	0.62	5.01	0.3	1.03e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9653442	0.564	rs2164711	chr2:100775422	G/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2120243	1.000	rs9289982	chr3:157144444	G/C	cg24825693	chr3:157122686	VEPH1	-0.36	-5.1	-0.31	6.66e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.11	-0.31	6.32e-7	Pulmonary function;
KIRP	trans	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.24	-0.37	1.95e-9	Schizophrenia;
KIRP	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg19171272	chr22:38449367	NA	-0.68	-9.6	-0.52	9.39e-19	Glioblastoma;Glioma;
KIRP	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg05347473	chr6:146136440	FBXO30	0.62	8.83	0.49	2.01e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.37	5.03	0.31	9.56e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs795544	0.608	rs1502048	chr5:13788282	C/T	cg07548982	chr5:13769939	DNAH5	0.45	5.52	0.33	8.55e-8	Corneal astigmatism;
KIRP	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg21427119	chr20:30132790	HM13	-0.46	-5.25	-0.32	3.32e-7	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg18306943	chr3:40428807	ENTPD3	0.38	5.13	0.31	5.85e-7	Renal cell carcinoma;
KIRP	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.65	-9.25	-0.51	1.16e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.54	7.94	0.45	7.02e-14	Red cell distribution width;
KIRP	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs11169552	0.510	rs10876076	chr12:51049083	G/C	cg12884762	chr12:50931848	DIP2B	-0.45	-5.15	-0.31	5.46e-7	Colorectal cancer;
KIRP	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.35	0.72	3.69e-41	Electrocardiographic conduction measures;
KIRP	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.68	9.32	0.51	6.75e-18	Obesity-related traits;
KIRP	trans	rs752590	0.623	rs66775912	chr2:113988729	T/C	cg10779423	chr3:50604763	C3orf18	0.5	6.2	0.37	2.31e-9	Mucinous ovarian carcinoma;
KIRP	trans	rs1864585	0.520	rs714370	chr8:10665847	C/T	cg26278703	chr11:58910052	FAM111A	0.65	6.45	0.38	5.96e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs11955398	0.584	rs62372964	chr5:59885798	C/A	cg02684056	chr5:59996105	DEPDC1B	0.46	5.43	0.33	1.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9311676	0.632	rs62258094	chr3:58371770	T/G	cg06643156	chr3:58380774	PXK	0.35	4.92	0.3	1.56e-6	Systemic lupus erythematosus;
KIRP	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.51	6.5	0.38	4.39e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg02100629	chr10:71892760	AIFM2	-0.39	-5.05	-0.31	8.64e-7	Blood protein levels;
KIRP	cis	rs1364705	1.000	rs13281087	chr8:120224470	T/C	cg09273054	chr8:120220131	MAL2	0.52	6.05	0.36	5.3e-9	Hippocampal atrophy;
KIRP	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	1.99e-8	Lung cancer;
KIRP	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg27490568	chr2:178487706	NA	0.52	7.07	0.41	1.59e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs16828019	0.852	rs12406620	chr1:41512664	A/T	cg03387723	chr1:41708464	SCMH1	-0.78	-6.48	-0.38	5.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs4789452	1.000	rs4789452	chr17:75372850	G/A	cg02320862	chr17:75370284	SEPT9	-0.37	-5.02	-0.31	9.77e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-7.83	-0.45	1.42e-13	Gut microbiome composition (summer);
KIRP	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.91	-0.3	1.67e-6	Pulmonary function;
KIRP	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg23601095	chr6:26197514	HIST1H3D	1.02	8.6	0.48	9.47e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs300890	0.513	rs72719180	chr4:144061673	C/T	cg01719995	chr4:144104893	USP38	-0.43	-5.51	-0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08748207	chr12:46777589	NA	0.54	6.08	0.36	4.53e-9	Lung cancer in ever smokers;
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-7.03	-0.41	2.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg01877450	chr7:97915802	BRI3	0.54	7.02	0.41	2.09e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg26022315	chr17:47021804	SNF8	0.45	5.81	0.35	1.92e-8	Type 2 diabetes;
KIRP	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg18478394	chr8:109455254	TTC35	0.49	5.99	0.36	7.59e-9	Dupuytren's disease;
KIRP	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg00278547	chr2:177037212	HOXD3	-0.39	-5.02	-0.3	9.96e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.38	6.52	0.38	3.86e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	4.95	0.3	1.4e-6	Tonsillectomy;
KIRP	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg08632701	chr21:37451849	NA	-0.44	-5.47	-0.33	1.13e-7	Mitral valve prolapse;
KIRP	cis	rs7572644	0.621	rs4464229	chr2:28038080	C/T	cg27432699	chr2:27873401	GPN1	0.48	5.49	0.33	1.01e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7560272	0.538	rs4852975	chr2:73932465	C/T	cg20560298	chr2:73613845	ALMS1	0.48	5.71	0.34	3.32e-8	Schizophrenia;
KIRP	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg23958373	chr8:599963	NA	0.97	7.77	0.44	2.08e-13	IgG glycosylation;
KIRP	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.51	-7.98	-0.45	5.66e-14	Huntington's disease progression;
KIRP	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg01721255	chr8:58191610	C8orf71	0.56	4.92	0.3	1.6e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.55e-10	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs1009181	0.585	rs4486004	chr6:26167710	G/T	cg13736514	chr6:26305472	NA	-0.6	-6.62	-0.39	2.25e-10	Childhood ear infection;
KIRP	cis	rs7640424	0.517	rs13099364	chr3:108022663	T/C	cg09227934	chr3:107805635	CD47	-0.33	-5.03	-0.31	9.55e-7	Body mass index;
KIRP	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg01559446	chr3:44596178	ZNF167	-0.36	-5.33	-0.32	2.18e-7	Depressive symptoms;
KIRP	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg21401794	chr1:90099060	LRRC8C	0.71	9.95	0.54	8.22e-20	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6575793	0.904	rs7493050	chr14:101037599	A/G	cg18516195	chr14:101012996	BEGAIN	0.5	7.29	0.42	4.25e-12	Menarche (age at onset);
KIRP	trans	rs7980799	0.935	rs2389194	chr12:33529164	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-6.54	-0.38	3.46e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.56	-10.05	-0.54	3.96e-20	Sjögren's syndrome;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15629447	chr6:47594195	CD2AP	0.37	6.34	0.37	1.08e-9	C-reactive protein;
KIRP	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.14	-0.36	3.28e-9	Breast cancer;
KIRP	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6893300	0.922	rs7735702	chr5:179132612	T/A	cg14593053	chr5:179126677	CANX	-0.58	-6.57	-0.39	3.04e-10	Resting heart rate;
KIRP	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.9	10.67	0.56	4.3e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25481680	chr10:105110878	PCGF6	0.49	6.29	0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs1376877	0.538	rs12474416	chr2:204226003	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.48	4.96	0.3	1.31e-6	Subclinical atherosclerosis traits (other);
KIRP	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.72	7.49	0.43	1.22e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-8.87	-0.49	1.56e-16	Platelet count;
KIRP	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.42e-11	Schizophrenia;
KIRP	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	cg12689670	chr1:183009347	LAMC1	0.54	7.26	0.42	4.97e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-6.28	-0.37	1.5e-9	Lung cancer;
KIRP	cis	rs9633740	0.504	rs1993484	chr10:82222698	T/C	cg01528321	chr10:82214614	TSPAN14	1.34	15.47	0.7	3.77e-38	Post bronchodilator FEV1;
KIRP	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg02574844	chr11:5959923	NA	-0.53	-5.77	-0.35	2.39e-8	DNA methylation (variation);
KIRP	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.53	-7.44	-0.43	1.63e-12	Bipolar disorder;
KIRP	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg12131826	chr15:77904385	NA	0.5	6.04	0.36	5.55e-9	Type 2 diabetes;
KIRP	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-7.24	-0.42	5.67e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7822232	0.908	rs1127096	chr8:145140472	A/G	cg27454946	chr8:145133526	EXOSC4	0.56	4.95	0.3	1.39e-6	Blood metabolite levels;
KIRP	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.24e-8	Lung cancer;
KIRP	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg01877450	chr7:97915802	BRI3	-0.54	-6.98	-0.41	2.72e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg09699651	chr6:150184138	LRP11	0.47	6.26	0.37	1.7e-9	Lung cancer;
KIRP	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg13393036	chr8:95962371	TP53INP1	-0.31	-5.99	-0.36	7.5e-9	Type 2 diabetes;
KIRP	cis	rs12220238	1.000	rs10824105	chr10:75952881	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.36	0.42	2.69e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11603020	0.950	rs78624400	chr11:57375463	G/C	cg19752551	chr11:57585705	CTNND1	-0.7	-9.79	-0.53	2.53e-19	Blood protein levels;
KIRP	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.81	11.5	0.59	8.67e-25	Multiple sclerosis;
KIRP	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18357526	chr6:26021779	HIST1H4A	0.58	8.32	0.47	6.21e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg14092988	chr3:52407081	DNAH1	0.35	6.13	0.36	3.53e-9	Bipolar disorder;
KIRP	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.75	9.63	0.52	7.9e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg05342945	chr12:48394962	COL2A1	-0.46	-5.04	-0.31	9e-7	Lung cancer;
KIRP	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	0.5	9.04	0.5	4.84e-17	QRS complex (12-leadsum);
KIRP	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs2274273	0.662	rs4040064	chr14:55678088	G/T	cg04306507	chr14:55594613	LGALS3	0.42	5.54	0.33	7.67e-8	Protein biomarker;
KIRP	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg14972814	chr11:95582409	MTMR2	0.35	5.86	0.35	1.48e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg04691961	chr3:161091175	C3orf57	0.46	6.82	0.4	7.08e-11	Morning vs. evening chronotype;
KIRP	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.38	-0.43	2.47e-12	Type 2 diabetes;
KIRP	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg27124370	chr19:33622961	WDR88	0.6	7.48	0.43	1.34e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.75	-0.34	2.58e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.4	-5.07	-0.31	7.68e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8179	0.648	rs42036	chr7:92241451	C/G	cg15732164	chr7:92237376	CDK6	-0.54	-6.73	-0.39	1.15e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.94	8.93	0.49	9.85e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00889227	chr1:205173544	DSTYK	-0.36	-4.88	-0.3	1.89e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg07636037	chr3:49044803	WDR6	-0.58	-5.5	-0.33	9.71e-8	Menarche (age at onset);
KIRP	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.29	-0.51	8.48e-18	Mean corpuscular volume;
KIRP	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-5.07	-0.31	7.84e-7	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13979800	chr9:140469108	WDR85	0.43	6.05	0.36	5.28e-9	Survival in pancreatic cancer;
KIRP	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs7534824	0.507	rs61780294	chr1:101398011	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	6.5	0.38	4.38e-10	Refractive astigmatism;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10633746	chr17:18164442	SMCR7	-0.47	-6.1	-0.36	4.01e-9	Pancreatic cancer;
KIRP	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.71	10.91	0.57	7.41e-23	Blood metabolite ratios;
KIRP	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.59	9.17	0.5	2.02e-17	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs7646881	0.767	rs73015629	chr3:158433840	C/A	cg19483011	chr3:158453295	NA	-0.5	-5.2	-0.31	4.2e-7	Tetralogy of Fallot;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg03518179	chr1:156470915	MEF2D	-0.47	-6.06	-0.36	5.02e-9	Blood metabolite levels;
KIRP	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7903847	0.642	rs10882926	chr10:99160690	C/T	cg20016023	chr10:99160130	RRP12	0.43	5.9	0.35	1.18e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7267005	1.000	rs113733573	chr20:34385136	C/A	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.4	9.95	0.54	7.89e-20	Corneal astigmatism;
KIRP	cis	rs4791746	0.901	rs4275897	chr17:8620609	A/G	cg03115937	chr17:8649504	CCDC42	-0.53	-6.44	-0.38	6.05e-10	Heroin dependence;
KIRP	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.75	7.7	0.44	3.33e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20087917	chr14:77924039	C14orf133;AHSA1	-0.47	-6.21	-0.37	2.25e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg20590849	chr17:73267439	MIF4GD	-0.46	-4.95	-0.3	1.37e-6	Systemic lupus erythematosus;
KIRP	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-11.09	-0.58	1.97e-23	Chronic sinus infection;
KIRP	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	10.45	0.55	2.12e-21	Mood instability;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07973140	chr15:75495174	C15orf39	0.5	6.89	0.4	4.56e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1978968	1.000	rs1076542	chr22:18446452	A/G	cg03078520	chr22:18463400	MICAL3	0.67	7.96	0.45	6.5e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs193541	0.593	rs246309	chr5:122269719	A/C	cg19412675	chr5:122181750	SNX24	0.56	5.93	0.35	1.03e-8	Glucose homeostasis traits;
KIRP	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	13.03	0.64	7.12e-30	Exhaled nitric oxide output;
KIRP	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg18190219	chr22:46762943	CELSR1	-0.93	-7.29	-0.42	4.32e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg13606994	chr1:44402422	ARTN	-0.28	-5.66	-0.34	4.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06481639	chr22:41940642	POLR3H	0.73	7.11	0.41	1.23e-11	Vitiligo;
KIRP	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	12.29	0.62	2.2e-27	Smoking behavior;
KIRP	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs4523957	0.757	rs216208	chr17:2195146	T/A	cg16513277	chr17:2031491	SMG6	0.62	8.34	0.47	5.36e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.68	-9.25	-0.51	1.1e-17	Rheumatoid arthritis;
KIRP	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs7737355	0.812	rs12514547	chr5:130973304	C/G	cg25547332	chr5:131281432	NA	0.41	4.98	0.3	1.18e-6	Life satisfaction;
KIRP	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.66	0.6	2.7e-25	Alzheimer's disease;
KIRP	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg04727924	chr7:799746	HEATR2	-0.64	-6.51	-0.38	4.25e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg15655495	chr12:38532458	NA	0.28	5.37	0.32	1.86e-7	Morning vs. evening chronotype;
KIRP	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.87	-10.66	-0.56	4.68e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg21926883	chr2:100939477	LONRF2	-0.57	-7.9	-0.45	9.53e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg17554472	chr22:41940697	POLR3H	0.42	5.01	0.3	1.06e-6	Vitiligo;
KIRP	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.7	10.8	0.57	1.71e-22	Blood metabolite ratios;
KIRP	cis	rs478607	1.000	rs60159753	chr11:64479112	G/T	cg09231725	chr11:64357281	SLC22A12	-0.61	-5.24	-0.32	3.49e-7	Urate levels;
KIRP	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	14.78	0.69	8.09e-36	Smoking behavior;
KIRP	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg10326726	chr10:51549505	MSMB	-0.56	-8.13	-0.46	2.13e-14	Prostate-specific antigen levels;
KIRP	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	7.23	0.42	6.13e-12	Eye color traits;
KIRP	cis	rs9400467	0.528	rs459403	chr6:111653877	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.71	-0.34	3.2e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	6.48	0.38	4.98e-10	Height;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07308232	chr7:1071921	C7orf50	-0.64	-8.18	-0.46	1.48e-14	Longevity;Endometriosis;
KIRP	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	1.06	10.22	0.55	1.15e-20	Blood protein levels;
KIRP	cis	rs8054556	0.787	rs11642612	chr16:30030195	A/C	cg06326092	chr16:30034487	C16orf92	0.44	5.94	0.35	9.78e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg07001201	chr5:642380	CEP72	0.68	6.38	0.38	8.52e-10	Obesity-related traits;
KIRP	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg09060608	chr5:178986726	RUFY1	0.51	7.63	0.44	5.26e-13	Lung cancer;
KIRP	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	cg21523751	chr1:182988639	NA	-0.41	-6.33	-0.37	1.13e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.79	-10.71	-0.56	3.12e-22	Height;
KIRP	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.52	5.75	0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs10073892	0.626	rs17334032	chr5:101881631	G/C	cg19774478	chr5:101632501	SLCO4C1	0.6	5.89	0.35	1.23e-8	Cognitive decline (age-related);
KIRP	cis	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.82	-0.45	1.54e-13	Mood instability;
KIRP	cis	rs10858047	0.883	rs6658815	chr1:115209050	T/C	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26002218	chr14:103986227	CKB	0.26	5.14	0.31	5.65e-7	Body mass index;
KIRP	cis	rs75920871	1.000	rs10892044	chr11:116766899	C/T	cg23684410	chr11:116897558	SIK3	-0.53	-5.78	-0.35	2.28e-8	Subjective well-being;
KIRP	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.97	-13.65	-0.66	6.06e-32	Cognitive ability;
KIRP	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg16606324	chr3:10149918	C3orf24	0.61	5.46	0.33	1.18e-7	Alzheimer's disease;
KIRP	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	9.54	0.52	1.45e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs2712184	0.756	rs2541393	chr2:217651230	G/C	cg05032264	chr2:217675019	NA	-0.47	-6.69	-0.39	1.46e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.16	21.24	0.8	1.45e-57	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs4262150	0.883	rs4260728	chr5:152225997	C/A	cg12297329	chr5:152029980	NA	-0.62	-8.17	-0.46	1.59e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.47	6.7	0.39	1.42e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	cg04338863	chr8:33670619	NA	0.39	5.0	0.3	1.1e-6	Body mass index;
KIRP	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg04398451	chr17:18023971	MYO15A	-0.85	-11.83	-0.6	7.16e-26	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06665941	chr21:34602869	IFNAR2	0.63	7.65	0.44	4.44e-13	Smoking initiation;
KIRP	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg01413848	chr1:3081226	PRDM16	-0.41	-5.36	-0.32	1.96e-7	Migraine;
KIRP	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg16049864	chr8:95962084	TP53INP1	-0.37	-5.82	-0.35	1.87e-8	Type 2 diabetes;
KIRP	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	8.19	0.46	1.46e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg16606324	chr3:10149918	C3orf24	0.61	4.94	0.3	1.45e-6	Alzheimer's disease;
KIRP	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg21775007	chr8:11205619	TDH	-0.47	-6.25	-0.37	1.84e-9	Triglycerides;
KIRP	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.64	-7.17	-0.42	8.53e-12	Asthma;
KIRP	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.42	5.6	0.34	5.57e-8	Immature fraction of reticulocytes;
KIRP	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg24169773	chr3:122142474	KPNA1	-0.58	-6.42	-0.38	6.99e-10	LDL cholesterol levels;
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg03152288	chr2:177042942	NA	0.61	8.52	0.48	1.58e-15	IgG glycosylation;
KIRP	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs75920871	0.528	rs7109649	chr11:116943544	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.33	-0.32	2.26e-7	Subjective well-being;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.69	10.15	0.54	1.95e-20	Menarche (age at onset);
KIRP	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg13319975	chr6:146136371	FBXO30	-0.45	-5.96	-0.35	8.9e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-1.0	-15.9	-0.71	1.24e-39	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.07	-0.36	4.89e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg23736307	chr8:27182930	PTK2B	0.54	6.79	0.4	8.2e-11	Neuroticism;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15129777	chr11:8008818	EIF3F	0.48	6.42	0.38	7.04e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg04306507	chr14:55594613	LGALS3	0.52	8.14	0.46	2.04e-14	Protein biomarker;
KIRP	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.32	-0.32	2.34e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2901656	0.677	rs2301455	chr1:172418268	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.48	6.3	0.37	1.33e-9	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.7e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs3731896	0.898	rs7596956	chr2:220152359	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.47	-5.24	-0.32	3.44e-7	Educational attainment;
KIRP	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.47	-6.06	-0.36	5.11e-9	Schizophrenia;
KIRP	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.66	10.38	0.55	3.59e-21	Obesity-related traits;
KIRP	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-5.95	-0.35	9.31e-9	Aortic root size;
KIRP	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs1978968	0.826	rs34596632	chr22:18463254	A/C	cg03078520	chr22:18463400	MICAL3	-0.8	-9.1	-0.5	3.25e-17	Presence of antiphospholipid antibodies;
KIRP	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg08126542	chr6:37504118	NA	0.6	8.29	0.47	7.54e-15	Cognitive performance;
KIRP	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg07701084	chr6:150067640	NUP43	0.62	8.0	0.45	4.93e-14	Testicular germ cell tumor;
KIRP	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg02404636	chr22:31891804	SFI1	-0.46	-5.09	-0.31	7.09e-7	Colorectal cancer;
KIRP	cis	rs6681460	1.000	rs6588207	chr1:67066555	A/G	cg02459107	chr1:67143332	SGIP1	0.47	6.64	0.39	2.02e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs7589728	1.000	rs7589728	chr2:88518440	G/A	cg04511125	chr2:88470314	THNSL2	0.71	5.43	0.33	1.37e-7	Plasma clusterin levels;
KIRP	cis	rs1456297	0.806	rs7181921	chr15:51992426	C/T	cg14296394	chr15:51910925	DMXL2	-0.57	-7.14	-0.41	1.03e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg10790698	chr19:18539756	SSBP4	-0.33	-7.24	-0.42	5.86e-12	Breast cancer;
KIRP	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.84	13.94	0.66	6.14e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.95	11.15	0.58	1.26e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.17	0.37	2.74e-9	Lung cancer;
KIRP	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.41	-7.3	-0.42	3.94e-12	Refractive error;
KIRP	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	trans	rs36715	1.000	rs36702	chr5:127552723	A/T	cg05141384	chr18:14378365	NA	0.5	6.35	0.38	1.01e-9	Breast cancer;
KIRP	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	1.05	14.82	0.69	6.02e-36	Menopause (age at onset);
KIRP	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg06115741	chr20:33292138	TP53INP2	-0.43	-5.81	-0.35	1.88e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg24169773	chr3:122142474	KPNA1	-0.58	-6.43	-0.38	6.7e-10	LDL cholesterol levels;
KIRP	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg23985595	chr17:80112537	CCDC57	-0.33	-4.94	-0.3	1.46e-6	Life satisfaction;
KIRP	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg01988459	chr11:68622903	NA	-0.39	-5.18	-0.31	4.72e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg03171003	chr2:111875934	NA	0.41	5.81	0.35	1.89e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.58	-12.17	-0.61	5.56e-27	Diabetic kidney disease;
KIRP	cis	rs6850606	0.536	rs1993061	chr4:42857243	T/C	cg24533989	chr4:42659536	ATP8A1	0.43	4.91	0.3	1.69e-6	Interferon alpha levels in systemic lupus erythematosus;
KIRP	trans	rs4775041	0.961	rs62001736	chr15:58674051	G/A	cg21369679	chr16:47007757	DNAJA2	0.58	6.62	0.39	2.18e-10	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	cis	rs17123764	0.892	rs74087134	chr12:50124257	T/C	cg20471783	chr12:50157085	TMBIM6	0.42	5.47	0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.56	-0.33	7.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-10.16	-0.54	1.79e-20	Hip circumference;
KIRP	cis	rs78487399	0.808	rs17030845	chr2:43687879	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.13	-0.31	5.89e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	1.02	9.95	0.54	8.09e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs300890	0.901	rs6537153	chr4:144230902	A/C	cg19876092	chr4:144208277	NA	0.36	5.61	0.34	5.43e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.39	-0.33	1.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.93	13.6	0.66	8.89e-32	Response to antipsychotic treatment;
KIRP	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.84	12.34	0.62	1.44e-27	N-glycan levels;
KIRP	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.46	-0.33	1.14e-7	Pulmonary function;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01879488	chr11:35160498	CD44	0.57	6.6	0.39	2.53e-10	Lung cancer in ever smokers;
KIRP	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg09003973	chr2:102972529	NA	0.56	5.79	0.35	2.16e-8	Blood protein levels;
KIRP	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg23307798	chr14:103986281	CKB	-0.43	-5.81	-0.35	1.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg16586182	chr3:47516702	SCAP	-0.66	-9.0	-0.5	6.16e-17	Colorectal cancer;
KIRP	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06647332	chr5:131281008	NA	-0.44	-4.88	-0.3	1.91e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg19773385	chr1:10388646	KIF1B	-0.73	-11.46	-0.59	1.23e-24	Hepatocellular carcinoma;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.52	-4.91	-0.3	1.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13315871	1.000	rs9869576	chr3:58401262	G/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg09676129	chr20:60540388	NA	-0.34	-4.91	-0.3	1.63e-6	Body mass index;
KIRP	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.48	5.88	0.35	1.37e-8	Height;
KIRP	cis	rs35995292	0.534	rs10274968	chr7:38939254	C/T	cg19327137	chr7:38886074	VPS41	0.84	13.74	0.66	2.89e-32	Subjective well-being (multi-trait analysis);
KIRP	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.49	-6.85	-0.4	5.87e-11	Obesity-related traits;
KIRP	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-7.36	-0.42	2.72e-12	Systemic lupus erythematosus;
KIRP	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.65	-8.83	-0.49	1.95e-16	Hypospadias;
KIRP	trans	rs1568657	0.779	rs2167602	chr15:83649292	C/T	cg17192681	chr2:10953115	PDIA6	-0.54	-6.48	-0.38	5.05e-10	Kawasaki disease;
KIRP	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.02	-0.41	2.13e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7429990	0.901	rs9825114	chr3:48138082	A/G	cg11946769	chr3:48343235	NME6	-0.52	-5.93	-0.35	1.01e-8	Educational attainment (years of education);
KIRP	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.04	0.31	9.1e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg03160526	chr17:80928410	B3GNTL1	0.42	5.2	0.31	4.11e-7	Glycated hemoglobin levels;
KIRP	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.68	-9.96	-0.54	7.42e-20	Prostate cancer;
KIRP	cis	rs7215564	0.730	rs2171023	chr17:78608913	A/T	cg06153925	chr17:78755379	RPTOR	0.42	5.81	0.35	1.96e-8	Myopia (pathological);
KIRP	cis	rs7106204	0.748	rs4382909	chr11:24236618	C/T	ch.11.24196551F	chr11:24239977	NA	0.79	9.48	0.52	2.31e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.43	5.75	0.34	2.68e-8	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs6504340	0.793	rs56128659	chr17:46621828	T/A	cg05487507	chr17:46671861	LOC404266;HOXB5	0.44	4.96	0.3	1.3e-6	Primary tooth development (number of teeth);
KIRP	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.95	14.65	0.68	2.26e-35	Systemic lupus erythematosus;
KIRP	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.71	-8.05	-0.46	3.45e-14	Body mass index;
KIRP	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg07395648	chr5:131743802	NA	-0.54	-7.56	-0.43	8.07e-13	Acylcarnitine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14964274	chr1:215796556	USH2A	0.52	7.17	0.42	8.96e-12	Interleukin-4 levels;
KIRP	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg19592336	chr6:28129416	ZNF389	0.48	5.51	0.33	8.85e-8	Depression;
KIRP	cis	rs7221595	0.778	rs2290439	chr17:3924306	A/G	cg09695851	chr17:3907499	NA	0.61	6.96	0.41	2.98e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.48	5.86	0.35	1.51e-8	Common traits (Other);
KIRP	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	8.51	0.48	1.7e-15	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg11693508	chr17:37793320	STARD3	0.5	6.77	0.4	9.64e-11	Neuroticism;
KIRP	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.18e-7	Obesity-related traits;
KIRP	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg19468946	chr17:37922297	IKZF3	-0.51	-7.02	-0.41	2.09e-11	Self-reported allergy;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.78	11.93	0.61	3.49e-26	Menarche (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10424330	chr16:71894309	ZNF821;ATXN1L	0.45	6.26	0.37	1.66e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg26681399	chr22:41777847	TEF	0.42	4.92	0.3	1.56e-6	Vitiligo;
KIRP	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.5	-0.33	9.6e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9469913	0.866	rs61431557	chr6:34717578	C/T	cg17674042	chr6:34482479	PACSIN1	-0.46	-5.73	-0.34	2.92e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg04369109	chr6:150039330	LATS1	-0.67	-8.87	-0.49	1.53e-16	Lung cancer;
KIRP	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg20744362	chr22:50050164	C22orf34	0.35	5.93	0.35	1.04e-8	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.77	-8.14	-0.46	1.95e-14	Asthma;
KIRP	cis	rs4664304	0.900	rs3828327	chr2:160742095	G/A	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.72	-0.39	1.26e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-5.75	-0.34	2.65e-8	Blood metabolite levels;
KIRP	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	10.0	0.54	5.67e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg13072238	chr3:49761600	GMPPB	0.57	5.3	0.32	2.61e-7	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.82	11.32	0.59	3.52e-24	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15352224	chr3:10157326	C3orf10	0.45	6.03	0.36	6.04e-9	Survival in pancreatic cancer;
KIRP	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.6	-9.55	-0.52	1.34e-18	Longevity;
KIRP	trans	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg02002194	chr4:3960332	NA	0.46	6.23	0.37	1.96e-9	Mood instability;
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-5.04	-0.31	8.89e-7	Life satisfaction;
KIRP	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg04733989	chr22:42467013	NAGA	-0.41	-5.21	-0.31	4.09e-7	Intelligence;
KIRP	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	5.3	0.32	2.51e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24591761	chr15:72410226	MYO9A;SENP8	0.55	6.91	0.4	4.12e-11	Parkinson's disease;
KIRP	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.53	6.39	0.38	8.39e-10	Resistin levels;
KIRP	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg21360079	chr12:107162445	NA	-0.7	-10.12	-0.54	2.38e-20	Heart rate;
KIRP	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07167872	chr1:205819463	PM20D1	-0.48	-5.63	-0.34	4.9e-8	Parkinson's disease;
KIRP	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg26441486	chr22:50317300	CRELD2	-0.46	-7.59	-0.44	6.79e-13	Schizophrenia;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-0.67	-5.11	-0.31	6.58e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg23601095	chr6:26197514	HIST1H3D	1.02	8.6	0.48	9.47e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs11249608	0.789	rs7733067	chr5:178425714	T/C	cg21905437	chr5:178450457	ZNF879	-0.5	-5.8	-0.35	2.05e-8	Pubertal anthropometrics;
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	1.04	11.27	0.58	4.88e-24	Alzheimer's disease;
KIRP	cis	rs7429990	0.901	rs7374482	chr3:48168390	A/G	cg11946769	chr3:48343235	NME6	-0.43	-5.16	-0.31	5.19e-7	Educational attainment (years of education);
KIRP	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg18944383	chr4:111397179	ENPEP	0.55	9.27	0.51	9.87e-18	Coronary artery disease;
KIRP	cis	rs4711336	1.000	rs2229642	chr6:33659472	C/G	cg15676125	chr6:33679581	C6orf125	0.41	5.5	0.33	9.37e-8	Height;
KIRP	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.45	15.47	0.7	3.71e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs4474465	1.000	rs4944202	chr11:78189558	T/C	cg27205649	chr11:78285834	NARS2	-0.64	-7.28	-0.42	4.38e-12	Alzheimer's disease (survival time);
KIRP	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.94	13.06	0.64	5.89e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg16586182	chr3:47516702	SCAP	-0.43	-5.33	-0.32	2.19e-7	Birth weight;
KIRP	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg00042356	chr1:8021962	PARK7	0.85	6.92	0.4	3.91e-11	Inflammatory bowel disease;
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.51	-0.33	9.11e-8	Obesity-related traits;
KIRP	cis	rs7584330	0.504	rs61213635	chr2:238428132	A/G	cg14458575	chr2:238380390	NA	0.52	6.15	0.36	3.15e-9	Prostate cancer;
KIRP	cis	rs1448094	0.967	rs7978132	chr12:86323484	T/C	cg00310523	chr12:86230176	RASSF9	0.37	5.67	0.34	4.08e-8	Major depressive disorder;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.64	0.44	4.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2625529	0.824	rs4776586	chr15:72430503	C/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-5.81	-0.35	1.9e-8	Aortic root size;
KIRP	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.66	8.84	0.49	1.86e-16	Schizophrenia;
KIRP	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg00647317	chr7:50633725	DDC	0.39	5.67	0.34	3.89e-8	Systemic sclerosis;
KIRP	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.42	-0.33	1.4e-7	IgG glycosylation;
KIRP	cis	rs17331151	0.505	rs35225119	chr3:52623465	A/T	cg04865290	chr3:52927548	TMEM110	-0.56	-4.88	-0.3	1.87e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg14673194	chr17:80132900	CCDC57	-0.64	-6.86	-0.4	5.68e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-7.46	-0.43	1.49e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-6.98	-0.41	2.8e-11	HDL cholesterol;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg17207736	chr8:142237307	SLC45A4	0.52	6.45	0.38	6.05e-10	Immature fraction of reticulocytes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03771185	chr4:775700	NA	0.61	7.25	0.42	5.31e-12	Smoking initiation;
KIRP	cis	rs60154123	0.730	rs652241	chr1:210465029	A/T	cg09074223	chr1:210466472	NA	0.53	5.59	0.34	6.07e-8	Coronary artery disease;
KIRP	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg09467607	chr2:36825704	FEZ2	0.84	11.47	0.59	1.11e-24	Height;
KIRP	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.4	-5.58	-0.34	6.36e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	7.47	0.43	1.37e-12	Monocyte count;
KIRP	cis	rs494562	0.892	rs573737	chr6:86118233	A/G	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs17401966	0.540	rs6541094	chr1:10467074	G/A	cg19773385	chr1:10388646	KIF1B	-0.44	-6.28	-0.37	1.5e-9	Hepatocellular carcinoma;
KIRP	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg14664628	chr15:75095509	CSK	-1.09	-16.74	-0.73	1.63e-42	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.18	0.31	4.7e-7	Bipolar disorder;
KIRP	cis	rs7737355	0.947	rs58991576	chr5:130589540	T/C	cg06647332	chr5:131281008	NA	-0.48	-5.27	-0.32	2.93e-7	Life satisfaction;
KIRP	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg14345882	chr6:26364793	BTN3A2	0.56	5.08	0.31	7.56e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6504622	0.905	rs736604	chr17:45024809	C/T	cg24703533	chr17:45055318	NA	0.38	5.28	0.32	2.86e-7	Orofacial clefts;
KIRP	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg16309518	chr5:176445507	NA	-0.81	-12.69	-0.63	1.05e-28	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.87	0.3	2.03e-6	Coronary artery disease;
KIRP	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	6.26	0.37	1.74e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-10.83	-0.57	1.35e-22	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.5	-0.33	9.37e-8	Life satisfaction;
KIRP	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.11	-0.8	3.83e-57	Ulcerative colitis;
KIRP	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs1018836	0.505	rs7015030	chr8:91460331	T/C	cg16814680	chr8:91681699	NA	-0.43	-5.15	-0.31	5.35e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.29	0.37	1.46e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.69	7.9	0.45	9.31e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.61	0.68	3.15e-35	Platelet count;
KIRP	cis	rs10751667	0.557	rs12281858	chr11:1022187	C/T	cg06064525	chr11:970664	AP2A2	-0.32	-5.82	-0.35	1.84e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2278796	0.639	rs4951152	chr1:204970495	G/T	cg04862289	chr1:204966208	NFASC	0.67	9.55	0.52	1.42e-18	Mean platelet volume;
KIRP	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.39	-0.7	6.59e-38	Gut microbiome composition (summer);
KIRP	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs9309473	0.950	rs6705977	chr2:73849170	C/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.21	-0.32	4e-7	Metabolite levels;
KIRP	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs1978968	0.956	rs12159837	chr22:18447491	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.79	-0.4	8.23e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs1629083	0.870	rs12362596	chr11:118105473	G/C	cg18857871	chr11:118064634	AMICA1	0.62	8.08	0.46	2.99e-14	Lung cancer;
KIRP	cis	rs7560272	0.512	rs12998980	chr2:73930726	A/C	cg20560298	chr2:73613845	ALMS1	0.5	6.1	0.36	4.11e-9	Schizophrenia;
KIRP	cis	rs17065868	1.000	rs17065859	chr13:45049498	T/A	cg10246903	chr13:45222710	NA	0.58	5.96	0.36	8.8e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.61	-0.6	3.83e-25	Body mass index;
KIRP	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs12282928	1.000	rs6485822	chr11:48292801	C/G	cg26585981	chr11:48327164	OR4S1	0.47	5.2	0.31	4.15e-7	Migraine - clinic-based;
KIRP	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.7	-0.44	3.26e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.78	11.36	0.59	2.61e-24	Heart rate;
KIRP	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg24375607	chr4:120327624	NA	0.57	6.49	0.38	4.81e-10	Corneal astigmatism;
KIRP	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.59e-12	Obesity-related traits;
KIRP	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.45	-6.94	-0.4	3.4e-11	Coronary artery disease;
KIRP	trans	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.87	0.4	5.16e-11	Retinal vascular caliber;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27063932	chr15:22872668	TUBGCP5	0.42	6.11	0.36	3.83e-9	Migraine with aura;
KIRP	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.88	-11.66	-0.6	2.69e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg11189052	chr15:85197271	WDR73	0.51	5.42	0.33	1.45e-7	Schizophrenia;
KIRP	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.27	-0.42	4.75e-12	Mood instability;
KIRP	cis	rs7105934	1.000	rs7939454	chr11:69234390	G/T	cg24478926	chr11:69237550	NA	-0.56	-5.48	-0.33	1.04e-7	Renal cell carcinoma;
KIRP	cis	rs273218	0.573	rs11742692	chr5:53343576	C/T	ch.5.1024479R	chr5:53302184	ARL15	-1.06	-12.32	-0.62	1.71e-27	Migraine;
KIRP	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg16141378	chr3:129829833	LOC729375	-0.52	-6.5	-0.38	4.47e-10	Retinal vascular caliber;
KIRP	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	5.94	0.35	9.67e-9	Depressive symptoms;
KIRP	cis	rs17023223	0.581	rs12064109	chr1:119642296	T/C	cg18261050	chr1:119551319	NA	0.54	7.11	0.41	1.25e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.74	6.66	0.39	1.78e-10	Diabetic retinopathy;
KIRP	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.84	-0.45	1.41e-13	Neuroticism;
KIRP	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.28	-0.47	7.76e-15	Neuroticism;
KIRP	cis	rs9372498	0.505	rs72956993	chr6:118949708	A/T	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg02725872	chr8:58115012	NA	-0.48	-6.03	-0.36	6.06e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9488822	0.662	rs195521	chr6:116244114	T/C	cg26893134	chr6:116381904	FRK	0.19	4.89	0.3	1.82e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.1	-0.46	2.53e-14	Monocyte percentage of white cells;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.75	11.97	0.61	2.46e-26	Longevity;Endometriosis;
KIRP	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.53	-6.88	-0.4	5.03e-11	Lung cancer;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.83	-0.35	1.73e-8	Obesity-related traits;
KIRP	cis	rs737693	0.564	rs72983568	chr11:102773998	T/G	cg19620758	chr11:102826565	MMP13	0.79	7.31	0.42	3.73e-12	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12579753	0.719	rs10862377	chr12:82270172	C/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-6.22	-0.37	2.07e-9	Resting heart rate;
KIRP	cis	rs1497828	0.956	rs2810787	chr1:217549038	A/G	cg04411442	chr1:217543379	NA	0.31	5.02	0.3	1e-6	Dialysis-related mortality;
KIRP	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.93	9.9	0.53	1.18e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs7923609	0.934	rs7923544	chr10:65182256	T/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.49	-0.33	9.84e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12049351	0.774	rs12030128	chr1:229622863	A/G	cg11742688	chr1:229674241	ABCB10	-0.38	-5.59	-0.34	6.16e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs9815354	0.812	rs10510731	chr3:41853310	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg11859384	chr17:80120422	CCDC57	0.45	5.8	0.35	2.02e-8	Life satisfaction;
KIRP	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg06671706	chr8:8559999	CLDN23	0.56	6.33	0.37	1.18e-9	Obesity-related traits;
KIRP	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg13334819	chr7:99746414	C7orf59	0.53	6.01	0.36	6.53e-9	Coronary artery disease;
KIRP	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg19507638	chr5:93509721	C5orf36	-0.59	-5.29	-0.32	2.71e-7	Diabetic retinopathy;
KIRP	cis	rs2346160	0.899	rs172283	chr6:167691225	T/C	cg04673565	chr6:167680447	NA	-0.38	-4.87	-0.3	2.04e-6	Parental extreme longevity (95 years and older);
KIRP	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.46	6.53	0.38	3.7e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.58	7.65	0.44	4.68e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.67	-9.11	-0.5	3.06e-17	Personality dimensions;
KIRP	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.51	-6.11	-0.36	3.95e-9	Tuberculosis;
KIRP	cis	rs10518128	1.000	rs1349636	chr4:75712260	T/C	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	trans	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg11693508	chr17:37793320	STARD3	0.81	8.18	0.46	1.54e-14	Neuroticism;
KIRP	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg02187348	chr16:89574699	SPG7	0.43	4.93	0.3	1.53e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg02696790	chr15:75250997	RPP25	0.33	5.41	0.33	1.52e-7	Caffeine consumption;
KIRP	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-14.67	-0.68	1.99e-35	Coronary artery disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17422427	chr2:241507521	RNPEPL1	-0.5	-6.32	-0.37	1.21e-9	Neuroticism;
KIRP	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg14675211	chr2:100938903	LONRF2	-0.49	-6.68	-0.39	1.61e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06808467	chr18:5237767	LOC339290;C18orf18	-0.43	-6.05	-0.36	5.39e-9	Metabolic traits;
KIRP	cis	rs4776059	0.550	rs55895733	chr15:52952159	T/G	cg25063058	chr15:52860530	ARPP19	-0.57	-4.84	-0.3	2.27e-6	Schizophrenia;
KIRP	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	0.93	14.58	0.68	3.99e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg06781948	chr3:72941472	GXYLT2	0.47	6.16	0.37	3.01e-9	Motion sickness;
KIRP	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.11	10.87	0.57	9.74e-23	Diabetic retinopathy;
KIRP	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg16141378	chr3:129829833	LOC729375	0.47	6.16	0.37	2.91e-9	Retinal vascular caliber;
KIRP	cis	rs4728302	0.869	rs6966403	chr7:133614421	A/C	cg10665199	chr7:133106180	EXOC4	-0.45	-5.49	-0.33	1.02e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-1.08	-11.61	-0.59	3.94e-25	Exhaled nitric oxide output;
KIRP	trans	rs4650994	0.623	rs35854525	chr1:178618604	C/T	cg05059571	chr16:84539110	KIAA1609	0.55	7.02	0.41	2.19e-11	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg11893236	chr16:68345102	PRMT7;SLC7A6OS	0.47	6.02	0.36	6.47e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.925	rs1134760	chr16:67964203	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-7.72	-0.44	2.85e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.52	6.82	0.4	7.15e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg11235152	chr1:67600687	NA	0.71	10.04	0.54	4.13e-20	Psoriasis;
KIRP	cis	rs300890	0.513	rs4309787	chr4:144049222	G/T	cg01719995	chr4:144104893	USP38	-0.41	-5.3	-0.32	2.59e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.78	-8.58	-0.48	1.06e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg05370193	chr1:21551575	ECE1	0.44	6.13	0.36	3.51e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13058734	chr1:246370933	SMYD3	0.44	6.32	0.37	1.2e-9	Interleukin-4 levels;
KIRP	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.33	12.07	0.61	1.14e-26	Diabetic retinopathy;
KIRP	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg01620082	chr3:125678407	NA	-1.15	-7.44	-0.43	1.65e-12	Depression;
KIRP	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg13444842	chr1:152974279	SPRR3	-0.35	-4.93	-0.3	1.5e-6	Inflammatory skin disease;
KIRP	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15448220	chr1:150897856	SETDB1	0.37	4.88	0.3	1.9e-6	Melanoma;
KIRP	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg25507518	chr7:2405875	EIF3B	0.45	4.91	0.3	1.64e-6	Multiple sclerosis;
KIRP	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg21775007	chr8:11205619	TDH	0.39	4.91	0.3	1.62e-6	Neuroticism;
KIRP	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg14703610	chr5:56206110	C5orf35	0.51	7.13	0.41	1.13e-11	Coronary artery disease;
KIRP	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.42	-0.59	1.65e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg11641102	chr8:27183873	PTK2B	0.46	6.0	0.36	7.15e-9	Neuroticism;
KIRP	cis	rs96067	0.772	rs1033891	chr1:36608402	A/G	cg24686825	chr1:36642396	MAP7D1	-0.58	-6.31	-0.37	1.28e-9	Corneal structure;
KIRP	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg24498760	chr8:49746867	NA	0.41	4.93	0.3	1.53e-6	Blood metabolite ratios;
KIRP	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.72	0.34	3.13e-8	Birth weight;
KIRP	cis	rs77688320	0.535	rs7579617	chr2:202248788	T/C	cg06431681	chr2:202330990	STRADB	0.51	6.78	0.4	8.81e-11	Breast cancer;
KIRP	trans	rs9944715	0.911	rs9956574	chr18:43782203	C/T	cg01718231	chr17:29326311	RNF135	-0.51	-6.24	-0.37	1.89e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg05527609	chr1:210001259	C1orf107	-0.5	-5.54	-0.33	7.67e-8	Red blood cell count;
KIRP	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	8.6	0.48	9.45e-16	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.57	-9.41	-0.51	3.71e-18	Prostate cancer;
KIRP	cis	rs1524927	0.933	rs12704874	chr7:96340744	A/G	cg03808172	chr7:96339361	SHFM1	0.37	4.9	0.3	1.74e-6	Total body bone mineral density;
KIRP	cis	rs6432018	1.000	rs7596929	chr2:9717645	A/T	cg27527593	chr2:8818326	NA	-0.37	-4.97	-0.3	1.25e-6	Heart rate variability traits;
KIRP	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	5.13	0.31	5.76e-7	Ovarian reserve;
KIRP	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg05187965	chr10:45406764	TMEM72	-0.29	-6.67	-0.39	1.66e-10	Mean corpuscular volume;
KIRP	cis	rs7078219	0.543	rs10786556	chr10:101278324	C/T	cg07044859	chr10:101282883	NA	-0.33	-6.2	-0.37	2.42e-9	Dental caries;
KIRP	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg17724175	chr1:150552817	MCL1	0.31	5.03	0.31	9.31e-7	Melanoma;
KIRP	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg01843034	chr6:37503916	NA	-0.95	-14.45	-0.68	1.11e-34	Cognitive performance;
KIRP	cis	rs4523957	0.855	rs1231206	chr17:2125605	G/A	cg16513277	chr17:2031491	SMG6	-0.68	-9.53	-0.52	1.59e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs952623	0.649	rs6952464	chr7:39076327	C/T	cg18850127	chr7:39170497	POU6F2	0.26	5.08	0.31	7.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg00977110	chr5:151150581	G3BP1	0.53	5.46	0.33	1.14e-7	Preschool internalizing problems;
KIRP	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.78	6.06	0.36	5.02e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9815354	0.680	rs73073294	chr3:42028053	A/G	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.41	-5.1	-0.31	6.93e-7	Longevity;Endometriosis;
KIRP	trans	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg01620082	chr3:125678407	NA	-1.23	-7.54	-0.43	8.83e-13	Breast cancer;
KIRP	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg00343986	chr7:65444356	GUSB	0.49	6.01	0.36	6.66e-9	Calcium levels;
KIRP	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.52	7.32	0.42	3.42e-12	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg17133734	chr15:86042851	AKAP13	-0.44	-5.41	-0.33	1.47e-7	Coronary artery disease;
KIRP	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs6579956	0.517	rs4318765	chr5:152046544	G/C	cg12297329	chr5:152029980	NA	-0.39	-4.95	-0.3	1.39e-6	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs501120	0.733	rs587375	chr10:44745808	T/C	cg09554077	chr10:44749378	NA	0.75	12.45	0.62	6.35e-28	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.44	8.41	0.47	3.44e-15	Coronary artery disease;
KIRP	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg13852791	chr20:30311386	BCL2L1	0.64	7.0	0.41	2.43e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.61	-0.39	2.41e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg27121462	chr16:89883253	FANCA	0.51	6.78	0.4	8.86e-11	Vitiligo;
KIRP	cis	rs6142102	0.961	rs6119447	chr20:32668576	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	6.95	0.41	3.3e-11	Skin pigmentation;
KIRP	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg04374321	chr14:90722782	PSMC1	0.49	5.35	0.32	2.05e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg08999081	chr20:33150536	PIGU	0.46	4.91	0.3	1.7e-6	Protein C levels;
KIRP	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg27471124	chr11:109292789	C11orf87	0.51	6.05	0.36	5.42e-9	Schizophrenia;
KIRP	cis	rs3126085	1.000	rs72698906	chr1:152307184	G/A	cg26876637	chr1:152193138	HRNR	-0.79	-7.85	-0.45	1.27e-13	Atopic dermatitis;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.49e-13	Life satisfaction;
KIRP	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	1.01	14.62	0.68	2.84e-35	Height;
KIRP	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.48	-6.97	-0.41	2.82e-11	DNA methylation (variation);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg15747156	chr2:27603833	ZNF513	0.44	6.13	0.36	3.54e-9	Educational attainment;
KIRP	cis	rs2151522	0.762	rs13215166	chr6:127164360	A/G	cg21431617	chr6:127135037	NA	0.29	5.16	0.31	5.07e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.71	10.81	0.57	1.52e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.75	10.06	0.54	3.7e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs2458413	0.500	rs2251930	chr8:105357764	G/A	cg08657449	chr8:105351661	TM7SF4	-0.38	-6.3	-0.37	1.37e-9	Paget's disease;
KIRP	cis	rs6496667	0.779	rs8041401	chr15:90958545	A/G	cg10434728	chr15:90938212	IQGAP1	0.36	4.92	0.3	1.6e-6	Rheumatoid arthritis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg12346351	chr4:152330392	FAM160A1	0.74	6.89	0.4	4.53e-11	Lung function (FEV1);
KIRP	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg15068132	chr12:102092402	CHPT1	-0.39	-5.09	-0.31	7.26e-7	Blood protein levels;
KIRP	cis	rs1978968	1.000	rs4410378	chr22:18451391	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.54	-6.34	-0.37	1.11e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg25019033	chr10:957182	NA	-0.49	-5.23	-0.32	3.64e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22975147	chr17:8021903	ALOXE3	0.48	6.31	0.37	1.3e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg17366294	chr4:99064904	C4orf37	0.35	4.93	0.3	1.54e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg16141378	chr3:129829833	LOC729375	0.6	7.61	0.44	5.66e-13	Systolic blood pressure;
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.24	-16.13	-0.72	1.96e-40	Platelet count;
KIRP	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.61	8.85	0.49	1.77e-16	Immature fraction of reticulocytes;
KIRP	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg00204512	chr16:28754710	NA	0.44	5.56	0.33	7.17e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg17691542	chr6:26056736	HIST1H1C	0.49	6.41	0.38	7.35e-10	Height;
KIRP	cis	rs73086581	1.000	rs73086581	chr20:3977325	T/C	cg02187196	chr20:3869020	PANK2	0.52	5.07	0.31	7.76e-7	Response to antidepressants in depression;
KIRP	cis	rs1829883	0.668	rs3850900	chr5:98990822	T/C	cg08333243	chr5:99726346	NA	0.39	4.99	0.3	1.12e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.68	-7.98	-0.45	5.5e-14	Neuroticism;
KIRP	cis	rs4805272	1.000	rs4804854	chr19:29320058	A/G	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs8077577	0.895	rs62073607	chr17:18071338	A/G	cg18869244	chr17:18121946	NA	0.47	5.22	0.32	3.79e-7	Obesity-related traits;
KIRP	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg10223061	chr2:219282414	VIL1	0.37	6.03	0.36	5.84e-9	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.84	0.35	1.66e-8	Breast cancer;
KIRP	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.6	-8.48	-0.48	2.15e-15	IgG glycosylation;
KIRP	cis	rs867371	0.896	rs8033831	chr15:82513294	C/A	cg00614314	chr15:82944287	LOC80154	0.54	6.25	0.37	1.84e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13113963	chr6:170863576	PSMB1;TBP	0.56	6.18	0.37	2.58e-9	Lung cancer in ever smokers;
KIRP	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-6.11	-0.36	3.95e-9	Breast cancer;
KIRP	cis	rs7712401	0.601	rs30047	chr5:122270524	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.52e-7	Mean platelet volume;
KIRP	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3741489	1.000	rs10781661	chr12:133431979	G/A	cg01499426	chr12:133417423	CHFR	0.73	5.67	0.34	4.03e-8	Cognitive function;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10866199	chr5:111506035	EPB41L4A	-0.44	-7.16	-0.42	9.32e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg19645103	chr12:69753606	YEATS4	-0.59	-4.96	-0.3	1.29e-6	Response to diuretic therapy;
KIRP	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.58	-6.63	-0.39	2.15e-10	Menarche (age at onset);
KIRP	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.56	-0.52	1.24e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg17031493	chr1:186343755	C1orf27;TPR;MIR548F1	0.34	6.05	0.36	5.43e-9	Suicide attempts in major depressive disorder;
KIRP	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.85	-0.35	1.57e-8	Electroencephalogram traits;
KIRP	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.08e-8	Retinal vascular caliber;
KIRP	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg15890332	chr12:107067104	RFX4	0.42	6.9	0.4	4.36e-11	Heart rate;
KIRP	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-10.09	-0.54	3.04e-20	Total body bone mineral density;
KIRP	cis	rs4783244	0.862	rs17175622	chr16:82654584	C/T	cg09415485	chr16:82663111	CDH13	-0.26	-5.05	-0.31	8.67e-7	Adiponectin levels;
KIRP	cis	rs10875746	0.625	rs2898065	chr12:48644619	C/A	cg20731937	chr12:48336164	NA	0.42	5.66	0.34	4.2e-8	Longevity (90 years and older);
KIRP	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.88e-7	Aortic root size;
KIRP	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg05991184	chr2:219186017	PNKD	0.36	5.09	0.31	7.11e-7	Colorectal cancer;
KIRP	cis	rs78487399	0.908	rs77613902	chr2:43843991	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.13	-0.31	5.87e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.45	-0.43	1.55e-12	Breast cancer;
KIRP	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg21858823	chr1:15850916	CASP9	0.54	5.81	0.35	1.92e-8	Systolic blood pressure;
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg01763666	chr17:80159506	CCDC57	0.36	4.98	0.3	1.21e-6	Life satisfaction;
KIRP	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.42	0.47	3.21e-15	Lung cancer;
KIRP	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg25486957	chr4:152246857	NA	-0.5	-5.62	-0.34	5.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs75064307	0.626	rs7632819	chr3:108071811	A/G	cg14703454	chr3:108065259	HHLA2	0.53	6.39	0.38	8.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg17644776	chr2:200775616	C2orf69	0.62	5.62	0.34	5.17e-8	Schizophrenia;
KIRP	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg18154014	chr19:37997991	ZNF793	0.63	5.59	0.34	6.05e-8	Coronary artery calcification;
KIRP	cis	rs1524927	1.000	rs1524927	chr7:96371732	C/T	cg00227355	chr7:96336147	SHFM1	0.33	5.08	0.31	7.46e-7	Total body bone mineral density;
KIRP	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg06197360	chr20:60970103	CABLES2	-0.49	-5.86	-0.35	1.47e-8	Colorectal cancer;
KIRP	cis	rs4363385	0.550	rs6661932	chr1:152896734	T/C	cg13444842	chr1:152974279	SPRR3	-0.38	-5.38	-0.32	1.72e-7	Inflammatory skin disease;
KIRP	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.49	0.48	2.03e-15	Motion sickness;
KIRP	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-1.07	-16.79	-0.73	1.12e-42	Personality dimensions;
KIRP	cis	rs9815354	0.767	rs73077390	chr3:41860255	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1134634	0.520	rs10008889	chr4:15624519	C/G	cg16509355	chr4:15471240	CC2D2A	-0.35	-5.82	-0.35	1.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12230513	0.732	rs4356858	chr12:55867290	A/T	cg19537932	chr12:55886519	OR6C68	-0.62	-7.46	-0.43	1.49e-12	Contrast sensitivity;
KIRP	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg11833968	chr6:79620685	NA	-0.45	-6.85	-0.4	5.92e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.54	-7.24	-0.42	5.7e-12	Blood metabolite levels;
KIRP	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	10.49	0.56	1.57e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg10932868	chr11:921992	NA	0.66	8.78	0.49	2.89e-16	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.52	-0.33	8.44e-8	Life satisfaction;
KIRP	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.54	-6.4	-0.38	7.64e-10	Obesity-related traits;
KIRP	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.47	6.46	0.38	5.66e-10	Red blood cell count;
KIRP	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.44	5.67	0.34	3.97e-8	Body mass index;
KIRP	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	1.0	17.17	0.74	5.83e-44	Menopause (age at onset);
KIRP	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg26084005	chr2:241760190	KIF1A	-0.51	-6.9	-0.4	4.41e-11	Urinary metabolites;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01813165	chr2:202646406	ALS2	0.55	7.24	0.42	5.68e-12	Smoking initiation;
KIRP	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.98	-0.41	2.8e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs986417	0.818	rs10873125	chr14:61035024	G/A	cg27398547	chr14:60952738	C14orf39	0.68	6.7	0.39	1.42e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs80282103	0.618	rs56004802	chr10:1159187	C/T	cg08668510	chr10:1095578	IDI1	0.93	6.16	0.37	2.96e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs1958560	0.932	rs61987992	chr14:66070731	C/T	cg03016385	chr14:66212404	NA	-0.55	-6.76	-0.4	9.94e-11	Menarche (age at onset);
KIRP	cis	rs1823913	0.637	rs897197	chr2:192146182	G/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.32	-0.37	1.22e-9	Obesity-related traits;
KIRP	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03352830	chr11:487213	PTDSS2	0.77	6.22	0.37	2.15e-9	Body mass index;
KIRP	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.83	-12.49	-0.62	4.87e-28	Neurofibrillary tangles;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg25856179	chr2:191878705	STAT1	0.53	6.24	0.37	1.91e-9	DNA methylation (variation);
KIRP	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17554472	chr22:41940697	POLR3H	-0.63	-6.72	-0.39	1.28e-10	Vitiligo;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.8	7.42	0.43	1.96e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.98	13.94	0.66	6.29e-33	Alcohol dependence;
KIRP	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg11569703	chr11:65557185	OVOL1	-0.48	-8.35	-0.47	4.88e-15	Acne (severe);
KIRP	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg07001201	chr5:642380	CEP72	0.66	5.82	0.35	1.86e-8	Obesity-related traits;
KIRP	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-7.29	-0.42	4.16e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.72	7.3	0.42	3.94e-12	Resting heart rate;
KIRP	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg17470723	chr8:74884337	TCEB1	-0.55	-7.09	-0.41	1.42e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.31	5.43	0.33	1.33e-7	Height;
KIRP	cis	rs7180079	0.620	rs4474637	chr15:65039719	C/T	cg15337035	chr15:64978493	NA	-0.49	-5.55	-0.33	7.2e-8	Monocyte count;
KIRP	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.91	-0.3	1.65e-6	Type 2 diabetes;
KIRP	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.06	-14.23	-0.67	6.25e-34	Body mass index;
KIRP	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg05914723	chr15:78953907	NA	0.6	5.49	0.33	1.01e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13011713	chr3:132176123	DNAJC13	0.43	6.24	0.37	1.91e-9	Interleukin-4 levels;
KIRP	cis	rs9361491	0.508	rs9352611	chr6:79396968	T/C	cg11833968	chr6:79620685	NA	-0.36	-4.93	-0.3	1.51e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs3935996	0.767	rs12058859	chr1:56302126	C/T	cg00020052	chr2:68546899	CNRIP1	0.41	6.2	0.37	2.34e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
KIRP	cis	rs953387	1.000	rs950176	chr2:136898078	A/G	cg05194412	chr2:137003533	NA	-0.41	-5.45	-0.33	1.25e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.98	-14.68	-0.68	1.8e-35	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.89	11.79	0.6	9.92e-26	Menopause (age at onset);
KIRP	trans	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs7712401	0.562	rs2407403	chr5:122174031	C/T	cg19412675	chr5:122181750	SNX24	0.43	4.96	0.3	1.31e-6	Mean platelet volume;
KIRP	cis	rs4302748	1.000	rs4302748	chr7:36191699	C/T	cg24442661	chr7:36192818	EEPD1	0.66	7.42	0.43	1.91e-12	Platelet count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08664652	chr17:28804287	GOSR1	0.54	6.41	0.38	7.57e-10	Smoking initiation;
KIRP	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.69	-0.53	5.12e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00933542	chr6:150070202	PCMT1	-0.28	-5.53	-0.33	8.32e-8	Lung cancer;
KIRP	trans	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs926938	0.583	rs12401670	chr1:115244337	C/T	cg12756093	chr1:115239321	AMPD1	-0.81	-11.8	-0.6	9.45e-26	Autism;
KIRP	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	7.79	0.44	1.85e-13	Systemic lupus erythematosus;
KIRP	cis	rs6466055	0.625	rs2074753	chr7:104786593	T/C	cg04380332	chr7:105027541	SRPK2	0.39	5.2	0.31	4.24e-7	Schizophrenia;
KIRP	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg23601095	chr6:26197514	HIST1H3D	1.1	8.19	0.46	1.46e-14	Gout;Renal underexcretion gout;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.88	8.37	0.47	4.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.04	0.41	1.94e-11	Height;
KIRP	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg06533319	chr4:3265114	C4orf44	0.55	7.03	0.41	1.99e-11	Parental longevity (mother's age at death);
KIRP	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.55	6.84	0.4	6.11e-11	Arsenic metabolism;
KIRP	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.46	-0.38	5.5e-10	Aortic root size;
KIRP	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg23301140	chr18:77439876	CTDP1	0.45	5.09	0.31	7.2e-7	Monocyte count;
KIRP	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg08603382	chr10:743973	NA	-0.68	-10.9	-0.57	7.79e-23	Psychosis in Alzheimer's disease;
KIRP	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg10556349	chr10:835070	NA	-0.42	-5.76	-0.34	2.56e-8	Survival in rectal cancer;
KIRP	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg05340658	chr4:99064831	C4orf37	0.66	8.01	0.45	4.63e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.55	-6.93	-0.4	3.59e-11	Glomerular filtration rate;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24149455	chr13:94214495	GPC6	-0.43	-6.7	-0.39	1.43e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.25	-0.32	3.36e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08704250	chr15:31115839	NA	-0.59	-8.39	-0.47	3.77e-15	Huntington's disease progression;
KIRP	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs4006360	0.522	rs72625953	chr17:39237157	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.91	-0.53	1.08e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-4.9	-0.3	1.78e-6	Fear of minor pain;
KIRP	cis	rs2494663	0.610	rs58300038	chr1:154070707	C/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.98	-0.3	1.21e-6	Mean platelet volume;
KIRP	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg07843065	chr1:150265600	MRPS21	0.4	5.46	0.33	1.14e-7	Migraine;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.24	-0.32	3.48e-7	Breast cancer;
KIRP	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.49	-5.49	-0.33	9.78e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	7.07e-13	Life satisfaction;
KIRP	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.14	0.36	3.33e-9	Putamen volume;
KIRP	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg20312557	chr2:97357134	FER1L5	-0.7	-4.91	-0.3	1.66e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.43	-0.38	6.74e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg20312557	chr2:97357134	FER1L5	-0.73	-5.34	-0.32	2.06e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg10381502	chr11:71823885	C11orf51	1.16	8.09	0.46	2.77e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg11271282	chr2:238384023	NA	-0.46	-5.11	-0.31	6.58e-7	Prostate cancer;
KIRP	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg13736514	chr6:26305472	NA	-0.44	-4.88	-0.3	1.95e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs4904167	0.841	rs1031787	chr14:84694489	C/G	cg06719973	chr7:207666	FAM20C	0.48	6.07	0.36	4.72e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.88	-13.96	-0.66	5.27e-33	Prostate cancer;
KIRP	cis	rs4664293	0.769	rs1365798	chr2:160652364	A/G	cg08347373	chr2:160653686	CD302	0.44	6.32	0.37	1.24e-9	Monocyte percentage of white cells;
KIRP	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg00086871	chr4:6988644	TBC1D14	1.01	6.69	0.39	1.53e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.08e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg27417294	chr10:81904244	PLAC9	-0.35	-4.93	-0.3	1.49e-6	Sarcoidosis;
KIRP	trans	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg06636001	chr8:8085503	FLJ10661	0.47	6.4	0.38	7.6e-10	Neuroticism;
KIRP	cis	rs10782582	1.000	rs5745499	chr1:76354711	T/C	cg10523679	chr1:76189770	ACADM	-0.38	-5.7	-0.34	3.46e-8	Daytime sleep phenotypes;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10146780	chr14:52897968	TXNDC16	0.5	6.07	0.36	4.75e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.09	0.46	2.69e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.5	-5.93	-0.35	1.05e-8	P wave terminal force;
KIRP	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg19338460	chr6:170058176	WDR27	-0.66	-7.7	-0.44	3.27e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg04132472	chr17:19861366	AKAP10	-0.4	-5.17	-0.31	4.81e-7	Schizophrenia;
KIRP	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	0.96	14.2	0.67	8.2e-34	Cognitive function;
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00802000	chr16:706648	WDR90	-0.4	-5.0	-0.3	1.07e-6	Height;
KIRP	cis	rs13720	0.778	rs163783	chr20:57567730	A/C	cg23907860	chr20:57583709	CTSZ	-0.5	-5.51	-0.33	9.26e-8	Platelet distribution width;
KIRP	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.66	7.89	0.45	1.02e-13	Corneal astigmatism;
KIRP	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.9	-13.35	-0.65	5.89e-31	Total body bone mineral density;
KIRP	cis	rs6545883	0.507	rs34668697	chr2:61568349	T/A	cg15711740	chr2:61764176	XPO1	0.45	5.4	0.33	1.54e-7	Tuberculosis;
KIRP	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg18882449	chr10:104885122	NT5C2	-0.41	-5.3	-0.32	2.54e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7084402	0.967	rs1658468	chr10:60292664	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.72	8.9	0.49	1.28e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.57	-5.99	-0.36	7.28e-9	Obesity-related traits;
KIRP	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg08126542	chr6:37504118	NA	-0.6	-6.91	-0.4	4.02e-11	Cognitive performance;
KIRP	cis	rs11169552	0.510	rs4768899	chr12:51000666	T/A	cg12884762	chr12:50931848	DIP2B	-0.42	-4.89	-0.3	1.81e-6	Colorectal cancer;
KIRP	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.64	9.43	0.52	3.29e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05776053	chr2:74358815	NA	0.67	6.45	0.38	5.84e-10	Gestational age at birth (maternal effect);
KIRP	cis	rs4356932	0.656	rs13111710	chr4:76859705	C/G	cg00809888	chr4:76862425	NAAA	-0.5	-7.09	-0.41	1.38e-11	Blood protein levels;
KIRP	cis	rs1318772	0.800	rs13160021	chr5:112935515	C/G	cg12552261	chr5:112820674	MCC	0.87	5.04	0.31	9.04e-7	F-cell distribution;
KIRP	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.74	-8.03	-0.46	3.96e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.73	-9.78	-0.53	2.66e-19	Huntington's disease progression;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13713771	chr3:116745574	NA	-0.44	-6.21	-0.37	2.3e-9	Myopia (pathological);
KIRP	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg16141378	chr3:129829833	LOC729375	0.59	7.4	0.43	2.11e-12	Triglycerides;
KIRP	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.93	10.0	0.54	5.44e-20	Alzheimer's disease;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg26911243	chr5:96401915	NA	-0.45	-6.22	-0.37	2.07e-9	Select biomarker traits;
KIRP	cis	rs8141529	0.529	rs5752790	chr22:29152965	G/A	cg02153584	chr22:29168773	CCDC117	0.56	5.1	0.31	6.94e-7	Lymphocyte counts;
KIRP	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.53	5.2	0.31	4.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9905704	0.549	rs302839	chr17:56673553	A/T	cg12560992	chr17:57184187	TRIM37	0.53	5.04	0.31	8.91e-7	Testicular germ cell tumor;
KIRP	cis	rs362296	0.624	rs362287	chr4:3257593	C/T	cg06533319	chr4:3265114	C4orf44	0.51	5.87	0.35	1.42e-8	Parental longevity (mother's age at death);
KIRP	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	8.51	0.48	1.71e-15	Educational attainment;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg26027482	chr12:1100598	ERC1	0.5	6.14	0.36	3.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs78049276	0.688	rs75697049	chr4:148375242	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.68	-7.06	-0.41	1.66e-11	Pulse pressure;
KIRP	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.59	-6.75	-0.4	1.07e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg06815112	chr8:27182871	PTK2B	0.53	6.7	0.39	1.38e-10	Neuroticism;
KIRP	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg12131826	chr15:77904385	NA	-0.42	-5.12	-0.31	6.18e-7	Type 2 diabetes;
KIRP	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg05991184	chr2:219186017	PNKD	-0.34	-4.95	-0.3	1.37e-6	Colorectal cancer;
KIRP	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg05868516	chr6:26286170	HIST1H4H	0.41	5.24	0.32	3.53e-7	Educational attainment;
KIRP	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg02336718	chr17:17403227	NA	0.34	5.15	0.31	5.32e-7	Total body bone mineral density;
KIRP	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg12046867	chr14:103022105	NA	-0.52	-6.32	-0.37	1.19e-9	Platelet count;
KIRP	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg18944383	chr4:111397179	ENPEP	-0.67	-11.23	-0.58	6.9e-24	Coronary artery disease;
KIRP	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-11.15	-0.58	1.19e-23	Alzheimer's disease;
KIRP	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.89	-0.49	1.37e-16	Retinal vascular caliber;
KIRP	cis	rs2820315	1.000	rs2250377	chr1:201860626	A/G	cg11586189	chr1:201857591	SHISA4	0.4	5.53	0.33	8.26e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.54	6.3	0.37	1.36e-9	Body mass index (adult);
KIRP	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg21782813	chr7:2030301	MAD1L1	0.48	6.13	0.36	3.52e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.83	-13.07	-0.64	5.46e-30	Asthma;
KIRP	cis	rs2073300	1.000	rs2207988	chr20:23446000	C/A	cg12062639	chr20:23401060	NAPB	0.8	6.97	0.41	2.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1983891	1.000	rs9381080	chr6:41527698	G/C	cg20194872	chr6:41519635	FOXP4	0.57	7.32	0.42	3.61e-12	Prostate cancer;
KIRP	trans	rs7999699	0.902	rs9316329	chr13:48296843	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs13006833	0.668	rs2582736	chr2:191144892	A/T	cg21644426	chr2:191273491	MFSD6	0.45	5.44	0.33	1.29e-7	Urinary metabolites;
KIRP	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg07741184	chr6:167504864	NA	-0.2	-4.98	-0.3	1.18e-6	Crohn's disease;
KIRP	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.87	-0.53	1.48e-19	Exhaled nitric oxide output;
KIRP	trans	rs7980799	1.000	rs7980799	chr12:33576990	A/C	cg26384229	chr12:38710491	ALG10B	-0.56	-6.93	-0.4	3.75e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-1.05	-20.55	-0.79	2.52e-55	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.45	0.43	1.57e-12	Mean corpuscular volume;
KIRP	cis	rs2235642	0.582	rs2235637	chr16:1567694	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.2	-4.92	-0.3	1.55e-6	Coronary artery disease;
KIRP	trans	rs1864585	0.520	rs73208773	chr8:10666791	T/A	cg26278703	chr11:58910052	FAM111A	0.64	6.25	0.37	1.8e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg27556566	chr18:29671984	RNF138	0.75	6.31	0.37	1.28e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.22	-0.42	6.6e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.44	-0.52	2.91e-18	Gut microbiome composition (summer);
KIRP	cis	rs6991838	0.584	rs1053087	chr8:66515865	A/G	cg13398993	chr8:66546079	ARMC1	-0.44	-5.08	-0.31	7.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.71	8.05	0.46	3.63e-14	Pursuit maintenance gain;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.45	-5.19	-0.31	4.3e-7	Lung cancer;
KIRP	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.87	-0.3	1.97e-6	Eosinophil percentage of white cells;
KIRP	cis	rs13272623	0.502	rs268599	chr8:71517401	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.51	-6.65	-0.39	1.87e-10	IgG glycosylation;
KIRP	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	9.35	0.51	5.74e-18	Response to bleomycin (chromatid breaks);
KIRP	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg23601095	chr6:26197514	HIST1H3D	0.92	7.54	0.43	9.21e-13	Gout;Renal underexcretion gout;
KIRP	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg16989719	chr2:238392110	NA	-0.6	-8.41	-0.47	3.46e-15	Prostate cancer;
KIRP	cis	rs2274273	0.967	rs2340931	chr14:55616937	T/G	cg04306507	chr14:55594613	LGALS3	0.51	7.84	0.45	1.36e-13	Protein biomarker;
KIRP	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg03289416	chr15:75166202	SCAMP2	-0.4	-5.58	-0.34	6.26e-8	Systemic lupus erythematosus;
KIRP	cis	rs9488822	0.614	rs195529	chr6:116251893	T/C	cg15226275	chr6:116381976	FRK	0.21	5.41	0.33	1.49e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg07426533	chr8:59803705	TOX	-0.39	-6.45	-0.38	5.95e-10	Pneumonia;
KIRP	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.02	18.11	0.76	3.69e-47	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg24315340	chr6:146058215	EPM2A	0.41	5.08	0.31	7.55e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073416	0.595	rs11158598	chr14:65923738	A/G	cg03016385	chr14:66212404	NA	-0.46	-6.01	-0.36	6.77e-9	N-glycan levels;
KIRP	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.13	0.69	5.33e-37	Platelet count;
KIRP	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.81	-0.4	7.33e-11	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg06740227	chr12:86229804	RASSF9	0.41	5.34	0.32	2.15e-7	Major depressive disorder;
KIRP	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg23281280	chr6:28129359	ZNF389	0.51	5.64	0.34	4.65e-8	Depression;
KIRP	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg16524733	chr11:117070046	TAGLN	-0.41	-5.41	-0.33	1.48e-7	Blood protein levels;
KIRP	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.41	5.38	0.32	1.73e-7	Hypertriglyceridemia;
KIRP	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg21926883	chr2:100939477	LONRF2	-0.57	-7.59	-0.44	6.75e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.47	0.43	1.4e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7870753	0.838	rs6477493	chr9:99253082	C/T	cg25260653	chr9:99212216	HABP4	0.56	5.84	0.35	1.61e-8	Height;
KIRP	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg05507819	chr15:63340323	TPM1	0.5	6.23	0.37	2e-9	Platelet count;
KIRP	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.75	6.46	0.38	5.61e-10	Body mass index;
KIRP	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.97	-0.3	1.27e-6	Metabolite levels;
KIRP	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg18944383	chr4:111397179	ENPEP	-0.43	-6.91	-0.4	4.03e-11	Coronary artery disease;
KIRP	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.81	8.73	0.49	3.85e-16	Prostate cancer;
KIRP	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.94	0.5	9.35e-17	Electroencephalogram traits;
KIRP	cis	rs981844	0.922	rs2118863	chr4:154657579	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.68	-8.3	-0.47	7.02e-15	Mean platelet volume;
KIRP	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg17425144	chr1:10567563	PEX14	0.39	6.78	0.4	8.81e-11	Prostate cancer;
KIRP	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg03060546	chr3:49711283	APEH	-0.72	-5.48	-0.33	1.04e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.75	-11.12	-0.58	1.53e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.42	5.9	0.35	1.21e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg10047753	chr17:41438598	NA	1.15	18.09	0.76	4.22e-47	Menopause (age at onset);
KIRP	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg18944383	chr4:111397179	ENPEP	-0.53	-9.11	-0.5	3.05e-17	Coronary artery disease;
KIRP	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	1.01	14.23	0.67	6.3e-34	Alcohol dependence;
KIRP	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.58	8.31	0.47	6.43e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7512898	0.583	rs6427852	chr1:200676208	A/T	cg07580975	chr1:200843333	NA	0.27	4.87	0.3	2.01e-6	Electrocardiographic conduction measures;
KIRP	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.49	6.51	0.38	4.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	cis	rs10214930	0.813	rs7786973	chr7:27582248	C/T	cg22168087	chr7:27702803	HIBADH	0.53	5.12	0.31	6.26e-7	Hypospadias;
KIRP	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg25039879	chr17:56429692	SUPT4H1	0.57	5.19	0.31	4.38e-7	Cognitive test performance;
KIRP	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.68	-0.39	1.56e-10	Lung cancer;
KIRP	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.75	11.08	0.58	2.14e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg00376283	chr12:123451042	ABCB9	-0.55	-5.94	-0.35	9.75e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.55	0.48	1.33e-15	Motion sickness;
KIRP	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.61	-0.44	5.88e-13	Mean platelet volume;
KIRP	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs11023787	1.000	rs10458876	chr11:15939080	A/G	cg19973338	chr17:76141249	C17orf99	-0.47	-6.27	-0.37	1.64e-9	Bone mineral density (wrist);
KIRP	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg12486944	chr17:80159399	CCDC57	-0.38	-5.17	-0.31	4.82e-7	Life satisfaction;
KIRP	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.53	7.97	0.45	5.89e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	1.96e-14	Testicular germ cell tumor;
KIRP	cis	rs7116495	0.881	rs1892921	chr11:71702138	G/A	cg18441811	chr11:71824068	C11orf51	-0.61	-4.9	-0.3	1.74e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	1.1	10.26	0.55	8.76e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg19767477	chr5:127420684	SLC12A2	0.37	5.42	0.33	1.45e-7	Ileal carcinoids;
KIRP	cis	rs548987	0.529	rs9467618	chr6:25824809	C/T	cg03264133	chr6:25882463	NA	-0.42	-5.0	-0.3	1.09e-6	Homocysteine levels;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg20119798	chr7:94954144	PON1	0.65	9.61	0.52	8.9e-19	Paraoxonase activity;
KIRP	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	9.04	0.5	4.79e-17	Lung cancer in ever smokers;
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg23985595	chr17:80112537	CCDC57	0.37	5.44	0.33	1.28e-7	Life satisfaction;
KIRP	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.68	0.66	4.8e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.45	6.01	0.36	6.8e-9	Red blood cell count;
KIRP	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg07395648	chr5:131743802	NA	-0.36	-4.97	-0.3	1.23e-6	Blood metabolite levels;
KIRP	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg17294928	chr15:75287854	SCAMP5	0.44	5.57	0.33	6.73e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4664293	0.867	rs16822556	chr2:160600903	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.8e-7	Major depressive disorder;
KIRP	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg01522456	chr1:115632236	TSPAN2	-0.37	-5.1	-0.31	6.81e-7	Autism;
KIRP	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg00031303	chr3:195681400	NA	0.67	7.61	0.44	5.77e-13	Pancreatic cancer;
KIRP	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.65	-6.87	-0.4	5.31e-11	Vitiligo;
KIRP	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg09491104	chr22:46646882	C22orf40	-0.61	-8.08	-0.46	2.84e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6969780	1.000	rs739734	chr7:27159405	C/T	cg26364809	chr7:27145159	NA	-0.57	-5.07	-0.31	7.77e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6142102	0.961	rs2284389	chr20:32656841	C/G	cg24642439	chr20:33292090	TP53INP2	0.57	6.89	0.4	4.76e-11	Skin pigmentation;
KIRP	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg21827317	chr3:136751795	NA	0.37	5.13	0.31	5.86e-7	Neuroticism;
KIRP	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	12.22	0.61	3.86e-27	Menopause (age at onset);
KIRP	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg12315302	chr6:26189340	HIST1H4D	0.7	5.01	0.3	1.03e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	0.83	12.04	0.61	1.45e-26	Lewy body disease;
KIRP	cis	rs1440410	0.763	rs9631769	chr4:144065741	G/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.98	15.56	0.7	1.86e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg24203234	chr3:128598194	ACAD9	0.44	5.02	0.3	1.01e-6	IgG glycosylation;
KIRP	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	-0.54	-6.47	-0.38	5.26e-10	Prudent dietary pattern;
KIRP	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg24130564	chr14:104152367	KLC1	-0.42	-5.55	-0.33	7.29e-8	Body mass index;
KIRP	cis	rs72634258	0.554	rs12745962	chr1:7919825	C/T	cg26816564	chr1:7831052	VAMP3	0.66	5.9	0.35	1.22e-8	Inflammatory bowel disease;
KIRP	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs6832769	0.961	rs11939815	chr4:56358283	T/G	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg11650704	chr1:154556575	ADAR	-0.38	-4.95	-0.3	1.36e-6	Blood protein levels;
KIRP	cis	rs6142102	0.812	rs6059558	chr20:32516830	G/C	cg08999081	chr20:33150536	PIGU	0.47	5.57	0.33	6.52e-8	Skin pigmentation;
KIRP	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.19	-0.37	2.45e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22129639	chr15:43785364	TP53BP1	0.5	7.24	0.42	5.67e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg04546413	chr19:29218101	NA	0.59	5.29	0.32	2.73e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.45	-0.52	2.87e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-6.38	-0.38	8.51e-10	Response to antipsychotic treatment;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg24972876	chr7:65420302	NA	0.4	5.57	0.33	6.52e-8	Aortic root size;
KIRP	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg20090143	chr19:45452003	APOC2	0.34	5.37	0.32	1.84e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.6	9.37	0.51	4.79e-18	C-reactive protein levels;
KIRP	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.8	-10.88	-0.57	9.33e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.73	7.58	0.44	7.07e-13	Uric acid levels;
KIRP	cis	rs4481887	0.741	rs11488135	chr1:248568961	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-5.66	-0.34	4.18e-8	Common traits (Other);
KIRP	cis	rs7224685	0.548	rs17710668	chr17:3880546	C/G	cg21734707	chr17:3908241	ZZEF1	0.56	5.66	0.34	4.2e-8	Type 2 diabetes;
KIRP	cis	rs4919044	0.641	rs11187231	chr10:94736462	T/A	cg05127821	chr10:94822908	CYP26C1	-1.03	-8.32	-0.47	6.01e-15	Coronary artery disease;
KIRP	cis	rs2151522	0.563	rs9372844	chr6:127128781	C/T	cg21431617	chr6:127135037	NA	0.34	6.14	0.36	3.37e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24631870	chr3:142297635	ATR	-0.52	-6.49	-0.38	4.64e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.54	0.38	3.58e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs745080	0.584	rs10132330	chr14:52969459	A/G	cg23333723	chr14:53022898	GPR137C	-0.41	-5.68	-0.34	3.79e-8	Orofacial clefts;
KIRP	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg05315796	chr3:52349193	DNAH1	0.43	6.48	0.38	5.01e-10	Bipolar disorder;
KIRP	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.77	10.69	0.56	3.79e-22	Longevity;
KIRP	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.42	5.39	0.32	1.68e-7	Aortic root size;
KIRP	cis	rs1978968	1.000	rs7285566	chr22:18445288	G/A	cg02610425	chr22:18483192	MICAL3	0.41	5.44	0.33	1.28e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6142102	0.961	rs2268088	chr20:32649064	G/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.78	0.4	8.7e-11	Skin pigmentation;
KIRP	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg06585982	chr3:143692056	C3orf58	0.6	7.64	0.44	4.84e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.9	16.36	0.72	3.37e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.74	11.04	0.58	2.75e-23	Oral cavity cancer;
KIRP	cis	rs2904967	0.759	rs625427	chr11:65003812	T/C	cg09225861	chr11:65069680	NA	-0.44	-5.35	-0.32	2.06e-7	Mean corpuscular volume;
KIRP	cis	rs2625529	0.761	rs972028	chr15:72173092	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-6.31	-0.37	1.28e-9	Red blood cell count;
KIRP	cis	rs11673344	0.642	rs73025481	chr19:37837339	G/A	cg14683738	chr19:37701593	ZNF585B	-0.43	-5.02	-0.3	9.98e-7	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs365132	0.934	rs149307	chr5:176471591	C/T	cg16309518	chr5:176445507	NA	-0.88	-13.48	-0.65	2.14e-31	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs59868192	0.925	rs7183879	chr15:42260456	A/G	cg20935245	chr15:42234343	EHD4	-0.53	-5.26	-0.32	3.11e-7	White blood cell count;
KIRP	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.76	-9.79	-0.53	2.53e-19	Aortic root size;
KIRP	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg20999797	chr1:1681921	NA	-0.38	-5.54	-0.33	7.63e-8	Body mass index;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg09579323	chr1:150459698	TARS2	-0.4	-5.05	-0.31	8.42e-7	Migraine;
KIRP	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	5.05	0.31	8.74e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.19	-0.77	8.39e-51	Schizophrenia;
KIRP	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.7	8.16	0.46	1.76e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7923609	0.756	rs7080386	chr10:65048306	C/A	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.1	-0.31	6.68e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.71	10.77	0.57	2.01e-22	Dupuytren's disease;
KIRP	cis	rs494562	1.000	rs494562	chr6:86117129	A/G	cg27039625	chr6:86159096	NT5E	0.43	5.81	0.35	1.89e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg09455208	chr3:40491958	NA	0.31	5.74	0.34	2.74e-8	Renal cell carcinoma;
KIRP	cis	rs6973256	0.897	rs7777805	chr7:133337074	T/C	cg10665199	chr7:133106180	EXOC4	-0.51	-6.37	-0.38	9.2e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06850241	chr22:41845214	NA	-0.46	-5.59	-0.34	5.96e-8	Vitiligo;
KIRP	cis	rs559555	0.512	rs655548	chr2:31836658	A/C	cg02381751	chr2:32503542	YIPF4	0.46	5.03	0.31	9.49e-7	Blood metabolite ratios;Blood metabolite levels;
KIRP	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg04132472	chr17:19861366	AKAP10	0.42	5.68	0.34	3.72e-8	Schizophrenia;
KIRP	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.87	-9.35	-0.51	5.53e-18	Type 2 diabetes;
KIRP	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg07701084	chr6:150067640	NUP43	0.57	7.23	0.42	6.13e-12	Testicular germ cell tumor;
KIRP	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg06521331	chr12:34319734	NA	-0.62	-7.46	-0.43	1.46e-12	Morning vs. evening chronotype;
KIRP	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg17788362	chr6:86352627	SYNCRIP	0.46	6.02	0.36	6.23e-9	Smooth-surface caries;
KIRP	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-5.44	-0.33	1.29e-7	Neuroticism;
KIRP	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg09184832	chr6:79620586	NA	-0.5	-7.06	-0.41	1.7e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs35740288	0.822	rs11629690	chr15:86287724	G/A	cg17133734	chr15:86042851	AKAP13	-0.49	-5.26	-0.32	3.09e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.1	0.31	6.71e-7	Self-reported allergy;
KIRP	cis	rs12210905	1.000	rs12213361	chr6:27138387	T/C	cg11502198	chr6:26597334	ABT1	-0.78	-5.1	-0.31	6.83e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.66	-7.84	-0.45	1.39e-13	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg12131826	chr15:77904385	NA	-0.46	-5.73	-0.34	2.97e-8	Type 2 diabetes;
KIRP	cis	rs2729354	0.768	rs2848640	chr11:57262680	A/G	cg24343310	chr11:57249947	NA	0.28	5.26	0.32	3.08e-7	Blood protein levels;
KIRP	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21747090	chr2:27597821	SNX17	-0.49	-6.84	-0.4	6.29e-11	Total body bone mineral density;
KIRP	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.61	-9.31	-0.51	7.56e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs17431357	0.737	rs11548264	chr12:120907332	C/T	cg25045489	chr12:120971538	RNF10	-0.65	-4.98	-0.3	1.2e-6	Insulin resistance/response;
KIRP	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.53	7.38	0.43	2.43e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.49	6.33	0.37	1.15e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-10.68	-0.56	3.93e-22	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.88	13.84	0.66	1.3e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.64	8.5	0.48	1.86e-15	Eosinophil percentage of white cells;
KIRP	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg19849509	chr2:175204996	NA	-0.53	-6.34	-0.37	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12354486	1	rs12354486	chr10:104124055	C/G	cg15320455	chr10:103880129	LDB1	0.58	5.28	0.32	2.77e-7	Educational attainment (college completion);
KIRP	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.83	-13.53	-0.65	1.48e-31	Height;
KIRP	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.7	8.59	0.48	1.01e-15	Aortic root size;
KIRP	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	7.42	0.43	1.92e-12	Height;
KIRP	cis	rs17641971	0.662	rs13268440	chr8:50000873	C/T	cg00325661	chr8:49890786	NA	0.44	5.69	0.34	3.54e-8	Blood metabolite levels;
KIRP	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.78	7.53	0.43	9.71e-13	Diisocyanate-induced asthma;
KIRP	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg04731861	chr2:219085781	ARPC2	-0.2	-5.09	-0.31	6.98e-7	Colorectal cancer;
KIRP	cis	rs2219968	0.701	rs1994035	chr8:79003651	C/T	cg00738934	chr8:78996279	NA	-0.45	-5.99	-0.36	7.56e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs112591243	0.685	rs115448966	chr21:47988420	G/A	cg26904215	chr21:47823096	PCNT	-0.74	-5.94	-0.35	9.67e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	trans	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6142102	0.812	rs4911375	chr20:32516022	C/A	cg24642439	chr20:33292090	TP53INP2	0.5	5.51	0.33	9.04e-8	Skin pigmentation;
KIRP	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-8.46	-0.47	2.41e-15	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.95e-15	Aortic root size;
KIRP	cis	rs2574975	0.679	rs2255387	chr10:52135672	G/A	cg10034176	chr10:52120283	SGMS1	-0.52	-6.95	-0.41	3.17e-11	Response to amphetamines;
KIRP	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg24375607	chr4:120327624	NA	0.58	6.68	0.39	1.57e-10	Corneal astigmatism;
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg08989290	chr16:615782	NHLRC4	0.42	6.11	0.36	3.88e-9	Height;
KIRP	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.31	0.32	2.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg23032965	chr3:12705835	RAF1	0.71	7.82	0.45	1.59e-13	Cholesterol, total;
KIRP	cis	rs7729447	0.776	rs58739438	chr5:32693994	G/C	cg16267343	chr5:32710456	NPR3	0.51	5.85	0.35	1.55e-8	Blood pressure;
KIRP	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.37	5.02	0.3	1e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.76	-12.48	-0.62	5.04e-28	Prostate cancer;
KIRP	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.45	6.38	0.38	8.58e-10	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17376030	chr22:41985996	PMM1	0.71	8.07	0.46	3.12e-14	Vitiligo;
KIRP	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg23748340	chr12:48592721	NA	-0.43	-4.89	-0.3	1.82e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg13798912	chr7:905769	UNC84A	0.78	7.31	0.42	3.65e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.62	-6.59	-0.39	2.6200000000000003e-10	DNA methylation (variation);
KIRP	cis	rs6442310	0.512	rs1175542	chr3:12466214	G/A	cg22839075	chr3:12045461	SYN2	-0.36	-5.17	-0.31	4.82e-7	Hematocrit;
KIRP	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg14993813	chr1:46806288	NSUN4	-0.47	-5.27	-0.32	3.04e-7	Menopause (age at onset);
KIRP	trans	rs78438709	1.000	rs74672221	chr10:124129667	G/A	cg08224212	chr11:34196093	ABTB2	-1.02	-6.59	-0.39	2.68e-10	Headache;
KIRP	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.43	6.33	0.37	1.15e-9	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg00666640	chr1:248458726	OR2T12	0.47	5.84	0.35	1.66e-8	Common traits (Other);
KIRP	cis	rs8018808	0.935	rs8018711	chr14:77921749	G/A	cg18872420	chr14:78023429	SPTLC2	0.35	5.16	0.31	4.99e-7	Myeloid white cell count;
KIRP	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg24579218	chr15:68104479	NA	-0.57	-9.33	-0.51	6.25e-18	Restless legs syndrome;
KIRP	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.39	-0.59	2.04e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg07936489	chr17:37558343	FBXL20	-0.56	-7.62	-0.44	5.55e-13	Asthma;
KIRP	cis	rs7520050	0.966	rs4660319	chr1:46341623	C/T	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27297192	chr10:134578999	INPP5A	0.57	6.93	0.4	3.66e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg23173402	chr1:227635558	NA	0.7	5.67	0.34	3.94e-8	Major depressive disorder;
KIRP	trans	rs8083850	0.666	rs4278818	chr18:50692978	C/T	cg06306636	chr18:12455633	SPIRE1	-0.46	-6.42	-0.38	6.89e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg18225595	chr11:63971243	STIP1	0.65	5.89	0.35	1.24e-8	Mean platelet volume;
KIRP	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	9.6	0.52	9.38e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05347473	chr6:146136440	FBXO30	0.6	8.51	0.48	1.77e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.33	5.23	0.32	3.58e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.33	0.32	2.25e-7	Menopause (age at onset);
KIRP	cis	rs12823128	0.967	rs2291262	chr12:26875235	A/G	cg14081884	chr12:26986758	ITPR2	0.4	5.01	0.3	1.06e-6	Birth weight;
KIRP	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.54	6.96	0.41	3.11e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07256732	chr16:621771	PIGQ	-0.46	-6.25	-0.37	1.84e-9	Height;
KIRP	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.29	0.58	4.2e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.96	-11.44	-0.59	1.39e-24	Alzheimer's disease;
KIRP	cis	rs72634258	0.554	rs12092614	chr1:7865710	C/T	cg26816564	chr1:7831052	VAMP3	0.8	8.14	0.46	2.01e-14	Inflammatory bowel disease;
KIRP	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.57	8.37	0.47	4.28e-15	Reticulocyte fraction of red cells;
KIRP	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg16141378	chr3:129829833	LOC729375	0.49	6.41	0.38	7.54e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12220238	0.841	rs7919010	chr10:76111137	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.61	0.39	2.34e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-10.65	-0.56	5.16e-22	Morning vs. evening chronotype;
KIRP	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.84	-0.35	1.66e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.27	17.42	0.74	8.12e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs6662572	0.737	rs56047133	chr1:46517228	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.65	0.34	4.36e-8	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03483641	chr2:152342216	NEB	-0.42	-6.45	-0.38	5.97e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2522056	0.935	rs757104	chr5:131795229	T/C	cg07395648	chr5:131743802	NA	0.58	6.81	0.4	7.29e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg07828340	chr4:882639	GAK	1.11	8.75	0.49	3.46e-16	Parkinson's disease;
KIRP	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg26751094	chr13:95954534	ABCC4	-0.7	-9.64	-0.52	7.17e-19	Blood metabolite levels;
KIRP	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.79	-11.54	-0.59	6.4e-25	Dental caries;
KIRP	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.67	8.81	0.49	2.29e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9652601	0.779	rs12708716	chr16:11179873	C/T	cg04616529	chr16:11181986	CLEC16A	-0.4	-5.3	-0.32	2.54e-7	Systemic lupus erythematosus;
KIRP	cis	rs35538253	0.522	rs12934297	chr16:72022821	A/G	cg09488090	chr16:72319766	NA	-0.44	-4.94	-0.3	1.45e-6	Post bronchodilator FEV1;
KIRP	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg16497661	chr14:103986332	CKB	0.52	7.19	0.42	7.9e-12	Body mass index;
KIRP	cis	rs1620921	0.967	rs1084656	chr6:161181292	A/C	cg01280913	chr6:161186852	NA	-0.45	-6.4	-0.38	7.99e-10	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg24585782	chr17:78113791	EIF4A3	0.51	6.1	0.36	4.06e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.45	-0.52	2.7e-18	Body mass index;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.58	0.34	6.29e-8	Lung cancer;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.59	-6.96	-0.41	3.07e-11	Menopause (age at onset);
KIRP	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg01304814	chr3:48885189	PRKAR2A	0.51	4.94	0.3	1.43e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.08	0.31	7.42e-7	Menopause (age at onset);
KIRP	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.72	-10.85	-0.57	1.18e-22	Hepatocellular carcinoma;
KIRP	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18252515	chr7:66147081	NA	-0.44	-5.12	-0.31	6.22e-7	Aortic root size;
KIRP	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg21858823	chr1:15850916	CASP9	0.51	5.47	0.33	1.09e-7	Systolic blood pressure;
KIRP	cis	rs9311676	0.632	rs56281646	chr3:58424917	G/A	cg06643156	chr3:58380774	PXK	0.35	4.89	0.3	1.8e-6	Systemic lupus erythematosus;
KIRP	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.98	12.97	0.64	1.13e-29	Multiple sclerosis;
KIRP	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.36	-0.32	1.96e-7	Metabolite levels;
KIRP	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg00409905	chr10:38381863	ZNF37A	0.51	5.63	0.34	4.97e-8	Obesity (extreme);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08007110	chr3:88198601	C3orf38	-0.51	-6.95	-0.41	3.26e-11	Interleukin-4 levels;
KIRP	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.87	-0.3	1.96e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.41	-6.64	-0.39	2.04e-10	Refractive error;
KIRP	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1823913	0.599	rs2124093	chr2:192153006	G/A	cg12404831	chr2:192114017	MYO1B	0.53	7.48	0.43	1.28e-12	Obesity-related traits;
KIRP	cis	rs9815354	1.000	rs1716688	chr3:41926546	G/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.25	-0.32	3.36e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg10664184	chr19:17420304	DDA1	0.79	9.05	0.5	4.46e-17	Systemic lupus erythematosus;
KIRP	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg17441377	chr17:3906640	NA	0.55	8.22	0.46	1.2e-14	Type 2 diabetes;
KIRP	cis	rs6977660	0.714	rs6977079	chr7:19818207	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.0	0.45	5.05e-14	Morning vs. evening chronotype;
KIRP	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.82	-0.35	1.85e-8	Bipolar disorder;
KIRP	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg07796016	chr1:152779584	LCE1C	0.48	6.0	0.36	6.91e-9	Psoriasis;
KIRP	cis	rs7523273	0.565	rs2761422	chr1:207893266	A/T	cg22525895	chr1:207977042	MIR29B2	0.47	5.72	0.34	3.02e-8	Schizophrenia;
KIRP	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg15556689	chr8:8085844	FLJ10661	0.64	8.07	0.46	3.17e-14	Retinal vascular caliber;
KIRP	cis	rs2997447	0.761	rs2783639	chr1:26429437	C/G	cg19633962	chr1:26362018	EXTL1	0.52	5.17	0.31	4.93e-7	QRS complex (12-leadsum);
KIRP	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg14675211	chr2:100938903	LONRF2	0.48	6.33	0.37	1.16e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.18	0.37	2.71e-9	Platelet count;
KIRP	cis	rs939574	0.790	rs2276635	chr2:220087441	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.82	5.56	0.33	7.14e-8	Platelet distribution width;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg22431228	chr1:16359049	CLCNKA	0.4	5.07	0.31	7.69e-7	Dilated cardiomyopathy;
KIRP	cis	rs2997447	0.748	rs2802346	chr1:26434354	G/A	cg19633962	chr1:26362018	EXTL1	-0.52	-4.88	-0.3	1.95e-6	QRS complex (12-leadsum);
KIRP	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg19875535	chr5:140030758	IK	-0.67	-9.32	-0.51	6.71e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7615316	1.000	rs2049326	chr3:142337672	C/T	cg20824294	chr3:142316082	PLS1	0.23	5.11	0.31	6.47e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.75	-8.36	-0.47	4.72e-15	Parkinson's disease;
KIRP	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.33	10.41	0.55	2.83e-21	Economic and political preferences (immigration/crime);
KIRP	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg27205649	chr11:78285834	NARS2	-0.67	-7.81	-0.45	1.7e-13	Alzheimer's disease (survival time);
KIRP	cis	rs151997	1.000	rs27249	chr5:50232678	A/G	cg06027927	chr5:50259733	NA	0.57	7.18	0.42	8.25e-12	Callous-unemotional behaviour;
KIRP	cis	rs9928842	0.722	rs1035540	chr16:75278795	A/G	cg09066997	chr16:75300724	BCAR1	0.62	5.32	0.32	2.32e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs11955398	0.585	rs9654363	chr5:60033232	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7897654	0.610	rs10883822	chr10:104796652	T/G	cg18882449	chr10:104885122	NT5C2	-0.46	-4.85	-0.3	2.23e-6	Schizophrenia;
KIRP	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.7	-0.34	3.45e-8	Aortic root size;
KIRP	cis	rs889398	0.771	rs3790080	chr16:69902139	A/G	cg09409435	chr16:70099608	PDXDC2	0.43	5.29	0.32	2.69e-7	Body mass index;
KIRP	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.26	-17.25	-0.74	2.96e-44	Breast cancer;
KIRP	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.28	0.51	9.09e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9914544	0.545	rs2386404	chr17:18769349	T/C	cg26378065	chr17:18585709	ZNF286B	0.38	4.93	0.3	1.49e-6	Educational attainment (years of education);
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	5.55	0.33	7.27e-8	Longevity;
KIRP	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg03959625	chr15:84868606	LOC388152	0.69	7.74	0.44	2.55e-13	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg14061069	chr19:46274453	DMPK	0.67	11.63	0.6	3.31e-25	Coronary artery disease;
KIRP	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	6.91	0.4	4.12e-11	Lung cancer;
KIRP	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4908768	0.911	rs12567592	chr1:8788907	C/T	cg25722041	chr1:8623473	RERE	0.53	7.06	0.41	1.74e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.79	-9.12	-0.5	2.75e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg15556689	chr8:8085844	FLJ10661	0.55	7.38	0.43	2.37e-12	Retinal vascular caliber;
KIRP	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00376283	chr12:123451042	ABCB9	0.6	6.73	0.39	1.16e-10	Allergy;
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.59	-0.39	2.7e-10	Renal cell carcinoma;
KIRP	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg05775895	chr3:12838266	CAND2	0.48	8.31	0.47	6.3e-15	QRS complex (12-leadsum);
KIRP	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.72	-0.49	4.28e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6968419	0.714	rs1048508	chr7:115892650	G/T	cg02561103	chr7:115862891	TES	0.39	5.52	0.33	8.53e-8	Intraocular pressure;
KIRP	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	1.19	8.99	0.5	6.84e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.5	-6.24	-0.37	1.94e-9	Post bronchodilator FEV1;
KIRP	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11669671	chr1:117679612	NA	0.43	6.03	0.36	5.89e-9	Interleukin-4 levels;
KIRP	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.5	7.24	0.42	5.79e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.73	-10.98	-0.57	4.37e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.03	-0.31	9.58e-7	Educational attainment (years of education);
KIRP	cis	rs4363385	0.510	rs11803710	chr1:153053096	C/G	cg13444842	chr1:152974279	SPRR3	-0.39	-5.41	-0.33	1.5e-7	Inflammatory skin disease;
KIRP	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-8.99	-0.5	6.98e-17	Neuroticism;
KIRP	trans	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17183009	chr3:120277827	NA	0.54	6.33	0.37	1.17e-9	Corneal astigmatism;
KIRP	cis	rs2273669	0.667	rs6651000	chr6:109281411	G/T	cg05315195	chr6:109294784	ARMC2	-0.61	-6.21	-0.37	2.27e-9	Prostate cancer;
KIRP	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.53	7.64	0.44	4.93e-13	Testicular germ cell tumor;
KIRP	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.6	-5.98	-0.36	7.67e-9	Body mass index;
KIRP	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.4	-0.51	4.07e-18	Personality dimensions;
KIRP	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.62	5.45	0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.67	-7.53	-0.43	9.86e-13	Gut microbiome composition (summer);
KIRP	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg25600027	chr14:23388339	RBM23	0.51	6.29	0.37	1.42e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.67	9.85	0.53	1.66e-19	Lymphocyte counts;
KIRP	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.94	13.94	0.66	5.95e-33	Longevity;Endometriosis;
KIRP	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg13010199	chr12:38710504	ALG10B	0.62	7.68	0.44	3.78e-13	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16048942	chr17:1953617	MIR132;MIR212	0.51	6.55	0.39	3.3e-10	Parkinson's disease;
KIRP	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.94	15.69	0.71	6.23e-39	Ulcerative colitis;
KIRP	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.94	-14.75	-0.69	1.07e-35	Sudden cardiac arrest;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04704963	chr11:33279091	HIPK3	-0.45	-6.19	-0.37	2.49e-9	Metabolic traits;
KIRP	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.31	13.46	0.65	2.48e-31	Diabetic retinopathy;
KIRP	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.9	-7.75	-0.44	2.44e-13	Smoking behavior;
KIRP	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg11833968	chr6:79620685	NA	-0.47	-6.94	-0.4	3.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg24803719	chr17:45855879	NA	0.38	5.52	0.33	8.6e-8	IgG glycosylation;
KIRP	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	1.09	20.64	0.8	1.32e-55	Monocyte count;
KIRP	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-7.53	-0.43	9.44e-13	Lung cancer;
KIRP	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg27129171	chr3:47204927	SETD2	-0.67	-9.07	-0.5	3.92e-17	Colorectal cancer;
KIRP	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg15839431	chr19:19639596	YJEFN3	-0.47	-5.14	-0.31	5.63e-7	Bipolar disorder;
KIRP	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.44	5.0	0.3	1.1e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg08508074	chr19:1848440	REXO1	0.48	6.02	0.36	6.25e-9	DNA methylation (variation);
KIRP	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.93	-0.3	1.51e-6	Resting heart rate;
KIRP	cis	rs4851250	0.565	rs60473748	chr2:100619785	T/C	cg17356467	chr2:100759845	AFF3	0.55	5.12	0.31	6.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg11859384	chr17:80120422	CCDC57	-0.4	-5.05	-0.31	8.42e-7	Life satisfaction;
KIRP	cis	rs7615316	1.000	rs9866958	chr3:142338441	T/C	cg20824294	chr3:142316082	PLS1	0.23	5.17	0.31	4.87e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.46	-5.89	-0.35	1.28e-8	Retinal vascular caliber;
KIRP	trans	rs7999699	0.967	rs4942693	chr13:48324330	T/C	cg23237801	chr1:16476620	EPHA2	0.53	6.53	0.38	3.72e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg26248373	chr2:1572462	NA	-0.67	-6.18	-0.37	2.6e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs62355272	1.000	rs62355272	chr5:35849941	C/A	cg13894535	chr5:35919491	CAPSL	-0.53	-5.89	-0.35	1.23e-8	Lymphocyte counts;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.49	6.68	0.39	1.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4690686	0.500	rs12501181	chr4:177264851	G/A	cg17059388	chr4:177262070	NA	0.87	12.66	0.63	1.25e-28	Essential tremor;
KIRP	cis	rs7766436	0.561	rs1342206	chr6:22593676	G/A	cg13666174	chr6:22585274	NA	-0.36	-4.96	-0.3	1.3e-6	Coronary artery disease;
KIRP	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.47	-6.96	-0.41	3.04e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7520050	0.966	rs12564541	chr1:46380237	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.32	-0.32	2.3e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7527798	0.592	rs12563520	chr1:207844062	C/T	cg09232269	chr1:207846808	CR1L	-0.35	-5.05	-0.31	8.43e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs9478638	0.592	rs162982	chr6:155634614	A/G	cg07943832	chr6:155568918	TIAM2	0.4	5.69	0.34	3.58e-8	Electroencephalogram traits;
KIRP	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg13147721	chr7:65941812	NA	-1.02	-7.1	-0.41	1.36e-11	Diabetic kidney disease;
KIRP	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11987759	chr7:65425863	GUSB	0.47	6.2	0.37	2.38e-9	Aortic root size;
KIRP	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.33	-0.32	2.18e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg04132472	chr17:19861366	AKAP10	-0.38	-4.9	-0.3	1.72e-6	Schizophrenia;
KIRP	cis	rs2281845	0.929	rs7549337	chr1:201097609	T/G	cg17810781	chr1:201082982	CACNA1S	0.37	5.68	0.34	3.77e-8	Permanent tooth development;
KIRP	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.66	7.84	0.45	1.39e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4345220	0.585	rs6848577	chr4:41642617	C/T	cg15232654	chr4:41643107	LIMCH1	0.45	5.73	0.34	2.9e-8	Migraine with aura;
KIRP	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg02725872	chr8:58115012	NA	-0.73	-7.83	-0.45	1.49e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4006360	0.601	rs7501863	chr17:39249898	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.66	-9.4	-0.51	3.85e-18	Bipolar disorder and schizophrenia;
KIRP	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg13615516	chr5:77269221	NA	0.51	7.87	0.45	1.12e-13	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg06636001	chr8:8085503	FLJ10661	0.56	6.95	0.41	3.24e-11	Retinal vascular caliber;
KIRP	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg02146966	chr17:18967117	NA	0.43	4.94	0.3	1.43e-6	Schizophrenia;
KIRP	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.27	-0.32	2.95e-7	Calcium levels;
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-5.92	-0.35	1.1e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg18308031	chr3:30391223	NA	0.39	6.1	0.36	4.09e-9	Warfarin maintenance dose;
KIRP	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.64	9.2	0.51	1.6e-17	Colorectal cancer;
KIRP	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.05e-17	Retinal vascular caliber;
KIRP	cis	rs4740619	0.619	rs1410455	chr9:16042277	A/G	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.74	9.96	0.54	7.57e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.55	6.58	0.39	2.87e-10	Axial length;
KIRP	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg05234568	chr11:5960015	NA	-0.64	-6.49	-0.38	4.66e-10	DNA methylation (variation);
KIRP	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.02	-0.41	2.19e-11	Obesity-related traits;
KIRP	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg19000871	chr14:103996768	TRMT61A	-0.45	-5.07	-0.31	7.81e-7	Reticulocyte count;
KIRP	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs113745635	1	rs113745635	chr12:95554771	C/T	cg07737802	chr12:95537812	FGD6	-0.82	-10.49	-0.56	1.61e-21	Lung function (FEV1/FVC);
KIRP	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07234876	chr8:600039	NA	0.75	5.94	0.35	9.86e-9	IgG glycosylation;
KIRP	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg16497661	chr14:103986332	CKB	-0.46	-6.04	-0.36	5.67e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.3	0.32	2.54e-7	Coronary artery disease;
KIRP	cis	rs11593576	0.550	rs1359513	chr10:80990736	A/T	cg18737081	chr10:80999807	ZMIZ1	-0.29	-4.96	-0.3	1.3e-6	Vitiligo;
KIRP	cis	rs3784262	0.669	rs10851632	chr15:58242475	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.03	-0.31	9.41e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.59	-0.48	9.8e-16	Total body bone mineral density;
KIRP	cis	rs58688157	0.960	rs112006329	chr11:617228	G/A	cg01616529	chr11:638424	DRD4	-0.37	-5.0	-0.3	1.08e-6	Systemic lupus erythematosus;
KIRP	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-6.33	-0.37	1.16e-9	Blood metabolite levels;
KIRP	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.74	0.34	2.73e-8	Menopause (age at onset);
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg17441377	chr17:3906640	NA	0.53	7.9	0.45	9.55e-14	Type 2 diabetes;
KIRP	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.79	-0.4	8.4e-11	Capecitabine sensitivity;
KIRP	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	12.13	0.61	7.65e-27	Blood protein levels;
KIRP	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.95	14.97	0.69	1.92e-36	Metabolite levels;
KIRP	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg19847130	chr8:10466454	RP1L1	-0.36	-5.11	-0.31	6.56e-7	Retinal vascular caliber;
KIRP	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-5.98	-0.36	7.97e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	1.04	14.81	0.69	6.59e-36	Alzheimer's disease;
KIRP	cis	rs6558530	0.653	rs6984632	chr8:1700434	G/A	cg08198773	chr8:1697536	NA	0.51	6.28	0.37	1.5e-9	Systolic blood pressure;
KIRP	cis	rs3857747	0.827	rs10263744	chr7:40436624	A/G	cg00420559	chr7:40367873	C7orf10	-0.57	-7.81	-0.45	1.62e-13	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs116161686	0.521	rs701941	chr1:210439529	G/A	cg09074223	chr1:210466472	NA	0.56	5.37	0.32	1.79e-7	Coronary artery disease;
KIRP	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.61	-6.9	-0.4	4.27e-11	Mean platelet volume;
KIRP	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg19554555	chr3:13937349	NA	-0.46	-6.2	-0.37	2.42e-9	Ovarian reserve;
KIRP	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.7	-0.6	2e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.62	0.52	8.32e-19	Pulse pressure;
KIRP	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.56	6.9	0.4	4.3e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	6.04	0.36	5.71e-9	Menarche (age at onset);
KIRP	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg09658497	chr7:2847517	GNA12	-0.36	-5.07	-0.31	7.88e-7	Height;
KIRP	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	1.02	12.67	0.63	1.18e-28	Post bronchodilator FEV1;
KIRP	cis	rs12476592	0.602	rs2421952	chr2:63749833	T/C	cg17519650	chr2:63277830	OTX1	-0.42	-4.88	-0.3	1.93e-6	Childhood ear infection;
KIRP	cis	rs7951870	0.504	rs3740973	chr11:46422237	G/A	cg16389345	chr11:46697382	NA	-0.49	-6.56	-0.39	3.14e-10	Schizophrenia;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg01391022	chr12:122360665	WDR66	-0.39	-5.59	-0.34	6.16e-8	Mean corpuscular volume;
KIRP	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20295186	chr1:70225930	LRRC7	-0.4	-6.09	-0.36	4.27e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.96e-7	Body mass index;
KIRP	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-5.27	-0.32	3.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg02487422	chr3:49467188	NICN1	0.4	5.58	0.34	6.4e-8	Parkinson's disease;
KIRP	cis	rs8014252	0.803	rs59233924	chr14:71050660	A/G	cg19730268	chr14:71022823	NA	-0.59	-5.6	-0.34	5.83e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs35740288	0.770	rs12907126	chr15:86171357	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-5.17	-0.31	4.78e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17641971	0.645	rs4873099	chr8:50025683	G/T	cg00325661	chr8:49890786	NA	0.43	5.54	0.33	7.9e-8	Blood metabolite levels;
KIRP	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg12311346	chr5:56204834	C5orf35	-0.37	-5.04	-0.31	9.1e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.58	6.48	0.38	4.85e-10	Monocyte percentage of white cells;
KIRP	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg03351412	chr1:154909251	PMVK	0.61	7.4	0.43	2.15e-12	Prostate cancer;
KIRP	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23097564	chr2:122494214	MKI67IP	0.54	6.68	0.39	1.59e-10	Parkinson's disease;
KIRP	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.46	-5.97	-0.36	8.33e-9	Renal cell carcinoma;
KIRP	cis	rs17121403	0.661	rs12132802	chr1:100565459	C/T	cg24955406	chr1:100503596	HIAT1	0.7	5.27	0.32	2.96e-7	Pulmonary function decline;
KIRP	cis	rs8113308	0.810	rs7255377	chr19:52451338	T/C	cg24732339	chr19:52471368	ZNF350	-0.45	-5.02	-0.3	9.83e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg22437258	chr11:111473054	SIK2	-0.49	-5.91	-0.35	1.11e-8	Primary sclerosing cholangitis;
KIRP	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.74	11.29	0.58	4.44e-24	Hepatocellular carcinoma;
KIRP	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.45	-0.38	5.87e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg23791538	chr6:167370224	RNASET2	-0.44	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.42	4.89e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.69	-9.11	-0.5	3.05e-17	Glomerular filtration rate;
KIRP	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-14.31	-0.67	3.25e-34	Electrocardiographic conduction measures;
KIRP	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg09462578	chr12:12878428	APOLD1	-0.69	-7.22	-0.42	6.43e-12	Systemic lupus erythematosus;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg04025307	chr7:1156635	C7orf50	0.55	5.44	0.33	1.29e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	cis	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg14019050	chr9:107690770	ABCA1	0.3	5.85	0.35	1.52e-8	Intraocular pressure;
KIRP	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-0.87	-10.07	-0.54	3.43e-20	Vitiligo;
KIRP	cis	rs13401104	0.796	rs11887905	chr2:237114756	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs2147904	0.867	rs1408947	chr1:42364198	C/T	cg16685388	chr1:42384056	HIVEP3	0.28	4.87	0.3	1.97e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.87	0.81	1.26e-59	Prudent dietary pattern;
KIRP	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.65	9.05	0.5	4.34e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.83	11.83	0.6	7.12e-26	Blood metabolite ratios;
KIRP	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs1050846	0.603	rs1050847	chr16:87443734	A/G	cg00512563	chr16:87398040	FBXO31	0.32	4.87	0.3	2.01e-6	Neuroticism;
KIRP	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.37	6.45	0.38	5.87e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4523957	0.620	rs8064309	chr17:2059961	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg11995313	chr8:8860691	ERI1	0.4	5.52	0.33	8.5e-8	Joint mobility (Beighton score);
KIRP	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.28	-0.47	7.73e-15	Mean corpuscular volume;
KIRP	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.62	8.92	0.49	1.09e-16	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg19468946	chr17:37922297	IKZF3	-0.41	-5.59	-0.34	6.09e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs2692947	0.740	rs59076415	chr2:96393944	A/G	cg23100626	chr2:96804247	ASTL	0.42	5.24	0.32	3.39e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg14982987	chr14:102302025	PPP2R5C	-0.39	-6.02	-0.36	6.37e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9928842	0.823	rs4888365	chr16:75282247	A/G	cg09066997	chr16:75300724	BCAR1	0.63	5.33	0.32	2.22e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.4	-5.95	-0.35	9.15e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-0.88	-9.98	-0.54	6.71e-20	Vitiligo;
KIRP	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18252515	chr7:66147081	NA	0.47	5.57	0.33	6.7e-8	Aortic root size;
KIRP	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.47	6.95	0.41	3.28e-11	Psoriasis;
KIRP	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.4	-6.36	-0.38	9.85e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6594713	0.531	rs13362189	chr5:112940706	A/G	cg12552261	chr5:112820674	MCC	0.54	5.19	0.31	4.48e-7	Brain cytoarchitecture;
KIRP	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27297192	chr10:134578999	INPP5A	0.62	7.65	0.44	4.66e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.29	-0.32	2.67e-7	Breast cancer;
KIRP	cis	rs17428704	0.522	rs16903497	chr5:14418419	C/T	cg26595256	chr5:14380529	TRIO	-0.68	-5.14	-0.31	5.66e-7	Electroencephalogram traits;
KIRP	cis	rs7828089	1.000	rs7823832	chr8:22264426	A/G	cg13512537	chr8:22265999	SLC39A14	-0.45	-6.09	-0.36	4.34e-9	Verbal declarative memory;
KIRP	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg01304814	chr3:48885189	PRKAR2A	0.56	4.93	0.3	1.53e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.63	7.61	0.44	6.02e-13	Post bronchodilator FEV1;
KIRP	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg02527881	chr3:46936655	PTH1R	-0.59	-9.24	-0.51	1.16e-17	Birth weight;
KIRP	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4132509	1.000	rs1458024	chr1:243937445	G/C	cg25706552	chr1:244017396	NA	0.56	7.5	0.43	1.16e-12	RR interval (heart rate);
KIRP	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg00999904	chr2:3704751	ALLC	0.45	5.23	0.32	3.57e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg27129171	chr3:47204927	SETD2	0.77	11.49	0.59	9.24e-25	Colorectal cancer;
KIRP	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg08975724	chr8:8085496	FLJ10661	0.81	10.87	0.57	9.61e-23	Neuroticism;
KIRP	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.74	9.25	0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg15181151	chr6:150070149	PCMT1	0.31	5.29	0.32	2.66e-7	Lung cancer;
KIRP	cis	rs4938330	0.552	rs3882895	chr11:117090545	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg05315796	chr3:52349193	DNAH1	0.4	5.26	0.32	3.17e-7	Schizophrenia;
KIRP	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg00982548	chr2:198649783	BOLL	-0.5	-4.94	-0.3	1.42e-6	Ulcerative colitis;
KIRP	cis	rs55692468	0.848	rs3811574	chr2:153346845	G/T	cg04681845	chr2:153283485	FMNL2	-0.41	-5.39	-0.33	1.65e-7	Intraocular pressure;
KIRP	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.7	-6.88	-0.4	4.8e-11	Vitiligo;
KIRP	cis	rs721917	0.531	rs2758551	chr10:81691940	A/G	cg17004975	chr10:81743287	NA	0.4	5.12	0.31	6.04e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.82	9.56	0.52	1.24e-18	Gestational age at birth (maternal effect);
KIRP	cis	rs10189230	0.935	rs3770146	chr2:222344196	G/A	cg14652038	chr2:222343519	EPHA4	0.49	7.06	0.41	1.71e-11	Urate levels in lean individuals;
KIRP	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg20140201	chr2:241835670	C2orf54	-0.35	-5.26	-0.32	3.17e-7	Urinary metabolites;
KIRP	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.5	-7.82	-0.45	1.5700000000000001e-13	IgG glycosylation;
KIRP	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.29	0.37	1.45e-9	Breast cancer;
KIRP	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.66	8.82	0.49	2.15e-16	Multiple sclerosis;
KIRP	cis	rs7084402	0.967	rs1658490	chr10:60281616	G/A	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.84e-24	Refractive error;
KIRP	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.94	0.57	6.02e-23	Personality dimensions;
KIRP	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg20090143	chr19:45452003	APOC2	0.33	5.24	0.32	3.4e-7	Blood protein levels;
KIRP	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg01294253	chr9:136912663	BRD3	0.43	5.64	0.34	4.62e-8	Platelet distribution width;
KIRP	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg19025524	chr12:109796872	NA	-0.58	-8.16	-0.46	1.69e-14	Neuroticism;
KIRP	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg20243544	chr17:37824526	PNMT	0.37	4.93	0.3	1.49e-6	Self-reported allergy;
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.72	-10.75	-0.57	2.31e-22	Monocyte percentage of white cells;
KIRP	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg22960616	chr11:71188716	NADSYN1	0.37	5.04	0.31	9.09e-7	Vitamin D levels;
KIRP	cis	rs6956675	0.793	rs6946559	chr7:62660568	A/T	cg08930214	chr7:62859557	LOC100287834	0.46	5.43	0.33	1.36e-7	Obesity-related traits;
KIRP	cis	rs9653442	0.564	rs4850924	chr2:100782273	A/G	cg17356467	chr2:100759845	AFF3	0.38	5.35	0.32	2.01e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06647332	chr5:131281008	NA	-0.44	-4.9	-0.3	1.74e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.32	0.62	1.76e-27	Platelet count;
KIRP	cis	rs2361718	0.501	rs12944619	chr17:78144109	T/C	cg09238746	chr17:78121135	EIF4A3	-0.73	-8.77	-0.49	3.01e-16	Yeast infection;
KIRP	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg24747557	chr10:131355152	MGMT	-0.46	-6.38	-0.38	8.77e-10	Response to temozolomide;
KIRP	cis	rs11945232	0.624	rs10035024	chr4:88367469	C/T	cg23841344	chr4:88312519	HSD17B11	-0.59	-6.49	-0.38	4.83e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7537052	0.669	rs2296263	chr1:36641729	C/T	cg24686825	chr1:36642396	MAP7D1	-0.72	-9.59	-0.52	1.06e-18	Schizophrenia;
KIRP	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.89	10.22	0.55	1.18e-20	Corneal astigmatism;
KIRP	cis	rs12143943	0.966	rs3795567	chr1:204585738	A/G	cg20240347	chr1:204465584	NA	-0.37	-6.66	-0.39	1.76e-10	Cognitive performance;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg13319975	chr6:146136371	FBXO30	-0.38	-5.14	-0.31	5.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.45	-0.33	1.23e-7	Neuroticism;
KIRP	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg08392591	chr16:89556376	ANKRD11	0.44	5.7	0.34	3.35e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs7577696	0.626	rs212754	chr2:32421628	A/G	cg02381751	chr2:32503542	YIPF4	0.55	5.58	0.34	6.19e-8	Inflammatory biomarkers;
KIRP	cis	rs7715811	1.000	rs6554814	chr5:13774231	T/A	cg07548982	chr5:13769939	DNAH5	-0.54	-6.63	-0.39	2.05e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs9436747	0.626	rs7516763	chr1:65972550	C/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.54	-5.56	-0.33	6.96e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg02012338	chr4:187126139	CYP4V2	-0.91	-7.94	-0.45	7.41e-14	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	trans	rs7980799	0.935	rs12301124	chr12:33543024	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-6.68	-0.39	1.62e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04961270	chr6:101308372	ASCC3	0.38	6.04	0.36	5.68e-9	C-reactive protein;
KIRP	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.39	-5.46	-0.33	1.14e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1200921	0.642	rs1200825	chr10:37564664	C/T	cg00409905	chr10:38381863	ZNF37A	0.39	5.01	0.3	1.05e-6	Breast cancer;
KIRP	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.68e-11	Hemoglobin concentration;
KIRP	cis	rs4363506	1.000	rs10765112	chr10:129273059	G/A	cg07804728	chr10:129284050	NA	0.41	5.76	0.34	2.51e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg02985724	chr1:159915429	IGSF9	-0.56	-6.64	-0.39	2e-10	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2219968	1.000	rs1481511	chr8:78955014	A/G	cg00738934	chr8:78996279	NA	0.41	5.12	0.31	6.21e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35934224	0.891	rs12158214	chr22:19871691	C/T	cg11182965	chr22:19864308	TXNRD2	-0.39	-5.7	-0.34	3.33e-8	Glaucoma (primary open-angle);
KIRP	cis	rs8067545	0.574	rs62067483	chr17:19948394	C/T	cg13482628	chr17:19912719	NA	0.46	5.15	0.31	5.23e-7	Schizophrenia;
KIRP	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.36e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9783347	0.961	rs2061163	chr11:18322924	A/C	cg15585147	chr11:18324498	HPS5	0.47	6.38	0.38	8.55e-10	Pancreatic cancer;
KIRP	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.57	-7.88	-0.45	1.05e-13	Motion sickness;
KIRP	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg06223162	chr1:101003688	GPR88	0.42	8.15	0.46	1.87e-14	Monocyte count;
KIRP	cis	rs2413583	0.818	rs9611131	chr22:39662480	T/C	cg24399712	chr22:39784796	NA	0.58	4.92	0.3	1.58e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg17724175	chr1:150552817	MCL1	0.34	5.93	0.35	1.03e-8	Tonsillectomy;
KIRP	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.7	-9.21	-0.51	1.52e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg16586182	chr3:47516702	SCAP	-0.75	-10.62	-0.56	6.44e-22	Colorectal cancer;
KIRP	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.79	10.91	0.57	7.56e-23	Aortic root size;
KIRP	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg16083429	chr3:49237500	CCDC36	-0.39	-5.13	-0.31	5.75e-7	Menarche (age at onset);
KIRP	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg02903104	chr8:1507517	DLGAP2	0.35	5.2	0.31	4.28e-7	Lung cancer;
KIRP	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg10950524	chr7:2139216	MAD1L1	0.3	5.02	0.3	1.01e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.64	-9.57	-0.52	1.2e-18	Total body bone mineral density;
KIRP	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg23594656	chr7:65796392	TPST1	-0.36	-5.32	-0.32	2.39e-7	Aortic root size;
KIRP	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg23216685	chr1:86174607	ZNHIT6	-0.51	-5.85	-0.35	1.53e-8	Urate levels in overweight individuals;
KIRP	cis	rs35995292	0.534	rs13228087	chr7:38909204	A/C	cg19327137	chr7:38886074	VPS41	0.8	13.07	0.64	5.29e-30	Subjective well-being (multi-trait analysis);
KIRP	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg23102388	chr7:1867652	MAD1L1	-0.49	-6.5	-0.38	4.54e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2625529	0.668	rs12914070	chr15:72334279	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs2278796	0.608	rs6700188	chr1:204969066	A/G	cg17449235	chr1:204966235	NFASC	0.58	7.94	0.45	7.18e-14	Mean platelet volume;
KIRP	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.47	-5.58	-0.34	6.37e-8	Body mass index;
KIRP	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.04	0.31	8.97e-7	Lymphocyte counts;
KIRP	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg22563815	chr15:78856949	CHRNA5	0.4	5.79	0.35	2.1e-8	Sudden cardiac arrest;
KIRP	cis	rs4950322	0.542	rs56080828	chr1:146655026	G/A	cg22381352	chr1:146742008	CHD1L	-0.42	-5.04	-0.31	9.21e-7	Protein quantitative trait loci;
KIRP	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.59	-0.39	2.65e-10	Neuroticism;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03943839	chr16:18995532	TMC7	-0.42	-6.08	-0.36	4.68e-9	Metabolic traits;
KIRP	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg17243659	chr21:48055224	PRMT2	1.06	6.26	0.37	1.66e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg11833968	chr6:79620685	NA	-0.45	-6.9	-0.4	4.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs737693	0.831	rs72981684	chr11:102724211	C/T	cg19620758	chr11:102826565	MMP13	0.71	5.65	0.34	4.42e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.2	-0.31	4.17e-7	Cervical cancer;
KIRP	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.61	6.95	0.4	3.31e-11	Schizophrenia;
KIRP	cis	rs757647	0.503	rs4835672	chr5:137568867	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.43	0.33	1.35e-7	Menarche (age at onset);
KIRP	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs2862064	1.000	rs2862064	chr5:156445827	C/G	cg12943317	chr5:156479607	HAVCR1	-0.74	-6.94	-0.4	3.37e-11	Platelet count;
KIRP	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	1.13	8.3	0.47	6.99e-15	Skin colour saturation;
KIRP	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-1.03	-12.44	-0.62	6.78e-28	Exhaled nitric oxide output;
KIRP	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.65	-9.88	-0.53	1.32e-19	Total body bone mineral density;
KIRP	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.85	-10.73	-0.56	2.86e-22	Coronary artery disease;
KIRP	cis	rs2635047	0.542	rs2684853	chr18:44793532	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.47	0.38	5.28e-10	Educational attainment;
KIRP	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07570687	chr10:102243282	WNT8B	0.54	7.11	0.41	1.25e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg20295408	chr7:1910781	MAD1L1	0.49	5.35	0.32	2.01e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7656342	0.653	rs35629527	chr4:9864232	C/T	cg11266682	chr4:10021025	SLC2A9	0.33	5.2	0.31	4.21e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.47	0.48	2.31e-15	Alzheimer's disease;
KIRP	cis	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.4	-0.33	1.61e-7	HDL cholesterol;
KIRP	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.14	0.41	1.07e-11	Prudent dietary pattern;
KIRP	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.6	6.57	0.39	3e-10	Schizophrenia;
KIRP	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.23	-0.32	3.65e-7	Metabolite levels;
KIRP	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	7.25	0.42	5.44e-12	Bone mineral density;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg13198984	chr17:80129470	CCDC57	0.56	8.57	0.48	1.15e-15	Life satisfaction;
KIRP	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg15934090	chr1:100435551	SLC35A3	0.5	6.27	0.37	1.58e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.44	5.18	0.31	4.57e-7	Aortic root size;
KIRP	cis	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs67311347	0.503	rs11719968	chr3:40241600	G/T	cg09455208	chr3:40491958	NA	0.35	6.2	0.37	2.39e-9	Renal cell carcinoma;
KIRP	trans	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg25214090	chr10:38739885	LOC399744	0.53	6.46	0.38	5.68e-10	Educational attainment;
KIRP	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.88	-15.01	-0.69	1.38e-36	Breast cancer;
KIRP	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.4e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3818717	0.541	rs55767800	chr17:17674967	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.43	-5.22	-0.32	3.83e-7	Lymphocyte counts;
KIRP	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg16926213	chr1:1841314	NA	0.32	5.37	0.32	1.86e-7	Body mass index;
KIRP	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-6.63	-0.39	2.1e-10	Aortic root size;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18363568	chr6:20402099	E2F3	-0.54	-6.08	-0.36	4.52e-9	Interleukin-4 levels;
KIRP	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.43	-5.98	-0.36	8.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg16989719	chr2:238392110	NA	-0.55	-7.4	-0.43	2.12e-12	Prostate cancer;
KIRP	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	cg04338863	chr8:33670619	NA	0.43	5.42	0.33	1.45e-7	Body mass index;
KIRP	trans	rs909341	0.868	rs6089961	chr20:62349491	G/A	cg01311341	chr22:25575246	KIAA1671	-0.63	-7.67	-0.44	3.95e-13	Atopic dermatitis;
KIRP	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.59	-7.22	-0.42	6.64e-12	Aortic root size;
KIRP	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.73e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg10756647	chr7:56101905	PSPH	1.12	9.01	0.5	5.91e-17	Diabetic kidney disease;
KIRP	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg12861170	chr19:19639553	YJEFN3	-0.47	-5.31	-0.32	2.43e-7	Bipolar disorder;
KIRP	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-8.69	-0.48	5.12e-16	Lung cancer;
KIRP	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.48	5.79	0.35	2.11e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg02551604	chr5:131831745	NA	-0.48	-5.8	-0.35	2.03e-8	Asthma (sex interaction);
KIRP	cis	rs687432	0.679	rs1031234	chr11:57882446	C/G	cg19752551	chr11:57585705	CTNND1	-0.36	-4.87	-0.3	1.97e-6	Parkinson's disease;
KIRP	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-5.41	-0.33	1.5e-7	Testicular germ cell tumor;
KIRP	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.05	0.46	3.51e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.15	0.36	3.18e-9	Colorectal cancer;
KIRP	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.89	11.0	0.57	3.81e-23	Monocyte percentage of white cells;
KIRP	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg02725872	chr8:58115012	NA	-0.55	-6.04	-0.36	5.65e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1003719	0.667	rs2298683	chr21:38445069	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	10.69	0.56	3.77e-22	Eye color traits;
KIRP	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.83	10.57	0.56	8.73e-22	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg05347473	chr6:146136440	FBXO30	0.59	8.29	0.47	7.2e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28489187	0.706	rs2300634	chr1:85791257	T/C	cg16011679	chr1:85725395	C1orf52	0.54	6.55	0.39	3.39e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11276456	chr10:74856846	P4HA1	0.51	6.44	0.38	6.18e-10	Parkinson's disease;
KIRP	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.45	-6.88	-0.4	4.93e-11	Coronary artery disease;
KIRP	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.51	-5.37	-0.32	1.84e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg27462398	chr1:86174642	ZNHIT6	-0.58	-8.52	-0.48	1.65e-15	Urate levels in overweight individuals;
KIRP	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.37	4.87	0.3	1.96e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.75	-0.4	1.07e-10	Aortic root size;
KIRP	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg05347473	chr6:146136440	FBXO30	0.46	6.72	0.39	1.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12210905	0.688	rs12374649	chr6:27343726	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.48	-0.38	5.1e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg14829155	chr15:31115871	NA	-0.73	-9.17	-0.5	1.98e-17	Huntington's disease progression;
KIRP	cis	rs963731	0.579	rs2168042	chr2:39273536	C/T	cg04010122	chr2:39346883	SOS1	-0.84	-5.96	-0.36	8.81e-9	Corticobasal degeneration;
KIRP	cis	rs2033908	0.620	rs1992334	chr11:12851645	C/T	cg25843174	chr11:12811716	TEAD1	-0.29	-5.39	-0.33	1.65e-7	Sitting height ratio;
KIRP	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg10253484	chr15:75165896	SCAMP2	-0.6	-6.83	-0.4	6.43e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-7.73	-0.44	2.76e-13	Bladder cancer;
KIRP	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg15488143	chr7:128924101	AHCYL2	0.43	4.92	0.3	1.61e-6	White matter hyperintensity burden;
KIRP	cis	rs4936894	0.500	rs7112726	chr11:124168688	A/G	cg27160556	chr11:124181099	OR8D1	-0.46	-6.51	-0.38	4.26e-10	Aging (time to death);
KIRP	cis	rs4783244	0.794	rs62040561	chr16:82646226	C/G	cg09415485	chr16:82663111	CDH13	-0.27	-4.91	-0.3	1.63e-6	Adiponectin levels;
KIRP	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.32	0.32	2.34e-7	Ovarian reserve;
KIRP	cis	rs7941030	0.812	rs7932357	chr11:122533079	T/C	cg20555462	chr11:122535518	UBASH3B	-0.43	-5.31	-0.32	2.46e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs472402	0.623	rs8192135	chr5:6636757	T/A	cg08700190	chr5:6636046	SRD5A1	-0.48	-6.08	-0.36	4.56e-9	Response to amphetamines;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.78	6.84	0.4	6.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg14952266	chr13:112191215	NA	0.46	6.77	0.4	9.5e-11	Hepatitis;
KIRP	cis	rs2811403	0.546	rs11713004	chr3:128174742	G/A	cg13327513	chr3:128181808	DNAJB8	0.36	4.85	0.3	2.23e-6	Basophil percentage of white cells;
KIRP	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.59	-7.22	-0.42	6.59e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.83	11.91	0.6	4.02e-26	Blood metabolite ratios;
KIRP	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg08761264	chr16:28874980	SH2B1	-0.49	-5.5	-0.33	9.4e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg21573476	chr21:45109991	RRP1B	-0.48	-6.0	-0.36	7e-9	Mean corpuscular hemoglobin;
KIRP	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-1.02	-17.35	-0.74	1.44e-44	Height;
KIRP	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.67	-9.29	-0.51	8.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg04691961	chr3:161091175	C3orf57	-0.59	-8.9	-0.49	1.22e-16	Morning vs. evening chronotype;
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg24488311	chr11:68621650	NA	0.43	5.06	0.31	8.14e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.57	7.52	0.43	9.96e-13	Resting heart rate;
KIRP	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26314531	chr2:26401878	FAM59B	0.48	4.9	0.3	1.72e-6	Gut microbiome composition (summer);
KIRP	cis	rs62413470	1.000	rs62404862	chr6:55943199	A/T	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg10935138	chr17:73851978	WBP2	0.6	7.67	0.44	4.13e-13	Psoriasis;
KIRP	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.48	-6.15	-0.36	3.19e-9	Systolic blood pressure;
KIRP	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.75	-10.78	-0.57	1.94e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.58	7.2	0.42	7.3e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	1.0	18.13	0.76	3.17e-47	Leprosy;
KIRP	cis	rs7630877	0.962	rs56395499	chr3:179644270	T/C	cg18765712	chr3:179670323	PEX5L	0.5	6.17	0.37	2.85e-9	Type 2 diabetes;
KIRP	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.9	14.23	0.67	6.26e-34	Coronary artery disease;
KIRP	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.22	0.64	1.62e-30	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1978968	1.000	rs1110660	chr22:18444693	A/C	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs888194	0.699	rs12321904	chr12:109989228	G/T	cg05360138	chr12:110035743	NA	0.44	5.46	0.33	1.14e-7	Neuroticism;
KIRP	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.73	-10.54	-0.56	1.13e-21	Height;
KIRP	cis	rs55788414	0.932	rs34110030	chr16:81185211	G/A	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.31	-0.47	6.41e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg13482628	chr17:19912719	NA	0.58	8.22	0.46	1.15e-14	Schizophrenia;
KIRP	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.68e-6	Pulmonary function;
KIRP	cis	rs6855629	0.808	rs4699165	chr4:106109381	A/G	cg08924430	chr4:106067052	TET2	0.35	5.15	0.31	5.27e-7	Height;
KIRP	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05220968	chr6:146057943	EPM2A	0.38	4.95	0.3	1.4e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13418717	1.000	rs10167924	chr2:127658694	G/A	cg25501666	chr2:127640322	NA	1.07	7.35	0.42	2.95e-12	Heart failure;
KIRP	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.39	4.84	0.3	2.25e-6	Blood protein levels;
KIRP	cis	rs10518128	1.000	rs28637863	chr4:75706357	G/T	cg20122727	chr4:75719957	BTC	0.56	5.4	0.33	1.57e-7	Electroencephalogram traits;
KIRP	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14396892	chr9:96623032	NA	-0.36	-4.87	-0.3	2.02e-6	DNA methylation (variation);
KIRP	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00857998	chr1:205179979	DSTYK	0.66	8.38	0.47	4.15e-15	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11955175	1.000	rs78855960	chr5:40657221	C/G	cg05478818	chr5:40835740	RPL37	0.68	5.32	0.32	2.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg26248373	chr2:1572462	NA	-0.66	-7.16	-0.42	9.22e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.58	-7.22	-0.42	6.46e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7681423	1.000	rs2066864	chr4:155525695	G/A	cg20735720	chr4:155535218	FGG	-0.63	-8.24	-0.46	1.05e-14	Fibrinogen;
KIRP	trans	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs7923609	0.967	rs2393977	chr10:65247609	A/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.86	-0.35	1.46e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg27446573	chr6:127587934	RNF146	0.79	10.44	0.55	2.32e-21	Breast cancer;
KIRP	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs77861329	1.000	rs9843852	chr3:52132029	C/G	cg08692210	chr3:52188851	WDR51A	0.96	7.52	0.43	1.03e-12	Macrophage inflammatory protein 1b levels;
KIRP	trans	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg13565492	chr6:43139072	SRF	-1.03	-11.22	-0.58	7.43e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs3809095	0.521	rs11024001	chr11:16657606	G/A	cg15531249	chr16:85744077	C16orf74	0.43	6.05	0.36	5.3300000000000004e-09	Total body bone mineral density;
KIRP	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg22764044	chr5:178986830	RUFY1	-0.39	-5.55	-0.33	7.54e-8	Lung cancer;
KIRP	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.85	11.95	0.61	3.02e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.46	8.97	0.5	7.55e-17	Educational attainment (years of education);
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00933542	chr6:150070202	PCMT1	0.32	6.06	0.36	5e-9	Lung cancer;
KIRP	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11622362	chr11:34938112	PDHX;APIP	-0.45	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	1.12	19.05	0.77	2.44e-50	Schizophrenia;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03647317	chr4:187891568	NA	-0.8	-13.12	-0.64	3.53e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	trans	rs3858145	0.588	rs7081284	chr10:70044792	C/G	cg04882175	chr6:131122610	NA	-0.6	-6.94	-0.4	3.45e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs137699	0.695	rs137653	chr22:39732171	A/G	cg24399712	chr22:39784796	NA	0.42	5.58	0.33	6.45e-8	IgG glycosylation;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.78	14.06	0.67	2.42e-33	Height;
KIRP	cis	rs2131877	0.529	rs3892194	chr3:194855675	C/T	cg13868855	chr3:194833887	C3orf21	-0.44	-4.99	-0.3	1.15e-6	Non-small cell lung cancer;
KIRP	cis	rs10864907	0.935	rs2723149	chr2:113643628	T/C	cg03712744	chr2:113669835	IL1F7	-0.35	-5.15	-0.31	5.45e-7	Pulmonary function;
KIRP	cis	rs12431939	1.000	rs66680859	chr14:51656399	A/G	cg23942311	chr14:51606299	NA	-0.5	-5.38	-0.32	1.69e-7	Cancer;
KIRP	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg02811702	chr13:24901961	NA	0.4	5.35	0.32	2e-7	Obesity-related traits;
KIRP	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	21.04	0.8	6.59e-57	Colorectal cancer;
KIRP	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-7.42	-0.43	1.91e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg21419209	chr3:44054225	NA	-0.75	-9.36	-0.51	5.28e-18	Coronary artery disease;
KIRP	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg08648136	chr8:956695	NA	0.44	5.78	0.35	2.27e-8	Schizophrenia;
KIRP	trans	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg05505450	chr2:58273643	VRK2	-0.58	-6.52	-0.38	3.94e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01256987	chr12:42539512	GXYLT1	-0.43	-5.62	-0.34	5.27e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg21775007	chr8:11205619	TDH	0.43	5.62	0.34	5.27e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg19407955	chr1:165599744	MGST3	-0.48	-5.42	-0.33	1.45e-7	Total ventricular volume;
KIRP	cis	rs1355223	0.902	rs836462	chr11:34743263	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25325159	chr1:19812210	CAPZB	0.44	6.05	0.36	5.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.54	6.71	0.39	1.34e-10	Menopause (age at onset);
KIRP	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.57	7.82	0.45	1.58e-13	Vitiligo;
KIRP	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg01631408	chr1:248437212	OR2T33	-0.61	-7.89	-0.45	9.67e-14	Common traits (Other);
KIRP	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg15117754	chr3:10150083	C3orf24	-0.51	-5.09	-0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs5753037	0.547	rs140140	chr22:30166437	G/A	cg01021169	chr22:30184971	ASCC2	-0.51	-7.25	-0.42	5.49e-12	Type 1 diabetes;
KIRP	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.07	0.5	4.02e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg06212747	chr3:49208901	KLHDC8B	0.63	8.86	0.49	1.6e-16	Resting heart rate;
KIRP	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg06740227	chr12:86229804	RASSF9	0.45	5.71	0.34	3.33e-8	Major depressive disorder;
KIRP	cis	rs6662572	0.671	rs11211220	chr1:46365501	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.35e-8	Blood protein levels;
KIRP	trans	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg07211511	chr3:129823064	LOC729375	-0.7	-7.23	-0.42	6.08e-12	Blood pressure (smoking interaction);
KIRP	cis	rs7681423	1.000	rs2066861	chr4:155527436	C/T	cg20735720	chr4:155535218	FGG	-0.63	-8.25	-0.47	9.67e-15	Fibrinogen;
KIRP	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	10.12	0.54	2.4e-20	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13181604	chr14:24701136	NEDD8;GMPR2	0.52	7.0	0.41	2.39e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.92	13.87	0.66	1.02e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs72932752	chr2:203667526	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.46	0.55	2e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.46	7.46	0.43	1.51e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.41	0.38	7.32e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs62413470	1.000	rs12196944	chr6:55941564	T/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.41	-0.38	7.33e-10	Neutrophil percentage of white cells;
KIRP	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.43	-6.28	-0.37	1.5e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1270639	0.778	rs1465250	chr7:157439075	C/G	cg13357408	chr7:157437802	PTPRN2	0.64	6.19	0.37	2.5e-9	Colorectal cancer;
KIRP	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg13731523	chr4:3047190	NA	-0.35	-5.88	-0.35	1.31e-8	Serum sulfate level;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg07636037	chr3:49044803	WDR6	0.57	5.3	0.32	2.63e-7	Menarche (age at onset);
KIRP	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg21775007	chr8:11205619	TDH	0.41	5.16	0.31	5.01e-7	Morning vs. evening chronotype;
KIRP	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg12046867	chr14:103022105	NA	-0.51	-6.16	-0.37	2.89e-9	Platelet count;
KIRP	cis	rs1867631	0.585	rs6694782	chr1:67126762	C/T	cg13052034	chr1:66999238	SGIP1	-0.44	-6.73	-0.39	1.17e-10	Menopause (age at onset);
KIRP	cis	rs5753037	0.774	rs140118	chr22:30135806	G/A	cg01021169	chr22:30184971	ASCC2	-0.39	-4.92	-0.3	1.55e-6	Type 1 diabetes;
KIRP	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.18	0.37	2.69e-9	Joint mobility (Beighton score);
KIRP	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.58	7.16	0.42	9.04e-12	Monobrow;
KIRP	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg18657303	chr4:1051139	NA	-0.54	-4.92	-0.3	1.62e-6	Recombination rate (females);
KIRP	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg01304814	chr3:48885189	PRKAR2A	0.57	4.91	0.3	1.68e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.65	0.34	4.41e-8	Aortic root size;
KIRP	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.45	-10.96	-0.57	5.21e-23	Diabetic kidney disease;
KIRP	cis	rs365132	0.840	rs58400555	chr5:176454081	A/T	cg16309518	chr5:176445507	NA	-0.88	-13.62	-0.66	7.48e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.4	0.33	1.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg18016565	chr1:150552671	MCL1	0.37	5.84	0.35	1.68e-8	Melanoma;
KIRP	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.65	-8.66	-0.48	6.44e-16	Colorectal cancer;
KIRP	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.91	-0.4	4.18e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.26	5.41	0.33	1.52e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.48	0.52	2.21e-18	Bipolar disorder;
KIRP	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg09873164	chr1:152488093	CRCT1	0.5	6.37	0.38	9.19e-10	Hair morphology;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg02733842	chr7:1102375	C7orf50	0.51	5.45	0.33	1.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.41	-0.43	2.07e-12	Type 2 diabetes;
KIRP	cis	rs11650494	0.710	rs11653775	chr17:47472365	A/G	cg08112188	chr17:47440006	ZNF652	1.06	6.52	0.38	3.92e-10	Prostate cancer;
KIRP	cis	rs11955398	0.669	rs11952735	chr5:59939146	T/C	cg02684056	chr5:59996105	DEPDC1B	0.43	5.09	0.31	7e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7999699	0.902	rs7986517	chr13:48300991	G/A	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05220968	chr6:146057943	EPM2A	-0.42	-5.43	-0.33	1.33e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9890032	0.532	rs1808257	chr17:29039966	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.38	-4.97	-0.3	1.25e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21433121	chr3:58477944	KCTD6	0.47	6.21	0.37	2.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.88	10.21	0.55	1.26e-20	Corneal astigmatism;
KIRP	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg08975724	chr8:8085496	FLJ10661	0.68	7.83	0.45	1.5e-13	Red cell distribution width;
KIRP	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.48	6.57	0.39	3.01e-10	Red blood cell count;
KIRP	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg14703610	chr5:56206110	C5orf35	0.5	6.97	0.41	2.82e-11	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.53e-10	Aortic root size;
KIRP	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.71	-9.82	-0.53	2.01e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3204270	0.683	rs13372	chr17:79617705	G/A	cg18367735	chr17:79674897	NA	0.68	6.25	0.37	1.78e-9	Dental caries;
KIRP	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.76	-12.59	-0.63	2.24e-28	Prostate cancer;
KIRP	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.73	-0.44	2.71e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.85	13.54	0.65	1.41e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-10.46	-0.55	1.99e-21	Joint mobility (Beighton score);
KIRP	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg03788504	chr6:150331562	NA	-0.31	-5.66	-0.34	4.13e-8	Alopecia areata;
KIRP	cis	rs896623	0.739	rs13104663	chr4:122137111	A/G	cg19463078	chr4:122099598	TNIP3	-0.31	-4.85	-0.3	2.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs78487399	0.808	rs6746058	chr2:43687542	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.06	-0.31	8.26e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7737355	0.836	rs10900800	chr5:130914946	G/A	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.74	10.66	0.56	4.52e-22	IgG glycosylation;
KIRP	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.46	0.33	1.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg04132472	chr17:19861366	AKAP10	0.48	6.91	0.4	4.1e-11	Schizophrenia;
KIRP	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.48	-0.33	1.05e-7	Height;
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg02462569	chr6:150064036	NUP43	-0.42	-6.56	-0.39	3.15e-10	Lung cancer;
KIRP	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.6	7.55	0.43	8.49e-13	Height;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.8	-11.53	-0.59	7.02e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07287384	chr6:132697112	MOXD1	-0.4	-6.26	-0.37	1.7e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.26	0.62	2.79e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs15676	0.783	rs2280843	chr9:131585069	A/G	cg00228799	chr9:131580591	ENDOG	0.57	6.38	0.38	8.5e-10	Blood metabolite levels;
KIRP	cis	rs9815354	1.000	rs1612124	chr3:41967893	C/A	cg03022575	chr3:42003672	ULK4	-0.56	-6.6	-0.39	2.52e-10	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	trans	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg06521331	chr12:34319734	NA	-0.46	-6.04	-0.36	5.63e-9	Heart rate;
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.46	0.33	1.19e-7	Lung cancer;
KIRP	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg12549451	chr6:135224345	NA	-0.43	-5.28	-0.32	2.78e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.54	6.8	0.4	7.85e-11	Obesity-related traits;
KIRP	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg21858823	chr1:15850916	CASP9	0.5	5.42	0.33	1.43e-7	Systolic blood pressure;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22905368	chr14:103996534	TRMT61A	0.48	6.51	0.38	4.31e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-1.19	-15.72	-0.71	5.08e-39	Platelet distribution width;
KIRP	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-0.79	-9.28	-0.51	9.09e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.42	0.47	3.16e-15	Prudent dietary pattern;
KIRP	cis	rs6142102	0.961	rs2284388	chr20:32655741	A/G	cg08999081	chr20:33150536	PIGU	0.51	6.06	0.36	5.16e-9	Skin pigmentation;
KIRP	cis	rs10140922	0.931	rs4982261	chr14:35822159	C/T	cg07166546	chr14:35805898	NA	-0.27	-6.79	-0.4	8.42e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.92	7.57	0.43	7.5e-13	Major depressive disorder;
KIRP	cis	rs6125597	1.000	rs6125597	chr20:47840772	T/C	cg03212862	chr20:47662828	CSE1L	-0.4	-5.06	-0.31	8.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs988913	0.581	rs1108888	chr6:54857288	C/T	cg03513858	chr6:54763001	FAM83B	0.35	5.04	0.31	9.22e-7	Menarche (age at onset);
KIRP	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.3	0.42	4.01e-12	Lung cancer;
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	14.02	0.67	3.25e-33	Platelet count;
KIRP	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg22162597	chr1:113214053	CAPZA1	-0.79	-9.44	-0.52	3.03e-18	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg02725872	chr8:58115012	NA	-0.53	-6.53	-0.38	3.74e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.44	5.99	0.36	7.52e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs42648	0.596	rs194511	chr7:89846727	A/G	cg25739043	chr7:89950458	NA	-0.43	-6.91	-0.4	4.22e-11	Homocysteine levels;
KIRP	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg18306943	chr3:40428807	ENTPD3	0.46	5.9	0.35	1.19e-8	Renal cell carcinoma;
KIRP	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1448094	0.845	rs10863123	chr12:86346254	G/A	cg00310523	chr12:86230176	RASSF9	0.39	5.99	0.36	7.48e-9	Major depressive disorder;
KIRP	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg20936604	chr3:58311152	NA	-0.66	-5.04	-0.31	9.16e-7	Cholesterol, total;
KIRP	cis	rs7851660	0.844	rs13287360	chr9:100637681	A/G	cg13688889	chr9:100608707	NA	-0.69	-8.83	-0.49	1.98e-16	Strep throat;
KIRP	cis	rs10073892	0.701	rs62372298	chr5:101675584	C/T	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.97e-11	Cognitive decline (age-related);
KIRP	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.92	-13.34	-0.65	6.48e-31	Tonsillectomy;
KIRP	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg04013166	chr16:89971882	TCF25	0.68	5.67	0.34	4.08e-8	Skin colour saturation;
KIRP	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7010267	0.773	rs4876869	chr8:119941277	A/G	cg01975934	chr8:119970761	NA	0.43	5.48	0.33	1.04e-7	Total body bone mineral density (age 45-60);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23758485	chr16:68482202	SMPD3	0.43	6.17	0.37	2.77e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.08	-0.36	4.65e-9	Aortic root size;
KIRP	trans	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg19694781	chr19:47549865	TMEM160	-0.51	-6.2	-0.37	2.34e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.34	0.37	1.11e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.7	9.01	0.5	5.77e-17	Prostate cancer;
KIRP	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.5	0.38	4.36e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs2018683	0.600	rs717891	chr7:29000374	C/T	cg19402173	chr7:128379420	CALU	-0.67	-9.59	-0.52	1.01e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg17844037	chr10:134117530	STK32C	-0.45	-6.11	-0.36	3.95e-9	Select biomarker traits;
KIRP	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.66	10.1	0.54	2.66e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.26	0.42	4.95e-12	Height;
KIRP	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.05	-13.16	-0.64	2.66e-30	Exhaled nitric oxide output;
KIRP	cis	rs6832769	1.000	rs13121235	chr4:56311947	A/G	cg09317128	chr4:56265301	TMEM165	0.55	7.22	0.42	6.38e-12	Personality dimensions;
KIRP	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03322129	chr1:1209673	UBE2J2	0.62	7.11	0.41	1.24e-11	Lung cancer in ever smokers;
KIRP	cis	rs7113850	0.541	rs114370606	chr11:24232247	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.34	0.47	5.17e-15	Bone fracture in osteoporosis;
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.49	5.68	0.34	3.71e-8	Lung cancer;
KIRP	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg05785598	chr3:49045655	WDR6	0.28	5.06	0.31	8.36e-7	Parkinson's disease;
KIRP	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.56	-7.77	-0.44	2.13e-13	Schizophrenia;
KIRP	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.35	9.02	0.5	5.38e-17	Crohn's disease;
KIRP	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.76	7.72	0.44	3e-13	Menarche (age at onset);
KIRP	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Renal cell carcinoma;
KIRP	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.9	13.33	0.65	7.32e-31	Coronary artery disease;
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg02996583	chr8:142237188	SLC45A4	0.48	5.94	0.35	9.91e-9	Immature fraction of reticulocytes;
KIRP	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Parkinson's disease;
KIRP	cis	rs9815354	1.000	rs1716676	chr3:41903208	T/C	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.62	8.78	0.49	2.81e-16	Colorectal cancer;
KIRP	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	12.0	0.61	1.99e-26	Monocyte percentage of white cells;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg26513180	chr16:89883248	FANCA	0.85	14.3	0.67	3.57e-34	Vitiligo;
KIRP	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4936894	0.500	rs11604309	chr11:124167162	A/C	cg27160556	chr11:124181099	OR8D1	-0.43	-6.19	-0.37	2.46e-9	Aging (time to death);
KIRP	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.87	0.71	1.62e-39	Chronic sinus infection;
KIRP	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg00262122	chr8:11665843	FDFT1	0.41	5.22	0.32	3.81e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg07701084	chr6:150067640	NUP43	0.71	9.41	0.51	3.8e-18	Lung cancer;
KIRP	cis	rs8077577	0.747	rs35738574	chr17:18151424	C/G	cg18869244	chr17:18121946	NA	0.46	5.26	0.32	3.2e-7	Obesity-related traits;
KIRP	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg04691961	chr3:161091175	C3orf57	-0.39	-5.33	-0.32	2.2e-7	Educational attainment (years of education);
KIRP	cis	rs7084402	0.967	rs1658419	chr10:60332812	A/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.49	-0.56	1.59e-21	Refractive error;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13978767	chr19:7620597	PNPLA6	0.45	6.41	0.38	7.43e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.44	7.75	0.44	2.42e-13	Renal cell carcinoma;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg01238044	chr22:24384105	GSTT1	-0.51	-6.5	-0.38	4.48e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.77	-0.35	2.4e-8	Schizophrenia;
KIRP	cis	rs250677	0.522	rs12520924	chr5:148349149	C/T	cg12140854	chr5:148520817	ABLIM3	0.46	5.13	0.31	5.86e-7	Breast cancer;
KIRP	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg09455208	chr3:40491958	NA	0.33	5.85	0.35	1.53e-8	Renal cell carcinoma;
KIRP	cis	rs580438	0.510	rs2280084	chr3:13395579	C/A	cg10657019	chr3:13328039	NA	-0.59	-7.7	-0.44	3.25e-13	Myringotomy;
KIRP	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg23517279	chr6:96025343	MANEA	0.6	5.41	0.33	1.46e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs8067545	0.586	rs2526459	chr17:20090042	G/T	cg13482628	chr17:19912719	NA	-0.49	-6.35	-0.38	1.05e-9	Schizophrenia;
KIRP	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.4	4.97	0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.76	-0.34	2.44e-8	Yeast infection;
KIRP	cis	rs6593803	0.732	rs36005900	chr1:147229662	G/A	cg27546670	chr1:147246839	GJA5	-0.69	-7.44	-0.43	1.66e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg13264159	chr8:625131	ERICH1	-0.81	-6.55	-0.39	3.33e-10	IgG glycosylation;
KIRP	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.96	-15.4	-0.7	6.25e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs2594989	0.945	rs2594969	chr3:11353399	C/G	cg01796438	chr3:11312864	ATG7	-0.57	-6.96	-0.41	3.03e-11	Circulating chemerin levels;
KIRP	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-1.05	-14.59	-0.68	3.65e-35	Alopecia areata;
KIRP	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs662064	0.962	rs6540933	chr1:10547263	C/T	cg19773385	chr1:10388646	KIF1B	0.39	5.15	0.31	5.21e-7	Asthma;
KIRP	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg04132472	chr17:19861366	AKAP10	0.43	5.93	0.35	1e-8	Schizophrenia;
KIRP	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.4	-6.34	-0.37	1.08e-9	Body mass index;
KIRP	trans	rs1106684	0.925	rs10954326	chr7:131457881	T/C	cg13607082	chr12:122652224	LRRC43	-0.65	-6.57	-0.39	2.97e-10	Body mass index;
KIRP	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.81	-0.4	7.52e-11	Blood metabolite levels;
KIRP	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.77	-0.44	2.13e-13	Mean platelet volume;
KIRP	cis	rs4959270	0.625	rs9328205	chr6:446093	T/A	cg13299325	chr6:447777	NA	0.28	5.82	0.35	1.86e-8	Limited cutaneous systemic scleroderma;
KIRP	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.31	-0.55	5.92e-21	Heart rate;
KIRP	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg10017260	chr10:834428	NA	-0.55	-5.41	-0.33	1.53e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12950624	chr19:46000154	RTN2	0.59	8.02	0.46	4.42e-14	Myopia (pathological);
KIRP	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg09264619	chr17:80180166	NA	0.51	6.05	0.36	5.42e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg16576597	chr16:28551801	NUPR1	0.33	5.1	0.31	6.78e-7	Mosquito bite size;
KIRP	cis	rs7267005	1.000	rs79194469	chr20:34471516	G/A	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg16141378	chr3:129829833	LOC729375	-0.55	-7.32	-0.42	3.52e-12	Myopia (pathological);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26819193	chr1:118412541	GDAP2	0.58	7.53	0.43	9.9e-13	Interleukin-4 levels;
KIRP	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg04306507	chr14:55594613	LGALS3	0.53	8.22	0.46	1.2e-14	Protein biomarker;
KIRP	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.41	-5.21	-0.32	4.05e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs9302635	0.625	rs34417180	chr16:72219756	C/A	cg01557791	chr16:72042693	DHODH	-0.65	-5.48	-0.33	1.03e-7	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18184219	chr1:243388524	CEP170	-0.41	-6.11	-0.36	3.93e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs860295	0.557	rs6696019	chr1:155864977	T/C	cg02153340	chr1:155202674	NA	-0.39	-5.03	-0.31	9.26e-7	Body mass index;
KIRP	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg07511934	chr16:89386912	ANKRD11	0.42	5.23	0.32	3.64e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.66	-7.34	-0.42	3.15e-12	Mean corpuscular hemoglobin;
KIRP	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.01	0.41	2.26e-11	Mean platelet volume;
KIRP	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.57	-6.06	-0.36	5.11e-9	Skin colour saturation;
KIRP	cis	rs28489187	0.617	rs7547571	chr1:85884091	G/T	cg16011679	chr1:85725395	C1orf52	-0.45	-5.57	-0.33	6.5e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs2882667	0.898	rs13182437	chr5:138387149	T/C	cg04439458	chr5:138467593	SIL1	-0.44	-7.36	-0.43	2.68e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.14	-0.5	2.35e-17	Mean corpuscular volume;
KIRP	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.57	0.56	9.22e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.0	-0.45	5.04e-14	Personality dimensions;
KIRP	cis	rs859767	0.501	rs12691869	chr2:135407641	T/C	cg25422880	chr2:135218333	TMEM163	0.38	5.57	0.33	6.78e-8	Neuroticism;
KIRP	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00684032	chr4:1343700	KIAA1530	0.45	5.93	0.35	1.05e-8	Obesity-related traits;
KIRP	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	13.1	0.64	4.12e-30	Alzheimer's disease;
KIRP	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg07005078	chr4:17578674	LAP3	0.43	4.9	0.3	1.71e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4006360	0.525	rs3907875	chr17:39268353	A/G	cg25341923	chr17:39239918	KRTAP4-7	0.43	6.04	0.36	5.69e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg23594656	chr7:65796392	TPST1	-0.46	-7.29	-0.42	4.21e-12	Aortic root size;
KIRP	cis	rs889398	0.771	rs1566454	chr16:69900083	C/T	cg09409435	chr16:70099608	PDXDC2	0.44	5.31	0.32	2.4e-7	Body mass index;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.43	5.65	0.34	4.51e-8	Testicular germ cell tumor;
KIRP	cis	rs7221595	0.825	rs9905748	chr17:3968639	C/T	cg09695851	chr17:3907499	NA	0.62	6.47	0.38	5.15e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.65	8.38	0.47	4.17e-15	Tonsillectomy;
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-8.76	-0.49	3.33e-16	Lymphocyte counts;
KIRP	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.71	6.93	0.4	3.76e-11	Gut microbiome composition (summer);
KIRP	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg05082376	chr22:42548792	NA	0.46	5.8	0.35	2.01e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg01238044	chr22:24384105	GSTT1	-0.52	-6.69	-0.39	1.52e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.74	10.43	0.55	2.53e-21	Coronary artery disease;
KIRP	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.65	7.83	0.45	1.5e-13	Gut microbiome composition (summer);
KIRP	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg26876637	chr1:152193138	HRNR	0.76	9.9	0.53	1.17e-19	Atopic dermatitis;
KIRP	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.79	11.28	0.58	4.57e-24	Bladder cancer;
KIRP	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg26875233	chr11:93583750	C11orf90	0.36	6.98	0.41	2.74e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	0.98	11.31	0.59	3.61e-24	Iron status biomarkers;
KIRP	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.34e-15	Bone mineral density;
KIRP	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.73	-10.13	-0.54	2.21e-20	Hypospadias;
KIRP	cis	rs1642645	0.566	rs1325504	chr1:42400931	A/T	cg26038582	chr1:42384390	HIVEP3	0.29	5.43	0.33	1.37e-7	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.35	6.17	0.37	2.72e-9	Renal cell carcinoma;
KIRP	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.93	-13.06	-0.64	5.87e-30	Cognitive function;
KIRP	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg23682824	chr7:23144976	KLHL7	0.55	6.91	0.4	4.09e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg00647317	chr7:50633725	DDC	0.45	6.0	0.36	6.87e-9	Malaria;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06123147	chr18:72342942	ZNF407	-0.46	-6.95	-0.41	3.32e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.57	-5.08	-0.31	7.37e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07114627	chr1:110155839	GNAT2	-0.4	-6.2	-0.37	2.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	8.14	0.46	2.03e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg16141378	chr3:129829833	LOC729375	-0.54	-7.15	-0.41	9.78e-12	Retinal vascular caliber;
KIRP	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg25233709	chr10:116636983	FAM160B1	0.34	5.22	0.32	3.75e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4950322	0.570	rs72692975	chr1:146805238	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-10.13	-0.54	2.23e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg20243544	chr17:37824526	PNMT	0.38	5.1	0.31	6.71e-7	Self-reported allergy;
KIRP	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg01677386	chr11:118938358	VPS11	-0.54	-6.4	-0.38	7.78e-10	Coronary artery disease;
KIRP	trans	rs1422110	0.616	rs6452688	chr5:85445038	C/T	cg01787110	chr1:109008453	NBPF6	0.76	9.52	0.52	1.65e-18	Attention function in attention deficit hyperactive disorder;
KIRP	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg16141378	chr3:129829833	LOC729375	0.57	7.0	0.41	2.44e-11	Triglycerides;
KIRP	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg27121462	chr16:89883253	FANCA	0.64	9.44	0.52	3.08e-18	Vitiligo;
KIRP	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.27	0.37	1.63e-9	Ovarian reserve;
KIRP	cis	rs4845875	0.600	rs1889293	chr1:11840862	G/A	cg24844545	chr1:11908347	NPPA	0.36	4.89	0.3	1.84e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg14061069	chr19:46274453	DMPK	-0.57	-8.66	-0.48	6.31e-16	Coronary artery disease;
KIRP	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.65	-10.46	-0.56	1.94e-21	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.57	-0.56	8.87e-22	Chronic sinus infection;
KIRP	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs6545883	0.894	rs2694643	chr2:61604383	A/G	cg15711740	chr2:61764176	XPO1	-0.6	-7.7	-0.44	3.29e-13	Tuberculosis;
KIRP	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.2	-0.37	2.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs4149423	1.000	rs4149420	chr2:108913090	G/T	cg25838818	chr2:108905173	SULT1C2	-0.72	-11.06	-0.58	2.45e-23	Lobe size;
KIRP	cis	rs12615966	0.584	rs72830474	chr2:105414217	C/T	cg16465502	chr2:105461796	NA	0.95	7.85	0.45	1.29e-13	Pancreatic cancer;
KIRP	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg11569703	chr11:65557185	OVOL1	0.78	14.98	0.69	1.78e-36	Acne (severe);
KIRP	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.78	-10.67	-0.56	4.36e-22	Aortic root size;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs2380220	0.720	rs9398251	chr6:95984709	C/T	cg15832292	chr6:96025679	MANEA	0.65	6.23	0.37	2.06e-9	Behavioural disinhibition (generation interaction);
KIRP	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.99	-15.47	-0.7	3.76e-38	Monocyte count;
KIRP	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7538876	1.000	rs7538876	chr1:17722363	G/A	cg07394400	chr1:17752023	RCC2	-0.36	-5.13	-0.31	5.93e-7	Basal cell carcinoma;
KIRP	cis	rs10814247	0.592	rs11790934	chr9:35503291	T/G	cg15271616	chr9:35490515	RUSC2	0.45	5.59	0.34	6.12e-8	Psoriasis;
KIRP	trans	rs12043259	0.730	rs4950966	chr1:204808170	A/C	cg11485465	chr5:54518469	NA	0.36	6.27	0.37	1.61e-9	Addiction;
KIRP	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg19746982	chr18:77552568	NA	0.29	4.98	0.3	1.17e-6	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg05785598	chr3:49045655	WDR6	0.3	5.49	0.33	9.82e-8	Parkinson's disease;
KIRP	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.63	8.86	0.49	1.66e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg25547332	chr5:131281432	NA	0.51	6.08	0.36	4.65e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.89	-10.1	-0.54	2.81e-20	White matter hyperintensity burden;
KIRP	cis	rs960902	0.544	rs6705305	chr2:37765176	A/G	cg25341268	chr2:37734390	NA	0.58	7.17	0.42	8.6e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg21926883	chr2:100939477	LONRF2	-0.56	-7.59	-0.44	6.64e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.4	-0.47	3.53e-15	Mean corpuscular volume;
KIRP	cis	rs2746347	0.722	rs11206887	chr1:57116909	G/A	cg09935045	chr1:57111199	PRKAA2	-0.51	-5.22	-0.32	3.83e-7	Lymphocyte counts;
KIRP	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg23950597	chr19:37808831	NA	-0.76	-7.65	-0.44	4.59e-13	Coronary artery calcification;
KIRP	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.19	0.31	4.45e-7	Schizophrenia;
KIRP	cis	rs7601312	0.844	rs978212	chr2:229272784	A/G	cg02542817	chr2:229291442	NA	0.57	8.76	0.49	3.17e-16	Schizophrenia;
KIRP	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.95	11.18	0.58	9.82e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.92	0.3	1.61e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2150410	0.915	rs973521	chr21:40650621	G/A	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.57	7.5	0.43	1.19e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg09699651	chr6:150184138	LRP11	0.42	5.37	0.32	1.82e-7	Lung cancer;
KIRP	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18932078	chr1:2524107	MMEL1	0.44	5.97	0.36	8.14e-9	Ulcerative colitis;
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg02462569	chr6:150064036	NUP43	-0.39	-5.92	-0.35	1.06e-8	Lung cancer;
KIRP	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.75	-7.85	-0.45	1.25e-13	Gout;
KIRP	cis	rs12912251	0.591	rs10520103	chr15:39006243	C/G	cg10631289	chr15:39006617	NA	0.8	8.72	0.49	4.13e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg18404041	chr3:52824283	ITIH1	-0.41	-5.48	-0.33	1.04e-7	Schizophrenia;
KIRP	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg08126542	chr6:37504118	NA	-0.83	-13.22	-0.64	1.7e-30	Cognitive performance;
KIRP	cis	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg21546286	chr11:48923668	NA	-0.41	-5.31	-0.32	2.45e-7	HDL cholesterol;
KIRP	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg23920097	chr1:209922102	NA	-0.46	-6.08	-0.36	4.49e-9	Red blood cell count;
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.05e-8	Lung cancer;
KIRP	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg24060327	chr5:131705240	SLC22A5	-0.47	-5.73	-0.34	2.93e-8	Blood metabolite levels;
KIRP	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.73	-8.42	-0.47	3.08e-15	Platelet count;
KIRP	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg25319279	chr11:5960081	NA	-0.59	-6.12	-0.36	3.73e-9	DNA methylation (variation);
KIRP	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.66	7.6	0.44	6.35e-13	Gut microbiome composition (summer);
KIRP	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02475777	chr4:1388615	CRIPAK	0.39	5.29	0.32	2.67e-7	Longevity;
KIRP	cis	rs2671245	0.933	rs2819488	chr1:56163984	G/A	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg01422370	chr2:73384389	NA	0.46	6.14	0.36	3.22e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25130672	chr12:104850576	CHST11	0.44	6.04	0.36	5.59e-9	Survival in pancreatic cancer;
KIRP	cis	rs28829049	0.597	rs2313509	chr1:19437860	C/T	cg13387374	chr1:19411106	UBR4	0.42	5.09	0.31	7.01e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.61	-9.14	-0.5	2.43e-17	Height;
KIRP	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.58	-5.01	-0.3	1.02e-6	Putamen volume;
KIRP	cis	rs712039	0.652	rs60112577	chr17:35833209	G/A	cg16670864	chr17:35848621	DUSP14	0.41	4.91	0.3	1.67e-6	Tuberculosis;
KIRP	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs6466055	0.669	rs2299304	chr7:104771857	T/C	cg04380332	chr7:105027541	SRPK2	-0.63	-9.57	-0.52	1.2e-18	Schizophrenia;
KIRP	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg24304309	chr1:154577895	ADAR	0.36	5.49	0.33	9.82e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.8	9.04	0.5	4.85e-17	Corneal astigmatism;
KIRP	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.57	7.03	0.41	1.98e-11	Aortic root size;
KIRP	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07151155	chr5:1473589	LPCAT1	-0.43	-5.79	-0.35	2.1e-8	Breast cancer;
KIRP	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg03060546	chr3:49711283	APEH	-0.62	-6.1	-0.36	4.16e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.59	6.25	0.37	1.77e-9	Crohn's disease;
KIRP	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	0.96	14.81	0.69	6.5e-36	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	trans	rs587242	1.000	rs12740202	chr1:96905594	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.06	-0.36	4.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs2587695	0.904	rs2579623	chr2:120298350	A/T	cg07176264	chr2:120281999	SCTR	0.32	5.0	0.3	1.09e-6	Attention deficit hyperactivity disorder;
KIRP	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.63	8.48	0.48	2.15e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.45	-5.71	-0.34	3.31e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.17	0.58	1.04e-23	Smoking behavior;
KIRP	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.52	6.34	0.37	1.07e-9	Monocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22185451	chr7:156433300	C7orf13;RNF32	0.45	6.03	0.36	6.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg08648136	chr8:956695	NA	0.42	6.12	0.36	3.58e-9	Schizophrenia;
KIRP	cis	rs7577696	0.512	rs9789593	chr2:32381110	T/G	cg02381751	chr2:32503542	YIPF4	-0.53	-5.4	-0.33	1.55e-7	Inflammatory biomarkers;
KIRP	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.99	-0.3	1.15e-6	Neutrophil percentage of white cells;
KIRP	cis	rs17067123	0.614	rs35522192	chr4:180064376	C/A	cg26610307	chr4:180072759	NA	-0.48	-5.35	-0.32	2.05e-7	Response to hepatitis C treatment;
KIRP	cis	rs72772090	0.710	rs112178674	chr5:96060355	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-5.81	-0.35	1.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.25e-10	Hypertriglyceridemia;
KIRP	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg24804195	chr5:87968844	LOC645323	0.47	6.15	0.36	3.16e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.6	7.38	0.43	2.38e-12	Schizophrenia;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.67	-6.34	-0.37	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15889003	chr4:6925288	TBC1D14	-0.49	-6.31	-0.37	1.32e-9	Parkinson's disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg27556566	chr18:29671984	RNF138	0.51	6.07	0.36	4.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7225151	0.634	rs76418084	chr17:5269183	T/C	cg24500398	chr17:5266808	RABEP1	-0.53	-5.08	-0.31	7.52e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19768357	chr5:77072009	TBCA	0.47	6.53	0.38	3.72e-10	Survival in pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg07395648	chr5:131743802	NA	0.56	7.75	0.44	2.4e-13	Breast cancer;Mosquito bite size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21815083	chr11:69458002	CCND1	0.56	7.32	0.42	3.61e-12	Parkinson's disease;
KIRP	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.15	-0.31	5.22e-7	Bladder cancer;
KIRP	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.98	14.22	0.67	6.75e-34	Cognitive function;
KIRP	cis	rs8523	0.697	rs59542081	chr6:11059209	T/G	cg13562911	chr6:11044106	ELOVL2	0.41	5.43	0.33	1.32e-7	Red blood cell fatty acid levels;
KIRP	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg21775007	chr8:11205619	TDH	0.7	9.66	0.52	6.43e-19	Retinal vascular caliber;
KIRP	cis	rs7429990	0.932	rs13085054	chr3:48134137	C/T	cg11946769	chr3:48343235	NME6	-0.43	-5.16	-0.31	4.97e-7	Educational attainment (years of education);
KIRP	cis	rs2380205	0.666	rs11819695	chr10:5887279	C/T	cg27141509	chr10:5886111	NA	-0.41	-5.71	-0.34	3.33e-8	Breast cancer;
KIRP	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg07212818	chr11:638076	DRD4	-0.39	-4.91	-0.3	1.69e-6	Systemic lupus erythematosus;
KIRP	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg10932868	chr11:921992	NA	0.62	7.95	0.45	6.88e-14	Alzheimer's disease (late onset);
KIRP	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg05552183	chr6:42928497	GNMT	0.54	6.74	0.39	1.15e-10	Blood protein levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13959595	chr9:139910220	ABCA2	0.52	7.36	0.42	2.82e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.54	5.71	0.34	3.22e-8	Response to diuretic therapy;
KIRP	cis	rs7809799	0.571	rs11978582	chr7:98915958	C/T	cg12290671	chr7:99195819	NA	0.69	5.27	0.32	2.97e-7	Ulcerative colitis;
KIRP	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.55	-7.43	-0.43	1.74e-12	Type 2 diabetes;
KIRP	cis	rs427941	0.703	rs201442	chr7:101737627	C/T	cg06246474	chr7:101738831	CUX1	-0.53	-6.7	-0.39	1.39e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4805272	1.000	rs10411061	chr19:29320206	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.72	9.8	0.53	2.39e-19	Post bronchodilator FEV1;
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.43	9.25	0.51	1.11e-17	Vitiligo;
KIRP	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg27211696	chr2:191398769	TMEM194B	-0.77	-8.98	-0.5	7.2e-17	Diastolic blood pressure;
KIRP	cis	rs4262150	0.883	rs72802889	chr5:152254829	T/C	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.98e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1185460	1.000	rs4614	chr11:118952371	A/G	cg23280166	chr11:118938394	VPS11	0.52	6.11	0.36	3.8e-9	Coronary artery disease;
KIRP	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.14	-0.31	5.56e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs7903847	0.596	rs10882934	chr10:99170995	T/G	cg20016023	chr10:99160130	RRP12	-0.4	-5.49	-0.33	1e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-8.5	-0.48	1.83e-15	Colorectal cancer;
KIRP	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg03929089	chr4:120376271	NA	0.71	6.29	0.37	1.44e-9	Axial length;
KIRP	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.65	-9.98	-0.54	6.33e-20	Endometriosis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22752506	chr17:79895093	PYCR1	-0.51	-6.68	-0.39	1.59e-10	Myopia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18132159	chr1:238110295	NA	0.5	6.54	0.38	3.45e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-5.98	-0.36	7.61e-9	Lung function (FEV1/FVC);
KIRP	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg16988262	chr1:15930761	NA	0.38	4.87	0.3	1.97e-6	Systolic blood pressure;
KIRP	cis	rs986417	1.000	rs1951115	chr14:60922006	G/C	cg27398547	chr14:60952738	C14orf39	-0.74	-7.43	-0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.72	0.49	4.14e-16	Motion sickness;
KIRP	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.48	11.07	0.58	2.2e-23	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.82	12.23	0.61	3.46e-27	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1864585	0.520	rs73208782	chr8:10677555	G/A	cg26278703	chr11:58910052	FAM111A	0.64	6.16	0.37	2.97e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.59	8.0	0.45	4.88e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg05527609	chr1:210001259	C1orf107	-0.47	-5.12	-0.31	6.06e-7	Red blood cell count;
KIRP	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	1.13	9.17	0.5	1.91e-17	Skin colour saturation;
KIRP	cis	rs3789045	1.000	rs45501495	chr1:204596454	C/T	cg18185008	chr1:204589407	LRRN2	-0.51	-6.69	-0.39	1.52e-10	Educational attainment (college completion);
KIRP	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22590775	chr19:49891494	CCDC155	0.61	7.3	0.42	3.95e-12	Multiple sclerosis;
KIRP	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-7.6	-0.44	6.2e-13	Personality dimensions;
KIRP	cis	rs9400467	0.537	rs78080415	chr6:111537016	T/C	cg15721981	chr6:111408429	SLC16A10	0.8	7.34	0.42	3.14e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1440410	0.835	rs6828369	chr4:144147484	C/G	cg01719995	chr4:144104893	USP38	0.38	5.06	0.31	8.38e-7	Ischemic stroke;
KIRP	cis	rs728616	0.510	rs12411989	chr10:81937850	G/A	cg27417294	chr10:81904244	PLAC9	0.53	5.03	0.31	9.42e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg03585969	chr10:35415529	CREM	0.66	7.71	0.44	3.21e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.69	7.86	0.45	1.19e-13	Obesity-related traits;
KIRP	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg08890418	chr1:21044141	KIF17	-0.43	-6.4	-0.38	7.95e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs909341	0.710	rs2297433	chr20:62293460	T/C	cg11503966	chr20:62272292	STMN3	0.46	6.41	0.38	7.43e-10	Atopic dermatitis;
KIRP	cis	rs17401966	0.540	rs4846219	chr1:10463888	C/A	cg19773385	chr1:10388646	KIF1B	-0.45	-6.47	-0.38	5.18e-10	Hepatocellular carcinoma;
KIRP	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.47	0.33	1.13e-7	Coronary artery disease;
KIRP	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg24060327	chr5:131705240	SLC22A5	0.58	6.03	0.36	6.1e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.46	0.38	5.58e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1971762	0.931	rs12818213	chr12:54072007	A/G	cg09709951	chr12:54017699	ATF7	0.42	5.31	0.32	2.47e-7	Height;
KIRP	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg27205649	chr11:78285834	NARS2	0.46	4.94	0.3	1.42e-6	Testicular germ cell tumor;
KIRP	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg13482628	chr17:19912719	NA	0.57	8.05	0.46	3.61e-14	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24010885	chr20:30102097	HM13	0.51	6.84	0.4	6.32e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg09795085	chr6:101329169	ASCC3	-0.46	-5.53	-0.33	8.05e-8	Neuroticism;
KIRP	cis	rs7640424	0.649	rs13082569	chr3:107870835	A/C	cg09227934	chr3:107805635	CD47	0.34	5.76	0.34	2.54e-8	Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10893370	chr17:30228961	UTP6	0.55	6.52	0.38	3.92e-10	Smoking initiation;
KIRP	cis	rs6968419	0.747	rs6953050	chr7:115888162	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.04	-0.36	5.73e-9	Intraocular pressure;
KIRP	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.85	-13.79	-0.66	1.91e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.44	-6.02	-0.36	6.23e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9398803	0.865	rs2326451	chr6:126811928	A/T	cg19875578	chr6:126661172	C6orf173	0.47	6.12	0.36	3.73e-9	Male-pattern baldness;
KIRP	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-0.5	-6.42	-0.38	7e-10	Acne (severe);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10307595	chr11:70330927	SHANK2	0.48	6.36	0.38	9.94e-10	Survival in pancreatic cancer;
KIRP	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.74	10.33	0.55	5.18e-21	Red blood cell count;
KIRP	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	trans	rs972578	0.668	rs4822207	chr22:43257261	A/G	cg15321293	chr3:36422198	STAC	-0.48	-6.2	-0.37	2.43e-9	Mean platelet volume;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.72e-7	Life satisfaction;
KIRP	cis	rs8033133	0.602	rs12439159	chr15:25323874	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.49	-6.27	-0.37	1.64e-9	Blood osmolality (transformed sodium);
KIRP	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg13409248	chr3:40428643	ENTPD3	0.41	5.38	0.32	1.77e-7	Renal cell carcinoma;
KIRP	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg16586182	chr3:47516702	SCAP	-0.72	-10.22	-0.55	1.16e-20	Colorectal cancer;
KIRP	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg18882449	chr10:104885122	NT5C2	-0.42	-5.4	-0.33	1.58e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.7	13.8	0.66	1.86e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg04166393	chr7:2884313	GNA12	0.65	8.37	0.47	4.29e-15	Height;
KIRP	cis	rs151997	0.962	rs32482	chr5:50207118	T/C	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.74	9.2	0.51	1.54e-17	Coronary artery disease;
KIRP	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg21132104	chr15:45694354	SPATA5L1	0.6	7.51	0.43	1.1e-12	Response to fenofibrate (adiponectin levels);
KIRP	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.17e-37	Height;
KIRP	cis	rs13067260	0.655	rs13326786	chr3:123747917	A/G	cg19918027	chr3:123987645	KALRN	-0.6	-5.42	-0.33	1.4e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.99	0.71	5.89e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-5.64	-0.34	4.62e-8	Huntington's disease progression;
KIRP	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.58	7.35	0.42	2.92e-12	Aortic root size;
KIRP	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.9	10.47	0.56	1.88e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.73	0.6	1.6e-25	Total body bone mineral density;
KIRP	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg26875233	chr11:93583750	C11orf90	-0.41	-7.57	-0.43	7.28e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.36	-0.38	9.64e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.83	11.48	0.59	1.01e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg24633833	chr3:10029261	TMEM111	-0.53	-5.11	-0.31	6.38e-7	Alzheimer's disease;
KIRP	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.92	-0.35	1.05e-8	Educational attainment (years of education);
KIRP	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.82	12.4	0.62	9.53e-28	Blood metabolite ratios;
KIRP	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.55	7.44	0.43	1.64e-12	Blood metabolite levels;
KIRP	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.08	-0.31	7.56e-7	Tonsillectomy;
KIRP	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.56	-4.97	-0.3	1.27e-6	Obesity (extreme);
KIRP	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg11833968	chr6:79620685	NA	-0.47	-6.99	-0.41	2.63e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.91	-0.3	1.68e-6	Longevity;
KIRP	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-0.86	-8.5	-0.48	1.82e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.62	6.7	0.39	1.4e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4006360	0.546	rs6416912	chr17:39253337	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.43	-0.47	2.97e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18255839	chr2:239335447	ASB1	0.44	5.23	0.32	3.62e-7	Multiple system atrophy;
KIRP	cis	rs35883536	0.967	rs1855788	chr1:101118331	A/G	cg06223162	chr1:101003688	GPR88	0.33	6.63	0.39	2.15e-10	Monocyte count;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26770187	chr3:14693171	C3orf19	-0.47	-6.25	-0.37	1.83e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.76	12.23	0.61	3.48e-27	Dupuytren's disease;
KIRP	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg16472389	chr18:74514291	NA	0.45	5.46	0.33	1.18e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
KIRP	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.72	7.57	0.43	7.68e-13	Pediatric areal bone mineral density (radius);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10511332	chr1:51166032	FAF1	0.44	6.7	0.39	1.37e-10	C-reactive protein;
KIRP	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg19257562	chr1:2043853	PRKCZ	0.41	6.75	0.4	1.07e-10	Height;
KIRP	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg08499158	chr17:42289980	UBTF	0.71	9.66	0.52	6.22e-19	Total body bone mineral density;
KIRP	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg05861140	chr6:150128134	PCMT1	-0.51	-7.15	-0.41	1e-11	Lung cancer;
KIRP	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.58	-0.34	6.38e-8	Diastolic blood pressure;
KIRP	cis	rs4262150	0.803	rs72799144	chr5:152102662	T/C	cg12297329	chr5:152029980	NA	-0.67	-8.34	-0.47	5.43e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.42	5.72	0.34	3.12e-8	Age-related hearing impairment;
KIRP	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/G	cg07918374	chr16:82182319	MPHOSPH6	-0.82	-8.47	-0.47	2.33e-15	Lung adenocarcinoma;
KIRP	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-7.09	-0.41	1.37e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	5.72	0.34	3.14e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg00677455	chr12:58241039	CTDSP2	-0.59	-7.01	-0.41	2.31e-11	Multiple sclerosis;
KIRP	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.43	-5.54	-0.33	7.81e-8	Renal cell carcinoma;
KIRP	cis	rs259842	0.859	rs259843	chr2:180736508	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.64	-0.34	4.77e-8	Blood protein levels;
KIRP	cis	rs7590368	0.779	rs3856465	chr2:10916670	C/T	cg15705551	chr2:10952987	PDIA6	0.46	4.95	0.3	1.39e-6	Educational attainment (years of education);
KIRP	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	11.06	0.58	2.33e-23	Smoking behavior;
KIRP	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg25173405	chr17:45401733	C17orf57	0.49	6.32	0.37	1.22e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.45	5.07	0.31	7.79e-7	Schizophrenia;
KIRP	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.34	5.94	0.35	9.83e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg23950597	chr19:37808831	NA	0.64	6.88	0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs17655565	0.543	rs2298797	chr12:52755189	A/G	cg07925835	chr12:52762777	KRT85	0.49	5.43	0.33	1.37e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.35	-5.1	-0.31	6.89e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-4.95	-0.3	1.4e-6	Response to amphetamines;
KIRP	cis	rs45430	0.635	rs398800	chr21:42742212	A/C	cg22778903	chr21:42741698	MX2	-0.41	-4.92	-0.3	1.61e-6	Melanoma;
KIRP	cis	rs1440410	0.835	rs7682068	chr4:144050379	A/G	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.16	0.42	9.02e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg26338869	chr17:61819248	STRADA	-0.54	-6.5	-0.38	4.46e-10	Prudent dietary pattern;
KIRP	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.49	-0.33	1e-7	Neutrophil percentage of white cells;
KIRP	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.51	-6.66	-0.39	1.75e-10	Aortic root size;
KIRP	cis	rs11625487	0.505	rs10145609	chr14:77957377	G/A	cg20045696	chr14:77926864	AHSA1	-0.5	-5.39	-0.33	1.62e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	trans	rs9944715	1.000	rs9944836	chr18:43831380	C/T	cg01718231	chr17:29326311	RNF135	0.52	6.12	0.36	3.7e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.37	0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9328573	1.000	rs9920711	chr15:100510478	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.45	-6.39	-0.38	8.29e-10	Urate levels in lean individuals;
KIRP	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.89	11.49	0.59	9.55e-25	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19856822	chr3:101293068	PCNP	0.51	6.2	0.37	2.37e-9	Parkinson's disease;
KIRP	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg05484376	chr2:27715224	FNDC4	0.4	6.46	0.38	5.52e-10	Total body bone mineral density;
KIRP	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg14930904	chr10:32216787	ARHGAP12	0.36	4.91	0.3	1.68e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs965513	1.000	rs7032019	chr9:100548144	G/A	cg13688889	chr9:100608707	NA	-0.6	-7.74	-0.44	2.61e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs7590368	0.683	rs12471762	chr2:10958258	C/T	cg15705551	chr2:10952987	PDIA6	0.61	5.66	0.34	4.2e-8	Educational attainment (years of education);
KIRP	trans	rs6810798	0.520	rs61435515	chr4:148329369	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.59	-6.96	-0.41	3.04e-11	Coronary artery disease;
KIRP	cis	rs11723261	0.527	rs11731581	chr4:87932	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.62	6.79	0.4	8.37e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs9896052	0.580	rs7406977	chr17:73460417	T/G	cg25649188	chr17:73499917	CASKIN2	0.51	6.63	0.39	2.11e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg27205649	chr11:78285834	NARS2	-0.61	-7.3	-0.42	3.91e-12	Alzheimer's disease (survival time);
KIRP	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg14541582	chr5:601475	NA	-0.57	-6.34	-0.37	1.09e-9	Obesity-related traits;
KIRP	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.75	-9.42	-0.51	3.55e-18	Height;
KIRP	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg13877915	chr19:58951672	ZNF132	0.9	13.28	0.65	1.06e-30	Uric acid clearance;
KIRP	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.65	-12.41	-0.62	8.66e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs728478	1.000	rs11079377	chr17:57453511	A/G	cg16535752	chr17:57448097	YPEL2	-0.22	-5.26	-0.32	3.16e-7	QT interval;
KIRP	cis	rs1712517	0.771	rs10883858	chr10:105127708	G/A	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.35e-9	Migraine;
KIRP	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.99	14.25	0.67	5.16e-34	Cognitive function;
KIRP	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.4	6.84	0.4	6.06e-11	Renal cell carcinoma;
KIRP	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7937612	0.965	rs4381380	chr11:120273316	A/G	cg24566217	chr11:120254723	ARHGEF12	0.49	7.15	0.41	9.93e-12	Intraocular pressure;
KIRP	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs2882667	0.515	rs13161286	chr5:138484105	A/G	cg04439458	chr5:138467593	SIL1	-0.53	-7.94	-0.45	6.98e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.74	-9.51	-0.52	1.84e-18	Coronary artery disease;
KIRP	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg21466736	chr12:48725269	NA	-0.53	-6.72	-0.39	1.28e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg17356467	chr2:100759845	AFF3	0.52	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21775007	chr8:11205619	TDH	-0.52	-7.25	-0.42	5.54e-12	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19485873	chr19:48972334	CYTH2	0.49	6.19	0.37	2.45e-9	Parkinson's disease;
KIRP	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.54	-6.41	-0.38	7.34e-10	Macular telangiectasia type 2;
KIRP	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.83	-0.4	6.8e-11	Aortic root size;
KIRP	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-4.84	-0.3	2.26e-6	Blood protein levels;
KIRP	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.26	-0.32	3.18e-7	Aortic root size;
KIRP	trans	rs12544026	0.548	rs542208	chr8:102900851	C/T	cg19131667	chr3:17236940	TBC1D5	0.38	6.07	0.36	4.84e-9	Major depression and alcohol dependence;
KIRP	cis	rs977987	0.800	rs11149815	chr16:75336173	T/G	cg03315344	chr16:75512273	CHST6	0.67	9.72	0.53	4.17e-19	Dupuytren's disease;
KIRP	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.25e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs17221829	0.733	rs11018684	chr11:89364863	A/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs367943	0.712	rs26959	chr5:112736615	A/G	cg12552261	chr5:112820674	MCC	0.56	6.68	0.39	1.62e-10	Type 2 diabetes;
KIRP	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	5.86	0.35	1.5e-8	Schizophrenia;
KIRP	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-6.18	-0.37	2.66e-9	Bladder cancer;
KIRP	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg11738485	chr19:12877000	HOOK2	-0.48	-5.57	-0.33	6.63e-8	Mean corpuscular volume;
KIRP	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.85	0.6	6.19e-26	Smoking behavior;
KIRP	cis	rs2970992	0.817	rs10197891	chr2:101334579	C/T	cg01042948	chr2:101319752	NA	0.4	5.78	0.35	2.25e-8	Educational attainment;
KIRP	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg02297831	chr4:17616191	MED28	-0.55	-6.43	-0.38	6.43e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.35	0.38	1.02e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg14703610	chr5:56206110	C5orf35	0.47	6.12	0.36	3.57e-9	Coronary artery disease;
KIRP	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.93	9.77	0.53	2.92e-19	Methadone dose in opioid dependence;
KIRP	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.78	-9.99	-0.54	5.96e-20	Coronary artery disease;
KIRP	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.37	0.32	1.82e-7	Retinal vascular caliber;
KIRP	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.64	6.38	0.38	8.71e-10	Axial length;
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg05627522	chr15:75251581	NA	0.34	4.98	0.3	1.19e-6	Caffeine consumption;
KIRP	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.5	-0.38	4.41e-10	Menopause (age at onset);
KIRP	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.04	-0.46	3.68e-14	Coronary artery disease;
KIRP	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.64	7.46	0.43	1.5e-12	Alcohol dependence;
KIRP	cis	rs13424612	1.000	rs13424612	chr2:240900121	C/T	cg01812947	chr2:240904978	NDUFA10	0.47	6.24	0.37	1.9e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg19847866	chr10:1019161	NA	-0.45	-5.26	-0.32	3.06e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg24747557	chr10:131355152	MGMT	-0.43	-5.69	-0.34	3.54e-8	Response to temozolomide;
KIRP	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-6.93	-0.4	3.65e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.62	9.57	0.52	1.19e-18	Lung cancer;
KIRP	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs2723064	0.516	rs17849707	chr2:65298839	A/G	cg05010058	chr2:65284262	CEP68	0.44	5.13	0.31	5.76e-7	Atrial fibrillation;
KIRP	cis	rs11138902	0.599	rs11139294	chr9:72165585	G/A	cg14397918	chr9:72078829	APBA1	0.34	5.28	0.32	2.85e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs11605924	0.901	rs7112505	chr11:45840939	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.48	-5.83	-0.35	1.69e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg13264159	chr8:625131	ERICH1	0.7	6.04	0.36	5.76e-9	IgG glycosylation;
KIRP	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.42	-4.99	-0.3	1.12e-6	Blood metabolite levels;
KIRP	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg08992911	chr2:238395768	MLPH	0.43	5.21	0.32	3.93e-7	Prostate cancer;
KIRP	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg00147788	chr6:125855365	NA	-0.34	-5.22	-0.32	3.88e-7	Brugada syndrome;
KIRP	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg15282417	chr9:129245246	FAM125B	0.44	7.46	0.43	1.46e-12	Intraocular pressure;
KIRP	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17554472	chr22:41940697	POLR3H	-0.69	-6.97	-0.41	2.92e-11	Vitiligo;
KIRP	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.65	9.15	0.5	2.28e-17	Bladder cancer;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg02733842	chr7:1102375	C7orf50	-0.5	-5.21	-0.32	4.02e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs1697139	0.528	rs7725332	chr5:66529458	T/C	cg11553311	chr5:66541588	NA	0.37	5.21	0.32	3.91e-7	Breast cancer;
KIRP	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg18932078	chr1:2524107	MMEL1	0.4	5.43	0.33	1.37e-7	Ulcerative colitis;
KIRP	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.21	-0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11708118	chr12:6862968	MLF2	0.43	6.13	0.36	3.52e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11997175	0.583	rs67830367	chr8:33833788	G/C	cg04338863	chr8:33670619	NA	0.49	6.62	0.39	2.26e-10	Body mass index;
KIRP	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg11204139	chr17:3907470	NA	0.5	5.61	0.34	5.32e-8	Type 2 diabetes;
KIRP	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg24375607	chr4:120327624	NA	-0.47	-5.68	-0.34	3.82e-8	Corneal astigmatism;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12074154	chr1:181074635	NA	-0.52	-7.17	-0.42	8.53e-12	Metabolic traits;
KIRP	cis	rs4774899	0.966	rs12904501	chr15:57507617	C/T	cg13626582	chr15:57592083	LOC283663	-0.21	-5.04	-0.31	8.88e-7	Urinary tract infection frequency;
KIRP	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.66	-7.16	-0.42	9.08e-12	Blood pressure (smoking interaction);
KIRP	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-0.79	-10.96	-0.57	5.22e-23	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs12517041	1.000	rs13156787	chr5:23280382	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.36	-0.47	4.82e-15	Calcium levels;
KIRP	cis	rs879620	1.000	rs2531995	chr16:4013467	C/T	cg09300795	chr16:4042428	ADCY9	0.41	5.41	0.33	1.52e-7	Hip circumference;Body mass index;
KIRP	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.53	-4.86	-0.3	2.05e-6	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18375586	chr10:15413437	FAM171A1	0.53	6.63	0.39	2.1e-10	Parkinson's disease;
KIRP	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg25547332	chr5:131281432	NA	-0.47	-5.3	-0.32	2.59e-7	Life satisfaction;
KIRP	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	12.29	0.62	2.14e-27	Menarche (age at onset);
KIRP	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.72	8.91	0.49	1.13e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.76	-0.34	2.49e-8	Huntington's disease progression;
KIRP	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.53	5.15	0.31	5.31e-7	Schizophrenia;
KIRP	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.39	-0.43	2.24e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.76	9.2	0.51	1.58e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	cg21523751	chr1:182988639	NA	0.34	4.9	0.3	1.72e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg08499158	chr17:42289980	UBTF	0.49	6.26	0.37	1.71e-9	Total body bone mineral density;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.14	-0.31	5.73e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2446066	0.605	rs7314664	chr12:53957586	T/C	cg16917193	chr12:54089295	NA	0.7	5.26	0.32	3.2e-7	Red blood cell count;
KIRP	cis	rs9475752	0.793	rs6904924	chr6:56813639	G/A	cg22880620	chr6:56820808	BEND6;DST	0.5	5.17	0.31	4.96e-7	Menarche (age at onset);
KIRP	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg25173405	chr17:45401733	C17orf57	-0.5	-6.52	-0.38	3.92e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.44	6.73	0.39	1.17e-10	Resistin levels;
KIRP	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg11508081	chr17:41442227	NA	-0.37	-4.95	-0.3	1.36e-6	Menopause (age at onset);
KIRP	trans	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	cis	rs12367572	0.663	rs1857926	chr12:45344524	C/T	cg04608330	chr12:45269318	NELL2	-0.4	-5.49	-0.33	1.02e-7	Gut microbiome composition (summer);
KIRP	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg23188430	chr6:125850052	NA	-0.35	-5.32	-0.32	2.33e-7	High light scatter reticulocyte count;
KIRP	cis	rs16936870	0.543	rs2957094	chr8:71070527	A/T	cg14232793	chr8:71155543	NCOA2	-0.55	-6.32	-0.37	1.21e-9	QT interval;
KIRP	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg00204512	chr16:28754710	NA	0.4	5.08	0.31	7.59e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16104446	chr8:48873951	MCM4;PRKDC	0.5	6.63	0.39	2.16e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.41	-0.33	1.47e-7	Bipolar disorder;
KIRP	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.87	0.53	1.4e-19	Corneal astigmatism;
KIRP	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs80215559	0.661	rs115740542	chr6:26123502	T/C	cg17691542	chr6:26056736	HIST1H1C	0.9	5.56	0.33	7.09e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs6684428	1.000	rs12141873	chr1:56374311	G/T	cg11651538	chr1:56320950	NA	-0.89	-11.08	-0.58	2.13e-23	Airflow obstruction;
KIRP	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.46	5.34	0.32	2.09e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg26784012	chr10:32216390	ARHGAP12	0.32	5.18	0.31	4.57e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-6.69	-0.39	1.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.64	-0.78	2.71e-52	Height;
KIRP	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.82	9.49	0.52	2.09e-18	Corneal astigmatism;
KIRP	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	9.14	0.5	2.4e-17	Systemic lupus erythematosus;
KIRP	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs6991838	0.584	rs6472218	chr8:66547737	G/C	cg13398993	chr8:66546079	ARMC1	0.45	5.2	0.31	4.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	1.000	rs73539529	chr11:71815596	T/C	cg07596299	chr11:71824057	C11orf51	0.62	4.94	0.3	1.43e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05347473	chr6:146136440	FBXO30	-0.46	-6.33	-0.37	1.13e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-7.13	-0.41	1.12e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.59	-7.64	-0.44	4.77e-13	Triglyceride levels;
KIRP	cis	rs7870753	0.786	rs10739886	chr9:99201983	A/G	cg25260653	chr9:99212216	HABP4	0.57	6.04	0.36	5.51e-9	Height;
KIRP	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-0.96	-9.39	-0.51	4.16e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs16828019	0.777	rs12748235	chr1:41466221	G/A	cg18742814	chr1:41828276	NA	0.68	5.73	0.34	2.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg13147721	chr7:65941812	NA	-0.89	-6.36	-0.38	9.62e-10	Diabetic kidney disease;
KIRP	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg03959625	chr15:84868606	LOC388152	0.59	6.99	0.41	2.63e-11	Schizophrenia;
KIRP	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg08501292	chr6:25962987	TRIM38	0.81	5.5	0.33	9.56e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.2	0.37	2.37e-9	Retinal vascular caliber;
KIRP	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.98	12.34	0.62	1.49e-27	Response to antineoplastic agents;
KIRP	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.51	-4.98	-0.3	1.17e-6	Diastolic blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07700062	chr1:236767390	HEATR1	0.46	6.32	0.37	1.22e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg02980000	chr4:1222292	CTBP1	0.78	8.91	0.49	1.15e-16	Systolic blood pressure;
KIRP	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg05768032	chr16:30646687	NA	0.44	5.07	0.31	7.9e-7	Multiple myeloma;
KIRP	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg01620082	chr3:125678407	NA	-1.18	-7.63	-0.44	5.19e-13	Depression;
KIRP	cis	rs4332428	1.000	rs5011018	chr10:4967006	C/G	cg19648686	chr10:5044992	AKR1C2	-0.89	-7.95	-0.45	6.81e-14	Height;
KIRP	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.73	-7.03	-0.41	2.02e-11	Body mass index;
KIRP	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg05347473	chr6:146136440	FBXO30	0.5	6.88	0.4	5.04e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg01658259	chr14:24837143	NFATC4	0.38	5.1	0.31	6.84e-7	Height;
KIRP	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg07936489	chr17:37558343	FBXL20	-0.79	-9.92	-0.53	9.83e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs4356932	1.000	rs6532121	chr4:76962606	A/T	cg00809888	chr4:76862425	NAAA	-0.44	-6.08	-0.36	4.66e-9	Blood protein levels;
KIRP	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.82	-11.93	-0.61	3.47e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg24250549	chr1:154909240	PMVK	0.42	5.23	0.32	3.61e-7	Schizophrenia;
KIRP	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg04317338	chr11:64019027	PLCB3	0.56	6.57	0.39	2.94e-10	Platelet count;
KIRP	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.7	8.94	0.5	9.29e-17	Coronary artery disease;
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg13198984	chr17:80129470	CCDC57	-0.55	-8.24	-0.47	1.02e-14	Life satisfaction;
KIRP	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00321850	chr1:175162397	KIAA0040	-0.34	-6.06	-0.36	5.05e-9	Alcohol dependence;
KIRP	cis	rs17123764	0.710	rs11169118	chr12:50102535	C/T	cg20471783	chr12:50157085	TMBIM6	0.31	4.89	0.3	1.83e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.46	-6.59	-0.39	2.59e-10	Gout;
KIRP	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.94	16.07	0.72	3.25e-40	Height;
KIRP	cis	rs1829883	0.697	rs2688917	chr5:98739033	A/G	cg08333243	chr5:99726346	NA	0.38	4.91	0.3	1.63e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4523957	0.928	rs422632	chr17:2162049	G/A	cg16513277	chr17:2031491	SMG6	0.58	8.01	0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs11786541	0.521	rs2409619	chr8:9817420	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.89	-0.4	4.71e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.65	-9.94	-0.54	8.51e-20	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13940125	chr1:197237119	CRB1	0.38	6.09	0.36	4.29e-9	C-reactive protein;
KIRP	cis	rs9876781	0.559	rs1841178	chr3:48397046	C/T	cg11946769	chr3:48343235	NME6	0.42	5.27	0.32	3.01e-7	Longevity;
KIRP	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg00977110	chr5:151150581	G3BP1	0.62	6.23	0.37	1.99e-9	Preschool internalizing problems;
KIRP	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.9	9.62	0.52	8.71e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg23698023	chr8:27181813	PTK2B	0.34	5.08	0.31	7.57e-7	Neuroticism;
KIRP	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	trans	rs12431410	0.536	rs2094058	chr14:60153555	A/G	cg20601314	chr10:104179541	FBXL15;PSD	-0.56	-6.11	-0.36	3.82e-9	Schizophrenia;
KIRP	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	cis	rs240764	0.817	rs239221	chr6:101113085	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.63	-9.67	-0.52	5.8e-19	Vitiligo;
KIRP	cis	rs330048	0.510	rs11784654	chr8:8969611	T/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.38	-0.32	1.74e-7	Systemic lupus erythematosus;
KIRP	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs6083	0.571	rs41294813	chr15:58847807	T/C	cg05156742	chr15:59063176	FAM63B	-0.5	-6.15	-0.37	3.06e-9	Schizophrenia;
KIRP	cis	rs2880765	0.527	rs35184622	chr15:86073035	A/G	cg15340431	chr15:86040528	AKAP13	-0.46	-5.85	-0.35	1.56e-8	Coronary artery disease;
KIRP	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-7.45	-0.43	1.55e-12	Electroencephalogram traits;
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg08989290	chr16:615782	NHLRC4	0.41	5.87	0.35	1.37e-8	Height;
KIRP	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.93	-11.07	-0.58	2.2e-23	White matter hyperintensity burden;
KIRP	cis	rs9309473	0.583	rs11899517	chr2:73573261	A/G	cg20560298	chr2:73613845	ALMS1	-0.52	-6.26	-0.37	1.71e-9	Metabolite levels;
KIRP	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg17279839	chr7:150038598	RARRES2	0.42	5.38	0.32	1.77e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02359409	chr6:42947317	PEX6	-0.5	-6.98	-0.41	2.79e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.94	-0.54	8.37e-20	Total body bone mineral density;
KIRP	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.79	10.82	0.57	1.44e-22	Aortic root size;
KIRP	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg07884673	chr3:53033167	SFMBT1	1.01	7.76	0.44	2.23e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg17810781	chr1:201082982	CACNA1S	0.43	6.98	0.41	2.8e-11	Permanent tooth development;
KIRP	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs4849845	0.889	rs1370380	chr2:121014895	G/A	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs6841333	0.812	rs4241577	chr4:76930776	C/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.47	-5.26	-0.32	3.07e-7	Monokine induced by gamma interferon levels;
KIRP	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-5.05	-0.31	8.44e-7	Renal cell carcinoma;
KIRP	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.78	0.4	8.62e-11	Lung cancer;
KIRP	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-8.33	-0.47	5.8e-15	Blood protein levels;
KIRP	cis	rs1010254	0.510	rs10515658	chr5:151758452	C/T	cg12297329	chr5:152029980	NA	-0.71	-6.92	-0.4	3.99e-11	Optic nerve measurement (cup area);
KIRP	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg01872077	chr2:219646372	CYP27A1	-0.37	-5.1	-0.31	6.78e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.4	-0.51	3.82e-18	Chronic sinus infection;
KIRP	cis	rs3774830	0.748	rs7698146	chr4:5465476	G/A	cg26943120	chr4:5472116	STK32B	0.24	5.87	0.35	1.4e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs16937956	0.688	rs10500704	chr11:8451224	C/T	cg08015107	chr11:8618950	NA	-0.58	-7.4	-0.43	2.16e-12	Body mass index;
KIRP	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg11130432	chr3:121712080	ILDR1	-0.48	-4.88	-0.3	1.88e-6	Multiple sclerosis;
KIRP	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg20673091	chr1:2541236	MMEL1	-0.78	-12.67	-0.63	1.21e-28	Ulcerative colitis;
KIRP	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg16268157	chr7:99778414	STAG3	-0.55	-6.02	-0.36	6.29e-9	Lung function (FEV1/FVC);
KIRP	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg03060546	chr3:49711283	APEH	0.48	5.38	0.32	1.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.72	11.05	0.58	2.53e-23	Dupuytren's disease;
KIRP	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg15841412	chr13:111365552	ING1	-0.53	-6.22	-0.37	2.07e-9	Coronary artery disease;
KIRP	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.91	-0.35	1.12e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg20699497	chr19:49944642	SLC17A7	0.46	6.13	0.36	3.47e-9	Bladder cancer;
KIRP	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg19875535	chr5:140030758	IK	-0.72	-10.41	-0.55	2.81e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2224391	0.628	rs6913120	chr6:5260505	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.33	-0.37	1.13e-9	Height;
KIRP	cis	rs4713118	0.540	rs469227	chr6:27970705	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.45	-4.99	-0.3	1.12e-6	Parkinson's disease;
KIRP	cis	rs4727443	0.736	rs4727444	chr7:99614851	T/A	cg22004693	chr7:99632812	ZKSCAN1	0.39	4.98	0.3	1.19e-6	Interstitial lung disease;
KIRP	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.15	-0.31	5.23e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-8.29	-0.47	7.54e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.26	-5.32	-0.32	2.39e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05051957	chr8:141522459	CHRAC1	0.55	6.16	0.37	2.96e-9	Lung cancer in ever smokers;
KIRP	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00290607	chr11:67383545	NA	0.35	4.9	0.3	1.76e-6	Mean corpuscular volume;
KIRP	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg00495681	chr13:53174319	NA	0.37	5.12	0.31	6.23e-7	Lewy body disease;
KIRP	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	12.02	0.61	1.79e-26	Blood protein levels;
KIRP	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg08975724	chr8:8085496	FLJ10661	0.63	8.31	0.47	6.46e-15	Joint mobility (Beighton score);
KIRP	cis	rs8084125	0.938	rs2097094	chr18:74942422	G/A	cg26065057	chr18:74961000	GALR1	0.77	7.54	0.43	9.21e-13	Obesity-related traits;
KIRP	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.47	5.17	0.31	4.91e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25809561	chr17:30822961	MYO1D	0.6	7.86	0.45	1.17e-13	Schizophrenia;
KIRP	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.61	8.6	0.48	9.67e-16	Schizophrenia;
KIRP	cis	rs6800768	0.633	rs58523227	chr3:24116856	C/A	cg10674438	chr3:24145617	LOC152024	-0.44	-5.91	-0.35	1.15e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.51	-5.12	-0.31	6.16e-7	Alzheimer's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22509679	chr12:10379548	NA	0.4	6.48	0.38	4.96e-10	Survival in pancreatic cancer;
KIRP	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg27124370	chr19:33622961	WDR88	0.59	7.27	0.42	4.72e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg17279839	chr7:150038598	RARRES2	0.46	6.12	0.36	3.58e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.37	6.19	0.37	2.49e-9	Heart rate;
KIRP	cis	rs7666738	0.515	rs11733968	chr4:98906448	A/C	cg05340658	chr4:99064831	C4orf37	-0.65	-7.82	-0.45	1.58e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs2179367	0.887	rs6570965	chr6:149717476	C/A	cg03678062	chr6:149772716	ZC3H12D	-0.31	-5.03	-0.31	9.5e-7	Dupuytren's disease;
KIRP	cis	rs4646404	0.582	rs35104205	chr17:17478775	C/A	cg01246520	chr17:17644344	RAI1	-0.3	-5.05	-0.31	8.69e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.82	8.05	0.46	3.6e-14	Neuroblastoma;
KIRP	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg07511668	chr11:68622177	NA	0.39	5.25	0.32	3.34e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.73	0.39	1.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.4	4.85	0.3	2.16e-6	Renal cell carcinoma;
KIRP	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00585698	chr12:123750864	CDK2AP1	0.42	5.24	0.32	3.41e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg02462569	chr6:150064036	NUP43	-0.34	-5.35	-0.32	1.99e-7	Lung cancer;
KIRP	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.5	6.4	0.38	8.01e-10	Asthma;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg10253484	chr15:75165896	SCAMP2	-0.48	-5.67	-0.34	4.09e-8	Breast cancer;
KIRP	cis	rs7870753	0.628	rs7857610	chr9:99189953	C/T	cg25260653	chr9:99212216	HABP4	0.56	5.72	0.34	3.06e-8	Height;
KIRP	cis	rs151997	0.671	rs152099	chr5:50210091	A/G	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	cis	rs7870753	0.838	rs7867323	chr9:99248057	A/C	cg25260653	chr9:99212216	HABP4	0.56	5.97	0.36	8.41e-9	Height;
KIRP	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-19.59	-0.78	3.86e-52	Schizophrenia;
KIRP	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg19468946	chr17:37922297	IKZF3	-0.43	-6.13	-0.36	3.51e-9	Asthma;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.42e-6	Life satisfaction;
KIRP	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg17554472	chr22:41940697	POLR3H	0.68	7.1	0.41	1.32e-11	Vitiligo;
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg08662619	chr6:150070041	PCMT1	0.36	5.94	0.35	9.46e-9	Lung cancer;
KIRP	cis	rs6968419	0.747	rs56293030	chr7:115857170	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.55	6.76	0.4	9.72e-11	Subjective well-being;
KIRP	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.91	13.94	0.66	5.91e-33	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg06521331	chr12:34319734	NA	0.54	6.78	0.4	9.06e-11	Heart rate;
KIRP	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg18190219	chr22:46762943	CELSR1	0.63	7.23	0.42	5.96e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08822215	chr16:89438651	ANKRD11	-0.5	-6.6	-0.39	2.48e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs4926611	1.000	rs2037739	chr1:54115023	G/T	cg08927728	chr1:54059983	GLIS1	-0.25	-5.45	-0.33	1.23e-7	Hand grip strength;
KIRP	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg15352829	chr14:105391018	PLD4	-0.47	-9.36	-0.51	5.05e-18	Rheumatoid arthritis;
KIRP	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.53	-8.14	-0.46	1.96e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07542475	chr3:44903330	MIR564;TMEM42	0.46	6.13	0.36	3.51e-9	Parkinson's disease;
KIRP	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-1.06	-10.16	-0.54	1.81e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.52	0.33	8.76e-8	Body mass index;
KIRP	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.69	-9.15	-0.5	2.2e-17	Huntington's disease progression;
KIRP	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	1.05	19.59	0.78	4.01e-52	Monocyte count;
KIRP	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg00405596	chr8:11794950	NA	-0.44	-5.8	-0.35	2.01e-8	Systolic blood pressure;
KIRP	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.52	-0.33	8.54e-8	Height;
KIRP	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	0.93	13.64	0.66	6.32e-32	Diastolic blood pressure;
KIRP	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.47	7.19	0.42	7.98e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18247638	chr13:103451366	KDELC1;BIVM	0.55	6.09	0.36	4.36e-9	Lung cancer in ever smokers;
KIRP	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.44	-0.43	1.73e-12	Bipolar disorder;
KIRP	cis	rs16858210	0.874	rs35717944	chr3:183607361	C/A	cg25686905	chr3:183603175	PARL	-0.5	-6.31	-0.37	1.31e-9	Menopause (age at onset);
KIRP	trans	rs74233809	0.901	rs4409766	chr10:104616663	A/G	cg26199906	chr8:145106246	OPLAH	-0.42	-6.45	-0.38	5.84e-10	Birth weight;
KIRP	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg25547332	chr5:131281432	NA	0.46	5.33	0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.37	0.59	2.42e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.75	7.81	0.45	1.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11955175	1.000	rs11954632	chr5:40674929	C/G	cg17351974	chr5:40835760	RPL37	0.54	4.9	0.3	1.73e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg09175582	chr1:161736000	ATF6	0.72	5.83	0.35	1.73e-8	IgG glycosylation;
KIRP	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg09904177	chr6:26538194	HMGN4	0.4	4.95	0.3	1.4e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23903597	chr17:61704154	MAP3K3	-0.57	-6.91	-0.4	4.14e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24229701	chr12:130821962	PIWIL1	-0.44	-5.58	-0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs57905270	1.000	rs57905270	chr2:228486714	G/T	cg12489444	chr2:228498029	C2orf83	-0.52	-5.99	-0.36	7.47e-9	Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction);
KIRP	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.74	-8.39	-0.47	3.81e-15	Coronary artery disease;
KIRP	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.95	18.19	0.76	2e-47	Dental caries;
KIRP	cis	rs17592366	0.838	rs79348607	chr14:35278675	A/G	cg09327582	chr14:35236912	BAZ1A	0.67	5.12	0.31	6.3e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs11731606	0.508	rs17021533	chr4:95280587	C/T	cg20625393	chr4:95128694	SMARCAD1	0.53	5.09	0.31	7.06e-7	Mean platelet volume;
KIRP	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	1.01	17.76	0.75	5.61e-46	Breast cancer;
KIRP	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.44	-0.47	2.78e-15	Colorectal cancer;
KIRP	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg21605333	chr4:119757512	SEC24D	1.67	11.86	0.6	5.89e-26	Cannabis dependence symptom count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02464098	chr8:26240309	BNIP3L	0.5	6.83	0.4	6.7e-11	Survival in pancreatic cancer;
KIRP	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.45	-5.38	-0.32	1.75e-7	Bacteremia;
KIRP	cis	rs7172677	1.000	rs11638746	chr15:75403108	A/C	cg14082893	chr15:75400931	NA	-0.37	-5.4	-0.33	1.58e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.66	-0.34	4.18e-8	Height;
KIRP	cis	rs6662572	0.737	rs111970066	chr1:46572817	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.77	0.35	2.41e-8	Blood protein levels;
KIRP	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.99	-0.36	7.42e-9	Obesity-related traits;
KIRP	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.34	-5.15	-0.31	5.44e-7	QRS complex (12-leadsum);
KIRP	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.13	0.5	2.62e-17	Colorectal cancer;
KIRP	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg19913688	chr11:428466	ANO9	-0.72	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg00343986	chr7:65444356	GUSB	0.43	5.14	0.31	5.64e-7	Aortic root size;
KIRP	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	0.97	10.59	0.56	7.97e-22	Eosinophil percentage of granulocytes;
KIRP	trans	rs1530530	1.000	rs3803221	chr13:25241724	A/G	cg03355690	chr6:35265616	DEF6	0.5	6.09	0.36	4.4e-9	Obesity-related traits;
KIRP	cis	rs1829883	0.835	rs2682139	chr5:98909924	G/A	cg08333243	chr5:99726346	NA	0.4	5.29	0.32	2.68e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2904967	0.703	rs676114	chr11:65076918	C/T	cg12562828	chr11:65076843	NA	0.89	11.76	0.6	1.23e-25	Mean corpuscular volume;
KIRP	cis	rs3812111	0.510	rs6930059	chr6:116577623	T/C	cg18828861	chr6:116576566	TSPYL4	0.42	4.87	0.3	1.98e-6	Age-related macular degeneration;
KIRP	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg14593290	chr7:50529359	DDC	-0.75	-9.36	-0.51	5.22e-18	Malaria;
KIRP	cis	rs7715806	0.500	rs72633984	chr5:75005899	A/G	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg16898833	chr6:26189333	HIST1H4D	0.64	4.89	0.3	1.8e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6545883	0.860	rs13023037	chr2:61620989	C/T	cg15711740	chr2:61764176	XPO1	0.61	8.1	0.46	2.62e-14	Tuberculosis;
KIRP	cis	rs4690686	0.500	rs35703625	chr4:177263286	G/A	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.58	6.04	0.36	5.64e-9	Vitiligo;
KIRP	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg16584676	chr17:46985605	UBE2Z	0.49	6.03	0.36	5.82e-9	Type 2 diabetes;
KIRP	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.61	8.22	0.46	1.21e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	1.08	19.66	0.78	2.32e-52	Systemic lupus erythematosus;
KIRP	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg11608241	chr8:8085544	FLJ10661	-0.45	-5.29	-0.32	2.68e-7	Recombination measurement;
KIRP	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.48	-0.38	4.93e-10	LDL cholesterol levels;
KIRP	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.83	-12.44	-0.62	6.76e-28	Neurofibrillary tangles;
KIRP	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg07167872	chr1:205819463	PM20D1	0.56	6.05	0.36	5.49e-9	Basophil percentage of granulocytes;
KIRP	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.69	8.76	0.49	3.16e-16	Resting heart rate;
KIRP	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-6.38	-0.38	8.52e-10	Asthma;
KIRP	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.06	0.36	4.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.97	13.8	0.66	1.82e-32	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	1.12	10.26	0.55	8.5e-21	Lymphocyte counts;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21994174	chr19:51870364	CLDND2;ETFB	0.52	6.19	0.37	2.49e-9	Inflammatory biomarkers;
KIRP	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.47	-6.96	-0.41	3.09e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7833787	0.965	rs7830045	chr8:18700282	A/C	cg17701159	chr8:18705777	PSD3	-0.33	-5.85	-0.35	1.58e-8	Obesity-related traits;
KIRP	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	trans	rs1106684	1.000	rs12531216	chr7:131466691	A/G	cg13607082	chr12:122652224	LRRC43	-0.66	-6.44	-0.38	6.27e-10	Body mass index;
KIRP	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.38	-0.47	3.97e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg01616529	chr11:638424	DRD4	-0.42	-5.62	-0.34	5.26e-8	Systemic lupus erythematosus;
KIRP	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg18657303	chr4:1051139	NA	0.54	4.95	0.3	1.38e-6	Recombination rate (females);
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg19893067	chr17:80732956	TBCD	-0.38	-5.29	-0.32	2.68e-7	Glycated hemoglobin levels;
KIRP	cis	rs7106204	0.748	rs12293729	chr11:24224679	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	9.61	0.52	9.01e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.4	0.38	7.91e-10	Aortic root size;
KIRP	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg20701182	chr2:24300061	SF3B14	0.5	4.97	0.3	1.24e-6	Lymphocyte counts;
KIRP	cis	rs4950322	0.515	rs11239958	chr1:146719108	G/A	cg22381352	chr1:146742008	CHD1L	-0.4	-4.96	-0.3	1.29e-6	Protein quantitative trait loci;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10188592	chr2:198364785	HSPE1;HSPD1	-0.56	-6.34	-0.37	1.08e-9	Menopause (age at onset);
KIRP	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg06217071	chr17:408420	NA	0.67	10.95	0.57	5.59e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg02725872	chr8:58115012	NA	-0.46	-5.36	-0.32	1.88e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg18190219	chr22:46762943	CELSR1	-0.7	-5.98	-0.36	7.77e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7809615	0.901	rs10215765	chr7:99101280	G/C	cg12290671	chr7:99195819	NA	-0.71	-6.76	-0.4	1.02e-10	Blood metabolite ratios;
KIRP	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg26513180	chr16:89883248	FANCA	0.75	5.28	0.32	2.89e-7	Skin colour saturation;
KIRP	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.74	-9.49	-0.52	2.06e-18	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.75	10.79	0.57	1.76e-22	Parkinson's disease;
KIRP	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg01877450	chr7:97915802	BRI3	0.48	6.55	0.39	3.34e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.59	-12.45	-0.62	6.65e-28	Diabetic kidney disease;
KIRP	cis	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg21775007	chr8:11205619	TDH	0.49	6.47	0.38	5.26e-10	Rheumatoid arthritis;
KIRP	cis	rs6499755	0.712	rs31101	chr16:55371678	G/A	cg05099576	chr16:55362342	IRX6	0.28	5.74	0.34	2.84e-8	Hypospadias;
KIRP	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs7520050	0.966	rs1707336	chr1:46493460	T/G	cg03146154	chr1:46216737	IPP	-0.43	-5.33	-0.32	2.2e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.68	-7.3	-0.42	3.97e-12	Corneal structure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09997339	chr21:35743006	KCNE2	0.58	7.32	0.42	3.41e-12	Interleukin-4 levels;
KIRP	cis	rs754423	0.674	rs979481	chr14:52533443	A/G	cg10149976	chr14:52535953	NID2	0.37	5.65	0.34	4.39e-8	Craniofacial microsomia;
KIRP	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg10117171	chr1:25599238	RHD	-0.4	-5.3	-0.32	2.63e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs6083	0.549	rs11858020	chr15:58852422	A/T	cg05156742	chr15:59063176	FAM63B	0.51	6.35	0.38	1.05e-9	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06130950	chr11:123612538	ZNF202	-0.45	-6.22	-0.37	2.18e-9	Survival in pancreatic cancer;
KIRP	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs2223471	0.742	rs13213461	chr6:50659931	G/T	cg03432817	chr6:50765336	NA	0.43	6.79	0.4	8.4e-11	Subcutaneous adipose tissue;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17408707	chr6:131905062	MED23;ARG1	0.4	6.25	0.37	1.81e-9	C-reactive protein;
KIRP	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg00933542	chr6:150070202	PCMT1	0.26	5.02	0.3	9.86e-7	Testicular germ cell tumor;
KIRP	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg04865290	chr3:52927548	TMEM110	0.54	6.21	0.37	2.21e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.88	0.35	1.3e-8	Neutrophil percentage of white cells;
KIRP	cis	rs12143943	0.866	rs4252713	chr1:204510528	G/A	cg20240347	chr1:204465584	NA	-0.35	-6.43	-0.38	6.64e-10	Cognitive performance;
KIRP	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.8	-0.53	2.39e-19	Response to antipsychotic treatment;
KIRP	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.51	7.14	0.41	1.06e-11	Glioblastoma;Glioma;
KIRP	cis	rs9311676	0.632	rs67904096	chr3:58365508	T/A	cg06643156	chr3:58380774	PXK	0.36	5.1	0.31	6.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg21926883	chr2:100939477	LONRF2	0.64	8.87	0.49	1.54e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg11814155	chr7:99998594	ZCWPW1	0.58	5.41	0.33	1.53e-7	Platelet count;
KIRP	cis	rs9815354	0.812	rs73071343	chr3:41826877	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg00806126	chr19:22604979	ZNF98	0.67	7.05	0.41	1.8e-11	Pain;
KIRP	cis	rs1050631	0.564	rs1625385	chr18:33717364	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs6732160	0.613	rs58317144	chr2:73388153	C/T	cg01422370	chr2:73384389	NA	0.51	6.82	0.4	7.05e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16345355	chr16:71928893	KIAA0174	0.49	6.16	0.37	3.02e-9	Parkinson's disease;
KIRP	cis	rs9310736	0.782	rs1505283	chr3:24345776	A/G	cg12405742	chr3:24535365	THRB	-0.32	-4.85	-0.3	2.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;Red blood cell traits;
KIRP	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg15131784	chr3:139108705	COPB2	0.4	5.01	0.3	1.04e-6	Obesity-related traits;
KIRP	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg00530320	chr1:46809349	NSUN4	0.41	5.06	0.31	8.32e-7	Menopause (age at onset);
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.57	-8.89	-0.49	1.35e-16	Lymphocyte counts;
KIRP	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg02297831	chr4:17616191	MED28	-0.47	-5.66	-0.34	4.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs960902	0.747	rs13412538	chr2:37724623	T/C	cg25341268	chr2:37734390	NA	0.54	7.15	0.41	9.81e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.8	-11.38	-0.59	2.22e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs13102973	0.640	rs11737779	chr4:135831516	C/T	cg14419869	chr4:135874104	NA	0.48	7.78	0.44	1.97e-13	Subjective well-being;
KIRP	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.73e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.29	-0.47	7.39e-15	Mood instability;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09517757	chr8:58174422	NA	0.6	8.61	0.48	8.66e-16	Interleukin-4 levels;
KIRP	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs2425143	1.000	rs4602287	chr20:34368028	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	6.0	0.36	7.1e-9	Blood protein levels;
KIRP	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.35	0.38	1.01e-9	Retinal vascular caliber;
KIRP	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg09873164	chr1:152488093	CRCT1	0.57	7.6	0.44	6.4e-13	Hair morphology;
KIRP	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg13147721	chr7:65941812	NA	-1.01	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26145223	chr11:63993388	NUDT22;TRPT1	0.5	6.67	0.39	1.68e-10	Cancer;
KIRP	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.24	0.42	5.87e-12	Retinal vascular caliber;
KIRP	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg26384229	chr12:38710491	ALG10B	0.66	8.37	0.47	4.49e-15	Resting heart rate;
KIRP	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.48	-6.42	-0.38	6.96e-10	Immature fraction of reticulocytes;
KIRP	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg00074818	chr8:8560427	CLDN23	0.41	6.33	0.37	1.12e-9	Obesity-related traits;
KIRP	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.56	4.98	0.3	1.21e-6	Bipolar disorder;
KIRP	cis	rs3818717	0.538	rs752579	chr17:17660347	C/T	cg01246520	chr17:17644344	RAI1	-0.33	-5.28	-0.32	2.9e-7	Lymphocyte counts;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.56	-7.62	-0.44	5.43e-13	Longevity;Endometriosis;
KIRP	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.54	-0.52	1.43e-18	Gut microbiome composition (summer);
KIRP	cis	rs2119480	0.762	rs418935	chr13:111309267	C/G	cg16216153	chr13:111290848	CARKD	0.42	5.78	0.35	2.3e-8	Diastolic blood pressure;
KIRP	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-0.88	-13.6	-0.66	8.33e-32	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10352719	chr14:24769404	DHRS1;C14orf21	0.47	6.15	0.37	3.11e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg17366294	chr4:99064904	C4orf37	0.36	4.95	0.3	1.38e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg01864069	chr14:103024347	NA	-0.97	-13.06	-0.64	5.98e-30	Platelet count;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.79	0.35	2.09e-8	Lung cancer;
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg13453750	chr1:205783389	SLC41A1	-0.5	-7.16	-0.42	9.14e-12	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	5.42	0.33	1.44e-7	Obesity-related traits;
KIRP	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.87	16.52	0.73	9.05e-42	Anterior chamber depth;
KIRP	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.12e-11	Blood metabolite levels;
KIRP	cis	rs4523957	0.614	rs2984941	chr17:2031543	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.62	-0.6	3.62e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.7	9.97	0.54	7.21e-20	Menarche (age at onset);
KIRP	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg21427119	chr20:30132790	HM13	-0.65	-6.26	-0.37	1.74e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.82	-0.35	1.85e-8	Educational attainment;
KIRP	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.68	8.5	0.48	1.83e-15	Recalcitrant atopic dermatitis;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg24562465	chr2:105191709	NA	0.53	6.03	0.36	5.99e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs42648	0.564	rs6975005	chr7:89826728	C/T	cg25739043	chr7:89950458	NA	0.38	5.97	0.36	8.15e-9	Homocysteine levels;
KIRP	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg04731861	chr2:219085781	ARPC2	-0.21	-5.2	-0.31	4.24e-7	Colorectal cancer;
KIRP	cis	rs1519814	0.956	rs7016388	chr8:121101865	A/G	cg22335954	chr8:121166405	COL14A1	-0.5	-5.2	-0.31	4.24e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11620238	chr5:32710663	NPR3	0.56	7.57	0.43	7.51e-13	Parkinson's disease;
KIRP	cis	rs4776059	1.000	rs8026800	chr15:52933548	C/G	cg22715398	chr15:52968154	KIAA1370	-0.68	-8.3	-0.47	6.83e-15	Schizophrenia;
KIRP	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.66	-0.52	6.51e-19	Myopia (pathological);
KIRP	cis	rs757081	0.667	rs644419	chr11:17212375	C/T	cg15432903	chr11:17409602	KCNJ11	0.53	5.97	0.36	8.42e-9	Systolic blood pressure;
KIRP	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.51	-6.3	-0.37	1.38e-9	Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00259882	chr11:70049130	FADD	0.53	7.37	0.43	2.63e-12	Parkinson's disease;
KIRP	cis	rs238295	0.805	rs6076852	chr20:5544502	A/G	cg24001556	chr20:5591874	RP5-1022P6.2	0.53	5.23	0.32	3.64e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg23283320	chr21:48055893	PRMT2	1.35	8.45	0.47	2.62e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.82	13.76	0.66	2.56e-32	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg26149184	chr10:133730230	NA	0.41	4.92	0.3	1.6e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg21366198	chr4:185655624	MLF1IP	-0.38	-5.08	-0.31	7.56e-7	Kawasaki disease;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg15541049	chr10:5931975	ANKRD16;FBXO18	0.55	6.42	0.38	6.97e-10	Electroencephalogram traits;
KIRP	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg23791538	chr6:167370224	RNASET2	-0.4	-4.95	-0.3	1.4e-6	Crohn's disease;
KIRP	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg01119278	chr6:110721349	DDO	-0.46	-7.08	-0.41	1.48e-11	Platelet distribution width;
KIRP	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg04398451	chr17:18023971	MYO15A	0.67	8.89	0.49	1.32e-16	Total body bone mineral density;
KIRP	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.64	-6.74	-0.4	1.09e-10	YKL-40 levels;
KIRP	cis	rs17023223	0.537	rs1325938	chr1:119582642	C/T	cg05756136	chr1:119680316	WARS2	-0.57	-7.72	-0.44	2.85e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9513627	0.831	rs9582301	chr13:100125814	C/T	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs714027	0.585	rs41173	chr22:30424863	C/G	cg27665648	chr22:30112403	NA	-0.41	-5.62	-0.34	5.24e-8	Lymphocyte counts;
KIRP	cis	rs7536700	0.915	rs7533987	chr1:153660989	A/G	cg08477332	chr1:153590243	S100A14	-0.74	-4.91	-0.3	1.67e-6	Multiple myeloma (IgH translocation);
KIRP	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg08313168	chr12:7315531	NA	0.7	6.28	0.37	1.56e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7084402	0.934	rs1579394	chr10:60294625	T/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg17376030	chr22:41985996	PMM1	-0.83	-8.87	-0.49	1.57e-16	Vitiligo;
KIRP	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.95	15.73	0.71	4.59e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.93	-0.49	1e-16	Total cholesterol levels;
KIRP	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.65	-0.44	4.46e-13	Response to antipsychotic treatment;
KIRP	cis	rs2625529	0.824	rs12595228	chr15:72267215	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs7615316	1.000	rs7631313	chr3:142354408	A/G	cg20824294	chr3:142316082	PLS1	0.25	5.41	0.33	1.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4006360	0.577	rs4986669	chr17:39250341	C/A	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg02344993	chr17:57696989	CLTC	0.54	5.22	0.32	3.82e-7	Hemoglobin concentration;
KIRP	cis	rs684232	0.583	rs10521106	chr17:510707	C/T	cg12384639	chr17:618140	VPS53	0.47	5.93	0.35	1e-8	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg05555928	chr11:63887634	MACROD1	-0.49	-6.02	-0.36	6.19e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg21775007	chr8:11205619	TDH	-0.44	-5.75	-0.34	2.63e-8	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11295801	chr6:150039190	LATS1	0.54	6.96	0.41	3.09e-11	Parkinson's disease;
KIRP	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.9	-10.56	-0.56	9.7e-22	Corneal astigmatism;
KIRP	cis	rs1867631	0.585	rs12094526	chr1:67126114	A/G	cg02459107	chr1:67143332	SGIP1	0.42	6.46	0.38	5.55e-10	Menopause (age at onset);
KIRP	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.64	4.57e-30	Bladder cancer;
KIRP	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg23594656	chr7:65796392	TPST1	-0.38	-5.41	-0.33	1.49e-7	Aortic root size;
KIRP	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg04940109	chr2:203240432	BMPR2	0.92	6.58	0.39	2.8e-10	P wave terminal force;
KIRP	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg20673091	chr1:2541236	MMEL1	0.67	10.1	0.54	2.76e-20	Ulcerative colitis;
KIRP	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg14004847	chr7:1930337	MAD1L1	-0.45	-4.94	-0.3	1.47e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	0.99	16.23	0.72	9.15e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.24	-0.32	3.49e-7	Morning vs. evening chronotype;
KIRP	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.37	-5.41	-0.33	1.5e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg25801113	chr15:45476975	SHF	-0.45	-8.27	-0.47	8.33e-15	Uric acid levels;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.87	0.53	1.42e-19	Lung cancer;
KIRP	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-5.05	-0.31	8.73e-7	Initial pursuit acceleration;
KIRP	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg07148914	chr20:33460835	GGT7	0.48	6.11	0.36	3.82e-9	Height;
KIRP	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.01	-0.36	6.51e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs7534824	0.625	rs7514731	chr1:101449675	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	6.08	0.36	4.62e-9	Refractive astigmatism;
KIRP	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg10760299	chr15:45669010	GATM	-0.34	-5.12	-0.31	6.06e-7	Homoarginine levels;
KIRP	trans	rs921874	0.586	rs2445535	chr11:86768330	T/A	cg22937172	chr2:240168862	HDAC4	0.51	6.48	0.38	4.84e-10	Total body bone mineral density;
KIRP	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.37	0.38	8.97e-10	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10779340	chr1:22817261	ZBTB40	0.43	6.13	0.36	3.53e-9	Interleukin-4 levels;
KIRP	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.74	-0.44	2.53e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg00376283	chr12:123451042	ABCB9	0.82	11.0	0.57	3.86e-23	Platelet count;
KIRP	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.27e-19	Prudent dietary pattern;
KIRP	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.87e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Diabetic kidney disease;
KIRP	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg09788416	chr12:39539408	NA	-0.39	-5.27	-0.32	2.93e-7	Morning vs. evening chronotype;
KIRP	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs13161895	1.000	rs4235504	chr5:179453680	T/C	cg02702477	chr5:179499311	RNF130	0.68	5.3	0.32	2.57e-7	LDL cholesterol;
KIRP	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.58	-9.02	-0.5	5.58e-17	Coronary artery disease;
KIRP	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg26566898	chr11:117069891	TAGLN	-0.4	-5.19	-0.31	4.35e-7	Blood protein levels;
KIRP	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg20999797	chr1:1681921	NA	0.52	8.16	0.46	1.78e-14	Body mass index;
KIRP	cis	rs7709377	0.597	rs2063253	chr5:115472544	G/T	cg23108291	chr5:115420582	COMMD10	0.42	5.02	0.3	9.98e-7	Metabolite levels  (X-11787);
KIRP	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg00277334	chr10:82204260	NA	-0.58	-5.5	-0.33	9.36e-8	Post bronchodilator FEV1;
KIRP	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg03235661	chr20:60525775	NA	-0.29	-4.92	-0.3	1.57e-6	Body mass index;
KIRP	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	7.77	0.44	2.19e-13	Total cholesterol levels;
KIRP	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg19875535	chr5:140030758	IK	-0.65	-8.72	-0.49	4.12e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg00857998	chr1:205179979	DSTYK	0.53	6.55	0.39	3.25e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7712401	0.715	rs424247	chr5:122347993	G/A	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11245990	chr11:68621969	NA	0.37	5.2	0.31	4.16e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg03351412	chr1:154909251	PMVK	0.58	7.63	0.44	5.06e-13	Prostate cancer;
KIRP	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	15.78	0.71	3.18e-39	Platelet count;
KIRP	cis	rs31771	0.564	rs2545520	chr5:165514347	G/C	cg13976338	chr5:165423657	NA	0.46	5.09	0.31	7.07e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02475777	chr4:1388615	CRIPAK	-0.54	-6.86	-0.4	5.61e-11	Obesity-related traits;
KIRP	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-14.28	-0.67	4.23e-34	Heart rate;
KIRP	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.8	10.7	0.56	3.51e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.31	0.37	1.32e-9	Mean platelet volume;
KIRP	cis	rs7929679	0.571	rs10768100	chr11:34798935	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.36e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	trans	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg11693508	chr17:37793320	STARD3	0.81	8.72	0.49	4.33e-16	Neuroticism;
KIRP	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.94	-0.35	9.54e-9	Morning vs. evening chronotype;
KIRP	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.6	-5.19	-0.31	4.45e-7	Narcolepsy;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg12692727	chr7:1102344	C7orf50	0.47	5.01	0.3	1.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs72843166	0.562	rs3760257	chr17:61496471	C/T	cg19683800	chr17:61518354	CYB561	-0.46	-5.9	-0.35	1.23e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs514024	0.661	rs515182	chr9:130494811	T/C	cg13643465	chr9:130375613	STXBP1	0.5	6.18	0.37	2.58e-9	Eating disorders (purging via substances);
KIRP	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg09165964	chr15:75287851	SCAMP5	0.4	5.05	0.31	8.51e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7611694	0.609	rs13091945	chr3:113172110	T/C	cg11138929	chr3:113251189	SIDT1	0.4	5.1	0.31	6.68e-7	Prostate cancer;
KIRP	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08280861	chr8:58055591	NA	0.71	5.5	0.33	9.34e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6681460	0.966	rs10749763	chr1:67062126	G/A	cg13052034	chr1:66999238	SGIP1	0.4	5.56	0.33	7.01e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.94	-13.19	-0.64	2.13e-30	Coronary artery disease;
KIRP	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg02524346	chr8:600233	NA	-0.87	-5.7	-0.34	3.39e-8	IgG glycosylation;
KIRP	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.6	-6.9	-0.4	4.39e-11	Diabetic retinopathy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23300289	chr9:132146083	NA	0.52	6.63	0.39	2.08e-10	Smoking initiation;
KIRP	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs35740288	0.822	rs1961601	chr15:86229606	T/C	cg17133734	chr15:86042851	AKAP13	-0.48	-5.23	-0.32	3.58e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11287039	chr11:67980200	SUV420H1	-0.48	-6.43	-0.38	6.65e-10	Metabolic traits;
KIRP	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.49	-0.43	1.2e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	0.98	7.07	0.41	1.55e-11	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00365499	chr7:104909430	SRPK2	0.45	6.18	0.37	2.66e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.63	8.63	0.48	7.54e-16	Bladder cancer;
KIRP	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg09571762	chr12:39539558	NA	0.35	5.04	0.31	8.91e-7	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.96	8.08	0.46	2.93e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs17023223	0.537	rs1325940	chr1:119586687	G/A	cg18261050	chr1:119551319	NA	0.53	7.01	0.41	2.33e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25221653	chr11:93276592	C11orf75	0.5	6.09	0.36	4.32e-9	Parkinson's disease;
KIRP	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.55	-6.32	-0.37	1.25e-9	Initial pursuit acceleration;
KIRP	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.78	0.66	2.16e-32	Electrocardiographic conduction measures;
KIRP	trans	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.36	3.81e-9	Mean corpuscular volume;
KIRP	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg12591125	chr7:1885375	MAD1L1	0.54	5.31	0.32	2.4e-7	Bipolar disorder;
KIRP	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14162927	chr1:155145774	TRIM46;KRTCAP2	0.44	6.3	0.37	1.33e-9	Survival in pancreatic cancer;
KIRP	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.32	-0.42	3.62e-12	Red cell distribution width;
KIRP	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg07636037	chr3:49044803	WDR6	0.81	10.28	0.55	7.55e-21	Menarche (age at onset);
KIRP	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.5	-6.5	-0.38	4.47e-10	Blood metabolite levels;
KIRP	cis	rs12210905	0.688	rs60888769	chr6:27490922	A/G	cg08851530	chr6:28072375	NA	0.87	5.01	0.3	1.04e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs10267417	0.603	rs28510133	chr7:19935487	A/T	cg05791153	chr7:19748676	TWISTNB	0.5	5.04	0.31	9.22e-7	Night sleep phenotypes;
KIRP	cis	rs7212590	0.655	rs8070039	chr17:57973585	G/C	cg10252138	chr17:58120427	NA	-0.69	-5.72	-0.34	3.09e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs7187994	0.806	rs12445172	chr16:84747016	C/G	cg07647771	chr16:84786436	USP10	-0.39	-5.16	-0.31	5e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg00958927	chr1:175162553	KIAA0040	-0.3	-5.07	-0.31	7.86e-7	Alcohol dependence;
KIRP	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.79	10.78	0.57	1.92e-22	Aortic root size;
KIRP	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.41	-5.33	-0.32	2.2e-7	Body mass index;
KIRP	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.34	10.33	0.55	5.06e-21	Economic and political preferences (immigration/crime);
KIRP	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg19338460	chr6:170058176	WDR27	-0.65	-7.53	-0.43	9.79e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1497828	0.871	rs2047401	chr1:217544107	T/A	cg04411442	chr1:217543379	NA	0.4	5.96	0.36	8.52e-9	Dialysis-related mortality;
KIRP	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.97	15.65	0.71	8.96e-39	Uric acid clearance;
KIRP	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.65	-6.95	-0.41	3.3e-11	DNA methylation (variation);
KIRP	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.72	9.83	0.53	1.9e-19	Eosinophil counts;
KIRP	cis	rs4671400	0.602	rs2694623	chr2:61553466	C/T	cg15711740	chr2:61764176	XPO1	0.61	6.53	0.38	3.79e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.46	5.53	0.33	8.28e-8	Longevity;
KIRP	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.48	-5.71	-0.34	3.19e-8	Monobrow;
KIRP	cis	rs2236918	1.000	rs2526704	chr1:242015820	A/G	cg17736920	chr1:242011382	EXO1	0.76	9.92	0.53	9.67e-20	Menopause (age at onset);
KIRP	cis	rs9326248	0.590	rs2542063	chr11:116684767	C/T	cg26566898	chr11:117069891	TAGLN	0.37	4.85	0.3	2.17e-6	Blood protein levels;
KIRP	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg12317470	chr15:67143691	NA	-0.57	-6.26	-0.37	1.71e-9	Lung cancer (smoking interaction);
KIRP	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.87	10.62	0.56	6.34e-22	Schizophrenia;
KIRP	trans	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg16141378	chr3:129829833	LOC729375	0.51	6.28	0.37	1.5e-9	Neuroticism;
KIRP	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.89	14.08	0.67	2e-33	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg23479056	chr15:41276147	INO80	0.36	5.01	0.3	1.03e-6	Menopause (age at onset);
KIRP	cis	rs4006360	0.575	rs6503607	chr17:39315344	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.53	-6.71	-0.39	1.32e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	6.42	0.38	6.78e-10	Mean platelet volume;
KIRP	cis	rs4595586	0.967	rs56149694	chr12:39263771	T/C	cg26384229	chr12:38710491	ALG10B	-0.39	-4.9	-0.3	1.73e-6	Morning vs. evening chronotype;
KIRP	cis	rs212524	0.544	rs6665399	chr1:21553933	T/C	cg21184320	chr1:21044207	KIF17	0.36	5.36	0.32	1.9e-7	Height;
KIRP	cis	rs2733201	1.000	rs12913809	chr15:44293211	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-5.91	-0.35	1.13e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs16976116	0.851	rs28889339	chr15:55503205	T/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02790122	chr10:65133532	JMJD1C;MIR1296	-0.44	-6.94	-0.4	3.53e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg16506815	chr2:162101123	NA	0.51	6.05	0.36	5.31e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg13877915	chr19:58951672	ZNF132	0.61	5.87	0.35	1.43e-8	Mean platelet volume;
KIRP	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg03235661	chr20:60525775	NA	-0.37	-5.08	-0.31	7.44e-7	Body mass index;
KIRP	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.54	0.52	1.46e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg06026331	chr20:60912101	LAMA5	-0.52	-6.81	-0.4	7.63e-11	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs656319	0.580	rs13279701	chr8:9969450	C/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.81	-0.4	7.34e-11	Myopia (pathological);
KIRP	cis	rs9549260	0.564	rs9549270	chr13:41284193	G/T	cg21288729	chr13:41239152	FOXO1	0.57	7.55	0.43	8.37e-13	Red blood cell count;
KIRP	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18252515	chr7:66147081	NA	-0.47	-5.57	-0.33	6.77e-8	Aortic root size;
KIRP	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	24.98	0.85	2.06e-69	Schizophrenia;
KIRP	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08508325	chr11:3079039	CARS	0.31	5.73	0.34	2.97e-8	Calcium levels;
KIRP	cis	rs12431939	0.948	rs67116854	chr14:51670464	G/A	cg23942311	chr14:51606299	NA	-0.57	-5.65	-0.34	4.32e-8	Cancer;
KIRP	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.88	-10.53	-0.56	1.24e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.52	6.34	0.37	1.12e-9	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25127850	chr7:6144372	USP42	0.44	6.1	0.36	4.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.48	-5.11	-0.31	6.5e-7	Platelet distribution width;
KIRP	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg26338869	chr17:61819248	STRADA	0.53	6.34	0.37	1.1e-9	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25176742	chr15:50647253	GABPB1;LOC100129387;FLJ10038	0.49	6.2	0.37	2.38e-9	Parkinson's disease;
KIRP	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg22676075	chr6:135203613	NA	0.51	7.32	0.42	3.41e-12	Red blood cell count;
KIRP	cis	rs76917914	0.820	rs7034147	chr9:100821691	T/G	cg03040243	chr9:100819229	NANS	0.62	6.68	0.39	1.6e-10	Immature fraction of reticulocytes;
KIRP	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.93	15.52	0.7	2.44e-38	Breast cancer;
KIRP	cis	rs1832871	0.578	rs262820	chr6:158663101	G/T	cg07215822	chr6:158701037	NA	-0.61	-9.18	-0.51	1.85e-17	Height;
KIRP	cis	rs7187994	0.848	rs3751759	chr16:84778222	G/A	cg07647771	chr16:84786436	USP10	-0.43	-5.54	-0.33	7.74e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.13	-0.31	5.84e-7	Psoriasis;
KIRP	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg05639522	chr1:247681581	NA	0.59	5.65	0.34	4.4e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.64	-6.71	-0.39	1.34e-10	DNA methylation (variation);
KIRP	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg13147721	chr7:65941812	NA	-0.97	-7.44	-0.43	1.63e-12	Diabetic kidney disease;
KIRP	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-4.98	-0.3	1.17e-6	Initial pursuit acceleration;
KIRP	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.77	0.4	9.22e-11	Electroencephalogram traits;
KIRP	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.85	12.46	0.62	5.78e-28	Blood metabolite ratios;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg21186296	chr8:27182909	PTK2B	0.51	6.35	0.38	1.04e-9	Neuroticism;
KIRP	cis	rs11025559	1.000	rs11025559	chr11:20443875	A/G	cg19653624	chr11:20408972	PRMT3	0.62	6.25	0.37	1.82e-9	Pursuit maintenance gain;
KIRP	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg05526886	chr2:227700861	RHBDD1	0.5	6.04	0.36	5.73e-9	Pulmonary function;
KIRP	cis	rs4233802	1.000	rs4425094	chr2:151139891	C/T	cg25300694	chr2:151184358	NA	0.86	6.7	0.39	1.42e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg25173405	chr17:45401733	C17orf57	0.5	6.63	0.39	2.17e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg00405596	chr8:11794950	NA	0.44	5.51	0.33	8.82e-8	Retinal vascular caliber;
KIRP	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg11846333	chr4:119757529	SEC24D	1.17	7.18	0.42	8.23e-12	Cannabis dependence symptom count;
KIRP	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-5.51	-0.33	8.98e-8	Chronic sinus infection;
KIRP	cis	rs12143943	0.774	rs6594014	chr1:204449434	A/G	cg20240347	chr1:204465584	NA	-0.31	-5.74	-0.34	2.79e-8	Cognitive performance;
KIRP	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg06636001	chr8:8085503	FLJ10661	0.79	11.08	0.58	2.08e-23	Mood instability;
KIRP	cis	rs12367572	0.501	rs3990143	chr12:45465042	A/G	cg04608330	chr12:45269318	NELL2	-0.45	-5.74	-0.34	2.72e-8	Gut microbiome composition (summer);
KIRP	cis	rs35740288	0.731	rs12898964	chr15:86161277	G/A	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.64	-6.31	-0.37	1.26e-9	Obesity-related traits;
KIRP	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.23	-0.37	2.06e-9	Systolic blood pressure;
KIRP	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.58	6.5	0.38	4.52e-10	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
KIRP	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.44	5.05	0.31	8.64e-7	Schizophrenia;
KIRP	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg22437258	chr11:111473054	SIK2	0.59	6.8	0.4	7.73e-11	Primary sclerosing cholangitis;
KIRP	cis	rs397969	0.596	rs7209653	chr17:19882084	A/G	cg13482628	chr17:19912719	NA	0.48	5.88	0.35	1.36e-8	Platelet count;
KIRP	trans	rs2055375	0.601	rs34635	chr5:60513501	A/G	cg03405114	chr18:43652430	PSTPIP2	-0.48	-6.33	-0.37	1.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.768	rs4760609	chr12:48415757	A/C	cg20731937	chr12:48336164	NA	-0.45	-6.05	-0.36	5.4e-9	Longevity (90 years and older);
KIRP	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.41	5.81	0.35	1.94e-8	Endometrial cancer;
KIRP	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.55	7.0	0.41	2.5e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.74	-0.34	2.77e-8	Morning vs. evening chronotype;
KIRP	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg00507259	chr4:95128692	SMARCAD1	0.41	5.25	0.32	3.25e-7	QT interval;
KIRP	cis	rs6681460	0.535	rs6588204	chr1:66991008	C/T	cg13052034	chr1:66999238	SGIP1	0.42	5.79	0.35	2.09e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.34	-0.37	1.11e-9	Lung cancer;
KIRP	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.4	-4.97	-0.3	1.23e-6	Neuroticism;
KIRP	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26207909	chr14:103986467	CKB	0.75	11.13	0.58	1.42e-23	Body mass index;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00933542	chr6:150070202	PCMT1	0.31	6.13	0.36	3.44e-9	Lung cancer;
KIRP	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-10.08	-0.54	3.25e-20	Coffee consumption (cups per day);
KIRP	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.95e-7	Red blood cell count;
KIRP	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs71636778	0.722	rs34502618	chr1:27094156	A/G	cg12203394	chr1:27248618	NUDC	0.69	5.46	0.33	1.18e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg01403660	chr11:68851641	TPCN2	0.69	6.8	0.4	8.02e-11	Blond vs. brown hair color;
KIRP	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg10117171	chr1:25599238	RHD	-0.41	-5.53	-0.33	8e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-6.36	-0.38	9.55e-10	Mean platelet volume;
KIRP	cis	rs17407555	0.821	rs56267284	chr4:10134370	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-4.86	-0.3	2.12e-6	Schizophrenia (age at onset);
KIRP	cis	rs11155671	0.530	rs9371504	chr6:150184080	A/T	cg09699651	chr6:150184138	LRP11	0.59	8.13	0.46	2.08e-14	Testicular germ cell tumor;
KIRP	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg23920097	chr1:209922102	NA	-0.4	-5.36	-0.32	1.92e-7	Red blood cell count;
KIRP	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg27211696	chr2:191398769	TMEM194B	-0.56	-6.46	-0.38	5.54e-10	Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.61	9.16	0.5	2.06e-17	Lung cancer;
KIRP	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-5.86	-0.35	1.51e-8	Skin colour saturation;
KIRP	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg21395723	chr22:39101663	GTPBP1	0.42	5.55	0.33	7.21e-8	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09375672	chr6:143858639	NA	0.6	7.04	0.41	1.96e-11	Smoking initiation;
KIRP	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg04166393	chr7:2884313	GNA12	0.67	8.35	0.47	4.88e-15	Height;
KIRP	cis	rs4356932	1.000	rs6811301	chr4:76970579	T/C	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg07274523	chr3:49395745	GPX1	-0.66	-7.78	-0.44	1.97e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.73	-7.44	-0.43	1.66e-12	DNA methylation (variation);
KIRP	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08280861	chr8:58055591	NA	0.81	6.42	0.38	7.03e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	1.22	11.15	0.58	1.22e-23	Lymphocyte counts;
KIRP	cis	rs300890	0.513	rs7692813	chr4:144099093	T/C	cg01719995	chr4:144104893	USP38	0.43	5.52	0.33	8.64e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs3126085	0.560	rs4378206	chr1:152369913	A/G	cg26876637	chr1:152193138	HRNR	0.69	7.01	0.41	2.34e-11	Atopic dermatitis;
KIRP	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg03465714	chr1:152285911	FLG	-0.42	-5.0	-0.3	1.07e-6	Atopic dermatitis;
KIRP	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.68	-6.6	-0.39	2.47e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg08975724	chr8:8085496	FLJ10661	0.48	6.12	0.36	3.75e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.99	-0.54	6e-20	Hemoglobin concentration;
KIRP	cis	rs78487399	0.710	rs57696714	chr2:43626521	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.01	-0.3	1.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg17595323	chr11:93583763	C11orf90	-0.38	-6.34	-0.37	1.1e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6888304	0.589	rs36003087	chr5:31053384	A/C	cg10919204	chr5:31193340	CDH6	0.37	4.91	0.3	1.69e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6973256	0.897	rs6970448	chr7:133343642	G/A	cg10665199	chr7:133106180	EXOC4	-0.51	-6.46	-0.38	5.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06544989	chr22:39130855	UNC84B	0.46	7.09	0.41	1.45e-11	Menopause (age at onset);
KIRP	cis	rs10267417	0.603	rs17142124	chr7:19903631	C/G	cg05791153	chr7:19748676	TWISTNB	0.51	5.27	0.32	3e-7	Night sleep phenotypes;
KIRP	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.15	15.92	0.71	1.07e-39	Lymphocyte percentage of white cells;
KIRP	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg00495681	chr13:53174319	NA	0.42	5.63	0.34	4.92e-8	Lewy body disease;
KIRP	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg16989719	chr2:238392110	NA	-0.55	-7.32	-0.42	3.54e-12	Prostate cancer;
KIRP	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg24972876	chr7:65420302	NA	0.4	5.56	0.33	7.1e-8	Aortic root size;
KIRP	cis	rs909341	0.818	rs67468102	chr20:62344883	G/C	cg03999872	chr20:62272968	STMN3	-0.56	-6.57	-0.39	2.93e-10	Atopic dermatitis;
KIRP	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.42	0.51	3.39e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.85	9.62	0.52	8.5e-19	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg17595323	chr11:93583763	C11orf90	0.29	5.15	0.31	5.32e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs10969557	0.600	rs7028627	chr9:315394	G/T	cg03871460	chr13:37004721	CCNA1	0.38	6.08	0.36	4.47e-9	Lung cancer;
KIRP	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg24375607	chr4:120327624	NA	0.63	7.19	0.42	7.85e-12	Corneal astigmatism;
KIRP	cis	rs752010	0.715	rs4660551	chr1:42099979	T/C	cg06885757	chr1:42089581	HIVEP3	0.88	14.68	0.68	1.85e-35	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.63	0.39	2.06e-10	Educational attainment;
KIRP	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.9	-14.4	-0.68	1.65e-34	Calcium levels;
KIRP	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg02461776	chr11:598696	PHRF1	0.49	5.16	0.31	4.97e-7	Systemic lupus erythematosus;
KIRP	trans	rs10819937	0.895	rs476668	chr9:104202434	G/A	cg24374857	chr1:41158439	NFYC;LOC100130557	-0.5	-6.74	-0.39	1.09e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6690583	0.623	rs1371142	chr1:85455373	A/T	cg22153463	chr1:85462885	MCOLN2	0.6	5.53	0.33	8.27e-8	Serum sulfate level;
KIRP	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.85e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7011049	0.778	rs114842851	chr8:53867405	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-5.11	-0.31	6.33e-7	Total body bone mineral density;
KIRP	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.3	0.42	3.96e-12	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg18944383	chr4:111397179	ENPEP	0.6	11.1	0.58	1.77e-23	Height;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg20743544	chr7:32982957	RP9P	0.54	6.26	0.37	1.7e-9	Sleep duration;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg13794888	chr15:75917792	SNUPN	0.5	6.4	0.38	7.8e-10	Asthma;
KIRP	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg18032046	chr6:28092343	ZSCAN16	0.46	5.5	0.33	9.52e-8	Cardiac Troponin-T levels;
KIRP	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg05082376	chr22:42548792	NA	-0.39	-5.19	-0.31	4.44e-7	Schizophrenia;
KIRP	cis	rs11731606	0.651	rs774989	chr4:95419878	T/A	cg20625393	chr4:95128694	SMARCAD1	-0.5	-4.86	-0.3	2.1e-6	Mean platelet volume;
KIRP	cis	rs4786125	0.512	rs55818804	chr16:6930199	T/C	cg03623568	chr16:6915990	A2BP1	-0.44	-5.26	-0.32	3.11e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	1.0	13.38	0.65	4.72e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs867371	1.000	rs881308	chr15:82475797	A/G	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs13095912	0.785	rs4686682	chr3:185307402	C/T	cg11274856	chr3:185301563	NA	0.64	8.1	0.46	2.58e-14	Systolic blood pressure;
KIRP	cis	rs830383	0.597	rs31768	chr5:165498279	A/T	cg13976338	chr5:165423657	NA	0.62	7.92	0.45	8.32e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-5.02	-0.3	1e-6	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	trans	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.13e-11	Bladder cancer;
KIRP	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg17524180	chr13:113633600	MCF2L	-0.31	-5.76	-0.34	2.44e-8	Systolic blood pressure;
KIRP	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11987759	chr7:65425863	GUSB	0.51	6.86	0.4	5.64e-11	Aortic root size;
KIRP	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg06060754	chr5:176797920	RGS14	-0.6	-6.94	-0.4	3.39e-11	Urate levels in lean individuals;
KIRP	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	6.97	0.41	2.92e-11	Monocyte count;
KIRP	cis	rs10924970	0.967	rs10802617	chr1:235485768	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	4.99	0.3	1.16e-6	Asthma;
KIRP	cis	rs7656342	0.653	rs2292917	chr4:9867277	C/G	cg11266682	chr4:10021025	SLC2A9	0.32	5.1	0.31	6.71e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	1.03	15.36	0.7	8.69e-38	Menopause (age at onset);
KIRP	cis	rs9596863	0.950	rs9563182	chr13:54395310	T/C	ch.13.53330881F	chr13:54432880	NA	0.62	6.25	0.37	1.82e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14240646	chr10:27532245	ACBD5	-0.44	-5.0	-0.3	1.07e-6	Breast cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24220766	chr17:40976513	BECN1	-0.49	-6.58	-0.39	2.88e-10	Myopia;
KIRP	cis	rs7011507	1.000	rs77019189	chr8:49146086	A/C	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.48	5.86	0.35	1.51e-8	Glycated hemoglobin levels;
KIRP	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.14	-15.45	-0.7	4.18e-38	Lymphocyte percentage of white cells;
KIRP	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.99	10.58	0.56	8.53e-22	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.5	0.48	1.88e-15	Motion sickness;
KIRP	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg02404636	chr22:31891804	SFI1	-0.48	-5.34	-0.32	2.09e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg00204512	chr16:28754710	NA	0.45	5.62	0.34	5.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg10818794	chr15:86012489	AKAP13	-0.58	-8.24	-0.47	1.03e-14	Interstitial lung disease;
KIRP	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.87	0.45	1.1e-13	Height;
KIRP	cis	rs11608355	0.508	rs12817730	chr12:109799330	G/A	cg19025524	chr12:109796872	NA	-0.43	-5.34	-0.32	2.16e-7	Neuroticism;
KIRP	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.89	13.66	0.66	5.47e-32	Coronary artery disease;
KIRP	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-8.4	-0.47	3.66e-15	Coronary artery disease;
KIRP	cis	rs501120	0.525	rs1704229	chr10:44689529	G/A	cg09554077	chr10:44749378	NA	0.49	6.69	0.39	1.46e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7539542	0.529	rs3766572	chr1:202860067	C/T	cg19681188	chr1:202830198	LOC148709	0.49	5.34	0.32	2.14e-7	Mean platelet volume;
KIRP	cis	rs7712401	0.580	rs30041	chr5:122275353	G/C	cg19412675	chr5:122181750	SNX24	0.47	5.2	0.31	4.22e-7	Mean platelet volume;
KIRP	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg07862535	chr7:139043722	LUC7L2	0.52	5.38	0.32	1.77e-7	Diisocyanate-induced asthma;
KIRP	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.4	-0.47	3.5e-15	Mean corpuscular volume;
KIRP	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg08501292	chr6:25962987	TRIM38	0.76	5.09	0.31	7.24e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-5.04	-0.31	9.01e-7	Oral cavity cancer;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg15112475	chr7:1198522	ZFAND2A	-0.53	-4.92	-0.3	1.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.56	7.57	0.43	7.41e-13	Alcohol dependence;
KIRP	cis	rs6467136	0.765	rs55657491	chr7:127204735	C/G	cg08586737	chr7:127225949	GCC1	-0.39	-5.08	-0.31	7.59e-7	Type 2 diabetes;
KIRP	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.53	-7.68	-0.44	3.74e-13	Height;
KIRP	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg21747090	chr2:27597821	SNX17	-0.39	-5.3	-0.32	2.61e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	cg12689670	chr1:183009347	LAMC1	-0.48	-6.84	-0.4	6.27e-11	Hypertriglyceridemia;
KIRP	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.72	-0.39	1.26e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg26876637	chr1:152193138	HRNR	-0.76	-10.37	-0.55	3.81e-21	Atopic dermatitis;
KIRP	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg18016565	chr1:150552671	MCL1	-0.49	-7.5	-0.43	1.19e-12	Tonsillectomy;
KIRP	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg07395648	chr5:131743802	NA	0.52	6.36	0.38	9.9e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg16077055	chr2:106428750	NCK2	0.3	6.02	0.36	6.4e-9	Addiction;
KIRP	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.69	-6.92	-0.4	3.82e-11	Migraine;Coronary artery disease;
KIRP	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg22705602	chr4:152727874	NA	-0.54	-9.37	-0.51	4.98e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.76	8.4	0.47	3.54e-15	Corneal astigmatism;
KIRP	cis	rs7551222	0.752	rs11240758	chr1:204528651	C/T	cg20240347	chr1:204465584	NA	-0.44	-8.58	-0.48	1.09e-15	Schizophrenia;
KIRP	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	1.04	14.35	0.67	2.51e-34	Menopause (age at onset);
KIRP	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.64	-0.52	7.38e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg20302533	chr7:39170763	POU6F2	0.29	6.26	0.37	1.67e-9	IgG glycosylation;
KIRP	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.84	0.4	6.3e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg00360474	chr6:37504404	NA	-0.45	-6.35	-0.38	1.04e-9	Cognitive performance;
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg19500275	chr17:80737654	TBCD	0.45	5.28	0.32	2.77e-7	Glycated hemoglobin levels;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg04025307	chr7:1156635	C7orf50	0.74	7.73	0.44	2.73e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	9.87	0.53	1.43e-19	Cognitive test performance;
KIRP	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg24289452	chr6:170231220	NA	-0.74	-4.86	-0.3	2.07e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg04731861	chr2:219085781	ARPC2	-0.2	-4.95	-0.3	1.37e-6	Colorectal cancer;
KIRP	cis	rs1538970	0.962	rs2153608	chr1:45813941	C/T	cg05343316	chr1:45956843	TESK2	-0.62	-7.23	-0.42	5.96e-12	Platelet count;
KIRP	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg00383909	chr3:49044727	WDR6	0.55	5.19	0.31	4.37e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.35	-0.32	2e-7	Tonsillectomy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15113090	chr2:26696104	OTOF	-0.43	-6.14	-0.36	3.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-0.86	-12.66	-0.63	1.26e-28	Total body bone mineral density;
KIRP	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.74	12.87	0.63	2.5e-29	Weight;
KIRP	cis	rs526231	0.667	rs187580	chr5:102627355	T/G	cg23492399	chr5:102201601	PAM	-0.58	-5.68	-0.34	3.8e-8	Primary biliary cholangitis;
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.86	-12.65	-0.63	1.4e-28	Height;
KIRP	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg20636351	chr8:55087400	NA	-0.62	-7.63	-0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.16	0.31	5.17e-7	Educational attainment;
KIRP	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.8	-10.89	-0.57	8.31e-23	Aortic root size;
KIRP	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17554472	chr22:41940697	POLR3H	0.67	7.04	0.41	1.96e-11	Vitiligo;
KIRP	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.13	-19.18	-0.77	9.28e-51	Exhaled nitric oxide levels;
KIRP	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg13010199	chr12:38710504	ALG10B	-0.39	-5.04	-0.31	9.03e-7	Heart rate;
KIRP	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.8	11.02	0.57	3.32e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1593	0.531	rs3822055	chr4:187179678	A/G	cg02012338	chr4:187126139	CYP4V2	0.52	5.09	0.31	7.01e-7	Activated partial thromboplastin time;
KIRP	cis	rs662064	0.962	rs2506901	chr1:10563492	A/G	cg19773385	chr1:10388646	KIF1B	-0.39	-5.16	-0.31	5.01e-7	Asthma;
KIRP	cis	rs7546668	0.652	rs12691551	chr1:15907908	C/G	cg21858823	chr1:15850916	CASP9	0.59	7.52	0.43	1.05e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs745080	0.674	rs1563673	chr14:52994331	A/C	cg23333723	chr14:53022898	GPR137C	-0.42	-5.72	-0.34	3.06e-8	Orofacial clefts;
KIRP	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.86	-11.53	-0.59	7.32e-25	Cognitive function;
KIRP	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.58	-7.3	-0.42	3.94e-12	Longevity;Endometriosis;
KIRP	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.75	11.25	0.58	6.04e-24	Oral cavity cancer;
KIRP	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg25772418	chr12:131519998	GPR133	-0.41	-5.68	-0.34	3.73e-8	Longevity;
KIRP	cis	rs3850699	0.609	rs12763720	chr10:104241983	T/C	cg04362960	chr10:104952993	NT5C2	0.64	6.06	0.36	5.03e-9	Prostate cancer;
KIRP	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1559473	0.572	rs2042470	chr2:222908391	A/G	cg14426312	chr9:71395063	FAM122A;PIP5K1B	0.52	6.06	0.36	5.03e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.4	5.64	0.34	4.58e-8	Optic cup area;
KIRP	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-6.22	-0.37	2.12e-9	Menarche (age at onset);
KIRP	cis	rs12973672	1.000	rs62109572	chr19:35778919	T/C	cg12095397	chr19:35769544	USF2	0.66	6.36	0.38	9.83e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.44	-5.03	-0.31	9.3e-7	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg26116260	chr4:7069785	GRPEL1	-1.03	-6.59	-0.39	2.59e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.21	-0.32	4.08e-7	Colorectal cancer;
KIRP	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	1.07	20.21	0.79	3.44e-54	Height;
KIRP	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg11972305	chr2:233791962	NGEF	-0.39	-5.32	-0.32	2.37e-7	Schizophrenia;
KIRP	cis	rs1978968	0.751	rs5992139	chr22:18458636	A/G	cg03078520	chr22:18463400	MICAL3	-0.79	-10.13	-0.54	2.27e-20	Presence of antiphospholipid antibodies;
KIRP	cis	rs4363385	0.626	rs11205179	chr1:153021399	A/G	cg07796016	chr1:152779584	LCE1C	-0.44	-5.7	-0.34	3.37e-8	Inflammatory skin disease;
KIRP	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.8	10.22	0.55	1.19e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg18132916	chr6:79620363	NA	-0.42	-5.68	-0.34	3.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg00360474	chr6:37504404	NA	-0.5	-7.46	-0.43	1.46e-12	Cognitive performance;
KIRP	cis	rs9815354	0.951	rs1717018	chr3:41913617	G/A	cg03022575	chr3:42003672	ULK4	0.49	5.57	0.33	6.67e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6540556	0.678	rs12094117	chr1:209888435	G/T	cg05527609	chr1:210001259	C1orf107	-0.49	-5.2	-0.31	4.17e-7	Red blood cell count;
KIRP	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.3	0.37	1.35e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg11584989	chr19:19387371	SF4	-0.41	-5.11	-0.31	6.46e-7	Tonsillectomy;
KIRP	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.03e-7	Schizophrenia;
KIRP	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.87	14.03	0.67	2.89e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg06074448	chr4:187884817	NA	-0.77	-12.96	-0.64	1.29e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg20818283	chr2:191399100	TMEM194B	0.53	6.57	0.39	3.01e-10	Pulse pressure;
KIRP	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.57	8.05	0.46	3.52e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9517302	0.615	rs3752974	chr13:99097827	T/C	cg22223119	chr13:99095684	FARP1	-0.44	-5.22	-0.32	3.76e-7	Obesity-related traits;
KIRP	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.34	0.67	2.56e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7721647	0.821	rs987092	chr5:90867681	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg10755058	chr3:40428713	ENTPD3	-0.47	-7.01	-0.41	2.29e-11	Renal cell carcinoma;
KIRP	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.58	6.87	0.4	5.38e-11	Aortic root size;
KIRP	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg04865290	chr3:52927548	TMEM110	-0.4	-5.06	-0.31	8.18e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.72	-0.34	3.03e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7757419	1.000	rs7773901	chr6:34435195	G/A	cg25473981	chr6:34433676	PACSIN1	0.42	5.14	0.31	5.54e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
KIRP	cis	rs6701037	1.000	rs6677097	chr1:175123897	C/G	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.28	-0.32	2.8e-7	Alcohol dependence;
KIRP	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	8.21	0.46	1.28e-14	Platelet count;
KIRP	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.7	9.49	0.52	2.13e-18	Personality dimensions;
KIRP	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg25922239	chr6:33757077	LEMD2	0.57	7.15	0.42	9.57e-12	Crohn's disease;
KIRP	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.73	9.1	0.5	3.17e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg20542592	chr8:11973495	FAM66D	0.38	4.87	0.3	1.99e-6	Triglycerides;
KIRP	cis	rs3751972	0.590	rs10512428	chr17:26268925	G/C	cg26853415	chr17:26127438	NOS2	0.44	4.94	0.3	1.47e-6	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg05555928	chr11:63887634	MACROD1	-0.58	-5.37	-0.32	1.78e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg27490568	chr2:178487706	NA	0.46	6.14	0.36	3.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.46	-0.38	5.57e-10	Daytime sleep phenotypes;
KIRP	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.88	-9.09	-0.5	3.33e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.63	9.67	0.52	5.72e-19	Lung cancer;
KIRP	cis	rs6959887	0.926	rs2429420	chr7:35276996	C/T	cg06685737	chr7:35301730	NA	0.43	6.29	0.37	1.42e-9	Birth weight;
KIRP	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg02475777	chr4:1388615	CRIPAK	0.51	4.87	0.3	2.02e-6	Recombination rate (females);
KIRP	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.47	-0.38	5.12e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg16486109	chr11:613632	IRF7	0.41	4.9	0.3	1.71e-6	Systemic lupus erythematosus;
KIRP	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg02524346	chr8:600233	NA	0.72	5.6	0.34	5.65e-8	IgG glycosylation;
KIRP	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg23307798	chr14:103986281	CKB	0.44	6.1	0.36	4.17e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.74	-0.39	1.12e-10	Coronary artery disease;
KIRP	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg24296786	chr1:45957014	TESK2	0.51	5.65	0.34	4.39e-8	Homocysteine levels;
KIRP	cis	rs1538970	0.961	rs4660854	chr1:45854087	A/T	cg05343316	chr1:45956843	TESK2	0.59	6.98	0.41	2.8e-11	Platelet count;
KIRP	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg16127683	chr15:40268777	EIF2AK4	-0.38	-4.9	-0.3	1.75e-6	Response to haloperidol in psychosis;
KIRP	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.58	7.74	0.44	2.56e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1568889	1.000	rs58502944	chr11:28060943	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	11.47	0.59	1.13e-24	Bipolar disorder;
KIRP	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.68	9.51	0.52	1.82e-18	Obesity-related traits;
KIRP	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.55	0.48	1.33e-15	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24452069	chr19:4867631	PLIN3	-0.44	-6.02	-0.36	6.43e-9	Metabolic traits;
KIRP	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg22153407	chr1:230290089	GALNT2	0.37	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.45	-5.51	-0.33	8.82e-8	Resistin levels;
KIRP	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-12.73	-0.63	7.67e-29	Chronic sinus infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03881711	chr4:118497266	NA	-0.4	-6.2	-0.37	2.38e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg23594656	chr7:65796392	TPST1	0.36	5.26	0.32	3.12e-7	Aortic root size;
KIRP	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg23649088	chr2:200775458	C2orf69	0.53	5.08	0.31	7.37e-7	Schizophrenia;
KIRP	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.83	-11.28	-0.58	4.49e-24	Coronary artery disease;
KIRP	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	10.03	0.54	4.52e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg02175503	chr12:58329896	NA	0.66	7.93	0.45	7.58e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg21775007	chr8:11205619	TDH	0.45	6.09	0.36	4.21e-9	Myopia (pathological);
KIRP	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.96	12.71	0.63	8.76e-29	Vitamin D levels;
KIRP	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10802521	chr3:52805072	NEK4	-0.38	-5.18	-0.31	4.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.97	11.54	0.59	6.8e-25	Corneal astigmatism;
KIRP	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg00784671	chr22:46762841	CELSR1	-0.76	-7.81	-0.45	1.63e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11710088	0.740	rs11710025	chr3:149193094	C/T	cg08667024	chr3:149219783	TM4SF4	-0.42	-5.04	-0.31	8.86e-7	QRS duration;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16018184	chr19:39322471	ECH1	-0.46	-6.46	-0.38	5.53e-10	Metabolic traits;
KIRP	trans	rs1864585	0.520	rs17774331	chr8:10631226	C/T	cg26278703	chr11:58910052	FAM111A	0.64	6.4	0.38	7.62e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.53	7.58	0.44	7.04e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13939156	chr17:80058883	NA	0.47	6.96	0.41	3.09e-11	Life satisfaction;
KIRP	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg14003231	chr6:33640908	ITPR3	0.28	4.95	0.3	1.37e-6	Plateletcrit;
KIRP	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg04398451	chr17:18023971	MYO15A	0.66	8.96	0.5	8.52e-17	Total body bone mineral density;
KIRP	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg16574807	chr4:6945745	TBC1D14	0.68	5.98	0.36	7.8e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg02158880	chr13:53174818	NA	0.52	6.62	0.39	2.18e-10	Lewy body disease;
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg11814155	chr7:99998594	ZCWPW1	0.54	5.41	0.33	1.49e-7	Platelet count;
KIRP	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.86	-0.63	2.63e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	8.54	0.48	1.42e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.53	-0.33	8.35e-8	Bipolar disorder;
KIRP	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	0.93	8.38	0.47	3.99e-15	Plateletcrit;
KIRP	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs5498	0.869	rs892188	chr19:10409793	A/G	cg10604476	chr19:10403908	ICAM5	-0.32	-4.85	-0.3	2.14e-6	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
KIRP	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.52	-6.75	-0.4	1.07e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.38	-0.47	4.06e-15	Platelet count;
KIRP	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.71	10.52	0.56	1.3e-21	Coronary artery disease;
KIRP	trans	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00950418	chr7:105029125	SRPK2	-0.55	-7.0	-0.41	2.45e-11	Height;
KIRP	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs6580649	0.941	rs4760614	chr12:48427884	A/G	cg26205652	chr12:48591994	NA	-0.47	-5.6	-0.34	5.7e-8	Lung cancer;
KIRP	cis	rs10129255	0.509	rs756583	chr14:107136019	C/T	cg23076370	chr14:107095027	NA	-0.42	-5.29	-0.32	2.75e-7	Kawasaki disease;
KIRP	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.69	-6.33	-0.37	1.15e-9	Menarche (age at onset);
KIRP	cis	rs9549260	0.753	rs9549254	chr13:41234763	G/A	cg21288729	chr13:41239152	FOXO1	0.49	4.95	0.3	1.4e-6	Red blood cell count;
KIRP	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg14675211	chr2:100938903	LONRF2	0.48	6.33	0.37	1.16e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs8060686	0.858	rs7187289	chr16:67967878	A/C	cg26727032	chr16:67993705	SLC12A4	-0.77	-8.75	-0.49	3.45e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg17376030	chr22:41985996	PMM1	-0.44	-5.29	-0.32	2.71e-7	Vitiligo;
KIRP	cis	rs2562456	0.833	rs11672583	chr19:21562165	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	9.23	0.51	1.3e-17	Mood instability;
KIRP	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg23533926	chr12:111358616	MYL2	-0.57	-7.94	-0.45	7.22e-14	Breast cancer;
KIRP	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09243735	chr2:215674664	BARD1	0.45	6.28	0.37	1.52e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg25486957	chr4:152246857	NA	-0.54	-5.62	-0.34	5.19e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4478037	1.000	rs4074415	chr3:33161745	A/G	cg19404215	chr3:33155277	CRTAP	0.71	6.6	0.39	2.57e-10	Major depressive disorder;
KIRP	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.83	-13.59	-0.65	9.65e-32	Prostate cancer;
KIRP	trans	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs1867631	0.585	rs4655639	chr1:67089090	T/C	cg13052034	chr1:66999238	SGIP1	0.42	6.25	0.37	1.77e-9	Menopause (age at onset);
KIRP	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-6.29	-0.37	1.48e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.46	-6.29	-0.37	1.42e-9	DNA methylation (variation);
KIRP	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-0.64	-5.84	-0.35	1.64e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.96	10.94	0.57	5.88e-23	HIV-1 control;
KIRP	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg07810366	chr2:100720526	AFF3	0.32	5.26	0.32	3.1e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg23594656	chr7:65796392	TPST1	0.51	7.89	0.45	9.9e-14	Aortic root size;
KIRP	cis	rs7712401	0.601	rs418562	chr5:122340262	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.39e-7	Mean platelet volume;
KIRP	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18876405	chr7:65276391	NA	0.41	5.08	0.31	7.59e-7	Aortic root size;
KIRP	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg16141378	chr3:129829833	LOC729375	0.53	6.99	0.41	2.62e-11	Retinal vascular caliber;
KIRP	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg13703089	chr14:106090767	NA	-0.35	-4.88	-0.3	1.89e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg03060546	chr3:49711283	APEH	-0.71	-5.06	-0.31	8.08e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2970992	0.728	rs1028043	chr2:101321427	G/A	cg01042948	chr2:101319752	NA	0.42	6.62	0.39	2.23e-10	Educational attainment;
KIRP	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.73e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg15691649	chr6:25882328	NA	0.39	5.04	0.31	9.19e-7	Blood metabolite levels;
KIRP	cis	rs1335645	0.570	rs6703407	chr1:111622807	G/A	cg00321911	chr1:111669324	DRAM2	-0.51	-4.99	-0.3	1.13e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg16141378	chr3:129829833	LOC729375	-0.62	-8.19	-0.46	1.46e-14	Morning vs. evening chronotype;
KIRP	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.37	-0.38	9.04e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.73	10.88	0.57	9.25e-23	Orofacial clefts;
KIRP	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg13165212	chr22:42675999	NA	0.4	6.97	0.41	2.92e-11	Cognitive function;
KIRP	trans	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg00405596	chr8:11794950	NA	-0.45	-6.04	-0.36	5.79e-9	Joint mobility (Beighton score);
KIRP	cis	rs2193412	0.502	rs58519896	chr2:51155839	C/A	cg10917619	chr2:51255627	NRXN1	-0.41	-4.96	-0.3	1.33e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-6.8	-0.4	7.91e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.33	-0.37	1.18e-9	Axial length;
KIRP	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg14993813	chr1:46806288	NSUN4	-0.62	-7.3	-0.42	3.99e-12	Menopause (age at onset);
KIRP	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.51	0.48	1.72e-15	Prudent dietary pattern;
KIRP	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.97	14.18	0.67	9e-34	Morning vs. evening chronotype;
KIRP	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg23391107	chr17:45924227	SP6	0.42	5.64	0.34	4.76e-8	Ease of getting up in the morning;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06818804	chr15:78441680	IDH3A	0.48	6.27	0.37	1.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.04	0.46	3.81e-14	Myopia (pathological);
KIRP	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg18944383	chr4:111397179	ENPEP	0.47	7.63	0.44	5.02e-13	Coronary artery disease;
KIRP	cis	rs35123781	1.000	rs585101	chr5:139058454	T/C	cg10513866	chr5:139070639	NA	0.35	4.91	0.3	1.63e-6	Schizophrenia;
KIRP	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg14683738	chr19:37701593	ZNF585B	0.49	4.99	0.3	1.16e-6	Coronary artery calcification;
KIRP	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.77	8.87	0.49	1.49e-16	Corneal astigmatism;
KIRP	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.15	0.54	1.85e-20	Cognitive test performance;
KIRP	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs8133932	0.654	rs410902	chr21:47341794	G/A	cg11214348	chr21:47283868	PCBP3	-0.44	-5.11	-0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs6987853	0.933	rs1343875	chr8:42424749	C/T	cg09913449	chr8:42400586	C8orf40	0.43	5.57	0.33	6.75e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17001868	1.000	rs73167022	chr22:40797256	A/T	cg07138101	chr22:40742427	ADSL	0.72	6.07	0.36	4.76e-9	Mammographic density (dense area);
KIRP	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg05805236	chr11:65401703	PCNXL3	0.5	6.61	0.39	2.41e-10	Acne (severe);
KIRP	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.03	-0.31	9.44e-7	Retinal vascular caliber;
KIRP	cis	rs834811	1.000	rs834811	chr7:135884571	A/G	cg01726295	chr7:135938950	NA	0.36	5.13	0.31	5.88e-7	Post-traumatic stress disorder;
KIRP	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.78e-7	Aortic root size;
KIRP	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.93	14.65	0.68	2.27e-35	Testicular germ cell tumor;
KIRP	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.12	-15.39	-0.7	6.78e-38	Breast cancer;
KIRP	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg04944784	chr2:26401820	FAM59B	-0.59	-6.92	-0.4	3.79e-11	Gut microbiome composition (summer);
KIRP	trans	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.45	-6.14	-0.36	3.29e-9	Mean corpuscular volume;
KIRP	trans	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg15469184	chr8:337539	NA	0.56	6.6	0.39	2.56e-10	Obesity-related traits;
KIRP	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.21	-0.32	3.94e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4664293	0.667	rs6432562	chr2:160648006	A/T	cg08347373	chr2:160653686	CD302	-0.39	-6.08	-0.36	4.57e-9	Monocyte percentage of white cells;
KIRP	cis	rs4356932	0.967	rs12509593	chr4:76987746	T/G	cg19388996	chr4:76862389	NAAA	0.39	5.11	0.31	6.63e-7	Blood protein levels;
KIRP	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.8	9.3	0.51	7.88e-18	Post bronchodilator FEV1;
KIRP	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg15832292	chr6:96025679	MANEA	0.81	8.63	0.48	7.51e-16	Behavioural disinhibition (generation interaction);
KIRP	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg21775007	chr8:11205619	TDH	0.47	5.97	0.36	8.24e-9	Neuroticism;
KIRP	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7116495	1.000	rs517837	chr11:71802359	A/G	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.4	-0.33	1.55e-7	Life satisfaction;
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.42	0.33	1.44e-7	Lung cancer;
KIRP	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.79	11.13	0.58	1.47e-23	Bone properties (heel);
KIRP	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.59	8.12	0.46	2.23e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg27411982	chr8:10470053	RP1L1	0.42	5.06	0.31	8.3e-7	Neuroticism;
KIRP	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs151997	0.508	rs9292165	chr5:50272619	T/C	cg06027927	chr5:50259733	NA	0.53	6.67	0.39	1.7e-10	Callous-unemotional behaviour;
KIRP	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-7.8	-0.45	1.79e-13	Monocyte percentage of white cells;
KIRP	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg26752888	chr8:11627280	NEIL2	-0.43	-4.91	-0.3	1.62e-6	Myopia (pathological);
KIRP	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.02	-0.41	2.19e-11	Menopause (age at onset);
KIRP	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg10047753	chr17:41438598	NA	0.89	12.65	0.63	1.4e-28	Menopause (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14232643	chr2:97481853	CNNM3	-0.46	-6.1	-0.36	4.12e-9	Metabolic traits;
KIRP	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.49	6.79	0.4	8.13e-11	Dupuytren's disease;
KIRP	cis	rs4765905	0.646	rs2238045	chr12:2299823	C/T	cg10668781	chr12:2307325	CACNA1C	-0.35	-7.01	-0.41	2.31e-11	Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12104346	chr6:43445233	TJAP1	-0.52	-6.12	-0.36	3.76e-9	Menopause (age at onset);
KIRP	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg12315302	chr6:26189340	HIST1H4D	0.76	5.4	0.33	1.6e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.17	0.46	1.59e-14	Personality dimensions;
KIRP	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.47	5.91	0.35	1.13e-8	Breast cancer;
KIRP	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg16141378	chr3:129829833	LOC729375	0.57	7.54	0.43	8.92e-13	Neuroticism;
KIRP	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg11130432	chr3:121712080	ILDR1	-0.43	-5.08	-0.31	7.62e-7	Multiple sclerosis;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.9	-0.3	1.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.95	16.65	0.73	3.3e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.85	12.84	0.63	3.18e-29	Menarche (age at onset);
KIRP	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg25036284	chr2:26402008	FAM59B	-0.53	-5.51	-0.33	9.02e-8	Gut microbiome composition (summer);
KIRP	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg17941049	chr3:63904683	ATXN7	-0.53	-5.27	-0.32	3.01e-7	Type 2 diabetes;
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg11641102	chr8:27183873	PTK2B	0.44	5.8	0.35	2.01e-8	Neuroticism;
KIRP	trans	rs11113894	0.579	rs17040444	chr12:108784727	G/A	cg27506254	chr8:56436472	XKR4	-0.73	-6.1	-0.36	4.17e-9	Obesity-related traits;
KIRP	cis	rs4789452	0.595	rs7359497	chr17:75352173	C/T	cg05865280	chr17:75406074	SEPT9	0.26	5.72	0.34	3.13e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg18586891	chr4:952366	TMEM175	0.63	5.43	0.33	1.33e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9864370	0.818	rs1685643	chr3:168935768	A/C	cg15645463	chr11:418251	SIGIRR;ANO9	0.55	6.1	0.36	4.15e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.78	9.77	0.53	2.91e-19	Corneal astigmatism;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	0.35	5.04	0.31	9.22e-7	Lymphocyte counts;
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg05562828	chr17:3906858	NA	0.58	8.94	0.5	9.52e-17	Type 2 diabetes;
KIRP	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19346786	chr7:2764209	NA	-0.52	-8.51	-0.48	1.74e-15	Height;
KIRP	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg02073558	chr3:44770973	ZNF501	0.62	8.89	0.49	1.32e-16	Depressive symptoms;
KIRP	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.79	9.73	0.53	3.92e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg05802129	chr4:122689817	NA	-0.59	-7.48	-0.43	1.31e-12	Type 2 diabetes;
KIRP	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.32	-0.32	2.29e-7	Major depressive disorder;
KIRP	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.35	-0.42	2.88e-12	Triglycerides;
KIRP	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.93	0.3	1.5e-6	Menopause (age at onset);
KIRP	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg05044414	chr3:183734942	ABCC5	0.37	5.6	0.34	5.77e-8	Anterior chamber depth;
KIRP	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg14458575	chr2:238380390	NA	0.68	7.01	0.41	2.3e-11	Prostate cancer;
KIRP	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.9e-9	Endometrial cancer;
KIRP	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.63	10.55	0.56	1.04e-21	Coronary artery disease;
KIRP	cis	rs2133450	0.508	rs6443100	chr3:7333382	G/T	cg19930620	chr3:7340148	GRM7	0.37	5.41	0.33	1.52e-7	Early response to risperidone in schizophrenia;
KIRP	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.6	6.9	0.4	4.34e-11	HDL cholesterol;
KIRP	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.58	-8.9	-0.49	1.22e-16	Coronary artery disease;
KIRP	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg02931644	chr1:25747376	RHCE	0.37	6.6	0.39	2.56e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.44	6.02	0.36	6.28e-9	Total body bone mineral density;
KIRP	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.47	6.56	0.39	3.21e-10	Childhood ear infection;
KIRP	cis	rs1957429	0.614	rs66883381	chr14:65334773	C/T	cg23373153	chr14:65346875	NA	-0.68	-5.61	-0.34	5.3e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.83	12.93	0.64	1.53e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	1.05	14.77	0.69	9.33e-36	Menopause (age at onset);
KIRP	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	5.67	0.34	4.07e-8	Bipolar disorder;
KIRP	cis	rs9400467	0.506	rs12215049	chr6:111618384	A/G	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs6725041	0.599	rs11693640	chr2:213046179	C/T	cg20637307	chr2:213403960	ERBB4	0.41	5.59	0.34	6.06e-8	QT interval (ambient particulate matter interaction);
KIRP	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.75	-9.98	-0.54	6.68e-20	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7011192	0.793	rs13269921	chr8:10520913	A/G	cg04501334	chr8:10513686	RP1L1	0.59	5.2	0.31	4.18e-7	Suicide;
KIRP	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.95	12.34	0.62	1.5e-27	Menopause (age at onset);
KIRP	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.42	7.79	0.45	1.82e-13	Educational attainment (years of education);
KIRP	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg22697864	chr1:46954754	NA	0.37	4.85	0.3	2.15e-6	Monobrow;
KIRP	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.4	-4.96	-0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg11498726	chr8:26250323	BNIP3L	-0.57	-7.83	-0.45	1.42e-13	Red cell distribution width;
KIRP	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg05973401	chr12:123451056	ABCB9	0.62	7.27	0.42	4.73e-12	Platelet count;
KIRP	cis	rs12995491	0.731	rs17435439	chr2:88511391	A/G	cg04511125	chr2:88470314	THNSL2	-0.45	-5.65	-0.34	4.51e-8	Response to metformin (IC50);
KIRP	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.74	9.39	0.51	4.16e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07620207	chr11:16430764	SOX6	0.34	6.04	0.36	5.71e-9	Survival in pancreatic cancer;
KIRP	cis	rs6142102	0.886	rs4911147	chr20:32667607	C/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.67	0.39	1.72e-10	Skin pigmentation;
KIRP	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg17294928	chr15:75287854	SCAMP5	0.37	5.06	0.31	8.39e-7	Breast cancer;
KIRP	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	0.99	8.47	0.48	2.19e-15	Blood protein levels;
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg26134248	chr17:3907702	NA	0.6	8.86	0.49	1.62e-16	Type 2 diabetes;
KIRP	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg04833713	chr10:74871078	NUDT13	0.46	5.1	0.31	6.83e-7	Incident atrial fibrillation;
KIRP	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.05	-0.46	3.47e-14	Mean corpuscular volume;
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.68	0.34	3.7e-8	Platelet count;
KIRP	cis	rs2071403	1.000	rs2071403	chr2:1417244	C/T	cg06500727	chr2:1417164	TPO	-0.44	-6.97	-0.41	2.87e-11	Thyroid peroxidase antibody positivity;
KIRP	cis	rs131805	1.000	rs131805	chr22:50964153	T/C	cg06345736	chr22:50966936	TYMP	0.67	7.09	0.41	1.38e-11	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21011830	chr19:17970855	RPL18AP3;RPL18A	0.55	6.74	0.39	1.13e-10	Smoking initiation;
KIRP	trans	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg03735916	chr2:200715285	NA	-0.45	-6.04	-0.36	5.61e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.54	6.63	0.39	2.14e-10	Asthma;
KIRP	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg00977110	chr5:151150581	G3BP1	0.61	6.0	0.36	7.11e-9	Preschool internalizing problems;
KIRP	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.59	-9.06	-0.5	4.06e-17	Mean corpuscular volume;
KIRP	cis	rs6466055	0.589	rs6976394	chr7:104632980	A/G	cg04380332	chr7:105027541	SRPK2	-0.4	-5.36	-0.32	1.94e-7	Schizophrenia;
KIRP	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg25801113	chr15:45476975	SHF	0.43	7.94	0.45	7.32e-14	Uric acid levels;
KIRP	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.48	5.71	0.34	3.24e-8	Uric acid levels;
KIRP	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg21605333	chr4:119757512	SEC24D	1.6	11.7	0.6	1.93e-25	Cannabis dependence symptom count;
KIRP	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg18490616	chr2:88469792	THNSL2	0.66	5.32	0.32	2.35e-7	Plasma clusterin levels;
KIRP	trans	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-6.53	-0.38	3.66e-10	Endometrial cancer;
KIRP	cis	rs1538970	1.000	rs1417578	chr1:45850590	A/G	cg05343316	chr1:45956843	TESK2	0.64	7.38	0.43	2.44e-12	Platelet count;
KIRP	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg16141378	chr3:129829833	LOC729375	0.55	6.64	0.39	1.99e-10	Retinal vascular caliber;
KIRP	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.87	-10.76	-0.57	2.27e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs6968419	0.692	rs10500060	chr7:115900686	C/T	cg02561103	chr7:115862891	TES	-0.4	-5.66	-0.34	4.23e-8	Intraocular pressure;
KIRP	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12292205	chr6:26970375	C6orf41	-0.65	-7.34	-0.42	3.09e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-9.14	-0.5	2.42e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg14289826	chr9:140003911	NA	-0.49	-8.9	-0.49	1.21e-16	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9311676	0.656	rs55783924	chr3:58403610	C/T	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs12145833	0.596	rs3926866	chr1:243437632	G/C	cg02356786	chr1:243265016	LOC731275	0.86	5.84	0.35	1.62e-8	Obesity (early onset extreme);
KIRP	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg11801959	chr13:50123613	RCBTB1	-0.38	-5.13	-0.31	5.87e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2839627	0.561	rs9808758	chr21:44262390	G/C	cg03543861	chr21:44258195	NA	0.53	6.15	0.37	3.1e-9	Information processing speed;
KIRP	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.67	-7.04	-0.41	1.95e-11	Menarche (age at onset);
KIRP	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.86	-10.16	-0.54	1.77e-20	Body mass index;
KIRP	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.77	-9.17	-0.5	1.95e-17	Pancreatic cancer;
KIRP	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.43	-7.52	-0.43	9.92e-13	Refractive error;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23346625	chr5:146619708	STK32A	0.42	6.02	0.36	6.22e-9	Survival in pancreatic cancer;
KIRP	cis	rs7174755	0.637	rs10152713	chr15:68471891	A/G	cg16038331	chr15:68503187	CLN6	-0.36	-4.85	-0.3	2.22e-6	Major depressive disorder;
KIRP	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.4	4.87	0.3	2.04e-6	Renal cell carcinoma;
KIRP	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	12.23	0.61	3.59e-27	Menopause (age at onset);
KIRP	cis	rs8018808	0.935	rs17824316	chr14:77930407	G/A	cg18872420	chr14:78023429	SPTLC2	0.36	5.24	0.32	3.52e-7	Myeloid white cell count;
KIRP	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg14675211	chr2:100938903	LONRF2	0.45	6.12	0.36	3.75e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11874712	0.545	rs3745002	chr18:43652345	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.35	-5.07	-0.31	7.85e-7	Migraine - clinic-based;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23393031	chr19:1249905	MIDN	0.54	7.11	0.41	1.22e-11	Parkinson's disease;
KIRP	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.01	12.43	0.62	7.52e-28	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19510180	chr4:69111580	TMPRSS11B	-0.48	-7.88	-0.45	1.08e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.74	-8.61	-0.48	8.64e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs13396424	0.639	rs2711302	chr2:46220888	A/G	cg17367816	chr10:42673902	NA	0.61	6.02	0.36	6.33e-9	Metabolite levels  (X-11787);
KIRP	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	8.26	0.47	8.98e-15	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.85	-0.49	1.72e-16	Retinal vascular caliber;
KIRP	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg02725872	chr8:58115012	NA	-0.49	-5.39	-0.33	1.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3120667	0.720	rs72698964	chr1:152416616	C/T	cg26876637	chr1:152193138	HRNR	-0.63	-5.87	-0.35	1.4e-8	Eating disorders;
KIRP	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.39	-8.5	-0.48	1.86e-15	Breast cancer;
KIRP	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg08738300	chr3:44038990	NA	0.66	9.16	0.5	2.08e-17	Coronary artery disease;
KIRP	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.42	5.98	0.36	7.68e-9	Body mass index;
KIRP	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.43	6.43	0.38	6.67e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg21174375	chr14:64681225	SYNE2	0.65	8.17	0.46	1.65e-14	Atrial fibrillation;
KIRP	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06634786	chr22:41940651	POLR3H	-0.45	-5.44	-0.33	1.28e-7	Vitiligo;
KIRP	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg26441486	chr22:50317300	CRELD2	0.43	7.11	0.41	1.29e-11	Schizophrenia;
KIRP	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	1.02	15.8	0.71	2.63e-39	Bipolar disorder;
KIRP	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg12549451	chr6:135224345	NA	-0.43	-5.33	-0.32	2.17e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.69	7.57	0.43	7.39e-13	Corneal astigmatism;
KIRP	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-12.55	-0.62	2.94e-28	Height;
KIRP	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg01411142	chr8:19674711	INTS10	0.51	5.56	0.33	7.17e-8	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs2048656	0.540	rs55868514	chr8:9680400	T/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.61	-0.44	5.79e-13	Schizophrenia;
KIRP	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg18477163	chr1:228402036	OBSCN	-0.31	-6.51	-0.38	4.12e-10	Diastolic blood pressure;
KIRP	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.17	0.42	8.68e-12	Mean corpuscular volume;
KIRP	cis	rs9308433	0.569	rs1353718	chr1:214459652	A/T	cg06198575	chr1:214491504	SMYD2	0.49	6.36	0.38	9.57e-10	IgG glycosylation;
KIRP	trans	rs4904167	0.841	rs1031787	chr14:84694489	C/G	cg12043473	chr7:66750978	NA	0.47	6.22	0.37	2.12e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04279596	chr4:120133691	USP53	-0.55	-6.17	-0.37	2.82e-9	Menopause (age at onset);
KIRP	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.75	-10.39	-0.55	3.28e-21	Hypospadias;
KIRP	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg12131826	chr15:77904385	NA	0.49	5.84	0.35	1.61e-8	Type 2 diabetes;
KIRP	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.73	0.49	3.99e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-10.08	-0.54	3.11e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs654950	0.743	rs115951861	chr1:41992488	C/T	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.46	-0.38	5.45e-10	Airway imaging phenotypes;
KIRP	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.26	0.37	1.65e-9	Breast cancer;
KIRP	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.86	12.9	0.64	2.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg05784532	chr1:230284198	GALNT2	0.41	6.2	0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs7394190	0.935	rs6480708	chr10:75420114	C/A	cg04833713	chr10:74871078	NUDT13	0.37	5.05	0.31	8.53e-7	Incident atrial fibrillation;
KIRP	cis	rs1558375	0.679	rs31672	chr7:87059699	C/T	cg00919237	chr7:87102261	ABCB4	0.54	6.85	0.4	5.97e-11	Gallbladder cancer;
KIRP	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	0.81	13.56	0.65	1.18e-31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.5	-6.43	-0.38	6.41e-10	Immature fraction of reticulocytes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17426184	chr15:42082708	MAPKBP1	0.44	6.21	0.37	2.27e-9	Interleukin-4 levels;
KIRP	cis	rs3829109	0.564	rs10781506	chr9:139271461	C/T	cg14169450	chr9:139327907	INPP5E	0.43	5.3	0.32	2.62e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg05914723	chr15:78953907	NA	-0.43	-5.27	-0.32	3.03e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.51	0.38	4.13e-10	Menarche (age at onset);
KIRP	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.66	9.68	0.53	5.43e-19	Dupuytren's disease;
KIRP	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg27432699	chr2:27873401	GPN1	-0.43	-5.55	-0.33	7.48e-8	Total body bone mineral density;
KIRP	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.95	14.84	0.69	5.28e-36	Glomerular filtration rate (creatinine);
KIRP	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg09029085	chr17:47094198	IGF2BP1	0.25	5.75	0.34	2.61e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-10.23	-0.55	1.08e-20	Total body bone mineral density;
KIRP	cis	rs2071426	0.633	rs12780874	chr10:96765018	T/C	cg09036531	chr10:96991505	NA	-0.63	-6.44	-0.38	6.21e-10	Blood metabolite levels;
KIRP	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.74	-9.4	-0.51	3.95e-18	Facial morphology (factor 19);
KIRP	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg10402321	chr1:26617780	UBXN11	-0.43	-5.61	-0.34	5.3e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg13206674	chr6:150067644	NUP43	0.51	7.23	0.42	6.04e-12	Testicular germ cell tumor;
KIRP	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.43	-5.81	-0.35	1.96e-8	Mean corpuscular volume;
KIRP	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.43	-5.16	-0.31	4.99e-7	IgG glycosylation;
KIRP	cis	rs2669010	1.000	rs2669010	chr12:77009060	A/G	cg14998926	chr12:77026162	NA	-0.43	-5.67	-0.34	4.09e-8	Systemic lupus erythematosus;
KIRP	cis	rs12367572	0.663	rs1118481	chr12:45354469	C/G	cg04608330	chr12:45269318	NELL2	-0.43	-5.73	-0.34	2.94e-8	Gut microbiome composition (summer);
KIRP	cis	rs4148660	1.000	rs1356370	chr12:22079567	G/A	cg14669847	chr12:22099120	NA	0.34	5.66	0.34	4.2e-8	Gout;
KIRP	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Hypertriglyceridemia;
KIRP	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg04727924	chr7:799746	HEATR2	-0.78	-8.92	-0.49	1.08e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.68	-8.48	-0.48	2.13e-15	Multiple sclerosis;
KIRP	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.72	9.02	0.5	5.43e-17	Huntington's disease progression;
KIRP	cis	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg07636037	chr3:49044803	WDR6	0.55	5.48	0.33	1.08e-7	Menarche (age at onset);
KIRP	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-9.01	-0.5	6e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg04166393	chr7:2884313	GNA12	0.48	6.26	0.37	1.67e-9	Height;
KIRP	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Parkinson's disease;
KIRP	cis	rs13361707	0.600	rs10078575	chr5:40704074	A/G	cg01087697	chr5:40835557	RPL37	-0.48	-5.03	-0.31	9.41e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.49	7.21	0.42	6.89e-12	Urate levels in lean individuals;
KIRP	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.44	-0.43	1.7e-12	Total cholesterol levels;
KIRP	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.51	6.26	0.37	1.73e-9	Monobrow;
KIRP	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.83	0.4	6.49e-11	Electroencephalogram traits;
KIRP	cis	rs11955398	0.583	rs7719726	chr5:59949537	T/C	cg02684056	chr5:59996105	DEPDC1B	0.5	5.62	0.34	5.29e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg19468946	chr17:37922297	IKZF3	-0.42	-6.03	-0.36	6.02e-9	Self-reported allergy;
KIRP	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg07862535	chr7:139043722	LUC7L2	-0.43	-4.94	-0.3	1.43e-6	Diisocyanate-induced asthma;
KIRP	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.48	0.38	4.99e-10	Myopia (pathological);
KIRP	cis	rs7582720	0.667	rs114863726	chr2:204158375	G/A	cg08076091	chr2:203926405	NBEAL1	0.82	7.6	0.44	6.2e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-6.67	-0.39	1.67e-10	Colorectal cancer;
KIRP	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg14675211	chr2:100938903	LONRF2	0.47	6.16	0.37	2.88e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg04013166	chr16:89971882	TCF25	0.57	5.98	0.36	7.8e-9	Skin colour saturation;
KIRP	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg06627628	chr2:24431161	ITSN2	-0.55	-4.85	-0.3	2.2e-6	Lymphocyte counts;
KIRP	cis	rs600806	0.778	rs11101962	chr1:110014187	A/T	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg01941274	chr14:50234650	KLHDC2	0.41	4.92	0.3	1.55e-6	Carotid intima media thickness;
KIRP	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg07930552	chr6:133119739	C6orf192	0.83	5.8	0.35	2.04e-8	Type 2 diabetes nephropathy;
KIRP	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg05315796	chr3:52349193	DNAH1	0.43	6.59	0.39	2.61e-10	Bipolar disorder;
KIRP	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg04310649	chr10:35416472	CREM	-0.54	-6.02	-0.36	6.23e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg03585969	chr10:35415529	CREM	0.78	9.69	0.53	5.11e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.83	0.4	6.61e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4006360	0.547	rs9892487	chr17:39252969	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.41	-0.47	3.36e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.86	14.37	0.68	2.15e-34	Prostate cancer;
KIRP	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg24812749	chr6:127587940	RNF146	0.61	7.55	0.43	8.51e-13	Breast cancer;
KIRP	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg05555928	chr11:63887634	MACROD1	-0.57	-5.27	-0.32	3.02e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.95	16.69	0.73	2.43e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs4765905	0.610	rs7308351	chr12:2303546	T/C	cg10668781	chr12:2307325	CACNA1C	-0.35	-6.9	-0.4	4.33e-11	Schizophrenia;
KIRP	cis	rs17401966	0.522	rs17396973	chr1:10334924	C/T	cg17425144	chr1:10567563	PEX14	-0.3	-5.34	-0.32	2.09e-7	Hepatocellular carcinoma;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.36e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06544989	chr22:39130855	UNC84B	0.5	8.14	0.46	2.01e-14	Menopause (age at onset);
KIRP	cis	rs6142102	0.961	rs4911390	chr20:32565207	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	6.51	0.38	4.19e-10	Skin pigmentation;
KIRP	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.54	-7.07	-0.41	1.61e-11	Waist-hip ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00026457	chr1:200116736	NR5A2	0.48	6.13	0.36	3.51e-9	Interleukin-4 levels;
KIRP	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.31	-6.12	-0.36	3.57e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.65	9.41	0.51	3.74e-18	Menarche (age at onset);
KIRP	cis	rs2380205	0.967	rs9663995	chr10:5897944	A/G	cg27141509	chr10:5886111	NA	-0.38	-5.54	-0.33	7.7e-8	Breast cancer;
KIRP	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.7	-0.44	3.21e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs714515	0.934	rs9425592	chr1:172359116	A/G	cg01573306	chr1:172330400	DNM3	0.44	5.79	0.35	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.61	-8.11	-0.46	2.41e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10465746	0.935	rs11163878	chr1:84442654	G/A	cg10977910	chr1:84465055	TTLL7	0.47	5.72	0.34	3.04e-8	Obesity-related traits;
KIRP	cis	rs1497828	1.000	rs1391286	chr1:217561510	C/T	cg04411442	chr1:217543379	NA	0.3	4.92	0.3	1.61e-6	Dialysis-related mortality;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg08821669	chr12:120875978	COX6A1	0.45	6.04	0.36	5.53e-9	Obesity-related traits;
KIRP	cis	rs6450176	1.000	rs3776715	chr5:53299095	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.82	-0.35	1.78e-8	Height;
KIRP	cis	rs13014235	0.592	rs55860809	chr2:202259070	C/T	cg06431681	chr2:202330990	STRADB	0.52	6.94	0.4	3.5e-11	Basal cell carcinoma;
KIRP	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.98	14.22	0.67	6.75e-34	Cognitive function;
KIRP	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg10760299	chr15:45669010	GATM	0.32	5.03	0.31	9.43e-7	Homoarginine levels;
KIRP	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06544989	chr22:39130855	UNC84B	0.51	8.26	0.47	9.2e-15	Menopause (age at onset);
KIRP	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg02175503	chr12:58329896	NA	-0.43	-4.98	-0.3	1.21e-6	Multiple sclerosis;
KIRP	cis	rs11997175	0.545	rs4428637	chr8:33666944	T/G	cg04338863	chr8:33670619	NA	0.44	5.53	0.33	8.05e-8	Body mass index;
KIRP	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg00241281	chr14:105779794	PACS2	-0.36	-5.05	-0.31	8.66e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6725041	0.792	rs11694300	chr2:213092028	T/C	cg20637307	chr2:213403960	ERBB4	-0.39	-5.12	-0.31	6.15e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg05802129	chr4:122689817	NA	-0.46	-6.69	-0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.61	-0.39	2.31e-10	Glomerular filtration rate;
KIRP	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.6	0.34	5.83e-8	Educational attainment;
KIRP	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.21	-0.32	4e-7	Alcohol dependence;
KIRP	trans	rs4083578	0.810	rs9542878	chr13:72754108	C/T	cg19577074	chr4:152405174	FAM160A1	0.37	6.07	0.36	4.88e-9	Cognitive performance;
KIRP	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.05	-0.31	8.56e-7	Metabolite levels;
KIRP	cis	rs1620921	0.967	rs1247556	chr6:161189595	G/C	cg01280913	chr6:161186852	NA	-0.41	-5.75	-0.34	2.66e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.65	8.97	0.5	7.89e-17	Longevity;
KIRP	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg07001201	chr5:642380	CEP72	0.66	6.06	0.36	4.99e-9	Obesity-related traits;
KIRP	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.61	-6.68	-0.39	1.6e-10	Corneal structure;
KIRP	cis	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.39	5.0	0.3	1.11e-6	Leprosy;
KIRP	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23161317	chr6:28129485	ZNF389	0.48	5.56	0.33	6.86e-8	Depression;
KIRP	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg08975724	chr8:8085496	FLJ10661	-0.72	-10.05	-0.54	3.83e-20	Retinal vascular caliber;
KIRP	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs6732160	0.809	rs13387480	chr2:73371007	C/T	cg01422370	chr2:73384389	NA	0.41	5.42	0.33	1.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.68	6.8	0.4	8.04e-11	Vitiligo;
KIRP	cis	rs258892	0.842	rs11952089	chr5:72020508	C/T	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg03959625	chr15:84868606	LOC388152	0.51	6.09	0.36	4.39e-9	Schizophrenia;
KIRP	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg06212747	chr3:49208901	KLHDC8B	0.5	5.1	0.31	6.82e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs6832769	1.000	rs3805157	chr4:56364103	A/G	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	8.39	0.47	3.79e-15	Total body bone mineral density;
KIRP	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.66	8.48	0.48	2.11e-15	Multiple sclerosis;
KIRP	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.82	-8.19	-0.46	1.43e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-4.88	-0.3	1.92e-6	Blood metabolite levels;
KIRP	trans	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg25288420	chr1:78511713	GIPC2	-0.51	-6.79	-0.4	8.55e-11	Obesity-related traits;
KIRP	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.37	10.83	0.57	1.37e-22	Economic and political preferences (immigration/crime);
KIRP	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg08975724	chr8:8085496	FLJ10661	0.52	6.82	0.4	7.16e-11	Systolic blood pressure;
KIRP	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.14	0.36	3.26e-9	Blood metabolite levels;
KIRP	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg25457927	chr22:38595422	NA	-0.3	-6.03	-0.36	5.97e-9	Breast cancer;
KIRP	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg08499158	chr17:42289980	UBTF	-0.64	-8.36	-0.47	4.83e-15	Total body bone mineral density;
KIRP	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.86	11.85	0.6	6.15e-26	Response to antipsychotic treatment;
KIRP	cis	rs13315871	0.929	rs11717783	chr3:58267642	A/T	cg12435725	chr3:58293450	RPP14	-0.42	-4.96	-0.3	1.31e-6	Cholesterol, total;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	ch.10.2633792F	chr10:123987885	TACC2	0.5	6.43	0.38	6.53e-10	C-reactive protein;
KIRP	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08704250	chr15:31115839	NA	-0.54	-8.23	-0.46	1.09e-14	Huntington's disease progression;
KIRP	cis	rs12930096	1.000	rs67188060	chr16:11679517	A/G	cg07439791	chr16:11680400	LITAF	0.64	5.35	0.32	1.99e-7	QT interval;
KIRP	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg02073558	chr3:44770973	ZNF501	0.58	8.32	0.47	6.26e-15	Depressive symptoms;
KIRP	cis	rs7779181	1.000	rs7779181	chr7:32345283	T/C	cg13207630	chr7:32358064	NA	0.45	5.58	0.34	6.38e-8	Body mass index;
KIRP	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg23752985	chr2:85803571	VAMP8	0.46	5.3	0.32	2.63e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs11166927	1.000	rs11166926	chr8:140795752	A/G	cg16909799	chr8:140841666	TRAPPC9	0.71	10.22	0.55	1.12e-20	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg00982548	chr2:198649783	BOLL	-0.58	-5.82	-0.35	1.79e-8	Ulcerative colitis;
KIRP	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01969796	chr4:750851	PCGF3	-0.45	-6.56	-0.39	3.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9972944	0.651	rs7221371	chr17:63765174	C/A	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg10932868	chr11:921992	NA	0.68	9.13	0.5	2.63e-17	Alzheimer's disease (late onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26422975	chr1:231473532	EXOC8;C1orf124	0.53	6.99	0.41	2.55e-11	Parkinson's disease;
KIRP	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.23	-0.37	1.99e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.69	-9.26	-0.51	1.03e-17	Total body bone mineral density;
KIRP	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	1.12	13.11	0.64	3.86e-30	Eosinophil percentage of granulocytes;
KIRP	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg04398451	chr17:18023971	MYO15A	0.4	4.9	0.3	1.75e-6	Body mass index;
KIRP	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.37	-5.28	-0.32	2.85e-7	Blood metabolite levels;
KIRP	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg27286337	chr10:134555280	INPP5A	0.57	5.35	0.32	1.99e-7	Primary sclerosing cholangitis;
KIRP	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs9400467	0.528	rs11153290	chr6:111718132	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.71	-0.34	3.22e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg07148914	chr20:33460835	GGT7	-0.53	-7.0	-0.41	2.46e-11	Height;
KIRP	trans	rs7594645	1.000	rs73985728	chr2:207668245	G/A	cg07589201	chr19:9546257	ZNF266	0.94	6.41	0.38	7.49e-10	Episodic memory;
KIRP	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.71	-0.34	3.27e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg18225595	chr11:63971243	STIP1	0.65	5.89	0.35	1.24e-8	Mean platelet volume;
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg10351095	chr21:47802916	PCNT	-0.41	-5.18	-0.31	4.67e-7	Testicular germ cell tumor;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg14242042	chr12:24715250	SOX5	0.91	6.48	0.38	4.96e-10	P wave terminal force;
KIRP	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.42	4.9	0.3	1.74e-6	Aortic root size;
KIRP	cis	rs10992471	0.729	rs1022844	chr9:95553464	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.45	-0.33	1.25e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg20368463	chr18:77673604	PQLC1	-0.61	-6.72	-0.39	1.22e-10	Opioid sensitivity;
KIRP	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg08501292	chr6:25962987	TRIM38	0.99	5.91	0.35	1.16e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg06815112	chr8:27182871	PTK2B	0.53	6.89	0.4	4.6e-11	Neuroticism;
KIRP	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg09408571	chr1:101003634	GPR88	-0.23	-5.25	-0.32	3.29e-7	Monocyte count;
KIRP	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.42	-6.21	-0.37	2.27e-9	Height;
KIRP	cis	rs71636778	0.722	rs34928032	chr1:27139229	A/G	cg12203394	chr1:27248618	NUDC	0.79	6.02	0.36	6.46e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg00343986	chr7:65444356	GUSB	0.43	5.1	0.31	6.75e-7	Aortic root size;
KIRP	cis	rs7119038	0.818	rs11217042	chr11:118682528	G/A	cg19308663	chr11:118741387	NA	0.53	9.04	0.5	4.65e-17	Sjögren's syndrome;
KIRP	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg07395648	chr5:131743802	NA	-0.38	-5.56	-0.33	7.07e-8	Acylcarnitine levels;
KIRP	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.81	-11.98	-0.61	2.31e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3762637	0.941	rs6788746	chr3:122106743	G/A	cg24169773	chr3:122142474	KPNA1	-0.54	-5.47	-0.33	1.09e-7	LDL cholesterol levels;
KIRP	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	1.09	8.15	0.46	1.88e-14	Gut microbiota (bacterial taxa);
KIRP	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-0.89	-10.75	-0.57	2.38e-22	Vitiligo;
KIRP	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.57	7.07	0.41	1.59e-11	Height;
KIRP	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg05340658	chr4:99064831	C4orf37	0.64	6.76	0.4	1.02e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.48e-6	Life satisfaction;
KIRP	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.85	0.3	2.14e-6	Menopause (age at onset);
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.48	6.55	0.39	3.4e-10	Mean corpuscular volume;
KIRP	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	5.96	0.36	8.85e-9	Menarche (age at onset);
KIRP	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg25019033	chr10:957182	NA	-0.49	-5.23	-0.32	3.64e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg15733309	chr7:157513707	PTPRN2	0.51	7.89	0.45	9.73e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs4835473	0.932	rs13129702	chr4:144706285	C/T	cg08833778	chr4:144622313	FREM3	0.34	4.91	0.3	1.67e-6	Immature fraction of reticulocytes;
KIRP	cis	rs17023223	0.537	rs2645300	chr1:119603067	C/A	cg05756136	chr1:119680316	WARS2	-0.54	-7.17	-0.42	8.73e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg04398451	chr17:18023971	MYO15A	0.69	9.33	0.51	6.47e-18	Total body bone mineral density;
KIRP	cis	rs78487399	0.808	rs79955955	chr2:43686985	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.13	-0.31	5.89e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg09890400	chr1:26503858	CNKSR1	0.43	5.87	0.35	1.42e-8	Height;
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg17441377	chr17:3906640	NA	0.47	6.68	0.39	1.59e-10	Type 2 diabetes;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg13453750	chr1:205783389	SLC41A1	-0.47	-7.33	-0.42	3.24e-12	Menarche (age at onset);
KIRP	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.59	-0.44	6.56e-13	Hemoglobin concentration;
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13939156	chr17:80058883	NA	0.5	7.6	0.44	6.33e-13	Life satisfaction;
KIRP	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.4	-5.44	-0.33	1.27e-7	Monocyte percentage of white cells;
KIRP	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.58	7.52	0.43	1.01e-12	Aortic root size;
KIRP	cis	rs1978968	0.869	rs5992931	chr22:18455914	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-7.21	-0.42	6.68e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs12982744	0.613	rs3786971	chr19:2141209	C/T	cg09261902	chr19:2140048	AP3D1	0.43	5.52	0.33	8.63e-8	Osteoarthritis;Height;
KIRP	cis	rs7646881	0.951	rs6441222	chr3:158449767	A/G	cg19483011	chr3:158453295	NA	-0.52	-5.98	-0.36	7.96e-9	Tetralogy of Fallot;
KIRP	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.81	0.4	7.4e-11	Neuroticism;
KIRP	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg18501202	chr6:125855421	NA	-0.35	-5.35	-0.32	1.99e-7	Brugada syndrome;
KIRP	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	6.31	0.37	1.32e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs34602589	0.535	rs7346579	chr20:43844722	A/G	cg10761708	chr20:43804764	PI3	0.51	5.37	0.32	1.87e-7	Parental longevity (mother's age at death);
KIRP	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.5	6.54	0.38	3.5e-10	Blood protein levels;
KIRP	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg03146154	chr1:46216737	IPP	-0.49	-6.43	-0.38	6.61e-10	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	11.14	0.58	1.34e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.34	-5.15	-0.31	5.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg12591125	chr7:1885375	MAD1L1	0.46	5.15	0.31	5.3e-7	Bipolar disorder;
KIRP	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs2637030	0.559	rs31303	chr5:52942197	C/T	cg06476337	chr5:52856530	NDUFS4	-0.57	-6.47	-0.38	5.4e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06544989	chr22:39130855	UNC84B	0.45	6.88	0.4	4.98e-11	Menopause (age at onset);
KIRP	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	8.31	0.47	6.32e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.38	7.61	0.44	5.67e-13	Diastolic blood pressure;
KIRP	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg06060754	chr5:176797920	RGS14	0.59	6.6	0.39	2.45e-10	Urate levels in lean individuals;
KIRP	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.76	9.43	0.52	3.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-11.3	-0.58	4.07e-24	Body mass index;
KIRP	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.37	-0.38	9.04e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg26134248	chr17:3907702	NA	-0.55	-7.99	-0.45	5.37e-14	Type 2 diabetes;
KIRP	cis	rs12476592	0.571	rs2028883	chr2:63804531	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs7852872	0.765	rs1861882	chr9:119256146	C/A	cg13792444	chr9:119245443	ASTN2	0.4	5.72	0.34	3.12e-8	Hippocampal volume;
KIRP	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.49	6.01	0.36	6.67e-9	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07592190	chr11:105785765	GRIA4	-0.4	-6.35	-0.38	1.05e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.02	-0.57	3.31e-23	Height;
KIRP	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg09699651	chr6:150184138	LRP11	0.6	8.23	0.46	1.13e-14	Testicular germ cell tumor;
KIRP	cis	rs17221829	0.673	rs1962257	chr11:89380737	G/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.23e-6	Anxiety in major depressive disorder;
KIRP	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	9.87	0.53	1.47e-19	Total body bone mineral density;
KIRP	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg23076370	chr14:107095027	NA	-0.42	-5.13	-0.31	5.8e-7	Kawasaki disease;
KIRP	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.82	-0.4	7.05e-11	Monocyte percentage of white cells;
KIRP	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.42	5.41	0.33	1.46e-7	Melanoma;
KIRP	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg03808351	chr9:123631620	PHF19	-0.35	-4.86	-0.3	2.12e-6	Rheumatoid arthritis;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16216227	chr4:174293382	SAP30	-0.47	-6.18	-0.37	2.7e-9	Myopia (pathological);
KIRP	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg17376030	chr22:41985996	PMM1	-0.83	-8.83	-0.49	1.98e-16	Vitiligo;
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg04025307	chr7:1156635	C7orf50	0.72	5.57	0.33	6.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-6.34	-0.37	1.09e-9	Chronic sinus infection;
KIRP	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.56	6.56	0.39	3.17e-10	Obesity-related traits;
KIRP	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.44	0.43	1.7e-12	Joint mobility (Beighton score);
KIRP	cis	rs6991838	0.557	rs4737222	chr8:66500113	G/T	cg13398993	chr8:66546079	ARMC1	-0.46	-5.22	-0.32	3.78e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-8.18	-0.46	1.51e-14	Monocyte count;
KIRP	cis	rs8077577	0.945	rs11654146	chr17:18076141	A/C	cg18869244	chr17:18121946	NA	0.49	5.5	0.33	9.56e-8	Obesity-related traits;
KIRP	trans	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs580438	0.529	rs6810132	chr3:13414864	G/A	cg10657019	chr3:13328039	NA	-0.51	-6.61	-0.39	2.41e-10	Myringotomy;
KIRP	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.79	-6.8	-0.4	7.78e-11	Bipolar disorder;
KIRP	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg05535760	chr7:792225	HEATR2	1.05	10.17	0.54	1.7e-20	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.07	0.41	1.58e-11	Height;
KIRP	trans	rs11158609	1.000	rs12879736	chr14:24674793	C/T	cg03265671	chr1:156616554	BCAN	-0.53	-6.48	-0.38	5.04e-10	Systolic blood pressure (cigarette smoking interaction);
KIRP	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs6546886	0.956	rs6755711	chr2:74301840	G/T	cg14702570	chr2:74259524	NA	-0.28	-5.55	-0.33	7.5e-8	Dialysis-related mortality;
KIRP	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.62	7.43	0.43	1.74e-12	Type 2 diabetes;
KIRP	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.91	-0.64	1.83e-29	Headache;
KIRP	cis	rs9898058	0.545	rs75764946	chr17:47782865	G/T	cg06375292	chr17:47786311	SLC35B1	-0.72	-5.33	-0.32	2.26e-7	Milk allergy;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg26754761	chr2:177040938	NA	0.33	5.79	0.35	2.16e-8	IgG glycosylation;
KIRP	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11987759	chr7:65425863	GUSB	0.49	6.43	0.38	6.58e-10	Aortic root size;
KIRP	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.36	-0.42	2.74e-12	Bone mineral density;
KIRP	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.47	-0.48	2.23e-15	Type 2 diabetes;
KIRP	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.62	11.15	0.58	1.19e-23	Total body bone mineral density;
KIRP	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.92	10.56	0.56	9.34e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg25019033	chr10:957182	NA	-0.59	-6.31	-0.37	1.31e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg26876637	chr1:152193138	HRNR	0.76	9.47	0.52	2.47e-18	Atopic dermatitis;
KIRP	cis	rs2273669	0.667	rs12215381	chr6:109363217	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.32	-0.37	1.2e-9	Prostate cancer;
KIRP	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.08	-0.36	4.66e-9	Height;
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.76	6.75	0.4	1.08e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05347473	chr6:146136440	FBXO30	-0.62	-9.14	-0.5	2.35e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073416	0.534	rs11623662	chr14:66021192	T/G	cg03016385	chr14:66212404	NA	-0.45	-5.62	-0.34	5.29e-8	N-glycan levels;
KIRP	trans	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19894588	chr14:64061835	NA	0.55	6.27	0.37	1.6e-9	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs3843585	0.870	rs10762324	chr10:71710262	A/G	cg07081753	chr10:71718679	COL13A1	0.32	5.04	0.31	8.94e-7	Middle childhood and early adolescence aggressive behavior;
KIRP	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg04998671	chr14:104000505	TRMT61A	-0.58	-6.9	-0.4	4.27e-11	Coronary artery disease;
KIRP	trans	rs12517041	1.000	rs12514453	chr5:23289951	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	0.91	8.9	0.49	1.23e-16	Calcium levels;
KIRP	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg04362960	chr10:104952993	NT5C2	0.64	7.51	0.43	1.1e-12	Arsenic metabolism;
KIRP	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg11641102	chr8:27183873	PTK2B	0.37	4.92	0.3	1.56e-6	Neuroticism;
KIRP	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.52	6.74	0.39	1.1e-10	Menopause (age at onset);
KIRP	cis	rs7083	0.875	rs536648	chr11:117143185	G/C	cg11523350	chr11:117171073	BACE1	-0.27	-5.15	-0.31	5.42e-7	Blood protein levels;
KIRP	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.46	-6.84	-0.4	6.29e-11	Electroencephalogram traits;
KIRP	cis	rs2278796	0.918	rs11240324	chr1:204955319	G/A	cg04862289	chr1:204966208	NFASC	0.56	7.83	0.45	1.47e-13	Mean platelet volume;
KIRP	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg20362242	chr5:692897	TPPP	0.58	5.0	0.3	1.08e-6	Obesity-related traits;
KIRP	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.22	0.32	3.9e-7	Lung cancer;
KIRP	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg24642439	chr20:33292090	TP53INP2	-0.58	-7.57	-0.43	7.67e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg10047753	chr17:41438598	NA	0.84	11.81	0.6	8.39e-26	Menopause (age at onset);
KIRP	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.52	-7.05	-0.41	1.75e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg27205649	chr11:78285834	NARS2	-0.54	-5.68	-0.34	3.73e-8	Testicular germ cell tumor;
KIRP	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg13010199	chr12:38710504	ALG10B	0.64	8.03	0.46	4.12e-14	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.84	12.28	0.62	2.43e-27	Colorectal cancer;
KIRP	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.72	-9.86	-0.53	1.58e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.61	-7.69	-0.44	3.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg24874828	chr4:187887005	NA	-0.47	-7.02	-0.41	2.21e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.96	0.36	8.68e-9	Morning vs. evening chronotype;
KIRP	cis	rs9826463	0.582	rs73238152	chr3:142071081	C/T	cg20824294	chr3:142316082	PLS1	0.46	6.6	0.39	2.51e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.72	0.44	2.93e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.68	8.3	0.47	7.15e-15	Aortic root size;
KIRP	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg13147721	chr7:65941812	NA	-0.98	-6.93	-0.4	3.75e-11	Diabetic kidney disease;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg10505658	chr17:80084571	CCDC57	-0.26	-4.86	-0.3	2.09e-6	Life satisfaction;
KIRP	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.43	-0.33	1.33e-7	Obesity-related traits;
KIRP	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.1	-0.41	1.31e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7590368	0.673	rs17365216	chr2:10939241	A/G	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9534288	0.699	rs2897028	chr13:46656915	C/T	cg15192986	chr13:46630673	CPB2	-0.78	-9.46	-0.52	2.66e-18	Blood protein levels;
KIRP	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.51	-0.43	1.07e-12	Bipolar disorder;
KIRP	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs10899021	1.000	rs11236190	chr11:74366755	G/T	cg25880958	chr11:74394337	NA	-0.61	-5.07	-0.31	7.97e-7	Response to metformin (IC50);
KIRP	cis	rs9217	0.841	rs55894190	chr17:7383238	C/T	cg02795151	chr17:7402630	POLR2A	-0.55	-6.74	-0.39	1.14e-10	Height;
KIRP	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8028182	0.501	rs11072553	chr15:75932777	C/T	cg20655648	chr15:75932815	IMP3	0.62	7.8	0.45	1.78e-13	Sudden cardiac arrest;
KIRP	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12963246	chr6:28129442	ZNF389	0.38	4.86	0.3	2.14e-6	Cardiac Troponin-T levels;
KIRP	cis	rs4713118	0.868	rs2893928	chr6:27738430	C/A	cg20933634	chr6:27740509	NA	0.42	5.05	0.31	8.8e-7	Parkinson's disease;
KIRP	cis	rs1209950	0.536	rs464476	chr21:40225441	C/T	cg02119577	chr21:40195074	ETS2	-0.38	-5.64	-0.34	4.68e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-5.56	-0.33	7.11e-8	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.81	-11.58	-0.59	5.02e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg14092571	chr14:90743983	NA	0.41	5.02	0.3	9.9e-7	Mortality in heart failure;
KIRP	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.63	8.39	0.47	3.9e-15	Height;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg24874828	chr4:187887005	NA	-0.48	-7.14	-0.41	1.05e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2151522	0.699	rs9398820	chr6:127167352	T/C	cg21431617	chr6:127135037	NA	0.29	5.14	0.31	5.67e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs3857747	0.557	rs10951635	chr7:40390091	T/C	cg00420559	chr7:40367873	C7orf10	-0.43	-6.07	-0.36	4.86e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg21361702	chr7:150065534	REPIN1	0.62	6.51	0.38	4.15e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg25650185	chr19:21324782	ZNF431	-0.49	-5.16	-0.31	4.97e-7	Pain;
KIRP	cis	rs11723261	0.582	rs7679573	chr4:151605	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.98	0.3	1.18e-6	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs7998202	0.567	rs7982570	chr13:113370892	T/C	cg04656015	chr13:113407548	ATP11A	-0.52	-5.24	-0.32	3.52e-7	Glycated hemoglobin levels;
KIRP	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.47	-5.97	-0.36	8.33e-9	Crohn's disease;
KIRP	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs41264869	0.657	rs6664360	chr1:205120640	C/T	cg21214746	chr1:205091277	RBBP5	0.53	6.88	0.4	4.91e-11	Blood protein levels;
KIRP	cis	rs9815354	0.812	rs73071330	chr3:41810553	T/G	cg03022575	chr3:42003672	ULK4	0.78	7.92	0.45	8.01e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg26681399	chr22:41777847	TEF	0.54	5.33	0.32	2.17e-7	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26515846	chr16:85646810	KIAA0182	0.48	6.11	0.36	3.85e-9	Parkinson's disease;
KIRP	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg11235152	chr1:67600687	NA	0.65	9.6	0.52	9.79e-19	Psoriasis;
KIRP	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.22	-0.32	3.81e-7	Alcohol dependence;
KIRP	cis	rs9547996	0.879	rs73184517	chr13:38194023	G/A	cg13634560	chr13:38173852	POSTN	-0.4	-5.57	-0.33	6.69e-8	Diastolic blood pressure;
KIRP	cis	rs17428704	0.571	rs12109756	chr5:14397682	T/C	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	Neuroticism;
KIRP	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.8	10.66	0.56	4.66e-22	Primary sclerosing cholangitis;
KIRP	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	5.33	0.32	2.23e-7	Renal cell carcinoma;
KIRP	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg13147721	chr7:65941812	NA	-0.97	-7.44	-0.43	1.63e-12	Diabetic kidney disease;
KIRP	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs6684428	0.505	rs4927274	chr1:56396501	A/G	cg11651538	chr1:56320950	NA	0.54	7.98	0.45	5.59e-14	Airflow obstruction;
KIRP	cis	rs4849845	0.925	rs7587975	chr2:121022740	G/T	cg24070213	chr2:121070622	NA	0.39	5.28	0.32	2.81e-7	Mean platelet volume;
KIRP	cis	rs2041895	0.509	rs1838445	chr12:107314585	T/A	cg15890332	chr12:107067104	RFX4	0.34	4.94	0.3	1.41e-6	Glaucoma (low intraocular pressure);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg16490470	chr1:208390388	PLXNA2	0.4	6.29	0.37	1.42e-9	Serum protein levels (sST2);
KIRP	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg03808351	chr9:123631620	PHF19	0.42	5.96	0.36	8.8e-9	Rheumatoid arthritis;
KIRP	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg24375607	chr4:120327624	NA	0.53	5.51	0.33	9e-8	Corneal astigmatism;
KIRP	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-9.59	-0.52	1.01e-18	Body mass index;
KIRP	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.92	-0.35	1.07e-8	IgG glycosylation;
KIRP	cis	rs687432	0.924	rs938011	chr11:57709997	G/T	cg19752551	chr11:57585705	CTNND1	0.5	6.93	0.4	3.66e-11	Parkinson's disease;
KIRP	cis	rs4950322	0.570	rs72691097	chr1:146771388	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-5.27	-0.32	2.96e-7	Protein quantitative trait loci;
KIRP	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg13072238	chr3:49761600	GMPPB	0.57	5.3	0.32	2.61e-7	Menarche (age at onset);
KIRP	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	1.09	8.24	0.47	1.01e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg13880726	chr7:1868755	MAD1L1	0.53	6.23	0.37	2e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.42	5.47	0.33	1.08e-7	Melanoma;
KIRP	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg20818283	chr2:191399100	TMEM194B	-0.5	-6.46	-0.38	5.46e-10	Pulse pressure;
KIRP	cis	rs9943753	0.508	rs7958071	chr12:109836089	G/A	cg19025524	chr12:109796872	NA	-0.46	-6.27	-0.37	1.61e-9	HDL cholesterol;
KIRP	cis	rs2288073	0.801	rs72797831	chr2:24366829	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-6.13	-0.36	3.39e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-0.47	-5.61	-0.34	5.56e-8	Acne (severe);
KIRP	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg21045802	chr8:109455806	TTC35	0.35	4.87	0.3	1.96e-6	Dupuytren's disease;
KIRP	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg10223061	chr2:219282414	VIL1	0.38	5.97	0.36	8.35e-9	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg26876637	chr1:152193138	HRNR	-0.75	-10.1	-0.54	2.79e-20	Atopic dermatitis;
KIRP	cis	rs9546312	1	rs9546312	chr13:83746951	C/T	cg23400607	chr13:83795968	NA	0.39	5.08	0.31	7.36e-7	Alzheimer disease and age of onset;
KIRP	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	1.01	14.86	0.69	4.41e-36	Homoarginine levels;
KIRP	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-6.63	-0.39	2.15e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.84	0.63	3.11e-29	Morning vs. evening chronotype;
KIRP	cis	rs2671245	0.586	rs12036264	chr1:56134432	T/G	cg11523071	chr1:56160889	NA	0.41	6.25	0.37	1.77e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.85	-9.24	-0.51	1.23e-17	Osteoarthritis;
KIRP	cis	rs7688540	0.800	rs10023604	chr4:281038	G/C	cg17891759	chr4:299121	NA	-0.4	-5.08	-0.31	7.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24450312	chr1:206681158	RASSF5	0.43	6.24	0.37	1.95e-9	Parkinson's disease;
KIRP	cis	rs9467773	0.572	rs9467737	chr6:26381630	T/C	cg09904177	chr6:26538194	HMGN4	-0.43	-5.35	-0.32	2.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg27490568	chr2:178487706	NA	0.5	6.84	0.4	6.34e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21643547	chr1:205240462	TMCC2	-0.83	-12.81	-0.63	4.1e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg01384173	chr19:17564348	NA	0.65	6.32	0.37	1.24e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.71	8.98	0.5	7.45e-17	Bladder cancer;
KIRP	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg00631329	chr6:26305371	NA	-0.72	-9.41	-0.51	3.78e-18	Educational attainment;
KIRP	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg21252483	chr19:49399788	TULP2	-0.58	-7.41	-0.43	1.97e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg04731861	chr2:219085781	ARPC2	0.28	6.99	0.41	2.57e-11	Colorectal cancer;
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03647317	chr4:187891568	NA	-0.77	-12.86	-0.63	2.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.66	-0.56	4.81e-22	Height;
KIRP	cis	rs13272623	0.502	rs268628	chr8:71560505	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.59	-7.66	-0.44	4.16e-13	IgG glycosylation;
KIRP	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg13165212	chr22:42675999	NA	-0.27	-4.96	-0.3	1.31e-6	Cognitive function;
KIRP	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	1.0	15.65	0.71	8.67e-39	Vitamin D levels;
KIRP	cis	rs654128	0.640	rs945080	chr6:117225343	G/A	cg12892004	chr6:117198278	RFX6	-0.41	-5.26	-0.32	3.07e-7	Telomere length;
KIRP	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.7	9.22	0.51	1.43e-17	Morning vs. evening chronotype;
KIRP	cis	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg19847130	chr8:10466454	RP1L1	0.36	5.01	0.3	1.03e-6	Neuroticism;
KIRP	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.82	8.78	0.49	2.73e-16	Alzheimer's disease;
KIRP	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	9.85	0.53	1.61e-19	Ileal carcinoids;
KIRP	cis	rs4671400	0.516	rs2600671	chr2:61394851	A/G	cg15711740	chr2:61764176	XPO1	-0.54	-5.6	-0.34	5.75e-8	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.68e-9	Breast cancer;
KIRP	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05220968	chr6:146057943	EPM2A	-0.38	-4.92	-0.3	1.57e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg10117171	chr1:25599238	RHD	-0.39	-5.45	-0.33	1.22e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg03060546	chr3:49711283	APEH	-0.66	-6.04	-0.36	5.75e-9	Cognitive function;
KIRP	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg25036284	chr2:26402008	FAM59B	0.52	4.86	0.3	2.06e-6	Gut microbiome composition (summer);
KIRP	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg16141378	chr3:129829833	LOC729375	0.52	6.87	0.4	5.1e-11	Retinal vascular caliber;
KIRP	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.77	6.98	0.41	2.69e-11	Alzheimer's disease;
KIRP	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg17108064	chr15:78857060	CHRNA5	0.35	4.97	0.3	1.24e-6	Sudden cardiac arrest;
KIRP	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.82	10.2	0.55	1.36e-20	Corneal astigmatism;
KIRP	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-11.42	-0.59	1.63e-24	Alzheimer's disease;
KIRP	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-12.75	-0.63	6.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.22	-0.32	3.77e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6988636	0.710	rs62521799	chr8:124134987	G/A	cg23067535	chr8:124195133	FAM83A	-0.67	-5.51	-0.33	8.99e-8	Urinary uromodulin levels;
KIRP	cis	rs1461503	0.838	rs7126962	chr11:122830551	T/C	cg27398637	chr11:122830231	C11orf63	-0.81	-11.77	-0.6	1.18e-25	Menarche (age at onset);
KIRP	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg16898833	chr6:26189333	HIST1H4D	1.01	5.75	0.34	2.64e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg18016565	chr1:150552671	MCL1	0.39	5.98	0.36	7.65e-9	Melanoma;
KIRP	cis	rs16854884	0.837	rs13083068	chr3:143801642	G/T	cg06585982	chr3:143692056	C3orf58	0.52	6.45	0.38	5.95e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.72	8.33	0.47	5.59e-15	Gestational age at birth (maternal effect);
KIRP	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg05552183	chr6:42928497	GNMT	0.47	5.48	0.33	1.06e-7	Blood protein levels;
KIRP	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.79	0.4	8.35e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs72792276	1.000	rs3805603	chr5:127451581	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	5.95	0.35	9.16e-9	Red cell distribution width;
KIRP	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20135002	chr11:47629003	NA	-0.47	-5.07	-0.31	7.76e-7	Subjective well-being;
KIRP	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg17554472	chr22:41940697	POLR3H	-0.58	-6.63	-0.39	2.06e-10	Vitiligo;
KIRP	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	5.99	0.36	7.37e-9	Mean platelet volume;
KIRP	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.97	-0.41	2.97e-11	Daytime sleep phenotypes;
KIRP	cis	rs7011049	1.000	rs4521776	chr8:53838833	G/C	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs10875746	0.517	rs12721420	chr12:48358794	C/T	cg24011408	chr12:48396354	COL2A1	-0.47	-4.89	-0.3	1.85e-6	Longevity (90 years and older);
KIRP	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.39	5.06	0.31	8.2e-7	Cognitive function;
KIRP	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs4523957	0.928	rs452363	chr17:2194028	T/C	cg16513277	chr17:2031491	SMG6	0.6	8.31	0.47	6.62e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7737355	0.898	rs3775999	chr5:130970090	T/C	cg25547332	chr5:131281432	NA	0.47	5.21	0.32	4.08e-7	Life satisfaction;
KIRP	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.45	-6.83	-0.4	6.57e-11	Coronary artery disease;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg26134248	chr17:3907702	NA	-0.55	-8.1	-0.46	2.6e-14	Type 2 diabetes;
KIRP	cis	rs7951870	1.000	rs34406563	chr11:46398916	T/C	cg16389345	chr11:46697382	NA	-0.47	-5.4	-0.33	1.54e-7	Schizophrenia;
KIRP	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg04166393	chr7:2884313	GNA12	0.44	5.73	0.34	2.99e-8	Height;
KIRP	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-0.86	-10.0	-0.54	5.64e-20	Pediatric areal bone mineral density (radius);
KIRP	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg14914422	chr1:46958856	NA	0.41	5.15	0.31	5.34e-7	Monobrow;
KIRP	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26306683	chr17:18585705	ZNF286B	-0.42	-5.34	-0.32	2.11e-7	Pancreatic cancer;
KIRP	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.94	15.02	0.69	1.26e-36	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.77	-10.41	-0.55	2.84e-21	Aortic root size;
KIRP	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8060686	0.516	rs13339471	chr16:68253008	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.46	-0.43	1.45e-12	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs13170463	0.579	rs35177434	chr5:8047994	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs10814247	0.702	rs10814211	chr9:35179278	A/G	cg15271616	chr9:35490515	RUSC2	0.35	4.91	0.3	1.68e-6	Psoriasis;
KIRP	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg19847130	chr8:10466454	RP1L1	0.36	5.38	0.32	1.72e-7	Neuroticism;
KIRP	trans	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg10756647	chr7:56101905	PSPH	0.99	7.0	0.41	2.41e-11	Diabetic kidney disease;
KIRP	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg07636037	chr3:49044803	WDR6	0.41	4.97	0.3	1.25e-6	Resting heart rate;
KIRP	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.76	-7.71	-0.44	3.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.27	-0.51	9.81e-18	Mood instability;
KIRP	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.1	0.41	1.31e-11	Aortic root size;
KIRP	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	0.99	18.45	0.76	2.55e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-1.01	-13.3	-0.65	9.16e-31	Breast cancer;
KIRP	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.71	10.27	0.55	7.74e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10344081	chr4:76555777	CDKL2	0.5	6.65	0.39	1.85e-10	Parkinson's disease;
KIRP	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06634786	chr22:41940651	POLR3H	-0.44	-5.46	-0.33	1.14e-7	Vitiligo;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.51	0.38	4.12e-10	Aortic root size;
KIRP	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.11	0.36	3.9e-9	Menopause (age at onset);
KIRP	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.04	-0.41	1.94e-11	Alzheimer's disease;
KIRP	cis	rs3935685	0.874	rs55858810	chr15:78004230	G/T	cg25212270	chr15:78015279	NA	0.59	7.74	0.44	2.52e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg15226275	chr6:116381976	FRK	0.22	5.92	0.35	1.1e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.51	-6.72	-0.39	1.28e-10	Aortic root size;
KIRP	cis	rs12704876	0.509	rs6966856	chr7:96367627	G/A	cg03808172	chr7:96339361	SHFM1	0.58	7.71	0.44	3.15e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3739034	0.639	rs17698151	chr2:135543367	T/C	cg15546071	chr2:135691756	CCNT2	-0.55	-5.33	-0.32	2.25e-7	Gut microbiome composition (winter);
KIRP	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17507749	chr15:85114479	UBE2QP1	0.72	8.16	0.46	1.79e-14	Schizophrenia;
KIRP	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07570687	chr10:102243282	WNT8B	0.51	6.29	0.37	1.48e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg05220968	chr6:146057943	EPM2A	-0.37	-4.85	-0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4006360	0.646	rs6503602	chr17:39301175	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-8.72	-0.49	4.25e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15059389	chr1:12079390	MIIP	0.48	6.05	0.36	5.38e-9	Parkinson's disease;
KIRP	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.52	7.31	0.42	3.71e-12	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.87	0.35	1.37e-8	Motion sickness;
KIRP	cis	rs7009516	0.625	rs1056222	chr8:24263345	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.3	6.59	0.39	2.71e-10	Hair greying;
KIRP	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-5.71	-0.34	3.24e-8	Crohn's disease;
KIRP	cis	rs16828019	0.777	rs35496942	chr1:41488904	G/A	cg18742814	chr1:41828276	NA	0.62	5.52	0.33	8.65e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.61	-11.98	-0.61	2.38e-26	Gout;
KIRP	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.82	-8.43	-0.47	3.04e-15	Systemic lupus erythematosus;
KIRP	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.32	5.11	0.31	6.33e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.45	-5.86	-0.35	1.49e-8	Dietary macronutrient intake;
KIRP	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.67	8.93	0.49	1.03e-16	Breast cancer;
KIRP	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	cis	rs7945718	0.905	rs6486032	chr11:12723693	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.41	-5.16	-0.31	4.98e-7	Educational attainment (years of education);
KIRP	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg02367723	chr1:46378857	MAST2	0.42	4.9	0.3	1.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35883536	0.525	rs2647321	chr1:101032006	T/G	cg09408571	chr1:101003634	GPR88	0.25	5.54	0.33	7.94e-8	Monocyte count;
KIRP	cis	rs2117029	0.586	rs7954521	chr12:49545640	G/A	cg24176009	chr12:49580217	TUBA1A	-0.36	-4.89	-0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg15744005	chr10:104629667	AS3MT	-0.31	-6.39	-0.38	8.43e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg02487422	chr3:49467188	NICN1	0.39	5.35	0.32	2.03e-7	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.26	0.42	4.99e-12	Prudent dietary pattern;
KIRP	cis	rs6662572	0.737	rs11211247	chr1:46476587	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.58	0.34	6.35e-8	Blood protein levels;
KIRP	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.6	7.26	0.42	4.95e-12	Osteoporosis;
KIRP	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.02	-20.12	-0.79	7e-54	Myeloid white cell count;
KIRP	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg05347473	chr6:146136440	FBXO30	0.45	5.93	0.35	1.04e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4919687	0.550	rs7904396	chr10:104456838	C/T	cg04362960	chr10:104952993	NT5C2	0.43	4.93	0.3	1.54e-6	Colorectal cancer;
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg04025307	chr7:1156635	C7orf50	0.81	8.38	0.47	4.15e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg05192639	chr6:26864778	GUSBL1	-0.24	-4.95	-0.3	1.35e-6	Educational attainment;
KIRP	cis	rs10131728	0.505	rs76360952	chr14:81773703	T/C	cg02996355	chr14:81879375	NA	-0.66	-4.93	-0.3	1.53e-6	IgG glycosylation;
KIRP	trans	rs1879637	0.600	rs1402711	chr2:212863006	G/T	cg11050527	chr8:54755511	ATP6V1H	-0.5	-6.08	-0.36	4.52e-9	Personality dimensions;
KIRP	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg02351056	chr10:126480372	METTL10	0.5	6.34	0.37	1.11e-9	DNA methylation (variation);
KIRP	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.8	11.01	0.57	3.56e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg01631408	chr1:248437212	OR2T33	-0.64	-8.62	-0.48	8.4e-16	Common traits (Other);
KIRP	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	1.27	10.54	0.56	1.11e-21	Parkinson's disease;
KIRP	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.9	11.35	0.59	2.85e-24	Platelet distribution width;
KIRP	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-0.7	-8.48	-0.48	2.1e-15	Non-obstructive azoospermia;
KIRP	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-5.96	-0.36	8.67e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-10.87	-0.57	9.85e-23	Exhaled nitric oxide output;
KIRP	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg07775547	chr4:1625484	NA	-0.45	-5.39	-0.33	1.65e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg20731937	chr12:48336164	NA	0.42	5.47	0.33	1.08e-7	Longevity (90 years and older);
KIRP	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.95	-12.32	-0.62	1.79e-27	Platelet distribution width;
KIRP	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.48	6.02	0.36	6.36e-9	Cognitive test performance;
KIRP	cis	rs7536201	0.967	rs7513156	chr1:25299836	T/C	cg23273869	chr1:25296894	NA	-0.39	-5.64	-0.34	4.6e-8	Psoriasis vulgaris;
KIRP	cis	rs7714584	1.000	rs4958843	chr5:150224924	T/C	cg22134413	chr5:150180641	NA	0.57	5.08	0.31	7.4e-7	Crohn's disease;
KIRP	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	13.3	0.65	9.17e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs7551222	0.614	rs4951386	chr1:204454547	A/G	cg20240347	chr1:204465584	NA	-0.42	-7.54	-0.43	8.86e-13	Schizophrenia;
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg24166112	chr17:73873905	TRIM47	0.54	6.27	0.37	1.57e-9	QT interval;
KIRP	cis	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.73	-0.34	2.97e-8	Atopic dermatitis;
KIRP	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.42	5.71	0.34	3.18e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs9810890	1.000	rs77303548	chr3:128454766	C/T	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg21433313	chr16:3507492	NAT15	-0.67	-6.23	-0.37	1.98e-9	Tuberculosis;
KIRP	cis	rs7084402	0.967	rs2917949	chr10:60329166	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.41	-0.55	2.88e-21	Refractive error;
KIRP	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg00405596	chr8:11794950	NA	-0.41	-5.34	-0.32	2.12e-7	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18883472	chr1:224548495	CNIH4	0.43	6.03	0.36	5.95e-9	Survival in pancreatic cancer;
KIRP	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.61	-0.59	3.97e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4356932	1.000	rs17288671	chr4:76932001	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.91	0.3	1.65e-6	Blood protein levels;
KIRP	cis	rs33912345	0.695	rs1254251	chr14:60818850	T/C	cg27398547	chr14:60952738	C14orf39	-0.4	-5.42	-0.33	1.42e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs3126085	0.515	rs11204997	chr1:152364653	T/A	cg26876637	chr1:152193138	HRNR	-0.61	-6.87	-0.4	5.28e-11	Atopic dermatitis;
KIRP	cis	rs554111	0.891	rs531044	chr1:21057011	T/C	cg21184320	chr1:21044207	KIF17	0.46	6.93	0.4	3.68e-11	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg07701084	chr6:150067640	NUP43	0.65	8.34	0.47	5.43e-15	Lung cancer;
KIRP	cis	rs76793172	0.920	rs113577760	chr19:46365177	T/C	cg00442267	chr19:46317840	RSPH6A	-0.82	-6.44	-0.38	6.11e-10	Eosinophil counts;
KIRP	cis	rs6772849	0.930	rs4857914	chr3:128350684	C/T	cg08795948	chr3:128337044	NA	0.45	5.59	0.34	6.07e-8	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg26681399	chr22:41777847	TEF	0.56	5.2	0.31	4.15e-7	Vitiligo;
KIRP	cis	rs1978968	0.717	rs5992934	chr22:18457119	C/T	cg03078520	chr22:18463400	MICAL3	-0.79	-11.07	-0.58	2.24e-23	Presence of antiphospholipid antibodies;
KIRP	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg21605333	chr4:119757512	SEC24D	1.56	11.04	0.58	2.74e-23	Cannabis dependence symptom count;
KIRP	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs10924309	0.882	rs10924305	chr1:245856763	A/G	cg00036263	chr1:245852353	KIF26B	0.5	6.71	0.39	1.37e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg06647332	chr5:131281008	NA	-0.46	-5.04	-0.31	8.93e-7	Life satisfaction;
KIRP	cis	rs1816752	0.638	rs9578730	chr13:24999683	G/A	cg02811702	chr13:24901961	NA	0.43	5.52	0.33	8.49e-8	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04266901	chr17:80236905	NA	0.48	6.09	0.36	4.37e-9	Interleukin-4 levels;
KIRP	cis	rs7951870	1.000	rs1489192	chr11:46509344	T/C	cg16389345	chr11:46697382	NA	-0.48	-5.1	-0.31	6.78e-7	Schizophrenia;
KIRP	cis	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg22586884	chr5:54832140	PPAP2A	-0.34	-5.26	-0.32	3.18e-7	Height;
KIRP	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs1009170	0.794	rs1950810	chr14:92586540	A/G	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.43	0.33	1.37e-7	Dialysis-related mortality;
KIRP	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg23216685	chr1:86174607	ZNHIT6	-0.53	-6.21	-0.37	2.3e-9	Urate levels in overweight individuals;
KIRP	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.5	-8.05	-0.46	3.61e-14	Waist circumference adjusted for body mass index;
KIRP	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg09911534	chr15:67153556	NA	0.43	5.6	0.34	5.64e-8	Lung cancer (smoking interaction);
KIRP	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.45	0.38	6.02e-10	Menarche (age at onset);
KIRP	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.77	11.87	0.6	5.24e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg21523564	chr15:75251491	NA	0.41	6.54	0.38	3.55e-10	Breast cancer;
KIRP	cis	rs4302748	0.818	rs11771125	chr7:36190426	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.19	0.37	2.46e-9	Platelet count;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg02056921	chr1:901892	PLEKHN1	0.71	6.1	0.36	4.19e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	5.66	0.34	4.18e-8	Renal cell carcinoma;
KIRP	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs4794202	0.755	rs11651698	chr17:45932303	A/T	cg02219949	chr17:45927392	SP6	0.55	5.58	0.34	6.28e-8	Alzheimer's disease (cognitive decline);
KIRP	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.81e-11	Vitiligo;
KIRP	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg01529538	chr14:23388837	RBM23	0.41	5.23	0.32	3.62e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs9928842	0.882	rs1107593	chr16:75261329	G/C	cg09066997	chr16:75300724	BCAR1	0.62	5.25	0.32	3.37e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.99	-0.36	7.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg08501292	chr6:25962987	TRIM38	1.01	7.59	0.44	6.75e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.52	0.38	4.06e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg23172400	chr8:95962367	TP53INP1	0.36	7.08	0.41	1.47e-11	Type 2 diabetes;
KIRP	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.96	8.96	0.5	8.24e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7808935	0.914	rs67746093	chr7:27985524	C/G	cg05786569	chr7:27702416	HIBADH	0.51	4.96	0.3	1.31e-6	Prostate cancer;
KIRP	cis	rs12579753	0.667	rs7484495	chr12:82301834	T/C	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.56	-0.33	6.93e-8	Resting heart rate;
KIRP	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12292205	chr6:26970375	C6orf41	-0.7	-7.43	-0.43	1.82e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.32	-0.65	7.71e-31	Primary sclerosing cholangitis;
KIRP	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-7.73	-0.44	2.78e-13	Mean corpuscular volume;
KIRP	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.77	8.69	0.48	5.16e-16	Corneal astigmatism;
KIRP	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg11498726	chr8:26250323	BNIP3L	-0.53	-8.0	-0.45	4.77e-14	Red cell distribution width;
KIRP	cis	rs4765905	0.524	rs7957545	chr12:2324042	T/C	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.85	-0.35	1.53e-8	Schizophrenia;
KIRP	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.09	0.31	7.06e-7	Systolic blood pressure;
KIRP	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg02951883	chr7:2050386	MAD1L1	0.58	6.78	0.4	9.02e-11	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs9653442	0.564	rs6707067	chr2:100767232	G/A	cg22139774	chr2:100720529	AFF3	-0.3	-5.07	-0.31	7.8e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.4	0.38	7.91e-10	Aortic root size;
KIRP	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg01559446	chr3:44596178	ZNF167	-0.38	-5.25	-0.32	3.32e-7	Depressive symptoms;
KIRP	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg27170947	chr2:26402098	FAM59B	0.46	5.57	0.33	6.56e-8	Gut microbiome composition (summer);
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.76	11.92	0.61	3.58e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs12282928	0.959	rs11039631	chr11:48297062	A/G	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.92e-9	Migraine - clinic-based;
KIRP	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	9.59	0.52	1.05e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs7709377	0.595	rs40192	chr5:115629523	C/T	cg23108291	chr5:115420582	COMMD10	-0.45	-5.41	-0.33	1.47e-7	Metabolite levels  (X-11787);
KIRP	cis	rs1978968	1.000	rs1076539	chr22:18439598	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.89	-0.4	4.64e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg22117172	chr7:91764530	CYP51A1	-0.42	-5.87	-0.35	1.41e-8	Breast cancer;
KIRP	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.03	-0.41	2.01e-11	Joint mobility (Beighton score);
KIRP	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.12e-22	Coronary artery disease;
KIRP	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.53	7.45	0.43	1.6e-12	Systemic lupus erythematosus;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg23628684	chr21:30446052	CCT8	0.45	6.18	0.37	2.58e-9	Ischemic stroke;
KIRP	cis	rs6832769	1.000	rs10005989	chr4:56405206	C/T	cg05960024	chr4:56376020	CLOCK	-0.62	-8.0	-0.45	4.94e-14	Personality dimensions;
KIRP	cis	rs4363385	0.510	rs10888528	chr1:153050516	A/G	cg13444842	chr1:152974279	SPRR3	0.42	6.09	0.36	4.29e-9	Inflammatory skin disease;
KIRP	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg00204512	chr16:28754710	NA	0.47	6.14	0.36	3.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6433857	0.536	rs4625864	chr2:181353942	G/C	cg23363182	chr2:181467187	NA	-0.39	-5.52	-0.33	8.4e-8	Body mass index;
KIRP	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg05775895	chr3:12838266	CAND2	0.45	7.44	0.43	1.68e-12	QRS complex (12-leadsum);
KIRP	cis	rs73086581	1.000	rs6052217	chr20:3970211	A/G	cg02187196	chr20:3869020	PANK2	0.47	4.9	0.3	1.72e-6	Response to antidepressants in depression;
KIRP	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.38	-4.98	-0.3	1.2e-6	Crohn's disease;
KIRP	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg11833968	chr6:79620685	NA	-0.38	-5.23	-0.32	3.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg19438565	chr8:143695827	ARC	-0.43	-4.92	-0.3	1.58e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg07828024	chr6:149772892	ZC3H12D	-0.29	-4.93	-0.3	1.5e-6	Dupuytren's disease;
KIRP	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg25358565	chr5:93447407	FAM172A	1.35	11.54	0.59	6.81e-25	Diabetic retinopathy;
KIRP	cis	rs4908768	0.906	rs12117910	chr1:8556953	A/C	cg25722041	chr1:8623473	RERE	0.79	10.01	0.54	5.12e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg01631408	chr1:248437212	OR2T33	-0.53	-7.25	-0.42	5.34e-12	Common traits (Other);
KIRP	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.89	-0.45	1.02e-13	Retinal vascular caliber;
KIRP	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.76	-10.92	-0.57	6.82e-23	Total body bone mineral density;
KIRP	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	0.89	7.52	0.43	1.01e-12	Plateletcrit;
KIRP	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs11074306	0.561	rs2311469	chr15:28069068	T/G	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.59e-6	Uveal melanoma;
KIRP	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.48	-5.81	-0.35	1.92e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs13102973	0.867	rs12501608	chr4:135896365	T/C	cg14419869	chr4:135874104	NA	0.47	7.38	0.43	2.45e-12	Subjective well-being;
KIRP	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7173743	0.756	rs11852830	chr15:79125429	A/T	cg00079375	chr15:79125835	NA	0.36	5.23	0.32	3.57e-7	Coronary artery disease;
KIRP	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg21573476	chr21:45109991	RRP1B	-0.62	-8.3	-0.47	6.78e-15	Mean corpuscular volume;
KIRP	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00745463	chr17:30367425	LRRC37B	-0.97	-6.52	-0.38	3.97e-10	Height;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg14338887	chr6:42928500	GNMT	0.47	7.04	0.41	1.93e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg06766960	chr11:133703094	NA	-0.75	-9.92	-0.53	9.97e-20	Childhood ear infection;
KIRP	trans	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg01311341	chr22:25575246	KIAA1671	-0.59	-6.32	-0.37	1.19e-9	Glioblastoma;
KIRP	cis	rs2274273	0.624	rs10141396	chr14:55816925	A/C	cg04306507	chr14:55594613	LGALS3	0.36	4.99	0.3	1.17e-6	Protein biomarker;
KIRP	trans	rs7999699	0.756	rs35901647	chr13:48309088	T/G	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	trans	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17183009	chr3:120277827	NA	0.54	6.32	0.37	1.22e-9	Corneal astigmatism;
KIRP	cis	rs7779181	0.951	rs6952609	chr7:32343335	A/G	cg13207630	chr7:32358064	NA	0.46	5.71	0.34	3.31e-8	Body mass index;
KIRP	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg01304814	chr3:48885189	PRKAR2A	0.73	5.61	0.34	5.33e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.58	8.12	0.46	2.24e-14	Blood metabolite levels;
KIRP	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.27	0.37	1.62e-9	Educational attainment;
KIRP	cis	rs72634030	0.536	rs72634014	chr17:5177150	A/G	cg27093376	chr17:5185073	RABEP1	0.52	5.08	0.31	7.61e-7	Rheumatoid arthritis;
KIRP	trans	rs11834041	1.000	rs56229335	chr12:128236902	A/T	cg08266923	chr10:70166773	RUFY2	-0.67	-6.23	-0.37	2e-9	Response to cognitive-behavioural therapy in anxiety disorder;
KIRP	cis	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg21775007	chr8:11205619	TDH	-0.43	-5.73	-0.34	3e-8	Neuroticism;
KIRP	cis	rs6102059	0.719	rs62211685	chr20:39230821	G/C	cg22477343	chr20:39312069	NA	0.48	6.38	0.38	8.86e-10	LDL cholesterol;
KIRP	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08392591	chr16:89556376	ANKRD11	0.41	5.19	0.31	4.38e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs76793172	0.623	rs10775546	chr19:46267534	C/T	cg00442267	chr19:46317840	RSPH6A	0.64	5.58	0.34	6.26e-8	Eosinophil counts;
KIRP	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.21	-0.42	7.06e-12	Body mass index;
KIRP	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg09594475	chr20:60884601	LAMA5	0.33	5.13	0.31	5.84e-7	Pelvic organ prolapse;
KIRP	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg17646820	chr3:66848679	NA	0.72	9.85	0.53	1.65e-19	Type 2 diabetes;
KIRP	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.82	6.89	0.4	4.67e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg03808351	chr9:123631620	PHF19	0.43	5.83	0.35	1.71e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.27	5.48	0.33	1.05e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.49	4.85	0.3	2.21e-6	Recombination rate (females);
KIRP	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.9	-14.2	-0.67	8.22e-34	Height;
KIRP	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg05729581	chr11:3078854	CARS	-0.4	-5.1	-0.31	6.64e-7	Longevity;
KIRP	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	1.03	14.77	0.69	8.72e-36	Menopause (age at onset);
KIRP	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.23	-0.51	1.33e-17	Bladder cancer;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg12692727	chr7:1102344	C7orf50	0.47	5.09	0.31	6.96e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg18461458	chr19:21324796	ZNF431	0.47	4.93	0.3	1.52e-6	Pain;
KIRP	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg05555928	chr11:63887634	MACROD1	-0.59	-5.35	-0.32	1.98e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs12043259	0.730	rs12043731	chr1:204794151	T/C	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs4523957	0.713	rs9906500	chr17:2129210	C/A	cg16513277	chr17:2031491	SMG6	-0.68	-9.33	-0.51	6.62e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg13736514	chr6:26305472	NA	0.44	5.0	0.3	1.09e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg11663144	chr21:46675770	NA	-0.57	-8.04	-0.46	3.76e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg24296786	chr1:45957014	TESK2	0.63	8.44	0.47	2.76e-15	High light scatter reticulocyte count;
KIRP	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg03474202	chr17:45855739	NA	-0.42	-5.85	-0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.75	10.53	0.56	1.17e-21	Calcium levels;
KIRP	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.13e-7	Retinal vascular caliber;
KIRP	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg11833968	chr6:79620685	NA	-0.45	-6.85	-0.4	5.92e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.48	-0.56	1.68e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.72	9.95	0.54	8.24e-20	Crohn's disease;
KIRP	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.42	6.38	0.38	8.73e-10	Lipoprotein (a) levels;
KIRP	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.56	8.17	0.46	1.65e-14	Lung cancer;
KIRP	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg07830794	chr1:228460260	OBSCN	0.41	4.88	0.3	1.92e-6	Diastolic blood pressure;
KIRP	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg14458575	chr2:238380390	NA	0.55	5.9	0.35	1.2e-8	Prostate cancer;
KIRP	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.69	-6.71	-0.39	1.37e-10	White matter integrity;
KIRP	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg10547527	chr2:198650123	BOLL	-0.54	-5.15	-0.31	5.28e-7	Ulcerative colitis;
KIRP	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.64	9.8	0.53	2.35e-19	Neuroticism;
KIRP	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg12692727	chr7:1102344	C7orf50	0.48	5.13	0.31	5.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11910985	0.546	rs9977877	chr21:48080493	G/A	cg17243659	chr21:48055224	PRMT2	0.94	6.78	0.4	8.98e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs2797160	0.547	rs9388442	chr6:125972608	G/C	cg05901451	chr6:126070800	HEY2	-0.37	-5.15	-0.31	5.35e-7	Endometrial cancer;
KIRP	cis	rs7221595	0.825	rs12601931	chr17:3986097	T/C	cg09597638	chr17:3907349	NA	0.56	5.75	0.34	2.66e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg04703221	chr16:69967063	WWP2;MIR140	-0.3	-5.06	-0.31	8.05e-7	Menarche (age at onset);
KIRP	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg21918786	chr6:109611834	NA	-0.37	-5.44	-0.33	1.28e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs13095912	0.778	rs11914529	chr3:185296513	C/T	cg11274856	chr3:185301563	NA	0.61	7.59	0.44	6.65e-13	Systolic blood pressure;
KIRP	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs504918	0.588	rs73188200	chr3:124031989	G/C	cg05766129	chr3:123988013	KALRN	-0.44	-5.57	-0.33	6.58e-8	Schizophrenia;
KIRP	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	11.13	0.58	1.4e-23	Personality dimensions;
KIRP	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.42	-0.33	1.4e-7	Carotid intima media thickness;
KIRP	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg11812906	chr14:75593930	NEK9	0.75	10.78	0.57	1.93e-22	Height;
KIRP	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.77	11.02	0.57	3.32e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.7	-0.44	3.4e-13	Migraine;Coronary artery disease;
KIRP	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.63	8.03	0.46	4.05e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12939527	chr4:2757706	TNIP2	-0.45	-6.09	-0.36	4.32e-9	Metabolic traits;
KIRP	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.83	11.1	0.58	1.8e-23	Morning vs. evening chronotype;
KIRP	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg26811252	chr16:29126840	RRN3P2	0.66	8.88	0.49	1.4e-16	Menopause (age at onset);
KIRP	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg05552183	chr6:42928497	GNMT	0.44	5.09	0.31	7.26e-7	Blood protein levels;
KIRP	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg16736954	chr20:23401023	NAPB	-0.65	-5.11	-0.31	6.49e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6484504	0.625	rs4922859	chr11:31382517	A/G	cg26647111	chr11:31128758	NA	0.43	4.98	0.3	1.21e-6	Red blood cell count;
KIRP	cis	rs7903847	0.642	rs11189174	chr10:99139600	C/G	cg20016023	chr10:99160130	RRP12	-0.41	-5.8	-0.35	1.99e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.21	0.37	2.23e-9	Lung cancer;
KIRP	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg24631222	chr15:78858424	CHRNA5	0.4	5.1	0.31	6.63e-7	Sudden cardiac arrest;
KIRP	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg17885191	chr8:135476712	NA	0.5	5.88	0.35	1.3e-8	Hypertension (SNP x SNP interaction);
KIRP	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg23920097	chr1:209922102	NA	-0.46	-5.46	-0.33	1.19e-7	Red blood cell count;
KIRP	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23903597	chr17:61704154	MAP3K3	-0.65	-8.42	-0.47	3.05e-15	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs575018	0.774	rs5019803	chr5:100589779	G/A	cg03848127	chr5:100126093	NA	-0.45	-5.5	-0.33	9.34e-8	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg03254818	chr6:169586852	NA	0.47	7.38	0.43	2.44e-12	Pulse pressure;
KIRP	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-5.59	-0.34	6.15e-8	Breast cancer;
KIRP	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	9.12	0.5	2.73e-17	Renal function-related traits (BUN);
KIRP	cis	rs3126085	0.932	rs11587676	chr1:152159961	C/T	cg26876637	chr1:152193138	HRNR	-0.82	-7.78	-0.44	2.05e-13	Atopic dermatitis;
KIRP	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg03734594	chr13:111297400	CARS2	0.37	5.73	0.34	2.98e-8	Coronary artery disease;
KIRP	cis	rs6102059	0.503	rs6029178	chr20:39178557	A/G	cg06665391	chr20:39312290	NA	-0.4	-5.07	-0.31	8e-7	LDL cholesterol;
KIRP	cis	rs7274811	0.744	rs2071056	chr20:32265513	A/G	cg12710480	chr20:32254216	NECAB3;C20orf134	-0.28	-4.86	-0.3	2.11e-6	Height;
KIRP	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg12405258	chr13:114927641	NA	0.48	6.98	0.41	2.73e-11	Schizophrenia;
KIRP	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg00933542	chr6:150070202	PCMT1	0.26	4.98	0.3	1.22e-6	Testicular germ cell tumor;
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	12.74	0.63	6.9e-29	Platelet count;
KIRP	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.34	5.35	0.32	2.06e-7	Asthma (childhood onset);
KIRP	cis	rs7737355	1.000	rs27873	chr5:130731151	T/C	cg06307176	chr5:131281290	NA	-0.47	-5.39	-0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.93	9.62	0.52	8.65e-19	Schizophrenia;
KIRP	cis	rs7614311	0.681	rs73119022	chr3:63979834	T/C	cg09006292	chr3:64049408	NA	-0.52	-4.93	-0.3	1.49e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg18350739	chr11:68623251	NA	-0.53	-7.94	-0.45	7.37e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs28489187	0.597	rs6576765	chr1:85871012	A/T	cg16011679	chr1:85725395	C1orf52	-0.42	-5.16	-0.31	5.15e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg26207909	chr14:103986467	CKB	-0.48	-6.11	-0.36	3.77e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.46	5.43	0.33	1.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.8	-15.3	-0.7	1.38e-37	Obesity-related traits;
KIRP	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.93	-0.35	9.95e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10518128	0.557	rs10005235	chr4:75697820	T/C	cg20122727	chr4:75719957	BTC	0.51	5.17	0.31	4.94e-7	Electroencephalogram traits;
KIRP	trans	rs9409565	0.826	rs4612412	chr9:97208627	C/G	cg05679027	chr9:99775184	HIATL2	-0.56	-6.91	-0.4	4.06e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs4149577	0.631	rs11064145	chr12:6455098	G/T	cg00556515	chr12:6442607	TNFRSF1A	-0.3	-5.04	-0.31	9.08e-7	Monocyte count;
KIRP	cis	rs8044868	0.530	rs7186155	chr16:72178196	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.47	-0.33	1.09e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.79e-11	Colorectal cancer;
KIRP	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg07741184	chr6:167504864	NA	0.22	6.04	0.36	5.58e-9	Crohn's disease;
KIRP	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.64	-0.34	4.73e-8	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16864975	chr3:12043404	NA	0.43	6.13	0.36	3.5e-9	Interleukin-4 levels;
KIRP	cis	rs714515	0.609	rs1009803	chr1:172452422	C/T	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg02733842	chr7:1102375	C7orf50	0.58	5.75	0.34	2.67e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg01566213	chr4:1579287	NA	-0.37	-5.13	-0.31	5.92e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg26513180	chr16:89883248	FANCA	0.57	7.55	0.43	8.36e-13	Vitiligo;
KIRP	cis	rs12931792	0.782	rs13331817	chr16:30172627	A/G	cg17640201	chr16:30407289	ZNF48	0.45	5.02	0.3	9.84e-7	Tonsillectomy;
KIRP	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.06	0.64	5.78e-30	Exhaled nitric oxide output;
KIRP	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg16083429	chr3:49237500	CCDC36	-0.39	-5.01	-0.3	1.04e-6	Menarche (age at onset);
KIRP	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.28	5.65	0.34	4.48e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-1.09	-21.72	-0.81	4.03e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7520050	0.933	rs6694340	chr1:46289416	C/T	cg03146154	chr1:46216737	IPP	-0.4	-5.05	-0.31	8.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.81	12.03	0.61	1.63e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg24110177	chr3:50126178	RBM5	-0.66	-7.38	-0.43	2.49e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.99	13.45	0.65	2.87e-31	Menopause (age at onset);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20261243	chr20:44718728	NCOA5	-0.51	-6.68	-0.39	1.57e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg04662943	chr10:102668895	NA	0.44	4.87	0.3	1.98e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg21573476	chr21:45109991	RRP1B	0.81	10.08	0.54	3.25e-20	Mean corpuscular volume;
KIRP	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg00745463	chr17:30367425	LRRC37B	0.72	6.69	0.39	1.45e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-7.78	-0.44	1.98e-13	Platelet count;
KIRP	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.38e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.76	-9.66	-0.52	6.17e-19	Longevity;Endometriosis;
KIRP	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg02696742	chr7:106810147	HBP1	-0.76	-7.89	-0.45	9.76e-14	Coronary artery disease;
KIRP	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg05868516	chr6:26286170	HIST1H4H	0.37	4.87	0.3	1.98e-6	Educational attainment;
KIRP	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.22	-0.42	6.28e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg23958373	chr8:599963	NA	1.01	7.62	0.44	5.43e-13	IgG glycosylation;
KIRP	trans	rs199950	1.000	rs199952	chr1:181592704	G/A	cg04237608	chr1:18659049	IGSF21	0.33	6.08	0.36	4.64e-9	Body mass index (change over time);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04180460	chr3:41240962	CTNNB1	0.56	6.69	0.39	1.47e-10	Smoking initiation;
KIRP	trans	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg13565492	chr6:43139072	SRF	-0.71	-6.75	-0.4	1.04e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg26513180	chr16:89883248	FANCA	0.81	5.39	0.32	1.67e-7	Skin colour saturation;
KIRP	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.95	13.01	0.64	8.4000000000000007e-30	Menopause (age at onset);
KIRP	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg06289844	chr6:126071538	HEY2	-0.36	-5.06	-0.31	8.08e-7	Brugada syndrome;
KIRP	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16405210	chr4:1374714	KIAA1530	0.55	7.47	0.43	1.39e-12	Obesity-related traits;
KIRP	cis	rs9826463	0.757	rs73240318	chr3:142277427	A/G	cg20824294	chr3:142316082	PLS1	0.41	6.47	0.38	5.22e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.55	-9.09	-0.5	3.31e-17	Prostate cancer;
KIRP	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.88	-0.3	1.92e-6	Neutrophil percentage of white cells;
KIRP	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.08	-0.5	3.52e-17	Retinal vascular caliber;
KIRP	trans	rs12049351	0.774	rs4925455	chr1:229623665	T/A	cg00551153	chr21:47333731	PCBP3	-0.49	-6.11	-0.36	3.9e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg08999081	chr20:33150536	PIGU	0.4	5.33	0.32	2.26e-7	Height;
KIRP	cis	rs10073892	0.581	rs12653584	chr5:101909268	A/T	cg19774478	chr5:101632501	SLCO4C1	0.56	5.6	0.34	5.65e-8	Cognitive decline (age-related);
KIRP	cis	rs804292	0.800	rs8191542	chr8:11629809	C/G	cg26752888	chr8:11627280	NEIL2	1.02	10.79	0.57	1.81e-22	Alcohol dependence;Nicotine use;
KIRP	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.52	-7.68	-0.44	3.83e-13	IgG glycosylation;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg10207240	chr12:122356781	WDR66	0.61	8.08	0.46	2.84e-14	Mean corpuscular volume;
KIRP	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	0.97	12.77	0.63	5.65e-29	Breast cancer;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.43	-0.33	1.32e-7	Lung cancer;
KIRP	cis	rs6832769	0.922	rs28726308	chr4:56234406	C/T	cg05960024	chr4:56376020	CLOCK	0.63	7.57	0.43	7.5e-13	Personality dimensions;
KIRP	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg16898833	chr6:26189333	HIST1H4D	0.83	5.89	0.35	1.23e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs667920	0.575	rs9861150	chr3:136183320	G/T	cg15507776	chr3:136538369	TMEM22	0.54	5.86	0.35	1.49e-8	Coronary artery disease;
KIRP	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg01689657	chr7:91764605	CYP51A1	0.39	5.72	0.34	3.04e-8	Breast cancer;
KIRP	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.74	-11.46	-0.59	1.21e-24	Hepatocellular carcinoma;
KIRP	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg23172400	chr8:95962367	TP53INP1	-0.3	-5.97	-0.36	8.04e-9	Type 2 diabetes;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg21285383	chr16:89894308	SPIRE2	-0.34	-6.37	-0.38	9.14e-10	Vitiligo;
KIRP	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.35	-0.42	2.98e-12	Mood instability;
KIRP	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg03808351	chr9:123631620	PHF19	0.44	6.01	0.36	6.64e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.53	6.38	0.38	8.84e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.28	0.58	4.68e-24	Alzheimer's disease;
KIRP	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.98	14.07	0.67	2.24e-33	Height;
KIRP	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg27121462	chr16:89883253	FANCA	0.5	6.4	0.38	8.01e-10	Vitiligo;
KIRP	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg04935436	chr20:30431758	NA	0.49	6.49	0.38	4.67e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.1	-0.54	2.78e-20	Schizophrenia;
KIRP	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.57	-6.81	-0.4	7.38e-11	Gut microbiome composition (summer);
KIRP	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg09408571	chr1:101003634	GPR88	0.23	5.36	0.32	1.87e-7	Monocyte count;
KIRP	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.89	-15.45	-0.7	4.39e-38	Breast cancer;
KIRP	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg05251000	chr9:132935664	FREQ	0.51	8.95	0.5	8.89e-17	Alzheimer's disease (cognitive decline);
KIRP	cis	rs3126085	0.825	rs4298736	chr1:152240269	A/T	cg26876637	chr1:152193138	HRNR	0.73	9.21	0.51	1.47e-17	Atopic dermatitis;
KIRP	cis	rs4262150	0.764	rs2964230	chr5:151932606	A/T	cg12297329	chr5:152029980	NA	-0.59	-7.4	-0.43	2.17e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.35	-0.42	2.85e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.47	-0.33	1.13e-7	Lymphocyte counts;
KIRP	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.66	-0.44	4.25e-13	Diisocyanate-induced asthma;
KIRP	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.76	-9.38	-0.51	4.52e-18	Height;
KIRP	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.64	7.9	0.45	9.12e-14	Age at first birth;
KIRP	cis	rs2279817	0.913	rs11203436	chr1:18019016	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.66	9.93	0.53	9.33e-20	Neuroticism;
KIRP	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg23555395	chr2:238036564	NA	-0.57	-6.72	-0.39	1.27e-10	Systemic lupus erythematosus;
KIRP	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.88	13.9	0.66	8.41e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.93	0.54	9.03e-20	Ileal carcinoids;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16608053	chr17:79633742	C17orf90;CCDC137	-0.45	-6.04	-0.36	5.75e-9	Metabolic traits;
KIRP	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.44	5.7	0.34	3.39e-8	Crohn's disease;
KIRP	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.86	-0.49	1.6e-16	Neuroticism;
KIRP	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg19773385	chr1:10388646	KIF1B	-0.72	-11.11	-0.58	1.63e-23	Hepatocellular carcinoma;
KIRP	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg10096100	chr1:26503862	CNKSR1	0.41	5.8	0.35	2.01e-8	Height;
KIRP	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg09873164	chr1:152488093	CRCT1	0.6	7.79	0.44	1.84e-13	Hair morphology;
KIRP	trans	rs1973993	0.561	rs59429612	chr1:96988808	C/T	cg10631902	chr5:14652156	NA	-0.54	-6.71	-0.39	1.3e-10	Weight;
KIRP	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs17123764	0.818	rs12314878	chr12:49942208	G/A	cg02054252	chr12:50078554	FMNL3	0.46	5.48	0.33	1.07e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.59	7.89	0.45	1.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.27	-0.32	2.92e-7	Coronary artery disease;
KIRP	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg05315796	chr3:52349193	DNAH1	0.4	6.34	0.37	1.1e-9	Electroencephalogram traits;
KIRP	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.51	7.37	0.43	2.62e-12	Sitting height ratio;
KIRP	cis	rs6956675	0.874	rs10266439	chr7:62647022	G/T	cg08930214	chr7:62859557	LOC100287834	0.4	5.08	0.31	7.32e-7	Obesity-related traits;
KIRP	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.55	-7.15	-0.41	9.95e-12	Schizophrenia;
KIRP	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg15880211	chr22:50250494	ZBED4	-0.67	-7.48	-0.43	1.3e-12	Schizophrenia;
KIRP	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.1	-10.73	-0.56	2.69e-22	Alzheimer's disease (late onset);
KIRP	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg26597838	chr10:835615	NA	-0.54	-6.69	-0.39	1.5e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4764487	0.760	rs4764486	chr12:6327989	A/G	cg08284733	chr12:6341482	CD9	0.53	8.92	0.49	1.13e-16	Mean platelet volume;
KIRP	cis	rs2692947	0.644	rs772178	chr2:96963684	C/T	cg23100626	chr2:96804247	ASTL	-0.51	-6.94	-0.4	3.43e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7209700	0.547	rs55845779	chr17:45354751	G/A	cg25173405	chr17:45401733	C17orf57	0.53	5.23	0.32	3.71e-7	IgG glycosylation;
KIRP	trans	rs7702057	0.522	rs2287684	chr5:115822384	C/A	cg06060731	chr2:86566113	REEP1	-0.78	-6.05	-0.36	5.45e-9	Amyotrophic lateral sclerosis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09786013	chr1:220864119	C1orf115	-0.91	-6.61	-0.39	2.43e-10	P wave terminal force;
KIRP	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg00310523	chr12:86230176	RASSF9	-0.49	-7.84	-0.45	1.4e-13	Major depressive disorder;
KIRP	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.57	-0.39	2.9e-10	Neuroticism;
KIRP	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg18200150	chr17:30822561	MYO1D	0.48	5.76	0.34	2.51e-8	Schizophrenia;
KIRP	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.08	0.58	2.02e-23	Exhaled nitric oxide levels;
KIRP	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.54	-6.34	-0.37	1.07e-9	Aortic root size;
KIRP	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-1.03	-17.35	-0.74	1.37e-44	Height;
KIRP	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg00825309	chr19:58991885	ZNF446	-0.56	-6.93	-0.4	3.67e-11	Uric acid clearance;
KIRP	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.92e-14	Coffee consumption (cups per day);
KIRP	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg24807547	chr6:37504484	NA	-0.65	-10.48	-0.56	1.69e-21	Cognitive performance;
KIRP	cis	rs34779708	0.702	rs4007272	chr10:35546859	T/G	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.65	8.32	0.47	5.99e-15	Red blood cell count;
KIRP	trans	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg16141378	chr3:129829833	LOC729375	-0.56	-6.58	-0.39	2.8e-10	Neuroticism;
KIRP	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg12623918	chr2:306882	NA	0.47	5.84	0.35	1.6e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.31e-14	Obesity-related traits;
KIRP	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.58	-7.41	-0.43	2.04e-12	Proinsulin levels;
KIRP	cis	rs7072216	0.770	rs7897357	chr10:100163597	C/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.05	-0.31	8.76e-7	Metabolite levels;
KIRP	cis	rs1018836	0.637	rs6471113	chr8:91519735	A/G	cg16814680	chr8:91681699	NA	-0.5	-5.87	-0.35	1.4e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg00383909	chr3:49044727	WDR6	0.66	5.89	0.35	1.24e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19346786	chr7:2764209	NA	-0.28	-5.01	-0.3	1.03e-6	Height;
KIRP	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	5.02	0.31	9.71e-7	Eosinophil percentage of white cells;
KIRP	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.83	8.66	0.48	6.46e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs806215	0.568	rs806188	chr7:127268806	T/C	cg08586737	chr7:127225949	GCC1	0.41	4.97	0.3	1.28e-6	Type 2 diabetes;
KIRP	cis	rs7180079	0.620	rs11632113	chr15:65040445	T/G	cg15337035	chr15:64978493	NA	-0.49	-5.33	-0.32	2.21e-7	Monocyte count;
KIRP	cis	rs9886651	0.935	rs4582525	chr8:128800947	A/G	cg24514600	chr8:128805414	PVT1	-0.73	-12.58	-0.63	2.45e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.48	5.69	0.34	3.58e-8	Renal function-related traits (BUN);
KIRP	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18364779	chr6:26104403	HIST1H4C	0.42	5.49	0.33	9.84e-8	Schizophrenia;
KIRP	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg06740227	chr12:86229804	RASSF9	0.4	4.98	0.3	1.21e-6	Major depressive disorder;
KIRP	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.54	-7.91	-0.45	8.67e-14	Birth weight;
KIRP	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.73	-8.76	-0.49	3.13e-16	Breast size;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg15147215	chr3:52552868	STAB1	-0.35	-6.06	-0.36	4.94e-9	Electroencephalogram traits;
KIRP	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.39	4.88	0.3	1.92e-6	Homoarginine levels;
KIRP	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.28	-0.37	1.49e-9	Total body bone mineral density;
KIRP	trans	rs1864729	1.000	rs1864729	chr8:98282189	G/A	cg08679828	chr8:102218111	ZNF706	-0.75	-6.86	-0.4	5.57e-11	Estradiol plasma levels (breast cancer);
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs1062746	0.502	rs11649601	chr16:87339220	G/C	cg02258303	chr16:87377426	FBXO31	-0.42	-5.25	-0.32	3.26e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.61	-9.06	-0.5	4.16e-17	Immature fraction of reticulocytes;
KIRP	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.6	7.52	0.43	9.94e-13	Alzheimer's disease;
KIRP	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-1.02	-18.55	-0.76	1.2e-48	Height;
KIRP	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	1.06	13.6	0.66	8.37e-32	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs6466055	0.692	rs4727621	chr7:105028370	T/C	cg04380332	chr7:105027541	SRPK2	-0.64	-9.48	-0.52	2.28e-18	Schizophrenia;
KIRP	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01493522	chr13:37497338	NA	0.41	5.43	0.33	1.37e-7	Coronary artery disease;
KIRP	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.2	-0.51	1.63e-17	Chronic sinus infection;
KIRP	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg25019033	chr10:957182	NA	-0.6	-6.42	-0.38	7.06e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.38e-8	Life satisfaction;
KIRP	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg11569703	chr11:65557185	OVOL1	0.81	13.62	0.66	7.14e-32	Acne (severe);
KIRP	cis	rs28834970	0.928	rs17057043	chr8:27220310	C/T	cg18234130	chr8:27182889	PTK2B	-0.44	-5.66	-0.34	4.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.95	15.56	0.7	1.77e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.41	-0.38	7.55e-10	Neuroticism;
KIRP	cis	rs10858047	0.883	rs6537841	chr1:115200808	A/G	cg12756093	chr1:115239321	AMPD1	-0.66	-6.42	-0.38	6.93e-10	Autism;
KIRP	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.61	-6.52	-0.38	4.07e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6545883	0.718	rs2694624	chr2:61672313	C/A	cg15711740	chr2:61764176	XPO1	-0.59	-7.69	-0.44	3.6e-13	Tuberculosis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg27305525	chr1:154955752	FLAD1	0.48	6.29	0.37	1.44e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.77	8.89	0.49	1.35e-16	Adiposity;
KIRP	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.09	0.31	7.24e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs12200782	0.932	rs12189841	chr6:26544798	A/T	cg11502198	chr6:26597334	ABT1	-0.78	-5.31	-0.32	2.49e-7	Small cell lung carcinoma;
KIRP	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.51	-6.3	-0.37	1.34e-9	Ulcerative colitis;
KIRP	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg12982090	chr3:42733453	KBTBD5	0.76	9.09	0.5	3.32e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg02297831	chr4:17616191	MED28	0.56	7.04	0.41	1.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.62	-6.71	-0.39	1.3100000000000001e-10	DNA methylation (variation);
KIRP	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg25019033	chr10:957182	NA	-0.57	-5.23	-0.32	3.65e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.91	-0.4	4.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg05973401	chr12:123451056	ABCB9	0.54	6.1	0.36	4.12e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg00792783	chr2:198669748	PLCL1	0.49	5.51	0.33	9.18e-8	Dermatomyositis;
KIRP	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.8	-13.1	-0.64	4.2000000000000004e-30	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.42	-0.38	7.15e-10	Myopia (pathological);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04134240	chr14:100680625	NA	0.54	6.53	0.38	3.79e-10	Parkinson's disease;
KIRP	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg22244940	chr12:132335942	MMP17	0.53	6.9	0.4	4.47e-11	Migraine;
KIRP	cis	rs7737355	0.681	rs11242094	chr5:131072622	A/G	cg06307176	chr5:131281290	NA	0.43	5.14	0.31	5.68e-7	Life satisfaction;
KIRP	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg21926883	chr2:100939477	LONRF2	-0.57	-7.67	-0.44	3.96e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.26	0.51	1.03e-17	Bladder cancer;
KIRP	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.12	0.5	2.82e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10875746	0.669	rs11168508	chr12:48683511	G/C	cg20731937	chr12:48336164	NA	0.42	5.46	0.33	1.18e-7	Longevity (90 years and older);
KIRP	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg21775007	chr8:11205619	TDH	-0.5	-6.43	-0.38	6.49e-10	Systolic blood pressure;
KIRP	cis	rs8054556	0.787	rs11649274	chr16:30026469	G/A	cg06326092	chr16:30034487	C16orf92	0.43	5.77	0.35	2.42e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.55	-6.77	-0.4	9.62e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.68	-8.8	-0.49	2.46e-16	IgG glycosylation;
KIRP	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.62	-8.2	-0.46	1.33e-14	Dilated cardiomyopathy;
KIRP	cis	rs10788264	0.504	rs7090214	chr10:124036494	T/C	cg09507567	chr10:124027408	NA	0.27	4.87	0.3	1.99e-6	Total body bone mineral density;
KIRP	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.95e-7	Bladder cancer;
KIRP	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.68	9.73	0.53	3.78e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.13	0.41	1.12e-11	Lung cancer;
KIRP	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.45	6.32	0.37	1.23e-9	Red blood cell count;
KIRP	cis	rs6987853	0.661	rs4641053	chr8:42352161	G/A	cg09913449	chr8:42400586	C8orf40	-0.37	-4.93	-0.3	1.48e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg04663916	chr13:50265991	EBPL	0.71	8.72	0.49	4.36e-16	Obesity-related traits;
KIRP	cis	rs7534801	0.656	rs2134268	chr1:244915579	A/C	cg20597013	chr1:244894274	NA	-0.33	-5.57	-0.33	6.57e-8	Longitudinal change in brain amyloid plaque burden;
KIRP	cis	rs7084402	0.967	rs1658493	chr10:60281090	C/T	cg05938607	chr10:60274200	BICC1	0.45	10.94	0.57	5.81e-23	Refractive error;
KIRP	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg13628971	chr7:2884303	GNA12	0.62	6.99	0.41	2.61e-11	Height;
KIRP	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11987759	chr7:65425863	GUSB	0.54	7.07	0.41	1.57e-11	Aortic root size;
KIRP	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg24631222	chr15:78858424	CHRNA5	0.79	9.51	0.52	1.78e-18	Post bronchodilator FEV1;
KIRP	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.63	0.56	5.95e-22	Lung cancer in ever smokers;
KIRP	cis	rs4478037	0.558	rs57502645	chr3:33082174	G/A	cg19404215	chr3:33155277	CRTAP	0.92	6.03	0.36	5.9e-9	Major depressive disorder;
KIRP	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.94	12.93	0.64	1.57e-29	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-6.55	-0.39	3.42e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.69	7.03	0.41	2.01e-11	Iron status biomarkers;
KIRP	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg08313168	chr12:7315531	NA	0.69	6.36	0.38	9.61e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-14.45	-0.68	1.13e-34	Gut microbiome composition (summer);
KIRP	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg18190219	chr22:46762943	CELSR1	-0.54	-6.05	-0.36	5.3e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.78	12.54	0.62	3.31e-28	Menarche (age at onset);
KIRP	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.69	-7.61	-0.44	5.92e-13	DNA methylation (variation);
KIRP	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg15117754	chr3:10150083	C3orf24	0.62	5.09	0.31	7.23e-7	Alzheimer's disease;
KIRP	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.76	-7.07	-0.41	1.64e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07256732	chr16:621771	PIGQ	-0.47	-6.55	-0.39	3.25e-10	Height;
KIRP	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.77	8.34	0.47	5.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs6987853	0.933	rs2974341	chr8:42398302	T/A	cg09913449	chr8:42400586	C8orf40	0.4	5.05	0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg24253500	chr15:84953950	NA	0.54	6.03	0.36	5.98e-9	Schizophrenia;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.82	12.86	0.63	2.63e-29	Menarche (age at onset);
KIRP	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.87	12.87	0.63	2.59e-29	Mean corpuscular hemoglobin;
KIRP	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.27	-21.59	-0.81	1.01e-58	Breast cancer;
KIRP	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg16606324	chr3:10149918	C3orf24	0.64	5.46	0.33	1.19e-7	Alzheimer's disease;
KIRP	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.65	7.61	0.44	5.74e-13	Schizophrenia;
KIRP	cis	rs3026101	0.671	rs2107151	chr17:5297338	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.4	5.17	0.31	4.82e-7	Immature fraction of reticulocytes;
KIRP	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	13.11	0.64	3.85e-30	Personality dimensions;
KIRP	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.46	-8.82	-0.49	2.21e-16	Longevity;
KIRP	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.64	0.52	7.35e-19	Bipolar disorder;
KIRP	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg07148914	chr20:33460835	GGT7	-0.54	-7.08	-0.41	1.47e-11	Height;
KIRP	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg07636037	chr3:49044803	WDR6	-0.58	-5.5	-0.33	9.71e-8	Menarche (age at onset);
KIRP	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.72	0.34	3.13e-8	Birth weight;
KIRP	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg15128208	chr22:42549153	NA	0.74	8.01	0.46	4.46e-14	Birth weight;
KIRP	cis	rs9653442	0.527	rs4851258	chr2:100780830	T/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.19	-0.31	4.35e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10131728	1.000	rs4592586	chr14:81692293	T/C	cg01989461	chr14:81687754	GTF2A1	-0.7	-5.61	-0.34	5.39e-8	IgG glycosylation;
KIRP	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg16989719	chr2:238392110	NA	-0.53	-5.97	-0.36	8.03e-9	Prostate cancer;
KIRP	cis	rs1440410	0.835	rs7693583	chr4:144051342	T/C	cg01719995	chr4:144104893	USP38	0.46	6.38	0.38	8.71e-10	Ischemic stroke;
KIRP	cis	rs2904967	0.778	rs603286	chr11:65095801	G/A	cg09225861	chr11:65069680	NA	0.44	5.93	0.35	1.04e-8	Mean corpuscular volume;
KIRP	cis	rs10782582	0.609	rs5745331	chr1:76273313	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.06	-0.36	5.05e-9	Daytime sleep phenotypes;
KIRP	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg10503236	chr1:231470652	EXOC8	-0.49	-6.78	-0.4	8.94e-11	Hemoglobin concentration;
KIRP	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg08885076	chr2:99613938	TSGA10	0.56	9.6	0.52	9.9e-19	Chronic sinus infection;
KIRP	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg10818794	chr15:86012489	AKAP13	0.52	7.26	0.42	5.03e-12	Coronary artery disease;
KIRP	cis	rs1185460	0.565	rs540261	chr11:118947634	C/T	cg23280166	chr11:118938394	VPS11	-0.61	-7.4	-0.43	2.09e-12	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16729016	chr1:213298061	RPS6KC1	0.68	9.17	0.5	2e-17	Interleukin-4 levels;
KIRP	cis	rs6901250	0.655	rs1117046	chr6:117136978	G/C	cg12892004	chr6:117198278	RFX6	0.42	6.92	0.4	3.88e-11	C-reactive protein levels;
KIRP	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.45	-5.1	-0.31	6.85e-7	Resistin levels;
KIRP	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.31	0.37	1.25e-9	Hypertriglyceridemia;
KIRP	cis	rs539514	0.516	rs9318377	chr13:76410018	G/A	cg04757411	chr13:76259545	LMO7	0.45	6.4	0.38	7.84e-10	Type 1 diabetes;
KIRP	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Body mass index;
KIRP	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.48	5.71	0.34	3.27e-8	Interleukin-18 levels;
KIRP	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.92	-0.35	1.06e-8	Height;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-5.91	-0.35	1.15e-8	Lung cancer;
KIRP	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.68	-0.39	1.62e-10	Diastolic blood pressure;
KIRP	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.58	-0.65	9.85e-32	Ulcerative colitis;
KIRP	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.57	-0.52	1.17e-18	Rheumatoid arthritis;
KIRP	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.93e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.71	8.88	0.49	1.42e-16	Resting heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13634501	chr15:60690026	ANXA2	0.52	7.14	0.41	1.03e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg25037394	chr1:24152592	HMGCL	0.37	4.95	0.3	1.36e-6	Immature fraction of reticulocytes;
KIRP	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.76	12.66	0.63	1.3e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.5e-39	Headache;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.54	5.38	0.32	1.75e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.36	-6.64	-0.39	2.03e-10	Monocyte percentage of white cells;
KIRP	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.4	-6.34	-0.37	1.07e-9	Body mass index;
KIRP	cis	rs8053891	0.507	rs66553600	chr16:72028198	G/C	cg01557791	chr16:72042693	DHODH	-0.47	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs3762637	0.943	rs9841897	chr3:122282569	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.0	-0.36	6.85e-9	LDL cholesterol levels;
KIRP	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	1.05	22.23	0.82	8.86e-61	Parkinson's disease;
KIRP	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.43	-0.52	3.3e-18	Coronary artery disease;
KIRP	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.75	-0.34	2.68e-8	Parkinson's disease;
KIRP	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg25124228	chr12:125621409	AACS	-0.75	-8.93	-0.49	1.01e-16	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7737355	0.812	rs3776013	chr5:130867404	C/T	cg25547332	chr5:131281432	NA	0.39	4.9	0.3	1.76e-6	Life satisfaction;
KIRP	trans	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg21775007	chr8:11205619	TDH	-0.52	-6.2	-0.37	2.32e-9	Neuroticism;
KIRP	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.5	6.35	0.38	1.06e-9	Total body bone mineral density;
KIRP	cis	rs6959887	0.821	rs7811472	chr7:35304164	C/T	cg06685737	chr7:35301730	NA	0.44	6.27	0.37	1.62e-9	Birth weight;
KIRP	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg04398451	chr17:18023971	MYO15A	0.65	8.35	0.47	4.92e-15	Total body bone mineral density;
KIRP	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-7.47	-0.43	1.4e-12	Vitiligo;
KIRP	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-8.89	-0.49	1.38e-16	Personality dimensions;
KIRP	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg15556689	chr8:8085844	FLJ10661	0.62	8.7	0.49	4.87e-16	Neuroticism;
KIRP	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	9.64	0.52	7.11e-19	Cognitive test performance;
KIRP	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-8.04	-0.46	3.8e-14	Myopia (pathological);
KIRP	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	8.26	0.47	9.13e-15	Neuroticism;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24449302	chr15:66679100	MAP2K1	-0.45	-6.36	-0.38	9.57e-10	Myopia;
KIRP	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.62	-11.73	-0.6	1.52e-25	Blood protein levels;
KIRP	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.34	0.55	4.65e-21	Cognitive test performance;
KIRP	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.73	8.51	0.48	1.75e-15	Diastolic blood pressure;
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg22903657	chr4:1355424	KIAA1530	-0.4	-5.73	-0.34	2.92e-8	Obesity-related traits;
KIRP	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.28	14.58	0.68	4e-35	Eosinophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23614229	chr17:48638594	CACNA1G	0.43	6.04	0.36	5.63e-9	Parkinson's disease;
KIRP	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.8	0.35	2.04e-8	Schizophrenia;
KIRP	cis	rs6142102	0.778	rs6059581	chr20:32528388	C/A	cg08999081	chr20:33150536	PIGU	0.51	6.05	0.36	5.32e-9	Skin pigmentation;
KIRP	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.08e-6	Aortic root size;
KIRP	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg25486957	chr4:152246857	NA	-0.43	-5.01	-0.3	1.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.41	-5.92	-0.35	1.06e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs13161895	1.000	rs4389651	chr5:179460968	T/A	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	cis	rs10203711	1.000	rs10187717	chr2:239558168	T/C	cg14580085	chr2:239553406	NA	0.39	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6589219	0.908	rs7130173	chr11:111154072	A/C	cg25129781	chr11:111156908	C11orf53	-0.49	-6.32	-0.37	1.2e-9	Colorectal cancer;
KIRP	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg24972876	chr7:65420302	NA	0.4	5.51	0.33	9.06e-8	Aortic root size;
KIRP	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.45	-7.34	-0.42	3.13e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs3796352	0.667	rs34860124	chr3:52857778	T/A	cg07884673	chr3:53033167	SFMBT1	0.69	5.21	0.32	4.02e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8177876	0.822	rs8056972	chr16:81112422	C/A	cg08591886	chr16:81111003	C16orf46	-0.62	-5.92	-0.35	1.09e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.65	-6.9	-0.4	4.46e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs2223471	0.624	rs6932224	chr6:50739074	A/G	cg03432817	chr6:50765336	NA	-0.34	-5.01	-0.3	1.02e-6	Subcutaneous adipose tissue;
KIRP	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg07449447	chr14:55228808	SAMD4A	0.48	6.82	0.4	7.02e-11	Morning vs. evening chronotype;
KIRP	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.61	-0.52	8.92e-19	Response to antipsychotic treatment;
KIRP	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.79	-0.53	2.5e-19	Morning vs. evening chronotype;
KIRP	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.55	8.42	0.47	3.04e-15	Anterior chamber depth;
KIRP	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg05484376	chr2:27715224	FNDC4	0.32	5.27	0.32	3.03e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg19761014	chr17:28927070	LRRC37B2	0.67	4.91	0.3	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1823913	1.000	rs4853563	chr2:192119534	G/A	cg12404831	chr2:192114017	MYO1B	-0.51	-6.84	-0.4	6.24e-11	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg08901578	chr4:187885870	NA	-0.46	-6.96	-0.41	3.08e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01105932	chr5:158635248	RNF145	-0.5	-6.37	-0.38	9.15e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	5.1	0.31	6.72e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24003216	chr8:100297748	VPS13B	-0.44	-6.83	-0.4	6.78e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.43	6.02	0.36	6.24e-9	Coronary artery disease;
KIRP	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg21361702	chr7:150065534	REPIN1	0.61	6.45	0.38	5.98e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4561483	0.545	rs9927446	chr16:11957164	A/T	cg08843971	chr16:11963173	GSPT1	0.54	7.56	0.43	7.81e-13	Testicular germ cell tumor;
KIRP	cis	rs8014252	0.803	rs56328037	chr14:71045341	A/C	cg19730268	chr14:71022823	NA	-0.7	-6.25	-0.37	1.77e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.93	13.72	0.66	3.31e-32	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2273669	0.667	rs16822	chr6:109307710	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21727117	chr19:2269525	OAZ1	0.54	6.93	0.4	3.62e-11	Parkinson's disease;
KIRP	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs1359582	0.736	rs1980813	chr10:90354888	A/T	cg15661332	chr10:90342814	RNLS	-0.55	-5.53	-0.33	7.98e-8	Depressive and manic episodes in bipolar disorder;
KIRP	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.63	-0.44	5.31e-13	Triglycerides;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.67	10.09	0.54	2.99e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.76	7.87	0.45	1.15e-13	Resting heart rate;
KIRP	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg05552183	chr6:42928497	GNMT	0.47	5.24	0.32	3.39e-7	Blood protein levels;
KIRP	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.47	5.93	0.35	1.03e-8	IgG glycosylation;
KIRP	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg13165212	chr22:42675999	NA	0.28	5.03	0.31	9.35e-7	Cognitive function;
KIRP	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg18350739	chr11:68623251	NA	-0.52	-7.96	-0.45	6.38e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.8	-0.35	1.98e-8	Joint mobility (Beighton score);
KIRP	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.91	10.59	0.56	7.88e-22	Corneal astigmatism;
KIRP	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.37	-0.55	3.99e-21	Coffee consumption (cups per day);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14579362	chr19:39926682	RPS16	-0.5	-6.69	-0.39	1.51e-10	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08112354	chr14:105452552	C14orf79	0.53	6.53	0.38	3.79e-10	Parkinson's disease;
KIRP	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.68	7.15	0.41	9.93e-12	Gout;
KIRP	cis	rs3844535	1	rs3844535	chr14:81884515	A/G	cg23690444	chr14:81902736	NA	0.67	7.25	0.42	5.36e-12	Plateletcrit;Platelet count;
KIRP	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.62	8.6	0.48	9.23e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4234798	0.933	rs10020957	chr4:7222436	C/T	cg18431297	chr4:7219810	SORCS2	-0.64	-8.81	-0.49	2.27e-16	Insulin-like growth factors;
KIRP	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.93	11.58	0.59	4.82e-25	Response to antineoplastic agents;
KIRP	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.19	0.46	1.42e-14	Motion sickness;
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg21851534	chr17:3907994	ZZEF1	-0.62	-9.77	-0.53	2.93e-19	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.69	-5.41	-0.33	1.48e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg27205649	chr11:78285834	NARS2	-0.55	-6.2	-0.37	2.43e-9	Testicular germ cell tumor;
KIRP	cis	rs8028182	0.636	rs11636199	chr15:75825337	A/G	cg20655648	chr15:75932815	IMP3	0.53	6.89	0.4	4.57e-11	Sudden cardiac arrest;
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg07216194	chr8:27182965	PTK2B	-0.43	-5.35	-0.32	2e-7	Neuroticism;
KIRP	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.69	-5.26	-0.32	3.13e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2299587	0.897	rs7015946	chr8:17785790	C/T	cg01800426	chr8:17659068	MTUS1	-0.41	-5.07	-0.31	7.99e-7	Economic and political preferences;
KIRP	cis	rs7903847	0.620	rs17112674	chr10:99122178	C/T	cg20016023	chr10:99160130	RRP12	0.4	5.49	0.33	1.02e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg03711944	chr11:47377212	SPI1	-0.32	-5.17	-0.31	4.9e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00027499	chr16:30759507	PHKG2	0.52	6.61	0.39	2.33e-10	Parkinson's disease;
KIRP	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs6723108	0.515	rs55687393	chr2:135540231	C/G	cg25422880	chr2:135218333	TMEM163	-0.44	-6.17	-0.37	2.77e-9	Type 2 diabetes;
KIRP	trans	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg10756647	chr7:56101905	PSPH	1.01	7.54	0.43	9.29e-13	Diabetic kidney disease;
KIRP	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.66	10.11	0.54	2.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg10189774	chr4:17578691	LAP3	0.5	6.03	0.36	5.82e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01202731	chr2:103377345	TMEM182	-0.4	-6.17	-0.37	2.73e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4683142	0.518	rs4682801	chr3:46021218	G/T	cg08033130	chr3:45983597	CXCR6;FYCO1	0.35	5.1	0.31	6.92e-7	Methadone dose in opioid dependence;
KIRP	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg18357526	chr6:26021779	HIST1H4A	0.42	4.84	0.3	2.25e-6	Blood metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03141158	chr11:110108737	RDX	-0.43	-6.4	-0.38	7.97e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9400467	0.537	rs12214886	chr6:111500081	C/T	cg15721981	chr6:111408429	SLC16A10	0.78	6.96	0.41	3.06e-11	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12028674	chr19:39306244	ECH1	0.45	6.1	0.36	4.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs554111	0.593	rs9426660	chr1:21520449	A/G	cg08890418	chr1:21044141	KIF17	0.44	6.66	0.39	1.73e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.85	-0.35	1.55e-8	Height;
KIRP	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg12131826	chr15:77904385	NA	-0.5	-6.32	-0.37	1.19e-9	Type 2 diabetes;
KIRP	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.59	12.45	0.62	6.65e-28	Diabetic kidney disease;
KIRP	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg01320579	chr17:75405842	SEPT9	0.77	6.96	0.41	3e-11	Airflow obstruction;
KIRP	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg02569458	chr12:86230093	RASSF9	0.36	5.18	0.31	4.71e-7	Major depressive disorder;
KIRP	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19346786	chr7:2764209	NA	-0.35	-5.95	-0.35	8.97e-9	Height;
KIRP	cis	rs501120	0.584	rs661697	chr10:44740698	G/T	cg09554077	chr10:44749378	NA	0.68	7.26	0.42	4.96e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg23335576	chr14:104009727	NA	0.36	5.27	0.32	2.96e-7	Body mass index;
KIRP	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.68	5.24	0.32	3.37e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.61	-7.67	-0.44	4e-13	Waist circumference;Body mass index;
KIRP	cis	rs4776059	0.724	rs11633933	chr15:52948357	T/C	cg22715398	chr15:52968154	KIAA1370	-0.62	-7.24	-0.42	5.62e-12	Schizophrenia;
KIRP	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg23752985	chr2:85803571	VAMP8	0.47	5.43	0.33	1.32e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs12936587	0.633	rs11869600	chr17:17504856	G/A	cg01246520	chr17:17644344	RAI1	-0.38	-5.67	-0.34	4e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs6991838	0.584	rs7842085	chr8:66549022	T/A	cg13398993	chr8:66546079	ARMC1	0.45	4.95	0.3	1.35e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	cg06064525	chr11:970664	AP2A2	-0.31	-6.3	-0.37	1.34e-9	Alzheimer's disease (late onset);
KIRP	cis	rs73198271	0.595	rs117424193	chr8:8591377	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.9e-20	Alzheimer's disease (late onset);
KIRP	cis	rs11586313	0.571	rs11583382	chr1:152874096	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-5.73	-0.34	2.88e-8	Vitamin D levels;
KIRP	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.91	9.23	0.51	1.32e-17	Gut microbiome composition (summer);
KIRP	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.66	-12.05	-0.61	1.36e-26	White blood cell count (basophil);
KIRP	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg22117172	chr7:91764530	CYP51A1	0.47	6.59	0.39	2.61e-10	Breast cancer;
KIRP	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg15490075	chr13:100150979	NA	0.66	6.94	0.4	3.5e-11	Obesity-related traits;
KIRP	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.79	-0.45	1.83e-13	Total cholesterol levels;
KIRP	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg26441486	chr22:50317300	CRELD2	-0.39	-5.45	-0.33	1.23e-7	Schizophrenia;
KIRP	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9920	1.000	rs75022895	chr7:116192330	C/T	cg24770985	chr7:116166421	CAV1	0.79	5.12	0.31	6.21e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
KIRP	trans	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg06521331	chr12:34319734	NA	-0.52	-6.4	-0.38	7.58e-10	Bladder cancer;
KIRP	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.67	0.52	6.01e-19	Prudent dietary pattern;
KIRP	cis	rs7224685	0.569	rs67005107	chr17:3991943	A/G	cg09597638	chr17:3907349	NA	0.48	4.93	0.3	1.51e-6	Type 2 diabetes;
KIRP	cis	rs10186029	0.676	rs1025820	chr2:213933778	T/G	cg08319019	chr2:214017104	IKZF2	0.42	4.86	0.3	2.08e-6	Systemic sclerosis;
KIRP	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.79	-0.4	8.37e-11	Monocyte percentage of white cells;
KIRP	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg25486957	chr4:152246857	NA	-0.43	-5.05	-0.31	8.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg26248373	chr2:1572462	NA	-0.66	-7.15	-0.42	9.6e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg27398547	chr14:60952738	C14orf39	0.68	6.7	0.39	1.42e-10	Gut microbiota (bacterial taxa);
KIRP	trans	rs12517041	1.000	rs1428617	chr5:23260918	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-6.38	-0.38	8.8e-10	Calcium levels;
KIRP	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg25039879	chr17:56429692	SUPT4H1	0.58	5.24	0.32	3.49e-7	Cognitive test performance;
KIRP	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.82	-8.93	-0.49	1.03e-16	Alzheimer's disease;
KIRP	cis	rs595982	0.661	rs657008	chr19:49373632	A/G	cg21252483	chr19:49399788	TULP2	-0.29	-5.48	-0.33	1.08e-7	Red cell distribution width;
KIRP	cis	rs747650	0.926	rs10838659	chr11:47148210	C/T	cg16389345	chr11:46697382	NA	0.39	5.16	0.31	5.06e-7	Acne (severe);
KIRP	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg04727924	chr7:799746	HEATR2	0.61	5.65	0.34	4.34e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.47	5.96	0.36	8.82e-9	Height;
KIRP	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg02297831	chr4:17616191	MED28	-0.51	-6.11	-0.36	3.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs904251	0.620	rs883372	chr6:37477605	A/C	cg08126542	chr6:37504118	NA	-0.62	-6.47	-0.38	5.25e-10	Cognitive performance;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12477288	chr6:135503465	MYB	-0.49	-6.55	-0.39	3.29e-10	Myopia;
KIRP	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.61	-0.48	9.01e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.61	-7.53	-0.43	9.46e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-23.34	-0.83	2.49e-64	Myeloid white cell count;
KIRP	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg03929089	chr4:120376271	NA	0.84	6.02	0.36	6.47e-9	Axial length;
KIRP	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.47	0.38	5.31e-10	Red blood cell count;
KIRP	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.31e-9	Schizophrenia;
KIRP	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06481639	chr22:41940642	POLR3H	0.65	7.14	0.41	1.04e-11	Vitiligo;
KIRP	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.7	8.46	0.47	2.41e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs9409565	0.516	rs114766729	chr9:97069901	C/T	cg05679027	chr9:99775184	HIATL2	0.58	6.98	0.41	2.7e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs73206853	0.702	rs7960516	chr12:110529238	T/A	cg12870014	chr12:110450643	ANKRD13A	0.45	5.29	0.32	2.7e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg10223061	chr2:219282414	VIL1	0.41	6.47	0.38	5.38e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08646051	chr12:26205524	RASSF8	0.51	6.2	0.37	2.35e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.23	-0.55	1.09e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg21866054	chr4:103748674	UBE2D3	0.53	6.36	0.38	9.75e-10	Body mass index in non-asthmatics;
KIRP	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.74	-9.81	-0.53	2.13e-19	Huntington's disease progression;
KIRP	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg26566898	chr11:117069891	TAGLN	0.4	5.2	0.31	4.24e-7	Blood protein levels;
KIRP	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.8	-10.56	-0.56	9.5e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8177876	0.841	rs8177851	chr16:81126352	A/C	cg08591886	chr16:81111003	C16orf46	-0.65	-4.91	-0.3	1.7e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	cis	rs35740288	0.770	rs12906580	chr15:86155287	C/T	cg17133734	chr15:86042851	AKAP13	0.52	5.71	0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.54	7.37	0.43	2.65e-12	Bipolar disorder;
KIRP	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.72	-11.82	-0.6	8.19e-26	Itch intensity from mosquito bite;
KIRP	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.68	-8.87	-0.49	1.53e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg22437258	chr11:111473054	SIK2	0.54	6.3	0.37	1.37e-9	Primary sclerosing cholangitis;
KIRP	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.97	-16.74	-0.73	1.72e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg14233861	chr9:102729907	STX17	0.39	6.12	0.36	3.59e-9	Warfarin maintenance dose;
KIRP	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg00079169	chr19:2811669	THOP1	0.5	5.55	0.33	7.38e-8	Total cholesterol levels;
KIRP	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg04731861	chr2:219085781	ARPC2	-0.21	-5.09	-0.31	7.11e-7	Colorectal cancer;
KIRP	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg16396542	chr1:89473148	GBP3	0.42	5.91	0.35	1.15e-8	Carotid intima media thickness;
KIRP	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.69	-0.39	1.48e-10	Coronary artery disease;
KIRP	cis	rs295140	0.506	rs4673854	chr2:201134736	G/A	cg23649088	chr2:200775458	C2orf69	-0.41	-5.14	-0.31	5.63e-7	QT interval;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs785830	0.644	rs1184590	chr9:262298	T/C	cg14500300	chr9:211689	NA	0.4	5.38	0.32	1.75e-7	Platelet distribution width;
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	7.14	0.41	1.02e-11	Lung function (FEV1/FVC);
KIRP	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	1.06	23.09	0.83	1.61e-63	Breast cancer;
KIRP	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.77	-8.16	-0.46	1.71e-14	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.48	-6.9	-0.4	4.45e-11	DNA methylation (variation);
KIRP	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg14580859	chr9:123691850	NA	0.35	5.06	0.31	8.21e-7	Rheumatoid arthritis;
KIRP	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg10755058	chr3:40428713	ENTPD3	0.44	6.22	0.37	2.16e-9	Renal cell carcinoma;
KIRP	cis	rs42648	0.819	rs10953006	chr7:90030153	A/G	cg25739043	chr7:89950458	NA	-0.41	-6.4	-0.38	7.59e-10	Homocysteine levels;
KIRP	cis	rs4363385	0.719	rs4845501	chr1:152937401	A/G	cg07796016	chr1:152779584	LCE1C	-0.41	-4.9	-0.3	1.71e-6	Inflammatory skin disease;
KIRP	cis	rs9311676	0.632	rs56288363	chr3:58374533	A/T	cg06643156	chr3:58380774	PXK	0.35	4.97	0.3	1.27e-6	Systemic lupus erythematosus;
KIRP	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.26	0.42	4.92e-12	Prudent dietary pattern;
KIRP	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.74	7.65	0.44	4.64e-13	Uric acid levels;
KIRP	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg13180566	chr4:1052158	NA	-0.51	-5.13	-0.31	5.75e-7	Recombination rate (females);
KIRP	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg08992911	chr2:238395768	MLPH	0.42	5.35	0.32	2e-7	Prostate cancer;
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	13.71	0.66	3.61e-32	Platelet count;
KIRP	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg27411982	chr8:10470053	RP1L1	0.4	5.0	0.3	1.1e-6	Neuroticism;
KIRP	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg00981070	chr1:2046702	PRKCZ	0.42	6.94	0.4	3.45e-11	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05360402	chr5:110848191	STARD4	0.63	7.45	0.43	1.53e-12	Smoking initiation;
KIRP	cis	rs12900413	0.603	rs2351493	chr15:90299536	A/G	cg24650279	chr15:90327240	NA	-0.43	-5.42	-0.33	1.46e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs12517041	1.000	rs6868335	chr5:23316641	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.29	-0.42	4.33e-12	Calcium levels;
KIRP	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	8.76	0.49	3.14e-16	Pulse pressure;
KIRP	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.09e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.9	0.3	1.73e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7246760	0.867	rs55846005	chr19:9796709	T/A	cg02900749	chr2:68251473	NA	-1.2	-9.9	-0.53	1.13e-19	Pursuit maintenance gain;
KIRP	cis	rs2997447	0.846	rs3008235	chr1:26408409	T/C	cg19633962	chr1:26362018	EXTL1	-0.49	-4.84	-0.3	2.24e-6	QRS complex (12-leadsum);
KIRP	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.55	-6.9	-0.4	4.25e-11	White blood cell count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08204369	chr17:73150733	HN1	0.54	7.28	0.42	4.55e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.93	14.79	0.69	7.41e-36	Menopause (age at onset);
KIRP	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg00074818	chr8:8560427	CLDN23	0.4	6.19	0.37	2.55e-9	Obesity-related traits;
KIRP	cis	rs3752645	1.000	rs2250121	chr7:106753248	A/G	cg02696742	chr7:106810147	HBP1	-0.57	-4.91	-0.3	1.7e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.56	-0.56	9.71e-22	Menopause (age at onset);
KIRP	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.32	-0.32	2.32e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.71	-10.44	-0.55	2.4e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg10207240	chr12:122356781	WDR66	0.57	7.59	0.44	6.76e-13	Mean corpuscular volume;
KIRP	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	1.03	14.17	0.67	1.01e-33	Neutrophil percentage of white cells;
KIRP	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs11637445	0.677	rs3784716	chr15:68084450	G/T	cg24579218	chr15:68104479	NA	-0.44	-6.58	-0.39	2.81e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.4	-5.55	-0.33	7.21e-8	Dilated cardiomyopathy;
KIRP	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.58	-9.4	-0.51	4.08e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24110177	chr3:50126178	RBM5	-0.77	-10.37	-0.55	3.88e-21	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16208369	chr2:10952727	PDIA6	0.5	6.33	0.37	1.18e-9	Parkinson's disease;
KIRP	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs883115	0.846	rs1566388	chr1:224795474	A/T	cg01808320	chr1:224927238	CNIH3	-0.37	-5.33	-0.32	2.25e-7	Cancer;
KIRP	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs5770917	1.000	rs2269381	chr22:51020069	G/C	cg25309564	chr22:51001381	C22orf41	0.9	5.22	0.32	3.87e-7	Narcolepsy;
KIRP	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg23899408	chr19:12877188	HOOK2	-0.45	-5.29	-0.32	2.75e-7	Mean corpuscular volume;
KIRP	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	8.96	0.5	8.27e-17	Eosinophil percentage of white cells;
KIRP	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.39	0.38	8.1e-10	Neuroticism;
KIRP	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg18261050	chr1:119551319	NA	0.49	6.37	0.38	9.39e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.93	0.35	1.03e-8	Depressive symptoms;
KIRP	cis	rs4959799	0.655	rs9503520	chr6:3281741	G/A	cg10513992	chr6:3293720	SLC22A23	-0.63	-5.2	-0.31	4.14e-7	Survival in rectal cancer;
KIRP	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.55	-15.76	-0.71	3.64e-39	Hip circumference adjusted for BMI;
KIRP	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs4523957	0.855	rs9897160	chr17:2121566	A/G	cg16513277	chr17:2031491	SMG6	-0.69	-9.62	-0.52	8.54e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg19913688	chr11:428466	ANO9	-0.77	-6.03	-0.36	6.05e-9	Body mass index;
KIRP	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg00656387	chr3:40428638	ENTPD3	0.39	4.87	0.3	1.96e-6	Renal cell carcinoma;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13686537	chr9:136573518	SARDH	0.43	6.11	0.36	3.92e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg23594656	chr7:65796392	TPST1	0.43	6.06	0.36	5e-9	Aortic root size;
KIRP	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg21231944	chr12:82153410	PPFIA2	-0.42	-5.11	-0.31	6.45e-7	Resting heart rate;
KIRP	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.88	-12.89	-0.63	2.23e-29	Glomerular filtration rate (creatinine);
KIRP	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.65	9.77	0.53	2.92e-19	Dupuytren's disease;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2290159	0.948	rs5746255	chr3:12624321	A/G	cg23032965	chr3:12705835	RAF1	0.66	7.57	0.43	7.51e-13	Cholesterol, total;
KIRP	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg00579200	chr11:133705235	NA	-0.39	-4.96	-0.3	1.34e-6	Childhood ear infection;
KIRP	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	cis	rs10488172	0.724	rs6958569	chr7:133354072	G/A	cg10665199	chr7:133106180	EXOC4	-0.49	-5.15	-0.31	5.32e-7	Tonometry;
KIRP	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-5.78	-0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.92	-13.58	-0.65	1.03e-31	Longevity;Endometriosis;
KIRP	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.9	0.35	1.2e-8	Motion sickness;
KIRP	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.07	-0.5	3.87e-17	Bone mineral density;
KIRP	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-19.07	-0.77	2.17e-50	Height;
KIRP	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.72	0.49	4.16e-16	Motion sickness;
KIRP	cis	rs6684428	0.610	rs12120132	chr1:56322054	G/A	cg11651538	chr1:56320950	NA	-0.93	-12.86	-0.63	2.63e-29	Airflow obstruction;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00767560	chr19:19887256	LOC284440	0.63	7.28	0.42	4.47e-12	Lung cancer in ever smokers;
KIRP	cis	rs737693	0.607	rs660599	chr11:102729757	G/A	cg19620758	chr11:102826565	MMP13	0.53	5.64	0.34	4.56e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg16255804	chr6:135334527	HBS1L	-0.34	-5.47	-0.33	1.12e-7	Red blood cell count;
KIRP	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.86	11.03	0.58	2.97e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.71	9.82	0.53	2.1e-19	Multiple sclerosis;
KIRP	cis	rs10463554	0.759	rs34781	chr5:102454439	C/T	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Parkinson's disease;
KIRP	cis	rs5997397	0.967	rs5752791	chr22:29153547	A/G	cg15103426	chr22:29168792	CCDC117	-0.46	-6.19	-0.37	2.57e-9	Red cell distribution width;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg02733842	chr7:1102375	C7orf50	0.56	5.76	0.34	2.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg21479132	chr6:26055353	NA	0.79	5.39	0.32	1.67e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.3	-0.32	2.59e-7	Bipolar disorder;
KIRP	trans	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.54	6.1	0.36	4.04e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg24344143	chr8:26050161	NA	0.4	6.25	0.37	1.78e-9	Serum protein levels (sST2);
KIRP	cis	rs829661	0.793	rs2177698	chr2:30793299	T/G	cg10949345	chr2:30726833	LCLAT1	1.13	14.25	0.67	5.41e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.5	-6.18	-0.37	2.67e-9	Neurofibrillary tangles;
KIRP	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.26	-0.47	9.12e-15	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.53e-13	Corneal astigmatism;
KIRP	cis	rs1823913	0.614	rs12616167	chr2:192176000	C/T	cg12404831	chr2:192114017	MYO1B	-0.45	-6.03	-0.36	6.11e-9	Obesity-related traits;
KIRP	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.85	12.64	0.63	1.52e-28	Longevity;
KIRP	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.52	7.51	0.43	1.07e-12	Obesity-related traits;
KIRP	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.93	8.43	0.47	3.02e-15	Body mass index;
KIRP	cis	rs59586681	0.902	rs6113390	chr20:2233776	C/T	cg26098768	chr20:2187533	NA	0.37	5.08	0.31	7.57e-7	Basal cell carcinoma;
KIRP	cis	rs787274	1.000	rs10733594	chr9:115552630	T/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.54	-0.39	3.45e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6496667	1.000	rs58436485	chr15:90900633	G/A	cg10434728	chr15:90938212	IQGAP1	0.39	5.04	0.31	9.07e-7	Rheumatoid arthritis;
KIRP	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.86	0.49	1.64e-16	Morning vs. evening chronotype;
KIRP	cis	rs4234798	0.585	rs13121616	chr4:7212389	A/G	cg18431297	chr4:7219810	SORCS2	0.57	6.26	0.37	1.73e-9	Insulin-like growth factors;
KIRP	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg06386533	chr2:46925753	SOCS5	0.52	4.96	0.3	1.33e-6	Height;
KIRP	trans	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg00938859	chr5:1591904	SDHAP3	0.53	6.26	0.37	1.69e-9	Breast cancer;
KIRP	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.69	7.96	0.45	6.53e-14	Corneal astigmatism;
KIRP	cis	rs17123764	0.892	rs1317131	chr12:50105166	C/T	cg20471783	chr12:50157085	TMBIM6	0.4	5.32	0.32	2.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11018874	0.709	rs11018854	chr11:89835191	A/G	cg06174606	chr11:89959870	NA	-0.6	-5.82	-0.35	1.84e-8	White blood cell types;
KIRP	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.52	-6.46	-0.38	5.42e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-7.14	-0.41	1.06e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.47	6.27	0.37	1.59e-9	Mean corpuscular volume;
KIRP	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg08126542	chr6:37504118	NA	-0.59	-6.81	-0.4	7.3e-11	Cognitive performance;
KIRP	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg18223153	chr7:540667	PDGFA	0.6	6.39	0.38	8.3e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.34	5.1	0.31	6.63e-7	Hypertriglyceridemia;
KIRP	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7572644	0.723	rs13019037	chr2:28024642	C/T	cg27432699	chr2:27873401	GPN1	0.48	5.25	0.32	3.24e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-9.23	-0.51	1.33e-17	Parkinson's disease;
KIRP	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	8.66	0.48	6.26e-16	Cognitive ability;
KIRP	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-8.92	-0.49	1.07e-16	Hepatocellular carcinoma;
KIRP	cis	rs6743068	0.521	rs1406122	chr2:202211443	A/G	cg06431681	chr2:202330990	STRADB	-0.36	-4.96	-0.3	1.29e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-6.07	-0.36	4.79e-9	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11987759	chr7:65425863	GUSB	0.54	7.3	0.42	3.87e-12	Aortic root size;
KIRP	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.24	-0.47	9.98e-15	Mood instability;
KIRP	cis	rs9513627	1.000	rs2390278	chr13:100159712	G/A	cg25919922	chr13:100150906	NA	0.71	5.43	0.33	1.38e-7	Obesity-related traits;
KIRP	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.61	-7.92	-0.45	8.27e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.66	-9.33	-0.51	6.43e-18	Beta-trace protein levels;
KIRP	cis	rs6102059	0.503	rs6029179	chr20:39178679	C/T	cg22477343	chr20:39312069	NA	0.46	6.01	0.36	6.56e-9	LDL cholesterol;
KIRP	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg17724175	chr1:150552817	MCL1	-0.42	-7.02	-0.41	2.18e-11	Blood protein levels;
KIRP	cis	rs6005807	0.719	rs12166245	chr22:28999890	C/T	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg06640241	chr16:89574553	SPG7	0.67	8.72	0.49	4.22e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg00361562	chr2:198649771	BOLL	-0.49	-5.04	-0.31	9.11e-7	Ulcerative colitis;
KIRP	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg27205649	chr11:78285834	NARS2	-0.66	-8.62	-0.48	8.43e-16	Alzheimer's disease (survival time);
KIRP	cis	rs6142102	0.812	rs761238	chr20:32519988	A/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-5.85	-0.35	1.52e-8	Skin pigmentation;
KIRP	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg23188430	chr6:125850052	NA	-0.33	-5.15	-0.31	5.39e-7	Brugada syndrome;
KIRP	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg01616529	chr11:638424	DRD4	-0.44	-5.72	-0.34	3.04e-8	Systemic lupus erythematosus;
KIRP	trans	rs7550636	0.964	rs10921278	chr1:192815682	G/A	cg24249403	chr15:101189058	ASB7	0.45	6.14	0.36	3.27e-9	Coronary artery calcification;
KIRP	cis	rs3755132	0.929	rs6746074	chr2:15743816	G/A	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.18	-0.42	8.19e-12	Colorectal cancer;
KIRP	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.56	-5.78	-0.35	2.28e-8	Motion sickness;
KIRP	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.53	0.52	1.56e-18	Colorectal cancer;
KIRP	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.59	0.44	6.6e-13	Major depressive disorder;
KIRP	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.41	6.01	0.36	6.7e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg04369109	chr6:150039330	LATS1	-0.5	-6.33	-0.37	1.16e-9	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05174924	chr6:90062691	UBE2J1	0.47	6.22	0.37	2.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg10495392	chr1:46806563	NSUN4	0.46	5.12	0.31	6.07e-7	Menopause (age at onset);
KIRP	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg27529037	chr20:44575021	PCIF1	0.47	5.71	0.34	3.24e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg26306683	chr17:18585705	ZNF286B	-0.44	-5.38	-0.32	1.72e-7	Educational attainment (years of education);
KIRP	trans	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg16141378	chr3:129829833	LOC729375	0.54	7.32	0.42	3.47e-12	Mood instability;
KIRP	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg16606324	chr3:10149918	C3orf24	-0.72	-6.12	-0.36	3.75e-9	Alzheimer's disease;
KIRP	cis	rs1010254	0.510	rs72808345	chr5:151759695	G/A	cg12297329	chr5:152029980	NA	-0.7	-6.76	-0.4	9.99e-11	Optic nerve measurement (cup area);
KIRP	cis	rs6707387	0.686	rs1961052	chr2:214475506	C/T	cg08319019	chr2:214017104	IKZF2	0.49	5.72	0.34	3.09e-8	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg02187348	chr16:89574699	SPG7	0.52	6.62	0.39	2.17e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs4308124	1.000	rs62160391	chr2:112008835	C/A	cg23466623	chr2:111982296	NA	0.4	5.65	0.34	4.5e-8	Vitiligo;
KIRP	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.7	10.84	0.57	1.19e-22	Coronary artery disease;
KIRP	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.08	-0.31	7.45e-7	Metabolite levels;
KIRP	cis	rs10045504	0.502	rs17456482	chr5:38737783	G/C	cg15396434	chr5:38725168	NA	-0.95	-9.53	-0.52	1.58e-18	Night sleep phenotypes;
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.77	-11.04	-0.58	2.75e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.79	-10.89	-0.57	8.76e-23	Prudent dietary pattern;
KIRP	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg02975922	chr3:195473998	MUC4	-0.56	-6.12	-0.36	3.68e-9	Pancreatic cancer;
KIRP	trans	rs9371601	0.819	rs551900	chr6:152717317	G/A	cg05529123	chr2:66910386	NA	-0.46	-6.2	-0.37	2.37e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1957429	0.614	rs73279834	chr14:65352544	G/A	cg23373153	chr14:65346875	NA	-0.67	-5.53	-0.33	8.22e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.48	0.38	4.99e-10	Breast cancer;
KIRP	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg00677455	chr12:58241039	CTDSP2	0.69	7.65	0.44	4.59e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2594989	0.779	rs111827101	chr3:11587736	T/C	cg01796438	chr3:11312864	ATG7	0.45	5.79	0.35	2.16e-8	Circulating chemerin levels;
KIRP	cis	rs2294693	0.945	rs932399	chr6:41011266	C/T	cg14769373	chr6:40998127	UNC5CL	-0.57	-5.93	-0.35	1.04e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-5.42	-0.33	1.39e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.24e-6	Recombination rate (females);
KIRP	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04100724	chr12:92539208	BTG1	0.78	6.79	0.4	8.51e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7534824	0.543	rs12568993	chr1:101386259	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.96	0.45	6.53e-14	Refractive astigmatism;
KIRP	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg10326726	chr10:51549505	MSMB	-0.57	-8.59	-0.48	1.02e-15	Prostate-specific antigen levels;
KIRP	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg16590910	chr6:42928470	GNMT	0.53	7.61	0.44	5.69e-13	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg04362960	chr10:104952993	NT5C2	-0.45	-4.87	-0.3	2.04e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg08917208	chr2:24149416	ATAD2B	1.17	10.32	0.55	5.49e-21	Lymphocyte counts;
KIRP	cis	rs9900972	0.720	rs6501257	chr17:76877655	G/A	cg20937029	chr17:76870563	TIMP2	0.44	5.14	0.31	5.53e-7	Obesity-related traits;
KIRP	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.48e-8	Schizophrenia;
KIRP	cis	rs1443512	0.773	rs2366146	chr12:54331002	G/A	cg17410650	chr12:54324560	NA	-0.48	-6.15	-0.37	3.04e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs6545883	0.826	rs2694651	chr2:61588642	T/C	cg15711740	chr2:61764176	XPO1	0.6	7.7	0.44	3.29e-13	Tuberculosis;
KIRP	cis	rs11877825	0.826	rs8082984	chr18:10571904	C/T	cg25239095	chr18:10589360	NA	0.42	4.87	0.3	1.97e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs35771425	1.000	rs7554421	chr1:211592087	G/C	cg10512769	chr1:211675356	NA	-0.54	-5.92	-0.35	1.07e-8	Educational attainment (years of education);
KIRP	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.92	14.57	0.68	4.26e-35	Mean corpuscular volume;
KIRP	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11987759	chr7:65425863	GUSB	-0.44	-5.51	-0.33	9.1e-8	Aortic root size;
KIRP	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	1.11	16.42	0.72	2.13e-41	Breast cancer;
KIRP	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	9.11	0.5	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.96	15.77	0.71	3.41e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.69	9.27	0.51	9.79e-18	Educational attainment;
KIRP	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg10117171	chr1:25599238	RHD	-0.4	-5.3	-0.32	2.63e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg15691649	chr6:25882328	NA	0.44	5.37	0.32	1.82e-7	Blood metabolite levels;
KIRP	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18252515	chr7:66147081	NA	0.48	5.58	0.34	6.27e-8	Aortic root size;
KIRP	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg24642844	chr7:1081250	C7orf50	-0.74	-6.76	-0.4	9.72e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs75920871	0.528	rs7484045	chr11:116946890	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.33	-0.32	2.26e-7	Subjective well-being;
KIRP	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg25251562	chr2:3704773	ALLC	-0.51	-6.02	-0.36	6.27e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg22004314	chr5:64223709	SDCCAG10	-0.62	-6.06	-0.36	5.21e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16386425	chr10:429943	DIP2C	-0.48	-6.68	-0.39	1.63e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.0	-0.45	4.95e-14	Mean corpuscular volume;
KIRP	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17376030	chr22:41985996	PMM1	-0.76	-8.1	-0.46	2.53e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.47	6.26	0.37	1.68e-9	Psychosis in Alzheimer's disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10519680	chr8:37707506	BRF2	0.6	6.7	0.39	1.41e-10	Lung cancer in ever smokers;
KIRP	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13409248	chr3:40428643	ENTPD3	0.39	5.07	0.31	7.83e-7	Renal cell carcinoma;
KIRP	cis	rs889512	0.642	rs60879082	chr16:75283065	G/A	cg03315344	chr16:75512273	CHST6	-0.63	-5.1	-0.31	6.72e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg06942064	chr1:208417143	PLXNA2	0.95	6.28	0.37	1.49e-9	P wave terminal force;
KIRP	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.38	5.15	0.31	5.26e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.42	5.39	0.33	1.63e-7	Aortic root size;
KIRP	cis	rs1497828	0.956	rs2646829	chr1:217542801	T/C	cg04411442	chr1:217543379	NA	0.41	6.21	0.37	2.22e-9	Dialysis-related mortality;
KIRP	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.76	-10.18	-0.54	1.57e-20	Coronary artery disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17353812	chr11:15959621	NA	0.5	6.12	0.36	3.6e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7011049	0.778	rs7843363	chr8:53874753	C/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg01843034	chr6:37503916	NA	-0.85	-12.16	-0.61	5.72e-27	Cognitive performance;
KIRP	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg13072238	chr3:49761600	GMPPB	0.65	5.67	0.34	4.09e-8	Menarche (age at onset);
KIRP	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24110177	chr3:50126178	RBM5	-0.43	-5.49	-0.33	9.98e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg18225595	chr11:63971243	STIP1	0.56	4.91	0.3	1.69e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs923375	0.857	rs74251309	chr17:3385379	A/T	cg02458198	chr17:3375211	SPATA22	0.6	5.39	0.33	1.64e-7	Myopia (pathological);
KIRP	cis	rs12986413	0.763	rs12983357	chr19:2170868	G/C	cg09261902	chr19:2140048	AP3D1	0.44	5.35	0.32	1.99e-7	Height;
KIRP	cis	rs2688419	0.588	rs55652823	chr3:23087440	T/A	cg00327796	chr3:23032191	NA	-0.45	-5.29	-0.32	2.74e-7	Type 2 diabetes;
KIRP	cis	rs7224685	0.569	rs35586982	chr17:4001993	G/A	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.72e-7	Type 2 diabetes;
KIRP	cis	rs2213920	0.619	rs4979528	chr9:118194902	G/A	cg13918206	chr9:118159781	DEC1	1.0	10.39	0.55	3.4e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.0	-0.3	1.07e-6	Iron status biomarkers;
KIRP	cis	rs13102973	0.640	rs4608865	chr4:135885434	G/A	cg14419869	chr4:135874104	NA	-0.46	-6.74	-0.39	1.14e-10	Subjective well-being;
KIRP	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.49	-5.96	-0.36	8.7e-9	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg08533674	chr1:46993347	NA	-0.41	-5.43	-0.33	1.37e-7	Monobrow;
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg19294448	chr17:6900799	ALOX12	-0.37	-4.91	-0.3	1.68e-6	Tonsillectomy;
KIRP	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg05973401	chr12:123451056	ABCB9	0.57	6.57	0.39	2.94e-10	Neutrophil percentage of white cells;
KIRP	cis	rs11718455	0.585	rs11719257	chr3:43914854	A/T	cg21419209	chr3:44054225	NA	-0.62	-7.21	-0.42	6.89e-12	Coronary artery disease;
KIRP	cis	rs6838801	0.927	rs4367198	chr4:77516320	T/C	cg17476223	chr4:77663285	SHROOM3	0.52	7.1	0.41	1.34e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.02	-0.36	6.37e-9	Type 2 diabetes;
KIRP	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg24315340	chr6:146058215	EPM2A	0.41	5.23	0.32	3.64e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.49	-5.89	-0.35	1.28e-8	Prudent dietary pattern;
KIRP	cis	rs2668423	1.000	rs2526140	chr19:1374450	G/C	cg02639931	chr19:1387894	NDUFS7	-0.73	-9.61	-0.52	9.23e-19	Nonalcoholic fatty liver disease;
KIRP	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg09904177	chr6:26538194	HMGN4	-0.45	-6.12	-0.36	3.61e-9	Schizophrenia;
KIRP	cis	rs7215564	0.908	rs2316062	chr17:78663558	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs78487399	0.908	rs12463527	chr2:43815945	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.87	-0.3	2.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	22.0	0.81	5.07e-60	Prudent dietary pattern;
KIRP	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.08	-0.31	7.31e-7	Bipolar disorder;
KIRP	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-0.97	-10.4	-0.55	3.15e-21	Blood pressure (smoking interaction);
KIRP	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.85	-13.06	-0.64	5.87e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08906898	chr20:34319899	RBM39	0.48	6.77	0.4	9.13e-11	Survival in pancreatic cancer;
KIRP	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.28	-0.47	8.02e-15	Monocyte percentage of white cells;
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg09597638	chr17:3907349	NA	-0.75	-13.89	-0.66	8.68e-33	Type 2 diabetes;
KIRP	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.42	5.65	0.34	4.5e-8	Melanoma;
KIRP	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.56	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg15655495	chr12:38532458	NA	-0.27	-4.85	-0.3	2.23e-6	Bladder cancer;
KIRP	cis	rs8060686	1.000	rs8060686	chr16:67911517	T/C	cg04539111	chr16:67997858	SLC12A4	-0.46	-5.23	-0.32	3.71e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6546324	0.625	rs4671817	chr2:67866437	T/G	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25663178	chr15:66161981	RAB11A	0.47	6.5	0.38	4.54e-10	Parkinson's disease;
KIRP	cis	rs588177	0.522	rs34358026	chr11:64015422	T/C	cg04317338	chr11:64019027	PLCB3	0.81	7.15	0.41	9.66e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-5.95	-0.35	9.13e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2281603	0.621	rs61985668	chr14:64956346	T/C	cg01860774	chr14:64969374	ZBTB25	0.34	5.62	0.34	5.1e-8	Lymphocyte counts;
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22618164	chr12:122356400	WDR66	0.68	9.77	0.53	2.88e-19	Mean platelet volume;
KIRP	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.86	-11.1	-0.58	1.79e-23	Cognitive function;
KIRP	trans	rs9650657	0.812	rs4240669	chr8:10629987	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.12	-0.36	3.59e-9	Neuroticism;
KIRP	cis	rs9362426	1.000	rs9450662	chr6:88088593	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	5.54	0.33	7.74e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs17221829	0.627	rs1844202	chr11:89420169	A/T	cg02982614	chr11:89391479	FOLH1B	-0.32	-4.91	-0.3	1.69e-6	Anxiety in major depressive disorder;
KIRP	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.89	-0.3	1.85e-6	Obesity-related traits;
KIRP	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.68	-0.34	3.74e-8	Aortic root size;
KIRP	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.58	7.21	0.42	6.99e-12	Uric acid clearance;
KIRP	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	1.1	17.48	0.74	5.05e-45	Migraine;
KIRP	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg03563238	chr19:33554763	RHPN2	0.34	6.26	0.37	1.66e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs669484	0.541	rs10809085	chr9:10397527	A/G	cg25509871	chr19:40871557	PLD3	-0.63	-6.1	-0.36	4.14e-9	Gestational age at birth (child effect);
KIRP	cis	rs11690462	0.514	rs11126465	chr2:26627689	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.4	5.11	0.31	6.46e-7	Coronary artery disease;
KIRP	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.72	-0.34	3e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs13343954	0.825	rs12462077	chr19:33529231	C/G	cg17764715	chr19:33622953	WDR88	0.75	8.36	0.47	4.54e-15	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21290839	chr6:97891300	NA	-0.39	-6.08	-0.36	4.52e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35883536	0.935	rs3904674	chr1:101138932	C/T	cg06223162	chr1:101003688	GPR88	0.33	6.69	0.39	1.45e-10	Monocyte count;
KIRP	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-5.88	-0.35	1.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg14835575	chr10:16859367	RSU1	0.66	9.14	0.5	2.38e-17	Platelet distribution width;
KIRP	cis	rs6681460	0.934	rs4655631	chr1:67054907	C/G	cg02459107	chr1:67143332	SGIP1	0.46	6.62	0.39	2.19e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-5.08	-0.31	7.37e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.75	-12.06	-0.61	1.25e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.65	8.32	0.47	6.21e-15	Menarche (age at onset);
KIRP	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg06565975	chr8:143823917	SLURP1	0.48	7.66	0.44	4.37e-13	Urinary tract infection frequency;
KIRP	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.11	12.65	0.63	1.37e-28	Vitiligo;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg23736307	chr8:27182930	PTK2B	0.54	6.86	0.4	5.7e-11	Neuroticism;
KIRP	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.66e-9	Colorectal cancer;
KIRP	cis	rs12230513	0.732	rs61956327	chr12:55828708	C/T	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.49	5.74	0.34	2.84e-8	Diastolic blood pressure;
KIRP	cis	rs4236601	0.745	rs11983865	chr7:116142462	A/G	cg05166801	chr7:116143459	CAV2	0.49	5.95	0.35	9.24e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.42	-5.42	-0.33	1.42e-7	Melanoma;
KIRP	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.48	-6.77	-0.4	9.45e-11	Daytime sleep phenotypes;
KIRP	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg06521331	chr12:34319734	NA	0.54	6.77	0.4	9.18e-11	Heart rate;
KIRP	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.91	0.3	1.65e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs5753037	0.809	rs713657	chr22:30211876	A/G	cg01021169	chr22:30184971	ASCC2	-0.39	-4.87	-0.3	1.96e-6	Type 1 diabetes;
KIRP	cis	rs4711336	1.000	rs764752	chr6:33658066	G/C	cg14003231	chr6:33640908	ITPR3	0.27	4.88	0.3	1.91e-6	Height;
KIRP	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.81	-8.54	-0.48	1.46e-15	Hair shape;
KIRP	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg20169779	chr10:135381914	SYCE1	-0.42	-4.99	-0.3	1.15e-6	Obesity-related traits;
KIRP	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.25	-0.42	5.5e-12	Retinal vascular caliber;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg06604058	chr11:63448992	RTN3	0.56	6.2	0.37	2.4e-9	Response to statin therapy;
KIRP	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.6	7.77	0.44	2.11e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.93e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.72	8.44	0.47	2.83e-15	High light scatter reticulocyte count;
KIRP	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.31	-0.32	2.49e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1829883	0.651	rs2460653	chr5:98825627	A/G	cg08333243	chr5:99726346	NA	-0.44	-5.68	-0.34	3.77e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4786125	0.587	rs1473515	chr16:6923092	T/G	cg03623568	chr16:6915990	A2BP1	-0.43	-5.27	-0.32	3.04e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.49	6.66	0.39	1.8e-10	Mean corpuscular volume;
KIRP	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs882732	0.576	rs2068790	chr14:95033944	C/T	cg05186455	chr14:95027692	SERPINA4	0.37	5.73	0.34	3e-8	Blood protein levels;
KIRP	cis	rs2147904	0.934	rs783622	chr1:42366988	C/T	cg16685388	chr1:42384056	HIVEP3	-0.3	-5.32	-0.32	2.38e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.87	-10.93	-0.57	6.5e-23	Vitamin D levels;
KIRP	cis	rs1355223	0.902	rs7129089	chr11:34699699	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.32	-0.32	2.39e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg26061582	chr7:22766209	IL6	0.41	5.11	0.31	6.49e-7	Lung cancer;
KIRP	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg07689907	chr11:61582574	FADS1	-0.46	-5.75	-0.34	2.64e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs11783469	0.524	rs4872139	chr8:23346641	A/G	cg00472375	chr8:23315376	ENTPD4	0.53	5.13	0.31	5.81e-7	Reticulocyte count;
KIRP	cis	rs13033859	0.758	rs4009	chr2:125309	C/T	cg21211680	chr2:198530	NA	0.38	4.87	0.3	2e-6	Mitochondrial DNA levels;
KIRP	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.79	9.62	0.52	8.68e-19	Corneal astigmatism;
KIRP	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs4862307	0.754	rs6846007	chr4:184991604	A/G	cg06737308	chr4:185021514	ENPP6	-0.52	-6.63	-0.39	2.1e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs2219968	0.770	rs12545292	chr8:78886841	A/T	cg00738934	chr8:78996279	NA	-0.39	-5.24	-0.32	3.4e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.83	-8.05	-0.46	3.61e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.66	7.67	0.44	4e-13	Aortic root size;
KIRP	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	10.81	0.57	1.57e-22	Lymphocyte counts;
KIRP	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg22535103	chr8:58192502	C8orf71	-0.81	-5.38	-0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.55	7.31	0.42	3.7e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.73	10.08	0.54	3.18e-20	Plateletcrit;Platelet count;
KIRP	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.44	5.16	0.31	5.07e-7	Aortic root size;
KIRP	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg18944383	chr4:111397179	ENPEP	0.43	6.85	0.4	5.84e-11	Height;
KIRP	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.34	0.47	5.38e-15	IgG glycosylation;
KIRP	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg01631408	chr1:248437212	OR2T33	-0.64	-8.4	-0.47	3.54e-15	Common traits (Other);
KIRP	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.5	7.5	0.43	1.12e-12	Resting heart rate;
KIRP	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-0.94	-13.35	-0.65	5.88e-31	Blood trace element (Zn levels);
KIRP	cis	rs1593	0.531	rs4241821	chr4:187176834	C/T	cg02012338	chr4:187126139	CYP4V2	-0.57	-5.05	-0.31	8.67e-7	Activated partial thromboplastin time;
KIRP	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg10818794	chr15:86012489	AKAP13	-0.51	-7.2	-0.42	7.39e-12	Coronary artery disease;
KIRP	cis	rs365132	1.000	rs353493	chr5:176432585	T/C	cg16309518	chr5:176445507	NA	-0.89	-13.8	-0.66	1.77e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg08132940	chr7:1081526	C7orf50	-0.46	-5.3	-0.32	2.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-10.93	-0.57	6.3e-23	Response to antipsychotic treatment;
KIRP	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg24060327	chr5:131705240	SLC22A5	-0.58	-7.8	-0.45	1.71e-13	Acylcarnitine levels;
KIRP	cis	rs4692589	0.581	rs6817357	chr4:170962516	A/G	cg19918862	chr4:170955249	NA	0.58	6.32	0.37	1.25e-9	Anxiety disorder;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg01721255	chr8:58191610	C8orf71	0.64	5.58	0.34	6.39e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg08462924	chr1:41848221	NA	0.45	6.5	0.38	4.56e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg24375607	chr4:120327624	NA	-0.47	-5.67	-0.34	4.04e-8	Corneal astigmatism;
KIRP	trans	rs2565065	0.567	rs7000364	chr8:27306551	T/A	cg00185066	chr13:80910763	SPRY2	-0.45	-6.03	-0.36	5.86e-9	Schizophrenia;
KIRP	cis	rs13102973	0.640	rs11722290	chr4:135832268	C/T	cg14419869	chr4:135874104	NA	0.5	8.3	0.47	7.16e-15	Subjective well-being;
KIRP	cis	rs2348418	0.715	rs1912782	chr12:28721707	A/C	cg13890972	chr12:28721907	NA	-0.33	-5.13	-0.31	5.88e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.51	-7.54	-0.43	8.82e-13	IgG glycosylation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09608876	chr3:53385659	NA	-0.37	-6.02	-0.36	6.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.13	8.87	0.49	1.54e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg00204512	chr16:28754710	NA	0.44	5.81	0.35	1.97e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.81	10.97	0.57	4.69e-23	Menopause (age at onset);
KIRP	cis	rs3096299	0.646	rs918722	chr16:89415081	C/G	cg08822215	chr16:89438651	ANKRD11	-0.53	-6.96	-0.41	3.16e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg19875535	chr5:140030758	IK	0.52	6.61	0.39	2.43e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7106204	0.668	rs7119198	chr11:24218267	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	9.61	0.52	9.01e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.62	7.62	0.44	5.47e-13	Corneal astigmatism;
KIRP	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.17e-6	Pulmonary function;
KIRP	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.46	-5.76	-0.34	2.56e-8	Iron status biomarkers;
KIRP	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg19847130	chr8:10466454	RP1L1	0.36	5.19	0.31	4.48e-7	Retinal vascular caliber;
KIRP	cis	rs11710088	0.931	rs11920457	chr3:149199869	G/A	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.54	-0.33	7.6e-8	QRS duration;
KIRP	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg15038512	chr6:170123185	PHF10	0.46	5.15	0.31	5.44e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6708331	0.517	rs12992553	chr2:70360262	A/G	cg05298696	chr2:70188691	ASPRV1	-0.4	-5.33	-0.32	2.21e-7	Obesity-related traits;
KIRP	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	9.19	0.51	1.71e-17	IgG glycosylation;
KIRP	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg24579218	chr15:68104479	NA	-0.57	-9.26	-0.51	1.07e-17	Restless legs syndrome;
KIRP	cis	rs911119	0.913	rs6048929	chr20:23588855	T/C	cg16589663	chr20:23618590	CST3	0.5	5.07	0.31	7.87e-7	Chronic kidney disease;
KIRP	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.45	6.52	0.38	4.03e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1359582	0.736	rs7899358	chr10:90373845	C/T	cg15661332	chr10:90342814	RNLS	0.57	6.32	0.37	1.2e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg12658694	chr1:38397304	INPP5B	0.64	8.77	0.49	3.05e-16	Coronary artery disease;
KIRP	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg26207909	chr14:103986467	CKB	0.39	4.95	0.3	1.37e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.98	0.61	2.35e-26	Alzheimer's disease;
KIRP	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg24565620	chr2:194026	NA	0.64	7.52	0.43	1.01e-12	Blood protein levels;
KIRP	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.55	-5.81	-0.35	1.97e-8	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22508905	chr4:20529994	MIR218-1;SLIT2	-0.39	-6.58	-0.39	2.85e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.9	0.35	1.18e-8	Bipolar disorder;
KIRP	cis	rs8177876	0.731	rs8177948	chr16:81116920	C/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.94	-0.4	3.53e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg15655495	chr12:38532458	NA	0.27	5.4	0.33	1.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.96	11.6	0.59	4.27e-25	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.79	9.45	0.52	2.81e-18	Corneal astigmatism;
KIRP	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg02344993	chr17:57696989	CLTC	0.61	5.85	0.35	1.57e-8	Hemoglobin concentration;
KIRP	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.81	10.12	0.54	2.37e-20	Corneal astigmatism;
KIRP	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.68	-11.27	-0.58	5.17e-24	Urate levels in overweight individuals;
KIRP	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.57	0.39	2.95e-10	Educational attainment;
KIRP	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg13628971	chr7:2884303	GNA12	0.39	4.89	0.3	1.85e-6	Height;
KIRP	cis	rs10170310	0.938	rs11680891	chr2:139264454	T/G	cg10095539	chr2:139258744	SPOPL	0.36	5.37	0.32	1.79e-7	Response to antipsychotic treatment;
KIRP	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg04310649	chr10:35416472	CREM	-0.59	-6.97	-0.41	2.95e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.88	14.67	0.68	1.91e-35	Alcohol dependence (age at onset);
KIRP	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.04	-0.36	5.59e-9	IgG glycosylation;
KIRP	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg10761708	chr20:43804764	PI3	0.5	5.22	0.32	3.79e-7	Blood protein levels;
KIRP	cis	rs11677416	1.000	rs3783520	chr2:113544339	C/T	cg23974023	chr2:113544294	IL1A	-0.37	-5.62	-0.34	5.2e-8	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.56	-8.05	-0.46	3.5e-14	Testicular germ cell tumor;
KIRP	cis	rs6580649	0.941	rs58046797	chr12:48487619	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.93	-0.35	1e-8	Lung cancer;
KIRP	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9815354	0.812	rs17282671	chr3:41887455	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.19	12.56	0.63	2.66e-28	Nonalcoholic fatty liver disease;
KIRP	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg12369402	chr1:90227771	NA	-0.39	-5.65	-0.34	4.45e-8	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg17133734	chr15:86042851	AKAP13	-0.47	-5.96	-0.36	8.84e-9	Coronary artery disease;
KIRP	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg08738300	chr3:44038990	NA	-0.7	-9.82	-0.53	1.97e-19	Coronary artery disease;
KIRP	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-1.07	-19.83	-0.78	6.26e-53	Height;
KIRP	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.65	-7.68	-0.44	3.78e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.0	14.48	0.68	9.09e-35	Subjective well-being;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18677834	chr6:101331608	NA	0.42	6.12	0.36	3.74e-9	Interleukin-4 levels;
KIRP	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg05692746	chr2:100937584	LONRF2	-0.4	-5.26	-0.32	3.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.2	0.37	2.42e-9	Aortic root size;
KIRP	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.73	7.54	0.43	8.93e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs72730918	0.590	rs2606145	chr15:51980311	G/A	cg14296394	chr15:51910925	DMXL2	-0.74	-10.0	-0.54	5.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	1.000	rs10212536	chr3:41827026	A/G	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.33	8.51e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	-0.77	-10.4	-0.55	3.07e-21	Inflammatory bowel disease;
KIRP	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg26587870	chr6:27730563	NA	-0.66	-5.32	-0.32	2.35e-7	Depression;
KIRP	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.02	0.46	4.28e-14	Morning vs. evening chronotype;
KIRP	cis	rs7221595	0.756	rs35852805	chr17:3892563	C/T	cg09597638	chr17:3907349	NA	0.56	5.86	0.35	1.5e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16246294	chr17:34122769	MMP28	-0.43	-6.25	-0.37	1.8e-9	Metabolic traits;
KIRP	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.97	-0.41	2.92e-11	Acylcarnitine levels;
KIRP	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg24209194	chr3:40518798	ZNF619	-0.38	-4.86	-0.3	2.13e-6	Renal cell carcinoma;
KIRP	cis	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg03342759	chr3:160939853	NMD3	0.44	5.35	0.32	1.99e-7	Morning vs. evening chronotype;
KIRP	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg25547332	chr5:131281432	NA	0.47	5.4	0.33	1.53e-7	Life satisfaction;
KIRP	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg06223162	chr1:101003688	GPR88	0.4	7.81	0.45	1.67e-13	Monocyte count;
KIRP	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	6.44	0.38	6.31e-10	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg00981070	chr1:2046702	PRKCZ	0.4	5.83	0.35	1.77e-8	Height;
KIRP	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg21204522	chr6:27730016	NA	-0.68	-5.07	-0.31	7.9e-7	Depression;
KIRP	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.76	10.68	0.56	3.99e-22	Body mass index;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.82	8.03	0.46	3.94e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.49	6.73	0.39	1.18e-10	Red blood cell count;
KIRP	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg00792783	chr2:198669748	PLCL1	-0.45	-4.86	-0.3	2.07e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.39	-9.3	-0.51	8.05e-18	Asthma (sex interaction);
KIRP	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg06637938	chr14:75390232	RPS6KL1	0.42	5.68	0.34	3.71e-8	Height;
KIRP	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs3734219	0.507	rs1887843	chr6:3354261	A/G	cg18842474	chr6:3356384	SLC22A23	0.51	6.57	0.39	2.91e-10	Red cell distribution width;
KIRP	cis	rs56079296	0.929	rs10054088	chr5:121274250	A/G	cg05256605	chr5:121412184	LOX	0.47	5.26	0.32	3.2e-7	Coronary artery disease;
KIRP	cis	rs2273669	0.667	rs2356575	chr6:109367255	T/C	cg05315195	chr6:109294784	ARMC2	-0.62	-6.2	-0.37	2.34e-9	Prostate cancer;
KIRP	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg04306507	chr14:55594613	LGALS3	-0.53	-8.42	-0.47	3.07e-15	Protein biomarker;
KIRP	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.9	12.4	0.62	9.18e-28	Menopause (age at onset);
KIRP	cis	rs9290877	0.667	rs9290878	chr3:188450118	C/T	cg17392043	chr3:188495102	LPP	-0.55	-6.83	-0.4	6.71e-11	IgE levels;
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.83	10.64	0.56	5.3e-22	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs61440199	1.000	rs12636856	chr3:20136959	C/T	cg08354614	chr10:80673607	NA	-0.48	-6.45	-0.38	6.02e-10	Staphylococcus aureus nasal carriage (intermittent);
KIRP	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.78	-10.13	-0.54	2.27e-20	Pancreatic cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04898316	chr2:110371848	SEPT10;ANKRD57	0.47	6.39	0.38	8.07e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg06204229	chr3:52865917	ITIH4	0.53	5.94	0.35	9.49e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs13424612	1.000	rs10193610	chr2:240940618	A/G	cg01812947	chr2:240904978	NDUFA10	0.47	6.1	0.36	4.08e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg08885076	chr2:99613938	TSGA10	0.56	9.6	0.52	9.9e-19	Chronic sinus infection;
KIRP	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-9.23	-0.51	1.28e-17	Hemoglobin concentration;
KIRP	cis	rs2275620	0.966	rs6583969	chr10:96826245	G/A	cg09036531	chr10:96991505	NA	-0.5	-6.41	-0.38	7.51e-10	Gout;
KIRP	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-1.07	-18.7	-0.77	3.73e-49	Monocyte count;
KIRP	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.67	-8.33	-0.47	5.84e-15	Vitiligo;
KIRP	cis	rs8054556	0.733	rs35467921	chr16:30048553	C/T	cg06326092	chr16:30034487	C16orf92	0.39	5.02	0.3	9.88e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7712401	0.601	rs454617	chr5:122321927	A/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	trans	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs11779988	0.545	rs431961	chr8:17786204	T/G	cg01800426	chr8:17659068	MTUS1	-0.6	-5.87	-0.35	1.43e-8	Breast cancer;
KIRP	cis	rs6725041	0.846	rs1521649	chr2:213065294	A/G	cg20637307	chr2:213403960	ERBB4	0.41	5.37	0.32	1.86e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-11.95	-0.61	2.85e-26	Systemic lupus erythematosus;
KIRP	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.5	6.02	0.36	6.27e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.03e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.86e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg17410650	chr12:54324560	NA	-0.48	-6.59	-0.39	2.64e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
KIRP	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.4	-5.96	-0.36	8.51e-9	Coronary artery disease;
KIRP	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18364779	chr6:26104403	HIST1H4C	-0.53	-5.6	-0.34	5.84e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.53	0.52	1.56e-18	Cognitive test performance;
KIRP	cis	rs778371	0.749	rs778345	chr2:233799633	A/T	cg08000102	chr2:233561755	GIGYF2	-0.48	-5.08	-0.31	7.4e-7	Schizophrenia;
KIRP	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.24	0.32	3.54e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07570687	chr10:102243282	WNT8B	0.48	5.98	0.36	7.99e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg08648136	chr8:956695	NA	0.47	7.08	0.41	1.49e-11	Schizophrenia;
KIRP	cis	rs2151522	0.544	rs4294027	chr6:127120710	C/T	cg21431617	chr6:127135037	NA	0.31	5.66	0.34	4.09e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg11861562	chr11:117069780	TAGLN	0.42	4.91	0.3	1.64e-6	Blood protein levels;
KIRP	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	11.9	0.6	4.24e-26	Systemic lupus erythematosus;
KIRP	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg13880726	chr7:1868755	MAD1L1	0.51	5.98	0.36	7.61e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs61990820	0.748	rs61990830	chr14:80374199	C/A	cg23664174	chr4:54357316	LNX1	0.74	6.06	0.36	5.01e-9	Schizophrenia;
KIRP	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg24296786	chr1:45957014	TESK2	-0.65	-8.64	-0.48	7.3e-16	High light scatter reticulocyte count;
KIRP	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.19	13.81	0.66	1.71e-32	Sexual dysfunction (female);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23361708	chr2:74692613	MOGS	0.5	6.16	0.37	3e-9	Parkinson's disease;
KIRP	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.71	9.54	0.52	1.49e-18	Personality dimensions;
KIRP	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.05	0.41	1.76e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1050631	1.000	rs1789504	chr18:33696772	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	6.28	0.37	1.56e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg17425144	chr1:10567563	PEX14	0.3	5.33	0.32	2.24e-7	Hepatocellular carcinoma;
KIRP	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg02336718	chr17:17403227	NA	0.37	5.47	0.33	1.09e-7	Total body bone mineral density;
KIRP	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.74	-9.09	-0.5	3.46e-17	Blood metabolite levels;
KIRP	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg11766577	chr21:47581405	C21orf56	-0.41	-5.04	-0.31	9.07e-7	Testicular germ cell tumor;
KIRP	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.61	-9.45	-0.52	2.72e-18	Sense of smell;
KIRP	cis	rs2179367	0.887	rs2143076	chr6:149746451	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.32	-5.08	-0.31	7.4e-7	Dupuytren's disease;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.59	-0.34	6.17e-8	Life satisfaction;
KIRP	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.96	-12.51	-0.62	3.99e-28	Platelet distribution width;
KIRP	cis	rs2348418	0.715	rs7971717	chr12:28723020	T/C	cg13890972	chr12:28721907	NA	-0.33	-5.13	-0.31	5.88e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg05775895	chr3:12838266	CAND2	0.34	5.49	0.33	9.87e-8	P wave duration;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg12486944	chr17:80159399	CCDC57	0.38	5.05	0.31	8.41e-7	Life satisfaction;
KIRP	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-13.1	-0.64	4.33e-30	Chronic sinus infection;
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.62	8.16	0.46	1.71e-14	Longevity;Endometriosis;
KIRP	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs357618	0.581	rs14160	chr5:150871280	T/C	cg22672639	chr5:150884813	FAT2	0.34	4.9	0.3	1.76e-6	Basophil percentage of white cells;
KIRP	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.67	-9.04	-0.5	4.83e-17	High light scatter reticulocyte count;
KIRP	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg04370829	chr17:406249	NA	0.4	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13939156	chr17:80058883	NA	0.5	7.5	0.43	1.16e-12	Life satisfaction;
KIRP	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg22283653	chr8:49824208	NA	0.48	6.81	0.4	7.31e-11	Sudden cardiac arrest;
KIRP	cis	rs7615316	0.902	rs6440093	chr3:142316036	A/G	cg20824294	chr3:142316082	PLS1	0.22	4.97	0.3	1.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg20712883	chr12:51590929	POU6F1	-0.47	-5.28	-0.32	2.78e-7	Cisplatin-induced ototoxicity;
KIRP	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.16	-0.42	9.07e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.92	0.35	1.09e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg05484376	chr2:27715224	FNDC4	0.3	4.92	0.3	1.61e-6	Oral cavity cancer;
KIRP	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.99	0.36	7.51e-9	Endometrial cancer;
KIRP	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-1.05	-14.86	-0.69	4.33e-36	Orofacial clefts;
KIRP	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.88	-0.49	1.48e-16	Total cholesterol levels;
KIRP	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.54	-6.84	-0.4	6.38e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.91	7.33	0.42	3.39e-12	Major depressive disorder;
KIRP	cis	rs6466055	0.636	rs12155184	chr7:104941798	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.05	0.31	8.8e-7	Schizophrenia;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg27532560	chr4:187881888	NA	-0.71	-11.34	-0.59	3.01e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.4	-5.39	-0.33	1.64e-7	Blood metabolite levels;
KIRP	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.96	12.95	0.64	1.34e-29	Menopause (age at onset);
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.53	0.33	8.26e-8	Life satisfaction;
KIRP	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Crohn's disease;
KIRP	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg08996748	chr15:40651036	DISP2	-0.45	-4.89	-0.3	1.78e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs290268	0.874	rs772407	chr9:93560850	A/C	cg02608019	chr9:93564028	SYK	0.81	11.42	0.59	1.59e-24	Platelet count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14151440	chr1:90478723	ZNF326	-0.49	-7.54	-0.43	8.88e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.79	10.51	0.56	1.38e-21	Menopause (age at onset);
KIRP	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.96	-0.3	1.32e-6	Cholesterol, total;
KIRP	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg26875233	chr11:93583750	C11orf90	0.3	5.6	0.34	5.64e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs3218477	1.000	rs3218382	chr7:152373416	G/A	cg06618968	chr7:152373420	XRCC2	-0.83	-5.38	-0.32	1.69e-7	Mean platelet volume;
KIRP	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg21827317	chr3:136751795	NA	0.38	5.28	0.32	2.88e-7	Neuroticism;
KIRP	cis	rs7221595	0.673	rs115725560	chr17:3980493	T/A	cg09597638	chr17:3907349	NA	0.55	5.69	0.34	3.66e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	0.95	10.55	0.56	1.06e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	8.05	0.46	3.54e-14	Mean platelet volume;
KIRP	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg04727924	chr7:799746	HEATR2	-0.78	-8.7	-0.49	4.71e-16	Cerebrospinal P-tau181p levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16863796	chr2:37458781	CEBPZ;C2orf56	0.57	7.34	0.42	3.05e-12	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08580056	chr13:60516055	DIAPH3	-0.42	-6.22	-0.37	2.13e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11987759	chr7:65425863	GUSB	0.47	6.04	0.36	5.68e-9	Aortic root size;
KIRP	trans	rs909341	0.909	rs2427530	chr20:62361737	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.95	-0.41	3.29e-11	Atopic dermatitis;
KIRP	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	ch.8.33884649F	chr8:33765107	NA	0.51	6.37	0.38	9.01e-10	Body mass index;
KIRP	cis	rs8077577	0.895	rs62073607	chr17:18071338	A/G	cg09161412	chr17:18057145	MYO15A	-0.4	-5.24	-0.32	3.54e-7	Obesity-related traits;
KIRP	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg16327482	chr19:10226339	EIF3G	0.65	9.13	0.5	2.62e-17	Narcolepsy;
KIRP	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13939156	chr17:80058883	NA	0.5	7.54	0.43	9.21e-13	Life satisfaction;
KIRP	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	cis	rs75216060	0.861	rs9657229	chr8:13819976	C/T	cg12665059	chr8:13787749	NA	0.31	4.94	0.3	1.45e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.59	-7.9	-0.45	9.28e-14	Breast cancer;
KIRP	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg04310649	chr10:35416472	CREM	-0.51	-5.64	-0.34	4.66e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg10818794	chr15:86012489	AKAP13	-0.53	-7.53	-0.43	9.9e-13	Coronary artery disease;
KIRP	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.57	8.03	0.46	3.91e-14	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.91	-0.3	1.66e-6	Renal cell carcinoma;
KIRP	cis	rs6908034	0.556	rs7750703	chr6:19804814	C/G	cg02682789	chr6:19804855	NA	0.87	6.47	0.38	5.26e-10	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
KIRP	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg22676075	chr6:135203613	NA	0.5	7.18	0.42	8.21e-12	Red blood cell count;
KIRP	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg09904177	chr6:26538194	HMGN4	0.39	4.93	0.3	1.54e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg09695851	chr17:3907499	NA	0.54	5.14	0.31	5.72e-7	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-1.19	-14.46	-0.68	1.02e-34	Breast cancer;
KIRP	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.85	-0.35	1.56e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7551222	0.716	rs6679717	chr1:204560677	A/G	cg20240347	chr1:204465584	NA	-0.4	-7.74	-0.44	2.56e-13	Schizophrenia;
KIRP	cis	rs9648716	0.577	rs11769042	chr7:140460169	T/C	cg11344121	chr7:140776653	NA	0.4	4.97	0.3	1.25e-6	Type 2 diabetes;
KIRP	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg23067535	chr8:124195133	FAM83A	-0.72	-7.1	-0.41	1.31e-11	Urinary uromodulin levels;
KIRP	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg10755058	chr3:40428713	ENTPD3	0.48	6.56	0.39	3.12e-10	Renal cell carcinoma;
KIRP	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-9.47	-0.52	2.47e-18	Response to antipsychotic treatment;
KIRP	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-6.83	-0.4	6.69e-11	Schizophrenia;
KIRP	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg02570527	chr1:10970165	NA	-0.41	-4.91	-0.3	1.69e-6	Body mass index;
KIRP	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg00585698	chr12:123750864	CDK2AP1	0.53	6.62	0.39	2.27e-10	Neutrophil percentage of white cells;
KIRP	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.88	12.92	0.64	1.74e-29	Eosinophil percentage of white cells;
KIRP	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg01798813	chr17:3906674	NA	-0.53	-7.43	-0.43	1.78e-12	Type 2 diabetes;
KIRP	cis	rs9400467	0.506	rs12197149	chr6:111656067	G/A	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.7	9.55	0.52	1.35e-18	Menarche (age at onset);
KIRP	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.74	11.92	0.61	3.76e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg14675211	chr2:100938903	LONRF2	0.5	6.54	0.38	3.56e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.7	-9.27	-0.51	9.59e-18	Schizophrenia;
KIRP	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.92	-0.35	1.05e-8	Height;
KIRP	cis	rs3770081	1.000	rs2303339	chr2:86346180	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.63	-5.31	-0.32	2.45e-7	Facial emotion recognition (sad faces);
KIRP	cis	rs2721195	0.810	rs2721142	chr8:145752467	A/T	cg15320075	chr8:145703422	NA	0.66	8.81	0.49	2.35e-16	Age at first birth;
KIRP	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05555928	chr11:63887634	MACROD1	0.43	6.1	0.36	4.02e-9	Platelet count;
KIRP	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg05022688	chr3:170137633	CLDN11	-0.41	-5.03	-0.31	9.55e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.77	-11.34	-0.59	3.04e-24	Height;
KIRP	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.82	7.08	0.41	1.54e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg21231944	chr12:82153410	PPFIA2	-0.41	-5.27	-0.32	2.92e-7	Resting heart rate;
KIRP	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.83	11.3	0.58	3.88e-24	Gestational age at birth (maternal effect);
KIRP	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg11303988	chr8:19266685	CSGALNACT1	-0.38	-5.4	-0.33	1.55e-7	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6840360	0.573	rs2407171	chr4:152256782	A/G	cg25486957	chr4:152246857	NA	-0.49	-6.13	-0.36	3.39e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.64	7.58	0.44	6.92e-13	Tuberculosis;
KIRP	cis	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.42	-5.29	-0.32	2.72e-7	Leprosy;
KIRP	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg22563815	chr15:78856949	CHRNA5	0.42	5.77	0.35	2.41e-8	Sudden cardiac arrest;
KIRP	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11987759	chr7:65425863	GUSB	-0.52	-7.0	-0.41	2.38e-11	Aortic root size;
KIRP	cis	rs4363385	0.776	rs1415957	chr1:152948909	A/G	cg07796016	chr1:152779584	LCE1C	-0.45	-5.2	-0.31	4.21e-7	Inflammatory skin disease;
KIRP	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-15.45	-0.7	4.28e-38	Electrocardiographic conduction measures;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.24	0.51	1.21e-17	Lung cancer;
KIRP	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg21775007	chr8:11205619	TDH	0.45	6.08	0.36	4.57e-9	Neuroticism;
KIRP	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12963246	chr6:28129442	ZNF389	-0.44	-5.4	-0.33	1.55e-7	Depression;
KIRP	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg24315340	chr6:146058215	EPM2A	0.41	5.12	0.31	6.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11874712	0.931	rs8095608	chr18:43678911	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.38	-5.21	-0.32	3.94e-7	Migraine - clinic-based;
KIRP	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.98	13.44	0.65	3.11e-31	Cognitive ability;
KIRP	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg22681709	chr2:178499509	PDE11A	-0.41	-5.61	-0.34	5.36e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg18882449	chr10:104885122	NT5C2	0.49	6.43	0.38	6.76e-10	Arsenic metabolism;
KIRP	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.48	-5.01	-0.3	1.04e-6	Psoriasis;
KIRP	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12893428	chr3:195717962	SDHAP1	0.41	5.58	0.33	6.47e-8	Pancreatic cancer;
KIRP	cis	rs4478037	0.822	rs9825335	chr3:33123292	A/C	cg19404215	chr3:33155277	CRTAP	0.57	5.46	0.33	1.15e-7	Major depressive disorder;
KIRP	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg19610905	chr11:61596333	FADS2	-0.71	-6.81	-0.4	7.46e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-5.38	-0.32	1.69e-7	Schizophrenia;
KIRP	cis	rs7951870	1.000	rs7936413	chr11:46393958	T/C	cg16389345	chr11:46697382	NA	-0.45	-4.9	-0.3	1.72e-6	Schizophrenia;
KIRP	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.83	-11.69	-0.6	2.09e-25	Platelet count;
KIRP	cis	rs16828019	0.852	rs34386859	chr1:41564024	C/T	cg18742814	chr1:41828276	NA	0.6	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.75	10.83	0.57	1.34e-22	Lung cancer;
KIRP	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg15848620	chr12:58087721	OS9	-0.48	-5.51	-0.33	9.19e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs12101261	0.560	rs1035144	chr14:81445121	C/T	cg06600135	chr14:81408086	NA	0.44	5.65	0.34	4.44e-8	Graves' disease;
KIRP	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.72	-8.57	-0.48	1.14e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.54	0.62	3.2e-28	Platelet count;
KIRP	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.85	0.35	1.59e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs28669119	0.778	rs674747	chr5:88079010	G/T	cg18498987	chr5:88179539	MEF2C	-0.53	-6.51	-0.38	4.22e-10	Schizophrenia;
KIRP	cis	rs3120667	0.720	rs72698947	chr1:152402337	A/T	cg26876637	chr1:152193138	HRNR	-0.57	-5.29	-0.32	2.77e-7	Eating disorders;
KIRP	cis	rs4356975	0.545	rs11249524	chr4:69946371	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg13660082	chr14:53194042	PSMC6	-0.67	-7.38	-0.43	2.48e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg22705602	chr4:152727874	NA	-0.53	-9.08	-0.5	3.54e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.22e-9	Breast cancer;
KIRP	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg03714773	chr7:91764589	CYP51A1	0.37	5.39	0.32	1.65e-7	Breast cancer;
KIRP	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs1371614	0.589	rs527267	chr2:27119655	G/C	cg00617064	chr2:27272375	NA	0.41	4.97	0.3	1.26e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.34	0.47	5.42e-15	Lung cancer;
KIRP	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.5	-7.94	-0.45	7.23e-14	Huntington's disease progression;
KIRP	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg18016565	chr1:150552671	MCL1	-0.48	-7.53	-0.43	9.5e-13	Tonsillectomy;
KIRP	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	trans	rs17065417	0.509	rs9499944	chr6:105191387	C/A	cg07271268	chr12:498129	KDM5A;CCDC77	-0.63	-6.28	-0.37	1.54e-9	Neuroblastoma;Sporadic neuroblastoma;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09441348	chr3:126290635	TXNRD3IT1	0.52	6.2	0.37	2.34e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7010267	0.681	rs7842942	chr8:120008587	T/C	cg01975934	chr8:119970761	NA	-0.39	-5.09	-0.31	7.06e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.11	-0.31	6.59e-7	Metabolite levels;
KIRP	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.76	11.02	0.58	3.13e-23	Prostate cancer;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.5	-7.26	-0.42	5.21e-12	Testicular germ cell tumor;
KIRP	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg02336718	chr17:17403227	NA	0.35	5.46	0.33	1.14e-7	Total body bone mineral density;
KIRP	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	cg21523751	chr1:182988639	NA	0.44	6.95	0.41	3.2e-11	Hypertriglyceridemia;
KIRP	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.5	-7.3	-0.42	3.88e-12	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.48e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10114408	0.959	rs1933675	chr9:96655212	C/T	cg14598338	chr9:96623480	NA	-0.32	-4.89	-0.3	1.81e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.61	7.68	0.44	3.87e-13	Personality dimensions;
KIRP	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.5	-9.34	-0.51	6.14e-18	Cystic fibrosis severity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16123319	chr15:49913299	DTWD1;C15orf33	0.46	6.23	0.37	1.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-6.86	-0.4	5.63e-11	Vitiligo;
KIRP	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.78	0.35	2.31e-8	Aortic root size;
KIRP	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.33	-5.27	-0.32	3.02e-7	Neuroticism;
KIRP	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.05	0.61	1.4e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg02887458	chr19:19495540	GATAD2A	0.48	5.75	0.34	2.65e-8	Bipolar disorder;
KIRP	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg23169111	chr20:3065582	AVP	0.49	6.7	0.39	1.43e-10	Hirschsprung disease;
KIRP	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-7.78	-0.44	2.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12210905	1.000	rs12203728	chr6:27051750	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs812925	0.502	rs778150	chr2:61608372	C/T	cg15711740	chr2:61764176	XPO1	0.45	5.72	0.34	3.05e-8	Immature fraction of reticulocytes;
KIRP	cis	rs2151522	0.603	rs62426327	chr6:127152669	T/A	cg21431617	chr6:127135037	NA	0.33	5.93	0.35	1.03e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1056053	0.514	rs3099269	chr6:166572242	T/A	cg11088901	chr6:166572345	T	-0.51	-7.28	-0.42	4.46e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs13132184	0.507	rs17607518	chr4:38092697	A/G	cg14409701	chr4:38048871	TBC1D1	-0.73	-6.8	-0.4	7.98e-11	Verbal declarative memory;
KIRP	cis	rs3741798	1.000	rs3741798	chr12:12496086	C/T	cg08615371	chr12:12503544	MANSC1	0.98	8.67	0.48	5.86e-16	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.94	-0.4	3.53e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs921943	1.000	rs921943	chr5:78316476	C/T	cg26802063	chr5:78281964	ARSB	0.49	6.18	0.37	2.69e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.49	-6.13	-0.36	3.47e-9	Menarche (age at onset);
KIRP	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.23	11.73	0.6	1.54e-25	Alzheimer's disease (late onset);
KIRP	cis	rs11203032	0.831	rs12570154	chr10:90951027	T/C	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.57	8.02	0.46	4.36e-14	Night sleep phenotypes;
KIRP	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.89	13.26	0.65	1.18e-30	Blood protein levels;
KIRP	cis	rs16828019	0.852	rs35190461	chr1:41543135	T/C	cg24596898	chr1:41849189	NA	0.62	5.14	0.31	5.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06850241	chr22:41845214	NA	0.44	5.07	0.31	7.87e-7	Vitiligo;
KIRP	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.85	12.92	0.64	1.65e-29	Ulcerative colitis;
KIRP	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg12315302	chr6:26189340	HIST1H4D	0.78	5.33	0.32	2.23e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20964082	chr1:236442072	ERO1LB	-0.42	-6.41	-0.38	7.23e-10	Inflammatory biomarkers;
KIRP	cis	rs815815	0.583	rs878665	chr2:47403129	G/T	cg17724938	chr2:46727096	NA	-0.42	-5.01	-0.3	1.04e-6	Dialysis-related mortality;
KIRP	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11987759	chr7:65425863	GUSB	0.5	6.39	0.38	8.44e-10	Aortic root size;
KIRP	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.7	10.29	0.55	6.84e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23198529	chr10:43362076	NA	0.44	6.29	0.37	1.48e-9	Parkinson's disease;
KIRP	trans	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg02030672	chr11:45687055	CHST1	0.7	9.29	0.51	8.34e-18	Obesity-related traits;
KIRP	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg13010199	chr12:38710504	ALG10B	0.47	6.07	0.36	4.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.67	0.71	7.75e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs67366981	1.000	rs67130018	chr14:77703280	C/T	cg22824376	chr14:77648248	TMEM63C	0.64	5.1	0.31	6.87e-7	Obsessive-compulsive symptoms;
KIRP	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.86	-13.45	-0.65	2.78e-31	Ulcerative colitis;
KIRP	cis	rs9810890	1.000	rs73198811	chr3:128470749	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.68	7.19	0.42	7.82e-12	Lymphocyte counts;
KIRP	cis	rs62413470	1.000	rs12212135	chr6:55965006	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.21	0.55	1.22e-20	Dupuytren's disease;
KIRP	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg20965017	chr5:231967	SDHA	-0.49	-5.68	-0.34	3.79e-8	Breast cancer;
KIRP	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.4	-0.38	7.85e-10	Axial length;
KIRP	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.84	12.48	0.62	5.02e-28	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7106204	0.748	rs12273426	chr11:24212058	T/C	ch.11.24196551F	chr11:24239977	NA	0.82	9.82	0.53	1.98e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1816752	0.777	rs6490915	chr13:24987862	G/C	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg24009623	chr19:33667908	NA	0.48	6.1	0.36	3.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6973256	0.897	rs10235846	chr7:133328222	G/T	cg10665199	chr7:133106180	EXOC4	-0.49	-6.3	-0.37	1.37e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26207909	chr14:103986467	CKB	0.48	6.5	0.38	4.5e-10	Body mass index;
KIRP	cis	rs1999930	0.527	rs12213847	chr6:116235705	G/A	cg15226275	chr6:116381976	FRK	0.25	5.31	0.32	2.43e-7	Age-related macular degeneration;
KIRP	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.95	15.04	0.69	1.09e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs882732	1.000	rs875958	chr14:95028667	A/T	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.57	-0.33	6.63e-8	Blood protein levels;
KIRP	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg22974920	chr21:40686053	BRWD1	0.45	5.3	0.32	2.56e-7	Cognitive function;
KIRP	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.85	15.77	0.71	3.42e-39	Anterior chamber depth;
KIRP	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-9.26	-0.51	1.04e-17	Hemoglobin concentration;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14082097	chr8:28573503	EXTL3	0.53	6.17	0.37	2.79e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7113874	0.613	rs2100067	chr11:8537050	T/C	cg08015107	chr11:8618950	NA	-0.51	-6.77	-0.4	9.37e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg06042504	chr8:55087323	NA	-0.53	-6.5	-0.38	4.46e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7521681	0.838	rs11185176	chr1:108324708	C/T	cg21202240	chr1:109285050	FNDC7	0.43	5.12	0.31	6.23e-7	Asthma and hay fever;
KIRP	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.99	16.78	0.73	1.2e-42	Breast cancer;
KIRP	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.82	-13.69	-0.66	4.27e-32	Heart rate;
KIRP	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg04310649	chr10:35416472	CREM	-0.53	-6.08	-0.36	4.45e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12404679	chr2:239049701	KLHL30	-0.49	-6.56	-0.39	3.22e-10	Parkinson's disease;
KIRP	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.36	-0.32	1.93e-7	Breast cancer;
KIRP	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs7523273	0.564	rs1570565	chr1:207881256	G/A	cg22525895	chr1:207977042	MIR29B2	0.48	5.78	0.35	2.2e-8	Schizophrenia;
KIRP	cis	rs397969	0.646	rs1638528	chr17:19837929	A/G	cg04132472	chr17:19861366	AKAP10	0.62	8.06	0.46	3.41e-14	Platelet count;
KIRP	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.63e-13	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24868830	chr4:140374821	RAB33B	0.55	6.66	0.39	1.82e-10	Parkinson's disease;
KIRP	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.5	6.38	0.38	8.88e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg18402987	chr7:1209562	NA	0.73	6.51	0.38	4.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg19671926	chr4:122722719	EXOSC9	0.46	5.36	0.32	1.94e-7	Type 2 diabetes;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04940962	chr6:170102116	WDR27;C6orf120	-0.47	-6.01	-0.36	6.48e-9	Myopia;
KIRP	cis	rs11235843	0.636	rs6592531	chr11:73412354	C/T	cg18195628	chr11:73498948	MRPL48	-0.48	-5.01	-0.3	1.05e-6	Hand grip strength;
KIRP	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.39	13.03	0.64	7.52e-30	Opioid sensitivity;
KIRP	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg09597638	chr17:3907349	NA	0.54	7.48	0.43	1.35e-12	Type 2 diabetes;
KIRP	cis	rs8014252	0.803	rs17108274	chr14:71070401	G/A	cg19730268	chr14:71022823	NA	-0.65	-6.05	-0.36	5.35e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg02138098	chr1:2040968	PRKCZ	0.37	4.86	0.3	2.08e-6	Height;
KIRP	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.4	-0.55	3.23e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6459788	1.000	rs6459783	chr7:157259927	G/A	cg06271696	chr7:157225062	NA	-0.5	-6.44	-0.38	6.26e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs17776563	0.959	rs1348002	chr15:89113138	C/G	cg05013243	chr15:89149849	MIR1179	0.38	5.0	0.3	1.12e-6	Thyroid hormone levels;
KIRP	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.41	-5.72	-0.34	3.01e-8	Depression;
KIRP	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg06815112	chr8:27182871	PTK2B	0.47	6.02	0.36	6.15e-9	Neuroticism;
KIRP	cis	rs6753739	0.871	rs12694452	chr2:220027399	C/T	cg01749213	chr2:219906749	CCDC108	-0.41	-5.06	-0.31	8.23e-7	Height;
KIRP	cis	rs7221595	0.825	rs8076743	chr17:3916537	A/T	cg21734707	chr17:3908241	ZZEF1	0.56	5.24	0.32	3.51e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8067354	0.645	rs2173119	chr17:57859705	C/T	cg02344993	chr17:57696989	CLTC	0.55	5.03	0.31	9.67e-7	Hemoglobin concentration;
KIRP	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg21905437	chr5:178450457	ZNF879	0.58	6.68	0.39	1.56e-10	Pubertal anthropometrics;
KIRP	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.77	-0.35	2.43e-8	Subjective well-being;
KIRP	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2249694	0.878	rs2480257	chr10:135352509	T/A	cg20169779	chr10:135381914	SYCE1	0.43	4.96	0.3	1.32e-6	Obesity-related traits;
KIRP	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg26876637	chr1:152193138	HRNR	0.74	9.54	0.52	1.44e-18	Atopic dermatitis;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.55e-7	Life satisfaction;
KIRP	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7923609	0.846	rs10740116	chr10:65094992	T/C	cg01631684	chr10:65280961	REEP3	-0.48	-5.64	-0.34	4.71e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.84	-14.4	-0.68	1.66e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.26	-0.51	1.05e-17	Neuroticism;
KIRP	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg06636001	chr8:8085503	FLJ10661	0.7	9.07	0.5	3.79e-17	Retinal vascular caliber;
KIRP	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg10818794	chr15:86012489	AKAP13	-0.46	-6.41	-0.38	7.56e-10	Interstitial lung disease;
KIRP	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg03060546	chr3:49711283	APEH	0.42	5.48	0.33	1.04e-7	Parkinson's disease;
KIRP	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg21858823	chr1:15850916	CASP9	0.53	5.63	0.34	4.93e-8	Systolic blood pressure;
KIRP	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.78	-13.16	-0.64	2.62e-30	Calcium levels;
KIRP	cis	rs17092148	0.895	rs4417778	chr20:33350987	T/C	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg02527881	chr3:46936655	PTH1R	-0.39	-5.32	-0.32	2.34e-7	Colorectal cancer;
KIRP	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.45e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.99	11.37	0.59	2.3e-24	Breast cancer;
KIRP	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.91	13.52	0.65	1.55e-31	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08051602	chr17:1394674	MYO1C	0.49	6.16	0.37	2.88e-9	Parkinson's disease;
KIRP	cis	rs9914544	0.591	rs9900052	chr17:18699398	G/A	cg26378065	chr17:18585709	ZNF286B	0.38	4.94	0.3	1.43e-6	Educational attainment (years of education);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08256761	chr12:80168523	PPP1R12A	-0.46	-7.06	-0.41	1.69e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8070740	1.000	rs8080400	chr17:5328633	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.38	0.43	2.45e-12	Menopause (age at onset);
KIRP	cis	rs4713118	0.629	rs149899	chr6:28019979	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-4.88	-0.3	1.92e-6	Parkinson's disease;
KIRP	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.6	-9.49	-0.52	2.1e-18	Vitamin D levels;
KIRP	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.66e-9	Colorectal cancer;
KIRP	cis	rs9815354	0.723	rs77572508	chr3:41938044	C/A	cg03022575	chr3:42003672	ULK4	0.77	7.9	0.45	9.42e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.61	-8.43	-0.47	2.94e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10875746	0.579	rs10875778	chr12:48624655	T/C	cg20731937	chr12:48336164	NA	0.48	5.99	0.36	7.55e-9	Longevity (90 years and older);
KIRP	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg09455208	chr3:40491958	NA	0.29	4.95	0.3	1.38e-6	Renal cell carcinoma;
KIRP	cis	rs72781680	0.611	rs55983206	chr2:24333995	A/C	cg06627628	chr2:24431161	ITSN2	-0.55	-4.91	-0.3	1.64e-6	Lymphocyte counts;
KIRP	cis	rs4704187	0.687	rs2161371	chr5:74520275	T/A	cg03227963	chr5:74354835	NA	0.41	5.99	0.36	7.27e-9	Response to amphetamines;
KIRP	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.88	11.81	0.6	8.45e-26	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-1.03	-12.18	-0.61	5.14e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6909279	0.933	rs9478219	chr6:151882362	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.46	-5.87	-0.35	1.38e-8	Bone mineral density;
KIRP	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg10047753	chr17:41438598	NA	1.15	18.14	0.76	2.88e-47	Menopause (age at onset);
KIRP	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.55	0.73	7.42e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg26513180	chr16:89883248	FANCA	-0.39	-5.08	-0.31	7.6e-7	Vitiligo;
KIRP	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg04935436	chr20:30431758	NA	-0.49	-6.7	-0.39	1.43e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg14541582	chr5:601475	NA	0.55	6.43	0.38	6.73e-10	Obesity-related traits;
KIRP	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	1.06	11.97	0.61	2.61e-26	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg01969543	chr11:61895209	INCENP	-0.53	-7.56	-0.43	8.05e-13	Breast cancer;
KIRP	cis	rs7590368	0.924	rs72779464	chr2:10963159	T/C	cg15705551	chr2:10952987	PDIA6	0.45	4.94	0.3	1.46e-6	Educational attainment (years of education);
KIRP	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg08885076	chr2:99613938	TSGA10	0.35	5.07	0.31	7.9e-7	Bipolar disorder;
KIRP	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.86	11.8	0.6	9.33e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg12205435	chr5:138714322	SLC23A1	0.38	4.9	0.3	1.71e-6	Esophageal squamous cell carcinoma;
KIRP	cis	rs11625487	0.609	rs74063377	chr14:77951431	C/G	cg20045696	chr14:77926864	AHSA1	-0.77	-6.31	-0.37	1.3e-9	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg02725872	chr8:58115012	NA	-0.53	-6.03	-0.36	5.81e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	8.6	0.48	9.28e-16	Personality dimensions;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg08662619	chr6:150070041	PCMT1	0.36	5.79	0.35	2.08e-8	Lung cancer;
KIRP	cis	rs77956314	1.000	rs11068224	chr12:117324967	G/A	cg02017074	chr12:117425053	FBXW8	-0.84	-4.86	-0.3	2.12e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs7084402	0.967	rs1427196	chr10:60278573	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs2299587	0.531	rs28839855	chr8:17855983	T/C	cg01800426	chr8:17659068	MTUS1	-0.64	-7.65	-0.44	4.59e-13	Economic and political preferences;
KIRP	cis	rs7072216	1.000	rs7072216	chr10:100156853	A/G	cg26618903	chr10:100175079	PYROXD2	-0.36	-5.27	-0.32	2.98e-7	Metabolite levels;
KIRP	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.55	6.39	0.38	8.14e-10	Monocyte count;
KIRP	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.94	-0.35	9.77e-9	Total cholesterol levels;
KIRP	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.16	0.5	2.15e-17	Lung cancer in ever smokers;
KIRP	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.75	-9.59	-0.52	1.03e-18	Aortic root size;
KIRP	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg03060546	chr3:49711283	APEH	0.43	5.69	0.34	3.55e-8	Parkinson's disease;
KIRP	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg11608241	chr8:8085544	FLJ10661	-0.48	-6.06	-0.36	4.97e-9	Triglycerides;
KIRP	trans	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg24644049	chr4:85504048	CDS1	0.95	6.41	0.38	7.18e-10	Skin colour saturation;
KIRP	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.66	0.39	1.82e-10	Renal cell carcinoma;
KIRP	cis	rs4523957	0.890	rs216218	chr17:2145329	A/G	cg16513277	chr17:2031491	SMG6	0.59	8.06	0.46	3.36e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs35740288	0.787	rs11635418	chr15:86244178	C/G	cg17133734	chr15:86042851	AKAP13	-0.5	-5.4	-0.33	1.6e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7005380	0.581	rs28546392	chr8:120931307	T/C	cg21645572	chr8:120931649	DEPDC6	-0.52	-7.24	-0.42	5.77e-12	Interstitial lung disease;
KIRP	cis	rs33912345	0.750	rs12878738	chr14:60935281	C/T	cg27398547	chr14:60952738	C14orf39	0.38	4.99	0.3	1.12e-6	Glaucoma (high intraocular pressure);
KIRP	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.71	-7.21	-0.42	7.01e-12	Multiple system atrophy;
KIRP	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg10189774	chr4:17578691	LAP3	0.52	6.43	0.38	6.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1440410	0.835	rs6820538	chr4:144129076	C/A	cg01719995	chr4:144104893	USP38	0.45	6.24	0.37	1.92e-9	Ischemic stroke;
KIRP	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg16388071	chr6:169726476	NA	-0.39	-5.28	-0.32	2.85e-7	Obesity-related traits;
KIRP	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.47	0.33	1.09e-7	Resistin levels;
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg01763666	chr17:80159506	CCDC57	-0.38	-5.17	-0.31	4.82e-7	Life satisfaction;
KIRP	cis	rs4268898	0.552	rs11125455	chr2:24374557	C/G	cg20701182	chr2:24300061	SF3B14	-0.41	-5.23	-0.32	3.69e-7	Asthma;
KIRP	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg02475777	chr4:1388615	CRIPAK	0.51	4.86	0.3	2.14e-6	Recombination rate (females);
KIRP	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.76	-0.4	9.7e-11	Triglycerides;
KIRP	cis	rs4356975	0.583	rs34630750	chr4:69966926	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs13064411	0.518	rs7646188	chr3:113219272	C/T	cg18753928	chr3:113234510	CCDC52	-0.49	-6.29	-0.37	1.41e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00585698	chr12:123750864	CDK2AP1	0.51	6.41	0.38	7.26e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7180079	0.620	rs576926	chr15:64793617	A/G	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg18234130	chr8:27182889	PTK2B	0.54	6.97	0.41	2.89e-11	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01889020	chr15:66545863	MEGF11	-0.48	-6.24	-0.37	1.85e-9	Survival in pancreatic cancer;
KIRP	cis	rs4851254	0.618	rs13001130	chr2:100668699	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-4.89	-0.3	1.81e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.49	-0.33	1.01e-7	Depression;
KIRP	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.8	10.77	0.57	2.08e-22	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.87	7.47	0.43	1.4e-12	Fat distribution (HIV);
KIRP	cis	rs2862064	1.000	rs1948760	chr5:156442784	T/A	cg12943317	chr5:156479607	HAVCR1	-0.73	-7.02	-0.41	2.16e-11	Platelet count;
KIRP	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.69	9.74	0.53	3.52e-19	Lymphocyte counts;
KIRP	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.32	5.09	0.31	7.15e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4356932	0.935	rs116135606	chr4:76967942	C/T	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.27	0.32	3.01e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs9888739	0.800	rs7200615	chr16:31337155	G/A	cg15817542	chr16:31343056	ITGAM	-0.47	-5.07	-0.31	7.93e-7	Systemic lupus erythematosus;
KIRP	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.63	-7.81	-0.45	1.64e-13	P wave terminal force;
KIRP	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.73	11.56	0.59	5.8e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	16.24	0.72	8.47e-41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg20090143	chr19:45452003	APOC2	0.34	5.47	0.33	1.12e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.73	-0.34	2.97e-8	Atopic dermatitis;
KIRP	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.66	7.59	0.44	6.65e-13	Corneal astigmatism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01931797	chr11:77899910	KCTD21;USP35	0.57	7.35	0.42	2.96e-12	Myopia (pathological);
KIRP	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.66	-10.95	-0.57	5.51e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg13880726	chr7:1868755	MAD1L1	0.5	5.56	0.33	7.06e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.89	0.4	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.49	-0.38	4.63e-10	Obesity-related traits;
KIRP	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.28	17.56	0.75	2.69e-45	Corneal structure;
KIRP	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg07636037	chr3:49044803	WDR6	-0.82	-7.58	-0.44	7.15e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05665937	chr4:1216051	CTBP1	0.5	7.11	0.41	1.28e-11	Obesity-related traits;
KIRP	cis	rs116095464	0.850	rs62330058	chr5:343564	G/A	cg22857025	chr5:266934	NA	-0.99	-6.5	-0.38	4.53e-10	Breast cancer;
KIRP	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.89	-17.96	-0.75	1.22e-46	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs687432	0.774	rs7938062	chr11:57904766	C/T	cg19752551	chr11:57585705	CTNND1	-0.65	-8.23	-0.46	1.13e-14	Parkinson's disease;
KIRP	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.8	-0.4	7.91e-11	Bladder cancer;
KIRP	cis	rs13185784	0.569	rs6877489	chr5:179677545	C/T	cg13944838	chr5:179740914	GFPT2	-0.51	-5.37	-0.32	1.81e-7	TRAIL levels;
KIRP	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-13.1	-0.64	4.13e-30	Blood metabolite levels;
KIRP	cis	rs867371	1.000	rs8037224	chr15:82464530	G/A	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	0.97	10.34	0.55	4.94e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs921874	0.553	rs2512395	chr11:86786129	C/G	cg20852851	chr2:240168848	HDAC4	0.47	6.4	0.38	7.63e-10	Total body bone mineral density;
KIRP	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg07701084	chr6:150067640	NUP43	0.51	5.75	0.34	2.63e-8	Lung cancer;
KIRP	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.73	10.82	0.57	1.4e-22	Prostate cancer;
KIRP	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.99	-16.52	-0.73	9.11e-42	Breast cancer;
KIRP	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.56	7.77	0.44	2.17e-13	Heart rate;
KIRP	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.59	0.39	2.64e-10	Rheumatoid arthritis;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20456258	chr4:962124	DGKQ	0.39	6.79	0.4	8.25e-11	Sjögren's syndrome;
KIRP	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.62	6.5	0.38	4.43e-10	Gut microbiome composition (summer);
KIRP	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17554472	chr22:41940697	POLR3H	0.69	7.08	0.41	1.48e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg10756647	chr7:56101905	PSPH	-1.08	-8.46	-0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.78e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs10267417	0.673	rs9297120	chr7:19934348	A/C	cg05791153	chr7:19748676	TWISTNB	0.45	4.93	0.3	1.51e-6	Night sleep phenotypes;
KIRP	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.94	-11.23	-0.58	6.62e-24	White matter hyperintensity burden;
KIRP	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.34	-0.32	2.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg00977110	chr5:151150581	G3BP1	0.63	6.29	0.37	1.42e-9	Preschool internalizing problems;
KIRP	cis	rs2997447	0.846	rs12069719	chr1:26411918	A/G	cg19633962	chr1:26362018	EXTL1	-0.51	-5.01	-0.3	1.04e-6	QRS complex (12-leadsum);
KIRP	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.76	-11.45	-0.59	1.3e-24	Obesity-related traits;
KIRP	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg07271561	chr3:50359363	HYAL2	-0.48	-5.88	-0.35	1.31e-8	Schizophrenia;
KIRP	cis	rs2230307	0.572	rs2810419	chr1:100643968	C/A	cg24955406	chr1:100503596	HIAT1	-0.58	-5.89	-0.35	1.26e-8	Carotid intima media thickness;
KIRP	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg08603382	chr10:743973	NA	0.47	6.87	0.4	5.13e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	1.03	7.57	0.43	7.29e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-0.87	-6.09	-0.36	4.43e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs8054556	1.000	rs4583255	chr16:29988941	A/G	cg06326092	chr16:30034487	C16orf92	0.35	4.87	0.3	1.96e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.69	6.77	0.4	9.35e-11	Breast cancer;
KIRP	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.66	8.07	0.46	3.08e-14	Obesity-related traits;
KIRP	cis	rs13064411	0.518	rs1471883	chr3:113211828	C/T	cg18753928	chr3:113234510	CCDC52	-0.49	-6.26	-0.37	1.72e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7174755	0.608	rs62004789	chr15:68440606	C/T	cg17095910	chr15:68523075	CLN6	0.38	4.89	0.3	1.84e-6	Major depressive disorder;
KIRP	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs193541	0.530	rs9327272	chr5:122073548	T/C	cg19412675	chr5:122181750	SNX24	0.52	5.77	0.35	2.33e-8	Glucose homeostasis traits;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02073427	chr10:15252052	NA	0.65	6.42	0.38	7.16e-10	Lung function (FEV1);
KIRP	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg24488311	chr11:68621650	NA	0.41	5.03	0.31	9.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.69	7.88	0.45	1.08e-13	Corneal astigmatism;
KIRP	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.88	-0.49	1.4e-16	Resting heart rate;
KIRP	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg12042659	chr19:58951599	ZNF132	0.75	9.07	0.5	3.99e-17	Mean platelet volume;
KIRP	cis	rs8523	0.901	rs1321536	chr6:11018812	A/C	cg13562911	chr6:11044106	ELOVL2	0.38	5.01	0.3	1.06e-6	Red blood cell fatty acid levels;
KIRP	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg05347473	chr6:146136440	FBXO30	0.48	6.7	0.39	1.44e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg10755058	chr3:40428713	ENTPD3	0.44	6.21	0.37	2.23e-9	Renal cell carcinoma;
KIRP	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.99	-0.36	7.5e-9	Height;
KIRP	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25517755	chr10:38738941	LOC399744	-0.51	-7.12	-0.41	1.19e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4523957	0.928	rs216179	chr17:2168878	T/A	cg16513277	chr17:2031491	SMG6	0.61	8.37	0.47	4.51e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg08132940	chr7:1081526	C7orf50	-0.7	-7.05	-0.41	1.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.88e-16	Immature fraction of reticulocytes;
KIRP	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg10932868	chr11:921992	NA	0.51	6.06	0.36	4.97e-9	Alzheimer's disease (late onset);
KIRP	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	5.71	0.34	3.27e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.47	-0.43	1.38e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg13962347	chr6:5174647	LYRM4	-0.72	-10.1	-0.54	2.79e-20	Height;
KIRP	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs16958440	1.000	rs62096468	chr18:44637566	C/A	cg17192377	chr18:44677553	HDHD2	0.72	6.25	0.37	1.81e-9	Sitting height ratio;
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	13.45	0.65	2.8e-31	Platelet count;
KIRP	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-0.95	-9.96	-0.54	7.43e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs6504622	0.537	rs1662594	chr17:44992737	C/T	cg16759221	chr17:45003025	GOSR2	-0.39	-5.95	-0.35	9.05e-9	Orofacial clefts;
KIRP	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.34	-0.7	1.04e-37	Gut microbiome composition (summer);
KIRP	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.43	7.18	0.42	8e-12	Heart rate;
KIRP	cis	rs6815814	0.851	rs5743551	chr4:38807654	T/C	cg06935464	chr4:38784597	TLR10	0.5	6.01	0.36	6.53e-9	Breast cancer;
KIRP	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg22681709	chr2:178499509	PDE11A	-0.64	-6.86	-0.4	5.69e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.48	5.84	0.35	1.61e-8	Squamous cell lung carcinoma;
KIRP	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.05	0.31	8.43e-7	Height;
KIRP	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.55	-7.24	-0.42	5.78e-12	Obesity-related traits;
KIRP	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg06636001	chr8:8085503	FLJ10661	0.85	12.32	0.62	1.71e-27	Neuroticism;
KIRP	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.5	0.52	1.99e-18	Cognitive test performance;
KIRP	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.58	-7.15	-0.42	9.59e-12	Diastolic blood pressure;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg22833807	chr22:36925177	EIF3D	0.51	6.02	0.36	6.42e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9309473	0.950	rs13427832	chr2:73844818	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.62	-0.34	5.19e-8	Metabolite levels;
KIRP	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg01304814	chr3:48885189	PRKAR2A	0.58	5.3	0.32	2.62e-7	Cognitive function;
KIRP	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg00823993	chr13:113535758	ATP11A	0.6	6.53	0.38	3.83e-10	Interstitial lung disease;
KIRP	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.46	5.68	0.34	3.74e-8	Height;
KIRP	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg00343986	chr7:65444356	GUSB	0.39	4.87	0.3	2.02e-6	Aortic root size;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg08742575	chr21:47604166	C21orf56	-0.54	-7.6	-0.44	6.02e-13	Testicular germ cell tumor;
KIRP	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg11569703	chr11:65557185	OVOL1	0.59	10.49	0.56	1.63e-21	Acne (severe);
KIRP	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg11130432	chr3:121712080	ILDR1	0.5	6.37	0.38	9.26e-10	Multiple sclerosis;
KIRP	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg00405596	chr8:11794950	NA	0.4	5.37	0.32	1.79e-7	Retinal vascular caliber;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.56	5.6	0.34	5.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs16957091	0.909	rs3742988	chr15:43016475	A/G	cg24196017	chr15:43021976	CDAN1	-0.53	-7.09	-0.41	1.39e-11	MGMT methylation in smokers;
KIRP	cis	rs3105593	0.933	rs7176874	chr15:50829980	T/C	cg05456662	chr15:50716270	USP8	0.39	4.96	0.3	1.32e-6	QT interval;
KIRP	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs1823913	0.637	rs10931493	chr2:192152868	C/T	cg12404831	chr2:192114017	MYO1B	0.46	6.12	0.36	3.63e-9	Obesity-related traits;
KIRP	cis	rs12714314	0.514	rs7591822	chr2:1942765	C/T	cg20846728	chr2:1843184	MYT1L	-0.38	-6.4	-0.38	7.71e-10	Type 2 diabetes (age of onset);
KIRP	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-7.31	-0.42	3.8e-12	Morning vs. evening chronotype;
KIRP	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22159483	chr17:1588198	PRPF8	0.58	6.97	0.41	2.89e-11	Smoking initiation;
KIRP	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg13010199	chr12:38710504	ALG10B	0.49	6.32	0.37	1.22e-9	Morning vs. evening chronotype;
KIRP	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg09918751	chr15:100517450	ADAMTS17	0.55	8.08	0.46	2.96e-14	Height;
KIRP	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs698833	0.819	rs12053381	chr2:44570804	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.93	0.35	1.02e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg16511985	chr3:153974050	SGEF	0.38	5.32	0.32	2.31e-7	Coronary artery disease;
KIRP	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.88	0.4	4.84e-11	Educational attainment;
KIRP	cis	rs9687846	0.877	rs3843467	chr5:55856375	A/C	cg15001016	chr5:55860904	NA	0.28	5.24	0.32	3.54e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4478037	0.558	rs80167648	chr3:33069317	A/G	cg19404215	chr3:33155277	CRTAP	0.84	5.19	0.31	4.32e-7	Major depressive disorder;
KIRP	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs4356932	1.000	rs4580676	chr4:76953295	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-9.28	-0.51	9.02e-18	Total body bone mineral density;
KIRP	cis	rs7671266	0.628	rs11734783	chr4:10240663	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.36	0.32	1.9e-7	Cardiovascular disease risk factors;
KIRP	cis	rs4938534	0.533	rs1806397	chr11:111264915	T/C	cg19148410	chr11:111250352	POU2AF1	0.36	5.15	0.31	5.25e-7	Primary biliary cholangitis;
KIRP	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.87	13.78	0.66	2.08e-32	Height;
KIRP	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg13147721	chr7:65941812	NA	-1.01	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs6142102	0.961	rs6088360	chr20:32557189	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	6.51	0.38	4.23e-10	Skin pigmentation;
KIRP	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.86	-13.16	-0.64	2.61e-30	Mean corpuscular volume;
KIRP	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	1.09	12.13	0.61	7.69e-27	Post bronchodilator FEV1;
KIRP	cis	rs60695258	0.726	rs1471251	chr4:87976359	A/T	cg11209507	chr4:87813803	C4orf36	-0.39	-5.32	-0.32	2.28e-7	Hematocrit;
KIRP	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	8.3	0.47	7.09e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.79	-8.52	-0.48	1.57e-15	Hair shape;
KIRP	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg11906718	chr8:101322791	RNF19A	-0.49	-6.45	-0.38	5.83e-10	Atrioventricular conduction;
KIRP	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg07741184	chr6:167504864	NA	-0.2	-5.24	-0.32	3.47e-7	Crohn's disease;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs11722228	0.790	rs13126729	chr4:9974186	G/A	cg00071950	chr4:10020882	SLC2A9	-0.42	-4.97	-0.3	1.27e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	trans	rs12517041	1.000	rs12697619	chr5:23288772	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.92	-0.49	1.11e-16	Calcium levels;
KIRP	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-0.9	-13.08	-0.64	4.82e-30	Dupuytren's disease;
KIRP	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.77	-9.04	-0.5	4.9e-17	Resting heart rate;
KIRP	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs259842	0.670	rs13399303	chr2:180668301	G/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	0.36	4.9	0.3	1.71e-6	Blood protein levels;
KIRP	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg21252483	chr19:49399788	TULP2	-0.56	-7.16	-0.42	9.36e-12	Red cell distribution width;
KIRP	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-5.81	-0.35	1.94e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.59	-7.15	-0.41	9.86e-12	Mosquito bite size;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3109167	0.524	rs3801512	chr7:83120677	A/G	cg14519356	chr7:83097669	SEMA3E	0.54	7.14	0.41	1.07e-11	Blood protein levels;
KIRP	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.6	-7.19	-0.42	7.77e-12	Initial pursuit acceleration;
KIRP	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg01872077	chr2:219646372	CYP27A1	0.39	5.49	0.33	9.98e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg24315340	chr6:146058215	EPM2A	-0.46	-6.03	-0.36	6e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg13180566	chr4:1052158	NA	-0.52	-5.34	-0.32	2.13e-7	Recombination rate (females);
KIRP	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.49	6.11	0.36	3.97e-9	Height;
KIRP	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg00981070	chr1:2046702	PRKCZ	-0.41	-6.68	-0.39	1.61e-10	Height;
KIRP	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.83	11.36	0.59	2.6e-24	Menarche (age at onset);
KIRP	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-5.56	-0.33	7.07e-8	Blood metabolite levels;
KIRP	cis	rs258892	0.895	rs34646	chr5:72113061	C/T	cg21869765	chr5:72125136	TNPO1	-0.56	-6.2	-0.37	2.42e-9	Small cell lung carcinoma;
KIRP	cis	rs7771547	0.573	rs619011	chr6:36476592	A/G	cg04289385	chr6:36355825	ETV7	0.44	6.84	0.4	6.23e-11	Platelet distribution width;
KIRP	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg17366294	chr4:99064904	C4orf37	0.39	5.28	0.32	2.8e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg20637307	chr2:213403960	ERBB4	0.61	8.27	0.47	8.29e-15	Symmetrical dimethylarginine levels;
KIRP	cis	rs11702148	0.552	rs3787708	chr21:34906039	C/T	cg14850771	chr21:34775459	IFNGR2	0.38	5.18	0.31	4.58e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.6	-9.24	-0.51	1.16e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.48	6.26	0.37	1.7e-9	Multiple sclerosis;
KIRP	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs4835473	0.932	rs6828935	chr4:144750266	C/T	cg08833778	chr4:144622313	FREM3	0.34	4.96	0.3	1.29e-6	Immature fraction of reticulocytes;
KIRP	cis	rs2692947	0.601	rs12473765	chr2:96387339	T/C	cg23100626	chr2:96804247	ASTL	0.39	4.96	0.3	1.34e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.79	9.69	0.53	5.25e-19	Corneal astigmatism;
KIRP	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.45	6.47	0.38	5.39e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-6.59	-0.39	2.63e-10	Vitamin D levels;
KIRP	cis	rs883565	0.655	rs6778963	chr3:39091812	T/G	cg01426195	chr3:39028469	NA	-0.74	-12.99	-0.64	1.01e-29	Handedness;
KIRP	trans	rs2048656	0.578	rs10095236	chr8:9684925	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.47	-0.43	1.39e-12	Schizophrenia;
KIRP	cis	rs72960926	0.744	rs16884519	chr6:74967946	C/T	cg03266952	chr6:74778945	NA	0.6	5.49	0.33	1e-7	Metabolite levels (MHPG);
KIRP	trans	rs13170463	0.579	rs76073484	chr5:8041960	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.68	-9.24	-0.51	1.19e-17	Facial morphology (factor 21, depth of nasal alae);
KIRP	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg13010199	chr12:38710504	ALG10B	-0.53	-6.91	-0.4	4.14e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg14092571	chr14:90743983	NA	0.42	5.16	0.31	5.15e-7	Mortality in heart failure;
KIRP	cis	rs6032067	0.929	rs2664581	chr20:43804522	A/C	cg10761708	chr20:43804764	PI3	0.51	5.51	0.33	9.15e-8	Blood protein levels;
KIRP	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg08133631	chr1:26527909	CATSPER4	-0.47	-5.2	-0.31	4.16e-7	Obesity-related traits;
KIRP	cis	rs7737355	0.812	rs2042252	chr5:130980027	A/G	cg06307176	chr5:131281290	NA	-0.41	-4.88	-0.3	1.94e-6	Life satisfaction;
KIRP	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.4	-0.38	7.87e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs17032980	0.641	rs6719951	chr2:67334411	A/G	cg13461890	chr9:4793992	RCL1	-0.45	-6.34	-0.37	1.07e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.6	-0.44	6.26e-13	Retinal vascular caliber;
KIRP	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Corneal astigmatism;
KIRP	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	1.0	17.72	0.75	7.68e-46	Breast cancer;
KIRP	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg06064525	chr11:970664	AP2A2	-0.37	-7.47	-0.43	1.44e-12	Alzheimer's disease (late onset);
KIRP	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.88	13.11	0.64	4.07e-30	Colorectal cancer;
KIRP	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg08807892	chr2:162101083	NA	0.4	4.88	0.3	1.9e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10988449	0.891	rs10988452	chr9:132376859	C/T	cg18327994	chr9:132372705	NA	-0.54	-5.17	-0.31	4.79e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg05361325	chr10:32636312	EPC1	-0.55	-4.9	-0.3	1.76e-6	Sexual dysfunction (female);
KIRP	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg23594656	chr7:65796392	TPST1	-0.45	-7.02	-0.41	2.13e-11	Aortic root size;
KIRP	cis	rs228437	0.913	rs1467434	chr6:134925349	C/T	cg24504307	chr6:134963096	NA	-0.41	-6.42	-0.38	7e-10	Melanoma;
KIRP	trans	rs6601327	0.641	rs10111376	chr8:9615470	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.98	0.41	2.74e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1594829	0.553	rs7003030	chr8:26172699	G/T	cg11498726	chr8:26250323	BNIP3L	-0.32	-4.9	-0.3	1.7e-6	Height;
KIRP	cis	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg27487796	chr7:28973253	NA	-0.22	-4.96	-0.3	1.32e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13837895	chr19:50145301	SCAF1	0.77	7.23	0.42	5.99e-12	Lung function (FEV1);
KIRP	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.38	0.51	4.46e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg23594656	chr7:65796392	TPST1	0.49	7.89	0.45	9.7e-14	Aortic root size;
KIRP	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg23533926	chr12:111358616	MYL2	-0.52	-7.04	-0.41	1.88e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg21523564	chr15:75251491	NA	0.43	6.65	0.39	1.93e-10	Caffeine consumption;
KIRP	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.41	5.81	0.35	1.9e-8	Endometrial cancer;
KIRP	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg16329650	chr2:213403929	ERBB4	0.39	5.46	0.33	1.14e-7	Symmetrical dimethylarginine levels;
KIRP	cis	rs7267005	0.661	rs2425099	chr20:34309643	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.01	-0.3	1.03e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.85	0.35	1.6e-8	Renal cell carcinoma;
KIRP	cis	rs10865541	0.806	rs10187625	chr2:3421168	A/G	cg11642891	chr2:3452563	TTC15	-0.53	-6.62	-0.39	2.21e-10	Obesity-related traits;
KIRP	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.43	-5.61	-0.34	5.51e-8	IgG glycosylation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24155937	chr1:97833212	DPYD	-0.41	-6.08	-0.36	4.62e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.55	-0.39	3.27e-10	Total cholesterol levels;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.64e-16	Life satisfaction;
KIRP	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg00898013	chr13:113819073	PROZ	0.48	5.09	0.31	6.99e-7	Blood protein levels;
KIRP	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	trans	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.76	-10.69	-0.56	3.74e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.41	5.31	0.32	2.43e-7	IgG glycosylation;
KIRP	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.68	0.63	1.11e-28	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7531932	0.709	rs12049457	chr1:72171477	A/G	cg20667729	chr19:43691878	PSG5	-0.43	-6.18	-0.37	2.61e-9	Schizophrenia;
KIRP	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg13798780	chr7:105162888	PUS7	0.66	6.09	0.36	4.31e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.73	-0.34	2.98e-8	Parkinson's disease;
KIRP	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.55	-0.7	1.96e-38	Gut microbiome composition (summer);
KIRP	trans	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg24644049	chr4:85504048	CDS1	0.99	6.64	0.39	2.03e-10	Skin colour saturation;
KIRP	cis	rs4786125	0.706	rs8062094	chr16:6902585	A/G	cg03623568	chr16:6915990	A2BP1	-0.42	-5.12	-0.31	6.24e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg01081584	chr15:40268610	EIF2AK4	-0.59	-6.73	-0.39	1.21e-10	Corneal curvature;
KIRP	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	5.91	0.35	1.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-6.98	-0.41	2.68e-11	Monocyte count;
KIRP	cis	rs7084783	0.519	rs1047425	chr10:105345201	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.45	5.78	0.35	2.31e-8	Fear of pain;
KIRP	cis	rs2802372	0.785	rs1250564	chr10:81047342	A/C	cg18688392	chr10:81059414	ZMIZ1	-0.43	-5.58	-0.34	6.33e-8	Granulocyte count;
KIRP	cis	rs17453880	0.929	rs7731459	chr5:152032506	C/T	cg12297329	chr5:152029980	NA	-0.72	-10.83	-0.57	1.31e-22	Subjective well-being;
KIRP	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.75	0.34	2.66e-8	Total cholesterol levels;
KIRP	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg00784671	chr22:46762841	CELSR1	-0.79	-7.29	-0.42	4.16e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg21775007	chr8:11205619	TDH	0.45	6.07	0.36	4.78e-9	Myopia (pathological);
KIRP	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.68	7.45	0.43	1.63e-12	Multiple sclerosis;
KIRP	cis	rs6681460	1.000	rs10889634	chr1:67065911	A/G	cg02459107	chr1:67143332	SGIP1	-0.46	-6.54	-0.38	3.52e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2820315	0.838	rs2819347	chr1:201884288	C/G	cg11586189	chr1:201857591	SHISA4	-0.41	-5.8	-0.35	1.98e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.7	-6.71	-0.39	1.34e-10	Opioid sensitivity;
KIRP	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.47	-9.79	-0.53	2.55e-19	Longevity;
KIRP	cis	rs2273156	0.929	rs12894820	chr14:35435525	A/G	cg09327582	chr14:35236912	BAZ1A	0.49	5.46	0.33	1.18e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.61	8.42	0.47	3.13e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg15556689	chr8:8085844	FLJ10661	0.72	9.29	0.51	8.36e-18	Neuroticism;
KIRP	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.76	9.24	0.51	1.17e-17	Response to antineoplastic agents;
KIRP	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.01	0.36	6.6e-9	Height;
KIRP	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.65	0.34	4.41e-8	Breast cancer;
KIRP	cis	rs10753787	0.811	rs2040443	chr1:169534966	T/A	cg25256723	chr1:169555944	F5	0.25	5.37	0.32	1.84e-7	Vertical cup-disc ratio;
KIRP	cis	rs13067260	0.655	rs13317852	chr3:123745900	G/T	cg19918027	chr3:123987645	KALRN	-0.61	-5.45	-0.33	1.2e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg21545522	chr1:205238299	TMCC2	0.43	5.81	0.35	1.91e-8	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02155528	chr15:90808716	NGRN	0.45	6.09	0.36	4.32e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21861644	chr18:13726504	C18orf19;RNMT	0.41	5.36	0.32	1.93e-7	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg05315796	chr3:52349193	DNAH1	0.43	6.43	0.38	6.5e-10	Bipolar disorder;
KIRP	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg02297831	chr4:17616191	MED28	0.58	7.05	0.41	1.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg20701182	chr2:24300061	SF3B14	0.56	4.88	0.3	1.94e-6	Lymphocyte counts;
KIRP	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.52	6.89	0.4	4.53e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs6430538	0.597	rs1942054	chr2:135579213	A/G	cg25422880	chr2:135218333	TMEM163	-0.43	-6.03	-0.36	5.91e-9	Parkinson's disease;
KIRP	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10959786	chr13:74708124	KLF12	0.58	6.87	0.4	5.23e-11	Smoking initiation;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg07476944	chr4:39978140	PDS5A	0.5	6.37	0.38	9.35e-10	Inflammatory biomarkers;
KIRP	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg15556689	chr8:8085844	FLJ10661	0.61	8.14	0.46	1.95e-14	Retinal vascular caliber;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.48	-6.16	-0.37	2.93e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11710088	0.740	rs13092900	chr3:149191100	T/G	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.42	-0.33	1.39e-7	QRS duration;
KIRP	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	cis	rs6681460	1.000	rs1562217	chr1:67073566	C/T	cg02459107	chr1:67143332	SGIP1	-0.48	-6.76	-0.4	9.74e-11	Presence of antiphospholipid antibodies;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27408887	chr6:16129570	MYLIP	0.46	6.05	0.36	5.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.49	-0.43	1.21e-12	Body mass index;
KIRP	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg16586182	chr3:47516702	SCAP	0.8	11.1	0.58	1.73e-23	Colorectal cancer;
KIRP	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg21775007	chr8:11205619	TDH	-0.42	-5.3	-0.32	2.52e-7	Joint mobility (Beighton score);
KIRP	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg20936604	chr3:58311152	NA	-0.68	-5.23	-0.32	3.64e-7	Cholesterol, total;
KIRP	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.6	-6.7	-0.39	1.4e-10	Neuroticism;
KIRP	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.6	-6.96	-0.41	3.1e-11	QRS complex (12-leadsum);
KIRP	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.61	7.64	0.44	4.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-8.94	-0.49	9.82e-17	Rheumatoid arthritis;
KIRP	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.79	7.54	0.43	8.94e-13	Diisocyanate-induced asthma;
KIRP	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	5.04	0.31	8.95e-7	Renal cell carcinoma;
KIRP	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-8.91	-0.49	1.15e-16	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03948139	chr10:120804863	EIF3A	-0.44	-6.43	-0.38	6.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.41	5.13	0.31	5.77e-7	Recombination rate (males);
KIRP	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.46	-5.99	-0.36	7.36e-9	Asthma;
KIRP	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg06766960	chr11:133703094	NA	-0.75	-9.1	-0.5	3.12e-17	Childhood ear infection;
KIRP	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg15436174	chr10:43711423	RASGEF1A	0.85	9.38	0.51	4.46e-18	Hirschsprung disease;
KIRP	cis	rs526231	0.578	rs59323174	chr5:102267869	T/C	cg23492399	chr5:102201601	PAM	-0.48	-5.37	-0.32	1.86e-7	Primary biliary cholangitis;
KIRP	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.5	5.8	0.35	2.07e-8	Platelet distribution width;
KIRP	cis	rs17030434	0.834	rs6535958	chr4:154760834	C/G	cg14289246	chr4:154710475	SFRP2	0.68	8.65	0.48	6.76e-16	Electrocardiographic conduction measures;
KIRP	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.36	0.55	4.29e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.66	7.9	0.45	9.27e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.62	8.68	0.48	5.44e-16	Economic and political preferences (feminism/equality);
KIRP	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.99	0.41	2.56e-11	Triglycerides;
KIRP	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23281280	chr6:28129359	ZNF389	-0.46	-5.11	-0.31	6.59e-7	Depression;
KIRP	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.59	-8.14	-0.46	1.93e-14	Breast cancer;
KIRP	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg27490568	chr2:178487706	NA	0.66	8.96	0.5	8.4e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg13679303	chr9:96623674	NA	-0.49	-6.97	-0.41	2.88e-11	DNA methylation (variation);
KIRP	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg02524346	chr8:600233	NA	0.68	5.12	0.31	6.12e-7	IgG glycosylation;
KIRP	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.76	-12.0	-0.61	2.05e-26	Hepatocellular carcinoma;
KIRP	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg15691649	chr6:25882328	NA	0.43	5.24	0.32	3.5e-7	Blood metabolite levels;
KIRP	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.4	-6.85	-0.4	6.01e-11	Refractive error;
KIRP	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.07	12.38	0.62	1.06e-27	Gut microbiome composition (summer);
KIRP	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.51	-11.3	-0.58	4.11e-24	Diabetic kidney disease;
KIRP	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.62	6.82	0.4	7.06e-11	Aortic root size;
KIRP	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	7.61	0.44	5.86e-13	Schizophrenia;
KIRP	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.88	10.02	0.54	4.95e-20	Osteoarthritis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20208648	chr7:44163237	POLD2	-0.47	-6.04	-0.36	5.72e-9	Myopia;
KIRP	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.32	-0.37	1.24e-9	Response to antipsychotic treatment;
KIRP	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.72	-9.43	-0.52	3.13e-18	Childhood ear infection;
KIRP	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	6.97	0.41	2.93e-11	Myopia (pathological);
KIRP	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.59	7.9	0.45	9.03e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg11189052	chr15:85197271	WDR73	0.47	4.89	0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.01	-18.02	-0.75	7.41e-47	Chronic sinus infection;
KIRP	cis	rs2061333	0.557	rs8104573	chr19:44603385	A/G	cg21636353	chr19:44617292	ZNF225	-0.51	-4.96	-0.3	1.34e-6	Alzheimer's disease;
KIRP	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg00106254	chr7:1943704	MAD1L1	0.43	4.95	0.3	1.39e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg24315340	chr6:146058215	EPM2A	0.44	5.46	0.33	1.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23077498	chr10:76801843	DUPD1	0.38	6.03	0.36	5.9e-9	Survival in pancreatic cancer;
KIRP	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.39	-0.38	8.12e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Bladder cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08812242	chr19:14606902	GIPC1	-0.55	-6.81	-0.4	7.4e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7923609	0.967	rs2393977	chr10:65247609	A/C	cg01631684	chr10:65280961	REEP3	-0.51	-6.0	-0.36	7.17e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.47	-0.33	1.11e-7	Height;
KIRP	cis	rs7621025	0.599	rs13063987	chr3:136445397	C/G	cg15507776	chr3:136538369	TMEM22	-0.41	-4.89	-0.3	1.8e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg16482183	chr6:26056742	HIST1H1C	-0.39	-5.17	-0.31	4.85e-7	Schizophrenia;
KIRP	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg01420254	chr6:26195488	NA	1.17	10.62	0.56	6.32e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs3126085	0.667	rs12747821	chr1:152240424	G/A	cg26876637	chr1:152193138	HRNR	0.73	8.91	0.49	1.14e-16	Atopic dermatitis;
KIRP	cis	rs76917914	0.820	rs6478539	chr9:100818720	C/T	cg03040243	chr9:100819229	NANS	0.63	6.64	0.39	1.95e-10	Immature fraction of reticulocytes;
KIRP	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.88	14.11	0.67	1.57e-33	Breast cancer;
KIRP	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	9.42	0.51	3.55e-18	Cognitive test performance;
KIRP	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.11	-0.41	1.27e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.48	-5.86	-0.35	1.47e-8	Asthma (sex interaction);
KIRP	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg05340658	chr4:99064831	C4orf37	-0.44	-5.0	-0.3	1.07e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.34	0.55	4.65e-21	Cognitive test performance;
KIRP	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg00405596	chr8:11794950	NA	-0.46	-5.71	-0.34	3.25e-8	Retinal vascular caliber;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05612640	chr18:77748679	TXNL4A	0.46	6.37	0.38	9.28e-10	Cancer;
KIRP	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg10117171	chr1:25599238	RHD	-0.46	-6.21	-0.37	2.19e-9	Erythrocyte sedimentation rate;
KIRP	cis	rs42648	0.837	rs4728879	chr7:89924237	T/G	cg25739043	chr7:89950458	NA	-0.43	-6.79	-0.4	8.4e-11	Homocysteine levels;
KIRP	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg00800038	chr16:89945340	TCF25	-0.8	-6.1	-0.36	4.05e-9	Skin colour saturation;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.87	-13.36	-0.65	5.65e-31	Height;
KIRP	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg18089426	chr14:101175970	NA	0.56	7.67	0.44	3.96e-13	Platelet count;
KIRP	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.13e-7	Retinal vascular caliber;
KIRP	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.65	8.17	0.46	1.68e-14	Corneal astigmatism;
KIRP	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg24253500	chr15:84953950	NA	0.51	5.7	0.34	3.37e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7712401	0.584	rs28373879	chr5:122372402	G/C	cg19412675	chr5:122181750	SNX24	0.49	5.45	0.33	1.21e-7	Mean platelet volume;
KIRP	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	cg21523751	chr1:182988639	NA	0.36	5.09	0.31	7.19e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.61	7.07	0.41	1.63e-11	Obesity-related traits;
KIRP	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.33	8.71	0.49	4.51e-16	Crohn's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25998860	chr5:126853954	PRRC1	0.61	7.11	0.41	1.22e-11	Smoking initiation;
KIRP	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg26149184	chr10:133730230	NA	0.43	5.08	0.31	7.36e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs1215050	0.765	rs687795	chr4:98754912	C/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.72	-7.17	-0.42	8.9e-12	Menarche (age at onset);
KIRP	cis	rs1978968	1.000	rs11705221	chr22:18443287	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6684514	1.000	rs10494304	chr1:156285764	C/G	cg16558208	chr1:156270281	VHLL	0.44	5.84	0.35	1.62e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg26531700	chr6:26746687	NA	0.4	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.12	0.36	3.7e-9	Height;
KIRP	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.57	-6.38	-0.38	8.82e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	5.14	0.31	5.65e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg13010199	chr12:38710504	ALG10B	-0.38	-4.96	-0.3	1.3e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg00360474	chr6:37504404	NA	-0.5	-7.46	-0.43	1.46e-12	Cognitive performance;
KIRP	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg25356066	chr3:128598488	ACAD9	0.48	5.52	0.33	8.42e-8	IgG glycosylation;
KIRP	cis	rs7903847	0.642	rs6584127	chr10:99142948	A/C	cg20016023	chr10:99160130	RRP12	-0.43	-5.96	-0.36	8.79e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.21e-6	Blood protein levels;
KIRP	cis	rs7534824	0.543	rs10493940	chr1:101377845	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.25	0.42	5.48e-12	Refractive astigmatism;
KIRP	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12826209	chr6:26865740	GUSBL1	0.66	5.26	0.32	3.13e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10373780	chr19:8455179	RAB11B	-0.59	-6.45	-0.38	5.87e-10	Menopause (age at onset);
KIRP	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	11.26	0.58	5.28e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6453429	0.536	rs673834	chr5:78367139	T/G	cg08328513	chr5:78365691	BHMT2;DMGDH	-0.28	-5.07	-0.31	7.94e-7	Urinary metabolites;
KIRP	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg16524733	chr11:117070046	TAGLN	0.38	4.95	0.3	1.35e-6	Blood protein levels;
KIRP	cis	rs997295	0.592	rs8026627	chr15:67770306	G/T	cg24579218	chr15:68104479	NA	-0.35	-5.06	-0.31	8.37e-7	Motion sickness;
KIRP	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.56	0.48	1.26e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg02375832	chr11:62437615	C11orf48	-0.42	-5.67	-0.34	4.03e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg06795125	chr2:108905320	SULT1C2	-0.51	-7.98	-0.45	5.46e-14	Blood pressure;
KIRP	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.43	5.85	0.35	1.56e-8	Coronary artery disease;
KIRP	cis	rs2649	0.542	rs8023506	chr15:63884462	A/G	cg22599514	chr15:63798201	USP3	0.39	5.06	0.31	8.03e-7	Aortic root size;
KIRP	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.5	-6.44	-0.38	6.06e-10	Testicular germ cell tumor;
KIRP	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg07622451	chr1:3079886	PRDM16	-0.37	-5.33	-0.32	2.2e-7	Migraine;
KIRP	cis	rs3105169	1.000	rs6468681	chr8:100317365	A/G	cg00191853	chr8:101177733	SPAG1	-0.39	-4.93	-0.3	1.5e-6	Smoking initiation;
KIRP	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.54	-4.95	-0.3	1.37e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4523957	0.890	rs8076939	chr17:2099931	C/A	cg16513277	chr17:2031491	SMG6	-0.69	-10.03	-0.54	4.66e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs494562	0.892	rs638745	chr6:86115587	C/G	cg27039625	chr6:86159096	NT5E	0.42	5.31	0.32	2.45e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg24488311	chr11:68621650	NA	0.43	5.3	0.32	2.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg08662619	chr6:150070041	PCMT1	0.37	6.23	0.37	2.05e-9	Lung cancer;
KIRP	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.66	9.5	0.52	1.96e-18	Dupuytren's disease;
KIRP	cis	rs11955175	1.000	rs45480797	chr5:40680964	C/G	cg05478818	chr5:40835740	RPL37	0.71	5.29	0.32	2.77e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-5.77	-0.35	2.38e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg07395648	chr5:131743802	NA	-0.36	-4.9	-0.3	1.73e-6	Blood metabolite levels;
KIRP	cis	rs9393813	0.626	rs9357038	chr6:27334573	G/A	cg18711553	chr6:27366782	ZNF391	0.4	5.47	0.33	1.12e-7	Bipolar disorder;
KIRP	trans	rs12517041	0.810	rs2356714	chr5:23284785	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.94	-9.07	-0.5	3.8e-17	Calcium levels;
KIRP	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.02	-0.57	3.22e-23	Height;
KIRP	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.69	6.74	0.4	1.09e-10	Breast cancer;
KIRP	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-1.06	-8.33	-0.47	5.6e-15	Obesity-related traits;
KIRP	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.88	0.53	1.38e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.26	-5.5	-0.33	9.7e-8	Menarche (age at onset);
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	13.59	0.65	9.62e-32	Platelet count;
KIRP	cis	rs516946	0.898	rs9694034	chr8:41523358	A/G	cg19441908	chr8:41529140	ANK1	0.5	7.12	0.41	1.17e-11	Type 2 diabetes;
KIRP	cis	rs7224685	0.569	rs8066707	chr17:3996550	T/C	cg05562828	chr17:3906858	NA	0.55	5.94	0.35	9.56e-9	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.27	-22.23	-0.82	8.87e-61	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00894559	chr18:22010361	IMPACT	-0.47	-7.24	-0.42	5.83e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.98	11.32	0.59	3.32e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg08873628	chr1:175162347	KIAA0040	-0.38	-5.34	-0.32	2.12e-7	Alcohol dependence;
KIRP	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg07395648	chr5:131743802	NA	-0.44	-6.3	-0.37	1.36e-9	Blood metabolite levels;
KIRP	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.76	-12.21	-0.61	4.01e-27	Monocyte percentage of white cells;
KIRP	trans	rs35100037	0.502	rs13356950	chr5:128450376	C/T	cg04903884	chr1:181031937	NA	-0.47	-6.03	-0.36	5.86e-9	Ankle injury;
KIRP	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.69	-7.86	-0.45	1.24e-13	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg10729496	chr3:10149963	C3orf24	0.54	5.02	0.31	9.71e-7	Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03655884	chr8:86230419	NA	-0.4	-6.87	-0.4	5.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs494003	0.951	rs11227283	chr11:65499022	C/T	cg11569703	chr11:65557185	OVOL1	-0.37	-4.86	-0.3	2.05e-6	Systemic lupus erythematosus;
KIRP	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.2	16.14	0.72	1.85e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg00277334	chr10:82204260	NA	-0.61	-6.19	-0.37	2.5e-9	Post bronchodilator FEV1;
KIRP	trans	rs10838634	1.000	rs9667108	chr11:46935185	G/C	cg09441501	chr11:798350	NA	-0.69	-6.05	-0.36	5.32e-9	Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14288266	chr2:204737672	CTLA4	-0.37	-6.02	-0.36	6.31e-9	Inflammatory biomarkers;
KIRP	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.49	-6.13	-0.36	3.55e-9	Facial morphology (factor 20);
KIRP	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.4	-4.96	-0.3	1.32e-6	Educational attainment (years of education);
KIRP	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg03714773	chr7:91764589	CYP51A1	0.34	5.03	0.31	9.6e-7	Breast cancer;
KIRP	cis	rs13185784	0.662	rs35759987	chr5:179679980	G/T	cg02891314	chr5:179741120	GFPT2	0.55	5.3	0.32	2.59e-7	TRAIL levels;
KIRP	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.49	-5.5	-0.33	9.46e-8	White matter hyperintensity burden;
KIRP	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.04	-0.31	9.07e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1010254	0.510	rs17446143	chr5:151697650	C/T	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-10.54	-0.56	1.11e-21	Morning vs. evening chronotype;
KIRP	cis	rs9915657	0.715	rs34624256	chr17:70105848	C/T	cg11350586	chr17:70115862	SOX9	0.38	5.1	0.31	6.75e-7	Thyroid hormone levels;
KIRP	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg24375607	chr4:120327624	NA	0.42	5.3	0.32	2.62e-7	Diastolic blood pressure;
KIRP	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.7	-10.43	-0.55	2.53e-21	Monocyte percentage of white cells;
KIRP	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	15.13	0.69	5.14e-37	Platelet count;
KIRP	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.79	10.37	0.55	4.01e-21	N-glycan levels;
KIRP	cis	rs918629	0.530	rs3777192	chr5:95246867	G/A	cg16656078	chr5:95278638	ELL2	-0.38	-5.82	-0.35	1.82e-8	IgG glycosylation;
KIRP	cis	rs6504950	0.566	rs12937360	chr17:53046298	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.52	6.1	0.36	4.19e-9	Breast cancer;
KIRP	cis	rs4728302	0.607	rs2042451	chr7:133593030	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.06	0.31	8.08e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.74	-0.39	1.15e-10	Type 2 diabetes;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09311052	chr1:154531418	UBE2Q1	0.54	7.19	0.42	7.57e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs7246760	1.000	rs112124298	chr19:9923154	T/C	cg02900749	chr2:68251473	NA	-0.9	-8.18	-0.46	1.55e-14	Pursuit maintenance gain;
KIRP	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg26876637	chr1:152193138	HRNR	0.72	9.89	0.53	1.26e-19	Atopic dermatitis;
KIRP	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg17376030	chr22:41985996	PMM1	0.58	6.45	0.38	5.77e-10	Vitiligo;
KIRP	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.56	-0.43	7.97e-13	Type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg09184832	chr6:79620586	NA	-0.53	-7.57	-0.43	7.4e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11217036	1	rs11217036	chr11:118675772	C/T	cg19308663	chr11:118741387	NA	0.59	9.86	0.53	1.53e-19	Allergy;
KIRP	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.59	7.35	0.42	2.86e-12	Homocysteine levels;
KIRP	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg11833968	chr6:79620685	NA	-0.38	-5.25	-0.32	3.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2599510	0.811	rs2583713	chr2:32822729	A/G	cg02381751	chr2:32503542	YIPF4	0.46	5.22	0.32	3.83e-7	Interleukin-18 levels;
KIRP	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.63	-9.01	-0.5	6.09e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15369054	chr17:80825471	TBCD	-0.47	-5.76	-0.34	2.53e-8	Breast cancer;
KIRP	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.84	-0.4	6.32e-11	Hemoglobin concentration;
KIRP	cis	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg21775007	chr8:11205619	TDH	-0.4	-5.06	-0.31	8.35e-7	Joint mobility (Beighton score);
KIRP	trans	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg06521331	chr12:34319734	NA	-0.57	-6.96	-0.41	3.14e-11	Morning vs. evening chronotype;
KIRP	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg03060546	chr3:49711283	APEH	-0.62	-6.44	-0.38	6.3e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1322639	0.614	rs9364356	chr6:169567108	G/A	cg04662567	chr6:169592167	NA	-0.72	-5.77	-0.35	2.43e-8	Pulse pressure;
KIRP	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg19610905	chr11:61596333	FADS2	-0.57	-8.71	-0.49	4.54e-16	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg08501292	chr6:25962987	TRIM38	0.82	5.22	0.32	3.85e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg02931644	chr1:25747376	RHCE	0.4	7.66	0.44	4.17e-13	Erythrocyte sedimentation rate;
KIRP	cis	rs75064307	0.603	rs35330061	chr3:108076563	C/T	cg14703454	chr3:108065259	HHLA2	0.53	6.39	0.38	8.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	9.69	0.53	5.11e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs13385	0.769	rs35543394	chr5:139592844	T/A	cg01860693	chr5:139557145	C5orf32	0.49	5.38	0.32	1.75e-7	Atrial fibrillation;
KIRP	cis	rs745080	1.000	rs1902865	chr14:52934139	T/A	cg23333723	chr14:53022898	GPR137C	-0.41	-5.65	-0.34	4.37e-8	Orofacial clefts;
KIRP	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs13006833	0.739	rs172366	chr2:191191233	G/T	cg27211696	chr2:191398769	TMEM194B	0.36	4.97	0.3	1.27e-6	Urinary metabolites;
KIRP	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.61	6.62	0.39	2.24e-10	Corneal astigmatism;
KIRP	cis	rs9912468	0.933	rs35433169	chr17:64322135	C/G	cg19474267	chr17:64306194	PRKCA	0.58	8.28	0.47	7.9e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.48	7.01	0.41	2.35e-11	Major depressive disorder;
KIRP	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.66	-0.63	1.31e-28	Chronic sinus infection;
KIRP	cis	rs6499255	0.904	rs74029403	chr16:69710472	A/C	cg15192750	chr16:69999425	NA	0.51	5.22	0.32	3.87e-7	IgE levels;
KIRP	cis	rs2591576	0.673	rs12518411	chr5:165420944	C/G	cg13976338	chr5:165423657	NA	-0.84	-13.17	-0.64	2.42e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.65	-8.18	-0.46	1.54e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9646944	0.636	rs72820194	chr2:102878108	C/T	cg22835712	chr2:102737379	NA	0.43	4.99	0.3	1.14e-6	Blood protein levels;
KIRP	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg05044414	chr3:183734942	ABCC5	0.34	5.03	0.31	9.41e-7	Anterior chamber depth;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.73	0.44	2.69e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg05361325	chr10:32636312	EPC1	-0.65	-6.14	-0.36	3.3e-9	Sexual dysfunction (female);
KIRP	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg17724175	chr1:150552817	MCL1	-0.35	-6.02	-0.36	6.19e-9	Tonsillectomy;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.95	16.64	0.73	3.78e-42	Longevity;Endometriosis;
KIRP	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.77	9.31	0.51	7.4e-18	Response to antipsychotic treatment;
KIRP	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.55	-7.33	-0.42	3.23e-12	Red blood cell count;
KIRP	cis	rs1062753	0.731	rs11914200	chr22:42378070	G/A	cg22189786	chr22:42395067	WBP2NL	0.44	5.32	0.32	2.3e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg24747557	chr10:131355152	MGMT	0.37	5.11	0.31	6.59e-7	Response to temozolomide;
KIRP	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.54	7.87	0.45	1.12e-13	Itch intensity from mosquito bite;
KIRP	trans	rs1864585	0.520	rs73200724	chr8:10592331	G/T	cg26278703	chr11:58910052	FAM111A	0.64	6.49	0.38	4.68e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs55675132	0.548	rs12120506	chr1:115377777	C/T	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs2625529	0.730	rs6494990	chr15:72401074	T/A	cg16672083	chr15:72433130	SENP8	0.46	6.29	0.37	1.48e-9	Red blood cell count;
KIRP	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.75	11.26	0.58	5.36e-24	Oral cavity cancer;
KIRP	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg16296679	chr22:42394374	WBP2NL	0.36	4.99	0.3	1.15e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7929679	0.602	rs10836310	chr11:34808920	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.34e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs6681460	0.966	rs4655646	chr1:67094336	G/A	cg13052034	chr1:66999238	SGIP1	0.4	5.41	0.33	1.51e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg08992911	chr2:238395768	MLPH	0.55	5.29	0.32	2.75e-7	Prostate cancer;
KIRP	cis	rs1519814	0.915	rs6992410	chr8:121113566	T/G	cg22335954	chr8:121166405	COL14A1	-0.59	-5.99	-0.36	7.34e-9	Breast cancer;
KIRP	cis	rs6960043	0.936	rs62448618	chr7:15052211	T/A	cg19272540	chr7:15055459	NA	-0.22	-5.94	-0.35	9.7e-9	Type 2 diabetes;
KIRP	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs780094	0.500	rs7577311	chr2:27793921	G/T	cg05484376	chr2:27715224	FNDC4	-0.37	-5.53	-0.33	8.04e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs10203711	0.933	rs10180937	chr2:239597184	A/G	cg14580085	chr2:239553406	NA	0.39	5.16	0.31	5.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12043259	0.730	rs10458592	chr1:204792280	A/C	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs7246865	0.954	rs10427132	chr19:17207156	T/G	cg18440316	chr19:18077727	KCNN1	-0.41	-5.81	-0.35	1.95e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.56	-0.39	3.19e-10	Response to antipsychotic treatment;
KIRP	cis	rs1021993	0.545	rs79212878	chr1:209547417	G/A	cg24446417	chr1:209558027	NA	-0.49	-5.27	-0.32	2.99e-7	Gut microbiome composition (winter);
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.62e-11	Lung cancer;
KIRP	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-7.55	-0.43	8.6e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.67	0.71	7.37e-39	Chronic sinus infection;
KIRP	cis	rs3744061	0.505	rs60239313	chr17:74647586	T/C	cg27546012	chr17:74684504	MXRA7	-0.44	-5.38	-0.32	1.71e-7	Retinal arteriolar caliber;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04127825	chr1:167503222	NA	0.52	6.33	0.37	1.15e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg04837898	chr3:45731254	SACM1L	0.37	4.96	0.3	1.29e-6	Hirschsprung disease;
KIRP	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.98	-0.5	7.26e-17	Retinal vascular caliber;
KIRP	cis	rs357618	0.581	rs165359	chr5:150861036	G/A	cg22672639	chr5:150884813	FAT2	0.43	5.72	0.34	3.07e-8	Basophil percentage of white cells;
KIRP	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.46	-5.74	-0.34	2.82e-8	Crohn's disease;
KIRP	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-11.85	-0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs1318772	0.932	rs7705255	chr5:112950169	C/A	cg12552261	chr5:112820674	MCC	0.78	5.28	0.32	2.89e-7	F-cell distribution;
KIRP	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.06	-0.36	5.02e-9	Mean corpuscular volume;
KIRP	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	cg10932868	chr11:921992	NA	0.51	5.74	0.34	2.73e-8	Alzheimer's disease (late onset);
KIRP	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.45	-5.9	-0.35	1.19e-8	Renal cell carcinoma;
KIRP	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg26354017	chr1:205819088	PM20D1	0.46	5.22	0.32	3.83e-7	Parkinson's disease;
KIRP	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-0.97	-7.7	-0.44	3.23e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6690583	0.623	rs7522239	chr1:85484366	C/T	cg22153463	chr1:85462885	MCOLN2	0.61	5.3	0.32	2.51e-7	Serum sulfate level;
KIRP	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.94	0.54	8.89e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.8	7.65	0.44	4.44e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17830980	chr10:43048298	ZNF37B	-0.51	-7.36	-0.42	2.67e-12	Breast cancer;
KIRP	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg03834567	chr2:218808745	TNS1	0.45	5.44	0.33	1.28e-7	Ulcerative colitis;
KIRP	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg07256732	chr16:621771	PIGQ	-0.46	-6.24	-0.37	1.93e-9	Height;
KIRP	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg24579218	chr15:68104479	NA	-0.42	-5.94	-0.35	9.58e-9	Obesity;
KIRP	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.73	-8.55	-0.48	1.29e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg09264619	chr17:80180166	NA	-0.39	-5.64	-0.34	4.72e-8	Life satisfaction;
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.72	6.05	0.36	5.37e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.14	0.36	3.35e-9	Blood metabolite levels;
KIRP	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.44	-0.43	1.68e-12	Retinal vascular caliber;
KIRP	cis	rs3784262	0.647	rs2414529	chr15:58317094	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.96	-0.3	1.33e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	7.67	0.44	4.05e-13	Total body bone mineral density;
KIRP	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.79	9.08	0.5	3.7e-17	Menarche (age at onset);
KIRP	cis	rs12712073	0.512	rs6710355	chr2:100699994	T/C	cg22139774	chr2:100720529	AFF3	-0.3	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1867631	1.000	rs10889640	chr1:67127851	G/A	cg13052034	chr1:66999238	SGIP1	0.47	6.63	0.39	2.11e-10	Menopause (age at onset);
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.56	-6.5	-0.38	4.32e-10	Menopause (age at onset);
KIRP	cis	rs8067287	0.546	rs62065425	chr17:16828711	C/T	cg26910001	chr17:16838321	NA	-0.61	-5.9	-0.35	1.18e-8	Diabetic kidney disease;
KIRP	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	5.91	0.35	1.13e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-6.97	-0.41	2.86e-11	Height;
KIRP	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg20387954	chr3:183756860	HTR3D	0.41	5.19	0.31	4.45e-7	Anterior chamber depth;
KIRP	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg02002194	chr4:3960332	NA	0.43	6.23	0.37	1.96e-9	Triglycerides;
KIRP	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14159672	chr1:205819179	PM20D1	-0.56	-5.59	-0.34	6.11e-8	Menarche (age at onset);
KIRP	cis	rs9513627	0.833	rs73556129	chr13:100113167	C/T	cg25919922	chr13:100150906	NA	-0.69	-5.31	-0.32	2.41e-7	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02725872	chr8:58115012	NA	-0.54	-6.28	-0.37	1.52e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4006360	0.686	rs1848814	chr17:39240281	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.55	-8.44	-0.47	2.72e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.55	0.33	7.35e-8	Lung cancer;
KIRP	cis	rs4363385	0.510	rs11577384	chr1:152899728	C/T	cg13444842	chr1:152974279	SPRR3	-0.47	-6.66	-0.39	1.77e-10	Inflammatory skin disease;
KIRP	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs12936587	0.748	rs62066210	chr17:17520978	C/T	cg01246520	chr17:17644344	RAI1	-0.35	-5.45	-0.33	1.21e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs1023500	1.000	rs6002552	chr22:42338351	G/A	cg04733989	chr22:42467013	NAGA	-0.5	-5.46	-0.33	1.18e-7	Schizophrenia;
KIRP	cis	rs4950322	0.570	rs72692904	chr1:146773136	T/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.38	-0.32	1.77e-7	Protein quantitative trait loci;
KIRP	cis	rs2380205	0.967	rs12774966	chr10:5898098	G/T	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.12e-8	Breast cancer;
KIRP	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-5.96	-0.36	8.52e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7082209	0.941	rs67379075	chr10:44811968	A/C	cg13191911	chr10:44806660	NA	-0.52	-5.25	-0.32	3.26e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.07	-11.89	-0.6	4.66e-26	Mitochondrial DNA levels;
KIRP	cis	rs10203711	1.000	rs6716457	chr2:239577621	C/T	cg14580085	chr2:239553406	NA	0.39	5.15	0.31	5.34e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg18815343	chr6:28367644	ZSCAN12	-0.41	-5.96	-0.36	8.73e-9	Pubertal anthropometrics;
KIRP	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.69	9.84	0.53	1.78e-19	Bladder cancer;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.78	6.83	0.4	6.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg03959625	chr15:84868606	LOC388152	0.5	6.0	0.36	6.84e-9	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.55	5.43	0.33	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg15038512	chr6:170123185	PHF10	-0.56	-8.58	-0.48	1.08e-15	Obesity-related traits;
KIRP	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.61	-0.39	2.35e-10	Total body bone mineral density;
KIRP	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	7.59	0.44	6.78e-13	Neuroticism;
KIRP	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.06	0.54	3.67e-20	Lung cancer in ever smokers;
KIRP	cis	rs7640424	0.691	rs17231712	chr3:107829562	C/G	cg09227934	chr3:107805635	CD47	0.3	5.16	0.31	5.19e-7	Body mass index;
KIRP	cis	rs10073892	0.703	rs9327821	chr5:101637995	A/G	cg19774478	chr5:101632501	SLCO4C1	-0.62	-6.36	-0.38	9.98e-10	Cognitive decline (age-related);
KIRP	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.6	8.27	0.47	8.6e-15	Schizophrenia;
KIRP	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.36	-4.96	-0.3	1.34e-6	Neuroticism;
KIRP	cis	rs6752107	0.840	rs2119505	chr2:234154651	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.51	6.76	0.4	9.97e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs7561273	0.609	rs10200844	chr2:24293363	A/C	cg20701182	chr2:24300061	SF3B14	0.44	5.41	0.33	1.5e-7	Quantitative traits;
KIRP	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.58	-7.53	-0.43	9.41e-13	Aortic root size;
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.41	6.39	0.38	8.24e-10	Lung cancer;
KIRP	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.62	-8.78	-0.49	2.77e-16	Colorectal cancer;
KIRP	cis	rs35123781	0.955	rs34530707	chr5:139059016	G/A	cg10513866	chr5:139070639	NA	0.35	4.93	0.3	1.53e-6	Schizophrenia;
KIRP	cis	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg13789015	chr9:136890014	NCRNA00094	0.67	5.79	0.35	2.19e-8	Mosquito bite size;
KIRP	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg00310523	chr12:86230176	RASSF9	0.52	8.26	0.47	8.86e-15	Major depressive disorder;
KIRP	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.59	8.48	0.48	2.17e-15	Mean corpuscular volume;
KIRP	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.64	8.14	0.46	2.04e-14	Prudent dietary pattern;
KIRP	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg19847130	chr8:10466454	RP1L1	-0.32	-4.87	-0.3	2.04e-6	Triglycerides;
KIRP	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.33	-0.47	5.72e-15	Urinary metabolites;
KIRP	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.87	-0.53	1.41e-19	Height;
KIRP	trans	rs4332037	0.530	rs62434669	chr7:1866946	G/A	cg11693508	chr17:37793320	STARD3	0.71	6.88	0.4	5e-11	Bipolar disorder;
KIRP	cis	rs7565981	1.000	rs11891990	chr2:101427480	G/A	cg02232089	chr2:101440696	NPAS2	-0.6	-5.47	-0.33	1.09e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg07777115	chr5:623756	CEP72	-0.53	-5.7	-0.34	3.5e-8	Lung disease severity in cystic fibrosis;
KIRP	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.17	-16.12	-0.72	2.23e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs8133932	0.521	rs1625244	chr21:47364499	C/T	cg11214348	chr21:47283868	PCBP3	-0.43	-5.04	-0.31	9.05e-7	Schizophrenia;
KIRP	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.04	0.36	5.55e-9	Neuroticism;
KIRP	cis	rs911119	1.000	rs3787498	chr20:23616781	C/T	cg16589663	chr20:23618590	CST3	0.72	6.74	0.4	1.09e-10	Chronic kidney disease;
KIRP	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.33e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13973351	chr11:60928923	VPS37C	-0.45	-6.35	-0.38	1.06e-9	Metabolic traits;
KIRP	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	1.09	7.88	0.45	1.04e-13	Skin colour saturation;
KIRP	cis	rs78487399	0.908	rs17031088	chr2:43807090	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.27	-0.32	3.04e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7809615	0.901	rs10215765	chr7:99101280	G/C	cg24024660	chr7:99195788	NA	-0.54	-4.92	-0.3	1.57e-6	Blood metabolite ratios;
KIRP	cis	rs12496230	0.794	rs12635644	chr3:66859046	C/T	cg17646820	chr3:66848679	NA	0.4	6.5	0.38	4.4e-10	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10705386	chr10:69644512	SIRT1	0.46	6.06	0.36	4.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6901004	0.805	rs354532	chr6:111548813	C/T	cg15721981	chr6:111408429	SLC16A10	-0.51	-6.88	-0.4	4.93e-11	Blood metabolite levels;
KIRP	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.52	6.05	0.36	5.3e-9	Aortic root size;
KIRP	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg04058563	chr4:185651563	MLF1IP	0.66	6.66	0.39	1.75e-10	Type 2 diabetes;
KIRP	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.3	-0.32	2.57e-7	Bladder cancer;
KIRP	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14598338	chr9:96623480	NA	0.6	9.07	0.5	3.79e-17	DNA methylation (variation);
KIRP	cis	rs9290877	0.667	rs9864167	chr3:188456896	T/C	cg17392043	chr3:188495102	LPP	-0.49	-6.45	-0.38	5.99e-10	IgE levels;
KIRP	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.34	0.32	2.1e-7	Breast cancer;
KIRP	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.53	0.38	3.69e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27121095	chr18:77155145	NFATC1	0.42	6.23	0.37	2.02e-9	Parkinson's disease;
KIRP	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.63	7.03	0.41	2.02e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg10790698	chr19:18539756	SSBP4	-0.34	-7.34	-0.42	3.11e-12	Breast cancer;
KIRP	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.81	10.72	0.56	3.07e-22	Breast cancer;
KIRP	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg08975724	chr8:8085496	FLJ10661	0.66	8.22	0.46	1.2e-14	Neuroticism;
KIRP	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.19	0.31	4.4e-7	Educational attainment;
KIRP	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.74	-8.9	-0.49	1.23e-16	Blood pressure (smoking interaction);
KIRP	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg10503236	chr1:231470652	EXOC8	-0.49	-6.73	-0.39	1.16e-10	Hemoglobin concentration;
KIRP	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	6.78	0.4	8.81e-11	LDL cholesterol;
KIRP	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs909341	0.909	rs2253829	chr20:62373079	G/C	cg01311341	chr22:25575246	KIAA1671	-0.59	-6.73	-0.39	1.15e-10	Atopic dermatitis;
KIRP	cis	rs2411233	1.000	rs12910426	chr15:39278738	A/G	cg02291532	chr15:39874776	THBS1	0.39	5.26	0.32	3.17e-7	Platelet count;
KIRP	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	5.01	0.3	1.06e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-9.31	-0.51	7.41e-18	Morning vs. evening chronotype;
KIRP	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.31	8.0	0.45	4.74e-14	Primary biliary cholangitis;
KIRP	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.36	-0.42	2.74e-12	Morning vs. evening chronotype;
KIRP	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg11965913	chr1:205819406	PM20D1	-0.6	-5.89	-0.35	1.26e-8	Menarche (age at onset);
KIRP	cis	rs9788682	0.948	rs905739	chr15:78845110	A/G	cg06917634	chr15:78832804	PSMA4	-0.62	-6.63	-0.39	2.06e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.11	0.36	3.91e-9	Vitiligo;
KIRP	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.62	6.88	0.4	4.81e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg14092571	chr14:90743983	NA	-0.41	-5.4	-0.33	1.54e-7	Mortality in heart failure;
KIRP	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.67	-0.34	3.96e-8	Cardiac Troponin-T levels;
KIRP	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.34	-0.32	2.11e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.87	-0.45	1.12e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg20637307	chr2:213403960	ERBB4	-0.54	-7.21	-0.42	6.68e-12	Symmetrical dimethylarginine levels;
KIRP	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.47e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.59	7.79	0.45	1.83e-13	Colorectal cancer;
KIRP	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-1.31	-12.69	-0.63	9.91e-29	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg01028140	chr2:1542097	TPO	-0.57	-6.2	-0.37	2.38e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.44	5.53	0.33	8.36e-8	Platelet count;
KIRP	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.87	13.2	0.64	1.97e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs62355272	0.965	rs700179	chr5:35879595	A/G	cg13894535	chr5:35919491	CAPSL	-0.42	-5.25	-0.32	3.33e-7	Lymphocyte counts;
KIRP	cis	rs9469913	0.799	rs9469890	chr6:34763982	C/T	cg17674042	chr6:34482479	PACSIN1	-0.38	-5.17	-0.31	4.73e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1461503	0.900	rs7115852	chr11:122831830	G/A	cg27398637	chr11:122830231	C11orf63	-0.71	-9.68	-0.53	5.36e-19	Menarche (age at onset);
KIRP	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg08888203	chr3:10149979	C3orf24	0.5	5.02	0.3	9.8e-7	Alzheimer's disease;
KIRP	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs16857609	0.564	rs12624106	chr2:218290445	A/G	cg15335768	chr2:218268053	DIRC3	-0.53	-6.92	-0.4	3.98e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg11764359	chr7:65958608	NA	0.78	5.12	0.31	6.21e-7	Diabetic kidney disease;
KIRP	cis	rs7719624	0.680	rs1442	chr5:135382989	G/C	cg00308130	chr5:135415190	NA	-0.31	-4.9	-0.3	1.71e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.67	7.12	0.41	1.15e-11	Lymphocyte counts;
KIRP	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg17376030	chr22:41985996	PMM1	-0.54	-6.19	-0.37	2.5e-9	Vitiligo;
KIRP	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.5	-0.38	4.42e-10	Aortic root size;
KIRP	cis	rs526231	0.511	rs62362558	chr5:102368493	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.2	-0.31	4.26e-7	Primary biliary cholangitis;
KIRP	cis	rs9427116	0.875	rs11264233	chr1:154625632	C/T	cg24304309	chr1:154577895	ADAR	0.33	5.0	0.3	1.1e-6	Blood protein levels;
KIRP	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	4.8e-11	Aortic root size;
KIRP	cis	rs731174	0.959	rs7546741	chr1:38191397	G/C	cg06917450	chr1:38156652	C1orf109	-0.41	-4.94	-0.3	1.44e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-1.04	-12.83	-0.63	3.43e-29	Breast cancer;
KIRP	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg20607798	chr8:58055168	NA	0.59	5.4	0.33	1.59e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.59	-7.62	-0.44	5.36e-13	Vitiligo;
KIRP	cis	rs654950	0.840	rs116241899	chr1:41994546	T/C	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.47	-0.38	5.23e-10	Airway imaging phenotypes;
KIRP	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.48	-5.81	-0.35	1.93e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs6973256	0.637	rs1362739	chr7:133430934	C/A	cg10665199	chr7:133106180	EXOC4	0.48	6.02	0.36	6.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg14703610	chr5:56206110	C5orf35	0.51	7.15	0.41	1e-11	Coronary artery disease;
KIRP	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg27490568	chr2:178487706	NA	0.61	7.78	0.44	1.97e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg23479056	chr15:41276147	INO80	-0.41	-5.96	-0.35	8.92e-9	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg23594656	chr7:65796392	TPST1	0.52	8.1	0.46	2.56e-14	Aortic root size;
KIRP	cis	rs16976116	0.951	rs8043029	chr15:55486011	C/G	cg11288833	chr15:55489084	RSL24D1	0.66	7.52	0.43	1.03e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.59	8.22	0.46	1.17e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7113874	0.802	rs35319120	chr11:8669694	C/T	cg08015107	chr11:8618950	NA	-0.42	-5.46	-0.33	1.16e-7	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg18366169	chr5:1948875	NA	0.43	4.97	0.3	1.28e-6	Gut microbiome composition (winter);
KIRP	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.98	-15.86	-0.71	1.69e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.34	-4.97	-0.3	1.25e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1712517	0.525	rs11191642	chr10:105055912	A/G	cg04362960	chr10:104952993	NT5C2	-0.59	-7.36	-0.42	2.69e-12	Migraine;
KIRP	trans	rs12545912	0.770	rs7822700	chr8:9540854	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.1	-0.36	4.19e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-6.83	-0.4	6.49e-11	Response to antipsychotic treatment;
KIRP	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg21253087	chr9:139290292	SNAPC4	0.46	6.47	0.38	5.29e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.05	-0.31	8.71e-7	Triglycerides;
KIRP	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.31	0.37	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.01	0.3	1.03e-6	Breast cancer;
KIRP	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg22771759	chr13:24902376	NA	0.38	4.96	0.3	1.32e-6	Obesity-related traits;
KIRP	trans	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg10756647	chr7:56101905	PSPH	0.92	6.68	0.39	1.58e-10	Diabetic kidney disease;
KIRP	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg01304814	chr3:48885189	PRKAR2A	0.64	5.05	0.31	8.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg26408565	chr15:76604113	ETFA	-0.43	-5.79	-0.35	2.16e-8	Blood metabolite levels;
KIRP	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg09873164	chr1:152488093	CRCT1	0.57	7.68	0.44	3.7e-13	Hair morphology;
KIRP	cis	rs7700895	0.737	rs3777184	chr5:95262044	G/C	cg16656078	chr5:95278638	ELL2	-0.39	-5.94	-0.35	9.81e-9	IgG glycosylation;
KIRP	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg15839431	chr19:19639596	YJEFN3	-0.53	-5.42	-0.33	1.4e-7	Bipolar disorder;
KIRP	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg03563238	chr19:33554763	RHPN2	-0.33	-5.62	-0.34	5.2e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2290402	0.536	rs73207791	chr4:865941	A/G	cg00846425	chr4:957561	DGKQ	-0.47	-4.98	-0.3	1.21e-6	Type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17482927	chr17:63133259	RGS9	0.56	7.17	0.42	8.61e-12	Smoking initiation;
KIRP	cis	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.23e-12	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg09699651	chr6:150184138	LRP11	0.44	5.7	0.34	3.4e-8	Lung cancer;
KIRP	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.79	6.78	0.4	8.78e-11	Mean platelet volume;
KIRP	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-0.97	-14.04	-0.67	2.83e-33	Blood trace element (Zn levels);
KIRP	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg02002194	chr4:3960332	NA	0.46	6.63	0.39	2.08e-10	Triglycerides;
KIRP	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	0.86	6.91	0.4	4.1e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-6.59	-0.39	2.7e-10	Mean platelet volume;
KIRP	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6991838	0.557	rs13266834	chr8:66543538	C/A	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.22e-7	Life satisfaction;
KIRP	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.62	-0.44	5.63e-13	Mood instability;
KIRP	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg02896835	chr1:92012615	NA	0.5	5.17	0.31	4.79e-7	Eosinophil percentage of white cells;
KIRP	cis	rs7975161	0.786	rs10861181	chr12:104651110	T/C	cg25273343	chr12:104657179	TXNRD1	-0.62	-5.99	-0.36	7.46e-9	Toenail selenium levels;
KIRP	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.44	-0.33	1.29e-7	Total body bone mineral density;
KIRP	cis	rs921943	0.957	rs6860801	chr5:78310914	C/G	cg26802063	chr5:78281964	ARSB	0.5	6.28	0.37	1.54e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	trans	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.44	-6.4	-0.38	7.88e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.52	0.48	1.64e-15	Motion sickness;
KIRP	cis	rs13359291	0.658	rs10077410	chr5:122450771	G/A	cg16368670	chr5:122501738	PRDM6	-0.45	-5.1	-0.31	6.88e-7	Systolic blood pressure;
KIRP	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.75	-9.86	-0.53	1.54e-19	Huntington's disease progression;
KIRP	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg24296786	chr1:45957014	TESK2	-0.65	-8.67	-0.48	5.76e-16	High light scatter reticulocyte count;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26413827	chr13:72441184	DACH1	-0.45	-6.17	-0.37	2.74e-9	Migraine with aura;
KIRP	cis	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg11502198	chr6:26597334	ABT1	-0.87	-5.32	-0.32	2.33e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg16141378	chr3:129829833	LOC729375	-0.59	-7.41	-0.43	2e-12	Mood instability;
KIRP	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.98	13.61	0.66	8.14e-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8018808	1.000	rs4903577	chr14:77847258	C/T	cg20045696	chr14:77926864	AHSA1	-0.42	-5.12	-0.31	6.09e-7	Myeloid white cell count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07254608	chr8:41997973	NA	0.63	7.64	0.44	4.94e-13	Smoking initiation;
KIRP	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.6	-6.22	-0.37	2.06e-9	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.86e-15	Prudent dietary pattern;
KIRP	trans	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg19694781	chr19:47549865	TMEM160	0.58	7.73	0.44	2.82e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg00405596	chr8:11794950	NA	-0.47	-6.09	-0.36	4.26e-9	Triglycerides;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09007161	chr11:22647650	FANCF	1.0	6.2	0.37	2.41e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.6	-8.45	-0.47	2.53e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs6752107	0.901	rs11679791	chr2:234156536	G/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.18	0.37	2.66e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.44	5.59	0.34	6.07e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg15247329	chr7:2764246	NA	-0.36	-5.03	-0.31	9.28e-7	Height;
KIRP	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.49	0.48	1.94e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	13.65	0.66	6.07e-32	Platelet count;
KIRP	trans	rs60752752	0.852	rs3014878	chr1:153343178	C/T	cg00420347	chr1:65362428	JAK1	0.71	6.47	0.38	5.4e-10	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs6987853	0.865	rs2923445	chr8:42400743	C/A	cg09913449	chr8:42400586	C8orf40	0.37	4.9	0.3	1.75e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6977660	0.607	rs7357321	chr7:19817636	C/T	cg05791153	chr7:19748676	TWISTNB	0.54	5.51	0.33	8.88e-8	Thyroid stimulating hormone;
KIRP	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	cis	rs6061231	0.571	rs482010	chr20:60927551	A/G	cg24112000	chr20:60950667	NA	0.59	9.32	0.51	6.98e-18	Colorectal cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg21684385	chr6:143772210	ADAT2;PEX3	0.77	6.54	0.38	3.45e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs13102973	0.932	rs11099305	chr4:135895569	C/G	cg14419869	chr4:135874104	NA	0.5	8.3	0.47	6.96e-15	Subjective well-being;
KIRP	trans	rs7999699	0.902	rs9534794	chr13:48316558	A/T	cg23237801	chr1:16476620	EPHA2	-0.49	-6.22	-0.37	2.17e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs7000551	0.659	rs2280521	chr8:22271995	G/T	cg13512537	chr8:22265999	SLC39A14	0.38	4.86	0.3	2.08e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg23594656	chr7:65796392	TPST1	0.46	7.24	0.42	5.73e-12	Aortic root size;
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg11204139	chr17:3907470	NA	-0.81	-14.65	-0.68	2.28e-35	Type 2 diabetes;
KIRP	cis	rs501120	0.584	rs1704218	chr10:44729599	C/T	cg09554077	chr10:44749378	NA	0.65	6.73	0.39	1.21e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg17425144	chr1:10567563	PEX14	0.45	8.43	0.47	2.94e-15	Breast cancer;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg23156509	chr2:114033830	PAX8;LOC440839	-0.37	-5.6	-0.34	5.72e-8	Lymphocyte counts;
KIRP	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg26924012	chr15:45694286	SPATA5L1	0.58	7.03	0.41	2.08e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.67	0.39	1.64e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13401104	0.796	rs1377446	chr2:237119668	A/G	cg19324714	chr2:237145437	ASB18	-0.48	-5.04	-0.31	8.97e-7	Educational attainment;
KIRP	cis	rs2979489	0.786	rs1106352	chr8:30404671	C/T	cg26383811	chr8:30366931	RBPMS	-0.43	-5.97	-0.36	8.4e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg19554555	chr3:13937349	NA	-0.46	-6.28	-0.37	1.49e-9	Ovarian reserve;
KIRP	cis	rs3105593	1.000	rs3131585	chr15:50845796	C/G	cg05456662	chr15:50716270	USP8	0.39	4.98	0.3	1.19e-6	QT interval;
KIRP	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg04369109	chr6:150039330	LATS1	-0.59	-7.41	-0.43	1.98e-12	Lung cancer;
KIRP	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg20991723	chr1:152506922	NA	-0.42	-5.04	-0.31	9.04e-7	Hair morphology;
KIRP	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.68	-8.53	-0.48	1.52e-15	Recalcitrant atopic dermatitis;
KIRP	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg20243544	chr17:37824526	PNMT	0.48	6.97	0.41	2.88e-11	Asthma;
KIRP	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.83	-11.61	-0.59	3.9e-25	Autism;
KIRP	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-6.83	-0.4	6.8e-11	Mean platelet volume;
KIRP	cis	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg00405596	chr8:11794950	NA	0.43	5.2	0.31	4.29e-7	Neuroticism;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg23131131	chr22:24373011	LOC391322	0.63	6.52	0.38	3.92e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.12	-0.46	2.31e-14	Monocyte percentage of white cells;
KIRP	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	11.54	0.59	6.6e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg15128208	chr22:42549153	NA	0.75	8.08	0.46	2.93e-14	Birth weight;
KIRP	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.75	-0.34	2.68e-8	Bipolar disorder;
KIRP	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.39	-0.68	1.75e-34	Alzheimer's disease;
KIRP	cis	rs7129556	0.728	rs34130561	chr11:77496691	A/T	cg12586386	chr11:77299805	AQP11	0.44	5.23	0.32	3.71e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg10381502	chr11:71823885	C11orf51	-1.03	-7.17	-0.42	8.64e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs986417	1.000	rs12147690	chr14:60924009	A/G	cg27398547	chr14:60952738	C14orf39	0.74	7.43	0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg19468946	chr17:37922297	IKZF3	-0.43	-6.26	-0.37	1.66e-9	Asthma;
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.11e-7	Life satisfaction;
KIRP	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.82	-11.62	-0.6	3.53e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs3087591	0.639	rs757378	chr17:29722619	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.6	-8.8	-0.49	2.49e-16	Hip circumference;
KIRP	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.41	-0.43	1.97e-12	Gut microbiome composition (summer);
KIRP	cis	rs5753037	0.838	rs140149	chr22:30185613	C/T	cg27665648	chr22:30112403	NA	0.45	6.17	0.37	2.83e-9	Type 1 diabetes;
KIRP	cis	rs2882667	0.898	rs11749944	chr5:138412779	T/C	cg04439458	chr5:138467593	SIL1	-0.45	-7.46	-0.43	1.45e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14431266	chr11:67057003	ANKRD13D	-0.49	-6.19	-0.37	2.47e-9	Neuroticism;
KIRP	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg13010199	chr12:38710504	ALG10B	-0.55	-7.44	-0.43	1.67e-12	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg13047869	chr3:10149882	C3orf24	0.54	5.3	0.32	2.63e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg18209359	chr17:80159595	CCDC57	0.41	5.34	0.32	2.11e-7	Life satisfaction;
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg07404485	chr7:94953653	PON1	-0.55	-7.45	-0.43	1.58e-12	Paraoxonase activity;
KIRP	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg03788504	chr6:150331562	NA	0.36	6.82	0.4	6.98e-11	Alopecia areata;
KIRP	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg08198773	chr8:1697536	NA	0.41	5.28	0.32	2.86e-7	Systolic blood pressure;
KIRP	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.41	5.26	0.32	3.15e-7	Birth weight;
KIRP	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg07689907	chr11:61582574	FADS1	0.48	6.01	0.36	6.59e-9	LDL cholesterol;
KIRP	cis	rs7945071	0.507	rs11213398	chr11:110301799	A/G	cg04157658	chr11:110243994	NA	0.32	5.11	0.31	6.48e-7	Cognitive function;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13412395	chr9:102583693	NR4A3	0.57	6.72	0.39	1.28e-10	Smoking initiation;
KIRP	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.39	-5.17	-0.31	4.96e-7	Body mass index;
KIRP	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.88	13.29	0.65	9.69e-31	Eosinophil percentage of white cells;
KIRP	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg13264159	chr8:625131	ERICH1	-0.84	-7.04	-0.41	1.87e-11	IgG glycosylation;
KIRP	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg10434728	chr15:90938212	IQGAP1	-0.4	-6.8	-0.4	7.97e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs6696239	0.794	rs11588850	chr1:227927242	A/G	cg27395484	chr1:227557617	NA	0.59	4.97	0.3	1.23e-6	Height;
KIRP	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.49	-0.43	1.21e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.43	5.56	0.33	6.85e-8	Blood metabolite levels;
KIRP	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg17279839	chr7:150038598	RARRES2	0.46	6.11	0.36	3.81e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8077059	0.959	rs3883322	chr17:55820399	G/A	cg12582317	chr17:55822272	NA	0.4	4.99	0.3	1.12e-6	Sex hormone-binding globulin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20757519	chr18:5238310	LOC339290;C18orf18	0.49	6.06	0.36	5.01e-9	Parkinson's disease;
KIRP	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg16512390	chr1:228756714	NA	0.74	6.01	0.36	6.54e-9	Chronic lymphocytic leukemia;
KIRP	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg03929089	chr4:120376271	NA	0.68	6.64	0.39	1.96e-10	Axial length;
KIRP	cis	rs34245846	0.769	rs12084791	chr1:154824973	A/G	cg06221963	chr1:154839813	KCNN3	0.52	5.46	0.33	1.14e-7	Atrial fibrillation;
KIRP	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg14664628	chr15:75095509	CSK	-0.62	-7.33	-0.42	3.38e-12	Caffeine consumption;
KIRP	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg11906718	chr8:101322791	RNF19A	-0.57	-7.39	-0.43	2.31e-12	Atrioventricular conduction;
KIRP	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.86	-11.24	-0.58	6.5e-24	Cognitive function;
KIRP	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.44	0.33	1.29e-7	Initial pursuit acceleration;
KIRP	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg21088686	chr8:109094228	RSPO2	0.41	5.64	0.34	4.77e-8	Dupuytren's disease;
KIRP	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg24631222	chr15:78858424	CHRNA5	-0.81	-9.6	-0.52	1e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.73	9.03	0.5	5.25e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg08533424	chr17:37009973	RPL23;SNORA21	0.95	6.38	0.38	8.93e-10	P wave terminal force;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg17441377	chr17:3906640	NA	-0.53	-7.98	-0.45	5.64e-14	Type 2 diabetes;
KIRP	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg25486957	chr4:152246857	NA	-0.49	-5.64	-0.34	4.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.28	-17.7	-0.75	8.74e-46	Corneal structure;
KIRP	cis	rs9659323	0.689	rs10923716	chr1:119536119	C/T	cg05756136	chr1:119680316	WARS2	-0.43	-5.61	-0.34	5.51e-8	Body mass index;
KIRP	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.72	-9.39	-0.51	4.13e-18	Breast size;
KIRP	cis	rs7187994	0.848	rs62050862	chr16:84781949	G/A	cg07647771	chr16:84786436	USP10	-0.43	-5.55	-0.33	7.48e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7630877	0.853	rs56263652	chr3:179631004	T/C	cg18765712	chr3:179670323	PEX5L	0.5	5.95	0.35	9.15e-9	Type 2 diabetes;
KIRP	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.6	-0.34	5.73e-8	Colorectal cancer;
KIRP	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.68	8.9	0.49	1.29e-16	Motion sickness;
KIRP	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg19507638	chr5:93509721	C5orf36	-0.52	-4.96	-0.3	1.32e-6	Diabetic retinopathy;
KIRP	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.57	8.2	0.46	1.38e-14	Carotid intima media thickness;
KIRP	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg16497661	chr14:103986332	CKB	-0.5	-6.44	-0.38	6.09e-10	Coronary artery disease;
KIRP	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg18478394	chr8:109455254	TTC35	0.52	6.55	0.39	3.32e-10	Dupuytren's disease;
KIRP	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.75	-7.59	-0.44	6.44e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.63	12.23	0.61	3.57e-27	Bone mineral density;
KIRP	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.69	-9.3	-0.51	8.19e-18	Lymphocyte counts;
KIRP	cis	rs2554380	0.843	rs7182216	chr15:84422506	C/G	cg14598478	chr15:84363061	ADAMTSL3	0.54	7.47	0.43	1.43e-12	Height;
KIRP	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.65	-0.52	6.92e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.27	-0.32	2.94e-7	Mean platelet volume;
KIRP	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.25	24.72	0.84	1.3e-68	Cognitive function;
KIRP	cis	rs2671245	0.586	rs1955317	chr1:56133982	G/C	cg11523071	chr1:56160889	NA	0.4	6.09	0.36	4.36e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4789452	0.744	rs1105409	chr17:75383940	T/C	cg12985929	chr17:75370611	SEPT9	-0.39	-5.31	-0.32	2.4e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.42	0.38	7.04e-10	Major depressive disorder;
KIRP	cis	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg26585981	chr11:48327164	OR4S1	-0.47	-5.64	-0.34	4.65e-8	HDL cholesterol;
KIRP	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg25036284	chr2:26402008	FAM59B	-0.52	-5.41	-0.33	1.51e-7	Gut microbiome composition (summer);
KIRP	trans	rs28595532	0.557	rs7696047	chr4:119303024	G/A	cg26518628	chr1:97050305	NA	-0.82	-8.0	-0.45	4.87e-14	Cannabis dependence symptom count;
KIRP	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.45	9.1	0.5	3.12e-17	Multiple system atrophy;
KIRP	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg07936489	chr17:37558343	FBXL20	-0.46	-5.89	-0.35	1.27e-8	Asthma;
KIRP	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg02975922	chr3:195473998	MUC4	0.52	6.18	0.37	2.64e-9	Pancreatic cancer;
KIRP	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.4	0.43	2.16e-12	Aortic root size;
KIRP	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.78	-9.19	-0.51	1.72e-17	Vitiligo;
KIRP	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.63	8.04	0.46	3.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg00262122	chr8:11665843	FDFT1	0.43	5.35	0.32	2.06e-7	Myopia (pathological);
KIRP	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg12560992	chr17:57184187	TRIM37	0.49	6.01	0.36	6.53e-9	Primary tooth development (time to first tooth eruption);
KIRP	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg02696742	chr7:106810147	HBP1	-0.75	-7.73	-0.44	2.76e-13	Coronary artery disease;
KIRP	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg04995300	chr3:66848608	NA	0.77	8.23	0.46	1.07e-14	Type 2 diabetes;
KIRP	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.65	0.48	6.75e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg04306507	chr14:55594613	LGALS3	0.47	7.34	0.42	3.03e-12	Protein biomarker;
KIRP	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	11.26	0.58	5.49e-24	Platelet count;
KIRP	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.01	-0.41	2.29e-11	Mood instability;
KIRP	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.89	-0.4	4.64e-11	Aortic root size;
KIRP	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs73198271	0.632	rs570396	chr8:8593652	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.18	-0.31	4.58e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4936891	1.000	rs4936891	chr11:123920645	C/G	cg22125253	chr11:123886957	OR10G4	0.39	5.61	0.34	5.37e-8	Male fertility;
KIRP	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.66	-10.98	-0.57	4.49e-23	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.23	0.32	3.68e-7	Lung cancer;
KIRP	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg21361702	chr7:150065534	REPIN1	-0.56	-6.0	-0.36	7e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7923609	1.000	rs7070296	chr10:65070438	T/A	cg01631684	chr10:65280961	REEP3	-0.5	-5.97	-0.36	8.21e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10053473	chr17:62856997	LRRC37A3	-0.88	-9.57	-0.52	1.21e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.43	8.47	0.48	2.31e-15	Coronary artery disease;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg10352719	chr14:24769404	DHRS1;C14orf21	0.53	6.11	0.36	3.9e-9	Sleep duration;
KIRP	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-12.16	-0.61	5.83e-27	Cognitive function;
KIRP	cis	rs9905704	0.801	rs2013182	chr17:56637770	G/A	cg12560992	chr17:57184187	TRIM37	-0.59	-6.68	-0.39	1.61e-10	Testicular germ cell tumor;
KIRP	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg27487796	chr7:28973253	NA	-0.22	-5.08	-0.31	7.33e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	1.0	13.52	0.65	1.57e-31	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg08662619	chr6:150070041	PCMT1	0.38	6.2	0.37	2.31e-9	Lung cancer;
KIRP	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg05973401	chr12:123451056	ABCB9	0.6	6.2	0.37	2.38e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg03609598	chr5:56110824	MAP3K1	-0.6	-5.61	-0.34	5.51e-8	Type 2 diabetes;
KIRP	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg26384229	chr12:38710491	ALG10B	0.46	5.2	0.31	4.1e-7	Morning vs. evening chronotype;
KIRP	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg00677455	chr12:58241039	CTDSP2	-0.64	-7.59	-0.44	6.56e-13	Multiple sclerosis;
KIRP	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg21926883	chr2:100939477	LONRF2	-0.63	-8.73	-0.49	4e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg09264619	chr17:80180166	NA	-0.41	-5.92	-0.35	1.05e-8	Life satisfaction;
KIRP	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.84	-0.35	1.6e-8	Height;
KIRP	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.3	-6.12	-0.36	3.62e-9	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.62	-6.07	-0.36	4.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	7.85e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7640424	0.649	rs13091474	chr3:107877134	A/T	cg09227934	chr3:107805635	CD47	-0.36	-6.11	-0.36	3.85e-9	Body mass index;
KIRP	cis	rs6840360	0.642	rs2724568	chr4:152352223	C/G	cg25486957	chr4:152246857	NA	-0.41	-4.92	-0.3	1.57e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	trans	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg19694781	chr19:47549865	TMEM160	0.58	7.7	0.44	3.26e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.45	6.3	0.37	1.37e-9	Dupuytren's disease;
KIRP	cis	rs78487399	0.710	rs76675804	chr2:43611883	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-5.19	-0.31	4.36e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7106204	0.609	rs72874176	chr11:24330205	C/T	ch.11.24196551F	chr11:24239977	NA	0.7	5.33	0.32	2.21e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-5.68	-0.34	3.88e-8	Lung cancer;
KIRP	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.75	-5.54	-0.33	7.74e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.41	0.38	7.57e-10	IgG glycosylation;
KIRP	cis	rs4417704	0.551	rs11886565	chr2:241898520	T/C	cg05025159	chr2:241905733	NA	0.39	4.94	0.3	1.42e-6	Joint mobility (Beighton score);
KIRP	cis	rs12210905	1.000	rs76889265	chr6:27008835	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.61	-0.39	2.31e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs1511802	0.666	rs6835646	chr4:187123519	T/C	cg24794857	chr4:187113578	CYP4V2	0.4	5.5	0.33	9.57e-8	Blood protein levels;
KIRP	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.99	0.71	5.89e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10901296	0.660	rs11789055	chr9:133766295	T/C	cg13397898	chr9:133768931	QRFP	0.31	5.42	0.33	1.4e-7	Bilirubin levels;
KIRP	cis	rs897080	0.515	rs786616	chr2:44592975	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.27	0.37	1.65e-9	Height;
KIRP	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.74	6.05	0.36	5.25e-9	IgG glycosylation;
KIRP	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.81	-9.51	-0.52	1.77e-18	Corneal astigmatism;
KIRP	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.69	10.2	0.55	1.3e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg17340268	chr14:105411764	AHNAK2	-0.38	-4.97	-0.3	1.26e-6	Rheumatoid arthritis;
KIRP	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg01721255	chr8:58191610	C8orf71	0.51	5.25	0.32	3.25e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.25	0.42	5.49e-12	Morning vs. evening chronotype;
KIRP	cis	rs7546094	0.841	rs663533	chr1:113128804	G/C	cg22162597	chr1:113214053	CAPZA1	0.41	5.31	0.32	2.49e-7	Platelet distribution width;
KIRP	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.34	0.51	6.06e-18	Prudent dietary pattern;
KIRP	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15316583	chr2:169312568	LASS6	0.55	6.87	0.4	5.28e-11	Parkinson's disease;
KIRP	cis	rs829661	0.843	rs829616	chr2:30747996	T/A	cg10949345	chr2:30726833	LCLAT1	1.0	12.79	0.63	4.54e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs8018808	0.869	rs4369582	chr14:77906389	C/T	cg20045696	chr14:77926864	AHSA1	0.45	5.38	0.32	1.74e-7	Myeloid white cell count;
KIRP	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16346588	chr10:242978	ZMYND11	-0.42	-4.95	-0.3	1.4e-6	Psychosis in Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01095395	chr3:101039372	IMPG2	-0.48	-7.42	-0.43	1.95e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg24315340	chr6:146058215	EPM2A	-0.37	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02475777	chr4:1388615	CRIPAK	0.52	4.88	0.3	1.89e-6	Systolic blood pressure;
KIRP	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg17724175	chr1:150552817	MCL1	0.34	5.58	0.34	6.38e-8	Tonsillectomy;
KIRP	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.12	-0.41	1.22e-11	Alzheimer's disease (late onset);
KIRP	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.69	10.68	0.56	4.1e-22	Blood metabolite ratios;
KIRP	cis	rs11024102	1.000	rs10766368	chr11:17014882	G/C	cg15378786	chr11:17036137	PLEKHA7	0.49	4.94	0.3	1.41e-6	Glaucoma (primary angle closure);
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs55863869	0.892	rs2627040	chr2:179601975	C/T	cg02880032	chr2:179629472	TTN	-0.64	-5.15	-0.31	5.34e-7	QT interval;
KIRP	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg02151108	chr14:50098012	C14orf104	-0.57	-7.99	-0.45	5.24e-14	Carotid intima media thickness;
KIRP	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.56	-6.36	-0.38	9.99e-10	Initial pursuit acceleration;
KIRP	cis	rs12044355	0.827	rs16854779	chr1:231827318	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.51	-6.53	-0.38	3.67e-10	Alzheimer's disease;
KIRP	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg06766960	chr11:133703094	NA	-0.45	-5.7	-0.34	3.43e-8	Childhood ear infection;
KIRP	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.84	0.3	2.25e-6	Menarche (age at onset);
KIRP	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.58	-7.51	-0.43	1.11e-12	Red cell distribution width;Reticulocyte count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09976981	chr22:43564007	TTLL12	0.58	7.05	0.41	1.85e-11	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12484487	chr18:33552551	C18orf21	0.55	7.19	0.42	7.56e-12	Parkinson's disease;
KIRP	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg09184832	chr6:79620586	NA	0.51	7.48	0.43	1.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.06	0.67	2.32e-33	Platelet count;
KIRP	cis	rs501120	1.000	rs501120	chr10:44753867	T/C	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10465746	0.935	rs11807807	chr1:84424071	C/T	cg10977910	chr1:84465055	TTLL7	0.48	5.81	0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg19784848	chr5:219127	SDHA;CCDC127	-0.46	-4.89	-0.3	1.78e-6	Breast cancer;
KIRP	cis	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg00967901	chr10:92617915	HTR7	-0.39	-5.16	-0.31	5.12e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg20703242	chr1:230279135	GALNT2	0.38	5.85	0.35	1.55e-8	Coronary artery disease;
KIRP	cis	rs68170813	0.559	rs77013162	chr7:107071674	A/C	cg02696742	chr7:106810147	HBP1	-0.78	-8.01	-0.45	4.6e-14	Coronary artery disease;
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	1.1	22.05	0.81	3.4e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.48	6.63	0.39	2.14e-10	Testicular germ cell tumor;
KIRP	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.76	12.45	0.62	6.27e-28	Vitiligo;
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.48	-0.33	1.03e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17199681	chr17:3540328	CTNS;SHPK	0.49	6.65	0.39	1.83e-10	Parkinson's disease;
KIRP	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.57	-0.39	3e-10	Blood pressure;
KIRP	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.95	-0.3	1.37e-6	Inflammatory bowel disease;
KIRP	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg03128060	chr6:142623767	GPR126	0.36	5.01	0.3	1.02e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg06483076	chr3:194406458	FAM43A	0.5	7.51	0.43	1.1e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.27	0.37	1.65e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs986417	0.636	rs8020587	chr14:60952612	A/G	cg27398547	chr14:60952738	C14orf39	0.73	7.28	0.42	4.38e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs7584330	0.740	rs13425580	chr2:238447168	T/C	cg14458575	chr2:238380390	NA	0.53	7.11	0.41	1.22e-11	Prostate cancer;
KIRP	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.46	-0.33	1.18e-7	Multiple sclerosis;
KIRP	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg19274270	chr17:78178856	CARD14	0.36	6.49	0.38	4.77e-10	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg13180566	chr4:1052158	NA	-0.51	-5.31	-0.32	2.44e-7	Recombination rate (females);
KIRP	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.12	0.41	1.17e-11	Bipolar disorder;
KIRP	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.45	5.76	0.34	2.49e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.75	-10.53	-0.56	1.18e-21	Caffeine consumption;
KIRP	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.66	0.44	4.24e-13	Lung cancer;
KIRP	cis	rs7219021	0.550	rs35929648	chr17:47002543	A/G	cg16584676	chr17:46985605	UBE2Z	0.42	4.92	0.3	1.55e-6	Schizophrenia or bipolar disorder;
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-5.61	-0.34	5.36e-8	Lung cancer;
KIRP	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.75	-8.46	-0.47	2.38e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg18850929	chr19:1828978	REXO1	0.44	5.24	0.32	3.52e-7	Bipolar disorder;
KIRP	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg04310649	chr10:35416472	CREM	-0.52	-5.89	-0.35	1.24e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.57	7.02	0.41	2.11e-11	Mosquito bite size;
KIRP	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs4356932	1.000	rs11097219	chr4:76980163	G/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg03060546	chr3:49711283	APEH	-0.61	-5.41	-0.33	1.5e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg00489477	chr7:2953019	CARD11	0.37	4.87	0.3	1.98e-6	Schizophrenia;
KIRP	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg09408571	chr1:101003634	GPR88	0.24	5.17	0.31	4.86e-7	Breast cancer;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.65	0.48	6.98e-16	Life satisfaction;
KIRP	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg21775007	chr8:11205619	TDH	-0.46	-6.16	-0.37	2.98e-9	Triglycerides;
KIRP	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.62	9.41	0.51	3.74e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg02780029	chr10:43622663	RET	-0.34	-5.2	-0.31	4.26e-7	Hirschsprung disease;
KIRP	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	8.3	0.47	6.95e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.41	5.15	0.31	5.44e-7	High light scatter reticulocyte count;
KIRP	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg05768032	chr16:30646687	NA	0.44	5.04	0.31	9.19e-7	Multiple myeloma;
KIRP	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	6.8	0.4	8.03e-11	Body mass index;
KIRP	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg06636001	chr8:8085503	FLJ10661	0.69	9.07	0.5	3.93e-17	Retinal vascular caliber;
KIRP	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.77	0.49	2.92e-16	Bipolar disorder;
KIRP	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.64	7.87	0.45	1.14e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-0.83	-14.85	-0.69	4.76e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg10755058	chr3:40428713	ENTPD3	0.43	6.13	0.36	3.52e-9	Renal cell carcinoma;
KIRP	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg21775007	chr8:11205619	TDH	0.41	5.05	0.31	8.63e-7	Neuroticism;
KIRP	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.69	9.21	0.51	1.47e-17	Total body bone mineral density;
KIRP	cis	rs6450176	0.909	rs7732139	chr5:53292017	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-10.96	-0.57	5.05e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs4936894	0.500	rs11219534	chr11:124119351	A/G	cg27160556	chr11:124181099	OR8D1	0.4	5.97	0.36	8.43e-9	Aging (time to death);
KIRP	cis	rs4523957	0.583	rs2957926	chr17:2024030	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg00603274	chr11:61596626	FADS2	-0.66	-6.53	-0.38	3.73e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg08600765	chr20:34638493	LOC647979	-0.84	-8.83	-0.49	2.06e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.41	-5.59	-0.34	5.95e-8	Red blood cell count;
KIRP	cis	rs3733418	0.799	rs13151735	chr4:165932516	G/C	cg10852876	chr4:165953100	TRIM60	-0.49	-5.58	-0.34	6.25e-8	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg10505658	chr17:80084571	CCDC57	-0.26	-4.86	-0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg13939156	chr17:80058883	NA	-0.47	-5.52	-0.33	8.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9905704	0.831	rs12949598	chr17:56707245	C/T	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.74	10.25	0.55	9.4499999999999992e-21	Schizophrenia;
KIRP	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg14403583	chr14:105418241	AHNAK2	-0.67	-9.27	-0.51	9.59e-18	Systemic lupus erythematosus;
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg22907277	chr7:1156413	C7orf50	0.83	7.84	0.45	1.39e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.54	8.24	0.47	9.99e-15	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06766450	chr1:16766999	NECAP2	0.59	6.96	0.41	3.15e-11	Smoking initiation;
KIRP	trans	rs3758785	0.512	rs11020758	chr11:94110284	C/A	cg06370422	chr11:125815188	NA	0.62	6.07	0.36	4.75e-9	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
KIRP	cis	rs7737355	0.812	rs3756289	chr5:130982194	A/G	cg25547332	chr5:131281432	NA	0.39	4.92	0.3	1.59e-6	Life satisfaction;
KIRP	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.98	-13.36	-0.65	5.52e-31	Cognitive ability;
KIRP	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.71	9.45	0.52	2.84e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12220238	0.722	rs12360087	chr10:76373904	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.56	6.08	0.36	4.55e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.84	-0.57	1.23e-22	Refractive error;
KIRP	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-1.01	-15.84	-0.71	2.04e-39	Coronary artery disease;
KIRP	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs9473924	0.632	rs987842	chr6:50895403	C/T	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.68	10.28	0.55	7.59e-21	Hip circumference;
KIRP	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.98	-0.36	7.94e-9	Obesity-related traits;
KIRP	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg00255919	chr5:131827918	IRF1	0.23	5.69	0.34	3.65e-8	Breast cancer;Mosquito bite size;
KIRP	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg04310649	chr10:35416472	CREM	-0.57	-6.88	-0.4	4.92e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.75	7.59	0.44	6.55e-13	Resting heart rate;
KIRP	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg25650185	chr19:21324782	ZNF431	0.48	5.02	0.31	9.74e-7	Pain;
KIRP	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg22437258	chr11:111473054	SIK2	0.61	7.13	0.41	1.11e-11	Primary sclerosing cholangitis;
KIRP	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	8.1	0.46	2.63e-14	Eosinophil percentage of white cells;
KIRP	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg12131826	chr15:77904385	NA	0.41	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs1656402	1.000	rs1190440	chr2:233422274	G/A	cg03852847	chr2:233439513	NA	0.7	11.62	0.6	3.69e-25	Non-small cell lung cancer (survival);
KIRP	cis	rs687432	0.688	rs7130381	chr11:57894443	A/G	cg19752551	chr11:57585705	CTNND1	-0.62	-8.29	-0.47	7.28e-15	Parkinson's disease;
KIRP	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9584850	0.834	rs9584854	chr13:99118590	C/T	cg20750642	chr13:99100586	FARP1	-0.48	-5.52	-0.33	8.38e-8	Neuroticism;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21214613	chr1:16344536	HSPB7	0.34	5.12	0.31	6.24e-7	Systolic blood pressure;
KIRP	cis	rs7771547	0.573	rs621796	chr6:36472259	A/T	cg04289385	chr6:36355825	ETV7	0.44	6.83	0.4	6.54e-11	Platelet distribution width;
KIRP	cis	rs6001982	0.665	rs58778028	chr22:40862974	T/C	cg07138101	chr22:40742427	ADSL	0.73	5.8	0.35	1.98e-8	Breast cancer;
KIRP	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.29	-0.32	2.73e-7	Breast cancer;
KIRP	cis	rs963731	0.522	rs297128	chr2:39298403	C/G	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg17105886	chr17:28927953	LRRC37B2	0.53	5.6	0.34	5.84e-8	Body mass index;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg19821404	chr6:91151394	NA	-0.44	-6.05	-0.36	5.26e-9	Select biomarker traits;
KIRP	trans	rs7943358	0.590	rs10500817	chr11:15648135	C/T	cg02399570	chr3:156877196	CCNL1	0.57	6.13	0.36	3.46e-9	Gut microbiome composition (summer);
KIRP	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.58	5.78	0.35	2.24e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.86	-11.79	-0.6	1.01e-25	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.58	7.37	0.43	2.66e-12	Retinal vascular caliber;
KIRP	cis	rs77688320	0.535	rs7561048	chr2:202253039	G/A	cg06431681	chr2:202330990	STRADB	0.52	6.97	0.41	2.95e-11	Breast cancer;
KIRP	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-0.74	-8.7	-0.49	4.84e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.44	-7.13	-0.41	1.13e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	cis	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs686320	1.000	rs686320	chr11:65244538	G/C	cg21890820	chr11:65308645	LTBP3	0.61	5.47	0.33	1.08e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.57	-0.43	7.59e-13	Bipolar disorder;
KIRP	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	1.02	7.04	0.41	1.86e-11	Type 2 diabetes nephropathy;
KIRP	cis	rs7551222	0.749	rs7532236	chr1:204561617	A/G	cg20240347	chr1:204465584	NA	0.42	7.89	0.45	1.01e-13	Schizophrenia;
KIRP	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg25281562	chr12:121454272	C12orf43	-0.48	-5.17	-0.31	4.89e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.56	-0.43	7.96e-13	Menopause (age at onset);
KIRP	cis	rs4494114	1.000	rs3790442	chr1:39357646	C/A	cg25970120	chr1:39325951	RRAGC	-0.4	-5.15	-0.31	5.37e-7	Blood protein levels;
KIRP	cis	rs3736485	0.934	rs2899475	chr15:51883051	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-7.08	-0.41	1.49e-11	Vitiligo;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21432745	chr6:26375990	BTN3A2	-0.45	-6.03	-0.36	6.07e-9	Inflammatory biomarkers;
KIRP	cis	rs9905704	0.681	rs2531728	chr17:56539792	T/C	cg12560992	chr17:57184187	TRIM37	0.55	5.2	0.31	4.29e-7	Testicular germ cell tumor;
KIRP	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.8	12.79	0.63	4.65e-29	Coronary artery disease;
KIRP	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg23894439	chr1:183413866	NA	0.42	5.53	0.33	8.13e-8	Systemic lupus erythematosus;
KIRP	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.29	0.37	1.47e-9	Homocysteine levels;
KIRP	cis	rs6681460	0.899	rs1280280	chr1:67173903	G/A	cg02459107	chr1:67143332	SGIP1	0.4	5.74	0.34	2.77e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.44	5.69	0.34	3.68e-8	Blood metabolite levels;
KIRP	cis	rs1465370	0.682	rs741486	chr7:130024010	C/T	cg03229158	chr7:130009420	NA	-0.36	-5.37	-0.32	1.86e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs35771425	1.000	rs11119742	chr1:211624504	A/T	cg10512769	chr1:211675356	NA	-0.56	-5.38	-0.32	1.76e-7	Educational attainment (years of education);
KIRP	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg26876637	chr1:152193138	HRNR	-0.66	-8.62	-0.48	8.56e-16	Atopic dermatitis;
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.64	9.82	0.53	2.05e-19	Lung cancer;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg02023728	chr11:77925099	USP35	-0.31	-5.37	-0.32	1.83e-7	Alzheimer's disease (survival time);
KIRP	cis	rs55962025	0.711	rs362319	chr4:3224933	T/G	cg06533319	chr4:3265114	C4orf44	0.43	5.5	0.33	9.71e-8	Parental longevity (mother's age at death);
KIRP	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.18	-0.37	2.65e-9	Breast cancer;
KIRP	cis	rs9549328	0.718	rs7139939	chr13:113634409	G/A	cg17524180	chr13:113633600	MCF2L	-0.29	-5.41	-0.33	1.48e-7	Systolic blood pressure;
KIRP	cis	rs75920871	0.858	rs11216168	chr11:116741553	G/A	cg23684410	chr11:116897558	SIK3	0.58	5.84	0.35	1.63e-8	Subjective well-being;
KIRP	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.41	-0.59	1.76e-24	Monocyte count;
KIRP	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.84	0.45	1.35e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs6684514	0.961	rs10908503	chr1:156300683	C/T	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.67e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg21204522	chr6:27730016	NA	-0.61	-5.24	-0.32	3.41e-7	Lung cancer in ever smokers;
KIRP	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.52	-5.83	-0.35	1.77e-8	Diastolic blood pressure;
KIRP	cis	rs17293817	0.957	rs7087129	chr10:1449140	C/G	cg02851212	chr10:1451418	ADARB2	0.4	5.16	0.31	5.13e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.61	-8.62	-0.48	8.31e-16	Glaucoma (primary open-angle);
KIRP	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.83	-14.59	-0.68	3.59e-35	Post bronchodilator FEV1;
KIRP	cis	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg26585981	chr11:48327164	OR4S1	-0.47	-5.64	-0.34	4.71e-8	HDL cholesterol;
KIRP	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.39	-0.43	2.26e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs58785573	0.608	rs7685520	chr4:38689031	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.42	-5.07	-0.31	8e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-1.04	-12.95	-0.64	1.39e-29	Breast cancer;
KIRP	cis	rs889398	0.677	rs68161338	chr16:69823778	T/G	cg09409435	chr16:70099608	PDXDC2	-0.44	-5.29	-0.32	2.66e-7	Body mass index;
KIRP	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg08992911	chr2:238395768	MLPH	0.41	5.28	0.32	2.83e-7	Prostate cancer;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.26	-5.24	-0.32	3.52e-7	Lymphocyte counts;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15446670	chr7:87257547	ABCB1;RUNDC3B	-0.49	-6.29	-0.37	1.46e-9	Pancreatic cancer;
KIRP	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg07068956	chr7:100330872	ZAN	0.38	5.07	0.31	7.74e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs4663866	0.901	rs76312449	chr2:239190906	A/G	cg16914508	chr2:239161102	PER2	0.72	5.17	0.31	4.81e-7	Irritable bowel syndrome;
KIRP	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg08890418	chr1:21044141	KIF17	0.35	5.31	0.32	2.43e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27286337	chr10:134555280	INPP5A	0.89	10.6	0.56	7.17e-22	Migraine;
KIRP	cis	rs4302748	0.862	rs12530870	chr7:36181501	A/G	cg24442661	chr7:36192818	EEPD1	0.52	5.8	0.35	1.99e-8	Platelet count;
KIRP	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg07636037	chr3:49044803	WDR6	-0.71	-6.55	-0.39	3.3e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg27490568	chr2:178487706	NA	0.52	7.07	0.41	1.64e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.39	5.46	0.33	1.17e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11987759	chr7:65425863	GUSB	-0.69	-9.71	-0.53	4.37e-19	Calcium levels;
KIRP	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.58	-7.06	-0.41	1.74e-11	Colorectal cancer;
KIRP	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27144592	chr16:783916	NARFL	0.36	5.01	0.3	1.02e-6	Height;
KIRP	cis	rs6120849	0.754	rs3746435	chr20:33587198	G/C	cg24642439	chr20:33292090	TP53INP2	0.66	6.63	0.39	2.09e-10	Protein C levels;
KIRP	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.66	7.94	0.45	7.28e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg25019722	chr6:37503610	NA	-0.95	-15.3	-0.7	1.43e-37	Cognitive performance;
KIRP	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg17347335	chr11:93583973	C11orf90	0.31	5.08	0.31	7.52e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.82	-0.4	7.21e-11	Coronary artery disease;
KIRP	cis	rs68170813	0.570	rs7794915	chr7:106849393	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-5.26	-0.32	3.08e-7	Coronary artery disease;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.53	0.52	1.61e-18	Lung cancer;
KIRP	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg10047753	chr17:41438598	NA	1.16	18.75	0.77	2.5e-49	Menopause (age at onset);
KIRP	cis	rs4774899	0.934	rs11631541	chr15:57361676	C/G	cg13626582	chr15:57592083	LOC283663	0.21	5.14	0.31	5.69e-7	Urinary tract infection frequency;
KIRP	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg18350739	chr11:68623251	NA	-0.53	-8.23	-0.46	1.13e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	9.73	0.53	3.89e-19	Cognitive test performance;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14363636	chr11:61129374	CYBASC3;TMEM138	0.49	6.53	0.38	3.77e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6142102	0.778	rs6059581	chr20:32528388	C/A	cg24642439	chr20:33292090	TP53INP2	0.52	5.72	0.34	3.1e-8	Skin pigmentation;
KIRP	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg01028140	chr2:1542097	TPO	-0.53	-6.1	-0.36	4.15e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.83	7.93	0.45	7.6e-14	Prostate cancer;
KIRP	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	5.18	0.31	4.52e-7	Schizophrenia;
KIRP	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.31	-0.32	2.41e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4523957	0.893	rs11078018	chr17:2162119	A/G	cg16513277	chr17:2031491	SMG6	-0.58	-8.01	-0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4006360	0.546	rs1846043	chr17:39265300	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.42	-5.75	-0.34	2.58e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9900972	0.918	rs8082041	chr17:76876542	A/G	cg20937029	chr17:76870563	TIMP2	0.43	4.91	0.3	1.67e-6	Obesity-related traits;
KIRP	cis	rs6684428	0.706	rs12058087	chr1:56319257	C/G	cg11651538	chr1:56320950	NA	-0.85	-12.12	-0.61	7.83e-27	Airflow obstruction;
KIRP	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.48	6.25	0.37	1.79e-9	Blood protein levels;
KIRP	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11987759	chr7:65425863	GUSB	-0.63	-8.38	-0.47	4.18e-15	Aortic root size;
KIRP	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg23601095	chr6:26197514	HIST1H3D	0.92	7.55	0.43	8.37e-13	Gout;Renal underexcretion gout;
KIRP	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	1.05	11.44	0.59	1.36e-24	Height;
KIRP	cis	rs477895	0.639	rs2289573	chr11:64127902	G/A	cg04317338	chr11:64019027	PLCB3	0.76	5.41	0.33	1.51e-7	Mean platelet volume;
KIRP	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg12935359	chr14:103987150	CKB	-0.48	-6.29	-0.37	1.45e-9	Body mass index;
KIRP	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg25356066	chr3:128598488	ACAD9	0.47	5.43	0.33	1.34e-7	IgG glycosylation;
KIRP	cis	rs77972916	0.561	rs4372955	chr2:43566146	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-7.08	-0.41	1.5e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-5.49	-0.33	1e-7	Systolic blood pressure;
KIRP	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.6	-6.7	-0.39	1.4e-10	Neuroticism;
KIRP	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18324242	chr19:33462789	CCDC123;C19orf40	0.97	6.37	0.38	9.12e-10	P wave terminal force;
KIRP	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg10792982	chr14:105748885	BRF1	0.75	11.62	0.6	3.59e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs12143943	0.866	rs35666383	chr1:204492784	T/C	cg20240347	chr1:204465584	NA	-0.36	-6.52	-0.38	4.01e-10	Cognitive performance;
KIRP	cis	rs60871478	1.000	rs62432223	chr7:787959	A/G	cg05535760	chr7:792225	HEATR2	0.86	8.89	0.49	1.33e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-5.78	-0.35	2.23e-8	Cutaneous nevi;
KIRP	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.57	-6.64	-0.39	1.98e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg18441811	chr11:71824068	C11orf51	-0.78	-5.29	-0.32	2.67e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9815354	1.000	rs9824731	chr3:41889698	G/T	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs17065868	1.000	rs73190808	chr13:45099541	G/A	cg10246903	chr13:45222710	NA	0.74	6.77	0.4	9.6e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg18404041	chr3:52824283	ITIH1	-0.45	-5.4	-0.33	1.56e-7	Schizophrenia;
KIRP	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.53	-5.77	-0.35	2.32e-8	Coronary artery disease;
KIRP	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.55	7.63	0.44	5.04e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.2	21.86	0.81	1.42e-59	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13181291	chr1:151089582	GABPB2	0.42	6.26	0.37	1.72e-9	Survival in pancreatic cancer;
KIRP	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg05082376	chr22:42548792	NA	0.47	6.05	0.36	5.23e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	0.731	rs9605462	chr22:18459859	C/T	cg03078520	chr22:18463400	MICAL3	-0.85	-12.25	-0.62	3.04e-27	Presence of antiphospholipid antibodies;
KIRP	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.63	7.66	0.44	4.28e-13	Blood protein levels;
KIRP	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg00250761	chr1:31883323	NA	-0.3	-5.37	-0.32	1.85e-7	Alcohol dependence;
KIRP	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.54	0.43	8.76e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs953387	1.000	rs4954569	chr2:136913375	C/T	cg05194412	chr2:137003533	NA	-0.41	-5.26	-0.32	3.08e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.37	5.03	0.31	9.61e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	1.03	15.25	0.7	2.1e-37	Blood protein levels;
KIRP	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	7.17	0.42	8.8e-12	Height;
KIRP	cis	rs62229266	0.605	rs2835275	chr21:37460001	C/T	cg08632701	chr21:37451849	NA	-0.59	-8.58	-0.48	1.07e-15	Mitral valve prolapse;
KIRP	cis	rs2071426	0.622	rs34294497	chr10:96770060	C/T	cg09036531	chr10:96991505	NA	-0.46	-5.4	-0.33	1.6e-7	Blood metabolite levels;
KIRP	cis	rs4903214	0.895	rs1548767	chr14:74694957	C/T	cg08255017	chr14:74727001	VSX2	-0.4	-4.85	-0.3	2.18e-6	Inflammatory bowel disease;
KIRP	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg03929089	chr4:120376271	NA	0.77	6.91	0.4	4.16e-11	Axial length;
KIRP	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg20573242	chr4:122745356	CCNA2	0.6	6.3	0.37	1.37e-9	Type 2 diabetes;
KIRP	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg00784671	chr22:46762841	CELSR1	-0.54	-7.27	-0.42	4.9e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7215564	0.543	rs78457522	chr17:78520896	G/T	cg06153925	chr17:78755379	RPTOR	0.39	5.13	0.31	5.96e-7	Myopia (pathological);
KIRP	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg20368463	chr18:77673604	PQLC1	0.73	6.99	0.41	2.61e-11	Opioid sensitivity;
KIRP	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg16506815	chr2:162101123	NA	0.48	5.76	0.34	2.56e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18946478	chr2:20866414	GDF7	-0.45	-6.4	-0.38	7.97e-10	Pancreatic cancer;
KIRP	trans	rs909341	1.000	rs909341	chr20:62328742	C/T	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.46	-0.43	1.53e-12	Atopic dermatitis;
KIRP	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg03959625	chr15:84868606	LOC388152	0.66	8.03	0.46	3.94e-14	Schizophrenia;
KIRP	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg26039829	chr8:22132926	PIWIL2	0.46	5.9	0.35	1.23e-8	Hypertriglyceridemia;
KIRP	cis	rs2505998	0.833	rs1800858	chr10:43595968	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.79	-0.35	2.19e-8	Hirschsprung disease;
KIRP	cis	rs1318772	0.800	rs4410636	chr5:112935406	A/T	cg12552261	chr5:112820674	MCC	0.79	5.49	0.33	1.02e-7	F-cell distribution;
KIRP	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.65	9.39	0.51	4.21e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs412050	0.547	rs61757982	chr22:22113740	A/G	cg17089214	chr22:22089827	YPEL1	0.64	5.99	0.36	7.45e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.65	-6.83	-0.4	6.42e-11	DNA methylation (variation);
KIRP	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-1.11	-9.13	-0.5	2.5e-17	Body mass index;
KIRP	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg06115741	chr20:33292138	TP53INP2	0.4	5.31	0.32	2.43e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.63	-0.34	4.95e-8	Aortic root size;
KIRP	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg18154014	chr19:37997991	ZNF793	0.74	6.62	0.39	2.28e-10	Coronary artery calcification;
KIRP	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg25319279	chr11:5960081	NA	-0.6	-6.12	-0.36	3.73e-9	DNA methylation (variation);
KIRP	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.45	-0.33	1.23e-7	Schizophrenia;
KIRP	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg07195126	chr1:160370843	VANGL2	0.45	6.14	0.36	3.28e-9	Squamous cell lung carcinoma;
KIRP	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.91	0.4	4.06e-11	Neuroticism;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10284592	chr11:57434942	ZDHHC5	1.12	7.53	0.43	9.85e-13	P wave terminal force;
KIRP	cis	rs997295	1.000	rs34583567	chr15:67983281	G/T	cg14210607	chr15:68128175	NA	-0.3	-5.01	-0.3	1.03e-6	Motion sickness;
KIRP	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	ch.8.33884649F	chr8:33765107	NA	0.6	7.45	0.43	1.62e-12	Body mass index;
KIRP	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg24747557	chr10:131355152	MGMT	0.44	6.09	0.36	4.29e-9	Response to temozolomide;
KIRP	cis	rs2274273	0.648	rs58553156	chr14:55582694	T/A	cg04306507	chr14:55594613	LGALS3	0.4	5.73	0.34	2.99e-8	Protein biomarker;
KIRP	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg11234688	chr2:1609660	NA	0.53	4.84	0.3	2.26e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg05805236	chr11:65401703	PCNXL3	-0.57	-7.02	-0.41	2.15e-11	Acne (severe);
KIRP	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.81	12.25	0.62	2.96e-27	Ulcerative colitis;
KIRP	cis	rs2346160	1.000	rs4709159	chr6:167664918	C/T	cg27333441	chr6:167680455	NA	-0.43	-5.75	-0.34	2.68e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg14972814	chr11:95582409	MTMR2	0.3	5.15	0.31	5.28e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-0.9	-9.94	-0.54	8.47e-20	Gut microbiome composition (summer);
KIRP	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg17757837	chr7:157058334	UBE3C	0.78	10.52	0.56	1.31e-21	Body mass index;
KIRP	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.06	-0.31	8.17e-7	Red blood cell count;
KIRP	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.26e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.81	-8.54	-0.48	1.39e-15	Type 2 diabetes;
KIRP	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg02336718	chr17:17403227	NA	0.33	5.21	0.32	3.92e-7	Total body bone mineral density;
KIRP	cis	rs72820985	0.935	rs1547990	chr16:80842618	T/C	cg04448709	chr16:81349954	GAN	-0.49	-5.03	-0.31	9.3e-7	Breast cancer;
KIRP	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg24060327	chr5:131705240	SLC22A5	-0.53	-6.52	-0.38	4.06e-10	Lung function (FEV1/FVC);
KIRP	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	1.06	19.97	0.79	2.13e-53	Heart rate;
KIRP	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.34	-0.37	1.1e-9	Mean corpuscular volume;
KIRP	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg18306943	chr3:40428807	ENTPD3	0.44	5.63	0.34	4.89e-8	Renal cell carcinoma;
KIRP	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.14	0.31	5.68e-7	Parkinson's disease;
KIRP	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6691722	0.503	rs1064842	chr1:24706269	A/G	cg18323236	chr1:24743029	NIPAL3	0.44	6.29	0.37	1.45e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs9815354	0.812	rs58442057	chr3:41827209	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6495367	1.000	rs1961579	chr15:79380516	G/A	cg17916960	chr15:79447300	NA	0.3	5.09	0.31	7.15e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01334186	chr1:151372572	PSMB4	0.52	7.41	0.43	2.04e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.79	10.76	0.57	2.25e-22	Aortic root size;
KIRP	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg22437258	chr11:111473054	SIK2	0.63	7.48	0.43	1.29e-12	Primary sclerosing cholangitis;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg01763666	chr17:80159506	CCDC57	0.37	5.06	0.31	8.31e-7	Life satisfaction;
KIRP	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.59e-12	Obesity-related traits;
KIRP	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.78e-11	Bipolar disorder;
KIRP	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg10223061	chr2:219282414	VIL1	0.43	7.0	0.41	2.42e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg23307798	chr14:103986281	CKB	-0.51	-6.91	-0.4	4.21e-11	Coronary artery disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07772309	chr9:140353475	NELF	-0.53	-7.03	-0.41	1.98e-11	Metabolic traits;
KIRP	cis	rs6714788	0.565	rs7599083	chr2:100658077	G/A	cg17356467	chr2:100759845	AFF3	0.37	5.02	0.3	9.9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.662	rs195520	chr6:116242740	A/G	cg05304507	chr6:116381966	FRK	0.19	4.88	0.3	1.89e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.45	-7.32	-0.42	3.56e-12	Eye color traits;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.64	8.36	0.47	4.82e-15	Motion sickness;
KIRP	cis	rs2299587	0.560	rs11987695	chr8:17781085	A/G	cg01800426	chr8:17659068	MTUS1	-0.6	-7.11	-0.41	1.25e-11	Economic and political preferences;
KIRP	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg24110177	chr3:50126178	RBM5	-0.53	-4.84	-0.3	2.24e-6	Menarche (age at onset);
KIRP	cis	rs2279817	0.735	rs71644064	chr1:18000044	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-8.67	-0.48	5.93e-16	Neuroticism;
KIRP	trans	rs7939886	0.920	rs7946368	chr11:55804219	C/T	cg15704280	chr7:45808275	SEPT13	0.82	6.03	0.36	5.87e-9	Myopia (pathological);
KIRP	cis	rs55962025	0.804	rs2269499	chr4:3239702	C/T	cg06533319	chr4:3265114	C4orf44	0.48	5.2	0.31	4.16e-7	Parental longevity (mother's age at death);
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.8	-10.16	-0.54	1.76e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.6	10.1	0.54	2.74e-20	Schizophrenia;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg00748821	chr4:83932227	LIN54	0.46	6.1	0.36	4.06e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4262150	0.693	rs3924315	chr5:152302638	T/A	cg12297329	chr5:152029980	NA	0.49	6.95	0.4	3.33e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7770628	0.653	rs113525646	chr6:161119901	G/A	cg14663533	chr6:160955178	LPA	0.48	6.23	0.37	2.05e-9	Protein quantitative trait loci;Lipoprotein (a) levels;
KIRP	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.8	-0.4	7.73e-11	Monocyte percentage of white cells;
KIRP	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-6.94	-0.4	3.55e-11	Self-reported allergy;
KIRP	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	10.48	0.56	1.74e-21	Bone mineral density;
KIRP	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.66	-11.51	-0.59	8.28e-25	Obesity-related traits;
KIRP	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.69	-9.51	-0.52	1.77e-18	Waist circumference;Body mass index;
KIRP	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg21475434	chr5:93447410	FAM172A	0.78	7.01	0.41	2.24e-11	Diabetic retinopathy;
KIRP	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-8.3	-0.47	6.92e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12580194	0.593	rs11171432	chr12:55757696	G/C	cg11794356	chr12:55725991	OR6C3	-0.55	-7.7	-0.44	3.25e-13	Cancer;
KIRP	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg13264159	chr8:625131	ERICH1	-0.73	-5.73	-0.34	2.94e-8	IgG glycosylation;
KIRP	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg20503657	chr10:835505	NA	-0.52	-6.14	-0.36	3.25e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs6684514	1.000	rs6679145	chr1:156256000	T/C	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.73	9.92	0.53	9.85e-20	Mood instability;
KIRP	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg01988459	chr11:68622903	NA	-0.39	-5.13	-0.31	5.98e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg24803719	chr17:45855879	NA	-0.39	-5.41	-0.33	1.47e-7	IgG glycosylation;
KIRP	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08392591	chr16:89556376	ANKRD11	-0.46	-5.92	-0.35	1.09e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg15893493	chr8:124194847	FAM83A	0.93	7.94	0.45	7.42e-14	Urinary uromodulin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13435101	chr6:74171350	MTO1	-0.5	-6.66	-0.39	1.74e-10	Survival in pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13198984	chr17:80129470	CCDC57	0.59	8.79	0.49	2.58e-16	Life satisfaction;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg04374321	chr14:90722782	PSMC1	0.52	5.66	0.34	4.21e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg05220968	chr6:146057943	EPM2A	-0.42	-5.57	-0.33	6.53e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	7.94	0.45	7.3e-14	Height;
KIRP	cis	rs6568686	0.786	rs6911772	chr6:111857638	G/C	cg15721981	chr6:111408429	SLC16A10	-0.55	-4.95	-0.3	1.35e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.69	-0.39	1.52e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg01097406	chr16:89675127	NA	-0.29	-4.9	-0.3	1.75e-6	Vitiligo;
KIRP	cis	rs9379832	1	rs9379832	chr6:26186200	A/G	cg13736514	chr6:26305472	NA	-0.66	-8.04	-0.46	3.76e-14	Birth weight;
KIRP	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.94	-16.25	-0.72	8.07e-41	Height;
KIRP	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg02158880	chr13:53174818	NA	0.37	5.0	0.3	1.08e-6	Lewy body disease;
KIRP	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.89	14.08	0.67	2e-33	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg18093559	chr17:18951025	GRAP	0.55	6.76	0.4	9.75e-11	Schizophrenia;
KIRP	cis	rs11212260	0.678	rs11212203	chr11:107267629	A/G	cg25435332	chr11:107328525	CWF19L2	0.84	5.16	0.31	5.14e-7	IgG glycosylation;
KIRP	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg21858823	chr1:15850916	CASP9	0.54	5.78	0.35	2.29e-8	Systolic blood pressure;
KIRP	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	1.06	19.48	0.78	9.28e-52	Systemic lupus erythematosus;
KIRP	cis	rs6959887	0.962	rs17674947	chr7:35281643	A/C	cg06685737	chr7:35301730	NA	-0.44	-6.34	-0.37	1.09e-9	Birth weight;
KIRP	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	6.91	0.4	4.12e-11	Lung cancer;
KIRP	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.83	-12.09	-0.61	1.05e-26	Ileal carcinoids;
KIRP	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg01721255	chr8:58191610	C8orf71	0.54	5.66	0.34	4.12e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6859018	1.000	rs3212218	chr5:158754596	C/A	cg26646896	chr5:158686746	NA	-0.34	-4.95	-0.3	1.39e-6	Serum sulfate level;
KIRP	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg14593290	chr7:50529359	DDC	-0.43	-5.42	-0.33	1.41e-7	Malaria;
KIRP	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg00360474	chr6:37504404	NA	-0.47	-6.57	-0.39	2.97e-10	Cognitive performance;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11291882	chr19:56090781	ZNF579	-0.47	-6.14	-0.36	3.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs12780845	0.540	rs2273734	chr10:17216556	C/T	cg01003015	chr10:17271136	VIM	0.47	6.16	0.37	2.97e-9	Homocysteine levels;
KIRP	trans	rs2055729	0.645	rs12543996	chr8:9742666	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.25	-0.37	1.77e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs12022452	0.591	rs16827359	chr1:41001438	C/G	cg25568243	chr1:40974465	DEM1	-0.51	-5.43	-0.33	1.32e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18932078	chr1:2524107	MMEL1	0.46	6.25	0.37	1.76e-9	Ulcerative colitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13949487	chr9:98637884	C9orf130;C9orf102	0.44	6.39	0.38	8.05e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg16606324	chr3:10149918	C3orf24	0.56	5.26	0.32	3.07e-7	Alzheimer's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07067904	chr2:74425934	MTHFD2	-0.47	-6.41	-0.38	7.49e-10	Metabolic traits;
KIRP	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	0.94	11.23	0.58	6.98e-24	Vitiligo;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg19500275	chr17:80737654	TBCD	0.55	7.22	0.42	6.35e-12	Glycated hemoglobin levels;
KIRP	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00889227	chr1:205173544	DSTYK	-0.37	-5.23	-0.32	3.66e-7	Red blood cell count;
KIRP	cis	rs7630877	0.962	rs11708154	chr3:179635808	T/C	cg18765712	chr3:179670323	PEX5L	0.58	7.08	0.41	1.54e-11	Type 2 diabetes;
KIRP	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg22138327	chr13:27999177	GTF3A	0.85	6.53	0.38	3.77e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs7542091	0.704	rs4133950	chr1:210044393	C/G	cg22029157	chr1:209979665	IRF6	0.38	5.88	0.35	1.35e-8	Monobrow;
KIRP	cis	rs4523957	0.820	rs7212249	chr17:2135980	A/T	cg16513277	chr17:2031491	SMG6	-0.69	-9.61	-0.52	8.94e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03674265	chr7:149322059	ZNF767	-0.63	-6.91	-0.4	4.23e-11	Menopause (age at onset);
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg11814155	chr7:99998594	ZCWPW1	0.54	5.26	0.32	3.13e-7	Platelet count;
KIRP	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg13736514	chr6:26305472	NA	-0.72	-9.28	-0.51	9e-18	Educational attainment;
KIRP	cis	rs3745672	0.590	rs79770870	chr19:12175358	C/A	cg20127191	chr19:12306497	NA	-0.73	-5.98	-0.36	7.7e-9	Multiple sclerosis;
KIRP	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11987759	chr7:65425863	GUSB	0.57	7.71	0.44	3.1e-13	Aortic root size;
KIRP	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-6.93	-0.4	3.77e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg07653901	chr22:50250238	ZBED4	0.47	5.58	0.33	6.46e-8	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.77	5.59	0.34	5.88e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs12517041	1.000	rs34515966	chr5:23310388	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.75	-0.44	2.49e-13	Calcium levels;
KIRP	cis	rs4776059	1.000	rs4776059	chr15:52886962	C/T	cg25063058	chr15:52860530	ARPP19	0.61	6.69	0.39	1.5e-10	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10503236	chr1:231470652	EXOC8	0.43	6.04	0.36	5.58e-9	C-reactive protein;
KIRP	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg21775007	chr8:11205619	TDH	0.45	6.03	0.36	5.86e-9	Myopia (pathological);
KIRP	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.89	12.53	0.62	3.53e-28	Body mass index (adult);
KIRP	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.4	5.1	0.31	6.71e-7	Migraine;Coronary artery disease;
KIRP	cis	rs16937956	0.657	rs3751095	chr11:8435077	C/T	cg08015107	chr11:8618950	NA	-0.56	-7.33	-0.42	3.28e-12	Body mass index;
KIRP	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.68	-9.13	-0.5	2.59e-17	Coronary artery disease;
KIRP	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.7	6.93	0.4	3.57e-11	Prostate cancer;
KIRP	cis	rs367943	0.723	rs1965429	chr5:112679373	G/T	cg12552261	chr5:112820674	MCC	-0.56	-6.64	-0.39	2.01e-10	Type 2 diabetes;
KIRP	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.49	-0.62	4.56e-28	Exhaled nitric oxide output;
KIRP	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.96	-0.41	3.13e-11	Initial pursuit acceleration;
KIRP	cis	rs4742903	1.000	rs10820603	chr9:106877939	G/A	cg14250997	chr9:106856677	SMC2	0.38	5.01	0.3	1.03e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg05347473	chr6:146136440	FBXO30	0.45	6.39	0.38	8.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2147904	0.704	rs783624	chr1:42366343	G/A	cg26038582	chr1:42384390	HIVEP3	0.26	5.4	0.33	1.58e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg14673194	chr17:80132900	CCDC57	0.76	8.48	0.48	2.06e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg00852783	chr1:26633632	UBXN11	-0.52	-5.57	-0.33	6.55e-8	Obesity-related traits;
KIRP	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.53	6.72	0.39	1.27e-10	Body mass index;
KIRP	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.75	-7.82	-0.45	1.53e-13	Vitiligo;
KIRP	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.8	9.52	0.52	1.7e-18	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg21411534	chr10:93558674	TNKS2	0.77	6.66	0.39	1.77e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1723838	0.510	rs2735572	chr11:73688492	C/T	cg10064339	chr11:73693792	UCP2	0.94	6.19	0.37	2.55e-9	Obesity-related traits;
KIRP	cis	rs4132509	1.000	rs7534117	chr1:243964902	A/C	cg21452805	chr1:244014465	NA	-0.54	-5.32	-0.32	2.35e-7	RR interval (heart rate);
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg12486944	chr17:80159399	CCDC57	0.4	5.34	0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg00262122	chr8:11665843	FDFT1	-0.41	-5.18	-0.31	4.53e-7	Triglycerides;
KIRP	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.96	-0.54	7.42e-20	Neuroticism;
KIRP	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg14416269	chr4:6271139	WFS1	0.34	5.07	0.31	8.01e-7	Cisplatin-induced ototoxicity;
KIRP	cis	rs1434579	0.864	rs12978167	chr19:44942628	T/C	cg15540054	chr19:45004280	ZNF180	0.54	5.8	0.35	2e-8	Tuberculosis;
KIRP	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.26e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.47	6.05	0.36	5.22e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs58688157	0.960	rs34449380	chr11:617221	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.64	-7.73	-0.44	2.71e-13	Systemic lupus erythematosus;
KIRP	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs2120243	0.534	rs35004310	chr3:157113800	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs7005380	0.581	rs9987142	chr8:120937021	G/C	cg21645572	chr8:120931649	DEPDC6	-0.5	-6.76	-0.4	9.94e-11	Interstitial lung disease;
KIRP	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg08975724	chr8:8085496	FLJ10661	0.58	8.05	0.46	3.49e-14	Neuroticism;
KIRP	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.73	8.64	0.48	7.42e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg00852783	chr1:26633632	UBXN11	-0.6	-6.17	-0.37	2.79e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7766436	0.885	rs12662891	chr6:22575096	C/T	cg13666174	chr6:22585274	NA	-0.43	-5.88	-0.35	1.33e-8	Coronary artery disease;
KIRP	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg01689657	chr7:91764605	CYP51A1	0.38	5.55	0.33	7.43e-8	Breast cancer;
KIRP	cis	rs1867631	0.585	rs5008753	chr1:67092248	A/G	cg02459107	chr1:67143332	SGIP1	0.39	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.7	-7.66	-0.44	4.2e-13	DNA methylation (variation);
KIRP	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.43	5.86	0.35	1.47e-8	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg14159672	chr1:205819179	PM20D1	-0.59	-5.79	-0.35	2.17e-8	Menarche (age at onset);
KIRP	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.43	-0.38	6.74e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.47	-5.43	-0.33	1.33e-7	Height;
KIRP	cis	rs1620921	0.774	rs2565721	chr6:161235098	A/G	cg01280913	chr6:161186852	NA	-0.37	-5.09	-0.31	7.18e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs27434	0.583	rs151953	chr5:96157648	C/G	cg16492584	chr5:96139282	ERAP1	-0.38	-5.17	-0.31	4.93e-7	Ankylosing spondylitis;
KIRP	cis	rs72960926	1.000	rs72950597	chr6:74921367	T/C	cg03266952	chr6:74778945	NA	-0.64	-5.4	-0.33	1.6e-7	Metabolite levels (MHPG);
KIRP	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg13385521	chr17:29058706	SUZ12P	0.6	6.03	0.36	5.96e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10724491	chr3:112738377	C3orf17	0.45	6.13	0.36	3.49e-9	Survival in pancreatic cancer;
KIRP	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.42e-11	Schizophrenia;
KIRP	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg21573476	chr21:45109991	RRP1B	-0.52	-7.05	-0.41	1.78e-11	Mean corpuscular volume;
KIRP	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg18850127	chr7:39170497	POU6F2	0.28	5.51	0.33	8.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-6.34	-0.37	1.09e-9	LDL cholesterol levels;
KIRP	cis	rs6693295	0.887	rs2153029	chr1:246232500	T/A	cg11798871	chr1:246315928	SMYD3	-0.42	-5.33	-0.32	2.23e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.49	-5.24	-0.32	3.4e-7	Initial pursuit acceleration;
KIRP	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg20636351	chr8:55087400	NA	-0.54	-6.47	-0.38	5.15e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg14768367	chr16:72042858	DHODH	-0.93	-10.29	-0.55	6.94e-21	Blood protein levels;
KIRP	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg19468946	chr17:37922297	IKZF3	-0.48	-7.04	-0.41	1.96e-11	Asthma;
KIRP	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs2219968	1.000	rs13276123	chr8:78975338	G/A	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.61	0.44	5.85e-13	Body mass index;
KIRP	cis	rs2733310	0.793	rs4774245	chr15:57225148	G/A	cg13626582	chr15:57592083	LOC283663	0.27	6.23	0.37	1.98e-9	Mean platelet volume;
KIRP	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	6.64	0.39	2.02e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs3762637	0.941	rs9863712	chr3:122099906	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.7	-0.34	3.46e-8	LDL cholesterol levels;
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg09699651	chr6:150184138	LRP11	0.48	6.22	0.37	2.15e-9	Lung cancer;
KIRP	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.35	4.85	0.3	2.2e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.78	10.94	0.57	6.06e-23	Menarche (age at onset);
KIRP	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg18944383	chr4:111397179	ENPEP	0.39	6.35	0.38	1.05e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.81	7.95	0.45	6.87e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.74	-0.34	2.72e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.64	-0.39	1.99e-10	Monocyte percentage of white cells;
KIRP	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.24	0.37	1.88e-9	Electroencephalogram traits;
KIRP	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg15841412	chr13:111365552	ING1	0.54	6.19	0.37	2.52e-9	Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.51	-11.49	-0.59	9.54e-25	Diabetic kidney disease;
KIRP	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg01620082	chr3:125678407	NA	-1.18	-7.22	-0.42	6.28e-12	Breast cancer;
KIRP	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.75	12.1	0.61	9.41e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg11814155	chr7:99998594	ZCWPW1	0.57	5.32	0.32	2.3e-7	Platelet count;
KIRP	cis	rs4363385	0.574	rs4845503	chr1:152959939	A/G	cg07796016	chr1:152779584	LCE1C	-0.41	-5.07	-0.31	7.76e-7	Inflammatory skin disease;
KIRP	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.6	7.38	0.43	2.4e-12	Corneal astigmatism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08711118	chr3:126327472	TXNRD3IT1	0.48	6.46	0.38	5.5e-10	Survival in pancreatic cancer;
KIRP	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg18225595	chr11:63971243	STIP1	0.66	5.85	0.35	1.57e-8	Mean platelet volume;
KIRP	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs6546886	0.912	rs13021880	chr2:74310787	C/G	cg14702570	chr2:74259524	NA	-0.3	-6.09	-0.36	4.39e-9	Dialysis-related mortality;
KIRP	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg20744362	chr22:50050164	C22orf34	0.31	4.88	0.3	1.91e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs10495907	0.591	rs10199649	chr2:43954792	C/T	cg11659317	chr2:43863985	PLEKHH2	-0.42	-5.01	-0.3	1.04e-6	Coronary artery disease;
KIRP	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.5	5.83	0.35	1.73e-8	Uric acid levels;
KIRP	cis	rs9393813	0.529	rs4711155	chr6:27446446	C/A	cg18711553	chr6:27366782	ZNF391	-0.37	-4.87	-0.3	2.01e-6	Bipolar disorder;
KIRP	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg22903471	chr2:27725779	GCKR	-0.54	-7.83	-0.45	1.43e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	1.06	15.24	0.7	2.16e-37	Menopause (age at onset);
KIRP	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.89	14.75	0.68	1.08e-35	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg23442198	chr4:187126114	CYP4V2	0.77	6.89	0.4	4.56e-11	Blood protein levels;
KIRP	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.25	0.37	1.77e-9	Personality dimensions;
KIRP	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.39	-6.19	-0.37	2.51e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	8.1e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.43	7.22	0.42	6.59e-12	Heart rate;
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.63	5.74	0.34	2.71e-8	Alzheimer's disease;
KIRP	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.51	-0.52	1.86e-18	Triglycerides;
KIRP	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg12560992	chr17:57184187	TRIM37	0.63	5.71	0.34	3.25e-8	Cognitive test performance;
KIRP	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.84	-0.35	1.6e-8	Height;
KIRP	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-6.7	-0.39	1.4e-10	Neuroticism;
KIRP	cis	rs9513627	0.748	rs61525545	chr13:100118261	T/C	cg25919922	chr13:100150906	NA	-0.65	-5.66	-0.34	4.24e-8	Obesity-related traits;
KIRP	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.6	-9.45	-0.52	2.79e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.45	-6.17	-0.37	2.79e-9	Renal function-related traits (BUN);
KIRP	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17554472	chr22:41940697	POLR3H	-0.6	-6.48	-0.38	5e-10	Vitiligo;
KIRP	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.59	5.56	0.33	6.85e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.82	9.91	0.53	1.08e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg13010199	chr12:38710504	ALG10B	0.47	5.96	0.36	8.69e-9	Morning vs. evening chronotype;
KIRP	cis	rs1847505	0.562	rs3861177	chr13:61446605	T/C	cg25164009	chr13:61490935	NA	0.47	5.1	0.31	6.66e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg00933542	chr6:150070202	PCMT1	0.31	5.95	0.35	9.26e-9	Lung cancer;
KIRP	cis	rs1505368	0.533	rs7560905	chr2:213261808	C/T	cg16329650	chr2:213403929	ERBB4	0.41	5.6	0.34	5.85e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs2562456	0.833	rs62109223	chr19:21532393	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03654618	chr4:3208354	HTT	-0.46	-6.36	-0.38	9.7e-10	Select biomarker traits;
KIRP	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.84	14.07	0.67	2.2e-33	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg25801113	chr15:45476975	SHF	-0.44	-7.98	-0.45	5.43e-14	Uric acid levels;
KIRP	cis	rs2963155	0.518	rs1438732	chr5:142756266	G/C	cg17617527	chr5:142782415	NR3C1	0.77	7.72	0.44	3e-13	Breast cancer;
KIRP	trans	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg19274270	chr17:78178856	CARD14	-0.37	-6.64	-0.39	1.99e-10	Morning vs. evening chronotype;
KIRP	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.4	0.38	7.88e-10	Bipolar disorder;
KIRP	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.88	-0.3	1.87e-6	Lung cancer;
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg08805041	chr16:621841	PIGQ	-0.37	-5.06	-0.31	8.26e-7	Height;
KIRP	cis	rs71403859	0.504	rs35203704	chr16:71959661	G/A	cg08717414	chr16:71523259	ZNF19	-0.67	-5.17	-0.31	4.76e-7	Post bronchodilator FEV1;
KIRP	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg08076091	chr2:203926405	NBEAL1	0.91	9.46	0.52	2.52e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2522056	1.000	rs757105	chr5:131795663	C/T	cg07395648	chr5:131743802	NA	0.55	6.56	0.39	3.2e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	trans	rs994014	0.727	rs2109662	chr4:82272565	A/G	cg04076444	chr16:85646805	KIAA0182	-0.55	-6.73	-0.39	1.16e-10	Height;
KIRP	cis	rs5995756	0.736	rs1883123	chr22:39996882	C/T	cg03390717	chr22:39966585	CACNA1I	-0.3	-5.35	-0.32	1.96e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.81	-12.16	-0.61	5.95e-27	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.36	-5.22	-0.32	3.82e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.26	15.38	0.7	7.54e-38	Eosinophil percentage of granulocytes;
KIRP	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.65	-9.67	-0.52	5.76e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg02975922	chr3:195473998	MUC4	-0.54	-6.26	-0.37	1.68e-9	Pancreatic cancer;
KIRP	cis	rs72843166	1.000	rs72843166	chr17:61098296	G/T	cg19683800	chr17:61518354	CYB561	-0.42	-4.96	-0.3	1.3e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg05941025	chr16:89927596	SPIRE2	0.38	5.98	0.36	7.98e-9	Vitiligo;
KIRP	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs9972944	0.702	rs987929	chr17:63765856	A/G	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg20573242	chr4:122745356	CCNA2	0.41	5.08	0.31	7.43e-7	Type 2 diabetes;
KIRP	cis	rs4356975	0.563	rs12647682	chr4:69963168	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.55	7.33	0.42	3.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17154702	0.524	rs2664041	chr8:8593144	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.18	-0.31	4.58e-7	Neurocognitive impairment in HIV-1 infection (continuous);
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.79	7.54	0.43	9.13e-13	Lung function (FEV1/FVC);
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.39	-0.55	3.47e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7010876	0.568	rs7357576	chr8:89229864	T/A	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg11494091	chr17:61959527	GH2	0.48	6.01	0.36	6.63e-9	Height;
KIRP	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	trans	rs1807837	1.000	rs10918140	chr1:165201326	C/T	cg14563637	chr9:98931801	NA	0.49	6.07	0.36	4.91e-9	Pursuit maintenance gain;
KIRP	cis	rs5756391	0.546	rs9607391	chr22:37314770	A/T	cg16356956	chr22:37317934	CSF2RB	-0.39	-5.32	-0.32	2.32e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2708977	0.637	rs675239	chr2:97076556	A/G	cg01950434	chr2:97203154	ARID5A	-0.41	-5.0	-0.3	1.11e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.02	10.88	0.57	9.33e-23	HIV-1 control;
KIRP	cis	rs2286379	1.000	rs10128890	chr12:1903390	A/T	cg05227549	chr12:1770782	NA	0.3	4.85	0.3	2.19e-6	Blood pressure (smoking interaction);
KIRP	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.29	0.42	4.31e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4953911	0.927	rs4144831	chr2:135064805	C/T	cg18482303	chr2:135041380	MGAT5	-0.26	-4.97	-0.3	1.25e-6	Multiple sclerosis (severity);
KIRP	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.54	-6.45	-0.38	5.9e-10	Corneal astigmatism;
KIRP	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.54	-6.29	-0.37	1.47e-9	Macular telangiectasia type 2;
KIRP	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.26	17.69	0.75	9.67e-46	Atopic dermatitis;
KIRP	trans	rs61884328	0.561	rs79203530	chr11:46601604	C/T	cg10758369	chr1:48459236	NA	0.49	6.17	0.37	2.75e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg05347473	chr6:146136440	FBXO30	0.47	6.65	0.39	1.87e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2230307	0.536	rs561119	chr1:100603891	G/A	cg24955406	chr1:100503596	HIAT1	-0.59	-6.34	-0.37	1.1e-9	Carotid intima media thickness;
KIRP	cis	rs11671005	0.610	rs11669345	chr19:59062259	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.58	-6.74	-0.4	1.09e-10	Mean platelet volume;
KIRP	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.01	-0.3	1.04e-6	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.82	-12.53	-0.62	3.48e-28	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg09695851	chr17:3907499	NA	0.91	17.63	0.75	1.58e-45	Type 2 diabetes;
KIRP	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06307176	chr5:131281290	NA	0.53	5.75	0.34	2.64e-8	Life satisfaction;
KIRP	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.42	5.76	0.34	2.51e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg03999872	chr20:62272968	STMN3	0.61	7.0	0.41	2.42e-11	Atopic dermatitis;
KIRP	cis	rs7180079	1.000	rs2062248	chr15:64672319	C/T	cg15337035	chr15:64978493	NA	-0.47	-4.86	-0.3	2.12e-6	Monocyte count;
KIRP	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg09137382	chr11:130731461	NA	0.55	8.07	0.46	3.14e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs367615	0.550	rs10060801	chr5:108881782	A/G	cg17395555	chr5:108820864	NA	0.37	5.15	0.31	5.4e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-0.85	-6.5	-0.38	4.52e-10	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.33	-5.16	-0.31	5.08e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg22800045	chr5:56110881	MAP3K1	-0.75	-7.35	-0.42	2.98e-12	Initial pursuit acceleration;
KIRP	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg00981070	chr1:2046702	PRKCZ	0.41	5.89	0.35	1.25e-8	Height;
KIRP	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg18154014	chr19:37997991	ZNF793	0.68	7.28	0.42	4.54e-12	Coronary artery calcification;
KIRP	cis	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg27487796	chr7:28973253	NA	-0.23	-5.2	-0.31	4.2e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23125898	chr21:42539633	BACE2	-0.46	-6.08	-0.36	4.45e-9	Myopia;
KIRP	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg19906672	chr4:6918868	TBC1D14	0.56	5.52	0.33	8.54e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.42	-0.43	1.94e-12	Bladder cancer;
KIRP	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.48	-5.96	-0.36	8.8e-9	Facial morphology (factor 20);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15645804	chr4:754410	PCGF3	0.57	7.59	0.44	6.76e-13	Interleukin-4 levels;
KIRP	cis	rs73058052	1.000	rs67546213	chr19:50082587	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.65	6.51	0.38	4.1e-10	Fibrinogen levels;
KIRP	cis	rs7534824	0.543	rs1074739	chr1:101362371	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.25	0.42	5.48e-12	Refractive astigmatism;
KIRP	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.5	-6.51	-0.38	4.2e-10	Coronary artery disease;
KIRP	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	0.85	11.14	0.58	1.32e-23	Primary sclerosing cholangitis;
KIRP	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.98	-12.34	-0.62	1.49e-27	Response to antineoplastic agents;
KIRP	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg13147721	chr7:65941812	NA	-1.02	-7.1	-0.41	1.36e-11	Diabetic kidney disease;
KIRP	cis	rs9826463	0.938	rs9816128	chr3:142327107	C/T	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs73200209	0.912	rs56381931	chr12:116491508	T/C	cg01776926	chr12:116560359	MED13L	-0.47	-5.53	-0.33	8.26e-8	Total body bone mineral density;
KIRP	cis	rs1971762	0.762	rs7312853	chr12:54073597	C/G	cg16917193	chr12:54089295	NA	-0.69	-9.71	-0.53	4.3e-19	Height;
KIRP	cis	rs7017914	0.869	rs11987511	chr8:71645871	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs4700695	0.925	rs381549	chr5:65383371	A/G	cg21114390	chr5:65439923	SFRS12	-0.55	-5.38	-0.32	1.71e-7	Facial morphology (factor 19);
KIRP	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg00405596	chr8:11794950	NA	-0.47	-6.12	-0.36	3.64e-9	Retinal vascular caliber;
KIRP	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg04132472	chr17:19861366	AKAP10	0.49	7.01	0.41	2.33e-11	Schizophrenia;
KIRP	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg13628971	chr7:2884303	GNA12	0.39	4.96	0.3	1.32e-6	Height;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14813417	chr11:13205282	NA	-0.41	-6.16	-0.37	2.96e-9	C-reactive protein;
KIRP	trans	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	trans	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.18	0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.72e-6	Systolic blood pressure;
KIRP	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.77	-0.4	9.15e-11	Type 2 diabetes;
KIRP	cis	rs6723108	0.967	rs10928513	chr2:135456759	C/T	cg25422880	chr2:135218333	TMEM163	-0.38	-5.12	-0.31	6.16e-7	Type 2 diabetes;
KIRP	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg00262122	chr8:11665843	FDFT1	0.43	5.41	0.33	1.52e-7	Myopia (pathological);
KIRP	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg22437258	chr11:111473054	SIK2	0.58	6.77	0.4	9.39e-11	Primary sclerosing cholangitis;
KIRP	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-5.95	-0.35	9.13e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11603020	0.950	rs11229066	chr11:57374871	C/G	cg19752551	chr11:57585705	CTNND1	-0.7	-9.76	-0.53	3.08e-19	Blood protein levels;
KIRP	cis	rs12519773	0.517	rs17360811	chr5:92492349	G/A	cg18783429	chr5:92414398	NA	0.31	5.33	0.32	2.19e-7	Migraine;
KIRP	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg07541023	chr7:19748670	TWISTNB	0.7	6.07	0.36	4.76e-9	Thyroid stimulating hormone;
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg18183042	chr17:80733038	TBCD	-0.39	-5.1	-0.31	6.63e-7	Glycated hemoglobin levels;
KIRP	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg08668510	chr10:1095578	IDI1	-0.74	-5.55	-0.33	7.28e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs12638540	0.543	rs13433871	chr3:32559673	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.68	5.67	0.34	4.09e-8	Mortality in heart failure;
KIRP	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	11.24	0.58	6.37e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs9608946	1.000	rs9606735	chr22:30884831	C/T	cg23383138	chr22:30885012	SEC14L4	0.4	4.93	0.3	1.52e-6	Red cell distribution width;
KIRP	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.48	5.82	0.35	1.81e-8	Iron status biomarkers;
KIRP	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg19770292	chr5:1868693	NA	0.41	5.44	0.33	1.31e-7	Cardiovascular disease risk factors;
KIRP	cis	rs8067545	1.000	rs7218708	chr17:19926836	A/G	cg13482628	chr17:19912719	NA	0.59	8.4	0.47	3.68e-15	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16727027	chr4:57844010	C4orf14;POLR2B	-0.52	-7.18	-0.42	8.38e-12	Survival in pancreatic cancer;
KIRP	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	1.0	16.71	0.73	2.1e-42	Adiposity;
KIRP	cis	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg07460842	chr6:66804631	NA	-0.47	-5.86	-0.35	1.48e-8	Blood trace element (Cu levels);
KIRP	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg25019722	chr6:37503610	NA	-0.78	-10.59	-0.56	7.84e-22	Cognitive performance;
KIRP	cis	rs787274	1.000	rs2796028	chr9:115528755	T/C	cg13803584	chr9:115635662	SNX30	-0.73	-6.62	-0.39	2.19e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.92	6.9	0.4	4.37e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg11317459	chr13:21872234	NA	-1.02	-11.88	-0.6	5.1e-26	White matter hyperintensity burden;
KIRP	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.18	-0.46	1.54e-14	Aortic root size;
KIRP	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.6	-7.15	-0.41	9.86e-12	Colorectal cancer;
KIRP	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.59	8.41	0.47	3.3e-15	Heart rate;
KIRP	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.14	14.68	0.68	1.79e-35	Lymphocyte percentage of white cells;
KIRP	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15987572	chr1:22137435	LDLRAD2	0.5	6.3	0.37	1.37e-9	Gut microbiome composition (summer);
KIRP	trans	rs1973993	0.537	rs1988854	chr1:96989786	A/G	cg10631902	chr5:14652156	NA	-0.52	-6.52	-0.38	4.01e-10	Weight;
KIRP	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg02725872	chr8:58115012	NA	-0.48	-5.27	-0.32	2.92e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.58	7.57	0.43	7.61e-13	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs6545883	0.894	rs2177962	chr2:61588070	T/A	cg15711740	chr2:61764176	XPO1	0.58	7.38	0.43	2.47e-12	Tuberculosis;
KIRP	cis	rs17221829	0.703	rs7944552	chr11:89377208	C/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.47	-5.25	-0.32	3.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.61	11.41	0.59	1.73e-24	Bone mineral density;
KIRP	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.53	-7.22	-0.42	6.32e-12	Mean corpuscular volume;
KIRP	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg12042659	chr19:58951599	ZNF132	0.5	6.09	0.36	4.35e-9	Uric acid clearance;
KIRP	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.61	6.3	0.37	1.4e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs4851254	0.921	rs11679078	chr2:100757881	C/G	cg17356467	chr2:100759845	AFF3	0.6	7.69	0.44	3.57e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.58	-7.31	-0.42	3.67e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4950322	0.570	rs17356184	chr1:146734601	A/T	cg22381352	chr1:146742008	CHD1L	-0.47	-5.51	-0.33	9.25e-8	Protein quantitative trait loci;
KIRP	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg22366001	chr1:2066006	PRKCZ	0.38	4.89	0.3	1.83e-6	Height;
KIRP	trans	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg10756647	chr7:56101905	PSPH	0.98	6.82	0.4	7.04e-11	Diabetic kidney disease;
KIRP	cis	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg21546286	chr11:48923668	NA	0.41	5.26	0.32	3.17e-7	HDL cholesterol;
KIRP	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.51	-11.28	-0.58	4.73e-24	Diabetic kidney disease;
KIRP	cis	rs9303542	0.559	rs1042818	chr17:46620111	T/C	cg04904318	chr17:46607828	HOXB1	-0.62	-6.76	-0.4	9.88e-11	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg06654118	chr4:1303317	MAEA	0.29	5.18	0.31	4.7e-7	Obesity-related traits;
KIRP	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg17279839	chr7:150038598	RARRES2	0.42	5.2	0.31	4.12e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7107770	1.000	rs12787088	chr11:125094583	G/A	cg04164023	chr11:125106101	PKNOX2	-0.53	-5.18	-0.31	4.58e-7	Photic sneeze reflex;
KIRP	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg14689365	chr7:158441557	NCAPG2	-0.4	-4.95	-0.3	1.39e-6	Height;
KIRP	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg19849509	chr2:175204996	NA	-0.54	-6.34	-0.37	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.16	0.64	2.57e-30	Platelet count;
KIRP	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg09201719	chr10:104596890	CYP17A1	0.35	5.07	0.31	7.93e-7	Arsenic metabolism;
KIRP	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08822215	chr16:89438651	ANKRD11	-0.45	-6.11	-0.36	3.93e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs7923609	0.875	rs10822143	chr10:64887856	C/T	cg08743896	chr10:65200160	JMJD1C	-0.36	-5.21	-0.32	4.03e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12311304	0.965	rs10846159	chr12:15363407	A/G	cg08258403	chr12:15378311	NA	0.34	5.01	0.3	1.05e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg00919237	chr7:87102261	ABCB4	-0.7	-9.26	-0.51	1.08e-17	Gallbladder cancer;
KIRP	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg26248373	chr2:1572462	NA	-0.69	-7.38	-0.43	2.39e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19138499	chr6:139248115	REPS1	-0.41	-6.27	-0.37	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg19554555	chr3:13937349	NA	-0.48	-6.43	-0.38	6.51e-10	Ovarian reserve;
KIRP	cis	rs6684514	1.000	rs3806409	chr1:156252291	A/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs7546094	1.000	rs2932536	chr1:113202417	G/A	cg22162597	chr1:113214053	CAPZA1	-0.5	-7.06	-0.41	1.67e-11	Platelet distribution width;
KIRP	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.09e-14	Lung cancer;
KIRP	cis	rs16958440	1.000	rs11082563	chr18:44659001	T/C	cg17192377	chr18:44677553	HDHD2	0.7	6.45	0.38	6.01e-10	Sitting height ratio;
KIRP	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.62	5.12	0.31	6.07e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.62	10.02	0.54	4.86e-20	HDL cholesterol;
KIRP	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27144592	chr16:783916	NARFL	0.36	5.09	0.31	7.27e-7	Height;
KIRP	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.74	7.27	0.42	4.87e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg04289385	chr6:36355825	ETV7	0.45	7.2	0.42	7.28e-12	Platelet distribution width;
KIRP	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg16141378	chr3:129829833	LOC729375	0.49	6.24	0.37	1.9e-9	Mood instability;
KIRP	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg18500431	chr7:1709489	NA	0.53	6.65	0.39	1.87e-10	Sleep duration;
KIRP	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg07741184	chr6:167504864	NA	-0.24	-6.39	-0.38	8.1e-10	Crohn's disease;
KIRP	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.17	-0.31	4.81e-7	Body mass index;
KIRP	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs9815354	0.680	rs73073266	chr3:42021116	A/G	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.43	0.43	1.77e-12	Mean corpuscular volume;
KIRP	cis	rs7481584	0.962	rs11603638	chr11:2990526	G/A	cg25174290	chr11:3078921	CARS	-0.59	-6.49	-0.38	4.62e-10	Calcium levels;
KIRP	cis	rs2644899	0.750	rs2607414	chr19:41267129	C/T	cg24958765	chr19:41283667	RAB4B	0.62	6.94	0.4	3.52e-11	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9535307	1.000	rs2897770	chr13:50325070	A/G	cg04663916	chr13:50265991	EBPL	0.65	6.53	0.38	3.68e-10	Obesity-related traits;
KIRP	cis	rs72634258	0.786	rs9434991	chr1:8178708	G/C	cg00042356	chr1:8021962	PARK7	0.49	4.86	0.3	2.09e-6	Inflammatory bowel disease;
KIRP	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg21401794	chr1:90099060	LRRC8C	0.69	9.4	0.51	4.08e-18	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11997175	0.713	rs6997661	chr8:33638554	A/G	cg04338863	chr8:33670619	NA	-0.42	-5.56	-0.33	6.91e-8	Body mass index;
KIRP	cis	rs930036	0.604	rs7603858	chr2:172036699	T/A	cg12801329	chr2:171670795	NA	0.47	5.47	0.33	1.11e-7	Menopause (age at onset);
KIRP	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11622362	chr11:34938112	PDHX;APIP	-0.48	-6.01	-0.36	6.63e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7849270	1.000	rs10988232	chr9:131915348	G/T	cg13538475	chr9:131942899	NA	-0.35	-5.6	-0.34	5.69e-8	Blood metabolite ratios;
KIRP	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.9	14.33	0.67	2.82e-34	Longevity;
KIRP	cis	rs1843834	0.755	rs11898692	chr2:225575173	T/C	cg22509189	chr2:225307070	NA	-0.43	-5.27	-0.32	3.01e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.48	0.33	1.05e-7	Lung cancer;
KIRP	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg13334819	chr7:99746414	C7orf59	-0.55	-6.27	-0.37	1.63e-9	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.79	10.68	0.56	3.92e-22	Aortic root size;
KIRP	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.59	-0.34	6.09e-8	Breast cancer;
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg18209359	chr17:80159595	CCDC57	0.42	5.49	0.33	1.02e-7	Life satisfaction;
KIRP	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg17724175	chr1:150552817	MCL1	0.3	5.15	0.31	5.43e-7	Melanoma;
KIRP	cis	rs7215564	0.818	rs4890054	chr17:78587195	C/T	cg06153925	chr17:78755379	RPTOR	0.44	5.85	0.35	1.57e-8	Myopia (pathological);
KIRP	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.7	8.15	0.46	1.89e-14	Small cell lung carcinoma;
KIRP	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.75	0.4	1.04e-10	Recombination measurement;
KIRP	cis	rs73086581	1.000	rs73084575	chr20:3906768	G/T	cg02187196	chr20:3869020	PANK2	0.52	5.06	0.31	8.39e-7	Response to antidepressants in depression;
KIRP	cis	rs4006360	0.551	rs11868548	chr17:39237132	C/G	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.91	-0.53	1.08e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs56161922	0.818	rs55638397	chr1:207856040	G/A	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg08738300	chr3:44038990	NA	0.7	9.83	0.53	1.92e-19	Coronary artery disease;
KIRP	cis	rs7258465	0.931	rs1560119	chr19:18573675	A/G	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.97	-0.36	8.37e-9	Breast cancer;
KIRP	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.3	0.65	9.13e-31	Cognitive function;
KIRP	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg27411982	chr8:10470053	RP1L1	0.39	5.01	0.3	1.05e-6	Retinal vascular caliber;
KIRP	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.11	-0.31	6.42e-7	Personality dimensions;
KIRP	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg09699651	chr6:150184138	LRP11	-0.47	-6.09	-0.36	4.33e-9	Lung cancer;
KIRP	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.59	-8.22	-0.46	1.16e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs12519773	0.576	rs1496337	chr5:92411293	C/T	cg18783429	chr5:92414398	NA	0.31	5.28	0.32	2.86e-7	Migraine;
KIRP	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg17425144	chr1:10567563	PEX14	0.43	7.73	0.44	2.7e-13	Prostate cancer;
KIRP	cis	rs7221595	0.825	rs9896963	chr17:3966591	T/C	cg21851534	chr17:3907994	ZZEF1	0.6	6.32	0.37	1.25e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.65	7.7	0.44	3.4e-13	Aortic root size;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07963361	chr7:87505792	SLC25A40;DBF4	-0.45	-6.11	-0.36	3.89e-9	Myopia;
KIRP	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg13147721	chr7:65941812	NA	1.05	7.4	0.43	2.09e-12	Diabetic kidney disease;
KIRP	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-9.38	-0.51	4.54e-18	QRS duration;
KIRP	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	5.04	0.31	8.84e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	6.7	0.39	1.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.29	0.32	2.75e-7	Homoarginine levels;
KIRP	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg01097406	chr16:89675127	NA	-0.35	-5.18	-0.31	4.7e-7	Vitiligo;
KIRP	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.56	8.43	0.47	2.86e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg10047753	chr17:41438598	NA	0.86	11.84	0.6	6.89e-26	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg18154014	chr19:37997991	ZNF793	0.91	9.24	0.51	1.22e-17	Coronary artery calcification;
KIRP	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.9e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2239815	0.515	rs12170231	chr22:29237824	C/T	cg02153584	chr22:29168773	CCDC117	0.59	5.73	0.34	2.93e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs6842047	0.520	rs4253425	chr4:187205929	T/C	cg09526685	chr4:187126073	CYP4V2	0.75	5.85	0.35	1.54e-8	Blood protein levels;
KIRP	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg23503501	chr22:45809793	SMC1B;RIBC2	0.58	5.46	0.33	1.17e-7	Tonsillectomy;
KIRP	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg19263494	chr1:156181616	PMF1;SLC25A44	0.44	4.86	0.3	2.05e-6	Testicular germ cell tumor;
KIRP	cis	rs17428704	0.571	rs73061636	chr5:14409060	T/A	cg26595256	chr5:14380529	TRIO	-0.83	-6.46	-0.38	5.59e-10	Electroencephalogram traits;
KIRP	cis	rs882732	0.576	rs3827893	chr14:95033671	A/T	cg05186455	chr14:95027692	SERPINA4	-0.38	-6.09	-0.36	4.3e-9	Blood protein levels;
KIRP	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18932078	chr1:2524107	MMEL1	-0.48	-6.76	-0.4	1.02e-10	Ulcerative colitis;
KIRP	cis	rs600806	0.778	rs4970767	chr1:110015183	G/A	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg16141378	chr3:129829833	LOC729375	-0.53	-7.21	-0.42	6.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	0.81	12.33	0.62	1.64e-27	Body mass index;
KIRP	cis	rs883565	0.696	rs7620304	chr3:39079623	T/A	cg01426195	chr3:39028469	NA	-0.67	-11.15	-0.58	1.24e-23	Handedness;
KIRP	cis	rs2594989	0.779	rs2437685	chr3:11593013	A/G	cg01796438	chr3:11312864	ATG7	-0.42	-5.64	-0.34	4.6e-8	Circulating chemerin levels;
KIRP	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.43	5.18	0.31	4.57e-7	Iron status biomarkers;
KIRP	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	7.46	0.43	1.49e-12	Neuroticism;
KIRP	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.38	0.38	8.68e-10	Bipolar disorder;
KIRP	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.47	5.8	0.35	2.02e-8	Coronary artery disease;
KIRP	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.48	-0.38	5.08e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15688767	chr3:125093330	ZNF148	0.67	8.19	0.46	1.41e-14	Smoking initiation;
KIRP	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs12580194	0.593	rs3935215	chr12:55792401	T/A	cg19537932	chr12:55886519	OR6C68	-0.52	-6.68	-0.39	1.55e-10	Cancer;
KIRP	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14598338	chr9:96623480	NA	-0.66	-11.24	-0.58	6.49e-24	DNA methylation (variation);
KIRP	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.66	-8.4	-0.47	3.57e-15	Body mass index;
KIRP	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.77	12.49	0.62	4.69e-28	Rheumatoid arthritis;
KIRP	cis	rs2273669	0.667	rs11752532	chr6:109335969	C/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs4690686	0.500	rs11723131	chr4:177268602	G/A	cg17059388	chr4:177262070	NA	0.87	12.83	0.63	3.42e-29	Essential tremor;
KIRP	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.85	16.16	0.72	1.64e-40	Anterior chamber depth;
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18252515	chr7:66147081	NA	-0.47	-5.5	-0.33	9.36e-8	Aortic root size;
KIRP	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg25019722	chr6:37503610	NA	-0.95	-15.3	-0.7	1.43e-37	Cognitive performance;
KIRP	cis	rs7215564	0.908	rs35584560	chr17:78668256	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.22	0.32	3.83e-7	Myopia (pathological);
KIRP	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.44	-0.47	2.8e-15	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg09455208	chr3:40491958	NA	0.31	5.56	0.33	6.84e-8	Renal cell carcinoma;
KIRP	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.66	9.71	0.53	4.56e-19	Retinal vascular caliber;
KIRP	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.86	13.17	0.64	2.49e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.8	10.38	0.55	3.63e-21	Breast cancer;
KIRP	cis	rs918629	0.761	rs7705720	chr5:95280033	T/C	cg16656078	chr5:95278638	ELL2	-0.49	-7.13	-0.41	1.14e-11	IgG glycosylation;
KIRP	cis	rs10203711	1.000	rs907113	chr2:239567724	T/C	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13315871	1.000	rs9869276	chr3:58401076	G/A	cg12435725	chr3:58293450	RPP14	-0.52	-5.5	-0.33	9.71e-8	Cholesterol, total;
KIRP	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.38	-6.92	-0.4	3.87e-11	Renal cell carcinoma;
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.45	-0.38	5.92e-10	Lung cancer;
KIRP	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg13385521	chr17:29058706	SUZ12P	0.77	6.52	0.38	3.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4700695	0.925	rs12653007	chr5:65396965	G/A	cg21114390	chr5:65439923	SFRS12	-0.46	-5.35	-0.32	2.06e-7	Facial morphology (factor 19);
KIRP	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg11693508	chr17:37793320	STARD3	0.75	8.36	0.47	4.69e-15	Bipolar disorder;
KIRP	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.83	-13.85	-0.66	1.24e-32	Brugada syndrome;
KIRP	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg01065977	chr19:18549689	ISYNA1	-0.43	-6.59	-0.39	2.73e-10	Breast cancer;
KIRP	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	10.26	0.55	8.55e-21	Exhaled nitric oxide output;
KIRP	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	4.1e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1692580	0.777	rs12136830	chr1:2189196	A/T	cg21194808	chr1:2205498	SKI	0.35	5.16	0.31	4.99e-7	Coronary artery disease;
KIRP	cis	rs10423674	0.526	rs34482977	chr19:18824038	C/G	cg14292368	chr19:18793705	CRTC1	-0.58	-7.58	-0.43	7.17e-13	Menarche (age at onset);
KIRP	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.05	20.16	0.79	5.05e-54	Testicular germ cell tumor;
KIRP	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.99	-0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.01	0.3	1.06e-6	Educational attainment;
KIRP	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg07317062	chr7:27170388	HOXA4	-0.32	-4.87	-0.3	2.02e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	ch.11.340609R	chr11:12831013	TEAD1	-0.44	-5.43	-0.33	1.34e-7	Educational attainment (years of education);
KIRP	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg06026331	chr20:60912101	LAMA5	0.51	5.54	0.33	7.66e-8	Colorectal cancer;
KIRP	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14893161	chr1:205819251	PM20D1	-0.55	-5.47	-0.33	1.11e-7	Menarche (age at onset);
KIRP	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.79	-12.56	-0.63	2.72e-28	Idiopathic membranous nephropathy;
KIRP	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg19650706	chr5:140594406	PCDHB13	-0.46	-5.02	-0.3	9.85e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7116495	0.881	rs1939243	chr11:71742735	A/G	cg26138937	chr11:71823887	C11orf51	0.67	5.13	0.31	6.01e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.86	-12.84	-0.63	3.11e-29	Height;
KIRP	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg04132472	chr17:19861366	AKAP10	0.4	5.24	0.32	3.52e-7	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	16.05	0.72	3.91e-40	Homoarginine levels;
KIRP	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg04310649	chr10:35416472	CREM	-0.57	-6.88	-0.4	4.92e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7078219	0.686	rs12412391	chr10:101288935	A/G	cg07044859	chr10:101282883	NA	-0.34	-5.04	-0.31	8.88e-7	Dental caries;
KIRP	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg25019033	chr10:957182	NA	-0.54	-5.8	-0.35	2.06e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs12044355	0.927	rs66909551	chr1:231834942	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	5.49	0.33	9.96e-8	Alzheimer's disease;
KIRP	cis	rs3825932	0.659	rs4778724	chr15:79238406	C/T	cg25744700	chr15:79237217	CTSH	0.42	5.24	0.32	3.49e-7	Type 1 diabetes;
KIRP	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.23	-0.32	3.62e-7	Bipolar disorder;
KIRP	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg18350739	chr11:68623251	NA	-0.46	-7.24	-0.42	5.63e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	10.67	0.56	4.31e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.59	8.85	0.49	1.79e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	1.0	17.83	0.75	3.29e-46	Leprosy;
KIRP	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.43	6.6	0.39	2.57e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg02153584	chr22:29168773	CCDC117	0.61	7.47	0.43	1.37e-12	Lymphocyte counts;
KIRP	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	1.22	9.09	0.5	3.42e-17	Gut microbiota (bacterial taxa);
KIRP	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.72	-8.55	-0.48	1.29e-15	Vitamin D levels;
KIRP	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.49	-0.33	9.96e-8	Mean corpuscular volume;
KIRP	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.68	11.61	0.59	3.92e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg24747557	chr10:131355152	MGMT	0.43	5.91	0.35	1.16e-8	Response to temozolomide;
KIRP	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.39	5.1	0.31	6.64e-7	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	0.86	11.83	0.6	7.26e-26	Homoarginine levels;
KIRP	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.23	13.53	0.65	1.52e-31	Uric acid levels;
KIRP	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-7.34	-0.42	3.08e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.31	12.44	0.62	7.1e-28	Diabetic retinopathy;
KIRP	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-18.9	-0.77	8.19e-50	Ulcerative colitis;
KIRP	cis	rs10773046	0.740	rs7313897	chr12:124350360	G/C	cg18594669	chr12:124364423	DNAH10	0.37	5.03	0.31	9.41e-7	Osteoarthritis (hip);
KIRP	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg17834443	chr8:19674713	INTS10	0.62	5.53	0.33	8.1e-8	Lipid metabolism phenotypes;
KIRP	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg04202892	chr2:111875749	ACOXL	0.5	6.93	0.4	3.76e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg16898833	chr6:26189333	HIST1H4D	0.95	5.43	0.33	1.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12986413	0.967	rs1074047	chr19:2158748	A/G	cg09261902	chr19:2140048	AP3D1	0.64	9.89	0.53	1.22e-19	Height;
KIRP	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.6	-8.14	-0.46	1.97e-14	HDL cholesterol;
KIRP	cis	rs580438	0.792	rs7633380	chr3:13332868	G/T	cg10657019	chr3:13328039	NA	0.74	9.81	0.53	2.26e-19	Myringotomy;
KIRP	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg08619932	chr19:49200058	FUT2	0.38	5.91	0.35	1.11e-8	Dietary macronutrient intake;
KIRP	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.46	5.27	0.32	2.96e-7	Schizophrenia;
KIRP	cis	rs4765905	0.671	rs10848642	chr12:2331572	A/G	cg10668781	chr12:2307325	CACNA1C	-0.29	-5.5	-0.33	9.7e-8	Schizophrenia;
KIRP	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg23978390	chr7:1156363	C7orf50	0.56	5.88	0.35	1.3e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg23719950	chr11:63933701	MACROD1	-0.58	-5.84	-0.35	1.68e-8	Mean platelet volume;
KIRP	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg21252483	chr19:49399788	TULP2	-0.43	-5.72	-0.34	3.1e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs16976116	0.901	rs28589384	chr15:55494366	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.79	13.84	0.66	1.28e-32	Height;
KIRP	cis	rs12913538	0.715	rs955529	chr15:62881864	A/T	cg09983546	chr15:62884068	NA	-0.45	-5.89	-0.35	1.27e-8	Sleep depth;
KIRP	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.82	10.1	0.54	2.77e-20	Menarche (age at onset);
KIRP	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg10253484	chr15:75165896	SCAMP2	0.67	7.28	0.42	4.48e-12	Systemic lupus erythematosus;
KIRP	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.14	-0.36	3.22e-9	Type 2 diabetes;
KIRP	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg03433033	chr1:76189801	ACADM	-0.47	-6.9	-0.4	4.27e-11	Daytime sleep phenotypes;
KIRP	cis	rs6693567	0.565	rs6685252	chr1:150259945	T/A	cg07843065	chr1:150265600	MRPS21	-0.5	-7.29	-0.42	4.31e-12	Migraine;
KIRP	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.68	-10.24	-0.55	1.02e-20	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09302448	chr16:67562672	FAM65A	0.48	6.18	0.37	2.64e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs654950	0.875	rs4660544	chr1:41996871	T/C	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.47	-0.38	5.23e-10	Airway imaging phenotypes;
KIRP	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs12496230	0.794	rs6549425	chr3:66866811	T/A	cg17646820	chr3:66848679	NA	0.39	6.28	0.37	1.51e-9	Type 2 diabetes;
KIRP	cis	rs76533333	0.646	rs71446626	chr13:113390361	G/A	cg04656015	chr13:113407548	ATP11A	0.64	5.63	0.34	4.84e-8	Red cell distribution width;
KIRP	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg26248373	chr2:1572462	NA	-0.66	-6.75	-0.4	1.05e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.08	-13.58	-0.65	1.05e-31	Exhaled nitric oxide output;
KIRP	cis	rs5743618	0.537	rs6531662	chr4:38767956	T/C	cg06935464	chr4:38784597	TLR10	0.42	5.24	0.32	3.53e-7	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02711726	chr17:80685570	FN3KRP	-0.6	-8.09	-0.46	2.77e-14	Glycated hemoglobin levels;
KIRP	cis	rs6732160	0.657	rs10171459	chr2:73434728	A/C	cg01422370	chr2:73384389	NA	0.41	5.41	0.33	1.46e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.81	9.21	0.51	1.51e-17	Corneal astigmatism;
KIRP	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.43	-6.89	-0.4	4.72e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg16141378	chr3:129829833	LOC729375	0.49	6.42	0.38	6.93e-10	Neuroticism;
KIRP	cis	rs7116495	1.000	rs488799	chr11:71561686	A/G	cg11196788	chr11:71737549	NUMA1	-0.5	-5.04	-0.31	8.88e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg25173405	chr17:45401733	C17orf57	0.41	5.4	0.33	1.59e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.55	6.44	0.38	6.24e-10	Aortic root size;
KIRP	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.29e-16	Prudent dietary pattern;
KIRP	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.9	0.53	1.11e-19	Multiple sclerosis;
KIRP	cis	rs2395528	0.597	rs2578117	chr10:80126046	G/A	cg08356028	chr10:80217969	NA	-0.38	-5.59	-0.34	6.07e-8	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg22800045	chr5:56110881	MAP3K1	0.52	5.86	0.35	1.51e-8	Coronary artery disease;
KIRP	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg01950434	chr2:97203154	ARID5A	-0.51	-6.4	-0.38	7.65e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.78	-13.08	-0.64	5.02e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.62	-0.34	5.06e-8	Ulcerative colitis;
KIRP	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg18944383	chr4:111397179	ENPEP	0.51	8.55	0.48	1.35e-15	Coronary artery disease;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg04025307	chr7:1156635	C7orf50	0.58	8.1	0.46	2.59e-14	Longevity;Endometriosis;
KIRP	cis	rs6859018	1.000	rs10056599	chr5:158722910	T/G	cg26646896	chr5:158686746	NA	-0.37	-5.3	-0.32	2.54e-7	Serum sulfate level;
KIRP	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.69	7.17	0.42	8.82e-12	Vitiligo;
KIRP	cis	rs55863869	0.748	rs4894037	chr2:179623142	C/T	cg02880032	chr2:179629472	TTN	-0.67	-5.53	-0.33	8.11e-8	QT interval;
KIRP	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg13540341	chr19:49222985	MAMSTR	0.35	5.58	0.34	6.36e-8	Dietary macronutrient intake;
KIRP	trans	rs7939886	0.920	rs59300271	chr11:55961792	G/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg04014002	chr1:33206468	KIAA1522	-0.46	-6.32	-0.37	1.19e-9	Bladder cancer;
KIRP	cis	rs72766638	0.848	rs55931012	chr9:136949669	C/T	cg13789015	chr9:136890014	NCRNA00094	0.69	5.87	0.35	1.39e-8	Mosquito bite size;
KIRP	cis	rs1656402	1.000	rs1210070	chr2:233423788	C/G	cg03852847	chr2:233439513	NA	0.7	11.53	0.59	6.86e-25	Non-small cell lung cancer (survival);
KIRP	cis	rs667920	0.512	rs13065626	chr3:136294757	C/G	cg15507776	chr3:136538369	TMEM22	-0.66	-5.81	-0.35	1.88e-8	Coronary artery disease;
KIRP	cis	rs7760949	0.889	rs9475787	chr6:13926102	G/C	cg27413430	chr6:13925136	RNF182	0.57	6.7	0.39	1.39e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-35.63	-0.92	4.25e-99	Myeloid white cell count;
KIRP	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.74	-9.93	-0.53	9.36e-20	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15136597	chr2:132250196	FAM128A;LOC150776	0.54	6.87	0.4	5.29e-11	Parkinson's disease;
KIRP	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg05127821	chr10:94822908	CYP26C1	-1.1	-11.26	-0.58	5.51e-24	Coronary artery disease;
KIRP	cis	rs59197085	0.515	rs2402938	chr7:128444295	T/C	cg00734629	chr7:128471146	FLNC	0.4	4.9	0.3	1.75e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg11814155	chr7:99998594	ZCWPW1	0.55	5.42	0.33	1.42e-7	Platelet count;
KIRP	cis	rs2548003	0.518	rs2548006	chr5:28732126	C/T	cg11015470	chr5:28928158	NA	-0.48	-5.35	-0.32	2.05e-7	Hip geometry;
KIRP	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.58	7.86	0.45	1.17e-13	Height;
KIRP	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg27417294	chr10:81904244	PLAC9	-0.35	-4.93	-0.3	1.5e-6	Sarcoidosis;
KIRP	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.63	-0.44	5.11e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22355463	chr4:146857475	ZNF827	0.46	6.33	0.37	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg25356066	chr3:128598488	ACAD9	0.57	6.59	0.39	2.71e-10	IgG glycosylation;
KIRP	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-6.0	-0.36	7.01e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3752645	0.764	rs74620117	chr7:106704730	T/A	cg02696742	chr7:106810147	HBP1	-0.76	-5.3	-0.32	2.59e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg07460842	chr6:66804631	NA	-0.49	-6.08	-0.36	4.46e-9	Blood trace element (Cu levels);
KIRP	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9309473	1.000	rs6756987	chr2:73687077	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.33	-0.32	2.21e-7	Metabolite levels;
KIRP	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg24881330	chr22:46731750	TRMU	0.64	5.49	0.33	9.92e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.35	-6.1	-0.36	4.03e-9	Height;
KIRP	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	9.68	0.53	5.46e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-1.12	-21.73	-0.81	3.62e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.73	7.37	0.43	2.56e-12	Bipolar disorder;
KIRP	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg00310523	chr12:86230176	RASSF9	0.39	5.96	0.36	8.8e-9	Major depressive disorder;
KIRP	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg04731861	chr2:219085781	ARPC2	0.29	7.34	0.42	3.18e-12	Colorectal cancer;
KIRP	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg04287289	chr16:89883240	FANCA	-0.42	-5.4	-0.33	1.54e-7	Vitiligo;
KIRP	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.56	-6.89	-0.4	4.62e-11	Uric acid clearance;
KIRP	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg05347473	chr6:146136440	FBXO30	0.62	8.85	0.49	1.81e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg00079375	chr15:79125835	NA	0.36	5.21	0.32	4.05e-7	Coronary artery disease;
KIRP	cis	rs4690686	0.500	rs17062797	chr4:177262063	G/A	cg17059388	chr4:177262070	NA	0.86	12.45	0.62	6.18e-28	Essential tremor;
KIRP	cis	rs427941	1.000	rs10270614	chr7:101837744	C/T	cg06246474	chr7:101738831	CUX1	0.55	6.81	0.4	7.42e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.59	7.84	0.45	1.37e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.73	0.34	2.92e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg21775007	chr8:11205619	TDH	0.42	5.15	0.31	5.24e-7	Monocyte count;
KIRP	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg18764771	chr6:116381957	FRK	0.19	5.33	0.32	2.17e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9381107	0.932	rs9357302	chr6:9442605	A/C	cg14735645	chr6:9486422	NA	-0.45	-5.36	-0.32	1.88e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg17644776	chr2:200775616	C2orf69	-0.57	-5.81	-0.35	1.93e-8	Schizophrenia;
KIRP	cis	rs216026	0.638	rs12312322	chr12:2771806	A/G	cg19945202	chr12:2788847	CACNA1C	-0.63	-8.01	-0.45	4.6e-14	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1978968	1.000	rs5992922	chr22:18445287	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg07645718	chr20:61493192	TCFL5	0.74	6.33	0.37	1.17e-9	Obesity-related traits;
KIRP	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.59	-9.25	-0.51	1.12e-17	Longevity;
KIRP	cis	rs42648	0.905	rs42641	chr7:89972764	T/C	cg25739043	chr7:89950458	NA	-0.47	-7.46	-0.43	1.46e-12	Homocysteine levels;
KIRP	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06481639	chr22:41940642	POLR3H	-0.7	-7.3	-0.42	4e-12	Vitiligo;
KIRP	cis	rs12282928	0.959	rs1566736	chr11:48238179	A/G	cg26585981	chr11:48327164	OR4S1	0.52	6.1	0.36	4.08e-9	Migraine - clinic-based;
KIRP	cis	rs6577655	0.517	rs6983560	chr8:135584553	C/T	cg17885191	chr8:135476712	NA	-0.66	-6.57	-0.39	2.93e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01398415	chr1:226309536	NA	-0.46	-6.23	-0.37	1.99e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.91	13.78	0.66	2.12e-32	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14925616	chr19:13125726	NFIX	-0.47	-6.4	-0.38	7.95e-10	Inflammatory biomarkers;
KIRP	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs34779708	0.931	rs4934697	chr10:35287192	C/T	cg03585969	chr10:35415529	CREM	0.84	10.09	0.54	2.9e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9473924	0.632	rs9395634	chr6:50863847	T/C	cg03432817	chr6:50765336	NA	0.35	5.41	0.33	1.52e-7	Body mass index;
KIRP	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-13.7	-0.66	3.9e-32	Heart rate;
KIRP	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg01411142	chr8:19674711	INTS10	0.5	5.72	0.34	3.15e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2591576	0.546	rs7729971	chr5:165431940	C/T	cg13976338	chr5:165423657	NA	-0.79	-12.02	-0.61	1.77e-26	Intelligence (multi-trait analysis);
KIRP	trans	rs17079247	0.841	rs9575846	chr13:85809437	G/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg00857998	chr1:205179979	DSTYK	0.65	8.02	0.46	4.29e-14	Red blood cell count;
KIRP	cis	rs11608355	0.521	rs6606706	chr12:109830173	C/T	cg19025524	chr12:109796872	NA	-0.51	-7.05	-0.41	1.84e-11	Neuroticism;
KIRP	cis	rs72634258	0.503	rs697675	chr1:7838113	A/C	cg26816564	chr1:7831052	VAMP3	0.81	8.07	0.46	3.08e-14	Inflammatory bowel disease;
KIRP	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg25173405	chr17:45401733	C17orf57	0.44	5.84	0.35	1.64e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6450176	1.000	rs3776705	chr5:53304955	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.4	-0.59	1.95e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.74	10.99	0.57	4.02e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25548615	chr4:2011379	WHSC2	0.48	6.03	0.36	5.84e-9	Parkinson's disease;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.94	-14.4	-0.68	1.71e-34	Longevity;Endometriosis;
KIRP	cis	rs7116495	0.609	rs73543612	chr11:71820350	C/T	cg07596299	chr11:71824057	C11orf51	0.93	5.89	0.35	1.29e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-12.76	-0.63	5.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	9.11	0.5	3e-17	Cognitive test performance;
KIRP	cis	rs860295	0.557	rs348196	chr1:155666961	A/G	cg02153340	chr1:155202674	NA	-0.43	-5.8	-0.35	2e-8	Body mass index;
KIRP	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg11846333	chr4:119757529	SEC24D	1.09	6.26	0.37	1.7e-9	Cannabis dependence symptom count;
KIRP	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.06	0.36	5.07e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	15.59	0.7	1.44e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg01403660	chr11:68851641	TPCN2	0.69	6.8	0.4	8.02e-11	Blond vs. brown hair color;
KIRP	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg00074818	chr8:8560427	CLDN23	0.4	6.33	0.37	1.16e-9	Obesity-related traits;
KIRP	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.32	5.77	0.35	2.36e-8	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
KIRP	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg13902645	chr11:5959945	NA	-0.6	-6.35	-0.38	1.01e-9	DNA methylation (variation);
KIRP	cis	rs2997447	0.761	rs12088601	chr1:26445504	G/A	cg19633962	chr1:26362018	EXTL1	-0.52	-4.87	-0.3	2.04e-6	QRS complex (12-leadsum);
KIRP	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.47	-0.38	5.33e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg14458575	chr2:238380390	NA	0.55	5.81	0.35	1.97e-8	Prostate cancer;
KIRP	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.18	-0.31	4.65e-7	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22971415	chr2:88355312	KRCC1	0.49	6.05	0.36	5.23e-9	Parkinson's disease;
KIRP	cis	rs73058052	1.000	rs12462756	chr19:50098423	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.66	7.37	0.43	2.57e-12	Fibrinogen levels;
KIRP	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg27205649	chr11:78285834	NARS2	0.86	11.84	0.6	6.73e-26	Alzheimer's disease (survival time);
KIRP	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg23740940	chr11:68924746	NA	0.3	5.09	0.31	7.09e-7	Blond vs. brown hair color;
KIRP	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.95	6.94	0.4	3.53e-11	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.84	12.46	0.62	6.13e-28	Lung cancer in ever smokers;
KIRP	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg24110177	chr3:50126178	RBM5	-0.65	-8.9	-0.49	1.27e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	1.0	10.19	0.54	1.48e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs806321	0.534	rs1149870	chr13:50899752	A/G	cg10393508	chr13:50950265	NA	-0.45	-6.4	-0.38	7.67e-10	Multiple sclerosis;
KIRP	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	7.86	0.45	1.18e-13	Mood instability;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg12560992	chr17:57184187	TRIM37	0.6	6.42	0.38	6.94e-10	Testicular germ cell tumor;
KIRP	cis	rs1440410	0.571	rs7675127	chr4:144041069	C/A	cg01719995	chr4:144104893	USP38	-0.45	-5.68	-0.34	3.86e-8	Ischemic stroke;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18807030	chr7:931980	C7orf20	0.51	6.51	0.38	4.18e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.35	-4.9	-0.3	1.71e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.46	-5.38	-0.32	1.78e-7	Total body bone mineral density;
KIRP	cis	rs4938573	0.526	rs11216973	chr11:118587001	T/C	cg19308663	chr11:118741387	NA	0.48	7.37	0.43	2.64e-12	Follicular lymphoma;
KIRP	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg01864069	chr14:103024347	NA	-0.85	-10.08	-0.54	3.14e-20	Platelet count;
KIRP	cis	rs12282928	1.000	rs1905287	chr11:48322153	A/C	cg26585981	chr11:48327164	OR4S1	0.51	6.22	0.37	2.09e-9	Migraine - clinic-based;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg14395546	chr16:66730808	CMTM4	0.55	6.31	0.37	1.32e-9	Electroencephalogram traits;
KIRP	cis	rs960902	0.738	rs6746868	chr2:37729551	T/C	cg25341268	chr2:37734390	NA	-0.56	-7.73	-0.44	2.77e-13	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.32	-4.96	-0.3	1.3e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.88	10.1	0.54	2.66e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.43	5.54	0.33	7.61e-8	Motion sickness;
KIRP	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg24531977	chr5:56204891	C5orf35	0.39	5.06	0.31	8.22e-7	Coronary artery disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10228629	chr1:1406955	ATAD3B	-0.5	-6.06	-0.36	5.19e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11644362	0.966	rs1433746	chr16:12992204	T/C	cg06890432	chr16:12997467	SHISA9	-0.41	-6.52	-0.38	3.87e-10	Positive affect;Subjective well-being;
KIRP	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg18705301	chr15:41695430	NDUFAF1	0.72	8.96	0.5	8.17e-17	Menopause (age at onset);
KIRP	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.39	-5.56	-0.33	7.04e-8	Monocyte count;
KIRP	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.75	-0.4	1.07e-10	Height;
KIRP	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg00684032	chr4:1343700	KIAA1530	0.42	5.43	0.33	1.36e-7	Obesity-related traits;
KIRP	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.08	-12.6	-0.63	2e-28	Vitiligo;
KIRP	cis	rs17095355	1.000	rs734165	chr10:111697789	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.39	-4.85	-0.3	2.24e-6	Biliary atresia;
KIRP	cis	rs17065868	0.764	rs56009336	chr13:45028527	A/G	cg10246903	chr13:45222710	NA	0.58	4.91	0.3	1.62e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg14985987	chr1:222763457	TAF1A	-0.55	-6.05	-0.36	5.5e-9	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09263875	chr16:632152	PIGQ	0.77	13.28	0.65	1.04e-30	Height;
KIRP	trans	rs7939886	0.920	rs78769647	chr11:55965527	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg25856811	chr1:152973957	SPRR3	0.36	4.94	0.3	1.47e-6	Inflammatory skin disease;
KIRP	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.56	-6.97	-0.41	2.85e-11	Uric acid clearance;
KIRP	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg19592336	chr6:28129416	ZNF389	-0.53	-6.0	-0.36	7.02e-9	Depression;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17864619	chr19:45971158	FOSB	0.54	6.62	0.39	2.22e-10	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg21851534	chr17:3907994	ZZEF1	0.66	10.66	0.56	4.73e-22	Type 2 diabetes;
KIRP	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg16988262	chr1:15930761	NA	0.39	5.16	0.31	5.1e-7	Systolic blood pressure;
KIRP	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg15556689	chr8:8085844	FLJ10661	0.73	8.56	0.48	1.26e-15	Red cell distribution width;
KIRP	cis	rs909341	0.909	rs2253829	chr20:62373079	G/C	cg03999872	chr20:62272968	STMN3	-0.58	-6.55	-0.39	3.32e-10	Atopic dermatitis;
KIRP	cis	rs2742417	1.000	rs2742392	chr3:45757282	T/C	cg04037228	chr3:45636386	LIMD1	0.35	5.11	0.31	6.37e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2274273	0.745	rs8005399	chr14:55542845	A/G	cg04306507	chr14:55594613	LGALS3	0.44	6.82	0.4	6.93e-11	Protein biomarker;
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18538332	chr22:24372958	LOC391322	-0.7	-9.89	-0.53	1.24e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.29	0.32	2.64e-7	Intracranial aneurysm;
KIRP	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg11707556	chr5:10655725	ANKRD33B	0.75	10.08	0.54	3.08e-20	Height;
KIRP	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.84	10.08	0.54	3.21e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12580194	0.593	rs7959837	chr12:55734511	G/A	cg11794356	chr12:55725991	OR6C3	-0.56	-7.85	-0.45	1.29e-13	Cancer;
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.61	-0.34	5.47e-8	Life satisfaction;
KIRP	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg17105886	chr17:28927953	LRRC37B2	0.52	5.35	0.32	2e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg10318148	chr7:1024673	CYP2W1	0.39	5.93	0.35	1.04e-8	Longevity;Endometriosis;
KIRP	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.35	-6.07	-0.36	4.81e-9	Height;
KIRP	cis	rs7666738	0.546	rs1813970	chr4:98887167	A/G	cg05340658	chr4:99064831	C4orf37	-0.64	-7.61	-0.44	5.91e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6496044	0.568	rs2880765	chr15:86056462	A/T	cg10818794	chr15:86012489	AKAP13	0.52	7.36	0.42	2.68e-12	Interstitial lung disease;
KIRP	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.64	4.57e-30	Bladder cancer;
KIRP	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.21	13.22	0.64	1.65e-30	Alzheimer's disease;
KIRP	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg04398451	chr17:18023971	MYO15A	-0.7	-9.5	-0.52	1.92e-18	Total body bone mineral density;
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01114163	chr5:1856713	NA	-0.45	-5.48	-0.33	1.05e-7	Cardiovascular disease risk factors;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg02733842	chr7:1102375	C7orf50	0.57	5.87	0.35	1.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.55	7.46	0.43	1.45e-12	Obesity-related traits;
KIRP	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.48	-6.22	-0.37	2.07e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg12559939	chr2:27858050	GPN1	0.41	5.16	0.31	5.01e-7	Oral cavity cancer;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.61	9.45	0.52	2.83e-18	Lung cancer;
KIRP	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.56	-6.5	-0.38	4.35e-10	Initial pursuit acceleration;
KIRP	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.69	7.87	0.45	1.16e-13	Smoking behavior;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19213194	chr7:101632618	CUX1	0.51	6.63	0.39	2.07e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.8	8.03	0.46	4.1e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs27434	0.539	rs40604	chr5:96155900	G/A	cg16492584	chr5:96139282	ERAP1	-0.41	-5.54	-0.33	7.82e-8	Ankylosing spondylitis;
KIRP	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	0.95	11.05	0.58	2.64e-23	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11733675	chr3:173115689	NLGN1	0.5	6.85	0.4	5.75e-11	Parkinson's disease;
KIRP	cis	rs2979489	0.891	rs2915625	chr8:30382651	G/A	cg26383811	chr8:30366931	RBPMS	-0.48	-6.42	-0.38	6.78e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.03	-0.36	6.05e-9	Height;
KIRP	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.64	8.12	0.46	2.31e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7267005	1.000	rs17093179	chr20:34450802	G/T	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs7554547	0.667	rs7525521	chr1:11975166	G/A	cg03536846	chr8:120886254	DEPDC6	-0.52	-6.12	-0.36	3.58e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs894344	0.650	rs4909912	chr8:135572297	C/T	cg09855544	chr8:135498122	ZFAT	0.39	5.13	0.31	5.92e-7	Systolic blood pressure;
KIRP	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.67	-0.44	4.13e-13	Monocyte percentage of white cells;
KIRP	cis	rs13102973	0.932	rs6858552	chr4:135864734	C/T	cg14419869	chr4:135874104	NA	-0.61	-10.82	-0.57	1.42e-22	Subjective well-being;
KIRP	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg04519387	chr11:65556438	OVOL1	0.33	4.96	0.3	1.31e-6	Acne (severe);
KIRP	cis	rs12190007	0.508	rs7452203	chr6:169741858	C/T	cg15038512	chr6:170123185	PHF10	-0.35	-5.05	-0.31	8.46e-7	Obesity-related traits;
KIRP	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	1.04	18.97	0.77	4.73e-50	Heart rate;
KIRP	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	9.65	0.52	6.94e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.89	11.87	0.6	5.31e-26	Cognitive function;
KIRP	cis	rs4356932	0.967	rs13113455	chr4:76972447	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.16	0.31	5.05e-7	Blood protein levels;
KIRP	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.83	-12.71	-0.63	9e-29	IgG glycosylation;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg03705947	chr1:68152081	GADD45A	-0.56	-7.16	-0.42	9.09e-12	Neuroticism;
KIRP	cis	rs16986825	0.570	rs5762879	chr22:29286180	C/T	cg02153584	chr22:29168773	CCDC117	0.49	5.36	0.32	1.93e-7	Pancreatic cancer;
KIRP	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.63	-10.44	-0.55	2.32e-21	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	6.45	0.38	5.76e-10	Renal cell carcinoma;
KIRP	cis	rs9612	1.000	rs346527	chr19:44259361	A/G	cg08581076	chr19:44259116	C19orf61	0.6	6.57	0.39	2.99e-10	Exhaled nitric oxide output;
KIRP	cis	rs17030434	0.906	rs57446135	chr4:154679331	A/G	cg14289246	chr4:154710475	SFRP2	-0.81	-9.33	-0.51	6.23e-18	Electrocardiographic conduction measures;
KIRP	cis	rs2637030	0.586	rs1552649	chr5:52870476	A/T	cg06476337	chr5:52856530	NDUFS4	0.54	5.86	0.35	1.46e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.45	-6.98	-0.41	2.68e-11	Platelet distribution width;
KIRP	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.55	-0.33	7.5e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg07653901	chr22:50250238	ZBED4	0.43	4.97	0.3	1.24e-6	Schizophrenia;
KIRP	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.52	-5.75	-0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	trans	rs2048656	0.605	rs7837008	chr8:9646506	T/C	cg15556689	chr8:8085844	FLJ10661	0.5	6.1	0.36	4.16e-9	Schizophrenia;
KIRP	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.9	-6.89	-0.4	4.54e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6681460	0.966	rs11208932	chr1:67097853	T/C	cg02459107	chr1:67143332	SGIP1	0.47	6.61	0.39	2.38e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs7582720	1.000	rs72932745	chr2:203662888	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.19	10.48	0.56	1.76e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg21573476	chr21:45109991	RRP1B	-0.54	-7.33	-0.42	3.21e-12	Mean corpuscular volume;
KIRP	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.64	-9.6	-0.52	9.48e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	1.1	8.84	0.49	1.83e-16	Plasma clusterin levels;
KIRP	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	0.57	7.7	0.44	3.37e-13	Prostate cancer;
KIRP	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg11235152	chr1:67600687	NA	0.68	10.05	0.54	3.87e-20	Psoriasis;
KIRP	cis	rs3105593	0.933	rs3109882	chr15:50840057	G/A	cg08437265	chr15:50716283	USP8	0.36	4.95	0.3	1.4e-6	QT interval;
KIRP	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg15790184	chr11:494944	RNH1	0.4	5.03	0.31	9.28e-7	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.23	0.46	1.1e-14	Lung cancer;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.66	-0.44	4.27e-13	Platelet count;
KIRP	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg20568497	chr10:133558893	NA	0.32	4.97	0.3	1.28e-6	Survival in rectal cancer;
KIRP	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.46	-6.99	-0.41	2.63e-11	Coronary artery disease;
KIRP	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.48	-7.14	-0.41	1.03e-11	Daytime sleep phenotypes;
KIRP	cis	rs6580649	0.941	rs17122612	chr12:48459488	C/G	cg26205652	chr12:48591994	NA	-0.51	-6.14	-0.36	3.31e-9	Lung cancer;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg11204139	chr17:3907470	NA	0.86	16.54	0.73	8.3e-42	Type 2 diabetes;
KIRP	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	0.62	5.35	0.32	2.05e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg18904891	chr8:8559673	CLDN23	0.67	7.65	0.44	4.54e-13	Obesity-related traits;
KIRP	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.41	-5.92	-0.35	1.06e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg17554472	chr22:41940697	POLR3H	0.59	6.41	0.38	7.48e-10	Vitiligo;
KIRP	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.79e-16	Motion sickness;
KIRP	cis	rs13401104	0.716	rs28821203	chr2:237140475	T/C	cg26422059	chr2:237146110	ASB18	0.51	5.22	0.32	3.77e-7	Educational attainment;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg23939001	chr4:940644	TMEM175	0.66	7.89	0.45	9.64e-14	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	cg12689670	chr1:183009347	LAMC1	0.42	5.91	0.35	1.16e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg04025307	chr7:1156635	C7orf50	0.64	5.09	0.31	7.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9831754	0.704	rs6774325	chr3:78458727	G/A	cg06138941	chr3:78371609	NA	-0.8	-10.93	-0.57	6.09e-23	Calcium levels;
KIRP	cis	rs12580194	0.593	rs7487895	chr12:55796720	T/C	cg19537932	chr12:55886519	OR6C68	-0.52	-6.68	-0.39	1.62e-10	Cancer;
KIRP	cis	rs5753618	0.509	rs5753500	chr22:31578879	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.35	-0.32	2.01e-7	Colorectal cancer;
KIRP	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg26335602	chr6:28129616	ZNF389	0.43	4.86	0.3	2.08e-6	Depression;
KIRP	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg11764359	chr7:65958608	NA	0.43	4.9	0.3	1.71e-6	Calcium levels;
KIRP	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg06634786	chr22:41940651	POLR3H	-0.46	-5.09	-0.31	7.09e-7	Neuroticism;
KIRP	cis	rs860295	0.702	rs12040100	chr1:155611847	G/T	cg02153340	chr1:155202674	NA	-0.5	-6.68	-0.39	1.6e-10	Body mass index;
KIRP	cis	rs1519814	1.000	rs7000609	chr8:121106264	C/T	cg22335954	chr8:121166405	COL14A1	0.59	5.99	0.36	7.34e-9	Breast cancer;
KIRP	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg19500275	chr17:80737654	TBCD	0.45	5.34	0.32	2.08e-7	Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.11e-7	Life satisfaction;
KIRP	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg00343986	chr7:65444356	GUSB	0.43	5.12	0.31	6.05e-7	Aortic root size;
KIRP	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg07537917	chr2:241836409	C2orf54	-0.26	-5.54	-0.33	7.69e-8	Urinary metabolites;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16405210	chr4:1374714	KIAA1530	-0.66	-9.42	-0.51	3.38e-18	Longevity;
KIRP	trans	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg06642503	chr19:35597415	LOC100128675	0.53	6.05	0.36	5.43e-9	White matter hyperintensity burden;
KIRP	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.19	0.51	1.71e-17	Multiple sclerosis;
KIRP	cis	rs2997447	0.846	rs12071062	chr1:26412199	T/G	cg19633962	chr1:26362018	EXTL1	-0.51	-5.01	-0.3	1.05e-6	QRS complex (12-leadsum);
KIRP	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.79	10.16	0.54	1.78e-20	Mean corpuscular hemoglobin;
KIRP	trans	rs17079247	0.841	rs9566054	chr13:85810460	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25391681	chr5:128930873	ADAMTS19	0.39	6.17	0.37	2.84e-9	Migraine with aura;
KIRP	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.81	0.35	1.91e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.24	-26.31	-0.86	1.85e-73	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.35	4.89	0.3	1.81e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.73	8.21	0.46	1.29e-14	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs12044355	0.858	rs1538975	chr1:231828372	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	6.24	0.37	1.87e-9	Alzheimer's disease;
KIRP	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.79	-0.35	2.16e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.7	-9.27	-0.51	9.8e-18	Resting heart rate;
KIRP	trans	rs7939886	0.920	rs11227434	chr11:55945251	G/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg14221460	chr8:27183342	PTK2B	0.52	6.82	0.4	7.18e-11	Neuroticism;
KIRP	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg23594656	chr7:65796392	TPST1	-0.45	-6.32	-0.37	1.23e-9	Aortic root size;
KIRP	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg10503236	chr1:231470652	EXOC8	-0.52	-7.34	-0.42	3.01e-12	Hemoglobin concentration;
KIRP	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg21573476	chr21:45109991	RRP1B	-0.59	-8.39	-0.47	3.87e-15	Mean corpuscular volume;
KIRP	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg10760299	chr15:45669010	GATM	0.34	5.02	0.3	9.97e-7	Homoarginine levels;
KIRP	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg10360139	chr7:1886902	MAD1L1	-0.45	-5.05	-0.31	8.68e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.58	7.07	0.41	1.64e-11	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.87	-0.35	1.43e-8	Type 2 diabetes;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg09264619	chr17:80180166	NA	0.38	5.43	0.33	1.34e-7	Life satisfaction;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23898951	chr10:4511903	NA	0.39	6.07	0.36	4.69e-9	Migraine with aura;
KIRP	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.76	0.53	3.05e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg27205649	chr11:78285834	NARS2	-0.55	-6.14	-0.36	3.36e-9	Testicular germ cell tumor;
KIRP	cis	rs7737355	0.812	rs10059807	chr5:130877684	T/C	cg25547332	chr5:131281432	NA	0.39	4.9	0.3	1.76e-6	Life satisfaction;
KIRP	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg20220242	chr21:30392188	RWDD2B	0.54	4.95	0.3	1.37e-6	Cognitive test performance;
KIRP	cis	rs4273100	1.000	rs57433322	chr17:19141582	C/G	cg18093559	chr17:18951025	GRAP	-0.62	-5.64	-0.34	4.64e-8	Schizophrenia;
KIRP	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg08885076	chr2:99613938	TSGA10	-0.43	-6.45	-0.38	5.98e-10	Bipolar disorder;
KIRP	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.84	13.07	0.64	5.51e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.39	7.86	0.45	1.2e-13	Mean corpuscular volume;
KIRP	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.53	-8.48	-0.48	2.07e-15	Lung cancer;
KIRP	cis	rs2882667	0.898	rs10079634	chr5:138413053	T/C	cg04439458	chr5:138467593	SIL1	-0.43	-7.17	-0.42	8.8e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12379764	chr21:47803548	PCNT	-0.44	-5.31	-0.32	2.43e-7	Testicular germ cell tumor;
KIRP	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg17810781	chr1:201082982	CACNA1S	0.44	7.02	0.41	2.12e-11	Permanent tooth development;
KIRP	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.65	8.7	0.49	4.78e-16	Breast cancer;
KIRP	cis	rs4356932	1.000	rs13130221	chr4:76955617	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.28	-0.32	2.86e-7	Retinal vascular caliber;
KIRP	cis	rs7172677	0.732	rs55922358	chr15:75313967	G/C	cg14664628	chr15:75095509	CSK	0.59	6.43	0.38	6.66e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg05347473	chr6:146136440	FBXO30	0.57	8.12	0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.71	-5.98	-0.36	7.84e-9	Lymphocyte percentage of white cells;
KIRP	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.51	6.35	0.38	1.04e-9	Birth weight;
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg07701084	chr6:150067640	NUP43	0.72	9.94	0.54	8.78e-20	Lung cancer;
KIRP	cis	rs3760047	0.668	rs2858922	chr16:207218	G/A	cg25425005	chr16:202905	HBZ	-0.45	-5.28	-0.32	2.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9443189	0.543	rs9294004	chr6:76606056	T/C	cg01950844	chr6:76311363	SENP6	-0.76	-4.87	-0.3	1.98e-6	Prostate cancer;
KIRP	cis	rs17092148	0.945	rs6060042	chr20:33361721	A/G	cg16810054	chr20:33298113	TP53INP2	-0.46	-5.44	-0.33	1.26e-7	Neuroticism;
KIRP	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.18	-0.46	1.52e-14	Mood instability;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.13e-8	Life satisfaction;
KIRP	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.68	10.02	0.54	4.85e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg05340658	chr4:99064831	C4orf37	0.54	6.52	0.38	3.9e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6545883	0.831	rs2592356	chr2:61810428	G/C	cg15711740	chr2:61764176	XPO1	-0.61	-8.29	-0.47	7.54e-15	Tuberculosis;
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.02	0.69	1.23e-36	Platelet count;
KIRP	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.28	0.37	1.55e-9	Breast cancer;
KIRP	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.81	13.57	0.65	1.11e-31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.93	14.96	0.69	2.07e-36	Mean corpuscular volume;
KIRP	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.55	7.34	0.42	3.2e-12	Blood metabolite levels;
KIRP	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.53	4.89	0.3	1.78e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.58	-11.9	-0.6	4.44e-26	Diabetic kidney disease;
KIRP	cis	rs11153730	0.503	rs283062	chr6:118621456	A/G	cg21191810	chr6:118973309	C6orf204	-0.37	-4.87	-0.3	1.97e-6	QT interval;Heart rate;QRS duration;QRS complex (Sokolow-Lyon);
KIRP	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.7	-0.34	3.44e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.78	9.49	0.52	2.07e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.51	-6.14	-0.36	3.31e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6032067	0.929	rs17424356	chr20:43804190	A/G	cg10761708	chr20:43804764	PI3	0.49	5.15	0.31	5.39e-7	Blood protein levels;
KIRP	cis	rs4971059	0.617	rs12127609	chr1:155133491	G/C	cg02153340	chr1:155202674	NA	-0.43	-5.97	-0.36	8.11e-9	Breast cancer;
KIRP	cis	rs12474201	0.851	rs2346882	chr2:47015813	G/A	cg06386533	chr2:46925753	SOCS5	1.06	14.28	0.67	4.07e-34	Height;
KIRP	cis	rs2120243	0.592	rs1456110	chr3:157106072	G/A	cg24825693	chr3:157122686	VEPH1	-0.49	-8.14	-0.46	1.98e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg00806126	chr19:22604979	ZNF98	0.68	7.14	0.41	1.07e-11	Pain;
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.61e-9	Life satisfaction;
KIRP	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-7.39	-0.43	2.29e-12	Gut microbiome composition (summer);
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.06e-10	Prudent dietary pattern;
KIRP	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.97	0.3	1.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.8	-11.36	-0.59	2.55e-24	Total body bone mineral density;
KIRP	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg27494647	chr7:150038898	RARRES2	0.36	5.53	0.33	8.27e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01294023	chr19:41816151	CCDC97	-0.43	-6.05	-0.36	5.3300000000000004e-09	Metabolic traits;
KIRP	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-6.78	-0.4	9.1e-11	Urate levels in overweight individuals;
KIRP	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.58	-7.57	-0.43	7.53e-13	Total body bone mineral density;
KIRP	cis	rs10929159	0.928	rs7598567	chr2:236920673	A/G	cg20128773	chr2:236923534	AGAP1	0.3	5.21	0.32	4e-7	Parkinson's disease;
KIRP	cis	rs3821902	0.646	rs10510901	chr3:64013062	A/G	cg09006292	chr3:64049408	NA	-0.48	-5.09	-0.31	7.27e-7	Breast cancer;
KIRP	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.65	0.34	4.5e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	9.88	0.53	1.35e-19	Hip circumference;
KIRP	cis	rs8113308	1.000	rs7246064	chr19:52442262	C/T	cg24732339	chr19:52471368	ZNF350	-0.5	-5.86	-0.35	1.51e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-6.9	-0.4	4.28e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg23594656	chr7:65796392	TPST1	0.52	8.28	0.47	7.91e-15	Aortic root size;
KIRP	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg08890418	chr1:21044141	KIF17	0.33	4.97	0.3	1.27e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.05	-0.31	8.69e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg07395648	chr5:131743802	NA	-0.6	-8.35	-0.47	5.15e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.26	5.45	0.33	1.23e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.23	0.32	3.61e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.79	-10.89	-0.57	8.5e-23	Educational attainment;
KIRP	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.9	6.56	0.39	3.19e-10	Major depressive disorder;
KIRP	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	0.67	7.83	0.45	1.47e-13	Initial pursuit acceleration;
KIRP	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.54	8.1	0.46	2.62e-14	Major depressive disorder;
KIRP	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg16584676	chr17:46985605	UBE2Z	0.45	5.47	0.33	1.13e-7	Type 2 diabetes;
KIRP	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.56	7.56	0.43	8.14e-13	Mean corpuscular volume;
KIRP	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg01620082	chr3:125678407	NA	-1.04	-7.27	-0.42	4.68e-12	Depression;
KIRP	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.59	7.09	0.41	1.39e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg11970804	chr8:8084126	NA	0.4	4.95	0.3	1.38e-6	Neuroticism;
KIRP	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	-0.42	-6.02	-0.36	6.38e-9	Resistin levels;
KIRP	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.53	7.35	0.42	2.84e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13182412	chr17:73776098	H3F3B	0.55	6.14	0.36	3.31e-9	Lung cancer in ever smokers;
KIRP	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.58	-0.39	2.79e-10	Obesity-related traits;
KIRP	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg09455208	chr3:40491958	NA	-0.29	-5.08	-0.31	7.49e-7	Renal cell carcinoma;
KIRP	cis	rs6987853	0.966	rs2974349	chr8:42404040	A/G	cg09913449	chr8:42400586	C8orf40	-0.41	-5.31	-0.32	2.41e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.91	0.3	1.64e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26430382	chr1:228270029	ARF1	-0.55	-6.25	-0.37	1.81e-9	Menopause (age at onset);
KIRP	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	9.39	0.51	4.19e-18	Renal function-related traits (BUN);
KIRP	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs8059260	0.604	rs9302458	chr16:11144209	C/G	cg16622652	chr7:100304425	POP7	-0.41	-6.02	-0.36	6.16e-9	Alcohol consumption over the past year;
KIRP	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg00101154	chr16:420108	MRPL28	-0.45	-5.15	-0.31	5.26e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs16854884	0.837	rs13062793	chr3:143808387	A/G	cg06585982	chr3:143692056	C3orf58	0.43	5.06	0.31	8.09e-7	Economic and political preferences (feminism/equality);
KIRP	cis	rs12982744	0.613	rs12981497	chr19:2133332	C/G	cg09261902	chr19:2140048	AP3D1	0.44	5.64	0.34	4.59e-8	Osteoarthritis;Height;
KIRP	cis	rs11997175	0.935	rs6990082	chr8:33708034	C/A	ch.8.33884649F	chr8:33765107	NA	0.44	5.29	0.32	2.67e-7	Body mass index;
KIRP	cis	rs7923609	0.902	rs4633333	chr10:65328539	C/G	cg01631684	chr10:65280961	REEP3	-0.46	-5.45	-0.33	1.19e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.25	-0.32	3.29e-7	Life satisfaction;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg07335843	chr2:133030691	NA	0.41	6.99	0.41	2.65e-11	Serum protein levels (sST2);
KIRP	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.02	-13.82	-0.66	1.5e-32	Alzheimer's disease;
KIRP	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg19847130	chr8:10466454	RP1L1	0.34	5.1	0.31	6.64e-7	Triglycerides;
KIRP	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.55	7.39	0.43	2.34e-12	Colorectal cancer;
KIRP	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.8	0.35	1.99e-8	Educational attainment;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.75	11.97	0.61	2.45e-26	Menarche (age at onset);
KIRP	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-7.06	-0.41	1.69e-11	Coronary artery disease;
KIRP	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg07001201	chr5:642380	CEP72	0.69	6.43	0.38	6.75e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs16976116	0.901	rs62020114	chr15:55501116	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	1.2	11.39	0.59	1.97e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	0.87	6.28	0.37	1.56e-9	Obesity-related traits;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg01391022	chr12:122360665	WDR66	-0.4	-5.63	-0.34	5.02e-8	Mean corpuscular volume;
KIRP	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.6	-6.43	-0.38	6.59e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1440410	0.835	rs4407450	chr4:144147007	C/T	cg01719995	chr4:144104893	USP38	0.38	5.06	0.31	8.38e-7	Ischemic stroke;
KIRP	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.97	0.71	7.13e-40	Bipolar disorder;
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.72	8.55	0.48	1.34e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7127900	1.000	rs4076054	chr11:2231341	G/A	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.09e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs494562	0.892	rs7750970	chr6:86128570	A/T	cg27039625	chr6:86159096	NT5E	0.44	5.75	0.34	2.67e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.97	-0.45	5.81e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.34	0.37	1.11e-9	Electroencephalogram traits;
KIRP	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg20965017	chr5:231967	SDHA	0.44	5.17	0.31	4.84e-7	Breast cancer;
KIRP	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.6	0.81	1e-58	Prudent dietary pattern;
KIRP	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.67	-7.24	-0.42	5.68e-12	Corneal structure;
KIRP	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs4073221	0.789	rs35228011	chr3:18204652	G/A	cg07694806	chr3:18168406	NA	-0.74	-6.7	-0.39	1.38e-10	Parkinson's disease;
KIRP	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-8.65	-0.48	6.64e-16	Bipolar disorder;
KIRP	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.37	-4.99	-0.3	1.15e-6	Dupuytren's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20922377	chr15:48623205	DUT	-0.54	-6.37	-0.38	9.13e-10	Interleukin-4 levels;
KIRP	cis	rs812925	0.512	rs1177309	chr2:61385248	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.14	-0.31	5.57e-7	Immature fraction of reticulocytes;
KIRP	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.24	0.42	5.71e-12	Mean platelet volume;
KIRP	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg27535305	chr1:53392650	SCP2	0.35	5.64	0.34	4.62e-8	Monocyte count;
KIRP	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.85	-0.35	1.58e-8	Obesity-related traits;
KIRP	cis	rs8014252	0.708	rs8010473	chr14:70988993	G/C	cg19730268	chr14:71022823	NA	-0.56	-5.39	-0.33	1.62e-7	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.42	5.29	0.32	2.71e-7	Cystic fibrosis severity;
KIRP	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2224391	0.704	rs17139985	chr6:5261603	T/C	cg13962347	chr6:5174647	LYRM4	-0.62	-8.48	-0.48	2.13e-15	Height;
KIRP	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.67	-9.29	-0.51	8.46e-18	Hip circumference;
KIRP	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg20744362	chr22:50050164	C22orf34	0.39	6.68	0.39	1.6e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02809263	chr1:70671218	LRRC40;SFRS11	0.57	6.78	0.4	8.85e-11	Smoking initiation;
KIRP	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg18225595	chr11:63971243	STIP1	0.65	5.98	0.36	7.85e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs45544231	0.569	rs9933638	chr16:52539597	A/G	cg09051775	chr16:52580266	TOX3	-0.4	-5.3	-0.32	2.57e-7	Restless legs syndrome;
KIRP	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.86	-0.35	1.47e-8	Morning vs. evening chronotype;
KIRP	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.91	-0.35	1.12e-8	LDL cholesterol levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00167539	chr7:150066156	REPIN1	-0.65	-7.46	-0.43	1.51e-12	Menopause (age at onset);
KIRP	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.11	-0.31	6.42e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.7	9.57	0.52	1.17e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.64	-9.6	-0.52	9.52e-19	Glomerular filtration rate (creatinine);
KIRP	trans	rs17079247	0.778	rs9575850	chr13:85810706	G/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	6.88	0.4	4.94e-11	Menarche (age at onset);
KIRP	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-6.43	-0.38	6.6e-10	Bladder cancer;
KIRP	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg25019722	chr6:37503610	NA	-0.86	-12.3	-0.62	1.97e-27	Cognitive performance;
KIRP	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.54	0.38	3.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.65	7.89	0.45	1.01e-13	Coronary artery disease;
KIRP	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-7.78	-0.44	2.02e-13	Total body bone mineral density;
KIRP	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.73	9.08	0.5	3.67e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.62	-6.7	-0.39	1.39e-10	DNA methylation (variation);
KIRP	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg00571178	chr13:114841904	RASA3	-0.42	-5.37	-0.32	1.82e-7	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs1134634	0.520	rs4698408	chr4:15659048	A/G	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.69	-0.34	3.68e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg25828445	chr12:7781288	NA	0.5	4.96	0.3	1.33e-6	HDL cholesterol levels;
KIRP	cis	rs698833	0.926	rs1067406	chr2:44674450	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	4.91	0.3	1.66e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-1.03	-17.26	-0.74	2.75e-44	Height;
KIRP	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.26	-0.47	8.89e-15	Platelet count;
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.87	-0.35	1.42e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.48	-0.38	4.95e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg16141378	chr3:129829833	LOC729375	0.47	6.29	0.37	1.45e-9	Mood instability;
KIRP	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.85	11.09	0.58	1.92e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs955333	0.540	rs62434185	chr6:154889016	T/G	cg20019720	chr6:154832845	CNKSR3	0.39	5.41	0.33	1.47e-7	Diabetic kidney disease;
KIRP	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg16482183	chr6:26056742	HIST1H1C	0.66	7.68	0.44	3.75e-13	Iron status biomarkers;
KIRP	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.88	0.4	4.87e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg03146154	chr1:46216737	IPP	-0.59	-6.8	-0.4	7.86e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg05220968	chr6:146057943	EPM2A	0.4	5.04	0.31	8.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg10932868	chr11:921992	NA	0.5	5.84	0.35	1.67e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.14	16.52	0.73	9.43e-42	Breast cancer;
KIRP	cis	rs687432	0.847	rs12419176	chr11:57706711	C/T	cg19752551	chr11:57585705	CTNND1	0.49	6.95	0.4	3.33e-11	Parkinson's disease;
KIRP	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg13660082	chr14:53194042	PSMC6	-0.67	-7.22	-0.42	6.49e-12	Alzheimer's disease (late onset);
KIRP	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26207909	chr14:103986467	CKB	0.75	11.54	0.59	6.72e-25	Body mass index;
KIRP	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.63	-7.36	-0.42	2.75e-12	Dental caries;
KIRP	cis	rs6743226	0.934	rs4303713	chr2:242257859	G/A	cg10021735	chr2:242295487	FARP2	0.51	6.26	0.37	1.74e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg12315302	chr6:26189340	HIST1H4D	0.87	6.2	0.37	2.42e-9	Urinary tract infection frequency;
KIRP	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg14092571	chr14:90743983	NA	-0.43	-5.55	-0.33	7.22e-8	Mortality in heart failure;
KIRP	trans	rs783540	1.000	rs11631963	chr15:83318202	T/C	cg16105309	chr15:79090380	ADAMTS7	-0.44	-6.13	-0.36	3.55e-9	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.09	0.31	7.1e-7	Parkinson's disease;
KIRP	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg01320579	chr17:75405842	SEPT9	0.45	7.36	0.42	2.74e-12	Airflow obstruction;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg20302533	chr7:39170763	POU6F2	0.29	6.26	0.37	1.69e-9	IgG glycosylation;
KIRP	cis	rs2191566	0.887	rs55703004	chr19:44504781	T/G	cg18700516	chr19:44507157	ZNF230	-0.48	-5.62	-0.34	5.05e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8018808	0.846	rs11624990	chr14:77943616	C/T	cg20045696	chr14:77926864	AHSA1	0.46	5.7	0.34	3.44e-8	Myeloid white cell count;
KIRP	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg00129232	chr17:37814104	STARD3	0.68	8.01	0.45	4.56e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs6815814	0.950	rs73236618	chr4:38794041	T/C	cg06935464	chr4:38784597	TLR10	0.54	5.37	0.32	1.85e-7	Breast cancer;
KIRP	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg04132472	chr17:19861366	AKAP10	-0.44	-6.1	-0.36	4.18e-9	Schizophrenia;
KIRP	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.88	0.4	5.01e-11	Menarche (age at onset);
KIRP	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs6142102	0.602	rs4911395	chr20:32579901	T/G	cg24642439	chr20:33292090	TP53INP2	0.47	5.74	0.34	2.74e-8	Skin pigmentation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09144098	chr16:56518581	BBS2	0.45	6.38	0.38	8.78e-10	Interleukin-4 levels;
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg08662619	chr6:150070041	PCMT1	0.39	6.59	0.39	2.69e-10	Lung cancer;
KIRP	trans	rs656319	0.513	rs688541	chr8:9818000	T/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.53	-0.43	9.62e-13	Myopia (pathological);
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg08662619	chr6:150070041	PCMT1	0.36	6.06	0.36	5.17e-9	Lung cancer;
KIRP	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg23719950	chr11:63933701	MACROD1	-0.69	-6.64	-0.39	2e-10	Mean platelet volume;
KIRP	trans	rs78944489	0.867	rs12104774	chr2:73472424	G/T	cg18655438	chr5:1077845	SLC12A7	-0.81	-6.1	-0.36	4e-9	Schizophrenia;
KIRP	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg01620082	chr3:125678407	NA	-1.18	-7.63	-0.44	5.19e-13	Depression;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg02058552	chr10:5454564	NET1	0.55	7.09	0.41	1.42e-11	DNA methylation (variation);
KIRP	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14769373	chr6:40998127	UNC5CL	-0.63	-6.76	-0.4	9.77e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs8077577	0.747	rs16961153	chr17:18227101	A/G	cg18869244	chr17:18121946	NA	-0.44	-4.93	-0.3	1.48e-6	Obesity-related traits;
KIRP	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg18404041	chr3:52824283	ITIH1	0.41	5.38	0.32	1.74e-7	Schizophrenia;
KIRP	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.17	0.37	2.74e-9	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg23594656	chr7:65796392	TPST1	0.52	8.15	0.46	1.91e-14	Aortic root size;
KIRP	cis	rs12210905	0.688	rs12212389	chr6:27326397	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg09416959	chr4:120243311	FABP2	0.35	6.26	0.37	1.66e-9	Schizophrenia;
KIRP	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg26587870	chr6:27730563	NA	-0.65	-5.06	-0.31	8.21e-7	Depression;
KIRP	cis	rs865483	0.860	rs2522968	chr17:35830300	G/A	cg06716730	chr17:35851459	DUSP14	0.25	6.04	0.36	5.61e-9	Monocyte count;
KIRP	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.48	6.0	0.36	6.87e-9	Testicular germ cell tumor;
KIRP	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-9.43	-0.52	3.31e-18	Coronary artery disease;
KIRP	trans	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg00405596	chr8:11794950	NA	-0.45	-6.04	-0.36	5.53e-9	Joint mobility (Beighton score);
KIRP	cis	rs4664293	0.867	rs12620924	chr2:160602963	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.4	0.38	7.66e-10	Putamen volume;
KIRP	cis	rs9650657	0.525	rs7819602	chr8:10726842	C/G	cg19847130	chr8:10466454	RP1L1	0.34	5.07	0.31	7.96e-7	Neuroticism;
KIRP	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.46	-6.22	-0.37	2.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.48	-10.69	-0.56	3.77e-22	Breast cancer;
KIRP	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg07796016	chr1:152779584	LCE1C	-0.41	-5.28	-0.32	2.81e-7	Inflammatory skin disease;
KIRP	cis	rs7129556	0.645	rs598071	chr11:77560652	G/T	cg12586386	chr11:77299805	AQP11	0.38	5.08	0.31	7.47e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg18944383	chr4:111397179	ENPEP	0.52	9.22	0.51	1.38e-17	Height;
KIRP	cis	rs35000415	0.938	rs34725944	chr7:128641653	T/C	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg00122941	chr17:4613640	ARRB2	0.82	8.71	0.49	4.49e-16	Lymphocyte counts;
KIRP	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg18016565	chr1:150552671	MCL1	0.35	5.26	0.32	3.15e-7	Tonsillectomy;
KIRP	cis	rs6001982	0.584	rs2294352	chr22:40827319	G/A	cg07138101	chr22:40742427	ADSL	0.68	5.24	0.32	3.4e-7	Breast cancer;
KIRP	cis	rs16958440	1.000	rs60228288	chr18:44640412	G/A	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	10.05	0.54	3.94e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1035491	0.715	rs10078390	chr5:63926120	G/A	cg01791865	chr5:63954708	NA	0.32	5.02	0.3	9.98e-7	Body mass index;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.74	9.72	0.53	4.3e-19	Longevity;Endometriosis;
KIRP	cis	rs9426935	0.604	rs1819663	chr1:154025891	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.35	-5.15	-0.31	5.31e-7	Lentiform nucleus volume;
KIRP	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.81	9.21	0.51	1.53e-17	High light scatter reticulocyte count;
KIRP	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.99	8.18	0.46	1.55e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg08125733	chr17:73851984	WBP2	-0.41	-5.11	-0.31	6.47e-7	White matter hyperintensity burden;
KIRP	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.37	0.38	9.08e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg12486944	chr17:80159399	CCDC57	0.39	5.17	0.31	4.75e-7	Life satisfaction;
KIRP	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.77	-8.35	-0.47	4.93e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9913711	0.899	rs9913936	chr17:70074148	A/G	cg11350586	chr17:70115862	SOX9	0.38	5.05	0.31	8.77e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.65	-8.47	-0.48	2.24e-15	Hypospadias;
KIRP	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	0.95	11.36	0.59	2.47e-24	Vitiligo;
KIRP	cis	rs981844	1.000	rs17371021	chr4:154664295	A/G	cg14289246	chr4:154710475	SFRP2	-0.67	-7.72	-0.44	3e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg06064525	chr11:970664	AP2A2	0.35	7.0	0.41	2.36e-11	Alzheimer's disease (late onset);
KIRP	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22105827	chr15:79852078	NA	-0.39	-6.19	-0.37	2.56e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg03146154	chr1:46216737	IPP	0.48	5.21	0.32	3.97e-7	Platelet count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12337011	chr2:28002424	MRPL33	0.46	7.11	0.41	1.29e-11	Survival in pancreatic cancer;
KIRP	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.95	12.51	0.62	4.1e-28	Menopause (age at onset);
KIRP	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.87	-8.32	-0.47	5.95e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg02461776	chr11:598696	PHRF1	0.7	7.48	0.43	1.34e-12	Systemic lupus erythematosus;
KIRP	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg03854865	chr6:26224070	HIST1H3E	0.62	4.85	0.3	2.16e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs9790314	0.613	rs6809177	chr3:160630477	G/T	cg04691961	chr3:161091175	C3orf57	0.43	6.23	0.37	1.96e-9	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.67	-7.34	-0.42	3.13e-12	DNA methylation (variation);
KIRP	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.56	-0.39	3.22e-10	Coronary artery calcification;
KIRP	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg15448220	chr1:150897856	SETDB1	0.38	5.1	0.31	6.71e-7	Tonsillectomy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02847575	chr16:30382517	TBC1D10B	0.5	6.13	0.36	3.49e-9	Smoking initiation;
KIRP	cis	rs7246865	0.510	rs3816549	chr19:17173937	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.52	6.59	0.39	2.68e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg23479056	chr15:41276147	INO80	-0.37	-4.88	-0.3	1.94e-6	Menopause (age at onset);
KIRP	cis	rs2115536	0.630	rs12102032	chr15:80233399	A/C	cg00225070	chr15:80189496	MTHFS	0.48	5.74	0.34	2.78e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg06204229	chr3:52865917	ITIH4	0.51	5.76	0.34	2.47e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs35079168	0.923	rs11103473	chr9:137287629	A/T	cg13941235	chr9:137270186	RXRA	0.25	5.33	0.32	2.22e-7	Intelligence;
KIRP	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.99	0.36	7.5e-9	Bipolar disorder;
KIRP	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg19592336	chr6:28129416	ZNF389	0.53	5.91	0.35	1.14e-8	Depression;
KIRP	cis	rs6690583	0.623	rs55721024	chr1:85454447	A/C	cg22153463	chr1:85462885	MCOLN2	0.59	5.33	0.32	2.19e-7	Serum sulfate level;
KIRP	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.04	13.13	0.64	3.48e-30	Platelet count;
KIRP	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.11	12.65	0.63	1.37e-28	Vitiligo;
KIRP	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg12310025	chr6:25882481	NA	0.42	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.69	10.3	0.55	6.31e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg04731861	chr2:219085781	ARPC2	0.3	7.56	0.43	7.99e-13	Colorectal cancer;
KIRP	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Smoking initiation;
KIRP	cis	rs72627123	0.582	rs62005102	chr14:74500586	T/A	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	5.12	0.31	6.04e-7	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.53	-0.33	8.34e-8	Lung cancer;
KIRP	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	5.81	0.35	1.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs35740288	0.770	rs62022909	chr15:86207481	A/G	cg17133734	chr15:86042851	AKAP13	-0.49	-5.53	-0.33	8e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.55	6.68	0.39	1.61e-10	Asthma;
KIRP	cis	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg19847130	chr8:10466454	RP1L1	0.37	5.24	0.32	3.39e-7	Triglycerides;
KIRP	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.34	5.41	0.33	1.48e-7	Asthma (childhood onset);
KIRP	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06028808	chr11:68637592	NA	0.72	8.92	0.49	1.08e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-5.3	-0.32	2.58e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg11833968	chr6:79620685	NA	-0.35	-4.87	-0.3	2.01e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4888378	0.600	rs729109	chr16:75316074	A/G	cg03315344	chr16:75512273	CHST6	-0.44	-5.29	-0.32	2.71e-7	Coronary artery disease;
KIRP	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.19	0.37	2.54e-9	Iron status biomarkers;
KIRP	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.08	-11.5	-0.59	8.79e-25	Hip circumference adjusted for BMI;
KIRP	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.97	-0.64	1.18e-29	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12107643	chr19:5231603	PTPRS	-0.39	-6.02	-0.36	6.31e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.59	-9.69	-0.53	5.27e-19	Total body bone mineral density;
KIRP	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg00852783	chr1:26633632	UBXN11	-0.53	-5.41	-0.33	1.5e-7	Obesity-related traits;
KIRP	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg10935138	chr17:73851978	WBP2	0.48	5.75	0.34	2.61e-8	White matter hyperintensity burden;
KIRP	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg18478394	chr8:109455254	TTC35	0.48	5.77	0.35	2.35e-8	Dupuytren's disease;
KIRP	cis	rs61990749	0.511	rs2052444	chr14:78312918	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.78	5.88	0.35	1.31e-8	Fibroblast growth factor basic levels;
KIRP	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07570687	chr10:102243282	WNT8B	0.49	6.36	0.38	9.51e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.83	-0.35	1.69e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.6	-5.83	-0.35	1.73e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg05347473	chr6:146136440	FBXO30	0.46	6.5	0.38	4.39e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg16139199	chr18:19180362	ESCO1	0.73	6.31	0.37	1.28e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg08992911	chr2:238395768	MLPH	0.42	5.35	0.32	2e-7	Prostate cancer;
KIRP	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.48	7.45	0.43	1.58e-12	Testicular germ cell tumor;
KIRP	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg25173405	chr17:45401733	C17orf57	-0.48	-6.26	-0.37	1.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg10818794	chr15:86012489	AKAP13	-0.49	-7.03	-0.41	1.98e-11	Coronary artery disease;
KIRP	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg06647332	chr5:131281008	NA	0.45	5.07	0.31	7.86e-7	Life satisfaction;
KIRP	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg08999081	chr20:33150536	PIGU	0.41	5.21	0.32	3.94e-7	Height;
KIRP	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg02725872	chr8:58115012	NA	-0.51	-5.74	-0.34	2.81e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg21775007	chr8:11205619	TDH	-0.65	-9.43	-0.52	3.24e-18	Retinal vascular caliber;
KIRP	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.97	-9.51	-0.52	1.84e-18	Type 2 diabetes;
KIRP	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.83	-12.76	-0.63	5.7e-29	Breast cancer;
KIRP	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.59	-0.44	6.6e-13	Type 2 diabetes;
KIRP	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.38	5.16	0.31	5.15e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg11635098	chr7:100497156	NA	-0.68	-7.32	-0.42	3.59e-12	Resting heart rate;
KIRP	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.97	-12.89	-0.64	2.1e-29	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7973719	0.865	rs12228393	chr12:7368182	A/G	cg07052231	chr12:7363540	PEX5	-0.4	-5.18	-0.31	4.57e-7	IgG glycosylation;
KIRP	cis	rs56161922	1.000	rs41274776	chr1:207812791	A/G	cg11752769	chr1:207818423	CR1L	-0.77	-5.0	-0.3	1.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg13206674	chr6:150067644	NUP43	0.61	8.8	0.49	2.54e-16	Lung cancer;
KIRP	cis	rs1270639	0.778	rs2530404	chr7:157445995	C/T	cg13357408	chr7:157437802	PTPRN2	-0.61	-6.1	-0.36	4.12e-9	Colorectal cancer;
KIRP	cis	rs477895	0.639	rs2289573	chr11:64127902	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	5.18	0.31	4.68e-7	Mean platelet volume;
KIRP	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.65	-6.79	-0.4	8.42e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2964802	0.505	rs6876703	chr5:10831629	G/A	cg14521931	chr5:10832172	NA	-0.73	-10.57	-0.56	8.87e-22	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13198984	chr17:80129470	CCDC57	-0.54	-8.06	-0.46	3.3e-14	Life satisfaction;
KIRP	cis	rs4690686	0.538	rs13120287	chr4:177260184	T/C	cg17059388	chr4:177262070	NA	0.85	11.58	0.59	4.73e-25	Essential tremor;
KIRP	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.74	10.72	0.56	2.9e-22	Huntington's disease progression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10017167	chr16:30683065	NA	0.59	7.73	0.44	2.81e-13	Interleukin-4 levels;
KIRP	cis	rs10073892	0.660	rs28490970	chr5:101943217	T/C	cg19774478	chr5:101632501	SLCO4C1	0.55	5.69	0.34	3.62e-8	Cognitive decline (age-related);
KIRP	cis	rs2929278	0.617	rs4617832	chr15:44030579	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.27	-0.37	1.58e-9	Schizophrenia;
KIRP	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.97	-0.5	7.77e-17	Total cholesterol levels;
KIRP	trans	rs12043259	0.730	rs12563611	chr1:204812476	A/G	cg11485465	chr5:54518469	NA	0.38	6.58	0.39	2.78e-10	Addiction;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg14821192	chr17:75137132	SEC14L1	-0.47	-6.06	-0.36	4.96e-9	Blood metabolite levels;
KIRP	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	1.12	16.87	0.73	6.23e-43	Monocyte percentage of white cells;
KIRP	cis	rs220519	0.811	rs220522	chr20:37278612	T/A	cg24308336	chr20:37270989	C20orf95	0.23	5.24	0.32	3.46e-7	Schizophrenia;
KIRP	cis	rs4720118	0.508	rs2392232	chr7:33436836	G/A	cg22798885	chr7:33102694	NT5C3	-0.42	-5.28	-0.32	2.78e-7	Leprosy;
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02475777	chr4:1388615	CRIPAK	0.4	5.3	0.32	2.55e-7	Longevity;
KIRP	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.89	12.92	0.64	1.69e-29	Total body bone mineral density;
KIRP	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.33	-0.55	5.22e-21	Alzheimer's disease (late onset);
KIRP	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.6	8.11	0.46	2.45e-14	Response to temozolomide;
KIRP	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg09788416	chr12:39539408	NA	0.39	5.32	0.32	2.3e-7	Morning vs. evening chronotype;
KIRP	cis	rs889398	0.741	rs6499268	chr16:69906529	G/A	cg09409435	chr16:70099608	PDXDC2	0.43	5.29	0.32	2.69e-7	Body mass index;
KIRP	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.84	10.44	0.55	2.32e-21	Vitamin D levels;
KIRP	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-6.1	-0.36	4.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs3780486	0.801	rs28517717	chr9:33179451	C/T	cg04842962	chr6:43655489	MRPS18A	1.06	12.1	0.61	9.66e-27	IgG glycosylation;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg04080417	chr5:1859792	NA	-0.59	-7.49	-0.43	1.27e-12	Cardiovascular disease risk factors;
KIRP	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg19899395	chr1:46959349	NA	0.46	5.61	0.34	5.5e-8	Monobrow;
KIRP	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.98	-0.36	7.98e-9	Breast cancer;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.55	-0.56	1.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.26	5.05	0.31	8.79e-7	Coronary artery disease;
KIRP	cis	rs7172677	1.000	rs11638746	chr15:75403108	A/C	cg10253484	chr15:75165896	SCAMP2	0.54	5.96	0.35	8.89e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg25042112	chr7:64838748	ZNF92	0.58	6.22	0.37	2.08e-9	Pain;
KIRP	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg12756093	chr1:115239321	AMPD1	0.52	7.03	0.41	2.04e-11	Autism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12286123	chr19:49977394	FLT3LG	0.5	6.32	0.37	1.23e-9	Myopia (pathological);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg06658637	chr5:466542	EXOC3	0.47	7.1	0.41	1.34e-11	Warfarin maintenance dose;
KIRP	cis	rs2882667	0.931	rs7720150	chr5:138334069	C/A	cg04439458	chr5:138467593	SIL1	-0.43	-7.31	-0.42	3.84e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.68	-0.39	1.54e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6832769	1.000	rs10002541	chr4:56395011	T/C	cg09317128	chr4:56265301	TMEM165	-0.56	-7.13	-0.41	1.11e-11	Personality dimensions;
KIRP	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.43	-0.38	6.64e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs112591243	0.685	rs2839338	chr21:47987984	C/T	cg26904215	chr21:47823096	PCNT	-0.74	-6.14	-0.36	3.31e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.62	-6.97	-0.41	2.85e-11	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg03714773	chr7:91764589	CYP51A1	0.36	5.22	0.32	3.73e-7	Breast cancer;
KIRP	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.55	-6.61	-0.39	2.33e-10	Mosquito bite size;
KIRP	cis	rs6545883	0.859	rs2694644	chr2:61604856	A/T	cg15711740	chr2:61764176	XPO1	0.61	7.85	0.45	1.27e-13	Tuberculosis;
KIRP	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-11.19	-0.58	8.87e-24	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.79	10.5	0.56	1.47e-21	Height;
KIRP	cis	rs7792596	1.000	rs6952539	chr7:93994003	A/G	cg20814616	chr7:94014465	NA	-0.32	-5.33	-0.32	2.26e-7	Intelligence;
KIRP	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.94	-13.56	-0.65	1.19e-31	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg00641009	chr7:106685553	PRKAR2B	0.48	6.16	0.37	3e-9	Educational attainment;
KIRP	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.57	6.96	0.41	3.14e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	8.57	0.48	1.2e-15	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	7.56	0.43	8.2e-13	Bipolar disorder;
KIRP	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.43	5.41	0.33	1.51e-7	Lung cancer;
KIRP	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.98	-17.43	-0.74	7.75e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs933688	0.689	rs12697808	chr5:90605389	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.65	-6.74	-0.39	1.13e-10	Smoking behavior;
KIRP	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg01689657	chr7:91764605	CYP51A1	0.45	6.5	0.38	4.45e-10	Breast cancer;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg26134248	chr17:3907702	NA	0.55	8.15	0.46	1.85e-14	Type 2 diabetes;
KIRP	cis	rs4262150	0.667	rs4958592	chr5:152288222	A/G	cg12297329	chr5:152029980	NA	0.45	6.21	0.37	2.25e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg06115741	chr20:33292138	TP53INP2	-0.57	-7.02	-0.41	2.18e-11	Coronary artery disease;
KIRP	cis	rs3105593	1.000	rs3131589	chr15:50841053	G/C	cg08437265	chr15:50716283	USP8	0.4	5.12	0.31	6.19e-7	QT interval;
KIRP	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg04362960	chr10:104952993	NT5C2	0.43	4.98	0.3	1.19e-6	Colorectal cancer;
KIRP	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg27490568	chr2:178487706	NA	0.47	6.14	0.36	3.29e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.06	-0.31	8.21e-7	Cognitive function;
KIRP	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg15893493	chr8:124194847	FAM83A	0.93	8.13	0.46	2.14e-14	Urinary uromodulin levels;
KIRP	cis	rs12930096	0.938	rs34096091	chr16:11676579	A/G	cg07439791	chr16:11680400	LITAF	0.73	6.15	0.37	3.04e-9	QT interval;
KIRP	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.51	0.48	1.69e-15	Motion sickness;
KIRP	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17691542	chr6:26056736	HIST1H1C	0.55	7.29	0.42	4.15e-12	Height;
KIRP	cis	rs3741151	0.892	rs60078907	chr11:73085834	T/C	cg17517138	chr11:73019481	ARHGEF17	0.78	6.97	0.41	2.85e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs918629	0.798	rs2161318	chr5:95288576	C/T	cg16656078	chr5:95278638	ELL2	0.47	6.84	0.4	6.37e-11	IgG glycosylation;
KIRP	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05220968	chr6:146057943	EPM2A	-0.41	-5.32	-0.32	2.35e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.86	-11.02	-0.57	3.33e-23	Platelet distribution width;
KIRP	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg25650185	chr19:21324782	ZNF431	0.48	5.19	0.31	4.46e-7	Pain;
KIRP	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs838147	0.733	rs12978499	chr19:49237552	A/C	cg13540341	chr19:49222985	MAMSTR	0.35	5.63	0.34	4.97e-8	Dietary macronutrient intake;
KIRP	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg08283408	chr3:49949060	MON1A	-0.43	-5.74	-0.34	2.8e-8	Body mass index;
KIRP	cis	rs9653442	0.545	rs13032454	chr2:100756009	T/C	cg22139774	chr2:100720529	AFF3	-0.32	-5.31	-0.32	2.46e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.37	-0.32	1.86e-7	Aortic root size;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg11184237	chr15:75748191	SIN3A	0.47	6.09	0.36	4.34e-9	Colorectal cancer;
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-9.42	-0.52	3.32e-18	Platelet count;
KIRP	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg23711669	chr6:146136114	FBXO30	-0.71	-9.93	-0.53	9.56e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7534824	0.860	rs6685428	chr1:101619780	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.94	5.16	0.31	5.07e-7	Refractive astigmatism;
KIRP	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.49	6.1	0.36	3.99e-9	Depressive symptoms;
KIRP	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.63	7.82	0.45	1.5700000000000001e-13	Multiple sclerosis;
KIRP	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.99	-0.5	6.95e-17	Blood metabolite levels;
KIRP	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.44	-6.64	-0.39	1.97e-10	Major depressive disorder;
KIRP	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.98	-0.36	7.79e-9	Obesity-related traits;
KIRP	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.45e-9	Type 2 diabetes;
KIRP	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs7017914	0.967	rs11989553	chr8:71640899	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.55	6.47	0.38	5.19e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-5.74	-0.34	2.74e-8	Obesity (extreme);
KIRP	trans	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.49	6.22	0.37	2.11e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.63	8.14	0.46	1.94e-14	Resistin levels;
KIRP	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.72	0.49	4.25e-16	Menopause (age at onset);
KIRP	cis	rs258892	0.843	rs4288100	chr5:72031760	C/T	cg21869765	chr5:72125136	TNPO1	-0.53	-6.06	-0.36	4.98e-9	Small cell lung carcinoma;
KIRP	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.27	-0.32	3.04e-7	Bladder cancer;
KIRP	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.46	6.19	0.37	2.47e-9	Coronary artery disease;
KIRP	cis	rs10924309	0.737	rs1122734	chr1:245853336	A/T	cg00036263	chr1:245852353	KIF26B	-0.53	-7.6	-0.44	6.04e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.91	-13.44	-0.65	3.12e-31	Lung cancer;
KIRP	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.73	-9.16	-0.5	2.04e-17	Urate levels in obese individuals;
KIRP	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.07	0.36	4.88e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs73086581	1.000	rs17286768	chr20:3924569	A/G	cg02187196	chr20:3869020	PANK2	0.5	4.9	0.3	1.7e-6	Response to antidepressants in depression;
KIRP	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg13731523	chr4:3047190	NA	-0.37	-6.28	-0.37	1.54e-9	Serum sulfate level;
KIRP	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.42	5.42	0.33	1.39e-7	Birth weight;
KIRP	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.16	-0.5	2.13e-17	Colorectal cancer;
KIRP	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13047869	chr3:10149882	C3orf24	0.52	4.91	0.3	1.63e-6	Alzheimer's disease;
KIRP	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg27532560	chr4:187881888	NA	-0.76	-13.15	-0.64	2.86e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs240764	0.658	rs9390685	chr6:101224725	A/T	cg09795085	chr6:101329169	ASCC3	0.43	5.17	0.31	4.81e-7	Neuroticism;
KIRP	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.43	6.34	0.37	1.07e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.55	-5.72	-0.34	3e-8	DNA methylation (variation);
KIRP	cis	rs2712184	0.683	rs2541403	chr2:217637885	A/G	cg05032264	chr2:217675019	NA	0.38	5.21	0.32	3.99e-7	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs2055729	0.500	rs1396186	chr8:9875204	T/C	cg21625330	chr8:9911636	MSRA	-0.56	-5.74	-0.34	2.75e-8	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11673344	0.864	rs55792845	chr19:37498685	T/C	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.18	-0.31	4.64e-7	Obesity-related traits;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07648498	chr16:89883185	FANCA	0.4	5.24	0.32	3.38e-7	Vitiligo;
KIRP	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.39	4.85	0.3	2.15e-6	Common traits (Other);
KIRP	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.56	7.42	0.43	1.85e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs13178130	0.515	rs2569343	chr5:133897103	A/G	cg06019726	chr5:133897654	PHF15	-0.4	-5.97	-0.36	8.41e-9	Menarche (age at onset);
KIRP	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg11972305	chr2:233791962	NGEF	-0.38	-5.28	-0.32	2.79e-7	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg22117172	chr7:91764530	CYP51A1	0.47	6.52	0.38	3.97e-10	Breast cancer;
KIRP	cis	rs10872587	0.555	rs9497426	chr6:146234644	G/A	cg05347473	chr6:146136440	FBXO30	-0.58	-6.36	-0.38	9.69e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.62	8.3	0.47	6.91e-15	HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.58	-6.12	-0.36	3.68e-9	Obesity-related traits;
KIRP	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.81	9.83	0.53	1.87e-19	Corneal astigmatism;
KIRP	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.98	-14.04	-0.67	2.77e-33	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.25	-0.37	1.81e-9	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26031255	chr6:150463965	PPP1R14C	0.49	6.11	0.36	3.94e-9	Parkinson's disease;
KIRP	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.49	-6.14	-0.36	3.37e-9	Post bronchodilator FEV1;
KIRP	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg26084005	chr2:241760190	KIF1A	-0.51	-6.84	-0.4	6.27e-11	Urinary metabolites;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17342216	chr3:170557991	NA	0.43	6.19	0.37	2.57e-9	Interleukin-4 levels;
KIRP	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.66	5.53	0.33	8.29e-8	Diabetic retinopathy;
KIRP	cis	rs4805272	1.000	rs888828	chr19:29325057	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.27	-0.32	2.96e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg13409248	chr3:40428643	ENTPD3	0.4	5.29	0.32	2.75e-7	Renal cell carcinoma;
KIRP	cis	rs3105593	1.000	rs3131582	chr15:50879670	C/T	cg08437265	chr15:50716283	USP8	0.39	4.95	0.3	1.35e-6	QT interval;
KIRP	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.86	-0.63	2.83e-29	Intelligence (multi-trait analysis);
KIRP	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.65	6.59	0.39	2.63e-10	Gastritis;
KIRP	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	cg21523751	chr1:182988639	NA	0.35	4.95	0.3	1.38e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.47	-5.53	-0.33	8.04e-8	Obesity-related traits;
KIRP	trans	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.77	9.63	0.52	7.62e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1355223	0.902	rs1539250	chr11:34742775	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.2	-0.31	4.16e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2151522	0.603	rs3195537	chr6:127201692	G/C	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg13798780	chr7:105162888	PUS7	0.66	6.09	0.36	4.31e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs11622475	0.580	rs36026329	chr14:104351661	T/A	cg20488157	chr14:104394430	TDRD9	0.64	8.5	0.48	1.84e-15	Bipolar disorder;
KIRP	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.36	5.0	0.3	1.09e-6	Axial length;
KIRP	cis	rs7721647	0.810	rs16876880	chr5:90796839	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.44	4.88	0.3	1.88e-6	Breast cancer;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg21734707	chr17:3908241	ZZEF1	0.66	9.99	0.54	6.24e-20	Type 2 diabetes;
KIRP	cis	rs2219968	0.828	rs60036550	chr8:78911936	G/A	cg00738934	chr8:78996279	NA	-0.39	-5.28	-0.32	2.79e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1538970	0.810	rs12067642	chr1:45927517	G/T	cg05343316	chr1:45956843	TESK2	0.69	8.11	0.46	2.42e-14	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05889321	chr10:97416837	ALDH18A1	-0.46	-6.32	-0.37	1.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4671458	1.000	rs12473894	chr2:63376570	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-5.58	-0.34	6.2e-8	Subjective well-being;
KIRP	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg18225595	chr11:63971243	STIP1	0.56	4.91	0.3	1.69e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14255396	chr19:10764458	ILF3;LOC147727	0.45	6.08	0.36	4.57e-9	Parkinson's disease;
KIRP	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.83	0.45	1.46e-13	Morning vs. evening chronotype;
KIRP	cis	rs13185784	0.632	rs4469167	chr5:179650964	C/T	cg23248424	chr5:179741104	GFPT2	-0.49	-5.18	-0.31	4.52e-7	TRAIL levels;
KIRP	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg02002194	chr4:3960332	NA	-0.49	-6.63	-0.39	2.17e-10	Mood instability;
KIRP	cis	rs10929956	0.593	rs61010155	chr2:160699166	C/A	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.18	-0.31	4.58e-7	Crohn's disease-related phenotypes;
KIRP	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11645453	chr3:52864694	ITIH4	0.35	5.51	0.33	9.26e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.63	7.42	0.43	1.89e-12	Type 2 diabetes;
KIRP	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.61	-7.57	-0.43	7.44e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg17595323	chr11:93583763	C11orf90	-0.41	-6.82	-0.4	7.18e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.96	15.11	0.69	6.18e-37	Systemic lupus erythematosus;
KIRP	cis	rs734999	0.588	rs745368	chr1:2524205	C/T	cg20673091	chr1:2541236	MMEL1	0.65	9.57	0.52	1.18e-18	Ulcerative colitis;
KIRP	cis	rs6500550	0.530	rs6501178	chr16:3566362	G/A	cg07396092	chr16:3662230	BTBD12	0.49	5.75	0.34	2.64e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.17	0.64	2.41e-30	Eye color traits;
KIRP	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg00204512	chr16:28754710	NA	0.46	6.05	0.36	5.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	0.95	9.89	0.53	1.23e-19	Blood protein levels;
KIRP	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	trans	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.26	0.42	4.97e-12	Mean corpuscular volume;
KIRP	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.69	9.23	0.51	1.32e-17	Crohn's disease;
KIRP	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg12140854	chr5:148520817	ABLIM3	0.45	5.06	0.31	8.23e-7	Breast cancer;
KIRP	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg18882449	chr10:104885122	NT5C2	-0.49	-6.33	-0.37	1.16e-9	Arsenic metabolism;
KIRP	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg10950524	chr7:2139216	MAD1L1	0.31	4.94	0.3	1.42e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg24315340	chr6:146058215	EPM2A	0.43	5.45	0.33	1.21e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22156867	chr6:37467762	C6orf129	0.54	6.27	0.37	1.6e-9	Smoking initiation;
KIRP	cis	rs2421770	0.701	rs7119757	chr11:35257316	G/A	cg16344511	chr11:35228261	CD44	0.45	4.86	0.3	2.07e-6	Staphylococcus aureus nasal carriage (persistent);
KIRP	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg02487422	chr3:49467188	NICN1	0.37	5.08	0.31	7.32e-7	Parkinson's disease;
KIRP	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg02733842	chr7:1102375	C7orf50	-0.54	-6.13	-0.36	3.41e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.91e-8	Life satisfaction;
KIRP	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.69	9.38	0.51	4.62e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.46	-5.58	-0.33	6.49e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.77	10.64	0.56	5.22e-22	Menarche (age at onset);
KIRP	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.22e-7	Life satisfaction;
KIRP	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg13010199	chr12:38710504	ALG10B	0.58	7.25	0.42	5.48e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs300890	0.536	rs10033104	chr4:144173483	A/G	cg01719995	chr4:144104893	USP38	0.41	5.24	0.32	3.5e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.8	13.17	0.64	2.49e-30	Longevity;Endometriosis;
KIRP	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-5.14	-0.31	5.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs867371	1.000	rs2088858	chr15:82474749	C/T	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.68	-8.34	-0.47	5.26e-15	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7771547	0.607	rs584196	chr6:36456243	G/C	cg04289385	chr6:36355825	ETV7	0.42	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.51	-0.33	8.89e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs287982	1.000	rs72780999	chr2:9981970	C/T	cg10881225	chr2:9984929	TAF1B	0.51	5.64	0.34	4.64e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg26681399	chr22:41777847	TEF	0.45	4.85	0.3	2.19e-6	Vitiligo;
KIRP	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.56	6.02	0.36	6.3e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12292205	chr6:26970375	C6orf41	-0.69	-7.99	-0.45	5.22e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg10189774	chr4:17578691	LAP3	0.49	6.06	0.36	5.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.73	-8.25	-0.47	9.6e-15	Tourette syndrome;
KIRP	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg10402321	chr1:26617780	UBXN11	-0.42	-5.55	-0.33	7.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4414128	0.579	rs1317212	chr10:5673327	G/T	cg12223502	chr10:5658492	NA	0.52	5.68	0.34	3.79e-8	Breast cancer;
KIRP	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg15068132	chr12:102092402	CHPT1	-0.41	-5.3	-0.32	2.63e-7	Blood protein levels;
KIRP	cis	rs6504622	0.517	rs11656362	chr17:45036255	C/G	cg16759221	chr17:45003025	GOSR2	-0.42	-6.04	-0.36	5.67e-9	Orofacial clefts;
KIRP	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-0.6	-6.71	-0.39	1.35e-10	Initial pursuit acceleration;
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.34	0.74	1.55e-44	Platelet count;
KIRP	cis	rs6545883	0.894	rs778144	chr2:61583128	A/C	cg15711740	chr2:61764176	XPO1	0.59	7.78	0.44	1.96e-13	Tuberculosis;
KIRP	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25517755	chr10:38738941	LOC399744	-0.38	-5.38	-0.32	1.7e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.44	-0.38	6.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.34	-0.37	1.09e-9	Triglycerides;
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg09597638	chr17:3907349	NA	-0.58	-8.92	-0.49	1.05e-16	Type 2 diabetes;
KIRP	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg08501292	chr6:25962987	TRIM38	1.14	8.15	0.46	1.81e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6442310	0.534	rs709148	chr3:12450166	C/A	cg22839075	chr3:12045461	SYN2	-0.39	-5.53	-0.33	8.2e-8	Hematocrit;
KIRP	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.5	5.95	0.35	8.97e-9	Menopause (age at onset);
KIRP	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.45e-9	Breast cancer;
KIRP	cis	rs2274273	0.624	rs12050123	chr14:55840386	G/A	cg04306507	chr14:55594613	LGALS3	0.38	5.3	0.32	2.54e-7	Protein biomarker;
KIRP	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-7.48	-0.43	1.31e-12	Longevity;
KIRP	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.55	-0.52	1.42e-18	Neuroticism;
KIRP	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg12568669	chr8:11666485	FDFT1	-0.26	-5.75	-0.34	2.64e-8	Morning vs. evening chronotype;
KIRP	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg01420254	chr6:26195488	NA	1.27	9.94	0.54	8.88e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs7116495	1.000	rs1939245	chr11:71742532	C/T	cg26138937	chr11:71823887	C11orf51	-0.7	-5.54	-0.33	7.78e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	5.24	0.32	3.42e-7	Height;
KIRP	cis	rs600806	0.693	rs10858087	chr1:109916890	T/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.64	-0.34	4.55e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6901004	0.803	rs193282	chr6:111543067	G/A	cg15721981	chr6:111408429	SLC16A10	-0.52	-7.09	-0.41	1.37e-11	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg09264619	chr17:80180166	NA	-0.4	-5.99	-0.36	7.26e-9	Life satisfaction;
KIRP	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.67	9.19	0.51	1.73e-17	Lymphocyte counts;
KIRP	cis	rs11203032	0.831	rs10887930	chr10:90950094	C/T	cg16672925	chr10:90967113	CH25H	-0.44	-5.58	-0.34	6.34e-8	Heart failure;
KIRP	cis	rs597583	0.806	rs11603340	chr11:117396527	C/G	cg27161313	chr11:117392002	DSCAML1	-0.53	-5.86	-0.35	1.46e-8	Putamen volume;
KIRP	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16603964	chr6:111803680	REV3L	-0.53	-6.26	-0.37	1.71e-9	Interleukin-4 levels;
KIRP	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg27205649	chr11:78285834	NARS2	-0.54	-5.22	-0.32	3.88e-7	Testicular germ cell tumor;
KIRP	cis	rs4234798	0.605	rs4689637	chr4:7211197	A/G	cg18431297	chr4:7219810	SORCS2	0.56	6.04	0.36	5.53e-9	Insulin-like growth factors;
KIRP	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg11608241	chr8:8085544	FLJ10661	-0.4	-5.05	-0.31	8.7e-7	Recombination measurement;
KIRP	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg19445457	chr11:5799446	OR52N5	-0.47	-5.56	-0.33	7.08e-8	DNA methylation (variation);
KIRP	cis	rs2033732	0.559	rs10504802	chr8:85033036	T/C	cg05716166	chr8:85095498	RALYL	0.55	5.12	0.31	6.09e-7	Body mass index;
KIRP	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg17554472	chr22:41940697	POLR3H	-0.61	-6.53	-0.38	3.74e-10	Vitiligo;
KIRP	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg16511985	chr3:153974050	SGEF	0.41	5.73	0.34	2.85e-8	Coronary artery disease;
KIRP	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.43	-5.37	-0.32	1.83e-7	Coronary heart disease;
KIRP	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg23202291	chr11:1979235	NA	0.39	5.1	0.31	6.67e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.8	10.78	0.57	1.97e-22	Coronary artery disease;
KIRP	cis	rs28655083	1.000	rs7197078	chr16:77072735	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.51	-5.54	-0.33	7.72e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.11e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.51	7.01	0.41	2.34e-11	Gout;
KIRP	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	7.94	0.45	7.14e-14	Neuroticism;
KIRP	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.49	5.28	0.32	2.79e-7	Alzheimer's disease;
KIRP	cis	rs6840360	0.870	rs1372978	chr4:152456180	A/G	cg22705602	chr4:152727874	NA	-0.4	-6.2	-0.37	2.41e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7119038	0.629	rs10892273	chr11:118602809	G/A	cg19308663	chr11:118741387	NA	0.48	7.89	0.45	1.01e-13	Sjögren's syndrome;
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg07701084	chr6:150067640	NUP43	0.65	8.36	0.47	4.8e-15	Lung cancer;
KIRP	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.6	11.22	0.58	7.26e-24	Bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22089800	chr15:90895588	ZNF774	0.49	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg17279839	chr7:150038598	RARRES2	-0.46	-6.25	-0.37	1.75e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-1.15	-14.64	-0.68	2.57e-35	Platelet distribution width;
KIRP	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7084402	0.967	rs1649025	chr10:60281584	C/G	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.84e-24	Refractive error;
KIRP	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg12140854	chr5:148520817	ABLIM3	0.51	5.88	0.35	1.34e-8	Breast cancer;
KIRP	cis	rs2071403	0.933	rs10183390	chr2:1404885	T/C	cg07083862	chr2:1417248	TPO	0.36	5.81	0.35	1.9e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.38e-7	Ileal carcinoids;
KIRP	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg11130432	chr3:121712080	ILDR1	-0.46	-5.66	-0.34	4.22e-8	Multiple sclerosis;
KIRP	cis	rs4700695	0.841	rs251304	chr5:65249700	A/G	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs4132509	0.566	rs1578275	chr1:243680442	C/G	cg21452805	chr1:244014465	NA	-0.61	-5.98	-0.36	7.73e-9	RR interval (heart rate);
KIRP	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.73	9.03	0.5	5.25e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7534824	0.543	rs6577221	chr1:101420406	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	6.42	0.38	6.85e-10	Refractive astigmatism;
KIRP	cis	rs2723064	0.543	rs2080385	chr2:65292762	G/T	cg05010058	chr2:65284262	CEP68	0.49	6.32	0.37	1.22e-9	Atrial fibrillation;
KIRP	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.93	-0.49	1e-16	Total cholesterol levels;
KIRP	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03934478	chr11:495069	RNH1	0.78	6.45	0.38	5.86e-10	Body mass index;
KIRP	cis	rs11650494	0.516	rs9900373	chr17:47512945	C/G	cg08112188	chr17:47440006	ZNF652	0.8	5.16	0.31	5.17e-7	Prostate cancer;
KIRP	cis	rs9890032	0.570	rs8068504	chr17:29112070	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.39	-5.0	-0.3	1.08e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.88	-11.65	-0.6	2.91e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg18477163	chr1:228402036	OBSCN	0.36	7.18	0.42	8.41e-12	Diastolic blood pressure;
KIRP	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.17e-37	Height;
KIRP	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg00094735	chr5:1949198	NA	0.46	5.52	0.33	8.53e-8	Gut microbiome composition (winter);
KIRP	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs56079296	0.929	rs10045728	chr5:121277101	A/G	cg05256605	chr5:121412184	LOX	0.52	5.62	0.34	5.06e-8	Coronary artery disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00969815	chr22:42536375	CYP2D7P1	0.46	6.14	0.36	3.33e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6723108	0.678	rs578384	chr2:135287914	A/G	cg25422880	chr2:135218333	TMEM163	-0.36	-5.05	-0.31	8.65e-7	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg07701084	chr6:150067640	NUP43	0.72	9.54	0.52	1.44e-18	Lung cancer;
KIRP	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.63	9.1	0.5	3.26e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1050631	0.592	rs1785927	chr18:33726447	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.93	0.35	1.02e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs981844	1.000	rs62325105	chr4:154673846	T/C	cg14289246	chr4:154710475	SFRP2	0.67	7.53	0.43	9.88e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.61	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg09344028	chr17:70110421	NA	0.49	12.31	0.62	1.86e-27	Thyroid hormone levels;
KIRP	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg10434728	chr15:90938212	IQGAP1	0.3	5.07	0.31	7.86e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-7.35	-0.42	2.88e-12	Prudent dietary pattern;
KIRP	trans	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg19407955	chr1:165599744	MGST3	-0.45	-5.31	-0.32	2.45e-7	Total ventricular volume;
KIRP	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	cg12689670	chr1:183009347	LAMC1	0.45	6.39	0.38	8.41e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Colorectal cancer;
KIRP	cis	rs4713675	0.584	rs560111	chr6:33706277	C/T	cg25922239	chr6:33757077	LEMD2	0.43	5.09	0.31	7.12e-7	Plateletcrit;
KIRP	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	0.93	11.85	0.6	6.12e-26	Corneal structure;
KIRP	cis	rs9783347	1.000	rs12286683	chr11:18348662	G/T	cg15585147	chr11:18324498	HPS5	0.44	5.95	0.35	9.4e-9	Pancreatic cancer;
KIRP	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.2e-6	Morning vs. evening chronotype;
KIRP	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs7737355	0.812	rs6881486	chr5:130793836	C/T	cg06307176	chr5:131281290	NA	-0.41	-4.91	-0.3	1.65e-6	Life satisfaction;
KIRP	cis	rs73526541	0.541	rs12544013	chr8:1071033	T/C	cg01049933	chr8:1047734	NA	0.73	5.58	0.34	6.4e-8	Verbal memory performance (immediate recall change);
KIRP	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg05791153	chr7:19748676	TWISTNB	0.71	6.3	0.37	1.39e-9	Thyroid stimulating hormone;
KIRP	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg19875535	chr5:140030758	IK	0.69	9.64	0.52	7.26e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.75	10.99	0.57	3.91e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08906898	chr20:34319899	RBM39	0.54	6.1	0.36	3.98e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10174797	chr19:8464628	RAB11B	0.51	6.33	0.37	1.16e-9	HDL cholesterol;
KIRP	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg24253500	chr15:84953950	NA	0.65	7.62	0.44	5.39e-13	Schizophrenia;
KIRP	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.41	-0.38	7.33e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	9.34	0.51	6.2e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg11608241	chr8:8085544	FLJ10661	-0.42	-5.31	-0.32	2.48e-7	Mood instability;
KIRP	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.55	7.3	0.42	3.96e-12	Mood instability;
KIRP	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg17145862	chr1:211918768	LPGAT1	0.68	6.75	0.4	1.07e-10	Crohn's disease;
KIRP	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg27205649	chr11:78285834	NARS2	0.61	7.96	0.45	6.31e-14	Alzheimer's disease (survival time);
KIRP	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.8	8.02	0.46	4.32e-14	Lung function (FEV1/FVC);
KIRP	cis	rs6893807	0.778	rs16903285	chr5:87978252	T/C	cg24804195	chr5:87968844	LOC645323	0.61	5.82	0.35	1.79e-8	Body mass index;
KIRP	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.59	-7.22	-0.42	6.64e-12	Aortic root size;
KIRP	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.44	-5.64	-0.34	4.71e-8	IgG glycosylation;
KIRP	cis	rs8064299	0.536	rs2290038	chr17:72786611	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	-1.0	-13.56	-0.65	1.18e-31	Monocyte count;
KIRP	cis	rs7638995	0.701	rs34550101	chr3:69185670	C/T	cg26574240	chr3:69171822	LMOD3	-0.77	-8.95	-0.5	8.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7007076	0.901	rs62519880	chr8:124729038	G/C	cg00283535	chr8:124749564	ANXA13	0.88	8.64	0.48	7.49e-16	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg00343986	chr7:65444356	GUSB	0.43	5.0	0.3	1.09e-6	Aortic root size;
KIRP	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.73	9.36	0.51	5.4e-18	Personality dimensions;
KIRP	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.46	-5.52	-0.33	8.57e-8	Body mass index;
KIRP	cis	rs7172677	0.732	rs2289583	chr15:75311036	C/A	cg14664628	chr15:75095509	CSK	0.59	6.39	0.38	8.18e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs16936870	0.543	rs6991199	chr8:71316597	G/A	cg14232793	chr8:71155543	NCOA2	0.53	6.33	0.37	1.14e-9	QT interval;
KIRP	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.54	-0.43	8.87e-13	Resting heart rate;
KIRP	cis	rs4711350	0.734	rs9380379	chr6:33766131	A/G	cg25922239	chr6:33757077	LEMD2	0.54	6.12	0.36	3.71e-9	Schizophrenia;
KIRP	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.2	-16.27	-0.72	6.68e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.71	10.45	0.55	2.12e-21	Lewy body disease;
KIRP	cis	rs754423	0.631	rs1497085	chr14:52521243	G/C	cg10149976	chr14:52535953	NID2	-0.37	-5.32	-0.32	2.37e-7	Craniofacial microsomia;
KIRP	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs10773046	0.740	rs10773045	chr12:124351666	A/G	cg18594669	chr12:124364423	DNAH10	0.39	5.34	0.32	2.15e-7	Osteoarthritis (hip);
KIRP	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg09555818	chr19:45449301	APOC2	0.5	7.26	0.42	4.94e-12	Blood protein levels;
KIRP	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.47	-0.48	2.24e-15	Common traits (Other);
KIRP	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs4517514	0.509	rs10830411	chr11:89865532	A/G	cg06174606	chr11:89959870	NA	-0.51	-5.2	-0.31	4.16e-7	Trans fatty acid levels;
KIRP	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.78	7.81	0.45	1.6e-13	White matter hyperintensity burden;
KIRP	cis	rs963731	0.649	rs297152	chr2:39326734	G/T	cg04010122	chr2:39346883	SOS1	-0.67	-5.08	-0.31	7.53e-7	Corticobasal degeneration;
KIRP	cis	rs33912345	0.669	rs1313240	chr14:60848527	T/C	cg27398547	chr14:60952738	C14orf39	-0.41	-5.56	-0.33	6.91e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs9682041	0.597	rs62295834	chr3:170075701	G/A	cg11886554	chr3:170076028	SKIL	0.46	5.08	0.31	7.31e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs2916247	0.954	rs4458918	chr8:93076553	C/T	cg10183463	chr8:93005414	RUNX1T1	0.52	6.44	0.38	6.14e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7119038	0.774	rs73005426	chr11:118681083	A/G	cg19308663	chr11:118741387	NA	0.52	9.02	0.5	5.52e-17	Sjögren's syndrome;
KIRP	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg10755058	chr3:40428713	ENTPD3	-0.38	-5.42	-0.33	1.39e-7	Renal cell carcinoma;
KIRP	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-6.71	-0.39	1.32e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4400599	0.618	rs10908751	chr1:154187305	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.4	-5.96	-0.36	8.62e-9	Platelet distribution width;
KIRP	trans	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.78	-0.4	8.66e-11	Neuroticism;
KIRP	cis	rs731174	0.759	rs575254	chr1:38149692	C/G	cg14170840	chr1:38155120	C1orf109	-0.41	-5.2	-0.31	4.2e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg13147721	chr7:65941812	NA	0.99	6.64	0.39	1.98e-10	Diabetic kidney disease;
KIRP	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.73	-11.05	-0.58	2.6e-23	Resting heart rate;
KIRP	cis	rs9638182	0.560	rs67644909	chr7:72995954	C/T	cg07452164	chr7:72993570	TBL2	0.53	6.05	0.36	5.22e-9	Triglycerides;
KIRP	cis	rs7215564	0.908	rs2316059	chr17:78663732	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	trans	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg16141378	chr3:129829833	LOC729375	0.48	6.15	0.37	3.14e-9	Mood instability;
KIRP	cis	rs7507204	0.572	rs7246730	chr19:3419781	A/G	cg08380311	chr19:3435252	NFIC	-0.67	-7.68	-0.44	3.76e-13	Height;
KIRP	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.14	0.76	3e-47	Chronic sinus infection;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.79	10.59	0.56	7.49e-22	Longevity;
KIRP	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg17724175	chr1:150552817	MCL1	0.36	6.0	0.36	6.95e-9	Tonsillectomy;
KIRP	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg21427119	chr20:30132790	HM13	-0.43	-5.18	-0.31	4.55e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs7577696	0.597	rs7556942	chr2:32295694	G/A	cg02381751	chr2:32503542	YIPF4	-0.52	-5.26	-0.32	3.08e-7	Inflammatory biomarkers;
KIRP	cis	rs787274	0.557	rs1570754	chr9:115669284	C/A	cg13803584	chr9:115635662	SNX30	-0.69	-5.96	-0.36	8.77e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1983891	0.706	rs745548	chr6:41557117	G/T	cg20194872	chr6:41519635	FOXP4	-0.52	-6.79	-0.4	8.22e-11	Prostate cancer;
KIRP	cis	rs10875746	0.669	rs10783244	chr12:48664989	A/C	cg20731937	chr12:48336164	NA	0.42	5.66	0.34	4.2e-8	Longevity (90 years and older);
KIRP	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-0.83	-11.0	-0.57	3.64e-23	Urate levels;
KIRP	cis	rs4302748	0.862	rs73335286	chr7:36184728	C/T	cg24442661	chr7:36192818	EEPD1	0.62	6.61	0.39	2.33e-10	Platelet count;
KIRP	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.98	16.61	0.73	4.77e-42	Breast cancer;
KIRP	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	8.05	0.46	3.53e-14	Lung function (FEV1/FVC);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23555592	chr10:91174309	IFIT5	-0.47	-6.01	-0.36	6.49e-9	Interleukin-4 levels;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.44	5.28	0.32	2.84e-7	Longevity;Endometriosis;
KIRP	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.82	9.79	0.53	2.61e-19	Corneal astigmatism;
KIRP	cis	rs2505998	0.833	rs2565204	chr10:43603173	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.45	-4.91	-0.3	1.68e-6	Hirschsprung disease;
KIRP	cis	rs16867335	0.652	rs1528439	chr2:181462035	C/T	cg23363182	chr2:181467187	NA	-0.39	-5.26	-0.32	3.18e-7	Survival in rectal cancer;
KIRP	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.66	8.4	0.47	3.67e-15	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-7.82	-0.45	1.59e-13	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.5	6.82	0.4	7.07e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.75	10.73	0.56	2.83e-22	Platelet distribution width;
KIRP	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.95	-0.41	3.27e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg16141378	chr3:129829833	LOC729375	-0.54	-7.19	-0.42	7.57e-12	Mood instability;
KIRP	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.8	0.4	7.76e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg23335576	chr14:104009727	NA	-0.65	-7.97	-0.45	5.85e-14	Bone mineral density;
KIRP	trans	rs12517041	1.000	rs6879720	chr5:23312477	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg23682824	chr7:23144976	KLHL7	0.51	5.97	0.36	8.4e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.69	-10.45	-0.55	2.19e-21	Heart rate;
KIRP	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.45	0.68	1.13e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.83	-12.25	-0.62	3.05e-27	Systemic lupus erythematosus;
KIRP	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg00129232	chr17:37814104	STARD3	-0.52	-6.42	-0.38	7.15e-10	Self-reported allergy;
KIRP	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.46	-0.33	1.16e-7	Crohn's disease;
KIRP	cis	rs10131728	0.892	rs35446669	chr14:81707588	T/G	cg01989461	chr14:81687754	GTF2A1	-0.72	-5.97	-0.36	8.43e-9	IgG glycosylation;
KIRP	cis	rs6032067	1.000	rs62205501	chr20:43864089	G/A	cg10761708	chr20:43804764	PI3	0.53	5.39	0.33	1.61e-7	Blood protein levels;
KIRP	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6430538	0.621	rs6753223	chr2:135576472	A/G	cg25422880	chr2:135218333	TMEM163	-0.43	-5.94	-0.35	9.62e-9	Parkinson's disease;
KIRP	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	trans	rs7157940	0.692	rs4905163	chr14:94570770	A/G	cg23970523	chr19:18654267	FKBP8	0.51	6.07	0.36	4.76e-9	Anthropometric traits;
KIRP	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg09137382	chr11:130731461	NA	-0.47	-6.67	-0.39	1.72e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg04166393	chr7:2884313	GNA12	0.67	7.86	0.45	1.24e-13	Height;
KIRP	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg05526886	chr2:227700861	RHBDD1	0.41	4.9	0.3	1.76e-6	Pulmonary function;
KIRP	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.4	3.46e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg18016565	chr1:150552671	MCL1	0.37	5.63	0.34	4.89e-8	Melanoma;
KIRP	cis	rs10465746	0.780	rs2147392	chr1:84404154	C/A	cg10977910	chr1:84465055	TTLL7	0.55	7.06	0.41	1.69e-11	Obesity-related traits;
KIRP	cis	rs2929278	0.589	rs7174732	chr15:44038463	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-6.28	-0.37	1.48e-9	Schizophrenia;
KIRP	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.64	-0.44	4.77e-13	Type 2 diabetes;
KIRP	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.42	-5.14	-0.31	5.63e-7	Diastolic blood pressure;
KIRP	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg17366294	chr4:99064904	C4orf37	-0.37	-5.17	-0.31	4.82e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12976411	0.867	rs71351160	chr19:32864679	C/T	cg02282382	chr19:32836354	ZNF507	0.62	5.33	0.32	2.26e-7	Coronary artery disease;
KIRP	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg02503808	chr4:7069936	GRPEL1	-1.03	-10.42	-0.55	2.74e-21	Monocyte percentage of white cells;
KIRP	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.88	9.85	0.53	1.64e-19	Gut microbiome composition (summer);
KIRP	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg11833968	chr6:79620685	NA	-0.52	-7.85	-0.45	1.29e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg19694781	chr19:47549865	TMEM160	-0.49	-6.14	-0.36	3.27e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg16141378	chr3:129829833	LOC729375	0.59	7.99	0.45	5.33e-14	Triglycerides;
KIRP	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.82	9.75	0.53	3.37e-19	Corneal astigmatism;
KIRP	cis	rs10214930	0.752	rs10951173	chr7:27662898	C/A	cg22168087	chr7:27702803	HIBADH	0.52	5.2	0.31	4.18e-7	Hypospadias;
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-5.78	-0.35	2.31e-8	Aortic root size;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15627593	chr17:17457836	PEMT	0.57	6.06	0.36	5.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.65	-9.2	-0.51	1.64e-17	Retinal vascular caliber;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01337508	chr17:40540572	STAT3	0.55	6.42	0.38	7.05e-10	Smoking initiation;
KIRP	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06505273	chr16:24850292	NA	0.39	5.14	0.31	5.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.71	0.39	1.29e-10	Height;
KIRP	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.15	0.37	3.03e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.71	-10.12	-0.54	2.35e-20	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	1.0	10.98	0.57	4.31e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.52	6.77	0.4	9.23e-11	Schizophrenia;
KIRP	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.08	-0.41	1.51e-11	Migraine;Coronary artery disease;
KIRP	cis	rs6910061	1.000	rs9468415	chr6:11100885	T/A	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.91	-0.3	1.63e-6	Inflammatory bowel disease;
KIRP	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.6	-6.16	-0.37	2.93e-9	Tuberculosis;
KIRP	cis	rs6681460	0.932	rs2044400	chr1:67054081	T/A	cg02459107	chr1:67143332	SGIP1	0.48	6.91	0.4	4.22e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs539514	0.612	rs9573648	chr13:76309279	A/G	cg04757411	chr13:76259545	LMO7	-0.37	-5.23	-0.32	3.56e-7	Type 1 diabetes;
KIRP	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.44e-11	Schizophrenia;
KIRP	cis	rs9311676	0.609	rs55845662	chr3:58424899	A/C	cg06643156	chr3:58380774	PXK	0.35	4.89	0.3	1.8e-6	Systemic lupus erythematosus;
KIRP	cis	rs9915657	0.715	rs34624256	chr17:70105848	C/T	cg09344028	chr17:70110421	NA	0.4	7.99	0.45	5.24e-14	Thyroid hormone levels;
KIRP	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg14784868	chr12:69753453	YEATS4	0.5	5.22	0.32	3.82e-7	Response to diuretic therapy;
KIRP	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23310975	chr8:121455224	MRPL13	0.53	7.1	0.41	1.36e-11	Interleukin-4 levels;
KIRP	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.72	8.18	0.46	1.52e-14	Tonometry;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.7	9.64	0.52	7.47e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06850241	chr22:41845214	NA	-0.39	-4.86	-0.3	2.09e-6	Vitiligo;
KIRP	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.68	-7.59	-0.44	6.53e-13	Type 2 diabetes;
KIRP	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4851254	0.961	rs7596385	chr2:100796598	A/T	cg17356467	chr2:100759845	AFF3	0.59	7.44	0.43	1.67e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.38	-5.07	-0.31	7.81e-7	Menarche (age at onset);
KIRP	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg07382826	chr16:28625726	SULT1A1	0.46	5.14	0.31	5.73e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.97	16.13	0.72	2.03e-40	Bone mineral density;
KIRP	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.27	-0.42	4.78e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs16976116	0.901	rs7165491	chr15:55500455	A/C	cg11288833	chr15:55489084	RSL24D1	0.57	6.32	0.37	1.25e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7527798	0.544	rs11118354	chr1:207856868	A/G	cg09232269	chr1:207846808	CR1L	-0.36	-5.27	-0.32	2.93e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6929812	0.934	rs2064221	chr6:27388448	C/A	cg03332623	chr6:27441972	ZNF184	-0.35	-4.96	-0.3	1.31e-6	Neuroticism (multi-trait analysis);
KIRP	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg20701182	chr2:24300061	SF3B14	0.47	4.93	0.3	1.51e-6	Asthma;
KIRP	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg00129232	chr17:37814104	STARD3	0.41	4.95	0.3	1.35e-6	Asthma and hay fever;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.46	-5.76	-0.34	2.45e-8	Longevity;Endometriosis;
KIRP	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.51	0.52	1.87e-18	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07387570	chr22:46663686	TTC38	-0.49	-6.29	-0.37	1.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.65	9.88	0.53	1.37e-19	Educational attainment;
KIRP	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.56	8.04	0.46	3.68e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs883565	0.525	rs9833327	chr3:39029631	A/G	cg01426195	chr3:39028469	NA	-0.77	-13.74	-0.66	2.82e-32	Handedness;
KIRP	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-13.33	-0.65	7.02e-31	Alzheimer's disease;
KIRP	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg25706552	chr1:244017396	NA	0.58	6.47	0.38	5.18e-10	RR interval (heart rate);
KIRP	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs10242455	0.702	rs28377312	chr7:98984213	G/A	cg00573235	chr16:56883532	NA	0.76	6.53	0.38	3.63e-10	Blood metabolite levels;
KIRP	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.16	-0.37	2.9e-9	Breast cancer;
KIRP	cis	rs9488822	0.585	rs529574	chr6:116268158	T/A	cg18764771	chr6:116381957	FRK	-0.2	-5.51	-0.33	8.92e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.83	9.81	0.53	2.25e-19	Gestational age at birth (maternal effect);
KIRP	cis	rs4423214	0.592	rs10898211	chr11:71210677	T/C	cg05163923	chr11:71159392	DHCR7	-0.71	-7.07	-0.41	1.64e-11	Vitamin D levels;
KIRP	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.12	-0.31	6.14e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.19	0.31	4.45e-7	Schizophrenia;
KIRP	cis	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.49	-0.33	1.02e-7	HDL cholesterol;
KIRP	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.65	7.76	0.44	2.2e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg17376030	chr22:41985996	PMM1	-0.44	-5.25	-0.32	3.23e-7	Vitiligo;
KIRP	cis	rs9400467	0.528	rs7752361	chr6:111780705	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.55	-0.33	7.23e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs11955175	1.000	rs79575541	chr5:40672422	C/G	cg17351974	chr5:40835760	RPL37	0.54	4.9	0.3	1.73e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg15038512	chr6:170123185	PHF10	-0.56	-8.38	-0.47	4.11e-15	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.46e-8	Life satisfaction;
KIRP	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.72	7.16	0.42	9.03e-12	Neutrophil percentage of white cells;
KIRP	cis	rs6772849	0.896	rs35535737	chr3:128383406	G/A	cg08795948	chr3:128337044	NA	0.49	6.17	0.37	2.8e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg12315302	chr6:26189340	HIST1H4D	1.09	6.45	0.38	5.72e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.97	-15.04	-0.69	1.12e-36	Height;
KIRP	cis	rs12476592	0.602	rs4671516	chr2:63790555	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg26134248	chr17:3907702	NA	0.55	8.2	0.46	1.34e-14	Type 2 diabetes;
KIRP	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg23127183	chr11:57508653	C11orf31	-0.53	-6.93	-0.4	3.59e-11	Schizophrenia;
KIRP	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00982357	chr20:23331308	NXT1	0.48	6.16	0.37	2.99e-9	Parkinson's disease;
KIRP	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg13206674	chr6:150067644	NUP43	0.49	6.72	0.39	1.27e-10	Testicular germ cell tumor;
KIRP	cis	rs2294369	1.000	rs8136019	chr22:40071545	C/T	cg10455938	chr22:40058150	CACNA1I	0.52	5.95	0.35	9.22e-9	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg06521331	chr12:34319734	NA	-0.53	-6.52	-0.38	3.91e-10	Morning vs. evening chronotype;
KIRP	cis	rs8018808	0.791	rs2205190	chr14:77886723	T/G	cg20045696	chr14:77926864	AHSA1	0.45	5.15	0.31	5.47e-7	Myeloid white cell count;
KIRP	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.46	6.97	0.41	2.9100000000000002e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	0.39	6.94	0.4	3.44e-11	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13493005	chr11:78371046	ODZ4	-0.37	-6.21	-0.37	2.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1524927	1.000	rs12704873	chr7:96336279	G/C	cg00227355	chr7:96336147	SHFM1	-0.32	-4.86	-0.3	2.12e-6	Total body bone mineral density;
KIRP	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.01	-10.92	-0.57	6.56e-23	Gut microbiome composition (summer);
KIRP	cis	rs6723108	0.515	rs4954179	chr2:135557737	A/G	cg25422880	chr2:135218333	TMEM163	-0.44	-6.12	-0.36	3.67e-9	Type 2 diabetes;
KIRP	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.41	-4.98	-0.3	1.19e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05377226	chr1:171810910	DNM3	0.49	6.23	0.37	2.03e-9	Parkinson's disease;
KIRP	cis	rs8018808	0.869	rs4369582	chr14:77906389	C/T	cg18872420	chr14:78023429	SPTLC2	0.36	5.22	0.32	3.8e-7	Myeloid white cell count;
KIRP	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg05717871	chr11:638507	DRD4	-0.39	-5.64	-0.34	4.76e-8	Systemic lupus erythematosus;
KIRP	cis	rs3849570	0.615	rs35779564	chr3:81982771	G/A	cg07356753	chr3:81810745	GBE1	-0.57	-7.14	-0.41	1.07e-11	Waist circumference;Body mass index;
KIRP	cis	rs3857747	0.827	rs10241646	chr7:40473750	C/T	cg00420559	chr7:40367873	C7orf10	0.61	7.77	0.44	2.17e-13	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.9	12.96	0.64	1.26e-29	Menopause (age at onset);
KIRP	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs4654899	0.931	rs4654730	chr1:21229286	A/T	cg05370193	chr1:21551575	ECE1	0.39	5.31	0.32	2.46e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg25110126	chr1:46999211	NA	0.46	5.53	0.33	8.26e-8	Monobrow;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04016744	chr4:156874766	CTSO	0.5	6.18	0.37	2.63e-9	Parkinson's disease;
KIRP	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg25922125	chr7:127225783	GCC1	0.46	4.85	0.3	2.19e-6	Type 2 diabetes;
KIRP	cis	rs2860975	0.620	rs6583968	chr10:96816357	A/T	cg09036531	chr10:96991505	NA	0.48	5.93	0.35	1.05e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12315302	chr6:26189340	HIST1H4D	0.65	5.1	0.31	6.92e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-6.06	-0.36	5.11e-9	Morning vs. evening chronotype;
KIRP	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg00012203	chr2:219082015	ARPC2	0.81	11.52	0.59	7.61e-25	Colorectal cancer;
KIRP	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg17294928	chr15:75287854	SCAMP5	-0.57	-5.56	-0.33	7.04e-8	Blood trace element (Zn levels);
KIRP	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.74	10.68	0.56	4.14e-22	Height;
KIRP	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg03468072	chr12:39539422	NA	0.43	5.79	0.35	2.13e-8	Morning vs. evening chronotype;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg17782706	chr4:184580436	C4orf41;RWDD4A	0.52	6.49	0.38	4.69e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1858037	0.806	rs12612780	chr2:65583101	A/G	cg08085232	chr2:65598271	SPRED2	-0.53	-6.4	-0.38	7.66e-10	Rheumatoid arthritis;
KIRP	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg26207909	chr14:103986467	CKB	0.41	5.24	0.32	3.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.49	6.2	0.37	2.32e-9	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06161317	chr16:88598525	ZFPM1	-0.49	-6.14	-0.36	3.33e-9	Parkinson's disease;
KIRP	cis	rs1045714	0.836	rs73033691	chr7:2636522	T/G	cg20813462	chr7:2646259	IQCE	0.66	6.21	0.37	2.25e-9	Urate levels in lean individuals;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24557133	chr1:234509059	C1orf31	0.47	6.42	0.38	7.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.51	-0.43	1.11e-12	Mood instability;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.61	-8.45	-0.47	2.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	1.03	19.06	0.77	2.28e-50	Heart rate;
KIRP	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.31	0.47	6.71e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22015030	chr1:54411349	LRRC42;HSPB11	0.48	6.45	0.38	5.76e-10	Parkinson's disease;
KIRP	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.7	0.39	1.41e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg27490568	chr2:178487706	NA	0.55	7.66	0.44	4.37e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.72	10.22	0.55	1.17e-20	High light scatter reticulocyte count;
KIRP	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.61	-8.57	-0.48	1.18e-15	Heart rate;
KIRP	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.53	5.17	0.31	4.78e-7	Breast cancer;
KIRP	cis	rs514024	0.700	rs557749	chr9:130492039	G/A	cg13643465	chr9:130375613	STXBP1	0.4	5.42	0.33	1.41e-7	Eating disorders (purging via substances);
KIRP	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.58	8.79	0.49	2.71e-16	Bipolar disorder;
KIRP	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.31	-5.11	-0.31	6.39e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11608355	0.810	rs12424599	chr12:109866615	A/G	cg05360138	chr12:110035743	NA	0.63	6.53	0.38	3.71e-10	Neuroticism;
KIRP	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.46	-0.52	2.52e-18	Height;
KIRP	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg02138098	chr1:2040968	PRKCZ	-0.43	-5.94	-0.35	9.85e-9	Height;
KIRP	cis	rs141670911	1	rs141670911	chr6:26581258	A/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.44	-5.1	-0.31	6.66e-7	Lung cancer;
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.22	-24.51	-0.84	5.66e-68	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.82e-7	Life satisfaction;
KIRP	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.61e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg17644776	chr2:200775616	C2orf69	0.57	4.86	0.3	2.11e-6	Schizophrenia;
KIRP	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg25447019	chr17:19030144	GRAPL	0.6	8.25	0.47	9.37e-15	Schizophrenia;
KIRP	cis	rs698833	0.561	rs696597	chr2:44722553	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	4.87	0.3	2.02e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.72	6.53	0.38	3.78e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.6	0.48	9.71e-16	Morning vs. evening chronotype;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	17.22	0.74	3.75e-44	Platelet count;
KIRP	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.78	7.84	0.45	1.39e-13	Resting heart rate;
KIRP	cis	rs4903604	0.560	rs4903605	chr14:78035619	C/T	cg18872420	chr14:78023429	SPTLC2	0.32	4.98	0.3	1.22e-6	Gut microbiome composition (winter);
KIRP	cis	rs15676	0.783	rs2977996	chr9:131582625	C/T	cg00228799	chr9:131580591	ENDOG	0.56	6.2	0.37	2.38e-9	Blood metabolite levels;
KIRP	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.85	16.16	0.72	1.64e-40	Anterior chamber depth;
KIRP	cis	rs62355272	0.828	rs57217480	chr5:35838185	C/T	cg13894535	chr5:35919491	CAPSL	-0.48	-5.4	-0.33	1.53e-7	Lymphocyte counts;
KIRP	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-7.38	-0.43	2.48e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.25	0.74	3.02e-44	Platelet count;
KIRP	cis	rs2463822	0.583	rs72917377	chr11:62025930	A/G	cg06239285	chr11:62104954	ASRGL1	-0.89	-6.7	-0.39	1.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg22732515	chr19:44031385	ETHE1	0.65	9.4	0.51	3.85e-18	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs4356932	0.967	rs28433437	chr4:76972653	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg21775007	chr8:11205619	TDH	-0.53	-6.78	-0.4	8.93e-11	Joint mobility (Beighton score);
KIRP	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.59	-0.52	1.03e-18	Neuroticism;
KIRP	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg07827796	chr19:33622959	WDR88	0.53	6.96	0.41	3.02e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.42	-5.52	-0.33	8.57e-8	Body mass index;
KIRP	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg17554472	chr22:41940697	POLR3H	0.59	6.27	0.37	1.65e-9	Vitiligo;
KIRP	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.86	-0.4	5.64e-11	Height;
KIRP	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9826463	0.757	rs73240314	chr3:142255090	T/C	cg20824294	chr3:142316082	PLS1	0.39	6.2	0.37	2.34e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg19913688	chr11:428466	ANO9	-0.71	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06461811	chr16:2097673	TSC2;NTHL1	0.5	6.35	0.38	1.06e-9	Parkinson's disease;
KIRP	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.5e-20	Coffee consumption (cups per day);
KIRP	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg05941025	chr16:89927596	SPIRE2	0.33	5.23	0.32	3.7e-7	Vitiligo;
KIRP	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg03627880	chr6:151815985	C6orf97	-0.43	-5.01	-0.3	1.03e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.1	-0.36	3.98e-9	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06688323	chr4:4858340	NA	0.45	6.13	0.36	3.53e-9	Smoking initiation;
KIRP	cis	rs858239	0.539	rs2141306	chr7:23191664	G/A	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	12.34	0.62	1.48e-27	Alzheimer's disease;
KIRP	cis	rs12049351	0.774	rs4148758	chr1:229693666	G/A	cg11742688	chr1:229674241	ABCB10	-0.38	-5.61	-0.34	5.47e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs2151522	0.762	rs9398819	chr6:127167175	T/C	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg17356467	chr2:100759845	AFF3	0.55	5.63	0.34	4.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.84	12.47	0.62	5.38e-28	Eosinophil percentage of white cells;
KIRP	cis	rs2151522	0.762	rs13210511	chr6:127155711	C/T	cg21431617	chr6:127135037	NA	0.31	5.51	0.33	8.83e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.07	-12.88	-0.63	2.27e-29	Vitiligo;
KIRP	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg02404636	chr22:31891804	SFI1	-0.47	-5.25	-0.32	3.3e-7	Colorectal cancer;
KIRP	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs10140922	0.531	rs2415267	chr14:35630544	G/A	cg07166546	chr14:35805898	NA	-0.23	-5.49	-0.33	9.94e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.88	-14.97	-0.69	1.9e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs62355272	0.965	rs1053496	chr5:35879429	T/C	cg13894535	chr5:35919491	CAPSL	-0.42	-5.25	-0.32	3.33e-7	Lymphocyte counts;
KIRP	cis	rs7202877	0.706	rs247447	chr16:75486648	A/G	cg03315344	chr16:75512273	CHST6	-0.57	-5.23	-0.32	3.7e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-14.23	-0.67	6.18e-34	Heart rate;
KIRP	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.61	6.12	0.36	3.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg09029085	chr17:47094198	IGF2BP1	0.24	5.6	0.34	5.63e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs4849845	0.889	rs11689112	chr2:121049166	A/C	cg24070213	chr2:121070622	NA	-0.4	-5.53	-0.33	8.08e-8	Mean platelet volume;
KIRP	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg00074818	chr8:8560427	CLDN23	-0.29	-5.12	-0.31	6.16e-7	Mood instability;
KIRP	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	11.74	0.6	1.47e-25	Smoking behavior;
KIRP	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.89	10.23	0.55	1.06e-20	Menopause (age at onset);
KIRP	cis	rs28834970	0.675	rs6557994	chr8:27232018	A/G	cg07216194	chr8:27182965	PTK2B	-0.44	-5.16	-0.31	5.1e-7	Alzheimer's disease (late onset);
KIRP	cis	rs80130819	0.591	rs17122651	chr12:48496660	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Prostate cancer;
KIRP	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.59	-7.88	-0.45	1.08e-13	Asthma;
KIRP	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-10.06	-0.54	3.57e-20	Mood instability;
KIRP	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.56	-0.39	3.18e-10	Triglycerides;
KIRP	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg19197139	chr17:4613644	ARRB2	-0.5	-6.19	-0.37	2.48e-9	Lymphocyte counts;
KIRP	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg09904177	chr6:26538194	HMGN4	0.45	6.04	0.36	5.71e-9	Schizophrenia;
KIRP	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg18225595	chr11:63971243	STIP1	-0.57	-7.25	-0.42	5.25e-12	Platelet count;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2230307	0.518	rs2810425	chr1:100665072	G/C	cg24955406	chr1:100503596	HIAT1	-0.6	-6.28	-0.37	1.54e-9	Carotid intima media thickness;
KIRP	cis	rs4666360	1.000	rs4233757	chr2:20336077	G/A	cg07142377	chr2:20335552	NA	-0.27	-4.86	-0.3	2.12e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
KIRP	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.39	-5.45	-0.33	1.2e-7	Bipolar disorder;
KIRP	cis	rs603446	0.678	rs664059	chr11:116642137	C/T	cg08672956	chr11:116640933	BUD13	0.29	5.31	0.32	2.48e-7	Triglycerides;
KIRP	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg12591125	chr7:1885375	MAD1L1	0.58	5.68	0.34	3.85e-8	Bipolar disorder;
KIRP	cis	rs13102973	0.965	rs6535050	chr4:135874115	A/C	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg00599163	chr2:162100495	NA	0.42	4.93	0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00721635	chr1:153572208	NA	0.51	6.55	0.39	3.31e-10	Interleukin-4 levels;
KIRP	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-7.92	-0.45	7.95e-14	Bipolar disorder;
KIRP	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg14829155	chr15:31115871	NA	-0.77	-9.32	-0.51	7.04e-18	Huntington's disease progression;
KIRP	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21643547	chr1:205240462	TMCC2	0.69	10.38	0.55	3.62e-21	Red blood cell count;
KIRP	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.3	-0.47	7.1e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.64	-6.94	-0.4	3.5e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2554380	0.843	rs1426160	chr15:84408634	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.47	-6.56	-0.39	3.08e-10	Height;
KIRP	cis	rs9815354	0.767	rs73077375	chr3:41853058	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00933542	chr6:150070202	PCMT1	0.26	4.94	0.3	1.45e-6	Lung cancer;
KIRP	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	7.42	0.43	1.9e-12	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.93	-11.24	-0.58	6.08e-24	Bipolar disorder and schizophrenia;
KIRP	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.89	-8.47	-0.48	2.31e-15	Rheumatoid arthritis;
KIRP	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.35	0.47	4.86e-15	Motion sickness;
KIRP	cis	rs11779988	0.545	rs439374	chr8:17786818	C/T	cg01800426	chr8:17659068	MTUS1	-0.63	-6.23	-0.37	1.96e-9	Breast cancer;
KIRP	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.87	-13.86	-0.66	1.15e-32	Menarche (age at onset);
KIRP	cis	rs10465746	0.747	rs1952066	chr1:84436456	T/C	cg10977910	chr1:84465055	TTLL7	0.57	7.26	0.42	5.19e-12	Obesity-related traits;
KIRP	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg20302533	chr7:39170763	POU6F2	0.28	6.04	0.36	5.8e-9	IgG glycosylation;
KIRP	trans	rs1223583	0.743	rs1223580	chr10:95771829	C/G	cg20300129	chr6:35058181	ANKS1A	0.38	6.05	0.36	5.45e-9	Coronary artery disease;
KIRP	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.78	-11.3	-0.58	4.04e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg00405596	chr8:11794950	NA	-0.39	-5.1	-0.31	6.77e-7	Triglycerides;
KIRP	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.93	14.22	0.67	6.92e-34	Mean platelet volume;
KIRP	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.78	8.37	0.47	4.4e-15	Body mass index;
KIRP	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.85e-7	Diabetic retinopathy;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg24842740	chr1:9973750	NA	-0.49	-6.48	-0.38	5.05e-10	Inflammatory biomarkers;
KIRP	cis	rs3017493	0.786	rs112552548	chr11:70675096	G/A	cg10362475	chr11:70507825	SHANK2	0.41	5.79	0.35	2.16e-8	Renal transplant outcome;
KIRP	cis	rs6991838	0.584	rs4449837	chr8:66488152	C/T	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.85	0.3	2.19e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg11245990	chr11:68621969	NA	0.41	5.5	0.33	9.34e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9398803	0.584	rs3850234	chr6:127001534	T/G	cg19875578	chr6:126661172	C6orf173	0.43	5.49	0.33	9.98e-8	Male-pattern baldness;
KIRP	cis	rs4389656	0.767	rs369769	chr5:6720712	T/C	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	trans	rs1462872	0.736	rs367830	chr8:31808604	C/T	cg01557648	chr19:51142883	SYT3	-1.01	-6.02	-0.36	6.26e-9	Coronary artery calcification;
KIRP	cis	rs2057178	0.696	rs12278882	chr11:32352400	C/G	cg05837727	chr11:32355149	NA	0.46	5.92	0.35	1.07e-8	Tuberculosis;
KIRP	cis	rs3736485	0.932	rs11633395	chr15:51917957	G/T	cg14296394	chr15:51910925	DMXL2	-0.33	-4.93	-0.3	1.54e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9393777	0.668	rs72839449	chr6:27261661	A/C	cg22548220	chr6:27277996	POM121L2	0.49	6.07	0.36	4.8e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7215564	0.730	rs34806161	chr17:78573839	T/C	cg06153925	chr17:78755379	RPTOR	0.41	5.48	0.33	1.06e-7	Myopia (pathological);
KIRP	cis	rs7084402	1.000	rs1427202	chr10:60267917	A/T	cg05938607	chr10:60274200	BICC1	0.4	9.58	0.52	1.1e-18	Refractive error;
KIRP	cis	rs9488822	0.662	rs495565	chr6:116262976	G/A	cg05304507	chr6:116381966	FRK	-0.2	-5.41	-0.33	1.5e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg18825076	chr15:78729989	IREB2	-0.43	-5.03	-0.31	9.5e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03664139	chr6:101329504	ASCC3	0.56	6.45	0.38	5.84e-10	Smoking initiation;
KIRP	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg13047869	chr3:10149882	C3orf24	0.52	5.13	0.31	5.81e-7	Alzheimer's disease;
KIRP	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-5.21	-0.31	4.09e-7	Ulcerative colitis;
KIRP	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.73	0.34	2.86e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg27147174	chr7:100797783	AP1S1	-0.59	-7.61	-0.44	5.8e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg26367366	chr8:4980734	NA	0.88	8.35	0.47	4.91e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg06042504	chr8:55087323	NA	0.53	6.6	0.39	2.45e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs975752	0.867	rs73337997	chr10:101973260	A/C	cg13817732	chr10:102046368	BLOC1S2	0.68	5.72	0.34	3.14e-8	Schizophrenia;
KIRP	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg26875137	chr12:53738046	NA	-0.39	-5.32	-0.32	2.34e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.67	-10.16	-0.54	1.82e-20	Airway imaging phenotypes;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.63	0.52	7.7e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17065868	1.000	rs17277505	chr13:45105586	A/C	cg10246903	chr13:45222710	NA	0.73	7.13	0.41	1.08e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg13010199	chr12:38710504	ALG10B	0.71	8.97	0.5	7.99e-17	Bladder cancer;
KIRP	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9398803	0.965	rs9388490	chr6:126704795	C/T	cg19875578	chr6:126661172	C6orf173	0.53	6.93	0.4	3.63e-11	Male-pattern baldness;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-1.08	-21.58	-0.81	1.11e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	6.5	0.38	4.47e-10	Height;
KIRP	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg03060546	chr3:49711283	APEH	0.43	5.46	0.33	1.14e-7	Parkinson's disease;
KIRP	trans	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg25042112	chr7:64838748	ZNF92	-0.59	-6.25	-0.37	1.76e-9	Pain;
KIRP	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7923609	0.905	rs7092784	chr10:65214749	C/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.11	-0.36	3.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg24101359	chr6:42928495	GNMT	0.62	9.23	0.51	1.32e-17	Plasma homocysteine levels (post-methionine load test);
KIRP	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.65	-0.66	5.64e-32	Height;
KIRP	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg17014757	chr1:203156097	CHI3L1	-0.63	-6.77	-0.4	9.29e-11	YKL-40 levels;
KIRP	cis	rs10089	0.552	rs59430737	chr5:127557568	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	8.53	0.48	1.51e-15	Ileal carcinoids;
KIRP	trans	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg26043149	chr18:55253948	FECH	0.51	6.19	0.37	2.5e-9	Bone mineral density;
KIRP	cis	rs1465370	0.682	rs6972781	chr7:130023179	A/G	cg03229158	chr7:130009420	NA	0.34	4.96	0.3	1.31e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg13165212	chr22:42675999	NA	-0.35	-5.98	-0.36	7.9e-9	Cognitive function;
KIRP	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-7.15	-0.41	1.01e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg27205649	chr11:78285834	NARS2	-0.52	-5.75	-0.34	2.57e-8	Testicular germ cell tumor;
KIRP	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.75	0.4	1.08e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	1.02	10.66	0.56	4.48e-22	Exhaled nitric oxide output;
KIRP	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg16898833	chr6:26189333	HIST1H4D	0.74	5.31	0.32	2.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-11.84	-0.6	6.64e-26	Chronic sinus infection;
KIRP	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg07117364	chr1:16154769	NA	-0.43	-5.16	-0.31	5.13e-7	Dilated cardiomyopathy;
KIRP	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.54	8.17	0.46	1.61e-14	Huntington's disease progression;
KIRP	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.98	16.35	0.72	3.69e-41	Systemic lupus erythematosus;
KIRP	cis	rs883565	0.612	rs784512	chr3:39165110	G/T	cg01426195	chr3:39028469	NA	0.52	8.31	0.47	6.35e-15	Handedness;
KIRP	cis	rs6693295	0.838	rs2787969	chr1:246233779	T/C	cg11798871	chr1:246315928	SMYD3	-0.41	-5.05	-0.31	8.63e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg09029085	chr17:47094198	IGF2BP1	0.25	5.7	0.34	3.33e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.93	-12.78	-0.63	4.86e-29	Cognitive function;
KIRP	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.18	12.59	0.63	2.24e-28	Eosinophil percentage of granulocytes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15783703	chr7:70209588	AUTS2	-0.44	-6.27	-0.37	1.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg06212747	chr3:49208901	KLHDC8B	0.65	9.12	0.5	2.84e-17	Resting heart rate;
KIRP	trans	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg10756647	chr7:56101905	PSPH	0.9	6.06	0.36	5.18e-9	Diabetic kidney disease;
KIRP	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09217309	chr6:150244204	RAET1G	0.43	5.29	0.32	2.77e-7	Testicular germ cell tumor;
KIRP	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-8.28	-0.47	7.82e-15	Mean corpuscular volume;
KIRP	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.01	11.76	0.6	1.27e-25	Body mass index;
KIRP	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg16141378	chr3:129829833	LOC729375	0.59	7.43	0.43	1.77e-12	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg09699651	chr6:150184138	LRP11	0.48	6.08	0.36	4.48e-9	Lung cancer;
KIRP	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg20965017	chr5:231967	SDHA	-0.54	-6.23	-0.37	1.96e-9	Breast cancer;
KIRP	cis	rs1847505	0.563	rs1514171	chr13:61410527	C/G	cg25164009	chr13:61490935	NA	-0.45	-5.16	-0.31	5.06e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs6684514	1.000	rs12132794	chr1:156281020	C/G	cg16558208	chr1:156270281	VHLL	0.43	5.78	0.35	2.29e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2591576	0.874	rs2591566	chr5:165407453	C/G	cg13976338	chr5:165423657	NA	-0.8	-11.81	-0.6	8.59e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.33	0.42	3.35e-12	Lung cancer;
KIRP	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-14.23	-0.67	6.09e-34	Gut microbiome composition (summer);
KIRP	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs9532580	0.620	rs2755210	chr13:41141282	C/G	cg21288729	chr13:41239152	FOXO1	0.7	9.54	0.52	1.49e-18	Mean corpuscular hemoglobin;
KIRP	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.63	0.48	7.99e-16	Morning vs. evening chronotype;
KIRP	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.85	-0.4	5.88e-11	Educational attainment;
KIRP	cis	rs911119	0.913	rs34792920	chr20:23581876	C/T	cg16589663	chr20:23618590	CST3	0.68	6.35	0.38	1.04e-9	Chronic kidney disease;
KIRP	cis	rs9815354	0.812	rs78342280	chr3:41948810	G/A	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg01557791	chr16:72042693	DHODH	-0.66	-7.26	-0.42	5.16e-12	Blood protein levels;
KIRP	cis	rs60311166	1.000	rs61220667	chr3:52744436	T/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.91	5.72	0.34	3.14e-8	CTACK levels;
KIRP	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.78	-10.24	-0.55	9.61e-21	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.88e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.17	12.83	0.63	3.51e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.55	0.39	3.33e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.84	-11.59	-0.59	4.37e-25	Longevity;Endometriosis;
KIRP	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	trans	rs11634944	1.000	rs11634690	chr15:25198135	G/A	cg10471437	chr16:28074462	GSG1L	0.51	6.29	0.37	1.47e-9	Interleukin-8 levels;
KIRP	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.42	5.6	0.34	5.67e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg19077165	chr18:44547161	KATNAL2	0.41	4.99	0.3	1.15e-6	Educational attainment;
KIRP	cis	rs2072732	0.687	rs10489588	chr1:2951834	C/T	cg11731671	chr1:2995604	PRDM16	-0.38	-4.96	-0.3	1.34e-6	Plateletcrit;
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16524936	chr4:1340807	KIAA1530	-0.5	-6.27	-0.37	1.65e-9	Longevity;
KIRP	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.34	-5.88	-0.35	1.35e-8	Height;
KIRP	cis	rs2475553	0.520	rs62437129	chr6:158655757	T/G	cg07215822	chr6:158701037	NA	-0.63	-6.91	-0.4	4.2e-11	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9972944	0.729	rs62065062	chr17:63777383	G/A	cg07283582	chr17:63770753	CCDC46	0.52	8.62	0.48	8.26e-16	Total body bone mineral density;
KIRP	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-1.05	-10.81	-0.57	1.57e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16364506	chr1:180805744	XPR1	-0.43	-6.21	-0.37	2.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-13.69	-0.66	4.29e-32	Gut microbiome composition (summer);
KIRP	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg22089800	chr15:90895588	ZNF774	0.59	8.04	0.46	3.67e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg05347473	chr6:146136440	FBXO30	0.57	8.21	0.46	1.26e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg21395723	chr22:39101663	GTPBP1	-0.39	-4.89	-0.3	1.78e-6	Menopause (age at onset);
KIRP	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg00310523	chr12:86230176	RASSF9	-0.47	-7.39	-0.43	2.25e-12	Major depressive disorder;
KIRP	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	0.98	10.51	0.56	1.35e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg23693289	chr8:27183097	PTK2B	0.57	7.39	0.43	2.27e-12	Neuroticism;
KIRP	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-7.54	-0.43	9.1e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.83	-11.31	-0.58	3.62e-24	Height;
KIRP	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg23594656	chr7:65796392	TPST1	-0.48	-7.22	-0.42	6.64e-12	Aortic root size;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.7	8.21	0.46	1.27e-14	Longevity;Endometriosis;
KIRP	cis	rs644148	0.836	rs2571111	chr19:45000581	C/A	cg15540054	chr19:45004280	ZNF180	-0.75	-9.13	-0.5	2.5e-17	Personality dimensions;
KIRP	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.65	-6.89	-0.4	4.71e-11	Vitiligo;
KIRP	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg03714773	chr7:91764589	CYP51A1	0.4	5.91	0.35	1.12e-8	Breast cancer;
KIRP	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg00360474	chr6:37504404	NA	-0.46	-6.42	-0.38	6.95e-10	Cognitive performance;
KIRP	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg27462398	chr1:86174642	ZNHIT6	-0.47	-5.5	-0.33	9.7e-8	Urate levels in overweight individuals;
KIRP	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.72	-8.35	-0.47	4.94e-15	Blood metabolite levels;
KIRP	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.96	13.55	0.65	1.25e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg24375607	chr4:120327624	NA	0.57	6.53	0.38	3.76e-10	Corneal astigmatism;
KIRP	cis	rs7172677	1.000	rs7177528	chr15:75409594	T/C	cg14664628	chr15:75095509	CSK	-0.56	-6.1	-0.36	4.2e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.47	-0.62	5.52e-28	Vitiligo;
KIRP	cis	rs9596863	0.898	rs9568924	chr13:54360952	T/G	ch.13.53330881F	chr13:54432880	NA	0.59	5.7	0.34	3.43e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9652601	0.959	rs741172	chr16:11200798	C/T	cg04616529	chr16:11181986	CLEC16A	0.4	5.01	0.3	1.03e-6	Systemic lupus erythematosus;
KIRP	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg00677455	chr12:58241039	CTDSP2	-0.49	-5.52	-0.33	8.74e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1816752	0.905	rs8002309	chr13:24976355	C/T	cg22771759	chr13:24902376	NA	0.39	5.07	0.31	7.88e-7	Obesity-related traits;
KIRP	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	5.71	0.34	3.19e-8	Renal cell carcinoma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17021725	chr1:178694150	RALGPS2	0.45	6.48	0.38	5.06e-10	Survival in pancreatic cancer;
KIRP	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.65	-0.39	1.92e-10	Diastolic blood pressure;
KIRP	cis	rs17221829	0.549	rs1844196	chr11:89389256	A/G	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18883530	chr7:69913915	AUTS2	0.47	6.42	0.38	7.14e-10	Interleukin-4 levels;
KIRP	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs8523	0.901	rs3798707	chr6:10991935	C/T	cg13562911	chr6:11044106	ELOVL2	0.41	5.36	0.32	1.92e-7	Red blood cell fatty acid levels;
KIRP	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.5	5.93	0.35	1.04e-8	Metabolite levels;
KIRP	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs2411233	0.839	rs1380939	chr15:39309815	T/C	cg19287857	chr15:39890699	NA	0.38	5.22	0.32	3.72e-7	Platelet count;
KIRP	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg21918786	chr6:109611834	NA	-0.4	-5.68	-0.34	3.86e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs780094	0.500	rs4665382	chr2:27783801	T/C	cg05484376	chr2:27715224	FNDC4	-0.38	-5.24	-0.32	3.4e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs6691722	0.503	rs3765425	chr1:24699872	G/C	cg18323236	chr1:24743029	NIPAL3	0.48	6.99	0.41	2.58e-11	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.03	0.64	7.35e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs858239	0.600	rs6461692	chr7:23139695	G/C	cg23682824	chr7:23144976	KLHL7	0.46	5.42	0.33	1.4e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg10189774	chr4:17578691	LAP3	0.54	6.81	0.4	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9547996	0.879	rs3934220	chr13:38206249	T/C	cg13634560	chr13:38173852	POSTN	-0.4	-5.61	-0.34	5.46e-8	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26549034	chr1:150337202	RPRD2	0.47	6.1	0.36	4.18e-9	Parkinson's disease;
KIRP	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.31	0.32	2.43e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.4	-5.48	-0.33	1.05e-7	Endometrial cancer;
KIRP	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg11271282	chr2:238384023	NA	-0.47	-5.42	-0.33	1.43e-7	Prostate cancer;
KIRP	cis	rs427941	0.703	rs201452	chr7:101739663	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.71	0.39	1.36e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs8054556	0.740	rs4609871	chr16:29932064	A/G	cg05445914	chr16:30134068	MAPK3	-0.38	-4.95	-0.3	1.37e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg21100191	chr22:23484243	RTDR1	1.05	18.13	0.76	3.27e-47	Bone mineral density;
KIRP	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.46	-5.39	-0.32	1.67e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs501120	0.584	rs1680636	chr10:44675941	G/A	cg09554077	chr10:44749378	NA	0.57	5.95	0.35	9.05e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs812925	0.859	rs2593624	chr2:61552484	T/A	cg15711740	chr2:61764176	XPO1	0.46	4.94	0.3	1.47e-6	Immature fraction of reticulocytes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18780412	chr3:179755086	PEX5L	-0.48	-6.5	-0.38	4.42e-10	Interleukin-4 levels;
KIRP	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	1.05	13.5	0.65	1.89e-31	Exhaled nitric oxide output;
KIRP	cis	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.69	-0.39	1.53e-10	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4805272	0.759	rs1030099	chr19:29343616	C/T	cg15000279	chr19:29285009	NA	0.4	6.03	0.36	6.09e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg00405596	chr8:11794950	NA	-0.47	-5.91	-0.35	1.14e-8	Joint mobility (Beighton score);
KIRP	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.51e-19	Prudent dietary pattern;
KIRP	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.62	10.3	0.55	6.63e-21	Schizophrenia;
KIRP	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.5	-6.54	-0.38	3.57e-10	Lung cancer;
KIRP	cis	rs9653442	0.545	rs1821827	chr2:100764717	T/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.26	0.32	3.14e-7	Smoking behavior;
KIRP	cis	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg21546286	chr11:48923668	NA	-0.44	-5.28	-0.32	2.77e-7	HDL cholesterol;
KIRP	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg04990556	chr1:26633338	UBXN11	-0.6	-7.45	-0.43	1.57e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs946836	0.562	rs10789521	chr1:48401587	T/C	cg08121652	chr1:48381824	NA	0.21	4.84	0.3	2.25e-6	White matter integrity;
KIRP	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.51	6.02	0.36	6.19e-9	Eosinophil percentage of white cells;
KIRP	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.78	0.6	1.04e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9815354	0.812	rs59138513	chr3:41908611	T/G	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.49	-5.91	-0.35	1.14e-8	Bone mineral density;
KIRP	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.62	-7.83	-0.45	1.41e-13	Alzheimer's disease;
KIRP	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.95e-15	Aortic root size;
KIRP	cis	rs10517025	0.673	rs73235560	chr4:42419712	T/C	cg13587180	chr4:42403248	SHISA3	0.42	4.89	0.3	1.86e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.64	-7.12	-0.41	1.19e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs143111788	1	rs143111788	chr6:41919175	CCAGCTACT/C	cg17623882	chr6:41773611	USP49	-0.47	-5.79	-0.35	2.11e-8	Red cell distribution width;
KIRP	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs4750440	0.671	rs1809305	chr10:14026780	G/A	cg27542038	chr10:14027202	FRMD4A	-0.57	-7.5	-0.43	1.18e-12	Adiponectin levels;
KIRP	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.45	-6.3	-0.37	1.4e-9	Height;
KIRP	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg10503236	chr1:231470652	EXOC8	-0.48	-5.78	-0.35	2.23e-8	Red blood cell count;
KIRP	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg16524733	chr11:117070046	TAGLN	0.39	4.85	0.3	2.18e-6	Blood protein levels;
KIRP	cis	rs6901004	0.803	rs2757571	chr6:111511124	T/G	cg15721981	chr6:111408429	SLC16A10	-0.52	-7.19	-0.42	7.69e-12	Blood metabolite levels;
KIRP	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg14703610	chr5:56206110	C5orf35	0.49	6.79	0.4	8.18e-11	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs12282928	0.921	rs7479951	chr11:48295508	C/G	cg26585981	chr11:48327164	OR4S1	-0.49	-5.95	-0.35	9.24e-9	Migraine - clinic-based;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05671585	chr4:186064123	SLC25A4	0.47	6.05	0.36	5.25e-9	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.11e-10	Prudent dietary pattern;
KIRP	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.19	-0.37	2.55e-9	Superior crus of antihelix expression;
KIRP	trans	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs75920871	0.589	rs67201490	chr11:117083004	T/G	cg23684410	chr11:116897558	SIK3	0.5	5.1	0.31	6.94e-7	Subjective well-being;
KIRP	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.03	-0.67	3.08e-33	Primary sclerosing cholangitis;
KIRP	cis	rs2071426	0.959	rs34909476	chr10:96811465	T/C	cg09036531	chr10:96991505	NA	-0.56	-6.47	-0.38	5.31e-10	Blood metabolite levels;
KIRP	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.45	-0.47	2.59e-15	Personality dimensions;
KIRP	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg22437258	chr11:111473054	SIK2	0.58	6.77	0.4	9.34e-11	Primary sclerosing cholangitis;
KIRP	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg04733989	chr22:42467013	NAGA	0.52	6.33	0.37	1.13e-9	Cognitive function;
KIRP	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg09904177	chr6:26538194	HMGN4	0.39	4.97	0.3	1.25e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg00579200	chr11:133705235	NA	-0.42	-5.56	-0.33	6.86e-8	Childhood ear infection;
KIRP	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg03714773	chr7:91764589	CYP51A1	0.39	5.62	0.34	5.03e-8	Breast cancer;
KIRP	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs9290065	0.622	rs11705811	chr3:160643787	C/T	cg04691961	chr3:161091175	C3orf57	-0.37	-5.42	-0.33	1.45e-7	Kawasaki disease;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.74	11.44	0.59	1.39e-24	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg01879757	chr17:41196368	BRCA1	-0.76	-10.51	-0.56	1.44e-21	Menopause (age at onset);
KIRP	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9372498	0.536	rs17424234	chr6:118808521	A/G	cg21191810	chr6:118973309	C6orf204	-0.44	-4.85	-0.3	2.19e-6	Diastolic blood pressure;
KIRP	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.74	0.39	1.1e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg05362011	chr13:21860987	NA	-0.46	-4.93	-0.3	1.51e-6	White matter hyperintensity burden;
KIRP	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.04	-0.58	2.72e-23	Height;
KIRP	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg22117172	chr7:91764530	CYP51A1	-0.42	-5.9	-0.35	1.21e-8	Breast cancer;
KIRP	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.56	-7.71	-0.44	3.11e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.58	-8.12	-0.46	2.32e-14	Prostate cancer;
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg09165964	chr15:75287851	SCAMP5	0.48	6.36	0.38	9.7e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs116726256	0.744	rs78579698	chr2:1850948	G/A	cg07855242	chr2:1841068	MYT1L	0.67	5.96	0.36	8.6e-9	Interleukin-8 levels;
KIRP	cis	rs2591576	0.935	rs153286	chr5:165409177	G/A	cg13976338	chr5:165423657	NA	-0.7	-9.77	-0.53	3.01e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg12940439	chr1:67600707	NA	0.46	6.85	0.4	5.89e-11	Psoriasis;
KIRP	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.32	0.51	7.09e-18	Bladder cancer;
KIRP	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg23594656	chr7:65796392	TPST1	0.42	6.47	0.38	5.13e-10	Aortic root size;
KIRP	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.99	0.45	5.35e-14	Corneal astigmatism;
KIRP	cis	rs2733310	0.947	rs1652746	chr15:57158731	A/C	cg13626582	chr15:57592083	LOC283663	-0.23	-5.37	-0.32	1.8e-7	Mean platelet volume;
KIRP	cis	rs6960043	0.620	rs11760782	chr7:15064788	A/T	cg19272540	chr7:15055459	NA	0.2	5.08	0.31	7.33e-7	Type 2 diabetes;
KIRP	cis	rs12716641	0.648	rs4367573	chr8:6896883	G/C	cg26123975	chr8:6873754	DEFA1;DEFA3;DEFA1B	-0.35	-4.85	-0.3	2.16e-6	IgA nephropathy;
KIRP	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.76	8.92	0.49	1.08e-16	High light scatter reticulocyte count;
KIRP	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	5.29	0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.47	-0.52	2.44e-18	Mean corpuscular volume;
KIRP	cis	rs7011507	1.000	rs77718885	chr8:49143150	G/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6707387	0.686	rs1554178	chr2:214494108	A/T	cg08319019	chr2:214017104	IKZF2	0.47	5.38	0.32	1.72e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg02475777	chr4:1388615	CRIPAK	0.52	4.97	0.3	1.26e-6	Recombination rate (females);
KIRP	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg25650185	chr19:21324782	ZNF431	-0.49	-5.16	-0.31	4.97e-7	Pain;
KIRP	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	1.02	17.32	0.74	1.72e-44	Bone mineral density;
KIRP	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.59	-7.81	-0.45	1.62e-13	Vitiligo;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20786246	chr2:72377174	NA	0.49	6.06	0.36	5.04e-9	Lung cancer in ever smokers;
KIRP	cis	rs2299587	0.623	rs12718384	chr8:17781112	T/C	cg01800426	chr8:17659068	MTUS1	-0.55	-6.6	-0.39	2.56e-10	Economic and political preferences;
KIRP	cis	rs7538876	1.000	rs4920603	chr1:17727379	C/G	cg01904812	chr1:17746340	RCC2	-0.29	-4.96	-0.3	1.34e-6	Basal cell carcinoma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09437283	chr3:13008096	IQSEC1	0.5	6.98	0.41	2.66e-11	Interleukin-4 levels;
KIRP	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.53	-0.43	9.45e-13	Neuroticism;
KIRP	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg03894339	chr8:19674705	INTS10	0.51	6.11	0.36	3.86e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	1.22	11.23	0.58	6.87e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	9.78	0.53	2.8e-19	Post bronchodilator FEV1;
KIRP	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg03808351	chr9:123631620	PHF19	0.43	5.99	0.36	7.52e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs612683	0.931	rs7517704	chr1:100885419	A/G	cg09408571	chr1:101003634	GPR88	0.28	5.86	0.35	1.49e-8	Breast cancer;
KIRP	cis	rs2625529	0.617	rs2306576	chr15:72170686	C/T	cg16672083	chr15:72433130	SENP8	0.46	6.43	0.38	6.57e-10	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14592024	chr15:48624386	DUT	0.51	6.79	0.4	8.28e-11	Parkinson's disease;
KIRP	cis	rs963731	0.649	rs9679498	chr2:39218458	G/C	cg04010122	chr2:39346883	SOS1	-0.87	-5.78	-0.35	2.31e-8	Corticobasal degeneration;
KIRP	cis	rs2733310	0.793	rs1660950	chr15:57117207	A/G	cg13626582	chr15:57592083	LOC283663	-0.24	-5.24	-0.32	3.37e-7	Mean platelet volume;
KIRP	cis	rs6662572	0.853	rs2065708	chr1:45977685	A/G	cg24296786	chr1:45957014	TESK2	-0.52	-5.22	-0.32	3.85e-7	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs7781597	chr7:91588194	T/C	cg17063962	chr7:91808500	NA	0.96	15.67	0.71	7.74e-39	Breast cancer;
KIRP	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg04111992	chr7:158790115	NA	0.4	4.95	0.3	1.4e-6	Facial morphology (factor 20);
KIRP	cis	rs17123764	0.710	rs12299513	chr12:50019967	T/G	cg02054252	chr12:50078554	FMNL3	0.41	4.93	0.3	1.53e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7546668	1.000	rs4233537	chr1:15849700	T/A	cg21858823	chr1:15850916	CASP9	0.46	5.13	0.31	5.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg12292205	chr6:26970375	C6orf41	0.35	5.13	0.31	5.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg24565620	chr2:194026	NA	0.69	5.9	0.35	1.21e-8	Blood protein levels;
KIRP	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.83	-7.41	-0.43	1.99e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	7.08	0.41	1.49e-11	Menarche (age at onset);
KIRP	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg02725872	chr8:58115012	NA	-0.52	-5.94	-0.35	9.7e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs76439304	1.000	rs76439304	chr12:27033470	G/T	cg14081884	chr12:26986758	ITPR2	0.67	5.11	0.31	6.47e-7	Mean corpuscular volume;
KIRP	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg08975724	chr8:8085496	FLJ10661	0.57	7.47	0.43	1.41e-12	Myopia (pathological);
KIRP	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.55	-8.62	-0.48	8.05e-16	Longevity;
KIRP	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg21174375	chr14:64681225	SYNE2	0.67	9.15	0.5	2.19e-17	Atrial fibrillation;
KIRP	cis	rs7011049	1.000	rs72648410	chr8:53859225	G/A	cg26025543	chr8:53854495	NA	0.75	7.43	0.43	1.75e-12	Systolic blood pressure;
KIRP	cis	rs2273669	0.504	rs17070181	chr6:109428184	C/A	cg05315195	chr6:109294784	ARMC2	-0.53	-5.12	-0.31	6.11e-7	Prostate cancer;
KIRP	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.79	0.44	1.89e-13	Morning vs. evening chronotype;
KIRP	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg01200585	chr1:228362443	C1orf69	0.41	5.14	0.31	5.47e-7	Diastolic blood pressure;
KIRP	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg22676075	chr6:135203613	NA	0.51	7.22	0.42	6.42e-12	Red blood cell count;
KIRP	cis	rs2594714	1.000	rs2594714	chr19:13954571	G/A	cg18576835	chr19:13944261	NA	-0.36	-5.11	-0.31	6.48e-7	Breast cancer;
KIRP	cis	rs3120667	0.720	rs56325026	chr1:152418579	G/T	cg26876637	chr1:152193138	HRNR	-0.64	-5.94	-0.35	9.63e-9	Eating disorders;
KIRP	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.38	-6.5	-0.38	4.41e-10	Pursuit maintenance gain;
KIRP	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.41	0.38	7.32e-10	Hypertriglyceridemia;
KIRP	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	9.07	0.5	3.96e-17	Neuroticism;
KIRP	cis	rs17384381	0.953	rs12120551	chr1:85810903	T/C	cg16011679	chr1:85725395	C1orf52	0.86	8.54	0.48	1.43e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.5	-5.75	-0.34	2.6e-8	Homocysteine levels;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.47	6.36	0.38	9.71e-10	Mean corpuscular volume;
KIRP	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-5.22	-0.32	3.73e-7	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg03563238	chr19:33554763	RHPN2	-0.3	-5.33	-0.32	2.19e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	7.29	0.42	4.34e-12	Response to fenofibrate (adiponectin levels);
KIRP	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	1.01	10.18	0.54	1.49e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.62	8.94	0.5	9.38e-17	Resting heart rate;
KIRP	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	ch.11.42038R	chr11:967971	AP2A2	0.46	6.05	0.36	5.45e-9	Alzheimer's disease (late onset);
KIRP	cis	rs4700695	0.641	rs386949	chr5:65231061	G/A	cg21114390	chr5:65439923	SFRS12	0.57	5.1	0.31	6.72e-7	Facial morphology (factor 19);
KIRP	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.65	9.32	0.51	6.68e-18	Lymphocyte counts;
KIRP	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.42	-5.95	-0.35	9.4e-9	Endometrial cancer;
KIRP	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg01631408	chr1:248437212	OR2T33	-0.67	-8.98	-0.5	7.24e-17	Common traits (Other);
KIRP	cis	rs7570971	0.583	rs1375132	chr2:135954405	A/G	cg07169764	chr2:136633963	MCM6	0.47	5.39	0.33	1.62e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg09264619	chr17:80180166	NA	-0.4	-5.96	-0.36	8.55e-9	Life satisfaction;
KIRP	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg04370829	chr17:406249	NA	0.39	4.92	0.3	1.55e-6	Prostate cancer;
KIRP	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.47	-0.48	2.31e-15	Joint mobility (Beighton score);
KIRP	cis	rs748404	0.578	rs1058298	chr15:43700930	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.56	0.39	3.2e-10	Lung cancer;
KIRP	cis	rs11651000	0.625	rs4794067	chr17:45808828	T/C	cg24803719	chr17:45855879	NA	-0.4	-5.45	-0.33	1.19e-7	IgG glycosylation;
KIRP	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.85	-0.78	5.44e-53	Height;
KIRP	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg27432699	chr2:27873401	GPN1	-0.53	-6.73	-0.39	1.16e-10	Total body bone mineral density;
KIRP	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	1.09	10.78	0.57	1.98e-22	Vitiligo;
KIRP	cis	rs514406	0.858	rs564640	chr1:53285187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.87	-12.5	-0.62	4.52e-28	Monocyte count;
KIRP	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.12	22.79	0.82	1.49e-62	Testicular germ cell tumor;
KIRP	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.59	7.76	0.44	2.33e-13	Height;
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg19142026	chr7:27170394	HOXA4	0.42	6.02	0.36	6.42e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	0.84	6.53	0.38	3.66e-10	Mitochondrial DNA levels;
KIRP	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.81e-8	Body mass index;
KIRP	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.85	0.3	2.19e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.01	0.67	3.42e-33	Chronic sinus infection;
KIRP	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg06002975	chr2:86422967	IMMT	0.39	5.05	0.31	8.8e-7	Night sleep phenotypes;
KIRP	cis	rs7267005	0.661	rs76012919	chr20:34398546	G/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg14228332	chr4:119757509	SEC24D	0.79	4.86	0.3	2.08e-6	Cannabis dependence symptom count;
KIRP	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg07148914	chr20:33460835	GGT7	-0.54	-7.16	-0.42	9.35e-12	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00761755	chr17:1531579	SLC43A2	0.55	7.69	0.44	3.54e-13	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4700695	0.614	rs394828	chr5:65209552	C/T	cg21114390	chr5:65439923	SFRS12	0.54	5.07	0.31	8e-7	Facial morphology (factor 19);
KIRP	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.75	9.12	0.5	2.8e-17	Monocyte count;
KIRP	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg04662567	chr6:169592167	NA	-0.64	-5.39	-0.33	1.64e-7	Pulse pressure;
KIRP	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg08313168	chr12:7315531	NA	0.71	6.24	0.37	1.86e-9	Obesity-related traits;
KIRP	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg19731401	chr7:2775893	GNA12	0.77	7.26	0.42	5.04e-12	Childhood ear infection;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23051811	chr6:44095108	MRPL14;TMEM63B	-0.47	-6.48	-0.38	4.94e-10	Metabolic traits;
KIRP	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg21361702	chr7:150065534	REPIN1	-0.56	-6.13	-0.36	3.47e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg05457628	chr5:178986728	RUFY1	-0.52	-8.28	-0.47	7.87e-15	Lung cancer;
KIRP	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg20936604	chr3:58311152	NA	-0.72	-5.36	-0.32	1.9e-7	Cholesterol, total;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12491094	chr11:62433124	C11orf48;METTL12	0.45	6.25	0.37	1.82e-9	Parkinson's disease;
KIRP	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	9.87	0.53	1.41e-19	Monocyte count;
KIRP	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs7428	1.000	rs7428	chr2:85545490	C/T	cg24342717	chr2:85555507	TGOLN2	0.54	6.29	0.37	1.44e-9	Ear protrusion;
KIRP	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.91	-0.35	1.12e-8	Breast cancer;
KIRP	cis	rs13315871	1.000	rs9869940	chr3:58401523	G/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23598886	chr18:12777645	NA	0.73	6.03	0.36	5.96e-9	Inflammatory skin disease;
KIRP	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.26	-0.32	3.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.68	8.75	0.49	3.49e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.22	0.61	3.78e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4865875	0.579	rs58538591	chr5:54183585	T/G	cg08820104	chr5:54183619	NA	-0.7	-5.17	-0.31	4.84e-7	Sense of smell;
KIRP	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg11965913	chr1:205819406	PM20D1	0.52	5.53	0.33	8.02e-8	Basophil percentage of granulocytes;
KIRP	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	6.56	0.39	3.09e-10	Putamen volume;
KIRP	trans	rs8054556	0.751	rs11642430	chr16:30045789	C/G	cg13500354	chr6:168617491	NA	0.33	6.11	0.36	3.81e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.88	9.81	0.53	2.15e-19	Gut microbiome composition (summer);
KIRP	trans	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg19274270	chr17:78178856	CARD14	-0.36	-6.5	-0.38	4.33e-10	Educational attainment (years of education);
KIRP	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.21	-14.09	-0.67	1.95e-33	Breast cancer;
KIRP	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.2	21.72	0.81	3.85e-59	Cognitive function;
KIRP	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg00999904	chr2:3704751	ALLC	-0.74	-7.83	-0.45	1.43e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg25547332	chr5:131281432	NA	0.47	5.31	0.32	2.44e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	trans	rs1568657	0.779	rs2167602	chr15:83649292	C/T	cg26040583	chr7:82286401	NA	-0.43	-6.51	-0.38	4.14e-10	Kawasaki disease;
KIRP	cis	rs427941	0.610	rs201489	chr7:101749901	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.66	0.39	1.79e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.78	9.43	0.52	3.1e-18	DNA methylation (variation);
KIRP	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.77	10.75	0.57	2.42e-22	Bipolar disorder;
KIRP	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23903597	chr17:61704154	MAP3K3	-0.62	-7.99	-0.45	5.33e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	cis	rs10463316	0.928	rs4958451	chr5:150740007	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.57	-0.39	2.95e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18867708	chr6:26865862	GUSBL1	-0.5	-6.28	-0.37	1.55e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9398803	0.865	rs9385401	chr6:126789472	C/T	cg19875578	chr6:126661172	C6orf173	0.51	6.57	0.39	2.98e-10	Male-pattern baldness;
KIRP	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.37	-0.32	1.78e-7	Aortic root size;
KIRP	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg10017260	chr10:834428	NA	-0.55	-5.41	-0.33	1.53e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs4950322	0.570	rs4950315	chr1:146736092	A/G	cg22381352	chr1:146742008	CHD1L	0.45	5.13	0.31	5.75e-7	Protein quantitative trait loci;
KIRP	cis	rs1975991	0.711	rs1351316	chr3:187964568	A/C	cg17585528	chr3:187988060	LPP	-0.47	-5.35	-0.32	1.98e-7	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs7096127	1.000	rs4747482	chr10:24506608	A/G	cg04122385	chr10:24535410	KIAA1217;PRINS	-0.4	-5.09	-0.31	7.24e-7	Lobe attachment (rater scored);
KIRP	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.86	10.83	0.57	1.34e-22	Coronary artery disease;
KIRP	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.46	5.27	0.32	2.99e-7	Schizophrenia;
KIRP	cis	rs10875746	0.680	rs4760610	chr12:48418225	C/T	cg26205652	chr12:48591994	NA	0.78	10.12	0.54	2.45e-20	Longevity (90 years and older);
KIRP	cis	rs10221833	0.602	rs355889	chr2:165634651	C/T	cg03182029	chr2:165697222	COBLL1	0.44	4.84	0.3	2.25e-6	Response to statin therapy;
KIRP	cis	rs7084402	1.000	rs7095501	chr10:60271940	T/C	cg05938607	chr10:60274200	BICC1	0.43	10.31	0.55	5.89e-21	Refractive error;
KIRP	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.06	-0.31	8.21e-7	Personality dimensions;
KIRP	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.78	-10.71	-0.56	3.22e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.67	9.44	0.52	2.96e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg02023728	chr11:77925099	USP35	0.34	5.38	0.32	1.71e-7	Alzheimer's disease (survival time);
KIRP	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg11382394	chr1:2564504	MMEL1	-0.45	-5.87	-0.35	1.4e-8	Ulcerative colitis;
KIRP	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg23894439	chr1:183413866	NA	-0.4	-5.2	-0.31	4.13e-7	Systemic lupus erythematosus;
KIRP	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.56	-13.7	-0.66	3.96e-32	Hip circumference adjusted for BMI;
KIRP	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	8.52	0.48	1.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg23173402	chr1:227635558	NA	0.63	5.16	0.31	4.98e-7	Major depressive disorder;
KIRP	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.43	5.67	0.34	3.99e-8	Monocyte count;
KIRP	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg23894439	chr1:183413866	NA	0.4	5.21	0.32	3.91e-7	Systemic lupus erythematosus;
KIRP	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.57	7.09	0.41	1.39e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg17376030	chr22:41985996	PMM1	-0.82	-8.94	-0.5	9.35e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg00125455	chr20:44574271	PCIF1	0.41	8.24	0.46	1.05e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6504950	0.888	rs244320	chr17:53222920	C/T	cg26251398	chr17:52985966	TOM1L1	0.38	5.02	0.3	1e-6	Breast cancer;
KIRP	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	10.17	0.54	1.6e-20	Monocyte percentage of white cells;
KIRP	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.44	5.51	0.33	9.18e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs72627123	0.619	rs79575309	chr14:74590230	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.91	0.3	1.7e-6	Morning vs. evening chronotype;
KIRP	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.89	-10.65	-0.56	5.13e-22	Response to antipsychotic treatment;
KIRP	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg01200585	chr1:228362443	C1orf69	0.47	5.62	0.34	5.16e-8	Diastolic blood pressure;
KIRP	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg13266496	chr6:110720918	DDO	-0.36	-5.87	-0.35	1.41e-8	Platelet distribution width;
KIRP	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.49	-6.05	-0.36	5.28e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.69	-5.79	-0.35	2.14e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.32	6.24	0.37	1.88e-9	Alcohol dependence;
KIRP	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg05669848	chr5:237993	SDHA	-0.48	-5.04	-0.31	8.88e-7	Breast cancer;
KIRP	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.97	13.46	0.65	2.61e-31	Menopause (age at onset);
KIRP	cis	rs7084402	0.935	rs1632584	chr10:60282078	T/C	cg05938607	chr10:60274200	BICC1	0.46	11.22	0.58	7.07e-24	Refractive error;
KIRP	cis	rs7084402	0.934	rs1649067	chr10:60305240	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	trans	rs7939886	0.920	rs11227212	chr11:55873334	A/G	cg03929089	chr4:120376271	NA	0.93	6.82	0.4	7.22e-11	Myopia (pathological);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg22394521	chr20:61569754	DIDO1;C20orf11	0.59	7.67	0.44	3.99e-13	Myopia (pathological);
KIRP	cis	rs954108	0.584	rs9314922	chr13:29379229	A/G	cg11788234	chr13:29393811	NA	0.62	7.97	0.45	5.77e-14	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.07	-13.26	-0.65	1.24e-30	Alzheimer's disease;
KIRP	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.15	-0.31	5.28e-7	Fear of minor pain;
KIRP	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-1.01	-16.92	-0.73	3.91e-43	Height;
KIRP	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs11825064	0.562	rs77092254	chr11:134512159	G/C	cg06603561	chr11:134479413	NA	-0.97	-7.06	-0.41	1.74e-11	Seasonality;
KIRP	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs4900538	0.963	rs2273905	chr14:102974999	T/C	cg18135206	chr14:102964638	TECPR2	0.97	15.1	0.69	6.59e-37	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg02820040	chr2:241836501	C2orf54	-0.25	-5.28	-0.32	2.77e-7	Urinary metabolites;
KIRP	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	1.14	9.06	0.5	4.13e-17	Skin colour saturation;
KIRP	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.83	-0.45	1.5e-13	Retinal vascular caliber;
KIRP	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg08126542	chr6:37504118	NA	-0.83	-13.22	-0.64	1.7e-30	Cognitive performance;
KIRP	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg19773385	chr1:10388646	KIF1B	-0.64	-8.54	-0.48	1.37e-15	Hepatocellular carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14881209	chr19:11546152	CCDC151;PRKCSH	0.53	6.96	0.41	3.16e-11	Parkinson's disease;
KIRP	cis	rs6662572	1.000	rs72688469	chr1:46118393	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.49	5.77	0.35	2.39e-8	Blood protein levels;
KIRP	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg06386533	chr2:46925753	SOCS5	0.52	4.96	0.3	1.33e-6	Height;
KIRP	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg16141378	chr3:129829833	LOC729375	0.53	6.54	0.38	3.54e-10	Joint mobility (Beighton score);
KIRP	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg24579218	chr15:68104479	NA	-0.44	-7.16	-0.42	9.33e-12	Restless legs syndrome;
KIRP	cis	rs8077577	0.945	rs997315	chr17:18085286	A/G	cg09161412	chr17:18057145	MYO15A	-0.38	-5.04	-0.31	9.23e-7	Obesity-related traits;
KIRP	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg21625330	chr8:9911636	MSRA	0.39	4.88	0.3	1.91e-6	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02025192	chr11:115375385	CADM1	-0.5	-6.45	-0.38	5.98e-10	Interleukin-4 levels;
KIRP	cis	rs1863824	0.625	rs10887598	chr10:88166160	T/A	cg07322936	chr10:88137208	NA	-0.54	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg12315302	chr6:26189340	HIST1H4D	0.76	5.14	0.31	5.47e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	cg12689670	chr1:183009347	LAMC1	0.45	6.43	0.38	6.45e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.24	-0.47	9.99e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs236907	0.859	rs61807979	chr1:171764281	G/A	cg01410279	chr1:171621941	MYOC	-0.47	-5.46	-0.33	1.14e-7	Mean platelet volume;
KIRP	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.34	5.28	0.32	2.85e-7	Asthma;
KIRP	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg08648136	chr8:956695	NA	0.47	7.09	0.41	1.43e-11	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg17691542	chr6:26056736	HIST1H1C	0.78	8.4	0.47	3.7e-15	Iron status biomarkers;
KIRP	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.31	-6.05	-0.36	5.46e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-6.98	-0.41	2.68e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3784262	0.643	rs8030766	chr15:58369209	A/G	cg12031962	chr15:58353849	ALDH1A2	0.38	5.11	0.31	6.42e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.97	-0.5	7.53e-17	Platelet count;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04952336	chr2:98852781	VWA3B	0.45	7.26	0.42	5.03e-12	C-reactive protein;
KIRP	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg26876637	chr1:152193138	HRNR	-0.8	-9.29	-0.51	8.3e-18	Atopic dermatitis;
KIRP	cis	rs981844	0.816	rs56413502	chr4:154721784	T/A	cg14289246	chr4:154710475	SFRP2	0.67	7.86	0.45	1.22e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.8	9.74	0.53	3.63e-19	Corneal astigmatism;
KIRP	cis	rs73206853	0.764	rs60027620	chr12:111103669	T/G	cg12870014	chr12:110450643	ANKRD13A	0.5	4.89	0.3	1.82e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg00310523	chr12:86230176	RASSF9	0.48	7.56	0.43	7.84e-13	Major depressive disorder;
KIRP	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg08885076	chr2:99613938	TSGA10	0.55	9.59	0.52	1.03e-18	Chronic sinus infection;
KIRP	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.37	0.47	4.3e-15	Menopause (age at onset);
KIRP	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.65	5.52	0.33	8.5e-8	Facial emotion recognition (sad faces);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16627646	chr10:49864382	NA	0.47	6.04	0.36	5.71e-9	Parkinson's disease;
KIRP	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.07	0.41	1.58e-11	Height;
KIRP	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.35	0.62	1.34e-27	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05364829	chr1:21671910	ECE1	0.47	6.13	0.36	3.52e-9	Myopia (pathological);
KIRP	cis	rs282587	0.569	rs7326827	chr13:113408866	T/C	cg04656015	chr13:113407548	ATP11A	0.66	7.86	0.45	1.18e-13	Glycated hemoglobin levels;
KIRP	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.52	-0.43	1.05e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.99	-0.45	5.32e-14	Monocyte percentage of white cells;
KIRP	cis	rs12765878	1.000	rs2902639	chr10:105658588	G/C	cg11005552	chr10:105648138	OBFC1	0.4	5.69	0.34	3.63e-8	Coronary artery disease;
KIRP	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg17644776	chr2:200775616	C2orf69	-0.58	-6.07	-0.36	4.94e-9	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg09597638	chr17:3907349	NA	0.64	10.75	0.57	2.37e-22	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	1.06	14.88	0.69	3.66e-36	Menopause (age at onset);
KIRP	cis	rs17001868	0.892	rs73167023	chr22:40799954	T/C	cg07138101	chr22:40742427	ADSL	0.72	6.08	0.36	4.55e-9	Mammographic density (dense area);
KIRP	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg00343986	chr7:65444356	GUSB	0.48	5.87	0.35	1.4e-8	Aortic root size;
KIRP	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-1.11	-9.13	-0.5	2.5e-17	Body mass index;
KIRP	cis	rs11603020	0.950	rs11229063	chr11:57369730	G/A	cg19752551	chr11:57585705	CTNND1	-0.67	-9.2	-0.51	1.61e-17	Blood protein levels;
KIRP	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.27	-0.32	2.98e-7	Neuroticism;
KIRP	cis	rs1983891	1.000	rs6458228	chr6:41543793	C/A	cg20194872	chr6:41519635	FOXP4	0.57	7.32	0.42	3.43e-12	Prostate cancer;
KIRP	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	cg21523751	chr1:182988639	NA	0.41	6.3	0.37	1.37e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.71	-8.84	-0.49	1.92e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg09231725	chr11:64357281	SLC22A12	-0.65	-8.68	-0.48	5.36e-16	Urate levels in obese individuals;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.52	-6.39	-0.38	8.36e-10	Longevity;Endometriosis;
KIRP	cis	rs9443189	1.000	rs1280048	chr6:76529583	C/T	cg01950844	chr6:76311363	SENP6	0.54	5.45	0.33	1.23e-7	Prostate cancer;
KIRP	cis	rs3087591	0.639	rs7223589	chr17:29728284	T/C	cg24425628	chr17:29625626	OMG;NF1	0.55	7.73	0.44	2.72e-13	Hip circumference;
KIRP	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg03146154	chr1:46216737	IPP	-0.41	-5.17	-0.31	4.93e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4262150	0.960	rs4285285	chr5:152289810	C/T	cg12297329	chr5:152029980	NA	0.48	6.63	0.39	2.07e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	12.19	0.61	4.54e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21545522	chr1:205238299	TMCC2	0.42	5.72	0.34	3.12e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs12230513	0.732	rs59438785	chr12:55811665	A/G	cg19537932	chr12:55886519	OR6C68	-0.57	-7.09	-0.41	1.44e-11	Contrast sensitivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24872076	chr19:16683269	SLC35E1	0.47	6.04	0.36	5.8e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24452069	chr19:4867631	PLIN3	0.55	7.15	0.41	1e-11	Parkinson's disease;
KIRP	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.49	7.72	0.44	3e-13	Multiple sclerosis;
KIRP	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.47	-0.33	1.1e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-9.45	-0.52	2.8e-18	Morning vs. evening chronotype;
KIRP	cis	rs1538970	0.924	rs7528573	chr1:45913860	T/C	cg05343316	chr1:45956843	TESK2	0.7	7.85	0.45	1.26e-13	Platelet count;
KIRP	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg17294928	chr15:75287854	SCAMP5	-0.58	-4.92	-0.3	1.59e-6	Lung cancer;
KIRP	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.78	11.36	0.59	2.61e-24	Heart rate;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg17029690	chr19:44009073	PHLDB3	-0.4	-6.12	-0.36	3.62e-9	Blood metabolite levels;
KIRP	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg24375607	chr4:120327624	NA	0.43	5.1	0.31	6.89e-7	Diastolic blood pressure;
KIRP	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.07	-13.3	-0.65	8.82e-31	Vitiligo;
KIRP	cis	rs5167	0.566	rs934427	chr19:45478816	T/G	cg13119609	chr19:45449297	APOC2	0.39	4.9	0.3	1.75e-6	Blood protein levels;
KIRP	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg00977110	chr5:151150581	G3BP1	0.62	6.24	0.37	1.93e-9	Preschool internalizing problems;
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.78	12.93	0.64	1.56e-29	Vitiligo;
KIRP	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg11833968	chr6:79620685	NA	-0.47	-7.11	-0.41	1.24e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg16141378	chr3:129829833	LOC729375	-0.58	-6.82	-0.4	7e-11	Neuroticism;
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	6.16	0.37	3.01e-9	Obesity-related traits;
KIRP	trans	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.54	-7.32	-0.42	3.52e-12	Blood trace element (Cu levels);
KIRP	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.73	0.53	3.96e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg21858823	chr1:15850916	CASP9	0.55	5.91	0.35	1.15e-8	Systolic blood pressure;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.54	6.98	0.41	2.72e-11	Testicular germ cell tumor;
KIRP	cis	rs6565681	1.000	rs4889848	chr17:78354661	C/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.7	-6.67	-0.39	1.67e-10	Moyamoya disease;
KIRP	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg26531700	chr6:26746687	NA	0.41	5.58	0.34	6.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.5	5.65	0.34	4.43e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs10465746	0.935	rs942848	chr1:84427707	G/C	cg10977910	chr1:84465055	TTLL7	0.48	5.81	0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	0.97	10.58	0.56	8.13e-22	Blood protein levels;
KIRP	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.92	9.92	0.53	1.02e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs6725041	0.663	rs6745160	chr2:213130540	A/C	cg20637307	chr2:213403960	ERBB4	0.38	4.92	0.3	1.6e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-8.7	-0.48	4.93e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07866137	chr8:67579786	VCPIP1	0.51	6.85	0.4	6.01e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg14703610	chr5:56206110	C5orf35	0.49	6.94	0.4	3.49e-11	Coronary artery disease;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg12463550	chr7:65579703	CRCP	-0.44	-4.94	-0.3	1.42e-6	Aortic root size;
KIRP	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg07701084	chr6:150067640	NUP43	0.61	7.71	0.44	3.11e-13	Lung cancer;
KIRP	cis	rs9475752	0.793	rs13193800	chr6:56820405	C/G	cg22880620	chr6:56820808	BEND6;DST	0.5	5.17	0.31	4.96e-7	Menarche (age at onset);
KIRP	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.84	-0.35	1.65e-8	Schizophrenia;
KIRP	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.72	-0.39	1.22e-10	Educational attainment;
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.43	0.38	6.57e-10	Retinal vascular caliber;
KIRP	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.87	7.47	0.43	1.4e-12	Fat distribution (HIV);
KIRP	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.55	-5.19	-0.31	4.36e-7	Narcolepsy;
KIRP	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.48	-5.22	-0.32	3.83e-7	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	-0.47	-6.43	-0.38	6.54e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg06121193	chr1:90282411	NA	-0.46	-6.5	-0.38	4.48e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3126085	0.515	rs12407319	chr1:152365929	T/C	cg26876637	chr1:152193138	HRNR	-0.61	-6.87	-0.4	5.28e-11	Atopic dermatitis;
KIRP	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.3	-5.92	-0.35	1.05e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.51	7.17	0.42	8.9e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg06223162	chr1:101003688	GPR88	-0.43	-8.87	-0.49	1.49e-16	Monocyte count;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08773029	chr2:241439536	ANKMY1	0.48	6.53	0.38	3.65e-10	Pancreatic cancer;
KIRP	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.42	-0.43	1.88e-12	Colorectal cancer;
KIRP	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.31	0.47	6.38e-15	Recombination measurement;
KIRP	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.54	8.29	0.47	7.64e-15	Huntington's disease progression;
KIRP	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.5	6.77	0.4	9.65e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg06740227	chr12:86229804	RASSF9	0.43	5.4	0.33	1.55e-7	Major depressive disorder;
KIRP	trans	rs12704645	0.836	rs1013803	chr7:92623141	C/T	cg24146349	chr7:1542769	INTS1	-0.46	-6.1	-0.36	4.16e-9	Age-related hearing impairment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18442453	chr3:195934411	ZDHHC19	0.47	6.14	0.36	3.22e-9	Parkinson's disease;
KIRP	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26314531	chr2:26401878	FAM59B	-0.48	-5.08	-0.31	7.3e-7	Gut microbiome composition (summer);
KIRP	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg11906718	chr8:101322791	RNF19A	-0.49	-6.5	-0.38	4.48e-10	Atrioventricular conduction;
KIRP	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	0.89	8.16	0.46	1.72e-14	Gut microbiota (bacterial taxa);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05628496	chr17:17991167	DRG2	0.49	6.72	0.39	1.29e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.73e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26459683	chr15:68346511	PIAS1	0.46	6.63	0.39	2.09e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.53	-6.53	-0.38	3.84e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9309473	0.653	rs6718843	chr2:73852505	C/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.73	-0.34	2.85e-8	Metabolite levels;
KIRP	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.57	7.03	0.41	1.99e-11	Systemic lupus erythematosus;
KIRP	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg22906224	chr7:99728672	NA	-0.5	-6.16	-0.37	2.95e-9	Coronary artery disease;
KIRP	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-10.34	-0.55	4.76e-21	Heart rate;
KIRP	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06154860	chr7:14029085	ETV1	0.49	6.58	0.39	2.89e-10	Smoking initiation;
KIRP	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg12826209	chr6:26865740	GUSBL1	0.73	4.9	0.3	1.75e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16275967	chr1:161172255	NDUFS2	0.5	6.75	0.4	1.08e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.93	13.92	0.66	7.08e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs397969	0.621	rs203480	chr17:19828959	G/A	cg04132472	chr17:19861366	AKAP10	0.58	6.99	0.41	2.59e-11	Platelet count;
KIRP	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05025164	chr4:1340916	KIAA1530	0.51	6.69	0.39	1.48e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg10117171	chr1:25599238	RHD	0.45	6.02	0.36	6.44e-9	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.69	9.5	0.52	1.99e-18	Diastolic blood pressure;
KIRP	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.5	6.01	0.36	6.81e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg07701084	chr6:150067640	NUP43	0.63	8.03	0.46	4.03e-14	Lung cancer;
KIRP	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg17366294	chr4:99064904	C4orf37	0.38	4.85	0.3	2.22e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.5	6.45	0.38	5.92e-10	Systolic blood pressure;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.43	6.36	0.38	9.7e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.73	-7.74	-0.44	2.56e-13	Corneal astigmatism;
KIRP	cis	rs554111	0.891	rs609880	chr1:21055891	A/G	cg08890418	chr1:21044141	KIF17	0.61	9.79	0.53	2.5e-19	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.48e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg07317062	chr7:27170388	HOXA4	-0.37	-5.27	-0.32	3.02e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7923609	0.846	rs7075901	chr10:65280994	C/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.97	-0.36	8.31e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg13175981	chr1:150552382	MCL1	0.61	7.55	0.43	8.71e-13	Tonsillectomy;
KIRP	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.67	-9.11	-0.5	3.06e-17	Personality dimensions;
KIRP	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.06	-0.54	3.63e-20	Hemoglobin concentration;
KIRP	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg04362960	chr10:104952993	NT5C2	0.55	6.71	0.39	1.37e-10	Arsenic metabolism;
KIRP	cis	rs4716602	0.828	rs10270046	chr7:156159047	T/C	cg04090468	chr7:156181990	NA	0.45	5.48	0.33	1.07e-7	Anti-saccade response;
KIRP	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.52	-5.74	-0.34	2.79e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.49	7.22	0.42	6.27e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	0.9	11.19	0.58	9.18e-24	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg15117754	chr3:10150083	C3orf24	0.52	5.08	0.31	7.41e-7	Alzheimer's disease;
KIRP	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs710987	0.935	rs1698000	chr5:3507019	T/C	cg14530963	chr5:3489551	NA	0.43	5.38	0.32	1.76e-7	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg06742321	chr12:123595122	PITPNM2	0.42	5.36	0.32	1.95e-7	Platelet count;
KIRP	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.32	-0.32	2.3e-7	Renal cell carcinoma;
KIRP	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.61	-7.61	-0.44	5.87e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg01879757	chr17:41196368	BRCA1	-0.51	-6.75	-0.4	1.09e-10	Menopause (age at onset);
KIRP	cis	rs7608910	0.668	rs10207958	chr2:61225330	A/C	cg10580144	chr2:61372316	C2orf74	0.42	5.72	0.34	3.14e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg20243544	chr17:37824526	PNMT	0.48	6.97	0.41	2.88e-11	Asthma;
KIRP	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg11859384	chr17:80120422	CCDC57	0.44	5.62	0.34	5.05e-8	Life satisfaction;
KIRP	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.24	0.37	1.89e-9	Neuroticism;
KIRP	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.05e-8	Motion sickness;
KIRP	cis	rs17065868	0.764	rs61949795	chr13:45030136	G/A	cg10246903	chr13:45222710	NA	0.58	4.92	0.3	1.59e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs8014252	0.803	rs7157618	chr14:71010166	C/T	cg11204974	chr14:71022665	NA	-0.61	-6.46	-0.38	5.41e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs8077577	1.000	rs7207276	chr17:18065737	G/C	cg09161412	chr17:18057145	MYO15A	-0.39	-5.07	-0.31	7.9e-7	Obesity-related traits;
KIRP	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg12173498	chr6:36355764	ETV7	-0.3	-4.96	-0.3	1.33e-6	Platelet distribution width;
KIRP	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg12560992	chr17:57184187	TRIM37	0.57	5.21	0.32	3.96e-7	Cognitive test performance;
KIRP	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg12315302	chr6:26189340	HIST1H4D	1.07	6.32	0.37	1.23e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg17507749	chr15:85114479	UBE2QP1	0.75	7.0	0.41	2.38e-11	Schizophrenia;
KIRP	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.65	6.67	0.39	1.7e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs10761482	0.813	rs10740026	chr10:62112842	G/A	cg01186212	chr10:62110162	ANK3	-0.29	-4.96	-0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg04995300	chr3:66848608	NA	0.77	8.55	0.48	1.34e-15	Type 2 diabetes;
KIRP	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg19554555	chr3:13937349	NA	-0.46	-6.28	-0.37	1.52e-9	Ovarian reserve;
KIRP	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-7.81	-0.45	1.61e-13	Colorectal cancer;
KIRP	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg06915872	chr16:87998081	BANP	0.48	5.17	0.31	4.85e-7	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05845236	chr13:67804635	PCDH9	0.48	6.94	0.4	3.41e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10073892	0.830	rs72777945	chr5:101600283	A/C	cg19774478	chr5:101632501	SLCO4C1	0.65	6.32	0.37	1.22e-9	Cognitive decline (age-related);
KIRP	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg16141378	chr3:129829833	LOC729375	0.56	7.7	0.44	3.23e-13	Mood instability;
KIRP	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.25	0.32	3.28e-7	Height;
KIRP	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg16558253	chr16:72132732	DHX38	-0.6	-8.95	-0.5	8.84e-17	Fibrinogen levels;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg08901578	chr4:187885870	NA	-0.45	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.7	-11.05	-0.58	2.55e-23	Educational attainment;
KIRP	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.72	0.34	3.09e-8	Birth weight;
KIRP	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-4.88	-0.3	1.91e-6	Cognitive test performance;
KIRP	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27297192	chr10:134578999	INPP5A	-0.64	-8.12	-0.46	2.21e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg08761264	chr16:28874980	SH2B1	0.45	5.36	0.32	1.92e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.41	-0.51	3.74e-18	Aortic root size;
KIRP	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.46	-5.72	-0.34	3.1e-8	IgG glycosylation;
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg09597638	chr17:3907349	NA	0.76	14.67	0.68	1.93e-35	Type 2 diabetes;
KIRP	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs2151522	0.603	rs1543707	chr6:127197516	C/T	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg19592336	chr6:28129416	ZNF389	0.51	5.54	0.33	7.75e-8	Depression;
KIRP	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.47	-6.22	-0.37	2.16e-9	Breast cancer;
KIRP	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	1.2	12.46	0.62	5.9e-28	Alzheimer's disease;
KIRP	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.69	-10.43	-0.55	2.44e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23422044	chr7:1970798	MAD1L1	-0.71	-7.31	-0.42	3.71e-12	Bipolar disorder;
KIRP	cis	rs11825064	0.725	rs78767978	chr11:134483272	C/T	cg06603561	chr11:134479413	NA	-0.65	-5.07	-0.31	7.69e-7	Seasonality;
KIRP	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg01294253	chr9:136912663	BRD3	0.43	5.59	0.34	6.09e-8	Platelet distribution width;
KIRP	cis	rs7119	0.666	rs2516302	chr15:77879842	C/G	cg12131826	chr15:77904385	NA	-0.46	-5.82	-0.35	1.8e-8	Type 2 diabetes;
KIRP	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg05072774	chr3:49840536	C3orf54	-0.42	-4.99	-0.3	1.17e-6	Resting heart rate;
KIRP	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21545522	chr1:205238299	TMCC2	0.5	6.5	0.38	4.55e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02993943	chr7:39605861	C7orf36	0.97	6.41	0.38	7.55e-10	P wave terminal force;
KIRP	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-1.04	-10.06	-0.54	3.72e-20	Blood pressure (smoking interaction);
KIRP	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.68	6.9	0.4	4.38e-11	Corneal astigmatism;
KIRP	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg16235748	chr6:149772707	ZC3H12D	-0.31	-5.05	-0.31	8.48e-7	Dupuytren's disease;
KIRP	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg16141378	chr3:129829833	LOC729375	0.52	6.38	0.38	8.84e-10	Neuroticism;
KIRP	cis	rs4950322	0.570	rs72691090	chr1:146769569	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.31	-0.32	2.51e-7	Protein quantitative trait loci;
KIRP	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg01566213	chr4:1579287	NA	-0.37	-5.05	-0.31	8.44e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.87	13.39	0.65	4.38e-31	Testicular germ cell tumor;
KIRP	cis	rs12823128	0.967	rs2306547	chr12:26877885	A/G	cg14081884	chr12:26986758	ITPR2	-0.38	-4.84	-0.3	2.27e-6	Birth weight;
KIRP	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.62	-8.2	-0.46	1.33e-14	Dilated cardiomyopathy;
KIRP	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.49	6.99	0.41	2.63e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	7.38	0.43	2.4e-12	Iron status biomarkers;
KIRP	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg26876637	chr1:152193138	HRNR	0.74	9.99	0.54	6.1e-20	Atopic dermatitis;
KIRP	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.58	6.72	0.39	1.28e-10	Schizophrenia;
KIRP	cis	rs11874712	0.545	rs12963615	chr18:43641707	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.48	-6.99	-0.41	2.58e-11	Migraine - clinic-based;
KIRP	cis	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg18809830	chr7:99032528	PTCD1	-0.93	-6.6	-0.39	2.45e-10	Blood metabolite levels;
KIRP	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg15976283	chr2:238042351	NA	0.39	5.39	0.32	1.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs7011507	0.891	rs4358826	chr8:49150176	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17677112	chr7:77428730	PHTF2;TMEM60	-0.5	-6.18	-0.37	2.64e-9	Neuroticism;
KIRP	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-7.5	-0.43	1.16e-12	Parkinson's disease;
KIRP	cis	rs629922	0.507	rs636577	chr11:114054424	C/T	cg01914181	chr11:114070210	ZBTB16	0.53	5.56	0.33	7.14e-8	Paneth cell defects in Crohn's disease;
KIRP	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.72	-7.29	-0.42	4.2e-12	Coronary artery calcification;
KIRP	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.92	11.88	0.6	5.04e-26	Obesity;Body mass index;
KIRP	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1950626	0.750	rs34228453	chr14:101440321	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.86	0.4	5.45e-11	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	0.69	6.19	0.37	2.55e-9	Ulcerative colitis;
KIRP	cis	rs7615316	0.779	rs9821271	chr3:142034522	A/C	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4650994	0.593	rs12568310	chr1:178514622	C/T	cg12486710	chr1:178512616	C1orf220	-0.25	-5.39	-0.33	1.63e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg24358246	chr11:122086266	NA	-0.48	-6.48	-0.38	4.99e-10	Type 1 diabetes nephropathy;
KIRP	cis	rs4740619	0.619	rs1887666	chr9:16032313	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.84	-13.78	-0.66	2.11e-32	Alcohol dependence (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06785624	chr8:144990484	PLEC1	0.47	6.12	0.36	3.71e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg16512390	chr1:228756714	NA	0.74	6.02	0.36	6.23e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.23	-0.32	3.67e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg15247329	chr7:2764246	NA	0.4	5.84	0.35	1.62e-8	Height;
KIRP	cis	rs6893300	0.961	rs56335144	chr5:179176627	C/T	cg14593053	chr5:179126677	CANX	-0.57	-6.33	-0.37	1.15e-9	Resting heart rate;
KIRP	cis	rs12608504	0.503	rs11086103	chr19:18402117	G/A	cg02790458	chr19:18386421	KIAA1683	0.44	6.19	0.37	2.47e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg10223061	chr2:219282414	VIL1	-0.37	-5.95	-0.35	9.12e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1413885	0.516	rs6659883	chr1:65838618	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	6.07	0.36	4.87e-9	Anticoagulant levels;
KIRP	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.07	-0.36	4.85e-9	Ulcerative colitis;
KIRP	cis	rs17533156	1.000	rs17533156	chr17:75114705	C/T	cg11416367	chr17:75137675	SEC14L1	0.52	5.42	0.33	1.4e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9649213	0.593	rs2158553	chr7:97951131	G/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.35	-0.47	5.06e-15	Common traits (Other);
KIRP	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.32	-0.32	2.38e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg23693289	chr8:27183097	PTK2B	0.57	7.18	0.42	8.34e-12	Neuroticism;
KIRP	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.14	0.31	5.58e-7	Menopause (age at onset);
KIRP	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg11266682	chr4:10021025	SLC2A9	0.37	5.19	0.31	4.33e-7	Psychosis and Alzheimer's disease;
KIRP	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.16	21.45	0.81	3.01e-58	Exhaled nitric oxide output;
KIRP	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	5.56	0.33	7e-8	Monocyte percentage of white cells;
KIRP	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.01	-0.36	6.51e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg19770292	chr5:1868693	NA	0.42	5.51	0.33	9.26e-8	Cardiovascular disease risk factors;
KIRP	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.12	0.46	2.19e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3936840	0.539	rs3742445	chr14:102975552	T/A	cg18135206	chr14:102964638	TECPR2	0.49	5.79	0.35	2.12e-8	Plateletcrit;
KIRP	cis	rs62460802	1	rs62460802	chr7:83052869	G/A	cg14519356	chr7:83097669	SEMA3E	-0.5	-6.61	-0.39	2.39e-10	Lobe attachment (rater scored);
KIRP	cis	rs12496230	0.794	rs4856968	chr3:66864932	A/G	cg17646820	chr3:66848679	NA	0.38	6.2	0.37	2.42e-9	Type 2 diabetes;
KIRP	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.45	4.98	0.3	1.18e-6	Schizophrenia;
KIRP	cis	rs9308731	0.583	rs6726007	chr2:111932122	A/T	cg18646521	chr2:111875858	NA	0.38	5.32	0.32	2.38e-7	Chronic lymphocytic leukemia;
KIRP	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg04226714	chr8:49833948	SNAI2	-0.48	-6.49	-0.38	4.75e-10	Life satisfaction;
KIRP	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.3	-0.42	3.97e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg02725872	chr8:58115012	NA	-0.73	-7.39	-0.43	2.25e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	7.94	0.45	7.14e-14	Neuroticism;
KIRP	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.58	0.39	2.75e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00958927	chr1:175162553	KIAA0040	-0.29	-4.97	-0.3	1.23e-6	Alcohol dependence;
KIRP	cis	rs752092	0.775	rs4965806	chr15:101752435	G/A	cg19997662	chr15:101784653	CHSY1	-0.61	-8.94	-0.5	9.44e-17	Corneal structure;
KIRP	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.76	7.72	0.44	3e-13	Menarche (age at onset);
KIRP	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01973587	chr1:228161476	NA	-0.4	-5.02	-0.3	9.86e-7	Diastolic blood pressure;
KIRP	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.58	7.88	0.45	1.03e-13	Height;
KIRP	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg14458575	chr2:238380390	NA	0.55	5.9	0.35	1.2e-8	Prostate cancer;
KIRP	cis	rs9488822	0.585	rs195522	chr6:116245016	G/A	cg15226275	chr6:116381976	FRK	0.21	5.51	0.33	9.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.33e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9596863	0.799	rs11148279	chr13:54309775	C/T	ch.13.53330881F	chr13:54432880	NA	0.55	5.29	0.32	2.77e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs10214930	0.671	rs2391452	chr7:27686152	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.53	0.38	3.8e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.52	7.19	0.42	7.65e-12	Coronary artery disease;
KIRP	cis	rs8032158	0.963	rs28778631	chr15:56255589	T/C	cg02198044	chr15:56286336	NEDD4	-0.44	-5.19	-0.31	4.46e-7	Keloid;
KIRP	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.71	-9.94	-0.54	8.68e-20	Menopause (age at onset);
KIRP	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg16989719	chr2:238392110	NA	-0.57	-6.33	-0.37	1.18e-9	Prostate cancer;
KIRP	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.4	-0.43	2.11e-12	Body mass index;
KIRP	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg01689657	chr7:91764605	CYP51A1	-0.37	-5.7	-0.34	3.47e-8	Breast cancer;
KIRP	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	8.1	0.46	2.62e-14	Iron status biomarkers;
KIRP	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg00405596	chr8:11794950	NA	0.47	5.85	0.35	1.57e-8	Retinal vascular caliber;
KIRP	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-5.83	-0.35	1.69e-8	Height;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg27203200	chr16:67193754	TRADD;FBXL8	0.52	6.54	0.38	3.53e-10	Myopia (pathological);
KIRP	cis	rs60311166	1.000	rs56259931	chr3:52574365	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.9	5.55	0.33	7.28e-8	CTACK levels;
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	4.86	0.3	2.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg07395648	chr5:131743802	NA	-0.51	-7.4	-0.43	2.09e-12	Breast cancer;
KIRP	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs71597109	0.599	rs35838403	chr4:102722868	C/T	cg14855874	chr4:102712397	BANK1	0.42	5.54	0.33	7.61e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	7.71	0.44	3.18e-13	Educational attainment;
KIRP	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.81	-12.22	-0.61	3.84e-27	Breast cancer;
KIRP	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.64	-7.97	-0.45	5.98e-14	Aortic root size;
KIRP	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.18	0.61	4.94e-27	Blood protein levels;
KIRP	cis	rs72781680	0.561	rs72783615	chr2:24296397	C/A	cg20701182	chr2:24300061	SF3B14	1.01	10.9	0.57	7.81e-23	Lymphocyte counts;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15544637	chr10:89513069	ATAD1	0.48	7.21	0.42	6.93e-12	Interleukin-4 levels;
KIRP	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.56	7.24	0.42	5.78e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs13102973	0.965	rs4280794	chr4:135857174	T/C	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.12e-16	Subjective well-being;
KIRP	cis	rs909341	0.818	rs6122154	chr20:62359345	C/T	cg03999872	chr20:62272968	STMN3	-0.59	-6.83	-0.4	6.8e-11	Atopic dermatitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19336577	chr19:5622501	SAFB;SAFB2	0.51	6.38	0.38	8.93e-10	Parkinson's disease;
KIRP	cis	rs7534824	0.582	rs17448827	chr1:101421407	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.84	7.25	0.42	5.38e-12	Refractive astigmatism;
KIRP	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg02820040	chr2:241836501	C2orf54	-0.24	-5.43	-0.33	1.35e-7	Urinary metabolites;
KIRP	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.59	7.38	0.43	2.42e-12	Arsenic metabolism;
KIRP	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg07167872	chr1:205819463	PM20D1	-0.51	-4.95	-0.3	1.38e-6	Menarche (age at onset);
KIRP	trans	rs62056376	0.736	rs885691	chr17:32641225	C/T	cg17635953	chr13:28535085	NA	-0.63	-6.75	-0.4	1.05e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg27205649	chr11:78285834	NARS2	-0.52	-5.9	-0.35	1.2e-8	Testicular germ cell tumor;
KIRP	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.62	-8.34	-0.47	5.3e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	1.01	18.29	0.76	8.97e-48	Heart rate;
KIRP	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Parkinson's disease;
KIRP	cis	rs4656940	0.527	rs34002161	chr1:160782231	C/T	cg17331569	chr1:160788135	LY9	-0.48	-5.91	-0.35	1.12e-8	Crohn's disease;
KIRP	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg05072774	chr3:49840536	C3orf54	0.43	5.46	0.33	1.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.74	-9.03	-0.5	5.19e-17	Cognitive function;
KIRP	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg05360138	chr12:110035743	NA	0.65	7.19	0.42	7.84e-12	Neuroticism;
KIRP	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-6.82	-0.4	7.06e-11	Obesity (extreme);
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg21734707	chr17:3908241	ZZEF1	-0.59	-8.63	-0.48	7.77e-16	Type 2 diabetes;
KIRP	cis	rs12900413	0.564	rs8035800	chr15:90314790	T/C	cg07116693	chr15:90310901	NA	-0.23	-4.99	-0.3	1.14e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs860295	0.535	rs2297649	chr1:155935244	A/C	cg02153340	chr1:155202674	NA	0.38	5.03	0.31	9.47e-7	Body mass index;
KIRP	cis	rs8014252	0.803	rs17108264	chr14:71066484	A/G	cg11204974	chr14:71022665	NA	-0.74	-7.32	-0.42	3.53e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2131877	0.573	rs4645095	chr3:194846894	C/T	cg16306870	chr3:194868790	C3orf21	0.21	4.97	0.3	1.26e-6	Non-small cell lung cancer;
KIRP	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.31	-0.32	2.51e-7	Aortic root size;
KIRP	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg04013166	chr16:89971882	TCF25	0.7	7.33	0.42	3.35e-12	Skin colour saturation;
KIRP	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs16937956	0.597	rs12793878	chr11:8402209	G/A	cg08015107	chr11:8618950	NA	-0.56	-7.31	-0.42	3.63e-12	Body mass index;
KIRP	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg24874828	chr4:187887005	NA	-0.5	-7.56	-0.43	7.97e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6959887	0.926	rs4723399	chr7:35273116	C/G	cg06685737	chr7:35301730	NA	-0.42	-6.26	-0.37	1.68e-9	Birth weight;
KIRP	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs13401104	0.716	rs12463651	chr2:237128272	A/G	cg19324714	chr2:237145437	ASB18	0.52	5.44	0.33	1.3e-7	Educational attainment;
KIRP	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.75	-10.66	-0.56	4.54e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16777620	chr3:11761382	VGLL4	0.48	6.19	0.37	2.45e-9	Parkinson's disease;
KIRP	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg08558340	chr7:100472263	SRRT	0.49	4.94	0.3	1.43e-6	Resting heart rate;
KIRP	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg08975724	chr8:8085496	FLJ10661	0.63	7.92	0.45	7.99e-14	Neuroticism;
KIRP	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.74	-7.47	-0.43	1.43e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.48	6.83	0.4	6.56e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13680054	chr22:28315185	PITPNB;LOC284900	-0.47	-6.56	-0.39	3.21e-10	Metabolic traits;
KIRP	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg15655495	chr12:38532458	NA	-0.28	-4.98	-0.3	1.19e-6	Bladder cancer;
KIRP	cis	rs6142102	0.602	rs4911402	chr20:32667645	A/G	cg08999081	chr20:33150536	PIGU	0.39	5.04	0.31	9.01e-7	Skin pigmentation;
KIRP	cis	rs12431939	1.000	rs12431939	chr14:51692699	A/G	cg23942311	chr14:51606299	NA	0.54	4.85	0.3	2.23e-6	Cancer;
KIRP	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg00631329	chr6:26305371	NA	-0.71	-9.06	-0.5	4.06e-17	Educational attainment;
KIRP	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-6.51	-0.38	4.13e-10	Acne (severe);
KIRP	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg18657303	chr4:1051139	NA	0.53	4.88	0.3	1.92e-6	Recombination rate (females);
KIRP	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg11189052	chr15:85197271	WDR73	-0.41	-5.02	-0.3	1e-6	P wave terminal force;
KIRP	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg00129232	chr17:37814104	STARD3	0.73	8.12	0.46	2.25e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg12486944	chr17:80159399	CCDC57	-0.41	-5.54	-0.33	7.74e-8	Life satisfaction;
KIRP	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.77	9.6	0.52	1e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.63	7.24	0.42	5.61e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs6690583	0.573	rs75119114	chr1:85451385	A/C	cg22153463	chr1:85462885	MCOLN2	0.59	5.37	0.32	1.84e-7	Serum sulfate level;
KIRP	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.4	-10.73	-0.56	2.83e-22	Diabetic kidney disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17233202	chr15:82338518	MEX3B	0.52	7.18	0.42	8.4e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2554380	0.843	rs1426162	chr15:84386003	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.52	-7.64	-0.44	4.98e-13	Height;
KIRP	cis	rs10518128	1.000	rs58242818	chr4:75699164	C/T	cg20122727	chr4:75719957	BTC	0.59	5.95	0.35	9.21e-9	Electroencephalogram traits;
KIRP	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.99	13.61	0.66	8.16e-32	Neutrophil percentage of white cells;
KIRP	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.55	7.23	0.42	6.03e-12	Red blood cell count;
KIRP	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.79	0.4	8.59e-11	Electroencephalogram traits;
KIRP	cis	rs2411233	0.837	rs12907480	chr15:39250334	C/T	cg19287857	chr15:39890699	NA	0.45	6.21	0.37	2.25e-9	Platelet count;
KIRP	cis	rs1485395	0.836	rs10876471	chr12:54024544	G/A	cg16917193	chr12:54089295	NA	0.62	6.47	0.38	5.39e-10	Migraine without aura;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04211818	chr16:3661492	BTBD12	-0.48	-6.05	-0.36	5.26e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.81	-10.89	-0.57	8.44e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7534824	0.625	rs7514731	chr1:101449675	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.13	0.41	1.14e-11	Refractive astigmatism;
KIRP	cis	rs10875746	0.810	rs10875732	chr12:48442105	A/C	cg26205652	chr12:48591994	NA	0.78	10.53	0.56	1.2e-21	Longevity (90 years and older);
KIRP	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.17	-0.46	1.62e-14	Personality dimensions;
KIRP	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg03647239	chr10:116582469	FAM160B1	0.52	5.95	0.35	9.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg08890418	chr1:21044141	KIF17	0.35	5.26	0.32	3.09e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.37e-9	Myopia (pathological);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15578091	chr1:236908064	ACTN2	-0.41	-6.03	-0.36	5.89e-9	Survival in pancreatic cancer;
KIRP	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.41	-0.33	1.53e-7	Autism;
KIRP	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.5	-5.78	-0.35	2.24e-8	Corneal curvature;
KIRP	cis	rs899997	0.773	rs8032156	chr15:78964498	A/G	cg04896959	chr15:78267971	NA	0.56	5.4	0.33	1.54e-7	Coronary artery disease or large artery stroke;
KIRP	cis	rs795484	0.926	rs353897	chr12:118639841	A/G	cg16572268	chr12:118583242	PEBP1	-0.38	-4.92	-0.3	1.6e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
KIRP	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-5.07	-0.31	7.65e-7	Ulcerative colitis;
KIRP	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.83	9.88	0.53	1.3e-19	Post bronchodilator FEV1;
KIRP	cis	rs10073892	0.743	rs2218926	chr5:101649996	G/T	cg19774478	chr5:101632501	SLCO4C1	-0.64	-6.59	-0.39	2.7e-10	Cognitive decline (age-related);
KIRP	cis	rs698833	0.859	rs1302175	chr2:44657024	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.13	0.31	5.95e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	0.9	14.21	0.67	7.59e-34	Breast cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg26567249	chr8:97247842	UQCRB	1.04	7.1	0.41	1.34e-11	P wave terminal force;
KIRP	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.99	-0.3	1.14e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.84	-13.22	-0.64	1.73e-30	Blood metabolite levels;
KIRP	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.2	-0.51	1.62e-17	Retinal vascular caliber;
KIRP	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.88e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg02725872	chr8:58115012	NA	-0.48	-5.27	-0.32	2.92e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg21546286	chr11:48923668	NA	-0.47	-6.09	-0.36	4.36e-9	HDL cholesterol;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11599998	chr3:160283537	KPNA4	0.37	5.01	0.3	1.03e-6	Parkinson's disease;
KIRP	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.75	9.28	0.51	8.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs55962025	0.846	rs363064	chr4:3141410	C/T	cg06533319	chr4:3265114	C4orf44	0.47	5.06	0.31	8.02e-7	Parental longevity (mother's age at death);
KIRP	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.54	6.61	0.39	2.43e-10	Dilated cardiomyopathy;
KIRP	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg17376030	chr22:41985996	PMM1	0.81	8.29	0.47	7.22e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.44	-7.26	-0.42	5.21e-12	Height;
KIRP	cis	rs2016266	0.502	rs9971671	chr12:53634238	G/C	cg04065151	chr12:53682969	ESPL1	-0.43	-5.3	-0.32	2.58e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg01475377	chr6:109611718	NA	-0.36	-4.89	-0.3	1.81e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs903263	0.520	rs12756327	chr1:84664640	T/G	cg04407776	chr1:84465009	TTLL7	-0.52	-5.63	-0.34	4.95e-8	Breast cancer (male);
KIRP	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg05665937	chr4:1216051	CTBP1	0.44	5.72	0.34	3.06e-8	Obesity-related traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg21727117	chr19:2269525	OAZ1	-0.47	-6.08	-0.36	4.52e-9	Myopia;
KIRP	trans	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg10756647	chr7:56101905	PSPH	0.77	7.25	0.42	5.5e-12	Diabetic kidney disease;
KIRP	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg22437258	chr11:111473054	SIK2	-0.5	-5.72	-0.34	3.04e-8	Primary sclerosing cholangitis;
KIRP	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg08975724	chr8:8085496	FLJ10661	0.61	8.23	0.46	1.07e-14	Retinal vascular caliber;
KIRP	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg07636037	chr3:49044803	WDR6	-0.7	-5.59	-0.34	5.97e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs732716	0.813	rs760369	chr19:4449287	C/T	cg03719555	chr19:4455413	UBXN6	-0.46	-7.22	-0.42	6.36e-12	Mean corpuscular volume;
KIRP	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg01244601	chr4:120671846	NA	-0.44	-5.49	-0.33	1.02e-7	Corneal astigmatism;
KIRP	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6977660	0.507	rs4719580	chr7:19784847	G/T	cg07541023	chr7:19748670	TWISTNB	0.6	6.1	0.36	4.09e-9	Thyroid stimulating hormone;
KIRP	cis	rs6681460	0.634	rs994396	chr1:67012236	G/A	cg02459107	chr1:67143332	SGIP1	0.38	5.22	0.32	3.89e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-0.71	-7.34	-0.42	3.13e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-6.02	-0.36	6.29e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg26384229	chr12:38710491	ALG10B	0.71	9.67	0.52	5.97e-19	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18809122	chr2:191513153	NAB1	0.41	6.03	0.36	5.84e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg10818794	chr15:86012489	AKAP13	-0.52	-7.38	-0.43	2.43e-12	Interstitial lung disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10730208	chr12:58290540	NA	-0.5	-6.64	-0.39	2.04e-10	Survival in pancreatic cancer;
KIRP	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.62	0.48	8.45e-16	Motion sickness;
KIRP	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.84e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.76	-9.8	-0.53	2.28e-19	Aortic root size;
KIRP	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-8.68	-0.48	5.56e-16	Extrinsic epigenetic age acceleration;
KIRP	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.86	-12.85	-0.63	2.92e-29	Height;
KIRP	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg01529538	chr14:23388837	RBM23	0.42	5.4	0.33	1.55e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.55	9.68	0.53	5.38e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
KIRP	cis	rs4356932	1.000	rs10021768	chr4:76951764	C/T	cg00809888	chr4:76862425	NAAA	-0.41	-5.41	-0.33	1.49e-7	Blood protein levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04788575	chr1:168170646	TIPRL	0.39	6.15	0.37	3.15e-9	C-reactive protein;
KIRP	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.65	5.9	0.35	1.22e-8	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19097648	chr5:115177461	ATG12;AP3S1	0.57	7.86	0.45	1.22e-13	Parkinson's disease;
KIRP	cis	rs96067	0.652	rs274764	chr1:36574912	T/C	cg27506609	chr1:36549197	TEKT2	-0.8	-5.88	-0.35	1.35e-8	Corneal structure;
KIRP	cis	rs244731	0.920	rs67008484	chr5:176735383	T/C	cg16006841	chr5:176797999	RGS14	0.67	7.42	0.43	1.87e-12	Urate levels in lean individuals;
KIRP	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.83	10.24	0.55	1.02e-20	Corneal astigmatism;
KIRP	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05665937	chr4:1216051	CTBP1	0.58	7.93	0.45	7.66e-14	Obesity-related traits;
KIRP	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17554472	chr22:41940697	POLR3H	-0.65	-6.91	-0.4	4.05e-11	Vitiligo;
KIRP	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.43	-5.41	-0.33	1.47e-7	Platelet count;
KIRP	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.36	0.65	5.55e-31	Bladder cancer;
KIRP	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25517755	chr10:38738941	LOC399744	0.39	5.53	0.33	8.16e-8	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.58	-11.9	-0.6	4.44e-26	Diabetic kidney disease;
KIRP	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	1.18	13.95	0.66	5.59e-33	Red blood cell traits;
KIRP	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08975828	chr12:112280180	C12orf47;MAPKAPK5	0.54	6.59	0.39	2.66e-10	Parkinson's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26924025	chr11:111749805	C11orf1;FDXACB1	-0.48	-6.41	-0.38	7.28e-10	Metabolic traits;
KIRP	cis	rs4356932	0.691	rs10008757	chr4:76903036	A/G	cg00809888	chr4:76862425	NAAA	0.5	6.97	0.41	2.83e-11	Blood protein levels;
KIRP	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27297192	chr10:134578999	INPP5A	0.57	7.11	0.41	1.22e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14237674	chr17:43239170	HEXIM2	0.46	6.05	0.36	5.47e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.74e-7	Schizophrenia;
KIRP	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	9.87	0.53	1.47e-19	Total body bone mineral density;
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.7	-0.39	1.41e-10	Immature fraction of reticulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10116431	chr3:143690928	C3orf58	0.6	8.04	0.46	3.88e-14	Parkinson's disease;
KIRP	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg17764715	chr19:33622953	WDR88	0.79	11.22	0.58	7.16e-24	Bone properties (heel);
KIRP	cis	rs11901793	0.505	rs11688053	chr2:237494289	A/T	cg25295825	chr2:237489920	CXCR7	0.76	7.63	0.44	5.09e-13	Total mean fractional anisotropy measurement in first episode schizophrenia;
KIRP	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg04733989	chr22:42467013	NAGA	0.55	7.49	0.43	1.27e-12	Cognitive function;
KIRP	cis	rs7814319	1.000	rs7814319	chr8:97263418	C/T	cg20787634	chr8:97240163	UQCRB	-0.6	-9.33	-0.51	6.62e-18	Lung function (FVC);
KIRP	cis	rs2412208	1.000	rs35447019	chr1:7093158	T/A	cg20434152	chr1:7120926	CAMTA1	-0.38	-4.97	-0.3	1.23e-6	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.74	9.25	0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9308731	0.568	rs6754736	chr2:111948541	T/C	cg04780086	chr2:111875790	ACOXL	0.37	4.99	0.3	1.12e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg26335602	chr6:28129616	ZNF389	0.43	4.86	0.3	2.08e-6	Depression;
KIRP	cis	rs4702718	0.549	rs267963	chr5:10736580	G/A	cg14521931	chr5:10832172	NA	-0.48	-6.43	-0.38	6.55e-10	Obesity-related traits;
KIRP	cis	rs4478137	0.501	rs6811330	chr4:164230038	G/T	cg06758707	chr4:164254230	NPY1R	-0.5	-5.64	-0.34	4.61e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00689492	chr4:1303491	MAEA	0.32	5.49	0.33	1.01e-7	Obesity-related traits;
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18811621	chr2:208207188	NA	-0.46	-6.4	-0.38	7.88e-10	Inflammatory biomarkers;
KIRP	cis	rs1816752	0.755	rs1981277	chr13:24983513	G/A	cg22771759	chr13:24902376	NA	0.38	4.87	0.3	2.02e-6	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	1.0	15.68	0.71	6.89e-39	Personality dimensions;
KIRP	cis	rs11078597	0.636	rs4790821	chr17:1654048	A/G	cg17514665	chr17:1657533	SERPINF2	0.45	5.33	0.32	2.22e-7	Serum albumin level;
KIRP	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg25173405	chr17:45401733	C17orf57	0.42	5.39	0.32	1.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs75804782	0.522	rs11889150	chr2:239324542	A/G	cg18131467	chr2:239335373	ASB1	-0.61	-6.02	-0.36	6.24e-9	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.76	9.37	0.51	4.9e-18	Monocyte count;
KIRP	cis	rs10073892	0.620	rs62369729	chr5:101931331	G/A	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27507545	chr10:103880405	LDB1	0.53	6.42	0.38	6.83e-10	Smoking initiation;
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05025164	chr4:1340916	KIAA1530	-0.54	-7.11	-0.41	1.25e-11	Obesity-related traits;
KIRP	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	15.28	0.7	1.61e-37	Electrocardiographic conduction measures;
KIRP	trans	rs4131099	0.793	rs4011592	chr16:51373048	A/G	cg02207200	chr8:17353980	SLC7A2	-0.59	-6.58	-0.39	2.87e-10	Personality dimensions;
KIRP	cis	rs7005380	0.581	rs2326432	chr8:120932912	A/G	cg21645572	chr8:120931649	DEPDC6	0.52	7.36	0.42	2.74e-12	Interstitial lung disease;
KIRP	cis	rs2791713	0.626	rs6685948	chr1:207171603	G/A	cg24040043	chr1:207224982	YOD1	0.29	4.95	0.3	1.4e-6	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.61	0.59	3.99e-25	Monocyte percentage of white cells;
KIRP	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg15832292	chr6:96025679	MANEA	0.68	5.3	0.32	2.52e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs12949688	0.601	rs11079325	chr17:55834785	A/C	cg12582317	chr17:55822272	NA	0.44	6.26	0.37	1.71e-9	Schizophrenia;
KIRP	cis	rs6546324	0.625	rs6717863	chr2:67844799	C/A	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.84e-13	Endometriosis;
KIRP	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.49	-11.44	-0.59	1.39e-24	Diabetic kidney disease;
KIRP	cis	rs2652822	0.584	rs1017546	chr15:63566702	G/T	cg02713581	chr15:63449717	RPS27L	-0.49	-5.49	-0.33	1.02e-7	Metabolic traits;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-5.68	-0.34	3.75e-8	Crohn's disease;
KIRP	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.42	-0.55	2.74e-21	Hemoglobin concentration;
KIRP	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00290607	chr11:67383545	NA	0.36	5.06	0.31	8.1e-7	Mean corpuscular volume;
KIRP	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.88	11.74	0.6	1.4e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.51	-6.31	-0.37	1.26e-9	Post bronchodilator FEV1;
KIRP	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.94	13.28	0.65	1.07e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.63	10.78	0.57	1.86e-22	Body mass index;
KIRP	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg21395723	chr22:39101663	GTPBP1	0.4	4.95	0.3	1.36e-6	Menopause (age at onset);
KIRP	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg00405596	chr8:11794950	NA	0.58	8.03	0.46	4.09e-14	Myopia (pathological);
KIRP	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.48	-0.33	1.08e-7	Pulmonary function;
KIRP	cis	rs9603616	0.719	rs4569133	chr13:40239044	T/G	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg09788416	chr12:39539408	NA	0.42	5.37	0.32	1.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.5	-0.33	9.36e-8	Menarche (age at onset);
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg07701084	chr6:150067640	NUP43	0.71	9.57	0.52	1.16e-18	Lung cancer;
KIRP	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg22676075	chr6:135203613	NA	0.51	7.41	0.43	1.97e-12	Red blood cell count;
KIRP	cis	rs7553864	1.000	rs7515367	chr1:87615798	A/T	cg17420885	chr1:87600446	LOC339524	-0.46	-6.04	-0.36	5.76e-9	Smoking behavior;
KIRP	cis	rs2411233	0.967	rs2035060	chr15:39287384	T/C	cg02291532	chr15:39874776	THBS1	0.37	5.02	0.3	9.9e-7	Platelet count;
KIRP	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.47	-5.58	-0.34	6.37e-8	Body mass index;
KIRP	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg16586182	chr3:47516702	SCAP	0.81	11.58	0.59	4.94e-25	Colorectal cancer;
KIRP	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.95e-8	Endometrial cancer;
KIRP	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00982548	chr2:198649783	BOLL	-0.57	-5.73	-0.34	2.87e-8	Ulcerative colitis;
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg23594656	chr7:65796392	TPST1	-0.38	-5.74	-0.34	2.72e-8	Aortic root size;
KIRP	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	14.74	0.68	1.13e-35	Chronic sinus infection;
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg22907277	chr7:1156413	C7orf50	0.42	5.12	0.31	6.07e-7	Longevity;Endometriosis;
KIRP	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg15655495	chr12:38532458	NA	-0.31	-5.33	-0.32	2.21e-7	Bladder cancer;
KIRP	trans	rs4349753	0.870	rs248564	chr5:144185238	C/G	cg16033277	chr17:80885358	TBCD	0.4	6.28	0.37	1.52e-9	Photic sneeze reflex;
KIRP	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.66	7.33	0.42	3.37e-12	Multiple sclerosis;
KIRP	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg13289132	chr10:30722225	MAP3K8	0.44	5.51	0.33	9.04e-8	Inflammatory bowel disease;
KIRP	cis	rs4073221	0.654	rs13087192	chr3:18307826	C/G	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.4e-9	Parkinson's disease;
KIRP	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg16141378	chr3:129829833	LOC729375	0.51	6.59	0.39	2.6200000000000003e-10	Retinal vascular caliber;
KIRP	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg09455208	chr3:40491958	NA	0.35	6.27	0.37	1.57e-9	Renal cell carcinoma;
KIRP	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.24	-6.19	-0.37	2.57e-9	Mean corpuscular volume;
KIRP	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.86	7.85	0.45	1.31e-13	Type 2 diabetes;
KIRP	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg13119609	chr19:45449297	APOC2	0.53	7.72	0.44	2.91e-13	Blood protein levels;
KIRP	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23903597	chr17:61704154	MAP3K3	-0.62	-8.22	-0.46	1.14e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11997175	0.766	rs4733178	chr8:33691899	A/T	cg04338863	chr8:33670619	NA	0.4	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs2273156	0.570	rs77477310	chr14:35615793	A/G	cg09327582	chr14:35236912	BAZ1A	-0.57	-5.72	-0.34	3.14e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.51	-0.59	8.15e-25	Total body bone mineral density;
KIRP	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg21108841	chr4:24914750	CCDC149	-0.45	-5.45	-0.33	1.22e-7	Heschl's gyrus morphology;
KIRP	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.44e-33	Alzheimer's disease;
KIRP	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	5.51	0.33	8.88e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	7.47	0.43	1.4e-12	Coronary artery disease;
KIRP	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg13798912	chr7:905769	UNC84A	0.64	6.19	0.37	2.51e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg03474202	chr17:45855739	NA	-0.41	-5.84	-0.35	1.65e-8	IgG glycosylation;
KIRP	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	1.02	8.94	0.5	9.73e-17	Lymphocyte counts;
KIRP	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg00852783	chr1:26633632	UBXN11	0.53	7.71	0.44	3.15e-13	Obesity-related traits;
KIRP	cis	rs698833	0.819	rs2340809	chr2:44536249	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	4.87	0.3	1.97e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.47	-0.38	5.2e-10	Aortic root size;
KIRP	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.83	9.78	0.53	2.8e-19	Post bronchodilator FEV1;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20467168	chr1:76081408	NA	0.5	6.59	0.39	2.6e-10	Parkinson's disease;
KIRP	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	cis	rs7215564	0.908	rs2316067	chr17:78659720	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.54	-6.53	-0.38	3.71e-10	Corneal astigmatism;
KIRP	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg05347473	chr6:146136440	FBXO30	0.49	7.05	0.41	1.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs897080	0.515	rs698790	chr2:44683018	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	5.81	0.35	1.97e-8	Height;
KIRP	cis	rs2562456	0.876	rs10424079	chr19:21589179	G/A	cg18461458	chr19:21324796	ZNF431	-0.54	-5.15	-0.31	5.22e-7	Pain;
KIRP	cis	rs828999	0.583	rs12047398	chr1:108693305	C/G	cg06207961	chr1:108661230	NA	0.44	6.41	0.38	7.37e-10	Monocyte percentage of white cells;
KIRP	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.55	5.86	0.35	1.46e-8	Crohn's disease;
KIRP	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	6.37	0.38	9.37e-10	Eosinophil percentage of white cells;
KIRP	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02725872	chr8:58115012	NA	-0.65	-6.29	-0.37	1.47e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg00405596	chr8:11794950	NA	0.44	5.48	0.33	1.05e-7	Retinal vascular caliber;
KIRP	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.42	-5.43	-0.33	1.36e-7	Blood metabolite levels;
KIRP	cis	rs4073221	0.654	rs66497815	chr3:18305719	G/T	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.4e-9	Parkinson's disease;
KIRP	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.54	8.57	0.48	1.17e-15	Glomerular filtration rate (creatinine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13249789	chr11:47600513	KBTBD4;NDUFS3	0.52	6.39	0.38	8.47e-10	Parkinson's disease;
KIRP	cis	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg00405596	chr8:11794950	NA	0.48	5.88	0.35	1.31e-8	Monocyte count;
KIRP	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.83	9.38	0.51	4.53e-18	Cognitive ability;
KIRP	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg03929089	chr4:120376271	NA	0.53	6.54	0.38	3.44e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17364234	chr19:59031070	ZBTB45	-0.5	-6.3	-0.37	1.4e-9	Myopia;
KIRP	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	0.56	8.44	0.47	2.78e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg12560992	chr17:57184187	TRIM37	0.55	5.12	0.31	6.05e-7	Cognitive test performance;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg02513924	chr11:124823857	CCDC15	-0.46	-6.23	-0.37	1.98e-9	Morning vs. evening chronotype;
KIRP	cis	rs10214930	0.697	rs10447552	chr7:27683298	A/G	cg22168087	chr7:27702803	HIBADH	-0.48	-5.21	-0.32	3.96e-7	Hypospadias;
KIRP	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.83	12.48	0.62	5.02e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6968419	0.641	rs17138519	chr7:115906178	T/C	cg02561103	chr7:115862891	TES	-0.42	-5.92	-0.35	1.08e-8	Intraocular pressure;
KIRP	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.4	-5.07	-0.31	7.72e-7	Educational attainment (years of education);
KIRP	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.75	-11.72	-0.6	1.66e-25	Rheumatoid arthritis;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg14022721	chr22:25507536	KIAA1671	0.48	6.12	0.36	3.66e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.76	-0.44	2.25e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg16141378	chr3:129829833	LOC729375	0.55	7.64	0.44	4.92e-13	Morning vs. evening chronotype;
KIRP	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.39	-8.16	-0.46	1.72e-14	Urinary metabolites;
KIRP	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.65	-6.86	-0.4	5.49e-11	Vitiligo;
KIRP	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg00806126	chr19:22604979	ZNF98	-0.58	-5.77	-0.35	2.4e-8	Pain;
KIRP	cis	rs7615316	0.779	rs2086933	chr3:142039406	G/A	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-11.12	-0.58	1.57e-23	Body mass index;
KIRP	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.07	-0.31	7.86e-7	Obesity-related traits;
KIRP	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.69	9.16	0.5	2.15e-17	Red blood cell count;
KIRP	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.79	-11.11	-0.58	1.71e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.9	-11.92	-0.61	3.76e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg18016565	chr1:150552671	MCL1	0.39	5.47	0.33	1.11e-7	Melanoma;
KIRP	cis	rs7143963	0.666	rs7161606	chr14:103307110	A/C	cg24154132	chr14:103367632	TRAF3	0.34	6.41	0.38	7.51e-10	Body mass index;
KIRP	cis	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg25276700	chr6:44698697	NA	0.35	4.98	0.3	1.21e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg17470723	chr8:74884337	TCEB1	0.62	7.77	0.44	2.1e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-7.31	-0.42	3.62e-12	Monocyte percentage of white cells;
KIRP	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg11465639	chr17:19241549	NA	-0.38	-4.9	-0.3	1.71e-6	Schizophrenia;
KIRP	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg13906792	chr15:75199810	C15orf17	-0.37	-5.48	-0.33	1.07e-7	Breast cancer;
KIRP	trans	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.07	-0.41	1.59e-11	Bladder cancer;
KIRP	cis	rs1505992	0.666	rs7713102	chr5:40586239	G/A	cg05478818	chr5:40835740	RPL37	-0.49	-5.24	-0.32	3.54e-7	Inflammatory bowel disease;
KIRP	cis	rs3857067	0.901	rs4693368	chr4:95046907	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-5.22	-0.32	3.76e-7	QT interval;
KIRP	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-5.88	-0.35	1.36e-8	Educational attainment;
KIRP	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg03808351	chr9:123631620	PHF19	0.37	4.91	0.3	1.66e-6	Rheumatoid arthritis;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg00908189	chr16:619842	PIGQ	0.84	11.6	0.59	4.13e-25	Height;
KIRP	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-8.12	-0.46	2.22e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.91	13.97	0.67	4.7e-33	Metabolite levels;
KIRP	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg08975724	chr8:8085496	FLJ10661	0.64	8.84	0.49	1.83e-16	Mood instability;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg25028639	chr11:9884897	SBF2	0.45	6.21	0.37	2.24e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.88	0.4	4.85e-11	Systolic blood pressure;
KIRP	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg06781948	chr3:72941472	GXYLT2	-0.51	-6.89	-0.4	4.74e-11	Motion sickness;
KIRP	cis	rs11628318	0.901	rs4900545	chr14:103051132	C/T	cg12046867	chr14:103022105	NA	-0.48	-6.48	-0.38	4.86e-10	Platelet count;
KIRP	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg18225595	chr11:63971243	STIP1	0.65	5.86	0.35	1.46e-8	Mean platelet volume;
KIRP	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg11663144	chr21:46675770	NA	-0.7	-9.49	-0.52	2.1e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg06636001	chr8:8085503	FLJ10661	0.68	8.88	0.49	1.4e-16	Neuroticism;
KIRP	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg02807482	chr3:125708958	NA	-0.55	-5.54	-0.33	7.62e-8	Blood pressure (smoking interaction);
KIRP	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg07636037	chr3:49044803	WDR6	0.58	5.5	0.33	9.71e-8	Menarche (age at onset);
KIRP	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	1.95e-15	Motion sickness;
KIRP	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.46	-5.71	-0.34	3.28e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.24	0.47	1.03e-14	Lung cancer;
KIRP	cis	rs7084402	0.565	rs11006188	chr10:60333471	G/C	cg05938607	chr10:60274200	BICC1	-0.37	-8.05	-0.46	3.44e-14	Refractive error;
KIRP	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.13	-0.31	5.99e-7	Fear of minor pain;
KIRP	cis	rs11138902	0.636	rs1330326	chr9:72165812	A/G	cg14397918	chr9:72078829	APBA1	0.32	4.98	0.3	1.18e-6	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg04369109	chr6:150039330	LATS1	-0.63	-8.12	-0.46	2.27e-14	Lung cancer;
KIRP	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.41	7.98	0.45	5.44e-14	Height;
KIRP	cis	rs2230307	0.656	rs568089	chr1:100495392	A/G	cg24955406	chr1:100503596	HIAT1	0.57	5.54	0.33	7.61e-8	Carotid intima media thickness;
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.17	0.64	2.5e-30	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20951949	chr17:34898162	NA	0.56	6.74	0.39	1.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg20701182	chr2:24300061	SF3B14	0.51	5.32	0.32	2.34e-7	Asthma;
KIRP	cis	rs654950	0.840	rs647146	chr1:41986286	G/A	cg06885757	chr1:42089581	HIVEP3	0.48	6.91	0.4	4.25e-11	Airway imaging phenotypes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08013914	chr16:89764279	SPATA2L	-0.51	-6.3	-0.37	1.35e-9	Parkinson's disease;
KIRP	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-0.99	-11.47	-0.59	1.09e-24	White matter hyperintensity burden;
KIRP	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.53	-5.38	-0.32	1.74e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs28655083	0.957	rs2171096	chr16:77079043	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-6.24	-0.37	1.89e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.58	6.44	0.38	6.35e-10	Menarche (age at onset);
KIRP	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg02353165	chr6:42928485	GNMT	0.44	4.95	0.3	1.36e-6	Blood protein levels;
KIRP	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.63	7.23	0.42	6.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg23594656	chr7:65796392	TPST1	0.49	7.8	0.45	1.81e-13	Aortic root size;
KIRP	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg03714773	chr7:91764589	CYP51A1	-0.35	-5.19	-0.31	4.4e-7	Breast cancer;
KIRP	cis	rs2733201	1.000	rs11635948	chr15:44286094	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.72	-5.48	-0.33	1.05e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg05072774	chr3:49840536	C3orf54	0.43	5.46	0.33	1.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.85	-0.4	5.96e-11	Self-reported allergy;
KIRP	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.46e-9	Obesity-related traits;
KIRP	cis	rs68170813	0.617	rs17486	chr7:107112890	C/T	cg02696742	chr7:106810147	HBP1	-0.69	-6.23	-0.37	2.05e-9	Coronary artery disease;
KIRP	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg19847130	chr8:10466454	RP1L1	-0.35	-4.97	-0.3	1.27e-6	Retinal vascular caliber;
KIRP	cis	rs6110278	0.685	rs6110284	chr20:14404886	G/A	cg17696268	chr20:14319035	FLRT3;MACROD2	-0.36	-5.06	-0.31	8.3e-7	Mean platelet volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14870128	chr10:70931312	VPS26A	0.4	6.14	0.36	3.27e-9	Survival in pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12057946	chr11:120195905	TMEM136	0.58	7.75	0.44	2.42e-13	Parkinson's disease;
KIRP	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.94	0.4	3.36e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg02319466	chr17:76381040	PGS1	0.46	6.29	0.37	1.45e-9	HDL cholesterol levels;
KIRP	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.44	-5.67	-0.34	4.02e-8	Aortic root size;
KIRP	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	1.06	19.32	0.78	3.05e-51	Height;
KIRP	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg13798780	chr7:105162888	PUS7	0.56	4.86	0.3	2.1e-6	Bipolar disorder (body mass index interaction);
KIRP	trans	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg22358067	chr17:16797159	NA	-0.52	-6.43	-0.38	6.74e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-8.23	-0.46	1.1e-14	Blood protein levels;
KIRP	cis	rs3857747	0.861	rs7779860	chr7:40421458	T/G	cg00420559	chr7:40367873	C7orf10	0.62	8.07	0.46	3.17e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	cg21523751	chr1:182988639	NA	0.45	6.97	0.41	2.86e-11	Colorectal cancer;
KIRP	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.52	7.02	0.41	2.12e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg00405596	chr8:11794950	NA	0.49	5.91	0.35	1.14e-8	Neuroticism;
KIRP	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.67	8.91	0.49	1.2e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2219968	0.962	rs4380933	chr8:78944192	A/G	cg00738934	chr8:78996279	NA	0.39	5.04	0.31	9.24e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg08807101	chr21:30365312	RNF160	0.43	5.22	0.32	3.86e-7	Pancreatic cancer;
KIRP	cis	rs9815354	0.680	rs73075219	chr3:42038429	A/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	1.14	16.36	0.72	3.37e-41	Breast cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg02562431	chr4:134070369	PCDH10	0.46	6.07	0.36	4.9e-9	Inflammatory biomarkers;
KIRP	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg22974920	chr21:40686053	BRWD1	0.51	6.11	0.36	3.83e-9	Cognitive function;
KIRP	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.62	-6.74	-0.39	1.13e-10	Body mass index;
KIRP	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-1.08	-19.9	-0.79	3.82e-53	Height;
KIRP	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.13	-0.31	5.9e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.89	-0.35	1.25e-8	Morning vs. evening chronotype;
KIRP	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.52	0.43	1.05e-12	Morning vs. evening chronotype;
KIRP	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.37	4.94	0.3	1.47e-6	Lewy body disease;
KIRP	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg04087571	chr11:116723030	SIK3	-0.26	-5.53	-0.33	8.28e-8	Blood protein levels;
KIRP	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg18190219	chr22:46762943	CELSR1	-0.93	-6.99	-0.41	2.57e-11	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-20.21	-0.79	3.37e-54	Height;
KIRP	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.79	7.19	0.42	7.61e-12	Methadone dose in opioid dependence;
KIRP	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg21095983	chr6:86352623	SYNCRIP	0.53	6.7	0.39	1.45e-10	Smooth-surface caries;
KIRP	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.39	5.15	0.31	5.41e-7	Oropharynx cancer;
KIRP	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.52	-5.91	-0.35	1.11e-8	Initial pursuit acceleration;
KIRP	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.95	0.3	1.4e-6	Bipolar disorder;
KIRP	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.62	7.8	0.45	1.76e-13	Body mass index (adult);
KIRP	cis	rs16936870	0.543	rs3763523	chr8:71033469	C/G	cg14232793	chr8:71155543	NCOA2	-0.53	-6.1	-0.36	4.1e-9	QT interval;
KIRP	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg00129232	chr17:37814104	STARD3	-0.52	-6.42	-0.38	7.15e-10	Self-reported allergy;
KIRP	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg05370193	chr1:21551575	ECE1	0.47	6.28	0.37	1.56e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg08076091	chr2:203926405	NBEAL1	0.83	8.85	0.49	1.78e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg17376030	chr22:41985996	PMM1	0.44	5.02	0.3	1.01e-6	Neuroticism;
KIRP	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.65	6.73	0.39	1.19e-10	Diisocyanate-induced asthma;
KIRP	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg13293535	chr8:11597251	GATA4	0.54	8.14	0.46	1.93e-14	Neuroticism;
KIRP	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg01028140	chr2:1542097	TPO	-0.78	-6.92	-0.4	3.9e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg11498726	chr8:26250323	BNIP3L	-0.53	-8.12	-0.46	2.28e-14	Red cell distribution width;
KIRP	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.06	-0.36	5.14e-9	Alcohol dependence;
KIRP	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-4.98	-0.3	1.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs734999	0.505	rs10910108	chr1:2539532	A/G	cg20673091	chr1:2541236	MMEL1	0.79	12.8	0.63	4.42e-29	Ulcerative colitis;
KIRP	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.6	-9.69	-0.53	5.31e-19	Itch intensity from mosquito bite;
KIRP	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg02475777	chr4:1388615	CRIPAK	0.53	5.0	0.3	1.09e-6	Recombination rate (females);
KIRP	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	1.06	23.28	0.83	3.94e-64	Breast cancer;
KIRP	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg05805236	chr11:65401703	PCNXL3	0.47	6.41	0.38	7.28e-10	Acne (severe);
KIRP	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	5.27	0.32	2.94e-7	Mean platelet volume;
KIRP	cis	rs4472734	0.646	rs6667098	chr1:214629640	T/C	cg00063699	chr1:214624242	PTPN14	-0.47	-6.63	-0.39	2.07e-10	Height;
KIRP	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.63	8.53	0.48	1.52e-15	Multiple sclerosis;
KIRP	cis	rs13053308	0.934	rs5755741	chr22:35938557	A/G	cg17807448	chr22:35932140	NA	0.33	5.15	0.31	5.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.56	-8.2	-0.46	1.32e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs7113850	0.541	rs11819948	chr11:24231257	A/C	ch.11.24196551F	chr11:24239977	NA	0.9	8.37	0.47	4.29e-15	Bone fracture in osteoporosis;
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.61	9.03	0.5	5.02e-17	Menarche (age at onset);
KIRP	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.5e-21	Bone mineral density;
KIRP	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg13010199	chr12:38710504	ALG10B	0.62	7.59	0.44	6.47e-13	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs899435	0.765	rs4763334	chr12:13451392	T/A	cg12827708	chr18:32172486	DTNA	0.41	6.04	0.36	5.65e-9	Coronary artery calcification;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.64	9.23	0.51	1.33e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs367943	0.666	rs10041899	chr5:112724742	A/T	cg12552261	chr5:112820674	MCC	0.57	6.76	0.4	9.88e-11	Type 2 diabetes;
KIRP	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.45	6.4	0.38	7.96e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.6	7.19	0.42	7.73e-12	Longevity;Endometriosis;
KIRP	cis	rs7252981	0.632	rs8113682	chr19:19743730	T/G	cg03709012	chr19:19516395	GATAD2A	-0.46	-4.93	-0.3	1.5e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.33	-0.32	2.24e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.76	-0.34	2.5e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.09	8.51	0.48	1.74e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg03235661	chr20:60525775	NA	-0.35	-5.37	-0.32	1.79e-7	Body mass index;
KIRP	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.5	-0.38	4.51e-10	Monocyte percentage of white cells;
KIRP	cis	rs9290877	0.667	rs6763591	chr3:188455971	T/C	cg17392043	chr3:188495102	LPP	-0.49	-6.45	-0.38	5.99e-10	IgE levels;
KIRP	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg05562828	chr17:3906858	NA	0.53	5.59	0.34	5.87e-8	Type 2 diabetes;
KIRP	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.78	-6.44	-0.38	6.37e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.8	9.17	0.5	1.92e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.59	0.39	2.6e-10	Renal cell carcinoma;
KIRP	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.93	10.88	0.57	9.44e-23	Cognitive ability;
KIRP	cis	rs580438	0.529	rs900082	chr3:13420005	A/C	cg10657019	chr3:13328039	NA	-0.51	-6.58	-0.39	2.77e-10	Myringotomy;
KIRP	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs12048904	0.533	rs12026932	chr1:101212881	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	8.06	0.46	3.41e-14	Multiple sclerosis;
KIRP	cis	rs9612	0.948	rs12609587	chr19:44268654	T/C	cg08581076	chr19:44259116	C19orf61	0.5	5.43	0.33	1.37e-7	Exhaled nitric oxide output;
KIRP	cis	rs17655565	0.505	rs2658654	chr12:52759239	G/A	cg07925835	chr12:52762777	KRT85	0.46	5.41	0.33	1.48e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg19404215	chr3:33155277	CRTAP	0.72	5.47	0.33	1.09e-7	Major depressive disorder;
KIRP	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg10755058	chr3:40428713	ENTPD3	0.49	6.73	0.39	1.15e-10	Renal cell carcinoma;
KIRP	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg08501292	chr6:25962987	TRIM38	1.09	6.52	0.38	4e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg20701182	chr2:24300061	SF3B14	0.47	4.85	0.3	2.17e-6	Asthma;
KIRP	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.67	6.77	0.4	9.24e-11	Vitiligo;
KIRP	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg17736920	chr1:242011382	EXO1	0.45	5.62	0.34	5.14e-8	Menopause (age at onset);
KIRP	cis	rs7119167	0.901	rs7925573	chr11:73167739	A/C	cg17517138	chr11:73019481	ARHGEF17	0.47	4.91	0.3	1.68e-6	Blood protein levels;
KIRP	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.53	6.2	0.37	2.34e-9	Aortic root size;
KIRP	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg00814883	chr7:100076585	TSC22D4	0.52	5.18	0.31	4.58e-7	Lung function (FEV1/FVC);
KIRP	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg15655495	chr12:38532458	NA	-0.25	-4.97	-0.3	1.27e-6	Heart rate;
KIRP	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg08975724	chr8:8085496	FLJ10661	0.55	7.43	0.43	1.77e-12	Neuroticism;
KIRP	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg02807482	chr3:125708958	NA	-0.5	-4.86	-0.3	2.08e-6	Blood pressure (smoking interaction);
KIRP	cis	rs3008706	0.920	rs2987043	chr9:16002831	G/T	cg14451791	chr9:16040625	NA	-0.49	-4.98	-0.3	1.21e-6	Bilirubin levels;
KIRP	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.8	10.38	0.55	3.63e-21	Breast cancer;
KIRP	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.27	-5.44	-0.33	1.28e-7	Menarche (age at onset);
KIRP	cis	rs2230307	0.656	rs2274569	chr1:100435079	T/C	cg24955406	chr1:100503596	HIAT1	0.5	4.86	0.3	2.1e-6	Carotid intima media thickness;
KIRP	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.73	-10.22	-0.55	1.15e-20	Plateletcrit;Platelet count;
KIRP	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	5.74	0.34	2.75e-8	Vitiligo;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23334507	chr12:46753241	SLC38A2	0.47	7.03	0.41	2.08e-11	Survival in pancreatic cancer;
KIRP	cis	rs1440410	0.835	rs7684481	chr4:144054405	C/G	cg01719995	chr4:144104893	USP38	0.45	6.12	0.36	3.63e-9	Ischemic stroke;
KIRP	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.47	6.85	0.4	5.92e-11	Urate levels in lean individuals;
KIRP	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg16325326	chr1:53192061	ZYG11B	0.72	8.71	0.49	4.52e-16	Monocyte count;
KIRP	cis	rs7929679	0.602	rs1588354	chr11:34808486	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.34e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.42	5.35	0.32	2.03e-7	Renal cell carcinoma;
KIRP	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg10932868	chr11:921992	NA	0.5	5.84	0.35	1.67e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-5.59	-0.34	6e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg05315796	chr3:52349193	DNAH1	-0.51	-8.0	-0.45	4.82e-14	Bipolar disorder;
KIRP	cis	rs10129255	0.500	rs10143385	chr14:107190796	G/A	cg23076370	chr14:107095027	NA	-0.41	-5.03	-0.31	9.62e-7	Kawasaki disease;
KIRP	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.6	0.34	5.63e-8	Total cholesterol levels;
KIRP	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-10.47	-0.56	1.81e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg05090351	chr10:126851162	NA	-0.45	-7.96	-0.45	6.44e-14	Menarche (age at onset);
KIRP	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg04317338	chr11:64019027	PLCB3	0.56	6.57	0.39	2.94e-10	Platelet count;
KIRP	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.56	-5.4	-0.33	1.59e-7	Narcolepsy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08217409	chr5:86423923	NA	-0.41	-6.18	-0.37	2.6e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs3789045	0.685	rs12036042	chr1:204469314	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.18	-0.37	2.59e-9	Educational attainment (college completion);
KIRP	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg20243544	chr17:37824526	PNMT	0.48	6.26	0.37	1.72e-9	Asthma;
KIRP	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.92	-0.3	1.57e-6	Renal cell carcinoma;
KIRP	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.7	9.46	0.52	2.53e-18	Eye color traits;
KIRP	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.67	-10.86	-0.57	1.05e-22	Hip circumference;Waist circumference;
KIRP	cis	rs2274273	0.682	rs7151224	chr14:55517262	G/A	cg04306507	chr14:55594613	LGALS3	0.42	6.3	0.37	1.39e-9	Protein biomarker;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21774281	chr1:72750124	NA	0.5	7.2	0.42	7.25e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.54	0.59	6.69e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.72	0.39	1.26e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg26134248	chr17:3907702	NA	-0.57	-8.27	-0.47	8.37e-15	Type 2 diabetes;
KIRP	cis	rs5756391	0.546	rs9607396	chr22:37315912	C/A	cg16356956	chr22:37317934	CSF2RB	0.37	5.12	0.31	6.02e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs6662572	0.703	rs4364819	chr1:46358510	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.58	7.51	0.43	1.1e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs62380364	0.602	rs606393	chr5:88058163	T/C	cg22951263	chr5:87985283	NA	-0.45	-6.26	-0.37	1.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.11	-0.61	9.02e-27	Alzheimer's disease;
KIRP	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	11.93	0.61	3.47e-26	Smoking behavior;
KIRP	cis	rs4950322	0.580	rs972368	chr1:146582724	C/G	cg22381352	chr1:146742008	CHD1L	-0.43	-4.98	-0.3	1.21e-6	Protein quantitative trait loci;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23545105	chr4:48908833	OCIAD2	0.48	6.87	0.4	5.21e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.92	-9.8	-0.53	2.38e-19	Systolic blood pressure;
KIRP	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.56	0.48	1.27e-15	Motion sickness;
KIRP	cis	rs17123764	1.000	rs73305012	chr12:49962637	A/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.98	0.3	1.21e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg16141378	chr3:129829833	LOC729375	0.52	6.61	0.39	2.4e-10	Retinal vascular caliber;
KIRP	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.68	9.25	0.51	1.16e-17	Height;
KIRP	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.41	5.41	0.33	1.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg06740227	chr12:86229804	RASSF9	-0.49	-5.93	-0.35	1.03e-8	Major depressive disorder;
KIRP	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg27189623	chr16:705930	WDR90	0.45	6.07	0.36	4.92e-9	Height;
KIRP	cis	rs6973256	0.569	rs12532950	chr7:133434286	C/T	cg10665199	chr7:133106180	EXOC4	0.49	6.17	0.37	2.74e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7843479	0.526	rs3816788	chr8:21832494	A/C	cg17168535	chr8:21777572	XPO7	0.9	13.35	0.65	5.99e-31	Mean corpuscular volume;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16863872	chr21:45526972	PWP2	0.51	6.59	0.39	2.7e-10	Myopia (pathological);
KIRP	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg21252483	chr19:49399788	TULP2	-0.49	-6.39	-0.38	8.12e-10	Red cell distribution width;
KIRP	cis	rs897080	0.552	rs1067326	chr2:44628605	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.95	0.35	8.95e-9	Height;
KIRP	cis	rs2279817	0.909	rs905390	chr1:18018255	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.64	9.86	0.53	1.53e-19	Neuroticism;
KIRP	cis	rs7011507	1.000	rs78902358	chr8:49179859	T/C	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14335767	chr8:124286570	ZHX1	0.54	6.87	0.4	5.31e-11	Parkinson's disease;
KIRP	cis	rs2150410	0.831	rs66746936	chr21:40530969	G/A	cg11890956	chr21:40555474	PSMG1	-0.75	-5.46	-0.33	1.15e-7	Temperament (bipolar disorder);
KIRP	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.61	6.64	0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg18198730	chr1:247681584	NA	0.63	5.8	0.35	1.99e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7084402	0.967	rs1649092	chr10:60289389	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.59	-0.56	7.89e-22	Refractive error;
KIRP	cis	rs7870753	0.578	rs7028361	chr9:99093719	C/T	cg25260653	chr9:99212216	HABP4	-0.53	-4.88	-0.3	1.93e-6	Height;
KIRP	cis	rs4262150	0.774	rs17565727	chr5:152081338	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.17	-0.46	1.67e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg07382826	chr16:28625726	SULT1A1	0.52	6.11	0.36	3.78e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15367925	chr2:99061241	INPP4A	0.52	6.41	0.38	7.37e-10	Parkinson's disease;
KIRP	cis	rs4363385	0.553	rs61813181	chr1:152942177	T/C	cg07796016	chr1:152779584	LCE1C	-0.48	-6.03	-0.36	6.05e-9	Inflammatory skin disease;
KIRP	cis	rs7534824	0.625	rs6676834	chr1:101463788	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.49	0.33	9.76e-8	Refractive astigmatism;
KIRP	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.83	0.63	3.46e-29	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.18	0.42	8.47e-12	Height;
KIRP	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg02527881	chr3:46936655	PTH1R	-0.37	-5.32	-0.32	2.36e-7	Colorectal cancer;
KIRP	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-4.87	-0.3	2.03e-6	IgG glycosylation;
KIRP	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg08885076	chr2:99613938	TSGA10	-0.48	-6.48	-0.38	5e-10	Chronic sinus infection;
KIRP	cis	rs2278796	0.693	rs2794859	chr1:204967256	A/G	cg04862289	chr1:204966208	NFASC	0.58	8.36	0.47	4.75e-15	Mean platelet volume;
KIRP	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs35079454	1	rs35079454	chr1:85780863	AG/A	cg16011679	chr1:85725395	C1orf52	0.49	5.86	0.35	1.45e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3736485	0.966	rs8042221	chr15:51774613	A/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.42	-0.33	1.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg07701084	chr6:150067640	NUP43	0.62	7.93	0.45	7.47e-14	Lung cancer;
KIRP	cis	rs71277158	0.688	rs76336713	chr3:169911957	G/T	cg04067573	chr3:169899625	PHC3	0.71	6.83	0.4	6.46e-11	Prostate cancer;
KIRP	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.14	0.5	2.45e-17	Morning vs. evening chronotype;
KIRP	trans	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17712092	chr4:129076599	LARP1B	-0.57	-6.47	-0.38	5.23e-10	Breast cancer;
KIRP	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg12599982	chr1:44399894	ARTN	0.41	5.04	0.31	9.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	0.743	rs61778528	chr1:21059837	C/T	cg05370193	chr1:21551575	ECE1	0.41	4.9	0.3	1.73e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg00310523	chr12:86230176	RASSF9	0.39	5.96	0.36	8.8e-9	Major depressive disorder;
KIRP	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.35	0.32	1.98e-7	Cognitive test performance;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14618681	chr20:32273893	E2F1	0.47	6.06	0.36	5.02e-9	Myopia (pathological);
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg25487775	chr2:162093969	NA	0.44	5.91	0.35	1.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-7.21	-0.42	6.67e-12	Gut microbiome composition (summer);
KIRP	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.6	-7.15	-0.41	1e-11	Vitiligo;
KIRP	cis	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.94	-13.84	-0.66	1.37e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg24826892	chr11:71159390	DHCR7	0.44	5.24	0.32	3.42e-7	Vitamin D levels;
KIRP	cis	rs6901004	0.803	rs9400470	chr6:111478131	T/C	cg15721981	chr6:111408429	SLC16A10	-0.57	-7.88	-0.45	1.08e-13	Blood metabolite levels;
KIRP	cis	rs9398803	0.865	rs9388494	chr6:126776094	G/T	cg19875578	chr6:126661172	C6orf173	0.5	6.45	0.38	5.8e-10	Male-pattern baldness;
KIRP	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.65	8.59	0.48	9.92e-16	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg10223061	chr2:219282414	VIL1	0.28	4.86	0.3	2.14e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	trans	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg10756647	chr7:56101905	PSPH	0.98	7.0	0.41	2.44e-11	Diabetic kidney disease;
KIRP	cis	rs897080	0.515	rs1067362	chr2:44660112	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.36	0.32	1.94e-7	Height;
KIRP	cis	rs600806	0.672	rs1144593	chr1:110030945	A/G	cg16988986	chr1:109941118	SORT1	0.26	5.13	0.31	5.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg13385521	chr17:29058706	SUZ12P	-0.53	-5.1	-0.31	6.94e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.23	4.89	0.3	1.8e-6	Height;
KIRP	cis	rs9815354	0.951	rs1617271	chr3:41914000	G/T	cg03022575	chr3:42003672	ULK4	0.49	5.57	0.33	6.67e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1408799	0.671	rs1134311	chr9:12713962	G/A	cg05274944	chr9:12693694	TYRP1	0.38	5.41	0.33	1.5e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.09	-0.36	4.38e-9	Schizophrenia;
KIRP	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.8	12.0	0.61	1.99e-26	Lymphocyte counts;
KIRP	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg17524180	chr13:113633600	MCF2L	-0.3	-5.47	-0.33	1.12e-7	Systolic blood pressure;
KIRP	trans	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.96	13.08	0.64	4.77e-30	Vitamin D levels;
KIRP	cis	rs1209950	1.000	rs1013841	chr21:40173345	A/G	cg01359822	chr21:40176597	ETS2	0.33	5.53	0.33	8e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs35079168	0.923	rs10858277	chr9:137287959	G/A	cg13941235	chr9:137270186	RXRA	-0.25	-5.32	-0.32	2.33e-7	Intelligence;
KIRP	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg24804195	chr5:87968844	LOC645323	-0.47	-6.25	-0.37	1.76e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg20701182	chr2:24300061	SF3B14	0.97	10.83	0.57	1.29e-22	Lymphocyte counts;
KIRP	cis	rs113123495	0.510	rs1572491	chr19:5704691	A/C	cg26242866	chr19:5711310	LONP1	0.83	5.86	0.35	1.48e-8	Obsessive-compulsive symptoms;
KIRP	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.51	-0.38	4.19e-10	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00023288	chr2:44223284	LRPPRC	1.02	6.77	0.4	9.34e-11	P wave terminal force;
KIRP	cis	rs10924309	0.924	rs10802245	chr1:245858321	G/A	cg00036263	chr1:245852353	KIF26B	-0.5	-6.67	-0.39	1.64e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.27	-0.42	4.63e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs988913	1.000	rs7753255	chr6:54832973	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.67	-0.34	3.97e-8	Menarche (age at onset);
KIRP	cis	rs1882538	0.901	rs35284403	chr7:132948884	T/C	cg10665199	chr7:133106180	EXOC4	0.5	5.93	0.35	1.05e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.6	0.34	5.59e-8	Breast cancer;
KIRP	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg08076091	chr2:203926405	NBEAL1	0.88	8.79	0.49	2.62e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg15556689	chr8:8085844	FLJ10661	0.61	7.6	0.44	6.12e-13	Neuroticism;
KIRP	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00933542	chr6:150070202	PCMT1	0.26	5.04	0.31	8.87e-7	Lung cancer;
KIRP	cis	rs2307121	0.700	rs13361244	chr5:64709481	C/T	cg11190754	chr5:64858552	CENPK;PPWD1	0.45	5.25	0.32	3.22e-7	Corneal structure;
KIRP	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.77	-9.82	-0.53	2.09e-19	Homoarginine levels;
KIRP	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.63	-7.03	-0.41	1.99e-11	Neuroticism;
KIRP	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.92	-14.9	-0.69	3.24e-36	Breast cancer;
KIRP	cis	rs7172677	0.960	rs11072526	chr15:75432517	T/C	cg14664628	chr15:75095509	CSK	-0.58	-6.21	-0.37	2.2e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4936891	0.563	rs78158860	chr11:123890220	A/G	cg22125253	chr11:123886957	OR10G4	0.63	8.82	0.49	2.18e-16	Male fertility;
KIRP	cis	rs78487399	0.808	rs74608713	chr2:43763539	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.01	-0.3	1.04e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2625529	0.730	rs2957368	chr15:72329906	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-6.39	-0.38	8.19e-10	Red blood cell count;
KIRP	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg01631408	chr1:248437212	OR2T33	0.6	7.77	0.44	2.11e-13	Common traits (Other);
KIRP	cis	rs7799006	0.862	rs733611	chr7:2256779	G/A	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.24	-0.32	3.4e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.63	9.71	0.53	4.4e-19	Lung cancer;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	5e-8	Lung cancer;
KIRP	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.38	-0.47	3.97e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.53	6.52	0.38	3.96e-10	Asthma;
KIRP	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg15128208	chr22:42549153	NA	-0.55	-6.0	-0.36	7.11e-9	Birth weight;
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.44	6.81	0.4	7.54e-11	Lung cancer;
KIRP	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg23594656	chr7:65796392	TPST1	0.38	5.61	0.34	5.51e-8	Aortic root size;
KIRP	trans	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.15	-0.41	9.86e-12	Bladder cancer;
KIRP	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.6	-0.44	6.26e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg17376030	chr22:41985996	PMM1	0.46	5.54	0.33	7.73e-8	Vitiligo;
KIRP	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.44	-6.14	-0.36	3.27e-9	Bone mineral density (spine);
KIRP	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg17366294	chr4:99064904	C4orf37	-0.37	-5.19	-0.31	4.3e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9913711	0.868	rs7216619	chr17:70079708	C/A	cg11350586	chr17:70115862	SOX9	0.39	5.27	0.32	3.04e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4523957	0.570	rs2126202	chr17:2095712	G/T	cg16513277	chr17:2031491	SMG6	0.5	6.98	0.41	2.79e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2273156	1.000	rs2273156	chr14:35438799	T/C	cg09327582	chr14:35236912	BAZ1A	-0.54	-5.8	-0.35	2.08e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	trans	rs62103177	0.733	rs80114941	chr18:77671740	G/A	cg05926928	chr17:57297772	GDPD1	1.14	10.46	0.55	2.08e-21	Opioid sensitivity;
KIRP	cis	rs745080	0.674	rs8007324	chr14:52992982	T/C	cg23333723	chr14:53022898	GPR137C	-0.42	-5.72	-0.34	3.06e-8	Orofacial clefts;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg05627522	chr15:75251581	NA	0.4	6.44	0.38	6.23e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg18657303	chr4:1051139	NA	0.55	4.99	0.3	1.17e-6	Recombination rate (females);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25221653	chr11:93276592	C11orf75	-0.51	-6.12	-0.36	3.62e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.3	-0.37	1.36e-9	Height;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27391396	chr19:13976740	NA	-0.5	-6.05	-0.36	5.26e-9	Menopause (age at onset);
KIRP	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.64	-6.54	-0.38	3.6e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11169552	0.510	rs10783376	chr12:50981249	C/G	cg12884762	chr12:50931848	DIP2B	-0.42	-4.89	-0.3	1.81e-6	Colorectal cancer;
KIRP	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs6901250	0.655	rs636252	chr6:117157774	A/G	cg05399210	chr6:117082661	FAM162B	0.38	5.21	0.32	3.93e-7	C-reactive protein levels;
KIRP	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-5.97	-0.36	8.19e-9	Bipolar disorder;
KIRP	cis	rs4474465	1.000	rs10793319	chr11:78217237	G/A	cg27205649	chr11:78285834	NARS2	0.59	7.22	0.42	6.42e-12	Alzheimer's disease (survival time);
KIRP	cis	rs7851660	0.654	rs2120264	chr9:100645728	A/G	cg13688889	chr9:100608707	NA	-0.67	-8.72	-0.49	4.24e-16	Strep throat;
KIRP	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg26876637	chr1:152193138	HRNR	0.77	10.38	0.55	3.52e-21	Atopic dermatitis;
KIRP	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.23	-4.96	-0.3	1.3e-6	Type 2 diabetes;
KIRP	trans	rs9693857	0.520	rs6601320	chr8:9355888	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	6.09	0.36	4.4e-9	Systolic blood pressure;
KIRP	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	4.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7534824	0.625	rs61782084	chr1:101515298	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.12	0.41	1.21e-11	Refractive astigmatism;
KIRP	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-6.19	-0.37	2.53e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg07936489	chr17:37558343	FBXL20	-0.41	-5.1	-0.31	6.95e-7	Asthma;
KIRP	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	10.98	0.57	4.43e-23	Total body bone mineral density;
KIRP	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.76	-10.86	-0.57	1.03e-22	Metabolic syndrome;
KIRP	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.66	8.17	0.46	1.63e-14	Aortic root size;
KIRP	cis	rs580438	0.792	rs357130	chr3:13332321	A/T	cg10657019	chr3:13328039	NA	0.86	11.54	0.59	6.41e-25	Myringotomy;
KIRP	cis	rs35264875	1.000	rs72917389	chr11:68822831	C/T	cg01403660	chr11:68851641	TPCN2	0.65	6.1	0.36	4.03e-9	Blond vs. brown hair color;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20929551	chr15:49788481	C15orf33	-0.42	-6.46	-0.38	5.42e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg04080417	chr5:1859792	NA	-0.64	-8.16	-0.46	1.72e-14	Cardiovascular disease risk factors;
KIRP	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.8	9.57	0.52	1.17e-18	Corneal astigmatism;
KIRP	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg26207909	chr14:103986467	CKB	-0.49	-6.25	-0.37	1.77e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6991838	0.584	rs4737748	chr8:66525865	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	4.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.66	11.44	0.59	1.4e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg00409905	chr10:38381863	ZNF37A	-0.73	-10.31	-0.55	5.95e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.48	-5.59	-0.34	5.97e-8	Resistin levels;
KIRP	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg23307798	chr14:103986281	CKB	0.73	11.89	0.6	4.53e-26	Body mass index;
KIRP	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg22974920	chr21:40686053	BRWD1	0.47	5.52	0.33	8.54e-8	Cognitive function;
KIRP	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg15556689	chr8:8085844	FLJ10661	0.57	7.71	0.44	3.19e-13	Retinal vascular caliber;
KIRP	cis	rs12643440	0.538	rs1522079	chr4:17134960	A/G	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26437306	chr5:38501577	LIFR	0.39	6.3	0.37	1.34e-9	Migraine with aura;
KIRP	cis	rs7520050	0.966	rs785464	chr1:46523089	T/C	cg03146154	chr1:46216737	IPP	-0.41	-5.39	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2944591	0.505	rs2004202	chr2:233790289	C/G	cg11972305	chr2:233791962	NGEF	-0.48	-7.18	-0.42	8.42e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04016957	chr4:1044486	NA	0.45	5.81	0.35	1.93e-8	Recombination rate (males);
KIRP	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg04731861	chr2:219085781	ARPC2	0.27	6.32	0.37	1.24e-9	Colorectal cancer;
KIRP	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.67	9.28	0.51	9.38e-18	Coronary artery disease;
KIRP	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.86	-0.73	6.45e-43	Height;
KIRP	cis	rs710216	0.957	rs2886876	chr1:43432741	A/G	cg03128534	chr1:43423976	SLC2A1	-0.48	-4.95	-0.3	1.37e-6	Red cell distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12571005	chr2:202316370	STRADB;TRAK2	0.5	6.12	0.36	3.57e-9	Parkinson's disease;
KIRP	cis	rs10073892	0.660	rs10479239	chr5:101947155	A/C	cg19774478	chr5:101632501	SLCO4C1	-0.56	-5.51	-0.33	9e-8	Cognitive decline (age-related);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg26882168	chr4:128819932	PLK4	0.4	6.47	0.38	5.35e-10	C-reactive protein;
KIRP	cis	rs7851660	0.809	rs3808893	chr9:100663745	C/T	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-13.22	-0.64	1.72e-30	Blood metabolite levels;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg01763666	chr17:80159506	CCDC57	0.37	5.07	0.31	7.72e-7	Life satisfaction;
KIRP	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.96	10.58	0.56	8.27e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.65e-30	Eye color traits;
KIRP	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg26441486	chr22:50317300	CRELD2	0.49	7.07	0.41	1.56e-11	Schizophrenia;
KIRP	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.73	11.36	0.59	2.47e-24	Resting heart rate;
KIRP	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg05425664	chr17:57184151	TRIM37	0.53	6.12	0.36	3.61e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05965430	chr12:49962171	MCRS1	0.48	6.39	0.38	8.23e-10	Parkinson's disease;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg07402062	chr16:89894098	SPIRE2	0.3	6.17	0.37	2.78e-9	Vitiligo;
KIRP	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg21285383	chr16:89894308	SPIRE2	-0.31	-5.83	-0.35	1.75e-8	Vitiligo;
KIRP	trans	rs10152811	0.714	rs17143	chr15:86795717	A/C	cg09774649	chr4:8476536	C4orf23	-0.57	-6.41	-0.38	7.34e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9603616	1.000	rs7993214	chr13:40350912	T/C	cg26701198	chr13:40229707	COG6	0.45	5.03	0.31	9.57e-7	Rheumatoid arthritis;
KIRP	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.56	6.58	0.39	2.89e-10	Mean corpuscular volume;
KIRP	cis	rs57994353	0.540	rs12379380	chr9:139279981	C/T	cg14169450	chr9:139327907	INPP5E	0.43	5.53	0.33	8.16e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.63	9.09	0.5	3.44e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6956675	1.000	rs1967430	chr7:62599308	C/T	cg08930214	chr7:62859557	LOC100287834	0.51	5.84	0.35	1.67e-8	Obesity-related traits;
KIRP	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06481639	chr22:41940642	POLR3H	0.74	7.74	0.44	2.5e-13	Vitiligo;
KIRP	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.84	0.45	1.41e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6580083	1.000	rs10068038	chr5:153867738	C/A	cg21964928	chr5:153872958	NA	0.42	5.79	0.35	2.19e-8	QRS duration;
KIRP	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg02527881	chr3:46936655	PTH1R	-0.38	-5.39	-0.32	1.68e-7	Colorectal cancer;
KIRP	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.76	-9.26	-0.51	1.04e-17	Response to antipsychotic treatment;
KIRP	cis	rs9972944	0.756	rs9899781	chr17:63769384	C/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.14e-13	Total body bone mineral density;
KIRP	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.46	5.65	0.34	4.5e-8	Aortic root size;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.23	-24.97	-0.85	2.1e-69	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77633900	0.772	rs283796	chr15:76774105	G/A	cg21673338	chr15:77095150	SCAPER	-0.58	-4.87	-0.3	2.04e-6	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs35740288	0.731	rs12913556	chr15:86102196	C/T	cg17133734	chr15:86042851	AKAP13	-0.53	-5.82	-0.35	1.81e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.43	0.33	1.37e-7	Total cholesterol levels;
KIRP	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg22029157	chr1:209979665	IRF6	0.39	6.11	0.36	3.93e-9	Monobrow;
KIRP	cis	rs3752645	0.764	rs76214791	chr7:106689421	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-5.2	-0.31	4.19e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg06618935	chr21:46677482	NA	-0.47	-5.89	-0.35	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4953911	0.893	rs10202994	chr2:135052633	A/G	cg18482303	chr2:135041380	MGAT5	-0.29	-5.43	-0.33	1.34e-7	Multiple sclerosis (severity);
KIRP	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1850744	0.609	rs2037315	chr4:9722408	C/G	cg15442990	chr4:9534313	NA	0.84	5.74	0.34	2.76e-8	Economic and political preferences;
KIRP	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.9	15.03	0.69	1.2e-36	Breast cancer;
KIRP	cis	rs795484	0.926	rs353893	chr12:118631765	T/C	cg16572268	chr12:118583242	PEBP1	-0.38	-4.96	-0.3	1.34e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
KIRP	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17252645	chr8:143867129	LY6D	-0.54	-9.82	-0.53	2.07e-19	Urinary tract infection frequency;
KIRP	cis	rs710216	0.763	rs9438964	chr1:43443742	C/T	cg03128534	chr1:43423976	SLC2A1	0.52	4.9	0.3	1.77e-6	Red cell distribution width;
KIRP	cis	rs2456568	0.564	rs7119708	chr11:93626641	T/C	cg17595323	chr11:93583763	C11orf90	0.31	5.47	0.33	1.13e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7551222	0.752	rs4252694	chr1:204499056	A/G	cg20240347	chr1:204465584	NA	-0.45	-8.73	-0.49	3.9e-16	Schizophrenia;
KIRP	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.69	-6.26	-0.37	1.69e-9	Menarche (age at onset);
KIRP	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg10326726	chr10:51549505	MSMB	-0.56	-8.22	-0.46	1.19e-14	Prostate-specific antigen levels;
KIRP	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.81	-13.94	-0.66	6.04e-33	Brugada syndrome;
KIRP	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.37	0.38	9.17e-10	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	6.01e-16	Bladder cancer;
KIRP	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.57	-6.94	-0.4	3.47e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7828089	1.000	rs7838127	chr8:22264561	G/A	cg13512537	chr8:22265999	SLC39A14	-0.46	-6.22	-0.37	2.11e-9	Verbal declarative memory;
KIRP	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	0.99	18.16	0.76	2.46e-47	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.82	12.88	0.63	2.36e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-6.04	-0.36	5.57e-9	Red blood cell count;
KIRP	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	0.69	6.45	0.38	5.84e-10	Obesity-related traits;
KIRP	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg19847130	chr8:10466454	RP1L1	0.43	6.38	0.38	8.62e-10	Joint mobility (Beighton score);
KIRP	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.42	-6.2	-0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg00405596	chr8:11794950	NA	0.4	5.11	0.31	6.59e-7	Morning vs. evening chronotype;
KIRP	cis	rs6693567	0.526	rs3818978	chr1:150266338	T/A	cg07843065	chr1:150265600	MRPS21	-0.44	-6.14	-0.36	3.26e-9	Migraine;
KIRP	cis	rs4791641	0.756	rs1132554	chr17:8173767	C/T	cg06726167	chr17:8076949	TMEM107	0.45	5.49	0.33	1.01e-7	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
KIRP	cis	rs7904368	0.806	rs7899923	chr10:16857394	G/A	cg14835575	chr10:16859367	RSU1	0.85	10.12	0.54	2.42e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs77633900	0.772	rs157760	chr15:76800260	A/G	cg21673338	chr15:77095150	SCAPER	-0.63	-5.82	-0.35	1.87e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.83	0.35	1.74e-8	Lung cancer;
KIRP	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.64	-8.32	-0.47	5.91e-15	IgG glycosylation;
KIRP	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.83	-0.4	6.78e-11	Body mass index;
KIRP	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg07843065	chr1:150265600	MRPS21	0.43	6.0	0.36	7.03e-9	Migraine;
KIRP	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.86	-15.51	-0.7	2.69e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs45544231	0.544	rs1123428	chr16:52577835	A/T	cg09051775	chr16:52580266	TOX3	0.38	5.3	0.32	2.52e-7	Restless legs syndrome;
KIRP	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.47	0.38	5.35e-10	Putamen volume;
KIRP	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.56	-7.11	-0.41	1.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-7.44	-0.43	1.7e-12	Neuroticism;
KIRP	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.99	0.41	2.65e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.91	0.35	1.13e-8	Total cholesterol levels;
KIRP	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg03714773	chr7:91764589	CYP51A1	0.42	6.33	0.37	1.16e-9	Breast cancer;
KIRP	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.62	7.68	0.44	3.87e-13	Post bronchodilator FEV1;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg08662619	chr6:150070041	PCMT1	0.37	6.01	0.36	6.56e-9	Lung cancer;
KIRP	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg23625390	chr15:77176239	SCAPER	0.52	7.2	0.42	7.46e-12	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25928603	chr2:200323017	SATB2	0.42	6.12	0.36	3.71e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg16306078	chr6:126000798	NA	0.26	4.93	0.3	1.53e-6	Endometrial cancer;
KIRP	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.38	-0.47	4.06e-15	Platelet count;
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.5	-0.43	1.17e-12	Life satisfaction;
KIRP	cis	rs4664304	0.531	rs11691616	chr2:160758680	G/C	cg23995753	chr2:160760732	LY75	-0.42	-5.45	-0.33	1.2e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg20673091	chr1:2541236	MMEL1	-0.69	-10.69	-0.56	3.7e-22	Ulcerative colitis;
KIRP	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.69	-0.44	3.54e-13	Mood instability;
KIRP	cis	rs6601327	0.602	rs35431433	chr8:9660621	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.91	-0.3	1.63e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.76	-9.83	-0.53	1.96e-19	Aortic root size;
KIRP	cis	rs7116495	1.000	rs10751193	chr11:71785356	A/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg07741184	chr6:167504864	NA	-0.24	-6.4	-0.38	7.85e-10	Crohn's disease;
KIRP	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg12131826	chr15:77904385	NA	0.46	6.21	0.37	2.22e-9	Type 2 diabetes;
KIRP	cis	rs6684514	1.000	rs12023438	chr1:156254358	A/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	9.06	0.5	4.17e-17	Resting heart rate;
KIRP	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg08975724	chr8:8085496	FLJ10661	0.51	6.34	0.37	1.1e-9	Retinal vascular caliber;
KIRP	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.63	-7.63	-0.44	5.28e-13	Menarche (age at onset);
KIRP	cis	rs9302635	0.515	rs36033103	chr16:72142038	G/T	cg09488090	chr16:72319766	NA	-0.59	-5.34	-0.32	2.1e-7	Blood protein levels;
KIRP	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Recalcitrant atopic dermatitis;
KIRP	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.95	12.04	0.61	1.44e-26	Obesity;Body mass index;
KIRP	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	7.49	0.43	1.25e-12	Neuroticism;
KIRP	cis	rs80207740	1.000	rs80207740	chr8:21779937	C/G	cg17168535	chr8:21777572	XPO7	0.72	6.39	0.38	8.06e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.59	-6.33	-0.37	1.13e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg06766960	chr11:133703094	NA	-0.67	-8.29	-0.47	7.58e-15	Childhood ear infection;
KIRP	cis	rs6087990	1.000	rs2018002	chr20:31351623	A/T	cg13636640	chr20:31349939	DNMT3B	1.03	19.31	0.78	3.54e-51	Ulcerative colitis;
KIRP	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.45	-0.52	2.87e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.3	-0.32	2.61e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21659725	chr3:3221576	CRBN	0.7	9.69	0.53	4.98e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.86	0.3	2.12e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.49	-5.88	-0.35	1.36e-8	Coronary artery disease;
KIRP	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.53	5.97	0.36	8.37e-9	Alzheimer's disease (late onset);
KIRP	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-5.91	-0.35	1.11e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.51	6.9	0.4	4.4e-11	Testicular germ cell tumor;
KIRP	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.83	-9.02	-0.5	5.59e-17	Asthma;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04294563	chr19:7694202	LOC100131801;XAB2	0.58	6.32	0.37	1.23e-9	Lung cancer in ever smokers;
KIRP	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg15103426	chr22:29168792	CCDC117	0.53	5.37	0.32	1.83e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	trans	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.2	-0.37	2.4e-9	Neuroticism;
KIRP	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.68	0.39	1.61e-10	Colorectal cancer;
KIRP	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg10755058	chr3:40428713	ENTPD3	0.38	5.28	0.32	2.78e-7	Renal cell carcinoma;
KIRP	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg09408571	chr1:101003634	GPR88	-0.24	-5.52	-0.33	8.56e-8	Monocyte count;
KIRP	cis	rs4594175	0.962	rs72688734	chr14:51634618	T/C	cg23942311	chr14:51606299	NA	0.52	6.84	0.4	6.26e-11	Cancer;
KIRP	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.5	-6.03	-0.36	5.97e-9	Response to antidepressants in depression;
KIRP	cis	rs7180079	0.620	rs563766	chr15:64862910	G/T	cg15337035	chr15:64978493	NA	-0.46	-5.02	-0.3	9.8e-7	Monocyte count;
KIRP	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.43	5.56	0.33	6.85e-8	Blood metabolite levels;
KIRP	cis	rs7870753	0.730	rs6479312	chr9:99167919	C/T	cg25260653	chr9:99212216	HABP4	-0.52	-5.73	-0.34	2.94e-8	Height;
KIRP	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.43	6.6	0.39	2.57e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg21186296	chr8:27182909	PTK2B	0.48	6.09	0.36	4.24e-9	Neuroticism;
KIRP	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.87	-0.3	2.01e-6	Blood metabolite levels;
KIRP	cis	rs75884327	0.584	rs2836901	chr21:40499194	A/G	cg11644478	chr21:40555479	PSMG1	0.65	5.66	0.34	4.18e-8	Daytime sleep phenotypes;
KIRP	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.51	6.43	0.38	6.47e-10	Total body bone mineral density;
KIRP	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.88	13.78	0.66	2.04e-32	Mean corpuscular volume;
KIRP	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg04519387	chr11:65556438	OVOL1	0.34	5.05	0.31	8.45e-7	Acne (severe);
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg07701084	chr6:150067640	NUP43	0.69	9.89	0.53	1.26e-19	Lung cancer;
KIRP	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg08501292	chr6:25962987	TRIM38	0.97	7.34	0.42	3.19e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg06204229	chr3:52865917	ITIH4	0.47	5.42	0.33	1.39e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg21252483	chr19:49399788	TULP2	-0.49	-6.39	-0.38	8.12e-10	Red cell distribution width;
KIRP	cis	rs12447804	0.871	rs12928392	chr16:58070964	T/A	cg03859792	chr16:58121049	NA	0.47	6.25	0.37	1.77e-9	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	7.01	0.41	2.34e-11	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.4	7.83	0.45	1.48e-13	Height;
KIRP	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.66	8.81	0.49	2.28e-16	Bladder cancer;
KIRP	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.11	-0.41	1.26e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.46	-5.69	-0.34	3.51e-8	Coronary artery disease;
KIRP	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.35	-0.42	2.89e-12	Alzheimer's disease;
KIRP	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21985251	chr5:1112346	SLC12A7	0.48	6.15	0.37	3.09e-9	Parkinson's disease;
KIRP	cis	rs9549260	0.564	rs7997896	chr13:41268823	T/A	cg21288729	chr13:41239152	FOXO1	0.57	7.49	0.43	1.26e-12	Red blood cell count;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06966887	chr5:443603	EXOC3;C5orf55	0.59	7.15	0.41	1.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12580194	0.593	rs7314118	chr12:55737403	A/C	cg19537932	chr12:55886519	OR6C68	-0.48	-6.35	-0.38	1.03e-9	Cancer;
KIRP	cis	rs986417	0.901	rs9743622	chr14:61037163	A/T	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs2273669	0.667	rs12204576	chr6:109318843	A/G	cg05315195	chr6:109294784	ARMC2	-0.62	-6.19	-0.37	2.5e-9	Prostate cancer;
KIRP	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.76	0.71	3.8e-39	Chronic sinus infection;
KIRP	cis	rs6977660	0.714	rs10950753	chr7:19817302	G/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg20243544	chr17:37824526	PNMT	0.52	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs11583043	0.546	rs6688545	chr1:101590335	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.07	0.31	7.7300000000000005e-07	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.19	0.37	2.53e-9	Breast cancer;
KIRP	cis	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-5.62	-0.34	5.22e-8	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3935685	0.874	rs4886898	chr15:78004743	T/C	cg25212270	chr15:78015279	NA	0.59	7.74	0.44	2.52e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg16988262	chr1:15930761	NA	0.4	5.11	0.31	6.32e-7	Systolic blood pressure;
KIRP	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.94	13.99	0.67	4.25e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.91	14.28	0.67	4.07e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg12568669	chr8:11666485	FDFT1	-0.26	-5.79	-0.35	2.15e-8	Morning vs. evening chronotype;
KIRP	trans	rs7939886	0.920	rs7934132	chr11:55942463	T/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	0.91	10.25	0.55	9.11e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg08901578	chr4:187885870	NA	-0.51	-7.95	-0.45	6.75e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg25486957	chr4:152246857	NA	-0.45	-5.45	-0.33	1.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2278796	0.558	rs35288741	chr1:204928155	A/G	cg04862289	chr1:204966208	NFASC	0.43	5.84	0.35	1.67e-8	Mean platelet volume;
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.51	0.33	9.25e-8	Life satisfaction;
KIRP	cis	rs10073892	1.000	rs62371013	chr5:101800313	A/G	cg19774478	chr5:101632501	SLCO4C1	0.61	6.41	0.38	7.19e-10	Cognitive decline (age-related);
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13047869	chr3:10149882	C3orf24	0.66	5.55	0.33	7.29e-8	Alzheimer's disease;
KIRP	cis	rs4356932	0.691	rs4859581	chr4:76906974	A/G	cg00809888	chr4:76862425	NAAA	0.51	7.13	0.41	1.1e-11	Blood protein levels;
KIRP	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.71	8.98	0.5	7.23e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg26205652	chr12:48591994	NA	0.78	10.49	0.56	1.58e-21	Longevity (90 years and older);
KIRP	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.61	8.13	0.46	2.06e-14	Retinal vascular caliber;
KIRP	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg20302533	chr7:39170763	POU6F2	0.26	5.18	0.31	4.7e-7	IgG glycosylation;
KIRP	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Urate levels;
KIRP	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.58	-0.44	7e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4908768	1.000	rs12122666	chr1:8741438	A/C	cg03610117	chr1:8450231	RERE	0.49	5.06	0.31	8.24e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.83	-15.06	-0.69	8.88e-37	Body mass index;
KIRP	cis	rs7116495	1.000	rs12272213	chr11:71816219	G/A	cg18441811	chr11:71824068	C11orf51	0.6	4.87	0.3	2.01e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7224685	0.569	rs12452393	chr17:3985427	G/A	cg09597638	chr17:3907349	NA	0.55	5.63	0.34	5e-8	Type 2 diabetes;
KIRP	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.25	-6.97	-0.41	2.88e-11	Type 2 diabetes;
KIRP	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.96	-11.89	-0.6	4.82e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.98	18.7	0.77	3.67e-49	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg24631222	chr15:78858424	CHRNA5	0.76	9.09	0.5	3.34e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg12315302	chr6:26189340	HIST1H4D	0.86	6.07	0.36	4.77e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.64	-0.52	7.16e-19	Total body bone mineral density;
KIRP	cis	rs13401104	0.732	rs11692797	chr2:237110032	C/A	cg19324714	chr2:237145437	ASB18	0.47	4.93	0.3	1.51e-6	Educational attainment;
KIRP	cis	rs7582720	0.945	rs72932722	chr2:203647598	C/A	cg08076091	chr2:203926405	NBEAL1	0.83	8.27	0.47	8.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg15556689	chr8:8085844	FLJ10661	0.65	8.21	0.46	1.27e-14	Retinal vascular caliber;
KIRP	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.89	10.02	0.54	5.03e-20	Corneal astigmatism;
KIRP	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.75	-10.44	-0.55	2.36e-21	Dental caries;
KIRP	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11987759	chr7:65425863	GUSB	0.5	6.47	0.38	5.22e-10	Aortic root size;
KIRP	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg13409248	chr3:40428643	ENTPD3	0.38	4.96	0.3	1.34e-6	Renal cell carcinoma;
KIRP	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg15358701	chr1:161410459	NA	-0.68	-6.31	-0.37	1.28e-9	Rheumatoid arthritis;
KIRP	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg08662619	chr6:150070041	PCMT1	0.33	5.14	0.31	5.5e-7	Lung cancer;
KIRP	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.76	10.93	0.57	6.53e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2742417	1.000	rs2742369	chr3:45754487	C/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04876069	chr12:132293656	NA	-0.52	-6.91	-0.4	4.22e-11	Migraine;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.37	-5.56	-0.33	6.94e-8	Lymphocyte counts;
KIRP	cis	rs56116382	0.668	rs4688759	chr3:50008118	T/C	cg00383909	chr3:49044727	WDR6	0.93	7.65	0.44	4.43e-13	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	5.99	0.36	7.33e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.65	-8.22	-0.46	1.2e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs16828019	0.704	rs12031277	chr1:41491801	A/G	cg03387723	chr1:41708464	SCMH1	-0.76	-6.21	-0.37	2.23e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12022452	0.556	rs12037288	chr1:40996297	G/A	cg25568243	chr1:40974465	DEM1	0.53	5.73	0.34	2.9e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg00999904	chr2:3704751	ALLC	-0.65	-6.84	-0.4	6.14e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg21204522	chr6:27730016	NA	-0.74	-5.45	-0.33	1.19e-7	Depression;
KIRP	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg27205649	chr11:78285834	NARS2	-0.68	-8.89	-0.49	1.35e-16	Alzheimer's disease (survival time);
KIRP	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.53	-0.43	9.6e-13	Type 2 diabetes;
KIRP	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.71	9.19	0.51	1.71e-17	Platelet count;
KIRP	cis	rs714515	0.868	rs10752944	chr1:172363524	C/T	cg01573306	chr1:172330400	DNM3	0.4	5.09	0.31	7.17e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.39	4.95	0.3	1.35e-6	Lung cancer;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg27287166	chr8:71315034	NCOA2	0.53	6.39	0.38	8.23e-10	Beard thickness;
KIRP	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.23	0.51	1.32e-17	Bladder cancer;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.68	-8.54	-0.48	1.45e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg24644049	chr4:85504048	CDS1	0.96	6.32	0.37	1.19e-9	Skin colour saturation;
KIRP	cis	rs4919044	0.866	rs4919592	chr10:94823413	G/A	cg05127821	chr10:94822908	CYP26C1	-0.92	-6.71	-0.39	1.36e-10	Coronary artery disease;
KIRP	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg17279839	chr7:150038598	RARRES2	0.46	6.11	0.36	3.81e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.81	10.78	0.57	1.93e-22	Aortic root size;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02891801	chr12:6472782	SCNN1A	0.44	6.73	0.39	1.18e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.06	-0.41	1.65e-11	Bladder cancer;
KIRP	trans	rs6601327	0.670	rs13259398	chr8:9659935	T/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.39	-0.38	8.17e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6929812	0.967	rs7509	chr6:27418847	T/G	cg03332623	chr6:27441972	ZNF184	-0.37	-5.2	-0.31	4.28e-7	Neuroticism (multi-trait analysis);
KIRP	cis	rs1978968	1.000	rs1076541	chr22:18440026	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.69	-7.94	-0.45	7.4e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs397969	0.646	rs850622	chr17:19837536	C/T	cg04132472	chr17:19861366	AKAP10	0.47	5.62	0.34	5.04e-8	Platelet count;
KIRP	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.13	0.36	3.53e-9	Height;
KIRP	cis	rs2041895	0.527	rs10861681	chr12:107334262	C/T	cg21360079	chr12:107162445	NA	-0.44	-4.84	-0.3	2.25e-6	Glaucoma (low intraocular pressure);
KIRP	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg15128208	chr22:42549153	NA	0.73	7.84	0.45	1.39e-13	Birth weight;
KIRP	cis	rs12949688	0.967	rs12451753	chr17:55822214	T/A	cg12582317	chr17:55822272	NA	0.64	10.64	0.56	5.22e-22	Schizophrenia;
KIRP	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg02524346	chr8:600233	NA	-0.96	-5.82	-0.35	1.83e-8	IgG glycosylation;
KIRP	cis	rs1355223	0.573	rs1097403	chr11:34730083	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.55	6.34	0.37	1.09e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.54	0.38	3.51e-10	Colorectal cancer;
KIRP	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-0.88	-9.72	-0.53	4.23e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.52	6.78	0.4	8.92e-11	HDL cholesterol;
KIRP	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg11970804	chr8:8084126	NA	-0.39	-4.95	-0.3	1.36e-6	Neuroticism;
KIRP	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.81	-14.12	-0.67	1.48e-33	Post bronchodilator FEV1;
KIRP	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	7.46	0.43	1.45e-12	Acne (severe);
KIRP	cis	rs4356932	1.000	rs6532121	chr4:76962606	A/T	cg19388996	chr4:76862389	NAAA	-0.4	-4.94	-0.3	1.48e-6	Blood protein levels;
KIRP	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06529459	chr11:67397595	NUDT8	0.48	6.42	0.38	6.91e-10	Parkinson's disease;
KIRP	cis	rs9633740	0.685	rs10749608	chr10:82243986	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	5.79	0.35	2.11e-8	Post bronchodilator FEV1;
KIRP	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg05315796	chr3:52349193	DNAH1	0.35	5.3	0.32	2.57e-7	Bipolar disorder;
KIRP	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.25	-0.42	5.41e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	7.75	0.44	2.37e-13	Electroencephalogram traits;
KIRP	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-5.54	-0.33	7.91e-8	Aortic root size;
KIRP	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.46	7.08	0.41	1.49e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.75	5.79	0.35	2.16e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.81	-11.95	-0.61	2.95e-26	Asthma;
KIRP	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00166722	chr3:10149974	C3orf24	0.49	5.02	0.31	9.7e-7	Alzheimer's disease;
KIRP	cis	rs2224391	0.590	rs72815603	chr6:5278701	A/C	cg24031505	chr6:4779396	CDYL	-0.61	-5.03	-0.31	9.67e-7	Height;
KIRP	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-5.24	-0.32	3.41e-7	Alzheimer's disease (late onset);
KIRP	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.09	0.5	3.32e-17	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.58	-9.26	-0.51	1.01e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs76793172	1.000	rs7249022	chr19:46354558	G/A	cg00442267	chr19:46317840	RSPH6A	-0.7	-5.98	-0.36	7.61e-9	Eosinophil counts;
KIRP	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg24130564	chr14:104152367	KLC1	-0.53	-7.14	-0.41	1.03e-11	Body mass index;
KIRP	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.32	0.37	1.22e-9	Neuroticism;
KIRP	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg21858823	chr1:15850916	CASP9	0.54	5.75	0.34	2.63e-8	Systolic blood pressure;
KIRP	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs7084783	0.519	rs10879	chr10:105354556	A/G	cg00126946	chr10:105363258	SH3PXD2A	-0.41	-5.05	-0.31	8.56e-7	Fear of pain;
KIRP	cis	rs174775	0.513	rs2283849	chr22:29743482	T/C	cg07256473	chr22:29710276	RASL10A	-0.45	-7.04	-0.41	1.86e-11	Immature fraction of reticulocytes;
KIRP	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.26	-0.32	3.06e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg06740227	chr12:86229804	RASSF9	0.43	5.43	0.33	1.34e-7	Major depressive disorder;
KIRP	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6545883	0.965	rs9989775	chr2:61761774	A/G	cg15711740	chr2:61764176	XPO1	-0.62	-8.5	-0.48	1.87e-15	Tuberculosis;
KIRP	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.8	13.16	0.64	2.69e-30	Vitiligo;
KIRP	cis	rs7937890	1.000	rs2915402	chr11:14377628	C/G	cg19336497	chr11:14380999	RRAS2	0.35	5.03	0.31	9.32e-7	Mitochondrial DNA levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17832277	chr13:103249000	TPP2	0.72	6.05	0.36	5.25e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.79	-12.29	-0.62	2.23e-27	Lung cancer;
KIRP	cis	rs10875746	0.904	rs11168422	chr12:48519505	T/G	cg26205652	chr12:48591994	NA	0.76	10.24	0.55	9.81e-21	Longevity (90 years and older);
KIRP	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.59	-8.36	-0.47	4.66e-15	Prostate cancer;
KIRP	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.61	-8.27	-0.47	8.48e-15	Aortic root size;
KIRP	cis	rs71636778	0.543	rs75305560	chr1:27242521	T/G	cg12203394	chr1:27248618	NUDC	0.61	5.37	0.32	1.82e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	1.29	10.43	0.55	2.48e-21	Prostate cancer;
KIRP	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.59	7.49	0.43	1.23e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.06	-0.5	4.2e-17	Mean corpuscular volume;
KIRP	cis	rs6088813	1.000	rs6142376	chr20:33992761	T/A	cg14752227	chr20:34000481	UQCC	-0.51	-6.61	-0.39	2.37e-10	Height;
KIRP	cis	rs12143943	0.966	rs3789047	chr1:204586184	A/G	cg20240347	chr1:204465584	NA	-0.35	-6.43	-0.38	6.51e-10	Cognitive performance;
KIRP	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26002218	chr14:103986227	CKB	0.32	6.68	0.39	1.54e-10	Body mass index;
KIRP	cis	rs7267005	0.661	rs17093134	chr20:34429740	A/G	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg13482628	chr17:19912719	NA	-0.53	-6.91	-0.4	4.08e-11	Schizophrenia;
KIRP	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.09	-0.31	7.03e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.92	12.29	0.62	2.13e-27	Cognitive function;
KIRP	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg11569703	chr11:65557185	OVOL1	-0.74	-13.7	-0.66	3.81e-32	Acne (severe);
KIRP	cis	rs7715806	0.517	rs253392	chr5:74928883	G/T	cg19683494	chr5:74908142	NA	-0.55	-5.98	-0.36	7.92e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.64	-8.89	-0.49	1.33e-16	Breast cancer;
KIRP	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg18404041	chr3:52824283	ITIH1	0.4	5.21	0.32	4.07e-7	Schizophrenia;
KIRP	cis	rs9303542	0.625	rs7222242	chr17:46565486	C/A	cg04904318	chr17:46607828	HOXB1	-0.56	-6.04	-0.36	5.77e-9	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs2275620	0.903	rs1341163	chr10:96810552	T/C	cg09036531	chr10:96991505	NA	-0.51	-6.53	-0.38	3.64e-10	Gout;
KIRP	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	8.09	0.46	2.81e-14	IgG glycosylation;
KIRP	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.45	7.31	0.42	3.74e-12	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27527736	chr17:36507744	SOCS7	0.5	6.18	0.37	2.62e-9	Parkinson's disease;
KIRP	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.79	8.08	0.46	2.95e-14	Hip geometry;
KIRP	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg18132916	chr6:79620363	NA	-0.41	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.12	-0.54	2.34e-20	Hemoglobin concentration;
KIRP	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.14	0.36	3.33e-9	Putamen volume;
KIRP	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg04990556	chr1:26633338	UBXN11	-0.6	-7.42	-0.43	1.95e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.19	-0.37	2.44e-9	IgG glycosylation;
KIRP	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.84	-8.79	-0.49	2.69e-16	Body mass index;
KIRP	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg11833968	chr6:79620685	NA	-0.37	-5.29	-0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.43	6.51	0.38	4.17e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.26	-16.91	-0.73	4.36e-43	Breast cancer;
KIRP	cis	rs11203032	0.831	rs10887921	chr10:90925667	T/G	cg16672925	chr10:90967113	CH25H	0.73	7.26	0.42	5.11e-12	Heart failure;
KIRP	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg11317459	chr13:21872234	NA	-0.87	-10.21	-0.55	1.25e-20	White matter hyperintensity burden;
KIRP	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg17143192	chr8:8559678	CLDN23	0.71	8.21	0.46	1.23e-14	Obesity-related traits;
KIRP	cis	rs1775715	0.870	rs10827003	chr10:32266216	A/G	cg14930904	chr10:32216787	ARHGAP12	0.37	4.86	0.3	2.08e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11520554	chr15:80216034	C15orf37;ST20	0.54	7.21	0.42	6.92e-12	Parkinson's disease;
KIRP	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg02461776	chr11:598696	PHRF1	0.61	6.66	0.39	1.76e-10	Systemic lupus erythematosus;
KIRP	cis	rs6504950	1.000	rs9902718	chr17:53061622	A/G	cg26251398	chr17:52985966	TOM1L1	0.37	5.13	0.31	5.82e-7	Breast cancer;
KIRP	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg11833968	chr6:79620685	NA	-0.45	-6.93	-0.4	3.74e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.52	-0.43	1.01e-12	Myopia (pathological);
KIRP	cis	rs6445967	1.000	rs12688	chr3:58305079	T/C	cg16569813	chr3:58235849	ABHD6	-0.33	-4.95	-0.3	1.38e-6	Platelet count;
KIRP	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-5.52	-0.33	8.75e-8	Neuroticism;
KIRP	cis	rs4332428	1.000	rs12774134	chr10:4963327	C/T	cg19648686	chr10:5044992	AKR1C2	-0.82	-6.8	-0.4	7.79e-11	Height;
KIRP	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.91	0.49	1.2e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	0.88	14.46	0.68	1.05e-34	Multiple myeloma;
KIRP	cis	rs11203032	1.000	rs11203032	chr10:90964614	T/G	cg16672925	chr10:90967113	CH25H	0.85	8.85	0.49	1.73e-16	Heart failure;
KIRP	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.59	7.57	0.43	7.69e-13	Endometrial cancer;
KIRP	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-4.99	-0.3	1.14e-6	Educational attainment;
KIRP	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.91	0.3	1.65e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs490234	0.702	rs10986788	chr9:128303942	G/C	cg14078157	chr9:128172775	NA	-0.62	-7.48	-0.43	1.3e-12	Mean arterial pressure;
KIRP	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.48e-9	Menopause (age at onset);
KIRP	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg12315302	chr6:26189340	HIST1H4D	0.97	6.83	0.4	6.66e-11	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6601450	0.519	rs34906836	chr8:10288992	C/A	cg06636001	chr8:8085503	FLJ10661	0.5	6.57	0.39	2.96e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg17376030	chr22:41985996	PMM1	-0.54	-6.56	-0.39	3.09e-10	Vitiligo;
KIRP	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.77	9.62	0.52	8.69e-19	Breast cancer;
KIRP	cis	rs9815354	0.812	rs116393551	chr3:41865476	G/A	cg03022575	chr3:42003672	ULK4	0.75	7.06	0.41	1.72e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.78	0.6	1.1e-25	Longevity;
KIRP	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06505273	chr16:24850292	NA	-0.36	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-6.66	-0.39	1.76e-10	Obesity-related traits;
KIRP	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.52	-6.03	-0.36	5.86e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.2e-24	Cognitive test performance;
KIRP	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-8.52	-0.48	1.57e-15	Mean corpuscular volume;
KIRP	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	11.54	0.59	6.4e-25	Response to antipsychotic treatment;
KIRP	cis	rs11583043	0.546	rs35363849	chr1:101591293	A/G	cg17443007	chr1:101659419	NA	0.42	5.88	0.35	1.36e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg19847130	chr8:10466454	RP1L1	0.38	5.74	0.34	2.71e-8	Retinal vascular caliber;
KIRP	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.71e-9	Colorectal cancer;
KIRP	cis	rs7520050	0.931	rs11211213	chr1:46342517	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.85	10.68	0.56	3.98e-22	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg16898833	chr6:26189333	HIST1H4D	0.86	5.62	0.34	5.25e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.51	7.34	0.42	3.08e-12	Testicular germ cell tumor;
KIRP	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-5.74	-0.34	2.77e-8	Personality dimensions;
KIRP	cis	rs500492	0.542	rs416055	chr16:1074931	G/A	cg03495660	chr16:1074500	NA	0.55	6.06	0.36	5.01e-9	Polycystic ovary syndrome;
KIRP	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg11839771	chr15:80205821	ST20	-0.43	-6.4	-0.38	7.67e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.4	-0.55	3.23e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg27205649	chr11:78285834	NARS2	-0.67	-7.64	-0.44	4.76e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg05304507	chr6:116381966	FRK	0.21	5.54	0.33	7.84e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7659604	0.517	rs55989500	chr4:122682155	C/T	cg05802129	chr4:122689817	NA	-0.66	-7.51	-0.43	1.11e-12	Type 2 diabetes;
KIRP	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.07	0.58	2.25e-23	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9653442	0.545	rs11123810	chr2:100759285	T/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.4	-0.33	1.61e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7578199	0.886	rs35614125	chr2:242374215	C/T	cg01632474	chr2:242799312	PDCD1	0.38	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg19847130	chr8:10466454	RP1L1	-0.4	-5.53	-0.33	8.17e-8	Retinal vascular caliber;
KIRP	cis	rs4561483	0.583	rs11645213	chr16:11942924	C/A	cg08843971	chr16:11963173	GSPT1	0.51	7.18	0.42	8.24e-12	Testicular germ cell tumor;
KIRP	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg05721485	chr17:44071124	MAPT	-0.55	-7.49	-0.43	1.26e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.49	6.54	0.38	3.49e-10	Schizophrenia;
KIRP	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg22878388	chr2:105853796	NA	0.4	6.38	0.38	8.61e-10	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6504340	0.739	rs1529334	chr17:46671792	C/T	cg04904318	chr17:46607828	HOXB1	0.48	5.46	0.33	1.18e-7	Primary tooth development (number of teeth);
KIRP	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.67	5.36	0.32	1.96e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.8	-0.35	2.04e-8	Bipolar disorder;
KIRP	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.57	-10.58	-0.56	8.15e-22	Cancer (pleiotropy);
KIRP	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	4.97	0.3	1.28e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	0.84	7.52	0.43	1.03e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.9	-11.53	-0.59	7.04e-25	Prostate cancer;
KIRP	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.85	11.51	0.59	8.31e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16720242	chr1:46196138	IPP	-0.43	-6.86	-0.4	5.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.66	-12.44	-0.62	6.87e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg13607699	chr17:42295918	UBTF	0.48	6.03	0.36	6.11e-9	Total body bone mineral density;
KIRP	cis	rs4591494	0.562	rs9843267	chr3:7925938	C/T	cg06740372	chr3:7957779	NA	-0.36	-4.86	-0.3	2.09e-6	Factor VII;
KIRP	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-0.74	-6.18	-0.37	2.58e-9	Metabolite levels (HVA/5-HIAA ratio);
KIRP	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.59	6.17	0.37	2.85e-9	Gut microbiome composition (summer);
KIRP	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg12940439	chr1:67600707	NA	0.37	5.67	0.34	3.96e-8	Psoriasis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16917537	chr7:73098262	DNAJC30;WBSCR22	0.54	7.23	0.42	6.26e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7945705	0.967	rs10840147	chr11:8920704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	6.26	0.37	1.72e-9	Hemoglobin concentration;
KIRP	cis	rs7523050	0.643	rs35907086	chr1:109406625	A/G	cg08274380	chr1:109419600	GPSM2	1.22	10.17	0.54	1.64e-20	Fat distribution (HIV);
KIRP	cis	rs2764980	1.000	rs11251794	chr10:3283931	C/T	cg11630169	chr10:3283847	NA	-0.49	-6.64	-0.39	1.95e-10	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg24881330	chr22:46731750	TRMU	0.65	4.96	0.3	1.31e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg22800045	chr5:56110881	MAP3K1	0.73	7.84	0.45	1.38e-13	Initial pursuit acceleration;
KIRP	cis	rs6681460	1.000	rs1445575	chr1:67052164	C/T	cg02459107	chr1:67143332	SGIP1	0.48	6.97	0.41	2.92e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	1.05	18.56	0.76	1.13e-48	Bone mineral density;
KIRP	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26314531	chr2:26401878	FAM59B	-0.49	-5.03	-0.31	9.45e-7	Gut microbiome composition (summer);
KIRP	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg06521331	chr12:34319734	NA	0.55	6.82	0.4	7.03e-11	Morning vs. evening chronotype;
KIRP	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Melanoma;
KIRP	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.8	10.24	0.55	9.64e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg02175503	chr12:58329896	NA	-0.5	-5.37	-0.32	1.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12949688	0.626	rs11869345	chr17:55839200	T/A	cg12582317	chr17:55822272	NA	0.45	6.39	0.38	8.17e-10	Schizophrenia;
KIRP	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-7.24	-0.42	5.78e-12	Morning vs. evening chronotype;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18883472	chr1:224548495	CNIH4	-0.45	-6.02	-0.36	6.44e-9	Inflammatory biomarkers;
KIRP	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.53	-6.34	-0.37	1.1e-9	Platelet count;
KIRP	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9940149	1.000	rs2239739	chr16:311853	A/G	cg26484247	chr16:313425	ITFG3	0.5	6.6	0.39	2.56e-10	Type 2 diabetes;
KIRP	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.37	-0.43	2.59e-12	Morning vs. evening chronotype;
KIRP	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg00074818	chr8:8560427	CLDN23	0.4	6.33	0.37	1.16e-9	Obesity-related traits;
KIRP	cis	rs7870753	0.838	rs7867618	chr9:99254440	A/G	cg25260653	chr9:99212216	HABP4	0.56	5.96	0.36	8.55e-9	Height;
KIRP	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg17764715	chr19:33622953	WDR88	0.67	8.41	0.47	3.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	1.06	16.88	0.73	5.55e-43	Cognitive function;
KIRP	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.54	-6.93	-0.4	3.65e-11	Blood metabolite levels;
KIRP	cis	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.84	-0.35	1.62e-8	HDL cholesterol;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27441689	chr15:41408716	INO80	0.49	6.6	0.39	2.55e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.78	-10.42	-0.55	2.77e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2733310	0.895	rs1657927	chr15:57139631	C/A	cg13626582	chr15:57592083	LOC283663	-0.24	-5.6	-0.34	5.74e-8	Mean platelet volume;
KIRP	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg23995753	chr2:160760732	LY75	-0.42	-5.72	-0.34	3.09e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg14851346	chr12:38532713	NA	-0.4	-5.02	-0.3	9.78e-7	Bladder cancer;
KIRP	cis	rs2273156	1.000	rs2273158	chr14:35465784	A/T	cg09327582	chr14:35236912	BAZ1A	0.55	5.77	0.35	2.36e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg25251562	chr2:3704773	ALLC	-0.51	-6.0	-0.36	7.07e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6973256	0.897	rs2483507	chr7:133339546	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.47	-0.38	5.13e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09400194	chr10:81107848	PPIF	0.53	6.15	0.37	3.14e-9	Smoking initiation;
KIRP	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-4.85	-0.3	2.2e-6	Testicular germ cell tumor;
KIRP	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg09455208	chr3:40491958	NA	-0.38	-7.01	-0.41	2.25e-11	Renal cell carcinoma;
KIRP	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg22974920	chr21:40686053	BRWD1	0.51	6.16	0.37	2.97e-9	Cognitive function;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.64	-6.42	-0.38	7.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2281845	0.929	rs10920126	chr1:201101081	G/A	cg08885800	chr1:201084119	NA	0.39	5.36	0.32	1.88e-7	Permanent tooth development;
KIRP	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg05784532	chr1:230284198	GALNT2	0.39	5.72	0.34	3.16e-8	Coronary artery disease;
KIRP	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.01	0.3	1.06e-6	Educational attainment;
KIRP	cis	rs4356932	0.935	rs116135606	chr4:76967942	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.43	-5.23	-0.32	3.58e-7	Neuroticism;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg22997113	chr7:27170241	HOXA4	-0.39	-5.42	-0.33	1.41e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg04362960	chr10:104952993	NT5C2	0.44	5.5	0.33	9.39e-8	Waist circumference;Hip circumference;
KIRP	cis	rs1971762	1.000	rs10876480	chr12:54066271	C/G	cg16917193	chr12:54089295	NA	0.68	9.08	0.5	3.77e-17	Height;
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg09264619	chr17:80180166	NA	0.34	4.89	0.3	1.82e-6	Life satisfaction;
KIRP	cis	rs8049040	0.500	rs7188475	chr16:71446358	C/T	cg08717414	chr16:71523259	ZNF19	-0.48	-5.59	-0.34	6.02e-8	Blood protein levels;
KIRP	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.43	-8.3	-0.47	7.1e-15	Educational attainment (years of education);
KIRP	cis	rs2411233	0.837	rs12913060	chr15:39250571	T/G	cg02291532	chr15:39874776	THBS1	0.4	5.13	0.31	5.75e-7	Platelet count;
KIRP	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg04289385	chr6:36355825	ETV7	-0.45	-7.2	-0.42	7.28e-12	Platelet distribution width;
KIRP	cis	rs36715	1.000	rs251212	chr5:127545910	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.86	0.49	1.63e-16	Breast cancer;
KIRP	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.78	-0.35	2.27e-8	Mood instability;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.47	-5.92	-0.35	1.06e-8	Longevity;Endometriosis;
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.8	0.4	8.02e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-9.22	-0.51	1.39e-17	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13728951	chr4:1872230	WHSC1	0.51	6.39	0.38	8.1e-10	Parkinson's disease;
KIRP	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.6	7.81	0.45	1.66e-13	Pulse pressure;
KIRP	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg08890418	chr1:21044141	KIF17	0.34	5.15	0.31	5.41e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg27211696	chr2:191398769	TMEM194B	-0.77	-9.0	-0.5	6.33e-17	Diastolic blood pressure;
KIRP	cis	rs6968419	0.755	rs3173919	chr7:115898177	G/C	cg02561103	chr7:115862891	TES	-0.41	-5.93	-0.35	1e-8	Intraocular pressure;
KIRP	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11987759	chr7:65425863	GUSB	-0.61	-8.13	-0.46	2.07e-14	Aortic root size;
KIRP	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg20965017	chr5:231967	SDHA	-0.6	-6.99	-0.41	2.59e-11	Breast cancer;
KIRP	cis	rs11637445	0.677	rs11631864	chr15:68067762	T/C	cg24579218	chr15:68104479	NA	0.44	6.59	0.39	2.6200000000000003e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg05861140	chr6:150128134	PCMT1	-0.55	-7.78	-0.44	2.06e-13	Lung cancer;
KIRP	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	1.04	13.47	0.65	2.41e-31	Exhaled nitric oxide output;
KIRP	cis	rs4073416	0.542	rs2411815	chr14:66020071	A/T	cg03016385	chr14:66212404	NA	0.51	6.12	0.36	3.61e-9	N-glycan levels;
KIRP	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg22643751	chr7:855365	UNC84A	0.36	5.06	0.31	8.18e-7	Perceived unattractiveness to mosquitoes;
KIRP	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.62	-0.48	8.44e-16	Neuroticism;
KIRP	cis	rs3206736	0.728	rs17800067	chr7:35120352	C/A	cg06685737	chr7:35301730	NA	0.4	5.54	0.33	7.66e-8	Diastolic blood pressure;
KIRP	cis	rs2562152	0.515	rs2562176	chr16:146487	G/C	cg02949481	chr16:131562	MPG	0.87	7.31	0.42	3.77e-12	Glioblastoma;
KIRP	cis	rs580438	0.529	rs6767830	chr3:13437275	T/C	cg10657019	chr3:13328039	NA	-0.49	-6.27	-0.37	1.65e-9	Myringotomy;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13789711	chr9:139743225	PHPT1	-0.49	-6.32	-0.37	1.21e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03424058	chr1:215791864	KCTD3	-0.43	-6.43	-0.38	6.55e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg23682824	chr7:23144976	KLHL7	0.54	6.57	0.39	3.01e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.65	8.05	0.46	3.49e-14	Dilated cardiomyopathy;
KIRP	cis	rs1448094	0.802	rs56391398	chr12:86424114	C/T	cg00310523	chr12:86230176	RASSF9	0.39	5.96	0.36	8.8e-9	Major depressive disorder;
KIRP	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.69	-10.25	-0.55	9.13e-21	Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg08662619	chr6:150070041	PCMT1	0.31	4.97	0.3	1.27e-6	Lung cancer;
KIRP	cis	rs72925845	0.577	rs7212019	chr17:76428553	G/A	cg03830375	chr17:76426088	DNAH17	0.5	5.14	0.31	5.61e-7	Triglycerides;
KIRP	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg17376030	chr22:41985996	PMM1	-0.83	-8.97	-0.5	7.63e-17	Vitiligo;
KIRP	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17377491	chr11:112096999	PTS	0.56	6.55	0.39	3.41e-10	Smoking initiation;
KIRP	cis	rs4845459	0.967	rs4112788	chr1:152551276	A/G	cg07796016	chr1:152779584	LCE1C	-0.44	-5.13	-0.31	5.79e-7	Psoriasis;
KIRP	cis	rs2882667	0.929	rs34846849	chr5:138360578	T/C	cg04439458	chr5:138467593	SIL1	-0.51	-7.57	-0.43	7.3e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.83	-11.45	-0.59	1.26e-24	Breast cancer;
KIRP	cis	rs4262150	0.544	rs55802718	chr5:151916541	G/A	cg12297329	chr5:152029980	NA	-0.7	-8.69	-0.48	5.12e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	6.38	0.38	8.79e-10	Retinal vascular caliber;
KIRP	trans	rs2222328	0.953	rs11921554	chr3:159250371	T/C	cg15815375	chr20:17594530	RRBP1	0.67	6.16	0.37	2.96e-9	Quantitative traits;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.8	9.78	0.53	2.8e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-6.33	-0.37	1.17e-9	Aortic root size;
KIRP	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg15979348	chr13:112237479	NA	0.38	4.98	0.3	1.19e-6	Menarche (age at onset);
KIRP	cis	rs4262150	0.764	rs4580766	chr5:151939939	A/G	cg12297329	chr5:152029980	NA	-0.61	-7.62	-0.44	5.46e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.43	-6.49	-0.38	4.56e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.1	-0.31	6.9e-7	Skin colour saturation;
KIRP	cis	rs12579753	0.667	rs11115071	chr12:82284926	G/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.48	-0.33	1.07e-7	Resting heart rate;
KIRP	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg24375607	chr4:120327624	NA	0.5	5.89	0.35	1.26e-8	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.64	10.23	0.55	1.08e-20	Bone mineral density;
KIRP	cis	rs2635047	0.638	rs2289133	chr18:44602249	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.64	0.39	2.01e-10	Educational attainment;
KIRP	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.51	-8.01	-0.45	4.51e-14	IgG glycosylation;
KIRP	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.65	-8.22	-0.46	1.16e-14	Diastolic blood pressure;
KIRP	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg02524346	chr8:600233	NA	0.63	5.58	0.34	6.2e-8	IgG glycosylation;
KIRP	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg01872077	chr2:219646372	CYP27A1	0.38	5.0	0.3	1.12e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.45	5.05	0.31	8.79e-7	HDL cholesterol;
KIRP	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.39	-0.43	2.29e-12	Type 2 diabetes;
KIRP	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-6.25	-0.37	1.81e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg16822606	chr1:43233339	LEPRE1;C1orf50	0.52	6.64	0.39	1.98e-10	Educational attainment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17053538	chr5:121766285	SNCAIP	-0.4	-6.14	-0.36	3.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.91	-0.35	1.11e-8	Height;
KIRP	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.53	6.16	0.37	3e-9	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg11168104	chr5:1857477	NA	-0.38	-4.94	-0.3	1.42e-6	Cardiovascular disease risk factors;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21834982	chr14:102484833	DYNC1H1	0.49	6.66	0.39	1.74e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs240764	0.817	rs151573	chr6:101086333	T/C	cg09795085	chr6:101329169	ASCC3	0.47	5.58	0.34	6.38e-8	Neuroticism;
KIRP	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.28	0.42	4.55e-12	Height;
KIRP	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.81	8.11	0.46	2.47e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg03060546	chr3:49711283	APEH	-0.56	-7.54	-0.43	9.21e-13	Menarche (age at onset);
KIRP	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg08847533	chr14:75593920	NEK9	0.52	6.21	0.37	2.3e-9	IgG glycosylation;
KIRP	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg19847130	chr8:10466454	RP1L1	0.37	5.52	0.33	8.8e-8	Retinal vascular caliber;
KIRP	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	0.66	6.23	0.37	2e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs62238980	0.614	rs117744580	chr22:32566631	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.71	5.15	0.31	5.33e-7	Childhood ear infection;
KIRP	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg19847130	chr8:10466454	RP1L1	-0.36	-5.2	-0.31	4.14e-7	Retinal vascular caliber;
KIRP	cis	rs743757	1.000	rs2236957	chr3:50440426	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.31	0.32	2.47e-7	Diastolic blood pressure;
KIRP	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.59	-7.19	-0.42	7.77e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs754423	0.662	rs3818186	chr14:52509501	A/G	cg05884192	chr14:52515736	NID2	0.55	6.41	0.38	7.28e-10	Craniofacial microsomia;
KIRP	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg24631222	chr15:78858424	CHRNA5	-0.81	-9.72	-0.53	4.27e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg03468072	chr12:39539422	NA	0.39	5.75	0.34	2.64e-8	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.54	7.33	0.42	3.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.85	10.3	0.55	6.46e-21	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg03653399	chr8:142233436	SLC45A4	-0.55	-6.9	-0.4	4.41e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.81	0.35	1.92e-8	Aortic root size;
KIRP	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.57	8.52	0.48	1.61e-15	Fat distribution (HIV);
KIRP	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-5.4	-0.33	1.54e-7	Total body bone mineral density;
KIRP	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg11833968	chr6:79620685	NA	-0.44	-6.76	-0.4	9.78e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11987759	chr7:65425863	GUSB	-0.45	-5.48	-0.33	1.05e-7	Aortic root size;
KIRP	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg23587288	chr2:27483067	SLC30A3	0.54	6.9	0.4	4.38e-11	Blood metabolite levels;
KIRP	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.73	8.88	0.49	1.47e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.39	5.7	0.34	3.43e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.46	5.5	0.33	9.65e-8	Airway imaging phenotypes;
KIRP	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-20.05	-0.79	1.13e-53	Height;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.96e-8	Life satisfaction;
KIRP	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg18709589	chr6:96969512	KIAA0776	0.34	5.18	0.31	4.59e-7	Headache;
KIRP	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg06935464	chr4:38784597	TLR10	0.52	5.27	0.32	3.02e-7	Breast cancer;
KIRP	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19882132	chr14:106167949	NA	-0.42	-5.19	-0.31	4.49e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	cg21523751	chr1:182988639	NA	0.41	6.3	0.37	1.37e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.69	11.47	0.59	1.14e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6832769	1.000	rs7668147	chr4:56339384	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.44	0.43	1.63e-12	Personality dimensions;
KIRP	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.41	-0.33	1.53e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.5	6.05	0.36	5.23e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.47	7.39	0.43	2.23e-12	Testicular germ cell tumor;
KIRP	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg07068956	chr7:100330872	ZAN	0.4	5.41	0.33	1.47e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs986417	1.000	rs2350900	chr14:60938681	T/A	cg27398547	chr14:60952738	C14orf39	0.74	7.15	0.41	9.68e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs7106204	0.748	rs28552633	chr11:24207518	A/C	ch.11.24196551F	chr11:24239977	NA	0.79	9.17	0.5	1.92e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg26727032	chr16:67993705	SLC12A4	-0.69	-6.1	-0.36	4.11e-9	HDL cholesterol;
KIRP	cis	rs11644362	0.966	rs36056252	chr16:12994672	T/G	cg06890432	chr16:12997467	SHISA9	-0.42	-6.52	-0.38	3.89e-10	Positive affect;Subjective well-being;
KIRP	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg23594656	chr7:65796392	TPST1	0.39	5.64	0.34	4.71e-8	Aortic root size;
KIRP	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.55	-7.21	-0.42	6.95e-12	Urate levels in overweight individuals;
KIRP	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-8.68	-0.48	5.52e-16	Morning vs. evening chronotype;
KIRP	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.6	-6.72	-0.39	1.29e-10	Response to antineoplastic agents;
KIRP	cis	rs3767633	0.925	rs10753666	chr1:161861147	C/G	cg09175582	chr1:161736000	ATF6	0.74	6.03	0.36	5.88e-9	IgG glycosylation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02126950	chr14:48143384	MDGA2	0.47	6.26	0.37	1.67e-9	Smoking initiation;
KIRP	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg04374321	chr14:90722782	PSMC1	0.89	14.96	0.69	1.98e-36	Mortality in heart failure;
KIRP	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.44	6.61	0.39	2.32e-10	Coronary artery disease;
KIRP	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.76	6.77	0.4	9.4e-11	Diabetic retinopathy;
KIRP	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.96	6.81	0.4	7.44e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21014159	chr11:117668035	DSCAML1	0.4	5.0	0.3	1.08e-6	Myopia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10344081	chr4:76555777	CDKL2	0.48	6.93	0.4	3.6e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg14346243	chr4:90757452	SNCA	-0.43	-5.34	-0.32	2.13e-7	Neuroticism;
KIRP	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.95	11.37	0.59	2.4e-24	Corneal astigmatism;
KIRP	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg15358701	chr1:161410459	NA	-0.63	-5.87	-0.35	1.43e-8	Rheumatoid arthritis;
KIRP	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.66	-0.73	3.11e-42	Height;
KIRP	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.68	-0.34	3.88e-8	Life satisfaction;
KIRP	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg01872077	chr2:219646372	CYP27A1	-0.36	-4.89	-0.3	1.79e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4523957	0.647	rs12950603	chr17:2194937	T/A	cg16513277	chr17:2031491	SMG6	0.61	8.33	0.47	5.6e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg15848620	chr12:58087721	OS9	-0.43	-5.0	-0.3	1.1e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.54	-5.78	-0.35	2.28e-8	Aortic root size;
KIRP	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	trans	rs4809219	1	rs4809219	chr20:62303115	C/A	cg01311341	chr22:25575246	KIAA1671	0.64	7.45	0.43	1.6e-12	Atopic dermatitis;
KIRP	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg22284058	chr8:142237359	SLC45A4	0.53	6.7	0.39	1.39e-10	Immature fraction of reticulocytes;
KIRP	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	-0.46	-5.74	-0.34	2.76e-8	Prudent dietary pattern;
KIRP	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg26875233	chr11:93583750	C11orf90	0.4	7.55	0.43	8.25e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.34	-7.05	-0.41	1.79e-11	Urinary metabolites;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg01238044	chr22:24384105	GSTT1	-0.45	-5.39	-0.33	1.62e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	0.87	11.48	0.59	1.01e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg03609598	chr5:56110824	MAP3K1	-0.73	-7.27	-0.42	4.7e-12	Initial pursuit acceleration;
KIRP	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs909341	0.909	rs1048665	chr20:62331989	T/G	cg11503966	chr20:62272292	STMN3	-0.41	-5.88	-0.35	1.35e-8	Atopic dermatitis;
KIRP	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-1.03	-16.86	-0.73	6.4e-43	Gut microbiome composition (winter);
KIRP	cis	rs9488822	0.662	rs580396	chr6:116263181	T/C	cg15226275	chr6:116381976	FRK	-0.2	-5.4	-0.33	1.56e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg01475377	chr6:109611718	NA	-0.42	-5.74	-0.34	2.83e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg21640587	chr11:117668038	DSCAML1	0.44	6.56	0.39	3.09e-10	Myopia;
KIRP	trans	rs11945798	1.000	rs16887512	chr4:12734271	C/T	cg11636504	chr2:99439883	C2orf55	-0.58	-6.3	-0.37	1.36e-9	Word reading;
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.66	-0.44	4.27e-13	Platelet count;
KIRP	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg12257156	chr7:158823799	VIPR2	0.3	4.95	0.3	1.37e-6	Facial morphology (factor 20);
KIRP	cis	rs9905704	0.918	rs34430710	chr17:56876627	A/T	cg12560992	chr17:57184187	TRIM37	0.62	6.71	0.39	1.3e-10	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08266417	chr2:201450575	AOX1	0.39	6.37	0.38	9.24e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg14675211	chr2:100938903	LONRF2	-0.49	-6.18	-0.37	2.66e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.51	-0.33	9.12e-8	Body mass index;
KIRP	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg13736514	chr6:26305472	NA	-0.68	-8.13	-0.46	2.16e-14	Educational attainment;
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-1.04	-20.44	-0.79	6.04e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6032067	0.929	rs17334064	chr20:43839197	T/C	cg10761708	chr20:43804764	PI3	0.52	5.34	0.32	2.08e-7	Blood protein levels;
KIRP	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17507749	chr15:85114479	UBE2QP1	0.72	8.16	0.46	1.79e-14	Schizophrenia;
KIRP	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.15	0.41	9.81e-12	Prudent dietary pattern;
KIRP	cis	rs6714788	0.546	rs12712062	chr2:100654307	A/T	cg17356467	chr2:100759845	AFF3	0.38	5.12	0.31	6.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.81	-0.49	2.28e-16	Response to antipsychotic treatment;
KIRP	cis	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	13.73	0.66	3.13e-32	Platelet count;
KIRP	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg23281280	chr6:28129359	ZNF389	0.52	5.26	0.32	3.13e-7	Depression;
KIRP	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.61	8.74	0.49	3.6e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.76	-9.31	-0.51	7.52e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs13170463	0.579	rs13156473	chr5:8051054	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs1971762	0.504	rs1843318	chr12:53958077	C/T	cg16917193	chr12:54089295	NA	0.68	10.94	0.57	5.96e-23	Height;
KIRP	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.36	5.28	0.32	2.91e-7	Body mass index;
KIRP	cis	rs9403317	0.960	rs8180607	chr6:141877035	G/A	cg15052665	chr6:141804349	NA	0.42	5.08	0.31	7.57e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-4.85	-0.3	2.22e-6	Educational attainment (years of education);
KIRP	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg19906672	chr4:6918868	TBC1D14	0.51	5.23	0.32	3.65e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs2635047	0.542	rs2684814	chr18:44754103	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.43	-7.0	-0.41	2.49e-11	Educational attainment;
KIRP	cis	rs365132	0.875	rs2962844	chr5:176333748	G/T	cg16309518	chr5:176445507	NA	-0.79	-12.1	-0.61	9.39e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.95	13.23	0.64	1.5e-30	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11987759	chr7:65425863	GUSB	0.49	6.51	0.38	4.12e-10	Aortic root size;
KIRP	cis	rs4132509	1.000	rs2168812	chr1:243777066	G/A	cg21452805	chr1:244014465	NA	0.54	5.58	0.34	6.42e-8	RR interval (heart rate);
KIRP	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.8	9.98	0.54	6.5e-20	Corneal astigmatism;
KIRP	cis	rs7044106	0.655	rs1359329	chr9:123370985	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	6.57	0.39	2.94e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg11189052	chr15:85197271	WDR73	0.52	5.33	0.32	2.26e-7	Schizophrenia;
KIRP	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26526719	chr5:1949144	NA	-0.53	-5.69	-0.34	3.51e-8	Gut microbiome composition (winter);
KIRP	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.35	-0.32	2.03e-7	Retinal vascular caliber;
KIRP	cis	rs13102973	1.000	rs4569802	chr4:135905371	A/C	cg14419869	chr4:135874104	NA	0.5	7.96	0.45	6.19e-14	Subjective well-being;
KIRP	cis	rs2223471	0.692	rs9381903	chr6:50773228	G/A	cg03432817	chr6:50765336	NA	-0.42	-6.53	-0.38	3.8e-10	Subcutaneous adipose tissue;
KIRP	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.91e-16	Morning vs. evening chronotype;
KIRP	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg00405596	chr8:11794950	NA	0.47	6.17	0.37	2.86e-9	Retinal vascular caliber;
KIRP	cis	rs3825932	0.961	rs11072815	chr15:79232319	C/T	cg25744700	chr15:79237217	CTSH	-0.42	-5.15	-0.31	5.33e-7	Type 1 diabetes;
KIRP	cis	rs9948	0.867	rs17119598	chr2:97486315	A/G	cg01990225	chr2:97406019	LMAN2L	1.07	7.64	0.44	4.8e-13	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs12580194	0.593	rs56677471	chr12:55749967	T/A	cg19537932	chr12:55886519	OR6C68	-0.47	-6.26	-0.37	1.68e-9	Cancer;
KIRP	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg13206674	chr6:150067644	NUP43	0.56	7.79	0.44	1.91e-13	Lung cancer;
KIRP	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.94	-0.54	8.37e-20	Total body bone mineral density;
KIRP	cis	rs6832769	0.925	rs2899037	chr4:56457347	C/G	cg09317128	chr4:56265301	TMEM165	-0.48	-6.25	-0.37	1.81e-9	Personality dimensions;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.62	9.52	0.52	1.66e-18	Lung cancer;
KIRP	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.98	-0.3	1.22e-6	Crohn's disease;
KIRP	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.66	0.39	1.79e-10	Breast cancer;
KIRP	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.4	4.88	0.3	1.93e-6	Colorectal cancer;
KIRP	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.43	6.59	0.39	2.73e-10	Major depressive disorder;
KIRP	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg00800038	chr16:89945340	TCF25	-0.76	-5.19	-0.31	4.41e-7	Skin colour saturation;
KIRP	cis	rs9880211	0.800	rs13433683	chr3:136518670	C/T	cg21827317	chr3:136751795	NA	0.49	5.06	0.31	8.38e-7	Body mass index;Height;
KIRP	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg06671706	chr8:8559999	CLDN23	-0.55	-6.35	-0.38	1.04e-9	Obesity-related traits;
KIRP	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg13147721	chr7:65941812	NA	0.74	6.29	0.37	1.44e-9	Diabetic kidney disease;
KIRP	cis	rs1147199	0.531	rs1659412	chr9:87278152	G/A	cg22402007	chr9:87282823	NTRK2	-0.4	-4.89	-0.3	1.86e-6	Body mass index;
KIRP	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	cg04338863	chr8:33670619	NA	0.41	5.33	0.32	2.18e-7	Body mass index;
KIRP	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.7	-0.34	3.36e-8	Parkinson's disease;
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg25703541	chr22:24373054	LOC391322	-0.76	-11.45	-0.59	1.26e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg22437258	chr11:111473054	SIK2	0.58	6.84	0.4	6.29e-11	Primary sclerosing cholangitis;
KIRP	cis	rs9603616	0.719	rs9532417	chr13:40258085	G/A	cg26701198	chr13:40229707	COG6	0.44	5.18	0.31	4.53e-7	Rheumatoid arthritis;
KIRP	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.92	9.49	0.52	2.15e-18	Platelet distribution width;
KIRP	trans	rs12544026	0.548	rs482023	chr8:102910007	G/T	cg19131667	chr3:17236940	TBC1D5	0.39	6.03	0.36	6.07e-9	Major depression and alcohol dependence;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13939156	chr17:80058883	NA	0.5	7.52	0.43	1e-12	Life satisfaction;
KIRP	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.16	-0.42	9.16e-12	Waist circumference adjusted for body mass index;
KIRP	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg24498760	chr8:49746867	NA	0.4	4.97	0.3	1.24e-6	Blood metabolite ratios;
KIRP	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg21204522	chr6:27730016	NA	-0.62	-5.27	-0.32	2.92e-7	Lung cancer in ever smokers;
KIRP	cis	rs2411233	1.000	rs8026431	chr15:39274261	C/A	cg02291532	chr15:39874776	THBS1	0.39	5.39	0.33	1.62e-7	Platelet count;
KIRP	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg02002194	chr4:3960332	NA	-0.43	-6.04	-0.36	5.51e-9	Mood instability;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24634519	chr20:13765725	C20orf7;ESF1	-0.5	-6.99	-0.41	2.65e-11	Metabolic traits;
KIRP	cis	rs787274	0.619	rs10115576	chr9:115617822	T/C	cg13803584	chr9:115635662	SNX30	-0.57	-6.63	-0.39	2.14e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2625529	0.824	rs12593134	chr15:72303007	G/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.12e-9	Red blood cell count;
KIRP	trans	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.76e-11	Diabetic kidney disease;
KIRP	cis	rs4363385	0.720	rs6704498	chr1:152964740	C/A	cg13444842	chr1:152974279	SPRR3	-0.35	-4.99	-0.3	1.16e-6	Inflammatory skin disease;
KIRP	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.43	-0.38	6.48e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg16898833	chr6:26189333	HIST1H4D	1.02	5.78	0.35	2.22e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2494938	0.716	rs846509	chr6:40530612	T/C	cg14084896	chr6:40530702	LRFN2	-0.4	-5.0	-0.3	1.11e-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg24747557	chr10:131355152	MGMT	-0.42	-5.61	-0.34	5.55e-8	Response to temozolomide;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01493318	chr18:8705700	NA	-0.48	-6.15	-0.37	3.16e-9	Survival in pancreatic cancer;
KIRP	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg10792982	chr14:105748885	BRF1	0.94	13.1	0.64	4.3e-30	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7084402	0.967	rs1649059	chr10:60312599	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.89	-0.57	8.63e-23	Refractive error;
KIRP	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.66	-9.44	-0.52	2.94e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.94	0.35	9.91e-9	Menopause (age at onset);
KIRP	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg02612397	chr6:125855124	NA	-0.33	-4.91	-0.3	1.67e-6	Brugada syndrome;
KIRP	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	7.56	0.43	8.15e-13	Height;
KIRP	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg16497661	chr14:103986332	CKB	-0.52	-6.52	-0.38	3.94e-10	Coronary artery disease;
KIRP	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.95	-8.75	-0.49	3.55e-16	Obesity-related traits;
KIRP	cis	rs6793245	0.845	rs4073796	chr3:38590849	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.5	-6.3	-0.37	1.33e-9	QT interval;
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg10254082	chr7:997346	NA	0.58	4.84	0.3	2.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.62	6.6	0.39	2.47e-10	Gut microbiome composition (summer);
KIRP	cis	rs2072732	0.821	rs58052947	chr1:2950094	T/C	cg11731671	chr1:2995604	PRDM16	-0.43	-5.7	-0.34	3.41e-8	Plateletcrit;
KIRP	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg13119609	chr19:45449297	APOC2	0.53	7.72	0.44	2.91e-13	Blood protein levels;
KIRP	cis	rs16854884	0.770	rs951865	chr3:143812677	G/A	cg06585982	chr3:143692056	C3orf58	0.47	5.81	0.35	1.97e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg01657329	chr11:68192670	LRP5	-0.51	-5.53	-0.33	8.3e-8	Total body bone mineral density;
KIRP	cis	rs9653442	0.545	rs2009094	chr2:100765077	G/A	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4006360	0.600	rs1828327	chr17:39249464	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.55	-0.48	1.37e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2979489	0.740	rs17554408	chr8:30427531	A/G	cg26383811	chr8:30366931	RBPMS	0.41	5.46	0.33	1.19e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.66	-8.44	-0.47	2.67e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg00981070	chr1:2046702	PRKCZ	0.38	6.4	0.38	7.69e-10	Height;
KIRP	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	5.06e-7	Parkinson's disease;
KIRP	cis	rs6993770	0.628	rs7003261	chr8:106519305	T/C	cg12797828	chr8:106520928	ZFPM2	-0.33	-4.92	-0.3	1.58e-6	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
KIRP	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	1.0	13.03	0.64	7.14e-30	Neutrophil percentage of white cells;
KIRP	cis	rs2718812	0.766	rs12497513	chr3:133388670	C/G	cg01448562	chr3:133502909	NA	0.37	4.84	0.3	2.25e-6	Iron status biomarkers;
KIRP	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg13902645	chr11:5959945	NA	-0.66	-6.87	-0.4	5.35e-11	DNA methylation (variation);
KIRP	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19524238	chr7:2802976	GNA12	-0.35	-5.24	-0.32	3.38e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	cis	rs11638352	0.661	rs2706490	chr15:44422238	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-4.92	-0.3	1.59e-6	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg17524854	chr12:67663046	CAND1	0.51	6.26	0.37	1.71e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09844907	chr16:15489619	MPV17L	0.46	7.43	0.43	1.79e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg03060546	chr3:49711283	APEH	-0.69	-5.0	-0.3	1.09e-6	Cognitive function;
KIRP	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.57	6.31	0.37	1.29e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17467752	chr17:38218738	THRA	-0.57	-7.24	-0.42	5.79e-12	Myeloid white cell count;
KIRP	cis	rs68170813	0.617	rs10464499	chr7:107137571	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-6.88	-0.4	4.87e-11	Coronary artery disease;
KIRP	cis	rs17092148	1.000	rs60789653	chr20:33447162	G/A	cg16810054	chr20:33298113	TP53INP2	0.43	5.23	0.32	3.59e-7	Neuroticism;
KIRP	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Body mass index;
KIRP	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg04087571	chr11:116723030	SIK3	-0.26	-5.44	-0.33	1.26e-7	Subjective well-being;
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.21	0.51	1.44e-17	Lung cancer;
KIRP	cis	rs9815354	1.000	rs1717017	chr3:41915616	A/C	cg03022575	chr3:42003672	ULK4	0.49	5.59	0.34	6.13e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg26571870	chr16:85723150	GINS2	-0.63	-6.96	-0.41	3.14e-11	Platelet distribution width;
KIRP	cis	rs8106542	0.906	rs2288904	chr19:10742170	A/G	cg23183932	chr19:10823679	QTRT1	0.43	4.87	0.3	2e-6	Platelet distribution width;
KIRP	cis	rs2302729	0.789	rs876503	chr12:2797179	A/G	cg19945202	chr12:2788847	CACNA1C	-0.8	-6.98	-0.41	2.78e-11	Sleep quality;
KIRP	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.4	5.75	0.34	2.69e-8	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	trans	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg16141378	chr3:129829833	LOC729375	0.49	6.18	0.37	2.71e-9	Joint mobility (Beighton score);
KIRP	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.54	-0.38	3.5e-10	Neuroticism;
KIRP	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg21419209	chr3:44054225	NA	-0.77	-9.32	-0.51	6.9e-18	Coronary artery disease;
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.62	7.62	0.44	5.51e-13	Menopause (age at onset);
KIRP	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.51	7.06	0.41	1.7e-11	Coronary artery disease;
KIRP	cis	rs12580194	0.593	rs59466585	chr12:55722736	T/G	cg19537932	chr12:55886519	OR6C68	-0.5	-6.68	-0.39	1.62e-10	Cancer;
KIRP	cis	rs1364705	1.000	rs13262685	chr8:120226145	A/G	cg09273054	chr8:120220131	MAL2	0.47	5.72	0.34	3.01e-8	Hippocampal atrophy;
KIRP	cis	rs9378796	0.598	rs17136575	chr6:3450266	C/T	cg00476032	chr6:3446245	SLC22A23	0.47	5.27	0.32	2.96e-7	Mean platelet volume;
KIRP	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.97	17.21	0.74	4.3e-44	Ulcerative colitis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18652121	chr3:179322868	MRPL47;NDUFB5	0.65	6.05	0.36	5.26e-9	Lung function (FEV1);
KIRP	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.56	10.36	0.55	4.1e-21	Iron status biomarkers (transferrin levels);
KIRP	cis	rs3741151	0.686	rs12290701	chr11:73271988	T/C	cg17517138	chr11:73019481	ARHGEF17	0.6	5.32	0.32	2.38e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.98	-15.86	-0.71	1.69e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs6838801	0.588	rs344140	chr4:77660162	G/C	cg17476223	chr4:77663285	SHROOM3	-0.56	-7.2	-0.42	7.26e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg14517863	chr17:44321492	NA	0.47	5.47	0.33	1.13e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10491083	1.000	rs10491083	chr17:6558557	A/G	cg08103988	chr17:6558365	NA	0.56	4.98	0.3	1.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12643440	0.538	rs62296683	chr4:17137441	C/G	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs11888559	0.573	rs7602826	chr2:203860716	G/A	cg24605529	chr2:203879461	NBEAL1	0.83	5.4	0.33	1.54e-7	Height;
KIRP	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg11833968	chr6:79620685	NA	-0.43	-6.29	-0.37	1.43e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2898681	0.581	rs936690	chr4:53691035	A/G	cg00338735	chr4:53728038	RASL11B	0.4	4.96	0.3	1.29e-6	Optic nerve measurement (cup area);
KIRP	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.59	5.47	0.33	1.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.54	7.64	0.44	4.84e-13	Night sleep phenotypes;
KIRP	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-9.98	-0.54	6.35e-20	Coronary artery disease;
KIRP	trans	rs1417352	0.535	rs2236073	chr6:106898421	A/G	cg25685456	chr6:143269881	NA	-0.45	-6.12	-0.36	3.69e-9	Select biomarker traits;
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg04804543	chr8:142233427	SLC45A4	-0.59	-7.62	-0.44	5.59e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.56	-0.33	6.96e-8	Neuroticism;
KIRP	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.25	0.32	3.24e-7	Alzheimer's disease;
KIRP	cis	rs8113308	0.810	rs11879040	chr19:52450109	A/C	cg25782003	chr19:52490127	ZNF350	0.54	5.08	0.31	7.35e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg07636037	chr3:49044803	WDR6	0.58	5.5	0.33	9.71e-8	Menarche (age at onset);
KIRP	cis	rs75920871	0.920	rs4938336	chr11:116948442	A/G	cg23684410	chr11:116897558	SIK3	0.55	5.69	0.34	3.65e-8	Subjective well-being;
KIRP	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs12210905	0.920	rs77380818	chr6:27305498	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.41	-0.38	7.43e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6662572	0.737	rs4388641	chr1:46522326	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.73	0.34	2.93e-8	Blood protein levels;
KIRP	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06505273	chr16:24850292	NA	0.36	4.98	0.3	1.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7937612	1.000	rs4938805	chr11:120274211	C/T	cg24566217	chr11:120254723	ARHGEF12	0.47	6.94	0.4	3.44e-11	Intraocular pressure;
KIRP	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.8	-11.73	-0.6	1.61e-25	Obesity-related traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07927839	chr12:53491483	IGFBP6	0.52	6.81	0.4	7.65e-11	Smoking initiation;
KIRP	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg25418670	chr11:30344373	C11orf46	-0.6	-5.02	-0.3	1e-6	Morning vs. evening chronotype;
KIRP	cis	rs830383	0.554	rs185080	chr5:165412870	C/T	cg13976338	chr5:165423657	NA	-0.62	-6.66	-0.39	1.79e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.76	11.56	0.59	5.7e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.42	-5.04	-0.31	8.9e-7	Osteoporosis;
KIRP	cis	rs4006360	0.575	rs404154	chr17:39315341	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.45	-6.14	-0.36	3.36e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg03571507	chr19:53239146	ZNF611	0.22	5.51	0.33	8.96e-8	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.52	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg05941025	chr16:89927596	SPIRE2	0.33	5.23	0.32	3.7e-7	Vitiligo;
KIRP	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6740322	0.696	rs10188539	chr2:43484675	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.83	-11.05	-0.58	2.66e-23	Coronary artery disease;
KIRP	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg00646381	chr17:77835854	NA	0.57	7.6	0.44	6.35e-13	Electroencephalogram traits;
KIRP	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02725872	chr8:58115012	NA	-0.7	-8.04	-0.46	3.69e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.57	7.4	0.43	2.17e-12	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	9.14	0.5	2.34e-17	Cognitive test performance;
KIRP	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg08662619	chr6:150070041	PCMT1	0.32	5.08	0.31	7.55e-7	Lung cancer;
KIRP	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.59	7.66	0.44	4.28e-13	Hip circumference;
KIRP	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs9303542	0.559	rs12947405	chr17:46614755	C/T	cg04904318	chr17:46607828	HOXB1	-0.62	-6.59	-0.39	2.59e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.7	-0.53	4.71e-19	Triglycerides;
KIRP	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg17554472	chr22:41940697	POLR3H	0.43	5.08	0.31	7.54e-7	Vitiligo;
KIRP	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.23	0.32	3.62e-7	Renal cell carcinoma;
KIRP	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	1.0	12.12	0.61	7.95e-27	Post bronchodilator FEV1;
KIRP	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg26207909	chr14:103986467	CKB	-0.46	-5.43	-0.33	1.37e-7	Coronary artery disease;
KIRP	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg22875332	chr1:76189707	ACADM	0.58	7.72	0.44	3.01e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.46	6.78	0.4	9.04e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.49	-6.5	-0.38	4.44e-10	Migraine;
KIRP	cis	rs6589219	0.788	rs11213823	chr11:111169990	T/C	cg25129781	chr11:111156908	C11orf53	-0.47	-5.99	-0.36	7.31e-9	Colorectal cancer;
KIRP	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.69	8.76	0.49	3.16e-16	Resting heart rate;
KIRP	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg01629716	chr15:45996671	NA	0.37	6.73	0.39	1.15e-10	Waist circumference;Weight;
KIRP	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.43	-7.51	-0.43	1.09e-12	Refractive error;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg07414643	chr4:187882934	NA	0.4	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg14835575	chr10:16859367	RSU1	0.54	7.22	0.42	6.4e-12	Platelet distribution width;
KIRP	cis	rs12900413	0.687	rs28435184	chr15:90306732	T/C	cg07116693	chr15:90310901	NA	-0.23	-4.86	-0.3	2.11e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.99	-0.5	6.7e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.51	-0.33	8.98e-8	Lung cancer;
KIRP	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.45	5.55	0.33	7.27e-8	Height;
KIRP	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg17279839	chr7:150038598	RARRES2	0.54	6.91	0.4	4.06e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.58	7.46	0.43	1.52e-12	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg16141378	chr3:129829833	LOC729375	0.57	7.57	0.43	7.26e-13	Neuroticism;
KIRP	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.56	-0.33	7.08e-8	Neuroticism;
KIRP	cis	rs4849845	0.925	rs934725	chr2:121012902	C/T	cg24070213	chr2:121070622	NA	0.38	5.12	0.31	6.19e-7	Mean platelet volume;
KIRP	cis	rs4700695	0.764	rs251277	chr5:65390177	A/G	cg21114390	chr5:65439923	SFRS12	-0.56	-5.47	-0.33	1.12e-7	Facial morphology (factor 19);
KIRP	cis	rs11638511	0.561	rs2139444	chr15:78551389	A/G	cg08594606	chr15:78556512	DNAJA4	-0.4	-5.28	-0.32	2.84e-7	Red blood cell count;
KIRP	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	7.42	0.43	1.95e-12	Schizophrenia;
KIRP	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.78	0.44	2e-13	Calcium levels;
KIRP	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg20560298	chr2:73613845	ALMS1	-0.42	-5.21	-0.32	3.96e-7	Metabolite levels;
KIRP	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg13679303	chr9:96623674	NA	0.45	5.9	0.35	1.19e-8	DNA methylation (variation);
KIRP	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	1.06	13.6	0.66	8.37e-32	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg00677455	chr12:58241039	CTDSP2	0.53	5.95	0.35	9.22e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg05083358	chr7:2394359	EIF3B	-0.73	-7.06	-0.41	1.64e-11	Multiple sclerosis;
KIRP	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg23992470	chr4:843637	GAK	0.63	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7027203	0.595	rs4308796	chr9:96570165	G/A	cg14598338	chr9:96623480	NA	0.48	7.49	0.43	1.26e-12	DNA methylation (variation);
KIRP	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.71	0.49	4.47e-16	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg08662619	chr6:150070041	PCMT1	0.38	6.16	0.37	2.88e-9	Lung cancer;
KIRP	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.79	-12.96	-0.64	1.27e-29	Prostate cancer;
KIRP	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg19683494	chr5:74908142	NA	0.44	5.05	0.31	8.66e-7	Age-related disease endophenotypes;
KIRP	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg26408565	chr15:76604113	ETFA	-0.44	-5.94	-0.35	9.56e-9	Blood metabolite levels;
KIRP	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg13607699	chr17:42295918	UBTF	-0.39	-5.05	-0.31	8.75e-7	Total body bone mineral density;
KIRP	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.74	0.34	2.71e-8	Asthma (sex interaction);
KIRP	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.89	-0.49	1.37e-16	Retinal vascular caliber;
KIRP	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	1.01	12.68	0.63	1.07e-28	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4908768	0.555	rs11582339	chr1:8898807	A/C	cg25722041	chr1:8623473	RERE	-0.49	-6.43	-0.38	6.42e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg08461772	chr7:95026248	PON3	0.41	5.81	0.35	1.9e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.55	7.12	0.41	1.15e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg25173405	chr17:45401733	C17orf57	0.41	5.4	0.33	1.59e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs859767	0.501	rs6705916	chr2:135397569	C/T	cg25422880	chr2:135218333	TMEM163	0.38	5.65	0.34	4.35e-8	Neuroticism;
KIRP	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg07382826	chr16:28625726	SULT1A1	-0.53	-6.27	-0.37	1.65e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg27129171	chr3:47204927	SETD2	0.39	4.88	0.3	1.87e-6	Birth weight;
KIRP	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.45	5.79	0.35	2.18e-8	Blood protein levels;
KIRP	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.67	8.48	0.48	2.1e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-13.68	-0.66	4.8e-32	Height;
KIRP	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	10.51	0.56	1.4e-21	HIV-1 control;
KIRP	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.98	-0.5	7.4e-17	Retinal vascular caliber;
KIRP	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.85	0.6	6.19e-26	Smoking behavior;
KIRP	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.98	-0.36	7.67e-9	Morning vs. evening chronotype;
KIRP	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.09	0.31	7.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs10033073	1	rs10033073	chr4:4775401	A/G	cg23139982	chr4:4763259	NA	-0.34	-5.53	-0.33	8.14e-8	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs830383	0.512	rs17460320	chr5:165441461	C/A	cg13976338	chr5:165423657	NA	-0.62	-6.16	-0.37	3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs55788414	1.000	rs28395434	chr16:81182222	G/A	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.27	-0.47	8.2e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg10755058	chr3:40428713	ENTPD3	0.49	6.65	0.39	1.9e-10	Renal cell carcinoma;
KIRP	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.08	0.5	3.57e-17	Colorectal cancer;
KIRP	cis	rs12900413	0.687	rs11629590	chr15:90304644	A/G	cg24650279	chr15:90327240	NA	0.41	5.16	0.31	5.21e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg21926883	chr2:100939477	LONRF2	-0.55	-7.86	-0.45	1.18e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	5.94	0.35	9.92e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs9875589	0.747	rs1488378	chr3:14014725	G/A	cg19554555	chr3:13937349	NA	-0.54	-6.77	-0.4	9.15e-11	Ovarian reserve;
KIRP	trans	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg06521331	chr12:34319734	NA	-0.5	-6.18	-0.37	2.7e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9788682	0.792	rs2869032	chr15:78714561	C/T	cg06917634	chr15:78832804	PSMA4	0.55	5.12	0.31	6.15e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.46	5.53	0.33	8e-8	Rheumatoid arthritis;
KIRP	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.54	7.21	0.42	6.73e-12	Menopause (age at onset);
KIRP	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg02487422	chr3:49467188	NICN1	0.41	5.45	0.33	1.24e-7	Resting heart rate;
KIRP	cis	rs9600832	0.597	rs9544444	chr13:36066578	G/A	cg20704442	chr13:36052768	MIR548F5;NBEA	0.36	6.06	0.36	5.05e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg03929089	chr4:120376271	NA	0.69	6.21	0.37	2.29e-9	Axial length;
KIRP	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg20487152	chr13:99095054	FARP1	-0.44	-6.22	-0.37	2.18e-9	Neuroticism;
KIRP	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.89	-0.63	2.12e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.67	7.84	0.45	1.34e-13	Corneal astigmatism;
KIRP	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-13.28	-0.65	1.01e-30	Heart rate;
KIRP	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg01081584	chr15:40268610	EIF2AK4	0.33	5.5	0.33	9.34e-8	Response to haloperidol in psychosis;
KIRP	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg16988262	chr1:15930761	NA	0.36	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg14673194	chr17:80132900	CCDC57	-0.74	-8.04	-0.46	3.79e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7078219	0.543	rs7095491	chr10:101274058	A/G	cg07044859	chr10:101282883	NA	-0.34	-6.27	-0.37	1.62e-9	Dental caries;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03762994	chr17:6899332	ALOX12	0.29	4.95	0.3	1.36e-6	Tonsillectomy;
KIRP	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg18350739	chr11:68623251	NA	-0.52	-7.96	-0.45	6.21e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7809615	0.901	rs11981478	chr7:99163950	C/T	cg24024660	chr7:99195788	NA	-0.57	-5.07	-0.31	7.78e-7	Blood metabolite ratios;
KIRP	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Hypertriglyceridemia;
KIRP	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg06212747	chr3:49208901	KLHDC8B	0.71	8.34	0.47	5.24e-15	Childhood ear infection;
KIRP	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.41	5.06	0.31	8.24e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.41e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7709377	0.570	rs10065178	chr5:115435148	G/A	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.89	15.32	0.7	1.19e-37	Headache;
KIRP	cis	rs10267417	0.603	rs10253272	chr7:19916190	G/T	cg05791153	chr7:19748676	TWISTNB	0.5	4.88	0.3	1.87e-6	Night sleep phenotypes;
KIRP	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.8	13.1	0.64	4.19e-30	Prostate cancer;
KIRP	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg01559446	chr3:44596178	ZNF167	-0.38	-5.25	-0.32	3.23e-7	Depressive symptoms;
KIRP	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg04025307	chr7:1156635	C7orf50	-0.57	-6.37	-0.38	9.16e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.57	7.33	0.42	3.36e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.65	7.81	0.45	1.61e-13	Alcohol dependence;
KIRP	cis	rs7267005	0.661	rs79637847	chr20:34419527	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg20208858	chr19:49865767	DKKL1;TEAD2	-0.41	-4.86	-0.3	2.11e-6	Multiple sclerosis;
KIRP	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9653442	0.900	rs4851269	chr2:100830348	C/T	cg07810366	chr2:100720526	AFF3	0.29	4.92	0.3	1.59e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg25019722	chr6:37503610	NA	-0.95	-15.45	-0.7	4.42e-38	Cognitive performance;
KIRP	cis	rs13102973	0.932	rs28801464	chr4:135876630	A/G	cg14419869	chr4:135874104	NA	-0.62	-11.12	-0.58	1.57e-23	Subjective well-being;
KIRP	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.58	-6.27	-0.37	1.6e-9	Serum sulfate level;
KIRP	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-10.58	-0.56	8.14e-22	Colorectal cancer;
KIRP	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	0.93	13.51	0.65	1.74e-31	Dupuytren's disease;
KIRP	trans	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.32	0.42	3.57e-12	Mean corpuscular volume;
KIRP	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg21919602	chr1:242011447	EXO1	-0.46	-5.93	-0.35	1.04e-8	Menopause (age at onset);
KIRP	cis	rs9467603	1.000	rs6940698	chr6:25821580	A/G	cg08501292	chr6:25962987	TRIM38	-0.9	-6.39	-0.38	8.35e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.65	9.99	0.54	6.13e-20	Educational attainment;
KIRP	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg22705602	chr4:152727874	NA	0.54	9.49	0.52	2.05e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.89	0.3	1.85e-6	Tonsillectomy;
KIRP	cis	rs72843166	0.947	rs75315481	chr17:61111542	G/A	cg19683800	chr17:61518354	CYB561	-0.42	-4.97	-0.3	1.24e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26207909	chr14:103986467	CKB	0.56	7.51	0.43	1.06e-12	Body mass index;
KIRP	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg23100626	chr2:96804247	ASTL	0.47	6.82	0.4	7.17e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg23422044	chr7:1970798	MAD1L1	0.5	5.09	0.31	7.01e-7	Bipolar disorder;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg13236315	chr12:53645720	MFSD5	0.49	6.12	0.36	3.63e-9	Asthma;
KIRP	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.57	-7.1	-0.41	1.36e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg23649088	chr2:200775458	C2orf69	0.55	5.37	0.32	1.85e-7	Schizophrenia;
KIRP	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.45	5.89	0.35	1.28e-8	Alcohol dependence;
KIRP	cis	rs17123764	1.000	rs7131915	chr12:49967660	C/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.98	0.3	1.21e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.91	0.35	1.16e-8	Total cholesterol levels;
KIRP	cis	rs714027	0.566	rs1548389	chr22:30573552	T/C	cg27665648	chr22:30112403	NA	0.45	6.36	0.38	9.5e-10	Lymphocyte counts;
KIRP	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.44	6.19	0.37	2.45e-9	Testicular germ cell tumor;
KIRP	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.77	11.24	0.58	6.14e-24	Height;
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg26134248	chr17:3907702	NA	0.58	8.63	0.48	8e-16	Type 2 diabetes;
KIRP	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-1.11	-9.37	-0.51	4.93e-18	Body mass index;
KIRP	cis	rs2574704	0.603	rs3856802	chr3:11667714	C/T	cg07643000	chr3:11666825	VGLL4	0.39	5.85	0.35	1.53e-8	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15030756	chr15:74907746	CLK3	0.47	6.23	0.37	2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12476592	0.602	rs2292793	chr2:63661280	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-4.9	-0.3	1.74e-6	Childhood ear infection;
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg21851534	chr17:3907994	ZZEF1	0.7	11.54	0.59	6.79e-25	Type 2 diabetes;
KIRP	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs4631830	0.540	rs2926493	chr10:51492131	G/A	cg10326726	chr10:51549505	MSMB	-0.56	-7.61	-0.44	5.88e-13	Prostate-specific antigen levels;
KIRP	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.51	7.2	0.42	7.22e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.55	-7.49	-0.43	1.2e-12	Response to temozolomide;
KIRP	cis	rs4356975	0.563	rs6600880	chr4:69960480	T/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.64	-0.44	4.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.22	-0.32	3.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7551222	0.752	rs4252718	chr1:204512195	A/T	cg20240347	chr1:204465584	NA	0.42	8.15	0.46	1.8e-14	Schizophrenia;
KIRP	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.6	-11.94	-0.61	3.11e-26	Diabetic kidney disease;
KIRP	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.88	13.75	0.66	2.63e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg17366294	chr4:99064904	C4orf37	0.36	4.93	0.3	1.52e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.85e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg24209194	chr3:40518798	ZNF619	-0.38	-4.87	-0.3	2.04e-6	Renal cell carcinoma;
KIRP	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.75	5.73	0.34	2.89e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.41	6.25	0.37	1.78e-9	PR interval;
KIRP	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg25182066	chr10:30743637	MAP3K8	-0.63	-8.71	-0.49	4.51e-16	Inflammatory bowel disease;
KIRP	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7005380	0.556	rs6996081	chr8:120947105	A/T	cg21645572	chr8:120931649	DEPDC6	0.44	4.96	0.3	1.34e-6	Interstitial lung disease;
KIRP	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.28	-0.32	2.86e-7	Retinal vascular caliber;
KIRP	cis	rs9653442	0.545	rs2009094	chr2:100765077	G/A	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08439880	chr3:133502540	NA	-0.41	-4.88	-0.3	1.9e-6	Iron status biomarkers;
KIRP	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.58	-7.01	-0.41	2.25e-11	Initial pursuit acceleration;
KIRP	cis	rs1456297	0.840	rs1017679	chr15:51968419	C/T	cg14296394	chr15:51910925	DMXL2	-0.59	-8.13	-0.46	2.07e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12292205	chr6:26970375	C6orf41	-0.65	-7.41	-0.43	1.96e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs11165623	0.564	rs7541109	chr1:96995960	C/A	cg10631902	chr5:14652156	NA	-0.51	-6.77	-0.4	9.14e-11	Hip circumference;Waist circumference;
KIRP	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg00262122	chr8:11665843	FDFT1	0.41	5.17	0.31	4.92e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13939156	chr17:80058883	NA	0.5	7.34	0.42	3.04e-12	Life satisfaction;
KIRP	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg20295408	chr7:1910781	MAD1L1	-0.55	-6.13	-0.36	3.55e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-4.87	-0.3	2.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.521	rs9430015	chr1:209911734	G/A	cg23920097	chr1:209922102	NA	-0.42	-5.75	-0.34	2.59e-8	Red blood cell count;
KIRP	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.85	0.35	1.58e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9937943	0.667	rs12919002	chr16:74612377	A/G	cg01733217	chr16:74700730	RFWD3	0.61	5.68	0.34	3.83e-8	Neutrophil percentage of white cells;
KIRP	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.52	-4.88	-0.3	1.94e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs4790333	0.813	rs2005029	chr17:2255138	G/T	cg02569219	chr17:2266849	SGSM2	-0.51	-6.23	-0.37	2e-9	Proinsulin levels;
KIRP	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.68	8.26	0.47	8.76e-15	Aortic root size;
KIRP	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.4	-0.43	2.19e-12	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg08132940	chr7:1081526	C7orf50	-0.52	-5.5	-0.33	9.46e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg26116260	chr4:7069785	GRPEL1	-0.82	-6.53	-0.38	3.82e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs58785573	0.513	rs10015581	chr4:38593646	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.88	0.3	1.94e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.62	4.94	0.3	1.47e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.54	0.38	3.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg05082376	chr22:42548792	NA	-0.46	-5.77	-0.35	2.41e-8	Schizophrenia;
KIRP	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.56	7.73	0.44	2.7e-13	Schizophrenia;
KIRP	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg07511668	chr11:68622177	NA	0.38	4.97	0.3	1.28e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-9.13	-0.5	2.65e-17	Colorectal cancer;
KIRP	cis	rs6466055	0.796	rs9649275	chr7:104935801	T/G	cg04380332	chr7:105027541	SRPK2	0.51	7.83	0.45	1.45e-13	Schizophrenia;
KIRP	cis	rs9534288	0.797	rs4142548	chr13:46535350	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-7.93	-0.45	7.69e-14	Blood protein levels;
KIRP	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.49	0.43	1.26e-12	Coffee consumption (cups per day);
KIRP	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17376030	chr22:41985996	PMM1	-0.59	-6.53	-0.38	3.67e-10	Vitiligo;
KIRP	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.93	11.0	0.57	3.71e-23	Diastolic blood pressure;
KIRP	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg04226714	chr8:49833948	SNAI2	0.45	6.34	0.37	1.09e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.68	-9.1	-0.5	3.25e-17	Morning vs. evening chronotype;
KIRP	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg20578329	chr17:80767326	TBCD	-0.7	-8.14	-0.46	2e-14	Breast cancer;
KIRP	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.13	0.41	1.08e-11	Height;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.47	4.93	0.3	1.48e-6	Diastolic blood pressure;
KIRP	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg26531700	chr6:26746687	NA	0.41	5.57	0.33	6.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg07460842	chr6:66804631	NA	-0.49	-6.08	-0.36	4.46e-9	Blood trace element (Cu levels);
KIRP	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg24060327	chr5:131705240	SLC22A5	0.61	6.23	0.37	1.98e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs9815354	0.516	rs75047809	chr3:42033437	T/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.43	6.15	0.37	3.04e-9	Blood metabolite levels;
KIRP	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.6	-8.94	-0.5	9.68e-17	Coronary artery disease;
KIRP	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.85	0.4	5.77e-11	Myopia (pathological);
KIRP	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-9.18	-0.51	1.85e-17	Morning vs. evening chronotype;
KIRP	cis	rs838147	0.815	rs28400015	chr19:49250633	G/A	cg08619932	chr19:49200058	FUT2	-0.34	-5.25	-0.32	3.27e-7	Dietary macronutrient intake;
KIRP	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.51	6.21	0.37	2.18e-9	Lymphocyte counts;
KIRP	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg16497661	chr14:103986332	CKB	-0.89	-15.48	-0.7	3.39e-38	Body mass index;
KIRP	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.62	-6.96	-0.41	2.99e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.32	0.32	2.34e-7	Cognitive test performance;
KIRP	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg00277334	chr10:82204260	NA	-0.44	-4.89	-0.3	1.79e-6	Post bronchodilator FEV1;
KIRP	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	5.13	0.31	5.98e-7	Menarche (age at onset);
KIRP	cis	rs1507153	0.851	rs9352610	chr6:79389398	A/G	cg11833968	chr6:79620685	NA	-0.36	-4.9	-0.3	1.73e-6	Sjögren's syndrome;
KIRP	cis	rs838147	0.873	rs11667321	chr19:49250538	A/G	cg21064579	chr19:49206444	FUT2	-0.38	-5.02	-0.3	9.78e-7	Dietary macronutrient intake;
KIRP	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.41	-7.39	-0.43	2.29e-12	Refractive error;
KIRP	cis	rs7113850	0.541	rs2896686	chr11:24213156	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	8.4	0.47	3.64e-15	Bone fracture in osteoporosis;
KIRP	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.87	13.61	0.66	8.1e-32	Blood protein levels;
KIRP	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.09e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.35	-0.38	1.03e-9	Height;
KIRP	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23161317	chr6:28129485	ZNF389	0.42	4.97	0.3	1.26e-6	Depression;
KIRP	cis	rs12496230	0.794	rs7641377	chr3:66867094	T/C	cg17646820	chr3:66848679	NA	0.39	6.22	0.37	2.13e-9	Type 2 diabetes;
KIRP	cis	rs5753037	0.543	rs131287	chr22:30158463	C/T	cg01021169	chr22:30184971	ASCC2	-0.52	-7.01	-0.41	2.31e-11	Type 1 diabetes;
KIRP	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.59	6.17	0.37	2.81e-9	Gut microbiome composition (summer);
KIRP	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.68	9.62	0.52	8.27e-19	Retinal vascular caliber;
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21211367	chr2:162094118	NA	0.41	5.45	0.33	1.22e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs4561483	0.583	rs1019814	chr16:11940764	T/C	cg08843971	chr16:11963173	GSPT1	0.49	6.77	0.4	9.43e-11	Testicular germ cell tumor;
KIRP	cis	rs13323323	0.728	rs1004631	chr3:44592979	T/G	cg02073558	chr3:44770973	ZNF501	0.45	5.29	0.32	2.67e-7	IgG glycosylation;
KIRP	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.42	-5.36	-0.32	1.89e-7	Crohn's disease;
KIRP	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg04780086	chr2:111875790	ACOXL	0.43	6.13	0.36	3.42e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-7.38	-0.43	2.44e-12	Personality dimensions;
KIRP	trans	rs6572548	0.885	rs10141232	chr14:49624163	A/T	cg27110129	chr4:15683224	LOC285550	0.48	6.02	0.36	6.14e-9	Subjective well-being;
KIRP	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.41	5.57	0.33	6.65e-8	Total body bone mineral density;
KIRP	cis	rs7312774	0.748	rs4964191	chr12:107306497	G/A	cg16260113	chr12:107380972	MTERFD3	0.71	6.44	0.38	6.26e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.71	0.49	4.66e-16	Motion sickness;
KIRP	cis	rs12983728	0.572	rs59114323	chr19:58649994	C/T	cg07378217	chr19:58662286	ZNF329	-0.45	-4.87	-0.3	1.98e-6	Cholesterol, total;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	0.83	14.51	0.68	6.98e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg24488311	chr11:68621650	NA	0.43	5.2	0.31	4.26e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6684514	1.000	rs12023704	chr1:156294149	C/A	cg16558208	chr1:156270281	VHLL	-0.43	-5.55	-0.33	7.28e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs3120667	0.720	rs72698953	chr1:152410394	G/T	cg26876637	chr1:152193138	HRNR	-0.58	-5.37	-0.32	1.82e-7	Eating disorders;
KIRP	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.88	-0.35	1.3e-8	IgG glycosylation;
KIRP	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-5.75	-0.34	2.61e-8	Menarche (age at onset);
KIRP	cis	rs7503807	1.000	rs12939613	chr17:78588202	A/G	cg09596252	chr17:78655493	RPTOR	0.53	6.67	0.39	1.69e-10	Obesity;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.51	-8.98	-0.5	7.31e-17	Lymphocyte counts;
KIRP	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.42	-7.39	-0.43	2.22e-12	Refractive error;
KIRP	cis	rs7729447	0.813	rs10941022	chr5:32691416	C/T	cg16267343	chr5:32710456	NPR3	0.53	6.02	0.36	6.3e-9	Blood pressure;
KIRP	cis	rs8067545	0.532	rs17759041	chr17:19959966	A/G	cg04132472	chr17:19861366	AKAP10	0.42	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.8	-8.4	-0.47	3.68e-15	Blood protein levels;
KIRP	cis	rs61884328	0.777	rs61897776	chr11:47133419	C/G	cg23433285	chr11:47201945	PACSIN3	0.62	5.16	0.31	5e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs524023	0.874	rs519090	chr11:64456240	G/C	cg09231725	chr11:64357281	SLC22A12	0.58	7.77	0.44	2.16e-13	Urate levels in obese individuals;
KIRP	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.57	-0.33	6.72e-8	Recombination measurement;
KIRP	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg26513180	chr16:89883248	FANCA	0.51	6.46	0.38	5.59e-10	Hemoglobin concentration;
KIRP	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	14.56	0.68	4.7e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	1.06	15.47	0.7	3.71e-38	Menopause (age at onset);
KIRP	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23281280	chr6:28129359	ZNF389	0.45	4.96	0.3	1.34e-6	Depression;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg21761045	chr8:87354805	WWP1	-1.1	-6.1	-0.36	4.1e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg25922125	chr7:127225783	GCC1	-0.47	-5.03	-0.31	9.3e-7	Type 2 diabetes;
KIRP	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.31	-0.47	6.58e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs6939532	0.517	rs733528	chr6:26374903	A/G	cg14345882	chr6:26364793	BTN3A2	0.32	4.91	0.3	1.67e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.81	9.81	0.53	2.22e-19	Corneal astigmatism;
KIRP	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.66	9.61	0.52	9.17e-19	Dupuytren's disease;
KIRP	cis	rs2191566	1.000	rs369106	chr19:44506930	C/T	cg20607764	chr19:44506953	ZNF230	0.47	5.41	0.33	1.51e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.42	-5.47	-0.33	1.13e-7	Height;
KIRP	cis	rs580438	0.510	rs7641686	chr3:13435860	G/T	cg10657019	chr3:13328039	NA	-0.49	-6.3	-0.37	1.38e-9	Myringotomy;
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg10207240	chr12:122356781	WDR66	0.6	7.89	0.45	1.01e-13	Mean corpuscular volume;
KIRP	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.8	-12.61	-0.63	1.87e-28	Idiopathic membranous nephropathy;
KIRP	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.7	9.19	0.51	1.67e-17	Glomerular filtration rate (creatinine);
KIRP	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.27	27.59	0.87	2.94e-77	IgG glycosylation;
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.52	-7.59	-0.44	6.55e-13	Obesity-related traits;
KIRP	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg15556689	chr8:8085844	FLJ10661	0.54	7.01	0.41	2.25e-11	Retinal vascular caliber;
KIRP	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg01320579	chr17:75405842	SEPT9	0.47	7.63	0.44	5.29e-13	Airflow obstruction;
KIRP	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.36	6.61	0.39	2.35e-10	Refractive error;
KIRP	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.45	0.68	1.13e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.22	-0.37	2.13e-9	Retinal vascular caliber;
KIRP	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg20673091	chr1:2541236	MMEL1	-0.68	-10.63	-0.56	5.94e-22	Ulcerative colitis;
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-4.93	-0.3	1.55e-6	Longevity;Endometriosis;
KIRP	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13132184	0.507	rs17579610	chr4:38078571	C/G	cg14409701	chr4:38048871	TBC1D1	0.72	6.84	0.4	6.15e-11	Verbal declarative memory;
KIRP	cis	rs3007168	1.000	rs2999360	chr14:51605429	G/A	cg23942311	chr14:51606299	NA	0.53	5.54	0.33	7.84e-8	Cancer;
KIRP	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.7	0.39	1.38e-10	Neuroticism;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.53	-6.94	-0.4	3.37e-11	Renal function-related traits (BUN);
KIRP	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg14851346	chr12:38532713	NA	-0.39	-4.89	-0.3	1.82e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2594989	0.733	rs2616539	chr3:11580371	C/A	cg01796438	chr3:11312864	ATG7	-0.4	-5.26	-0.32	3.16e-7	Circulating chemerin levels;
KIRP	cis	rs997295	1.000	rs997295	chr15:68016343	G/T	cg14210607	chr15:68128175	NA	-0.31	-5.06	-0.31	8.37e-7	Motion sickness;
KIRP	cis	rs6882076	0.925	rs1393207	chr5:156397540	T/A	cg12943317	chr5:156479607	HAVCR1	-0.65	-7.97	-0.45	5.88e-14	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.73	-0.39	1.17e-10	Coronary artery disease;
KIRP	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.88	-0.3	1.92e-6	Cervical cancer;
KIRP	cis	rs918629	0.679	rs6883880	chr5:95271173	A/T	cg16656078	chr5:95278638	ELL2	-0.5	-7.24	-0.42	5.65e-12	IgG glycosylation;
KIRP	cis	rs7215564	0.908	rs55886624	chr17:78658657	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs494562	0.892	rs567686	chr6:86124164	A/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg01420254	chr6:26195488	NA	1.12	9.7	0.53	4.8e-19	Gout;Renal underexcretion gout;
KIRP	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg10503236	chr1:231470652	EXOC8	-0.53	-7.42	-0.43	1.86e-12	Hemoglobin concentration;
KIRP	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg07001201	chr5:642380	CEP72	0.68	6.1	0.36	4.08e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg02367723	chr1:46378857	MAST2	0.44	5.13	0.31	5.85e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg17595323	chr11:93583763	C11orf90	-0.41	-6.94	-0.4	3.52e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs981844	1.000	rs62325085	chr4:154663283	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.62	8.81	0.49	2.27e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07080220	chr10:102295463	HIF1AN	0.78	7.43	0.43	1.83e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs714515	0.934	rs2227200	chr1:172333448	A/G	cg01573306	chr1:172330400	DNM3	0.46	5.95	0.35	9.15e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	10.4	0.55	3.08e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs11209185	0.509	rs9436357	chr1:68452488	C/T	cg22082780	chr1:68452167	NA	0.37	5.43	0.33	1.38e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6681460	0.932	rs2146904	chr1:67160336	C/T	cg13052034	chr1:66999238	SGIP1	-0.38	-5.44	-0.33	1.28e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.77	10.22	0.55	1.15e-20	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.74	7.34	0.42	3.05e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-0.84	-9.24	-0.51	1.22e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12986413	0.935	rs36065733	chr19:2163771	T/G	cg09261902	chr19:2140048	AP3D1	0.64	9.92	0.53	9.65e-20	Height;
KIRP	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg18461458	chr19:21324796	ZNF431	-0.52	-4.86	-0.3	2.1e-6	Pain;
KIRP	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.93	14.58	0.68	4.03e-35	Coronary artery disease;
KIRP	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.59	7.28	0.42	4.61e-12	Monobrow;
KIRP	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg10547527	chr2:198650123	BOLL	-0.49	-4.87	-0.3	2.04e-6	Ulcerative colitis;
KIRP	cis	rs4073221	0.585	rs7426729	chr3:18320922	G/A	cg07694806	chr3:18168406	NA	-0.68	-5.96	-0.36	8.55e-9	Parkinson's disease;
KIRP	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg04691961	chr3:161091175	C3orf57	0.46	6.93	0.4	3.73e-11	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.66	-9.86	-0.53	1.48e-19	Total body bone mineral density;
KIRP	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.65	8.56	0.48	1.24e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg20312557	chr2:97357134	FER1L5	-0.75	-5.2	-0.31	4.29e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs4654899	0.802	rs2290381	chr1:21213271	C/A	cg05370193	chr1:21551575	ECE1	0.41	5.33	0.32	2.22e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg15839431	chr19:19639596	YJEFN3	-0.47	-5.14	-0.31	5.63e-7	Bipolar disorder;
KIRP	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg05187965	chr10:45406764	TMEM72	-0.32	-7.63	-0.44	5.23e-13	Mean corpuscular volume;
KIRP	trans	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg20285546	chr19:58728728	NA	-0.8	-6.05	-0.36	5.3300000000000004e-09	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.98	17.18	0.74	5.12e-44	Bone mineral density;
KIRP	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	1.17	10.23	0.55	1.06e-20	Skin colour saturation;
KIRP	cis	rs806321	0.510	rs1149866	chr13:50900431	T/C	cg10393508	chr13:50950265	NA	-0.44	-6.25	-0.37	1.76e-9	Multiple sclerosis;
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05665937	chr4:1216051	CTBP1	0.46	6.35	0.38	1.04e-9	Obesity-related traits;
KIRP	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg21827317	chr3:136751795	NA	0.37	5.1	0.31	6.68e-7	Neuroticism;
KIRP	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.95	-16.07	-0.72	3.29e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs7560272	0.538	rs4852977	chr2:73938295	C/T	cg20560298	chr2:73613845	ALMS1	0.46	5.44	0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg06307176	chr5:131281290	NA	0.54	5.96	0.36	8.47e-9	Life satisfaction;
KIRP	cis	rs6662572	0.737	rs4660901	chr1:46445257	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.18e-8	Blood protein levels;
KIRP	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg13385521	chr17:29058706	SUZ12P	0.56	5.14	0.31	5.68e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17209837	1.000	rs45447097	chr7:87086144	G/A	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.83	12.02	0.61	1.68e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg08662619	chr6:150070041	PCMT1	0.35	5.54	0.33	7.74e-8	Lung cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13794888	chr15:75917792	SNUPN	0.48	6.55	0.39	3.28e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.76	-10.12	-0.54	2.34e-20	Body mass index;
KIRP	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.47	-7.04	-0.41	1.95e-11	Daytime sleep phenotypes;
KIRP	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg16898833	chr6:26189333	HIST1H4D	0.92	5.66	0.34	4.26e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg03171003	chr2:111875934	NA	0.41	5.81	0.35	1.93e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.14	12.14	0.61	6.95e-27	Platelet count;
KIRP	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.09	0.41	1.45e-11	Retinal vascular caliber;
KIRP	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg10223061	chr2:219282414	VIL1	-0.37	-6.13	-0.36	3.39e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19671926	chr4:122722719	EXOSC9	0.5	6.04	0.36	5.54e-9	Type 2 diabetes;
KIRP	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.91	-14.52	-0.68	6.6e-35	Total body bone mineral density;
KIRP	cis	rs9400467	0.506	rs78344470	chr6:111761783	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.17	0.31	4.84e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.16	21.61	0.81	9.02e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.31	-0.32	2.51e-7	Body mass index;
KIRP	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg02175503	chr12:58329896	NA	0.54	5.84	0.35	1.69e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6539288	0.641	rs12318060	chr12:107340612	T/C	cg15890332	chr12:107067104	RFX4	0.37	5.95	0.35	8.98e-9	Total body bone mineral density;
KIRP	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.5	-7.9	-0.45	9.1e-14	Platelet distribution width;
KIRP	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.43	0.52	3.29e-18	Dupuytren's disease;
KIRP	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	7.25	0.42	5.43e-12	Retinal vascular caliber;
KIRP	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.71	-0.34	3.19e-8	Reticulocyte count;
KIRP	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.97	14.21	0.67	7.11e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg05347473	chr6:146136440	FBXO30	0.5	6.96	0.41	3.06e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg19773385	chr1:10388646	KIF1B	-0.72	-11.11	-0.58	1.63e-23	Hepatocellular carcinoma;
KIRP	cis	rs4774899	1.000	rs12899588	chr15:57476858	A/G	cg13626582	chr15:57592083	LOC283663	-0.21	-4.97	-0.3	1.28e-6	Urinary tract infection frequency;
KIRP	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.87	0.63	2.61e-29	Electrocardiographic conduction measures;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18317531	chr1:225688425	ENAH	0.46	7.25	0.42	5.5e-12	Migraine with aura;
KIRP	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg19045956	chr2:200819837	C2orf60;C2orf47	0.45	5.69	0.34	3.55e-8	Osteoporosis;
KIRP	cis	rs4132509	1.000	rs10803158	chr1:243923229	A/G	cg25706552	chr1:244017396	NA	0.57	7.77	0.44	2.09e-13	RR interval (heart rate);
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.62	8.8	0.49	2.53e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg10434728	chr15:90938212	IQGAP1	-0.43	-7.82	-0.45	1.51e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg23594656	chr7:65796392	TPST1	-0.45	-6.88	-0.4	5.02e-11	Aortic root size;
KIRP	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.46	-0.52	2.68e-18	Coronary artery disease;
KIRP	cis	rs4073416	0.518	rs7141536	chr14:65987312	T/A	cg03016385	chr14:66212404	NA	-0.53	-6.49	-0.38	4.62e-10	N-glycan levels;
KIRP	cis	rs17065868	1.000	rs61949805	chr13:45052265	G/C	cg10246903	chr13:45222710	NA	0.58	5.96	0.36	8.8e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.53	7.1	0.41	1.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg07741184	chr6:167504864	NA	-0.21	-5.46	-0.33	1.18e-7	Crohn's disease;
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs883565	0.519	rs704960	chr3:39184353	C/T	cg01426195	chr3:39028469	NA	0.43	6.55	0.39	3.34e-10	Handedness;
KIRP	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg09788416	chr12:39539408	NA	0.39	5.3	0.32	2.62e-7	Morning vs. evening chronotype;
KIRP	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	9.81	0.53	2.2e-19	Lymphocyte counts;
KIRP	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.31	0.47	6.48e-15	Total body bone mineral density;
KIRP	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg12623918	chr2:306882	NA	0.48	6.04	0.36	5.54e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14396892	chr9:96623032	NA	-0.36	-4.91	-0.3	1.67e-6	DNA methylation (variation);
KIRP	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg03929089	chr4:120376271	NA	0.65	6.43	0.38	6.52e-10	Axial length;
KIRP	cis	rs7123876	0.504	rs1157343	chr11:72429141	A/G	cg03713592	chr11:72463424	ARAP1	-0.42	-5.42	-0.33	1.45e-7	Body mass index;
KIRP	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-7.83	-0.45	1.43e-13	Platelet distribution width;
KIRP	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.38	0.43	2.41e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1712517	0.740	rs4293062	chr10:105052624	G/A	cg05636881	chr10:105038444	INA	0.45	6.58	0.39	2.8e-10	Migraine;
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13939156	chr17:80058883	NA	-0.5	-7.38	-0.43	2.41e-12	Life satisfaction;
KIRP	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.48	-5.74	-0.34	2.82e-8	Lung function (FVC);Lung function (FEV1);
KIRP	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg15556689	chr8:8085844	FLJ10661	0.54	7.35	0.42	2.96e-12	Neuroticism;
KIRP	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.41	8.4	0.47	3.49e-15	Vitiligo;
KIRP	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg17724175	chr1:150552817	MCL1	0.32	4.87	0.3	2e-6	Melanoma;
KIRP	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.47	7.56	0.43	7.76e-13	Eye color traits;
KIRP	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-1.04	-10.0	-0.54	5.55e-20	Blood pressure (smoking interaction);
KIRP	cis	rs3136516	1.000	rs3136516	chr11:46760756	G/A	cg16389345	chr11:46697382	NA	0.55	7.38	0.43	2.48e-12	Venous thromboembolism;
KIRP	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.54	-6.54	-0.38	3.5e-10	Uric acid levels;
KIRP	cis	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg11015470	chr5:28928158	NA	0.49	5.31	0.32	2.42e-7	Hip geometry;
KIRP	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.77	7.74	0.44	2.52e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg25730555	chr22:47059586	GRAMD4	0.6	9.12	0.5	2.73e-17	Urate levels in obese individuals;
KIRP	cis	rs9488822	0.662	rs195534	chr6:116254834	T/C	cg15226275	chr6:116381976	FRK	0.21	5.41	0.33	1.49e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs698833	1.000	rs1067352	chr2:44669724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.77	0.35	2.35e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13409248	chr3:40428643	ENTPD3	0.36	4.92	0.3	1.58e-6	Renal cell carcinoma;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13939156	chr17:80058883	NA	-0.49	-7.44	-0.43	1.72e-12	Life satisfaction;
KIRP	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-7.54	-0.43	9.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg15839431	chr19:19639596	YJEFN3	0.5	5.18	0.31	4.56e-7	Bipolar disorder;
KIRP	cis	rs7172809	0.573	rs1374201	chr15:77477873	G/A	cg05673287	chr15:77411982	SGK269	0.42	4.87	0.3	2e-6	Glucose homeostasis traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25313289	chr16:2264884	PGP	0.51	6.89	0.4	4.73e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4936894	0.500	rs6590056	chr11:124170064	A/G	cg27160556	chr11:124181099	OR8D1	0.43	6.16	0.37	2.88e-9	Aging (time to death);
KIRP	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.58	0.73	6.09e-42	Electrocardiographic conduction measures;
KIRP	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg10047753	chr17:41438598	NA	1.08	17.22	0.74	3.75e-44	Menopause (age at onset);
KIRP	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.67	-8.97	-0.5	7.61e-17	Huntington's disease progression;
KIRP	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg23280166	chr11:118938394	VPS11	0.63	7.71	0.44	3.05e-13	Coronary artery disease;
KIRP	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg13679303	chr9:96623674	NA	0.44	5.8	0.35	2e-8	DNA methylation (variation);
KIRP	cis	rs7640424	0.691	rs7648181	chr3:107833289	C/A	cg09227934	chr3:107805635	CD47	0.3	5.19	0.31	4.3e-7	Body mass index;
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.42	5.57	0.33	6.64e-8	Cardiovascular disease risk factors;
KIRP	cis	rs9810890	1.000	rs115394279	chr3:128493714	C/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs10864302	0.525	rs7528931	chr1:7429606	T/G	cg22122925	chr1:8073906	ERRFI1	0.38	4.93	0.3	1.53e-6	Photic sneeze reflex;
KIRP	trans	rs921874	0.553	rs2512396	chr11:86785643	A/C	cg20852851	chr2:240168848	HDAC4	0.47	6.08	0.36	4.54e-9	Total body bone mineral density;
KIRP	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.58	8.17	0.46	1.64e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.52e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg17764715	chr19:33622953	WDR88	0.68	8.25	0.47	9.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.87	8.4	0.47	3.47e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs12580194	0.593	rs58254871	chr12:55750281	G/A	cg19537932	chr12:55886519	OR6C68	-0.5	-6.38	-0.38	8.51e-10	Cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17781879	chr2:32234829	MEMO1	0.49	6.14	0.36	3.36e-9	Parkinson's disease;
KIRP	cis	rs858239	0.539	rs6955969	chr7:23186699	C/T	cg23682824	chr7:23144976	KLHL7	0.53	6.21	0.37	2.22e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.55	-7.52	-0.43	1.03e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	10.87	0.57	1.02e-22	Exhaled nitric oxide output;
KIRP	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.86	0.45	1.23e-13	Coffee consumption (cups per day);
KIRP	cis	rs4865169	0.691	rs1056364	chr4:57889677	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.48	-5.73	-0.34	2.93e-8	Breast cancer;
KIRP	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg14829360	chr17:73884958	NA	-0.6	-8.51	-0.48	1.74e-15	Psoriasis;
KIRP	cis	rs62413470	1.000	rs62406153	chr6:55935232	G/A	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24111466	chr12:886615	WNK1	-0.43	-6.37	-0.38	9.43e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	5.61	0.34	5.42e-8	Schizophrenia;
KIRP	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.61	7.64	0.44	4.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs780094	0.500	rs6760250	chr2:27812252	G/A	cg05484376	chr2:27715224	FNDC4	-0.37	-5.48	-0.33	1.06e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.4	0.33	1.54e-7	Type 2 diabetes;
KIRP	cis	rs4006360	0.601	rs349785	chr17:39254557	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.51	-7.67	-0.44	4.01e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs10858047	0.883	rs41274118	chr1:115119392	T/C	cg12756093	chr1:115239321	AMPD1	0.69	6.52	0.38	4.07e-10	Autism;
KIRP	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.6	6.28	0.37	1.51e-9	Urinary tract infection frequency;
KIRP	cis	rs12230513	0.732	rs61956303	chr12:55818071	C/A	cg11794356	chr12:55725991	OR6C3	-0.47	-5.83	-0.35	1.75e-8	Contrast sensitivity;
KIRP	cis	rs687432	0.924	rs714942	chr11:57696694	T/C	cg19752551	chr11:57585705	CTNND1	-0.72	-9.49	-0.52	2.08e-18	Parkinson's disease;
KIRP	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.37	-5.49	-0.33	9.95e-8	Alcoholic chronic pancreatitis;
KIRP	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg18357526	chr6:26021779	HIST1H4A	0.45	5.24	0.32	3.52e-7	Height;
KIRP	cis	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg25650185	chr19:21324782	ZNF431	0.48	4.97	0.3	1.25e-6	Pain;
KIRP	cis	rs2071403	0.509	rs11678852	chr2:1408101	A/T	cg07083862	chr2:1417248	TPO	0.33	4.97	0.3	1.27e-6	Thyroid peroxidase antibody positivity;
KIRP	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg07148914	chr20:33460835	GGT7	-0.52	-7.04	-0.41	1.94e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	trans	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg24644049	chr4:85504048	CDS1	1.0	6.97	0.41	2.88e-11	Skin colour saturation;
KIRP	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-9.84	-0.53	1.75e-19	Colorectal cancer;
KIRP	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.18	-0.42	8.45e-12	Aortic root size;
KIRP	cis	rs4356975	0.563	rs7441774	chr4:69964554	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.8	10.79	0.57	1.84e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg17646820	chr3:66848679	NA	0.76	9.43	0.52	3.29e-18	Type 2 diabetes;
KIRP	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.41	-4.86	-0.3	2.09e-6	Schizophrenia;
KIRP	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg25706552	chr1:244017396	NA	0.59	6.87	0.4	5.2e-11	RR interval (heart rate);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05064645	chr7:55086868	EGFR	0.48	6.69	0.39	1.51e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8084125	0.832	rs62105168	chr18:74944848	T/C	cg15443732	chr18:74961078	GALR1	0.51	4.91	0.3	1.65e-6	Obesity-related traits;
KIRP	cis	rs12042938	0.507	rs1765776	chr1:231731607	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.04	-0.54	4.21e-20	Neuranatomic and neurocognitive phenotypes;
KIRP	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg16141378	chr3:129829833	LOC729375	-0.47	-6.08	-0.36	4.48e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg26531700	chr6:26746687	NA	0.41	5.63	0.34	4.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.5	7.56	0.43	8.02e-13	Resting heart rate;
KIRP	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.43	5.41	0.33	1.47e-7	Platelet count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17422427	chr2:241507521	RNPEPL1	0.54	7.33	0.42	3.23e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg20991723	chr1:152506922	NA	-0.49	-5.93	-0.35	1.01e-8	Hair morphology;
KIRP	cis	rs501120	0.584	rs61857460	chr10:44688877	A/C	cg09554077	chr10:44749378	NA	0.58	6.02	0.36	6.44e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.79	-7.18	-0.42	8.2e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg03468072	chr12:39539422	NA	0.42	5.75	0.34	2.69e-8	Morning vs. evening chronotype;
KIRP	cis	rs1823913	0.637	rs12992372	chr2:192153977	A/G	cg12404831	chr2:192114017	MYO1B	0.52	6.97	0.41	2.89e-11	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14398548	chr9:136836252	VAV2	-0.44	-6.13	-0.36	3.52e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17023223	0.553	rs55696509	chr1:119686656	A/G	cg18261050	chr1:119551319	NA	0.57	6.5	0.38	4.37e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	9.11	0.5	3.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21659725	chr3:3221576	CRBN	-0.58	-7.15	-0.41	9.79e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.33	0.37	1.14e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.4	5.18	0.31	4.58e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.8	11.79	0.6	1.03e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.64	-6.21	-0.37	2.23e-9	White matter integrity;Neutrophil percentage of white cells;
KIRP	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17376030	chr22:41985996	PMM1	0.75	7.84	0.45	1.33e-13	Vitiligo;
KIRP	cis	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg06521331	chr12:34319734	NA	-0.6	-7.39	-0.43	2.32e-12	Morning vs. evening chronotype;
KIRP	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg17595323	chr11:93583763	C11orf90	0.37	6.38	0.38	8.64e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg00982548	chr2:198649783	BOLL	-0.54	-5.07	-0.31	7.65e-7	Ulcerative colitis;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg00684032	chr4:1343700	KIAA1530	0.54	7.31	0.42	3.85e-12	Longevity;
KIRP	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg12288994	chr5:1860383	NA	0.54	7.41	0.43	2.07e-12	Cardiovascular disease risk factors;
KIRP	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.79	-12.02	-0.61	1.66e-26	Dental caries;
KIRP	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg04990556	chr1:26633338	UBXN11	0.7	6.3	0.37	1.35e-9	Obesity-related traits;
KIRP	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg15556689	chr8:8085844	FLJ10661	-0.76	-10.99	-0.57	4.04e-23	Retinal vascular caliber;
KIRP	cis	rs9303542	0.625	rs8064626	chr17:46567851	G/A	cg04904318	chr17:46607828	HOXB1	-0.54	-5.83	-0.35	1.73e-8	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	1.04	14.54	0.68	5.39e-35	Menopause (age at onset);
KIRP	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.41	-5.78	-0.35	2.24e-8	Blood metabolite levels;
KIRP	cis	rs6545883	0.965	rs6545872	chr2:61724568	G/A	cg15711740	chr2:61764176	XPO1	-0.6	-8.13	-0.46	2.11e-14	Tuberculosis;
KIRP	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg01721255	chr8:58191610	C8orf71	0.57	5.19	0.31	4.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg14458575	chr2:238380390	NA	0.62	8.31	0.47	6.33e-15	Prostate cancer;
KIRP	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.43	5.38	0.32	1.69e-7	Melanoma;
KIRP	cis	rs1712517	0.836	rs11191649	chr10:105067037	T/C	cg05636881	chr10:105038444	INA	0.46	6.69	0.39	1.48e-10	Migraine;
KIRP	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27005255	chr2:198365139	HSPE1;HSPD1	0.53	6.78	0.4	8.9e-11	Parkinson's disease;
KIRP	cis	rs1805008	0.561	rs8046635	chr16:90123493	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.54	-5.55	-0.33	7.29e-8	Skin colour saturation;
KIRP	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.34	-4.85	-0.3	2.16e-6	Monocyte count;
KIRP	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg04310649	chr10:35416472	CREM	-0.57	-6.94	-0.4	3.45e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg16524733	chr11:117070046	TAGLN	-0.42	-5.42	-0.33	1.39e-7	Blood protein levels;
KIRP	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.12	-0.36	3.68e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22288737	chr3:52232028	ALAS1	0.48	6.1	0.36	4.1e-9	Parkinson's disease;
KIRP	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg19650706	chr5:140594406	PCDHB13	-0.45	-5.0	-0.3	1.07e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.15	0.36	3.17e-9	Menopause (age at onset);
KIRP	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.66	9.65	0.52	7.06e-19	Dupuytren's disease;
KIRP	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.35	0.32	2.06e-7	Homoarginine levels;
KIRP	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.67	-7.48	-0.43	1.31e-12	Gut microbiome composition (summer);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08643618	chr1:1189466	UBE2J2	0.53	6.5	0.38	4.52e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.93	0.35	1.04e-8	Total cholesterol levels;
KIRP	cis	rs6601327	0.665	rs9286060	chr8:9653145	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.06	-0.31	8.24e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg01200585	chr1:228362443	C1orf69	0.44	5.39	0.33	1.64e-7	Diastolic blood pressure;
KIRP	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.0	0.3	1.1e-6	Childhood ear infection;
KIRP	cis	rs10858047	0.883	rs1564824	chr1:115123747	A/G	cg12756093	chr1:115239321	AMPD1	0.69	6.52	0.38	4.07e-10	Autism;
KIRP	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg02297831	chr4:17616191	MED28	0.6	7.66	0.44	4.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-4.97	-0.3	1.28e-6	IgG glycosylation;
KIRP	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg04398451	chr17:18023971	MYO15A	0.65	8.86	0.49	1.63e-16	Total body bone mineral density;
KIRP	cis	rs5753037	0.809	rs17711377	chr22:30212986	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.0	-0.3	1.11e-6	Type 1 diabetes;
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.69	-10.57	-0.56	9.18e-22	Monocyte percentage of white cells;
KIRP	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg16558253	chr16:72132732	DHX38	-0.6	-9.04	-0.5	4.93e-17	Fibrinogen levels;
KIRP	cis	rs8067354	0.645	rs2645489	chr17:57883371	T/G	cg02344993	chr17:57696989	CLTC	0.61	5.86	0.35	1.46e-8	Hemoglobin concentration;
KIRP	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.62	-6.99	-0.41	2.54e-11	Asthma;
KIRP	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg00121533	chr1:75199117	CRYZ;TYW3	0.44	5.47	0.33	1.11e-7	Resistin levels;
KIRP	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.83	13.28	0.65	1.06e-30	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.95	7.59	0.44	6.51e-13	Type 2 diabetes nephropathy;
KIRP	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.42	7.17	0.42	8.49e-12	Renal cell carcinoma;
KIRP	cis	rs45544231	0.569	rs9933556	chr16:52548302	C/T	cg09051775	chr16:52580266	TOX3	-0.36	-5.01	-0.3	1.02e-6	Restless legs syndrome;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09379162	chr12:26267213	NA	0.45	6.03	0.36	5.84e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.53	5.11	0.31	6.5e-7	Gut microbiome composition (summer);
KIRP	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-7.98	-0.45	5.53e-14	Glomerular filtration rate;
KIRP	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.65	0.8	1.22e-55	Prudent dietary pattern;
KIRP	cis	rs17030434	0.954	rs6847810	chr4:154752789	C/T	cg14289246	chr4:154710475	SFRP2	-0.76	-9.42	-0.51	3.44e-18	Electrocardiographic conduction measures;
KIRP	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg22974920	chr21:40686053	BRWD1	-0.44	-5.19	-0.31	4.43e-7	Cognitive function;
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.83	-12.64	-0.63	1.52e-28	Paraoxonase activity;
KIRP	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.36	0.38	9.95e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg07653901	chr22:50250238	ZBED4	-0.46	-5.4	-0.33	1.58e-7	Schizophrenia;
KIRP	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	1.04	20.17	0.79	4.62e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.39	-0.47	3.86e-15	Total cholesterol levels;
KIRP	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.61	-8.81	-0.49	2.33e-16	Educational attainment;
KIRP	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6783573	0.894	rs939408	chr3:46599079	C/A	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.39	-4.95	-0.3	1.38e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7998202	0.614	rs420431	chr13:113346317	C/G	cg02820901	chr13:113351484	ATP11A	-0.69	-6.37	-0.38	9.15e-10	Glycated hemoglobin levels;
KIRP	cis	rs62344088	1.000	rs10037843	chr5:120078	G/C	cg22857025	chr5:266934	NA	-0.77	-4.95	-0.3	1.41e-6	Asthma (childhood onset);
KIRP	cis	rs829661	1.000	rs829671	chr2:30712152	C/T	cg10949345	chr2:30726833	LCLAT1	0.72	10.05	0.54	3.97e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg22508957	chr16:3507546	NAT15	0.58	7.16	0.42	9.46e-12	Tuberculosis;
KIRP	cis	rs12949688	0.967	rs7220397	chr17:55823522	C/G	cg12582317	chr17:55822272	NA	0.62	10.32	0.55	5.48e-21	Schizophrenia;
KIRP	cis	rs644148	1.000	rs644148	chr19:44970935	T/G	cg15540054	chr19:45004280	ZNF180	-0.65	-7.27	-0.42	4.65e-12	Personality dimensions;
KIRP	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.52	0.38	3.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.26	26.64	0.86	1.85e-74	IgG glycosylation;
KIRP	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg01631408	chr1:248437212	OR2T33	-0.65	-8.24	-0.47	1.01e-14	Common traits (Other);
KIRP	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.44	5.14	0.31	5.53e-7	Aortic root size;
KIRP	cis	rs1298062	0.790	rs2463245	chr19:50967250	C/G	cg17071417	chr19:50962282	MYBPC2	0.46	5.22	0.32	3.82e-7	Age of smoking initiation;
KIRP	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg04226714	chr8:49833948	SNAI2	-0.47	-6.68	-0.39	1.54e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg08761264	chr16:28874980	SH2B1	-0.51	-5.85	-0.35	1.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.13	-0.46	2.16e-14	Response to antipsychotic treatment;
KIRP	cis	rs2191566	0.576	rs393195	chr19:44493142	T/G	cg18700516	chr19:44507157	ZNF230	0.43	5.01	0.3	1.04e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.43	-5.87	-0.35	1.4e-8	Schizophrenia;
KIRP	cis	rs7258015	1.000	rs3176766	chr19:10449778	G/A	cg25279553	chr19:10444815	RAVER1;ICAM3	0.47	6.2	0.37	2.4e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs2067663	0.633	rs34317	chr5:88016008	A/G	cg18498987	chr5:88179539	MEF2C	-0.38	-5.1	-0.31	6.69e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	trans	rs17046216	0.930	rs6829944	chr4:166260601	A/G	cg23384093	chr5:170745466	NA	-0.45	-6.07	-0.36	4.82e-9	Insulin-related traits;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg16550656	chr5:61874017	LRRC70;IPO11	0.42	6.68	0.39	1.54e-10	Migraine with aura;
KIRP	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg23682824	chr7:23144976	KLHL7	0.48	5.55	0.33	7.28e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.06e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.46	-5.6	-0.34	5.75e-8	Longevity;Endometriosis;
KIRP	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg27165867	chr14:105738592	BRF1	-0.42	-5.07	-0.31	7.87e-7	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg20697188	chr5:82360356	TMEM167A;SCARNA18	0.4	6.33	0.37	1.15e-9	C-reactive protein;
KIRP	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.44	-6.0	-0.36	7.12e-9	Blood protein levels;
KIRP	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg08501292	chr6:25962987	TRIM38	1.08	8.17	0.46	1.67e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg24112000	chr20:60950667	NA	0.59	9.32	0.51	6.98e-18	Colorectal cancer;
KIRP	trans	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg00405596	chr8:11794950	NA	-0.46	-6.16	-0.37	2.89e-9	Joint mobility (Beighton score);
KIRP	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.75e-8	Neuroticism;
KIRP	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg14689365	chr7:158441557	NCAPG2	0.45	5.79	0.35	2.19e-8	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04781764	chr12:89893765	WDR51B	-0.48	-6.1	-0.36	4.19e-9	Parkinson's disease;
KIRP	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.14	0.31	5.56e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.82	10.86	0.57	1.02e-22	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16696536	chr3:59035729	C3orf67	-0.5	-6.51	-0.38	4.2e-10	Interleukin-4 levels;
KIRP	cis	rs2150410	0.764	rs2225425	chr21:40562130	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00261534	chr10:3826854	KLF6	0.71	6.45	0.38	5.84e-10	Lung function (FEV1);
KIRP	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg20169779	chr10:135381914	SYCE1	0.62	5.99	0.36	7.24e-9	Gout;
KIRP	cis	rs7551222	0.716	rs10900601	chr1:204572050	A/G	cg20240347	chr1:204465584	NA	-0.29	-4.86	-0.3	2.05e-6	Schizophrenia;
KIRP	cis	rs1420338	0.869	rs1362452	chr7:34170519	G/A	cg01275685	chr7:34179230	BMPER	-0.61	-9.43	-0.52	3.15e-18	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-6.69	-0.39	1.49e-10	Body mass index;
KIRP	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.18	20.73	0.8	6.56e-56	Cognitive function;
KIRP	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg19913688	chr11:428466	ANO9	-0.75	-5.53	-0.33	7.98e-8	Body mass index;
KIRP	cis	rs580438	0.529	rs6783861	chr3:13422989	T/G	cg10657019	chr3:13328039	NA	-0.51	-6.63	-0.39	2.16e-10	Myringotomy;
KIRP	cis	rs62384625	0.924	rs62384603	chr5:141480209	C/A	cg08523384	chr5:141488047	NDFIP1	-0.38	-5.13	-0.31	5.83e-7	White blood cell count (basophil);
KIRP	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg15352829	chr14:105391018	PLD4	0.49	10.17	0.54	1.69e-20	Rheumatoid arthritis;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg24874828	chr4:187887005	NA	-0.46	-6.7	-0.39	1.38e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.91	11.47	0.59	1.14e-24	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17376030	chr22:41985996	PMM1	0.72	7.69	0.44	3.44e-13	Vitiligo;
KIRP	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.56	-6.97	-0.41	2.98e-11	Longevity;Endometriosis;
KIRP	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00745463	chr17:30367425	LRRC37B	-0.72	-7.05	-0.41	1.81e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg05768032	chr16:30646687	NA	0.53	6.61	0.39	2.35e-10	Multiple myeloma;
KIRP	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.67	5.84	0.35	1.68e-8	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg01689657	chr7:91764605	CYP51A1	0.36	5.1	0.31	6.66e-7	Breast cancer;
KIRP	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg14458575	chr2:238380390	NA	0.55	6.07	0.36	4.77e-9	Prostate cancer;
KIRP	cis	rs2273156	0.706	rs35030792	chr14:35489123	C/T	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.16	-0.31	5.01e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg12435725	chr3:58293450	RPP14	-0.54	-5.67	-0.34	4e-8	Cholesterol, total;
KIRP	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg27624424	chr6:160112604	SOD2	0.54	6.49	0.38	4.69e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg13385521	chr17:29058706	SUZ12P	0.86	6.44	0.38	6.21e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg16482183	chr6:26056742	HIST1H1C	0.43	5.41	0.33	1.47e-7	Height;
KIRP	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg17764715	chr19:33622953	WDR88	0.54	5.8	0.35	1.98e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.92	13.88	0.66	1e-32	Mean corpuscular hemoglobin;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10836401	chr19:18654433	FKBP8	0.48	6.06	0.36	5.18e-9	Parkinson's disease;
KIRP	cis	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg00262122	chr8:11665843	FDFT1	-0.44	-5.33	-0.32	2.2e-7	Triglycerides;
KIRP	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg11833968	chr6:79620685	NA	-0.47	-7.1	-0.41	1.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg04132472	chr17:19861366	AKAP10	0.38	4.85	0.3	2.22e-6	Schizophrenia;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg25921512	chr19:36347698	KIRREL2	0.54	6.78	0.4	9.02e-11	Electroencephalogram traits;
KIRP	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.57	-8.5	-0.48	1.82e-15	Endometriosis;
KIRP	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.76	12.38	0.62	1.11e-27	Cancer;
KIRP	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.67	-7.42	-0.43	1.86e-12	Menarche (age at onset);
KIRP	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.57	-5.99	-0.36	7.28e-9	Obesity-related traits;
KIRP	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs3767633	0.925	rs10737502	chr1:161792321	G/A	cg09175582	chr1:161736000	ATF6	0.75	6.14	0.36	3.25e-9	IgG glycosylation;
KIRP	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Hypertriglyceridemia;
KIRP	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.87	-11.91	-0.6	3.99e-26	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.59	7.33	0.42	3.36e-12	Breast cancer;
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13732083	chr21:47605072	C21orf56	0.43	5.74	0.34	2.78e-8	Testicular germ cell tumor;
KIRP	cis	rs17095355	1.000	rs61614979	chr10:111743994	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.1	-0.36	4.11e-9	Biliary atresia;
KIRP	cis	rs1152591	0.505	rs968257	chr14:64680285	T/C	cg21174375	chr14:64681225	SYNE2	0.58	7.77	0.44	2.14e-13	Atrial fibrillation;
KIRP	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg02836325	chr17:76403955	PGS1	0.4	6.78	0.4	8.81e-11	HDL cholesterol;
KIRP	trans	rs1462872	0.736	rs327345	chr8:31796017	A/G	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs3026101	0.624	rs1806255	chr17:5314263	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	7.11	0.41	1.29e-11	Body mass index;
KIRP	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.42	-5.08	-0.31	7.32e-7	Iron status biomarkers;
KIRP	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.74	10.62	0.56	6.43e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs9393813	0.967	rs1883403	chr6:27350329	G/A	cg18711553	chr6:27366782	ZNF391	-0.37	-5.47	-0.33	1.13e-7	Bipolar disorder;
KIRP	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.7	-9.49	-0.52	2.14e-18	Breast cancer;
KIRP	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg09060608	chr5:178986726	RUFY1	0.52	8.22	0.46	1.17e-14	Lung cancer;
KIRP	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-8.5	-0.48	1.83e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs1978968	1.000	rs1076541	chr22:18440026	C/T	cg03078520	chr22:18463400	MICAL3	-0.76	-8.8	-0.49	2.4e-16	Presence of antiphospholipid antibodies;
KIRP	cis	rs7582720	1.000	rs74675536	chr2:203673073	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.63e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.56	6.59	0.39	2.6200000000000003e-10	Breast cancer;
KIRP	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg07843065	chr1:150265600	MRPS21	0.42	5.85	0.35	1.57e-8	Migraine;
KIRP	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.82	14.0	0.67	3.9e-33	Breast cancer;
KIRP	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg13072238	chr3:49761600	GMPPB	-0.59	-5.54	-0.33	7.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	0.609	rs7924834	chr11:71644333	C/T	cg26138937	chr11:71823887	C11orf51	0.91	6.64	0.39	2.01e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs1215050	0.791	rs783950	chr4:98878395	C/T	cg05340658	chr4:99064831	C4orf37	-0.58	-7.07	-0.41	1.61e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	1.18	12.94	0.64	1.41e-29	Psoriasis;
KIRP	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.57	-9.23	-0.51	1.31e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg23920097	chr1:209922102	NA	-0.46	-5.4	-0.33	1.6e-7	Red blood cell count;
KIRP	cis	rs7520050	0.966	rs10789481	chr1:46383583	C/G	cg03146154	chr1:46216737	IPP	-0.41	-5.1	-0.31	6.81e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg24879335	chr3:133465180	TF	0.5	8.02	0.46	4.22e-14	Iron status biomarkers;
KIRP	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg01879757	chr17:41196368	BRCA1	-0.56	-7.52	-0.43	1.04e-12	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.76	-0.44	2.29e-13	Blood protein levels;
KIRP	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg24488311	chr11:68621650	NA	0.43	5.5	0.33	9.72e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	6.32	0.37	1.2e-9	Menarche (age at onset);
KIRP	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.93	13.5	0.65	1.94e-31	Bladder cancer;
KIRP	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg25309564	chr22:51001381	C22orf41	0.77	5.36	0.32	1.94e-7	Narcolepsy;
KIRP	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg05527609	chr1:210001259	C1orf107	-0.46	-5.7	-0.34	3.34e-8	Red blood cell count;
KIRP	cis	rs9311676	0.632	rs57700771	chr3:58360327	G/A	cg06643156	chr3:58380774	PXK	0.36	5.14	0.31	5.72e-7	Systemic lupus erythematosus;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08167039	chr1:762232	NCRNA00115;LOC643837	0.55	6.37	0.38	9.16e-10	Lung cancer in ever smokers;
KIRP	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg27124370	chr19:33622961	WDR88	0.45	4.88	0.3	1.93e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg18132916	chr6:79620363	NA	-0.53	-7.44	-0.43	1.68e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21171335	chr12:122356390	WDR66	0.62	8.45	0.47	2.63e-15	Mean corpuscular volume;
KIRP	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.51	6.67	0.39	1.72e-10	Prudent dietary pattern;
KIRP	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg03714773	chr7:91764589	CYP51A1	0.33	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.27	-0.32	3.05e-7	Major depressive disorder;
KIRP	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-1.02	-10.01	-0.54	5.16e-20	IgG glycosylation;
KIRP	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg27411982	chr8:10470053	RP1L1	0.39	4.96	0.3	1.31e-6	Retinal vascular caliber;
KIRP	cis	rs3007168	1.000	rs3007167	chr14:51613041	C/T	cg23942311	chr14:51606299	NA	0.52	5.54	0.33	7.92e-8	Cancer;
KIRP	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs73200209	0.912	rs61935854	chr12:116655496	T/C	cg01776926	chr12:116560359	MED13L	-0.48	-5.66	-0.34	4.12e-8	Total body bone mineral density;
KIRP	cis	rs12210905	0.920	rs72839453	chr6:27265761	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.71	-0.39	1.35e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs5753618	0.583	rs5753612	chr22:31821479	T/C	cg02404636	chr22:31891804	SFI1	0.52	5.81	0.35	1.97e-8	Colorectal cancer;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.87	14.84	0.69	5.25e-36	Longevity;Endometriosis;
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.6	7.75	0.44	2.44e-13	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg19116668	chr7:99932089	PMS2L1	-0.42	-4.88	-0.3	1.87e-6	Coronary artery disease;
KIRP	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg05220968	chr6:146057943	EPM2A	0.41	5.18	0.31	4.55e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6142102	0.602	rs4911402	chr20:32667645	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.78	0.35	2.31e-8	Skin pigmentation;
KIRP	cis	rs9810890	1.000	rs79217699	chr3:128445585	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.55	-6.7	-0.39	1.39e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.66	8.99	0.5	6.74e-17	Coronary artery disease;
KIRP	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.92	11.51	0.59	8.41e-25	Obesity;Body mass index;
KIRP	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg26681399	chr22:41777847	TEF	-0.49	-5.0	-0.3	1.09e-6	Vitiligo;
KIRP	cis	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg00405596	chr8:11794950	NA	-0.51	-6.84	-0.4	6.08e-11	Monocyte count;
KIRP	cis	rs72634030	0.536	rs2309382	chr17:5268848	A/G	cg20802942	chr17:5185005	RABEP1	0.5	5.02	0.3	9.88e-7	Rheumatoid arthritis;
KIRP	cis	rs9972944	0.651	rs9897920	chr17:63832286	C/T	cg07283582	chr17:63770753	CCDC46	-0.5	-7.88	-0.45	1.08e-13	Total body bone mineral density;
KIRP	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	1.1	18.19	0.76	1.93e-47	Cognitive function;
KIRP	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.85	7.58	0.44	6.85e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.51	-0.33	9.14e-8	Neutrophil percentage of white cells;
KIRP	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.81	12.13	0.61	7.63e-27	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg06915872	chr16:87998081	BANP	-0.47	-5.03	-0.31	9.42e-7	Menopause (age at onset);
KIRP	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg10547527	chr2:198650123	BOLL	-0.54	-4.86	-0.3	2.08e-6	Ulcerative colitis;
KIRP	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.88	-15.41	-0.7	5.96e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.44	-6.2	-0.37	2.43e-9	Blood metabolite levels;
KIRP	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.66	-12.09	-0.61	1.03e-26	White blood cell count (basophil);
KIRP	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg00405596	chr8:11794950	NA	-0.48	-6.54	-0.38	3.45e-10	Neuroticism;
KIRP	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs490234	0.934	rs13284832	chr9:128435126	A/C	cg14078157	chr9:128172775	NA	-0.56	-6.74	-0.39	1.15e-10	Mean arterial pressure;
KIRP	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.54	7.14	0.41	1.08e-11	Tuberculosis;
KIRP	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.69	0.48	5.07e-16	Prudent dietary pattern;
KIRP	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg06740227	chr12:86229804	RASSF9	0.45	5.73	0.34	2.85e-8	Major depressive disorder;
KIRP	cis	rs882300	0.967	rs12691876	chr2:136963794	A/G	cg05194412	chr2:137003533	NA	-0.44	-5.91	-0.35	1.16e-8	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs6838801	0.964	rs4859701	chr4:77564469	T/G	cg17476223	chr4:77663285	SHROOM3	-0.52	-7.38	-0.43	2.48e-12	Cleft lip with or without cleft palate;
KIRP	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg12856521	chr11:46389249	DGKZ	0.49	6.7	0.39	1.37e-10	Crohn's disease;
KIRP	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg20587970	chr11:113659929	NA	-0.88	-9.52	-0.52	1.69e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs10267417	0.603	rs10250128	chr7:19940123	G/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.27	0.32	3.04e-7	Night sleep phenotypes;
KIRP	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg25856811	chr1:152973957	SPRR3	-0.36	-4.91	-0.3	1.64e-6	Inflammatory skin disease;
KIRP	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7017914	0.967	rs6993170	chr8:71693519	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.11	-0.31	6.32e-7	Bone mineral density;
KIRP	cis	rs17023223	0.537	rs1057990	chr1:119575232	T/C	cg05756136	chr1:119680316	WARS2	-0.56	-7.53	-0.43	9.6e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.62	-6.64	-0.39	2.04e-10	Iron status biomarkers;
KIRP	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.56	-6.27	-0.37	1.61e-9	Menarche (age at onset);
KIRP	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg10950524	chr7:2139216	MAD1L1	0.33	5.41	0.33	1.47e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.47	5.94	0.35	9.73e-9	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg01798813	chr17:3906674	NA	-0.52	-7.24	-0.42	5.89e-12	Type 2 diabetes;
KIRP	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg06640241	chr16:89574553	SPG7	0.83	13.15	0.64	2.92e-30	Multiple myeloma (IgH translocation);
KIRP	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.88	8.5	0.48	1.87e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	8.5	0.48	1.9e-15	Response to antipsychotic treatment;
KIRP	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.29	-0.37	1.44e-9	Acne (severe);
KIRP	cis	rs13132184	0.507	rs13129650	chr4:38025101	A/G	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.19	-0.31	4.35e-7	Verbal declarative memory;
KIRP	cis	rs3935685	0.874	rs4886521	chr15:78000321	A/G	cg25212270	chr15:78015279	NA	0.62	8.05	0.46	3.44e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.89	9.0	0.5	6.36e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs17641971	0.662	rs1828495	chr8:49945281	C/T	cg00325661	chr8:49890786	NA	0.38	4.86	0.3	2.14e-6	Blood metabolite levels;
KIRP	cis	rs2594989	1.000	rs2594990	chr3:11317897	G/T	cg01796438	chr3:11312864	ATG7	-0.7	-8.03	-0.46	4.02e-14	Circulating chemerin levels;
KIRP	cis	rs6110278	0.685	rs8116105	chr20:14417197	A/C	cg17696268	chr20:14319035	FLRT3;MACROD2	0.35	4.87	0.3	1.98e-6	Mean platelet volume;
KIRP	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.61	-7.29	-0.42	4.1e-12	Mosquito bite size;
KIRP	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-11.43	-0.59	1.51e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg07701084	chr6:150067640	NUP43	-0.56	-7.15	-0.41	1.01e-11	Testicular germ cell tumor;
KIRP	cis	rs16976116	0.901	rs1061822	chr15:55496058	A/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4664304	0.629	rs3792168	chr2:160846472	T/C	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.31	-0.32	2.4e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-6.98	-0.41	2.78e-11	Hip circumference adjusted for BMI;
KIRP	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	1.24	9.47	0.52	2.44e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs72829446	0.932	rs72827565	chr17:7469607	G/A	cg02795151	chr17:7402630	POLR2A	0.71	4.93	0.3	1.52e-6	Androgen levels;
KIRP	cis	rs9469913	0.799	rs6938239	chr6:34683635	G/A	cg17674042	chr6:34482479	PACSIN1	0.45	5.91	0.35	1.16e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg23649088	chr2:200775458	C2orf69	-0.6	-5.39	-0.32	1.69e-7	Schizophrenia;
KIRP	cis	rs4663866	0.901	rs35713061	chr2:239183774	C/T	cg16914508	chr2:239161102	PER2	0.73	5.29	0.32	2.74e-7	Irritable bowel syndrome;
KIRP	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.65	0.44	4.53e-13	Myopia (pathological);
KIRP	cis	rs12549025	0.782	rs3736030	chr8:23392733	C/T	cg08322043	chr8:23340750	NA	-0.61	-5.94	-0.35	9.83e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.66	7.76	0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.38	-0.32	1.69e-7	Bipolar disorder;
KIRP	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.39	0.43	2.34e-12	Retinal vascular caliber;
KIRP	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.79	11.66	0.6	2.59e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.34	0.62	1.47e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.38	5.56	0.33	7.18e-8	Insulin-like growth factors;
KIRP	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15533453	chr10:2542242	NA	0.32	5.64	0.34	4.66e-8	Age-related hearing impairment;
KIRP	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.51	6.27	0.37	1.65e-9	Menopause (age at onset);
KIRP	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.52	6.62	0.39	2.24e-10	Coronary heart disease;
KIRP	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	5.96	0.36	8.58e-9	Coffee consumption (cups per day);
KIRP	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg03684893	chr10:554711	DIP2C	0.35	4.88	0.3	1.88e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg01557791	chr16:72042693	DHODH	-0.65	-7.25	-0.42	5.28e-12	Blood protein levels;
KIRP	cis	rs7015630	0.657	rs6984540	chr8:90847952	A/T	cg18493113	chr8:90847772	NA	-0.55	-6.22	-0.37	2.18e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs28655083	0.956	rs35848061	chr16:77101327	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.5	-5.38	-0.32	1.7e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.58	-4.85	-0.3	2.2e-6	Menarche (age at onset);
KIRP	cis	rs11638511	0.582	rs2176752	chr15:78551678	T/C	cg08594606	chr15:78556512	DNAJA4	-0.4	-5.28	-0.32	2.84e-7	Red blood cell count;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-0.59	-8.15	-0.46	1.86e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg05315796	chr3:52349193	DNAH1	-0.44	-6.71	-0.39	1.3100000000000001e-10	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.37	-0.32	1.83e-7	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17286790	chr17:80096513	CCDC57	-0.42	-6.24	-0.37	1.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg17182837	chr8:41585554	ANK1	-0.47	-6.52	-0.38	4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.69	9.44	0.52	3.07e-18	Body mass index;
KIRP	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.12	0.5	2.82e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14579362	chr19:39926682	RPS16	0.54	7.05	0.41	1.76e-11	Parkinson's disease;
KIRP	cis	rs7640424	0.649	rs62262371	chr3:107896108	C/T	cg09227934	chr3:107805635	CD47	-0.36	-6.11	-0.36	3.85e-9	Body mass index;
KIRP	trans	rs12517041	0.938	rs7356572	chr5:23267525	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.58	-6.17	-0.37	2.81e-9	Calcium levels;
KIRP	cis	rs1961637	0.514	rs1440073	chr2:223891324	A/G	cg02552189	chr2:223891284	NA	-0.56	-8.13	-0.46	2.05e-14	Oropharynx cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg25989057	chr11:67250443	AIP	0.52	6.35	0.38	1.04e-9	Educational attainment;
KIRP	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18367020	chr2:73461259	CCT7;C2orf7	-0.45	-6.4	-0.38	7.86e-10	Metabolic traits;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg26826136	chr8:95274566	GEM	0.49	6.02	0.36	6.31e-9	Electroencephalogram traits;
KIRP	cis	rs8077577	1.000	rs62073605	chr17:18066791	C/T	cg09161412	chr17:18057145	MYO15A	-0.4	-5.11	-0.31	6.46e-7	Obesity-related traits;
KIRP	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Colorectal cancer;
KIRP	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg00631329	chr6:26305371	NA	0.56	7.01	0.41	2.22e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.51	0.43	1.06e-12	Testicular germ cell tumor;
KIRP	cis	rs7246657	0.722	rs6508736	chr19:38061757	A/G	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.48	-0.43	1.29e-12	Type 2 diabetes;
KIRP	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.62	8.1	0.46	2.62e-14	Coronary artery disease;
KIRP	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.67	10.6	0.56	7.32e-22	Cancer;
KIRP	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	7.31	0.42	3.69e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09845883	chr1:154197610	UBAP2L	0.51	6.36	0.38	9.68e-10	Interleukin-4 levels;
KIRP	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg05370193	chr1:21551575	ECE1	0.42	5.92	0.35	1.07e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-7.65	-0.44	4.56e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24549020	chr5:56110836	MAP3K1	0.58	5.54	0.33	7.87e-8	Initial pursuit acceleration;
KIRP	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg03808351	chr9:123631620	PHF19	0.45	6.32	0.37	1.22e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.69	8.7	0.49	4.69e-16	Height;
KIRP	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.32	18.83	0.77	1.38e-49	Corneal structure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27611857	chr2:99347979	MGAT4A	0.52	6.52	0.38	3.9e-10	Parkinson's disease;
KIRP	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.9	13.63	0.66	6.64e-32	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg18441811	chr11:71824068	C11orf51	-0.72	-4.85	-0.3	2.17e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-6.37	-0.38	9e-10	Self-reported allergy;
KIRP	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.86	-0.35	1.49e-8	Bipolar disorder;
KIRP	cis	rs7849270	0.959	rs913275	chr9:131910644	G/A	cg13538475	chr9:131942899	NA	-0.32	-5.27	-0.32	2.92e-7	Blood metabolite ratios;
KIRP	cis	rs1943345	0.536	rs12269817	chr11:82858667	T/C	cg07047830	chr11:82868014	PCF11	0.71	9.67	0.52	6.07e-19	Obesity-related traits;
KIRP	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.21	-0.37	2.19e-9	Bladder cancer;
KIRP	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.98	0.36	7.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08048268	chr3:133502702	NA	-0.4	-4.96	-0.3	1.31e-6	Iron status biomarkers;
KIRP	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.84	-0.35	1.65e-8	IgG glycosylation;
KIRP	cis	rs1832871	0.672	rs9457343	chr6:158740567	A/G	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg11189052	chr15:85197271	WDR73	0.56	5.9	0.35	1.18e-8	Schizophrenia;
KIRP	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg07001201	chr5:642380	CEP72	0.49	5.89	0.35	1.25e-8	Obesity-related traits;
KIRP	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.65	8.32	0.47	5.99e-15	Red blood cell count;
KIRP	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.96	0.54	7.57e-20	Body mass index;
KIRP	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.45	-5.83	-0.35	1.72e-8	Aortic root size;
KIRP	cis	rs7078219	0.505	rs6584282	chr10:101286495	A/G	cg07044859	chr10:101282883	NA	-0.27	-4.86	-0.3	2.08e-6	Dental caries;
KIRP	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.42	-8.42	-0.47	3.21e-15	Longevity;
KIRP	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.48	6.98	0.41	2.8e-11	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-1.0	-10.39	-0.55	3.24e-21	Systemic lupus erythematosus;
KIRP	cis	rs1009181	0.585	rs9379827	chr6:26153335	G/T	cg13736514	chr6:26305472	NA	-0.54	-5.65	-0.34	4.4e-8	Childhood ear infection;
KIRP	cis	rs503734	0.502	rs348876	chr3:100930989	A/G	cg27318481	chr3:100970896	IMPG2	-0.55	-7.31	-0.42	3.68e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs2898681	0.581	rs730247	chr4:53680696	T/G	cg00338735	chr4:53728038	RASL11B	0.43	5.34	0.32	2.09e-7	Optic nerve measurement (cup area);
KIRP	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.88	0.4	5e-11	Lung cancer;
KIRP	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg07701084	chr6:150067640	NUP43	0.7	9.37	0.51	4.92e-18	Lung cancer;
KIRP	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18932078	chr1:2524107	MMEL1	-0.41	-5.81	-0.35	1.9e-8	Ulcerative colitis;
KIRP	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-8.24	-0.46	1.06e-14	Homocysteine levels;
KIRP	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg21643547	chr1:205240462	TMCC2	-0.7	-10.64	-0.56	5.51e-22	Red blood cell count;
KIRP	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg19077165	chr18:44547161	KATNAL2	0.53	6.38	0.38	8.49e-10	Educational attainment;
KIRP	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg11608241	chr8:8085544	FLJ10661	-0.53	-6.85	-0.4	5.87e-11	Triglycerides;
KIRP	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.63	10.57	0.56	9.29e-22	Coronary artery disease;
KIRP	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.92	15.31	0.7	1.26e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.94	15.1	0.69	6.81e-37	Mean corpuscular volume;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg21786334	chr1:156265430	C1orf85	0.5	6.41	0.38	7.5e-10	Educational attainment;
KIRP	cis	rs12913538	0.552	rs8037466	chr15:62910862	C/T	cg09983546	chr15:62884068	NA	-0.48	-6.79	-0.4	8.32e-11	Sleep depth;
KIRP	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg03808351	chr9:123631620	PHF19	0.43	5.95	0.35	9.15e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg22974920	chr21:40686053	BRWD1	0.51	6.12	0.36	3.58e-9	Cognitive function;
KIRP	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg27205649	chr11:78285834	NARS2	0.84	11.61	0.59	4e-25	Alzheimer's disease (survival time);
KIRP	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.73	-5.81	-0.35	1.92e-8	Blood protein levels;
KIRP	cis	rs9948	1.000	rs72811623	chr2:97496473	C/T	cg20312557	chr2:97357134	FER1L5	-0.75	-5.44	-0.33	1.31e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.07	-0.36	4.76e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg12560992	chr17:57184187	TRIM37	-0.51	-6.07	-0.36	4.76e-9	Cognitive test performance;
KIRP	trans	rs12043259	0.730	rs7535216	chr1:204797460	A/C	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07522190	chr16:28925877	RABEP2	0.5	6.82	0.4	7.02e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg21775007	chr8:11205619	TDH	0.41	5.49	0.33	9.9e-8	Neuroticism;
KIRP	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg13607699	chr17:42295918	UBTF	-0.49	-6.06	-0.36	5.01e-9	Total body bone mineral density;
KIRP	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.46	5.46	0.33	1.18e-7	Carotid intima media thickness;
KIRP	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06382459	chr1:2159373	SKI	0.54	6.85	0.4	5.74e-11	Parkinson's disease;
KIRP	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.46	9.87	0.53	1.4e-19	Mean corpuscular volume;
KIRP	cis	rs10411936	0.682	rs6512113	chr19:16598269	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.48	5.02	0.3	9.94e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26207909	chr14:103986467	CKB	0.73	11.08	0.58	2.08e-23	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14260521	chr10:45496672	ZNF22;C10orf25	0.48	6.58	0.39	2.79e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2446066	0.659	rs11170569	chr12:53913426	T/G	cg16917193	chr12:54089295	NA	0.64	5.69	0.34	3.56e-8	Red blood cell count;
KIRP	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg18825076	chr15:78729989	IREB2	-0.44	-5.14	-0.31	5.59e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.19	-19.28	-0.78	4.35e-51	Ulcerative colitis;
KIRP	cis	rs6496667	0.779	rs3213649	chr15:90999128	A/C	cg10434728	chr15:90938212	IQGAP1	0.36	4.9	0.3	1.71e-6	Rheumatoid arthritis;
KIRP	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.71	-7.19	-0.42	7.84e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs4356975	0.563	rs4521414	chr4:69973525	C/A	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs2131877	0.529	rs1009642	chr3:194857586	A/G	cg13868855	chr3:194833887	C3orf21	0.43	4.93	0.3	1.49e-6	Non-small cell lung cancer;
KIRP	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.86	10.17	0.54	1.71e-20	Obesity-related traits;
KIRP	cis	rs6442310	0.534	rs709148	chr3:12450166	C/A	cg15873301	chr3:12045459	SYN2	-0.41	-5.55	-0.33	7.28e-8	Hematocrit;
KIRP	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg01422370	chr2:73384389	NA	0.42	5.5	0.33	9.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.1	0.5	3.11e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg16268157	chr7:99778414	STAG3	0.51	5.64	0.34	4.66e-8	Lung function (FEV1/FVC);
KIRP	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.54	-5.35	-0.32	2.02e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.72	10.92	0.57	6.85e-23	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09820084	chr6:18387507	RNF144B	0.52	7.02	0.41	2.21e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18845578	chr2:240003174	HDAC4	0.48	6.31	0.37	1.32e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg11833968	chr6:79620685	NA	-0.45	-6.87	-0.4	5.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.904	rs10875750	chr12:48545630	C/T	cg26205652	chr12:48591994	NA	0.78	10.47	0.56	1.84e-21	Longevity (90 years and older);
KIRP	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.31	-5.2	-0.31	4.11e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.21	22.03	0.81	3.85e-60	Cognitive function;
KIRP	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.66	-0.34	4.28e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs7180079	0.544	rs11071804	chr15:64975763	C/G	cg15337035	chr15:64978493	NA	-0.53	-5.67	-0.34	3.92e-8	Monocyte count;
KIRP	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg11189052	chr15:85197271	WDR73	0.48	4.95	0.3	1.35e-6	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg10254082	chr7:997346	NA	0.48	5.07	0.31	7.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2738048	0.724	rs2615768	chr8:6822606	C/T	cg02787689	chr8:6828103	DEFA10P	-0.31	-6.04	-0.36	5.79e-9	IgA nephropathy;
KIRP	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg05692746	chr2:100937584	LONRF2	-0.4	-5.25	-0.32	3.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7106204	0.534	rs16912285	chr11:24252528	A/G	ch.11.24196551F	chr11:24239977	NA	0.84	6.94	0.4	3.5e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.33	-4.94	-0.3	1.42e-6	Dupuytren's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11719452	chr7:100027776	MEPCE;ZCWPW1	0.54	7.09	0.41	1.43e-11	Parkinson's disease;
KIRP	trans	rs76288851	0.799	rs11708343	chr3:126501776	A/G	cg13821433	chr2:26726535	OTOF	0.57	6.45	0.38	6.05e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg20813462	chr7:2646259	IQCE	0.65	6.22	0.37	2.08e-9	Urate levels in lean individuals;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg07434166	chr2:3504718	ADI1	-0.46	-6.02	-0.36	6.19e-9	Select biomarker traits;
KIRP	cis	rs7572644	0.699	rs2337374	chr2:28200152	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26301689	chr3:142681704	PAQR9	0.47	6.42	0.38	6.8e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg11350586	chr17:70115862	SOX9	0.37	5.51	0.33	9.13e-8	Thyroid hormone levels;
KIRP	trans	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg06521331	chr12:34319734	NA	-0.6	-6.99	-0.41	2.59e-11	Bladder cancer;
KIRP	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	11.11	0.58	1.61e-23	Monocyte percentage of white cells;
KIRP	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.8	-0.4	7.87e-11	Hemoglobin concentration;
KIRP	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg06453172	chr10:134556979	INPP5A	-0.51	-5.82	-0.35	1.85e-8	Migraine;
KIRP	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11987759	chr7:65425863	GUSB	0.51	6.78	0.4	8.89e-11	Aortic root size;
KIRP	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg13397359	chr6:42928475	GNMT	0.42	4.95	0.3	1.41e-6	Blood protein levels;
KIRP	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.74	-9.38	-0.51	4.7e-18	Height;
KIRP	cis	rs7084402	0.967	rs1620186	chr10:60314275	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.53	-0.56	1.22e-21	Refractive error;
KIRP	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg06565975	chr8:143823917	SLURP1	0.46	7.3	0.42	3.9e-12	Urinary tract infection frequency;
KIRP	cis	rs9928842	0.882	rs6564241	chr16:75263974	T/C	cg09066997	chr16:75300724	BCAR1	0.65	5.32	0.32	2.39e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.45e-16	Motion sickness;
KIRP	cis	rs7560272	0.538	rs4241257	chr2:73938607	T/C	cg20560298	chr2:73613845	ALMS1	0.44	5.12	0.31	6.04e-7	Schizophrenia;
KIRP	cis	rs6142102	0.923	rs4911379	chr20:32535305	A/C	cg24642439	chr20:33292090	TP53INP2	0.52	5.7	0.34	3.47e-8	Skin pigmentation;
KIRP	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg06027949	chr8:82754900	SNX16	0.45	5.59	0.34	6.1e-8	Diastolic blood pressure;
KIRP	cis	rs9290877	0.667	rs9881900	chr3:188456990	A/G	cg17392043	chr3:188495102	LPP	-0.53	-6.89	-0.4	4.57e-11	IgE levels;
KIRP	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg05973401	chr12:123451056	ABCB9	0.64	7.67	0.44	3.9e-13	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.71	8.18	0.46	1.54e-14	Body mass index;
KIRP	cis	rs7923609	0.967	rs4454603	chr10:65012750	C/T	cg01631684	chr10:65280961	REEP3	-0.48	-5.66	-0.34	4.21e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19524238	chr7:2802976	GNA12	-0.39	-5.43	-0.33	1.32e-7	Height;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.67	7.67	0.44	3.89e-13	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.24	0.58	6.31e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9596863	0.749	rs11148280	chr13:54309804	A/G	ch.13.53330881F	chr13:54432880	NA	0.55	5.29	0.32	2.77e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs977987	0.528	rs9926933	chr16:75501567	A/G	cg03315344	chr16:75512273	CHST6	-0.5	-6.08	-0.36	4.59e-9	Dupuytren's disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25806613	chr6:131923464	MED23	0.41	6.04	0.36	5.59e-9	Migraine with aura;
KIRP	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	1.03	14.03	0.67	2.95e-33	Menopause (age at onset);
KIRP	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.74	-8.91	-0.49	1.16e-16	Response to antineoplastic agents;
KIRP	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.58	8.47	0.48	2.25e-15	Itch intensity from mosquito bite;
KIRP	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.81	-8.94	-0.5	9.65e-17	Neuroblastoma;
KIRP	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg10434728	chr15:90938212	IQGAP1	0.42	7.29	0.42	4.32e-12	Rheumatoid arthritis;
KIRP	cis	rs8084125	1.000	rs62105170	chr18:74945570	A/G	cg26065057	chr18:74961000	GALR1	0.76	7.41	0.43	1.99e-12	Obesity-related traits;
KIRP	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.44	-5.96	-0.36	8.51e-9	Systolic blood pressure;
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg16586182	chr3:47516702	SCAP	-0.75	-10.49	-0.56	1.67e-21	Colorectal cancer;
KIRP	cis	rs6882046	0.513	rs1081158	chr5:88004616	C/T	cg24804195	chr5:87968844	LOC645323	-0.45	-6.05	-0.36	5.49e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs7252505	0.772	rs6510356	chr19:33617583	C/T	cg17764715	chr19:33622953	WDR88	0.64	5.64	0.34	4.58e-8	Colorectal cancer;
KIRP	cis	rs9473924	0.632	rs9369988	chr6:50921271	G/T	cg03432817	chr6:50765336	NA	0.35	5.4	0.33	1.59e-7	Body mass index;
KIRP	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.67	-8.53	-0.48	1.48e-15	Longevity;
KIRP	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15369054	chr17:80825471	TBCD	-0.59	-6.4	-0.38	7.77e-10	Breast cancer;
KIRP	cis	rs4835473	0.932	rs6851999	chr4:144663720	G/C	cg08833778	chr4:144622313	FREM3	0.34	4.98	0.3	1.19e-6	Immature fraction of reticulocytes;
KIRP	cis	rs7709377	0.546	rs2063250	chr5:115436807	A/G	cg23108291	chr5:115420582	COMMD10	0.43	5.15	0.31	5.21e-7	Metabolite levels  (X-11787);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20445883	chr11:61129875	TMEM138;CYBASC3	0.49	6.24	0.37	1.87e-9	Parkinson's disease;
KIRP	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.73	10.98	0.57	4.29e-23	Menarche (age at onset);
KIRP	cis	rs2273669	0.510	rs11757590	chr6:109370003	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.41	-0.38	7.27e-10	Prostate cancer;
KIRP	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.93	14.83	0.69	5.77e-36	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19231632	chr19:49661071	TRPM4	0.51	6.72	0.39	1.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg25174290	chr11:3078921	CARS	-0.69	-8.96	-0.5	8.26e-17	Calcium levels;
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.84	11.5	0.59	8.82e-25	Height;
KIRP	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg18882449	chr10:104885122	NT5C2	-0.51	-6.5	-0.38	4.48e-10	Arsenic metabolism;
KIRP	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg13512537	chr8:22265999	SLC39A14	-0.48	-6.56	-0.39	3.21e-10	Verbal declarative memory;
KIRP	cis	rs6973256	0.583	rs2345943	chr7:133340630	A/G	cg10665199	chr7:133106180	EXOC4	-0.48	-5.99	-0.36	7.39e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg25338242	chr13:114786047	RASA3	0.43	5.02	0.3	1e-6	Schizophrenia;
KIRP	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.48	-5.79	-0.35	2.14e-8	Blood metabolite levels;
KIRP	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg23127183	chr11:57508653	C11orf31	-0.46	-6.3	-0.37	1.33e-9	Schizophrenia;
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	6.0	0.36	6.98e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.07	-13.43	-0.65	3.21e-31	Vitiligo;
KIRP	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10421328	0.821	rs2288867	chr19:19765568	C/T	cg03709012	chr19:19516395	GATAD2A	0.44	5.13	0.31	5.94e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.85	-0.35	1.57e-8	Electroencephalogram traits;
KIRP	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg04369109	chr6:150039330	LATS1	-0.65	-8.3	-0.47	6.96e-15	Lung cancer;
KIRP	trans	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg25214090	chr10:38739885	LOC399744	0.67	7.55	0.43	8.36e-13	Corneal astigmatism;
KIRP	cis	rs7017914	0.967	rs62530792	chr8:71618767	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs1009170	0.794	rs61988399	chr14:92581494	T/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.55	5.46	0.33	1.18e-7	Dialysis-related mortality;
KIRP	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg09579323	chr1:150459698	TARS2	0.41	4.86	0.3	2.1e-6	Migraine;
KIRP	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11987759	chr7:65425863	GUSB	-0.62	-8.29	-0.47	7.24e-15	Aortic root size;
KIRP	cis	rs2820315	0.867	rs2819346	chr1:201882087	A/C	cg11586189	chr1:201857591	SHISA4	-0.41	-6.04	-0.36	5.79e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7215564	0.818	rs1471790	chr17:78670565	C/A	cg06153925	chr17:78755379	RPTOR	0.32	5.14	0.31	5.6e-7	Myopia (pathological);
KIRP	cis	rs2916247	1.000	rs2920465	chr8:92996143	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.61	-0.48	8.66e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs7737355	1.000	rs12517604	chr5:130748500	T/C	cg06647332	chr5:131281008	NA	-0.46	-5.08	-0.31	7.57e-7	Life satisfaction;
KIRP	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg11271282	chr2:238384023	NA	0.46	5.36	0.32	1.89e-7	Prostate cancer;
KIRP	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.09	0.36	4.21e-9	Height;
KIRP	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24110177	chr3:50126178	RBM5	-0.65	-8.78	-0.49	2.86e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs568617	0.533	rs679147	chr11:65644363	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.52	-6.17	-0.37	2.87e-9	Crohn's disease;
KIRP	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-1.0	-14.52	-0.68	6.5e-35	Diastolic blood pressure;
KIRP	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.65	7.76	0.44	2.2e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg18876405	chr7:65276391	NA	0.41	4.9	0.3	1.74e-6	Aortic root size;
KIRP	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.42	0.59	1.59e-24	Alzheimer's disease;
KIRP	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.66	9.38	0.51	4.5e-18	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.41	-4.92	-0.3	1.58e-6	Coronary artery disease;
KIRP	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg21545522	chr1:205238299	TMCC2	0.39	5.29	0.32	2.69e-7	Red blood cell count;
KIRP	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg08807101	chr21:30365312	RNF160	0.59	7.05	0.41	1.79e-11	Pancreatic cancer;
KIRP	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	5.82	0.35	1.84e-8	Homoarginine levels;
KIRP	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg19077165	chr18:44547161	KATNAL2	0.47	5.57	0.33	6.64e-8	Educational attainment;
KIRP	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.67	8.82	0.49	2.2e-16	Motion sickness;
KIRP	cis	rs10046574	0.561	rs6966294	chr7:135196479	G/A	cg27474649	chr7:135195673	CNOT4	0.55	4.97	0.3	1.24e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg21918786	chr6:109611834	NA	0.39	5.57	0.33	6.64e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg20368463	chr18:77673604	PQLC1	-0.46	-5.77	-0.35	2.33e-8	Schizophrenia;
KIRP	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg02151108	chr14:50098012	C14orf104	-0.59	-8.19	-0.46	1.39e-14	Carotid intima media thickness;
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg07701084	chr6:150067640	NUP43	0.72	9.8	0.53	2.39e-19	Lung cancer;
KIRP	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.74	8.07	0.46	3.19e-14	Plateletcrit;
KIRP	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.53	0.33	8.06e-8	Lung cancer;
KIRP	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg15083037	chr5:83017644	HAPLN1	-0.6	-8.33	-0.47	5.59e-15	Prostate cancer;
KIRP	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg05785598	chr3:49045655	WDR6	0.29	5.29	0.32	2.64e-7	Parkinson's disease;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.76	6.24	0.37	1.86e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.63	-6.61	-0.39	2.41e-10	Menarche (age at onset);
KIRP	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg07395648	chr5:131743802	NA	-0.38	-5.59	-0.34	6.13e-8	Acylcarnitine levels;
KIRP	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg15704280	chr7:45808275	SEPT13	-0.56	-6.32	-0.37	1.2e-9	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg20587970	chr11:113659929	NA	-0.88	-9.53	-0.52	1.57e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs2151522	0.603	rs9401920	chr6:127189394	G/A	cg21431617	chr6:127135037	NA	0.31	5.47	0.33	1.11e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.96	-0.41	3e-11	Mean corpuscular volume;
KIRP	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg08662619	chr6:150070041	PCMT1	0.32	4.92	0.3	1.59e-6	Lung cancer;
KIRP	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.41	-4.96	-0.3	1.31e-6	P wave terminal force;
KIRP	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.44	5.16	0.31	5.07e-7	Aortic root size;
KIRP	cis	rs478607	0.831	rs59739006	chr11:64415903	C/T	cg09231725	chr11:64357281	SLC22A12	-0.66	-5.19	-0.31	4.41e-7	Urate levels;
KIRP	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg18461458	chr19:21324796	ZNF431	-0.48	-5.06	-0.31	8.19e-7	Pain;
KIRP	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.56	5.19	0.31	4.39e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
KIRP	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg01181863	chr3:195395398	SDHAP2	-0.44	-4.95	-0.3	1.35e-6	Mean corpuscular volume;
KIRP	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.45e-7	Alzheimer's disease (survival time);
KIRP	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg16141378	chr3:129829833	LOC729375	0.52	6.43	0.38	6.57e-10	Joint mobility (Beighton score);
KIRP	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	8.19	0.46	1.41e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg21905437	chr5:178450457	ZNF879	0.57	6.66	0.39	1.74e-10	Pubertal anthropometrics;
KIRP	cis	rs62355272	0.900	rs10052964	chr5:35832221	C/T	cg13894535	chr5:35919491	CAPSL	-0.4	-5.08	-0.31	7.31e-7	Lymphocyte counts;
KIRP	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17507749	chr15:85114479	UBE2QP1	0.7	7.87	0.45	1.14e-13	Schizophrenia;
KIRP	cis	rs12983728	0.505	rs35511051	chr19:58665817	C/A	cg07378217	chr19:58662286	ZNF329	-0.45	-4.96	-0.3	1.34e-6	Cholesterol, total;
KIRP	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.36	-0.38	9.69e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-1.08	-21.48	-0.81	2.32e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-6.18	-0.37	2.57e-9	Height;
KIRP	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg05347473	chr6:146136440	FBXO30	0.61	8.51	0.48	1.79e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg07395648	chr5:131743802	NA	0.6	8.85	0.49	1.77e-16	Blood metabolite levels;
KIRP	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg08648136	chr8:956695	NA	0.42	6.27	0.37	1.59e-9	Schizophrenia;
KIRP	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.61	-6.36	-0.38	9.52e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1440410	0.763	rs1039762	chr4:144168046	T/C	cg01719995	chr4:144104893	USP38	0.41	5.42	0.33	1.43e-7	Ischemic stroke;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.82	7.48	0.43	1.33e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.61	8.08	0.46	2.99e-14	Economic and political preferences (feminism/equality);
KIRP	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.72	0.34	3.02e-8	Breast cancer;
KIRP	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.48	-7.24	-0.42	5.76e-12	Vitamin D levels;
KIRP	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.76	9.5	0.52	1.97e-18	White matter hyperintensity burden;
KIRP	cis	rs9547996	0.879	rs11618138	chr13:38195296	C/T	cg13634560	chr13:38173852	POSTN	-0.38	-5.2	-0.31	4.24e-7	Diastolic blood pressure;
KIRP	cis	rs80282103	0.618	rs74117850	chr10:1165777	T/C	cg08668510	chr10:1095578	IDI1	0.93	6.16	0.37	2.96e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.18	16.11	0.72	2.33e-40	White matter hyperintensity burden;
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.61	5.76	0.34	2.45e-8	Alzheimer's disease;
KIRP	cis	rs1975991	0.711	rs1479934	chr3:187966553	A/G	cg17585528	chr3:187988060	LPP	-0.41	-4.89	-0.3	1.85e-6	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.76	-6.4	-0.38	7.84e-10	Diabetic retinopathy;
KIRP	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg25482853	chr8:67687455	SGK3	0.8	7.01	0.41	2.26e-11	Obesity-related traits;
KIRP	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg19913688	chr11:428466	ANO9	-0.83	-6.53	-0.38	3.76e-10	Body mass index;
KIRP	cis	rs1355223	0.902	rs1258470	chr11:34729265	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.42	5.05	0.31	8.76e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs34779708	0.801	rs12246600	chr10:35538121	A/C	cg03585969	chr10:35415529	CREM	0.64	7.53	0.43	9.49e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs42648	0.564	rs10270950	chr7:89807296	A/T	cg25739043	chr7:89950458	NA	-0.32	-4.99	-0.3	1.16e-6	Homocysteine levels;
KIRP	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.33	-0.37	1.16e-9	Arsenic metabolism;
KIRP	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-9.3	-0.51	7.72e-18	Colorectal cancer;
KIRP	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.8	13.64	0.66	6.41e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02298881	chr14:74318444	PTGR2	0.46	6.17	0.37	2.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg15488143	chr7:128924101	AHCYL2	0.61	6.59	0.39	2.64e-10	White matter hyperintensity burden;
KIRP	cis	rs2131877	0.573	rs950257	chr3:194847650	T/A	cg19775763	chr3:194786989	NA	-0.42	-5.25	-0.32	3.33e-7	Non-small cell lung cancer;
KIRP	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg06636001	chr8:8085503	FLJ10661	0.52	6.6	0.39	2.51e-10	Myopia (pathological);
KIRP	cis	rs6992848	0.759	rs4736021	chr8:141173692	G/A	cg13911501	chr8:141220320	TRAPPC9	0.41	5.03	0.31	9.59e-7	Response to amphetamines;
KIRP	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.62	-0.34	5.17e-8	Aortic root size;
KIRP	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.87	-9.05	-0.5	4.4e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg09267113	chr7:98030324	BAIAP2L1	0.44	5.27	0.32	2.94e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg07701084	chr6:150067640	NUP43	0.59	7.6	0.44	6.18e-13	Lung cancer;
KIRP	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-8.05	-0.46	3.47e-14	Response to antipsychotic treatment;
KIRP	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg10189774	chr4:17578691	LAP3	0.49	5.94	0.35	9.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.94	9.7	0.53	4.67e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs897080	0.515	rs698791	chr2:44683168	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	5.81	0.35	1.97e-8	Height;
KIRP	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.12	0.31	6.2e-7	Depression;
KIRP	cis	rs2380205	0.689	rs12769593	chr10:5897993	C/G	cg27141509	chr10:5886111	NA	-0.43	-5.97	-0.36	8.27e-9	Breast cancer;
KIRP	cis	rs4901847	1.000	rs12884702	chr14:58555329	A/T	cg15908186	chr14:58618357	C14orf37	0.41	5.38	0.32	1.72e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-6.83	-0.4	6.74e-11	Vitiligo;
KIRP	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg24631222	chr15:78858424	CHRNA5	0.75	9.02	0.5	5.68e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-10.11	-0.54	2.58e-20	Plateletcrit;Platelet count;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09246302	chr7:112121036	C7orf53	0.56	6.57	0.39	3.05e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg06521331	chr12:34319734	NA	-0.54	-6.7	-0.39	1.41e-10	Bladder cancer;
KIRP	cis	rs10924970	0.781	rs10802590	chr1:235444051	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg02782426	chr3:40428986	ENTPD3	-0.32	-4.88	-0.3	1.92e-6	Renal cell carcinoma;
KIRP	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs4835473	0.932	rs2323200	chr4:144686601	G/A	cg08833778	chr4:144622313	FREM3	0.35	5.03	0.31	9.59e-7	Immature fraction of reticulocytes;
KIRP	cis	rs4594175	0.926	rs10135534	chr14:51617970	C/A	cg23942311	chr14:51606299	NA	0.54	7.08	0.41	1.47e-11	Cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14159971	chr2:239228995	TRAF3IP1	0.49	6.34	0.37	1.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2013441	0.670	rs4924802	chr17:19955895	G/T	cg04132472	chr17:19861366	AKAP10	0.43	4.98	0.3	1.2e-6	Obesity-related traits;
KIRP	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg08076091	chr2:203926405	NBEAL1	0.94	9.12	0.5	2.8e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg10495392	chr1:46806563	NSUN4	0.48	5.5	0.33	9.56e-8	Menopause (age at onset);
KIRP	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.3	-5.25	-0.32	3.35e-7	Height;
KIRP	cis	rs9487051	0.714	rs6932503	chr6:109607958	G/A	cg21918786	chr6:109611834	NA	-0.44	-6.28	-0.37	1.55e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg24579218	chr15:68104479	NA	0.39	6.43	0.38	6.65e-10	Restless legs syndrome;
KIRP	cis	rs12765878	0.692	rs10883926	chr10:105608838	G/A	cg11005552	chr10:105648138	OBFC1	0.38	5.12	0.31	6.32e-7	Coronary artery disease;
KIRP	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg08761264	chr16:28874980	SH2B1	-0.51	-5.9	-0.35	1.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg02820040	chr2:241836501	C2orf54	-0.24	-5.42	-0.33	1.44e-7	Urinary metabolites;
KIRP	cis	rs737008	0.500	rs7189239	chr16:11402515	T/C	cg00044050	chr16:11439710	C16orf75	0.68	8.53	0.48	1.49e-15	Obesity-related traits;
KIRP	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg20701182	chr2:24300061	SF3B14	0.91	10.15	0.54	1.92e-20	Lymphocyte counts;
KIRP	cis	rs6504622	0.557	rs7225428	chr17:45000997	G/A	cg16759221	chr17:45003025	GOSR2	0.35	5.26	0.32	3.13e-7	Orofacial clefts;
KIRP	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg10503236	chr1:231470652	EXOC8	0.47	6.67	0.39	1.63e-10	Hemoglobin concentration;
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg09699651	chr6:150184138	LRP11	0.46	5.95	0.35	9.22e-9	Lung cancer;
KIRP	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg21775007	chr8:11205619	TDH	-0.43	-5.64	-0.34	4.59e-8	Monocyte count;
KIRP	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.47	6.55	0.39	3.32e-10	Testicular germ cell tumor;
KIRP	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.19e-9	Breast cancer;
KIRP	cis	rs362272	0.525	rs1313768	chr4:3054017	T/C	cg13731523	chr4:3047190	NA	-0.36	-6.62	-0.39	2.18e-10	Serum sulfate level;
KIRP	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23544223	chr18:12777786	NA	0.76	6.46	0.38	5.61e-10	Inflammatory skin disease;
KIRP	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg25173405	chr17:45401733	C17orf57	0.41	5.34	0.32	2.13e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	0.93	14.16	0.67	1.11e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4713675	0.584	rs4711339	chr6:33667199	A/G	cg15676125	chr6:33679581	C6orf125	0.42	5.53	0.33	8.32e-8	Plateletcrit;
KIRP	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg04132472	chr17:19861366	AKAP10	-0.41	-5.33	-0.32	2.19e-7	Schizophrenia;
KIRP	cis	rs3540	0.960	rs60825716	chr15:90958053	G/A	cg22089800	chr15:90895588	ZNF774	0.42	4.95	0.3	1.4e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.28	0.58	4.68e-24	Alzheimer's disease;
KIRP	cis	rs939574	0.790	rs72955440	chr2:220091765	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	6.12	0.36	3.67e-9	Platelet distribution width;
KIRP	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.55	6.38	0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-5.02	-0.3	9.86e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.26	-0.37	1.66e-9	Asthma;
KIRP	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg04833713	chr10:74871078	NUDT13	0.5	5.81	0.35	1.95e-8	Incident atrial fibrillation;
KIRP	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.79	0.63	4.52e-29	Ileal carcinoids;
KIRP	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg24747557	chr10:131355152	MGMT	-0.4	-5.39	-0.32	1.67e-7	Response to temozolomide;
KIRP	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg02574844	chr11:5959923	NA	-0.55	-5.61	-0.34	5.38e-8	DNA methylation (variation);
KIRP	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	1.05	19.05	0.77	2.59e-50	Heart rate;
KIRP	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg16309518	chr5:176445507	NA	-0.88	-13.69	-0.66	4.31e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg06647332	chr5:131281008	NA	0.47	5.13	0.31	5.75e-7	Life satisfaction;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg09699651	chr6:150184138	LRP11	0.45	6.01	0.36	6.5e-9	Lung cancer;
KIRP	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.46	-9.63	-0.52	7.75e-19	Longevity;
KIRP	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg25783544	chr11:47291846	MADD	0.44	4.92	0.3	1.58e-6	HDL cholesterol;
KIRP	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.82	-0.35	1.81e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg24631222	chr15:78858424	CHRNA5	0.4	5.1	0.31	6.63e-7	Sudden cardiac arrest;
KIRP	cis	rs6142102	1.000	rs4911414	chr20:32729444	T/G	cg24642439	chr20:33292090	TP53INP2	0.55	5.97	0.36	8.46e-9	Skin pigmentation;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.9	-13.57	-0.65	1.08e-31	Longevity;Endometriosis;
KIRP	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg18944383	chr4:111397179	ENPEP	-0.53	-6.29	-0.37	1.43e-9	Axial length;
KIRP	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.67	9.0	0.5	6.46e-17	Breast cancer;
KIRP	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.12	-0.41	1.17e-11	Neuroticism;
KIRP	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg09795085	chr6:101329169	ASCC3	-0.48	-5.75	-0.34	2.67e-8	Neuroticism;
KIRP	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18932078	chr1:2524107	MMEL1	-0.43	-6.04	-0.36	5.62e-9	Ulcerative colitis;
KIRP	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.57	-8.11	-0.46	2.41e-14	Testicular germ cell tumor;
KIRP	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.45	4.98	0.3	1.2e-6	Schizophrenia;
KIRP	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg00241281	chr14:105779794	PACS2	-0.36	-4.99	-0.3	1.12e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.05	-0.36	5.27e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	1.02	9.56	0.52	1.31e-18	Alzheimer's disease;
KIRP	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg03647239	chr10:116582469	FAM160B1	0.52	5.95	0.35	9.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-7.64	-0.44	4.78e-13	Personality dimensions;
KIRP	cis	rs6696239	0.955	rs12129894	chr1:227776988	A/T	cg27395484	chr1:227557617	NA	0.45	4.98	0.3	1.18e-6	Height;
KIRP	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg03532005	chr7:56119028	CCT6A;PSPH	0.92	6.23	0.37	2.03e-9	P wave terminal force;
KIRP	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.61	8.29	0.47	7.48e-15	Response to temozolomide;
KIRP	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg25358565	chr5:93447407	FAM172A	1.29	11.13	0.58	1.41e-23	Diabetic retinopathy;
KIRP	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg19257562	chr1:2043853	PRKCZ	-0.37	-5.41	-0.33	1.53e-7	Height;
KIRP	cis	rs6593803	0.732	rs6593808	chr1:147219250	A/G	cg27546670	chr1:147246839	GJA5	0.69	7.96	0.45	6.16e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg01557791	chr16:72042693	DHODH	-0.74	-10.26	-0.55	8.38e-21	Fibrinogen levels;
KIRP	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.18	-0.61	5.18e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs17030434	0.911	rs17030490	chr4:154738340	C/T	cg14289246	chr4:154710475	SFRP2	-0.76	-9.42	-0.51	3.44e-18	Electrocardiographic conduction measures;
KIRP	cis	rs4851254	0.550	rs13402299	chr2:100659409	C/T	cg22139774	chr2:100720529	AFF3	-0.4	-5.12	-0.31	6.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg23108931	chr8:105342351	NA	-0.35	-4.94	-0.3	1.46e-6	Paget's disease;
KIRP	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.85	-13.27	-0.65	1.1e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.17	-0.37	2.79e-9	Response to antipsychotic treatment;
KIRP	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.1	-13.85	-0.66	1.22e-32	Vitiligo;
KIRP	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.81	-0.4	7.39e-11	Morning vs. evening chronotype;
KIRP	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg09579323	chr1:150459698	TARS2	-0.42	-5.22	-0.32	3.76e-7	Migraine;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg04025307	chr7:1156635	C7orf50	0.76	11.84	0.6	6.77e-26	Longevity;Endometriosis;
KIRP	cis	rs9912468	1.000	rs12940610	chr17:64312463	A/G	cg19474267	chr17:64306194	PRKCA	-0.66	-9.34	-0.51	5.98e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg07862535	chr7:139043722	LUC7L2	-0.48	-5.44	-0.33	1.29e-7	Diisocyanate-induced asthma;
KIRP	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	1.0	18.54	0.76	1.34e-48	Parkinson's disease;
KIRP	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-12.73	-0.63	7.5e-29	Chronic sinus infection;
KIRP	cis	rs10114408	0.837	rs10115198	chr9:96632030	A/G	cg14598338	chr9:96623480	NA	-0.34	-5.09	-0.31	6.97e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.17	-0.42	9e-12	Joint mobility (Beighton score);
KIRP	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.23	0.32	3.55e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.49	-0.43	1.2e-12	Body mass index;
KIRP	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg07741184	chr6:167504864	NA	-0.23	-6.12	-0.36	3.63e-9	Crohn's disease;
KIRP	cis	rs11574514	1.000	rs8061384	chr16:67911874	T/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.38	-0.32	1.77e-7	Crohn's disease;
KIRP	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg26248373	chr2:1572462	NA	-0.65	-6.76	-0.4	9.88e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.5	7.56	0.43	7.74e-13	Carotid intima media thickness;
KIRP	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg13736514	chr6:26305472	NA	0.51	6.44	0.38	6.22e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.41	-5.19	-0.31	4.39e-7	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg06066596	chr15:83166174	LOC80154	-0.45	-6.04	-0.36	5.51e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs71277158	0.688	rs12493804	chr3:169799704	G/A	cg04067573	chr3:169899625	PHC3	0.53	5.16	0.31	5.16e-7	Prostate cancer;
KIRP	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs6684514	1.000	rs12045339	chr1:156294211	C/T	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.87e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg00684032	chr4:1343700	KIAA1530	0.46	5.33	0.32	2.23e-7	Longevity;
KIRP	cis	rs904251	0.686	rs2776911	chr6:37439950	T/A	cg01843034	chr6:37503916	NA	-0.62	-6.41	-0.38	7.34e-10	Cognitive performance;
KIRP	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.87	-9.97	-0.54	7.15e-20	Gut microbiome composition (summer);
KIRP	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	8.89	0.49	1.36e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.37	-4.86	-0.3	2.05e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg23173402	chr1:227635558	NA	0.63	5.14	0.31	5.52e-7	Major depressive disorder;
KIRP	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.46	5.7	0.34	3.42e-8	Common traits (Other);
KIRP	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.83	-0.35	1.7e-8	Breast cancer;
KIRP	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg17689763	chr4:710664	PCGF3	-0.74	-10.41	-0.55	2.86e-21	White blood cell count;
KIRP	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg01294253	chr9:136912663	BRD3	0.44	5.74	0.34	2.84e-8	Platelet distribution width;
KIRP	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg16388071	chr6:169726476	NA	-0.41	-5.67	-0.34	3.92e-8	Obesity-related traits;
KIRP	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-0.39	-4.87	-0.3	2.03e-6	Type 2 diabetes;
KIRP	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg06634786	chr22:41940651	POLR3H	-0.46	-5.63	-0.34	5.02e-8	Neuroticism;
KIRP	trans	rs9409565	0.717	rs61470662	chr9:97189472	T/C	cg05679027	chr9:99775184	HIATL2	-0.56	-6.74	-0.39	1.12e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.78	-12.16	-0.61	5.79e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg04990556	chr1:26633338	UBXN11	0.67	6.36	0.38	9.94e-10	Obesity-related traits;
KIRP	cis	rs8114671	0.647	rs6060267	chr20:33734012	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	6.01	0.36	6.8e-9	Height;
KIRP	cis	rs236907	0.859	rs7522582	chr1:171770111	G/C	cg01410279	chr1:171621941	MYOC	-0.47	-5.37	-0.32	1.84e-7	Mean platelet volume;
KIRP	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg21523564	chr15:75251491	NA	0.37	6.18	0.37	2.57e-9	Breast cancer;
KIRP	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg27347728	chr4:17578864	LAP3	0.42	4.84	0.3	2.26e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg24631222	chr15:78858424	CHRNA5	0.41	4.9	0.3	1.72e-6	Sudden cardiac arrest;
KIRP	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.37	0.32	1.86e-7	Parkinson's disease;
KIRP	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	6.34	0.38	1.06e-9	Renal cell carcinoma;
KIRP	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg17691542	chr6:26056736	HIST1H1C	0.41	5.51	0.33	9.06e-8	Schizophrenia;
KIRP	cis	rs2649	0.518	rs28531781	chr15:63879235	T/C	cg22599514	chr15:63798201	USP3	0.48	5.94	0.35	9.84e-9	Aortic root size;
KIRP	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-7.28	-0.42	4.46e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg20194872	chr6:41519635	FOXP4	0.58	7.36	0.42	2.7e-12	Prostate cancer;
KIRP	cis	rs9398803	0.713	rs3861455	chr6:126897969	A/C	cg19875578	chr6:126661172	C6orf173	0.42	5.41	0.33	1.47e-7	Male-pattern baldness;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg27519869	chr7:92219805	FAM133B	0.5	6.14	0.36	3.22e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.66	8.81	0.49	2.23e-16	Multiple sclerosis;
KIRP	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.7	7.06	0.41	1.67e-11	Menarche (age at onset);
KIRP	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.52	-8.06	-0.46	3.37e-14	Huntington's disease progression;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg08901578	chr4:187885870	NA	-0.49	-7.4	-0.43	2.19e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.66	-8.1	-0.46	2.53e-14	Aortic root size;
KIRP	cis	rs504918	0.556	rs73188197	chr3:124029897	A/G	cg05766129	chr3:123988013	KALRN	-0.44	-5.57	-0.33	6.58e-8	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg08501292	chr6:25962987	TRIM38	1.06	8.25	0.47	9.54e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17065868	1.000	rs9533926	chr13:45190035	G/C	cg10246903	chr13:45222710	NA	0.68	6.23	0.37	2.03e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6832769	0.925	rs60992571	chr4:56440812	C/A	cg09317128	chr4:56265301	TMEM165	-0.5	-6.7	-0.39	1.37e-10	Personality dimensions;
KIRP	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.73	-7.54	-0.43	9.17e-13	Vitiligo;
KIRP	cis	rs11673344	0.526	rs8111790	chr19:38056763	C/G	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.52	-0.33	8.41e-8	Obesity-related traits;
KIRP	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg07653901	chr22:50250238	ZBED4	-0.63	-6.91	-0.4	4.15e-11	Schizophrenia;
KIRP	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg26893134	chr6:116381904	FRK	0.2	5.75	0.34	2.67e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.51	-7.01	-0.41	2.33e-11	Diisocyanate-induced asthma;
KIRP	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg07827796	chr19:33622959	WDR88	0.42	5.03	0.31	9.26e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.77	-12.36	-0.62	1.27e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	cg21523751	chr1:182988639	NA	0.45	7.1	0.41	1.36e-11	Colorectal cancer;
KIRP	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	4.93e-11	Blood metabolite levels;
KIRP	cis	rs66569888	0.633	rs11124085	chr2:106758629	A/G	cg16099169	chr2:106886729	NA	-0.48	-6.06	-0.36	5.06e-9	Facial morphology (factor 23);
KIRP	cis	rs6011002	0.683	rs112087793	chr20:62284170	C/T	cg23957118	chr20:62200850	PRIC285	0.77	4.9	0.3	1.77e-6	Dental caries;
KIRP	cis	rs494562	0.892	rs567686	chr6:86124164	A/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs4664293	0.833	rs10170336	chr2:160589343	T/C	cg08347373	chr2:160653686	CD302	-0.36	-5.54	-0.33	7.65e-8	Monocyte percentage of white cells;
KIRP	cis	rs71597109	0.681	rs10446706	chr4:102721732	C/T	cg14855874	chr4:102712397	BANK1	0.41	5.44	0.33	1.3e-7	Chronic lymphocytic leukemia;
KIRP	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg16141378	chr3:129829833	LOC729375	0.61	8.82	0.49	2.12e-16	Neuroticism;
KIRP	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg01391022	chr12:122360665	WDR66	-0.38	-5.42	-0.33	1.39e-7	Mean corpuscular volume;
KIRP	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.23	0.37	1.96e-9	Aortic root size;
KIRP	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.58	7.63	0.44	5.17e-13	Schizophrenia;
KIRP	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.48	-5.92	-0.35	1.07e-8	Initial pursuit acceleration;
KIRP	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.17	13.43	0.65	3.21e-31	Uric acid levels;
KIRP	cis	rs6832769	0.767	rs6850524	chr4:56381997	C/G	cg05960024	chr4:56376020	CLOCK	0.57	7.29	0.42	4.25e-12	Personality dimensions;
KIRP	cis	rs9355814	0.508	rs1864449	chr6:161122763	T/C	cg14663533	chr6:160955178	LPA	0.56	7.83	0.45	1.41e-13	Lipoprotein (a) levels;
KIRP	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.53	-7.14	-0.41	1.05e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg23958373	chr8:599963	NA	-0.71	-5.03	-0.31	9.32e-7	IgG glycosylation;
KIRP	cis	rs6832769	1.000	rs6554286	chr4:56400304	T/G	cg05960024	chr4:56376020	CLOCK	-0.74	-9.46	-0.52	2.67e-18	Personality dimensions;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20791841	chr19:12777736	MORG1;MAN2B1	0.53	6.4	0.38	8e-10	Smoking initiation;
KIRP	cis	rs11628318	0.564	rs8013957	chr14:103140254	C/T	cg01864069	chr14:103024347	NA	0.43	5.25	0.32	3.26e-7	Platelet count;
KIRP	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg11815991	chr20:30193098	ID1	-0.45	-4.87	-0.3	2.02e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs7119167	0.686	rs6592519	chr11:73045074	T/C	cg17517138	chr11:73019481	ARHGEF17	0.46	4.96	0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.81	-0.4	7.59e-11	Menopause (age at onset);
KIRP	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg10932868	chr11:921992	NA	0.67	8.99	0.5	6.53e-17	Alzheimer's disease (late onset);
KIRP	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.34	4.88	0.3	1.9e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.91	-9.23	-0.51	1.26e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4073221	0.789	rs35115317	chr3:18205159	G/A	cg07694806	chr3:18168406	NA	-0.74	-6.7	-0.39	1.38e-10	Parkinson's disease;
KIRP	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16346588	chr10:242978	ZMYND11	-0.48	-5.96	-0.36	8.72e-9	Psychosis in Alzheimer's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07346700	chr16:71748967	PHLPP2	0.42	6.52	0.38	3.92e-10	Survival in pancreatic cancer;
KIRP	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.77	-0.4	9.59e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-4.93	-0.3	1.53e-6	Tonsillectomy;
KIRP	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg20387954	chr3:183756860	HTR3D	0.63	9.21	0.51	1.45e-17	Anterior chamber depth;
KIRP	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.74	-7.88	-0.45	1.07e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs3755132	0.929	rs4668948	chr2:15771586	A/C	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17827154	chr12:41323612	CNTN1	0.41	6.03	0.36	6.1e-9	Interleukin-4 levels;
KIRP	cis	rs2742417	1.000	rs17328701	chr3:45734258	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.43e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-8.58	-0.48	1.1e-15	Coronary artery disease;
KIRP	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg18154014	chr19:37997991	ZNF793	0.79	8.56	0.48	1.23e-15	Coronary artery calcification;
KIRP	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.8200000000000003e-11	Hypertriglyceridemia;
KIRP	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.51	-6.78	-0.4	8.68e-11	Hip circumference;Waist circumference;
KIRP	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg14580859	chr9:123691850	NA	0.35	5.16	0.31	5.14e-7	Rheumatoid arthritis;
KIRP	cis	rs732716	0.853	rs1127888	chr19:4454083	C/T	cg21720385	chr19:4455239	UBXN6	0.71	8.76	0.49	3.27e-16	Mean corpuscular volume;
KIRP	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.62	6.36	0.38	9.92e-10	Gastritis;
KIRP	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs7213347	0.581	rs2873195	chr17:2064702	A/T	cg15816464	chr17:2026533	SMG6	0.4	6.0	0.36	6.92e-9	Total body bone mineral density;
KIRP	cis	rs447921	0.861	rs12949638	chr17:74444758	C/T	cg17201438	chr17:74438067	UBE2O	0.47	5.06	0.31	8.16e-7	Mitochondrial DNA levels;
KIRP	trans	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.68	-0.44	3.87e-13	Retinal vascular caliber;
KIRP	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.33e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.5	7.13	0.41	1.1e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.6	8.83	0.49	1.98e-16	Lung cancer;
KIRP	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.59e-8	Aortic root size;
KIRP	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.19	-0.31	4.49e-7	Neuroticism;
KIRP	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.91	0.4	4.1e-11	Platelet count;
KIRP	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs78487399	0.908	rs12474102	chr2:43835570	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.07	-0.31	7.95e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg21926883	chr2:100939477	LONRF2	-0.52	-6.95	-0.41	3.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg19575753	chr5:1948995	NA	-0.51	-5.35	-0.32	2.01e-7	Gut microbiome composition (winter);
KIRP	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg08755490	chr11:65554678	OVOL1	0.38	5.4	0.33	1.58e-7	Acne (severe);
KIRP	trans	rs1106684	1.000	rs56288570	chr7:131461800	C/G	cg13607082	chr12:122652224	LRRC43	-0.66	-6.72	-0.39	1.25e-10	Body mass index;
KIRP	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg00495681	chr13:53174319	NA	0.39	5.36	0.32	1.94e-7	Lewy body disease;
KIRP	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.55	-7.44	-0.43	1.69e-12	White matter hyperintensity burden;
KIRP	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.45	-6.03	-0.36	6.06e-9	Ankylosing spondylitis;
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg08742575	chr21:47604166	C21orf56	0.51	7.14	0.41	1.02e-11	Testicular germ cell tumor;
KIRP	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.41	5.42	0.33	1.45e-7	Birth weight;
KIRP	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1620921	0.967	rs11902	chr6:161174871	C/G	cg01280913	chr6:161186852	NA	-0.44	-6.21	-0.37	2.26e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-5.44	-0.33	1.32e-7	Colorectal cancer;
KIRP	trans	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.05	-0.41	1.83e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg07636037	chr3:49044803	WDR6	-0.77	-7.73	-0.44	2.69e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg25706552	chr1:244017396	NA	0.62	6.64	0.39	1.97e-10	RR interval (heart rate);
KIRP	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.63	9.16	0.5	2.14e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs1420338	0.967	rs10271544	chr7:34147159	C/T	cg01275685	chr7:34179230	BMPER	-0.6	-8.99	-0.5	6.81e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.64	-0.6	3.13e-25	Diabetic kidney disease;
KIRP	cis	rs1816752	0.783	rs9507333	chr13:24978310	G/A	cg22771759	chr13:24902376	NA	0.38	4.92	0.3	1.62e-6	Obesity-related traits;
KIRP	trans	rs13100616	1.000	rs4560280	chr3:178416987	G/A	cg26530345	chr2:220312410	SPEG	0.49	6.02	0.36	6.17e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg09915433	chr19:53449742	NA	-0.38	-5.51	-0.33	9.15e-8	Psoriasis;
KIRP	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg04691961	chr3:161091175	C3orf57	-0.56	-8.68	-0.48	5.56e-16	Morning vs. evening chronotype;
KIRP	cis	rs4262150	0.507	rs72795350	chr5:151909997	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.85	-0.49	1.73e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs926938	0.527	rs360667	chr1:115481451	C/G	cg01522456	chr1:115632236	TSPAN2	0.4	5.48	0.33	1.05e-7	Autism;
KIRP	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	1.04	18.63	0.76	6.5e-49	Heart rate;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg00129232	chr17:37814104	STARD3	-0.52	-6.42	-0.38	7.15e-10	Self-reported allergy;
KIRP	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg01721255	chr8:58191610	C8orf71	0.61	5.48	0.33	1.08e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7172677	0.737	rs8033754	chr15:75439780	C/T	cg14664628	chr15:75095509	CSK	0.45	5.06	0.31	8.08e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21747090	chr2:27597821	SNX17	-0.46	-6.21	-0.37	2.2e-9	Total body bone mineral density;
KIRP	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg04317338	chr11:64019027	PLCB3	0.56	6.56	0.39	3.18e-10	Platelet count;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg19358731	chr22:38713456	CSNK1E	-0.45	-4.94	-0.3	1.43e-6	Menopause (age at onset);
KIRP	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.73	0.34	2.92e-8	Personality dimensions;
KIRP	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.34	-0.42	3.04e-12	Type 2 diabetes;
KIRP	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.57	0.39	2.98e-10	Colorectal cancer;
KIRP	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.34	0.37	1.11e-9	Monocyte percentage of white cells;
KIRP	cis	rs28834970	0.675	rs7013346	chr8:27228666	C/A	cg23736307	chr8:27182930	PTK2B	-0.44	-5.07	-0.31	7.77e-7	Alzheimer's disease (late onset);
KIRP	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg25512537	chr17:76250053	NA	-0.33	-5.74	-0.34	2.78e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.87	0.3	2.03e-6	Tonsillectomy;
KIRP	cis	rs9815354	0.812	rs7639859	chr3:42001987	C/T	cg03022575	chr3:42003672	ULK4	0.79	8.37	0.47	4.39e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs13438712	0.932	rs28520423	chr7:105542965	G/A	cg17511829	chr1:149510892	NA	0.48	6.03	0.36	5.82e-9	Obesity-related traits;
KIRP	cis	rs12210905	1.000	rs12192049	chr6:27056739	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg11189052	chr15:85197271	WDR73	0.47	4.89	0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs155346	1.000	rs265153	chr5:139380832	C/A	cg01090482	chr5:139365336	NRG2	-0.42	-5.05	-0.31	8.52e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.69	10.31	0.55	5.85e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.74	9.82	0.53	2.04e-19	Renal function-related traits (BUN);
KIRP	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	5.67	0.34	3.99e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2295359	1.000	rs11209007	chr1:67619345	C/G	cg12940439	chr1:67600707	NA	0.32	4.89	0.3	1.8e-6	Psoriasis;
KIRP	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-6.67	-0.39	1.67e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-9.81	-0.53	2.13e-19	Brugada syndrome;
KIRP	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg06533319	chr4:3265114	C4orf44	0.54	6.12	0.36	3.71e-9	Parental longevity (mother's age at death);
KIRP	cis	rs62070183	0.882	rs17781136	chr17:31185042	C/T	cg05781649	chr17:31146240	MYO1D	-0.5	-5.03	-0.31	9.63e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg24633833	chr3:10029261	TMEM111	0.53	5.18	0.31	4.72e-7	Alzheimer's disease;
KIRP	cis	rs2574975	0.531	rs2461912	chr10:52213394	G/A	cg10034176	chr10:52120283	SGMS1	0.39	5.55	0.33	7.2e-8	Response to amphetamines;
KIRP	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	IgG glycosylation;
KIRP	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-0.45	-6.2	-0.37	2.42e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-5.64	-0.34	4.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10880689	1	rs10880689	chr12:37930102	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.89	-0.4	4.72e-11	Resting heart rate;
KIRP	cis	rs10518128	0.702	rs28489508	chr4:75710545	T/C	cg20122727	chr4:75719957	BTC	0.55	5.61	0.34	5.31e-8	Electroencephalogram traits;
KIRP	cis	rs7301016	0.793	rs11174557	chr12:62979216	C/T	cg01804193	chr12:63026212	NA	0.54	5.96	0.36	8.58e-9	IgG glycosylation;
KIRP	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg19847130	chr8:10466454	RP1L1	-0.35	-4.93	-0.3	1.52e-6	Retinal vascular caliber;
KIRP	cis	rs2151522	0.762	rs9385408	chr6:127169355	G/T	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg10326726	chr10:51549505	MSMB	-0.59	-8.42	-0.47	3.2e-15	Prostate-specific antigen levels;
KIRP	cis	rs7188861	1.000	rs889648	chr16:11455816	G/C	cg01510278	chr16:11456238	NA	0.51	5.3	0.32	2.58e-7	HDL cholesterol;
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.18	0.7	3.46e-37	Platelet count;
KIRP	cis	rs9311676	0.656	rs56028017	chr3:58372508	C/T	cg06643156	chr3:58380774	PXK	0.35	4.93	0.3	1.51e-6	Systemic lupus erythematosus;
KIRP	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.84	-10.66	-0.56	4.67e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.51	6.36	0.38	9.86e-10	Subjective well-being;
KIRP	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.65e-30	Eye color traits;
KIRP	trans	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg02030672	chr11:45687055	CHST1	0.51	6.89	0.4	4.66e-11	Obesity-related traits;
KIRP	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg15848620	chr12:58087721	OS9	-0.51	-5.89	-0.35	1.28e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg26531700	chr6:26746687	NA	0.45	6.47	0.38	5.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10214930	0.752	rs1015265	chr7:27639609	G/A	cg22168087	chr7:27702803	HIBADH	0.53	5.18	0.31	4.54e-7	Hypospadias;
KIRP	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg08890418	chr1:21044141	KIF17	-0.4	-5.95	-0.35	9.21e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs1424233	1.000	rs1424236	chr16:79677167	C/G	cg11120865	chr14:21853037	SUPT16H	-0.38	-6.29	-0.37	1.42e-9	Obesity;
KIRP	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg22852734	chr6:133119734	C6orf192	1.12	7.47	0.43	1.41e-12	Type 2 diabetes nephropathy;
KIRP	cis	rs897080	0.515	rs1067346	chr2:44618811	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.29	0.37	1.47e-9	Height;
KIRP	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.99	-6.68	-0.39	1.59e-10	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg06740227	chr12:86229804	RASSF9	0.44	5.61	0.34	5.44e-8	Major depressive disorder;
KIRP	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.0	-8.08	-0.46	2.89e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3741151	0.686	rs17132115	chr11:73264656	C/T	cg17517138	chr11:73019481	ARHGEF17	0.6	5.32	0.32	2.38e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg10096100	chr1:26503862	CNKSR1	0.42	5.94	0.35	9.69e-9	Height;
KIRP	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.49	-0.59	9.48e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs6723108	0.654	rs621341	chr2:135295180	T/C	cg25422880	chr2:135218333	TMEM163	-0.41	-5.53	-0.33	8.14e-8	Type 2 diabetes;
KIRP	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-1.04	-10.0	-0.54	5.55e-20	Blood pressure (smoking interaction);
KIRP	cis	rs524023	0.837	rs12362590	chr11:64352540	T/A	cg09231725	chr11:64357281	SLC22A12	0.61	8.07	0.46	3.14e-14	Urate levels in obese individuals;
KIRP	cis	rs4006360	0.551	rs2320193	chr17:39243414	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.96	-11.35	-0.59	2.8e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.62	-8.46	-0.47	2.45e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7760535	0.930	rs10872069	chr6:111861726	A/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.39	-0.33	1.63e-7	Metabolic traits;
KIRP	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg09788416	chr12:39539408	NA	0.45	5.63	0.34	4.99e-8	Heart rate;
KIRP	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg26441486	chr22:50317300	CRELD2	-0.4	-5.61	-0.34	5.56e-8	Schizophrenia;
KIRP	cis	rs714031	0.902	rs4820388	chr22:40070642	C/G	cg21377881	chr22:40064566	CACNA1I	-0.69	-10.67	-0.56	4.37e-22	Schizophrenia;
KIRP	cis	rs9400467	0.506	rs77549436	chr6:111690730	T/G	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.11	0.61	8.66e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7122257	0.507	rs869872	chr11:11162347	C/A	cg16931664	chr11:11169707	NA	-0.45	-6.17	-0.37	2.86e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg24375607	chr4:120327624	NA	0.58	6.69	0.39	1.48e-10	Corneal astigmatism;
KIRP	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg00977110	chr5:151150581	G3BP1	0.59	5.9	0.35	1.21e-8	Preschool internalizing problems;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg07701084	chr6:150067640	NUP43	0.71	9.96	0.54	7.67e-20	Lung cancer;
KIRP	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.53	-6.7	-0.39	1.42e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.49	0.33	1e-7	Immature fraction of reticulocytes;
KIRP	cis	rs5753037	0.653	rs140129	chr22:30150549	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-6.18	-0.37	2.57e-9	Type 1 diabetes;
KIRP	cis	rs13006833	0.668	rs2664253	chr2:191148558	G/A	cg27211696	chr2:191398769	TMEM194B	0.38	5.27	0.32	2.92e-7	Urinary metabolites;
KIRP	cis	rs7937682	0.564	rs1944114	chr11:111366460	T/C	cg09085632	chr11:111637200	PPP2R1B	0.52	6.82	0.4	6.9e-11	Primary sclerosing cholangitis;
KIRP	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.32	-0.32	2.3e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.75	-10.22	-0.55	1.15e-20	Pulse pressure;
KIRP	cis	rs6960043	0.818	rs2191349	chr7:15064309	G/T	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.66e-11	Type 2 diabetes;
KIRP	cis	rs829661	0.793	rs1447187	chr2:30868859	A/G	cg10949345	chr2:30726833	LCLAT1	1.08	13.31	0.65	8.61e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10073892	0.620	rs56076606	chr5:101935865	T/A	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs2072732	0.904	rs2981857	chr1:2971521	T/C	cg11731671	chr1:2995604	PRDM16	-0.38	-5.05	-0.31	8.42e-7	Plateletcrit;
KIRP	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs9547996	0.879	rs1006416	chr13:38164445	G/A	cg13634560	chr13:38173852	POSTN	0.4	5.57	0.33	6.77e-8	Diastolic blood pressure;
KIRP	cis	rs3736485	0.932	rs4775946	chr15:51775930	A/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.42	-0.33	1.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg11707556	chr5:10655725	ANKRD33B	0.54	6.83	0.4	6.56e-11	Coronary artery disease;
KIRP	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.34	5.74	0.34	2.77e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.68	-0.34	3.72e-8	Bipolar disorder;
KIRP	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg12369402	chr1:90227771	NA	-0.36	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg24060327	chr5:131705240	SLC22A5	-0.44	-5.42	-0.33	1.43e-7	Blood metabolite levels;
KIRP	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	1.02	7.49	0.43	1.2e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9815354	1.000	rs1564716	chr3:41862613	A/G	cg03022575	chr3:42003672	ULK4	0.6	6.9	0.4	4.36e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2219968	1.000	rs13255746	chr8:78954214	A/T	cg00738934	chr8:78996279	NA	0.41	5.12	0.31	6.21e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1538970	0.924	rs12046816	chr1:45891543	G/T	cg05343316	chr1:45956843	TESK2	0.72	8.11	0.46	2.33e-14	Platelet count;
KIRP	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.55	-0.59	6.11e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.46	6.87	0.4	5.25e-11	Coronary artery disease;
KIRP	cis	rs6977660	0.714	rs6976854	chr7:19818311	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.75	-0.44	2.49e-13	Response to antipsychotic treatment;
KIRP	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg04287289	chr16:89883240	FANCA	-0.59	-7.44	-0.43	1.66e-12	Vitiligo;
KIRP	cis	rs11674184	0.564	rs746579	chr2:11744694	C/T	cg07314298	chr2:11723111	GREB1	-0.67	-8.83	-0.49	2e-16	Endometriosis;
KIRP	cis	rs17123764	0.892	rs74087188	chr12:50149544	T/C	cg20471783	chr12:50157085	TMBIM6	0.37	5.06	0.31	8.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg21479132	chr6:26055353	NA	0.78	5.23	0.32	3.65e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23678070	chr7:75831205	SRRM3	0.48	6.07	0.36	4.82e-9	Parkinson's disease;
KIRP	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.52	5.55	0.33	7.55e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg15655495	chr12:38532458	NA	-0.3	-5.16	-0.31	5.06e-7	Bladder cancer;
KIRP	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg24375607	chr4:120327624	NA	0.57	6.53	0.38	3.64e-10	Corneal astigmatism;
KIRP	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg18441811	chr11:71824068	C11orf51	0.79	5.29	0.32	2.72e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.53	-6.76	-0.4	1.01e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.92	10.92	0.57	6.67e-23	Corneal astigmatism;
KIRP	cis	rs6691722	0.506	rs1016209	chr1:24745615	A/G	cg18323236	chr1:24743029	NIPAL3	-0.54	-7.96	-0.45	6.24e-14	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.72	0.39	1.26e-10	Bipolar disorder;
KIRP	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg06060754	chr5:176797920	RGS14	0.64	7.34	0.42	3.1e-12	Urate levels in lean individuals;
KIRP	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg14440974	chr22:39074834	NA	0.38	4.95	0.3	1.4e-6	Menopause (age at onset);
KIRP	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.89	-0.45	9.74e-14	Morning vs. evening chronotype;
KIRP	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg00262122	chr8:11665843	FDFT1	-0.46	-5.63	-0.34	5e-8	Triglycerides;
KIRP	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg26834624	chr7:6662329	ZNF853	-0.67	-6.07	-0.36	4.73e-9	Hirschsprung disease;
KIRP	cis	rs526231	0.543	rs6881225	chr5:102307592	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.24	-0.32	3.42e-7	Primary biliary cholangitis;
KIRP	trans	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg06941879	chr19:45971137	FOSB	-0.55	-6.2	-0.37	2.32e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6596140	0.620	rs7721131	chr5:133029010	C/A	cg08567913	chr11:114082594	ZBTB16	-0.43	-6.08	-0.36	4.55e-9	Hypertension;
KIRP	cis	rs6005807	0.563	rs7288792	chr22:29015603	C/T	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg01689657	chr7:91764605	CYP51A1	0.42	5.98	0.36	7.96e-9	Breast cancer;
KIRP	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.51	6.22	0.37	2.07e-9	Menopause (age at onset);
KIRP	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.87	13.37	0.65	5.03e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2072732	0.861	rs10909865	chr1:2956163	A/G	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	cis	rs13385	0.769	rs10037401	chr5:139568762	A/T	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.79	11.64	0.6	3.08e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.01	-0.3	1.03e-6	Pulmonary function;
KIRP	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.47	6.69	0.39	1.51e-10	Bone mineral density;
KIRP	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg10117171	chr1:25599238	RHD	-0.38	-5.16	-0.31	5.09e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg12559939	chr2:27858050	GPN1	-0.41	-4.96	-0.3	1.31e-6	Total body bone mineral density;
KIRP	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg26138937	chr11:71823887	C11orf51	-1.04	-7.13	-0.41	1.12e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-8.66	-0.48	6.42e-16	Monocyte percentage of white cells;
KIRP	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg15440763	chr7:158190612	PTPRN2	0.43	5.53	0.33	8.3e-8	Obesity-related traits;
KIRP	trans	rs2797160	0.547	rs10872298	chr6:125956348	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.23	-0.37	2.03e-9	Endometrial cancer;
KIRP	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.62	8.03	0.46	4.15e-14	Coronary artery disease;
KIRP	trans	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs311392	0.967	rs4255114	chr8:55089450	G/A	cg06042504	chr8:55087323	NA	-0.61	-7.37	-0.43	2.53e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg21775007	chr8:11205619	TDH	-0.47	-6.18	-0.37	2.6e-9	Neuroticism;
KIRP	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.72	-8.91	-0.49	1.16e-16	Coronary artery disease;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02325243	chr19:19729568	PBX4	0.45	6.24	0.37	1.87e-9	Cancer;
KIRP	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.25	-0.42	5.52e-12	Glomerular filtration rate;
KIRP	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-1.16	-15.14	-0.69	5.06e-37	Platelet distribution width;
KIRP	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg00274965	chr21:34405681	NA	0.42	6.06	0.36	5.1e-9	Sum eosinophil basophil counts;
KIRP	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.69	6.51	0.38	4.29e-10	Diisocyanate-induced asthma;
KIRP	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg22963979	chr7:1858916	MAD1L1	-0.61	-8.43	-0.47	3.03e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg20673091	chr1:2541236	MMEL1	0.67	9.85	0.53	1.61e-19	Ulcerative colitis;
KIRP	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.83	-12.93	-0.64	1.56e-29	Dental caries;
KIRP	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.55	-6.88	-0.4	4.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg17757837	chr7:157058334	UBE3C	0.82	11.14	0.58	1.28e-23	Body mass index;
KIRP	cis	rs1816752	0.819	rs7317504	chr13:24985425	C/T	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-7.27	-0.42	4.77e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18402987	chr7:1209562	NA	0.46	5.53	0.33	8.36e-8	Longevity;Endometriosis;
KIRP	cis	rs10208940	0.920	rs35005506	chr2:68814238	A/T	cg12452813	chr2:68675892	NA	0.45	4.91	0.3	1.64e-6	Urate levels in lean individuals;
KIRP	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.83	-9.02	-0.5	5.59e-17	Asthma;
KIRP	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.31	0.47	6.37e-15	IgG glycosylation;
KIRP	cis	rs35740288	0.618	rs11630755	chr15:86108737	A/G	cg06993955	chr15:86301167	NA	-0.41	-5.31	-0.32	2.51e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg06212747	chr3:49208901	KLHDC8B	0.56	5.73	0.34	2.94e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.2e-15	Motion sickness;
KIRP	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.51	-6.9	-0.4	4.45e-11	Ulcerative colitis;
KIRP	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg11657440	chr19:46296263	DMWD	-0.71	-9.03	-0.5	4.97e-17	Coronary artery disease;
KIRP	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12893428	chr3:195717962	SDHAP1	0.48	6.43	0.38	6.57e-10	Pancreatic cancer;
KIRP	cis	rs4654899	0.606	rs13376428	chr1:21120027	T/C	cg08890418	chr1:21044141	KIF17	0.35	5.15	0.31	5.31e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	7.33	0.42	3.36e-12	Iron status biomarkers;
KIRP	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg01620082	chr3:125678407	NA	-1.15	-7.24	-0.42	5.63e-12	Depression;
KIRP	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.81	-11.81	-0.6	8.53e-26	Coronary artery disease;
KIRP	cis	rs9815354	0.812	rs73079324	chr3:41864564	T/C	cg03022575	chr3:42003672	ULK4	0.51	5.96	0.36	8.8e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg19752551	chr11:57585705	CTNND1	0.79	12.93	0.64	1.57e-29	Schizophrenia;
KIRP	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.15	12.98	0.64	1.11e-29	Uric acid levels;
KIRP	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg04037228	chr3:45636386	LIMD1	0.36	5.43	0.33	1.32e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg25753631	chr6:25732923	NA	-0.27	-5.0	-0.3	1.07e-6	Iron status biomarkers;
KIRP	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.54	-0.39	3.46e-10	Coronary artery disease;
KIRP	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg00931491	chr16:28608288	SULT1A2	-0.25	-4.85	-0.3	2.23e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.94	-0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.59	0.44	6.45e-13	Educational attainment;
KIRP	cis	rs8067545	0.532	rs12449914	chr17:20003969	T/C	cg13482628	chr17:19912719	NA	0.46	5.21	0.32	4.02e-7	Schizophrenia;
KIRP	cis	rs4851254	0.920	rs11689956	chr2:100795329	T/C	cg17356467	chr2:100759845	AFF3	0.59	7.44	0.43	1.67e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	4.91	0.3	1.68e-6	Educational attainment;
KIRP	cis	rs5753037	0.753	rs131289	chr22:30161133	C/G	cg27665648	chr22:30112403	NA	0.46	5.91	0.35	1.14e-8	Type 1 diabetes;
KIRP	trans	rs13100616	1.000	rs4557135	chr3:178411882	G/A	cg26530345	chr2:220312410	SPEG	0.49	6.02	0.36	6.17e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg13770153	chr20:60521292	NA	-0.44	-5.17	-0.31	4.81e-7	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01553230	chr7:931849	C7orf20	-0.52	-6.84	-0.4	6.4e-11	Parkinson's disease;
KIRP	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg04727924	chr7:799746	HEATR2	-0.77	-8.53	-0.48	1.56e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg00409905	chr10:38381863	ZNF37A	0.58	6.36	0.38	9.51e-10	Obesity (extreme);
KIRP	cis	rs4454254	1.000	rs4454254	chr8:141060027	C/T	cg05910124	chr8:141057427	TRAPPC9	-0.28	-5.62	-0.34	5.1e-8	Pulse pressure;
KIRP	cis	rs12210905	0.541	rs56099947	chr6:27490937	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.76	-5.47	-0.33	1.12e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg12573791	chr2:3828286	NA	0.41	5.68	0.34	3.88e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg21401794	chr1:90099060	LRRC8C	0.66	9.15	0.5	2.18e-17	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18255839	chr2:239335447	ASB1	0.42	5.06	0.31	8.11e-7	Multiple system atrophy;
KIRP	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.68	10.22	0.55	1.17e-20	Height;
KIRP	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg08134877	chr2:44394819	PPM1B	0.43	5.0	0.3	1.09e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.51	-7.01	-0.41	2.27e-11	Obesity-related traits;
KIRP	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.82	9.99	0.54	5.96e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs2034088	1.000	rs2034088	chr17:423051	T/C	cg13332499	chr17:408570	NA	0.63	8.53	0.48	1.47e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.42	-0.43	1.86e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.87	10.92	0.57	6.93e-23	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.87	-0.57	1.02e-22	Height;
KIRP	cis	rs9826463	0.757	rs73240316	chr3:142266061	A/G	cg20824294	chr3:142316082	PLS1	0.38	6.19	0.37	2.53e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.59	-6.34	-0.37	1.1e-9	Carotid intima media thickness;
KIRP	cis	rs3126085	0.735	rs35061954	chr1:152240583	G/T	cg26876637	chr1:152193138	HRNR	0.75	9.32	0.51	6.96e-18	Atopic dermatitis;
KIRP	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.7	-8.55	-0.48	1.3e-15	Aortic root size;
KIRP	cis	rs7246657	0.679	rs12461113	chr19:38083188	G/A	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.64	8.5	0.48	1.88e-15	Longevity;Endometriosis;
KIRP	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg26441486	chr22:50317300	CRELD2	0.51	7.23	0.42	6.12e-12	Schizophrenia;
KIRP	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg18198730	chr1:247681584	NA	0.81	5.29	0.32	2.67e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg14851346	chr12:38532713	NA	-0.4	-4.97	-0.3	1.25e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg09873164	chr1:152488093	CRCT1	0.5	6.25	0.37	1.84e-9	Hair morphology;
KIRP	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg20302533	chr7:39170763	POU6F2	-0.28	-5.49	-0.33	9.85e-8	IgG glycosylation;
KIRP	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.74	9.2	0.51	1.55e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg15181151	chr6:150070149	PCMT1	0.31	5.32	0.32	2.38e-7	Lung cancer;
KIRP	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.02e-8	Motion sickness;
KIRP	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.64	-9.48	-0.52	2.23e-18	Colorectal cancer;
KIRP	cis	rs3857067	1.000	rs1585652	chr4:95014313	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.78e-13	Lung cancer;
KIRP	cis	rs7804356	0.906	rs17323934	chr7:26904330	C/G	cg03456212	chr7:26904342	SKAP2	0.58	5.29	0.32	2.67e-7	Type 1 diabetes;
KIRP	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.68	-7.12	-0.41	1.18e-11	Urate levels in lean individuals;
KIRP	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg21360079	chr12:107162445	NA	-0.66	-9.0	-0.5	6.09e-17	Heart rate;
KIRP	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg09626299	chr10:82213104	TSPAN14	-0.33	-5.04	-0.31	8.86e-7	Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.27	-0.32	2.93e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg13906792	chr15:75199810	C15orf17	-0.35	-4.89	-0.3	1.85e-6	Breast cancer;
KIRP	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg02117656	chr17:79614917	TSPAN10	0.45	5.32	0.32	2.35e-7	Myopia;
KIRP	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.62e-8	Neuroticism;
KIRP	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05025164	chr4:1340916	KIAA1530	-0.54	-7.12	-0.41	1.21e-11	Obesity-related traits;
KIRP	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg16141378	chr3:129829833	LOC729375	-0.58	-8.05	-0.46	3.45e-14	Neuroticism;
KIRP	cis	rs4700695	0.925	rs12518262	chr5:65414004	A/G	cg21114390	chr5:65439923	SFRS12	-0.5	-4.84	-0.3	2.25e-6	Facial morphology (factor 19);
KIRP	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07570687	chr10:102243282	WNT8B	0.41	4.99	0.3	1.17e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg19678392	chr7:94953810	PON1	0.66	9.88	0.53	1.34e-19	Paraoxonase activity;
KIRP	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.63	-7.77	-0.44	2.09e-13	Multiple sclerosis;
KIRP	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg00319359	chr11:70116639	PPFIA1	0.78	6.93	0.4	3.73e-11	Coronary artery disease;
KIRP	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.81	12.6	0.63	2e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.42	-5.21	-0.32	3.91e-7	Aortic root size;
KIRP	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg16388071	chr6:169726476	NA	-0.4	-5.53	-0.33	7.99e-8	Obesity-related traits;
KIRP	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg00129232	chr17:37814104	STARD3	0.63	6.93	0.4	3.76e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.76	8.75	0.49	3.5e-16	Corneal astigmatism;
KIRP	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.83	12.79	0.63	4.61e-29	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07089235	chr4:141294546	SCOC	0.45	6.25	0.37	1.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.67	7.2	0.42	7.24e-12	Obesity-related traits;
KIRP	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.43	-5.5	-0.33	9.33e-8	Menarche (age at onset);
KIRP	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.86	12.69	0.63	1.01e-28	Height;
KIRP	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.49	-0.48	2.03e-15	Retinal vascular caliber;
KIRP	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.42	0.62	7.93e-28	Smoking behavior;
KIRP	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24531977	chr5:56204891	C5orf35	-0.47	-5.1	-0.31	6.69e-7	Type 2 diabetes;
KIRP	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg23719950	chr11:63933701	MACROD1	-0.66	-6.49	-0.38	4.6e-10	Mean platelet volume;
KIRP	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.18	-0.31	4.61e-7	Metabolite levels;
KIRP	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-1.02	-17.26	-0.74	2.74e-44	Height;
KIRP	cis	rs662064	0.962	rs596537	chr1:10554709	G/T	cg07384165	chr1:10488281	NA	-0.4	-4.93	-0.3	1.54e-6	Asthma;
KIRP	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg19919209	chr11:64804476	SNX15	0.4	5.1	0.31	6.91e-7	Atopic dermatitis;
KIRP	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg21858823	chr1:15850916	CASP9	0.54	5.74	0.34	2.81e-8	Systolic blood pressure;
KIRP	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg26408565	chr15:76604113	ETFA	-0.42	-5.63	-0.34	4.89e-8	Blood metabolite levels;
KIRP	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-8.05	-0.46	3.51e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.62	-8.19	-0.46	1.41e-14	Aortic root size;
KIRP	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.48e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2587695	0.935	rs2587654	chr2:120299172	C/G	cg07176264	chr2:120281999	SCTR	0.32	5.02	0.31	9.75e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg05562828	chr17:3906858	NA	0.59	8.88	0.49	1.38e-16	Type 2 diabetes;
KIRP	cis	rs7709377	0.570	rs1129494	chr5:115428334	G/T	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.61	8.17	0.46	1.68e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg20731937	chr12:48336164	NA	0.41	5.3	0.32	2.58e-7	Longevity (90 years and older);
KIRP	cis	rs72848980	0.512	rs12359556	chr10:105390677	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.74	9.01	0.5	6.04e-17	White matter hyperintensity burden;
KIRP	cis	rs732716	0.889	rs62129355	chr19:4397034	T/C	cg21720385	chr19:4455239	UBXN6	0.71	8.68	0.48	5.49e-16	Mean corpuscular volume;
KIRP	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg04731861	chr2:219085781	ARPC2	0.29	7.34	0.42	3.18e-12	Colorectal cancer;
KIRP	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.43	-5.03	-0.31	9.35e-7	P wave terminal force;
KIRP	cis	rs6539288	0.803	rs4479083	chr12:107321245	G/C	cg26297688	chr12:107349093	C12orf23	-0.38	-5.23	-0.32	3.7e-7	Total body bone mineral density;
KIRP	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26207909	chr14:103986467	CKB	0.55	7.49	0.43	1.2e-12	Body mass index;
KIRP	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg25039879	chr17:56429692	SUPT4H1	0.57	5.11	0.31	6.58e-7	Cognitive test performance;
KIRP	cis	rs2554380	0.891	rs2562782	chr15:84300081	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.56	-0.48	1.26e-15	Height;
KIRP	trans	rs61440199	0.786	rs58629324	chr3:20143809	T/C	cg08354614	chr10:80673607	NA	0.47	6.27	0.37	1.57e-9	Staphylococcus aureus nasal carriage (intermittent);
KIRP	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.04	8.02	0.46	4.31e-14	Skin colour saturation;
KIRP	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Parkinson's disease;
KIRP	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.43	-6.46	-0.38	5.52e-10	Schizophrenia;
KIRP	cis	rs698833	0.886	rs1056865	chr2:44546741	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.16	0.31	5.01e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.38	-7.11	-0.41	1.23e-11	Refractive error;
KIRP	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	5.17	0.31	4.93e-7	Schizophrenia;
KIRP	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.49	0.33	1e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs10129255	0.642	rs11624918	chr14:107120688	T/C	cg23076370	chr14:107095027	NA	-0.47	-5.11	-0.31	6.5e-7	Kawasaki disease;
KIRP	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.53	7.06	0.41	1.72e-11	Adiposity;
KIRP	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.95	12.47	0.62	5.34e-28	Homoarginine levels;
KIRP	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.52	-6.9	-0.4	4.37e-11	Adiposity;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17335440	chr11:48161380	PTPRJ	0.48	6.6	0.39	2.52e-10	Survival in pancreatic cancer;
KIRP	cis	rs17321999	1.000	rs17009304	chr2:30479283	A/T	cg05247661	chr2:30472410	LBH	0.69	7.82	0.45	1.52e-13	Systemic lupus erythematosus;
KIRP	cis	rs68170813	1.000	rs68170813	chr7:107259721	T/C	cg02696742	chr7:106810147	HBP1	-0.61	-6.04	-0.36	5.6e-9	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg21360079	chr12:107162445	NA	-0.69	-9.97	-0.54	7.01e-20	Heart rate;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg19500275	chr17:80737654	TBCD	0.45	5.25	0.32	3.27e-7	Glycated hemoglobin levels;
KIRP	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.42	-5.84	-0.35	1.67e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs507080	0.769	rs745663	chr11:118529595	A/G	cg04173919	chr11:118528438	PHLDB1	0.35	5.04	0.31	8.96e-7	Serum metabolite levels;
KIRP	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs12580194	1.000	rs58332180	chr12:55711353	C/A	cg11794356	chr12:55725991	OR6C3	-0.4	-5.45	-0.33	1.24e-7	Cancer;
KIRP	cis	rs4664293	0.967	rs35975814	chr2:160547791	G/A	cg08347373	chr2:160653686	CD302	-0.39	-6.14	-0.36	3.31e-9	Monocyte percentage of white cells;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg16608617	chr2:202898681	FZD7	-0.45	-6.11	-0.36	3.81e-9	Serum protein levels (sST2);
KIRP	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg18404041	chr3:52824283	ITIH1	-0.48	-5.86	-0.35	1.5e-8	Schizophrenia;
KIRP	cis	rs8054556	1.000	rs11150580	chr16:30014564	C/T	cg06326092	chr16:30034487	C16orf92	0.36	5.02	0.3	9.92e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	1.01	11.29	0.58	4.31e-24	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17030434	0.953	rs76442373	chr4:154694783	G/A	cg14289246	chr4:154710475	SFRP2	-0.83	-9.68	-0.53	5.45e-19	Electrocardiographic conduction measures;
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.88	-0.3	1.87e-6	Lung cancer;
KIRP	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.77	-7.33	-0.42	3.36e-12	Schizophrenia;
KIRP	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11645453	chr3:52864694	ITIH4	0.33	4.85	0.3	2.16e-6	Bipolar disorder;
KIRP	cis	rs3736485	0.966	rs7177471	chr15:51911232	C/T	cg14296394	chr15:51910925	DMXL2	-0.36	-5.38	-0.32	1.76e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.32	0.47	6.21e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	4.98e-9	Depression;
KIRP	cis	rs1847202	0.762	rs13093504	chr3:72949855	T/C	cg06781948	chr3:72941472	GXYLT2	0.48	6.2	0.37	2.39e-9	Motion sickness;
KIRP	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.47	6.55	0.39	3.4e-10	Sitting height ratio;
KIRP	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.86	13.04	0.64	6.53e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7751419	0.651	rs10947778	chr6:39093606	T/C	cg25014318	chr6:39016776	GLP1R	0.35	4.96	0.3	1.33e-6	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg21395723	chr22:39101663	GTPBP1	0.48	6.42	0.38	6.92e-10	Menopause (age at onset);
KIRP	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	9.3	0.51	7.87e-18	Systolic blood pressure;
KIRP	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-5.76	-0.34	2.45e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.59	6.33	0.37	1.18e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3112255	0.967	rs2137675	chr2:101310912	C/T	cg01042948	chr2:101319752	NA	-0.4	-5.99	-0.36	7.34e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.74	9.83	0.53	1.88e-19	Aortic root size;
KIRP	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-0.97	-9.41	-0.51	3.72e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.96	11.54	0.59	6.73e-25	Corneal astigmatism;
KIRP	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.26e-12	Prudent dietary pattern;
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg07216194	chr8:27182965	PTK2B	0.45	5.61	0.34	5.54e-8	Neuroticism;
KIRP	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg23594656	chr7:65796392	TPST1	-0.43	-6.11	-0.36	3.87e-9	Aortic root size;
KIRP	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg15893493	chr8:124194847	FAM83A	0.93	7.94	0.45	7.42e-14	Urinary uromodulin levels;
KIRP	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.77	6.63	0.39	2.14e-10	Alzheimer's disease (late onset);
KIRP	cis	rs860295	0.871	rs12724079	chr1:155433942	A/G	cg02153340	chr1:155202674	NA	0.38	4.96	0.3	1.29e-6	Body mass index;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12977696	chr17:1303516	YWHAE	-0.57	-6.12	-0.36	3.71e-9	Menopause (age at onset);
KIRP	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.13	0.61	7.74e-27	Bipolar disorder;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg11306587	chr16:58497714	NDRG4	0.46	6.19	0.37	2.45e-9	DNA methylation (variation);
KIRP	cis	rs4006360	0.578	rs9893220	chr17:39231963	C/A	cg25341923	chr17:39239918	KRTAP4-7	-0.57	-8.86	-0.49	1.62e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.46	6.94	0.4	3.54e-11	Total body bone mineral density;
KIRP	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg15212455	chr7:39170539	POU6F2	0.26	6.05	0.36	5.42e-9	IgG glycosylation;
KIRP	cis	rs6997458	0.651	rs2403105	chr8:86343133	A/G	cg02393479	chr8:86352350	CA3	-0.32	-4.95	-0.3	1.36e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-8.97	-0.5	7.95e-17	Body mass index;
KIRP	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg00612595	chr21:47717864	NA	-0.41	-5.38	-0.32	1.72e-7	Testicular germ cell tumor;
KIRP	cis	rs11710088	0.711	rs35884523	chr3:149188217	T/C	cg08667024	chr3:149219783	TM4SF4	-0.44	-5.6	-0.34	5.83e-8	QRS duration;
KIRP	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13606994	chr1:44402422	ARTN	0.26	4.95	0.3	1.35e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4671458	0.626	rs4671062	chr2:63724044	G/A	cg17519650	chr2:63277830	OTX1	-0.49	-4.99	-0.3	1.15e-6	Subjective well-being;
KIRP	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.61	8.89	0.49	1.35e-16	Menarche (age at onset);
KIRP	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.86	-11.53	-0.59	7.32e-25	Cognitive function;
KIRP	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.85	-11.47	-0.59	1.12e-24	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	12.57	0.63	2.63e-28	Bone mineral density;
KIRP	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.8	-13.04	-0.64	6.8e-30	Prostate cancer;
KIRP	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg04317338	chr11:64019027	PLCB3	0.79	7.26	0.42	5.05e-12	Mean platelet volume;
KIRP	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.4	0.38	7.74e-10	Hemoglobin concentration;
KIRP	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4851254	0.961	rs6713524	chr2:100747357	A/G	cg17356467	chr2:100759845	AFF3	0.61	7.45	0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7119167	0.686	rs7342205	chr11:73044351	A/G	cg17517138	chr11:73019481	ARHGEF17	0.47	5.05	0.31	8.64e-7	Blood protein levels;
KIRP	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.41	-0.38	7.56e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg02002194	chr4:3960332	NA	0.47	6.84	0.4	6.33e-11	Schizophrenia;
KIRP	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.84	0.35	1.64e-8	Height;
KIRP	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.85	-0.57	1.18e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.49	0.38	4.68e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.12	-0.5	2.77e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6753739	0.826	rs6711613	chr2:219947691	A/G	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg05315796	chr3:52349193	DNAH1	0.4	5.24	0.32	3.38e-7	Schizophrenia;
KIRP	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs9303542	0.559	rs56038617	chr17:46612578	C/T	cg04904318	chr17:46607828	HOXB1	-0.62	-6.64	-0.39	2.04e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.39	5.23	0.32	3.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22168489	chr12:122356033	WDR66	0.66	9.84	0.53	1.75e-19	Mean corpuscular volume;
KIRP	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg06521331	chr12:34319734	NA	-0.59	-7.38	-0.43	2.41e-12	Morning vs. evening chronotype;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.43	-6.3	-0.37	1.34e-9	Renal function-related traits (BUN);
KIRP	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg13939156	chr17:80058883	NA	-0.49	-5.7	-0.34	3.43e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-8.51	-0.48	1.74e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg26174226	chr8:58114915	NA	-0.53	-5.22	-0.32	3.76e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6062509	0.965	rs2315008	chr20:62343956	T/G	cg06226150	chr20:62369956	SLC2A4RG;LIME1	-0.31	-4.88	-0.3	1.87e-6	Prostate cancer;
KIRP	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	1.1	15.72	0.71	5.01e-39	Breast cancer;
KIRP	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.73	9.43	0.52	3.17e-18	Monocyte count;
KIRP	cis	rs7017914	0.934	rs1993862	chr8:71579362	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.39	-4.87	-0.3	1.99e-6	Bone mineral density;
KIRP	cis	rs2411233	1.000	rs13379846	chr15:39272413	T/A	cg02291532	chr15:39874776	THBS1	0.39	5.4	0.33	1.58e-7	Platelet count;
KIRP	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg26207909	chr14:103986467	CKB	-0.49	-6.19	-0.37	2.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.43e-12	Obesity-related traits;
KIRP	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.44	5.98	0.36	7.91e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg05861140	chr6:150128134	PCMT1	0.41	5.52	0.33	8.77e-8	Lung cancer;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	7.48	0.43	1.29e-12	Lymphocyte counts;
KIRP	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg13611997	chr5:233750	SDHA	-0.42	-4.89	-0.3	1.83e-6	Breast cancer;
KIRP	cis	rs12431939	0.762	rs12435765	chr14:51702128	A/G	cg23942311	chr14:51606299	NA	-0.57	-5.53	-0.33	8e-8	Cancer;
KIRP	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg00405596	chr8:11794950	NA	0.42	5.43	0.33	1.37e-7	Retinal vascular caliber;
KIRP	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05220968	chr6:146057943	EPM2A	0.4	5.1	0.31	6.63e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4400599	0.901	rs2494671	chr1:154100779	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.35	5.01	0.3	1.04e-6	Platelet distribution width;
KIRP	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.63	0.44	5.13e-13	Tonsillectomy;
KIRP	cis	rs7106204	0.688	rs4462347	chr11:24218865	G/A	ch.11.24196551F	chr11:24239977	NA	0.82	8.27	0.47	8.57e-15	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.67	7.21	0.42	6.94e-12	Diastolic blood pressure;
KIRP	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg17376030	chr22:41985996	PMM1	0.54	6.13	0.36	3.43e-9	Vitiligo;
KIRP	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg24296786	chr1:45957014	TESK2	0.5	5.54	0.33	7.81e-8	Homocysteine levels;
KIRP	cis	rs494562	1.000	rs7763191	chr6:86118317	A/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg17810781	chr1:201082982	CACNA1S	0.41	6.53	0.38	3.82e-10	Permanent tooth development;
KIRP	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg21361702	chr7:150065534	REPIN1	0.62	6.52	0.38	3.99e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs282587	0.597	rs1756075	chr13:113396211	T/C	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.82e-12	Glycated hemoglobin levels;
KIRP	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg01304814	chr3:48885189	PRKAR2A	0.78	5.7	0.34	3.46e-8	Cognitive function;
KIRP	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.3e-15	Life satisfaction;
KIRP	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.85	0.45	1.25e-13	Coffee consumption (cups per day);
KIRP	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg01689657	chr7:91764605	CYP51A1	0.42	5.94	0.35	9.75e-9	Breast cancer;
KIRP	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11987759	chr7:65425863	GUSB	0.6	7.94	0.45	6.99e-14	Aortic root size;
KIRP	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg23484912	chr5:273055	PDCD6	0.59	7.37	0.43	2.66e-12	Pancreatic cancer;
KIRP	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00801868	chr3:155588370	GMPS	0.48	6.2	0.37	2.43e-9	Parkinson's disease;
KIRP	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.56	7.61	0.44	6e-13	Schizophrenia;
KIRP	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg02569458	chr12:86230093	RASSF9	-0.42	-6.27	-0.37	1.57e-9	Major depressive disorder;
KIRP	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.78	-10.36	-0.55	4.27e-21	Dental caries;
KIRP	cis	rs12042938	0.600	rs1865225	chr1:231763004	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-6.79	-0.4	8.42e-11	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.67	-11.6	-0.59	4.19e-25	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	cis	rs75920871	0.528	rs11216255	chr11:116929995	A/G	cg04087571	chr11:116723030	SIK3	-0.26	-5.68	-0.34	3.76e-8	Subjective well-being;
KIRP	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg15848620	chr12:58087721	OS9	-0.43	-4.93	-0.3	1.51e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg13072238	chr3:49761600	GMPPB	-0.58	-5.38	-0.32	1.73e-7	Menarche (age at onset);
KIRP	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg00405596	chr8:11794950	NA	0.43	5.35	0.32	2.01e-7	Retinal vascular caliber;
KIRP	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg09184832	chr6:79620586	NA	0.51	7.39	0.43	2.29e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg03146154	chr1:46216737	IPP	0.55	5.6	0.34	5.73e-8	Platelet count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14291257	chr11:125490757	STT3A	0.45	6.42	0.38	6.96e-10	Survival in pancreatic cancer;
KIRP	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7246657	0.722	rs12979640	chr19:38179156	T/C	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.06	-0.31	8.32e-7	Coronary artery calcification;
KIRP	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs2223471	0.523	rs280291	chr6:50555591	T/G	cg03432817	chr6:50765336	NA	-0.37	-5.5	-0.33	9.66e-8	Subcutaneous adipose tissue;
KIRP	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.94	10.64	0.56	5.31e-22	HIV-1 control;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07292445	chr17:27055725	NEK8	0.5	6.85	0.4	5.97e-11	Survival in pancreatic cancer;
KIRP	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-8.95	-0.5	9.09e-17	Coronary artery disease;
KIRP	cis	rs12765878	0.812	rs7076119	chr10:105667110	T/C	cg11005552	chr10:105648138	OBFC1	-0.41	-5.66	-0.34	4.27e-8	Coronary artery disease;
KIRP	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.77	-11.52	-0.59	7.63e-25	Obesity-related traits;
KIRP	cis	rs7555523	0.778	rs2790052	chr1:165738463	G/C	cg24409356	chr1:165738333	TMCO1	0.72	6.05	0.36	5.25e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg05072774	chr3:49840536	C3orf54	-0.4	-5.14	-0.31	5.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg12405258	chr13:114927641	NA	0.48	6.89	0.4	4.66e-11	Schizophrenia;
KIRP	cis	rs6987853	0.966	rs2974342	chr8:42436651	A/C	cg09913449	chr8:42400586	C8orf40	0.39	5.12	0.31	6.14e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.42	-0.33	1.46e-7	Aortic root size;
KIRP	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.05	20.26	0.79	2.31e-54	Schizophrenia;
KIRP	cis	rs755109	0.967	rs17431614	chr9:100684387	T/C	cg13688889	chr9:100608707	NA	-0.42	-4.85	-0.3	2.18e-6	Quantitative traits;
KIRP	cis	rs12949688	0.967	rs9910446	chr17:55821485	G/C	cg12582317	chr17:55822272	NA	0.63	10.62	0.56	6.06e-22	Schizophrenia;
KIRP	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-8.05	-0.46	3.65e-14	Response to antipsychotic treatment;
KIRP	cis	rs7666738	0.512	rs165251	chr4:98758490	C/G	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11997175	0.902	rs7462610	chr8:33693318	A/T	cg04338863	chr8:33670619	NA	0.4	5.32	0.32	2.38e-7	Body mass index;
KIRP	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg15660573	chr17:549704	VPS53	0.5	6.41	0.38	7.37e-10	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.92	15.96	0.71	7.66e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.37	-0.43	2.66e-12	Retinal vascular caliber;
KIRP	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg09238746	chr17:78121135	EIF4A3	-0.41	-5.13	-0.31	5.85e-7	Yeast infection;
KIRP	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	1.05	15.55	0.7	2.01e-38	Blood protein levels;
KIRP	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg04374321	chr14:90722782	PSMC1	0.87	13.44	0.65	3.01e-31	Mortality in heart failure;
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg07701084	chr6:150067640	NUP43	0.72	9.91	0.53	1.06e-19	Lung cancer;
KIRP	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg19875535	chr5:140030758	IK	0.53	6.59	0.39	2.59e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.09	-0.31	7.13e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg23594656	chr7:65796392	TPST1	0.36	5.22	0.32	3.81e-7	Aortic root size;
KIRP	cis	rs6467136	0.782	rs10281944	chr7:127160364	T/C	cg23081781	chr7:127225937	GCC1	-0.38	-5.11	-0.31	6.58e-7	Type 2 diabetes;
KIRP	cis	rs2970992	0.764	rs2175791	chr2:101330661	G/A	cg01042948	chr2:101319752	NA	0.41	5.93	0.35	9.98e-9	Educational attainment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26413987	chr12:121124951	MLEC	0.49	6.68	0.39	1.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13316171	chr2:187351035	ZC3H15	0.47	6.24	0.37	1.86e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg05187965	chr10:45406764	TMEM72	-0.29	-6.81	-0.4	7.49e-11	Mean corpuscular volume;
KIRP	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.62	7.35	0.42	2.85e-12	Schizophrenia;
KIRP	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.64	7.71	0.44	3.2e-13	Schizophrenia;
KIRP	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg00405596	chr8:11794950	NA	0.47	5.85	0.35	1.57e-8	Retinal vascular caliber;
KIRP	cis	rs34375054	0.660	rs12303416	chr12:125593358	C/T	cg25124228	chr12:125621409	AACS	-0.58	-7.1	-0.41	1.36e-11	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9815354	0.627	rs115971784	chr3:42016146	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.78	-10.66	-0.56	4.57e-22	Inflammatory bowel disease;
KIRP	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.2	13.21	0.64	1.84e-30	Nonalcoholic fatty liver disease;
KIRP	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15595627	chr8:108401517	ANGPT1	0.41	6.53	0.38	3.73e-10	C-reactive protein;
KIRP	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.84	-14.23	-0.67	6.49e-34	Prostate cancer;
KIRP	cis	rs12210905	1.000	rs115268625	chr6:26948229	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.79	-0.4	8.28e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs2172802	0.570	rs12233820	chr4:62545693	T/C	cg04118610	chr4:62707027	LPHN3	-0.43	-5.25	-0.32	3.26e-7	Partial epilepsies;
KIRP	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18867708	chr6:26865862	GUSBL1	-0.52	-6.42	-0.38	7.01e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg24585782	chr17:78113791	EIF4A3	-0.5	-5.97	-0.36	8.03e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03079549	chr15:45879223	PLDN	0.5	6.73	0.39	1.22e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg01721255	chr8:58191610	C8orf71	0.65	5.53	0.33	8.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.75	-9.89	-0.53	1.21e-19	Blood metabolite levels;
KIRP	cis	rs62413470	1.000	rs12203464	chr6:55934339	G/T	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.48	9.88	0.53	1.29e-19	Multiple system atrophy;
KIRP	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg13293535	chr8:11597251	GATA4	-0.42	-5.45	-0.33	1.25e-7	Retinal vascular caliber;
KIRP	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg19743168	chr1:23544995	NA	0.52	7.29	0.42	4.27e-12	Height;
KIRP	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.31	-6.02	-0.36	6.31e-9	Monocyte percentage of white cells;
KIRP	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.92	9.87	0.53	1.42e-19	Blood protein levels;
KIRP	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg13731523	chr4:3047190	NA	-0.32	-5.59	-0.34	5.92e-8	Serum sulfate level;
KIRP	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.56	6.07	0.36	4.8e-9	Alcohol dependence;
KIRP	cis	rs78487399	0.808	rs12105399	chr2:43676939	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg16309518	chr5:176445507	NA	-0.78	-11.68	-0.6	2.29e-25	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg12560992	chr17:57184187	TRIM37	0.64	5.87	0.35	1.38e-8	Cognitive test performance;
KIRP	trans	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10888329	0.720	rs4428922	chr1:248406894	C/T	cg01631408	chr1:248437212	OR2T33	-0.49	-6.3	-0.37	1.36e-9	Autism spectrum disorder;
KIRP	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.22	-0.32	3.74e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1440410	0.798	rs10012434	chr4:144077518	G/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.16	9.13	0.5	2.63e-17	Mitochondrial DNA levels;
KIRP	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.48	-0.33	1.04e-7	Aortic root size;
KIRP	cis	rs6142102	0.812	rs6059554	chr20:32514092	A/T	cg08999081	chr20:33150536	PIGU	0.47	5.64	0.34	4.76e-8	Skin pigmentation;
KIRP	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg26875233	chr11:93583750	C11orf90	-0.4	-7.52	-0.43	1.02e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7929679	0.521	rs11499809	chr11:34790743	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs1298062	0.861	rs2431821	chr19:50995098	G/A	cg17071417	chr19:50962282	MYBPC2	0.44	5.14	0.31	5.66e-7	Age of smoking initiation;
KIRP	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.05	-19.51	-0.78	7.08e-52	Schizophrenia;
KIRP	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.69	-7.6	-0.44	6.35e-13	Vitiligo;
KIRP	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-7.9	-0.45	9.26e-14	Migraine;Coronary artery disease;
KIRP	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.78	-0.4	9e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26002218	chr14:103986227	CKB	0.27	5.57	0.33	6.74e-8	Body mass index;
KIRP	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.65	8.31	0.47	6.35e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2213920	0.679	rs4979533	chr9:118210764	C/T	cg13918206	chr9:118159781	DEC1	0.96	9.97	0.54	6.87e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg25019033	chr10:957182	NA	-0.63	-6.57	-0.39	2.95e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs4671458	1.000	rs4671459	chr2:63392872	A/C	cg17519650	chr2:63277830	OTX1	-0.56	-5.63	-0.34	4.82e-8	Subjective well-being;
KIRP	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	6.06	0.36	5.11e-9	Hypertriglyceridemia;
KIRP	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.33	-6.02	-0.36	6.33e-9	Renal cell carcinoma;
KIRP	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg22029157	chr1:209979665	IRF6	0.39	5.98	0.36	7.66e-9	Monobrow;
KIRP	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.8	9.96	0.54	7.69e-20	Response to diuretic therapy;
KIRP	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	11.39	0.59	2.08e-24	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26545983	chr19:18632784	ELL	0.52	6.31	0.37	1.31e-9	Parkinson's disease;
KIRP	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.29	0.37	1.46e-9	Rheumatoid arthritis;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.52	1.07e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg17376030	chr22:41985996	PMM1	-0.72	-7.59	-0.44	6.56e-13	Vitiligo;
KIRP	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.35	5.48	0.33	1.05e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg05255149	chr17:80675120	FN3KRP	0.47	5.07	0.31	7.78e-7	Glycated hemoglobin levels;
KIRP	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg16141378	chr3:129829833	LOC729375	0.55	6.95	0.41	3.18e-11	Triglycerides;
KIRP	cis	rs35883536	0.528	rs1577512	chr1:101030832	G/A	cg09408571	chr1:101003634	GPR88	0.24	5.36	0.32	1.91e-7	Monocyte count;
KIRP	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.9	0.88	4.82e-81	Chronic sinus infection;
KIRP	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.7	-9.36	-0.51	5.35e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4356932	0.967	rs5005109	chr4:76986342	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.92	-0.4	3.89e-11	Type 2 diabetes;
KIRP	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20135002	chr11:47629003	NA	-0.48	-5.82	-0.35	1.87e-8	Subjective well-being;
KIRP	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.26	0.32	3.14e-7	Smoking behavior;
KIRP	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.45	-5.7	-0.34	3.41e-8	Blood metabolite levels;
KIRP	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg15839431	chr19:19639596	YJEFN3	0.48	5.14	0.31	5.72e-7	Bipolar disorder;
KIRP	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.48	-6.14	-0.36	3.23e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2179367	0.959	rs4895789	chr6:149764654	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.29	-4.95	-0.3	1.41e-6	Dupuytren's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24353058	chr8:68255883	ARFGEF1	-0.5	-6.2	-0.37	2.4e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21824413	chr3:23987438	NR1D2	0.55	7.92	0.45	8.36e-14	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08897924	chr1:52832660	CC2D1B	0.48	6.06	0.36	5.18e-9	Interleukin-4 levels;
KIRP	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-7.9	-0.45	9.02e-14	Alzheimer's disease;
KIRP	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	IgG glycosylation;
KIRP	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg20701182	chr2:24300061	SF3B14	0.94	10.22	0.55	1.16e-20	Lymphocyte counts;
KIRP	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.86	13.66	0.66	5.58e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs17221829	0.733	rs2200750	chr11:89416160	G/A	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.12	-0.31	6.28e-7	Anxiety in major depressive disorder;
KIRP	cis	rs9584850	0.834	rs8481	chr13:99105395	G/A	cg20750642	chr13:99100586	FARP1	-0.54	-6.52	-0.38	3.93e-10	Neuroticism;
KIRP	cis	rs1978968	1.000	rs1110660	chr22:18444693	A/C	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg13409248	chr3:40428643	ENTPD3	0.41	5.32	0.32	2.35e-7	Renal cell carcinoma;
KIRP	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.72e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.87	-9.09	-0.5	3.49e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.65	8.76	0.49	3.33e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg23587288	chr2:27483067	SLC30A3	0.56	7.17	0.42	8.9e-12	Blood metabolite levels;
KIRP	cis	rs4908768	0.906	rs12117910	chr1:8556953	A/C	cg03610117	chr1:8450231	RERE	-0.49	-5.23	-0.32	3.56e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13939156	chr17:80058883	NA	0.5	7.54	0.43	8.98e-13	Life satisfaction;
KIRP	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	7.12	0.41	1.17e-11	Menarche (age at onset);
KIRP	cis	rs7116495	0.786	rs10736785	chr11:71718912	C/A	cg18441811	chr11:71824068	C11orf51	-0.6	-4.88	-0.3	1.92e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs10875746	0.903	rs11168386	chr12:48467977	C/T	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-11.14	-0.58	1.33e-23	Morning vs. evening chronotype;
KIRP	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg00319359	chr11:70116639	PPFIA1	0.66	6.46	0.38	5.58e-10	Coronary artery disease;
KIRP	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg01304814	chr3:48885189	PRKAR2A	0.7	5.44	0.33	1.26e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg03605463	chr16:89740564	NA	-0.42	-5.04	-0.31	9.15e-7	Vitiligo;
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg14221460	chr8:27183342	PTK2B	0.51	6.67	0.39	1.68e-10	Neuroticism;
KIRP	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg19025524	chr12:109796872	NA	-0.38	-5.06	-0.31	8.06e-7	Neuroticism;
KIRP	cis	rs3789045	1.000	rs3789044	chr1:204589101	C/T	cg08641003	chr1:204589008	LRRN2	-0.68	-7.34	-0.42	3.06e-12	Educational attainment (college completion);
KIRP	cis	rs300890	0.642	rs12649592	chr4:144293524	G/A	cg01719995	chr4:144104893	USP38	-0.42	-5.19	-0.31	4.37e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	8.08	0.46	2.99e-14	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg00542384	chr5:68868293	GTF2H2C;GTF2H2D	-0.34	-6.23	-0.37	2.04e-9	Response to metformin in type 2 diabetes (glycemic);
KIRP	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.2	21.77	0.81	2.68e-59	Cognitive function;
KIRP	cis	rs3026101	0.671	rs8081480	chr17:5282761	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.88	0.35	1.3e-8	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10168434	chr2:71295172	NAGK	-0.44	-6.2	-0.37	2.36e-9	Metabolic traits;
KIRP	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.57	-7.57	-0.43	7.46e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs834603	0.575	rs834597	chr7:47464488	A/T	cg09696706	chr7:47479511	TNS3	0.42	4.86	0.3	2.11e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg11204139	chr17:3907470	NA	0.81	15.03	0.69	1.18e-36	Type 2 diabetes;
KIRP	cis	rs4902647	0.728	rs4902651	chr14:69272125	C/T	cg03189333	chr14:69283534	NA	0.39	4.92	0.3	1.59e-6	Multiple sclerosis;
KIRP	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.75	-0.34	2.68e-8	Coronary artery disease;
KIRP	trans	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg00938859	chr5:1591904	SDHAP3	0.54	6.28	0.37	1.53e-9	Breast cancer;
KIRP	cis	rs9984896	0.541	rs11702057	chr21:37909704	T/A	cg16719517	chr21:37442385	CBR1	-0.44	-5.07	-0.31	8.01e-7	QT interval;
KIRP	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.14e-10	Axial length;
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg21851534	chr17:3907994	ZZEF1	0.51	7.53	0.43	9.57e-13	Type 2 diabetes;
KIRP	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.73	11.4	0.59	1.89e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.64	7.98	0.45	5.74e-14	QRS duration;
KIRP	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.58	-0.34	6.27e-8	Aortic root size;
KIRP	cis	rs7119038	0.818	rs1048024	chr11:118618776	A/T	cg19308663	chr11:118741387	NA	0.55	8.69	0.48	5.22e-16	Sjögren's syndrome;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15822934	chr2:71357313	MPHOSPH10;MCEE	0.49	6.64	0.39	2.05e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.43	5.01	0.3	1.06e-6	Schizophrenia;
KIRP	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg12218747	chr21:37451666	NA	-0.43	-5.37	-0.32	1.8e-7	Mitral valve prolapse;
KIRP	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg13206674	chr6:150067644	NUP43	0.52	7.4	0.43	2.22e-12	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg07701084	chr6:150067640	NUP43	0.59	7.65	0.44	4.68e-13	Lung cancer;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.43	-5.14	-0.31	5.61e-7	Longevity;Endometriosis;
KIRP	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-11.44	-0.59	1.42e-24	Personality dimensions;
KIRP	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.77	-0.35	2.42e-8	Bipolar disorder;
KIRP	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg15028436	chr7:37888078	TXNDC3	0.71	9.51	0.52	1.78e-18	Alzheimer's disease (late onset);
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg18306943	chr3:40428807	ENTPD3	-0.46	-6.44	-0.38	6.12e-10	Renal cell carcinoma;
KIRP	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	1.05	14.77	0.69	9.33e-36	Menopause (age at onset);
KIRP	cis	rs7601312	1.000	rs7575093	chr2:229320049	G/A	cg02542817	chr2:229291442	NA	-0.39	-5.8	-0.35	2.07e-8	Schizophrenia;
KIRP	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg01843034	chr6:37503916	NA	-0.85	-12.21	-0.61	4.2e-27	Cognitive performance;
KIRP	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.53	7.51	0.43	1.1e-12	Metabolite levels;
KIRP	cis	rs7712401	0.580	rs383262	chr5:122345684	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.41	-0.33	1.48e-7	Mean platelet volume;
KIRP	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.58	8.0	0.45	4.79e-14	Multiple system atrophy;
KIRP	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.67	-9.23	-0.51	1.26e-17	Longevity;
KIRP	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.16e-8	Life satisfaction;
KIRP	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.81	10.04	0.54	4.33e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20312087	chr8:145754193	MGC70857	-0.56	-6.04	-0.36	5.77e-9	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17987059	chr13:28752067	PAN3	0.48	6.94	0.4	3.46e-11	Interleukin-4 levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14305943	chr10:120820318	SNORA19;EIF3A	0.43	6.45	0.38	6.04e-10	Interleukin-4 levels;
KIRP	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs17123764	0.710	rs12315224	chr12:50109517	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.89	0.3	1.83e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg21573476	chr21:45109991	RRP1B	-0.63	-8.76	-0.49	3.31e-16	Mean corpuscular volume;
KIRP	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	1.22	11.17	0.58	1.02e-23	Lymphocyte counts;
KIRP	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.44	-0.47	2.75e-15	Type 2 diabetes;
KIRP	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.68	9.13	0.5	2.64e-17	Personality dimensions;
KIRP	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg18357526	chr6:26021779	HIST1H4A	0.39	5.08	0.31	7.58e-7	Height;
KIRP	cis	rs10203711	1.000	rs6711116	chr2:239596636	T/G	cg14580085	chr2:239553406	NA	0.39	5.16	0.31	5.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.53	-0.33	8.13e-8	Life satisfaction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16605982	chr13:97762345	NA	-0.51	-6.55	-0.39	3.35e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.75	-7.6	-0.44	6.22e-13	Gut microbiome composition (summer);
KIRP	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.75	8.3	0.47	7.01e-15	Cholesterol, total;
KIRP	cis	rs7190997	0.544	rs41440449	chr16:31337677	A/G	cg02846316	chr16:31340340	ITGAM	0.39	4.85	0.3	2.2e-6	IgA nephropathy;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.63	9.58	0.52	1.11e-18	Lung cancer;
KIRP	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	10.63	0.56	5.65e-22	Blood protein levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27261641	chr11:95523641	FAM76B;CEP57	-0.52	-6.05	-0.36	5.5e-9	Interleukin-4 levels;
KIRP	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.64	-7.26	-0.42	5.2e-12	Menarche (age at onset);
KIRP	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.75	11.29	0.58	4.25e-24	Blood metabolite ratios;
KIRP	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9912468	1.000	rs11867573	chr17:64320085	A/G	cg19474267	chr17:64306194	PRKCA	-0.65	-9.46	-0.52	2.69e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg04132472	chr17:19861366	AKAP10	0.48	6.73	0.39	1.19e-10	Schizophrenia;
KIRP	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.38	-9.34	-0.51	5.99e-18	Asthma (sex interaction);
KIRP	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.85	-0.4	5.77e-11	Response to antipsychotic treatment;
KIRP	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg23422044	chr7:1970798	MAD1L1	-0.68	-6.44	-0.38	6.37e-10	Neuroticism;
KIRP	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.63	9.48	0.52	2.23e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.64	-9.16	-0.5	2.04e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00933542	chr6:150070202	PCMT1	0.29	5.75	0.34	2.65e-8	Lung cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13749939	chr11:796434	SLC25A22	0.65	6.37	0.38	9.19e-10	Lung function (FEV1);
KIRP	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg21775007	chr8:11205619	TDH	-0.54	-6.93	-0.4	3.74e-11	Joint mobility (Beighton score);
KIRP	cis	rs12200782	0.872	rs59438701	chr6:26412527	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.52	-4.97	-0.3	1.23e-6	Small cell lung carcinoma;
KIRP	cis	rs6466055	0.661	rs7802168	chr7:104925206	T/A	cg04380332	chr7:105027541	SRPK2	0.37	5.01	0.3	1.05e-6	Schizophrenia;
KIRP	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg21919602	chr1:242011447	EXO1	-0.5	-6.51	-0.38	4.3e-10	Menopause (age at onset);
KIRP	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.62	7.74	0.44	2.51e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2594989	0.677	rs7631716	chr3:11576689	T/C	cg01796438	chr3:11312864	ATG7	0.41	5.33	0.32	2.24e-7	Circulating chemerin levels;
KIRP	cis	rs2273156	1.000	rs56686328	chr14:35458070	G/A	cg09327582	chr14:35236912	BAZ1A	-0.48	-5.27	-0.32	2.94e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.63	7.65	0.44	4.53e-13	Aortic root size;
KIRP	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg25019033	chr10:957182	NA	-0.69	-9.13	-0.5	2.54e-17	Eosinophil percentage of granulocytes;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg17552696	chr17:78940266	NA	-0.5	-6.06	-0.36	5.03e-9	Bladder cancer;
KIRP	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.41	-0.47	3.35e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2860975	0.967	rs7902572	chr10:96772717	C/A	cg09036531	chr10:96991505	NA	-0.54	-6.94	-0.4	3.54e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg06453172	chr10:134556979	INPP5A	-0.6	-6.58	-0.39	2.85e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.31	0.55	5.85e-21	Coffee consumption (cups per day);
KIRP	cis	rs4073416	0.542	rs8019762	chr14:66087178	A/G	cg03016385	chr14:66212404	NA	-0.54	-6.58	-0.39	2.73e-10	N-glycan levels;
KIRP	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.15	-10.21	-0.55	1.25e-20	Body mass index;
KIRP	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.09	-0.31	7.27e-7	Pulmonary function;
KIRP	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.45	0.33	1.21e-7	Coronary artery disease;
KIRP	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg24375607	chr4:120327624	NA	0.74	8.37	0.47	4.36e-15	Corneal astigmatism;
KIRP	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.03	11.7	0.6	1.96e-25	Vitiligo;
KIRP	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24110177	chr3:50126178	RBM5	-0.43	-5.5	-0.33	9.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-6.83	-0.4	6.66e-11	Vitiligo;
KIRP	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.65	-10.08	-0.54	3.07e-20	Menopause (age at onset);
KIRP	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.45	0.55	2.19e-21	Hip circumference;
KIRP	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.44	0.38	6.25e-10	Height;
KIRP	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg05457628	chr5:178986728	RUFY1	0.53	8.19	0.46	1.41e-14	Lung cancer;
KIRP	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg17366294	chr4:99064904	C4orf37	0.38	5.23	0.32	3.63e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg16339924	chr4:17578868	LAP3	-0.54	-6.99	-0.41	2.55e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-8.62	-0.48	8.06e-16	Longevity;
KIRP	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.48e-11	Diabetic kidney disease;
KIRP	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	6.79	0.4	8.14e-11	Tonsillectomy;
KIRP	cis	rs2299587	0.897	rs3853532	chr8:17782868	C/T	cg01800426	chr8:17659068	MTUS1	-0.41	-5.11	-0.31	6.56e-7	Economic and political preferences;
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.7	11.38	0.59	2.18e-24	Mean corpuscular volume;
KIRP	cis	rs7903847	0.642	rs2275089	chr10:99141205	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg18016565	chr1:150552671	MCL1	0.39	5.87	0.35	1.41e-8	Tonsillectomy;
KIRP	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06481639	chr22:41940642	POLR3H	-0.75	-7.72	-0.44	2.84e-13	Vitiligo;
KIRP	cis	rs7976059	0.895	rs12367434	chr12:52247915	C/T	cg09126859	chr12:52244063	NA	0.47	8.11	0.46	2.37e-14	Urate levels;
KIRP	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	1.04	14.23	0.67	6.33e-34	Menopause (age at onset);
KIRP	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg06417478	chr19:12876846	HOOK2	0.45	5.09	0.31	6.97e-7	Mean corpuscular volume;
KIRP	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26526719	chr5:1949144	NA	0.47	5.38	0.32	1.69e-7	Gut microbiome composition (winter);
KIRP	cis	rs4683142	0.518	rs7653682	chr3:46029271	A/G	cg08033130	chr3:45983597	CXCR6;FYCO1	0.34	4.91	0.3	1.67e-6	Methadone dose in opioid dependence;
KIRP	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg20302533	chr7:39170763	POU6F2	0.26	5.18	0.31	4.7e-7	IgG glycosylation;
KIRP	cis	rs883565	0.569	rs784515	chr3:39163848	C/T	cg01426195	chr3:39028469	NA	0.52	8.31	0.47	6.35e-15	Handedness;
KIRP	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-7.0	-0.41	2.47e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.83	-11.19	-0.58	9.01e-24	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg10756647	chr7:56101905	PSPH	0.95	7.03	0.41	2.05e-11	Diabetic kidney disease;
KIRP	cis	rs4523957	0.614	rs2760736	chr17:2036653	A/G	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-1.02	-8.74	-0.49	3.79e-16	Blood protein levels;
KIRP	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	8.49	0.48	1.98e-15	Post bronchodilator FEV1;
KIRP	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.52	6.7	0.39	1.41e-10	IgG glycosylation;
KIRP	cis	rs4638749	0.501	rs1000173	chr2:108762878	A/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.12	-0.31	6.06e-7	Blood pressure;
KIRP	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.56	-6.93	-0.4	3.73e-11	Coronary artery disease;
KIRP	cis	rs490234	0.676	rs1129	chr9:128199873	A/G	cg14078157	chr9:128172775	NA	0.66	7.82	0.45	1.55e-13	Mean arterial pressure;
KIRP	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.78	-12.09	-0.61	1.03e-26	Heart rate;
KIRP	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.52	0.38	3.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	7.63	0.44	5.09e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-0.96	-15.63	-0.71	1.02e-38	Height;
KIRP	cis	rs7572644	0.662	rs13402420	chr2:28271435	T/G	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs17331151	0.505	rs79979130	chr3:52551010	C/T	cg04865290	chr3:52927548	TMEM110	-0.61	-5.24	-0.32	3.54e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg05072774	chr3:49840536	C3orf54	0.43	5.54	0.33	7.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg19847130	chr8:10466454	RP1L1	0.39	5.71	0.34	3.26e-8	Retinal vascular caliber;
KIRP	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg17133734	chr15:86042851	AKAP13	-0.47	-5.96	-0.36	8.74e-9	Coronary artery disease;
KIRP	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg11031976	chr2:198649780	BOLL	-0.52	-5.01	-0.3	1.05e-6	Ulcerative colitis;
KIRP	cis	rs7665939	1.000	rs72709215	chr4:190112465	C/A	cg09826759	chr4:190284978	NA	-0.77	-5.16	-0.31	5.16e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-0.64	-9.19	-0.51	1.69e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg12855166	chr17:30846586	MYO1D	0.36	5.08	0.31	7.32e-7	Schizophrenia;
KIRP	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.51	-6.06	-0.36	5.04e-9	Corneal curvature;
KIRP	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	10.31	0.55	6.03e-21	Hip circumference;
KIRP	trans	rs2980439	0.729	rs2955585	chr8:8093511	A/G	cg02002194	chr4:3960332	NA	-0.47	-6.57	-0.39	3.03e-10	Neuroticism;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg07701084	chr6:150067640	NUP43	0.71	9.65	0.52	6.77e-19	Lung cancer;
KIRP	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.29	-0.51	8.48e-18	Mean corpuscular volume;
KIRP	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.44e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg19476082	chr7:2414320	EIF3B	0.54	4.94	0.3	1.45e-6	Multiple sclerosis;
KIRP	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg01338139	chr15:38987640	C15orf53	-0.49	-5.58	-0.34	6.24e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	trans	rs1462872	0.673	rs400794	chr8:31805572	A/G	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.35	8.34	0.47	5.51e-15	Asthma (sex interaction);
KIRP	cis	rs603446	0.703	rs1263151	chr11:116641028	C/T	cg08672956	chr11:116640933	BUD13	0.28	5.03	0.31	9.42e-7	Triglycerides;
KIRP	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.35	-5.13	-0.31	5.79e-7	Body mass index;
KIRP	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.83	8.59	0.48	1.02e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	1.13	14.24	0.67	5.99e-34	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg01620082	chr3:125678407	NA	-1.05	-6.87	-0.4	5.25e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg15660573	chr17:549704	VPS53	-0.85	-12.79	-0.63	4.66e-29	Prostate cancer;
KIRP	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.02	-0.46	4.22e-14	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06870995	chr15:83349171	AP3B2	0.44	6.3	0.37	1.38e-9	Parkinson's disease;
KIRP	cis	rs136211	0.619	rs9607337	chr22:36758849	A/T	cg21778268	chr22:36877729	TXN2	-0.43	-5.28	-0.32	2.8e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.61	-7.38	-0.43	2.44e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	1.01	13.97	0.67	4.62e-33	Menopause (age at onset);
KIRP	cis	rs4780401	0.933	rs4584833	chr16:11798758	C/T	cg01061890	chr16:11836724	TXNDC11	-0.46	-5.57	-0.33	6.71e-8	Rheumatoid arthritis;
KIRP	cis	rs7546094	0.967	rs351372	chr1:113059220	A/T	cg22162597	chr1:113214053	CAPZA1	0.42	5.93	0.35	1.04e-8	Platelet distribution width;
KIRP	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg05315796	chr3:52349193	DNAH1	0.35	5.43	0.33	1.36e-7	Bipolar disorder;
KIRP	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.14	0.36	3.32e-9	Height;
KIRP	cis	rs17221829	0.614	rs10765236	chr11:89450030	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-4.96	-0.3	1.32e-6	Anxiety in major depressive disorder;
KIRP	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.53	6.58	0.39	2.78e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg13409248	chr3:40428643	ENTPD3	0.35	4.88	0.3	1.9e-6	Renal cell carcinoma;
KIRP	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg25356066	chr3:128598488	ACAD9	0.52	5.97	0.36	8.35e-9	IgG glycosylation;
KIRP	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.53	-5.91	-0.35	1.12e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.24	-0.51	1.23e-17	Total body bone mineral density;
KIRP	trans	rs76288851	0.756	rs56036679	chr3:126486945	G/A	cg13821433	chr2:26726535	OTOF	0.55	6.3	0.37	1.34e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15557168	chr22:42548783	NA	-0.43	-5.79	-0.35	2.18e-8	Cognitive function;
KIRP	cis	rs7213347	0.707	rs9898390	chr17:2177484	C/G	cg15816464	chr17:2026533	SMG6	0.36	5.35	0.32	1.97e-7	Total body bone mineral density;
KIRP	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.94	-15.11	-0.69	6.37e-37	Height;
KIRP	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.41	-0.47	3.29e-15	Mood instability;
KIRP	trans	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs8054556	0.967	rs9932702	chr16:29982961	C/T	cg06326092	chr16:30034487	C16orf92	0.34	5.01	0.3	1.06e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6589219	0.908	rs10891246	chr11:111170540	A/G	cg25129781	chr11:111156908	C11orf53	-0.49	-6.28	-0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.01	0.41	2.29e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.51	6.67	0.39	1.66e-10	Calcium levels;
KIRP	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.81	-8.1	-0.46	2.55e-14	Type 2 diabetes nephropathy;
KIRP	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.45	-6.14	-0.36	3.28e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.79	-10.92	-0.57	6.97e-23	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.87	-0.45	1.16e-13	Triglycerides;
KIRP	cis	rs6681460	1.000	rs10889634	chr1:67065911	A/G	cg13052034	chr1:66999238	SGIP1	-0.38	-5.24	-0.32	3.51e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15821401	chr1:44482420	SLC6A9	0.46	6.26	0.37	1.66e-9	Survival in pancreatic cancer;
KIRP	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.9	14.74	0.68	1.13e-35	Dental caries;
KIRP	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.95	16.19	0.72	1.29e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-5.32	-0.32	2.31e-7	Crohn's disease;
KIRP	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg19507638	chr5:93509721	C5orf36	-0.54	-5.08	-0.31	7.32e-7	Diabetic retinopathy;
KIRP	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.65	-7.16	-0.42	9.13e-12	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.7	-0.44	3.36e-13	Type 2 diabetes;
KIRP	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-7.87	-0.45	1.09e-13	Vitiligo;
KIRP	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg00343986	chr7:65444356	GUSB	0.43	4.97	0.3	1.25e-6	Aortic root size;
KIRP	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.91	12.51	0.62	4.12e-28	Coronary artery disease;
KIRP	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.64	-7.49	-0.43	1.2e-12	Menarche (age at onset);
KIRP	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs795484	0.633	rs904661	chr12:118581860	C/T	cg16572268	chr12:118583242	PEBP1	0.36	5.41	0.33	1.46e-7	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
KIRP	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg03808351	chr9:123631620	PHF19	0.42	5.7	0.34	3.41e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.89	13.27	0.65	1.15e-30	Mean platelet volume;
KIRP	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg02574844	chr11:5959923	NA	-0.63	-6.51	-0.38	4.21e-10	DNA methylation (variation);
KIRP	cis	rs3782089	1.000	rs11605810	chr11:65300619	A/G	cg21890820	chr11:65308645	LTBP3	0.96	5.74	0.34	2.82e-8	Height;
KIRP	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg16988262	chr1:15930761	NA	0.4	5.11	0.31	6.32e-7	Systolic blood pressure;
KIRP	cis	rs7614311	0.594	rs58473894	chr3:63857208	G/C	cg22134162	chr3:63841271	THOC7	-0.37	-5.31	-0.32	2.49e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg20701182	chr2:24300061	SF3B14	0.58	5.17	0.31	4.74e-7	Lymphocyte counts;
KIRP	cis	rs76693355	0.512	rs11217843	chr11:120239937	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.42	-5.41	-0.33	1.48e-7	Intraocular pressure;
KIRP	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.93	16.12	0.72	2.12e-40	Metabolic syndrome;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg18877309	chr1:2105343	PRKCZ	0.57	6.29	0.37	1.48e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.2	13.81	0.66	1.61e-32	Corneal structure;
KIRP	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-17.69	-0.75	9.6e-46	Ulcerative colitis;
KIRP	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg16077055	chr2:106428750	NCK2	0.31	6.06	0.36	4.96e-9	Addiction;
KIRP	trans	rs17150703	0.500	rs55791035	chr8:9806604	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.08	-0.36	4.54e-9	Obesity (early onset extreme);
KIRP	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.4	-6.2	-0.37	2.31e-9	Colorectal cancer;
KIRP	cis	rs12210905	1.000	rs72843611	chr6:27131382	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.76	-6.5	-0.38	4.37e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.16	0.37	2.99e-9	Ovarian reserve;
KIRP	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg05315796	chr3:52349193	DNAH1	0.39	5.61	0.34	5.56e-8	Bipolar disorder;
KIRP	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	1.02	17.06	0.74	1.39e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs4594175	0.926	rs116372620	chr14:51599682	T/C	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06544989	chr22:39130855	UNC84B	0.41	6.33	0.37	1.17e-9	Menopause (age at onset);
KIRP	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17554472	chr22:41940697	POLR3H	0.54	5.88	0.35	1.32e-8	Vitiligo;
KIRP	trans	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg21775007	chr8:11205619	TDH	0.45	6.23	0.37	1.95e-9	Joint mobility (Beighton score);
KIRP	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.53	-0.33	8.13e-8	Aortic root size;
KIRP	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	12.2	0.61	4.52e-27	Menopause (age at onset);
KIRP	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.96	12.57	0.63	2.6e-28	Breast cancer;
KIRP	cis	rs3752645	0.536	rs56704102	chr7:106715282	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-5.45	-0.33	1.2e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs17286411	0.836	rs4788578	chr16:71938372	C/G	cg04254540	chr16:71951199	KIAA0174	-0.38	-5.0	-0.3	1.07e-6	Blood protein levels;
KIRP	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg08603382	chr10:743973	NA	-0.51	-7.49	-0.43	1.22e-12	Psychosis in Alzheimer's disease;
KIRP	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.54	0.59	6.62e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg17576719	chr12:46121221	LOC400027	0.93	6.14	0.36	3.23e-9	P wave terminal force;
KIRP	cis	rs12579753	0.667	rs7397307	chr12:82300161	G/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.67	-0.34	3.93e-8	Resting heart rate;
KIRP	cis	rs11637445	0.677	rs1564278	chr15:68107388	G/C	cg24579218	chr15:68104479	NA	-0.44	-6.58	-0.39	2.81e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2988277	0.737	rs1723015	chr1:167432894	T/C	cg22356347	chr1:167427500	CD247	-0.41	-5.91	-0.35	1.16e-8	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07113065	chr1:226595494	PARP1	0.51	6.73	0.39	1.18e-10	Parkinson's disease;
KIRP	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.42	-0.33	1.4e-7	Colorectal cancer;
KIRP	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg08761264	chr16:28874980	SH2B1	-0.51	-5.9	-0.35	1.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg23978390	chr7:1156363	C7orf50	0.54	5.69	0.34	3.55e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs1816752	0.905	rs9511242	chr13:24993399	G/A	cg22771759	chr13:24902376	NA	0.38	4.85	0.3	2.2e-6	Obesity-related traits;
KIRP	cis	rs7175404	1.000	rs7170008	chr15:94036207	A/G	cg23502883	chr15:93959149	NA	0.52	5.69	0.34	3.57e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs11203032	0.831	rs7091822	chr10:90957403	G/T	cg16672925	chr10:90967113	CH25H	0.43	5.3	0.32	2.58e-7	Heart failure;
KIRP	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg20368463	chr18:77673604	PQLC1	-0.59	-7.73	-0.44	2.81e-13	Schizophrenia;
KIRP	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg26516362	chr5:178986906	RUFY1	0.39	6.77	0.4	9.5e-11	Lung cancer;
KIRP	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08357651	chr2:198318030	COQ10B	0.5	6.38	0.38	8.64e-10	Parkinson's disease;
KIRP	trans	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg17822266	chr1:2720087	NA	-0.48	-6.55	-0.39	3.4e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.36	-5.25	-0.32	3.36e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg14703610	chr5:56206110	C5orf35	0.52	7.04	0.41	1.96e-11	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.08	0.61	1.11e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg08901578	chr4:187885870	NA	-0.51	-7.93	-0.45	7.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg01200585	chr1:228362443	C1orf69	0.44	5.4	0.33	1.61e-7	Diastolic blood pressure;
KIRP	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg03060546	chr3:49711283	APEH	-0.65	-6.04	-0.36	5.71e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.97	-0.41	2.87e-11	Bone mineral density;
KIRP	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg07636037	chr3:49044803	WDR6	-0.71	-6.48	-0.38	4.91e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs71636778	0.631	rs12747620	chr1:27182261	A/G	cg12203394	chr1:27248618	NUDC	0.71	5.69	0.34	3.63e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.26	-9.11	-0.5	2.88e-17	Diabetic kidney disease;
KIRP	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs17401966	0.538	rs7418410	chr1:10236402	A/G	cg19773385	chr1:10388646	KIF1B	0.49	6.68	0.39	1.58e-10	Hepatocellular carcinoma;
KIRP	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	5.25	0.32	3.32e-7	Breast cancer;
KIRP	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.72	8.11	0.46	2.4e-14	Corneal astigmatism;
KIRP	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg21573476	chr21:45109991	RRP1B	-0.85	-13.47	-0.65	2.34e-31	Mean corpuscular volume;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00089353	chr3:160473693	PPM1L	0.47	6.02	0.36	6.44e-9	Parkinson's disease;
KIRP	cis	rs13359291	0.841	rs6890251	chr5:122486419	C/T	cg16368670	chr5:122501738	PRDM6	-0.5	-6.17	-0.37	2.76e-9	Systolic blood pressure;
KIRP	trans	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg13565492	chr6:43139072	SRF	-0.87	-8.04	-0.46	3.8e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3739821	0.789	rs10987787	chr9:130729153	C/G	cg21181453	chr9:130700954	DPM2	0.47	7.11	0.41	1.26e-11	Glaucoma (primary angle closure);
KIRP	cis	rs807029	0.577	rs7902510	chr10:102757934	C/T	cg04662943	chr10:102668895	NA	0.46	5.05	0.31	8.51e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.61	9.86	0.53	1.52e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg23477460	chr3:66848765	NA	0.69	7.12	0.41	1.19e-11	Type 2 diabetes;
KIRP	trans	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-0.82	-9.23	-0.51	1.26e-17	Gut microbiome composition (summer);
KIRP	cis	rs4363385	0.510	rs2068678	chr1:152906956	G/A	cg25856811	chr1:152973957	SPRR3	-0.4	-5.48	-0.33	1.08e-7	Inflammatory skin disease;
KIRP	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg18833306	chr6:118973337	C6orf204	0.42	5.32	0.32	2.39e-7	Electrocardiographic conduction measures;
KIRP	cis	rs7578199	0.924	rs7563873	chr2:242349803	A/G	cg01632474	chr2:242799312	PDCD1	0.38	4.86	0.3	2.1e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs7017914	0.783	rs13252584	chr8:71689031	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg01620082	chr3:125678407	NA	-0.91	-6.32	-0.37	1.2e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.64	-0.34	4.58e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62355272	0.965	rs10491434	chr5:35877914	A/G	cg13894535	chr5:35919491	CAPSL	-0.42	-5.26	-0.32	3.18e-7	Lymphocyte counts;
KIRP	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg12131826	chr15:77904385	NA	0.5	5.94	0.35	9.78e-9	Type 2 diabetes;
KIRP	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.45	5.14	0.31	5.66e-7	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.33	-5.7	-0.34	3.44e-8	Height;
KIRP	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.64	-8.32	-0.47	6.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3764563	0.935	rs1654592	chr19:15690296	T/A	cg20725493	chr19:15740067	CYP4F8	0.89	6.45	0.38	6e-10	Inflammatory biomarkers;
KIRP	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg17385448	chr1:15911702	AGMAT	0.26	5.4	0.33	1.56e-7	Systolic blood pressure;
KIRP	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00290607	chr11:67383545	NA	0.36	5.06	0.31	8.1e-7	Mean corpuscular volume;
KIRP	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg07636037	chr3:49044803	WDR6	0.46	5.5	0.33	9.71e-8	Resting heart rate;
KIRP	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg11833968	chr6:79620685	NA	-0.48	-7.28	-0.42	4.5e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.57	-5.99	-0.36	7.28e-9	Obesity-related traits;
KIRP	trans	rs6734238	0.934	rs6741180	chr2:113844384	G/A	cg11332951	chr1:2396472	NA	-0.41	-6.01	-0.36	6.48e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.0	-0.3	1.09e-6	Glycated hemoglobin levels;
KIRP	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.96	6.81	0.4	7.44e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-4.91	-0.3	1.64e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.39	-5.2	-0.31	4.24e-7	Abdominal aortic aneurysm;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08463298	chr1:21503432	EIF4G3	0.47	6.64	0.39	1.95e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.31	9.77e-7	Initial pursuit acceleration;
KIRP	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg27124370	chr19:33622961	WDR88	0.56	6.98	0.41	2.77e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg00977110	chr5:151150581	G3BP1	0.59	5.9	0.35	1.23e-8	Preschool internalizing problems;
KIRP	cis	rs10849893	0.576	rs889970	chr12:121856217	G/A	cg01154721	chr12:121881891	KDM2B	-0.39	-5.1	-0.31	6.71e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg21174375	chr14:64681225	SYNE2	-0.52	-6.09	-0.36	4.35e-9	Atrial fibrillation;
KIRP	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.91	11.67	0.6	2.47e-25	Breast cancer;
KIRP	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs440932	0.717	rs330944	chr8:9021293	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	7.48	0.43	1.28e-12	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	9.2	0.51	1.64e-17	Cognitive test performance;
KIRP	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.96	7.8	0.45	1.79e-13	Alzheimer's disease (late onset);
KIRP	cis	rs16912285	0.579	rs73438263	chr11:24265205	C/T	ch.11.24196551F	chr11:24239977	NA	0.68	5.59	0.34	6.02e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.49	-0.33	9.79e-8	Life satisfaction;
KIRP	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.1	-0.64	4.19e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs17065868	0.881	rs61949804	chr13:45049965	T/C	cg10246903	chr13:45222710	NA	0.67	6.33	0.37	1.13e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg01320130	chr1:67600311	NA	-0.38	-4.86	-0.3	2.09e-6	Psoriasis;
KIRP	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.62	7.04	0.41	1.88e-11	Sum neutrophil eosinophil counts;
KIRP	cis	rs3760982	1.000	rs10405457	chr19:44296582	G/T	cg11993925	chr19:44307056	LYPD5	0.36	5.0	0.3	1.07e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.08	-0.31	7.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs76793172	1.000	rs3810328	chr19:46368222	G/T	cg00442267	chr19:46317840	RSPH6A	-0.74	-6.23	-0.37	2.03e-9	Eosinophil counts;
KIRP	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.73	-10.02	-0.54	4.95e-20	Asthma;
KIRP	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.46	6.47	0.38	5.37e-10	Sitting height ratio;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14178294	chr17:43109690	DCAKD	0.57	6.08	0.36	4.55e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg10381502	chr11:71823885	C11orf51	-1.17	-8.23	-0.46	1.08e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.05e-17	Retinal vascular caliber;
KIRP	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.56	-5.28	-0.32	2.84e-7	Narcolepsy;
KIRP	cis	rs300890	0.513	rs4690780	chr4:144123567	C/T	cg01719995	chr4:144104893	USP38	0.4	5.19	0.31	4.35e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.58	-7.07	-0.41	1.55e-11	Iron status biomarkers;
KIRP	cis	rs7107770	1.000	rs4936998	chr11:125096254	C/T	cg04164023	chr11:125106101	PKNOX2	-0.56	-5.12	-0.31	6.14e-7	Photic sneeze reflex;
KIRP	cis	rs4786125	0.587	rs12920700	chr16:6926397	C/T	cg03623568	chr16:6915990	A2BP1	-0.44	-5.52	-0.33	8.75e-8	Heart rate variability traits (SDNN);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15137760	chr8:21988747	HR	0.41	6.23	0.37	1.96e-9	Survival in pancreatic cancer;
KIRP	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg05991184	chr2:219186017	PNKD	0.35	4.95	0.3	1.38e-6	Colorectal cancer;
KIRP	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.07	-0.46	3.16e-14	Migraine;Coronary artery disease;
KIRP	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg00784671	chr22:46762841	CELSR1	-0.82	-8.17	-0.46	1.6e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs1465370	0.720	rs3823579	chr7:130017374	T/C	cg03229158	chr7:130009420	NA	0.33	4.87	0.3	2.01e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.56	7.53	0.43	9.42e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg01238044	chr22:24384105	GSTT1	-0.49	-6.17	-0.37	2.76e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg01990225	chr2:97406019	LMAN2L	-0.85	-7.07	-0.41	1.58e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2120243	0.572	rs6803628	chr3:157125584	G/A	cg24825693	chr3:157122686	VEPH1	-0.55	-8.97	-0.5	7.8e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs8060686	0.516	rs9938020	chr16:68251784	C/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.46	-0.43	1.45e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg07511668	chr11:68622177	NA	0.43	5.75	0.34	2.64e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2698530	0.791	rs869739	chr2:64493146	A/G	cg04647370	chr7:44613073	DDX56	0.5	6.08	0.36	4.61e-9	Iron status biomarkers;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg04650786	chr6:108395545	OSTM1	0.56	6.55	0.39	3.32e-10	Sleep duration;
KIRP	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg21191810	chr6:118973309	C6orf204	-0.42	-4.89	-0.3	1.86e-6	Diastolic blood pressure;
KIRP	cis	rs35892873	0.959	rs9845572	chr3:126092217	C/T	cg15490784	chr3:126061950	KLF15	0.51	6.59	0.39	2.68e-10	Male-pattern baldness;
KIRP	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg01657329	chr11:68192670	LRP5	0.49	5.28	0.32	2.78e-7	Total body bone mineral density;
KIRP	cis	rs6032067	1.000	rs6032065	chr20:43855649	C/T	cg10761708	chr20:43804764	PI3	0.51	5.24	0.32	3.4e-7	Blood protein levels;
KIRP	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.24	-0.32	3.4e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs12496230	0.794	rs4856968	chr3:66864932	A/G	cg04995300	chr3:66848608	NA	0.43	6.53	0.38	3.78e-10	Type 2 diabetes;
KIRP	cis	rs60311166	1.000	rs72950424	chr3:52687190	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.97	6.88	0.4	5e-11	CTACK levels;
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.7	11.65	0.6	2.96e-25	Mean platelet volume;
KIRP	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg18944383	chr4:111397179	ENPEP	0.61	11.1	0.58	1.78e-23	Height;
KIRP	cis	rs9322193	0.923	rs9322225	chr6:150184882	G/C	cg00933542	chr6:150070202	PCMT1	0.27	5.1	0.31	6.66e-7	Lung cancer;
KIRP	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.84	-0.4	6.13e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs16858210	0.607	rs60244260	chr3:183570734	G/A	cg25686905	chr3:183603175	PARL	-0.49	-5.3	-0.32	2.56e-7	Menopause (age at onset);
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg04804543	chr8:142233427	SLC45A4	1.01	18.02	0.75	7.56e-47	Immature fraction of reticulocytes;
KIRP	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg00122941	chr17:4613640	ARRB2	0.78	8.25	0.47	9.47e-15	Lymphocyte counts;
KIRP	cis	rs7635838	0.819	rs2454476	chr3:11545442	G/A	cg00170343	chr3:11313890	ATG7	0.48	6.04	0.36	5.54e-9	HDL cholesterol;
KIRP	cis	rs6832769	1.000	rs6824057	chr4:56367278	G/C	cg09317128	chr4:56265301	TMEM165	0.53	6.58	0.39	2.84e-10	Personality dimensions;
KIRP	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg00129232	chr17:37814104	STARD3	-0.56	-6.81	-0.4	7.36e-11	Self-reported allergy;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10053149	chr1:28908509	SNHG12;SNORA44;SNORA16A	-0.47	-6.22	-0.37	2.14e-9	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-8.52	-0.48	1.66e-15	Monocyte count;
KIRP	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg24879335	chr3:133465180	TF	0.33	4.87	0.3	1.99e-6	Iron status biomarkers;
KIRP	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.51	6.27	0.37	1.65e-9	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19450531	chr3:47422572	PTPN23	0.48	6.04	0.36	5.69e-9	Parkinson's disease;
KIRP	trans	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs3755132	0.778	rs73915402	chr2:15732238	G/C	cg12888861	chr2:15731646	DDX1	0.41	5.51	0.33	9.2e-8	Wilms tumor;
KIRP	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.76	-8.65	-0.48	6.77e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs882732	1.000	rs10144453	chr14:95045774	T/C	cg05186455	chr14:95027692	SERPINA4	-0.39	-5.01	-0.3	1.05e-6	Blood protein levels;
KIRP	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.81	12.99	0.64	1e-29	Multiple myeloma (IgH translocation);
KIRP	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg19468946	chr17:37922297	IKZF3	-0.46	-6.54	-0.38	3.6e-10	Asthma;
KIRP	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg00677455	chr12:58241039	CTDSP2	0.98	12.84	0.63	3.12e-29	Multiple sclerosis;
KIRP	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	8.02e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg01839850	chr22:38240395	ANKRD54;MIR658	0.74	6.26	0.37	1.68e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg07274523	chr3:49395745	GPX1	0.56	5.28	0.32	2.89e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.82	11.39	0.59	2.08e-24	Total body bone mineral density;
KIRP	cis	rs9653442	0.564	rs7565895	chr2:100774773	G/A	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg17822266	chr1:2720087	NA	-0.46	-6.3	-0.37	1.33e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs137699	0.652	rs137706	chr22:39751400	T/G	cg11247378	chr22:39784982	NA	-0.47	-5.9	-0.35	1.22e-8	IgG glycosylation;
KIRP	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.97	-0.45	6.02e-14	Monocyte percentage of white cells;
KIRP	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg03152288	chr2:177042942	NA	-0.49	-5.84	-0.35	1.62e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs526231	0.578	rs3776870	chr5:102295070	G/A	cg23492399	chr5:102201601	PAM	-0.5	-5.57	-0.33	6.68e-8	Primary biliary cholangitis;
KIRP	cis	rs80208956	1.000	rs76941912	chr11:69451864	C/T	cg27021553	chr11:69462783	CCND1	0.46	5.59	0.34	6.06e-8	Major depressive disorder;
KIRP	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg15848620	chr12:58087721	OS9	-0.5	-5.86	-0.35	1.44e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.61	9.33	0.51	6.61e-18	Height;
KIRP	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25517755	chr10:38738941	LOC399744	0.38	5.07	0.31	7.93e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03647317	chr4:187891568	NA	-0.77	-12.86	-0.63	2.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.53	-0.43	9.77e-13	Retinal vascular caliber;
KIRP	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.52	-7.74	-0.44	2.6e-13	Sudden cardiac arrest;
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg05665937	chr4:1216051	CTBP1	0.44	5.63	0.34	4.96e-8	Obesity-related traits;
KIRP	cis	rs4700695	0.841	rs36302	chr5:65349061	T/A	cg21114390	chr5:65439923	SFRS12	0.57	5.19	0.31	4.33e-7	Facial morphology (factor 19);
KIRP	cis	rs6681460	0.866	rs485521	chr1:67209562	T/C	cg13052034	chr1:66999238	SGIP1	-0.39	-5.34	-0.32	2.13e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs13315871	1.000	rs35792042	chr3:58409668	C/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.17	-0.31	4.94e-7	Cholesterol, total;
KIRP	cis	rs4132509	0.895	rs7556516	chr1:243782009	G/A	cg25706552	chr1:244017396	NA	0.53	6.82	0.4	7.21e-11	RR interval (heart rate);
KIRP	cis	rs4523957	0.855	rs216172	chr17:2126504	G/C	cg16513277	chr17:2031491	SMG6	-0.67	-9.22	-0.51	1.39e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.43	-5.7	-0.34	3.51e-8	Menarche (age at onset);
KIRP	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.45	5.26	0.32	3.13e-7	Schizophrenia;
KIRP	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00889227	chr1:205173544	DSTYK	-0.38	-5.45	-0.33	1.25e-7	Red blood cell count;
KIRP	cis	rs2282978	0.557	rs191777	chr7:92250374	T/A	cg15732164	chr7:92237376	CDK6	-0.35	-4.91	-0.3	1.7e-6	Height;
KIRP	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	cg07049167	chr1:166818506	POGK	0.6	6.18	0.37	2.71e-9	Refractive astigmatism;
KIRP	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.4	4.99	0.3	1.15e-6	Aortic root size;
KIRP	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.9	10.26	0.55	8.73e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs807029	0.577	rs750866	chr10:102761458	A/G	cg04662943	chr10:102668895	NA	0.47	5.12	0.31	6.26e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg22508957	chr16:3507546	NAT15	0.35	4.88	0.3	1.87e-6	Body mass index (adult);
KIRP	cis	rs4919044	0.599	rs11187215	chr10:94670849	A/G	cg05127821	chr10:94822908	CYP26C1	-0.9	-7.0	-0.41	2.36e-11	Coronary artery disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg11940663	chr21:46962454	SLC19A1	0.47	6.06	0.36	5.21e-9	DNA methylation (variation);
KIRP	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.61	-7.44	-0.43	1.68e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs7903847	0.596	rs9787426	chr10:99155327	A/G	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.94	0.3	1.44e-6	Educational attainment;
KIRP	trans	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.37	-5.97	-0.36	8.07e-9	Body mass index;
KIRP	cis	rs2286379	0.933	rs10773997	chr12:1903496	C/T	cg05227549	chr12:1770782	NA	-0.31	-4.99	-0.3	1.12e-6	Blood pressure (smoking interaction);
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.58	7.28	0.42	4.44e-12	Longevity;Endometriosis;
KIRP	trans	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg08645402	chr16:4508243	NA	0.53	6.81	0.4	7.23e-11	Schizophrenia;
KIRP	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.38	7.69	0.44	3.57e-13	Diastolic blood pressure;
KIRP	cis	rs7562790	0.500	rs3821160	chr2:36644228	C/G	cg09467607	chr2:36825704	FEZ2	0.41	5.0	0.3	1.11e-6	QRS duration;QRS complex (Cornell);
KIRP	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg10047753	chr17:41438598	NA	1.14	17.79	0.75	4.34e-46	Menopause (age at onset);
KIRP	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.48	8.42	0.47	3.12e-15	Iron status biomarkers (transferrin levels);
KIRP	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg08198773	chr8:1697536	NA	0.38	4.85	0.3	2.19e-6	Systolic blood pressure;
KIRP	cis	rs57590327	0.679	rs13071810	chr3:81618478	T/C	cg07356753	chr3:81810745	GBE1	-0.56	-5.99	-0.36	7.32e-9	Extraversion;
KIRP	cis	rs72843166	0.891	rs76326339	chr17:61053778	A/G	cg19683800	chr17:61518354	CYB561	-0.44	-5.1	-0.31	6.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	0.812	rs17283677	chr3:41926148	C/T	cg03022575	chr3:42003672	ULK4	-0.75	-7.97	-0.45	5.92e-14	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14943877	chr10:112257612	DUSP5	0.5	6.23	0.37	1.98e-9	Parkinson's disease;
KIRP	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.34	-4.85	-0.3	2.18e-6	Congenital heart disease (maternal effect);
KIRP	cis	rs7215564	0.908	rs35128297	chr17:78652909	A/C	cg06153925	chr17:78755379	RPTOR	0.34	5.42	0.33	1.45e-7	Myopia (pathological);
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg10351095	chr21:47802916	PCNT	0.44	5.56	0.33	7.18e-8	Testicular germ cell tumor;
KIRP	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.76	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00916432	chr4:137829844	NA	-0.39	-6.5	-0.38	4.45e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.2	-0.55	1.3e-20	Hemoglobin concentration;
KIRP	trans	rs629535	1.000	rs644951	chr8:70009082	C/T	cg21567404	chr3:27674614	NA	-0.92	-13.22	-0.64	1.64e-30	Dupuytren's disease;
KIRP	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.57	8.45	0.47	2.51e-15	Fat distribution (HIV);
KIRP	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.52	7.15	0.41	9.66e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.66	8.97	0.5	7.53e-17	Crohn's disease;
KIRP	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.53	0.52	1.56e-18	Colorectal cancer;
KIRP	cis	rs28489187	0.617	rs233072	chr1:85807695	A/G	cg16011679	chr1:85725395	C1orf52	0.44	5.51	0.33	8.94e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg04935436	chr20:30431758	NA	0.53	6.52	0.38	4.05e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.6	-7.32	-0.42	3.51e-12	Iron status biomarkers;
KIRP	cis	rs12823128	0.729	rs12579514	chr12:26929834	C/G	cg14081884	chr12:26986758	ITPR2	0.4	5.01	0.3	1.02e-6	Birth weight;
KIRP	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.63	7.81	0.45	1.7e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.18	0.67	8.93e-34	Platelet count;
KIRP	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg18877969	chr2:232395326	NMUR1	-0.35	-4.89	-0.3	1.85e-6	Height;
KIRP	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-7.63	-0.44	5.12e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1829883	0.795	rs115354460	chr5:98911214	T/C	cg08333243	chr5:99726346	NA	0.43	5.46	0.33	1.18e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg25547332	chr5:131281432	NA	0.49	5.72	0.34	3.11e-8	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.17e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.68	9.95	0.54	8.33e-20	Dupuytren's disease;
KIRP	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg05805236	chr11:65401703	PCNXL3	-0.59	-7.34	-0.42	3.02e-12	Acne (severe);
KIRP	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.38	-0.43	2.39e-12	Morning vs. evening chronotype;
KIRP	cis	rs300890	0.642	rs2196909	chr4:144281926	A/G	cg01719995	chr4:144104893	USP38	-0.42	-5.11	-0.31	6.4e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-7.0	-0.41	2.41e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.46	7.42	0.43	1.93e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7792596	0.539	rs17252513	chr7:94010623	C/T	cg20814616	chr7:94014465	NA	-0.45	-5.21	-0.32	3.91e-7	Intelligence;
KIRP	cis	rs2882877	0.513	rs10206897	chr2:190459793	A/T	cg10752008	chr2:190445175	SLC40A1	-0.41	-4.93	-0.3	1.51e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.75	12.38	0.62	1.06e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.68	-10.1	-0.54	2.79e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg02780029	chr10:43622663	RET	-0.35	-5.28	-0.32	2.9e-7	Hirschsprung disease;
KIRP	cis	rs96067	0.805	rs2231317	chr1:36603290	C/T	cg27506609	chr1:36549197	TEKT2	-0.49	-5.91	-0.35	1.16e-8	Corneal structure;
KIRP	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.76	7.79	0.44	1.86e-13	Hip geometry;
KIRP	cis	rs2213920	0.749	rs4978637	chr9:118222448	T/A	cg13918206	chr9:118159781	DEC1	0.99	10.15	0.54	1.88e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.72	-8.07	-0.46	3.17e-14	Menarche (age at onset);
KIRP	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.72	9.61	0.52	9.13e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.54	-6.91	-0.4	4.12e-11	Eye color traits;
KIRP	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06481639	chr22:41940642	POLR3H	0.69	6.84	0.4	6.19e-11	Vitiligo;
KIRP	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg00405596	chr8:11794950	NA	0.41	5.13	0.31	5.74e-7	Retinal vascular caliber;
KIRP	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg08461772	chr7:95026248	PON3	0.41	5.79	0.35	2.11e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg08975724	chr8:8085496	FLJ10661	0.69	9.4	0.51	3.91e-18	Mood instability;
KIRP	cis	rs17776563	0.959	rs13329353	chr15:89113877	A/G	cg05013243	chr15:89149849	MIR1179	0.42	5.45	0.33	1.25e-7	Thyroid hormone levels;
KIRP	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	16.99	0.73	2.26e-43	Platelet count;
KIRP	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.96	15.78	0.71	3.25e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.09	0.54	3.04e-20	Total body bone mineral density;
KIRP	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs920590	0.679	rs4577973	chr8:19658017	A/G	cg03894339	chr8:19674705	INTS10	0.4	4.96	0.3	1.3e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.04	-12.01	-0.61	1.84e-26	Vitiligo;
KIRP	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg11608241	chr8:8085544	FLJ10661	-0.46	-6.12	-0.36	3.75e-9	Neuroticism;
KIRP	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg26898376	chr11:64110657	CCDC88B	0.61	5.02	0.3	9.85e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.5	5.03	0.31	9.32e-7	Obesity (extreme);
KIRP	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.08	12.97	0.64	1.12e-29	Vitiligo;
KIRP	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.3	1.44e-6	Cognitive test performance;
KIRP	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg07423050	chr13:99094983	FARP1	0.32	5.29	0.32	2.73e-7	Longevity;
KIRP	cis	rs4979906	1.000	rs68092325	chr10:79446719	T/A	cg07817648	chr10:79422355	NA	-0.48	-5.14	-0.31	5.5e-7	Mortality in heart failure;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg07701084	chr6:150067640	NUP43	0.6	7.57	0.43	7.47e-13	Lung cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13778499	chr9:35814820	HINT2	0.43	6.22	0.37	2.08e-9	Survival in pancreatic cancer;
KIRP	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg08501292	chr6:25962987	TRIM38	1.09	6.52	0.38	4e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg13010199	chr12:38710504	ALG10B	0.5	6.43	0.38	6.5e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg06197360	chr20:60970103	CABLES2	-0.53	-6.35	-0.38	1.01e-9	Colorectal cancer;
KIRP	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-14.02	-0.67	3.28e-33	Blood trace element (Zn levels);
KIRP	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.12	-0.31	6.12e-7	Life satisfaction;
KIRP	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg21419209	chr3:44054225	NA	-0.73	-9.0	-0.5	6.18e-17	Coronary artery disease;
KIRP	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg01629716	chr15:45996671	NA	0.37	6.7	0.39	1.39e-10	Waist circumference;Weight;
KIRP	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.68	7.92	0.45	8.27e-14	Breast cancer;
KIRP	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.49	-6.38	-0.38	8.6e-10	White blood cell count;
KIRP	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12230010	chr10:72163718	EIF4EBP2	0.54	6.39	0.38	8.45e-10	Smoking initiation;
KIRP	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg12560992	chr17:57184187	TRIM37	0.61	6.51	0.38	4.17e-10	Testicular germ cell tumor;
KIRP	cis	rs6142102	0.923	rs6057961	chr20:32573811	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	6.57	0.39	3.01e-10	Skin pigmentation;
KIRP	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.83	10.8	0.57	1.68e-22	N-glycan levels;
KIRP	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.79	10.1	0.54	2.7e-20	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20595745	chr1:63249763	ATG4C	0.51	6.12	0.36	3.75e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.81	-10.09	-0.54	2.89e-20	Longevity;
KIRP	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.07	-7.75	-0.44	2.42e-13	Mitochondrial DNA levels;
KIRP	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg07862535	chr7:139043722	LUC7L2	-0.49	-5.55	-0.33	7.23e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg04306507	chr14:55594613	LGALS3	0.44	6.82	0.4	7.02e-11	Protein biomarker;
KIRP	cis	rs8077577	0.943	rs62073603	chr17:18064316	C/T	cg18869244	chr17:18121946	NA	0.48	5.38	0.32	1.78e-7	Obesity-related traits;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg08501292	chr6:25962987	TRIM38	1.03	8.2	0.46	1.31e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.57	7.24	0.42	5.61e-12	Tonsillectomy;
KIRP	cis	rs7737355	0.947	rs6596007	chr5:130588550	A/G	cg06307176	chr5:131281290	NA	-0.52	-5.64	-0.34	4.64e-8	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.43	7.57	0.43	7.28e-13	Renal cell carcinoma;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg17188901	chr7:150672175	KCNH2	0.41	6.04	0.36	5.77e-9	Educational attainment;
KIRP	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.45	-5.1	-0.31	6.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	0.956	rs2017932	chr22:18439190	C/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.89	-0.4	4.64e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-4.99	-0.3	1.15e-6	Neutrophil percentage of white cells;
KIRP	trans	rs12043259	0.730	rs10458589	chr1:204792001	A/G	cg11485465	chr5:54518469	NA	0.34	6.11	0.36	3.97e-9	Addiction;
KIRP	cis	rs16912285	0.688	rs10834313	chr11:24348447	G/C	ch.11.24196551F	chr11:24239977	NA	0.59	5.29	0.32	2.66e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.86	12.57	0.63	2.53e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.04	0.41	1.91e-11	Bipolar disorder;
KIRP	cis	rs2131877	0.827	rs6784890	chr3:194842145	A/C	cg16306870	chr3:194868790	C3orf21	0.25	5.35	0.32	1.96e-7	Non-small cell lung cancer;
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg01763666	chr17:80159506	CCDC57	-0.38	-5.16	-0.31	5.13e-7	Life satisfaction;
KIRP	trans	rs76288851	0.799	rs11710423	chr3:126679654	G/A	cg13821433	chr2:26726535	OTOF	0.57	6.31	0.37	1.27e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs7804356	1.000	rs73067437	chr7:26850313	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-4.88	-0.3	1.9e-6	Type 1 diabetes;
KIRP	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg02002194	chr4:3960332	NA	0.45	6.69	0.39	1.49e-10	Mood instability;
KIRP	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.88	-0.3	1.92e-6	Monocyte percentage of white cells;
KIRP	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.6	0.34	5.82e-8	Neuroticism;
KIRP	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg26513180	chr16:89883248	FANCA	-0.39	-5.05	-0.31	8.53e-7	Vitiligo;
KIRP	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg05370193	chr1:21551575	ECE1	0.36	4.86	0.3	2.12e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg22777020	chr22:31556080	RNF185	0.48	5.21	0.32	4.08e-7	Colorectal cancer;
KIRP	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.49	-6.47	-0.38	5.23e-10	Survival in pancreatic cancer;
KIRP	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15369054	chr17:80825471	TBCD	0.54	5.01	0.3	1.06e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs16828019	0.852	rs11209531	chr1:41571021	C/T	cg03387723	chr1:41708464	SCMH1	-0.76	-6.7	-0.39	1.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4762326	0.932	rs10777675	chr12:95602319	A/T	cg07737802	chr12:95537812	FGD6	0.45	6.2	0.37	2.4e-9	Endometriosis;
KIRP	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg07274523	chr3:49395745	GPX1	0.51	5.0	0.3	1.07e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6540559	0.673	rs6540561	chr1:209982255	C/T	cg22029157	chr1:209979665	IRF6	0.52	5.9	0.35	1.21e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg11245181	chr6:149772854	ZC3H12D	-0.33	-5.03	-0.31	9.44e-7	Dupuytren's disease;
KIRP	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg06740227	chr12:86229804	RASSF9	0.41	5.18	0.31	4.68e-7	Major depressive disorder;
KIRP	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.85	11.84	0.6	6.88e-26	Total body bone mineral density;
KIRP	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	1.08	11.06	0.58	2.39e-23	Nonalcoholic fatty liver disease;
KIRP	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.65	9.44	0.52	3.03e-18	Vitiligo;
KIRP	cis	rs5750854	0.530	rs5750863	chr22:40026948	A/T	cg10455938	chr22:40058150	CACNA1I	0.44	6.27	0.37	1.65e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs35740288	0.929	rs3858927	chr15:86301616	C/G	cg17133734	chr15:86042851	AKAP13	-0.49	-5.4	-0.33	1.6e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg22117172	chr7:91764530	CYP51A1	0.41	5.77	0.35	2.39e-8	Breast cancer;
KIRP	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	1.15	10.33	0.55	5.23e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.86	-12.74	-0.63	6.65e-29	Height;
KIRP	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.18	-0.31	4.61e-7	Breast cancer;
KIRP	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.63	8.06	0.46	3.27e-14	Height;
KIRP	cis	rs10121009	0.565	rs10758306	chr9:35431152	C/T	cg15271616	chr9:35490515	RUSC2	0.37	5.13	0.31	5.76e-7	Parkinson's disease;
KIRP	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18357526	chr6:26021779	HIST1H4A	0.46	6.52	0.38	4.02e-10	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-8.84	-0.49	1.87e-16	Platelet count;
KIRP	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.94	9.58	0.52	1.1e-18	Gut microbiome composition (summer);
KIRP	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.51	11.3	0.58	4.06e-24	Diabetic kidney disease;
KIRP	cis	rs8084125	1.000	rs72978668	chr18:74953748	A/C	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs2483058	0.515	rs2987936	chr1:206606078	C/G	cg19452316	chr1:206680966	RASSF5	-0.42	-5.47	-0.33	1.12e-7	Cholesterol and Triglycerides;
KIRP	trans	rs78944489	0.764	rs9917225	chr2:73480422	C/T	cg18655438	chr5:1077845	SLC12A7	-0.83	-6.06	-0.36	5.19e-9	Schizophrenia;
KIRP	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.47	9.45	0.52	2.85e-18	Longevity;
KIRP	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.41	0.33	1.48e-7	Breast cancer;
KIRP	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg11972305	chr2:233791962	NGEF	-0.39	-5.33	-0.32	2.27e-7	Schizophrenia;
KIRP	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg02012338	chr4:187126139	CYP4V2	-0.95	-7.97	-0.45	5.77e-14	Blood protein levels;
KIRP	trans	rs6561151	0.957	rs9316058	chr13:44485076	G/C	cg12856521	chr11:46389249	DGKZ	0.5	6.81	0.4	7.43e-11	Crohn's disease;
KIRP	cis	rs62413470	0.938	rs12194397	chr6:55931595	A/G	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.16	0.37	3e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.67	-0.34	4.02e-8	Aortic root size;
KIRP	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.03	-0.31	9.64e-7	Coronary artery disease;
KIRP	cis	rs17020663	0.771	rs2278722	chr2:101620136	A/G	cg15506514	chr2:101638852	TBC1D8	-0.53	-5.24	-0.32	3.42e-7	Pulse pressure;
KIRP	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-5.07	-0.31	7.72e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-5.55	-0.33	7.3e-8	Height;
KIRP	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.58	6.42	0.38	7.16e-10	Alcohol dependence;
KIRP	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.54	7.18	0.42	8.19e-12	Colorectal cancer;
KIRP	cis	rs35123781	1.000	rs600848	chr5:139057270	T/C	cg10513866	chr5:139070639	NA	0.35	4.87	0.3	2e-6	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg01879757	chr17:41196368	BRCA1	-0.8	-11.09	-0.58	1.92e-23	Menopause (age at onset);
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.63	-0.34	4.79e-8	Life satisfaction;
KIRP	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.62	-8.34	-0.47	5.44e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	1.0	13.02	0.64	7.7e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.2	0.58	8.19e-24	Bladder cancer;
KIRP	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.85	-0.3	2.18e-6	Pulmonary function;
KIRP	cis	rs78487399	0.808	rs74365854	chr2:43661482	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.93	12.67	0.63	1.18e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.71	-6.15	-0.37	3.11e-9	Small cell lung carcinoma;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg15181151	chr6:150070149	PCMT1	0.3	5.12	0.31	6.1e-7	Lung cancer;
KIRP	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg17691542	chr6:26056736	HIST1H1C	0.99	11.2	0.58	8.35e-24	Iron status biomarkers;
KIRP	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg21174375	chr14:64681225	SYNE2	0.44	4.93	0.3	1.52e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.79	-12.75	-0.63	6.55e-29	Prostate cancer;
KIRP	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-5.58	-0.34	6.24e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4761097	0.516	rs7964816	chr12:85229680	A/G	cg00765312	chr12:85674694	ALX1	0.52	6.07	0.36	4.76e-9	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg00129232	chr17:37814104	STARD3	0.48	6.04	0.36	5.54e-9	Self-reported allergy;
KIRP	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.52	-0.33	8.69e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-5.86	-0.35	1.45e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg17207736	chr8:142237307	SLC45A4	0.45	5.77	0.35	2.32e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.71	9.89	0.53	1.24e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs76793172	0.557	rs6509234	chr19:46229711	T/G	cg11657440	chr19:46296263	DMWD	0.74	5.28	0.32	2.85e-7	Eosinophil counts;
KIRP	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg06360820	chr2:242988706	NA	-0.7	-6.62	-0.39	2.23e-10	Obesity-related traits;
KIRP	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-1.1	-8.03	-0.46	3.93e-14	Obesity-related traits;
KIRP	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06481639	chr22:41940642	POLR3H	0.74	7.88	0.45	1.05e-13	Vitiligo;
KIRP	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg02175503	chr12:58329896	NA	0.5	5.38	0.32	1.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7849270	0.801	rs10819475	chr9:131930840	G/A	cg13538475	chr9:131942899	NA	0.37	5.31	0.32	2.44e-7	Blood metabolite ratios;
KIRP	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-5.98	-0.36	7.71e-9	Type 2 diabetes;
KIRP	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-5.57	-0.33	6.58e-8	Bipolar disorder;
KIRP	cis	rs11038871	1.000	rs11038871	chr11:46379442	C/T	cg16389345	chr11:46697382	NA	0.52	7.14	0.41	1.06e-11	Immunoglobulin A;
KIRP	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-5.34	-0.32	2.15e-7	Personality dimensions;
KIRP	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg06204229	chr3:52865917	ITIH4	0.53	5.93	0.35	1.02e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13409248	chr3:40428643	ENTPD3	0.39	5.1	0.31	6.82e-7	Renal cell carcinoma;
KIRP	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.1	-0.36	4.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00495681	chr13:53174319	NA	0.42	5.82	0.35	1.84e-8	Lewy body disease;
KIRP	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg17595323	chr11:93583763	C11orf90	-0.41	-6.82	-0.4	7.18e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26662579	chr1:109969051	PSMA5	-0.48	-6.03	-0.36	5.97e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.37	-0.32	1.8e-7	Red blood cell count;
KIRP	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.88	-0.4	4.95e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8033133	0.647	rs1124767	chr15:25326173	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.48	-5.85	-0.35	1.58e-8	Blood osmolality (transformed sodium);
KIRP	cis	rs9596863	0.898	rs114009192	chr13:54399899	T/A	ch.13.53330881F	chr13:54432880	NA	0.62	6.24	0.37	1.9e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2579500	0.845	rs1585272	chr2:97161749	T/C	cg23100626	chr2:96804247	ASTL	0.39	5.32	0.32	2.35e-7	Eosinophil counts;Eosinophil percentage of white cells;
KIRP	cis	rs7903847	0.527	rs11189223	chr10:99203348	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.26	-0.32	3.06e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.47	-10.61	-0.56	6.86e-22	Alzheimer's disease (late onset);
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg23102388	chr7:1867652	MAD1L1	-0.44	-5.98	-0.36	7.77e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg14972814	chr11:95582409	MTMR2	0.33	5.4	0.33	1.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs656319	0.729	rs671370	chr8:9813317	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.0	-0.41	2.48e-11	Myopia (pathological);
KIRP	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.36	9.4	0.51	4.07e-18	Crohn's disease;
KIRP	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.91	-14.33	-0.67	2.75e-34	Height;
KIRP	cis	rs735860	0.726	rs209519	chr6:53208680	G/A	cg10236188	chr6:53219634	NA	0.41	5.48	0.33	1.06e-7	Glaucoma;
KIRP	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs7395662	0.687	rs11602892	chr11:48959152	G/A	cg21546286	chr11:48923668	NA	-0.47	-5.77	-0.35	2.37e-8	HDL cholesterol;
KIRP	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.61	-5.59	-0.34	5.88e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.07	-0.41	1.55e-11	Menopause (age at onset);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg13538257	chr6:153324006	MTRF1L	-0.45	-6.15	-0.37	3.19e-9	Migraine with aura;
KIRP	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg22974920	chr21:40686053	BRWD1	0.46	5.47	0.33	1.13e-7	Cognitive function;
KIRP	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.58	7.91	0.45	8.8e-14	Prostate cancer;
KIRP	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.29e-11	Type 2 diabetes;
KIRP	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg26681399	chr22:41777847	TEF	-0.52	-5.18	-0.31	4.6e-7	Vitiligo;
KIRP	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg01631408	chr1:248437212	OR2T33	-0.67	-8.44	-0.47	2.76e-15	Common traits (Other);
KIRP	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.93	-10.77	-0.57	2.05e-22	Breast cancer;
KIRP	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg17595323	chr11:93583763	C11orf90	-0.37	-6.23	-0.37	1.96e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.79	0.63	4.52e-29	Ileal carcinoids;
KIRP	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs6840360	0.870	rs1372978	chr4:152456180	A/G	cg25486957	chr4:152246857	NA	-0.49	-5.64	-0.34	4.72e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7572644	0.640	rs11127126	chr2:28023284	C/T	cg27432699	chr2:27873401	GPN1	0.49	5.81	0.35	1.9e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08138807	chr3:195164060	ACAP2	0.59	7.29	0.42	4.34e-12	Parkinson's disease;
KIRP	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.03	-0.31	9.46e-7	Bipolar disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18929251	chr7:107744567	LAMB4	0.38	6.39	0.38	8.03e-10	Survival in pancreatic cancer;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg22482801	chr22:29724443	AP1B1	-0.43	-6.11	-0.36	3.81e-9	Bladder cancer;
KIRP	cis	rs4523957	0.719	rs1532292	chr17:2097483	T/G	cg16513277	chr17:2031491	SMG6	-0.63	-9.14	-0.5	2.42e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs77861329	0.669	rs2878438	chr3:52103045	A/G	cg08692210	chr3:52188851	WDR51A	0.56	5.41	0.33	1.5e-7	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg23920097	chr1:209922102	NA	-0.45	-5.39	-0.33	1.62e-7	Red blood cell count;
KIRP	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.61	8.56	0.48	1.22e-15	Multiple system atrophy;
KIRP	cis	rs7187994	0.848	rs35019923	chr16:84782214	A/C	cg11201751	chr16:85158047	NA	0.48	4.98	0.3	1.19e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9649213	0.593	rs7458551	chr7:97952167	G/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg19731401	chr7:2775893	GNA12	0.56	5.81	0.35	1.95e-8	Childhood ear infection;
KIRP	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg05973401	chr12:123451056	ABCB9	0.61	6.43	0.38	6.42e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg15181151	chr6:150070149	PCMT1	0.29	4.86	0.3	2.12e-6	Lung cancer;
KIRP	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.76	11.52	0.59	7.79e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg19847130	chr8:10466454	RP1L1	0.38	5.76	0.34	2.44e-8	Neuroticism;
KIRP	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg19899395	chr1:46959349	NA	-0.43	-5.3	-0.32	2.61e-7	Monobrow;
KIRP	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg09066997	chr16:75300724	BCAR1	-0.58	-5.08	-0.31	7.31e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg02591564	chr12:125578355	AACS	-0.43	-4.98	-0.3	1.2e-6	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg17517138	chr11:73019481	ARHGEF17	0.71	5.94	0.35	9.8e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.26	5.13	0.31	5.82e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-6.47	-0.38	5.36e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg06521331	chr12:34319734	NA	-0.63	-7.41	-0.43	2.08e-12	Morning vs. evening chronotype;
KIRP	cis	rs7119038	0.818	rs10892287	chr11:118642999	C/T	cg19308663	chr11:118741387	NA	-0.51	-8.13	-0.46	2.13e-14	Sjögren's syndrome;
KIRP	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.72	9.57	0.52	1.16e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg12486944	chr17:80159399	CCDC57	-0.37	-4.96	-0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.95	16.25	0.72	7.82e-41	Breast cancer;
KIRP	cis	rs12519773	0.967	rs4242239	chr5:92482226	A/G	cg18783429	chr5:92414398	NA	0.28	4.94	0.3	1.42e-6	Migraine;
KIRP	cis	rs10411936	0.720	rs4808513	chr19:16580498	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	5.14	0.31	5.71e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs2131877	0.573	rs1552893	chr3:194851700	A/G	cg19775763	chr3:194786989	NA	-0.41	-5.0	-0.3	1.08e-6	Non-small cell lung cancer;
KIRP	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	3.98e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg24060327	chr5:131705240	SLC22A5	-0.57	-6.99	-0.41	2.56e-11	Blood metabolite levels;
KIRP	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.48	-7.18	-0.42	8.46e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg04289385	chr6:36355825	ETV7	0.45	7.2	0.42	7.28e-12	Platelet distribution width;
KIRP	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg04865290	chr3:52927548	TMEM110	-0.62	-6.81	-0.4	7.65e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-7.15	-0.41	9.86e-12	Morning vs. evening chronotype;
KIRP	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.62	0.44	5.34e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7712401	0.601	rs154502	chr5:122207046	C/T	cg19412675	chr5:122181750	SNX24	0.5	5.48	0.33	1.07e-7	Mean platelet volume;
KIRP	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.92	-13.03	-0.64	7.2e-30	Coronary artery disease;
KIRP	cis	rs867371	1.000	rs13380319	chr15:82506867	G/T	cg06066596	chr15:83166174	LOC80154	-0.47	-5.54	-0.33	7.69e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg08499158	chr17:42289980	UBTF	-0.49	-6.3	-0.37	1.38e-9	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22614265	chr7:100425456	EPHB4	0.52	6.46	0.38	5.58e-10	Smoking initiation;
KIRP	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg11952622	chr19:58962976	ZNF324B	0.43	5.01	0.3	1.04e-6	Uric acid clearance;
KIRP	cis	rs7221595	0.825	rs8081260	chr17:3981937	T/C	cg11204139	chr17:3907470	NA	0.58	5.78	0.35	2.24e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.61	-7.92	-0.45	8.27e-14	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.12	0.41	1.18e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.67	-8.27	-0.47	8.71e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg16141378	chr3:129829833	LOC729375	0.62	8.41	0.47	3.4e-15	Triglycerides;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg08126542	chr6:37504118	NA	-0.72	-10.06	-0.54	3.75e-20	Cognitive performance;
KIRP	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg07645718	chr20:61493192	TCFL5	0.73	6.08	0.36	4.67e-9	Obesity-related traits;
KIRP	cis	rs4363385	0.588	rs6698361	chr1:153023184	T/G	cg13444842	chr1:152974279	SPRR3	-0.44	-6.34	-0.37	1.1e-9	Inflammatory skin disease;
KIRP	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.85	0.63	2.91e-29	Morning vs. evening chronotype;
KIRP	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.74	-0.34	2.74e-8	Obesity-related traits;
KIRP	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg13010199	chr12:38710504	ALG10B	0.54	6.68	0.39	1.6e-10	Resting heart rate;
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg01238044	chr22:24384105	GSTT1	-0.52	-6.76	-0.4	9.7e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg16586182	chr3:47516702	SCAP	-0.73	-10.08	-0.54	3.24e-20	Colorectal cancer;
KIRP	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.71	8.32	0.47	6.04e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.94	10.43	0.55	2.45e-21	Corneal astigmatism;
KIRP	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.29	-0.78	4.04e-51	Schizophrenia;
KIRP	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.59	-8.98	-0.5	7.06e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs17079247	0.841	rs1927723	chr13:85810813	G/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.38	5.03	0.31	9.54e-7	Hypertriglyceridemia;
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.51	-6.4	-0.38	8.01e-10	Testicular germ cell tumor;
KIRP	cis	rs17065868	1.000	rs17065868	chr13:45055091	A/G	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.92	11.6	0.59	4.27e-25	Homoarginine levels;
KIRP	cis	rs7534824	0.625	rs61782085	chr1:101518270	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.87	6.71	0.39	1.36e-10	Refractive astigmatism;
KIRP	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.42	-5.69	-0.34	3.62e-8	Type 2 diabetes;
KIRP	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.53	7.01	0.41	2.34e-11	Obesity-related traits;
KIRP	cis	rs13361707	0.763	rs1001684	chr5:40810426	C/A	cg01087697	chr5:40835557	RPL37	-0.43	-4.96	-0.3	1.34e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg11663144	chr21:46675770	NA	-0.59	-8.62	-0.48	8.24e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24826355	chr10:32344604	KIF5B	0.53	6.78	0.4	8.92e-11	Parkinson's disease;
KIRP	cis	rs4774899	1.000	rs2116065	chr15:57254593	T/A	cg13626582	chr15:57592083	LOC283663	-0.21	-5.12	-0.31	6.27e-7	Urinary tract infection frequency;
KIRP	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.79	-13.02	-0.64	8.08e-30	Prostate cancer;
KIRP	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg21427119	chr20:30132790	HM13	-0.54	-6.22	-0.37	2.15e-9	Monocyte count;
KIRP	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.68	-9.08	-0.5	3.69e-17	Huntington's disease progression;
KIRP	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg13319975	chr6:146136371	FBXO30	0.47	6.37	0.38	9.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-5.87	-0.35	1.37e-8	Longevity;
KIRP	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg24315340	chr6:146058215	EPM2A	0.4	5.14	0.31	5.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg25110126	chr1:46999211	NA	-0.45	-5.66	-0.34	4.22e-8	Monobrow;
KIRP	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-5.74	-0.34	2.71e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2880765	0.546	rs11637726	chr15:86059271	C/T	cg10818794	chr15:86012489	AKAP13	0.52	6.74	0.4	1.09e-10	Coronary artery disease;
KIRP	cis	rs1062177	0.547	rs2915818	chr5:151115290	T/A	cg00977110	chr5:151150581	G3BP1	-0.52	-5.48	-0.33	1.03e-7	Preschool internalizing problems;
KIRP	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.47	-0.38	5.11e-10	Morning vs. evening chronotype;
KIRP	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg09873164	chr1:152488093	CRCT1	0.59	7.59	0.44	6.76e-13	Hair morphology;
KIRP	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.68	5.69	0.34	3.52e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.37	-0.38	9.35e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.72	-11.44	-0.59	1.38e-24	Hepatocellular carcinoma;
KIRP	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.68	-9.13	-0.5	2.59e-17	Huntington's disease progression;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10297430	chr16:11272440	CLEC16A	0.48	6.04	0.36	5.77e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.89	-12.41	-0.62	8.56e-28	Coronary artery disease;
KIRP	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg13482628	chr17:19912719	NA	0.54	6.99	0.41	2.61e-11	Schizophrenia;
KIRP	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.95	11.05	0.58	2.64e-23	Corneal astigmatism;
KIRP	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg16988262	chr1:15930761	NA	0.37	4.85	0.3	2.17e-6	Systolic blood pressure;
KIRP	cis	rs1983891	0.955	rs4714480	chr6:41520891	T/C	cg20194872	chr6:41519635	FOXP4	0.55	7.01	0.41	2.29e-11	Prostate cancer;
KIRP	cis	rs7000551	0.581	rs11787182	chr8:22256727	T/C	cg12081754	chr8:22256438	SLC39A14	0.81	9.45	0.52	2.69e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	5.58	0.34	6.35e-8	Bipolar disorder;
KIRP	cis	rs7188697	0.921	rs12445577	chr16:58587164	T/C	cg21335942	chr16:58549945	SETD6	-0.47	-5.13	-0.31	5.8e-7	QT interval;
KIRP	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3120667	0.720	rs72698982	chr1:152441415	A/G	cg26876637	chr1:152193138	HRNR	-0.65	-5.73	-0.34	2.86e-8	Eating disorders;
KIRP	cis	rs3105593	1.000	rs3109894	chr15:50878574	C/T	cg05456662	chr15:50716270	USP8	0.39	4.96	0.3	1.3e-6	QT interval;
KIRP	cis	rs9302690	0.557	rs223869	chr16:57494992	C/A	cg27017172	chr16:57497170	POLR2C	0.63	5.78	0.35	2.26e-8	Blood protein levels;
KIRP	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.67	-7.3	-0.42	3.89e-12	Smoking initiation;
KIRP	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg05156742	chr15:59063176	FAM63B	0.45	5.6	0.34	5.83e-8	Asperger disorder;
KIRP	cis	rs600806	0.672	rs1144593	chr1:110030945	A/G	cg02175308	chr1:109941060	SORT1	0.3	5.58	0.34	6.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.69	10.81	0.57	1.59e-22	Lung cancer;
KIRP	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg04369109	chr6:150039330	LATS1	-0.68	-8.75	-0.49	3.44e-16	Lung cancer;
KIRP	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.44	-5.72	-0.34	3.1e-8	Aortic root size;
KIRP	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.69	-8.32	-0.47	5.95e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.5	-6.98	-0.41	2.75e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21545522	chr1:205238299	TMCC2	0.5	6.5	0.38	4.55e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg01872077	chr2:219646372	CYP27A1	-0.38	-5.25	-0.32	3.23e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.6	-0.34	5.82e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04775566	chr17:59079434	BCAS3	-0.42	-6.59	-0.39	2.6e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg18209359	chr17:80159595	CCDC57	-0.4	-5.31	-0.32	2.44e-7	Life satisfaction;
KIRP	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg11569703	chr11:65557185	OVOL1	0.49	7.44	0.43	1.72e-12	Breast cancer;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg15112475	chr7:1198522	ZFAND2A	-0.57	-5.19	-0.31	4.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	0.97	9.9	0.53	1.14e-19	Lung cancer;
KIRP	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-12.83	-0.63	3.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg24375607	chr4:120327624	NA	0.64	7.25	0.42	5.44e-12	Corneal astigmatism;
KIRP	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg12292205	chr6:26970375	C6orf41	0.49	7.04	0.41	1.89e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62070183	0.882	rs17183628	chr17:31184631	C/T	cg05781649	chr17:31146240	MYO1D	0.49	4.91	0.3	1.68e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.72	9.87	0.53	1.45e-19	Red blood cell count;
KIRP	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg17376030	chr22:41985996	PMM1	-0.73	-7.72	-0.44	2.92e-13	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4132509	1.000	rs2881275	chr1:243918313	G/C	cg21452805	chr1:244014465	NA	0.57	5.56	0.33	7.1e-8	RR interval (heart rate);
KIRP	cis	rs365132	0.875	rs353476	chr5:176424035	A/G	cg16309518	chr5:176445507	NA	-0.81	-12.38	-0.62	1.06e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10219512	chr6:43337449	ZNF318	0.43	6.1	0.36	4.07e-9	Survival in pancreatic cancer;
KIRP	cis	rs10214930	0.813	rs2391451	chr7:27685822	C/A	cg22168087	chr7:27702803	HIBADH	0.51	5.13	0.31	5.91e-7	Hypospadias;
KIRP	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg22705602	chr4:152727874	NA	0.55	9.23	0.51	1.28e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9469913	0.740	rs2092344	chr6:34570922	G/C	cg17674042	chr6:34482479	PACSIN1	-0.49	-6.53	-0.38	3.68e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	8.46	0.47	2.34e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.57	-9.31	-0.51	7.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.77	-0.63	5.55e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.22	-6.06	-0.36	4.98e-9	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.84	11.83	0.6	7.36e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs71636778	0.631	rs34924059	chr1:27158844	G/T	cg12203394	chr1:27248618	NUDC	0.69	5.53	0.33	8.13e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg02175308	chr1:109941060	SORT1	-0.31	-5.79	-0.35	2.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.1	-0.54	2.66e-20	Hemoglobin concentration;
KIRP	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.901	rs1946999	chr4:152455339	T/C	cg22705602	chr4:152727874	NA	-0.39	-5.97	-0.36	8.09e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1434579	0.897	rs12977016	chr19:44942756	G/A	cg15540054	chr19:45004280	ZNF180	0.54	5.54	0.33	7.79e-8	Tuberculosis;
KIRP	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg06740227	chr12:86229804	RASSF9	0.51	6.7	0.39	1.44e-10	Major depressive disorder;
KIRP	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.75	-9.8	-0.53	2.41e-19	Aortic root size;
KIRP	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.97	11.0	0.57	3.79e-23	Smoking behavior;
KIRP	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.49	6.45	0.38	5.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg03115019	chr17:80708279	FN3K	-0.43	-5.16	-0.31	5.2e-7	Glycated hemoglobin levels;
KIRP	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06481639	chr22:41940642	POLR3H	-0.65	-6.84	-0.4	6.39e-11	Vitiligo;
KIRP	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg14851346	chr12:38532713	NA	-0.41	-5.03	-0.31	9.45e-7	Bladder cancer;
KIRP	cis	rs1707322	0.613	rs1473840	chr1:46601197	A/G	cg03146154	chr1:46216737	IPP	-0.59	-6.87	-0.4	5.18e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-14.56	-0.68	4.73e-35	Height;
KIRP	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	0.78	12.16	0.61	5.86e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs17321999	0.516	rs72787734	chr2:30500839	G/A	cg05247661	chr2:30472410	LBH	0.64	4.87	0.3	1.98e-6	Systemic lupus erythematosus;
KIRP	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg20673091	chr1:2541236	MMEL1	0.65	9.49	0.52	2.15e-18	Ulcerative colitis;
KIRP	cis	rs1894292	0.715	rs2010989	chr4:74472896	C/T	cg12566645	chr4:74483141	RASSF6	-0.37	-5.23	-0.32	3.7e-7	Prostate cancer;
KIRP	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.41	5.11	0.31	6.37e-7	Lung cancer;
KIRP	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.48	-6.33	-0.37	1.15e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg15538193	chr10:1068763	C10orf110;IDI2	0.4	4.86	0.3	2.14e-6	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg04727924	chr7:799746	HEATR2	-0.61	-5.89	-0.35	1.27e-8	Cerebrospinal P-tau181p levels;
KIRP	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-15.01	-0.69	1.4e-36	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12452946	chr4:128886867	MFSD8;C4orf29	0.54	7.19	0.42	7.64e-12	Parkinson's disease;
KIRP	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.82	11.32	0.59	3.52e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg24315340	chr6:146058215	EPM2A	0.4	5.07	0.31	7.7e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12475964	0.740	rs3936292	chr2:37387486	A/G	cg26124318	chr8:38965122	ADAM32	0.43	6.16	0.37	3e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.82	10.5	0.56	1.48e-21	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg19507638	chr5:93509721	C5orf36	-0.55	-5.13	-0.31	5.79e-7	Diabetic retinopathy;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03442064	chr6:41515050	FOXP4	0.79	6.97	0.41	2.96e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1256061	0.624	rs1152586	chr14:64690784	T/C	cg21174375	chr14:64681225	SYNE2	0.5	5.62	0.34	5.15e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.17	-0.37	2.83e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.61	7.14	0.41	1.05e-11	Pancreatic cancer;
KIRP	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg01428437	chr1:1852164	TMEM52	0.29	5.05	0.31	8.75e-7	Body mass index;
KIRP	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg01346077	chr3:125931526	NA	0.5	7.92	0.45	8.16e-14	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.61	-9.31	-0.51	7.56e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg11130432	chr3:121712080	ILDR1	-0.49	-5.79	-0.35	2.09e-8	Multiple sclerosis;
KIRP	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	0.85	9.12	0.5	2.75e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg13385521	chr17:29058706	SUZ12P	-0.55	-5.36	-0.32	1.87e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg13736514	chr6:26305472	NA	-0.7	-8.84	-0.49	1.82e-16	Educational attainment;
KIRP	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.17	-0.31	4.8e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg09564133	chr5:176738847	MXD3	0.52	6.04	0.36	5.55e-9	Sleep duration;
KIRP	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	5.99	0.36	7.4e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10115368	chr14:100435663	NA	0.45	6.17	0.37	2.76e-9	Interleukin-4 levels;
KIRP	cis	rs10484885	0.775	rs62416027	chr6:90608054	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-6.6	-0.39	2.55e-10	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs1010254	0.559	rs72808330	chr5:151746569	A/G	cg12297329	chr5:152029980	NA	-0.66	-6.75	-0.4	1.09e-10	Optic nerve measurement (cup area);
KIRP	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Colorectal cancer;
KIRP	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.94	-15.06	-0.69	8.9e-37	Coronary artery disease;
KIRP	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg03834567	chr2:218808745	TNS1	0.47	5.7	0.34	3.4e-8	Ulcerative colitis;
KIRP	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs925946	0.541	rs12269837	chr11:27593570	A/G	cg18117895	chr11:27722066	BDNF	-0.46	-5.07	-0.31	7.83e-7	Body mass index;Weight;
KIRP	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05564831	chr3:52568323	NT5DC2	0.36	5.79	0.35	2.11e-8	Bipolar disorder;
KIRP	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg11584989	chr19:19387371	SF4	0.43	5.37	0.32	1.83e-7	Tonsillectomy;
KIRP	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	5.48	0.33	1.05e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6700559	0.740	rs4072554	chr1:200649366	A/G	cg07804481	chr1:200639085	DDX59	0.5	6.6	0.39	2.52e-10	Coronary artery disease;
KIRP	cis	rs6466055	0.669	rs2003506	chr7:104761741	A/G	cg04380332	chr7:105027541	SRPK2	-0.64	-9.66	-0.52	6.15e-19	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26450740	chr10:134756169	C10orf93	0.46	6.45	0.38	5.98e-10	Survival in pancreatic cancer;
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.6	-7.99	-0.45	5.24e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg27129171	chr3:47204927	SETD2	0.54	7.17	0.42	8.82e-12	Colorectal cancer;
KIRP	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg10950924	chr17:47092072	IGF2BP1	0.48	6.27	0.37	1.58e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg03808351	chr9:123631620	PHF19	0.38	5.2	0.31	4.17e-7	Rheumatoid arthritis;
KIRP	cis	rs4704187	0.687	rs10805893	chr5:74507390	C/A	cg03227963	chr5:74354835	NA	0.39	5.66	0.34	4.1e-8	Response to amphetamines;
KIRP	cis	rs394563	0.591	rs11964335	chr6:149658101	A/T	cg16235748	chr6:149772707	ZC3H12D	0.3	5.0	0.3	1.09e-6	Dupuytren's disease;
KIRP	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27297192	chr10:134578999	INPP5A	0.61	7.64	0.44	4.88e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.84	13.94	0.66	6.14e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg05805236	chr11:65401703	PCNXL3	-0.57	-7.42	-0.43	1.92e-12	Acne (severe);
KIRP	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg04310649	chr10:35416472	CREM	-0.54	-6.2	-0.37	2.3e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1873147	0.731	rs12902152	chr15:63313968	T/C	cg12160578	chr15:63334699	TPM1	-0.44	-4.89	-0.3	1.85e-6	Orofacial clefts;
KIRP	cis	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg04607699	chr11:48328132	OR4S1	-0.35	-4.88	-0.3	1.9e-6	HDL cholesterol;
KIRP	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg02820901	chr13:113351484	ATP11A	0.68	6.34	0.37	1.08e-9	Glycated hemoglobin levels;
KIRP	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11987759	chr7:65425863	GUSB	-0.54	-7.13	-0.41	1.1e-11	Aortic root size;
KIRP	cis	rs12973672	1.000	rs10421768	chr19:35772899	A/G	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg04733911	chr16:78082701	NA	-0.45	-5.07	-0.31	7.72e-7	Systolic blood pressure (alcohol consumption interaction);
KIRP	cis	rs77688320	0.500	rs4129011	chr2:202308586	C/T	cg06431681	chr2:202330990	STRADB	0.56	7.66	0.44	4.34e-13	Breast cancer;
KIRP	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.58	-6.29	-0.37	1.45e-9	DNA methylation (variation);
KIRP	cis	rs6959887	0.821	rs4723404	chr7:35278551	C/T	cg06685737	chr7:35301730	NA	0.43	6.29	0.37	1.47e-9	Birth weight;
KIRP	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.81	10.9	0.57	7.97e-23	Morning vs. evening chronotype;
KIRP	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg18261050	chr1:119551319	NA	0.51	6.79	0.4	8.49e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2953174	1.000	rs2953176	chr2:241520754	T/A	cg07929629	chr2:241523174	NA	0.63	5.41	0.33	1.49e-7	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14556425	chr8:79721111	NA	0.49	6.49	0.38	4.73e-10	Interleukin-4 levels;
KIRP	cis	rs72820985	1.000	rs74030463	chr16:80841661	T/C	cg04448709	chr16:81349954	GAN	-0.49	-5.01	-0.3	1.04e-6	Breast cancer;
KIRP	cis	rs4834770	0.717	rs1022146	chr4:120236103	A/G	cg09307838	chr4:120376055	NA	0.49	5.76	0.34	2.53e-8	Blood protein levels;
KIRP	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.57	5.57	0.33	6.63e-8	Height;
KIRP	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg03808351	chr9:123631620	PHF19	0.38	5.2	0.31	4.17e-7	Rheumatoid arthritis;
KIRP	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg09597638	chr17:3907349	NA	-0.5	-6.32	-0.37	1.23e-9	Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs2290419	0.730	rs75158992	chr11:68944759	A/G	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs6539288	0.677	rs1348565	chr12:107329104	G/T	cg21360079	chr12:107162445	NA	-0.44	-5.52	-0.33	8.74e-8	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg13357408	chr7:157437802	PTPRN2	-0.59	-5.98	-0.36	7.92e-9	Colorectal cancer;
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.55e-11	Electroencephalogram traits;
KIRP	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg19575753	chr5:1948995	NA	0.56	6.56	0.39	3.11e-10	Gut microbiome composition (winter);
KIRP	cis	rs1062746	0.517	rs11646227	chr16:87359419	C/T	cg02258303	chr16:87377426	FBXO31	-0.56	-6.91	-0.4	4.11e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26755928	chr19:10363173	MRPL4	0.57	6.63	0.39	2.16e-10	Smoking initiation;
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	trans	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg16141378	chr3:129829833	LOC729375	0.51	6.32	0.37	1.21e-9	Mood instability;
KIRP	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg18357526	chr6:26021779	HIST1H4A	0.4	5.24	0.32	3.39e-7	Height;
KIRP	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.01	0.45	4.72e-14	Height;
KIRP	cis	rs4690686	0.500	rs12498564	chr4:177264827	T/C	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.88	-0.57	8.82e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg21775007	chr8:11205619	TDH	-0.49	-6.53	-0.38	3.68e-10	Triglycerides;
KIRP	cis	rs11790388	0.505	rs643940	chr9:129694414	A/G	cg13970942	chr9:129673409	NA	0.39	5.22	0.32	3.86e-7	Schizophrenia;
KIRP	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg20991723	chr1:152506922	NA	-0.45	-5.22	-0.32	3.88e-7	Hair morphology;
KIRP	cis	rs4936894	0.500	rs7929241	chr11:124151614	G/T	cg27160556	chr11:124181099	OR8D1	-0.39	-5.76	-0.34	2.54e-8	Aging (time to death);
KIRP	trans	rs7238033	0.705	rs474270	chr18:43328295	A/G	cg10186219	chr22:39769995	SYNGR1	0.41	6.03	0.36	5.86e-9	Bladder cancer;
KIRP	cis	rs6681460	1.000	rs9662962	chr1:67121364	C/T	cg13052034	chr1:66999238	SGIP1	0.45	6.31	0.37	1.28e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg02527881	chr3:46936655	PTH1R	-0.41	-5.97	-0.36	8.46e-9	Colorectal cancer;
KIRP	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.17	0.37	2.8e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.74	0.34	2.79e-8	Menopause (age at onset);
KIRP	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg00405596	chr8:11794950	NA	-0.44	-5.39	-0.33	1.65e-7	Retinal vascular caliber;
KIRP	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.73	6.76	0.4	9.77e-11	Bipolar disorder;
KIRP	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg09238746	chr17:78121135	EIF4A3	-0.39	-4.97	-0.3	1.23e-6	Yeast infection;
KIRP	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.48	-9.95	-0.54	8.01e-20	Longevity;
KIRP	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.5	-7.49	-0.43	1.26e-12	Bone mineral density;
KIRP	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg02551604	chr5:131831745	NA	-0.46	-5.31	-0.32	2.4e-7	Asthma (sex interaction);
KIRP	cis	rs4720750	0.510	rs2024371	chr7:7767915	C/G	cg12383621	chr7:7735611	RPA3	-0.4	-5.0	-0.3	1.11e-6	Neuroticism;
KIRP	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg10189774	chr4:17578691	LAP3	0.54	6.51	0.38	4.12e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4523957	0.786	rs59428454	chr17:2114063	T/A	cg16513277	chr17:2031491	SMG6	-0.69	-9.57	-0.52	1.22e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg04607235	chr12:12878440	APOLD1	-0.78	-8.48	-0.48	2.07e-15	Systemic lupus erythematosus;
KIRP	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg06204229	chr3:52865917	ITIH4	0.53	7.14	0.41	1.03e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.1	0.69	6.82e-37	Platelet count;
KIRP	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.56	-7.49	-0.43	1.25e-12	Blood metabolite levels;
KIRP	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.43	4.88	0.3	1.91e-6	Airway imaging phenotypes;
KIRP	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.66	0.34	4.1e-8	Total cholesterol levels;
KIRP	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg18404041	chr3:52824283	ITIH1	0.36	5.21	0.32	3.93e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs11112613	0.818	rs117644588	chr12:106022040	G/C	cg03607813	chr12:105948248	NA	0.58	5.86	0.35	1.45e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.77	-11.07	-0.58	2.18e-23	Height;
KIRP	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg17470449	chr10:769945	NA	0.69	6.75	0.4	1.08e-10	Uric acid levels;
KIRP	cis	rs367943	0.698	rs10046061	chr5:112976533	A/G	cg12552261	chr5:112820674	MCC	0.45	5.04	0.31	9.03e-7	Type 2 diabetes;
KIRP	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.6	-0.34	5.7e-8	Response to antipsychotic treatment;
KIRP	cis	rs2455799	0.613	rs13071161	chr3:15958166	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-4.91	-0.3	1.69e-6	Mean platelet volume;
KIRP	cis	rs10214930	0.781	rs12700823	chr7:27659221	G/A	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs2273669	0.667	rs12198088	chr6:109338433	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs3026101	0.671	rs8076560	chr17:5299527	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.96	0.36	8.81e-9	Body mass index;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs1971762	0.545	rs10747675	chr12:54000031	A/G	cg16917193	chr12:54089295	NA	-0.72	-11.93	-0.61	3.37e-26	Height;
KIRP	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.83	13.98	0.67	4.54e-33	Longevity;
KIRP	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg11846333	chr4:119757529	SEC24D	0.94	5.68	0.34	3.86e-8	Cannabis dependence symptom count;
KIRP	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.74	-0.44	2.62e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.72	8.27	0.47	8.57e-15	Corneal astigmatism;
KIRP	cis	rs9393692	0.578	rs806795	chr6:26205293	G/A	cg13736514	chr6:26305472	NA	-0.74	-10.18	-0.54	1.53e-20	Educational attainment;
KIRP	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg02574844	chr11:5959923	NA	-0.56	-5.72	-0.34	3e-8	DNA methylation (variation);
KIRP	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.42	6.75	0.4	1.07e-10	Testicular germ cell tumor;
KIRP	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.91	10.38	0.55	3.73e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg16497661	chr14:103986332	CKB	-0.5	-6.43	-0.38	6.43e-10	Coronary artery disease;
KIRP	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg11764359	chr7:65958608	NA	-0.44	-5.13	-0.31	5.76e-7	Calcium levels;
KIRP	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.69	8.89	0.49	1.31e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg19894588	chr14:64061835	NA	-0.46	-6.19	-0.37	2.56e-9	Fat distribution (HIV);
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg08132940	chr7:1081526	C7orf50	-0.54	-5.92	-0.35	1.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9634489	0.588	rs7336212	chr13:96936469	C/A	cg02571835	chr13:96230311	CLDN10	-0.34	-4.85	-0.3	2.15e-6	Body mass index;
KIRP	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg10503236	chr1:231470652	EXOC8	-0.53	-7.4	-0.43	2.16e-12	Hemoglobin concentration;
KIRP	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.61	7.63	0.44	5.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4332428	0.764	rs12764498	chr10:5042294	T/C	cg19648686	chr10:5044992	AKR1C2	-0.91	-7.76	-0.44	2.28e-13	Height;
KIRP	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.62e-8	Neuroticism;
KIRP	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.44	-15.64	-0.71	9.48e-39	Schizophrenia;
KIRP	cis	rs2625529	0.824	rs35167572	chr15:72378960	A/G	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	cis	rs3774830	0.846	rs17367340	chr4:5457009	T/G	cg26943120	chr4:5472116	STK32B	0.27	6.31	0.37	1.27e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12049351	0.719	rs12129135	chr1:229695687	T/A	cg11742688	chr1:229674241	ABCB10	-0.41	-6.06	-0.36	5.04e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13198984	chr17:80129470	CCDC57	-0.47	-6.99	-0.41	2.61e-11	Life satisfaction;
KIRP	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.73	-10.12	-0.54	2.44e-20	Leprosy;
KIRP	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg27124370	chr19:33622961	WDR88	0.6	7.48	0.43	1.34e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg15252951	chr6:33757062	LEMD2	0.43	5.05	0.31	8.79e-7	Crohn's disease;
KIRP	cis	rs1983891	0.909	rs4714482	chr6:41528199	G/A	cg20194872	chr6:41519635	FOXP4	0.57	7.32	0.42	3.61e-12	Prostate cancer;
KIRP	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg17986701	chr20:44574422	PCIF1	0.49	7.42	0.43	1.87e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg10254082	chr7:997346	NA	0.47	4.99	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.07	0.54	3.45e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7520050	0.966	rs1768803	chr1:46546208	T/C	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-6.35	-0.38	1.04e-9	Height;
KIRP	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg04034577	chr2:241836375	C2orf54	-0.28	-5.41	-0.33	1.46e-7	Urinary metabolites;
KIRP	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.5	7.27	0.42	4.72e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.71	10.79	0.57	1.76e-22	Menarche (age at onset);
KIRP	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.21	0.37	2.2e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg08017634	chr8:144659831	NAPRT1	0.81	5.28	0.32	2.85e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg03146154	chr1:46216737	IPP	-0.41	-5.25	-0.32	3.22e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6834538	0.597	rs4833414	chr4:113469913	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.44	5.4	0.33	1.56e-7	Free thyroxine concentration;
KIRP	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg24565620	chr2:194026	NA	-0.65	-5.72	-0.34	3.16e-8	Blood protein levels;
KIRP	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg00405596	chr8:11794950	NA	0.49	6.46	0.38	5.41e-10	Joint mobility (Beighton score);
KIRP	cis	rs1823913	0.614	rs4853463	chr2:192143425	G/T	cg12404831	chr2:192114017	MYO1B	-0.45	-6.12	-0.36	3.74e-9	Obesity-related traits;
KIRP	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.9	0.45	9.11e-14	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg18209359	chr17:80159595	CCDC57	-0.44	-5.71	-0.34	3.26e-8	Life satisfaction;
KIRP	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg16230307	chr14:35515116	FAM177A1	0.74	6.97	0.41	2.88e-11	Psoriasis;
KIRP	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	1.05	20.44	0.79	5.89e-55	Breast cancer;
KIRP	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg21775007	chr8:11205619	TDH	0.5	6.09	0.36	4.43e-9	Systolic blood pressure;
KIRP	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg16988262	chr1:15930761	NA	0.38	5.03	0.31	9.66e-7	Systolic blood pressure;
KIRP	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.5	-6.31	-0.37	1.29e-9	Coronary heart disease;
KIRP	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg00129232	chr17:37814104	STARD3	0.7	7.85	0.45	1.3e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg02038168	chr22:39784481	NA	-0.45	-5.49	-0.33	1.01e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7432375	0.519	rs34799319	chr3:136586618	G/A	cg15507776	chr3:136538369	TMEM22	0.41	5.39	0.32	1.67e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-7.07	-0.41	1.6e-11	Systemic lupus erythematosus;
KIRP	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.99	-14.04	-0.67	2.7e-33	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg00022858	chr4:55096616	PDGFRA	0.43	6.08	0.36	4.56e-9	Protein C levels;
KIRP	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.68	8.96	0.5	8.21e-17	Motion sickness;
KIRP	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs7814319	0.901	rs13253635	chr8:97240847	A/G	cg20787634	chr8:97240163	UQCRB	-0.69	-11.36	-0.59	2.5e-24	Lung function (FVC);
KIRP	cis	rs4812048	0.649	rs116580814	chr20:57618141	G/T	cg14073986	chr20:57617431	SLMO2	0.66	5.68	0.34	3.77e-8	Mean platelet volume;
KIRP	cis	rs1866706	1.000	rs4757953	chr11:12874513	C/T	cg25843174	chr11:12811716	TEAD1	0.31	5.27	0.32	2.93e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.24	0.32	3.4e-7	Height;
KIRP	trans	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg13565492	chr6:43139072	SRF	-0.94	-8.68	-0.48	5.62e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.64	-0.39	2.05e-10	Menopause (age at onset);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg22534621	chr1:82276730	LPHN2	0.47	7.7	0.44	3.23e-13	C-reactive protein;
KIRP	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.12	-0.41	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.56	6.23	0.37	1.97e-9	Coronary artery disease;
KIRP	cis	rs9400271	0.632	rs6899616	chr6:109584885	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.65	-0.34	4.5e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.54	-7.21	-0.42	6.8e-12	Longevity;Endometriosis;
KIRP	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg21366198	chr4:185655624	MLF1IP	0.39	5.16	0.31	5.18e-7	Kawasaki disease;
KIRP	cis	rs6832769	0.696	rs7660054	chr4:56268507	T/C	cg05960024	chr4:56376020	CLOCK	0.61	7.83	0.45	1.43e-13	Personality dimensions;
KIRP	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	1.1	17.28	0.74	2.34e-44	Cognitive function;
KIRP	cis	rs1981331	0.609	rs77725404	chr21:48080376	C/T	cg23283320	chr21:48055893	PRMT2	1.45	9.12	0.5	2.82e-17	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12245438	chr18:3012994	LPIN2	0.52	6.57	0.39	3.02e-10	Parkinson's disease;
KIRP	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11987759	chr7:65425863	GUSB	-0.55	-7.38	-0.43	2.4e-12	Aortic root size;
KIRP	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg02951883	chr7:2050386	MAD1L1	-0.43	-5.02	-0.3	1.01e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.42	-0.33	1.44e-7	Life satisfaction;
KIRP	cis	rs1629083	0.790	rs647573	chr11:118067132	C/T	cg18857871	chr11:118064634	AMICA1	0.71	10.14	0.54	2.02e-20	Lung cancer;
KIRP	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg23594656	chr7:65796392	TPST1	-0.45	-7.09	-0.41	1.39e-11	Aortic root size;
KIRP	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg19847866	chr10:1019161	NA	0.5	5.81	0.35	1.93e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.93	15.79	0.71	2.92e-39	Ulcerative colitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26007049	chr14:96000930	GLRX5;SNHG10;SCARNA13	0.51	6.72	0.39	1.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2380205	0.875	rs10795592	chr10:5895755	G/T	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.52e-8	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14465900	chr9:132805755	FNBP1	0.44	6.1	0.36	4.02e-9	Parkinson's disease;
KIRP	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg03563238	chr19:33554763	RHPN2	-0.33	-6.14	-0.36	3.36e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.47	6.57	0.39	2.95e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-8.16	-0.46	1.76e-14	Morning vs. evening chronotype;
KIRP	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.53	-11.69	-0.6	2.05e-25	Diabetic kidney disease;
KIRP	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Body mass index;
KIRP	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11987759	chr7:65425863	GUSB	0.51	6.93	0.4	3.73e-11	Aortic root size;
KIRP	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.61	7.12	0.41	1.17e-11	Corneal astigmatism;
KIRP	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.79	8.77	0.49	3.03e-16	Cholesterol, total;
KIRP	cis	rs1823913	0.599	rs55862924	chr2:192138535	A/G	cg12404831	chr2:192114017	MYO1B	0.53	7.39	0.43	2.22e-12	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg00792783	chr2:198669748	PLCL1	-0.46	-5.33	-0.32	2.22e-7	Intracranial aneurysm;
KIRP	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-4.96	-0.3	1.33e-6	Pulmonary function;
KIRP	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.89	0.35	1.29e-8	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg17376030	chr22:41985996	PMM1	0.46	5.29	0.32	2.65e-7	Vitiligo;
KIRP	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.99	-0.36	7.32e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg13482628	chr17:19912719	NA	0.57	8.11	0.46	2.42e-14	Schizophrenia;
KIRP	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.9	14.09	0.67	1.86e-33	Height;
KIRP	cis	rs2916247	1.000	rs2976510	chr8:93005015	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.59	-8.12	-0.46	2.24e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.69	-5.79	-0.35	2.14e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-9.7	-0.53	4.86e-19	Chronic sinus infection;
KIRP	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-5.47	-0.33	1.11e-7	Aortic root size;
KIRP	cis	rs6546886	0.912	rs10164943	chr2:74306056	C/T	cg14702570	chr2:74259524	NA	-0.29	-5.84	-0.35	1.63e-8	Dialysis-related mortality;
KIRP	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg13293535	chr8:11597251	GATA4	-0.38	-4.86	-0.3	2.09e-6	Retinal vascular caliber;
KIRP	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11785400	0.793	rs12546978	chr8:143750205	T/A	cg24634471	chr8:143751801	JRK	-0.43	-4.93	-0.3	1.53e-6	Schizophrenia;
KIRP	trans	rs1555399	0.901	rs12887115	chr14:67990648	C/T	cg22936975	chr13:61989412	PCDH20	-0.49	-6.04	-0.36	5.75e-9	Parkinson's disease;
KIRP	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.63	-0.39	2.08e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg19116668	chr7:99932089	PMS2L1	-0.51	-5.82	-0.35	1.86e-8	Coronary artery disease;
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg08662619	chr6:150070041	PCMT1	0.38	6.19	0.37	2.44e-9	Lung cancer;
KIRP	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg04202892	chr2:111875749	ACOXL	0.46	6.34	0.37	1.09e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.29	0.37	1.45e-9	Total body bone mineral density;
KIRP	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.56	7.45	0.43	1.63e-12	Colorectal cancer;
KIRP	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg02175308	chr1:109941060	SORT1	-0.29	-5.55	-0.33	7.27e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.5	-5.95	-0.35	9.3e-9	Multiple sclerosis;
KIRP	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.17	-0.37	2.83e-9	Type 2 diabetes;
KIRP	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg03585969	chr10:35415529	CREM	0.84	9.99	0.54	5.87e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12496230	0.794	rs12635644	chr3:66859046	C/T	cg04995300	chr3:66848608	NA	0.46	7.13	0.41	1.13e-11	Type 2 diabetes;
KIRP	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg05304507	chr6:116381966	FRK	0.21	5.76	0.34	2.5e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.86	-12.01	-0.61	1.86e-26	Total body bone mineral density;
KIRP	cis	rs6978712	0.591	rs6963225	chr7:127078239	T/C	cg24655706	chr7:127078268	NA	0.68	5.36	0.32	1.88e-7	Medication adherence in chronic diseases;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00456086	chr3:197283111	BDH1	0.46	6.13	0.36	3.41e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg09264619	chr17:80180166	NA	-0.4	-5.87	-0.35	1.44e-8	Life satisfaction;
KIRP	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.83	11.24	0.58	6.42e-24	Menarche (age at onset);
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg09695851	chr17:3907499	NA	0.86	16.66	0.73	3.21e-42	Type 2 diabetes;
KIRP	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs7614311	0.731	rs17401592	chr3:63954490	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.77	-0.35	2.37e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	1.2	19.91	0.79	3.37e-53	Total cholesterol levels;
KIRP	cis	rs10814247	0.522	rs10972492	chr9:35493132	C/T	cg15271616	chr9:35490515	RUSC2	0.46	5.65	0.34	4.32e-8	Psoriasis;
KIRP	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg16586182	chr3:47516702	SCAP	0.82	11.29	0.58	4.36e-24	Colorectal cancer;
KIRP	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg07511934	chr16:89386912	ANKRD11	0.48	6.5	0.38	4.5e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs4523957	0.560	rs1994884	chr17:2084008	G/A	cg16513277	chr17:2031491	SMG6	-0.8	-11.62	-0.6	3.67e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3112255	0.905	rs4851361	chr2:101286249	A/G	cg01042948	chr2:101319752	NA	-0.4	-5.98	-0.36	7.71e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg26513180	chr16:89883248	FANCA	0.58	7.34	0.42	3.03e-12	Vitiligo;
KIRP	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.37	5.48	0.33	1.03e-7	Survival in rectal cancer;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg15216925	chr5:179921655	CNOT6	-0.42	-6.1	-0.36	4.07e-9	Serum protein levels (sST2);
KIRP	cis	rs2224391	0.554	rs114825667	chr6:5242618	A/T	cg13962347	chr6:5174647	LYRM4	-0.75	-10.29	-0.55	7.06e-21	Height;
KIRP	cis	rs2011503	0.782	rs35545554	chr19:19715613	A/G	cg11584989	chr19:19387371	SF4	-0.55	-5.82	-0.35	1.84e-8	Bipolar disorder;
KIRP	trans	rs17079247	0.841	rs9575841	chr13:85807262	A/G	cg07750655	chr16:5121855	ALG1	-0.58	-6.11	-0.36	3.83e-9	Bipolar disorder (mania);
KIRP	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21545522	chr1:205238299	TMCC2	-0.49	-6.84	-0.4	6.38e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.76	-11.04	-0.58	2.78e-23	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03384915	chr19:16986822	SIN3B	-0.47	-6.36	-0.38	9.98e-10	Parkinson's disease;
KIRP	cis	rs2290402	0.505	rs9328759	chr4:882845	C/T	cg14517359	chr4:903473	GAK	0.59	6.08	0.36	4.54e-9	Type 2 diabetes;
KIRP	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.61	-7.33	-0.42	3.32e-12	Mosquito bite size;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.62	-7.69	-0.44	3.55e-13	Breast cancer;
KIRP	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg27494647	chr7:150038898	RARRES2	0.44	6.23	0.37	2.02e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.42	5.74	0.34	2.74e-8	Age-related hearing impairment;
KIRP	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg05083358	chr7:2394359	EIF3B	-0.56	-5.75	-0.34	2.67e-8	Multiple sclerosis;
KIRP	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg05805236	chr11:65401703	PCNXL3	0.53	7.05	0.41	1.79e-11	Acne (severe);
KIRP	trans	rs56336142	0.619	rs9394577	chr6:39149784	T/C	cg17445213	chr7:47408746	TNS3	0.46	6.26	0.37	1.67e-9	Coronary artery disease;
KIRP	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg24304309	chr1:154577895	ADAR	0.36	5.87	0.35	1.43e-8	Blood protein levels;
KIRP	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	9.98	0.54	6.39e-20	Post bronchodilator FEV1;
KIRP	cis	rs7578199	0.888	rs9967861	chr2:242328078	G/A	cg01632474	chr2:242799312	PDCD1	0.38	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.54	0.43	9.09e-13	Joint mobility (Beighton score);
KIRP	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg08873628	chr1:175162347	KIAA0040	-0.42	-6.22	-0.37	2.12e-9	Alcohol dependence;
KIRP	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.76	0.4	1.01e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.61	8.27	0.47	8.49e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs12200782	0.932	rs72844476	chr6:26574150	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.99	15.8	0.71	2.77e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.65	8.27	0.47	8.35e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7712401	0.601	rs30055	chr5:122301079	T/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs42648	0.591	rs11770630	chr7:89805241	C/T	cg25739043	chr7:89950458	NA	-0.34	-5.19	-0.31	4.41e-7	Homocysteine levels;
KIRP	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.67	7.1	0.41	1.32e-11	Lymphocyte counts;
KIRP	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.6	-6.68	-0.39	1.59e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg21419209	chr3:44054225	NA	-0.74	-8.99	-0.5	6.76e-17	Coronary artery disease;
KIRP	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg09904177	chr6:26538194	HMGN4	0.45	5.5	0.33	9.31e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.68	-8.97	-0.5	7.67e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.13	0.46	2.06e-14	Morning vs. evening chronotype;
KIRP	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.66	-9.48	-0.52	2.25e-18	Retinal vascular caliber;
KIRP	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg04519387	chr11:65556438	OVOL1	0.34	5.02	0.3	9.96e-7	Acne (severe);
KIRP	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-8.82	-0.49	2.15e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9359856	0.518	rs11965790	chr6:90261621	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.49	-4.94	-0.3	1.41e-6	Bipolar disorder;
KIRP	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.61	9.58	0.52	1.14e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.59	6.34	0.37	1.09e-9	Type 2 diabetes;
KIRP	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg26149184	chr10:133730230	NA	-0.4	-4.99	-0.3	1.17e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14298792	chr15:30685198	CHRFAM7A	0.5	6.3	0.37	1.37e-9	Huntington's disease progression;
KIRP	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.92	-16.18	-0.72	1.32e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4742903	0.509	rs10820611	chr9:106910264	A/G	cg14250997	chr9:106856677	SMC2	0.41	5.6	0.34	5.78e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs2976388	0.647	rs2920288	chr8:143753289	C/T	cg06565975	chr8:143823917	SLURP1	0.46	6.99	0.41	2.53e-11	Urinary tract infection frequency;
KIRP	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-16.76	-0.73	1.41e-42	Height;
KIRP	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.88	-15.3	-0.7	1.44e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg23602478	chr1:26503979	CNKSR1	0.45	6.48	0.38	4.84e-10	Height;
KIRP	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg25457927	chr22:38595422	NA	-0.32	-6.33	-0.37	1.17e-9	Breast cancer;
KIRP	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg04132472	chr17:19861366	AKAP10	0.49	6.86	0.4	5.61e-11	Schizophrenia;
KIRP	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.69	-8.57	-0.48	1.19e-15	Height;
KIRP	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg06671706	chr8:8559999	CLDN23	0.52	6.07	0.36	4.72e-9	Obesity-related traits;
KIRP	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.65	-7.64	-0.44	4.76e-13	DNA methylation (variation);
KIRP	cis	rs8177876	0.841	rs117310590	chr16:81128395	A/T	cg08591886	chr16:81111003	C16orf46	-0.66	-4.96	-0.3	1.29e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.44	0.52	2.91e-18	Bipolar disorder;
KIRP	cis	rs8523	0.901	rs1225737	chr6:10982652	C/T	cg13562911	chr6:11044106	ELOVL2	0.44	5.77	0.35	2.33e-8	Red blood cell fatty acid levels;
KIRP	cis	rs6450176	0.909	rs12659966	chr5:53292892	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.83	10.63	0.56	6e-22	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs8067545	1.000	rs2108980	chr17:19920518	G/A	cg13482628	chr17:19912719	NA	0.69	10.73	0.56	2.74e-22	Schizophrenia;
KIRP	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg01629716	chr15:45996671	NA	0.37	6.69	0.39	1.49e-10	Waist circumference;Weight;
KIRP	trans	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg24644049	chr4:85504048	CDS1	1.08	6.94	0.4	3.39e-11	Skin colour saturation;
KIRP	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg05621596	chr22:47072043	GRAMD4	-0.61	-6.92	-0.4	3.79e-11	Urate levels in obese individuals;
KIRP	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19882132	chr14:106167949	NA	-0.42	-5.13	-0.31	5.8e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs78487399	0.710	rs7572923	chr2:43685109	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.1	-0.31	6.92e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11987759	chr7:65425863	GUSB	-0.46	-5.43	-0.33	1.34e-7	Aortic root size;
KIRP	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.86	-13.02	-0.64	7.62e-30	Height;
KIRP	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.93	-9.96	-0.54	7.66e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.69	-7.9	-0.45	9.46e-14	Obesity-related traits;
KIRP	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.87	13.69	0.66	4.18e-32	Leprosy;
KIRP	cis	rs8177876	0.822	rs8177959	chr16:81115687	A/G	cg08591886	chr16:81111003	C16orf46	-0.59	-5.5	-0.33	9.31e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg19767650	chr1:183605181	ARPC5;RGL1	1.0	6.5	0.38	4.4e-10	P wave terminal force;
KIRP	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.76	-8.52	-0.48	1.62e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg27432699	chr2:27873401	GPN1	-0.42	-5.43	-0.33	1.38e-7	Total body bone mineral density;
KIRP	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.66	-0.52	6.42e-19	Neuroticism;
KIRP	cis	rs55675132	0.548	rs10858055	chr1:115359213	T/C	cg12756093	chr1:115239321	AMPD1	0.54	5.3	0.32	2.57e-7	Schizophrenia;
KIRP	trans	rs2007126	0.925	rs6478927	chr9:132675694	C/T	cg06848185	chr17:75368902	SEPT9	0.5	6.02	0.36	6.26e-9	LDL peak particle diameter (total fat intake interaction);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02919997	chr22:42310476	NA	0.44	7.15	0.41	9.96e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21051989	chr6:90121833	RRAGD	0.51	6.56	0.39	3.14e-10	Parkinson's disease;
KIRP	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg00990874	chr7:1149470	C7orf50	-0.7	-7.3	-0.42	3.95e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	5.22	0.32	3.75e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg10755058	chr3:40428713	ENTPD3	0.34	4.88	0.3	1.9e-6	Renal cell carcinoma;
KIRP	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.9	-0.4	4.5e-11	Total body bone mineral density;
KIRP	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	1.12	13.37	0.65	5.27e-31	Type 2 diabetes nephropathy;
KIRP	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-5.39	-0.33	1.64e-7	Skin colour saturation;
KIRP	cis	rs7175404	0.938	rs7176624	chr15:94053018	A/T	cg23502883	chr15:93959149	NA	0.52	5.13	0.31	5.81e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22618164	chr12:122356400	WDR66	0.56	7.69	0.44	3.49e-13	Mean corpuscular volume;
KIRP	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg22974920	chr21:40686053	BRWD1	0.47	5.6	0.34	5.64e-8	Cognitive function;
KIRP	cis	rs2299587	0.607	rs2237848	chr8:17874604	A/C	cg01800426	chr8:17659068	MTUS1	-0.56	-6.64	-0.39	1.98e-10	Economic and political preferences;
KIRP	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg22654495	chr11:116658782	ZNF259	0.73	6.16	0.37	2.87e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg04607699	chr11:48328132	OR4S1	-0.36	-5.14	-0.31	5.65e-7	HDL cholesterol;
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg09597638	chr17:3907349	NA	0.75	13.97	0.67	4.77e-33	Type 2 diabetes;
KIRP	cis	rs10463316	0.862	rs13354553	chr5:150758128	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-7.03	-0.41	2.06e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.51	6.63	0.39	2.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg26338869	chr17:61819248	STRADA	0.52	6.13	0.36	3.49e-9	Prudent dietary pattern;
KIRP	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg18306943	chr3:40428807	ENTPD3	0.47	6.45	0.38	5.94e-10	Renal cell carcinoma;
KIRP	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	13.81	0.66	1.62e-32	Tonsillectomy;
KIRP	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg27129171	chr3:47204927	SETD2	-0.67	-9.07	-0.5	3.92e-17	Colorectal cancer;
KIRP	cis	rs11264213	0.901	rs72661644	chr1:36453894	G/A	cg27506609	chr1:36549197	TEKT2	1.17	7.3	0.42	3.88e-12	Schizophrenia;
KIRP	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.52	-0.38	3.99e-10	Myopia (pathological);
KIRP	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.13	-0.36	3.53e-9	Blood metabolite levels;
KIRP	cis	rs6987853	0.787	rs2923413	chr8:42455308	A/G	cg09913449	chr8:42400586	C8orf40	0.4	5.23	0.32	3.69e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2916247	0.909	rs7004147	chr8:93024405	G/C	cg10183463	chr8:93005414	RUNX1T1	-0.6	-7.87	-0.45	1.15e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs580438	0.529	rs6774485	chr3:13414992	T/C	cg10657019	chr3:13328039	NA	-0.52	-6.82	-0.4	7.16e-11	Myringotomy;
KIRP	cis	rs2591576	0.904	rs153285	chr5:165409348	G/A	cg13976338	chr5:165423657	NA	-0.66	-9.03	-0.5	5e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	1.05	15.95	0.71	8.02e-40	Gut microbiome composition (winter);
KIRP	cis	rs6450176	0.909	rs67199213	chr5:53290648	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-10.96	-0.57	5.05e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg25866889	chr13:114914595	NA	-0.38	-5.35	-0.32	2.01e-7	Schizophrenia;
KIRP	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg26531700	chr6:26746687	NA	0.4	5.47	0.33	1.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21643547	chr1:205240462	TMCC2	0.81	13.6	0.66	8.37e-32	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	1.02	11.31	0.58	3.73e-24	Alzheimer's disease;
KIRP	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.31	-0.42	3.72e-12	Response to antipsychotic treatment;
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.63	9.45	0.52	2.88e-18	Vitiligo;
KIRP	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.81	12.48	0.62	5.28e-28	Prostate cancer;
KIRP	cis	rs2224391	0.540	rs1570085	chr6:5253063	G/A	cg13962347	chr6:5174647	LYRM4	-0.73	-10.18	-0.54	1.54e-20	Height;
KIRP	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.22	-0.37	2.13e-9	Retinal vascular caliber;
KIRP	cis	rs4722404	0.533	rs2396960	chr7:3110933	A/G	cg19214707	chr7:3157722	NA	-0.47	-5.42	-0.33	1.41e-7	Atopic dermatitis;
KIRP	cis	rs77861329	1.000	rs123681	chr3:52209320	A/G	cg08692210	chr3:52188851	WDR51A	0.92	7.26	0.42	5.03e-12	Macrophage inflammatory protein 1b levels;
KIRP	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.83	11.94	0.61	3.09e-26	Colorectal cancer;
KIRP	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.42	0.33	1.43e-7	Cognitive test performance;
KIRP	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg02725872	chr8:58115012	NA	-0.48	-5.76	-0.34	2.45e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.4	5.65	0.34	4.41e-8	Aortic root size;
KIRP	cis	rs7712401	0.601	rs246322	chr5:122307269	C/T	cg19412675	chr5:122181750	SNX24	-0.47	-5.22	-0.32	3.83e-7	Mean platelet volume;
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg01324507	chr7:1177794	C7orf50	0.55	4.96	0.3	1.3e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg04369109	chr6:150039330	LATS1	-0.45	-5.55	-0.33	7.46e-8	Lung cancer;
KIRP	cis	rs4006360	0.657	rs6503588	chr17:39235453	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.51	-7.23	-0.42	6.2e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.75	-0.34	2.62e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg09231725	chr11:64357281	SLC22A12	-0.52	-5.91	-0.35	1.13e-8	Body mass index;Urate levels;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg05336094	chr1:38512238	POU3F1	0.46	6.1	0.36	4.03e-9	DNA methylation (variation);
KIRP	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-11.82	-0.6	7.98e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg19894588	chr14:64061835	NA	-0.62	-7.29	-0.42	4.13e-12	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg26769984	chr7:1090371	C7orf50	0.54	5.02	0.3	1e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.72	8.23	0.46	1.12e-14	Corneal astigmatism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17423711	chr1:167190178	POU2F1	-0.44	-6.04	-0.36	5.58e-9	Survival in pancreatic cancer;
KIRP	trans	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.23	-0.46	1.08e-14	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9815354	0.904	rs62258655	chr3:41932330	G/A	cg03022575	chr3:42003672	ULK4	-0.55	-6.15	-0.37	3.11e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs58649573	0.509	rs4838093	chr9:126788876	G/T	cg14112217	chr9:126806003	NA	0.36	5.2	0.31	4.13e-7	Post-traumatic stress disorder;
KIRP	trans	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.45	-0.52	2.82e-18	Rheumatoid arthritis;
KIRP	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.8	-0.53	2.34e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs6960043	0.738	rs10266209	chr7:15058691	C/T	cg19272540	chr7:15055459	NA	-0.25	-7.22	-0.42	6.62e-12	Type 2 diabetes;
KIRP	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg02487422	chr3:49467188	NICN1	0.43	4.87	0.3	2.04e-6	Menarche (age at onset);
KIRP	cis	rs4704187	0.687	rs6860441	chr5:74389799	G/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg19025524	chr12:109796872	NA	-0.53	-6.76	-0.4	9.71e-11	Neuroticism;
KIRP	cis	rs4805272	1.000	rs8106785	chr19:29322712	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1788820	0.957	rs1652340	chr18:21099831	A/C	cg14672496	chr18:21087552	C18orf8	0.42	5.9	0.35	1.17e-8	Body mass index;
KIRP	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.96	-10.69	-0.56	3.61e-22	Lung cancer in ever smokers;
KIRP	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-7.91	-0.45	8.87e-14	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.99	-0.69	1.65e-36	Height;
KIRP	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	-0.54	-6.51	-0.38	4.25e-10	Prudent dietary pattern;
KIRP	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.94	0.45	6.98e-14	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg18190219	chr22:46762943	CELSR1	-0.67	-8.0	-0.45	4.79e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.51	-7.24	-0.42	5.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7744392	1.000	rs111815981	chr6:35340115	C/T	cg06087101	chr6:35551932	FKBP5	0.58	5.18	0.31	4.72e-7	Cataracts in type 2 diabetes;
KIRP	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg14650228	chr8:144573510	ZC3H3	-0.7	-4.96	-0.3	1.31e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.45	6.26	0.37	1.7e-9	Coronary artery disease;
KIRP	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.65	-0.44	4.4e-13	Resting heart rate;
KIRP	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-7.43	-0.43	1.76e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	-0.57	-5.64	-0.34	4.56e-8	Tonsillectomy;
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.64	-8.76	-0.49	3.26e-16	Paraoxonase activity;
KIRP	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.97	9.68	0.53	5.53e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg02660097	chr11:68866761	NA	0.37	5.12	0.31	6.12e-7	Blond vs. brown hair color;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07786258	chr4:158125560	NA	-0.45	-6.38	-0.38	8.71e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2274459	0.841	rs3818532	chr6:33679807	C/T	cg06253072	chr6:33679850	C6orf125	-0.53	-5.55	-0.33	7.33e-8	Obesity (extreme);
KIRP	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.52	-11.26	-0.58	5.57e-24	Refractive error;
KIRP	cis	rs1971762	0.545	rs7485472	chr12:54044438	T/C	cg23533419	chr12:54090519	NA	-0.35	-5.31	-0.32	2.46e-7	Height;
KIRP	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg02367723	chr1:46378857	MAST2	0.44	5.12	0.31	6.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs28489187	0.706	rs233131	chr1:85795259	G/A	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.75e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs7618501	0.699	rs11713193	chr3:49924424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.6	0.44	6.24e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11877825	0.826	rs9675768	chr18:10571709	T/C	cg07277756	chr18:10589357	NA	0.5	6.05	0.36	5.25e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.6	-8.35	-0.47	4.99e-15	Systolic blood pressure;
KIRP	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	0.57	8.41	0.47	3.42e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg02336718	chr17:17403227	NA	0.36	5.26	0.32	3.07e-7	Total body bone mineral density;
KIRP	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17221829	0.733	rs7942295	chr11:89372341	T/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg05044414	chr3:183734942	ABCC5	0.37	5.58	0.34	6.36e-8	Anterior chamber depth;
KIRP	cis	rs735539	0.645	rs1329518	chr13:21203611	C/G	cg27499820	chr13:21296301	IL17D	0.35	5.08	0.31	7.41e-7	Dental caries;
KIRP	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.74	-0.39	1.14e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg06212747	chr3:49208901	KLHDC8B	0.63	8.72	0.49	4.16e-16	Resting heart rate;
KIRP	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.68	-0.56	4.14e-22	Blood metabolite levels;
KIRP	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-1.03	-20.02	-0.79	1.49e-53	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21016266	chr12:122356598	WDR66	0.66	8.84	0.49	1.82e-16	Mean corpuscular volume;
KIRP	cis	rs144861591	1	rs144861591	chr6:26072992	C/T	cg17691542	chr6:26056736	HIST1H1C	0.92	5.66	0.34	4.2e-8	Red cell distribution width;Hemoglobin concentration;Mean corpuscular volume;Hematocrit;Mean corpuscular hemoglobin;
KIRP	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.64	8.2	0.46	1.36e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.92	0.4	3.78e-11	Height;
KIRP	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.66e-7	Diabetic retinopathy;
KIRP	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg13010199	chr12:38710504	ALG10B	0.65	8.13	0.46	2.05e-14	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg22907277	chr7:1156413	C7orf50	0.66	8.12	0.46	2.3e-14	Longevity;Endometriosis;
KIRP	cis	rs10802346	0.636	rs10924582	chr1:246398611	G/T	cg15962031	chr1:246363574	SMYD3	0.79	5.92	0.35	1.07e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.5	6.57	0.39	2.93e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.72	10.34	0.55	4.78e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.6	0.52	9.42e-19	Parkinson's disease;
KIRP	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg02151108	chr14:50098012	C14orf104	-0.53	-7.16	-0.42	9.14e-12	Carotid intima media thickness;
KIRP	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	1.12	8.33	0.47	5.66e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7246760	0.867	rs8112764	chr19:9748907	G/A	cg02900749	chr2:68251473	NA	-1.13	-9.11	-0.5	3.04e-17	Pursuit maintenance gain;
KIRP	cis	rs496547	0.588	rs473298	chr11:118679387	C/T	cg19308663	chr11:118741387	NA	-0.28	-5.02	-0.3	1.01e-6	Hip minimal joint space width;
KIRP	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.66	8.87	0.49	1.51e-16	Height;
KIRP	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.62	-0.34	5.05e-8	Breast cancer;
KIRP	cis	rs5498	0.671	rs12150978	chr19:10408318	A/G	cg10604476	chr19:10403908	ICAM5	0.35	5.46	0.33	1.18e-7	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
KIRP	trans	rs1941687	0.797	rs12963024	chr18:31389547	A/G	cg27147174	chr7:100797783	AP1S1	-0.5	-6.24	-0.37	1.95e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-6.05	-0.36	5.26e-9	Morning vs. evening chronotype;
KIRP	cis	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg07585502	chr8:101912084	NA	-0.63	-8.96	-0.5	8.3e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs8054556	0.787	rs12935701	chr16:30026748	C/T	cg06326092	chr16:30034487	C16orf92	0.43	5.75	0.34	2.65e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09838262	chr17:37921981	IKZF3	0.53	6.08	0.36	4.66e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10865541	1.000	rs11692425	chr2:3395383	A/G	cg11642891	chr2:3452563	TTC15	-0.48	-6.16	-0.37	2.93e-9	Obesity-related traits;
KIRP	cis	rs2223471	0.546	rs657257	chr6:50582570	A/C	cg03432817	chr6:50765336	NA	-0.36	-5.32	-0.32	2.34e-7	Subcutaneous adipose tissue;
KIRP	cis	rs11264213	0.686	rs72661655	chr1:36475401	G/T	cg27506609	chr1:36549197	TEKT2	1.15	7.04	0.41	1.95e-11	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.68	0.6	2.33e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11225247	0.881	rs10895292	chr11:102245718	G/C	cg06323957	chr11:102217781	BIRC2	0.92	5.66	0.34	4.25e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23903597	chr17:61704154	MAP3K3	-0.5	-6.05	-0.36	5.35e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg26818010	chr10:134567672	INPP5A	-0.69	-7.64	-0.44	4.85e-13	Migraine;
KIRP	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22110650	chr3:136578209	NA	0.55	7.1	0.41	1.35e-11	Interleukin-4 levels;
KIRP	cis	rs9840812	0.567	rs2655008	chr3:136123775	A/T	cg15507776	chr3:136538369	TMEM22	0.46	5.79	0.35	2.15e-8	Fibrinogen levels;
KIRP	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.36	4.89	0.3	1.79e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg22508957	chr16:3507546	NAT15	0.49	6.15	0.36	3.13e-9	Body mass index (adult);
KIRP	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.81	-12.9	-0.64	2.03e-29	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2411233	1.000	rs11070162	chr15:39270290	C/T	cg02291532	chr15:39874776	THBS1	0.37	4.97	0.3	1.24e-6	Platelet count;
KIRP	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg07741184	chr6:167504864	NA	0.24	6.18	0.37	2.62e-9	Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09862076	chr3:118959840	B4GALT4	0.51	6.76	0.4	9.67e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg19507638	chr5:93509721	C5orf36	-0.56	-4.88	-0.3	1.91e-6	Diabetic retinopathy;
KIRP	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg15655495	chr12:38532458	NA	0.26	5.01	0.3	1.05e-6	Morning vs. evening chronotype;
KIRP	cis	rs1971762	0.965	rs1800633	chr12:54063501	G/A	cg09709951	chr12:54017699	ATF7	0.45	5.65	0.34	4.31e-8	Height;
KIRP	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg02725872	chr8:58115012	NA	-0.5	-5.4	-0.33	1.6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4654899	0.680	rs4233274	chr1:21121678	C/T	cg08890418	chr1:21044141	KIF17	0.32	4.85	0.3	2.16e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg16512390	chr1:228756714	NA	0.73	5.88	0.35	1.32e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg23335576	chr14:104009727	NA	0.4	5.54	0.33	7.6e-8	Body mass index;
KIRP	cis	rs7116495	1.000	rs10736786	chr11:71763274	C/T	cg26138937	chr11:71823887	C11orf51	-0.7	-5.59	-0.34	6.07e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.56	-7.83	-0.45	1.42e-13	Diastolic blood pressure;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg26134248	chr17:3907702	NA	0.58	8.63	0.48	8e-16	Type 2 diabetes;
KIRP	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg03468072	chr12:39539422	NA	0.42	6.05	0.36	5.39e-9	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.57	0.52	1.22e-18	Corneal astigmatism;
KIRP	cis	rs684232	0.543	rs4968095	chr17:507539	A/G	cg12384639	chr17:618140	VPS53	0.48	6.08	0.36	4.59e-9	Prostate cancer;
KIRP	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.57	-6.43	-0.38	6.55e-10	Menarche (age at onset);
KIRP	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg09491104	chr22:46646882	C22orf40	-0.52	-6.26	-0.37	1.71e-9	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16815379	chr1:165797173	UCK2	0.49	6.52	0.38	4.03e-10	Parkinson's disease;
KIRP	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.83	-0.4	6.8e-11	Aortic root size;
KIRP	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg21605333	chr4:119757512	SEC24D	1.41	9.98	0.54	6.38e-20	Cannabis dependence symptom count;
KIRP	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg19077165	chr18:44547161	KATNAL2	0.45	5.59	0.34	5.94e-8	Personality dimensions;
KIRP	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.69	-9.92	-0.53	1.01e-19	Plateletcrit;Platelet count;
KIRP	cis	rs16976116	0.951	rs6493768	chr15:55484294	T/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.5	0.43	1.12e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs27434	0.583	rs149544	chr5:96157854	C/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.06e-8	Ankylosing spondylitis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03856450	chr2:73298881	SFXN5	-0.55	-6.03	-0.36	5.92e-9	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18462226	chr4:76598323	G3BP2	0.52	6.6	0.39	2.46e-10	Parkinson's disease;
KIRP	cis	rs9815354	0.680	rs73073280	chr3:42025772	T/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg07884673	chr3:53033167	SFMBT1	0.79	6.02	0.36	6.41e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg17425144	chr1:10567563	PEX14	0.43	7.73	0.44	2.68e-13	Prostate cancer;
KIRP	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg19633962	chr1:26362018	EXTL1	-0.82	-8.73	-0.49	4.07e-16	QRS complex (12-leadsum);
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.74	6.5	0.38	4.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg05361325	chr10:32636312	EPC1	-0.66	-6.28	-0.37	1.53e-9	Sexual dysfunction (female);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00878827	chr14:75229987	YLPM1	0.45	6.32	0.37	1.24e-9	Survival in pancreatic cancer;
KIRP	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg17724175	chr1:150552817	MCL1	0.33	5.54	0.33	7.91e-8	Melanoma;
KIRP	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.72	10.28	0.55	7.3e-21	Obesity-related traits;
KIRP	cis	rs9308731	0.568	rs6754736	chr2:111948541	T/C	cg04202892	chr2:111875749	ACOXL	0.4	5.41	0.33	1.46e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.58	-7.43	-0.43	1.83e-12	Aortic root size;
KIRP	cis	rs4919044	0.599	rs17378057	chr10:94703333	A/G	cg05127821	chr10:94822908	CYP26C1	-0.89	-7.3	-0.42	4.03e-12	Coronary artery disease;
KIRP	cis	rs7113874	0.802	rs11042025	chr11:8675475	C/A	cg08015107	chr11:8618950	NA	0.42	5.88	0.35	1.36e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg22681709	chr2:178499509	PDE11A	-0.54	-7.66	-0.44	4.28e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9810890	1.000	rs73198839	chr3:128500442	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs4356932	1.000	rs4637430	chr4:76962223	G/T	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.38	-0.68	1.86e-34	Primary sclerosing cholangitis;
KIRP	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.29	5.86	0.35	1.51e-8	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg15181151	chr6:150070149	PCMT1	0.32	5.45	0.33	1.22e-7	Lung cancer;
KIRP	trans	rs7246760	0.867	rs67634928	chr19:9802397	C/G	cg02900749	chr2:68251473	NA	-1.2	-9.9	-0.53	1.13e-19	Pursuit maintenance gain;
KIRP	cis	rs75229567	0.717	rs77874289	chr12:70234203	A/G	cg10114359	chr12:70132523	RAB3IP	0.95	7.13	0.41	1.12e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.72	-0.53	4.22e-19	Schizophrenia;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27552081	chr17:25621774	WSB1	0.63	7.04	0.41	1.95e-11	Lung cancer in ever smokers;
KIRP	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg19847866	chr10:1019161	NA	0.41	5.01	0.3	1.02e-6	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.43	-6.15	-0.37	3.03e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs8077577	0.747	rs11868708	chr17:18244613	T/C	cg18869244	chr17:18121946	NA	0.45	5.06	0.31	8.21e-7	Obesity-related traits;
KIRP	cis	rs4776059	1.000	rs4776065	chr15:52929716	A/G	cg22715398	chr15:52968154	KIAA1370	0.57	6.95	0.4	3.33e-11	Schizophrenia;
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg08662619	chr6:150070041	PCMT1	-0.35	-5.59	-0.34	5.99e-8	Lung cancer;
KIRP	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20135002	chr11:47629003	NA	-0.43	-4.93	-0.3	1.52e-6	Subjective well-being;
KIRP	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg26516362	chr5:178986906	RUFY1	0.39	6.75	0.4	1.07e-10	Lung cancer;
KIRP	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg17145862	chr1:211918768	LPGAT1	-0.91	-13.34	-0.65	6.8e-31	Leprosy;
KIRP	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.67	-6.02	-0.36	6.22e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6662572	0.737	rs10890357	chr1:46318054	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	0.5	9.04	0.5	4.84e-17	QRS complex (12-leadsum);
KIRP	cis	rs6956675	0.915	rs4717501	chr7:62652936	C/T	cg08930214	chr7:62859557	LOC100287834	0.42	5.27	0.32	3.05e-7	Obesity-related traits;
KIRP	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg08999081	chr20:33150536	PIGU	0.46	6.12	0.36	3.59e-9	Height;
KIRP	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.55	-0.39	3.4e-10	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	15.05	0.69	1e-36	Chronic sinus infection;
KIRP	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg13010199	chr12:38710504	ALG10B	0.55	6.81	0.4	7.42e-11	Morning vs. evening chronotype;
KIRP	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.46	5.41	0.33	1.52e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	5.81	0.35	1.88e-8	Mean platelet volume;
KIRP	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-9.04	-0.5	4.83e-17	Parkinson's disease;
KIRP	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg01843034	chr6:37503916	NA	-0.85	-12.13	-0.61	7.53e-27	Cognitive performance;
KIRP	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25062197	chr8:90894030	NA	-0.41	-6.14	-0.36	3.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	10.04	0.54	4.35e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10929159	0.928	rs6761121	chr2:236922541	T/C	cg20128773	chr2:236923534	AGAP1	0.3	5.15	0.31	5.25e-7	Parkinson's disease;
KIRP	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.95	-0.35	9.1e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg09137382	chr11:130731461	NA	0.53	7.74	0.44	2.65e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.55	0.43	8.28e-13	Coffee consumption (cups per day);
KIRP	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg04731861	chr2:219085781	ARPC2	-0.23	-5.92	-0.35	1.08e-8	Colorectal cancer;
KIRP	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.95	16.06	0.72	3.57e-40	Breast cancer;
KIRP	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.52	-7.76	-0.44	2.26e-13	IgG glycosylation;
KIRP	cis	rs2505998	0.833	rs1864405	chr10:43604148	A/C	cg15436174	chr10:43711423	RASGEF1A	-0.53	-5.69	-0.34	3.63e-8	Hirschsprung disease;
KIRP	cis	rs2594989	0.670	rs9845397	chr3:11470263	C/T	cg01796438	chr3:11312864	ATG7	-0.72	-8.29	-0.47	7.47e-15	Circulating chemerin levels;
KIRP	cis	rs501120	1.000	rs573141	chr10:44758587	G/A	cg09554077	chr10:44749378	NA	0.7	10.63	0.56	5.74e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.59	-7.51	-0.43	1.12e-12	Height;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00908189	chr16:619842	PIGQ	0.85	11.5	0.59	9e-25	Height;
KIRP	cis	rs397969	0.646	rs1638526	chr17:19848450	T/C	cg04132472	chr17:19861366	AKAP10	0.62	8.11	0.46	2.34e-14	Platelet count;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.83	-9.24	-0.51	1.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.64	-8.63	-0.48	7.87e-16	Platelet count;
KIRP	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-5.78	-0.35	2.2e-8	Blood metabolite levels;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.81	-8.71	-0.49	4.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg13939156	chr17:80058883	NA	-0.48	-7.24	-0.42	5.76e-12	Life satisfaction;
KIRP	cis	rs1440410	0.835	rs10155324	chr4:144056973	A/T	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-7.41	-0.43	2.06e-12	Morning vs. evening chronotype;
KIRP	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.24	-0.47	1.06e-14	Neuroticism;
KIRP	cis	rs1318772	0.932	rs67382821	chr5:112902324	C/G	cg12552261	chr5:112820674	MCC	0.82	5.68	0.34	3.81e-8	F-cell distribution;
KIRP	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.2	-0.31	4.19e-7	Neuroticism;
KIRP	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.74	-11.98	-0.61	2.34e-26	Prostate cancer;
KIRP	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg04374321	chr14:90722782	PSMC1	0.57	6.93	0.4	3.7e-11	Longevity;
KIRP	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.68	10.91	0.57	7.14e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7116495	0.609	rs501308	chr11:71581325	C/G	cg10381502	chr11:71823885	C11orf51	0.72	5.09	0.31	7.04e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg18643199	chr10:82363313	SH2D4B	-0.47	-5.0	-0.3	1.1e-6	Post bronchodilator FEV1;
KIRP	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.6	-9.75	-0.53	3.38e-19	Itch intensity from mosquito bite;
KIRP	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.91	0.45	8.67e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs12282928	1.000	rs10160559	chr11:48280684	T/C	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.17e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7301016	1.000	rs73141014	chr12:62891412	T/G	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs11690961	0.627	rs11690238	chr2:46371723	C/T	cg12428440	chr2:46370979	PRKCE	-0.56	-6.05	-0.36	5.5e-9	Pulse pressure;
KIRP	cis	rs2737618	0.674	rs2737683	chr1:200092448	G/A	cg21825944	chr1:200113062	NR5A2	-0.57	-8.12	-0.46	2.23e-14	Uric acid levels;
KIRP	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.5	-0.43	1.18e-12	Type 2 diabetes;
KIRP	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg18357526	chr6:26021779	HIST1H4A	0.41	5.37	0.32	1.82e-7	Height;
KIRP	cis	rs7833787	1.000	rs7833787	chr8:18707871	A/G	cg17701159	chr8:18705777	PSD3	-0.39	-7.33	-0.42	3.32e-12	Obesity-related traits;
KIRP	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-6.86	-0.4	5.7e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg07701084	chr6:150067640	NUP43	0.67	8.44	0.47	2.68e-15	Lung cancer;
KIRP	cis	rs11071200	0.550	rs12438177	chr15:55951432	A/G	cg17396834	chr15:56014697	PRTG	-0.38	-5.23	-0.32	3.7e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs8001976	0.537	rs9534804	chr13:48325736	A/C	cg23237801	chr1:16476620	EPHA2	0.51	6.56	0.39	3.18e-10	Aging (time to event);
KIRP	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-12.04	-0.61	1.49e-26	Gut microbiome composition (summer);
KIRP	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg00631329	chr6:26305371	NA	-0.65	-8.71	-0.49	4.54e-16	Educational attainment;
KIRP	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg16141378	chr3:129829833	LOC729375	0.54	7.37	0.43	2.6e-12	Morning vs. evening chronotype;
KIRP	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg13147721	chr7:65941812	NA	-0.91	-6.56	-0.39	3.19e-10	Diabetic kidney disease;
KIRP	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg13395646	chr4:1353034	KIAA1530	-0.38	-5.06	-0.31	8.09e-7	Longevity;
KIRP	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	7.18	0.42	8.1e-12	Menarche (age at onset);
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26380756	chr22:39097154	JOSD1	-0.48	-5.07	-0.31	7.88e-7	Menopause (age at onset);
KIRP	cis	rs2387326	0.638	rs76288438	chr10:129940554	A/C	cg16087940	chr10:129947807	NA	-0.36	-4.88	-0.3	1.87e-6	Select biomarker traits;
KIRP	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.27	12.8	0.63	4.22e-29	Diabetic retinopathy;
KIRP	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.74	-0.49	3.65e-16	Personality dimensions;
KIRP	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.43	-7.88	-0.45	1.08e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.56	-0.39	3.12e-10	Myopia (pathological);
KIRP	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.81	0.35	1.88e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.9	14.8	0.69	7.21e-36	Prostate cancer;
KIRP	cis	rs3736594	0.513	rs62138964	chr2:27814438	C/T	cg27432699	chr2:27873401	GPN1	0.55	6.14	0.36	3.34e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6430538	0.671	rs4954176	chr2:135543649	C/T	cg25422880	chr2:135218333	TMEM163	-0.45	-6.18	-0.37	2.6e-9	Parkinson's disease;
KIRP	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.37	5.38	0.32	1.71e-7	Body mass index;
KIRP	cis	rs783147	0.652	rs1782629	chr6:161195866	C/A	cg01280913	chr6:161186852	NA	0.43	5.67	0.34	4.03e-8	Lp (a) levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18986330	chr14:100772766	SLC25A29;MIR345	0.57	7.47	0.43	1.4e-12	Parkinson's disease;
KIRP	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.68	-8.76	-0.49	3.32e-16	Cognitive test performance;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26114595	chr17:28395749	EFCAB5	0.45	7.0	0.41	2.36e-11	Cancer;
KIRP	cis	rs17095355	1.000	rs11194922	chr10:111695656	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.09	-0.36	4.42e-9	Biliary atresia;
KIRP	cis	rs13385	0.769	rs4913071	chr5:139560498	T/G	cg01860693	chr5:139557145	C5orf32	0.49	5.46	0.33	1.17e-7	Atrial fibrillation;
KIRP	cis	rs501120	1.000	rs687175	chr10:44751910	C/T	cg09554077	chr10:44749378	NA	-0.77	-12.66	-0.63	1.31e-28	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.73	10.46	0.55	2.01e-21	Body mass index;
KIRP	cis	rs35740288	0.770	rs11631449	chr15:86148653	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg25482853	chr8:67687455	SGK3	0.83	7.23	0.42	6.14e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.05	0.31	8.42e-7	Smoking behavior;
KIRP	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.53	-6.77	-0.4	9.14e-11	Immature fraction of reticulocytes;
KIRP	cis	rs282587	0.542	rs914021	chr13:113375548	T/C	cg04656015	chr13:113407548	ATP11A	-0.56	-5.9	-0.35	1.2e-8	Glycated hemoglobin levels;
KIRP	cis	rs6838801	0.893	rs17002103	chr4:77512356	C/G	cg17476223	chr4:77663285	SHROOM3	0.55	7.52	0.43	1.04e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs1018697	0.966	rs10748832	chr10:104568480	G/A	cg04362960	chr10:104952993	NT5C2	0.48	5.53	0.33	7.98e-8	Colorectal adenoma (advanced);
KIRP	cis	rs282587	0.627	rs388242	chr13:113415188	T/C	cg04656015	chr13:113407548	ATP11A	0.67	7.77	0.44	2.06e-13	Glycated hemoglobin levels;
KIRP	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg07148914	chr20:33460835	GGT7	-0.54	-7.07	-0.41	1.62e-11	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09311052	chr1:154531418	UBE2Q1	0.69	8.48	0.48	2.14e-15	Smoking initiation;
KIRP	cis	rs879620	0.890	rs2601781	chr16:4017392	T/A	cg09300795	chr16:4042428	ADCY9	0.4	5.09	0.31	7.04e-7	Hip circumference;Body mass index;
KIRP	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06481639	chr22:41940642	POLR3H	0.65	7.14	0.41	1.04e-11	Vitiligo;
KIRP	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg10755058	chr3:40428713	ENTPD3	0.4	5.45	0.33	1.22e-7	Renal cell carcinoma;
KIRP	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.79	11.17	0.58	1.09e-23	Mean platelet volume;
KIRP	trans	rs3770194	0.582	rs13404409	chr2:222318577	C/T	cg01604210	chr1:24129185	HMGCL	-0.78	-6.47	-0.38	5.34e-10	Left ventricle wall thickness;
KIRP	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg16497661	chr14:103986332	CKB	0.5	6.66	0.39	1.78e-10	Body mass index;
KIRP	cis	rs3789045	0.560	rs4626956	chr1:204407298	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.89	-8.23	-0.46	1.12e-14	Educational attainment (college completion);
KIRP	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.54	7.46	0.43	1.44e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-1.28	-12.85	-0.63	2.85e-29	Post bronchodilator FEV1;
KIRP	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	1.17	10.25	0.55	9.21e-21	Skin colour saturation;
KIRP	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg16497661	chr14:103986332	CKB	0.77	11.47	0.59	1.09e-24	Body mass index;
KIRP	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.07	11.94	0.61	3.29e-26	Vitiligo;
KIRP	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg18806716	chr10:30721971	MAP3K8	-0.33	-5.09	-0.31	7.09e-7	Inflammatory bowel disease;
KIRP	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-4.97	-0.3	1.28e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs16828019	0.852	rs11209545	chr1:41576357	T/G	cg18742814	chr1:41828276	NA	0.67	5.89	0.35	1.24e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg17524265	chr8:144659883	NAPRT1	0.79	5.05	0.31	8.58e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg03171003	chr2:111875934	NA	0.45	6.37	0.38	9e-10	Chronic lymphocytic leukemia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01506766	chr13:46626746	ZC3H13	0.48	6.99	0.41	2.54e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	5.12	0.31	6.25e-7	Coronary artery disease;
KIRP	cis	rs6952809	1.000	rs7350030	chr7:2449157	G/A	cg23289794	chr7:2394357	EIF3B	-0.4	-5.01	-0.3	1.06e-6	Multiple sclerosis;
KIRP	cis	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg21204522	chr6:27730016	NA	-0.6	-5.06	-0.31	8.29e-7	Lung cancer in ever smokers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06235973	chr19:14183619	LOC113230	0.65	8.17	0.46	1.66e-14	Smoking initiation;
KIRP	cis	rs5756391	0.546	rs9607398	chr22:37316041	C/T	cg16356956	chr22:37317934	CSF2RB	0.36	4.98	0.3	1.21e-6	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs829661	0.947	rs829618	chr2:30748321	A/G	cg10949345	chr2:30726833	LCLAT1	0.71	10.19	0.54	1.41e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs10203711	0.933	rs10187441	chr2:239577654	C/G	cg14580085	chr2:239553406	NA	0.39	5.15	0.31	5.34e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.35	0.42	2.88e-12	Asthma;
KIRP	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg19592336	chr6:28129416	ZNF389	0.51	5.76	0.34	2.5e-8	Depression;
KIRP	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04960941	chr16:68056948	DDX28;DUS2L	0.51	6.31	0.37	1.26e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg07827796	chr19:33622959	WDR88	0.5	6.53	0.38	3.83e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17252645	chr8:143867129	LY6D	-0.53	-9.67	-0.52	5.9e-19	Urinary tract infection frequency;
KIRP	cis	rs7636293	1.000	rs9816623	chr3:129042716	A/G	cg11882307	chr3:128968397	COPG	-0.44	-4.92	-0.3	1.58e-6	Height;
KIRP	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg11965913	chr1:205819406	PM20D1	0.48	5.32	0.32	2.28e-7	Parkinson's disease;
KIRP	cis	rs4356932	0.935	rs4605683	chr4:76979327	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.5	11.86	0.6	5.93e-26	Ewing sarcoma;
KIRP	cis	rs76662990	1.000	rs76662990	chr5:73847916	A/G	cg01264639	chr5:73839484	NA	0.55	4.94	0.3	1.47e-6	Residual cognition;
KIRP	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg08461772	chr7:95026248	PON3	0.38	5.24	0.32	3.46e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	5.15	0.31	5.33e-7	Renal cell carcinoma;
KIRP	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.6	7.74	0.44	2.51e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.4	-0.43	2.1e-12	Response to antipsychotic treatment;
KIRP	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg16898833	chr6:26189333	HIST1H4D	0.62	4.99	0.3	1.15e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg26876637	chr1:152193138	HRNR	0.71	9.19	0.51	1.71e-17	Atopic dermatitis;
KIRP	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19623624	chr10:135278901	LOC619207	-0.63	-6.9	-0.4	4.27e-11	Systemic lupus erythematosus;
KIRP	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.52	6.59	0.39	2.61e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4363385	0.647	rs56158137	chr1:152994380	A/T	cg13444842	chr1:152974279	SPRR3	-0.43	-6.17	-0.37	2.8e-9	Inflammatory skin disease;
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.41	-0.33	1.51e-7	Lung cancer;
KIRP	cis	rs6545883	0.929	rs2252662	chr2:61670731	T/C	cg15711740	chr2:61764176	XPO1	-0.61	-8.19	-0.46	1.41e-14	Tuberculosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13984515	chr1:86046961	CYR61	0.48	6.55	0.39	3.26e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg12140854	chr5:148520817	ABLIM3	0.42	4.84	0.3	2.25e-6	Breast cancer;
KIRP	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.54	6.14	0.36	3.28e-9	Coronary artery disease;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.57	-7.1	-0.41	1.37e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.53	-6.35	-0.38	1.02e-9	HIV-1 control;
KIRP	trans	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03602288	chr17:46641863	HOXB3	0.45	6.15	0.37	3.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11055008	0.620	rs12816452	chr12:12833006	A/T	cg04607235	chr12:12878440	APOLD1	-0.42	-4.97	-0.3	1.26e-6	Pulse pressure;
KIRP	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	1.1	15.58	0.7	1.59e-38	Breast cancer;
KIRP	cis	rs33912345	0.712	rs61991551	chr14:60982515	G/A	cg27398547	chr14:60952738	C14orf39	0.38	4.98	0.3	1.19e-6	Glaucoma (high intraocular pressure);
KIRP	cis	rs1497828	0.956	rs2646824	chr1:217537766	C/G	cg04411442	chr1:217543379	NA	-0.31	-4.97	-0.3	1.27e-6	Dialysis-related mortality;
KIRP	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.98	-0.41	2.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg25173405	chr17:45401733	C17orf57	0.44	5.92	0.35	1.1e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg21573476	chr21:45109991	RRP1B	-0.51	-6.8	-0.4	7.77e-11	Mean corpuscular volume;
KIRP	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs259842	0.585	rs4894130	chr2:180715929	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-4.88	-0.3	1.9e-6	Blood protein levels;
KIRP	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.62	-5.5	-0.33	9.65e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg25486957	chr4:152246857	NA	-0.48	-5.43	-0.33	1.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs554111	0.891	rs646786	chr1:21054726	A/G	cg08890418	chr1:21044141	KIF17	0.63	10.03	0.54	4.7e-20	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.55e-10	Morning vs. evening chronotype;
KIRP	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.51	-5.05	-0.31	8.65e-7	Type 2 diabetes;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.39	5.45	0.33	1.24e-7	Lung cancer;
KIRP	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg21573476	chr21:45109991	RRP1B	-0.6	-8.34	-0.47	5.23e-15	Mean corpuscular volume;
KIRP	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.84	-8.84	-0.49	1.92e-16	Hair shape;
KIRP	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.18	-0.51	1.83e-17	Triglycerides;
KIRP	cis	rs10518128	1.000	rs7655399	chr4:75705096	A/C	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg09597638	chr17:3907349	NA	0.52	5.22	0.32	3.81e-7	Type 2 diabetes;
KIRP	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.51	6.52	0.38	3.92e-10	White matter hyperintensity burden;
KIRP	cis	rs76533333	0.646	rs71446628	chr13:113393611	C/T	cg04656015	chr13:113407548	ATP11A	0.72	5.99	0.36	7.34e-9	Red cell distribution width;
KIRP	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.88	-0.35	1.33e-8	Height;
KIRP	cis	rs3735025	0.927	rs10954579	chr7:137047182	C/G	cg13839563	chr7:136910420	NA	-0.43	-4.85	-0.3	2.19e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1712517	0.771	rs11191666	chr10:105127278	A/G	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.39e-9	Migraine;
KIRP	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg08499158	chr17:42289980	UBTF	0.52	6.49	0.38	4.64e-10	Total body bone mineral density;
KIRP	cis	rs17373728	0.710	rs12544686	chr8:76218074	C/T	cg07016329	chr8:76221503	NA	-0.55	-7.29	-0.42	4.29e-12	Diabetic kidney disease;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.65	-10.64	-0.56	5.53e-22	Lymphocyte counts;
KIRP	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-12.83	-0.63	3.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg04804543	chr8:142233427	SLC45A4	0.99	16.7	0.73	2.34e-42	Immature fraction of reticulocytes;
KIRP	cis	rs258892	0.895	rs11950735	chr5:72031813	G/C	cg21869765	chr5:72125136	TNPO1	-0.53	-6.06	-0.36	4.98e-9	Small cell lung carcinoma;
KIRP	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg17366294	chr4:99064904	C4orf37	-0.35	-4.92	-0.3	1.57e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg07596299	chr11:71824057	C11orf51	0.9	5.93	0.35	1.03e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.47	-6.96	-0.41	3e-11	Major depressive disorder;
KIRP	cis	rs4805272	1.000	rs10403537	chr19:29324127	A/C	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.22	16.46	0.72	1.54e-41	Corneal structure;
KIRP	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.97	-16.74	-0.73	1.72e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg18944383	chr4:111397179	ENPEP	-0.55	-6.46	-0.38	5.69e-10	Axial length;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.71	-0.34	3.18e-8	Life satisfaction;
KIRP	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.97	-0.41	2.97e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12249377	0.519	rs11599902	chr10:92598823	A/G	cg14313238	chr10:92632228	RPP30	0.49	5.99	0.36	7.22e-9	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg02804510	chr19:49199965	FUT2	0.36	5.24	0.32	3.37e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg16586182	chr3:47516702	SCAP	-0.65	-8.8	-0.49	2.41e-16	Colorectal cancer;
KIRP	cis	rs16976116	0.901	rs1050931	chr15:55497691	G/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19171272	chr22:38449367	NA	-0.55	-7.95	-0.45	6.6e-14	Glioblastoma;Glioma;
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.79	9.92	0.53	1.01e-19	Longevity;
KIRP	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg08076091	chr2:203926405	NBEAL1	0.83	8.85	0.49	1.78e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.79	-11.07	-0.58	2.24e-23	Dental caries;
KIRP	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.85	12.33	0.62	1.55e-27	Menopause (age at onset);
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.42	-0.33	1.45e-7	Obesity-related traits;
KIRP	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.23	-0.32	3.68e-7	Bipolar disorder;
KIRP	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.94	-0.4	3.45e-11	Aortic root size;
KIRP	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg11833968	chr6:79620685	NA	-0.48	-7.26	-0.42	5.12e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4073416	0.542	rs1113962	chr14:66005798	C/T	cg03016385	chr14:66212404	NA	-0.52	-6.3	-0.37	1.36e-9	N-glycan levels;
KIRP	cis	rs6968419	0.755	rs3807981	chr7:115896716	G/A	cg02561103	chr7:115862891	TES	-0.41	-5.82	-0.35	1.83e-8	Intraocular pressure;
KIRP	trans	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg11693508	chr17:37793320	STARD3	0.54	7.24	0.42	5.77e-12	Neuroticism;
KIRP	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.45	6.9	0.4	4.36e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-12.34	-0.62	1.44e-27	Chronic sinus infection;
KIRP	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg23649088	chr2:200775458	C2orf69	0.68	5.91	0.35	1.15e-8	Schizophrenia;
KIRP	cis	rs2172802	0.570	rs11131340	chr4:62535059	C/T	cg04118610	chr4:62707027	LPHN3	-0.43	-5.26	-0.32	3.12e-7	Partial epilepsies;
KIRP	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg13939156	chr17:80058883	NA	0.48	5.58	0.34	6.19e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.97	-15.64	-0.71	9.47e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-1.3	-10.07	-0.54	3.5e-20	Atopic dermatitis;
KIRP	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11987759	chr7:65425863	GUSB	-0.46	-5.48	-0.33	1.06e-7	Aortic root size;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26526709	chr7:35077807	DPY19L1	0.55	6.04	0.36	5.6e-9	Lung cancer in ever smokers;
KIRP	cis	rs7527798	1.000	rs7527798	chr1:207872290	T/C	cg09232269	chr1:207846808	CR1L	-0.42	-5.01	-0.3	1.04e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg11632617	chr15:75315747	PPCDC	0.59	4.9	0.3	1.77e-6	Lung cancer;
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.61	10.63	0.56	5.7e-22	Lung cancer;
KIRP	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	7.48	0.43	1.34e-12	Coronary artery disease;
KIRP	cis	rs501120	0.657	rs10899998	chr10:44688524	G/C	cg09554077	chr10:44749378	NA	0.5	5.87	0.35	1.4e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2380220	1.000	rs2380220	chr6:95967412	T/C	cg15832292	chr6:96025679	MANEA	0.65	5.02	0.3	9.8e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs4664293	1.000	rs12692554	chr2:160451288	G/A	cg08347373	chr2:160653686	CD302	-0.37	-5.61	-0.34	5.45e-8	Monocyte percentage of white cells;
KIRP	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.27	-0.32	3.01e-7	Bladder cancer;
KIRP	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11987759	chr7:65425863	GUSB	0.47	6.2	0.37	2.41e-9	Aortic root size;
KIRP	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.8	12.54	0.62	3.22e-28	Skin aging (microtopography measurement);
KIRP	trans	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg10756647	chr7:56101905	PSPH	0.98	6.99	0.41	2.63e-11	Diabetic kidney disease;
KIRP	cis	rs78487399	0.634	rs77881454	chr2:43757293	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.95	-0.3	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.72	11.24	0.58	6.33e-24	Menarche (age at onset);
KIRP	cis	rs9547692	0.878	rs9547688	chr13:37449413	G/A	cg01493522	chr13:37497338	NA	-0.46	-5.52	-0.33	8.79e-8	Coronary artery disease;
KIRP	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	11.56	0.59	5.83e-25	Personality dimensions;
KIRP	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg23950597	chr19:37808831	NA	-0.76	-6.6	-0.39	2.54e-10	Coronary artery calcification;
KIRP	cis	rs7180079	0.620	rs7403071	chr15:65048309	G/A	cg15337035	chr15:64978493	NA	-0.51	-5.46	-0.33	1.16e-7	Monocyte count;
KIRP	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.87	12.99	0.64	9.61e-30	Eosinophil percentage of white cells;
KIRP	cis	rs2282978	0.557	rs42045	chr7:92250354	C/T	cg15732164	chr7:92237376	CDK6	-0.35	-4.91	-0.3	1.7e-6	Height;
KIRP	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.29	12.33	0.62	1.61e-27	Diabetic retinopathy;
KIRP	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg23102388	chr7:1867652	MAD1L1	-0.47	-6.36	-0.38	9.77e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16327227	chr2:25896721	DTNB	0.46	6.09	0.36	4.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11381792	chr21:45432451	TRAPPC10	-0.44	-6.36	-0.38	1e-9	Metabolic traits;
KIRP	cis	rs4774899	0.934	rs4774913	chr15:57487770	T/C	cg13626582	chr15:57592083	LOC283663	-0.2	-4.85	-0.3	2.16e-6	Urinary tract infection frequency;
KIRP	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.62	-8.37	-0.47	4.45e-15	Total body bone mineral density;
KIRP	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg13157960	chr19:33183277	NUDT19	0.55	4.96	0.3	1.29e-6	Red blood cell traits;
KIRP	cis	rs7215564	0.908	rs35103651	chr17:78666732	T/C	cg06153925	chr17:78755379	RPTOR	0.35	5.53	0.33	8.06e-8	Myopia (pathological);
KIRP	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg05729581	chr11:3078854	CARS	-0.5	-6.21	-0.37	2.24e-9	Longevity;
KIRP	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg05082376	chr22:42548792	NA	0.46	5.8	0.35	2.01e-8	Schizophrenia;
KIRP	cis	rs7224685	0.569	rs8070737	chr17:3981066	G/T	cg09695851	chr17:3907499	NA	0.6	5.72	0.34	3.11e-8	Type 2 diabetes;
KIRP	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-13.28	-0.65	1.01e-30	Heart rate;
KIRP	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.92	-0.4	3.98e-11	Myopia (pathological);
KIRP	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.56	6.27	0.37	1.6e-9	Educational attainment;
KIRP	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg16497661	chr14:103986332	CKB	0.4	5.23	0.32	3.68e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-15.01	-0.69	1.4e-36	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.64e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	11.06	0.58	2.46e-23	Response to antipsychotic treatment;
KIRP	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg06243866	chr13:111019493	COL4A2	0.58	7.35	0.42	2.92e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs240764	0.817	rs6938440	chr6:101152009	T/C	cg09795085	chr6:101329169	ASCC3	-0.43	-5.23	-0.32	3.65e-7	Neuroticism;
KIRP	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	5.18	0.31	4.73e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.73	9.1	0.5	3.17e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-7.27	-0.42	4.86e-12	Morning vs. evening chronotype;
KIRP	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg00125455	chr20:44574271	PCIF1	0.46	9.12	0.5	2.67e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.920	rs67114979	chr16:67691645	G/T	cg04539111	chr16:67997858	SLC12A4	-0.56	-5.01	-0.3	1.06e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2274273	0.662	rs2147970	chr14:55660217	C/T	cg04306507	chr14:55594613	LGALS3	0.42	5.58	0.34	6.18e-8	Protein biomarker;
KIRP	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg08461772	chr7:95026248	PON3	0.44	5.98	0.36	7.73e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-8.41	-0.47	3.28e-15	Response to antipsychotic treatment;
KIRP	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-8.37	-0.47	4.39e-15	Morning vs. evening chronotype;
KIRP	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg23477460	chr3:66848765	NA	-0.68	-7.89	-0.45	1e-13	Type 2 diabetes;
KIRP	cis	rs9409565	0.826	rs9409546	chr9:97209066	T/C	cg04523069	chr9:97136363	HIATL1	0.47	6.19	0.37	2.56e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs2273156	1.000	rs12897044	chr14:35423144	T/C	cg09327582	chr14:35236912	BAZ1A	-0.52	-5.76	-0.34	2.46e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-8.2	-0.46	1.29e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-5.38	-0.32	1.7e-7	Aortic root size;
KIRP	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.75	9.4	0.51	3.98e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20050194	chr10:116046732	VWA2	0.44	6.37	0.38	9.48e-10	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19365062	chr6:127440000	RSPO3	0.5	6.3	0.37	1.39e-9	Parkinson's disease;
KIRP	cis	rs7712401	0.601	rs246321	chr5:122308299	A/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.08	0.36	4.54e-9	Bipolar disorder;
KIRP	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	trans	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg10756647	chr7:56101905	PSPH	0.92	6.4	0.38	7.75e-10	Diabetic kidney disease;
KIRP	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.51	7.15	0.41	9.79e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4746818	0.711	rs2491024	chr10:70847084	T/C	cg11621586	chr10:70884670	VPS26A	0.69	7.53	0.43	9.38e-13	Left atrial antero-posterior diameter;
KIRP	cis	rs9393813	0.868	rs2393963	chr6:27475100	G/C	cg03332623	chr6:27441972	ZNF184	-0.35	-5.34	-0.32	2.06e-7	Bipolar disorder;
KIRP	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	11.49	0.59	9.25e-25	Lung cancer in ever smokers;
KIRP	cis	rs3126085	0.515	rs9633409	chr1:152362329	G/T	cg26876637	chr1:152193138	HRNR	-0.66	-6.73	-0.39	1.17e-10	Atopic dermatitis;
KIRP	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.6	8.25	0.47	9.5e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg00086871	chr4:6988644	TBC1D14	0.95	6.32	0.37	1.22e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.97	-11.8	-0.6	8.92e-26	Response to antineoplastic agents;
KIRP	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.68	-8.21	-0.46	1.27e-14	Aortic root size;
KIRP	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.63	-0.34	4.95e-8	Aortic root size;
KIRP	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.38	-0.32	1.73e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2302729	0.625	rs1592573	chr12:2831556	A/T	cg19945202	chr12:2788847	CACNA1C	-0.66	-6.59	-0.39	2.67e-10	Sleep quality;
KIRP	cis	rs12096438	1.000	rs6661159	chr1:25890050	A/G	cg21452808	chr1:25900135	NA	-0.4	-6.51	-0.38	4.3e-10	Platelet count;Mean platelet volume;
KIRP	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg21518248	chr2:162101506	NA	0.44	5.24	0.32	3.46e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.87	-13.02	-0.64	7.64e-30	Height;
KIRP	cis	rs1971762	0.527	rs1247957	chr12:53961493	G/T	cg16917193	chr12:54089295	NA	-0.84	-14.15	-0.67	1.17e-33	Height;
KIRP	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.62	-6.86	-0.4	5.39e-11	Urate levels in lean individuals;
KIRP	cis	rs490234	0.776	rs10115455	chr9:128458850	T/C	cg14078157	chr9:128172775	NA	-0.57	-6.7	-0.39	1.37e-10	Mean arterial pressure;
KIRP	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.58	9.41	0.51	3.62e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs17401966	0.540	rs3748581	chr1:10441664	T/C	cg17425144	chr1:10567563	PEX14	-0.29	-5.09	-0.31	7.02e-7	Hepatocellular carcinoma;
KIRP	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.19	0.51	1.68e-17	Bipolar disorder;
KIRP	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg26412358	chr1:26503933	CNKSR1	0.41	5.72	0.34	3.09e-8	Height;
KIRP	cis	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg03511173	chr18:77590860	NA	-0.46	-5.04	-0.31	9.21e-7	Opioid sensitivity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09949816	chr15:34503491	C15orf29	-0.41	-6.49	-0.38	4.63e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.52	-0.52	1.65e-18	Neuroticism;
KIRP	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg04398451	chr17:18023971	MYO15A	-0.69	-9.56	-0.52	1.25e-18	Total body bone mineral density;
KIRP	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	1.09	20.32	0.79	1.52e-54	Bone mineral density;
KIRP	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg01629716	chr15:45996671	NA	0.35	6.3	0.37	1.33e-9	Waist circumference;Weight;
KIRP	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg15896084	chr13:114927664	NA	-0.45	-5.99	-0.36	7.42e-9	Schizophrenia;
KIRP	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs73198271	1.000	rs11776513	chr8:8609057	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.8	-0.35	2.01e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg19847130	chr8:10466454	RP1L1	0.37	5.53	0.33	8.36e-8	Retinal vascular caliber;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.6	8.36	0.47	4.72e-15	Longevity;Endometriosis;
KIRP	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-7.6	-0.44	6.12e-13	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	0.9	13.14	0.64	3.03e-30	Dupuytren's disease;
KIRP	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.73	-0.6	1.61e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17297254	chr11:33375412	HIPK3	0.36	6.25	0.37	1.85e-9	C-reactive protein;
KIRP	cis	rs741951	0.887	rs56399780	chr21:46265500	T/C	cg08823554	chr21:46269191	NA	-0.72	-6.42	-0.38	6.93e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg26875233	chr11:93583750	C11orf90	-0.28	-5.57	-0.33	6.69e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.19	0.31	4.32e-7	Lung cancer;
KIRP	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.7	0.48	4.98e-16	Colorectal cancer;
KIRP	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg10932868	chr11:921992	NA	0.7	9.58	0.52	1.15e-18	Alzheimer's disease (late onset);
KIRP	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	trans	rs1941687	1.000	rs1941687	chr18:31334667	A/C	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.25e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg05347473	chr6:146136440	FBXO30	-0.46	-6.54	-0.39	3.43e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7119	0.643	rs12904384	chr15:77410878	T/G	cg17802220	chr15:77601643	NA	-0.36	-5.14	-0.31	5.71e-7	Type 2 diabetes;
KIRP	cis	rs4794202	0.579	rs9904503	chr17:45884372	T/C	cg02219949	chr17:45927392	SP6	0.62	7.4	0.43	2.14e-12	Alzheimer's disease (cognitive decline);
KIRP	cis	rs33912345	0.695	rs1268616	chr14:60855039	T/A	cg27398547	chr14:60952738	C14orf39	-0.41	-5.55	-0.33	7.33e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.82	-9.22	-0.51	1.34e-17	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-8.04	-0.46	3.86e-14	Response to antipsychotic treatment;
KIRP	cis	rs2692947	0.726	rs13009727	chr2:96769883	C/G	cg23100626	chr2:96804247	ASTL	-0.52	-7.63	-0.44	5.06e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.76	-7.52	-0.43	1.03e-12	Gut microbiome composition (summer);
KIRP	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg02640540	chr1:67518911	SLC35D1	0.4	4.95	0.3	1.36e-6	Lymphocyte percentage of white cells;
KIRP	trans	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg26043149	chr18:55253948	FECH	0.51	6.19	0.37	2.5e-9	Bone mineral density;
KIRP	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.94	16.31	0.72	4.84e-41	Breast cancer;
KIRP	cis	rs28595532	0.925	rs10000445	chr4:119485311	C/T	cg21605333	chr4:119757512	SEC24D	1.36	9.38	0.51	4.61e-18	Cannabis dependence symptom count;
KIRP	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.83	8.25	0.47	9.74e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.48	-5.86	-0.35	1.47e-8	Asthma (sex interaction);
KIRP	trans	rs1864585	0.520	rs11998382	chr8:10659517	A/G	cg26278703	chr11:58910052	FAM111A	0.63	6.38	0.38	8.92e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs4938534	0.533	rs1806397	chr11:111264915	T/C	cg24049888	chr11:111250129	POU2AF1	0.38	6.49	0.38	4.7e-10	Primary biliary cholangitis;
KIRP	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg17757837	chr7:157058334	UBE3C	0.78	10.53	0.56	1.2e-21	Body mass index;
KIRP	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.58	5.41	0.33	1.48e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg05562828	chr17:3906858	NA	0.42	5.23	0.32	3.68e-7	Type 2 diabetes;
KIRP	cis	rs490234	0.902	rs12351538	chr9:128281503	A/G	cg14078157	chr9:128172775	NA	-0.4	-5.07	-0.31	7.91e-7	Mean arterial pressure;
KIRP	cis	rs1318772	1.000	rs66629800	chr5:112712238	G/T	cg12552261	chr5:112820674	MCC	0.72	5.15	0.31	5.37e-7	F-cell distribution;
KIRP	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	cg04338863	chr8:33670619	NA	0.48	6.31	0.37	1.31e-9	Body mass index;
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg24874828	chr4:187887005	NA	-0.48	-7.13	-0.41	1.08e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.82	-0.35	1.82e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.59	-5.92	-0.35	1.1e-8	Schizophrenia;
KIRP	cis	rs34779708	0.702	rs4244995	chr10:35547175	A/G	cg03585969	chr10:35415529	CREM	0.57	6.62	0.39	2.23e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg12486944	chr17:80159399	CCDC57	-0.41	-5.54	-0.33	7.84e-8	Life satisfaction;
KIRP	cis	rs71277158	0.688	rs76646441	chr3:169885103	A/G	cg04067573	chr3:169899625	PHC3	0.67	6.33	0.37	1.18e-9	Prostate cancer;
KIRP	cis	rs3779635	0.967	rs750538	chr8:27275726	G/T	cg14221460	chr8:27183342	PTK2B	0.44	5.73	0.34	2.98e-8	Neuroticism;
KIRP	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg03929089	chr4:120376271	NA	0.75	6.59	0.39	2.59e-10	Axial length;
KIRP	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.77	0.49	2.92e-16	IgG glycosylation;
KIRP	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.61	6.05	0.36	5.34e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	7.65	0.44	4.51e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-5.74	-0.34	2.73e-8	Educational attainment;
KIRP	cis	rs5753037	0.753	rs131289	chr22:30161133	C/G	cg01021169	chr22:30184971	ASCC2	-0.5	-5.84	-0.35	1.62e-8	Type 1 diabetes;
KIRP	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	0.72	7.67	0.44	3.91e-13	Pediatric autoimmune diseases;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08186508	chr14:68067006	PIGH	0.48	6.06	0.36	5.09e-9	Parkinson's disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12356431	chr5:177591266	NA	0.56	6.3	0.37	1.36e-9	Lung cancer in ever smokers;
KIRP	cis	rs4720750	0.510	rs4725016	chr7:7762152	G/A	cg12383621	chr7:7735611	RPA3	-0.4	-4.89	-0.3	1.81e-6	Neuroticism;
KIRP	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg00933542	chr6:150070202	PCMT1	0.26	4.94	0.3	1.41e-6	Testicular germ cell tumor;
KIRP	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg12315302	chr6:26189340	HIST1H4D	-0.91	-6.27	-0.37	1.58e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg05785598	chr3:49045655	WDR6	0.32	5.83	0.35	1.76e-8	Parkinson's disease;
KIRP	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	0.75	6.68	0.39	1.55e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-7.26	-0.42	5.12e-12	Common traits (Other);
KIRP	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.74	-10.93	-0.57	6.31e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.58	-6.75	-0.4	1.08e-10	Menarche (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02958133	chr14:50779008	ATP5S;L2HGDH	-0.58	-6.6	-0.39	2.54e-10	Interleukin-4 levels;
KIRP	cis	rs9488822	0.585	rs7756746	chr6:116239881	C/T	cg05304507	chr6:116381966	FRK	-0.23	-5.45	-0.33	1.2e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg04374321	chr14:90722782	PSMC1	0.88	13.13	0.64	3.48e-30	Mortality in heart failure;
KIRP	cis	rs1978968	1.000	rs1076540	chr22:18439958	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.89	-0.4	4.64e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.43	-5.14	-0.31	5.74e-7	Facial morphology (factor 20);
KIRP	cis	rs6580649	0.941	rs10492080	chr12:48501411	A/G	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg09201719	chr10:104596890	CYP17A1	0.36	5.14	0.31	5.55e-7	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs11997175	0.603	rs12156112	chr8:33791598	T/C	ch.8.33884649F	chr8:33765107	NA	0.45	5.43	0.33	1.32e-7	Body mass index;
KIRP	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg24253500	chr15:84953950	NA	-0.53	-6.46	-0.38	5.69e-10	Schizophrenia;
KIRP	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.42	-5.36	-0.32	1.9e-7	Blood protein levels;
KIRP	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg01872077	chr2:219646372	CYP27A1	0.43	5.61	0.34	5.57e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs7712401	0.765	rs10079941	chr5:122381363	G/A	cg19412675	chr5:122181750	SNX24	0.42	4.88	0.3	1.87e-6	Mean platelet volume;
KIRP	cis	rs4308124	0.708	rs2137168	chr2:111986509	C/T	cg04571233	chr2:111982156	NA	-0.61	-6.6	-0.39	2.58e-10	Vitiligo;
KIRP	cis	rs240764	0.782	rs369125	chr6:101118400	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Bladder cancer;
KIRP	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg05347473	chr6:146136440	FBXO30	0.6	8.45	0.47	2.51e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17321999	0.904	rs6708792	chr2:30468860	C/T	cg05247661	chr2:30472410	LBH	0.73	7.54	0.43	9.07e-13	Systemic lupus erythematosus;
KIRP	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.53	5.44	0.33	1.27e-7	Menarche (age at onset);
KIRP	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg25039879	chr17:56429692	SUPT4H1	0.57	5.11	0.31	6.58e-7	Cognitive test performance;
KIRP	cis	rs4742903	0.509	rs1507506	chr9:106956123	A/G	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	2.04e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs144658219	1	rs144658219	chr7:80296965	G/GTACTTGAT	cg21369886	chr7:80305251	CD36	-0.38	-5.2	-0.31	4.23e-7	Red blood cell count;
KIRP	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.78	-0.35	2.3e-8	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg18478394	chr8:109455254	TTC35	0.53	6.55	0.39	3.34e-10	Dupuytren's disease;
KIRP	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	7.37	0.43	2.57e-12	Joint mobility (Beighton score);
KIRP	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.46	6.07	0.36	4.8e-9	Hypertriglyceridemia;
KIRP	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.57	-7.15	-0.41	9.9e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Electroencephalogram traits;
KIRP	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-8.0	-0.45	5e-14	Response to antipsychotic treatment;
KIRP	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg06598544	chr20:61472147	COL9A3	-0.77	-5.78	-0.35	2.26e-8	Obesity-related traits;
KIRP	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg06027949	chr8:82754900	SNX16	-0.61	-6.61	-0.39	2.34e-10	Diastolic blood pressure;
KIRP	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.68	9.17	0.5	1.93e-17	Systemic lupus erythematosus;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15112923	chr1:173155033	TNFSF4	0.45	6.11	0.36	3.79e-9	Interleukin-4 levels;
KIRP	cis	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg07585502	chr8:101912084	NA	-0.63	-9.0	-0.5	6.29e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg20991723	chr1:152506922	NA	-0.45	-5.22	-0.32	3.88e-7	Hair morphology;
KIRP	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.61	-0.34	5.41e-8	Joint mobility (Beighton score);
KIRP	cis	rs2072732	0.861	rs56176404	chr1:2940998	A/G	cg11731671	chr1:2995604	PRDM16	-0.55	-5.96	-0.36	8.67e-9	Plateletcrit;
KIRP	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.66	0.48	6.15e-16	Motion sickness;
KIRP	cis	rs2219968	0.692	rs9657044	chr8:78942084	A/G	cg00738934	chr8:78996279	NA	-0.37	-5.02	-0.3	1e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12143943	0.966	rs12038102	chr1:204551407	G/A	cg20240347	chr1:204465584	NA	-0.36	-6.66	-0.39	1.82e-10	Cognitive performance;
KIRP	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg14675211	chr2:100938903	LONRF2	-0.46	-5.43	-0.33	1.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs829661	0.512	rs11676852	chr2:30792898	A/C	cg10949345	chr2:30726833	LCLAT1	0.44	6.18	0.37	2.71e-9	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.09e-8	Life satisfaction;
KIRP	cis	rs10186029	0.509	rs2371793	chr2:213945082	G/C	cg08319019	chr2:214017104	IKZF2	-0.46	-5.46	-0.33	1.18e-7	Systemic sclerosis;
KIRP	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.47	0.48	2.31e-15	Alzheimer's disease;
KIRP	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg11584989	chr19:19387371	SF4	-0.41	-5.27	-0.32	2.99e-7	Tonsillectomy;
KIRP	cis	rs4845459	0.967	rs4112787	chr1:152551325	A/G	cg07796016	chr1:152779584	LCE1C	0.43	5.12	0.31	6.13e-7	Psoriasis;
KIRP	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.87	11.87	0.6	5.33e-26	Glomerular filtration rate (creatinine);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg16725865	chr1:92546135	BTBD8	0.52	6.53	0.38	3.76e-10	Asthma;
KIRP	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.43	-5.33	-0.32	2.22e-7	Aortic root size;
KIRP	cis	rs7671900	1.000	rs7671900	chr4:88266289	G/A	cg23841344	chr4:88312519	HSD17B11	-0.55	-7.12	-0.41	1.22e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.65	9.35	0.51	5.5e-18	Lymphocyte counts;
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg06815112	chr8:27182871	PTK2B	0.51	6.62	0.39	2.27e-10	Neuroticism;
KIRP	cis	rs16912285	0.748	rs7952223	chr11:24256443	G/C	ch.11.24196551F	chr11:24239977	NA	0.82	9.19	0.51	1.74e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.55	-7.33	-0.42	3.33e-12	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07506299	chr16:30389104	MYLPF	0.43	6.09	0.36	4.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg04289385	chr6:36355825	ETV7	0.43	6.85	0.4	5.85e-11	Platelet distribution width;
KIRP	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00166722	chr3:10149974	C3orf24	0.47	4.85	0.3	2.15e-6	Alzheimer's disease;
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.25	-5.27	-0.32	3e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg03959625	chr15:84868606	LOC388152	0.6	6.63	0.39	2.12e-10	Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15615436	chr19:50354304	PTOV1	-0.45	-6.03	-0.36	5.87e-9	Metabolic traits;
KIRP	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.62	-8.0	-0.45	4.85e-14	Colorectal cancer;
KIRP	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.81	-0.45	1.63e-13	Body mass index;
KIRP	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.78	-0.44	2.03e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7618501	0.521	rs11712056	chr3:49914397	T/C	cg24110177	chr3:50126178	RBM5	-0.77	-10.8	-0.57	1.63e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19524238	chr7:2802976	GNA12	-0.39	-5.25	-0.32	3.37e-7	Height;
KIRP	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg19592336	chr6:28129416	ZNF389	0.44	4.94	0.3	1.44e-6	Parkinson's disease;
KIRP	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.22	-0.42	6.44e-12	Menopause (age at onset);
KIRP	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg07884673	chr3:53033167	SFMBT1	0.87	6.92	0.4	3.97e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg20965017	chr5:231967	SDHA	0.58	6.69	0.39	1.52e-10	Breast cancer;
KIRP	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.45	5.74	0.34	2.83e-8	Birth weight;
KIRP	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg00319359	chr11:70116639	PPFIA1	0.82	6.46	0.38	5.59e-10	Coronary artery disease;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.43	-0.38	6.67e-10	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10892158	chr8:24857894	NA	0.61	8.25	0.47	9.45e-15	Smoking initiation;
KIRP	cis	rs960902	0.592	rs10199137	chr2:37735381	C/T	cg25341268	chr2:37734390	NA	-0.6	-8.53	-0.48	1.5e-15	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	6.21	0.37	2.26e-9	Ulcerative colitis;
KIRP	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-7.68	-0.44	3.71e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg24747557	chr10:131355152	MGMT	-0.46	-6.31	-0.37	1.26e-9	Response to temozolomide;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg27302870	chr10:43904768	HNRNPF	-0.47	-6.55	-0.39	3.3e-10	Hippocampal sclerosis of aging;
KIRP	cis	rs7116495	1.000	rs7121260	chr11:71700566	C/T	cg26138937	chr11:71823887	C11orf51	-0.64	-5.32	-0.32	2.38e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2033732	0.706	rs7835031	chr8:85076187	C/T	cg05716166	chr8:85095498	RALYL	0.58	6.56	0.39	3.15e-10	Body mass index;
KIRP	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg05861140	chr6:150128134	PCMT1	-0.49	-6.96	-0.41	3.1e-11	Lung cancer;
KIRP	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.43	5.9	0.35	1.18e-8	Coronary artery disease;
KIRP	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.71	0.44	3.07e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.85	-8.9	-0.49	1.27e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs2077654	0.556	rs2299638	chr11:17443587	A/G	cg25308976	chr11:17434268	ABCC8	-0.64	-7.15	-0.42	9.61e-12	Gout;
KIRP	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.42	-5.33	-0.32	2.26e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg04935436	chr20:30431758	NA	0.52	6.38	0.38	8.56e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.66	10.48	0.56	1.74e-21	Bone mineral density;
KIRP	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.77	-10.44	-0.55	2.31e-21	Huntington's disease progression;
KIRP	cis	rs72772090	0.908	rs11750510	chr5:96042095	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.51	-4.89	-0.3	1.8e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10012599	chr11:46744754	F2	0.5	6.73	0.39	1.18e-10	Survival in pancreatic cancer;
KIRP	cis	rs10073892	0.619	rs10041015	chr5:101712324	C/T	cg19774478	chr5:101632501	SLCO4C1	-0.46	-5.23	-0.32	3.71e-7	Cognitive decline (age-related);
KIRP	cis	rs9826463	1.000	rs6440097	chr3:142331719	G/C	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs812925	1.000	rs4672441	chr2:61638952	T/C	cg15711740	chr2:61764176	XPO1	0.46	5.28	0.32	2.83e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	trans	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.54	6.1	0.36	4.04e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.77	0.35	2.4e-8	Bipolar disorder;
KIRP	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg03959625	chr15:84868606	LOC388152	0.51	6.07	0.36	4.83e-9	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17848848	chr1:77956526	AK5	-0.41	-6.2	-0.37	2.33e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.8	-11.73	-0.6	1.61e-25	Obesity-related traits;
KIRP	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.71	-8.66	-0.48	6.42e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.39	-0.47	3.92e-15	Triglycerides;
KIRP	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26690034	chr1:75198963	CRYZ;TYW3	-0.42	-5.07	-0.31	7.83e-7	Resistin levels;
KIRP	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18255839	chr2:239335447	ASB1	0.41	4.92	0.3	1.59e-6	Multiple system atrophy;
KIRP	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.96	11.18	0.58	1.01e-23	Corneal astigmatism;
KIRP	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.81	-10.68	-0.56	4.01e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg09695851	chr17:3907499	NA	0.52	5.35	0.32	1.98e-7	Type 2 diabetes;
KIRP	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.59	-8.71	-0.49	4.6e-16	Electroencephalogram traits;
KIRP	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.26	-16.73	-0.73	1.86e-42	Corneal structure;
KIRP	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.93	10.22	0.55	1.11e-20	Alzheimer's disease;
KIRP	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.91	-0.35	1.15e-8	Educational attainment;
KIRP	cis	rs6973256	0.897	rs17601462	chr7:133347066	A/G	cg10665199	chr7:133106180	EXOC4	-0.5	-6.31	-0.37	1.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12580194	0.593	rs61957943	chr12:55749330	A/G	cg11794356	chr12:55725991	OR6C3	-0.55	-7.73	-0.44	2.69e-13	Cancer;
KIRP	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.14e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg23100626	chr2:96804247	ASTL	0.46	5.92	0.35	1.05e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs2652822	0.525	rs58789072	chr15:63497553	G/A	cg02713581	chr15:63449717	RPS27L	0.47	5.33	0.32	2.23e-7	Metabolic traits;
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.57	-7.48	-0.43	1.31e-12	Aortic root size;
KIRP	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg25019033	chr10:957182	NA	-0.65	-7.9	-0.45	9.17e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs6888304	0.589	rs13162806	chr5:31058626	G/A	cg10919204	chr5:31193340	CDH6	0.37	4.86	0.3	2.09e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	8.55	0.48	1.36e-15	Neuroticism;
KIRP	cis	rs12210905	1.000	rs12214848	chr6:27063348	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.58	-0.39	2.81e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg03834567	chr2:218808745	TNS1	0.46	5.45	0.33	1.22e-7	Ulcerative colitis;
KIRP	cis	rs899997	0.773	rs7178423	chr15:78964961	T/G	cg04896959	chr15:78267971	NA	0.61	5.64	0.34	4.59e-8	Coronary artery disease or large artery stroke;
KIRP	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.54	6.98	0.41	2.65e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22496380	chr5:211416	CCDC127	0.79	9.16	0.5	2.08e-17	Breast cancer;
KIRP	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-5.85	-0.35	1.53e-8	Crohn's disease;
KIRP	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	cg04338863	chr8:33670619	NA	0.41	5.31	0.32	2.44e-7	Body mass index;
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg24874828	chr4:187887005	NA	-0.48	-7.14	-0.41	1.03e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6546886	0.912	rs7584777	chr2:74317747	T/C	cg14702570	chr2:74259524	NA	-0.32	-6.42	-0.38	6.97e-10	Dialysis-related mortality;
KIRP	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.61	-8.13	-0.46	2.07e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.6	-0.44	6.15e-13	Retinal vascular caliber;
KIRP	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg01403660	chr11:68851641	TPCN2	0.59	5.98	0.36	7.68e-9	Blond vs. brown hair color;
KIRP	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg04539111	chr16:67997858	SLC12A4	-0.61	-6.3	-0.37	1.34e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	7.68	0.44	3.69e-13	Migraine;Coronary artery disease;
KIRP	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.49	-0.43	1.23e-12	Type 2 diabetes;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-5.02	-0.3	9.86e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.61	6.76	0.4	1.02e-10	Menarche (age at onset);
KIRP	cis	rs742614	0.533	rs2092737	chr20:32428135	A/C	cg06304546	chr20:32448765	NA	-0.78	-12.01	-0.61	1.88e-26	Stearic acid (18:0) levels;
KIRP	trans	rs7246760	0.867	rs66927855	chr19:9811728	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.02	-0.54	4.82e-20	Pursuit maintenance gain;
KIRP	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.71	8.93	0.49	1.05e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.31	0.47	6.48e-15	Total body bone mineral density;
KIRP	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08048268	chr3:133502702	NA	-0.4	-4.97	-0.3	1.25e-6	Iron status biomarkers;
KIRP	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg02696742	chr7:106810147	HBP1	-0.81	-8.24	-0.47	1.01e-14	Coronary artery disease;
KIRP	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.58	-0.34	6.18e-8	Neutrophil percentage of white cells;
KIRP	cis	rs10214930	0.697	rs1880370	chr7:27583312	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.96	0.3	1.31e-6	Hypospadias;
KIRP	cis	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg27487796	chr7:28973253	NA	-0.22	-5.35	-0.32	2e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.81	-11.72	-0.6	1.63e-25	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6893807	0.623	rs112862634	chr5:87970352	G/C	cg24804195	chr5:87968844	LOC645323	0.54	5.29	0.32	2.65e-7	Body mass index;
KIRP	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.46	-7.12	-0.41	1.21e-11	Coronary artery disease;
KIRP	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.95	13.04	0.64	6.55e-30	Multiple sclerosis;
KIRP	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg06766960	chr11:133703094	NA	-0.46	-5.82	-0.35	1.78e-8	Childhood ear infection;
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg02462569	chr6:150064036	NUP43	-0.33	-4.86	-0.3	2.07e-6	Lung cancer;
KIRP	cis	rs7852872	0.734	rs767432	chr9:119258187	C/T	cg13792444	chr9:119245443	ASTN2	0.4	5.77	0.35	2.35e-8	Hippocampal volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00540891	chr10:43572244	RET	0.45	6.5	0.38	4.41e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-6.38	-0.38	8.91e-10	Lung cancer;
KIRP	cis	rs460214	0.576	rs28446127	chr21:40029568	C/A	cg05519781	chr21:40033154	ERG	-0.45	-4.95	-0.3	1.39e-6	Response to cognitive-behavioural therapy in anxiety disorder;
KIRP	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.73	-9.76	-0.53	3.06e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.38	5.14	0.31	5.64e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg23649088	chr2:200775458	C2orf69	0.39	5.08	0.31	7.37e-7	QT interval;
KIRP	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg07166546	chr14:35805898	NA	-0.27	-6.32	-0.37	1.21e-9	Psoriasis;
KIRP	trans	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	8.06	0.46	3.37e-14	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs897080	0.552	rs1068714	chr2:44634063	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.95	0.35	8.95e-9	Height;
KIRP	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg25547332	chr5:131281432	NA	-0.51	-6.15	-0.37	3.04e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-6.14	-0.36	3.32e-9	Fear of minor pain;
KIRP	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.6	-7.01	-0.41	2.27e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	10.37	0.55	3.85e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.69	-10.09	-0.54	2.99e-20	Lung cancer;
KIRP	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg13385521	chr17:29058706	SUZ12P	0.74	6.47	0.38	5.25e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7646881	1.000	rs59313096	chr3:158452242	G/C	cg19483011	chr3:158453295	NA	-0.58	-6.35	-0.38	1.03e-9	Tetralogy of Fallot;
KIRP	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg12435725	chr3:58293450	RPP14	-0.5	-5.43	-0.33	1.36e-7	Cholesterol, total;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13471184	chr18:44702735	IER3IP1	0.57	7.24	0.42	5.58e-12	Parkinson's disease;
KIRP	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.56	6.26	0.37	1.71e-9	Breast cancer;
KIRP	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg14829360	chr17:73884958	NA	-0.59	-7.86	-0.45	1.21e-13	Psoriasis;
KIRP	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg05072774	chr3:49840536	C3orf54	-0.41	-5.1	-0.31	6.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9783347	1.000	rs4150641	chr11:18370739	C/A	cg15585147	chr11:18324498	HPS5	0.37	4.98	0.3	1.2e-6	Pancreatic cancer;
KIRP	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg23594656	chr7:65796392	TPST1	-0.45	-6.27	-0.37	1.62e-9	Aortic root size;
KIRP	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg26248373	chr2:1572462	NA	-0.8	-10.9	-0.57	8.14e-23	IgG glycosylation;
KIRP	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs8067287	0.708	rs56408153	chr17:16841034	G/C	cg26910001	chr17:16838321	NA	-0.63	-6.02	-0.36	6.16e-9	Diabetic kidney disease;
KIRP	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.58	-0.33	6.47e-8	Aortic root size;
KIRP	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.92	-0.53	1e-19	Triglycerides;
KIRP	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.82	-12.23	-0.62	3.4e-27	Asthma;
KIRP	cis	rs2790457	0.792	rs1265845	chr10:28927223	C/T	cg05705492	chr10:28955341	NA	-0.55	-8.22	-0.46	1.16e-14	Multiple myeloma;
KIRP	cis	rs62413470	1.000	rs12209529	chr6:55932278	C/T	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.38	-4.93	-0.3	1.48e-6	Urate levels;
KIRP	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.68	9.4	0.51	4.01e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg20651018	chr11:3035856	CARS	-0.38	-5.32	-0.32	2.28e-7	Longevity;
KIRP	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs11779988	0.528	rs376771	chr8:17864985	G/A	cg01800426	chr8:17659068	MTUS1	-0.55	-5.81	-0.35	1.89e-8	Breast cancer;
KIRP	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.8	11.04	0.58	2.87e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7615316	0.934	rs4273389	chr3:142213930	A/G	cg20824294	chr3:142316082	PLS1	0.23	4.96	0.3	1.3e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.56	6.99	0.41	2.61e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.13	-0.31	5.9e-7	Multiple sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01395659	chr5:6633232	NSUN2;SRD5A1	0.45	6.1	0.36	4.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11997175	0.655	rs4380889	chr8:33663381	C/T	cg04338863	chr8:33670619	NA	0.4	5.45	0.33	1.25e-7	Body mass index;
KIRP	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	5.98	0.36	7.8e-9	Height;
KIRP	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.95	-14.56	-0.68	4.69e-35	Bipolar disorder;
KIRP	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.52	6.85	0.4	5.89e-11	HDL cholesterol;
KIRP	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.03	-0.41	2e-11	Initial pursuit acceleration;
KIRP	cis	rs1975991	0.576	rs6767993	chr3:187969897	G/A	cg17585528	chr3:187988060	LPP	-0.5	-5.87	-0.35	1.39e-8	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.51	-7.17	-0.42	8.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.59	-0.48	1.04e-15	Joint mobility (Beighton score);
KIRP	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-9.0	-0.5	6.35e-17	Vitiligo;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04777683	chr1:185286462	IVNS1ABP	0.45	6.07	0.36	4.84e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg11130432	chr3:121712080	ILDR1	-0.46	-5.45	-0.33	1.2e-7	Multiple sclerosis;
KIRP	cis	rs73086581	1.000	rs14047	chr20:3914215	G/A	cg02187196	chr20:3869020	PANK2	0.5	4.9	0.3	1.76e-6	Response to antidepressants in depression;
KIRP	cis	rs12208915	0.848	rs955765	chr6:79532610	C/T	cg18132916	chr6:79620363	NA	0.53	4.92	0.3	1.62e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	cg12689670	chr1:183009347	LAMC1	0.42	6.09	0.36	4.29e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.37	5.56	0.33	7.01e-8	Platelet distribution width;
KIRP	cis	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg21546286	chr11:48923668	NA	0.45	5.49	0.33	9.82e-8	HDL cholesterol;
KIRP	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-6.72	-0.39	1.28e-10	Mean platelet volume;
KIRP	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.34e-8	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7539542	0.556	rs4950889	chr1:202874786	T/C	cg08940984	chr1:202857613	RABIF	0.46	5.79	0.35	2.15e-8	Mean platelet volume;
KIRP	cis	rs829661	0.793	rs2602799	chr2:30849319	C/A	cg10949345	chr2:30726833	LCLAT1	1.14	13.85	0.66	1.27e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9534288	0.619	rs9526143	chr13:46675991	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.29	-0.47	7.37e-15	Blood protein levels;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00601350	chr5:178450758	ZNF879	-0.49	-6.48	-0.38	5.01e-10	Morning vs. evening chronotype;
KIRP	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09203029	chr20:61431311	C20orf20	-0.45	-6.49	-0.38	4.78e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.58	7.94	0.45	6.98e-14	Depressive symptoms;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg13206674	chr6:150067644	NUP43	0.6	8.84	0.49	1.92e-16	Lung cancer;
KIRP	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg09888468	chr15:81410853	NA	0.57	6.62	0.39	2.28e-10	QT interval (drug interaction);
KIRP	cis	rs11638352	0.661	rs2042738	chr15:44426553	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.06	-0.36	5.1e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.7	7.57	0.43	7.49e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05267876	chr1:229644265	NUP133	0.58	7.27	0.42	4.63e-12	Parkinson's disease;
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.67	0.34	4.02e-8	Lung cancer;
KIRP	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.64	8.55	0.48	1.33e-15	Bladder cancer;
KIRP	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.89	-0.45	9.9e-14	Morning vs. evening chronotype;
KIRP	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.79	8.26	0.47	9.11e-15	Bipolar disorder;
KIRP	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.77	-10.27	-0.55	8.15e-21	Aortic root size;
KIRP	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.81	9.21	0.51	1.53e-17	High light scatter reticulocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00568984	chr19:7712354	STXBP2	-0.44	-6.03	-0.36	5.94e-9	Parkinson's disease;
KIRP	cis	rs9880406	1.000	rs9880406	chr3:126049305	C/T	cg15490784	chr3:126061950	KLF15	0.45	4.99	0.3	1.15e-6	Macular telangiectasia type 2;
KIRP	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg15128208	chr22:42549153	NA	-0.64	-5.72	-0.34	3.06e-8	Birth weight;
KIRP	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-6.04	-0.36	5.79e-9	Breast cancer;
KIRP	cis	rs10924970	0.967	rs2185021	chr1:235452744	G/A	cg26050004	chr1:235667680	B3GALNT2	0.4	4.96	0.3	1.32e-6	Asthma;
KIRP	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.87	13.02	0.64	7.87e-30	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg01879757	chr17:41196368	BRCA1	0.57	7.61	0.44	5.93e-13	Menopause (age at onset);
KIRP	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg10840412	chr1:235813424	GNG4	0.76	6.75	0.4	1.03e-10	Bipolar disorder;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.93	10.26	0.55	8.43e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs988913	1.000	rs9367601	chr6:54839162	G/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.51	-0.33	9.11e-8	Menarche (age at onset);
KIRP	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg20607798	chr8:58055168	NA	0.62	4.85	0.3	2.2e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6743226	0.870	rs4675966	chr2:242244342	T/C	cg10021735	chr2:242295487	FARP2	0.47	5.81	0.35	1.98e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00255919	chr5:131827918	IRF1	0.27	5.74	0.34	2.71e-8	Asthma (sex interaction);
KIRP	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg06795125	chr2:108905320	SULT1C2	0.48	8.49	0.48	1.94e-15	Blood pressure;
KIRP	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg02996583	chr8:142237188	SLC45A4	-0.43	-5.26	-0.32	3.14e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13922124	chr7:105221991	EFCAB10	-0.44	-6.34	-0.37	1.11e-9	Pancreatic cancer;
KIRP	cis	rs10129255	0.530	rs11624912	chr14:107129907	A/G	cg23076370	chr14:107095027	NA	-0.45	-5.61	-0.34	5.33e-8	Kawasaki disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05845236	chr13:67804635	PCDH9	0.52	6.87	0.4	5.28e-11	Parkinson's disease;
KIRP	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg04398451	chr17:18023971	MYO15A	-0.62	-8.35	-0.47	5.05e-15	Total body bone mineral density;
KIRP	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	1.02	18.01	0.75	8.31e-47	Leprosy;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03647317	chr4:187891568	NA	-0.73	-11.49	-0.59	9.39e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.47	6.74	0.39	1.11e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13192880	chr2:208994529	CRYGC	0.48	6.85	0.4	5.79e-11	Survival in pancreatic cancer;
KIRP	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg23587288	chr2:27483067	SLC30A3	-0.59	-7.22	-0.42	6.31e-12	Blood metabolite levels;
KIRP	cis	rs7017914	0.967	rs13272523	chr8:71641472	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.85e-7	Bone mineral density;
KIRP	cis	rs2671245	1.000	rs2671245	chr1:56179614	C/T	cg11523071	chr1:56160889	NA	0.4	6.3	0.37	1.33e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg09904177	chr6:26538194	HMGN4	0.45	6.04	0.36	5.71e-9	Schizophrenia;
KIRP	cis	rs12210905	0.920	rs9348759	chr6:27290888	C/T	cg11502198	chr6:26597334	ABT1	-0.8	-4.94	-0.3	1.43e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs2071403	0.933	rs938326	chr2:1401781	C/T	cg06500727	chr2:1417164	TPO	0.47	7.41	0.43	2.03e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.7	8.78	0.49	2.89e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.69	9.3	0.51	8.21e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs859767	0.501	rs10171371	chr2:135372159	C/T	cg12500956	chr2:135428796	TMEM163	-0.42	-5.67	-0.34	4.08e-8	Neuroticism;
KIRP	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg22563815	chr15:78856949	CHRNA5	0.52	8.04	0.46	3.85e-14	Sudden cardiac arrest;
KIRP	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.53	-8.42	-0.47	3.21e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	6.03	0.36	5.84e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4363385	0.747	rs1577965	chr1:152968294	T/C	cg13444842	chr1:152974279	SPRR3	-0.36	-5.01	-0.3	1.02e-6	Inflammatory skin disease;
KIRP	cis	rs7534824	0.625	rs12565777	chr1:101485794	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.38	0.32	1.71e-7	Refractive astigmatism;
KIRP	cis	rs8054556	1.000	rs9932196	chr16:29983119	G/T	cg06326092	chr16:30034487	C16orf92	0.36	5.3	0.32	2.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6725041	0.547	rs1505353	chr2:213203057	C/A	cg20637307	chr2:213403960	ERBB4	-0.48	-6.05	-0.36	5.36e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg23594656	chr7:65796392	TPST1	-0.46	-6.5	-0.38	4.46e-10	Aortic root size;
KIRP	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.4	9.82	0.53	2.03e-19	Corneal astigmatism;
KIRP	cis	rs12701220	0.895	rs3808348	chr7:1028448	C/T	cg00990874	chr7:1149470	C7orf50	-0.75	-7.77	-0.44	2.18e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg09695851	chr17:3907499	NA	-0.61	-8.3	-0.47	6.72e-15	Type 2 diabetes;
KIRP	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg04733989	chr22:42467013	NAGA	0.85	11.88	0.6	5.15e-26	Schizophrenia;
KIRP	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg16736954	chr20:23401023	NAPB	0.64	5.15	0.31	5.3e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7923609	0.846	rs10740116	chr10:65094992	T/C	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.48e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6929812	0.967	rs34185469	chr6:27391935	G/A	cg03332623	chr6:27441972	ZNF184	-0.35	-4.96	-0.3	1.31e-6	Neuroticism (multi-trait analysis);
KIRP	cis	rs9921338	1.000	rs8049173	chr16:11436882	G/A	cg00044050	chr16:11439710	C16orf75	-0.54	-5.77	-0.35	2.35e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.03	-0.36	5.86e-9	Obesity-related traits;
KIRP	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.79	6.4	0.38	7.67e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.76	11.4	0.59	1.87e-24	Skin aging (microtopography measurement);
KIRP	cis	rs72634030	0.536	rs7209903	chr17:5239296	A/G	cg20802942	chr17:5185005	RABEP1	0.54	5.32	0.32	2.34e-7	Rheumatoid arthritis;
KIRP	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.35	-4.94	-0.3	1.42e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg15691649	chr6:25882328	NA	-0.43	-4.92	-0.3	1.56e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg26207909	chr14:103986467	CKB	0.53	7.11	0.41	1.24e-11	Body mass index;
KIRP	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs5753037	0.754	rs4820824	chr22:30360915	G/A	cg01021169	chr22:30184971	ASCC2	-0.36	-4.96	-0.3	1.3e-6	Type 1 diabetes;
KIRP	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg01353569	chr7:106810328	HBP1	0.52	6.24	0.37	1.93e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.9	0.35	1.2e-8	Motion sickness;
KIRP	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.66	-0.34	4.18e-8	Type 2 diabetes;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg12736359	chr6:126964499	NA	0.38	6.03	0.36	5.97e-9	Migraine with aura;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04582539	chr19:9938647	UBL5	0.46	6.08	0.36	4.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.78	-0.35	2.24e-8	Breast cancer;
KIRP	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.46	-7.05	-0.41	1.78e-11	Coronary artery disease;
KIRP	cis	rs2235642	0.551	rs1966171	chr16:1562804	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-5.17	-0.31	4.83e-7	Coronary artery disease;
KIRP	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg04013166	chr16:89971882	TCF25	0.71	7.62	0.44	5.62e-13	Skin colour saturation;
KIRP	cis	rs10782582	0.609	rs12138898	chr1:76375183	G/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.22	-0.42	6.32e-12	Daytime sleep phenotypes;
KIRP	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg08462924	chr1:41848221	NA	0.45	6.55	0.39	3.35e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs228437	0.874	rs7743660	chr6:134943460	A/G	cg24504307	chr6:134963096	NA	-0.41	-6.5	-0.38	4.31e-10	Melanoma;
KIRP	cis	rs9473924	0.657	rs13197379	chr6:50869868	G/A	cg03432817	chr6:50765336	NA	0.34	5.37	0.32	1.81e-7	Body mass index;
KIRP	cis	rs17655565	0.581	rs73094908	chr12:52767984	C/T	cg07925835	chr12:52762777	KRT85	0.51	5.58	0.34	6.27e-8	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg11783602	chr8:55087084	NA	-0.58	-7.24	-0.42	5.82e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.43	-0.52	3.23e-18	Colorectal cancer;
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg26754761	chr2:177040938	NA	0.31	5.31	0.32	2.44e-7	IgG glycosylation;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg15105011	chr4:940614	TMEM175	0.48	7.05	0.41	1.83e-11	Sjögren's syndrome;
KIRP	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.78	-10.94	-0.57	5.66e-23	Dental caries;
KIRP	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs35995292	0.534	rs2008199	chr7:38939678	T/C	cg19327137	chr7:38886074	VPS41	0.84	13.11	0.64	3.78e-30	Subjective well-being (multi-trait analysis);
KIRP	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-0.88	-12.62	-0.63	1.7e-28	Dupuytren's disease;
KIRP	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.85	-0.6	6.52e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7429990	0.932	rs6766641	chr3:48145224	G/A	cg11946769	chr3:48343235	NME6	-0.52	-5.93	-0.35	1.01e-8	Educational attainment (years of education);
KIRP	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-6.82	-0.4	7.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.77	8.66	0.48	6.43e-16	Corneal astigmatism;
KIRP	cis	rs7312774	0.618	rs3803122	chr12:107354680	G/A	cg16260113	chr12:107380972	MTERFD3	0.82	7.16	0.42	9.52e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg06740227	chr12:86229804	RASSF9	0.4	5.07	0.31	7.84e-7	Major depressive disorder;
KIRP	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg09699651	chr6:150184138	LRP11	0.41	5.29	0.32	2.64e-7	Lung cancer;
KIRP	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	0.74	10.26	0.55	8.63e-21	Red blood cell count;
KIRP	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18357526	chr6:26021779	HIST1H4A	0.79	8.7	0.48	4.9e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	1.35	10.84	0.57	1.19e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.6	7.79	0.44	1.87e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11671005	0.735	rs11667723	chr19:58927489	A/G	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs6558530	0.965	rs6558535	chr8:1710632	T/C	cg08198773	chr8:1697536	NA	0.38	4.89	0.3	1.81e-6	Systolic blood pressure;
KIRP	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.6	-0.44	6.2800000000000005e-13	Bladder cancer;
KIRP	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg21546286	chr11:48923668	NA	-0.44	-5.63	-0.34	4.85e-8	HDL cholesterol;
KIRP	cis	rs17221829	0.536	rs7943784	chr11:89377310	G/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.89	-0.3	1.81e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7106204	0.609	rs34376029	chr11:24291233	C/T	ch.11.24196551F	chr11:24239977	NA	0.68	5.16	0.31	5.19e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.32	0.32	2.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.79	-9.64	-0.52	7.2e-19	Parkinson's disease;
KIRP	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.77	-0.35	2.34e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-7.79	-0.44	1.87e-13	Initial pursuit acceleration;
KIRP	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-1.12	-18.53	-0.76	1.46e-48	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.58	7.75	0.44	2.44e-13	Vitiligo;
KIRP	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.77	6.98	0.41	2.69e-11	Alzheimer's disease;
KIRP	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg21415424	chr6:37503074	NA	-0.33	-4.91	-0.3	1.62e-6	Cognitive performance;
KIRP	cis	rs4664293	0.867	rs10204867	chr2:160589185	C/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs13361707	1.000	rs28544962	chr5:40781187	T/C	cg01087697	chr5:40835557	RPL37	-0.45	-5.24	-0.32	3.48e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17456994	chr10:6130864	RBM17	0.48	6.67	0.39	1.66e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.81	-12.66	-0.63	1.32e-28	Blood metabolite levels;
KIRP	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.65	8.64	0.48	7.07e-16	Bladder cancer;
KIRP	trans	rs7550636	1.000	rs7534380	chr1:192805990	C/T	cg24249403	chr15:101189058	ASB7	0.45	6.34	0.37	1.1e-9	Coronary artery calcification;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	2.95e-7	Life satisfaction;
KIRP	cis	rs6142102	0.602	rs1054534	chr20:32605327	G/C	cg08999081	chr20:33150536	PIGU	0.38	4.88	0.3	1.92e-6	Skin pigmentation;
KIRP	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00166722	chr3:10149974	C3orf24	0.48	4.93	0.3	1.53e-6	Alzheimer's disease;
KIRP	cis	rs10073892	0.664	rs9327861	chr5:101867877	G/A	cg19774478	chr5:101632501	SLCO4C1	0.64	6.23	0.37	1.97e-9	Cognitive decline (age-related);
KIRP	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.73	9.24	0.51	1.17e-17	Mood instability;
KIRP	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg10223061	chr2:219282414	VIL1	-0.37	-6.1	-0.36	4.06e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4789452	1.000	rs4789452	chr17:75372850	G/A	cg05184938	chr17:75369939	SEPT9	-0.37	-5.06	-0.31	8.26e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	11.95	0.61	3.05e-26	Ulcerative colitis;
KIRP	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.43	-6.4	-0.38	7.74e-10	Height;
KIRP	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	0.84	10.73	0.56	2.87e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs981844	0.775	rs62324020	chr4:154763851	G/A	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.56	7.66	0.44	4.38e-13	Multiple system atrophy;
KIRP	cis	rs7106204	0.514	rs1443044	chr11:24255575	C/G	ch.11.24196551F	chr11:24239977	NA	-0.86	-10.33	-0.55	5.19e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7078012	0.504	rs11815922	chr10:81688079	G/A	cg24613050	chr10:81743128	NA	-0.53	-4.96	-0.3	1.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6997458	0.785	rs1389247	chr8:86322583	C/T	cg02393479	chr8:86352350	CA3	-0.33	-5.23	-0.32	3.62e-7	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4664308	0.618	rs4665138	chr2:160890427	C/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.02	-0.54	5.02e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg20701182	chr2:24300061	SF3B14	0.48	4.99	0.3	1.13e-6	Asthma;
KIRP	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.65	-0.34	4.35e-8	Schizophrenia;
KIRP	cis	rs1318772	0.932	rs13187776	chr5:112910850	G/A	cg12552261	chr5:112820674	MCC	0.87	5.02	0.31	9.77e-7	F-cell distribution;
KIRP	cis	rs13401104	0.587	rs62190974	chr2:237145263	C/T	cg26422059	chr2:237146110	ASB18	0.46	5.27	0.32	3.01e-7	Educational attainment;
KIRP	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.52	-6.2	-0.37	2.42e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg00599163	chr2:162100495	NA	-0.42	-4.91	-0.3	1.69e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.1	-0.36	4.1e-9	Alcohol dependence;
KIRP	cis	rs34375054	0.573	rs12823172	chr12:125646283	C/G	cg25124228	chr12:125621409	AACS	-0.59	-6.27	-0.37	1.61e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	1.1	20.42	0.79	6.93e-55	Bone mineral density;
KIRP	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg24253500	chr15:84953950	NA	0.59	6.91	0.4	4.13e-11	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27448595	chr11:875569	CHID1	0.48	6.18	0.37	2.65e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.61	8.68	0.48	5.56e-16	Colorectal cancer;
KIRP	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.76	-9.66	-0.52	6.4e-19	Coronary artery disease;
KIRP	cis	rs9815354	0.857	rs7652369	chr3:42020973	T/G	cg03022575	chr3:42003672	ULK4	0.63	6.93	0.4	3.6e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.63	-6.56	-0.39	3.23e-10	Bipolar disorder (body mass index interaction);
KIRP	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.4	5.29	0.32	2.73e-7	Hypertriglyceridemia;
KIRP	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg00012203	chr2:219082015	ARPC2	-0.59	-7.49	-0.43	1.26e-12	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	4.95	0.3	1.39e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.63	7.44	0.43	1.69e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg27205649	chr11:78285834	NARS2	0.58	7.33	0.42	3.25e-12	Alzheimer's disease (survival time);
KIRP	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.54	7.23	0.42	6.24e-12	Mean corpuscular volume;
KIRP	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg17691542	chr6:26056736	HIST1H1C	0.43	5.62	0.34	5.03e-8	Schizophrenia;
KIRP	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg11635098	chr7:100497156	NA	-0.64	-6.88	-0.4	4.96e-11	Resting heart rate;
KIRP	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	15.59	0.7	1.37e-38	Colorectal cancer;
KIRP	cis	rs7267005	1.000	rs41365845	chr20:34501151	A/G	cg17201900	chr20:34330562	RBM39	0.9	5.34	0.32	2.13e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9308731	0.583	rs4848406	chr2:111933758	G/A	cg18646521	chr2:111875858	NA	0.38	5.31	0.32	2.49e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg03161606	chr19:29218774	NA	-0.69	-5.63	-0.34	4.86e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg13615516	chr5:77269221	NA	0.51	7.91	0.45	8.95e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg08885076	chr2:99613938	TSGA10	-0.38	-5.46	-0.33	1.17e-7	Bipolar disorder;
KIRP	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.69	9.12	0.5	2.8e-17	Bladder cancer;
KIRP	cis	rs830124	0.714	rs1177589	chr12:122403933	A/G	cg12705353	chr12:122356852	WDR66	0.47	4.86	0.3	2.07e-6	Urinary metabolites;
KIRP	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg13010199	chr12:38710504	ALG10B	0.63	8.53	0.48	1.53e-15	Morning vs. evening chronotype;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02234820	chr1:85358327	LPAR3	0.8	6.16	0.37	2.97e-9	P wave terminal force;
KIRP	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.85	-0.49	1.79e-16	Total cholesterol levels;
KIRP	cis	rs7560272	0.723	rs12995433	chr2:73641326	C/T	cg20560298	chr2:73613845	ALMS1	0.4	4.94	0.3	1.46e-6	Schizophrenia;
KIRP	cis	rs57590327	0.504	rs4856349	chr3:81502928	C/T	cg07356753	chr3:81810745	GBE1	0.5	6.26	0.37	1.66e-9	Extraversion;
KIRP	cis	rs427941	0.703	rs10953358	chr7:101738226	T/C	cg06246474	chr7:101738831	CUX1	-0.54	-6.72	-0.39	1.24e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.11	-0.31	6.45e-7	IgG glycosylation;
KIRP	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.24e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2151522	0.762	rs9375471	chr6:127168152	A/C	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.51	-5.7	-0.34	3.44e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35300120	0.757	rs7518012	chr1:233651778	C/T	cg23054119	chr1:233659267	NA	-0.42	-5.89	-0.35	1.27e-8	Cognitive function;
KIRP	cis	rs1511802	0.625	rs7667777	chr4:187126077	C/G	cg24794857	chr4:187113578	CYP4V2	0.39	5.43	0.33	1.37e-7	Blood protein levels;
KIRP	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg04315214	chr1:2043799	PRKCZ	-0.36	-5.68	-0.34	3.87e-8	Height;
KIRP	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.76	-11.19	-0.58	9.27e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.95	0.3	1.4e-6	Tonsillectomy;
KIRP	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg26248373	chr2:1572462	NA	-0.8	-10.76	-0.57	2.17e-22	IgG glycosylation;
KIRP	cis	rs12220238	0.722	rs7901055	chr10:76415029	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.56	-6.02	-0.36	6.4e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg16049864	chr8:95962084	TP53INP1	-0.37	-5.82	-0.35	1.87e-8	Type 2 diabetes;
KIRP	cis	rs959260	1.000	rs2033609	chr17:73367021	C/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	1.09	13.74	0.66	2.79e-32	IgG glycosylation;
KIRP	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.69	-12.55	-0.62	3.01e-28	White blood cell count (basophil);
KIRP	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.38	-0.32	1.75e-7	Aortic root size;
KIRP	cis	rs490234	0.812	rs4329365	chr9:128445758	A/C	cg14078157	chr9:128172775	NA	-0.6	-7.1	-0.41	1.36e-11	Mean arterial pressure;
KIRP	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg13010199	chr12:38710504	ALG10B	0.64	7.93	0.45	7.79e-14	Morning vs. evening chronotype;
KIRP	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.57	-0.43	7.48e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.98	13.95	0.66	5.68e-33	Cognitive function;
KIRP	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg08975724	chr8:8085496	FLJ10661	0.63	8.79	0.49	2.68e-16	Neuroticism;
KIRP	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg05340658	chr4:99064831	C4orf37	-0.59	-7.27	-0.42	4.86e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.41	0.47	3.44e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9831754	0.756	rs13084140	chr3:78426004	G/A	cg06138941	chr3:78371609	NA	-0.76	-10.8	-0.57	1.65e-22	Calcium levels;
KIRP	cis	rs9326248	0.515	rs2727793	chr11:116683374	C/T	cg26566898	chr11:117069891	TAGLN	0.41	5.19	0.31	4.35e-7	Blood protein levels;
KIRP	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg22916017	chr11:64110731	CCDC88B	0.49	5.21	0.31	4.09e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs731174	0.722	rs553888	chr1:38152509	C/G	cg14170840	chr1:38155120	C1orf109	-0.41	-5.27	-0.32	3.04e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.74	0.71	4.27e-39	Headache;
KIRP	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.65	8.18	0.46	1.57e-14	Diastolic blood pressure;
KIRP	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-7.4	-0.43	2.15e-12	Gut microbiome composition (summer);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21411534	chr10:93558674	TNKS2	0.57	6.27	0.37	1.57e-9	Lung cancer in ever smokers;
KIRP	cis	rs35740288	0.770	rs11631018	chr15:86140534	G/A	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.49	6.3	0.37	1.39e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.62	-6.52	-0.38	3.94e-10	Initial pursuit acceleration;
KIRP	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.75	-9.09	-0.5	3.29e-17	Response to bleomycin (chromatid breaks);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23857200	chr19:39882127	MED29;PAF1	0.53	6.2	0.37	2.42e-9	Smoking initiation;
KIRP	cis	rs9309473	0.500	rs6546862	chr2:73860348	G/A	cg20560298	chr2:73613845	ALMS1	0.46	5.68	0.34	3.74e-8	Metabolite levels;
KIRP	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg21734707	chr17:3908241	ZZEF1	0.64	9.6	0.52	9.84e-19	Type 2 diabetes;
KIRP	cis	rs8033133	0.560	rs11161166	chr15:25324677	A/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.49	6.18	0.37	2.66e-9	Blood osmolality (transformed sodium);
KIRP	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21545522	chr1:205238299	TMCC2	0.5	6.55	0.39	3.37e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg04310649	chr10:35416472	CREM	-0.5	-5.87	-0.35	1.43e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6662572	0.737	rs6680647	chr1:46345478	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.62	0.34	5.05e-8	Blood protein levels;
KIRP	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg09060608	chr5:178986726	RUFY1	0.47	6.98	0.41	2.67e-11	Lung cancer;
KIRP	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.68	9.24	0.51	1.19e-17	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.94	12.25	0.62	2.93e-27	Menopause (age at onset);
KIRP	cis	rs8077577	0.708	rs2290502	chr17:18133495	G/A	cg18869244	chr17:18121946	NA	-0.44	-4.96	-0.3	1.31e-6	Obesity-related traits;
KIRP	cis	rs9372498	0.536	rs62422227	chr6:118957200	C/G	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.64	8.48	0.48	2.1e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.71	9.38	0.51	4.52e-18	Longevity;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg21186296	chr8:27182909	PTK2B	0.51	6.42	0.38	7.14e-10	Neuroticism;
KIRP	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.93	12.01	0.61	1.84e-26	Menopause (age at onset);
KIRP	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	7.63	0.44	5.01e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.82	-11.7	-0.6	1.97e-25	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.77	0.4	9.53e-11	Tonsillectomy;
KIRP	cis	rs12282928	0.802	rs1105164	chr11:48285025	G/A	cg26585981	chr11:48327164	OR4S1	0.47	5.2	0.31	4.15e-7	Migraine - clinic-based;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09318120	chr6:149638382	MAP3K7IP2	-0.54	-6.04	-0.36	5.58e-9	Menopause (age at onset);
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.5	6.73	0.39	1.21e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.01	0.41	2.33e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7267005	0.661	rs75742093	chr20:34409737	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs6032067	0.929	rs62205504	chr20:43867894	C/G	cg10761708	chr20:43804764	PI3	0.47	4.88	0.3	1.9e-6	Blood protein levels;
KIRP	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21545522	chr1:205238299	TMCC2	0.5	6.54	0.38	3.63e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	1.04	15.71	0.71	5.51e-39	Menopause (age at onset);
KIRP	cis	rs7083	1.000	rs495438	chr11:117144727	A/C	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.82	8.66	0.48	6.2e-16	Prostate cancer;
KIRP	cis	rs5769707	0.967	rs8141807	chr22:50043738	C/G	cg20744362	chr22:50050164	C22orf34	0.38	6.45	0.38	5.96e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs960902	0.818	rs2192942	chr2:37731493	C/T	cg25341268	chr2:37734390	NA	-0.49	-6.55	-0.39	3.42e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg00147788	chr6:125855365	NA	-0.32	-5.06	-0.31	8.07e-7	Brugada syndrome;
KIRP	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs72730918	0.564	rs1902596	chr15:51910875	A/G	cg14296394	chr15:51910925	DMXL2	-0.82	-11.32	-0.59	3.35e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.84	7.95	0.45	6.67e-14	Methadone dose in opioid dependence;
KIRP	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Colorectal cancer;
KIRP	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-7.33	-0.42	3.22e-12	Chronic sinus infection;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13079154	chr12:111180884	PPP1CC	0.48	6.13	0.36	3.41e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs714027	1.000	rs5763821	chr22:30549071	A/C	cg27665648	chr22:30112403	NA	-0.41	-5.84	-0.35	1.68e-8	Lymphocyte counts;
KIRP	trans	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg05059571	chr16:84539110	KIAA1609	-0.55	-7.23	-0.42	6.15e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg21161173	chr5:140098174	VTRNA1-2	-0.42	-5.28	-0.32	2.84e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2223471	0.546	rs627762	chr6:50584548	T/C	cg03432817	chr6:50765336	NA	-0.36	-5.32	-0.32	2.34e-7	Subcutaneous adipose tissue;
KIRP	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.96	13.05	0.64	6.47e-30	Multiple sclerosis;
KIRP	trans	rs7607659	1	rs7607659	chr2:105267490	C/T	cg11566521	chr4:160127802	NA	-0.67	-6.09	-0.36	4.4e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.75	7.27	0.42	4.73e-12	Vitiligo;
KIRP	cis	rs9311676	0.632	rs62258126	chr3:58396114	T/C	cg06643156	chr3:58380774	PXK	0.35	4.86	0.3	2.13e-6	Systemic lupus erythematosus;
KIRP	cis	rs9914544	0.564	rs11868500	chr17:18770254	A/G	cg26378065	chr17:18585709	ZNF286B	0.38	4.93	0.3	1.49e-6	Educational attainment (years of education);
KIRP	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg10755058	chr3:40428713	ENTPD3	0.44	6.22	0.37	2.1e-9	Renal cell carcinoma;
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.08	-0.5	3.68e-17	Platelet count;
KIRP	cis	rs12995491	0.933	rs34029976	chr2:88537797	T/C	cg04511125	chr2:88470314	THNSL2	-0.44	-5.5	-0.33	9.64e-8	Response to metformin (IC50);
KIRP	cis	rs4481887	0.604	rs4642918	chr1:248411057	A/C	cg01631408	chr1:248437212	OR2T33	0.46	5.22	0.32	3.9e-7	Common traits (Other);
KIRP	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg24803719	chr17:45855879	NA	-0.4	-5.39	-0.33	1.65e-7	IgG glycosylation;
KIRP	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	8.41	0.47	3.44e-15	Acne (severe);
KIRP	cis	rs2274459	0.749	rs2281831	chr6:33695815	G/A	cg06253072	chr6:33679850	C6orf125	0.52	5.63	0.34	5.02e-8	Obesity (extreme);
KIRP	cis	rs6584283	0.846	rs10883370	chr10:101291472	T/C	cg07044859	chr10:101282883	NA	-0.28	-5.06	-0.31	8.13e-7	Ulcerative colitis;
KIRP	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg03834567	chr2:218808745	TNS1	0.47	5.58	0.34	6.25e-8	Ulcerative colitis;
KIRP	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.95	11.37	0.59	2.4e-24	Corneal astigmatism;
KIRP	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.73e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12949688	1.000	rs7211686	chr17:55816300	T/C	cg12582317	chr17:55822272	NA	0.6	10.0	0.54	5.66e-20	Schizophrenia;
KIRP	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg05623727	chr3:50126028	RBM5	-0.36	-5.4	-0.33	1.6e-7	Body mass index;
KIRP	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.43	0.38	6.69e-10	Major depressive disorder;
KIRP	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg06740227	chr12:86229804	RASSF9	0.52	6.74	0.39	1.12e-10	Major depressive disorder;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg27121462	chr16:89883253	FANCA	0.62	8.84	0.49	1.87e-16	Vitiligo;
KIRP	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg11833968	chr6:79620685	NA	-0.45	-6.87	-0.4	5.14e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9409565	0.826	rs4744345	chr9:97207669	G/A	cg04523069	chr9:97136363	HIATL1	0.47	6.19	0.37	2.56e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs1298062	0.563	rs2445828	chr19:50941807	A/G	cg10687087	chr19:50962411	MYBPC2	0.44	5.1	0.31	6.85e-7	Age of smoking initiation;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg00738919	chr7:1100172	C7orf50	0.4	5.14	0.31	5.69e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs57561814	0.655	rs113221056	chr7:22743596	A/C	cg01770232	chr7:22766155	IL6	0.54	4.99	0.3	1.16e-6	Tonsillectomy;
KIRP	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg21385522	chr1:16154831	NA	0.5	6.35	0.38	1.01e-9	Dilated cardiomyopathy;
KIRP	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg03128534	chr1:43423976	SLC2A1	0.51	5.01	0.3	1.04e-6	Red cell distribution width;
KIRP	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-1.0	-15.86	-0.71	1.67e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg02903104	chr8:1507517	DLGAP2	0.39	5.87	0.35	1.37e-8	Lung cancer;
KIRP	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg01988459	chr11:68622903	NA	-0.43	-5.94	-0.35	9.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.75	9.21	0.51	1.45e-17	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.62	-0.34	5.06e-8	Aortic root size;
KIRP	trans	rs1106684	1.000	rs7457100	chr7:131465222	G/A	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18753341	chr7:157202405	DNAJB6	0.5	6.89	0.4	4.63e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	8.09	0.46	2.73e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg00405596	chr8:11794950	NA	-0.45	-5.8	-0.35	1.98e-8	Triglycerides;
KIRP	cis	rs405956	1.000	rs1018810	chr6:105559609	A/G	cg22580625	chr6:105627791	POPDC3	-0.62	-6.77	-0.4	9.65e-11	QT interval;
KIRP	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.93	10.97	0.57	4.78e-23	Cognitive ability;
KIRP	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg25797454	chr6:150327115	RAET1K	0.35	6.5	0.38	4.4e-10	Alopecia areata;
KIRP	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg07541023	chr7:19748670	TWISTNB	0.63	5.69	0.34	3.55e-8	Thyroid stimulating hormone;
KIRP	cis	rs775227	0.574	rs55693215	chr3:113064094	T/C	cg10517650	chr3:113235015	CCDC52	-0.41	-5.08	-0.31	7.45e-7	Dental caries;
KIRP	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg13010199	chr12:38710504	ALG10B	0.57	7.0	0.41	2.42e-11	Morning vs. evening chronotype;
KIRP	trans	rs4650994	0.623	rs12121188	chr1:178622499	G/A	cg05059571	chr16:84539110	KIAA1609	0.55	6.92	0.4	3.78e-11	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.39	4.98	0.3	1.21e-6	Platelet count;
KIRP	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.38	4.89	0.3	1.86e-6	Pulmonary function;
KIRP	cis	rs7651039	0.619	rs924814	chr3:15649550	G/A	cg16303742	chr3:15540471	COLQ	0.6	7.95	0.45	6.66e-14	Coronary heart disease;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg27144592	chr16:783916	NARFL	0.38	5.21	0.32	4.07e-7	Height;
KIRP	cis	rs714027	1.000	rs2412975	chr22:30540590	T/C	cg27665648	chr22:30112403	NA	-0.41	-5.9	-0.35	1.21e-8	Lymphocyte counts;
KIRP	cis	rs2494938	0.655	rs2494944	chr6:40542911	G/T	cg14084896	chr6:40530702	LRFN2	-0.4	-4.9	-0.3	1.78e-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.64	9.86	0.53	1.58e-19	Weight;
KIRP	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.29	7.93	0.45	7.44e-14	Crohn's disease;
KIRP	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.71	-0.39	1.36e-10	Renal cell carcinoma;
KIRP	cis	rs10214930	0.697	rs6974932	chr7:27696830	A/C	cg22168087	chr7:27702803	HIBADH	-0.46	-4.95	-0.3	1.37e-6	Hypospadias;
KIRP	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg21573476	chr21:45109991	RRP1B	-0.64	-8.62	-0.48	8.54e-16	Mean corpuscular volume;
KIRP	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.23	-6.27	-0.37	1.62e-9	Crohn's disease;
KIRP	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg06042504	chr8:55087323	NA	-0.53	-6.5	-0.38	4.46e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11317019	chr17:42219250	C17orf53	0.5	6.54	0.38	3.63e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.51	-0.33	9.05e-8	Breast cancer;
KIRP	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg23587288	chr2:27483067	SLC30A3	-0.67	-7.63	-0.44	5.13e-13	Blood metabolite levels;
KIRP	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg17595323	chr11:93583763	C11orf90	-0.37	-6.27	-0.37	1.59e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg10503236	chr1:231470652	EXOC8	-0.53	-7.44	-0.43	1.69e-12	Hemoglobin concentration;
KIRP	cis	rs6466055	0.720	rs2040914	chr7:104972174	A/G	cg04380332	chr7:105027541	SRPK2	0.55	8.35	0.47	5.04e-15	Schizophrenia;
KIRP	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.54	6.61	0.39	2.36e-10	Monocyte count;
KIRP	cis	rs56336142	1.000	rs1544935	chr6:39124448	A/C	cg08089693	chr6:39098871	NA	0.47	4.97	0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.7	13.88	0.66	9.9e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg13165212	chr22:42675999	NA	0.3	5.18	0.31	4.66e-7	Cognitive function;
KIRP	cis	rs9596863	1.000	rs9596858	chr13:54421858	A/G	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-0.57	-7.77	-0.44	2.18e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs738321	0.756	rs12167576	chr22:38512562	G/A	cg25457927	chr22:38595422	NA	-0.27	-5.35	-0.32	1.98e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08166232	chr12:89918718	WDR51B;GALNT4	0.47	6.09	0.36	4.37e-9	Parkinson's disease;
KIRP	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.91	14.93	0.69	2.55e-36	Breast cancer;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19117501	chr11:134206074	GLB1L2	0.42	6.82	0.4	7.06e-11	Warfarin maintenance dose;
KIRP	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.9	0.35	1.18e-8	Birth weight;
KIRP	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg12962167	chr3:53033115	SFMBT1	0.64	4.94	0.3	1.42e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	1.09	7.88	0.45	1.04e-13	Skin colour saturation;
KIRP	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.03	10.77	0.57	2.08e-22	Cognitive test performance;
KIRP	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	6.7	0.39	1.44e-10	Aortic root size;
KIRP	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06850241	chr22:41845214	NA	-0.45	-5.77	-0.35	2.33e-8	Vitiligo;
KIRP	cis	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.85	-0.35	1.53e-8	Monocyte count;
KIRP	cis	rs7127900	0.583	rs67379609	chr11:2233630	C/T	cg25635251	chr11:2234043	NA	0.43	6.85	0.4	5.78e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00014285	chr2:200716175	NA	0.54	6.61	0.39	2.42e-10	Smoking initiation;
KIRP	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	5.95	0.35	9.03e-9	Bipolar disorder;
KIRP	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg27624424	chr6:160112604	SOD2	0.49	5.48	0.33	1.03e-7	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4740619	0.648	rs752489	chr9:16032679	G/C	cg14451791	chr9:16040625	NA	-0.41	-5.38	-0.32	1.72e-7	Body mass index;
KIRP	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg15556689	chr8:8085844	FLJ10661	0.63	8.22	0.46	1.15e-14	Retinal vascular caliber;
KIRP	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg11062466	chr8:58055876	NA	0.57	5.39	0.32	1.66e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2033732	0.706	rs1370414	chr8:85076043	G/A	cg05716166	chr8:85095498	RALYL	0.58	6.63	0.39	2.11e-10	Body mass index;
KIRP	cis	rs829883	0.966	rs249818	chr12:98896994	A/C	cg25150519	chr12:98850993	NA	0.86	12.97	0.64	1.12e-29	Colorectal adenoma (advanced);
KIRP	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg26384229	chr12:38710491	ALG10B	0.54	7.25	0.42	5.44e-12	Morning vs. evening chronotype;
KIRP	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg04804543	chr8:142233427	SLC45A4	-0.51	-6.34	-0.37	1.08e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg07606381	chr6:8435919	SLC35B3	-0.4	-4.93	-0.3	1.49e-6	Motion sickness;
KIRP	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg12315302	chr6:26189340	HIST1H4D	0.78	5.35	0.32	1.97e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg26587870	chr6:27730563	NA	-0.66	-5.0	-0.3	1.09e-6	Depression;
KIRP	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg05562828	chr17:3906858	NA	0.5	5.24	0.32	3.38e-7	Type 2 diabetes;
KIRP	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg23100626	chr2:96804247	ASTL	0.44	5.56	0.33	6.84e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.7	8.46	0.47	2.41e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10464059	0.511	rs3805705	chr5:179738237	T/C	cg23221052	chr5:179740743	GFPT2	0.61	5.67	0.34	3.89e-8	Parkinson's disease;
KIRP	cis	rs6496667	0.779	rs10083679	chr15:91022139	A/G	cg10434728	chr15:90938212	IQGAP1	0.36	4.96	0.3	1.3e-6	Rheumatoid arthritis;
KIRP	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg02297831	chr4:17616191	MED28	0.6	7.45	0.43	1.59e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Systemic lupus erythematosus;
KIRP	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg24747557	chr10:131355152	MGMT	-0.47	-6.4	-0.38	7.98e-10	Response to temozolomide;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03523744	chr5:108746281	PJA2	0.54	6.02	0.36	6.16e-9	Lung cancer in ever smokers;
KIRP	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-0.84	-9.36	-0.51	5.22e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11603020	0.950	rs28362951	chr11:57372526	A/G	cg19752551	chr11:57585705	CTNND1	-0.68	-9.54	-0.52	1.44e-18	Blood protein levels;
KIRP	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-9.26	-0.51	1.04e-17	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg16141378	chr3:129829833	LOC729375	-0.55	-7.19	-0.42	7.64e-12	Mood instability;
KIRP	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.43	5.47	0.33	1.09e-7	Melanoma;
KIRP	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.05	-0.31	8.69e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.62	8.61	0.48	9.14e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	1.22	13.18	0.64	2.31e-30	Eosinophil percentage of granulocytes;
KIRP	cis	rs4704187	0.687	rs10035303	chr5:74505495	A/C	cg03227963	chr5:74354835	NA	0.4	5.8	0.35	2.01e-8	Response to amphetamines;
KIRP	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	12.06	0.61	1.29e-26	Menarche (age at onset);
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg12486944	chr17:80159399	CCDC57	0.38	5.06	0.31	8.26e-7	Life satisfaction;
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.55e-7	Life satisfaction;
KIRP	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.48	0.62	5.02e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2625529	0.652	rs2929525	chr15:72287856	G/A	cg16672083	chr15:72433130	SENP8	0.45	6.27	0.37	1.57e-9	Red blood cell count;
KIRP	cis	rs806215	1.000	rs712698	chr7:127249098	C/T	cg25922125	chr7:127225783	GCC1	0.47	5.05	0.31	8.61e-7	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs26232	0.521	rs67019105	chr5:102374163	T/A	cg23492399	chr5:102201601	PAM	-0.48	-5.35	-0.32	2.03e-7	Rheumatoid arthritis;
KIRP	cis	rs714515	0.868	rs4916253	chr1:172361032	G/T	cg01573306	chr1:172330400	DNM3	0.42	5.32	0.32	2.37e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs3736485	0.934	rs11635592	chr15:51859786	A/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9649213	0.613	rs2286074	chr7:97952011	G/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6991838	0.584	rs13268343	chr8:66543977	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.68	9.58	0.52	1.08e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.01	0.3	1.05e-6	Lung cancer;
KIRP	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.78	8.88	0.49	1.42e-16	Triglycerides;
KIRP	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg07068956	chr7:100330872	ZAN	0.41	5.44	0.33	1.28e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs2880765	0.506	rs719138	chr15:86055062	T/G	cg15340431	chr15:86040528	AKAP13	-0.46	-5.83	-0.35	1.72e-8	Coronary artery disease;
KIRP	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-8.23	-0.46	1.1e-14	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.73	-10.22	-0.55	1.15e-20	Plateletcrit;Platelet count;
KIRP	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.39	5.05	0.31	8.57e-7	Pulmonary function;
KIRP	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.71	-7.74	-0.44	2.61e-13	Gut microbiome composition (summer);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg19650197	chr19:30156396	PLEKHF1	-0.56	-6.11	-0.36	3.94e-9	Menopause (age at onset);
KIRP	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg23594656	chr7:65796392	TPST1	-0.47	-7.48	-0.43	1.28e-12	Aortic root size;
KIRP	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.67	6.38	0.38	8.78e-10	Lung function (FEV1/FVC);
KIRP	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-5.01	-0.3	1.04e-6	Bipolar disorder;
KIRP	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.28	-0.58	4.66e-24	Body mass index;
KIRP	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg23517279	chr6:96025343	MANEA	-0.62	-5.37	-0.32	1.79e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs76533333	0.831	rs12876143	chr13:113366291	T/C	cg04656015	chr13:113407548	ATP11A	0.6	4.96	0.3	1.32e-6	Red cell distribution width;
KIRP	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg16926213	chr1:1841314	NA	0.31	5.37	0.32	1.84e-7	Body mass index;
KIRP	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.65	-8.6	-0.48	9.28e-16	Aortic root size;
KIRP	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.45	-8.39	-0.47	3.72e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7712401	0.715	rs434789	chr5:122357310	C/T	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs7215564	0.730	rs76008137	chr17:78586213	G/C	cg06153925	chr17:78755379	RPTOR	0.42	5.85	0.35	1.55e-8	Myopia (pathological);
KIRP	cis	rs7945718	0.591	rs7926971	chr11:12698040	A/G	cg25843174	chr11:12811716	TEAD1	0.31	5.41	0.33	1.49e-7	Educational attainment (years of education);
KIRP	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg23411274	chr6:26421120	BTN2A3	-0.31	-4.87	-0.3	2.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs494562	1.000	rs494562	chr6:86117129	A/G	cg21730993	chr6:86159210	NT5E	0.48	5.05	0.31	8.54e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20736513	chr12:69756579	YEATS4	-0.41	-6.26	-0.37	1.7e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg21108841	chr4:24914750	CCDC149	-0.46	-5.54	-0.33	7.86e-8	Heschl's gyrus morphology;
KIRP	cis	rs13053817	1.000	rs13053817	chr22:29847722	A/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	0.42	5.04	0.31	8.97e-7	Carotid atherosclerosis in HIV infection;
KIRP	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.49	-8.14	-0.46	1.94e-14	Pneumonia;
KIRP	cis	rs7923609	0.936	rs10761778	chr10:65273782	A/G	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.86	-0.35	1.44e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06481639	chr22:41940642	POLR3H	0.65	7.14	0.41	1.04e-11	Vitiligo;
KIRP	trans	rs1106684	0.929	rs888539	chr7:131454208	G/A	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05742721	chr11:58350606	ZFP91;ZFP91-CNTF	0.4	6.94	0.4	3.39e-11	C-reactive protein;
KIRP	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs4494114	1.000	rs10890491	chr1:39354602	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-5.1	-0.31	6.75e-7	Blood protein levels;
KIRP	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	IgG glycosylation;
KIRP	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.51	6.75	0.4	1.05e-10	Coronary heart disease;
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg23985595	chr17:80112537	CCDC57	-0.33	-4.86	-0.3	2.11e-6	Life satisfaction;
KIRP	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.79	11.29	0.58	4.22e-24	Parkinson's disease;
KIRP	cis	rs16857609	0.628	rs35856653	chr2:218350206	C/A	cg15335768	chr2:218268053	DIRC3	-0.38	-5.53	-0.33	8.03e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs9815354	0.812	rs60927633	chr3:41844010	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.72	8.8	0.49	2.43e-16	Monocyte count;
KIRP	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg17182837	chr8:41585554	ANK1	-0.54	-5.87	-0.35	1.42e-8	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.87	8.81	0.49	2.31e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	trans	rs10027350	0.704	rs313545	chr4:25241207	C/T	cg09449104	chr2:200935	NA	-0.38	-6.14	-0.36	3.31e-9	Childhood ear infection;
KIRP	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.94	-0.4	3.55e-11	Self-reported allergy;
KIRP	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.7	8.97	0.5	7.76e-17	Bladder cancer;
KIRP	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.57	10.46	0.55	1.96e-21	Bone mineral density;
KIRP	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg23594656	chr7:65796392	TPST1	-0.47	-7.31	-0.42	3.71e-12	Aortic root size;
KIRP	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	1.24	13.13	0.64	3.36e-30	Red blood cell traits;
KIRP	cis	rs2742417	1.000	rs1609554	chr3:45735192	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs780096	1.000	rs780095	chr2:27741105	A/G	cg22903471	chr2:27725779	GCKR	-0.48	-7.1	-0.41	1.32e-11	Total body bone mineral density;
KIRP	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	12.22	0.61	3.86e-27	Menopause (age at onset);
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.24	-25.04	-0.85	1.29e-69	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14114033	chr7:105752648	SYPL1	0.45	6.13	0.36	3.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg07648498	chr16:89883185	FANCA	-0.39	-4.97	-0.3	1.25e-6	Vitiligo;
KIRP	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg05347473	chr6:146136440	FBXO30	0.49	6.76	0.4	9.88e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg00319359	chr11:70116639	PPFIA1	0.78	7.08	0.41	1.5e-11	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg07169764	chr2:136633963	MCM6	0.53	6.18	0.37	2.63e-9	Mosquito bite size;
KIRP	cis	rs501120	0.584	rs629213	chr10:44736784	C/T	cg09554077	chr10:44749378	NA	0.66	7.0	0.41	2.4e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg05973401	chr12:123451056	ABCB9	0.55	6.2	0.37	2.35e-9	Neutrophil percentage of white cells;
KIRP	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg22857025	chr5:266934	NA	-0.71	-5.77	-0.35	2.32e-8	Asthma (childhood onset);
KIRP	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.67	-0.34	4.06e-8	Bipolar disorder;
KIRP	cis	rs10901296	0.660	rs2855199	chr9:133765044	T/C	cg03924115	chr9:133768966	QRFP	0.34	4.88	0.3	1.87e-6	Bilirubin levels;
KIRP	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.53	-6.65	-0.39	1.89e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.14	-0.31	5.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6734238	0.966	rs12329129	chr2:113847007	G/A	cg11332951	chr1:2396472	NA	-0.41	-6.01	-0.36	6.48e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	cis	rs1010254	0.510	rs72806389	chr5:151704933	T/C	cg12297329	chr5:152029980	NA	-0.63	-6.45	-0.38	5.82e-10	Optic nerve measurement (cup area);
KIRP	cis	rs661054	0.956	rs560174	chr11:114431554	T/C	cg19465033	chr11:114479364	NA	0.37	5.17	0.31	4.93e-7	Ulcerative colitis;
KIRP	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.91	-14.58	-0.68	3.95e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs912330	0.529	rs4772100	chr13:99196573	G/T	cg07423050	chr13:99094983	FARP1	-0.33	-5.34	-0.32	2.13e-7	Alzheimer's disease;
KIRP	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg24112000	chr20:60950667	NA	0.59	9.16	0.5	2.03e-17	Colorectal cancer;
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.05	-0.31	8.62e-7	Life satisfaction;
KIRP	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg27124370	chr19:33622961	WDR88	0.55	6.57	0.39	3e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg18306943	chr3:40428807	ENTPD3	0.46	5.88	0.35	1.35e-8	Renal cell carcinoma;
KIRP	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.76	9.36	0.51	5.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.53	7.45	0.43	1.54e-12	Coronary artery disease;
KIRP	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg09165964	chr15:75287851	SCAMP5	-0.8	-7.55	-0.43	8.58e-13	Lung cancer;
KIRP	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg00262122	chr8:11665843	FDFT1	0.41	5.16	0.31	4.97e-7	Neuroticism;
KIRP	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.52	6.96	0.41	3.11e-11	Breast cancer;
KIRP	cis	rs7129556	0.702	rs7123080	chr11:77499387	C/T	cg12586386	chr11:77299805	AQP11	0.4	5.32	0.32	2.29e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg19500275	chr17:80737654	TBCD	0.45	5.3	0.32	2.53e-7	Glycated hemoglobin levels;
KIRP	cis	rs4702	0.611	rs2071382	chr15:91428197	T/C	cg05469396	chr15:91419421	FURIN	0.37	4.85	0.3	2.18e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-5.63	-0.34	4.89e-8	Aortic root size;
KIRP	cis	rs9815354	1.000	rs6599178	chr3:41842129	C/T	cg03022575	chr3:42003672	ULK4	0.5	5.83	0.35	1.75e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.55	0.33	7.56e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg26929925	chr5:138714136	SLC23A1	-0.37	-5.41	-0.33	1.49e-7	Esophageal squamous cell carcinoma;
KIRP	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-1.09	-13.28	-0.65	1.01e-30	Exhaled nitric oxide output;
KIRP	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg07596299	chr11:71824057	C11orf51	0.92	6.17	0.37	2.8e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs4664308	0.618	rs17830755	chr2:160888835	T/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-10.21	-0.55	1.23e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs4132509	1.000	rs10927050	chr1:243805907	A/G	cg21452805	chr1:244014465	NA	0.48	4.87	0.3	2.03e-6	RR interval (heart rate);
KIRP	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg05775895	chr3:12838266	CAND2	0.34	5.7	0.34	3.48e-8	QRS complex (12-leadsum);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16529440	chr12:93323219	EEA1	0.55	7.19	0.42	7.53e-12	Parkinson's disease;
KIRP	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg06915872	chr16:87998081	BANP	0.52	5.24	0.32	3.39e-7	Menopause (age at onset);
KIRP	cis	rs7224685	0.569	rs67533014	chr17:3993910	C/T	cg09597638	chr17:3907349	NA	0.52	5.24	0.32	3.41e-7	Type 2 diabetes;
KIRP	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.45e-8	Schizophrenia;
KIRP	cis	rs6663390	0.831	rs11118880	chr1:208085583	T/A	cg00387621	chr1:208086895	NA	0.61	5.38	0.32	1.72e-7	Facial morphology (factor 18);
KIRP	cis	rs9828933	0.516	rs704371	chr3:63867528	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.97	10.01	0.54	5.07e-20	Type 2 diabetes;
KIRP	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.58	-0.56	8.66e-22	Height;
KIRP	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg26039829	chr8:22132926	PIWIL2	0.48	6.02	0.36	6.3e-9	Hypertriglyceridemia;
KIRP	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs6684514	1.000	rs2277871	chr1:156246742	A/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.74	-10.74	-0.56	2.63e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9303542	0.559	rs12603976	chr17:46617163	C/A	cg04904318	chr17:46607828	HOXB1	-0.61	-6.66	-0.39	1.73e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.99	-15.75	-0.71	4.13e-39	Chronic sinus infection;
KIRP	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.54	6.9	0.4	4.35e-11	Mean platelet volume;
KIRP	cis	rs7173743	0.525	rs4533253	chr15:79138841	T/C	cg00079375	chr15:79125835	NA	-0.4	-5.57	-0.33	6.75e-8	Coronary artery disease;
KIRP	cis	rs17123764	0.818	rs74089570	chr12:49973282	G/C	cg02054252	chr12:50078554	FMNL3	0.49	4.94	0.3	1.43e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.73	9.27	0.51	9.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09473763	chr3:112282684	SLC35A5	-0.41	-6.29	-0.37	1.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg17366294	chr4:99064904	C4orf37	-0.4	-5.43	-0.33	1.34e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg17333051	chr19:2783644	SGTA	0.42	5.48	0.33	1.04e-7	Total cholesterol levels;
KIRP	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg17470723	chr8:74884337	TCEB1	0.64	8.25	0.47	9.51e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.66	10.11	0.54	2.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.59	-6.11	-0.36	3.8e-9	Pancreatic cancer;
KIRP	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21659725	chr3:3221576	CRBN	0.66	8.9	0.49	1.27e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg19468946	chr17:37922297	IKZF3	-0.43	-6.12	-0.36	3.63e-9	Asthma;
KIRP	cis	rs10046574	0.561	rs7789858	chr7:135212285	A/G	cg27474649	chr7:135195673	CNOT4	0.55	5.18	0.31	4.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs362296	0.698	rs362283	chr4:3259558	T/C	cg06533319	chr4:3265114	C4orf44	0.56	6.71	0.39	1.3e-10	Parental longevity (mother's age at death);
KIRP	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg09699651	chr6:150184138	LRP11	0.42	5.37	0.32	1.82e-7	Lung cancer;
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.43	5.3	0.32	2.56e-7	Longevity;
KIRP	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg12756093	chr1:115239321	AMPD1	0.52	6.99	0.41	2.57e-11	Autism;
KIRP	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-5.02	-0.3	9.92e-7	Life satisfaction;
KIRP	cis	rs2562456	0.793	rs62109212	chr19:21526518	T/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg10207240	chr12:122356781	WDR66	0.49	6.56	0.39	3.08e-10	Mean corpuscular volume;
KIRP	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg26384229	chr12:38710491	ALG10B	0.72	9.64	0.52	7.52e-19	Morning vs. evening chronotype;
KIRP	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.47	0.43	1.41e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7714584	1.000	rs11957134	chr5:150230950	A/G	cg22134413	chr5:150180641	NA	-0.82	-7.18	-0.42	8.37e-12	Crohn's disease;
KIRP	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.19	0.37	2.46e-9	Platelet count;
KIRP	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.45	-5.75	-0.34	2.61e-8	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.1	0.36	4.04e-9	Lung cancer;
KIRP	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Colorectal cancer;
KIRP	cis	rs3087591	0.639	rs2854333	chr17:29713300	T/C	cg24425628	chr17:29625626	OMG;NF1	0.63	9.08	0.5	3.52e-17	Hip circumference;
KIRP	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	8.25	0.47	9.84e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.78	9.17	0.5	1.98e-17	Corneal astigmatism;
KIRP	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.63	8.36	0.47	4.75e-15	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs2213920	0.522	rs4978640	chr9:118241462	G/T	cg13918206	chr9:118159781	DEC1	0.56	7.1	0.41	1.31e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27280279	chr2:33820674	FAM98A	-0.4	-6.15	-0.37	3.13e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.44	0.33	1.3e-7	Cognitive test performance;
KIRP	cis	rs1298062	0.689	rs12985344	chr19:50954750	T/C	cg10687087	chr19:50962411	MYBPC2	0.44	5.07	0.31	7.82e-7	Age of smoking initiation;
KIRP	trans	rs921874	0.586	rs2512358	chr11:86775294	C/T	cg20852851	chr2:240168848	HDAC4	0.45	6.15	0.37	3.16e-9	Total body bone mineral density;
KIRP	cis	rs1635	0.826	rs4713159	chr6:28283772	G/A	cg15743358	chr6:28303923	ZNF323	-0.76	-5.47	-0.33	1.13e-7	Schizophrenia;
KIRP	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs9840812	0.610	rs34967300	chr3:136268818	A/G	cg15507776	chr3:136538369	TMEM22	-0.43	-4.94	-0.3	1.44e-6	Fibrinogen levels;
KIRP	cis	rs7715811	1.000	rs6554813	chr5:13763039	G/A	cg07548982	chr5:13769939	DNAH5	-0.52	-6.38	-0.38	8.87e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs6882046	0.513	rs587490	chr5:88032522	C/T	cg22951263	chr5:87985283	NA	-0.47	-6.66	-0.39	1.79e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.46	0.38	5.64e-10	Obesity-related traits;
KIRP	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg24881330	chr22:46731750	TRMU	0.77	7.52	0.43	9.98e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08280861	chr8:58055591	NA	0.77	6.13	0.36	3.43e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg15327641	chr2:3715039	ALLC	0.45	5.83	0.35	1.73e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1050631	1.000	rs1789550	chr18:33699553	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.47	-5.78	-0.35	2.29e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05047319	chr11:86748661	TMEM135	-0.46	-6.06	-0.36	4.99e-9	Myopia;
KIRP	cis	rs7536201	0.936	rs7414934	chr1:25293216	A/C	cg23273869	chr1:25296894	NA	-0.37	-5.05	-0.31	8.54e-7	Psoriasis vulgaris;
KIRP	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg05555928	chr11:63887634	MACROD1	-0.47	-5.87	-0.35	1.39e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg00738919	chr7:1100172	C7orf50	0.43	5.06	0.31	8.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.14	0.41	1.04e-11	Prudent dietary pattern;
KIRP	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.85	-0.3	2.2e-6	Resting heart rate;
KIRP	cis	rs17065868	1.000	rs61947991	chr13:45128009	G/T	cg10246903	chr13:45222710	NA	0.72	6.4	0.38	7.86e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs12249377	0.519	rs12259060	chr10:92579949	A/G	cg14313238	chr10:92632228	RPP30	0.43	5.26	0.32	3.15e-7	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs741951	0.667	rs55745009	chr21:46281998	T/A	cg08823554	chr21:46269191	NA	-0.7	-5.92	-0.35	1.1e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.42	-5.21	-0.32	3.91e-7	Aortic root size;
KIRP	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09699651	chr6:150184138	LRP11	0.56	7.47	0.43	1.41e-12	Testicular germ cell tumor;
KIRP	cis	rs8054556	1.000	rs9924686	chr16:30003076	G/A	cg06326092	chr16:30034487	C16orf92	0.36	4.97	0.3	1.25e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.46	5.36	0.32	1.92e-7	Schizophrenia;
KIRP	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg25801113	chr15:45476975	SHF	0.48	9.43	0.52	3.12e-18	Uric acid levels;
KIRP	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg25486957	chr4:152246857	NA	-0.48	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.61	7.71	0.44	3.17e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.27	0.37	1.6e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.86	-13.09	-0.64	4.56e-30	Breast cancer;
KIRP	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.87	-9.97	-0.54	7.15e-20	Gut microbiome composition (summer);
KIRP	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.53	6.16	0.37	3.03e-9	Blood metabolite levels;
KIRP	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg26384229	chr12:38710491	ALG10B	-0.68	-9.39	-0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg09904177	chr6:26538194	HMGN4	-0.56	-5.17	-0.31	4.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg12559939	chr2:27858050	GPN1	0.41	5.16	0.31	5.01e-7	Oral cavity cancer;
KIRP	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.85	12.16	0.61	6.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.74	10.31	0.55	5.8e-21	Coronary artery disease;
KIRP	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg02023728	chr11:77925099	USP35	-0.31	-5.52	-0.33	8.57e-8	Alzheimer's disease (survival time);
KIRP	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg17425144	chr1:10567563	PEX14	0.49	9.05	0.5	4.37e-17	Breast size;
KIRP	cis	rs2071403	0.901	rs12471910	chr2:1412802	A/G	cg06500727	chr2:1417164	TPO	0.47	7.45	0.43	1.6e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-1.04	-20.44	-0.79	6.04e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2307121	0.700	rs12187081	chr5:64756859	T/G	cg11190754	chr5:64858552	CENPK;PPWD1	0.44	5.66	0.34	4.18e-8	Corneal structure;
KIRP	cis	rs79881201	1.000	rs17623144	chr5:110430488	C/G	cg04022379	chr5:110408740	TSLP	0.46	5.84	0.35	1.69e-8	Sum eosinophil basophil counts;
KIRP	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-6.02	-0.36	6.38e-9	Body mass index;
KIRP	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg12591125	chr7:1885375	MAD1L1	0.54	5.17	0.31	4.87e-7	Bipolar disorder;
KIRP	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	8.3	0.47	6.76e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.48	5.86	0.35	1.51e-8	Common traits (Other);
KIRP	cis	rs17739794	0.764	rs2336409	chr8:809079	A/C	cg01971667	chr8:817044	NA	-0.41	-5.73	-0.34	2.89e-8	Clozapine-induced cytotoxicity;
KIRP	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg04226714	chr8:49833948	SNAI2	-0.51	-6.96	-0.41	3.11e-11	Life satisfaction;
KIRP	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.34	5.28	0.32	2.85e-7	Asthma;
KIRP	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg04226714	chr8:49833948	SNAI2	-0.44	-6.05	-0.36	5.22e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7714584	1.000	rs2115069	chr5:150252365	G/A	cg22134413	chr5:150180641	NA	0.7	6.01	0.36	6.64e-9	Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26535835	chr2:197036297	STK17B	0.52	6.84	0.4	6.27e-11	Parkinson's disease;
KIRP	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.69	9.09	0.5	3.38e-17	Eosinophil percentage of white cells;
KIRP	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg19906672	chr4:6918868	TBC1D14	0.56	5.52	0.33	8.54e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09326272	chr3:101540573	FAM55C	-0.47	-6.3	-0.37	1.34e-9	Cancer;
KIRP	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg10503236	chr1:231470652	EXOC8	0.52	6.89	0.4	4.77e-11	Red blood cell count;
KIRP	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.54	-6.11	-0.36	3.8e-9	Schizophrenia;
KIRP	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg12140854	chr5:148520817	ABLIM3	0.42	4.89	0.3	1.79e-6	Breast cancer;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.35	5.01	0.3	1.02e-6	Lymphocyte counts;
KIRP	cis	rs2274273	0.870	rs2016931	chr14:55842332	C/G	cg04306507	chr14:55594613	LGALS3	0.47	7.41	0.43	2e-12	Protein biomarker;
KIRP	cis	rs860295	0.812	rs2297775	chr1:155735012	C/T	cg02153340	chr1:155202674	NA	0.44	6.04	0.36	5.58e-9	Body mass index;
KIRP	cis	rs35000415	0.938	rs13236009	chr7:128663173	T/G	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.47	7.91	0.45	8.59e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.15	-0.31	5.34e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg19507638	chr5:93509721	C5orf36	-0.53	-5.01	-0.3	1.02e-6	Diabetic retinopathy;
KIRP	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.71	9.89	0.53	1.22e-19	Mean corpuscular volume;
KIRP	cis	rs12900413	0.603	rs2882678	chr15:90299542	A/G	cg24650279	chr15:90327240	NA	-0.41	-5.13	-0.31	5.91e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06370812	chr3:195501042	MUC4	0.41	6.06	0.36	4.98e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17101923	0.853	rs12424216	chr12:66320891	A/G	cg06712651	chr12:66351869	HMGA2	-0.53	-5.78	-0.35	2.28e-8	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	1.11	8.06	0.46	3.38e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg00129232	chr17:37814104	STARD3	-0.52	-6.37	-0.38	9.2e-10	Self-reported allergy;
KIRP	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg23791538	chr6:167370224	RNASET2	-0.47	-5.71	-0.34	3.2e-8	Rheumatoid arthritis;
KIRP	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.95	13.02	0.64	7.59e-30	Multiple sclerosis;
KIRP	cis	rs2411233	0.837	rs12911780	chr15:39250617	A/G	cg19287857	chr15:39890699	NA	0.45	6.22	0.37	2.18e-9	Platelet count;
KIRP	cis	rs8028182	0.636	rs4322627	chr15:75810659	C/T	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs11671005	0.693	rs11666928	chr19:58914231	A/G	cg13877915	chr19:58951672	ZNF132	0.6	5.76	0.34	2.5e-8	Mean platelet volume;
KIRP	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.57	7.9	0.45	9.06e-14	Prostate cancer;
KIRP	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	15.05	0.69	1e-36	Chronic sinus infection;
KIRP	cis	rs876084	0.630	rs2037343	chr8:121019769	A/G	cg22335954	chr8:121166405	COL14A1	-0.41	-5.01	-0.3	1.05e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs28669119	0.841	rs10044342	chr5:88178683	C/T	cg18498987	chr5:88179539	MEF2C	-0.51	-6.3	-0.37	1.34e-9	Schizophrenia;
KIRP	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.34	0.62	1.47e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs907612	0.638	rs907611	chr11:1874072	G/A	cg05305434	chr11:1874049	LSP1	0.39	8.26	0.47	8.99e-15	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7106204	0.514	rs34587986	chr11:24253053	T/C	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg14952266	chr13:112191215	NA	0.45	6.71	0.39	1.32e-10	Hepatitis;
KIRP	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg06636001	chr8:8085503	FLJ10661	0.62	8.5	0.48	1.9e-15	Retinal vascular caliber;
KIRP	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg11569703	chr11:65557185	OVOL1	0.5	7.46	0.43	1.44e-12	Breast cancer;
KIRP	cis	rs61884328	0.703	rs60201196	chr11:47110592	C/T	cg23433285	chr11:47201945	PACSIN3	0.69	5.6	0.34	5.68e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg11846333	chr4:119757529	SEC24D	0.99	6.0	0.36	7.02e-9	Cannabis dependence symptom count;
KIRP	cis	rs6504950	0.720	rs7216138	chr17:52995664	G/A	cg26251398	chr17:52985966	TOM1L1	0.43	5.99	0.36	7.35e-9	Breast cancer;
KIRP	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.17	0.37	2.77e-9	Morning vs. evening chronotype;
KIRP	cis	rs2644899	0.793	rs2644916	chr19:41309211	A/G	cg24958765	chr19:41283667	RAB4B	-0.51	-5.68	-0.34	3.72e-8	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4262150	0.883	rs72802887	chr5:152249082	A/G	cg12297329	chr5:152029980	NA	-0.61	-7.69	-0.44	3.58e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-8.62	-0.48	8.13e-16	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg16586182	chr3:47516702	SCAP	0.75	9.98	0.54	6.33e-20	Colorectal cancer;
KIRP	cis	rs1832871	1.000	rs827858	chr6:158707396	T/C	cg07215822	chr6:158701037	NA	-0.49	-6.3	-0.37	1.4e-9	Height;
KIRP	cis	rs2297441	0.550	rs73622887	chr20:62379339	C/T	cg03999872	chr20:62272968	STMN3	-0.52	-5.21	-0.32	3.92e-7	Ulcerative colitis;
KIRP	cis	rs1298062	0.825	rs1673019	chr19:50987775	T/G	cg11430371	chr19:50961752	MYBPC2	0.35	4.93	0.3	1.51e-6	Age of smoking initiation;
KIRP	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.79	12.03	0.61	1.61e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.26	0.51	1.03e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg16898833	chr6:26189333	HIST1H4D	1.05	6.27	0.37	1.64e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2733310	0.741	rs2615226	chr15:57543124	A/C	cg13626582	chr15:57592083	LOC283663	-0.28	-6.32	-0.37	1.23e-9	Mean platelet volume;
KIRP	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	7.56	0.43	8.11e-13	Total cholesterol levels;
KIRP	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.8	9.95	0.54	8.19e-20	Post bronchodilator FEV1;
KIRP	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.23	-0.37	1.97e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg05347473	chr6:146136440	FBXO30	0.62	8.81	0.49	2.27e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg19197139	chr17:4613644	ARRB2	0.74	7.6	0.44	6.27e-13	Lymphocyte counts;
KIRP	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg06212747	chr3:49208901	KLHDC8B	0.48	5.53	0.33	8.12e-8	Resting heart rate;
KIRP	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.72	0.44	2.84e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.47	7.29	0.42	4.31e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg13736514	chr6:26305472	NA	-0.52	-6.31	-0.37	1.27e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	9.74	0.53	3.52e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg06675538	chr2:114033490	PAX8;LOC440839	-0.39	-5.14	-0.31	5.52e-7	Renal function-related traits (BUN);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24141233	chr1:212781895	ATF3	-0.45	-6.26	-0.37	1.68e-9	Metabolic traits;
KIRP	cis	rs9653442	0.545	rs11123813	chr2:100765692	C/T	cg07810366	chr2:100720526	AFF3	-0.31	-5.22	-0.32	3.8e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.8	-0.49	2.53e-16	Response to antipsychotic treatment;
KIRP	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.06	-14.23	-0.67	6.25e-34	Body mass index;
KIRP	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg03060546	chr3:49711283	APEH	0.49	6.39	0.38	8.28e-10	Parkinson's disease;
KIRP	cis	rs4478858	0.806	rs6686845	chr1:31708796	A/T	cg00250761	chr1:31883323	NA	-0.29	-5.21	-0.32	3.96e-7	Alcohol dependence;
KIRP	cis	rs8060686	0.920	rs73593810	chr16:67866783	C/T	cg04539111	chr16:67997858	SLC12A4	-0.65	-6.6	-0.39	2.51e-10	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg06012730	chr15:75315579	PPCDC	-0.38	-4.9	-0.3	1.75e-6	Blood trace element (Zn levels);
KIRP	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	5.96	0.36	8.86e-9	Longevity;
KIRP	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg11608241	chr8:8085544	FLJ10661	-0.46	-5.57	-0.33	6.64e-8	Joint mobility (Beighton score);
KIRP	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.58	6.87	0.4	5.36e-11	Alcohol dependence;
KIRP	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.28	-0.32	2.78e-7	Coronary artery disease;
KIRP	cis	rs7178909	0.902	rs3853638	chr15:90443140	C/T	cg19708238	chr15:90437601	AP3S2	-0.56	-7.63	-0.44	5.17e-13	Common traits (Other);
KIRP	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg06212747	chr3:49208901	KLHDC8B	0.53	5.95	0.35	9.02e-9	Resting heart rate;
KIRP	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg02297831	chr4:17616191	MED28	0.57	7.27	0.42	4.76e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg08738300	chr3:44038990	NA	0.69	9.74	0.53	3.69e-19	Coronary artery disease;
KIRP	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.92	-12.44	-0.62	6.78e-28	Cognitive function;
KIRP	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.91	11.85	0.6	6.2e-26	Homoarginine levels;
KIRP	cis	rs7615316	0.751	rs9847364	chr3:142155763	A/G	cg20824294	chr3:142316082	PLS1	0.24	5.38	0.32	1.72e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.81	0.49	2.34e-16	Bipolar disorder;
KIRP	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.2	0.37	2.37e-9	Retinal vascular caliber;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22994272	chr14:104346241	NA	0.51	6.86	0.4	5.66e-11	Smoking initiation;
KIRP	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg00310523	chr12:86230176	RASSF9	-0.47	-7.48	-0.43	1.3e-12	Major depressive disorder;
KIRP	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.57	6.82	0.4	7.03e-11	Colorectal cancer;
KIRP	cis	rs11191205	1.000	rs11191205	chr10:103831598	G/A	cg15320455	chr10:103880129	LDB1	0.76	5.75	0.34	2.57e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08005809	chr8:144895082	SCRIB	0.44	6.07	0.36	4.79e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05491852	chr1:3663832	KIAA0495	0.57	7.23	0.42	6.26e-12	Smoking initiation;
KIRP	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.96	0.41	2.99e-11	Height;
KIRP	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg02023728	chr11:77925099	USP35	0.35	5.38	0.32	1.71e-7	Alzheimer's disease (survival time);
KIRP	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg06684201	chr7:157447249	PTPRN2	-0.51	-5.09	-0.31	7.26e-7	Colorectal cancer;
KIRP	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.35	-6.12	-0.36	3.59e-9	Refractive error;
KIRP	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.32	5.11	0.31	6.33e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.3	0.42	4.02e-12	Lung cancer;
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.7	10.79	0.57	1.75e-22	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	8.69	0.48	5.25e-16	Total body bone mineral density;
KIRP	trans	rs13394458	0.556	rs10496881	chr2:142244913	G/T	cg21164727	chr9:95858436	C9orf89	1.11	6.03	0.36	5.96e-9	Night sleep phenotypes;
KIRP	cis	rs6662572	0.737	rs6702764	chr1:46252717	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.47	-5.77	-0.35	2.36e-8	Blood protein levels;
KIRP	cis	rs7106204	0.514	rs12293105	chr11:24256048	T/C	ch.11.24196551F	chr11:24239977	NA	0.88	10.55	0.56	1.01e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6546324	0.580	rs1430785	chr2:67869292	A/G	cg15745817	chr2:67799979	NA	-0.6	-7.34	-0.42	3.06e-12	Endometriosis;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.37	0.65	5.38e-31	Platelet count;
KIRP	cis	rs7923609	0.967	rs10509189	chr10:65264126	T/C	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.18e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1364705	1.000	rs12675172	chr8:120222625	G/A	cg09273054	chr8:120220131	MAL2	0.57	6.55	0.39	3.26e-10	Hippocampal atrophy;
KIRP	cis	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg26585981	chr11:48327164	OR4S1	-0.47	-5.66	-0.34	4.12e-8	HDL cholesterol;
KIRP	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.17	-21.91	-0.81	9.31e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.7	-10.96	-0.57	4.95e-23	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2151522	0.762	rs9372847	chr6:127169422	T/C	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg20814179	chr4:940893	TMEM175	-0.43	-6.06	-0.36	5.07e-9	Parkinson's disease;
KIRP	cis	rs501120	0.636	rs3123689	chr10:44773121	G/A	cg09554077	chr10:44749378	NA	0.71	10.94	0.57	6.01e-23	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.92e-34	Menopause (age at onset);
KIRP	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.6	6.85	0.4	5.85e-11	Menarche (age at onset);
KIRP	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.51	7.15	0.41	9.79e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg07682378	chr3:150128910	TSC22D2	0.45	6.04	0.36	5.53e-9	Ischemic stroke;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18221891	chr8:27632578	ESCO2	0.52	6.06	0.36	5.16e-9	Lung cancer in ever smokers;
KIRP	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg12131826	chr15:77904385	NA	-0.4	-5.04	-0.31	9.22e-7	Type 2 diabetes;
KIRP	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg07856975	chr6:36356162	ETV7	0.39	5.83	0.35	1.74e-8	Platelet distribution width;
KIRP	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg09473613	chr1:24152604	HMGCL	-0.47	-6.52	-0.38	4.03e-10	Immature fraction of reticulocytes;
KIRP	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg16141378	chr3:129829833	LOC729375	0.56	7.26	0.42	5.19e-12	Retinal vascular caliber;
KIRP	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg01879757	chr17:41196368	BRCA1	-0.78	-11.05	-0.58	2.59e-23	Menopause (age at onset);
KIRP	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19524238	chr7:2802976	GNA12	-0.38	-5.3	-0.32	2.52e-7	Height;
KIRP	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	6.36	0.38	9.87e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.31	0.32	2.46e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs35661897	0.920	rs13033214	chr2:227317638	T/C	cg03426602	chr2:227312417	NA	-0.53	-6.77	-0.4	9.34e-11	Urinary tract infection frequency;
KIRP	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.55	-7.48	-0.43	1.35e-12	Bladder cancer;
KIRP	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.76	11.39	0.59	1.99e-24	Oral cavity cancer;
KIRP	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.9	-0.4	4.51e-11	Systolic blood pressure;
KIRP	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-9.16	-0.5	2.1e-17	Triglycerides;
KIRP	cis	rs12643440	0.800	rs35587700	chr4:17227852	A/G	cg22650099	chr4:17144496	NA	-0.5	-6.09	-0.36	4.31e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17554472	chr22:41940697	POLR3H	-0.61	-6.55	-0.39	3.28e-10	Vitiligo;
KIRP	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.85	-0.66	1.24e-32	Ulcerative colitis;
KIRP	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg01246520	chr17:17644344	RAI1	0.47	8.25	0.47	9.5e-15	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs6009824	1.000	rs6009824	chr22:50086373	C/T	cg27029450	chr22:50098074	NA	0.53	5.51	0.33	8.88e-8	Natriuretic peptide levels;
KIRP	cis	rs2273669	0.667	rs11153156	chr6:109365911	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.41	-0.38	7.27e-10	Prostate cancer;
KIRP	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.94	-0.4	3.48e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	1.03	20.25	0.79	2.49e-54	Parkinson's disease;
KIRP	cis	rs526231	0.543	rs40092	chr5:102424213	A/G	cg23492399	chr5:102201601	PAM	-0.54	-5.96	-0.36	8.85e-9	Primary biliary cholangitis;
KIRP	cis	rs11955398	0.585	rs4398599	chr5:60032413	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.33	-0.32	2.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs16854884	0.837	rs6767236	chr3:143758399	A/C	cg06585982	chr3:143692056	C3orf58	0.51	5.95	0.35	9.15e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg05714579	chr10:131428358	MGMT	0.39	4.99	0.3	1.14e-6	Response to temozolomide;
KIRP	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.64	8.54	0.48	1.43e-15	Lymphocyte counts;
KIRP	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.3	13.33	0.65	6.84e-31	Diabetic retinopathy;
KIRP	cis	rs1629083	0.790	rs605908	chr11:118067192	C/A	cg18857871	chr11:118064634	AMICA1	0.74	10.64	0.56	5.2e-22	Lung cancer;
KIRP	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-5.88	-0.35	1.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	6.2	0.37	2.41e-9	Putamen volume;
KIRP	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14769373	chr6:40998127	UNC5CL	-0.53	-6.0	-0.36	7.01e-9	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.62	7.74	0.44	2.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18252515	chr7:66147081	NA	0.45	5.15	0.31	5.33e-7	Aortic root size;
KIRP	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg12560992	chr17:57184187	TRIM37	0.6	5.39	0.33	1.62e-7	Cognitive test performance;
KIRP	cis	rs9469913	0.733	rs11759235	chr6:34795102	A/G	cg17674042	chr6:34482479	PACSIN1	-0.37	-5.18	-0.31	4.57e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg23335576	chr14:104009727	NA	0.39	5.67	0.34	4.02e-8	Body mass index;
KIRP	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.48	-7.77	-0.44	2.14e-13	Height;
KIRP	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-1.07	-13.56	-0.65	1.18e-31	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05025164	chr4:1340916	KIAA1530	0.41	5.07	0.31	7.94e-7	Obesity-related traits;
KIRP	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.15	0.31	5.4e-7	Educational attainment;
KIRP	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.72	10.42	0.55	2.68e-21	Bladder cancer;
KIRP	cis	rs2733310	0.842	rs1657936	chr15:57113013	C/T	cg13626582	chr15:57592083	LOC283663	-0.23	-5.04	-0.31	9.18e-7	Mean platelet volume;
KIRP	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.75	-0.34	2.68e-8	Bipolar disorder;
KIRP	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.52	-7.08	-0.41	1.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg20913747	chr6:44695427	NA	-0.39	-4.94	-0.3	1.44e-6	Total body bone mineral density;
KIRP	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs6055685	1.000	rs6055676	chr20:8210782	T/C	cg13423151	chr9:107526487	NIPSNAP3B	0.56	6.1	0.36	4.16e-9	Suicide ideation score in major depressive disorder;
KIRP	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-6.1	-0.36	4.14e-9	Sudden cardiac arrest;
KIRP	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.39e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.34	-6.09	-0.36	4.43e-9	Height;
KIRP	cis	rs5770917	1.000	rs5770924	chr22:51024542	C/T	cg25309564	chr22:51001381	C22orf41	0.9	5.22	0.32	3.87e-7	Narcolepsy;
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.74	-6.77	-0.4	9.51e-11	Vitiligo;
KIRP	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs244899	0.935	rs590784	chr5:167917504	G/T	cg06604206	chr5:167912465	RARS	-0.52	-7.46	-0.43	1.51e-12	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg11814155	chr7:99998594	ZCWPW1	0.67	6.09	0.36	4.4e-9	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07808661	chr18:5237922	C18orf18;LOC339290	0.52	6.36	0.38	9.66e-10	Parkinson's disease;
KIRP	cis	rs7941030	0.967	rs6589941	chr11:122519022	T/G	cg20555462	chr11:122535518	UBASH3B	-0.4	-4.86	-0.3	2.12e-6	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg16497661	chr14:103986332	CKB	0.83	14.4	0.68	1.7e-34	Body mass index;
KIRP	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.86e-8	Lung cancer;
KIRP	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.0	0.36	7.1e-9	Menopause (age at onset);
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg11337261	chr6:3118923	BPHL	-0.49	-6.05	-0.36	5.31e-9	Brain structure;
KIRP	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-5.84	-0.35	1.68e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg20312557	chr2:97357134	FER1L5	-0.7	-4.91	-0.3	1.66e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.57	-8.93	-0.49	1.02e-16	Coronary artery disease;
KIRP	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg25019722	chr6:37503610	NA	-0.95	-15.32	-0.7	1.18e-37	Cognitive performance;
KIRP	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	cg04338863	chr8:33670619	NA	0.48	6.36	0.38	1e-9	Body mass index;
KIRP	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.71	-0.44	3.1400000000000003e-13	Retinal vascular caliber;
KIRP	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.76	12.4	0.62	9.54e-28	Vitiligo;
KIRP	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.75	-10.53	-0.56	1.19e-21	Body mass index;
KIRP	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.62	7.68	0.44	3.73e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11825064	0.725	rs113937925	chr11:134474364	A/G	cg06603561	chr11:134479413	NA	-0.71	-5.71	-0.34	3.3e-8	Seasonality;
KIRP	cis	rs259842	0.800	rs10930887	chr2:180713962	G/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	0.34	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs2274273	1.000	rs7493394	chr14:55617755	A/T	cg04306507	chr14:55594613	LGALS3	0.47	7.22	0.42	6.4e-12	Protein biomarker;
KIRP	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg11608241	chr8:8085544	FLJ10661	0.43	5.3	0.32	2.61e-7	Mood instability;
KIRP	cis	rs3026101	0.671	rs3026115	chr17:5285222	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	6.77	0.4	9.37e-11	Body mass index;
KIRP	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg07741184	chr6:167504864	NA	-0.24	-6.42	-0.38	7.08e-10	Crohn's disease;
KIRP	cis	rs2882667	0.861	rs10075541	chr5:138390318	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-7.6	-0.44	6.31e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.69	-8.31	-0.47	6.56e-15	Cognitive function;
KIRP	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.38	5.1	0.31	6.94e-7	Dupuytren's disease;
KIRP	cis	rs1981331	0.609	rs77725404	chr21:48080376	C/T	cg17243659	chr21:48055224	PRMT2	1.37	8.45	0.47	2.6e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg04306507	chr14:55594613	LGALS3	0.47	7.28	0.42	4.47e-12	Protein biomarker;
KIRP	cis	rs7127900	0.950	rs6579002	chr11:2232229	A/G	cg25635251	chr11:2234043	NA	0.52	7.86	0.45	1.22e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.56	7.61	0.44	5.86e-13	Mean corpuscular volume;
KIRP	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg08890418	chr1:21044141	KIF17	-0.42	-6.3	-0.37	1.38e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.81	0.35	1.88e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg01631408	chr1:248437212	OR2T33	-0.68	-9.21	-0.51	1.48e-17	Common traits (Other);
KIRP	cis	rs6847149	0.929	rs4698752	chr4:110780964	A/G	cg07850274	chr4:110748770	RRH	0.4	4.89	0.3	1.8e-6	Exercise treadmill test traits;
KIRP	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.33	6.33	0.37	1.12e-9	Monocyte percentage of white cells;
KIRP	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.75	9.21	0.51	1.44e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.38	-5.69	-0.34	3.62e-8	Body mass index;
KIRP	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg03808351	chr9:123631620	PHF19	0.4	5.43	0.33	1.34e-7	Rheumatoid arthritis;
KIRP	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg05220968	chr6:146057943	EPM2A	0.41	5.37	0.32	1.83e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.88	-0.3	1.89e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.82	9.85	0.53	1.69e-19	Post bronchodilator FEV1;
KIRP	cis	rs3741151	1.000	rs1892855	chr11:73017972	G/T	cg17517138	chr11:73019481	ARHGEF17	1.21	8.26	0.47	9.27e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.53	7.04	0.41	1.89e-11	HDL cholesterol;
KIRP	cis	rs35123781	0.696	rs356429	chr5:139073143	C/T	cg10513866	chr5:139070639	NA	0.54	7.61	0.44	5.74e-13	Schizophrenia;
KIRP	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.86	10.73	0.56	2.78e-22	Coronary artery disease;
KIRP	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg22029157	chr1:209979665	IRF6	-0.48	-7.75	-0.44	2.38e-13	Monobrow;
KIRP	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg25418670	chr11:30344373	C11orf46	0.61	5.29	0.32	2.71e-7	Morning vs. evening chronotype;
KIRP	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg11584989	chr19:19387371	SF4	0.4	5.17	0.31	4.78e-7	Tonsillectomy;
KIRP	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.67	-6.26	-0.37	1.66e-9	Schizophrenia;
KIRP	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg08999081	chr20:33150536	PIGU	-0.39	-5.01	-0.3	1.03e-6	Height;
KIRP	cis	rs28785552	0.931	rs10424385	chr19:53239133	C/G	cg03571507	chr19:53239146	ZNF611	0.25	6.47	0.38	5.29e-10	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.69	10.15	0.54	1.95e-20	Menarche (age at onset);
KIRP	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.52	6.49	0.38	4.74e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg00806126	chr19:22604979	ZNF98	0.68	7.14	0.41	1.02e-11	Pain;
KIRP	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.79	-10.43	-0.55	2.57e-21	Coronary artery disease;
KIRP	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg08847533	chr14:75593920	NEK9	0.51	6.29	0.37	1.45e-9	IgG glycosylation;
KIRP	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	0.86	7.87	0.45	1.11e-13	Severe influenza A (H1N1) infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03946269	chr1:38259490	MANEAL	0.49	6.3	0.37	1.4e-9	Parkinson's disease;
KIRP	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	1.14	20.98	0.8	1.03e-56	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.04e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-10.89	-0.57	8.61e-23	Exhaled nitric oxide levels;
KIRP	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.42	-5.26	-0.32	3.14e-7	Testicular germ cell tumor;
KIRP	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14598338	chr9:96623480	NA	-0.63	-10.15	-0.54	1.93e-20	DNA methylation (variation);
KIRP	cis	rs6662572	0.686	rs72690855	chr1:46266210	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.19	0.31	4.43e-7	Blood protein levels;
KIRP	cis	rs10073892	0.660	rs56170429	chr5:101944414	T/A	cg19774478	chr5:101632501	SLCO4C1	0.56	5.77	0.35	2.42e-8	Cognitive decline (age-related);
KIRP	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.51	6.57	0.39	2.91e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs9517302	0.615	rs3752974	chr13:99097827	T/C	cg24044564	chr13:99115944	STK24	0.58	6.56	0.39	3.22e-10	Obesity-related traits;
KIRP	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.51e-15	Mortality in heart failure;
KIRP	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg13010199	chr12:38710504	ALG10B	0.48	6.38	0.38	8.64e-10	Morning vs. evening chronotype;
KIRP	trans	rs2504916	0.911	rs2457577	chr6:160854138	A/C	cg16431687	chr12:89919797	GALNT4;WDR51B	0.66	6.06	0.36	5.08e-9	Response to hepatitis C treatment;
KIRP	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg01988459	chr11:68622903	NA	-0.36	-5.25	-0.32	3.37e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12924262	chr12:102091054	CHPT1	0.45	5.87	0.35	1.37e-8	Blood protein levels;
KIRP	cis	rs9876781	0.530	rs11708617	chr3:48396309	C/T	cg11946769	chr3:48343235	NME6	0.46	5.56	0.33	7.14e-8	Longevity;
KIRP	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs4774830	0.744	rs76851035	chr15:56165642	G/A	cg05129572	chr15:56138634	NEDD4	0.76	4.96	0.3	1.3e-6	Delta-5 desaturase activity;
KIRP	cis	rs7327064	0.666	rs9531717	chr13:36862561	T/C	cg13455704	chr13:36871754	C13orf38	0.61	5.6	0.34	5.7e-8	Economic and political preferences;
KIRP	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.47	-0.38	5.26e-10	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.99	-0.36	7.41e-9	Renal cell carcinoma;
KIRP	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.15	-28.02	-0.87	1.64e-78	Myeloid white cell count;
KIRP	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.87	-10.19	-0.54	1.44e-20	White matter hyperintensity burden;
KIRP	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.59	9.47	0.52	2.38e-18	Neuroticism;
KIRP	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.76	-0.34	2.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4236601	1.000	rs2024211	chr7:116153025	A/C	cg05166801	chr7:116143459	CAV2	0.51	6.2	0.37	2.3e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg06654118	chr4:1303317	MAEA	0.28	5.17	0.31	4.92e-7	Obesity-related traits;
KIRP	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg00504896	chr12:9437009	LOC642846	-0.51	-6.33	-0.37	1.18e-9	Breast size;
KIRP	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.47	-5.55	-0.33	7.48e-8	Bacteremia;
KIRP	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.62	-7.42	-0.43	1.93e-12	Obesity-related traits;
KIRP	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	4.85	0.3	2.15e-6	Eosinophil percentage of white cells;
KIRP	cis	rs12949688	0.967	rs8064970	chr17:55824687	T/C	cg12582317	chr17:55822272	NA	0.62	10.45	0.55	2.09e-21	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg09455208	chr3:40491958	NA	0.36	6.29	0.37	1.46e-9	Renal cell carcinoma;
KIRP	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg17366294	chr4:99064904	C4orf37	-0.37	-5.03	-0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg10890403	chr12:132336407	NA	-0.42	-5.16	-0.31	5e-7	Migraine;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15711240	chr10:32856510	CCDC7;C10orf68	-0.47	-7.37	-0.43	2.66e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20285559	chr1:6688542	THAP3	0.47	6.16	0.37	3.03e-9	Pancreatic cancer;
KIRP	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.67	9.33	0.51	6.5e-18	Red blood cell count;
KIRP	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg13319975	chr6:146136371	FBXO30	0.47	6.28	0.37	1.55e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg18833306	chr6:118973337	C6orf204	0.39	4.89	0.3	1.82e-6	Electrocardiographic conduction measures;
KIRP	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg03388025	chr16:89894329	SPIRE2	-0.33	-6.04	-0.36	5.56e-9	Vitiligo;
KIRP	cis	rs6752107	0.936	rs13411660	chr2:234208258	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	8.89	0.49	1.37e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg00262122	chr8:11665843	FDFT1	-0.45	-5.26	-0.32	3.11e-7	Triglycerides;
KIRP	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-5.61	-0.34	5.51e-8	Height;
KIRP	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.18	-0.42	8.33e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg21573476	chr21:45109991	RRP1B	-0.83	-12.66	-0.63	1.29e-28	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01290068	chr5:162932702	MAT2B	0.46	6.31	0.37	1.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg16141378	chr3:129829833	LOC729375	0.52	6.17	0.37	2.82e-9	Systemic lupus erythematosus;
KIRP	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg00800038	chr16:89945340	TCF25	-0.83	-6.22	-0.37	2.14e-9	Skin colour saturation;
KIRP	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.77	-10.63	-0.56	5.58e-22	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17690086	chr6:36344146	ETV7	-0.41	-6.15	-0.37	3.1e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.97	-10.26	-0.55	8.46e-21	Schizophrenia;
KIRP	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg11569703	chr11:65557185	OVOL1	0.69	12.42	0.62	7.86e-28	Acne (severe);
KIRP	cis	rs4523957	0.583	rs2641443	chr17:2036162	G/A	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.5	0.38	4.47e-10	Personality dimensions;
KIRP	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.33	-5.74	-0.34	2.74e-8	Refractive error;
KIRP	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Morning vs. evening chronotype;
KIRP	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.35	-5.33	-0.32	2.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.71	9.38	0.51	4.62e-18	Renal function-related traits (BUN);
KIRP	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg01559446	chr3:44596178	ZNF167	-0.36	-5.14	-0.31	5.5e-7	Depressive symptoms;
KIRP	cis	rs13006833	0.739	rs291430	chr2:191198727	A/C	cg21644426	chr2:191273491	MFSD6	0.45	5.43	0.33	1.36e-7	Urinary metabolites;
KIRP	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.47	-6.18	-0.37	2.71e-9	Dietary macronutrient intake;
KIRP	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg16255804	chr6:135334527	HBS1L	-0.38	-5.93	-0.35	1.01e-8	Red blood cell count;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26425730	chr6:153304295	FBXO5	0.52	6.32	0.37	1.2e-9	Myopia (pathological);
KIRP	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg01877450	chr7:97915802	BRI3	-0.53	-6.86	-0.4	5.45e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12693043	0.790	rs17257938	chr2:175407780	C/T	cg11778734	chr2:175439522	WIPF1	-0.52	-7.28	-0.42	4.55e-12	Urate levels (BMI interaction);
KIRP	cis	rs7113874	0.659	rs12295855	chr11:8527418	A/G	cg08015107	chr11:8618950	NA	-0.49	-6.45	-0.38	5.99e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.41	5.13	0.31	5.76e-7	Aortic root size;
KIRP	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.79	7.66	0.44	4.3e-13	Inflammatory bowel disease;
KIRP	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.64	-7.11	-0.41	1.25e-11	Primary sclerosing cholangitis;
KIRP	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.32	6.44	0.38	6.08e-10	Schizophrenia;
KIRP	cis	rs6585424	1.000	rs56190825	chr10:81934736	C/T	cg27417294	chr10:81904244	PLAC9	0.52	5.13	0.31	5.93e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg00631329	chr6:26305371	NA	-0.66	-8.89	-0.49	1.37e-16	Educational attainment;
KIRP	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg11718315	chr15:65579480	PARP16	0.52	6.36	0.38	9.75e-10	Educational attainment;
KIRP	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.17e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	cg12689670	chr1:183009347	LAMC1	0.56	7.9	0.45	9.36e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg20542592	chr8:11973495	FAM66D	0.37	4.89	0.3	1.83e-6	Neuroticism;
KIRP	cis	rs6832769	0.922	rs9993675	chr4:56243522	C/T	cg05960024	chr4:56376020	CLOCK	0.61	7.57	0.43	7.43e-13	Personality dimensions;
KIRP	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg26022315	chr17:47021804	SNF8	0.41	5.24	0.32	3.5e-7	Type 2 diabetes;
KIRP	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg21775007	chr8:11205619	TDH	-0.46	-6.06	-0.36	5.06e-9	Neuroticism;
KIRP	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg02297831	chr4:17616191	MED28	0.54	6.84	0.4	6.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.81	10.52	0.56	1.33e-21	Mean platelet volume;
KIRP	cis	rs6700559	0.565	rs12728040	chr1:200595879	G/A	cg07804481	chr1:200639085	DDX59	0.46	5.84	0.35	1.68e-8	Coronary artery disease;
KIRP	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.75	9.88	0.53	1.32e-19	Menopause (age at onset);
KIRP	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-1.09	-14.46	-0.68	9.91e-35	Alopecia areata;
KIRP	cis	rs71403859	0.614	rs12149533	chr16:71801946	C/T	cg08717414	chr16:71523259	ZNF19	-1.02	-8.43	-0.47	3.01e-15	Post bronchodilator FEV1;
KIRP	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg00361562	chr2:198649771	BOLL	-0.53	-5.19	-0.31	4.41e-7	Ulcerative colitis;
KIRP	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.2e-8	Aortic root size;
KIRP	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.05	-0.54	3.82e-20	Hypospadias;
KIRP	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.81	7.74	0.44	2.53e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg12975709	chr7:47317262	TNS3	0.44	6.04	0.36	5.66e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.58	-0.34	6.31e-8	IgG glycosylation;
KIRP	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg19000871	chr14:103996768	TRMT61A	0.43	5.79	0.35	2.1e-8	Coronary artery disease;
KIRP	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg00919237	chr7:87102261	ABCB4	-0.75	-9.44	-0.52	3.05e-18	Gallbladder cancer;
KIRP	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg21775007	chr8:11205619	TDH	0.44	5.97	0.36	8.43e-9	Neuroticism;
KIRP	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.64	-7.72	-0.44	2.9e-13	Morning vs. evening chronotype;
KIRP	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg21360079	chr12:107162445	NA	-0.69	-9.51	-0.52	1.87e-18	Heart rate;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22134634	chr17:57970430	TUBD1;RPS6KB1	0.54	6.36	0.38	9.98e-10	Smoking initiation;
KIRP	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg12560992	chr17:57184187	TRIM37	0.62	5.7	0.34	3.34e-8	Cognitive test performance;
KIRP	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.81	-11.33	-0.59	3.15e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.79	0.4	8.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg03351412	chr1:154909251	PMVK	-0.61	-8.08	-0.46	2.99e-14	Prostate cancer;
KIRP	cis	rs580438	0.529	rs6442381	chr3:13428235	G/A	cg10657019	chr3:13328039	NA	-0.5	-6.47	-0.38	5.21e-10	Myringotomy;
KIRP	cis	rs1440410	0.571	rs13116507	chr4:144039438	G/A	cg01719995	chr4:144104893	USP38	0.45	5.99	0.36	7.54e-9	Ischemic stroke;
KIRP	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg00647317	chr7:50633725	DDC	0.43	6.19	0.37	2.45e-9	Systemic sclerosis;
KIRP	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-7.54	-0.43	9.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26002218	chr14:103986227	CKB	0.26	4.96	0.3	1.33e-6	Body mass index;
KIRP	cis	rs4683702	0.965	rs11716897	chr3:142605556	G/A	cg22826874	chr3:142608218	PCOLCE2	-0.39	-5.76	-0.34	2.49e-8	Blood protein levels;
KIRP	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.77	-11.72	-0.6	1.69e-25	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-5.78	-0.35	2.26e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.38	-0.43	2.41e-12	Glomerular filtration rate (creatinine);
KIRP	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg18944383	chr4:111397179	ENPEP	-0.53	-6.18	-0.37	2.71e-9	Axial length;
KIRP	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg21548813	chr6:291882	DUSP22	-0.58	-6.74	-0.39	1.13e-10	Menopause (age at onset);
KIRP	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.64	9.49	0.52	2.08e-18	Educational attainment;
KIRP	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg06204229	chr3:52865917	ITIH4	0.47	4.99	0.3	1.16e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00119011	chr13:45694603	GTF2F2	0.47	6.44	0.38	6.33e-10	Survival in pancreatic cancer;
KIRP	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg07541023	chr7:19748670	TWISTNB	0.66	5.8	0.35	2e-8	Thyroid stimulating hormone;
KIRP	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.64	-7.25	-0.42	5.32e-12	Longevity;Endometriosis;
KIRP	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.85	12.55	0.62	2.89e-28	Eosinophil percentage of white cells;
KIRP	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.33	0.32	2.19e-7	Cannabis dependence symptom count;
KIRP	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg23533926	chr12:111358616	MYL2	-0.5	-6.52	-0.38	4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg06212747	chr3:49208901	KLHDC8B	0.72	9.95	0.54	7.99e-20	Parkinson's disease;
KIRP	cis	rs9393813	1.000	rs9393813	chr6:27331596	C/A	cg18711553	chr6:27366782	ZNF391	0.37	5.41	0.33	1.51e-7	Bipolar disorder;
KIRP	cis	rs72781680	0.611	rs7602797	chr2:24318148	C/T	cg20701182	chr2:24300061	SF3B14	0.95	10.41	0.55	2.83e-21	Lymphocyte counts;
KIRP	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.51	-6.79	-0.4	8.27e-11	Primary sclerosing cholangitis;
KIRP	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	11.07	0.58	2.27e-23	Total body bone mineral density;
KIRP	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-6.99	-0.41	2.55e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs258892	0.895	rs9654412	chr5:72040659	A/G	cg21869765	chr5:72125136	TNPO1	-0.5	-5.72	-0.34	3e-8	Small cell lung carcinoma;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg26351039	chr19:49138730	DBP	-0.44	-6.12	-0.36	3.67e-9	Warfarin maintenance dose;
KIRP	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19171272	chr22:38449367	NA	-0.57	-8.57	-0.48	1.16e-15	Glioblastoma;Glioma;
KIRP	cis	rs703980	1.000	rs12571751	chr10:80942631	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.29	-4.85	-0.3	2.21e-6	Type 2 diabetes;
KIRP	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.79	-9.78	-0.53	2.75e-19	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg01879757	chr17:41196368	BRCA1	-0.57	-7.86	-0.45	1.23e-13	Menopause (age at onset);
KIRP	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-7.58	-0.44	6.89e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34779708	0.733	rs4007271	chr10:35546611	C/T	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg17401720	chr7:158221031	PTPRN2	0.32	5.13	0.31	5.83e-7	Obesity-related traits;
KIRP	cis	rs59868192	0.925	rs72726032	chr15:42258417	C/T	cg20935245	chr15:42234343	EHD4	-0.56	-5.52	-0.33	8.57e-8	White blood cell count;
KIRP	cis	rs12780845	0.505	rs10904893	chr10:17204944	T/C	cg01003015	chr10:17271136	VIM	-0.4	-4.96	-0.3	1.32e-6	Homocysteine levels;
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg18183042	chr17:80733038	TBCD	-0.37	-4.99	-0.3	1.13e-6	Glycated hemoglobin levels;
KIRP	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.33	-0.32	2.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7274811	0.711	rs291680	chr20:32022251	A/C	cg14921437	chr20:32255988	NECAB3;C20orf134	0.44	5.26	0.32	3.13e-7	Height;
KIRP	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg25019033	chr10:957182	NA	-0.62	-7.23	-0.42	6.06e-12	Eosinophil percentage of granulocytes;
KIRP	trans	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.55	7.13	0.41	1.12e-11	Endometrial cancer;
KIRP	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg21775007	chr8:11205619	TDH	-0.42	-5.43	-0.33	1.36e-7	Neuroticism;
KIRP	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.66	-7.94	-0.45	7.28e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8133932	0.654	rs10854474	chr21:47332700	A/G	cg11214348	chr21:47283868	PCBP3	0.45	5.13	0.31	5.99e-7	Schizophrenia;
KIRP	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.55	0.39	3.33e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6973256	0.569	rs9649595	chr7:133385921	G/C	cg10665199	chr7:133106180	EXOC4	0.49	6.02	0.36	6.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3105593	0.575	rs3098174	chr15:50778853	C/T	cg08437265	chr15:50716283	USP8	0.42	5.63	0.34	4.88e-8	QT interval;
KIRP	cis	rs9649213	0.574	rs6979373	chr7:97961844	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.71	10.1	0.54	2.65e-20	Inflammatory bowel disease;
KIRP	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg06050784	chr16:88016603	BANP	0.4	5.06	0.31	8.17e-7	Menopause (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13671128	chr19:1612344	TCF3	0.53	7.03	0.41	1.97e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17829914	chr5:72385895	FCHO2	-0.41	-6.13	-0.36	3.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg00677455	chr12:58241039	CTDSP2	0.87	8.81	0.49	2.34e-16	Multiple sclerosis;
KIRP	cis	rs12044355	0.896	rs11122324	chr1:231859181	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	6.09	0.36	4.35e-9	Alzheimer's disease;
KIRP	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg15247329	chr7:2764246	NA	-0.34	-4.95	-0.3	1.39e-6	Height;
KIRP	trans	rs76288851	0.799	rs73205626	chr3:126597242	A/G	cg13821433	chr2:26726535	OTOF	0.58	6.49	0.38	4.61e-10	Alcoholic chronic pancreatitis;
KIRP	trans	rs35100037	0.803	rs34057383	chr5:128599903	A/T	cg23338408	chr14:31289523	NA	-0.7	-6.08	-0.36	4.47e-9	Ankle injury;
KIRP	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.44	5.53	0.33	8.13e-8	Aortic root size;
KIRP	trans	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg03067462	chr11:2422131	TSSC4	-0.48	-6.04	-0.36	5.74e-9	Atopic dermatitis;
KIRP	cis	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.29	0.37	1.41e-9	Leprosy;
KIRP	cis	rs6840360	0.582	rs11733820	chr4:152316139	T/C	cg25486957	chr4:152246857	NA	-0.42	-5.01	-0.3	1.06e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.44	6.0	0.36	7.19e-9	Red blood cell count;
KIRP	trans	rs9650657	0.740	rs12676417	chr8:10668634	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	6.21	0.37	2.3e-9	Neuroticism;
KIRP	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2290402	0.536	rs2279175	chr4:852013	G/A	cg00846425	chr4:957561	DGKQ	-0.48	-5.23	-0.32	3.58e-7	Type 2 diabetes;
KIRP	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	14.17	0.67	9.83e-34	Platelet count;
KIRP	cis	rs10073892	0.509	rs1354620	chr5:101985206	T/G	cg19774478	chr5:101632501	SLCO4C1	0.53	5.48	0.33	1.05e-7	Cognitive decline (age-related);
KIRP	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.7	-0.53	4.74e-19	Morning vs. evening chronotype;
KIRP	cis	rs2882667	0.898	rs6890272	chr5:138371116	G/A	cg04439458	chr5:138467593	SIL1	-0.45	-7.52	-0.43	1.02e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14169450	chr9:139327907	INPP5E	0.34	4.91	0.3	1.67e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Bladder cancer;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	6.73	0.39	1.19e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg04733989	chr22:42467013	NAGA	0.66	8.17	0.46	1.6e-14	Schizophrenia;
KIRP	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg03929089	chr4:120376271	NA	0.97	6.95	0.41	3.17e-11	Myopia (pathological);
KIRP	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg10326726	chr10:51549505	MSMB	-0.55	-7.72	-0.44	3e-13	Prostate-specific antigen levels;
KIRP	cis	rs4950322	0.570	rs4301678	chr1:146733564	C/T	cg22381352	chr1:146742008	CHD1L	-0.47	-5.5	-0.33	9.32e-8	Protein quantitative trait loci;
KIRP	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.15	9.92	0.53	1e-19	Atopic dermatitis;
KIRP	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.69	-10.02	-0.54	5.04e-20	Brugada syndrome;
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg05527609	chr1:210001259	C1orf107	0.55	7.63	0.44	4.99e-13	Monobrow;
KIRP	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	1.05	15.06	0.69	9.04e-37	Menopause (age at onset);
KIRP	cis	rs1298062	0.663	rs1274685	chr19:50997828	G/A	cg11430371	chr19:50961752	MYBPC2	0.36	4.96	0.3	1.29e-6	Age of smoking initiation;
KIRP	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg17764715	chr19:33622953	WDR88	0.79	11.52	0.59	7.41e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.45	5.51	0.33	9.23e-8	Facial morphology (factor 20);
KIRP	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.1	0.46	2.6e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs7577696	0.525	rs10153876	chr2:32011477	T/C	cg02381751	chr2:32503542	YIPF4	-0.52	-5.04	-0.31	9.1e-7	Inflammatory biomarkers;
KIRP	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg01689657	chr7:91764605	CYP51A1	-0.34	-5.05	-0.31	8.62e-7	Breast cancer;
KIRP	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.28	0.37	1.51e-9	Aortic root size;
KIRP	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg10047753	chr17:41438598	NA	1.13	17.92	0.75	1.64e-46	Menopause (age at onset);
KIRP	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.79	-0.35	2.19e-8	Electroencephalogram traits;
KIRP	cis	rs7246657	0.722	rs1564206	chr19:38040076	C/T	cg18154014	chr19:37997991	ZNF793	0.61	6.66	0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.86	-10.16	-0.54	1.74e-20	Osteoarthritis;
KIRP	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.7	9.78	0.53	2.7e-19	Schizophrenia;
KIRP	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.82	0.45	1.55e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.82	-8.9	-0.49	1.27e-16	Motion sickness;
KIRP	cis	rs2275565	0.872	rs7536446	chr1:237023442	G/A	cg17297354	chr1:237056641	MTR	-0.4	-5.13	-0.31	5.9e-7	Homocysteine levels;
KIRP	cis	rs7578199	0.886	rs34882686	chr2:242374519	C/T	cg01632474	chr2:242799312	PDCD1	0.38	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg17207736	chr8:142237307	SLC45A4	0.51	6.38	0.38	8.85e-10	Immature fraction of reticulocytes;
KIRP	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.73	8.96	0.5	8.52e-17	Mammographic density (dense area);
KIRP	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg22029157	chr1:209979665	IRF6	0.38	5.78	0.35	2.3e-8	Monobrow;
KIRP	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg16414030	chr3:133502952	NA	-0.46	-5.4	-0.33	1.57e-7	Ankle injury;
KIRP	cis	rs4073221	0.789	rs35051749	chr3:18217673	T/C	cg07694806	chr3:18168406	NA	-0.72	-6.29	-0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs12930096	1.000	rs55947021	chr16:11678949	C/A	cg07439791	chr16:11680400	LITAF	0.67	5.86	0.35	1.48e-8	QT interval;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18751306	chr15:81294292	MESDC1	0.97	6.58	0.39	2.84e-10	P wave terminal force;
KIRP	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	0.99	7.71	0.44	3.02e-13	Arsenic metabolism;
KIRP	cis	rs80130819	0.515	rs72644846	chr12:48508283	A/G	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Prostate cancer;
KIRP	cis	rs661054	1.000	rs2045241	chr11:114428783	G/A	cg19465033	chr11:114479364	NA	0.38	5.17	0.31	4.9e-7	Ulcerative colitis;
KIRP	trans	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg13565492	chr6:43139072	SRF	-0.93	-8.6	-0.48	9.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg15488143	chr7:128924101	AHCYL2	-0.46	-5.9	-0.35	1.23e-8	White matter hyperintensity burden;
KIRP	cis	rs77633900	0.772	rs283799	chr15:76752834	A/C	cg21673338	chr15:77095150	SCAPER	-0.65	-6.2	-0.37	2.39e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg27462398	chr1:86174642	ZNHIT6	-0.53	-7.16	-0.42	9.42e-12	Urate levels in overweight individuals;
KIRP	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.83	12.5	0.62	4.38e-28	Body mass index;
KIRP	cis	rs55962025	0.883	rs82332	chr4:3225466	A/G	cg06533319	chr4:3265114	C4orf44	0.45	5.14	0.31	5.47e-7	Parental longevity (mother's age at death);
KIRP	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14169450	chr9:139327907	INPP5E	0.5	7.21	0.42	6.74e-12	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs6708331	0.517	rs6743372	chr2:70352640	G/T	cg05298696	chr2:70188691	ASPRV1	-0.39	-5.1	-0.31	6.8e-7	Obesity-related traits;
KIRP	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.45	-6.98	-0.41	2.68e-11	Platelet distribution width;
KIRP	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	10.5	0.56	1.48e-21	Cognitive test performance;
KIRP	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.67	-0.34	3.92e-8	Longevity;Endometriosis;
KIRP	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.41	5.44	0.33	1.28e-7	Bipolar disorder;
KIRP	cis	rs10751667	0.600	rs7950955	chr11:1011490	G/A	cg06064525	chr11:970664	AP2A2	-0.31	-5.72	-0.34	3.1e-8	Alzheimer's disease (late onset);
KIRP	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.11	12.12	0.61	8.3e-27	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg05784532	chr1:230284198	GALNT2	0.41	6.2	0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs16857609	0.628	rs1072086	chr2:218351950	A/T	cg15335768	chr2:218268053	DIRC3	-0.4	-5.73	-0.34	3e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg26681399	chr22:41777847	TEF	0.45	4.96	0.3	1.32e-6	Vitiligo;
KIRP	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.66	-9.29	-0.51	8.34e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	7.68	0.44	3.76e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.56	7.14	0.41	1.05e-11	Coronary artery disease;
KIRP	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2882667	0.858	rs13176497	chr5:138446074	T/C	cg04439458	chr5:138467593	SIL1	-0.54	-7.96	-0.45	6.43e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04276069	chr19:2061849	NA	0.51	6.62	0.39	2.18e-10	Parkinson's disease;
KIRP	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg23127183	chr11:57508653	C11orf31	0.53	6.84	0.4	6.32e-11	Schizophrenia;
KIRP	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.46	6.67	0.39	1.71e-10	Sitting height ratio;
KIRP	cis	rs2299587	0.545	rs28603021	chr8:17760754	C/T	cg01800426	chr8:17659068	MTUS1	-0.42	-5.02	-0.3	9.96e-7	Economic and political preferences;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14234805	chr20:37101345	RALGAPB	0.48	6.05	0.36	5.29e-9	Myopia (pathological);
KIRP	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.19	13.07	0.64	5.4e-30	Eosinophil percentage of granulocytes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01180167	chr11:84620643	DLG2	-0.37	-6.02	-0.36	6.45e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs559928	0.502	rs7127926	chr11:64190767	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.47	4.95	0.3	1.4e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.21	0.37	2.27e-9	Leprosy;
KIRP	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.46	-0.33	1.14e-7	Life satisfaction;
KIRP	cis	rs2273669	0.667	rs12210444	chr6:109305743	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs9403521	0.673	rs3934959	chr6:143979710	A/G	cg18240653	chr6:144019428	PHACTR2	-0.52	-6.38	-0.38	8.59e-10	Obesity-related traits;
KIRP	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg23100626	chr2:96804247	ASTL	0.44	5.67	0.34	4e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg24881330	chr22:46731750	TRMU	0.75	6.11	0.36	3.87e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs735539	0.645	rs7995773	chr13:21251235	T/C	cg04906043	chr13:21280425	IL17D	-0.54	-6.61	-0.39	2.39e-10	Dental caries;
KIRP	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.67	-7.28	-0.42	4.41e-12	DNA methylation (variation);
KIRP	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg08603382	chr10:743973	NA	-0.55	-8.08	-0.46	2.86e-14	Psychosis in Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24613083	chr17:59539715	TBX4	0.44	6.65	0.39	1.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7520050	0.966	rs10749860	chr1:46328210	C/G	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.05	0.46	3.44e-14	Menarche (age at onset);
KIRP	cis	rs7538876	1.000	rs56384645	chr1:17722952	T/C	cg07965774	chr1:17746286	RCC2	0.28	4.87	0.3	2e-6	Basal cell carcinoma;
KIRP	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.54	-7.9	-0.45	9.31e-14	Immature fraction of reticulocytes;
KIRP	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg20607798	chr8:58055168	NA	0.59	5.45	0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-0.89	-6.76	-0.4	9.83e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg11271282	chr2:238384023	NA	0.47	5.31	0.32	2.47e-7	Prostate cancer;
KIRP	cis	rs5753618	0.583	rs8138596	chr22:31786961	T/A	cg02404636	chr22:31891804	SFI1	0.53	5.71	0.34	3.22e-8	Colorectal cancer;
KIRP	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.8e-17	Lymphocyte counts;
KIRP	cis	rs6681460	0.546	rs1998716	chr1:67117106	T/A	cg02459107	chr1:67143332	SGIP1	0.37	5.26	0.32	3.06e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.71	10.58	0.56	8.12e-22	Eosinophilic esophagitis;
KIRP	cis	rs367943	0.666	rs10051834	chr5:112693803	C/T	cg12552261	chr5:112820674	MCC	0.52	6.16	0.37	3.02e-9	Type 2 diabetes;
KIRP	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.48	-5.97	-0.36	8.24e-9	Initial pursuit acceleration;
KIRP	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg14024328	chr4:719362	PCGF3	-0.56	-8.63	-0.48	7.61e-16	White blood cell count;
KIRP	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.46	8.62	0.48	8.39e-16	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg03388025	chr16:89894329	SPIRE2	0.44	8.97	0.5	7.74e-17	Vitiligo;
KIRP	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19700328	chr14:106028568	NA	0.54	5.84	0.35	1.61e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs2671245	0.933	rs2767518	chr1:56163493	T/G	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.4	-5.83	-0.35	1.75e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.54	-0.43	9.27e-13	Bipolar disorder;
KIRP	cis	rs508618	1.000	rs508618	chr1:231532312	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-5.98	-0.36	7.89e-9	Red blood cell count;
KIRP	cis	rs9381107	0.932	rs9369200	chr6:9453471	C/T	cg14735645	chr6:9486422	NA	-0.44	-5.3	-0.32	2.57e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6840360	0.870	rs6814554	chr4:152454334	G/A	cg22705602	chr4:152727874	NA	-0.39	-5.97	-0.36	8.2e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-4.88	-0.3	1.91e-6	IgG glycosylation;
KIRP	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.9e-8	Depression;
KIRP	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg01244601	chr4:120671846	NA	-0.39	-4.94	-0.3	1.43e-6	Corneal astigmatism;
KIRP	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg16141378	chr3:129829833	LOC729375	0.57	7.64	0.44	4.91e-13	Retinal vascular caliber;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg27532560	chr4:187881888	NA	-0.74	-12.53	-0.62	3.59e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.78	0.35	2.2e-8	Total cholesterol levels;
KIRP	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg04731861	chr2:219085781	ARPC2	0.22	5.38	0.32	1.71e-7	Colorectal cancer;
KIRP	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.71	6.1	0.36	4.17e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg17554472	chr22:41940697	POLR3H	0.61	6.39	0.38	8.06e-10	Vitiligo;
KIRP	cis	rs4671458	0.724	rs56219461	chr2:63669666	G/A	cg17519650	chr2:63277830	OTX1	-0.51	-5.08	-0.31	7.64e-7	Subjective well-being;
KIRP	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg07972983	chr1:205091412	RBBP5	0.43	5.23	0.32	3.7e-7	Red blood cell count;
KIRP	cis	rs62481355	1.000	rs55791028	chr7:127204881	T/C	cg25922125	chr7:127225783	GCC1	-0.46	-4.89	-0.3	1.81e-6	Type 2 diabetes;
KIRP	trans	rs12517041	1.000	rs10520890	chr5:23290143	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.93	9.19	0.51	1.71e-17	Calcium levels;
KIRP	cis	rs10875746	0.623	rs10875793	chr12:48697430	T/A	cg26205652	chr12:48591994	NA	0.79	9.88	0.53	1.3e-19	Longevity (90 years and older);
KIRP	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg01028140	chr2:1542097	TPO	-0.58	-6.63	-0.39	2.06e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7546094	1.000	rs7524494	chr1:113197800	A/G	cg22162597	chr1:113214053	CAPZA1	-0.5	-7.06	-0.41	1.67e-11	Platelet distribution width;
KIRP	cis	rs1190552	0.894	rs1190546	chr14:102904966	A/G	cg10241871	chr14:102965420	TECPR2	0.51	5.68	0.34	3.77e-8	Blood protein levels;
KIRP	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.59	7.25	0.42	5.26e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg03465714	chr1:152285911	FLG	0.48	5.29	0.32	2.68e-7	Atopic dermatitis;
KIRP	cis	rs3789045	0.866	rs61817482	chr1:204570347	G/A	cg08641003	chr1:204589008	LRRN2	-0.52	-5.14	-0.31	5.53e-7	Educational attainment (college completion);
KIRP	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg22676075	chr6:135203613	NA	0.52	7.71	0.44	3.17e-13	Red blood cell count;
KIRP	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.67	7.42	0.43	1.91e-12	Hair shape;
KIRP	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.39	9.47	0.52	2.47e-18	Corneal astigmatism;
KIRP	cis	rs12190007	0.776	rs2981940	chr6:169785501	C/G	cg15038512	chr6:170123185	PHF10	-0.43	-5.78	-0.35	2.25e-8	Obesity-related traits;
KIRP	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.69	-10.02	-0.54	5.04e-20	Brugada syndrome;
KIRP	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.85	0.3	2.18e-6	Educational attainment;
KIRP	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.24	24.02	0.84	1.85e-66	Cognitive function;
KIRP	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.68	0.48	5.57e-16	Motion sickness;
KIRP	trans	rs9409565	0.826	rs9409767	chr9:97228524	T/C	cg05679027	chr9:99775184	HIATL2	-0.57	-6.89	-0.4	4.77e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.69	-11.99	-0.61	2.19e-26	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg25214090	chr10:38739885	LOC399744	0.47	6.02	0.36	6.33e-9	Diastolic blood pressure;
KIRP	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.48	-0.33	1.05e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2661868	0.918	rs2636314	chr1:8440643	G/A	cg25722041	chr1:8623473	RERE	0.41	4.86	0.3	2.09e-6	Life satisfaction;
KIRP	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.72e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.76	-9.86	-0.53	1.49e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs42648	1.000	rs42656	chr7:89981636	A/G	cg25739043	chr7:89950458	NA	-0.47	-7.62	-0.44	5.36e-13	Homocysteine levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg01235203	chr3:187461998	BCL6	0.93	6.19	0.37	2.46e-9	P wave terminal force;
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.45	0.52	2.8e-18	Lung cancer;
KIRP	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg06740227	chr12:86229804	RASSF9	-0.49	-6.21	-0.37	2.24e-9	Major depressive disorder;
KIRP	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs8084125	1.000	rs62105167	chr18:74944594	G/A	cg26065057	chr18:74961000	GALR1	0.76	7.46	0.43	1.44e-12	Obesity-related traits;
KIRP	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	9.74	0.53	3.51e-19	Total body bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20704247	chr8:144409764	TOP1MT	0.54	6.35	0.38	1.04e-9	Interleukin-4 levels;
KIRP	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg09137382	chr11:130731461	NA	0.57	8.23	0.46	1.07e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs76793172	0.623	rs8107744	chr19:46300848	C/A	cg11657440	chr19:46296263	DMWD	0.74	5.34	0.32	2.09e-7	Eosinophil counts;
KIRP	cis	rs9393777	0.547	rs2893910	chr6:27283254	A/T	cg12292205	chr6:26970375	C6orf41	-0.46	-4.9	-0.3	1.73e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7712401	0.601	rs398142	chr5:122345576	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.41	-0.33	1.48e-7	Mean platelet volume;
KIRP	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.45	5.11	0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.89	14.07	0.67	2.19e-33	Height;
KIRP	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.37	-5.27	-0.32	2.96e-7	Motion sickness;
KIRP	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg20991723	chr1:152506922	NA	-0.46	-5.52	-0.33	8.42e-8	Hair morphology;
KIRP	cis	rs7646881	0.812	rs6788069	chr3:158459459	C/T	cg19483011	chr3:158453295	NA	0.54	6.09	0.36	4.31e-9	Tetralogy of Fallot;
KIRP	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-0.99	-15.28	-0.7	1.58e-37	Dilated cardiomyopathy;
KIRP	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.63	-0.44	5.09e-13	Type 2 diabetes;
KIRP	cis	rs12044355	1.000	rs12044355	chr1:231844347	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	4.86	0.3	2.06e-6	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07391610	chr1:211432754	RCOR3	0.52	7.54	0.43	8.76e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9807841	0.670	rs8099926	chr19:10778647	A/G	cg09936142	chr19:10668400	KRI1	-0.44	-4.87	-0.3	2.02e-6	Inflammatory skin disease;
KIRP	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs4780401	0.933	rs1592572	chr16:11810382	T/C	cg10503133	chr16:11766667	SNN	-0.22	-4.85	-0.3	2.22e-6	Rheumatoid arthritis;
KIRP	cis	rs3105593	1.000	rs3131596	chr15:50877575	T/C	cg08437265	chr15:50716283	USP8	0.41	5.14	0.31	5.72e-7	QT interval;
KIRP	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-0.56	-8.07	-0.46	3.14e-14	Coronary artery disease;
KIRP	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg00405596	chr8:11794950	NA	-0.42	-5.26	-0.32	3.07e-7	Triglycerides;
KIRP	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg25486957	chr4:152246857	NA	-0.43	-5.01	-0.3	1.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7520050	0.778	rs3014218	chr1:46026328	A/C	cg24296786	chr1:45957014	TESK2	0.48	5.96	0.36	8.67e-9	Red blood cell count;Reticulocyte count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27649522	chr12:12877729	APOLD1	0.55	6.43	0.38	6.61e-10	Smoking initiation;
KIRP	cis	rs1555895	0.576	rs4362075	chr10:865476	A/G	cg10017260	chr10:834428	NA	-0.47	-6.98	-0.41	2.8e-11	Survival in rectal cancer;
KIRP	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.81	7.25	0.42	5.51e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7551222	0.613	rs10900592	chr1:204460681	T/C	cg20240347	chr1:204465584	NA	-0.4	-7.35	-0.42	2.95e-12	Schizophrenia;
KIRP	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.48	-6.11	-0.36	3.86e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg19847130	chr8:10466454	RP1L1	0.38	5.75	0.34	2.61e-8	Retinal vascular caliber;
KIRP	cis	rs2150410	1.000	rs6517531	chr21:40637647	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs787274	1.000	rs787297	chr9:115542133	G/T	cg13803584	chr9:115635662	SNX30	-0.73	-8.28	-0.47	7.7e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.73	10.46	0.55	2.04e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.63	-10.76	-0.57	2.25e-22	White blood cell count (basophil);
KIRP	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg19743168	chr1:23544995	NA	0.51	7.13	0.41	1.11e-11	Height;
KIRP	cis	rs12135191	0.771	rs12724867	chr1:236497614	G/A	cg21399712	chr1:236511386	NA	-0.48	-6.19	-0.37	2.54e-9	Urate levels (BMI interaction);
KIRP	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg21366198	chr4:185655624	MLF1IP	0.39	5.31	0.32	2.4e-7	Kawasaki disease;
KIRP	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg00982548	chr2:198649783	BOLL	-0.57	-5.4	-0.33	1.55e-7	Ulcerative colitis;
KIRP	cis	rs12580194	0.593	rs58709231	chr12:55719090	T/C	cg19537932	chr12:55886519	OR6C68	-0.46	-6.09	-0.36	4.28e-9	Cancer;
KIRP	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.12	-0.31	6.12e-7	Life satisfaction;
KIRP	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.48	-0.38	4.86e-10	Type 2 diabetes;
KIRP	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg10189774	chr4:17578691	LAP3	0.44	5.26	0.32	3.06e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.44	-6.89	-0.4	4.62e-11	Fractional excretion of uric acid;
KIRP	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.61	-9.0	-0.5	6.42e-17	Body mass index;
KIRP	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.58	15.07	0.69	8.82e-37	Airflow obstruction;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-6.27	-0.37	1.63e-9	Lung cancer;
KIRP	cis	rs1692580	0.807	rs4648818	chr1:2178999	C/T	cg21194808	chr1:2205498	SKI	0.35	5.16	0.31	4.99e-7	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.59	5.49	0.33	9.94e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs76288851	0.733	rs11707883	chr3:126414066	T/C	cg13821433	chr2:26726535	OTOF	0.55	6.02	0.36	6.19e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.89	11.21	0.58	8.12e-24	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08439880	chr3:133502540	NA	-0.49	-6.23	-0.37	1.97e-9	Iron status biomarkers;
KIRP	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-0.6	-6.61	-0.39	2.35e-10	Initial pursuit acceleration;
KIRP	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-6.77	-0.4	9.2e-11	Heart rate;
KIRP	cis	rs10484885	0.559	rs7776115	chr6:90192376	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.49	-5.09	-0.31	7.03e-7	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16434002	chr17:42200994	HDAC5	-0.54	-6.87	-0.4	5.26e-11	Total body bone mineral density;
KIRP	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.8	11.61	0.59	3.9e-25	Neuroticism;
KIRP	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	0.85	6.99	0.41	2.63e-11	Alzheimer's disease;
KIRP	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.28e-6	Menopause (age at onset);
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13198984	chr17:80129470	CCDC57	0.56	8.6	0.48	9.44e-16	Life satisfaction;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.17	-0.37	2.83e-9	Longevity;Endometriosis;
KIRP	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.18	0.42	8.46e-12	Joint mobility (Beighton score);
KIRP	cis	rs3741151	0.773	rs17244602	chr11:73219907	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.89	-6.49	-0.38	4.67e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg04374321	chr14:90722782	PSMC1	-0.83	-11.56	-0.59	5.77e-25	Mortality in heart failure;
KIRP	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg24812749	chr6:127587940	RNF146	0.63	7.95	0.45	6.75e-14	Breast cancer;
KIRP	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.48	6.9	0.4	4.36e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg02367723	chr1:46378857	MAST2	-0.43	-4.98	-0.3	1.17e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.68	9.26	0.51	1.07e-17	Longevity;Endometriosis;
KIRP	cis	rs4144743	0.528	rs11868894	chr17:45353189	T/C	cg18085866	chr17:45331354	ITGB3	-0.55	-5.41	-0.33	1.48e-7	Body mass index;
KIRP	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-4.95	-0.3	1.38e-6	Menarche (age at onset);
KIRP	cis	rs1461503	0.900	rs1057704	chr11:122830274	T/C	cg27398637	chr11:122830231	C11orf63	-0.83	-12.07	-0.61	1.18e-26	Menarche (age at onset);
KIRP	cis	rs35995292	0.534	rs917322	chr7:38943165	A/T	cg19327137	chr7:38886074	VPS41	-0.8	-12.57	-0.63	2.57e-28	Subjective well-being (multi-trait analysis);
KIRP	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.64	-7.85	-0.45	1.24e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.49	-7.71	-0.44	3.05e-13	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08646372	chr13:31191727	USPL1	0.43	6.31	0.37	1.29e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg21427119	chr20:30132790	HM13	-0.42	-5.01	-0.3	1.03e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.43	-5.17	-0.31	4.91e-7	P wave terminal force;
KIRP	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg10818794	chr15:86012489	AKAP13	0.47	6.6	0.39	2.46e-10	Interstitial lung disease;
KIRP	cis	rs2281603	0.951	rs60908674	chr14:64980899	A/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs4132509	0.744	rs10803146	chr1:243709454	T/G	cg21452805	chr1:244014465	NA	0.75	6.69	0.39	1.5e-10	RR interval (heart rate);
KIRP	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg25182066	chr10:30743637	MAP3K8	0.64	8.34	0.47	5.29e-15	Inflammatory bowel disease;
KIRP	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg10223061	chr2:219282414	VIL1	0.31	5.01	0.3	1.06e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg24315340	chr6:146058215	EPM2A	0.4	5.1	0.31	6.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4704187	0.687	rs6866661	chr5:74534372	A/G	cg03227963	chr5:74354835	NA	0.4	5.84	0.35	1.65e-8	Response to amphetamines;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23330828	chr3:129611968	TMCC1	0.49	6.44	0.38	6.14e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	6.56	0.39	3.09e-10	Putamen volume;
KIRP	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.47	-0.38	5.12e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg03929089	chr4:120376271	NA	0.69	6.2	0.37	2.31e-9	Axial length;
KIRP	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-1.27	-12.73	-0.63	7.2e-29	Post bronchodilator FEV1;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02867650	chr6:11094066	LOC221710	0.54	6.25	0.37	1.78e-9	Smoking initiation;
KIRP	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.11	-0.36	3.81e-9	Cutaneous nevi;
KIRP	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.82	-13.57	-0.65	1.08e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.23	0.37	2.06e-9	Lung cancer;
KIRP	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.97	-16.44	-0.72	1.71e-41	Breast cancer;
KIRP	trans	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg24644049	chr4:85504048	CDS1	1.04	7.22	0.42	6.3e-12	Skin colour saturation;
KIRP	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.31	5.91	0.35	1.16e-8	Educational attainment (years of education);
KIRP	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.78	10.49	0.56	1.58e-21	Platelet count;
KIRP	cis	rs6956675	0.915	rs1609795	chr7:62650531	T/C	cg08930214	chr7:62859557	LOC100287834	0.44	5.43	0.33	1.36e-7	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	17.34	0.74	1.56e-44	Height;
KIRP	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.63	7.25	0.42	5.34e-12	Height;
KIRP	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18876405	chr7:65276391	NA	0.41	5.05	0.31	8.81e-7	Aortic root size;
KIRP	cis	rs3736485	0.966	rs62016017	chr15:51897402	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.17	-0.31	4.74e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.99	-16.75	-0.73	1.52e-42	Breast cancer;
KIRP	cis	rs909341	0.909	rs2427530	chr20:62361737	G/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.8	-0.4	7.85e-11	Atopic dermatitis;
KIRP	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.57	7.7	0.44	3.35e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.68	9.68	0.53	5.64e-19	Vitiligo;
KIRP	cis	rs1014246	0.848	rs10787715	chr10:118459571	C/T	cg14919929	chr10:118506882	NA	0.76	9.83	0.53	1.89e-19	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs9644630	1.000	rs9644628	chr8:19369134	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.26	-5.0	-0.3	1.11e-6	Oropharynx cancer;
KIRP	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg07636037	chr3:49044803	WDR6	-0.69	-6.37	-0.38	9.2e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg07274523	chr3:49395745	GPX1	0.71	8.58	0.48	1.05e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.62e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-10.97	-0.57	4.74e-23	Coronary artery disease;
KIRP	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	10.82	0.57	1.42e-22	Smoking behavior;
KIRP	cis	rs113084984	0.718	rs7568108	chr2:11683324	C/T	cg07314298	chr2:11723111	GREB1	0.39	5.18	0.31	4.61e-7	Breast cancer;
KIRP	trans	rs2898857	0.545	rs12942379	chr17:47358733	C/T	cg11430096	chr6:110968061	CDK19	0.52	6.52	0.38	3.9e-10	Cancer;
KIRP	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg02367723	chr1:46378857	MAST2	0.44	5.1	0.31	6.94e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.99	13.95	0.66	5.53e-33	Alcohol dependence;
KIRP	cis	rs11731606	0.508	rs57403425	chr4:95312411	G/T	cg20625393	chr4:95128694	SMARCAD1	0.64	5.53	0.33	8.04e-8	Mean platelet volume;
KIRP	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	1.13	8.26	0.47	9.25e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg12292205	chr6:26970375	C6orf41	0.34	4.86	0.3	2.09e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg26681399	chr22:41777847	TEF	-0.45	-5.35	-0.32	2.06e-7	Vitiligo;
KIRP	trans	rs13100616	1.000	rs6792781	chr3:178397422	T/C	cg26530345	chr2:220312410	SPEG	0.51	6.2	0.37	2.38e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs7493138	0.967	rs12886205	chr14:28995860	C/T	cg08496086	chr5:2176142	NA	0.44	6.23	0.37	2e-9	Longevity;
KIRP	cis	rs2120243	0.539	rs1456097	chr3:157098630	T/C	cg24825693	chr3:157122686	VEPH1	-0.56	-9.03	-0.5	5.22e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	cis	rs60311166	1.000	rs60058353	chr3:52778409	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	1.0	7.06	0.41	1.65e-11	CTACK levels;
KIRP	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.63e-13	IgG glycosylation;
KIRP	cis	rs2880765	0.525	rs35899940	chr15:86053697	A/G	cg17133734	chr15:86042851	AKAP13	-0.55	-6.76	-0.4	9.92e-11	Coronary artery disease;
KIRP	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg22974920	chr21:40686053	BRWD1	0.47	5.6	0.34	5.85e-8	Cognitive function;
KIRP	cis	rs11638352	1.000	rs1365456	chr15:44378843	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.75	-5.14	-0.31	5.63e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs17065868	1.000	rs57884038	chr13:45156063	A/T	cg10246903	chr13:45222710	NA	0.75	6.68	0.39	1.62e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg00310523	chr12:86230176	RASSF9	0.55	8.49	0.48	2.01e-15	Major depressive disorder;
KIRP	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.97	0.54	6.75e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12412942	1.000	rs4364983	chr10:2358409	C/G	cg23939236	chr10:2357224	NA	-0.37	-5.61	-0.34	5.45e-8	Schizophrenia;
KIRP	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg21930842	chr2:241631663	AQP12A	0.43	5.61	0.34	5.53e-8	Response to metformin (IC50);
KIRP	cis	rs10465746	0.846	rs9700285	chr1:84336685	G/A	cg10977910	chr1:84465055	TTLL7	0.46	5.47	0.33	1.12e-7	Obesity-related traits;
KIRP	cis	rs2425143	0.643	rs6058324	chr20:34388789	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.02	-0.3	9.87e-7	Blood protein levels;
KIRP	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.45	5.23	0.32	3.7e-7	Schizophrenia;
KIRP	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.81	0.35	1.93e-8	Educational attainment;
KIRP	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.51	0.43	1.09e-12	Neuroticism;
KIRP	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.82	-0.4	6.93e-11	Breast cancer;
KIRP	cis	rs2071403	1.000	rs2071399	chr2:1416528	A/G	cg07083862	chr2:1417248	TPO	0.32	5.11	0.31	6.38e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs3779635	1.000	rs725788	chr8:27265371	T/C	cg18234130	chr8:27182889	PTK2B	0.44	5.74	0.34	2.84e-8	Neuroticism;
KIRP	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	7.96	0.45	6.37e-14	Exhaled nitric oxide output;
KIRP	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-12.64	-0.63	1.54e-28	Alzheimer's disease;
KIRP	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.7	-0.44	3.39e-13	Alcohol dependence;
KIRP	trans	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg11693508	chr17:37793320	STARD3	0.55	6.66	0.39	1.8e-10	Bipolar disorder;
KIRP	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg05802129	chr4:122689817	NA	-0.58	-7.31	-0.42	3.83e-12	Type 2 diabetes;
KIRP	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.96	-0.36	8.54e-9	Breast cancer;
KIRP	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs9596863	1.000	rs9596866	chr13:54459385	A/T	ch.13.53330881F	chr13:54432880	NA	0.6	6.23	0.37	2.01e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg19700328	chr14:106028568	NA	-0.57	-6.13	-0.36	3.55e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	trans	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg19274270	chr17:78178856	CARD14	-0.37	-6.64	-0.39	1.99e-10	Morning vs. evening chronotype;
KIRP	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg10223061	chr2:219282414	VIL1	-0.35	-5.83	-0.35	1.71e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.16	15.04	0.69	1.08e-36	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.62	-8.64	-0.48	7.36e-16	Obesity-related traits;
KIRP	cis	rs72772090	0.710	rs56122780	chr5:96059895	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-5.81	-0.35	1.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg12131826	chr15:77904385	NA	-0.43	-5.81	-0.35	1.95e-8	Type 2 diabetes;
KIRP	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.01	-0.5	5.93e-17	Retinal vascular caliber;
KIRP	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.54	6.76	0.4	9.89e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.43	-6.32	-0.37	1.23e-9	Personality dimensions;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00603498	chr17:5322775	RPAIN;NUP88	0.92	6.06	0.36	4.99e-9	P wave terminal force;
KIRP	cis	rs4654899	1.000	rs6426669	chr1:21430584	C/A	cg05370193	chr1:21551575	ECE1	0.37	5.01	0.3	1.03e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1440410	0.798	rs4511955	chr4:144070234	A/G	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg23649088	chr2:200775458	C2orf69	-0.6	-5.23	-0.32	3.68e-7	Schizophrenia;
KIRP	cis	rs9420	0.784	rs10896656	chr11:57668941	C/G	cg23127183	chr11:57508653	C11orf31	-0.48	-5.59	-0.34	5.93e-8	Schizophrenia;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.3	5.86	0.35	1.5e-8	Lymphocyte counts;
KIRP	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.43	-7.01	-0.41	2.31e-11	Superior crus of antihelix expression;
KIRP	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg09184832	chr6:79620586	NA	-0.38	-4.97	-0.3	1.25e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-1.18	-9.85	-0.53	1.64e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg11382394	chr1:2564504	MMEL1	0.39	5.0	0.3	1.07e-6	Ulcerative colitis;
KIRP	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.8	-10.67	-0.56	4.24e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2380205	0.967	rs4421659	chr10:5898406	C/T	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.22e-8	Breast cancer;
KIRP	cis	rs6001982	0.588	rs6001915	chr22:40840614	A/G	cg07138101	chr22:40742427	ADSL	0.68	5.27	0.32	2.98e-7	Breast cancer;
KIRP	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.02	-0.5	5.67e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.38	7.96	0.45	6.37e-14	Body mass index;
KIRP	cis	rs12210905	1.000	rs41269245	chr6:27100096	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6142102	0.923	rs3787230	chr20:32640272	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	6.85	0.4	5.99e-11	Skin pigmentation;
KIRP	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg26876637	chr1:152193138	HRNR	0.73	10.07	0.54	3.34e-20	Atopic dermatitis;
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg25347419	chr2:177043501	NA	0.48	6.48	0.38	4.93e-10	IgG glycosylation;
KIRP	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.18	-16.51	-0.72	1.04e-41	Type 1 diabetes nephropathy;
KIRP	trans	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg16141378	chr3:129829833	LOC729375	0.63	8.35	0.47	5.08e-15	Triglycerides;
KIRP	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg01620082	chr3:125678407	NA	0.88	6.36	0.38	9.74e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.09	0.69	7.04e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs2380205	0.967	rs11255581	chr10:5898882	G/A	cg27141509	chr10:5886111	NA	-0.4	-5.9	-0.35	1.22e-8	Breast cancer;
KIRP	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.68	9.48	0.52	2.21e-18	Colorectal cancer;
KIRP	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.87	12.12	0.61	8.36e-27	Breast cancer;
KIRP	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.8	-11.52	-0.59	7.53e-25	Total body bone mineral density;
KIRP	cis	rs28834970	0.925	rs2322599	chr8:27211910	G/A	cg07216194	chr8:27182965	PTK2B	-0.44	-5.52	-0.33	8.39e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	8.49	0.48	2.03e-15	Motion sickness;
KIRP	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.59	-6.73	-0.39	1.16e-10	Menarche (age at onset);
KIRP	cis	rs2562456	0.833	rs56187954	chr19:21528060	T/A	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.49	-4.93	-0.3	1.48e-6	Pubertal anthropometrics;
KIRP	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg24009623	chr19:33667908	NA	0.49	6.55	0.39	3.42e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25517427	chr17:12921477	ELAC2	0.54	7.81	0.45	1.64e-13	Survival in pancreatic cancer;
KIRP	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.49	0.59	9.75e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16854884	1.000	rs2370171	chr3:143765177	C/T	cg06585982	chr3:143692056	C3orf58	0.54	5.96	0.36	8.5e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs6539288	0.677	rs1348566	chr12:107325648	C/T	cg21360079	chr12:107162445	NA	-0.44	-5.56	-0.33	7.02e-8	Total body bone mineral density;
KIRP	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.51	-5.72	-0.34	3.01e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg01631408	chr1:248437212	OR2T33	-0.69	-9.11	-0.5	2.87e-17	Common traits (Other);
KIRP	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19171272	chr22:38449367	NA	-0.56	-8.26	-0.47	9.01e-15	Glioblastoma;Glioma;
KIRP	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.67	0.44	4.1e-13	Aortic root size;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-5.97	-0.36	8.37e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1440410	0.830	rs1440411	chr4:144158285	C/T	cg01719995	chr4:144104893	USP38	0.45	6.12	0.36	3.68e-9	Ischemic stroke;
KIRP	cis	rs113075218	1	rs113075218	chr5:121361750	T/A	cg05256605	chr5:121412184	LOX	-0.53	-5.92	-0.35	1.07e-8	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.88	0.35	1.33e-8	Renal cell carcinoma;
KIRP	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.53	7.72	0.44	2.95e-13	Major depressive disorder;
KIRP	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.74	-8.11	-0.46	2.41e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.55	0.33	7.43e-8	Menopause (age at onset);
KIRP	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.77	-11.64	-0.6	3.02e-25	Hip circumference;
KIRP	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.39	-0.47	3.84e-15	Total cholesterol levels;
KIRP	cis	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg00614314	chr15:82944287	LOC80154	0.54	6.12	0.36	3.6e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs11605275	1.000	rs78913308	chr11:20027477	A/G	cg14835545	chr11:20032148	NAV2	-0.74	-5.65	-0.34	4.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.62	6.83	0.4	6.58e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg21419209	chr3:44054225	NA	-0.74	-9.43	-0.52	3.17e-18	Coronary artery disease;
KIRP	cis	rs2880765	0.506	rs719138	chr15:86055062	T/G	cg17133734	chr15:86042851	AKAP13	-0.58	-7.08	-0.41	1.49e-11	Coronary artery disease;
KIRP	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.24e-6	Parkinson's disease;
KIRP	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg08501292	chr6:25962987	TRIM38	0.99	5.91	0.35	1.16e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.37	-10.16	-0.54	1.84e-20	Diabetic kidney disease;
KIRP	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg03733263	chr8:22462867	KIAA1967	1.08	16.89	0.73	5.14e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.13	0.31	5.91e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg08501292	chr6:25962987	TRIM38	0.91	6.45	0.38	5.82e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg11189052	chr15:85197271	WDR73	0.53	5.47	0.33	1.12e-7	Schizophrenia;
KIRP	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.59	-0.39	2.58e-10	Urinary tract infection frequency;
KIRP	cis	rs400736	0.535	rs4418631	chr1:8174197	A/G	cg25007680	chr1:8021821	PARK7	0.45	5.91	0.35	1.13e-8	Response to antidepressants and depression;
KIRP	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.5	-5.71	-0.34	3.24e-8	Osteoporosis;
KIRP	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.51	-0.33	9.16e-8	IgG glycosylation;
KIRP	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.58	-7.34	-0.42	3.11e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs698833	0.547	rs1067348	chr2:44671409	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.07	0.31	7.81e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg06647332	chr5:131281008	NA	0.45	5.04	0.31	9.23e-7	Life satisfaction;
KIRP	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11987759	chr7:65425863	GUSB	-0.45	-5.4	-0.33	1.58e-7	Aortic root size;
KIRP	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.26	7.09	0.41	1.43e-11	Crohn's disease;
KIRP	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg16077055	chr2:106428750	NCK2	0.31	5.95	0.35	8.93e-9	Addiction;
KIRP	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-6.45	-0.38	6.04e-10	Body mass index;
KIRP	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.8	0.4	7.77e-11	Electroencephalogram traits;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg19935506	chr2:242626874	DTYMK	0.75	6.4	0.38	7.86e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.71	-8.8	-0.49	2.52e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6032067	0.929	rs2233898	chr20:43850525	A/G	cg10761708	chr20:43804764	PI3	0.51	5.22	0.32	3.78e-7	Blood protein levels;
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg21186296	chr8:27182909	PTK2B	0.51	6.45	0.38	5.83e-10	Neuroticism;
KIRP	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.5e-10	Coronary artery disease;
KIRP	cis	rs780096	0.967	rs1313566	chr2:27748904	G/A	cg22903471	chr2:27725779	GCKR	-0.45	-6.42	-0.38	7.11e-10	Total body bone mineral density;
KIRP	cis	rs6445967	0.722	rs6445961	chr3:58232659	C/T	cg16569813	chr3:58235849	ABHD6	-0.35	-5.46	-0.33	1.15e-7	Platelet count;
KIRP	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.91	-0.45	8.77e-14	Homocysteine levels;
KIRP	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.25	0.65	1.3e-30	Electrocardiographic conduction measures;
KIRP	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs62229266	0.618	rs11088334	chr21:37466829	A/T	cg12218747	chr21:37451666	NA	-0.44	-5.22	-0.32	3.75e-7	Mitral valve prolapse;
KIRP	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg23594656	chr7:65796392	TPST1	0.53	8.32	0.47	6.29e-15	Aortic root size;
KIRP	cis	rs829661	0.843	rs866680	chr2:30720191	C/A	cg10949345	chr2:30726833	LCLAT1	1.13	15.69	0.71	6.25e-39	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.6	-8.32	-0.47	6.25e-15	Paraoxonase activity;
KIRP	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg20637307	chr2:213403960	ERBB4	0.55	7.67	0.44	3.99e-13	Symmetrical dimethylarginine levels;
KIRP	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg07936489	chr17:37558343	FBXL20	-0.56	-7.62	-0.44	5.55e-13	Asthma;
KIRP	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	12.73	0.63	7.21e-29	Menopause (age at onset);
KIRP	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.27	-0.37	1.6e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.49	-5.81	-0.35	1.93e-8	Carotid intima media thickness;
KIRP	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.0	-0.61	2.05e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg17425144	chr1:10567563	PEX14	-0.29	-5.1	-0.31	6.9e-7	Hepatocellular carcinoma;
KIRP	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg27432699	chr2:27873401	GPN1	-0.49	-6.21	-0.37	2.24e-9	Total body bone mineral density;
KIRP	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.37	6.93	0.4	3.68e-11	Alopecia areata;
KIRP	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg21784768	chr11:537496	LRRC56	-0.59	-4.97	-0.3	1.24e-6	Body mass index;
KIRP	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg00495681	chr13:53174319	NA	0.39	5.28	0.32	2.77e-7	Lewy body disease;
KIRP	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.63	-8.28	-0.47	7.84e-15	Motion sickness;
KIRP	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg10189261	chr14:101176105	NA	-0.49	-4.89	-0.3	1.86e-6	Plateletcrit;
KIRP	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.55	-0.39	3.26e-10	Urinary tract infection frequency;
KIRP	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg21775007	chr8:11205619	TDH	0.46	6.47	0.38	5.15e-10	Myopia (pathological);
KIRP	trans	rs2048656	0.637	rs10107396	chr8:9673152	T/C	cg16141378	chr3:129829833	LOC729375	0.51	6.62	0.39	2.24e-10	Schizophrenia;
KIRP	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.67	9.99	0.54	6.11e-20	Pulse pressure;
KIRP	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg08645402	chr16:4508243	NA	0.49	6.24	0.37	1.91e-9	Schizophrenia;
KIRP	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.79	-9.83	-0.53	1.91e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.51	-6.41	-0.38	7.49e-10	Longevity;
KIRP	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs9475752	0.793	rs35090265	chr6:56847813	A/G	cg22880620	chr6:56820808	BEND6;DST	0.51	5.2	0.31	4.17e-7	Menarche (age at onset);
KIRP	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-0.97	-19.32	-0.78	3.06e-51	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23033906	chr14:21769332	RPGRIP1	0.42	6.16	0.37	2.93e-9	Survival in pancreatic cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06492699	chr3:39149242	GORASP1;TTC21A	0.47	6.6	0.39	2.47e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg19875535	chr5:140030758	IK	0.56	6.97	0.41	2.85e-11	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg27216630	chr2:201374900	KCTD18	0.5	6.82	0.4	6.91e-11	Cancer;
KIRP	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.84	10.17	0.54	1.68e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.48	6.31	0.37	1.31e-9	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24714147	chr19:14629240	DNAJB1	0.52	7.14	0.41	1.07e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-4.87	-0.3	1.99e-6	IgG glycosylation;
KIRP	cis	rs9913711	0.899	rs9913936	chr17:70074148	A/G	cg04438997	chr17:70115868	SOX9	0.38	5.07	0.31	7.77e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg08885076	chr2:99613938	TSGA10	0.52	8.71	0.49	4.4e-16	Chronic sinus infection;
KIRP	cis	rs6001930	0.579	rs73167052	chr22:40847848	A/T	cg07138101	chr22:40742427	ADSL	0.73	5.16	0.31	5.09e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.7.125452233F	chr7:125664997	NA	0.49	6.79	0.4	8.32e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.57	-0.33	6.69e-8	Body mass index;
KIRP	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.4	5.19	0.31	4.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg19773385	chr1:10388646	KIF1B	-0.69	-9.01	-0.5	5.97e-17	Hepatocellular carcinoma;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04742505	chr7:72936528	BAZ1B	0.56	6.78	0.4	9.06e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2964802	0.505	rs1438714	chr5:10811422	G/A	cg14521931	chr5:10832172	NA	-0.74	-11.21	-0.58	7.64e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.72	10.62	0.56	6.2e-22	Oral cavity cancer;
KIRP	cis	rs2278796	0.639	rs4951153	chr1:204970844	C/A	cg17947172	chr1:204966197	NFASC	0.64	8.45	0.47	2.64e-15	Mean platelet volume;
KIRP	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg03929089	chr4:120376271	NA	0.7	6.34	0.37	1.11e-9	Axial length;
KIRP	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg07747251	chr5:1868357	NA	0.49	6.49	0.38	4.82e-10	Cardiovascular disease risk factors;
KIRP	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.56	-5.98	-0.36	7.86e-9	Body mass index;
KIRP	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg19476082	chr7:2414320	EIF3B	0.54	5.08	0.31	7.38e-7	Multiple sclerosis;
KIRP	cis	rs2131877	0.619	rs6794540	chr3:194867162	C/T	cg19775763	chr3:194786989	NA	-0.42	-5.05	-0.31	8.77e-7	Non-small cell lung cancer;
KIRP	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg24881330	chr22:46731750	TRMU	0.78	5.28	0.32	2.83e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.08	0.46	2.94e-14	Height;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg08901578	chr4:187885870	NA	-0.53	-8.16	-0.46	1.69e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.85	-0.63	3e-29	Electrocardiographic conduction measures;
KIRP	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg17847044	chr15:42102381	MAPKBP1	0.26	5.3	0.32	2.56e-7	Diastolic blood pressure;
KIRP	cis	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.41	-5.14	-0.31	5.7e-7	Leprosy;
KIRP	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.04	-0.41	1.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg27494647	chr7:150038898	RARRES2	-0.38	-5.73	-0.34	2.9e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.61	0.39	2.37e-10	Triglycerides;
KIRP	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg12131826	chr15:77904385	NA	0.46	5.57	0.33	6.73e-8	Type 2 diabetes;
KIRP	cis	rs1978968	1.000	rs1076544	chr22:18446565	G/A	cg02610425	chr22:18483192	MICAL3	0.36	5.07	0.31	7.72e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.64	8.84	0.49	1.94e-16	Multiple sclerosis;
KIRP	cis	rs6601327	0.632	rs4841220	chr8:9656059	T/G	cg27411982	chr8:10470053	RP1L1	-0.4	-5.12	-0.31	6.18e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg08501292	chr6:25962987	TRIM38	1.09	8.0	0.45	4.79e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	10.02	0.54	4.97e-20	Cognitive test performance;
KIRP	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.56	6.88	0.4	4.98e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.54	5.16	0.31	5.15e-7	Skin colour saturation;
KIRP	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs2625529	0.652	rs8040216	chr15:72255249	C/T	cg16672083	chr15:72433130	SENP8	0.42	6.05	0.36	5.38e-9	Red blood cell count;
KIRP	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg25233709	chr10:116636983	FAM160B1	0.33	5.02	0.3	1.01e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg18132916	chr6:79620363	NA	0.39	5.36	0.32	1.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.61	9.05	0.5	4.56e-17	Lung cancer;
KIRP	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg02375832	chr11:62437615	C11orf48	-0.42	-5.44	-0.33	1.28e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg20060108	chr2:102954350	IL1RL1	-0.66	-5.42	-0.33	1.43e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02310562	chr12:117348663	FBXW8	-0.45	-6.02	-0.36	6.15e-9	Myopia;
KIRP	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Retinal vascular caliber;
KIRP	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	9.42	0.51	3.55e-18	Cognitive test performance;
KIRP	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg21433313	chr16:3507492	NAT15	0.63	7.27	0.42	4.87e-12	Tuberculosis;
KIRP	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg22681709	chr2:178499509	PDE11A	-0.69	-10.64	-0.56	5.57e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.79	-0.35	2.12e-8	Depression;
KIRP	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.61	-5.58	-0.34	6.41e-8	Schizophrenia;
KIRP	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17376030	chr22:41985996	PMM1	-0.72	-7.64	-0.44	4.97e-13	Vitiligo;
KIRP	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg12369402	chr1:90227771	NA	-0.36	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-5.18	-0.31	4.63e-7	Tonsillectomy;
KIRP	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg05973401	chr12:123451056	ABCB9	0.51	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.68	9.54	0.52	1.53e-18	Lymphocyte counts;
KIRP	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	1.02	10.74	0.57	2.51e-22	Cerebrospinal P-tau181p levels;
KIRP	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15175194	chr3:113775337	QTRTD1;KIAA1407	0.5	6.31	0.37	1.26e-9	Parkinson's disease;
KIRP	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.19	0.51	1.69e-17	Bipolar disorder;
KIRP	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18252515	chr7:66147081	NA	0.43	5.19	0.31	4.31e-7	Aortic root size;
KIRP	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.25	-35.01	-0.91	1.5e-97	Myeloid white cell count;
KIRP	cis	rs4356975	0.563	rs34814736	chr4:69980478	C/G	cg27372994	chr4:70080453	UGT2B11	0.36	4.85	0.3	2.18e-6	Obesity-related traits;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04968835	chr1:143913847	FAM72D	0.75	6.38	0.38	8.79e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.01	11.64	0.6	3.19e-25	Body mass index;
KIRP	cis	rs8054556	0.751	rs11642430	chr16:30045789	C/G	cg06326092	chr16:30034487	C16orf92	0.45	6.03	0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.84	11.76	0.6	1.28e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1514687	0.534	rs58529796	chr2:1473693	C/T	cg03133821	chr2:1513998	TPO	-0.63	-5.05	-0.31	8.8e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs72627509	1.000	rs57265257	chr4:57839280	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-4.95	-0.3	1.41e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6662572	0.703	rs56278140	chr1:46357544	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.62	0.34	5.05e-8	Blood protein levels;
KIRP	cis	rs539514	0.805	rs7997101	chr13:76334818	C/T	cg04757411	chr13:76259545	LMO7	-0.37	-5.47	-0.33	1.08e-7	Type 1 diabetes;
KIRP	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs10788972	0.844	rs6588502	chr1:54563156	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.29	-4.88	-0.3	1.93e-6	Parkinson disease and lewy body pathology;
KIRP	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18932078	chr1:2524107	MMEL1	-0.43	-5.96	-0.36	8.82e-9	Ulcerative colitis;
KIRP	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	5.95	0.35	9.09e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.79	-10.34	-0.55	4.94e-21	Height;
KIRP	cis	rs4280164	0.945	rs1131941	chr14:24760808	C/T	cg18688254	chr14:24701745	GMPR2;NEDD8	-0.51	-4.9	-0.3	1.72e-6	Parent of origin effect on language impairment (paternal);
KIRP	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.06	-0.31	8.16e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4728302	0.631	rs7798355	chr7:133583899	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.0	0.3	1.1e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs10073892	0.785	rs1823692	chr5:101637590	T/C	cg19774478	chr5:101632501	SLCO4C1	0.66	6.47	0.38	5.11e-10	Cognitive decline (age-related);
KIRP	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg01522456	chr1:115632236	TSPAN2	-0.44	-6.12	-0.36	3.63e-9	Autism;
KIRP	cis	rs2150410	0.831	rs9981656	chr21:40695042	C/T	cg11890956	chr21:40555474	PSMG1	0.82	5.74	0.34	2.83e-8	Temperament (bipolar disorder);
KIRP	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.67	6.92	0.4	3.84e-11	Corneal astigmatism;
KIRP	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.41	8.4	0.47	3.49e-15	Vitiligo;
KIRP	cis	rs4363385	0.693	rs6690672	chr1:152930564	C/T	cg07796016	chr1:152779584	LCE1C	-0.41	-4.97	-0.3	1.24e-6	Inflammatory skin disease;
KIRP	cis	rs9309473	0.519	rs13017182	chr2:73891004	G/T	cg20560298	chr2:73613845	ALMS1	0.48	5.99	0.36	7.27e-9	Metabolite levels;
KIRP	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.56	-0.33	7.04e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6546324	0.615	rs4233939	chr2:67782735	A/C	cg15745817	chr2:67799979	NA	-0.66	-6.84	-0.4	6.17e-11	Endometriosis;
KIRP	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-6.17	-0.37	2.81e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg18357526	chr6:26021779	HIST1H4A	0.39	5.08	0.31	7.58e-7	Height;
KIRP	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs9815354	1.000	rs9875107	chr3:41822313	A/T	cg03022575	chr3:42003672	ULK4	0.49	5.57	0.33	6.58e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7766436	0.885	rs1418312	chr6:22589704	C/T	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.18	0.46	1.53e-14	Hip circumference adjusted for BMI;
KIRP	trans	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.76	0.4	1.02e-10	Mean corpuscular volume;
KIRP	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	0.97	16.62	0.73	4.25e-42	Ulcerative colitis;
KIRP	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg24253500	chr15:84953950	NA	0.61	6.91	0.4	4.24e-11	Schizophrenia;
KIRP	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg03711944	chr11:47377212	SPI1	-0.32	-5.61	-0.34	5.48e-8	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs600806	0.672	rs1144594	chr1:110029475	A/G	cg02175308	chr1:109941060	SORT1	-0.3	-5.64	-0.34	4.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.39	-0.51	4.34e-18	Mean corpuscular volume;
KIRP	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg03808351	chr9:123631620	PHF19	0.45	6.13	0.36	3.51e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7005380	0.538	rs6469875	chr8:120926633	C/G	cg21645572	chr8:120931649	DEPDC6	0.51	7.05	0.41	1.82e-11	Interstitial lung disease;
KIRP	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg00495681	chr13:53174319	NA	-0.36	-4.87	-0.3	1.97e-6	Lewy body disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09370884	chr6:151773689	C6orf211;RMND1	0.53	6.66	0.39	1.78e-10	Parkinson's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg00067365	chr5:43121575	ZNF131	0.48	6.06	0.36	4.98e-9	Myopia (pathological);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg05538983	chr1:229730023	TAF5L	0.59	6.21	0.37	2.24e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-0.75	-5.91	-0.35	1.12e-8	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs258892	0.895	rs34672	chr5:72165389	G/A	cg21869765	chr5:72125136	TNPO1	0.57	6.33	0.37	1.14e-9	Small cell lung carcinoma;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.84	10.05	0.54	3.86e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10463451	chr21:37432625	SETD4	-0.44	-6.44	-0.38	6.12e-10	Metabolic traits;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg12419862	chr22:24373484	LOC391322	-0.62	-7.86	-0.45	1.23e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg23521916	chr3:48754752	IP6K2	0.52	6.12	0.36	3.71e-9	Plasma plasminogen activator levels;
KIRP	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg26876637	chr1:152193138	HRNR	0.75	10.04	0.54	4.2e-20	Atopic dermatitis;
KIRP	cis	rs10114408	0.959	rs10761291	chr9:96640967	C/T	cg14598338	chr9:96623480	NA	-0.33	-4.85	-0.3	2.24e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7551222	0.752	rs11240755	chr1:204478649	C/T	cg20240347	chr1:204465584	NA	-0.45	-8.53	-0.48	1.54e-15	Schizophrenia;
KIRP	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg06740227	chr12:86229804	RASSF9	0.44	5.57	0.33	6.82e-8	Major depressive disorder;
KIRP	cis	rs3733418	0.929	rs1401401	chr4:165927956	G/A	cg10852876	chr4:165953100	TRIM60	-0.53	-5.72	-0.34	3.13e-8	Obesity-related traits;
KIRP	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg27494647	chr7:150038898	RARRES2	0.36	5.42	0.33	1.43e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg01843034	chr6:37503916	NA	-0.74	-8.48	-0.48	2.14e-15	Cognitive performance;
KIRP	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.29	-0.32	2.7e-7	Blood pressure;
KIRP	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg04691961	chr3:161091175	C3orf57	-0.5	-7.72	-0.44	2.98e-13	Morning vs. evening chronotype;
KIRP	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.38	-0.43	2.5e-12	Morning vs. evening chronotype;
KIRP	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.52	6.66	0.39	1.78e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-9.35	-0.51	5.61e-18	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.66	-7.16	-0.42	9.5e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.92	-9.8	-0.53	2.31e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.92	-0.35	1.09e-8	Diastolic blood pressure;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13939156	chr17:80058883	NA	-0.49	-7.36	-0.42	2.8e-12	Life satisfaction;
KIRP	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.57	-7.59	-0.44	6.68e-13	HDL cholesterol;
KIRP	cis	rs9840812	0.683	rs8045	chr3:136055459	T/C	cg15507776	chr3:136538369	TMEM22	-0.44	-5.05	-0.31	8.55e-7	Fibrinogen levels;
KIRP	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.1	0.41	1.36e-11	Height;
KIRP	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg00409905	chr10:38381863	ZNF37A	-0.57	-6.08	-0.36	4.64e-9	Obesity (extreme);
KIRP	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.58	-0.44	6.95e-13	Triglycerides;
KIRP	cis	rs597583	0.715	rs11216436	chr11:117391374	G/A	cg27161313	chr11:117392002	DSCAML1	-0.71	-7.16	-0.42	9.46e-12	Putamen volume;
KIRP	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.34	-0.42	3.03e-12	Total cholesterol levels;
KIRP	trans	rs7999699	0.902	rs9534771	chr13:48309555	G/A	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg01251548	chr11:17372745	DKFZp686O24166	-0.39	-5.19	-0.31	4.36e-7	Type 2 diabetes;
KIRP	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg09455208	chr3:40491958	NA	0.36	6.29	0.37	1.46e-9	Renal cell carcinoma;
KIRP	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.78	0.4	8.88e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12044355	0.827	rs11583715	chr1:231829039	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-6.51	-0.38	4.17e-10	Alzheimer's disease;
KIRP	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9308433	0.553	rs1048791	chr1:214511519	T/C	cg06198575	chr1:214491504	SMYD2	0.47	5.71	0.34	3.17e-8	IgG glycosylation;
KIRP	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg02297831	chr4:17616191	MED28	0.52	6.58	0.39	2.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.38	-5.17	-0.31	4.88e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs155346	1.000	rs7728075	chr5:139382353	G/A	cg01090482	chr5:139365336	NRG2	-0.42	-5.14	-0.31	5.62e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs4478858	0.684	rs2271074	chr1:31734841	C/T	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs7011049	0.915	rs67767021	chr8:53860855	A/G	cg26025543	chr8:53854495	NA	0.59	6.3	0.37	1.36e-9	Systolic blood pressure;
KIRP	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.24	-6.32	-0.37	1.19e-9	Mean corpuscular volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08926982	chr1:10270439	KIF1B	-0.5	-6.69	-0.39	1.48e-10	Metabolic traits;
KIRP	cis	rs7827290	0.863	rs7014099	chr8:142305766	C/T	cg05176958	chr8:142316435	NA	0.38	5.17	0.31	4.78e-7	Bipolar disorder;
KIRP	cis	rs889312	0.961	rs6450401	chr5:56033234	G/C	cg14703610	chr5:56206110	C5orf35	0.42	5.06	0.31	8.22e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs7849270	1.000	rs10819464	chr9:131876277	G/A	cg13538475	chr9:131942899	NA	-0.34	-5.4	-0.33	1.59e-7	Blood metabolite ratios;
KIRP	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.57	-5.91	-0.35	1.12e-8	DNA methylation (variation);
KIRP	cis	rs9487051	0.676	rs9386780	chr6:109584410	A/G	cg01475377	chr6:109611718	NA	-0.36	-4.93	-0.3	1.54e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg02023728	chr11:77925099	USP35	-0.31	-5.18	-0.31	4.51e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.74e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	10.29	0.55	7.07e-21	Parkinson's disease;
KIRP	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.35	-0.32	2.04e-7	IgG glycosylation;
KIRP	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg01320579	chr17:75405842	SEPT9	0.47	7.76	0.44	2.23e-13	Airflow obstruction;
KIRP	cis	rs2329775	0.534	rs10250287	chr7:40436763	T/C	cg00420559	chr7:40367873	C7orf10	-0.38	-5.37	-0.32	1.86e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.38	17.54	0.75	3.17e-45	Uric acid levels;
KIRP	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg02160872	chr5:212506	CCDC127	0.45	4.92	0.3	1.57e-6	Breast cancer;
KIRP	cis	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg21775007	chr8:11205619	TDH	0.43	5.36	0.32	1.96e-7	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.97	14.18	0.67	9e-34	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg03188948	chr7:1209495	NA	0.83	7.72	0.44	2.96e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.39e-8	Depression;
KIRP	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.59	-7.21	-0.42	6.71e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg15534755	chr11:117069859	TAGLN	0.46	5.8	0.35	2.04e-8	Blood protein levels;
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.24	-0.51	1.24e-17	Platelet count;
KIRP	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05347473	chr6:146136440	FBXO30	-0.55	-7.66	-0.44	4.16e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10203711	1.000	rs11682137	chr2:239588939	G/A	cg14580085	chr2:239553406	NA	0.38	4.95	0.3	1.39e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16912285	0.688	rs1899540	chr11:24339992	A/G	ch.11.24196551F	chr11:24239977	NA	0.72	6.74	0.39	1.15e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6684428	1.000	rs12124871	chr1:56372247	C/T	cg11651538	chr1:56320950	NA	-0.87	-10.35	-0.55	4.62e-21	Airflow obstruction;
KIRP	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg09264619	chr17:80180166	NA	0.48	5.5	0.33	9.59e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16318349	chr1:154917307	PBXIP1	0.32	5.71	0.34	3.26e-8	Prostate cancer;
KIRP	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.74	-10.3	-0.55	6.6e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg21419209	chr3:44054225	NA	0.7	8.46	0.47	2.4e-15	Coronary artery disease;
KIRP	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg13206674	chr6:150067644	NUP43	0.42	5.24	0.32	3.51e-7	Testicular germ cell tumor;
KIRP	trans	rs1962073	0.528	rs12544112	chr8:10318815	C/A	cg06636001	chr8:8085503	FLJ10661	0.48	6.14	0.36	3.27e-9	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs4523957	0.928	rs216220	chr17:2148821	G/T	cg16513277	chr17:2031491	SMG6	0.61	8.36	0.47	4.53e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3857747	0.557	rs11770113	chr7:40384494	G/A	cg00420559	chr7:40367873	C7orf10	-0.44	-6.2	-0.37	2.34e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10193935	0.901	rs13022188	chr2:42704423	A/C	cg27598129	chr2:42591480	NA	0.71	6.83	0.4	6.71e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1829883	0.775	rs2682159	chr5:98922742	G/A	cg08333243	chr5:99726346	NA	0.4	5.07	0.31	7.85e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg04990556	chr1:26633338	UBXN11	0.65	6.16	0.37	2.98e-9	Obesity-related traits;
KIRP	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs17095355	1.000	rs11194933	chr10:111725862	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.04	-0.36	5.58e-9	Biliary atresia;
KIRP	trans	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg16141378	chr3:129829833	LOC729375	-0.56	-7.4	-0.43	2.15e-12	Joint mobility (Beighton score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03024619	chr3:71803308	GPR27;EIF4E3	0.45	6.19	0.37	2.5e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19494762	chr3:184279498	EPHB3	0.46	6.26	0.37	1.67e-9	Parkinson's disease;
KIRP	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.78	-0.35	2.26e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9311474	0.713	rs352167	chr3:52238656	C/T	cg05315796	chr3:52349193	DNAH1	-0.39	-5.87	-0.35	1.41e-8	Electroencephalogram traits;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg20994084	chr17:79269488	SLC38A10	0.94	6.26	0.37	1.73e-9	P wave terminal force;
KIRP	cis	rs1950626	0.750	rs12895798	chr14:101442793	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.86	0.4	5.45e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs2979489	0.699	rs62508370	chr8:30417026	G/A	cg26383811	chr8:30366931	RBPMS	-0.44	-5.98	-0.36	7.81e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs4908768	0.581	rs2784740	chr1:8501057	T/A	cg03610117	chr1:8450231	RERE	-0.71	-8.75	-0.49	3.34e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.44	-0.43	1.71e-12	Life satisfaction;
KIRP	cis	rs4594175	0.926	rs10145287	chr14:51626808	G/T	cg23942311	chr14:51606299	NA	0.5	6.61	0.39	2.36e-10	Cancer;
KIRP	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.94	-14.84	-0.69	5.14e-36	Body mass index;
KIRP	cis	rs960902	0.521	rs35083077	chr2:37747309	A/G	cg25341268	chr2:37734390	NA	0.57	6.56	0.39	3.21e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9298506	1.000	rs28615248	chr8:55451193	T/C	cg19005830	chr8:55467175	NA	-0.58	-5.06	-0.31	8.14e-7	Intracranial aneurysm;
KIRP	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg17294928	chr15:75287854	SCAMP5	-0.64	-5.56	-0.33	7.09e-8	Lung cancer;
KIRP	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.52	-6.34	-0.37	1.07e-9	Obesity-related traits;
KIRP	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.44	-5.81	-0.35	1.88e-8	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7712401	0.601	rs30058	chr5:122297703	A/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg27494647	chr7:150038898	RARRES2	0.36	5.53	0.33	8.27e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.51	-6.71	-0.39	1.35e-10	Aortic root size;
KIRP	trans	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg16141378	chr3:129829833	LOC729375	-0.48	-6.03	-0.36	6.13e-9	Mean corpuscular volume;
KIRP	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.38	5.04	0.31	9e-7	Blood metabolite levels;
KIRP	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg21548813	chr6:291882	DUSP22	-0.59	-6.91	-0.4	4.15e-11	Menopause (age at onset);
KIRP	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.2	13.91	0.66	7.79e-33	Sexual dysfunction (female);
KIRP	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18357526	chr6:26021779	HIST1H4A	0.53	6.95	0.41	3.26e-11	Height;
KIRP	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-0.77	-9.58	-0.52	1.13e-18	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.24	-0.47	1.03e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	6.57	0.39	2.91e-10	Coronary artery disease;
KIRP	cis	rs687432	0.887	rs12807528	chr11:57725648	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.18	-0.5	1.89e-17	Parkinson's disease;
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	trans	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg06521331	chr12:34319734	NA	-0.5	-6.24	-0.37	1.93e-9	Bladder cancer;
KIRP	cis	rs12780845	0.540	rs6602180	chr10:17192362	T/C	cg01003015	chr10:17271136	VIM	0.48	6.27	0.37	1.57e-9	Homocysteine levels;
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09597638	chr17:3907349	NA	0.64	10.74	0.56	2.63e-22	Type 2 diabetes;
KIRP	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs11671005	0.695	rs12972898	chr19:58956888	A/G	cg13877915	chr19:58951672	ZNF132	0.59	5.44	0.33	1.31e-7	Mean platelet volume;
KIRP	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	1.0	13.52	0.65	1.57e-31	Menopause (age at onset);
KIRP	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.61	-7.2	-0.42	7.33e-12	P wave terminal force;
KIRP	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.49	6.46	0.38	5.58e-10	Height;
KIRP	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.51	-6.36	-0.38	9.59e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.05	-8.12	-0.46	2.22e-14	Mitochondrial DNA levels;
KIRP	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg16989719	chr2:238392110	NA	-0.56	-6.09	-0.36	4.36e-9	Prostate cancer;
KIRP	cis	rs3736594	0.513	rs78170284	chr2:27835082	G/A	cg27432699	chr2:27873401	GPN1	0.58	6.2	0.37	2.42e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2882667	0.898	rs6882583	chr5:138385796	C/T	cg04439458	chr5:138467593	SIL1	-0.44	-7.36	-0.43	2.68e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.57	0.52	1.2e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg03808351	chr9:123631620	PHF19	0.41	5.5	0.33	9.37e-8	Rheumatoid arthritis;
KIRP	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-4.96	-0.3	1.32e-6	Psychosis and Alzheimer's disease;
KIRP	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.48	0.33	1.07e-7	Breast cancer;
KIRP	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.47	-5.65	-0.34	4.34e-8	P wave terminal force;
KIRP	cis	rs3767633	0.858	rs10753645	chr1:161815364	T/C	cg09175582	chr1:161736000	ATF6	0.74	5.97	0.36	8.39e-9	IgG glycosylation;
KIRP	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg00241281	chr14:105779794	PACS2	-0.36	-4.97	-0.3	1.24e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.58	7.78	0.44	1.95e-13	HDL cholesterol;
KIRP	cis	rs7646881	1.000	rs61558956	chr3:158452655	T/A	cg19483011	chr3:158453295	NA	-0.55	-6.29	-0.37	1.43e-9	Tetralogy of Fallot;
KIRP	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.92	-12.69	-0.63	1.04e-28	Cognitive function;
KIRP	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04317338	chr11:64019027	PLCB3	-0.45	-5.52	-0.33	8.74e-8	Platelet count;
KIRP	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.44	6.62	0.39	2.19e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg06521331	chr12:34319734	NA	-0.59	-7.25	-0.42	5.53e-12	Bladder cancer;
KIRP	cis	rs4704187	0.663	rs4404659	chr5:74422119	T/C	cg03227963	chr5:74354835	NA	0.41	5.94	0.35	9.57e-9	Response to amphetamines;
KIRP	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.48	-4.92	-0.3	1.56e-6	Fibroblast growth factor basic levels;
KIRP	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.55	-0.52	1.42e-18	Triglycerides;
KIRP	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg00864860	chr1:7907996	UTS2	-0.48	-5.72	-0.34	3.04e-8	Crohn's disease;
KIRP	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.69	10.25	0.55	9.31e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04122601	chr12:10826785	STYK1	0.57	6.73	0.39	1.18e-10	Smoking initiation;
KIRP	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.6	-9.1	-0.5	3.1e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs735539	0.645	rs9552251	chr13:21180247	A/G	cg04906043	chr13:21280425	IL17D	0.5	5.66	0.34	4.27e-8	Dental caries;
KIRP	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-1.04	-19.26	-0.78	4.97e-51	Height;
KIRP	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-0.88	-13.08	-0.64	4.84e-30	Total body bone mineral density;
KIRP	cis	rs7175404	0.730	rs6497076	chr15:94032909	T/C	cg23502883	chr15:93959149	NA	0.47	5.55	0.33	7.49e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-9.55	-0.52	1.41e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-7.63	-0.44	5.11e-13	Vitiligo;
KIRP	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.66	-10.65	-0.56	4.88e-22	Menopause (age at onset);
KIRP	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg00409905	chr10:38381863	ZNF37A	-0.56	-6.03	-0.36	5.82e-9	Obesity (extreme);
KIRP	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-1.01	-12.21	-0.61	4.16e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13130787	0.802	rs62322301	chr4:94895848	G/A	cg11021082	chr4:95130006	SMARCAD1	0.4	5.04	0.31	8.9e-7	Colorectal cancer;
KIRP	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.51	5.96	0.36	8.86e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-5.47	-0.33	1.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.83	10.67	0.56	4.15e-22	Lymphocyte percentage of white cells;
KIRP	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg02297831	chr4:17616191	MED28	0.59	7.61	0.44	5.7e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg12560992	chr17:57184187	TRIM37	0.63	5.6	0.34	5.67e-8	Cognitive test performance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23330828	chr3:129611968	TMCC1	-0.54	-6.06	-0.36	5.15e-9	Interleukin-4 levels;
KIRP	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs368755101	1	rs368755101	chr2:100762215	AG/A	cg17356467	chr2:100759845	AFF3	0.42	5.56	0.33	6.93e-8	Plateletcrit;Red blood cell count;
KIRP	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.92	15.54	0.7	2.15e-38	Prostate cancer;
KIRP	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05585630	chr7:157510462	PTPRN2	-0.55	-8.25	-0.47	9.65e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg16586182	chr3:47516702	SCAP	-0.76	-10.84	-0.57	1.22e-22	Colorectal cancer;
KIRP	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg08890418	chr1:21044141	KIF17	0.36	5.37	0.32	1.8e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs6733011	0.628	rs1983352	chr2:99454227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-5.43	-0.33	1.35e-7	Bipolar disorder;
KIRP	cis	rs6700559	0.692	rs4915447	chr1:200593468	A/T	cg07804481	chr1:200639085	DDX59	0.39	5.06	0.31	8.19e-7	Coronary artery disease;
KIRP	cis	rs4740619	0.619	rs1410450	chr9:16037123	A/C	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.53e-7	Body mass index;
KIRP	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.77	8.97	0.5	7.82e-17	Adiposity;
KIRP	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.65	-10.46	-0.55	1.95e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs1800682	0.528	rs3758485	chr10:90747847	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.57	7.25	0.42	5.27e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg19077165	chr18:44547161	KATNAL2	0.44	5.53	0.33	8.14e-8	Personality dimensions;
KIRP	cis	rs4594175	0.926	rs72688713	chr14:51598375	C/T	cg23942311	chr14:51606299	NA	0.51	6.65	0.39	1.91e-10	Cancer;
KIRP	cis	rs9398803	0.865	rs1538171	chr6:126752884	C/G	cg19875578	chr6:126661172	C6orf173	0.5	6.39	0.38	8.16e-10	Male-pattern baldness;
KIRP	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.63	-0.44	5.19e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg11608241	chr8:8085544	FLJ10661	-0.49	-6.36	-0.38	9.5e-10	Triglycerides;
KIRP	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.97	0.41	2.93e-11	Coffee consumption (cups per day);
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.29	-0.37	1.47e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg09165964	chr15:75287851	SCAMP5	0.56	7.13	0.41	1.15e-11	Caffeine consumption;
KIRP	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg10326726	chr10:51549505	MSMB	-0.57	-8.6	-0.48	9.54e-16	Prostate-specific antigen levels;
KIRP	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg15848620	chr12:58087721	OS9	-0.48	-5.66	-0.34	4.22e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg21399703	chr1:247681439	NA	-0.52	-5.42	-0.33	1.41e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-5.13	-0.31	5.99e-7	Major depressive disorder;
KIRP	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.54	-7.36	-0.42	2.76e-12	Total body bone mineral density;
KIRP	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.88	-11.26	-0.58	5.51e-24	Vitamin D levels;
KIRP	cis	rs2412459	1.000	rs2412459	chr15:40295959	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.34	-4.97	-0.3	1.26e-6	Response to haloperidol in psychosis;
KIRP	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg10402321	chr1:26617780	UBXN11	-0.4	-5.09	-0.31	7.27e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg00262122	chr8:11665843	FDFT1	-0.44	-5.24	-0.32	3.48e-7	Neuroticism;
KIRP	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg20991723	chr1:152506922	NA	-0.44	-5.19	-0.31	4.41e-7	Hair morphology;
KIRP	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.59	-7.28	-0.42	4.38e-12	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.72	0.39	1.29e-10	Coffee consumption (cups per day);
KIRP	cis	rs12501032	1.000	rs12501032	chr4:23951018	C/G	cg10328393	chr4:23934534	NA	-0.52	-6.22	-0.37	2.1e-9	Resting heart rate;Gout;
KIRP	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05347473	chr6:146136440	FBXO30	0.57	8.12	0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg07274523	chr3:49395745	GPX1	0.71	8.55	0.48	1.31e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg16060761	chr17:80687452	NA	0.55	7.01	0.41	2.33e-11	Glycated hemoglobin levels;
KIRP	cis	rs17253792	0.822	rs17685053	chr14:56125771	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.75	5.94	0.35	9.62e-9	Putamen volume;
KIRP	cis	rs7017914	0.902	rs7831792	chr8:71565356	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.11	-0.31	6.58e-7	Bone mineral density;
KIRP	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.75	-0.63	6.4e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs12976411	0.867	rs16966931	chr19:32829216	G/A	cg02282382	chr19:32836354	ZNF507	0.7	4.91	0.3	1.64e-6	Coronary artery disease;
KIRP	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg19052272	chr2:3704530	ALLC	-0.57	-5.51	-0.33	9.11e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg05784532	chr1:230284198	GALNT2	0.5	6.24	0.37	1.91e-9	Coronary artery disease;
KIRP	cis	rs1619661	0.505	rs10793525	chr10:44683833	C/A	cg09554077	chr10:44749378	NA	0.44	6.5	0.38	4.49e-10	QT interval (ambient particulate matter interaction);
KIRP	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg23505145	chr19:12996616	KLF1	0.56	8.24	0.47	1e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.07	-0.5	4.01e-17	Blood metabolite levels;
KIRP	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs4236601	1.000	rs6969706	chr7:116154831	G/T	cg05166801	chr7:116143459	CAV2	0.46	5.69	0.34	3.53e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.96	-0.41	3.11e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.48e-6	Life satisfaction;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg16275967	chr1:161172255	NDUFS2	0.65	6.02	0.36	6.34e-9	Lung function (FEV1);
KIRP	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.62	5.93	0.35	1.01e-8	Breast cancer;
KIRP	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.69	6.83	0.4	6.65e-11	Psoriasis vulgaris;
KIRP	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg00071950	chr4:10020882	SLC2A9	-0.43	-4.96	-0.3	1.34e-6	Schizophrenia (age at onset);
KIRP	cis	rs911119	0.955	rs6114201	chr20:23607231	T/A	cg16589663	chr20:23618590	CST3	0.47	5.0	0.3	1.09e-6	Chronic kidney disease;
KIRP	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs6466055	0.661	rs2079340	chr7:104897964	G/A	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.59	-0.34	5.92e-8	Crohn's disease;
KIRP	cis	rs4234798	0.588	rs4689640	chr4:7214066	G/A	cg18431297	chr4:7219810	SORCS2	0.53	5.85	0.35	1.56e-8	Insulin-like growth factors;
KIRP	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg24375607	chr4:120327624	NA	0.42	5.3	0.32	2.63e-7	Diastolic blood pressure;
KIRP	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg00405596	chr8:11794950	NA	0.48	6.0	0.36	6.88e-9	Retinal vascular caliber;
KIRP	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.93	-0.3	1.52e-6	Dupuytren's disease;
KIRP	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg25486957	chr4:152246857	NA	-0.54	-5.88	-0.35	1.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.72	7.92	0.45	8.41e-14	Corneal astigmatism;
KIRP	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-7.42	-0.43	1.93e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	8.07	0.46	3.09e-14	Educational attainment;
KIRP	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.77	7.91	0.45	8.82e-14	Gut microbiome composition (summer);
KIRP	cis	rs988913	1.000	rs9349741	chr6:54841709	G/C	cg03513858	chr6:54763001	FAM83B	-0.37	-5.44	-0.33	1.27e-7	Menarche (age at onset);
KIRP	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-0.98	-9.68	-0.53	5.63e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg17644776	chr2:200775616	C2orf69	0.49	4.97	0.3	1.27e-6	Schizophrenia;
KIRP	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg16083429	chr3:49237500	CCDC36	-0.37	-4.85	-0.3	2.21e-6	Menarche (age at onset);
KIRP	cis	rs494562	0.892	rs9294335	chr6:86126680	C/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg25288420	chr1:78511713	GIPC2	0.48	6.35	0.38	1.05e-9	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21888241	chr11:14541921	PSMA1	-0.51	-6.08	-0.36	4.47e-9	Interleukin-4 levels;
KIRP	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs17384381	0.734	rs12129013	chr1:85891709	A/C	cg16011679	chr1:85725395	C1orf52	0.46	5.22	0.32	3.82e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg03808351	chr9:123631620	PHF19	-0.42	-5.89	-0.35	1.23e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9900972	0.918	rs6501258	chr17:76877824	T/A	cg20937029	chr17:76870563	TIMP2	0.44	5.15	0.31	5.24e-7	Obesity-related traits;
KIRP	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg06640241	chr16:89574553	SPG7	0.67	9.27	0.51	9.89e-18	Multiple myeloma (IgH translocation);
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg08132940	chr7:1081526	C7orf50	-0.43	-5.04	-0.31	9.11e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.59	-6.64	-0.39	2.01e-10	Coronary artery disease;
KIRP	cis	rs501120	0.584	rs680091	chr10:44738932	G/A	cg09554077	chr10:44749378	NA	0.71	8.28	0.47	7.92e-15	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1867631	1.000	rs6665859	chr1:67077555	A/T	cg13052034	chr1:66999238	SGIP1	0.46	6.45	0.38	6.01e-10	Menopause (age at onset);
KIRP	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.53	7.2	0.42	7.19e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2964802	0.505	rs11133627	chr5:10830474	T/G	cg14521931	chr5:10832172	NA	-0.75	-11.34	-0.59	2.95e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs16828019	0.929	rs10524	chr1:41726473	T/C	cg18742814	chr1:41828276	NA	0.62	5.65	0.34	4.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs6992848	0.791	rs11166956	chr8:141177402	C/T	cg13911501	chr8:141220320	TRAPPC9	0.43	5.11	0.31	6.42e-7	Response to amphetamines;
KIRP	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.45e-9	Type 2 diabetes;
KIRP	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg09676129	chr20:60540388	NA	-0.36	-5.12	-0.31	6.06e-7	Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12346351	chr4:152330392	FAM160A1	0.58	6.73	0.39	1.15e-10	Smoking initiation;
KIRP	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.16	-0.37	2.94e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.62	-6.61	-0.39	2.37e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs490234	0.702	rs5016056	chr9:128310807	C/T	cg14078157	chr9:128172775	NA	-0.63	-7.53	-0.43	9.77e-13	Mean arterial pressure;
KIRP	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.89	-0.35	1.29e-8	Colorectal cancer;
KIRP	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg05692746	chr2:100937584	LONRF2	-0.39	-5.03	-0.31	9.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg17736920	chr1:242011382	EXO1	0.7	9.11	0.5	3.06e-17	Menopause (age at onset);
KIRP	cis	rs1866706	1.000	rs11022518	chr11:12888164	G/T	cg25843174	chr11:12811716	TEAD1	0.32	5.41	0.33	1.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13161895	0.941	rs438050	chr5:179414645	T/C	cg02702477	chr5:179499311	RNF130	0.65	5.04	0.31	9.08e-7	LDL cholesterol;
KIRP	cis	rs9381107	0.932	rs2327168	chr6:9437498	G/A	cg14735645	chr6:9486422	NA	-0.46	-5.53	-0.33	8.26e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	4.9	0.3	1.76e-6	Breast cancer;
KIRP	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.48	-0.38	4.84e-10	Morning vs. evening chronotype;
KIRP	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg08755490	chr11:65554678	OVOL1	0.53	7.26	0.42	4.96e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg11189052	chr15:85197271	WDR73	0.53	5.38	0.32	1.7e-7	Schizophrenia;
KIRP	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.79	12.3	0.62	2.1e-27	Multiple myeloma (IgH translocation);
KIRP	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	9.57	0.52	1.17e-18	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4671458	1.000	rs72813408	chr2:63363242	G/T	cg17519650	chr2:63277830	OTX1	-0.56	-5.58	-0.34	6.2e-8	Subjective well-being;
KIRP	cis	rs4713675	0.584	rs2966	chr6:33689520	C/T	cg15676125	chr6:33679581	C6orf125	0.42	5.52	0.33	8.68e-8	Plateletcrit;
KIRP	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.68	-7.88	-0.45	1.09e-13	Pancreatic cancer;
KIRP	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.92	-0.3	1.61e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs12049351	0.832	rs28798529	chr1:229671614	G/A	cg11742688	chr1:229674241	ABCB10	-0.42	-6.83	-0.4	6.49e-11	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs7804356	1.000	rs3801819	chr7:26866698	T/G	cg03456212	chr7:26904342	SKAP2	-0.54	-5.09	-0.31	7.15e-7	Type 1 diabetes;
KIRP	cis	rs7534824	0.625	rs72736234	chr1:101526098	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	6.87	0.4	5.3e-11	Refractive astigmatism;
KIRP	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg06481639	chr22:41940642	POLR3H	-0.44	-4.87	-0.3	2.03e-6	Neuroticism;
KIRP	cis	rs1978968	0.717	rs28406897	chr22:18402012	T/C	cg03078520	chr22:18463400	MICAL3	-0.53	-6.35	-0.38	1.03e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.59	7.32	0.42	3.55e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg25019722	chr6:37503610	NA	-0.95	-15.32	-0.7	1.18e-37	Cognitive performance;
KIRP	cis	rs1891498	0.602	rs10793707	chr1:147244022	G/A	cg27546670	chr1:147246839	GJA5	-0.82	-11.31	-0.59	3.62e-24	Cognitive performance;
KIRP	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.72	9.66	0.52	6.33e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg25734977	chr19:11670027	ELOF1	-0.44	-6.14	-0.36	3.37e-9	Hippocampal sclerosis of aging;
KIRP	cis	rs4791641	0.967	rs8078338	chr17:8129160	A/G	cg06726167	chr17:8076949	TMEM107	0.46	5.42	0.33	1.42e-7	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.48	-6.6	-0.39	2.51e-10	Testicular germ cell tumor;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08617354	chr10:68858663	CTNNA3;LRRTM3	0.41	6.25	0.37	1.83e-9	C-reactive protein;
KIRP	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.13	-0.36	3.5e-9	Triglycerides;
KIRP	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg04660111	chr19:49199234	FUT2	0.34	5.22	0.32	3.72e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06873352	chr17:61820015	STRADA	-0.58	-7.31	-0.42	3.79e-12	Prudent dietary pattern;
KIRP	cis	rs72653721	0.730	rs9468304	chr6:11042165	A/G	cg13562911	chr6:11044106	ELOVL2	-0.58	-5.84	-0.35	1.63e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Parkinson's disease;
KIRP	cis	rs4262150	0.883	rs72802877	chr5:152241855	A/G	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.78	-5.47	-0.33	1.12e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg11621586	chr10:70884670	VPS26A	1.11	14.23	0.67	6.12e-34	Left atrial antero-posterior diameter;
KIRP	cis	rs10181042	0.565	rs1177233	chr2:61262134	C/T	cg10580144	chr2:61372316	C2orf74	-0.41	-5.14	-0.31	5.69e-7	Crohn's disease;
KIRP	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.91	0.4	4.19e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs72634030	0.536	rs56960906	chr17:5229455	C/T	cg20802942	chr17:5185005	RABEP1	0.52	5.14	0.31	5.56e-7	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.44	-0.33	1.27e-7	Life satisfaction;
KIRP	cis	rs7395581	0.918	rs1052373	chr11:47354787	A/G	cg26139080	chr11:47293733	MADD	0.43	5.35	0.32	1.97e-7	HDL cholesterol;
KIRP	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.48e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg24633833	chr3:10029261	TMEM111	0.53	5.18	0.31	4.72e-7	Alzheimer's disease;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.85	7.83	0.45	1.44e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06481639	chr22:41940642	POLR3H	-0.6	-6.84	-0.4	6.24e-11	Vitiligo;
KIRP	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	6.16	0.37	2.89e-9	Menarche (age at onset);
KIRP	cis	rs9478638	0.507	rs335368	chr6:155640881	C/T	cg07943832	chr6:155568918	TIAM2	-0.36	-5.59	-0.34	5.88e-8	Electroencephalogram traits;
KIRP	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	11.07	0.58	2.16e-23	Bone mineral density;
KIRP	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.29	-0.32	2.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7009516	0.669	rs4872231	chr8:24247556	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.3	-6.15	-0.36	3.18e-9	Hair greying;
KIRP	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.68e-11	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg05973401	chr12:123451056	ABCB9	-0.48	-5.36	-0.32	1.94e-7	Neutrophil percentage of white cells;
KIRP	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg00684032	chr4:1343700	KIAA1530	0.54	7.28	0.42	4.5e-12	Obesity-related traits;
KIRP	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs687432	0.737	rs61902767	chr11:57889731	C/G	cg19752551	chr11:57585705	CTNND1	-0.64	-8.23	-0.46	1.09e-14	Parkinson's disease;
KIRP	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg18190219	chr22:46762943	CELSR1	-0.94	-7.44	-0.43	1.68e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.52	0.62	3.78e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.65	7.77	0.44	2.11e-13	Corneal astigmatism;
KIRP	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	9.79	0.53	2.53e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16774013	chr18:77160150	NFATC1	0.53	6.29	0.37	1.44e-9	Myopia (pathological);
KIRP	cis	rs10870468	0.574	rs12827428	chr12:133019964	A/C	cg14071137	chr12:133020030	NA	-0.45	-6.07	-0.36	4.93e-9	Gait speed in old age;
KIRP	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.29e-16	Prudent dietary pattern;
KIRP	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg14092571	chr14:90743983	NA	0.4	5.14	0.31	5.71e-7	Mortality in heart failure;
KIRP	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.72	0.44	2.87e-13	Coffee consumption (cups per day);
KIRP	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.76	9.65	0.52	6.9e-19	Neutrophil percentage of white cells;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg02733842	chr7:1102375	C7orf50	0.52	5.46	0.33	1.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg21775007	chr8:11205619	TDH	0.47	6.23	0.37	2e-9	Systolic blood pressure;
KIRP	trans	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-7.46	-0.43	1.46e-12	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.44	-5.75	-0.34	2.68e-8	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12143125	chr20:44044875	PIGT	0.5	6.74	0.39	1.09e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg05991184	chr2:219186017	PNKD	0.36	5.06	0.31	8.39e-7	Colorectal cancer;
KIRP	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg13010199	chr12:38710504	ALG10B	0.62	7.64	0.44	4.82e-13	Morning vs. evening chronotype;
KIRP	cis	rs7209460	0.518	rs6503222	chr17:1977862	G/A	cg15816464	chr17:2026533	SMG6	0.35	5.5	0.33	9.43e-8	Coronary artery disease;Total body bone mineral density;
KIRP	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.65	-0.34	4.37e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.03	0.41	2e-11	Arsenic metabolism;
KIRP	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	8.16	0.46	1.76e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	6.78	0.4	8.82e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.68	9.65	0.52	7.05e-19	Diastolic blood pressure;
KIRP	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg00094735	chr5:1949198	NA	-0.44	-5.29	-0.32	2.7e-7	Gut microbiome composition (winter);
KIRP	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg23594656	chr7:65796392	TPST1	0.51	7.97	0.45	5.76e-14	Aortic root size;
KIRP	cis	rs9875589	0.915	rs9835402	chr3:13954396	A/G	cg19554555	chr3:13937349	NA	0.52	7.76	0.44	2.21e-13	Ovarian reserve;
KIRP	cis	rs6540556	0.678	rs12094117	chr1:209888435	G/T	cg23920097	chr1:209922102	NA	-0.5	-5.72	-0.34	3.04e-8	Red blood cell count;
KIRP	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.4	5.44	0.33	1.27e-7	HIV-1 susceptibility;
KIRP	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.76	-8.17	-0.46	1.6e-14	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23956068	chr18:33647542	RPRD1A	0.56	7.01	0.41	2.27e-11	Parkinson's disease;
KIRP	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg09571762	chr12:39539558	NA	0.37	5.19	0.31	4.39e-7	Morning vs. evening chronotype;
KIRP	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7520050	0.966	rs6669522	chr1:46397941	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.71e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg00094735	chr5:1949198	NA	0.47	5.53	0.33	8.12e-8	Gut microbiome composition (winter);
KIRP	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.56	8.96	0.5	8.27e-17	Prostate cancer;
KIRP	cis	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg12292205	chr6:26970375	C6orf41	-0.63	-7.64	-0.44	4.96e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	cis	rs56161922	1.000	rs74692669	chr1:207818120	G/C	cg11752769	chr1:207818423	CR1L	-0.77	-5.0	-0.3	1.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.84	11.45	0.59	1.25e-24	Total body bone mineral density;
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.74	-7.09	-0.41	1.43e-11	Platelet count;
KIRP	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs1816752	0.712	rs9507335	chr13:24983904	G/A	cg02811702	chr13:24901961	NA	0.39	5.06	0.31	8.1e-7	Obesity-related traits;
KIRP	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4849845	0.889	rs4848583	chr2:121018760	T/C	cg24070213	chr2:121070622	NA	0.4	5.31	0.32	2.46e-7	Mean platelet volume;
KIRP	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg23307798	chr14:103986281	CKB	0.51	6.91	0.4	4.18e-11	Coronary artery disease;
KIRP	cis	rs7215564	0.908	rs4889879	chr17:78662573	A/T	cg06153925	chr17:78755379	RPTOR	-0.28	-4.84	-0.3	2.26e-6	Myopia (pathological);
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg10351095	chr21:47802916	PCNT	0.41	5.1	0.31	6.82e-7	Testicular germ cell tumor;
KIRP	cis	rs829883	1.000	rs249837	chr12:98876535	A/G	cg25150519	chr12:98850993	NA	0.87	13.14	0.64	3.09e-30	Colorectal adenoma (advanced);
KIRP	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	6.79	0.4	8.4e-11	Multiple sclerosis;
KIRP	cis	rs1729407	0.647	rs2727791	chr11:116684562	C/G	cg11861562	chr11:117069780	TAGLN	0.38	5.01	0.3	1.02e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg09491104	chr22:46646882	C22orf40	-0.59	-7.85	-0.45	1.28e-13	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19146587	chr7:2165490	MAD1L1	-0.46	-6.53	-0.38	3.72e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-6.36	-0.38	9.64e-10	Aortic root size;
KIRP	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg14683738	chr19:37701593	ZNF585B	0.47	4.87	0.3	1.97e-6	Coronary artery calcification;
KIRP	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg13736514	chr6:26305472	NA	-0.6	-7.69	-0.44	3.53e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg25214090	chr10:38739885	LOC399744	0.48	6.09	0.36	4.28e-9	Diastolic blood pressure;
KIRP	trans	rs9371601	0.798	rs550065	chr6:152717507	A/G	cg05529123	chr2:66910386	NA	-0.46	-6.2	-0.37	2.37e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg27490568	chr2:178487706	NA	0.46	5.99	0.36	7.55e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.66	9.83	0.53	1.94e-19	Schizophrenia;
KIRP	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg10018233	chr7:150070692	REPIN1	0.71	8.6	0.48	9.36e-16	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs963731	0.649	rs4670901	chr2:39199271	T/C	cg04010122	chr2:39346883	SOS1	-0.88	-5.84	-0.35	1.67e-8	Corticobasal degeneration;
KIRP	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7674212	0.507	rs223471	chr4:103698786	G/C	cg16532752	chr4:104119610	CENPE	-0.41	-4.88	-0.3	1.9e-6	Type 2 diabetes;
KIRP	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.75	-0.34	2.7e-8	Educational attainment;
KIRP	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.82	-8.19	-0.46	1.43e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-8.16	-0.46	1.79e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs9914544	0.544	rs4244595	chr17:18677329	C/T	cg04702396	chr17:15466718	FAM18B2	0.59	8.17	0.46	1.61e-14	Educational attainment (years of education);
KIRP	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	1.05	10.86	0.57	1.04e-22	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.9	0.35	1.17e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg12292205	chr6:26970375	C6orf41	0.34	4.86	0.3	2.09e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.2.1294774R	chr2:55598321	CCDC88A	0.45	6.63	0.39	2.07e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11874712	0.933	rs8097521	chr18:43666952	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.83	12.81	0.63	4.15e-29	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-6.19	-0.37	2.56e-9	Lung cancer;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22397447	chr9:38392975	ALDH1B1	0.61	6.78	0.4	8.78e-11	Lung cancer in ever smokers;
KIRP	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.17	-0.54	1.6e-20	Coffee consumption (cups per day);
KIRP	cis	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg00262122	chr8:11665843	FDFT1	-0.45	-5.25	-0.32	3.27e-7	Triglycerides;
KIRP	cis	rs2737618	0.674	rs2258280	chr1:200097648	G/A	cg21825944	chr1:200113062	NR5A2	-0.54	-7.58	-0.43	7.2e-13	Uric acid levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09059988	chr1:150693299	HORMAD1	0.46	6.59	0.39	2.73e-10	Survival in pancreatic cancer;
KIRP	cis	rs9473924	0.632	rs9473926	chr6:50835815	C/T	cg03432817	chr6:50765336	NA	0.34	5.33	0.32	2.21e-7	Body mass index;
KIRP	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.75	-9.48	-0.52	2.24e-18	Aortic root size;
KIRP	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.67	8.95	0.5	9.18e-17	Educational attainment;
KIRP	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg14952266	chr13:112191215	NA	0.42	6.22	0.37	2.15e-9	Hepatitis;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg08667777	chr3:51422532	MANF	0.73	6.34	0.37	1.1e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2671245	0.586	rs4367813	chr1:56138735	A/G	cg11523071	chr1:56160889	NA	-0.41	-6.01	-0.36	6.48e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg19468946	chr17:37922297	IKZF3	-0.49	-6.81	-0.4	7.64e-11	Self-reported allergy;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06666157	chr19:4791552	FEM1A	-0.49	-6.08	-0.36	4.5e-9	Neuroticism;
KIRP	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg16396542	chr1:89473148	GBP3	0.42	5.91	0.35	1.15e-8	Carotid intima media thickness;
KIRP	cis	rs55788414	1.000	rs7499792	chr16:81184318	C/T	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg22800045	chr5:56110881	MAP3K1	0.82	8.54	0.48	1.38e-15	Initial pursuit acceleration;
KIRP	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.49	-5.81	-0.35	1.92e-8	Neurofibrillary tangles;
KIRP	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs4849845	0.889	rs3860373	chr2:121037233	A/C	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg03834567	chr2:218808745	TNS1	0.41	5.19	0.31	4.32e-7	Ulcerative colitis;
KIRP	cis	rs151997	1.000	rs151997	chr5:50233199	A/G	cg06027927	chr5:50259733	NA	-0.59	-7.4	-0.43	2.09e-12	Callous-unemotional behaviour;
KIRP	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg24375607	chr4:120327624	NA	0.58	6.73	0.39	1.15e-10	Corneal astigmatism;
KIRP	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.24	-0.37	1.85e-9	IgG glycosylation;
KIRP	cis	rs7712401	0.715	rs395981	chr5:122347911	C/T	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg25482853	chr8:67687455	SGK3	0.8	7.01	0.41	2.32e-11	Obesity-related traits;
KIRP	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.14	0.41	1.06e-11	Height;
KIRP	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.54	-5.07	-0.31	7.82e-7	Narcolepsy;
KIRP	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Alcohol dependence;
KIRP	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.41	7.11	0.41	1.24e-11	Renal cell carcinoma;
KIRP	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg02073558	chr3:44770973	ZNF501	0.59	8.02	0.46	4.37e-14	Depressive symptoms;
KIRP	cis	rs10128264	0.902	rs1250584	chr10:80976442	G/T	cg18737081	chr10:80999807	ZMIZ1	-0.32	-5.83	-0.35	1.77e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.39	5.98	0.36	7.84e-9	Body mass index;
KIRP	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg14664628	chr15:75095509	CSK	0.5	5.58	0.33	6.45e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.95	14.98	0.69	1.78e-36	Height;
KIRP	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	5.61	0.34	5.41e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.85	-13.7	-0.66	3.98e-32	Prostate cancer;
KIRP	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.5	6.24	0.37	1.94e-9	Subjective well-being;
KIRP	cis	rs4148660	0.895	rs7137250	chr12:22072529	C/T	cg14669847	chr12:22099120	NA	0.34	5.79	0.35	2.17e-8	Gout;
KIRP	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22808750	chr8:9123484	NA	0.42	6.28	0.37	1.52e-9	Interleukin-4 levels;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.62	8.38	0.47	4.15e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25354858	chr15:56530082	RFX7	0.43	6.35	0.38	1.03e-9	Migraine with aura;
KIRP	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.45	7.33	0.42	3.22e-12	Fibrinogen levels;
KIRP	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07570687	chr10:102243282	WNT8B	0.52	6.69	0.39	1.5e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19337852	chr19:38755293	SPINT2	0.58	7.18	0.42	8.42e-12	Parkinson's disease;
KIRP	trans	rs2302464	1.000	rs10939631	chr4:15658569	G/A	cg03228132	chr7:129781429	NA	-0.73	-7.08	-0.41	1.52e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	5.2	0.31	4.25e-7	Diabetic retinopathy;
KIRP	cis	rs10782582	0.668	rs1250876	chr1:76193232	A/G	cg03433033	chr1:76189801	ACADM	0.38	5.75	0.34	2.65e-8	Daytime sleep phenotypes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09231673	chr11:33049259	DEPDC7	-0.36	-6.04	-0.36	5.78e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.79	10.78	0.57	1.98e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2057178	0.860	rs7123725	chr11:32355336	G/T	cg06489367	chr11:32355509	NA	0.44	5.34	0.32	2.08e-7	Tuberculosis;
KIRP	trans	rs656319	0.702	rs587328	chr8:9809722	C/T	cg16141378	chr3:129829833	LOC729375	0.48	6.08	0.36	4.61e-9	Myopia (pathological);
KIRP	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.72	-7.75	-0.44	2.39e-13	Diastolic blood pressure;
KIRP	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg02569458	chr12:86230093	RASSF9	-0.39	-5.71	-0.34	3.26e-8	Major depressive disorder;
KIRP	cis	rs6466055	0.649	rs111563282	chr7:104898327	G/C	cg04380332	chr7:105027541	SRPK2	0.38	5.21	0.32	3.92e-7	Schizophrenia;
KIRP	cis	rs2380205	0.651	rs1512694	chr10:5916771	C/T	cg27141509	chr10:5886111	NA	-0.35	-4.93	-0.3	1.52e-6	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13180787	chr1:24127146	GALE	0.45	6.04	0.36	5.77e-9	Parkinson's disease;
KIRP	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg15676125	chr6:33679581	C6orf125	0.4	5.22	0.32	3.81e-7	Plateletcrit;
KIRP	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-7.18	-0.42	8.3e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.56	5.05	0.31	8.45e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10211205	1.000	rs10173638	chr2:236613478	G/A	cg13770573	chr2:236586376	AGAP1	-0.54	-5.85	-0.35	1.56e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg01559446	chr3:44596178	ZNF167	-0.36	-5.1	-0.31	6.79e-7	Depressive symptoms;
KIRP	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.74	9.83	0.53	1.85e-19	Parkinson's disease;
KIRP	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg00982548	chr2:198649783	BOLL	-0.59	-5.46	-0.33	1.17e-7	Ulcerative colitis;
KIRP	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg03563238	chr19:33554763	RHPN2	-0.33	-6.08	-0.36	4.6e-9	Bone properties (heel);
KIRP	cis	rs6964587	1.000	rs7781597	chr7:91588194	T/C	cg03714773	chr7:91764589	CYP51A1	0.35	5.02	0.3	1.02e-6	Breast cancer;
KIRP	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.87	0.4	5.16e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17123764	0.579	rs11836837	chr12:50149948	C/T	cg20471783	chr12:50157085	TMBIM6	0.42	5.5	0.33	9.61e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg26138937	chr11:71823887	C11orf51	-1.11	-7.13	-0.41	1.1e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs16828019	0.852	rs16827876	chr1:41539536	T/G	cg03387723	chr1:41708464	SCMH1	-0.75	-6.67	-0.39	1.68e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg19683494	chr5:74908142	NA	0.55	5.46	0.33	1.16e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2791713	0.663	rs6672060	chr1:207159378	C/A	cg24040043	chr1:207224982	YOD1	0.29	5.0	0.3	1.1e-6	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg00543991	chr22:32367038	NA	0.53	4.87	0.3	1.97e-6	Childhood ear infection;
KIRP	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg06565975	chr8:143823917	SLURP1	0.47	7.49	0.43	1.24e-12	Urinary tract infection frequency;
KIRP	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.86	-12.82	-0.63	3.81e-29	Height;
KIRP	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	4.87	0.3	2.03e-6	Schizophrenia;
KIRP	cis	rs2048656	0.578	rs4841235	chr8:9683358	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-5.32	-0.32	2.35e-7	Schizophrenia;
KIRP	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	5.84	0.35	1.67e-8	Thyroid stimulating hormone;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg12170299	chr20:33880195	FAM83C	0.42	6.81	0.4	7.24e-11	Serum protein levels (sST2);
KIRP	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	1.0	14.31	0.67	3.31e-34	Cognitive function;
KIRP	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg00409905	chr10:38381863	ZNF37A	0.55	5.78	0.35	2.25e-8	Obesity (extreme);
KIRP	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg00405596	chr8:11794950	NA	-0.46	-6.03	-0.36	5.87e-9	Neuroticism;
KIRP	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.44	-0.33	1.31e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.65	8.89	0.49	1.37e-16	Alcohol dependence;
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.61	8.74	0.49	3.64e-16	Longevity;Endometriosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25926008	chr6:110012635	AKD1;FIG4	0.45	6.05	0.36	5.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.73	9.24	0.51	1.22e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.57	-6.66	-0.39	1.81e-10	Initial pursuit acceleration;
KIRP	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	trans	rs4143844	0.867	rs11635880	chr15:62156042	A/C	cg04814990	chr13:111957387	ARHGEF7	0.99	6.51	0.38	4.3e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg00857998	chr1:205179979	DSTYK	0.59	7.19	0.42	7.89e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.9	0.53	1.14e-19	Total body bone mineral density;
KIRP	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.67	-7.27	-0.42	4.65e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7007076	0.609	rs6470184	chr8:124755460	G/T	cg00283535	chr8:124749564	ANXA13	0.59	7.46	0.43	1.48e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs8033133	0.881	rs8031260	chr15:25316831	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.48	-5.43	-0.33	1.38e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs2380205	0.967	rs713588	chr10:5886962	A/G	cg27141509	chr10:5886111	NA	-0.39	-5.62	-0.34	5.2100000000000003e-08	Breast cancer;
KIRP	cis	rs17030434	0.953	rs6535953	chr4:154728186	G/A	cg14289246	chr4:154710475	SFRP2	-0.82	-9.76	-0.53	3.12e-19	Electrocardiographic conduction measures;
KIRP	cis	rs9972944	0.631	rs6504345	chr17:63757052	T/G	cg07283582	chr17:63770753	CCDC46	-0.41	-6.63	-0.39	2.15e-10	Total body bone mineral density;
KIRP	cis	rs6142102	0.580	rs4911139	chr20:32551535	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	5.99	0.36	7.24e-9	Skin pigmentation;
KIRP	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.24	-6.43	-0.38	6.55e-10	Mean corpuscular volume;
KIRP	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-6.33	-0.37	1.17e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg25173405	chr17:45401733	C17orf57	0.47	6.28	0.37	1.52e-9	Multiple sclerosis or amyotrophic lateral sclerosis;
KIRP	cis	rs13102973	0.931	rs12499856	chr4:135868573	C/T	cg14419869	chr4:135874104	NA	0.54	9.18	0.51	1.86e-17	Subjective well-being;
KIRP	cis	rs15676	0.783	rs2417128	chr9:131571756	G/A	cg00228799	chr9:131580591	ENDOG	0.55	6.0	0.36	6.99e-9	Blood metabolite levels;
KIRP	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.77	12.63	0.63	1.56e-28	Cancer;
KIRP	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	6.55	0.39	3.34e-10	Tonsillectomy;
KIRP	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05025164	chr4:1340916	KIAA1530	0.42	5.33	0.32	2.2e-7	Obesity-related traits;
KIRP	cis	rs10761482	0.645	rs10761498	chr10:62183385	T/C	cg01186212	chr10:62110162	ANK3	-0.31	-5.08	-0.31	7.3e-7	Schizophrenia;
KIRP	trans	rs6477998	1.000	rs6477998	chr9:115997249	A/C	cg21160472	chr1:212782112	ATF3	-0.5	-6.16	-0.37	2.96e-9	Hematology traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06646488	chr20:61569335	C20orf11;DIDO1	0.52	6.66	0.39	1.8e-10	Parkinson's disease;
KIRP	cis	rs829661	0.947	rs829665	chr2:30724701	T/G	cg10949345	chr2:30726833	LCLAT1	0.52	7.02	0.41	2.19e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7615316	1.000	rs1983434	chr3:142347757	A/G	cg20824294	chr3:142316082	PLS1	0.25	5.41	0.33	1.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07402062	chr16:89894098	SPIRE2	0.31	6.52	0.38	4.04e-10	Vitiligo;
KIRP	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.48	-0.43	1.27e-12	Mean corpuscular volume;
KIRP	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg00360474	chr6:37504404	NA	-0.5	-7.21	-0.42	7.02e-12	Cognitive performance;
KIRP	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.74	-0.53	3.57e-19	Body mass index;
KIRP	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18252515	chr7:66147081	NA	0.46	5.63	0.34	4.85e-8	Aortic root size;
KIRP	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg23307798	chr14:103986281	CKB	0.74	12.5	0.62	4.49e-28	Body mass index;
KIRP	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg09085632	chr11:111637200	PPP2R1B	0.51	6.85	0.4	5.71e-11	Primary sclerosing cholangitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17783641	chr4:166249014	SC4MOL	0.54	7.28	0.42	4.45e-12	Parkinson's disease;
KIRP	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg16396542	chr1:89473148	GBP3	0.4	5.69	0.34	3.65e-8	Carotid intima media thickness;
KIRP	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.01	-0.5	5.75e-17	Neuroticism;
KIRP	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.6	-6.95	-0.41	3.23e-11	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00968021	chr1:70876888	CTH	0.51	6.62	0.39	2.27e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25987185	chr17:18129087	LLGL1	0.54	6.67	0.39	1.66e-10	Parkinson's disease;
KIRP	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	1.01	14.18	0.67	9.24e-34	Cognitive function;
KIRP	cis	rs8077577	0.789	rs11078411	chr17:18088094	C/T	cg18869244	chr17:18121946	NA	0.47	5.37	0.32	1.83e-7	Obesity-related traits;
KIRP	cis	rs7174755	0.608	rs62004789	chr15:68440606	C/T	cg22576950	chr15:68522787	CLN6	0.38	5.55	0.33	7.26e-8	Major depressive disorder;
KIRP	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg25319279	chr11:5960081	NA	-0.59	-6.04	-0.36	5.66e-9	DNA methylation (variation);
KIRP	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.43e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg15360169	chr6:170124317	PHF10	0.56	6.51	0.38	4.24e-10	Plasma plasminogen activator levels;
KIRP	trans	rs1941687	1.000	rs1941687	chr18:31334667	A/C	cg27147174	chr7:100797783	AP1S1	-0.61	-7.91	-0.45	8.46e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg11995313	chr8:8860691	ERI1	0.39	5.4	0.33	1.57e-7	Joint mobility (Beighton score);
KIRP	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs1050631	0.592	rs1010955	chr18:33710610	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.74	0.34	2.82e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs876084	0.505	rs10216978	chr8:121105620	C/A	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg09264619	chr17:80180166	NA	-0.41	-5.93	-0.35	1.01e-8	Life satisfaction;
KIRP	cis	rs11264213	0.711	rs10752603	chr1:36161576	C/A	cg27506609	chr1:36549197	TEKT2	0.61	5.68	0.34	3.76e-8	Schizophrenia;
KIRP	cis	rs490234	0.841	rs7863341	chr9:128449085	A/G	cg14078157	chr9:128172775	NA	0.39	4.87	0.3	2.02e-6	Mean arterial pressure;
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13939156	chr17:80058883	NA	-0.49	-7.48	-0.43	1.34e-12	Life satisfaction;
KIRP	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg02297831	chr4:17616191	MED28	-0.48	-5.92	-0.35	1.07e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg08662619	chr6:150070041	PCMT1	-0.35	-5.46	-0.33	1.14e-7	Lung cancer;
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg02462569	chr6:150064036	NUP43	-0.34	-5.11	-0.31	6.38e-7	Lung cancer;
KIRP	cis	rs7096127	0.966	rs11013973	chr10:24502629	G/C	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.92	0.3	1.59e-6	Lobe attachment (rater scored);
KIRP	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg18196295	chr10:418757	DIP2C	-0.39	-4.85	-0.3	2.22e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	15.96	0.71	7.69e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-7.92	-0.45	7.94e-14	Colorectal cancer;
KIRP	cis	rs4664293	0.802	rs13025347	chr2:160577567	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs7903847	0.527	rs11189223	chr10:99203348	C/T	cg07052063	chr10:99255236	MMS19	0.47	5.27	0.32	2.91e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg22681709	chr2:178499509	PDE11A	-0.54	-7.09	-0.41	1.43e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.36	-0.42	2.69e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1345301	1.000	rs1345302	chr2:102873369	A/G	cg12451869	chr2:102867685	NA	0.39	5.75	0.34	2.7e-8	Waist circumference;
KIRP	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.47	0.43	1.37e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1788820	1.000	rs1788820	chr18:21101944	A/G	cg14672496	chr18:21087552	C18orf8	0.37	5.52	0.33	8.62e-8	Body mass index;
KIRP	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	7.32	0.42	3.56e-12	Renal function-related traits (BUN);
KIRP	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg22903471	chr2:27725779	GCKR	0.35	4.96	0.3	1.34e-6	Oral cavity cancer;
KIRP	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg10760299	chr15:45669010	GATM	0.35	5.09	0.31	7.03e-7	Homoarginine levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25978167	chr4:57301353	PAICS;PPAT	-0.5	-6.54	-0.38	3.53e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.42	0.33	1.46e-7	Blood protein levels;
KIRP	cis	rs17092148	1.000	rs3787220	chr20:33337751	T/C	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	trans	rs7819412	0.582	rs2409685	chr8:10909193	C/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.03	-0.41	1.99e-11	Triglycerides;
KIRP	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs6684514	0.922	rs12047994	chr1:156284535	C/A	cg16558208	chr1:156270281	VHLL	-0.45	-5.98	-0.36	7.67e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00376283	chr12:123451042	ABCB9	0.67	8.13	0.46	2.05e-14	Neutrophil percentage of white cells;
KIRP	trans	rs196889	0.808	rs196766	chr8:24711009	C/T	cg15569292	chr11:3022005	NA	-0.37	-6.04	-0.36	5.68e-9	Seasonality;
KIRP	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	0.98	10.51	0.56	1.35e-21	Iron status biomarkers;
KIRP	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4791641	0.756	rs4791663	chr17:8185902	C/T	cg06726167	chr17:8076949	TMEM107	0.42	5.07	0.31	7.72e-7	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27144592	chr16:783916	NARFL	0.36	5.08	0.31	7.53e-7	Height;
KIRP	cis	rs2281603	0.904	rs59440409	chr14:64980967	A/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs11955398	0.585	rs2409794	chr5:60016798	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.25	-0.32	3.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.3	17.71	0.75	8.26e-46	Corneal structure;
KIRP	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.8	-10.8	-0.57	1.7e-22	Prostate cancer;
KIRP	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg13565492	chr6:43139072	SRF	-0.98	-8.82	-0.49	2.15e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.63	8.54	0.48	1.39e-15	Alcohol dependence;
KIRP	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.63	-8.02	-0.46	4.23e-14	Diastolic blood pressure;
KIRP	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.71	-8.98	-0.5	7.25e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2929278	0.588	rs1975364	chr15:44150189	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.38	0.38	8.63e-10	Schizophrenia;
KIRP	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.44	-5.05	-0.31	8.67e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	1.01	14.94	0.69	2.33e-36	Height;
KIRP	cis	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg06521852	chr22:38141419	TRIOBP	0.45	6.65	0.39	1.84e-10	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.65	12.16	0.61	5.89e-27	White blood cell count (basophil);
KIRP	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg17376030	chr22:41985996	PMM1	0.66	6.87	0.4	5.1e-11	Vitiligo;
KIRP	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.67	-7.29	-0.42	4.22e-12	DNA methylation (variation);
KIRP	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-1.02	-19.23	-0.77	6.34e-51	Breast cancer;
KIRP	cis	rs11731606	0.508	rs7677981	chr4:95299736	C/T	cg00507259	chr4:95128692	SMARCAD1	0.54	5.25	0.32	3.28e-7	Mean platelet volume;
KIRP	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg27490568	chr2:178487706	NA	0.48	6.31	0.37	1.29e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-8.36	-0.47	4.83e-15	Type 2 diabetes;
KIRP	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg04315214	chr1:2043799	PRKCZ	0.39	6.05	0.36	5.28e-9	Height;
KIRP	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg26207909	chr14:103986467	CKB	-0.44	-5.36	-0.32	1.92e-7	Coronary artery disease;
KIRP	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	1.06	17.65	0.75	1.35e-45	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg04025307	chr7:1156635	C7orf50	0.54	7.45	0.43	1.54e-12	Longevity;Endometriosis;
KIRP	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg19875535	chr5:140030758	IK	-0.72	-10.39	-0.55	3.29e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	0.99	10.76	0.57	2.17e-22	Blood protein levels;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg24874828	chr4:187887005	NA	-0.48	-7.15	-0.41	9.93e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	1.0	17.54	0.75	3.22e-45	Breast cancer;
KIRP	cis	rs57590327	0.716	rs4352391	chr3:81802318	T/C	cg07356753	chr3:81810745	GBE1	-0.71	-8.31	-0.47	6.42e-15	Extraversion;
KIRP	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.97	-0.41	2.89e-11	Initial pursuit acceleration;
KIRP	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg10755058	chr3:40428713	ENTPD3	0.48	6.66	0.39	1.82e-10	Renal cell carcinoma;
KIRP	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg00262122	chr8:11665843	FDFT1	-0.42	-5.26	-0.32	3.06e-7	Morning vs. evening chronotype;
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07256732	chr16:621771	PIGQ	-0.46	-6.42	-0.38	7e-10	Height;
KIRP	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg20701182	chr2:24300061	SF3B14	0.61	5.23	0.32	3.64e-7	Lymphocyte counts;
KIRP	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-5.29	-0.32	2.75e-7	Arsenic metabolism;
KIRP	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg24009623	chr19:33667908	NA	0.48	6.1	0.36	3.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12912184	0.950	rs12901615	chr15:92847304	A/C	cg12155969	chr15:92849000	NA	0.4	5.01	0.3	1.05e-6	Smoking initiation;
KIRP	cis	rs35740288	0.770	rs12907126	chr15:86171357	A/G	cg17133734	chr15:86042851	AKAP13	-0.47	-5.18	-0.31	4.71e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.53	-0.43	9.33e-13	Type 2 diabetes;
KIRP	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-1.05	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	cis	rs2803122	0.501	rs10811140	chr9:19230399	T/C	cg19584733	chr9:19298547	DENND4C	-0.48	-5.73	-0.34	3e-8	Pulse pressure;
KIRP	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Hypertriglyceridemia;
KIRP	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.69	-0.44	3.44e-13	Retinal vascular caliber;
KIRP	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg10556349	chr10:835070	NA	-0.38	-4.89	-0.3	1.81e-6	Survival in rectal cancer;
KIRP	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.83e-10	Colorectal cancer;
KIRP	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.83	-0.45	1.49e-13	Retinal vascular caliber;
KIRP	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.48	4.94	0.3	1.41e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs1440410	0.835	rs6537151	chr4:144067906	T/C	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg19500275	chr17:80737654	TBCD	0.46	5.41	0.33	1.53e-7	Glycated hemoglobin levels;
KIRP	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.91	-10.86	-0.57	1.04e-22	Cognitive ability;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.83	-0.35	1.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35740288	0.770	rs11635587	chr15:86173633	C/T	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg02503808	chr4:7069936	GRPEL1	-0.94	-6.09	-0.36	4.28e-9	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10678749	chr5:129238767	NA	-0.38	-6.28	-0.37	1.52e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs911119	1.000	rs6114206	chr20:23611789	A/G	cg16589663	chr20:23618590	CST3	0.63	6.17	0.37	2.83e-9	Chronic kidney disease;
KIRP	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.57	-0.39	3e-10	Blood pressure;
KIRP	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg00852783	chr1:26633632	UBXN11	-0.58	-5.96	-0.36	8.73e-9	Obesity-related traits;
KIRP	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-13.88	-0.66	1.01e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg21518248	chr2:162101506	NA	0.45	5.45	0.33	1.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6832769	1.000	rs3736544	chr4:56309992	A/G	cg05960024	chr4:56376020	CLOCK	0.73	9.4	0.51	3.9e-18	Personality dimensions;
KIRP	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg07212818	chr11:638076	DRD4	-0.42	-5.23	-0.32	3.61e-7	Systemic lupus erythematosus;
KIRP	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg24807547	chr6:37504484	NA	-0.48	-7.23	-0.42	6.02e-12	Cognitive performance;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.45	-6.07	-0.36	4.69e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs10982256	0.774	rs13286430	chr9:117246424	G/A	cg13636371	chr9:117264095	DFNB31	0.57	8.06	0.46	3.29e-14	Bipolar disorder;
KIRP	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	10.47	0.56	1.91e-21	Calcium levels;
KIRP	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.91	-0.35	1.16e-8	IgG glycosylation;
KIRP	cis	rs1010254	0.510	rs2348422	chr5:151759909	G/A	cg12297329	chr5:152029980	NA	-0.71	-6.92	-0.4	3.85e-11	Optic nerve measurement (cup area);
KIRP	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg14505434	chr11:89522851	NA	0.5	5.49	0.33	1.02e-7	White blood cell types;
KIRP	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.49	-0.33	9.98e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	14.85	0.69	4.63e-36	Platelet count;
KIRP	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.47	0.33	1.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	0.81	10.2	0.54	1.38e-20	Menopause (age at onset);
KIRP	cis	rs4664304	0.658	rs2667015	chr2:160868586	T/C	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.49	-0.43	1.22e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg02462569	chr6:150064036	NUP43	-0.38	-5.8	-0.35	2e-8	Lung cancer;
KIRP	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg02733842	chr7:1102375	C7orf50	-0.54	-6.15	-0.37	3.12e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs12786942	0.502	rs1938990	chr11:101282436	G/A	cg03942599	chr11:101341554	TRPC6	0.38	4.9	0.3	1.74e-6	Facial depth;
KIRP	cis	rs698833	0.886	rs2241871	chr2:44548613	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.84	0.35	1.62e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.06	-0.5	4.22e-17	Chronic sinus infection;
KIRP	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.79	11.3	0.58	4.11e-24	Prostate cancer;
KIRP	cis	rs6545883	0.894	rs2600660	chr2:61549600	G/T	cg15711740	chr2:61764176	XPO1	0.59	7.49	0.43	1.21e-12	Tuberculosis;
KIRP	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg05791153	chr7:19748676	TWISTNB	-0.63	-6.42	-0.38	7.13e-10	Thyroid stimulating hormone;
KIRP	cis	rs11078597	0.731	rs8077638	chr17:1640793	C/T	cg17514665	chr17:1657533	SERPINF2	0.44	5.49	0.33	9.95e-8	Serum albumin level;
KIRP	cis	rs4919044	0.808	rs9420608	chr10:94800903	C/G	cg05127821	chr10:94822908	CYP26C1	1.06	11.15	0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.48	-0.43	1.32e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.63	-0.44	5.05e-13	Neuroticism;
KIRP	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg21361702	chr7:150065534	REPIN1	0.66	6.9	0.4	4.38e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg14345882	chr6:26364793	BTN3A2	0.55	4.97	0.3	1.26e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	trans	rs66573146	0.901	rs55882710	chr4:7030704	G/A	cg07817883	chr1:32538562	TMEM39B	1.06	6.7	0.39	1.42e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	0.83	9.12	0.5	2.82e-17	Gut microbiome composition (summer);
KIRP	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg17507749	chr15:85114479	UBE2QP1	0.84	9.4	0.51	4.09e-18	Schizophrenia;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06665941	chr21:34602869	IFNAR2	0.72	6.16	0.37	3.02e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	cg12689670	chr1:183009347	LAMC1	0.52	7.15	0.41	9.96e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg20936604	chr3:58311152	NA	-0.65	-5.05	-0.31	8.6e-7	Cholesterol, total;
KIRP	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg00361562	chr2:198649771	BOLL	-0.48	-5.01	-0.3	1.02e-6	Ulcerative colitis;
KIRP	cis	rs9394841	0.667	rs1891453	chr6:41765265	T/C	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-11.56	-0.59	5.85e-25	Idiopathic membranous nephropathy;
KIRP	cis	rs1823913	0.599	rs17412239	chr2:192150663	C/T	cg12404831	chr2:192114017	MYO1B	0.52	7.27	0.42	4.69e-12	Obesity-related traits;
KIRP	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.24	0.37	1.88e-9	Retinal vascular caliber;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06101274	chr16:19125772	ITPRIPL2	-0.43	-6.29	-0.37	1.41e-9	Myopia;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg17133734	chr15:86042851	AKAP13	-0.47	-6.02	-0.36	6.2e-9	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.73	-0.34	2.88e-8	Life satisfaction;
KIRP	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.76	-9.26	-0.51	1.04e-17	Response to antipsychotic treatment;
KIRP	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.53	-0.52	1.55e-18	Response to antipsychotic treatment;
KIRP	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg16672083	chr15:72433130	SENP8	-0.45	-6.27	-0.37	1.57e-9	Red blood cell count;
KIRP	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg13444842	chr1:152974279	SPRR3	-0.41	-5.94	-0.35	9.75e-9	Inflammatory skin disease;
KIRP	cis	rs593531	0.571	rs35170680	chr11:74085420	T/G	cg18195628	chr11:73498948	MRPL48	-0.42	-4.9	-0.3	1.72e-6	Neuroticism;
KIRP	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.7	6.84	0.4	6.3e-11	Axial length;
KIRP	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.87	-9.97	-0.54	7.15e-20	Gut microbiome composition (summer);
KIRP	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.24	-0.32	3.51e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	9.02	0.5	5.64e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg01879757	chr17:41196368	BRCA1	-0.76	-9.28	-0.51	9.29e-18	Menopause (age at onset);
KIRP	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.9	0.3	1.76e-6	Breast cancer;
KIRP	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	10.24	0.55	1.01e-20	Hip circumference;
KIRP	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg21479132	chr6:26055353	NA	0.79	5.6	0.34	5.84e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17095355	1.000	rs12570612	chr10:111717685	C/T	cg00817464	chr10:111662876	XPNPEP1	0.43	6.14	0.36	3.31e-9	Biliary atresia;
KIRP	cis	rs2120243	0.539	rs1456105	chr3:157123461	A/C	cg24825693	chr3:157122686	VEPH1	-0.56	-9.38	-0.51	4.65e-18	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9843304	0.568	rs10935763	chr3:149219070	A/C	cg08667024	chr3:149219783	TM4SF4	0.43	6.08	0.36	4.59e-9	Gallstone disease;
KIRP	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg16497277	chr3:49208875	KLHDC8B	0.42	5.43	0.33	1.38e-7	Parkinson's disease;
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg18183042	chr17:80733038	TBCD	-0.38	-5.11	-0.31	6.53e-7	Glycated hemoglobin levels;
KIRP	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.46	-5.66	-0.34	4.21e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg17145862	chr1:211918768	LPGAT1	-0.54	-6.91	-0.4	4.01e-11	Leprosy;
KIRP	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.25	-5.27	-0.32	3.01e-7	Menarche (age at onset);
KIRP	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.17	-0.31	4.91e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.91	11.79	0.6	1.01e-25	Homoarginine levels;
KIRP	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06505273	chr16:24850292	NA	-0.37	-5.11	-0.31	6.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs963731	0.649	rs6725356	chr2:39238395	C/G	cg04010122	chr2:39346883	SOS1	0.88	6.15	0.37	3.11e-9	Corticobasal degeneration;
KIRP	trans	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg23484912	chr5:273055	PDCD6	0.65	7.89	0.45	9.79e-14	Pancreatic cancer;
KIRP	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.81	-10.73	-0.56	2.69e-22	Body mass index;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg21523564	chr15:75251491	NA	0.44	7.05	0.41	1.85e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.88	9.32	0.51	6.79e-18	Cisplatin-induced ototoxicity;
KIRP	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg13147721	chr7:65941812	NA	1.01	7.07	0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg14703610	chr5:56206110	C5orf35	0.4	5.19	0.31	4.39e-7	Coronary artery disease;
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02359409	chr6:42947317	PEX6	-0.43	-5.64	-0.34	4.56e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg19077165	chr18:44547161	KATNAL2	0.5	6.31	0.37	1.27e-9	Personality dimensions;
KIRP	cis	rs12478665	1	rs12478665	chr2:210123032	C/T	cg09336323	chr2:210074276	NA	0.49	6.06	0.36	4.99e-9	Hippocampal volume;
KIRP	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg27205649	chr11:78285834	NARS2	-0.56	-5.42	-0.33	1.46e-7	Testicular germ cell tumor;
KIRP	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg02487422	chr3:49467188	NICN1	-0.43	-6.02	-0.36	6.47e-9	Menarche (age at onset);
KIRP	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.62	-7.7	-0.44	3.37e-13	Iron status biomarkers;
KIRP	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg19500275	chr17:80737654	TBCD	0.42	5.15	0.31	5.28e-7	Glycated hemoglobin levels;
KIRP	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-12.86	-0.63	2.76e-29	Heart rate;
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg13906792	chr15:75199810	C15orf17	-0.36	-5.07	-0.31	7.82e-7	Breast cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02164492	chr11:46414469	NA	0.45	6.31	0.37	1.32e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	17.34	0.74	1.51e-44	Homoarginine levels;
KIRP	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15664640	chr17:80829946	TBCD	-0.72	-6.12	-0.36	3.73e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs10073892	0.703	rs13359098	chr5:101640563	G/T	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs11690462	0.963	rs7603413	chr2:26561117	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.41	4.93	0.3	1.55e-6	Coronary artery disease;
KIRP	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.59	-8.23	-0.46	1.1e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg22705602	chr4:152727874	NA	0.52	8.67	0.48	5.87e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg04780086	chr2:111875790	ACOXL	0.43	6.09	0.36	4.37e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.51	-9.68	-0.53	5.54e-19	Cystic fibrosis severity;
KIRP	cis	rs62413470	1.000	rs4388288	chr6:55948205	C/A	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs7129556	0.954	rs4509797	chr11:77263203	C/T	cg12586386	chr11:77299805	AQP11	-0.41	-5.51	-0.33	8.98e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg00495681	chr13:53174319	NA	0.38	5.13	0.31	5.91e-7	Lewy body disease;
KIRP	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.74	-9.42	-0.51	3.49e-18	Aortic root size;
KIRP	cis	rs6788895	1.000	rs76801042	chr3:150482720	A/C	cg09723797	chr3:150481914	SIAH2	0.76	4.95	0.3	1.37e-6	Breast cancer;
KIRP	cis	rs981844	0.848	rs10006303	chr4:154645223	G/A	cg14289246	chr4:154710475	SFRP2	0.63	7.01	0.41	2.26e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg08313168	chr12:7315531	NA	0.7	6.26	0.37	1.72e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg06212747	chr3:49208901	KLHDC8B	0.63	8.64	0.48	7.03e-16	Resting heart rate;
KIRP	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.59	-6.85	-0.4	5.92e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.67	7.91	0.45	8.79e-14	Diabetic retinopathy;
KIRP	trans	rs7660760	0.763	rs10023049	chr4:177497169	A/G	cg11970806	chr17:56066485	VEZF1	-0.42	-6.61	-0.39	2.31e-10	Left ventricle wall thickness;
KIRP	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-8.11	-0.46	2.46e-14	High light scatter reticulocyte count;
KIRP	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	6.07	0.36	4.85e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.61	7.68	0.44	3.84e-13	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09321965	chr1:198201193	NEK7	-0.41	-6.37	-0.38	9.11e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg06634786	chr22:41940651	POLR3H	0.47	5.22	0.32	3.72e-7	Neuroticism;
KIRP	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.4	-0.55	3.23e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg18595228	chr15:67193261	NA	0.56	5.01	0.3	1.05e-6	Lung cancer (smoking interaction);
KIRP	cis	rs2688608	0.967	rs9971038	chr10:75661149	C/T	cg23231163	chr10:75533350	FUT11	-0.33	-5.05	-0.31	8.72e-7	Inflammatory bowel disease;
KIRP	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg02807482	chr3:125708958	NA	-0.52	-4.91	-0.3	1.69e-6	Blood pressure (smoking interaction);
KIRP	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.54	-5.75	-0.34	2.68e-8	Subjective well-being;
KIRP	cis	rs12580194	0.593	rs55898514	chr12:55736238	G/A	cg11794356	chr12:55725991	OR6C3	-0.61	-8.72	-0.49	4.11e-16	Cancer;
KIRP	cis	rs11637445	0.677	rs12441598	chr15:68073205	G/A	cg24579218	chr15:68104479	NA	-0.44	-6.58	-0.39	2.74e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg13393036	chr8:95962371	TP53INP1	0.34	6.49	0.38	4.81e-10	Type 2 diabetes;
KIRP	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08280861	chr8:58055591	NA	0.74	6.07	0.36	4.86e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14992155	chr4:150999905	DCLK2	0.48	6.2	0.37	2.32e-9	Parkinson's disease;
KIRP	cis	rs4728302	0.869	rs6963032	chr7:133599527	T/C	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.72	-0.53	4.01e-19	Response to antipsychotic treatment;
KIRP	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg00981070	chr1:2046702	PRKCZ	0.42	6.86	0.4	5.49e-11	Height;
KIRP	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg09165964	chr15:75287851	SCAMP5	0.59	7.98	0.45	5.59e-14	Breast cancer;
KIRP	cis	rs4728302	0.934	rs4129572	chr7:133636888	T/C	cg10665199	chr7:133106180	EXOC4	-0.41	-5.03	-0.31	9.39e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.15	0.31	5.28e-7	Parkinson's disease;
KIRP	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg04691961	chr3:161091175	C3orf57	-0.63	-10.09	-0.54	3.02e-20	Morning vs. evening chronotype;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13634713	chr1:14027167	PRDM2	-0.47	-6.62	-0.39	2.21e-10	Metabolic traits;
KIRP	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.71	11.1	0.58	1.75e-23	Resting heart rate;
KIRP	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg04935436	chr20:30431758	NA	0.38	5.25	0.32	3.36e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs4851254	0.660	rs4851244	chr2:100671449	C/T	cg17356467	chr2:100759845	AFF3	-0.51	-5.29	-0.32	2.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.73	-7.77	-0.44	2.17e-13	Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.49	0.33	1.02e-7	Resting heart rate;
KIRP	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.45	5.61	0.34	5.55e-8	Height;
KIRP	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg19760965	chr3:194868843	C3orf21	0.32	5.19	0.31	4.45e-7	Non-small cell lung cancer;
KIRP	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg10224037	chr5:178157518	ZNF354A	0.64	7.03	0.41	2.07e-11	Neutrophil percentage of white cells;
KIRP	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg17145862	chr1:211918768	LPGAT1	0.61	6.63	0.39	2.07e-10	Crohn's disease;
KIRP	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg10818794	chr15:86012489	AKAP13	-0.52	-7.49	-0.43	1.27e-12	Coronary artery disease;
KIRP	trans	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg01599189	chr1:16939520	NBPF1	-0.49	-6.18	-0.37	2.61e-9	Prostate cancer;
KIRP	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.24e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.26	-17.25	-0.74	2.96e-44	Breast cancer;
KIRP	cis	rs6681460	1.000	rs2031478	chr1:67123742	C/A	cg13052034	chr1:66999238	SGIP1	0.44	6.22	0.37	2.15e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-0.93	-9.96	-0.54	7.37e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.52	7.35	0.42	2.94e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	cg04338863	chr8:33670619	NA	0.48	6.04	0.36	5.6e-9	Body mass index;
KIRP	cis	rs55728055	0.661	rs55931230	chr22:32028028	T/A	cg01338084	chr22:32026380	PISD	1.02	6.35	0.38	1.01e-9	Age-related hearing impairment;
KIRP	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	11.63	0.6	3.39e-25	Smoking behavior;
KIRP	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.45	5.06	0.31	8.32e-7	Schizophrenia;
KIRP	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.33e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg13736514	chr6:26305472	NA	-0.69	-8.77	-0.49	2.99e-16	Educational attainment;
KIRP	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.47e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.47	-7.21	-0.42	6.97e-12	Coronary artery disease;
KIRP	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.88	0.4	4.84e-11	Electroencephalogram traits;
KIRP	cis	rs12210905	1.000	rs3531	chr6:27095313	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08822215	chr16:89438651	ANKRD11	-0.44	-5.85	-0.35	1.55e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.69	10.7	0.56	3.37e-22	Blood metabolite ratios;
KIRP	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg08132940	chr7:1081526	C7orf50	-0.62	-6.29	-0.37	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg08125733	chr17:73851984	WBP2	0.54	6.82	0.4	7.21e-11	White matter hyperintensity burden;
KIRP	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.72	-7.93	-0.45	7.49e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg21280719	chr6:42927975	GNMT	-0.26	-5.31	-0.32	2.44e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg06521331	chr12:34319734	NA	-0.58	-6.97	-0.41	2.88e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.66	9.57	0.52	1.18e-18	Dupuytren's disease;
KIRP	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.34	-7.05	-0.41	1.79e-11	Urinary metabolites;
KIRP	cis	rs4635969	0.718	rs27071	chr5:1346081	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.44	-5.18	-0.31	4.65e-7	Testicular germ cell tumor;Testicular germ cell cancer;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	9.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4742903	0.527	rs10991114	chr9:106885616	A/G	cg14250997	chr9:106856677	SMC2	0.43	5.87	0.35	1.41e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-7.08	-0.41	1.53e-11	Monocyte percentage of white cells;
KIRP	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.77	10.35	0.55	4.63e-21	Huntington's disease progression;
KIRP	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.48	5.08	0.31	7.51e-7	Lung cancer;
KIRP	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg24315340	chr6:146058215	EPM2A	-0.39	-4.95	-0.3	1.38e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9488822	0.702	rs540981	chr6:116266592	A/G	cg05304507	chr6:116381966	FRK	-0.22	-5.55	-0.33	7.48e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.93	-17.13	-0.74	7.58e-44	Dental caries;
KIRP	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.01	0.36	6.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.25	-0.47	9.38e-15	Bone mineral density;
KIRP	cis	rs12549025	0.677	rs62503282	chr8:23387192	C/T	cg08322043	chr8:23340750	NA	-0.54	-5.3	-0.32	2.54e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.6	8.27	0.47	8.48e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg00933542	chr6:150070202	PCMT1	0.27	5.08	0.31	7.53e-7	Lung cancer;
KIRP	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.64	-0.44	4.87e-13	Bipolar disorder;
KIRP	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg16584676	chr17:46985605	UBE2Z	-0.51	-6.25	-0.37	1.83e-9	Type 2 diabetes;
KIRP	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg21184320	chr1:21044207	KIF17	-0.37	-5.48	-0.33	1.06e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7116495	1.000	rs517837	chr11:71802359	A/G	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs7677751	0.708	rs6554160	chr4:55077549	T/A	cg17183009	chr3:120277827	NA	0.55	6.45	0.38	5.81e-10	Corneal astigmatism;
KIRP	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00889227	chr1:205173544	DSTYK	-0.37	-4.92	-0.3	1.55e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs17453880	0.712	rs7733573	chr5:152048219	C/T	cg12297329	chr5:152029980	NA	-0.71	-10.54	-0.56	1.11e-21	Subjective well-being;
KIRP	cis	rs10225163	1.000	rs10225163	chr7:27925645	C/G	cg22168087	chr7:27702803	HIBADH	-0.38	-4.94	-0.3	1.45e-6	Gout;
KIRP	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.58	7.45	0.43	1.59e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg05360138	chr12:110035743	NA	0.49	5.51	0.33	8.94e-8	Neuroticism;
KIRP	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg11642891	chr2:3452563	TTC15	-0.55	-7.02	-0.41	2.14e-11	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.37	-5.14	-0.31	5.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35771425	0.619	rs7529900	chr1:211442661	C/T	cg11089029	chr1:211432536	RCOR3	0.44	5.09	0.31	7.22e-7	Educational attainment (years of education);
KIRP	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.04	0.36	5.72e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.4	-5.13	-0.31	5.99e-7	IgG glycosylation;
KIRP	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.46	-0.43	1.5e-12	Bipolar disorder;
KIRP	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-9.72	-0.53	4.14e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-0.8	-10.99	-0.57	4.03e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs975752	0.764	rs2242052	chr10:102050514	C/T	cg13817732	chr10:102046368	BLOC1S2	-0.62	-5.28	-0.32	2.79e-7	Schizophrenia;
KIRP	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	0.64	8.56	0.48	1.24e-15	Prostate cancer;
KIRP	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg12573674	chr2:1569213	NA	-0.56	-5.05	-0.31	8.42e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-5.55	-0.33	7.3900000000000007e-08	Aortic root size;
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg10505658	chr17:80084571	CCDC57	-0.26	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.58	7.95	0.45	6.9e-14	Blood metabolite levels;
KIRP	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg09526685	chr4:187126073	CYP4V2	0.67	6.19	0.37	2.46e-9	Blood protein levels;
KIRP	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg02570527	chr1:10970165	NA	-0.4	-4.9	-0.3	1.73e-6	Body mass index;
KIRP	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23903597	chr17:61704154	MAP3K3	0.63	8.65	0.48	6.88e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7665939	0.932	rs10022377	chr4:190108803	C/T	cg14840187	chr4:190284988	NA	-0.58	-5.26	-0.32	3.12e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs7929679	0.521	rs11032852	chr11:34788308	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-7.84	-0.45	1.35e-13	Neuroticism;
KIRP	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	cis	rs2151522	0.584	rs9375456	chr6:127122164	C/G	cg21431617	chr6:127135037	NA	0.33	6.01	0.36	6.73e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2904967	0.584	rs3015997	chr11:65000244	C/G	cg12562828	chr11:65076843	NA	0.67	8.41	0.47	3.29e-15	Mean corpuscular volume;
KIRP	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg05507819	chr15:63340323	TPM1	0.44	5.05	0.31	8.8e-7	HDL cholesterol;
KIRP	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.64	8.24	0.46	1.05e-14	Breast cancer;
KIRP	cis	rs9400467	0.506	rs12198788	chr6:111686791	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2573652	1.000	rs1469828	chr15:100517210	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.7	-10.21	-0.55	1.22e-20	Height;
KIRP	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg24972876	chr7:65420302	NA	0.4	5.51	0.33	9e-8	Aortic root size;
KIRP	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg15839431	chr19:19639596	YJEFN3	0.51	5.14	0.31	5.57e-7	Bipolar disorder;
KIRP	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg05347473	chr6:146136440	FBXO30	-0.58	-8.14	-0.46	2e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.56	6.22	0.37	2.07e-9	Coronary artery disease;
KIRP	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-0.78	-7.74	-0.44	2.65e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.19	-0.37	2.52e-9	Body mass index;
KIRP	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.32	0.42	3.62e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg22532475	chr10:104410764	TRIM8	-0.31	-5.04	-0.31	9.23e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.63	-6.8	-0.4	8.03e-11	Alcohol dependence;
KIRP	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.48	6.24	0.37	1.94e-9	QT interval;
KIRP	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	1.09	8.04	0.46	3.69e-14	Skin colour saturation;
KIRP	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.76	10.78	0.57	1.89e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11069349	0.608	rs9585056	chr13:100081766	A/G	cg25919922	chr13:100150906	NA	-0.67	-7.79	-0.44	1.88e-13	Self-reported allergy;
KIRP	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02187348	chr16:89574699	SPG7	0.52	6.92	0.4	3.95e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs1298062	0.790	rs2445841	chr19:50966531	T/A	cg11430371	chr19:50961752	MYBPC2	0.39	5.3	0.32	2.6e-7	Age of smoking initiation;
KIRP	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg25801113	chr15:45476975	SHF	-0.42	-7.67	-0.44	3.99e-13	Uric acid levels;
KIRP	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07509240	chr7:65420297	NA	-0.35	-4.94	-0.3	1.46e-6	Calcium levels;
KIRP	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.59	9.17	0.5	2e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.2	-0.31	4.12e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.39	-5.17	-0.31	4.95e-7	Body mass index;
KIRP	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.47	5.82	0.35	1.8e-8	Personality dimensions;
KIRP	cis	rs9473924	0.632	rs9349562	chr6:50876740	C/T	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs35740288	0.929	rs11073537	chr15:86312681	G/A	cg17133734	chr15:86042851	AKAP13	-0.5	-5.44	-0.33	1.28e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7224685	0.569	rs8070737	chr17:3981066	G/T	cg21851534	chr17:3907994	ZZEF1	0.53	5.01	0.3	1.06e-6	Type 2 diabetes;
KIRP	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00791764	chr4:53727839	RASL11B	0.42	5.9	0.35	1.17e-8	Optic nerve measurement (cup area);
KIRP	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg17545662	chr6:170176663	C6orf70	0.48	4.95	0.3	1.35e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	1.05	10.53	0.56	1.17e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3857747	0.895	rs10236169	chr7:40408314	T/C	cg00420559	chr7:40367873	C7orf10	0.66	8.48	0.48	2.15e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10055139	chr11:111797552	C11orf52	0.57	6.79	0.4	8.6e-11	Smoking initiation;
KIRP	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.67	-9.6	-0.52	9.83e-19	Cancer;
KIRP	cis	rs13424612	0.930	rs6748327	chr2:240902511	G/A	cg01812947	chr2:240904978	NDUFA10	0.41	5.31	0.32	2.47e-7	Odorant perception (isobutyraldehyde);
KIRP	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.74	11.18	0.58	9.66e-24	Oral cavity cancer;
KIRP	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.59	0.52	1.04e-18	Coronary artery disease;
KIRP	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.53	6.73	0.39	1.16e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg13453750	chr1:205783389	SLC41A1	-0.49	-7.22	-0.42	6.38e-12	Menarche (age at onset);
KIRP	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.57	-6.21	-0.37	2.29e-9	Menopause (age at onset);
KIRP	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-5.26	-0.32	3.18e-7	Crohn's disease;
KIRP	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.93	0.49	9.9e-17	Colorectal cancer;
KIRP	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.79	-10.16	-0.54	1.76e-20	Coronary artery disease;
KIRP	cis	rs2000999	0.514	rs35930480	chr16:72217681	G/A	cg04254540	chr16:71951199	KIAA0174	-0.74	-5.26	-0.32	3.2e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg26695010	chr11:65641043	EFEMP2	0.47	5.65	0.34	4.5e-8	Eosinophil percentage of white cells;
KIRP	cis	rs501120	1.000	rs554565	chr10:44755448	G/A	cg09554077	chr10:44749378	NA	0.74	12.09	0.61	1.02e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg00074818	chr8:8560427	CLDN23	0.42	6.34	0.37	1.07e-9	Obesity-related traits;
KIRP	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Bladder cancer;
KIRP	cis	rs7523273	0.927	rs2796275	chr1:207950490	C/T	cg22525895	chr1:207977042	MIR29B2	0.65	8.32	0.47	6.24e-15	Schizophrenia;
KIRP	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs9400467	0.506	rs12200610	chr6:111663567	C/G	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	1.09	23.38	0.83	1.9e-64	Parkinson's disease;
KIRP	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.85	-0.45	1.31e-13	Mood instability;
KIRP	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.76	0.44	2.31e-13	Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.17	-0.37	2.78e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg26554054	chr8:600488	NA	0.67	4.96	0.3	1.29e-6	IgG glycosylation;
KIRP	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg07636037	chr3:49044803	WDR6	-0.73	-7.81	-0.45	1.66e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs258892	0.843	rs34455289	chr5:72053282	G/C	cg21869765	chr5:72125136	TNPO1	-0.53	-5.79	-0.35	2.13e-8	Small cell lung carcinoma;
KIRP	cis	rs6681460	1.000	rs1536115	chr1:67121001	A/T	cg02459107	chr1:67143332	SGIP1	0.48	6.77	0.4	9.57e-11	Presence of antiphospholipid antibodies;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23248324	chr6:80714171	TTK	-0.43	-6.41	-0.38	7.18e-10	Survival in pancreatic cancer;
KIRP	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.71	9.75	0.53	3.39e-19	Mean corpuscular volume;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg10177748	chr19:41770160	HNRNPUL1	0.49	6.18	0.37	2.59e-9	Colorectal cancer;
KIRP	cis	rs1010254	0.510	rs72806368	chr5:151692742	A/G	cg12297329	chr5:152029980	NA	-0.65	-6.57	-0.39	3.01e-10	Optic nerve measurement (cup area);
KIRP	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08439880	chr3:133502540	NA	-0.48	-5.85	-0.35	1.58e-8	Iron status biomarkers;
KIRP	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	6.07	0.36	4.88e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs7523050	0.908	rs17621621	chr1:109398917	G/T	cg08274380	chr1:109419600	GPSM2	0.7	6.49	0.38	4.65e-10	Fat distribution (HIV);
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.68e-8	Life satisfaction;
KIRP	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.19	0.51	1.69e-17	Bipolar disorder;
KIRP	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.75	-11.6	-0.59	4.14e-25	Beta-trace protein levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11624479	chr11:9285586	DENND5A	0.5	6.49	0.38	4.78e-10	Lung cancer in ever smokers;
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.49	-5.79	-0.35	2.13e-8	Systolic blood pressure;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11381792	chr21:45432451	TRAPPC10	-0.45	-6.18	-0.37	2.57e-9	Myopia;
KIRP	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.02	-11.0	-0.57	3.72e-23	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg15181151	chr6:150070149	PCMT1	0.29	4.94	0.3	1.46e-6	Lung cancer;
KIRP	cis	rs4262150	0.726	rs4406125	chr5:152016594	G/A	cg12297329	chr5:152029980	NA	-0.63	-8.16	-0.46	1.78e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.91	10.13	0.54	2.21e-20	Corneal astigmatism;
KIRP	cis	rs11997175	0.583	rs7459675	chr8:33837097	G/A	ch.8.33884649F	chr8:33765107	NA	0.49	5.87	0.35	1.38e-8	Body mass index;
KIRP	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.78	-0.49	2.78e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.18	-0.51	1.76e-17	Bladder cancer;
KIRP	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.06	0.46	3.38e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07570687	chr10:102243282	WNT8B	0.51	6.17	0.37	2.72e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.86	0.4	5.43e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.38	-0.43	2.39e-12	Morning vs. evening chronotype;
KIRP	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.36	-5.8	-0.35	2e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.69	-7.95	-0.45	6.93e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.11	-0.64	3.87e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.73	9.33	0.51	6.36e-18	Coronary artery disease;
KIRP	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg23576507	chr14:21571844	ZNF219;C14orf176	-0.5	-6.14	-0.36	3.24e-9	Vertical cup-disc ratio;
KIRP	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.91	13.21	0.64	1.81e-30	Bladder cancer;
KIRP	cis	rs7737355	0.812	rs11242083	chr5:130927526	A/T	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs55788414	0.932	rs9940095	chr16:81182108	A/G	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.29	-0.47	7.58e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs597583	0.806	rs1941390	chr11:117396991	G/A	cg27161313	chr11:117392002	DSCAML1	-0.53	-5.86	-0.35	1.46e-8	Putamen volume;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg04025307	chr7:1156635	C7orf50	0.64	9.4	0.51	4.02e-18	Longevity;Endometriosis;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg00738919	chr7:1100172	C7orf50	0.46	5.22	0.32	3.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg20673841	chr7:107026890	COG5	0.41	5.03	0.31	9.31e-7	Coronary artery disease;
KIRP	cis	rs10924970	0.967	rs8179454	chr1:235460719	C/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.73e-7	Asthma;
KIRP	cis	rs6894268	0.762	rs6892309	chr5:179031198	T/A	cg22014891	chr5:179071901	C5orf60	-0.39	-4.91	-0.3	1.69e-6	Eating disorders;
KIRP	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs785830	0.558	rs557716	chr9:263321	A/G	cg14500300	chr9:211689	NA	0.4	5.39	0.33	1.61e-7	Platelet distribution width;
KIRP	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg23172400	chr8:95962367	TP53INP1	0.28	5.41	0.33	1.53e-7	Type 2 diabetes;
KIRP	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.52	7.51	0.43	1.06e-12	Blood metabolite levels;
KIRP	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.69	10.21	0.55	1.25e-20	Prostate cancer;
KIRP	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.51	7.09	0.41	1.38e-11	Mean corpuscular volume;
KIRP	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg01689657	chr7:91764605	CYP51A1	-0.36	-5.44	-0.33	1.27e-7	Breast cancer;
KIRP	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs3755132	0.929	rs16862822	chr2:15772958	G/A	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg00981070	chr1:2046702	PRKCZ	0.41	5.86	0.35	1.5e-8	Height;
KIRP	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.87	7.81	0.45	1.68e-13	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.63	9.28	0.51	9.15e-18	Alcohol dependence;
KIRP	cis	rs938554	0.501	rs7671266	chr4:10056376	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.76	-0.34	2.56e-8	Blood metabolite levels;
KIRP	cis	rs7180079	0.620	rs2046356	chr15:64706259	G/A	cg15337035	chr15:64978493	NA	-0.48	-5.29	-0.32	2.76e-7	Monocyte count;
KIRP	cis	rs7572263	0.724	rs6705133	chr2:209054422	G/A	cg23998903	chr2:209048830	C2orf80	-0.36	-5.25	-0.32	3.22e-7	Glioma;Non-glioblastoma glioma;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13152856	chr4:38691626	KLF3	-0.43	-6.05	-0.36	5.26e-9	Inflammatory biomarkers;
KIRP	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1712517	0.771	rs11191676	chr10:105155066	C/A	cg05636881	chr10:105038444	INA	0.44	6.3	0.37	1.33e-9	Migraine;
KIRP	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg09788416	chr12:39539408	NA	0.36	5.03	0.31	9.32e-7	Morning vs. evening chronotype;
KIRP	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.13	-0.31	5.81e-7	Post bronchodilator FEV1;
KIRP	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg00981070	chr1:2046702	PRKCZ	0.41	5.88	0.35	1.31e-8	Height;
KIRP	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18252515	chr7:66147081	NA	0.44	5.2	0.31	4.23e-7	Aortic root size;
KIRP	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06818804	chr15:78441680	IDH3A	0.51	6.21	0.37	2.29e-9	Parkinson's disease;
KIRP	cis	rs73200209	0.744	rs73200239	chr12:116684424	G/C	cg01776926	chr12:116560359	MED13L	-0.55	-6.19	-0.37	2.54e-9	Total body bone mineral density;
KIRP	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg00405596	chr8:11794950	NA	-0.48	-6.35	-0.38	1.05e-9	Retinal vascular caliber;
KIRP	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.25	0.51	1.13e-17	Lymphocyte counts;
KIRP	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.54	-6.88	-0.4	4.91e-11	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17554472	chr22:41940697	POLR3H	0.74	7.34	0.42	3.13e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7172677	0.961	rs62027287	chr15:75429721	A/C	cg14664628	chr15:75095509	CSK	-0.49	-5.27	-0.32	3e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7180079	0.620	rs11635211	chr15:65016298	A/C	cg15337035	chr15:64978493	NA	-0.5	-5.44	-0.33	1.3e-7	Monocyte count;
KIRP	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.47	-5.63	-0.34	4.86e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.66	-6.07	-0.36	4.81e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11169552	0.510	rs10783381	chr12:51016450	G/A	cg12884762	chr12:50931848	DIP2B	-0.41	-4.9	-0.3	1.72e-6	Colorectal cancer;
KIRP	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.33	-0.47	5.7e-15	Neuroticism;
KIRP	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-5.6	-0.34	5.79e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.44	5.99	0.36	7.21e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs8077577	0.895	rs16960990	chr17:18108601	A/G	cg18869244	chr17:18121946	NA	0.48	5.52	0.33	8.44e-8	Obesity-related traits;
KIRP	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg25356066	chr3:128598488	ACAD9	0.5	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs7975161	0.671	rs7314893	chr12:104597769	C/T	cg25273343	chr12:104657179	TXNRD1	-0.48	-5.5	-0.33	9.55e-8	Toenail selenium levels;
KIRP	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.51	-5.77	-0.35	2.42e-8	Coronary artery disease;
KIRP	cis	rs3764563	1.000	rs2031062	chr19:15717573	T/C	cg20725493	chr19:15740067	CYP4F8	-0.94	-6.18	-0.37	2.58e-9	Inflammatory biomarkers;
KIRP	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11987759	chr7:65425863	GUSB	0.57	7.71	0.44	3.1e-13	Aortic root size;
KIRP	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.29	-4.85	-0.3	2.21e-6	Dupuytren's disease;
KIRP	cis	rs61823972	0.547	rs12048743	chr1:205114873	C/G	cg21643547	chr1:205240462	TMCC2	-0.47	-6.99	-0.41	2.5e-11	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
KIRP	cis	rs7520050	0.966	rs12139630	chr1:46350935	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg27205649	chr11:78285834	NARS2	-0.52	-5.87	-0.35	1.41e-8	Testicular germ cell tumor;
KIRP	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg00686598	chr14:53173677	PSMC6	-0.63	-5.77	-0.35	2.41e-8	Alzheimer's disease (late onset);
KIRP	cis	rs78761021	0.720	rs7221637	chr17:9797209	C/T	cg26853458	chr17:9805074	RCVRN	0.52	5.05	0.31	8.81e-7	Type 2 diabetes;
KIRP	cis	rs42648	0.935	rs42635	chr7:89966198	T/A	cg25739043	chr7:89950458	NA	-0.46	-7.21	-0.42	6.96e-12	Homocysteine levels;
KIRP	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	0.64	7.48	0.43	1.29e-12	Pulmonary function decline;
KIRP	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg10513866	chr5:139070639	NA	0.52	7.09	0.41	1.41e-11	Schizophrenia;
KIRP	cis	rs10073892	0.701	rs10055840	chr5:101724448	C/G	cg19774478	chr5:101632501	SLCO4C1	0.62	6.38	0.38	8.72e-10	Cognitive decline (age-related);
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg15556689	chr8:8085844	FLJ10661	0.61	8.07	0.46	3.07e-14	Retinal vascular caliber;
KIRP	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.88	0.4	4.82e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg27211696	chr2:191398769	TMEM194B	-0.74	-9.01	-0.5	5.92e-17	Diastolic blood pressure;
KIRP	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.02	-0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs12973672	1.000	rs10410675	chr19:35768828	T/C	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.2	-0.31	4.19e-7	Coronary artery disease;
KIRP	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15557168	chr22:42548783	NA	-0.47	-6.14	-0.36	3.24e-9	Cognitive function;
KIRP	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.58	7.83	0.45	1.44e-13	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs75920871	0.841	rs7112967	chr11:116831912	C/T	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg09455208	chr3:40491958	NA	0.31	5.44	0.33	1.29e-7	Renal cell carcinoma;
KIRP	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs5747327	0.771	rs5746453	chr22:18137274	C/T	cg19898043	chr22:18121309	BCL2L13	-0.42	-5.04	-0.31	9.01e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.4	6.44	0.38	6.16e-10	Eye color traits;
KIRP	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg26513180	chr16:89883248	FANCA	-0.41	-5.1	-0.31	6.85e-7	Vitiligo;
KIRP	cis	rs7116495	1.000	rs679926	chr11:71769936	A/G	cg18441811	chr11:71824068	C11orf51	0.62	5.02	0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7010876	0.568	rs16879913	chr8:89226029	A/G	cg08624180	chr8:89339080	MMP16	-0.54	-5.07	-0.31	7.89e-7	Schizophrenia;
KIRP	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.44	-5.77	-0.35	2.37e-8	Vitamin D levels;
KIRP	cis	rs9596863	1.000	rs1458268	chr13:54405594	C/T	ch.13.53330881F	chr13:54432880	NA	-0.51	-5.57	-0.33	6.7e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-6.64	-0.39	1.95e-10	Acylcarnitine levels;
KIRP	trans	rs61931739	0.547	rs7966400	chr12:33703107	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-6.29	-0.37	1.44e-9	Morning vs. evening chronotype;
KIRP	cis	rs741951	1.000	rs741951	chr21:46269526	G/A	cg11950982	chr21:46269126	NA	-0.48	-5.0	-0.3	1.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs7923609	0.740	rs10761784	chr10:65308750	A/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.17	-0.37	2.82e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg05315796	chr3:52349193	DNAH1	0.38	5.96	0.36	8.68e-9	Bipolar disorder;
KIRP	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg08975724	chr8:8085496	FLJ10661	0.54	6.64	0.39	1.97e-10	Neuroticism;
KIRP	trans	rs11786541	0.521	rs4841261	chr8:9817299	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.89	-0.4	4.71e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.85	-12.33	-0.62	1.63e-27	Calcium levels;
KIRP	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.15	0.69	4.37e-37	Gut microbiome composition (summer);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16510485	chr5:111506044	EPB41L4A	-0.41	-6.52	-0.38	3.93e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs882732	1.000	rs12586297	chr14:95032394	G/A	cg08495878	chr14:95027859	SERPINA4	-0.41	-5.06	-0.31	8.19e-7	Blood protein levels;
KIRP	cis	rs11885103	0.791	rs2724902	chr2:588777	T/C	cg21195176	chr2:593345	NA	0.34	4.86	0.3	2.11e-6	Heschl's gyrus morphology;
KIRP	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg16898833	chr6:26189333	HIST1H4D	0.7	5.57	0.33	6.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.97	0.36	8.09e-9	Educational attainment;
KIRP	cis	rs12579753	0.667	rs7487640	chr12:82286681	A/G	cg07988820	chr12:82153109	PPFIA2	0.44	5.31	0.32	2.39e-7	Resting heart rate;
KIRP	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs6942756	0.531	rs7800983	chr7:128971130	C/T	cg02491457	chr7:128862824	NA	0.48	6.14	0.36	3.29e-9	White matter hyperintensity burden;
KIRP	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg04370829	chr17:406249	NA	0.4	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.2e-16	Motion sickness;
KIRP	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg23594656	chr7:65796392	TPST1	-0.39	-5.79	-0.35	2.08e-8	Aortic root size;
KIRP	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs7481584	0.564	rs432585	chr11:3084903	G/A	cg25174290	chr11:3078921	CARS	-0.65	-8.44	-0.47	2.76e-15	Calcium levels;
KIRP	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg21427119	chr20:30132790	HM13	0.49	5.64	0.34	4.54e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg27432699	chr2:27873401	GPN1	-0.57	-7.06	-0.41	1.72e-11	Total body bone mineral density;
KIRP	cis	rs9653442	0.545	rs1821827	chr2:100764717	T/C	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.83	9.97	0.54	7.02e-20	Corneal astigmatism;
KIRP	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg12369402	chr1:90227771	NA	-0.37	-5.28	-0.32	2.78e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.69	8.76	0.49	3.25e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.62	9.73	0.53	3.91e-19	HDL cholesterol levels;
KIRP	cis	rs364477	1.000	rs364477	chr9:955794	A/G	cg13952963	chr9:998547	NA	-0.53	-5.23	-0.32	3.59e-7	Major depressive disorder;
KIRP	trans	rs17079247	0.841	rs9575844	chr13:85808125	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20999427	chr12:24381595	SOX5	0.41	6.25	0.37	1.84e-9	Survival in pancreatic cancer;
KIRP	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg19445457	chr11:5799446	OR52N5	-0.5	-5.55	-0.33	7.37e-8	DNA methylation (variation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02782622	chr2:69534307	NA	0.47	7.29	0.42	4.14e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg24633833	chr3:10029261	TMEM111	0.56	5.25	0.32	3.33e-7	Alzheimer's disease;
KIRP	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.93	-13.63	-0.66	7.08e-32	Height;
KIRP	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	6.21	0.37	2.22e-9	Iron status biomarkers;
KIRP	cis	rs1440410	0.830	rs12499485	chr4:144174860	T/C	cg01719995	chr4:144104893	USP38	0.38	4.99	0.3	1.15e-6	Ischemic stroke;
KIRP	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11987759	chr7:65425863	GUSB	0.6	7.89	0.45	1e-13	Aortic root size;
KIRP	cis	rs13132184	0.507	rs2303422	chr4:38091800	C/T	cg14409701	chr4:38048871	TBC1D1	0.73	6.88	0.4	4.85e-11	Verbal declarative memory;
KIRP	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg23594656	chr7:65796392	TPST1	0.43	6.06	0.36	5.17e-9	Aortic root size;
KIRP	cis	rs580438	0.610	rs357159	chr3:13308740	C/G	cg10657019	chr3:13328039	NA	-0.68	-9.65	-0.52	7.02e-19	Myringotomy;
KIRP	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg22800045	chr5:56110881	MAP3K1	-0.58	-6.83	-0.4	6.46e-11	Initial pursuit acceleration;
KIRP	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.58	0.39	2.85e-10	Coffee consumption (cups per day);
KIRP	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.99	12.77	0.63	5.51e-29	Platelet distribution width;
KIRP	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-0.78	-8.76	-0.49	3.13e-16	Diastolic blood pressure;
KIRP	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs6952809	0.961	rs7796798	chr7:2450794	T/A	cg23289794	chr7:2394357	EIF3B	-0.4	-4.95	-0.3	1.38e-6	Multiple sclerosis;
KIRP	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg00262122	chr8:11665843	FDFT1	-0.42	-5.06	-0.31	8.31e-7	Triglycerides;
KIRP	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.59	-7.75	-0.44	2.43e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12976411	1.000	rs12976411	chr19:32882020	A/T	cg02282382	chr19:32836354	ZNF507	-0.69	-5.16	-0.31	4.99e-7	Coronary artery disease;
KIRP	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.43	-0.55	2.56e-21	Colorectal cancer;
KIRP	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg23682824	chr7:23144976	KLHL7	0.47	5.69	0.34	3.52e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.28	-0.37	1.56e-9	Migraine - clinic-based;
KIRP	cis	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg19171272	chr22:38449367	NA	0.61	9.58	0.52	1.09e-18	Glioblastoma;Glioma;
KIRP	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.77	10.89	0.57	8.47e-23	Caffeine consumption;
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg18209359	chr17:80159595	CCDC57	0.41	5.4	0.33	1.57e-7	Life satisfaction;
KIRP	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.82	-0.6	7.88e-26	Eye color traits;
KIRP	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg02527881	chr3:46936655	PTH1R	-0.59	-9.24	-0.51	1.16e-17	Birth weight;
KIRP	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs526231	0.543	rs158395	chr5:102411389	T/C	cg23492399	chr5:102201601	PAM	-0.49	-5.41	-0.33	1.48e-7	Primary biliary cholangitis;
KIRP	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-16.57	-0.73	6.43e-42	Height;
KIRP	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg00531865	chr16:30841666	NA	-0.38	-4.91	-0.3	1.69e-6	Multiple myeloma;
KIRP	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg03476357	chr21:30257390	N6AMT1	0.44	4.87	0.3	2e-6	Cognitive test performance;
KIRP	cis	rs7301016	0.846	rs7297093	chr12:63033387	C/T	cg01804193	chr12:63026212	NA	0.59	6.28	0.37	1.49e-9	IgG glycosylation;
KIRP	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.81	-11.27	-0.58	4.88e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg21851534	chr17:3907994	ZZEF1	-0.65	-10.66	-0.56	4.64e-22	Type 2 diabetes;
KIRP	cis	rs7116495	1.000	rs73543609	chr11:71816619	G/T	cg26138937	chr11:71823887	C11orf51	0.69	5.51	0.33	9.2e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1322639	0.614	rs6937001	chr6:169565086	C/T	cg04662567	chr6:169592167	NA	0.66	5.63	0.34	5e-8	Pulse pressure;
KIRP	cis	rs4356932	1.000	rs10017431	chr4:76955406	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.57	-7.13	-0.41	1.08e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2522056	0.935	rs757104	chr5:131795229	T/C	cg24060327	chr5:131705240	SLC22A5	0.6	6.05	0.36	5.27e-9	Lymphocyte counts;Fibrinogen;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17543885	chr6:151562429	AKAP12	0.62	6.41	0.38	7.52e-10	Lung function (FEV1);
KIRP	cis	rs9398803	0.763	rs576049	chr6:126730543	T/G	cg19875578	chr6:126661172	C6orf173	0.49	6.44	0.38	6.36e-10	Male-pattern baldness;
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg27532560	chr4:187881888	NA	0.76	12.98	0.64	1.04e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2033732	0.520	rs10958204	chr8:85040808	A/G	cg05716166	chr8:85095498	RALYL	0.54	5.04	0.31	9.16e-7	Body mass index;
KIRP	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.5	-0.33	9.6e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg14972814	chr11:95582409	MTMR2	0.35	5.6	0.34	5.82e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05181186	chr4:85504391	CDS1	0.5	6.37	0.38	9.35e-10	Parkinson's disease;
KIRP	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-1.07	-17.66	-0.75	1.27e-45	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	5.96	0.36	8.85e-9	Menarche (age at onset);
KIRP	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.66	5.54	0.33	7.79e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07387570	chr22:46663686	TTC38	0.49	6.43	0.38	6.42e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.16	-0.72	1.56e-40	Height;
KIRP	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg06027949	chr8:82754900	SNX16	0.57	6.06	0.36	5.06e-9	Diastolic blood pressure;
KIRP	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.62	-8.34	-0.47	5.19e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg16497661	chr14:103986332	CKB	0.49	6.72	0.39	1.28e-10	Body mass index;
KIRP	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg19784848	chr5:219127	SDHA;CCDC127	-0.47	-5.0	-0.3	1.08e-6	Breast cancer;
KIRP	cis	rs2273156	0.570	rs79199019	chr14:35581125	T/A	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.05	-0.31	8.58e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.65	5.48	0.33	1.03e-7	Facial emotion recognition (sad faces);
KIRP	cis	rs9393777	0.668	rs7746199	chr6:27261324	A/G	cg22548220	chr6:27277996	POM121L2	-0.37	-4.99	-0.3	1.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.45	5.07	0.31	7.89e-7	Schizophrenia;
KIRP	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Alcohol dependence;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.2	-0.37	2.36e-9	Longevity;
KIRP	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg01294253	chr9:136912663	BRD3	-0.45	-5.76	-0.34	2.46e-8	Platelet distribution width;
KIRP	trans	rs1973993	0.745	rs6683508	chr1:96955038	T/C	cg10631902	chr5:14652156	NA	-0.56	-8.11	-0.46	2.43e-14	Weight;
KIRP	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26526719	chr5:1949144	NA	-0.47	-5.37	-0.32	1.82e-7	Gut microbiome composition (winter);
KIRP	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg08501292	chr6:25962987	TRIM38	1.03	8.2	0.46	1.31e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs76533333	0.607	rs34809726	chr13:113386338	G/A	cg04656015	chr13:113407548	ATP11A	0.64	5.63	0.34	4.9e-8	Red cell distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11338088	chr19:48893974	KDELR1	0.59	7.6	0.44	6.3e-13	Parkinson's disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00982830	chr12:82752388	C12orf26;CCDC59	0.66	6.19	0.37	2.52e-9	Lung function (FEV1);
KIRP	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg25811766	chr13:21894605	NA	-0.63	-6.16	-0.37	2.95e-9	White matter hyperintensity burden;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24203851	chr6:111136481	CDK19	0.49	6.24	0.37	1.88e-9	Parkinson's disease;
KIRP	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.76	-8.87	-0.49	1.55e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs35883536	1.000	rs2297716	chr1:101092526	G/C	cg06223162	chr1:101003688	GPR88	0.32	6.54	0.38	3.6e-10	Monocyte count;
KIRP	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs6700559	0.679	rs12076946	chr1:200662835	T/C	cg07804481	chr1:200639085	DDX59	0.48	6.1	0.36	3.99e-9	Coronary artery disease;
KIRP	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	7.83	0.45	1.41e-13	Type 2 diabetes;
KIRP	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg22168489	chr12:122356033	WDR66	-0.57	-7.7	-0.44	3.32e-13	Mean corpuscular volume;
KIRP	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg00310523	chr12:86230176	RASSF9	0.39	6.06	0.36	5.03e-9	Major depressive disorder;
KIRP	cis	rs17121403	1.000	rs12141518	chr1:100441444	C/T	cg24955406	chr1:100503596	HIAT1	0.78	5.08	0.31	7.35e-7	Pulmonary function decline;
KIRP	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.97	11.09	0.58	1.96e-23	Pulmonary function decline;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg12868349	chr11:71639594	RNF121;LOC100133315	0.64	6.09	0.36	4.39e-9	Lung function (FEV1);
KIRP	cis	rs7903847	0.598	rs1932001	chr10:99172751	A/G	cg20016023	chr10:99160130	RRP12	-0.4	-5.01	-0.3	1.06e-6	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg00361562	chr2:198649771	BOLL	-0.54	-5.28	-0.32	2.83e-7	Ulcerative colitis;
KIRP	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg19401529	chr3:49056140	DALRD3	0.92	6.88	0.4	4.91e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs9488822	0.585	rs569201	chr6:116265861	C/T	cg05304507	chr6:116381966	FRK	-0.21	-5.56	-0.33	6.98e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.46	-5.7	-0.34	3.39e-8	Coronary artery disease;
KIRP	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.41	1.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs981844	0.712	rs1037652	chr4:154746565	C/T	cg14289246	chr4:154710475	SFRP2	0.54	6.97	0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.6	-9.63	-0.52	8.06e-19	Longevity;
KIRP	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg18306943	chr3:40428807	ENTPD3	0.45	5.75	0.34	2.6e-8	Renal cell carcinoma;
KIRP	cis	rs7719624	0.756	rs2302038	chr5:135397018	A/G	cg00308130	chr5:135415190	NA	0.3	4.86	0.3	2.14e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg11635098	chr7:100497156	NA	-0.69	-7.75	-0.44	2.36e-13	Resting heart rate;
KIRP	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.36	8.28	0.47	7.96e-15	Asthma (sex interaction);
KIRP	cis	rs4356932	1.000	rs4593163	chr4:76976056	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.33e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2151522	0.584	rs983668	chr6:127122967	T/C	cg21431617	chr6:127135037	NA	0.33	6.01	0.36	6.73e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.75	-9.44	-0.52	3e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.72e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg11833968	chr6:79620685	NA	-0.47	-6.99	-0.41	2.63e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg10117171	chr1:25599238	RHD	-0.4	-5.27	-0.32	3.01e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.96	11.29	0.58	4.45e-24	Corneal astigmatism;
KIRP	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg26681399	chr22:41777847	TEF	-0.5	-5.48	-0.33	1.03e-7	Vitiligo;
KIRP	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs9381107	0.932	rs9349224	chr6:9471146	G/T	cg14735645	chr6:9486422	NA	-0.51	-6.33	-0.37	1.18e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-7.53	-0.43	9.65e-13	Platelet count;
KIRP	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-0.71	-7.34	-0.42	3.13e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg21573476	chr21:45109991	RRP1B	-0.63	-8.46	-0.47	2.44e-15	Mean corpuscular volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01174459	chr12:105761853	C12orf75	-0.41	-6.23	-0.37	2e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.78	-9.79	-0.53	2.48e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2371030	0.965	rs12998879	chr2:211583332	G/A	cg18417063	chr2:211583084	NA	-0.51	-7.3	-0.42	3.97e-12	Non-small cell lung cancer;
KIRP	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.39	6.49	0.38	4.82e-10	Testicular germ cell tumor;
KIRP	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg08645402	chr16:4508243	NA	0.49	5.96	0.36	8.77e-9	Schizophrenia;
KIRP	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg25281562	chr12:121454272	C12orf43	-0.51	-5.64	-0.34	4.56e-8	N-glycan levels;
KIRP	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.5	-0.59	8.96e-25	Breast cancer;
KIRP	cis	rs11779988	0.503	rs411173	chr8:17768264	G/A	cg01800426	chr8:17659068	MTUS1	-0.59	-6.21	-0.37	2.28e-9	Breast cancer;
KIRP	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.62	-6.9	-0.4	4.25e-11	Neuroticism;
KIRP	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.55	-0.33	7.34e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg13699009	chr12:122356056	WDR66	0.62	9.76	0.53	3.23e-19	Mean corpuscular volume;
KIRP	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.79	-0.6	1.03e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7221595	0.825	rs12450845	chr17:3972784	G/A	cg21734707	chr17:3908241	ZZEF1	0.53	4.91	0.3	1.69e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.8	0.49	2.47e-16	Motion sickness;
KIRP	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.53	-0.43	9.46e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.79e-16	Life satisfaction;
KIRP	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.93	-12.29	-0.62	2.25e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.07	0.61	1.15e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg26795923	chr22:19165960	SLC25A1	0.45	6.2	0.37	2.39e-9	Cancer;
KIRP	cis	rs7481584	0.962	rs11024766	chr11:2984645	C/G	cg25174290	chr11:3078921	CARS	-0.59	-6.48	-0.38	5.05e-10	Calcium levels;
KIRP	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg12623918	chr2:306882	NA	0.47	5.85	0.35	1.56e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.16	-0.42	9.31e-12	Menopause (age at onset);
KIRP	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.61	7.33	0.42	3.32e-12	Menarche (age at onset);
KIRP	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.77	-0.49	2.98e-16	Total cholesterol levels;
KIRP	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.77	5.77	0.35	2.33e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11785693	0.862	rs62491202	chr8:5001470	C/A	cg26367366	chr8:4980734	NA	0.83	8.62	0.48	8.3e-16	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs8028182	0.636	rs4886715	chr15:75831449	C/T	cg20655648	chr15:75932815	IMP3	0.54	6.77	0.4	9.49e-11	Sudden cardiac arrest;
KIRP	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg19717773	chr7:2847554	GNA12	-0.31	-5.25	-0.32	3.24e-7	Height;
KIRP	cis	rs490234	0.702	rs1891035	chr9:128258684	T/C	cg14078157	chr9:128172775	NA	-0.65	-7.72	-0.44	2.92e-13	Mean arterial pressure;
KIRP	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	9.0	0.5	6.21e-17	Personality dimensions;
KIRP	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	-0.35	-4.97	-0.3	1.26e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.41	5.15	0.31	5.24e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	cg21523751	chr1:182988639	NA	0.36	5.15	0.31	5.38e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs2273669	0.915	rs67708237	chr6:109292058	G/A	cg05315195	chr6:109294784	ARMC2	-0.48	-5.46	-0.33	1.19e-7	Prostate cancer;
KIRP	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.93	11.15	0.58	1.22e-23	Post bronchodilator FEV1;
KIRP	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs501120	1.000	rs607363	chr10:44761623	A/G	cg09554077	chr10:44749378	NA	0.7	10.7	0.56	3.46e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-6.86	-0.4	5.59e-11	Tonsillectomy;
KIRP	cis	rs508618	0.697	rs7534248	chr1:231554531	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	5.96	0.36	8.56e-9	Red blood cell count;
KIRP	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg13119609	chr19:45449297	APOC2	0.39	5.03	0.31	9.52e-7	Blood protein levels;
KIRP	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.43	-8.35	-0.47	5.04e-15	Urinary metabolites;
KIRP	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg25281562	chr12:121454272	C12orf43	0.49	5.5	0.33	9.55e-8	N-glycan levels;
KIRP	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg04037228	chr3:45636386	LIMD1	-0.35	-4.97	-0.3	1.25e-6	Hirschsprung disease;
KIRP	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.69	8.48	0.48	2.07e-15	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg04369109	chr6:150039330	LATS1	-0.52	-6.6	-0.39	2.49e-10	Lung cancer;
KIRP	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	0.88	7.07	0.41	1.6e-11	Mitochondrial DNA levels;
KIRP	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.84	12.14	0.61	6.8e-27	Eye color traits;
KIRP	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	6.28	0.37	1.54e-9	Protein C levels;
KIRP	cis	rs7615316	0.934	rs13085998	chr3:142263812	C/T	cg20824294	chr3:142316082	PLS1	-0.22	-4.86	-0.3	2.11e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg04731861	chr2:219085781	ARPC2	0.26	6.38	0.38	8.53e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-5.4	-0.33	1.6e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs997154	0.608	rs8007089	chr14:23391913	T/C	cg25600027	chr14:23388339	RBM23	-0.44	-4.98	-0.3	1.22e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs4764487	0.735	rs3181301	chr12:6345784	G/T	cg08284733	chr12:6341482	CD9	0.54	9.01	0.5	5.75e-17	Mean platelet volume;
KIRP	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	15.18	0.7	3.68e-37	Chronic sinus infection;
KIRP	cis	rs6466055	0.720	rs3801999	chr7:105027646	G/A	cg04380332	chr7:105027541	SRPK2	0.54	8.16	0.46	1.76e-14	Schizophrenia;
KIRP	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg19770292	chr5:1868693	NA	0.38	4.92	0.3	1.6e-6	Cardiovascular disease risk factors;
KIRP	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs12643440	0.879	rs62294495	chr4:17231903	G/A	cg22650099	chr4:17144496	NA	-0.49	-5.76	-0.34	2.56e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg00409905	chr10:38381863	ZNF37A	-0.61	-7.95	-0.45	6.9e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg09873164	chr1:152488093	CRCT1	0.6	7.79	0.44	1.85e-13	Hair morphology;
KIRP	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.32	-7.24	-0.42	5.72e-12	Cutaneous nevi;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25846339	chr11:85359022	TMEM126A	0.54	6.35	0.38	1.05e-9	Smoking initiation;
KIRP	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.8	-9.99	-0.54	6.05e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7998202	0.667	rs282579	chr13:113358436	G/C	cg02820901	chr13:113351484	ATP11A	0.52	4.97	0.3	1.23e-6	Glycated hemoglobin levels;
KIRP	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg23307798	chr14:103986281	CKB	0.5	7.09	0.41	1.41e-11	Body mass index;
KIRP	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.89	0.3	1.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07721276	chr19:18119064	ARRDC2	0.49	6.5	0.38	4.32e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08626939	chr2:227656417	IRS1	0.5	6.34	0.37	1.12e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02583736	chr1:115124362	BCAS2	0.42	6.02	0.36	6.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	24.1	0.84	1.03e-66	Chronic sinus infection;
KIRP	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.0	-10.74	-0.56	2.67e-22	Alzheimer's disease;
KIRP	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg17507749	chr15:85114479	UBE2QP1	0.89	9.91	0.53	1.08e-19	Schizophrenia;
KIRP	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	1.11	8.37	0.47	4.31e-15	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11665333	chr3:52312957	WDR82	-0.5	-6.14	-0.36	3.27e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.8	11.1	0.58	1.76e-23	Response to antipsychotic treatment;
KIRP	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.05	0.5	4.35e-17	Morning vs. evening chronotype;
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.37	0.65	5.21e-31	Platelet count;
KIRP	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.97	-0.3	1.25e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.11	-0.31	6.42e-7	Menarche (age at onset);
KIRP	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.58	7.13	0.41	1.12e-11	Iron status biomarkers;
KIRP	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg10547527	chr2:198650123	BOLL	-0.56	-5.06	-0.31	8.05e-7	Ulcerative colitis;
KIRP	cis	rs6992848	0.759	rs11166958	chr8:141177498	G/A	cg13911501	chr8:141220320	TRAPPC9	0.43	5.11	0.31	6.42e-7	Response to amphetamines;
KIRP	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	1.23	12.74	0.63	6.73e-29	Red blood cell traits;
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg11131117	chr7:1891496	MAD1L1	0.42	4.88	0.3	1.93e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg17410650	chr12:54324560	NA	-0.48	-6.58	-0.39	2.78e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
KIRP	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.41	-5.58	-0.34	6.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.47	-7.4	-0.43	2.12e-12	Platelet distribution width;
KIRP	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg23758822	chr17:41437982	NA	0.94	14.22	0.67	6.6e-34	Menopause (age at onset);
KIRP	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.42	4.93	0.3	1.48e-6	Resistin levels;
KIRP	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.11	-0.46	2.48e-14	Retinal vascular caliber;
KIRP	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	1.01	9.96	0.54	7.55e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg20744362	chr22:50050164	C22orf34	0.34	5.23	0.32	3.69e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs12942207	1	rs12942207	chr17:45968294	C/T	cg02219949	chr17:45927392	SP6	0.43	5.59	0.34	6.02e-8	Birth weight;
KIRP	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg01028140	chr2:1542097	TPO	-0.75	-6.69	-0.39	1.5e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.64	9.17	0.5	1.92e-17	Coronary artery disease;
KIRP	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.7	0.34	3.39e-8	Lung cancer;
KIRP	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg19575753	chr5:1948995	NA	-0.57	-6.58	-0.39	2.78e-10	Gut microbiome composition (winter);
KIRP	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	1.06	20.27	0.79	2.15e-54	Height;
KIRP	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.51	7.42	0.43	1.88e-12	Metabolite levels;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.46e-8	Life satisfaction;
KIRP	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.83	11.37	0.59	2.33e-24	Morning vs. evening chronotype;
KIRP	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.06	0.31	8.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6684428	0.505	rs6684261	chr1:56359669	C/T	cg11651538	chr1:56320950	NA	0.47	6.8	0.4	7.9e-11	Airflow obstruction;
KIRP	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg06060754	chr5:176797920	RGS14	0.48	7.28	0.42	4.44e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg19743168	chr1:23544995	NA	0.49	6.53	0.38	3.8e-10	Height;
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.79	9.91	0.53	1.04e-19	Longevity;
KIRP	cis	rs77688320	0.553	rs2540340	chr2:202281200	C/T	cg06431681	chr2:202330990	STRADB	-0.47	-5.46	-0.33	1.18e-7	Breast cancer;
KIRP	cis	rs6545883	0.862	rs778141	chr2:61682178	A/G	cg15711740	chr2:61764176	XPO1	-0.61	-7.95	-0.45	6.61e-14	Tuberculosis;
KIRP	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg08126542	chr6:37504118	NA	-0.59	-7.02	-0.41	2.11e-11	Cognitive performance;
KIRP	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.69	9.65	0.52	6.64e-19	Blood protein levels;
KIRP	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.02	11.42	0.59	1.68e-24	Vitiligo;
KIRP	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.79	11.8	0.6	9.04e-26	Coronary artery disease;
KIRP	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg16091543	chr12:123718047	C12orf65	-0.43	-6.22	-0.37	2.16e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.93	10.58	0.56	8.52e-22	Corneal astigmatism;
KIRP	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg19338460	chr6:170058176	WDR27	-1.22	-10.04	-0.54	4.32e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-11.1	-0.58	1.77e-23	Morning vs. evening chronotype;
KIRP	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs3748682	0.861	rs28411034	chr1:38276997	G/A	cg12658694	chr1:38397304	INPP5B	0.55	6.02	0.36	6.31e-9	Hypothyroidism;
KIRP	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.6	-7.59	-0.44	6.56e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	12.73	0.63	7.26e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.18	0.7	3.63e-37	Platelet count;
KIRP	cis	rs11997175	0.646	rs6468196	chr8:33734183	T/C	cg04338863	chr8:33670619	NA	0.42	4.89	0.3	1.82e-6	Body mass index;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg08662619	chr6:150070041	PCMT1	0.39	6.41	0.38	7.52e-10	Lung cancer;
KIRP	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg15117754	chr3:10150083	C3orf24	0.5	5.01	0.3	1.03e-6	Alzheimer's disease;
KIRP	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg17330251	chr7:94953956	PON1	-0.46	-5.16	-0.31	5.18e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg11031976	chr2:198649780	BOLL	-0.49	-5.02	-0.3	9.82e-7	Ulcerative colitis;
KIRP	cis	rs73200209	0.789	rs74420242	chr12:116551289	A/T	cg01776926	chr12:116560359	MED13L	-0.58	-6.41	-0.38	7.31e-10	Total body bone mineral density;
KIRP	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	0.91	10.58	0.56	8.39e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg10351095	chr21:47802916	PCNT	0.44	5.24	0.32	3.44e-7	Testicular germ cell tumor;
KIRP	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.21	-0.32	3.99e-7	Headache;
KIRP	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg20003494	chr4:90757398	SNCA	-0.39	-5.18	-0.31	4.63e-7	Neuroticism;
KIRP	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg15147215	chr3:52552868	STAB1	0.3	5.32	0.32	2.31e-7	Electroencephalogram traits;
KIRP	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg17347104	chr14:75034677	LTBP2	-0.44	-5.3	-0.32	2.61e-7	Caffeine consumption;
KIRP	cis	rs72772090	0.539	rs72773991	chr5:96163775	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.71	-6.07	-0.36	4.82e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg12140854	chr5:148520817	ABLIM3	-0.43	-4.95	-0.3	1.37e-6	Breast cancer;
KIRP	cis	rs259282	0.538	rs8105481	chr19:33118095	T/C	cg02997394	chr19:33096574	ANKRD27	-0.51	-5.1	-0.31	6.78e-7	Schizophrenia;
KIRP	cis	rs6681460	1.000	rs6696927	chr1:67070381	A/G	cg13052034	chr1:66999238	SGIP1	0.36	4.93	0.3	1.48e-6	Presence of antiphospholipid antibodies;
KIRP	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.82	-11.33	-0.59	3.16e-24	Height;
KIRP	cis	rs9311474	0.713	rs181274	chr3:52233861	T/A	cg05315796	chr3:52349193	DNAH1	0.41	6.04	0.36	5.58e-9	Electroencephalogram traits;
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg22335246	chr12:120763591	PLA2G1B	0.56	7.21	0.42	6.89e-12	Body mass index in non-asthmatics;
KIRP	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg10223061	chr2:219282414	VIL1	0.43	6.91	0.4	4.23e-11	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.79	11.58	0.59	4.77e-25	Systolic blood pressure;
KIRP	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-6.19	-0.37	2.56e-9	Morning vs. evening chronotype;
KIRP	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.03	11.47	0.59	1.15e-24	HIV-1 control;
KIRP	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.45	-5.14	-0.31	5.61e-7	Neutrophil percentage of white cells;
KIRP	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.84	10.17	0.54	1.68e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg12560992	chr17:57184187	TRIM37	0.58	5.61	0.34	5.43e-8	Cognitive test performance;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16758348	chr14:58335480	NA	0.39	6.3	0.37	1.38e-9	C-reactive protein;
KIRP	cis	rs17401966	0.522	rs7368073	chr1:10314962	G/T	cg19773385	chr1:10388646	KIF1B	-0.42	-6.11	-0.36	3.82e-9	Hepatocellular carcinoma;
KIRP	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.59	9.79	0.53	2.56e-19	Schizophrenia;
KIRP	cis	rs2273669	0.667	rs75263286	chr6:109350489	G/C	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs4356932	0.691	rs4859582	chr4:76907213	T/C	cg19388996	chr4:76862389	NAAA	0.44	5.65	0.34	4.49e-8	Blood protein levels;
KIRP	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.67	8.95	0.5	8.85e-17	Breast cancer;
KIRP	cis	rs10875746	0.669	rs61941003	chr12:48619625	G/A	cg20731937	chr12:48336164	NA	0.49	5.94	0.35	9.58e-9	Longevity (90 years and older);
KIRP	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.55	0.43	8.58e-13	Neuroticism;
KIRP	cis	rs11645898	0.504	rs79489472	chr16:71870359	C/T	cg14768367	chr16:72042858	DHODH	-0.81	-7.04	-0.41	1.86e-11	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg11814155	chr7:99998594	ZCWPW1	0.56	5.45	0.33	1.2e-7	Platelet count;
KIRP	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.55	7.38	0.43	2.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg08992911	chr2:238395768	MLPH	0.42	5.26	0.32	3.12e-7	Prostate cancer;
KIRP	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.73	-10.89	-0.57	8.71e-23	Height;
KIRP	trans	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg10756647	chr7:56101905	PSPH	0.98	7.0	0.41	2.44e-11	Diabetic kidney disease;
KIRP	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg17764715	chr19:33622953	WDR88	0.67	8.41	0.47	3.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6723108	0.738	rs10928512	chr2:135451302	A/C	cg25422880	chr2:135218333	TMEM163	-0.45	-6.43	-0.38	6.51e-10	Type 2 diabetes;
KIRP	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-6.63	-0.39	2.07e-10	HDL cholesterol;
KIRP	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs4700695	0.686	rs251710	chr5:65347357	G/C	cg21114390	chr5:65439923	SFRS12	0.57	6.03	0.36	6.01e-9	Facial morphology (factor 19);
KIRP	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.57	6.87	0.4	5.21e-11	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10916998	chr6:30711832	FLOT1;IER3	-0.56	-6.16	-0.37	2.87e-9	Menopause (age at onset);
KIRP	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg25547332	chr5:131281432	NA	-0.45	-5.1	-0.31	6.68e-7	Life satisfaction;
KIRP	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.99	10.48	0.56	1.76e-21	Exhaled nitric oxide output;
KIRP	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	7.82	0.45	1.51e-13	IgG glycosylation;
KIRP	cis	rs1021993	0.545	rs74155473	chr1:209545863	A/G	cg24446417	chr1:209558027	NA	-0.49	-5.37	-0.32	1.8e-7	Gut microbiome composition (winter);
KIRP	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.08	-0.31	7.6e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg07546262	chr12:54753490	NA	0.55	6.64	0.39	1.96e-10	Body mass index in non-asthmatics;
KIRP	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11079969	chr15:82339920	NA	0.45	6.05	0.36	5.4e-9	Smoking initiation;
KIRP	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.78	-12.63	-0.63	1.56e-28	Dupuytren's disease;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg00405596	chr8:11794950	NA	-0.48	-6.35	-0.38	1.02e-9	Retinal vascular caliber;
KIRP	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg24110177	chr3:50126178	RBM5	0.45	5.8	0.35	2.08e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	13.6	0.66	8.84e-32	Colorectal cancer;
KIRP	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg06050784	chr16:88016603	BANP	0.45	5.43	0.33	1.33e-7	Menopause (age at onset);
KIRP	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.53	6.24	0.37	1.92e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.55e-23	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg27165867	chr14:105738592	BRF1	-0.42	-5.03	-0.31	9.53e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.82	-0.35	1.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg01988459	chr11:68622903	NA	0.34	4.85	0.3	2.2e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21984481	chr17:79567631	NPLOC4	-0.41	-6.28	-0.37	1.54e-9	Eye color traits;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg15434853	chr3:52570586	NT5DC2;LOC440957	-0.5	-7.0	-0.41	2.49e-11	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16422343	chr6:36564708	SFRS3	0.44	6.34	0.37	1.11e-9	Survival in pancreatic cancer;
KIRP	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg13147721	chr7:65941812	NA	1.02	7.05	0.41	1.84e-11	Diabetic kidney disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19120125	chr12:10978950	TAS2R10	-0.44	-7.06	-0.41	1.66e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.49	-0.62	4.56e-28	Exhaled nitric oxide output;
KIRP	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg02725872	chr8:58115012	NA	-0.52	-5.94	-0.35	9.7e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1712517	0.588	rs12220267	chr10:105075712	C/T	cg04362960	chr10:104952993	NT5C2	-0.58	-7.29	-0.42	4.14e-12	Migraine;
KIRP	trans	rs12517041	0.935	rs16892409	chr5:23324350	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.83	-7.4	-0.43	2.19e-12	Calcium levels;
KIRP	cis	rs216205	0.547	rs2641431	chr17:2030507	C/G	cg16513277	chr17:2031491	SMG6	-0.73	-8.89	-0.49	1.3e-16	Mitral valve prolapse;
KIRP	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg00612595	chr21:47717864	NA	0.39	5.21	0.32	4.02e-7	Testicular germ cell tumor;
KIRP	cis	rs6466055	0.661	rs12532188	chr7:104922834	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.03	0.31	9.68e-7	Schizophrenia;
KIRP	cis	rs698833	0.798	rs1067391	chr2:44639434	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.08	0.36	4.52e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.76e-11	Aortic root size;
KIRP	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg02175308	chr1:109941060	SORT1	-0.26	-4.94	-0.3	1.41e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.62	9.32	0.51	6.96e-18	Height;
KIRP	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09857708	chr16:66586376	CKLF	0.56	6.67	0.39	1.63e-10	Smoking initiation;
KIRP	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg08916839	chr5:415575	AHRR	0.82	7.31	0.42	3.74e-12	Fat distribution (HIV);
KIRP	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06544989	chr22:39130855	UNC84B	0.5	9.01	0.5	5.77e-17	Menopause (age at onset);
KIRP	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.57	7.87	0.45	1.13e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.58	-7.42	-0.43	1.91e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	Myopia (pathological);
KIRP	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg05756136	chr1:119680316	WARS2	-0.62	-8.36	-0.47	4.76e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2019216	0.500	rs4325621	chr17:21926257	T/G	cg22648282	chr17:21454238	C17orf51	-0.51	-6.22	-0.37	2.17e-9	Pelvic organ prolapse;
KIRP	cis	rs14168	1.000	rs11812909	chr10:53461266	C/T	cg18823846	chr10:53459691	PRKG1;CSTF2T	0.6	5.39	0.32	1.65e-7	Mammographic density (non-dense area);
KIRP	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg16141378	chr3:129829833	LOC729375	-0.47	-6.18	-0.37	2.62e-9	Mood instability;
KIRP	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.6e-25	Morning vs. evening chronotype;
KIRP	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg06637938	chr14:75390232	RPS6KL1	0.51	7.35	0.42	2.88e-12	Height;
KIRP	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07685180	chr8:600429	NA	0.69	5.44	0.33	1.31e-7	IgG glycosylation;
KIRP	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg07382826	chr16:28625726	SULT1A1	0.48	5.65	0.34	4.51e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.07	-13.44	-0.65	2.92e-31	Alzheimer's disease;
KIRP	cis	rs12579753	0.719	rs4384447	chr12:82268069	G/C	cg07988820	chr12:82153109	PPFIA2	-0.48	-6.12	-0.36	3.59e-9	Resting heart rate;
KIRP	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5753037	0.869	rs5752973	chr22:30264274	G/A	cg27665648	chr22:30112403	NA	0.35	4.98	0.3	1.21e-6	Type 1 diabetes;
KIRP	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.37	5.21	0.32	3.97e-7	Coronary artery disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg27305525	chr1:154955752	FLAD1	0.55	6.5	0.38	4.54e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.68	6.78	0.4	9e-11	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.55	-7.29	-0.42	4.14e-12	Testicular germ cell tumor;
KIRP	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	9.33	0.51	6.31e-18	Neuroticism;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.73	11.86	0.6	5.8e-26	Longevity;Endometriosis;
KIRP	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg02138098	chr1:2040968	PRKCZ	-0.38	-4.94	-0.3	1.48e-6	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20141105	chr3:48343184	NME6	0.47	6.48	0.38	5.06e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.73	8.58	0.48	1.12e-15	Cocaine dependence;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06826908	chr1:52155720	OSBPL9	0.44	6.82	0.4	6.95e-11	C-reactive protein;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg10207240	chr12:122356781	WDR66	0.6	7.89	0.45	9.87e-14	Mean corpuscular volume;
KIRP	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18252515	chr7:66147081	NA	-0.48	-5.55	-0.33	7.45e-8	Aortic root size;
KIRP	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.43	-5.5	-0.33	9.36e-8	Childhood ear infection;
KIRP	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	5.99	0.36	7.46e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04106633	chr4:1044584	NA	-0.47	-5.68	-0.34	3.72e-8	Recombination rate (males);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17913255	chr3:195595244	TNK2	0.48	6.17	0.37	2.8e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17401966	0.540	rs10864452	chr1:10395683	G/T	cg17425144	chr1:10567563	PEX14	-0.3	-5.18	-0.31	4.69e-7	Hepatocellular carcinoma;
KIRP	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.37	6.72	0.39	1.23e-10	Renal cell carcinoma;
KIRP	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.65	-0.44	4.56e-13	Neuroticism;
KIRP	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.49	-6.85	-0.4	5.77e-11	Endometrial cancer;
KIRP	cis	rs7980687	0.527	rs1626703	chr12:123710835	A/C	cg00585698	chr12:123750864	CDK2AP1	-0.42	-5.12	-0.31	6.05e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.54	-8.28	-0.47	8.11e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.67	7.67	0.44	3.91e-13	Arsenic metabolism;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.21	0.64	1.87e-30	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00357503	chr15:44119060	WDR76	0.51	6.45	0.38	5.88e-10	Parkinson's disease;
KIRP	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.64	-10.05	-0.54	3.91e-20	Endometriosis;
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg02462569	chr6:150064036	NUP43	-0.43	-6.46	-0.38	5.59e-10	Lung cancer;
KIRP	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg05370193	chr1:21551575	ECE1	0.43	6.09	0.36	4.29e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg15436174	chr10:43711423	RASGEF1A	0.79	8.53	0.48	1.48e-15	Hirschsprung disease;
KIRP	trans	rs7479949	0.798	rs715859	chr11:83488901	C/T	cg05583831	chr3:27772705	NA	-0.41	-6.02	-0.36	6.14e-9	Parkinson's disease;
KIRP	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg11707556	chr5:10655725	ANKRD33B	0.54	6.6	0.39	2.48e-10	Coronary artery disease;
KIRP	cis	rs734999	0.505	rs60687045	chr1:2539603	G/A	cg18932078	chr1:2524107	MMEL1	0.44	6.13	0.36	3.5e-9	Ulcerative colitis;
KIRP	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.84	0.49	1.89e-16	Morning vs. evening chronotype;
KIRP	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg11005552	chr10:105648138	OBFC1	0.4	5.73	0.34	2.95e-8	Coronary artery disease;
KIRP	cis	rs6500550	0.636	rs2158443	chr16:3685782	C/G	cg07396092	chr16:3662230	BTBD12	0.53	6.3	0.37	1.38e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.76	-9.26	-0.51	1.04e-17	Response to antipsychotic treatment;
KIRP	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg25358565	chr5:93447407	FAM172A	-0.57	-6.51	-0.38	4.31e-10	Diabetic retinopathy;
KIRP	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg04254540	chr16:71951199	KIAA0174	-0.53	-5.85	-0.35	1.55e-8	Coronary artery disease;
KIRP	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg17644776	chr2:200775616	C2orf69	-0.56	-5.32	-0.32	2.38e-7	Schizophrenia;
KIRP	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg00083206	chr6:110721305	DDO	-0.42	-6.02	-0.36	6.35e-9	Platelet distribution width;
KIRP	trans	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg15469184	chr8:337539	NA	0.58	6.35	0.38	1.03e-9	Obesity-related traits;
KIRP	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	1.02	13.1	0.64	4.16e-30	IgG glycosylation;
KIRP	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.45	-0.52	2.8e-18	Gut microbiome composition (summer);
KIRP	cis	rs10865541	0.869	rs6548162	chr2:3434332	C/T	cg11642891	chr2:3452563	TTC15	-0.56	-7.18	-0.42	8.43e-12	Obesity-related traits;
KIRP	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.14e-21	Alzheimer's disease (late onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03674265	chr7:149322059	ZNF767	0.49	6.03	0.36	6.07e-9	Parkinson's disease;
KIRP	cis	rs17209837	0.527	rs4148824	chr7:87075362	A/G	cg00919237	chr7:87102261	ABCB4	-0.7	-8.79	-0.49	2.56e-16	Gallbladder cancer;
KIRP	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg10223061	chr2:219282414	VIL1	0.43	7.0	0.41	2.42e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.81	-11.59	-0.59	4.43e-25	Glomerular filtration rate (creatinine);
KIRP	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.37	1.37e-9	Morning vs. evening chronotype;
KIRP	cis	rs4356932	0.905	rs6532086	chr4:76937278	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.36	-4.87	-0.3	1.97e-6	Blood protein levels;
KIRP	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.81	-0.35	1.96e-8	Recombination measurement;
KIRP	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg03959625	chr15:84868606	LOC388152	0.63	7.06	0.41	1.74e-11	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-5.07	-0.31	7.84e-7	Height;
KIRP	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.72	-8.27	-0.47	8.32e-15	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.77	9.36	0.51	5.23e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1943345	0.556	rs555586	chr11:82911879	C/T	cg07047830	chr11:82868014	PCF11	0.44	5.12	0.31	6.31e-7	Obesity-related traits;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.44	6.47	0.38	5.33e-10	Lymphocyte counts;
KIRP	cis	rs9653442	0.564	rs2309753	chr2:100775920	C/A	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.79	10.48	0.56	1.76e-21	Body mass index;
KIRP	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.82e-9	Motion sickness;
KIRP	cis	rs12643440	0.922	rs16894648	chr4:17205620	T/C	cg22650099	chr4:17144496	NA	-0.51	-6.14	-0.36	3.33e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6545883	0.895	rs2256617	chr2:61679924	A/G	cg15711740	chr2:61764176	XPO1	-0.6	-8.08	-0.46	2.98e-14	Tuberculosis;
KIRP	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.59	-6.68	-0.39	1.57e-10	Menarche (age at onset);
KIRP	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg02820040	chr2:241836501	C2orf54	-0.24	-5.52	-0.33	8.7e-8	Urinary metabolites;
KIRP	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.53e-7	Plateletcrit;
KIRP	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg00745463	chr17:30367425	LRRC37B	0.53	5.0	0.3	1.08e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs5743618	0.537	rs6531661	chr4:38767796	G/A	cg06935464	chr4:38784597	TLR10	0.38	4.88	0.3	1.9e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02219607	chr4:70504750	UGT2A2;UGT2A1	0.41	6.45	0.38	5.93e-10	C-reactive protein;
KIRP	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.67	7.93	0.45	7.48e-14	Menarche (age at onset);
KIRP	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg00784671	chr22:46762841	CELSR1	-0.84	-8.26	-0.47	8.93e-15	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg22565399	chr5:176890677	DBN1	0.57	6.11	0.36	3.97e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg15247329	chr7:2764246	NA	-0.37	-5.33	-0.32	2.22e-7	Height;
KIRP	trans	rs1106684	1.000	rs11767029	chr7:131466070	C/T	cg13607082	chr12:122652224	LRRC43	-0.67	-6.7	-0.39	1.4e-10	Body mass index;
KIRP	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg03929089	chr4:120376271	NA	0.68	6.64	0.39	1.97e-10	Axial length;
KIRP	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24110177	chr3:50126178	RBM5	-0.41	-5.38	-0.32	1.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs73198271	0.565	rs575920	chr8:8594254	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.18	-0.31	4.58e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg06671706	chr8:8559999	CLDN23	0.43	4.92	0.3	1.61e-6	Obesity-related traits;
KIRP	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg27422857	chr2:105853526	NA	-0.46	-6.06	-0.36	4.97e-9	Type 2 diabetes;
KIRP	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21214613	chr1:16344536	HSPB7	0.36	5.14	0.31	5.54e-7	Dilated cardiomyopathy;
KIRP	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.82	-8.72	-0.49	4.13e-16	Colorectal cancer;
KIRP	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11638352	1.000	rs6493093	chr15:44305495	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-5.9	-0.35	1.17e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs6991838	0.584	rs6997959	chr8:66540482	T/C	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg04080417	chr5:1859792	NA	-0.63	-8.16	-0.46	1.77e-14	Cardiovascular disease risk factors;
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg21734707	chr17:3908241	ZZEF1	-0.59	-8.64	-0.48	7.49e-16	Type 2 diabetes;
KIRP	trans	rs61440199	1.000	rs76999560	chr3:20129946	T/C	cg08354614	chr10:80673607	NA	0.5	6.28	0.37	1.48e-9	Staphylococcus aureus nasal carriage (intermittent);
KIRP	cis	rs4924590	0.531	rs12913835	chr15:42227869	C/T	cg20935245	chr15:42234343	EHD4	0.5	7.83	0.45	1.44e-13	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
KIRP	cis	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg03999872	chr20:62272968	STMN3	0.41	4.88	0.3	1.89e-6	Prostate cancer;
KIRP	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.42	-5.95	-0.35	9.4e-9	Endometrial cancer;
KIRP	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg09624528	chr10:1369823	ADARB2	0.45	5.63	0.34	4.8e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg00982548	chr2:198649783	BOLL	-0.54	-5.11	-0.31	6.51e-7	Ulcerative colitis;
KIRP	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg10578777	chr12:7781093	NA	0.54	5.49	0.33	9.78e-8	HDL cholesterol levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25710815	chr4:89300116	HERC6	0.5	6.79	0.4	8.27e-11	Parkinson's disease;
KIRP	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg26531700	chr6:26746687	NA	0.39	5.25	0.32	3.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg02462569	chr6:150064036	NUP43	-0.34	-5.02	-0.3	1e-6	Lung cancer;
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg20821713	chr7:1055600	C7orf50	-0.33	-5.08	-0.31	7.64e-7	Longevity;Endometriosis;
KIRP	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-12.08	-0.61	1.12e-26	Systemic lupus erythematosus;
KIRP	cis	rs2764980	1.000	rs2764979	chr10:3283882	T/C	cg11630169	chr10:3283847	NA	-0.48	-6.41	-0.38	7.19e-10	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6893807	1.000	rs2304608	chr5:87962298	C/A	cg24804195	chr5:87968844	LOC645323	0.61	6.52	0.38	3.87e-10	Body mass index;
KIRP	cis	rs7941030	1.000	rs1945390	chr11:122520253	C/T	cg20555462	chr11:122535518	UBASH3B	0.4	4.96	0.3	1.3e-6	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-0.54	-7.44	-0.43	1.66e-12	Coronary artery disease;
KIRP	cis	rs1413885	0.525	rs1334878	chr1:65846124	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.58	6.24	0.37	1.95e-9	Anticoagulant levels;
KIRP	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.68	-11.23	-0.58	6.81e-24	Hip circumference;Waist circumference;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11848740	chr1:185113945	C1orf25	0.42	6.53	0.38	3.73e-10	Migraine with aura;
KIRP	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg15880211	chr22:50250494	ZBED4	0.43	5.22	0.32	3.84e-7	Schizophrenia;
KIRP	cis	rs6662572	0.578	rs6662306	chr1:46287286	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.55	0.33	7.57e-8	Blood protein levels;
KIRP	cis	rs303806	1	rs303806	chr12:52166503	A/G	cg07929700	chr12:52204284	NA	-0.57	-5.67	-0.34	3.92e-8	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01219382	chr4:184328462	NA	0.5	6.11	0.36	3.77e-9	Parkinson's disease;
KIRP	cis	rs10493773	0.775	rs6667672	chr1:86171072	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.44	-5.17	-0.31	4.77e-7	Urate levels in overweight individuals;
KIRP	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg03060546	chr3:49711283	APEH	-0.61	-5.4	-0.33	1.55e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.37	0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05220968	chr6:146057943	EPM2A	0.39	5.01	0.3	1.03e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10582639	chr11:121526840	NA	0.55	7.53	0.43	9.57e-13	Parkinson's disease;
KIRP	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg05352754	chr2:101034825	CHST10	-0.38	-6.4	-0.38	7.84e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	trans	rs11165623	0.765	rs12749081	chr1:96970371	A/C	cg10631902	chr5:14652156	NA	-0.6	-9.06	-0.5	4.16e-17	Hip circumference;Waist circumference;
KIRP	cis	rs6541297	0.887	rs6541295	chr1:230281698	A/G	cg20703242	chr1:230279135	GALNT2	0.38	5.85	0.35	1.55e-8	Coronary artery disease;
KIRP	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17507749	chr15:85114479	UBE2QP1	0.75	8.45	0.47	2.57e-15	Schizophrenia;
KIRP	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.47	6.05	0.36	5.5e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg23950597	chr19:37808831	NA	-0.59	-6.39	-0.38	8.04e-10	Coronary artery calcification;
KIRP	cis	rs7572644	0.679	rs6745545	chr2:28021845	C/G	cg27432699	chr2:27873401	GPN1	0.47	5.56	0.33	7.01e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs687432	0.774	rs1814059	chr11:57894770	T/G	cg19752551	chr11:57585705	CTNND1	-0.67	-8.52	-0.48	1.66e-15	Parkinson's disease;
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.62	9.38	0.51	4.49e-18	Immature fraction of reticulocytes;
KIRP	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-5.39	-0.32	1.67e-7	HDL cholesterol;
KIRP	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.74	-0.34	2.82e-8	Breast cancer;
KIRP	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs12580194	0.593	rs7485979	chr12:55789043	A/T	cg19537932	chr12:55886519	OR6C68	0.52	6.61	0.39	2.31e-10	Cancer;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-5.16	-0.31	5.02e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.56	7.69	0.44	3.48e-13	Night sleep phenotypes;
KIRP	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.72	-7.08	-0.41	1.46e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg13978929	chr19:21580086	ZNF493	0.52	5.06	0.31	8.17e-7	Pain;
KIRP	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg23422044	chr7:1970798	MAD1L1	-0.53	-7.13	-0.41	1.1e-11	Neuroticism;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03647317	chr4:187891568	NA	-0.77	-12.87	-0.63	2.45e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs244899	0.935	rs2445786	chr5:167930877	G/A	cg13011109	chr5:167955758	FBLL1	0.36	4.93	0.3	1.52e-6	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs2241685	0.646	rs13016585	chr2:1934252	G/C	cg22511877	chr2:1942942	MYT1L	-0.53	-5.61	-0.34	5.45e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg03060546	chr3:49711283	APEH	0.49	6.44	0.38	6.14e-10	Parkinson's disease;
KIRP	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	cis	rs78487399	0.710	rs72879276	chr2:43627101	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.01	-0.3	1.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.73	-0.39	1.16e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	1.02	18.28	0.76	9.53e-48	Heart rate;
KIRP	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.65	7.03	0.41	2.07e-11	Gut microbiome composition (summer);
KIRP	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.54	6.83	0.4	6.52e-11	Eye color traits;
KIRP	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.15	0.31	5.47e-7	Menopause (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02079880	chr6:157802436	ZDHHC14	-0.45	-6.14	-0.36	3.38e-9	Metabolic traits;
KIRP	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg02023728	chr11:77925099	USP35	0.3	4.91	0.3	1.65e-6	Alzheimer's disease (survival time);
KIRP	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.98	10.44	0.55	2.31e-21	Blood protein levels;
KIRP	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg09408571	chr1:101003634	GPR88	0.24	5.36	0.32	1.87e-7	Monocyte count;
KIRP	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.08e-11	Blood metabolite levels;
KIRP	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.31	-6.37	-0.38	9.43e-10	Asthma (sex interaction);
KIRP	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-0.94	-13.09	-0.64	4.67e-30	Blood trace element (Zn levels);
KIRP	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg13010199	chr12:38710504	ALG10B	0.69	9.16	0.5	2.03e-17	Morning vs. evening chronotype;
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg11814155	chr7:99998594	ZCWPW1	0.55	5.27	0.32	2.94e-7	Platelet count;
KIRP	cis	rs77372450	0.636	rs55699399	chr5:157028363	C/A	cg23851860	chr5:157002805	ADAM19	0.45	4.99	0.3	1.14e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg21775007	chr8:11205619	TDH	-0.5	-6.34	-0.37	1.11e-9	Neuroticism;
KIRP	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg21187068	chr8:144659627	NAPRT1	0.72	4.92	0.3	1.62e-6	Attention deficit hyperactivity disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04446303	chr16:4322834	TFAP4	0.48	6.04	0.36	5.79e-9	Parkinson's disease;
KIRP	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.46	6.37	0.38	9.23e-10	Childhood ear infection;
KIRP	cis	rs2820315	1.000	rs2820314	chr1:201872209	A/C	cg11586189	chr1:201857591	SHISA4	-0.4	-5.6	-0.34	5.6e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.73	9.41	0.51	3.73e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10131728	0.892	rs12880512	chr14:81647457	A/C	cg01989461	chr14:81687754	GTF2A1	-0.68	-5.47	-0.33	1.13e-7	IgG glycosylation;
KIRP	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7010267	0.773	rs72680380	chr8:119932741	T/A	cg01975934	chr8:119970761	NA	0.44	5.64	0.34	4.76e-8	Total body bone mineral density (age 45-60);
KIRP	cis	rs3931020	0.566	rs1327086	chr1:75271032	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.43	5.21	0.32	3.92e-7	Resistin levels;
KIRP	cis	rs731174	0.959	rs11264092	chr1:38190625	T/C	cg06917450	chr1:38156652	C1orf109	-0.41	-4.94	-0.3	1.44e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.45	-0.33	1.2e-7	Bipolar disorder;
KIRP	cis	rs11203032	0.831	rs12219735	chr10:90922890	C/T	cg16672925	chr10:90967113	CH25H	0.78	7.67	0.44	3.95e-13	Heart failure;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.73	0.44	2.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs858239	0.720	rs10227559	chr7:23272144	G/A	cg23682824	chr7:23144976	KLHL7	0.45	4.99	0.3	1.14e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg07661805	chr8:143867942	LY6D	-0.29	-5.08	-0.31	7.34e-7	Urinary tract infection frequency;
KIRP	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-6.19	-0.37	2.47e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.54	0.38	3.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.55	7.3	0.42	3.96e-12	Subjective well-being;Cardiovascular disease risk factors;
KIRP	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg21918786	chr6:109611834	NA	-0.39	-5.72	-0.34	3.04e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.51	6.26	0.37	1.66e-9	HIV-1 control;
KIRP	cis	rs644148	0.781	rs630469	chr19:44970167	T/C	cg15540054	chr19:45004280	ZNF180	-0.65	-7.34	-0.42	3.08e-12	Personality dimensions;
KIRP	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	cg21523751	chr1:182988639	NA	0.34	4.85	0.3	2.23e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg11130432	chr3:121712080	ILDR1	-0.47	-5.82	-0.35	1.79e-8	Multiple sclerosis;
KIRP	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.56	-0.43	8e-13	Aortic root size;
KIRP	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18252515	chr7:66147081	NA	0.42	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	8.19	0.46	1.4e-14	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26306683	chr17:18585705	ZNF286B	0.59	7.69	0.44	3.51e-13	Educational attainment (years of education);
KIRP	cis	rs9549260	0.564	rs9549271	chr13:41295477	T/C	cg21288729	chr13:41239152	FOXO1	0.55	7.35	0.42	2.96e-12	Red blood cell count;
KIRP	cis	rs62229266	0.804	rs880221	chr21:37420785	C/T	cg08632701	chr21:37451849	NA	-0.43	-5.38	-0.32	1.72e-7	Mitral valve prolapse;
KIRP	cis	rs35740288	0.770	rs56092539	chr15:86182512	A/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.76	-0.34	2.55e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.67	0.71	7.37e-39	Chronic sinus infection;
KIRP	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.64	8.24	0.46	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7640424	0.929	rs326358	chr3:107822310	C/T	cg09227934	chr3:107805635	CD47	0.34	5.75	0.34	2.61e-8	Body mass index;
KIRP	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.8	0.49	2.47e-16	Motion sickness;
KIRP	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg20991723	chr1:152506922	NA	-0.44	-5.3	-0.32	2.59e-7	Plantar warts;
KIRP	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.15e-51	Height;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02475777	chr4:1388615	CRIPAK	0.41	5.37	0.32	1.78e-7	Longevity;
KIRP	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-1.03	-17.18	-0.74	5.42e-44	Height;
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.28	15.82	0.71	2.27e-39	Platelet count;
KIRP	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Hypertriglyceridemia;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg13293650	chr15:28341193	OCA2	0.43	6.07	0.36	4.79e-9	Asthma;
KIRP	cis	rs2820315	0.867	rs2820318	chr1:201878620	T/C	cg11586189	chr1:201857591	SHISA4	-0.44	-6.43	-0.38	6.5e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg25008857	chr14:105974488	NA	0.43	4.89	0.3	1.79e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.65	-8.67	-0.48	5.76e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg11895451	chr1:16533891	ARHGEF19	0.5	6.79	0.4	8.22e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.76	10.92	0.57	6.75e-23	Dental caries;
KIRP	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.83	8.54	0.48	1.39e-15	Pulmonary function decline;
KIRP	cis	rs10824796	0.951	rs3925313	chr10:54533873	A/G	cg27418851	chr10:54531653	MBL2	0.44	5.24	0.32	3.52e-7	Blood protein levels;
KIRP	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.95	13.23	0.64	1.57e-30	Primary sclerosing cholangitis;
KIRP	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	7.91	0.45	8.96e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.18	0.37	2.64e-9	Bipolar disorder;
KIRP	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.72	-7.51	-0.43	1.08e-12	Body mass index;
KIRP	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg00094735	chr5:1949198	NA	0.45	5.44	0.33	1.3e-7	Gut microbiome composition (winter);
KIRP	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	1.08	20.53	0.79	3.08e-55	Height;
KIRP	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg21775007	chr8:11205619	TDH	0.47	6.34	0.37	1.09e-9	Mood instability;
KIRP	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg13206674	chr6:150067644	NUP43	0.56	7.86	0.45	1.22e-13	Lung cancer;
KIRP	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Immature fraction of reticulocytes;
KIRP	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.46	0.43	1.48e-12	Myopia (pathological);
KIRP	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg03959625	chr15:84868606	LOC388152	0.63	6.73	0.39	1.2e-10	Schizophrenia;
KIRP	cis	rs7577696	0.509	rs681482	chr2:31871256	A/G	cg02381751	chr2:32503542	YIPF4	0.45	4.94	0.3	1.42e-6	Inflammatory biomarkers;
KIRP	cis	rs4774899	0.934	rs12904602	chr15:57491818	C/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.55	-0.33	7.48e-8	Urinary tract infection frequency;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07276957	chr12:46122733	ARID2;LOC400027	-0.51	-6.07	-0.36	4.74e-9	Migraine with aura;
KIRP	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.11	0.64	3.9e-30	Electrocardiographic conduction measures;
KIRP	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12016809	chr21:47604291	C21orf56	0.39	5.29	0.32	2.73e-7	Testicular germ cell tumor;
KIRP	trans	rs2816316	0.502	rs6684404	chr1:192530615	C/T	cg20577538	chr2:207140030	ZDBF2	-0.51	-6.12	-0.36	3.58e-9	Celiac disease;
KIRP	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.78	7.67	0.44	4.08e-13	Neuroblastoma;
KIRP	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.78	7.94	0.45	6.99e-14	Uric acid levels;
KIRP	cis	rs10267417	0.603	rs4634527	chr7:19911019	C/G	cg05791153	chr7:19748676	TWISTNB	0.5	5.14	0.31	5.58e-7	Night sleep phenotypes;
KIRP	cis	rs883565	0.528	rs4504116	chr3:38953768	A/G	cg01426195	chr3:39028469	NA	0.49	7.46	0.43	1.48e-12	Handedness;
KIRP	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18364779	chr6:26104403	HIST1H4C	0.41	5.34	0.32	2.08e-7	Schizophrenia;
KIRP	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg19142026	chr7:27170394	HOXA4	-0.39	-5.73	-0.34	2.94e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.08	-0.36	4.52e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1950626	0.833	rs35151884	chr14:101394196	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.6	6.63	0.39	2.07e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.85	-13.44	-0.65	2.96e-31	Breast cancer;
KIRP	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.8	-8.6	-0.48	9.48e-16	Hair shape;
KIRP	cis	rs2224391	0.590	rs72813693	chr6:5273464	T/C	cg24031505	chr6:4779396	CDYL	-0.6	-4.92	-0.3	1.59e-6	Height;
KIRP	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.7	8.38	0.47	4.19e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-4.95	-0.3	1.4e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.08	0.61	1.13e-26	Ileal carcinoids;
KIRP	cis	rs4356975	0.563	rs57216626	chr4:69958823	G/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg23594656	chr7:65796392	TPST1	0.41	5.72	0.34	3.11e-8	Aortic root size;
KIRP	cis	rs11644362	0.932	rs3848239	chr16:12996642	A/G	cg06890432	chr16:12997467	SHISA9	-0.4	-6.27	-0.37	1.65e-9	Positive affect;Subjective well-being;
KIRP	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	8.99	0.5	6.68e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg23484912	chr5:273055	PDCD6	0.58	7.25	0.42	5.52e-12	Pancreatic cancer;
KIRP	cis	rs7119167	0.851	rs7122560	chr11:73091913	G/A	cg17517138	chr11:73019481	ARHGEF17	0.51	5.28	0.32	2.84e-7	Blood protein levels;
KIRP	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg13736514	chr6:26305472	NA	-0.73	-9.04	-0.5	4.87e-17	Educational attainment;
KIRP	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg11657440	chr19:46296263	DMWD	0.93	14.99	0.69	1.59e-36	Coronary artery disease;
KIRP	trans	rs9914544	0.602	rs4924929	chr17:18714241	G/A	cg04702396	chr17:15466718	FAM18B2	0.72	10.95	0.57	5.27e-23	Educational attainment (years of education);
KIRP	cis	rs56146971	0.703	rs79190905	chr14:91848149	C/T	cg16433844	chr14:91963127	SMEK1	-0.53	-4.88	-0.3	1.9e-6	Alzheimer disease and age of onset;
KIRP	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.5	-5.33	-0.32	2.23e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	trans	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg06774039	chr2:74056087	STAMBP	0.45	6.02	0.36	6.15e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg23698023	chr8:27181813	PTK2B	0.36	5.39	0.32	1.65e-7	Neuroticism;
KIRP	cis	rs4783244	0.897	rs4783241	chr16:82650384	G/C	cg09415485	chr16:82663111	CDH13	-0.26	-5.02	-0.31	9.77e-7	Adiponectin levels;
KIRP	cis	rs745821	0.701	rs753328	chr18:48108008	C/T	cg18923635	chr18:48083994	NA	-0.42	-5.07	-0.31	7.9e-7	Diastolic blood pressure;
KIRP	cis	rs6882076	0.961	rs4704827	chr5:156392089	T/C	cg12943317	chr5:156479607	HAVCR1	-0.65	-7.79	-0.44	1.85e-13	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg16797656	chr11:68205561	LRP5	0.62	11.19	0.58	9.26e-24	Total body bone mineral density;
KIRP	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.81	9.05	0.5	4.45e-17	Phospholipid levels (plasma);
KIRP	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg13615516	chr5:77269221	NA	0.51	7.87	0.45	1.12e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17384381	0.636	rs11161615	chr1:85906816	A/G	cg16011679	chr1:85725395	C1orf52	-0.49	-5.62	-0.34	5.2100000000000003e-08	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.72	9.95	0.54	8.24e-20	Crohn's disease;
KIRP	cis	rs7534824	0.582	rs41312670	chr1:101443431	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.43	0.33	1.38e-7	Refractive astigmatism;
KIRP	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.37	0.32	1.82e-7	Smoking behavior;
KIRP	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg13877915	chr19:58951672	ZNF132	0.61	5.99	0.36	7.27e-9	Mean platelet volume;
KIRP	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg15556689	chr8:8085844	FLJ10661	0.61	7.59	0.44	6.74e-13	Neuroticism;
KIRP	cis	rs17592366	0.517	rs1967722	chr14:35285274	A/G	cg09327582	chr14:35236912	BAZ1A	0.55	5.71	0.34	3.2e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg14703610	chr5:56206110	C5orf35	-0.44	-5.69	-0.34	3.67e-8	Coronary artery disease;
KIRP	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17376030	chr22:41985996	PMM1	-0.61	-6.49	-0.38	4.68e-10	Vitiligo;
KIRP	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	0.77	7.56	0.43	8.01e-13	Prostate cancer;
KIRP	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.52	-6.64	-0.39	2.02e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.47	-7.9	-0.45	9.26e-14	Type 2 diabetes;
KIRP	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.63	-6.75	-0.4	1.04e-10	Gut microbiome composition (summer);
KIRP	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.59	7.92	0.45	8.22e-14	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11696861	chr19:6739997	TRIP10	0.53	6.87	0.4	5.17e-11	Parkinson's disease;
KIRP	cis	rs4765905	0.610	rs10848627	chr12:2312408	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg15556689	chr8:8085844	FLJ10661	-0.75	-10.63	-0.56	5.93e-22	Triglycerides;
KIRP	cis	rs5758511	0.573	rs2284082	chr22:42240797	C/T	cg15128208	chr22:42549153	NA	-0.44	-4.98	-0.3	1.22e-6	Birth weight;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24013618	chr4:870925	GAK	-0.45	-6.76	-0.4	9.68e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg10047753	chr17:41438598	NA	-0.83	-11.09	-0.58	1.96e-23	Menopause (age at onset);
KIRP	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.58	6.35	0.38	1.03e-9	Gastritis;
KIRP	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg12131826	chr15:77904385	NA	0.49	6.46	0.38	5.47e-10	Type 2 diabetes;
KIRP	cis	rs4523957	0.651	rs1994883	chr17:2083881	T/A	cg16513277	chr17:2031491	SMG6	-0.8	-11.62	-0.6	3.67e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1971762	0.545	rs6580949	chr12:53924293	T/C	cg16917193	chr12:54089295	NA	0.65	10.36	0.55	4.29e-21	Height;
KIRP	cis	rs3136516	0.696	rs4752926	chr11:46692870	C/T	cg16389345	chr11:46697382	NA	0.52	7.38	0.43	2.39e-12	Venous thromboembolism;
KIRP	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.66	9.52	0.52	1.71e-18	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-12.79	-0.63	4.51e-29	Coronary artery disease;
KIRP	cis	rs17221829	0.645	rs11018705	chr11:89382700	T/G	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.7	7.57	0.43	7.49e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg15103426	chr22:29168792	CCDC117	0.55	7.1	0.41	1.32e-11	Lymphocyte counts;
KIRP	cis	rs262150	0.788	rs2657389	chr7:158763795	G/A	cg19418458	chr7:158789849	NA	-0.52	-6.54	-0.38	3.48e-10	Facial morphology (factor 20);
KIRP	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-0.81	-8.19	-0.46	1.42e-14	Lung cancer;
KIRP	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg17595323	chr11:93583763	C11orf90	0.32	5.33	0.32	2.23e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg17294928	chr15:75287854	SCAMP5	-0.76	-4.84	-0.3	2.24e-6	Lung cancer;
KIRP	cis	rs6142102	0.961	rs1555075	chr20:32610401	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	6.53	0.38	3.77e-10	Skin pigmentation;
KIRP	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg18234130	chr8:27182889	PTK2B	0.47	6.02	0.36	6.35e-9	Neuroticism;
KIRP	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg13147721	chr7:65941812	NA	1.04	7.24	0.42	5.57e-12	Diabetic kidney disease;
KIRP	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg04315214	chr1:2043799	PRKCZ	0.38	5.66	0.34	4.15e-8	Height;
KIRP	cis	rs11731606	0.583	rs7670371	chr4:95339036	C/T	cg20625393	chr4:95128694	SMARCAD1	0.66	5.89	0.35	1.29e-8	Mean platelet volume;
KIRP	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.98	-14.8	-0.69	7.03e-36	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-1.0	-16.6	-0.73	5.01e-42	Height;
KIRP	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg18132916	chr6:79620363	NA	-0.41	-5.6	-0.34	5.78e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg26617929	chr16:1858877	NA	-0.71	-5.88	-0.35	1.35e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg10840412	chr1:235813424	GNG4	0.69	6.16	0.37	2.99e-9	Bipolar disorder;
KIRP	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.81	-11.5	-0.59	9.1e-25	Body mass index;
KIRP	cis	rs1355223	0.902	rs11603774	chr11:34732891	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs61440199	0.786	rs73818815	chr3:20148087	A/T	cg08354614	chr10:80673607	NA	0.56	6.19	0.37	2.54e-9	Staphylococcus aureus nasal carriage (intermittent);
KIRP	cis	rs9810890	1.000	rs73207989	chr3:128588205	A/C	cg15033153	chr3:128514015	RAB7A	0.73	5.13	0.31	6.01e-7	Dental caries;
KIRP	cis	rs832187	0.640	rs56293138	chr3:63888935	G/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.49	-5.52	-0.33	8.67e-8	Schizophrenia;
KIRP	cis	rs4722404	0.592	rs7791687	chr7:3119643	G/A	cg19214707	chr7:3157722	NA	-0.48	-5.61	-0.34	5.51e-8	Atopic dermatitis;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	14.04	0.67	2.83e-33	Platelet count;
KIRP	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.59	-8.77	-0.49	3.06e-16	Prostate cancer;
KIRP	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	7.62	0.44	5.64e-13	Mood instability;
KIRP	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg17691542	chr6:26056736	HIST1H1C	0.41	5.55	0.33	7.52e-8	Schizophrenia;
KIRP	cis	rs7998202	0.667	rs282584	chr13:113349819	C/T	cg04656015	chr13:113407548	ATP11A	0.54	5.86	0.35	1.49e-8	Glycated hemoglobin levels;
KIRP	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	9.04	0.5	4.84e-17	IgG glycosylation;
KIRP	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2916247	0.865	rs2920467	chr8:93001261	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.64	-8.85	-0.49	1.74e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg08603382	chr10:743973	NA	0.55	7.63	0.44	5.03e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs2635047	0.542	rs2668764	chr18:44790218	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-5.35	-0.32	2.03e-7	Educational attainment;
KIRP	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10988336	chr5:95767768	PCSK1	0.98	6.7	0.39	1.37e-10	P wave terminal force;
KIRP	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.43	4.94	0.3	1.44e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs2070677	0.736	rs6537612	chr10:135336717	A/T	cg20169779	chr10:135381914	SYCE1	-0.74	-5.13	-0.31	5.78e-7	Gout;
KIRP	cis	rs1978968	0.912	rs13057016	chr22:18466779	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-7.59	-0.44	6.73e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs7246657	0.722	rs3829688	chr19:38077100	T/C	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.46	-6.87	-0.4	5.37e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg11972305	chr2:233791962	NGEF	0.38	5.19	0.31	4.38e-7	Schizophrenia;
KIRP	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.49e-13	IgG glycosylation;
KIRP	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	4.94	0.3	1.42e-6	Cognitive test performance;
KIRP	cis	rs7779181	1.000	rs7780009	chr7:32341543	G/A	cg13207630	chr7:32358064	NA	0.48	5.84	0.35	1.66e-8	Body mass index;
KIRP	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18028347	chr3:32822518	NA	0.45	6.36	0.38	9.77e-10	Parkinson's disease;
KIRP	cis	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.16	-0.31	5.05e-7	Triglycerides;
KIRP	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.66	-8.11	-0.46	2.35e-14	Age at first birth;
KIRP	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	5.9	0.35	1.18e-8	Colorectal cancer;
KIRP	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.55	7.31	0.42	3.77e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg09264619	chr17:80180166	NA	-0.34	-4.96	-0.3	1.29e-6	Life satisfaction;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06990529	chr11:130099296	ZBTB44	0.37	6.06	0.36	4.99e-9	C-reactive protein;
KIRP	cis	rs6568686	0.786	rs6929494	chr6:111857330	T/A	cg15721981	chr6:111408429	SLC16A10	-0.55	-4.86	-0.3	2.07e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	0.91	13.78	0.66	2.11e-32	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg08439880	chr3:133502540	NA	-0.38	-5.11	-0.31	6.54e-7	Iron status biomarkers;
KIRP	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.45	-5.92	-0.35	1.07e-8	Body mass index;
KIRP	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg21856205	chr7:94953877	PON1	-0.45	-5.01	-0.3	1.04e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs12580194	0.593	rs55637917	chr12:55747565	T/C	cg19537932	chr12:55886519	OR6C68	-0.5	-6.46	-0.38	5.44e-10	Cancer;
KIRP	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg03235661	chr20:60525775	NA	-0.37	-5.64	-0.34	4.68e-8	Body mass index;
KIRP	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.61	-7.05	-0.41	1.76e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg27411982	chr8:10470053	RP1L1	0.41	4.87	0.3	1.97e-6	Neuroticism;
KIRP	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-5.32	-0.32	2.31e-7	Crohn's disease;
KIRP	cis	rs16857609	0.586	rs2568156	chr2:218335440	T/C	cg15335768	chr2:218268053	DIRC3	-0.36	-5.36	-0.32	1.88e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19455335	chr8:22457658	C8orf58	0.5	6.13	0.36	3.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1978968	0.956	rs8135939	chr22:18434284	A/G	cg03078520	chr22:18463400	MICAL3	-0.68	-8.17	-0.46	1.58e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.49	-5.8	-0.35	2.01e-8	Body mass index;
KIRP	cis	rs3789045	1.000	rs11588857	chr1:204587047	G/A	cg18185008	chr1:204589407	LRRN2	-0.67	-7.47	-0.43	1.36e-12	Educational attainment (college completion);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14128259	chr12:27848523	REP15	0.49	6.38	0.38	8.71e-10	Interleukin-4 levels;
KIRP	cis	rs9535307	0.799	rs2146143	chr13:50245620	A/C	cg04663916	chr13:50265991	EBPL	0.72	7.68	0.44	3.8e-13	Obesity-related traits;
KIRP	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs8060686	0.516	rs8048365	chr16:68253326	T/A	cg26727032	chr16:67993705	SLC12A4	-0.75	-8.93	-0.49	1.02e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg08999081	chr20:33150536	PIGU	0.45	5.73	0.34	2.92e-8	Height;
KIRP	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.54e-10	Fibrinogen levels;
KIRP	cis	rs11955175	1.000	rs112647987	chr5:40635920	G/T	cg04002187	chr5:40835754	RPL37	0.71	5.11	0.31	6.56e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9972944	0.756	rs9907996	chr17:63754889	C/T	cg07283582	chr17:63770753	CCDC46	-0.44	-7.39	-0.43	2.23e-12	Total body bone mineral density;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09332650	chr19:50120000	PRR12	1.07	6.5	0.38	4.4e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg24399712	chr22:39784796	NA	-0.52	-7.4	-0.43	2.11e-12	IgG glycosylation;
KIRP	cis	rs55728055	0.661	rs62237843	chr22:32026946	C/G	cg01338084	chr22:32026380	PISD	1.02	6.35	0.38	1.01e-9	Age-related hearing impairment;
KIRP	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.78	-11.0	-0.57	3.73e-23	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.59	7.94	0.45	7.34e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg05315796	chr3:52349193	DNAH1	-0.38	-5.94	-0.35	9.77e-9	Bipolar disorder;
KIRP	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.53	8.69	0.48	5.22e-16	Rheumatoid arthritis;
KIRP	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.9	-13.19	-0.64	2.18e-30	Height;
KIRP	trans	rs7246760	1.000	rs67507476	chr19:9852948	G/A	cg02900749	chr2:68251473	NA	-1.2	-10.05	-0.54	3.86e-20	Pursuit maintenance gain;
KIRP	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.75	-10.25	-0.55	9.25e-21	Mean platelet volume;
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-5.92	-0.35	1.06e-8	Aortic root size;
KIRP	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg05527609	chr1:210001259	C1orf107	0.49	6.9	0.4	4.49e-11	Orofacial clefts;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.54	-6.93	-0.4	3.65e-11	Testicular germ cell tumor;
KIRP	cis	rs2820315	1.000	rs903678	chr1:201809918	G/A	cg11586189	chr1:201857591	SHISA4	-0.43	-6.23	-0.37	2.03e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.55	8.42	0.47	3.09e-15	Lung cancer;
KIRP	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.58	7.75	0.44	2.4e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg02297831	chr4:17616191	MED28	0.6	7.45	0.43	1.59e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.69	11.11	0.58	1.61e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg10818794	chr15:86012489	AKAP13	-0.48	-6.76	-0.4	1.01e-10	Interstitial lung disease;
KIRP	cis	rs7554547	0.667	rs7525521	chr1:11975166	G/A	cg07603449	chr1:11986842	KIAA2013	-0.4	-5.11	-0.31	6.44e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg02030672	chr11:45687055	CHST1	-0.62	-8.12	-0.46	2.25e-14	Obesity-related traits;
KIRP	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg04691961	chr3:161091175	C3orf57	-0.61	-9.12	-0.5	2.68e-17	Morning vs. evening chronotype;
KIRP	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	0.96	18.11	0.76	3.79e-47	Dental caries;
KIRP	cis	rs6450176	0.909	rs80213371	chr5:53300874	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.1	-0.58	1.78e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-0.85	-9.21	-0.51	1.49e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg03714773	chr7:91764589	CYP51A1	0.4	6.06	0.36	5.05e-9	Breast cancer;
KIRP	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg04034577	chr2:241836375	C2orf54	-0.28	-5.36	-0.32	1.92e-7	Urinary metabolites;
KIRP	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.41	-5.05	-0.31	8.52e-7	Aortic root size;
KIRP	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg26531700	chr6:26746687	NA	0.41	5.63	0.34	4.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.68	0.34	3.73e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.08	0.41	1.55e-11	Bipolar disorder;
KIRP	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.28	0.37	1.49e-9	Colorectal cancer;
KIRP	cis	rs55788414	0.527	rs2873368	chr16:81184208	C/G	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18220666	chr4:75252994	EREG	0.45	7.12	0.41	1.2e-11	C-reactive protein;
KIRP	trans	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.89	-0.4	4.63e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg26681399	chr22:41777847	TEF	0.45	4.85	0.3	2.19e-6	Vitiligo;
KIRP	cis	rs7779181	1.000	rs12531858	chr7:32340099	G/T	cg13207630	chr7:32358064	NA	0.48	5.71	0.34	3.28e-8	Body mass index;
KIRP	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.56	-6.52	-0.38	4.04e-10	Body mass index (adult);
KIRP	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg03609598	chr5:56110824	MAP3K1	-0.61	-5.77	-0.35	2.34e-8	Type 2 diabetes;
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg03289416	chr15:75166202	SCAMP2	0.58	7.62	0.44	5.5e-13	Caffeine consumption;
KIRP	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.92	-14.06	-0.67	2.41e-33	Height;
KIRP	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.98	-8.33	-0.47	5.78e-15	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15356195	chr7:5569741	ACTB	0.56	7.63	0.44	5.13e-13	Parkinson's disease;
KIRP	cis	rs4474465	1.000	rs7102316	chr11:78149365	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-7.37	-0.43	2.53e-12	Alzheimer's disease (survival time);
KIRP	cis	rs12580194	0.593	rs7488940	chr12:55802591	C/T	cg11794356	chr12:55725991	OR6C3	-0.54	-7.04	-0.41	1.88e-11	Cancer;
KIRP	cis	rs16828019	0.929	rs1032728	chr1:41679566	A/T	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.65	10.47	0.56	1.82e-21	Pulse pressure;
KIRP	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11987759	chr7:65425863	GUSB	0.49	6.2	0.37	2.42e-9	Aortic root size;
KIRP	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.42	-5.41	-0.33	1.48e-7	Body mass index;
KIRP	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg12658694	chr1:38397304	INPP5B	-0.62	-7.35	-0.42	2.85e-12	Coronary artery disease;
KIRP	cis	rs3218477	0.925	rs79343405	chr7:152371024	T/G	cg06618968	chr7:152373420	XRCC2	-0.83	-5.38	-0.32	1.69e-7	Mean platelet volume;
KIRP	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.48	5.82	0.35	1.84e-8	Common traits (Other);
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.61e-6	Lung cancer;
KIRP	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg20578329	chr17:80767326	TBCD	-0.67	-7.78	-0.44	2e-13	Breast cancer;
KIRP	cis	rs883565	0.655	rs6768957	chr3:39100094	G/A	cg01426195	chr3:39028469	NA	-0.73	-12.8	-0.63	4.17e-29	Handedness;
KIRP	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.44	-0.65	3.06e-31	Height;
KIRP	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.63	-8.37	-0.47	4.31e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs6701037	0.555	rs10912899	chr1:175120715	C/T	cg08873628	chr1:175162347	KIAA0040	0.36	5.34	0.32	2.12e-7	Alcohol dependence;
KIRP	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-15.4	-0.7	6.31e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	9.16	0.5	2.17e-17	Cognitive test performance;
KIRP	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs1021993	0.545	rs79960084	chr1:209556170	C/A	cg24446417	chr1:209558027	NA	-0.5	-4.85	-0.3	2.18e-6	Gut microbiome composition (winter);
KIRP	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg19445457	chr11:5799446	OR52N5	-0.4	-4.93	-0.3	1.5e-6	DNA methylation (variation);
KIRP	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.84	15.73	0.71	4.85e-39	Anterior chamber depth;
KIRP	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.96	-0.36	8.56e-9	Schizophrenia;
KIRP	cis	rs77633900	0.772	rs79181196	chr15:76656281	G/T	cg21673338	chr15:77095150	SCAPER	-0.6	-5.53	-0.33	7.98e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.63	-6.24	-0.37	1.92e-9	Schizophrenia;
KIRP	cis	rs12220238	0.722	rs11001087	chr10:76384602	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.54	6.09	0.36	4.25e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.51	-7.58	-0.44	6.85e-13	Schizophrenia;
KIRP	cis	rs9309473	0.500	rs10865398	chr2:73741497	A/C	cg20560298	chr2:73613845	ALMS1	0.45	5.53	0.33	8.36e-8	Metabolite levels;
KIRP	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	5.6	0.34	5.68e-8	Coronary artery disease;
KIRP	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg04455712	chr21:45112962	RRP1B	-0.4	-5.21	-0.32	3.99e-7	Mean corpuscular volume;
KIRP	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg08462924	chr1:41848221	NA	0.5	7.4	0.43	2.1e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg25019722	chr6:37503610	NA	-0.96	-15.31	-0.7	1.24e-37	Cognitive performance;
KIRP	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg22437258	chr11:111473054	SIK2	0.53	6.07	0.36	4.8e-9	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26437306	chr5:38501577	LIFR	-0.45	-7.39	-0.43	2.27e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23903597	chr17:61704154	MAP3K3	-0.62	-8.04	-0.46	3.71e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs75920871	0.925	rs11827828	chr11:116755584	A/G	cg23684410	chr11:116897558	SIK3	-0.5	-5.39	-0.33	1.65e-7	Subjective well-being;
KIRP	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	7.09	0.41	1.43e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs57502260	1.000	rs57502260	chr11:68220905	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.06	0.31	8.2e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs2737618	0.722	rs2258675	chr1:200091548	G/C	cg21825944	chr1:200113062	NR5A2	-0.57	-7.98	-0.45	5.6e-14	Uric acid levels;
KIRP	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-7.13	-0.41	1.1e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9783347	0.961	rs4150526	chr11:18343209	G/A	cg15585147	chr11:18324498	HPS5	0.44	5.97	0.36	8.28e-9	Pancreatic cancer;
KIRP	trans	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg14472470	chr4:156298264	MAP9	-0.45	-6.17	-0.37	2.85e-9	Thyroid hormone levels;
KIRP	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.37	0.65	5.32e-31	Personality dimensions;
KIRP	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg12292205	chr6:26970375	C6orf41	0.33	4.92	0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.77	7.87	0.45	1.13e-13	Body mass index;
KIRP	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.54	-6.66	-0.39	1.8e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg25801113	chr15:45476975	SHF	0.42	7.87	0.45	1.11e-13	Uric acid levels;
KIRP	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.18	-0.54	1.54e-20	Response to antipsychotic treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12756521	chr8:131028985	NA	0.54	6.9	0.4	4.28e-11	Parkinson's disease;
KIRP	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.92	-0.35	1.09e-8	Menarche (age at onset);
KIRP	cis	rs7007076	0.634	rs2010301	chr8:124732388	G/T	cg00283535	chr8:124749564	ANXA13	0.84	7.7	0.44	3.29e-13	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg13565492	chr6:43139072	SRF	-0.93	-8.61	-0.48	8.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62413470	0.515	rs17221418	chr6:56064305	T/C	cg13327911	chr6:55965977	COL21A1	0.83	5.13	0.31	6e-7	Joint mobility (Beighton score);
KIRP	cis	rs9815354	0.812	rs56332587	chr3:42012714	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.87	0.45	1.16e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9517320	1.000	rs7338549	chr13:99142745	C/T	cg07423050	chr13:99094983	FARP1	0.31	5.19	0.31	4.43e-7	Longevity;
KIRP	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg07843065	chr1:150265600	MRPS21	-0.51	-7.36	-0.42	2.76e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9311676	0.632	rs6785572	chr3:58361517	A/G	cg06643156	chr3:58380774	PXK	-0.36	-5.11	-0.31	6.32e-7	Systemic lupus erythematosus;
KIRP	cis	rs11203032	1.000	rs17117088	chr10:90961799	G/A	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	6.91	0.4	4.16e-11	Body mass index;
KIRP	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg20488157	chr14:104394430	TDRD9	0.76	10.96	0.57	5.1e-23	Bipolar disorder;
KIRP	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg20307385	chr11:47447363	PSMC3	0.6	7.16	0.42	9.52e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs490234	0.812	rs12553699	chr9:128294526	C/G	cg14078157	chr9:128172775	NA	-0.61	-7.25	-0.42	5.49e-12	Mean arterial pressure;
KIRP	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.6	8.23	0.46	1.08e-14	Bladder cancer;
KIRP	cis	rs4594175	0.926	rs4318127	chr14:51624897	G/C	cg23942311	chr14:51606299	NA	0.51	6.86	0.4	5.7e-11	Cancer;
KIRP	cis	rs1165472	0.708	rs3862237	chr1:56185027	C/T	cg11523071	chr1:56160889	NA	-0.59	-7.36	-0.42	2.77e-12	Paclitaxel-induced neuropathy;
KIRP	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.94	15.15	0.69	4.41e-37	Menopause (age at onset);
KIRP	cis	rs829661	0.532	rs2363073	chr2:30796008	A/C	cg10949345	chr2:30726833	LCLAT1	0.45	6.4	0.38	7.76e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.07	0.36	4.89e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.88	-12.79	-0.63	4.52e-29	Ileal carcinoids;
KIRP	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.62	-0.34	5.11e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs6782228	0.675	rs56141228	chr3:128386042	C/T	cg18648031	chr3:128330563	NA	0.27	5.49	0.33	9.91e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.54	-5.66	-0.34	4.19e-8	Response to diuretic therapy;
KIRP	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.1	-0.5	3.27e-17	Schizophrenia;
KIRP	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.29	0.37	1.45e-9	Breast cancer;
KIRP	cis	rs8084125	1.000	rs8084125	chr18:74952758	T/C	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	7.51	0.43	1.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.65	-0.34	4.45e-8	Life satisfaction;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg21523564	chr15:75251491	NA	0.48	8.15	0.46	1.91e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs2274273	0.686	rs11624679	chr14:55624244	G/A	cg04306507	chr14:55594613	LGALS3	0.42	5.54	0.33	7.86e-8	Protein biomarker;
KIRP	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg08501292	chr6:25962987	TRIM38	-0.72	-4.87	-0.3	2.04e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.67	8.07	0.46	3.14e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.4	-6.29	-0.37	1.41e-9	Body mass index;
KIRP	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-7.48	-0.43	1.31e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg11657440	chr19:46296263	DMWD	-0.71	-9.43	-0.52	3.26e-18	Coronary artery disease;
KIRP	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.77	0.49	3.04e-16	Colorectal cancer;
KIRP	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.65	-9.89	-0.53	1.24e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg10763598	chr19:19431466	KIAA0892;SF4	0.62	5.2	0.31	4.29e-7	Nonalcoholic fatty liver disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09554701	chr1:180323123	ACBD6	0.36	6.21	0.37	2.21e-9	C-reactive protein;
KIRP	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.71	7.63	0.44	5.17e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg01114163	chr5:1856713	NA	-0.42	-5.18	-0.31	4.55e-7	Cardiovascular disease risk factors;
KIRP	cis	rs2380205	0.967	rs4287254	chr10:5888141	C/T	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	cis	rs6445967	1.000	rs62259324	chr3:58291107	T/C	cg16569813	chr3:58235849	ABHD6	-0.33	-4.89	-0.3	1.83e-6	Platelet count;
KIRP	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg15128208	chr22:42549153	NA	-0.45	-5.66	-0.34	4.29e-8	Cognitive function;
KIRP	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg11632617	chr15:75315747	PPCDC	-0.59	-5.12	-0.31	6.27e-7	Lung cancer;
KIRP	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.79	9.71	0.53	4.31e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg21360079	chr12:107162445	NA	-0.67	-9.59	-0.52	1.06e-18	Heart rate;
KIRP	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg07741184	chr6:167504864	NA	0.24	6.45	0.38	5.8e-10	Crohn's disease;
KIRP	cis	rs4919044	0.808	rs11187252	chr10:94796166	A/T	cg05127821	chr10:94822908	CYP26C1	-0.99	-7.26	-0.42	5.16e-12	Coronary artery disease;
KIRP	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.79	-11.47	-0.59	1.14e-24	Obesity-related traits;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg24069935	chr14:74226554	C14orf43	-0.49	-6.56	-0.39	3.24e-10	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16346588	chr10:242978	ZMYND11	0.43	5.24	0.32	3.49e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.88	13.73	0.66	3.08e-32	Coronary artery disease;
KIRP	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.71	8.21	0.46	1.24e-14	Resting heart rate;
KIRP	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg18709589	chr6:96969512	KIAA0776	-0.39	-5.68	-0.34	3.88e-8	Headache;
KIRP	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-5.52	-0.33	8.71e-8	Alzheimer's disease (late onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02478448	chr13:37006063	CCNA1	0.39	6.02	0.36	6.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7267005	1.000	rs7275167	chr20:34484245	C/T	cg17201900	chr20:34330562	RBM39	0.85	5.34	0.32	2.07e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs684232	0.901	rs1741275	chr17:630363	C/G	cg12384639	chr17:618140	VPS53	0.4	5.04	0.31	9.16e-7	Prostate cancer;
KIRP	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg19468946	chr17:37922297	IKZF3	-0.47	-6.63	-0.39	2.17e-10	Self-reported allergy;
KIRP	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.59	8.03	0.46	4e-14	Height;
KIRP	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.16	-0.37	2.94e-9	Total cholesterol levels;
KIRP	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg10117171	chr1:25599238	RHD	-0.38	-5.3	-0.32	2.53e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs4302748	0.909	rs35766501	chr7:36186069	G/A	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1461503	0.512	rs4293126	chr11:122804133	A/G	cg27398637	chr11:122830231	C11orf63	0.56	7.31	0.42	3.83e-12	Menarche (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09799789	chr1:245836746	KIF26B	0.51	6.57	0.39	2.93e-10	Interleukin-4 levels;
KIRP	cis	rs7666738	0.546	rs62320963	chr4:98839297	A/G	cg17366294	chr4:99064904	C4orf37	0.38	4.86	0.3	2.07e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.05	-0.41	1.83e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg04398451	chr17:18023971	MYO15A	0.41	4.92	0.3	1.6e-6	Body mass index;
KIRP	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.4	-0.33	1.58e-7	Schizophrenia;
KIRP	cis	rs9826463	0.582	rs73238150	chr3:142062457	C/A	cg20824294	chr3:142316082	PLS1	0.5	6.97	0.41	2.87e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.82	-12.38	-0.62	1.11e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg19847130	chr8:10466454	RP1L1	-0.35	-5.17	-0.31	4.75e-7	Retinal vascular caliber;
KIRP	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	12.42	0.62	8.24e-28	Electrocardiographic conduction measures;
KIRP	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.68	-9.89	-0.53	1.28e-19	Waist circumference;Body mass index;
KIRP	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.95	14.91	0.69	2.91e-36	Blood protein levels;
KIRP	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.84	10.13	0.54	2.23e-20	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.74	-9.93	-0.53	9.57e-20	Pancreatic cancer;
KIRP	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg09597638	chr17:3907349	NA	0.48	5.88	0.35	1.36e-8	Type 2 diabetes;
KIRP	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg25547332	chr5:131281432	NA	0.47	5.31	0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.73	0.49	3.83e-16	Colorectal cancer;
KIRP	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg18944383	chr4:111397179	ENPEP	0.63	11.51	0.59	8.02e-25	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11339840	chr1:203596058	ATP2B4	0.55	6.61	0.39	2.35e-10	Smoking initiation;
KIRP	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.74	-0.34	2.83e-8	IgG glycosylation;
KIRP	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg00784671	chr22:46762841	CELSR1	-0.56	-6.5	-0.38	4.53e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs963731	0.649	rs78905728	chr2:39339241	G/T	cg04010122	chr2:39346883	SOS1	0.93	6.39	0.38	8.09e-10	Corticobasal degeneration;
KIRP	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.44	-6.41	-0.38	7.51e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.61	-6.19	-0.37	2.44e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.38	-0.38	8.65e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.76	11.11	0.58	1.68e-23	Hip circumference;
KIRP	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg10556349	chr10:835070	NA	0.62	5.74	0.34	2.85e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg07596299	chr11:71824057	C11orf51	-0.9	-6.08	-0.36	4.49e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.81	10.74	0.56	2.63e-22	Blood metabolite levels;
KIRP	cis	rs2299587	0.604	rs11203933	chr8:17901910	G/T	cg01800426	chr8:17659068	MTUS1	-0.43	-5.32	-0.32	2.33e-7	Economic and political preferences;
KIRP	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.57	-6.48	-0.38	4.97e-10	Hypospadias;
KIRP	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.71	9.19	0.51	1.66e-17	Morning vs. evening chronotype;
KIRP	cis	rs7113850	0.541	rs74708033	chr11:24223512	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.35	0.47	5.02e-15	Bone fracture in osteoporosis;
KIRP	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg13393036	chr8:95962371	TP53INP1	0.32	6.05	0.36	5.31e-9	Type 2 diabetes;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.42	-0.33	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg06953865	chr19:18549723	ISYNA1	0.37	5.4	0.33	1.54e-7	Breast cancer;
KIRP	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.6	0.48	9.28e-16	Motion sickness;
KIRP	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.8	-9.61	-0.52	8.91e-19	Schizophrenia;
KIRP	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg26513180	chr16:89883248	FANCA	0.75	5.27	0.32	2.99e-7	Skin colour saturation;
KIRP	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg23594656	chr7:65796392	TPST1	-0.42	-6.35	-0.38	1.05e-9	Aortic root size;
KIRP	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.62	8.49	0.48	1.99e-15	Platelet count;
KIRP	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.67	9.94	0.54	8.71e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg00262122	chr8:11665843	FDFT1	0.41	5.13	0.31	5.86e-7	Neuroticism;
KIRP	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.87	10.52	0.56	1.28e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs7011049	0.778	rs6995569	chr8:53866259	C/T	cg26025543	chr8:53854495	NA	0.59	6.54	0.38	3.57e-10	Systolic blood pressure;
KIRP	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	12.07	0.61	1.16e-26	Smoking behavior;
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg24807547	chr6:37504484	NA	-0.52	-7.84	-0.45	1.38e-13	Cognitive performance;
KIRP	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.29	0.37	1.41e-9	Breast cancer;
KIRP	cis	rs2554380	0.943	rs2562777	chr15:84366066	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-9.02	-0.5	5.41e-17	Height;
KIRP	cis	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.22e-12	Morning vs. evening chronotype;
KIRP	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.58	-0.39	2.87e-10	Axial length;
KIRP	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.9	-12.67	-0.63	1.14e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.33	-0.42	3.29e-12	Mood instability;
KIRP	cis	rs6681460	0.546	rs1998716	chr1:67117106	T/A	cg13052034	chr1:66999238	SGIP1	0.43	6.18	0.37	2.68e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg24416660	chr17:73865998	NA	-0.38	-5.47	-0.33	1.1e-7	Psoriasis;
KIRP	cis	rs72634258	0.732	rs6577464	chr1:8171302	T/C	cg00042356	chr1:8021962	PARK7	-0.48	-4.85	-0.3	2.15e-6	Inflammatory bowel disease;
KIRP	cis	rs711830	0.965	rs2072590	chr2:177042633	A/C	cg13092806	chr2:177043255	NA	0.62	6.47	0.38	5.2400000000000005e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.09	-0.5	3.45e-17	Mood instability;
KIRP	cis	rs62229266	0.557	rs4817761	chr21:37395556	C/T	cg08632701	chr21:37451849	NA	-0.52	-6.27	-0.37	1.61e-9	Mitral valve prolapse;
KIRP	cis	rs741951	0.832	rs2838701	chr21:46257269	A/G	cg08823554	chr21:46269191	NA	0.6	5.52	0.33	8.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg12560992	chr17:57184187	TRIM37	0.59	5.62	0.34	5.26e-8	Cognitive test performance;
KIRP	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg08501292	chr6:25962987	TRIM38	1.11	8.49	0.48	2.01e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg23280166	chr11:118938394	VPS11	-0.59	-7.05	-0.41	1.83e-11	Coronary artery disease;
KIRP	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.96	15.0	0.69	1.44e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.42	-5.83	-0.35	1.69e-8	Blood protein levels;
KIRP	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.81	-11.61	-0.59	4.02e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.82	7.33	0.42	3.38e-12	Diisocyanate-induced asthma;
KIRP	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.69	-6.74	-0.39	1.11e-10	Breast cancer;
KIRP	cis	rs55962025	1.000	rs2285087	chr4:3088211	A/G	cg06533319	chr4:3265114	C4orf44	0.46	5.52	0.33	8.68e-8	Parental longevity (mother's age at death);
KIRP	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.1	0.41	1.32e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg01879757	chr17:41196368	BRCA1	-0.74	-10.27	-0.55	7.95e-21	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11307812	chr13:38910516	NA	-0.46	-7.07	-0.41	1.6e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.46	-4.87	-0.3	2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.53	-6.29	-0.37	1.45e-9	Body mass index (adult);
KIRP	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.37	4.98	0.3	1.22e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs2637030	0.559	rs372135	chr5:52944948	T/C	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs3112255	0.935	rs870321	chr2:101296124	A/G	cg01042948	chr2:101319752	NA	0.44	6.28	0.37	1.54e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.96	14.57	0.68	4.23e-35	Vitamin D levels;
KIRP	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg19554555	chr3:13937349	NA	-0.47	-6.35	-0.38	1.02e-9	Ovarian reserve;
KIRP	cis	rs10875746	0.551	rs2054903	chr12:48724493	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-5.13	-0.31	6.02e-7	Longevity (90 years and older);
KIRP	cis	rs4835473	0.932	rs2127788	chr4:144663149	G/C	cg08833778	chr4:144622313	FREM3	0.35	5.13	0.31	5.82e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7714584	1.000	rs11746560	chr5:150185925	T/G	cg22134413	chr5:150180641	NA	1.05	7.58	0.44	6.99e-13	Crohn's disease;
KIRP	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.49	5.87	0.35	1.44e-8	Common traits (Other);
KIRP	cis	rs62413470	0.938	rs12201286	chr6:55932935	G/T	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg05085585	chr16:30420623	ZNF771	0.35	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs6545883	0.540	rs11687956	chr2:61851342	T/C	cg15711740	chr2:61764176	XPO1	0.51	6.57	0.39	2.91e-10	Tuberculosis;
KIRP	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg08126542	chr6:37504118	NA	-0.83	-12.26	-0.62	2.78e-27	Cognitive performance;
KIRP	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg07402062	chr16:89894098	SPIRE2	0.31	6.5	0.38	4.34e-10	Vitiligo;
KIRP	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.48	-6.3	-0.37	1.34e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16738915	chr19:39390806	SIRT2;NFKBIB	0.52	6.31	0.37	1.26e-9	Parkinson's disease;
KIRP	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.86	-10.61	-0.56	6.52e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07671620	chr17:1627765	WDR81	0.55	6.79	0.4	8.19e-11	Parkinson's disease;
KIRP	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.48	-5.94	-0.35	9.6e-9	Rheumatoid arthritis;
KIRP	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	5.35	0.32	2.05e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg01879757	chr17:41196368	BRCA1	-0.8	-11.19	-0.58	9.14e-24	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19305147	chr1:232765605	NA	0.52	6.61	0.39	2.41e-10	Parkinson's disease;
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg14789911	chr21:47582049	C21orf56	-0.4	-4.98	-0.3	1.2e-6	Testicular germ cell tumor;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.5	6.09	0.36	4.22e-9	Longevity;Endometriosis;
KIRP	cis	rs35264875	0.846	rs2924534	chr11:68870516	C/G	cg23845249	chr11:68861649	NA	-0.5	-7.38	-0.43	2.4e-12	Blond vs. brown hair color;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11932961	chr4:129733571	PHF17	-0.44	-6.12	-0.36	3.66e-9	Metabolic traits;
KIRP	cis	rs4791641	0.756	rs2313286	chr17:8178328	C/G	cg06726167	chr17:8076949	TMEM107	0.43	5.22	0.32	3.74e-7	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
KIRP	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.35	-6.94	-0.4	3.42e-11	Type 2 diabetes;
KIRP	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.68	-0.34	3.86e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg01988459	chr11:68622903	NA	0.42	5.89	0.35	1.29e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.82	8.13	0.46	2.17e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg10503236	chr1:231470652	EXOC8	-0.49	-6.69	-0.39	1.46e-10	Hemoglobin concentration;
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg01763666	chr17:80159506	CCDC57	-0.36	-4.96	-0.3	1.33e-6	Life satisfaction;
KIRP	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.42	5.36	0.32	1.91e-7	Melanoma;
KIRP	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	11.64	0.6	3.05e-25	Exhaled nitric oxide output;
KIRP	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg08885076	chr2:99613938	TSGA10	0.46	7.84	0.45	1.38e-13	Chronic sinus infection;
KIRP	cis	rs7481311	0.956	rs6484314	chr11:27550199	A/G	cg18117895	chr11:27722066	BDNF	0.46	5.09	0.31	7.22e-7	Body mass index;Weight;
KIRP	cis	rs7621025	0.617	rs12637102	chr3:136211960	A/G	cg15507776	chr3:136538369	TMEM22	0.43	5.43	0.33	1.34e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.92	15.66	0.71	8.06e-39	Menarche (age at onset);
KIRP	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.96e-18	Morning vs. evening chronotype;
KIRP	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24564603	chr7:158456404	NCAPG2	-0.4	-4.87	-0.3	2e-6	Height;
KIRP	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg08283408	chr3:49949060	MON1A	0.37	5.11	0.31	6.33e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.66	9.07	0.5	3.97e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.57	-0.33	6.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.58	-8.02	-0.46	4.33e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6684514	1.000	rs12139321	chr1:156230429	A/G	cg16558208	chr1:156270281	VHLL	-0.45	-5.86	-0.35	1.51e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.81	8.55	0.48	1.31e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.94	13.05	0.64	6.14e-30	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs3821902	0.646	rs66672237	chr3:64012172	C/A	cg09006292	chr3:64049408	NA	-0.5	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	trans	rs933360	0.585	rs2074719	chr7:50823216	C/T	cg20003124	chr12:4557277	NA	0.52	6.33	0.37	1.14e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-0.59	-6.66	-0.39	1.76e-10	Initial pursuit acceleration;
KIRP	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	0.79	6.98	0.41	2.79e-11	Obesity-related traits;
KIRP	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.72	6.58	0.39	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.47	6.09	0.36	4.42e-9	Monocyte count;
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg09695851	chr17:3907499	NA	0.88	17.04	0.74	1.52e-43	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg04369109	chr6:150039330	LATS1	-0.51	-6.43	-0.38	6.6e-10	Lung cancer;
KIRP	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.96	13.86	0.66	1.09e-32	Height;
KIRP	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.59	-9.46	-0.52	2.64e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs17209837	1.000	rs45590633	chr7:87090480	C/T	cg00919237	chr7:87102261	ABCB4	-0.75	-7.28	-0.42	4.49e-12	Gallbladder cancer;
KIRP	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.4	7.82	0.45	1.53e-13	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4006360	0.575	rs436266	chr17:39313798	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.37	-5.35	-0.32	2.02e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.6	-9.53	-0.52	1.59e-18	Sense of smell;
KIRP	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	7.94	0.45	7.04e-14	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22399232	chr2:33824342	FAM98A	0.52	6.77	0.4	9.4e-11	Parkinson's disease;
KIRP	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.32	-0.32	2.39e-7	Cholesterol, total;
KIRP	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg15676125	chr6:33679581	C6orf125	0.4	5.22	0.32	3.84e-7	Plateletcrit;
KIRP	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.57	7.5	0.43	1.13e-12	Height;
KIRP	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.83	-0.45	1.46e-13	Bone mineral density;
KIRP	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg11707556	chr5:10655725	ANKRD33B	0.56	7.09	0.41	1.4e-11	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg18209359	chr17:80159595	CCDC57	-0.41	-5.4	-0.33	1.56e-7	Life satisfaction;
KIRP	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	4.86	0.3	2.1e-6	Educational attainment;
KIRP	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.72	-9.37	-0.51	5.04e-18	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs61935443	0.614	rs61935662	chr12:95313296	A/G	cg21533806	chr12:95267307	NA	0.57	5.18	0.31	4.67e-7	Schizophrenia;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg21851534	chr17:3907994	ZZEF1	0.43	5.7	0.34	3.37e-8	Type 2 diabetes;
KIRP	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.83	-9.18	-0.51	1.81e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg04166393	chr7:2884313	GNA12	0.63	7.68	0.44	3.74e-13	Height;
KIRP	cis	rs9434723	0.920	rs11801562	chr1:9293156	G/A	cg04199779	chr1:9294473	H6PD	0.63	7.27	0.42	4.9e-12	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11289296	chr17:74383131	SPHK1	0.53	6.12	0.36	3.68e-9	Interleukin-4 levels;
KIRP	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.64	-9.67	-0.52	6.06e-19	Educational attainment;
KIRP	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.88	9.09	0.5	3.45e-17	Methadone dose in opioid dependence;
KIRP	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg04554929	chr8:105342491	NA	-0.35	-5.3	-0.32	2.52e-7	Paget's disease;
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05665937	chr4:1216051	CTBP1	0.55	7.9	0.45	9.1e-14	Obesity-related traits;
KIRP	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg17757837	chr7:157058334	UBE3C	-0.82	-11.29	-0.58	4.37e-24	Body mass index;
KIRP	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg00857998	chr1:205179979	DSTYK	0.58	7.39	0.43	2.27e-12	Red blood cell count;
KIRP	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.97	-0.41	2.95e-11	Initial pursuit acceleration;
KIRP	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg02073558	chr3:44770973	ZNF501	0.73	11.56	0.59	5.82e-25	Depressive symptoms;
KIRP	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.29	0.37	1.41e-9	Breast cancer;
KIRP	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-1.16	-14.27	-0.67	4.61e-34	Type 2 diabetes nephropathy;
KIRP	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.65	-0.8	1.2e-55	Height;
KIRP	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.66	-11.37	-0.59	2.3e-24	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2671245	0.933	rs2819476	chr1:56157479	T/C	cg11523071	chr1:56160889	NA	0.41	6.71	0.39	1.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.48	-0.33	1.07e-7	Triglycerides;
KIRP	cis	rs9603616	0.650	rs6563738	chr13:40239764	G/A	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.64	9.02	0.5	5.62e-17	Menarche (age at onset);
KIRP	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17554472	chr22:41940697	POLR3H	0.73	7.47	0.43	1.42e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs5753037	0.543	rs140128	chr22:30150140	T/C	cg01021169	chr22:30184971	ASCC2	-0.53	-7.18	-0.42	8.28e-12	Type 1 diabetes;
KIRP	cis	rs4704187	0.663	rs1422697	chr5:74445817	G/A	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg04213235	chr1:145826932	GPR89A	0.66	6.08	0.36	4.45e-9	Lung function (FEV1);
KIRP	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00889227	chr1:205173544	DSTYK	-0.37	-5.23	-0.32	3.66e-7	Red blood cell count;
KIRP	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-6.37	-0.38	9.32e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs8018808	0.935	rs11159263	chr14:77930188	G/C	cg20045696	chr14:77926864	AHSA1	0.46	5.61	0.34	5.39e-8	Myeloid white cell count;
KIRP	cis	rs17608059	0.634	rs10852819	chr17:13921426	C/A	cg11395062	chr17:14139857	CDRT15	0.53	6.69	0.39	1.46e-10	Temperament;
KIRP	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg04672837	chr16:48644449	N4BP1	0.5	6.89	0.4	4.7e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.72	-0.34	3e-8	Cognitive function;
KIRP	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.34	-0.32	2.12e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7975161	0.671	rs7313063	chr12:104602208	G/A	cg25273343	chr12:104657179	TXNRD1	-0.49	-5.56	-0.33	6.87e-8	Toenail selenium levels;
KIRP	cis	rs4523957	0.671	rs9910849	chr17:2175768	A/G	cg16513277	chr17:2031491	SMG6	0.45	5.66	0.34	4.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.5	-5.84	-0.35	1.61e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.66	7.21	0.42	6.75e-12	Platelet count;
KIRP	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.59	0.39	2.7e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25732961	chr17:7755877	KDM6B	0.47	6.21	0.37	2.22e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.56	-5.44	-0.33	1.32e-7	Platelet distribution width;
KIRP	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13198984	chr17:80129470	CCDC57	0.49	7.7	0.44	3.36e-13	Life satisfaction;
KIRP	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.45	6.32	0.37	1.24e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs6681460	1.000	rs7532173	chr1:67086111	A/G	cg13052034	chr1:66999238	SGIP1	0.39	5.27	0.32	3.02e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs6810798	0.711	rs10519886	chr4:148236732	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	0.52	6.15	0.37	3.06e-9	Coronary artery disease;
KIRP	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.55	6.58	0.39	2.87e-10	Axial length;
KIRP	cis	rs12210905	1.000	rs72842200	chr6:27068036	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs73058052	0.530	rs10421333	chr19:50086080	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.52	6.22	0.37	2.1e-9	Fibrinogen levels;
KIRP	cis	rs12780845	0.931	rs1885393	chr10:17247573	A/G	cg01003015	chr10:17271136	VIM	0.46	5.04	0.31	8.88e-7	Homocysteine levels;
KIRP	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg05721485	chr17:44071124	MAPT	-0.35	-5.07	-0.31	7.68e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1982963	0.950	rs61973203	chr14:52510567	A/G	cg10843707	chr14:52510701	NID2	0.34	4.93	0.3	1.54e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.61	-0.39	2.39e-10	Mean platelet volume;
KIRP	cis	rs4851250	0.559	rs13032879	chr2:100602759	C/T	cg17356467	chr2:100759845	AFF3	0.56	5.15	0.31	5.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10267417	0.625	rs2390203	chr7:19970430	C/T	cg05791153	chr7:19748676	TWISTNB	-0.45	-4.9	-0.3	1.77e-6	Night sleep phenotypes;
KIRP	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.27	-0.32	2.95e-7	Calcium levels;
KIRP	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.55	-0.52	1.38e-18	Retinal vascular caliber;
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.66	-0.39	1.73e-10	Lung cancer;
KIRP	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.17	0.54	1.67e-20	Bladder cancer;
KIRP	cis	rs400736	0.562	rs7551900	chr1:8178526	A/C	cg25007680	chr1:8021821	PARK7	-0.39	-5.08	-0.31	7.52e-7	Response to antidepressants and depression;
KIRP	cis	rs12282928	0.837	rs7125962	chr11:48245266	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-5.76	-0.34	2.54e-8	Migraine - clinic-based;
KIRP	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg18501202	chr6:125855421	NA	-0.35	-5.42	-0.33	1.39e-7	Brugada syndrome;
KIRP	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.55	-0.39	3.38e-10	Urinary tract infection frequency;
KIRP	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs42648	0.837	rs12375075	chr7:89940331	G/A	cg25739043	chr7:89950458	NA	-0.43	-6.77	-0.4	9.32e-11	Homocysteine levels;
KIRP	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.5	6.16	0.37	2.88e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg08662619	chr6:150070041	PCMT1	0.37	6.14	0.36	3.35e-9	Lung cancer;
KIRP	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.06	0.31	8.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-7.08	-0.41	1.54e-11	Vitiligo;
KIRP	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.54	-6.65	-0.39	1.85e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.9	9.31	0.51	7.27e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg12119029	chr16:89752879	CDK10	0.24	4.99	0.3	1.15e-6	Vitiligo;
KIRP	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.64	-9.4	-0.51	3.99e-18	Brugada syndrome;
KIRP	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg13047869	chr3:10149882	C3orf24	0.54	5.24	0.32	3.48e-7	Alzheimer's disease;
KIRP	cis	rs4262150	0.810	rs72797217	chr5:151961639	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.05e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	0.82	9.43	0.52	3.21e-18	Gut microbiome composition (summer);
KIRP	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.52	5.55	0.33	7.42e-8	Morning vs. evening chronotype;
KIRP	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg26531700	chr6:26746687	NA	0.4	5.54	0.33	7.72e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg18944383	chr4:111397179	ENPEP	0.5	8.05	0.46	3.63e-14	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6430538	0.671	rs6736792	chr2:135572090	T/C	cg12500956	chr2:135428796	TMEM163	0.42	5.27	0.32	3e-7	Parkinson's disease;
KIRP	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg18306943	chr3:40428807	ENTPD3	0.46	5.87	0.35	1.4e-8	Renal cell carcinoma;
KIRP	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg24315340	chr6:146058215	EPM2A	0.44	5.44	0.33	1.3e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.69	7.04	0.41	1.88e-11	Vitiligo;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10055580	chr17:46707781	NA	0.54	7.09	0.41	1.44e-11	Interleukin-4 levels;
KIRP	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06544989	chr22:39130855	UNC84B	0.48	7.5	0.43	1.19e-12	Menopause (age at onset);
KIRP	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg07843065	chr1:150265600	MRPS21	0.44	6.22	0.37	2.14e-9	Migraine;
KIRP	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.8	11.03	0.58	2.99e-23	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26298387	chr1:160068041	IGSF8	0.53	6.26	0.37	1.73e-9	Smoking initiation;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.67	9.21	0.51	1.52e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg13206674	chr6:150067644	NUP43	0.57	8.23	0.46	1.1e-14	Lung cancer;
KIRP	trans	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.52	-7.0	-0.41	2.44e-11	Mean corpuscular volume;
KIRP	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18252515	chr7:66147081	NA	0.44	5.11	0.31	6.43e-7	Aortic root size;
KIRP	cis	rs501120	0.584	rs7100370	chr10:44698508	A/C	cg09554077	chr10:44749378	NA	0.53	5.64	0.34	4.69e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs8114671	0.647	rs6060268	chr20:33734293	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.0	0.36	6.9e-9	Height;
KIRP	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.29	-0.42	4.3e-12	Myopia (pathological);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08890084	chr1:51425800	FAF1	-0.47	-6.1	-0.36	3.99e-9	Metabolic traits;
KIRP	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.39	-0.55	3.23e-21	Alzheimer's disease (late onset);
KIRP	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs4262150	0.883	rs72804758	chr5:152259430	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.93e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.58	-7.39	-0.43	2.35e-12	Aortic root size;
KIRP	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg23301140	chr18:77439876	CTDP1	-0.44	-5.04	-0.31	8.84e-7	Monocyte count;
KIRP	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.28	25.03	0.85	1.39e-69	IgG glycosylation;
KIRP	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.97	-0.3	1.27e-6	Metabolite levels;
KIRP	cis	rs17321999	1.000	rs17321999	chr2:30479857	A/C	cg05247661	chr2:30472410	LBH	-0.72	-8.72	-0.49	4.36e-16	Systemic lupus erythematosus;
KIRP	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.8	-0.49	2.4e-16	Extrinsic epigenetic age acceleration;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10762132	chr2:113403533	SLC20A1	-0.46	-6.03	-0.36	5.95e-9	Morning vs. evening chronotype;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.51	-7.07	-0.41	1.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12480562	chr20:23434244	CST11	0.64	5.25	0.32	3.36e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg02660097	chr11:68866761	NA	0.37	5.36	0.32	1.95e-7	Blond vs. brown hair color;
KIRP	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.25	0.32	3.32e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.85	11.21	0.58	7.87e-24	Menarche (age at onset);
KIRP	cis	rs7116495	1.000	rs656640	chr11:71781710	T/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6681460	0.934	rs4655628	chr1:67052609	T/C	cg02459107	chr1:67143332	SGIP1	0.48	6.97	0.41	2.92e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7011049	0.908	rs79560601	chr8:53853614	C/T	cg26025543	chr8:53854495	NA	0.75	7.68	0.44	3.83e-13	Systolic blood pressure;
KIRP	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.38	-0.43	2.39e-12	Morning vs. evening chronotype;
KIRP	cis	rs17023223	0.537	rs2645292	chr1:119573194	C/T	cg05756136	chr1:119680316	WARS2	-0.56	-7.53	-0.43	9.6e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1829883	0.898	rs2511899	chr5:98776319	G/A	cg08333243	chr5:99726346	NA	-0.39	-5.2	-0.31	4.22e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.44	-0.33	1.31e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-8.62	-0.48	8.47e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs9329221	0.539	rs35060302	chr8:10264771	C/G	cg08975724	chr8:8085496	FLJ10661	0.55	6.87	0.4	5.21e-11	Neuroticism;
KIRP	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.62	0.34	5.1e-8	Personality dimensions;
KIRP	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.38	-7.36	-0.42	2.74e-12	Height;
KIRP	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.69	8.86	0.49	1.63e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs290268	0.605	rs12350798	chr9:93534619	A/T	cg02608019	chr9:93564028	SYK	-0.67	-8.28	-0.47	7.77e-15	Platelet count;
KIRP	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.18	-0.31	4.57e-7	Bipolar disorder;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg24874828	chr4:187887005	NA	0.48	7.04	0.41	1.88e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs7539542	0.529	rs12070941	chr1:202885628	C/T	cg19681188	chr1:202830198	LOC148709	-0.47	-5.11	-0.31	6.38e-7	Mean platelet volume;
KIRP	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg27124370	chr19:33622961	WDR88	0.61	7.43	0.43	1.75e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00857326	chr8:144920813	NRBP2	-0.39	-6.02	-0.36	6.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7178572	0.889	rs7171448	chr15:77832316	C/G	cg12131826	chr15:77904385	NA	0.43	5.82	0.35	1.85e-8	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.96	0.3	1.31e-6	Menopause (age at onset);
KIRP	cis	rs7534824	0.625	rs3087816	chr1:101441775	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.14	0.41	1.05e-11	Refractive astigmatism;
KIRP	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	1.07	21.62	0.81	8.34e-59	Height;
KIRP	cis	rs2016266	0.684	rs4759021	chr12:53714868	G/A	cg16917193	chr12:54089295	NA	-0.5	-6.05	-0.36	5.46e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs7116495	1.000	rs4945434	chr11:71759087	A/G	cg18441811	chr11:71824068	C11orf51	0.65	5.25	0.32	3.27e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.2	0.72	1.19e-40	Lymphocyte percentage of white cells;
KIRP	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.38	0.51	4.46e-18	Morning vs. evening chronotype;
KIRP	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg16111737	chr12:117408163	FBXW8	-0.53	-5.17	-0.31	4.88e-7	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs13006833	0.703	rs291427	chr2:191194059	C/T	cg21644426	chr2:191273491	MFSD6	0.46	5.68	0.34	3.75e-8	Urinary metabolites;
KIRP	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg14593290	chr7:50529359	DDC	0.8	10.01	0.54	5.36e-20	Malaria;
KIRP	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.77	9.22	0.51	1.42e-17	Migraine;Coronary artery disease;
KIRP	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg26681399	chr22:41777847	TEF	-0.5	-5.16	-0.31	5.07e-7	Vitiligo;
KIRP	cis	rs4919044	0.599	rs11187206	chr10:94659515	C/G	cg05127821	chr10:94822908	CYP26C1	-0.97	-7.69	-0.44	3.47e-13	Coronary artery disease;
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg15105011	chr4:940614	TMEM175	0.49	7.2	0.42	7.15e-12	Sjögren's syndrome;
KIRP	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.42	6.47	0.38	5.39e-10	Inflammatory bowel disease;
KIRP	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	0.92	13.36	0.65	5.45e-31	Dupuytren's disease;
KIRP	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.79	0.57	1.78e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	1.02	10.5	0.56	1.52e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6921919	0.609	rs9461455	chr6:28329731	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.38	-5.26	-0.32	3.06e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.91	-11.86	-0.6	6.01e-26	Coronary artery disease;
KIRP	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.45	5.15	0.31	5.46e-7	Schizophrenia;
KIRP	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg20387954	chr3:183756860	HTR3D	0.64	9.41	0.51	3.56e-18	Anterior chamber depth;
KIRP	cis	rs3741798	1.000	rs61922052	chr12:12497620	A/G	cg08615371	chr12:12503544	MANSC1	0.96	8.49	0.48	2.04e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	0.91	10.39	0.55	3.32e-21	Triglycerides;
KIRP	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg12756093	chr1:115239321	AMPD1	0.53	6.93	0.4	3.58e-11	Autism;
KIRP	cis	rs7601312	0.903	rs6711138	chr2:229291721	G/C	cg02542817	chr2:229291442	NA	-0.54	-8.35	-0.47	4.84e-15	Schizophrenia;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg27532560	chr4:187881888	NA	-0.77	-12.87	-0.63	2.48e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.22	0.37	2.07e-9	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs1823913	1.000	rs4853564	chr2:192123665	C/T	cg12404831	chr2:192114017	MYO1B	-0.5	-6.77	-0.4	9.57e-11	Obesity-related traits;
KIRP	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg17507749	chr15:85114479	UBE2QP1	0.89	9.93	0.53	9.33e-20	Schizophrenia;
KIRP	cis	rs7116495	1.000	rs4944232	chr11:71642258	A/G	cg11196788	chr11:71737549	NUMA1	-0.55	-4.94	-0.3	1.45e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.56	7.16	0.42	9.15e-12	Total body bone mineral density;
KIRP	trans	rs4650994	0.789	rs2811300	chr1:178590394	T/C	cg05059571	chr16:84539110	KIAA1609	0.56	7.45	0.43	1.54e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs11779988	0.545	rs10095395	chr8:17750589	T/A	cg01800426	chr8:17659068	MTUS1	-0.43	-5.09	-0.31	7.02e-7	Breast cancer;
KIRP	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9535307	0.929	rs3851162	chr13:50354150	T/G	cg04663916	chr13:50265991	EBPL	0.65	6.91	0.4	4.03e-11	Obesity-related traits;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18036763	chr22:45404910	PHF21B	0.94	6.79	0.4	8.33e-11	P wave terminal force;
KIRP	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg01631408	chr1:248437212	OR2T33	-0.59	-7.59	-0.44	6.63e-13	Common traits (Other);
KIRP	cis	rs79387448	0.564	rs77375846	chr2:103155075	T/C	cg09003973	chr2:102972529	NA	0.82	5.95	0.35	9.24e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.75	-9.54	-0.52	1.44e-18	Pancreatic cancer;
KIRP	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.58	6.38	0.38	8.69e-10	Alcohol dependence;
KIRP	cis	rs2579519	0.547	rs2463560	chr2:96595589	T/C	cg23100626	chr2:96804247	ASTL	0.45	6.67	0.39	1.67e-10	Diastolic blood pressure;
KIRP	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.53	7.03	0.41	2.02e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs867371	1.000	rs8041924	chr15:82473661	A/T	cg00614314	chr15:82944287	LOC80154	0.54	6.46	0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.49	-6.42	-0.38	6.97e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs9409565	0.513	rs16912862	chr9:97050005	A/G	cg05679027	chr9:99775184	HIATL2	-0.52	-6.29	-0.37	1.41e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.61	-10.02	-0.54	4.93e-20	Sense of smell;
KIRP	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg06636001	chr8:8085503	FLJ10661	0.75	10.56	0.56	9.82e-22	Mood instability;
KIRP	cis	rs17407555	0.683	rs6833142	chr4:10275982	A/G	cg11266682	chr4:10021025	SLC2A9	0.33	5.16	0.31	4.97e-7	Schizophrenia (age at onset);
KIRP	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs10203711	0.933	rs7584327	chr2:239584203	A/T	cg14580085	chr2:239553406	NA	0.4	5.13	0.31	5.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2769264	0.649	rs9436029	chr1:151367378	C/T	cg18801370	chr1:151430492	POGZ	-0.86	-7.04	-0.41	1.93e-11	Blood trace element (Cu levels);
KIRP	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	trans	rs587242	1.000	rs4341405	chr1:96902589	A/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs496547	0.721	rs2508570	chr11:118678609	A/G	cg19308663	chr11:118741387	NA	-0.28	-5.12	-0.31	6.19e-7	Hip minimal joint space width;
KIRP	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg02297831	chr4:17616191	MED28	0.55	6.89	0.4	4.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1595825	0.735	rs57603546	chr2:198918524	C/A	cg11031976	chr2:198649780	BOLL	-0.53	-5.08	-0.31	7.56e-7	Ulcerative colitis;
KIRP	cis	rs6997458	0.785	rs931505	chr8:86348243	A/G	cg02393479	chr8:86352350	CA3	-0.32	-4.96	-0.3	1.32e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.37	-0.32	1.79e-7	Schizophrenia;
KIRP	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg23845249	chr11:68861649	NA	0.34	5.07	0.31	7.66e-7	Blond vs. brown hair color;
KIRP	cis	rs6466055	0.661	rs17640472	chr7:104813097	T/C	cg04380332	chr7:105027541	SRPK2	0.36	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg21926883	chr2:100939477	LONRF2	-0.55	-7.44	-0.43	1.66e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg17507749	chr15:85114479	UBE2QP1	0.87	9.92	0.53	1e-19	Schizophrenia;
KIRP	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg00677455	chr12:58241039	CTDSP2	-0.6	-7.1	-0.41	1.31e-11	Multiple sclerosis;
KIRP	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.24	0.37	1.87e-9	Tonsillectomy;
KIRP	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.73	5.87	0.35	1.41e-8	Diabetic retinopathy;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18757267	chr1:164704545	PBX1	-0.39	-6.15	-0.37	3.07e-9	Inflammatory biomarkers;
KIRP	cis	rs1635	0.655	rs16893975	chr6:28302278	C/T	cg15743358	chr6:28303923	ZNF323	0.84	6.17	0.37	2.76e-9	Schizophrenia;
KIRP	cis	rs7178909	0.872	rs7174330	chr15:90434579	C/T	cg19708238	chr15:90437601	AP3S2	-0.54	-7.6	-0.44	6.27e-13	Common traits (Other);
KIRP	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	6.68	0.39	1.62e-10	Rheumatoid arthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20286094	chr1:99190917	SNX7	-0.41	-6.22	-0.37	2.12e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2019216	0.500	rs2880292	chr17:21869537	A/G	cg22648282	chr17:21454238	C17orf51	-0.53	-6.23	-0.37	2.03e-9	Pelvic organ prolapse;
KIRP	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.36e-13	Height;
KIRP	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.59	-7.01	-0.41	2.27e-11	Initial pursuit acceleration;
KIRP	cis	rs4740619	0.619	rs10738426	chr9:16041615	T/C	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs2625529	0.730	rs2957737	chr15:72265410	A/G	cg16672083	chr15:72433130	SENP8	0.45	6.18	0.37	2.68e-9	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17654217	chr7:100282651	GIGYF1	-0.48	-6.4	-0.38	8.01e-10	Parkinson's disease;
KIRP	trans	rs13191038	1	rs13191038	chr6:28482917	T/C	cg01620082	chr3:125678407	NA	-1.24	-7.57	-0.43	7.7e-13	Urinary tract infection frequency;
KIRP	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.52	5.7	0.34	3.45e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.69	10.21	0.55	1.22e-20	Dupuytren's disease;
KIRP	cis	rs72730918	0.502	rs12904583	chr15:51797253	C/T	cg14296394	chr15:51910925	DMXL2	0.82	11.15	0.58	1.23e-23	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-1.02	-17.32	-0.74	1.81e-44	Height;
KIRP	cis	rs4974559	0.739	rs3817604	chr4:1291337	C/T	cg02980000	chr4:1222292	CTBP1	0.99	8.0	0.45	4.87e-14	Systolic blood pressure;
KIRP	trans	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg24644049	chr4:85504048	CDS1	1.02	6.8	0.4	7.99e-11	Skin colour saturation;
KIRP	cis	rs2395528	0.597	rs7911504	chr10:80116204	A/C	cg08356028	chr10:80217969	NA	0.4	5.89	0.35	1.26e-8	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26872138	chr3:154797892	MME	0.42	6.06	0.36	5.13e-9	Parkinson's disease;
KIRP	cis	rs71403859	0.730	rs12923781	chr16:71653464	G/A	cg08717414	chr16:71523259	ZNF19	-1.1	-9.69	-0.53	5.07e-19	Post bronchodilator FEV1;
KIRP	cis	rs13401104	0.754	rs11902623	chr2:237117624	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.2	-0.37	2.39e-9	QT interval;
KIRP	cis	rs4851250	0.518	rs34490534	chr2:100616060	T/G	cg17356467	chr2:100759845	AFF3	0.54	4.99	0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	1.02	17.03	0.74	1.66e-43	Bone mineral density;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03124478	chr11:67169560	PPP1CA	-0.5	-6.62	-0.39	2.3e-10	Myopia;
KIRP	cis	rs963731	0.649	rs1454221	chr2:39215672	C/T	cg04010122	chr2:39346883	SOS1	-0.85	-5.85	-0.35	1.57e-8	Corticobasal degeneration;
KIRP	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg17554472	chr22:41940697	POLR3H	0.66	6.85	0.4	5.93e-11	Vitiligo;
KIRP	trans	rs13019227	0.658	rs10195547	chr2:137796450	C/G	cg12599275	chr1:3011274	PRDM16	0.74	6.15	0.37	3.04e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.95e-8	Endometrial cancer;
KIRP	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg20243544	chr17:37824526	PNMT	0.53	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs785830	0.744	rs471756	chr9:239313	G/C	cg14500300	chr9:211689	NA	0.53	7.18	0.42	8.19e-12	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12957096	chr22:41777779	TEF	0.47	6.12	0.36	3.69e-9	Parkinson's disease;
KIRP	cis	rs12913538	1.000	rs4569205	chr15:62894319	A/G	cg09983546	chr15:62884068	NA	0.58	8.29	0.47	7.3e-15	Sleep depth;
KIRP	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.57	7.81	0.45	1.68e-13	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.75	11.17	0.58	1.07e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs494562	0.730	rs9450269	chr6:86114684	C/G	cg21730993	chr6:86159210	NT5E	-0.54	-5.1	-0.31	6.95e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs10982256	0.711	rs10817635	chr9:117288169	A/C	cg13636371	chr9:117264095	DFNB31	-0.55	-7.46	-0.43	1.52e-12	Bipolar disorder;
KIRP	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.25	0.37	1.77e-9	Menopause (age at onset);
KIRP	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg18209359	chr17:80159595	CCDC57	0.36	4.86	0.3	2.07e-6	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6504340	0.739	rs66459980	chr17:46672716	C/T	cg04904318	chr17:46607828	HOXB1	-0.54	-5.53	-0.33	8.11e-8	Primary tooth development (number of teeth);
KIRP	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg05043794	chr9:111880884	C9orf5	-0.24	-4.96	-0.3	1.29e-6	Menarche (age at onset);
KIRP	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00864171	chr11:67383662	NA	-0.42	-5.64	-0.34	4.64e-8	Mean corpuscular volume;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	8.89e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	1.04	16.05	0.72	3.91e-40	Homoarginine levels;
KIRP	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg23978390	chr7:1156363	C7orf50	0.49	5.03	0.31	9.34e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs953387	0.744	rs115224560	chr2:136896041	T/A	cg05194412	chr2:137003533	NA	-0.4	-5.19	-0.31	4.41e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.47	5.42	0.33	1.41e-7	Schizophrenia;
KIRP	cis	rs8033133	0.560	rs12441340	chr15:25323964	G/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.5	-6.26	-0.37	1.73e-9	Blood osmolality (transformed sodium);
KIRP	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg04226714	chr8:49833948	SNAI2	-0.53	-7.16	-0.42	9.5e-12	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19657380	chr8:135724771	ZFAT	0.49	6.39	0.38	8.43e-10	Parkinson's disease;
KIRP	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg08499158	chr17:42289980	UBTF	-0.63	-7.81	-0.45	1.66e-13	Total body bone mineral density;
KIRP	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.27	-0.47	8.38e-15	Triglycerides;
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg13206674	chr6:150067644	NUP43	0.59	8.51	0.48	1.74e-15	Lung cancer;
KIRP	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg26248373	chr2:1572462	NA	-0.65	-7.88	-0.45	1.08e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg00080972	chr5:178986291	RUFY1	0.36	5.41	0.33	1.49e-7	Lung cancer;
KIRP	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg26338869	chr17:61819248	STRADA	0.54	6.41	0.38	7.37e-10	Prudent dietary pattern;
KIRP	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	10.26	0.55	8.55e-21	Exhaled nitric oxide output;
KIRP	cis	rs10121009	0.591	rs10814221	chr9:35291473	T/C	cg15271616	chr9:35490515	RUSC2	0.38	4.85	0.3	2.19e-6	Parkinson's disease;
KIRP	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg10018233	chr7:150070692	REPIN1	0.73	9.4	0.51	4.07e-18	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg06521331	chr12:34319734	NA	-0.45	-5.41	-0.33	1.52e-7	Morning vs. evening chronotype;
KIRP	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg20368463	chr18:77673604	PQLC1	-0.48	-4.97	-0.3	1.28e-6	Opioid sensitivity;
KIRP	cis	rs4713675	0.546	rs10947434	chr6:33691501	G/T	cg15676125	chr6:33679581	C6orf125	0.4	5.22	0.32	3.88e-7	Plateletcrit;
KIRP	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.76	8.97	0.5	7.59e-17	Corneal astigmatism;
KIRP	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.6	9.45	0.52	2.81e-18	Personality dimensions;
KIRP	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg03808351	chr9:123631620	PHF19	0.41	5.58	0.34	6.33e-8	Rheumatoid arthritis;
KIRP	cis	rs74181299	0.591	rs10205598	chr2:65379251	A/T	cg05010058	chr2:65284262	CEP68	-0.46	-6.19	-0.37	2.52e-9	Pulse pressure;
KIRP	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.52	5.68	0.34	3.88e-8	Lung cancer;
KIRP	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg25036284	chr2:26402008	FAM59B	-0.53	-5.51	-0.33	9.02e-8	Gut microbiome composition (summer);
KIRP	cis	rs1364705	0.955	rs12677274	chr8:120222541	C/T	cg09273054	chr8:120220131	MAL2	-0.51	-6.04	-0.36	5.64e-9	Hippocampal atrophy;
KIRP	cis	rs4979906	1.000	rs2395494	chr10:79458340	C/T	cg07817648	chr10:79422355	NA	-0.43	-5.1	-0.31	6.85e-7	Mortality in heart failure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17346426	chr2:216946392	TMEM169;PECR	0.47	6.27	0.37	1.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7011049	0.778	rs79555929	chr8:53866655	C/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.29e-10	Systolic blood pressure;
KIRP	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg15534755	chr11:117069859	TAGLN	0.41	4.94	0.3	1.43e-6	Blood protein levels;
KIRP	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg03929089	chr4:120376271	NA	0.97	6.95	0.41	3.17e-11	Myopia (pathological);
KIRP	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	0.88	7.66	0.44	4.32e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg07843065	chr1:150265600	MRPS21	-0.47	-6.66	-0.39	1.82e-10	Migraine;
KIRP	cis	rs514024	0.765	rs497632	chr9:130475442	A/C	cg13643465	chr9:130375613	STXBP1	0.4	5.37	0.32	1.79e-7	Eating disorders (purging via substances);
KIRP	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg23625390	chr15:77176239	SCAPER	0.52	6.81	0.4	7.6e-11	Blood metabolite levels;
KIRP	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg23594656	chr7:65796392	TPST1	0.52	8.03	0.46	4.12e-14	Aortic root size;
KIRP	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	8.56	0.48	1.24e-15	Response to antipsychotic treatment;
KIRP	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg16141378	chr3:129829833	LOC729375	0.57	6.95	0.41	3.28e-11	Systemic lupus erythematosus;
KIRP	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-7.62	-0.44	5.59e-13	Tonsillectomy;
KIRP	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg23682824	chr7:23144976	KLHL7	-0.5	-6.09	-0.36	4.4e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg00383909	chr3:49044727	WDR6	0.44	4.92	0.3	1.58e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg04398451	chr17:18023971	MYO15A	0.7	9.33	0.51	6.26e-18	Total body bone mineral density;
KIRP	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.91e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03672602	chr19:19754555	GMIP	0.67	6.36	0.38	9.85e-10	Lung function (FEV1);
KIRP	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg10434728	chr15:90938212	IQGAP1	0.42	7.39	0.43	2.35e-12	Rheumatoid arthritis;
KIRP	cis	rs6783573	0.895	rs1049667	chr3:46623690	C/A	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.39	-5.01	-0.3	1.02e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs798766	1.000	rs11732213	chr4:1704244	T/C	cg07775547	chr4:1625484	NA	0.46	5.1	0.31	6.79e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.8	9.39	0.51	4.38e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.14	-0.41	1.05e-11	Migraine;Coronary artery disease;
KIRP	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.33	12.23	0.61	3.44e-27	Diabetic retinopathy;
KIRP	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.9	-14.13	-0.67	1.34e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg00647317	chr7:50633725	DDC	-0.38	-5.0	-0.3	1.08e-6	Malaria;
KIRP	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.72	9.64	0.52	7.5e-19	Neuroticism;
KIRP	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg19743168	chr1:23544995	NA	0.49	6.57	0.39	2.9e-10	Height;
KIRP	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs3736485	0.966	rs12102203	chr15:51791559	A/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.37	-0.32	1.85e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.62	-8.21	-0.46	1.23e-14	Motion sickness;
KIRP	cis	rs1209950	1.000	rs1209950	chr21:40173528	A/G	cg01359822	chr21:40176597	ETS2	-0.35	-5.9	-0.35	1.21e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg14972814	chr11:95582409	MTMR2	0.35	5.89	0.35	1.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg15704280	chr7:45808275	SEPT13	-0.51	-6.19	-0.37	2.48e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.66	9.64	0.52	7.41e-19	Schizophrenia;
KIRP	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.34	-0.32	2.1e-7	Metabolite levels;
KIRP	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg13628971	chr7:2884303	GNA12	0.44	5.74	0.34	2.77e-8	Height;
KIRP	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs631288	0.655	rs2120004	chr1:146690562	A/T	cg25205988	chr1:146714368	CHD1L	1.0	5.47	0.33	1.09e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg23034840	chr1:205782522	SLC41A1	0.56	7.39	0.43	2.31e-12	Menarche (age at onset);
KIRP	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg18404041	chr3:52824283	ITIH1	-0.47	-5.46	-0.33	1.18e-7	Schizophrenia;
KIRP	cis	rs7147624	1.000	rs8021889	chr14:66214811	A/G	cg03016385	chr14:66212404	NA	-0.94	-9.88	-0.53	1.37e-19	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg12741994	chr3:170137321	CLDN11	-0.44	-5.0	-0.3	1.07e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg18944383	chr4:111397179	ENPEP	-0.42	-7.0	-0.41	2.5e-11	Coronary artery disease;
KIRP	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.68	10.02	0.54	5.03e-20	Dupuytren's disease;
KIRP	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.53	-7.94	-0.45	7.17e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.04	0.31	8.95e-7	Menopause (age at onset);
KIRP	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg03714773	chr7:91764589	CYP51A1	0.33	4.92	0.3	1.6e-6	Breast cancer;
KIRP	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.77	11.15	0.58	1.19e-23	Morning vs. evening chronotype;
KIRP	cis	rs4141404	0.706	rs5753698	chr22:31970054	A/C	cg02404636	chr22:31891804	SFI1	0.56	6.34	0.37	1.1e-9	Paclitaxel-induced neuropathy;
KIRP	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg06636001	chr8:8085503	FLJ10661	0.67	8.52	0.48	1.66e-15	Neuroticism;
KIRP	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.62	7.55	0.43	8.29e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01843018	chr9:123813144	C5	-0.47	-6.81	-0.4	7.63e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg01338084	chr22:32026380	PISD	0.76	5.54	0.33	7.78e-8	Age-related hearing impairment;
KIRP	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	1.03	12.77	0.63	5.53e-29	White matter hyperintensity burden;
KIRP	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg03714773	chr7:91764589	CYP51A1	0.43	6.47	0.38	5.38e-10	Breast cancer;
KIRP	cis	rs6546324	0.625	rs1430790	chr2:67864912	G/T	cg15745817	chr2:67799979	NA	0.61	6.87	0.4	5.36e-11	Endometriosis;
KIRP	cis	rs7998202	0.667	rs282583	chr13:113349642	G/T	cg02820901	chr13:113351484	ATP11A	0.6	5.65	0.34	4.39e-8	Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs73058052	1.000	rs3760707	chr19:50084454	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.64	7.18	0.42	8.12e-12	Fibrinogen levels;
KIRP	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg13606994	chr1:44402422	ARTN	-0.25	-4.92	-0.3	1.55e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs526231	0.543	rs246906	chr5:102566471	A/G	cg23492399	chr5:102201601	PAM	-0.48	-5.1	-0.31	6.8e-7	Primary biliary cholangitis;
KIRP	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg27490568	chr2:178487706	NA	0.45	5.84	0.35	1.62e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.49	-7.99	-0.45	5.29e-14	Height;
KIRP	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs10782582	0.706	rs964024	chr1:76365637	A/C	cg10523679	chr1:76189770	ACADM	-0.35	-5.15	-0.31	5.4e-7	Daytime sleep phenotypes;
KIRP	cis	rs2970992	0.764	rs4850948	chr2:101324333	C/T	cg01042948	chr2:101319752	NA	-0.49	-7.18	-0.42	8.1e-12	Educational attainment;
KIRP	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.48	-5.85	-0.35	1.58e-8	Iron status biomarkers;
KIRP	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	1.15	12.37	0.62	1.19e-27	Post bronchodilator FEV1;
KIRP	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg04607699	chr11:48328132	OR4S1	-0.4	-5.64	-0.34	4.67e-8	Migraine - clinic-based;
KIRP	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.03	0.41	2.08e-11	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4302748	0.862	rs61003864	chr7:36189798	T/C	cg24442661	chr7:36192818	EEPD1	0.62	6.83	0.4	6.5500000000000006e-11	Platelet count;
KIRP	cis	rs9309473	1.000	rs6546836	chr2:73677833	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.09	-0.31	7.09e-7	Metabolite levels;
KIRP	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg05315796	chr3:52349193	DNAH1	0.4	5.24	0.32	3.51e-7	Schizophrenia;
KIRP	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.14	-0.41	1.05e-11	Migraine;Coronary artery disease;
KIRP	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.59	-9.36	-0.51	5.19e-18	Total body bone mineral density;
KIRP	cis	rs17655565	0.581	rs74672767	chr12:52764049	C/A	cg07925835	chr12:52762777	KRT85	0.48	5.23	0.32	3.55e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.23	13.57	0.65	1.1e-31	Uric acid levels;
KIRP	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg06042504	chr8:55087323	NA	-0.53	-6.5	-0.38	4.46e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.62	-6.93	-0.4	3.68e-11	Initial pursuit acceleration;
KIRP	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.71	-7.46	-0.43	1.45e-12	DNA methylation (variation);
KIRP	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.55	-6.18	-0.37	2.7e-9	Menarche (age at onset);
KIRP	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg06307176	chr5:131281290	NA	-0.56	-6.19	-0.37	2.51e-9	Life satisfaction;
KIRP	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.93	14.04	0.67	2.8e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2150410	0.915	rs13051430	chr21:40574030	T/C	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs848512	0.562	rs918052	chr2:36720386	G/A	cg09467607	chr2:36825704	FEZ2	0.36	5.04	0.31	8.85e-7	IgE levels in asthmatics;
KIRP	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.59	-7.83	-0.45	1.45e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg01879757	chr17:41196368	BRCA1	-0.57	-7.38	-0.43	2.36e-12	Menopause (age at onset);
KIRP	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.29	0.32	2.71e-7	Melanoma;
KIRP	cis	rs4789452	0.967	rs12451315	chr17:75372126	C/G	cg02320862	chr17:75370284	SEPT9	-0.35	-5.14	-0.31	5.66e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.61	-7.34	-0.42	3.02e-12	Neuroticism;
KIRP	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg22974920	chr21:40686053	BRWD1	0.51	6.12	0.36	3.58e-9	Cognitive function;
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.64	-10.14	-0.54	2e-20	Paraoxonase activity;
KIRP	trans	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.21	-0.42	6.96e-12	Bladder cancer;
KIRP	cis	rs4389656	0.775	rs274668	chr5:6711630	C/T	cg10857441	chr5:6722123	POLS	-0.44	-6.08	-0.36	4.56e-9	Coronary artery disease;
KIRP	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.74	10.58	0.56	8.29e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-0.67	-5.53	-0.33	8.22e-8	Pediatric areal bone mineral density (radius);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22322375	chr11:11978034	USP47	-0.44	-6.99	-0.41	2.64e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg04362960	chr10:104952993	NT5C2	0.53	5.99	0.36	7.43e-9	Waist circumference;Hip circumference;
KIRP	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg22676075	chr6:135203613	NA	0.49	6.95	0.41	3.3e-11	Red blood cell count;
KIRP	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.59	0.39	2.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	4.88	0.3	1.93e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.41	-6.36	-0.38	9.71e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg16235748	chr6:149772707	ZC3H12D	0.31	5.15	0.31	5.33e-7	Dupuytren's disease;
KIRP	trans	rs61931739	0.613	rs61927732	chr12:33678166	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.13	-0.36	3.45e-9	Morning vs. evening chronotype;
KIRP	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.74	-0.39	1.11e-10	Bipolar disorder;
KIRP	cis	rs13315871	1.000	rs71311870	chr3:58399283	T/C	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.48	-6.37	-0.38	9.41e-10	Multiple sclerosis;
KIRP	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.32	0.37	1.23e-9	Height;
KIRP	cis	rs3857067	1.000	rs1509943	chr4:95013366	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.55	7.46	0.43	1.53e-12	Blood metabolite levels;
KIRP	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7524258	0.517	rs6577430	chr1:7324468	C/T	cg07173049	chr1:7289937	CAMTA1	0.45	6.44	0.38	6.16e-10	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08439880	chr3:133502540	NA	-0.42	-5.1	-0.31	6.95e-7	Iron status biomarkers;
KIRP	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-7.08	-0.41	1.54e-11	Monocyte percentage of white cells;
KIRP	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	1.0	15.29	0.7	1.47e-37	Sudden cardiac arrest;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg21734707	chr17:3908241	ZZEF1	0.68	10.35	0.55	4.53e-21	Type 2 diabetes;
KIRP	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.02	17.39	0.74	9.99e-45	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.69e-59	Prudent dietary pattern;
KIRP	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.6	-6.61	-0.39	2.41e-10	Pancreatic cancer;
KIRP	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Colorectal cancer;
KIRP	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	1.11	7.89	0.45	9.87e-14	Skin colour saturation;
KIRP	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.74	-12.83	-0.63	3.32e-29	Obesity-related traits;
KIRP	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.69	9.92	0.53	9.76e-20	Prostate cancer;
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg23693289	chr8:27183097	PTK2B	0.56	7.13	0.41	1.1e-11	Neuroticism;
KIRP	cis	rs687432	0.812	rs7118004	chr11:57861667	A/C	cg19752551	chr11:57585705	CTNND1	-0.68	-8.67	-0.48	5.74e-16	Parkinson's disease;
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.6	8.37	0.47	4.28e-15	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01498883	chr20:2451474	SNRPB	0.52	6.73	0.39	1.17e-10	Parkinson's disease;
KIRP	trans	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.5	0.43	1.16e-12	Diabetic kidney disease;
KIRP	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg02569458	chr12:86230093	RASSF9	-0.43	-6.39	-0.38	8.06e-10	Major depressive disorder;
KIRP	cis	rs2033908	0.589	rs4757060	chr11:12842990	G/A	cg25843174	chr11:12811716	TEAD1	-0.28	-5.22	-0.32	3.9e-7	Sitting height ratio;
KIRP	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.55	-7.2	-0.42	7.4e-12	Urate levels in overweight individuals;
KIRP	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.38	-4.89	-0.3	1.83e-6	Crohn's disease;
KIRP	cis	rs986417	0.748	rs4141684	chr14:61069351	C/T	cg27398547	chr14:60952738	C14orf39	0.57	5.43	0.33	1.35e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs11621710	0.557	rs799474	chr14:35516099	C/G	cg16230307	chr14:35515116	FAM177A1	0.45	5.24	0.32	3.53e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs728616	0.681	rs12412762	chr10:81907470	A/G	cg27417294	chr10:81904244	PLAC9	-0.58	-5.14	-0.31	5.65e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4664293	0.836	rs13403371	chr2:160593114	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.77	-9.77	-0.53	2.85e-19	Facial morphology (factor 19);
KIRP	cis	rs4908768	0.822	rs12122737	chr1:8616404	C/A	cg03610117	chr1:8450231	RERE	-0.49	-5.82	-0.35	1.85e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6684514	1.000	rs11264464	chr1:156250887	T/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.68	-9.2	-0.51	1.56e-17	Huntington's disease progression;
KIRP	cis	rs10992471	0.528	rs10429459	chr9:95258119	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.42	4.95	0.3	1.4e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs11671005	0.610	rs8103813	chr19:59072684	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.57	-6.67	-0.39	1.7e-10	Mean platelet volume;
KIRP	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.61	8.6	0.48	9.67e-16	Schizophrenia;
KIRP	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.5	6.5	0.38	4.51e-10	HDL cholesterol levels;
KIRP	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.5	-4.96	-0.3	1.3e-6	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11739721	chr1:65532755	NA	0.48	6.48	0.38	4.83e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08109568	chr15:31115862	NA	-0.77	-9.31	-0.51	7.18e-18	Huntington's disease progression;
KIRP	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	10.72	0.56	3.08e-22	Psoriasis;
KIRP	cis	rs2119480	0.793	rs7317796	chr13:111313674	C/T	cg21368354	chr13:111267856	CARKD	-0.41	-4.92	-0.3	1.6e-6	Diastolic blood pressure;
KIRP	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	8.12	0.46	2.2e-14	Joint mobility (Beighton score);
KIRP	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.56	6.87	0.4	5.22e-11	Iron status biomarkers;
KIRP	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.31e-11	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15106226	chr19:11878036	ZNF441	0.53	6.49	0.38	4.73e-10	Parkinson's disease;
KIRP	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.72	-9.32	-0.51	6.86e-18	Body mass index;
KIRP	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg00646381	chr17:77835854	NA	0.53	7.86	0.45	1.19e-13	Glucocorticoid-induced osteonecrosis (age 10 years and older);
KIRP	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.53	0.38	3.65e-10	Lung cancer;
KIRP	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.8	10.28	0.55	7.37e-21	Platelet count;
KIRP	cis	rs17034641	0.744	rs2053797	chr2:46370892	C/T	cg12428440	chr2:46370979	PRKCE	0.44	5.02	0.3	1e-6	Hemoglobin;Hematocrit;
KIRP	cis	rs4930561	0.714	rs7950451	chr11:67962406	C/A	cg16338278	chr11:67432957	ALDH3B2	0.38	4.88	0.3	1.89e-6	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg14221460	chr8:27183342	PTK2B	0.53	6.88	0.4	4.86e-11	Neuroticism;
KIRP	cis	rs73086581	0.787	rs67633417	chr20:3868257	C/G	cg02187196	chr20:3869020	PANK2	0.58	5.36	0.32	1.94e-7	Response to antidepressants in depression;
KIRP	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg04727924	chr7:799746	HEATR2	0.61	5.74	0.34	2.77e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6137287	0.668	rs6082331	chr20:21108350	A/G	cg04219410	chr20:21106687	PLK1S1	0.42	5.09	0.31	7.18e-7	Height;
KIRP	cis	rs17407555	0.738	rs10516198	chr4:10059448	T/C	cg11266682	chr4:10021025	SLC2A9	-0.4	-4.89	-0.3	1.84e-6	Schizophrenia (age at onset);
KIRP	cis	rs2625529	0.818	rs16956241	chr15:72111688	G/T	cg16672083	chr15:72433130	SENP8	-0.51	-6.27	-0.37	1.57e-9	Red blood cell count;
KIRP	cis	rs12476592	0.602	rs4671068	chr2:63798333	C/T	cg17519650	chr2:63277830	OTX1	-0.42	-4.87	-0.3	2.02e-6	Childhood ear infection;
KIRP	cis	rs41005	1.000	rs35398717	chr2:8115041	A/T	cg03155496	chr2:8117019	LOC339788	-0.59	-9.65	-0.52	6.95e-19	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg22117172	chr7:91764530	CYP51A1	0.49	7.02	0.41	2.13e-11	Breast cancer;
KIRP	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.43	-4.87	-0.3	1.96e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2790457	0.874	rs1265840	chr10:28919641	C/T	cg05705492	chr10:28955341	NA	-0.52	-8.03	-0.46	4.01e-14	Multiple myeloma;
KIRP	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.81	0.35	1.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07439679	chr10:70137262	RUFY2	0.42	6.35	0.38	1.02e-9	Interleukin-4 levels;
KIRP	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.66	6.14	0.36	3.2e-9	Plateletcrit;
KIRP	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-6.75	-0.4	1.07e-10	Menarche (age at onset);
KIRP	trans	rs7230711	1.000	rs11663585	chr18:48687098	G/A	cg09299053	chr7:57509762	ZNF716	-0.79	-6.08	-0.36	4.55e-9	Immune response to anthrax vaccine;
KIRP	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg14972814	chr11:95582409	MTMR2	0.34	5.71	0.34	3.24e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4716602	0.572	rs10271030	chr7:156159796	T/C	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	trans	rs921874	0.585	rs2513239	chr11:86782728	T/G	cg22937172	chr2:240168862	HDAC4	0.51	6.59	0.39	2.72e-10	Total body bone mineral density;
KIRP	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.62	9.18	0.51	1.87e-17	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg02782426	chr3:40428986	ENTPD3	-0.33	-5.04	-0.31	9.01e-7	Renal cell carcinoma;
KIRP	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26002218	chr14:103986227	CKB	-0.3	-6.14	-0.36	3.23e-9	Bone mineral density;
KIRP	cis	rs220519	0.895	rs220525	chr20:37277618	A/G	cg24308336	chr20:37270989	C20orf95	0.23	5.01	0.3	1.06e-6	Schizophrenia;
KIRP	cis	rs4774899	0.934	rs12904561	chr15:57510974	G/A	cg13626582	chr15:57592083	LOC283663	-0.21	-5.06	-0.31	8.31e-7	Urinary tract infection frequency;
KIRP	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg24130564	chr14:104152367	KLC1	0.41	5.12	0.31	6.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.8	0.49	2.47e-16	Motion sickness;
KIRP	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.04	-0.46	3.83e-14	Fibrinogen levels;
KIRP	cis	rs4656940	0.574	rs527253	chr1:160785991	C/G	cg17331569	chr1:160788135	LY9	0.41	4.94	0.3	1.43e-6	Crohn's disease;
KIRP	cis	rs7635838	0.785	rs9837162	chr3:11548202	C/T	cg00170343	chr3:11313890	ATG7	0.44	5.53	0.33	8.04e-8	HDL cholesterol;
KIRP	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.9	10.73	0.56	2.83e-22	Response to antineoplastic agents;
KIRP	cis	rs7536201	1.000	rs7550635	chr1:25299637	C/G	cg23273869	chr1:25296894	NA	-0.4	-5.71	-0.34	3.32e-8	Psoriasis vulgaris;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.39	5.12	0.31	6.3e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg09667013	chr22:42394590	WBP2NL	0.36	4.86	0.3	2.11e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.75	10.6	0.56	7.09e-22	Parkinson's disease;
KIRP	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg16989719	chr2:238392110	NA	-0.64	-6.07	-0.36	4.76e-9	Prostate cancer;
KIRP	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg14092571	chr14:90743983	NA	-0.4	-5.37	-0.32	1.81e-7	Mortality in heart failure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23260799	chr11:451101	PTDSS2	0.69	8.45	0.47	2.53e-15	Smoking initiation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05384413	chr15:101142580	LINS1;ASB7	0.5	6.76	0.4	1.01e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.73	-9.16	-0.5	2.04e-17	Urate levels in obese individuals;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg09730017	chr11:118955708	HMBS	0.51	6.48	0.38	4.86e-10	Beard thickness;
KIRP	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg19507638	chr5:93509721	C5orf36	-0.58	-5.05	-0.31	8.67e-7	Diabetic retinopathy;
KIRP	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.6	7.3	0.42	3.94e-12	Initial pursuit acceleration;
KIRP	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg09990169	chr2:241835740	C2orf54	-0.38	-5.85	-0.35	1.58e-8	Urinary metabolites;
KIRP	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg13319975	chr6:146136371	FBXO30	-0.43	-5.98	-0.36	7.76e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.74	9.89	0.53	1.2e-19	Breast cancer;
KIRP	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg06565975	chr8:143823917	SLURP1	0.46	7.16	0.42	9.56e-12	Urinary tract infection frequency;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10624784	chr7:77427913	PHTF2;TMEM60	0.46	6.74	0.39	1.12e-10	Survival in pancreatic cancer;
KIRP	cis	rs394563	0.619	rs4895787	chr6:149646500	G/A	cg03678062	chr6:149772716	ZC3H12D	0.31	4.94	0.3	1.43e-6	Dupuytren's disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22138219	chr8:117355748	NA	-0.44	-6.07	-0.36	4.89e-9	Inflammatory biomarkers;
KIRP	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg25486957	chr4:152246857	NA	-0.52	-5.73	-0.34	2.89e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs9815354	1.000	rs1717033	chr3:41910216	C/T	cg03022575	chr3:42003672	ULK4	0.51	5.87	0.35	1.37e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.41	-0.38	7.37e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2120243	0.539	rs2047649	chr3:157085605	G/C	cg24825693	chr3:157122686	VEPH1	-0.56	-8.46	-0.47	2.42e-15	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.64e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg03128060	chr6:142623767	GPR126	0.36	5.26	0.32	3.16e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs2224391	0.590	rs2773298	chr6:5242067	C/T	cg13962347	chr6:5174647	LYRM4	-0.77	-10.9	-0.57	7.6e-23	Height;
KIRP	cis	rs4889855	0.505	rs6565467	chr17:78610113	A/G	cg09596252	chr17:78655493	RPTOR	0.48	5.69	0.34	3.67e-8	Fractional excretion of uric acid;
KIRP	trans	rs9650657	0.525	rs7819602	chr8:10726842	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.59	-0.39	2.72e-10	Neuroticism;
KIRP	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	9.78	0.53	2.77e-19	Coffee consumption (cups per day);
KIRP	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.67	-8.76	-0.49	3.28e-16	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.85	12.21	0.61	4.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs10802346	0.541	rs12134377	chr1:246372081	A/T	cg15962031	chr1:246363574	SMYD3	0.62	4.97	0.3	1.27e-6	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.64	-6.31	-0.37	1.31e-9	Body mass index;
KIRP	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg04519387	chr11:65556438	OVOL1	0.35	5.01	0.3	1.03e-6	Acne (severe);
KIRP	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs7539542	0.529	rs960707	chr1:202888223	A/T	cg19681188	chr1:202830198	LOC148709	-0.48	-5.16	-0.31	5.09e-7	Mean platelet volume;
KIRP	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs12220238	0.722	rs6480744	chr10:76398989	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	6.01	0.36	6.82e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg24154853	chr7:158122151	PTPRN2	0.37	5.23	0.32	3.65e-7	Calcium levels;
KIRP	cis	rs12496230	0.794	rs6549424	chr3:66866748	T/C	cg17646820	chr3:66848679	NA	0.39	6.27	0.37	1.57e-9	Type 2 diabetes;
KIRP	cis	rs41005	1.000	rs193929	chr2:8107620	G/T	cg03155496	chr2:8117019	LOC339788	0.61	10.53	0.56	1.19e-21	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.76	9.28	0.51	9.18e-18	Multiple sclerosis;
KIRP	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.68	10.07	0.54	3.43e-20	Dupuytren's disease;
KIRP	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg20607798	chr8:58055168	NA	0.66	5.15	0.31	5.39e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.68	9.01	0.5	6.07e-17	Glomerular filtration rate;
KIRP	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	0.86	10.19	0.54	1.48e-20	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.72	6.05	0.36	5.37e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.87	0.4	5.16e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3857067	0.806	rs1585651	chr4:95058755	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-5.9	-0.35	1.18e-8	QT interval;
KIRP	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg21926883	chr2:100939477	LONRF2	-0.57	-7.67	-0.44	3.96e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs6453111	chr5:74379926	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg03388025	chr16:89894329	SPIRE2	-0.29	-5.44	-0.33	1.3e-7	Vitiligo;
KIRP	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.47	7.43	0.43	1.79e-12	Platelet distribution width;
KIRP	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.41	-0.47	3.44e-15	Mean corpuscular volume;
KIRP	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg26876637	chr1:152193138	HRNR	0.71	9.19	0.51	1.71e-17	Atopic dermatitis;
KIRP	cis	rs7712401	0.601	rs442911	chr5:122325551	T/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg20991723	chr1:152506922	NA	-0.45	-5.22	-0.32	3.88e-7	Hair morphology;
KIRP	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.66	9.89	0.53	1.21e-19	Schizophrenia;
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.7	-0.39	1.42e-10	Immature fraction of reticulocytes;
KIRP	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.76	0.4	9.81e-11	Platelet count;
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00933542	chr6:150070202	PCMT1	0.29	5.83	0.35	1.74e-8	Lung cancer;
KIRP	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg01320579	chr17:75405842	SEPT9	-0.4	-6.63	-0.39	2.12e-10	Airflow obstruction;
KIRP	cis	rs7589728	1.000	rs11893832	chr2:88507537	G/C	cg04511125	chr2:88470314	THNSL2	0.71	5.21	0.32	4.06e-7	Plasma clusterin levels;
KIRP	cis	rs16828019	0.852	rs12729586	chr1:41522377	C/A	cg18742814	chr1:41828276	NA	0.69	5.91	0.35	1.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.47	6.01	0.36	6.72e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.8200000000000003e-11	Bladder cancer;
KIRP	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg25486957	chr4:152246857	NA	-0.5	-5.31	-0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.7	-7.64	-0.44	4.88e-13	Gut microbiome composition (summer);
KIRP	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.78	-11.36	-0.59	2.5300000000000002e-24	Asthma;
KIRP	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg17724175	chr1:150552817	MCL1	0.35	5.93	0.35	1.05e-8	Melanoma;
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.69	-0.39	1.49e-10	Immature fraction of reticulocytes;
KIRP	trans	rs1864585	0.520	rs73208793	chr8:10680785	T/C	cg26278703	chr11:58910052	FAM111A	0.64	6.41	0.38	7.25e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02773019	chr3:135684688	PPP2R3A	0.62	7.39	0.43	2.33e-12	Smoking initiation;
KIRP	cis	rs7665939	1.000	rs7665939	chr4:190123318	C/T	cg14840187	chr4:190284988	NA	-0.8	-6.13	-0.36	3.49e-9	Amyotrophic lateral sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16411863	chr14:76448962	TGFB3	0.51	6.28	0.37	1.56e-9	Parkinson's disease;
KIRP	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	10.17	0.54	1.6e-20	Hip circumference;
KIRP	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.3	-0.37	1.39e-9	Cardiac Troponin-T levels;
KIRP	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.49	-0.38	4.81e-10	Mood instability;
KIRP	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg12315302	chr6:26189340	HIST1H4D	0.99	6.87	0.4	5.2e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg14851346	chr12:38532713	NA	-0.39	-4.85	-0.3	2.24e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.26	0.32	3.14e-7	Smoking behavior;
KIRP	cis	rs35883536	1.000	rs2297715	chr1:101092594	A/G	cg06223162	chr1:101003688	GPR88	0.32	6.54	0.38	3.6e-10	Monocyte count;
KIRP	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg10189774	chr4:17578691	LAP3	-0.47	-5.37	-0.32	1.84e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7113874	0.659	rs12274454	chr11:8521966	G/C	cg08015107	chr11:8618950	NA	-0.51	-6.79	-0.4	8.28e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg12908607	chr1:44402522	ARTN	-0.45	-6.32	-0.37	1.2e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg00689492	chr4:1303491	MAEA	0.29	5.25	0.32	3.29e-7	Longevity;
KIRP	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.4	7.9	0.45	9.44e-14	Multiple system atrophy;
KIRP	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.86	13.68	0.66	4.53e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg00405596	chr8:11794950	NA	0.46	6.1	0.36	4e-9	Retinal vascular caliber;
KIRP	cis	rs2737618	0.651	rs2816974	chr1:200082686	C/G	cg21825944	chr1:200113062	NR5A2	0.52	7.38	0.43	2.5e-12	Uric acid levels;
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg01238044	chr22:24384105	GSTT1	-0.63	-8.39	-0.47	3.86e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs151997	0.962	rs27272	chr5:50181865	A/G	cg06027927	chr5:50259733	NA	0.59	7.41	0.43	2.02e-12	Callous-unemotional behaviour;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21852761	chr6:130340620	L3MBTL3	0.5	6.25	0.37	1.79e-9	Parkinson's disease;
KIRP	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.34	-0.42	3.13e-12	Triglycerides;
KIRP	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.06e-7	Coronary artery disease;
KIRP	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.26	-0.42	4.95e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.09e-8	Motion sickness;
KIRP	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.14	-0.31	5.63e-7	Autism;
KIRP	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.92	15.57	0.7	1.61e-38	Metabolic syndrome;
KIRP	cis	rs2591576	0.718	rs114121835	chr5:165396027	A/G	cg13976338	chr5:165423657	NA	-0.65	-8.78	-0.49	2.78e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs12936587	0.633	rs12937108	chr17:17499544	A/G	cg01246520	chr17:17644344	RAI1	0.38	5.62	0.34	5.1e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs4356932	1.000	rs6532142	chr4:76970905	C/T	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	trans	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg11109621	chr5:26881128	CDH9	-0.34	-6.05	-0.36	5.3300000000000004e-09	Response to metformin in type 2 diabetes (glycemic);
KIRP	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.46	6.16	0.37	2.97e-9	Triglycerides;
KIRP	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.8	-0.45	1.75e-13	Sudden cardiac arrest;
KIRP	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.66	-8.66	-0.48	6.13e-16	Migraine;Coronary artery disease;
KIRP	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	1.36	11.76	0.6	1.2e-25	Sexual dysfunction (female);
KIRP	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg00806126	chr19:22604979	ZNF98	0.63	6.77	0.4	9.22e-11	Pain;
KIRP	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.89	-14.05	-0.67	2.55e-33	Height;
KIRP	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.79	-11.35	-0.59	2.66e-24	Blood metabolite levels;
KIRP	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-0.64	-5.73	-0.34	2.93e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.91e-8	Life satisfaction;
KIRP	cis	rs4302748	0.862	rs11974973	chr7:36184850	A/T	cg24442661	chr7:36192818	EEPD1	-0.59	-6.63	-0.39	2.14e-10	Platelet count;
KIRP	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.8	7.69	0.44	3.45e-13	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg13147721	chr7:65941812	NA	-1.01	-7.0	-0.41	2.46e-11	Diabetic kidney disease;
KIRP	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg24296786	chr1:45957014	TESK2	0.52	5.76	0.34	2.49e-8	Homocysteine levels;
KIRP	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.42e-13	Morning vs. evening chronotype;
KIRP	cis	rs11650494	0.710	rs2119935	chr17:47471334	T/C	cg08112188	chr17:47440006	ZNF652	1.06	6.53	0.38	3.66e-10	Prostate cancer;
KIRP	cis	rs8179	0.553	rs42038	chr7:92243719	A/G	cg15732164	chr7:92237376	CDK6	0.5	6.75	0.4	1.06e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs7565981	0.826	rs17024792	chr2:101423777	A/G	cg02232089	chr2:101440696	NPAS2	0.6	5.38	0.32	1.75e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg08501292	chr6:25962987	TRIM38	0.98	5.89	0.35	1.25e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-5.72	-0.34	3.02e-8	Lung cancer;
KIRP	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.82e-10	Bipolar disorder;
KIRP	cis	rs501120	1.000	rs1746047	chr10:44774086	T/G	cg09554077	chr10:44749378	NA	0.71	10.92	0.57	6.68e-23	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06634786	chr22:41940651	POLR3H	0.43	5.06	0.31	8.32e-7	Vitiligo;
KIRP	cis	rs34779708	0.733	rs7083266	chr10:35541632	C/A	cg03585969	chr10:35415529	CREM	0.62	7.15	0.41	9.83e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg13271783	chr10:134563150	INPP5A	-0.6	-7.77	-0.44	2.08e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-0.87	-9.01	-0.5	5.69e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg06365898	chr1:16533907	ARHGEF19	0.48	6.76	0.4	1.01e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.91	13.91	0.66	7.48e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.72	-9.6	-0.52	9.48e-19	Breast cancer;
KIRP	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.64	6.68	0.39	1.61e-10	Menarche (age at onset);
KIRP	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.04	-8.13	-0.46	2.11e-14	Skin colour saturation;
KIRP	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg08761264	chr16:28874980	SH2B1	-0.51	-5.9	-0.35	1.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg03834567	chr2:218808745	TNS1	0.42	5.24	0.32	3.45e-7	Ulcerative colitis;
KIRP	cis	rs7215564	0.643	rs59992540	chr17:78658265	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.38	-0.43	2.41e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.6	-6.95	-0.41	3.23e-11	Height;
KIRP	cis	rs2635047	0.631	rs2668778	chr18:44745185	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.61	0.34	5.44e-8	Educational attainment;
KIRP	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg26769984	chr7:1090371	C7orf50	0.73	6.03	0.36	5.93e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs11605924	1.000	rs1401419	chr11:45879739	T/C	cg23097878	chr11:45879730	CRY2	0.31	6.41	0.38	7.54e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.7	-7.87	-0.45	1.15e-13	Pursuit maintenance gain;
KIRP	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.72	8.3	0.47	7.02e-15	Obesity-related traits;
KIRP	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg12435725	chr3:58293450	RPP14	-0.48	-5.12	-0.31	6.19e-7	Cholesterol, total;
KIRP	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg23594656	chr7:65796392	TPST1	0.42	5.91	0.35	1.17e-8	Aortic root size;
KIRP	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.72	-10.05	-0.54	3.94e-20	Glaucoma (primary open-angle);
KIRP	cis	rs8016982	0.611	rs11159493	chr14:81639159	A/T	cg01989461	chr14:81687754	GTF2A1	0.78	11.74	0.6	1.45e-25	Schizophrenia;
KIRP	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.75	7.75	0.44	2.36e-13	Corneal astigmatism;
KIRP	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.56	-6.95	-0.41	3.29e-11	Uric acid clearance;
KIRP	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg16255804	chr6:135334527	HBS1L	-0.31	-4.91	-0.3	1.69e-6	Red blood cell count;
KIRP	cis	rs7665939	1.000	rs72709217	chr4:190113079	C/T	cg14840187	chr4:190284988	NA	-0.66	-5.58	-0.34	6.44e-8	Amyotrophic lateral sclerosis;
KIRP	cis	rs539514	0.539	rs1408060	chr13:76289980	G/C	cg04757411	chr13:76259545	LMO7	-0.39	-5.48	-0.33	1.07e-7	Type 1 diabetes;
KIRP	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg01689657	chr7:91764605	CYP51A1	-0.44	-6.31	-0.37	1.32e-9	Breast cancer;
KIRP	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg16141378	chr3:129829833	LOC729375	0.51	6.34	0.37	1.07e-9	Joint mobility (Beighton score);
KIRP	cis	rs930036	0.603	rs34453397	chr2:172034112	A/C	cg12801329	chr2:171670795	NA	0.49	5.59	0.34	6.13e-8	Menopause (age at onset);
KIRP	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-5.31	-0.32	2.51e-7	Neuroticism;
KIRP	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg17595323	chr11:93583763	C11orf90	-0.37	-6.21	-0.37	2.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.77	9.95	0.54	8.22e-20	Coronary artery disease;
KIRP	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.22	-0.32	3.72e-7	Bladder cancer;
KIRP	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg09904177	chr6:26538194	HMGN4	0.46	6.2	0.37	2.41e-9	Schizophrenia;
KIRP	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	4.99	0.3	1.13e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg24579218	chr15:68104479	NA	-0.6	-9.98	-0.54	6.29e-20	Restless legs syndrome;
KIRP	cis	rs2400749	0.830	rs12434962	chr14:100031986	C/T	cg19965031	chr14:100038389	CCDC85C	-0.42	-5.13	-0.31	5.92e-7	Alzheimer's disease (survival time);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg15563057	chr5:139493612	PURA	0.48	6.19	0.37	2.52e-9	Asthma;
KIRP	cis	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg08501292	chr6:25962987	TRIM38	0.91	6.48	0.38	5.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.53	-0.38	3.77e-10	Urinary tract infection frequency;
KIRP	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.12	-0.31	6.12e-7	Life satisfaction;
KIRP	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-5.93	-0.35	1.01e-8	Metabolite levels;
KIRP	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg26695010	chr11:65641043	EFEMP2	0.43	5.16	0.31	5.16e-7	Eosinophil percentage of white cells;
KIRP	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg24110177	chr3:50126178	RBM5	-0.42	-5.5	-0.33	9.29e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Colorectal cancer;
KIRP	cis	rs17384381	1.000	rs12138852	chr1:85878208	C/T	cg16011679	chr1:85725395	C1orf52	0.81	8.15	0.46	1.83e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg01620082	chr3:125678407	NA	-1.19	-7.59	-0.44	6.51e-13	Depression;
KIRP	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg15556689	chr8:8085844	FLJ10661	0.59	7.76	0.44	2.25e-13	Triglycerides;
KIRP	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.99	-13.27	-0.65	1.1e-30	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21097698	chr4:76932399	ART3	-0.47	-6.41	-0.38	7.23e-10	Parkinson's disease;
KIRP	cis	rs986417	0.901	rs1955693	chr14:61012331	T/C	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.57	7.21	0.42	6.87e-12	Obesity-related traits;
KIRP	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg26875233	chr11:93583750	C11orf90	-0.36	-6.66	-0.39	1.75e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10112022	chr14:91527130	RPS6KA5	0.5	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.93	13.61	0.66	8.14e-32	Bladder cancer;
KIRP	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.82	-0.57	1.39e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2742417	0.967	rs9311378	chr3:45763135	C/T	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	2.97e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg20194872	chr6:41519635	FOXP4	0.57	7.3	0.42	3.86e-12	Prostate cancer;
KIRP	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27297192	chr10:134578999	INPP5A	0.61	7.57	0.43	7.28e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg13798780	chr7:105162888	PUS7	0.65	6.0	0.36	6.85e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg20387954	chr3:183756860	HTR3D	0.57	8.32	0.47	6.16e-15	Anterior chamber depth;
KIRP	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.89	-11.97	-0.61	2.56e-26	Coronary artery disease;
KIRP	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	9.58	0.52	1.15e-18	Personality dimensions;
KIRP	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.77	-9.88	-0.53	1.38e-19	Homoarginine levels;
KIRP	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg26681399	chr22:41777847	TEF	0.42	4.85	0.3	2.16e-6	Vitiligo;
KIRP	cis	rs7116495	1.000	rs10751190	chr11:71680757	C/T	cg11196788	chr11:71737549	NUMA1	0.55	4.94	0.3	1.45e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs1395	0.925	rs1659676	chr2:27399294	C/T	cg23587288	chr2:27483067	SLC30A3	0.55	6.98	0.41	2.72e-11	Blood metabolite levels;
KIRP	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg16049864	chr8:95962084	TP53INP1	-0.39	-6.3	-0.37	1.38e-9	Type 2 diabetes;
KIRP	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.82	-8.25	-0.47	9.95e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg20701182	chr2:24300061	SF3B14	0.47	5.52	0.33	8.57e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9815354	0.953	rs1613233	chr3:41945144	A/G	cg03022575	chr3:42003672	ULK4	-0.48	-5.49	-0.33	9.89e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16524936	chr4:1340807	KIAA1530	-0.46	-6.08	-0.36	4.66e-9	Longevity;
KIRP	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs258892	0.895	rs9293450	chr5:72068476	G/A	cg21869765	chr5:72125136	TNPO1	-0.54	-5.92	-0.35	1.1e-8	Small cell lung carcinoma;
KIRP	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.34	-5.77	-0.35	2.31e-8	Height;
KIRP	trans	rs10513788	1.000	rs115329674	chr3:182067083	C/T	cg22158252	chr1:39958494	BMP8A	0.54	6.07	0.36	4.77e-9	Cognitive function;
KIRP	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg13319975	chr6:146136371	FBXO30	-0.5	-6.54	-0.38	3.63e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg22974920	chr21:40686053	BRWD1	0.43	5.05	0.31	8.72e-7	Cognitive function;
KIRP	cis	rs2077654	0.822	rs4148627	chr11:17436271	G/A	cg25308976	chr11:17434268	ABCC8	1.06	10.72	0.56	2.91e-22	Gout;
KIRP	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.69	6.95	0.41	3.26e-11	Vitiligo;
KIRP	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.65	-9.01	-0.5	6.06e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.02	-0.36	6.14e-9	Type 2 diabetes;
KIRP	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	6.78	0.4	8.81e-11	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg12131826	chr15:77904385	NA	0.48	6.44	0.38	6.39e-10	Type 2 diabetes;
KIRP	cis	rs3825932	0.961	rs11856301	chr15:79232330	T/C	cg25744700	chr15:79237217	CTSH	0.43	5.3	0.32	2.61e-7	Type 1 diabetes;
KIRP	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg11833968	chr6:79620685	NA	-0.36	-4.95	-0.3	1.4e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg23594656	chr7:65796392	TPST1	-0.37	-5.35	-0.32	1.99e-7	Aortic root size;
KIRP	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.55	-7.61	-0.44	5.79e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs600806	0.850	rs6537757	chr1:109936682	G/A	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4566357	1.000	rs2177597	chr2:227922546	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.04	-0.31	9.03e-7	Coronary artery disease;
KIRP	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg09165964	chr15:75287851	SCAMP5	-0.99	-9.73	-0.53	3.92e-19	Lung cancer;
KIRP	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.07	-0.31	7.78e-7	Dupuytren's disease;
KIRP	trans	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.35	0.42	2.88e-12	Exhaled nitric oxide output;
KIRP	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg04727924	chr7:799746	HEATR2	-0.78	-8.85	-0.49	1.8e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg22907277	chr7:1156413	C7orf50	0.48	6.02	0.36	6.34e-9	Longevity;Endometriosis;
KIRP	cis	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.19	-0.31	4.44e-7	Leprosy;
KIRP	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.63	-7.08	-0.41	1.49e-11	Type 2 diabetes;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg23664459	chr14:36004097	INSM2	0.62	6.17	0.37	2.72e-9	Response to statin therapy;
KIRP	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg26605046	chr4:2439731	NA	-0.39	-6.05	-0.36	5.42e-9	Cognitive function;
KIRP	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.54	-7.53	-0.43	9.63e-13	Gut microbiome composition (summer);
KIRP	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.88	10.46	0.55	2.08e-21	Alzheimer's disease;
KIRP	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.05	-13.16	-0.64	2.65e-30	Exhaled nitric oxide output;
KIRP	cis	rs2920503	0.959	rs2920502	chr3:12329195	G/C	cg04748988	chr3:12329223	PPARG	0.57	6.57	0.39	2.98e-10	LDL cholesterol;
KIRP	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg05347473	chr6:146136440	FBXO30	0.54	7.81	0.45	1.63e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.67	8.55	0.48	1.34e-15	Total cholesterol levels;
KIRP	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-11.15	-0.58	1.21e-23	Body mass index;
KIRP	cis	rs57590327	0.527	rs7610703	chr3:81613942	G/A	cg07356753	chr3:81810745	GBE1	-0.57	-7.33	-0.42	3.32e-12	Extraversion;
KIRP	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.11	14.34	0.67	2.59e-34	Type 1 diabetes nephropathy;
KIRP	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-8.32	-0.47	6.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.65	-0.34	4.45e-8	Type 2 diabetes;
KIRP	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-8.59	-0.48	1.01e-15	Triglycerides;
KIRP	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.68	5.61	0.34	5.57e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg09549813	chr16:4587862	C16orf5	-0.32	-4.89	-0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs812925	0.533	rs35507645	chr2:61396766	A/G	cg15711740	chr2:61764176	XPO1	-0.44	-5.3	-0.32	2.52e-7	Immature fraction of reticulocytes;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg20256403	chr2:97523850	ANKRD39	-1.09	-6.08	-0.36	4.54e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg12573674	chr2:1569213	NA	-0.52	-5.03	-0.31	9.27e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17243582	chr15:59969081	BNIP2	0.43	6.73	0.39	1.2e-10	Cancer;
KIRP	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.46	-5.98	-0.36	7.89e-9	Dietary macronutrient intake;
KIRP	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.85	-0.35	1.55e-8	Educational attainment;
KIRP	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg27490568	chr2:178487706	NA	0.51	6.67	0.39	1.72e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg01200585	chr1:228362443	C1orf69	0.41	5.11	0.31	6.58e-7	Diastolic blood pressure;
KIRP	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg11914812	chr12:56904792	NA	0.4	6.03	0.36	6.12e-9	Cancer;
KIRP	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-4.95	-0.3	1.35e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg06221963	chr1:154839813	KCNN3	0.52	5.54	0.33	7.78e-8	Atrial fibrillation;
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg11301795	chr4:187892539	NA	-1.0	-17.98	-0.75	1.03e-46	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05585630	chr7:157510462	PTPRN2	-0.53	-7.75	-0.44	2.39e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00933542	chr6:150070202	PCMT1	0.31	6.11	0.36	3.92e-9	Lung cancer;
KIRP	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg19875535	chr5:140030758	IK	-0.68	-9.76	-0.53	3.16e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs258892	0.895	rs13171293	chr5:72034307	T/G	cg21869765	chr5:72125136	TNPO1	-0.55	-6.03	-0.36	5.88e-9	Small cell lung carcinoma;
KIRP	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg24631222	chr15:78858424	CHRNA5	0.79	10.82	0.57	1.44e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-0.93	-10.36	-0.55	4.15e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs4356975	0.563	rs4538548	chr4:69960669	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.49e-7	Obesity-related traits;
KIRP	trans	rs11593840	0.690	rs1907348	chr10:78184816	A/G	cg18555199	chr3:180630509	FXR1	0.49	6.23	0.37	2.02e-9	Male-pattern baldness;
KIRP	cis	rs7607369	0.596	rs56304256	chr2:219276138	T/C	cg02176678	chr2:219576539	TTLL4	-0.31	-5.44	-0.33	1.26e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs7252981	0.632	rs8113682	chr19:19743730	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-4.96	-0.3	1.35e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg07827796	chr19:33622959	WDR88	0.5	6.39	0.38	8.21e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.4	0.38	7.71e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg09800026	chr21:45662262	ICOSLG	0.46	6.14	0.36	3.21e-9	DNA methylation (variation);
KIRP	cis	rs3026101	0.671	rs57085931	chr17:5305370	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.76	8.75	0.49	3.35e-16	Corneal astigmatism;
KIRP	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	7.44	0.43	1.68e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9715521	0.775	rs12646141	chr4:59846130	G/C	cg11281224	chr4:60001000	NA	-0.46	-5.53	-0.33	8.11e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.59	-0.34	6.02e-8	Triglycerides;
KIRP	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg18016565	chr1:150552671	MCL1	-0.34	-5.3	-0.32	2.61e-7	Tonsillectomy;
KIRP	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.17	0.31	4.79e-7	Lung cancer;
KIRP	cis	rs4474465	0.831	rs12287010	chr11:78161452	A/T	cg02023728	chr11:77925099	USP35	-0.34	-5.36	-0.32	1.92e-7	Alzheimer's disease (survival time);
KIRP	cis	rs11638352	1.000	rs6493094	chr15:44310790	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.78	-6.12	-0.36	3.76e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.88	-11.61	-0.59	3.87e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	6.95	0.41	3.22e-11	Rheumatoid arthritis;
KIRP	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.43	-0.43	1.81e-12	Neuroticism;
KIRP	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.38	0.38	8.57e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.55	-0.43	8.23e-13	Mean corpuscular volume;
KIRP	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg26338869	chr17:61819248	STRADA	-0.52	-6.47	-0.38	5.19e-10	Prudent dietary pattern;
KIRP	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.21	0.37	2.23e-9	Ovarian reserve;
KIRP	cis	rs4664293	0.867	rs2081722	chr2:160594208	A/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs6479901	0.501	rs7084396	chr10:64876725	A/G	cg25356468	chr10:64875536	NA	-0.47	-5.41	-0.33	1.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22307297	chr20:60903441	LAMA5	-0.41	-5.01	-0.3	1.06e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.49	6.13	0.36	3.51e-9	Height;
KIRP	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.15	-0.37	3.09e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs3858145	0.588	rs4142049	chr10:70044452	C/A	cg04882175	chr6:131122610	NA	-0.6	-6.94	-0.4	3.45e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg10017260	chr10:834428	NA	-0.46	-6.58	-0.39	2.87e-10	Survival in rectal cancer;
KIRP	cis	rs796364	0.616	rs2140486	chr2:200690102	C/T	cg17644776	chr2:200775616	C2orf69	0.57	5.23	0.32	3.56e-7	Schizophrenia;
KIRP	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.39	0.38	8.3e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg13198984	chr17:80129470	CCDC57	-0.5	-7.68	-0.44	3.69e-13	Life satisfaction;
KIRP	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.51	5.85	0.35	1.54e-8	Mean platelet volume;
KIRP	cis	rs1448094	0.802	rs7487591	chr12:86434112	T/C	cg06740227	chr12:86229804	RASSF9	0.42	5.27	0.32	3.03e-7	Major depressive disorder;
KIRP	trans	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.34	-0.37	1.09e-9	Triglycerides;
KIRP	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg02012338	chr4:187126139	CYP4V2	0.88	7.75	0.44	2.46e-13	Blood protein levels;
KIRP	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.5	-6.75	-0.4	1.03e-10	Schizophrenia;
KIRP	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	7.62	0.44	5.47e-13	Prudent dietary pattern;
KIRP	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg11608241	chr8:8085544	FLJ10661	-0.46	-6.06	-0.36	5.07e-9	Acne (severe);
KIRP	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg07395648	chr5:131743802	NA	-0.33	-4.86	-0.3	2.05e-6	Blood metabolite levels;
KIRP	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg03959625	chr15:84868606	LOC388152	0.47	5.5	0.33	9.44e-8	Schizophrenia;
KIRP	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.74	10.91	0.57	7.14e-23	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs42648	0.935	rs42660	chr7:89982522	C/T	cg25739043	chr7:89950458	NA	-0.43	-6.74	-0.39	1.13e-10	Homocysteine levels;
KIRP	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	5.84	0.35	1.63e-8	Educational attainment;
KIRP	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg00684032	chr4:1343700	KIAA1530	0.44	5.62	0.34	5.29e-8	Obesity-related traits;
KIRP	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.66	9.69	0.53	5.01e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.17	-0.54	1.6e-20	Coffee consumption (cups per day);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00088033	chr17:35969707	SYNRG	0.55	6.43	0.38	6.6e-10	Smoking initiation;
KIRP	cis	rs2151522	0.603	rs7766269	chr6:127195740	T/C	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1440410	0.571	rs11728569	chr4:144036653	G/C	cg01719995	chr4:144104893	USP38	0.46	6.08	0.36	4.55e-9	Ischemic stroke;
KIRP	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.64	-7.54	-0.43	9.03e-13	DNA methylation (variation);
KIRP	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg13939156	chr17:80058883	NA	-0.48	-5.49	-0.33	1.02e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg18154014	chr19:37997991	ZNF793	0.73	7.92	0.45	8.32e-14	Coronary artery calcification;
KIRP	cis	rs2151522	0.563	rs9388525	chr6:127129860	C/T	cg21431617	chr6:127135037	NA	0.34	6.14	0.36	3.37e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.81	-8.58	-0.48	1.05e-15	Systemic lupus erythematosus;
KIRP	cis	rs860295	0.702	rs34620961	chr1:155649827	G/C	cg02153340	chr1:155202674	NA	-0.51	-6.91	-0.4	4.08e-11	Body mass index;
KIRP	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.31	-0.32	2.47e-7	Neuroticism;
KIRP	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.34	7.82	0.45	1.52e-13	Asthma (sex interaction);
KIRP	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg21419209	chr3:44054225	NA	0.75	9.29	0.51	8.52e-18	Coronary artery disease;
KIRP	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.82	-8.19	-0.46	1.43e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg21698718	chr17:80085957	CCDC57	0.35	5.11	0.31	6.51e-7	Life satisfaction;
KIRP	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	5.55	0.33	7.3e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.32e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs490234	0.676	rs12202	chr9:128200299	C/G	cg14078157	chr9:128172775	NA	-0.6	-7.19	-0.42	7.87e-12	Mean arterial pressure;
KIRP	cis	rs9972944	0.702	rs987930	chr17:63765862	C/T	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	trans	rs9693857	0.520	rs10107887	chr8:9364664	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.24	0.37	1.87e-9	Systolic blood pressure;
KIRP	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.65	7.9	0.45	9.13e-14	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.7	9.18	0.51	1.77e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9649213	0.574	rs34830366	chr7:97899535	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.45	0.33	1.23e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg01971667	chr8:817044	NA	-0.48	-6.02	-0.36	6.28e-9	Clozapine-induced cytotoxicity;
KIRP	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.72	-10.33	-0.55	5.3e-21	Breast cancer;
KIRP	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	cg12689670	chr1:183009347	LAMC1	0.45	6.52	0.38	3.94e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs13226913	1.000	rs13226913	chr7:7246846	T/C	cg04827551	chr7:7268805	C1GALT1	-0.36	-5.27	-0.32	2.92e-7	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.21	22.4	0.82	2.55e-61	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14780540	chr1:247242157	ZNF670	0.49	6.3	0.37	1.37e-9	Parkinson's disease;
KIRP	cis	rs745080	0.674	rs7144509	chr14:53023607	C/T	cg23333723	chr14:53022898	GPR137C	-0.35	-4.91	-0.3	1.64e-6	Orofacial clefts;
KIRP	cis	rs8060686	0.858	rs11553287	chr16:67905407	A/G	cg26727032	chr16:67993705	SLC12A4	-0.79	-9.21	-0.51	1.5e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6430538	0.646	rs11887093	chr2:135538418	G/C	cg25422880	chr2:135218333	TMEM163	-0.39	-5.5	-0.33	9.35e-8	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01799862	chr16:67143802	C16orf70	0.46	6.09	0.36	4.32e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg20673091	chr1:2541236	MMEL1	-0.38	-5.04	-0.31	8.99e-7	Ulcerative colitis;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	6.98e-7	Life satisfaction;
KIRP	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg14338887	chr6:42928500	GNMT	0.47	6.88	0.4	4.89e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.83	9.97	0.54	7.1e-20	Corneal astigmatism;
KIRP	cis	rs1050631	0.564	rs8098627	chr18:33721636	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg07645718	chr20:61493192	TCFL5	-0.72	-6.09	-0.36	4.25e-9	Obesity-related traits;
KIRP	cis	rs7546668	1.000	rs4661640	chr1:15854882	T/G	cg21858823	chr1:15850916	CASP9	0.47	5.2	0.31	4.2e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7404095	0.505	rs4047243	chr16:23826417	A/G	cg21745164	chr16:23765304	CHP2	0.37	5.24	0.32	3.52e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.45	4.94	0.3	1.47e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.41	0.38	7.53e-10	Hypertriglyceridemia;
KIRP	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.54	-0.33	7.58e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09491104	chr22:46646882	C22orf40	-0.58	-6.57	-0.39	2.99e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-5.06	-0.31	8.05e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs3767633	0.502	rs2499845	chr1:161933066	G/C	cg27519958	chr1:161735129	ATF6	-0.51	-5.63	-0.34	4.97e-8	IgG glycosylation;
KIRP	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.01	13.95	0.66	5.63e-33	Response to antipsychotic treatment;
KIRP	cis	rs6959887	0.962	rs1346021	chr7:35284161	G/A	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.82	-11.78	-0.6	1.07e-25	Educational attainment;
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg09597638	chr17:3907349	NA	0.8	15.98	0.71	6.8e-40	Type 2 diabetes;
KIRP	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.59	7.79	0.45	1.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg23307798	chr14:103986281	CKB	0.49	7.03	0.41	1.98e-11	Body mass index;
KIRP	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.78	6.68	0.39	1.63e-10	Body mass index;
KIRP	cis	rs7923609	0.967	rs2393966	chr10:65134814	T/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.55	-0.33	7.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3735025	0.926	rs1431098	chr7:137051371	T/A	cg13839563	chr7:136910420	NA	-0.44	-5.09	-0.31	7.21e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.71	8.6	0.48	9.24e-16	Type 2 diabetes;
KIRP	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs988913	0.957	rs1910350	chr6:54852462	C/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.45	-0.33	1.25e-7	Menarche (age at onset);
KIRP	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs503734	0.502	rs513154	chr3:100953212	T/G	cg27318481	chr3:100970896	IMPG2	-0.51	-6.96	-0.41	3.15e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs600806	0.714	rs2781552	chr1:110025881	A/G	cg02175308	chr1:109941060	SORT1	0.31	5.9	0.35	1.21e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1165472	0.755	rs4927261	chr1:56161500	T/C	cg11523071	chr1:56160889	NA	-0.72	-10.96	-0.57	4.94e-23	Paclitaxel-induced neuropathy;
KIRP	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg24110177	chr3:50126178	RBM5	-0.67	-7.79	-0.44	1.84e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-1.16	-14.97	-0.69	1.92e-36	Platelet distribution width;
KIRP	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.47	-5.97	-0.36	8.23e-9	Blood metabolite levels;
KIRP	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg21684588	chr1:67600265	NA	-0.43	-5.0	-0.3	1.11e-6	Psoriasis;
KIRP	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg18105134	chr13:113819100	PROZ	-0.67	-7.49	-0.43	1.21e-12	Blood protein levels;
KIRP	trans	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-7.92	-0.45	7.98e-14	Triglycerides;
KIRP	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.91	-14.64	-0.68	2.41e-35	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2795502	0.702	rs3123750	chr10:43227824	C/A	cg11150807	chr10:43354902	NA	-0.56	-5.27	-0.32	2.98e-7	Blood protein levels;
KIRP	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.42	-6.57	-0.39	2.92e-10	Eye color traits;
KIRP	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.03e-10	Schizophrenia;
KIRP	cis	rs2273669	0.667	rs11153147	chr6:109304058	A/G	cg05315195	chr6:109294784	ARMC2	-0.61	-6.08	-0.36	4.65e-9	Prostate cancer;
KIRP	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg18190219	chr22:46762943	CELSR1	-0.62	-6.3	-0.37	1.33e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2929278	0.617	rs3087657	chr15:44063859	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.13	0.41	1.1e-11	Schizophrenia;
KIRP	cis	rs6450176	0.564	rs406621	chr5:53326232	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-8.69	-0.48	5.24e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg05775895	chr3:12838266	CAND2	0.4	6.53	0.38	3.75e-10	QRS complex (12-leadsum);
KIRP	cis	rs9905704	0.918	rs369184	chr17:56709086	C/T	cg12560992	chr17:57184187	TRIM37	0.62	6.62	0.39	2.17e-10	Testicular germ cell tumor;
KIRP	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.64	8.3	0.47	7.11e-15	Height;
KIRP	cis	rs6504950	0.720	rs9910653	chr17:52992268	C/T	cg26251398	chr17:52985966	TOM1L1	0.44	6.07	0.36	4.94e-9	Breast cancer;
KIRP	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg00800038	chr16:89945340	TCF25	-0.89	-7.28	-0.42	4.62e-12	Skin colour saturation;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg04369038	chr3:50649626	CISH	-0.52	-6.68	-0.39	1.62e-10	Metabolite levels (MHPG);
KIRP	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.84	0.53	1.79e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs11138902	0.673	rs11139246	chr9:72157997	A/G	cg14397918	chr9:72078829	APBA1	0.33	5.31	0.32	2.47e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg01689657	chr7:91764605	CYP51A1	0.42	6.05	0.36	5.28e-9	Breast cancer;
KIRP	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg25828445	chr12:7781288	NA	0.51	5.1	0.31	6.7e-7	HDL cholesterol levels;
KIRP	cis	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg12923728	chr3:195709715	SDHAP1	-0.54	-6.15	-0.37	3.08e-9	Mean corpuscular volume;
KIRP	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg00310523	chr12:86230176	RASSF9	-0.47	-7.52	-0.43	1e-12	Major depressive disorder;
KIRP	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg13444842	chr1:152974279	SPRR3	-0.38	-5.42	-0.33	1.42e-7	Inflammatory skin disease;
KIRP	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.82	9.38	0.51	4.45e-18	Response to diuretic therapy;
KIRP	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7106204	0.514	rs11027789	chr11:24260906	T/C	ch.11.24196551F	chr11:24239977	NA	0.81	8.01	0.45	4.71e-14	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg01097406	chr16:89675127	NA	-0.33	-5.41	-0.33	1.52e-7	Vitiligo;
KIRP	cis	rs9625935	0.917	rs5763675	chr22:30386385	A/G	cg01021169	chr22:30184971	ASCC2	-0.43	-4.91	-0.3	1.62e-6	Tonsillectomy;
KIRP	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.0	13.88	0.66	9.64e-33	Response to antipsychotic treatment;
KIRP	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	9.55	0.52	1.35e-18	Cognitive test performance;
KIRP	trans	rs2302464	1.000	rs6811179	chr4:15685351	A/T	cg25002788	chr4:1166873	LOC100130872-SPON2;SPON2	0.5	6.09	0.36	4.42e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg06647332	chr5:131281008	NA	-0.48	-5.38	-0.32	1.74e-7	Life satisfaction;
KIRP	cis	rs79839061	0.636	rs73207778	chr4:836762	C/T	cg07828340	chr4:882639	GAK	1.12	7.09	0.41	1.41e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.68	5.0	0.3	1.11e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.41	6.75	0.4	1.05e-10	Renal cell carcinoma;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.22	-24.51	-0.84	5.66e-68	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.7	8.46	0.47	2.45e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg18306943	chr3:40428807	ENTPD3	0.45	5.96	0.36	8.66e-9	Renal cell carcinoma;
KIRP	trans	rs7980799	1.000	rs7980799	chr12:33576990	A/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.14	-0.36	3.38e-9	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4713675	0.546	rs3818521	chr6:33657246	C/T	cg14003231	chr6:33640908	ITPR3	0.3	5.31	0.32	2.43e-7	Plateletcrit;
KIRP	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	1.17	10.24	0.55	1e-20	Skin colour saturation;
KIRP	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Bipolar disorder;
KIRP	cis	rs2292864	0.764	rs2292867	chr17:45357489	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-6.04	-0.36	5.71e-9	Left atrial antero-posterior diameter;
KIRP	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg10932868	chr11:921992	NA	-0.68	-9.31	-0.51	7.51e-18	Alzheimer's disease (late onset);
KIRP	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.8	11.41	0.59	1.82e-24	Blood metabolite ratios;
KIRP	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.04	-0.31	9.14e-7	Menarche (age at onset);
KIRP	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg23307798	chr14:103986281	CKB	0.47	6.58	0.39	2.8e-10	Body mass index;
KIRP	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.78	10.48	0.56	1.68e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-6.79	-0.4	8.37e-11	Vitiligo;
KIRP	cis	rs1143633	0.537	rs4625908	chr2:113627966	C/T	cg03712744	chr2:113669835	IL1F7	-0.35	-4.88	-0.3	1.93e-6	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.19	0.31	4.42e-7	Breast cancer;
KIRP	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg26876637	chr1:152193138	HRNR	0.78	10.24	0.55	9.91e-21	Atopic dermatitis;
KIRP	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg16006841	chr5:176797999	RGS14	0.79	10.68	0.56	4.11e-22	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg16497661	chr14:103986332	CKB	0.48	6.13	0.36	3.52e-9	Coronary artery disease;
KIRP	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.6	7.16	0.42	9.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.41	-4.9	-0.3	1.77e-6	Cognitive function;
KIRP	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.33	-0.32	2.22e-7	Coronary artery disease;
KIRP	trans	rs7999699	0.902	rs12428846	chr13:48322743	G/A	cg23237801	chr1:16476620	EPHA2	0.52	6.56	0.39	3.19e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs35740288	0.770	rs11631386	chr15:86191995	A/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.76	-0.34	2.55e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.9	-11.6	-0.59	4.28e-25	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.54	7.47	0.43	1.37e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg27205649	chr11:78285834	NARS2	-0.67	-7.69	-0.44	3.55e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg05973401	chr12:123451056	ABCB9	0.57	6.62	0.39	2.21e-10	Neutrophil percentage of white cells;
KIRP	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg21174375	chr14:64681225	SYNE2	0.67	9.21	0.51	1.52e-17	Atrial fibrillation;
KIRP	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.22	0.37	2.09e-9	Neuroticism;
KIRP	cis	rs9323205	0.677	rs11620820	chr14:51734445	C/T	cg23942311	chr14:51606299	NA	-0.53	-5.06	-0.31	8.06e-7	Cancer;
KIRP	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg05340658	chr4:99064831	C4orf37	-0.54	-6.74	-0.39	1.12e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg17294928	chr15:75287854	SCAMP5	-0.78	-4.98	-0.3	1.2e-6	Lung cancer;
KIRP	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.61	-7.83	-0.45	1.49e-13	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07701084	chr6:150067640	NUP43	0.59	7.0	0.41	2.46e-11	Lung cancer;
KIRP	cis	rs4523957	0.523	rs2760746	chr17:2034806	G/C	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.56	-6.12	-0.36	3.76e-9	DNA methylation (variation);
KIRP	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg10523679	chr1:76189770	ACADM	0.73	9.35	0.51	5.46e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs785830	0.558	rs549707	chr9:259575	G/A	cg14500300	chr9:211689	NA	0.41	5.54	0.33	7.89e-8	Platelet distribution width;
KIRP	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14737332	chr10:114709880	TCF7L2	0.48	6.74	0.39	1.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9920506	0.536	rs11072768	chr15:78929478	A/C	cg24631222	chr15:78858424	CHRNA5	-0.44	-5.02	-0.3	1e-6	Post bronchodilator FEV1;
KIRP	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11987759	chr7:65425863	GUSB	0.48	6.25	0.37	1.75e-9	Aortic root size;
KIRP	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg01804193	chr12:63026212	NA	0.59	6.31	0.37	1.27e-9	IgG glycosylation;
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.45	-5.35	-0.32	2.05e-7	Longevity;Endometriosis;
KIRP	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.66	8.09	0.46	2.67e-14	Blood metabolite levels;
KIRP	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg27205649	chr11:78285834	NARS2	-0.66	-8.36	-0.47	4.59e-15	Alzheimer's disease (survival time);
KIRP	cis	rs7572644	0.621	rs4462754	chr2:28063994	C/T	cg27432699	chr2:27873401	GPN1	0.47	5.7	0.34	3.36e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg25683012	chr12:57030113	BAZ2A	-0.49	-6.22	-0.37	2.12e-9	Neuroticism;
KIRP	cis	rs7534824	0.625	rs12561853	chr1:101457863	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.66	-5.92	-0.35	1.07e-8	Refractive astigmatism;
KIRP	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-1.04	-19.49	-0.78	8.62e-52	Bone mineral density;
KIRP	cis	rs9535307	1.000	rs9535307	chr13:50291842	A/C	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.53	0.38	3.8e-10	Rheumatoid arthritis;
KIRP	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.64	0.48	7.3e-16	Prudent dietary pattern;
KIRP	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.57	7.47	0.43	1.39e-12	HDL cholesterol;
KIRP	trans	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg06521331	chr12:34319734	NA	-0.49	-6.23	-0.37	1.97e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15251212	chr17:36508330	SOCS7	0.52	6.66	0.39	1.8e-10	Parkinson's disease;
KIRP	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.23	0.32	3.71e-7	Educational attainment;
KIRP	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.41	-11.39	-0.59	1.99e-24	Plateletcrit;
KIRP	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg13482628	chr17:19912719	NA	0.53	6.9	0.4	4.36e-11	Schizophrenia;
KIRP	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.24	-0.47	1.03e-14	Retinal vascular caliber;
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg23985595	chr17:80112537	CCDC57	0.34	5.1	0.31	6.8e-7	Life satisfaction;
KIRP	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	7.85e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239815	0.515	rs5762848	chr22:29236308	A/G	cg02153584	chr22:29168773	CCDC117	0.59	5.73	0.34	2.93e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg02297831	chr4:17616191	MED28	0.55	6.83	0.4	6.5500000000000006e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.77	-0.35	2.32e-8	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25485651	chr12:93167359	EEA1	-0.46	-7.03	-0.41	2.02e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg15839431	chr19:19639596	YJEFN3	-0.49	-5.24	-0.32	3.53e-7	Bipolar disorder;
KIRP	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.87	13.01	0.64	8.22e-30	Coronary artery disease;
KIRP	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.59	-7.97	-0.45	5.86e-14	Pulse pressure;
KIRP	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg18261050	chr1:119551319	NA	-0.51	-6.75	-0.4	1.08e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.04	19.51	0.78	7.23e-52	Schizophrenia;
KIRP	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg00806126	chr19:22604979	ZNF98	0.6	6.41	0.38	7.52e-10	Pain;
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.66	9.83	0.53	1.92e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.63	9.13	0.5	2.59e-17	Resting heart rate;
KIRP	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.66	-8.75	-0.49	3.35e-16	Red blood cell count;
KIRP	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-1.0	-19.85	-0.78	5.58e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.16	15.43	0.7	4.96e-38	Platelet count;
KIRP	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg24579218	chr15:68104479	NA	-0.57	-9.27	-0.51	9.49e-18	Restless legs syndrome;
KIRP	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg11845111	chr2:191398756	TMEM194B	-0.95	-10.6	-0.56	7.08e-22	Diastolic blood pressure;
KIRP	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.7	0.44	3.35e-13	Iron status biomarkers;
KIRP	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.43	5.5	0.33	9.33e-8	IgG glycosylation;
KIRP	cis	rs5753037	0.809	rs2074707	chr22:30210356	G/A	cg01021169	chr22:30184971	ASCC2	-0.41	-5.02	-0.3	9.97e-7	Type 1 diabetes;
KIRP	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.48	7.0	0.41	2.38e-11	Lewy body disease;
KIRP	cis	rs2882667	0.537	rs6887866	chr5:138437696	T/C	cg26929925	chr5:138714136	SLC23A1	0.34	4.94	0.3	1.47e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.18	-0.31	4.68e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21659725	chr3:3221576	CRBN	-0.58	-7.01	-0.41	2.29e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.7	8.79	0.49	2.64e-16	Coronary artery disease;
KIRP	cis	rs7615316	0.779	rs4441672	chr3:142149212	C/T	cg20824294	chr3:142316082	PLS1	0.24	5.35	0.32	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.25	-0.32	3.27e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg02297831	chr4:17616191	MED28	-0.51	-6.26	-0.37	1.66e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.83	13.83	0.66	1.44e-32	Longevity;
KIRP	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg01238044	chr22:24384105	GSTT1	-0.55	-7.3	-0.42	3.95e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs824248	0.566	rs824251	chr9:28773458	A/G	cg07986222	chr10:134550649	INPP5A	-0.49	-6.03	-0.36	5.99e-9	Type 2 diabetes;
KIRP	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.72	-10.28	-0.55	7.66e-21	Height;
KIRP	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.52	-6.74	-0.39	1.12e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg02487422	chr3:49467188	NICN1	0.37	5.16	0.31	5.19e-7	Parkinson's disease;
KIRP	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.11	-0.31	6.6e-7	Breast cancer;
KIRP	cis	rs9488822	0.614	rs195529	chr6:116251893	T/C	cg05304507	chr6:116381966	FRK	0.21	5.36	0.32	1.95e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs7221595	0.825	rs12951359	chr17:3921731	T/A	cg21734707	chr17:3908241	ZZEF1	0.53	5.11	0.31	6.52e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.49	6.19	0.37	2.45e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg01879757	chr17:41196368	BRCA1	-0.78	-10.73	-0.56	2.7e-22	Menopause (age at onset);
KIRP	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-4.9	-0.3	1.71e-6	Aortic root size;
KIRP	cis	rs6120849	0.901	rs6088737	chr20:33745938	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	6.12	0.36	3.65e-9	Protein C levels;
KIRP	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-5.71	-0.34	3.19e-8	Coronary artery disease;
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.5	7.49	0.43	1.26e-12	Lung cancer;
KIRP	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg02257048	chr17:78880031	RPTOR	0.47	6.21	0.37	2.24e-9	Educational attainment;
KIRP	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.84	9.87	0.53	1.44e-19	Eosinophil percentage of granulocytes;
KIRP	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.58	-7.88	-0.45	1.08e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs55986470	0.703	rs11887099	chr2:239447550	T/C	cg18131467	chr2:239335373	ASB1	-0.62	-6.14	-0.36	3.28e-9	Chronotype;
KIRP	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.98	12.7	0.63	9.08e-29	IgG glycosylation;
KIRP	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg04132472	chr17:19861366	AKAP10	0.41	5.41	0.33	1.52e-7	Schizophrenia;
KIRP	cis	rs2241685	0.570	rs2195905	chr2:1907728	C/T	cg22511877	chr2:1942942	MYT1L	-0.58	-5.37	-0.32	1.86e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	1.04	13.42	0.65	3.63e-31	Neutrophil percentage of white cells;
KIRP	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg18646521	chr2:111875858	NA	0.4	5.73	0.34	2.94e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.7	9.01	0.5	5.7e-17	Dilated cardiomyopathy;
KIRP	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.65	7.44	0.43	1.65e-12	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06294630	chr7:123181238	NDUFA5	-0.44	-6.83	-0.4	6.77e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg01214346	chr17:406501	NA	0.4	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-1.08	-12.03	-0.61	1.55e-26	Psoriasis;
KIRP	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.84	11.75	0.6	1.31e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7766436	0.524	rs6938780	chr6:22556791	C/A	cg13666174	chr6:22585274	NA	-0.42	-4.95	-0.3	1.36e-6	Coronary artery disease;
KIRP	cis	rs3862030	0.510	rs11591780	chr10:104225316	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-6.31	-0.37	1.27e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs4363385	0.647	rs56158137	chr1:152994380	A/T	cg07796016	chr1:152779584	LCE1C	-0.49	-6.3	-0.37	1.33e-9	Inflammatory skin disease;
KIRP	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg05347473	chr6:146136440	FBXO30	0.41	5.58	0.34	6.44e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.64	7.93	0.45	7.66e-14	Type 2 diabetes;
KIRP	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-10.89	-0.57	8.51e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.53	8.09	0.46	2.72e-14	Huntington's disease progression;
KIRP	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.34	0.32	2.15e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs9469913	0.740	rs2744938	chr6:34552110	A/G	cg17674042	chr6:34482479	PACSIN1	-0.43	-5.88	-0.35	1.31e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs8014252	0.803	rs74938470	chr14:71040022	T/C	cg11204974	chr14:71022665	NA	-0.71	-6.99	-0.41	2.61e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg01631408	chr1:248437212	OR2T33	0.61	7.87	0.45	1.11e-13	Common traits (Other);
KIRP	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg08885076	chr2:99613938	TSGA10	0.48	8.14	0.46	2.01e-14	Chronic sinus infection;
KIRP	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs714027	0.585	rs960987	chr22:30343477	C/T	cg27665648	chr22:30112403	NA	0.41	5.66	0.34	4.27e-8	Lymphocyte counts;
KIRP	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.35	-4.93	-0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.45	5.82	0.35	1.83e-8	Crohn's disease;
KIRP	cis	rs4751006	0.543	rs61875503	chr10:128771532	G/A	cg05702161	chr10:128779687	DOCK1	-1.17	-9.14	-0.5	2.38e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg03959625	chr15:84868606	LOC388152	0.72	8.62	0.48	8.3e-16	Schizophrenia;
KIRP	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.83	0.4	6.47e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg25356066	chr3:128598488	ACAD9	-0.48	-5.62	-0.34	5.06e-8	IgG glycosylation;
KIRP	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg04414720	chr1:150670196	GOLPH3L	0.37	4.86	0.3	2.13e-6	Blood protein levels;
KIRP	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.72	-0.53	4.18e-19	Schizophrenia;
KIRP	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.3	-0.32	2.54e-7	Blood metabolite levels;
KIRP	cis	rs3931020	0.566	rs1327086	chr1:75271032	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.41	5.94	0.35	9.71e-9	Resistin levels;
KIRP	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.58	7.12	0.41	1.16e-11	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.75	6.4	0.38	7.94e-10	Body mass index;
KIRP	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg26116260	chr4:7069785	GRPEL1	-0.85	-5.32	-0.32	2.34e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3885907	0.626	rs9315049	chr13:31330981	A/C	cg19953038	chr13:31306303	NA	0.47	5.6	0.34	5.74e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
KIRP	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg26022315	chr17:47021804	SNF8	0.41	5.42	0.33	1.41e-7	Type 2 diabetes;
KIRP	cis	rs9473924	0.580	rs58105163	chr6:50832730	C/T	cg14470998	chr6:50812995	TFAP2B	0.79	7.47	0.43	1.39e-12	Body mass index;
KIRP	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.57	-6.24	-0.37	1.9e-9	DNA methylation (variation);
KIRP	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg25797454	chr6:150327115	RAET1K	0.36	6.77	0.4	9.33e-11	Alopecia areata;
KIRP	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.4	5.19	0.31	4.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.65	-7.78	-0.44	1.97e-13	Iron status biomarkers;
KIRP	cis	rs740698	0.521	rs9891713	chr17:60789405	C/T	cg00648184	chr17:60828157	MARCH10	0.31	5.04	0.31	9.09e-7	Pulse pressure;
KIRP	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17554472	chr22:41940697	POLR3H	-0.66	-6.79	-0.4	8.39e-11	Vitiligo;
KIRP	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg16558253	chr16:72132732	DHX38	-0.6	-8.95	-0.5	8.84e-17	Fibrinogen levels;
KIRP	cis	rs6723108	0.664	rs6741007	chr2:135537119	T/G	cg25422880	chr2:135218333	TMEM163	-0.49	-7.11	-0.41	1.25e-11	Type 2 diabetes;
KIRP	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg10189774	chr4:17578691	LAP3	0.48	5.48	0.33	1.08e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg04727924	chr7:799746	HEATR2	-0.66	-6.52	-0.38	3.9e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.96	15.74	0.71	4.39e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg01763666	chr17:80159506	CCDC57	0.36	4.94	0.3	1.47e-6	Life satisfaction;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg02303361	chr19:47354240	AP2S1	0.49	6.16	0.37	2.88e-9	Asthma;
KIRP	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg04374321	chr14:90722782	PSMC1	-0.86	-12.5	-0.62	4.22e-28	Mortality in heart failure;
KIRP	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.68	10.01	0.54	5.41e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg04691961	chr3:161091175	C3orf57	-0.54	-8.22	-0.46	1.14e-14	Morning vs. evening chronotype;
KIRP	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.23	0.7	2.45e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg05564831	chr3:52568323	NT5DC2	0.32	4.88	0.3	1.88e-6	Electroencephalogram traits;
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.09e-16	Life satisfaction;
KIRP	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	6.81	0.4	7.33e-11	Homocysteine levels;
KIRP	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg04691961	chr3:161091175	C3orf57	-0.37	-5.7	-0.34	3.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.48	-0.33	1.05e-7	Metabolite levels;
KIRP	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg27432699	chr2:27873401	GPN1	-0.51	-6.63	-0.39	2.06e-10	Total body bone mineral density;
KIRP	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg09695851	chr17:3907499	NA	-0.82	-15.04	-0.69	1.1e-36	Type 2 diabetes;
KIRP	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26314531	chr2:26401878	FAM59B	-0.46	-4.9	-0.3	1.72e-6	Gut microbiome composition (summer);
KIRP	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.27	-5.53	-0.33	8.24e-8	Menarche (age at onset);
KIRP	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg03959625	chr15:84868606	LOC388152	0.65	7.85	0.45	1.29e-13	Schizophrenia;
KIRP	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg17376030	chr22:41985996	PMM1	-0.64	-6.74	-0.39	1.1e-10	Vitiligo;
KIRP	trans	rs78438709	1.000	rs74765115	chr10:124126358	T/G	cg08224212	chr11:34196093	ABTB2	-0.99	-6.32	-0.37	1.25e-9	Headache;
KIRP	cis	rs6690583	0.623	rs74761855	chr1:85432947	A/C	cg22153463	chr1:85462885	MCOLN2	0.59	4.91	0.3	1.63e-6	Serum sulfate level;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11442052	chr3:35723321	ARPP-21	0.43	6.89	0.4	4.75e-11	Survival in pancreatic cancer;
KIRP	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.74	11.79	0.6	9.97e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg03060546	chr3:49711283	APEH	-0.62	-6.1	-0.36	4.16e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs61935443	0.832	rs11107771	chr12:95276844	A/G	cg21533806	chr12:95267307	NA	0.65	6.55	0.39	3.42e-10	Schizophrenia;
KIRP	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg25356066	chr3:128598488	ACAD9	0.52	6.0	0.36	6.87e-9	IgG glycosylation;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg14933266	chr17:29422051	NF1	0.49	6.12	0.36	3.76e-9	Educational attainment;
KIRP	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg04013166	chr16:89971882	TCF25	0.59	4.99	0.3	1.12e-6	Skin colour saturation;
KIRP	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg20607798	chr8:58055168	NA	0.67	5.26	0.32	3.19e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg14458575	chr2:238380390	NA	0.5	5.64	0.34	4.6e-8	Prostate cancer;
KIRP	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.7	9.33	0.51	6.35e-18	Mood instability;
KIRP	cis	rs17253792	0.545	rs12894613	chr14:56016221	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.68	-0.39	1.55e-10	Coronary artery disease;
KIRP	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.22	0.46	1.14e-14	Retinal vascular caliber;
KIRP	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.29	0.37	1.45e-9	Uric acid levels;
KIRP	cis	rs73058052	0.597	rs2288921	chr19:50092002	G/T	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.47	-5.77	-0.35	2.42e-8	Fibrinogen levels;
KIRP	cis	rs4704187	0.640	rs4704183	chr5:74471048	C/G	cg03227963	chr5:74354835	NA	0.4	6.0	0.36	7.09e-9	Response to amphetamines;
KIRP	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.49	-6.11	-0.36	3.94e-9	Iron status biomarkers;
KIRP	trans	rs10242455	0.702	rs917152	chr7:99004497	T/C	cg09045935	chr12:6379348	NA	0.87	6.13	0.36	3.44e-9	Blood metabolite levels;
KIRP	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg18306943	chr3:40428807	ENTPD3	0.43	5.73	0.34	2.97e-8	Renal cell carcinoma;
KIRP	cis	rs7215564	0.730	rs9901550	chr17:78584464	T/C	cg06153925	chr17:78755379	RPTOR	0.36	5.67	0.34	4.05e-8	Myopia (pathological);
KIRP	trans	rs9790314	0.589	rs1447618	chr3:160610438	C/T	cg19274270	chr17:78178856	CARD14	0.35	6.16	0.37	2.88e-9	Morning vs. evening chronotype;
KIRP	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.67	7.42	0.43	1.91e-12	Hair shape;
KIRP	cis	rs12580194	0.593	rs61957885	chr12:55720876	C/G	cg11794356	chr12:55725991	OR6C3	-0.6	-8.41	-0.47	3.31e-15	Cancer;
KIRP	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg05805236	chr11:65401703	PCNXL3	-0.56	-7.11	-0.41	1.28e-11	Acne (severe);
KIRP	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.24	0.51	1.21e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17795291	chr8:27692811	PBK	-0.42	-6.09	-0.36	4.41e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg19847130	chr8:10466454	RP1L1	0.32	4.92	0.3	1.62e-6	Neuroticism;
KIRP	cis	rs7119167	0.686	rs6592520	chr11:73048267	T/G	cg17517138	chr11:73019481	ARHGEF17	0.48	5.06	0.31	8.05e-7	Blood protein levels;
KIRP	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.89	-0.35	1.25e-8	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs514024	0.665	rs534652	chr9:130494667	G/A	cg13643465	chr9:130375613	STXBP1	0.47	6.21	0.37	2.25e-9	Eating disorders (purging via substances);
KIRP	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.94	15.67	0.71	7.25e-39	Ulcerative colitis;
KIRP	cis	rs1620921	0.967	rs1247558	chr6:161190199	A/G	cg01280913	chr6:161186852	NA	-0.42	-5.86	-0.35	1.48e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg07936489	chr17:37558343	FBXL20	-0.46	-5.64	-0.34	4.74e-8	Asthma;
KIRP	cis	rs9900972	0.720	rs6501257	chr17:76877655	G/A	cg00961940	chr17:76876995	TIMP2	0.55	7.18	0.42	8.01e-12	Obesity-related traits;
KIRP	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg11995313	chr8:8860691	ERI1	0.39	5.41	0.33	1.5e-7	Joint mobility (Beighton score);
KIRP	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg05914723	chr15:78953907	NA	0.44	5.23	0.32	3.63e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1696756	0.877	rs1663223	chr17:77826509	A/G	cg00646381	chr17:77835854	NA	0.54	6.67	0.39	1.7e-10	Glucocorticoid-induced osteonecrosis (age 10 years and older);
KIRP	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg00129232	chr17:37814104	STARD3	0.48	6.15	0.37	3.06e-9	Self-reported allergy;
KIRP	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg07741184	chr6:167504864	NA	-0.21	-5.5	-0.33	9.62e-8	Graves' disease;
KIRP	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg14459158	chr9:96720562	NA	0.28	5.01	0.3	1.04e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6921919	0.583	rs16894060	chr6:28362471	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.25	-0.37	1.8e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.9	-8.95	-0.5	8.58e-17	Blood protein levels;
KIRP	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg15128208	chr22:42549153	NA	0.69	7.67	0.44	3.97e-13	Birth weight;
KIRP	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg00376283	chr12:123451042	ABCB9	-0.64	-7.38	-0.43	2.49e-12	Neutrophil percentage of white cells;
KIRP	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg25019033	chr10:957182	NA	-0.36	-4.93	-0.3	1.53e-6	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.51	6.37	0.38	9.15e-10	Longevity;Endometriosis;
KIRP	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg13175981	chr1:150552382	MCL1	0.52	6.65	0.39	1.87e-10	Tonsillectomy;
KIRP	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.83	11.22	0.58	7.28e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.28e-8	Pubertal anthropometrics;
KIRP	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.56	-7.12	-0.41	1.21e-11	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.85	7.54	0.43	9.19e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13939156	chr17:80058883	NA	0.56	9.03	0.5	5.03e-17	Life satisfaction;
KIRP	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs12930096	1.000	rs12921437	chr16:11680148	T/C	cg07439791	chr16:11680400	LITAF	0.69	5.49	0.33	9.94e-8	QT interval;
KIRP	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg00981070	chr1:2046702	PRKCZ	0.41	5.86	0.35	1.5e-8	Height;
KIRP	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg17366294	chr4:99064904	C4orf37	0.47	5.76	0.34	2.55e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7715811	0.913	rs6869474	chr5:13768691	C/T	cg07548982	chr5:13769939	DNAH5	-0.57	-7.0	-0.41	2.43e-11	Subclinical atherosclerosis traits (other);
KIRP	cis	rs988913	0.706	rs4296891	chr6:54938193	A/T	cg03513858	chr6:54763001	FAM83B	-0.39	-5.69	-0.34	3.54e-8	Menarche (age at onset);
KIRP	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg25753631	chr6:25732923	NA	0.27	5.01	0.3	1.04e-6	Iron status biomarkers;
KIRP	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.66	0.34	4.16e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs854624	0.792	rs1719199	chr17:34337997	A/G	cg23743114	chr17:34328396	CCL15;CCL14-CCL15	0.53	4.94	0.3	1.46e-6	Blood protein levels;
KIRP	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg00262122	chr8:11665843	FDFT1	0.38	4.89	0.3	1.85e-6	Neuroticism;
KIRP	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.59	0.65	9.3900000000000005e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4523957	0.522	rs8081921	chr17:2021490	C/A	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg17764715	chr19:33622953	WDR88	0.64	7.7	0.44	3.28e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.6e-9	Lung cancer;
KIRP	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-1.0	-16.32	-0.72	4.39e-41	Height;
KIRP	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.47	-0.33	1.1e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg17356467	chr2:100759845	AFF3	0.55	5.63	0.34	4.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	7.85	0.45	1.25e-13	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.25e-11	Diabetic kidney disease;
KIRP	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.32	1.9e-7	Menopause (age at onset);
KIRP	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.59	7.82	0.45	1.58e-13	Lung cancer;
KIRP	cis	rs2346160	0.899	rs206972	chr6:167689552	C/T	cg27333441	chr6:167680455	NA	-0.38	-5.13	-0.31	5.92e-7	Parental extreme longevity (95 years and older);
KIRP	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.67	8.96	0.5	8.02e-17	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05220968	chr6:146057943	EPM2A	-0.4	-5.02	-0.3	1.01e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	10.13	0.54	2.15e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg00938859	chr5:1591904	SDHAP3	0.53	6.26	0.37	1.69e-9	Breast cancer;
KIRP	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.63	-7.77	-0.44	2.14e-13	P wave terminal force;
KIRP	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg02297831	chr4:17616191	MED28	0.6	7.64	0.44	4.94e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs860295	0.836	rs1360554	chr1:155473356	C/T	cg02153340	chr1:155202674	NA	0.37	4.97	0.3	1.27e-6	Body mass index;
KIRP	cis	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg03511173	chr18:77590860	NA	-0.46	-5.04	-0.31	9.21e-7	Opioid sensitivity;
KIRP	cis	rs6545883	0.931	rs12713438	chr2:61725501	G/A	cg15711740	chr2:61764176	XPO1	-0.59	-8.12	-0.46	2.25e-14	Tuberculosis;
KIRP	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.94	13.53	0.65	1.44e-31	Gestational age at birth (maternal effect);
KIRP	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg01877450	chr7:97915802	BRI3	0.55	7.16	0.42	9.35e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7078219	0.714	rs10883363	chr10:101287580	C/T	cg07044859	chr10:101282883	NA	-0.34	-5.02	-0.3	1.01e-6	Dental caries;
KIRP	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.02	0.31	9.74e-7	Schizophrenia;
KIRP	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg21684588	chr1:67600265	NA	0.44	5.26	0.32	3.16e-7	Psoriasis;
KIRP	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-7.31	-0.42	3.83e-12	Blood metabolite levels;
KIRP	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.98	0.3	1.19e-6	Menopause (age at onset);
KIRP	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.79	-11.62	-0.6	3.51e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg07451762	chr16:28383216	NA	0.42	5.43	0.33	1.34e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg13546538	chr9:111754815	CTNNAL1	-0.38	-6.2	-0.37	2.33e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg26138937	chr11:71823887	C11orf51	-1.15	-8.03	-0.46	3.95e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg23719950	chr11:63933701	MACROD1	-0.63	-5.39	-0.32	1.67e-7	Mean platelet volume;
KIRP	cis	rs11586313	0.507	rs3856026	chr1:152869763	T/C	cg13444842	chr1:152974279	SPRR3	-0.36	-4.98	-0.3	1.18e-6	Vitamin D levels;
KIRP	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg15038512	chr6:170123185	PHF10	-0.56	-8.58	-0.48	1.08e-15	Obesity-related traits;
KIRP	cis	rs10463554	0.553	rs72785712	chr5:102324397	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.77	-0.35	2.42e-8	Parkinson's disease;
KIRP	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.02	0.75	7.47e-47	Chronic sinus infection;
KIRP	cis	rs17453880	0.890	rs4958319	chr5:151961998	T/A	cg12297329	chr5:152029980	NA	-0.68	-10.16	-0.54	1.74e-20	Subjective well-being;
KIRP	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg17554472	chr22:41940697	POLR3H	-0.61	-6.53	-0.38	3.74e-10	Vitiligo;
KIRP	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-8.6	-0.48	9.76e-16	Mean corpuscular volume;
KIRP	cis	rs13202913	0.639	rs9397407	chr6:151748995	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	4.98	0.3	1.22e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.13.80601193R	chr13:81703192	NA	0.45	6.4	0.38	7.95e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg06027949	chr8:82754900	SNX16	-0.62	-6.61	-0.39	2.3e-10	Diastolic blood pressure;
KIRP	cis	rs62120679	0.552	rs4807227	chr19:2318180	C/T	cg07474816	chr19:2321113	NA	0.41	4.95	0.3	1.39e-6	Parkinson's disease;
KIRP	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.44	4.04e-13	Bladder cancer;
KIRP	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.77	9.83	0.53	1.84e-19	Aortic root size;
KIRP	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg03235661	chr20:60525775	NA	-0.3	-5.06	-0.31	8.35e-7	Body mass index;
KIRP	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-8.45	-0.47	2.62e-15	Monocyte percentage of white cells;
KIRP	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.45e-21	Diabetic kidney disease;
KIRP	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg19035181	chr20:25580630	NA	0.44	5.01	0.3	1.03e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg08773314	chr2:239334832	ASB1	-0.53	-5.36	-0.32	1.95e-7	Chronotype;
KIRP	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.68	9.87	0.53	1.42e-19	Dupuytren's disease;
KIRP	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.69	9.06	0.5	4.05e-17	Cognitive function;
KIRP	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.79	0.49	2.68e-16	Bipolar disorder;
KIRP	cis	rs6001982	0.667	rs73167090	chr22:40888363	G/A	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-5.53	-0.33	8.3e-8	Body mass index;
KIRP	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.89	9.65	0.52	6.66e-19	Pulmonary function decline;
KIRP	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.32	-0.42	3.56e-12	Neuroticism;
KIRP	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	8.74	0.49	3.67e-16	Cognitive test performance;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs2278796	0.693	rs2794859	chr1:204967256	A/G	cg17449235	chr1:204966235	NFASC	0.47	6.6	0.39	2.44e-10	Mean platelet volume;
KIRP	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.71	10.03	0.54	4.54e-20	Mean corpuscular volume;
KIRP	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-1.09	-10.39	-0.55	3.41e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-8.16	-0.46	1.7e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4654899	1.000	rs4654899	chr1:21410231	G/T	cg05370193	chr1:21551575	ECE1	0.39	5.2	0.31	4.12e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.9	0.53	1.18e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg13072238	chr3:49761600	GMPPB	0.65	5.62	0.34	5.05e-8	Menarche (age at onset);
KIRP	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.65	0.44	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20952358	chr5:95297817	ELL2	0.57	6.68	0.39	1.62e-10	Lung cancer in ever smokers;
KIRP	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg00919237	chr7:87102261	ABCB4	-0.75	-9.54	-0.52	1.49e-18	Gallbladder cancer;
KIRP	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg22617819	chr1:44378782	ST3GAL3	-0.32	-4.89	-0.3	1.84e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7937890	1.000	rs2915401	chr11:14375013	T/C	cg19336497	chr11:14380999	RRAS2	0.35	5.03	0.31	9.32e-7	Mitochondrial DNA levels;
KIRP	cis	rs9879311	1.000	rs9879311	chr3:10415343	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.4	5.32	0.32	2.3e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg01320579	chr17:75405842	SEPT9	0.47	7.71	0.44	3.21e-13	Airflow obstruction;
KIRP	cis	rs2708977	0.698	rs772159	chr2:97036439	G/A	cg01950434	chr2:97203154	ARID5A	-0.41	-5.43	-0.33	1.34e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2625529	0.701	rs2306490	chr15:72227837	A/G	cg16672083	chr15:72433130	SENP8	-0.5	-6.08	-0.36	4.49e-9	Red blood cell count;
KIRP	cis	rs13067260	0.655	rs9813249	chr3:123732711	G/C	cg19918027	chr3:123987645	KALRN	-0.61	-5.35	-0.32	1.99e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17554472	chr22:41940697	POLR3H	0.69	7.1	0.41	1.35e-11	Vitiligo;
KIRP	cis	rs911119	0.913	rs13043610	chr20:23586941	G/A	cg09631192	chr20:23583594	CST9	-0.64	-6.19	-0.37	2.44e-9	Chronic kidney disease;
KIRP	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.61	0.48	8.84e-16	Prudent dietary pattern;
KIRP	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg01420254	chr6:26195488	NA	1.24	11.27	0.58	4.85e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.73	8.21	0.46	1.29e-14	Platelet count;
KIRP	cis	rs4700695	0.841	rs44267	chr5:65274311	G/A	cg21114390	chr5:65439923	SFRS12	0.54	5.12	0.31	6.14e-7	Facial morphology (factor 19);
KIRP	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg05234568	chr11:5960015	NA	-0.6	-6.18	-0.37	2.71e-9	DNA methylation (variation);
KIRP	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	1.03	18.37	0.76	4.93e-48	Leprosy;
KIRP	cis	rs2742417	1.000	rs2742435	chr3:45740863	C/T	cg04037228	chr3:45636386	LIMD1	0.35	5.02	0.3	1.01e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4671458	0.762	rs1109027	chr2:63815206	A/G	cg17519650	chr2:63277830	OTX1	-0.52	-5.39	-0.32	1.67e-7	Subjective well-being;
KIRP	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	10.32	0.55	5.73e-21	Cognitive test performance;
KIRP	cis	rs2718058	0.836	rs4723711	chr7:37844263	T/A	cg15028436	chr7:37888078	TXNDC3	-0.48	-6.39	-0.38	8.03e-10	Alzheimer's disease (late onset);
KIRP	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg20387954	chr3:183756860	HTR3D	0.62	9.06	0.5	4.19e-17	Anterior chamber depth;
KIRP	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.5	-5.17	-0.31	4.9e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.77	-10.24	-0.55	1.01e-20	Neuroblastoma (high-risk);
KIRP	cis	rs6466055	0.720	rs6466057	chr7:104952483	A/G	cg04380332	chr7:105027541	SRPK2	0.62	9.52	0.52	1.73e-18	Schizophrenia;
KIRP	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.8	-10.41	-0.55	2.93e-21	Platelet count;
KIRP	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg12131826	chr15:77904385	NA	-0.43	-5.4	-0.33	1.59e-7	Type 2 diabetes;
KIRP	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg25801113	chr15:45476975	SHF	-0.45	-8.21	-0.46	1.28e-14	Uric acid levels;
KIRP	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg03060546	chr3:49711283	APEH	-0.68	-5.22	-0.32	3.85e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg07741184	chr6:167504864	NA	-0.24	-6.42	-0.38	7e-10	Crohn's disease;
KIRP	cis	rs4711336	1.000	rs4711337	chr6:33659987	T/C	cg15676125	chr6:33679581	C6orf125	0.41	5.52	0.33	8.65e-8	Height;
KIRP	cis	rs787274	1.000	rs787294	chr9:115540424	T/C	cg13803584	chr9:115635662	SNX30	-0.72	-6.34	-0.37	1.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg23024343	chr7:107201750	COG5	0.43	4.96	0.3	1.31e-6	Coronary artery disease;
KIRP	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs6750047	0.585	rs336033	chr2:38263808	A/G	cg07380506	chr2:38303506	CYP1B1	-0.45	-5.89	-0.35	1.29e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg02002194	chr4:3960332	NA	-0.47	-7.14	-0.41	1.07e-11	Mood instability;
KIRP	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.92	11.7	0.6	1.91e-25	Homoarginine levels;
KIRP	cis	rs7709377	0.570	rs11738674	chr5:115443149	C/G	cg23108291	chr5:115420582	COMMD10	0.41	4.94	0.3	1.43e-6	Metabolite levels  (X-11787);
KIRP	cis	rs4478137	0.931	rs4057797	chr4:164245053	T/A	cg06758707	chr4:164254230	NPY1R	0.71	9.2	0.51	1.63e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg12435725	chr3:58293450	RPP14	-0.43	-4.87	-0.3	1.97e-6	Cholesterol, total;
KIRP	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.08	-0.5	3.6e-17	Retinal vascular caliber;
KIRP	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.62	7.67	0.44	3.93e-13	Multiple sclerosis;
KIRP	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.41	-4.94	-0.3	1.43e-6	Iron status biomarkers;
KIRP	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg07596299	chr11:71824057	C11orf51	0.9	5.21	0.31	4.09e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs10518128	1.000	rs7692503	chr4:75712852	T/A	cg20122727	chr4:75719957	BTC	0.56	5.66	0.34	4.11e-8	Electroencephalogram traits;
KIRP	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg21775007	chr8:11205619	TDH	-0.41	-5.02	-0.3	1e-6	Systolic blood pressure;
KIRP	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	1.03	15.63	0.71	1.05e-38	Cognitive function;
KIRP	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.74	0.53	3.56e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.77	-6.43	-0.38	6.53e-10	Blood pressure (smoking interaction);
KIRP	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg11569703	chr11:65557185	OVOL1	-0.32	-5.12	-0.31	6.21e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.02	-0.54	4.77e-20	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.18	0.31	4.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.74	-9.38	-0.51	4.54e-18	Facial morphology (factor 19);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11916800	chr8:67943173	NA	-0.43	-6.99	-0.41	2.57e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg18944383	chr4:111397179	ENPEP	0.54	9.41	0.51	3.74e-18	Height;
KIRP	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.61	-9.01	-0.5	5.91e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg00225070	chr15:80189496	MTHFS	0.48	5.78	0.35	2.25e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg26681399	chr22:41777847	TEF	0.51	5.12	0.31	6.03e-7	Vitiligo;
KIRP	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.06	-14.23	-0.67	6.25e-34	Body mass index;
KIRP	cis	rs9473924	0.632	rs1547210	chr6:50930485	T/G	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs9815354	1.000	rs17062109	chr3:41810364	C/T	cg03022575	chr3:42003672	ULK4	0.46	5.13	0.31	5.86e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.39	-0.38	8.42e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06481639	chr22:41940642	POLR3H	0.72	7.5	0.43	1.12e-12	Vitiligo;
KIRP	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg25486957	chr4:152246857	NA	-0.48	-5.04	-0.31	8.85e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78545713	1.000	rs3734534	chr6:26240649	A/G	cg01420254	chr6:26195488	NA	-0.75	-6.29	-0.37	1.46e-9	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg19442545	chr10:75533431	FUT11	0.36	4.93	0.3	1.52e-6	Inflammatory bowel disease;
KIRP	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.72	-0.34	3.12e-8	Breast cancer;
KIRP	cis	rs9318086	0.935	rs9553083	chr13:24441525	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-7.86	-0.45	1.23e-13	Myopia (pathological);
KIRP	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg02336718	chr17:17403227	NA	0.35	5.47	0.33	1.1e-7	Total body bone mineral density;
KIRP	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg10189774	chr4:17578691	LAP3	0.51	6.23	0.37	2.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs698833	0.962	rs1085447	chr2:44670996	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.43	-4.96	-0.3	1.34e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.45	7.89	0.45	9.65e-14	Systemic lupus erythematosus;
KIRP	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21643547	chr1:205240462	TMCC2	-0.87	-13.89	-0.66	9.11e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00127505	chr10:131763820	NA	0.38	6.07	0.36	4.69e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7721647	0.810	rs7723015	chr5:90796876	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.43	4.87	0.3	1.99e-6	Breast cancer;
KIRP	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg24189917	chr7:1970923	MAD1L1	-0.54	-4.91	-0.3	1.69e-6	Bipolar disorder;
KIRP	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.93	12.33	0.62	1.66e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13202913	0.608	rs17054363	chr6:151746586	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	5.1	0.31	6.64e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.48	-5.76	-0.34	2.46e-8	Initial pursuit acceleration;
KIRP	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.58	11.96	0.61	2.68e-26	Diabetic kidney disease;
KIRP	trans	rs9987353	0.784	rs330014	chr8:9128844	G/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.18	-0.37	2.61e-9	Recombination measurement;
KIRP	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.58	7.99	0.45	5.19e-14	Height;
KIRP	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg04691961	chr3:161091175	C3orf57	-0.5	-7.55	-0.43	8.44e-13	Morning vs. evening chronotype;
KIRP	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg23032965	chr3:12705835	RAF1	0.67	7.37	0.43	2.56e-12	Cholesterol, total;
KIRP	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.64	-7.05	-0.41	1.78e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11858210	1	rs11858210	chr15:79078358	G/A	cg04896959	chr15:78267971	NA	0.52	6.71	0.39	1.3e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg05340658	chr4:99064831	C4orf37	-0.54	-6.74	-0.39	1.12e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg01958934	chr19:45449099	APOC2	-0.41	-5.23	-0.32	3.61e-7	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09814151	chr13:45151437	TSC22D1	0.43	6.19	0.37	2.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05385496	chr1:28099963	STX12	0.6	7.39	0.43	2.26e-12	Parkinson's disease;
KIRP	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.5	-5.22	-0.32	3.82e-7	Corneal structure;
KIRP	cis	rs11166927	0.548	rs28366721	chr8:140827797	C/G	cg16909799	chr8:140841666	TRAPPC9	-0.79	-11.73	-0.6	1.54e-25	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.53	7.05	0.41	1.77e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.78	-10.63	-0.56	5.62e-22	Educational attainment;
KIRP	cis	rs273218	0.951	rs428213	chr5:53382790	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.64	-7.09	-0.41	1.42e-11	Migraine;
KIRP	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg22029157	chr1:209979665	IRF6	0.38	5.88	0.35	1.35e-8	Monobrow;
KIRP	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg10189774	chr4:17578691	LAP3	0.54	6.5	0.38	4.41e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.71	7.69	0.44	3.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-5.06	-0.31	8.09e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg23594656	chr7:65796392	TPST1	-0.37	-5.36	-0.32	1.92e-7	Aortic root size;
KIRP	cis	rs72634030	0.702	rs3026105	chr17:5281758	C/T	cg20802942	chr17:5185005	RABEP1	0.6	5.73	0.34	2.93e-8	Rheumatoid arthritis;
KIRP	cis	rs3931020	0.688	rs452242	chr1:75225625	G/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.45	-5.1	-0.31	6.77e-7	Resistin levels;
KIRP	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg00262122	chr8:11665843	FDFT1	-0.41	-5.19	-0.31	4.32e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.52	-0.33	8.6e-8	Hip geometry;
KIRP	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg23594656	chr7:65796392	TPST1	0.51	7.89	0.45	9.9e-14	Aortic root size;
KIRP	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.53	6.81	0.4	7.37e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-8.72	-0.49	4.24e-16	Morning vs. evening chronotype;
KIRP	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.4	6.85	0.4	5.95e-11	QRS complex (12-leadsum);
KIRP	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg08076091	chr2:203926405	NBEAL1	0.85	8.77	0.49	3.08e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	1.0	17.22	0.74	3.89e-44	Bone mineral density;
KIRP	cis	rs5995756	0.736	rs1883123	chr22:39996882	C/T	cg10455938	chr22:40058150	CACNA1I	-0.54	-8.11	-0.46	2.45e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12586317	0.557	rs10137757	chr14:35653853	A/G	cg07166546	chr14:35805898	NA	-0.27	-6.54	-0.38	3.54e-10	Psoriasis;
KIRP	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg18154014	chr19:37997991	ZNF793	0.72	6.34	0.37	1.1e-9	Coronary artery calcification;
KIRP	cis	rs1468333	1.000	rs2967782	chr5:137529682	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.47	5.54	0.33	7.74e-8	Resting heart rate;
KIRP	cis	rs11955398	0.716	rs56191602	chr5:59954444	T/A	cg02684056	chr5:59996105	DEPDC1B	0.43	5.09	0.31	7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg21775007	chr8:11205619	TDH	0.45	5.99	0.36	7.53e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11766298	0.702	rs10255583	chr7:128976554	G/C	cg06809055	chr7:129142284	NA	0.69	4.99	0.3	1.12e-6	Response to fenofibrate;
KIRP	cis	rs6450176	1.000	rs5024170	chr5:53300827	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg13482628	chr17:19912719	NA	0.69	10.44	0.55	2.39e-21	Schizophrenia;
KIRP	cis	rs3736485	0.966	rs7170217	chr15:51890678	A/G	cg14296394	chr15:51910925	DMXL2	-0.34	-5.04	-0.31	8.88e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg26531700	chr6:26746687	NA	0.41	5.58	0.33	6.47e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg07777115	chr5:623756	CEP72	-0.58	-5.91	-0.35	1.16e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg05370193	chr1:21551575	ECE1	0.46	6.24	0.37	1.87e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs427941	0.843	rs10255251	chr7:101828876	G/T	cg06246474	chr7:101738831	CUX1	0.55	6.57	0.39	2.98e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6968419	0.674	rs12669768	chr7:115907140	C/T	cg02561103	chr7:115862891	TES	-0.41	-5.84	-0.35	1.65e-8	Intraocular pressure;
KIRP	cis	rs735539	0.521	rs2585898	chr13:21400301	T/C	cg04906043	chr13:21280425	IL17D	-0.46	-5.49	-0.33	9.79e-8	Dental caries;
KIRP	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.39	0.43	2.28e-12	Mean corpuscular volume;
KIRP	cis	rs7614311	0.636	rs66490742	chr3:63913653	G/A	cg22134162	chr3:63841271	THOC7	-0.46	-5.46	-0.33	1.19e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9394169	0.875	rs1547670	chr6:33775868	G/A	cg25922239	chr6:33757077	LEMD2	0.48	5.69	0.34	3.53e-8	Essential tremor;
KIRP	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.85	-9.26	-0.51	1.06e-17	Osteoarthritis;
KIRP	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Bipolar disorder;
KIRP	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.56	6.44	0.38	6.07e-10	Coronary artery disease;
KIRP	cis	rs367943	0.712	rs7714734	chr5:112691261	G/A	cg12552261	chr5:112820674	MCC	0.54	6.34	0.37	1.1e-9	Type 2 diabetes;
KIRP	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.6	-8.58	-0.48	1.07e-15	Urate levels in overweight individuals;
KIRP	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.44	0.55	2.24e-21	Hip circumference;
KIRP	cis	rs612683	0.896	rs12568038	chr1:100879914	C/T	cg09408571	chr1:101003634	GPR88	0.28	5.91	0.35	1.11e-8	Breast cancer;
KIRP	trans	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.93	-0.4	3.66e-11	Bladder cancer;
KIRP	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-13.74	-0.66	2.96e-32	Height;
KIRP	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg15664640	chr17:80829946	TBCD	-0.59	-5.8	-0.35	2.07e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg27121462	chr16:89883253	FANCA	-0.51	-6.62	-0.39	2.27e-10	Vitiligo;
KIRP	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.53	7.38	0.43	2.49e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2281603	0.951	rs73267743	chr14:64978142	G/T	cg25009451	chr14:65006716	HSPA2	0.48	5.17	0.31	4.78e-7	Lymphocyte counts;
KIRP	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18145393	chr4:520203	PIGG	0.42	6.17	0.37	2.8e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg08499158	chr17:42289980	UBTF	-0.72	-9.86	-0.53	1.5700000000000001e-19	Total body bone mineral density;
KIRP	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.67	-7.11	-0.41	1.23e-11	Lymphocyte counts;
KIRP	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.5	5.89	0.35	1.25e-8	Metabolite levels;
KIRP	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.38	-4.9	-0.3	1.74e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.72	-0.39	1.27e-10	Hemoglobin concentration;
KIRP	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	7.92e-7	Electrocardiographic conduction measures;
KIRP	cis	rs2061333	0.557	rs8104573	chr19:44603385	A/G	cg18700516	chr19:44507157	ZNF230	-0.53	-5.04	-0.31	8.84e-7	Alzheimer's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18050194	chr3:42623358	SEC22C	-0.48	-6.4	-0.38	7.9e-10	Metabolic traits;
KIRP	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.44	-0.38	6.17e-10	Obesity-related traits;
KIRP	cis	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg18427987	chr14:74551089	LIN52;ALDH6A1	0.4	5.36	0.32	1.94e-7	Caffeine consumption;
KIRP	cis	rs12134040	0.646	rs11801269	chr1:236506676	C/T	cg21399712	chr1:236511386	NA	-0.54	-7.44	-0.43	1.67e-12	Urate levels (BMI interaction);
KIRP	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg13444842	chr1:152974279	SPRR3	-0.37	-5.21	-0.32	4.07e-7	Inflammatory skin disease;
KIRP	cis	rs8038465	1.000	rs67257650	chr15:73979507	C/T	cg15420318	chr15:73925796	NPTN	0.56	7.1	0.41	1.31e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.97	-0.57	4.62e-23	Height;
KIRP	trans	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg06521331	chr12:34319734	NA	-0.54	-6.69	-0.39	1.53e-10	Heart rate;
KIRP	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg00784671	chr22:46762841	CELSR1	-0.7	-8.58	-0.48	1.1e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.96	16.0	0.71	5.65e-40	Bone mineral density;
KIRP	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.44	-6.08	-0.36	4.6e-9	Coronary artery disease;
KIRP	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.3	0.32	2.61e-7	Bipolar disorder;
KIRP	cis	rs35000415	0.938	rs80086012	chr7:128711874	C/T	cg19972273	chr7:128594194	NA	0.82	6.34	0.37	1.12e-9	Systemic lupus erythematosus;
KIRP	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.85	0.3	2.14e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg23649088	chr2:200775458	C2orf69	-0.68	-5.87	-0.35	1.4e-8	Schizophrenia;
KIRP	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.8	8.16	0.46	1.75e-14	Educational attainment;
KIRP	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg16497661	chr14:103986332	CKB	-0.49	-6.31	-0.37	1.26e-9	Coronary artery disease;
KIRP	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.5	5.24	0.32	3.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg05973401	chr12:123451056	ABCB9	0.61	7.16	0.42	9.38e-12	Neutrophil percentage of white cells;
KIRP	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.3	-6.2	-0.37	2.43e-9	Breast cancer;
KIRP	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-5.79	-0.35	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.45	5.76	0.34	2.51e-8	Testicular germ cell tumor;
KIRP	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.73	9.47	0.52	2.41e-18	Platelet count;
KIRP	cis	rs9329289	0.510	rs11251289	chr10:2560777	G/A	cg15501526	chr10:2543763	NA	0.43	5.75	0.34	2.69e-8	Age-related hearing impairment;
KIRP	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-10.95	-0.57	5.54e-23	Systemic lupus erythematosus;
KIRP	cis	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg16260113	chr12:107380972	MTERFD3	-0.43	-5.55	-0.33	7.31e-8	Total body bone mineral density;
KIRP	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg01721255	chr8:58191610	C8orf71	0.56	5.68	0.34	3.83e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	6.94	0.4	3.45e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.85	-13.06	-0.64	5.87e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg06521331	chr12:34319734	NA	-0.61	-7.31	-0.42	3.79e-12	Bladder cancer;
KIRP	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	1.05	15.21	0.7	2.89e-37	Height;
KIRP	cis	rs12210905	1.000	rs72843613	chr6:27138467	G/A	cg11502198	chr6:26597334	ABT1	-0.81	-5.23	-0.32	3.56e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg01097406	chr16:89675127	NA	-0.3	-5.0	-0.3	1.07e-6	Vitiligo;
KIRP	cis	rs9308731	0.563	rs6760053	chr2:111932997	C/G	cg03171003	chr2:111875934	NA	0.41	5.71	0.34	3.21e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.08	0.41	1.55e-11	Retinal vascular caliber;
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07570687	chr10:102243282	WNT8B	0.47	5.58	0.34	6.36e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg03433033	chr1:76189801	ACADM	0.75	10.48	0.56	1.68e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg21466736	chr12:48725269	NA	0.52	7.0	0.41	2.44e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	8.22	0.46	1.15e-14	Total body bone mineral density;
KIRP	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.51	-5.97	-0.36	8.24e-9	Systolic blood pressure;
KIRP	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.75	-9.72	-0.53	4.21e-19	Coronary artery disease;
KIRP	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg23505145	chr19:12996616	KLF1	0.56	8.06	0.46	3.3e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg07493874	chr5:1342172	CLPTM1L	0.49	6.27	0.37	1.58e-9	Lung cancer;
KIRP	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg26205652	chr12:48591994	NA	-0.48	-5.15	-0.31	5.38e-7	Lung cancer;
KIRP	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.25e-10	Colorectal cancer;
KIRP	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.4.2662600F	chr4:146038071	ABCE1	0.44	6.22	0.37	2.11e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.71	-8.83	-0.49	2e-16	Total body bone mineral density;
KIRP	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.95	16.25	0.72	7.82e-41	Breast cancer;
KIRP	trans	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg16141378	chr3:129829833	LOC729375	0.51	6.9	0.4	4.28e-11	Mood instability;
KIRP	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.7	-0.44	3.21e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg09699651	chr6:150184138	LRP11	-0.43	-4.87	-0.3	2.02e-6	Lung cancer;
KIRP	cis	rs35995292	0.500	rs6945239	chr7:38932208	C/T	cg19327137	chr7:38886074	VPS41	0.79	12.21	0.61	4.11e-27	Subjective well-being (multi-trait analysis);
KIRP	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24110177	chr3:50126178	RBM5	-0.43	-5.5	-0.33	9.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.42	6.24	0.37	1.9e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.74	8.08	0.46	2.83e-14	Uric acid levels;
KIRP	cis	rs4936894	0.500	rs12282624	chr11:124164611	C/T	cg27160556	chr11:124181099	OR8D1	-0.46	-6.6	-0.39	2.45e-10	Aging (time to death);
KIRP	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	1.2	13.0	0.64	9.23e-30	Corneal structure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16935709	chr3:130745618	NEK11;ASTE1	0.53	6.66	0.39	1.75e-10	Parkinson's disease;
KIRP	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	5.65	0.34	4.41e-8	Electroencephalogram traits;
KIRP	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg25600027	chr14:23388339	RBM23	-0.52	-6.43	-0.38	6.66e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.09	0.69	7.04e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs6832769	0.925	rs11133383	chr4:56317045	A/G	cg09317128	chr4:56265301	TMEM165	-0.53	-6.97	-0.41	2.9e-11	Personality dimensions;
KIRP	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.24	6.3	0.37	1.33e-9	Crohn's disease;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg09758671	chr8:99058522	RPL30	0.48	6.04	0.36	5.56e-9	Asthma;
KIRP	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg16586182	chr3:47516702	SCAP	-0.49	-6.1	-0.36	4e-9	Birth weight;
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg06815112	chr8:27182871	PTK2B	0.53	6.91	0.4	4.22e-11	Neuroticism;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22769031	chr20:35580195	SAMHD1	0.47	6.13	0.36	3.44e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg21186296	chr8:27182909	PTK2B	0.48	6.09	0.36	4.43e-9	Neuroticism;
KIRP	cis	rs12643440	0.538	rs1581402	chr4:17139877	T/A	cg22650099	chr4:17144496	NA	-0.7	-8.78	-0.49	2.83e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6120849	0.754	rs6120819	chr20:33653038	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.37	0.38	9.47e-10	Protein C levels;
KIRP	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	1.16	8.35	0.47	5.1e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4356932	0.967	rs6856681	chr4:76975113	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg27124370	chr19:33622961	WDR88	0.72	10.41	0.55	2.97e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8756	0.685	rs7968902	chr12:66363070	G/T	cg06712651	chr12:66351869	HMGA2	0.6	9.52	0.52	1.75e-18	Height;
KIRP	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs9535307	0.769	rs9535306	chr13:50290817	A/G	cg03658251	chr13:50265850	EBPL	0.46	5.11	0.31	6.39e-7	Obesity-related traits;
KIRP	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	7.33	0.42	3.33e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	14.53	0.68	5.84e-35	Alzheimer's disease;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16524936	chr4:1340807	KIAA1530	-0.42	-5.32	-0.32	2.29e-7	Longevity;
KIRP	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg20493526	chr2:3714936	ALLC	0.47	4.92	0.3	1.55e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg21475434	chr5:93447410	FAM172A	0.45	5.29	0.32	2.74e-7	Diabetic retinopathy;
KIRP	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-7.38	-0.43	2.48e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.82	9.38	0.51	4.46e-18	Platelet count;
KIRP	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.71	7.85	0.45	1.28e-13	Cholesterol, total;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13865352	chr18:22006621	IMPACT	0.51	6.48	0.38	4.97e-10	Parkinson's disease;
KIRP	cis	rs10214930	0.697	rs1404278	chr7:27634726	T/C	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs62109865	0.655	rs62113562	chr19:12620508	T/A	cg19721055	chr19:12753329	NA	-0.84	-4.94	-0.3	1.48e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8018808	0.905	rs11159259	chr14:77892393	C/T	cg18872420	chr14:78023429	SPTLC2	0.34	4.94	0.3	1.45e-6	Myeloid white cell count;
KIRP	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg07777115	chr5:623756	CEP72	-0.61	-6.17	-0.37	2.8e-9	Obesity-related traits;
KIRP	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.16	16.39	0.72	2.51e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	0.93	10.24	0.55	9.95e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs876084	0.604	rs11986628	chr8:121008764	G/T	cg22335954	chr8:121166405	COL14A1	-0.4	-5.06	-0.31	8.26e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs747782	0.583	rs11039666	chr11:48324841	C/G	cg03929089	chr4:120376271	NA	0.88	6.6	0.39	2.58e-10	Intraocular pressure;
KIRP	cis	rs72634258	0.554	rs12723500	chr1:7857374	G/C	cg26816564	chr1:7831052	VAMP3	0.92	8.22	0.46	1.2e-14	Inflammatory bowel disease;
KIRP	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.46	-5.64	-0.34	4.77e-8	Diisocyanate-induced asthma;
KIRP	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.76	-12.64	-0.63	1.51e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7601312	0.903	rs2194546	chr2:229292469	A/G	cg02542817	chr2:229291442	NA	-0.55	-8.53	-0.48	1.56e-15	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs501120	0.925	rs684521	chr10:44752523	G/A	cg09554077	chr10:44749378	NA	0.71	10.68	0.56	4.04e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg14458575	chr2:238380390	NA	0.76	7.28	0.42	4.49e-12	Prostate cancer;
KIRP	cis	rs13418717	0.793	rs58039373	chr2:127667254	C/T	cg25501666	chr2:127640322	NA	0.79	6.29	0.37	1.44e-9	Heart failure;
KIRP	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.75	-11.0	-0.57	3.7e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9915657	0.870	rs918081	chr17:70127808	G/A	cg09344028	chr17:70110421	NA	0.41	8.16	0.46	1.79e-14	Thyroid hormone levels;
KIRP	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.56	5.97	0.36	8.43e-9	Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.21e-15	Motion sickness;
KIRP	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg13293535	chr8:11597251	GATA4	0.36	4.9	0.3	1.75e-6	Neuroticism;
KIRP	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7572644	0.713	rs13026758	chr2:28041273	A/G	cg27432699	chr2:27873401	GPN1	0.48	5.49	0.33	1.01e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs859767	0.603	rs842359	chr2:135345568	G/C	cg12500956	chr2:135428796	TMEM163	0.48	6.32	0.37	1.25e-9	Neuroticism;
KIRP	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.16	0.31	5.14e-7	Parkinson's disease;
KIRP	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs963731	0.649	rs2123876	chr2:39255873	C/G	cg04010122	chr2:39346883	SOS1	-1.02	-6.82	-0.4	7.09e-11	Corticobasal degeneration;
KIRP	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.47	0.48	2.24e-15	Eosinophil percentage of white cells;
KIRP	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.45	0.47	2.65e-15	Motion sickness;
KIRP	trans	rs9329221	0.636	rs6999466	chr8:10265712	A/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.27	-0.37	1.6e-9	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13651693	chr5:110464727	WDR36	-0.42	-6.28	-0.37	1.51e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs4356932	1.000	rs12233806	chr4:76984263	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs2150410	1.000	rs2150410	chr21:40569779	C/T	cg11890956	chr21:40555474	PSMG1	0.85	6.05	0.36	5.26e-9	Temperament (bipolar disorder);
KIRP	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.67	5.88	0.35	1.35e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg04731861	chr2:219085781	ARPC2	-0.21	-5.01	-0.3	1.04e-6	Colorectal cancer;
KIRP	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.76	-11.84	-0.6	6.62e-26	Hepatocellular carcinoma;
KIRP	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.07	-0.36	4.88e-9	Triglycerides;
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg02462569	chr6:150064036	NUP43	-0.39	-5.98	-0.36	7.73e-9	Lung cancer;
KIRP	cis	rs4356932	1.000	rs7689664	chr4:76963351	T/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.47	6.36	0.38	9.76e-10	Mean corpuscular volume;
KIRP	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg19773385	chr1:10388646	KIF1B	0.41	5.88	0.35	1.34e-8	Hepatocellular carcinoma;
KIRP	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.82	9.82	0.53	2.06e-19	Gestational age at birth (maternal effect);
KIRP	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg23533419	chr12:54090519	NA	-0.32	-4.93	-0.3	1.52e-6	Height;
KIRP	cis	rs3017493	0.786	rs79792601	chr11:70675171	G/A	cg10362475	chr11:70507825	SHANK2	0.38	5.47	0.33	1.1e-7	Renal transplant outcome;
KIRP	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.94	16.36	0.72	3.28e-41	Metabolic syndrome;
KIRP	cis	rs490234	0.702	rs7864945	chr9:128373469	C/T	cg14078157	chr9:128172775	NA	-0.66	-7.6	-0.44	6.3e-13	Mean arterial pressure;
KIRP	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.98	0.3	1.2e-6	Menopause (age at onset);
KIRP	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.54	-5.46	-0.33	1.17e-7	Ankle injury;
KIRP	cis	rs7624766	0.555	rs1455869	chr3:160475488	C/T	cg22637730	chr3:160473554	PPM1L	0.45	5.64	0.34	4.57e-8	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg20243544	chr17:37824526	PNMT	0.46	6.4	0.38	7.86e-10	Asthma;
KIRP	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.51	-7.06	-0.41	1.74e-11	Obesity-related traits;
KIRP	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13939156	chr17:80058883	NA	0.47	6.9	0.4	4.42e-11	Life satisfaction;
KIRP	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-7.04	-0.41	1.91e-11	Gut microbiome composition (summer);
KIRP	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.59	-6.4	-0.38	7.68e-10	Menarche (age at onset);
KIRP	cis	rs8077577	0.747	rs11078415	chr17:18255498	C/T	cg18869244	chr17:18121946	NA	0.45	4.98	0.3	1.2e-6	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg18209359	chr17:80159595	CCDC57	0.43	5.56	0.33	6.93e-8	Life satisfaction;
KIRP	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	0.96	8.54	0.48	1.38e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.76	9.87	0.53	1.45e-19	Mean platelet volume;
KIRP	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9354308	0.770	rs2802048	chr6:66525044	C/G	cg07460842	chr6:66804631	NA	0.48	5.5	0.33	9.71e-8	Metabolite levels;
KIRP	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.84	7.58	0.44	6.87e-13	Prostate cancer;
KIRP	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg07274523	chr3:49395745	GPX1	0.69	8.36	0.47	4.56e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg03929089	chr4:120376271	NA	-0.61	-6.36	-0.38	9.6e-10	Axial length;
KIRP	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.69	7.88	0.45	1.07e-13	Alcohol dependence;
KIRP	cis	rs2213920	0.619	rs7857548	chr9:118199365	C/T	cg13918206	chr9:118159781	DEC1	1.0	10.34	0.55	4.68e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	trans	rs1864585	0.520	rs73209921	chr8:10707724	C/T	cg26278703	chr11:58910052	FAM111A	0.63	6.1	0.36	4.19e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs9399401	0.922	rs9403382	chr6:142667380	C/T	cg03128060	chr6:142623767	GPR126	0.31	5.01	0.3	1.03e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs10982256	0.763	rs1535965	chr9:117273208	C/T	cg13636371	chr9:117264095	DFNB31	-0.41	-5.25	-0.32	3.26e-7	Bipolar disorder;
KIRP	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg11161011	chr14:65562177	MAX	-0.6	-7.75	-0.44	2.49e-13	Obesity-related traits;
KIRP	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.78	10.79	0.57	1.81e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6973256	0.897	rs9656423	chr7:133324987	C/T	cg10665199	chr7:133106180	EXOC4	0.52	6.59	0.39	2.73e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12049351	0.774	rs2295624	chr1:229644157	G/T	cg11742688	chr1:229674241	ABCB10	-0.37	-5.82	-0.35	1.83e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.64	-8.09	-0.46	2.7e-14	Iron status biomarkers;
KIRP	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg01557791	chr16:72042693	DHODH	-0.49	-6.15	-0.36	3.15e-9	Fibrinogen levels;
KIRP	cis	rs2446066	0.538	rs1485394	chr12:53955485	A/C	cg16917193	chr12:54089295	NA	0.62	5.77	0.35	2.34e-8	Red blood cell count;
KIRP	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.82	-9.12	-0.5	2.83e-17	High light scatter reticulocyte count;
KIRP	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17507749	chr15:85114479	UBE2QP1	0.52	6.01	0.36	6.49e-9	Schizophrenia;
KIRP	cis	rs7809615	0.901	rs13243267	chr7:99053314	C/G	cg12290671	chr7:99195819	NA	0.73	7.19	0.42	7.52e-12	Blood metabolite ratios;
KIRP	cis	rs6142618	0.555	rs242603	chr20:30667059	T/C	cg09796376	chr20:30640595	HCK	0.4	5.47	0.33	1.11e-7	Inflammatory bowel disease;
KIRP	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.94	-0.3	1.46e-6	Lung cancer;
KIRP	cis	rs894734	1.000	rs894734	chr12:54319727	A/G	cg17410650	chr12:54324560	NA	-0.39	-5.16	-0.31	5.12e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
KIRP	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg12119029	chr16:89752879	CDK10	0.28	6.34	0.37	1.12e-9	Vitiligo;
KIRP	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.65	-9.76	-0.53	3.21e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.86	-15.81	-0.71	2.59e-39	Body mass index;
KIRP	cis	rs12731740	1.000	rs72729053	chr1:208012294	C/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-4.96	-0.3	1.31e-6	Biomedical quantitative traits;
KIRP	cis	rs12580194	0.635	rs61957879	chr12:55716971	A/C	cg19537932	chr12:55886519	OR6C68	-0.46	-6.09	-0.36	4.24e-9	Cancer;
KIRP	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	1.05	19.46	0.78	1.08e-51	Height;
KIRP	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.7	8.56	0.48	1.28e-15	Aortic root size;
KIRP	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.28	-0.37	1.52e-9	Waist circumference adjusted for body mass index;
KIRP	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.56e-17	Retinal vascular caliber;
KIRP	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.42	0.47	3.21e-15	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17451422	chr2:61293253	KIAA1841	0.48	6.53	0.38	3.73e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs73086581	0.687	rs73082600	chr20:3844365	G/A	cg02187196	chr20:3869020	PANK2	0.55	5.01	0.3	1.02e-6	Response to antidepressants in depression;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg09033563	chr22:24373618	LOC391322	0.39	4.96	0.3	1.34e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.78	-0.35	2.29e-8	Breast cancer;
KIRP	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg11972305	chr2:233791962	NGEF	-0.39	-5.32	-0.32	2.37e-7	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16266536	chr12:56660626	COQ10A	0.49	6.26	0.37	1.69e-9	Parkinson's disease;
KIRP	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.83	10.05	0.54	4.04e-20	Menarche (age at onset);
KIRP	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs7712401	0.580	rs10066632	chr5:122364683	C/A	cg19412675	chr5:122181750	SNX24	0.55	5.91	0.35	1.14e-8	Mean platelet volume;
KIRP	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs2658782	1.000	rs2605585	chr11:93171862	C/T	cg15737290	chr11:93063684	CCDC67	0.82	8.68	0.48	5.66e-16	Pulmonary function decline;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18997433	chr4:24585879	DHX15	0.53	6.82	0.4	7.05e-11	Parkinson's disease;
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg07701084	chr6:150067640	NUP43	0.67	8.33	0.47	5.8e-15	Lung cancer;
KIRP	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.6	8.04	0.46	3.72e-14	Endometriosis;
KIRP	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg01475377	chr6:109611718	NA	-0.36	-4.93	-0.3	1.51e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg08662619	chr6:150070041	PCMT1	0.35	5.57	0.33	6.6e-8	Lung cancer;
KIRP	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg12560992	chr17:57184187	TRIM37	-0.47	-5.58	-0.34	6.44e-8	Cognitive test performance;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg05300996	chr3:119814693	GSK3B	0.49	6.31	0.37	1.31e-9	Asthma;
KIRP	cis	rs112998813	0.571	rs7982085	chr13:114984698	T/A	cg19814280	chr13:114963695	NA	-0.6	-4.89	-0.3	1.84e-6	Nodular sclerosis Hodgkin lymphoma;
KIRP	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.5	-7.78	-0.44	1.98e-13	IgG glycosylation;
KIRP	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.75	7.97	0.45	5.81e-14	Bipolar disorder;
KIRP	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs1978968	0.717	rs8139578	chr22:18468208	A/G	cg02610425	chr22:18483192	MICAL3	0.35	5.35	0.32	2.06e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19213242	chr20:55966434	RBM38	0.45	6.16	0.37	2.97e-9	Cancer;
KIRP	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg12623918	chr2:306882	NA	0.5	6.18	0.37	2.63e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6987853	0.933	rs2923434	chr8:42422307	A/G	cg09913449	chr8:42400586	C8orf40	0.41	5.37	0.32	1.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.91	0.35	1.16e-8	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.13e-8	Life satisfaction;
KIRP	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19524238	chr7:2802976	GNA12	-0.38	-5.34	-0.32	2.15e-7	Height;
KIRP	cis	rs12643440	0.538	rs981886	chr4:17136883	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6102059	0.692	rs2865504	chr20:39203614	T/A	cg22477343	chr20:39312069	NA	0.44	5.77	0.35	2.33e-8	LDL cholesterol;
KIRP	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.41	-7.8	-0.45	1.78e-13	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg06647332	chr5:131281008	NA	0.45	5.07	0.31	7.86e-7	Life satisfaction;
KIRP	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.48	6.29	0.37	1.44e-9	High light scatter reticulocyte count;
KIRP	cis	rs2019216	0.500	rs7210996	chr17:21917331	G/A	cg22648282	chr17:21454238	C17orf51	-0.48	-5.97	-0.36	8.38e-9	Pelvic organ prolapse;
KIRP	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg14664628	chr15:75095509	CSK	0.54	6.37	0.38	9.05e-10	Systemic lupus erythematosus;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg13453750	chr1:205783389	SLC41A1	-0.5	-7.23	-0.42	6.16e-12	Menarche (age at onset);
KIRP	cis	rs4356932	1.000	rs7664354	chr4:76982068	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs72730918	0.564	rs10851501	chr15:51832484	A/G	cg14296394	chr15:51910925	DMXL2	-0.76	-10.53	-0.56	1.23e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-8.19	-0.46	1.38e-14	Bipolar disorder;
KIRP	trans	rs6600671	0.934	rs67718113	chr1:121238910	C/T	cg00646200	chr1:148855367	NA	-0.55	-6.47	-0.38	5.25e-10	Hip geometry;
KIRP	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.42	0.33	1.41e-7	Putamen volume;
KIRP	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.91	-12.24	-0.62	3.21e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.41	8.19	0.46	1.4e-14	Coronary artery disease;
KIRP	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg15605315	chr1:45957053	TESK2	-0.54	-6.94	-0.4	3.41e-11	High light scatter reticulocyte count;
KIRP	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.69	-8.7	-0.49	4.8e-16	Triglycerides;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.21	-0.32	3.9e-7	Longevity;Endometriosis;
KIRP	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	6.06	0.36	4.94e-9	Motion sickness;
KIRP	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	1.07	17.33	0.74	1.62e-44	Homoarginine levels;
KIRP	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.69	7.87	0.45	1.11e-13	Smoking initiation;
KIRP	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg11833968	chr6:79620685	NA	-0.42	-6.17	-0.37	2.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg17644776	chr2:200775616	C2orf69	0.62	5.67	0.34	4.01e-8	Schizophrenia;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg12486944	chr17:80159399	CCDC57	0.38	5.02	0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs7503807	0.688	rs12942347	chr17:78587942	C/T	cg09596252	chr17:78655493	RPTOR	0.46	4.97	0.3	1.26e-6	Obesity;
KIRP	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.75	6.4	0.38	7.94e-10	Body mass index;
KIRP	cis	rs2625529	0.824	rs1074330	chr15:72250741	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.04	-0.36	5.57e-9	Red blood cell count;
KIRP	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg02807482	chr3:125708958	NA	-0.53	-5.18	-0.31	4.65e-7	Blood pressure (smoking interaction);
KIRP	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.53	0.33	8.09e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2671245	0.604	rs9436984	chr1:56148647	G/C	cg11523071	chr1:56160889	NA	0.41	6.07	0.36	4.72e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg02012338	chr4:187126139	CYP4V2	0.87	7.52	0.43	1e-12	Blood protein levels;
KIRP	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg04398451	chr17:18023971	MYO15A	0.65	8.55	0.48	1.3e-15	Total body bone mineral density;
KIRP	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.63	-8.66	-0.48	6.41e-16	Gut microbiome composition (summer);
KIRP	cis	rs11574514	1.000	rs9929423	chr16:67733113	T/C	cg26727032	chr16:67993705	SLC12A4	-0.71	-5.91	-0.35	1.15e-8	Crohn's disease;
KIRP	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	13.59	0.65	9.3900000000000005e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs11997175	0.545	rs7388496	chr8:33667898	A/G	ch.8.33884649F	chr8:33765107	NA	0.48	5.63	0.34	4.88e-8	Body mass index;
KIRP	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg16396542	chr1:89473148	GBP3	0.4	5.56	0.33	6.92e-8	Carotid intima media thickness;
KIRP	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg02569458	chr12:86230093	RASSF9	0.34	4.9	0.3	1.77e-6	Major depressive disorder;
KIRP	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.95	12.86	0.63	2.69e-29	Breast cancer;
KIRP	cis	rs3849570	0.555	rs6790351	chr3:82008988	C/T	cg07356753	chr3:81810745	GBE1	-0.54	-6.6	-0.39	2.48e-10	Waist circumference;Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13981034	chr14:21860709	SNORD9;CHD8	0.49	6.42	0.38	6.88e-10	Survival in pancreatic cancer;
KIRP	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.69	10.3	0.55	6.31e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg07148914	chr20:33460835	GGT7	-0.52	-6.93	-0.4	3.69e-11	Height;
KIRP	cis	rs7520050	0.778	rs12404197	chr1:46232420	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.39	0.32	1.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.41	-5.2	-0.31	4.14e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.46	-5.4	-0.33	1.55e-7	Longevity;Endometriosis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06178387	chr17:17585774	RAI1	-0.44	-6.11	-0.36	3.91e-9	Metabolic traits;
KIRP	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-6.73	-0.39	1.16e-10	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg05938607	chr10:60274200	BICC1	-0.46	-11.25	-0.58	5.96e-24	Refractive error;
KIRP	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg26022315	chr17:47021804	SNF8	0.42	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs4332428	1.000	rs35468197	chr10:4978256	C/G	cg19648686	chr10:5044992	AKR1C2	-0.92	-8.01	-0.45	4.68e-14	Height;
KIRP	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg12140854	chr5:148520817	ABLIM3	-0.51	-5.96	-0.36	8.53e-9	Breast cancer;
KIRP	cis	rs6142102	0.580	rs761233	chr20:32568886	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.97	0.36	8.21e-9	Skin pigmentation;
KIRP	cis	rs9297145	0.565	rs4729516	chr7:98745679	G/A	cg05967295	chr7:98741636	SMURF1	-0.63	-9.19	-0.51	1.67e-17	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.85	0.57	1.17e-22	Cognitive test performance;
KIRP	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs587242	1.000	rs12758621	chr1:96898421	C/T	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs986417	1.000	rs1024223	chr14:60926119	C/T	cg27398547	chr14:60952738	C14orf39	0.74	7.43	0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	0.85	7.45	0.43	1.59e-12	Cognitive function;
KIRP	cis	rs1847505	0.693	rs9539006	chr13:61587853	C/T	cg25164009	chr13:61490935	NA	-0.6	-7.22	-0.42	6.61e-12	Polychlorinated biphenyl levels;
KIRP	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg14541582	chr5:601475	NA	-0.54	-6.16	-0.37	2.91e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg08807101	chr21:30365312	RNF160	-0.63	-7.09	-0.41	1.44e-11	Cognitive test performance;
KIRP	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2494663	0.610	rs11586701	chr1:154055592	G/C	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.35	-5.1	-0.31	6.7e-7	Mean platelet volume;
KIRP	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.54	-7.7	-0.44	3.32e-13	Colorectal cancer;
KIRP	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.46	0.33	1.18e-7	Homoarginine levels;
KIRP	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.69	-8.37	-0.47	4.44e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8044868	0.521	rs3852782	chr16:72169023	T/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.47	-0.33	1.09e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-4.89	-0.3	1.82e-6	Ulcerative colitis;
KIRP	cis	rs6450176	0.564	rs31228	chr5:53325994	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-8.88	-0.49	1.4e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg07541023	chr7:19748670	TWISTNB	0.65	5.76	0.34	2.44e-8	Thyroid stimulating hormone;
KIRP	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.07	0.54	3.33e-20	Total body bone mineral density;
KIRP	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.86	-0.35	1.46e-8	Type 2 diabetes;
KIRP	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.94	-0.4	3.44e-11	Acne (severe);
KIRP	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.45	-5.71	-0.34	3.17e-8	Initial pursuit acceleration;
KIRP	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg16898833	chr6:26189333	HIST1H4D	0.8	5.28	0.32	2.88e-7	Lung cancer in ever smokers;
KIRP	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.18	-0.37	2.66e-9	Mood instability;
KIRP	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg08501292	chr6:25962987	TRIM38	0.9	7.09	0.41	1.46e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	6.38	0.38	8.76e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26314531	chr2:26401878	FAM59B	-0.49	-4.98	-0.3	1.18e-6	Gut microbiome composition (summer);
KIRP	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg01879757	chr17:41196368	BRCA1	-0.54	-7.14	-0.41	1.06e-11	Menopause (age at onset);
KIRP	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg01777586	chr17:80163174	CCDC57	0.46	4.97	0.3	1.25e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	1.07	16.76	0.73	1.43e-42	Cognitive function;
KIRP	cis	rs9928842	0.823	rs889514	chr16:75272512	A/G	cg09066997	chr16:75300724	BCAR1	0.57	5.47	0.33	1.12e-7	Alcoholic chronic pancreatitis;
KIRP	trans	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg09872104	chr7:134855509	C7orf49	0.74	6.18	0.37	2.61e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg00981070	chr1:2046702	PRKCZ	0.4	5.71	0.34	3.31e-8	Height;
KIRP	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.87	-0.4	5.12e-11	Menopause (age at onset);
KIRP	cis	rs2072732	0.950	rs1109251	chr1:2973576	G/A	cg11731671	chr1:2995604	PRDM16	-0.59	-6.6	-0.39	2.54e-10	Plateletcrit;
KIRP	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg11861562	chr11:117069780	TAGLN	0.4	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	7.38	0.43	2.39e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.6	7.36	0.42	2.79e-12	Red cell distribution width;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs78487399	0.808	rs7556744	chr2:43672795	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.6	5.36	0.32	1.89e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7941030	1.000	rs7941030	chr11:122522375	T/C	cg20555462	chr11:122535518	UBASH3B	-0.43	-5.3	-0.32	2.61e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg04374321	chr14:90722782	PSMC1	0.88	14.96	0.69	1.98e-36	Mortality in heart failure;
KIRP	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg04672837	chr16:48644449	N4BP1	0.51	7.1	0.41	1.3e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17033621	1.000	rs13416655	chr2:107621925	C/T	cg17818308	chr2:107502146	ST6GAL2	0.35	4.86	0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs78487399	0.710	rs11899863	chr2:43618819	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-5.32	-0.32	2.39e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.85	11.09	0.58	1.92e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg10254082	chr7:997346	NA	0.46	4.88	0.3	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.64	-0.34	4.62e-8	Cotinine glucuronidation;
KIRP	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg14851346	chr12:38532713	NA	-0.39	-4.85	-0.3	2.17e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.63	-7.08	-0.41	1.53e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.2	-0.42	7.17e-12	Myopia (pathological);
KIRP	cis	rs7187994	0.895	rs12598223	chr16:84783873	A/G	cg07647771	chr16:84786436	USP10	-0.36	-5.23	-0.32	3.59e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17554472	chr22:41940697	POLR3H	-0.65	-6.97	-0.41	2.94e-11	Vitiligo;
KIRP	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.68	0.66	4.6e-32	Mean platelet volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17191518	chr15:52468850	GNB5	0.46	6.33	0.37	1.12e-9	Survival in pancreatic cancer;
KIRP	cis	rs9513593	1.000	rs35912802	chr13:99886236	A/C	cg21788972	chr13:99853209	UBAC2	0.54	5.48	0.33	1.06e-7	Psoriasis;
KIRP	cis	rs4704187	0.649	rs7717415	chr5:74558893	A/G	cg03227963	chr5:74354835	NA	0.41	5.95	0.35	9.01e-9	Response to amphetamines;
KIRP	cis	rs4683702	0.932	rs4683434	chr3:142609913	T/C	cg22826874	chr3:142608218	PCOLCE2	-0.38	-5.58	-0.34	6.4e-8	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13919506	chr9:131535850	NA	0.45	6.33	0.37	1.15e-9	Survival in pancreatic cancer;
KIRP	cis	rs4728302	0.869	rs889825	chr7:133596227	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.63	-0.48	7.59e-16	Lymphocyte counts;
KIRP	cis	rs1659258	0.614	rs1258399	chr2:88622423	A/G	cg00685853	chr2:88648947	NA	-0.53	-5.92	-0.35	1.05e-8	Visceral fat;
KIRP	cis	rs35955747	0.869	rs8141987	chr22:31587155	C/G	cg02404636	chr22:31891804	SFI1	-0.39	-5.24	-0.32	3.52e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs12210905	1.000	rs12189835	chr6:27198271	T/C	cg11502198	chr6:26597334	ABT1	-0.83	-5.28	-0.32	2.87e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1215050	0.669	rs783962	chr4:98884473	G/A	cg05340658	chr4:99064831	C4orf37	-0.52	-6.25	-0.37	1.83e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3026101	0.671	rs3026128	chr17:5293962	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.73	6.92	0.4	3.91e-11	Chronic lymphocytic leukemia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01388144	chr15:43785382	TP53BP1	0.52	7.41	0.43	2.01e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12480562	chr20:23434244	CST11	0.65	5.22	0.32	3.83e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg04317338	chr11:64019027	PLCB3	0.53	6.21	0.37	2.3e-9	Platelet count;
KIRP	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg26338869	chr17:61819248	STRADA	0.54	6.41	0.38	7.37e-10	Prudent dietary pattern;
KIRP	trans	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg10756647	chr7:56101905	PSPH	-0.95	-7.07	-0.41	1.56e-11	Diabetic kidney disease;
KIRP	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.82	11.89	0.6	4.65e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11848740	chr1:185113945	C1orf25	-0.42	-6.43	-0.38	6.72e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7980799	0.935	rs10844582	chr12:33560873	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-6.54	-0.38	3.53e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs787274	1.000	rs7038684	chr9:115601431	A/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.55	-0.39	3.31e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.92	-14.82	-0.69	6.23e-36	Height;
KIRP	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg18709589	chr6:96969512	KIAA0776	0.34	5.04	0.31	8.89e-7	Headache;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04974121	chr4:20701990	PACRGL	-0.49	-6.31	-0.37	1.26e-9	Electrocardiographic conduction measures;
KIRP	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg00409905	chr10:38381863	ZNF37A	-0.55	-5.77	-0.35	2.32e-8	Obesity (extreme);
KIRP	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.74	-10.87	-0.57	9.78e-23	Height;
KIRP	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-4.99	-0.3	1.15e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg19847130	chr8:10466454	RP1L1	0.41	5.89	0.35	1.26e-8	Retinal vascular caliber;
KIRP	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg25428297	chr7:1022841	CYP2W1	0.33	5.23	0.32	3.58e-7	Longevity;Endometriosis;
KIRP	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.62	11.89	0.6	4.75e-26	Bone mineral density;
KIRP	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg03959625	chr15:84868606	LOC388152	0.52	6.28	0.37	1.53e-9	Schizophrenia;
KIRP	cis	rs9311676	0.656	rs11917529	chr3:58382158	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	8.75	0.49	3.48e-16	Resting heart rate;
KIRP	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg09029085	chr17:47094198	IGF2BP1	0.25	5.69	0.34	3.6e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg04025307	chr7:1156635	C7orf50	0.49	4.91	0.3	1.69e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.46	6.65	0.39	1.87e-10	Sitting height ratio;
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.1	-0.31	6.89e-7	Longevity;Endometriosis;
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.24	-26.31	-0.86	1.85e-73	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.58	-6.58	-0.39	2.85e-10	Mean platelet volume;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg04080417	chr5:1859792	NA	-0.6	-7.6	-0.44	6.31e-13	Cardiovascular disease risk factors;
KIRP	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs477692	0.637	rs7098627	chr10:131315866	C/T	cg24747557	chr10:131355152	MGMT	-0.42	-5.52	-0.33	8.54e-8	Response to temozolomide;
KIRP	cis	rs6832769	0.961	rs7660808	chr4:56456672	G/A	cg09317128	chr4:56265301	TMEM165	-0.51	-6.71	-0.39	1.37e-10	Personality dimensions;
KIRP	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg22809023	chr3:195622598	TNK2	-0.38	-4.97	-0.3	1.24e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.68	-9.58	-0.52	1.13e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.86	-12.8	-0.63	4.2e-29	Height;
KIRP	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.23	-0.37	2.04e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg12131826	chr15:77904385	NA	-0.41	-5.49	-0.33	9.8e-8	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25172825	chr11:118955635	HMBS	0.51	6.38	0.38	8.6e-10	Parkinson's disease;
KIRP	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg21427119	chr20:30132790	HM13	-0.53	-6.0	-0.36	6.93e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg17595323	chr11:93583763	C11orf90	-0.39	-6.49	-0.38	4.67e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.02	-0.5	5.38e-17	Urate levels in overweight individuals;
KIRP	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.45	7.87	0.45	1.14e-13	Bone mineral density;
KIRP	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	13.54	0.65	1.43e-31	Menopause (age at onset);
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02711726	chr17:80685570	FN3KRP	-0.56	-7.49	-0.43	1.24e-12	Glycated hemoglobin levels;
KIRP	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg10223061	chr2:219282414	VIL1	-0.4	-6.41	-0.38	7.18e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg23307798	chr14:103986281	CKB	-0.51	-6.83	-0.4	6.6e-11	Coronary artery disease;
KIRP	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg17757837	chr7:157058334	UBE3C	0.71	9.47	0.52	2.37e-18	Body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09688763	chr10:114206798	VTI1A;ZDHHC6	0.98	6.38	0.38	8.71e-10	P wave terminal force;
KIRP	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.55	-0.48	1.3e-15	Triglycerides;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.55	7.02	0.41	2.15e-11	Menarche (age at onset);
KIRP	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg18461021	chr18:74961002	GALR1	0.53	5.39	0.33	1.64e-7	Obesity-related traits;
KIRP	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.32	-0.37	1.2e-9	IgG glycosylation;
KIRP	cis	rs10861342	1.000	rs7136344	chr12:105528268	A/G	cg23923672	chr12:105501055	KIAA1033	0.91	9.44	0.52	3e-18	IgG glycosylation;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.85	14.08	0.67	1.97e-33	Vitiligo;
KIRP	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25603603	chr2:25264793	EFR3B	0.44	6.04	0.36	5.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1801239	1.000	rs45619139	chr10:16940846	C/G	cg24571822	chr10:17009592	CUBN	0.64	5.14	0.31	5.73e-7	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
KIRP	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.44	5.84	0.35	1.61e-8	Hypertriglyceridemia;
KIRP	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07395648	chr5:131743802	NA	-0.58	-8.19	-0.46	1.4e-14	Breast cancer;Mosquito bite size;
KIRP	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg01620082	chr3:125678407	NA	-0.88	-6.43	-0.38	6.75e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7116495	0.609	rs1791449	chr11:71579662	C/T	cg11196788	chr11:71737549	NUMA1	-0.5	-4.95	-0.3	1.36e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.51	6.61	0.39	2.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7836436	0.818	rs7818635	chr8:121028061	C/T	cg06265175	chr8:121136014	COL14A1	-0.68	-4.87	-0.3	1.98e-6	HIV-1 viral setpoint;
KIRP	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10267417	0.603	rs4721836	chr7:19910497	A/G	cg05791153	chr7:19748676	TWISTNB	0.55	5.79	0.35	2.09e-8	Night sleep phenotypes;
KIRP	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	7.86	0.45	1.19e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12976411	0.867	rs12981453	chr19:32842281	C/T	cg02282382	chr19:32836354	ZNF507	0.66	5.57	0.33	6.79e-8	Coronary artery disease;
KIRP	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg01097406	chr16:89675127	NA	-0.31	-5.25	-0.32	3.23e-7	Hemoglobin concentration;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg16654801	chr10:119301763	EMX2;EMX2OS	0.42	6.04	0.36	5.57e-9	Coronary artery disease;
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.27	-17.33	-0.74	1.57e-44	Platelet count;
KIRP	cis	rs829661	1.000	rs829583	chr2:30677459	C/T	cg10949345	chr2:30726833	LCLAT1	0.73	10.31	0.55	6.05e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03900353	chr1:212732456	NA	0.48	6.21	0.37	2.2e-9	Smoking initiation;
KIRP	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg01304814	chr3:48885189	PRKAR2A	0.57	5.17	0.31	4.9e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg04935436	chr20:30431758	NA	0.51	5.94	0.35	9.62e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.51	-7.42	-0.43	1.85e-12	Daytime sleep phenotypes;
KIRP	cis	rs12200782	1.000	rs12213722	chr6:26473083	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-6.07	-0.36	4.76e-9	Small cell lung carcinoma;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14060719	chr14:96797241	ATG2B	0.4	6.12	0.36	3.58e-9	C-reactive protein;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07355551	chr20:2489285	ZNF343	0.6	7.26	0.42	4.98e-12	Smoking initiation;
KIRP	cis	rs6539288	0.803	rs2374651	chr12:107328124	A/G	cg26297688	chr12:107349093	C12orf23	-0.38	-5.23	-0.32	3.7e-7	Total body bone mineral density;
KIRP	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg15896084	chr13:114927664	NA	0.49	6.66	0.39	1.77e-10	Schizophrenia;
KIRP	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg11846333	chr4:119757529	SEC24D	1.15	6.65	0.39	1.84e-10	Cannabis dependence symptom count;
KIRP	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg17764715	chr19:33622953	WDR88	0.68	8.44	0.47	2.77e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11574514	0.661	rs9972635	chr16:67682580	T/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-5.82	-0.35	1.85e-8	Crohn's disease;
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg13939156	chr17:80058883	NA	0.48	7.14	0.41	1.05e-11	Life satisfaction;
KIRP	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg03929089	chr4:120376271	NA	0.93	6.82	0.4	7.22e-11	Myopia (pathological);
KIRP	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.55	-6.79	-0.4	8.19e-11	Hirschsprung disease;
KIRP	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg23335576	chr14:104009727	NA	-0.36	-4.98	-0.3	1.2e-6	Body mass index;
KIRP	cis	rs1062746	0.528	rs891092	chr16:87338226	G/A	cg02258303	chr16:87377426	FBXO31	-0.46	-6.2	-0.37	2.34e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.68	-0.34	3.74e-8	Response to antipsychotic treatment;
KIRP	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg07843065	chr1:150265600	MRPS21	0.44	6.22	0.37	2.14e-9	Migraine;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.73	9.13	0.5	2.56e-17	Longevity;
KIRP	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.37	-0.32	1.8e-7	Metabolite levels;
KIRP	trans	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.82	0.4	6.92e-11	Mean corpuscular volume;
KIRP	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	0.92	14.91	0.69	2.89e-36	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.97	0.45	5.98e-14	Type 2 diabetes;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20899383	chr2:176046573	ATP5G3	0.64	6.27	0.37	1.57e-9	Lung function (FEV1);
KIRP	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg05315796	chr3:52349193	DNAH1	-0.38	-4.89	-0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.58	7.88	0.45	1.03e-13	Height;
KIRP	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.67	-12.12	-0.61	8.22e-27	White blood cell count (basophil);
KIRP	cis	rs4780355	0.877	rs243317	chr16:11357331	G/T	cg00044050	chr16:11439710	C16orf75	-0.45	-5.09	-0.31	7.17e-7	Crohn's disease and psoriasis;
KIRP	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.18e-19	Prudent dietary pattern;
KIRP	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.66	-0.52	6.18e-19	Schizophrenia;
KIRP	cis	rs2411233	0.837	rs1897738	chr15:39261480	G/A	cg05886626	chr15:39873553	THBS1	0.34	5.04	0.31	8.92e-7	Platelet count;
KIRP	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.89	10.42	0.55	2.69e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg11266682	chr4:10021025	SLC2A9	0.42	5.05	0.31	8.56e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs698833	0.509	rs4952709	chr2:44519142	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.15	0.31	5.24e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg00074818	chr8:8560427	CLDN23	0.43	6.44	0.38	6.06e-10	Obesity-related traits;
KIRP	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.42	-5.2	-0.31	4.2e-7	IgG glycosylation;
KIRP	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.88	13.37	0.65	5.02e-31	Body mass index;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg18209359	chr17:80159595	CCDC57	-0.41	-5.29	-0.32	2.65e-7	Life satisfaction;
KIRP	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg14983838	chr19:29218262	NA	0.65	5.46	0.33	1.15e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.13	0.31	5.78e-7	Bipolar disorder;
KIRP	cis	rs7809615	0.901	rs10230784	chr7:99113672	G/A	cg12290671	chr7:99195819	NA	-0.71	-6.76	-0.4	1.02e-10	Blood metabolite ratios;
KIRP	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.0	0.36	6.88e-9	Ovarian reserve;
KIRP	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.69	11.08	0.58	2e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.9	15.31	0.7	1.3e-37	Headache;
KIRP	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.53	7.43	0.43	1.81e-12	Obesity-related traits;
KIRP	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.54	-8.73	-0.49	4.01e-16	Prostate cancer;
KIRP	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg24253500	chr15:84953950	NA	0.62	6.99	0.41	2.55e-11	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.33	-0.32	2.17e-7	Skin colour saturation;
KIRP	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.83	9.13	0.5	2.55e-17	Alzheimer's disease;
KIRP	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg12405258	chr13:114927641	NA	0.5	7.14	0.41	1.07e-11	Schizophrenia;
KIRP	cis	rs860295	0.812	rs12131079	chr1:155319668	C/T	cg02153340	chr1:155202674	NA	0.37	4.86	0.3	2.08e-6	Body mass index;
KIRP	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.6	9.26	0.51	1.05e-17	Personality dimensions;
KIRP	cis	rs6725041	0.819	rs13407289	chr2:213068734	C/T	cg20637307	chr2:213403960	ERBB4	-0.39	-5.01	-0.3	1.06e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.93	14.99	0.69	1.58e-36	Coronary artery disease;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg20725035	chr3:148709344	GYG1	0.47	6.1	0.36	4.2e-9	Bladder cancer;
KIRP	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.82	-11.5	-0.59	9.2e-25	Total body bone mineral density;
KIRP	cis	rs981844	0.775	rs62323975	chr4:154737617	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7258015	1.000	rs7254041	chr19:10448636	T/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.48	6.21	0.37	2.22e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg11608241	chr8:8085544	FLJ10661	-0.51	-6.27	-0.37	1.59e-9	Joint mobility (Beighton score);
KIRP	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg09699651	chr6:150184138	LRP11	0.59	7.91	0.45	9.01e-14	Testicular germ cell tumor;
KIRP	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg26513180	chr16:89883248	FANCA	0.8	5.34	0.32	2.1e-7	Skin colour saturation;
KIRP	cis	rs66569888	0.523	rs4522599	chr2:106926004	G/C	cg16099169	chr2:106886729	NA	0.52	6.6	0.39	2.45e-10	Facial morphology (factor 23);
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.71	-0.44	3.08e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg24579218	chr15:68104479	NA	-0.4	-5.86	-0.35	1.47e-8	Obesity;
KIRP	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.42	-5.36	-0.32	1.94e-7	Aortic root size;
KIRP	cis	rs981844	0.712	rs897610	chr4:154755439	C/A	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs7520050	0.807	rs6671802	chr1:46124663	A/G	cg03146154	chr1:46216737	IPP	0.43	5.38	0.32	1.75e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	0.7	6.5	0.38	4.39e-10	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg12623918	chr2:306882	NA	0.46	5.85	0.35	1.57e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	10.8	0.57	1.61e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs930036	0.628	rs34143031	chr2:171936542	A/T	cg12801329	chr2:171670795	NA	0.46	5.14	0.31	5.52e-7	Menopause (age at onset);
KIRP	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg03474202	chr17:45855739	NA	-0.49	-8.14	-0.46	2.01e-14	IgG glycosylation;
KIRP	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.43	7.68	0.44	3.68e-13	Urinary metabolites;
KIRP	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.16	0.31	4.97e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs5753037	0.869	rs5763559	chr22:30258357	A/G	cg27665648	chr22:30112403	NA	0.35	4.94	0.3	1.42e-6	Type 1 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07040405	chr2:174828875	SP3	0.51	6.95	0.41	3.26e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17123764	1.000	rs75278574	chr12:50000945	C/T	cg02054252	chr12:50078554	FMNL3	0.5	5.06	0.31	8.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	0.67	9.46	0.52	2.66e-18	Inflammatory bowel disease;
KIRP	cis	rs7011507	1.000	rs7011118	chr8:49185102	G/T	cg15325961	chr8:49183143	NA	0.61	5.2	0.31	4.17e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.79	8.18	0.46	1.48e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12230513	0.732	rs7980098	chr12:55844694	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs988913	0.678	rs4518495	chr6:54955122	A/G	cg03513858	chr6:54763001	FAM83B	-0.36	-5.1	-0.31	6.64e-7	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs882732	0.576	rs3827893	chr14:95033671	A/T	cg08495878	chr14:95027859	SERPINA4	-0.5	-6.53	-0.38	3.75e-10	Blood protein levels;
KIRP	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg27490568	chr2:178487706	NA	0.71	8.64	0.48	7.44e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16895254	chr4:26322328	RBPJ	0.41	6.02	0.36	6.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg16988262	chr1:15930761	NA	0.39	5.12	0.31	6.13e-7	Systolic blood pressure;
KIRP	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg04935436	chr20:30431758	NA	0.35	4.86	0.3	2.11e-6	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.25	7.03	0.41	1.98e-11	Type 2 diabetes;
KIRP	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg21427119	chr20:30132790	HM13	-0.55	-6.07	-0.36	4.9e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs4959799	0.557	rs9503517	chr6:3272109	C/T	cg03657281	chr6:3270030	SLC22A23	0.78	6.03	0.36	6.04e-9	Survival in rectal cancer;
KIRP	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg15839431	chr19:19639596	YJEFN3	-0.53	-5.23	-0.32	3.71e-7	Bipolar disorder;
KIRP	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.89	0.57	8.41e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg09904177	chr6:26538194	HMGN4	-0.53	-6.73	-0.39	1.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg09408571	chr1:101003634	GPR88	-0.24	-5.54	-0.33	7.85e-8	Monocyte count;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.65	-8.24	-0.47	1e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.49	-5.91	-0.35	1.12e-8	Prudent dietary pattern;
KIRP	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.87	13.8	0.66	1.76e-32	Blood protein levels;
KIRP	cis	rs1656402	0.569	rs80234614	chr2:233424159	A/T	cg03852847	chr2:233439513	NA	0.7	11.21	0.58	7.8e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg18709589	chr6:96969512	KIAA0776	0.33	4.97	0.3	1.26e-6	Headache;
KIRP	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg25547332	chr5:131281432	NA	0.49	5.57	0.33	6.73e-8	Life satisfaction;
KIRP	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.7	-11.06	-0.58	2.4e-23	Neuroticism;
KIRP	cis	rs12643440	0.538	rs10939707	chr4:17146776	G/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs13185784	0.709	rs6703	chr5:179660786	A/T	cg23221052	chr5:179740743	GFPT2	-0.45	-5.04	-0.31	9.04e-7	TRAIL levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01112927	chr2:71357293	MCEE;MPHOSPH10	0.49	6.97	0.41	2.84e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs494562	0.892	rs1322404	chr6:86126912	T/A	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05221385	chr11:6633504	TAF10	0.52	6.37	0.38	9.04e-10	Parkinson's disease;
KIRP	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg13647721	chr17:30228624	UTP6	0.53	5.06	0.31	8.19e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.2	0.46	1.35e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.5	-0.43	1.18e-12	Type 2 diabetes;
KIRP	trans	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.57	-0.39	3.02e-10	Neuroticism;
KIRP	cis	rs1642645	0.597	rs4660585	chr1:42393001	G/A	cg26038582	chr1:42384390	HIVEP3	0.29	5.43	0.33	1.37e-7	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.79	-11.07	-0.58	2.24e-23	Dental caries;
KIRP	cis	rs6977660	0.714	rs12672320	chr7:19813594	G/T	cg07541023	chr7:19748670	TWISTNB	0.54	5.03	0.31	9.45e-7	Thyroid stimulating hormone;
KIRP	cis	rs10073892	0.743	rs62372215	chr5:101650796	G/T	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs4389656	0.826	rs192443	chr5:6733664	G/T	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.53	6.51	0.38	4.16e-10	HIV-1 control;
KIRP	trans	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg16141378	chr3:129829833	LOC729375	-0.56	-7.75	-0.44	2.35e-13	Mood instability;
KIRP	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.37	0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12973672	0.812	rs12979792	chr19:35748706	A/G	cg12095397	chr19:35769544	USF2	0.67	6.2	0.37	2.33e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2625529	0.761	rs972029	chr15:72172986	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-6.41	-0.38	7.3e-10	Red blood cell count;
KIRP	cis	rs2562456	0.833	rs2061916	chr19:21541708	A/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01924320	chr4:147364608	SLC10A7	0.4	6.41	0.38	7.56e-10	C-reactive protein;
KIRP	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.62	-6.53	-0.38	3.65e-10	Menarche (age at onset);
KIRP	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.61	6.8	0.4	8.1e-11	Multiple sclerosis;
KIRP	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.6	-0.39	2.45e-10	Morning vs. evening chronotype;
KIRP	cis	rs7818345	0.967	rs13255946	chr8:19275354	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.29	0.37	1.45e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs2562456	0.793	rs7259396	chr19:21523463	G/A	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.24e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.59	-0.48	1.02e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.85	10.44	0.55	2.41e-21	Neutrophil percentage of white cells;
KIRP	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	5.58	0.34	6.43e-8	Renal cell carcinoma;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg09699651	chr6:150184138	LRP11	0.45	5.92	0.35	1.07e-8	Lung cancer;
KIRP	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg04166393	chr7:2884313	GNA12	0.45	5.82	0.35	1.79e-8	Height;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg16358155	chr3:195490169	MUC4	0.51	4.93	0.3	1.49e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.52	0.48	1.57e-15	Motion sickness;
KIRP	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	6.25	0.37	1.76e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10426930	0.752	rs56249413	chr19:5036730	G/A	cg18473234	chr19:5097819	KDM4B	0.55	5.97	0.36	8.24e-9	Monocyte percentage of white cells;
KIRP	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.39	-0.32	1.67e-7	Neuroticism;
KIRP	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg08890418	chr1:21044141	KIF17	-0.43	-6.43	-0.38	6.45e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2412208	0.585	rs11120824	chr1:7113591	G/A	cg20434152	chr1:7120926	CAMTA1	-0.41	-5.93	-0.35	1.02e-8	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	5e-8	Lung cancer;
KIRP	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4845459	0.967	rs9633406	chr1:152591446	C/G	cg07796016	chr1:152779584	LCE1C	-0.49	-6.0	-0.36	7.03e-9	Psoriasis;
KIRP	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05835761	chr10:73648991	NA	0.53	6.68	0.39	1.62e-10	Smoking initiation;
KIRP	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.51	-6.48	-0.38	4.85e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs13170463	0.579	rs13160786	chr5:8051369	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.65	-7.43	-0.43	1.82e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.47	5.32	0.32	2.34e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg02462569	chr6:150064036	NUP43	-0.33	-4.96	-0.3	1.32e-6	Lung cancer;
KIRP	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg14972814	chr11:95582409	MTMR2	0.34	5.71	0.34	3.24e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.76	9.43	0.52	3.16e-18	Migraine;Coronary artery disease;
KIRP	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.25	-0.37	1.82e-9	Neuroticism;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10136077	chr3:63853226	ATXN7	0.42	6.26	0.37	1.67e-9	Migraine with aura;
KIRP	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.82	-13.03	-0.64	7.38e-30	Idiopathic membranous nephropathy;
KIRP	cis	rs6893300	0.961	rs62406219	chr5:179211629	G/A	cg14593053	chr5:179126677	CANX	-0.55	-6.62	-0.39	2.21e-10	Resting heart rate;
KIRP	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.51	-7.53	-0.43	9.47e-13	IgG glycosylation;
KIRP	cis	rs4973397	0.509	rs10191571	chr2:232279975	C/A	cg09339159	chr2:232260559	B3GNT7	0.43	5.72	0.34	3.03e-8	Anti-saccade response;
KIRP	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.44	0.43	1.65e-12	Aortic root size;
KIRP	cis	rs2573652	1.000	rs11634977	chr15:100516472	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.74	-11.69	-0.6	2.05e-25	Height;
KIRP	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.37	-5.64	-0.34	4.58e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs12043259	0.730	rs10458594	chr1:204792556	C/G	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.46	-5.72	-0.34	3.06e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04098458	chr2:149402448	EPC2	0.52	6.63	0.39	2.09e-10	Parkinson's disease;
KIRP	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg17279839	chr7:150038598	RARRES2	0.47	6.42	0.38	6.95e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs56346965	0.506	rs2159818	chr2:191532789	A/G	cg11845111	chr2:191398756	TMEM194B	-0.51	-5.74	-0.34	2.85e-8	Bone mineral density (Ward's triangle area);
KIRP	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.23	-0.64	1.52e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.76e-11	Diabetic kidney disease;
KIRP	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.72	-7.29	-0.42	4.2e-12	Coronary artery calcification;
KIRP	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs963731	0.649	rs1377861	chr2:39293858	T/C	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs394563	0.559	rs13219868	chr6:149686518	T/G	cg03678062	chr6:149772716	ZC3H12D	0.32	5.12	0.31	6.25e-7	Dupuytren's disease;
KIRP	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg04310649	chr10:35416472	CREM	-0.59	-7.16	-0.42	9.33e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	6.12	0.36	3.68e-9	Breast cancer;
KIRP	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg12046867	chr14:103022105	NA	-0.51	-6.16	-0.37	2.89e-9	Platelet count;
KIRP	cis	rs1823913	0.637	rs921737	chr2:192150823	C/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.24	-0.37	1.87e-9	Obesity-related traits;
KIRP	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.52	6.76	0.4	1e-10	Menopause (age at onset);
KIRP	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.38	7.44e-10	Height;
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.54e-13	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08280861	chr8:58055591	NA	0.61	5.32	0.32	2.34e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg21775007	chr8:11205619	TDH	0.43	5.67	0.34	3.91e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.24e-6	Depression;
KIRP	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.11	-0.46	2.42e-14	Retinal vascular caliber;
KIRP	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg14458575	chr2:238380390	NA	0.5	5.52	0.33	8.71e-8	Prostate cancer;
KIRP	trans	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg02002194	chr4:3960332	NA	0.42	6.03	0.36	5.92e-9	Neuroticism;
KIRP	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg05973401	chr12:123451056	ABCB9	0.66	7.97	0.45	5.76e-14	Platelet count;
KIRP	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg05775895	chr3:12838266	CAND2	0.33	5.19	0.31	4.46e-7	QRS complex (12-leadsum);
KIRP	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.39	0.33	1.61e-7	Height;
KIRP	cis	rs12472274	0.941	rs6748440	chr2:239100375	C/T	cg17459225	chr2:239074497	NA	0.8	9.74	0.53	3.7e-19	Phospholipid levels (plasma);
KIRP	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.53	6.84	0.4	6.23e-11	IgG glycosylation;
KIRP	cis	rs12580194	1.000	rs4491341	chr12:55697838	G/A	cg11794356	chr12:55725991	OR6C3	-0.46	-6.61	-0.39	2.43e-10	Cancer;
KIRP	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.55	-7.99	-0.45	5.09e-14	Immature fraction of reticulocytes;
KIRP	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.28	0.37	1.51e-9	Rheumatoid arthritis;
KIRP	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg08501292	chr6:25962987	TRIM38	0.99	7.58	0.44	6.93e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg23594656	chr7:65796392	TPST1	-0.43	-5.97	-0.36	8.43e-9	Aortic root size;
KIRP	trans	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.71	0.49	4.46e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg11555438	chr13:111297484	CARS2	0.38	5.95	0.35	9.19e-9	Coronary artery disease;
KIRP	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg24375607	chr4:120327624	NA	-0.41	-5.11	-0.31	6.47e-7	Diastolic blood pressure;
KIRP	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.54e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1971762	0.545	rs10783586	chr12:53980821	C/T	cg16917193	chr12:54089295	NA	0.73	12.09	0.61	1.01e-26	Height;
KIRP	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.62	-7.06	-0.41	1.7e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.81	9.6	0.52	9.51e-19	Corneal astigmatism;
KIRP	cis	rs2733310	0.843	rs16977374	chr15:57581592	G/T	cg13626582	chr15:57592083	LOC283663	0.28	6.56	0.39	3.2e-10	Mean platelet volume;
KIRP	cis	rs13315871	1.000	rs71311858	chr3:58323793	G/C	cg12435725	chr3:58293450	RPP14	-0.48	-5.14	-0.31	5.49e-7	Cholesterol, total;
KIRP	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg26681399	chr22:41777847	TEF	-0.5	-4.95	-0.3	1.37e-6	Vitiligo;
KIRP	cis	rs10465746	0.967	rs12140068	chr1:84394286	A/C	cg10977910	chr1:84465055	TTLL7	0.44	5.3	0.32	2.58e-7	Obesity-related traits;
KIRP	cis	rs6751744	0.513	rs10173538	chr2:160569276	C/T	cg08347373	chr2:160653686	CD302	-0.4	-6.05	-0.36	5.25e-9	Dysphagia;
KIRP	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg15557168	chr22:42548783	NA	-0.37	-4.99	-0.3	1.15e-6	Cognitive function;
KIRP	cis	rs2384207	0.584	rs73192860	chr12:113766135	G/A	cg13296563	chr12:112847257	RPL6	-0.6	-4.92	-0.3	1.61e-6	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs80282103	1.000	rs80282103	chr10:899071	A/T	cg08847335	chr10:891726	LARP4B	-0.67	-5.71	-0.34	3.27e-8	Glomerular filtration rate (creatinine);
KIRP	trans	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs2587695	0.935	rs2920695	chr2:120318903	T/C	cg07176264	chr2:120281999	SCTR	0.32	4.93	0.3	1.48e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs16858210	0.913	rs1879255	chr3:183609445	C/A	cg25686905	chr3:183603175	PARL	-0.47	-6.02	-0.36	6.35e-9	Menopause (age at onset);
KIRP	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs4671458	0.626	rs75934274	chr2:63748815	T/G	cg17519650	chr2:63277830	OTX1	-0.49	-4.93	-0.3	1.54e-6	Subjective well-being;
KIRP	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.47	5.08	0.31	7.31e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.86	-0.35	1.48e-8	Response to antipsychotic treatment;
KIRP	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	trans	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg13565492	chr6:43139072	SRF	-0.94	-8.9	-0.49	1.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.02	0.31	9.74e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4765905	0.610	rs2238050	chr12:2306707	G/A	cg10668781	chr12:2307325	CACNA1C	-0.29	-5.69	-0.34	3.68e-8	Schizophrenia;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.56	-7.57	-0.43	7.66e-13	Longevity;Endometriosis;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17815252	chr3:142838682	CHST2	0.47	6.05	0.36	5.5e-9	Myopia (pathological);
KIRP	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.05	-0.41	1.81e-11	Menopause (age at onset);
KIRP	cis	rs7818345	1.000	rs4430112	chr8:19293365	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.76	0.34	2.44e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg03060546	chr3:49711283	APEH	0.43	5.66	0.34	4.27e-8	Parkinson's disease;
KIRP	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg18192325	chr2:105854051	NA	-0.38	-5.19	-0.31	4.34e-7	Type 2 diabetes;
KIRP	cis	rs10814247	0.702	rs10972381	chr9:35208145	T/C	cg15271616	chr9:35490515	RUSC2	-0.4	-5.73	-0.34	2.97e-8	Psoriasis;
KIRP	cis	rs698833	0.962	rs786409	chr2:44731344	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.89	0.3	1.81e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg25182066	chr10:30743637	MAP3K8	0.56	7.35	0.42	2.97e-12	Inflammatory bowel disease;
KIRP	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg02461776	chr11:598696	PHRF1	0.5	5.3	0.32	2.57e-7	Systemic lupus erythematosus;
KIRP	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.84	-13.08	-0.64	4.89e-30	Height;
KIRP	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.41	7.03	0.41	2.03e-11	Heart rate;
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02475777	chr4:1388615	CRIPAK	0.49	6.48	0.38	4.98e-10	Longevity;
KIRP	cis	rs73200209	0.704	rs17498131	chr12:116436185	C/G	cg01776926	chr12:116560359	MED13L	-0.53	-5.76	-0.34	2.52e-8	Total body bone mineral density;
KIRP	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.84	-13.07	-0.64	5.55e-30	Systemic lupus erythematosus;
KIRP	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg23307798	chr14:103986281	CKB	-0.5	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.93	-15.63	-0.71	1.02e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg07044859	chr10:101282883	NA	-0.32	-5.9	-0.35	1.21e-8	Dental caries;
KIRP	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.9	14.21	0.67	7.23e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg13147721	chr7:65941812	NA	1.04	7.22	0.42	6.28e-12	Diabetic kidney disease;
KIRP	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.61	8.81	0.49	2.34e-16	Colorectal cancer;
KIRP	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.41	5.31	0.32	2.4e-7	Aortic root size;
KIRP	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	1.2	11.08	0.58	2.01e-23	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.54	-7.19	-0.42	7.76e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17554472	chr22:41940697	POLR3H	-0.69	-7.24	-0.42	5.68e-12	Vitiligo;
KIRP	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg01879757	chr17:41196368	BRCA1	-0.75	-10.28	-0.55	7.41e-21	Menopause (age at onset);
KIRP	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg17014757	chr1:203156097	CHI3L1	0.56	6.39	0.38	8.26e-10	YKL-40 levels;
KIRP	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01616529	chr11:638424	DRD4	-0.42	-5.66	-0.34	4.28e-8	Systemic lupus erythematosus;
KIRP	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.64	8.72	0.49	4.09e-16	Cognitive test performance;
KIRP	cis	rs478607	0.748	rs61884413	chr11:64459406	C/T	cg09231725	chr11:64357281	SLC22A12	-0.66	-5.16	-0.31	5.15e-7	Urate levels;
KIRP	cis	rs9815354	0.597	rs73075211	chr3:42033424	G/T	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	1.0	16.96	0.73	3.01e-43	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01957971	chr8:26214431	PPP2R2A	-0.46	-7.37	-0.43	2.53e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs580438	0.529	rs6769425	chr3:13374732	A/G	cg10657019	chr3:13328039	NA	-0.46	-6.15	-0.36	3.13e-9	Myringotomy;
KIRP	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg13264159	chr8:625131	ERICH1	0.82	5.3	0.32	2.64e-7	IgG glycosylation;
KIRP	cis	rs11718455	0.573	rs4682701	chr3:43905870	G/A	cg21419209	chr3:44054225	NA	0.46	5.96	0.36	8.6e-9	Coronary artery disease;
KIRP	cis	rs7572644	0.665	rs4233716	chr2:28034384	C/T	cg27432699	chr2:27873401	GPN1	0.46	5.21	0.32	4.07e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg14558114	chr2:88469736	THNSL2	0.66	5.08	0.31	7.48e-7	Plasma clusterin levels;
KIRP	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs1816752	0.875	rs7993132	chr13:24987041	C/T	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02187348	chr16:89574699	SPG7	-0.44	-5.13	-0.31	5.92e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.71	9.58	0.52	1.13e-18	Longevity;
KIRP	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg20090143	chr19:45452003	APOC2	0.34	5.47	0.33	1.12e-7	Blood protein levels;
KIRP	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg24101359	chr6:42928495	GNMT	-0.51	-7.6	-0.44	6.15e-13	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-6.85	-0.4	5.74e-11	Morning vs. evening chronotype;
KIRP	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.79	10.17	0.54	1.62e-20	Migraine;Coronary artery disease;
KIRP	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	10.52	0.56	1.34e-21	Parkinson's disease;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg01798813	chr17:3906674	NA	0.47	5.73	0.34	2.99e-8	Type 2 diabetes;
KIRP	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg16558253	chr16:72132732	DHX38	-0.55	-8.2	-0.46	1.33e-14	Fibrinogen levels;
KIRP	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.68	-7.04	-0.41	1.9e-11	Parkinson's disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13265914	chr8:21999630	REEP4	0.66	6.07	0.36	4.9e-9	Lung function (FEV1);
KIRP	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg21854759	chr1:92012499	NA	-0.47	-6.09	-0.36	4.38e-9	Breast cancer;
KIRP	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg17366294	chr4:99064904	C4orf37	0.47	5.86	0.35	1.5e-8	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs6088813	0.677	rs6088826	chr20:33998486	C/T	cg14752227	chr20:34000481	UQCC	0.45	5.13	0.31	5.8e-7	Height;
KIRP	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg17376030	chr22:41985996	PMM1	0.58	6.6	0.39	2.44e-10	Vitiligo;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg00933542	chr6:150070202	PCMT1	0.31	5.85	0.35	1.54e-8	Lung cancer;
KIRP	cis	rs7116495	1.000	rs10898814	chr11:71736505	T/C	cg26138937	chr11:71823887	C11orf51	-0.7	-5.65	-0.34	4.46e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.42	-5.31	-0.32	2.44e-7	Blood metabolite levels;
KIRP	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.77	12.81	0.63	4.05e-29	Dupuytren's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01523285	chr1:52301876	NRD1	-0.39	-6.12	-0.36	3.64e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg25281562	chr12:121454272	C12orf43	-0.49	-5.31	-0.32	2.48e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.45	-0.47	2.59e-15	Systolic blood pressure;
KIRP	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	0.59	6.11	0.36	3.84e-9	Eotaxin levels;
KIRP	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	1.19	8.43	0.47	3e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg07952391	chr2:88470173	THNSL2	0.69	4.87	0.3	1.95e-6	Plasma clusterin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25902616	chr11:47789193	FNBP4	0.49	6.28	0.37	1.55e-9	Parkinson's disease;
KIRP	trans	rs12517041	1.000	rs1366454	chr5:23319172	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.55	-0.43	8.27e-13	Calcium levels;
KIRP	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg04691961	chr3:161091175	C3orf57	-0.36	-5.27	-0.32	2.99e-7	Educational attainment (years of education);
KIRP	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg17554472	chr22:41940697	POLR3H	0.43	5.21	0.32	4.01e-7	Vitiligo;
KIRP	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg04226714	chr8:49833948	SNAI2	-0.52	-7.0	-0.41	2.38e-11	Life satisfaction;
KIRP	cis	rs10181042	0.565	rs3108630	chr2:61268160	A/G	cg15711740	chr2:61764176	XPO1	0.38	5.01	0.3	1.06e-6	Crohn's disease;
KIRP	cis	rs1506636	0.539	rs17701547	chr7:123383461	A/G	cg03229431	chr7:123269106	ASB15	-0.59	-6.57	-0.39	2.92e-10	Plateletcrit;Platelet count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10663220	chr12:13249129	GSG1	0.49	6.66	0.39	1.77e-10	Survival in pancreatic cancer;
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.79	7.54	0.43	9.13e-13	Lung function (FEV1/FVC);
KIRP	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg02487422	chr3:49467188	NICN1	0.4	5.72	0.34	3.15e-8	Menarche (age at onset);
KIRP	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.63	-8.22	-0.46	1.2e-14	Colorectal cancer;
KIRP	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	4.07e-15	Protein biomarker;
KIRP	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.99	-0.5	6.69e-17	Common traits (Other);
KIRP	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-5.27	-0.32	2.94e-7	Coronary artery disease;
KIRP	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.61	5.02	0.3	1.01e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.76	9.62	0.52	8.58e-19	Aortic root size;
KIRP	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg21366198	chr4:185655624	MLF1IP	-0.41	-5.46	-0.33	1.15e-7	Kawasaki disease;
KIRP	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.91	10.99	0.57	4.03e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11697464	chr6:143382034	AIG1	0.52	6.62	0.39	2.2e-10	Parkinson's disease;
KIRP	cis	rs12190007	0.508	rs6605539	chr6:169731997	A/T	cg16388071	chr6:169726476	NA	0.52	7.73	0.44	2.74e-13	Obesity-related traits;
KIRP	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg01879757	chr17:41196368	BRCA1	-0.78	-11.05	-0.58	2.59e-23	Menopause (age at onset);
KIRP	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.56	7.58	0.43	7.23e-13	Endometrial cancer;
KIRP	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.0	-16.43	-0.72	1.93e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-6.1	-0.36	4.08e-9	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02952494	chr16:1818699	MAPK8IP3	-0.44	-6.29	-0.37	1.45e-9	Survival in pancreatic cancer;
KIRP	cis	rs2425143	1.000	rs73902908	chr20:34365112	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-4.88	-0.3	1.89e-6	Blood protein levels;
KIRP	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.47	0.38	5.34e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4638749	0.677	rs7570544	chr2:108848137	C/T	cg06795125	chr2:108905320	SULT1C2	-0.35	-6.45	-0.38	5.91e-10	Blood pressure;
KIRP	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.31	0.37	1.32e-9	Joint mobility (Beighton score);
KIRP	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg11608241	chr8:8085544	FLJ10661	-0.54	-6.99	-0.41	2.55e-11	Triglycerides;
KIRP	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.83	-11.6	-0.59	4.26e-25	Height;
KIRP	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg02073558	chr3:44770973	ZNF501	0.61	8.61	0.48	8.94e-16	Depressive symptoms;
KIRP	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.95	0.3	1.35e-6	Educational attainment;
KIRP	cis	rs5752326	0.510	rs5761542	chr22:26859524	A/C	cg20819150	chr22:26891497	TFIP11	0.53	4.98	0.3	1.18e-6	Ischemic stroke;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16211328	chr22:38794952	LOC400927	-0.53	-5.67	-0.34	3.98e-8	Menopause (age at onset);
KIRP	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg04731861	chr2:219085781	ARPC2	0.28	7.25	0.42	5.45e-12	Colorectal cancer;
KIRP	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.53	-6.53	-0.38	3.74e-10	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15529551	chr14:61283164	MNAT1	-0.5	-7.92	-0.45	8.3e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.24	-0.37	1.9e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24551570	chr4:174255085	HMGB2	0.43	6.21	0.37	2.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs208520	0.909	rs62414636	chr6:67015723	T/G	cg07460842	chr6:66804631	NA	0.89	7.62	0.44	5.55e-13	Exhaled nitric oxide output;
KIRP	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.51	-6.72	-0.39	1.28e-10	Aortic root size;
KIRP	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg23625390	chr15:77176239	SCAPER	0.53	7.03	0.41	2.09e-11	Blood metabolite levels;
KIRP	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.39	3.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg22705602	chr4:152727874	NA	-0.61	-9.25	-0.51	1.1e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.16	0.42	9.43e-12	Height;
KIRP	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	-0.26	-5.11	-0.31	6.48e-7	Coronary artery disease;
KIRP	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg26138937	chr11:71823887	C11orf51	-1.02	-7.07	-0.41	1.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19717773	chr7:2847554	GNA12	-0.34	-5.88	-0.35	1.34e-8	Height;
KIRP	cis	rs11016883	1.000	rs7069143	chr10:131498258	C/T	cg14312783	chr10:131504572	MGMT	0.41	5.03	0.31	9.26e-7	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	1.99e-8	Lung cancer;
KIRP	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.25	0.37	1.84e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg00074818	chr8:8560427	CLDN23	0.42	6.29	0.37	1.45e-9	Obesity-related traits;
KIRP	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg23100626	chr2:96804247	ASTL	-0.51	-7.04	-0.41	1.95e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.7	0.34	3.36e-8	Lung cancer;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.18	-0.37	2.68e-9	Lung cancer;
KIRP	cis	rs6693295	0.877	rs4607842	chr1:246313723	A/G	cg11798871	chr1:246315928	SMYD3	-0.56	-6.36	-0.38	9.54e-10	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.68e-8	Life satisfaction;
KIRP	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.82	12.23	0.61	3.46e-27	Bladder cancer;
KIRP	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10518128	1.000	rs10518128	chr4:75713368	T/G	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg24631222	chr15:78858424	CHRNA5	-0.7	-8.67	-0.48	5.88e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35740288	0.787	rs2008916	chr15:86221190	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-4.97	-0.3	1.28e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26207909	chr14:103986467	CKB	0.73	10.31	0.55	6e-21	Body mass index;
KIRP	cis	rs921943	1.000	rs6453424	chr5:78315367	A/C	cg26802063	chr5:78281964	ARSB	-0.5	-6.31	-0.37	1.26e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs4716602	0.898	rs4717047	chr7:156160671	T/C	cg04090468	chr7:156181990	NA	0.46	5.53	0.33	8.2e-8	Anti-saccade response;
KIRP	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.73	-7.85	-0.45	1.31e-13	Diastolic blood pressure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03657573	chr3:182972326	MCF2L2;B3GNT5	-0.45	-6.12	-0.36	3.57e-9	Metabolic traits;
KIRP	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg04374321	chr14:90722782	PSMC1	0.91	15.84	0.71	1.98e-39	Mortality in heart failure;
KIRP	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.63	-9.07	-0.5	3.92e-17	Testicular germ cell tumor;
KIRP	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.82	0.4	6.89e-11	Bipolar disorder;
KIRP	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs7106204	0.534	rs78879754	chr11:24279312	G/A	ch.11.24196551F	chr11:24239977	NA	0.71	4.93	0.3	1.52e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg13010199	chr12:38710504	ALG10B	0.41	5.35	0.32	2e-7	Heart rate;
KIRP	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.56	0.48	1.21e-15	Motion sickness;
KIRP	cis	rs6662572	0.737	rs6700974	chr1:46371735	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.35e-8	Blood protein levels;
KIRP	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.51	7.1	0.41	1.37e-11	Alcohol dependence;
KIRP	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-8.1	-0.46	2.52e-14	Colorectal cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg12284171	chr11:129814770	PRDM10	0.42	6.06	0.36	5e-9	Migraine with aura;
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg05627522	chr15:75251581	NA	0.32	4.91	0.3	1.65e-6	Breast cancer;
KIRP	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg26384229	chr12:38710491	ALG10B	0.74	9.65	0.52	6.75e-19	Morning vs. evening chronotype;
KIRP	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.17	0.54	1.64e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.71	-0.56	3.31e-22	Height;
KIRP	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg01620082	chr3:125678407	NA	-1.11	-7.23	-0.42	6.11e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.62	-0.39	2.2e-10	Neuroticism;
KIRP	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg18198730	chr1:247681584	NA	0.81	5.33	0.32	2.23e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs997295	1.000	rs36004835	chr15:67951542	A/C	cg24579218	chr15:68104479	NA	0.36	5.44	0.33	1.29e-7	Motion sickness;
KIRP	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg02153584	chr22:29168773	CCDC117	0.57	5.93	0.35	1.01e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.35	-0.42	2.89e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs34638686	1	rs34638686	chr3:48682658	C/T	cg00383909	chr3:49044727	WDR6	0.66	5.96	0.36	8.62e-9	Educational attainment (years of education);
KIRP	cis	rs8027181	1.000	rs2162269	chr15:73090262	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.37	4.86	0.3	2.06e-6	Triglyceride levels;
KIRP	cis	rs7116495	0.588	rs547208	chr11:71779668	A/G	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.64	9.54	0.52	1.51e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.41	-0.38	7.22e-10	Uric acid levels;
KIRP	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg24796726	chr7:884288	UNC84A	-0.6	-5.25	-0.32	3.33e-7	Initial pursuit acceleration;
KIRP	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2281603	0.951	rs61985707	chr14:64979564	G/T	cg25009451	chr14:65006716	HSPA2	0.47	5.06	0.31	8.26e-7	Lymphocyte counts;
KIRP	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-6.38	-0.38	8.6e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs61931739	0.711	rs7968821	chr12:34318351	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.13	0.36	3.55e-9	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg17554472	chr22:41940697	POLR3H	-0.6	-6.49	-0.38	4.63e-10	Vitiligo;
KIRP	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	9.06	0.5	4.09e-17	Motion sickness;
KIRP	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg08126542	chr6:37504118	NA	-0.82	-12.12	-0.61	8.17e-27	Cognitive performance;
KIRP	cis	rs8077577	0.945	rs11871039	chr17:18078904	C/G	cg18869244	chr17:18121946	NA	0.47	5.07	0.31	7.87e-7	Obesity-related traits;
KIRP	cis	rs9400467	0.528	rs7750792	chr6:111783759	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.56	-0.33	7.03e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4713675	0.584	rs6917140	chr6:33678394	C/G	cg15676125	chr6:33679581	C6orf125	0.42	5.49	0.33	1.02e-7	Plateletcrit;
KIRP	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg13256891	chr4:100009986	ADH5	0.5	6.13	0.36	3.5e-9	Alcohol dependence;
KIRP	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs965513	1.000	rs10759927	chr9:100542176	A/G	cg13688889	chr9:100608707	NA	-0.59	-7.52	-0.43	1.03e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs745821	0.879	rs1025686	chr18:48147127	A/G	cg18923635	chr18:48083994	NA	0.43	4.94	0.3	1.44e-6	Diastolic blood pressure;
KIRP	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.72	9.35	0.51	5.64e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26769984	chr7:1090371	C7orf50	0.79	7.46	0.43	1.53e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.07	0.31	7.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg22437258	chr11:111473054	SIK2	0.6	7.1	0.41	1.37e-11	Primary sclerosing cholangitis;
KIRP	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	11.24	0.58	6.07e-24	Birth weight;
KIRP	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.85	-11.84	-0.6	6.92e-26	Total body bone mineral density;
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg22764044	chr5:178986830	RUFY1	0.52	7.71	0.44	3.1e-13	Lung cancer;
KIRP	cis	rs1062177	0.855	rs6896664	chr5:151265274	A/G	cg00977110	chr5:151150581	G3BP1	0.55	5.85	0.35	1.53e-8	Preschool internalizing problems;
KIRP	cis	rs4791746	1.000	rs4791746	chr17:8626357	C/T	cg03115937	chr17:8649504	CCDC42	0.52	6.38	0.38	8.73e-10	Heroin dependence;
KIRP	cis	rs490234	0.841	rs13291593	chr9:128228483	A/G	cg14078157	chr9:128172775	NA	-0.55	-6.4	-0.38	7.62e-10	Mean arterial pressure;
KIRP	cis	rs1364705	1.000	rs6986732	chr8:120225428	A/C	cg09273054	chr8:120220131	MAL2	0.5	5.97	0.36	8.08e-9	Hippocampal atrophy;
KIRP	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.78	10.5	0.56	1.45e-21	Mood instability;
KIRP	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.82	-11.43	-0.59	1.52e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg11845111	chr2:191398756	TMEM194B	-0.94	-9.95	-0.54	8.19e-20	Diastolic blood pressure;
KIRP	cis	rs503734	0.521	rs348884	chr3:100975293	C/G	cg27318481	chr3:100970896	IMPG2	-0.58	-7.93	-0.45	7.83e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg11707556	chr5:10655725	ANKRD33B	0.67	8.44	0.47	2.7e-15	Coronary artery disease;
KIRP	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.42	-5.52	-0.33	8.57e-8	Body mass index;
KIRP	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg12292205	chr6:26970375	C6orf41	0.34	5.02	0.3	9.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10924970	0.967	rs4481838	chr1:235442626	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	8.09	0.46	2.73e-14	Response to antipsychotic treatment;
KIRP	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg18171855	chr10:2543474	NA	-0.47	-5.85	-0.35	1.54e-8	Age-related hearing impairment;
KIRP	cis	rs4664304	0.620	rs3951216	chr2:160711045	G/C	cg03641300	chr2:160917029	PLA2R1	0.39	5.87	0.35	1.37e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg21433313	chr16:3507492	NAT15	0.66	7.27	0.42	4.82e-12	Tuberculosis;
KIRP	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.38	0.32	1.7e-7	Homoarginine levels;
KIRP	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.6	7.83	0.45	1.46e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs7187994	0.836	rs16974519	chr16:84782750	A/C	cg07647771	chr16:84786436	USP10	-0.44	-5.59	-0.34	6.04e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg12369402	chr1:90227771	NA	-0.37	-5.12	-0.31	6.09e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.62	-5.85	-0.35	1.58e-8	Alzheimer's disease;
KIRP	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.56	7.75	0.44	2.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg17294928	chr15:75287854	SCAMP5	-0.67	-5.53	-0.33	8.1e-8	Lung cancer;
KIRP	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.26	-26.87	-0.86	3.89e-75	IgG glycosylation;
KIRP	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg15976283	chr2:238042351	NA	-0.4	-5.6	-0.34	5.64e-8	Systemic lupus erythematosus;
KIRP	cis	rs78487399	0.710	rs80100685	chr2:43650413	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.19	-0.31	4.46e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.67	-9.92	-0.53	9.75e-20	Dupuytren's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18827097	chr2:3522506	ADI1	0.63	7.58	0.44	7.09e-13	Smoking initiation;
KIRP	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg17764715	chr19:33622953	WDR88	0.65	7.86	0.45	1.22e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17592366	0.517	rs7147621	chr14:35275704	G/A	cg09327582	chr14:35236912	BAZ1A	0.6	6.01	0.36	6.63e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs6546324	0.625	rs2861644	chr2:67799964	A/G	cg15745817	chr2:67799979	NA	-0.69	-7.97	-0.45	5.95e-14	Endometriosis;
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg24874828	chr4:187887005	NA	-0.47	-7.05	-0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.52	-7.24	-0.42	5.83e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg09904177	chr6:26538194	HMGN4	0.39	4.92	0.3	1.57e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.12	-0.61	8.24e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.46	5.81	0.35	1.9e-8	Eosinophil percentage of white cells;
KIRP	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.25	6.73	0.39	1.21e-10	Crohn's disease;
KIRP	cis	rs9372253	0.564	rs2057151	chr6:110716608	G/C	cg00083206	chr6:110721305	DDO	-0.35	-4.91	-0.3	1.66e-6	Platelet distribution width;
KIRP	cis	rs8093481	1.000	rs35162682	chr18:10692665	T/C	cg21165219	chr18:10698044	FAM38B	-0.44	-5.49	-0.33	9.81e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg10017260	chr10:834428	NA	-0.66	-5.9	-0.35	1.17e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	0.94	11.19	0.58	9.06e-24	Vitiligo;
KIRP	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg01422370	chr2:73384389	NA	0.39	5.15	0.31	5.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.35	6.22	0.37	2.12e-9	Renal cell carcinoma;
KIRP	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.59	-0.34	5.97e-8	Menopause (age at onset);
KIRP	cis	rs34421088	0.532	rs1545073	chr8:11167700	C/T	cg00405596	chr8:11794950	NA	0.45	5.66	0.34	4.1e-8	Neuroticism;
KIRP	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-8.34	-0.47	5.47e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg06766960	chr11:133703094	NA	0.46	5.93	0.35	1e-8	Childhood ear infection;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg03289416	chr15:75166202	SCAMP2	0.52	7.05	0.41	1.83e-11	Breast cancer;
KIRP	cis	rs6674970	0.777	rs11204782	chr1:151118035	C/G	cg11822372	chr1:151115635	SEMA6C	-0.57	-6.22	-0.37	2.14e-9	Childhood ear infection;
KIRP	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg15420906	chr14:67688261	FAM71D	-0.46	-6.38	-0.38	8.61e-10	Select biomarker traits;
KIRP	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.37	4.88	0.3	1.9e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg12435725	chr3:58293450	RPP14	-0.51	-5.36	-0.32	1.91e-7	Cholesterol, total;
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg11859384	chr17:80120422	CCDC57	0.44	5.51	0.33	9.16e-8	Life satisfaction;
KIRP	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.6	-5.56	-0.33	6.89e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27437944	chr3:180630533	FXR1	0.44	6.08	0.36	4.55e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7870753	0.628	rs2406005	chr9:99197655	A/C	cg25260653	chr9:99212216	HABP4	0.58	5.94	0.35	9.59e-9	Height;
KIRP	cis	rs62380364	0.602	rs588282	chr5:88032651	G/T	cg24804195	chr5:87968844	LOC645323	-0.45	-5.94	-0.35	9.67e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg20790798	chr5:1857306	NA	-0.45	-5.41	-0.33	1.49e-7	Cardiovascular disease risk factors;
KIRP	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	5.55	0.33	7.27e-8	Monocyte percentage of white cells;
KIRP	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs9596863	1.000	rs9596863	chr13:54434647	T/G	ch.13.53330881F	chr13:54432880	NA	0.58	5.66	0.34	4.21e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs11628318	0.853	rs11626063	chr14:103024706	G/C	cg01864069	chr14:103024347	NA	-1.0	-13.1	-0.64	4.27e-30	Platelet count;
KIRP	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg08885076	chr2:99613938	TSGA10	-0.37	-4.98	-0.3	1.17e-6	Chronic sinus infection;
KIRP	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.85	-0.57	1.15e-22	Menopause (age at onset);
KIRP	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg23587288	chr2:27483067	SLC30A3	0.55	6.85	0.4	5.91e-11	Blood metabolite levels;
KIRP	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg04727924	chr7:799746	HEATR2	0.63	5.88	0.35	1.33e-8	Cerebrospinal P-tau181p levels;
KIRP	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg18944383	chr4:111397179	ENPEP	0.41	6.39	0.38	8.47e-10	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.66	0.34	4.22e-8	Menopause (age at onset);
KIRP	cis	rs4851266	0.898	rs13026143	chr2:100865406	A/G	cg05692746	chr2:100937584	LONRF2	0.41	4.99	0.3	1.12e-6	Educational attainment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16760971	chr2:172912454	MAP1D	-0.47	-7.37	-0.43	2.65e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg06636001	chr8:8085503	FLJ10661	0.69	8.98	0.5	7.07e-17	Retinal vascular caliber;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09998004	chr4:88244909	HSD17B13	0.48	6.34	0.37	1.08e-9	Interleukin-4 levels;
KIRP	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg02297831	chr4:17616191	MED28	-0.55	-6.4	-0.38	7.74e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.72	9.54	0.52	1.49e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.43	-5.0	-0.3	1.07e-6	Iron status biomarkers;
KIRP	trans	rs7500067	1.000	rs11150296	chr16:80644663	T/C	cg20673611	chr12:27166943	TM7SF3	0.54	6.04	0.36	5.63e-9	Breast cancer;
KIRP	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.45	8.49	0.48	1.92e-15	Educational attainment (years of education);
KIRP	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01256987	chr12:42539512	GXYLT1	-0.44	-5.78	-0.35	2.26e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs72960926	0.744	rs55792900	chr6:74924010	C/A	cg03266952	chr6:74778945	NA	-0.6	-5.12	-0.31	6.2e-7	Metabolite levels (MHPG);
KIRP	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.85	12.89	0.63	2.22e-29	Height;
KIRP	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.54	5.98	0.36	8e-9	Vitiligo;
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs7221595	0.825	rs12951359	chr17:3921731	T/A	cg05562828	chr17:3906858	NA	0.61	6.92	0.4	3.99e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10276381	0.786	rs28430601	chr7:28238811	A/G	cg23620719	chr7:28220237	JAZF1	0.57	5.99	0.36	7.48e-9	Crohn's disease;
KIRP	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06634786	chr22:41940651	POLR3H	-0.47	-5.21	-0.32	4.03e-7	Vitiligo;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.94	16.57	0.73	6.52e-42	Longevity;Endometriosis;
KIRP	cis	rs28489187	0.683	rs2177461	chr1:85861976	C/G	cg16011679	chr1:85725395	C1orf52	-0.49	-5.99	-0.36	7.33e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.75	-9.89	-0.53	1.21e-19	Blood metabolite levels;
KIRP	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg19847130	chr8:10466454	RP1L1	0.34	4.99	0.3	1.13e-6	Retinal vascular caliber;
KIRP	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg04132472	chr17:19861366	AKAP10	-0.68	-10.8	-0.57	1.66e-22	Schizophrenia;
KIRP	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.91	-12.18	-0.61	5.14e-27	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.37	5.37	0.32	1.85e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs4262150	0.544	rs17451810	chr5:151901848	C/G	cg12297329	chr5:152029980	NA	-0.68	-8.41	-0.47	3.3e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg22081084	chr1:89990230	LRRC8B	0.53	6.08	0.36	4.54e-9	Sleep duration;
KIRP	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.74	11.51	0.59	8.5e-25	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03587150	chr1:154193741	C1orf43;UBAP2L	0.54	7.1	0.41	1.31e-11	Parkinson's disease;
KIRP	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.4	5.13	0.31	5.76e-7	Social autistic-like traits;
KIRP	cis	rs6662572	0.737	rs72690901	chr1:46378028	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.64	0.34	4.57e-8	Blood protein levels;
KIRP	cis	rs12936587	0.692	rs12943416	chr17:17535535	A/C	cg01246520	chr17:17644344	RAI1	-0.38	-6.15	-0.37	3.04e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	trans	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg02030672	chr11:45687055	CHST1	0.49	6.53	0.38	3.75e-10	Obesity-related traits;
KIRP	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.69	9.85	0.53	1.67e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg27205649	chr11:78285834	NARS2	-0.46	-4.92	-0.3	1.6e-6	Testicular germ cell tumor;
KIRP	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.55	7.03	0.41	2e-11	Eye color traits;
KIRP	cis	rs7635838	0.859	rs9812885	chr3:11508326	G/C	cg00170343	chr3:11313890	ATG7	0.44	5.74	0.34	2.73e-8	HDL cholesterol;
KIRP	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.8	13.06	0.64	5.71e-30	Schizophrenia;
KIRP	cis	rs1847505	0.559	rs2323133	chr13:61568946	G/A	cg25164009	chr13:61490935	NA	-0.6	-7.63	-0.44	5.03e-13	Polychlorinated biphenyl levels;
KIRP	trans	rs800082	0.690	rs2118001	chr3:144336609	T/C	cg24215973	chr2:240111563	HDAC4	-0.54	-7.32	-0.42	3.49e-12	Smoking behavior;
KIRP	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg24296786	chr1:45957014	TESK2	0.41	5.4	0.33	1.58e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg07741184	chr6:167504864	NA	-0.24	-6.4	-0.38	7.85e-10	Crohn's disease;
KIRP	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.97	10.29	0.55	6.78e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.91	14.06	0.67	2.41e-33	Selective IgA deficiency;
KIRP	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-0.66	-7.74	-0.44	2.65e-13	Initial pursuit acceleration;
KIRP	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg03788504	chr6:150331562	NA	-0.33	-6.28	-0.37	1.51e-9	Alopecia areata;
KIRP	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg01689657	chr7:91764605	CYP51A1	0.43	6.28	0.37	1.55e-9	Breast cancer;
KIRP	cis	rs752010	0.934	rs11210503	chr1:42101134	A/G	cg06885757	chr1:42089581	HIVEP3	0.61	9.4	0.51	4e-18	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2411233	1.000	rs8029263	chr15:39301246	A/G	cg05886626	chr15:39873553	THBS1	0.32	4.88	0.3	1.89e-6	Platelet count;
KIRP	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.45	-0.33	1.23e-7	Platelet count;
KIRP	cis	rs62229266	0.771	rs11701590	chr21:37384730	A/C	cg08632701	chr21:37451849	NA	-0.42	-5.18	-0.31	4.62e-7	Mitral valve prolapse;
KIRP	cis	rs4791746	0.846	rs9895426	chr17:8647127	C/T	cg03115937	chr17:8649504	CCDC42	0.57	7.13	0.41	1.13e-11	Heroin dependence;
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.15	0.46	1.81e-14	Electroencephalogram traits;
KIRP	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg13010199	chr12:38710504	ALG10B	-0.39	-5.05	-0.31	8.5e-7	Heart rate;
KIRP	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg24253500	chr15:84953950	NA	0.48	5.5	0.33	9.6e-8	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg04369109	chr6:150039330	LATS1	-0.52	-6.61	-0.39	2.31e-10	Lung cancer;
KIRP	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05220968	chr6:146057943	EPM2A	-0.39	-5.16	-0.31	5.2e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7116495	1.000	rs4944258	chr11:71743393	T/A	cg26138937	chr11:71823887	C11orf51	-0.69	-5.51	-0.33	8.83e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg09698166	chr20:21106763	PLK1S1	0.54	6.47	0.38	5.32e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26207909	chr14:103986467	CKB	0.55	7.48	0.43	1.29e-12	Body mass index;
KIRP	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.86	-12.8	-0.63	4.2e-29	Height;
KIRP	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs12764182	0.851	rs17445202	chr10:77909366	G/A	cg06487870	chr10:77542354	C10orf11	0.29	5.12	0.31	6.04e-7	QRS complex (Cornell);
KIRP	cis	rs10170310	1.000	rs12691947	chr2:139264471	A/G	cg03782584	chr2:139258740	SPOPL	0.3	4.86	0.3	2.06e-6	Response to antipsychotic treatment;
KIRP	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.97	0.5	7.58e-17	IgG glycosylation;
KIRP	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg19468946	chr17:37922297	IKZF3	-0.49	-6.9	-0.4	4.42e-11	Self-reported allergy;
KIRP	cis	rs6968419	0.674	rs11767092	chr7:115907865	C/T	cg02561103	chr7:115862891	TES	-0.41	-5.84	-0.35	1.65e-8	Intraocular pressure;
KIRP	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.65	7.99	0.45	5.23e-14	Calcium levels;
KIRP	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg07622451	chr1:3079886	PRDM16	0.37	5.35	0.32	2.03e-7	Migraine;
KIRP	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.73	10.22	0.55	1.17e-20	Plateletcrit;Platelet count;
KIRP	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg13180566	chr4:1052158	NA	-0.54	-5.23	-0.32	3.61e-7	Recombination rate (females);
KIRP	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg11859384	chr17:80120422	CCDC57	0.48	6.29	0.37	1.48e-9	Life satisfaction;
KIRP	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg01689657	chr7:91764605	CYP51A1	0.36	5.3	0.32	2.59e-7	Breast cancer;
KIRP	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.88	0.35	1.32e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg17554472	chr22:41940697	POLR3H	-0.43	-5.22	-0.32	3.73e-7	Vitiligo;
KIRP	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.82	-11.86	-0.6	5.91e-26	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00095276	chr5:1068111	SLC12A7	0.54	6.78	0.4	8.63e-11	Interleukin-4 levels;
KIRP	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.68	-7.79	-0.44	1.88e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9487051	0.702	rs670414	chr6:109529912	A/G	cg21918786	chr6:109611834	NA	0.33	5.02	0.31	9.74e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg13482628	chr17:19912719	NA	-0.53	-6.93	-0.4	3.68e-11	Schizophrenia;
KIRP	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg23505145	chr19:12996616	KLF1	0.55	8.09	0.46	2.71e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs78487399	0.908	rs6725688	chr2:43846553	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.51	-0.33	9.04e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.77	8.49	0.48	1.91e-15	Obesity-related traits;
KIRP	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg26576206	chr19:1064938	ABCA7	0.37	5.14	0.31	5.55e-7	Alzheimer's disease (late onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13499966	chr2:10220719	CYS1	0.51	6.43	0.38	6.5e-10	Parkinson's disease;
KIRP	cis	rs76288851	0.627	rs9838548	chr3:126747367	T/C	cg00307254	chr3:126706825	PLXNA1	-0.47	-5.73	-0.34	2.94e-8	Alcoholic chronic pancreatitis;
KIRP	cis	rs10129255	0.500	rs988132	chr14:107184997	C/T	cg23076370	chr14:107095027	NA	-0.41	-4.99	-0.3	1.14e-6	Kawasaki disease;
KIRP	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg24687543	chr11:63912206	MACROD1	0.53	4.95	0.3	1.35e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs860295	0.702	rs10908470	chr1:155527013	A/C	cg02153340	chr1:155202674	NA	-0.56	-7.28	-0.42	4.53e-12	Body mass index;
KIRP	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg05362011	chr13:21860987	NA	0.56	5.74	0.34	2.8e-8	White matter hyperintensity burden;
KIRP	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.61	-0.39	2.39e-10	Obesity-related traits;
KIRP	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg26876637	chr1:152193138	HRNR	0.76	9.9	0.53	1.13e-19	Atopic dermatitis;
KIRP	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg00977110	chr5:151150581	G3BP1	-0.6	-6.01	-0.36	6.81e-9	Preschool internalizing problems;
KIRP	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.54	7.97	0.45	5.92e-14	Blood protein levels;
KIRP	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.45	-5.65	-0.34	4.4e-8	Monobrow;
KIRP	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg15556689	chr8:8085844	FLJ10661	0.63	7.82	0.45	1.5e-13	Parkinson's disease;
KIRP	cis	rs9318086	0.534	rs17338049	chr13:24382148	G/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.41	-4.93	-0.3	1.48e-6	Myopia (pathological);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10740880	chr2:170365212	KBTBD10	-0.45	-6.55	-0.39	3.4e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7565981	0.850	rs6542988	chr2:101432861	T/C	cg02232089	chr2:101440696	NPAS2	-0.62	-5.6	-0.34	5.75e-8	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg14972814	chr11:95582409	MTMR2	0.3	5.22	0.32	3.77e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg08975724	chr8:8085496	FLJ10661	0.6	7.67	0.44	3.99e-13	Retinal vascular caliber;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03306564	chr11:64902099	SYVN1	0.55	6.28	0.37	1.55e-9	Smoking initiation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15029192	chr15:49447345	GALK2;COPS2	0.46	6.6	0.39	2.49e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07810072	chr11:66610236	RCE1;C11orf80	0.49	6.22	0.37	2.08e-9	Parkinson's disease;
KIRP	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.54	-6.22	-0.37	2.11e-9	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.61	8.31	0.47	6.63e-15	Pulse pressure;
KIRP	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg00677455	chr12:58241039	CTDSP2	-0.44	-5.05	-0.31	8.81e-7	Multiple sclerosis;
KIRP	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs17453880	0.853	rs6885419	chr5:152027678	T/C	cg12297329	chr5:152029980	NA	-0.74	-11.32	-0.59	3.43e-24	Subjective well-being;
KIRP	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg12559939	chr2:27858050	GPN1	0.49	6.12	0.36	3.76e-9	Oral cavity cancer;
KIRP	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.61	-6.8	-0.4	7.85e-11	Pancreatic cancer;
KIRP	cis	rs15676	0.783	rs7860949	chr9:131586883	C/T	cg00228799	chr9:131580591	ENDOG	-0.55	-6.04	-0.36	5.63e-9	Blood metabolite levels;
KIRP	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg10241871	chr14:102965420	TECPR2	-0.48	-5.54	-0.33	7.65e-8	Plateletcrit;
KIRP	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	1.01	17.67	0.75	1.13e-45	Breast cancer;
KIRP	cis	rs7017914	0.934	rs7006615	chr8:71639807	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.79	9.05	0.5	4.5e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-4.97	-0.3	1.24e-6	Life satisfaction;
KIRP	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg16586182	chr3:47516702	SCAP	0.68	9.25	0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs1417569	0.519	rs3011601	chr10:31245329	C/T	cg00428179	chr10:31322131	ZNF438	-0.45	-6.31	-0.37	1.31e-9	Tuberculosis;
KIRP	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg23280166	chr11:118938394	VPS11	0.62	7.58	0.44	6.91e-13	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-5.0	-0.3	1.09e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg02696742	chr7:106810147	HBP1	-0.78	-8.8	-0.49	2.53e-16	Coronary artery disease;
KIRP	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.59	7.54	0.43	9.05e-13	Corneal astigmatism;
KIRP	cis	rs34524635	1	rs34524635	chr10:65261176	CT/C	cg01631684	chr10:65280961	REEP3	-0.52	-6.15	-0.36	3.19e-9	Vascular endothelial growth factor levels;
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.42	6.38	0.38	8.93e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09667134	chr7:98550922	TRRAP	-0.51	-6.67	-0.39	1.71e-10	Inflammatory biomarkers;
KIRP	cis	rs6466055	0.625	rs73186025	chr7:104878705	C/T	cg04380332	chr7:105027541	SRPK2	0.38	5.21	0.32	3.99e-7	Schizophrenia;
KIRP	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.59	7.36	0.42	2.79e-12	Tonsillectomy;
KIRP	cis	rs17125944	0.686	rs9646151	chr14:53354464	C/G	cg00686598	chr14:53173677	PSMC6	-0.67	-6.43	-0.38	6.64e-10	Alzheimer's disease (late onset);
KIRP	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.77	-0.49	3.02e-16	Personality dimensions;
KIRP	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg00405596	chr8:11794950	NA	-0.47	-6.13	-0.36	3.52e-9	Retinal vascular caliber;
KIRP	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg13206674	chr6:150067644	NUP43	0.51	7.02	0.41	2.18e-11	Testicular germ cell tumor;
KIRP	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.81	9.43	0.52	3.3e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs12580194	0.957	rs56380243	chr12:55690727	A/G	cg11794356	chr12:55725991	OR6C3	-0.44	-6.12	-0.36	3.63e-9	Cancer;
KIRP	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg00405596	chr8:11794950	NA	-0.46	-5.69	-0.34	3.61e-8	Neuroticism;
KIRP	cis	rs34526934	0.566	rs35563571	chr2:177044459	T/G	cg26754761	chr2:177040938	NA	-0.46	-7.78	-0.44	2.05e-13	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.77	8.6	0.48	9.53e-16	Corneal astigmatism;
KIRP	cis	rs1497828	1.000	rs2810766	chr1:217565056	G/A	cg04411442	chr1:217543379	NA	0.3	4.86	0.3	2.13e-6	Dialysis-related mortality;
KIRP	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg14650228	chr8:144573510	ZC3H3	-0.68	-4.89	-0.3	1.83e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs4889855	0.530	rs78012645	chr17:78550939	C/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.4	-0.33	1.55e-7	Fractional excretion of uric acid;
KIRP	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg05347473	chr6:146136440	FBXO30	0.56	8.05	0.46	3.63e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.54	6.86	0.4	5.66e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.43	-0.33	1.33e-7	Obesity-related traits;
KIRP	cis	rs8113308	0.810	rs8100521	chr19:52449643	A/G	cg25782003	chr19:52490127	ZNF350	0.54	5.11	0.31	6.44e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7651039	0.641	rs2455810	chr3:15657082	A/T	cg16303742	chr3:15540471	COLQ	0.58	7.75	0.44	2.37e-13	Coronary heart disease;
KIRP	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg22676075	chr6:135203613	NA	0.47	6.56	0.39	3.19e-10	Red blood cell count;
KIRP	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg15880211	chr22:50250494	ZBED4	0.57	5.0	0.3	1.11e-6	Mean platelet volume;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15190599	chr6:26156487	HIST1H1E	0.53	6.58	0.39	2.81e-10	DNA methylation (variation);
KIRP	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.66	-0.52	6.57e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs4148087	1.000	rs4148101	chr21:43640183	G/A	cg08841829	chr21:43638893	ABCG1	-0.58	-4.92	-0.3	1.58e-6	Eating disorder in bipolar disorder;
KIRP	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg06585982	chr3:143692056	C3orf58	0.61	7.73	0.44	2.67e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg08738300	chr3:44038990	NA	0.68	9.65	0.52	6.79e-19	Coronary artery disease;
KIRP	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg01843034	chr6:37503916	NA	-0.97	-15.6	-0.71	1.28e-38	Cognitive performance;
KIRP	cis	rs9914988	0.830	rs7221773	chr17:27202888	C/T	cg20469991	chr17:27169893	C17orf63	-0.7	-5.86	-0.35	1.46e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2281603	0.951	rs61985711	chr14:64993258	T/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs830383	0.584	rs6555674	chr5:165509898	A/C	cg13976338	chr5:165423657	NA	0.47	5.55	0.33	7.3900000000000007e-08	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19734201	chr4:39699603	UBE2K	0.43	6.33	0.37	1.15e-9	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	5.05	0.31	8.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg25486957	chr4:152246857	NA	-0.5	-5.26	-0.32	3.09e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.54	-7.19	-0.42	7.72e-12	Schizophrenia;
KIRP	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.82	9.83	0.53	1.85e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8453	0.608	rs3126218	chr1:115348476	C/T	cg12756093	chr1:115239321	AMPD1	-0.51	-5.56	-0.33	7.03e-8	Autism;
KIRP	cis	rs3762637	0.943	rs10222564	chr3:122266336	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.05	-0.36	5.24e-9	LDL cholesterol levels;
KIRP	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	cg21523751	chr1:182988639	NA	0.41	6.32	0.37	1.22e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg04989706	chr14:50066350	PPIL5	-0.45	-5.22	-0.32	3.81e-7	Carotid intima media thickness;
KIRP	trans	rs9463078	0.585	rs9472451	chr6:45198796	A/C	cg26834624	chr7:6662329	ZNF853	-0.47	-6.17	-0.37	2.83e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.97	-0.36	8.23e-9	Schizophrenia;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19202786	chr6:166797286	BRP44L	0.5	6.03	0.36	5.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05147070	chr3:160283469	KPNA4	0.44	5.5	0.33	9.33e-8	Parkinson's disease;
KIRP	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	0.97	12.77	0.63	5.65e-29	Breast cancer;
KIRP	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8113308	0.752	rs11882377	chr19:52504130	G/A	cg25782003	chr19:52490127	ZNF350	0.79	7.39	0.43	2.32e-12	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7078219	0.714	rs10883368	chr10:101289998	A/G	cg07044859	chr10:101282883	NA	-0.33	-5.08	-0.31	7.37e-7	Dental caries;
KIRP	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg02415014	chr8:143852576	LYNX1	0.33	5.21	0.32	3.94e-7	Urinary tract infection frequency;
KIRP	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06212747	chr3:49208901	KLHDC8B	0.7	9.42	0.51	3.53e-18	Parkinson's disease;
KIRP	cis	rs7084402	1.000	rs36097682	chr10:60269738	G/A	cg05938607	chr10:60274200	BICC1	0.42	10.11	0.54	2.53e-20	Refractive error;
KIRP	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.57	7.53	0.43	9.6e-13	HDL cholesterol;
KIRP	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.54	-8.85	-0.49	1.78e-16	Eye color traits;
KIRP	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg27494647	chr7:150038898	RARRES2	-0.38	-5.72	-0.34	3.07e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg01320130	chr1:67600311	NA	-0.41	-5.38	-0.32	1.78e-7	Psoriasis;
KIRP	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.58	-7.65	-0.44	4.67e-13	Schizophrenia;
KIRP	trans	rs2594989	0.831	rs13324245	chr3:11570769	T/G	cg02538783	chr10:35102505	PARD3	0.37	6.31	0.37	1.31e-9	Circulating chemerin levels;
KIRP	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.64	6.61	0.39	2.38e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg27490568	chr2:178487706	NA	-0.52	-7.07	-0.41	1.64e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg01941274	chr14:50234650	KLHDC2	0.4	4.94	0.3	1.48e-6	Carotid intima media thickness;
KIRP	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.31	-5.22	-0.32	3.82e-7	Height;
KIRP	cis	rs4262150	0.883	rs72804786	chr5:152317799	G/A	cg12297329	chr5:152029980	NA	-0.66	-8.65	-0.48	6.59e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg08076091	chr2:203926405	NBEAL1	0.75	8.35	0.47	4.86e-15	LDL cholesterol;
KIRP	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg26412358	chr1:26503933	CNKSR1	0.4	5.64	0.34	4.7e-8	Height;
KIRP	cis	rs4774830	0.590	rs4774837	chr15:56255774	G/T	cg05129572	chr15:56138634	NEDD4	0.65	4.86	0.3	2.08e-6	Delta-5 desaturase activity;
KIRP	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.23	0.46	1.1e-14	Lung cancer;
KIRP	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.89	-10.59	-0.56	7.81e-22	Homoarginine levels;
KIRP	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.55	6.25	0.37	1.82e-9	Alzheimer's disease (late onset);
KIRP	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg02461776	chr11:598696	PHRF1	0.67	7.13	0.41	1.08e-11	Systemic lupus erythematosus;
KIRP	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg22676075	chr6:135203613	NA	0.48	6.74	0.39	1.13e-10	Red blood cell count;
KIRP	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg27170947	chr2:26402098	FAM59B	0.63	6.8	0.4	7.77e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg23736307	chr8:27182930	PTK2B	0.48	6.05	0.36	5.35e-9	Neuroticism;
KIRP	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.56	-6.25	-0.37	1.8e-9	Hypospadias;
KIRP	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.45	5.87	0.35	1.38e-8	Breast cancer;
KIRP	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg08603382	chr10:743973	NA	0.46	6.66	0.39	1.78e-10	Psychosis in Alzheimer's disease;
KIRP	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg16141378	chr3:129829833	LOC729375	-0.53	-7.0	-0.41	2.45e-11	Mood instability;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.27	-5.5	-0.33	9.52e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2562456	0.550	rs4809143	chr19:21772728	C/A	cg00806126	chr19:22604979	ZNF98	-0.67	-6.41	-0.38	7.32e-10	Pain;
KIRP	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg21479132	chr6:26055353	NA	0.81	5.67	0.34	4.09e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4950322	0.570	rs72692973	chr1:146805013	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.36	-0.59	2.62e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	1.04	14.82	0.69	6.05e-36	Cognitive function;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19929852	chr4:15068643	CPEB2	-0.44	-6.94	-0.4	3.47e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2275565	0.872	rs58213669	chr1:237037881	A/T	cg17297354	chr1:237056641	MTR	-0.4	-5.25	-0.32	3.22e-7	Homocysteine levels;
KIRP	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg02775129	chr4:119771670	NA	-0.87	-4.91	-0.3	1.62e-6	Cannabis dependence symptom count;
KIRP	cis	rs7508	0.535	rs13261745	chr8:17787005	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-5.09	-0.31	7e-7	Atrial fibrillation;
KIRP	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg00800038	chr16:89945340	TCF25	-0.83	-6.13	-0.36	3.53e-9	Skin colour saturation;
KIRP	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	6.84	0.4	6.3e-11	Bone mineral density;
KIRP	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.37	7.63	0.44	5.02e-13	IgG glycosylation;
KIRP	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.43	-5.34	-0.32	2.1e-7	Tuberculosis;
KIRP	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.56	9.38	0.51	4.7e-18	Prostate cancer;
KIRP	cis	rs6001982	0.588	rs73167058	chr22:40856837	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11645453	chr3:52864694	ITIH4	-0.33	-4.99	-0.3	1.12e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg13206674	chr6:150067644	NUP43	0.6	8.57	0.48	1.14e-15	Lung cancer;
KIRP	cis	rs6681460	0.800	rs539014	chr1:67211887	C/T	cg13052034	chr1:66999238	SGIP1	-0.38	-5.23	-0.32	3.61e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11645453	chr3:52864694	ITIH4	-0.38	-5.75	-0.34	2.63e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6142102	0.923	rs2284377	chr20:32586682	T/C	cg08999081	chr20:33150536	PIGU	0.49	5.83	0.35	1.7e-8	Skin pigmentation;
KIRP	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12560992	chr17:57184187	TRIM37	0.61	7.02	0.41	2.15e-11	Testicular germ cell tumor;
KIRP	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.68	-10.71	-0.56	3.18e-22	Urate levels in overweight individuals;
KIRP	cis	rs7523050	0.730	rs12734623	chr1:109442654	A/G	cg08274380	chr1:109419600	GPSM2	1.16	10.2	0.55	1.34e-20	Fat distribution (HIV);
KIRP	cis	rs4900069	0.573	rs12589587	chr14:91611001	T/C	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.44	-5.3	-0.32	2.59e-7	Resting heart rate;
KIRP	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.58	8.02	0.46	4.37e-14	Heart rate;
KIRP	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.85	10.3	0.55	6.46e-21	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.52	8.91	0.49	1.13e-16	Erythrocyte sedimentation rate;
KIRP	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg23307798	chr14:103986281	CKB	-0.51	-5.37	-0.32	1.86e-7	Coronary artery disease;
KIRP	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg00982548	chr2:198649783	BOLL	-0.59	-5.46	-0.33	1.17e-7	Ulcerative colitis;
KIRP	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.94	0.45	7.06e-14	Aortic root size;
KIRP	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.09e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6001982	0.667	rs73167069	chr22:40878253	A/G	cg07138101	chr22:40742427	ADSL	0.71	4.91	0.3	1.63e-6	Breast cancer;
KIRP	cis	rs4666002	0.917	rs4666000	chr2:27839369	T/C	cg05484376	chr2:27715224	FNDC4	-0.34	-5.09	-0.31	7.1e-7	Phospholipid levels (plasma);
KIRP	cis	rs28735056	0.935	rs552957	chr18:77595748	G/A	cg20368463	chr18:77673604	PQLC1	-0.42	-5.14	-0.31	5.69e-7	Schizophrenia;
KIRP	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg23601095	chr6:26197514	HIST1H3D	0.91	7.46	0.43	1.45e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs6832769	1.000	rs6834676	chr4:56298414	C/G	cg09317128	chr4:56265301	TMEM165	0.55	6.96	0.41	3.11e-11	Personality dimensions;
KIRP	trans	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg16141378	chr3:129829833	LOC729375	0.49	6.32	0.37	1.2e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg24253500	chr15:84953950	NA	0.62	6.87	0.4	5.19e-11	Schizophrenia;
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg10253484	chr15:75165896	SCAMP2	-0.43	-4.99	-0.3	1.15e-6	Breast cancer;
KIRP	cis	rs7714584	1.000	rs6875011	chr5:150182710	G/A	cg22134413	chr5:150180641	NA	1.06	8.79	0.49	2.67e-16	Crohn's disease;
KIRP	cis	rs4956211	0.507	rs9307322	chr4:109711152	A/G	cg07086381	chr4:109682776	AGXT2L1	-0.45	-5.98	-0.36	7.76e-9	Systemic lupus erythematosus;
KIRP	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.09	-0.41	1.4e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs6450176	0.564	rs390420	chr5:53326731	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-8.64	-0.48	7.09e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg08648136	chr8:956695	NA	0.48	7.32	0.42	3.56e-12	Schizophrenia;
KIRP	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Educational attainment (college completion);
KIRP	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.51	-5.18	-0.31	4.54e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.61	-0.39	2.43e-10	Metabolite levels;
KIRP	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg08873628	chr1:175162347	KIAA0040	-0.42	-6.17	-0.37	2.72e-9	Alcohol dependence;
KIRP	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg03146154	chr1:46216737	IPP	-0.41	-5.13	-0.31	5.92e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs889398	0.835	rs62050037	chr16:69784670	T/C	cg09409435	chr16:70099608	PDXDC2	-0.44	-5.25	-0.32	3.31e-7	Body mass index;
KIRP	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs16958440	1.000	rs57928699	chr18:44645593	T/A	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg02725872	chr8:58115012	NA	-0.52	-5.92	-0.35	1.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg02725872	chr8:58115012	NA	-0.59	-8.39	-0.47	3.84e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.81	-0.45	1.67e-13	Height;
KIRP	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-6.31	-0.37	1.27e-9	Lung function (FEV1/FVC);
KIRP	trans	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg25042112	chr7:64838748	ZNF92	0.58	6.25	0.37	1.75e-9	Pain;
KIRP	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.08	-0.46	2.95e-14	Personality dimensions;
KIRP	trans	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg01311341	chr22:25575246	KIAA1671	0.64	7.45	0.43	1.6e-12	Atopic dermatitis;
KIRP	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg09137382	chr11:130731461	NA	0.59	8.58	0.48	1.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.65	-0.52	6.96e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.52	-0.43	1.05e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg03605463	chr16:89740564	NA	0.5	6.48	0.38	4.99e-10	Vitiligo;
KIRP	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs490234	0.783	rs937481	chr9:128194443	C/G	cg14078157	chr9:128172775	NA	-0.41	-5.12	-0.31	6.23e-7	Mean arterial pressure;
KIRP	cis	rs16828019	0.777	rs12047657	chr1:41461513	G/C	cg03387723	chr1:41708464	SCMH1	-0.75	-6.0	-0.36	6.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.54	7.18	0.42	8.09e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg08975724	chr8:8085496	FLJ10661	-0.75	-9.99	-0.54	5.9e-20	Neuroticism;
KIRP	cis	rs11673344	0.864	rs7247589	chr19:37510781	G/A	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.18	-0.31	4.64e-7	Obesity-related traits;
KIRP	cis	rs17381785	0.903	rs10213507	chr4:14911772	A/C	cg12377275	chr4:15005593	CPEB2	0.54	6.51	0.38	4.25e-10	Urate levels in overweight individuals;
KIRP	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.44	0.33	1.27e-7	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs17020663	0.771	rs2278722	chr2:101620136	A/G	cg12594615	chr2:101643137	TBC1D8	-0.34	-4.88	-0.3	1.94e-6	Pulse pressure;
KIRP	cis	rs11264213	0.901	rs72661625	chr1:36401003	T/C	cg27506609	chr1:36549197	TEKT2	1.21	7.05	0.41	1.77e-11	Schizophrenia;
KIRP	cis	rs12282928	0.959	rs873043	chr11:48278965	T/A	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg06050784	chr16:88016603	BANP	0.4	5.03	0.31	9.36e-7	Menopause (age at onset);
KIRP	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.73	-7.85	-0.45	1.31e-13	Diastolic blood pressure;
KIRP	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg23594656	chr7:65796392	TPST1	0.42	5.76	0.34	2.45e-8	Aortic root size;
KIRP	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.45	5.06	0.31	8.18e-7	Schizophrenia;
KIRP	cis	rs7106204	0.748	rs7946633	chr11:24237411	C/T	ch.11.24196551F	chr11:24239977	NA	0.79	9.48	0.52	2.31e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	1.0	14.28	0.67	4.2e-34	Height;
KIRP	cis	rs6681460	0.932	rs603750	chr1:67177488	A/G	cg13052034	chr1:66999238	SGIP1	0.38	5.45	0.33	1.24e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.12	0.36	3.76e-9	Intraocular pressure;
KIRP	cis	rs17023223	0.537	rs10923756	chr1:119674648	A/T	cg05756136	chr1:119680316	WARS2	-0.6	-8.02	-0.46	4.4e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg12560992	chr17:57184187	TRIM37	0.61	6.68	0.39	1.58e-10	Testicular germ cell tumor;
KIRP	trans	rs710987	0.935	rs1698000	chr5:3507019	T/C	cg19782746	chr15:76669278	SCAPER	0.44	6.1	0.36	4.17e-9	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs2281603	0.951	rs10142835	chr14:64993451	C/T	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.75	11.08	0.58	2e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg02023728	chr11:77925099	USP35	0.29	4.91	0.3	1.69e-6	Alzheimer's disease (survival time);
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg24101359	chr6:42928495	GNMT	0.59	8.47	0.48	2.24e-15	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9398803	0.865	rs9375446	chr6:126835015	G/A	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.15e-10	Male-pattern baldness;
KIRP	cis	rs1359582	0.793	rs701824	chr10:90417712	A/G	cg15661332	chr10:90342814	RNLS	0.57	5.81	0.35	1.92e-8	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg08807892	chr2:162101083	NA	0.43	5.24	0.32	3.45e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16746026	chr10:31273335	ZNF438	-0.4	-6.12	-0.36	3.73e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	9.65	0.52	6.8e-19	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.64	8.59	0.48	1.03e-15	Lymphocyte percentage of white cells;
KIRP	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.34e-11	Type 2 diabetes;
KIRP	cis	rs42648	0.869	rs10266179	chr7:89909982	C/T	cg25739043	chr7:89950458	NA	-0.46	-7.47	-0.43	1.38e-12	Homocysteine levels;
KIRP	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.61	-8.53	-0.48	1.49e-15	Resting heart rate;
KIRP	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.4	-6.95	-0.41	3.31e-11	Refractive error;
KIRP	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.8	-10.96	-0.57	5.11e-23	Lung cancer;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg04312406	chr1:226497240	LIN9	-0.47	-6.13	-0.36	3.5e-9	Erectile dysfunction in type 1 diabetes;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08810419	chr16:84696447	NA	0.53	6.29	0.37	1.42e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12765878	0.603	rs2475213	chr10:105664459	A/T	cg11005552	chr10:105648138	OBFC1	0.39	4.86	0.3	2.14e-6	Coronary artery disease;
KIRP	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.77	10.77	0.57	2.02e-22	Colorectal cancer;
KIRP	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.67	-11.02	-0.57	3.35e-23	Urate levels in overweight individuals;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03088475	chr8:145981210	ZNF251	-0.49	-6.83	-0.4	6.54e-11	Survival in pancreatic cancer;
KIRP	cis	rs4716602	0.827	rs10270019	chr7:156158973	T/C	cg04090468	chr7:156181990	NA	0.45	5.48	0.33	1.07e-7	Anti-saccade response;
KIRP	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20465933	chr4:152376761	FAM160A1	0.42	6.12	0.36	3.67e-9	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17086808	chr2:8822276	ID2	0.48	6.26	0.37	1.67e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg16898833	chr6:26189333	HIST1H4D	0.67	4.96	0.3	1.34e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.72	10.16	0.54	1.75e-20	Body mass index;
KIRP	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.68	0.34	3.83e-8	Lung cancer;
KIRP	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg20913747	chr6:44695427	NA	-0.39	-4.94	-0.3	1.47e-6	Total body bone mineral density;
KIRP	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg06781948	chr3:72941472	GXYLT2	0.47	6.17	0.37	2.85e-9	Motion sickness;
KIRP	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg02487422	chr3:49467188	NICN1	0.39	5.39	0.32	1.66e-7	Parkinson's disease;
KIRP	cis	rs10073892	0.711	rs62372236	chr5:101666753	A/G	cg19774478	chr5:101632501	SLCO4C1	0.66	6.37	0.38	9.42e-10	Cognitive decline (age-related);
KIRP	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.17	12.83	0.63	3.51e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs9783347	0.961	rs12293544	chr11:18348581	T/C	cg15585147	chr11:18324498	HPS5	0.44	5.97	0.36	8.28e-9	Pancreatic cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09321965	chr1:198201193	NEK7	0.38	6.13	0.36	3.47e-9	C-reactive protein;
KIRP	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.64	-9.27	-0.51	9.75e-18	Educational attainment;
KIRP	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg01522456	chr1:115632236	TSPAN2	0.37	4.94	0.3	1.47e-6	Autism;
KIRP	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg21361702	chr7:150065534	REPIN1	0.6	5.82	0.35	1.78e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg21775007	chr8:11205619	TDH	-0.52	-6.81	-0.4	7.37e-11	Retinal vascular caliber;
KIRP	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.66	0.48	6.55e-16	Electroencephalogram traits;
KIRP	cis	rs35883536	0.587	rs2809812	chr1:101032087	G/T	cg09408571	chr1:101003634	GPR88	0.22	5.19	0.31	4.45e-7	Monocyte count;
KIRP	cis	rs12153243	0.675	rs17401501	chr5:142894711	G/A	cg13907255	chr5:142895549	NA	-0.38	-4.92	-0.3	1.57e-6	Migraine;
KIRP	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.91	-0.4	4.04e-11	Menopause (age at onset);
KIRP	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg20637307	chr2:213403960	ERBB4	0.93	16.28	0.72	6.22e-41	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg11641102	chr8:27183873	PTK2B	0.43	5.59	0.34	5.9e-8	Neuroticism;
KIRP	cis	rs9303542	0.625	rs6504340	chr17:46617019	A/G	cg04904318	chr17:46607828	HOXB1	0.46	5.75	0.34	2.7e-8	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg13611997	chr5:233750	SDHA	0.43	5.12	0.31	6.31e-7	Breast cancer;
KIRP	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg16989719	chr2:238392110	NA	-0.56	-5.65	-0.34	4.33e-8	Prostate cancer;
KIRP	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.65	-0.44	4.58e-13	Height;
KIRP	cis	rs1712517	0.525	rs7911488	chr10:105154089	A/G	cg04362960	chr10:104952993	NT5C2	-0.57	-7.09	-0.41	1.39e-11	Migraine;
KIRP	trans	rs2048656	0.561	rs12544371	chr8:9542071	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.3	-0.37	1.34e-9	Schizophrenia;
KIRP	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg02297831	chr4:17616191	MED28	0.51	5.83	0.35	1.75e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7936323	1	rs7936323	chr11:76293758	G/A	cg17647271	chr11:76299819	NA	-0.39	-5.28	-0.32	2.8e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of white cells;Allergy;Allergic disease (asthma, hay fever or eczema);Asthma;
KIRP	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.77	0.44	2.17e-13	Height;
KIRP	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.9	13.47	0.65	2.31e-31	Menopause (age at onset);
KIRP	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg06742321	chr12:123595122	PITPNM2	0.42	5.08	0.31	7.45e-7	Platelet count;
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.27	-0.32	3.02e-7	Breast cancer;
KIRP	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.62	-6.75	-0.4	1.09e-10	Bronchopulmonary dysplasia;
KIRP	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10053473	chr17:62856997	LRRC37A3	0.67	7.42	0.43	1.89e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10073892	0.830	rs28864102	chr5:101615894	G/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.38	0.38	8.87e-10	Cognitive decline (age-related);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18494192	chr6:116448231	COL10A1;NT5DC1	-0.45	-6.67	-0.39	1.66e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg03788504	chr6:150331562	NA	-0.32	-5.92	-0.35	1.09e-8	Alopecia areata;
KIRP	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.63	6.81	0.4	7.56e-11	Exhaled nitric oxide output;
KIRP	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.25	-0.37	1.81e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6968419	0.674	rs57756655	chr7:115927168	C/T	cg02561103	chr7:115862891	TES	-0.42	-5.97	-0.36	8.27e-9	Intraocular pressure;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg16497661	chr14:103986332	CKB	0.49	6.53	0.38	3.74e-10	Body mass index;
KIRP	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg19743168	chr1:23544995	NA	0.47	6.26	0.37	1.66e-9	Height;
KIRP	cis	rs1593	0.734	rs4253407	chr4:187193308	A/T	cg02012338	chr4:187126139	CYP4V2	0.71	5.96	0.36	8.72e-9	Activated partial thromboplastin time;
KIRP	cis	rs10267417	0.673	rs6461468	chr7:19957040	G/T	cg05791153	chr7:19748676	TWISTNB	0.47	4.96	0.3	1.31e-6	Night sleep phenotypes;
KIRP	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11645453	chr3:52864694	ITIH4	-0.34	-5.45	-0.33	1.25e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg27205649	chr11:78285834	NARS2	0.64	8.2	0.46	1.3e-14	Alzheimer's disease (survival time);
KIRP	cis	rs2585417	0.743	rs6013925	chr20:52828077	A/G	cg14415559	chr20:52836060	PFDN4	0.35	5.26	0.32	3.18e-7	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg26513180	chr16:89883248	FANCA	0.62	4.87	0.3	2.04e-6	Skin colour saturation;
KIRP	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg01877450	chr7:97915802	BRI3	-0.52	-6.77	-0.4	9.18e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	0.95	17.16	0.74	6.35e-44	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7011049	0.749	rs112133624	chr8:53866605	T/C	cg26025543	chr8:53854495	NA	0.59	6.45	0.38	6e-10	Systolic blood pressure;
KIRP	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.08	0.46	2.96e-14	Aortic root size;
KIRP	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg06307176	chr5:131281290	NA	-0.56	-6.37	-0.38	9.09e-10	Life satisfaction;
KIRP	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.55	-0.39	3.42e-10	Response to antipsychotic treatment;
KIRP	cis	rs3736594	0.513	rs1881396	chr2:27844601	G/T	cg27432699	chr2:27873401	GPN1	-0.56	-6.3	-0.37	1.39e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.01	-0.3	1.06e-6	Life satisfaction;
KIRP	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-8.15	-0.46	1.9e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg02487422	chr3:49467188	NICN1	0.4	5.48	0.33	1.07e-7	Parkinson's disease;
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16477317	chr18:12702819	PSMG2;CEP76	0.37	4.87	0.3	2.01e-6	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.16	-0.5	2.16e-17	Total body bone mineral density;
KIRP	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.64	-8.23	-0.46	1.07e-14	Prudent dietary pattern;
KIRP	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs4805272	0.962	rs7255736	chr19:29321419	G/A	cg04546413	chr19:29218101	NA	0.43	4.88	0.3	1.89e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.88e-13	Bipolar disorder;
KIRP	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.68	10.52	0.56	1.26e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs35304300	0.779	rs10484821	chr6:139868910	A/G	cg05219445	chr6:139855396	NA	0.42	4.94	0.3	1.44e-6	Mean platelet volume;
KIRP	cis	rs7175404	1.000	rs28428665	chr15:94036827	G/A	cg23502883	chr15:93959149	NA	0.53	5.69	0.34	3.61e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.64	-7.71	-0.44	3.04e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	0.75	10.49	0.56	1.59e-21	Red blood cell count;
KIRP	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.52	-5.84	-0.35	1.62e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.64	8.55	0.48	1.36e-15	Colorectal cancer;
KIRP	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg26681399	chr22:41777847	TEF	-0.47	-5.13	-0.31	5.96e-7	Vitiligo;
KIRP	cis	rs4356932	0.967	rs6532103	chr4:76953885	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.91	0.3	1.64e-6	Blood protein levels;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg24874828	chr4:187887005	NA	-0.49	-7.06	-0.41	1.73e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.01	14.1	0.67	1.67e-33	Response to antipsychotic treatment;
KIRP	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg01294253	chr9:136912663	BRD3	0.47	5.89	0.35	1.27e-8	Platelet distribution width;
KIRP	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18252515	chr7:66147081	NA	-0.48	-5.59	-0.34	6.17e-8	Aortic root size;
KIRP	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg23752985	chr2:85803571	VAMP8	0.6	9.15	0.5	2.19e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs16828019	0.929	rs11209734	chr1:41698074	C/T	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17023223	0.581	rs61808932	chr1:119643820	T/C	cg18261050	chr1:119551319	NA	0.53	6.74	0.4	1.09e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7116495	1.000	rs542752	chr11:71810644	T/A	cg18441811	chr11:71824068	C11orf51	0.6	4.87	0.3	2.01e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs859767	0.501	rs71348712	chr2:135391590	T/A	cg25422880	chr2:135218333	TMEM163	0.38	5.63	0.34	4.94e-8	Neuroticism;
KIRP	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.56	-5.07	-0.31	7.74e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg22705602	chr4:152727874	NA	-0.55	-9.69	-0.53	4.99e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.72e-15	Prudent dietary pattern;
KIRP	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg05315796	chr3:52349193	DNAH1	0.44	6.77	0.4	9.34e-11	Bipolar disorder;
KIRP	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	6.55	0.39	3.4e-10	Obesity-related traits;
KIRP	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.45	-8.36	-0.47	4.68e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs17095355	1.000	rs59804002	chr10:111692043	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.65	-0.34	4.41e-8	Biliary atresia;
KIRP	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.47	-7.06	-0.41	1.69e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4356932	0.935	rs10336	chr4:76922988	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.1	0.31	6.65e-7	Blood protein levels;
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg27532560	chr4:187881888	NA	-0.76	-12.83	-0.63	3.5e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9581857	0.685	rs12585587	chr13:28024694	G/A	cg22138327	chr13:27999177	GTF3A	0.78	6.29	0.37	1.45e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-7.51	-0.43	1.08e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg07004394	chr14:106090750	NA	-0.43	-4.9	-0.3	1.74e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.28e-7	Bipolar disorder;
KIRP	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.18	-0.37	2.71e-9	Myopia (pathological);
KIRP	cis	rs7903847	0.642	rs10882910	chr10:99138043	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1867631	0.585	rs6694782	chr1:67126762	C/T	cg02459107	chr1:67143332	SGIP1	-0.41	-6.26	-0.37	1.7e-9	Menopause (age at onset);
KIRP	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg22325292	chr17:80708367	FN3K	0.37	4.92	0.3	1.58e-6	Glycated hemoglobin levels;
KIRP	cis	rs13095912	0.889	rs6778977	chr3:185302532	T/G	cg11274856	chr3:185301563	NA	0.54	6.91	0.4	4.03e-11	Systolic blood pressure;
KIRP	cis	rs77972171	0.558	rs2402672	chr7:123385499	G/C	cg03229431	chr7:123269106	ASB15	-0.57	-4.92	-0.3	1.57e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg27432699	chr2:27873401	GPN1	-0.59	-7.68	-0.44	3.72e-13	Total body bone mineral density;
KIRP	trans	rs909341	0.909	rs2427532	chr20:62363817	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.91	-0.4	4.04e-11	Atopic dermatitis;
KIRP	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21014159	chr11:117668035	DSCAML1	0.41	5.14	0.31	5.71e-7	Myopia;
KIRP	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg08992911	chr2:238395768	MLPH	0.72	6.78	0.4	9.03e-11	Prostate cancer;
KIRP	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg25019033	chr10:957182	NA	-0.64	-7.79	-0.44	1.84e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs9603616	0.719	rs4551909	chr13:40238649	C/T	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs2594989	0.943	rs4684780	chr3:11478960	C/T	cg01796438	chr3:11312864	ATG7	-0.51	-6.62	-0.39	2.26e-10	Circulating chemerin levels;
KIRP	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21643547	chr1:205240462	TMCC2	0.69	10.46	0.55	2.05e-21	Red blood cell count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15815767	chr2:46769831	RHOQ	-0.47	-6.31	-0.37	1.29e-9	Metabolic traits;
KIRP	cis	rs1134634	0.520	rs10003739	chr4:15618686	A/C	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.79	-0.35	2.18e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs4650994	0.550	rs10913573	chr1:178530455	G/A	cg12486710	chr1:178512616	C1orf220	-0.23	-4.93	-0.3	1.52e-6	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.69	9.92	0.53	9.76e-20	Prostate cancer;
KIRP	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.23	0.37	2e-9	Retinal vascular caliber;
KIRP	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	0.89	6.76	0.4	1e-10	Mitochondrial DNA levels;
KIRP	cis	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg21696256	chr3:125484277	NA	-0.44	-4.84	-0.3	2.24e-6	Blood pressure (smoking interaction);
KIRP	trans	rs2123959	0.553	rs62311123	chr4:91773926	A/T	cg26127345	chr10:89621940	PTEN;KILLIN	-0.66	-6.39	-0.38	8.3e-10	Gut microbiome composition (summer);
KIRP	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05347473	chr6:146136440	FBXO30	0.58	8.2	0.46	1.35e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs17209837	1.000	rs45526438	chr7:87089927	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-7.48	-0.43	1.35e-12	Gallbladder cancer;
KIRP	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.71	10.31	0.55	6.03e-21	Oral cavity cancer;
KIRP	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.66	-0.39	1.83e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg27144592	chr16:783916	NARFL	0.38	5.23	0.32	3.56e-7	Height;
KIRP	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Life satisfaction;
KIRP	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg16989719	chr2:238392110	NA	-0.54	-7.58	-0.44	7.12e-13	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.58	7.75	0.44	2.45e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12431939	0.546	rs4424815	chr14:51714360	C/A	cg23942311	chr14:51606299	NA	0.42	4.87	0.3	2.01e-6	Cancer;
KIRP	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg09890400	chr1:26503858	CNKSR1	0.43	5.65	0.34	4.39e-8	Height;
KIRP	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.2	-0.37	2.37e-9	Height;
KIRP	trans	rs1864585	0.520	rs7826036	chr8:10657820	G/A	cg26278703	chr11:58910052	FAM111A	0.63	6.46	0.38	5.57e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6062509	0.965	rs6062504	chr20:62348907	A/G	cg11503966	chr20:62272292	STMN3	0.33	5.03	0.31	9.29e-7	Prostate cancer;
KIRP	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg24169773	chr3:122142474	KPNA1	-0.57	-5.9	-0.35	1.22e-8	LDL cholesterol levels;
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	13.57	0.65	1.07e-31	Platelet count;
KIRP	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	11.26	0.58	5.59e-24	Personality dimensions;
KIRP	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.58	0.44	7.03e-13	Retinal vascular caliber;
KIRP	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg15880211	chr22:50250494	ZBED4	0.59	5.14	0.31	5.48e-7	Mean platelet volume;
KIRP	cis	rs6545883	0.826	rs777591	chr2:61417617	A/G	cg15711740	chr2:61764176	XPO1	-0.57	-7.54	-0.43	9.11e-13	Tuberculosis;
KIRP	cis	rs601339	0.877	rs2649991	chr12:123179461	A/G	cg18578876	chr12:123200353	GPR109B	0.49	4.85	0.3	2.19e-6	Adiponectin levels;
KIRP	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.4	-4.96	-0.3	1.29e-6	Coronary artery disease;
KIRP	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24838063	chr12:130822603	PIWIL1	0.56	6.79	0.4	8.28e-11	Menopause (age at onset);
KIRP	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.72	-0.63	7.99e-29	Headache;
KIRP	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-4.97	-0.3	1.23e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs3736485	0.903	rs750162	chr15:51907153	A/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.16e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg26207909	chr14:103986467	CKB	-0.45	-5.43	-0.33	1.39e-7	Coronary artery disease;
KIRP	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg17842918	chr13:113540400	ATP11A	-0.32	-4.85	-0.3	2.15e-6	Interstitial lung disease;
KIRP	cis	rs7202877	0.656	rs4887812	chr16:75310052	G/A	cg03315344	chr16:75512273	CHST6	0.59	5.26	0.32	3.06e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.65	6.97	0.41	2.9e-11	Response to diuretic therapy;
KIRP	cis	rs9488822	0.662	rs496311	chr6:116274730	A/G	cg18764771	chr6:116381957	FRK	0.22	6.03	0.36	5.87e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10875746	0.729	rs1990028	chr12:48408013	A/G	cg26205652	chr12:48591994	NA	0.78	9.96	0.54	7.36e-20	Longevity (90 years and older);
KIRP	cis	rs13185784	0.709	rs6703	chr5:179660786	A/T	cg02891314	chr5:179741120	GFPT2	-0.44	-4.97	-0.3	1.28e-6	TRAIL levels;
KIRP	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.63	6.93	0.4	3.67e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.46	-9.95	-0.54	7.91e-20	Alzheimer's disease (late onset);
KIRP	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.27	5.5	0.33	9.6e-8	Height;
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.57	9.59	0.52	1.02e-18	Lung cancer;
KIRP	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg23100626	chr2:96804247	ASTL	0.46	6.4	0.38	7.82e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.5	6.25	0.37	1.77e-9	Height;
KIRP	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.49	7.16	0.42	9.06e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.6	6.91	0.4	4.08e-11	Fear of minor pain;
KIRP	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.4	8.11	0.46	2.42e-14	Ewing sarcoma;
KIRP	cis	rs939574	0.790	rs114196239	chr2:220094307	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.83	6.12	0.36	3.67e-9	Platelet distribution width;
KIRP	cis	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.81	9.92	0.53	1.01e-19	Corneal astigmatism;
KIRP	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.11	-0.54	2.63e-20	Coffee consumption (cups per day);
KIRP	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg26668828	chr6:292823	DUSP22	-0.52	-6.13	-0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.58	-7.43	-0.43	1.84e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.75	6.85	0.4	5.94e-11	Mean platelet volume;
KIRP	cis	rs6005807	0.719	rs9625514	chr22:29022188	T/C	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg05340658	chr4:99064831	C4orf37	-0.54	-6.64	-0.39	1.99e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.29	0.32	2.76e-7	Lung cancer;
KIRP	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg25036284	chr2:26402008	FAM59B	-0.6	-6.0	-0.36	7.17e-9	Gut microbiome composition (summer);
KIRP	cis	rs4478037	0.558	rs56106158	chr3:33081833	A/G	cg19404215	chr3:33155277	CRTAP	0.92	5.95	0.35	9.14e-9	Major depressive disorder;
KIRP	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg16701003	chr16:89028210	CBFA2T3	0.39	5.1	0.31	6.85e-7	Social autistic-like traits;
KIRP	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg08061076	chr7:1943177	MAD1L1	-0.43	-5.38	-0.32	1.73e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.85	-13.36	-0.65	5.44e-31	Blood metabolite levels;
KIRP	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.49	7.42	0.43	1.89e-12	Total body bone mineral density;
KIRP	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.34	-0.32	2.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.55	-7.2	-0.42	7.39e-12	Blood metabolite levels;
KIRP	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.73	-0.44	2.68e-13	Height;
KIRP	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg06219351	chr7:158114137	PTPRN2	0.56	8.11	0.46	2.39e-14	Calcium levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10388316	chr1:1710208	NADK	0.53	7.08	0.41	1.51e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg19752551	chr11:57585705	CTNND1	-0.79	-13.23	-0.64	1.5e-30	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10073892	0.660	rs10035133	chr5:101985673	A/G	cg19774478	chr5:101632501	SLCO4C1	-0.57	-5.71	-0.34	3.19e-8	Cognitive decline (age-related);
KIRP	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg18154014	chr19:37997991	ZNF793	0.7	7.64	0.44	4.94e-13	Coronary artery calcification;
KIRP	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg05335186	chr13:53173507	NA	0.32	5.02	0.3	1.01e-6	Lewy body disease;
KIRP	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg14650228	chr8:144573510	ZC3H3	-0.75	-5.37	-0.32	1.79e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7408868	0.611	rs11671336	chr19:15294043	C/T	cg14696996	chr19:15285081	NOTCH3	0.61	6.51	0.38	4.11e-10	Pulse pressure;
KIRP	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg11906718	chr8:101322791	RNF19A	-0.65	-8.26	-0.47	8.81e-15	Atrioventricular conduction;
KIRP	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg13264159	chr8:625131	ERICH1	-0.74	-5.56	-0.33	7.16e-8	IgG glycosylation;
KIRP	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.66	5.36	0.32	1.89e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7221595	0.877	rs35321558	chr17:3892909	G/A	cg05562828	chr17:3906858	NA	0.62	6.99	0.41	2.6e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg15117754	chr3:10150083	C3orf24	0.49	4.94	0.3	1.44e-6	Alzheimer's disease;
KIRP	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	4.98	0.3	1.19e-6	Diabetic retinopathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16793199	chr2:3453196	TTC15	0.48	6.13	0.36	3.45e-9	Interleukin-4 levels;
KIRP	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg11382394	chr1:2564504	MMEL1	0.39	5.07	0.31	7.81e-7	Ulcerative colitis;
KIRP	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.6	6.68	0.39	1.59e-10	Vitiligo;
KIRP	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg15117754	chr3:10150083	C3orf24	0.48	4.85	0.3	2.17e-6	Alzheimer's disease;
KIRP	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.67	9.08	0.5	3.76e-17	Crohn's disease;
KIRP	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg24154853	chr7:158122151	PTPRN2	0.39	5.56	0.33	7.1e-8	Calcium levels;
KIRP	cis	rs6707387	0.594	rs6761365	chr2:214419540	A/T	cg08319019	chr2:214017104	IKZF2	0.44	5.04	0.31	9e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg12589839	chr18:39575942	PIK3C3	0.42	6.15	0.37	3.19e-9	Migraine with aura;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15765054	chr17:900260	TIMM22	0.44	6.12	0.36	3.61e-9	Survival in pancreatic cancer;
KIRP	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.33	-0.32	2.25e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26540535	chr10:63555356	NA	0.41	6.2	0.37	2.4e-9	Migraine with aura;
KIRP	cis	rs7221595	0.778	rs62072386	chr17:3896168	T/C	cg21851534	chr17:3907994	ZZEF1	0.48	5.04	0.31	8.92e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs16828019	0.852	rs16827876	chr1:41539536	T/G	cg08144172	chr1:41849203	NA	0.62	5.13	0.31	5.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	1.23	10.82	0.57	1.46e-22	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg05362011	chr13:21860987	NA	-0.47	-5.02	-0.31	9.77e-7	White matter hyperintensity burden;
KIRP	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.15	-0.41	9.91e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9462846	1.000	rs2092555	chr6:42863842	C/G	cg02353165	chr6:42928485	GNMT	0.42	4.97	0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg19847130	chr8:10466454	RP1L1	-0.33	-4.86	-0.3	2.08e-6	Retinal vascular caliber;
KIRP	cis	rs7011507	0.947	rs76545455	chr8:49120183	C/G	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg04876069	chr12:132293656	NA	-0.41	-5.09	-0.31	7.08e-7	Migraine;
KIRP	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.48	-8.32	-0.47	6.1e-15	Cystic fibrosis severity;
KIRP	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.36	-0.42	2.71e-12	Height;
KIRP	cis	rs10267417	0.603	rs4543442	chr7:19911140	G/A	cg05791153	chr7:19748676	TWISTNB	0.55	5.3	0.32	2.53e-7	Night sleep phenotypes;
KIRP	cis	rs9890032	0.581	rs62070592	chr17:29022549	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.49	-6.28	-0.37	1.5e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg09184832	chr6:79620586	NA	-0.54	-7.76	-0.44	2.25e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	5.35	0.32	2.03e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg04362960	chr10:104952993	NT5C2	-0.43	-5.45	-0.33	1.22e-7	Waist circumference;Hip circumference;
KIRP	cis	rs11264213	0.901	rs55762724	chr1:36382702	C/T	cg27506609	chr1:36549197	TEKT2	1.14	6.67	0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.81	0.53	2.23e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg05639522	chr1:247681581	NA	0.57	5.44	0.33	1.28e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg01879757	chr17:41196368	BRCA1	-0.74	-10.27	-0.55	7.95e-21	Menopause (age at onset);
KIRP	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05585630	chr7:157510462	PTPRN2	-0.53	-7.8	-0.45	1.72e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg04414720	chr1:150670196	GOLPH3L	0.38	4.99	0.3	1.13e-6	Tonsillectomy;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg21502482	chr14:88892856	SPATA7	-0.44	-6.21	-0.37	2.23e-9	Myopia (pathological);
KIRP	cis	rs4936894	0.500	rs11219498	chr11:124076699	G/A	cg27160556	chr11:124181099	OR8D1	-0.4	-5.91	-0.35	1.16e-8	Aging (time to death);
KIRP	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg17553881	chr5:443987	EXOC3;C5orf55	-0.27	-4.87	-0.3	2e-6	Cystic fibrosis severity;
KIRP	cis	rs12360000	0.864	rs34695673	chr10:1907540	G/T	cg26364871	chr10:1889757	NA	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs12750249	0.662	rs1756248	chr1:94739646	A/G	cg22045340	chr1:95392675	CNN3	-0.39	-5.02	-0.3	1.01e-6	IgG glycosylation;
KIRP	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.85	13.54	0.65	1.41e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06058618	chr1:155057452	EFNA3	-0.44	-6.02	-0.36	6.22e-9	Myopia;
KIRP	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.84	-12.09	-0.61	1.01e-26	Prostate cancer;
KIRP	cis	rs2230307	0.536	rs687513	chr1:100598867	C/T	cg24955406	chr1:100503596	HIAT1	-0.6	-6.28	-0.37	1.55e-9	Carotid intima media thickness;
KIRP	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.27	0.51	9.62e-18	Height;
KIRP	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg17554472	chr22:41940697	POLR3H	-0.44	-5.47	-0.33	1.11e-7	Vitiligo;
KIRP	cis	rs4774899	0.966	rs12914481	chr15:57484613	G/A	cg13626582	chr15:57592083	LOC283663	-0.21	-4.94	-0.3	1.43e-6	Urinary tract infection frequency;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.71	-0.39	1.36e-10	Immature fraction of reticulocytes;
KIRP	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	5.06e-7	Parkinson's disease;
KIRP	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg04287289	chr16:89883240	FANCA	0.7	4.93	0.3	1.48e-6	Skin colour saturation;
KIRP	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	1.06	19.85	0.78	5.27e-53	Height;
KIRP	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs7113874	0.545	rs12791925	chr11:8551585	G/C	cg08015107	chr11:8618950	NA	-0.71	-8.56	-0.48	1.22e-15	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4363385	0.574	rs4041402	chr1:152947397	T/C	cg25856811	chr1:152973957	SPRR3	-0.36	-4.88	-0.3	1.9e-6	Inflammatory skin disease;
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.74	-11.25	-0.58	5.68e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.57	-6.69	-0.39	1.49e-10	Diabetic retinopathy;
KIRP	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23329073	chr17:81038827	METRNL	0.5	6.09	0.36	4.27e-9	Parkinson's disease;
KIRP	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.55	8.24	0.46	1.04e-14	Schizophrenia;
KIRP	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.64	8.53	0.48	1.51e-15	Breast cancer;
KIRP	cis	rs2239815	0.515	rs9625595	chr22:29238913	C/T	cg02153584	chr22:29168773	CCDC117	0.62	5.98	0.36	7.88e-9	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02992881	chr13:50699806	DLEU2	0.53	7.46	0.43	1.47e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.5	-7.54	-0.43	9.17e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.56	6.23	0.37	1.97e-9	Coronary artery disease;
KIRP	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.65	-5.77	-0.35	2.39e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.58	0.52	1.15e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2458413	0.564	rs2458431	chr8:105367096	T/C	cg08657449	chr8:105351661	TM7SF4	-0.34	-5.63	-0.34	4.93e-8	Paget's disease;
KIRP	trans	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg19274270	chr17:78178856	CARD14	0.37	6.7	0.39	1.45e-10	Morning vs. evening chronotype;
KIRP	cis	rs2377585	0.653	rs11046806	chr12:8844322	A/G	cg03761649	chr12:8850719	RIMKLB	0.52	5.14	0.31	5.63e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg18944383	chr4:111397179	ENPEP	0.39	6.33	0.37	1.12e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.36	6.17e-9	Morning vs. evening chronotype;
KIRP	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.38	5.02	0.3	1e-6	Blood protein levels;
KIRP	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg24699146	chr1:24152579	HMGCL	0.43	5.62	0.34	5.26e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	15.41	0.7	5.96e-38	Platelet count;
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.61	8.96	0.5	8.18e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10073892	0.673	rs924680	chr5:101880713	A/C	cg19774478	chr5:101632501	SLCO4C1	0.6	5.91	0.35	1.16e-8	Cognitive decline (age-related);
KIRP	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg13010199	chr12:38710504	ALG10B	0.54	7.34	0.42	3.13e-12	Morning vs. evening chronotype;
KIRP	cis	rs4740619	0.616	rs10756734	chr9:16026444	T/C	cg14451791	chr9:16040625	NA	-0.41	-5.34	-0.32	2.17e-7	Body mass index;
KIRP	cis	rs877426	0.634	rs867438	chr13:114757361	C/T	cg00571178	chr13:114841904	RASA3	-0.53	-5.64	-0.34	4.55e-8	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs7083	1.000	rs673738	chr11:117143581	T/C	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.67	-9.28	-0.51	9.38e-18	Rheumatoid arthritis;
KIRP	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg04990556	chr1:26633338	UBXN11	0.66	6.23	0.37	2.03e-9	Obesity-related traits;
KIRP	cis	rs6504340	0.739	rs4793939	chr17:46665235	G/A	cg04904318	chr17:46607828	HOXB1	-0.55	-5.61	-0.34	5.48e-8	Primary tooth development (number of teeth);
KIRP	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg06636001	chr8:8085503	FLJ10661	0.64	8.11	0.46	2.37e-14	Neuroticism;
KIRP	cis	rs1629083	0.935	rs1793151	chr11:118126920	C/T	cg18857871	chr11:118064634	AMICA1	0.69	10.07	0.54	3.38e-20	Lung cancer;
KIRP	cis	rs13343954	0.825	rs12462077	chr19:33529231	C/G	cg27124370	chr19:33622961	WDR88	0.64	7.02	0.41	2.17e-11	Colorectal cancer;
KIRP	cis	rs71277158	0.688	rs6808506	chr3:169839239	G/C	cg04067573	chr3:169899625	PHC3	0.65	6.14	0.36	3.29e-9	Prostate cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09309973	chr4:47033248	GABRB1	0.45	6.37	0.38	9.18e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2790457	0.958	rs2772432	chr10:28894295	G/A	cg05705492	chr10:28955341	NA	-0.54	-8.3	-0.47	6.74e-15	Multiple myeloma;
KIRP	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg07972983	chr1:205091412	RBBP5	0.42	4.99	0.3	1.12e-6	Red blood cell count;
KIRP	cis	rs3008706	0.680	rs2987044	chr9:16008856	A/G	cg14451791	chr9:16040625	NA	-0.5	-5.16	-0.31	5.05e-7	Bilirubin levels;
KIRP	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg27147174	chr7:100797783	AP1S1	-0.58	-7.5	-0.43	1.14e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs10170310	1.000	rs10803568	chr2:139290914	T/C	cg03782584	chr2:139258740	SPOPL	0.3	4.86	0.3	2.06e-6	Response to antipsychotic treatment;
KIRP	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg05082376	chr22:42548792	NA	-0.45	-5.89	-0.35	1.25e-8	Schizophrenia;
KIRP	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.92	-0.35	1.1e-8	Obesity-related traits;
KIRP	cis	rs735539	0.609	rs7332034	chr13:21214943	T/C	cg27499820	chr13:21296301	IL17D	0.36	5.19	0.31	4.41e-7	Dental caries;
KIRP	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.98	10.78	0.57	1.86e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg07701084	chr6:150067640	NUP43	0.57	7.23	0.42	6.13e-12	Testicular germ cell tumor;
KIRP	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.9	-12.97	-0.64	1.19e-29	Blood protein levels;
KIRP	trans	rs7160151	0.621	rs2816756	chr14:49813155	T/C	cg24274272	chr17:72278023	DNAI2	0.48	6.16	0.37	2.93e-9	C-reactive protein (red blood cell fatty acid level interaction);
KIRP	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.88	10.55	0.56	1.03e-21	Post bronchodilator FEV1;
KIRP	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg05791153	chr7:19748676	TWISTNB	0.8	6.96	0.41	3.16e-11	Thyroid stimulating hormone;
KIRP	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.18	0.46	1.53e-14	Personality dimensions;
KIRP	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	12.16	0.61	5.92e-27	Bipolar disorder;
KIRP	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.41	-0.33	1.49e-7	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.55	-0.33	7.49e-8	Depression;
KIRP	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.91	14.33	0.67	2.95e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-7.17	-0.42	8.93e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.62	8.27	0.47	8.56e-15	Mood instability;
KIRP	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.05	0.41	1.83e-11	Mean platelet volume;
KIRP	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg00343986	chr7:65444356	GUSB	-0.46	-5.74	-0.34	2.84e-8	Aortic root size;
KIRP	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.76	10.43	0.55	2.54e-21	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg21466736	chr12:48725269	NA	-0.43	-5.48	-0.33	1.03e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.21	-0.37	2.19e-9	Lung cancer;
KIRP	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11987759	chr7:65425863	GUSB	0.53	6.93	0.4	3.6e-11	Aortic root size;
KIRP	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.63	8.66	0.48	6.36e-16	Myopia (pathological);
KIRP	cis	rs830124	0.673	rs529736	chr12:122384457	A/C	cg01765077	chr12:122356316	WDR66	0.55	5.75	0.34	2.7e-8	Urinary metabolites;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07222414	chr1:98550994	NA	-0.49	-7.77	-0.44	2.07e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04444674	chr3:38495333	LOC100128640;ACVR2B	0.51	6.15	0.37	3.08e-9	Parkinson's disease;
KIRP	cis	rs2625529	0.556	rs35603965	chr15:72523043	C/T	cg16672083	chr15:72433130	SENP8	0.39	5.43	0.33	1.34e-7	Red blood cell count;
KIRP	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.63	-6.46	-0.38	5.41e-10	D-dimer levels;
KIRP	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.65	-7.57	-0.43	7.33e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7395581	1.000	rs7395581	chr11:47246397	G/A	cg26139080	chr11:47293733	MADD	0.4	4.96	0.3	1.31e-6	HDL cholesterol;
KIRP	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.99	15.16	0.7	4.13e-37	Personality dimensions;
KIRP	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	8.91	0.49	1.18e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.22	-6.04	-0.36	5.61e-9	Coronary artery disease;
KIRP	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg09699651	chr6:150184138	LRP11	0.55	7.47	0.43	1.41e-12	Testicular germ cell tumor;
KIRP	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.66	-0.48	6.29e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.21	-0.42	6.69e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.44	-0.43	1.69e-12	Bipolar disorder;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg23693289	chr8:27183097	PTK2B	0.54	7.0	0.41	2.4e-11	Neuroticism;
KIRP	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg08890418	chr1:21044141	KIF17	0.35	5.25	0.32	3.32e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg19224249	chr19:55574677	RDH13	0.5	6.09	0.36	4.41e-9	Educational attainment;
KIRP	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.53	7.34	0.42	3.16e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.65	6.41	0.38	7.53e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.88	-0.45	1.07e-13	Platelet count;
KIRP	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg07511934	chr16:89386912	ANKRD11	0.44	5.58	0.34	6.43e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02018176	chr4:1364513	KIAA1530	0.38	5.17	0.31	4.84e-7	Longevity;
KIRP	cis	rs7106204	0.764	rs28833840	chr11:24206736	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	7.16	0.42	9.17e-12	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.03	-0.41	2e-11	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg13444842	chr1:152974279	SPRR3	0.36	5.08	0.31	7.56e-7	Inflammatory skin disease;
KIRP	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg01304814	chr3:48885189	PRKAR2A	-0.58	-4.94	-0.3	1.46e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.84	-0.35	1.63e-8	IgG glycosylation;
KIRP	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.47	6.49	0.38	4.74e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.36	7.6	0.44	6.38e-13	Body mass index;
KIRP	cis	rs904251	0.686	rs931649	chr6:37466079	T/C	cg08126542	chr6:37504118	NA	-0.56	-5.94	-0.35	9.58e-9	Cognitive performance;
KIRP	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg16434002	chr17:42200994	HDAC5	0.45	5.6	0.34	5.61e-8	Total body bone mineral density;
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.72	12.82	0.63	3.59e-29	Sjögren's syndrome;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	15.39	0.7	6.8e-38	Alzheimer's disease;
KIRP	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.15	0.41	1.01e-11	Height;
KIRP	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18252515	chr7:66147081	NA	-0.46	-5.54	-0.33	7.94e-8	Aortic root size;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.54	-7.45	-0.43	1.57e-12	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20873478	chr7:73097773	WBSCR22;DNAJC30	0.59	7.49	0.43	1.26e-12	Parkinson's disease;
KIRP	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs897080	0.552	rs698793	chr2:44685685	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.71	0.34	3.18e-8	Height;
KIRP	cis	rs6921919	0.583	rs6899603	chr6:28381305	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg22906224	chr7:99728672	NA	-0.64	-7.85	-0.45	1.31e-13	Coronary artery disease;
KIRP	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-9.15	-0.5	2.24e-17	Morning vs. evening chronotype;
KIRP	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.82	0.4	7.06e-11	Mean platelet volume;
KIRP	cis	rs9535307	0.719	rs1211304	chr13:50381016	G/A	cg04663916	chr13:50265991	EBPL	-0.56	-6.05	-0.36	5.39e-9	Obesity-related traits;
KIRP	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.69	-8.12	-0.46	2.31e-14	Menarche (age at onset);
KIRP	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg11062466	chr8:58055876	NA	0.6	5.45	0.33	1.23e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg07001201	chr5:642380	CEP72	0.62	5.89	0.35	1.28e-8	Ulcerative colitis;
KIRP	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.94	14.55	0.68	5.24e-35	Menarche (age at onset);
KIRP	cis	rs12050794	0.671	rs2052713	chr15:72520392	G/C	cg16672083	chr15:72433130	SENP8	0.4	5.65	0.34	4.4e-8	Metabolite levels (HVA/MHPG ratio);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09763839	chr4:15004091	CPEB2	-0.44	-6.02	-0.36	6.43e-9	Metabolic traits;
KIRP	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg02487422	chr3:49467188	NICN1	0.45	4.89	0.3	1.83e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10207628	0.941	rs17014923	chr2:127841930	A/G	cg06223080	chr2:127868745	NA	0.57	7.43	0.43	1.77e-12	Psychosis and Alzheimer's disease;
KIRP	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg07777115	chr5:623756	CEP72	-0.59	-6.0	-0.36	7.19e-9	Obesity-related traits;
KIRP	cis	rs10875746	0.537	rs4760625	chr12:48673743	A/T	cg24011408	chr12:48396354	COL2A1	-0.45	-5.19	-0.31	4.45e-7	Longevity (90 years and older);
KIRP	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg00405596	chr8:11794950	NA	0.44	5.51	0.33	9.08e-8	Retinal vascular caliber;
KIRP	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg01763666	chr17:80159506	CCDC57	-0.38	-5.28	-0.32	2.82e-7	Life satisfaction;
KIRP	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.67	8.75	0.49	3.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg26207909	chr14:103986467	CKB	0.4	5.11	0.31	6.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.45	-5.34	-0.32	2.12e-7	Longevity;Endometriosis;
KIRP	cis	rs4786125	0.587	rs6500861	chr16:6923966	A/G	cg03623568	chr16:6915990	A2BP1	-0.44	-5.31	-0.32	2.48e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.5e-21	Bone mineral density;
KIRP	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.66	7.91	0.45	8.9e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg19913688	chr11:428466	ANO9	-0.72	-5.43	-0.33	1.34e-7	Body mass index;
KIRP	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.87e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs10267417	0.603	rs4236297	chr7:19910884	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.36	-5.66	-0.34	4.13e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg06223162	chr1:101003688	GPR88	-0.42	-8.41	-0.47	3.28e-15	Monocyte count;
KIRP	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.88	0.49	1.45e-16	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.21	-0.37	2.25e-9	Lung cancer;
KIRP	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.94	-0.4	3.44e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6433857	0.536	rs1971135	chr2:181351508	G/A	cg23363182	chr2:181467187	NA	-0.37	-5.25	-0.32	3.32e-7	Body mass index;
KIRP	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.7	8.99	0.5	6.85e-17	Bladder cancer;
KIRP	cis	rs17221829	0.733	rs11018689	chr11:89367791	G/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2802372	0.630	rs1250566	chr10:81046453	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.68	-8.32	-0.47	5.96e-15	Granulocyte count;
KIRP	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg08603382	chr10:743973	NA	-0.57	-8.15	-0.46	1.81e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.15	0.31	5.47e-7	Menopause (age at onset);
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.61	-7.64	-0.44	4.71e-13	Breast cancer;
KIRP	cis	rs4699052	0.928	rs2126473	chr4:104141533	G/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.19	-0.31	4.3e-7	Testicular germ cell tumor;
KIRP	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-5.92	-0.35	1.07e-8	Aortic root size;
KIRP	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg00277334	chr10:82204260	NA	-0.5	-5.76	-0.34	2.53e-8	Post bronchodilator FEV1;
KIRP	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12667521	chr19:29218732	NA	-0.71	-5.81	-0.35	1.91e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09656405	chr15:69745057	RPLP1	0.59	6.96	0.41	3.04e-11	Smoking initiation;
KIRP	cis	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.93	0.3	1.49e-6	Leprosy;
KIRP	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.01	-0.41	2.25e-11	Neuroticism;
KIRP	trans	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg26513180	chr16:89883248	FANCA	0.62	5.34	0.32	2.12e-7	Skin colour saturation;
KIRP	cis	rs4273100	0.512	rs7502682	chr17:19295450	G/T	cg18093559	chr17:18951025	GRAP	0.49	5.78	0.35	2.29e-8	Schizophrenia;
KIRP	cis	rs4919044	0.641	rs7914449	chr10:94723370	G/T	cg05127821	chr10:94822908	CYP26C1	-0.98	-7.87	-0.45	1.14e-13	Coronary artery disease;
KIRP	cis	rs71403859	0.730	rs17356316	chr16:71746921	C/T	cg08717414	chr16:71523259	ZNF19	-1.05	-8.43	-0.47	2.91e-15	Post bronchodilator FEV1;
KIRP	cis	rs10982256	0.774	rs10817626	chr9:117254541	G/A	cg13636371	chr9:117264095	DFNB31	0.57	7.96	0.45	6.31e-14	Bipolar disorder;
KIRP	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.66	8.31	0.47	6.45e-15	Resting heart rate;
KIRP	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.21	14.13	0.67	1.39e-33	Sexual dysfunction (female);
KIRP	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg05791153	chr7:19748676	TWISTNB	0.64	5.9	0.35	1.21e-8	Thyroid stimulating hormone;
KIRP	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.79	-11.29	-0.58	4.38e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.3	6.08	0.36	4.49e-9	Schizophrenia;
KIRP	trans	rs1864585	0.520	rs73208789	chr8:10679187	A/G	cg26278703	chr11:58910052	FAM111A	0.64	6.26	0.37	1.7e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs12681963	0.610	rs2174133	chr8:30005763	G/A	cg04374813	chr8:30012889	DCTN6	0.46	5.07	0.31	7.96e-7	Migraine;
KIRP	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22117172	chr7:91764530	CYP51A1	0.47	6.53	0.38	3.8e-10	Breast cancer;
KIRP	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	1.01	13.13	0.64	3.38e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg22974920	chr21:40686053	BRWD1	0.5	6.01	0.36	6.51e-9	Cognitive function;
KIRP	cis	rs7808935	0.591	rs62451117	chr7:27942357	T/C	cg22168087	chr7:27702803	HIBADH	0.74	7.84	0.45	1.35e-13	Prostate cancer;
KIRP	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-8.74	-0.49	3.59e-16	Developmental language disorder (linguistic errors);
KIRP	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.43	6.33	0.37	1.17e-9	Major depressive disorder;
KIRP	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg21573476	chr21:45109991	RRP1B	-0.59	-7.87	-0.45	1.16e-13	Mean corpuscular volume;
KIRP	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	5.16	0.31	5e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.05	-19.22	-0.77	6.63e-51	Height;
KIRP	cis	rs35160687	0.787	rs10186289	chr2:86512988	G/A	cg23811061	chr2:86423046	IMMT	0.38	5.09	0.31	7.17e-7	Night sleep phenotypes;
KIRP	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs6585424	1.000	rs34332933	chr10:81926750	G/C	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	0.82	9.05	0.5	4.52e-17	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg15181151	chr6:150070149	PCMT1	0.31	5.22	0.32	3.88e-7	Lung cancer;
KIRP	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.99	0.41	2.54e-11	Bipolar disorder;
KIRP	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.64	0.48	7.34e-16	Bipolar disorder;
KIRP	cis	rs7870753	0.838	rs7037607	chr9:99244798	G/A	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.48	0.38	5.07e-10	Platelet count;
KIRP	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.96	11.16	0.58	1.1e-23	Corneal astigmatism;
KIRP	cis	rs10056811	0.538	rs56174528	chr5:74400516	G/C	cg19683494	chr5:74908142	NA	0.55	4.93	0.3	1.5e-6	Coronary artery disease;
KIRP	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.3	0.37	1.39e-9	Breast cancer;
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.46	5.92	0.35	1.09e-8	Life satisfaction;
KIRP	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg01338139	chr15:38987640	C15orf53	-0.5	-5.39	-0.33	1.65e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs9535307	0.522	rs3851166	chr13:50409236	G/T	cg04663916	chr13:50265991	EBPL	-0.55	-5.45	-0.33	1.22e-7	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg21605333	chr4:119757512	SEC24D	1.6	11.71	0.6	1.76e-25	Cannabis dependence symptom count;
KIRP	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.56	0.65	1.2e-31	Chronic sinus infection;
KIRP	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.87	14.84	0.69	5.35e-36	Multiple myeloma;
KIRP	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg04691961	chr3:161091175	C3orf57	0.44	6.47	0.38	5.15e-10	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	11.26	0.58	5.58e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.63	-7.53	-0.43	9.83e-13	Iron status biomarkers;
KIRP	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs17253792	0.545	rs12879564	chr14:56017694	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg05347473	chr6:146136440	FBXO30	0.62	8.74	0.49	3.8e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2479106	0.591	rs10760293	chr9:126353327	T/C	cg16191174	chr9:126692580	DENND1A	0.38	5.16	0.31	5.03e-7	Polycystic ovary syndrome;
KIRP	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-4.94	-0.3	1.45e-6	Coronary artery disease;
KIRP	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg00919237	chr7:87102261	ABCB4	-0.68	-8.85	-0.49	1.76e-16	Gallbladder cancer;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	7.73	0.44	2.77e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21643547	chr1:205240462	TMCC2	-0.88	-14.11	-0.67	1.62e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.59	-7.34	-0.42	3.13e-12	Personality dimensions;
KIRP	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.66	-12.19	-0.61	4.87e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs9843304	0.501	rs34540967	chr3:149204381	T/C	cg08667024	chr3:149219783	TM4SF4	-0.41	-6.12	-0.36	3.57e-9	Gallstone disease;
KIRP	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-1.13	-18.14	-0.76	2.95e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg10117171	chr1:25599238	RHD	-0.37	-5.09	-0.31	7.13e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg20744362	chr22:50050164	C22orf34	0.35	5.4	0.33	1.55e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg21926883	chr2:100939477	LONRF2	-0.48	-6.32	-0.37	1.21e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	1.000	rs17064124	chr3:41890803	A/G	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg11970804	chr8:8084126	NA	-0.38	-5.01	-0.3	1.06e-6	Systolic blood pressure;
KIRP	cis	rs12900413	0.603	rs12909833	chr15:90301518	G/A	cg24650279	chr15:90327240	NA	-0.41	-5.08	-0.31	7.51e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg19894588	chr14:64061835	NA	-0.66	-8.18	-0.46	1.54e-14	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.82	11.54	0.59	6.63e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg01879757	chr17:41196368	BRCA1	-0.79	-10.85	-0.57	1.15e-22	Menopause (age at onset);
KIRP	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg26850624	chr5:429559	AHRR	-0.45	-7.02	-0.41	2.1e-11	Cystic fibrosis severity;
KIRP	cis	rs1620921	0.967	rs1084658	chr6:161180477	G/A	cg01280913	chr6:161186852	NA	-0.45	-6.42	-0.38	6.91e-10	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg22117172	chr7:91764530	CYP51A1	0.42	5.8	0.35	2.02e-8	Breast cancer;
KIRP	cis	rs2718812	0.766	rs10935071	chr3:133394159	T/C	cg11941060	chr3:133502564	NA	-0.38	-4.86	-0.3	2.11e-6	Iron status biomarkers;
KIRP	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Alcohol dependence;
KIRP	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg18646521	chr2:111875858	NA	0.41	5.88	0.35	1.35e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs13185784	0.662	rs35759987	chr5:179679980	G/T	cg23221052	chr5:179740743	GFPT2	0.54	5.21	0.32	3.93e-7	TRAIL levels;
KIRP	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg03289416	chr15:75166202	SCAMP2	0.4	5.4	0.33	1.55e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg13072238	chr3:49761600	GMPPB	0.67	5.96	0.36	8.61e-9	Menarche (age at onset);
KIRP	cis	rs9603616	0.719	rs7330515	chr13:40233404	T/C	cg26701198	chr13:40229707	COG6	0.45	5.28	0.32	2.85e-7	Rheumatoid arthritis;
KIRP	trans	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg12210378	chr14:105685021	BRF1	0.4	6.14	0.36	3.27e-9	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.42	-0.33	1.41e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.33	5.44	0.33	1.3e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg07541023	chr7:19748670	TWISTNB	0.67	5.93	0.35	1.02e-8	Thyroid stimulating hormone;
KIRP	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.59	-7.57	-0.43	7.55e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2574975	0.531	rs1203408	chr10:52197398	C/T	cg10034176	chr10:52120283	SGMS1	0.39	5.62	0.34	5.14e-8	Response to amphetamines;
KIRP	cis	rs4774899	0.966	rs2414497	chr15:57493993	C/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.39	-0.32	1.65e-7	Urinary tract infection frequency;
KIRP	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.61	8.39	0.47	3.91e-15	Lymphocyte counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21568206	chr2:120861711	EPB41L5	-0.4	-6.37	-0.38	9.35e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.79	11.58	0.59	4.71e-25	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg13206674	chr6:150067644	NUP43	0.47	6.57	0.39	3.03e-10	Testicular germ cell tumor;
KIRP	cis	rs2594989	0.887	rs7632902	chr3:11476884	T/C	cg01796438	chr3:11312864	ATG7	-0.63	-7.64	-0.44	4.88e-13	Circulating chemerin levels;
KIRP	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg12315302	chr6:26189340	HIST1H4D	0.97	6.76	0.4	9.72e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5995756	0.666	rs5750857	chr22:40000221	A/C	cg21377881	chr22:40064566	CACNA1I	0.39	5.19	0.31	4.45e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2235573	0.662	rs2018980	chr22:38450620	A/G	cg19171272	chr22:38449367	NA	-0.65	-9.09	-0.5	3.45e-17	Glioblastoma;Glioma;
KIRP	cis	rs4936894	0.500	rs4354702	chr11:124156637	T/G	cg27160556	chr11:124181099	OR8D1	-0.39	-5.75	-0.34	2.65e-8	Aging (time to death);
KIRP	cis	rs2346160	0.899	rs172283	chr6:167691225	T/C	cg27333441	chr6:167680455	NA	-0.44	-5.71	-0.34	3.29e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg24826892	chr11:71159390	DHCR7	0.44	5.27	0.32	3.01e-7	Vitamin D levels;
KIRP	trans	rs76288851	0.740	rs6777746	chr3:126678169	C/T	cg13821433	chr2:26726535	OTOF	-0.54	-6.42	-0.38	7.11e-10	Alcoholic chronic pancreatitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22171358	chr4:17934261	LCORL	-0.42	-6.35	-0.38	1.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg05861140	chr6:150128134	PCMT1	-0.51	-7.15	-0.41	9.93e-12	Lung cancer;
KIRP	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21545522	chr1:205238299	TMCC2	0.5	6.57	0.39	3.02e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3857067	0.934	rs2865336	chr4:95029357	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.91	-0.3	1.67e-6	QT interval;
KIRP	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.2	0.42	7.11e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.15	-14.93	-0.69	2.65e-36	Alzheimer's disease;
KIRP	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.48	5.55	0.33	7.5e-8	Schizophrenia;
KIRP	cis	rs2033732	0.954	rs10808859	chr8:85085400	A/T	cg05716166	chr8:85095498	RALYL	-0.57	-6.05	-0.36	5.28e-9	Body mass index;
KIRP	cis	rs654128	0.640	rs6914581	chr6:117228916	C/T	cg12892004	chr6:117198278	RFX6	0.47	6.08	0.36	4.68e-9	Telomere length;
KIRP	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.21	0.37	2.29e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg14791747	chr16:20752902	THUMPD1	-0.57	-6.14	-0.36	3.24e-9	Cognitive test performance;
KIRP	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs8027181	0.839	rs10459647	chr15:73035241	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.61	0.44	5.98e-13	Triglyceride levels;
KIRP	cis	rs11779988	0.545	rs208749	chr8:17777204	T/A	cg01800426	chr8:17659068	MTUS1	-0.61	-6.0	-0.36	7.03e-9	Breast cancer;
KIRP	cis	rs13361707	0.666	rs59585832	chr5:40744038	C/T	cg01087697	chr5:40835557	RPL37	-0.49	-5.08	-0.31	7.39e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.48	6.23	0.37	2e-9	High light scatter reticulocyte count;
KIRP	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-1.01	-10.2	-0.55	1.3e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7582180	0.838	rs6754867	chr2:100895081	A/G	cg14675211	chr2:100938903	LONRF2	-0.44	-5.9	-0.35	1.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.96	0.5	8.26e-17	IgG glycosylation;
KIRP	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg01879757	chr17:41196368	BRCA1	0.56	7.61	0.44	5.74e-13	Menopause (age at onset);
KIRP	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.6	6.36	0.38	1e-9	Diisocyanate-induced asthma;
KIRP	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs71277158	0.688	rs17471922	chr3:169779394	A/G	cg04067573	chr3:169899625	PHC3	0.56	5.13	0.31	6.01e-7	Prostate cancer;
KIRP	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg16414030	chr3:133502952	NA	0.44	5.1	0.31	6.79e-7	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.88	13.01	0.64	8.21e-30	Coronary artery disease;
KIRP	cis	rs8070740	0.838	rs1050390	chr17:5336058	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	6.65	0.39	1.92e-10	Menopause (age at onset);
KIRP	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9900972	0.918	rs2889530	chr17:76878706	C/T	cg00961940	chr17:76876995	TIMP2	0.54	7.15	0.41	9.95e-12	Obesity-related traits;
KIRP	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2073300	1.000	rs6048811	chr20:23446719	G/C	cg12062639	chr20:23401060	NAPB	0.8	6.96	0.41	3.01e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12913496	chr3:52273291	TWF2	0.51	6.27	0.37	1.58e-9	Parkinson's disease;
KIRP	cis	rs112591243	0.570	rs4819254	chr21:47887462	T/A	cg12379764	chr21:47803548	PCNT	0.73	4.93	0.3	1.53e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6466055	0.661	rs6945585	chr7:104905277	T/G	cg04380332	chr7:105027541	SRPK2	0.41	5.68	0.34	3.88e-8	Schizophrenia;
KIRP	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	1.12	8.1	0.46	2.53e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.07	-22.87	-0.82	7.85e-63	Myeloid white cell count;
KIRP	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.54	-6.59	-0.39	2.66e-10	Metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13686331	chr21:40557788	BRWD1	-0.41	-6.48	-0.38	5.02e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4791746	0.948	rs7211295	chr17:8628684	C/T	cg03115937	chr17:8649504	CCDC42	-0.52	-5.85	-0.35	1.56e-8	Heroin dependence;
KIRP	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.67	8.17	0.46	1.64e-14	Blood protein levels;
KIRP	cis	rs4560672	1.000	rs35728263	chr6:158584058	C/T	cg14029994	chr6:158589857	SERAC1;GTF2H5	-0.56	-4.96	-0.3	1.33e-6	Smoking quantity;
KIRP	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs7523273	0.565	rs2985104	chr1:207892012	C/T	cg22525895	chr1:207977042	MIR29B2	-0.47	-5.84	-0.35	1.63e-8	Schizophrenia;
KIRP	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg05973401	chr12:123451056	ABCB9	0.54	6.13	0.36	3.44e-9	Neutrophil percentage of white cells;
KIRP	cis	rs1215050	0.791	rs1530904	chr4:98805436	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.4	0.38	7.89e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.77	9.83	0.53	1.84e-19	Aortic root size;
KIRP	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08280861	chr8:58055591	NA	0.72	5.96	0.36	8.8e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22565399	chr5:176890677	DBN1	0.46	6.16	0.37	2.96e-9	Survival in pancreatic cancer;
KIRP	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.71	8.74	0.49	3.65e-16	Cognitive function;
KIRP	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg06219351	chr7:158114137	PTPRN2	-0.55	-7.77	-0.44	2.19e-13	Calcium levels;
KIRP	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg17524265	chr8:144659883	NAPRT1	0.82	5.29	0.32	2.72e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.66	9.73	0.53	3.81e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	trans	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg19694781	chr19:47549865	TMEM160	-0.5	-6.07	-0.36	4.69e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.66	8.79	0.49	2.67e-16	Renal function-related traits (BUN);
KIRP	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg20821713	chr7:1055600	C7orf50	-0.31	-4.87	-0.3	2.04e-6	Longevity;Endometriosis;
KIRP	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.53	-5.89	-0.35	1.25e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.9	-10.97	-0.57	4.85e-23	Vitiligo;
KIRP	cis	rs3126085	0.560	rs6693160	chr1:152341321	C/T	cg26876637	chr1:152193138	HRNR	-0.73	-6.93	-0.4	3.73e-11	Atopic dermatitis;
KIRP	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg00343986	chr7:65444356	GUSB	-0.47	-5.73	-0.34	2.9e-8	Aortic root size;
KIRP	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg17143192	chr8:8559678	CLDN23	0.53	6.75	0.4	1.06e-10	Obesity-related traits;
KIRP	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.86	-0.35	1.5e-8	Breast cancer;
KIRP	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.59	7.33	0.42	3.36e-12	Coronary artery disease;
KIRP	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg15655495	chr12:38532458	NA	0.27	5.36	0.32	1.89e-7	Morning vs. evening chronotype;
KIRP	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.07	-0.5	3.79e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.44	5.22	0.32	3.89e-7	Aortic root size;
KIRP	cis	rs981844	0.735	rs111822747	chr4:154734629	G/C	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs6723108	1.000	rs1942055	chr2:135498924	C/G	cg12500956	chr2:135428796	TMEM163	-0.43	-5.42	-0.33	1.4e-7	Type 2 diabetes;
KIRP	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.66	9.53	0.52	1.54e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.53	-0.48	1.47e-15	Triglycerides;
KIRP	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.79	-9.5	-0.52	2.02e-18	Corneal astigmatism;
KIRP	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg11845111	chr2:191398756	TMEM194B	-0.96	-10.14	-0.54	2.04e-20	Diastolic blood pressure;
KIRP	cis	rs6681460	0.649	rs4655494	chr1:67002876	G/A	cg02459107	chr1:67143332	SGIP1	0.38	5.43	0.33	1.35e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs273218	0.573	rs10513033	chr5:53333477	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.96	-12.14	-0.61	7.08e-27	Migraine;
KIRP	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg05082376	chr22:42548792	NA	0.45	5.72	0.34	3.04e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6684428	1.000	rs10888948	chr1:56382722	G/A	cg11651538	chr1:56320950	NA	-0.9	-11.19	-0.58	8.98e-24	Airflow obstruction;
KIRP	cis	rs2151522	0.762	rs9375469	chr6:127167919	T/A	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg09631192	chr20:23583594	CST9	-0.52	-5.19	-0.31	4.3e-7	Chronic kidney disease;
KIRP	cis	rs11252926	0.673	rs553326	chr10:749238	G/T	cg08603382	chr10:743973	NA	-0.47	-7.15	-0.41	9.94e-12	Psychosis in Alzheimer's disease;
KIRP	cis	rs981844	0.712	rs4632640	chr4:154742389	G/C	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs72772090	0.539	rs72775809	chr5:96183556	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg16989719	chr2:238392110	NA	-0.56	-7.61	-0.44	5.73e-13	Prostate cancer;
KIRP	cis	rs896543	0.702	rs6711119	chr2:237494334	C/T	cg25295825	chr2:237489920	CXCR7	0.86	14.15	0.67	1.21e-33	Alcohol dependence (age at onset);
KIRP	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.84	10.15	0.54	1.97e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs73200209	0.744	rs2392967	chr12:116531742	T/C	cg01776926	chr12:116560359	MED13L	-0.57	-6.29	-0.37	1.4e-9	Total body bone mineral density;
KIRP	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.55	5.28	0.32	2.89e-7	Height;
KIRP	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.81	-8.73	-0.49	3.85e-16	Prostate cancer;
KIRP	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.78	10.33	0.55	5.01e-21	Osteoporosis;
KIRP	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg00981070	chr1:2046702	PRKCZ	-0.38	-6.26	-0.37	1.72e-9	Height;
KIRP	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10620530	chr9:139922595	C9orf139;ABCA2	0.51	6.74	0.39	1.11e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14169450	chr9:139327907	INPP5E	0.54	8.0	0.45	4.9e-14	Monocyte percentage of white cells;
KIRP	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	6.07	0.36	4.87e-9	Response to antipsychotic treatment;
KIRP	cis	rs10214930	0.813	rs12700830	chr7:27688859	T/C	cg22168087	chr7:27702803	HIBADH	0.51	5.13	0.31	5.91e-7	Hypospadias;
KIRP	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg25173405	chr17:45401733	C17orf57	0.48	6.42	0.38	6.98e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.6	-8.08	-0.46	2.99e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2733310	0.895	rs1657938	chr15:57109533	G/A	cg13626582	chr15:57592083	LOC283663	-0.23	-5.12	-0.31	6.27e-7	Mean platelet volume;
KIRP	cis	rs4664293	0.867	rs7565297	chr2:160572519	G/A	cg08347373	chr2:160653686	CD302	-0.42	-6.52	-0.38	4.05e-10	Monocyte percentage of white cells;
KIRP	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-8.65	-0.48	6.64e-16	Bipolar disorder;
KIRP	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg02375832	chr11:62437615	C11orf48	-0.41	-5.1	-0.31	6.68e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg23992470	chr4:843637	GAK	0.63	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7560272	0.695	rs13022149	chr2:73641515	T/A	cg20560298	chr2:73613845	ALMS1	0.47	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg05729581	chr11:3078854	CARS	-0.5	-6.21	-0.37	2.26e-9	Type 2 diabetes;
KIRP	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.78	9.72	0.53	4.15e-19	Monocyte percentage of white cells;
KIRP	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.12	-0.31	6.08e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg04166393	chr7:2884313	GNA12	0.71	8.49	0.48	2.04e-15	Height;
KIRP	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.85	-13.46	-0.65	2.54e-31	Systemic lupus erythematosus;
KIRP	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg04780086	chr2:111875790	ACOXL	0.47	6.55	0.39	3.36e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.89	9.58	0.52	1.12e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg11693508	chr17:37793320	STARD3	0.81	8.53	0.48	1.53e-15	Bipolar disorder;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg12913429	chr14:73360857	DPF3	0.5	6.32	0.37	1.23e-9	Inflammatory biomarkers;
KIRP	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg04132472	chr17:19861366	AKAP10	-0.69	-10.85	-0.57	1.11e-22	Schizophrenia;
KIRP	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.83	-9.61	-0.52	9.08e-19	Menarche (age at onset);
KIRP	cis	rs2071403	0.509	rs11675342	chr2:1407628	C/T	cg07083862	chr2:1417248	TPO	0.35	5.35	0.32	2.05e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg03653399	chr8:142233436	SLC45A4	0.98	15.69	0.71	6.48e-39	Immature fraction of reticulocytes;
KIRP	cis	rs7173743	1.000	rs4420501	chr15:79138478	A/T	cg00079375	chr15:79125835	NA	-0.38	-5.42	-0.33	1.42e-7	Coronary artery disease;
KIRP	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.5	6.48	0.38	4.83e-10	White matter hyperintensity burden;
KIRP	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-8.13	-0.46	2.08e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	14.41	0.68	1.58e-34	Platelet count;
KIRP	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.69	8.38	0.47	4.23e-15	Multiple sclerosis;
KIRP	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.2	-0.37	2.43e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7792596	0.539	rs71562851	chr7:94011557	C/T	cg20814616	chr7:94014465	NA	-0.45	-5.21	-0.32	3.91e-7	Intelligence;
KIRP	cis	rs2816062	0.786	rs735946	chr1:18901323	T/C	cg18795169	chr1:18902165	NA	-0.9	-14.76	-0.69	9.68e-36	Urate levels in lean individuals;
KIRP	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.07	-0.36	4.7e-9	Schizophrenia;
KIRP	cis	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg03342759	chr3:160939853	NMD3	0.47	5.68	0.34	3.86e-8	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg06647332	chr5:131281008	NA	0.48	5.33	0.32	2.27e-7	Life satisfaction;
KIRP	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.97	-15.43	-0.7	4.96e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg11608241	chr8:8085544	FLJ10661	0.48	6.32	0.37	1.21e-9	Retinal vascular caliber;
KIRP	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg20493526	chr2:3714936	ALLC	0.5	6.41	0.38	7.38e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg19767477	chr5:127420684	SLC12A2	0.38	5.47	0.33	1.09e-7	Ileal carcinoids;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15566921	chr13:67645170	PCDH9	-0.43	-6.64	-0.39	1.98e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7402982	0.625	rs4966011	chr15:99204006	G/A	cg03437748	chr15:99193247	IGF1R	0.75	9.34	0.51	5.81e-18	Birth weight;
KIRP	cis	rs986417	1.000	rs1254302	chr14:60885343	A/C	cg27398547	chr14:60952738	C14orf39	-0.66	-5.78	-0.35	2.25e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg20526800	chr20:33880825	FAM83C	-0.4	-4.96	-0.3	1.32e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	6.37	0.38	9.05e-10	Response to antipsychotic treatment;
KIRP	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg08514558	chr10:81106712	PPIF	0.39	5.36	0.32	1.92e-7	Height;
KIRP	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	8.33	0.47	5.81e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.41	5.45	0.33	1.24e-7	Hypertriglyceridemia;
KIRP	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg19774624	chr17:42201019	HDAC5	-0.64	-8.1	-0.46	2.56e-14	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27664390	chr15:59171928	SLTM	0.48	6.24	0.37	1.9e-9	Survival in pancreatic cancer;
KIRP	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.77	-9.51	-0.52	1.79e-18	Corneal structure;
KIRP	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg25025879	chr12:53359317	NA	-0.37	-5.18	-0.31	4.71e-7	Prostate cancer;
KIRP	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg25173405	chr17:45401733	C17orf57	0.48	6.4	0.38	7.81e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs997295	1.000	rs938875	chr15:67952922	A/G	cg14210607	chr15:68128175	NA	-0.3	-4.99	-0.3	1.14e-6	Motion sickness;
KIRP	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.6	-0.44	6.21e-13	Type 2 diabetes;
KIRP	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg04733989	chr22:42467013	NAGA	0.56	7.5	0.43	1.15e-12	Cognitive function;
KIRP	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-7.06	-0.41	1.73e-11	Menarche (age at onset);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07044724	chr16:30406465	ZNF48	0.71	6.77	0.4	9.51e-11	Lung function (FEV1);
KIRP	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	1.07	21.62	0.81	8.26e-59	Height;
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.23	-0.32	3.59e-7	Obesity-related traits;
KIRP	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.76	9.99	0.54	5.93e-20	Mean platelet volume;
KIRP	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.79	9.78	0.53	2.79e-19	Sudden cardiac arrest;
KIRP	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.84	-14.22	-0.67	6.98e-34	Post bronchodilator FEV1;
KIRP	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.66	-9.6	-0.52	9.93e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs11731606	0.508	rs7696494	chr4:95285174	G/A	cg20625393	chr4:95128694	SMARCAD1	0.53	5.09	0.31	7.06e-7	Mean platelet volume;
KIRP	cis	rs59868192	0.925	rs72726037	chr15:42263979	G/A	cg20935245	chr15:42234343	EHD4	-0.54	-5.28	-0.32	2.84e-7	White blood cell count;
KIRP	cis	rs3925075	0.553	rs3087796	chr16:31343653	A/G	cg02846316	chr16:31340340	ITGAM	0.46	5.55	0.33	7.5e-8	IgA nephropathy;
KIRP	cis	rs4443656	0.933	rs7821419	chr8:21530742	T/C	cg03964515	chr8:21588527	GFRA2	-0.33	-4.94	-0.3	1.44e-6	Blood protein levels;
KIRP	cis	rs17428704	0.571	rs11959397	chr5:14349603	C/T	cg26595256	chr5:14380529	TRIO	-0.8	-6.15	-0.37	3.11e-9	Electroencephalogram traits;
KIRP	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg22974920	chr21:40686053	BRWD1	-0.45	-5.22	-0.32	3.89e-7	Cognitive function;
KIRP	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg20977078	chr3:50606503	HEMK1;C3orf18	-0.65	-4.86	-0.3	2.14e-6	Schizophrenia;
KIRP	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.06	-0.36	5.19e-9	Response to antipsychotic treatment;
KIRP	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs600806	0.676	rs573491	chr1:110026891	T/G	cg02175308	chr1:109941060	SORT1	0.31	5.9	0.35	1.21e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.48	0.43	1.3e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.38	-5.79	-0.35	2.12e-8	Hypertriglyceridemia;
KIRP	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.59	-8.69	-0.48	5.25e-16	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7680126	0.596	rs10020887	chr4:10140751	C/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-4.96	-0.3	1.32e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00938859	chr5:1591904	SDHAP3	-0.6	-8.0	-0.45	4.92e-14	Breast cancer;
KIRP	cis	rs13102973	0.720	rs4473702	chr4:135851159	C/G	cg14419869	chr4:135874104	NA	0.43	6.93	0.4	3.63e-11	Subjective well-being;
KIRP	cis	rs78487399	0.808	rs6746610	chr2:43677253	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.69	-0.34	3.55e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4950322	0.570	rs72692946	chr1:146791684	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	13.03	0.64	7.3e-30	Platelet count;
KIRP	cis	rs4774899	0.966	rs10518899	chr15:57491182	G/A	cg13626582	chr15:57592083	LOC283663	-0.21	-5.38	-0.32	1.72e-7	Urinary tract infection frequency;
KIRP	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.57	7.78	0.44	2.04e-13	Mean corpuscular volume;
KIRP	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.99	-15.41	-0.7	5.76e-38	Coronary artery disease;
KIRP	cis	rs4363506	0.625	rs10765125	chr10:129286780	A/G	cg07804728	chr10:129284050	NA	0.42	5.78	0.35	2.25e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26526719	chr5:1949144	NA	0.44	5.25	0.32	3.29e-7	Gut microbiome composition (winter);
KIRP	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.47	-5.79	-0.35	2.17e-8	Body mass index;
KIRP	cis	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg26116260	chr4:7069785	GRPEL1	-0.92	-5.08	-0.31	7.38e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.68	8.87	0.49	1.49e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.78	0.44	2.06e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.59	-11.44	-0.59	1.45e-24	Diabetic kidney disease;
KIRP	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.42	-5.38	-0.32	1.74e-7	Blood metabolite levels;
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.77	-10.97	-0.57	4.86e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg24747557	chr10:131355152	MGMT	-0.41	-5.58	-0.34	6.18e-8	Response to temozolomide;
KIRP	cis	rs883565	0.792	rs1274958	chr3:39184959	C/T	cg01426195	chr3:39028469	NA	0.54	6.86	0.4	5.53e-11	Handedness;
KIRP	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.07	-0.41	1.57e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs918629	1.000	rs3777167	chr5:95286017	A/G	cg16656078	chr5:95278638	ELL2	-0.44	-6.52	-0.38	3.87e-10	IgG glycosylation;
KIRP	cis	rs735860	0.712	rs2294864	chr6:53140928	T/A	cg10236188	chr6:53219634	NA	-0.39	-5.2	-0.31	4.26e-7	Glaucoma;
KIRP	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.5	7.61	0.44	5.93e-13	Resting heart rate;
KIRP	cis	rs812925	0.502	rs13028833	chr2:61644329	C/G	cg15711740	chr2:61764176	XPO1	0.44	5.61	0.34	5.45e-8	Immature fraction of reticulocytes;
KIRP	cis	rs988913	0.581	rs2134537	chr6:54858006	C/T	cg03513858	chr6:54763001	FAM83B	-0.34	-4.9	-0.3	1.76e-6	Menarche (age at onset);
KIRP	cis	rs17123764	0.818	rs3887728	chr12:49972332	G/A	cg20471783	chr12:50157085	TMBIM6	0.31	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.93e-11	Retinal vascular caliber;
KIRP	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.92	12.57	0.63	2.49e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg07962218	chr7:65219954	SNORA22;CCT6P1	-0.35	-5.18	-0.31	4.55e-7	Calcium levels;
KIRP	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.65	7.78	0.44	2e-13	Vitamin D levels;
KIRP	cis	rs1335587	0.714	rs12431251	chr13:102133914	T/G	cg13538571	chr13:102108074	ITGBL1	0.4	5.19	0.31	4.31e-7	Obesity-related traits;
KIRP	trans	rs7999699	0.967	rs10507561	chr13:48336231	A/G	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	6.82e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg12692727	chr7:1102344	C7orf50	0.47	5.08	0.31	7.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.59	9.49	0.52	2.12e-18	Obesity-related traits;
KIRP	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.9	11.96	0.61	2.65e-26	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12580194	0.593	rs11171416	chr12:55731490	A/G	cg11794356	chr12:55725991	OR6C3	-0.61	-8.75	-0.49	3.44e-16	Cancer;
KIRP	cis	rs10789491	0.767	rs1595898	chr1:47193577	G/A	cg15501359	chr1:47185051	KIAA0494	1.06	11.47	0.59	1.07e-24	Response to hepatitis C treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26082174	chr14:105444897	AHNAK2	0.46	6.42	0.38	6.8e-10	Parkinson's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01180513	chr20:3388407	C20orf194	-0.47	-6.04	-0.36	5.64e-9	Myopia;
KIRP	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg20362242	chr5:692897	TPPP	0.57	4.95	0.3	1.39e-6	Obesity-related traits;
KIRP	cis	rs6723108	0.738	rs6430538	chr2:135539967	A/G	cg25422880	chr2:135218333	TMEM163	0.49	7.0	0.41	2.39e-11	Type 2 diabetes;
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.23	0.32	3.58e-7	Lung cancer;
KIRP	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.76	-11.21	-0.58	7.89e-24	Prostate cancer;
KIRP	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg22676075	chr6:135203613	NA	0.5	7.41	0.43	2.01e-12	Reticulocyte count;High light scatter reticulocyte count;
KIRP	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-5.07	-0.31	7.76e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9815354	0.716	rs73087368	chr3:41930379	A/G	cg03022575	chr3:42003672	ULK4	0.77	7.99	0.45	5.18e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs17209837	0.607	rs4148813	chr7:87092376	A/G	cg00919237	chr7:87102261	ABCB4	-0.69	-8.77	-0.49	2.97e-16	Gallbladder cancer;
KIRP	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	4.93	0.3	1.5e-6	Psychosis and Alzheimer's disease;
KIRP	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg15488143	chr7:128924101	AHCYL2	-0.45	-5.81	-0.35	1.91e-8	White matter hyperintensity burden;
KIRP	cis	rs12200782	0.722	rs12205731	chr6:26370660	G/A	cg00631329	chr6:26305371	NA	-0.87	-5.04	-0.31	8.82e-7	Small cell lung carcinoma;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07520141	chr5:10564205	ANKRD33B	-0.53	-6.87	-0.4	5.36e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.2	0.64	1.95e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.57	7.58	0.44	6.9e-13	Lymphocyte counts;
KIRP	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.55	6.05	0.36	5.26e-9	Bone mineral density (spine);
KIRP	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg09876464	chr15:85330779	ZNF592	0.37	4.9	0.3	1.72e-6	P wave terminal force;
KIRP	cis	rs6142102	0.923	rs4911383	chr20:32555779	A/G	cg08999081	chr20:33150536	PIGU	0.5	5.99	0.36	7.38e-9	Skin pigmentation;
KIRP	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.75	9.57	0.52	1.17e-18	Huntington's disease progression;
KIRP	cis	rs62413470	1.000	rs1555095	chr6:56003683	C/T	cg13327911	chr6:55965977	COL21A1	0.58	4.99	0.3	1.12e-6	Joint mobility (Beighton score);
KIRP	cis	rs6142102	0.812	rs6059574	chr20:32523172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.26	-0.32	3.2e-7	Skin pigmentation;
KIRP	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.12	0.31	6.04e-7	Body mass index;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg18350739	chr11:68623251	NA	-0.51	-7.75	-0.44	2.4e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9473924	0.542	rs9473923	chr6:50833565	A/T	cg14470998	chr6:50812995	TFAP2B	0.83	7.68	0.44	3.65e-13	Body mass index;
KIRP	cis	rs16858210	0.520	rs35586421	chr3:183544607	G/A	cg03417191	chr3:183542750	MAP6D1	-0.56	-5.97	-0.36	8.05e-9	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg24315340	chr6:146058215	EPM2A	0.43	5.22	0.32	3.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	6.27	0.37	1.6e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg00784671	chr22:46762841	CELSR1	-0.78	-7.84	-0.45	1.39e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg00784671	chr22:46762841	CELSR1	-0.56	-7.3	-0.42	4.04e-12	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03508346	chr11:89059855	NOX4	-0.46	-7.48	-0.43	1.3e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.56	0.43	7.95e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.57	7.45	0.43	1.57e-12	Tuberculosis;
KIRP	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg09904177	chr6:26538194	HMGN4	-0.4	-4.91	-0.3	1.68e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-5.06	-0.31	8.24e-7	Triglycerides;
KIRP	cis	rs7224685	0.569	rs34356467	chr17:3978531	G/T	cg09695851	chr17:3907499	NA	0.59	5.73	0.34	2.91e-8	Type 2 diabetes;
KIRP	cis	rs75920871	0.563	rs112895963	chr11:116937159	A/T	cg23684410	chr11:116897558	SIK3	0.58	6.22	0.37	2.17e-9	Subjective well-being;
KIRP	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.11	14.65	0.68	2.28e-35	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.15	0.41	1e-11	Migraine;Coronary artery disease;
KIRP	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.85	12.62	0.63	1.74e-28	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.9	-13.68	-0.66	4.81e-32	Height;
KIRP	cis	rs6693295	0.625	rs6697670	chr1:246347944	A/G	cg11798871	chr1:246315928	SMYD3	-0.5	-5.82	-0.35	1.85e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg00290607	chr11:67383545	NA	-0.4	-5.51	-0.33	9.19e-8	Mean corpuscular volume;
KIRP	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	0.9	10.31	0.55	5.86e-21	Testicular germ cell tumor;
KIRP	cis	rs1878931	0.554	rs3207360	chr16:3498115	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.61	7.91	0.45	8.85e-14	Body mass index (adult);
KIRP	cis	rs7149242	1.000	rs7149242	chr14:101159416	G/T	cg18089426	chr14:101175970	NA	0.52	6.84	0.4	6.25e-11	Platelet count;
KIRP	cis	rs6110278	0.961	rs4464346	chr20:14353386	C/T	cg17696268	chr20:14319035	FLRT3;MACROD2	-0.37	-4.97	-0.3	1.25e-6	Mean platelet volume;
KIRP	cis	rs2916247	0.908	rs6471318	chr8:93086731	C/G	cg10183463	chr8:93005414	RUNX1T1	0.51	6.23	0.37	2.03e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6978712	0.591	rs10269088	chr7:127078490	A/T	cg24655706	chr7:127078268	NA	0.68	5.36	0.32	1.88e-7	Medication adherence in chronic diseases;
KIRP	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.81	-8.98	-0.5	7.16e-17	Coronary artery disease;
KIRP	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.41	-5.64	-0.34	4.56e-8	Obesity-related traits;
KIRP	cis	rs6545883	0.894	rs6709441	chr2:61436930	A/T	cg15711740	chr2:61764176	XPO1	0.56	7.17	0.42	8.63e-12	Tuberculosis;
KIRP	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.87	-15.02	-0.69	1.23e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.49	-5.35	-0.32	1.97e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg24642439	chr20:33292090	TP53INP2	0.47	5.67	0.34	4.09e-8	Height;
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg00129232	chr17:37814104	STARD3	-0.52	-6.42	-0.38	7.15e-10	Self-reported allergy;
KIRP	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.53	7.45	0.43	1.6e-12	Systemic lupus erythematosus;
KIRP	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg10503236	chr1:231470652	EXOC8	-0.49	-6.78	-0.4	8.94e-11	Hemoglobin concentration;
KIRP	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.61	-7.56	-0.43	8.14e-13	Extraversion;
KIRP	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg01879757	chr17:41196368	BRCA1	-0.76	-10.5	-0.56	1.52e-21	Menopause (age at onset);
KIRP	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.91	11.25	0.58	5.62e-24	Response to bleomycin (chromatid breaks);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg21211866	chr9:35111727	KIAA1539	0.5	6.1	0.36	4.11e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs829883	1.000	rs1347956	chr12:98889564	A/G	cg25150519	chr12:98850993	NA	0.87	13.17	0.64	2.43e-30	Colorectal adenoma (advanced);
KIRP	cis	rs1562975	0.722	rs4593211	chr4:109457433	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.4	4.98	0.3	1.22e-6	Height;
KIRP	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.27	-0.42	4.63e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg08126542	chr6:37504118	NA	-0.81	-11.8	-0.6	8.87e-26	Cognitive performance;
KIRP	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	cg21523751	chr1:182988639	NA	0.34	4.9	0.3	1.72e-6	Fuchs's corneal dystrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25846285	chr18:13217819	C18orf1	0.62	7.76	0.44	2.3e-13	Parkinson's disease;
KIRP	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg15557168	chr22:42548783	NA	-0.4	-5.0	-0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg11204139	chr17:3907470	NA	-0.81	-14.52	-0.68	6.38e-35	Type 2 diabetes;
KIRP	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg11584989	chr19:19387371	SF4	0.41	5.28	0.32	2.81e-7	Tonsillectomy;
KIRP	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.66	9.73	0.53	3.81e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	trans	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg04702396	chr17:15466718	FAM18B2	0.53	6.82	0.4	6.83e-11	Educational attainment (years of education);
KIRP	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.95	15.11	0.69	6.21e-37	Bone mineral density;
KIRP	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg13047869	chr3:10149882	C3orf24	0.54	5.3	0.32	2.63e-7	Alzheimer's disease;
KIRP	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	1.2	12.46	0.62	5.9e-28	Alzheimer's disease;
KIRP	trans	rs2548003	0.518	rs2014316	chr5:28723711	T/C	cg23224356	chr2:98206733	ANKRD36B	0.65	6.36	0.38	9.81e-10	Hip geometry;
KIRP	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.98	-0.5	7.37e-17	Hirschsprung disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14051046	chr9:128510172	PBX3	0.56	7.06	0.41	1.66e-11	Parkinson's disease;
KIRP	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.55	-15.72	-0.71	5e-39	Hip circumference adjusted for BMI;
KIRP	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.81	-0.4	7.45e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.76	12.21	0.61	4.16e-27	Ewing sarcoma;
KIRP	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg18064842	chr5:14874549	NA	0.56	8.39	0.47	3.83e-15	Blood metabolite levels;
KIRP	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.9	-13.18	-0.64	2.34e-30	Height;
KIRP	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.13	-0.46	2.07e-14	Aortic root size;
KIRP	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.47	6.33	0.37	1.18e-9	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.79	-8.74	-0.49	3.58e-16	Platelet count;
KIRP	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.7	-0.39	1.42e-10	Obesity-related traits;
KIRP	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg17328964	chr8:145687451	CYHR1	-0.56	-7.12	-0.41	1.22e-11	Age at first birth;
KIRP	cis	rs10465746	0.967	rs6703382	chr1:84435700	G/A	cg10977910	chr1:84465055	TTLL7	0.48	5.82	0.35	1.82e-8	Obesity-related traits;
KIRP	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.73	11.56	0.59	5.8e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.12	0.41	1.16e-11	Neuroticism;
KIRP	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg10645314	chr2:3704589	ALLC	-1.12	-12.33	-0.62	1.67e-27	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.84	-11.26	-0.58	5.2e-24	Prostate cancer;
KIRP	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.57	8.0	0.45	4.79e-14	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.57	-11.85	-0.6	6.49e-26	Diabetic kidney disease;
KIRP	cis	rs62012628	0.527	rs12437868	chr15:79088460	T/C	cg00639195	chr15:79103007	ADAMTS7	0.41	4.85	0.3	2.24e-6	Diastolic blood pressure;
KIRP	trans	rs10874322	1.000	rs9729834	chr1:83039338	C/T	cg12753787	chr1:3239712	PRDM16	0.55	6.14	0.36	3.37e-9	Response to taxane treatment (docetaxel);
KIRP	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.55	7.59	0.44	6.62e-13	Blood metabolite levels;
KIRP	cis	rs2230307	0.656	rs6699449	chr1:100542638	G/A	cg24955406	chr1:100503596	HIAT1	0.59	5.59	0.34	6.05e-8	Carotid intima media thickness;
KIRP	cis	rs11760633	0.672	rs7811019	chr7:1843541	C/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-4.88	-0.3	1.94e-6	Coronary artery disease;
KIRP	trans	rs9409565	0.826	rs639276	chr9:97206737	G/T	cg05679027	chr9:99775184	HIATL2	-0.56	-6.71	-0.39	1.33e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs4356932	1.000	rs6845396	chr4:76951550	G/T	cg00809888	chr4:76862425	NAAA	-0.45	-6.32	-0.37	1.2e-9	Blood protein levels;
KIRP	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg04727924	chr7:799746	HEATR2	-0.75	-8.53	-0.48	1.5e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.18	-0.46	1.54e-14	Aortic root size;
KIRP	trans	rs3779273	0.776	rs1969441	chr7:77835255	G/T	cg05596911	chr5:118502651	DMXL1	-0.44	-7.22	-0.42	6.63e-12	Body mass index;
KIRP	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg06115741	chr20:33292138	TP53INP2	-0.41	-5.54	-0.33	7.7e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg26855724	chr1:75198818	TYW3;CRYZ	-0.43	-4.91	-0.3	1.64e-6	Resistin levels;
KIRP	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.56	-7.77	-0.44	2.15e-13	Motion sickness;
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg06871246	chr4:1363661	KIAA1530	-0.55	-6.88	-0.4	4.97e-11	Longevity;
KIRP	cis	rs12643440	0.502	rs56163730	chr4:17143120	A/G	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2671245	0.933	rs2671234	chr1:56166119	C/T	cg11523071	chr1:56160889	NA	0.42	6.91	0.4	4.11e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs920590	0.643	rs2083641	chr8:19660217	A/C	cg03894339	chr8:19674705	INTS10	0.41	4.95	0.3	1.39e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-4.85	-0.3	2.17e-6	Bone mineral density;
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.41	5.35	0.32	2e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg03388025	chr16:89894329	SPIRE2	0.44	9.3	0.51	8.16e-18	Vitiligo;
KIRP	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.92	12.75	0.63	6.22e-29	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.1	0.5	3.22e-17	Lung cancer in ever smokers;
KIRP	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.52	-0.33	8.38e-8	Obesity-related traits;
KIRP	trans	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg16141378	chr3:129829833	LOC729375	0.52	6.49	0.38	4.72e-10	Mood instability;
KIRP	cis	rs732716	0.785	rs11667543	chr19:4374850	C/T	cg21720385	chr19:4455239	UBXN6	0.7	8.36	0.47	4.57e-15	Mean corpuscular volume;
KIRP	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.36e-16	Prudent dietary pattern;
KIRP	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.58	7.74	0.44	2.56e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg00495681	chr13:53174319	NA	0.37	5.11	0.31	6.43e-7	Lewy body disease;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.84	8.0	0.45	4.78e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs33912345	0.695	rs1254259	chr14:60833271	C/T	cg27398547	chr14:60952738	C14orf39	-0.42	-5.63	-0.34	4.9e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.42	-6.08	-0.36	4.61e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg11642891	chr2:3452563	TTC15	-0.54	-6.92	-0.4	3.84e-11	Obesity-related traits;
KIRP	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg06585982	chr3:143692056	C3orf58	0.58	7.36	0.42	2.77e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.57	-8.87	-0.49	1.54e-16	Huntington's disease progression;
KIRP	cis	rs7538876	1.000	rs7538876	chr1:17722363	G/A	cg07965774	chr1:17746286	RCC2	0.28	4.9	0.3	1.71e-6	Basal cell carcinoma;
KIRP	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg00405596	chr8:11794950	NA	-0.47	-5.77	-0.35	2.38e-8	Retinal vascular caliber;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg06654118	chr4:1303317	MAEA	0.28	5.22	0.32	3.83e-7	Obesity-related traits;
KIRP	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.31	-0.37	1.29e-9	Recombination measurement;
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg21851534	chr17:3907994	ZZEF1	0.49	6.37	0.38	9.13e-10	Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.73	10.09	0.54	3.03e-20	Schizophrenia;
KIRP	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.96	0.3	1.3e-6	Rheumatoid arthritis;
KIRP	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg12315302	chr6:26189340	HIST1H4D	0.69	5.45	0.33	1.22e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs7246657	0.722	rs10417576	chr19:38119212	A/C	cg23950597	chr19:37808831	NA	-0.61	-6.53	-0.38	3.7e-10	Coronary artery calcification;
KIRP	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.83	-6.72	-0.39	1.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg09344028	chr17:70110421	NA	0.4	7.85	0.45	1.24e-13	Thyroid hormone levels;
KIRP	cis	rs4971059	0.617	rs12025371	chr1:155119327	A/T	cg02153340	chr1:155202674	NA	-0.42	-6.06	-0.36	5.21e-9	Breast cancer;
KIRP	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg05991184	chr2:219186017	PNKD	-0.36	-5.08	-0.31	7.4e-7	Colorectal cancer;
KIRP	cis	rs11264213	0.551	rs172081	chr1:36497498	T/G	cg27506609	chr1:36549197	TEKT2	1.16	7.64	0.44	4.72e-13	Schizophrenia;
KIRP	cis	rs8077577	0.945	rs11655731	chr17:18107525	G/T	cg18869244	chr17:18121946	NA	0.49	5.22	0.32	3.8e-7	Obesity-related traits;
KIRP	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg21419209	chr3:44054225	NA	-0.74	-8.97	-0.5	7.52e-17	Coronary artery disease;
KIRP	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	14.73	0.68	1.28e-35	Smoking behavior;
KIRP	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg18882449	chr10:104885122	NT5C2	-0.52	-6.74	-0.39	1.12e-10	Arsenic metabolism;
KIRP	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg19875578	chr6:126661172	C6orf173	-0.51	-6.78	-0.4	8.89e-11	Male-pattern baldness;
KIRP	cis	rs7246657	0.678	rs4802024	chr19:38052193	T/C	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg21858823	chr1:15850916	CASP9	0.54	5.7	0.34	3.36e-8	Systolic blood pressure;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg11859384	chr17:80120422	CCDC57	0.47	5.83	0.35	1.76e-8	Life satisfaction;
KIRP	cis	rs2273669	0.915	rs6651002	chr6:109318516	G/C	cg05315195	chr6:109294784	ARMC2	-0.48	-5.49	-0.33	9.92e-8	Prostate cancer;
KIRP	cis	rs9475752	0.793	rs35735810	chr6:56843715	C/T	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18357526	chr6:26021779	HIST1H4A	0.55	7.38	0.43	2.4e-12	Height;
KIRP	cis	rs12643440	0.538	rs2314602	chr4:17144535	A/G	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	1.11	7.89	0.45	9.87e-14	Skin colour saturation;
KIRP	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg20140201	chr2:241835670	C2orf54	-0.35	-5.35	-0.32	2.04e-7	Urinary metabolites;
KIRP	cis	rs2916247	1.000	rs2920464	chr8:92987753	C/T	cg10183463	chr8:93005414	RUNX1T1	0.56	6.96	0.41	3.11e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14296446	chr14:74683524	NA	0.5	6.8	0.4	7.89e-11	Interleukin-4 levels;
KIRP	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.73	9.28	0.51	8.82e-18	Mean platelet volume;
KIRP	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	0.83	9.64	0.52	7.17e-19	Gut microbiome composition (summer);
KIRP	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03576123	chr11:487126	PTDSS2	-1.02	-8.36	-0.47	4.55e-15	Body mass index;
KIRP	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.94	15.51	0.7	2.56e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	ch.11.29638519R	chr11:29681943	NA	-0.44	-6.02	-0.36	6.3e-9	Obesity-related traits;
KIRP	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.51	6.65	0.39	1.92e-10	HDL cholesterol levels;
KIRP	cis	rs7005380	0.581	rs12677306	chr8:120916082	G/C	cg21645572	chr8:120931649	DEPDC6	0.48	6.75	0.4	1.08e-10	Interstitial lung disease;
KIRP	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs367615	0.918	rs115145487	chr5:108888146	A/G	cg17395555	chr5:108820864	NA	0.56	5.92	0.35	1.07e-8	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6547741	0.563	rs10196039	chr2:27971195	C/T	cg27432699	chr2:27873401	GPN1	-0.78	-12.39	-0.62	1.04e-27	Oral cavity cancer;
KIRP	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.96	15.81	0.71	2.41e-39	Diastolic blood pressure;
KIRP	cis	rs10128264	0.902	rs942797	chr10:80986432	C/T	cg18737081	chr10:80999807	ZMIZ1	-0.32	-5.89	-0.35	1.23e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.96	14.73	0.68	1.28e-35	Coronary artery disease;
KIRP	cis	rs7180079	0.620	rs2733382	chr15:64856394	A/G	cg15337035	chr15:64978493	NA	0.46	5.08	0.31	7.58e-7	Monocyte count;
KIRP	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.03	-0.31	9.54e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.5	0.38	4.47e-10	Personality dimensions;
KIRP	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.5	6.91	0.4	4.23e-11	Mean corpuscular volume;
KIRP	cis	rs17401966	0.540	rs6541094	chr1:10467074	G/A	cg17425144	chr1:10567563	PEX14	-0.31	-5.25	-0.32	3.23e-7	Hepatocellular carcinoma;
KIRP	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg08131204	chr22:41487073	MIR1281	-0.42	-4.85	-0.3	2.19e-6	Neuroticism;
KIRP	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg22875332	chr1:76189707	ACADM	0.59	7.65	0.44	4.56e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.41	-0.47	3.34e-15	Colorectal cancer;
KIRP	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.78	5.68	0.34	3.72e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg01427869	chr13:113580562	NA	-0.51	-6.63	-0.39	2.17e-10	Inflammatory biomarkers;
KIRP	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg09904177	chr6:26538194	HMGN4	0.45	6.04	0.36	5.71e-9	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19092999	chr3:113415735	KIAA2018	-0.49	-7.0	-0.41	2.48e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	15.83	0.71	2.11e-39	Homoarginine levels;
KIRP	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg18833306	chr6:118973337	C6orf204	0.42	5.32	0.32	2.39e-7	Electrocardiographic conduction measures;
KIRP	cis	rs10875746	0.551	rs11168536	chr12:48745051	C/T	cg26205652	chr12:48591994	NA	0.79	10.0	0.54	5.46e-20	Longevity (90 years and older);
KIRP	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.21	0.37	2.21e-9	Ovarian reserve;
KIRP	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.3	0.37	1.37e-9	Mean platelet volume;
KIRP	cis	rs7852872	0.812	rs1876475	chr9:119253472	A/T	cg13792444	chr9:119245443	ASTN2	-0.43	-6.53	-0.38	3.71e-10	Hippocampal volume;
KIRP	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.69	-8.27	-0.47	8.49e-15	Obesity-related traits;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg22081084	chr1:89990230	LRRC8B	0.53	6.27	0.37	1.64e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9888739	0.800	rs7193268	chr16:31340997	A/G	cg02846316	chr16:31340340	ITGAM	0.43	4.85	0.3	2.16e-6	Systemic lupus erythematosus;
KIRP	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg21452805	chr1:244014465	NA	0.65	5.55	0.33	7.36e-8	RR interval (heart rate);
KIRP	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg18441811	chr11:71824068	C11orf51	-0.65	-5.31	-0.32	2.49e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.15	-0.46	1.84e-14	Triglycerides;
KIRP	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.56	-6.56	-0.39	3.23e-10	HDL cholesterol;
KIRP	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg16386425	chr10:429943	DIP2C	0.39	5.15	0.31	5.45e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.38	-5.72	-0.34	3.02e-8	Body mass index;
KIRP	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg18135206	chr14:102964638	TECPR2	-0.43	-5.11	-0.31	6.32e-7	Plateletcrit;
KIRP	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-5.96	-0.36	8.47e-9	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06666157	chr19:4791552	FEM1A	0.59	6.84	0.4	6.37e-11	Smoking initiation;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg27532560	chr4:187881888	NA	-0.73	-12.26	-0.62	2.7e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16828019	0.852	rs12729448	chr1:41509834	G/A	cg03387723	chr1:41708464	SCMH1	-0.78	-6.48	-0.38	5.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2072732	0.768	rs12045368	chr1:2960192	A/G	cg11731671	chr1:2995604	PRDM16	-0.52	-5.96	-0.36	8.66e-9	Plateletcrit;
KIRP	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-1.15	-20.39	-0.79	9.16e-55	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg24565620	chr2:194026	NA	0.72	7.71	0.44	3.05e-13	Blood protein levels;
KIRP	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.03	0.41	1.98e-11	Mean platelet volume;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.73	6.48	0.38	4.92e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9644630	0.862	rs7830404	chr8:19357346	A/T	cg01280390	chr8:19363452	CSGALNACT1	-0.41	-5.54	-0.33	7.57e-8	Oropharynx cancer;
KIRP	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg24130564	chr14:104152367	KLC1	-0.57	-7.94	-0.45	7.28e-14	Body mass index;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg24874828	chr4:187887005	NA	-0.48	-7.2	-0.42	7.39e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg16141378	chr3:129829833	LOC729375	0.47	6.18	0.37	2.6e-9	Triglycerides;
KIRP	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg26205652	chr12:48591994	NA	-0.78	-10.61	-0.56	6.77e-22	Longevity (90 years and older);
KIRP	cis	rs7551222	0.646	rs7556371	chr1:204457336	A/G	cg20240347	chr1:204465584	NA	0.44	7.96	0.45	6.41e-14	Schizophrenia;
KIRP	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Bladder cancer;
KIRP	cis	rs7903847	0.642	rs1537645	chr10:99149914	T/C	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.83	12.01	0.61	1.81e-26	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs57590327	0.528	rs7642112	chr3:81674927	C/T	cg07356753	chr3:81810745	GBE1	-0.69	-8.49	-0.48	1.96e-15	Extraversion;
KIRP	cis	rs11924390	0.800	rs5030059	chr3:186452455	C/G	cg12454167	chr3:186435060	KNG1	0.5	8.49	0.48	2.03e-15	Adiponectin levels;
KIRP	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.24	0.42	5.6e-12	Aortic root size;
KIRP	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	0.95	12.13	0.61	7.65e-27	Blood protein levels;
KIRP	cis	rs904251	0.647	rs2776908	chr6:37434857	T/C	cg01843034	chr6:37503916	NA	-0.61	-6.2	-0.37	2.38e-9	Cognitive performance;
KIRP	cis	rs3126085	0.560	rs12403031	chr1:152343394	T/C	cg26876637	chr1:152193138	HRNR	-0.73	-6.93	-0.4	3.73e-11	Atopic dermatitis;
KIRP	cis	rs6681460	0.866	rs996123	chr1:67025343	T/C	cg13052034	chr1:66999238	SGIP1	0.43	5.96	0.36	8.79e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs10518128	1.000	rs72867594	chr4:75706808	T/C	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.99	14.33	0.67	2.86e-34	Cognitive function;
KIRP	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg11941060	chr3:133502564	NA	-0.52	-6.28	-0.37	1.49e-9	Iron status biomarkers;
KIRP	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.77	7.19	0.42	7.87e-12	Mean platelet volume;
KIRP	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg21546286	chr11:48923668	NA	-0.48	-6.17	-0.37	2.75e-9	HDL cholesterol;
KIRP	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.92	12.57	0.63	2.49e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.42	4.85	0.3	2.15e-6	Menopause (age at onset);
KIRP	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs714515	0.934	rs2213732	chr1:172333595	G/A	cg01573306	chr1:172330400	DNM3	0.45	5.78	0.35	2.28e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06620762	chr15:76136437	UBE2Q2	0.73	6.28	0.37	1.52e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg27490568	chr2:178487706	NA	-0.47	-6.28	-0.37	1.55e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4073221	0.585	rs34630061	chr3:18318863	T/G	cg07694806	chr3:18168406	NA	-0.68	-6.03	-0.36	6e-9	Parkinson's disease;
KIRP	cis	rs2862064	0.932	rs1553316	chr5:156479509	A/G	cg12943317	chr5:156479607	HAVCR1	-0.82	-7.57	-0.43	7.39e-13	Platelet count;
KIRP	cis	rs35883536	1.000	rs1577508	chr1:101089289	T/C	cg06223162	chr1:101003688	GPR88	0.32	6.48	0.38	5e-10	Monocyte count;
KIRP	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.76	8.09	0.46	2.68e-14	QRS complex (12-leadsum);
KIRP	cis	rs4671458	0.689	rs114780236	chr2:63789049	G/A	cg17519650	chr2:63277830	OTX1	-0.49	-5.0	-0.3	1.07e-6	Subjective well-being;
KIRP	cis	rs35740288	0.770	rs75039806	chr15:86105044	C/T	cg10818794	chr15:86012489	AKAP13	-0.46	-5.49	-0.33	9.78e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.67	-9.49	-0.52	2.13e-18	Colorectal cancer;
KIRP	cis	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg21546286	chr11:48923668	NA	-0.48	-6.12	-0.36	3.74e-9	HDL cholesterol;
KIRP	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg01864069	chr14:103024347	NA	-0.96	-12.79	-0.63	4.59e-29	Platelet count;
KIRP	cis	rs35740288	0.770	rs67253156	chr15:86105045	A/G	cg17133734	chr15:86042851	AKAP13	-0.43	-5.0	-0.3	1.08e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.55	6.99	0.41	2.51e-11	Coronary heart disease;
KIRP	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg23188430	chr6:125850052	NA	-0.33	-5.03	-0.31	9.56e-7	High light scatter reticulocyte count;
KIRP	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.32	0.51	6.99e-18	Height;
KIRP	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg07810366	chr2:100720526	AFF3	0.34	6.34	0.37	1.11e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.49	-6.51	-0.38	4.22e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25517755	chr10:38738941	LOC399744	-0.37	-5.01	-0.3	1.05e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.75	-9.61	-0.52	8.78e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg21466736	chr12:48725269	NA	-0.46	-5.76	-0.34	2.56e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg18016565	chr1:150552671	MCL1	0.41	6.1	0.36	3.98e-9	Tonsillectomy;
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.36	0.65	5.42e-31	Platelet count;
KIRP	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg12131826	chr15:77904385	NA	0.46	6.19	0.37	2.57e-9	Type 2 diabetes;
KIRP	cis	rs2084898	0.527	rs561498	chr11:120002927	C/T	cg07435449	chr11:120005650	TRIM29	0.51	6.57	0.39	2.98e-10	Stroke (pediatric);
KIRP	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.39	0.59	2.07e-24	Alzheimer's disease;
KIRP	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.91	10.72	0.56	2.92e-22	Eosinophil percentage of granulocytes;
KIRP	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2299587	0.554	rs7815429	chr8:17737357	T/C	cg01800426	chr8:17659068	MTUS1	-0.42	-5.16	-0.31	4.99e-7	Economic and political preferences;
KIRP	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21659725	chr3:3221576	CRBN	-0.58	-6.97	-0.41	2.88e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7017914	0.934	rs78923624	chr8:71677839	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.38e-7	Bone mineral density;
KIRP	cis	rs6088813	1.000	rs6087703	chr20:33996433	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-6.83	-0.4	6.58e-11	Height;
KIRP	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg01557791	chr16:72042693	DHODH	-0.43	-5.28	-0.32	2.83e-7	Fibrinogen levels;
KIRP	cis	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg06521331	chr12:34319734	NA	-0.43	-5.5	-0.33	9.38e-8	Morning vs. evening chronotype;
KIRP	cis	rs7538876	1.000	rs942457	chr1:17739586	G/A	cg07965774	chr1:17746286	RCC2	0.28	4.87	0.3	2.02e-6	Basal cell carcinoma;
KIRP	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg13679303	chr9:96623674	NA	0.47	6.09	0.36	4.42e-9	DNA methylation (variation);
KIRP	cis	rs7011507	1.000	rs78483123	chr8:49173503	G/A	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2191566	0.960	rs7255315	chr19:44510933	A/T	cg18700516	chr19:44507157	ZNF230	-0.48	-5.56	-0.33	7.09e-8	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23817347	chr20:49126808	PTPN1	0.49	6.31	0.37	1.26e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg18350739	chr11:68623251	NA	-0.5	-7.36	-0.42	2.73e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg09699651	chr6:150184138	LRP11	0.46	5.95	0.35	9.22e-9	Lung cancer;
KIRP	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.61	7.8	0.45	1.81e-13	Menopause (age at onset);
KIRP	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.67	6.77	0.4	9.24e-11	Vitiligo;
KIRP	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs6669919	0.553	rs1122745	chr1:211663261	C/T	cg10512769	chr1:211675356	NA	-0.51	-6.53	-0.38	3.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.04	-0.31	8.87e-7	Coronary artery disease;
KIRP	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg18944383	chr4:111397179	ENPEP	0.51	8.51	0.48	1.7e-15	Coronary artery disease;
KIRP	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.49	-0.33	9.78e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4984778	0.717	rs2738892	chr16:1268758	A/G	cg01744552	chr16:1261315	CACNA1H	0.38	4.89	0.3	1.82e-6	Blood protein levels;
KIRP	cis	rs897080	0.515	rs1067398	chr2:44678882	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.97	0.36	8.42e-9	Height;
KIRP	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.28	6.42	0.38	6.85e-10	Mean corpuscular volume;
KIRP	cis	rs12220238	0.822	rs10824193	chr10:76261759	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.37	0.38	9.48e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.74	0.34	2.76e-8	Educational attainment;
KIRP	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.22	24.12	0.84	9.46e-67	Exhaled nitric oxide output;
KIRP	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.61	5.51	0.33	9.02e-8	Major depressive disorder;
KIRP	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg22535103	chr8:58192502	C8orf71	-0.72	-7.26	-0.42	5.12e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.31	-7.82	-0.45	1.58e-13	Primary biliary cholangitis;
KIRP	cis	rs2425143	1.000	rs11696369	chr20:34378629	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-5.73	-0.34	2.95e-8	Blood protein levels;
KIRP	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.68	7.96	0.45	6.24e-14	Schizophrenia;
KIRP	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg06223162	chr1:101003688	GPR88	-0.42	-8.65	-0.48	6.73e-16	Monocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01243246	chr11:124823843	CCDC15	0.42	6.18	0.37	2.59e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	0.9	14.06	0.67	2.36e-33	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.69	9.8	0.53	2.34e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs17209837	1.000	rs67721532	chr7:87084403	A/G	cg00919237	chr7:87102261	ABCB4	-0.75	-7.28	-0.42	4.49e-12	Gallbladder cancer;
KIRP	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg00405596	chr8:11794950	NA	0.46	5.81	0.35	1.88e-8	Monocyte count;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg14271438	chr4:119757241	SEC24D	-0.48	-6.18	-0.37	2.67e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.42	6.19	0.37	2.53e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9535307	0.522	rs9596200	chr13:50416370	G/A	cg04663916	chr13:50265991	EBPL	-0.6	-5.94	-0.35	9.51e-9	Obesity-related traits;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4363385	0.509	rs11576882	chr1:152918785	T/G	cg07796016	chr1:152779584	LCE1C	-0.46	-5.82	-0.35	1.87e-8	Inflammatory skin disease;
KIRP	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-9.25	-0.51	1.16e-17	Red cell distribution width;
KIRP	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.67	-7.25	-0.42	5.39e-12	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.57	-7.49	-0.43	1.22e-12	Aortic root size;
KIRP	cis	rs7520050	0.966	rs7550746	chr1:46351719	T/A	cg03146154	chr1:46216737	IPP	-0.42	-5.31	-0.32	2.49e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7394190	0.748	rs2242254	chr10:75585307	G/A	cg04833713	chr10:74871078	NUDT13	0.45	4.98	0.3	1.23e-6	Incident atrial fibrillation;
KIRP	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26002218	chr14:103986227	CKB	0.28	5.71	0.34	3.26e-8	Body mass index;
KIRP	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.64	0.44	4.87e-13	Depressive symptoms;
KIRP	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg04013166	chr16:89971882	TCF25	0.58	6.08	0.36	4.56e-9	Skin colour saturation;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg04025307	chr7:1156635	C7orf50	0.68	7.39	0.43	2.25e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7939886	0.920	rs7946368	chr11:55804219	C/T	cg03929089	chr4:120376271	NA	0.95	7.05	0.41	1.75e-11	Myopia (pathological);
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	7.62	0.44	5.41e-13	Height;
KIRP	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg13206674	chr6:150067644	NUP43	0.52	7.4	0.43	2.22e-12	Testicular germ cell tumor;
KIRP	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.56	-0.33	7.11e-8	Neuroticism;
KIRP	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.39	-5.05	-0.31	8.51e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg18350739	chr11:68623251	NA	-0.48	-7.65	-0.44	4.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg07395648	chr5:131743802	NA	-0.55	-7.76	-0.44	2.33e-13	Breast cancer;
KIRP	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg07636037	chr3:49044803	WDR6	-0.75	-7.32	-0.42	3.6e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.12	0.41	1.19e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	6.01	0.36	6.75e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.93	14.68	0.68	1.81e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1355223	0.902	rs35032224	chr11:34698154	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-4.95	-0.3	1.41e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12580194	0.593	rs61956272	chr12:55779559	A/T	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-9.02	-0.5	5.35e-17	Schizophrenia;
KIRP	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.8	8.26	0.47	9.15e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.45	5.72	0.34	3.01e-8	Depressive symptoms;
KIRP	cis	rs7923609	1.000	rs4595427	chr10:65012944	A/C	cg01631684	chr10:65280961	REEP3	-0.48	-5.66	-0.34	4.21e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03938800	chr1:168029713	DCAF6	-0.48	-7.62	-0.44	5.34e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-0.61	-6.81	-0.4	7.46e-11	Initial pursuit acceleration;
KIRP	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.58	-7.37	-0.43	2.65e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.53	-6.36	-0.38	9.71e-10	Menopause (age at onset);
KIRP	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.45	-0.43	1.57e-12	Blood pressure;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03647317	chr4:187891568	NA	-0.78	-13.1	-0.64	4.28e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.99	-0.5	6.64e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	1.22	7.15	0.41	9.9e-12	LDL cholesterol;
KIRP	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg00204512	chr16:28754710	NA	0.44	5.71	0.34	3.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14987002	chr4:151496830	LRBA	-0.39	-6.31	-0.37	1.31e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.41	-0.38	7.53e-10	Body mass index;
KIRP	cis	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg02972257	chr16:68554789	NA	-0.58	-5.71	-0.34	3.25e-8	Ulcerative colitis;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11697258	chr17:61919381	SMARCD2	0.55	6.26	0.37	1.72e-9	Lung cancer in ever smokers;
KIRP	cis	rs11955175	1.000	rs11955175	chr5:40626753	C/T	cg17351974	chr5:40835760	RPL37	-0.57	-5.23	-0.32	3.55e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.25	-5.38	-0.32	1.73e-7	Menarche (age at onset);
KIRP	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg10381502	chr11:71823885	C11orf51	1.07	7.37	0.43	2.62e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg18836844	chr8:998428	NA	0.38	4.86	0.3	2.05e-6	Schizophrenia;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg01721255	chr8:58191610	C8orf71	0.64	5.58	0.34	6.39e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4740619	0.682	rs10738422	chr9:15998987	C/G	cg14451791	chr9:16040625	NA	-0.38	-4.85	-0.3	2.2e-6	Body mass index;
KIRP	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg18225595	chr11:63971243	STIP1	-0.63	-5.38	-0.32	1.75e-7	Mean platelet volume;
KIRP	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.87	-12.28	-0.62	2.38e-27	Coronary artery disease;
KIRP	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.78	0.44	2.06e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg11598736	chr3:195384522	SDHAP2	-0.62	-5.56	-0.33	6.9e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg02996583	chr8:142237188	SLC45A4	-0.49	-6.03	-0.36	6.13e-9	Immature fraction of reticulocytes;
KIRP	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.86	-11.32	-0.59	3.57e-24	Cognitive function;
KIRP	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.8	10.92	0.57	6.9e-23	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13198984	chr17:80129470	CCDC57	-0.51	-7.56	-0.43	7.95e-13	Life satisfaction;
KIRP	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.6	6.89	0.4	4.6e-11	Height;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg18234130	chr8:27182889	PTK2B	0.56	7.21	0.42	6.91e-12	Neuroticism;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.8	-0.35	1.98e-8	Obesity-related traits;
KIRP	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.4	-5.0	-0.3	1.1e-6	Aortic root size;
KIRP	cis	rs9426935	0.604	rs2790686	chr1:154024652	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.35	-5.19	-0.31	4.36e-7	Lentiform nucleus volume;
KIRP	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg16141378	chr3:129829833	LOC729375	-0.52	-6.64	-0.39	1.97e-10	Retinal vascular caliber;
KIRP	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg02175503	chr12:58329896	NA	0.49	5.22	0.32	3.76e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-1.01	-16.87	-0.73	5.9e-43	Height;
KIRP	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs1800469	1.000	rs2241715	chr19:41856886	A/C	cg09537434	chr19:41945824	ATP5SL	-0.54	-6.01	-0.36	6.65e-9	Colorectal cancer;
KIRP	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.67e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg07460842	chr6:66804631	NA	-0.49	-6.14	-0.36	3.34e-9	Blood trace element (Cu levels);
KIRP	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg12046867	chr14:103022105	NA	-0.51	-6.14	-0.36	3.33e-9	Platelet count;
KIRP	cis	rs7523050	0.643	rs67567504	chr1:109402580	C/A	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs4262150	0.883	rs72802853	chr5:152218058	C/T	cg12297329	chr5:152029980	NA	-0.61	-8.07	-0.46	3.11e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs9371601	0.859	rs20585	chr6:152714446	C/A	cg05529123	chr2:66910386	NA	-0.46	-6.23	-0.37	2.02e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.38	-0.38	8.58e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg12560992	chr17:57184187	TRIM37	0.59	5.24	0.32	3.47e-7	Cognitive test performance;
KIRP	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg25019722	chr6:37503610	NA	-0.98	-14.95	-0.69	2.13e-36	Cognitive performance;
KIRP	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.08	-0.41	1.47e-11	Type 2 diabetes;
KIRP	cis	rs4302748	0.862	rs58221920	chr7:36181963	C/A	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	trans	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg06521331	chr12:34319734	NA	-0.53	-6.58	-0.39	2.75e-10	Heart rate;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07402062	chr16:89894098	SPIRE2	0.33	6.9	0.4	4.34e-11	Vitiligo;
KIRP	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg19554555	chr3:13937349	NA	-0.45	-6.25	-0.37	1.83e-9	Ovarian reserve;
KIRP	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg26874164	chr19:58962979	ZNF324B	0.48	5.79	0.35	2.19e-8	Uric acid clearance;
KIRP	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg03684893	chr10:554711	DIP2C	-0.52	-7.89	-0.45	9.91e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-1.26	-13.74	-0.66	2.97e-32	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.66	8.62	0.48	8.3e-16	Cognitive function;
KIRP	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg20493526	chr2:3714936	ALLC	0.46	5.9	0.35	1.18e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.56	9.02	0.5	5.55e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.54	7.94	0.45	7.33e-14	Major depressive disorder;
KIRP	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.66	7.76	0.44	2.24e-13	Alcohol dependence;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12072333	chr7:134896347	WDR91	-0.47	-6.42	-0.38	7.09e-10	Metabolic traits;
KIRP	cis	rs16828019	0.852	rs12048187	chr1:41616183	A/G	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs13102973	0.965	rs28826933	chr4:135876644	T/A	cg14419869	chr4:135874104	NA	-0.62	-11.12	-0.58	1.57e-23	Subjective well-being;
KIRP	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.43	7.54	0.43	9.11e-13	Renal cell carcinoma;
KIRP	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.59	-7.44	-0.43	1.7e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.71	9.95	0.54	8.1e-20	Mean corpuscular volume;
KIRP	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.81	7.29	0.42	4.17e-12	Obesity-related traits;
KIRP	cis	rs8067545	0.532	rs35915823	chr17:19973397	A/G	cg13482628	chr17:19912719	NA	0.47	5.34	0.32	2.11e-7	Schizophrenia;
KIRP	cis	rs10214930	0.697	rs12700817	chr7:27591093	C/T	cg22168087	chr7:27702803	HIBADH	0.47	5.02	0.3	1.01e-6	Hypospadias;
KIRP	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg26531700	chr6:26746687	NA	0.51	7.23	0.42	5.92e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-6.66	-0.39	1.77e-10	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg23594656	chr7:65796392	TPST1	0.35	5.02	0.3	9.85e-7	Aortic root size;
KIRP	cis	rs2019216	0.521	rs12449447	chr17:21888786	C/T	cg22648282	chr17:21454238	C17orf51	-0.52	-6.56	-0.39	3.16e-10	Pelvic organ prolapse;
KIRP	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg25173405	chr17:45401733	C17orf57	0.49	6.35	0.38	1e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs13315871	0.615	rs7618604	chr3:58357785	G/A	cg12435725	chr3:58293450	RPP14	-0.36	-5.0	-0.3	1.07e-6	Cholesterol, total;
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.42	5.22	0.32	3.83e-7	Longevity;
KIRP	cis	rs865483	0.895	rs7501983	chr17:35783812	A/G	cg06716730	chr17:35851459	DUSP14	-0.25	-5.99	-0.36	7.52e-9	Monocyte count;
KIRP	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg05669848	chr5:237993	SDHA	-0.5	-5.17	-0.31	4.74e-7	Breast cancer;
KIRP	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg04080417	chr5:1859792	NA	-0.55	-6.08	-0.36	4.55e-9	Cardiovascular disease risk factors;
KIRP	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg01864069	chr14:103024347	NA	-0.85	-10.14	-0.54	2.1e-20	Platelet count;
KIRP	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg15128208	chr22:42549153	NA	0.74	8.05	0.46	3.49e-14	Birth weight;
KIRP	trans	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.25	7.23	0.42	6.18e-12	Type 2 diabetes;
KIRP	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	18.93	0.77	6.56e-50	Height;
KIRP	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.79	-9.3	-0.51	8.14e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg22029157	chr1:209979665	IRF6	0.43	6.68	0.39	1.58e-10	Monobrow;
KIRP	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg03714773	chr7:91764589	CYP51A1	0.39	5.59	0.34	5.95e-8	Breast cancer;
KIRP	trans	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00950418	chr7:105029125	SRPK2	-0.52	-6.3	-0.37	1.34e-9	Height;
KIRP	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs11161851	0.901	rs61791269	chr1:75316945	A/G	cg11196437	chr1:75593865	LHX8	-0.39	-5.65	-0.34	4.53e-8	Visceral fat;
KIRP	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg07317062	chr7:27170388	HOXA4	-0.37	-5.21	-0.32	4.05e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.47	0.47	2.32e-15	Prudent dietary pattern;
KIRP	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.66	-7.3	-0.42	3.96e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.92	13.39	0.65	4.6e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs75920871	0.925	rs61903418	chr11:116956665	G/A	cg23684410	chr11:116897558	SIK3	0.52	5.21	0.32	3.94e-7	Subjective well-being;
KIRP	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.66	0.39	1.81e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11645453	chr3:52864694	ITIH4	0.33	5.11	0.31	6.61e-7	Body mass index;
KIRP	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.95	-14.47	-0.68	9.64e-35	Height;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg02462569	chr6:150064036	NUP43	-0.42	-6.48	-0.38	4.95e-10	Lung cancer;
KIRP	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.14	-0.31	5.62e-7	Bipolar disorder;
KIRP	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.16	-11.09	-0.58	1.88e-23	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.44	-0.43	1.67e-12	Triglycerides;
KIRP	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs4460629	0.742	rs11264314	chr1:155078423	C/G	cg02153340	chr1:155202674	NA	-0.35	-5.03	-0.31	9.59e-7	Serum magnesium levels;
KIRP	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.7	10.72	0.56	3.09e-22	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg10167378	chr1:228756711	NA	0.88	7.37	0.43	2.57e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs35883536	1.000	rs12410168	chr1:101115321	G/A	cg06223162	chr1:101003688	GPR88	0.34	7.01	0.41	2.28e-11	Monocyte count;
KIRP	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.61	8.15	0.46	1.8e-14	Total body bone mineral density;
KIRP	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.72	7.75	0.44	2.44e-13	Gut microbiome composition (summer);
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg20578329	chr17:80767326	TBCD	-0.47	-5.61	-0.34	5.55e-8	Glycated hemoglobin levels;
KIRP	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg19338460	chr6:170058176	WDR27	-0.67	-7.98	-0.45	5.44e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.43	-6.16	-0.37	2.95e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs6504622	0.905	rs197926	chr17:45012087	A/G	cg24703533	chr17:45055318	NA	0.37	5.35	0.32	1.96e-7	Orofacial clefts;
KIRP	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg20587970	chr11:113659929	NA	-1.28	-9.1	-0.5	3.14e-17	Height;
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.47	-0.48	2.28e-15	Total cholesterol levels;
KIRP	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.42	-6.22	-0.37	2.07e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg07827796	chr19:33622959	WDR88	0.41	4.96	0.3	1.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg24011408	chr12:48396354	COL2A1	-0.39	-5.34	-0.32	2.08e-7	Plateletcrit;
KIRP	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.59	-7.31	-0.42	3.8e-12	Extraversion;
KIRP	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg00129232	chr17:37814104	STARD3	0.72	10.26	0.55	8.71e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.89	12.33	0.62	1.67e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.74	-0.44	2.6e-13	Neuroticism;
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg17457637	chr7:27170717	HOXA4	-0.35	-5.19	-0.31	4.47e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7973719	1.000	rs1839622	chr12:7334534	G/C	cg07052231	chr12:7363540	PEX5	0.4	5.16	0.31	4.98e-7	IgG glycosylation;
KIRP	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg04935436	chr20:30431758	NA	0.5	6.56	0.39	3.09e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-8.13	-0.46	2.17e-14	Platelet count;
KIRP	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg23995753	chr2:160760732	LY75	-0.4	-5.4	-0.33	1.61e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs34057264	1	rs34057264	chr8:23372787	T/TTTTG	cg08322043	chr8:23340750	NA	-0.57	-5.35	-0.32	1.98e-7	Mean corpuscular hemoglobin;Hemoglobin concentration;
KIRP	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.39e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg19554555	chr3:13937349	NA	-0.53	-7.67	-0.44	4.12e-13	Ovarian reserve;
KIRP	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.71	8.32	0.47	6.04e-15	Red cell distribution width;
KIRP	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg25801113	chr15:45476975	SHF	0.42	7.7	0.44	3.29e-13	Uric acid levels;
KIRP	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.16	18.83	0.77	1.38e-49	Cognitive function;
KIRP	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.97	-0.3	1.25e-6	Cognitive function;
KIRP	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg03854865	chr6:26224070	HIST1H3E	0.62	4.85	0.3	2.16e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs10486003	1.000	rs6946227	chr7:97196765	C/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.63	-5.35	-0.32	1.97e-7	Response to platinum-based agents;
KIRP	cis	rs2901656	0.677	rs10752957	chr1:172408271	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.42	5.44	0.33	1.25e-7	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26398408	chr14:51135030	SAV1	0.52	6.24	0.37	1.91e-9	Parkinson's disease;
KIRP	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg10755058	chr3:40428713	ENTPD3	-0.4	-5.59	-0.34	5.93e-8	Renal cell carcinoma;
KIRP	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg13409248	chr3:40428643	ENTPD3	-0.4	-5.62	-0.34	5.05e-8	Renal cell carcinoma;
KIRP	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09491104	chr22:46646882	C22orf40	-0.54	-5.8	-0.35	2.06e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10214930	0.697	rs6462036	chr7:27641063	A/G	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg00784671	chr22:46762841	CELSR1	-0.67	-8.37	-0.47	4.38e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs76693355	0.512	rs17123861	chr11:120256337	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.44	-5.38	-0.32	1.74e-7	Intraocular pressure;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs3857747	0.578	rs7807217	chr7:40379594	T/C	cg00420559	chr7:40367873	C7orf10	-0.43	-6.24	-0.37	1.92e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.87	12.18	0.61	5.14e-27	Multiple system atrophy;
KIRP	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg10818794	chr15:86012489	AKAP13	-0.49	-7.01	-0.41	2.33e-11	Coronary artery disease;
KIRP	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-9.22	-0.51	1.35e-17	Menarche (age at onset);
KIRP	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg21361702	chr7:150065534	REPIN1	0.58	6.2	0.37	2.32e-9	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.28	0.37	1.49e-9	Retinal vascular caliber;
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.37	5.4	0.33	1.59e-7	Lymphocyte counts;
KIRP	cis	rs6546886	0.912	rs6745236	chr2:74283728	C/T	cg14702570	chr2:74259524	NA	-0.34	-6.85	-0.4	6e-11	Dialysis-related mortality;
KIRP	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-8.28	-0.47	8.05e-15	Morning vs. evening chronotype;
KIRP	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg18171855	chr10:2543474	NA	0.47	6.6	0.39	2.46e-10	Age-related hearing impairment;
KIRP	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14893161	chr1:205819251	PM20D1	-0.59	-5.83	-0.35	1.74e-8	Menarche (age at onset);
KIRP	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg16988262	chr1:15930761	NA	0.4	5.2	0.31	4.2e-7	Systolic blood pressure;
KIRP	trans	rs76288851	0.733	rs11706588	chr3:126448513	T/C	cg13821433	chr2:26726535	OTOF	0.56	6.27	0.37	1.59e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs4920343	0.890	rs4920531	chr1:19095746	A/G	cg19637330	chr1:19110922	NA	-0.44	-5.46	-0.33	1.16e-7	Knee osteoarthritis;
KIRP	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.12	0.61	7.75e-27	Bipolar disorder;
KIRP	cis	rs2274273	0.840	rs3742569	chr14:55818706	T/C	cg04306507	chr14:55594613	LGALS3	0.46	7.12	0.41	1.18e-11	Protein biomarker;
KIRP	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.47	6.84	0.4	6.28e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4356932	1.000	rs4859587	chr4:76943296	A/C	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg26585981	chr11:48327164	OR4S1	-0.47	-5.67	-0.34	4.09e-8	HDL cholesterol;
KIRP	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06481639	chr22:41940642	POLR3H	0.64	6.81	0.4	7.36e-11	Vitiligo;
KIRP	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-1.14	-13.53	-0.65	1.48e-31	Breast cancer;
KIRP	cis	rs6840360	0.582	rs11732918	chr4:152319045	C/T	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs986417	1.000	rs1313249	chr14:60881997	C/G	cg27398547	chr14:60952738	C14orf39	-0.66	-5.84	-0.35	1.67e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs11731606	0.508	rs56943028	chr4:95285813	T/C	cg20625393	chr4:95128694	SMARCAD1	0.53	5.09	0.31	7.06e-7	Mean platelet volume;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg23698023	chr8:27181813	PTK2B	0.34	5.15	0.31	5.35e-7	Neuroticism;
KIRP	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.35	-4.96	-0.3	1.31e-6	Motion sickness;
KIRP	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.28	0.51	9.09e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9816226	0.591	rs75135487	chr3:185805294	C/G	cg00760338	chr3:185826511	ETV5	-0.73	-6.4	-0.38	7.82e-10	Obesity;Body mass index;
KIRP	cis	rs6545883	0.794	rs12053388	chr2:61532320	G/A	cg15711740	chr2:61764176	XPO1	0.59	7.51	0.43	1.08e-12	Tuberculosis;
KIRP	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg21798802	chr22:38057573	PDXP	0.43	5.24	0.32	3.47e-7	Fat distribution (HIV);
KIRP	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	0.98	12.88	0.63	2.29e-29	Corneal structure;
KIRP	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg23995753	chr2:160760732	LY75	-0.4	-5.34	-0.32	2.11e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12560992	chr17:57184187	TRIM37	0.61	7.02	0.41	2.15e-11	Testicular germ cell tumor;
KIRP	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.38	-0.38	8.61e-10	Response to antipsychotic treatment;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22955491	chr19:5661782	SAFB	0.49	6.83	0.4	6.65e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg06647332	chr5:131281008	NA	-0.43	-4.89	-0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-8.57	-0.48	1.15e-15	Platelet count;
KIRP	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.57	-6.95	-0.41	3.24e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4523957	0.928	rs216223	chr17:2155948	C/T	cg16513277	chr17:2031491	SMG6	0.59	8.14	0.46	1.96e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg26681399	chr22:41777847	TEF	0.51	5.19	0.31	4.41e-7	Vitiligo;
KIRP	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21659725	chr3:3221576	CRBN	0.7	9.62	0.52	8.53e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.57	-0.33	6.69e-8	Vitiligo;
KIRP	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.54	0.33	7.59e-8	Putamen volume;
KIRP	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.47	-6.11	-0.36	3.96e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1881396	0.947	rs8731	chr2:27873326	C/G	cg27432699	chr2:27873401	GPN1	0.62	6.9	0.4	4.5e-11	Nonalcoholic fatty liver disease;
KIRP	cis	rs28595532	0.547	rs1913576	chr4:119297789	C/T	cg21605333	chr4:119757512	SEC24D	0.97	6.78	0.4	8.8e-11	Cannabis dependence symptom count;
KIRP	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg00647317	chr7:50633725	DDC	0.46	6.89	0.4	4.59e-11	Body mass index;
KIRP	cis	rs9400467	0.528	rs455726	chr6:111699368	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.8	-0.35	1.98e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs3784262	0.669	rs17820990	chr15:58349568	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.87	-0.3	2.04e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.5	6.42	0.38	6.97e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-1.05	-14.71	-0.68	1.42e-35	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11369026	chr2:24583578	ITSN2	0.52	6.44	0.38	6.16e-10	Parkinson's disease;
KIRP	cis	rs1359582	0.836	rs1359581	chr10:90360515	A/G	cg15661332	chr10:90342814	RNLS	0.59	6.04	0.36	5.57e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.21	0.32	4.05e-7	Childhood ear infection;
KIRP	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg11738485	chr19:12877000	HOOK2	0.42	5.17	0.31	4.84e-7	Bipolar disorder;
KIRP	cis	rs7737355	1.000	rs798416	chr5:130693100	T/C	cg06647332	chr5:131281008	NA	-0.45	-4.99	-0.3	1.14e-6	Life satisfaction;
KIRP	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg00262122	chr8:11665843	FDFT1	-0.41	-5.14	-0.31	5.57e-7	Neuroticism;
KIRP	cis	rs17065868	1.000	rs9533880	chr13:45076189	A/T	cg10246903	chr13:45222710	NA	0.6	6.1	0.36	4.2e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg06740227	chr12:86229804	RASSF9	0.44	5.58	0.34	6.37e-8	Major depressive disorder;
KIRP	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.63	0.39	2.17e-10	Bipolar disorder;
KIRP	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg07451762	chr16:28383216	NA	0.42	5.52	0.33	8.76e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.54	7.18	0.42	8.24e-12	Menopause (age at onset);
KIRP	cis	rs737693	0.834	rs1940938	chr11:102774844	G/A	cg19620758	chr11:102826565	MMP13	0.8	6.39	0.38	8.31e-10	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.42	11.13	0.58	1.42e-23	Prostate cancer;
KIRP	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.76e-11	Aortic root size;
KIRP	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	10.69	0.56	3.73e-22	Blood protein levels;
KIRP	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg25356066	chr3:128598488	ACAD9	0.56	6.43	0.38	6.48e-10	IgG glycosylation;
KIRP	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	0.76	7.97	0.45	5.94e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs4561483	0.583	rs11075030	chr16:11976414	C/A	cg08843971	chr16:11963173	GSPT1	0.53	7.54	0.43	9.09e-13	Testicular germ cell tumor;
KIRP	cis	rs9296095	0.948	rs75080135	chr6:33552707	A/C	cg14003231	chr6:33640908	ITPR3	0.39	5.23	0.32	3.67e-7	Platelet count;
KIRP	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.88	-0.35	1.35e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.48	-0.33	1.08e-7	Pulmonary function;
KIRP	cis	rs55962025	0.842	rs362267	chr4:3243218	C/T	cg13731523	chr4:3047190	NA	0.33	5.15	0.31	5.29e-7	Parental longevity (mother's age at death);
KIRP	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg10755058	chr3:40428713	ENTPD3	0.47	6.51	0.38	4.26e-10	Renal cell carcinoma;
KIRP	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg22138327	chr13:27999177	GTF3A	0.75	7.48	0.43	1.33e-12	Weight;
KIRP	cis	rs367943	0.712	rs10062004	chr5:112694914	T/C	cg12552261	chr5:112820674	MCC	0.54	6.34	0.37	1.1e-9	Type 2 diabetes;
KIRP	cis	rs367943	0.712	rs10035686	chr5:112683357	C/T	cg12552261	chr5:112820674	MCC	0.5	5.71	0.34	3.24e-8	Type 2 diabetes;
KIRP	trans	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg13309027	chr11:47870224	NUP160	-0.57	-8.25	-0.47	9.77e-15	Gait speed in old age;
KIRP	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.78	0.44	1.96e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-1.0	-14.43	-0.68	1.26e-34	Cognitive function;
KIRP	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.34	-0.51	6.14e-18	Gut microbiome composition (summer);
KIRP	cis	rs55863869	0.748	rs3754953	chr2:179618019	A/T	cg02880032	chr2:179629472	TTN	0.69	6.13	0.36	3.51e-9	QT interval;
KIRP	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg17554472	chr22:41940697	POLR3H	-0.44	-5.05	-0.31	8.62e-7	Neuroticism;
KIRP	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	7.0	0.41	2.48e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8084125	0.765	rs62105165	chr18:74944464	A/G	cg26065057	chr18:74961000	GALR1	0.61	6.15	0.37	3.07e-9	Obesity-related traits;
KIRP	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.23	-0.46	1.13e-14	Bone mineral density;
KIRP	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.45	-7.26	-0.42	5.03e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.22	14.11	0.67	1.61e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg05887092	chr17:76393375	PGS1	0.54	7.49	0.43	1.22e-12	HDL cholesterol levels;
KIRP	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg25174290	chr11:3078921	CARS	-0.59	-6.46	-0.38	5.7e-10	Calcium levels;
KIRP	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg18944383	chr4:111397179	ENPEP	0.55	9.64	0.52	7.19e-19	Height;
KIRP	cis	rs151997	0.629	rs27288	chr5:50194920	T/A	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.32e-12	Callous-unemotional behaviour;
KIRP	cis	rs35995292	0.517	rs6948026	chr7:38920854	A/G	cg19327137	chr7:38886074	VPS41	0.79	12.13	0.61	7.34e-27	Subjective well-being (multi-trait analysis);
KIRP	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg04025307	chr7:1156635	C7orf50	0.71	5.54	0.33	7.72e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg09699651	chr6:150184138	LRP11	0.5	6.7	0.39	1.4e-10	Lung cancer;
KIRP	cis	rs116726256	0.744	rs80058910	chr2:1841143	A/G	cg07855242	chr2:1841068	MYT1L	0.61	5.83	0.35	1.69e-8	Interleukin-8 levels;
KIRP	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg05973401	chr12:123451056	ABCB9	-0.54	-6.12	-0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.16	-0.31	5.02e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg12826209	chr6:26865740	GUSBL1	0.64	4.85	0.3	2.21e-6	Depression;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19149454	chr22:40742374	ADSL	0.52	6.01	0.36	6.48e-9	Smoking initiation;
KIRP	trans	rs10242455	0.702	rs17161726	chr7:99008395	C/G	cg09045935	chr12:6379348	NA	0.82	6.19	0.37	2.46e-9	Blood metabolite levels;
KIRP	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg01872077	chr2:219646372	CYP27A1	-0.38	-4.85	-0.3	2.22e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.72	8.86	0.49	1.63e-16	Menarche (age at onset);
KIRP	cis	rs397969	0.573	rs203475	chr17:19850975	A/G	cg13482628	chr17:19912719	NA	0.48	5.47	0.33	1.08e-7	Platelet count;
KIRP	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.37	-0.38	9.4e-10	Coronary artery disease;
KIRP	cis	rs6960043	0.818	rs6967891	chr7:15065074	T/C	cg19272540	chr7:15055459	NA	-0.24	-7.05	-0.41	1.81e-11	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg00738919	chr7:1100172	C7orf50	0.43	5.07	0.31	8e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg07930552	chr6:133119739	C6orf192	1.07	9.37	0.51	5.02e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-6.16	-0.37	3e-9	Total body bone mineral density;
KIRP	cis	rs870825	0.518	rs12512933	chr4:185665055	C/T	cg04058563	chr4:185651563	MLF1IP	1.06	10.29	0.55	7.12e-21	Blood protein levels;
KIRP	cis	rs8060686	0.623	rs56303487	chr16:68029739	C/T	cg26727032	chr16:67993705	SLC12A4	-0.71	-7.87	-0.45	1.11e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7084402	0.565	rs11006187	chr10:60333383	A/G	cg05938607	chr10:60274200	BICC1	0.37	8.0	0.45	4.9e-14	Refractive error;
KIRP	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg02375832	chr11:62437615	C11orf48	-0.55	-6.65	-0.39	1.87e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	9.36	0.51	5.18e-18	Cognitive test performance;
KIRP	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg07274523	chr3:49395745	GPX1	0.68	8.48	0.48	2.06e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg05627522	chr15:75251581	NA	0.4	6.44	0.38	6.23e-10	Breast cancer;
KIRP	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg09455208	chr3:40491958	NA	0.36	6.43	0.38	6.63e-10	Renal cell carcinoma;
KIRP	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.64	8.48	0.48	2.08e-15	Aortic root size;
KIRP	cis	rs7534824	0.543	rs12568993	chr1:101386259	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	6.69	0.39	1.52e-10	Refractive astigmatism;
KIRP	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg02569458	chr12:86230093	RASSF9	0.36	5.27	0.32	3.03e-7	Major depressive disorder;
KIRP	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.83	-12.96	-0.64	1.27e-29	Blood metabolite levels;
KIRP	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg09408571	chr1:101003634	GPR88	-0.23	-5.28	-0.32	2.85e-7	Monocyte count;
KIRP	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.51	7.5	0.43	1.15e-12	Bone mineral density;
KIRP	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.67	8.77	0.49	3e-16	Aortic root size;
KIRP	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.43	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg21734707	chr17:3908241	ZZEF1	-0.62	-9.44	-0.52	3.06e-18	Type 2 diabetes;
KIRP	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.48e-9	Menopause (age at onset);
KIRP	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg05370193	chr1:21551575	ECE1	0.42	5.99	0.36	7.3e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7301016	0.846	rs7302094	chr12:62967430	C/T	cg01804193	chr12:63026212	NA	0.53	5.9	0.35	1.23e-8	IgG glycosylation;
KIRP	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.44	-0.52	2.99e-18	Body mass index;
KIRP	cis	rs9359856	0.517	rs112527288	chr6:90509141	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.74	-0.44	2.65e-13	Bipolar disorder;
KIRP	cis	rs201798	0.901	rs430269	chr13:50953088	A/G	cg10393508	chr13:50950265	NA	0.36	4.94	0.3	1.47e-6	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
KIRP	cis	rs12995849	0.905	rs6712210	chr2:106449251	G/A	cg16077055	chr2:106428750	NCK2	0.24	5.11	0.31	6.6e-7	Addiction;
KIRP	cis	rs897080	0.514	rs1067376	chr2:44648361	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.78	0.35	2.27e-8	Height;
KIRP	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg18154014	chr19:37997991	ZNF793	0.89	9.15	0.5	2.19e-17	Coronary artery calcification;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg15112475	chr7:1198522	ZFAND2A	-0.47	-4.91	-0.3	1.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.58	6.92	0.4	3.94e-11	Aortic root size;
KIRP	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.12	0.31	6.2e-7	Menopause (age at onset);
KIRP	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.45	9.75	0.53	3.38e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.64	0.52	7.52e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg12046867	chr14:103022105	NA	0.53	6.09	0.36	4.43e-9	Platelet count;
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.53	0.52	1.57e-18	Lung cancer;
KIRP	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg16339924	chr4:17578868	LAP3	-0.43	-5.64	-0.34	4.67e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.31	-0.37	1.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.62	7.47	0.43	1.43e-12	Menarche (age at onset);
KIRP	cis	rs7542091	0.637	rs9429826	chr1:210052146	G/A	cg05527609	chr1:210001259	C1orf107	-0.37	-4.96	-0.3	1.3e-6	Monobrow;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05923103	chr1:51701583	RNF11	0.49	6.21	0.37	2.21e-9	Smoking initiation;
KIRP	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg07148914	chr20:33460835	GGT7	0.61	7.58	0.44	6.86e-13	Height;
KIRP	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg08975724	chr8:8085496	FLJ10661	0.72	8.33	0.47	5.82e-15	Red cell distribution width;
KIRP	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.52	17.73	0.75	7.02e-46	Opioid sensitivity;
KIRP	cis	rs6504622	0.935	rs740617	chr17:45028001	C/T	cg24703533	chr17:45055318	NA	0.38	5.31	0.32	2.39e-7	Orofacial clefts;
KIRP	cis	rs7582720	0.945	rs72932723	chr2:203647646	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	9.63	0.52	8.09e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs501120	1.000	rs620828	chr10:44760958	A/G	cg09554077	chr10:44749378	NA	0.7	10.73	0.56	2.84e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1678542	1.000	rs1678542	chr12:57968715	C/G	cg00677455	chr12:58241039	CTDSP2	-0.49	-5.54	-0.33	7.95e-8	Rheumatoid arthritis;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg11204139	chr17:3907470	NA	0.81	14.65	0.68	2.36e-35	Type 2 diabetes;
KIRP	cis	rs4363506	1.000	rs10830090	chr10:129273673	C/T	cg07804728	chr10:129284050	NA	0.4	5.6	0.34	5.78e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs997295	0.713	rs9302245	chr15:68021137	C/T	cg24579218	chr15:68104479	NA	0.35	4.91	0.3	1.67e-6	Motion sickness;
KIRP	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.6	-7.89	-0.45	9.91e-14	Vitiligo;
KIRP	cis	rs7246657	0.722	rs28512414	chr19:38056574	T/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.93	14.6	0.68	3.34e-35	Lung cancer;
KIRP	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.63	3.22e-29	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg12315302	chr6:26189340	HIST1H4D	1.08	6.42	0.38	7.16e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.79	10.71	0.56	3.14e-22	Coronary artery disease;
KIRP	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.07	0.41	1.63e-11	Rheumatoid arthritis;
KIRP	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.66	6.2	0.37	2.32e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35740288	0.770	rs12898597	chr15:86189919	T/C	cg17133734	chr15:86042851	AKAP13	-0.51	-5.76	-0.34	2.55e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7941030	0.867	rs11606532	chr11:122535611	G/A	cg20555462	chr11:122535518	UBASH3B	-0.47	-5.83	-0.35	1.73e-8	HDL cholesterol;Cholesterol, total;
KIRP	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg06636001	chr8:8085503	FLJ10661	0.6	8.02	0.46	4.26e-14	Neuroticism;
KIRP	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg19507638	chr5:93509721	C5orf36	-0.59	-5.31	-0.32	2.47e-7	Diabetic retinopathy;
KIRP	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.71	9.78	0.53	2.65e-19	Mean corpuscular volume;
KIRP	cis	rs10181042	0.514	rs1177283	chr2:61348804	A/G	cg15711740	chr2:61764176	XPO1	-0.5	-6.1	-0.36	4e-9	Crohn's disease;
KIRP	cis	rs6545883	0.929	rs3821222	chr2:61713526	C/G	cg15711740	chr2:61764176	XPO1	-0.59	-7.78	-0.44	2.04e-13	Tuberculosis;
KIRP	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.64	0.71	9.78e-39	Platelet count;
KIRP	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.94	10.85	0.57	1.12e-22	Neuroticism;
KIRP	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg12559939	chr2:27858050	GPN1	-0.42	-5.2	-0.31	4.26e-7	Oral cavity cancer;
KIRP	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.75	10.98	0.57	4.5e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg01689657	chr7:91764605	CYP51A1	0.44	6.42	0.38	7.09e-10	Breast cancer;
KIRP	cis	rs882732	0.744	rs11847476	chr14:95047605	G/T	cg05186455	chr14:95027692	SERPINA4	-0.39	-4.97	-0.3	1.26e-6	Blood protein levels;
KIRP	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg15534755	chr11:117069859	TAGLN	0.4	4.95	0.3	1.38e-6	Blood protein levels;
KIRP	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.01	-0.41	2.24e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	7.33	0.42	3.3e-12	Obesity-related traits;
KIRP	cis	rs4664304	0.816	rs67045814	chr2:160821119	A/C	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.15	-0.31	5.21e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.11	10.94	0.57	5.71e-23	Alzheimer's disease (late onset);
KIRP	trans	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg16141378	chr3:129829833	LOC729375	0.6	8.06	0.46	3.4e-14	Neuroticism;
KIRP	cis	rs16828019	0.852	rs12022978	chr1:41554088	A/G	cg08144172	chr1:41849203	NA	0.63	5.17	0.31	4.88e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7078012	0.504	rs17879405	chr10:81689540	C/T	cg24613050	chr10:81743128	NA	-0.53	-4.96	-0.3	1.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs2898857	0.524	rs2960172	chr17:47379581	G/A	cg11430096	chr6:110968061	CDK19	0.54	6.65	0.39	1.88e-10	Cancer;
KIRP	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.68	-9.15	-0.5	2.2e-17	Huntington's disease progression;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.5	-6.97	-0.41	2.98e-11	Hematocrit;
KIRP	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.59	7.32	0.42	3.49e-12	Arsenic metabolism;
KIRP	cis	rs7301016	0.894	rs11174487	chr12:62849999	T/C	cg01804193	chr12:63026212	NA	0.56	5.83	0.35	1.7e-8	IgG glycosylation;
KIRP	cis	rs13401104	0.796	rs72620807	chr2:237114205	T/G	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg15556689	chr8:8085844	FLJ10661	0.73	9.3	0.51	7.72e-18	Parkinson's disease;
KIRP	cis	rs3733418	0.860	rs13124015	chr4:165930282	G/A	cg10852876	chr4:165953100	TRIM60	-0.46	-4.9	-0.3	1.75e-6	Obesity-related traits;
KIRP	cis	rs2073300	1.000	rs2207989	chr20:23446014	T/G	cg12480562	chr20:23434244	CST11	0.6	5.99	0.36	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12200782	1.000	rs12195971	chr6:26460424	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-5.36	-0.32	1.87e-7	Small cell lung carcinoma;
KIRP	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.55	-7.46	-0.43	1.45e-12	Response to temozolomide;
KIRP	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg13206674	chr6:150067644	NUP43	0.59	8.55	0.48	1.29e-15	Lung cancer;
KIRP	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg26207909	chr14:103986467	CKB	-0.45	-5.49	-0.33	9.77e-8	Coronary artery disease;
KIRP	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.88	0.45	1.03e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7027203	0.576	rs7851269	chr9:96540530	C/T	cg14598338	chr9:96623480	NA	0.46	7.15	0.41	9.75e-12	DNA methylation (variation);
KIRP	cis	rs9321453	1.000	rs4896048	chr6:134770472	A/T	cg08754004	chr6:134775465	NA	-0.43	-5.02	-0.3	9.98e-7	Urate levels;
KIRP	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	cg21523751	chr1:182988639	NA	-0.41	-6.5	-0.38	4.35e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.79	0.53	2.44e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg11204139	chr17:3907470	NA	0.82	14.97	0.69	1.91e-36	Type 2 diabetes;
KIRP	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg13271783	chr10:134563150	INPP5A	-0.59	-7.55	-0.43	8.53e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.46	7.13	0.41	1.12e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.72	9.99	0.54	5.92e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.11	0.36	3.9e-9	Menopause (age at onset);
KIRP	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.6	-8.66	-0.48	6.31e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.88e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg00745463	chr17:30367425	LRRC37B	-0.51	-5.39	-0.32	1.69e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg16578609	chr1:2399051	NA	-0.47	-6.24	-0.37	1.9e-9	Non-obstructive azoospermia;
KIRP	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg17420585	chr12:42539391	GXYLT1	-0.41	-5.64	-0.34	4.61e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.73	9.14	0.5	2.35e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04322504	chr10:98287001	TM9SF3	-0.39	-6.08	-0.36	4.6e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11767191	0.846	rs10258119	chr7:48755648	C/T	ch.7.1147807F	chr7:49473528	NA	0.38	4.91	0.3	1.66e-6	Response to amphetamines;
KIRP	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.67	6.59	0.39	2.68e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg11494091	chr17:61959527	GH2	0.47	6.05	0.36	5.51e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06206471	chr16:4364052	NA	0.52	6.7	0.39	1.45e-10	Parkinson's disease;
KIRP	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg26513180	chr16:89883248	FANCA	0.79	5.3	0.32	2.64e-7	Skin colour saturation;
KIRP	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg17133734	chr15:86042851	AKAP13	-0.46	-5.69	-0.34	3.68e-8	Interstitial lung disease;
KIRP	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20135002	chr11:47629003	NA	-0.48	-5.69	-0.34	3.66e-8	Subjective well-being;
KIRP	cis	rs66561647	0.719	rs4733582	chr8:128947967	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.48	6.04	0.36	5.73e-9	Hemoglobin concentration;
KIRP	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg06636001	chr8:8085503	FLJ10661	0.6	8.02	0.46	4.26e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14820908	chr5:178986412	RUFY1	0.45	6.33	0.37	1.16e-9	Lung cancer;
KIRP	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.56	-5.41	-0.33	1.5e-7	Hip geometry;
KIRP	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg23974023	chr2:113544294	IL1A	-0.32	-4.85	-0.3	2.17e-6	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg00933542	chr6:150070202	PCMT1	0.28	5.46	0.33	1.14e-7	Lung cancer;
KIRP	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg09754948	chr16:28834200	ATXN2L	0.5	5.82	0.35	1.87e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg26876637	chr1:152193138	HRNR	-0.81	-8.89	-0.49	1.34e-16	Atopic dermatitis;
KIRP	cis	rs72730918	0.590	rs1378893	chr15:51964788	A/G	cg14296394	chr15:51910925	DMXL2	-0.77	-10.82	-0.57	1.47e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.24	-26.19	-0.86	4.35e-73	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg17644776	chr2:200775616	C2orf69	-0.56	-5.91	-0.35	1.13e-8	Schizophrenia;
KIRP	cis	rs7172677	0.695	rs8029756	chr15:75435790	C/T	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg08807101	chr21:30365312	RNF160	-0.59	-7.25	-0.42	5.28e-12	Cognitive test performance;
KIRP	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.35	-5.33	-0.32	2.19e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26745394	chr17:42856616	ADAM11	0.48	6.6	0.39	2.49e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35123781	0.502	rs355157	chr5:138993415	T/C	cg12205435	chr5:138714322	SLC23A1	-0.39	-5.16	-0.31	5.07e-7	Schizophrenia;
KIRP	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Hypertriglyceridemia;
KIRP	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.76e-8	Life satisfaction;
KIRP	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg02487422	chr3:49467188	NICN1	0.35	5.0	0.3	1.08e-6	Parkinson's disease;
KIRP	cis	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg21775007	chr8:11205619	TDH	-0.48	-5.96	-0.36	8.84e-9	Triglycerides;
KIRP	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.95	16.75	0.73	1.6e-42	Monocyte count;
KIRP	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg22563815	chr15:78856949	CHRNA5	0.33	4.94	0.3	1.44e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-11.31	-0.59	3.59e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs3755132	0.929	rs60269778	chr2:15753604	A/G	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.03	-0.36	5.98e-9	Cutaneous nevi;
KIRP	cis	rs2671245	0.565	rs3914413	chr1:56148968	A/G	cg11523071	chr1:56160889	NA	0.41	6.06	0.36	4.96e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg13731523	chr4:3047190	NA	0.35	5.9	0.35	1.19e-8	Serum sulfate level;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.6	9.05	0.5	4.38e-17	Lung cancer;
KIRP	trans	rs6993813	0.678	rs4416847	chr8:120009258	C/A	cg22961513	chr11:14280813	SPON1	0.36	6.08	0.36	4.45e-9	Bone mineral density (hip);
KIRP	cis	rs8028182	0.636	rs4299117	chr15:75789444	C/T	cg20655648	chr15:75932815	IMP3	0.53	6.53	0.38	3.77e-10	Sudden cardiac arrest;
KIRP	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg24375607	chr4:120327624	NA	-0.47	-5.72	-0.34	3.05e-8	Corneal astigmatism;
KIRP	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg03258749	chr1:151040405	MLLT11	-0.5	-6.69	-0.39	1.5e-10	Childhood ear infection;
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.56	-6.5	-0.38	4.32e-10	Menopause (age at onset);
KIRP	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10174797	chr19:8464628	RAB11B	0.5	6.15	0.36	3.15e-9	HDL cholesterol;
KIRP	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs7246657	0.722	rs1564208	chr19:38041221	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.66	-0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg24296786	chr1:45957014	TESK2	-0.5	-5.56	-0.33	6.96e-8	Homocysteine levels;
KIRP	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg02297831	chr4:17616191	MED28	0.6	7.69	0.44	3.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6662572	0.737	rs4423055	chr1:46259980	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.47	-5.69	-0.34	3.56e-8	Blood protein levels;
KIRP	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg18366169	chr5:1948875	NA	-0.42	-4.85	-0.3	2.18e-6	Gut microbiome composition (winter);
KIRP	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.63	-0.34	4.98e-8	Aortic root size;
KIRP	cis	rs28595532	0.545	rs13132957	chr4:119250841	G/C	cg21605333	chr4:119757512	SEC24D	0.69	5.84	0.35	1.67e-8	Cannabis dependence symptom count;
KIRP	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg23173402	chr1:227635558	NA	0.62	5.85	0.35	1.59e-8	Major depressive disorder;
KIRP	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.68	9.01	0.5	5.71e-17	Bladder cancer;
KIRP	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	1.12	18.46	0.76	2.45e-48	Cognitive function;
KIRP	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.76e-11	Aortic root size;
KIRP	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.32	-0.32	2.34e-7	Body mass index;
KIRP	cis	rs8077577	0.895	rs10048161	chr17:18082796	C/G	cg18869244	chr17:18121946	NA	0.48	5.36	0.32	1.92e-7	Obesity-related traits;
KIRP	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg00507259	chr4:95128692	SMARCAD1	0.42	5.35	0.32	2.03e-7	QT interval;
KIRP	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs35740288	0.770	rs11630112	chr15:86120246	T/C	cg17133734	chr15:86042851	AKAP13	-0.5	-5.59	-0.34	5.92e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg21605333	chr4:119757512	SEC24D	1.52	11.71	0.6	1.78e-25	Cannabis dependence symptom count;
KIRP	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg23594656	chr7:65796392	TPST1	-0.44	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs9469890	0.604	rs78121911	chr6:34503739	T/C	cg14254433	chr6:34482411	PACSIN1	-0.53	-6.1	-0.36	4.01e-9	Pubertal anthropometrics;Coronary artery disease;
KIRP	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg25281562	chr12:121454272	C12orf43	0.52	5.59	0.34	5.92e-8	N-glycan levels;
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.81	-12.36	-0.62	1.33e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg22852734	chr6:133119734	C6orf192	1.24	11.14	0.58	1.34e-23	Type 2 diabetes nephropathy;
KIRP	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	1.04	9.88	0.53	1.29e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.12e-15	Mood instability;
KIRP	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.81e-7	Bladder cancer;
KIRP	cis	rs6838801	1.000	rs4582178	chr4:77552782	A/G	cg17476223	chr4:77663285	SHROOM3	0.5	6.84	0.4	6.32e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs1832871	0.616	rs55675950	chr6:158773994	T/A	cg07215822	chr6:158701037	NA	-0.63	-7.27	-0.42	4.72e-12	Height;
KIRP	cis	rs6545883	0.965	rs1992765	chr2:61751333	A/G	cg15711740	chr2:61764176	XPO1	-0.59	-7.98	-0.45	5.43e-14	Tuberculosis;
KIRP	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg06386533	chr2:46925753	SOCS5	0.47	5.01	0.3	1.02e-6	Height;
KIRP	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg27205649	chr11:78285834	NARS2	-0.48	-5.26	-0.32	3.06e-7	Testicular germ cell tumor;
KIRP	cis	rs2882667	0.861	rs11959727	chr5:138396965	C/T	cg04439458	chr5:138467593	SIL1	-0.44	-7.5	-0.43	1.12e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg09699651	chr6:150184138	LRP11	0.45	5.85	0.35	1.53e-8	Lung cancer;
KIRP	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.69	-0.34	3.69e-8	Testicular germ cell tumor;
KIRP	cis	rs7688540	0.723	rs61794999	chr4:232367	T/A	cg17891759	chr4:299121	NA	-0.47	-4.85	-0.3	2.24e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs7937612	0.931	rs10892562	chr11:120221618	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.55	-0.39	3.3e-10	Intraocular pressure;
KIRP	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg06818126	chr11:68850279	TPCN2	-0.48	-5.5	-0.33	9.32e-8	Hair color;
KIRP	cis	rs34779708	0.931	rs13377158	chr10:35370465	A/C	cg03585969	chr10:35415529	CREM	-0.76	-9.13	-0.5	2.51e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg18944383	chr4:111397179	ENPEP	0.61	11.17	0.58	1.03e-23	Height;
KIRP	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.63	5.05	0.31	8.57e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.5	0.38	4.55e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.97	-13.97	-0.67	4.89e-33	Menopause (age at onset);
KIRP	cis	rs4523957	0.583	rs8077597	chr17:2043818	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-12.82	-0.63	3.79e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.86	12.43	0.62	7.51e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.13	0.41	1.1e-11	Aortic root size;
KIRP	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06544989	chr22:39130855	UNC84B	-0.42	-6.75	-0.4	1.06e-10	Menopause (age at onset);
KIRP	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-10.04	-0.54	4.33e-20	Coffee consumption (cups per day);
KIRP	cis	rs10792830	0.706	rs3016786	chr11:85774562	T/G	cg07180834	chr11:85838833	NA	-0.33	-4.92	-0.3	1.61e-6	Psychosis and Alzheimer's disease;
KIRP	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg27490568	chr2:178487706	NA	0.53	7.3	0.42	3.99e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg17443007	chr1:101659419	NA	0.4	5.69	0.34	3.68e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.95e-7	Red blood cell count;
KIRP	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.89	12.43	0.62	7.45e-28	Gestational age at birth (maternal effect);
KIRP	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.53	-8.09	-0.46	2.73e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg19077165	chr18:44547161	KATNAL2	0.45	5.63	0.34	4.91e-8	Personality dimensions;
KIRP	cis	rs7572263	0.724	rs35551278	chr2:209056128	A/G	cg23998903	chr2:209048830	C2orf80	-0.37	-5.19	-0.31	4.39e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs7236492	0.748	rs7228738	chr18:77231307	C/T	cg15644404	chr18:77186268	NFATC1	-0.87	-6.77	-0.4	9.21e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg21864845	chr1:1208426	UBE2J2	0.5	6.6	0.39	2.44e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4740619	0.618	rs10738421	chr9:15975380	T/A	cg14451791	chr9:16040625	NA	-0.38	-4.93	-0.3	1.48e-6	Body mass index;
KIRP	cis	rs2290402	0.572	rs3775119	chr4:893712	C/T	cg00846425	chr4:957561	DGKQ	-0.54	-5.28	-0.32	2.88e-7	Type 2 diabetes;
KIRP	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.96	-0.41	3.15e-11	Aortic root size;
KIRP	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.94	13.48	0.65	2.17e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs13102973	0.614	rs56199725	chr4:135873448	T/C	cg14419869	chr4:135874104	NA	-0.56	-9.2	-0.51	1.62e-17	Subjective well-being;
KIRP	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg11608241	chr8:8085544	FLJ10661	0.49	5.76	0.34	2.49e-8	Mood instability;
KIRP	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg01420254	chr6:26195488	NA	1.27	9.94	0.54	8.88e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.4	6.72	0.39	1.26e-10	Heart rate;
KIRP	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.88	-11.73	-0.6	1.61e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs4363506	1.000	rs4363506	chr10:129274503	C/T	cg07804728	chr10:129284050	NA	-0.4	-5.62	-0.34	5.19e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.16	0.31	5.08e-7	Smoking behavior;
KIRP	cis	rs12143943	0.966	rs3789046	chr1:204586805	G/A	cg20240347	chr1:204465584	NA	-0.35	-6.43	-0.38	6.65e-10	Cognitive performance;
KIRP	cis	rs539514	0.690	rs2328953	chr13:76317459	T/G	cg04757411	chr13:76259545	LMO7	-0.36	-5.06	-0.31	8.07e-7	Type 1 diabetes;
KIRP	cis	rs16857609	0.628	rs874840	chr2:218354130	C/T	cg15335768	chr2:218268053	DIRC3	-0.39	-5.6	-0.34	5.57e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.66	-10.55	-0.56	1.08e-21	Intelligence (multi-trait analysis);
KIRP	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.69	-8.23	-0.46	1.13e-14	Educational attainment;
KIRP	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.89	-12.74	-0.63	7.07e-29	Ileal carcinoids;
KIRP	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.43	-0.62	7.75e-28	Exhaled nitric oxide output;
KIRP	cis	rs1712517	0.525	rs2271751	chr10:105175131	A/G	cg04362960	chr10:104952993	NT5C2	-0.55	-6.83	-0.4	6.51e-11	Migraine;
KIRP	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.92	-0.35	1.05e-8	Height;
KIRP	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.6	-5.08	-0.31	7.62e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg17441377	chr17:3906640	NA	0.52	7.81	0.45	1.6e-13	Type 2 diabetes;
KIRP	cis	rs6988985	0.594	rs12543598	chr8:143955318	T/G	cg10324643	chr8:143916377	GML	0.43	5.1	0.31	6.71e-7	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	cis	rs427941	0.872	rs420920	chr7:101859159	A/G	cg06246474	chr7:101738831	CUX1	-0.42	-4.85	-0.3	2.17e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.51	7.27	0.42	4.72e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg06630425	chr16:818451	MSLN	-0.57	-7.16	-0.42	9.02e-12	Mean corpuscular volume;
KIRP	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg23950597	chr19:37808831	NA	-0.77	-7.76	-0.44	2.28e-13	Coronary artery calcification;
KIRP	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-9.77	-0.53	2.99e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg16497661	chr14:103986332	CKB	0.82	13.93	0.66	6.72e-33	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23071808	chr14:103021642	NA	0.4	6.21	0.37	2.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10875595	0.723	rs62378371	chr5:140680211	G/A	cg24830062	chr5:140700576	TAF7	-0.61	-5.55	-0.33	7.54e-8	Pulmonary function decline;
KIRP	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.34	0.55	4.65e-21	Cognitive test performance;
KIRP	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg22676075	chr6:135203613	NA	0.5	7.41	0.43	2.01e-12	Red blood cell count;
KIRP	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.75	7.6	0.44	6.07e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.89	14.14	0.67	1.24e-33	Height;
KIRP	cis	rs7534824	0.860	rs7411264	chr1:101606449	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	5.3	0.32	2.62e-7	Refractive astigmatism;
KIRP	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.46e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6442310	0.545	rs2972163	chr3:12438022	G/A	cg15873301	chr3:12045459	SYN2	0.39	5.23	0.32	3.7e-7	Hematocrit;
KIRP	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.04	-0.36	5.53e-9	Pulmonary function;
KIRP	cis	rs6450176	0.625	rs35027270	chr5:53289068	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-12.99	-0.64	9.68e-30	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	4.88	0.3	1.89e-6	Neuroticism;
KIRP	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg17133734	chr15:86042851	AKAP13	-0.44	-5.43	-0.33	1.33e-7	Interstitial lung disease;
KIRP	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs1448094	0.845	rs7966131	chr12:86350633	T/G	cg02569458	chr12:86230093	RASSF9	0.38	5.52	0.33	8.76e-8	Major depressive disorder;
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg01097406	chr16:89675127	NA	-0.29	-4.84	-0.3	2.26e-6	Vitiligo;
KIRP	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg10645314	chr2:3704589	ALLC	-0.42	-5.31	-0.32	2.46e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-7.11	-0.41	1.26e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	7.49	0.43	1.27e-12	Mood instability;
KIRP	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-4.93	-0.3	1.53e-6	Tonsillectomy;
KIRP	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.67	9.27	0.51	9.89e-18	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00149659	chr3:10157352	C3orf10	0.56	6.79	0.4	8.24e-11	Alzheimer's disease;
KIRP	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.2e-8	Aortic root size;
KIRP	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg16497661	chr14:103986332	CKB	-0.51	-6.47	-0.38	5.22e-10	Coronary artery disease;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.65	7.31	0.42	3.85e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg09455208	chr3:40491958	NA	0.3	5.15	0.31	5.27e-7	Renal cell carcinoma;
KIRP	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.09e-8	Life satisfaction;
KIRP	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs13401104	0.796	rs12464503	chr2:237113007	C/T	cg19324714	chr2:237145437	ASB18	0.48	5.11	0.31	6.39e-7	Educational attainment;
KIRP	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg03060546	chr3:49711283	APEH	-0.59	-6.3	-0.37	1.35e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.57	-7.44	-0.43	1.68e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17141500	chr11:77532182	C11orf67;RSF1	0.43	6.09	0.36	4.29e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Life satisfaction;
KIRP	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.82	-0.45	1.51e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg06558623	chr16:89946397	TCF25	0.94	7.3	0.42	4.02e-12	Skin colour saturation;
KIRP	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2481665	0.739	rs6674622	chr1:62534938	A/G	cg18591186	chr1:62594603	INADL	-0.54	-7.99	-0.45	5.06e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.76	7.94	0.45	7.29e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs28489187	0.683	rs6576764	chr1:85866411	A/T	cg16011679	chr1:85725395	C1orf52	-0.48	-5.9	-0.35	1.18e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs2717559	0.515	rs55720963	chr8:143895957	T/A	cg17252645	chr8:143867129	LY6D	-0.37	-5.85	-0.35	1.56e-8	Urinary tract infection frequency;
KIRP	cis	rs4654899	0.680	rs3125160	chr1:21127803	G/C	cg08890418	chr1:21044141	KIF17	-0.33	-4.87	-0.3	2.03e-6	Superior frontal gyrus grey matter volume;
KIRP	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.76	7.96	0.45	6.37e-14	Exhaled nitric oxide output;
KIRP	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg02475777	chr4:1388615	CRIPAK	0.51	4.87	0.3	2.02e-6	Recombination rate (females);
KIRP	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.59	-0.39	2.58e-10	Urinary tract infection frequency;
KIRP	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.68	-0.48	5.53e-16	Response to antipsychotic treatment;
KIRP	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	9.07	0.5	3.78e-17	Mood instability;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	ch.11.41140287R	chr11:41183711	NA	-0.42	-6.15	-0.37	3.16e-9	Interleukin-4 levels;
KIRP	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.43	-6.4	-0.38	7.79e-10	Refractive error;
KIRP	cis	rs867371	0.964	rs7169961	chr15:82478929	C/T	cg06066596	chr15:83166174	LOC80154	-0.47	-5.53	-0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.83	-14.43	-0.68	1.28e-34	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs12210905	1.000	rs12198077	chr6:27169307	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.73	-0.39	1.16e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7870753	0.838	rs10820626	chr9:99204180	G/T	cg25260653	chr9:99212216	HABP4	0.57	6.04	0.36	5.51e-9	Height;
KIRP	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	1.09	11.89	0.6	4.61e-26	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg02570527	chr1:10970165	NA	0.43	5.28	0.32	2.9e-7	Body mass index;
KIRP	cis	rs2997447	0.761	rs2783670	chr1:26455182	A/G	cg19633962	chr1:26362018	EXTL1	-0.49	-4.89	-0.3	1.8e-6	QRS complex (12-leadsum);
KIRP	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg23625390	chr15:77176239	SCAPER	0.49	6.55	0.39	3.4e-10	Blood metabolite levels;
KIRP	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-20.07	-0.79	1e-53	Height;
KIRP	cis	rs7017914	0.934	rs62530772	chr8:71601541	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Corneal astigmatism;
KIRP	cis	rs2573652	0.722	rs12908133	chr15:100544405	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.51	-7.21	-0.42	6.81e-12	Height;
KIRP	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.5	8.57	0.48	1.16e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs876084	0.604	rs4520205	chr8:121014669	G/A	cg22335954	chr8:121166405	COL14A1	-0.4	-5.06	-0.31	8.26e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.45	5.78	0.35	2.22e-8	Height;
KIRP	cis	rs8114671	0.967	rs2180568	chr20:33794794	C/G	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.18	-0.31	4.57e-7	Height;
KIRP	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.73	9.54	0.52	1.48e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.81e-16	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14431266	chr11:67057003	ANKRD13D	0.56	6.54	0.38	3.5e-10	Smoking initiation;
KIRP	cis	rs6545883	0.929	rs55806663	chr2:61740487	G/T	cg15711740	chr2:61764176	XPO1	-0.61	-8.3	-0.47	7.11e-15	Tuberculosis;
KIRP	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.81	-8.58	-0.48	1.05e-15	Systemic lupus erythematosus;
KIRP	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.61	-9.55	-0.52	1.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg16434002	chr17:42200994	HDAC5	-0.53	-6.22	-0.37	2.06e-9	Total body bone mineral density;
KIRP	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.8	-8.57	-0.48	1.13e-15	Hair shape;
KIRP	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.75	11.29	0.58	4.42e-24	Blood metabolite ratios;
KIRP	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.66	9.07	0.5	3.89e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg19673125	chr6:150240577	RAET1G	0.21	4.91	0.3	1.65e-6	Testicular germ cell tumor;
KIRP	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg19077165	chr18:44547161	KATNAL2	0.49	6.34	0.37	1.08e-9	Educational attainment;
KIRP	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.86	0.49	1.61e-16	Electroencephalogram traits;
KIRP	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.14	16.52	0.73	9.43e-42	Breast cancer;
KIRP	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.55	-0.48	1.35e-15	Monocyte percentage of white cells;
KIRP	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.65	9.03	0.5	5.09e-17	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18451529	chr2:15698011	NBAS	0.45	6.48	0.38	4.88e-10	Interleukin-4 levels;
KIRP	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.68	6.33	0.37	1.14e-9	Schizophrenia;
KIRP	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	1.01	16.61	0.73	4.58e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg20636351	chr8:55087400	NA	0.53	6.63	0.39	2.09e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs13170463	0.522	rs7711682	chr5:8034275	G/T	cg03862380	chr20:43029895	HNF4A	0.39	6.03	0.36	6.1e-9	Colorectal cancer;
KIRP	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs11997175	0.603	rs7016580	chr8:33824135	G/A	cg04338863	chr8:33670619	NA	0.39	4.94	0.3	1.42e-6	Body mass index;
KIRP	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.5	7.85	0.45	1.31e-13	Testicular germ cell tumor;
KIRP	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg10755058	chr3:40428713	ENTPD3	0.34	4.88	0.3	1.93e-6	Renal cell carcinoma;
KIRP	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.46	6.4	0.38	7.94e-10	Dupuytren's disease;
KIRP	cis	rs14057	0.864	rs3761925	chr1:6761702	C/T	cg16431369	chr1:6694556	THAP3;DNAJC11	-0.41	-4.95	-0.3	1.35e-6	Systolic blood pressure;
KIRP	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg17507749	chr15:85114479	UBE2QP1	0.89	9.91	0.53	1.08e-19	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04319097	chr18:5293279	ZFP161	-0.43	-6.26	-0.37	1.66e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs80282103	0.618	rs10794720	chr10:1156165	A/G	cg08668510	chr10:1095578	IDI1	-0.84	-6.49	-0.38	4.81e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg06365898	chr1:16533907	ARHGEF19	0.47	6.62	0.39	2.25e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	4.92	0.3	1.56e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg19507638	chr5:93509721	C5orf36	0.57	4.94	0.3	1.42e-6	Diabetic retinopathy;
KIRP	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg05941025	chr16:89927596	SPIRE2	0.35	5.49	0.33	1.01e-7	Vitiligo;
KIRP	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.72	-8.63	-0.48	7.78e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.96	12.8	0.63	4.17e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs988913	1.000	rs6902245	chr6:54813006	C/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.57	-0.33	6.59e-8	Menarche (age at onset);
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.79	12.6	0.63	2.08e-28	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	cg04338863	chr8:33670619	NA	0.43	5.61	0.34	5.33e-8	Body mass index;
KIRP	cis	rs16976116	0.951	rs28706531	chr15:55477072	G/A	cg11288833	chr15:55489084	RSL24D1	0.62	7.0	0.41	2.37e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2274273	0.624	rs7154796	chr14:55771458	T/C	cg04306507	chr14:55594613	LGALS3	0.39	5.42	0.33	1.44e-7	Protein biomarker;
KIRP	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg07636037	chr3:49044803	WDR6	-0.77	-7.37	-0.43	2.59e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.72	-9.13	-0.5	2.58e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4523957	0.818	rs4790887	chr17:2130592	C/A	cg16513277	chr17:2031491	SMG6	0.68	9.49	0.52	2.13e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.38	17.54	0.75	3.17e-45	Uric acid levels;
KIRP	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01973587	chr1:228161476	NA	0.37	4.86	0.3	2.09e-6	Diastolic blood pressure;
KIRP	cis	rs612683	0.694	rs6688364	chr1:101000874	G/A	cg09408571	chr1:101003634	GPR88	0.35	7.9	0.45	9.45e-14	Breast cancer;
KIRP	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	6.32	0.37	1.24e-9	Hemoglobin concentration;
KIRP	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.97	9.73	0.53	3.81e-19	Eosinophilic esophagitis;
KIRP	cis	rs397969	0.621	rs203449	chr17:19824621	C/T	cg04132472	chr17:19861366	AKAP10	0.64	8.45	0.47	2.56e-15	Platelet count;
KIRP	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1152591	0.524	rs1255992	chr14:64662895	A/G	cg21174375	chr14:64681225	SYNE2	0.67	9.44	0.52	2.95e-18	Atrial fibrillation;
KIRP	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg26587870	chr6:27730563	NA	-0.65	-4.92	-0.3	1.56e-6	Breast cancer;
KIRP	cis	rs1983891	0.874	rs3747744	chr6:41516351	A/G	cg20194872	chr6:41519635	FOXP4	0.55	6.85	0.4	5.98e-11	Prostate cancer;
KIRP	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.27	-0.42	4.86e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg23950597	chr19:37808831	NA	-0.72	-6.21	-0.37	2.21e-9	Coronary artery calcification;
KIRP	cis	rs6088813	1.000	rs1570004	chr20:33958253	A/T	cg14752227	chr20:34000481	UQCC	-0.5	-6.64	-0.39	2.03e-10	Height;
KIRP	cis	rs2880765	0.546	rs36098649	chr15:86056807	C/T	cg15340431	chr15:86040528	AKAP13	-0.47	-5.62	-0.34	5.1e-8	Coronary artery disease;
KIRP	cis	rs830383	0.515	rs2591579	chr5:165406695	G/A	cg13976338	chr5:165423657	NA	-0.59	-6.14	-0.36	3.23e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.59	-6.78	-0.4	9.06e-11	Mean platelet volume;
KIRP	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg02158880	chr13:53174818	NA	0.38	5.06	0.31	8.04e-7	Lewy body disease;
KIRP	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.76	-10.79	-0.57	1.74e-22	Waist circumference;Body mass index;
KIRP	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg02993010	chr8:124780839	FAM91A1	-0.6	-6.22	-0.37	2.17e-9	Pancreatic cancer;
KIRP	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg26516362	chr5:178986906	RUFY1	0.39	6.77	0.4	9.5e-11	Lung cancer;
KIRP	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg03733263	chr8:22462867	KIAA1967	-0.94	-14.79	-0.69	7.89e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-8.99	-0.5	6.64e-17	Menarche (age at onset);
KIRP	cis	rs12765878	1.000	rs3850671	chr10:105659387	T/C	cg11005552	chr10:105648138	OBFC1	0.39	5.47	0.33	1.12e-7	Coronary artery disease;
KIRP	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg00086871	chr4:6988644	TBC1D14	0.77	6.42	0.38	7.15e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg11731671	chr1:2995604	PRDM16	-0.42	-5.31	-0.32	2.51e-7	Plateletcrit;
KIRP	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-5.29	-0.32	2.66e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg24315340	chr6:146058215	EPM2A	-0.37	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg23100626	chr2:96804247	ASTL	0.45	5.66	0.34	4.26e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.76	9.24	0.51	1.2e-17	Multiple sclerosis;
KIRP	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.77	-10.48	-0.56	1.72e-21	Aortic root size;
KIRP	cis	rs6728302	0.557	rs7600132	chr2:233248198	C/A	cg06555452	chr2:233241558	NA	0.73	5.06	0.31	8.19e-7	Height;
KIRP	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.48	6.65	0.39	1.85e-10	Testicular germ cell tumor;
KIRP	cis	rs2030114	0.531	rs1072858	chr16:51593364	C/T	cg03758633	chr16:51611768	NA	0.24	4.88	0.3	1.94e-6	Blood pressure measurement (high sodium and potassium intervention);
KIRP	trans	rs7404843	0.852	rs111259294	chr16:15511930	C/T	cg02716450	chr16:28638775	NA	1.02	10.39	0.55	3.43e-21	Testicular germ cell tumor;
KIRP	cis	rs981844	0.816	rs62325145	chr4:154725687	G/C	cg14289246	chr4:154710475	SFRP2	0.67	7.86	0.45	1.22e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7010876	0.568	rs28649468	chr8:89241535	A/T	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-7.65	-0.44	4.62e-13	Electroencephalogram traits;
KIRP	cis	rs7113874	0.885	rs11042016	chr11:8647124	C/T	cg08015107	chr11:8618950	NA	0.35	4.89	0.3	1.8e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13385	0.769	rs13188675	chr5:139606718	G/A	cg01860693	chr5:139557145	C5orf32	0.46	4.96	0.3	1.32e-6	Atrial fibrillation;
KIRP	cis	rs11718455	0.582	rs6763436	chr3:43913653	A/G	cg08738300	chr3:44038990	NA	-0.59	-7.49	-0.43	1.22e-12	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07494646	chr22:37415349	MPST;TST	0.5	6.91	0.4	4.08e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.75	7.11	0.41	1.27e-11	Axial length;
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13732083	chr21:47605072	C21orf56	0.49	6.48	0.38	5.06e-10	Testicular germ cell tumor;
KIRP	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26002218	chr14:103986227	CKB	0.26	4.98	0.3	1.19e-6	Body mass index;
KIRP	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	1.05	18.99	0.77	3.93e-50	Monocyte count;
KIRP	cis	rs2944591	0.505	rs1083515	chr2:233789463	C/T	cg11972305	chr2:233791962	NGEF	-0.48	-7.14	-0.41	1.04e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	1.0	6.72	0.39	1.24e-10	Type 2 diabetes nephropathy;
KIRP	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.41	0.38	7.45e-10	Bipolar disorder;
KIRP	cis	rs9436747	0.626	rs17412682	chr1:65952293	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.46	-4.86	-0.3	2.08e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg18234130	chr8:27182889	PTK2B	0.56	7.21	0.42	6.91e-12	Neuroticism;
KIRP	cis	rs7769051	0.522	rs77652453	chr6:133142421	A/G	cg07930552	chr6:133119739	C6orf192	0.95	5.04	0.31	9.07e-7	Type 2 diabetes nephropathy;
KIRP	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.75	-11.76	-0.6	1.21e-25	Prostate cancer;
KIRP	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.48	6.21	0.37	2.21e-9	Blood metabolite levels;
KIRP	cis	rs10858047	0.883	rs72698003	chr1:115080934	C/G	cg12756093	chr1:115239321	AMPD1	0.64	6.11	0.36	3.87e-9	Autism;
KIRP	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg14993813	chr1:46806288	NSUN4	-0.48	-5.45	-0.33	1.25e-7	Menopause (age at onset);
KIRP	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg27205649	chr11:78285834	NARS2	-0.52	-5.63	-0.34	4.85e-8	Testicular germ cell tumor;
KIRP	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg05044414	chr3:183734942	ABCC5	0.4	6.07	0.36	4.79e-9	Anterior chamber depth;
KIRP	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg00495681	chr13:53174319	NA	0.38	5.18	0.31	4.61e-7	Lewy body disease;
KIRP	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg12598211	chr12:123634384	NA	-0.42	-5.17	-0.31	4.95e-7	Platelet count;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg02667081	chr16:71880439	ATXN1L	-0.46	-6.15	-0.37	3.08e-9	Neuroticism;
KIRP	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.34	-6.19	-0.37	2.56e-9	Refractive error;
KIRP	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg25356066	chr3:128598488	ACAD9	-0.51	-5.95	-0.35	9.28e-9	IgG glycosylation;
KIRP	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs6960043	0.738	rs6461153	chr7:15059796	G/C	cg19272540	chr7:15055459	NA	-0.25	-7.27	-0.42	4.89e-12	Type 2 diabetes;
KIRP	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02773889	chr13:42615649	NA	1.01	7.25	0.42	5.45e-12	P wave terminal force;
KIRP	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.22	0.37	2.11e-9	Bipolar disorder;
KIRP	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg12598211	chr12:123634384	NA	-0.45	-5.44	-0.33	1.27e-7	Neutrophil percentage of white cells;
KIRP	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	12.18	0.61	4.95e-27	Smoking behavior;
KIRP	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.62	9.05	0.5	4.36e-17	Resting heart rate;
KIRP	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg24296786	chr1:45957014	TESK2	0.62	8.37	0.47	4.3e-15	High light scatter reticulocyte count;
KIRP	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.5	6.45	0.38	5.88e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.41	-5.1	-0.31	6.7e-7	Refractive error;
KIRP	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg09455208	chr3:40491958	NA	0.3	4.96	0.3	1.3e-6	Renal cell carcinoma;
KIRP	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg26876637	chr1:152193138	HRNR	0.76	9.9	0.53	1.17e-19	Atopic dermatitis;
KIRP	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.77	-10.4	-0.55	3.22e-21	Aortic root size;
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg09264619	chr17:80180166	NA	-0.34	-4.87	-0.3	1.96e-6	Life satisfaction;
KIRP	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-6.22	-0.37	2.06e-9	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10211861	chr1:59762176	FGGY	0.49	6.25	0.37	1.81e-9	Parkinson's disease;
KIRP	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.75	0.49	3.36e-16	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12935497	chr15:82339233	MEX3B	0.49	6.04	0.36	5.63e-9	Parkinson's disease;
KIRP	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.03	0.36	5.9e-9	Menopause (age at onset);
KIRP	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg06671706	chr8:8559999	CLDN23	0.42	5.21	0.32	3.9e-7	Obesity-related traits;
KIRP	cis	rs35740288	0.822	rs11630179	chr15:86282934	G/A	cg17133734	chr15:86042851	AKAP13	-0.48	-5.2	-0.31	4.22e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7255045	0.700	rs11085818	chr19:12952271	G/A	cg04657146	chr19:12876947	HOOK2	-0.44	-5.0	-0.3	1.09e-6	Mean corpuscular volume;
KIRP	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.49e-13	IgG glycosylation;
KIRP	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.11	12.29	0.62	2.27e-27	Corneal structure;
KIRP	cis	rs7719624	0.870	rs3792900	chr5:135393754	A/G	cg16684184	chr5:135415129	NA	0.32	4.84	0.3	2.25e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.73	-0.34	2.94e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg17252645	chr8:143867129	LY6D	-0.31	-4.92	-0.3	1.61e-6	Urinary tract infection frequency;
KIRP	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	cg04338863	chr8:33670619	NA	0.49	6.38	0.38	8.73e-10	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19215677	chr7:2395142	EIF3B	0.49	6.64	0.39	2.01e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg25214090	chr10:38739885	LOC399744	0.48	6.09	0.36	4.41e-9	Diastolic blood pressure;
KIRP	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.54	-0.33	7.7e-8	Parkinson's disease;
KIRP	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05025164	chr4:1340916	KIAA1530	0.45	6.02	0.36	6.23e-9	Obesity-related traits;
KIRP	cis	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg15590007	chr10:45870220	ALOX5	0.59	5.62	0.34	5.23e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.66	-7.56	-0.43	8.04e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.76	0.34	2.5e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs918629	0.530	rs7702674	chr5:95237365	A/C	cg16656078	chr5:95278638	ELL2	-0.37	-5.65	-0.34	4.37e-8	IgG glycosylation;
KIRP	trans	rs76288851	0.799	rs7611422	chr3:126634929	T/C	cg13821433	chr2:26726535	OTOF	0.58	6.44	0.38	6.29e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-1.11	-25.5	-0.85	5.25e-71	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.77	-9.17	-0.5	2e-17	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17376030	chr22:41985996	PMM1	0.83	8.78	0.49	2.73e-16	Vitiligo;
KIRP	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-5.69	-0.34	3.69e-8	Renal function-related traits (BUN);
KIRP	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.54	-7.38	-0.43	2.46e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg24807547	chr6:37504484	NA	-0.55	-8.22	-0.46	1.19e-14	Cognitive performance;
KIRP	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.69	9.16	0.5	2.08e-17	Morning vs. evening chronotype;
KIRP	cis	rs2290402	0.536	rs4690339	chr4:854712	T/C	cg00846425	chr4:957561	DGKQ	-0.48	-5.29	-0.32	2.76e-7	Type 2 diabetes;
KIRP	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg12315302	chr6:26189340	HIST1H4D	0.87	5.61	0.34	5.37e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.79e-15	Prudent dietary pattern;
KIRP	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.67	-6.56	-0.39	3.24e-10	Migraine;Coronary artery disease;
KIRP	cis	rs7258465	1.000	rs3810429	chr19:18543270	G/T	cg06953865	chr19:18549723	ISYNA1	-0.4	-6.12	-0.36	3.66e-9	Breast cancer;
KIRP	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg11845111	chr2:191398756	TMEM194B	-0.74	-8.05	-0.46	3.54e-14	Diastolic blood pressure;
KIRP	cis	rs7973683	0.513	rs57316347	chr12:124389053	A/G	cg12597309	chr12:124393772	DNAH10	0.4	4.88	0.3	1.88e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg21285383	chr16:89894308	SPIRE2	0.34	6.5	0.38	4.48e-10	Vitiligo;
KIRP	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg27205649	chr11:78285834	NARS2	-0.56	-5.48	-0.33	1.05e-7	Testicular germ cell tumor;
KIRP	cis	rs7503807	0.688	rs901062	chr17:78595674	C/T	cg09596252	chr17:78655493	RPTOR	0.53	5.97	0.36	8.27e-9	Obesity;
KIRP	cis	rs427941	0.668	rs201461	chr7:101741625	T/C	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.27e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.81	8.22	0.46	1.2e-14	Prostate cancer;
KIRP	cis	rs6466055	0.576	rs1011468	chr7:104613791	G/A	cg04380332	chr7:105027541	SRPK2	-0.41	-5.62	-0.34	5.26e-8	Schizophrenia;
KIRP	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6684428	0.706	rs10493183	chr1:56333648	T/C	cg11651538	chr1:56320950	NA	-0.93	-12.57	-0.63	2.48e-28	Airflow obstruction;
KIRP	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg02820040	chr2:241836501	C2orf54	-0.24	-5.52	-0.33	8.7e-8	Urinary metabolites;
KIRP	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg00343986	chr7:65444356	GUSB	-0.44	-5.24	-0.32	3.39e-7	Aortic root size;
KIRP	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.3	0.47	6.98e-15	Motion sickness;
KIRP	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.31	-0.32	2.47e-7	Pulmonary function;
KIRP	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg18461458	chr19:21324796	ZNF431	0.48	5.08	0.31	7.57e-7	Pain;
KIRP	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.95	10.61	0.56	6.66e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-6.57	-0.39	3.02e-10	Gut microbiome composition (summer);
KIRP	cis	rs714027	0.585	rs41156	chr22:30404653	T/C	cg01021169	chr22:30184971	ASCC2	0.4	5.0	0.3	1.1e-6	Lymphocyte counts;
KIRP	cis	rs9469913	0.740	rs2814977	chr6:34576433	G/A	cg17674042	chr6:34482479	PACSIN1	-0.49	-6.48	-0.38	5.04e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05220968	chr6:146057943	EPM2A	-0.41	-5.41	-0.33	1.48e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-9.05	-0.5	4.49e-17	Hemoglobin concentration;
KIRP	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.66	9.63	0.52	7.69e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7084783	0.500	rs10883892	chr10:105397102	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.45	5.57	0.33	6.58e-8	Fear of pain;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg05627522	chr15:75251581	NA	0.33	5.02	0.31	9.72e-7	Breast cancer;
KIRP	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7248779	0.512	rs3848635	chr19:2410332	T/C	cg22729335	chr19:2427816	TIMM13	1.09	17.34	0.74	1.53e-44	Cortisol levels (saliva);
KIRP	cis	rs580438	0.889	rs357127	chr3:13337290	C/T	cg10657019	chr3:13328039	NA	0.82	10.77	0.57	2.06e-22	Myringotomy;
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg12463550	chr7:65579703	CRCP	-0.43	-4.89	-0.3	1.79e-6	Aortic root size;
KIRP	cis	rs9309473	0.519	rs6730785	chr2:73642403	A/C	cg20560298	chr2:73613845	ALMS1	0.5	6.07	0.36	4.74e-9	Metabolite levels;
KIRP	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg18478394	chr8:109455254	TTC35	0.49	5.96	0.36	8.86e-9	Dupuytren's disease;
KIRP	cis	rs1440410	0.835	rs13107465	chr4:144068817	T/C	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.73	5.86	0.35	1.51e-8	Diabetic retinopathy;
KIRP	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg16586182	chr3:47516702	SCAP	0.75	10.03	0.54	4.45e-20	Colorectal cancer;
KIRP	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg04374321	chr14:90722782	PSMC1	-0.84	-12.11	-0.61	8.57e-27	Mortality in heart failure;
KIRP	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg01304814	chr3:48885189	PRKAR2A	0.71	5.4	0.33	1.56e-7	Cognitive function;
KIRP	cis	rs9900972	0.918	rs4789940	chr17:76877671	G/T	cg00961940	chr17:76876995	TIMP2	0.52	7.04	0.41	1.91e-11	Obesity-related traits;
KIRP	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.12	0.41	1.19e-11	Aortic root size;
KIRP	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs16828019	0.852	rs2300649	chr1:41569203	T/C	cg24596898	chr1:41849189	NA	0.63	5.19	0.31	4.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.63	10.36	0.55	4.02e-21	Coronary artery disease;
KIRP	cis	rs412050	0.547	rs79111189	chr22:22164597	T/G	cg17089214	chr22:22089827	YPEL1	0.62	5.6	0.34	5.7e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.62	0.34	5.16e-8	Lung cancer;
KIRP	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Hypertriglyceridemia;
KIRP	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.59e-9	Colorectal cancer;
KIRP	cis	rs3829251	0.786	rs7103591	chr11:71237619	T/C	cg05163923	chr11:71159392	DHCR7	-0.7	-6.73	-0.39	1.17e-10	Vitamin D levels;
KIRP	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01256987	chr12:42539512	GXYLT1	-0.45	-5.88	-0.35	1.35e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg20673091	chr1:2541236	MMEL1	0.67	10.23	0.55	1.08e-20	Ulcerative colitis;
KIRP	cis	rs11214589	0.747	rs1893695	chr11:113206085	A/C	cg14159747	chr11:113255604	NA	0.39	5.92	0.35	1.07e-8	Neuroticism;
KIRP	cis	rs3789045	0.707	rs61421373	chr1:204560440	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.5	-5.19	-0.31	4.34e-7	Educational attainment (college completion);
KIRP	cis	rs7246657	0.722	rs12979640	chr19:38179156	T/C	cg18154014	chr19:37997991	ZNF793	-0.55	-6.19	-0.37	2.55e-9	Coronary artery calcification;
KIRP	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.57	8.2	0.46	1.38e-14	Carotid intima media thickness;
KIRP	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.43	-7.51	-0.43	1.09e-12	Refractive error;
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07570687	chr10:102243282	WNT8B	0.48	6.21	0.37	2.29e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs67478160	0.608	rs11628787	chr14:104323984	G/A	cg01849466	chr14:104193079	ZFYVE21	0.6	7.9	0.45	9.09e-14	Schizophrenia;
KIRP	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.61	6.07	0.36	4.74e-9	Breast cancer;
KIRP	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.74	-9.32	-0.51	6.78e-18	Response to antipsychotic treatment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16968413	chr4:39183824	WDR19	0.43	6.56	0.39	3.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs62355272	0.897	rs11950831	chr5:35922070	A/G	cg13894535	chr5:35919491	CAPSL	-0.54	-6.42	-0.38	6.78e-10	Lymphocyte counts;
KIRP	cis	rs9815354	0.812	rs73069292	chr3:41973963	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.48	1.5e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6450176	0.585	rs255761	chr5:53321956	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-11.65	-0.6	2.93e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg08533674	chr1:46993347	NA	0.4	5.24	0.32	3.47e-7	Monobrow;
KIRP	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg05315796	chr3:52349193	DNAH1	0.41	5.28	0.32	2.87e-7	Schizophrenia;
KIRP	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.53	0.38	3.8e-10	Rheumatoid arthritis;
KIRP	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18364779	chr6:26104403	HIST1H4C	0.38	5.1	0.31	6.88e-7	Schizophrenia;
KIRP	cis	rs2905347	0.726	rs2961294	chr7:22695031	T/C	cg23521230	chr7:22704884	NA	0.41	5.19	0.31	4.46e-7	Major depression and alcohol dependence;
KIRP	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	15.2	0.7	3.03e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8048576	0.512	rs8063863	chr16:84400850	C/T	cg03548384	chr16:84403863	ATP2C2	-0.57	-8.51	-0.48	1.76e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg00666640	chr1:248458726	OR2T12	0.45	5.41	0.33	1.47e-7	Common traits (Other);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01112927	chr2:71357293	MCEE;MPHOSPH10	0.47	6.17	0.37	2.73e-9	Parkinson's disease;
KIRP	cis	rs1010254	0.559	rs55693068	chr5:151750439	T/A	cg12297329	chr5:152029980	NA	-0.66	-6.62	-0.39	2.28e-10	Optic nerve measurement (cup area);
KIRP	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.57	-0.33	6.52e-8	Height;
KIRP	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.52	7.96	0.45	6.26e-14	Migraine;
KIRP	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.44	6.19	0.37	2.45e-9	Testicular germ cell tumor;
KIRP	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg03315344	chr16:75512273	CHST6	0.72	11.3	0.58	4.08e-24	Dupuytren's disease;
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg22325292	chr17:80708367	FN3K	-0.42	-6.34	-0.37	1.11e-9	Glycated hemoglobin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13747199	chr9:2016340	SMARCA2	0.47	6.63	0.39	2.09e-10	Survival in pancreatic cancer;
KIRP	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.59	7.97	0.45	6.1e-14	Bladder cancer;
KIRP	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.81	-10.87	-0.57	9.6e-23	Eosinophil percentage of white cells;
KIRP	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	6.62	0.39	2.19e-10	Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg11204139	chr17:3907470	NA	0.58	5.76	0.34	2.54e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.56	8.85	0.49	1.77e-16	Bone mineral density;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.72	10.52	0.56	1.32e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg08662619	chr6:150070041	PCMT1	0.39	6.2	0.37	2.4e-9	Lung cancer;
KIRP	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg01620082	chr3:125678407	NA	-0.85	-6.31	-0.37	1.26e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg16590910	chr6:42928470	GNMT	0.41	5.73	0.34	2.89e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-1.02	-17.35	-0.74	1.44e-44	Height;
KIRP	cis	rs882732	1.000	rs1005348	chr14:95033275	T/G	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.6	-0.34	5.79e-8	Blood protein levels;
KIRP	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg05802129	chr4:122689817	NA	-0.47	-6.08	-0.36	4.51e-9	Type 2 diabetes;
KIRP	cis	rs10210302	0.502	rs880116	chr2:234246264	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.55	6.66	0.39	1.8e-10	Crohn's disease;
KIRP	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.43	-0.47	2.88e-15	Type 2 diabetes;
KIRP	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.55	-7.11	-0.41	1.22e-11	Morning vs. evening chronotype;
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.49	-6.34	-0.37	1.11e-9	Testicular germ cell tumor;
KIRP	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.38	-5.15	-0.31	5.39e-7	Monocyte percentage of white cells;
KIRP	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.92	-0.4	3.85e-11	Acne (severe);
KIRP	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg09165964	chr15:75287851	SCAMP5	0.42	5.37	0.32	1.78e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs501120	0.584	rs2664856	chr10:44702967	G/T	cg09554077	chr10:44749378	NA	0.6	6.26	0.37	1.67e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg17764715	chr19:33622953	WDR88	-0.67	-8.28	-0.47	8.04e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg10381502	chr11:71823885	C11orf51	1.18	7.21	0.42	6.73e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs9513627	1.000	rs7334844	chr13:100121047	G/C	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs72730918	0.590	rs2606137	chr15:51970335	G/A	cg14296394	chr15:51910925	DMXL2	-0.66	-9.36	-0.51	5.14e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg10254082	chr7:997346	NA	0.48	5.03	0.31	9.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.2	0.31	4.22e-7	Life satisfaction;
KIRP	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.73	-8.67	-0.48	5.83e-16	Diastolic blood pressure;
KIRP	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	1.09	20.0	0.79	1.68e-53	Bone mineral density;
KIRP	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.77	0.4	9.58e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.22	-0.32	3.86e-7	Cognitive function;
KIRP	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	1.09	17.85	0.75	2.83e-46	Cognitive function;
KIRP	cis	rs17604090	0.938	rs850029	chr7:29678087	A/G	cg19413766	chr7:29689036	LOC646762	-0.58	-5.14	-0.31	5.7e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18191867	chr1:65722872	NA	0.49	6.46	0.38	5.68e-10	Interleukin-4 levels;
KIRP	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg06637938	chr14:75390232	RPS6KL1	0.55	7.85	0.45	1.31e-13	Height;
KIRP	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.98	-0.36	7.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2569991	0.636	rs9211	chr3:12939546	A/G	cg22481960	chr3:13008800	IQSEC1	0.48	4.89	0.3	1.83e-6	Periodontitis (DPAL);
KIRP	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.7	0.39	1.37e-10	Colorectal cancer;
KIRP	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg13318129	chr22:45737514	FAM118A	0.62	7.2	0.42	7.37e-12	Tonsillectomy;
KIRP	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.33	-0.65	7.29e-31	Primary sclerosing cholangitis;
KIRP	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg26876637	chr1:152193138	HRNR	0.78	10.24	0.55	9.91e-21	Atopic dermatitis;
KIRP	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.46	-6.16	-0.37	2.98e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.46	5.84	0.35	1.68e-8	HDL cholesterol;
KIRP	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-13.1	-0.64	4.35e-30	Blood metabolite levels;
KIRP	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	trans	rs12043259	0.730	rs2093539	chr1:204785215	C/T	cg11485465	chr5:54518469	NA	0.37	6.5	0.38	4.55e-10	Addiction;
KIRP	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg09788416	chr12:39539408	NA	0.4	5.43	0.33	1.33e-7	Morning vs. evening chronotype;
KIRP	trans	rs55728055	0.661	rs62237845	chr22:32027892	G/A	cg02791973	chr19:1132256	SBNO2	-0.61	-6.64	-0.39	1.96e-10	Age-related hearing impairment;
KIRP	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.7	0.34	3.46e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg02811702	chr13:24901961	NA	0.42	5.34	0.32	2.11e-7	Obesity-related traits;
KIRP	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg13319975	chr6:146136371	FBXO30	0.43	5.89	0.35	1.28e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.58	-0.39	2.75e-10	Joint mobility (Beighton score);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10089324	chr1:51984752	EPS15	0.48	6.25	0.37	1.77e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.07	0.41	1.58e-11	Height;
KIRP	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	1.1	12.2	0.61	4.46e-27	Psoriasis;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg20362242	chr5:692897	TPPP	0.56	4.86	0.3	2.06e-6	Obesity-related traits;
KIRP	cis	rs2172802	0.543	rs1497897	chr4:62544055	T/A	cg04118610	chr4:62707027	LPHN3	0.44	5.49	0.33	9.8e-8	Partial epilepsies;
KIRP	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.46	-5.91	-0.35	1.11e-8	Body mass index;
KIRP	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.01	9.07	0.5	3.93e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg11814155	chr7:99998594	ZCWPW1	0.58	5.39	0.33	1.65e-7	Platelet count;
KIRP	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-5.77	-0.35	2.43e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	6.38	0.38	8.76e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.65	7.95	0.45	6.63e-14	Alcohol dependence;
KIRP	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg26811252	chr16:29126840	RRN3P2	0.66	8.91	0.49	1.19e-16	Menopause (age at onset);
KIRP	cis	rs35995292	0.534	rs11980627	chr7:38907533	T/C	cg19327137	chr7:38886074	VPS41	0.82	13.06	0.64	5.81e-30	Subjective well-being (multi-trait analysis);
KIRP	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	Neuroticism;
KIRP	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg11833968	chr6:79620685	NA	-0.35	-4.86	-0.3	2.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg11608241	chr8:8085544	FLJ10661	0.45	5.76	0.34	2.5e-8	Systolic blood pressure;
KIRP	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.59	5.49	0.33	9.94e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg24972876	chr7:65420302	NA	-0.45	-6.38	-0.38	8.56e-10	Calcium levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03056341	chr11:64546100	SF1	0.48	6.13	0.36	3.48e-9	Parkinson's disease;
KIRP	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg11945507	chr8:142233382	SLC45A4	0.87	14.63	0.68	2.67e-35	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg13319975	chr6:146136371	FBXO30	0.49	6.84	0.4	6.24e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4236601	0.720	rs17516287	chr7:116154186	C/G	cg12739419	chr7:116140593	CAV2	0.45	5.67	0.34	3.9e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg06769989	chr5:115929014	NA	-0.42	-6.2	-0.37	2.3e-9	Select biomarker traits;
KIRP	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg18944383	chr4:111397179	ENPEP	0.64	12.37	0.62	1.22e-27	Height;
KIRP	cis	rs2274273	0.624	rs7147247	chr14:55777713	A/T	cg04306507	chr14:55594613	LGALS3	0.38	5.29	0.32	2.71e-7	Protein biomarker;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7119038	0.509	rs11216956	chr11:118575326	G/A	cg19308663	chr11:118741387	NA	0.42	6.52	0.38	3.93e-10	Sjögren's syndrome;
KIRP	cis	rs17608059	0.611	rs62052300	chr17:13916799	G/A	cg11395062	chr17:14139857	CDRT15	0.51	6.44	0.38	6.09e-10	Temperament;
KIRP	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.02	0.3	1.01e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.41	0.33	1.46e-7	Melanoma;
KIRP	cis	rs6484504	0.532	rs7117286	chr11:31283810	T/A	cg26647111	chr11:31128758	NA	-0.43	-5.1	-0.31	6.69e-7	Red blood cell count;
KIRP	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg21095983	chr6:86352623	SYNCRIP	0.57	7.49	0.43	1.24e-12	Smooth-surface caries;
KIRP	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg14159672	chr1:205819179	PM20D1	-0.57	-5.17	-0.31	4.88e-7	Menarche (age at onset);
KIRP	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg18806716	chr10:30721971	MAP3K8	-0.31	-5.08	-0.31	7.43e-7	Inflammatory bowel disease;
KIRP	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg04025307	chr7:1156635	C7orf50	0.49	4.9	0.3	1.76e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.53	0.43	9.41e-13	Mean corpuscular volume;
KIRP	cis	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.1	-0.31	6.64e-7	Leprosy;
KIRP	cis	rs7224685	0.569	rs12940782	chr17:3992712	T/C	cg11204139	chr17:3907470	NA	0.57	5.31	0.32	2.4e-7	Type 2 diabetes;
KIRP	cis	rs859767	0.501	rs1568121	chr2:135406606	G/A	cg12500956	chr2:135428796	TMEM163	-0.41	-5.59	-0.34	6.07e-8	Neuroticism;
KIRP	cis	rs2294693	0.685	rs67525613	chr6:41008956	G/T	cg14769373	chr6:40998127	UNC5CL	-0.59	-5.52	-0.33	8.77e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg24972876	chr7:65420302	NA	0.36	4.93	0.3	1.52e-6	Aortic root size;
KIRP	cis	rs7116495	1.000	rs7106748	chr11:71645803	A/C	cg11196788	chr11:71737549	NUMA1	0.57	5.12	0.31	6.31e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs10849605	1.000	rs10849605	chr12:1064438	C/T	cg22243222	chr12:1059299	RAD52	0.43	6.37	0.38	9.39e-10	Lung cancer;
KIRP	cis	rs7116495	0.609	rs2508860	chr11:71805052	C/T	cg26138937	chr11:71823887	C11orf51	1.13	7.27	0.42	4.73e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs2562456	0.833	rs2562416	chr19:21613411	A/G	cg18461458	chr19:21324796	ZNF431	-0.57	-5.45	-0.33	1.25e-7	Pain;
KIRP	cis	rs6681460	0.649	rs1856315	chr1:67005229	A/G	cg13052034	chr1:66999238	SGIP1	0.42	5.99	0.36	7.21e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg07423050	chr13:99094983	FARP1	0.32	5.32	0.32	2.37e-7	Longevity;
KIRP	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg14092988	chr3:52407081	DNAH1	0.32	5.87	0.35	1.43e-8	Bipolar disorder;
KIRP	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs7246865	0.954	rs1060367	chr19:17215202	G/A	cg18440316	chr19:18077727	KCNN1	-0.39	-5.43	-0.33	1.37e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	4.99	0.3	1.13e-6	Renal cell carcinoma;
KIRP	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.94	10.96	0.57	5.16e-23	Menarche (age at onset);
KIRP	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg24826892	chr11:71159390	DHCR7	-0.46	-5.14	-0.31	5.62e-7	Vitamin D levels;
KIRP	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg01620082	chr3:125678407	NA	-1.03	-6.55	-0.39	3.28e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.54	-6.18	-0.37	2.63e-9	Coronary artery disease;
KIRP	cis	rs988913	0.874	rs4712084	chr6:54861284	G/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.44	-0.33	1.29e-7	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07185584	chr20:19997881	NAA20	0.54	6.35	0.38	1e-9	Smoking initiation;
KIRP	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg06121193	chr1:90282411	NA	0.52	7.34	0.42	3.07e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.65	-11.01	-0.57	3.44e-23	White blood cell count (basophil);
KIRP	trans	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.51	0.43	1.08e-12	Diabetic kidney disease;
KIRP	cis	rs7870753	1.000	rs7857261	chr9:99219779	C/T	cg25260653	chr9:99212216	HABP4	0.53	5.96	0.36	8.71e-9	Height;
KIRP	cis	rs9525927	0.521	rs4942298	chr13:44798622	G/A	cg19190762	chr13:44806055	NA	0.5	5.33	0.32	2.26e-7	Dupuytren's disease;
KIRP	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.25	0.47	9.82e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10633746	chr17:18164442	SMCR7	0.48	6.38	0.38	8.78e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs55788414	0.932	rs35424543	chr16:81181983	G/A	cg06400318	chr16:81190750	PKD1L2	-1.21	-8.18	-0.46	1.5e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs9921338	0.961	rs9936328	chr16:11438221	T/A	cg00044050	chr16:11439710	C16orf75	-0.56	-5.98	-0.36	7.84e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.84	-0.53	1.77e-19	Menopause (age at onset);
KIRP	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.66	-0.48	6.21e-16	Coronary artery disease;
KIRP	cis	rs4006360	0.511	rs7503699	chr17:39258027	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.47	-6.74	-0.39	1.14e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.99	17.44	0.74	7.08e-45	Breast cancer;
KIRP	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.78	7.06	0.41	1.67e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.66	-9.65	-0.52	6.82e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs16857609	0.564	rs13425215	chr2:218288580	A/G	cg15335768	chr2:218268053	DIRC3	-0.48	-6.08	-0.36	4.46e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08831369	chr1:197511177	DENND1B	0.41	6.3	0.37	1.39e-9	Migraine with aura;
KIRP	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg24579218	chr15:68104479	NA	-0.4	-6.15	-0.36	3.16e-9	Restless legs syndrome;
KIRP	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg04998671	chr14:104000505	TRMT61A	-0.54	-6.38	-0.38	8.83e-10	Coronary artery disease;
KIRP	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg00784671	chr22:46762841	CELSR1	-0.76	-7.75	-0.44	2.37e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg03315344	chr16:75512273	CHST6	0.72	11.3	0.58	4.08e-24	Dupuytren's disease;
KIRP	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.75	6.97	0.41	2.87e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg24253500	chr15:84953950	NA	0.51	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-1.0	-11.99	-0.61	2.17e-26	Breast cancer;
KIRP	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs7760535	0.794	rs12529158	chr6:111822447	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.46	5.93	0.35	1e-8	Metabolic traits;
KIRP	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.37	1.98e-9	Aortic root size;
KIRP	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg23649088	chr2:200775458	C2orf69	-0.57	-4.93	-0.3	1.51e-6	Schizophrenia;
KIRP	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg03714773	chr7:91764589	CYP51A1	-0.38	-5.56	-0.33	7.01e-8	Breast cancer;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14472025	chr9:136039125	GBGT1	0.44	6.27	0.37	1.58e-9	Myopia (pathological);
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.79	10.74	0.56	2.61e-22	Longevity;
KIRP	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg23024343	chr7:107201750	COG5	0.42	4.87	0.3	1.98e-6	Coronary artery disease;
KIRP	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-5.78	-0.35	2.27e-8	Educational attainment;
KIRP	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.46	-0.38	5.69e-10	Aortic root size;
KIRP	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.45	0.33	1.21e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	1.11	17.89	0.75	2.12e-46	Homoarginine levels;
KIRP	cis	rs988913	0.647	rs4715519	chr6:54988593	T/A	cg03513858	chr6:54763001	FAM83B	0.39	5.55	0.33	7.49e-8	Menarche (age at onset);
KIRP	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.8	11.49	0.59	9.54e-25	Bladder cancer;
KIRP	cis	rs2273156	1.000	rs17102904	chr14:35441049	A/C	cg09327582	chr14:35236912	BAZ1A	0.47	5.27	0.32	3.02e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs231513	0.655	rs231446	chr17:42005193	G/A	cg26893861	chr17:41843967	DUSP3	-0.51	-5.11	-0.31	6.57e-7	Cognitive function;
KIRP	cis	rs6450176	0.564	rs374050	chr5:53331646	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-8.71	-0.49	4.54e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.69	-11.51	-0.59	8.43e-25	Urate levels in overweight individuals;
KIRP	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs1961637	1.000	rs1961637	chr2:223905108	G/T	cg02552189	chr2:223891284	NA	-0.38	-5.21	-0.32	4.04e-7	Oropharynx cancer;
KIRP	cis	rs7033996	1.000	rs16932775	chr9:35935066	G/C	cg00918944	chr9:35908117	LOC158376	0.36	5.08	0.31	7.29e-7	Urate levels (BMI interaction);
KIRP	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.12	0.5	2.75e-17	Total body bone mineral density;
KIRP	cis	rs7527798	0.955	rs36019152	chr1:207862698	T/A	cg09232269	chr1:207846808	CR1L	-0.42	-5.03	-0.31	9.48e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs4776059	1.000	rs2414166	chr15:52901977	C/T	cg22715398	chr15:52968154	KIAA1370	-0.66	-8.23	-0.46	1.12e-14	Schizophrenia;
KIRP	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-8.05	-0.46	3.49e-14	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.84	0.35	1.65e-8	Aortic root size;
KIRP	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg07148914	chr20:33460835	GGT7	-0.54	-7.12	-0.41	1.21e-11	Height;
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg11204139	chr17:3907470	NA	-0.81	-14.22	-0.67	6.5e-34	Type 2 diabetes;
KIRP	cis	rs6959887	0.926	rs56834372	chr7:35276234	T/C	cg06685737	chr7:35301730	NA	0.44	6.3	0.37	1.34e-9	Birth weight;
KIRP	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs4774899	1.000	rs12899036	chr15:57476452	C/A	cg08128148	chr15:57256372	TCF12	-0.34	-4.93	-0.3	1.52e-6	Urinary tract infection frequency;
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg02807482	chr3:125708958	NA	-0.52	-4.91	-0.3	1.69e-6	Blood pressure (smoking interaction);
KIRP	cis	rs3540	0.513	rs2589957	chr15:90903311	A/G	cg22089800	chr15:90895588	ZNF774	0.62	8.47	0.48	2.27e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg19773385	chr1:10388646	KIF1B	-0.67	-8.8	-0.49	2.48e-16	Hepatocellular carcinoma;
KIRP	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.11e-10	Prudent dietary pattern;
KIRP	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.32	0.37	1.24e-9	Educational attainment;
KIRP	cis	rs2425143	1.000	rs2425141	chr20:34350123	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.06	-0.36	5.04e-9	Blood protein levels;
KIRP	cis	rs7590368	0.673	rs17456162	chr2:10948090	C/T	cg15705551	chr2:10952987	PDIA6	-0.65	-6.28	-0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs812925	0.784	rs7588041	chr2:61461412	C/T	cg15711740	chr2:61764176	XPO1	0.43	5.01	0.3	1.05e-6	Immature fraction of reticulocytes;
KIRP	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg22974920	chr21:40686053	BRWD1	0.5	5.64	0.34	4.77e-8	Cognitive function;
KIRP	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.64	8.12	0.46	2.2e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg15704280	chr7:45808275	SEPT13	0.69	6.11	0.36	3.94e-9	Axial length;
KIRP	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.6	-0.39	2.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.57	7.55	0.43	8.61e-13	Endometrial cancer;
KIRP	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.74	-10.93	-0.57	6.31e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.6	7.26	0.42	5.07e-12	Platelet count;
KIRP	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg25801113	chr15:45476975	SHF	0.43	7.93	0.45	7.77e-14	Uric acid levels;
KIRP	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.85	0.49	1.78e-16	Motion sickness;
KIRP	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.36	-0.38	9.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4716602	0.596	rs36013171	chr7:156160511	C/T	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs35123781	0.696	rs13179952	chr5:139070573	C/G	cg10513866	chr5:139070639	NA	0.54	7.41	0.43	2.04e-12	Schizophrenia;
KIRP	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-9.29	-0.51	8.27e-18	Coronary artery disease;
KIRP	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.33	0.47	5.8e-15	Lung cancer in ever smokers;
KIRP	cis	rs6991838	0.584	rs4320587	chr8:66499226	G/A	cg13398993	chr8:66546079	ARMC1	-0.47	-5.44	-0.33	1.31e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8014252	0.803	rs57339942	chr14:71083307	T/A	cg11204974	chr14:71022665	NA	-0.78	-7.65	-0.44	4.65e-13	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg06223162	chr1:101003688	GPR88	-0.42	-8.65	-0.48	6.73e-16	Monocyte count;
KIRP	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16386425	chr10:429943	DIP2C	-0.5	-6.94	-0.4	3.43e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-8.92	-0.49	1.07e-16	Hepatocellular carcinoma;
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg11814155	chr7:99998594	ZCWPW1	0.62	5.5	0.33	9.47e-8	Platelet count;
KIRP	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg24579218	chr15:68104479	NA	-0.37	-5.37	-0.32	1.79e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg20387954	chr3:183756860	HTR3D	0.59	8.57	0.48	1.19e-15	Anterior chamber depth;
KIRP	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-1.0	-16.44	-0.72	1.76e-41	Monocyte count;
KIRP	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg02073558	chr3:44770973	ZNF501	0.74	11.96	0.61	2.72e-26	Depressive symptoms;
KIRP	cis	rs72634258	0.945	rs12727642	chr1:8046672	C/A	cg00042356	chr1:8021962	PARK7	0.93	7.43	0.43	1.81e-12	Inflammatory bowel disease;
KIRP	trans	rs199950	0.911	rs199951	chr1:181592697	T/C	cg04237608	chr1:18659049	IGSF21	0.33	6.08	0.36	4.64e-9	Body mass index (change over time);
KIRP	cis	rs10901296	0.660	rs2855197	chr9:133764406	A/G	cg13397898	chr9:133768931	QRFP	0.34	5.96	0.36	8.81e-9	Bilirubin levels;
KIRP	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg25173405	chr17:45401733	C17orf57	-0.47	-6.03	-0.36	5.86e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg17724175	chr1:150552817	MCL1	0.38	6.54	0.38	3.53e-10	Tonsillectomy;
KIRP	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	8.8	0.49	2.48e-16	Exhaled nitric oxide output;
KIRP	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.49	6.87	0.4	5.37e-11	Type 2 diabetes;
KIRP	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg09137382	chr11:130731461	NA	0.43	5.9	0.35	1.17e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs17065868	0.764	rs6561176	chr13:45015449	T/C	cg10246903	chr13:45222710	NA	0.51	4.94	0.3	1.45e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.42	5.64	0.34	4.65e-8	Childhood ear infection;
KIRP	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg00405596	chr8:11794950	NA	-0.51	-6.72	-0.39	1.22e-10	Triglycerides;
KIRP	cis	rs904251	0.802	rs2646933	chr6:37402070	C/G	cg25019722	chr6:37503610	NA	-0.72	-8.18	-0.46	1.52e-14	Cognitive performance;
KIRP	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg26084005	chr2:241760190	KIF1A	-0.48	-6.77	-0.4	9.66e-11	Urinary metabolites;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04358685	chr3:12598421	MKRN2	-0.5	-6.81	-0.4	7.23e-11	Myopia;
KIRP	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	1.04	11.27	0.58	4.88e-24	Alzheimer's disease;
KIRP	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.95e-9	Response to antipsychotic treatment;
KIRP	cis	rs57994353	0.600	rs10870172	chr9:139319469	G/A	cg14169450	chr9:139327907	INPP5E	0.53	6.1	0.36	4.12e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-6.91	-0.4	4.04e-11	Retinal vascular caliber;
KIRP	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg25019033	chr10:957182	NA	-0.59	-6.41	-0.38	7.21e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs12580194	0.593	rs73326725	chr12:55749222	G/C	cg11794356	chr12:55725991	OR6C3	-0.53	-7.09	-0.41	1.41e-11	Cancer;
KIRP	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg06636001	chr8:8085503	FLJ10661	0.66	8.36	0.47	4.78e-15	Neuroticism;
KIRP	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27297192	chr10:134578999	INPP5A	-0.65	-8.09	-0.46	2.8e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.53	-0.38	3.66e-10	Cardiac Troponin-T levels;
KIRP	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.96	12.89	0.63	2.13e-29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg08923054	chr8:41654455	ANK1	0.74	8.59	0.48	1.04e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg11518657	chr1:67396239	MIER1	0.49	4.89	0.3	1.86e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.71	0.49	4.39e-16	Morning vs. evening chronotype;
KIRP	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.54	-0.33	7.91e-8	Bipolar disorder;
KIRP	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.57	7.57	0.43	7.67e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg12560992	chr17:57184187	TRIM37	0.6	6.38	0.38	8.81e-10	Testicular germ cell tumor;
KIRP	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg09788416	chr12:39539408	NA	0.4	5.11	0.31	6.38e-7	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.67	9.57	0.52	1.16e-18	Colorectal cancer;
KIRP	cis	rs72772090	0.539	rs72773989	chr5:96163613	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7721647	0.853	rs6867266	chr5:90873294	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.29	0.51	8.32e-18	Cognitive test performance;
KIRP	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.96	11.36	0.59	2.48e-24	Exhaled nitric oxide levels;
KIRP	cis	rs17123764	0.892	rs12306430	chr12:50123915	T/G	cg20471783	chr12:50157085	TMBIM6	0.42	5.99	0.36	7.49e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg26384229	chr12:38710491	ALG10B	0.62	7.86	0.45	1.19e-13	Resting heart rate;
KIRP	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg18261050	chr1:119551319	NA	0.49	6.17	0.37	2.82e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs2151522	0.724	rs761356	chr6:127135132	A/G	cg21431617	chr6:127135037	NA	0.3	5.52	0.33	8.66e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs9359856	0.636	rs3748085	chr6:90315789	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.59	-6.74	-0.39	1.14e-10	Bipolar disorder;
KIRP	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.09	-0.31	7.28e-7	Rheumatoid arthritis;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-1.1	-25.26	-0.85	2.71e-70	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	0.47	6.06	0.36	5.11e-9	Systemic lupus erythematosus;
KIRP	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18252515	chr7:66147081	NA	-0.47	-5.46	-0.33	1.14e-7	Aortic root size;
KIRP	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg07423050	chr13:99094983	FARP1	0.32	5.34	0.32	2.08e-7	Longevity;
KIRP	trans	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.46	-0.38	5.59e-10	Neuroticism;
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg16034541	chr3:195490309	MUC4	0.52	5.09	0.31	7.04e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.56	6.97	0.41	2.96e-11	P wave terminal force;
KIRP	cis	rs9596863	0.851	rs1379832	chr13:54429818	C/T	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.64	8.03	0.46	4.04e-14	Tonsillectomy;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg08282784	chr12:121454133	C12orf43	0.5	6.17	0.37	2.77e-9	Bladder cancer;
KIRP	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.71	9.1	0.5	3.08e-17	Heart rate;
KIRP	trans	rs12043259	0.772	rs1543869	chr1:204823097	C/T	cg11485465	chr5:54518469	NA	0.41	6.53	0.38	3.76e-10	Addiction;
KIRP	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	6.08	0.36	4.53e-9	Schizophrenia;
KIRP	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg21360079	chr12:107162445	NA	-0.67	-9.48	-0.52	2.2e-18	Heart rate;
KIRP	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.47	4.95	0.3	1.37e-6	Pancreatic cancer;
KIRP	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg11731671	chr1:2995604	PRDM16	-0.43	-5.16	-0.31	5.15e-7	Plateletcrit;
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.09e-8	Life satisfaction;
KIRP	cis	rs4262150	0.883	rs12188079	chr5:152201527	T/C	cg12297329	chr5:152029980	NA	-0.62	-8.03	-0.46	4.14e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs2882667	0.929	rs17207828	chr5:138299835	A/G	cg04439458	chr5:138467593	SIL1	-0.48	-7.31	-0.42	3.81e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.55	-0.33	7.45e-8	Breast cancer;
KIRP	cis	rs4748857	0.947	rs4748856	chr10:23599342	C/T	cg12804278	chr10:23633326	C10orf67	-0.42	-5.1	-0.31	6.75e-7	Systemic lupus erythematosus;
KIRP	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg20169779	chr10:135381914	SYCE1	0.47	5.59	0.34	5.91e-8	Obesity-related traits;
KIRP	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.81	11.5	0.59	8.67e-25	Multiple sclerosis;
KIRP	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.89	0.57	8.64e-23	Cognitive test performance;
KIRP	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg12560992	chr17:57184187	TRIM37	0.61	5.52	0.33	8.6e-8	Cognitive test performance;
KIRP	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.85	10.03	0.54	4.47e-20	Body mass index;
KIRP	cis	rs10995505	0.589	rs1553789	chr10:64879229	A/G	cg25356468	chr10:64875536	NA	0.44	5.12	0.31	6.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg00677455	chr12:58241039	CTDSP2	0.97	12.77	0.63	5.56e-29	Multiple sclerosis;
KIRP	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg06521331	chr12:34319734	NA	-0.58	-7.12	-0.41	1.15e-11	Morning vs. evening chronotype;
KIRP	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg00129232	chr17:37814104	STARD3	-0.51	-6.21	-0.37	2.19e-9	Self-reported allergy;
KIRP	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Colorectal cancer;
KIRP	cis	rs675026	0.963	rs632457	chr6:154417209	G/T	cg07813322	chr6:154414604	OPRM1	-0.5	-6.39	-0.38	8.18e-10	Hypertension;
KIRP	cis	rs1832871	0.672	rs12525675	chr6:158708749	A/T	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.7	0.44	3.3e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01087392	chr10:104005670	GBF1	0.53	7.06	0.41	1.71e-11	Parkinson's disease;
KIRP	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.68	10.28	0.55	7.59e-21	Hip circumference;
KIRP	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	0.43	5.86	0.35	1.5e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg09184832	chr6:79620586	NA	-0.52	-7.44	-0.43	1.65e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs9790314	0.613	rs1447619	chr3:160616077	A/T	cg19274270	chr17:78178856	CARD14	0.34	6.18	0.37	2.69e-9	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg13180566	chr4:1052158	NA	-0.51	-5.15	-0.31	5.37e-7	Recombination rate (females);
KIRP	cis	rs1958560	0.932	rs10138671	chr14:65860092	C/T	cg03016385	chr14:66212404	NA	0.4	5.1	0.31	6.83e-7	Menarche (age at onset);
KIRP	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg17145862	chr1:211918768	LPGAT1	0.81	11.48	0.59	1.01e-24	Leprosy;
KIRP	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.49	6.0	0.36	6.87e-9	Initial pursuit acceleration;
KIRP	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg19077165	chr18:44547161	KATNAL2	-0.38	-4.87	-0.3	1.99e-6	Educational attainment;
KIRP	cis	rs9400467	0.528	rs7451051	chr6:111744818	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.72	-0.34	3.04e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	5.17	0.31	4.82e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg03653399	chr8:142233436	SLC45A4	-0.94	-14.75	-0.69	1.05e-35	Immature fraction of reticulocytes;
KIRP	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg26248373	chr2:1572462	NA	-0.67	-7.12	-0.41	1.16e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-5.67	-0.34	4.01e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg11764359	chr7:65958608	NA	0.43	5.05	0.31	8.41e-7	Calcium levels;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21016266	chr12:122356598	WDR66	0.67	8.83	0.49	1.98e-16	Mean corpuscular volume;
KIRP	cis	rs4886920	0.894	rs4886527	chr15:78113557	G/A	cg10461261	chr15:78109450	NA	-0.33	-5.36	-0.32	1.92e-7	Neuroticism;
KIRP	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.86	11.01	0.57	3.47e-23	Gestational age at birth (maternal effect);
KIRP	cis	rs6540556	0.608	rs3817821	chr1:209918503	A/T	cg23920097	chr1:209922102	NA	-0.36	-4.86	-0.3	2.11e-6	Red blood cell count;
KIRP	cis	rs12476592	0.602	rs1374308	chr2:63895436	G/C	cg17519650	chr2:63277830	OTX1	-0.45	-4.94	-0.3	1.41e-6	Childhood ear infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15481429	chr15:94945799	MCTP2	0.58	7.36	0.42	2.78e-12	Interleukin-4 levels;
KIRP	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg05335186	chr13:53173507	NA	0.36	5.64	0.34	4.61e-8	Lewy body disease;
KIRP	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.11	12.2	0.61	4.35e-27	Corneal structure;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg07191189	chr2:37193690	STRN	-0.61	-6.69	-0.39	1.48e-10	Menopause (age at onset);
KIRP	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg25922239	chr6:33757077	LEMD2	0.61	6.88	0.4	4.96e-11	Crohn's disease;
KIRP	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.56	8.17	0.46	1.59e-14	Mean corpuscular volume;
KIRP	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.69	6.74	0.4	1.09e-10	Breast cancer;
KIRP	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.41	0.33	1.46e-7	Diisocyanate-induced asthma;
KIRP	cis	rs631288	0.557	rs894467	chr1:146662018	C/T	cg25205988	chr1:146714368	CHD1L	1.02	6.08	0.36	4.57e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg06066596	chr15:83166174	LOC80154	-0.51	-5.83	-0.35	1.7e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	2.97e-7	Tonsillectomy;
KIRP	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg18261050	chr1:119551319	NA	0.5	6.43	0.38	6.74e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.34	0.51	6.18e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.88	7.39	0.43	2.22e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs2224391	0.590	rs72813697	chr6:5274266	T/A	cg24031505	chr6:4779396	CDYL	-0.6	-4.92	-0.3	1.59e-6	Height;
KIRP	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.64	7.46	0.43	1.48e-12	Diabetic retinopathy;
KIRP	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.45e-9	Breast cancer;
KIRP	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.73	9.24	0.51	1.18e-17	Coronary artery disease;
KIRP	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg00745463	chr17:30367425	LRRC37B	-0.73	-6.92	-0.4	3.88e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.77	0.35	2.38e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.59	7.65	0.44	4.48e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs11997175	0.603	rs11778978	chr8:33804743	G/T	ch.8.33884649F	chr8:33765107	NA	0.45	5.42	0.33	1.42e-7	Body mass index;
KIRP	cis	rs5753037	0.586	rs140120	chr22:30138548	T/C	cg01021169	chr22:30184971	ASCC2	-0.46	-6.36	-0.38	9.82e-10	Type 1 diabetes;
KIRP	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg24315340	chr6:146058215	EPM2A	-0.47	-6.15	-0.36	3.17e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.67e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-7.25	-0.42	5.47e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg20607798	chr8:58055168	NA	0.62	4.85	0.3	2.2e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg18635645	chr1:85667791	SYDE2	0.45	6.22	0.37	2.08e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg04249525	chr7:152373324	XRCC2	0.48	6.15	0.37	3.05e-9	DNA methylation (variation);
KIRP	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg20818283	chr2:191399100	TMEM194B	0.54	7.05	0.41	1.8e-11	Pulse pressure;
KIRP	cis	rs741677	1.000	rs9911960	chr17:466598	T/C	cg06217071	chr17:408420	NA	0.51	7.41	0.43	1.96e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23422044	chr7:1970798	MAD1L1	-0.47	-5.97	-0.36	8.3e-9	Neuroticism;
KIRP	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg13753209	chr17:57696993	CLTC	0.52	5.11	0.31	6.36e-7	Hemoglobin concentration;
KIRP	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.18	0.54	1.54e-20	Coffee consumption (cups per day);
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.6	-7.14	-0.41	1.06e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg06521331	chr12:34319734	NA	-0.51	-6.27	-0.37	1.57e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg24699146	chr1:24152579	HMGCL	0.42	5.41	0.33	1.46e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg04691961	chr3:161091175	C3orf57	-0.37	-5.05	-0.31	8.65e-7	Kawasaki disease;
KIRP	cis	rs1014246	0.796	rs2420331	chr10:118471197	A/G	cg14919929	chr10:118506882	NA	-0.57	-7.46	-0.43	1.47e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs78487399	0.908	rs80075345	chr2:43810698	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.13	-0.31	6.01e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.48	-5.17	-0.31	4.85e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs897080	0.515	rs1067356	chr2:44663072	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.85	0.35	1.54e-8	Height;
KIRP	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.92	-14.82	-0.69	6.23e-36	Height;
KIRP	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.53	-5.88	-0.35	1.37e-8	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26539593	chr5:137774958	REEP2	0.43	6.11	0.36	3.83e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	0.87	8.65	0.48	6.93e-16	Methadone dose in opioid dependence;
KIRP	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.66	-6.96	-0.41	3.1e-11	Bipolar disorder;
KIRP	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg02336718	chr17:17403227	NA	-0.33	-5.19	-0.31	4.32e-7	Total body bone mineral density;
KIRP	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg10253484	chr15:75165896	SCAMP2	0.51	6.03	0.36	6.01e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.54	7.83	0.45	1.43e-13	Immature fraction of reticulocytes;
KIRP	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg22906224	chr7:99728672	NA	-0.66	-8.03	-0.46	4.05e-14	Coronary artery disease;
KIRP	cis	rs17221829	0.673	rs10741307	chr11:89367271	G/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.29	-0.32	2.64e-7	Anxiety in major depressive disorder;
KIRP	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	1.06	20.03	0.79	1.42e-53	Heart rate;
KIRP	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.7	-11.43	-0.59	1.47e-24	Menopause (age at onset);
KIRP	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17409876	chr11:66436470	RBM4B	0.44	6.74	0.39	1.12e-10	Survival in pancreatic cancer;
KIRP	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.5	-6.12	-0.36	3.66e-9	Red blood cell count;
KIRP	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.73	10.93	0.57	6.53e-23	Orofacial clefts;
KIRP	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.42	-5.49	-0.33	1.02e-7	Menarche (age at onset);
KIRP	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	1.09	20.57	0.8	2.3e-55	Systemic lupus erythematosus;
KIRP	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	ch.11.340609R	chr11:12831013	TEAD1	-0.41	-5.24	-0.32	3.4e-7	Educational attainment (years of education);
KIRP	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.51	-6.03	-0.36	6.13e-9	Blood metabolite levels;
KIRP	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg06742321	chr12:123595122	PITPNM2	0.46	5.61	0.34	5.34e-8	Platelet count;
KIRP	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg01493522	chr13:37497338	NA	-0.46	-5.46	-0.33	1.14e-7	Coronary artery disease;
KIRP	trans	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg00938859	chr5:1591904	SDHAP3	0.53	6.22	0.37	2.08e-9	Breast cancer;
KIRP	cis	rs4430311	1.000	rs3008657	chr1:244023667	A/G	cg25706552	chr1:244017396	NA	0.58	9.51	0.52	1.83e-18	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	cis	rs6735179	0.958	rs1424921	chr2:1771874	A/G	cg08166568	chr2:1746647	PXDN	-0.4	-4.88	-0.3	1.94e-6	Response to antipsychotic treatment;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11228876	chr1:236227653	NID1	-0.49	-6.34	-0.37	1.07e-9	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07612497	chr3:48672985	SLC26A6	0.54	6.59	0.39	2.61e-10	Parkinson's disease;
KIRP	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.89	0.49	1.37e-16	Electroencephalogram traits;
KIRP	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg15586392	chr8:142238691	SLC45A4	-0.36	-4.87	-0.3	2e-6	Immature fraction of reticulocytes;
KIRP	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg07689907	chr11:61582574	FADS1	0.49	6.08	0.36	4.46e-9	Trans fatty acid levels;
KIRP	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg08822215	chr16:89438651	ANKRD11	-0.55	-6.93	-0.4	3.62e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.64	5.55	0.33	7.3e-8	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg05220968	chr6:146057943	EPM2A	-0.38	-5.03	-0.31	9.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11955398	0.563	rs10471493	chr5:60035222	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg05861140	chr6:150128134	PCMT1	-0.4	-5.39	-0.32	1.68e-7	Lung cancer;
KIRP	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.75	7.63	0.44	5.25e-13	Bipolar disorder;
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg07859478	chr19:808116	PTBP1	-0.47	-6.14	-0.36	3.3e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg02367723	chr1:46378857	MAST2	0.44	5.12	0.31	6.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21392281	chr1:146752023	CHD1L	0.36	6.25	0.37	1.81e-9	C-reactive protein;
KIRP	cis	rs7520050	0.966	rs11211199	chr1:46287869	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.43	-4.99	-0.3	1.13e-6	Bipolar disorder;
KIRP	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.71	0.39	1.29e-10	Hypertriglyceridemia;
KIRP	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.52	-5.57	-0.33	6.81e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs997295	0.868	rs3784699	chr15:68007591	T/C	cg24579218	chr15:68104479	NA	0.37	5.61	0.34	5.54e-8	Motion sickness;
KIRP	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.12	-0.36	3.64e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs10129255	0.500	rs34326748	chr14:107190760	G/C	cg23076370	chr14:107095027	NA	-0.41	-5.03	-0.31	9.62e-7	Kawasaki disease;
KIRP	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs7173743	0.525	rs8028410	chr15:79134267	C/T	cg00079375	chr15:79125835	NA	0.39	5.56	0.33	7.07e-8	Coronary artery disease;
KIRP	cis	rs3857067	0.680	rs1509946	chr4:95109078	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.47	-0.38	5.33e-10	QT interval;
KIRP	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.68	8.26	0.47	8.76e-15	Aortic root size;
KIRP	cis	rs7129556	0.815	rs72947625	chr11:77399602	G/T	cg12586386	chr11:77299805	AQP11	0.47	5.45	0.33	1.22e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg21214613	chr1:16344536	HSPB7	0.33	4.86	0.3	2.1e-6	Systolic blood pressure;
KIRP	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.57	-5.89	-0.35	1.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08121760	chr12:111126960	HVCN1	0.43	6.45	0.38	6.02e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.57	-7.61	-0.44	5.71e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs12580194	0.593	rs61957936	chr12:55745719	A/G	cg19537932	chr12:55886519	OR6C68	-0.48	-6.36	-0.38	9.58e-10	Cancer;
KIRP	cis	rs6545883	0.929	rs2593626	chr2:61665184	C/A	cg15711740	chr2:61764176	XPO1	-0.6	-8.0	-0.45	4.99e-14	Tuberculosis;
KIRP	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	1.19	8.77	0.49	3.11e-16	Economic and political preferences (immigration/crime);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04000234	chr1:39568852	MACF1	0.39	6.32	0.37	1.24e-9	Interleukin-4 levels;
KIRP	cis	rs8018808	0.905	rs7142380	chr14:77931231	T/C	cg18872420	chr14:78023429	SPTLC2	0.36	5.23	0.32	3.69e-7	Myeloid white cell count;
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg08132940	chr7:1081526	C7orf50	-0.62	-6.28	-0.37	1.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.76	-7.65	-0.44	4.51e-13	Platelet count;
KIRP	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.6	-0.56	6.99e-22	Height;
KIRP	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-1.14	-15.26	-0.7	1.89e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg26513180	chr16:89883248	FANCA	0.86	5.73	0.34	2.94e-8	Skin colour saturation;
KIRP	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.77	7.91	0.45	8.81e-14	Uric acid levels;
KIRP	trans	rs6596140	0.620	rs62373493	chr5:133030698	T/C	cg08567913	chr11:114082594	ZBTB16	-0.44	-6.21	-0.37	2.26e-9	Hypertension;
KIRP	cis	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg21546286	chr11:48923668	NA	-0.46	-5.97	-0.36	8.18e-9	HDL cholesterol;
KIRP	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.05e-7	Initial pursuit acceleration;
KIRP	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.17	-0.5	1.9e-17	Colorectal cancer;
KIRP	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.96	0.5	8.26e-17	IgG glycosylation;
KIRP	cis	rs7172677	1.000	rs11072525	chr15:75419110	G/A	cg14082893	chr15:75400931	NA	0.33	4.97	0.3	1.23e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg22283653	chr8:49824208	NA	-0.45	-6.14	-0.36	3.28e-9	Sudden cardiac arrest;
KIRP	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-6.09	-0.36	4.21e-9	Total cholesterol levels;
KIRP	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.43	-0.33	1.32e-7	Mean platelet volume;
KIRP	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg23307798	chr14:103986281	CKB	-0.47	-6.51	-0.38	4.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs4789452	0.774	rs55727612	chr17:75381723	C/T	cg12985929	chr17:75370611	SEPT9	-0.36	-5.0	-0.3	1.07e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg02487422	chr3:49467188	NICN1	0.4	5.59	0.34	5.87e-8	Menarche (age at onset);
KIRP	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg11189052	chr15:85197271	WDR73	0.53	5.31	0.32	2.51e-7	Schizophrenia;
KIRP	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.54	0.59	6.67e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.74	8.67	0.48	5.89e-16	Obesity-related traits;
KIRP	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg22437258	chr11:111473054	SIK2	0.56	6.41	0.38	7.57e-10	Primary sclerosing cholangitis;
KIRP	cis	rs17384381	0.859	rs35761966	chr1:85918357	G/A	cg16011679	chr1:85725395	C1orf52	0.82	8.05	0.46	3.55e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62380364	0.507	rs34321	chr5:88020319	C/G	cg24804195	chr5:87968844	LOC645323	-0.48	-6.27	-0.37	1.64e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-8.05	-0.46	3.63e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs1035491	0.715	rs4116460	chr5:63919981	C/T	cg01791865	chr5:63954708	NA	0.33	5.33	0.32	2.18e-7	Body mass index;
KIRP	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg10018233	chr7:150070692	REPIN1	0.56	7.01	0.41	2.29e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7084402	0.967	rs1658459	chr10:60299246	C/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.47	-0.56	1.88e-21	Refractive error;
KIRP	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-5.03	-0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs8016982	0.633	rs55643303	chr14:81708872	A/G	cg01989461	chr14:81687754	GTF2A1	0.77	11.81	0.6	8.58e-26	Schizophrenia;
KIRP	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg22705602	chr4:152727874	NA	-0.6	-9.16	-0.5	2.11e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7558233	0.614	rs55777935	chr2:23678167	G/A	cg00747342	chr2:23700632	KLHL29	0.62	5.73	0.34	2.95e-8	Cannabis use (initiation);
KIRP	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg15192750	chr16:69999425	NA	0.47	4.92	0.3	1.62e-6	IgE levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12713142	chr12:57081325	PTGES3	0.47	6.22	0.37	2.1e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-16.08	-0.72	3.07e-40	Electrocardiographic conduction measures;
KIRP	trans	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-7.91	-0.45	8.91e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.62	-8.45	-0.47	2.65e-15	Total body bone mineral density;
KIRP	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	1.13	17.26	0.74	2.86e-44	Monocyte percentage of white cells;
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.67	9.27	0.51	9.85e-18	Mean corpuscular volume;
KIRP	cis	rs8084125	1.000	rs72981154	chr18:74944135	C/T	cg26065057	chr18:74961000	GALR1	0.76	7.48	0.43	1.35e-12	Obesity-related traits;
KIRP	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg05791153	chr7:19748676	TWISTNB	0.68	6.14	0.36	3.21e-9	Thyroid stimulating hormone;
KIRP	cis	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14291622	chr9:19127549	PLIN2	-0.36	-4.94	-0.3	1.45e-6	Myopia;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02805822	chr17:6916868	RNASEK;C17orf49	1.05	7.71	0.44	3.04e-13	P wave terminal force;
KIRP	cis	rs1364705	0.955	rs4871600	chr8:120226576	C/G	cg09273054	chr8:120220131	MAL2	-0.49	-5.25	-0.32	3.31e-7	Hippocampal atrophy;
KIRP	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.57	7.49	0.43	1.24e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg26876637	chr1:152193138	HRNR	-0.82	-8.34	-0.47	5.26e-15	Atopic dermatitis;
KIRP	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg21361702	chr7:150065534	REPIN1	0.55	5.92	0.35	1.06e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs258892	0.895	rs13181437	chr5:72051657	G/A	cg21869765	chr5:72125136	TNPO1	-0.51	-5.92	-0.35	1.08e-8	Small cell lung carcinoma;
KIRP	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.53	-5.83	-0.35	1.7e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg13010199	chr12:38710504	ALG10B	0.41	5.35	0.32	2e-7	Heart rate;
KIRP	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.62	-0.48	8.29e-16	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22509041	chr12:53574524	CSAD;ZNF740	0.48	6.02	0.36	6.28e-9	Parkinson's disease;
KIRP	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg16586182	chr3:47516702	SCAP	-0.66	-8.16	-0.46	1.77e-14	Granulocyte count;Sum neutrophil eosinophil counts;
KIRP	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.29e-16	Prudent dietary pattern;
KIRP	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.16	-0.37	2.93e-9	Self-reported allergy;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg25707994	chr7:157129685	DNAJB6	1.02	7.03	0.41	2.07e-11	P wave terminal force;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18234089	chr10:70939902	SUPV3L1	0.53	6.03	0.36	5.95e-9	Lung cancer in ever smokers;
KIRP	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg12598211	chr12:123634384	NA	-0.43	-5.29	-0.32	2.74e-7	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26395828	chr5:14665166	FAM105B	0.53	6.89	0.4	4.55e-11	Parkinson's disease;
KIRP	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.32e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs1864585	0.520	rs73208773	chr8:10666791	T/A	cg21775007	chr8:11205619	TDH	-0.5	-4.93	-0.3	1.52e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.98	13.97	0.67	4.61e-33	Platelet distribution width;
KIRP	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg08392591	chr16:89556376	ANKRD11	0.5	6.91	0.4	4.09e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg07622451	chr1:3079886	PRDM16	0.37	5.31	0.32	2.45e-7	Migraine;
KIRP	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg14703610	chr5:56206110	C5orf35	0.51	5.96	0.36	8.53e-9	Initial pursuit acceleration;
KIRP	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.41	-0.78	1.56e-51	Schizophrenia;
KIRP	cis	rs4683142	0.518	rs4682811	chr3:46164795	A/G	cg08033130	chr3:45983597	CXCR6;FYCO1	0.42	5.34	0.32	2.1e-7	Methadone dose in opioid dependence;
KIRP	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg03060546	chr3:49711283	APEH	0.44	5.81	0.35	1.9e-8	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg01763666	chr17:80159506	CCDC57	0.37	5.04	0.31	9.1e-7	Life satisfaction;
KIRP	trans	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.55	-7.07	-0.41	1.61e-11	Mean corpuscular volume;
KIRP	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.55	0.59	6.09e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6546886	0.956	rs10168408	chr2:74243596	A/C	cg14702570	chr2:74259524	NA	-0.33	-6.74	-0.39	1.14e-10	Dialysis-related mortality;
KIRP	cis	rs9972944	0.729	rs10512505	chr17:63776696	A/G	cg07283582	chr17:63770753	CCDC46	0.51	8.54	0.48	1.42e-15	Total body bone mineral density;
KIRP	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg01843524	chr15:80216276	C15orf37;ST20	0.41	5.24	0.32	3.38e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	0.96	10.28	0.55	7.39e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9381040	1.000	rs9394767	chr6:41159905	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.52	-5.39	-0.32	1.69e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12667521	chr19:29218732	NA	0.71	5.76	0.34	2.48e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.71	9.08	0.5	3.63e-17	Triglycerides;
KIRP	cis	rs13102973	0.899	rs17496	chr4:135900227	C/T	cg14419869	chr4:135874104	NA	-0.49	-7.71	-0.44	3.04e-13	Subjective well-being;
KIRP	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.36	-4.86	-0.3	2.08e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.91	10.37	0.55	3.86e-21	Corneal astigmatism;
KIRP	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.39	5.21	0.32	3.93e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.1	-0.36	4.04e-9	Morning vs. evening chronotype;
KIRP	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.5	5.86	0.35	1.49e-8	Menopause (age at onset);
KIRP	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg09904177	chr6:26538194	HMGN4	-0.47	-5.71	-0.34	3.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs1981331	0.609	rs76937225	chr21:48069682	C/T	cg17243659	chr21:48055224	PRMT2	1.37	8.45	0.47	2.6e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	9.71	0.53	4.49e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg05887092	chr17:76393375	PGS1	-0.43	-6.22	-0.37	2.15e-9	HDL cholesterol levels;
KIRP	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	7.25e-7	Bladder cancer;
KIRP	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.57	-9.23	-0.51	1.3e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg17207736	chr8:142237307	SLC45A4	0.5	6.47	0.38	5.35e-10	Immature fraction of reticulocytes;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg08132940	chr7:1081526	C7orf50	-0.7	-7.05	-0.41	1.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg10495392	chr1:46806563	NSUN4	0.51	5.71	0.34	3.18e-8	Menopause (age at onset);
KIRP	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.44	0.47	2.72e-15	Lung cancer in ever smokers;
KIRP	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.06	-0.41	1.66e-11	Diabetic kidney disease;
KIRP	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg16512390	chr1:228756714	NA	0.45	5.1	0.31	6.93e-7	Diastolic blood pressure;
KIRP	cis	rs2916247	0.954	rs11784233	chr8:93080925	C/A	cg10183463	chr8:93005414	RUNX1T1	-0.52	-6.23	-0.37	1.96e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03489495	chr6:33588875	ITPR3	0.47	6.06	0.36	4.96e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg00800038	chr16:89945340	TCF25	-0.89	-7.28	-0.42	4.62e-12	Skin colour saturation;
KIRP	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.39	-5.2	-0.31	4.27e-7	Bipolar disorder;
KIRP	cis	rs867371	1.000	rs1392976	chr15:82446175	A/G	cg00614314	chr15:82944287	LOC80154	-0.54	-6.46	-0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs7688540	0.771	rs11737268	chr4:224452	G/A	cg11678896	chr4:568514	NA	-0.44	-5.09	-0.31	7.11e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.91	14.45	0.68	1.13e-34	Testicular germ cell tumor;
KIRP	cis	rs7508	0.512	rs12335028	chr8:17888377	C/T	cg01800426	chr8:17659068	MTUS1	0.4	5.0	0.3	1.08e-6	Atrial fibrillation;
KIRP	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-6.19	-0.37	2.48e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18252515	chr7:66147081	NA	0.46	5.67	0.34	3.9e-8	Aortic root size;
KIRP	cis	rs7584330	0.737	rs6758246	chr2:238359891	G/C	cg16989719	chr2:238392110	NA	-0.57	-7.77	-0.44	2.16e-13	Prostate cancer;
KIRP	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg18944383	chr4:111397179	ENPEP	0.61	11.1	0.58	1.78e-23	Height;
KIRP	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.83	8.59	0.48	1.02e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6956675	1.000	rs4718791	chr7:62577991	G/C	cg08930214	chr7:62859557	LOC100287834	0.52	5.94	0.35	9.69e-9	Obesity-related traits;
KIRP	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.23	0.55	1.05e-20	Dupuytren's disease;
KIRP	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.32	11.8	0.6	9.42e-26	Diabetic retinopathy;
KIRP	cis	rs12580194	0.593	rs59136392	chr12:55748204	C/T	cg19537932	chr12:55886519	OR6C68	-0.48	-6.36	-0.38	9.58e-10	Cancer;
KIRP	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.35	-0.32	1.98e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.08e-10	Axial length;
KIRP	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.95	0.45	6.81e-14	Aortic root size;
KIRP	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg07585502	chr8:101912084	NA	-0.62	-8.87	-0.49	1.51e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.77	0.44	2.14e-13	Morning vs. evening chronotype;
KIRP	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	0.94	10.1	0.54	2.75e-20	Height;
KIRP	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg12940923	chr8:10282607	MSRA	0.37	4.85	0.3	2.22e-6	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19302295	chr19:14228590	PRKACA	0.65	8.37	0.47	4.51e-15	Parkinson's disease;
KIRP	cis	rs7534824	0.543	rs1074739	chr1:101362371	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.97	0.36	8.28e-9	Refractive astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18882091	chr7:99058544	ATP5J2	0.49	6.52	0.38	4.03e-10	Interleukin-4 levels;
KIRP	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg12140854	chr5:148520817	ABLIM3	-0.49	-6.04	-0.36	5.75e-9	Breast cancer;
KIRP	cis	rs2223471	0.719	rs2744485	chr6:50772616	C/G	cg03432817	chr6:50765336	NA	-0.55	-9.39	-0.51	4.37e-18	Subcutaneous adipose tissue;
KIRP	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.63	8.97	0.5	7.87e-17	Schizophrenia;
KIRP	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26207909	chr14:103986467	CKB	0.75	11.5	0.59	8.59e-25	Bone mineral density;
KIRP	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.02	17.19	0.74	5.01e-44	Multiple system atrophy;
KIRP	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.15	14.28	0.67	4.14e-34	Type 2 diabetes nephropathy;
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	14.43	0.68	1.29e-34	Platelet count;
KIRP	cis	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg08798685	chr6:27730294	NA	-0.57	-4.9	-0.3	1.73e-6	Lung cancer in ever smokers;
KIRP	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.51	6.93	0.4	3.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg24324837	chr19:49891574	CCDC155	-0.65	-8.36	-0.47	4.58e-15	Multiple sclerosis;
KIRP	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.09e-14	Lung cancer;
KIRP	cis	rs8018808	0.935	rs7146595	chr14:77932017	A/C	cg18872420	chr14:78023429	SPTLC2	0.36	5.24	0.32	3.52e-7	Myeloid white cell count;
KIRP	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg12405258	chr13:114927641	NA	0.44	6.54	0.38	3.53e-10	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	1.0	13.52	0.65	1.57e-31	Menopause (age at onset);
KIRP	cis	rs2281603	0.951	rs3783724	chr14:64983477	G/A	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.78	0.35	2.2e-8	Total cholesterol levels;
KIRP	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.6	-6.82	-0.4	7.04e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4654899	0.680	rs10799670	chr1:21179445	T/C	cg08890418	chr1:21044141	KIF17	-0.35	-5.3	-0.32	2.55e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.73	-9.48	-0.52	2.21e-18	Total body bone mineral density;
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg27144592	chr16:783916	NARFL	0.38	5.3	0.32	2.57e-7	Height;
KIRP	cis	rs7172809	0.548	rs79036117	chr15:77474832	G/A	cg05673287	chr15:77411982	SGK269	0.42	4.87	0.3	2e-6	Glucose homeostasis traits;
KIRP	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg00122941	chr17:4613640	ARRB2	0.8	8.65	0.48	6.93e-16	Lymphocyte counts;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg15999098	chr1:186928365	PLA2G4A	0.46	6.89	0.4	4.63e-11	Migraine with aura;
KIRP	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg22676075	chr6:135203613	NA	0.52	7.71	0.44	3.17e-13	Red blood cell count;
KIRP	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.75	9.99	0.54	5.89e-20	Breast cancer;
KIRP	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg15832292	chr6:96025679	MANEA	-0.72	-6.72	-0.39	1.26e-10	Behavioural disinhibition (generation interaction);
KIRP	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-1.08	-10.52	-0.56	1.34e-21	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.36	5.74	0.34	2.81e-8	Colorectal cancer;
KIRP	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.69	8.12	0.46	2.25e-14	Blood protein levels;
KIRP	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg09699651	chr6:150184138	LRP11	0.51	6.66	0.39	1.82e-10	Lung cancer;
KIRP	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg17554472	chr22:41940697	POLR3H	-0.43	-5.14	-0.31	5.49e-7	Neuroticism;
KIRP	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.61	7.05	0.41	1.81e-11	Height;
KIRP	cis	rs7809950	0.678	rs7790080	chr7:107031322	G/A	cg23024343	chr7:107201750	COG5	-0.56	-7.92	-0.45	8.01e-14	Coronary artery disease;
KIRP	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.07	-0.36	4.89e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.58	-6.14	-0.36	3.37e-9	Ulcerative colitis;
KIRP	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg21427119	chr20:30132790	HM13	0.49	5.83	0.35	1.76e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.49	6.49	0.38	4.57e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.22	-0.58	7.37e-24	Body mass index;
KIRP	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg16586182	chr3:47516702	SCAP	0.66	8.93	0.49	9.93e-17	Colorectal cancer;
KIRP	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.6	-7.36	-0.42	2.81e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.66	-0.34	4.23e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.52	-5.32	-0.32	2.38e-7	Total cholesterol levels;
KIRP	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg13147721	chr7:65941812	NA	-1.02	-7.05	-0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26002218	chr14:103986227	CKB	0.29	5.92	0.35	1.08e-8	Body mass index;
KIRP	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs2692947	0.860	rs2579520	chr2:96660300	C/T	cg23100626	chr2:96804247	ASTL	-0.46	-6.87	-0.4	5.12e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs199950	0.736	rs183220	chr1:181600001	A/G	cg04237608	chr1:18659049	IGSF21	0.35	6.08	0.36	4.5e-9	Body mass index (change over time);
KIRP	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.91	7.69	0.44	3.53e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.59	0.39	2.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.4	-0.33	1.57e-7	Bipolar disorder;
KIRP	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.07	0.46	3.14e-14	Lung cancer;
KIRP	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	cg21523751	chr1:182988639	NA	0.42	6.48	0.38	5.04e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6977660	0.714	rs12334267	chr7:19810265	A/G	cg07541023	chr7:19748670	TWISTNB	0.66	5.79	0.35	2.17e-8	Thyroid stimulating hormone;
KIRP	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.86	12.57	0.63	2.54e-28	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.56	8.14	0.46	2.04e-14	Huntington's disease progression;
KIRP	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.9	-0.4	4.26e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs263063	1.000	rs8110642	chr19:5004477	C/T	cg10466548	chr16:10965217	NA	0.57	6.2	0.37	2.41e-9	Periodontitis (CDC/AAP);
KIRP	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg13206674	chr6:150067644	NUP43	0.6	8.63	0.48	7.73e-16	Lung cancer;
KIRP	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.56	-7.07	-0.41	1.62e-11	Longevity;
KIRP	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.65	9.53	0.52	1.62e-18	Retinal vascular caliber;
KIRP	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg02228329	chr11:64053129	BAD;GPR137	0.68	5.73	0.34	2.95e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.77	9.85	0.53	1.59e-19	Corneal astigmatism;
KIRP	cis	rs4716602	0.596	rs10265909	chr7:156158095	T/C	cg16983916	chr7:156159713	NA	-0.43	-5.44	-0.33	1.26e-7	Anti-saccade response;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg04369109	chr6:150039330	LATS1	-0.51	-6.38	-0.38	8.59e-10	Lung cancer;
KIRP	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg25801113	chr15:45476975	SHF	-0.44	-8.13	-0.46	2.1e-14	Uric acid levels;
KIRP	cis	rs981844	1.000	rs17298985	chr4:154664261	C/T	cg14289246	chr4:154710475	SFRP2	0.68	7.68	0.44	3.79e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.27e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Bladder cancer;
KIRP	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.74	0.6	1.41e-25	Alzheimer's disease;
KIRP	trans	rs972578	0.765	rs4822210	chr22:43264770	A/G	cg15321293	chr3:36422198	STAC	-0.48	-6.24	-0.37	1.94e-9	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17575721	chr8:9957329	MSRA	-0.41	-6.32	-0.37	1.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.85	9.53	0.52	1.58e-18	Gestational age at birth (maternal effect);
KIRP	cis	rs1783925	0.959	rs671789	chr11:125294614	C/A	cg03464685	chr11:125439445	EI24	-0.46	-4.96	-0.3	1.33e-6	Formal thought disorder in schizophrenia;
KIRP	cis	rs6088813	1.000	rs725908	chr20:33968067	T/C	cg14752227	chr20:34000481	UQCC	-0.48	-5.87	-0.35	1.39e-8	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16094832	chr10:43133979	ZNF33B	0.54	7.05	0.41	1.8e-11	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21411534	chr10:93558674	TNKS2	0.56	6.59	0.39	2.6200000000000003e-10	Smoking initiation;
KIRP	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.5	-0.33	9.64e-8	Cognitive function;
KIRP	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	10.01	0.54	5.2e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4664293	0.934	rs7604482	chr2:160513826	T/C	cg08347373	chr2:160653686	CD302	-0.38	-5.83	-0.35	1.75e-8	Monocyte percentage of white cells;
KIRP	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.61	5.49	0.33	1.02e-7	Major depressive disorder;
KIRP	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.57	6.13	0.36	3.41e-9	Type 2 diabetes;
KIRP	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg23649088	chr2:200775458	C2orf69	0.83	11.15	0.58	1.24e-23	Osteoporosis;
KIRP	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs4886920	0.573	rs11854573	chr15:78108112	C/A	cg10461261	chr15:78109450	NA	0.35	5.43	0.33	1.36e-7	Neuroticism;
KIRP	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.67	-9.61	-0.52	9.22e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs7941600	0.708	rs12287120	chr11:9311760	C/T	cg19415743	chr11:9336845	TMEM41B	0.73	6.48	0.38	5.1e-10	Coronary artery disease;
KIRP	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg00204512	chr16:28754710	NA	0.43	5.64	0.34	4.62e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7246657	0.722	rs28512414	chr19:38056574	T/A	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-4.85	-0.3	2.18e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg14650228	chr8:144573510	ZC3H3	-0.69	-5.12	-0.31	6.19e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg19847130	chr8:10466454	RP1L1	0.35	5.02	0.3	1e-6	Retinal vascular caliber;
KIRP	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.6	7.85	0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.66	8.91	0.49	1.19e-16	Multiple sclerosis;
KIRP	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.0	0.5	6.4e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.61	8.81	0.49	2.34e-16	Colorectal cancer;
KIRP	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-8.27	-0.47	8.56e-15	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs427941	0.655	rs201472	chr7:101744428	C/T	cg06246474	chr7:101738831	CUX1	0.53	6.49	0.38	4.6e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg21918786	chr6:109611834	NA	-0.41	-5.76	-0.34	2.51e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.86	-0.4	5.63e-11	Aortic root size;
KIRP	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg01689657	chr7:91764605	CYP51A1	-0.33	-4.89	-0.3	1.8e-6	Breast cancer;
KIRP	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg00405596	chr8:11794950	NA	-0.48	-6.22	-0.37	2.16e-9	Mood instability;
KIRP	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.64	-7.73	-0.44	2.8e-13	Aortic root size;
KIRP	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg00631329	chr6:26305371	NA	-0.45	-4.95	-0.3	1.37e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13279522	0.572	rs11993997	chr8:67030128	A/G	cg04041976	chr8:67085823	TRIM55	-0.45	-5.67	-0.34	4.06e-8	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.79	-0.4	8.45e-11	Obesity-related traits;
KIRP	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg18461458	chr19:21324796	ZNF431	-0.48	-4.96	-0.3	1.29e-6	Pain;
KIRP	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.2e-8	Aortic root size;
KIRP	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.05	-0.5	4.58e-17	Retinal vascular caliber;
KIRP	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.49	5.88	0.35	1.35e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.54	-0.38	3.53e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs405956	1.000	rs923404	chr6:105617761	A/G	cg22580625	chr6:105627791	POPDC3	0.52	4.97	0.3	1.24e-6	QT interval;
KIRP	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.42	5.81	0.35	1.93e-8	Red blood cell count;
KIRP	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg24585782	chr17:78113791	EIF4A3	-0.53	-6.16	-0.37	2.91e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.75	7.37	0.43	2.51e-12	Lung function (FEV1/FVC);
KIRP	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg07856975	chr6:36356162	ETV7	-0.41	-6.05	-0.36	5.26e-9	Platelet distribution width;
KIRP	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.81	-8.81	-0.49	2.31e-16	Coronary artery disease;
KIRP	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.91	-0.45	8.84e-14	Homocysteine levels;
KIRP	cis	rs6442310	0.534	rs1875796	chr3:12443657	C/T	cg02700894	chr3:12045449	SYN2	0.42	5.71	0.34	3.3e-8	Hematocrit;
KIRP	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg07001201	chr5:642380	CEP72	-0.7	-6.47	-0.38	5.25e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.25	0.51	1.1e-17	Colorectal cancer;
KIRP	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.59	-7.45	-0.43	1.61e-12	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1408799	0.664	rs2762460	chr9:12696478	T/C	cg05274944	chr9:12693694	TYRP1	0.42	6.01	0.36	6.77e-9	Eye color;Blue vs. green eyes;
KIRP	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05601917	chr6:125855416	NA	0.33	5.04	0.31	9.18e-7	Brugada syndrome;
KIRP	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.67	9.27	0.51	9.82e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg02811702	chr13:24901961	NA	0.44	5.83	0.35	1.75e-8	Obesity-related traits;
KIRP	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.41	-11.66	-0.6	2.68e-25	Plateletcrit;
KIRP	cis	rs96067	0.652	rs7553155	chr1:36568236	A/T	cg27506609	chr1:36549197	TEKT2	0.76	6.27	0.37	1.59e-9	Corneal structure;
KIRP	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.84	11.12	0.58	1.56e-23	Menarche (age at onset);
KIRP	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.5	-6.47	-0.38	5.32e-10	Schizophrenia;
KIRP	cis	rs11169552	0.510	rs10783384	chr12:51117994	A/G	cg12884762	chr12:50931848	DIP2B	-0.45	-5.23	-0.32	3.59e-7	Colorectal cancer;
KIRP	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03934478	chr11:495069	RNH1	0.95	7.66	0.44	4.28e-13	Body mass index;
KIRP	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.91e-25	Vitiligo;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11295777	chr19:6110313	RFX2	-0.67	-7.2	-0.42	7.15e-12	Menopause (age at onset);
KIRP	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.45	1.59e-13	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-1.01	-10.54	-0.56	1.12e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg26876637	chr1:152193138	HRNR	0.76	10.07	0.54	3.33e-20	Atopic dermatitis;
KIRP	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.99	0.36	7.39e-9	Total cholesterol levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20912896	chr3:197833199	NA	0.44	6.31	0.37	1.27e-9	Survival in pancreatic cancer;
KIRP	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.4	-5.78	-0.35	2.2e-8	Monocyte count;
KIRP	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	1.07	15.81	0.71	2.56e-39	Eosinophil percentage of white cells;
KIRP	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08280861	chr8:58055591	NA	0.72	5.71	0.34	3.31e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg16141378	chr3:129829833	LOC729375	0.54	6.7	0.39	1.42e-10	Joint mobility (Beighton score);
KIRP	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg02070118	chr4:952128	TMEM175	0.6	5.03	0.31	9.51e-7	Parkinson's disease;
KIRP	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	cg21523751	chr1:182988639	NA	-0.46	-7.3	-0.42	4.07e-12	Colorectal cancer;
KIRP	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg18882449	chr10:104885122	NT5C2	-0.49	-6.29	-0.37	1.43e-9	Arsenic metabolism;
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg03160526	chr17:80928410	B3GNTL1	0.4	5.0	0.3	1.08e-6	Glycated hemoglobin levels;
KIRP	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.98	-0.3	1.2e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.31	-0.65	8.15e-31	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.25	-5.29	-0.32	2.77e-7	Menarche (age at onset);
KIRP	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.69	-8.56	-0.48	1.25e-15	Schizophrenia;
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18402987	chr7:1209562	NA	0.44	5.19	0.31	4.48e-7	Longevity;Endometriosis;
KIRP	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg01528321	chr10:82214614	TSPAN14	0.81	9.45	0.52	2.74e-18	Post bronchodilator FEV1;
KIRP	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.63	-8.12	-0.46	2.29e-14	Colorectal cancer;
KIRP	cis	rs1619661	0.591	rs605414	chr10:44744110	C/T	cg09554077	chr10:44749378	NA	0.77	12.03	0.61	1.61e-26	QT interval (ambient particulate matter interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00759295	chr19:42388476	ARHGEF1	-0.44	-6.18	-0.37	2.7e-9	Myopia;
KIRP	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.74	-6.97	-0.41	2.84e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg00981070	chr1:2046702	PRKCZ	-0.41	-5.93	-0.35	1.03e-8	Height;
KIRP	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.33	-0.37	1.15e-9	QT interval;
KIRP	cis	rs687432	0.924	rs7102929	chr11:57731052	C/T	cg19752551	chr11:57585705	CTNND1	-0.54	-7.44	-0.43	1.66e-12	Parkinson's disease;
KIRP	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.9	0.35	1.18e-8	Bipolar disorder;
KIRP	cis	rs7007076	0.519	rs2891800	chr8:124744926	C/T	cg00283535	chr8:124749564	ANXA13	-0.64	-7.94	-0.45	7.05e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs17102423	0.533	rs3783715	chr14:65490018	C/G	cg11161011	chr14:65562177	MAX	-0.64	-7.28	-0.42	4.36e-12	Obesity-related traits;
KIRP	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg09699651	chr6:150184138	LRP11	0.47	5.75	0.34	2.65e-8	Lung cancer;
KIRP	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.47	6.43	0.38	6.63e-10	Age-related hearing impairment;
KIRP	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg12501888	chr15:85177176	SCAND2	-0.42	-5.1	-0.31	6.76e-7	P wave terminal force;
KIRP	cis	rs9513627	0.833	rs4605005	chr13:100132471	T/C	cg25919922	chr13:100150906	NA	0.72	6.47	0.38	5.22e-10	Obesity-related traits;
KIRP	cis	rs2273156	0.925	rs12890056	chr14:35422134	A/G	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.69	-0.34	3.54e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-8.33	-0.47	5.58e-15	Renal function-related traits (BUN);
KIRP	trans	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.54	0.38	3.61e-10	Retinal vascular caliber;
KIRP	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.91	-9.21	-0.51	1.44e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.62	6.33	0.37	1.14e-9	Axial length;
KIRP	cis	rs7551222	0.714	rs2926534	chr1:204464181	C/T	cg20240347	chr1:204465584	NA	0.36	5.82	0.35	1.78e-8	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05199084	chr10:53493554	PRKG1	-0.4	-6.24	-0.37	1.95e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.56	6.76	0.4	9.78e-11	Aortic root size;
KIRP	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.69	0.39	1.51e-10	Educational attainment;
KIRP	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.56	7.43	0.43	1.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.55	7.91	0.45	8.47e-14	Carotid intima media thickness;
KIRP	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.37	-0.59	2.4e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg09695851	chr17:3907499	NA	0.88	17.24	0.74	3.35e-44	Type 2 diabetes;
KIRP	cis	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg21775007	chr8:11205619	TDH	0.48	6.57	0.39	3.02e-10	Systolic blood pressure;
KIRP	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.75	-0.49	3.36e-16	Migraine;Coronary artery disease;
KIRP	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.57	7.75	0.44	2.44e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg05865280	chr17:75406074	SEPT9	0.51	12.02	0.61	1.78e-26	Airflow obstruction;
KIRP	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.51	-5.81	-0.35	1.93e-8	Urate levels in overweight individuals;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.6	7.85	0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg21918786	chr6:109611834	NA	-0.41	-5.76	-0.34	2.51e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg00982548	chr2:198649783	BOLL	-0.6	-5.5	-0.33	9.46e-8	Ulcerative colitis;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.47	6.56	0.39	3.17e-10	Renal function-related traits (BUN);
KIRP	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.61	8.64	0.48	7.03e-16	Menarche (age at onset);
KIRP	cis	rs1847505	0.520	rs78824663	chr13:61486175	C/G	cg25164009	chr13:61490935	NA	0.54	6.11	0.36	3.9e-9	Polychlorinated biphenyl levels;
KIRP	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	9.33	0.51	6.41e-18	Mood instability;
KIRP	cis	rs8079658	1.000	rs62065089	chr17:63843058	C/A	cg18091269	chr17:63822838	CCDC46	-0.52	-7.05	-0.41	1.81e-11	Post bronchodilator FEV1;
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.86	-0.35	1.44e-8	Longevity;Endometriosis;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg25347419	chr2:177043501	NA	0.45	6.25	0.37	1.78e-9	IgG glycosylation;
KIRP	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg01872077	chr2:219646372	CYP27A1	0.42	5.45	0.33	1.2e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg26681399	chr22:41777847	TEF	0.45	4.9	0.3	1.72e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12496230	0.794	rs7642618	chr3:66863002	A/G	cg04995300	chr3:66848608	NA	0.44	6.81	0.4	7.28e-11	Type 2 diabetes;
KIRP	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg06740227	chr12:86229804	RASSF9	0.47	5.73	0.34	2.96e-8	Major depressive disorder;
KIRP	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.66	-9.78	-0.53	2.79e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7845219	0.544	rs2123647	chr8:95931782	A/G	cg16049864	chr8:95962084	TP53INP1	0.38	5.95	0.35	9.23e-9	Type 2 diabetes;
KIRP	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.98	8.46	0.47	2.49e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.59	-0.48	1.04e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg27490568	chr2:178487706	NA	0.43	5.69	0.34	3.63e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs42648	0.748	rs10225744	chr7:89946003	T/C	cg25739043	chr7:89950458	NA	-0.41	-6.39	-0.38	8.15e-10	Homocysteine levels;
KIRP	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg06647332	chr5:131281008	NA	0.43	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg03714773	chr7:91764589	CYP51A1	0.34	5.12	0.31	6.17e-7	Breast cancer;
KIRP	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.57	8.18	0.46	1.54e-14	Huntington's disease progression;
KIRP	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.44	5.96	0.36	8.51e-9	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22712703	chr1:38061501	GNL2	0.51	6.16	0.37	3.02e-9	Parkinson's disease;
KIRP	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.77	6.37	0.38	9.06e-10	Initial pursuit acceleration;
KIRP	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg01214346	chr17:406501	NA	0.4	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg23649088	chr2:200775458	C2orf69	-0.67	-5.85	-0.35	1.53e-8	Schizophrenia;
KIRP	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.53	6.78	0.4	9.03e-11	Tonsillectomy;
KIRP	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg12435725	chr3:58293450	RPP14	-0.49	-4.92	-0.3	1.6e-6	Cholesterol, total;
KIRP	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg06243866	chr13:111019493	COL4A2	-0.58	-7.66	-0.44	4.22e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs1355223	0.902	rs34751755	chr11:34694243	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.19	-0.31	4.37e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg22676075	chr6:135203613	NA	0.5	7.41	0.43	2.01e-12	Red blood cell count;
KIRP	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg18198730	chr1:247681584	NA	0.6	5.67	0.34	3.94e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs7665939	0.932	rs66626876	chr4:190101569	T/G	cg14840187	chr4:190284988	NA	-0.63	-5.62	-0.34	5.15e-8	Amyotrophic lateral sclerosis;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-1.01	-18.13	-0.76	3.24e-47	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	6.01	0.36	6.65e-9	Response to antipsychotic treatment;
KIRP	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg23978390	chr7:1156363	C7orf50	0.56	5.99	0.36	7.51e-9	Bronchopulmonary dysplasia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27302007	chr6:114291608	HDAC2	0.49	6.71	0.39	1.3100000000000001e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.61	-9.02	-0.5	5.67e-17	Vitiligo;
KIRP	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.59	-8.53	-0.48	1.54e-15	Vitiligo;
KIRP	cis	rs11637783	1	rs11637783	chr15:79139000	T/C	cg00079375	chr15:79125835	NA	-0.41	-5.87	-0.35	1.37e-8	Coronary artery disease;
KIRP	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg18461458	chr19:21324796	ZNF431	0.48	4.98	0.3	1.19e-6	Pain;
KIRP	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg06027949	chr8:82754900	SNX16	-0.57	-7.21	-0.42	6.69e-12	Diastolic blood pressure;
KIRP	cis	rs16857609	0.564	rs13406698	chr2:218283085	A/G	cg15335768	chr2:218268053	DIRC3	-0.53	-6.93	-0.4	3.68e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg01631408	chr1:248437212	OR2T33	-0.67	-8.84	-0.49	1.88e-16	Common traits (Other);
KIRP	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.51	-5.49	-0.33	1e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.21	-0.46	1.27e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7224685	0.569	rs10521129	chr17:4008820	C/T	cg05562828	chr17:3906858	NA	0.47	5.35	0.32	1.97e-7	Type 2 diabetes;
KIRP	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg15744005	chr10:104629667	AS3MT	-0.27	-4.88	-0.3	1.92e-6	Arsenic metabolism;
KIRP	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg08558340	chr7:100472263	SRRT	0.49	4.88	0.3	1.91e-6	Resting heart rate;
KIRP	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.7	-9.23	-0.51	1.26e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13937449	chr12:56320970	WIBG	0.54	6.37	0.38	8.99e-10	Smoking initiation;
KIRP	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08280861	chr8:58055591	NA	0.74	6.07	0.36	4.86e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg24881330	chr22:46731750	TRMU	0.74	5.23	0.32	3.68e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.97	11.74	0.6	1.49e-25	Corneal astigmatism;
KIRP	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.36	-0.59	2.49e-24	Monocyte count;
KIRP	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg07636037	chr3:49044803	WDR6	-0.76	-5.64	-0.34	4.58e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Colorectal cancer;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.73	11.48	0.59	1.03e-24	Menarche (age at onset);
KIRP	cis	rs5752326	0.510	rs2032574	chr22:26888725	T/C	cg20819150	chr22:26891497	TFIP11	0.6	5.29	0.32	2.7e-7	Ischemic stroke;
KIRP	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg13906792	chr15:75199810	C15orf17	-0.35	-4.94	-0.3	1.41e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06505273	chr16:24850292	NA	0.44	5.93	0.35	9.94e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg18132916	chr6:79620363	NA	-0.37	-4.89	-0.3	1.84e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.95	-10.19	-0.54	1.43e-20	Schizophrenia;
KIRP	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.61	5.18	0.31	4.61e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6593803	0.810	rs1539418	chr1:147210110	A/C	cg27546670	chr1:147246839	GJA5	0.6	6.66	0.39	1.83e-10	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.17e-37	Height;
KIRP	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg13206674	chr6:150067644	NUP43	-0.53	-7.32	-0.42	3.47e-12	Lung cancer;
KIRP	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2882667	0.898	rs3925110	chr5:138371365	C/G	cg04439458	chr5:138467593	SIL1	-0.44	-7.35	-0.42	2.93e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	9.02	0.5	5.41e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-1.05	-12.64	-0.63	1.47e-28	Exhaled nitric oxide output;
KIRP	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.82	0.49	2.11e-16	Motion sickness;
KIRP	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg14092988	chr3:52407081	DNAH1	0.34	5.82	0.35	1.87e-8	Bipolar disorder;
KIRP	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.61	-9.6	-0.52	9.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs12540874	0.542	rs10238413	chr7:50648184	G/A	cg04490037	chr7:50633773	DDC	0.38	4.92	0.3	1.58e-6	Systemic sclerosis;
KIRP	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg00277334	chr10:82204260	NA	-0.49	-5.65	-0.34	4.31e-8	Post bronchodilator FEV1;
KIRP	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg12315302	chr6:26189340	HIST1H4D	0.7	5.19	0.31	4.51e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg26874164	chr19:58962979	ZNF324B	0.47	5.54	0.33	7.6e-8	Uric acid clearance;
KIRP	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.64	-9.27	-0.51	9.57e-18	Anterior chamber depth;
KIRP	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23903597	chr17:61704154	MAP3K3	-0.64	-8.31	-0.47	6.53e-15	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19524238	chr7:2802976	GNA12	-0.39	-5.33	-0.32	2.24e-7	Height;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg18183042	chr17:80733038	TBCD	-0.37	-4.99	-0.3	1.13e-6	Glycated hemoglobin levels;
KIRP	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06544989	chr22:39130855	UNC84B	0.4	6.61	0.39	2.33e-10	Menopause (age at onset);
KIRP	cis	rs2411233	1.000	rs8034438	chr15:39278909	C/T	cg02291532	chr15:39874776	THBS1	0.42	5.75	0.34	2.63e-8	Platelet count;
KIRP	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg06654118	chr4:1303317	MAEA	-0.31	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	0.96	16.78	0.73	1.2e-42	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6800768	0.633	rs59715267	chr3:24100414	C/A	cg10674438	chr3:24145617	LOC152024	-0.39	-5.48	-0.33	1.05e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg17376030	chr22:41985996	PMM1	-0.53	-6.09	-0.36	4.39e-9	Cannabis dependence symptom count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02396668	chr19:50528878	VRK3;ZNF473	0.5	6.61	0.39	2.32e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg05527609	chr1:210001259	C1orf107	-0.49	-5.21	-0.32	4.07e-7	Red blood cell count;
KIRP	cis	rs12282928	0.959	rs1393788	chr11:48279416	A/G	cg26585981	chr11:48327164	OR4S1	0.5	6.05	0.36	5.27e-9	Migraine - clinic-based;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03510606	chr2:160303360	BAZ2B	0.39	6.33	0.37	1.18e-9	C-reactive protein;
KIRP	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	9.98	0.54	6.69e-20	Post bronchodilator FEV1;
KIRP	cis	rs2274273	0.868	rs1572611	chr14:55833874	T/A	cg04306507	chr14:55594613	LGALS3	0.4	5.99	0.36	7.4e-9	Protein biomarker;
KIRP	trans	rs6762644	0.504	rs13059562	chr3:4729730	C/T	cg06150299	chr16:30993485	SETD1A	0.45	6.06	0.36	5.08e-9	Breast cancer;
KIRP	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.83	-0.35	1.77e-8	Height;
KIRP	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.71	8.42	0.47	3.09e-15	Corneal astigmatism;
KIRP	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg23587288	chr2:27483067	SLC30A3	-0.4	-5.02	-0.3	9.96e-7	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.47	-0.43	1.38e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.59	-6.62	-0.39	2.3e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22509189	chr2:225307070	NA	-0.44	-5.4	-0.33	1.55e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg10253484	chr15:75165896	SCAMP2	-0.54	-5.97	-0.36	8.24e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6593803	0.774	rs1342711	chr1:147219835	G/A	cg27546670	chr1:147246839	GJA5	0.69	7.96	0.45	6.16e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg03929089	chr4:120376271	NA	0.61	6.17	0.37	2.73e-9	Axial length;
KIRP	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg06636001	chr8:8085503	FLJ10661	0.59	8.01	0.45	4.5e-14	Myopia (pathological);
KIRP	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg02023728	chr11:77925099	USP35	0.52	8.47	0.48	2.23e-15	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	trans	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg01620082	chr3:125678407	NA	-0.88	-6.43	-0.38	6.54e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-9.95	-0.54	7.8e-20	Colorectal cancer;
KIRP	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.53	8.1	0.46	2.52e-14	Itch intensity from mosquito bite;
KIRP	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08392591	chr16:89556376	ANKRD11	0.51	6.91	0.4	4.17e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg02462569	chr6:150064036	NUP43	-0.5	-7.32	-0.42	3.47e-12	Lung cancer;
KIRP	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg27413430	chr6:13925136	RNF182	0.54	6.47	0.38	5.36e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg01311341	chr22:25575246	KIAA1671	0.6	6.54	0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.18	0.7	3.51e-37	Platelet count;
KIRP	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-10.83	-0.57	1.34e-22	Response to antipsychotic treatment;
KIRP	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg06636001	chr8:8085503	FLJ10661	0.65	8.92	0.49	1.08e-16	Retinal vascular caliber;
KIRP	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg10852876	chr4:165953100	TRIM60	-0.48	-5.26	-0.32	3.14e-7	Obesity-related traits;
KIRP	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg19847130	chr8:10466454	RP1L1	0.38	5.32	0.32	2.37e-7	Retinal vascular caliber;
KIRP	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg06223162	chr1:101003688	GPR88	-0.43	-8.8	-0.49	2.41e-16	Monocyte count;
KIRP	cis	rs507080	0.769	rs12290522	chr11:118486325	C/T	cg04173919	chr11:118528438	PHLDB1	0.35	5.08	0.31	7.6e-7	Serum metabolite levels;
KIRP	cis	rs2904967	0.929	rs655433	chr11:65069275	G/C	cg12562828	chr11:65076843	NA	0.61	8.94	0.5	9.46e-17	Mean corpuscular volume;
KIRP	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg16141378	chr3:129829833	LOC729375	0.62	8.38	0.47	4.08e-15	Triglycerides;
KIRP	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg06307176	chr5:131281290	NA	0.53	5.92	0.35	1.06e-8	Life satisfaction;
KIRP	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg17377491	chr11:112096999	PTS	0.51	6.07	0.36	4.79e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.7	9.49	0.52	2.11e-18	Systemic lupus erythematosus;
KIRP	cis	rs960902	0.719	rs2192940	chr2:37722876	G/C	cg25341268	chr2:37734390	NA	0.5	6.59	0.39	2.66e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs73200209	0.744	rs17426970	chr12:116665099	T/C	cg01776926	chr12:116560359	MED13L	-0.56	-6.23	-0.37	1.96e-9	Total body bone mineral density;
KIRP	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.46	5.39	0.33	1.61e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03079208	chr4:87855937	AFF1	0.49	6.43	0.38	6.58e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12411876	chr2:131116574	PTPN18	0.48	6.29	0.37	1.45e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg15556689	chr8:8085844	FLJ10661	0.56	7.63	0.44	5.11e-13	Neuroticism;
KIRP	trans	rs1106684	1.000	rs11773898	chr7:131465908	A/G	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	cis	rs15676	0.947	rs6478854	chr9:131588888	G/C	cg00228799	chr9:131580591	ENDOG	-0.55	-6.11	-0.36	3.78e-9	Blood metabolite levels;
KIRP	cis	rs2067663	0.786	rs652660	chr5:88041932	C/G	cg18498987	chr5:88179539	MEF2C	0.42	5.41	0.33	1.51e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.56	6.84	0.4	6.39e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs2742417	1.000	rs2742397	chr3:45758946	C/G	cg04837898	chr3:45731254	SACM1L	0.38	5.37	0.32	1.79e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6001982	0.667	rs4299422	chr22:40871251	T/C	cg07138101	chr22:40742427	ADSL	0.73	5.15	0.31	5.41e-7	Breast cancer;
KIRP	cis	rs4132509	0.744	rs7519673	chr1:243993123	A/G	cg25706552	chr1:244017396	NA	0.66	6.85	0.4	5.84e-11	RR interval (heart rate);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19640029	chr5:91065434	NA	-0.43	-6.3	-0.37	1.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.5	0.33	9.75e-8	Vitiligo;
KIRP	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	8.59	0.48	1.01e-15	Motion sickness;
KIRP	cis	rs12541635	0.677	rs1817939	chr8:107029820	A/G	cg10147462	chr8:107024639	NA	0.34	5.14	0.31	5.65e-7	Age of smoking initiation;
KIRP	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.74	-0.44	2.61e-13	IgG glycosylation;
KIRP	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.93	-16.78	-0.73	1.21e-42	Electrocardiographic conduction measures;
KIRP	cis	rs57338032	0.891	rs58766815	chr15:78796221	C/T	cg06917634	chr15:78832804	PSMA4	0.55	4.89	0.3	1.78e-6	CTACK levels;
KIRP	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg12559939	chr2:27858050	GPN1	0.42	5.28	0.32	2.87e-7	Oral cavity cancer;
KIRP	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.55	0.43	8.56e-13	Educational attainment;
KIRP	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.58	6.94	0.4	3.52e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	8.42	0.47	3.08e-15	Migraine;Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15884905	chr6:45294599	RUNX2;SUPT3H	-0.44	-6.62	-0.39	2.17e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg24846343	chr22:24311635	DDTL	0.46	5.96	0.36	8.72e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.83	9.86	0.53	1.55e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg19025524	chr12:109796872	NA	-0.41	-5.43	-0.33	1.38e-7	Neuroticism;
KIRP	cis	rs7011049	1.000	rs72643574	chr8:53844501	G/C	cg26025543	chr8:53854495	NA	0.75	7.86	0.45	1.16e-13	Systolic blood pressure;
KIRP	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.84	13.25	0.65	1.31e-30	Prostate cancer;
KIRP	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.27	0.47	8.32e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.99	0.45	5.35e-14	Corneal astigmatism;
KIRP	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg03806693	chr22:41940476	POLR3H	-0.46	-5.17	-0.31	4.86e-7	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06537019	chr1:178420683	RASAL2	-0.4	-6.15	-0.37	3.14e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-28.33	-0.87	2e-79	Myeloid white cell count;
KIRP	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.59	-9.56	-0.52	1.28e-18	Obesity-related traits;
KIRP	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	0.73	6.56	0.39	3.17e-10	Skin colour saturation;
KIRP	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg03315344	chr16:75512273	CHST6	-0.52	-4.93	-0.3	1.5e-6	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs4664304	0.802	rs1511224	chr2:160750861	C/T	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.79	-0.35	2.19e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7591446	0.517	rs7596942	chr2:45839700	G/T	cg15146906	chr2:45838581	SRBD1	0.53	5.17	0.31	4.9e-7	Squamous cell lung carcinoma;
KIRP	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg12940439	chr1:67600707	NA	0.36	5.37	0.32	1.84e-7	Psoriasis;
KIRP	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-8.98	-0.5	7.44e-17	Schizophrenia;
KIRP	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.72	-8.84	-0.49	1.86e-16	Cognitive function;
KIRP	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg25019033	chr10:957182	NA	-0.59	-6.31	-0.37	1.31e-9	Eosinophil percentage of granulocytes;
KIRP	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.65	-10.46	-0.56	1.94e-21	Morning vs. evening chronotype;
KIRP	cis	rs8028182	0.636	rs4886707	chr15:75755467	C/T	cg20655648	chr15:75932815	IMP3	0.53	6.66	0.39	1.77e-10	Sudden cardiac arrest;
KIRP	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.8	-0.63	4.41e-29	Alzheimer's disease;
KIRP	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.02	0.36	6.19e-9	Menopause (age at onset);
KIRP	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.5	6.79	0.4	8.38e-11	Mean corpuscular volume;
KIRP	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.57	6.79	0.4	8.4e-11	HDL cholesterol;
KIRP	cis	rs1978968	0.731	rs9605468	chr22:18461180	T/C	cg02610425	chr22:18483192	MICAL3	0.37	5.59	0.34	6.06e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg08662619	chr6:150070041	PCMT1	0.39	6.48	0.38	5e-10	Lung cancer;
KIRP	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg07274523	chr3:49395745	GPX1	0.69	8.36	0.47	4.56e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg17366294	chr4:99064904	C4orf37	0.44	6.38	0.38	8.94e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg26681399	chr22:41777847	TEF	-0.5	-4.89	-0.3	1.83e-6	Vitiligo;
KIRP	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.04	-0.31	9.03e-7	Heart rate;
KIRP	cis	rs72730918	0.564	rs34662965	chr15:51784689	T/G	cg14296394	chr15:51910925	DMXL2	0.78	10.66	0.56	4.67e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.88e-11	Aortic root size;
KIRP	cis	rs6585424	1.000	rs6585454	chr10:81940701	C/T	cg27417294	chr10:81904244	PLAC9	-0.52	-5.06	-0.31	8.06e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	8.58	0.48	1.06e-15	Personality dimensions;
KIRP	cis	rs8084125	1.000	rs62105167	chr18:74944594	G/A	cg18461021	chr18:74961002	GALR1	0.62	5.9	0.35	1.19e-8	Obesity-related traits;
KIRP	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg06636001	chr8:8085503	FLJ10661	0.62	8.17	0.46	1.64e-14	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13259118	chr14:62161958	HIF1A	0.49	6.82	0.4	6.92e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg05552183	chr6:42928497	GNMT	0.44	5.06	0.31	8.38e-7	Blood protein levels;
KIRP	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.56	5.94	0.35	9.81e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.74	-7.85	-0.45	1.32e-13	Blood pressure (smoking interaction);
KIRP	cis	rs12282928	1.000	rs6485821	chr11:48292594	C/G	cg26585981	chr11:48327164	OR4S1	0.51	6.09	0.36	4.42e-9	Migraine - clinic-based;
KIRP	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.47e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.79	6.23	0.37	2.01e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg07701084	chr6:150067640	NUP43	0.73	10.1	0.54	2.7e-20	Lung cancer;
KIRP	cis	rs35661897	0.920	rs62190909	chr2:227294858	C/G	cg03426602	chr2:227312417	NA	-0.56	-6.94	-0.4	3.41e-11	Urinary tract infection frequency;
KIRP	cis	rs9309473	0.500	rs10189578	chr2:73728609	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.63	-0.34	4.93e-8	Metabolite levels;
KIRP	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.57	8.16	0.46	1.76e-14	Multiple system atrophy;
KIRP	cis	rs72960926	0.744	rs72957999	chr6:74973822	T/C	cg03266952	chr6:74778945	NA	-0.7	-4.98	-0.3	1.23e-6	Metabolite levels (MHPG);
KIRP	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg16586182	chr3:47516702	SCAP	0.68	9.25	0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg11584989	chr19:19387371	SF4	-0.41	-5.11	-0.31	6.38e-7	Tonsillectomy;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18765753	chr7:1198926	ZFAND2A	0.47	5.62	0.34	5.18e-8	Longevity;Endometriosis;
KIRP	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.47	-6.33	-0.37	1.14e-9	Schizophrenia;
KIRP	cis	rs7709377	0.597	rs11241364	chr5:115466026	T/C	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.38	5.04	0.31	8.92e-7	Depressive episodes in bipolar disorder;
KIRP	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.56	7.36	0.42	2.72e-12	Obesity-related traits;
KIRP	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.44	-0.38	6.21e-10	Daytime sleep phenotypes;
KIRP	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06505273	chr16:24850292	NA	0.42	5.77	0.35	2.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg16482183	chr6:26056742	HIST1H1C	0.63	7.16	0.42	9.09e-12	Iron status biomarkers;
KIRP	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg03188948	chr7:1209495	NA	0.47	5.08	0.31	7.56e-7	Longevity;Endometriosis;
KIRP	cis	rs1981331	0.609	rs57896262	chr21:48028188	C/T	cg23283320	chr21:48055893	PRMT2	0.8	5.82	0.35	1.83e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.56	6.62	0.39	2.24e-10	Height;
KIRP	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.62	-7.11	-0.41	1.22e-11	QRS complex (12-leadsum);
KIRP	cis	rs12986413	0.624	rs3786970	chr19:2141150	C/G	cg09261902	chr19:2140048	AP3D1	0.68	10.67	0.56	4.42e-22	Height;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-4.91	-0.3	1.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs282587	0.569	rs7986147	chr13:113398784	A/C	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.64e-12	Glycated hemoglobin levels;
KIRP	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.82	10.36	0.55	4.02e-21	Total cholesterol levels;
KIRP	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.69	9.26	0.51	1.08e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.79	-8.56	-0.48	1.26e-15	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg06640241	chr16:89574553	SPG7	0.81	12.29	0.62	2.27e-27	Multiple myeloma (IgH translocation);
KIRP	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.46	-6.04	-0.36	5.6e-9	Schizophrenia;
KIRP	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg23682824	chr7:23144976	KLHL7	0.44	4.87	0.3	2.01e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg01025720	chr13:113346439	ATP11A	0.51	4.84	0.3	2.25e-6	Glycated hemoglobin levels;
KIRP	cis	rs2274273	0.564	rs3783649	chr14:55834410	G/A	cg04306507	chr14:55594613	LGALS3	0.37	5.27	0.32	3.01e-7	Protein biomarker;
KIRP	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.6	-9.56	-0.52	1.27e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.22	14.04	0.67	2.88e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg09579323	chr1:150459698	TARS2	-0.4	-5.04	-0.31	9.22e-7	Migraine;
KIRP	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.84	0.35	1.65e-8	Breast cancer;
KIRP	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg07435449	chr11:120005650	TRIM29	-0.48	-6.43	-0.38	6.51e-10	Stroke (pediatric);
KIRP	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14769373	chr6:40998127	UNC5CL	-0.55	-5.42	-0.33	1.4e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.79	10.2	0.55	1.36e-20	Mean platelet volume;
KIRP	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.39e-10	Bipolar disorder;
KIRP	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg13180566	chr4:1052158	NA	-0.54	-5.46	-0.33	1.19e-7	Recombination rate (females);
KIRP	cis	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg06521331	chr12:34319734	NA	0.44	5.18	0.31	4.67e-7	Resting heart rate;
KIRP	cis	rs2223471	0.546	rs280323	chr6:50634359	G/A	cg03432817	chr6:50765336	NA	-0.37	-5.43	-0.33	1.38e-7	Subcutaneous adipose tissue;
KIRP	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.08	-0.36	4.52e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs8084125	0.938	rs2097094	chr18:74942422	G/A	cg05528293	chr18:74961138	GALR1	0.5	4.91	0.3	1.67e-6	Obesity-related traits;
KIRP	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs72848980	0.582	rs72848953	chr10:105277168	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.46	4.96	0.3	1.3e-6	White matter hyperintensity burden;
KIRP	cis	rs7481311	0.912	rs10767645	chr11:27544739	T/G	cg18117895	chr11:27722066	BDNF	0.48	5.21	0.32	4.05e-7	Body mass index;Weight;
KIRP	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.88	0.35	1.32e-8	Schizophrenia;
KIRP	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.56	-8.39	-0.47	3.72e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12683173	chr7:69063404	AUTS2	0.52	6.67	0.39	1.72e-10	Parkinson's disease;
KIRP	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg01214346	chr17:406501	NA	-0.47	-6.01	-0.36	6.6e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs8049040	0.524	rs891125	chr16:71431621	C/T	cg08717414	chr16:71523259	ZNF19	-0.62	-7.14	-0.41	1.05e-11	Blood protein levels;
KIRP	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.63	6.54	0.38	3.61e-10	Breast cancer;
KIRP	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.26e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.65	-7.43	-0.43	1.82e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2746347	0.915	rs72666493	chr1:57137886	G/C	cg09935045	chr1:57111199	PRKAA2	0.53	5.5	0.33	9.32e-8	Lymphocyte counts;
KIRP	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26207909	chr14:103986467	CKB	-0.81	-12.52	-0.62	3.79e-28	Body mass index;
KIRP	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg01849789	chr22:41697279	ZC3H7B	-0.5	-5.52	-0.33	8.56e-8	Neuroticism;
KIRP	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg04310649	chr10:35416472	CREM	-0.59	-6.99	-0.41	2.51e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.95	-0.45	6.67e-14	Retinal vascular caliber;
KIRP	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.1e-9	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.59e-8	Life satisfaction;
KIRP	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.75	-0.4	1.05e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20135002	chr11:47629003	NA	-0.46	-5.13	-0.31	5.97e-7	Subjective well-being;
KIRP	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.81	-10.03	-0.54	4.61e-20	Blood protein levels;
KIRP	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.24	0.42	5.71e-12	Mean platelet volume;
KIRP	cis	rs6662572	0.703	rs6689417	chr1:46388008	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.55e-8	Blood protein levels;
KIRP	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.36	-0.32	1.92e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4474465	0.920	rs7125628	chr11:78223028	C/G	cg27205649	chr11:78285834	NARS2	0.65	7.94	0.45	7.26e-14	Alzheimer's disease (survival time);
KIRP	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.51	6.45	0.38	5.81e-10	Tonsillectomy;
KIRP	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg24130564	chr14:104152367	KLC1	-0.57	-7.94	-0.45	7.28e-14	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23234832	chr3:24536323	THRB	0.54	7.01	0.41	2.27e-11	Parkinson's disease;
KIRP	cis	rs7714584	1.000	rs11167515	chr5:150239471	G/T	cg22134413	chr5:150180641	NA	0.8	7.01	0.41	2.26e-11	Crohn's disease;
KIRP	cis	rs1215050	0.791	rs165252	chr4:98758728	A/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03384915	chr19:16986822	SIN3B	-0.44	-6.39	-0.38	8.2e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg10932868	chr11:921992	NA	0.58	7.25	0.42	5.28e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7084402	0.967	rs3001717	chr10:60329125	A/G	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	cis	rs4919044	0.808	rs835277	chr10:94809677	T/C	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs12532214	0.617	rs73673328	chr7:3149140	G/C	cg19214707	chr7:3157722	NA	-0.66	-6.27	-0.37	1.57e-9	Itch intensity from mosquito bite;
KIRP	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.81	10.72	0.56	3.07e-22	Blood metabolite levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10005894	chr3:186649165	ST6GAL1	0.61	7.91	0.45	8.45e-14	Smoking initiation;
KIRP	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.43	6.57	0.39	2.94e-10	Schizophrenia;
KIRP	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.64	10.17	0.54	1.68e-20	Platelet count;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.24	-24.78	-0.84	8.28e-69	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1359582	0.793	rs3980065	chr10:90398803	T/C	cg15661332	chr10:90342814	RNLS	0.56	5.94	0.35	9.84e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg19116668	chr7:99932089	PMS2L1	0.44	5.11	0.31	6.48e-7	Coronary artery disease;
KIRP	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg23335576	chr14:104009727	NA	0.39	5.67	0.34	4.02e-8	Body mass index;
KIRP	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.39	-5.17	-0.31	4.93e-7	Renal function-related traits (BUN);
KIRP	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.14e-11	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.42	5.9	0.35	1.21e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.46	-8.91	-0.49	1.15e-16	Educational attainment (years of education);
KIRP	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.04e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	0.64	5.59	0.34	5.93e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.55	8.12	0.46	2.25e-14	Monocyte percentage of white cells;
KIRP	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg18154014	chr19:37997991	ZNF793	0.8	8.28	0.47	7.85e-15	Coronary artery calcification;
KIRP	cis	rs6987853	0.787	rs1343874	chr8:42424746	C/T	cg09913449	chr8:42400586	C8orf40	0.41	5.55	0.33	7.23e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-10.53	-0.56	1.18e-21	Bladder cancer;
KIRP	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.22e-15	Motion sickness;
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg08989290	chr16:615782	NHLRC4	0.4	5.77	0.35	2.33e-8	Height;
KIRP	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg25019033	chr10:957182	NA	0.46	7.81	0.45	1.61e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.37e-14	Aortic root size;
KIRP	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg26384229	chr12:38710491	ALG10B	0.56	7.12	0.41	1.17e-11	Resting heart rate;
KIRP	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg13010199	chr12:38710504	ALG10B	0.51	6.21	0.37	2.23e-9	Morning vs. evening chronotype;
KIRP	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2997447	0.761	rs17257127	chr1:26452386	C/T	cg19633962	chr1:26362018	EXTL1	-0.55	-4.88	-0.3	1.92e-6	QRS complex (12-leadsum);
KIRP	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.47	6.82	0.4	6.84e-11	Blood metabolite levels;
KIRP	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	8.11	0.46	2.34e-14	Menarche (age at onset);
KIRP	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.71	9.5	0.52	1.91e-18	Height;
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg08805041	chr16:621841	PIGQ	-0.38	-5.23	-0.32	3.62e-7	Height;
KIRP	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg23920097	chr1:209922102	NA	0.38	5.17	0.31	4.77e-7	Red blood cell count;
KIRP	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13132184	0.507	rs34119528	chr4:38023302	C/G	cg14409701	chr4:38048871	TBC1D1	-0.79	-7.57	-0.43	7.51e-13	Verbal declarative memory;
KIRP	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg26248373	chr2:1572462	NA	-0.76	-10.39	-0.55	3.35e-21	IgG glycosylation;
KIRP	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg24642439	chr20:33292090	TP53INP2	-0.58	-7.59	-0.44	6.58e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs7712401	0.601	rs448505	chr5:122336690	T/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.39e-7	Mean platelet volume;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.2	-0.55	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.52	6.36	0.38	9.75e-10	Subjective well-being;
KIRP	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.76	-8.63	-0.48	7.88e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg05926928	chr17:57297772	GDPD1	-0.74	-7.47	-0.43	1.35e-12	Opioid sensitivity;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg21851534	chr17:3907994	ZZEF1	-0.64	-10.37	-0.55	3.82e-21	Type 2 diabetes;
KIRP	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	1.21	10.52	0.56	1.33e-21	Alzheimer's disease (late onset);
KIRP	cis	rs4663866	0.908	rs35093813	chr2:239153765	T/A	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15745973	chr2:27850661	CCDC121;GPN1	0.43	6.27	0.37	1.59e-9	Survival in pancreatic cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16388829	chr2:97202323	ARID5A	0.52	6.46	0.38	5.5e-10	Smoking initiation;
KIRP	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.66	0.52	6.24e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.7e-10	Red blood cell count;
KIRP	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.46	-7.16	-0.42	9.11e-12	Height;
KIRP	cis	rs2862064	1.000	rs7731951	chr5:156449685	A/T	cg12943317	chr5:156479607	HAVCR1	0.98	8.54	0.48	1.38e-15	Platelet count;
KIRP	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg22906224	chr7:99728672	NA	0.51	6.21	0.37	2.28e-9	Coronary artery disease;
KIRP	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06481639	chr22:41940642	POLR3H	0.66	7.19	0.42	7.71e-12	Vitiligo;
KIRP	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg03609598	chr5:56110824	MAP3K1	-0.49	-5.28	-0.32	2.79e-7	Type 2 diabetes;
KIRP	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg23625390	chr15:77176239	SCAPER	0.5	6.59	0.39	2.73e-10	Blood metabolite levels;
KIRP	cis	rs4363506	0.625	rs10765119	chr10:129285189	G/A	cg07804728	chr10:129284050	NA	0.42	5.78	0.35	2.25e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg12483005	chr1:23474871	LUZP1	-0.55	-7.19	-0.42	7.92e-12	Height;
KIRP	cis	rs1978968	1.000	rs7291169	chr22:18449038	A/G	cg03078520	chr22:18463400	MICAL3	-0.64	-7.57	-0.43	7.6e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.64e-11	Lung cancer;
KIRP	cis	rs13102973	0.538	rs13139929	chr4:135912516	C/A	cg14419869	chr4:135874104	NA	0.38	5.71	0.34	3.29e-8	Subjective well-being;
KIRP	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.73	8.26	0.47	8.9e-15	Corneal astigmatism;
KIRP	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.58	6.9	0.4	4.35e-11	Aortic root size;
KIRP	cis	rs9309473	0.950	rs10207264	chr2:73714097	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.36	-0.38	9.8e-10	Metabolite levels;
KIRP	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg03808351	chr9:123631620	PHF19	0.42	5.78	0.35	2.26e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg18350739	chr11:68623251	NA	-0.51	-7.52	-0.43	1e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.85	0.45	1.31e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs6467136	0.818	rs62481345	chr7:127165537	T/C	cg23081781	chr7:127225937	GCC1	-0.38	-5.11	-0.31	6.58e-7	Type 2 diabetes;
KIRP	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg11693508	chr17:37793320	STARD3	0.76	8.16	0.46	1.78e-14	Bipolar disorder;
KIRP	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.37	-0.32	1.78e-7	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.63	-0.39	2.11e-10	Lung cancer;
KIRP	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.98	13.0	0.64	9.55e-30	Vitamin D levels;
KIRP	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg05315796	chr3:52349193	DNAH1	0.45	6.76	0.4	1e-10	Bipolar disorder;
KIRP	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.44	-0.38	6.11e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.44	6.21	0.37	2.25e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.7	9.57	0.52	1.16e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg08662619	chr6:150070041	PCMT1	0.34	5.38	0.32	1.73e-7	Lung cancer;
KIRP	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg24644049	chr4:85504048	CDS1	1.0	6.97	0.41	2.88e-11	Skin colour saturation;
KIRP	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.55	-5.81	-0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg10434728	chr15:90938212	IQGAP1	-0.4	-7.32	-0.42	3.5e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7937612	1.000	rs10892566	chr11:120241923	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.18	-0.42	8.01e-12	Intraocular pressure;
KIRP	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.93	-0.4	3.77e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.47	-7.16	-0.42	9.04e-12	Vitamin D levels;
KIRP	trans	rs10782582	0.622	rs10873795	chr1:76373684	T/C	cg10283277	chr11:111472630	SIK2	-0.31	-6.33	-0.37	1.18e-9	Daytime sleep phenotypes;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg10254082	chr7:997346	NA	0.4	4.85	0.3	2.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg18585693	chr11:117668161	DSCAML1	0.31	5.09	0.31	7.12e-7	Myopia;
KIRP	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs3739034	0.877	rs13033373	chr2:135520534	T/C	cg15546071	chr2:135691756	CCNT2	-0.53	-4.95	-0.3	1.38e-6	Gut microbiome composition (winter);
KIRP	cis	rs2729354	0.817	rs2250673	chr11:57268170	T/C	cg24343310	chr11:57249947	NA	0.28	5.48	0.33	1.04e-7	Blood protein levels;
KIRP	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.84	-11.38	-0.59	2.24e-24	Cocaine dependence;
KIRP	cis	rs28834970	0.675	rs17057051	chr8:27227554	C/T	cg07216194	chr8:27182965	PTK2B	0.48	5.26	0.32	3.19e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2494663	0.585	rs12021641	chr1:154064443	T/G	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.98	-0.3	1.21e-6	Mean platelet volume;
KIRP	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg13319975	chr6:146136371	FBXO30	0.43	5.73	0.34	2.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7662987	0.793	rs12697	chr4:99993376	C/T	cg13256891	chr4:100009986	ADH5	0.65	5.63	0.34	4.78e-8	Smoking initiation;
KIRP	cis	rs714031	0.900	rs5757762	chr22:40064581	C/T	cg21377881	chr22:40064566	CACNA1I	-0.71	-11.51	-0.59	8.54e-25	Schizophrenia;
KIRP	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.67e-19	Prudent dietary pattern;
KIRP	cis	rs11225247	0.881	rs7114048	chr11:102253780	C/T	cg06323957	chr11:102217781	BIRC2	0.93	5.96	0.36	8.49e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs13064411	0.518	rs6438160	chr3:113217591	A/C	cg18753928	chr3:113234510	CCDC52	-0.49	-6.29	-0.37	1.41e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.56	6.56	0.39	3.17e-10	HDL cholesterol;
KIRP	cis	rs7106204	0.514	rs7107321	chr11:24259879	T/C	ch.11.24196551F	chr11:24239977	NA	0.79	7.87	0.45	1.14e-13	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-0.6	-6.63	-0.39	2.08e-10	Initial pursuit acceleration;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg24488311	chr11:68621650	NA	0.44	5.2	0.31	4.15e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg02574844	chr11:5959923	NA	-0.59	-5.96	-0.36	8.65e-9	DNA methylation (variation);
KIRP	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.19	-0.37	2.57e-9	Joint mobility (Beighton score);
KIRP	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg10790698	chr19:18539756	SSBP4	-0.33	-7.03	-0.41	2.03e-11	Breast cancer;
KIRP	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.56	-0.7	1.85e-38	Gut microbiome composition (summer);
KIRP	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.72	10.93	0.57	6.54e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4478858	0.735	rs10914344	chr1:31769025	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.39	-0.32	1.67e-7	Alcohol dependence;
KIRP	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.11	-0.54	2.63e-20	Coffee consumption (cups per day);
KIRP	cis	rs2929278	0.617	rs694461	chr15:44096063	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.46	-5.53	-0.33	8.21e-8	Schizophrenia;
KIRP	cis	rs4356932	0.967	rs7659236	chr4:76953611	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs501120	0.810	rs473501	chr10:44749171	G/A	cg09554077	chr10:44749378	NA	0.75	12.45	0.62	6.35e-28	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.1	0.41	1.32e-11	Retinal vascular caliber;
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg14664628	chr15:75095509	CSK	-0.6	-7.23	-0.42	5.92e-12	Breast cancer;
KIRP	trans	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.78	0.4	8.98e-11	Retinal vascular caliber;
KIRP	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg03342759	chr3:160939853	NMD3	0.44	5.26	0.32	3.08e-7	Morning vs. evening chronotype;
KIRP	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.83	-0.35	1.74e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs9381107	0.932	rs11756620	chr6:9423799	T/C	cg14735645	chr6:9486422	NA	-0.45	-5.33	-0.32	2.28e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs4363385	0.510	rs2339386	chr1:152892307	C/T	cg25856811	chr1:152973957	SPRR3	-0.41	-5.67	-0.34	4.01e-8	Inflammatory skin disease;
KIRP	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg15880211	chr22:50250494	ZBED4	0.44	5.16	0.31	5.13e-7	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.63	8.58	0.48	1.1e-15	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs12936587	0.692	rs35660942	chr17:17527185	G/A	cg01246520	chr17:17644344	RAI1	-0.36	-5.77	-0.35	2.42e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.28	-0.32	2.82e-7	Primary biliary cholangitis;
KIRP	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg05973401	chr12:123451056	ABCB9	0.57	6.62	0.39	2.21e-10	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.66	5.49	0.33	1.02e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.69	-8.35	-0.47	4.94e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg03733263	chr8:22462867	KIAA1967	1.03	16.22	0.72	1.01e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs13279522	0.536	rs13266516	chr8:67011471	C/T	cg04041976	chr8:67085823	TRIM55	-0.43	-5.34	-0.32	2.1e-7	Coronary heart disease event reduction (statin therapy interaction);
KIRP	trans	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg12929700	chr20:62947519	NA	-0.59	-6.11	-0.36	3.9e-9	Refractive error;
KIRP	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.85	11.91	0.6	3.87e-26	Breast cancer;
KIRP	cis	rs2273669	0.667	rs12196143	chr6:109302372	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs2072732	0.756	rs55949537	chr1:2936746	A/T	cg22517653	chr1:2918612	NA	-0.42	-4.96	-0.3	1.29e-6	Plateletcrit;
KIRP	cis	rs585287	0.512	rs660800	chr11:114040510	A/G	cg25009965	chr11:114031120	ZBTB16	0.48	4.95	0.3	1.36e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
KIRP	cis	rs526231	0.543	rs60633061	chr5:102330049	C/T	cg23492399	chr5:102201601	PAM	-0.48	-5.54	-0.33	7.81e-8	Primary biliary cholangitis;
KIRP	cis	rs4262150	0.511	rs72795339	chr5:151904788	A/C	cg12297329	chr5:152029980	NA	-0.72	-8.89	-0.49	1.31e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.73	9.67	0.52	5.74e-19	Mood instability;
KIRP	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	6.28	0.37	1.5e-9	Bipolar disorder;
KIRP	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg06640241	chr16:89574553	SPG7	0.81	12.28	0.62	2.35e-27	Multiple myeloma (IgH translocation);
KIRP	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.33	0.37	1.18e-9	Educational attainment;
KIRP	cis	rs2908668	1.000	rs2972284	chr16:5068152	C/T	cg00849365	chr16:5074999	NAGPA	-0.42	-4.92	-0.3	1.6e-6	Cancer;
KIRP	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-7.48	-0.43	1.28e-12	Cognitive test performance;
KIRP	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs897080	0.515	rs698763	chr2:44573624	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.26	0.37	1.69e-9	Height;
KIRP	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.98	-15.95	-0.71	8.26e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs9467711	0.606	rs9393735	chr6:26582327	A/G	cg12315302	chr6:26189340	HIST1H4D	0.63	5.02	0.31	9.7e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg06212747	chr3:49208901	KLHDC8B	0.52	5.07	0.31	7.75e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg22705602	chr4:152727874	NA	-0.55	-9.66	-0.52	6.22e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg07541023	chr7:19748670	TWISTNB	0.9	7.45	0.43	1.59e-12	Thyroid stimulating hormone;
KIRP	cis	rs7534824	0.860	rs7524946	chr1:101604781	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	4.87	0.3	1.97e-6	Refractive astigmatism;
KIRP	trans	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg03468072	chr12:39539422	NA	0.41	5.96	0.36	8.47e-9	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg03959625	chr15:84868606	LOC388152	0.62	6.48	0.38	4.93e-10	Schizophrenia;
KIRP	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.48	0.65	2.21e-31	Electrocardiographic conduction measures;
KIRP	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11786666	chr7:105173132	RINT1	0.54	6.39	0.38	8.31e-10	Lung cancer in ever smokers;
KIRP	cis	rs4765905	0.610	rs10848636	chr12:2316493	A/C	cg10668781	chr12:2307325	CACNA1C	0.34	6.9	0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg03171003	chr2:111875934	NA	0.38	5.34	0.32	2.08e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg00262122	chr8:11665843	FDFT1	0.43	5.41	0.33	1.52e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05595602	chr1:1343077	MRPL20	0.48	6.58	0.39	2.89e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg01493522	chr13:37497338	NA	-0.41	-5.27	-0.32	2.97e-7	Coronary artery disease;
KIRP	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs255758	0.627	rs426659	chr5:53319404	A/G	cg22592108	chr5:53304441	ARL15	-0.4	-5.58	-0.34	6.25e-8	Rheumatoid arthritis;
KIRP	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.55	-6.82	-0.4	6.92e-11	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg02574844	chr11:5959923	NA	-0.53	-5.35	-0.32	2.04e-7	DNA methylation (variation);
KIRP	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.92	14.91	0.69	2.93e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg07511934	chr16:89386912	ANKRD11	0.41	5.05	0.31	8.48e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg16482183	chr6:26056742	HIST1H1C	0.4	5.24	0.32	3.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9393813	0.605	rs12529458	chr6:27361681	A/G	cg03332623	chr6:27441972	ZNF184	-0.39	-5.42	-0.33	1.4e-7	Bipolar disorder;
KIRP	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.56	6.67	0.39	1.71e-10	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24918715	chr16:31225234	TRIM72	0.5	6.67	0.39	1.64e-10	Interleukin-4 levels;
KIRP	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg06307176	chr5:131281290	NA	0.57	6.41	0.38	7.48e-10	Life satisfaction;
KIRP	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.61	7.14	0.41	1.08e-11	Height;
KIRP	cis	rs970548	0.688	rs1059696	chr10:45934437	G/A	cg15590007	chr10:45870220	ALOX5	0.52	5.76	0.34	2.56e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs4950322	0.570	rs4950401	chr1:146791289	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.84	-0.35	1.66e-8	Crohn's disease;
KIRP	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.8	0.35	2.05e-8	Depressive symptoms;
KIRP	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg18234130	chr8:27182889	PTK2B	0.49	6.18	0.37	2.71e-9	Neuroticism;
KIRP	cis	rs6681460	0.898	rs2483704	chr1:67195353	C/T	cg13052034	chr1:66999238	SGIP1	-0.36	-5.07	-0.31	7.77e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7614311	0.731	rs3733121	chr3:63850660	C/G	cg22134162	chr3:63841271	THOC7	-0.45	-5.29	-0.32	2.75e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg08283408	chr3:49949060	MON1A	-0.37	-4.99	-0.3	1.16e-6	Body mass index;
KIRP	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.35	-10.28	-0.55	7.71e-21	Diabetic kidney disease;
KIRP	cis	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.13	0.31	5.86e-7	Triglycerides;
KIRP	cis	rs2380205	0.967	rs7898059	chr10:5889038	C/A	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg14061069	chr19:46274453	DMPK	-0.61	-9.56	-0.52	1.25e-18	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg21698718	chr17:80085957	CCDC57	-0.34	-4.98	-0.3	1.19e-6	Life satisfaction;
KIRP	cis	rs997295	0.713	rs9302246	chr15:68021280	A/G	cg24579218	chr15:68104479	NA	0.35	4.96	0.3	1.31e-6	Motion sickness;
KIRP	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg05315796	chr3:52349193	DNAH1	0.45	6.95	0.41	3.3e-11	Bipolar disorder;
KIRP	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg19847130	chr8:10466454	RP1L1	0.33	5.01	0.3	1.05e-6	Triglycerides;
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.86	14.11	0.67	1.61e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg17788362	chr6:86352627	SYNCRIP	0.49	6.49	0.38	4.6e-10	Smooth-surface caries;
KIRP	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg12559939	chr2:27858050	GPN1	0.41	5.23	0.32	3.61e-7	Oral cavity cancer;
KIRP	cis	rs7221595	0.778	rs62072386	chr17:3896168	T/C	cg09695851	chr17:3907499	NA	0.57	6.04	0.36	5.62e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.76	-0.53	3.17e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.85	13.58	0.65	1.03e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.4	4.97	0.3	1.28e-6	Aortic root size;
KIRP	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.62	-8.44	-0.47	2.81e-15	Total body bone mineral density;
KIRP	cis	rs12230513	0.732	rs7966770	chr12:55844717	T/C	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.63	-7.97	-0.45	5.98e-14	Colorectal cancer;
KIRP	cis	rs311392	0.584	rs388075	chr8:55099893	T/C	cg06042504	chr8:55087323	NA	-0.54	-6.69	-0.39	1.5e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg02187348	chr16:89574699	SPG7	0.47	5.6	0.34	5.84e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs960902	0.747	rs13387905	chr2:37728625	A/G	cg25341268	chr2:37734390	NA	0.6	8.29	0.47	7.32e-15	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs4073221	0.654	rs7373842	chr3:18294022	T/C	cg07694806	chr3:18168406	NA	-0.65	-5.95	-0.35	9.03e-9	Parkinson's disease;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg17868363	chr19:57752307	ZNF805	-0.48	-6.92	-0.4	3.9e-11	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs13130787	0.802	rs35992541	chr4:94908030	C/T	cg11021082	chr4:95130006	SMARCAD1	0.39	5.03	0.31	9.65e-7	Colorectal cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg21523528	chr20:32077966	CBFA2T2	0.5	6.12	0.36	3.67e-9	Educational attainment;
KIRP	cis	rs514024	0.656	rs537881	chr9:130485618	C/T	cg13643465	chr9:130375613	STXBP1	0.39	5.33	0.32	2.2e-7	Eating disorders (purging via substances);
KIRP	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.36	-4.96	-0.3	1.32e-6	Depressive symptoms;
KIRP	cis	rs6504950	0.830	rs12949538	chr17:53010670	A/G	cg26251398	chr17:52985966	TOM1L1	-0.43	-5.27	-0.32	2.98e-7	Breast cancer;
KIRP	cis	rs7973683	0.541	rs7976319	chr12:124388511	A/G	cg12597309	chr12:124393772	DNAH10	0.41	5.13	0.31	6e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs4955124	0.558	rs12632539	chr3:32024369	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.76	6.87	0.4	5.16e-11	Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09778919	chr12:40019907	C12orf40	-0.46	-6.18	-0.37	2.61e-9	Inflammatory biomarkers;
KIRP	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg12131826	chr15:77904385	NA	0.5	6.01	0.36	6.68e-9	Type 2 diabetes;
KIRP	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-15.35	-0.7	9.05e-38	Electrocardiographic conduction measures;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17300353	chr2:137522211	NA	0.46	6.41	0.38	7.48e-10	Parkinson's disease;
KIRP	cis	rs8062405	0.573	rs8045689	chr16:28988269	C/T	cg07382826	chr16:28625726	SULT1A1	-0.49	-5.43	-0.33	1.34e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Bladder cancer;
KIRP	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.56	7.72	0.44	2.95e-13	Colorectal cancer;
KIRP	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.58	7.45	0.43	1.6e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs73129298	0.551	rs6020179	chr20:48604276	T/C	cg25655593	chr20:48599521	SNAI1	0.51	5.31	0.32	2.44e-7	Inflammatory skin disease;
KIRP	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19717773	chr7:2847554	GNA12	-0.35	-5.4	-0.33	1.54e-7	Height;
KIRP	cis	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg08773314	chr2:239334832	ASB1	-0.55	-5.7	-0.34	3.39e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg22800045	chr5:56110881	MAP3K1	0.81	8.64	0.48	7.22e-16	Initial pursuit acceleration;
KIRP	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-7.71	-0.44	3.1400000000000003e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7221595	0.825	rs12942967	chr17:3921834	C/T	cg21734707	chr17:3908241	ZZEF1	0.53	5.11	0.31	6.52e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Bipolar disorder;
KIRP	cis	rs944722	0.511	rs2297520	chr17:26108040	T/C	cg07704981	chr17:26127537	NOS2	-0.54	-7.1	-0.41	1.35e-11	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.39	4.9	0.3	1.75e-6	Eosinophil percentage of white cells;
KIRP	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.49	6.38	0.38	8.84e-10	Systolic blood pressure;
KIRP	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	1.01	6.95	0.4	3.34e-11	LDL cholesterol;
KIRP	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.42	-5.26	-0.32	3.2e-7	Aortic root size;
KIRP	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.0	-0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs13161895	1.000	rs27018	chr5:179405144	A/G	cg02702477	chr5:179499311	RNF130	0.63	4.9	0.3	1.77e-6	LDL cholesterol;
KIRP	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg03894339	chr8:19674705	INTS10	0.82	8.78	0.49	2.86e-16	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6722613	0.771	rs13401241	chr2:25518470	C/A	cg10614445	chr2:25526696	DNMT3A	-0.35	-5.92	-0.35	1.05e-8	Ossification of the posterior longitudinal ligament of the spine;
KIRP	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.76	11.09	0.58	1.92e-23	Hip circumference;
KIRP	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.7	-9.93	-0.53	9.11e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.75	0.4	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg04719120	chr6:96025338	MANEA	-0.6	-5.73	-0.34	2.9e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10214930	0.697	rs6963421	chr7:27692428	T/G	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs2219968	1.000	rs2128014	chr8:78963292	T/C	cg00738934	chr8:78996279	NA	0.42	5.3	0.32	2.52e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12714314	0.560	rs3748988	chr2:1946914	A/G	cg20846728	chr2:1843184	MYT1L	-0.39	-6.52	-0.38	3.87e-10	Type 2 diabetes (age of onset);
KIRP	cis	rs13102973	0.965	rs7656631	chr4:135869921	C/T	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg22617819	chr1:44378782	ST3GAL3	-0.4	-6.44	-0.38	6.3e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.81	-11.34	-0.59	2.98e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.55	7.37	0.43	2.51e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg16434002	chr17:42200994	HDAC5	-0.49	-5.8	-0.35	2.07e-8	Total body bone mineral density;
KIRP	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg00666640	chr1:248458726	OR2T12	-0.47	-5.81	-0.35	1.91e-8	Common traits (Other);
KIRP	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-0.92	-10.66	-0.56	4.57e-22	Breast cancer;
KIRP	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23544223	chr18:12777786	NA	0.76	6.46	0.38	5.61e-10	Inflammatory skin disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20074142	chr15:56035371	PRTG	0.5	6.18	0.37	2.57e-9	Parkinson's disease;
KIRP	cis	rs34245846	0.769	rs12084791	chr1:154824973	A/G	cg09359103	chr1:154839909	KCNN3	0.52	5.71	0.34	3.21e-8	Atrial fibrillation;
KIRP	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg06781948	chr3:72941472	GXYLT2	0.47	6.16	0.37	3.01e-9	Motion sickness;
KIRP	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg24807547	chr6:37504484	NA	-0.4	-5.76	-0.34	2.45e-8	Cognitive performance;
KIRP	cis	rs77688320	0.553	rs2243791	chr2:202342802	T/C	cg06431681	chr2:202330990	STRADB	-0.43	-5.02	-0.31	9.73e-7	Breast cancer;
KIRP	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg21858823	chr1:15850916	CASP9	0.55	5.88	0.35	1.36e-8	Systolic blood pressure;
KIRP	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.74	10.24	0.55	1.01e-20	Red blood cell count;
KIRP	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.7	9.38	0.51	4.49e-18	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.62	-0.56	6.23e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs9463078	0.585	rs9472451	chr6:45198796	A/C	cg24241925	chr17:46125675	NFE2L1	0.49	6.14	0.36	3.38e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg15744005	chr10:104629667	AS3MT	0.26	5.28	0.32	2.86e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.71	-8.51	-0.48	1.71e-15	DNA methylation (variation);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14323456	chr7:151205434	RHEB	-0.43	-6.42	-0.38	7.07e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2425143	0.908	rs74784474	chr20:34422464	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.33	0.42	3.29e-12	Neuroticism;
KIRP	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.67	-0.34	3.94e-8	Recombination measurement;
KIRP	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.61	6.63	0.39	2.06e-10	Exhaled nitric oxide output;
KIRP	cis	rs7601312	0.869	rs2216874	chr2:229308795	A/G	cg02542817	chr2:229291442	NA	-0.55	-8.26	-0.47	9.26e-15	Schizophrenia;
KIRP	cis	rs7116495	1.000	rs12272213	chr11:71816219	G/A	cg26138937	chr11:71823887	C11orf51	0.69	5.51	0.33	9.2e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.81	12.68	0.63	1.11e-28	Menarche (age at onset);
KIRP	cis	rs4979906	1.000	rs12264636	chr10:79448539	C/G	cg07817648	chr10:79422355	NA	0.45	4.92	0.3	1.59e-6	Mortality in heart failure;
KIRP	cis	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.52	-0.33	8.56e-8	HDL cholesterol;
KIRP	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg25547332	chr5:131281432	NA	0.46	5.33	0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs9810890	1.000	rs73210618	chr3:128645968	C/T	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs4849845	0.598	rs11690576	chr2:121019800	A/G	cg24070213	chr2:121070622	NA	-0.41	-6.31	-0.37	1.29e-9	Mean platelet volume;
KIRP	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.7	-9.11	-0.5	3e-17	Coronary artery disease;
KIRP	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	1.15	9.34	0.51	5.98e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.26	-0.32	3.13e-7	Menarche (age at onset);
KIRP	cis	rs72634258	0.945	rs17523802	chr1:8021740	G/A	cg00042356	chr1:8021962	PARK7	0.76	6.85	0.4	5.98e-11	Inflammatory bowel disease;
KIRP	cis	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg08501292	chr6:25962987	TRIM38	0.97	6.64	0.39	1.98e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4919694	0.667	rs117927731	chr10:105112852	C/A	cg04362960	chr10:104952993	NT5C2	0.83	6.14	0.36	3.28e-9	Arsenic metabolism;
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.48	0.38	4.95e-10	Lung cancer;
KIRP	cis	rs1538970	0.962	rs9429158	chr1:45821393	A/G	cg05343316	chr1:45956843	TESK2	0.64	7.19	0.42	7.82e-12	Platelet count;
KIRP	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg05340658	chr4:99064831	C4orf37	-0.59	-7.27	-0.42	4.86e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9788682	0.747	rs2869045	chr15:78718899	T/C	cg24631222	chr15:78858424	CHRNA5	-0.87	-9.82	-0.53	1.97e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03647317	chr4:187891568	NA	-0.74	-11.99	-0.61	2.24e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.967	rs2180568	chr20:33794794	C/G	cg07148914	chr20:33460835	GGT7	-0.41	-5.13	-0.31	5.87e-7	Height;
KIRP	cis	rs698833	0.852	rs2241869	chr2:44549229	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.5	-5.84	-0.35	1.61e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs8179	0.645	rs10264916	chr7:92286376	A/G	cg15732164	chr7:92237376	CDK6	-0.42	-5.68	-0.34	3.82e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg20488157	chr14:104394430	TDRD9	0.75	10.57	0.56	8.66e-22	Bipolar disorder;
KIRP	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs10073892	0.743	rs1584715	chr5:101653362	T/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs10861342	1.000	rs11112394	chr12:105551570	C/T	cg23923672	chr12:105501055	KIAA1033	-0.8	-6.09	-0.36	4.33e-9	IgG glycosylation;
KIRP	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	0.98	13.76	0.66	2.51e-32	Primary sclerosing cholangitis;
KIRP	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg12560992	chr17:57184187	TRIM37	0.63	5.66	0.34	4.22e-8	Cognitive test performance;
KIRP	cis	rs4073416	0.518	rs2149839	chr14:65983448	G/A	cg03016385	chr14:66212404	NA	-0.52	-6.27	-0.37	1.62e-9	N-glycan levels;
KIRP	cis	rs4664293	0.867	rs2357531	chr2:160597418	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.36	-0.32	1.94e-7	Lung cancer;
KIRP	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	5.99	0.36	7.47e-9	Neuroticism;
KIRP	cis	rs687432	0.924	rs12792638	chr11:57751354	C/T	cg19752551	chr11:57585705	CTNND1	-0.54	-7.45	-0.43	1.55e-12	Parkinson's disease;
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.45	-5.32	-0.32	2.37e-7	Longevity;Endometriosis;
KIRP	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.44	6.61	0.39	2.43e-10	Neuroticism;
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.8	12.24	0.62	3.17e-27	Menarche (age at onset);
KIRP	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.77	0.44	2.17e-13	Height;
KIRP	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.25	0.65	1.34e-30	Smoking behavior;
KIRP	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg03289416	chr15:75166202	SCAMP2	0.47	6.46	0.38	5.6e-10	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03041700	chr1:1407645	ATAD3B	0.65	6.04	0.36	5.54e-9	Lung function (FEV1);
KIRP	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.19	14.32	0.67	3.19e-34	Corneal structure;
KIRP	cis	rs7536201	0.967	rs7542123	chr1:25299816	G/A	cg23273869	chr1:25296894	NA	-0.39	-5.64	-0.34	4.6e-8	Psoriasis vulgaris;
KIRP	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06045579	chr16:87425660	FBXO31;MAP1LC3B	0.5	6.73	0.39	1.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27297192	chr10:134578999	INPP5A	0.62	7.65	0.44	4.67e-13	Migraine;
KIRP	cis	rs1021993	0.597	rs10494921	chr1:209513501	A/G	cg24446417	chr1:209558027	NA	-0.5	-5.12	-0.31	6.19e-7	Gut microbiome composition (winter);
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg20821713	chr7:1055600	C7orf50	-0.34	-5.27	-0.32	2.91e-7	Longevity;Endometriosis;
KIRP	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.99	14.19	0.67	8.48e-34	Cognitive function;
KIRP	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg13010199	chr12:38710504	ALG10B	0.48	6.05	0.36	5.42e-9	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.7	-0.56	3.48e-22	Triglycerides;
KIRP	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg05347473	chr6:146136440	FBXO30	0.57	8.08	0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4727443	0.866	rs35228488	chr7:99617852	G/C	cg22004693	chr7:99632812	ZKSCAN1	0.41	5.23	0.32	3.54e-7	Interstitial lung disease;
KIRP	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg08847533	chr14:75593920	NEK9	0.4	4.86	0.3	2.11e-6	Caffeine consumption;
KIRP	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg09469691	chr10:81107165	PPIF	0.69	8.96	0.5	8.26e-17	Height;
KIRP	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23903597	chr17:61704154	MAP3K3	-0.6	-6.91	-0.4	4.03e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg21515159	chr19:11639617	ECSIT	0.57	5.17	0.31	4.89e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg08052428	chr9:135996421	RALGDS	0.51	6.25	0.37	1.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.36	6.84	0.4	6.1e-11	Longevity;
KIRP	cis	rs6977660	0.714	rs10950753	chr7:19817302	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.81	-7.33	-0.42	3.38e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg12549451	chr6:135224345	NA	0.42	5.23	0.32	3.57e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.58	-7.25	-0.42	5.46e-12	Uric acid levels;
KIRP	cis	rs9398803	0.865	rs9401883	chr6:126797111	A/G	cg19875578	chr6:126661172	C6orf173	0.51	6.58	0.39	2.84e-10	Male-pattern baldness;
KIRP	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-6.67	-0.39	1.65e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg03060546	chr3:49711283	APEH	0.54	7.35	0.42	2.99e-12	Menarche (age at onset);
KIRP	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg13010199	chr12:38710504	ALG10B	0.68	8.92	0.49	1.08e-16	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg17507749	chr15:85114479	UBE2QP1	0.82	8.83	0.49	1.97e-16	Schizophrenia;
KIRP	cis	rs4666360	1.000	rs4666360	chr2:20335709	G/A	cg07142377	chr2:20335552	NA	-0.29	-5.18	-0.31	4.69e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
KIRP	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.27	0.58	5.18e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg04013166	chr16:89971882	TCF25	0.65	5.17	0.31	4.87e-7	Skin colour saturation;
KIRP	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg12311346	chr5:56204834	C5orf35	-0.36	-5.07	-0.31	7.71e-7	Breast cancer;Breast cancer (early onset);
KIRP	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.35	-0.38	1.02e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);
KIRP	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18867708	chr6:26865862	GUSBL1	-0.5	-6.28	-0.37	1.55e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.63	7.95	0.45	6.71e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs889312	0.924	rs1910020	chr5:56026500	T/C	cg14703610	chr5:56206110	C5orf35	0.42	5.24	0.32	3.44e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs3850699	0.651	rs35485301	chr10:104370827	C/T	cg04362960	chr10:104952993	NT5C2	0.63	5.99	0.36	7.27e-9	Prostate cancer;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg08650290	chr5:14410363	TRIO	-0.48	-6.42	-0.38	7.08e-10	Bladder cancer;
KIRP	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg11211951	chr8:145729740	GPT	0.42	6.6	0.39	2.56e-10	Age at first birth;
KIRP	cis	rs1420338	0.933	rs1362460	chr7:34147964	C/T	cg01275685	chr7:34179230	BMPER	-0.59	-8.9	-0.49	1.23e-16	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.45	5.11	0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs3755132	0.929	rs4668942	chr2:15750443	A/G	cg12888861	chr2:15731646	DDX1	0.4	5.31	0.32	2.43e-7	Wilms tumor;
KIRP	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg03808351	chr9:123631620	PHF19	0.46	6.16	0.37	3.03e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9426935	0.681	rs4845360	chr1:153966660	A/C	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.32	-5.45	-0.33	1.21e-7	Lentiform nucleus volume;
KIRP	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.72	8.31	0.47	6.6e-15	Obesity-related traits;
KIRP	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-6.82	-0.4	7.04e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1823913	0.637	rs4613316	chr2:192190800	T/C	cg12404831	chr2:192114017	MYO1B	0.43	5.81	0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.23	0.37	1.99e-9	Depression;
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg05861140	chr6:150128134	PCMT1	-0.46	-6.51	-0.38	4.11e-10	Lung cancer;
KIRP	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg04865290	chr3:52927548	TMEM110	-0.41	-5.11	-0.31	6.51e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1440410	0.798	rs11724872	chr4:144140665	C/T	cg01719995	chr4:144104893	USP38	0.44	6.01	0.36	6.74e-9	Ischemic stroke;
KIRP	cis	rs17065868	1.000	rs9533900	chr13:45116132	A/T	cg10246903	chr13:45222710	NA	0.72	6.4	0.38	7.86e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-9.52	-0.52	1.74e-18	Triglycerides;
KIRP	cis	rs9815354	1.000	rs1716997	chr3:41924333	A/G	cg03022575	chr3:42003672	ULK4	-0.5	-5.55	-0.33	7.36e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.47	-6.28	-0.37	1.53e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11997175	0.603	rs1603197	chr8:33966328	C/T	cg04338863	chr8:33670619	NA	0.44	5.03	0.31	9.28e-7	Body mass index;
KIRP	cis	rs13102973	0.864	rs7697346	chr4:135899283	G/A	cg14419869	chr4:135874104	NA	0.47	7.4	0.43	2.19e-12	Subjective well-being;
KIRP	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg20965017	chr5:231967	SDHA	-0.56	-6.52	-0.38	3.98e-10	Breast cancer;
KIRP	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6450176	1.000	rs6450176	chr5:53298025	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs10073892	0.703	rs1823691	chr5:101637564	T/C	cg19774478	chr5:101632501	SLCO4C1	0.61	6.37	0.38	9.38e-10	Cognitive decline (age-related);
KIRP	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg04935436	chr20:30431758	NA	0.48	6.25	0.37	1.79e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.64	-5.43	-0.33	1.37e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9807841	0.670	rs8102380	chr19:10801185	G/A	cg09936142	chr19:10668400	KRI1	-0.43	-4.85	-0.3	2.16e-6	Inflammatory skin disease;
KIRP	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg24972876	chr7:65420302	NA	0.41	5.6	0.34	5.65e-8	Aortic root size;
KIRP	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.34	-0.32	2.12e-7	Autism;
KIRP	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06558623	chr16:89946397	TCF25	0.61	5.85	0.35	1.56e-8	Skin colour saturation;
KIRP	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg08807892	chr2:162101083	NA	-0.4	-5.28	-0.32	2.84e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs9547692	1.000	rs2147167	chr13:37467404	G/A	cg01493522	chr13:37497338	NA	-0.41	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.57	7.56	0.43	8.02e-13	Lymphocyte counts;
KIRP	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.48	6.1	0.36	4.19e-9	Menopause (age at onset);
KIRP	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg10047753	chr17:41438598	NA	1.11	17.08	0.74	1.12e-43	Menopause (age at onset);
KIRP	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12826209	chr6:26865740	GUSBL1	0.43	4.93	0.3	1.49e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13424612	0.839	rs6722915	chr2:240902569	C/A	cg19172429	chr2:240878313	NA	0.29	4.94	0.3	1.48e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.98	15.1	0.69	6.81e-37	Chronic sinus infection;
KIRP	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-7.42	-0.43	1.88e-12	Osteoporosis;
KIRP	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.63	6.24	0.37	1.91e-9	Gastritis;
KIRP	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	1.06	11.76	0.6	1.24e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg05347473	chr6:146136440	FBXO30	-0.59	-8.42	-0.47	3.11e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg06885757	chr1:42089581	HIVEP3	0.42	6.21	0.37	2.28e-9	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.91	15.6	0.71	1.31e-38	Metabolic syndrome;
KIRP	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg17554472	chr22:41940697	POLR3H	-0.57	-5.89	-0.35	1.26e-8	Vitiligo;
KIRP	cis	rs7572644	0.664	rs12473340	chr2:28023797	G/A	cg27432699	chr2:27873401	GPN1	0.48	5.25	0.32	3.24e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg11204139	chr17:3907470	NA	0.88	17.07	0.74	1.3e-43	Type 2 diabetes;
KIRP	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.36	0.38	9.86e-10	Subjective well-being;
KIRP	cis	rs17431357	1.000	rs73221373	chr12:120901045	G/A	cg25045489	chr12:120971538	RNF10	-0.65	-4.98	-0.3	1.2e-6	Insulin resistance/response;
KIRP	cis	rs9659323	1.000	rs6700415	chr1:119516174	A/T	cg18261050	chr1:119551319	NA	0.35	4.9	0.3	1.76e-6	Body mass index;
KIRP	cis	rs2594989	0.943	rs346072	chr3:11306851	A/G	cg01796438	chr3:11312864	ATG7	0.61	7.14	0.41	1.02e-11	Circulating chemerin levels;
KIRP	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg06565975	chr8:143823917	SLURP1	-0.57	-7.84	-0.45	1.35e-13	Urinary tract infection frequency;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06734429	chr19:39926689	RPS16	-0.46	-6.25	-0.37	1.82e-9	Metabolic traits;
KIRP	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.35	-4.86	-0.3	2.08e-6	Height;
KIRP	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.56	8.37	0.47	4.36e-15	Body mass index;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg11106836	chr11:117852822	NA	0.5	6.15	0.37	3.07e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.42	-5.44	-0.33	1.26e-7	Blood metabolite levels;
KIRP	cis	rs4851254	0.961	rs11692215	chr2:100746573	C/T	cg17356467	chr2:100759845	AFF3	0.58	7.33	0.42	3.38e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.42	0.65	3.47e-31	Bladder cancer;
KIRP	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg13180566	chr4:1052158	NA	-0.52	-5.34	-0.32	2.13e-7	Recombination rate (females);
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.1	-0.31	6.73e-7	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.34	0.37	1.1e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg05484376	chr2:27715224	FNDC4	0.3	4.88	0.3	1.91e-6	Oral cavity cancer;
KIRP	cis	rs860295	0.812	rs4278368	chr1:155722557	G/A	cg02153340	chr1:155202674	NA	-0.41	-5.7	-0.34	3.36e-8	Body mass index;
KIRP	trans	rs2270927	0.510	rs4352583	chr5:75576716	A/G	cg13563193	chr19:33072644	PDCD5	0.9	6.48	0.38	5.04e-10	Mean corpuscular volume;
KIRP	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.81	10.24	0.55	9.84e-21	Phospholipid levels (plasma);
KIRP	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg13319975	chr6:146136371	FBXO30	0.42	5.67	0.34	3.96e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.92	-12.02	-0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.97	11.58	0.59	4.73e-25	Exhaled nitric oxide levels;
KIRP	cis	rs12210905	0.610	rs12204953	chr6:27396737	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.74	-0.34	2.75e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-1.1	-17.58	-0.75	2.29e-45	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.87	0.3	1.99e-6	Tonsillectomy;
KIRP	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-12.62	-0.63	1.68e-28	Breast cancer;
KIRP	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.5	-7.31	-0.42	3.74e-12	Diastolic blood pressure;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.7	0.44	3.3e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs13170463	0.579	rs7711842	chr5:8034365	G/T	cg03862380	chr20:43029895	HNF4A	0.39	6.03	0.36	6.1e-9	Colorectal cancer;
KIRP	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	7.66	0.44	4.31e-13	Body mass index;
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21171335	chr12:122356390	WDR66	0.52	6.84	0.4	6.14e-11	Mean corpuscular volume;
KIRP	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03934478	chr11:495069	RNH1	0.8	6.3	0.37	1.39e-9	Body mass index;
KIRP	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg09699651	chr6:150184138	LRP11	0.48	6.49	0.38	4.69e-10	Lung cancer;
KIRP	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg00484396	chr16:3507460	NAT15	0.54	7.15	0.41	9.81e-12	Tuberculosis;
KIRP	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg22800045	chr5:56110881	MAP3K1	0.73	7.83	0.45	1.42e-13	Initial pursuit acceleration;
KIRP	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.23	0.32	3.63e-7	Personality dimensions;
KIRP	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	0.92	8.83	0.49	2.03e-16	Blood protein levels;
KIRP	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg17376030	chr22:41985996	PMM1	0.66	6.96	0.41	3.13e-11	Vitiligo;
KIRP	trans	rs1937787	0.522	rs12070989	chr1:80841004	G/T	cg25350635	chr12:49182847	ADCY6	-0.44	-6.08	-0.36	4.53e-9	Stroke;
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg05025164	chr4:1340916	KIAA1530	0.63	8.2	0.46	1.3e-14	Longevity;
KIRP	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg12591125	chr7:1885375	MAD1L1	0.59	5.8	0.35	2e-8	Bipolar disorder;
KIRP	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3857747	0.537	rs11766930	chr7:40421614	C/G	cg00420559	chr7:40367873	C7orf10	-0.43	-6.0	-0.36	7.21e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9400467	0.528	rs455247	chr6:111667799	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs501120	0.584	rs61857484	chr10:44719215	C/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.74	7.63	0.44	5.11e-13	Gestational age at birth (maternal effect);
KIRP	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.91	-15.47	-0.7	3.7e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.49	-8.18	-0.46	1.48e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs1950626	0.833	rs34463495	chr14:101411186	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.83	0.4	6.72e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.66	0.39	1.78e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25517755	chr10:38738941	LOC399744	-0.5	-7.02	-0.41	2.19e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.07	23.69	0.83	2.06e-65	Multiple myeloma;
KIRP	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.58	7.4	0.43	2.09e-12	Lymphocyte counts;
KIRP	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.37	-5.65	-0.34	4.4e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-1.19	-15.85	-0.71	1.84e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs4332428	1.000	rs59428599	chr10:4970849	A/T	cg19648686	chr10:5044992	AKR1C2	-0.91	-8.0	-0.45	4.88e-14	Height;
KIRP	cis	rs10045504	0.502	rs10512692	chr5:38762993	G/A	cg15396434	chr5:38725168	NA	-0.86	-8.45	-0.47	2.57e-15	Night sleep phenotypes;
KIRP	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00857998	chr1:205179979	DSTYK	-0.66	-8.4	-0.47	3.63e-15	Red blood cell count;
KIRP	cis	rs7681423	0.951	rs13109457	chr4:155514879	G/A	cg20735720	chr4:155535218	FGG	-0.57	-7.37	-0.43	2.51e-12	Fibrinogen;
KIRP	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.55	-8.31	-0.47	6.55e-15	Trans fatty acid levels;
KIRP	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg03724423	chr7:27170755	HOXA4	-0.37	-4.98	-0.3	1.18e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg09597638	chr17:3907349	NA	0.48	6.75	0.4	1.05e-10	Type 2 diabetes;
KIRP	cis	rs7577696	0.597	rs375050	chr2:32413765	C/T	cg02381751	chr2:32503542	YIPF4	0.56	5.77	0.35	2.4e-8	Inflammatory biomarkers;
KIRP	cis	rs830383	0.554	rs6893850	chr5:165509528	G/A	cg13976338	chr5:165423657	NA	0.46	5.12	0.31	6.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	0.77	7.63	0.44	5.04e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.66	8.41	0.47	3.45e-15	Red blood cell count;
KIRP	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	9.22	0.51	1.41e-17	Schizophrenia;
KIRP	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs7770731	0.694	rs857469	chr6:14602862	C/A	cg01527307	chr6:14500441	NA	-0.39	-5.05	-0.31	8.65e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg23594656	chr7:65796392	TPST1	-0.5	-7.83	-0.45	1.43e-13	Aortic root size;
KIRP	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.75	0.49	3.53e-16	Eosinophil percentage of white cells;
KIRP	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg12131826	chr15:77904385	NA	-0.46	-5.87	-0.35	1.41e-8	Type 2 diabetes;
KIRP	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg24631222	chr15:78858424	CHRNA5	-0.8	-9.59	-0.52	1.06e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.89	-12.05	-0.61	1.35e-26	Multiple sclerosis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23300289	chr9:132146083	NA	0.66	6.82	0.4	7.15e-11	Lung function (FEV1);
KIRP	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg14228332	chr4:119757509	SEC24D	0.76	5.05	0.31	8.52e-7	Cannabis dependence symptom count;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg04902049	chr1:36622448	MAP7D1	-0.49	-6.1	-0.36	4.17e-9	Neuroticism;
KIRP	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg17554472	chr22:41940697	POLR3H	0.65	6.7	0.39	1.45e-10	Cannabis dependence symptom count;
KIRP	cis	rs6832769	1.000	rs28448438	chr4:56416665	C/T	cg05960024	chr4:56376020	CLOCK	-0.71	-9.07	-0.5	3.98e-17	Personality dimensions;
KIRP	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.88	0.49	1.45e-16	Colorectal cancer;
KIRP	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg21523564	chr15:75251491	NA	0.37	6.18	0.37	2.58e-9	Breast cancer;
KIRP	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg04287289	chr16:89883240	FANCA	-0.55	-7.3	-0.42	3.93e-12	Vitiligo;
KIRP	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.57	0.52	1.17e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8177876	0.822	rs1563075	chr16:81107748	T/C	cg08591886	chr16:81111003	C16orf46	-0.64	-5.79	-0.35	2.18e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.75	-0.44	2.38e-13	Height;
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01283332	chr5:1856932	NA	-0.5	-6.55	-0.39	3.26e-10	Cardiovascular disease risk factors;
KIRP	cis	rs193541	0.564	rs407230	chr5:122345727	G/A	cg19412675	chr5:122181750	SNX24	-0.6	-6.42	-0.38	6.97e-10	Glucose homeostasis traits;
KIRP	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.4	-5.89	-0.35	1.29e-8	Pubertal anthropometrics;
KIRP	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.77	-0.35	2.34e-8	Type 2 diabetes;
KIRP	cis	rs9654415	0.560	rs12188333	chr5:72556379	C/G	cg14879418	chr5:72571312	NA	-0.44	-5.66	-0.34	4.24e-8	Eyebrow thickness;
KIRP	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.81	-0.4	7.59e-11	Menopause (age at onset);
KIRP	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.71	-0.34	3.29e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg09596252	chr17:78655493	RPTOR	0.59	7.83	0.45	1.43e-13	Obesity;
KIRP	cis	rs13315871	1.000	rs9864824	chr3:58394835	A/G	cg12435725	chr3:58293450	RPP14	0.51	5.48	0.33	1.07e-7	Cholesterol, total;
KIRP	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg16306078	chr6:126000798	NA	-0.26	-4.97	-0.3	1.25e-6	Endometrial cancer;
KIRP	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg14580859	chr9:123691850	NA	0.36	5.1	0.31	6.75e-7	Rheumatoid arthritis;
KIRP	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.52	5.15	0.31	5.31e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg15455979	chr11:119473908	NA	0.4	6.12	0.36	3.63e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4742903	0.509	rs10991107	chr9:106860969	T/C	cg14250997	chr9:106856677	SMC2	0.43	5.82	0.35	1.86e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg17554472	chr22:41940697	POLR3H	-0.43	-5.19	-0.31	4.49e-7	Vitiligo;
KIRP	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.47	-0.48	2.22e-15	Colorectal cancer;
KIRP	cis	rs3736485	0.903	rs8039835	chr15:51865864	A/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.18	-0.31	4.57e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg19500275	chr17:80737654	TBCD	0.45	5.25	0.32	3.27e-7	Glycated hemoglobin levels;
KIRP	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.62	8.1	0.46	2.6e-14	Inhibitory control;
KIRP	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.55	6.46	0.38	5.48e-10	Mean corpuscular volume;
KIRP	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-7.79	-0.44	1.87e-13	Initial pursuit acceleration;
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg22284058	chr8:142237359	SLC45A4	0.52	6.38	0.38	8.52e-10	Immature fraction of reticulocytes;
KIRP	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg00405596	chr8:11794950	NA	0.49	6.17	0.37	2.73e-9	Retinal vascular caliber;
KIRP	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.76	9.86	0.53	1.52e-19	Dilated cardiomyopathy;
KIRP	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.15	-0.41	9.77e-12	Mood instability;
KIRP	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.54	-6.29	-0.37	1.46e-9	Inhibitory control;
KIRP	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	11.12	0.58	1.53e-23	Total body bone mineral density;
KIRP	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	5.84	0.35	1.67e-8	Thyroid stimulating hormone;
KIRP	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	1.02	10.39	0.55	3.42e-21	Psoriasis;
KIRP	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.38	-6.32	-0.37	1.24e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21923884	chr14:100626084	DEGS2	0.51	6.95	0.41	3.23e-11	Parkinson's disease;
KIRP	cis	rs4845459	1.000	rs4845459	chr1:152603842	C/A	cg07796016	chr1:152779584	LCE1C	-0.44	-5.13	-0.31	5.95e-7	Psoriasis;
KIRP	trans	rs7939886	0.920	rs17149859	chr11:55795356	G/A	cg03929089	chr4:120376271	NA	0.95	7.05	0.41	1.75e-11	Myopia (pathological);
KIRP	cis	rs7105934	1.000	rs10908259	chr11:69237595	C/T	cg24478926	chr11:69237550	NA	-0.59	-5.29	-0.32	2.75e-7	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25424642	chr2:240100522	HDAC4	-0.47	-6.48	-0.38	5.01e-10	Parkinson's disease;
KIRP	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02972257	chr16:68554789	NA	-0.73	-7.1	-0.41	1.37e-11	Ulcerative colitis;
KIRP	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg06647332	chr5:131281008	NA	-0.47	-5.2	-0.31	4.22e-7	Life satisfaction;
KIRP	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.44	-0.38	6.29e-10	Diastolic blood pressure;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12044749	chr8:144995682	PLEC1	0.46	6.1	0.36	4.16e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.59	-6.62	-0.39	2.24e-10	Hypospadias;
KIRP	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg08885076	chr2:99613938	TSGA10	-0.46	-7.55	-0.43	8.48e-13	Chronic sinus infection;
KIRP	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06850241	chr22:41845214	NA	-0.45	-5.44	-0.33	1.3e-7	Vitiligo;
KIRP	cis	rs6782228	0.565	rs67445542	chr3:128330526	T/C	cg18648031	chr3:128330563	NA	0.27	5.49	0.33	9.86e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs6545883	0.965	rs11887205	chr2:61774473	T/G	cg15711740	chr2:61764176	XPO1	-0.63	-8.6	-0.48	9.58e-16	Tuberculosis;
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22618164	chr12:122356400	WDR66	0.68	9.13	0.5	2.66e-17	Mean corpuscular volume;
KIRP	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg06742321	chr12:123595122	PITPNM2	0.46	5.37	0.32	1.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg23950597	chr19:37808831	NA	-0.89	-8.87	-0.49	1.55e-16	Coronary artery calcification;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg00738919	chr7:1100172	C7orf50	0.43	5.07	0.31	8e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg00784671	chr22:46762841	CELSR1	-0.61	-6.1	-0.36	3.98e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.95	-13.26	-0.65	1.23e-30	Blood trace element (Zn levels);
KIRP	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg08126542	chr6:37504118	NA	-0.56	-7.36	-0.42	2.75e-12	Cognitive performance;
KIRP	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg23894439	chr1:183413866	NA	0.42	5.52	0.33	8.5e-8	Systemic lupus erythematosus;
KIRP	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4233802	0.737	rs4664428	chr2:151168009	G/A	cg25300694	chr2:151184358	NA	0.71	5.39	0.33	1.63e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7770227	0.868	rs2184906	chr6:114707360	C/T	cg18406000	chr6:114650610	NA	-0.4	-5.24	-0.32	3.44e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03388025	chr16:89894329	SPIRE2	-0.32	-5.57	-0.33	6.72e-8	Vitiligo;
KIRP	cis	rs8028182	0.609	rs10220738	chr15:75666546	A/T	cg20655648	chr15:75932815	IMP3	-0.51	-6.53	-0.38	3.78e-10	Sudden cardiac arrest;
KIRP	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1847505	0.914	rs7990897	chr13:61524612	G/A	cg25164009	chr13:61490935	NA	-0.57	-6.04	-0.36	5.62e-9	Polychlorinated biphenyl levels;
KIRP	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.84	12.31	0.62	1.88e-27	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg07585587	chr3:45730688	SACM1L	-0.47	-6.11	-0.36	3.88e-9	Morning vs. evening chronotype;
KIRP	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg24796726	chr7:884288	UNC84A	-0.55	-5.26	-0.32	3.08e-7	Initial pursuit acceleration;
KIRP	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg13147721	chr7:65941812	NA	-1.02	-7.05	-0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.78	11.62	0.6	3.59e-25	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg10117171	chr1:25599238	RHD	0.38	5.2	0.31	4.18e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.7	9.42	0.52	3.35e-18	Menarche (age at onset);
KIRP	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.17	0.7	3.81e-37	Platelet count;
KIRP	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.51	6.44	0.38	6.16e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.74	9.91	0.53	1.07e-19	Personality dimensions;
KIRP	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg13147721	chr7:65941812	NA	-1.02	-6.47	-0.38	5.12e-10	Diabetic kidney disease;
KIRP	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.3	-0.37	1.34e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.28e-7	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25527915	chr10:99078702	FRAT1	0.47	6.23	0.37	1.98e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.04	0.36	5.52e-9	Height;
KIRP	cis	rs7909791	0.678	rs10883932	chr10:105623956	T/A	cg11005552	chr10:105648138	OBFC1	0.43	5.1	0.31	6.75e-7	White matter hyperintensity burden;
KIRP	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10017260	chr10:834428	NA	-0.52	-5.19	-0.31	4.42e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs6832769	0.961	rs28713343	chr4:56457091	C/T	cg09317128	chr4:56265301	TMEM165	-0.49	-6.48	-0.38	4.89e-10	Personality dimensions;
KIRP	cis	rs806321	0.534	rs1269278	chr13:50892313	T/C	cg10393508	chr13:50950265	NA	-0.45	-6.38	-0.38	8.55e-10	Multiple sclerosis;
KIRP	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.61	-7.92	-0.45	8.27e-14	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.88	9.75	0.53	3.42e-19	Gut microbiome composition (summer);
KIRP	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.28	-0.47	7.68e-15	Morning vs. evening chronotype;
KIRP	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg03834567	chr2:218808745	TNS1	0.47	5.58	0.34	6.25e-8	Ulcerative colitis;
KIRP	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.89	-0.35	1.25e-8	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs7181230	1.000	rs11638521	chr15:40360314	T/C	cg20592017	chr15:40364740	NA	-0.36	-5.38	-0.32	1.76e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg12962167	chr3:53033115	SFMBT1	0.71	5.28	0.32	2.8e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.22	0.32	3.76e-7	Life satisfaction;
KIRP	cis	rs73198271	0.586	rs3789850	chr8:8686845	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.19	-0.37	2.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.67	-7.36	-0.42	2.74e-12	Schizophrenia;
KIRP	cis	rs4889855	0.530	rs4890052	chr17:78564245	G/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.41	-0.33	1.46e-7	Fractional excretion of uric acid;
KIRP	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg15556689	chr8:8085844	FLJ10661	0.55	7.41	0.43	2.04e-12	Neuroticism;
KIRP	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.01	-0.41	2.23e-11	Mood instability;
KIRP	cis	rs8028182	0.636	rs8036884	chr15:75862893	T/C	cg20655648	chr15:75932815	IMP3	0.57	7.28	0.42	4.53e-12	Sudden cardiac arrest;
KIRP	cis	rs7766436	0.813	rs7773580	chr6:22587114	C/T	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12271199	chr1:59248280	JUN	-0.5	-7.09	-0.41	1.39e-11	Metabolic traits;
KIRP	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.34	5.08	0.31	7.53e-7	Body mass index;
KIRP	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.39	-4.86	-0.3	2.08e-6	Carotid intima media thickness;
KIRP	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.55	-7.31	-0.42	3.83e-12	Primary sclerosing cholangitis;
KIRP	cis	rs7116495	0.609	rs4945392	chr11:71694645	C/T	cg26138937	chr11:71823887	C11orf51	-1.01	-6.94	-0.4	3.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg13798912	chr7:905769	UNC84A	0.66	6.33	0.37	1.17e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10411936	0.720	rs2885706	chr19:16582937	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	5.14	0.31	5.71e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.76e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	13.11	0.64	3.91e-30	Personality dimensions;
KIRP	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6725041	0.637	rs1402762	chr2:213122059	G/A	cg20637307	chr2:213403960	ERBB4	-0.4	-5.09	-0.31	7.21e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs3850699	0.651	rs74557492	chr10:104350225	A/G	cg04362960	chr10:104952993	NT5C2	0.63	5.99	0.36	7.27e-9	Prostate cancer;
KIRP	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg07606381	chr6:8435919	SLC35B3	-0.65	-8.49	-0.48	2.04e-15	Motion sickness;
KIRP	cis	rs9381040	0.672	rs6458197	chr6:41144658	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.43	-5.16	-0.31	5.05e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4356932	1.000	rs4583787	chr4:76955069	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.49	6.73	0.39	1.18e-10	Red blood cell count;
KIRP	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg08648136	chr8:956695	NA	0.42	6.39	0.38	8.43e-10	Schizophrenia;
KIRP	cis	rs4356932	0.790	rs6848620	chr4:76973549	G/C	cg19388996	chr4:76862389	NAAA	0.4	5.15	0.31	5.31e-7	Blood protein levels;
KIRP	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg08283408	chr3:49949060	MON1A	0.37	5.15	0.31	5.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4908768	0.906	rs10492966	chr1:8598005	C/T	cg03610117	chr1:8450231	RERE	-0.58	-6.48	-0.38	5.08e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg01444801	chr10:135216882	MTG1	-0.56	-6.24	-0.37	1.9e-9	Systemic lupus erythematosus;
KIRP	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.63	7.25	0.42	5.34e-12	Height;
KIRP	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.79	9.21	0.51	1.5e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs11690462	0.926	rs12615704	chr2:26551903	G/C	cg26119090	chr2:26468346	HADHA;HADHB	0.43	5.17	0.31	4.75e-7	Coronary artery disease;
KIRP	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.43	-0.33	1.38e-7	Autism;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.04	0.41	1.86e-11	Lymphocyte counts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12297814	chr1:201197846	IGFN1	-0.45	-6.65	-0.39	1.88e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.65	-8.65	-0.48	6.8e-16	Colorectal cancer;
KIRP	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg18404041	chr3:52824283	ITIH1	-0.36	-5.05	-0.31	8.53e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.34	-0.37	1.08e-9	Bladder cancer;
KIRP	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.94	-0.3	1.43e-6	Schizophrenia;
KIRP	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.45	-6.33	-0.37	1.14e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs9972944	0.756	rs2873818	chr17:63762867	A/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.83	-0.45	1.44e-13	Total body bone mineral density;
KIRP	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg03647239	chr10:116582469	FAM160B1	0.45	5.42	0.33	1.4e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2414059	0.518	rs2289108	chr15:50782335	G/A	cg05456662	chr15:50716270	USP8	-0.43	-5.85	-0.35	1.54e-8	QT interval;
KIRP	trans	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg06521331	chr12:34319734	NA	-0.53	-6.54	-0.38	3.43e-10	Heart rate;
KIRP	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg13165212	chr22:42675999	NA	-0.34	-5.78	-0.35	2.28e-8	Cognitive function;
KIRP	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	10.7	0.56	3.41e-22	Smoking behavior;
KIRP	trans	rs13170463	0.579	rs34608809	chr5:8041076	G/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs61884328	0.852	rs12574558	chr11:47069748	G/A	cg23433285	chr11:47201945	PACSIN3	0.77	6.26	0.37	1.67e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg25019033	chr10:957182	NA	-0.59	-7.12	-0.41	1.17e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.41	6.27	0.37	1.63e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.88	13.94	0.66	6.23e-33	Longevity;Endometriosis;
KIRP	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg21827317	chr3:136751795	NA	0.37	5.18	0.31	4.6e-7	Neuroticism;
KIRP	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.82	-0.6	7.88e-26	Eye color traits;
KIRP	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg10189774	chr4:17578691	LAP3	0.47	5.6	0.34	5.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9394169	0.875	rs1547669	chr6:33775641	A/G	cg25922239	chr6:33757077	LEMD2	0.48	5.69	0.34	3.53e-8	Essential tremor;
KIRP	cis	rs228437	0.586	rs6935311	chr6:134911038	C/T	cg24504307	chr6:134963096	NA	0.29	4.91	0.3	1.64e-6	Melanoma;
KIRP	trans	rs12517041	1.000	rs7720974	chr5:23300191	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.87	-7.96	-0.45	6.4e-14	Calcium levels;
KIRP	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.62	10.01	0.54	5.05e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.06	0.5	4.27e-17	Colorectal cancer;
KIRP	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.75	8.95	0.5	9.02e-17	Breast cancer;
KIRP	cis	rs4690686	0.538	rs4690687	chr4:177259635	A/G	cg17059388	chr4:177262070	NA	-0.77	-10.74	-0.57	2.53e-22	Essential tremor;
KIRP	cis	rs10465746	0.780	rs12145258	chr1:84401211	G/A	cg10977910	chr1:84465055	TTLL7	0.56	7.14	0.41	1.04e-11	Obesity-related traits;
KIRP	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg12454167	chr3:186435060	KNG1	0.65	12.14	0.61	6.87e-27	Blood protein levels;
KIRP	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs986417	0.901	rs1955694	chr14:61020617	G/T	cg27398547	chr14:60952738	C14orf39	0.56	5.93	0.35	9.95e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg18527119	chr7:66119851	NA	-0.44	-4.94	-0.3	1.45e-6	Aortic root size;
KIRP	cis	rs4851254	0.961	rs11680485	chr2:100749744	A/G	cg17356467	chr2:100759845	AFF3	0.61	7.45	0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21016266	chr12:122356598	WDR66	0.67	9.12	0.5	2.71e-17	Mean corpuscular volume;
KIRP	cis	rs7187994	0.848	rs8051512	chr16:84781101	C/G	cg07647771	chr16:84786436	USP10	-0.37	-5.17	-0.31	4.81e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.17	0.61	5.44e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs11120822	0.787	rs11120829	chr1:7123793	A/C	cg20434152	chr1:7120926	CAMTA1	-0.41	-5.77	-0.35	2.35e-8	Stearic acid (18:0) levels;
KIRP	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.63	-0.34	4.92e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9733	1.000	rs9733	chr1:150618961	A/C	cg13175981	chr1:150552382	MCL1	0.52	6.31	0.37	1.31e-9	Tonsillectomy;
KIRP	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	0.88	11.88	0.6	5.05e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.73	-0.44	2.71e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg00981070	chr1:2046702	PRKCZ	-0.34	-5.95	-0.35	9.11e-9	Height;
KIRP	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.78	-10.64	-0.56	5.54e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.88	-11.75	-0.6	1.36e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg12165864	chr7:66369176	NA	-0.51	-5.25	-0.32	3.34e-7	Corneal structure;
KIRP	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.26	-0.37	1.7e-9	Daytime sleep phenotypes;
KIRP	cis	rs6838801	0.734	rs750743	chr4:77610347	T/G	cg17476223	chr4:77663285	SHROOM3	0.51	6.64	0.39	1.96e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.79	7.51	0.43	1.08e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.51	-7.16	-0.42	9.51e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg03235661	chr20:60525775	NA	-0.37	-5.76	-0.34	2.55e-8	Body mass index;
KIRP	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.47	5.58	0.34	6.41e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.77	-11.67	-0.6	2.44e-25	Idiopathic membranous nephropathy;
KIRP	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.29	5.19	0.31	4.35e-7	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg24488311	chr11:68621650	NA	0.42	4.96	0.3	1.31e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17799476	0.938	rs72808770	chr2:46361322	G/A	cg12428440	chr2:46370979	PRKCE	0.55	5.12	0.31	6.18e-7	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg22617819	chr1:44378782	ST3GAL3	-0.37	-5.92	-0.35	1.05e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.51	-5.57	-0.33	6.8e-8	Total body bone mineral density;
KIRP	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg24253500	chr15:84953950	NA	0.69	8.06	0.46	3.31e-14	Schizophrenia;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-8.92	-0.49	1.12e-16	Longevity;Endometriosis;
KIRP	cis	rs10048158	0.743	rs2215415	chr17:64215571	G/A	cg19474267	chr17:64306194	PRKCA	-0.42	-5.0	-0.3	1.07e-6	&beta2-Glycoprotein I (β2-GPI) plasma levels;
KIRP	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.6	0.34	5.83e-8	Educational attainment;
KIRP	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg24488311	chr11:68621650	NA	0.47	5.6	0.34	5.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg05791153	chr7:19748676	TWISTNB	-0.48	-5.31	-0.32	2.42e-7	Thyroid stimulating hormone;
KIRP	trans	rs6076960	0.564	rs3852935	chr20:6143180	C/G	cg21095983	chr6:86352623	SYNCRIP	0.5	6.94	0.4	3.52e-11	Smooth-surface caries;
KIRP	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.41	-0.33	1.47e-7	Body mass index;
KIRP	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg23533419	chr12:54090519	NA	-0.33	-5.16	-0.31	5.05e-7	Height;
KIRP	cis	rs4690686	0.510	rs10520348	chr4:177261738	T/A	cg17059388	chr4:177262070	NA	0.85	12.18	0.61	4.9e-27	Essential tremor;
KIRP	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.47	6.13	0.36	3.52e-9	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16591054	chr19:50145354	SCAF1	0.47	6.22	0.37	2.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11138902	0.673	rs10511966	chr9:72114423	C/G	cg14397918	chr9:72078829	APBA1	-0.36	-5.79	-0.35	2.18e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg07169764	chr2:136633963	MCM6	0.53	6.17	0.37	2.74e-9	Mosquito bite size;
KIRP	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.42	-5.8	-0.35	2.07e-8	Systolic blood pressure;
KIRP	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg02297831	chr4:17616191	MED28	0.52	6.04	0.36	5.78e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg01556091	chr17:57970327	TUBD1;RPS6KB1	-0.45	-6.03	-0.36	5.95e-9	Morning vs. evening chronotype;
KIRP	cis	rs7520050	0.966	rs11810993	chr1:46478793	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.37	-0.32	1.85e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1975991	0.711	rs6793597	chr3:187965285	A/G	cg17585528	chr3:187988060	LPP	-0.45	-5.21	-0.32	4.06e-7	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-1.0	-15.02	-0.69	1.26e-36	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-7.08	-0.41	1.53e-11	Morning vs. evening chronotype;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20382089	chr8:22462724	KIAA1967	-0.5	-6.54	-0.38	3.54e-10	Myopia;
KIRP	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs1035491	1.000	rs1035491	chr5:63962177	A/G	cg01791865	chr5:63954708	NA	0.33	4.94	0.3	1.43e-6	Body mass index;
KIRP	cis	rs76693355	0.512	rs10892569	chr11:120270249	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.43	-5.52	-0.33	8.49e-8	Intraocular pressure;
KIRP	cis	rs11997175	0.580	rs34398087	chr8:33813800	A/G	ch.8.33884649F	chr8:33765107	NA	-0.43	-5.11	-0.31	6.49e-7	Body mass index;
KIRP	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg15117754	chr3:10150083	C3orf24	-0.48	-4.86	-0.3	2.1e-6	Alzheimer's disease;
KIRP	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg05784532	chr1:230284198	GALNT2	-0.52	-7.9	-0.45	9.49e-14	Coronary artery disease;
KIRP	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.71	-7.34	-0.42	3.16e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	7.95	0.45	6.83e-14	Height;
KIRP	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.66	7.59	0.44	6.69e-13	Arsenic metabolism;
KIRP	cis	rs7172677	0.960	rs8026273	chr15:75413766	T/A	cg14082893	chr15:75400931	NA	0.37	5.38	0.32	1.76e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26526719	chr5:1949144	NA	0.43	5.21	0.32	4.01e-7	Gut microbiome composition (winter);
KIRP	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.57	-7.18	-0.42	8.29e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.02	0.54	4.94e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2071403	0.933	rs12328062	chr2:1400567	C/T	cg07083862	chr2:1417248	TPO	-0.34	-5.45	-0.33	1.2e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.82	11.61	0.59	3.99e-25	Total body bone mineral density;
KIRP	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.47	6.42	0.38	7.11e-10	Testicular germ cell tumor;
KIRP	cis	rs6449957	0.832	rs960383	chr5:67450986	A/G	cg09038926	chr5:67483109	NA	-0.39	-5.21	-0.32	3.95e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.51	-6.32	-0.37	1.21e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.66	-5.85	-0.35	1.54e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs7404928	1.000	rs113366623	chr16:23898931	A/T	cg21745164	chr16:23765304	CHP2	-0.48	-6.19	-0.37	2.47e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.84	-15.69	-0.71	6.46e-39	Anterior chamber depth;
KIRP	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs394563	0.726	rs6942381	chr6:149662991	G/C	cg03678062	chr6:149772716	ZC3H12D	0.31	5.1	0.31	6.92e-7	Dupuytren's disease;
KIRP	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg21419209	chr3:44054225	NA	-0.74	-9.22	-0.51	1.43e-17	Coronary artery disease;
KIRP	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg21775007	chr8:11205619	TDH	-0.4	-4.97	-0.3	1.25e-6	Neuroticism;
KIRP	trans	rs9650657	0.741	rs10100333	chr8:10584288	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.34	-0.37	1.11e-9	Neuroticism;
KIRP	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg26876637	chr1:152193138	HRNR	-0.79	-9.88	-0.53	1.29e-19	Atopic dermatitis;
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20887711	chr4:1340912	KIAA1530	0.51	6.37	0.38	9.38e-10	Longevity;
KIRP	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.73	9.72	0.53	4.05e-19	Parkinson's disease;
KIRP	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg18190219	chr22:46762943	CELSR1	-0.86	-6.99	-0.41	2.61e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.52	-7.63	-0.44	5.03e-13	Itch intensity from mosquito bite;
KIRP	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-5.3	-0.32	2.55e-7	Schizophrenia;
KIRP	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg03647239	chr10:116582469	FAM160B1	-0.52	-6.24	-0.37	1.91e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.68	9.08	0.5	3.56e-17	Personality dimensions;
KIRP	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.52	7.25	0.42	5.26e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg14458575	chr2:238380390	NA	0.48	5.4	0.33	1.59e-7	Prostate cancer;
KIRP	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg00277334	chr10:82204260	NA	0.45	4.88	0.3	1.87e-6	Post bronchodilator FEV1;
KIRP	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-1.07	-19.04	-0.77	2.65e-50	Height;
KIRP	cis	rs6987853	0.966	rs2923428	chr8:42388301	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.05	0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7084402	1.000	rs7917717	chr10:60269100	C/A	cg05938607	chr10:60274200	BICC1	0.41	9.98	0.54	6.68e-20	Refractive error;
KIRP	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg23791538	chr6:167370224	RNASET2	-0.4	-5.05	-0.31	8.76e-7	Crohn's disease;
KIRP	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.62	8.26	0.47	8.85e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.86	-12.27	-0.62	2.63e-27	Cocaine dependence;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03797768	chr13:24040813	NA	0.56	7.16	0.42	9.25e-12	Smoking initiation;
KIRP	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.63	7.29	0.42	4.19e-12	Pancreatic cancer;
KIRP	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.49	-0.38	4.58e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.49	7.84	0.45	1.33e-13	IgG glycosylation;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-5.28	-0.32	2.77e-7	Longevity;Endometriosis;
KIRP	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.56	-6.26	-0.37	1.67e-9	Breast cancer;
KIRP	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.53e-24	Height;
KIRP	cis	rs4974559	0.947	rs7659916	chr4:1361013	C/T	cg02980000	chr4:1222292	CTBP1	0.76	7.45	0.43	1.62e-12	Systolic blood pressure;
KIRP	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg10932868	chr11:921992	NA	0.65	8.77	0.49	3.03e-16	Alzheimer's disease (late onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02117342	chr7:30408819	DKFZP586I1420	-0.51	-7.78	-0.44	2.03e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13606994	chr1:44402422	ARTN	0.29	5.45	0.33	1.21e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23097686	chr12:98910128	TMPO;LOC100128191	-0.5	-6.81	-0.4	7.22e-11	Myopia;
KIRP	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg17724175	chr1:150552817	MCL1	0.33	4.97	0.3	1.26e-6	Melanoma;
KIRP	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg25019033	chr10:957182	NA	-0.57	-6.06	-0.36	5.18e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.79	9.62	0.52	8.68e-19	Corneal astigmatism;
KIRP	cis	rs10814247	0.565	rs10972495	chr9:35494703	T/A	cg15271616	chr9:35490515	RUSC2	0.43	5.21	0.32	3.95e-7	Psoriasis;
KIRP	trans	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg17822266	chr1:2720087	NA	-0.48	-6.56	-0.39	3.17e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.63	-0.39	2.14e-10	Axial length;
KIRP	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg07274523	chr3:49395745	GPX1	0.69	8.34	0.47	5.4e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.67	-6.35	-0.38	1.06e-9	Menarche (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04633600	chr5:101632286	SLCO4C1	0.43	6.19	0.37	2.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg26035817	chr1:114414802	PTPN22	0.64	8.45	0.47	2.53e-15	Bacteremia;
KIRP	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg06204229	chr3:52865917	ITIH4	0.49	6.68	0.39	1.55e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.58	7.43	0.43	1.82e-12	Aortic root size;
KIRP	cis	rs7225151	0.522	rs78534596	chr17:5135360	A/C	cg24500398	chr17:5266808	RABEP1	-0.54	-5.29	-0.32	2.74e-7	Alzheimer's disease (late onset);
KIRP	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg04539111	chr16:67997858	SLC12A4	-0.45	-5.2	-0.31	4.26e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.32	-0.32	2.36e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg07402062	chr16:89894098	SPIRE2	0.31	6.48	0.38	4.9e-10	Vitiligo;
KIRP	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-5.48	-0.33	1.05e-7	Chronic sinus infection;
KIRP	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.59	6.74	0.39	1.11e-10	Platelet distribution width;
KIRP	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.62	-0.48	8.21e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg07777115	chr5:623756	CEP72	-0.52	-5.66	-0.34	4.15e-8	Obesity-related traits;
KIRP	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg00852783	chr1:26633632	UBXN11	-0.53	-5.41	-0.33	1.5e-7	Obesity-related traits;
KIRP	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.5	0.33	9.4e-8	Lung cancer;
KIRP	cis	rs12210905	0.610	rs72845208	chr6:27395664	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.74	-0.34	2.75e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.62	7.76	0.44	2.29e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.83	8.66	0.48	6.45e-16	Cerebrospinal P-tau181p levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11952604	chr15:69113456	ANP32A	0.54	6.83	0.4	6.58e-11	Parkinson's disease;
KIRP	trans	rs13170463	0.579	rs11749496	chr5:8045686	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	9.27	0.51	9.46e-18	Cognitive test performance;
KIRP	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.06	-12.18	-0.61	5.24e-27	Lung cancer in ever smokers;
KIRP	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg02151108	chr14:50098012	C14orf104	-0.58	-8.24	-0.46	1.05e-14	Carotid intima media thickness;
KIRP	cis	rs12997796	1.000	rs12997796	chr2:86974318	A/G	cg25203885	chr2:87302643	LOC285074	-0.64	-5.34	-0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.34	-0.42	3.06e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.51	6.95	0.4	3.33e-11	Red blood cell count;
KIRP	cis	rs4243830	0.850	rs12046229	chr1:6580397	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.91	7.32	0.42	3.54e-12	Body mass index;
KIRP	cis	rs7709377	0.595	rs253950	chr5:115626590	C/T	cg23108291	chr5:115420582	COMMD10	-0.44	-5.35	-0.32	2e-7	Metabolite levels  (X-11787);
KIRP	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg20090143	chr19:45452003	APOC2	0.34	5.47	0.33	1.12e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg18016565	chr1:150552671	MCL1	-0.34	-5.22	-0.32	3.76e-7	Tonsillectomy;
KIRP	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.63	12.01	0.61	1.86e-26	Bone mineral density;
KIRP	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg14132834	chr19:41945861	ATP5SL	-0.63	-8.57	-0.48	1.16e-15	Height;
KIRP	cis	rs8028182	0.636	rs7166737	chr15:75682513	A/G	cg20655648	chr15:75932815	IMP3	0.53	6.73	0.39	1.22e-10	Sudden cardiac arrest;
KIRP	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.55	7.18	0.42	8.4e-12	Breast cancer;
KIRP	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg00745463	chr17:30367425	LRRC37B	-0.59	-6.12	-0.36	3.66e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs1461503	0.903	rs7124683	chr11:122834036	A/G	cg27398637	chr11:122830231	C11orf63	0.71	9.19	0.51	1.67e-17	Menarche (age at onset);
KIRP	cis	rs2599510	0.703	rs762023	chr2:32713170	G/A	cg02381751	chr2:32503542	YIPF4	0.5	5.88	0.35	1.3e-8	Interleukin-18 levels;
KIRP	cis	rs329674	0.516	rs329650	chr11:133765897	C/T	cg06766960	chr11:133703094	NA	-0.61	-5.24	-0.32	3.44e-7	Bipolar disorder;
KIRP	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg00677455	chr12:58241039	CTDSP2	-0.49	-5.52	-0.33	8.48e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	15.57	0.7	1.65e-38	Chronic sinus infection;
KIRP	cis	rs1978968	1.000	rs13053667	chr22:18443404	G/A	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.54	6.08	0.36	4.56e-9	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg23920097	chr1:209922102	NA	-0.43	-5.82	-0.35	1.83e-8	Red blood cell count;
KIRP	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.6	-0.48	9.68e-16	Total cholesterol levels;
KIRP	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg10645314	chr2:3704589	ALLC	-0.6	-6.44	-0.38	6.36e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13801670	chr10:65347896	REEP3	-0.4	-6.62	-0.39	2.27e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs6601450	0.519	rs34906836	chr8:10288992	C/A	cg08975724	chr8:8085496	FLJ10661	0.47	6.08	0.36	4.62e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg00931491	chr16:28608288	SULT1A2	-0.25	-5.01	-0.3	1.02e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.31	5.01	0.3	1.03e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs6893807	1.000	rs16903275	chr5:87950543	A/C	cg24804195	chr5:87968844	LOC645323	-0.57	-6.14	-0.36	3.33e-9	Body mass index;
KIRP	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.11	0.61	8.66e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7424096	0.582	rs7600245	chr2:37220614	A/C	cg14987922	chr2:37194071	STRN	0.57	5.92	0.35	1.09e-8	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6988636	0.534	rs62520601	chr8:124095571	A/G	cg15893493	chr8:124194847	FAM83A	0.85	6.32	0.37	1.2e-9	Urinary uromodulin levels;
KIRP	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.28	-0.51	8.89e-18	Personality dimensions;
KIRP	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg12432903	chr7:1882776	MAD1L1	0.52	4.85	0.3	2.17e-6	Bipolar disorder;
KIRP	cis	rs859767	0.501	rs12691869	chr2:135407641	T/C	cg12500956	chr2:135428796	TMEM163	-0.42	-5.68	-0.34	3.76e-8	Neuroticism;
KIRP	cis	rs2548003	0.518	rs2014316	chr5:28723711	T/C	cg11015470	chr5:28928158	NA	0.54	5.99	0.36	7.38e-9	Hip geometry;
KIRP	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-1.18	-15.26	-0.7	1.85e-37	Response to hepatitis C treatment;
KIRP	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg25390334	chr2:241827778	C2orf54	-0.34	-4.88	-0.3	1.95e-6	Urinary metabolites;
KIRP	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg10047753	chr17:41438598	NA	1.15	18.21	0.76	1.71e-47	Menopause (age at onset);
KIRP	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg26531700	chr6:26746687	NA	0.4	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	10.72	0.56	2.95e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.86	-13.11	-0.64	3.81e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06320134	chr1:6663664	KLHL21	0.42	6.16	0.37	2.9e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.39	-4.89	-0.3	1.81e-6	Blood protein levels;
KIRP	cis	rs7404928	0.718	rs12443784	chr16:23860837	G/A	cg21745164	chr16:23765304	CHP2	-0.71	-8.28	-0.47	7.72e-15	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg21466736	chr12:48725269	NA	-0.45	-5.87	-0.35	1.39e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15807973	chr10:88281572	WAPAL	0.53	6.6	0.39	2.51e-10	DNA methylation (variation);
KIRP	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.37	-7.8	-0.45	1.77e-13	Body mass index;
KIRP	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs8192282	0.691	rs6696177	chr1:154477263	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.33	-4.87	-0.3	1.98e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	1.18	9.02	0.5	5.45e-17	Gut microbiota (bacterial taxa);
KIRP	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg00656387	chr3:40428638	ENTPD3	-0.38	-5.18	-0.31	4.7e-7	Renal cell carcinoma;
KIRP	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.02	11.37	0.59	2.45e-24	Vitiligo;
KIRP	cis	rs6687430	0.562	rs12139169	chr1:10635328	C/T	cg17425144	chr1:10567563	PEX14	0.41	6.88	0.4	4.87e-11	Hand grip strength;
KIRP	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.43	7.35	0.42	2.86e-12	Renal cell carcinoma;
KIRP	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg04398451	chr17:18023971	MYO15A	-0.88	-13.69	-0.66	4.29e-32	Total body bone mineral density;
KIRP	trans	rs13170463	0.579	rs71606017	chr5:8045493	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.54	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.71	-0.6	1.86e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00585698	chr12:123750864	CDK2AP1	0.47	6.11	0.36	3.79e-9	Neutrophil percentage of white cells;
KIRP	cis	rs8070740	0.559	rs1806263	chr17:5317492	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	-0.42	-5.16	-0.31	5.09e-7	Menopause (age at onset);
KIRP	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.29	-0.47	7.39e-15	Mood instability;
KIRP	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	5.77	0.35	2.33e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2671245	0.898	rs2819491	chr1:56164515	C/T	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg11952622	chr19:58962976	ZNF324B	0.43	5.03	0.31	9.38e-7	Uric acid clearance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14519850	chr15:39873209	THBS1	0.5	6.24	0.37	1.88e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg24315340	chr6:146058215	EPM2A	-0.41	-5.12	-0.31	6.17e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs787274	1.000	rs2153837	chr9:115463001	A/T	cg13803584	chr9:115635662	SNX30	0.72	6.58	0.39	2.74e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs986417	0.901	rs1955692	chr14:61008408	C/A	cg27398547	chr14:60952738	C14orf39	0.63	5.25	0.32	3.32e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	1.23	13.06	0.64	5.93e-30	Uric acid levels;
KIRP	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	1.04	10.65	0.56	5.07e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16434002	chr17:42200994	HDAC5	-0.54	-6.76	-0.4	9.95e-11	Total body bone mineral density;
KIRP	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.5	-6.06	-0.36	4.95e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg22244940	chr12:132335942	MMP17	-0.57	-7.27	-0.42	4.72e-12	Migraine;
KIRP	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg20016023	chr10:99160130	RRP12	-0.44	-6.06	-0.36	5.16e-9	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-0.9	-13.2	-0.64	1.93e-30	Dupuytren's disease;
KIRP	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.33	4.99	0.3	1.13e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-5.72	-0.34	3.02e-8	Schizophrenia;
KIRP	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg03609598	chr5:56110824	MAP3K1	0.68	6.67	0.39	1.69e-10	Initial pursuit acceleration;
KIRP	cis	rs7119038	0.818	rs6589685	chr11:118612197	T/C	cg19308663	chr11:118741387	NA	0.45	7.29	0.42	4.2e-12	Sjögren's syndrome;
KIRP	cis	rs12200782	0.674	rs12207224	chr6:26519280	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-5.98	-0.36	8.01e-9	Small cell lung carcinoma;
KIRP	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg01028140	chr2:1542097	TPO	-0.6	-6.09	-0.36	4.38e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.37	0.32	1.8e-7	Osteoporosis;
KIRP	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.56	7.67	0.44	4.08e-13	Vitiligo;
KIRP	cis	rs3736485	0.966	rs4775965	chr15:51908251	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.19e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg05484376	chr2:27715224	FNDC4	0.37	6.15	0.36	3.13e-9	Total body bone mineral density;
KIRP	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.5	5.75	0.34	2.59e-8	Platelet distribution width;
KIRP	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.73	9.08	0.5	3.54e-17	Monocyte count;
KIRP	cis	rs7113874	1.000	rs2316901	chr11:8679016	G/A	cg08015107	chr11:8618950	NA	-0.35	-4.88	-0.3	1.92e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11104914	chr4:37828384	PGM2	0.5	6.64	0.39	2.01e-10	Parkinson's disease;
KIRP	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.67	-9.03	-0.5	5.19e-17	Colorectal cancer;
KIRP	trans	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg24644049	chr4:85504048	CDS1	1.06	6.86	0.4	5.62e-11	Skin colour saturation;
KIRP	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.83	11.25	0.58	5.98e-24	Morning vs. evening chronotype;
KIRP	cis	rs7560272	0.538	rs11126414	chr2:73932044	G/A	cg20560298	chr2:73613845	ALMS1	0.49	5.79	0.35	2.17e-8	Schizophrenia;
KIRP	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.87	-12.62	-0.63	1.7e-28	Calcium levels;
KIRP	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg04202892	chr2:111875749	ACOXL	0.5	6.94	0.4	3.48e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs7577696	0.525	rs2366547	chr2:32251109	G/A	cg02381751	chr2:32503542	YIPF4	-0.51	-5.03	-0.31	9.26e-7	Inflammatory biomarkers;
KIRP	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	10.44	0.55	2.38e-21	Post bronchodilator FEV1;
KIRP	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.3	-0.47	6.97e-15	Retinal vascular caliber;
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg22907277	chr7:1156413	C7orf50	0.61	8.18	0.46	1.55e-14	Longevity;Endometriosis;
KIRP	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg08514558	chr10:81106712	PPIF	0.42	5.8	0.35	1.99e-8	Height;
KIRP	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.41	-4.98	-0.3	1.21e-6	Crohn's disease;
KIRP	cis	rs259842	0.641	rs16867014	chr2:180674147	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	0.41	5.63	0.34	4.98e-8	Blood protein levels;
KIRP	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.54	7.53	0.43	9.7e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.79e-7	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18147569	chr3:113871615	DRD3	0.5	6.45	0.38	6.03e-10	Parkinson's disease;
KIRP	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg03808351	chr9:123631620	PHF19	0.4	5.41	0.33	1.52e-7	Rheumatoid arthritis;
KIRP	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg16586182	chr3:47516702	SCAP	-0.43	-5.06	-0.31	8.28e-7	Birth weight;
KIRP	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-5.89	-0.35	1.27e-8	Mean corpuscular volume;
KIRP	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.53	0.56	1.18e-21	Bone mineral density;
KIRP	cis	rs7546668	1.000	rs6686966	chr1:15835472	C/T	cg21858823	chr1:15850916	CASP9	0.47	5.19	0.31	4.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.5	6.37	0.38	9.15e-10	Menopause (age at onset);
KIRP	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.27	0.32	2.99e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.68	-9.2	-0.51	1.59e-17	Huntington's disease progression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27209679	chr6:143220056	HIVEP2	0.49	6.1	0.36	4.03e-9	Interleukin-4 levels;
KIRP	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg00666640	chr1:248458726	OR2T12	0.37	5.13	0.31	5.84e-7	Common traits (Other);
KIRP	cis	rs4742903	1.000	rs2274724	chr9:106860568	C/T	cg14250997	chr9:106856677	SMC2	0.38	4.98	0.3	1.22e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg23958373	chr8:599963	NA	-0.97	-6.3	-0.37	1.35e-9	IgG glycosylation;
KIRP	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg02175308	chr1:109941060	SORT1	-0.26	-4.94	-0.3	1.41e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.76	-9.17	-0.5	1.98e-17	Response to antipsychotic treatment;
KIRP	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg16586182	chr3:47516702	SCAP	-0.69	-9.79	-0.53	2.49e-19	Colorectal cancer;
KIRP	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4908768	0.906	rs28422051	chr1:8618337	T/C	cg25722041	chr1:8623473	RERE	0.81	10.18	0.54	1.52e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.96	11.91	0.6	4.12e-26	Vitiligo;
KIRP	cis	rs867371	1.000	rs7173339	chr15:82467594	A/G	cg06066596	chr15:83166174	LOC80154	-0.46	-5.39	-0.33	1.65e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.8	11.01	0.57	3.59e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg14675211	chr2:100938903	LONRF2	0.48	6.21	0.37	2.3e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	8.47	0.48	2.26e-15	Neuroticism;
KIRP	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg01872077	chr2:219646372	CYP27A1	0.39	5.08	0.31	7.45e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg04990556	chr1:26633338	UBXN11	0.63	5.87	0.35	1.4e-8	Obesity-related traits;
KIRP	trans	rs909341	0.909	rs2236510	chr20:62368804	C/T	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.91	-0.4	4.04e-11	Atopic dermatitis;
KIRP	cis	rs10463316	0.894	rs6579875	chr5:150782574	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.49	-0.38	4.6e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs11874712	1.000	rs3765636	chr18:43653660	G/T	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.5	-0.33	9.35e-8	Migraine - clinic-based;
KIRP	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	9.44	0.52	3.02e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.75	-0.63	6.56e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.64	-7.47	-0.43	1.41e-12	Neutrophil percentage of white cells;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg27532560	chr4:187881888	NA	-0.75	-12.75	-0.63	6.41e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.2	-0.37	2.42e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg06718696	chr17:78121285	EIF4A3	0.7	7.29	0.42	4.24e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.68	-0.53	5.57e-19	Mean corpuscular volume;
KIRP	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6956675	0.957	rs28541324	chr7:62608767	G/A	cg08930214	chr7:62859557	LOC100287834	0.53	6.13	0.36	3.43e-9	Obesity-related traits;
KIRP	cis	rs4006360	0.520	rs4986664	chr17:39250248	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs1014246	0.848	rs10749227	chr10:118468631	G/C	cg14919929	chr10:118506882	NA	0.58	7.21	0.42	6.86e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg15664640	chr17:80829946	TBCD	0.39	4.93	0.3	1.49e-6	Glycated hemoglobin levels;
KIRP	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.69	-9.72	-0.53	4.17e-19	Height;
KIRP	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs9399186	1.000	rs17796516	chr6:136918854	T/C	cg03049340	chr13:114085732	ADPRHL1	-0.93	-6.36	-0.38	9.54e-10	Pursuit maintenance gain;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19684190	chr10:54759379	NA	0.37	6.32	0.37	1.19e-9	C-reactive protein;
KIRP	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg08847533	chr14:75593920	NEK9	0.52	6.25	0.37	1.85e-9	IgG glycosylation;
KIRP	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.63	-7.29	-0.42	4.17e-12	Bone mineral density;
KIRP	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-8.95	-0.5	9.09e-17	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.78e-8	Lung cancer;
KIRP	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.81	-12.61	-0.63	1.88e-28	Dental caries;
KIRP	cis	rs9323205	0.765	rs2999388	chr14:51654157	A/G	cg23942311	chr14:51606299	NA	0.65	9.09	0.5	3.32e-17	Cancer;
KIRP	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.43	5.14	0.31	5.51e-7	Body mass index;
KIRP	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg00310523	chr12:86230176	RASSF9	0.45	7.21	0.42	6.91e-12	Major depressive disorder;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg23156509	chr2:114033830	PAX8;LOC440839	-0.38	-5.78	-0.35	2.28e-8	Lymphocyte counts;
KIRP	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.7	-0.34	3.36e-8	IgG glycosylation;
KIRP	cis	rs894344	0.650	rs16905182	chr8:135576794	C/A	cg09855544	chr8:135498122	ZFAT	0.37	4.87	0.3	1.99e-6	Systolic blood pressure;
KIRP	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg14132834	chr19:41945861	ATP5SL	0.58	7.55	0.43	8.52e-13	Height;
KIRP	cis	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg24110177	chr3:50126178	RBM5	-0.45	-5.28	-0.32	2.9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3935685	0.874	rs35028279	chr15:78003542	T/C	cg25212270	chr15:78015279	NA	0.62	8.19	0.46	1.42e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg04369109	chr6:150039330	LATS1	-0.52	-6.59	-0.39	2.63e-10	Lung cancer;
KIRP	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.99	15.06	0.69	9.31e-37	Monocyte count;
KIRP	cis	rs4650994	0.593	rs7552110	chr1:178542154	A/T	cg12486710	chr1:178512616	C1orf220	-0.26	-5.5	-0.33	9.6e-8	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1506636	0.512	rs1035015	chr7:123309842	G/C	cg03229431	chr7:123269106	ASB15	0.65	7.01	0.41	2.33e-11	Plateletcrit;Platelet count;
KIRP	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23903597	chr17:61704154	MAP3K3	-0.6	-7.44	-0.43	1.72e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11603020	1.000	rs11603020	chr11:57374332	C/T	cg19752551	chr11:57585705	CTNND1	0.71	9.84	0.53	1.78e-19	Blood protein levels;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	1.03	10.91	0.57	7.29e-23	Alzheimer's disease;
KIRP	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg17937102	chr1:165667565	ALDH9A1	-0.49	-6.4	-0.38	7.69e-10	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg00310523	chr12:86230176	RASSF9	0.56	8.69	0.48	5.29e-16	Major depressive disorder;
KIRP	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08439880	chr3:133502540	NA	0.46	5.91	0.35	1.14e-8	Iron status biomarkers;
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg21285383	chr16:89894308	SPIRE2	0.33	6.2	0.37	2.38e-9	Vitiligo;
KIRP	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.93	12.33	0.62	1.66e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.59	-9.46	-0.52	2.68e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg27205649	chr11:78285834	NARS2	-0.65	-8.5	-0.48	1.83e-15	Alzheimer's disease (survival time);
KIRP	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.55	-0.39	3.27e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs12980942	0.591	rs1946613	chr19:41767785	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.6	4.84	0.3	2.25e-6	Coronary artery disease;
KIRP	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-13.25	-0.65	1.37e-30	Alzheimer's disease;
KIRP	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg20673091	chr1:2541236	MMEL1	0.49	6.92	0.4	3.89e-11	Ulcerative colitis;
KIRP	cis	rs12049351	0.613	rs12037690	chr1:229642385	G/A	cg11742688	chr1:229674241	ABCB10	-0.38	-5.7	-0.34	3.34e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.72	-7.88	-0.45	1.06e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4073221	0.519	rs4128294	chr3:18318327	A/G	cg07694806	chr3:18168406	NA	0.68	6.04	0.36	5.66e-9	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10869376	chr13:41345315	MRPS31	0.55	6.33	0.37	1.18e-9	Smoking initiation;
KIRP	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.3	5.65	0.34	4.39e-8	Total body bone mineral density;
KIRP	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.7	-6.96	-0.41	3.06e-11	Body mass index;
KIRP	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.6	-8.58	-0.48	1.07e-15	Urate levels in overweight individuals;
KIRP	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.94	-11.44	-0.59	1.41e-24	Alzheimer's disease;
KIRP	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg17366294	chr4:99064904	C4orf37	0.37	4.91	0.3	1.68e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2273156	1.000	rs36112862	chr14:35478433	C/T	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.37	-0.32	1.87e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs7760535	0.735	rs240974	chr6:111649316	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.49	-6.46	-0.38	5.57e-10	Metabolic traits;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06907347	chr1:214714924	PTPN14	0.39	6.34	0.37	1.09e-9	C-reactive protein;
KIRP	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.65	9.14	0.5	2.37e-17	Mood instability;
KIRP	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.51	0.48	1.71e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.73	-7.87	-0.45	1.13e-13	DNA methylation (variation);
KIRP	cis	rs3755132	0.778	rs4668953	chr2:15785856	T/C	cg12888861	chr2:15731646	DDX1	0.4	5.3	0.32	2.62e-7	Wilms tumor;
KIRP	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg25486957	chr4:152246857	NA	-0.55	-5.96	-0.36	8.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg24631222	chr15:78858424	CHRNA5	0.84	10.6	0.56	7.1e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs35300120	0.757	rs12096351	chr1:233655610	G/A	cg23054119	chr1:233659267	NA	-0.41	-5.75	-0.34	2.63e-8	Cognitive function;
KIRP	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.64	9.26	0.51	1.03e-17	Resting heart rate;
KIRP	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.16	0.58	1.18e-23	Cognitive test performance;
KIRP	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.18	-0.77	9.19e-51	Schizophrenia;
KIRP	cis	rs9914578	0.943	rs7225843	chr17:2001825	A/G	cg16513277	chr17:2031491	SMG6	-0.73	-8.75	-0.49	3.47e-16	Body mass index;
KIRP	cis	rs3739034	0.697	rs76894945	chr2:135491298	T/G	cg15546071	chr2:135691756	CCNT2	-0.52	-4.93	-0.3	1.5e-6	Gut microbiome composition (winter);
KIRP	cis	rs738144	0.542	rs4303811	chr22:39157755	A/G	cg06022373	chr22:39101656	GTPBP1	-0.59	-5.27	-0.32	3.01e-7	IgG glycosylation;
KIRP	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.35	-5.09	-0.31	6.98e-7	Ovarian reserve;
KIRP	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	3.99e-15	Protein biomarker;
KIRP	trans	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg17145862	chr1:211918768	LPGAT1	-0.54	-6.79	-0.4	8.24e-11	Leprosy;
KIRP	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs2371030	0.632	rs13422990	chr2:211567790	A/G	cg18417063	chr2:211583084	NA	-0.41	-4.89	-0.3	1.78e-6	Non-small cell lung cancer;
KIRP	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00495681	chr13:53174319	NA	-0.44	-6.05	-0.36	5.45e-9	Lewy body disease;
KIRP	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.57	-0.56	9.31e-22	Menopause (age at onset);
KIRP	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.36	-5.1	-0.31	6.88e-7	Monocyte count;
KIRP	cis	rs7172677	1.000	rs2415159	chr15:75430715	T/A	cg14664628	chr15:75095509	CSK	-0.48	-5.2	-0.31	4.24e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27100806	chr3:180630217	FXR1	0.52	6.5	0.38	4.37e-10	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.55e-6	Lung cancer;
KIRP	cis	rs904251	0.686	rs931649	chr6:37466079	T/C	cg25019722	chr6:37503610	NA	-0.66	-6.8	-0.4	7.91e-11	Cognitive performance;
KIRP	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.74	10.45	0.55	2.19e-21	Body mass index;
KIRP	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.38	-5.48	-0.33	1.06e-7	Headache;
KIRP	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.77	0.44	2.17e-13	Height;
KIRP	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.66	-0.34	4.23e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.51	-7.11	-0.41	1.22e-11	Plateletcrit;
KIRP	cis	rs3764563	0.935	rs4807958	chr19:15718042	T/C	cg20725493	chr19:15740067	CYP4F8	-0.94	-6.18	-0.37	2.58e-9	Inflammatory biomarkers;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05025164	chr4:1340916	KIAA1530	0.57	7.73	0.44	2.74e-13	Obesity-related traits;
KIRP	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg02138098	chr1:2040968	PRKCZ	0.37	4.87	0.3	1.98e-6	Height;
KIRP	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-5.61	-0.34	5.3e-8	Cognitive function;
KIRP	cis	rs7973683	0.541	rs6488910	chr12:124393697	G/T	cg12597309	chr12:124393772	DNAH10	0.42	5.41	0.33	1.51e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.84	-7.9	-0.45	9.34e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg11833968	chr6:79620685	NA	-0.47	-7.09	-0.41	1.42e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18252515	chr7:66147081	NA	0.46	5.67	0.34	3.9e-8	Aortic root size;
KIRP	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg00310523	chr12:86230176	RASSF9	-0.44	-6.38	-0.38	8.71e-10	Major depressive disorder;
KIRP	cis	rs9583531	0.660	rs61971611	chr13:111335319	C/T	cg07595035	chr13:111291582	CARKD	0.68	5.01	0.3	1.02e-6	Coronary artery disease;
KIRP	trans	rs7939886	0.844	rs10501350	chr11:56058690	G/A	cg03929089	chr4:120376271	NA	0.95	6.56	0.39	3.22e-10	Myopia (pathological);
KIRP	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.26	21.81	0.81	2.03e-59	Breast cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06586915	chr7:65958596	NA	0.55	6.35	0.38	1.05e-9	Smoking initiation;
KIRP	cis	rs2573652	1.000	rs1469829	chr15:100517332	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.78	-12.77	-0.63	5.44e-29	Height;
KIRP	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg05785598	chr3:49045655	WDR6	0.3	5.43	0.33	1.32e-7	Parkinson's disease;
KIRP	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.4	-0.33	1.56e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs258892	0.793	rs13168325	chr5:72021520	T/A	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.73	0.34	2.89e-8	Educational attainment;
KIRP	cis	rs2737618	0.574	rs2252801	chr1:200076652	C/T	cg21825944	chr1:200113062	NR5A2	-0.5	-6.49	-0.38	4.6e-10	Uric acid levels;
KIRP	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg16586182	chr3:47516702	SCAP	0.74	9.94	0.54	8.55e-20	Colorectal cancer;
KIRP	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg23100626	chr2:96804247	ASTL	0.45	6.58	0.39	2.77e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.59	-0.48	1.01e-15	Triglycerides;
KIRP	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.61	6.73	0.39	1.22e-10	Aortic root size;
KIRP	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.29	0.37	1.45e-9	Breast cancer;
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	5.26	0.32	3.12e-7	Obesity-related traits;
KIRP	cis	rs9612	0.664	rs164069	chr19:44260199	T/C	cg08581076	chr19:44259116	C19orf61	0.44	5.1	0.31	6.85e-7	Exhaled nitric oxide output;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15842317	chr1:159824538	VSIG8;C1orf204	0.41	6.03	0.36	6.01e-9	Survival in pancreatic cancer;
KIRP	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.56	-6.11	-0.36	3.88e-9	DNA methylation (variation);
KIRP	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.66	-8.2	-0.46	1.37e-14	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs10203711	1.000	rs6707795	chr2:239555580	T/C	cg14580085	chr2:239553406	NA	0.39	5.2	0.31	4.23e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.42	-5.37	-0.32	1.86e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	8.42	0.47	3.21e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.81	6.53	0.38	3.7e-10	Initial pursuit acceleration;
KIRP	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.73	-8.82	-0.49	2.22e-16	Coronary artery disease;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.73	0.53	3.76e-19	Lung cancer;
KIRP	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.05e-17	Retinal vascular caliber;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00338852	chr3:93773657	ARL13B	-0.46	-7.11	-0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg07577569	chr20:40245965	CHD6	-0.44	-6.02	-0.36	6.15e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07234876	chr8:600039	NA	-0.96	-6.25	-0.37	1.8e-9	IgG glycosylation;
KIRP	cis	rs6568686	0.679	rs7776184	chr6:111809918	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.57	-5.26	-0.32	3.09e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg16141378	chr3:129829833	LOC729375	0.53	6.63	0.39	2.07e-10	Neuroticism;
KIRP	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg08885076	chr2:99613938	TSGA10	-0.38	-4.95	-0.3	1.39e-6	Chronic sinus infection;
KIRP	cis	rs7116495	0.786	rs1894003	chr11:71750276	A/G	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1858037	0.867	rs964505	chr2:65623189	G/A	cg08085232	chr2:65598271	SPRED2	-0.54	-6.43	-0.38	6.55e-10	Rheumatoid arthritis;
KIRP	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.84	0.49	1.82e-16	Motion sickness;
KIRP	cis	rs7011507	1.000	rs78957025	chr8:49139945	T/G	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4523957	0.614	rs2641439	chr17:2017561	C/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.76	6.66	0.39	1.78e-10	Body mass index;
KIRP	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg24579218	chr15:68104479	NA	-0.43	-5.97	-0.36	8.28e-9	Obesity;
KIRP	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg19847130	chr8:10466454	RP1L1	-0.4	-6.33	-0.37	1.14e-9	Neuroticism;
KIRP	cis	rs988913	1.000	rs9396011	chr6:54836739	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.7	-0.34	3.49e-8	Menarche (age at onset);
KIRP	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg22906224	chr7:99728672	NA	-0.64	-7.85	-0.45	1.31e-13	Coronary artery disease;
KIRP	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg00689492	chr4:1303491	MAEA	0.31	5.59	0.34	6.02e-8	Longevity;
KIRP	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.4	9.97	0.54	6.81e-20	Corneal astigmatism;
KIRP	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg05484376	chr2:27715224	FNDC4	0.4	6.77	0.4	9.58e-11	Menopause (age at onset);
KIRP	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.52	6.86	0.4	5.68e-11	Smooth-surface caries;
KIRP	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.85	13.58	0.65	1.04e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs1448094	0.842	rs10779231	chr12:86462237	T/C	cg00310523	chr12:86230176	RASSF9	-0.41	-6.25	-0.37	1.78e-9	Major depressive disorder;
KIRP	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg11508081	chr17:41442227	NA	0.37	4.98	0.3	1.2e-6	Menopause (age at onset);
KIRP	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-7.32	-0.42	3.49e-12	Body mass index;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.65	8.58	0.48	1.11e-15	Longevity;Endometriosis;
KIRP	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.87	0.4	5.2e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.77	11.67	0.6	2.47e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13198984	chr17:80129470	CCDC57	-0.54	-8.15	-0.46	1.83e-14	Life satisfaction;
KIRP	cis	rs6142102	0.961	rs6059587	chr20:32542926	C/G	cg08999081	chr20:33150536	PIGU	0.5	5.89	0.35	1.26e-8	Skin pigmentation;
KIRP	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.54	7.59	0.44	6.74e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21643547	chr1:205240462	TMCC2	-0.71	-10.86	-0.57	1.06e-22	Red blood cell count;
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg22903657	chr4:1355424	KIAA1530	-0.47	-6.55	-0.39	3.26e-10	Obesity-related traits;
KIRP	cis	rs2290402	0.536	rs7684266	chr4:856609	T/C	cg00846425	chr4:957561	DGKQ	-0.5	-5.37	-0.32	1.82e-7	Type 2 diabetes;
KIRP	cis	rs55788414	0.932	rs55991107	chr16:81181066	G/A	cg06400318	chr16:81190750	PKD1L2	-1.19	-7.65	-0.44	4.58e-13	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg09264619	chr17:80180166	NA	0.42	4.86	0.3	2.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4273100	0.541	rs973649	chr17:19292068	A/G	cg25447019	chr17:19030144	GRAPL	0.56	7.65	0.44	4.68e-13	Schizophrenia;
KIRP	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.48	7.06	0.41	1.66e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02828054	chr19:8478160	MARCH2	0.52	6.31	0.37	1.3e-9	Parkinson's disease;
KIRP	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.85	9.81	0.53	2.24e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs11834862	0.653	rs11246997	chr12:132690684	G/A	cg05229598	chr12:132699923	GALNT9	-0.58	-6.21	-0.37	2.2e-9	Anti-saccade response;
KIRP	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.68	9.18	0.51	1.77e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg10326726	chr10:51549505	MSMB	-0.59	-8.33	-0.47	5.65e-15	Prostate-specific antigen levels;
KIRP	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.43	-6.32	-0.37	1.21e-9	Height;
KIRP	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	1.14	8.9	0.49	1.28e-16	Parkinson's disease;
KIRP	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg06223162	chr1:101003688	GPR88	0.44	9.19	0.51	1.66e-17	Monocyte count;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.62	8.2	0.46	1.31e-14	Aortic root size;
KIRP	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg24253500	chr15:84953950	NA	0.63	6.9	0.4	4.35e-11	Schizophrenia;
KIRP	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.7	0.53	4.65e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg23601095	chr6:26197514	HIST1H3D	-1.01	-7.49	-0.43	1.21e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.27	-0.37	1.57e-9	IgG glycosylation;
KIRP	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.58	-0.39	2.84e-10	Type 2 diabetes;
KIRP	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg12591125	chr7:1885375	MAD1L1	-0.55	-5.51	-0.33	9.19e-8	Bipolar disorder;
KIRP	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.69	-6.8	-0.4	7.99e-11	Breast cancer;
KIRP	cis	rs6987853	0.933	rs2974355	chr8:42414117	C/T	cg09913449	chr8:42400586	C8orf40	0.41	5.25	0.32	3.23e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	10.29	0.55	6.89e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.84	9.44	0.52	2.94e-18	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.78	10.06	0.54	3.62e-20	Neutrophil percentage of white cells;
KIRP	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.74	-0.49	3.66e-16	Mean corpuscular volume;
KIRP	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg03469862	chr11:68924853	NA	0.28	4.84	0.3	2.25e-6	Blond vs. brown hair color;
KIRP	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.98	-0.64	1.09e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg04691961	chr3:161091175	C3orf57	-0.39	-5.35	-0.32	2.01e-7	Parkinson's disease;
KIRP	cis	rs9815354	0.812	rs35263917	chr3:41952852	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1265507	0.689	rs1265508	chr12:114867127	A/T	cg12437821	chr12:114852027	NA	0.37	5.14	0.31	5.68e-7	Percent mammographic density;
KIRP	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.81	12.37	0.62	1.16e-27	Height;
KIRP	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	7.76	0.44	2.22e-13	Caffeine consumption;
KIRP	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.43	-6.55	-0.39	3.4e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25823578	chr14:52781312	PTGER2	0.52	6.68	0.39	1.57e-10	Smoking initiation;
KIRP	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.96	0.35	8.89e-9	Type 2 diabetes;
KIRP	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.89	-0.4	4.76e-11	Systolic blood pressure;
KIRP	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg25319279	chr11:5960081	NA	-0.6	-6.21	-0.37	2.23e-9	DNA methylation (variation);
KIRP	cis	rs8177876	0.570	rs11863158	chr16:81068130	A/T	cg08591886	chr16:81111003	C16orf46	-0.56	-5.24	-0.32	3.4e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.51	7.13	0.41	1.14e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg08501292	chr6:25962987	TRIM38	0.78	5.26	0.32	3.1e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11967292	chr1:225997655	EPHX1	0.49	6.12	0.36	3.65e-9	Parkinson's disease;
KIRP	cis	rs7119038	0.818	rs10892280	chr11:118611817	C/T	cg19308663	chr11:118741387	NA	0.55	8.56	0.48	1.2e-15	Sjögren's syndrome;
KIRP	cis	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg26751094	chr13:95954534	ABCC4	-0.7	-9.74	-0.53	3.65e-19	Blood metabolite levels;
KIRP	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-1.02	-17.47	-0.74	5.63e-45	Height;
KIRP	cis	rs11225247	0.764	rs11225237	chr11:102250527	A/G	cg06323957	chr11:102217781	BIRC2	0.92	5.66	0.34	4.25e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.42	4.94	0.3	1.44e-6	Aortic root size;
KIRP	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.94	-13.91	-0.66	7.87e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg09571762	chr12:39539558	NA	0.33	4.91	0.3	1.64e-6	Morning vs. evening chronotype;
KIRP	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.01	-0.3	1.04e-6	Coronary artery disease;
KIRP	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg27462398	chr1:86174642	ZNHIT6	-0.53	-7.12	-0.41	1.19e-11	Urate levels in overweight individuals;
KIRP	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	9.87	0.53	1.38e-19	Smoking behavior;
KIRP	cis	rs7010267	0.508	rs1385500	chr8:119976186	A/T	cg13268132	chr8:119964037	TNFRSF11B	0.41	5.16	0.31	5.02e-7	Total body bone mineral density (age 45-60);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05925971	chr19:36485966	SDHAF1	0.58	7.22	0.42	6.43e-12	Myopia (pathological);
KIRP	cis	rs4870684	1.000	rs4870684	chr7:57699151	C/T	cg01314568	chr7:57830625	NA	-0.6	-7.45	-0.43	1.6e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs796364	0.616	rs7574313	chr2:200681040	C/G	cg17644776	chr2:200775616	C2orf69	0.57	5.23	0.32	3.56e-7	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.7	0.49	4.71e-16	Prudent dietary pattern;
KIRP	cis	rs72829446	0.932	rs62059824	chr17:7478213	C/T	cg02795151	chr17:7402630	POLR2A	0.74	4.87	0.3	1.98e-6	Androgen levels;
KIRP	cis	rs7084402	0.967	rs1658447	chr10:60313174	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.89	-0.57	8.19e-23	Refractive error;
KIRP	cis	rs11577318	0.528	rs11247935	chr1:26698622	G/C	cg00852783	chr1:26633632	UBXN11	-0.47	-5.43	-0.33	1.37e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg00383909	chr3:49044727	WDR6	0.43	4.87	0.3	1.96e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);
KIRP	trans	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg00938859	chr5:1591904	SDHAP3	0.54	6.28	0.37	1.53e-9	Breast cancer;
KIRP	cis	rs2651899	0.902	rs1736522	chr1:3080940	C/G	cg01413848	chr1:3081226	PRDM16	0.4	5.56	0.33	7.18e-8	Migraine;
KIRP	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.63	-7.75	-0.44	2.4e-13	Recalcitrant atopic dermatitis;
KIRP	trans	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.5	-0.38	4.52e-10	Neuroticism;
KIRP	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg02023728	chr11:77925099	USP35	-0.33	-5.34	-0.32	2.1e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.66	-0.52	6.17e-19	Response to antipsychotic treatment;
KIRP	cis	rs10486003	0.881	rs112923031	chr7:97212186	A/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.66	-5.19	-0.31	4.32e-7	Response to platinum-based agents;
KIRP	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg27124370	chr19:33622961	WDR88	0.72	10.35	0.55	4.62e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2273669	0.667	rs76430494	chr6:109350128	C/A	cg05315195	chr6:109294784	ARMC2	-0.64	-6.32	-0.37	1.2e-9	Prostate cancer;
KIRP	cis	rs55962025	0.644	rs6446723	chr4:3126813	T/C	cg06533319	chr4:3265114	C4orf44	0.39	5.02	0.3	9.82e-7	Parental longevity (mother's age at death);
KIRP	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	9.08	0.5	3.68e-17	Morning vs. evening chronotype;
KIRP	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs11577318	0.579	rs11548246	chr1:26697166	G/A	cg00852783	chr1:26633632	UBXN11	-0.46	-5.22	-0.32	3.81e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg14003231	chr6:33640908	ITPR3	0.28	4.94	0.3	1.42e-6	Height;
KIRP	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.73	-10.5	-0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14507427	chr7:2076633	MAD1L1	-0.41	-5.08	-0.31	7.56e-7	Schizophrenia;
KIRP	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg18306943	chr3:40428807	ENTPD3	0.41	5.63	0.34	4.86e-8	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17678946	chr2:32235925	MEMO1	0.51	6.39	0.38	8.41e-10	Parkinson's disease;
KIRP	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg25007680	chr1:8021821	PARK7	0.62	8.62	0.48	8.18e-16	Response to antidepressants and depression;
KIRP	cis	rs4144743	0.528	rs2292866	chr17:45356782	T/C	cg18085866	chr17:45331354	ITGB3	-0.66	-5.06	-0.31	8.22e-7	Body mass index;
KIRP	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	6.67	0.39	1.67e-10	Initial pursuit acceleration;
KIRP	trans	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg01311341	chr22:25575246	KIAA1671	0.51	6.12	0.36	3.77e-9	Atopic dermatitis;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg09033563	chr22:24373618	LOC391322	-0.38	-4.92	-0.3	1.57e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.8	9.25	0.51	1.12e-17	Pulmonary function decline;
KIRP	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg17863274	chr19:49399704	TULP2	-0.41	-5.84	-0.35	1.61e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs17539620	0.565	rs61383594	chr6:154841632	A/T	cg20019720	chr6:154832845	CNKSR3	0.41	5.98	0.36	7.62e-9	Lipoprotein (a) levels;
KIRP	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.84	12.69	0.63	9.87e-29	Height;
KIRP	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.52	-6.38	-0.38	8.63e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.65	7.55	0.43	8.4e-13	Obesity-related traits;
KIRP	cis	rs4006360	0.575	rs7502215	chr17:39306261	C/T	cg16985667	chr17:39306289	KRTAP4-5	0.48	6.1	0.36	4.05e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs10863681	0.764	rs12038701	chr1:222242777	A/G	cg18908524	chr11:64002295	VEGFB	0.56	6.44	0.38	6.31e-10	Metabolite levels (HVA-5-HIAA Factor score);
KIRP	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06109949	chr2:178937838	PDE11A	0.54	7.02	0.41	2.19e-11	Smoking initiation;
KIRP	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.25	-0.7	2.03e-37	Headache;
KIRP	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.43	0.65	3.34e-31	Mean platelet volume;
KIRP	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.8	9.19	0.51	1.65e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2391754	1.000	rs757327	chr7:29394048	A/G	cg00901138	chr7:29329370	CHN2	-0.37	-4.9	-0.3	1.72e-6	CSF tryptophan concentration in tuberculous meningitis;
KIRP	cis	rs9815354	0.903	rs9822598	chr3:41954587	G/A	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10940138	1.000	rs10940138	chr5:67194469	C/T	ch.5.1281357F	chr5:67228439	NA	0.68	10.83	0.57	1.34e-22	Menarche (age at onset);
KIRP	cis	rs853679	0.546	rs483143	chr6:27846744	G/C	cg26587870	chr6:27730563	NA	-0.6	-4.93	-0.3	1.54e-6	Depression;
KIRP	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.4	-9.42	-0.51	3.52e-18	Cutaneous nevi;
KIRP	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.52	-5.24	-0.32	3.4e-7	Total cholesterol levels;
KIRP	cis	rs735860	0.712	rs3736732	chr6:53160383	G/T	cg10236188	chr6:53219634	NA	-0.41	-5.57	-0.33	6.72e-8	Glaucoma;
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.73e-9	Life satisfaction;
KIRP	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg09873164	chr1:152488093	CRCT1	0.52	6.57	0.39	2.97e-10	Hair morphology;
KIRP	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.46	6.27	0.37	1.57e-9	Coronary artery disease;
KIRP	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7106204	0.764	rs57490470	chr11:24234370	A/G	ch.11.24196551F	chr11:24239977	NA	0.88	8.1	0.46	2.56e-14	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1595825	0.891	rs75946628	chr2:198546239	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-4.85	-0.3	2.16e-6	Ulcerative colitis;
KIRP	cis	rs11871801	0.517	rs645692	chr17:40701073	C/T	cg14558262	chr17:40713999	COASY	0.49	5.22	0.32	3.87e-7	Crohn's disease;
KIRP	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg10760299	chr15:45669010	GATM	0.31	4.89	0.3	1.86e-6	Homoarginine levels;
KIRP	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.42	-5.46	-0.33	1.15e-7	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01716380	chr13:41885273	NAA16	0.45	6.8	0.4	7.83e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-6.81	-0.4	7.6e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs13343954	0.778	rs2016944	chr19:33550010	T/A	cg27124370	chr19:33622961	WDR88	0.52	5.3	0.32	2.58e-7	Colorectal cancer;
KIRP	cis	rs3540	0.960	rs60825716	chr15:90958053	G/A	cg10434728	chr15:90938212	IQGAP1	0.32	5.32	0.32	2.38e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	12.86	0.63	2.75e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7737355	0.812	rs32107	chr5:131039633	C/A	cg06307176	chr5:131281290	NA	0.41	4.92	0.3	1.59e-6	Life satisfaction;
KIRP	cis	rs4704187	0.687	rs2335136	chr5:74407994	T/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg08198773	chr8:1697536	NA	-0.39	-5.21	-0.32	4.01e-7	Systolic blood pressure;
KIRP	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.67	8.83	0.49	1.95e-16	Schizophrenia;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg26754761	chr2:177040938	NA	0.31	5.43	0.33	1.37e-7	IgG glycosylation;
KIRP	cis	rs8018808	0.935	rs963283	chr14:77901456	C/A	cg18872420	chr14:78023429	SPTLC2	0.36	5.27	0.32	2.94e-7	Myeloid white cell count;
KIRP	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg18944383	chr4:111397179	ENPEP	0.51	8.51	0.48	1.7e-15	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg07148914	chr20:33460835	GGT7	-0.4	-5.02	-0.31	9.74e-7	Height;
KIRP	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg16309518	chr5:176445507	NA	-0.89	-13.82	-0.66	1.57e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs4356975	0.563	rs11249527	chr4:69954985	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.4	0.33	1.58e-7	Alzheimer's disease;
KIRP	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.19	0.31	4.49e-7	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09429161	chr19:893169	MED16	0.48	6.03	0.36	5.92e-9	Parkinson's disease;
KIRP	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.51	-8.4	-0.47	3.51e-15	Height;
KIRP	cis	rs7646881	0.812	rs9864589	chr3:158430706	A/G	cg19483011	chr3:158453295	NA	-0.51	-5.35	-0.32	2.04e-7	Tetralogy of Fallot;
KIRP	cis	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg06521331	chr12:34319734	NA	-0.46	-5.61	-0.34	5.52e-8	Morning vs. evening chronotype;
KIRP	trans	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.98e-12	Bladder cancer;
KIRP	cis	rs4262150	0.960	rs10056647	chr5:152286477	T/G	cg12297329	chr5:152029980	NA	0.41	5.68	0.34	3.84e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.65	-10.09	-0.54	3e-20	Menopause (age at onset);
KIRP	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.67	6.11	0.36	3.81e-9	Eotaxin levels;
KIRP	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg25281562	chr12:121454272	C12orf43	0.56	6.75	0.4	1.03e-10	N-glycan levels;
KIRP	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg12042659	chr19:58951599	ZNF132	0.49	5.93	0.35	1.01e-8	Uric acid clearance;
KIRP	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs62355272	0.541	rs11955690	chr5:35920686	C/T	cg13894535	chr5:35919491	CAPSL	-0.39	-5.25	-0.32	3.23e-7	Lymphocyte counts;
KIRP	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.47	7.29	0.42	4.17e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4646404	0.509	rs1531100	chr17:17464828	G/A	cg01246520	chr17:17644344	RAI1	-0.32	-5.49	-0.33	9.98e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg08508325	chr11:3079039	CARS	-0.39	-7.48	-0.43	1.34e-12	Longevity;
KIRP	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.51	-6.68	-0.39	1.62e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.93	-14.39	-0.68	1.75e-34	Sudden cardiac arrest;
KIRP	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg06740227	chr12:86229804	RASSF9	0.4	5.09	0.31	6.95e-7	Major depressive disorder;
KIRP	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs12982744	0.613	rs12981780	chr19:2133465	C/T	cg09261902	chr19:2140048	AP3D1	0.43	5.45	0.33	1.22e-7	Osteoarthritis;Height;
KIRP	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.71	9.6	0.52	9.42e-19	Parkinson's disease;
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.49	6.68	0.39	1.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.81	0.53	2.25e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg11031976	chr2:198649780	BOLL	-0.51	-4.85	-0.3	2.21e-6	Ulcerative colitis;
KIRP	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.62	12.13	0.61	7.46e-27	Bone mineral density;
KIRP	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.91	-0.49	1.19e-16	Total cholesterol levels;
KIRP	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.78	-11.92	-0.61	3.74e-26	Hip circumference;
KIRP	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.46	-6.59	-0.39	2.64e-10	Refractive error;
KIRP	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.61	-0.44	5.74e-13	Resting heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23064951	chr11:62389256	B3GAT3	0.51	6.26	0.37	1.66e-9	Parkinson's disease;
KIRP	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg11650704	chr1:154556575	ADAR	-0.45	-5.6	-0.34	5.81e-8	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	13.47	0.65	2.45e-31	Platelet count;
KIRP	cis	rs6545883	0.860	rs6545847	chr2:61445333	C/T	cg15711740	chr2:61764176	XPO1	0.57	7.45	0.43	1.59e-12	Tuberculosis;
KIRP	cis	rs7011049	1.000	rs72643588	chr8:53849335	C/T	cg26025543	chr8:53854495	NA	0.77	7.93	0.45	7.74e-14	Systolic blood pressure;
KIRP	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-4.91	-0.3	1.65e-6	IgG glycosylation;
KIRP	cis	rs2236918	0.687	rs851778	chr1:242037110	A/G	cg21919602	chr1:242011447	EXO1	-0.46	-5.84	-0.35	1.67e-8	Menopause (age at onset);
KIRP	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.68	-9.22	-0.51	1.36e-17	Red blood cell count;
KIRP	cis	rs853679	0.546	rs200977	chr6:27854301	T/C	cg21204522	chr6:27730016	NA	-0.69	-5.16	-0.31	5.15e-7	Depression;
KIRP	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.56	-8.19	-0.46	1.39e-14	Carotid intima media thickness;
KIRP	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.65	9.45	0.52	2.83e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs10242455	0.614	rs2014764	chr7:99347506	C/T	cg19090437	chr4:38080799	TBC1D1	-0.54	-6.11	-0.36	3.85e-9	Blood metabolite levels;
KIRP	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg22617819	chr1:44378782	ST3GAL3	0.32	5.09	0.31	7.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.49	-5.72	-0.34	3.16e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.68	6.81	0.4	7.3e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg06042504	chr8:55087323	NA	0.59	7.23	0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.59	7.69	0.44	3.53e-13	Diastolic blood pressure;
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.47	6.28	0.37	1.53e-9	Mean corpuscular volume;
KIRP	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	1.08	21.52	0.81	1.75e-58	Height;
KIRP	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg21427119	chr20:30132790	HM13	-0.62	-6.67	-0.39	1.7e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs514024	0.644	rs564754	chr9:130495633	C/G	cg13643465	chr9:130375613	STXBP1	0.46	5.98	0.36	7.63e-9	Eating disorders (purging via substances);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22664400	chr11:66445111	RBM4B	0.53	6.55	0.39	3.33e-10	Parkinson's disease;
KIRP	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg18461021	chr18:74961002	GALR1	0.5	5.21	0.32	3.95e-7	Obesity-related traits;
KIRP	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.95	12.35	0.62	1.38e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs11203032	0.901	rs4074851	chr10:90958618	A/G	cg16672925	chr10:90967113	CH25H	-0.82	-8.56	-0.48	1.24e-15	Heart failure;
KIRP	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.66	-7.87	-0.45	1.09e-13	IgG glycosylation;
KIRP	cis	rs829661	0.793	rs2593452	chr2:30831036	T/A	cg10949345	chr2:30726833	LCLAT1	1.0	12.45	0.62	6.63e-28	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-0.85	-6.45	-0.38	5.94e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs3935685	0.874	rs28406214	chr15:77996537	G/A	cg25212270	chr15:78015279	NA	0.58	7.58	0.44	6.99e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg16396542	chr1:89473148	GBP3	0.36	4.86	0.3	2.1e-6	Carotid intima media thickness;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07645614	chr16:11836653	TXNDC11	-0.54	-7.4	-0.43	2.17e-12	Myopia;
KIRP	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg03929089	chr4:120376271	NA	-0.53	-6.54	-0.38	3.44e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs12043259	0.730	rs750088	chr1:204810195	C/G	cg11485465	chr5:54518469	NA	0.36	6.35	0.38	1.03e-9	Addiction;
KIRP	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	0.86	8.09	0.46	2.72e-14	Pulse pressure;
KIRP	cis	rs4936894	0.500	rs10893201	chr11:124165209	A/C	cg27160556	chr11:124181099	OR8D1	-0.46	-6.57	-0.39	3e-10	Aging (time to death);
KIRP	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg05484376	chr2:27715224	FNDC4	-0.38	-6.2	-0.37	2.31e-9	Total body bone mineral density;
KIRP	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.34	0.51	6.08e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.9	13.63	0.66	6.64e-32	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.81	11.43	0.59	1.54e-24	Mean platelet volume;
KIRP	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg24503407	chr1:205819492	PM20D1	0.46	5.22	0.32	3.79e-7	Parkinson's disease;
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.83	0.35	1.71e-8	Lung cancer;
KIRP	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg05370193	chr1:21551575	ECE1	0.45	6.23	0.37	2.04e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	14.58	0.68	3.99e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.9e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg02733842	chr7:1102375	C7orf50	0.56	5.81	0.35	1.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03113683	chr21:34852656	TMEM50B	0.46	6.2	0.37	2.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg19468946	chr17:37922297	IKZF3	0.51	7.32	0.42	3.45e-12	Self-reported allergy;
KIRP	cis	rs10875746	0.859	rs4760680	chr12:48466697	G/T	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.39	0.33	1.61e-7	Height;
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg23693289	chr8:27183097	PTK2B	0.57	7.32	0.42	3.5e-12	Neuroticism;
KIRP	cis	rs4889855	1.000	rs4889855	chr17:78513280	G/A	cg16591659	chr17:78472290	NA	-0.41	-5.76	-0.34	2.56e-8	Fractional excretion of uric acid;
KIRP	cis	rs2562456	0.833	rs74711277	chr19:21505443	C/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.76	8.42	0.47	3.12e-15	Bipolar disorder;
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs9815354	0.723	rs79741604	chr3:41947321	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.79	0.35	2.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17407813	chr8:76323405	NA	0.47	6.26	0.37	1.69e-9	Interleukin-4 levels;
KIRP	cis	rs748404	0.578	rs2244746	chr15:43695083	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.85	0.4	5.79e-11	Lung cancer;
KIRP	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg15764593	chr10:829463	NA	-0.8	-8.39	-0.47	3.95e-15	Uric acid levels;
KIRP	cis	rs7129556	0.690	rs588217	chr11:77583376	A/G	cg12586386	chr11:77299805	AQP11	-0.38	-5.08	-0.31	7.47e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs9308731	0.563	rs11899831	chr2:111932694	G/A	cg18646521	chr2:111875858	NA	0.38	5.32	0.32	2.38e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg00409905	chr10:38381863	ZNF37A	0.58	6.18	0.37	2.64e-9	Obesity (extreme);
KIRP	cis	rs7615316	0.839	rs6798232	chr3:142369839	A/G	cg20824294	chr3:142316082	PLS1	-0.23	-4.87	-0.3	2e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg02527881	chr3:46936655	PTH1R	0.35	5.0	0.3	1.1e-6	Colorectal cancer;
KIRP	cis	rs7737355	0.812	rs10078640	chr5:131071246	C/G	cg25547332	chr5:131281432	NA	0.42	5.19	0.31	4.37e-7	Life satisfaction;
KIRP	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16727006	chr16:87470545	ZCCHC14	0.48	7.37	0.43	2.56e-12	Survival in pancreatic cancer;
KIRP	cis	rs10958369	0.613	rs10095702	chr8:54436111	C/T	cg12485204	chr8:54507357	NA	0.43	5.48	0.33	1.03e-7	Response to antineoplastic agents;
KIRP	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg03711944	chr11:47377212	SPI1	0.3	5.18	0.31	4.55e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.54	-0.52	1.53e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.71	9.62	0.52	8.6e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.74	-5.43	-0.33	1.36e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.25	-0.32	3.29e-7	Obesity-related traits;
KIRP	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg27432699	chr2:27873401	GPN1	-0.46	-5.88	-0.35	1.32e-8	Total body bone mineral density;
KIRP	trans	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg08975724	chr8:8085496	FLJ10661	0.5	6.08	0.36	4.63e-9	Retinal vascular caliber;
KIRP	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg10381502	chr11:71823885	C11orf51	-1.2	-7.91	-0.45	8.61e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs3789045	0.774	rs12031912	chr1:204476113	A/G	cg18185008	chr1:204589407	LRRN2	-0.6	-6.56	-0.39	3.06e-10	Educational attainment (college completion);
KIRP	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.43	0.62	7.32e-28	Morning vs. evening chronotype;
KIRP	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg21100191	chr22:23484243	RTDR1	1.07	18.56	0.76	1.1e-48	Bone mineral density;
KIRP	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg04990556	chr1:26633338	UBXN11	0.66	6.28	0.37	1.56e-9	Obesity-related traits;
KIRP	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.38	4.92	0.3	1.56e-6	Melanoma;
KIRP	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.97	-0.64	1.18e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg25486957	chr4:152246857	NA	-0.51	-5.43	-0.33	1.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs490234	0.756	rs1398142	chr9:128226712	C/A	cg14078157	chr9:128172775	NA	-0.41	-5.19	-0.31	4.46e-7	Mean arterial pressure;
KIRP	trans	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg00938859	chr5:1591904	SDHAP3	0.59	8.19	0.46	1.47e-14	Breast cancer;
KIRP	cis	rs11016883	0.875	rs4751111	chr10:131502995	C/T	cg14312783	chr10:131504572	MGMT	0.43	5.5	0.33	9.28e-8	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	cis	rs6589219	0.908	rs3087967	chr11:111156836	A/G	cg25129781	chr11:111156908	C11orf53	-0.44	-5.8	-0.35	2.04e-8	Colorectal cancer;
KIRP	cis	rs981844	0.857	rs62325140	chr4:154714161	C/A	cg14289246	chr4:154710475	SFRP2	0.69	8.03	0.46	4.06e-14	Response to statins (LDL cholesterol change);
KIRP	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg27205649	chr11:78285834	NARS2	-0.62	-7.38	-0.43	2.44e-12	Alzheimer's disease (survival time);
KIRP	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.85	11.36	0.59	2.65e-24	Primary sclerosing cholangitis;
KIRP	cis	rs7493	0.755	rs740264	chr7:95021803	T/G	cg21856205	chr7:94953877	PON1	-0.46	-4.95	-0.3	1.36e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03902565	chr5:43603176	NNT	0.44	6.41	0.38	7.41e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.76	9.37	0.51	4.73e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	5.03	0.31	9.6e-7	Breast cancer;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.62	-0.34	5.29e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21643547	chr1:205240462	TMCC2	-0.89	-14.42	-0.68	1.41e-34	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg23166289	chr1:210001082	C1orf107	0.39	5.13	0.31	5.93e-7	Orofacial clefts;
KIRP	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg18833306	chr6:118973337	C6orf204	0.39	5.0	0.3	1.07e-6	Electrocardiographic conduction measures;
KIRP	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.3	0.47	6.97e-15	Neutrophil percentage of white cells;
KIRP	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.84	7.22	0.42	6.34e-12	Fat distribution (HIV);
KIRP	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg05973401	chr12:123451056	ABCB9	0.58	6.75	0.4	1.04e-10	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.58	-6.86	-0.4	5.43e-11	Initial pursuit acceleration;
KIRP	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	8.18	0.46	1.5e-14	Mean corpuscular volume;
KIRP	cis	rs1507153	0.651	rs9350781	chr6:79481815	A/T	cg11833968	chr6:79620685	NA	-0.37	-4.92	-0.3	1.56e-6	Sjögren's syndrome;
KIRP	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05665937	chr4:1216051	CTBP1	0.46	6.19	0.37	2.57e-9	Obesity-related traits;
KIRP	cis	rs6466055	0.777	rs3801285	chr7:104837801	C/A	cg04380332	chr7:105027541	SRPK2	-0.63	-9.72	-0.53	4.15e-19	Schizophrenia;
KIRP	cis	rs3849570	0.533	rs6548782	chr3:81993287	T/G	cg07356753	chr3:81810745	GBE1	-0.52	-6.77	-0.4	9.28e-11	Waist circumference;Body mass index;
KIRP	cis	rs2916247	0.954	rs7461004	chr8:93088828	T/G	cg10183463	chr8:93005414	RUNX1T1	0.52	6.85	0.4	5.95e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg00204512	chr16:28754710	NA	0.46	6.05	0.36	5.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg11382394	chr1:2564504	MMEL1	-0.38	-4.87	-0.3	2.02e-6	Ulcerative colitis;
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	14.83	0.69	5.56e-36	Platelet count;
KIRP	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg23752985	chr2:85803571	VAMP8	0.6	9.13	0.5	2.61e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1978968	0.957	rs55865752	chr22:18444227	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.59	-7.01	-0.41	2.29e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg24633833	chr3:10029261	TMEM111	0.54	5.26	0.32	3.18e-7	Alzheimer's disease;
KIRP	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg10523679	chr1:76189770	ACADM	0.73	9.59	0.52	1.01e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg06289844	chr6:126071538	HEY2	0.37	5.37	0.32	1.8e-7	Brugada syndrome;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20363904	chr8:22552821	NA	0.44	6.88	0.4	4.85e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg07596299	chr11:71824057	C11orf51	-0.91	-6.11	-0.36	3.79e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs3105593	1.000	rs12439744	chr15:50899211	C/T	cg05456662	chr15:50716270	USP8	0.41	5.04	0.31	8.84e-7	QT interval;
KIRP	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.5	-6.41	-0.38	7.39e-10	Corneal astigmatism;
KIRP	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg08885076	chr2:99613938	TSGA10	-0.61	-10.98	-0.57	4.51e-23	Chronic sinus infection;
KIRP	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.82	-12.68	-0.63	1.08e-28	Asthma;
KIRP	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.33	-0.37	1.13e-9	Parkinson's disease;
KIRP	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.59	0.52	1.02e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15128208	chr22:42549153	NA	-0.41	-5.18	-0.31	4.73e-7	Cognitive function;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.57	9.56	0.52	1.26e-18	Lung cancer;
KIRP	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.7	-0.44	3.31e-13	Triglycerides;
KIRP	cis	rs9905704	0.633	rs757484	chr17:56457097	C/G	cg12560992	chr17:57184187	TRIM37	-0.55	-5.26	-0.32	3.15e-7	Testicular germ cell tumor;
KIRP	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.55	-0.43	8.74e-13	Type 2 diabetes;
KIRP	cis	rs9534288	0.833	rs56813530	chr13:46622039	A/C	cg15192986	chr13:46630673	CPB2	-0.83	-10.14	-0.54	2.09e-20	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.78	-11.86	-0.6	5.99e-26	Prostate cancer;
KIRP	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.51	-0.48	1.71e-15	Coronary artery disease;
KIRP	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg06204229	chr3:52865917	ITIH4	0.53	6.41	0.38	7.53e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg19592336	chr6:28129416	ZNF389	0.52	4.84	0.3	2.25e-6	Parkinson's disease;
KIRP	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg18198730	chr1:247681584	NA	0.57	5.37	0.32	1.86e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg15440763	chr7:158190612	PTPRN2	0.46	5.96	0.36	8.58e-9	Obesity-related traits;
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.76	12.04	0.61	1.49e-26	Menarche (age at onset);
KIRP	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg05220968	chr6:146057943	EPM2A	0.38	4.86	0.3	2.06e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.2	0.42	7.39e-12	Bipolar disorder;
KIRP	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg11657440	chr19:46296263	DMWD	-0.7	-8.86	-0.49	1.66e-16	Coronary artery disease;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26690034	chr1:75198963	CRYZ;TYW3	0.44	5.37	0.32	1.82e-7	Resistin levels;
KIRP	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.82	11.96	0.61	2.78e-26	Bladder cancer;
KIRP	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg08133631	chr1:26527909	CATSPER4	-0.46	-5.15	-0.31	5.36e-7	Obesity-related traits;
KIRP	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg13852791	chr20:30311386	BCL2L1	0.64	7.0	0.41	2.43e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06998765	chr14:75389618	RPS6KL1	-0.27	-5.34	-0.32	2.11e-7	Caffeine consumption;
KIRP	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg06360820	chr2:242988706	NA	-0.71	-6.14	-0.36	3.23e-9	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12408293	chr12:77459343	E2F7	0.5	6.27	0.37	1.58e-9	Parkinson's disease;
KIRP	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.23	0.32	3.55e-7	Educational attainment;
KIRP	trans	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg10756647	chr7:56101905	PSPH	1.09	8.64	0.48	7.48e-16	Diabetic kidney disease;
KIRP	cis	rs687432	0.885	rs11606464	chr11:57796647	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs6466055	0.669	rs7797912	chr7:104769415	C/T	cg04380332	chr7:105027541	SRPK2	0.62	9.51	0.52	1.88e-18	Schizophrenia;
KIRP	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-8.47	-0.48	2.27e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.76	10.09	0.54	2.89e-20	Hemoglobin concentration;
KIRP	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.67	6.61	0.39	2.43e-10	Axial length;
KIRP	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.71	-10.6	-0.56	7.29e-22	Prostate cancer;
KIRP	cis	rs6690583	1.000	rs2304641	chr1:85513398	C/T	cg22153463	chr1:85462885	MCOLN2	0.57	5.02	0.3	9.88e-7	Serum sulfate level;
KIRP	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.39	8.24	0.46	1.04e-14	IgG glycosylation;
KIRP	cis	rs1978968	0.763	rs13055106	chr22:18465208	G/A	cg02610425	chr22:18483192	MICAL3	0.37	5.1	0.31	6.75e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg25457927	chr22:38595422	NA	-0.3	-6.15	-0.37	3.1e-9	Breast cancer;
KIRP	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-9.07	-0.5	3.82e-17	Neuroticism;
KIRP	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.37	-5.79	-0.35	2.1e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg13456812	chr6:167369504	RNASET2	0.72	6.04	0.36	5.8e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10924970	0.967	rs10495362	chr1:235390396	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.1	0.31	6.95e-7	Asthma;
KIRP	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.67	10.2	0.55	1.31e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.46	7.0	0.41	2.42e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2241685	0.573	rs11127302	chr2:1935709	A/G	cg22511877	chr2:1942942	MYT1L	-0.55	-5.83	-0.35	1.73e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.8	-11.79	-0.6	9.66e-26	Obesity-related traits;
KIRP	cis	rs72843166	0.562	rs2286571	chr17:61518220	A/C	cg19683800	chr17:61518354	CYB561	-0.4	-5.37	-0.32	1.78e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23816928	chr3:150264597	SERP1;EIF2A	0.51	6.66	0.39	1.76e-10	Parkinson's disease;
KIRP	cis	rs4262150	0.667	rs13188558	chr5:152274276	G/A	cg12297329	chr5:152029980	NA	0.46	6.5	0.38	4.34e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg21360079	chr12:107162445	NA	-0.71	-10.13	-0.54	2.23e-20	Heart rate;
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg01763666	chr17:80159506	CCDC57	0.36	4.98	0.3	1.21e-6	Life satisfaction;
KIRP	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg21775007	chr8:11205619	TDH	0.51	6.28	0.37	1.55e-9	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10568931	chr12:100536436	UHRF1BP1L	0.5	6.21	0.37	2.26e-9	Parkinson's disease;
KIRP	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.57	9.16	0.5	2.16e-17	Sense of smell;
KIRP	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.83	12.27	0.62	2.56e-27	Eye color traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06583696	chr2:26101536	ASXL2	0.55	6.44	0.38	6.12e-10	Smoking initiation;
KIRP	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.26	-5.42	-0.33	1.45e-7	Menarche (age at onset);
KIRP	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.95	-0.3	1.4e-6	Schizophrenia;
KIRP	cis	rs11622475	1.000	rs11625697	chr14:104464800	C/T	cg20488157	chr14:104394430	TDRD9	0.74	10.89	0.57	8.66e-23	Bipolar disorder;
KIRP	cis	rs7149242	1.000	rs11620937	chr14:101151012	C/G	cg18089426	chr14:101175970	NA	0.63	8.25	0.47	9.72e-15	Platelet count;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-7.08	-0.41	1.47e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg07274523	chr3:49395745	GPX1	0.7	8.8	0.49	2.48e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.44	0.38	6.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.47	-0.38	5.38e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.79	7.57	0.43	7.53e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-7.11	-0.41	1.28e-11	Gut microbiome composition (summer);
KIRP	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.74	0.34	2.84e-8	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24040382	chr1:224622855	WDR26	0.44	6.45	0.38	6.04e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9473924	0.505	rs7745565	chr6:50860083	A/G	cg14470998	chr6:50812995	TFAP2B	0.84	7.83	0.45	1.46e-13	Body mass index;
KIRP	cis	rs911119	0.913	rs6048924	chr20:23578996	G/A	cg09631192	chr20:23583594	CST9	-0.48	-5.0	-0.3	1.07e-6	Chronic kidney disease;
KIRP	cis	rs894344	0.812	rs11166612	chr8:135600954	A/G	cg09855544	chr8:135498122	ZFAT	0.42	5.62	0.34	5.23e-8	Systolic blood pressure;
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-5.92	-0.35	1.06e-8	Aortic root size;
KIRP	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	5.32	0.32	2.35e-7	Schizophrenia;
KIRP	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg01294253	chr9:136912663	BRD3	0.39	5.15	0.31	5.39e-7	Platelet distribution width;
KIRP	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg11031976	chr2:198649780	BOLL	-0.54	-5.2	-0.31	4.14e-7	Ulcerative colitis;
KIRP	trans	rs12517041	1.000	rs2099090	chr5:23287823	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.68	-0.48	5.57e-16	Calcium levels;
KIRP	cis	rs4073221	0.654	rs7373125	chr3:18297522	A/G	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	cis	rs6500395	0.588	rs6500393	chr16:48568108	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.09	0.36	4.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg09344028	chr17:70110421	NA	0.49	11.81	0.6	8.54e-26	Thyroid hormone levels;
KIRP	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.72	0.34	3.08e-8	Bipolar disorder;
KIRP	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	0.96	11.31	0.58	3.73e-24	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2594989	0.887	rs2447604	chr3:11574297	G/A	cg01796438	chr3:11312864	ATG7	0.61	6.23	0.37	2.05e-9	Circulating chemerin levels;
KIRP	cis	rs2562456	0.833	rs2650776	chr19:21613397	C/T	cg18461458	chr19:21324796	ZNF431	-0.56	-5.43	-0.33	1.37e-7	Pain;
KIRP	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.48	6.21	0.37	2.25e-9	Blood protein levels;
KIRP	cis	rs3750082	0.817	rs2060731	chr7:32968346	G/A	cg08946731	chr7:32981826	RP9P	-0.36	-5.41	-0.33	1.47e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg13514129	chr1:39547527	MACF1	0.53	7.78	0.44	1.96e-13	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg08885076	chr2:99613938	TSGA10	0.58	9.89	0.53	1.26e-19	Chronic sinus infection;
KIRP	cis	rs986417	0.748	rs10133403	chr14:60945298	C/T	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg21548788	chr4:77997565	CCNI	0.5	6.55	0.39	3.41e-10	Asthma;
KIRP	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg01879757	chr17:41196368	BRCA1	-0.62	-8.4	-0.47	3.62e-15	Menopause (age at onset);
KIRP	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg12591125	chr7:1885375	MAD1L1	0.55	5.47	0.33	1.13e-7	Bipolar disorder;
KIRP	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.97	-15.05	-0.69	1.02e-36	Height;
KIRP	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07080220	chr10:102295463	HIF1AN	0.96	8.86	0.49	1.64e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.71	7.21	0.42	6.9e-12	Menarche (age at onset);
KIRP	cis	rs3774830	0.714	rs7657964	chr4:5466327	C/G	cg26943120	chr4:5472116	STK32B	-0.25	-6.13	-0.36	3.45e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs787274	0.867	rs1361719	chr9:115535576	A/G	cg13803584	chr9:115635662	SNX30	-0.74	-8.4	-0.47	3.67e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg21523564	chr15:75251491	NA	0.43	6.82	0.4	6.97e-11	Breast cancer;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2274273	1.000	rs67805055	chr14:55587552	C/T	cg04306507	chr14:55594613	LGALS3	0.46	6.99	0.41	2.56e-11	Protein biomarker;
KIRP	cis	rs1351164	0.591	rs9752576	chr2:218269445	G/A	cg15335768	chr2:218268053	DIRC3	-0.51	-6.65	-0.39	1.85e-10	Height;
KIRP	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.64	-0.39	1.98e-10	Bipolar disorder;
KIRP	trans	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg10756647	chr7:56101905	PSPH	-0.96	-6.94	-0.4	3.56e-11	Diabetic kidney disease;
KIRP	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg23307798	chr14:103986281	CKB	-0.82	-14.25	-0.67	5.24e-34	Body mass index;
KIRP	trans	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg07211511	chr3:129823064	LOC729375	-0.7	-7.25	-0.42	5.37e-12	Blood pressure (smoking interaction);
KIRP	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg14952266	chr13:112191215	NA	0.43	6.17	0.37	2.72e-9	Hepatitis;
KIRP	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.91	-12.2	-0.61	4.34e-27	Gut microbiota (bacterial taxa);
KIRP	cis	rs4395908	0.567	rs2407308	chr8:4022811	C/T	cg01921437	chr8:3974145	CSMD1	-0.42	-5.18	-0.31	4.7e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.62	8.06	0.46	3.32e-14	Recalcitrant atopic dermatitis;
KIRP	cis	rs6467136	0.765	rs1419430	chr7:127195294	C/T	cg23081781	chr7:127225937	GCC1	-0.37	-4.85	-0.3	2.19e-6	Type 2 diabetes;
KIRP	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.68	10.54	0.56	1.13e-21	Hepatocellular carcinoma;
KIRP	cis	rs2274273	0.624	rs11848456	chr14:55755392	A/G	cg04306507	chr14:55594613	LGALS3	0.38	5.25	0.32	3.29e-7	Protein biomarker;
KIRP	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.64	-0.56	5.23e-22	Height;
KIRP	cis	rs2481665	0.765	rs2481679	chr1:62634303	T/A	cg18591186	chr1:62594603	INADL	-0.56	-8.47	-0.48	2.24e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg09264619	chr17:80180166	NA	-0.33	-4.95	-0.3	1.35e-6	Life satisfaction;
KIRP	cis	rs2652822	0.525	rs8037296	chr15:63516759	A/G	cg02713581	chr15:63449717	RPS27L	0.48	5.44	0.33	1.32e-7	Metabolic traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02287918	chr21:30396957	USP16	-0.45	-6.41	-0.38	7.17e-10	Metabolic traits;
KIRP	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.59	7.85	0.45	1.3e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.1	0.46	2.63e-14	Height;
KIRP	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.19	-0.37	2.53e-9	QT interval;
KIRP	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17507749	chr15:85114479	UBE2QP1	0.72	8.07	0.46	3.02e-14	Schizophrenia;
KIRP	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg21191810	chr6:118973309	C6orf204	-0.42	-4.86	-0.3	2.14e-6	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07998374	chr3:113234057	CCDC52	0.5	6.26	0.37	1.67e-9	Parkinson's disease;
KIRP	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	9.58	0.52	1.09e-18	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21161649	chr21:45284362	AGPAT3	0.47	6.08	0.36	4.57e-9	Parkinson's disease;
KIRP	cis	rs4908768	0.717	rs12119207	chr1:8829499	A/G	cg03610117	chr1:8450231	RERE	-0.44	-4.9	-0.3	1.74e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2970992	0.764	rs2942885	chr2:101322332	C/T	cg01042948	chr2:101319752	NA	0.5	7.27	0.42	4.66e-12	Educational attainment;
KIRP	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg09455208	chr3:40491958	NA	0.35	6.05	0.36	5.5e-9	Renal cell carcinoma;
KIRP	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg11584989	chr19:19387371	SF4	0.41	5.27	0.32	3.05e-7	Tonsillectomy;
KIRP	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6738627	0.895	rs12692735	chr2:165504565	G/T	cg03182029	chr2:165697222	COBLL1	0.39	5.01	0.3	1.03e-6	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs6832769	1.000	rs10034433	chr4:56421176	A/T	cg05960024	chr4:56376020	CLOCK	-0.62	-7.95	-0.45	6.62e-14	Personality dimensions;
KIRP	cis	rs11568819	1.000	rs11568819	chr11:102401633	C/T	cg01813071	chr11:102401616	MMP7	1.29	7.84	0.45	1.33e-13	Blood protein levels;
KIRP	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg22508957	chr16:3507546	NAT15	0.55	7.01	0.41	2.25e-11	Tuberculosis;
KIRP	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.75	-9.69	-0.53	5.2e-19	Total body bone mineral density;
KIRP	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	0.99	18.45	0.76	2.6e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.49	6.3	0.37	1.34e-9	Facial morphology (factor 20);
KIRP	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg03453431	chr7:157225567	NA	-0.38	-4.97	-0.3	1.28e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.79	0.4	8.41e-11	Electroencephalogram traits;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.87	0.35	1.38e-8	Lung cancer;
KIRP	cis	rs7546094	0.875	rs11584092	chr1:113176262	T/A	cg22162597	chr1:113214053	CAPZA1	-0.46	-5.97	-0.36	8.1e-9	Platelet distribution width;
KIRP	cis	rs503734	0.502	rs2660803	chr3:100914035	A/G	cg27318481	chr3:100970896	IMPG2	-0.52	-6.84	-0.4	6.23e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2635047	0.507	rs2668767	chr18:44785302	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.23	0.37	1.96e-9	Educational attainment;
KIRP	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg25856811	chr1:152973957	SPRR3	-0.36	-4.98	-0.3	1.18e-6	Inflammatory skin disease;
KIRP	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg01864069	chr14:103024347	NA	0.9	10.49	0.56	1.63e-21	Platelet count;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.62	-8.54	-0.48	1.41e-15	Longevity;Endometriosis;
KIRP	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.81	-12.43	-0.62	7.52e-28	Breast cancer;
KIRP	cis	rs2708977	0.698	rs772161	chr2:97043803	C/A	cg22654517	chr2:96458247	NA	0.31	5.01	0.3	1.03e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.34	5.07	0.31	7.76e-7	Calcium levels;
KIRP	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.79	10.83	0.57	1.33e-22	Aortic root size;
KIRP	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg07051648	chr19:49177693	NTN5;SEC1	-0.49	-5.91	-0.35	1.13e-8	Dietary macronutrient intake;
KIRP	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.11	0.46	2.43e-14	Morning vs. evening chronotype;
KIRP	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg20891283	chr12:69753455	YEATS4	0.63	6.56	0.39	3.21e-10	Response to diuretic therapy;
KIRP	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg00405596	chr8:11794950	NA	-0.49	-6.58	-0.39	2.89e-10	Monocyte count;
KIRP	trans	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.54	-6.79	-0.4	8.56e-11	Eotaxin levels;
KIRP	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.76	0.53	3.09e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.24	-4.98	-0.3	1.21e-6	Menarche (age at onset);
KIRP	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.76	-8.98	-0.5	7.47e-17	Pancreatic cancer;
KIRP	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.37	6.83	0.4	6.53e-11	Refractive error;
KIRP	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg03678062	chr6:149772716	ZC3H12D	0.32	5.12	0.31	6.25e-7	Dupuytren's disease;
KIRP	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.96	-15.63	-0.71	1.03e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.09	-0.36	4.35e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg25486957	chr4:152246857	NA	-0.43	-5.13	-0.31	5.96e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.39	-0.32	1.67e-7	Neuroticism;
KIRP	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg01657329	chr11:68192670	LRP5	0.46	4.98	0.3	1.18e-6	Total body bone mineral density;
KIRP	cis	rs6466055	0.589	rs6947388	chr7:104639583	G/C	cg04380332	chr7:105027541	SRPK2	-0.39	-5.34	-0.32	2.16e-7	Schizophrenia;
KIRP	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg25486957	chr4:152246857	NA	-0.43	-5.01	-0.3	1.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg26754761	chr2:177040938	NA	0.31	5.18	0.31	4.64e-7	IgG glycosylation;
KIRP	cis	rs1847505	0.574	rs17822177	chr13:61491537	G/C	cg25164009	chr13:61490935	NA	0.54	5.51	0.33	8.91e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.79	8.65	0.48	6.57e-16	Corneal astigmatism;
KIRP	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.22	-10.61	-0.56	6.49e-22	Diabetic retinopathy;
KIRP	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.41	7.01	0.41	2.31e-11	Renal cell carcinoma;
KIRP	cis	rs17020663	0.552	rs8179740	chr2:101653528	C/T	cg12594615	chr2:101643137	TBC1D8	-0.36	-5.53	-0.33	8.22e-8	Pulse pressure;
KIRP	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg18764771	chr6:116381957	FRK	0.19	5.22	0.32	3.78e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg03735888	chr19:58951602	ZNF132	0.46	5.51	0.33	9e-8	Uric acid clearance;
KIRP	cis	rs12780845	0.540	rs11254423	chr10:17218346	G/A	cg01003015	chr10:17271136	VIM	-0.4	-4.87	-0.3	1.99e-6	Homocysteine levels;
KIRP	cis	rs6800768	0.663	rs12492765	chr3:24091865	C/T	cg10674438	chr3:24145617	LOC152024	-0.39	-5.45	-0.33	1.24e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9783347	1.000	rs2061164	chr11:18329006	T/C	cg15585147	chr11:18324498	HPS5	0.47	6.37	0.38	9.31e-10	Pancreatic cancer;
KIRP	cis	rs17065868	0.764	rs61949763	chr13:45007475	T/C	cg10246903	chr13:45222710	NA	0.51	5.13	0.31	5.86e-7	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg10845886	chr2:3471009	TTC15	-0.55	-7.84	-0.45	1.34e-13	Neurofibrillary tangles;
KIRP	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-5.54	-0.33	7.75e-8	Ulcerative colitis;
KIRP	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg16386425	chr10:429943	DIP2C	-0.39	-5.12	-0.31	6.27e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg06219351	chr7:158114137	PTPRN2	-0.56	-6.42	-0.38	6.88e-10	Response to amphetamines;
KIRP	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.59	0.44	6.52e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.58	7.73	0.44	2.76e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2718058	0.692	rs2709117	chr7:37787807	A/G	cg15028436	chr7:37888078	TXNDC3	0.53	6.24	0.37	1.9e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg12486944	chr17:80159399	CCDC57	0.38	5.05	0.31	8.43e-7	Life satisfaction;
KIRP	cis	rs1134634	0.520	rs12645849	chr4:15629080	G/A	cg16509355	chr4:15471240	CC2D2A	-0.35	-5.98	-0.36	7.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs580438	0.588	rs665064	chr3:13367406	C/T	cg10657019	chr3:13328039	NA	0.53	6.85	0.4	5.92e-11	Myringotomy;
KIRP	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.66	-10.01	-0.54	5.43e-20	Heart rate;
KIRP	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg21573476	chr21:45109991	RRP1B	-0.55	-7.26	-0.42	5.13e-12	Mean corpuscular volume;
KIRP	trans	rs1928295	0.786	rs7032255	chr9:120400087	C/T	cg04204072	chr16:20752857	THUMPD1	-0.53	-6.47	-0.38	5.19e-10	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4262150	0.726	rs4958560	chr5:151929836	A/G	cg12297329	chr5:152029980	NA	-0.59	-7.39	-0.43	2.31e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.88	0.35	1.3e-8	Motion sickness;
KIRP	cis	rs2882667	0.898	rs2882792	chr5:138380480	G/T	cg04439458	chr5:138467593	SIL1	-0.45	-7.55	-0.43	8.73e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs412050	0.547	rs5999842	chr22:22214889	G/A	cg17089214	chr22:22089827	YPEL1	0.62	5.37	0.32	1.78e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg20045696	chr14:77926864	AHSA1	0.53	5.44	0.33	1.27e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg04025307	chr7:1156635	C7orf50	0.73	7.78	0.44	2.06e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.66	-0.44	4.34e-13	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.78	6.83	0.4	6.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg07775675	chr17:74379922	SPHK1	0.44	6.05	0.36	5.5e-9	Asthma;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg12598048	chr15:22892705	CYFIP1	-0.45	-6.33	-0.37	1.16e-9	Metabolite levels (MHPG);
KIRP	cis	rs860295	0.812	rs10908481	chr1:155713650	T/G	cg02153340	chr1:155202674	NA	-0.43	-5.89	-0.35	1.25e-8	Body mass index;
KIRP	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.55	-0.39	3.39e-10	Morning vs. evening chronotype;
KIRP	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	0.87	8.65	0.48	6.93e-16	Methadone dose in opioid dependence;
KIRP	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.68	-0.44	3.69e-13	Response to antipsychotic treatment;
KIRP	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.97	11.39	0.59	2.01e-24	Platelet count;
KIRP	cis	rs9972944	0.702	rs11654471	chr17:63784144	C/G	cg18091269	chr17:63822838	CCDC46	-0.46	-5.82	-0.35	1.85e-8	Total body bone mineral density;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.63	8.99	0.5	6.79e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs75920871	1.000	rs59294170	chr11:116841446	A/T	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.81	10.06	0.54	3.61e-20	Corneal astigmatism;
KIRP	cis	rs17221829	0.703	rs17818747	chr11:89373690	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.39	0.32	1.67e-7	Renal cell carcinoma;
KIRP	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.96	16.92	0.73	3.95e-43	Breast cancer;
KIRP	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg27247782	chr7:158767135	NA	-0.43	-5.21	-0.32	3.92e-7	Facial morphology (factor 20);
KIRP	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.55	5.51	0.33	9.17e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs4481887	0.508	rs4347239	chr1:248401116	A/G	cg01631408	chr1:248437212	OR2T33	-0.42	-5.26	-0.32	3.12e-7	Common traits (Other);
KIRP	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.8	8.03	0.46	4.1e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.6	-7.65	-0.44	4.65e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg04731861	chr2:219085781	ARPC2	-0.22	-5.36	-0.32	1.88e-7	Colorectal cancer;
KIRP	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	1.05	8.92	0.49	1.09e-16	Blood protein levels;
KIRP	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg15430464	chr8:114450065	CSMD3	0.45	6.2	0.37	2.36e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.59	0.34	6.03e-8	Lung cancer;
KIRP	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.84	-0.3	2.26e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg04787407	chr4:99916511	METAP1	0.49	6.3	0.37	1.39e-9	Asthma;
KIRP	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06850241	chr22:41845214	NA	0.43	4.96	0.3	1.33e-6	Vitiligo;
KIRP	cis	rs55788414	1.000	rs55788414	chr16:81184939	C/T	cg06400318	chr16:81190750	PKD1L2	-1.27	-8.39	-0.47	3.87e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.08	-0.41	1.54e-11	Platelet count;
KIRP	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.58	6.75	0.4	1.05e-10	Height;
KIRP	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.43	0.65	3.16e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs2151522	0.603	rs11755390	chr6:127195439	A/G	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1559088	0.512	rs60197880	chr19:33562695	C/A	cg27124370	chr19:33622961	WDR88	0.51	4.89	0.3	1.8e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg27205649	chr11:78285834	NARS2	-0.54	-5.0	-0.3	1.07e-6	Testicular germ cell tumor;
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg02696790	chr15:75250997	RPP25	0.31	5.4	0.33	1.58e-7	Breast cancer;
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg01391022	chr12:122360665	WDR66	-0.39	-5.59	-0.34	6.16e-8	Mean corpuscular volume;
KIRP	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg25811766	chr13:21894605	NA	-0.63	-6.16	-0.37	2.95e-9	White matter hyperintensity burden;
KIRP	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.34	0.37	1.08e-9	Subjective well-being;
KIRP	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-1.13	-9.88	-0.53	1.36e-19	Body mass index;
KIRP	cis	rs7565981	0.826	rs115957893	chr2:101440155	G/A	cg02232089	chr2:101440696	NPAS2	-0.64	-5.68	-0.34	3.84e-8	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs6062302	0.540	rs2281926	chr20:62384309	G/C	cg03999872	chr20:62272968	STMN3	-0.5	-5.19	-0.31	4.32e-7	Glioblastoma;
KIRP	trans	rs9650657	0.836	rs11250067	chr8:10606954	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.15	-0.37	3.13e-9	Neuroticism;
KIRP	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg04398451	chr17:18023971	MYO15A	-0.44	-5.61	-0.34	5.53e-8	Lymphocyte counts;
KIRP	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.48	-7.21	-0.42	6.84e-12	Daytime sleep phenotypes;
KIRP	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.6	0.34	5.71e-8	Melanoma;
KIRP	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg11945507	chr8:142233382	SLC45A4	-0.57	-7.42	-0.43	1.92e-12	Immature fraction of reticulocytes;
KIRP	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05665937	chr4:1216051	CTBP1	0.49	6.81	0.4	7.63e-11	Obesity-related traits;
KIRP	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.66	8.06	0.46	3.23e-14	Calcium levels;
KIRP	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.74e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72925845	0.519	rs72907438	chr17:76425973	G/A	cg03830375	chr17:76426088	DNAH17	0.5	5.16	0.31	5.07e-7	Triglycerides;
KIRP	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.33	-0.32	2.22e-7	Colorectal cancer;
KIRP	trans	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg13565492	chr6:43139072	SRF	-0.61	-6.18	-0.37	2.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.74	0.49	3.7e-16	Skin colour saturation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04432275	chr3:70901528	NA	0.49	6.6	0.39	2.45e-10	Interleukin-4 levels;
KIRP	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.48	-6.27	-0.37	1.59e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.61	-7.67	-0.44	4e-13	Waist circumference;Body mass index;
KIRP	cis	rs734999	0.588	rs745367	chr1:2524457	T/C	cg20673091	chr1:2541236	MMEL1	0.78	12.61	0.63	1.94e-28	Ulcerative colitis;
KIRP	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg12046867	chr14:103022105	NA	0.53	6.3	0.37	1.33e-9	Platelet count;
KIRP	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.57	0.33	6.54e-8	Putamen volume;
KIRP	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.76	9.5	0.52	1.97e-18	Corneal astigmatism;
KIRP	cis	rs1485395	0.945	rs10876477	chr12:54053246	C/T	cg16917193	chr12:54089295	NA	0.63	5.87	0.35	1.41e-8	Migraine without aura;
KIRP	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.24	-0.37	1.94e-9	Neuroticism;
KIRP	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg24009623	chr19:33667908	NA	0.48	6.1	0.36	3.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Tonsillectomy;
KIRP	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.38	-0.68	1.86e-34	Primary sclerosing cholangitis;
KIRP	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.64	6.18	0.37	2.6e-9	Vitiligo;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07981599	chr16:68119049	NFATC3	-0.45	-6.33	-0.37	1.13e-9	Warfarin maintenance dose;
KIRP	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg05526886	chr2:227700861	RHBDD1	0.46	5.57	0.33	6.55e-8	Pulmonary function;
KIRP	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.94	-0.35	9.76e-9	Alzheimer's disease (late onset);
KIRP	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.82	-12.13	-0.61	7.37e-27	Longevity;Endometriosis;
KIRP	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg26065057	chr18:74961000	GALR1	0.6	6.33	0.37	1.16e-9	Obesity-related traits;
KIRP	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg10932868	chr11:921992	NA	0.67	9.06	0.5	4.32e-17	Alzheimer's disease (late onset);
KIRP	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg02038168	chr22:39784481	NA	-0.43	-4.97	-0.3	1.28e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg05220968	chr6:146057943	EPM2A	0.42	5.56	0.33	6.89e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-11.41	-0.59	1.71e-24	Response to antipsychotic treatment;
KIRP	cis	rs6005807	0.719	rs12169880	chr22:29054875	G/C	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg11784071	chr10:104629166	AS3MT	-0.36	-5.04	-0.31	9.04e-7	Arsenic metabolism;
KIRP	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.57	7.91	0.45	8.94e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs4663866	1.000	rs6741269	chr2:239179418	A/G	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.65	7.97	0.45	5.84e-14	Crohn's disease;
KIRP	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.82	-8.24	-0.47	1.02e-14	Gut microbiome composition (summer);
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.72	5.73	0.34	2.87e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.84	9.95	0.54	7.91e-20	Multiple sclerosis;
KIRP	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.7	9.5	0.52	1.97e-18	Systemic lupus erythematosus;
KIRP	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.42	5.9	0.35	1.21e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.6	7.35	0.42	2.92e-12	Monocyte count;
KIRP	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg16141378	chr3:129829833	LOC729375	0.57	7.53	0.43	9.58e-13	Neuroticism;
KIRP	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-12.86	-0.63	2.67e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1476670	0.683	rs2057967	chr1:44515446	T/C	cg09470012	chr1:44509516	NA	0.34	5.4	0.33	1.53e-7	Eotaxin levels;
KIRP	cis	rs4716602	0.596	rs10458244	chr7:156164285	C/T	cg16983916	chr7:156159713	NA	-0.44	-5.58	-0.34	6.21e-8	Anti-saccade response;
KIRP	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.68	-0.34	3.72e-8	Bipolar disorder;
KIRP	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.42	6.24	0.37	1.9e-9	Schizophrenia;
KIRP	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	1.1	21.85	0.81	1.46e-59	Height;
KIRP	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.43e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	1.01	15.16	0.7	4.05e-37	Menopause (age at onset);
KIRP	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs151997	0.569	rs62367393	chr5:50270360	C/A	cg06027927	chr5:50259733	NA	0.52	6.54	0.38	3.54e-10	Callous-unemotional behaviour;
KIRP	cis	rs7180079	0.620	rs4777561	chr15:65064585	T/C	cg15337035	chr15:64978493	NA	-0.5	-5.4	-0.33	1.57e-7	Monocyte count;
KIRP	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg25706552	chr1:244017396	NA	-0.68	-7.1	-0.41	1.31e-11	RR interval (heart rate);
KIRP	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg27205649	chr11:78285834	NARS2	-0.57	-6.34	-0.37	1.11e-9	Testicular germ cell tumor;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg03112782	chr1:37979729	MEAF6	-0.49	-6.31	-0.37	1.31e-9	Neuroticism;
KIRP	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg12560992	chr17:57184187	TRIM37	0.62	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg27255678	chr10:102756921	LZTS2	0.44	5.11	0.31	6.48e-7	Educational attainment;
KIRP	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.93	10.03	0.54	4.62e-20	Alzheimer's disease;
KIRP	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg05370193	chr1:21551575	ECE1	0.39	5.29	0.32	2.73e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-8.45	-0.47	2.53e-15	Colorectal cancer;
KIRP	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02666008	chr1:110880366	NA	-0.51	-6.45	-0.38	5.85e-10	Interleukin-4 levels;
KIRP	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.3	-5.99	-0.36	7.26e-9	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg15103426	chr22:29168792	CCDC117	0.55	6.74	0.39	1.14e-10	Lymphocyte counts;
KIRP	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.44	5.22	0.32	3.78e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.08	-0.41	1.51e-11	Mood instability;
KIRP	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.62	8.14	0.46	2.04e-14	Height;
KIRP	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	1.1	10.14	0.54	2.03e-20	Post bronchodilator FEV1;
KIRP	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg06521331	chr12:34319734	NA	0.47	5.95	0.35	9.2e-9	Morning vs. evening chronotype;
KIRP	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg25811766	chr13:21894605	NA	-0.6	-5.98	-0.36	7.84e-9	White matter hyperintensity burden;
KIRP	trans	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg25214090	chr10:38739885	LOC399744	0.49	6.17	0.37	2.74e-9	Diastolic blood pressure;
KIRP	cis	rs2625529	0.938	rs4777464	chr15:72131763	C/T	cg16672083	chr15:72433130	SENP8	-0.53	-7.18	-0.42	8.26e-12	Red blood cell count;
KIRP	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-5.18	-0.31	4.6e-7	Obesity-related traits;
KIRP	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg14061069	chr19:46274453	DMPK	-0.37	-5.03	-0.31	9.53e-7	Coronary artery disease;
KIRP	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.97	0.3	1.28e-6	Lung cancer;
KIRP	cis	rs8033133	0.514	rs58498746	chr15:25294236	C/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.41	-4.98	-0.3	1.2e-6	Blood osmolality (transformed sodium);
KIRP	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-4.93	-0.3	1.53e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.08	-0.31	7.31e-7	Bipolar disorder;
KIRP	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10553204	chr2:20871195	GDF7	0.33	4.88	0.3	1.9e-6	Abdominal aortic aneurysm;
KIRP	cis	rs4356932	1.000	rs4619915	chr4:76955201	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.36	-0.59	2.49e-24	Monocyte count;
KIRP	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg23933602	chr10:16859644	RSU1	0.52	5.76	0.34	2.47e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg24315340	chr6:146058215	EPM2A	-0.46	-5.75	-0.34	2.59e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.48	6.09	0.36	4.41e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg17376030	chr22:41985996	PMM1	-0.53	-5.66	-0.34	4.13e-8	Vitiligo;
KIRP	cis	rs6707387	0.662	rs12694306	chr2:214403809	C/T	cg08319019	chr2:214017104	IKZF2	0.45	5.09	0.31	7.2e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	trans	rs10405744	0.744	rs8112652	chr19:20183808	G/A	cg15934607	chr13:114802548	RASA3	0.49	6.05	0.36	5.24e-9	Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio);
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg24972876	chr7:65420302	NA	0.36	4.87	0.3	1.96e-6	Aortic root size;
KIRP	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15557168	chr22:42548783	NA	-0.42	-5.73	-0.34	2.98e-8	Cognitive function;
KIRP	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg05692746	chr2:100937584	LONRF2	-0.41	-5.32	-0.32	2.31e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.13	-0.5	2.66e-17	Exhaled nitric oxide output;
KIRP	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.8	-5.0	-0.3	1.1e-6	LDL cholesterol levels;Total cholesterol levels;
KIRP	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg16141378	chr3:129829833	LOC729375	-0.48	-6.4	-0.38	7.97e-10	Neuroticism;
KIRP	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.87	13.21	0.64	1.86e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Bladder cancer;
KIRP	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.29	6.94	0.4	3.38e-11	IgG glycosylation;
KIRP	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg00277334	chr10:82204260	NA	0.59	5.41	0.33	1.52e-7	Post bronchodilator FEV1;
KIRP	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg00262122	chr8:11665843	FDFT1	-0.44	-5.4	-0.33	1.6e-7	Retinal vascular caliber;
KIRP	cis	rs7027203	0.576	rs7865043	chr9:96549004	G/T	cg14598338	chr9:96623480	NA	0.48	7.45	0.43	1.61e-12	DNA methylation (variation);
KIRP	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs2795502	0.554	rs1620395	chr10:43341185	G/A	cg20628663	chr10:43360327	NA	-0.47	-6.0	-0.36	6.91e-9	Blood protein levels;
KIRP	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.36	0.32	1.93e-7	Initial pursuit acceleration;
KIRP	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.14	-0.36	3.35e-9	Triglycerides;
KIRP	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg18357526	chr6:26021779	HIST1H4A	0.44	5.78	0.35	2.22e-8	Height;
KIRP	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg20991723	chr1:152506922	NA	-0.46	-5.52	-0.33	8.46e-8	Hair morphology;
KIRP	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.86	9.02	0.5	5.44e-17	Methadone dose in opioid dependence;
KIRP	trans	rs7178375	1.000	rs28881289	chr15:31223955	A/G	cg04373760	chr16:53404718	NA	0.64	7.17	0.42	8.99e-12	Hypertriglyceridemia;
KIRP	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg11062466	chr8:58055876	NA	0.51	4.9	0.3	1.73e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.91	0.3	1.65e-6	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.5	-6.45	-0.38	6.04e-10	Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06710522	chr17:45908972	MRPL10;LRRC46	0.48	6.47	0.38	5.14e-10	Survival in pancreatic cancer;
KIRP	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg22676075	chr6:135203613	NA	-0.61	-8.15	-0.46	1.86e-14	Red blood cell count;
KIRP	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	cg21523751	chr1:182988639	NA	0.36	5.09	0.31	7.19e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs12210905	1.000	rs12210905	chr6:27151309	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.73	-0.39	1.16e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	1.06	15.4	0.7	6.36e-38	Cognitive function;
KIRP	cis	rs7224685	0.569	rs8082227	chr17:3991563	C/T	cg05562828	chr17:3906858	NA	0.57	5.82	0.35	1.87e-8	Type 2 diabetes;
KIRP	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg16497661	chr14:103986332	CKB	0.39	5.09	0.31	7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.93	15.27	0.7	1.76e-37	Height;
KIRP	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	4.91	0.3	1.68e-6	Cystic fibrosis severity;
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg03929089	chr4:120376271	NA	0.69	6.16	0.37	3.01e-9	Axial length;
KIRP	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs4400599	0.618	rs4845610	chr1:154205428	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.96	-0.35	8.89e-9	Platelet distribution width;
KIRP	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06481639	chr22:41940642	POLR3H	0.43	5.1	0.31	6.63e-7	Vitiligo;
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.75	11.8	0.6	9.32e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.24	0.42	5.71e-12	Mean platelet volume;
KIRP	cis	rs1850744	0.826	rs7661082	chr4:9755665	C/G	cg15442990	chr4:9534313	NA	0.79	5.1	0.31	6.9e-7	Economic and political preferences;
KIRP	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg25706552	chr1:244017396	NA	0.55	6.7	0.39	1.42e-10	RR interval (heart rate);
KIRP	cis	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.1	-0.5	3.09e-17	Mood instability;
KIRP	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg05315796	chr3:52349193	DNAH1	0.4	5.26	0.32	3.17e-7	Schizophrenia;
KIRP	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg19468946	chr17:37922297	IKZF3	-0.43	-5.81	-0.35	1.9e-8	Asthma;
KIRP	trans	rs936674	1.000	rs936673	chr15:93903034	C/G	cg14187895	chr17:37843818	ERBB2;PGAP3	-0.68	-6.11	-0.36	3.87e-9	Body mass index;
KIRP	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.25	-0.32	3.32e-7	Colorectal cancer;
KIRP	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg02696790	chr15:75250997	RPP25	0.32	5.48	0.33	1.05e-7	Breast cancer;
KIRP	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.21e-16	Motion sickness;
KIRP	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	0.96	12.26	0.62	2.71e-27	Blood protein levels;
KIRP	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg11569703	chr11:65557185	OVOL1	0.42	7.22	0.42	6.51e-12	Systemic lupus erythematosus;
KIRP	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg25174290	chr11:3078921	CARS	-0.65	-8.19	-0.46	1.39e-14	Calcium levels;
KIRP	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.71	8.69	0.48	5.34e-16	Type 2 diabetes;
KIRP	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg16586182	chr3:47516702	SCAP	0.82	11.67	0.6	2.5e-25	Colorectal cancer;
KIRP	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg09408571	chr1:101003634	GPR88	0.24	5.38	0.32	1.69e-7	Monocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03940137	chr1:200708937	CAMSAP1L1	0.47	6.56	0.39	3.11e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2554380	0.628	rs2401131	chr15:84470896	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.32	-4.96	-0.3	1.34e-6	Height;
KIRP	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-11.69	-0.6	2.16e-25	Monocyte percentage of white cells;
KIRP	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.72	6.2	0.37	2.35e-9	RR interval (heart rate);
KIRP	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.72	9.27	0.51	1.01e-17	Coronary artery disease;
KIRP	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.5	-6.28	-0.37	1.49e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.55	7.91	0.45	8.93e-14	Uric acid levels;
KIRP	cis	rs1712517	0.873	rs1891292	chr10:105001510	A/G	cg05636881	chr10:105038444	INA	-0.41	-6.08	-0.36	4.46e-9	Migraine;
KIRP	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.07	0.67	2.12e-33	Tonsillectomy;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.39	-0.33	1.65e-7	Lymphocyte counts;
KIRP	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.98	10.93	0.57	6.34e-23	HIV-1 control;
KIRP	cis	rs2970992	0.764	rs3112257	chr2:101326877	G/T	cg01042948	chr2:101319752	NA	0.42	5.98	0.36	7.73e-9	Educational attainment;
KIRP	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg18016565	chr1:150552671	MCL1	0.39	6.06	0.36	5.03e-9	Melanoma;
KIRP	cis	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg01181863	chr3:195395398	SDHAP2	-0.45	-4.97	-0.3	1.24e-6	Pancreatic cancer;
KIRP	cis	rs231513	0.911	rs124721	chr17:41959808	T/C	cg26893861	chr17:41843967	DUSP3	-0.58	-5.06	-0.31	8.04e-7	Cognitive function;
KIRP	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-7.19	-0.42	7.64e-12	Vitiligo;
KIRP	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg02640540	chr1:67518911	SLC35D1	0.49	4.89	0.3	1.83e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg15896084	chr13:114927664	NA	0.44	5.65	0.34	4.45e-8	Schizophrenia;
KIRP	cis	rs45544231	0.544	rs7193453	chr16:52565150	C/T	cg09051775	chr16:52580266	TOX3	-0.38	-5.22	-0.32	3.76e-7	Restless legs syndrome;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg24801244	chr19:58774332	ZNF544	-0.54	-6.92	-0.4	3.85e-11	Inflammatory biomarkers;
KIRP	cis	rs61542988	0.570	rs62448267	chr7:22822501	T/C	cg11367502	chr7:22862612	TOMM7	0.51	5.27	0.32	3.01e-7	Fibrinogen levels;
KIRP	cis	rs490234	0.783	rs13283793	chr9:128441641	C/T	cg14078157	chr9:128172775	NA	-0.45	-5.58	-0.34	6.24e-8	Mean arterial pressure;
KIRP	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.64	-6.83	-0.4	6.75e-11	Bipolar disorder;
KIRP	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-6.74	-0.39	1.09e-10	HDL cholesterol;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-0.82	-14.9	-0.69	3.28e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg18306943	chr3:40428807	ENTPD3	0.46	6.31	0.37	1.32e-9	Renal cell carcinoma;
KIRP	cis	rs6684428	0.706	rs12118218	chr1:56320445	C/T	cg11651538	chr1:56320950	NA	-0.85	-11.73	-0.6	1.55e-25	Airflow obstruction;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18693528	chr14:32668091	NA	0.44	7.06	0.41	1.7e-11	C-reactive protein;
KIRP	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg04990556	chr1:26633338	UBXN11	-0.6	-7.42	-0.43	1.95e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.93	13.95	0.66	5.46e-33	Response to bleomycin (chromatid breaks);
KIRP	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.54	7.39	0.43	2.26e-12	Mean corpuscular volume;
KIRP	cis	rs4794202	0.534	rs8078688	chr17:45919869	T/C	cg02219949	chr17:45927392	SP6	0.61	7.17	0.42	8.49e-12	Alzheimer's disease (cognitive decline);
KIRP	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg16141378	chr3:129829833	LOC729375	0.52	6.33	0.37	1.14e-9	Systolic blood pressure;
KIRP	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg21161173	chr5:140098174	VTRNA1-2	0.4	5.15	0.31	5.45e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2434422	0.708	rs7253555	chr19:52840032	G/T	cg17271561	chr19:52839334	ZNF610	-0.81	-6.18	-0.37	2.71e-9	Cannabis use (initiation);
KIRP	cis	rs231513	0.911	rs124719	chr17:41960343	T/C	cg26893861	chr17:41843967	DUSP3	-0.48	-4.93	-0.3	1.54e-6	Cognitive function;
KIRP	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg11859384	chr17:80120422	CCDC57	0.45	5.98	0.36	8e-9	Life satisfaction;
KIRP	cis	rs11622475	0.626	rs34533310	chr14:104352233	C/T	cg20488157	chr14:104394430	TDRD9	0.48	6.42	0.38	6.8e-10	Bipolar disorder;
KIRP	cis	rs4950322	0.543	rs4453096	chr1:146788287	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg22903471	chr2:27725779	GCKR	0.36	5.01	0.3	1.05e-6	Oral cavity cancer;
KIRP	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg16083429	chr3:49237500	CCDC36	0.38	4.87	0.3	2.04e-6	Menarche (age at onset);
KIRP	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23308107	chr11:47429939	SLC39A13	-0.47	-6.3	-0.37	1.36e-9	Metabolic traits;
KIRP	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.81	-11.33	-0.59	3.15e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.32	4.92	0.3	1.58e-6	Asthma;
KIRP	cis	rs7289126	0.966	rs2267380	chr22:38631768	T/C	cg25457927	chr22:38595422	NA	-0.31	-6.91	-0.4	4.08e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs2084898	0.527	rs561498	chr11:120002927	C/T	cg24611264	chr11:120008944	TRIM29	-0.31	-5.56	-0.33	7.16e-8	Stroke (pediatric);
KIRP	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg02775129	chr4:119771670	NA	-0.9	-5.53	-0.33	8.05e-8	Cannabis dependence symptom count;
KIRP	cis	rs6893300	0.785	rs55654737	chr5:179218842	G/A	cg14593053	chr5:179126677	CANX	-0.6	-7.3	-0.42	4e-12	Resting heart rate;
KIRP	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.49	-5.3	-0.32	2.62e-7	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	1.1	17.84	0.75	3.08e-46	Cognitive function;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.75	-10.78	-0.57	1.86e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6740322	0.643	rs13390381	chr2:43534414	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.93	-0.45	7.66e-14	Coronary artery disease;
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg23034840	chr1:205782522	SLC41A1	0.58	7.65	0.44	4.66e-13	Menarche (age at onset);
KIRP	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg00405596	chr8:11794950	NA	0.39	5.02	0.3	9.84e-7	Retinal vascular caliber;
KIRP	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.33	5.28	0.32	2.86e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27297192	chr10:134578999	INPP5A	0.65	8.13	0.46	2.12e-14	Migraine;
KIRP	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg01403660	chr11:68851641	TPCN2	0.69	6.79	0.4	8.47e-11	Blond vs. brown hair color;
KIRP	cis	rs4787491	0.765	rs8054507	chr16:30046042	G/A	cg06326092	chr16:30034487	C16orf92	0.5	7.82	0.45	1.5700000000000001e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.68e-36	Prostate cancer;
KIRP	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	7.05	0.41	1.78e-11	Retinal vascular caliber;
KIRP	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9309473	0.500	rs2421668	chr2:73885096	G/A	cg20560298	chr2:73613845	ALMS1	0.46	5.78	0.35	2.27e-8	Metabolite levels;
KIRP	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs5753618	0.561	rs2283879	chr22:31638448	G/A	cg02404636	chr22:31891804	SFI1	-0.47	-5.22	-0.32	3.77e-7	Colorectal cancer;
KIRP	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.53	8.03	0.46	4.14e-14	Itch intensity from mosquito bite;
KIRP	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg06121193	chr1:90282411	NA	0.52	7.29	0.42	4.3e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.6	-5.81	-0.35	1.97e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg26587870	chr6:27730563	NA	-0.66	-5.0	-0.3	1.09e-6	Depression;
KIRP	cis	rs11581903	0.568	rs7537727	chr1:53090345	A/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.75	5.92	0.35	1.07e-8	Joint mobility (Beighton score);
KIRP	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.56	6.25	0.37	1.82e-9	Diisocyanate-induced asthma;
KIRP	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg21926883	chr2:100939477	LONRF2	-0.65	-8.87	-0.49	1.52e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.96	12.94	0.64	1.45e-29	Menopause (age at onset);
KIRP	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	7.11	0.41	1.25e-11	Iron status biomarkers;
KIRP	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.91	10.73	0.56	2.8e-22	Menarche (age at onset);
KIRP	cis	rs6545883	0.929	rs1186700	chr2:61663372	A/C	cg15711740	chr2:61764176	XPO1	-0.61	-8.01	-0.45	4.63e-14	Tuberculosis;
KIRP	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06481639	chr22:41940642	POLR3H	-0.67	-7.48	-0.43	1.32e-12	Vitiligo;
KIRP	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-5.34	-0.32	2.15e-7	Total body bone mineral density;
KIRP	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.5	-0.38	4.37e-10	Lung cancer;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg12486944	chr17:80159399	CCDC57	-0.41	-5.69	-0.34	3.57e-8	Life satisfaction;
KIRP	cis	rs6882046	0.513	rs601942	chr5:88031820	T/C	cg24804195	chr5:87968844	LOC645323	-0.45	-5.94	-0.35	9.67e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs2479106	0.791	rs12237685	chr9:126689557	T/C	cg16191174	chr9:126692580	DENND1A	0.57	6.99	0.41	2.52e-11	Polycystic ovary syndrome;
KIRP	cis	rs7572644	0.699	rs7595986	chr2:28085311	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-5.39	-0.33	1.61e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs4950322	0.518	rs72692968	chr1:146804615	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg13332499	chr17:408570	NA	0.59	8.12	0.46	2.19e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs2882667	0.788	rs11959691	chr5:138481088	C/T	cg04439458	chr5:138467593	SIL1	-0.53	-7.88	-0.45	1.02e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.57	6.93	0.4	3.7e-11	Breast cancer;
KIRP	trans	rs9558996	0.785	rs9558983	chr13:107919281	G/A	cg20062893	chr1:68628444	GPR177	0.46	6.02	0.36	6.34e-9	Carboplatin disposition in epthelial ovarian cancer;
KIRP	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg10760299	chr15:45669010	GATM	0.35	5.11	0.31	6.55e-7	Homoarginine levels;
KIRP	cis	rs1359582	0.958	rs1409133	chr10:90319212	T/C	cg15661332	chr10:90342814	RNLS	0.57	5.51	0.33	9.2e-8	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs9309473	1.000	rs10175180	chr2:73673123	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.79	-0.35	2.13e-8	Metabolite levels;
KIRP	cis	rs9329221	0.636	rs6999466	chr8:10265712	A/G	cg27411982	chr8:10470053	RP1L1	0.39	4.97	0.3	1.27e-6	Neuroticism;
KIRP	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.07	-0.46	3.07e-14	Joint mobility (Beighton score);
KIRP	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg18154014	chr19:37997991	ZNF793	-0.7	-7.94	-0.45	7.27e-14	Coronary artery calcification;
KIRP	trans	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg10756647	chr7:56101905	PSPH	-0.99	-7.11	-0.41	1.22e-11	Diabetic kidney disease;
KIRP	cis	rs34421088	0.560	rs11780851	chr8:11401116	G/A	cg00405596	chr8:11794950	NA	-0.48	-5.88	-0.35	1.34e-8	Neuroticism;
KIRP	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg20302533	chr7:39170763	POU6F2	-0.28	-5.89	-0.35	1.24e-8	IgG glycosylation;
KIRP	cis	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg27411982	chr8:10470053	RP1L1	-0.49	-6.0	-0.36	6.95e-9	Neuroticism;
KIRP	cis	rs9290877	0.667	rs7356022	chr3:188459669	C/T	cg17392043	chr3:188495102	LPP	-0.49	-6.34	-0.37	1.1e-9	IgE levels;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17203840	chr5:134209212	TXNDC15	0.54	6.38	0.38	8.73e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7747724	1.000	rs4644038	chr6:20749677	G/A	cg25235770	chr12:63254420	PPM1H	0.45	6.09	0.36	4.39e-9	Bladder cancer;
KIRP	cis	rs77372450	0.636	rs6890471	chr5:157024032	C/T	cg23851860	chr5:157002805	ADAM19	0.43	4.91	0.3	1.69e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs742614	0.533	rs2747541	chr20:32418772	G/T	cg06304546	chr20:32448765	NA	-0.78	-11.97	-0.61	2.45e-26	Stearic acid (18:0) levels;
KIRP	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg12560992	chr17:57184187	TRIM37	0.61	5.62	0.34	5.09e-8	Cognitive test performance;
KIRP	trans	rs2945733	1.000	rs2922445	chr8:134608745	T/G	cg01793161	chr3:69974592	MITF	-0.71	-6.02	-0.36	6.3e-9	Intraocular pressure;
KIRP	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.82	-12.99	-0.64	9.66e-30	Blood metabolite levels;
KIRP	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg05914723	chr15:78953907	NA	0.46	5.46	0.33	1.14e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.45	9.98	0.54	6.33e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg03342759	chr3:160939853	NMD3	0.42	5.1	0.31	6.79e-7	Morning vs. evening chronotype;
KIRP	cis	rs812925	0.519	rs10199672	chr2:61627634	T/G	cg15711740	chr2:61764176	XPO1	0.47	5.93	0.35	1.04e-8	Immature fraction of reticulocytes;
KIRP	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg12861170	chr19:19639553	YJEFN3	-0.45	-4.99	-0.3	1.14e-6	Bipolar disorder;
KIRP	cis	rs76288851	0.778	rs9840115	chr3:126751478	C/T	cg00307254	chr3:126706825	PLXNA1	-0.47	-5.41	-0.33	1.48e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs997295	0.966	rs3784692	chr15:67988133	C/T	cg14210607	chr15:68128175	NA	-0.31	-5.11	-0.31	6.51e-7	Motion sickness;
KIRP	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg19539972	chr4:7069911	GRPEL1	0.84	9.43	0.52	3.14e-18	Monocyte percentage of white cells;
KIRP	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg18164611	chr1:46958628	NA	0.39	5.06	0.31	8.37e-7	Monobrow;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg02570527	chr1:10970165	NA	-0.42	-5.12	-0.31	6.11e-7	Body mass index;
KIRP	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg19913688	chr11:428466	ANO9	-0.69	-5.15	-0.31	5.29e-7	Body mass index;
KIRP	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg18016565	chr1:150552671	MCL1	-0.34	-5.04	-0.31	8.87e-7	Monocyte chemoattractant protein-1 levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25075015	chr11:40138552	LRRC4C	-0.38	-6.03	-0.36	6.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg25486957	chr4:152246857	NA	-0.43	-5.16	-0.31	5.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-5.32	-0.32	2.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	cis	rs8060686	0.920	rs73591961	chr16:67801309	G/A	cg04539111	chr16:67997858	SLC12A4	-0.61	-6.01	-0.36	6.64e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	1.04	10.59	0.56	7.84e-22	Blood protein levels;
KIRP	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg26207909	chr14:103986467	CKB	-0.44	-5.38	-0.32	1.73e-7	Coronary artery disease;
KIRP	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.49	4.94e-16	Retinal vascular caliber;
KIRP	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.45	5.04	0.31	9.12e-7	Osteoporosis;
KIRP	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.97	10.42	0.55	2.76e-21	Blood protein levels;
KIRP	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg01631684	chr10:65280961	REEP3	-0.49	-5.72	-0.34	3.01e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.86	-12.73	-0.63	7.63e-29	Colorectal cancer;
KIRP	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.41	-0.38	7.28e-10	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg21844472	chr3:160559936	PPM1L	0.9	6.05	0.36	5.38e-9	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.74	9.96	0.54	7.42e-20	Breast cancer;
KIRP	cis	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-5.43	-0.33	1.33e-7	HDL cholesterol;
KIRP	cis	rs10858047	0.883	rs6691804	chr1:115193549	T/C	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.61	-7.01	-0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs3026101	0.671	rs2301738	chr17:5308279	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.65	0.39	1.84e-10	Body mass index;
KIRP	cis	rs1823913	0.561	rs60479498	chr2:192139923	C/A	cg12404831	chr2:192114017	MYO1B	0.53	7.41	0.43	2.02e-12	Obesity-related traits;
KIRP	cis	rs6708331	0.715	rs11899723	chr2:70196019	G/A	cg05298696	chr2:70188691	ASPRV1	-0.41	-5.07	-0.31	7.87e-7	Obesity-related traits;
KIRP	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-0.8	-10.15	-0.54	1.88e-20	Blood trace element (Zn levels);
KIRP	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.53	-7.38	-0.43	2.46e-12	Prostate cancer;
KIRP	cis	rs2916247	1.000	rs36005889	chr8:93058638	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1318772	1.000	rs13189851	chr5:112592294	A/G	cg12552261	chr5:112820674	MCC	0.8	5.03	0.31	9.52e-7	F-cell distribution;
KIRP	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.51	6.78	0.4	8.87e-11	Childhood ear infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15612392	chr12:74931289	LOC552889	0.48	6.86	0.4	5.67e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.49	2.6e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	8.19	0.46	1.39e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	11.23	0.58	6.55e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg17595323	chr11:93583763	C11orf90	-0.41	-6.79	-0.4	8.59e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg13256891	chr4:100009986	ADH5	0.49	5.98	0.36	7.82e-9	Alcohol dependence;
KIRP	cis	rs6840360	0.573	rs11099807	chr4:152269228	C/T	cg25486957	chr4:152246857	NA	-0.44	-5.57	-0.33	6.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7084402	0.967	rs11815274	chr10:60328891	A/G	cg05938607	chr10:60274200	BICC1	0.44	10.32	0.55	5.51e-21	Refractive error;
KIRP	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.46	-8.59	-0.48	1.01e-15	Superior crus of antihelix expression;
KIRP	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.55	-7.63	-0.44	5.02e-13	Height;
KIRP	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg10755058	chr3:40428713	ENTPD3	0.48	6.6	0.39	2.52e-10	Renal cell carcinoma;
KIRP	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-5.7	-0.34	3.43e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00149659	chr3:10157352	C3orf10	0.83	9.09	0.5	3.4e-17	Alzheimer's disease;
KIRP	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.5	7.12	0.41	1.18e-11	Endometrial cancer;
KIRP	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.45	-5.52	-0.33	8.8e-8	Tuberculosis;
KIRP	cis	rs9409565	0.826	rs9409556	chr9:97239268	T/C	cg04523069	chr9:97136363	HIATL1	0.48	6.37	0.38	9.14e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.72	8.8	0.49	2.43e-16	Monocyte count;
KIRP	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg07511934	chr16:89386912	ANKRD11	0.39	5.03	0.31	9.36e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg21294424	chr19:58662284	ZNF329	0.63	5.85	0.35	1.55e-8	Cholesterol, total;
KIRP	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.77	-9.63	-0.52	7.7e-19	Height;
KIRP	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	1.03	13.24	0.65	1.42e-30	Exhaled nitric oxide output;
KIRP	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19346786	chr7:2764209	NA	-0.4	-6.62	-0.39	2.25e-10	Height;
KIRP	cis	rs3741151	1.000	rs7930880	chr11:73068769	A/C	cg17517138	chr11:73019481	ARHGEF17	0.67	6.22	0.37	2.08e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.38	-0.38	8.61e-10	Response to antipsychotic treatment;
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27144592	chr16:783916	NARFL	0.36	4.97	0.3	1.24e-6	Height;
KIRP	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg20243544	chr17:37824526	PNMT	0.38	4.91	0.3	1.69e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg13264159	chr8:625131	ERICH1	-0.83	-6.68	-0.39	1.58e-10	IgG glycosylation;
KIRP	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.52e-7	Tonsillectomy;
KIRP	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.6	9.74	0.53	3.48e-19	Total body bone mineral density;
KIRP	trans	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-6.83	-0.4	6.59e-11	Mean corpuscular volume;
KIRP	cis	rs10982213	1.000	rs10982213	chr9:117189193	C/T	cg00969271	chr9:117093052	ORM2	0.46	4.93	0.3	1.48e-6	Interleukin-6 levels;
KIRP	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.55	10.02	0.54	4.76e-20	Iron status biomarkers (transferrin levels);
KIRP	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.21	-0.37	2.27e-9	Retinal vascular caliber;
KIRP	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.45	5.07	0.31	7.79e-7	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg10760299	chr15:45669010	GATM	0.35	5.02	0.3	9.88e-7	Homoarginine levels;
KIRP	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg12501888	chr15:85177176	SCAND2	-0.4	-4.99	-0.3	1.15e-6	P wave terminal force;
KIRP	trans	rs10911902	0.602	rs3736595	chr1:186300877	C/T	cg04055345	chr10:116264862	ABLIM1	0.47	6.02	0.36	6.25e-9	Schizophrenia;
KIRP	cis	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg19202786	chr6:166797286	BRP44L	0.42	5.22	0.32	3.78e-7	Asthma;
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.75	-10.99	-0.57	3.95e-23	Paraoxonase activity;
KIRP	cis	rs2400749	0.830	rs4905856	chr14:100032256	G/A	cg19965031	chr14:100038389	CCDC85C	-0.43	-5.3	-0.32	2.6e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7267005	0.661	rs17093095	chr20:34381123	G/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-6.01	-0.36	6.56e-9	Alzheimer's disease (late onset);
KIRP	cis	rs4664304	0.620	rs55664214	chr2:160708059	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.9	-0.35	1.18e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg13482628	chr17:19912719	NA	0.53	6.91	0.4	4.08e-11	Schizophrenia;
KIRP	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.85	0.4	5.8200000000000003e-11	Mean platelet volume;
KIRP	cis	rs6142102	0.961	rs8119937	chr20:32645551	C/T	cg08999081	chr20:33150536	PIGU	0.54	6.98	0.41	2.75e-11	Skin pigmentation;
KIRP	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg05535760	chr7:792225	HEATR2	-0.43	-4.92	-0.3	1.55e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs6988636	0.818	rs62521808	chr8:124169568	C/T	cg15893493	chr8:124194847	FAM83A	0.93	6.57	0.39	2.91e-10	Urinary uromodulin levels;
KIRP	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg27147174	chr7:100797783	AP1S1	-0.59	-7.4	-0.43	2.1e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21952419	chr13:52027225	INTS6	0.46	6.11	0.36	3.88e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.72	-9.1	-0.5	3.07e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg11005552	chr10:105648138	OBFC1	0.41	5.85	0.35	1.57e-8	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01870679	chr19:19903883	ZNF506	-0.41	-6.12	-0.36	3.72e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.57	-6.07	-0.36	4.9e-9	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	15.9	0.71	1.22e-39	Homoarginine levels;
KIRP	cis	rs5167	0.504	rs7258345	chr19:45453151	T/G	cg20090143	chr19:45452003	APOC2	0.34	5.42	0.33	1.41e-7	Blood protein levels;
KIRP	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	1.07	20.14	0.79	5.88e-54	Platelet distribution width;
KIRP	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2384207	0.584	rs67591431	chr12:113766317	T/G	cg13296563	chr12:112847257	RPL6	-0.6	-4.92	-0.3	1.61e-6	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs3822411	0.541	rs2930057	chr5:10742128	T/C	cg14521931	chr5:10832172	NA	0.52	6.45	0.38	5.81e-10	Sum eosinophil basophil counts;
KIRP	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-7.12	-0.41	1.19e-11	Morning vs. evening chronotype;
KIRP	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.46	0.47	2.47e-15	Neuroticism;
KIRP	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.41	6.35	0.38	1.05e-9	Neuroticism;
KIRP	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg13611997	chr5:233750	SDHA	-0.41	-4.87	-0.3	2.01e-6	Breast cancer;
KIRP	trans	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08382705	chr11:45687319	CHST1	-0.51	-6.28	-0.37	1.53e-9	Height;
KIRP	cis	rs9921338	0.961	rs7206749	chr16:11376922	T/C	cg00044050	chr16:11439710	C16orf75	-0.49	-5.03	-0.31	9.54e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03777405	chr17:46125833	NFE2L1	-0.48	-6.29	-0.37	1.47e-9	Myopia;
KIRP	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg18527119	chr7:66119851	NA	-0.45	-4.92	-0.3	1.59e-6	Aortic root size;
KIRP	cis	rs8523	0.697	rs57549068	chr6:11059210	T/C	cg13562911	chr6:11044106	ELOVL2	0.41	5.43	0.33	1.32e-7	Red blood cell fatty acid levels;
KIRP	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.64	-8.23	-0.46	1.12e-14	Glomerular filtration rate;
KIRP	cis	rs12044355	0.929	rs6696914	chr1:231853480	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	4.96	0.3	1.33e-6	Alzheimer's disease;
KIRP	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.42	5.6	0.34	5.57e-8	Immature fraction of reticulocytes;
KIRP	trans	rs4809760	0.737	rs17786105	chr20:48466885	A/G	cg08479635	chr11:45114570	PRDM11	-0.38	-6.11	-0.36	3.87e-9	Gut microbiota (beta diversity);
KIRP	cis	rs644148	0.738	rs2686768	chr19:44995990	C/T	cg15540054	chr19:45004280	ZNF180	-0.52	-5.97	-0.36	8.08e-9	Personality dimensions;
KIRP	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.2	0.46	1.3e-14	IgG glycosylation;
KIRP	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg21174375	chr14:64681225	SYNE2	-0.59	-6.95	-0.4	3.34e-11	Atrial fibrillation;
KIRP	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	ch.11.340609R	chr11:12831013	TEAD1	-0.45	-5.53	-0.33	8.04e-8	Educational attainment (years of education);
KIRP	cis	rs4262150	0.810	rs113759615	chr5:151953062	G/A	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.33e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs738321	0.756	rs11570745	chr22:38513493	C/T	cg25457927	chr22:38595422	NA	-0.28	-5.43	-0.33	1.34e-7	Breast cancer;
KIRP	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.56	-7.53	-0.43	9.82e-13	Total body bone mineral density;
KIRP	cis	rs8077577	0.708	rs7211573	chr17:18131613	T/C	cg18869244	chr17:18121946	NA	-0.49	-5.46	-0.33	1.18e-7	Obesity-related traits;
KIRP	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg20387954	chr3:183756860	HTR3D	-0.63	-9.47	-0.52	2.41e-18	Anterior chamber depth;
KIRP	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.37	-0.32	1.8e-7	Colorectal cancer;
KIRP	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg27165867	chr14:105738592	BRF1	-0.42	-4.96	-0.3	1.35e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-1.08	-14.73	-0.68	1.23e-35	Alopecia areata;
KIRP	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.22	-0.42	6.57e-12	Neuroticism;
KIRP	cis	rs10073892	0.879	rs10067990	chr5:101688219	T/C	cg19774478	chr5:101632501	SLCO4C1	0.65	6.7	0.39	1.41e-10	Cognitive decline (age-related);
KIRP	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.58	-7.18	-0.42	8.13e-12	Iron status biomarkers;
KIRP	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.12	-0.41	1.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg10818794	chr15:86012489	AKAP13	-0.49	-6.98	-0.41	2.8e-11	Coronary artery disease;
KIRP	cis	rs6142102	0.602	rs932388	chr20:32657378	C/T	cg08999081	chr20:33150536	PIGU	0.38	4.95	0.3	1.36e-6	Skin pigmentation;
KIRP	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.71	-9.59	-0.52	1.01e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.96	-7.03	-0.41	2.05e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	1.09	8.9	0.49	1.26e-16	Plasma clusterin levels;
KIRP	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg08975724	chr8:8085496	FLJ10661	0.66	8.64	0.48	7.34e-16	Systolic blood pressure;
KIRP	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	1.04	11.27	0.58	4.88e-24	Alzheimer's disease;
KIRP	cis	rs4523957	0.583	rs923864	chr17:2031507	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-12.77	-0.63	5.55e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.59	8.17	0.46	1.58e-14	Menarche (age at onset);
KIRP	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg07148914	chr20:33460835	GGT7	0.59	7.58	0.44	6.91e-13	Height;
KIRP	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.35	-0.62	1.41e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg04287289	chr16:89883240	FANCA	-0.42	-5.49	-0.33	1e-7	Vitiligo;
KIRP	cis	rs447921	0.861	rs62084971	chr17:74425318	T/G	cg16776035	chr17:74542680	NA	0.52	4.91	0.3	1.67e-6	Mitochondrial DNA levels;
KIRP	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg02487422	chr3:49467188	NICN1	0.37	5.12	0.31	6.18e-7	Parkinson's disease;
KIRP	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	1.01	10.68	0.56	3.86e-22	Height;
KIRP	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg16524936	chr4:1340807	KIAA1530	-0.43	-5.11	-0.31	6.52e-7	Obesity-related traits;
KIRP	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	9.6	0.52	9.97e-19	Body mass index;
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.8	7.63	0.44	5.09e-13	Lung function (FEV1/FVC);
KIRP	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.45	-0.38	6.05e-10	Vitiligo;
KIRP	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg23594656	chr7:65796392	TPST1	0.35	5.06	0.31	8.17e-7	Aortic root size;
KIRP	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg06483076	chr3:194406458	FAM43A	0.43	6.33	0.37	1.14e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg26043149	chr18:55253948	FECH	-0.63	-6.89	-0.4	4.77e-11	Gout;Urate levels;Serum uric acid levels;
KIRP	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.85	-11.82	-0.6	7.99e-26	Coronary artery disease;
KIRP	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg19052272	chr2:3704530	ALLC	0.37	5.22	0.32	3.83e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg06223162	chr1:101003688	GPR88	0.35	7.36	0.42	2.82e-12	Monocyte count;
KIRP	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-6.71	-0.39	1.3e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg07689907	chr11:61582574	FADS1	0.58	7.11	0.41	1.24e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-10.81	-0.57	1.59e-22	Colorectal cancer;
KIRP	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.29	-7.77	-0.44	2.1e-13	Crohn's disease;
KIRP	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.67	-10.36	-0.55	4.16e-21	Hepatocellular carcinoma;
KIRP	cis	rs7119038	0.686	rs55894437	chr11:118607417	C/T	cg19308663	chr11:118741387	NA	0.5	7.97	0.45	5.76e-14	Sjögren's syndrome;
KIRP	cis	rs10225163	0.590	rs10266923	chr7:27918229	C/T	cg22168087	chr7:27702803	HIBADH	-0.36	-4.95	-0.3	1.36e-6	Gout;
KIRP	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25517755	chr10:38738941	LOC399744	-0.52	-7.18	-0.42	8.46e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs67257959	0.708	rs10406406	chr19:17198073	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	5.81	0.35	1.97e-8	Selective IgA deficiency;
KIRP	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg05220968	chr6:146057943	EPM2A	0.4	5.12	0.31	6.17e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4262150	0.883	rs12652844	chr5:152315418	T/C	cg12297329	chr5:152029980	NA	-0.66	-8.65	-0.48	6.59e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.26	-0.32	3.19e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12826209	chr6:26865740	GUSBL1	0.48	6.06	0.36	5.04e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	0.812	rs73079360	chr3:41888372	T/A	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.71	7.14	0.41	1.04e-11	Chronic kidney disease;
KIRP	trans	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg10756647	chr7:56101905	PSPH	0.92	6.84	0.4	6.07e-11	Diabetic kidney disease;
KIRP	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.63	-0.48	7.84e-16	Triglycerides;
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.24	-0.51	1.24e-17	Platelet count;
KIRP	cis	rs2717559	0.541	rs12549240	chr8:143881380	C/T	cg17252645	chr8:143867129	LY6D	-0.37	-5.84	-0.35	1.64e-8	Urinary tract infection frequency;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14293102	chr19:2232170	DOT1L	-0.5	-6.7	-0.39	1.37e-10	Inflammatory biomarkers;
KIRP	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.38	5.06	0.31	8.39e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg00981070	chr1:2046702	PRKCZ	-0.41	-6.85	-0.4	5.73e-11	Height;
KIRP	cis	rs9920	0.901	rs56014347	chr7:116166400	C/T	cg24770985	chr7:116166421	CAV1	0.75	5.03	0.31	9.67e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Immature fraction of reticulocytes;QT interval;
KIRP	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.04	-0.31	9.15e-7	Vitamin D levels;
KIRP	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg07843065	chr1:150265600	MRPS21	0.43	5.71	0.34	3.17e-8	Migraine;
KIRP	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg03714773	chr7:91764589	CYP51A1	0.37	5.49	0.33	1.01e-7	Breast cancer;
KIRP	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg15128208	chr22:42549153	NA	0.56	6.47	0.38	5.21e-10	Birth weight;
KIRP	cis	rs4936894	0.500	rs10790655	chr11:124109822	T/C	cg27160556	chr11:124181099	OR8D1	-0.46	-6.7	-0.39	1.37e-10	Aging (time to death);
KIRP	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg24565620	chr2:194026	NA	0.72	7.87	0.45	1.16e-13	Blood protein levels;
KIRP	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.37	-0.38	9.46e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg05717871	chr11:638507	DRD4	-0.38	-5.53	-0.33	8.12e-8	Systemic lupus erythematosus;
KIRP	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	cg07049167	chr1:166818506	POGK	0.56	6.08	0.36	4.45e-9	Refractive astigmatism;
KIRP	cis	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg26585981	chr11:48327164	OR4S1	-0.42	-5.47	-0.33	1.1e-7	HDL cholesterol;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs494562	0.667	rs494688	chr6:86100089	G/A	cg21730993	chr6:86159210	NT5E	0.6	5.84	0.35	1.67e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs4664293	0.967	rs7590607	chr2:160545635	T/C	cg08347373	chr2:160653686	CD302	-0.38	-5.79	-0.35	2.15e-8	Monocyte percentage of white cells;
KIRP	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg23736307	chr8:27182930	PTK2B	0.47	6.08	0.36	4.45e-9	Neuroticism;
KIRP	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg11234688	chr2:1609660	NA	0.61	5.41	0.33	1.46e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg26043149	chr18:55253948	FECH	0.5	6.1	0.36	4.06e-9	Bone mineral density;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg10254082	chr7:997346	NA	0.41	5.0	0.3	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2224391	0.554	rs928170	chr6:5255154	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.52	-0.38	4.06e-10	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13943141	chr9:93205862	NA	-0.46	-6.15	-0.37	3.12e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15174463	chr3:160118190	SMC4;IFT80	0.47	6.32	0.37	1.23e-9	Parkinson's disease;
KIRP	cis	rs3105593	1.000	rs3131577	chr15:50863516	G/A	cg05456662	chr15:50716270	USP8	0.39	4.9	0.3	1.78e-6	QT interval;
KIRP	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.62	-7.8	-0.45	1.79e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-6.59	-0.39	2.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.66	-9.14	-0.5	2.36e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.94	15.09	0.69	7.11e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2425143	1.000	rs73902914	chr20:34432882	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-4.99	-0.3	1.16e-6	Blood protein levels;
KIRP	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg00784671	chr22:46762841	CELSR1	-0.82	-8.14	-0.46	2.02e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	-0.45	-5.43	-0.33	1.35e-7	Resistin levels;
KIRP	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.92	-0.69	2.74e-36	Alzheimer's disease;
KIRP	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.5	6.74	0.4	1.09e-10	Menopause (age at onset);
KIRP	trans	rs10782582	0.758	rs1303870	chr1:76359535	G/T	cg10283277	chr11:111472630	SIK2	0.3	6.18	0.37	2.62e-9	Daytime sleep phenotypes;
KIRP	cis	rs4790312	0.819	rs4061659	chr17:1997444	C/G	cg24156229	chr17:1948635	NA	-0.46	-6.25	-0.37	1.82e-9	Left atrial antero-posterior diameter;
KIRP	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg02820040	chr2:241836501	C2orf54	-0.24	-5.2	-0.31	4.26e-7	Urinary metabolites;
KIRP	cis	rs8100891	0.614	rs6510243	chr19:32833671	A/G	cg16662424	chr19:32837316	ZNF507	-0.4	-4.86	-0.3	2.05e-6	Neuroticism;
KIRP	cis	rs4494114	1.000	rs9439081	chr1:39343012	A/G	cg25970120	chr1:39325951	RRAGC	-0.39	-5.0	-0.3	1.09e-6	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg05861140	chr6:150128134	PCMT1	-0.45	-6.23	-0.37	1.97e-9	Lung cancer;
KIRP	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.46	5.72	0.34	3.08e-8	Lung cancer;
KIRP	cis	rs138171347	1	rs138171347	chr17:5183203	AAAAT/A	cg27093376	chr17:5185073	RABEP1	0.34	5.38	0.32	1.78e-7	White blood cell count;
KIRP	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg16989719	chr2:238392110	NA	-0.53	-5.97	-0.36	8.37e-9	Prostate cancer;
KIRP	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-9.86	-0.53	1.48e-19	Dental caries;
KIRP	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg15660573	chr17:549704	VPS53	-0.84	-12.8	-0.63	4.16e-29	Prostate cancer;
KIRP	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg25110126	chr1:46999211	NA	-0.41	-5.04	-0.31	8.96e-7	Monobrow;
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.04	-0.36	5.66e-9	Lung cancer;
KIRP	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg10253484	chr15:75165896	SCAMP2	0.53	5.86	0.35	1.48e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg10047753	chr17:41438598	NA	1.13	17.78	0.75	4.96e-46	Menopause (age at onset);
KIRP	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.48	0.33	1.05e-7	Menopause (age at onset);
KIRP	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg15270235	chr3:195682595	NA	0.32	4.93	0.3	1.54e-6	Mean corpuscular volume;
KIRP	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.56	-7.29	-0.42	4.17e-12	Aortic root size;
KIRP	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.51	6.96	0.41	3.15e-11	Menopause (age at onset);
KIRP	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg05315796	chr3:52349193	DNAH1	0.39	6.35	0.38	1.02e-9	Bipolar disorder;
KIRP	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg21698718	chr17:80085957	CCDC57	-0.33	-4.85	-0.3	2.15e-6	Life satisfaction;
KIRP	cis	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg27411982	chr8:10470053	RP1L1	0.45	5.63	0.34	4.91e-8	Neuroticism;
KIRP	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17554472	chr22:41940697	POLR3H	-0.66	-6.76	-0.4	9.87e-11	Vitiligo;
KIRP	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26526719	chr5:1949144	NA	0.44	5.25	0.32	3.29e-7	Gut microbiome composition (winter);
KIRP	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.85	12.32	0.62	1.74e-27	Eye color traits;
KIRP	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg14558114	chr2:88469736	THNSL2	0.66	5.37	0.32	1.81e-7	Plasma clusterin levels;
KIRP	cis	rs7116495	0.609	rs2508860	chr11:71805052	C/T	cg10381502	chr11:71823885	C11orf51	1.12	7.31	0.42	3.65e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.37	0.51	4.99e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg04306507	chr14:55594613	LGALS3	0.53	8.37	0.47	4.49e-15	Protein biomarker;
KIRP	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06360820	chr2:242988706	NA	-0.85	-8.64	-0.48	7.07e-16	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg00629928	chr5:358741	AHRR	0.51	4.97	0.3	1.27e-6	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20974424	chr5:640382	CEP72	0.54	6.83	0.4	6.71e-11	Interleukin-4 levels;
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	11.76	0.6	1.26e-25	Platelet count;
KIRP	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs490234	0.702	rs12553311	chr9:128398996	T/C	cg14078157	chr9:128172775	NA	-0.62	-7.2	-0.42	7.16e-12	Mean arterial pressure;
KIRP	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg20673091	chr1:2541236	MMEL1	0.66	9.67	0.52	5.94e-19	Ulcerative colitis;
KIRP	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg21191810	chr6:118973309	C6orf204	0.4	5.67	0.34	3.94e-8	Electrocardiographic conduction measures;
KIRP	cis	rs11628318	0.851	rs4243735	chr14:103023574	T/C	cg01864069	chr14:103024347	NA	-1.01	-12.92	-0.64	1.67e-29	Platelet count;
KIRP	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.8	-0.4	7.74e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10484885	0.514	rs10944450	chr6:90228498	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.49	-5.03	-0.31	9.52e-7	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	1.07	21.34	0.81	6.82e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18357526	chr6:26021779	HIST1H4A	0.61	6.75	0.4	1.05e-10	Urate levels;
KIRP	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg04310649	chr10:35416472	CREM	-0.57	-7.04	-0.41	1.91e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3737883	1.000	rs2275354	chr1:203036757	T/C	cg03900565	chr1:203031815	PPFIA4	0.41	5.99	0.36	7.35e-9	Early onset atrial fibrillation;
KIRP	trans	rs1977584	0.667	rs73277463	chr10:45405309	A/G	cg26279152	chr13:20356101	PSPC1	-0.77	-6.08	-0.36	4.65e-9	Selective IgA deficiency;
KIRP	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9584850	0.834	rs745639	chr13:99119279	C/T	cg20750642	chr13:99100586	FARP1	-0.49	-5.83	-0.35	1.69e-8	Neuroticism;
KIRP	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-4.96	-0.3	1.3e-6	Aortic root size;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10660249	chr9:5833007	ERMP1	0.59	6.58	0.39	2.81e-10	Lung cancer in ever smokers;
KIRP	cis	rs6681460	0.932	rs602513	chr1:67177270	G/A	cg13052034	chr1:66999238	SGIP1	0.38	5.21	0.32	3.92e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg04310649	chr10:35416472	CREM	-0.53	-5.97	-0.36	8.41e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs62056376	0.736	rs758293	chr17:32640523	A/T	cg09712683	chr2:95692352	MAL	0.47	6.36	0.38	9.51e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs3741151	0.686	rs12277924	chr11:73219678	T/C	cg17517138	chr11:73019481	ARHGEF17	0.6	5.34	0.32	2.09e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg02558537	chr11:107328586	CWF19L2	0.3	5.0	0.3	1.07e-6	Response to metformin in type 2 diabetes (glycemic);
KIRP	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.65	-9.98	-0.54	6.38e-20	Hepatocellular carcinoma;
KIRP	cis	rs3755132	0.929	rs4668950	chr2:15780191	T/C	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.58	-7.07	-0.41	1.64e-11	Breast cancer;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg02696790	chr15:75250997	RPP25	0.32	5.57	0.33	6.74e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.73	9.1	0.5	3.17e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.31	-0.47	6.43e-15	Systolic blood pressure;
KIRP	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2635047	0.519	rs2668771	chr18:44775897	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	7.18	0.42	8.28e-12	Educational attainment;
KIRP	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.9	16.24	0.72	8.56e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg11859384	chr17:80120422	CCDC57	0.4	5.13	0.31	6.02e-7	Life satisfaction;
KIRP	cis	rs8084125	0.765	rs62105165	chr18:74944464	A/G	cg15443732	chr18:74961078	GALR1	0.51	4.91	0.3	1.65e-6	Obesity-related traits;
KIRP	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg06598544	chr20:61472147	COL9A3	-0.73	-6.39	-0.38	8.36e-10	Obesity-related traits;
KIRP	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg02175308	chr1:109941060	SORT1	-0.31	-5.79	-0.35	2.11e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13986501	chr9:115142201	HSDL2	0.46	6.11	0.36	3.81e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.69	-9.5	-0.52	1.99e-18	Schizophrenia;
KIRP	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg07001201	chr5:642380	CEP72	0.7	6.37	0.38	9.42e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.49	0.33	9.78e-8	Life satisfaction;
KIRP	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg23727983	chr11:125774082	DDX25;PUS3	0.59	4.9	0.3	1.78e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs981844	1.000	rs55722886	chr4:154668335	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05665937	chr4:1216051	CTBP1	-0.43	-5.44	-0.33	1.31e-7	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10285711	chr2:135762012	YSK4	0.5	6.57	0.39	3e-10	Parkinson's disease;
KIRP	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg08619932	chr19:49200058	FUT2	0.35	5.48	0.33	1.05e-7	Dietary macronutrient intake;
KIRP	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.27	14.75	0.69	1.05e-35	Uric acid levels;
KIRP	cis	rs259282	0.605	rs17692992	chr19:33099430	T/G	cg02997394	chr19:33096574	ANKRD27	-0.42	-4.98	-0.3	1.18e-6	Schizophrenia;
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.8	-11.82	-0.6	8.06e-26	Neurofibrillary tangles;
KIRP	trans	rs587242	1.000	rs550739	chr1:96887109	G/A	cg10631902	chr5:14652156	NA	0.52	6.06	0.36	5.04e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg06289844	chr6:126071538	HEY2	0.43	6.22	0.37	2.09e-9	Brugada syndrome;
KIRP	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg02073558	chr3:44770973	ZNF501	0.6	8.38	0.47	4.08e-15	Depressive symptoms;
KIRP	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.68	-0.34	3.76e-8	Aortic root size;
KIRP	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.14	10.58	0.56	8.24e-22	Body mass index;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	0.72	6.54	0.38	3.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.66	-6.79	-0.4	8.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.73	-0.34	2.95e-8	Height;
KIRP	cis	rs10178094	0.647	rs6746839	chr2:161280881	G/T	cg03641300	chr2:160917029	PLA2R1	-0.36	-4.98	-0.3	1.19e-6	White blood cell count;
KIRP	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg07741184	chr6:167504864	NA	-0.24	-6.43	-0.38	6.41e-10	Crohn's disease;
KIRP	cis	rs2041895	0.509	rs7970139	chr12:107312430	T/C	cg15890332	chr12:107067104	RFX4	0.36	5.02	0.31	9.73e-7	Glaucoma (low intraocular pressure);
KIRP	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.52	7.5	0.43	1.13e-12	Schizophrenia;
KIRP	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.52	-5.75	-0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.78	-0.35	2.29e-8	Breast cancer;
KIRP	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.65	8.25	0.47	9.37e-15	Coronary artery disease;
KIRP	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg20240347	chr1:204465584	NA	-0.41	-7.93	-0.45	7.57e-14	Schizophrenia;
KIRP	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg04166393	chr7:2884313	GNA12	0.45	5.89	0.35	1.28e-8	Height;
KIRP	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.52	5.71	0.34	3.2e-8	Schizophrenia;
KIRP	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg06740227	chr12:86229804	RASSF9	0.45	5.7	0.34	3.45e-8	Major depressive disorder;
KIRP	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	8.04	0.46	3.67e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1182180	0.538	rs4722006	chr7:2765723	A/G	cg04166393	chr7:2884313	GNA12	0.41	5.07	0.31	7.87e-7	Platelet count;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg12183978	chr5:102203071	PAM	0.42	6.56	0.39	3.08e-10	C-reactive protein;
KIRP	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.7	8.8	0.49	2.44e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs42648	0.567	rs12669304	chr7:89891040	T/C	cg25739043	chr7:89950458	NA	-0.43	-6.85	-0.4	5.97e-11	Homocysteine levels;
KIRP	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg04546413	chr19:29218101	NA	0.89	8.99	0.5	6.98e-17	Methadone dose in opioid dependence;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg01162425	chr9:31253952	NA	-0.95	-6.32	-0.37	1.21e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs4908768	0.906	rs12410336	chr1:8623664	A/G	cg03610117	chr1:8450231	RERE	-0.5	-5.24	-0.32	3.54e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.68	-0.39	1.62e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	0.85	7.35	0.42	2.89e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.67	7.11	0.41	1.23e-11	Lymphocyte counts;
KIRP	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.97	-14.47	-0.68	9.85e-35	Vitamin D levels;
KIRP	cis	rs2224391	0.590	rs72813693	chr6:5273464	T/C	cg13962347	chr6:5174647	LYRM4	-0.81	-8.16	-0.46	1.75e-14	Height;
KIRP	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	1.01	16.56	0.73	6.97e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	5.89	0.35	1.26e-8	Putamen volume;
KIRP	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg19554555	chr3:13937349	NA	-0.46	-6.14	-0.36	3.29e-9	Ovarian reserve;
KIRP	cis	rs4944092	1.000	rs4944092	chr11:75909619	C/T	cg04588336	chr11:75916460	WNT11	-0.39	-5.93	-0.35	1.01e-8	PR interval;
KIRP	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-1.05	-14.82	-0.69	6.25e-36	Orofacial clefts;
KIRP	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.69	9.31	0.51	7.44e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-1.04	-12.45	-0.62	6.18e-28	Breast cancer;
KIRP	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg09990169	chr2:241835740	C2orf54	-0.45	-6.8	-0.4	7.86e-11	Urinary metabolites;
KIRP	cis	rs9403521	0.673	rs7772565	chr6:143993070	A/T	cg18240653	chr6:144019428	PHACTR2	0.45	5.63	0.34	5e-8	Obesity-related traits;
KIRP	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.74	8.71	0.49	4.55e-16	Small cell lung carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03308706	chr7:91763433	CYP51A1	0.5	6.29	0.37	1.41e-9	Parkinson's disease;
KIRP	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg20703242	chr1:230279135	GALNT2	0.33	5.2	0.31	4.18e-7	Coronary artery disease;
KIRP	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	9.91e-17	Lymphocyte percentage of white cells;
KIRP	cis	rs10073892	0.789	rs62369688	chr5:101863839	C/T	cg19774478	chr5:101632501	SLCO4C1	0.64	6.28	0.37	1.54e-9	Cognitive decline (age-related);
KIRP	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.54	5.23	0.32	3.69e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg26784012	chr10:32216390	ARHGAP12	0.3	4.86	0.3	2.12e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs10203711	0.966	rs10187949	chr2:239558408	T/C	cg14580085	chr2:239553406	NA	0.39	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12184988	chr22:28280411	PITPNB	0.41	6.15	0.37	3.11e-9	Interleukin-4 levels;
KIRP	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg21360079	chr12:107162445	NA	-0.65	-9.17	-0.5	1.9e-17	Heart rate;
KIRP	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.13	10.87	0.57	9.52e-23	Alzheimer's disease (late onset);
KIRP	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg25019033	chr10:957182	NA	0.38	5.0	0.3	1.09e-6	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.68	6.57	0.39	3.01e-10	Eotaxin levels;
KIRP	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg03714773	chr7:91764589	CYP51A1	0.34	5.01	0.3	1.04e-6	Breast cancer;
KIRP	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.45	6.34	0.37	1.08e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.65	-12.42	-0.62	7.92e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.75	-0.34	2.65e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.35	0.51	5.49e-18	Multiple sclerosis;
KIRP	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21545522	chr1:205238299	TMCC2	0.43	5.75	0.34	2.64e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg27490568	chr2:178487706	NA	0.53	6.75	0.4	1.06e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg24101359	chr6:42928495	GNMT	0.73	11.36	0.59	2.55e-24	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs741677	1.000	rs9911960	chr17:466598	T/C	cg13332499	chr17:408570	NA	0.37	4.88	0.3	1.88e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25362542	chr19:9434924	ZNF559	0.47	6.32	0.37	1.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg04006718	chr10:1068667	C10orf110;IDI2	-0.7	-4.9	-0.3	1.74e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg08901578	chr4:187885870	NA	-0.51	-7.96	-0.45	6.46e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg15534755	chr11:117069859	TAGLN	0.42	5.21	0.32	4e-7	Blood protein levels;
KIRP	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg20725493	chr19:15740067	CYP4F8	-0.87	-6.03	-0.36	5.88e-9	Inflammatory biomarkers;
KIRP	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.39	5.48	0.33	1.04e-7	Endometrial cancer;
KIRP	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg11833968	chr6:79620685	NA	-0.46	-6.92	-0.4	3.87e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-5.47	-0.33	1.13e-7	Total body bone mineral density;
KIRP	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg06307176	chr5:131281290	NA	-0.55	-6.4	-0.38	7.71e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7267005	0.661	rs112837782	chr20:34377181	C/A	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4594175	0.926	rs7493621	chr14:51623665	C/T	cg23942311	chr14:51606299	NA	0.48	6.48	0.38	5.03e-10	Cancer;
KIRP	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.8	10.89	0.57	8.67e-23	Morning vs. evening chronotype;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09455096	chr2:61765470	XPO1	0.7	6.53	0.38	3.77e-10	Lung function (FEV1);
KIRP	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.18	18.84	0.77	1.29e-49	Cognitive function;
KIRP	cis	rs988913	0.957	rs1503146	chr6:54759495	G/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.53	-0.33	8.1e-8	Menarche (age at onset);
KIRP	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.19	-0.64	2.14e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg00343986	chr7:65444356	GUSB	0.43	5.1	0.31	6.89e-7	Aortic root size;
KIRP	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17376030	chr22:41985996	PMM1	-0.72	-7.64	-0.44	4.97e-13	Vitiligo;
KIRP	cis	rs4954585	0.762	rs12986776	chr2:136991517	C/G	cg05194412	chr2:137003533	NA	0.54	7.39	0.43	2.23e-12	Colorectal cancer;
KIRP	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.43	-5.43	-0.33	1.38e-7	Blood metabolite levels;
KIRP	cis	rs6684428	0.536	rs11206686	chr1:56394673	A/G	cg11651538	chr1:56320950	NA	-0.56	-7.91	-0.45	8.46e-14	Airflow obstruction;
KIRP	cis	rs4702718	0.616	rs267985	chr5:10713395	A/G	cg14521931	chr5:10832172	NA	0.44	5.88	0.35	1.34e-8	Obesity-related traits;
KIRP	cis	rs8060686	0.623	rs7205935	chr16:68152157	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.59	-0.44	6.55e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	-0.53	-5.83	-0.35	1.76e-8	Menopause (age at onset);
KIRP	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	8.13	0.46	2.13e-14	Bone mineral density;
KIRP	cis	rs7680126	0.596	rs4698030	chr4:10315850	A/G	cg20640774	chr4:10143053	NA	0.47	4.89	0.3	1.83e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs10789491	0.767	rs4660359	chr1:47190019	C/G	cg15501359	chr1:47185051	KIAA0494	0.99	10.64	0.56	5.48e-22	Response to hepatitis C treatment;
KIRP	cis	rs2694528	0.686	rs7729781	chr5:59872406	C/T	cg11474532	chr5:59995715	DEPDC1B	0.86	6.29	0.37	1.46e-9	Parkinson's disease;
KIRP	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg11693508	chr17:37793320	STARD3	0.74	8.14	0.46	1.98e-14	Bipolar disorder;
KIRP	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14169450	chr9:139327907	INPP5E	0.58	6.61	0.39	2.31e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg24253500	chr15:84953950	NA	0.48	5.36	0.32	1.88e-7	Schizophrenia;
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg08662619	chr6:150070041	PCMT1	0.36	5.88	0.35	1.34e-8	Lung cancer;
KIRP	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.69	-0.44	3.59e-13	Lung cancer;
KIRP	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.86	8.9	0.49	1.21e-16	Prostate cancer;
KIRP	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.75	0.66	2.75e-32	Height;
KIRP	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs10486187	0.584	rs6954931	chr7:7764390	A/G	cg12383621	chr7:7735611	RPA3	-0.55	-5.75	-0.34	2.69e-8	Smooth-surface caries;
KIRP	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg07382826	chr16:28625726	SULT1A1	0.47	5.49	0.33	1.02e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23281280	chr6:28129359	ZNF389	0.45	4.94	0.3	1.46e-6	Parkinson's disease;
KIRP	cis	rs8077577	0.945	rs11653988	chr17:18088833	C/T	cg18869244	chr17:18121946	NA	0.47	5.37	0.32	1.83e-7	Obesity-related traits;
KIRP	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg16989719	chr2:238392110	NA	-0.57	-6.33	-0.37	1.18e-9	Prostate cancer;
KIRP	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-0.94	-10.22	-0.55	1.18e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.45	0.52	2.72e-18	Bipolar disorder;
KIRP	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.22	-0.32	3.78e-7	Height;
KIRP	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg20887711	chr4:1340912	KIAA1530	0.4	5.09	0.31	7.22e-7	Obesity-related traits;
KIRP	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.59	7.84	0.45	1.33e-13	Prostate cancer;
KIRP	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.92	-9.67	-0.52	5.85e-19	Lung cancer in ever smokers;
KIRP	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.64	-7.61	-0.44	5.86e-13	Menarche (age at onset);
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.89	0.4	4.54e-11	Lymphocyte counts;
KIRP	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg13798912	chr7:905769	UNC84A	0.6	5.93	0.35	1e-8	Cerebrospinal P-tau181p levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15258265	chr4:160024237	NA	0.5	6.06	0.36	5.08e-9	Parkinson's disease;
KIRP	cis	rs2219968	0.923	rs7822053	chr8:78979111	A/G	cg00738934	chr8:78996279	NA	0.49	6.74	0.4	1.09e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.81	9.61	0.52	8.82e-19	Corneal astigmatism;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06966887	chr5:443603	EXOC3;C5orf55	-0.5	-6.29	-0.37	1.44e-9	Neuroticism;
KIRP	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.89	-10.09	-0.54	2.92e-20	White matter hyperintensity burden;
KIRP	cis	rs6142102	0.961	rs2284387	chr20:32644588	C/T	cg08999081	chr20:33150536	PIGU	0.52	6.09	0.36	4.33e-9	Skin pigmentation;
KIRP	cis	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg12623918	chr2:306882	NA	0.46	5.77	0.35	2.32e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg03209412	chr4:183728196	NA	0.48	6.24	0.37	1.95e-9	Pediatric autoimmune diseases;
KIRP	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.64	-9.38	-0.51	4.62e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg15896084	chr13:114927664	NA	0.47	6.16	0.37	2.9e-9	Schizophrenia;
KIRP	cis	rs400736	0.637	rs2300428	chr1:7996894	A/G	cg25007680	chr1:8021821	PARK7	-0.55	-7.47	-0.43	1.4e-12	Response to antidepressants and depression;
KIRP	cis	rs4523957	0.928	rs216204	chr17:2196659	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.31	0.47	6.62e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg16988262	chr1:15930761	NA	0.39	5.16	0.31	5.16e-7	Systolic blood pressure;
KIRP	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg10556349	chr10:835070	NA	0.58	5.12	0.31	6.14e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	0.97	12.77	0.63	5.65e-29	Breast cancer;
KIRP	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg20636351	chr8:55087400	NA	-0.62	-7.63	-0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.89	12.48	0.62	5.25e-28	Coronary artery disease;
KIRP	cis	rs8063160	0.756	rs34878706	chr16:89723870	G/A	cg07984980	chr16:89898383	SPIRE2	0.95	5.32	0.32	2.39e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg23985595	chr17:80112537	CCDC57	0.37	5.6	0.34	5.66e-8	Life satisfaction;
KIRP	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.84	-12.11	-0.61	8.84e-27	Total body bone mineral density;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09960727	chr20:39765952	PLCG1	-0.49	-6.52	-0.38	3.86e-10	Metabolic traits;
KIRP	cis	rs1215050	0.765	rs644839	chr4:98716357	C/A	cg05340658	chr4:99064831	C4orf37	0.52	6.21	0.37	2.24e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.75	11.25	0.58	6.04e-24	Oral cavity cancer;
KIRP	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.79	10.74	0.56	2.54e-22	Coronary artery disease;
KIRP	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	6.52	0.38	3.89e-10	Iron status biomarkers;
KIRP	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg24565620	chr2:194026	NA	-0.71	-8.07	-0.46	3.11e-14	Blood protein levels;
KIRP	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg07148914	chr20:33460835	GGT7	-0.53	-7.11	-0.41	1.23e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs9900062	0.586	rs12600679	chr17:62687327	T/G	cg02097616	chr17:62675921	NA	0.5	5.9	0.35	1.17e-8	QT interval;
KIRP	cis	rs194045	0.511	rs1611991	chr16:29151593	C/T	cg16691023	chr16:29205632	NA	-0.52	-5.69	-0.34	3.58e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs490234	0.676	rs4838263	chr9:128225199	G/A	cg14078157	chr9:128172775	NA	-0.62	-7.32	-0.42	3.62e-12	Mean arterial pressure;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg26769984	chr7:1090371	C7orf50	0.76	7.05	0.41	1.75e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs687432	0.627	rs1031360	chr11:57871866	A/G	cg19752551	chr11:57585705	CTNND1	-0.35	-4.85	-0.3	2.17e-6	Parkinson's disease;
KIRP	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-5.11	-0.31	6.52e-7	Tonsillectomy;
KIRP	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-7.82	-0.45	1.59e-13	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.68	6.23	0.37	1.99e-9	Eotaxin levels;
KIRP	cis	rs7916697	0.898	rs1900005	chr10:69998055	A/C	cg06988349	chr10:69991859	ATOH7	-0.39	-5.16	-0.31	5.1e-7	Optic disc area;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10776104	chr1:62953857	DOCK7	-0.48	-7.39	-0.43	2.29e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.56	-0.43	8.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9290065	0.622	rs6797798	chr3:160646598	G/A	cg04691961	chr3:161091175	C3orf57	0.36	5.19	0.31	4.33e-7	Kawasaki disease;
KIRP	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.68	-0.34	3.72e-8	Bipolar disorder;
KIRP	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.79	0.4	8.59e-11	Electroencephalogram traits;
KIRP	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.45	5.02	0.31	9.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.55	7.37	0.43	2.56e-12	Bladder cancer;
KIRP	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg11518657	chr1:67396239	MIER1	0.61	6.0	0.36	7.04e-9	Lymphocyte percentage of white cells;
KIRP	trans	rs12517041	1.000	rs10805750	chr5:23300753	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.75	-0.44	2.43e-13	Calcium levels;
KIRP	cis	rs42648	0.935	rs42659	chr7:89981958	A/G	cg25739043	chr7:89950458	NA	-0.43	-6.6	-0.39	2.55e-10	Homocysteine levels;
KIRP	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.74	-10.21	-0.55	1.26e-20	Red blood cell count;
KIRP	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg18882449	chr10:104885122	NT5C2	-0.52	-6.73	-0.39	1.2e-10	Arsenic metabolism;
KIRP	cis	rs4481887	0.573	rs10888329	chr1:248404654	C/T	cg01631408	chr1:248437212	OR2T33	0.43	5.05	0.31	8.61e-7	Common traits (Other);
KIRP	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg09788416	chr12:39539408	NA	0.38	5.13	0.31	5.85e-7	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00095276	chr5:1068111	SLC12A7	-0.53	-7.95	-0.45	6.61e-14	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg11707556	chr5:10655725	ANKRD33B	0.51	6.15	0.37	3.19e-9	Coronary artery disease;
KIRP	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg23231163	chr10:75533350	FUT11	-0.33	-4.87	-0.3	2.03e-6	Inflammatory bowel disease;
KIRP	cis	rs17453880	0.929	rs4958321	chr5:152020604	G/T	cg12297329	chr5:152029980	NA	-0.72	-10.87	-0.57	9.59e-23	Subjective well-being;
KIRP	cis	rs11574514	1.000	rs8051653	chr16:67848515	T/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-5.64	-0.34	4.6e-8	Crohn's disease;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg08805041	chr16:621841	PIGQ	-0.4	-5.45	-0.33	1.21e-7	Height;
KIRP	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg10818794	chr15:86012489	AKAP13	-0.49	-6.97	-0.41	2.85e-11	Interstitial lung disease;
KIRP	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.43	0.52	3.15e-18	Hirschsprung disease;
KIRP	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.72	-10.51	-0.56	1.36e-21	Hip circumference;
KIRP	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.98	-0.36	7.94e-9	Obesity-related traits;
KIRP	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg04101203	chr11:20408940	PRMT3	0.47	4.86	0.3	2.1e-6	Pursuit maintenance gain;
KIRP	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.66	0.34	4.14e-8	Menopause (age at onset);
KIRP	cis	rs7084402	0.967	rs1658491	chr10:60281354	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.84e-24	Refractive error;
KIRP	cis	rs7072216	0.666	rs11189592	chr10:100155642	C/A	cg19567339	chr10:100142640	NA	0.52	5.58	0.34	6.3e-8	Metabolite levels;
KIRP	cis	rs258892	0.895	rs13156244	chr5:72032166	A/G	cg21869765	chr5:72125136	TNPO1	-0.53	-6.05	-0.36	5.23e-9	Small cell lung carcinoma;
KIRP	cis	rs684232	0.602	rs34167561	chr17:509268	G/A	cg12384639	chr17:618140	VPS53	0.48	5.93	0.35	1.03e-8	Prostate cancer;
KIRP	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.58	-12.05	-0.61	1.34e-26	Diabetic kidney disease;
KIRP	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.9	-15.55	-0.7	1.98e-38	Menarche (age at onset);
KIRP	trans	rs863345	0.548	rs857687	chr1:158577998	T/C	cg05360176	chr12:48357394	TMEM106C	0.47	6.04	0.36	5.53e-9	Pneumococcal bacteremia;
KIRP	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.26	0.42	4.95e-12	Height;
KIRP	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg08648136	chr8:956695	NA	0.39	5.43	0.33	1.35e-7	Schizophrenia;
KIRP	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.76	-8.85	-0.49	1.79e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22360964	chr2:1078439	SNTG2	-0.36	-6.37	-0.38	9.45e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg26605046	chr4:2439731	NA	-0.35	-5.36	-0.32	1.96e-7	Cognitive function;
KIRP	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg19468946	chr17:37922297	IKZF3	-0.46	-6.29	-0.37	1.47e-9	Self-reported allergy;
KIRP	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.35	0.32	1.98e-7	Cognitive test performance;
KIRP	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.43	-6.56	-0.39	3.15e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg23845249	chr11:68861649	NA	0.56	8.01	0.45	4.71e-14	Blond vs. brown hair color;
KIRP	cis	rs1635	0.655	rs77986494	chr6:28261497	A/G	cg15743358	chr6:28303923	ZNF323	-0.8	-5.54	-0.33	7.64e-8	Schizophrenia;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	6.5	0.38	4.54e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg21858823	chr1:15850916	CASP9	0.55	5.88	0.35	1.36e-8	Systolic blood pressure;
KIRP	cis	rs10129255	0.500	rs2105991	chr14:107138039	C/G	cg23076370	chr14:107095027	NA	-0.45	-5.68	-0.34	3.85e-8	Kawasaki disease;
KIRP	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	5.04	0.31	9.09e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg09754948	chr16:28834200	ATXN2L	0.52	5.82	0.35	1.86e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg10397082	chr2:1609832	NA	-0.54	-5.02	-0.3	1e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Hypertriglyceridemia;
KIRP	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.9	10.51	0.56	1.44e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9831754	0.526	rs11927217	chr3:78341723	A/G	cg06138941	chr3:78371609	NA	-0.56	-8.18	-0.46	1.57e-14	Calcium levels;
KIRP	cis	rs78579285	0.583	rs77376965	chr16:88800477	G/A	cg09054528	chr16:88821542	FAM38A	-0.65	-5.36	-0.32	1.91e-7	Joint mobility (Beighton score);
KIRP	trans	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13401104	0.740	rs12465430	chr2:237113578	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs1832871	0.541	rs62438578	chr6:158871624	C/T	cg07215822	chr6:158701037	NA	-0.52	-5.57	-0.33	6.51e-8	Height;
KIRP	cis	rs16976116	0.901	rs1061823	chr15:55496043	T/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs960902	0.935	rs12151464	chr2:37717936	G/C	cg25341268	chr2:37734390	NA	0.52	7.09	0.41	1.45e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.53	0.68	5.85e-35	Alzheimer's disease;
KIRP	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.5	6.67	0.39	1.63e-10	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.85	-13.2	-0.64	1.94e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.6	0.44	6.1e-13	White blood cell count;
KIRP	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg05315796	chr3:52349193	DNAH1	0.41	6.56	0.39	3.07e-10	Bipolar disorder;
KIRP	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.71	-10.41	-0.55	2.82e-21	Schizophrenia;
KIRP	cis	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg21546286	chr11:48923668	NA	-0.49	-6.29	-0.37	1.41e-9	HDL cholesterol;
KIRP	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg23594656	chr7:65796392	TPST1	-0.39	-5.58	-0.34	6.32e-8	Aortic root size;
KIRP	cis	rs10267417	0.657	rs12668709	chr7:19858946	T/G	cg05791153	chr7:19748676	TWISTNB	0.52	4.95	0.3	1.35e-6	Night sleep phenotypes;
KIRP	cis	rs17123764	0.605	rs11169104	chr12:50076287	T/C	cg20471783	chr12:50157085	TMBIM6	0.32	4.93	0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg02367723	chr1:46378857	MAST2	-0.43	-4.95	-0.3	1.37e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13335434	chr3:195270319	PPP1R2	0.49	6.19	0.37	2.48e-9	Parkinson's disease;
KIRP	cis	rs10484885	0.818	rs117562849	chr6:90249804	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.58	-5.38	-0.32	1.72e-7	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg20243544	chr17:37824526	PNMT	-0.4	-4.93	-0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.79e-7	Life satisfaction;
KIRP	cis	rs1546924	0.692	rs197379	chr1:112292303	T/C	cg23955903	chr1:112298873	DDX20;C1orf183	0.47	5.98	0.36	7.98e-9	Body mass index;
KIRP	cis	rs687432	0.887	rs34015013	chr11:57768862	A/G	cg19752551	chr11:57585705	CTNND1	-0.68	-8.81	-0.49	2.38e-16	Parkinson's disease;
KIRP	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg19875535	chr5:140030758	IK	-0.67	-9.38	-0.51	4.45e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg14768367	chr16:72042858	DHODH	-0.93	-10.29	-0.55	6.94e-21	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.51	6.65	0.39	1.93e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg08847533	chr14:75593920	NEK9	0.52	6.21	0.37	2.3e-9	IgG glycosylation;
KIRP	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.01	-0.3	1.03e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4954585	0.659	rs13018756	chr2:137008235	C/T	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.14e-13	Colorectal cancer;
KIRP	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.42	-0.43	1.96e-12	Neuroticism;
KIRP	cis	rs10782582	0.758	rs5745557	chr1:76379337	G/A	cg10523679	chr1:76189770	ACADM	-0.36	-5.12	-0.31	6.27e-7	Daytime sleep phenotypes;
KIRP	cis	rs244731	0.920	rs72813185	chr5:176739110	C/A	cg16006841	chr5:176797999	RGS14	0.59	6.23	0.37	2.04e-9	Urate levels in lean individuals;
KIRP	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.23	-0.32	3.69e-7	Pulmonary function;
KIRP	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg16141378	chr3:129829833	LOC729375	-0.59	-7.58	-0.44	7.01e-13	Mood instability;
KIRP	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	cg04338863	chr8:33670619	NA	-0.42	-5.66	-0.34	4.25e-8	Body mass index;
KIRP	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.58	7.45	0.43	1.55e-12	Cognitive test performance;
KIRP	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.16	-0.37	3.01e-9	Body mass index;
KIRP	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.63	-0.34	5.01e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg04080417	chr5:1859792	NA	-0.57	-6.25	-0.37	1.8e-9	Cardiovascular disease risk factors;
KIRP	cis	rs2223471	0.602	rs9395615	chr6:50694988	A/G	cg03432817	chr6:50765336	NA	-0.35	-4.89	-0.3	1.84e-6	Subcutaneous adipose tissue;
KIRP	cis	rs258892	0.895	rs10036866	chr5:72068932	A/G	cg21869765	chr5:72125136	TNPO1	-0.56	-6.19	-0.37	2.53e-9	Small cell lung carcinoma;
KIRP	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.7	8.42	0.47	3.05e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg24169773	chr3:122142474	KPNA1	-0.58	-6.47	-0.38	5.12e-10	LDL cholesterol levels;
KIRP	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg26207909	chr14:103986467	CKB	0.52	6.96	0.41	3.09e-11	Body mass index;
KIRP	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.46	6.37	0.38	9.08e-10	Dupuytren's disease;
KIRP	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.71	-0.63	8.44e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs13161895	0.818	rs114211674	chr5:179484518	A/C	cg02702477	chr5:179499311	RNF130	1.03	7.14	0.41	1.03e-11	LDL cholesterol;
KIRP	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.44	5.73	0.34	2.91e-8	Schizophrenia;
KIRP	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.09	-0.31	7.13e-7	Life satisfaction;
KIRP	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg23594656	chr7:65796392	TPST1	-0.38	-5.39	-0.33	1.62e-7	Aortic root size;
KIRP	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg18190219	chr22:46762943	CELSR1	-0.61	-6.39	-0.38	8.3e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	17.24	0.74	3.43e-44	Platelet count;
KIRP	cis	rs11710088	0.791	rs4481102	chr3:149200630	C/T	cg08667024	chr3:149219783	TM4SF4	-0.48	-6.87	-0.4	5.24e-11	QRS duration;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg06815112	chr8:27182871	PTK2B	0.49	6.37	0.38	9.4e-10	Neuroticism;
KIRP	cis	rs7221595	0.778	rs36054194	chr17:3900280	C/T	cg11204139	chr17:3907470	NA	0.52	5.46	0.33	1.14e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg24881330	chr22:46731750	TRMU	0.68	5.26	0.32	3.19e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg09491104	chr22:46646882	C22orf40	-0.48	-5.01	-0.3	1.03e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg16898833	chr6:26189333	HIST1H4D	1.02	5.78	0.35	2.29e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7635838	0.859	rs6784883	chr3:11444453	G/A	cg00170343	chr3:11313890	ATG7	0.47	5.94	0.35	9.5e-9	HDL cholesterol;
KIRP	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.44	-5.96	-0.36	8.84e-9	Refractive error;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10338232	chr14:42683574	NA	-0.43	-6.47	-0.38	5.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10929956	0.760	rs2729704	chr2:160707866	T/A	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.63	-0.34	4.86e-8	Crohn's disease-related phenotypes;
KIRP	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.65	-7.76	-0.44	2.29e-13	Menopause (age at onset);
KIRP	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg25319279	chr11:5960081	NA	-0.52	-5.45	-0.33	1.23e-7	DNA methylation (variation);
KIRP	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11987759	chr7:65425863	GUSB	0.56	7.37	0.43	2.53e-12	Aortic root size;
KIRP	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg27624424	chr6:160112604	SOD2	0.55	6.63	0.39	2.1e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg00677455	chr12:58241039	CTDSP2	-0.54	-6.55	-0.39	3.3e-10	Multiple sclerosis;
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.59	8.82	0.49	2.2e-16	Lung cancer;
KIRP	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.83	13.04	0.64	7.01e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg01943577	chr7:158741284	NA	-0.37	-5.25	-0.32	3.35e-7	Height;
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.81	0.35	1.88e-8	Lung cancer;
KIRP	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg22138327	chr13:27999177	GTF3A	0.93	7.36	0.42	2.75e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg16388071	chr6:169726476	NA	-0.36	-4.97	-0.3	1.28e-6	Obesity-related traits;
KIRP	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.43	-0.33	1.37e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.67	7.56	0.43	7.76e-13	Schizophrenia;
KIRP	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.14	-0.31	5.64e-7	Breast cancer;
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.19	-15.44	-0.7	4.72e-38	Alzheimer's disease;
KIRP	trans	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg18187862	chr3:45730750	SACM1L	0.53	6.1	0.36	4.05e-9	Primary sclerosing cholangitis;
KIRP	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg07827796	chr19:33622959	WDR88	0.41	4.94	0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7077164	1.000	rs1227764	chr10:71583223	G/A	cg20696214	chr10:71583771	COL13A1	-0.46	-6.56	-0.39	3.2e-10	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs3936840	0.565	rs8006911	chr14:102975265	A/G	cg18135206	chr14:102964638	TECPR2	0.49	6.14	0.36	3.26e-9	Plateletcrit;
KIRP	cis	rs2120243	0.539	rs35218020	chr3:157115416	G/A	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.75e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.06e-8	Life satisfaction;
KIRP	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg09231725	chr11:64357281	SLC22A12	0.61	8.0	0.45	4.78e-14	Urate levels in obese individuals;
KIRP	cis	rs2425143	1.000	rs17093027	chr20:34319118	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.81	7.74	0.44	2.64e-13	Methadone dose in opioid dependence;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	15.15	0.69	4.58e-37	Alzheimer's disease;
KIRP	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg14847009	chr1:175162515	KIAA0040	-0.24	-4.91	-0.3	1.7e-6	Alcohol dependence;
KIRP	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.71	9.92	0.53	1.02e-19	Mean corpuscular volume;
KIRP	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs4474465	0.831	rs10899510	chr11:78170841	G/A	cg27205649	chr11:78285834	NARS2	-0.66	-7.46	-0.43	1.53e-12	Alzheimer's disease (survival time);
KIRP	cis	rs3741151	0.881	rs10898917	chr11:73065979	G/A	cg17517138	chr11:73019481	ARHGEF17	0.71	6.27	0.37	1.62e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg04310649	chr10:35416472	CREM	-0.58	-6.85	-0.4	5.85e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1894633	0.582	rs9425627	chr1:172451408	G/A	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg21775007	chr8:11205619	TDH	0.45	6.03	0.36	5.86e-9	Myopia (pathological);
KIRP	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.85e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05025164	chr4:1340916	KIAA1530	-0.53	-6.94	-0.4	3.4e-11	Obesity-related traits;
KIRP	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg07701084	chr6:150067640	NUP43	0.51	5.89	0.35	1.23e-8	Lung cancer;
KIRP	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg13264159	chr8:625131	ERICH1	-0.78	-6.71	-0.39	1.3e-10	IgG glycosylation;
KIRP	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg02336718	chr17:17403227	NA	-0.4	-6.16	-0.37	2.98e-9	Total body bone mineral density;
KIRP	cis	rs1014246	0.778	rs12256473	chr10:118478448	G/A	cg14919929	chr10:118506882	NA	0.67	8.1	0.46	2.56e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.91	-0.35	1.12e-8	LDL cholesterol levels;
KIRP	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg23587288	chr2:27483067	SLC30A3	-0.61	-7.86	-0.45	1.18e-13	Blood metabolite levels;
KIRP	cis	rs2290416	0.786	rs77951814	chr8:144657152	C/G	cg14650228	chr8:144573510	ZC3H3	-0.69	-4.9	-0.3	1.77e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg07827796	chr19:33622959	WDR88	-0.52	-6.82	-0.4	7.01e-11	Bone properties (heel);
KIRP	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.46	-5.82	-0.35	1.8e-8	Asthma;
KIRP	cis	rs4908768	0.906	rs12405049	chr1:8626117	C/T	cg03610117	chr1:8450231	RERE	-0.5	-5.22	-0.32	3.79e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	trans	rs5745709	0.950	rs4728474	chr7:81327065	T/C	cg16218980	chr15:93631991	RGMA	0.54	6.24	0.37	1.89e-9	Gout;
KIRP	cis	rs4762326	1.000	rs10859863	chr12:95661809	T/C	cg07737802	chr12:95537812	FGD6	0.46	6.43	0.38	6.5e-10	Endometriosis;
KIRP	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.53	6.98	0.41	2.75e-11	Dupuytren's disease;
KIRP	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg24747557	chr10:131355152	MGMT	-0.38	-5.19	-0.31	4.4e-7	Response to temozolomide;
KIRP	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg05528293	chr18:74961138	GALR1	-0.54	-6.11	-0.36	3.89e-9	Obesity-related traits;
KIRP	trans	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg10756647	chr7:56101905	PSPH	0.97	7.18	0.42	8.18e-12	Diabetic kidney disease;
KIRP	cis	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg16898833	chr6:26189333	HIST1H4D	0.77	5.57	0.33	6.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg04132472	chr17:19861366	AKAP10	0.69	10.61	0.56	6.74e-22	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24425342	chr19:3114929	GNA11	0.51	6.2	0.37	2.33e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9427116	0.840	rs9427114	chr1:154626705	T/C	cg24304309	chr1:154577895	ADAR	0.33	4.99	0.3	1.14e-6	Blood protein levels;
KIRP	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.03	0.36	5.83e-9	Melanoma;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg27305525	chr1:154955752	FLAD1	-0.51	-6.31	-0.37	1.3e-9	Neuroticism;
KIRP	cis	rs735539	0.645	rs9552250	chr13:21175217	C/G	cg04906043	chr13:21280425	IL17D	-0.53	-6.49	-0.38	4.71e-10	Dental caries;
KIRP	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17376030	chr22:41985996	PMM1	0.7	7.37	0.43	2.63e-12	Vitiligo;
KIRP	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.8	12.14	0.61	7.15e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4523957	0.890	rs62069332	chr17:2112720	A/G	cg16513277	chr17:2031491	SMG6	-0.69	-9.61	-0.52	8.76e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.44	6.46	0.38	5.54e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.59	6.51	0.38	4.23e-10	Gut microbiome composition (summer);
KIRP	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg13147721	chr7:65941812	NA	-1.0	-6.93	-0.4	3.77e-11	Diabetic kidney disease;
KIRP	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.35	-0.32	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg01988459	chr11:68622903	NA	-0.36	-4.95	-0.3	1.36e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-1.23	-12.55	-0.62	3.03e-28	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-17.89	-0.75	2.13e-46	Primary sclerosing cholangitis;
KIRP	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg13173536	chr2:3403300	TTC15	-0.36	-4.89	-0.3	1.86e-6	Obesity-related traits;
KIRP	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg08499158	chr17:42289980	UBTF	0.51	6.33	0.37	1.16e-9	Total body bone mineral density;
KIRP	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.26	-0.78	4.82e-51	Height;
KIRP	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.9	-14.81	-0.69	6.45e-36	Urate levels in lean individuals;
KIRP	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.57	-7.34	-0.42	3.16e-12	Prudent dietary pattern;
KIRP	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg02023728	chr11:77925099	USP35	0.4	5.64	0.34	4.57e-8	Testicular germ cell tumor;
KIRP	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg18806716	chr10:30721971	MAP3K8	-0.34	-5.06	-0.31	8.4e-7	Itch intensity from mosquito bite;
KIRP	cis	rs10940138	0.779	rs62370675	chr5:67247975	G/A	ch.5.1281357F	chr5:67228439	NA	0.72	10.35	0.55	4.38e-21	Menarche (age at onset);
KIRP	cis	rs2274273	0.588	rs7154831	chr14:55823965	A/C	cg04306507	chr14:55594613	LGALS3	0.38	5.25	0.32	3.27e-7	Protein biomarker;
KIRP	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.62	8.71	0.49	4.48e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.54	-6.79	-0.4	8.3e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg18132916	chr6:79620363	NA	-0.4	-5.62	-0.34	5.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg04989706	chr14:50066350	PPIL5	-0.49	-5.83	-0.35	1.71e-8	Carotid intima media thickness;
KIRP	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.63	7.83	0.45	1.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16518742	chr17:40811438	TUBG2	0.51	6.26	0.37	1.7e-9	Parkinson's disease;
KIRP	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-0.9	-14.16	-0.67	1.08e-33	Total body bone mineral density;
KIRP	cis	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg21546286	chr11:48923668	NA	-0.46	-5.81	-0.35	1.89e-8	HDL cholesterol;
KIRP	cis	rs9652601	0.779	rs12935413	chr16:11210447	C/T	cg04616529	chr16:11181986	CLEC16A	0.38	4.98	0.3	1.2e-6	Systemic lupus erythematosus;
KIRP	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg02073558	chr3:44770973	ZNF501	0.72	11.27	0.58	4.85e-24	Depressive symptoms;
KIRP	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg09904177	chr6:26538194	HMGN4	-0.49	-6.59	-0.39	2.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.44	6.24	0.37	1.89e-9	Coronary artery disease;
KIRP	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.5	-5.59	-0.34	6.1e-8	Obesity-related traits;
KIRP	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.93	-12.96	-0.64	1.26e-29	Cognitive function;
KIRP	cis	rs397969	0.621	rs203480	chr17:19828959	G/A	cg13482628	chr17:19912719	NA	0.47	5.3	0.32	2.62e-7	Platelet count;
KIRP	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs686320	1.000	rs667196	chr11:65247092	A/T	cg21890820	chr11:65308645	LTBP3	0.61	5.53	0.33	8.22e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.52	-0.33	8.65e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2625529	0.938	rs2723343	chr15:72108269	C/T	cg16672083	chr15:72433130	SENP8	-0.58	-7.08	-0.41	1.46e-11	Red blood cell count;
KIRP	cis	rs35160687	0.901	rs7571424	chr2:86539160	A/G	cg10973622	chr2:86423274	IMMT	0.41	5.09	0.31	7.21e-7	Night sleep phenotypes;
KIRP	cis	rs593254	0.556	rs388305	chr6:164434628	G/T	cg00040411	chr6:164393165	NA	-0.49	-5.02	-0.3	9.99e-7	Gestational age at birth in labor-initiated deliveries (maternal effect);
KIRP	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-7.05	-0.41	1.75e-11	Personality dimensions;
KIRP	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.73	-0.44	2.68e-13	Height;
KIRP	trans	rs2504916	1.000	rs2457570	chr6:160829518	A/G	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.57	-6.03	-0.36	5.99e-9	Response to hepatitis C treatment;
KIRP	trans	rs10507577	0.685	rs17059411	chr13:54020773	A/C	cg15685971	chr8:145729126	GPT	-0.39	-6.19	-0.37	2.54e-9	Select biomarker traits;
KIRP	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs897080	0.552	rs1067374	chr2:44650250	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.54	-5.75	-0.34	2.69e-8	Height;
KIRP	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	5.95	0.35	9.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.24	11.82	0.6	7.8e-26	Diabetic retinopathy;
KIRP	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23544223	chr18:12777786	NA	-0.67	-4.95	-0.3	1.39e-6	Inflammatory skin disease;
KIRP	cis	rs6504622	0.537	rs1662576	chr17:44996245	C/T	cg16759221	chr17:45003025	GOSR2	-0.4	-5.94	-0.35	9.72e-9	Orofacial clefts;
KIRP	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.76	-0.73	1.41e-42	Height;
KIRP	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs2281603	0.570	rs73265639	chr14:64949691	T/A	cg01860774	chr14:64969374	ZBTB25	0.33	5.38	0.32	1.77e-7	Lymphocyte counts;
KIRP	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.26	5.45	0.33	1.22e-7	Menarche (age at onset);
KIRP	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-7.74	-0.44	2.65e-13	Initial pursuit acceleration;
KIRP	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg02367723	chr1:46378857	MAST2	-0.43	-4.95	-0.3	1.37e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	cg21523751	chr1:182988639	NA	0.39	5.96	0.36	8.74e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg15704280	chr7:45808275	SEPT13	-0.53	-6.14	-0.36	3.32e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg20701182	chr2:24300061	SF3B14	0.48	4.99	0.3	1.13e-6	Asthma;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg15897613	chr1:23418405	LUZP1	0.55	6.08	0.36	4.57e-9	Response to statin therapy;
KIRP	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	0.89	10.53	0.56	1.25e-21	Corneal structure;
KIRP	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg20312557	chr2:97357134	FER1L5	-0.73	-5.35	-0.32	2.05e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg14458575	chr2:238380390	NA	0.46	5.23	0.32	3.55e-7	Prostate cancer;
KIRP	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.12e-22	Coronary artery disease;
KIRP	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.92	10.75	0.57	2.42e-22	Corneal astigmatism;
KIRP	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg01877450	chr7:97915802	BRI3	-0.54	-7.08	-0.41	1.49e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.96	0.3	1.29e-6	Personality dimensions;
KIRP	cis	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.89e-16	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.49	0.59	9.75e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.45	-6.98	-0.41	2.68e-11	Platelet distribution width;
KIRP	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs4262150	0.667	rs4404733	chr5:152251897	T/G	cg12297329	chr5:152029980	NA	0.46	6.42	0.38	7.16e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg22618752	chr2:145147450	ZEB2	0.92	6.58	0.39	2.81e-10	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg23995753	chr2:160760732	LY75	-0.44	-5.84	-0.35	1.61e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-8.69	-0.48	5.29e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg02297831	chr4:17616191	MED28	0.55	6.89	0.4	4.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.58	-7.23	-0.42	6.09e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.93	14.87	0.69	4.2e-36	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.68	0.48	5.67e-16	Life satisfaction;
KIRP	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.77	-0.4	9.62e-11	Systemic lupus erythematosus;
KIRP	cis	rs1190552	0.846	rs1061924	chr14:102975655	C/T	cg18135206	chr14:102964638	TECPR2	0.45	5.01	0.3	1.04e-6	Blood protein levels;
KIRP	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.55	-6.42	-0.38	7.09e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg01872077	chr2:219646372	CYP27A1	0.37	4.87	0.3	2.04e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg15790184	chr11:494944	RNH1	0.41	5.13	0.31	6e-7	Systemic lupus erythematosus;
KIRP	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.61	7.6	0.44	6.13e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg15247329	chr7:2764246	NA	-0.38	-5.56	-0.33	7.06e-8	Height;
KIRP	trans	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	0.94	12.37	0.62	1.17e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs16936870	0.543	rs4571760	chr8:71029754	C/G	cg14232793	chr8:71155543	NCOA2	0.53	6.14	0.36	3.21e-9	QT interval;
KIRP	cis	rs7665939	0.860	rs72709247	chr4:190126086	A/G	cg01790032	chr4:190285510	NA	-0.73	-5.02	-0.3	9.89e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg27205649	chr11:78285834	NARS2	-0.52	-5.53	-0.33	8.36e-8	Testicular germ cell tumor;
KIRP	cis	rs372883	1.000	rs372883	chr21:30717737	A/G	cg24692254	chr21:30365293	RNF160	-0.4	-5.18	-0.31	4.59e-7	Pancreatic cancer;
KIRP	trans	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg27542767	chr6:40253980	NA	0.41	6.09	0.36	4.35e-9	Breast size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06836181	chr2:64995545	NA	0.6	7.18	0.42	8.16e-12	Smoking initiation;
KIRP	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.37	-5.47	-0.33	1.08e-7	Coronary artery disease;
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.83	-12.48	-0.62	5.12e-28	Height;
KIRP	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.28	5.82	0.35	1.86e-8	Body mass index;
KIRP	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.33	-5.03	-0.31	9.47e-7	Inflammatory bowel disease;
KIRP	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg04662567	chr6:169592167	NA	-0.64	-5.39	-0.33	1.64e-7	Pulse pressure;
KIRP	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs427941	0.773	rs56235745	chr7:101828769	A/G	cg06246474	chr7:101738831	CUX1	0.46	5.3	0.32	2.54e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg21360079	chr12:107162445	NA	-0.71	-10.07	-0.54	3.42e-20	Heart rate;
KIRP	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg05343316	chr1:45956843	TESK2	0.72	8.18	0.46	1.56e-14	Platelet count;
KIRP	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg07777115	chr5:623756	CEP72	-0.56	-5.71	-0.34	3.33e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11628318	0.515	rs8009257	chr14:103155594	A/G	cg01864069	chr14:103024347	NA	0.55	6.44	0.38	6.12e-10	Platelet count;
KIRP	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg23100626	chr2:96804247	ASTL	0.52	8.06	0.46	3.28e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7010267	0.668	rs4563920	chr8:119993689	A/G	cg01975934	chr8:119970761	NA	-0.41	-5.38	-0.32	1.69e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs7106204	0.620	rs12805125	chr11:24258967	A/T	ch.11.24196551F	chr11:24239977	NA	-0.65	-5.09	-0.31	7e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs2746347	0.722	rs2796528	chr1:57127839	C/T	cg09935045	chr1:57111199	PRKAA2	0.49	5.09	0.31	7.18e-7	Lymphocyte counts;
KIRP	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	1.06	21.71	0.81	4.27e-59	Parkinson's disease;
KIRP	cis	rs2860975	1.000	rs2860974	chr10:96779866	A/G	cg09036531	chr10:96991505	NA	-0.43	-5.44	-0.33	1.31e-7	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg20673091	chr1:2541236	MMEL1	-0.67	-10.16	-0.54	1.8e-20	Ulcerative colitis;
KIRP	cis	rs8018808	0.967	rs10133896	chr14:77853806	C/T	cg20045696	chr14:77926864	AHSA1	-0.42	-5.12	-0.31	6.09e-7	Myeloid white cell count;
KIRP	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg10434728	chr15:90938212	IQGAP1	0.45	8.55	0.48	1.33e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg04025307	chr7:1156635	C7orf50	0.58	5.89	0.35	1.29e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs17023223	0.537	rs2361273	chr1:119603700	A/T	cg05756136	chr1:119680316	WARS2	-0.54	-7.17	-0.42	8.73e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.68	5.5	0.33	9.49e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	7.41	0.43	1.98e-12	Height;
KIRP	cis	rs9826463	0.582	rs11708870	chr3:142070013	A/G	cg20824294	chr3:142316082	PLS1	0.44	6.39	0.38	8.47e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06481639	chr22:41940642	POLR3H	-0.44	-5.15	-0.31	5.32e-7	Neuroticism;
KIRP	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.73	6.99	0.41	2.52e-11	Arsenic metabolism;
KIRP	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	17.44	0.74	6.65e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.71	8.38	0.47	4e-15	Obesity-related traits;
KIRP	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	8.25	0.47	9.81e-15	Response to antipsychotic treatment;
KIRP	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.57	-9.31	-0.51	7.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg24972876	chr7:65420302	NA	0.4	5.55	0.33	7.49e-8	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08462117	chr11:62432583	SNORA57;C11orf48;METTL12	-0.48	-6.16	-0.37	2.96e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg22563815	chr15:78856949	CHRNA5	0.5	7.7	0.44	3.24e-13	Sudden cardiac arrest;
KIRP	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg14825094	chr17:61818420	STRADA	-0.42	-4.85	-0.3	2.23e-6	Height;
KIRP	cis	rs7578199	0.924	rs6746127	chr2:242340540	G/A	cg01632474	chr2:242799312	PDCD1	0.38	4.86	0.3	2.1e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs4666002	0.956	rs34502053	chr2:27854524	G/A	cg05484376	chr2:27715224	FNDC4	-0.39	-5.18	-0.31	4.63e-7	Phospholipid levels (plasma);
KIRP	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg21775007	chr8:11205619	TDH	-0.72	-10.14	-0.54	2.12e-20	Retinal vascular caliber;
KIRP	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg08076091	chr2:203926405	NBEAL1	0.92	9.52	0.52	1.69e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg03929089	chr4:120376271	NA	-0.65	-6.78	-0.4	8.71e-11	Axial length;
KIRP	trans	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg05926928	chr17:57297772	GDPD1	0.85	7.45	0.43	1.56e-12	Opioid sensitivity;
KIRP	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.16	0.46	1.7e-14	Aortic root size;
KIRP	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs6681460	0.625	rs12127199	chr1:67103742	T/C	cg13052034	chr1:66999238	SGIP1	0.35	4.97	0.3	1.23e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.62	8.68	0.48	5.44e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg03468072	chr12:39539422	NA	0.41	5.96	0.36	8.47e-9	Morning vs. evening chronotype;
KIRP	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.81	-10.86	-0.57	1.08e-22	Total body bone mineral density;
KIRP	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.56	7.7	0.44	3.27e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.967	rs11117116	chr12:86331087	A/T	cg06740227	chr12:86229804	RASSF9	0.41	5.16	0.31	5.15e-7	Major depressive disorder;
KIRP	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg19773385	chr1:10388646	KIF1B	-0.66	-9.04	-0.5	4.76e-17	Hepatocellular carcinoma;
KIRP	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg03576123	chr11:487126	PTDSS2	0.87	8.03	0.46	4.07e-14	Body mass index;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.41	6.1	0.36	4.19e-9	Lymphocyte counts;
KIRP	cis	rs10170310	1.000	rs12691947	chr2:139264471	A/G	cg10095539	chr2:139258744	SPOPL	0.37	5.88	0.35	1.35e-8	Response to antipsychotic treatment;
KIRP	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg15534755	chr11:117069859	TAGLN	-0.4	-4.95	-0.3	1.36e-6	Blood protein levels;
KIRP	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg12549451	chr6:135224345	NA	0.41	5.07	0.31	7.7e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg21174375	chr14:64681225	SYNE2	0.45	5.04	0.31	9.05e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs699371	0.507	rs10149538	chr14:74925397	A/G	cg16374328	chr14:74960395	NPC2;ISCA2	0.5	6.29	0.37	1.48e-9	Height;
KIRP	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg24747557	chr10:131355152	MGMT	-0.38	-5.03	-0.31	9.59e-7	Response to temozolomide;
KIRP	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17554472	chr22:41940697	POLR3H	-0.67	-6.77	-0.4	9.18e-11	Vitiligo;
KIRP	cis	rs501120	0.584	rs11238911	chr10:44695862	A/G	cg09554077	chr10:44749378	NA	-0.58	-6.26	-0.37	1.75e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs13161895	0.591	rs12655422	chr5:179480825	C/A	cg02702477	chr5:179499311	RNF130	1.07	7.39	0.43	2.25e-12	LDL cholesterol;
KIRP	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg03684893	chr10:554711	DIP2C	-0.35	-4.87	-0.3	1.98e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	1.03	13.09	0.64	4.71e-30	Alzheimer's disease;
KIRP	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg23301140	chr18:77439876	CTDP1	0.44	4.91	0.3	1.63e-6	Monocyte count;
KIRP	cis	rs2274273	0.870	rs946059	chr14:55847466	A/G	cg04306507	chr14:55594613	LGALS3	0.52	8.25	0.47	9.93e-15	Protein biomarker;
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg01798813	chr17:3906674	NA	-0.42	-5.34	-0.32	2.15e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18252515	chr7:66147081	NA	0.46	5.51	0.33	9.21e-8	Aortic root size;
KIRP	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.69	-0.56	3.74e-22	Exhaled nitric oxide output;
KIRP	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg01028140	chr2:1542097	TPO	-0.5	-5.73	-0.34	2.92e-8	IgG glycosylation;
KIRP	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg16797656	chr11:68205561	LRP5	-0.41	-5.85	-0.35	1.54e-8	Bone mineral density (spine);
KIRP	cis	rs12791968	0.527	rs4755300	chr11:45013421	C/T	cg11846598	chr11:44996168	LOC221122	0.51	5.4	0.33	1.6e-7	Inhibitory control;
KIRP	cis	rs9457247	0.935	rs2769345	chr6:167366394	T/C	cg23791538	chr6:167370224	RNASET2	0.42	5.13	0.31	6.01e-7	Crohn's disease;
KIRP	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg26811252	chr16:29126840	RRN3P2	0.65	8.86	0.49	1.69e-16	Menopause (age at onset);
KIRP	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.28	4.86	0.3	2.11e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg15896084	chr13:114927664	NA	0.47	6.42	0.38	6.8e-10	Schizophrenia;
KIRP	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	ch.8.33884649F	chr8:33765107	NA	0.54	6.77	0.4	9.62e-11	Body mass index;
KIRP	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg20312557	chr2:97357134	FER1L5	-0.77	-5.67	-0.34	4.03e-8	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.6	8.59	0.48	9.85e-16	Mean corpuscular volume;
KIRP	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg01320579	chr17:75405842	SEPT9	0.45	7.36	0.42	2.74e-12	Airflow obstruction;
KIRP	cis	rs1448094	0.967	rs2044617	chr12:86324089	T/C	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.34	3.27e-8	Major depressive disorder;
KIRP	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.81	10.93	0.57	6.3e-23	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11203032	0.831	rs10887927	chr10:90940687	T/C	cg16672925	chr10:90967113	CH25H	0.76	8.01	0.45	4.68e-14	Heart failure;
KIRP	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg02023728	chr11:77925099	USP35	0.3	5.17	0.31	4.78e-7	Alzheimer's disease (survival time);
KIRP	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.72	5.89	0.35	1.28e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.54	7.64	0.44	4.73e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7267005	0.661	rs74431448	chr20:34427680	T/C	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7520050	0.902	rs4638056	chr1:46458153	T/G	cg24296786	chr1:45957014	TESK2	0.4	5.05	0.31	8.55e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg08668510	chr10:1095578	IDI1	0.94	6.91	0.4	4.13e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05025164	chr4:1340916	KIAA1530	-0.5	-6.42	-0.38	6.85e-10	Obesity-related traits;
KIRP	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.51	6.23	0.37	2.01e-9	Menopause (age at onset);
KIRP	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg08662619	chr6:150070041	PCMT1	0.32	5.01	0.3	1.02e-6	Lung cancer;
KIRP	cis	rs10073892	0.664	rs2895833	chr5:101880489	G/A	cg19774478	chr5:101632501	SLCO4C1	0.59	5.87	0.35	1.42e-8	Cognitive decline (age-related);
KIRP	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8033133	0.678	rs7496110	chr15:25347013	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.41	-4.85	-0.3	2.24e-6	Blood osmolality (transformed sodium);
KIRP	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg08847533	chr14:75593920	NEK9	-0.43	-5.13	-0.31	5.93e-7	IgG glycosylation;
KIRP	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.98	-0.41	2.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg26134248	chr17:3907702	NA	0.59	8.78	0.49	2.92e-16	Type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23961059	chr19:57874869	ZNF547;TRAPPC2P1	0.59	7.23	0.42	6.14e-12	Smoking initiation;
KIRP	cis	rs7587476	0.501	rs11888027	chr2:215639612	A/C	cg04004882	chr2:215674386	BARD1	-0.47	-5.29	-0.32	2.73e-7	Neuroblastoma;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-1.06	-19.81	-0.78	7.14e-53	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	1.05	19.05	0.77	2.59e-50	Heart rate;
KIRP	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.95	15.24	0.7	2.3e-37	Testicular germ cell tumor;
KIRP	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.65	10.32	0.55	5.56e-21	Bone mineral density;
KIRP	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg11569703	chr11:65557185	OVOL1	-0.48	-8.57	-0.48	1.18e-15	Acne (severe);
KIRP	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.6	-6.72	-0.39	1.25e-10	Aortic root size;
KIRP	cis	rs9603616	0.934	rs34394770	chr13:40333369	T/C	cg26701198	chr13:40229707	COG6	-0.47	-5.18	-0.31	4.58e-7	Rheumatoid arthritis;
KIRP	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.63	8.02	0.46	4.44e-14	Tonsillectomy;
KIRP	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	11.05	0.58	2.52e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg14930904	chr10:32216787	ARHGAP12	0.36	4.88	0.3	1.89e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg08975724	chr8:8085496	FLJ10661	0.63	7.96	0.45	6.51e-14	Platelet distribution width;
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg23693289	chr8:27183097	PTK2B	0.56	7.13	0.41	1.1e-11	Neuroticism;
KIRP	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg24881330	chr22:46731750	TRMU	0.74	5.22	0.32	3.87e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Colorectal cancer;
KIRP	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg18279126	chr7:2041391	MAD1L1	-0.45	-5.15	-0.31	5.34e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.9	12.59	0.63	2.25e-28	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01300405	chr19:19626978	NDUFA13;TSSK6	0.49	6.36	0.38	9.98e-10	Parkinson's disease;
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21016266	chr12:122356598	WDR66	0.48	6.53	0.38	3.83e-10	Mean corpuscular volume;
KIRP	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.41	-0.47	3.34e-15	Colorectal cancer;
KIRP	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg25866889	chr13:114914595	NA	-0.39	-5.28	-0.32	2.82e-7	Schizophrenia;
KIRP	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22117172	chr7:91764530	CYP51A1	0.46	6.29	0.37	1.41e-9	Breast cancer;
KIRP	cis	rs787274	0.681	rs787284	chr9:115538040	A/G	cg13803584	chr9:115635662	SNX30	-0.74	-8.4	-0.47	3.67e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02711726	chr17:80685570	FN3KRP	0.5	7.41	0.43	2.08e-12	Glycated hemoglobin levels;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg25360059	chr21:44040169	NA	-0.92	-6.03	-0.36	6e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs236907	0.859	rs7536142	chr1:171770336	A/G	cg01410279	chr1:171621941	MYOC	-0.47	-5.37	-0.32	1.84e-7	Mean platelet volume;
KIRP	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg04438997	chr17:70115868	SOX9	0.38	5.7	0.34	3.41e-8	Thyroid hormone levels;
KIRP	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.63	-7.6	-0.44	6.18e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2562456	0.641	rs62107468	chr19:21489979	A/C	cg24072202	chr19:22235272	ZNF257	-0.53	-4.92	-0.3	1.59e-6	Pain;
KIRP	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg08885076	chr2:99613938	TSGA10	0.55	9.66	0.52	6.16e-19	Chronic sinus infection;
KIRP	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.19	-19.28	-0.78	4.35e-51	Ulcerative colitis;
KIRP	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.76	-0.44	2.21e-13	Total cholesterol levels;
KIRP	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg23335576	chr14:104009727	NA	0.4	5.47	0.33	1.11e-7	Body mass index;
KIRP	cis	rs80282103	0.618	rs74117848	chr10:1160974	T/G	cg08668510	chr10:1095578	IDI1	0.93	6.16	0.37	2.96e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-5.3	-0.32	2.53e-7	Testicular germ cell tumor;
KIRP	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.24	17.86	0.75	2.65e-46	White matter hyperintensity burden;
KIRP	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg12042659	chr19:58951599	ZNF132	0.5	6.06	0.36	5.06e-9	Uric acid clearance;
KIRP	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs12210905	0.688	rs72845025	chr6:27524443	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-5.83	-0.35	1.72e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.65	0.39	1.89e-10	Bipolar disorder;
KIRP	cis	rs4889855	0.530	rs9914854	chr17:78598662	A/G	cg09596252	chr17:78655493	RPTOR	0.51	5.86	0.35	1.51e-8	Fractional excretion of uric acid;
KIRP	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.27	-0.32	2.92e-7	Pulmonary function;
KIRP	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.52	6.48	0.38	4.96e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.95	0.3	1.4e-6	Menopause (age at onset);
KIRP	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.22	-6.46	-0.38	5.42e-10	Coronary artery disease;
KIRP	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg20003494	chr4:90757398	SNCA	-0.41	-5.16	-0.31	5.15e-7	Neuroticism;
KIRP	cis	rs11583043	0.708	rs17123647	chr1:101529018	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	5.6	0.34	5.83e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.66	9.48	0.52	2.19e-18	Retinal vascular caliber;
KIRP	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.63	6.12	0.36	3.66e-9	Menarche (age at onset);
KIRP	cis	rs1020064	0.636	rs1529975	chr2:105929901	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.38	4.87	0.3	2e-6	AIDS;
KIRP	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-1.04	-13.69	-0.66	4.44e-32	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12697442	chr11:101981167	YAP1	-0.44	-6.2	-0.37	2.38e-9	Metabolic traits;
KIRP	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg06740227	chr12:86229804	RASSF9	0.44	5.57	0.33	6.82e-8	Major depressive disorder;
KIRP	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg18755752	chr8:142205143	DENND3	-0.46	-6.09	-0.36	4.42e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg11757124	chr7:157526947	PTPRN2	0.47	6.13	0.36	3.41e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7751419	0.651	rs4324776	chr6:39095146	G/T	cg08089693	chr6:39098871	NA	-0.67	-9.42	-0.51	3.36e-18	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg11502198	chr6:26597334	ABT1	0.53	6.59	0.39	2.6200000000000003e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.6	0.44	6.11e-13	Personality dimensions;
KIRP	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.7	9.58	0.52	1.16e-18	Mean corpuscular volume;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.41	4.99	0.3	1.13e-6	Common traits (Other);
KIRP	cis	rs10861661	1.000	rs4964491	chr12:107222515	G/A	cg21360079	chr12:107162445	NA	-0.62	-7.63	-0.44	5.02e-13	Triglyceride levels;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg23693289	chr8:27183097	PTK2B	0.58	7.47	0.43	1.42e-12	Neuroticism;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg01532694	chr8:8243576	NA	0.92	6.24	0.37	1.89e-9	P wave terminal force;
KIRP	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.51	6.38	0.38	8.59e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg16141378	chr3:129829833	LOC729375	0.51	6.37	0.38	9.26e-10	Retinal vascular caliber;
KIRP	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.9	-14.81	-0.69	6.41e-36	Urate levels in lean individuals;
KIRP	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg24296786	chr1:45957014	TESK2	0.62	8.37	0.47	4.3e-15	High light scatter reticulocyte count;
KIRP	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.46	6.01	0.36	6.58e-9	Hypertriglyceridemia;
KIRP	cis	rs7714584	1.000	rs11743488	chr5:150279218	A/G	cg22134413	chr5:150180641	NA	0.91	6.9	0.4	4.44e-11	Crohn's disease;
KIRP	trans	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg13565492	chr6:43139072	SRF	-0.93	-8.54	-0.48	1.46e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	0.62	5.35	0.32	2.05e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg06481639	chr22:41940642	POLR3H	-0.45	-4.95	-0.3	1.37e-6	Neuroticism;
KIRP	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.44	-0.38	6.32e-10	Neuroticism;
KIRP	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	1.0	8.13	0.46	2.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.47	0.33	1.09e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg18032046	chr6:28092343	ZSCAN16	0.54	5.7	0.34	3.34e-8	Parkinson's disease;
KIRP	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.64	-7.58	-0.44	7.16e-13	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg03788504	chr6:150331562	NA	-0.27	-4.91	-0.3	1.68e-6	Alopecia areata;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10667709	chr2:218712772	TNS1	0.53	6.5	0.38	4.55e-10	Interleukin-4 levels;
KIRP	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg09795085	chr6:101329169	ASCC3	0.47	5.48	0.33	1.03e-7	Neuroticism;
KIRP	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.3	-0.37	1.4e-9	IgG glycosylation;
KIRP	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg04287289	chr16:89883240	FANCA	-0.42	-5.33	-0.32	2.25e-7	Vitiligo;
KIRP	cis	rs2486288	0.656	rs12908581	chr15:45548635	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.46	-5.28	-0.32	2.89e-7	Glomerular filtration rate;
KIRP	cis	rs8002861	0.747	rs12866387	chr13:44391936	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.24	0.32	3.46e-7	Leprosy;
KIRP	cis	rs9790314	0.582	rs13071909	chr3:160604864	A/G	cg04691961	chr3:161091175	C3orf57	0.44	6.25	0.37	1.82e-9	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.08	-0.58	2.01e-23	Height;
KIRP	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg21419209	chr3:44054225	NA	-0.67	-8.3	-0.47	6.97e-15	Coronary artery disease;
KIRP	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6840360	0.582	rs4473638	chr4:152322146	C/T	cg25486957	chr4:152246857	NA	-0.42	-5.03	-0.31	9.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6539288	0.803	rs7307895	chr12:107332126	A/C	cg26297688	chr12:107349093	C12orf23	-0.37	-5.13	-0.31	5.88e-7	Total body bone mineral density;
KIRP	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg24375607	chr4:120327624	NA	0.57	5.87	0.35	1.37e-8	Corneal astigmatism;
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.52	0.65	1.65e-31	Platelet count;
KIRP	cis	rs4971059	0.654	rs10157801	chr1:155120012	A/G	cg02153340	chr1:155202674	NA	-0.44	-6.38	-0.38	8.54e-10	Breast cancer;
KIRP	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.59	8.37	0.47	4.28e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs675026	0.926	rs678122	chr6:154450103	A/T	cg07813322	chr6:154414604	OPRM1	-0.44	-5.72	-0.34	3.04e-8	Hypertension;
KIRP	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg05333889	chr7:157238977	NA	-0.53	-7.87	-0.45	1.13e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs4664293	0.867	rs13022404	chr2:160589492	C/A	cg08347373	chr2:160653686	CD302	-0.45	-6.69	-0.39	1.53e-10	Monocyte percentage of white cells;
KIRP	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05665937	chr4:1216051	CTBP1	-0.44	-5.45	-0.33	1.24e-7	Obesity-related traits;
KIRP	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	0.89	12.9	0.64	1.95e-29	Dupuytren's disease;
KIRP	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.37	5.88	0.35	1.36e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2239815	0.545	rs5762855	chr22:29246605	A/T	cg02153584	chr22:29168773	CCDC117	0.57	5.24	0.32	3.43e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.7	-10.73	-0.56	2.72e-22	Height;
KIRP	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18252515	chr7:66147081	NA	0.45	5.3	0.32	2.59e-7	Aortic root size;
KIRP	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs7084402	0.967	rs1658454	chr10:60306770	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg01849466	chr14:104193079	ZFYVE21	0.41	4.86	0.3	2.09e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs12230513	1.000	rs7304684	chr12:55895538	C/T	cg19537932	chr12:55886519	OR6C68	-0.46	-5.05	-0.31	8.5e-7	Contrast sensitivity;
KIRP	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg27490568	chr2:178487706	NA	0.48	6.45	0.38	6.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg01721255	chr8:58191610	C8orf71	0.59	5.42	0.33	1.43e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.89	0.3	1.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.77	11.47	0.59	1.08e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg21361702	chr7:150065534	REPIN1	0.74	7.49	0.43	1.22e-12	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22610533	chr12:64238379	SRGAP1	0.49	6.25	0.37	1.78e-9	Parkinson's disease;
KIRP	cis	rs236907	0.859	rs2232813	chr1:171750577	T/C	cg01410279	chr1:171621941	MYOC	-0.52	-5.94	-0.35	9.55e-9	Mean platelet volume;
KIRP	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.57	6.92	0.4	3.87e-11	Aortic root size;
KIRP	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.22	13.44	0.65	2.98e-31	Nonalcoholic fatty liver disease;
KIRP	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.17	-0.37	2.83e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1978968	0.956	rs4992882	chr22:18445021	T/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs11679564	0.714	rs10490657	chr2:37178255	C/T	cg14987922	chr2:37194071	STRN	0.48	5.58	0.34	6.24e-8	Immature fraction of reticulocytes;
KIRP	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg00919237	chr7:87102261	ABCB4	-0.75	-9.44	-0.52	3.05e-18	Gallbladder cancer;
KIRP	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.75	9.21	0.51	1.45e-17	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.06	-0.31	8.18e-7	Schizophrenia;
KIRP	cis	rs3818717	0.539	rs12950737	chr17:17678573	G/A	cg02336718	chr17:17403227	NA	-0.34	-5.31	-0.32	2.4e-7	Lymphocyte counts;
KIRP	cis	rs78487399	0.808	rs75934770	chr2:43659694	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg23100626	chr2:96804247	ASTL	0.46	6.45	0.38	5.94e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.37	-6.81	-0.4	7.25e-11	Renal cell carcinoma;
KIRP	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg19338460	chr6:170058176	WDR27	0.67	7.4	0.43	2.18e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.41	-5.11	-0.31	6.59e-7	Obesity-related traits;
KIRP	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.51	6.85	0.4	6.05e-11	Schizophrenia;
KIRP	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.69	9.77	0.53	2.88e-19	Retinal vascular caliber;
KIRP	cis	rs4073416	0.508	rs6573619	chr14:66061560	T/C	cg03016385	chr14:66212404	NA	-0.53	-6.46	-0.38	5.51e-10	N-glycan levels;
KIRP	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.44	-5.56	-0.33	6.91e-8	Schizophrenia;
KIRP	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg08885800	chr1:201084119	NA	0.36	4.94	0.3	1.45e-6	Permanent tooth development;
KIRP	cis	rs731174	0.797	rs586252	chr1:38155265	G/C	cg14170840	chr1:38155120	C1orf109	-0.41	-5.27	-0.32	3.04e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-6.9	-0.4	4.33e-11	Vitiligo;
KIRP	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg10818794	chr15:86012489	AKAP13	-0.5	-7.16	-0.42	9.39e-12	Coronary artery disease;
KIRP	cis	rs7998202	0.667	rs410948	chr13:113370140	C/T	cg04656015	chr13:113407548	ATP11A	-0.57	-6.3	-0.37	1.35e-9	Glycated hemoglobin levels;
KIRP	cis	rs7011049	0.778	rs11785654	chr8:53873364	A/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg11833968	chr6:79620685	NA	-0.42	-6.17	-0.37	2.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs714515	0.934	rs7517737	chr1:172341975	C/A	cg01573306	chr1:172330400	DNM3	0.45	5.81	0.35	1.92e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg00738919	chr7:1100172	C7orf50	0.43	4.97	0.3	1.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.61	8.81	0.49	2.34e-16	Colorectal cancer;
KIRP	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.61	-8.21	-0.46	1.24e-14	Colorectal cancer;
KIRP	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg11189052	chr15:85197271	WDR73	-0.41	-4.98	-0.3	1.21e-6	P wave terminal force;
KIRP	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg10130564	chr11:117069849	TAGLN	0.4	5.01	0.3	1.04e-6	Blood protein levels;
KIRP	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.66	10.11	0.54	2.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs11997175	0.740	rs4733462	chr8:33679904	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.91	0.35	1.14e-8	Body mass index;
KIRP	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.54	-6.48	-0.38	5.04e-10	Corneal astigmatism;
KIRP	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.14	16.16	0.72	1.64e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.6	-0.48	9.25e-16	Blood trace element (Zn levels);
KIRP	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.7	-8.96	-0.5	8.27e-17	Body mass index;
KIRP	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg00656387	chr3:40428638	ENTPD3	0.4	5.07	0.31	7.81e-7	Renal cell carcinoma;
KIRP	cis	rs4956211	0.579	rs11098002	chr4:109712594	C/G	cg07086381	chr4:109682776	AGXT2L1	-0.39	-5.14	-0.31	5.52e-7	Systemic lupus erythematosus;
KIRP	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.79	-0.57	1.74e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs520865	0.786	rs659130	chr5:80343558	T/G	cg17330048	chr5:80257322	RASGRF2	-0.46	-6.77	-0.4	9.24e-11	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.66	-7.02	-0.41	2.13e-11	Vitiligo;
KIRP	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.34	12.18	0.61	4.94e-27	Diabetic retinopathy;
KIRP	cis	rs780094	0.500	rs4666002	chr2:27840640	G/C	cg05484376	chr2:27715224	FNDC4	-0.37	-5.1	-0.31	6.89e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.62e-12	Menopause (age at onset);
KIRP	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.74e-7	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg19507638	chr5:93509721	C5orf36	-0.57	-5.45	-0.33	1.21e-7	Diabetic retinopathy;
KIRP	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.78	0.6	1.1e-25	Total body bone mineral density;
KIRP	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.66	9.77	0.53	2.85e-19	Retinal vascular caliber;
KIRP	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.92	-10.44	-0.55	2.32e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.34	0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.77e-10	Protein C levels;
KIRP	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg03289416	chr15:75166202	SCAMP2	-0.43	-6.11	-0.36	3.78e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs10465746	0.967	rs11163874	chr1:84424437	G/C	cg10977910	chr1:84465055	TTLL7	0.48	5.86	0.35	1.44e-8	Obesity-related traits;
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg09165964	chr15:75287851	SCAMP5	0.55	7.15	0.41	9.84e-12	Caffeine consumption;
KIRP	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	1.04	20.21	0.79	3.54e-54	Breast cancer;
KIRP	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.84	8.44	0.47	2.77e-15	Iron status biomarkers;
KIRP	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00585698	chr12:123750864	CDK2AP1	-0.5	-6.12	-0.36	3.64e-9	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs4389656	0.922	rs35768130	chr5:6704551	C/T	cg10857441	chr5:6722123	POLS	0.43	5.35	0.32	2.02e-7	Coronary artery disease;
KIRP	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg20542592	chr8:11973495	FAM66D	0.39	4.99	0.3	1.12e-6	Neuroticism;
KIRP	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.03	-0.41	2e-11	Breast cancer;
KIRP	cis	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	5.29	0.32	2.64e-7	Leprosy;
KIRP	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.78	9.04	0.5	4.7e-17	Mean platelet volume;
KIRP	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23903597	chr17:61704154	MAP3K3	-0.64	-8.31	-0.47	6.53e-15	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.89	11.23	0.58	6.6e-24	Platelet distribution width;
KIRP	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.66	0.48	6.17e-16	Motion sickness;
KIRP	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.44	-5.23	-0.32	3.56e-7	Neurofibrillary tangles;
KIRP	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg13819577	chr1:248512075	OR14C36	-0.36	-5.1	-0.31	6.7e-7	Common traits (Other);
KIRP	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-8.93	-0.49	1.01e-16	Total body bone mineral density;
KIRP	cis	rs7113874	0.802	rs4272783	chr11:8685393	C/T	cg08015107	chr11:8618950	NA	-0.42	-5.84	-0.35	1.63e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs490234	0.812	rs10121109	chr9:128455206	C/A	cg14078157	chr9:128172775	NA	-0.58	-6.73	-0.39	1.21e-10	Mean arterial pressure;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg18386867	chr2:39347986	SOS1	0.5	6.06	0.36	4.96e-9	Plasma plasminogen activator levels;
KIRP	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg19913688	chr11:428466	ANO9	-0.69	-5.15	-0.31	5.29e-7	Body mass index;
KIRP	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg11569703	chr11:65557185	OVOL1	0.73	13.88	0.66	9.89e-33	Acne (severe);
KIRP	cis	rs4148660	0.697	rs7138546	chr12:22039987	A/G	cg14669847	chr12:22099120	NA	0.35	5.56	0.33	7e-8	Gout;
KIRP	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg11859384	chr17:80120422	CCDC57	-0.47	-5.98	-0.36	7.72e-9	Life satisfaction;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19925801	chr2:175083424	OLA1	0.38	6.16	0.37	2.9e-9	C-reactive protein;
KIRP	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.81	5.12	0.31	6.22e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11987759	chr7:65425863	GUSB	0.47	6.02	0.36	6.33e-9	Aortic root size;
KIRP	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg19773385	chr1:10388646	KIF1B	-0.67	-10.52	-0.56	1.27e-21	Hepatocellular carcinoma;
KIRP	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg21573476	chr21:45109991	RRP1B	-0.51	-6.71	-0.39	1.34e-10	Mean corpuscular volume;
KIRP	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00563238	chr6:26055103	NA	-0.46	-6.12	-0.36	3.66e-9	Obesity-related traits;
KIRP	cis	rs7614311	0.594	rs3774709	chr3:63882476	A/G	cg22134162	chr3:63841271	THOC7	-0.41	-5.92	-0.35	1.06e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7520050	0.966	rs12760175	chr1:46447840	G/C	cg24296786	chr1:45957014	TESK2	0.42	4.99	0.3	1.12e-6	Red blood cell count;Reticulocyte count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03157738	chr19:11308118	KANK2	0.48	6.39	0.38	8.03e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-8.08	-0.46	2.85e-14	Body mass index;
KIRP	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg04166393	chr7:2884313	GNA12	0.4	5.26	0.32	3.21e-7	Height;
KIRP	cis	rs17321999	0.516	rs7569754	chr2:30502177	A/C	cg05247661	chr2:30472410	LBH	0.59	5.15	0.31	5.36e-7	Systemic lupus erythematosus;
KIRP	cis	rs867371	0.502	rs8025964	chr15:82521770	G/A	cg00614314	chr15:82944287	LOC80154	0.4	5.08	0.31	7.42e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Breast cancer;
KIRP	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg26354017	chr1:205819088	PM20D1	-0.4	-5.04	-0.31	9.07e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02099313	chr1:231114956	TTC13;ARV1	0.54	6.32	0.37	1.2e-9	Smoking initiation;
KIRP	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.92	0.35	1.05e-8	Type 2 diabetes;
KIRP	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	1.05	11.03	0.58	3.1e-23	Nonalcoholic fatty liver disease;
KIRP	cis	rs1983170	0.799	rs2063055	chr1:92020835	G/T	cg02896835	chr1:92012615	NA	0.44	4.99	0.3	1.15e-6	Eosinophil percentage of white cells;
KIRP	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg10017260	chr10:834428	NA	-0.56	-5.51	-0.33	9.09e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg16988262	chr1:15930761	NA	0.39	5.01	0.3	1.06e-6	Systolic blood pressure;
KIRP	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.53	7.09	0.41	1.38e-11	Alcohol dependence;
KIRP	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg21827317	chr3:136751795	NA	0.37	5.09	0.31	7.1e-7	Neuroticism;
KIRP	cis	rs6504950	0.821	rs8066588	chr17:53025689	C/T	cg26251398	chr17:52985966	TOM1L1	0.42	5.2	0.31	4.12e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23071808	chr14:103021642	NA	0.51	7.54	0.43	8.85e-13	Parkinson's disease;
KIRP	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg13147721	chr7:65941812	NA	-1.02	-7.05	-0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7830939	0.586	rs9918809	chr8:9320959	A/C	cg16141378	chr3:129829833	LOC729375	0.49	6.05	0.36	5.26e-9	Neuroticism;
KIRP	cis	rs220519	0.708	rs220510	chr20:37291962	T/C	cg24308336	chr20:37270989	C20orf95	0.23	4.89	0.3	1.79e-6	Schizophrenia;
KIRP	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg03808351	chr9:123631620	PHF19	0.4	5.45	0.33	1.23e-7	Rheumatoid arthritis;
KIRP	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg11569703	chr11:65557185	OVOL1	0.4	6.7	0.39	1.4e-10	Systemic lupus erythematosus;
KIRP	cis	rs9863706	1.000	rs9863706	chr3:72437413	C/T	cg05607079	chr3:72387937	NA	0.44	5.3	0.32	2.52e-7	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08655493	chr21:33765248	URB1;C21orf119	0.52	6.04	0.36	5.79e-9	Smoking initiation;
KIRP	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg05361325	chr10:32636312	EPC1	-0.67	-6.34	-0.37	1.08e-9	Sexual dysfunction (female);
KIRP	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.71	-0.73	2.19e-42	Intelligence (multi-trait analysis);
KIRP	trans	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg06521331	chr12:34319734	NA	-0.57	-6.94	-0.4	3.53e-11	Bladder cancer;
KIRP	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg08873628	chr1:175162347	KIAA0040	-0.4	-5.89	-0.35	1.28e-8	Alcohol dependence;
KIRP	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.13	-0.36	3.48e-9	Dilated cardiomyopathy;
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg11859384	chr17:80120422	CCDC57	-0.47	-5.89	-0.35	1.26e-8	Life satisfaction;
KIRP	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg17372223	chr3:52568218	NT5DC2	0.32	5.34	0.32	2.12e-7	Bipolar disorder;
KIRP	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg23958373	chr8:599963	NA	1.05	7.85	0.45	1.28e-13	IgG glycosylation;
KIRP	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg05714579	chr10:131428358	MGMT	0.46	5.94	0.35	9.43e-9	Response to temozolomide;
KIRP	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg19913688	chr11:428466	ANO9	-0.75	-5.91	-0.35	1.15e-8	Body mass index;
KIRP	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.08	0.31	7.4e-7	Personality dimensions;
KIRP	cis	rs6691722	0.503	rs2274167	chr1:24707296	C/T	cg18323236	chr1:24743029	NIPAL3	0.45	6.51	0.38	4.21e-10	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs7225151	0.710	rs113151753	chr17:5185365	C/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.88	-0.35	1.35e-8	Alzheimer's disease (late onset);
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg00538017	chr6:64029870	LGSN	0.43	6.31	0.37	1.32e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg16988262	chr1:15930761	NA	0.38	4.97	0.3	1.28e-6	Systolic blood pressure;
KIRP	cis	rs6973256	0.828	rs10954431	chr7:133430901	A/C	cg10665199	chr7:133106180	EXOC4	0.48	5.65	0.34	4.5e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.65	0.48	6.69e-16	Prudent dietary pattern;
KIRP	trans	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg21775007	chr8:11205619	TDH	0.47	6.32	0.37	1.24e-9	Mood instability;
KIRP	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.71	-8.03	-0.46	4.04e-14	Pursuit maintenance gain;
KIRP	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg16511985	chr3:153974050	SGEF	0.42	5.79	0.35	2.13e-8	Coronary artery disease;
KIRP	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.51	-6.33	-0.37	1.13e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	0.83	8.23	0.46	1.07e-14	Mitochondrial DNA levels;
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	5.58	0.34	6.3e-8	Longevity;
KIRP	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg25486957	chr4:152246857	NA	-0.43	-5.14	-0.31	5.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg21573476	chr21:45109991	RRP1B	-0.62	-8.29	-0.47	7.54e-15	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12571005	chr2:202316370	STRADB;TRAK2	0.48	6.45	0.38	6.04e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.45	8.61	0.48	9.06e-16	Educational attainment (years of education);
KIRP	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.38	-0.32	1.71e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg04691961	chr3:161091175	C3orf57	-0.37	-5.56	-0.33	7.12e-8	Morning vs. evening chronotype;
KIRP	trans	rs1973993	0.745	rs6593602	chr1:96951281	G/A	cg10631902	chr5:14652156	NA	-0.59	-8.31	-0.47	6.62e-15	Weight;
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs8054556	1.000	rs4788197	chr16:29970834	G/A	cg06326092	chr16:30034487	C16orf92	0.36	5.12	0.31	6.29e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg05717871	chr11:638507	DRD4	-0.39	-5.35	-0.32	2.03e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.61	-0.34	5.37e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg23396286	chr10:99258505	UBTD1;MMS19	0.46	6.04	0.36	5.72e-9	Pneumonia;
KIRP	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.5	8.67	0.48	5.97e-16	Erythrocyte sedimentation rate;
KIRP	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg21108841	chr4:24914750	CCDC149	-0.46	-5.65	-0.34	4.42e-8	Heschl's gyrus morphology;
KIRP	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	1.03	19.06	0.77	2.28e-50	Heart rate;
KIRP	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.57	-7.18	-0.42	8.39e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.46	-0.33	1.19e-7	Homoarginine levels;
KIRP	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21747090	chr2:27597821	SNX17	-0.46	-6.4	-0.38	7.62e-10	Total body bone mineral density;
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	12.2	0.61	4.5e-27	Platelet count;
KIRP	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg12437481	chr16:420112	MRPL28	0.48	6.47	0.38	5.17e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.74	-0.39	1.15e-10	Type 2 diabetes;
KIRP	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg06636001	chr8:8085503	FLJ10661	0.62	8.87	0.49	1.52e-16	Neuroticism;
KIRP	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg11941060	chr3:133502564	NA	-0.48	-5.9	-0.35	1.23e-8	Iron status biomarkers;
KIRP	cis	rs4523957	0.788	rs11651451	chr17:2098417	C/T	cg16513277	chr17:2031491	SMG6	-0.62	-8.83	-0.49	1.99e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1635	0.512	rs73742545	chr6:28319023	T/G	cg15743358	chr6:28303923	ZNF323	-0.89	-5.82	-0.35	1.83e-8	Schizophrenia;
KIRP	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs11214589	0.747	rs10502172	chr11:113199146	C/T	cg14159747	chr11:113255604	NA	0.41	6.1	0.36	4.06e-9	Neuroticism;
KIRP	cis	rs9831754	1.000	rs1028024	chr3:78371577	A/C	cg06138941	chr3:78371609	NA	-0.94	-14.59	-0.68	3.69e-35	Calcium levels;
KIRP	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-11.85	-0.6	6.52e-26	Vitiligo;
KIRP	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.45	6.65	0.39	1.89e-10	Major depressive disorder;
KIRP	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg12435725	chr3:58293450	RPP14	-0.47	-5.07	-0.31	7.85e-7	Cholesterol, total;
KIRP	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-0.78	-10.67	-0.56	4.2e-22	Uric acid levels;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg01765077	chr12:122356316	WDR66	-0.59	-8.37	-0.47	4.39e-15	Mean corpuscular volume;
KIRP	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs13082711	1.000	rs35944308	chr3:27536356	G/A	cg02860705	chr3:27208620	NA	0.59	7.55	0.43	8.53e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs745080	0.674	rs35763882	chr14:52996184	C/G	cg23333723	chr14:53022898	GPR137C	-0.41	-5.64	-0.34	4.67e-8	Orofacial clefts;
KIRP	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg13939156	chr17:80058883	NA	-0.46	-6.87	-0.4	5.19e-11	Life satisfaction;
KIRP	cis	rs6708331	0.540	rs11890701	chr2:70360457	T/A	cg01613454	chr2:70366299	NA	0.4	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg09201719	chr10:104596890	CYP17A1	0.36	5.02	0.3	9.87e-7	Arsenic metabolism;
KIRP	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4006360	0.525	rs3907875	chr17:39268353	A/G	cg15015397	chr17:39261100	KRTAP4-9	0.39	5.48	0.33	1.07e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg24315340	chr6:146058215	EPM2A	-0.4	-4.98	-0.3	1.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg12861170	chr19:19639553	YJEFN3	-0.47	-5.31	-0.32	2.43e-7	Bipolar disorder;
KIRP	trans	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.34	0.37	1.1e-9	Retinal vascular caliber;
KIRP	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg09990169	chr2:241835740	C2orf54	-0.45	-6.68	-0.39	1.57e-10	Urinary metabolites;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.55	-0.56	1.04e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg11663144	chr21:46675770	NA	-0.67	-9.85	-0.53	1.67e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2790457	0.958	rs2532742	chr10:28867220	C/G	cg05705492	chr10:28955341	NA	-0.54	-8.24	-0.46	1.05e-14	Multiple myeloma;
KIRP	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.78	10.33	0.55	5.32e-21	Gestational age at birth (maternal effect);
KIRP	cis	rs832540	0.519	rs10036895	chr5:56273693	G/A	cg12311346	chr5:56204834	C5orf35	-0.38	-5.08	-0.31	7.48e-7	Coronary artery disease;
KIRP	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg26818010	chr10:134567672	INPP5A	-0.64	-7.11	-0.41	1.27e-11	Migraine;
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21016266	chr12:122356598	WDR66	-0.59	-7.91	-0.45	8.8e-14	Mean corpuscular volume;
KIRP	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.9	-14.13	-0.67	1.4e-33	Total body bone mineral density;
KIRP	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg24110177	chr3:50126178	RBM5	-0.75	-10.23	-0.55	1.08e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs12580194	0.593	rs7971053	chr12:55729947	A/C	cg19537932	chr12:55886519	OR6C68	-0.49	-6.64	-0.39	2.04e-10	Cancer;
KIRP	cis	rs7937612	1.000	rs7117321	chr11:120239051	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.07	-0.41	1.61e-11	Intraocular pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12885476	chr2:191514216	NAB1	-0.53	-6.15	-0.37	3.07e-9	Interleukin-4 levels;
KIRP	cis	rs2120243	0.658	rs7626884	chr3:157144149	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.45	5.8	0.35	2.08e-8	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17977556	chr15:69553073	GLCE	0.39	6.1	0.36	4.08e-9	C-reactive protein;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg08132940	chr7:1081526	C7orf50	-0.46	-5.28	-0.32	2.79e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg13699009	chr12:122356056	WDR66	-0.54	-7.41	-0.43	2.07e-12	Mean corpuscular volume;
KIRP	cis	rs362296	0.671	rs1006798	chr4:3258373	A/G	cg06533319	chr4:3265114	C4orf44	0.56	6.72	0.39	1.23e-10	Parental longevity (mother's age at death);
KIRP	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	trans	rs10863936	0.558	rs7522330	chr1:212234104	A/T	cg01877301	chr20:25371700	ABHD12	-0.55	-6.5	-0.38	4.44e-10	Height;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7172677	0.695	rs8029756	chr15:75435790	C/T	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg06671706	chr8:8559999	CLDN23	0.56	6.29	0.37	1.47e-9	Obesity-related traits;
KIRP	cis	rs2733310	0.947	rs8024901	chr15:57574308	G/A	cg13626582	chr15:57592083	LOC283663	0.28	6.56	0.39	3.13e-10	Mean platelet volume;
KIRP	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.31	0.32	2.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs66569888	0.789	rs17213510	chr2:106742778	T/C	cg16099169	chr2:106886729	NA	-0.69	-8.09	-0.46	2.65e-14	Facial morphology (factor 23);
KIRP	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg24826892	chr11:71159390	DHCR7	0.44	5.24	0.32	3.42e-7	Vitamin D levels;
KIRP	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg12573791	chr2:3828286	NA	0.41	5.68	0.34	3.88e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg00405596	chr8:11794950	NA	-0.5	-6.5	-0.38	4.34e-10	Triglycerides;
KIRP	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.5	7.55	0.43	8.3e-13	Lung cancer;
KIRP	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg25902810	chr10:99078978	FRAT1	0.6	7.6	0.44	6.24e-13	Monocyte count;
KIRP	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.97	0.45	5.97e-14	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.89	0.71	1.37e-39	Metabolic syndrome;
KIRP	cis	rs9517320	1.000	rs912337	chr13:99141272	A/G	cg07423050	chr13:99094983	FARP1	-0.31	-5.02	-0.31	9.76e-7	Longevity;
KIRP	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg18585693	chr11:117668161	DSCAML1	0.32	5.19	0.31	4.34e-7	Myopia;
KIRP	cis	rs6832769	0.925	rs6829182	chr4:56454156	C/T	cg09317128	chr4:56265301	TMEM165	0.5	6.59	0.39	2.68e-10	Personality dimensions;
KIRP	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.44	-5.3	-0.32	2.57e-7	Menarche (age at onset);
KIRP	cis	rs7175404	0.877	rs56404011	chr15:94064880	A/G	cg23502883	chr15:93959149	NA	0.53	5.6	0.34	5.85e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg11833968	chr6:79620685	NA	-0.46	-6.91	-0.4	4.03e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.78e-7	Aortic root size;
KIRP	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.78	7.26	0.42	5e-12	Mean platelet volume;
KIRP	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs7709377	0.570	rs13184073	chr5:115437906	T/C	cg23108291	chr5:115420582	COMMD10	0.43	5.15	0.31	5.21e-7	Metabolite levels  (X-11787);
KIRP	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-4.92	-0.3	1.58e-6	Mean platelet volume;
KIRP	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg07382826	chr16:28625726	SULT1A1	0.51	5.53	0.33	8.24e-8	Body mass index;
KIRP	trans	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg13565492	chr6:43139072	SRF	-0.96	-10.93	-0.57	6.14e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-5.2	-0.31	4.21e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.54	0.38	3.63e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	0.71	6.37	0.38	9.32e-10	Skin colour saturation;
KIRP	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.11	-0.64	3.87e-30	Intelligence (multi-trait analysis);
KIRP	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.81	-0.45	1.62e-13	Neuroticism;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.66	8.47	0.48	2.22e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg21892295	chr12:121157589	UNC119B	-0.4	-5.68	-0.34	3.8e-8	Mean corpuscular volume;
KIRP	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg02415014	chr8:143852576	LYNX1	-0.31	-5.07	-0.31	7.74e-7	Urinary tract infection frequency;
KIRP	cis	rs7224314	1.000	rs8066725	chr17:65387326	G/A	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.33	-0.42	3.37e-12	Diisocyanate-induced asthma;
KIRP	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.65	8.35	0.47	5.02e-15	Red blood cell count;
KIRP	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.64	7.96	0.45	6.51e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	cis	rs1018697	0.966	rs10748831	chr10:104558743	T/C	cg04362960	chr10:104952993	NT5C2	0.5	6.04	0.36	5.74e-9	Colorectal adenoma (advanced);
KIRP	cis	rs9462846	0.959	rs9471958	chr6:42883669	C/T	cg02353165	chr6:42928485	GNMT	0.48	5.25	0.32	3.3e-7	Blood protein levels;
KIRP	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.48	-0.56	1.73e-21	Neuroticism;
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.91	14.54	0.68	5.51e-35	Dental caries;
KIRP	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg23352942	chr3:46931381	PTH1R	-0.52	-6.94	-0.4	3.38e-11	Birth weight;
KIRP	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg05333889	chr7:157238977	NA	-0.4	-5.58	-0.34	6.3e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs4742903	0.509	rs10991159	chr9:106960542	C/A	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.09	-0.36	4.36e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs35955747	0.633	rs5998021	chr22:31907427	C/G	cg02404636	chr22:31891804	SFI1	-0.38	-5.12	-0.31	6.12e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs4478137	0.501	rs4146926	chr4:164230788	C/G	cg06758707	chr4:164254230	NPY1R	-0.5	-5.51	-0.33	9.01e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9815354	0.812	rs967619	chr3:41876710	C/G	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	0.79	6.98	0.41	2.79e-11	Obesity-related traits;
KIRP	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.78	-0.35	2.27e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs35740288	0.770	rs11631449	chr15:86148653	T/C	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	0.81	8.77	0.49	3.1e-16	Gut microbiome composition (summer);
KIRP	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs12476592	0.602	rs1348805	chr2:63895673	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.94	-0.3	1.41e-6	Childhood ear infection;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.51	-0.56	1.34e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg05861140	chr6:150128134	PCMT1	-0.46	-5.87	-0.35	1.41e-8	Lung cancer;
KIRP	cis	rs9409565	0.787	rs11789704	chr9:97233408	C/T	cg04523069	chr9:97136363	HIATL1	0.46	6.22	0.37	2.09e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg25457927	chr22:38595422	NA	-0.32	-6.5	-0.38	4.47e-10	Breast cancer;
KIRP	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg11707556	chr5:10655725	ANKRD33B	0.67	8.45	0.47	2.61e-15	Coronary artery disease;
KIRP	cis	rs6585424	0.925	rs11201964	chr10:81931367	A/G	cg27417294	chr10:81904244	PLAC9	0.55	5.41	0.33	1.5e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.56e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9308731	0.583	rs2165107	chr2:111931350	C/G	cg04780086	chr2:111875790	ACOXL	0.44	6.02	0.36	6.19e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.46	-6.02	-0.36	6.24e-9	Height;
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.73	9.16	0.5	2.12e-17	Longevity;
KIRP	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-0.94	-11.64	-0.6	2.99e-25	Blood protein levels;
KIRP	cis	rs8077577	0.945	rs11656035	chr17:18086025	T/C	cg18869244	chr17:18121946	NA	0.5	5.74	0.34	2.74e-8	Obesity-related traits;
KIRP	cis	rs9581857	0.547	rs9579095	chr13:28082555	C/T	cg22138327	chr13:27999177	GTF3A	0.83	6.45	0.38	5.79e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.08	-0.54	3.25e-20	Response to antipsychotic treatment;
KIRP	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.48	6.39	0.38	8.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg15068132	chr12:102092402	CHPT1	-0.4	-5.22	-0.32	3.75e-7	Blood protein levels;
KIRP	cis	rs56079296	0.929	rs9327236	chr5:121279021	A/C	cg05256605	chr5:121412184	LOX	0.48	5.36	0.32	1.93e-7	Coronary artery disease;
KIRP	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg09137382	chr11:130731461	NA	0.56	8.16	0.46	1.71e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.07	-0.5	3.92e-17	Colorectal cancer;
KIRP	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.04	-0.36	5.76e-9	Body mass index;
KIRP	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-6.51	-0.38	4.25e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11955398	0.529	rs62373032	chr5:59956159	G/C	cg02684056	chr5:59996105	DEPDC1B	0.43	5.1	0.31	6.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12681366	0.734	rs13281619	chr8:95396886	A/G	cg13257157	chr8:95487014	RAD54B	0.4	4.93	0.3	1.52e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.65	-7.98	-0.45	5.44e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	4.99	0.3	1.16e-6	Diabetic retinopathy;
KIRP	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	4.95	0.3	1.38e-6	Breast cancer;
KIRP	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg25838818	chr2:108905173	SULT1C2	0.42	6.72	0.39	1.28e-10	Blood pressure;
KIRP	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg11503966	chr20:62272292	STMN3	-0.38	-4.85	-0.3	2.16e-6	Atopic dermatitis;
KIRP	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.88	10.43	0.55	2.47e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs3925075	1.000	rs9674009	chr16:31347541	C/A	cg02846316	chr16:31340340	ITGAM	0.61	9.65	0.52	6.7e-19	IgA nephropathy;
KIRP	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.47	5.82	0.35	1.83e-8	Mean platelet volume;
KIRP	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	1.17	7.66	0.44	4.38e-13	Type 2 diabetes nephropathy;
KIRP	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg23815491	chr16:72088622	HP	0.49	7.19	0.42	7.65e-12	Blood protein levels;
KIRP	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-7.07	-0.41	1.59e-11	Response to antipsychotic treatment;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.5	-0.52	2.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.77	-0.53	3.01e-19	Body mass index;
KIRP	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-1.16	-10.05	-0.54	4.06e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg05340658	chr4:99064831	C4orf37	-0.46	-5.19	-0.31	4.39e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs882732	1.000	rs3762122	chr14:95029351	A/T	cg08495878	chr14:95027859	SERPINA4	-0.43	-5.24	-0.32	3.48e-7	Blood protein levels;
KIRP	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	1.05	19.0	0.77	3.6e-50	Monocyte count;
KIRP	cis	rs10499694	0.967	rs7786398	chr7:50612906	G/A	cg00647317	chr7:50633725	DDC	0.41	6.12	0.36	3.66e-9	Body mass index;
KIRP	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs687432	0.924	rs11600171	chr11:57700763	T/C	cg19752551	chr11:57585705	CTNND1	-0.7	-9.24	-0.51	1.2e-17	Parkinson's disease;
KIRP	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg08873628	chr1:175162347	KIAA0040	0.44	6.52	0.38	3.87e-10	Alcohol dependence;
KIRP	cis	rs10231759	0.761	rs6955948	chr7:150508720	C/T	cg05726600	chr7:150498594	TMEM176B;TMEM176A	0.32	4.86	0.3	2.09e-6	Height;
KIRP	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	7.94	0.45	7.41e-14	LDL cholesterol;
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg24642844	chr7:1081250	C7orf50	-0.79	-8.72	-0.49	4.12e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7615316	0.779	rs9861997	chr3:142060862	T/A	cg20824294	chr3:142316082	PLS1	0.24	5.5	0.33	9.38e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	trans	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.28	0.37	1.55e-9	Mean corpuscular volume;
KIRP	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg05692746	chr2:100937584	LONRF2	-0.41	-5.34	-0.32	2.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg11150807	chr10:43354902	NA	-0.61	-5.31	-0.32	2.47e-7	Blood protein levels;
KIRP	cis	rs6882046	0.513	rs446219	chr5:88005827	T/C	cg22951263	chr5:87985283	NA	-0.44	-6.22	-0.37	2.06e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	trans	rs61931739	0.613	rs61927728	chr12:33667690	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.16	-0.37	2.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.46	9.33	0.51	6.32e-18	Multiple system atrophy;
KIRP	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.83	-14.17	-0.67	9.73e-34	Heart rate;
KIRP	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	12.31	0.62	1.88e-27	Menarche (age at onset);
KIRP	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.6	-8.92	-0.49	1.06e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg11498726	chr8:26250323	BNIP3L	-0.54	-8.06	-0.46	3.36e-14	Red cell distribution width;
KIRP	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-1.14	-14.69	-0.68	1.73e-35	Platelet distribution width;
KIRP	cis	rs28655083	0.673	rs2220233	chr16:77050294	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.61	-5.86	-0.35	1.51e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02599293	chr5:137090023	HNRNPA0	-0.57	-6.63	-0.39	2.12e-10	Interleukin-4 levels;
KIRP	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg09184832	chr6:79620586	NA	-0.53	-7.57	-0.43	7.4e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs34421088	0.532	rs3808515	chr8:11156041	C/T	cg00405596	chr8:11794950	NA	0.42	5.14	0.31	5.53e-7	Neuroticism;
KIRP	trans	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs10170310	1.000	rs6720716	chr2:139268802	A/G	cg03782584	chr2:139258740	SPOPL	0.3	4.86	0.3	2.06e-6	Response to antipsychotic treatment;
KIRP	cis	rs4132509	1.000	rs12049228	chr1:243995271	C/A	cg21452805	chr1:244014465	NA	0.56	5.23	0.32	3.63e-7	RR interval (heart rate);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02876066	chr19:18632993	ELL	0.48	6.74	0.39	1.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.5	6.42	0.38	6.93e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg05709478	chr1:6581295	PLEKHG5	-0.59	-5.44	-0.33	1.28e-7	Body mass index;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.33	0.47	5.63e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg14403583	chr14:105418241	AHNAK2	-0.71	-9.76	-0.53	3.23e-19	Rheumatoid arthritis;
KIRP	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.33	-0.32	2.22e-7	Coronary artery disease;
KIRP	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs859767	0.540	rs17789633	chr2:135386474	G/T	cg12500956	chr2:135428796	TMEM163	0.42	5.64	0.34	4.69e-8	Neuroticism;
KIRP	cis	rs4748857	0.947	rs4237360	chr10:23547519	T/C	cg12804278	chr10:23633326	C10orf67	0.45	5.61	0.34	5.56e-8	Systemic lupus erythematosus;
KIRP	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.52	-0.65	1.61e-31	Height;
KIRP	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.74	0.49	3.7e-16	Lung cancer in ever smokers;
KIRP	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg04731861	chr2:219085781	ARPC2	0.28	6.77	0.4	9.2e-11	Colorectal cancer;
KIRP	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.95	15.82	0.71	2.33e-39	Height;
KIRP	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.74	12.0	0.61	2.06e-26	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.26	-0.32	3.06e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg00405596	chr8:11794950	NA	0.49	6.36	0.38	9.62e-10	Joint mobility (Beighton score);
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg02696790	chr15:75250997	RPP25	0.31	5.4	0.33	1.58e-7	Breast cancer;
KIRP	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg04362960	chr10:104952993	NT5C2	0.43	5.39	0.32	1.66e-7	Waist circumference;Hip circumference;
KIRP	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg19507638	chr5:93509721	C5orf36	-0.61	-5.22	-0.32	3.74e-7	Diabetic retinopathy;
KIRP	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg05315796	chr3:52349193	DNAH1	0.41	6.53	0.38	3.77e-10	Bipolar disorder;
KIRP	cis	rs6593803	1.000	rs7514182	chr1:147207229	G/T	cg27546670	chr1:147246839	GJA5	0.62	7.29	0.42	4.13e-12	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9217	0.610	rs11654638	chr17:7437181	C/T	cg02795151	chr17:7402630	POLR2A	-0.51	-6.25	-0.37	1.84e-9	Height;
KIRP	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9398803	0.830	rs1415671	chr6:126759587	T/G	cg19875578	chr6:126661172	C6orf173	0.48	6.25	0.37	1.75e-9	Male-pattern baldness;
KIRP	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.32	0.37	1.22e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs7523273	1.000	rs12410786	chr1:207976205	T/A	cg22525895	chr1:207977042	MIR29B2	-0.68	-8.69	-0.48	5.34e-16	Schizophrenia;
KIRP	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.62	-8.29	-0.47	7.33e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs882732	1.000	rs17091071	chr14:95033708	A/C	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.6	-0.34	5.79e-8	Blood protein levels;
KIRP	cis	rs2916247	0.909	rs2083844	chr8:93014149	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.66	-9.2	-0.51	1.6e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg26913058	chr16:419975	MRPL28	-0.42	-5.23	-0.32	3.55e-7	Morning vs. evening chronotype;
KIRP	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.25	24.72	0.84	1.3e-68	Cognitive function;
KIRP	cis	rs9381107	0.932	rs9380847	chr6:9442372	T/C	cg14735645	chr6:9486422	NA	-0.45	-5.36	-0.32	1.88e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.52	-5.85	-0.35	1.57e-8	Schizophrenia;
KIRP	cis	rs12900413	0.687	rs34484228	chr15:90304067	A/G	cg24650279	chr15:90327240	NA	-0.41	-5.17	-0.31	4.79e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.55	-7.09	-0.41	1.46e-11	Prudent dietary pattern;
KIRP	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg16141378	chr3:129829833	LOC729375	0.5	6.54	0.38	3.61e-10	Morning vs. evening chronotype;
KIRP	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg11783602	chr8:55087084	NA	-0.59	-7.34	-0.42	3.11e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs74181299	0.504	rs4671638	chr2:65312217	C/T	cg05010058	chr2:65284262	CEP68	-0.44	-5.6	-0.34	5.84e-8	Pulse pressure;
KIRP	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.38	-4.91	-0.3	1.69e-6	Neuroticism;
KIRP	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.44	-5.14	-0.31	5.65e-7	P wave terminal force;
KIRP	cis	rs7027203	0.576	rs4424329	chr9:96560806	G/C	cg14598338	chr9:96623480	NA	0.47	7.26	0.42	5e-12	DNA methylation (variation);
KIRP	cis	rs4523957	0.583	rs2760744	chr17:2017029	T/C	cg16513277	chr17:2031491	SMG6	-0.81	-11.71	-0.6	1.78e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	10.11	0.54	2.63e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg13160058	chr8:26243215	BNIP3L	-0.5	-7.15	-0.41	9.75e-12	Red cell distribution width;
KIRP	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.81	-9.48	-0.52	2.23e-18	Bronchopulmonary dysplasia;
KIRP	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.61	-7.55	-0.43	8.59e-13	Neuroticism;
KIRP	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg21419209	chr3:44054225	NA	-0.71	-8.83	-0.49	2.07e-16	Coronary artery disease;
KIRP	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.42	5.75	0.34	2.64e-8	Age-related hearing impairment;
KIRP	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.79	-9.71	-0.53	4.38e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7709377	0.524	rs11750725	chr5:115465034	A/G	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs1978968	0.869	rs35035092	chr22:18463274	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.72	-8.08	-0.46	2.84e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs427941	0.632	rs201497	chr7:101755928	A/C	cg06246474	chr7:101738831	CUX1	0.54	6.66	0.39	1.79e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.83	13.04	0.64	7.01e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs714031	0.967	rs4821910	chr22:40067470	T/C	cg21377881	chr22:40064566	CACNA1I	-0.68	-10.54	-0.56	1.14e-21	Schizophrenia;
KIRP	cis	rs6838801	0.765	rs1826526	chr4:77607479	T/A	cg17476223	chr4:77663285	SHROOM3	0.52	7.09	0.41	1.45e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.07	12.34	0.62	1.45e-27	Vitiligo;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.25	-0.32	3.23e-7	Life satisfaction;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg08901578	chr4:187885870	NA	-0.51	-7.58	-0.43	7.24e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg22676075	chr6:135203613	NA	0.49	7.17	0.42	8.81e-12	Red blood cell count;
KIRP	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.98	15.2	0.7	3e-37	Diastolic blood pressure;
KIRP	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.66	-0.44	4.15e-13	IgG glycosylation;
KIRP	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.61e-21	Diabetic kidney disease;
KIRP	cis	rs10090774	0.760	rs13257090	chr8:141729463	C/T	cg26074100	chr8:141568712	EIF2C2	0.32	5.04	0.31	9.23e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01786151	chr1:41347977	NA	0.55	7.19	0.42	7.52e-12	Interleukin-4 levels;
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.82	-12.69	-0.63	9.75e-29	Prostate cancer;
KIRP	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg00646381	chr17:77835854	NA	0.54	7.66	0.44	4.38e-13	Electroencephalogram traits;
KIRP	cis	rs2882667	0.537	rs10057545	chr5:138431008	G/A	cg26929925	chr5:138714136	SLC23A1	0.34	4.86	0.3	2.09e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg01879757	chr17:41196368	BRCA1	-0.79	-10.89	-0.57	8.37e-23	Menopause (age at onset);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg04047827	chr16:24740859	TNRC6A	0.53	6.74	0.39	1.14e-10	Asthma;
KIRP	cis	rs7582180	0.934	rs2309822	chr2:100900406	G/A	cg14675211	chr2:100938903	LONRF2	0.54	6.42	0.38	7.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.1e-23	Prudent dietary pattern;
KIRP	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg19913688	chr11:428466	ANO9	-0.76	-6.1	-0.36	4.09e-9	Body mass index;
KIRP	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.66	8.54	0.48	1.37e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4805272	1.000	rs2042193	chr19:29320925	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02463440	chr8:22132932	PIWIL2	0.43	5.6	0.34	5.7e-8	Hypertriglyceridemia;
KIRP	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg11861562	chr11:117069780	TAGLN	0.4	5.09	0.31	7.03e-7	Blood protein levels;
KIRP	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.64	6.66	0.39	1.78e-10	Graves' disease;
KIRP	cis	rs17023223	0.537	rs2361269	chr1:119602215	A/G	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	3e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.61	-0.44	5.89e-13	Lung cancer;
KIRP	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.44	6.71	0.39	1.36e-10	Fractional excretion of uric acid;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg24308654	chr4:48908619	OCIAD2	0.53	6.48	0.38	4.91e-10	Educational attainment;
KIRP	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.64	8.74	0.49	3.62e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs17046216	0.930	rs11726725	chr4:166262193	T/C	cg23384093	chr5:170745466	NA	-0.5	-6.18	-0.37	2.67e-9	Insulin-related traits;
KIRP	cis	rs3857067	1.000	rs899134	chr4:95019675	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs11718455	0.767	rs13076333	chr3:43955070	G/A	cg08738300	chr3:44038990	NA	0.65	8.34	0.47	5.46e-15	Coronary artery disease;
KIRP	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.86	5.58	0.33	6.46e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4950322	0.542	rs28381210	chr1:146673507	C/A	cg22381352	chr1:146742008	CHD1L	-0.41	-4.96	-0.3	1.34e-6	Protein quantitative trait loci;
KIRP	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.22	0.42	6.29e-12	Bipolar disorder;
KIRP	cis	rs1497828	0.912	rs2646825	chr1:217539194	A/G	cg04411442	chr1:217543379	NA	-0.43	-6.63	-0.39	2.06e-10	Dialysis-related mortality;
KIRP	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg00241281	chr14:105779794	PACS2	-0.36	-4.99	-0.3	1.12e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg04374321	chr14:90722782	PSMC1	0.91	15.44	0.7	4.64e-38	Mortality in heart failure;
KIRP	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs1420338	0.967	rs9655014	chr7:34148632	T/C	cg01275685	chr7:34179230	BMPER	-0.51	-7.55	-0.43	8.68e-13	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.08	0.31	7.59e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12145833	0.596	rs12043646	chr1:243281992	G/A	cg02356786	chr1:243265016	LOC731275	0.96	6.69	0.39	1.48e-10	Obesity (early onset extreme);
KIRP	cis	rs6835098	0.520	rs2127896	chr4:174211285	G/A	cg08422745	chr4:174089978	GALNT7	-0.54	-6.6	-0.39	2.56e-10	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.76e-9	Breast cancer;
KIRP	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.75	-9.06	-0.5	4.28e-17	Iron status biomarkers;
KIRP	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs10875746	0.551	rs11168536	chr12:48745051	C/T	cg20731937	chr12:48336164	NA	0.45	5.56	0.33	7.06e-8	Longevity (90 years and older);
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg26754761	chr2:177040938	NA	0.34	5.86	0.35	1.48e-8	IgG glycosylation;
KIRP	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.89	12.2	0.61	4.36e-27	Breast cancer;
KIRP	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg14541582	chr5:601475	NA	-0.58	-6.52	-0.38	3.94e-10	Obesity-related traits;
KIRP	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg26681399	chr22:41777847	TEF	0.53	5.38	0.32	1.73e-7	Vitiligo;
KIRP	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	1.09	12.21	0.61	4.04e-27	Post bronchodilator FEV1;
KIRP	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.7	5.99	0.36	7.48e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs12049351	0.719	rs10799537	chr1:229664544	C/G	cg11742688	chr1:229674241	ABCB10	-0.41	-6.7	-0.39	1.45e-10	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1440410	0.835	rs13121583	chr4:144070585	T/C	cg01719995	chr4:144104893	USP38	0.41	5.37	0.32	1.86e-7	Ischemic stroke;
KIRP	cis	rs2820315	0.867	rs2644121	chr1:201881284	A/G	cg11586189	chr1:201857591	SHISA4	-0.43	-6.36	-0.38	1e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	trans	rs9329221	0.585	rs12550717	chr8:10266706	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	7.17	0.42	8.54e-12	Neuroticism;
KIRP	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18255839	chr2:239335447	ASB1	0.44	5.26	0.32	3.09e-7	Multiple system atrophy;
KIRP	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.67	8.38	0.47	4.04e-15	Alzheimer's disease;
KIRP	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg00409905	chr10:38381863	ZNF37A	-0.6	-6.73	-0.39	1.18e-10	Obesity (extreme);
KIRP	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg06307176	chr5:131281290	NA	-0.55	-5.73	-0.34	2.98e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4700695	0.614	rs153387	chr5:65422236	G/A	cg21114390	chr5:65439923	SFRS12	-0.72	-5.77	-0.35	2.42e-8	Facial morphology (factor 19);
KIRP	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg13147721	chr7:65941812	NA	-1.0	-6.94	-0.4	3.42e-11	Diabetic kidney disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11965514	chr8:124253535	C8orf76	0.46	6.03	0.36	6.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.37	0.47	4.33e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	1.11	8.99	0.5	6.87e-17	Prostate cancer;
KIRP	cis	rs10267417	0.603	rs10950760	chr7:19912040	A/G	cg05791153	chr7:19748676	TWISTNB	-0.52	-5.33	-0.32	2.25e-7	Night sleep phenotypes;
KIRP	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16414030	chr3:133502952	NA	-0.51	-5.99	-0.36	7.37e-9	Iron status biomarkers;
KIRP	cis	rs2591576	0.781	rs12519271	chr5:165422367	C/A	cg13976338	chr5:165423657	NA	-0.81	-12.74	-0.63	6.62e-29	Intelligence (multi-trait analysis);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg14655649	chr8:30769870	NA	-0.5	-6.32	-0.37	1.19e-9	Blood metabolite levels;
KIRP	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg20590849	chr17:73267439	MIF4GD	-0.45	-4.88	-0.3	1.94e-6	Systemic lupus erythematosus;
KIRP	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.31	4.88	0.3	1.93e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18760194	chr8:35186363	UNC5D	-0.42	-6.06	-0.36	5.06e-9	Inflammatory biomarkers;
KIRP	trans	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg00717180	chr2:96193071	NA	-0.49	-6.1	-0.36	4.09e-9	HDL cholesterol;
KIRP	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.65	7.51	0.43	1.12e-12	Bone mineral density;
KIRP	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.65	-7.9	-0.45	9.56e-14	Height;
KIRP	cis	rs7546668	1.000	rs7515244	chr1:15873386	A/G	cg21858823	chr1:15850916	CASP9	0.47	5.17	0.31	4.85e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17082662	chr3:88198710	C3orf38	-0.5	-6.31	-0.37	1.32e-9	Interleukin-4 levels;
KIRP	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg16083429	chr3:49237500	CCDC36	-0.39	-5.14	-0.31	5.63e-7	Menarche (age at onset);
KIRP	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg04362960	chr10:104952993	NT5C2	-0.57	-7.31	-0.42	3.83e-12	Arsenic metabolism;
KIRP	cis	rs10875746	0.904	rs11168422	chr12:48519505	T/G	cg20731937	chr12:48336164	NA	0.41	5.24	0.32	3.49e-7	Longevity (90 years and older);
KIRP	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.03	0.41	2.04e-11	Rheumatoid arthritis;
KIRP	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.33	0.87	1.76e-76	Chronic sinus infection;
KIRP	trans	rs12517041	1.000	rs2356713	chr5:23284777	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.25	-0.47	9.63e-15	Calcium levels;
KIRP	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg23815491	chr16:72088622	HP	0.4	6.61	0.39	2.36e-10	Fibrinogen levels;
KIRP	cis	rs1642645	0.872	rs348139	chr1:42470901	C/T	cg26038582	chr1:42384390	HIVEP3	0.27	4.87	0.3	2.01e-6	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg06521331	chr12:34319734	NA	-0.42	-5.29	-0.32	2.66e-7	Morning vs. evening chronotype;
KIRP	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.42	-0.51	3.4e-18	Brugada syndrome;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-0.94	-16.21	-0.72	1.04e-40	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg24110177	chr3:50126178	RBM5	-0.43	-5.53	-0.33	7.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.89	-11.78	-0.6	1.06e-25	Orofacial clefts;
KIRP	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	1.13	17.03	0.74	1.7e-43	Eosinophil percentage of white cells;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.76	11.92	0.61	3.68e-26	Menarche (age at onset);
KIRP	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27297192	chr10:134578999	INPP5A	0.63	7.73	0.44	2.82e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10053473	chr17:62856997	LRRC37A3	0.72	7.67	0.44	4.09e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9309473	0.528	rs6546820	chr2:73553397	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-6.16	-0.37	2.9e-9	Metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02240686	chr2:37339522	EIF2AK2	-0.42	-6.68	-0.39	1.57e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg02404636	chr22:31891804	SFI1	-0.48	-5.37	-0.32	1.8e-7	Colorectal cancer;
KIRP	cis	rs5995756	0.666	rs3788566	chr22:40006024	G/T	cg21377881	chr22:40064566	CACNA1I	-0.37	-4.91	-0.3	1.66e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6594499	0.903	rs1438672	chr5:110467753	G/A	cg04022379	chr5:110408740	TSLP	0.45	6.71	0.39	1.33e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.37	0.38	9.12e-10	Red blood cell count;
KIRP	cis	rs12431939	0.762	rs60225624	chr14:51704366	C/T	cg23942311	chr14:51606299	NA	-0.59	-5.77	-0.35	2.37e-8	Cancer;
KIRP	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.59	-10.16	-0.54	1.84e-20	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
KIRP	cis	rs2916247	0.908	rs7002049	chr8:93114414	T/C	cg10183463	chr8:93005414	RUNX1T1	0.49	5.68	0.34	3.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg22974920	chr21:40686053	BRWD1	0.5	5.92	0.35	1.05e-8	Cognitive function;
KIRP	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	11.09	0.58	1.97e-23	Monocyte percentage of white cells;
KIRP	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06544989	chr22:39130855	UNC84B	0.47	7.45	0.43	1.54e-12	Menopause (age at onset);
KIRP	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.21	0.46	1.25e-14	Response to antipsychotic treatment;
KIRP	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.79	12.14	0.61	6.73e-27	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg18944383	chr4:111397179	ENPEP	-0.6	-10.37	-0.55	3.94e-21	Coronary artery disease;
KIRP	cis	rs9596863	0.898	rs9568911	chr13:54338082	A/G	ch.13.53330881F	chr13:54432880	NA	0.49	4.95	0.3	1.39e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg09184832	chr6:79620586	NA	-0.51	-7.3	-0.42	3.91e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.78	-10.71	-0.56	3.22e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.84	0.35	1.63e-8	Educational attainment;
KIRP	cis	rs7599312	0.586	rs7565257	chr2:213388276	G/A	cg20637307	chr2:213403960	ERBB4	0.43	5.08	0.31	7.44e-7	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06481639	chr22:41940642	POLR3H	0.46	5.6	0.34	5.85e-8	Vitiligo;
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg17294928	chr15:75287854	SCAMP5	0.52	6.92	0.4	3.94e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg23625390	chr15:77176239	SCAPER	0.52	6.85	0.4	5.97e-11	Blood metabolite levels;
KIRP	cis	rs1215050	0.791	rs1025201	chr4:98902938	A/G	cg05340658	chr4:99064831	C4orf37	-0.58	-6.99	-0.41	2.64e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9308731	0.591	rs10199020	chr2:111946456	T/A	cg04202892	chr2:111875749	ACOXL	0.41	5.48	0.33	1.03e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs2014572	0.510	rs8111661	chr19:57752326	C/G	cg12963866	chr19:57752005	ZNF805	0.47	5.96	0.36	8.6e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg12131826	chr15:77904385	NA	0.49	5.83	0.35	1.72e-8	Type 2 diabetes;
KIRP	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.49	7.06	0.41	1.67e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	6.02	0.36	6.33e-9	Personality dimensions;
KIRP	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg22508957	chr16:3507546	NAT15	0.52	6.66	0.39	1.76e-10	Tuberculosis;
KIRP	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.59	6.94	0.4	3.5e-11	Pulmonary function decline;
KIRP	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.89	-11.65	-0.6	2.84e-25	Type 2 diabetes;
KIRP	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg02297831	chr4:17616191	MED28	0.53	6.6	0.39	2.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.88	0.3	1.88e-6	Renal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg20243544	chr17:37824526	PNMT	0.51	7.36	0.42	2.74e-12	Asthma;
KIRP	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.35	1.28e-8	Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.06	0.61	1.27e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg05636881	chr10:105038444	INA	0.66	5.53	0.33	8.19e-8	Arsenic metabolism;
KIRP	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00585698	chr12:123750864	CDK2AP1	0.42	5.35	0.32	1.97e-7	Platelet count;
KIRP	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg25418670	chr11:30344373	C11orf46	0.61	5.21	0.32	4.08e-7	Morning vs. evening chronotype;
KIRP	cis	rs7116495	1.000	rs585228	chr11:71773289	G/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2070488	0.965	rs6802071	chr3:38574237	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-14.44	-0.68	1.18e-34	Electrocardiographic conduction measures;
KIRP	trans	rs2292298	0.513	rs3756143	chr4:37640389	T/C	cg27215768	chr10:98425148	PIK3AP1	-0.54	-6.03	-0.36	6.12e-9	IgG glycosylation;
KIRP	cis	rs6005807	0.719	rs12166475	chr22:28860167	T/G	cg12565055	chr22:29076175	TTC28	0.59	5.1	0.31	6.69e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg09699651	chr6:150184138	LRP11	0.43	5.6	0.34	5.75e-8	Lung cancer;
KIRP	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-0.77	-10.96	-0.57	5.16e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.87	-7.72	-0.44	2.89e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs13108043	0.605	rs62306514	chr4:87976338	C/T	cg11209507	chr4:87813803	C4orf36	0.48	5.03	0.31	9.28e-7	Red blood cell count;
KIRP	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.96	13.15	0.64	2.93e-30	Menopause (age at onset);
KIRP	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05665937	chr4:1216051	CTBP1	-0.49	-6.69	-0.39	1.47e-10	Obesity-related traits;
KIRP	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs8133932	0.654	rs402039	chr21:47358809	A/G	cg11214348	chr21:47283868	PCBP3	-0.42	-4.97	-0.3	1.25e-6	Schizophrenia;
KIRP	cis	rs894344	0.572	rs16905167	chr8:135550073	T/C	cg04050898	chr8:135490694	ZFAT	-0.38	-5.26	-0.32	3.12e-7	Systolic blood pressure;
KIRP	cis	rs3857747	0.578	rs6945101	chr7:40402430	A/G	cg00420559	chr7:40367873	C7orf10	-0.43	-6.17	-0.37	2.86e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.49	6.35	0.38	1.03e-9	Waist-hip ratio;
KIRP	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.66	8.3	0.47	7.01e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.67	7.88	0.45	1.03e-13	Pancreatic cancer;
KIRP	cis	rs13102973	0.611	rs4298187	chr4:135886186	G/A	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg05973401	chr12:123451056	ABCB9	-0.63	-5.71	-0.34	3.25e-8	Neutrophil percentage of white cells;
KIRP	cis	rs8113308	0.810	rs8100541	chr19:52449695	A/G	cg24732339	chr19:52471368	ZNF350	-0.45	-5.02	-0.3	9.83e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs17065868	0.764	rs9525956	chr13:45038973	C/T	cg10246903	chr13:45222710	NA	0.59	4.95	0.3	1.36e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs4356975	0.527	rs4385139	chr4:69991629	C/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.06	0.31	8.15e-7	Obesity-related traits;
KIRP	trans	rs17394429	0.524	rs270077	chr8:3280226	C/T	cg08428819	chr10:123924042	TACC2	0.42	6.03	0.36	6.01e-9	Obesity-related traits;
KIRP	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg14993813	chr1:46806288	NSUN4	-0.48	-5.58	-0.34	6.22e-8	Menopause (age at onset);
KIRP	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg12591125	chr7:1885375	MAD1L1	0.61	5.97	0.36	8.14e-9	Bipolar disorder;
KIRP	cis	rs6893807	0.943	rs13166120	chr5:87948883	G/A	cg24804195	chr5:87968844	LOC645323	0.52	5.53	0.33	8.16e-8	Body mass index;
KIRP	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.56	-7.71	-0.44	3.11e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg10223061	chr2:219282414	VIL1	-0.31	-5.06	-0.31	8.35e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg18944383	chr4:111397179	ENPEP	0.58	10.68	0.56	3.96e-22	Height;
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg08662619	chr6:150070041	PCMT1	0.38	6.25	0.37	1.8e-9	Lung cancer;
KIRP	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg09873164	chr1:152488093	CRCT1	0.51	6.48	0.38	4.91e-10	Hair morphology;
KIRP	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.9	14.36	0.68	2.31e-34	Mean corpuscular volume;
KIRP	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg02023728	chr11:77925099	USP35	0.3	5.12	0.31	6.02e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	6.62	0.39	2.25e-10	Breast cancer;
KIRP	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg06115741	chr20:33292138	TP53INP2	-0.36	-4.92	-0.3	1.6e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs12365397	0.634	rs12807758	chr11:43298130	C/T	cg07515919	chr11:43391688	TTC17	0.36	4.87	0.3	2.02e-6	Migraine;
KIRP	cis	rs4273100	0.512	rs973650	chr17:19291785	A/G	cg25447019	chr17:19030144	GRAPL	0.56	7.56	0.43	8.04e-13	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	11.76	0.6	1.2e-25	Platelet count;
KIRP	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg17366294	chr4:99064904	C4orf37	0.37	5.0	0.3	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.85	10.68	0.56	3.98e-22	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs3947	1.000	rs1736085	chr8:11703659	T/C	cg21775007	chr8:11205619	TDH	-0.5	-5.14	-0.31	5.5e-7	Blood protein levels;
KIRP	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs4262150	0.764	rs3923209	chr5:151937593	A/T	cg12297329	chr5:152029980	NA	-0.61	-7.4	-0.43	2.09e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs77688320	0.553	rs4507084	chr2:202285100	A/G	cg06431681	chr2:202330990	STRADB	0.51	6.25	0.37	1.79e-9	Breast cancer;
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-8.42	-0.47	3.16e-15	Obesity-related traits;
KIRP	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.53	-5.35	-0.32	1.99e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-19.96	-0.79	2.38e-53	Heart rate;
KIRP	cis	rs3857536	0.874	rs10806524	chr6:66900486	T/C	cg07460842	chr6:66804631	NA	-0.4	-5.26	-0.32	3.11e-7	Blood trace element (Cu levels);
KIRP	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs7539409	0.651	rs969724	chr1:84300712	T/G	cg10977910	chr1:84465055	TTLL7	0.61	5.52	0.33	8.56e-8	Alzheimer's disease;
KIRP	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.27	-0.42	4.63e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4699052	1.000	rs6533060	chr4:104139996	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.19	-0.31	4.3e-7	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-5.66	-0.34	4.11e-8	Blood metabolite levels;
KIRP	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg01877450	chr7:97915802	BRI3	-0.53	-6.9	-0.4	4.33e-11	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg15351736	chr11:111808104	DIXDC1	0.52	6.57	0.39	2.97e-10	Sleep duration;
KIRP	cis	rs920590	0.796	rs10888170	chr8:19635328	C/T	cg03894339	chr8:19674705	INTS10	0.46	5.58	0.34	6.19e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12595433	0.891	rs35817592	chr15:63290445	A/T	cg03196360	chr15:63270641	NA	-0.27	-4.99	-0.3	1.16e-6	Obesity-related traits;
KIRP	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.46	-6.66	-0.39	1.74e-10	Coronary artery disease;
KIRP	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg19847866	chr10:1019161	NA	-0.63	-5.79	-0.35	2.1e-8	Eosinophil percentage of granulocytes;
KIRP	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.93	13.74	0.66	2.86e-32	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg24881330	chr22:46731750	TRMU	0.64	5.49	0.33	9.92e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg03235661	chr20:60525775	NA	-0.32	-5.39	-0.33	1.63e-7	Body mass index;
KIRP	cis	rs13185784	0.703	rs62406991	chr5:179658323	A/G	cg13944838	chr5:179740914	GFPT2	0.51	4.91	0.3	1.65e-6	TRAIL levels;
KIRP	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg07701084	chr6:150067640	NUP43	0.64	8.07	0.46	3.06e-14	Lung cancer;
KIRP	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.3	-0.42	3.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7630877	0.886	rs2302742	chr3:179605206	T/C	cg18765712	chr3:179670323	PEX5L	0.56	6.7	0.39	1.4e-10	Type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg05220968	chr6:146057943	EPM2A	-0.41	-5.4	-0.33	1.57e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7267005	1.000	rs58039765	chr20:34467460	C/T	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.15	-0.31	5.27e-7	Life satisfaction;
KIRP	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg24579218	chr15:68104479	NA	-0.6	-9.93	-0.54	9e-20	Restless legs syndrome;
KIRP	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg09596252	chr17:78655493	RPTOR	0.53	6.07	0.36	4.86e-9	Fractional excretion of uric acid;
KIRP	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs1866706	0.865	rs4757956	chr11:12876666	G/A	cg25843174	chr11:12811716	TEAD1	-0.36	-6.13	-0.36	3.5e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12292205	chr6:26970375	C6orf41	-0.64	-7.1	-0.41	1.36e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	1.000	rs482013	chr11:71803962	G/A	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.65	8.49	0.48	1.95e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.81	-11.61	-0.59	4.02e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.83	-0.35	1.74e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs78545713	0.649	rs79662647	chr6:26217845	G/A	cg23601095	chr6:26197514	HIST1H3D	0.88	5.22	0.32	3.83e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg20742981	chr22:31644190	LIMK2	0.33	4.86	0.3	2.07e-6	Paclitaxel-induced neuropathy;
KIRP	trans	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg10756647	chr7:56101905	PSPH	-0.9	-6.93	-0.4	3.68e-11	Diabetic kidney disease;
KIRP	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg24699146	chr1:24152579	HMGCL	0.47	6.56	0.39	3.07e-10	Immature fraction of reticulocytes;
KIRP	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.28	5.5	0.33	9.68e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13361707	0.649	rs6876367	chr5:40829311	C/T	cg01087697	chr5:40835557	RPL37	-0.41	-4.98	-0.3	1.2e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	5.17	0.31	4.85e-7	Renal cell carcinoma;
KIRP	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.23	0.72	8.9e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.79	0.4	8.33e-11	Electroencephalogram traits;
KIRP	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg13119609	chr19:45449297	APOC2	0.52	7.36	0.42	2.69e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18714586	chr13:30831499	KATNAL1	-0.42	-6.42	-0.38	6.92e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10840526	chr7:100813242	NA	-0.53	-6.94	-0.4	3.56e-11	Myopia;
KIRP	trans	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg19274270	chr17:78178856	CARD14	-0.36	-6.54	-0.38	3.58e-10	Morning vs. evening chronotype;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04590956	chr2:70057467	GMCL1	0.47	6.21	0.37	2.28e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11622362	chr11:34938112	PDHX;APIP	-0.48	-6.08	-0.36	4.52e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2299587	0.786	rs115457436	chr8:17889093	T/G	cg01800426	chr8:17659068	MTUS1	-0.4	-4.95	-0.3	1.4e-6	Economic and political preferences;
KIRP	cis	rs4936894	0.500	rs10790647	chr11:124075438	C/T	cg27160556	chr11:124181099	OR8D1	-0.4	-5.92	-0.35	1.09e-8	Aging (time to death);
KIRP	cis	rs6987853	0.787	rs2923402	chr8:42445400	G/A	cg09913449	chr8:42400586	C8orf40	0.4	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	10.22	0.55	1.18e-20	Eye color traits;
KIRP	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.99	8.13	0.46	2.1e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1165472	0.760	rs12239728	chr1:56133430	A/G	cg11523071	chr1:56160889	NA	-0.64	-9.42	-0.52	3.33e-18	Paclitaxel-induced neuropathy;
KIRP	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.93	12.23	0.61	3.57e-27	Menopause (age at onset);
KIRP	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17376030	chr22:41985996	PMM1	0.54	5.94	0.35	9.68e-9	Vitiligo;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.47	7.73	0.44	2.66e-13	Testicular germ cell tumor;
KIRP	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.52	-6.03	-0.36	5.85e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06475006	chr16:89985975	MC1R	-0.67	-4.88	-0.3	1.87e-6	Skin colour saturation;
KIRP	cis	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg24331049	chr13:111365604	ING1	-0.75	-6.65	-0.39	1.89e-10	Coronary artery disease;
KIRP	cis	rs62007496	0.520	rs1052912	chr14:103603653	C/T	cg09274347	chr14:103599552	TNFAIP2	0.5	4.9	0.3	1.74e-6	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs12282928	0.851	rs4980421	chr11:48301482	G/A	cg26585981	chr11:48327164	OR4S1	-0.52	-6.31	-0.37	1.26e-9	Migraine - clinic-based;
KIRP	cis	rs2880765	0.506	rs719138	chr15:86055062	T/G	cg10818794	chr15:86012489	AKAP13	-0.52	-6.98	-0.41	2.77e-11	Coronary artery disease;
KIRP	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.68	8.19	0.46	1.38e-14	Height;
KIRP	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.22	-0.37	2.13e-9	Acne (severe);
KIRP	cis	rs2997447	0.706	rs12062488	chr1:26466253	G/A	cg19633962	chr1:26362018	EXTL1	-0.52	-4.9	-0.3	1.72e-6	QRS complex (12-leadsum);
KIRP	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg03585969	chr10:35415529	CREM	-0.77	-9.31	-0.51	7.26e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg16141378	chr3:129829833	LOC729375	0.52	6.65	0.39	1.92e-10	Mood instability;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24531714	chr8:67475459	MYBL1	-0.45	-7.12	-0.41	1.16e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs478607	0.749	rs61884370	chr11:64361955	T/G	cg09231725	chr11:64357281	SLC22A12	-0.7	-5.51	-0.33	9.22e-8	Urate levels;
KIRP	cis	rs9308731	0.505	rs10169613	chr2:111934977	C/T	cg18646521	chr2:111875858	NA	0.4	5.65	0.34	4.34e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	5.81	0.35	1.88e-8	Mean platelet volume;
KIRP	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.02	0.31	9.71e-7	Iron status biomarkers;
KIRP	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg21399703	chr1:247681439	NA	0.51	5.31	0.32	2.45e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.03	-0.31	9.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.57	0.56	9.26e-22	Cognitive test performance;
KIRP	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06481639	chr22:41940642	POLR3H	0.45	5.37	0.32	1.84e-7	Vitiligo;
KIRP	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.75	10.81	0.57	1.51e-22	Body mass index;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01669482	chr16:25043131	NA	0.65	6.06	0.36	5.19e-9	Lung function (FEV1);
KIRP	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06307176	chr5:131281290	NA	-0.54	-5.9	-0.35	1.23e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.76	7.74	0.44	2.57e-13	Uric acid levels;
KIRP	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg13607699	chr17:42295918	UBTF	0.46	5.76	0.34	2.52e-8	Total body bone mineral density;
KIRP	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.43	-5.22	-0.32	3.87e-7	Diastolic blood pressure;
KIRP	cis	rs798766	1.000	rs798719	chr4:1698183	C/T	cg07775547	chr4:1625484	NA	-0.48	-5.8	-0.35	2.05e-8	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs735539	0.521	rs2818998	chr13:21369911	T/C	cg04906043	chr13:21280425	IL17D	-0.43	-4.99	-0.3	1.16e-6	Dental caries;
KIRP	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.61	-8.07	-0.46	3.03e-14	Huntington's disease progression;
KIRP	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.84	10.96	0.57	4.9e-23	Menarche (age at onset);
KIRP	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.55	-6.31	-0.37	1.29e-9	Mean corpuscular volume;
KIRP	cis	rs9303542	0.625	rs4793889	chr17:46592352	A/G	cg04904318	chr17:46607828	HOXB1	0.43	5.21	0.32	4.01e-7	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.7	9.21	0.51	1.51e-17	Plateletcrit;Platelet count;
KIRP	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg00982548	chr2:198649783	BOLL	-0.57	-5.62	-0.34	5.06e-8	Ulcerative colitis;
KIRP	cis	rs9905704	0.627	rs1267543	chr17:56656624	A/G	cg12560992	chr17:57184187	TRIM37	-0.52	-5.33	-0.32	2.27e-7	Testicular germ cell tumor;
KIRP	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-10.46	-0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg03929089	chr4:120376271	NA	0.69	6.07	0.36	4.88e-9	Axial length;
KIRP	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-8.58	-0.48	1.11e-15	Platelet count;
KIRP	cis	rs9653442	0.545	rs11123813	chr2:100765692	C/T	cg22139774	chr2:100720529	AFF3	-0.33	-5.45	-0.33	1.2e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	9.23	0.51	1.29e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06406300	chr17:40828394	PLEKHH3	-0.58	-6.3	-0.37	1.38e-9	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.93	-14.09	-0.67	1.83e-33	Height;
KIRP	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg26207909	chr14:103986467	CKB	-0.44	-5.39	-0.32	1.66e-7	Coronary artery disease;
KIRP	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-5.84	-0.35	1.63e-8	Height;
KIRP	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-1.07	-20.89	-0.8	1.96e-56	Height;
KIRP	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.94	12.61	0.63	1.94e-28	Gestational age at birth (maternal effect);
KIRP	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg22800045	chr5:56110881	MAP3K1	0.52	5.8	0.35	2.01e-8	Coronary artery disease;
KIRP	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg08648136	chr8:956695	NA	0.46	7.04	0.41	1.96e-11	Schizophrenia;
KIRP	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.63	-8.37	-0.47	4.31e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs199955185	1	rs199955185	chr5:153938270	CTGTA/C	cg22512536	chr5:154134507	LARP1	0.42	4.87	0.3	1.95e-6	Monobrow;
KIRP	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs137887	0.935	rs137885	chr22:50463231	T/C	cg17558497	chr22:50464837	TTLL8	0.49	7.27	0.42	4.68e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-0.54	-7.6	-0.44	6.06e-13	Coronary artery disease;
KIRP	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.94	15.51	0.7	2.56e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg12384639	chr17:618140	VPS53	0.47	5.92	0.35	1.05e-8	Prostate cancer;
KIRP	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg07777115	chr5:623756	CEP72	-0.58	-5.91	-0.35	1.16e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs367943	0.666	rs7717422	chr5:112704089	A/G	cg12552261	chr5:112820674	MCC	0.55	6.51	0.38	4.22e-10	Type 2 diabetes;
KIRP	cis	rs10861342	0.892	rs10459207	chr12:105531072	C/T	cg23923672	chr12:105501055	KIAA1033	0.89	9.06	0.5	4.27e-17	IgG glycosylation;
KIRP	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.43	0.52	3.16e-18	IgG glycosylation;
KIRP	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg01378222	chr16:28622494	SULT1A1	-0.68	-5.99	-0.36	7.3e-9	Platelet distribution width;
KIRP	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.42	0.33	1.41e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	1.09	13.15	0.64	2.82e-30	Iron status biomarkers;
KIRP	cis	rs8084125	1.000	rs62105167	chr18:74944594	G/A	cg05528293	chr18:74961138	GALR1	0.5	4.92	0.3	1.61e-6	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22862412	chr14:105964848	C14orf80	0.46	6.01	0.36	6.5e-9	Interleukin-4 levels;
KIRP	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.23	-0.32	3.59e-7	Fear of minor pain;
KIRP	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7223966	0.655	rs9896476	chr17:61629692	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-6.06	-0.36	5.02e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg08847533	chr14:75593920	NEK9	-0.42	-5.06	-0.31	8.14e-7	IgG glycosylation;
KIRP	cis	rs2033732	0.706	rs4740000	chr8:85075376	G/T	cg05716166	chr8:85095498	RALYL	0.58	6.63	0.39	2.11e-10	Body mass index;
KIRP	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg23950597	chr19:37808831	NA	-0.64	-6.57	-0.39	2.9e-10	Coronary artery calcification;
KIRP	cis	rs7084402	0.967	rs1658463	chr10:60298208	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg06636001	chr8:8085503	FLJ10661	0.71	9.22	0.51	1.36e-17	Retinal vascular caliber;
KIRP	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.61	-0.34	5.41e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.15	-0.41	9.59e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg17279839	chr7:150038598	RARRES2	0.47	6.45	0.38	5.97e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg20933634	chr6:27740509	NA	0.36	4.89	0.3	1.79e-6	Parkinson's disease;
KIRP	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg16989719	chr2:238392110	NA	-0.54	-7.27	-0.42	4.66e-12	Prostate cancer;
KIRP	cis	rs675026	0.926	rs494328	chr6:154459486	T/C	cg07813322	chr6:154414604	OPRM1	-0.42	-5.47	-0.33	1.08e-7	Hypertension;
KIRP	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.57	6.7	0.39	1.44e-10	HDL cholesterol;
KIRP	cis	rs10782582	0.609	rs1630587	chr1:76399787	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.44	-0.38	6.18e-10	Daytime sleep phenotypes;
KIRP	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.37	5.63	0.34	4.84e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs8141529	0.600	rs916332	chr22:29308414	C/T	cg15103426	chr22:29168792	CCDC117	0.53	5.17	0.31	4.75e-7	Lymphocyte counts;
KIRP	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.61	7.26	0.42	5.05e-12	Height;
KIRP	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg22176566	chr1:43424700	SLC2A1	-0.49	-4.87	-0.3	1.98e-6	Red cell distribution width;
KIRP	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.42	-0.43	1.88e-12	Bipolar disorder;
KIRP	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.22	0.37	2.16e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21747090	chr2:27597821	SNX17	-0.51	-7.08	-0.41	1.52e-11	Total body bone mineral density;
KIRP	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.51	-5.32	-0.32	2.34e-7	Corneal structure;
KIRP	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg10932868	chr11:921992	NA	0.65	8.76	0.49	3.21e-16	Alzheimer's disease (late onset);
KIRP	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg20368463	chr18:77673604	PQLC1	0.78	7.32	0.42	3.42e-12	Opioid sensitivity;
KIRP	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.58	7.63	0.44	5.3e-13	Hip circumference;
KIRP	cis	rs4950322	0.570	rs72692980	chr1:146809568	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.33	-0.32	2.21e-7	Protein quantitative trait loci;
KIRP	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg08999081	chr20:33150536	PIGU	0.47	6.44	0.38	6.2e-10	Height;
KIRP	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.09	0.36	4.25e-9	Schizophrenia;
KIRP	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg11584989	chr19:19387371	SF4	-0.41	-5.27	-0.32	2.99e-7	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22317668	chr19:42772446	NA	0.53	6.59	0.39	2.67e-10	Parkinson's disease;
KIRP	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg24807547	chr6:37504484	NA	-0.52	-7.71	-0.44	3.2e-13	Cognitive performance;
KIRP	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.37	-5.46	-0.33	1.15e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-9.02	-0.5	5.45e-17	Monocyte percentage of white cells;
KIRP	cis	rs2273156	1.000	rs761506	chr14:35417180	C/G	cg09327582	chr14:35236912	BAZ1A	0.5	5.68	0.34	3.79e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.48	6.18	0.37	2.58e-9	Systolic blood pressure;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23521980	chr3:107779873	CD47	0.41	6.26	0.37	1.67e-9	Migraine with aura;
KIRP	cis	rs7612445	0.756	rs4855075	chr3:179170494	C/T	cg01750654	chr3:179170617	GNB4	-0.89	-8.74	-0.49	3.71e-16	Resting heart rate;Heart rate;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.59	-8.77	-0.49	3.02e-16	Lung cancer;
KIRP	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.72e-15	Prudent dietary pattern;
KIRP	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.27	0.37	1.62e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12513920	chr5:107717972	FBXL17	0.56	7.28	0.42	4.52e-12	Parkinson's disease;
KIRP	cis	rs77633900	0.772	rs284897	chr15:76750722	T/C	cg21673338	chr15:77095150	SCAPER	-0.65	-6.2	-0.37	2.39e-9	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg03929089	chr4:120376271	NA	-0.71	-6.45	-0.38	6.02e-10	Axial length;
KIRP	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg00241281	chr14:105779794	PACS2	-0.36	-5.08	-0.31	7.46e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg21479132	chr6:26055353	NA	0.76	5.17	0.31	4.87e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg03342759	chr3:160939853	NMD3	-0.47	-5.56	-0.33	6.97e-8	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06273454	chr20:17949326	C20orf72;SNX5	-0.51	-6.38	-0.38	8.48e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg07001201	chr5:642380	CEP72	0.67	6.2	0.37	2.42e-9	Obesity-related traits;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13689156	chr12:50017412	PRPF40B	-0.59	-6.38	-0.38	8.93e-10	Menopause (age at onset);
KIRP	cis	rs1978968	1.000	rs13057203	chr22:18446024	A/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg08970460	chr7:65841426	NCRNA00174	-0.45	-6.75	-0.4	1.03e-10	Bladder cancer;
KIRP	cis	rs7005380	0.538	rs7000488	chr8:120923299	A/G	cg21645572	chr8:120931649	DEPDC6	0.52	7.25	0.42	5.39e-12	Interstitial lung disease;
KIRP	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.66e-7	Diabetic retinopathy;
KIRP	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg01025720	chr13:113346439	ATP11A	0.52	5.02	0.31	9.76e-7	Glycated hemoglobin levels;
KIRP	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.55	6.68	0.39	1.61e-10	Total body bone mineral density;
KIRP	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg11608241	chr8:8085544	FLJ10661	0.42	5.02	0.31	9.74e-7	Mood instability;
KIRP	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.49	-8.11	-0.46	2.37e-14	Height;
KIRP	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06915872	chr16:87998081	BANP	0.56	5.81	0.35	1.92e-8	Menopause (age at onset);
KIRP	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs155346	1.000	rs265152	chr5:139379707	C/T	cg01090482	chr5:139365336	NRG2	-0.43	-5.55	-0.33	7.28e-8	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	1.04	20.21	0.79	3.54e-54	Breast cancer;
KIRP	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg10253484	chr15:75165896	SCAMP2	0.63	7.19	0.42	7.64e-12	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10875746	0.859	rs3782910	chr12:48483507	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs16976116	0.901	rs28630909	chr15:55500102	G/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2290402	0.536	rs4690340	chr4:848280	G/T	cg00846425	chr4:957561	DGKQ	-0.48	-5.23	-0.32	3.58e-7	Type 2 diabetes;
KIRP	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.75	7.63	0.44	5.25e-13	Bipolar disorder;
KIRP	cis	rs6504950	0.745	rs12949718	chr17:52981853	A/G	cg26251398	chr17:52985966	TOM1L1	-0.4	-5.42	-0.33	1.42e-7	Breast cancer;
KIRP	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.46	0.33	1.18e-7	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09137423	chr10:51827642	FAM21A	0.55	6.65	0.39	1.92e-10	Smoking initiation;
KIRP	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.61	8.96	0.5	8.39e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg26513180	chr16:89883248	FANCA	0.86	6.04	0.36	5.56e-9	Skin colour saturation;
KIRP	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg07395648	chr5:131743802	NA	-0.37	-5.41	-0.33	1.47e-7	Blood metabolite levels;
KIRP	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.55	-5.44	-0.33	1.31e-7	Initial pursuit acceleration;
KIRP	cis	rs9972944	0.729	rs1541609	chr17:63773564	G/A	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg05785598	chr3:49045655	WDR6	0.33	5.91	0.35	1.14e-8	Parkinson's disease;
KIRP	cis	rs2219968	0.717	rs4739188	chr8:78912778	G/T	cg00738934	chr8:78996279	NA	-0.37	-4.92	-0.3	1.62e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg11131117	chr7:1891496	MAD1L1	0.4	4.91	0.3	1.68e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.63	5.25	0.32	3.27e-7	Glioblastoma;
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg11168104	chr5:1857477	NA	-0.4	-5.04	-0.31	9.08e-7	Cardiovascular disease risk factors;
KIRP	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.89	-0.66	8.74e-33	Ulcerative colitis;
KIRP	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg19338460	chr6:170058176	WDR27	-0.64	-7.54	-0.43	8.91e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg17762617	chr12:118573850	PEBP1	0.52	6.54	0.38	3.6e-10	Asthma;
KIRP	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs754423	0.515	rs1956283	chr14:52550736	T/C	cg05884192	chr14:52515736	NID2	0.47	5.2	0.31	4.29e-7	Craniofacial microsomia;
KIRP	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg02297831	chr4:17616191	MED28	0.51	5.89	0.35	1.28e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10073892	0.830	rs10479190	chr5:101631790	T/G	cg19774478	chr5:101632501	SLCO4C1	0.65	6.4	0.38	7.8e-10	Cognitive decline (age-related);
KIRP	cis	rs67385638	1.000	rs2855036	chr11:5272682	C/T	cg12559170	chr11:5275217	HBG2	0.57	8.73	0.49	3.91e-16	Hemoglobin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09755102	chr1:33283495	S100PBP;YARS	0.65	7.9	0.45	9.5e-14	Smoking initiation;
KIRP	cis	rs155346	0.625	rs155348	chr5:139365216	C/T	cg24724630	chr5:139362307	NRG2	-0.4	-5.43	-0.33	1.33e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg20750642	chr13:99100586	FARP1	0.41	4.96	0.3	1.29e-6	Longevity;
KIRP	cis	rs4356932	0.967	rs4547819	chr4:76977768	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg13206674	chr6:150067644	NUP43	0.54	7.7	0.44	3.24e-13	Lung cancer;
KIRP	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg17652424	chr22:38574118	PLA2G6	-0.28	-5.95	-0.35	9.18e-9	Cutaneous nevi;
KIRP	cis	rs939574	0.722	rs72955435	chr2:220087354	A/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.86	6.3	0.37	1.35e-9	Platelet distribution width;
KIRP	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	12.97	0.64	1.18e-29	Smoking behavior;
KIRP	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg21775007	chr8:11205619	TDH	-0.52	-6.65	-0.39	1.87e-10	Neuroticism;
KIRP	cis	rs1050631	0.564	rs948416	chr18:33715673	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.46	5.74	0.34	2.71e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.63	8.26	0.47	8.88e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg25547332	chr5:131281432	NA	0.45	5.01	0.3	1.03e-6	Life satisfaction;
KIRP	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg05315796	chr3:52349193	DNAH1	0.44	6.54	0.38	3.54e-10	Bipolar disorder;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05107686	chr2:27616225	FTHL3;PPM1G	0.44	6.63	0.39	2.09e-10	Cancer;
KIRP	cis	rs7173743	0.525	rs11856903	chr15:79140017	A/G	cg00079375	chr15:79125835	NA	-0.45	-6.38	-0.38	8.66e-10	Coronary artery disease;
KIRP	cis	rs7011507	1.000	rs77711786	chr8:49134118	A/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23281280	chr6:28129359	ZNF389	0.49	5.47	0.33	1.08e-7	Depression;
KIRP	cis	rs10267417	0.673	rs2190413	chr7:19958386	A/G	cg05791153	chr7:19748676	TWISTNB	-0.47	-4.93	-0.3	1.55e-6	Night sleep phenotypes;
KIRP	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg07952391	chr2:88470173	THNSL2	0.92	7.57	0.43	7.56e-13	Plasma clusterin levels;
KIRP	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg04517722	chr19:17905589	B3GNT3	0.33	4.92	0.3	1.56e-6	Tumor biomarkers;
KIRP	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11987759	chr7:65425863	GUSB	0.5	6.78	0.4	8.68e-11	Aortic root size;
KIRP	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg18132916	chr6:79620363	NA	-0.42	-5.67	-0.34	4.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.65	-0.34	4.32e-8	Depression;
KIRP	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg24881330	chr22:46731750	TRMU	0.75	4.89	0.3	1.82e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.74	0.34	2.79e-8	Aortic root size;
KIRP	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.8	11.49	0.59	9.52e-25	Mood instability;
KIRP	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg05564831	chr3:52568323	NT5DC2	-0.33	-5.25	-0.32	3.36e-7	Electroencephalogram traits;
KIRP	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03517284	chr6:25882590	NA	-0.38	-5.44	-0.33	1.29e-7	Height;
KIRP	trans	rs2048656	0.578	rs4841235	chr8:9683358	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.36	-0.42	2.72e-12	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.75	-9.43	-0.52	3.32e-18	Facial morphology (factor 19);
KIRP	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.64	-8.62	-0.48	8.1e-16	Corneal structure;
KIRP	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg23533926	chr12:111358616	MYL2	-0.48	-6.33	-0.37	1.18e-9	Extrinsic epigenetic age acceleration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18880005	chr4:87927975	AFF1	0.53	6.63	0.39	2.13e-10	Parkinson's disease;
KIRP	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg13962347	chr6:5174647	LYRM4	-0.6	-8.19	-0.46	1.45e-14	Height;
KIRP	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg08807101	chr21:30365312	RNF160	0.59	6.9	0.4	4.41e-11	Cognitive test performance;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11245990	chr11:68621969	NA	0.37	5.26	0.32	3.09e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs10242455	0.702	rs10251282	chr7:98990236	T/C	cg09045935	chr12:6379348	NA	0.87	6.11	0.36	3.81e-9	Blood metabolite levels;
KIRP	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-7.83	-0.45	1.46e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06145708	chr11:124824151	CCDC15	0.46	6.14	0.36	3.3e-9	Parkinson's disease;
KIRP	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.83	-12.11	-0.61	8.74e-27	Calcium levels;
KIRP	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.82	8.21	0.46	1.26e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	1.04	19.55	0.78	5.19e-52	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg08662619	chr6:150070041	PCMT1	0.36	5.98	0.36	7.89e-9	Lung cancer;
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.61	9.05	0.5	4.53e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg16141378	chr3:129829833	LOC729375	0.52	7.16	0.42	9.26e-12	Neuroticism;
KIRP	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-5.74	-0.34	2.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg25447019	chr17:19030144	GRAPL	0.6	8.4	0.47	3.69e-15	Schizophrenia;
KIRP	cis	rs9914544	0.628	rs67053020	chr17:18680061	G/C	cg26378065	chr17:18585709	ZNF286B	0.4	5.06	0.31	8.04e-7	Educational attainment (years of education);
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg18234130	chr8:27182889	PTK2B	0.55	6.98	0.41	2.79e-11	Neuroticism;
KIRP	trans	rs2048656	0.508	rs7387886	chr8:9676575	T/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.26	-0.37	1.7e-9	Schizophrenia;
KIRP	cis	rs7577696	0.597	rs6756085	chr2:32336522	A/G	cg02381751	chr2:32503542	YIPF4	-0.53	-5.35	-0.32	2.02e-7	Inflammatory biomarkers;
KIRP	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg12131826	chr15:77904385	NA	0.51	6.1	0.36	4.12e-9	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08714886	chr8:121457617	MTBP;MRPL13	-0.47	-6.17	-0.37	2.83e-9	Interleukin-4 levels;
KIRP	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.93	-16.2	-0.72	1.12e-40	Electrocardiographic conduction measures;
KIRP	cis	rs1957429	0.520	rs7144515	chr14:65333725	G/A	cg23373153	chr14:65346875	NA	-0.68	-5.61	-0.34	5.3e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-8.72	-0.49	4.28e-16	Alzheimer's disease (survival time);
KIRP	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg21926883	chr2:100939477	LONRF2	-0.56	-7.48	-0.43	1.32e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg23307798	chr14:103986281	CKB	-0.77	-13.33	-0.65	7.32e-31	Body mass index;
KIRP	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.65	9.25	0.51	1.13e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg26681399	chr22:41777847	TEF	0.44	5.06	0.31	8.29e-7	Vitiligo;
KIRP	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg24009623	chr19:33667908	NA	0.47	6.1	0.36	4.06e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.68	-9.15	-0.5	2.29e-17	Eye color traits;
KIRP	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg13147721	chr7:65941812	NA	-0.88	-6.6	-0.39	2.54e-10	Diabetic kidney disease;
KIRP	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.26	-0.32	3.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.77	-0.4	9.46e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2904967	0.778	rs77130160	chr11:65122694	C/T	cg12562828	chr11:65076843	NA	0.91	10.23	0.55	1.07e-20	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23910786	chr18:47721232	MYO5B	0.47	6.02	0.36	6.29e-9	Parkinson's disease;
KIRP	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	cg12689670	chr1:183009347	LAMC1	0.49	7.11	0.41	1.29e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs8053891	0.756	rs28629271	chr16:72003732	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-4.86	-0.3	2.12e-6	Coronary artery disease;
KIRP	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.59	7.5	0.43	1.15e-12	Schizophrenia;
KIRP	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg16141378	chr3:129829833	LOC729375	0.55	7.3	0.42	4.05e-12	Morning vs. evening chronotype;
KIRP	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.77	-8.75	-0.49	3.55e-16	Coronary artery disease;
KIRP	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.65	-7.21	-0.42	6.91e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg20243544	chr17:37824526	PNMT	0.45	6.16	0.37	3.01e-9	Asthma;
KIRP	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.9	-12.33	-0.62	1.63e-27	Platelet distribution width;
KIRP	trans	rs7246760	0.867	rs10410379	chr19:9902197	G/A	cg02900749	chr2:68251473	NA	-0.94	-8.77	-0.49	3.11e-16	Pursuit maintenance gain;
KIRP	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.45	6.28	0.37	1.52e-9	Red blood cell count;
KIRP	cis	rs9400467	0.537	rs73530952	chr6:111486242	G/A	cg15721981	chr6:111408429	SLC16A10	0.77	7.13	0.41	1.1e-11	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14507002	chr2:73089775	NA	0.45	6.07	0.36	4.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg01304814	chr3:48885189	PRKAR2A	0.73	5.61	0.34	5.33e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06544989	chr22:39130855	UNC84B	0.47	8.24	0.47	1.02e-14	Menopause (age at onset);
KIRP	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	1.09	21.76	0.81	2.97e-59	Parkinson's disease;
KIRP	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	6.28	0.37	1.55e-9	Breast cancer;
KIRP	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05472934	chr7:22766657	IL6	0.81	10.7	0.56	3.36e-22	Lung cancer;
KIRP	cis	rs2591576	0.662	rs3843905	chr5:165427280	C/T	cg13976338	chr5:165423657	NA	-0.87	-13.44	-0.65	3.07e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs16958440	0.708	rs57468764	chr18:44624856	T/C	cg17192377	chr18:44677553	HDHD2	0.44	4.88	0.3	1.94e-6	Sitting height ratio;
KIRP	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.88	12.4	0.62	9.26e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg21401794	chr1:90099060	LRRC8C	0.54	7.14	0.41	1.06e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.55	6.94	0.4	3.38e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg13939156	chr17:80058883	NA	-0.51	-7.66	-0.44	4.15e-13	Life satisfaction;
KIRP	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg15507776	chr3:136538369	TMEM22	0.4	5.47	0.33	1.12e-7	Neuroticism;
KIRP	cis	rs7630877	0.886	rs2302741	chr3:179605294	T/C	cg18765712	chr3:179670323	PEX5L	0.56	6.7	0.39	1.4e-10	Type 2 diabetes;
KIRP	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg17385448	chr1:15911702	AGMAT	0.27	5.3	0.32	2.51e-7	Systolic blood pressure;
KIRP	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-6.18	-0.37	2.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.71	10.26	0.55	8.63e-21	Bladder cancer;
KIRP	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg26384229	chr12:38710491	ALG10B	0.54	7.26	0.42	5.06e-12	Morning vs. evening chronotype;
KIRP	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.71	-6.97	-0.41	2.97e-11	Breast cancer;
KIRP	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg10523679	chr1:76189770	ACADM	0.73	9.31	0.51	7.27e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7258950	1.000	rs7258950	chr19:11250139	C/T	cg07962303	chr19:11253944	NA	0.36	4.92	0.3	1.57e-6	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs301901	0.796	rs1517789	chr5:37510680	C/T	cg00076645	chr5:171711562	UBTD2	0.47	6.14	0.36	3.33e-9	Height;
KIRP	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg16497661	chr14:103986332	CKB	0.55	7.66	0.44	4.23e-13	Body mass index;
KIRP	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg15605315	chr1:45957053	TESK2	0.42	5.56	0.33	7.14e-8	Red blood cell count;Reticulocyte count;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02237855	chr2:74329332	TET3	0.43	6.29	0.37	1.42e-9	Serum protein levels (sST2);
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-1.05	-20.8	-0.8	3.81e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.06	-16.1	-0.72	2.53e-40	Homoarginine levels;
KIRP	cis	rs17453880	0.890	rs11167585	chr5:152029577	A/C	cg12297329	chr5:152029980	NA	-0.72	-11.2	-0.58	8.35e-24	Subjective well-being;
KIRP	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.31	4.85	0.3	2.24e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs17023223	0.537	rs12072768	chr1:119593918	A/G	cg05756136	chr1:119680316	WARS2	-0.54	-7.18	-0.42	8.13e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	7.84	0.45	1.38e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-6.76	-0.4	1.01e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.59	-7.96	-0.45	6.21e-14	High light scatter reticulocyte count;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg24815885	chr19:36486437	SDHAF1	0.57	6.15	0.37	3.15e-9	Electroencephalogram traits;
KIRP	cis	rs1062177	0.756	rs2915817	chr5:151115517	T/C	cg00977110	chr5:151150581	G3BP1	-0.59	-5.86	-0.35	1.47e-8	Preschool internalizing problems;
KIRP	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.62	0.39	2.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg02503808	chr4:7069936	GRPEL1	-1.02	-11.1	-0.58	1.82e-23	Monocyte percentage of white cells;
KIRP	cis	rs10048158	0.510	rs8082415	chr17:64205481	T/C	cg19474267	chr17:64306194	PRKCA	0.39	4.86	0.3	2.13e-6	&beta2-Glycoprotein I (β2-GPI) plasma levels;
KIRP	cis	rs12210905	0.841	rs28410967	chr6:27265235	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.71	-0.39	1.35e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.57	7.25	0.42	5.25e-12	Eosinophil percentage of white cells;
KIRP	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.22	14.04	0.67	2.88e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs4356975	0.583	rs11936822	chr4:69979947	C/T	cg27372994	chr4:70080453	UGT2B11	0.36	4.85	0.3	2.18e-6	Obesity-related traits;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg22794378	chr14:89029563	ZC3H14	-0.54	-6.02	-0.36	6.4e-9	Menopause (age at onset);
KIRP	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg11833968	chr6:79620685	NA	-0.45	-6.83	-0.4	6.57e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7808935	0.632	rs6969285	chr7:27997214	G/C	cg22168087	chr7:27702803	HIBADH	0.56	5.45	0.33	1.24e-7	Prostate cancer;
KIRP	cis	rs2282032	1.000	rs115026813	chr14:90747728	A/G	cg04374321	chr14:90722782	PSMC1	0.5	4.92	0.3	1.58e-6	Longevity;
KIRP	cis	rs477692	0.596	rs12247555	chr10:131370520	T/C	cg05714579	chr10:131428358	MGMT	-0.43	-5.51	-0.33	8.83e-8	Response to temozolomide;
KIRP	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.63	-7.57	-0.43	7.27e-13	Menarche (age at onset);
KIRP	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.47	-0.38	5.3e-10	Lung cancer;
KIRP	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.48	6.01	0.36	6.69e-9	Tonsillectomy;
KIRP	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.88	-0.35	1.34e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.69	-8.99	-0.5	6.92e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg05791153	chr7:19748676	TWISTNB	0.68	6.18	0.37	2.69e-9	Thyroid stimulating hormone;
KIRP	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.53	6.75	0.4	1.05e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10556830	chr5:68462986	CCNB1	0.48	6.29	0.37	1.46e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg21399703	chr1:247681439	NA	-0.5	-5.12	-0.31	6.05e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.82	8.95	0.5	8.92e-17	Alzheimer's disease;
KIRP	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.18	-0.37	2.63e-9	Colorectal cancer;
KIRP	cis	rs2380205	0.935	rs3954757	chr10:5888066	G/T	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15369054	chr17:80825471	TBCD	-0.37	-4.84	-0.3	2.24e-6	Breast cancer;
KIRP	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.75	10.83	0.57	1.35e-22	Bladder cancer;
KIRP	cis	rs11209002	0.614	rs10732837	chr1:67573120	A/G	cg02640540	chr1:67518911	SLC35D1	0.57	6.48	0.38	5.08e-10	Crohn's disease;
KIRP	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg03959625	chr15:84868606	LOC388152	0.61	6.23	0.37	2.05e-9	Schizophrenia;
KIRP	cis	rs10129255	0.500	rs7161740	chr14:107184358	G/T	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs6545883	0.718	rs3771260	chr2:61762384	G/T	cg15711740	chr2:61764176	XPO1	-0.58	-7.91	-0.45	8.51e-14	Tuberculosis;
KIRP	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21014159	chr11:117668035	DSCAML1	0.42	5.32	0.32	2.36e-7	Myopia;
KIRP	cis	rs9399135	0.682	rs9402684	chr6:135419305	T/C	cg24558204	chr6:135376177	HBS1L	0.44	5.57	0.33	6.67e-8	Red blood cell count;
KIRP	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.6	7.59	0.44	6.42e-13	Red blood cell count;
KIRP	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.83	0.35	1.75e-8	Melanoma;
KIRP	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg00745463	chr17:30367425	LRRC37B	-0.92	-8.63	-0.48	7.62e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.78	10.24	0.55	1e-20	Aortic root size;
KIRP	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.49	6.67	0.39	1.66e-10	Mean corpuscular volume;
KIRP	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.75	-10.95	-0.57	5.63e-23	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.31	0.42	3.82e-12	Neuroticism;
KIRP	cis	rs427941	0.703	rs201435	chr7:101732865	G/C	cg06246474	chr7:101738831	CUX1	0.55	6.8	0.4	7.91e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs3850699	0.926	rs2002916	chr10:104432053	A/G	cg04362960	chr10:104952993	NT5C2	0.52	5.96	0.36	8.6e-9	Prostate cancer;
KIRP	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.3	0.47	6.76e-15	IgG glycosylation;
KIRP	cis	rs12210905	1.000	rs12209429	chr6:27054867	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs930036	0.576	rs35230775	chr2:171770315	G/A	cg12801329	chr2:171670795	NA	0.47	5.15	0.31	5.45e-7	Menopause (age at onset);
KIRP	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.97	9.96	0.54	7.47e-20	Bronchopulmonary dysplasia;
KIRP	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.07	0.36	4.72e-9	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg21851534	chr17:3907994	ZZEF1	0.62	9.7	0.53	4.86e-19	Type 2 diabetes;
KIRP	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.48	7.34	0.42	3.12e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	6.64	0.39	2.01e-10	Menarche (age at onset);
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg01283332	chr5:1856932	NA	-0.51	-6.53	-0.38	3.81e-10	Cardiovascular disease risk factors;
KIRP	cis	rs3026101	0.647	rs4790263	chr17:5307084	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	7.04	0.41	1.88e-11	Body mass index;
KIRP	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.91	11.18	0.58	9.9899999999999993e-24	Vitiligo;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-8.72	-0.49	4.15e-16	Lymphocyte counts;
KIRP	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-1.1	-8.03	-0.46	4.11e-14	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13862419	chr11:120038190	NA	0.46	6.27	0.37	1.58e-9	Survival in pancreatic cancer;
KIRP	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.62	-8.13	-0.46	2.12e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12282928	1.000	rs11039671	chr11:48332985	G/C	cg26585981	chr11:48327164	OR4S1	0.5	6.09	0.36	4.28e-9	Migraine - clinic-based;
KIRP	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.06	0.46	3.42e-14	Menarche (age at onset);
KIRP	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg05335186	chr13:53173507	NA	0.38	5.7	0.34	3.51e-8	Lewy body disease;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.63	8.62	0.48	8.52e-16	Longevity;Endometriosis;
KIRP	cis	rs72925845	0.577	rs691328	chr17:76429313	G/A	cg03830375	chr17:76426088	DNAH17	0.5	5.14	0.31	5.61e-7	Triglycerides;
KIRP	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.07	-0.58	2.23e-23	Height;
KIRP	cis	rs7274811	0.744	rs6119395	chr20:32244711	G/T	cg21523528	chr20:32077966	CBFA2T2	0.42	4.85	0.3	2.18e-6	Height;
KIRP	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.73	-8.59	-0.48	1.03e-15	Body mass index;
KIRP	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27297192	chr10:134578999	INPP5A	0.61	7.57	0.43	7.28e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.85	-12.59	-0.63	2.23e-28	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.54	-7.3	-0.42	3.87e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18937225	chr1:51793660	TTC39A	0.48	6.58	0.39	2.86e-10	Interleukin-4 levels;
KIRP	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg00319359	chr11:70116639	PPFIA1	0.81	7.33	0.42	3.28e-12	Coronary artery disease;
KIRP	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-12.42	-0.62	8.1e-28	Vitiligo;
KIRP	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg21775007	chr8:11205619	TDH	-0.51	-6.69	-0.39	1.51e-10	Triglycerides;
KIRP	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	cis	rs9547996	0.879	rs7985686	chr13:38128643	C/T	cg13634560	chr13:38173852	POSTN	0.41	5.69	0.34	3.53e-8	Diastolic blood pressure;
KIRP	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	6.25	0.37	1.76e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.64	0.71	9.78e-39	Platelet count;
KIRP	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.71	10.19	0.54	1.43e-20	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg14593290	chr7:50529359	DDC	-0.39	-5.36	-0.32	1.96e-7	Systemic sclerosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11970301	chr16:30087888	PPP4C	0.53	6.22	0.37	2.1e-9	Smoking initiation;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.59	8.89	0.49	1.38e-16	Lung cancer;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.73	6.45	0.38	5.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg00405596	chr8:11794950	NA	-0.4	-4.94	-0.3	1.47e-6	Systolic blood pressure;
KIRP	cis	rs745821	0.701	rs17741814	chr18:48098624	C/A	cg18923635	chr18:48083994	NA	0.43	4.97	0.3	1.27e-6	Diastolic blood pressure;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16415121	chr6:88299659	ORC3L;RARS2	0.49	6.63	0.39	2.16e-10	Survival in pancreatic cancer;
KIRP	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	cg21523751	chr1:182988639	NA	0.42	6.43	0.38	6.44e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	7.61	0.44	5.81e-13	Joint mobility (Beighton score);
KIRP	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg14914422	chr1:46958856	NA	0.43	5.35	0.32	1.97e-7	Monobrow;
KIRP	cis	rs10267417	0.603	rs10278800	chr7:19909594	A/G	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.08	-0.5	3.59e-17	Response to antipsychotic treatment;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18745217	chr4:56215882	SRD5A3	0.55	7.05	0.41	1.84e-11	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21505940	chr18:46477173	SMAD7	0.53	6.87	0.4	5.34e-11	Parkinson's disease;
KIRP	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg26681399	chr22:41777847	TEF	-0.43	-4.92	-0.3	1.62e-6	Vitiligo;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02737782	chr1:8014393	NA	0.43	6.06	0.36	5.07e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.92	14.01	0.67	3.51e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.75	-10.98	-0.57	4.49e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.13	0.31	5.79e-7	Height;
KIRP	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.77	-7.96	-0.45	6.42e-14	Gut microbiome composition (summer);
KIRP	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg07856975	chr6:36356162	ETV7	0.45	5.89	0.35	1.29e-8	Platelet distribution width;
KIRP	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg06191203	chr2:152266755	RIF1	-0.53	-5.85	-0.35	1.54e-8	Lung cancer;
KIRP	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg16111737	chr12:117408163	FBXW8	0.53	5.17	0.31	4.88e-7	Subcortical brain region volumes;Hippocampal volume;
KIRP	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.19	0.37	2.48e-9	Triglycerides;
KIRP	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.29	6.66	0.39	1.77e-10	IgG glycosylation;
KIRP	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	9.01	0.5	5.73e-17	Resting heart rate;
KIRP	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg25356066	chr3:128598488	ACAD9	0.47	5.6	0.34	5.74e-8	IgG glycosylation;
KIRP	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs3857747	0.895	rs6462979	chr7:40401376	G/A	cg00420559	chr7:40367873	C7orf10	-0.61	-8.34	-0.47	5.42e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg22903471	chr2:27725779	GCKR	0.41	5.65	0.34	4.5e-8	Oral cavity cancer;
KIRP	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg11608241	chr8:8085544	FLJ10661	0.51	6.02	0.36	6.35e-9	Mood instability;
KIRP	cis	rs9596863	1.000	rs9568940	chr13:54419251	C/A	ch.13.53330881F	chr13:54432880	NA	0.64	6.57	0.39	2.98e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.46	7.62	0.44	5.37e-13	Testicular germ cell tumor;
KIRP	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.5	-0.48	1.9e-15	Coronary artery disease;
KIRP	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.54	6.69	0.39	1.45e-10	Body mass index;
KIRP	cis	rs12786942	0.502	rs2513176	chr11:101268666	G/T	cg03942599	chr11:101341554	TRPC6	0.45	5.28	0.32	2.78e-7	Facial depth;
KIRP	cis	rs7175404	0.793	rs6497080	chr15:94033802	A/G	cg23502883	chr15:93959149	NA	-0.44	-5.11	-0.31	6.62e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg07596299	chr11:71824057	C11orf51	-0.84	-5.64	-0.34	4.61e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.58	0.48	1.09e-15	Bladder cancer;
KIRP	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg04398451	chr17:18023971	MYO15A	-0.61	-8.37	-0.47	4.46e-15	Total body bone mineral density;
KIRP	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg02660097	chr11:68866761	NA	0.4	5.16	0.31	5.17e-7	Blond vs. brown hair color;
KIRP	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg25356066	chr3:128598488	ACAD9	0.52	5.97	0.36	8.35e-9	IgG glycosylation;
KIRP	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-7.17	-0.42	8.73e-12	Morning vs. evening chronotype;
KIRP	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg15832292	chr6:96025679	MANEA	0.83	8.44	0.47	2.8e-15	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg04990556	chr1:26633338	UBXN11	0.64	6.44	0.38	6.08e-10	Obesity-related traits;
KIRP	cis	rs7646881	1.000	rs73015652	chr3:158451383	A/G	cg19483011	chr3:158453295	NA	-0.52	-6.0	-0.36	7.14e-9	Tetralogy of Fallot;
KIRP	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.56	0.33	7.06e-8	Educational attainment;
KIRP	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg22563815	chr15:78856949	CHRNA5	0.5	7.8	0.45	1.8e-13	Sudden cardiac arrest;
KIRP	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-5.99	-0.36	7.48e-9	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg10756647	chr7:56101905	PSPH	1.09	8.64	0.48	7.48e-16	Diabetic kidney disease;
KIRP	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg18154014	chr19:37997991	ZNF793	0.73	7.81	0.45	1.69e-13	Coronary artery calcification;
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.47	5.94	0.35	9.78e-9	Life satisfaction;
KIRP	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.98	-0.45	5.7e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.57e-7	Recombination rate (females);
KIRP	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg16583315	chr14:65563665	MAX	-0.34	-5.11	-0.31	6.6e-7	Obesity-related traits;
KIRP	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.57	-7.49	-0.43	1.21e-12	Aortic root size;
KIRP	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg06740227	chr12:86229804	RASSF9	0.41	5.17	0.31	4.93e-7	Major depressive disorder;
KIRP	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.56	-0.56	9.89e-22	Triglycerides;
KIRP	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.61	-0.44	5.88e-13	Mean platelet volume;
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg07169764	chr2:136633963	MCM6	0.53	6.17	0.37	2.74e-9	Mosquito bite size;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg08591472	chr7:1030197	NA	-0.41	-5.09	-0.31	7.23e-7	Longevity;Endometriosis;
KIRP	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg14972814	chr11:95582409	MTMR2	0.35	5.56	0.33	7.04e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13808325	chr4:25915922	C4orf52	-0.47	-6.29	-0.37	1.44e-9	Metabolic traits;
KIRP	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.97	-0.54	7.01e-20	Coronary artery disease;
KIRP	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg24807547	chr6:37504484	NA	-0.43	-6.18	-0.37	2.68e-9	Cognitive performance;
KIRP	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11644478	chr21:40555479	PSMG1	-0.53	-5.29	-0.32	2.73e-7	Menarche (age at onset);
KIRP	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.62	-6.75	-0.4	1.08e-10	DNA methylation (variation);
KIRP	cis	rs6725041	0.740	rs4673654	chr2:213093403	C/A	cg20637307	chr2:213403960	ERBB4	-0.39	-5.0	-0.3	1.12e-6	QT interval (ambient particulate matter interaction);
KIRP	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.42	4.9	0.3	1.74e-6	Aortic root size;
KIRP	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg00982548	chr2:198649783	BOLL	-0.54	-5.1	-0.31	6.76e-7	Ulcerative colitis;
KIRP	cis	rs4700695	0.764	rs251278	chr5:65381826	G/A	cg21114390	chr5:65439923	SFRS12	-0.49	-5.81	-0.35	1.9e-8	Facial morphology (factor 19);
KIRP	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-6.78	-0.4	8.67e-11	Height;
KIRP	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.5	-6.39	-0.38	8.23e-10	Schizophrenia;
KIRP	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg06598631	chr6:88300029	RARS2;ORC3L	0.4	5.0	0.3	1.1e-6	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.65	-7.99	-0.45	5.12e-14	Aortic root size;
KIRP	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.83	6.82	0.4	6.86e-11	Initial pursuit acceleration;
KIRP	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.75	9.49	0.52	2.07e-18	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
KIRP	cis	rs2230307	0.536	rs7530361	chr1:100462860	T/C	cg24955406	chr1:100503596	HIAT1	0.56	6.14	0.36	3.22e-9	Carotid intima media thickness;
KIRP	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg07701084	chr6:150067640	NUP43	0.56	7.26	0.42	4.92e-12	Testicular germ cell tumor;
KIRP	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.5	-6.04	-0.36	5.79e-9	Subjective well-being;
KIRP	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg13010199	chr12:38710504	ALG10B	0.53	6.72	0.39	1.24e-10	Morning vs. evening chronotype;
KIRP	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg03647239	chr10:116582469	FAM160B1	-0.44	-4.89	-0.3	1.85e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10242455	0.702	rs74552228	chr7:98977046	C/T	cg18809830	chr7:99032528	PTCD1	-1.06	-6.11	-0.36	3.91e-9	Blood metabolite levels;
KIRP	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.93	-0.45	7.91e-14	Bipolar disorder;
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22168489	chr12:122356033	WDR66	0.62	9.03	0.5	5.06e-17	Mean corpuscular volume;
KIRP	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs1355223	0.902	rs2185700	chr11:34724204	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.75e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs5753618	0.561	rs1858821	chr22:31676454	T/C	cg22777020	chr22:31556080	RNF185	-0.5	-5.29	-0.32	2.74e-7	Colorectal cancer;
KIRP	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg08975724	chr8:8085496	FLJ10661	0.61	7.44	0.43	1.69e-12	Retinal vascular caliber;
KIRP	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg13010199	chr12:38710504	ALG10B	0.63	8.31	0.47	6.29e-15	Heart rate;
KIRP	cis	rs7116495	0.737	rs7126838	chr11:71826237	A/G	cg26138937	chr11:71823887	C11orf51	0.7	5.54	0.33	7.96e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6142102	0.961	rs6087557	chr20:32698275	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	6.74	0.39	1.1e-10	Skin pigmentation;
KIRP	cis	rs9581857	0.547	rs9579087	chr13:28059780	G/A	cg22138327	chr13:27999177	GTF3A	0.89	6.61	0.39	2.35e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs12282928	0.918	rs7948903	chr11:48247305	T/C	cg26585981	chr11:48327164	OR4S1	-0.5	-5.99	-0.36	7.55e-9	Migraine - clinic-based;
KIRP	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.84	10.47	0.56	1.91e-21	Cognitive function;
KIRP	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.64	-8.2	-0.46	1.35e-14	Response to antipsychotic treatment;
KIRP	cis	rs4901847	0.967	rs6573188	chr14:58549613	C/G	cg15908186	chr14:58618357	C14orf37	0.4	5.34	0.32	2.14e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.63	-0.48	7.7e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09978546	chr15:25981255	ATP10A	0.42	6.04	0.36	5.77e-9	Survival in pancreatic cancer;
KIRP	cis	rs1318772	1.000	rs72797916	chr5:112690587	C/T	cg12552261	chr5:112820674	MCC	0.8	5.06	0.31	8.05e-7	F-cell distribution;
KIRP	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10901296	0.660	rs2855198	chr9:133764606	T/C	cg13397898	chr9:133768931	QRFP	0.34	5.96	0.36	8.81e-9	Bilirubin levels;
KIRP	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg08807101	chr21:30365312	RNF160	-0.58	-5.75	-0.34	2.69e-8	Cognitive test performance;
KIRP	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.63	-0.39	2.11e-10	Bipolar disorder;
KIRP	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.98	0.3	1.22e-6	Personality dimensions;
KIRP	cis	rs76917914	0.589	rs6478563	chr9:100864919	T/C	cg03040243	chr9:100819229	NANS	0.47	5.07	0.31	7.85e-7	Immature fraction of reticulocytes;
KIRP	cis	rs10865541	0.869	rs6711292	chr2:3422170	A/T	cg11642891	chr2:3452563	TTC15	-0.55	-6.96	-0.41	3.03e-11	Obesity-related traits;
KIRP	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg26207909	chr14:103986467	CKB	0.47	5.71	0.34	3.26e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.6	-8.16	-0.46	1.73e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12220238	0.822	rs2395087	chr10:76082637	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.65	0.39	1.92e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs629922	0.671	rs513039	chr11:114037158	G/A	cg25009965	chr11:114031120	ZBTB16	0.45	5.77	0.35	2.4e-8	Paneth cell defects in Crohn's disease;
KIRP	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg21573476	chr21:45109991	RRP1B	-0.6	-8.2	-0.46	1.3e-14	Mean corpuscular volume;
KIRP	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	1.03	14.21	0.67	7.47e-34	Menopause (age at onset);
KIRP	cis	rs7215564	0.822	rs10871488	chr17:78739079	T/C	cg06153925	chr17:78755379	RPTOR	-0.37	-6.43	-0.38	6.46e-10	Myopia (pathological);
KIRP	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.04	0.36	5.64e-9	Lung cancer;
KIRP	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-5.45	-0.33	1.25e-7	Life satisfaction;
KIRP	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg15676125	chr6:33679581	C6orf125	0.39	5.03	0.31	9.55e-7	Plateletcrit;
KIRP	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11987759	chr7:65425863	GUSB	-0.62	-8.29	-0.47	7.27e-15	Aortic root size;
KIRP	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg00898013	chr13:113819073	PROZ	-0.47	-5.06	-0.31	8.05e-7	Blood protein levels;
KIRP	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.89	-13.55	-0.65	1.3e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.95	13.11	0.64	3.97e-30	Breast cancer;
KIRP	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	0.98	10.9	0.57	7.88e-23	Iron status biomarkers;
KIRP	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg17764715	chr19:33622953	WDR88	0.67	8.38	0.47	4.1e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4955124	0.558	rs62244405	chr3:32037605	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	6.69	0.39	1.52e-10	Schizophrenia;
KIRP	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.47	-0.33	1.12e-7	Height;
KIRP	cis	rs6732160	0.691	rs7599223	chr2:73427103	A/G	cg01422370	chr2:73384389	NA	0.41	5.42	0.33	1.43e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.32	-0.32	2.29e-7	Renal cell carcinoma;
KIRP	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg26875233	chr11:93583750	C11orf90	0.35	7.04	0.41	1.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.75	11.04	0.58	2.7e-23	Hip circumference;
KIRP	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.88	-12.77	-0.63	5.52e-29	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7523273	0.597	rs4844390	chr1:207934849	A/G	cg22525895	chr1:207977042	MIR29B2	-0.56	-4.9	-0.3	1.72e-6	Schizophrenia;
KIRP	trans	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-6.23	-0.37	2e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.39	-0.43	2.29e-12	Gut microbiome composition (summer);
KIRP	cis	rs2625529	0.824	rs11072339	chr15:72247190	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.04	-0.36	5.57e-9	Red blood cell count;
KIRP	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.62	-7.04	-0.41	1.93e-11	Mean platelet volume;
KIRP	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg24253500	chr15:84953950	NA	0.41	4.95	0.3	1.36e-6	Schizophrenia;
KIRP	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.82	0.63	3.63e-29	Platelet count;
KIRP	trans	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg06521331	chr12:34319734	NA	-0.53	-6.42	-0.38	7.06e-10	Bladder cancer;
KIRP	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg05220968	chr6:146057943	EPM2A	0.41	5.05	0.31	8.74e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.26	26.34	0.86	1.52e-73	IgG glycosylation;
KIRP	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.55	-7.47	-0.43	1.43e-12	Systolic blood pressure;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg23715435	chr6:26027513	HIST1H4B	-0.49	-6.22	-0.37	2.18e-9	Obesity-related traits;
KIRP	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.26	0.47	8.93e-15	Obesity-related traits;
KIRP	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.27	-0.32	3.05e-7	Major depressive disorder;
KIRP	cis	rs3540	0.960	rs2238329	chr15:91028401	G/A	cg10434728	chr15:90938212	IQGAP1	0.3	5.13	0.31	5.98e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.78	9.88	0.53	1.35e-19	Corneal astigmatism;
KIRP	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.76	-8.89	-0.49	1.36e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.87	-0.45	1.09e-13	Sudden cardiac arrest;
KIRP	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg19849509	chr2:175204996	NA	-0.53	-6.31	-0.37	1.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg16898833	chr6:26189333	HIST1H4D	0.66	5.01	0.3	1.05e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4356932	1.000	rs7670789	chr4:76940381	G/A	cg00809888	chr4:76862425	NAAA	0.45	6.27	0.37	1.59e-9	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24616589	chr7:151038719	NUB1	0.45	6.46	0.38	5.51e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.83	8.3	0.47	6.85e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.51	7.55	0.43	8.47e-13	Immature fraction of reticulocytes;
KIRP	cis	rs13102973	0.720	rs7687463	chr4:135885773	G/T	cg14419869	chr4:135874104	NA	0.41	6.5	0.38	4.54e-10	Subjective well-being;
KIRP	cis	rs1707322	0.638	rs1707302	chr1:46600917	A/G	cg03146154	chr1:46216737	IPP	-0.52	-6.45	-0.38	5.98e-10	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2997105	0.938	rs7329634	chr13:56348275	A/G	cg08528735	chr3:184428879	MAGEF1	0.57	6.28	0.37	1.49e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.09	-14.32	-0.67	3.03e-34	Corneal structure;
KIRP	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.93	9.7	0.53	4.62e-19	Neuroticism;
KIRP	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.54	-0.43	9.09e-13	Type 2 diabetes;
KIRP	cis	rs7712401	0.715	rs1139334	chr5:122358419	A/G	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.55	-7.63	-0.44	5.2e-13	IgG glycosylation;
KIRP	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg16141378	chr3:129829833	LOC729375	0.59	8.1	0.46	2.56e-14	Neuroticism;
KIRP	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.77	-11.87	-0.6	5.25e-26	Neurofibrillary tangles;
KIRP	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.56	-0.48	1.27e-15	Mean corpuscular volume;
KIRP	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.8	-12.07	-0.61	1.14e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-1.08	-21.22	-0.8	1.61e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	0.96	8.46	0.47	2.42e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.57	-0.52	1.17e-18	Rheumatoid arthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13883904	chr4:54292066	FIP1L1	-0.44	-6.32	-0.37	1.21e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg00677455	chr12:58241039	CTDSP2	-0.98	-12.68	-0.63	1.09e-28	Multiple sclerosis;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.52	5.32	0.32	2.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.34	5.23	0.32	3.69e-7	Loneliness (linear analysis);
KIRP	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg16586182	chr3:47516702	SCAP	-0.77	-11.17	-0.58	1.02e-23	Colorectal cancer;
KIRP	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg12962167	chr3:53033115	SFMBT1	0.65	5.0	0.3	1.09e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-0.79	-12.33	-0.62	1.56e-27	Prudent dietary pattern;
KIRP	cis	rs10751667	0.600	rs4076915	chr11:1012464	C/G	cg06064525	chr11:970664	AP2A2	-0.31	-5.72	-0.34	3.1e-8	Alzheimer's disease (late onset);
KIRP	cis	rs56146971	0.763	rs11160005	chr14:91872587	G/C	cg16433844	chr14:91963127	SMEK1	-0.59	-5.88	-0.35	1.35e-8	Alzheimer disease and age of onset;
KIRP	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg15841412	chr13:111365552	ING1	0.55	6.2	0.37	2.31e-9	Coronary artery disease;
KIRP	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg03645007	chr3:50255295	SLC38A3	0.36	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.5	6.73	0.39	1.22e-10	Mean corpuscular volume;
KIRP	cis	rs6977660	0.714	rs28605851	chr7:19815219	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.41	0.33	1.52e-7	Thyroid stimulating hormone;
KIRP	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.74	9.96	0.54	7.27e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7712401	0.623	rs538424	chr5:122228763	G/A	cg19412675	chr5:122181750	SNX24	0.51	5.58	0.34	6.28e-8	Mean platelet volume;
KIRP	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.41	-0.38	7.46e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg23625390	chr15:77176239	SCAPER	0.5	6.52	0.38	3.92e-10	Blood metabolite levels;
KIRP	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.18	-0.37	2.69e-9	Educational attainment;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-1.12	-21.95	-0.81	6.97e-60	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg01114951	chr1:117664707	TRIM45	0.94	6.35	0.38	1.01e-9	P wave terminal force;
KIRP	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg17554472	chr22:41940697	POLR3H	0.68	6.86	0.4	5.64e-11	Cannabis dependence symptom count;
KIRP	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	16.43	0.72	1.89e-41	Chronic sinus infection;
KIRP	cis	rs17065868	0.764	rs61949803	chr13:45048498	C/G	cg10246903	chr13:45222710	NA	0.59	5.02	0.3	1.02e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs397969	0.596	rs17605101	chr17:19877634	T/C	cg04132472	chr17:19861366	AKAP10	0.46	5.09	0.31	7.16e-7	Platelet count;
KIRP	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.38	-5.72	-0.34	3.08e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.61	-7.45	-0.43	1.55e-12	Neuroticism;
KIRP	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00149659	chr3:10157352	C3orf10	0.95	10.34	0.55	4.7e-21	Alzheimer's disease;
KIRP	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-1.02	-13.26	-0.65	1.21e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-6.86	-0.4	5.71e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.17e-6	Pulmonary function;
KIRP	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.45	-5.3	-0.32	2.53e-7	Reticulocyte count;
KIRP	cis	rs2637030	0.559	rs7728496	chr5:52867330	G/T	cg06476337	chr5:52856530	NDUFS4	-0.54	-6.07	-0.36	4.79e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs2273669	0.588	rs11153158	chr6:109376118	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.24	-0.37	1.89e-9	Prostate cancer;
KIRP	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.2	17.33	0.74	1.68e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.81	10.49	0.56	1.58e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg00981070	chr1:2046702	PRKCZ	0.37	5.47	0.33	1.12e-7	Height;
KIRP	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.21	-0.32	3.95e-7	Personality dimensions;
KIRP	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.63	-0.39	2.13e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.52	7.24	0.42	5.68e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs4073221	0.585	rs34078971	chr3:18323115	A/G	cg07694806	chr3:18168406	NA	-0.68	-5.91	-0.35	1.12e-8	Parkinson's disease;
KIRP	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg05768032	chr16:30646687	NA	0.46	5.54	0.33	7.61e-8	Multiple myeloma;
KIRP	cis	rs9420	0.784	rs12798206	chr11:57668479	T/G	cg19752551	chr11:57585705	CTNND1	-0.75	-10.41	-0.55	2.91e-21	Schizophrenia;
KIRP	cis	rs631288	0.793	rs1822312	chr1:146687250	A/T	cg25205988	chr1:146714368	CHD1L	-0.9	-5.28	-0.32	2.84e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-14.97	-0.69	1.9e-36	Alzheimer's disease;
KIRP	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.49	6.88	0.4	5e-11	Personality dimensions;
KIRP	cis	rs926392	0.666	rs56877916	chr20:37696192	A/T	cg16355469	chr20:37678765	NA	0.56	6.77	0.4	9.6e-11	Dialysis-related mortality;
KIRP	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.62	9.56	0.52	1.29e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs2594989	0.943	rs346070	chr3:11303874	T/C	cg01796438	chr3:11312864	ATG7	-0.65	-7.37	-0.43	2.56e-12	Circulating chemerin levels;
KIRP	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg11965913	chr1:205819406	PM20D1	-0.42	-5.25	-0.32	3.32e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg01334186	chr1:151372572	PSMB4	0.69	6.12	0.36	3.68e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.75	7.59	0.44	6.6e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.6	-6.08	-0.36	4.48e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg07796016	chr1:152779584	LCE1C	-0.46	-5.71	-0.34	3.28e-8	Inflammatory skin disease;
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg11062466	chr8:58055876	NA	0.66	5.43	0.33	1.33e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6142102	1.000	rs6142102	chr20:32704627	C/G	cg24642439	chr20:33292090	TP53INP2	0.52	5.99	0.36	7.54e-9	Skin pigmentation;
KIRP	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.59	6.86	0.4	5.59e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.92	11.7	0.6	2.03e-25	Vitiligo;
KIRP	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-9.06	-0.5	4.27e-17	Morning vs. evening chronotype;
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.74	10.71	0.56	3.32e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg06212747	chr3:49208901	KLHDC8B	0.67	7.08	0.41	1.5e-11	Menarche (age at onset);
KIRP	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.59	6.3	0.37	1.37e-9	Gut microbiome composition (summer);
KIRP	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.5	-0.43	1.17e-12	Bipolar disorder;
KIRP	cis	rs2671245	1.000	rs2671243	chr1:56168509	C/T	cg11523071	chr1:56160889	NA	0.41	6.31	0.37	1.27e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4704187	0.687	rs4389672	chr5:74368642	G/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.63	8.72	0.49	4.22e-16	Autism;
KIRP	cis	rs2172802	0.570	rs12507326	chr4:62544952	T/C	cg04118610	chr4:62707027	LPHN3	0.44	5.46	0.33	1.18e-7	Partial epilepsies;
KIRP	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.69	10.75	0.57	2.34e-22	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01893041	chr5:67583972	PIK3R1	0.64	6.13	0.36	3.49e-9	Lung function (FEV1);
KIRP	trans	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg13565492	chr6:43139072	SRF	-0.94	-8.67	-0.48	5.79e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Bipolar disorder;
KIRP	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-1.03	-11.39	-0.59	2.02e-24	Cognitive test performance;
KIRP	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.63	-6.77	-0.4	9.22e-11	Initial pursuit acceleration;
KIRP	cis	rs11610422	1.000	rs12824070	chr12:31414280	C/T	cg14306366	chr12:31406441	NA	-0.58	-5.95	-0.35	9.35e-9	Coronary artery disease;
KIRP	cis	rs3017493	0.786	rs74344478	chr11:70681107	G/A	cg10362475	chr11:70507825	SHANK2	0.37	5.58	0.34	6.33e-8	Renal transplant outcome;
KIRP	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.42	5.43	0.33	1.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs55962025	1.000	rs55962025	chr4:3112109	A/C	cg06533319	chr4:3265114	C4orf44	0.47	5.52	0.33	8.53e-8	Parental longevity (mother's age at death);
KIRP	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-7.4	-0.43	2.1e-12	Exhaled nitric oxide output;
KIRP	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg21184320	chr1:21044207	KIF17	-0.35	-5.22	-0.32	3.82e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg21775007	chr8:11205619	TDH	0.46	6.22	0.37	2.11e-9	Neuroticism;
KIRP	cis	rs362296	0.698	rs362289	chr4:3256378	G/A	cg06436626	chr4:3257686	C4orf44	0.44	5.04	0.31	8.93e-7	Parental longevity (mother's age at death);
KIRP	cis	rs6707387	0.686	rs10460417	chr2:214519631	T/G	cg08319019	chr2:214017104	IKZF2	0.47	5.48	0.33	1.03e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg26965718	chr17:79658957	HGS	-0.62	-5.78	-0.35	2.23e-8	Dental caries;
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg14221460	chr8:27183342	PTK2B	0.49	6.52	0.38	3.94e-10	Neuroticism;
KIRP	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.43	-0.52	3.3e-18	Coronary artery disease;
KIRP	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg20302533	chr7:39170763	POU6F2	0.28	6.08	0.36	4.67e-9	IgG glycosylation;
KIRP	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.46	-0.33	1.15e-7	Total body bone mineral density;
KIRP	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg02678768	chr17:74002944	EVPL	0.41	5.34	0.32	2.11e-7	White matter hyperintensity burden;
KIRP	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.81	-13.21	-0.64	1.82e-30	Pulse pressure;
KIRP	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.97	11.34	0.59	2.99e-24	Corneal astigmatism;
KIRP	cis	rs4523957	0.928	rs12453323	chr17:2160214	T/C	cg16513277	chr17:2031491	SMG6	0.58	8.01	0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.73	-0.34	2.92e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.83	-12.88	-0.63	2.28e-29	Dental caries;
KIRP	cis	rs8177876	0.822	rs1414	chr16:81115857	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg18306943	chr3:40428807	ENTPD3	0.46	5.9	0.35	1.19e-8	Renal cell carcinoma;
KIRP	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.97	-0.36	8.38e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg03714773	chr7:91764589	CYP51A1	0.36	5.37	0.32	1.86e-7	Breast cancer;
KIRP	trans	rs3779273	0.722	rs4730115	chr7:77833976	A/G	cg05596911	chr5:118502651	DMXL1	-0.4	-6.63	-0.39	2.14e-10	Body mass index;
KIRP	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.81	-0.49	2.27e-16	Common traits (Other);
KIRP	trans	rs6596140	0.620	rs10515463	chr5:133032214	C/T	cg08567913	chr11:114082594	ZBTB16	0.43	6.36	0.38	9.84e-10	Hypertension;
KIRP	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg24558204	chr6:135376177	HBS1L	-0.6	-7.65	-0.44	4.61e-13	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg05315796	chr3:52349193	DNAH1	0.46	7.0	0.41	2.47e-11	Bipolar disorder;
KIRP	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.92	-0.35	1.05e-8	Neuroticism;
KIRP	cis	rs66530629	0.958	rs4024244	chr1:25050228	G/A	cg07201717	chr1:25031947	NA	0.33	4.87	0.3	1.96e-6	Plateletcrit;
KIRP	cis	rs6681460	1.000	rs9662943	chr1:67121132	A/G	cg02459107	chr1:67143332	SGIP1	-0.49	-6.65	-0.39	1.86e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.88	-0.35	1.35e-8	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05794042	chr18:45687771	NA	0.5	6.25	0.37	1.83e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00434991	chr10:134504552	INPP5A	-0.47	-6.12	-0.36	3.74e-9	Parkinson's disease;
KIRP	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg12140854	chr5:148520817	ABLIM3	0.59	6.16	0.37	2.94e-9	Breast cancer;
KIRP	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.37	-0.43	2.67e-12	Aortic root size;
KIRP	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.5	7.08	0.41	1.52e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg05044414	chr3:183734942	ABCC5	0.33	4.96	0.3	1.29e-6	Anterior chamber depth;
KIRP	cis	rs17030434	1.000	rs10026531	chr4:154727070	C/T	cg14289246	chr4:154710475	SFRP2	-0.81	-9.71	-0.53	4.3e-19	Electrocardiographic conduction measures;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg27309920	chr12:6798957	ZNF384	0.49	6.04	0.36	5.78e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.58	-8.94	-0.5	9.47e-17	Calcium levels;
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02475777	chr4:1388615	CRIPAK	0.42	5.7	0.34	3.33e-8	Longevity;
KIRP	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg08600765	chr20:34638493	LOC647979	-0.68	-6.58	-0.39	2.78e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.98	-10.57	-0.56	8.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.58	-7.49	-0.43	1.26e-12	Retinal vascular caliber;
KIRP	cis	rs1978968	1.000	rs2099944	chr22:18438578	G/A	cg03078520	chr22:18463400	MICAL3	-0.68	-8.7	-0.49	4.84e-16	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg10254082	chr7:997346	NA	0.48	5.03	0.31	9.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6723226	0.750	rs3769597	chr2:32691400	T/G	cg02381751	chr2:32503542	YIPF4	0.69	9.04	0.5	4.67e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg06565975	chr8:143823917	SLURP1	0.47	7.49	0.43	1.24e-12	Urinary tract infection frequency;
KIRP	cis	rs6088813	0.883	rs2425055	chr20:33903636	C/T	cg14752227	chr20:34000481	UQCC	0.46	5.49	0.33	1.01e-7	Height;
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.76e-7	Life satisfaction;
KIRP	cis	rs5753037	0.702	rs140101	chr22:30128380	C/T	cg27665648	chr22:30112403	NA	0.38	5.45	0.33	1.23e-7	Type 1 diabetes;
KIRP	cis	rs1656402	1.000	rs2077929	chr2:233425738	G/A	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.58	-0.34	6.29e-8	Life satisfaction;
KIRP	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.56	-6.85	-0.4	6.02e-11	Schizophrenia;
KIRP	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.12	-0.36	3.71e-9	Schizophrenia;
KIRP	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg21475434	chr5:93447410	FAM172A	0.79	6.15	0.37	3.07e-9	Diabetic retinopathy;
KIRP	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12560992	chr17:57184187	TRIM37	-0.61	-7.05	-0.41	1.8e-11	Testicular germ cell tumor;
KIRP	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12667521	chr19:29218732	NA	0.61	5.8	0.35	1.98e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg25042112	chr7:64838748	ZNF92	-0.6	-6.42	-0.38	6.88e-10	Pain;
KIRP	cis	rs2820315	1.000	rs2494115	chr1:201832864	G/C	cg11586189	chr1:201857591	SHISA4	-0.39	-5.46	-0.33	1.14e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	1.1	14.56	0.68	4.62e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7582720	0.731	rs934287	chr2:203708307	A/G	cg08076091	chr2:203926405	NBEAL1	-0.48	-5.86	-0.35	1.44e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17183009	chr3:120277827	NA	0.53	6.36	0.38	9.59e-10	Corneal astigmatism;
KIRP	cis	rs7607369	0.536	rs4646535	chr2:219664663	C/T	cg10223061	chr2:219282414	VIL1	0.32	5.33	0.32	2.18e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.5	6.77	0.4	9.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg06875740	chr19:51307921	C19orf48	-0.57	-7.55	-0.43	8.62e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg05220968	chr6:146057943	EPM2A	-0.39	-5.07	-0.31	7.88e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs742614	0.533	rs6087526	chr20:32398295	A/C	cg06304546	chr20:32448765	NA	-0.87	-13.48	-0.65	2.13e-31	Stearic acid (18:0) levels;
KIRP	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg24585782	chr17:78113791	EIF4A3	-0.52	-6.35	-0.38	1.06e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.95	0.5	8.84e-17	Lymphocyte percentage of white cells;
KIRP	trans	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg03735916	chr2:200715285	NA	-0.46	-6.16	-0.37	2.88e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4664304	0.620	rs2357691	chr2:160725139	A/G	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.52	-0.33	8.68e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.12	-0.36	3.6e-9	Breast cancer;
KIRP	cis	rs2273669	0.667	rs11153154	chr6:109357324	G/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.32	-0.37	1.2e-9	Prostate cancer;
KIRP	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg18404041	chr3:52824283	ITIH1	-0.45	-5.45	-0.33	1.21e-7	Schizophrenia;
KIRP	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.55	-4.97	-0.3	1.28e-6	Other erythrocyte phenotypes;
KIRP	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg11906718	chr8:101322791	RNF19A	-0.54	-7.3	-0.42	3.93e-12	Atrioventricular conduction;
KIRP	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.35	1.28e-8	Mean platelet volume;
KIRP	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.83	9.96	0.54	7.25e-20	Corneal astigmatism;
KIRP	cis	rs7607369	0.536	rs13032993	chr2:219666377	T/C	cg10223061	chr2:219282414	VIL1	0.3	5.08	0.31	7.49e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs2479724	0.870	rs7766960	chr6:41918190	T/G	cg17623882	chr6:41773611	USP49	-0.47	-5.79	-0.35	2.11e-8	Menarche (age at onset);
KIRP	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.58	7.0	0.41	2.39e-11	Mosquito bite size;
KIRP	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg20243544	chr17:37824526	PNMT	0.4	4.93	0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.45	-6.01	-0.36	6.6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.7	-0.34	3.36e-8	Parkinson's disease;
KIRP	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26207909	chr14:103986467	CKB	-0.78	-12.19	-0.61	4.54e-27	Body mass index;
KIRP	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg22907277	chr7:1156413	C7orf50	0.44	4.92	0.3	1.6e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs13418717	0.793	rs13398472	chr2:127622469	G/A	cg25501666	chr2:127640322	NA	1.16	7.32	0.42	3.41e-12	Heart failure;
KIRP	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg05802129	chr4:122689817	NA	-0.47	-6.93	-0.4	3.72e-11	Type 2 diabetes;
KIRP	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg08126542	chr6:37504118	NA	-0.54	-7.07	-0.41	1.64e-11	Cognitive performance;
KIRP	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21214613	chr1:16344536	HSPB7	0.35	4.97	0.3	1.28e-6	Dilated cardiomyopathy;
KIRP	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs2963155	0.518	rs55817235	chr5:142765733	C/T	cg17617527	chr5:142782415	NR3C1	0.76	6.59	0.39	2.71e-10	Breast cancer;
KIRP	cis	rs1345301	0.609	rs56389410	chr2:102867663	C/T	cg12451869	chr2:102867685	NA	0.47	6.69	0.39	1.52e-10	Waist circumference;
KIRP	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg13010199	chr12:38710504	ALG10B	0.71	8.97	0.5	7.99e-17	Bladder cancer;
KIRP	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.68	8.69	0.48	5.23e-16	Sudden cardiac arrest;
KIRP	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg10189774	chr4:17578691	LAP3	0.51	6.11	0.36	3.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20786246	chr2:72377174	NA	0.52	6.91	0.4	4.08e-11	Smoking initiation;
KIRP	cis	rs728478	0.846	rs11079373	chr17:57440584	A/G	cg16535752	chr17:57448097	YPEL2	-0.21	-4.98	-0.3	1.2e-6	QT interval;
KIRP	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg16736954	chr20:23401023	NAPB	0.63	4.96	0.3	1.31e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg27411982	chr8:10470053	RP1L1	0.43	5.25	0.32	3.23e-7	Neuroticism;
KIRP	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	0.86	14.62	0.68	2.94e-35	Vitiligo;
KIRP	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg00684032	chr4:1343700	KIAA1530	0.41	4.88	0.3	1.87e-6	Longevity;
KIRP	cis	rs10861342	1.000	rs11112373	chr12:105503708	G/A	cg23923672	chr12:105501055	KIAA1033	0.9	7.34	0.42	3.03e-12	IgG glycosylation;
KIRP	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.36	-0.47	4.71e-15	Joint mobility (Beighton score);
KIRP	cis	rs755109	0.934	rs4743147	chr9:100700157	T/C	cg13688889	chr9:100608707	NA	-0.43	-5.0	-0.3	1.1e-6	Quantitative traits;
KIRP	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.65	8.31	0.47	6.3e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-0.84	-7.12	-0.41	1.15e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg27398817	chr8:82754497	SNX16	-0.74	-8.06	-0.46	3.26e-14	Diastolic blood pressure;
KIRP	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg23950597	chr19:37808831	NA	-0.63	-6.73	-0.39	1.18e-10	Coronary artery calcification;
KIRP	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg01426195	chr3:39028469	NA	-0.57	-8.25	-0.47	9.67e-15	Handedness;
KIRP	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.44	5.02	0.3	9.86e-7	Schizophrenia;
KIRP	cis	rs9473924	0.505	rs55653665	chr6:50812984	T/C	cg14470998	chr6:50812995	TFAP2B	1.01	9.04	0.5	4.86e-17	Body mass index;
KIRP	cis	rs17209837	0.607	rs4148821	chr7:87079602	G/C	cg00919237	chr7:87102261	ABCB4	-0.68	-7.8	-0.45	1.78e-13	Gallbladder cancer;
KIRP	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg21452805	chr1:244014465	NA	0.69	6.33	0.37	1.15e-9	RR interval (heart rate);
KIRP	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg19468946	chr17:37922297	IKZF3	-0.45	-6.3	-0.37	1.34e-9	Asthma;
KIRP	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-1.01	-16.99	-0.73	2.29e-43	Height;
KIRP	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg19338460	chr6:170058176	WDR27	-0.58	-6.87	-0.4	5.26e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.29	-0.47	7.66e-15	Mood instability;
KIRP	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.5	-6.07	-0.36	4.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6681460	0.966	rs7519747	chr1:67140723	T/C	cg02459107	chr1:67143332	SGIP1	0.52	7.47	0.43	1.39e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg00647317	chr7:50633725	DDC	0.45	6.94	0.4	3.55e-11	Body mass index;
KIRP	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg03959625	chr15:84868606	LOC388152	0.47	5.54	0.33	7.76e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1775715	0.614	rs806808	chr10:32381186	T/C	cg14930904	chr10:32216787	ARHGAP12	-0.4	-4.95	-0.3	1.35e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg07395648	chr5:131743802	NA	-0.5	-7.34	-0.42	3.15e-12	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13198984	chr17:80129470	CCDC57	0.57	8.5	0.48	1.79e-15	Life satisfaction;
KIRP	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs2649	0.518	rs4984250	chr15:63866834	A/T	cg22599514	chr15:63798201	USP3	0.46	5.76	0.34	2.51e-8	Aortic root size;
KIRP	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.28	-5.51	-0.33	8.93e-8	Monocyte percentage of white cells;
KIRP	cis	rs3789045	0.615	rs11240748	chr1:204453320	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.57	-6.27	-0.37	1.59e-9	Educational attainment (college completion);
KIRP	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg12598211	chr12:123634384	NA	0.42	5.06	0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs3752645	1.000	rs3752645	chr7:106782683	C/T	cg02696742	chr7:106810147	HBP1	-0.66	-5.11	-0.31	6.4e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg03289416	chr15:75166202	SCAMP2	0.58	8.25	0.47	9.6e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.57	-0.39	2.95e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.67	7.96	0.45	6.46e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.76	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg07777115	chr5:623756	CEP72	-0.57	-5.74	-0.34	2.83e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.98	8.14	0.46	1.92e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	0.44	7.58	0.43	7.23e-13	Lymphocyte counts;
KIRP	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg10852876	chr4:165953100	TRIM60	-0.47	-5.08	-0.31	7.32e-7	Obesity-related traits;
KIRP	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.7	0.6	1.9e-25	Heart rate;
KIRP	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg12598211	chr12:123634384	NA	-0.45	-5.22	-0.32	3.74e-7	Neutrophil percentage of white cells;
KIRP	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.94	-11.32	-0.59	3.5e-24	Dilated cardiomyopathy;
KIRP	cis	rs7809615	0.901	rs6947941	chr7:99156446	G/T	cg12290671	chr7:99195819	NA	-0.75	-6.99	-0.41	2.57e-11	Blood metabolite ratios;
KIRP	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.78	9.69	0.53	5.02e-19	Monocyte percentage of white cells;
KIRP	cis	rs7221595	0.825	rs7225453	chr17:3960620	T/C	cg09597638	chr17:3907349	NA	0.52	5.36	0.32	1.93e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.65	9.16	0.5	2.1e-17	Alcohol dependence;
KIRP	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.36	0.32	1.94e-7	Educational attainment;
KIRP	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg21775007	chr8:11205619	TDH	0.71	10.35	0.55	4.57e-21	Retinal vascular caliber;
KIRP	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.82	-12.01	-0.61	1.83e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg17133734	chr15:86042851	AKAP13	-0.47	-5.94	-0.35	9.71e-9	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07775675	chr17:74379922	SPHK1	0.48	6.16	0.37	2.99e-9	Smoking initiation;
KIRP	cis	rs1957429	0.520	rs72625648	chr14:65344602	A/G	cg23373153	chr14:65346875	NA	-0.74	-5.09	-0.31	7.16e-7	Pediatric areal bone mineral density (radius);
KIRP	cis	rs6893807	0.667	rs2304607	chr5:87988733	A/G	cg24804195	chr5:87968844	LOC645323	0.54	5.39	0.33	1.63e-7	Body mass index;
KIRP	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.08	-0.41	1.49e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4478137	0.501	rs28437702	chr4:164231410	C/T	cg06758707	chr4:164254230	NPY1R	-0.48	-5.47	-0.33	1.1e-7	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs830124	0.714	rs658957	chr12:122409664	T/C	cg01765077	chr12:122356316	WDR66	0.56	5.87	0.35	1.42e-8	Urinary metabolites;
KIRP	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.58	0.34	6.36e-8	Renal cell carcinoma;
KIRP	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.27	14.18	0.67	9.38e-34	Eosinophil percentage of granulocytes;
KIRP	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.44	-7.34	-0.42	3.07e-12	Height;
KIRP	cis	rs6859018	0.950	rs2421047	chr5:158746307	G/A	cg26646896	chr5:158686746	NA	-0.34	-4.94	-0.3	1.47e-6	Serum sulfate level;
KIRP	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg06217071	chr17:408420	NA	0.38	5.03	0.31	9.49e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12282928	0.807	rs4980429	chr11:48298148	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg11608241	chr8:8085544	FLJ10661	0.43	5.04	0.31	9.02e-7	Parkinson's disease;
KIRP	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.42	5.45	0.33	1.22e-7	Hypertriglyceridemia;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00789731	chr1:19577941	KIAA0090;MRTO4	-0.47	-6.18	-0.37	2.59e-9	Warfarin maintenance dose;
KIRP	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg00074818	chr8:8560427	CLDN23	0.38	6.11	0.36	3.93e-9	Obesity-related traits;
KIRP	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.86	-12.62	-0.63	1.68e-28	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.95	-15.68	-0.71	7.19e-39	Breast cancer;
KIRP	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.88e-18	Height;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-5.51	-0.33	9.15e-8	Lung cancer;
KIRP	cis	rs4262150	0.883	rs72804775	chr5:152303195	C/T	cg12297329	chr5:152029980	NA	-0.63	-7.81	-0.45	1.62e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg09323728	chr8:95962352	TP53INP1	-0.24	-5.19	-0.31	4.39e-7	Type 2 diabetes;
KIRP	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.12	-19.09	-0.77	1.85e-50	Schizophrenia;
KIRP	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg05973401	chr12:123451056	ABCB9	0.61	5.55	0.33	7.37e-8	Platelet count;
KIRP	cis	rs7250872	0.578	rs8102879	chr19:1832317	G/A	cg18850929	chr19:1828978	REXO1	0.42	4.92	0.3	1.56e-6	Bipolar disorder;
KIRP	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.59	7.24	0.42	5.62e-12	Mean corpuscular volume;
KIRP	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.32	-0.32	2.3e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg01631408	chr1:248437212	OR2T33	-0.44	-5.82	-0.35	1.82e-8	Common traits (Other);
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg09264619	chr17:80180166	NA	0.39	5.53	0.33	8.11e-8	Life satisfaction;
KIRP	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs8060686	0.516	rs8044995	chr16:68189340	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-7.42	-0.43	1.92e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg20430773	chr1:16534157	ARHGEF19	0.52	6.4	0.38	7.78e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.87	13.0	0.64	9.24e-30	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.59	-6.94	-0.4	3.56e-11	Corneal astigmatism;
KIRP	cis	rs12949688	0.601	rs11079327	chr17:55837375	C/T	cg12582317	chr17:55822272	NA	0.45	6.33	0.37	1.16e-9	Schizophrenia;
KIRP	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs9790314	0.613	rs4679666	chr3:160629025	C/G	cg04691961	chr3:161091175	C3orf57	0.42	6.18	0.37	2.68e-9	Morning vs. evening chronotype;
KIRP	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.49e-9	Neuroticism;
KIRP	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.15	-0.42	9.6e-12	Joint mobility (Beighton score);
KIRP	cis	rs4762326	0.546	rs4762166	chr12:95675407	T/C	cg07737802	chr12:95537812	FGD6	0.39	5.21	0.32	3.94e-7	Endometriosis;
KIRP	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg21605333	chr4:119757512	SEC24D	1.66	10.42	0.55	2.7e-21	Cannabis dependence symptom count;
KIRP	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg15068132	chr12:102092402	CHPT1	0.37	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.49	-6.98	-0.41	2.69e-11	Daytime sleep phenotypes;
KIRP	cis	rs77633900	0.772	rs157778	chr15:76759444	G/C	cg21673338	chr15:77095150	SCAPER	-0.65	-6.22	-0.37	2.13e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs778371	0.748	rs1878287	chr2:233790649	G/T	cg08000102	chr2:233561755	GIGYF2	-0.54	-5.95	-0.35	9.15e-9	Schizophrenia;
KIRP	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg01631408	chr1:248437212	OR2T33	-0.6	-7.86	-0.45	1.23e-13	Common traits (Other);
KIRP	cis	rs8010715	0.816	rs11574503	chr14:24601318	C/G	cg23112188	chr14:24563095	PCK2	0.34	4.89	0.3	1.85e-6	IgG glycosylation;
KIRP	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	5.29	0.32	2.75e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg12384639	chr17:618140	VPS53	0.49	5.99	0.36	7.33e-9	Prostate cancer;
KIRP	trans	rs1962073	0.528	rs9329223	chr8:10331754	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.21	-0.37	2.21e-9	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg02002194	chr4:3960332	NA	-0.46	-6.2	-0.37	2.33e-9	Systemic lupus erythematosus;
KIRP	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.72	-8.38	-0.47	4.03e-15	Obesity-related traits;
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg26513180	chr16:89883248	FANCA	0.86	14.02	0.67	3.12e-33	Schizophrenia;
KIRP	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg21926883	chr2:100939477	LONRF2	-0.53	-7.1	-0.41	1.33e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03527887	chr11:108463926	EXPH5	0.53	6.26	0.37	1.71e-9	C-reactive protein;
KIRP	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	7.05	0.41	1.85e-11	Menarche (age at onset);
KIRP	cis	rs4363385	0.747	rs6670614	chr1:152964338	A/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.88	-0.3	1.92e-6	Inflammatory skin disease;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg18595228	chr15:67193261	NA	-0.71	-8.86	-0.49	1.63e-16	Lung cancer (smoking interaction);
KIRP	cis	rs13294100	0.929	rs10435770	chr9:17581168	C/G	cg11213383	chr9:17579734	SH3GL2	-0.5	-6.6	-0.39	2.47e-10	Parkinson's disease;
KIRP	cis	rs9513593	1.000	rs1964898	chr13:99997181	A/G	cg21788972	chr13:99853209	UBAC2	0.53	5.65	0.34	4.41e-8	Psoriasis;
KIRP	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg16988262	chr1:15930761	NA	0.4	5.29	0.32	2.74e-7	Systolic blood pressure;
KIRP	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.17	-0.42	8.85e-12	Glomerular filtration rate;
KIRP	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.68	6.33	0.37	1.14e-9	Schizophrenia;
KIRP	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.97	15.28	0.7	1.58e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg02951883	chr7:2050386	MAD1L1	-0.44	-5.09	-0.31	7.01e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3935685	0.874	rs56370262	chr15:77996708	G/C	cg25212270	chr15:78015279	NA	0.6	7.89	0.45	9.85e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.76	-7.28	-0.42	4.44e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.6e-10	Morning vs. evening chronotype;
KIRP	trans	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.76	0.44	2.24e-13	Breast cancer;
KIRP	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	1.03	14.21	0.67	7.47e-34	Menopause (age at onset);
KIRP	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	13.92	0.66	6.83e-33	Cognitive ability;
KIRP	cis	rs55675132	0.585	rs12135727	chr1:115342732	C/T	cg12756093	chr1:115239321	AMPD1	0.58	5.54	0.33	7.69e-8	Schizophrenia;
KIRP	cis	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg21546286	chr11:48923668	NA	-0.43	-5.13	-0.31	6e-7	HDL cholesterol;
KIRP	cis	rs11161851	0.839	rs11162081	chr1:75319612	G/A	cg11196437	chr1:75593865	LHX8	-0.37	-5.39	-0.32	1.68e-7	Visceral fat;
KIRP	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg12486944	chr17:80159399	CCDC57	-0.38	-5.09	-0.31	6.98e-7	Life satisfaction;
KIRP	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg07952391	chr2:88470173	THNSL2	0.92	7.57	0.43	7.56e-13	Plasma clusterin levels;
KIRP	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg01338084	chr22:32026380	PISD	1.13	7.72	0.44	2.99e-13	Age-related hearing impairment;
KIRP	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.6	7.6	0.44	6.18e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.59	0.39	2.65e-10	Myopia (pathological);
KIRP	cis	rs4656940	0.574	rs482921	chr1:160767498	G/A	cg17331569	chr1:160788135	LY9	0.43	5.1	0.31	6.78e-7	Crohn's disease;
KIRP	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.48e-12	Aortic root size;
KIRP	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.03	-0.41	2.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17376030	chr22:41985996	PMM1	0.71	7.61	0.44	5.71e-13	Vitiligo;
KIRP	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.72	8.98	0.5	6.99e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg01620082	chr3:125678407	NA	-1.17	-7.47	-0.43	1.39e-12	Depression;
KIRP	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.54	8.2	0.46	1.35e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7215564	0.818	rs4889776	chr17:78592385	C/T	cg06153925	chr17:78755379	RPTOR	0.49	6.26	0.37	1.7e-9	Myopia (pathological);
KIRP	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.24	0.32	3.38e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6001982	0.584	rs73167031	chr22:40821818	A/C	cg07138101	chr22:40742427	ADSL	0.7	4.88	0.3	1.92e-6	Breast cancer;
KIRP	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05025164	chr4:1340916	KIAA1530	0.42	5.19	0.31	4.49e-7	Obesity-related traits;
KIRP	cis	rs494003	1.000	rs72922733	chr11:65520746	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.48	4.88	0.3	1.87e-6	Systemic lupus erythematosus;
KIRP	cis	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg11503966	chr20:62272292	STMN3	-0.42	-6.0	-0.36	6.88e-9	Atopic dermatitis;
KIRP	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.45	-0.47	2.61e-15	Lung cancer;
KIRP	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.63	-6.77	-0.4	9.14e-11	Gut microbiome composition (summer);
KIRP	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	0.67	9.76	0.53	3.13e-19	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg15181151	chr6:150070149	PCMT1	0.32	5.3	0.32	2.57e-7	Lung cancer;
KIRP	trans	rs6549358	0.713	rs7641789	chr3:70793765	T/C	cg17498523	chr14:81687766	GTF2A1	-0.51	-6.21	-0.37	2.24e-9	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15160780	chr2:159825180	TANC1	0.52	6.31	0.37	1.32e-9	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.54	0.38	3.56e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4132509	1.000	rs10927040	chr1:243731693	T/C	cg21452805	chr1:244014465	NA	0.57	5.84	0.35	1.65e-8	RR interval (heart rate);
KIRP	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.91	12.45	0.62	6.47e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs4262150	0.883	rs72799173	chr5:152149398	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7555523	0.887	rs10800155	chr1:165723770	A/G	cg24409356	chr1:165738333	TMCO1	0.68	6.2	0.37	2.39e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg04804543	chr8:142233427	SLC45A4	-1.03	-17.96	-0.75	1.18e-46	Immature fraction of reticulocytes;
KIRP	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg05785598	chr3:49045655	WDR6	0.3	5.49	0.33	9.82e-8	Parkinson's disease;
KIRP	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg18306943	chr3:40428807	ENTPD3	-0.48	-6.63	-0.39	2.06e-10	Renal cell carcinoma;
KIRP	cis	rs11638511	0.561	rs8025227	chr15:78551216	C/G	cg08594606	chr15:78556512	DNAJA4	-0.38	-5.04	-0.31	9.23e-7	Red blood cell count;
KIRP	cis	rs9810890	1.000	rs73198826	chr3:128487388	T/C	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg22384356	chr8:124195192	FAM83A	-0.55	-5.04	-0.31	9.01e-7	Urinary uromodulin levels;
KIRP	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg03929089	chr4:120376271	NA	0.53	6.08	0.36	4.51e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg05347473	chr6:146136440	FBXO30	-0.57	-8.11	-0.46	2.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	1.97e-7	Life satisfaction;
KIRP	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	0.83	9.6	0.52	9.95e-19	Gut microbiome composition (summer);
KIRP	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	1.11	11.88	0.6	5.17e-26	Psoriasis;
KIRP	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.48	-0.43	1.28e-12	Type 2 diabetes;
KIRP	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg26207909	chr14:103986467	CKB	-0.44	-5.39	-0.32	1.65e-7	Coronary artery disease;
KIRP	cis	rs77106637	0.932	rs1783598	chr11:72851463	C/T	cg03713592	chr11:72463424	ARAP1	-0.61	-6.14	-0.36	3.23e-9	Type 2 diabetes;
KIRP	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.25	15.2	0.7	3.01e-37	Eosinophil percentage of granulocytes;
KIRP	cis	rs2235573	0.662	rs2076370	chr22:38463968	A/G	cg19171272	chr22:38449367	NA	-0.67	-9.42	-0.51	3.52e-18	Glioblastoma;Glioma;
KIRP	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03651054	chr13:50194643	NA	0.74	11.43	0.59	1.46e-24	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg17764715	chr19:33622953	WDR88	0.64	7.7	0.44	3.28e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	0.93	10.97	0.57	4.62e-23	Vitiligo;
KIRP	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.48e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18364779	chr6:26104403	HIST1H4C	0.39	5.17	0.31	4.92e-7	Schizophrenia;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg07317062	chr7:27170388	HOXA4	-0.43	-5.84	-0.35	1.66e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.44	-4.94	-0.3	1.43e-6	Cognitive function;
KIRP	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.56	-0.63	2.69e-28	Chronic sinus infection;
KIRP	cis	rs228437	1.000	rs4896083	chr6:134932535	G/A	cg24504307	chr6:134963096	NA	-0.53	-7.72	-0.44	2.84e-13	Melanoma;
KIRP	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg02175503	chr12:58329896	NA	0.59	6.38	0.38	8.49e-10	Multiple sclerosis;
KIRP	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg27432699	chr2:27873401	GPN1	-0.54	-7.08	-0.41	1.48e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.69	10.56	0.56	9.9700000000000009e-22	Menarche (age at onset);
KIRP	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.93	-0.53	9.51e-20	Hemoglobin concentration;
KIRP	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.93	16.05	0.72	3.77e-40	Menarche (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15776560	chr3:25916362	NA	0.51	7.17	0.42	8.78e-12	Survival in pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg09264619	chr17:80180166	NA	0.37	5.36	0.32	1.9e-7	Life satisfaction;
KIRP	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.3	-6.07	-0.36	4.83e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg11584989	chr19:19387371	SF4	-0.4	-5.06	-0.31	8.15e-7	Tonsillectomy;
KIRP	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	0.82	9.52	0.52	1.72e-18	Gut microbiome composition (summer);
KIRP	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.7	-7.62	-0.44	5.63e-13	Blood pressure (smoking interaction);
KIRP	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg08999081	chr20:33150536	PIGU	0.46	4.91	0.3	1.7e-6	Protein C levels;
KIRP	trans	rs10184704	0.889	rs13410353	chr2:127456896	C/G	cg16752876	chr2:19553237	OSR1	-0.24	-6.04	-0.36	5.7e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs7822232	0.908	rs56138570	chr8:145142206	G/A	cg27454946	chr8:145133526	EXOSC4	0.59	5.25	0.32	3.25e-7	Blood metabolite levels;
KIRP	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.51	6.95	0.41	3.18e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs753955	0.553	rs1886973	chr13:24423070	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.46	-5.78	-0.35	2.29e-8	Lung cancer;
KIRP	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Dermatomyositis;
KIRP	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.15	-0.37	3.12e-9	Hippocampal volume;
KIRP	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	1.03	11.62	0.6	3.55e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.5	6.48	0.38	5e-10	Menopause (age at onset);
KIRP	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.58	-0.63	2.41e-28	Breast cancer;
KIRP	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7572644	0.640	rs9678430	chr2:28057129	G/C	cg27432699	chr2:27873401	GPN1	0.46	5.66	0.34	4.29e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs12912251	1.000	rs2172835	chr15:38990171	C/T	cg01338139	chr15:38987640	C15orf53	-0.57	-6.44	-0.38	6.31e-10	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg03160526	chr17:80928410	B3GNTL1	0.43	5.34	0.32	2.09e-7	Glycated hemoglobin levels;
KIRP	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg03128060	chr6:142623767	GPR126	0.36	5.21	0.32	4.07e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg01864069	chr14:103024347	NA	0.87	10.22	0.55	1.18e-20	Platelet count;
KIRP	cis	rs7113874	0.659	rs12577287	chr11:8519917	A/T	cg08015107	chr11:8618950	NA	-0.51	-6.79	-0.4	8.28e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7712401	0.715	rs6859163	chr5:122354920	A/G	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17492891	chr22:41843204	TOB2	0.64	7.79	0.44	1.89e-13	Smoking initiation;
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-9.89	-0.53	1.23e-19	Platelet count;
KIRP	cis	rs4762326	0.584	rs7967299	chr12:95673184	G/A	cg07737802	chr12:95537812	FGD6	0.37	4.92	0.3	1.59e-6	Endometriosis;
KIRP	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg09873164	chr1:152488093	CRCT1	0.57	7.6	0.44	6.4e-13	Hair morphology;
KIRP	cis	rs6450176	0.909	rs67721004	chr5:53290571	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-10.96	-0.57	5.05e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6684428	0.831	rs4313435	chr1:56338281	C/A	cg11651538	chr1:56320950	NA	-0.75	-9.56	-0.52	1.26e-18	Airflow obstruction;
KIRP	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.31	7.38	0.43	2.47e-12	IgG glycosylation;
KIRP	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.89	13.31	0.65	7.98e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg06223162	chr1:101003688	GPR88	0.51	10.43	0.55	2.55e-21	Breast cancer;
KIRP	cis	rs193541	0.632	rs39821	chr5:122295472	T/C	cg19412675	chr5:122181750	SNX24	0.61	6.48	0.38	5.06e-10	Glucose homeostasis traits;
KIRP	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.51	6.36	0.38	9.71e-10	Total body bone mineral density;
KIRP	trans	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg06521331	chr12:34319734	NA	-0.5	-6.18	-0.37	2.63e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	4.95	0.3	1.39e-6	Mean platelet volume;
KIRP	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.99	-15.23	-0.7	2.37e-37	Coronary artery disease;
KIRP	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.85	13.45	0.65	2.74e-31	Prostate cancer;
KIRP	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs1568657	0.779	rs2167602	chr15:83649292	C/T	cg03400403	chr17:20536885	NA	-0.44	-6.47	-0.38	5.25e-10	Kawasaki disease;
KIRP	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.66	8.85	0.49	1.72e-16	Personality dimensions;
KIRP	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.67	-8.24	-0.47	1.01e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg19187155	chr2:232395269	NMUR1	0.42	5.03	0.31	9.35e-7	Noise-induced hearing loss;
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.47	5.75	0.34	2.7e-8	Longevity;
KIRP	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.8e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs7011507	1.000	rs55697403	chr8:49168591	C/T	cg15325961	chr8:49183143	NA	0.59	5.03	0.31	9.3e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg15038512	chr6:170123185	PHF10	0.46	5.16	0.31	5.04e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.63	-6.97	-0.41	2.92e-11	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg06640241	chr16:89574553	SPG7	0.61	7.59	0.44	6.64e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.86	-0.3	2.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7520050	0.807	rs6656279	chr1:46124088	C/G	cg24296786	chr1:45957014	TESK2	-0.42	-5.3	-0.32	2.58e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg03161606	chr19:29218774	NA	0.75	6.78	0.4	8.96e-11	Methadone dose in opioid dependence;
KIRP	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg26513180	chr16:89883248	FANCA	0.79	5.27	0.32	2.98e-7	Skin colour saturation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18322023	chr17:7141420	PHF23	0.47	6.11	0.36	3.92e-9	Parkinson's disease;
KIRP	cis	rs894344	0.650	rs10111965	chr8:135590960	C/T	cg04050898	chr8:135490694	ZFAT	0.34	4.85	0.3	2.19e-6	Systolic blood pressure;
KIRP	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.29	0.47	7.19e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg13736514	chr6:26305472	NA	-0.59	-8.35	-0.47	4.87e-15	Educational attainment;
KIRP	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg19847130	chr8:10466454	RP1L1	0.37	5.37	0.32	1.79e-7	Retinal vascular caliber;
KIRP	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.07	-0.41	1.56e-11	Capecitabine sensitivity;
KIRP	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg25902810	chr10:99078978	FRAT1	0.58	7.34	0.42	3.05e-12	Monocyte count;
KIRP	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg06740227	chr12:86229804	RASSF9	0.48	6.28	0.37	1.51e-9	Major depressive disorder;
KIRP	cis	rs9815354	0.951	rs9868066	chr3:41794161	T/A	cg03022575	chr3:42003672	ULK4	0.53	6.02	0.36	6.15e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10518128	1.000	rs28773168	chr4:75709804	A/G	cg20122727	chr4:75719957	BTC	0.57	5.7	0.34	3.41e-8	Electroencephalogram traits;
KIRP	cis	rs911119	0.954	rs2405367	chr20:23622880	A/G	cg16589663	chr20:23618590	CST3	-0.54	-5.72	-0.34	3.15e-8	Chronic kidney disease;
KIRP	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.37	-5.18	-0.31	4.62e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06719391	chr11:2554330	KCNQ1	0.49	6.24	0.37	1.93e-9	C-reactive protein;
KIRP	cis	rs829883	0.646	rs1641638	chr12:98891031	A/G	cg25150519	chr12:98850993	NA	0.57	7.7	0.44	3.3e-13	Colorectal adenoma (advanced);
KIRP	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.37	-4.97	-0.3	1.23e-6	Bipolar disorder;
KIRP	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.57	0.52	1.18e-18	Dupuytren's disease;
KIRP	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.63	9.21	0.51	1.5e-17	Oral cavity cancer;
KIRP	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg17764715	chr19:33622953	WDR88	0.66	8.39	0.47	3.81e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7011049	0.778	rs6473774	chr8:53875003	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.7	9.23	0.51	1.33e-17	Morning vs. evening chronotype;
KIRP	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-0.93	-9.19	-0.51	1.69e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg21427119	chr20:30132790	HM13	0.65	6.8	0.4	8.01e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs17123764	0.710	rs74089182	chr12:50063768	G/A	cg20471783	chr12:50157085	TMBIM6	0.4	5.55	0.33	7.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.64	0.48	7.42e-16	Electroencephalogram traits;
KIRP	cis	rs1440410	0.795	rs10461280	chr4:144184903	G/A	cg01719995	chr4:144104893	USP38	0.39	5.11	0.31	6.45e-7	Ischemic stroke;
KIRP	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-6.16	-0.37	2.95e-9	HDL cholesterol;
KIRP	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg02696790	chr15:75250997	RPP25	0.3	5.27	0.32	3.05e-7	Breast cancer;
KIRP	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12016809	chr21:47604291	C21orf56	0.37	5.0	0.3	1.08e-6	Testicular germ cell tumor;
KIRP	cis	rs4646404	0.509	rs744925	chr17:17467501	G/A	cg01246520	chr17:17644344	RAI1	-0.33	-5.59	-0.34	5.92e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.98	13.47	0.65	2.37e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.99	14.28	0.67	4.27e-34	Cognitive function;
KIRP	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg22800045	chr5:56110881	MAP3K1	0.82	8.73	0.49	3.89e-16	Initial pursuit acceleration;
KIRP	cis	rs7562790	0.535	rs28705335	chr2:36655721	T/C	cg09467607	chr2:36825704	FEZ2	0.43	5.43	0.33	1.33e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.24	-0.37	1.9e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg07884673	chr3:53033167	SFMBT1	0.8	6.41	0.38	7.38e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg05347473	chr6:146136440	FBXO30	0.62	8.88	0.49	1.44e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4356932	0.691	rs9995007	chr4:76897791	T/A	cg00809888	chr4:76862425	NAAA	0.5	6.94	0.4	3.48e-11	Blood protein levels;
KIRP	trans	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.16	-0.37	2.93e-9	Neuroticism;
KIRP	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs9682041	0.561	rs7616830	chr3:170146445	A/G	cg11886554	chr3:170076028	SKIL	0.5	5.07	0.31	7.99e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs3017493	0.786	rs78344725	chr11:70687830	G/A	cg10362475	chr11:70507825	SHANK2	0.36	5.39	0.33	1.63e-7	Renal transplant outcome;
KIRP	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.63	7.12	0.41	1.19e-11	Alcohol dependence;
KIRP	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.77	0.49	3.04e-16	Colorectal cancer;
KIRP	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.46	-6.11	-0.36	3.84e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08018356	chr19:36706053	ZNF146;ZNF565	-0.45	-6.13	-0.36	3.46e-9	Electrocardiographic conduction measures;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg05433285	chr19:1261271	NA	0.51	6.34	0.37	1.11e-9	Educational attainment;
KIRP	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-1.03	-17.35	-0.74	1.37e-44	Height;
KIRP	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.68	8.43	0.47	2.87e-15	Corneal astigmatism;
KIRP	cis	rs7851660	0.809	rs9299258	chr9:100666543	T/G	cg13688889	chr9:100608707	NA	-0.68	-8.66	-0.48	6.18e-16	Strep throat;
KIRP	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.6	0.56	7.26e-22	Cognitive test performance;
KIRP	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.75	9.87	0.53	1.46e-19	Height;
KIRP	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-0.85	-11.62	-0.6	3.53e-25	Urate levels;
KIRP	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.47	-0.38	5.27e-10	LDL cholesterol levels;
KIRP	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.92	13.87	0.66	1.02e-32	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-0.73	-8.45	-0.47	2.5e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg23100626	chr2:96804247	ASTL	0.5	7.0	0.41	2.37e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.85	-10.78	-0.57	1.85e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.76	12.44	0.62	6.87e-28	Vitiligo;
KIRP	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg14132834	chr19:41945861	ATP5SL	0.57	7.37	0.43	2.64e-12	Height;
KIRP	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.16	-0.54	1.84e-20	Colorectal cancer;
KIRP	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.92	-10.66	-0.56	4.52e-22	Exhaled nitric oxide output;
KIRP	cis	rs2223471	0.624	rs2206275	chr6:50733776	C/A	cg03432817	chr6:50765336	NA	-0.35	-5.09	-0.31	7.05e-7	Subcutaneous adipose tissue;
KIRP	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.83	0.66	1.46e-32	Electrocardiographic conduction measures;
KIRP	trans	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17183009	chr3:120277827	NA	0.56	6.55	0.39	3.42e-10	Corneal astigmatism;
KIRP	trans	rs8007846	0.569	rs11848463	chr14:66257294	A/G	cg20426415	chr10:96446783	CYP2C18	-0.39	-6.18	-0.37	2.66e-9	Multiple sclerosis--Brain Glutamate Levels;
KIRP	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.38	-5.18	-0.31	4.58e-7	Schizophrenia;
KIRP	cis	rs7520050	0.966	rs7556615	chr1:46461369	G/A	cg03146154	chr1:46216737	IPP	-0.44	-5.51	-0.33	8.82e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.59	7.88	0.45	1.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4787491	0.729	rs4788213	chr16:30034524	T/C	cg06326092	chr16:30034487	C16orf92	0.5	7.86	0.45	1.23e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.44	5.21	0.32	4.05e-7	Systemic lupus erythematosus;
KIRP	cis	rs981844	1.000	rs55702511	chr4:154665978	A/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.49	5.1	0.31	6.95e-7	Corneal structure;
KIRP	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg00405596	chr8:11794950	NA	0.58	8.03	0.46	4.09e-14	Myopia (pathological);
KIRP	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.95	15.52	0.7	2.43e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6993813	0.678	rs2062376	chr8:120010009	C/G	cg22961513	chr11:14280813	SPON1	0.36	6.08	0.36	4.45e-9	Bone mineral density (hip);
KIRP	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg05044414	chr3:183734942	ABCC5	0.35	5.4	0.33	1.58e-7	Anterior chamber depth;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18252515	chr7:66147081	NA	0.47	5.58	0.34	6.37e-8	Aortic root size;
KIRP	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg23719950	chr11:63933701	MACROD1	-0.67	-6.39	-0.38	8.47e-10	Mean platelet volume;
KIRP	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11890956	chr21:40555474	PSMG1	-0.56	-6.06	-0.36	5.16e-9	Menarche (age at onset);
KIRP	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg12369402	chr1:90227771	NA	-0.37	-5.3	-0.32	2.56e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.24	-0.37	1.93e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7301016	1.000	rs11520127	chr12:62906965	C/G	cg01804193	chr12:63026212	NA	0.52	5.28	0.32	2.85e-7	IgG glycosylation;
KIRP	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.93	-0.35	1.01e-8	Menarche (age at onset);
KIRP	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg04310649	chr10:35416472	CREM	-0.54	-6.04	-0.36	5.79e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.8	0.45	1.81e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs258892	0.843	rs34329209	chr5:72045517	T/C	cg21869765	chr5:72125136	TNPO1	-0.5	-5.64	-0.34	4.56e-8	Small cell lung carcinoma;
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg00933542	chr6:150070202	PCMT1	0.27	5.09	0.31	7.2e-7	Lung cancer;
KIRP	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23161317	chr6:28129485	ZNF389	0.43	5.06	0.31	8.25e-7	Parkinson's disease;
KIRP	cis	rs3124314	1.000	rs3124315	chr1:152039711	A/G	cg13071333	chr1:152595882	LCE3A	-0.37	-5.08	-0.31	7.48e-7	Hair morphology;
KIRP	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg00491522	chr10:135256596	NA	0.53	5.69	0.34	3.51e-8	Systemic lupus erythematosus;
KIRP	cis	rs10518128	1.000	rs72867579	chr4:75698204	T/C	cg20122727	chr4:75719957	BTC	0.58	4.85	0.3	2.22e-6	Electroencephalogram traits;
KIRP	cis	rs7582180	0.817	rs7559464	chr2:100906323	A/G	cg14675211	chr2:100938903	LONRF2	0.58	6.94	0.4	3.43e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg03788504	chr6:150331562	NA	-0.34	-6.52	-0.38	3.98e-10	Alopecia areata;
KIRP	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.94	10.02	0.54	4.85e-20	Cognitive test performance;
KIRP	cis	rs10767971	0.565	rs10767969	chr11:32892881	T/A	cg14042352	chr11:32815968	CCDC73	-0.47	-5.41	-0.33	1.48e-7	Parkinson's disease (age of onset);
KIRP	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.73	8.95	0.5	8.76e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22117172	chr7:91764530	CYP51A1	0.5	7.02	0.41	2.11e-11	Breast cancer;
KIRP	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-0.99	-9.92	-0.53	9.97e-20	Vitiligo;
KIRP	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.41	5.42	0.33	1.39e-7	Aortic root size;
KIRP	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg01181863	chr3:195395398	SDHAP2	-0.82	-9.45	-0.52	2.87e-18	Pancreatic cancer;
KIRP	cis	rs8177876	0.822	rs10514515	chr16:81115322	T/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.71	-0.34	3.25e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.7	-9.91	-0.53	1.05e-19	Brugada syndrome;
KIRP	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.91	15.51	0.7	2.74e-38	Metabolic syndrome;
KIRP	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.76	0.81	2.97e-59	Prudent dietary pattern;
KIRP	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg18876405	chr7:65276391	NA	0.38	4.88	0.3	1.91e-6	Aortic root size;
KIRP	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.5	-0.52	1.96e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg16989719	chr2:238392110	NA	-0.41	-5.45	-0.33	1.22e-7	Prostate cancer;
KIRP	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg13660082	chr14:53194042	PSMC6	0.8	7.39	0.43	2.3e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg00277334	chr10:82204260	NA	-0.48	-5.61	-0.34	5.57e-8	Post bronchodilator FEV1;
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13047869	chr3:10149882	C3orf24	0.61	5.64	0.34	4.69e-8	Alzheimer's disease;
KIRP	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg15744005	chr10:104629667	AS3MT	-0.29	-5.84	-0.35	1.65e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.63	-6.92	-0.4	3.84e-11	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs1043099	0.571	rs4820844	chr22:30795215	A/G	cg03868770	chr22:30783737	RNF215	-0.45	-4.88	-0.3	1.95e-6	Rheumatoid arthritis;
KIRP	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg20999797	chr1:1681921	NA	0.52	8.24	0.46	1.05e-14	Body mass index;
KIRP	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.29	0.32	2.75e-7	Alzheimer's disease;
KIRP	cis	rs1620921	1.000	rs1614840	chr6:161197845	A/G	cg01280913	chr6:161186852	NA	-0.4	-5.49	-0.33	1.01e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.62	6.23	0.37	2.05e-9	Plateletcrit;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11080379	chr8:25364185	CDCA2	-0.4	-6.2	-0.37	2.34e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.61	6.62	0.39	2.22e-10	Exhaled nitric oxide output;
KIRP	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg00405596	chr8:11794950	NA	0.58	8.03	0.46	4.09e-14	Myopia (pathological);
KIRP	cis	rs1971762	0.545	rs10747676	chr12:54049930	T/C	cg23533419	chr12:54090519	NA	-0.33	-5.07	-0.31	7.88e-7	Height;
KIRP	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg09177884	chr7:1199841	ZFAND2A	0.57	5.51	0.33	8.86e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs1978968	0.763	rs9605479	chr22:18464611	T/C	cg03078520	chr22:18463400	MICAL3	-0.83	-11.74	-0.6	1.43e-25	Presence of antiphospholipid antibodies;
KIRP	cis	rs35740288	0.770	rs1382538	chr15:86165896	G/C	cg17133734	chr15:86042851	AKAP13	-0.51	-5.33	-0.32	2.26e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.18	0.31	4.53e-7	Height;
KIRP	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg03235661	chr20:60525775	NA	-0.32	-5.31	-0.32	2.41e-7	Body mass index;
KIRP	cis	rs9815354	0.597	rs59432762	chr3:41812294	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	8.63	0.48	7.52e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	5.14	0.31	5.68e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg00784671	chr22:46762841	CELSR1	-0.83	-8.18	-0.46	1.54e-14	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg14209926	chr17:79849790	ANAPC11;THOC4	-0.46	-6.04	-0.36	5.55e-9	Morning vs. evening chronotype;
KIRP	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.49	0.38	4.75e-10	Colorectal cancer;
KIRP	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg23659134	chr10:106035168	GSTO2	-0.42	-6.17	-0.37	2.82e-9	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	trans	rs13170463	0.579	rs6887957	chr5:8042457	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.54	6.7	0.39	1.42e-10	Monocyte count;
KIRP	cis	rs977987	0.864	rs37592	chr16:75496791	G/C	cg03315344	chr16:75512273	CHST6	-0.7	-10.54	-0.56	1.09e-21	Dupuytren's disease;
KIRP	cis	rs3790645	0.874	rs9438508	chr1:26893069	T/C	cg23229016	chr1:26872525	RPS6KA1	0.23	6.15	0.36	3.14e-9	Glucose homeostasis traits;
KIRP	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.63	6.99	0.41	2.59e-11	Gut microbiome composition (summer);
KIRP	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.13	0.58	1.42e-23	Bipolar disorder;
KIRP	cis	rs12210905	0.688	rs12374607	chr6:27343620	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.57	-6.63	-0.39	2.11e-10	Testicular germ cell tumor;
KIRP	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.36	-8.05	-0.46	3.62e-14	Cutaneous nevi;
KIRP	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.89	-11.62	-0.6	3.52e-25	Schizophrenia;
KIRP	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.68	7.01	0.41	2.28e-11	Bipolar disorder;
KIRP	cis	rs74181299	0.684	rs12713532	chr2:65356552	G/C	cg05010058	chr2:65284262	CEP68	-0.42	-5.56	-0.33	7.02e-8	Pulse pressure;
KIRP	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.2	-0.31	4.14e-7	Pulmonary function;
KIRP	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.72	-10.39	-0.55	3.23e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4794202	0.534	rs8078688	chr17:45919869	T/C	cg10638573	chr17:45915098	SCRN2	0.47	5.51	0.33	8.86e-8	Alzheimer's disease (cognitive decline);
KIRP	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	12.71	0.63	8.46e-29	Smoking behavior;
KIRP	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg08283408	chr3:49949060	MON1A	0.36	4.85	0.3	2.22e-6	Body mass index;
KIRP	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.03	13.34	0.65	6.39e-31	Exhaled nitric oxide output;
KIRP	cis	rs2223471	0.546	rs188104	chr6:50576644	A/C	cg03432817	chr6:50765336	NA	-0.36	-5.32	-0.32	2.34e-7	Subcutaneous adipose tissue;
KIRP	cis	rs4523957	0.928	rs216198	chr17:2201735	C/T	cg16513277	chr17:2031491	SMG6	0.54	7.38	0.43	2.42e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg13736514	chr6:26305472	NA	-0.66	-8.71	-0.49	4.48e-16	Educational attainment;
KIRP	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs6545883	0.931	rs12713437	chr2:61722904	C/T	cg15711740	chr2:61764176	XPO1	-0.6	-8.08	-0.46	2.83e-14	Tuberculosis;
KIRP	cis	rs2851682	0.908	rs2727265	chr11:61609004	C/A	cg07689907	chr11:61582574	FADS1	0.68	5.26	0.32	3.1e-7	Gestational age at birth (child effect);Trans fatty acid levels;
KIRP	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.93	13.19	0.64	2.07e-30	Bladder cancer;
KIRP	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs7215564	0.908	rs34914062	chr17:78655909	C/T	cg06153925	chr17:78755379	RPTOR	0.41	5.73	0.34	2.88e-8	Myopia (pathological);
KIRP	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg11707556	chr5:10655725	ANKRD33B	0.56	7.22	0.42	6.38e-12	Coronary artery disease;
KIRP	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.45	5.64	0.34	4.72e-8	Childhood ear infection;
KIRP	trans	rs2834485	1.000	rs2834484	chr21:35816941	G/T	cg07474852	chr4:123073612	NA	-0.53	-6.52	-0.38	4e-10	Cancer;
KIRP	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.23	-0.32	3.6e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.15	-0.31	5.31e-7	Post bronchodilator FEV1;
KIRP	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.65	0.44	4.49e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.62	-7.97	-0.45	5.85e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.73e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.76	11.56	0.59	5.7e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs2625529	0.730	rs2957725	chr15:72248205	C/A	cg16672083	chr15:72433130	SENP8	0.46	6.45	0.38	5.82e-10	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24008117	chr14:55510053	SOCS4	0.43	6.13	0.36	3.53e-9	Interleukin-4 levels;
KIRP	cis	rs1620921	0.711	rs1652465	chr6:161248552	T/A	cg01280913	chr6:161186852	NA	-0.37	-5.03	-0.31	9.48e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg26207909	chr14:103986467	CKB	-0.48	-4.9	-0.3	1.72e-6	Coronary artery disease;
KIRP	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.06	0.64	5.83e-30	Bladder cancer;
KIRP	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.56	-5.58	-0.34	6.24e-8	Type 2 diabetes;
KIRP	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-6.93	-0.4	3.77e-11	Response to antipsychotic treatment;
KIRP	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.74	11.5	0.59	9.13e-25	Neuroticism;
KIRP	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.46	5.86	0.35	1.46e-8	Colorectal cancer;
KIRP	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg01522456	chr1:115632236	TSPAN2	-0.36	-4.87	-0.3	1.99e-6	Autism;
KIRP	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg08917208	chr2:24149416	ATAD2B	0.56	5.02	0.3	9.95e-7	Lymphocyte counts;
KIRP	cis	rs12823128	0.729	rs34699075	chr12:26930500	G/A	cg14081884	chr12:26986758	ITPR2	0.4	5.01	0.3	1.02e-6	Birth weight;
KIRP	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07685180	chr8:600429	NA	0.56	4.96	0.3	1.31e-6	IgG glycosylation;
KIRP	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-7.82	-0.45	1.58e-13	Plateletcrit;Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04585517	chr2:37899444	CDC42EP3	0.5	6.09	0.36	4.36e-9	Parkinson's disease;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.65	-0.34	4.37e-8	Lung cancer;
KIRP	cis	rs7809615	0.901	rs17161761	chr7:99156934	C/T	cg24024660	chr7:99195788	NA	-0.57	-5.07	-0.31	7.78e-7	Blood metabolite ratios;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19280121	chr17:21117780	TMEM11	0.7	6.55	0.39	3.31e-10	Lung function (FEV1);
KIRP	cis	rs1943345	0.556	rs523414	chr11:82910666	C/G	cg07047830	chr11:82868014	PCF11	0.44	5.2	0.31	4.21e-7	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg10729496	chr3:10149963	C3orf24	0.55	5.01	0.3	1.04e-6	Alzheimer's disease;
KIRP	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg05315796	chr3:52349193	DNAH1	0.44	5.52	0.33	8.49e-8	Schizophrenia;
KIRP	cis	rs7555523	0.887	rs2814471	chr1:165739598	C/T	cg24409356	chr1:165738333	TMCO1	0.73	6.23	0.37	1.97e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.63	6.97	0.41	2.95e-11	Asthma;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs2522056	1.000	rs2405528	chr5:131794298	G/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.26	0.37	1.71e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.84	6.59	0.39	2.67e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg21775007	chr8:11205619	TDH	-0.44	-5.83	-0.35	1.7e-8	Triglycerides;
KIRP	cis	rs6120849	0.708	rs6087659	chr20:33606383	C/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.36	0.38	9.82e-10	Protein C levels;
KIRP	cis	rs17253792	0.822	rs17746106	chr14:56069168	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	6.5	0.38	4.37e-10	Putamen volume;
KIRP	cis	rs1823913	0.637	rs4853579	chr2:192162139	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.18	-0.37	2.6e-9	Obesity-related traits;
KIRP	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg14689365	chr7:158441557	NCAPG2	-0.41	-5.04	-0.31	9.19e-7	Height;
KIRP	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26378065	chr17:18585709	ZNF286B	-0.48	-5.97	-0.36	8.44e-9	Educational attainment (years of education);
KIRP	cis	rs258892	0.895	rs155426	chr5:72117128	G/T	cg21869765	chr5:72125136	TNPO1	-0.56	-6.23	-0.37	2.01e-9	Small cell lung carcinoma;
KIRP	cis	rs12360000	0.832	rs12761504	chr10:1907561	C/A	cg26364871	chr10:1889757	NA	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg13319975	chr6:146136371	FBXO30	0.48	6.34	0.37	1.1e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08964912	chr20:60982779	CABLES2	0.56	6.7	0.39	1.43e-10	Smoking initiation;
KIRP	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1050631	0.623	rs7242481	chr18:33709217	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	6.0	0.36	7.14e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs17030434	0.953	rs10014299	chr4:154700858	A/G	cg14289246	chr4:154710475	SFRP2	-0.81	-9.72	-0.53	4.01e-19	Electrocardiographic conduction measures;
KIRP	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	cg12689670	chr1:183009347	LAMC1	0.45	6.39	0.38	8.41e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.97	-12.56	-0.63	2.67e-28	Platelet distribution width;
KIRP	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18932078	chr1:2524107	MMEL1	-0.43	-6.02	-0.36	6.29e-9	Multiple sclerosis;
KIRP	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg27205649	chr11:78285834	NARS2	0.82	11.45	0.59	1.26e-24	Alzheimer's disease (survival time);
KIRP	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.55e-13	Life satisfaction;
KIRP	cis	rs11955398	0.625	rs286154	chr5:59926911	C/T	cg02684056	chr5:59996105	DEPDC1B	0.45	5.23	0.32	3.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.77	11.02	0.57	3.32e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg00585698	chr12:123750864	CDK2AP1	0.44	5.1	0.31	6.75e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14598338	chr9:96623480	NA	-0.68	-11.7	-0.6	1.9e-25	DNA methylation (variation);
KIRP	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg08668510	chr10:1095578	IDI1	0.81	5.55	0.33	7.23e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs8077577	0.895	rs16960980	chr17:18100858	C/T	cg09161412	chr17:18057145	MYO15A	-0.39	-5.22	-0.32	3.76e-7	Obesity-related traits;
KIRP	cis	rs2802372	0.620	rs1749855	chr10:81040209	T/G	cg18688392	chr10:81059414	ZMIZ1	-0.45	-5.65	-0.34	4.53e-8	Granulocyte count;
KIRP	cis	rs6882076	0.961	rs58198139	chr5:156399039	C/T	cg12943317	chr5:156479607	HAVCR1	-0.6	-7.43	-0.43	1.82e-12	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg04166393	chr7:2884313	GNA12	0.7	8.46	0.47	2.46e-15	Height;
KIRP	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg22875332	chr1:76189707	ACADM	-0.34	-4.94	-0.3	1.44e-6	Daytime sleep phenotypes;
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.07	18.86	0.77	1.1e-49	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17065868	1.000	rs9525984	chr13:45149662	G/A	cg10246903	chr13:45222710	NA	0.74	6.64	0.39	2.02e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg16006841	chr5:176797999	RGS14	0.6	6.42	0.38	6.88e-10	Urate levels in lean individuals;
KIRP	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.42	-0.38	6.99e-10	Schizophrenia;
KIRP	cis	rs10214930	0.697	rs12155430	chr7:27671296	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.96	0.3	1.34e-6	Hypospadias;
KIRP	cis	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg04607699	chr11:48328132	OR4S1	-0.36	-5.13	-0.31	5.81e-7	Coronary artery disease;
KIRP	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.78	-10.72	-0.56	3.07e-22	Educational attainment;
KIRP	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.54	7.32	0.42	3.61e-12	HDL cholesterol;
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg24503407	chr1:205819492	PM20D1	0.74	9.88	0.53	1.36e-19	Monocyte percentage of white cells;
KIRP	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg03647239	chr10:116582469	FAM160B1	-0.52	-6.28	-0.37	1.49e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg00491522	chr10:135256596	NA	0.59	7.93	0.45	7.74e-14	Systemic lupus erythematosus;
KIRP	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	6.44	0.38	6.21e-10	Breast cancer;
KIRP	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg03929089	chr4:120376271	NA	0.83	6.03	0.36	5.96e-9	Axial length;
KIRP	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg24154853	chr7:158122151	PTPRN2	0.38	5.55	0.33	7.47e-8	Calcium levels;
KIRP	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.62	-9.13	-0.5	2.61e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7662987	0.793	rs28730632	chr4:99995703	G/A	cg13256891	chr4:100009986	ADH5	-0.65	-5.58	-0.33	6.49e-8	Smoking initiation;
KIRP	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.44	-8.33	-0.47	5.79e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg16311410	chr22:31892793	SFI1	0.74	6.34	0.37	1.07e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg03970086	chr16:88974840	CBFA2T3	-0.44	-5.84	-0.35	1.62e-8	Social autistic-like traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24250450	chr4:40058375	N4BP2;LOC344967	0.51	6.48	0.38	4.89e-10	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.59	7.08	0.41	1.53e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs12210905	0.920	rs9368500	chr6:27290981	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.71	-0.39	1.35e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.81e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2733310	0.947	rs1660958	chr15:57184307	G/A	cg13626582	chr15:57592083	LOC283663	-0.25	-5.9	-0.35	1.22e-8	Mean platelet volume;
KIRP	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.5	-0.56	1.51e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.77	7.75	0.44	2.45e-13	Lung function (FEV1/FVC);
KIRP	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg17509989	chr5:176798049	RGS14	0.66	6.69	0.39	1.47e-10	Urate levels in lean individuals;
KIRP	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.57	-5.59	-0.34	6.03e-8	Birth weight;
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.44	-0.33	1.26e-7	Lung cancer;
KIRP	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg13206674	chr6:150067644	NUP43	0.61	8.64	0.48	7.41e-16	Lung cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17795611	chr8:144987450	NA	0.5	6.48	0.38	5.08e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	18.82	0.77	1.47e-49	Height;
KIRP	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.23	-6.28	-0.37	1.49e-9	Mean corpuscular volume;
KIRP	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-6.33	-0.37	1.13e-9	Bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23270582	chr4:70514724	UGT2A1	-0.45	-7.6	-0.44	6.08e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.53	6.6	0.39	2.46e-10	Aortic root size;
KIRP	cis	rs7172677	0.732	rs2289583	chr15:75311036	C/A	cg10253484	chr15:75165896	SCAMP2	0.66	7.33	0.42	3.4e-12	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs965513	0.901	rs1877431	chr9:100534147	C/T	cg13688889	chr9:100608707	NA	0.44	5.51	0.33	8.98e-8	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs4523957	0.583	rs7212589	chr17:2042393	A/G	cg16513277	chr17:2031491	SMG6	-0.86	-12.82	-0.63	3.79e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.82	11.92	0.61	3.62e-26	Menopause (age at onset);
KIRP	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.78	10.18	0.54	1.58e-20	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg04289385	chr6:36355825	ETV7	0.45	7.22	0.42	6.58e-12	Platelet distribution width;
KIRP	cis	rs7712401	0.584	rs30037	chr5:122277990	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg00806126	chr19:22604979	ZNF98	-0.67	-7.1	-0.41	1.36e-11	Pain;
KIRP	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg21605333	chr4:119757512	SEC24D	1.41	9.98	0.54	6.38e-20	Cannabis dependence symptom count;
KIRP	cis	rs11264213	0.681	rs35490896	chr1:36202585	G/A	cg27506609	chr1:36549197	TEKT2	0.92	5.41	0.33	1.52e-7	Schizophrenia;
KIRP	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.27	26.67	0.86	1.58e-74	IgG glycosylation;
KIRP	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25517755	chr10:38738941	LOC399744	-0.51	-6.94	-0.4	3.39e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20932251	chr11:72852302	FCHSD2	0.47	6.35	0.38	1e-9	Parkinson's disease;
KIRP	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg03735888	chr19:58951602	ZNF132	0.46	5.43	0.33	1.35e-7	Uric acid clearance;
KIRP	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.49	-6.38	-0.38	8.56e-10	Dietary macronutrient intake;
KIRP	cis	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg07460842	chr6:66804631	NA	0.87	9.08	0.5	3.67e-17	Exhaled nitric oxide output;
KIRP	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg21523564	chr15:75251491	NA	0.43	6.67	0.39	1.66e-10	Caffeine consumption;
KIRP	cis	rs1514687	0.534	rs11674407	chr2:1464530	G/C	cg03133821	chr2:1513998	TPO	-0.71	-6.05	-0.36	5.23e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs7267005	0.661	rs17093097	chr20:34387006	A/G	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	5.71	0.34	3.25e-8	Longevity;
KIRP	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.18	0.31	4.59e-7	Height;
KIRP	cis	rs9876781	0.588	rs11715932	chr3:48408345	C/A	cg11946769	chr3:48343235	NME6	0.44	5.26	0.32	3.12e-7	Longevity;
KIRP	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs1823913	0.622	rs55787447	chr2:192153322	T/C	cg12404831	chr2:192114017	MYO1B	0.54	7.46	0.43	1.53e-12	Obesity-related traits;
KIRP	cis	rs7998202	0.667	rs282569	chr13:113371507	T/C	cg04656015	chr13:113407548	ATP11A	-0.61	-6.77	-0.4	9.29e-11	Glycated hemoglobin levels;
KIRP	cis	rs897080	0.552	rs1067397	chr2:44679285	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.11	0.36	3.83e-9	Height;
KIRP	cis	rs7712401	0.562	rs377316	chr5:122259875	G/C	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg01629716	chr15:45996671	NA	0.37	6.73	0.39	1.19e-10	Waist circumference;Weight;
KIRP	cis	rs1881396	0.783	rs10181342	chr2:27757343	A/G	cg27432699	chr2:27873401	GPN1	0.54	6.04	0.36	5.75e-9	Nonalcoholic fatty liver disease;
KIRP	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg07701084	chr6:150067640	NUP43	0.57	7.32	0.42	3.6e-12	Testicular germ cell tumor;
KIRP	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.91	15.31	0.7	1.33e-37	Menarche (age at onset);
KIRP	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg27205649	chr11:78285834	NARS2	-0.66	-7.67	-0.44	3.96e-13	Alzheimer's disease (survival time);
KIRP	cis	rs4273100	0.850	rs11204306	chr17:19267371	A/G	cg18093559	chr17:18951025	GRAP	-0.53	-4.98	-0.3	1.21e-6	Schizophrenia;
KIRP	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.58	7.3	0.42	3.87e-12	Monocyte count;
KIRP	cis	rs986417	1.000	rs1116853	chr14:60917476	A/G	cg27398547	chr14:60952738	C14orf39	0.64	5.52	0.33	8.8e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs687432	0.885	rs12792435	chr11:57801732	T/A	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg04731861	chr2:219085781	ARPC2	0.28	6.83	0.4	6.51e-11	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg08662619	chr6:150070041	PCMT1	0.37	6.18	0.37	2.71e-9	Lung cancer;
KIRP	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.92	0.66	7.11e-33	Electrocardiographic conduction measures;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06699275	chr11:68518961	MTL5	-0.45	-6.87	-0.4	5.38e-11	Metabolic traits;
KIRP	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.2	0.51	1.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	9.44	0.52	3.09e-18	Cognitive test performance;
KIRP	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg21191810	chr6:118973309	C6orf204	-0.42	-4.86	-0.3	2.14e-6	Diastolic blood pressure;
KIRP	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.57	-5.74	-0.34	2.8e-8	Platelet distribution width;
KIRP	cis	rs7721647	0.821	rs987092	chr5:90867681	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.41	5.04	0.31	8.88e-7	Breast cancer;
KIRP	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.41	5.31	0.32	2.42e-7	Aortic root size;
KIRP	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	8.87	0.49	1.54e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	5.42	0.33	1.42e-7	Renal cell carcinoma;
KIRP	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg10047753	chr17:41438598	NA	1.13	17.76	0.75	5.67e-46	Menopause (age at onset);
KIRP	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg06204229	chr3:52865917	ITIH4	-0.4	-5.14	-0.31	5.62e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6496667	1.000	rs16944168	chr15:90859095	A/G	cg10434728	chr15:90938212	IQGAP1	0.38	4.99	0.3	1.15e-6	Rheumatoid arthritis;
KIRP	cis	rs4664293	1.000	rs11676412	chr2:160508071	G/T	cg08347373	chr2:160653686	CD302	-0.39	-5.86	-0.35	1.51e-8	Monocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26351039	chr19:49138730	DBP	0.47	6.32	0.37	1.22e-9	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18753541	chr4:121841743	PRDM5	0.53	7.69	0.44	3.47e-13	Interleukin-4 levels;
KIRP	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Bipolar disorder;
KIRP	cis	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg21546286	chr11:48923668	NA	-0.43	-5.45	-0.33	1.25e-7	HDL cholesterol;
KIRP	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.59	7.94	0.45	7.14e-14	Retinal vascular caliber;
KIRP	cis	rs4776059	0.550	rs8036979	chr15:52947995	A/T	cg25063058	chr15:52860530	ARPP19	-0.58	-5.0	-0.3	1.08e-6	Schizophrenia;
KIRP	cis	rs10242455	0.702	rs116671616	chr7:98954558	C/T	cg18809830	chr7:99032528	PTCD1	-0.96	-5.67	-0.34	3.97e-8	Blood metabolite levels;
KIRP	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.88	-0.45	1.08e-13	Mood instability;
KIRP	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg19847130	chr8:10466454	RP1L1	-0.32	-4.9	-0.3	1.76e-6	Retinal vascular caliber;
KIRP	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.46	5.85	0.35	1.58e-8	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg02487422	chr3:49467188	NICN1	0.38	5.05	0.31	8.55e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg08888203	chr3:10149979	C3orf24	0.5	5.27	0.32	2.96e-7	Alzheimer's disease;
KIRP	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg00405596	chr8:11794950	NA	0.45	5.58	0.34	6.42e-8	Retinal vascular caliber;
KIRP	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.62	-0.34	5.29e-8	IgG glycosylation;
KIRP	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.1	-0.31	6.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7580658	0.534	rs2089109	chr2:127951458	G/A	cg16751203	chr2:127950803	CYP27C1	0.39	5.31	0.32	2.48e-7	Protein C levels;
KIRP	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg04691961	chr3:161091175	C3orf57	-0.55	-8.31	-0.47	6.46e-15	Morning vs. evening chronotype;
KIRP	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.1	-0.36	4.11e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6545883	0.931	rs7557230	chr2:61736652	A/T	cg15711740	chr2:61764176	XPO1	-0.61	-8.26	-0.47	9.32e-15	Tuberculosis;
KIRP	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.63	-7.58	-0.44	7.03e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7523273	0.597	rs2724384	chr1:207930203	G/A	cg22525895	chr1:207977042	MIR29B2	0.57	5.45	0.33	1.24e-7	Schizophrenia;
KIRP	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.24	0.37	1.95e-9	Aortic root size;
KIRP	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	1.05	13.5	0.65	1.89e-31	Exhaled nitric oxide output;
KIRP	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg01338139	chr15:38987640	C15orf53	-0.56	-6.31	-0.37	1.31e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs11169552	0.510	rs4131769	chr12:50952022	A/G	cg12884762	chr12:50931848	DIP2B	-0.46	-5.19	-0.31	4.5e-7	Colorectal cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05755239	chr4:166128480	KLHL2	-0.57	-6.4	-0.38	7.7e-10	Menopause (age at onset);
KIRP	cis	rs9583531	0.660	rs61971610	chr13:111330476	T/C	cg24331049	chr13:111365604	ING1	-0.84	-5.8	-0.35	2e-8	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18317474	chr19:14142577	IL27RA	0.48	6.15	0.37	3.15e-9	Parkinson's disease;
KIRP	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.31	-0.62	1.85e-27	Primary sclerosing cholangitis;
KIRP	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg10223061	chr2:219282414	VIL1	0.32	5.4	0.33	1.58e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.33	-7.35	-0.42	2.9e-12	Cutaneous nevi;
KIRP	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg16989719	chr2:238392110	NA	-0.39	-4.88	-0.3	1.92e-6	Prostate cancer;
KIRP	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.82	-11.64	-0.6	3.1e-25	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	1.0	13.11	0.64	3.96e-30	Breast cancer;
KIRP	cis	rs10861342	0.892	rs12227605	chr12:105501100	G/A	cg23923672	chr12:105501055	KIAA1033	0.91	9.29	0.51	8.24e-18	IgG glycosylation;
KIRP	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs422249	0.819	rs174608	chr11:61627484	A/G	cg19610905	chr11:61596333	FADS2	-0.49	-6.29	-0.37	1.46e-9	Trans fatty acid levels;
KIRP	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.76	8.85	0.49	1.71e-16	Adiposity;
KIRP	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.97	14.77	0.69	8.87e-36	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7009516	0.692	rs9650409	chr8:24240704	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.3	6.38	0.38	8.76e-10	Hair greying;
KIRP	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg11235152	chr1:67600687	NA	-0.65	-9.65	-0.52	6.6e-19	Psoriasis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03073431	chr7:44887862	H2AFV	0.49	6.15	0.37	3.06e-9	Parkinson's disease;
KIRP	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	8.41	0.47	3.29e-15	Response to antipsychotic treatment;
KIRP	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.44	0.33	1.28e-7	Thyroid stimulating hormone;
KIRP	cis	rs240764	0.658	rs12174806	chr6:101219581	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-4.97	-0.3	1.24e-6	Neuroticism;
KIRP	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg12598211	chr12:123634384	NA	-0.45	-5.19	-0.31	4.34e-7	Neutrophil percentage of white cells;
KIRP	trans	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00950418	chr7:105029125	SRPK2	-0.55	-6.95	-0.41	3.31e-11	Height;
KIRP	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg06640241	chr16:89574553	SPG7	0.66	8.84	0.49	1.85e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.41	5.13	0.31	5.83e-7	Aortic root size;
KIRP	cis	rs35883536	1.000	rs11586051	chr1:101096240	A/T	cg06223162	chr1:101003688	GPR88	-0.33	-6.75	-0.4	1.07e-10	Monocyte count;
KIRP	cis	rs6088813	1.000	rs6088815	chr20:33976474	G/C	cg14752227	chr20:34000481	UQCC	-0.5	-6.61	-0.39	2.34e-10	Height;
KIRP	cis	rs12643440	0.503	rs7699243	chr4:17159265	T/G	cg22650099	chr4:17144496	NA	-0.73	-8.7	-0.48	4.9e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.58	-7.12	-0.41	1.17e-11	Aortic root size;
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg20578329	chr17:80767326	TBCD	-0.44	-5.81	-0.35	1.96e-8	Glycated hemoglobin levels;
KIRP	cis	rs7017697	0.507	rs10113140	chr8:19684745	A/C	cg03894339	chr8:19674705	INTS10	-0.43	-4.9	-0.3	1.73e-6	Breast cancer;
KIRP	cis	rs2120243	0.504	rs1824058	chr3:157124780	C/A	cg24825693	chr3:157122686	VEPH1	-0.56	-9.15	-0.5	2.24e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs11955175	1.000	rs113120818	chr5:40642896	T/A	cg05478818	chr5:40835740	RPL37	0.68	5.32	0.32	2.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs12615966	0.872	rs72830464	chr2:105395283	G/A	cg16465502	chr2:105461796	NA	0.62	5.47	0.33	1.11e-7	Pancreatic cancer;
KIRP	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.16	0.46	1.76e-14	Neuroticism;
KIRP	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.52	7.14	0.41	1.08e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.54	7.36	0.42	2.74e-12	HDL cholesterol;
KIRP	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg12384639	chr17:618140	VPS53	0.49	5.99	0.36	7.33e-9	Prostate cancer;
KIRP	cis	rs7737355	0.812	rs3756289	chr5:130982194	A/G	cg06307176	chr5:131281290	NA	0.41	4.93	0.3	1.54e-6	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07926074	chr7:112406584	TMEM168	-0.43	-7.07	-0.41	1.62e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-8.11	-0.46	2.34e-14	Homocysteine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11521979	chr1:67266410	INSL5	0.43	6.22	0.37	2.09e-9	Interleukin-4 levels;
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.54	5.07	0.31	7.66e-7	Alzheimer's disease;
KIRP	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.61	-0.34	5.45e-8	Colorectal cancer;
KIRP	trans	rs4617118	0.591	rs4733534	chr8:130010432	C/T	cg04043264	chr2:233471076	EFHD1	-0.68	-6.05	-0.36	5.47e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6832769	1.000	rs1522111	chr4:56329563	T/A	cg05960024	chr4:56376020	CLOCK	0.74	9.52	0.52	1.72e-18	Personality dimensions;
KIRP	cis	rs4899260	0.779	rs4899261	chr14:69283375	C/T	cg03189333	chr14:69283534	NA	-0.41	-4.9	-0.3	1.73e-6	Celiac disease;
KIRP	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.25e-11	Diabetic kidney disease;
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg27144592	chr16:783916	NARFL	0.37	5.14	0.31	5.5e-7	Height;
KIRP	cis	rs698833	0.886	rs4953087	chr2:44561627	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.79	0.35	2.13e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.62	-5.17	-0.31	4.97e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	9.47	0.52	2.35e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.9	-15.46	-0.7	3.83e-38	Breast cancer;
KIRP	cis	rs7011507	1.000	rs4552930	chr8:49170958	A/G	cg15325961	chr8:49183143	NA	0.59	4.96	0.3	1.31e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.3	-0.32	2.6e-7	Life satisfaction;
KIRP	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg21252483	chr19:49399788	TULP2	-0.47	-6.19	-0.37	2.5e-9	Red cell distribution width;
KIRP	cis	rs12949688	0.967	rs9905938	chr17:55824351	G/A	cg12582317	chr17:55822272	NA	0.62	10.29	0.55	6.98e-21	Schizophrenia;
KIRP	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	cg21523751	chr1:182988639	NA	0.44	6.97	0.41	2.9100000000000002e-11	Colorectal cancer;
KIRP	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.6	-7.47	-0.43	1.41e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.49	-7.53	-0.43	9.57e-13	Lymphocyte counts;
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg07701084	chr6:150067640	NUP43	0.75	10.26	0.55	8.45e-21	Lung cancer;
KIRP	cis	rs755109	1.000	rs10984506	chr9:100716140	A/T	cg13688889	chr9:100608707	NA	-0.43	-5.04	-0.31	9.16e-7	Quantitative traits;
KIRP	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.37	-0.32	1.86e-7	Neuroticism;
KIRP	cis	rs13315871	0.615	rs6794695	chr3:58423498	A/C	cg12435725	chr3:58293450	RPP14	-0.42	-5.78	-0.35	2.2e-8	Cholesterol, total;
KIRP	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg11130432	chr3:121712080	ILDR1	-0.43	-5.09	-0.31	7.24e-7	Multiple sclerosis;
KIRP	cis	rs812925	0.537	rs778153	chr2:61608652	A/G	cg15711740	chr2:61764176	XPO1	0.47	5.89	0.35	1.24e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg04607699	chr11:48328132	OR4S1	-0.35	-4.94	-0.3	1.43e-6	HDL cholesterol;
KIRP	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.75	-10.4	-0.55	3.2e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg03171003	chr2:111875934	NA	0.44	6.24	0.37	1.86e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.43	-0.47	2.86e-15	Morning vs. evening chronotype;
KIRP	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.65	-12.51	-0.62	3.94e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	0.812	rs55748698	chr3:41805233	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.35	0.47	4.88e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs9810890	1.000	rs73198806	chr3:128465094	A/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.61	-7.35	-0.42	2.85e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg22974920	chr21:40686053	BRWD1	-0.45	-5.06	-0.31	8.02e-7	Cognitive function;
KIRP	cis	rs76793172	0.660	rs4803852	chr19:46238926	G/T	cg00442267	chr19:46317840	RSPH6A	0.66	5.7	0.34	3.4e-8	Eosinophil counts;
KIRP	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-8.19	-0.46	1.42e-14	Chronic sinus infection;
KIRP	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.46	5.85	0.35	1.57e-8	Height;
KIRP	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg01843034	chr6:37503916	NA	-0.88	-12.24	-0.62	3.34e-27	Cognitive performance;
KIRP	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-9.59	-0.52	1.01e-18	Body mass index;
KIRP	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg11845111	chr2:191398756	TMEM194B	-0.95	-10.6	-0.56	7.08e-22	Diastolic blood pressure;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11158430	chr3:191001413	UTS2D	0.39	6.39	0.38	8.31e-10	C-reactive protein;
KIRP	cis	rs9937943	0.614	rs35148538	chr16:74613575	G/C	cg01733217	chr16:74700730	RFWD3	0.59	5.33	0.32	2.17e-7	Neutrophil percentage of white cells;
KIRP	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg20991723	chr1:152506922	NA	-0.46	-5.47	-0.33	1.1e-7	Hair morphology;
KIRP	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.75	11.24	0.58	6.24e-24	Oral cavity cancer;
KIRP	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.83	-11.86	-0.6	5.72e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs7119038	0.818	rs4936441	chr11:118725660	C/G	cg19308663	chr11:118741387	NA	-0.56	-9.84	-0.53	1.76e-19	Sjögren's syndrome;
KIRP	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg17366294	chr4:99064904	C4orf37	0.43	6.27	0.37	1.62e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg15117754	chr3:10150083	C3orf24	0.48	4.91	0.3	1.67e-6	Alzheimer's disease;
KIRP	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg21775007	chr8:11205619	TDH	0.46	5.88	0.35	1.36e-8	Monocyte count;
KIRP	cis	rs830383	0.568	rs830384	chr5:165476616	A/C	cg13976338	chr5:165423657	NA	0.63	6.15	0.36	3.19e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7849270	0.879	rs10760587	chr9:131846016	C/G	cg13538475	chr9:131942899	NA	0.35	5.47	0.33	1.13e-7	Blood metabolite ratios;
KIRP	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.96	0.45	6.26e-14	Height;
KIRP	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.66	7.54	0.43	9.07e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.56	7.24	0.42	5.71e-12	Pulse pressure;
KIRP	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.36	-0.42	2.72e-12	Daytime sleep phenotypes;
KIRP	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg09571762	chr12:39539558	NA	0.37	5.09	0.31	7.1e-7	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.97	-0.5	7.54e-17	Personality dimensions;
KIRP	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.5	6.77	0.4	9.41e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg17376030	chr22:41985996	PMM1	-0.83	-8.98	-0.5	7.17e-17	Cannabis dependence symptom count;
KIRP	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.64	8.85	0.49	1.73e-16	Blood protein levels;
KIRP	cis	rs62355272	0.932	rs6872082	chr5:35831690	A/G	cg13894535	chr5:35919491	CAPSL	-0.4	-5.07	-0.31	7.93e-7	Lymphocyte counts;
KIRP	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.59	-7.98	-0.45	5.7e-14	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg02570527	chr1:10970165	NA	-0.43	-5.18	-0.31	4.67e-7	Body mass index;
KIRP	trans	rs6687758	0.687	rs7520544	chr1:222117198	T/C	cg11122944	chr17:9924800	GAS7	0.47	6.02	0.36	6.14e-9	Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);Colorectal cancer;
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-5.52	-0.33	8.44e-8	Life satisfaction;
KIRP	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.68	10.02	0.54	4.93e-20	Dupuytren's disease;
KIRP	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg18441811	chr11:71824068	C11orf51	-0.81	-5.43	-0.33	1.33e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.54	4.98	0.3	1.19e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg27205649	chr11:78285834	NARS2	-0.49	-4.97	-0.3	1.24e-6	Testicular germ cell tumor;
KIRP	cis	rs9372498	0.536	rs62422229	chr6:118959288	T/C	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg04398451	chr17:18023971	MYO15A	0.77	11.23	0.58	6.91e-24	Total body bone mineral density;
KIRP	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.53	-6.59	-0.39	2.68e-10	Total body bone mineral density;
KIRP	cis	rs10864907	0.553	rs7578034	chr2:113718077	C/T	cg06156847	chr2:113672199	IL1F7	-0.42	-5.86	-0.35	1.45e-8	Pulmonary function;
KIRP	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.12	0.31	6.19e-7	Educational attainment;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15190354	chr11:125494874	CHEK1	0.47	6.21	0.37	2.3e-9	Survival in pancreatic cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05152925	chr14:45603667	FKBP3;FANCM	0.48	6.51	0.38	4.23e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.23	-4.96	-0.3	1.3e-6	Type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg10503236	chr1:231470652	EXOC8	-0.49	-6.83	-0.4	6.47e-11	Hemoglobin concentration;
KIRP	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg09904177	chr6:26538194	HMGN4	0.63	8.95	0.5	8.92e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg23307798	chr14:103986281	CKB	0.43	5.96	0.35	8.91e-9	Coronary artery disease;
KIRP	trans	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg21775007	chr8:11205619	TDH	-0.5	-6.18	-0.37	2.62e-9	Mood instability;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg01763666	chr17:80159506	CCDC57	0.38	5.09	0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs4959799	0.557	rs9501975	chr6:3272807	A/G	cg03657281	chr6:3270030	SLC22A23	-0.8	-6.15	-0.36	3.17e-9	Survival in rectal cancer;
KIRP	cis	rs35955747	0.869	rs5997971	chr22:31792292	C/T	cg02404636	chr22:31891804	SFI1	-0.38	-5.24	-0.32	3.43e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg11784071	chr10:104629166	AS3MT	-0.38	-5.28	-0.32	2.85e-7	Arsenic metabolism;
KIRP	cis	rs3789045	0.560	rs1002779	chr1:204405098	T/A	cg17419461	chr1:204415978	PIK3C2B	-0.87	-8.04	-0.46	3.88e-14	Educational attainment (college completion);
KIRP	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg20701182	chr2:24300061	SF3B14	0.57	5.08	0.31	7.61e-7	Lymphocyte counts;
KIRP	cis	rs10411936	0.712	rs8103521	chr19:16589750	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.34	0.32	2.07e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg12315302	chr6:26189340	HIST1H4D	0.76	5.26	0.32	3.19e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.8	6.43	0.38	6.76e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg08662619	chr6:150070041	PCMT1	0.38	6.39	0.38	8.4e-10	Lung cancer;
KIRP	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.02	0.46	4.26e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.35	-0.32	2.05e-7	Obesity-related traits;
KIRP	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.82	10.27	0.55	8.1e-21	Menopause (age at onset);
KIRP	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.57	7.26	0.42	5.1e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.11	0.41	1.23e-11	Educational attainment;
KIRP	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg09904177	chr6:26538194	HMGN4	-0.53	-6.73	-0.39	1.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg23791538	chr6:167370224	RNASET2	-0.46	-5.71	-0.34	3.24e-8	Crohn's disease;
KIRP	cis	rs2150410	0.915	rs2150412	chr21:40574669	T/C	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg13409248	chr3:40428643	ENTPD3	-0.39	-5.48	-0.33	1.06e-7	Renal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-6.53	-0.38	3.82e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.99	-0.3	1.15e-6	Neutrophil percentage of white cells;
KIRP	cis	rs1620921	0.524	rs7450979	chr6:161186889	A/C	cg01280913	chr6:161186852	NA	0.69	9.7	0.53	4.89e-19	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-7.34	-0.42	3.14e-12	Body mass index;
KIRP	cis	rs2599510	0.729	rs1135484	chr2:32749060	G/A	cg02381751	chr2:32503542	YIPF4	0.52	5.95	0.35	9.3e-9	Interleukin-18 levels;
KIRP	cis	rs6974574	0.922	rs2462184	chr7:38115495	G/C	cg10754659	chr7:38110151	NA	-0.37	-4.98	-0.3	1.22e-6	Height;
KIRP	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-7.7	-0.44	3.22e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	15.93	0.71	9.55e-40	Colorectal cancer;
KIRP	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg09754948	chr16:28834200	ATXN2L	0.5	5.71	0.34	3.16e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.69	10.7	0.56	3.4e-22	Blood metabolite ratios;
KIRP	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.53	9.24	0.51	1.22e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.49	-5.8	-0.35	2.01e-8	Body mass index;
KIRP	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg13010199	chr12:38710504	ALG10B	0.63	7.8	0.45	1.8e-13	Morning vs. evening chronotype;
KIRP	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg19592336	chr6:28129416	ZNF389	0.51	5.73	0.34	2.91e-8	Depression;
KIRP	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.38	-5.49	-0.33	9.92e-8	Coronary artery disease;
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg16590910	chr6:42928470	GNMT	0.47	6.71	0.39	1.36e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.82	0.35	1.86e-8	Renal cell carcinoma;
KIRP	cis	rs1978968	0.763	rs9605473	chr22:18463266	C/T	cg03078520	chr22:18463400	MICAL3	0.81	11.33	0.59	3.25e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg15896084	chr13:114927664	NA	0.48	6.36	0.38	1e-9	Schizophrenia;
KIRP	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.5	7.4	0.43	2.1e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg03342759	chr3:160939853	NMD3	-0.57	-6.98	-0.41	2.67e-11	Morning vs. evening chronotype;
KIRP	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-7.24	-0.42	5.66e-12	Systolic blood pressure;
KIRP	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.17	0.5	1.93e-17	Morning vs. evening chronotype;
KIRP	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs7523050	0.643	rs12725689	chr1:109405151	T/C	cg08274380	chr1:109419600	GPSM2	1.18	9.86	0.53	1.5e-19	Fat distribution (HIV);
KIRP	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.74	8.45	0.47	2.5e-15	Adiposity;
KIRP	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg24296786	chr1:45957014	TESK2	-0.44	-5.51	-0.33	8.87e-8	Red blood cell count;Reticulocyte count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17409876	chr11:66436470	RBM4B	0.49	6.82	0.4	7.12e-11	Interleukin-4 levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05318427	chr2:85199320	KCMF1	0.54	6.38	0.38	8.56e-10	Smoking initiation;
KIRP	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg18586891	chr4:952366	TMEM175	0.62	5.1	0.31	6.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.74	-0.34	2.77e-8	Parkinson's disease;
KIRP	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.79	-0.35	2.18e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.52	6.33	0.37	1.17e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.95	-10.6	-0.56	7.24e-22	Body mass index;
KIRP	cis	rs930036	0.628	rs6761889	chr2:171945020	A/C	cg12801329	chr2:171670795	NA	0.43	4.89	0.3	1.78e-6	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.27e-19	Prudent dietary pattern;
KIRP	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs240764	0.746	rs240141	chr6:101084946	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.29	0.32	2.71e-7	Neuroticism;
KIRP	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg18944383	chr4:111397179	ENPEP	0.55	9.72	0.53	4.1e-19	Height;
KIRP	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.56e-17	Retinal vascular caliber;
KIRP	cis	rs11874712	0.545	rs35935345	chr18:43651549	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.35	-5.0	-0.3	1.08e-6	Migraine - clinic-based;
KIRP	cis	rs7113874	0.659	rs2121313	chr11:8523042	T/C	cg08015107	chr11:8618950	NA	-0.72	-8.72	-0.49	4.22e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg21858823	chr1:15850916	CASP9	0.54	5.81	0.35	1.92e-8	Systolic blood pressure;
KIRP	cis	rs4236601	1.000	rs10281661	chr7:116153329	A/G	cg05166801	chr7:116143459	CAV2	0.5	6.07	0.36	4.92e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.32	0.32	2.31e-7	Parkinson's disease;
KIRP	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.14	-0.31	5.6e-7	Bladder cancer;
KIRP	cis	rs8077577	0.747	rs62072507	chr17:18172335	G/A	cg18869244	chr17:18121946	NA	0.47	5.31	0.32	2.51e-7	Obesity-related traits;
KIRP	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg22875332	chr1:76189707	ACADM	0.35	5.0	0.3	1.1e-6	Daytime sleep phenotypes;
KIRP	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.47	11.64	0.6	3.04e-25	Gout;
KIRP	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.4	9.95	0.54	7.89e-20	Corneal astigmatism;
KIRP	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg11815991	chr20:30193098	ID1	-0.5	-5.07	-0.31	7.7e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.38	-5.54	-0.33	7.88e-8	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs33912345	0.722	rs1254261	chr14:60837516	T/G	cg27398547	chr14:60952738	C14orf39	-0.39	-5.17	-0.31	4.93e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.54	6.97	0.41	2.89e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.7	-0.53	4.73e-19	Morning vs. evening chronotype;
KIRP	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.28	-0.37	1.52e-9	Response to antipsychotic treatment;
KIRP	cis	rs9488822	0.623	rs195516	chr6:116241548	T/A	cg15226275	chr6:116381976	FRK	0.21	5.44	0.33	1.3e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4765905	0.610	rs10848634	chr12:2316127	C/T	cg10668781	chr12:2307325	CACNA1C	0.33	6.61	0.39	2.38e-10	Schizophrenia;
KIRP	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24229701	chr12:130821962	PIWIL1	0.43	5.42	0.33	1.45e-7	Menopause (age at onset);
KIRP	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.45	5.15	0.31	5.46e-7	Schizophrenia;
KIRP	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-9.66	-0.52	6.18e-19	Body mass index;
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-0.87	-14.79	-0.69	7.6e-36	Vitiligo;
KIRP	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.85	12.87	0.63	2.53e-29	Height;
KIRP	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.73	9.36	0.51	5.14e-18	Coronary artery disease;
KIRP	cis	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg21204522	chr6:27730016	NA	-0.61	-5.17	-0.31	4.87e-7	Lung cancer in ever smokers;
KIRP	cis	rs4523957	0.579	rs57130712	chr17:2089035	A/G	cg16513277	chr17:2031491	SMG6	-0.72	-10.38	-0.55	3.69e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.4	-5.05	-0.31	8.47e-7	Platelet count;
KIRP	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.47	-7.11	-0.41	1.26e-11	Bipolar disorder;
KIRP	cis	rs4936894	0.500	rs10790649	chr11:124080360	G/A	cg27160556	chr11:124181099	OR8D1	-0.4	-5.93	-0.35	1.02e-8	Aging (time to death);
KIRP	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg21385522	chr1:16154831	NA	0.5	6.35	0.38	1.01e-9	Dilated cardiomyopathy;
KIRP	cis	rs7033996	1.000	rs7861968	chr9:35924396	C/G	cg00918944	chr9:35908117	LOC158376	0.36	5.27	0.32	2.94e-7	Urate levels (BMI interaction);
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg03732293	chr1:179335087	C1orf125	0.42	6.08	0.36	4.62e-9	Ischemic stroke;
KIRP	cis	rs7837860	0.541	rs35658486	chr8:89279419	A/G	cg08624180	chr8:89339080	MMP16	-0.62	-5.3	-0.32	2.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17384381	1.000	rs79695640	chr1:85836073	T/C	cg16011679	chr1:85725395	C1orf52	0.85	8.29	0.47	7.6e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg15556689	chr8:8085844	FLJ10661	0.57	6.98	0.41	2.7e-11	Neuroticism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02021337	chr3:183397091	KLHL24	0.38	6.3	0.37	1.36e-9	C-reactive protein;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22618164	chr12:122356400	WDR66	0.62	8.73	0.49	3.88e-16	Mean corpuscular volume;
KIRP	cis	rs6466055	0.552	rs4727618	chr7:104662862	G/A	cg04380332	chr7:105027541	SRPK2	-0.39	-5.28	-0.32	2.86e-7	Schizophrenia;
KIRP	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.93	-13.49	-0.65	2.11e-31	Coronary artery disease;
KIRP	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs6545883	0.862	rs11691734	chr2:61702466	C/T	cg15711740	chr2:61764176	XPO1	-0.6	-8.06	-0.46	3.38e-14	Tuberculosis;
KIRP	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.26	17.21	0.74	4.16e-44	Corneal structure;
KIRP	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.53	6.14	0.36	3.24e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg04414720	chr1:150670196	GOLPH3L	0.39	5.15	0.31	5.22e-7	Tonsillectomy;
KIRP	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.83	-0.4	6.5e-11	Bipolar disorder;
KIRP	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.57	7.56	0.43	8.2e-13	Bladder cancer;
KIRP	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg23791538	chr6:167370224	RNASET2	-0.42	-5.32	-0.32	2.31e-7	Crohn's disease;
KIRP	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg15192750	chr16:69999425	NA	0.48	4.95	0.3	1.37e-6	IgE levels;
KIRP	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg01631408	chr1:248437212	OR2T33	-0.67	-8.63	-0.48	7.85e-16	Common traits (Other);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07027685	chr9:95055737	IARS;SNORA84	0.46	6.39	0.38	8.4e-10	Survival in pancreatic cancer;
KIRP	cis	rs9311676	0.656	rs11918201	chr3:58387777	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	10.9	0.57	8.14e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.66	9.68	0.53	5.39e-19	Menarche (age at onset);
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg27121462	chr16:89883253	FANCA	0.65	9.47	0.52	2.47e-18	Schizophrenia;
KIRP	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg26084005	chr2:241760190	KIF1A	-0.49	-6.71	-0.39	1.33e-10	Urinary metabolites;
KIRP	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	4.92	0.3	1.55e-6	Cognitive test performance;
KIRP	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg21892295	chr12:121157589	UNC119B	-0.4	-5.67	-0.34	3.9e-8	Mean corpuscular volume;
KIRP	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08280861	chr8:58055591	NA	0.72	5.71	0.34	3.31e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	7.6	0.44	6.29e-13	Mean corpuscular volume;
KIRP	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg00656387	chr3:40428638	ENTPD3	0.38	4.87	0.3	1.96e-6	Renal cell carcinoma;
KIRP	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg04362960	chr10:104952993	NT5C2	0.56	6.81	0.4	7.37e-11	Arsenic metabolism;
KIRP	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg04731861	chr2:219085781	ARPC2	-0.2	-4.97	-0.3	1.27e-6	Colorectal cancer;
KIRP	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg21546286	chr11:48923668	NA	0.45	5.57	0.33	6.82e-8	HDL cholesterol;
KIRP	cis	rs7975161	0.535	rs6539138	chr12:104735928	G/A	cg25273343	chr12:104657179	TXNRD1	-0.61	-5.6	-0.34	5.81e-8	Toenail selenium levels;
KIRP	cis	rs9409565	0.717	rs61470662	chr9:97189472	T/C	cg04523069	chr9:97136363	HIATL1	0.47	6.17	0.37	2.76e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.85	0.35	1.56e-8	Lung cancer;
KIRP	cis	rs2929278	0.561	rs3099045	chr15:43923955	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.81	0.4	7.24e-11	Schizophrenia;
KIRP	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.5e-20	Coffee consumption (cups per day);
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01765077	chr12:122356316	WDR66	0.45	6.17	0.37	2.86e-9	Mean corpuscular volume;
KIRP	cis	rs1062753	0.527	rs6519296	chr22:42348602	G/C	cg15128208	chr22:42549153	NA	0.43	5.69	0.34	3.65e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg00579200	chr11:133705235	NA	-0.42	-5.37	-0.32	1.86e-7	Childhood ear infection;
KIRP	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.34	-4.85	-0.3	2.16e-6	Monocyte count;
KIRP	trans	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.23	0.42	5.97e-12	Mean corpuscular volume;
KIRP	cis	rs7027203	0.538	rs2265570	chr9:96512169	C/T	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.88e-10	DNA methylation (variation);
KIRP	cis	rs1829883	1.000	rs2461971	chr5:98777650	A/G	cg08333243	chr5:99726346	NA	-0.38	-5.04	-0.31	8.97e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg16736954	chr20:23401023	NAPB	0.63	5.0	0.3	1.08e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.97	-0.3	1.28e-6	Renal cell carcinoma;
KIRP	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.2	26.49	0.86	5.19e-74	Schizophrenia;
KIRP	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg22852734	chr6:133119734	C6orf192	0.96	6.86	0.4	5.54e-11	Type 2 diabetes nephropathy;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.77	11.55	0.59	6.11e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7009516	0.716	rs4559243	chr8:24221015	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.25	5.22	0.32	3.78e-7	Hair greying;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19671926	chr4:122722719	EXOSC9	0.5	6.05	0.36	5.43e-9	Type 2 diabetes;
KIRP	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-9.28	-0.51	9.13e-18	Response to antipsychotic treatment;
KIRP	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.41	5.93	0.35	1.03e-8	Body mass index;
KIRP	cis	rs10267417	0.603	rs4593428	chr7:19864061	T/A	cg05791153	chr7:19748676	TWISTNB	0.52	5.12	0.31	6.26e-7	Night sleep phenotypes;
KIRP	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-8.98	-0.5	7.17e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21643547	chr1:205240462	TMCC2	-0.77	-11.49	-0.59	9.25e-25	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.21	-5.13	-0.31	6.02e-7	Coronary artery disease;
KIRP	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg16558253	chr16:72132732	DHX38	-0.41	-5.58	-0.34	6.17e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs9653442	0.863	rs10865035	chr2:100835734	A/G	cg07810366	chr2:100720526	AFF3	-0.34	-5.92	-0.35	1.1e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg00405596	chr8:11794950	NA	-0.5	-6.83	-0.4	6.58e-11	Monocyte count;
KIRP	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg06392426	chr19:10676186	KRI1	0.37	4.85	0.3	2.21e-6	Red cell distribution width;
KIRP	cis	rs362296	0.698	rs3095080	chr4:3264418	C/T	cg06533319	chr4:3265114	C4orf44	0.54	6.29	0.37	1.43e-9	Parental longevity (mother's age at death);
KIRP	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg10818794	chr15:86012489	AKAP13	-0.52	-7.26	-0.42	5.14e-12	Coronary artery disease;
KIRP	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg10130564	chr11:117069849	TAGLN	-0.4	-4.86	-0.3	2.12e-6	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.25	-0.51	1.14e-17	Platelet count;
KIRP	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.74	10.24	0.55	1.01e-20	Plateletcrit;Platelet count;
KIRP	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.76	8.95	0.5	8.77e-17	Tonsillectomy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12831148	chr6:146136093	FBXO30	0.53	6.17	0.37	2.79e-9	Smoking initiation;
KIRP	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.14	0.46	1.95e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-5.05	-0.31	8.71e-7	Eosinophil percentage of white cells;
KIRP	cis	rs12460243	1.000	rs2287937	chr19:8130420	C/G	cg06488775	chr19:8115360	NA	0.5	4.94	0.3	1.41e-6	Neurocognitive impairment in HIV-1 infection (continuous);
KIRP	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.87	12.47	0.62	5.6e-28	Coronary artery disease;
KIRP	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	12.64	0.63	1.49e-28	Colorectal cancer;
KIRP	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-0.82	-6.56	-0.39	3.13e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.18	0.54	1.56e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.56	7.45	0.43	1.58e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-1.0	-8.05	-0.46	3.49e-14	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13409248	chr3:40428643	ENTPD3	0.4	5.2	0.31	4.23e-7	Renal cell carcinoma;
KIRP	cis	rs7007076	0.901	rs10089910	chr8:124723631	A/G	cg00283535	chr8:124749564	ANXA13	-0.62	-6.93	-0.4	3.58e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg17646820	chr3:66848679	NA	0.79	9.29	0.51	8.5e-18	Type 2 diabetes;
KIRP	cis	rs10129255	0.518	rs8009612	chr14:107185749	G/T	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs13082711	0.911	rs35532045	chr3:27515870	A/G	cg02860705	chr3:27208620	NA	0.47	6.62	0.39	2.2e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg00343986	chr7:65444356	GUSB	0.49	5.9	0.35	1.2e-8	Aortic root size;
KIRP	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg00241281	chr14:105779794	PACS2	-0.37	-5.05	-0.31	8.8e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2273669	0.667	rs79285264	chr6:109318279	G/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs2224391	0.784	rs67285271	chr6:5279267	T/G	cg13962347	chr6:5174647	LYRM4	-0.53	-5.66	-0.34	4.14e-8	Height;
KIRP	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg22117172	chr7:91764530	CYP51A1	0.42	5.94	0.35	9.56e-9	Breast cancer;
KIRP	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-5.11	-0.31	6.39e-7	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	trans	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg24644049	chr4:85504048	CDS1	0.99	6.46	0.38	5.48e-10	Skin colour saturation;
KIRP	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.66	8.71	0.49	4.48e-16	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.87	0.53	1.42e-19	Lung cancer;
KIRP	cis	rs1697938	0.640	rs1376182	chr5:40912811	T/G	cg01087697	chr5:40835557	RPL37	-0.48	-5.44	-0.33	1.32e-7	Multiple system atrophy;
KIRP	cis	rs2071403	0.527	rs11694732	chr2:1408350	G/C	cg07083862	chr2:1417248	TPO	0.33	4.97	0.3	1.27e-6	Thyroid peroxidase antibody positivity;
KIRP	cis	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg04607699	chr11:48328132	OR4S1	-0.33	-4.99	-0.3	1.15e-6	Height;
KIRP	cis	rs4478037	1.000	rs56733391	chr3:33161434	G/A	cg19404215	chr3:33155277	CRTAP	0.71	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg06671706	chr8:8559999	CLDN23	0.59	6.73	0.39	1.16e-10	Obesity-related traits;
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg18751306	chr15:81294292	MESDC1	-0.47	-6.45	-0.38	5.95e-10	Platelet-derived growth factor BB levels;
KIRP	cis	rs12694997	0.503	rs3771588	chr2:242412109	T/C	cg10021735	chr2:242295487	FARP2	0.39	4.84	0.3	2.25e-6	Height;
KIRP	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.45	-6.73	-0.39	1.2e-10	Vitamin D levels;
KIRP	cis	rs273218	0.590	rs156828	chr5:53364230	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.43	5.19	0.31	4.43e-7	Migraine;
KIRP	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.49	-5.82	-0.35	1.81e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.11	12.29	0.62	2.27e-27	Corneal structure;
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	13.59	0.65	9.62e-32	Platelet count;
KIRP	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.71	-0.39	1.35e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.78	-0.4	8.76e-11	Heart rate;
KIRP	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg22852734	chr6:133119734	C6orf192	1.01	10.92	0.57	6.76e-23	Type 2 diabetes nephropathy;
KIRP	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.32	0.42	3.53e-12	Systolic blood pressure;
KIRP	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg15880211	chr22:50250494	ZBED4	0.48	5.8	0.35	2e-8	Schizophrenia;
KIRP	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg09408571	chr1:101003634	GPR88	-0.23	-5.28	-0.32	2.85e-7	Monocyte count;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.27	-5.3	-0.32	2.61e-7	Lymphocyte counts;
KIRP	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.23	-0.46	1.13e-14	Retinal vascular caliber;
KIRP	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.52	6.35	0.38	1.03e-9	Subjective well-being;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19850565	chr19:35168394	ZNF302	0.52	6.17	0.37	2.76e-9	Smoking initiation;
KIRP	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs981844	0.725	rs872453	chr4:154727131	T/C	cg14289246	chr4:154710475	SFRP2	0.57	6.96	0.41	3.12e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.82	-12.09	-0.61	1.04e-26	Total body bone mineral density;
KIRP	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg05347473	chr6:146136440	FBXO30	0.56	7.77	0.44	2.07e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.75	-0.4	1.03e-10	Obesity-related traits;
KIRP	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08439880	chr3:133502540	NA	-0.57	-6.92	-0.4	3.95e-11	Iron status biomarkers;
KIRP	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.11	-0.31	6.62e-7	Triglycerides;
KIRP	trans	rs61440199	1.000	rs73818808	chr3:20136085	T/C	cg08354614	chr10:80673607	NA	0.57	6.38	0.38	8.63e-10	Staphylococcus aureus nasal carriage (intermittent);
KIRP	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.62	0.34	5.12e-8	Blood protein levels;
KIRP	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27297192	chr10:134578999	INPP5A	0.58	7.28	0.42	4.62e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg12369402	chr1:90227771	NA	-0.36	-5.28	-0.32	2.83e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18745217	chr4:56215882	SRD5A3	-0.48	-6.35	-0.38	1.06e-9	Inflammatory biomarkers;
KIRP	cis	rs7851660	0.679	rs7033765	chr9:100591705	A/T	cg13688889	chr9:100608707	NA	0.7	9.9	0.53	1.13e-19	Strep throat;
KIRP	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg19575753	chr5:1948995	NA	-0.42	-4.9	-0.3	1.75e-6	Gut microbiome composition (winter);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg11184682	chr3:50365769	TUSC2	0.53	6.05	0.36	5.42e-9	Sleep duration;
KIRP	cis	rs11608355	0.846	rs35393419	chr12:109881809	C/T	cg05360138	chr12:110035743	NA	0.64	6.7	0.39	1.38e-10	Neuroticism;
KIRP	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.65	9.4	0.51	3.83e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg04310649	chr10:35416472	CREM	-0.52	-5.93	-0.35	1.03e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.67e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24202620	chr15:23034457	NIPA2	0.46	6.38	0.38	8.95e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6681460	0.649	rs967322	chr1:67003446	C/T	cg13052034	chr1:66999238	SGIP1	0.42	5.87	0.35	1.43e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs10761482	0.813	rs10509130	chr10:62121112	C/T	cg01186212	chr10:62110162	ANK3	-0.29	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg07395648	chr5:131743802	NA	-0.51	-7.4	-0.43	2.09e-12	Blood metabolite levels;
KIRP	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.11	-0.41	1.24e-11	Systemic lupus erythematosus;
KIRP	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	9.14	0.5	2.33e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs78487399	0.710	rs6743071	chr2:43586287	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.04	-0.31	9.19e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg00024416	chr22:24240387	NA	-0.36	-5.13	-0.31	5.81e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg05861140	chr6:150128134	PCMT1	-0.45	-6.29	-0.37	1.47e-9	Lung cancer;
KIRP	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg07775547	chr4:1625484	NA	-0.43	-5.28	-0.32	2.9e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.12	-0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg26752003	chr8:145688521	CYHR1	-0.48	-5.79	-0.35	2.12e-8	Age at first birth;
KIRP	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg24826892	chr11:71159390	DHCR7	0.43	4.85	0.3	2.17e-6	Vitamin D levels;
KIRP	cis	rs7582180	0.838	rs4851284	chr2:100894887	C/T	cg14675211	chr2:100938903	LONRF2	0.56	6.83	0.4	6.48e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	7.18	0.42	8.38e-12	Mean corpuscular hemoglobin;
KIRP	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg13482628	chr17:19912719	NA	0.59	8.23	0.46	1.09e-14	Schizophrenia;
KIRP	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg07777115	chr5:623756	CEP72	-0.61	-6.17	-0.37	2.8e-9	Obesity-related traits;
KIRP	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg23815491	chr16:72088622	HP	0.39	6.29	0.37	1.41e-9	Fibrinogen levels;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg07402062	chr16:89894098	SPIRE2	0.33	7.29	0.42	4.31e-12	Vitiligo;
KIRP	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.89	12.8	0.63	4.49e-29	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg07701084	chr6:150067640	NUP43	0.54	6.97	0.41	2.87e-11	Lung cancer;
KIRP	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4776059	1.000	rs3751614	chr15:52901638	T/C	cg25063058	chr15:52860530	ARPP19	0.59	6.56	0.39	3.22e-10	Schizophrenia;
KIRP	cis	rs12049351	0.774	rs12024146	chr1:229660891	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.52	-0.33	8.56e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11987759	chr7:65425863	GUSB	0.51	6.87	0.4	5.35e-11	Aortic root size;
KIRP	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg11569703	chr11:65557185	OVOL1	0.78	15.18	0.7	3.63e-37	Acne (severe);
KIRP	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg05085585	chr16:30420623	ZNF771	0.33	5.1	0.31	6.64e-7	Tonsillectomy;
KIRP	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	1.15	9.34	0.51	5.98e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-5.1	-0.31	6.93e-7	P wave terminal force;
KIRP	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.73	11.93	0.61	3.33e-26	Cancer;
KIRP	cis	rs11758351	0.660	rs6918339	chr6:26211780	G/C	cg01420254	chr6:26195488	NA	0.58	5.73	0.34	2.94e-8	Gout;Renal underexcretion gout;
KIRP	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg13409248	chr3:40428643	ENTPD3	0.37	5.03	0.31	9.28e-7	Renal cell carcinoma;
KIRP	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.57	-0.39	3.06e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs909341	0.678	rs6011018	chr20:62303622	T/G	cg01311341	chr22:25575246	KIAA1671	0.63	7.31	0.42	3.8e-12	Atopic dermatitis;
KIRP	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.92	14.01	0.67	3.6e-33	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27430961	chr16:77246657	SYCE1L	0.45	6.11	0.36	3.93e-9	Parkinson's disease;
KIRP	cis	rs4006360	0.610	rs4986661	chr17:39250448	C/G	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836633	0.895	rs2212606	chr21:40044940	A/C	cg05519781	chr21:40033154	ERG	0.51	6.83	0.4	6.74e-11	Coronary artery disease;
KIRP	cis	rs3789045	1.000	rs3747631	chr1:204587569	G/C	cg08641003	chr1:204589008	LRRN2	-0.59	-6.15	-0.37	3.1e-9	Educational attainment (college completion);
KIRP	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg27147174	chr7:100797783	AP1S1	-0.72	-9.27	-0.51	9.93e-18	Life satisfaction;
KIRP	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs77633900	0.685	rs2469556	chr15:76650148	G/A	cg21673338	chr15:77095150	SCAPER	-0.6	-5.53	-0.33	7.98e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.38	-6.91	-0.4	4.12e-11	Renal cell carcinoma;
KIRP	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg17143192	chr8:8559678	CLDN23	0.71	8.33	0.47	5.6e-15	Obesity-related traits;
KIRP	cis	rs12282928	0.885	rs10838874	chr11:48347140	T/C	cg26585981	chr11:48327164	OR4S1	0.52	6.26	0.37	1.69e-9	Migraine - clinic-based;
KIRP	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.58	7.42	0.43	1.87e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg23340505	chr13:114927933	NA	0.32	4.98	0.3	1.18e-6	Schizophrenia;
KIRP	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.94	14.42	0.68	1.46e-34	Triglycerides;
KIRP	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4281086	0.603	rs6601475	chr8:10354972	A/G	cg21775007	chr8:11205619	TDH	0.41	5.38	0.32	1.73e-7	Obesity-related traits;
KIRP	cis	rs9393692	0.577	rs9358914	chr6:26262063	G/T	cg00631329	chr6:26305371	NA	-0.67	-8.17	-0.46	1.62e-14	Educational attainment;
KIRP	cis	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.66	-0.34	4.22e-8	HDL cholesterol;
KIRP	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-1.01	-16.76	-0.73	1.41e-42	Height;
KIRP	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.85	6.74	0.39	1.1e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.45	4.94	0.3	1.46e-6	Psoriasis;
KIRP	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg19731401	chr7:2775893	GNA12	0.73	6.94	0.4	3.55e-11	Childhood ear infection;
KIRP	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.42	-5.12	-0.31	6.16e-7	Melanoma;
KIRP	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.38	-5.28	-0.32	2.88e-7	Electroencephalogram traits;
KIRP	cis	rs11155671	0.530	rs9371504	chr6:150184080	A/T	cg07701084	chr6:150067640	NUP43	0.59	7.64	0.44	4.93e-13	Testicular germ cell tumor;
KIRP	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg26207909	chr14:103986467	CKB	-0.43	-5.21	-0.32	3.96e-7	Coronary artery disease;
KIRP	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	1.07	22.78	0.82	1.54e-62	Parkinson's disease;
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.86	-0.35	1.48e-8	Life satisfaction;
KIRP	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	0.87	7.01	0.41	2.34e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6088813	1.000	rs6088820	chr20:33987298	T/C	cg14752227	chr20:34000481	UQCC	-0.5	-6.49	-0.38	4.8e-10	Height;
KIRP	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg24692254	chr21:30365293	RNF160	0.68	9.01	0.5	6.03e-17	Pancreatic cancer;
KIRP	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg17133734	chr15:86042851	AKAP13	0.45	5.58	0.34	6.25e-8	Coronary artery disease;
KIRP	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-6.46	-0.38	5.66e-10	Response to antipsychotic treatment;
KIRP	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.64	7.02	0.41	2.17e-11	Smoking initiation;
KIRP	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.47	-0.48	2.28e-15	Myopia (pathological);
KIRP	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg00147788	chr6:125855365	NA	-0.3	-4.85	-0.3	2.15e-6	Brugada syndrome;
KIRP	cis	rs738322	0.839	rs2413505	chr22:38592967	G/A	cg17652424	chr22:38574118	PLA2G6	0.28	5.69	0.34	3.54e-8	Cutaneous nevi;
KIRP	cis	rs533123	0.818	rs618886	chr1:29170005	T/C	cg08366446	chr1:29138936	OPRD1	0.65	6.25	0.37	1.83e-9	Schizophrenia;
KIRP	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.91	-14.81	-0.69	6.34e-36	Urate levels in lean individuals;
KIRP	cis	rs8077577	0.747	rs12451698	chr17:18237116	A/G	cg18869244	chr17:18121946	NA	0.45	5.06	0.31	8.21e-7	Obesity-related traits;
KIRP	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.25	-0.47	9.82e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg12560992	chr17:57184187	TRIM37	0.59	5.61	0.34	5.32e-8	Cognitive test performance;
KIRP	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.56	6.84	0.4	6.39e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.87	-13.17	-0.64	2.49e-30	Longevity;
KIRP	cis	rs4908768	0.871	rs11121221	chr1:8767529	A/G	cg25722041	chr1:8623473	RERE	0.49	6.45	0.38	5.98e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs953387	1.000	rs953387	chr2:136907170	A/C	cg05194412	chr2:137003533	NA	-0.4	-5.18	-0.31	4.52e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.75	9.89	0.53	1.27e-19	Morning vs. evening chronotype;
KIRP	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	trans	rs7493138	0.967	rs1476402	chr14:28997927	A/G	cg08496086	chr5:2176142	NA	0.45	6.1	0.36	4.14e-9	Longevity;
KIRP	cis	rs1497828	0.871	rs2815238	chr1:217543384	T/A	cg04411442	chr1:217543379	NA	0.45	6.49	0.38	4.58e-10	Dialysis-related mortality;
KIRP	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.37	-0.38	9.31e-10	Coronary artery disease;
KIRP	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-10.23	-0.55	1.1e-20	Bladder cancer;
KIRP	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.11	-0.41	1.22e-11	Response to antipsychotic treatment;
KIRP	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	1.22	11.23	0.58	6.87e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6142102	0.581	rs4911148	chr20:32668244	A/G	cg08999081	chr20:33150536	PIGU	0.39	5.04	0.31	9.24e-7	Skin pigmentation;
KIRP	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.64	-8.65	-0.48	6.95e-16	Cognitive test performance;
KIRP	cis	rs10875746	0.551	rs3751273	chr12:48739438	T/C	cg20731937	chr12:48336164	NA	0.46	5.61	0.34	5.32e-8	Longevity (90 years and older);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17665260	chr19:55814068	BRSK1	0.59	6.26	0.37	1.67e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg08761264	chr16:28874980	SH2B1	-0.48	-5.56	-0.33	7.17e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg12738264	chr7:148725795	PDIA4	0.57	6.65	0.39	1.9e-10	Sleep duration;
KIRP	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.23	6.45	0.38	5.81e-10	Type 2 diabetes;
KIRP	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg24110177	chr3:50126178	RBM5	-0.62	-7.81	-0.45	1.65e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.3	-0.32	2.53e-7	Parkinson's disease;
KIRP	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg18154014	chr19:37997991	ZNF793	0.61	6.68	0.39	1.57e-10	Coronary artery calcification;
KIRP	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.71	8.38	0.47	4e-15	Obesity-related traits;
KIRP	cis	rs11955398	0.585	rs6887434	chr5:60035420	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.35	-0.32	1.99e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9367716	0.917	rs1013146	chr6:57125043	G/A	cg03371099	chr6:57305889	PRIM2	0.45	5.94	0.35	9.52e-9	Coronary artery disease;
KIRP	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.64	9.84	0.53	1.77e-19	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.52	-0.43	1.04e-12	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.91	15.18	0.7	3.6e-37	Metabolic syndrome;
KIRP	cis	rs6959887	0.548	rs1861095	chr7:35305324	G/T	cg06685737	chr7:35301730	NA	-0.62	-10.31	-0.55	6.04e-21	Birth weight;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg05777319	chr3:97483919	ARL6	-0.48	-6.18	-0.37	2.64e-9	Bladder cancer;
KIRP	trans	rs1106684	1.000	rs73148846	chr7:131464201	C/T	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs834811	0.829	rs10252049	chr7:135903178	G/A	cg01726295	chr7:135938950	NA	-0.37	-5.02	-0.3	9.94e-7	Post-traumatic stress disorder;
KIRP	cis	rs2708977	0.698	rs772161	chr2:97043803	C/A	cg01950434	chr2:97203154	ARID5A	-0.41	-5.43	-0.33	1.34e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.43	-5.48	-0.33	1.06e-7	Menarche (age at onset);
KIRP	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg19554555	chr3:13937349	NA	-0.46	-6.28	-0.37	1.49e-9	Ovarian reserve;
KIRP	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg00360474	chr6:37504404	NA	-0.53	-7.71	-0.44	3.03e-13	Cognitive performance;
KIRP	cis	rs9314323	0.737	rs7818293	chr8:26264116	C/A	cg13160058	chr8:26243215	BNIP3L	0.49	6.64	0.39	2.01e-10	Red cell distribution width;
KIRP	cis	rs9475752	0.793	rs13214255	chr6:56830549	G/T	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.07	-8.97	-0.5	7.95e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4356932	0.967	rs7436646	chr4:76955229	T/G	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24923311	chr20:30697516	TM9SF4	0.53	6.05	0.36	5.25e-9	Lung cancer in ever smokers;
KIRP	cis	rs6681460	1.000	rs7524818	chr1:67072031	C/T	cg13052034	chr1:66999238	SGIP1	0.38	5.18	0.31	4.56e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.7	7.85	0.45	1.25e-13	Obesity-related traits;
KIRP	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-9.86	-0.53	1.52e-19	Coronary artery disease;
KIRP	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs2224391	0.628	rs2753234	chr6:5251050	G/A	cg13962347	chr6:5174647	LYRM4	-0.72	-9.98	-0.54	6.29e-20	Height;
KIRP	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg26354017	chr1:205819088	PM20D1	-0.45	-4.98	-0.3	1.18e-6	Parkinson's disease;
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg17286790	chr17:80096513	CCDC57	-0.43	-6.26	-0.37	1.67e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	9.39	0.51	4.15e-18	Total body bone mineral density;
KIRP	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.82	0.49	2.11e-16	Motion sickness;
KIRP	trans	rs1864585	0.520	rs73208766	chr8:10664537	C/T	cg26278703	chr11:58910052	FAM111A	0.65	6.45	0.38	5.96e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg16255804	chr6:135334527	HBS1L	-0.33	-5.37	-0.32	1.78e-7	Red blood cell count;
KIRP	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg03929089	chr4:120376271	NA	0.7	6.14	0.36	3.33e-9	Axial length;
KIRP	cis	rs73195822	0.667	rs7967408	chr12:111164408	A/C	cg12870014	chr12:110450643	ANKRD13A	0.49	4.85	0.3	2.22e-6	Itch intensity from mosquito bite;
KIRP	cis	rs10875746	0.859	rs12305511	chr12:48582716	C/T	cg20731937	chr12:48336164	NA	-0.42	-5.44	-0.33	1.28e-7	Longevity (90 years and older);
KIRP	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg11555438	chr13:111297484	CARS2	-0.3	-4.94	-0.3	1.44e-6	Coronary artery disease;
KIRP	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg08807101	chr21:30365312	RNF160	-0.43	-5.16	-0.31	5.1e-7	Pancreatic cancer;
KIRP	cis	rs9309711	0.736	rs13409102	chr2:3496321	G/A	cg10845886	chr2:3471009	TTC15	-0.73	-9.62	-0.52	8.38e-19	Neurofibrillary tangles;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17203840	chr5:134209212	TXNDC15	0.46	6.02	0.36	6.33e-9	Interleukin-4 levels;
KIRP	cis	rs524023	0.874	rs495130	chr11:64449307	C/T	cg09231725	chr11:64357281	SLC22A12	0.59	7.89	0.45	9.83e-14	Urate levels in obese individuals;
KIRP	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	cis	rs11673344	0.566	rs185369	chr19:37867039	T/C	cg14683738	chr19:37701593	ZNF585B	0.46	5.41	0.33	1.47e-7	Obesity-related traits;
KIRP	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg20573242	chr4:122745356	CCNA2	0.48	5.05	0.31	8.72e-7	Type 2 diabetes;
KIRP	cis	rs1434579	0.897	rs2037904	chr19:44945091	A/G	cg15540054	chr19:45004280	ZNF180	0.52	5.72	0.34	3.12e-8	Tuberculosis;
KIRP	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.61	8.63	0.48	7.73e-16	Multiple system atrophy;
KIRP	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.3	-5.29	-0.32	2.68e-7	Dupuytren's disease;
KIRP	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	trans	rs1864585	0.520	rs55848210	chr8:10693727	T/C	cg26278703	chr11:58910052	FAM111A	0.63	6.27	0.37	1.59e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	7.81	0.45	1.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs13401104	0.716	rs11682806	chr2:237138825	A/T	cg26422059	chr2:237146110	ASB18	0.51	5.22	0.32	3.77e-7	Educational attainment;
KIRP	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg22676075	chr6:135203613	NA	0.5	7.41	0.43	2.01e-12	Red blood cell count;
KIRP	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg20578329	chr17:80767326	TBCD	0.46	5.43	0.33	1.32e-7	Glycated hemoglobin levels;
KIRP	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-7.3	-0.42	4.01e-12	Colorectal cancer;
KIRP	cis	rs710987	1.000	rs710989	chr5:3523131	C/T	cg14530963	chr5:3489551	NA	0.39	4.88	0.3	1.92e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.14	-0.36	3.22e-9	Neuroticism;
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs11779988	0.501	rs3760	chr8:17886345	T/C	cg01800426	chr8:17659068	MTUS1	-0.48	-4.93	-0.3	1.52e-6	Breast cancer;
KIRP	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-1.03	-10.4	-0.55	3.03e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7084402	0.935	rs4948523	chr10:60339098	A/C	cg05938607	chr10:60274200	BICC1	-0.41	-10.06	-0.54	3.71e-20	Refractive error;
KIRP	cis	rs78487399	0.808	rs13414619	chr2:43699406	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.41	-0.33	1.49e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05025164	chr4:1340916	KIAA1530	-0.53	-6.94	-0.4	3.49e-11	Obesity-related traits;
KIRP	cis	rs6840360	0.557	rs4696261	chr4:152322659	C/G	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.71	0.44	3.07e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7236492	0.630	rs8086439	chr18:77173038	A/G	cg15644404	chr18:77186268	NFATC1	-1.0	-6.34	-0.37	1.09e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs888194	0.677	rs7973253	chr12:109878115	A/G	cg19025524	chr12:109796872	NA	-0.37	-5.07	-0.31	7.91e-7	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09236130	chr13:27330614	GPR12	0.52	7.28	0.42	4.44e-12	Interleukin-4 levels;
KIRP	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.84	12.31	0.62	1.91e-27	Eosinophil percentage of white cells;
KIRP	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg26681399	chr22:41777847	TEF	0.55	5.32	0.32	2.37e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg23752985	chr2:85803571	VAMP8	0.56	8.04	0.46	3.78e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg21734707	chr17:3908241	ZZEF1	-0.6	-8.86	-0.49	1.61e-16	Type 2 diabetes;
KIRP	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg24296786	chr1:45957014	TESK2	-0.41	-5.13	-0.31	5.89e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6832769	0.826	rs58894703	chr4:56358538	G/A	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.68	6.9	0.4	4.38e-11	Corneal astigmatism;
KIRP	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.2	-0.51	1.59e-17	Brugada syndrome;
KIRP	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.61	-5.21	-0.32	4.05e-7	Putamen volume;
KIRP	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg26876637	chr1:152193138	HRNR	0.75	9.63	0.52	7.62e-19	Atopic dermatitis;
KIRP	cis	rs1143633	0.509	rs2068777	chr2:113696126	A/G	cg12858261	chr2:113808755	IL1F8	0.46	5.36	0.32	1.91e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.15e-51	Height;
KIRP	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27297192	chr10:134578999	INPP5A	0.63	7.82	0.45	1.59e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.72	-10.85	-0.57	1.18e-22	Hepatocellular carcinoma;
KIRP	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg04306507	chr14:55594613	LGALS3	0.52	8.01	0.45	4.7e-14	Protein biomarker;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15805921	chr6:42952109	PPP2R5D	0.59	6.71	0.39	1.36e-10	Lung cancer in ever smokers;
KIRP	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	7.96	0.45	6.24e-14	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg20673091	chr1:2541236	MMEL1	0.44	6.18	0.37	2.7e-9	Ulcerative colitis;
KIRP	cis	rs35123781	0.533	rs7728485	chr5:139077144	A/G	cg10513866	chr5:139070639	NA	0.55	7.73	0.44	2.66e-13	Schizophrenia;
KIRP	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.27	26.37	0.86	1.25e-73	IgG glycosylation;
KIRP	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	8.15	0.46	1.86e-14	Mood instability;
KIRP	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg19077165	chr18:44547161	KATNAL2	-0.55	-6.93	-0.4	3.72e-11	Educational attainment;
KIRP	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg06026331	chr20:60912101	LAMA5	0.45	5.67	0.34	3.92e-8	Pelvic organ prolapse;
KIRP	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg18833306	chr6:118973337	C6orf204	0.4	5.05	0.31	8.78e-7	Electrocardiographic conduction measures;
KIRP	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.32	-0.37	1.25e-9	Retinal vascular caliber;
KIRP	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.62	-6.59	-0.39	2.6200000000000003e-10	DNA methylation (variation);
KIRP	cis	rs4929947	0.515	rs67191473	chr11:8552190	A/G	cg08015107	chr11:8618950	NA	-0.72	-8.83	-0.49	1.99e-16	Menarche (age at onset);
KIRP	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.44	-0.33	1.26e-7	Personality dimensions;
KIRP	cis	rs9928842	0.824	rs889515	chr16:75251299	T/C	cg09066997	chr16:75300724	BCAR1	0.6	4.96	0.3	1.29e-6	Alcoholic chronic pancreatitis;
KIRP	cis	rs684232	0.666	rs2254134	chr17:628664	A/G	cg15660573	chr17:549704	VPS53	-0.78	-11.69	-0.6	2.15e-25	Prostate cancer;
KIRP	cis	rs2380205	0.689	rs12359234	chr10:5902711	G/T	cg27141509	chr10:5886111	NA	0.39	5.57	0.33	6.73e-8	Breast cancer;
KIRP	cis	rs60154123	0.730	rs679042	chr1:210457122	A/G	cg09074223	chr1:210466472	NA	0.58	6.21	0.37	2.28e-9	Coronary artery disease;
KIRP	cis	rs17065868	1.000	rs9805321	chr13:45094447	A/G	cg10246903	chr13:45222710	NA	-0.67	-7.15	-0.42	9.59e-12	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7766436	0.845	rs1342207	chr6:22587762	G/A	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg14345882	chr6:26364793	BTN3A2	0.54	4.98	0.3	1.21e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.49	6.42	0.38	6.9e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6125597	0.967	rs6122781	chr20:47903826	T/G	cg03212862	chr20:47662828	CSE1L	-0.41	-5.29	-0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg11189052	chr15:85197271	WDR73	0.48	4.96	0.3	1.31e-6	Schizophrenia;
KIRP	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.87	-11.18	-0.58	1.01e-23	Parkinson's disease;
KIRP	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg25390334	chr2:241827778	C2orf54	-0.34	-4.86	-0.3	2.08e-6	Urinary metabolites;
KIRP	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.43	5.25	0.32	3.33e-7	Iron status biomarkers;
KIRP	cis	rs10073892	0.511	rs6596505	chr5:101881166	A/T	cg19774478	chr5:101632501	SLCO4C1	0.51	5.54	0.33	7.59e-8	Cognitive decline (age-related);
KIRP	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg00666640	chr1:248458726	OR2T12	0.46	5.55	0.33	7.33e-8	Common traits (Other);
KIRP	cis	rs4684776	0.676	rs2067471	chr3:11299602	A/G	cg00170343	chr3:11313890	ATG7	-0.49	-4.87	-0.3	1.97e-6	Small vessel stroke;
KIRP	cis	rs6539288	0.803	rs7305715	chr12:107326552	G/A	cg26297688	chr12:107349093	C12orf23	-0.38	-5.23	-0.32	3.7e-7	Total body bone mineral density;
KIRP	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.04	0.41	1.93e-11	Bipolar disorder;
KIRP	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08026941	chr19:17336882	OCEL1	0.46	6.05	0.36	5.24e-9	Parkinson's disease;
KIRP	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.58	6.75	0.4	1.03e-10	Height;
KIRP	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg09873164	chr1:152488093	CRCT1	0.56	7.45	0.43	1.6e-12	Hair morphology;
KIRP	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg18016565	chr1:150552671	MCL1	0.36	5.54	0.33	7.82e-8	Melanoma;
KIRP	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.88	-13.95	-0.66	5.68e-33	Height;
KIRP	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg10167378	chr1:228756711	NA	0.51	5.77	0.35	2.32e-8	Diastolic blood pressure;
KIRP	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.6	-5.08	-0.31	7.62e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.57	7.01	0.41	2.25e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg13147721	chr7:65941812	NA	1.05	7.4	0.43	2.09e-12	Diabetic kidney disease;
KIRP	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-0.57	-4.99	-0.3	1.12e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs4699052	1.000	rs7661702	chr4:104140129	C/G	cg16532752	chr4:104119610	CENPE	-0.4	-5.1	-0.31	6.81e-7	Testicular germ cell tumor;
KIRP	cis	rs62355272	0.965	rs1494571	chr5:35880087	G/C	cg13894535	chr5:35919491	CAPSL	-0.51	-5.7	-0.34	3.46e-8	Lymphocyte counts;
KIRP	trans	rs7246760	1.000	rs10412903	chr19:9880927	C/A	cg02900749	chr2:68251473	NA	-0.96	-8.77	-0.49	3e-16	Pursuit maintenance gain;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg00777555	chr3:57583074	ARF4	-0.49	-6.04	-0.36	5.57e-9	Type 1 diabetes nephropathy;
KIRP	trans	rs76288851	0.799	rs7627238	chr3:126495481	G/A	cg13821433	chr2:26726535	OTOF	0.55	6.3	0.37	1.34e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-1.03	-12.12	-0.61	7.75e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.87	0.35	1.4e-8	Motion sickness;
KIRP	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.32	-0.32	2.29e-7	Pulmonary function;
KIRP	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.95	-16.66	-0.73	3.13e-42	Blood protein levels;
KIRP	trans	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg20993868	chr7:22813445	NA	0.44	6.71	0.39	1.3100000000000001e-10	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg04438997	chr17:70115868	SOX9	0.38	5.48	0.33	1.06e-7	Thyroid hormone levels;
KIRP	cis	rs61884328	0.733	rs79044335	chr11:47200402	G/C	cg23433285	chr11:47201945	PACSIN3	0.68	5.27	0.32	2.99e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.06	0.46	3.39e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.5	6.03	0.36	5.85e-9	Height;
KIRP	cis	rs259842	0.830	rs187745	chr2:180699771	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.58	-0.34	6.22e-8	Blood protein levels;
KIRP	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg07636037	chr3:49044803	WDR6	-0.72	-6.85	-0.4	5.92e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.45	-5.92	-0.35	1.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1629083	0.935	rs1793149	chr11:118127347	A/G	cg18857871	chr11:118064634	AMICA1	0.69	10.07	0.54	3.38e-20	Lung cancer;
KIRP	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	1.06	14.42	0.68	1.38e-34	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11363513	chr4:151508942	LRBA	-0.4	-6.28	-0.37	1.51e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7737355	0.773	rs32112	chr5:131048122	G/A	cg25547332	chr5:131281432	NA	0.39	4.85	0.3	2.23e-6	Life satisfaction;
KIRP	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.72	-8.47	-0.47	2.32e-15	Resting heart rate;
KIRP	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg00631329	chr6:26305371	NA	-0.73	-9.48	-0.52	2.3e-18	Educational attainment;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg03152288	chr2:177042942	NA	0.68	9.53	0.52	1.54e-18	IgG glycosylation;
KIRP	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.88	-13.51	-0.65	1.75e-31	Schizophrenia;
KIRP	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-9.9	-0.53	1.16e-19	Alzheimer's disease;
KIRP	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	5.85	0.35	1.6e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13786513	chr19:45648562	NA	-0.52	-6.73	-0.39	1.18e-10	Parkinson's disease;
KIRP	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.72	-5.88	-0.35	1.3e-8	Diabetic retinopathy;
KIRP	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs11608355	0.521	rs10850131	chr12:109837052	A/G	cg19025524	chr12:109796872	NA	0.47	6.48	0.38	4.98e-10	Neuroticism;
KIRP	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg15979348	chr13:112237479	NA	0.41	5.41	0.33	1.5e-7	Menarche (age at onset);
KIRP	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.85	7.0	0.41	2.42e-11	Major depressive disorder;
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.55	-5.69	-0.34	3.61e-8	Lung function (FEV1/FVC);
KIRP	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.32	16.08	0.72	2.96e-40	Corneal structure;
KIRP	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.24	-0.42	5.82e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.87	0.35	1.4e-8	Platelet count;
KIRP	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.39	-5.76	-0.34	2.56e-8	Pubertal anthropometrics;
KIRP	cis	rs7546668	0.947	rs4233538	chr1:15849855	G/T	cg21858823	chr1:15850916	CASP9	0.46	5.13	0.31	5.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19524238	chr7:2802976	GNA12	-0.36	-4.89	-0.3	1.82e-6	Height;
KIRP	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg06533319	chr4:3265114	C4orf44	0.57	6.69	0.39	1.53e-10	Parental longevity (mother's age at death);
KIRP	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg21684588	chr1:67600265	NA	0.43	4.99	0.3	1.16e-6	Psoriasis;
KIRP	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-1.03	-12.2	-0.61	4.5e-27	Breast cancer;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg14323456	chr7:151205434	RHEB	-0.44	-6.03	-0.36	6.04e-9	Select biomarker traits;
KIRP	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg07810366	chr2:100720526	AFF3	-0.38	-6.95	-0.41	3.27e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg07636037	chr3:49044803	WDR6	0.54	5.12	0.31	6.26e-7	Menarche (age at onset);
KIRP	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.74	8.75	0.49	3.49e-16	Corneal astigmatism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17932484	chr13:24463526	MIPEP;PCOTH	0.49	6.14	0.36	3.26e-9	Myopia (pathological);
KIRP	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg04691961	chr3:161091175	C3orf57	-0.54	-8.24	-0.47	1.01e-14	Morning vs. evening chronotype;
KIRP	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-0.93	-8.32	-0.47	6.1e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.96	15.44	0.7	4.65e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.38	-4.84	-0.3	2.27e-6	Platelet count;
KIRP	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg02297831	chr4:17616191	MED28	0.61	7.81	0.45	1.7e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1975991	0.765	rs1871518	chr3:187948972	G/A	cg17585528	chr3:187988060	LPP	-0.45	-5.06	-0.31	8.27e-7	White matter integrity (bipolar disorder risk interaction);
KIRP	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.27	-0.42	4.64e-12	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00931619	chr1:6052495	NPHP4	0.47	6.16	0.37	2.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.49	-7.28	-0.42	4.59e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg10047753	chr17:41438598	NA	0.86	12.03	0.61	1.6e-26	Menopause (age at onset);
KIRP	cis	rs11945232	1.000	rs13113575	chr4:88327224	G/A	cg23841344	chr4:88312519	HSD17B11	-0.72	-8.8	-0.49	2.49e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.18	-0.42	8.46e-12	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg00495681	chr13:53174319	NA	0.4	5.36	0.32	1.87e-7	Lewy body disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14284404	chr1:118472380	GDAP2;WDR3	0.45	6.39	0.38	8.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg01849789	chr22:41697279	ZC3H7B	-0.4	-4.97	-0.3	1.23e-6	Neuroticism;
KIRP	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-10.2	-0.55	1.34e-20	Myopia (pathological);
KIRP	cis	rs662064	0.748	rs12375	chr1:10596341	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-5.18	-0.31	4.65e-7	Asthma;
KIRP	cis	rs3857747	0.931	rs4613890	chr7:40381031	A/C	cg00420559	chr7:40367873	C7orf10	-0.59	-8.12	-0.46	2.19e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.43	8.52	0.48	1.65e-15	Coronary artery disease;
KIRP	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.71	9.01	0.5	5.88e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg23307798	chr14:103986281	CKB	0.49	7.1	0.41	1.31e-11	Body mass index;
KIRP	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.28	17.93	0.75	1.56e-46	Corneal structure;
KIRP	cis	rs2625529	0.730	rs2957373	chr15:72340929	T/C	cg16672083	chr15:72433130	SENP8	0.46	6.37	0.38	9.09e-10	Red blood cell count;
KIRP	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.6	7.85	0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs4919044	0.641	rs11187232	chr10:94737477	A/G	cg05127821	chr10:94822908	CYP26C1	-1.03	-8.32	-0.47	6.01e-15	Coronary artery disease;
KIRP	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.76	11.81	0.6	8.38e-26	Schizophrenia;
KIRP	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.75	-0.49	3.52e-16	Mood instability;
KIRP	cis	rs7577696	0.568	rs7562653	chr2:32478629	T/C	cg02381751	chr2:32503542	YIPF4	0.52	5.28	0.32	2.85e-7	Inflammatory biomarkers;
KIRP	cis	rs6504622	0.577	rs197915	chr17:44990522	A/G	cg16759221	chr17:45003025	GOSR2	-0.34	-5.2	-0.31	4.28e-7	Orofacial clefts;
KIRP	cis	rs1440410	0.835	rs4234886	chr4:144124492	G/A	cg01719995	chr4:144104893	USP38	0.45	6.24	0.37	1.92e-9	Ischemic stroke;
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.57	-8.69	-0.48	5.06e-16	Lymphocyte counts;
KIRP	cis	rs10875746	0.903	rs11168403	chr12:48484958	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.82	9.78	0.53	2.76e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.53	-6.92	-0.4	3.91e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs4356932	1.000	rs7699624	chr4:76962631	G/T	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs12973672	1.000	rs8101606	chr19:35774556	A/C	cg12095397	chr19:35769544	USF2	0.63	6.57	0.39	2.9e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg13289132	chr10:30722225	MAP3K8	0.41	5.22	0.32	3.81e-7	Inflammatory bowel disease;
KIRP	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg08885076	chr2:99613938	TSGA10	-0.55	-9.67	-0.52	6.06e-19	Chronic sinus infection;
KIRP	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	5.77	0.35	2.41e-8	Blood metabolite levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09311052	chr1:154531418	UBE2Q1	-0.49	-6.14	-0.36	3.22e-9	Neuroticism;
KIRP	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg25019033	chr10:957182	NA	-0.52	-5.7	-0.34	3.38e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-10.16	-0.54	1.82e-20	Schizophrenia;
KIRP	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.15e-51	Height;
KIRP	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg00806126	chr19:22604979	ZNF98	0.64	6.74	0.39	1.14e-10	Pain;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-8.49	-0.48	1.92e-15	Colorectal cancer;
KIRP	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg25547332	chr5:131281432	NA	0.49	5.4	0.33	1.55e-7	Life satisfaction;
KIRP	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.48	5.91	0.35	1.14e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.5	6.54	0.38	3.49e-10	Breast cancer;
KIRP	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07234876	chr8:600039	NA	1.0	7.44	0.43	1.71e-12	IgG glycosylation;
KIRP	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-9.39	-0.51	4.19e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg00405596	chr8:11794950	NA	0.43	5.43	0.33	1.36e-7	Retinal vascular caliber;
KIRP	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg00405596	chr8:11794950	NA	0.52	7.03	0.41	2.07e-11	Mood instability;
KIRP	cis	rs11735612	0.624	rs62331775	chr4:138526021	G/A	cg12033966	chr4:138453416	PCDH18	0.36	5.01	0.3	1.04e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs73198271	1.000	rs4841030	chr8:8607011	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.62	-0.34	5.28e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2625529	0.526	rs16956623	chr15:72536695	T/C	cg16672083	chr15:72433130	SENP8	0.38	5.22	0.32	3.79e-7	Red blood cell count;
KIRP	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-6.8	-0.4	7.7e-11	Aortic root size;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.79	7.57	0.43	7.53e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs953387	0.869	rs1519525	chr2:136965117	C/T	cg05194412	chr2:137003533	NA	-0.38	-4.94	-0.3	1.43e-6	Arthritis (juvenile idiopathic);
KIRP	cis	rs754423	0.662	rs10145619	chr14:52510091	G/T	cg05884192	chr14:52515736	NID2	0.53	5.83	0.35	1.71e-8	Craniofacial microsomia;
KIRP	cis	rs1562975	0.609	rs55707402	chr4:109418264	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.42	5.2	0.31	4.22e-7	Height;
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.79	9.84	0.53	1.75e-19	Longevity;
KIRP	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.44	-0.38	6.19e-10	Response to antipsychotic treatment;
KIRP	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.48	-0.52	2.31e-18	Joint mobility (Beighton score);
KIRP	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.67	9.31	0.51	7.5e-18	Body mass index;
KIRP	trans	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-6.39	-0.38	8.16e-10	Neuroticism;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18402987	chr7:1209562	NA	0.45	5.33	0.32	2.27e-7	Longevity;Endometriosis;
KIRP	trans	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg09238957	chr16:46723420	ORC6L;VPS35	-0.51	-6.04	-0.36	5.67e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg25019033	chr10:957182	NA	-0.58	-7.2	-0.42	7.21e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg00361562	chr2:198649771	BOLL	-0.52	-5.13	-0.31	5.99e-7	Ulcerative colitis;
KIRP	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg11235152	chr1:67600687	NA	0.7	10.15	0.54	1.94e-20	Psoriasis;
KIRP	cis	rs2151522	0.563	rs6908339	chr6:127138103	A/G	cg21431617	chr6:127135037	NA	0.33	5.87	0.35	1.43e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	0.93	10.13	0.54	2.25e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg00106254	chr7:1943704	MAD1L1	-0.62	-6.84	-0.4	6.33e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs490234	0.702	rs13284551	chr9:128411969	C/T	cg14078157	chr9:128172775	NA	-0.66	-7.65	-0.44	4.58e-13	Mean arterial pressure;
KIRP	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.95	0.35	9.13e-9	Bipolar disorder;
KIRP	cis	rs6882076	1.000	rs12657266	chr5:156396003	C/T	cg12943317	chr5:156479607	HAVCR1	-0.6	-7.42	-0.43	1.88e-12	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.84	-12.94	-0.64	1.52e-29	IgG glycosylation;
KIRP	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.76	-7.94	-0.45	7.11e-14	Hair shape;
KIRP	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.67	7.72	0.44	2.92e-13	Arsenic metabolism;
KIRP	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	trans	rs800082	0.668	rs9821986	chr3:144292701	T/G	cg24215973	chr2:240111563	HDAC4	-0.57	-7.76	-0.44	2.29e-13	Smoking behavior;
KIRP	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg08499158	chr17:42289980	UBTF	0.46	5.95	0.35	8.94e-9	Total body bone mineral density;
KIRP	cis	rs7712401	0.540	rs27617	chr5:122236534	T/A	cg19412675	chr5:122181750	SNX24	0.49	5.17	0.31	4.75e-7	Mean platelet volume;
KIRP	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.32	-0.32	2.38e-7	Testicular germ cell tumor;
KIRP	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg17724175	chr1:150552817	MCL1	0.36	6.04	0.36	5.55e-9	Tonsillectomy;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg25703541	chr22:24373054	LOC391322	0.52	6.36	0.38	9.66e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02592615	chr6:12012261	HIVEP1	0.48	6.11	0.36	3.87e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11681126	chr10:44144525	ZNF32	0.52	6.52	0.38	3.95e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05916588	chr19:3700332	PIP5K1C	0.55	7.18	0.42	8.07e-12	Parkinson's disease;
KIRP	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg17443007	chr1:101659419	NA	0.4	5.58	0.34	6.26e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.45	-5.51	-0.33	9.03e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs290268	1.000	rs290268	chr9:93552450	A/G	cg02608019	chr9:93564028	SYK	0.8	11.03	0.58	2.92e-23	Platelet count;
KIRP	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg18165381	chr3:44552316	NA	-0.43	-5.07	-0.31	7.85e-7	Depressive symptoms;
KIRP	cis	rs2346160	1.000	rs6937935	chr6:167670223	T/C	cg27333441	chr6:167680455	NA	0.45	6.01	0.36	6.66e-9	Parental extreme longevity (95 years and older);
KIRP	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg00277334	chr10:82204260	NA	-0.45	-4.95	-0.3	1.41e-6	Post bronchodilator FEV1;
KIRP	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.96	-0.3	1.34e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs72627123	0.656	rs11159064	chr14:74614743	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.81	-4.94	-0.3	1.45e-6	Morning vs. evening chronotype;
KIRP	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.44	-6.05	-0.36	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.47	5.76	0.34	2.56e-8	Longevity;
KIRP	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	7.41	0.43	2.01e-12	Menarche (age at onset);
KIRP	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg20744362	chr22:50050164	C22orf34	0.31	4.88	0.3	1.91e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs2594989	0.943	rs2606748	chr3:11373989	T/C	cg01796438	chr3:11312864	ATG7	-0.72	-8.08	-0.46	2.92e-14	Circulating chemerin levels;
KIRP	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	4.97	0.3	1.26e-6	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06984945	chr6:26660160	ZNF322A	0.56	6.47	0.38	5.16e-10	Smoking initiation;
KIRP	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs17834760	0.955	rs62423545	chr6:62041599	A/G	cg24246628	chr6:168435914	KIF25	0.53	6.04	0.36	5.69e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.7	8.32	0.47	6.15e-15	Blood metabolite levels;
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.86	-0.45	1.21e-13	Platelet count;
KIRP	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg24699146	chr1:24152579	HMGCL	0.48	6.75	0.4	1.06e-10	Immature fraction of reticulocytes;
KIRP	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	4.85e-11	Blood metabolite levels;
KIRP	cis	rs4273100	0.646	rs6587216	chr17:19224397	G/C	cg25447019	chr17:19030144	GRAPL	0.48	6.09	0.36	4.34e-9	Schizophrenia;
KIRP	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.21	0.46	1.28e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.8	11.39	0.59	2.06e-24	Chronic sinus infection;
KIRP	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.71	-10.6	-0.56	7.37e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.52	0.43	1.03e-12	Educational attainment;
KIRP	cis	rs9972944	0.729	rs7502798	chr17:63781615	C/T	cg07283582	chr17:63770753	CCDC46	0.54	8.8	0.49	2.49e-16	Total body bone mineral density;
KIRP	cis	rs687432	0.688	rs1868881	chr11:57901176	A/G	cg19752551	chr11:57585705	CTNND1	0.58	7.85	0.45	1.25e-13	Parkinson's disease;
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg10305451	chr2:177043427	NA	0.53	7.46	0.43	1.53e-12	IgG glycosylation;
KIRP	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.55	-6.85	-0.4	5.93e-11	Iron status biomarkers;
KIRP	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.29	0.37	1.47e-9	Red blood cell count;
KIRP	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg26587870	chr6:27730563	NA	-0.65	-4.92	-0.3	1.56e-6	Breast cancer;
KIRP	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.1	0.31	6.73e-7	Lung cancer;
KIRP	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.68	9.01	0.5	5.71e-17	Bladder cancer;
KIRP	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.89	13.63	0.66	6.84e-32	Coronary artery disease;
KIRP	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg06636001	chr8:8085503	FLJ10661	0.52	5.87	0.35	1.41e-8	Myopia (pathological);
KIRP	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.07	18.77	0.77	2.23e-49	Triglycerides;
KIRP	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-15.43	-0.7	4.98e-38	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09096860	chr8:99057917	RPL30	0.47	6.76	0.4	9.75e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26717215	chr19:45347921	PVRL2	0.46	6.15	0.37	3.04e-9	Parkinson's disease;
KIRP	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg27494647	chr7:150038898	RARRES2	0.42	5.8	0.35	2e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs778371	0.788	rs2675959	chr2:233791988	T/A	cg08000102	chr2:233561755	GIGYF2	-0.54	-5.93	-0.35	1.01e-8	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	trans	rs7939886	0.841	rs79254833	chr11:55986896	T/C	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.71	8.61	0.48	8.73e-16	Alcohol dependence;
KIRP	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4716602	0.548	rs34245976	chr7:156160897	T/G	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs9323205	0.861	rs56137183	chr14:51693463	C/A	cg23942311	chr14:51606299	NA	-0.58	-6.2	-0.37	2.36e-9	Cancer;
KIRP	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.55	7.29	0.42	4.34e-12	Blood metabolite levels;
KIRP	cis	rs7615316	0.934	rs1129393	chr3:142283813	A/G	cg20824294	chr3:142316082	PLS1	0.22	4.94	0.3	1.42e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs3007168	0.951	rs3007078	chr14:51612550	T/A	cg23942311	chr14:51606299	NA	0.52	5.54	0.33	7.63e-8	Cancer;
KIRP	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg08975724	chr8:8085496	FLJ10661	-0.67	-8.63	-0.48	7.95e-16	Joint mobility (Beighton score);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg18782564	chr6:158365130	SNX9	0.59	6.56	0.39	3.11e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.98	14.12	0.67	1.47e-33	Cognitive function;
KIRP	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs986417	0.818	rs1010051	chr14:61002988	G/C	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.7	7.32	0.42	3.49e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.43	0.7	4.95e-38	Metabolic syndrome;
KIRP	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs10465746	0.780	rs1952065	chr1:84464205	T/C	cg10977910	chr1:84465055	TTLL7	0.58	7.3	0.42	3.89e-12	Obesity-related traits;
KIRP	cis	rs259842	0.794	rs28520865	chr2:180680489	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.45	-0.33	1.24e-7	Blood protein levels;
KIRP	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg21545522	chr1:205238299	TMCC2	0.43	5.81	0.35	1.91e-8	Red blood cell count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18907656	chr8:30888925	PURG	-0.45	-6.5	-0.38	4.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg04374321	chr14:90722782	PSMC1	0.99	18.13	0.76	3.17e-47	Mortality in heart failure;
KIRP	cis	rs2625529	0.824	rs4445848	chr15:72354598	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	0.7	6.27	0.37	1.57e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg12131826	chr15:77904385	NA	-0.4	-5.32	-0.32	2.38e-7	Type 2 diabetes;
KIRP	cis	rs920590	0.643	rs2083640	chr8:19660212	T/C	cg03894339	chr8:19674705	INTS10	0.41	4.95	0.3	1.39e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs4702718	0.574	rs2930050	chr5:10700127	G/A	cg14521931	chr5:10832172	NA	0.48	5.21	0.32	4.03e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg05340658	chr4:99064831	C4orf37	-0.54	-6.74	-0.39	1.12e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12580194	0.593	rs7489047	chr12:55759851	A/G	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs7319311	0.748	rs9515198	chr13:111029065	C/T	cg06243866	chr13:111019493	COL4A2	0.64	7.67	0.44	4.06e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.41	0.59	1.7e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg21014159	chr11:117668035	DSCAML1	0.41	6.24	0.37	1.88e-9	Myopia;
KIRP	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	1.01	17.62	0.75	1.69e-45	Breast cancer;
KIRP	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg11214544	chr1:2391121	NA	-0.43	-5.42	-0.33	1.43e-7	Schizophrenia;
KIRP	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-6.01	-0.36	6.63e-9	Asthma;
KIRP	cis	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.37	-0.32	1.86e-7	Leprosy;
KIRP	cis	rs78487399	0.808	rs10189235	chr2:43745520	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.87	-0.3	2.02e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs12431939	0.857	rs4547259	chr14:51669224	T/G	cg23942311	chr14:51606299	NA	0.47	5.63	0.34	4.78e-8	Cancer;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.67	8.96	0.5	8.03e-17	Menarche (age at onset);
KIRP	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg25486957	chr4:152246857	NA	-0.47	-5.81	-0.35	1.93e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2742417	1.000	rs2673057	chr3:45735730	A/T	cg04037228	chr3:45636386	LIMD1	0.34	5.05	0.31	8.6e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg10189774	chr4:17578691	LAP3	0.44	5.32	0.32	2.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.49	-6.73	-0.39	1.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.3	1.44e-6	Cognitive test performance;
KIRP	cis	rs4262150	0.810	rs72797237	chr5:151998463	A/C	cg12297329	chr5:152029980	NA	-0.67	-8.11	-0.46	2.42e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.42	5.37	0.32	1.81e-7	High light scatter reticulocyte count;
KIRP	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-6.75	-0.4	1.06e-10	Alzheimer's disease;
KIRP	cis	rs13424612	0.896	rs878925	chr2:240918502	A/G	cg01812947	chr2:240904978	NDUFA10	0.48	6.26	0.37	1.68e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs11686934	0.780	rs6731423	chr2:70173327	A/C	cg05298696	chr2:70188691	ASPRV1	-0.37	-4.87	-0.3	1.99e-6	High light scatter reticulocyte count;
KIRP	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.34	8.47	0.48	2.27e-15	Primary biliary cholangitis;
KIRP	cis	rs4664304	0.620	rs10168271	chr2:160729186	T/C	cg03641300	chr2:160917029	PLA2R1	0.39	5.79	0.35	2.19e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.96	8.71	0.49	4.56e-16	Eosinophilic esophagitis;
KIRP	cis	rs12210905	0.920	rs6911234	chr6:27086859	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.46	5.28	0.32	2.82e-7	Schizophrenia;
KIRP	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg04990556	chr1:26633338	UBXN11	-0.59	-7.25	-0.42	5.54e-12	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg01311341	chr22:25575246	KIAA1671	-0.58	-6.25	-0.37	1.8e-9	Glioblastoma;
KIRP	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg18501202	chr6:125855421	NA	0.33	4.98	0.3	1.19e-6	Brugada syndrome;
KIRP	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.71	-8.05	-0.46	3.45e-14	Body mass index;
KIRP	trans	rs9393777	0.841	rs13207082	chr6:27251379	A/G	cg01620082	chr3:125678407	NA	-1.02	-7.42	-0.43	1.91e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	5.23	0.32	3.71e-7	Schizophrenia;
KIRP	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17507749	chr15:85114479	UBE2QP1	0.72	8.16	0.46	1.79e-14	Schizophrenia;
KIRP	cis	rs6589219	1.000	rs6589220	chr11:111173290	C/T	cg25129781	chr11:111156908	C11orf53	-0.46	-5.82	-0.35	1.78e-8	Colorectal cancer;
KIRP	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.43	7.3	0.42	3.99e-12	Heart rate;
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.76	-10.94	-0.57	6.06e-23	Lung cancer;
KIRP	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.71	10.65	0.56	4.9e-22	Height;
KIRP	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.81	-0.4	7.5e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.64	9.34	0.51	6.07e-18	Prudent dietary pattern;
KIRP	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.94	7.56	0.43	7.99e-13	Body mass index;
KIRP	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.55	-6.26	-0.37	1.66e-9	Breast cancer;
KIRP	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.74	5.9	0.35	1.18e-8	Diabetic retinopathy;
KIRP	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg24315340	chr6:146058215	EPM2A	0.44	5.46	0.33	1.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.74	-10.81	-0.57	1.58e-22	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg22244940	chr12:132335942	MMP17	-0.54	-7.22	-0.42	6.28e-12	Migraine;
KIRP	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg25356066	chr3:128598488	ACAD9	0.49	5.75	0.34	2.64e-8	IgG glycosylation;
KIRP	trans	rs62056376	0.736	rs62054939	chr17:32645165	T/C	cg17635953	chr13:28535085	NA	-0.66	-6.81	-0.4	7.55e-11	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs1971762	1.000	rs3892761	chr12:54070445	A/T	cg09709951	chr12:54017699	ATF7	0.45	5.65	0.34	4.31e-8	Height;
KIRP	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg04733989	chr22:42467013	NAGA	-0.6	-7.57	-0.43	7.5e-13	Cognitive function;
KIRP	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg18833306	chr6:118973337	C6orf204	-0.48	-4.86	-0.3	2.13e-6	Diastolic blood pressure;
KIRP	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.58e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21747090	chr2:27597821	SNX17	-0.5	-6.94	-0.4	3.41e-11	Total body bone mineral density;
KIRP	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.91	14.99	0.69	1.59e-36	IgG glycosylation;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg03594822	chr16:8891458	TMEM186;PMM2	0.53	6.8	0.4	7.95e-11	Educational attainment;
KIRP	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	7.52	0.43	1.04e-12	Retinal vascular caliber;
KIRP	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.43	-0.38	6.48e-10	Aortic root size;
KIRP	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg24296786	chr1:45957014	TESK2	-0.52	-5.2	-0.31	4.27e-7	Blood protein levels;
KIRP	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg24375607	chr4:120327624	NA	0.55	5.6	0.34	5.71e-8	Corneal astigmatism;
KIRP	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.44	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.63	-7.13	-0.41	1.08e-11	Menarche (age at onset);
KIRP	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.38	0.47	4.23e-15	IgG glycosylation;
KIRP	cis	rs7973719	0.865	rs12830671	chr12:7347278	T/G	cg07052231	chr12:7363540	PEX5	0.4	5.3	0.32	2.61e-7	IgG glycosylation;
KIRP	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg12315302	chr6:26189340	HIST1H4D	1.16	6.97	0.41	2.9e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs986417	1.000	rs1951114	chr14:60922005	C/G	cg27398547	chr14:60952738	C14orf39	-0.74	-7.43	-0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs75920871	0.925	rs7950381	chr11:116963897	C/A	cg23684410	chr11:116897558	SIK3	0.52	5.21	0.32	3.94e-7	Subjective well-being;
KIRP	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg06076350	chr7:157294107	NA	0.42	5.59	0.34	5.87e-8	Inattentive symptoms;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02501479	chr16:85045147	ZDHHC7	0.51	6.29	0.37	1.46e-9	Parkinson's disease;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg02462569	chr6:150064036	NUP43	-0.34	-5.27	-0.32	3.04e-7	Lung cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14454440	chr9:137620443	COL5A1	0.43	6.28	0.37	1.55e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	8.55	0.48	1.3e-15	Neuroticism;
KIRP	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg23262073	chr20:60523788	NA	0.57	5.58	0.34	6.25e-8	Body mass index;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg10254082	chr7:997346	NA	0.48	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs12043259	0.730	rs10458587	chr1:204793512	T/G	cg11485465	chr5:54518469	NA	0.38	6.31	0.37	1.26e-9	Addiction;
KIRP	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.23	17.83	0.75	3.24e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.19	-0.31	4.41e-7	Skin colour saturation;
KIRP	trans	rs29784	0.838	rs251230	chr5:172526570	A/G	cg19447692	chr5:149357747	SLC26A2	0.43	6.24	0.37	1.91e-9	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.92	13.23	0.64	1.53e-30	Menopause (age at onset);
KIRP	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.57	-6.04	-0.36	5.57e-9	DNA methylation (variation);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14250130	chr10:3109361	PFKP	-0.52	-6.25	-0.37	1.75e-9	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22885975	chr20:55926578	RAE1	0.48	6.77	0.4	9.2e-11	Survival in pancreatic cancer;
KIRP	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.75	-8.82	-0.49	2.18e-16	Corneal astigmatism;
KIRP	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.7	-6.87	-0.4	5.2e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg13939156	chr17:80058883	NA	0.5	5.92	0.35	1.06e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg02297831	chr4:17616191	MED28	0.6	7.69	0.44	3.51e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.46	-0.38	5.53e-10	Lung cancer;
KIRP	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.6	0.44	6.25e-13	Lung cancer;
KIRP	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.77	-12.19	-0.61	4.54e-27	Prostate cancer;
KIRP	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.96	0.71	7.59e-40	Bipolar disorder;
KIRP	cis	rs7301016	1.000	rs11613132	chr12:62856444	A/C	cg01804193	chr12:63026212	NA	0.54	5.68	0.34	3.88e-8	IgG glycosylation;
KIRP	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.75	0.4	1.07e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	trans	rs17834760	0.955	rs9500665	chr6:62094690	C/A	cg08476511	chr6:168435923	KIF25	0.51	6.11	0.36	3.93e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg10505658	chr17:80084571	CCDC57	-0.26	-4.86	-0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.42	-5.36	-0.32	1.91e-7	Blood metabolite levels;
KIRP	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	13.39	0.65	4.55e-31	Ulcerative colitis;
KIRP	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.03	-11.14	-0.58	1.31e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg02336718	chr17:17403227	NA	0.32	5.07	0.31	7.88e-7	Total body bone mineral density;
KIRP	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12311346	chr5:56204834	C5orf35	-0.44	-5.54	-0.33	7.84e-8	Coronary artery disease;
KIRP	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.63	8.77	0.49	2.94e-16	Autism;
KIRP	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3736485	0.966	rs6493513	chr15:51910174	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.26	-0.32	3.16e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.54	-7.38	-0.43	2.46e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.45	-5.24	-0.32	3.41e-7	Body mass index;
KIRP	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg11569703	chr11:65557185	OVOL1	-0.48	-8.45	-0.47	2.5e-15	Acne (severe);
KIRP	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-1.12	-8.78	-0.49	2.74e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6882046	0.513	rs639725	chr5:88001969	A/G	cg24804195	chr5:87968844	LOC645323	-0.47	-6.23	-0.37	2.05e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg00343986	chr7:65444356	GUSB	-0.43	-4.99	-0.3	1.12e-6	Aortic root size;
KIRP	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg23682824	chr7:23144976	KLHL7	0.52	6.08	0.36	4.51e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg17646820	chr3:66848679	NA	0.79	9.32	0.51	7.06e-18	Type 2 diabetes;
KIRP	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.84	9.65	0.52	6.67e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.69	0.48	5.04e-16	Morning vs. evening chronotype;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00006032	chr14:66974439	GPHN	0.54	6.48	0.38	4.84e-10	Smoking initiation;
KIRP	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.79	8.02	0.46	4.33e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.47	5.99	0.36	7.48e-9	Height;
KIRP	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs61884328	0.777	rs17790342	chr11:47127706	G/A	cg23433285	chr11:47201945	PACSIN3	0.69	5.6	0.34	5.68e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg10645314	chr2:3704589	ALLC	0.68	7.64	0.44	4.83e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg19077165	chr18:44547161	KATNAL2	0.5	6.33	0.37	1.18e-9	Personality dimensions;
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.27	0.37	1.65e-9	Lung cancer;
KIRP	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg26384229	chr12:38710491	ALG10B	0.68	9.05	0.5	4.35e-17	Morning vs. evening chronotype;
KIRP	cis	rs7624766	0.555	rs6794047	chr3:160523531	T/C	cg22637730	chr3:160473554	PPM1L	0.44	5.45	0.33	1.22e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg13147721	chr7:65941812	NA	-0.91	-6.56	-0.39	3.19e-10	Diabetic kidney disease;
KIRP	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg01879757	chr17:41196368	BRCA1	-0.76	-10.45	-0.55	2.12e-21	Menopause (age at onset);
KIRP	cis	rs10858047	0.883	rs79867	chr1:115165110	A/C	cg12756093	chr1:115239321	AMPD1	-0.68	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs34779708	0.733	rs4102764	chr10:35545392	T/C	cg03585969	chr10:35415529	CREM	0.56	6.43	0.38	6.53e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.71	-8.05	-0.46	3.45e-14	Body mass index;
KIRP	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.38e-7	Oral cavity cancer;
KIRP	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1978968	1.000	rs12158906	chr22:18437382	A/G	cg03078520	chr22:18463400	MICAL3	-0.68	-8.62	-0.48	8.21e-16	Presence of antiphospholipid antibodies;
KIRP	cis	rs6832769	0.922	rs6825994	chr4:56390411	C/A	cg09317128	chr4:56265301	TMEM165	-0.55	-7.4	-0.43	2.09e-12	Personality dimensions;
KIRP	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg00012203	chr2:219082015	ARPC2	0.82	11.66	0.6	2.68e-25	Colorectal cancer;
KIRP	cis	rs75920871	0.843	rs61905713	chr11:116909429	C/T	cg23684410	chr11:116897558	SIK3	0.57	6.15	0.37	3.05e-9	Subjective well-being;
KIRP	cis	rs80208956	1.000	rs3862792	chr11:69462856	A/G	cg27021553	chr11:69462783	CCND1	-0.62	-7.6	-0.44	6.38e-13	Major depressive disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23590262	chr4:173470589	GALNTL6	-0.4	-6.62	-0.39	2.21e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.44	0.38	6.07e-10	Mean platelet volume;
KIRP	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.74	-9.94	-0.54	8.85e-20	Educational attainment;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24684336	chr15:42565701	GANC;TMEM87A	-0.47	-6.23	-0.37	1.98e-9	Warfarin maintenance dose;
KIRP	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	10.83	0.57	1.35e-22	Platelet count;
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.46	6.01	0.36	6.62e-9	Life satisfaction;
KIRP	cis	rs4523957	0.620	rs58187837	chr17:2073272	G/C	cg16513277	chr17:2031491	SMG6	-0.85	-12.43	-0.62	7.25e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg26384229	chr12:38710491	ALG10B	0.68	8.8	0.49	2.4e-16	Morning vs. evening chronotype;
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.61	8.08	0.46	3e-14	Longevity;
KIRP	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg25418670	chr11:30344373	C11orf46	-0.61	-5.25	-0.32	3.3e-7	Morning vs. evening chronotype;
KIRP	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.22	-5.27	-0.32	3.01e-7	Primary biliary cholangitis;
KIRP	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.7	-0.34	3.33e-8	Breast cancer;
KIRP	cis	rs4762326	0.527	rs7134554	chr12:95522477	A/G	cg07737802	chr12:95537812	FGD6	0.44	5.68	0.34	3.85e-8	Endometriosis;
KIRP	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg26876637	chr1:152193138	HRNR	-0.75	-8.84	-0.49	1.84e-16	Atopic dermatitis;
KIRP	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg07701084	chr6:150067640	NUP43	0.63	6.59	0.39	2.61e-10	Lung cancer;
KIRP	cis	rs10463316	0.832	rs1019467	chr5:150734323	A/G	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.14	-0.36	3.25e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg13289132	chr10:30722225	MAP3K8	-0.41	-5.17	-0.31	4.83e-7	Inflammatory bowel disease;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg21186296	chr8:27182909	PTK2B	0.47	5.96	0.36	8.57e-9	Neuroticism;
KIRP	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	6.18	0.37	2.64e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.11	0.72	2.37e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2380205	0.538	rs11255698	chr10:5920893	A/G	cg27141509	chr10:5886111	NA	-0.4	-4.91	-0.3	1.66e-6	Breast cancer;
KIRP	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.66e-7	Diabetic retinopathy;
KIRP	cis	rs7252981	0.632	rs11878202	chr19:19744079	T/C	cg11584989	chr19:19387371	SF4	-0.48	-5.67	-0.34	4.02e-8	Perceived unattractiveness to mosquitoes;
KIRP	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-9.33	-0.51	6.31e-18	Triglycerides;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg04369109	chr6:150039330	LATS1	-0.63	-8.2	-0.46	1.36e-14	Lung cancer;
KIRP	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.42	5.62	0.34	5.03e-8	Systolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18661731	chr18:59854239	PIGN;KIAA1468	0.47	6.12	0.36	3.73e-9	Parkinson's disease;
KIRP	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.57	0.52	1.18e-18	Dupuytren's disease;
KIRP	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg25019722	chr6:37503610	NA	-0.88	-12.73	-0.63	7.18e-29	Cognitive performance;
KIRP	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	10.56	0.56	9.96e-22	Personality dimensions;
KIRP	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	7.79	0.44	1.87e-13	Cognitive test performance;
KIRP	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg23803603	chr1:2058230	PRKCZ	0.38	5.84	0.35	1.67e-8	Height;
KIRP	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.94	-0.45	7.42e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.53	7.24	0.42	5.58e-12	Schizophrenia;
KIRP	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.69	-7.97	-0.45	6.1e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg00262122	chr8:11665843	FDFT1	0.42	5.32	0.32	2.34e-7	Neuroticism;
KIRP	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.71	6.81	0.4	7.48e-11	Breast cancer;
KIRP	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.9	-10.08	-0.54	3.16e-20	Gut microbiome composition (summer);
KIRP	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg14847009	chr1:175162515	KIAA0040	-0.3	-6.13	-0.36	3.55e-9	Diastolic blood pressure;
KIRP	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.55	0.59	6.19e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs60311166	1.000	rs57560655	chr3:52577334	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.9	5.55	0.33	7.28e-8	CTACK levels;
KIRP	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.42	-0.33	1.41e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20746096	chr12:64238043	SRGAP1	0.5	6.17	0.37	2.73e-9	Parkinson's disease;
KIRP	cis	rs6102059	0.503	rs6102033	chr20:39184691	C/G	cg06665391	chr20:39312290	NA	0.43	5.27	0.32	2.92e-7	LDL cholesterol;
KIRP	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg23594656	chr7:65796392	TPST1	-0.39	-5.41	-0.33	1.48e-7	Aortic root size;
KIRP	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.46	-0.47	2.37e-15	Joint mobility (Beighton score);
KIRP	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.68	-8.01	-0.45	4.71e-14	Aortic root size;
KIRP	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg07212818	chr11:638076	DRD4	-0.42	-5.28	-0.32	2.82e-7	Systemic lupus erythematosus;
KIRP	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg17182837	chr8:41585554	ANK1	-0.47	-6.52	-0.38	4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg01559446	chr3:44596178	ZNF167	-0.4	-5.63	-0.34	4.87e-8	Depressive symptoms;
KIRP	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg25019722	chr6:37503610	NA	-0.94	-15.13	-0.69	5.47e-37	Cognitive performance;
KIRP	cis	rs714027	0.545	rs1807513	chr22:30289819	A/C	cg27665648	chr22:30112403	NA	0.39	5.48	0.33	1.04e-7	Lymphocyte counts;
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.43	-0.33	1.36e-7	Lung cancer;
KIRP	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.39	-6.6	-0.39	2.52e-10	Birth weight;
KIRP	cis	rs7209700	0.614	rs7225927	chr17:45323934	A/G	cg18085866	chr17:45331354	ITGB3	-0.46	-5.97	-0.36	8.1e-9	IgG glycosylation;
KIRP	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08828664	chr3:149688512	PFN2	0.51	6.55	0.39	3.25e-10	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7589728	0.844	rs77144652	chr2:88496684	G/A	cg04511125	chr2:88470314	THNSL2	0.76	5.51	0.33	9.23e-8	Plasma clusterin levels;
KIRP	cis	rs7640424	0.649	rs6795280	chr3:107876232	T/C	cg09227934	chr3:107805635	CD47	-0.36	-6.11	-0.36	3.85e-9	Body mass index;
KIRP	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.94	-0.4	3.45e-11	Height;
KIRP	cis	rs503734	0.521	rs348881	chr3:100970920	A/C	cg27318481	chr3:100970896	IMPG2	-0.58	-7.91	-0.45	8.76e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02631906	chr1:45987864	PRDX1	0.52	6.2	0.37	2.32e-9	Smoking initiation;
KIRP	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	0.9	9.72	0.53	4.22e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.2e-6	Morning vs. evening chronotype;
KIRP	cis	rs904251	0.647	rs2776908	chr6:37434857	T/C	cg25019722	chr6:37503610	NA	-0.62	-6.36	-0.38	9.85e-10	Cognitive performance;
KIRP	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg24304309	chr1:154577895	ADAR	-0.36	-5.39	-0.33	1.62e-7	Blood protein levels;
KIRP	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg05347473	chr6:146136440	FBXO30	0.61	8.69	0.48	5.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.24	23.64	0.83	2.91e-65	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg03171003	chr2:111875934	NA	0.45	6.38	0.38	8.51e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15557168	chr22:42548783	NA	-0.46	-5.92	-0.35	1.06e-8	Cognitive function;
KIRP	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg19507638	chr5:93509721	C5orf36	-0.54	-5.08	-0.31	7.32e-7	Diabetic retinopathy;
KIRP	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05472579	chr8:37757063	RAB11FIP1	0.48	6.16	0.37	2.96e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.64	5.19	0.31	4.4e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg16105309	chr15:79090380	ADAMTS7	0.62	7.42	0.43	1.85e-12	Schizophrenia;
KIRP	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg10253484	chr15:75165896	SCAMP2	-0.46	-5.62	-0.34	5.22e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg14132834	chr19:41945861	ATP5SL	-0.59	-8.03	-0.46	4.02e-14	Height;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg06992027	chr1:159895302	TAGLN2	0.5	6.23	0.37	1.98e-9	Asthma;
KIRP	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg05802129	chr4:122689817	NA	-0.46	-6.69	-0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.33	-0.32	2.24e-7	Life satisfaction;
KIRP	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg14092571	chr14:90743983	NA	0.41	5.03	0.31	9.61e-7	Mortality in heart failure;
KIRP	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg06453172	chr10:134556979	INPP5A	-0.57	-6.88	-0.4	4.81e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.66	-8.72	-0.49	4.32e-16	Huntington's disease progression;
KIRP	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.63	8.67	0.48	5.92e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs4703655	chr5:74455063	A/G	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.18	0.31	4.63e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs12786942	0.569	rs4255512	chr11:101313991	A/T	cg03942599	chr11:101341554	TRPC6	0.55	7.64	0.44	4.83e-13	Facial depth;
KIRP	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg04037228	chr3:45636386	LIMD1	0.35	5.22	0.32	3.82e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.24	-0.32	3.46e-7	Blood metabolite levels;
KIRP	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg03999872	chr20:62272968	STMN3	0.43	5.11	0.31	6.33e-7	Prostate cancer;
KIRP	cis	rs3857536	0.704	rs7775899	chr6:66969860	C/A	cg07460842	chr6:66804631	NA	-0.46	-5.48	-0.33	1.07e-7	Blood trace element (Cu levels);
KIRP	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.52	-7.12	-0.41	1.16e-11	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg08822215	chr16:89438651	ANKRD11	-0.52	-6.66	-0.39	1.79e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs12541635	0.677	rs10086055	chr8:107024129	C/T	cg10147462	chr8:107024639	NA	0.34	4.97	0.3	1.28e-6	Age of smoking initiation;
KIRP	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg26513180	chr16:89883248	FANCA	0.57	7.51	0.43	1.07e-12	Vitiligo;
KIRP	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.45	7.39	0.43	2.31e-12	Eye color traits;
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00802000	chr16:706648	WDR90	-0.4	-5.02	-0.3	9.97e-7	Height;
KIRP	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.58	0.39	2.87e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.82	11.87	0.6	5.22e-26	Bladder cancer;
KIRP	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg23100626	chr2:96804247	ASTL	0.46	6.4	0.38	7.82e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg21972741	chr5:435613	AHRR	0.5	6.08	0.36	4.52e-9	Cystic fibrosis severity;
KIRP	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg14343924	chr8:8086146	FLJ10661	0.43	5.0	0.3	1.1e-6	Mood instability;
KIRP	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.69	8.33	0.47	5.58e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7870753	0.628	rs2406004	chr9:99193210	G/A	cg25260653	chr9:99212216	HABP4	0.58	6.04	0.36	5.79e-9	Height;
KIRP	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg01529538	chr14:23388837	RBM23	0.42	5.29	0.32	2.68e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.43	7.52	0.43	1.01e-12	Renal cell carcinoma;
KIRP	cis	rs7116495	0.609	rs12275171	chr11:71835373	C/T	cg18441811	chr11:71824068	C11orf51	0.78	5.14	0.31	5.53e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.09	-0.41	1.39e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg18944383	chr4:111397179	ENPEP	-0.54	-6.13	-0.36	3.46e-9	Axial length;
KIRP	cis	rs4776059	1.000	rs11857150	chr15:52922216	G/A	cg25063058	chr15:52860530	ARPP19	0.53	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg25418670	chr11:30344373	C11orf46	0.6	5.11	0.31	6.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs4728302	0.869	rs6943986	chr7:133616965	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.71	0.34	3.21e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs4692589	0.556	rs2279267	chr4:170990053	A/G	cg19918862	chr4:170955249	NA	-0.53	-5.93	-0.35	1.04e-8	Anxiety disorder;
KIRP	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs240764	0.817	rs239207	chr6:101137765	A/C	cg09795085	chr6:101329169	ASCC3	0.46	5.51	0.33	8.82e-8	Neuroticism;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg00738919	chr7:1100172	C7orf50	0.43	5.06	0.31	8.2e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.79	10.87	0.57	9.76e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg15691649	chr6:25882328	NA	-0.42	-5.03	-0.31	9.62e-7	Blood metabolite levels;
KIRP	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg18709589	chr6:96969512	KIAA0776	0.34	5.18	0.31	4.59e-7	Headache;
KIRP	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.52	6.09	0.36	4.27e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08192560	chr2:24149860	ATAD2B	-0.57	-6.09	-0.36	4.24e-9	Menopause (age at onset);
KIRP	cis	rs11671005	0.735	rs11668789	chr19:58928309	C/T	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.69	9.25	0.51	1.1e-17	Crohn's disease;
KIRP	cis	rs7536201	0.936	rs7532198	chr1:25294208	C/T	cg23273869	chr1:25296894	NA	-0.35	-4.86	-0.3	2.11e-6	Psoriasis vulgaris;
KIRP	cis	rs888194	0.677	rs10850139	chr12:109875934	A/C	cg19025524	chr12:109796872	NA	-0.38	-5.09	-0.31	7.25e-7	Neuroticism;
KIRP	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.75	0.44	2.42e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.73	-10.94	-0.57	6.03e-23	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg18882449	chr10:104885122	NT5C2	-0.38	-4.89	-0.3	1.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg06223162	chr1:101003688	GPR88	0.41	7.74	0.44	2.58e-13	Breast cancer;
KIRP	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg22907277	chr7:1156413	C7orf50	0.56	6.85	0.4	5.97e-11	Longevity;Endometriosis;
KIRP	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg18132916	chr6:79620363	NA	-0.4	-5.59	-0.34	6.06e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8077577	0.747	rs62072511	chr17:18193157	G/A	cg18869244	chr17:18121946	NA	0.46	5.14	0.31	5.55e-7	Obesity-related traits;
KIRP	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16405210	chr4:1374714	KIAA1530	0.56	7.46	0.43	1.45e-12	Obesity-related traits;
KIRP	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg02820901	chr13:113351484	ATP11A	0.64	6.01	0.36	6.48e-9	Glycated hemoglobin levels;
KIRP	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg09624528	chr10:1369823	ADARB2	0.45	5.61	0.34	5.36e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg19770292	chr5:1868693	NA	0.42	5.5	0.33	9.71e-8	Cardiovascular disease risk factors;
KIRP	trans	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg06521331	chr12:34319734	NA	-0.57	-6.94	-0.4	3.48e-11	Bladder cancer;
KIRP	trans	rs34421088	0.531	rs2245232	chr8:11400944	G/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.39	-0.43	2.27e-12	Neuroticism;
KIRP	cis	rs2398893	0.924	rs7855830	chr9:96798659	A/G	cg14459158	chr9:96720562	NA	0.27	4.89	0.3	1.83e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	1.01	14.55	0.68	5.1e-35	Height;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg00353422	chr21:34863790	DNAJC28	0.55	6.48	0.38	5e-10	Plasma plasminogen activator levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22236250	chr19:46580441	NA	0.39	6.11	0.36	3.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11650494	0.710	rs16948078	chr17:47474800	C/T	cg08112188	chr17:47440006	ZNF652	-1.23	-7.52	-0.43	1.01e-12	Prostate cancer;
KIRP	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.56	-6.98	-0.41	2.76e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.43	-5.93	-0.35	1.01e-8	Tuberculosis;
KIRP	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.72	-7.33	-0.42	3.23e-12	Bipolar disorder;
KIRP	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg23625390	chr15:77176239	SCAPER	0.51	6.59	0.39	2.66e-10	Blood metabolite levels;
KIRP	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.88	0.45	1.07e-13	Corneal astigmatism;
KIRP	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg02404636	chr22:31891804	SFI1	0.53	5.49	0.33	1.01e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg02367723	chr1:46378857	MAST2	0.43	5.04	0.31	9.03e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.66	9.2	0.51	1.55e-17	Multiple sclerosis;
KIRP	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-5.04	-0.31	8.97e-7	Blood protein levels;
KIRP	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.47	-5.6	-0.34	5.58e-8	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11954110	chr11:113644656	ZW10	0.47	7.02	0.41	2.21e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs6062509	0.931	rs4809329	chr20:62348460	C/T	cg01311341	chr22:25575246	KIAA1671	0.54	6.68	0.39	1.6e-10	Prostate cancer;
KIRP	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.71	10.07	0.54	3.49e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg05802129	chr4:122689817	NA	-0.59	-7.39	-0.43	2.25e-12	Type 2 diabetes;
KIRP	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.47	-0.38	5.12e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.66	7.42	0.43	1.93e-12	Corneal astigmatism;
KIRP	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	cg12689670	chr1:183009347	LAMC1	0.53	7.29	0.42	4.26e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg22437258	chr11:111473054	SIK2	0.63	7.68	0.44	3.81e-13	Primary sclerosing cholangitis;
KIRP	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg24315340	chr6:146058215	EPM2A	0.4	5.09	0.31	6.96e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg06647332	chr5:131281008	NA	0.46	4.97	0.3	1.25e-6	Life satisfaction;
KIRP	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.43	6.57	0.39	2.94e-10	Schizophrenia;
KIRP	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg02527881	chr3:46936655	PTH1R	-0.43	-6.06	-0.36	5.03e-9	Colorectal cancer;
KIRP	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.91	-14.91	-0.69	2.98e-36	Urate levels in lean individuals;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg03188948	chr7:1209495	NA	0.5	5.37	0.32	1.82e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.11	0.31	6.42e-7	Height;
KIRP	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.27	0.37	1.65e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg19610905	chr11:61596333	FADS2	-0.47	-6.8	-0.4	7.76e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs2599510	0.744	rs4952212	chr2:32618493	G/C	cg02381751	chr2:32503542	YIPF4	-0.44	-5.12	-0.31	6.28e-7	Interleukin-18 levels;
KIRP	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg00852783	chr1:26633632	UBXN11	0.52	7.48	0.43	1.29e-12	Obesity-related traits;
KIRP	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.21	-0.46	1.27e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg22974920	chr21:40686053	BRWD1	0.47	5.66	0.34	4.18e-8	Cognitive function;
KIRP	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-6.26	-0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.37	-7.86	-0.45	1.23e-13	Body mass index;
KIRP	trans	rs399593	0.848	rs7896682	chr10:30909392	A/G	cg02831383	chr1:3329820	PRDM16	-0.58	-6.15	-0.37	3.19e-9	Dental caries;
KIRP	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg26681399	chr22:41777847	TEF	-0.47	-4.95	-0.3	1.35e-6	Vitiligo;
KIRP	cis	rs35955747	0.714	rs5997989	chr22:31839950	T/C	cg02404636	chr22:31891804	SFI1	-0.4	-5.49	-0.33	9.88e-8	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26314531	chr2:26401878	FAM59B	-0.54	-5.78	-0.35	2.29e-8	Gut microbiome composition (summer);
KIRP	cis	rs2733310	0.843	rs7180558	chr15:57559387	G/T	cg13626582	chr15:57592083	LOC283663	0.28	6.44	0.38	6.16e-10	Mean platelet volume;
KIRP	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	0.84	7.49	0.43	1.21e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.0	-0.61	2.05e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg19507638	chr5:93509721	C5orf36	0.59	5.31	0.32	2.47e-7	Diabetic retinopathy;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25948328	chr10:119768195	RAB11FIP2	0.43	6.21	0.37	2.18e-9	Migraine with aura;
KIRP	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg00405596	chr8:11794950	NA	-0.45	-5.88	-0.35	1.3e-8	Triglycerides;
KIRP	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg18132916	chr6:79620363	NA	-0.42	-5.73	-0.34	2.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.86	-0.57	1.06e-22	Menopause (age at onset);
KIRP	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs7116495	1.000	rs7949480	chr11:71697588	T/C	cg11196788	chr11:71737549	NUMA1	0.56	5.04	0.31	9.07e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs4704187	0.687	rs6894048	chr5:74456838	A/G	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg00684032	chr4:1343700	KIAA1530	0.45	5.88	0.35	1.31e-8	Longevity;
KIRP	cis	rs2019216	0.500	rs12450390	chr17:21910636	G/T	cg22648282	chr17:21454238	C17orf51	-0.48	-5.88	-0.35	1.33e-8	Pelvic organ prolapse;
KIRP	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg01677386	chr11:118938358	VPS11	-0.55	-6.58	-0.39	2.87e-10	Coronary artery disease;
KIRP	cis	rs654128	0.640	rs339337	chr6:117214675	G/A	cg12892004	chr6:117198278	RFX6	-0.39	-5.1	-0.31	6.89e-7	Telomere length;
KIRP	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg17595323	chr11:93583763	C11orf90	-0.38	-6.34	-0.37	1.1e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg22117172	chr7:91764530	CYP51A1	0.42	5.67	0.34	4.03e-8	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03097336	chr16:84178939	LRRC50;HSDL1	0.5	6.08	0.36	4.46e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.7	-7.36	-0.42	2.73e-12	Vitiligo;
KIRP	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg17340268	chr14:105411764	AHNAK2	0.4	5.27	0.32	3.03e-7	Rheumatoid arthritis;
KIRP	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg03647239	chr10:116582469	FAM160B1	0.49	5.61	0.34	5.32e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9400467	0.537	rs12191266	chr6:111528041	T/C	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12936587	0.633	rs12950093	chr17:17511203	C/T	cg01246520	chr17:17644344	RAI1	-0.35	-5.27	-0.32	3.03e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg17757837	chr7:157058334	UBE3C	-0.82	-11.3	-0.58	4.04e-24	Body mass index;
KIRP	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg03929089	chr4:120376271	NA	0.69	6.17	0.37	2.74e-9	Axial length;
KIRP	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.95	-0.45	6.69e-14	Retinal vascular caliber;
KIRP	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.54	-5.53	-0.33	8.05e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg16989719	chr2:238392110	NA	-0.53	-7.3	-0.42	3.94e-12	Prostate cancer;
KIRP	cis	rs7523273	0.925	rs2745977	chr1:208017360	C/A	cg22525895	chr1:207977042	MIR29B2	-0.58	-7.5	-0.43	1.14e-12	Schizophrenia;
KIRP	cis	rs501120	0.810	rs684196	chr10:44745950	A/T	cg09554077	chr10:44749378	NA	0.74	12.39	0.62	1.01e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg00310523	chr12:86230176	RASSF9	0.39	6.07	0.36	4.88e-9	Major depressive disorder;
KIRP	cis	rs7113874	1.000	rs4929925	chr11:8655187	C/A	cg08015107	chr11:8618950	NA	0.35	4.94	0.3	1.43e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12137294	0.866	rs1172153	chr1:205220661	T/C	cg21643547	chr1:205240462	TMCC2	-0.48	-6.83	-0.4	6.8e-11	Red cell distribution width;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.58	7.69	0.44	3.46e-13	Longevity;Endometriosis;
KIRP	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.75	-0.34	2.67e-8	Breast cancer;
KIRP	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg18016565	chr1:150552671	MCL1	0.37	5.88	0.35	1.33e-8	Tonsillectomy;
KIRP	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-1.03	-9.52	-0.52	1.74e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.73	7.13	0.41	1.14e-11	Lung function (FEV1/FVC);
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg08132940	chr7:1081526	C7orf50	-0.67	-6.75	-0.4	1.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.3.76029796F	chr3:75947106	NA	0.45	6.21	0.37	2.26e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs741677	0.963	rs8064649	chr17:472610	T/C	cg13332499	chr17:408570	NA	0.39	5.17	0.31	4.94e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.6	-7.06	-0.41	1.68e-11	Menarche (age at onset);
KIRP	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18252515	chr7:66147081	NA	0.46	5.72	0.34	3.13e-8	Aortic root size;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12444845	chr8:56685709	TMEM68;TGS1	-0.49	-6.12	-0.36	3.59e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1035491	0.715	rs10063301	chr5:63925947	A/T	cg01791865	chr5:63954708	NA	0.33	5.21	0.32	4.07e-7	Body mass index;
KIRP	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-10.17	-0.54	1.65e-20	Body mass index;
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg00343986	chr7:65444356	GUSB	-0.48	-5.77	-0.35	2.31e-8	Aortic root size;
KIRP	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg19761014	chr17:28927070	LRRC37B2	0.68	5.04	0.31	9.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.56	8.33	0.47	5.72e-15	Itch intensity from mosquito bite;
KIRP	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.84	11.88	0.6	5.17e-26	Colorectal cancer;
KIRP	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg04608330	chr12:45269318	NELL2	-0.56	-7.69	-0.44	3.43e-13	Gut microbiome composition (summer);
KIRP	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg05802129	chr4:122689817	NA	-0.58	-7.21	-0.42	6.85e-12	Type 2 diabetes;
KIRP	cis	rs17401966	0.522	rs10864450	chr1:10333959	G/T	cg19773385	chr1:10388646	KIF1B	-0.43	-6.22	-0.37	2.17e-9	Hepatocellular carcinoma;
KIRP	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg11861562	chr11:117069780	TAGLN	0.41	5.29	0.32	2.67e-7	Blood protein levels;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-7.75	-0.44	2.4e-13	Platelet count;
KIRP	cis	rs2006771	0.647	rs138280	chr22:32131610	T/C	cg02404636	chr22:31891804	SFI1	-0.46	-5.76	-0.34	2.48e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg06521331	chr12:34319734	NA	-0.51	-6.35	-0.38	1.04e-9	Heart rate;
KIRP	cis	rs7520050	0.966	rs785495	chr1:46587887	A/G	cg24296786	chr1:45957014	TESK2	0.39	5.0	0.3	1.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7147624	0.572	rs72714498	chr14:66037734	C/T	cg03016385	chr14:66212404	NA	0.98	5.83	0.35	1.78e-8	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg15447662	chr7:55979688	ZNF713	0.43	6.68	0.39	1.6e-10	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.54	-6.74	-0.39	1.14e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg26139080	chr11:47293733	MADD	-0.42	-5.19	-0.31	4.33e-7	HDL cholesterol;
KIRP	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg09795085	chr6:101329169	ASCC3	0.51	6.19	0.37	2.51e-9	Neuroticism;
KIRP	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg08017634	chr8:144659831	NAPRT1	0.84	5.44	0.33	1.27e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7534824	0.625	rs61782078	chr1:101498212	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.71	5.71	0.34	3.22e-8	Refractive astigmatism;
KIRP	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.76	-10.95	-0.57	5.51e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.65	7.64	0.44	4.88e-13	Red cell distribution width;
KIRP	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06634786	chr22:41940651	POLR3H	0.44	5.06	0.31	8.32e-7	Vitiligo;
KIRP	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	4.88e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg12384639	chr17:618140	VPS53	0.49	5.96	0.36	8.84e-9	Prostate cancer;
KIRP	cis	rs2278796	0.608	rs6700069	chr1:204968945	A/G	cg04862289	chr1:204966208	NFASC	0.67	9.47	0.52	2.48e-18	Mean platelet volume;
KIRP	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.65	11.16	0.58	1.15e-23	White blood cell count (basophil);
KIRP	trans	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.46	-0.43	1.44e-12	Morning vs. evening chronotype;
KIRP	cis	rs8077577	0.943	rs62072467	chr17:18116455	C/T	cg09161412	chr17:18057145	MYO15A	-0.44	-5.27	-0.32	2.95e-7	Obesity-related traits;
KIRP	cis	rs2071403	0.966	rs11682968	chr2:1412230	C/T	cg06500727	chr2:1417164	TPO	0.47	7.45	0.43	1.6e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs929596	0.697	rs17863787	chr2:234611094	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.66	-8.53	-0.48	1.56e-15	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	6.21	0.37	2.24e-9	HIV-1 control;
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg00343986	chr7:65444356	GUSB	0.48	5.85	0.35	1.55e-8	Aortic root size;
KIRP	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.31	-0.32	2.41e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6921919	0.583	rs1361385	chr6:28358320	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-1.07	-19.95	-0.79	2.5e-53	Height;
KIRP	trans	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg01311341	chr22:25575246	KIAA1671	-0.49	-6.24	-0.37	1.85e-9	Prostate cancer;
KIRP	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-6.01	-0.36	6.69e-9	Self-reported allergy;
KIRP	cis	rs6832769	1.000	rs28582059	chr4:56408404	G/C	cg05960024	chr4:56376020	CLOCK	-0.62	-8.0	-0.45	4.94e-14	Personality dimensions;
KIRP	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs7084402	0.905	rs7914888	chr10:60308558	T/C	cg05938607	chr10:60274200	BICC1	0.39	9.14	0.5	2.38e-17	Refractive error;
KIRP	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.59	-8.27	-0.47	8.51e-15	Neuroticism;
KIRP	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4268898	0.529	rs4426488	chr2:24372815	A/G	cg20701182	chr2:24300061	SF3B14	-0.41	-5.27	-0.32	3.03e-7	Asthma;
KIRP	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg13798912	chr7:905769	UNC84A	0.55	5.53	0.33	8.11e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7909791	0.632	rs3752948	chr10:105670762	G/A	cg11005552	chr10:105648138	OBFC1	0.45	5.08	0.31	7.3e-7	White matter hyperintensity burden;
KIRP	cis	rs11628318	0.851	rs4243734	chr14:103023569	T/C	cg01864069	chr14:103024347	NA	-1.01	-12.92	-0.64	1.67e-29	Platelet count;
KIRP	cis	rs960902	0.689	rs888101	chr2:37732062	A/T	cg25341268	chr2:37734390	NA	-0.49	-6.41	-0.38	7.51e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	13.12	0.64	3.73e-30	Post bronchodilator FEV1;
KIRP	cis	rs1883415	0.750	rs2076316	chr6:24489741	A/C	cg20631270	chr6:24437470	GPLD1	0.42	5.22	0.32	3.79e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg23985595	chr17:80112537	CCDC57	-0.34	-4.99	-0.3	1.15e-6	Life satisfaction;
KIRP	cis	rs6988636	0.710	rs17315999	chr8:124153763	A/G	cg23067535	chr8:124195133	FAM83A	-0.6	-5.34	-0.32	2.11e-7	Urinary uromodulin levels;
KIRP	cis	rs6708331	0.517	rs6546570	chr2:70350033	G/C	cg05298696	chr2:70188691	ASPRV1	-0.41	-5.41	-0.33	1.47e-7	Obesity-related traits;
KIRP	cis	rs12586317	0.576	rs2415264	chr14:35630377	C/G	cg07166546	chr14:35805898	NA	-0.26	-6.06	-0.36	4.99e-9	Psoriasis;
KIRP	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.87	11.46	0.59	1.17e-24	Gestational age at birth (maternal effect);
KIRP	cis	rs501120	0.713	rs676966	chr10:44739594	A/G	cg09554077	chr10:44749378	NA	-0.7	-8.1	-0.46	2.59e-14	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg00405596	chr8:11794950	NA	-0.45	-5.62	-0.34	5.2100000000000003e-08	Neuroticism;
KIRP	cis	rs17030434	0.834	rs11734251	chr4:154732218	C/T	cg14289246	chr4:154710475	SFRP2	-0.71	-8.61	-0.48	8.94e-16	Electrocardiographic conduction measures;
KIRP	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.73	9.24	0.51	1.18e-17	Coronary artery disease;
KIRP	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.7	9.04	0.5	4.65e-17	Blood metabolite levels;
KIRP	cis	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg04607699	chr11:48328132	OR4S1	-0.35	-4.93	-0.3	1.5e-6	HDL cholesterol;
KIRP	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.23	0.42	6.13e-12	Height;
KIRP	cis	rs7666738	0.546	rs10461174	chr4:98698293	G/A	cg05340658	chr4:99064831	C4orf37	0.66	7.67	0.44	4.04e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg06204229	chr3:52865917	ITIH4	0.46	5.32	0.32	2.28e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.92	-0.3	1.58e-6	Breast cancer;Mosquito bite size;
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.42	-7.35	-0.42	2.94e-12	Lung cancer;
KIRP	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	1.18	11.1	0.58	1.81e-23	Opioid sensitivity;
KIRP	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.43	-5.83	-0.35	1.72e-8	Monocyte count;
KIRP	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-7.54	-0.43	8.99e-13	Prudent dietary pattern;
KIRP	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg06204229	chr3:52865917	ITIH4	0.52	5.81	0.35	1.94e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs7818345	1.000	rs7835461	chr8:19307051	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.38	5.62	0.34	5.1e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.79	9.95	0.54	8.25e-20	Longevity;
KIRP	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.53	-7.06	-0.41	1.73e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.4	-6.49	-0.38	4.69e-10	Body mass index;
KIRP	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg04519387	chr11:65556438	OVOL1	0.35	5.36	0.32	1.9e-7	Acne (severe);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg02492759	chr16:1401824	C16orf42;GNPTG	-1.12	-6.21	-0.37	2.27e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg23693289	chr8:27183097	PTK2B	0.56	7.13	0.41	1.1e-11	Neuroticism;
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg23594656	chr7:65796392	TPST1	0.35	5.02	0.31	9.71e-7	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00049973	chr17:58603597	APPBP2	0.47	6.04	0.36	5.75e-9	Parkinson's disease;
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	13.63	0.66	7.09e-32	Platelet count;
KIRP	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.57	7.41	0.43	1.97e-12	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-0.94	-11.64	-0.6	2.99e-25	Blood protein levels;
KIRP	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg25706552	chr1:244017396	NA	0.64	6.79	0.4	8.35e-11	RR interval (heart rate);
KIRP	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg24296786	chr1:45957014	TESK2	-0.43	-5.31	-0.32	2.44e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	0.85	6.35	0.38	1.01e-9	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.86	-0.4	5.68e-11	Lung cancer;
KIRP	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg17366294	chr4:99064904	C4orf37	0.44	6.35	0.38	1.01e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9494145	0.531	rs9399136	chr6:135402339	T/C	cg22676075	chr6:135203613	NA	0.43	4.86	0.3	2.07e-6	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
KIRP	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.62	9.83	0.53	1.96e-19	Bone mineral density;
KIRP	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.53	14.06	0.67	2.32e-33	Systolic blood pressure;
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg03289416	chr15:75166202	SCAMP2	0.57	7.93	0.45	7.88e-14	Breast cancer;
KIRP	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.98	0.3	1.22e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	5.55	0.33	7.42e-8	Menarche (age at onset);
KIRP	cis	rs9603616	0.719	rs7330016	chr13:40233691	C/T	cg26701198	chr13:40229707	COG6	0.46	5.42	0.33	1.43e-7	Rheumatoid arthritis;
KIRP	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.82	-11.28	-0.58	4.52e-24	Prudent dietary pattern;
KIRP	cis	rs9486719	1.000	rs11153070	chr6:97039720	C/G	cg06623918	chr6:96969491	KIAA0776	-0.66	-6.11	-0.36	3.97e-9	Migraine;Coronary artery disease;
KIRP	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg21523564	chr15:75251491	NA	0.36	5.73	0.34	2.9e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02725872	chr8:58115012	NA	-0.55	-6.37	-0.38	8.97e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	trans	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.32	-0.37	1.2e-9	Obesity-related traits;
KIRP	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg26681399	chr22:41777847	TEF	-0.42	-4.97	-0.3	1.25e-6	Neuroticism;
KIRP	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg23920097	chr1:209922102	NA	0.45	5.47	0.33	1.11e-7	Red blood cell count;
KIRP	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.74	0.39	1.12e-10	Educational attainment;
KIRP	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.63	-0.44	5.05e-13	Retinal vascular caliber;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.62	-5.58	-0.34	6.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.89	-0.45	9.74e-14	Retinal vascular caliber;
KIRP	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.81	0.49	2.36e-16	Bipolar disorder;
KIRP	cis	rs7534824	0.625	rs61780284	chr1:101355166	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.71	0.34	3.31e-8	Refractive astigmatism;
KIRP	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.26	0.72	7.32e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.61	7.92	0.45	8.09e-14	Height;
KIRP	cis	rs7851660	0.874	rs7037175	chr9:100631662	G/C	cg13688889	chr9:100608707	NA	-0.67	-8.78	-0.49	2.74e-16	Strep throat;
KIRP	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.63	-9.1	-0.5	3.07e-17	Total body bone mineral density;
KIRP	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.51	-5.24	-0.32	3.53e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9815354	1.000	rs73079316	chr3:41863859	G/A	cg03022575	chr3:42003672	ULK4	0.64	6.72	0.39	1.27e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg18350739	chr11:68623251	NA	-0.51	-8.03	-0.46	3.93e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg08975724	chr8:8085496	FLJ10661	0.66	9.29	0.51	8.6e-18	Mood instability;
KIRP	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.63	8.96	0.5	8.55e-17	Schizophrenia;
KIRP	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.91	-0.45	8.52e-14	NT-proBNP levels in acute coronary syndrome;
KIRP	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.59	-0.39	2.63e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08822215	chr16:89438651	ANKRD11	-0.4	-5.37	-0.32	1.8e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05376524	chr12:96673206	CDK17	-0.4	-6.14	-0.36	3.38e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.4	5.07	0.31	7.94e-7	Testicular germ cell tumor;
KIRP	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	8.68	0.48	5.48e-16	Breast cancer;
KIRP	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg08885076	chr2:99613938	TSGA10	-0.54	-7.34	-0.42	3.14e-12	Chronic sinus infection;
KIRP	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9761603	0.812	rs9685314	chr4:138411620	C/T	cg12033966	chr4:138453416	PCDH18	0.42	5.54	0.33	7.59e-8	Diastolic blood pressure;
KIRP	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7113850	0.541	rs4360696	chr11:24217119	C/G	ch.11.24196551F	chr11:24239977	NA	0.85	8.61	0.48	8.68e-16	Bone fracture in osteoporosis;
KIRP	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.5	6.57	0.39	3.02e-10	Height;
KIRP	trans	rs12049351	0.774	rs2295624	chr1:229644157	G/T	cg00551153	chr21:47333731	PCBP3	-0.49	-6.21	-0.37	2.29e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-6.31	-0.37	1.32e-9	Chronic sinus infection;
KIRP	cis	rs7010876	0.568	rs10113080	chr8:89248749	C/T	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.05e-7	Schizophrenia;
KIRP	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19524238	chr7:2802976	GNA12	-0.35	-4.85	-0.3	2.21e-6	Height;
KIRP	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg05717871	chr11:638507	DRD4	-0.39	-5.58	-0.34	6.29e-8	Systemic lupus erythematosus;
KIRP	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-13.58	-0.65	1.01e-31	Ulcerative colitis;
KIRP	cis	rs9820353	1	rs9820353	chr3:142299926	A/G	cg20824294	chr3:142316082	PLS1	0.24	5.24	0.32	3.51e-7	Mean corpuscular volume;
KIRP	cis	rs4073221	1.000	rs4073221	chr3:18277488	T/G	cg07694806	chr3:18168406	NA	-0.85	-7.15	-0.42	9.6e-12	Parkinson's disease;
KIRP	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg03060546	chr3:49711283	APEH	0.48	6.4	0.38	7.74e-10	Parkinson's disease;
KIRP	cis	rs6696846	0.515	rs6593924	chr1:205110452	A/G	cg21643547	chr1:205240462	TMCC2	-0.47	-6.18	-0.37	2.63e-9	Red blood cell count;
KIRP	cis	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.13	-0.41	1.08e-11	Morning vs. evening chronotype;
KIRP	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg09365446	chr1:150670422	GOLPH3L	0.38	4.94	0.3	1.45e-6	Tonsillectomy;
KIRP	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	7.42	0.43	1.91e-12	Body mass index;
KIRP	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg05361325	chr10:32636312	EPC1	-0.65	-6.14	-0.36	3.26e-9	Sexual dysfunction (female);
KIRP	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg25486957	chr4:152246857	NA	-0.43	-5.14	-0.31	5.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3026101	0.671	rs739766	chr17:5290599	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg02375832	chr11:62437615	C11orf48	-0.52	-6.21	-0.37	2.21e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	1.07	14.02	0.67	3.36e-33	Post bronchodilator FEV1;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg03339469	chr19:44259181	C19orf61	0.47	6.18	0.37	2.7e-9	Colorectal cancer;
KIRP	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.89	13.45	0.65	2.8e-31	Testicular germ cell tumor;
KIRP	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.82	-0.4	6.92e-11	Menopause (age at onset);
KIRP	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23422044	chr7:1970798	MAD1L1	0.67	7.39	0.43	2.29e-12	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08597319	chr8:103876573	AZIN1	0.47	6.17	0.37	2.75e-9	Parkinson's disease;
KIRP	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.49	-6.58	-0.39	2.79e-10	Multiple sclerosis;
KIRP	cis	rs72781680	0.611	rs72783625	chr2:24315540	C/T	cg20701182	chr2:24300061	SF3B14	0.95	10.41	0.55	2.83e-21	Lymphocyte counts;
KIRP	cis	rs2708977	0.637	rs618454	chr2:97080093	C/G	cg01950434	chr2:97203154	ARID5A	-0.43	-5.33	-0.32	2.17e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10818894	1.000	rs10818894	chr9:126695770	A/G	cg16191174	chr9:126692580	DENND1A	-0.69	-8.85	-0.49	1.7e-16	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
KIRP	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg13902645	chr11:5959945	NA	-0.59	-6.26	-0.37	1.69e-9	DNA methylation (variation);
KIRP	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12756686	chr19:29218302	NA	-0.56	-4.92	-0.3	1.57e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7116495	0.786	rs610004	chr11:71797939	C/T	cg26138937	chr11:71823887	C11orf51	-0.65	-5.06	-0.31	8.15e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.39e-11	Arsenic metabolism;
KIRP	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.81	8.57	0.48	1.17e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7187994	0.945	rs16974444	chr16:84753740	T/C	cg07647771	chr16:84786436	USP10	-0.39	-5.03	-0.31	9.67e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs10073892	0.660	rs10067699	chr5:101953116	C/T	cg19774478	chr5:101632501	SLCO4C1	0.53	5.43	0.33	1.38e-7	Cognitive decline (age-related);
KIRP	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.89	11.76	0.6	1.29e-25	Cognitive function;
KIRP	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg18944383	chr4:111397179	ENPEP	0.54	9.58	0.52	1.1e-18	Height;
KIRP	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg06204229	chr3:52865917	ITIH4	0.47	5.4	0.33	1.59e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.56	-0.39	3.16e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg26528668	chr16:1614120	IFT140	0.4	4.85	0.3	2.16e-6	Coronary artery disease;
KIRP	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg17554472	chr22:41940697	POLR3H	0.63	6.28	0.37	1.55e-9	Cannabis dependence symptom count;
KIRP	cis	rs4589502	1.000	rs75502100	chr15:67131417	T/C	cg09911534	chr15:67153556	NA	-0.53	-4.87	-0.3	2.03e-6	Lung cancer (smoking interaction);
KIRP	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.81	-10.31	-0.55	5.89e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg25039879	chr17:56429692	SUPT4H1	0.59	5.07	0.31	7.95e-7	Cognitive test performance;
KIRP	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	0.86	10.04	0.54	4.12e-20	Neutrophil percentage of white cells;
KIRP	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17322444	chr19:33572249	GPATCH1	0.47	6.19	0.37	2.49e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14851114	chr7:27704471	NA	0.5	6.48	0.38	5.01e-10	Interleukin-4 levels;
KIRP	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg02378861	chr5:212933	CCDC127	-0.71	-5.61	-0.34	5.43e-8	Fat distribution (HIV);
KIRP	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.63	7.33	0.42	3.29e-12	Obesity-related traits;
KIRP	cis	rs4262150	0.810	rs72797215	chr5:151960560	C/G	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7113850	0.541	rs4536215	chr11:24245374	C/A	ch.11.24196551F	chr11:24239977	NA	0.94	7.83	0.45	1.46e-13	Bone fracture in osteoporosis;
KIRP	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10901296	0.660	rs2855198	chr9:133764606	T/C	cg03924115	chr9:133768966	QRFP	0.34	4.92	0.3	1.56e-6	Bilirubin levels;
KIRP	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg08133631	chr1:26527909	CATSPER4	-0.49	-5.21	-0.32	4e-7	Obesity-related traits;
KIRP	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.47	-0.38	5.15e-10	Blood pressure;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	13.42	0.65	3.4e-31	Platelet count;
KIRP	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg05484376	chr2:27715224	FNDC4	0.4	6.77	0.4	9.3e-11	Total body bone mineral density;
KIRP	cis	rs889512	0.642	rs73605139	chr16:75300038	C/T	cg03315344	chr16:75512273	CHST6	-0.67	-5.16	-0.31	5.07e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12826209	chr6:26865740	GUSBL1	0.71	8.74	0.49	3.65e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.66	-0.39	1.76e-10	Monocyte percentage of white cells;
KIRP	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.49	6.97	0.41	2.82e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8179	1.000	rs42033	chr7:92237533	A/T	cg15732164	chr7:92237376	CDK6	-0.68	-8.13	-0.46	2.09e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.47	-7.29	-0.42	4.28e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg21734707	chr17:3908241	ZZEF1	0.5	6.85	0.4	5.79e-11	Type 2 diabetes;
KIRP	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg04374321	chr14:90722782	PSMC1	0.51	5.59	0.34	6.15e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.15	-0.41	9.72e-12	Rheumatoid arthritis;
KIRP	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg03609598	chr5:56110824	MAP3K1	-0.42	-4.94	-0.3	1.45e-6	Coronary artery disease;
KIRP	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	1.03	18.6	0.76	7.93e-49	Systemic lupus erythematosus;
KIRP	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.74	0.39	1.15e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13161895	0.702	rs12652904	chr5:179496422	C/T	cg02702477	chr5:179499311	RNF130	1.09	7.06	0.41	1.69e-11	LDL cholesterol;
KIRP	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg27243121	chr11:70281584	CTTN	-0.43	-6.07	-0.36	4.81e-9	Inflammatory biomarkers;
KIRP	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.23	0.55	1.06e-20	Cognitive test performance;
KIRP	cis	rs11603020	0.904	rs11606677	chr11:57383377	G/A	cg19752551	chr11:57585705	CTNND1	-0.71	-9.84	-0.53	1.71e-19	Blood protein levels;
KIRP	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.6	-6.42	-0.38	6.92e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.46	0.74	5.75e-45	Platelet count;
KIRP	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.58	7.51	0.43	1.09e-12	Corneal astigmatism;
KIRP	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.73	-8.05	-0.46	3.47e-14	QRS complex (12-leadsum);
KIRP	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg07843065	chr1:150265600	MRPS21	-0.41	-5.78	-0.35	2.26e-8	Migraine;
KIRP	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.91	10.4	0.55	3.1e-21	Corneal astigmatism;
KIRP	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.52	6.03	0.36	5.83e-9	Primary sclerosing cholangitis;
KIRP	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	10.37	0.55	4e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09974990	chr16:67204447	NA	0.51	6.7	0.39	1.42e-10	Parkinson's disease;
KIRP	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.62	-7.0	-0.41	2.4e-11	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-9.01	-0.5	5.8e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18986451	chr3:100428869	TFG	0.63	7.65	0.44	4.49e-13	Smoking initiation;
KIRP	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg00745463	chr17:30367425	LRRC37B	0.82	6.78	0.4	8.62e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.86	-8.94	-0.5	9.34e-17	Educational attainment;
KIRP	cis	rs11627756	0.801	rs4906237	chr14:103077649	T/G	cg01864069	chr14:103024347	NA	-0.53	-6.28	-0.37	1.51e-9	Mean platelet volume;
KIRP	cis	rs7178909	0.902	rs3784386	chr15:90437426	A/G	cg19708238	chr15:90437601	AP3S2	0.58	8.03	0.46	4.03e-14	Common traits (Other);
KIRP	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg10760299	chr15:45669010	GATM	0.33	4.85	0.3	2.21e-6	Homoarginine levels;
KIRP	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg21181453	chr9:130700954	DPM2	-0.48	-7.13	-0.41	1.09e-11	Glaucoma (primary angle closure);
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-8.74	-0.49	3.7e-16	Platelet count;
KIRP	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.4e-11	Response to antipsychotic treatment;
KIRP	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	8.23	0.46	1.11e-14	Lymphocyte percentage of white cells;
KIRP	cis	rs11203032	0.831	rs10887929	chr10:90948864	T/C	cg16672925	chr10:90967113	CH25H	0.78	8.07	0.46	3.2e-14	Heart failure;
KIRP	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg26022315	chr17:47021804	SNF8	0.45	5.86	0.35	1.5e-8	Type 2 diabetes;
KIRP	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg23811061	chr2:86423046	IMMT	0.38	5.28	0.32	2.9e-7	Night sleep phenotypes;
KIRP	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.6	-6.82	-0.4	6.86e-11	Bipolar disorder;
KIRP	cis	rs7719624	0.571	rs13157486	chr5:135579422	G/A	cg12897067	chr5:135418308	NA	0.43	4.89	0.3	1.81e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs7116495	0.609	rs7924834	chr11:71644333	C/T	cg07596299	chr11:71824057	C11orf51	0.77	5.56	0.33	7.07e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs651907	0.967	rs694936	chr3:101587793	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.13	0.31	5.87e-7	Colorectal cancer;
KIRP	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg21778268	chr22:36877729	TXN2	-0.45	-6.01	-0.36	6.57e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg26149184	chr10:133730230	NA	0.42	5.16	0.31	5.03e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.27	0.47	8.42e-15	Menopause (age at onset);
KIRP	cis	rs7714584	1.000	rs12656600	chr5:150311872	A/G	cg22134413	chr5:150180641	NA	0.8	6.3	0.37	1.34e-9	Crohn's disease;
KIRP	cis	rs925255	0.743	rs7589485	chr2:28645120	C/A	cg01273330	chr2:28605224	NA	-0.32	-5.51	-0.33	8.99e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs589691	0.502	rs487662	chr11:64481880	G/A	cg09231725	chr11:64357281	SLC22A12	0.51	6.42	0.38	7.04e-10	Urate levels;
KIRP	cis	rs2505998	0.833	rs2742243	chr10:43601749	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.45	-4.91	-0.3	1.68e-6	Hirschsprung disease;
KIRP	cis	rs10463316	0.817	rs7701271	chr5:150776708	A/G	cg03212797	chr5:150827313	SLC36A1	0.45	5.83	0.35	1.77e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7870753	0.838	rs7871404	chr9:99262296	A/G	cg25260653	chr9:99212216	HABP4	0.53	5.77	0.35	2.33e-8	Height;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02004672	chr5:110074800	SLC25A46	-0.45	-6.02	-0.36	6.24e-9	Migraine with aura;
KIRP	cis	rs2040771	0.745	rs362148	chr22:19262852	T/C	cg02655711	chr22:19163373	SLC25A1	0.48	6.6	0.39	2.47e-10	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11987759	chr7:65425863	GUSB	0.5	6.47	0.38	5.22e-10	Aortic root size;
KIRP	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.64	-8.17	-0.46	1.64e-14	Colorectal cancer;
KIRP	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.5	-0.33	9.72e-8	Metabolite levels;
KIRP	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.72e-6	Systolic blood pressure;
KIRP	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.41	-6.57	-0.39	2.95e-10	Lung cancer;
KIRP	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	0.95	14.03	0.67	2.91e-33	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg27205649	chr11:78285834	NARS2	-0.67	-7.39	-0.43	2.29e-12	Alzheimer's disease (survival time);
KIRP	cis	rs829661	0.895	rs6749074	chr2:30791152	A/G	cg10949345	chr2:30726833	LCLAT1	0.72	9.53	0.52	1.6e-18	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02287918	chr21:30396957	USP16	-0.45	-6.17	-0.37	2.86e-9	Myopia;
KIRP	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg06042504	chr8:55087323	NA	-0.6	-7.18	-0.42	8.1e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg10223061	chr2:219282414	VIL1	0.43	6.97	0.41	2.92e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-1.06	-17.61	-0.75	1.88e-45	Intelligence (multi-trait analysis);
KIRP	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	5.76	0.34	2.47e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg07636037	chr3:49044803	WDR6	0.65	6.73	0.39	1.19e-10	Menarche (age at onset);
KIRP	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg10503236	chr1:231470652	EXOC8	-0.53	-7.48	-0.43	1.35e-12	Hemoglobin concentration;
KIRP	cis	rs9309473	0.948	rs2421550	chr2:73658686	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.71	-0.34	3.26e-8	Metabolite levels;
KIRP	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.34	-0.32	2.06e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	1.03	14.23	0.67	6.42e-34	Menopause (age at onset);
KIRP	cis	rs7851660	0.874	rs7847010	chr9:100630439	T/C	cg13688889	chr9:100608707	NA	-0.69	-8.92	-0.49	1.1e-16	Strep throat;
KIRP	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.9	-12.37	-0.62	1.22e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4356932	0.905	rs4859597	chr4:76956630	A/T	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs62413470	1.000	rs17818151	chr6:55943812	G/T	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	trans	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg02002194	chr4:3960332	NA	-0.49	-6.64	-0.39	2.02e-10	Parkinson's disease;
KIRP	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.68	6.22	0.37	2.07e-9	Menarche (age at onset);
KIRP	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.91	14.64	0.68	2.53e-35	Ulcerative colitis;
KIRP	cis	rs7084402	0.967	rs10763552	chr10:60273977	C/T	cg05938607	chr10:60274200	BICC1	0.42	10.2	0.55	1.35e-20	Refractive error;
KIRP	cis	rs7534824	0.625	rs12568338	chr1:101500622	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	6.75	0.4	1.03e-10	Refractive astigmatism;
KIRP	cis	rs6831352	0.704	rs1800759	chr4:100065509	T/G	cg12011299	chr4:100065546	ADH4	0.69	9.51	0.52	1.83e-18	Alcohol dependence;
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.24	-4.88	-0.3	1.87e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8038465	0.623	rs6495073	chr15:73947534	A/T	cg15420318	chr15:73925796	NPTN	0.66	9.59	0.52	1.02e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg10932868	chr11:921992	NA	0.67	9.13	0.5	2.59e-17	Alzheimer's disease (late onset);
KIRP	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg12756093	chr1:115239321	AMPD1	0.53	7.1	0.41	1.31e-11	Autism;
KIRP	cis	rs2569991	0.636	rs2600222	chr3:12937617	C/G	cg22481960	chr3:13008800	IQSEC1	-0.54	-5.42	-0.33	1.39e-7	Periodontitis (DPAL);
KIRP	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg23587288	chr2:27483067	SLC30A3	-0.64	-7.23	-0.42	6.19e-12	Blood metabolite levels;
KIRP	cis	rs4692589	1.000	rs11732126	chr4:170937416	A/G	cg19918862	chr4:170955249	NA	0.42	5.07	0.31	7.77e-7	Anxiety disorder;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01238044	chr22:24384105	GSTT1	-0.49	-6.32	-0.37	1.23e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.64	5.49	0.33	9.78e-8	Schizophrenia;
KIRP	cis	rs1215050	0.765	rs471500	chr4:98714820	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.69	-0.39	1.46e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg24565620	chr2:194026	NA	0.7	7.81	0.45	1.6e-13	Blood protein levels;
KIRP	cis	rs9653442	0.564	rs4851256	chr2:100775045	A/G	cg17356467	chr2:100759845	AFF3	0.41	5.82	0.35	1.83e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg06042504	chr8:55087323	NA	-0.54	-6.68	-0.39	1.6e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.71	7.84	0.45	1.33e-13	Tourette syndrome;
KIRP	cis	rs7980687	0.527	rs1727295	chr12:123616861	G/A	cg06742321	chr12:123595122	PITPNM2	0.41	5.09	0.31	7.09e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg10207240	chr12:122356781	WDR66	0.45	5.86	0.35	1.48e-8	Mean corpuscular volume;
KIRP	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg14675211	chr2:100938903	LONRF2	0.6	7.89	0.45	9.69e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11955175	1.000	rs11956743	chr5:40677593	G/A	cg17351974	chr5:40835760	RPL37	0.61	5.32	0.32	2.29e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.05	-0.41	1.81e-11	Menopause (age at onset);
KIRP	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg25730555	chr22:47059586	GRAMD4	0.48	5.42	0.33	1.39e-7	Urate levels in obese individuals;
KIRP	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.26	-0.37	1.67e-9	Alcohol dependence;
KIRP	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.87	7.47	0.43	1.4e-12	Fat distribution (HIV);
KIRP	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg18833306	chr6:118973337	C6orf204	0.4	5.04	0.31	8.85e-7	Electrocardiographic conduction measures;
KIRP	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.67	9.53	0.52	1.56e-18	Colorectal cancer;
KIRP	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg17652424	chr22:38574118	PLA2G6	-0.28	-5.74	-0.34	2.73e-8	Cutaneous nevi;
KIRP	cis	rs7180079	0.620	rs11071796	chr15:64712608	A/G	cg15337035	chr15:64978493	NA	-0.48	-5.29	-0.32	2.76e-7	Monocyte count;
KIRP	cis	rs918629	0.679	rs57471342	chr5:95272429	A/C	cg16656078	chr5:95278638	ELL2	-0.5	-7.24	-0.42	5.65e-12	IgG glycosylation;
KIRP	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.67	-7.46	-0.43	1.49e-12	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	7.13e-8	Life satisfaction;
KIRP	cis	rs6681460	0.800	rs539014	chr1:67211887	C/T	cg02459107	chr1:67143332	SGIP1	-0.4	-5.53	-0.33	8.01e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9815354	0.680	rs73073239	chr3:42014597	G/C	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.53	-6.39	-0.38	8.45e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9826463	0.759	rs73228782	chr3:142341896	G/A	cg20824294	chr3:142316082	PLS1	0.53	7.09	0.41	1.38e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg22431228	chr1:16359049	CLCNKA	0.44	5.36	0.32	1.9e-7	Dilated cardiomyopathy;
KIRP	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.62	7.48	0.43	1.31e-12	Corneal astigmatism;
KIRP	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg25801113	chr15:45476975	SHF	0.49	9.66	0.52	6.21e-19	Uric acid levels;
KIRP	cis	rs10090774	0.760	rs6993266	chr8:141762659	G/A	cg26074100	chr8:141568712	EIF2C2	-0.32	-4.95	-0.3	1.4e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.51	0.33	9.11e-8	Educational attainment (years of education);
KIRP	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.5	-5.96	-0.36	8.6e-9	Ulcerative colitis;
KIRP	cis	rs4835473	0.932	rs7356157	chr4:144660386	T/C	cg08833778	chr4:144622313	FREM3	0.35	5.12	0.31	6.14e-7	Immature fraction of reticulocytes;
KIRP	cis	rs11610422	1.000	rs34325065	chr12:31414505	C/G	cg14306366	chr12:31406441	NA	-0.57	-5.88	-0.35	1.36e-8	Coronary artery disease;
KIRP	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.39	3.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs580438	0.530	rs4684128	chr3:13380095	T/C	cg10657019	chr3:13328039	NA	-0.59	-7.76	-0.44	2.32e-13	Myringotomy;
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg11641102	chr8:27183873	PTK2B	0.46	6.03	0.36	5.9e-9	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12530353	chr6:8435731	SLC35B3	0.49	6.04	0.36	5.61e-9	Parkinson's disease;
KIRP	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg10538030	chr17:27276405	PHF12	0.48	4.9	0.3	1.77e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg09911534	chr15:67153556	NA	-0.53	-4.87	-0.3	1.98e-6	Lung cancer (smoking interaction);
KIRP	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	0.95	17.16	0.74	6.35e-44	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs737008	0.960	rs949429	chr16:11376029	C/T	cg00044050	chr16:11439710	C16orf75	-0.61	-7.53	-0.43	9.37e-13	Obesity-related traits;
KIRP	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.42	5.3	0.32	2.51e-7	White matter hyperintensity burden;
KIRP	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	1.02	14.82	0.69	5.98e-36	Menopause (age at onset);
KIRP	cis	rs10073892	0.620	rs10035158	chr5:101922775	G/T	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg02487422	chr3:49467188	NICN1	0.37	5.24	0.32	3.44e-7	Parkinson's disease;
KIRP	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.66	9.11	0.5	2.86e-17	Coronary artery disease;
KIRP	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.51	7.1	0.41	1.37e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10421328	0.821	rs2288867	chr19:19765568	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.46	5.29	0.32	2.67e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg02733842	chr7:1102375	C7orf50	-0.5	-5.81	-0.35	1.93e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg23736307	chr8:27182930	PTK2B	0.52	6.77	0.4	9.57e-11	Neuroticism;
KIRP	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg14675211	chr2:100938903	LONRF2	-0.51	-6.3	-0.37	1.4e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs6845263	1.000	rs6845263	chr4:102276682	A/G	cg06665941	chr21:34602869	IFNAR2	-0.59	-6.04	-0.36	5.68e-9	Superior crus of antihelix expression;
KIRP	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.33	-0.32	2.21e-7	Type 2 diabetes;
KIRP	cis	rs17453880	0.929	rs4618416	chr5:152028995	G/A	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg05044414	chr3:183734942	ABCC5	0.38	5.75	0.34	2.62e-8	Anterior chamber depth;
KIRP	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.94	15.67	0.71	7.25e-39	Ulcerative colitis;
KIRP	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg22437258	chr11:111473054	SIK2	-0.56	-6.15	-0.36	3.13e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7130144	0.541	rs7925596	chr11:130463610	C/G	cg26307797	chr11:130446613	NA	-0.63	-5.21	-0.32	4.02e-7	Urate levels in lean individuals;
KIRP	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg04733989	chr22:42467013	NAGA	0.58	7.58	0.44	6.89e-13	Cognitive function;
KIRP	cis	rs524023	0.874	rs506338	chr11:64440920	T/C	cg09231725	chr11:64357281	SLC22A12	0.61	8.03	0.46	3.98e-14	Urate levels in obese individuals;
KIRP	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	1.1	12.09	0.61	1.05e-26	Post bronchodilator FEV1;
KIRP	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg20387954	chr3:183756860	HTR3D	0.41	5.43	0.33	1.34e-7	Anterior chamber depth;
KIRP	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	1.02	15.95	0.71	8.27e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7837860	0.588	rs28630437	chr8:89298359	A/G	cg08624180	chr8:89339080	MMP16	-0.59	-5.01	-0.3	1.04e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4149577	0.630	rs4149570	chr12:6451590	A/C	cg00556515	chr12:6442607	TNFRSF1A	0.37	6.29	0.37	1.41e-9	Monocyte count;
KIRP	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.94	-13.64	-0.66	6.14e-32	Coronary artery disease;
KIRP	cis	rs17608059	0.611	rs2108591	chr17:13922625	C/A	cg11395062	chr17:14139857	CDRT15	0.52	6.43	0.38	6.64e-10	Temperament;
KIRP	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg00343986	chr7:65444356	GUSB	0.44	5.16	0.31	5.06e-7	Aortic root size;
KIRP	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	9.13	0.5	2.55e-17	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.57	7.52	0.43	9.98e-13	White matter hyperintensity burden;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17286253	chr1:185703489	HMCN1	0.47	6.38	0.38	8.49e-10	Smoking initiation;
KIRP	cis	rs6968419	0.747	rs3779509	chr7:115864889	C/A	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-6.83	-0.4	6.73e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg06521331	chr12:34319734	NA	0.49	6.11	0.36	3.96e-9	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00936141	chr2:17935227	SMC6;GEN1	0.46	6.74	0.39	1.14e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.86	-7.08	-0.41	1.54e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9549328	0.800	rs9549326	chr13:113630453	C/T	cg17524180	chr13:113633600	MCF2L	-0.32	-5.96	-0.35	8.89e-9	Systolic blood pressure;
KIRP	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.63	9.06	0.5	4.24e-17	Schizophrenia;
KIRP	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.53	-0.38	3.66e-10	Aortic root size;
KIRP	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	0.64	6.06	0.36	5.14e-9	Skin colour saturation;
KIRP	trans	rs9379774	0.935	rs212927	chr6:25534677	C/T	cg06340200	chr16:11836643	TXNDC11	0.58	6.05	0.36	5.43e-9	Coronary artery disease;
KIRP	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg06636001	chr8:8085503	FLJ10661	0.91	12.81	0.63	3.88e-29	Mood instability;
KIRP	cis	rs212524	0.544	rs9426748	chr1:21558490	C/A	cg08890418	chr1:21044141	KIF17	0.39	5.76	0.34	2.51e-8	Height;
KIRP	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21747090	chr2:27597821	SNX17	0.47	6.64	0.39	2.03e-10	Total body bone mineral density;
KIRP	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg16482183	chr6:26056742	HIST1H1C	0.6	6.82	0.4	6.95e-11	Iron status biomarkers;
KIRP	cis	rs13202913	0.837	rs3734800	chr6:151766552	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.58	4.87	0.3	2.03e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.85	-9.49	-0.52	2.15e-18	Schizophrenia;
KIRP	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg08619932	chr19:49200058	FUT2	0.37	5.83	0.35	1.72e-8	Dietary macronutrient intake;
KIRP	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs2213920	1.000	rs9409169	chr9:118273407	A/G	cg13918206	chr9:118159781	DEC1	-0.89	-8.75	-0.49	3.53e-16	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	8.64	0.48	7.13e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7084402	0.967	rs1658486	chr10:60288081	A/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs1832871	0.672	rs9457363	chr6:158777515	C/T	cg07215822	chr6:158701037	NA	-0.63	-7.27	-0.42	4.72e-12	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12714793	chr17:74303886	QRICH2	-0.48	-6.03	-0.36	6.1e-9	Parkinson's disease;
KIRP	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-6.77	-0.4	9.43e-11	Total body bone mineral density;
KIRP	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.12e-6	Atopic dermatitis;
KIRP	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs3849570	0.555	rs9968070	chr3:82010368	G/A	cg07356753	chr3:81810745	GBE1	-0.54	-6.46	-0.38	5.62e-10	Waist circumference;Body mass index;
KIRP	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-0.85	-9.15	-0.5	2.21e-17	Gut microbiome composition (summer);
KIRP	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg07212818	chr11:638076	DRD4	-0.4	-5.12	-0.31	6.14e-7	Systemic lupus erythematosus;
KIRP	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg26065057	chr18:74961000	GALR1	0.62	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg10223061	chr2:219282414	VIL1	0.28	4.86	0.3	2.06e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg17764715	chr19:33622953	WDR88	0.68	8.44	0.47	2.77e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg26084005	chr2:241760190	KIF1A	-0.5	-6.56	-0.39	3.21e-10	Urinary metabolites;
KIRP	trans	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.97	12.93	0.64	1.62e-29	Breast cancer;
KIRP	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	7.97	0.45	6.07e-14	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.57	8.59	0.48	1.02e-15	Personality dimensions;
KIRP	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.41	-5.74	-0.34	2.74e-8	Blood metabolite levels;
KIRP	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.47	6.36	0.38	9.84e-10	Red blood cell count;
KIRP	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg05528293	chr18:74961138	GALR1	0.49	5.2	0.31	4.22e-7	Obesity-related traits;
KIRP	trans	rs995758	0.605	rs10029430	chr4:145498412	G/A	cg06049171	chr15:69126265	MIR548H4	0.5	6.12	0.36	3.58e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs35740288	0.822	rs4843090	chr15:86220629	T/C	cg10818794	chr15:86012489	AKAP13	-0.44	-5.08	-0.31	7.39e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.47	0.38	5.27e-10	Major depressive disorder;
KIRP	cis	rs9815354	1.000	rs939558	chr3:41976040	C/A	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06850241	chr22:41845214	NA	0.44	4.95	0.3	1.4e-6	Vitiligo;
KIRP	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.7	9.58	0.52	1.16e-18	Mean corpuscular volume;
KIRP	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.59	-0.39	2.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.72	6.61	0.39	2.39e-10	Methadone dose in opioid dependence;
KIRP	cis	rs4658101	0.700	rs10874796	chr1:92050825	T/C	cg09075522	chr1:92031145	NA	0.45	5.57	0.33	6.83e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs7709377	0.574	rs13162293	chr5:115507893	A/G	cg23108291	chr5:115420582	COMMD10	0.43	5.05	0.31	8.7e-7	Metabolite levels  (X-11787);
KIRP	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	9.0	0.5	6.46e-17	IgG glycosylation;
KIRP	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg01616529	chr11:638424	DRD4	-0.42	-5.35	-0.32	1.99e-7	Systemic lupus erythematosus;
KIRP	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg23188430	chr6:125850052	NA	-0.34	-5.28	-0.32	2.86e-7	Brugada syndrome;
KIRP	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.59	-9.5	-0.52	1.95e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4765905	0.733	rs1108222	chr12:2332856	C/A	cg10668781	chr12:2307325	CACNA1C	-0.31	-5.82	-0.35	1.83e-8	Schizophrenia;
KIRP	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.51	-5.29	-0.32	2.66e-7	Corneal structure;
KIRP	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00857998	chr1:205179979	DSTYK	0.61	7.67	0.44	3.96e-13	Red blood cell count;
KIRP	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.95	0.4	3.36e-11	Platelet count;
KIRP	cis	rs11638352	0.661	rs2615269	chr15:44427956	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	6.06	0.36	5.1e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg23307798	chr14:103986281	CKB	-0.44	-6.03	-0.36	6.09e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.64	7.77	0.44	2.14e-13	Coronary artery disease;
KIRP	cis	rs11718455	0.573	rs4682701	chr3:43905870	G/A	cg08738300	chr3:44038990	NA	-0.42	-6.12	-0.36	3.69e-9	Coronary artery disease;
KIRP	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg03735888	chr19:58951602	ZNF132	0.46	5.51	0.33	9e-8	Uric acid clearance;
KIRP	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.66	8.08	0.46	2.97e-14	Vitiligo;
KIRP	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg00079169	chr19:2811669	THOP1	0.46	5.01	0.3	1.02e-6	Total cholesterol levels;
KIRP	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg23815491	chr16:72088622	HP	0.47	7.52	0.43	1.04e-12	Fibrinogen levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14552260	chr9:36572685	MELK	0.47	6.32	0.37	1.2e-9	Parkinson's disease;
KIRP	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.41	5.27	0.32	2.98e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs830233	0.697	rs62383304	chr5:165440981	C/T	cg13976338	chr5:165423657	NA	-0.63	-6.08	-0.36	4.59e-9	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs7903847	0.642	rs7084654	chr10:99135262	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-5.86	-0.35	1.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7010876	0.568	rs28904614	chr8:89233623	G/A	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg05315796	chr3:52349193	DNAH1	0.42	6.1	0.36	4.16e-9	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00933542	chr6:150070202	PCMT1	0.29	5.68	0.34	3.7e-8	Lung cancer;
KIRP	cis	rs763512	0.504	rs11652399	chr17:35869781	G/T	cg16670864	chr17:35848621	DUSP14	0.45	5.29	0.32	2.71e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.43	7.04	0.41	1.89e-11	Testicular germ cell tumor;
KIRP	cis	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg19847130	chr8:10466454	RP1L1	0.32	5.11	0.31	6.53e-7	Neuroticism;
KIRP	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.42	-5.22	-0.32	3.78e-7	Aortic root size;
KIRP	cis	rs12362504	0.504	rs1546542	chr11:9900458	G/T	cg07197493	chr11:9884649	SBF2	-0.44	-6.08	-0.36	4.55e-9	Survival in pancreatic cancer;
KIRP	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg10189774	chr4:17578691	LAP3	0.51	6.2	0.37	2.32e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg10254082	chr7:997346	NA	0.48	5.0	0.3	1.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg20060108	chr2:102954350	IL1RL1	-0.64	-5.67	-0.34	4.06e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.22	-0.37	2.09e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.5	6.52	0.38	3.86e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg22903471	chr2:27725779	GCKR	0.4	5.46	0.33	1.15e-7	Oral cavity cancer;
KIRP	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg03060546	chr3:49711283	APEH	0.46	6.22	0.37	2.16e-9	Parkinson's disease;
KIRP	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg04398451	chr17:18023971	MYO15A	-0.68	-9.08	-0.5	3.74e-17	Total body bone mineral density;
KIRP	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg12560992	chr17:57184187	TRIM37	0.63	6.11	0.36	3.85e-9	Cognitive test performance;
KIRP	cis	rs4148660	1.000	rs12366938	chr12:22064714	A/G	cg14669847	chr12:22099120	NA	-0.37	-6.03	-0.36	6.09e-9	Gout;
KIRP	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.54	4.9	0.3	1.76e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs735860	0.763	rs2817111	chr6:53125700	G/C	cg10236188	chr6:53219634	NA	-0.38	-4.96	-0.3	1.31e-6	Glaucoma;
KIRP	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.49	-5.49	-0.33	1.02e-7	Neuroticism;
KIRP	cis	rs2073499	0.872	rs78671882	chr3:50411188	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.65	4.89	0.3	1.82e-6	Schizophrenia;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg07364009	chr16:48381505	LONP2	-0.5	-6.23	-0.37	2.02e-9	Select biomarker traits;
KIRP	cis	rs4776059	0.550	rs17651941	chr15:52948626	C/G	cg25063058	chr15:52860530	ARPP19	-0.59	-4.99	-0.3	1.16e-6	Schizophrenia;
KIRP	cis	rs10464059	0.511	rs3805705	chr5:179738237	T/C	cg02891314	chr5:179741120	GFPT2	0.64	6.01	0.36	6.49e-9	Parkinson's disease;
KIRP	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg23479056	chr15:41276147	INO80	-0.41	-6.07	-0.36	4.86e-9	Menopause (age at onset);
KIRP	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.75	-0.63	6.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.83	-11.95	-0.61	2.92e-26	Platelet count;
KIRP	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.28	-0.32	2.83e-7	Neutrophil percentage of white cells;
KIRP	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.83e-8	Lung cancer;
KIRP	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.85	12.5	0.62	4.33e-28	Lung cancer in ever smokers;
KIRP	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.36	5.16	0.31	5.06e-7	Resistin levels;
KIRP	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	6.74	0.39	1.14e-10	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg17207736	chr8:142237307	SLC45A4	-0.52	-6.68	-0.39	1.62e-10	Immature fraction of reticulocytes;
KIRP	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.58	7.82	0.45	1.56e-13	Schizophrenia;
KIRP	cis	rs6991838	0.584	rs6994213	chr8:66513732	A/G	cg13398993	chr8:66546079	ARMC1	-0.45	-5.23	-0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.67	8.29	0.47	7.29e-15	Neutrophil percentage of white cells;
KIRP	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05220968	chr6:146057943	EPM2A	-0.43	-5.37	-0.32	1.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.46	-6.2	-0.37	2.38e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.45	0.38	5.84e-10	Height;
KIRP	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.76	-0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs3857747	0.538	rs11764504	chr7:40372958	G/A	cg00420559	chr7:40367873	C7orf10	-0.43	-6.25	-0.37	1.81e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.58	0.33	6.45e-8	Lung cancer;
KIRP	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.7	0.44	3.23e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg13266496	chr6:110720918	DDO	-0.36	-5.87	-0.35	1.41e-8	Platelet distribution width;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.71	-9.64	-0.52	7.29e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg14768367	chr16:72042858	DHODH	-0.92	-10.12	-0.54	2.37e-20	Blood protein levels;
KIRP	cis	rs11586313	0.507	rs6658967	chr1:152870372	C/G	cg13444842	chr1:152974279	SPRR3	-0.45	-6.28	-0.37	1.49e-9	Vitamin D levels;
KIRP	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg08662619	chr6:150070041	PCMT1	0.33	5.26	0.32	3.1e-7	Lung cancer;
KIRP	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.46	-4.84	-0.3	2.26e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs6688613	0.759	rs61815132	chr1:166920911	A/G	cg07049167	chr1:166818506	POGK	0.47	5.0	0.3	1.1e-6	Refractive astigmatism;
KIRP	trans	rs6810798	0.780	rs11735996	chr4:148296166	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	0.54	6.33	0.37	1.14e-9	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12107626	chr17:39992626	KLHL10;NT5C3L	0.63	7.4	0.43	2.18e-12	Smoking initiation;
KIRP	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg26554054	chr8:600488	NA	0.72	5.17	0.31	4.92e-7	IgG glycosylation;
KIRP	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.39	7.57	0.43	7.39e-13	Educational attainment (years of education);
KIRP	cis	rs238295	0.766	rs6139762	chr20:5546694	C/T	cg24001556	chr20:5591874	RP5-1022P6.2	0.51	5.26	0.32	3.08e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs1678542	0.651	rs2888334	chr12:57976647	C/G	cg00677455	chr12:58241039	CTDSP2	-0.6	-6.25	-0.37	1.84e-9	Rheumatoid arthritis;
KIRP	cis	rs5753037	0.809	rs740041	chr22:30200099	A/G	cg27665648	chr22:30112403	NA	0.45	6.23	0.37	1.97e-9	Type 1 diabetes;
KIRP	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07402062	chr16:89894098	SPIRE2	0.36	7.71	0.44	3.11e-13	Vitiligo;
KIRP	cis	rs714027	0.565	rs2285667	chr22:30384104	T/A	cg01021169	chr22:30184971	ASCC2	-0.41	-4.99	-0.3	1.13e-6	Lymphocyte counts;
KIRP	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.07	-0.36	4.93e-9	Personality dimensions;
KIRP	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.63	-6.46	-0.38	5.58e-10	Platelet distribution width;
KIRP	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg11814155	chr7:99998594	ZCWPW1	0.62	5.76	0.34	2.5e-8	Platelet count;
KIRP	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-0.78	-7.48	-0.43	1.3e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.74	10.54	0.56	1.1e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.15	15.99	0.71	6.03e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg02297831	chr4:17616191	MED28	-0.5	-6.19	-0.37	2.54e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.16e-7	Aortic root size;
KIRP	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.72	5.79	0.35	2.12e-8	Diabetic retinopathy;
KIRP	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg08975724	chr8:8085496	FLJ10661	0.69	9.6	0.52	9.82e-19	Mood instability;
KIRP	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.53	6.13	0.36	3.54e-9	Tonsillectomy;
KIRP	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.57	6.88	0.4	5.02e-11	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg05484376	chr2:27715224	FNDC4	0.4	6.71	0.39	1.34e-10	Total body bone mineral density;
KIRP	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.88	0.45	1.06e-13	Corneal astigmatism;
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg09355771	chr2:177043147	NA	0.56	7.11	0.41	1.27e-11	IgG glycosylation;
KIRP	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.83	10.22	0.55	1.14e-20	Corneal astigmatism;
KIRP	cis	rs10463316	0.608	rs7700423	chr5:150769155	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.6	-0.39	2.51e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg01689657	chr7:91764605	CYP51A1	0.39	5.65	0.34	4.42e-8	Breast cancer;
KIRP	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs4786125	0.596	rs12149100	chr16:6922512	T/G	cg03623568	chr16:6915990	A2BP1	-0.44	-5.31	-0.32	2.48e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg19507638	chr5:93509721	C5orf36	-0.54	-5.13	-0.31	5.8e-7	Diabetic retinopathy;
KIRP	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.54	-7.82	-0.45	1.58e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9443189	0.813	rs2748948	chr6:76437994	T/A	cg01950844	chr6:76311363	SENP6	-0.59	-6.44	-0.38	6.39e-10	Prostate cancer;
KIRP	cis	rs1712517	1.000	rs1712517	chr10:105033015	C/T	cg05636881	chr10:105038444	INA	0.43	6.29	0.37	1.4e-9	Migraine;
KIRP	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.8	12.25	0.62	3.01e-27	IgG glycosylation;
KIRP	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11987759	chr7:65425863	GUSB	-0.67	-9.11	-0.5	3.01e-17	Aortic root size;
KIRP	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.71	8.35	0.47	4.95e-15	Coronary artery disease;
KIRP	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.47	-5.44	-0.33	1.31e-7	Response to amphetamines;
KIRP	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.64	-9.26	-0.51	1.06e-17	Educational attainment;
KIRP	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg15556689	chr8:8085844	FLJ10661	0.61	7.67	0.44	4.01e-13	Neuroticism;
KIRP	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.53	7.6	0.44	6.16e-13	Mean corpuscular volume;
KIRP	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.13	0.31	5.99e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.78	-0.4	8.98e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	cg12689670	chr1:183009347	LAMC1	0.42	5.91	0.35	1.16e-8	Colorectal cancer;
KIRP	cis	rs2073300	1.000	rs6137967	chr20:23447108	A/T	cg12480562	chr20:23434244	CST11	-0.59	-5.94	-0.35	9.49e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1903068	0.853	rs28680424	chr4:56009245	T/C	cg20092376	chr4:56023423	NA	0.42	5.17	0.31	4.83e-7	Endometriosis;
KIRP	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg20818283	chr2:191399100	TMEM194B	0.54	7.05	0.41	1.8e-11	Pulse pressure;
KIRP	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg11635098	chr7:100497156	NA	-0.63	-6.7	-0.39	1.4e-10	Resting heart rate;
KIRP	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15644404	chr18:77186268	NFATC1	-0.97	-7.92	-0.45	8.04e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs656319	0.591	rs17734690	chr8:9713196	T/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.0	-0.45	4.89e-14	Myopia (pathological);
KIRP	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.93	14.26	0.67	4.87e-34	Chronic sinus infection;
KIRP	trans	rs1106684	1.000	rs67810505	chr7:131463968	C/G	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg16341495	chr8:142228727	SLC45A4	0.39	4.87	0.3	2.04e-6	Immature fraction of reticulocytes;
KIRP	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.73	0.34	2.86e-8	Aortic root size;
KIRP	trans	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.12e-12	Bladder cancer;
KIRP	cis	rs34245846	0.769	rs12058931	chr1:154825093	C/A	cg09359103	chr1:154839909	KCNN3	0.52	5.78	0.35	2.28e-8	Atrial fibrillation;
KIRP	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.21	-0.37	2.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg18135555	chr8:22132992	PIWIL2	0.39	6.01	0.36	6.67e-9	Hypertriglyceridemia;
KIRP	cis	rs11264213	0.901	rs683622	chr1:36443569	C/T	cg27506609	chr1:36549197	TEKT2	-0.75	-6.74	-0.39	1.13e-10	Schizophrenia;
KIRP	cis	rs7808935	0.914	rs11982766	chr7:27983781	C/T	cg22168087	chr7:27702803	HIBADH	0.76	7.77	0.44	2.09e-13	Prostate cancer;
KIRP	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.26	11.81	0.6	8.44e-26	Alzheimer's disease (late onset);
KIRP	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.35e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7737355	0.947	rs6895586	chr5:130588008	C/A	cg06307176	chr5:131281290	NA	0.51	5.47	0.33	1.11e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.03e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg27121462	chr16:89883253	FANCA	0.53	6.9	0.4	4.35e-11	Vitiligo;
KIRP	cis	rs9311474	0.713	rs352168	chr3:52237970	C/T	cg05315796	chr3:52349193	DNAH1	0.42	6.35	0.38	1.01e-9	Electroencephalogram traits;
KIRP	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg18306943	chr3:40428807	ENTPD3	0.45	5.81	0.35	1.96e-8	Renal cell carcinoma;
KIRP	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.5	-5.88	-0.35	1.35e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.66	8.97	0.5	7.56e-17	Coronary artery disease;
KIRP	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.97	-0.41	2.92e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg19610905	chr11:61596333	FADS2	-0.53	-6.6	-0.39	2.49e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.75	-8.21	-0.46	1.24e-14	Corneal astigmatism;
KIRP	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg26784012	chr10:32216390	ARHGAP12	0.31	4.98	0.3	1.21e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg21475434	chr5:93447410	FAM172A	0.76	7.0	0.41	2.43e-11	Diabetic retinopathy;
KIRP	cis	rs59868192	0.925	rs1002774	chr15:42261781	C/T	cg20935245	chr15:42234343	EHD4	-0.53	-5.3	-0.32	2.61e-7	White blood cell count;
KIRP	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.08	-8.0	-0.45	5e-14	Mitochondrial DNA levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24663490	chr6:27832932	HIST1H2AL	-0.44	-6.11	-0.36	3.84e-9	Survival in pancreatic cancer;
KIRP	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.53	7.11	0.41	1.25e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.35	-6.16	-0.37	2.98e-9	Renal cell carcinoma;
KIRP	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.44	-0.38	6.32e-10	Neuroticism;
KIRP	cis	rs11203032	0.831	rs11203022	chr10:90954068	G/A	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs6910061	1.000	rs9468446	chr6:11118718	C/T	cg27233058	chr6:11094804	LOC221710	0.56	5.64	0.34	4.54e-8	Diabetic kidney disease;
KIRP	cis	rs4132509	0.843	rs6671475	chr1:243789342	A/G	cg25706552	chr1:244017396	NA	0.54	6.98	0.41	2.7e-11	RR interval (heart rate);
KIRP	cis	rs6504622	0.537	rs1662577	chr17:44996759	C/A	cg16759221	chr17:45003025	GOSR2	-0.39	-5.85	-0.35	1.54e-8	Orofacial clefts;
KIRP	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12311346	chr5:56204834	C5orf35	-0.37	-4.9	-0.3	1.71e-6	Coronary artery disease;
KIRP	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.75	-9.89	-0.53	1.21e-19	Blood metabolite levels;
KIRP	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18932078	chr1:2524107	MMEL1	-0.46	-6.34	-0.37	1.08e-9	Ulcerative colitis;
KIRP	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg14683738	chr19:37701593	ZNF585B	0.52	5.2	0.31	4.13e-7	Coronary artery calcification;
KIRP	cis	rs6449957	0.832	rs12660017	chr5:67450350	T/C	cg09038926	chr5:67483109	NA	-0.37	-4.87	-0.3	2.04e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs10988449	1.000	rs10988449	chr9:132370360	C/T	cg18327994	chr9:132372705	NA	-0.55	-5.45	-0.33	1.2e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.15	-0.5	2.3e-17	Neuroticism;
KIRP	cis	rs12936587	0.633	rs12941217	chr17:17503206	G/A	cg01246520	chr17:17644344	RAI1	-0.37	-5.5	-0.33	9.5e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg00495681	chr13:53174319	NA	-0.44	-5.96	-0.36	8.53e-9	Lewy body disease;
KIRP	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg00405596	chr8:11794950	NA	0.6	8.68	0.48	5.48e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4073221	0.789	rs35407649	chr3:18231373	C/A	cg07694806	chr3:18168406	NA	-0.78	-6.65	-0.39	1.85e-10	Parkinson's disease;
KIRP	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.52	6.75	0.4	1.08e-10	Endometrial cancer;
KIRP	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.71	9.82	0.53	2.1e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs282587	0.569	rs378491	chr13:113398408	C/A	cg04656015	chr13:113407548	ATP11A	0.65	7.73	0.44	2.75e-13	Glycated hemoglobin levels;
KIRP	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs7010876	0.568	rs13256568	chr8:89227970	A/C	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs12362504	0.504	rs56207687	chr11:9901663	T/C	cg07197493	chr11:9884649	SBF2	-0.43	-6.05	-0.36	5.31e-9	Survival in pancreatic cancer;
KIRP	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg13264159	chr8:625131	ERICH1	-0.83	-7.19	-0.42	7.97e-12	IgG glycosylation;
KIRP	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.54	8.92	0.49	1.12e-16	Testicular germ cell tumor;
KIRP	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg24804195	chr5:87968844	LOC645323	-0.47	-6.21	-0.37	2.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.64	0.44	4.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg08901578	chr4:187885870	NA	-0.56	-9.3	-0.51	8.2e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-11.83	-0.6	7.35e-26	Glomerular filtration rate (creatinine);
KIRP	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.84	12.59	0.63	2.22e-28	Eosinophil percentage of white cells;
KIRP	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg05692746	chr2:100937584	LONRF2	-0.41	-5.32	-0.32	2.35e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg15084945	chr3:39452455	SNORA62;RPSA	0.41	6.25	0.37	1.75e-9	Serum protein levels (sST2);
KIRP	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.96	-0.5	8.29e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.5	7.17	0.42	8.63e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg15848620	chr12:58087721	OS9	-0.51	-5.96	-0.36	8.53e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.58	7.67	0.44	3.98e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6088813	1.000	rs6088825	chr20:33995972	C/T	cg14752227	chr20:34000481	UQCC	-0.51	-6.61	-0.39	2.37e-10	Height;
KIRP	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.4	-0.33	1.6e-7	Bladder cancer;
KIRP	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.37	-5.05	-0.31	8.64e-7	Coronary artery disease;
KIRP	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.51	-0.38	4.29e-10	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.01	0.61	1.93e-26	Platelet count;
KIRP	trans	rs7178375	0.941	rs35497908	chr15:31224071	C/T	cg04373760	chr16:53404718	NA	0.64	7.17	0.42	8.99e-12	Hypertriglyceridemia;
KIRP	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.31e-34	Breast cancer;
KIRP	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg18357645	chr12:58087776	OS9	0.47	5.78	0.35	2.24e-8	Multiple sclerosis;
KIRP	trans	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg00405596	chr8:11794950	NA	-0.46	-6.19	-0.37	2.44e-9	Joint mobility (Beighton score);
KIRP	cis	rs2398893	0.924	rs11789837	chr9:96817369	T/G	cg14459158	chr9:96720562	NA	0.29	5.17	0.31	4.88e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg03788504	chr6:150331562	NA	-0.27	-5.03	-0.31	9.36e-7	Alopecia areata;
KIRP	cis	rs2415984	0.622	rs2415997	chr14:46930446	A/C	cg14871534	chr14:47121158	RPL10L	-0.43	-5.15	-0.31	5.35e-7	Number of children ever born;
KIRP	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg23796481	chr11:64053134	BAD;GPR137	0.73	6.24	0.37	1.86e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17376030	chr22:41985996	PMM1	0.75	7.76	0.44	2.27e-13	Vitiligo;
KIRP	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.75	11.24	0.58	6.24e-24	Oral cavity cancer;
KIRP	cis	rs10484885	0.553	rs6901718	chr6:90243843	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.49	-4.9	-0.3	1.71e-6	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-1.04	-6.94	-0.4	3.55e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg23750338	chr8:142222470	SLC45A4	0.45	5.81	0.35	1.88e-8	Immature fraction of reticulocytes;
KIRP	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07080220	chr10:102295463	HIF1AN	0.73	7.0	0.41	2.44e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs615632	0.516	rs13279794	chr8:9684014	A/C	cg16141378	chr3:129829833	LOC729375	-0.49	-6.37	-0.38	9.09e-10	Neuroticism;
KIRP	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs2151522	0.762	rs13201060	chr6:127164442	T/C	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg19847130	chr8:10466454	RP1L1	-0.38	-5.69	-0.34	3.6e-8	Retinal vascular caliber;
KIRP	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.92	14.65	0.68	2.3e-35	Dental caries;
KIRP	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.55	8.65	0.48	6.72e-16	Prostate cancer;
KIRP	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.01	-0.3	1.06e-6	Inflammatory skin disease;
KIRP	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.2	-0.46	1.37e-14	Monocyte percentage of white cells;
KIRP	cis	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg17885191	chr8:135476712	NA	0.67	6.35	0.38	1.05e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs7551222	0.752	rs16853865	chr1:204465659	A/G	cg20240347	chr1:204465584	NA	-0.48	-8.99	-0.5	6.95e-17	Schizophrenia;
KIRP	cis	rs7909791	0.809	rs12570462	chr10:105613329	A/G	cg11005552	chr10:105648138	OBFC1	-0.41	-5.05	-0.31	8.79e-7	White matter hyperintensity burden;
KIRP	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	9.89	0.53	1.24e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	1.21	8.59	0.48	9.83e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg22947322	chr17:47091978	IGF2BP1	-0.43	-5.45	-0.33	1.24e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.26	-0.37	1.73e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.94	11.08	0.58	2.1e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg24503407	chr1:205819492	PM20D1	0.45	5.12	0.31	6.08e-7	Parkinson's disease;
KIRP	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	cis	rs10790268	1	rs10790268	chr11:118729391	A/G	cg19308663	chr11:118741387	NA	-0.57	-9.95	-0.54	8.28e-20	Rheumatoid arthritis;
KIRP	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.88	-0.49	1.41e-16	Retinal vascular caliber;
KIRP	cis	rs10510057	0.592	rs4752331	chr10:121323976	C/T	cg06765389	chr10:121379685	NA	0.44	6.83	0.4	6.69e-11	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.62	-9.41	-0.51	3.77e-18	Fibrinogen levels;
KIRP	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.79	-11.36	-0.59	2.52e-24	Blood metabolite levels;
KIRP	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.38	0.51	4.46e-18	Morning vs. evening chronotype;
KIRP	cis	rs631288	0.557	rs4534444	chr1:146679283	T/C	cg25205988	chr1:146714368	CHD1L	0.92	6.02	0.36	6.25e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.82	13.93	0.66	6.55e-33	Longevity;
KIRP	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.72	9.79	0.53	2.46e-19	Blood protein levels;
KIRP	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg03098644	chr7:100410630	EPHB4	0.51	5.14	0.31	5.69e-7	Other erythrocyte phenotypes;
KIRP	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.44	5.13	0.31	5.97e-7	Aortic root size;
KIRP	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg08975724	chr8:8085496	FLJ10661	0.82	10.72	0.56	3.02e-22	Mood instability;
KIRP	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.7	11.03	0.58	3.02e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg20243544	chr17:37824526	PNMT	0.48	6.35	0.38	1e-9	Asthma;
KIRP	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	6.2	0.37	2.31e-9	Response to antipsychotic treatment;
KIRP	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.42	-5.23	-0.32	3.6e-7	Schizophrenia;
KIRP	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.61	-0.44	5.88e-13	Type 2 diabetes;
KIRP	cis	rs4926611	0.966	rs10888800	chr1:54108494	G/A	cg08927728	chr1:54059983	GLIS1	-0.24	-5.19	-0.31	4.36e-7	Hand grip strength;
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.1	-0.41	1.3e-11	Platelet count;
KIRP	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.76	8.85	0.49	1.75e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg26174226	chr8:58114915	NA	-0.58	-6.44	-0.38	6.18e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs1459104	0.789	rs28896554	chr11:54812637	C/T	cg26562691	chr16:23850404	PRKCB	0.61	6.04	0.36	5.55e-9	Body mass index;
KIRP	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Electroencephalogram traits;
KIRP	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg23845249	chr11:68861649	NA	0.41	5.94	0.35	9.87e-9	Blond vs. brown hair color;
KIRP	cis	rs9815354	0.680	rs57525756	chr3:41843591	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg06606381	chr12:133084897	FBRSL1	-1.03	-6.21	-0.37	2.22e-9	Depression;
KIRP	cis	rs7737355	0.812	rs244738	chr5:130851170	A/G	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.85e-6	Life satisfaction;
KIRP	cis	rs2594989	0.943	rs2606737	chr3:11398654	A/G	cg01796438	chr3:11312864	ATG7	-0.69	-8.27	-0.47	8.58e-15	Circulating chemerin levels;
KIRP	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.67	9.63	0.52	7.73e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.6	0.34	5.59e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.33	0.32	2.27e-7	Cognitive test performance;
KIRP	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.22	-0.46	1.16e-14	Fibroblast growth factor basic levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01162425	chr9:31253952	NA	0.47	7.74	0.44	2.52e-13	Cancer;
KIRP	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg10504392	chr12:110044639	NA	0.26	5.1	0.31	6.68e-7	Neuroticism;
KIRP	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.8	10.47	0.56	1.92e-21	Platelet count;
KIRP	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.62	-9.54	-0.52	1.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs12681288	0.963	rs35220148	chr8:1027602	G/A	cg08648136	chr8:956695	NA	0.44	6.49	0.38	4.78e-10	Schizophrenia;
KIRP	trans	rs877282	0.583	rs7072970	chr10:822757	G/A	cg22713356	chr15:30763199	NA	0.88	8.69	0.48	5.04e-16	Uric acid levels;
KIRP	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg21775007	chr8:11205619	TDH	-0.47	-6.14	-0.36	3.23e-9	Systolic blood pressure;
KIRP	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	0.95	11.18	0.58	9.82e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg07511934	chr16:89386912	ANKRD11	0.41	5.33	0.32	2.25e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs9513593	1.000	rs7331894	chr13:99852952	C/T	cg21788972	chr13:99853209	UBAC2	0.55	5.86	0.35	1.5e-8	Psoriasis;
KIRP	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg01338084	chr22:32026380	PISD	1.13	7.72	0.44	2.99e-13	Age-related hearing impairment;
KIRP	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.38	5.04	0.31	9.09e-7	Dupuytren's disease;
KIRP	cis	rs10464059	0.511	rs3805705	chr5:179738237	T/C	cg13944838	chr5:179740914	GFPT2	0.63	5.87	0.35	1.43e-8	Parkinson's disease;
KIRP	cis	rs743757	1.000	rs1107265	chr3:50431995	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.31	0.32	2.47e-7	Diastolic blood pressure;
KIRP	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	1.1	16.15	0.72	1.69e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.41	-5.0	-0.3	1.11e-6	Lung cancer;
KIRP	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg08975724	chr8:8085496	FLJ10661	0.45	5.0	0.3	1.08e-6	Myopia (pathological);
KIRP	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg23387468	chr7:139079360	LUC7L2	-0.31	-5.37	-0.32	1.79e-7	Diisocyanate-induced asthma;
KIRP	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.78	7.35	0.42	2.9e-12	Menopause (age at onset);
KIRP	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.16	-0.37	3.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs57590327	0.503	rs13066091	chr3:81589912	T/C	cg07356753	chr3:81810745	GBE1	-0.57	-7.1	-0.41	1.3e-11	Extraversion;
KIRP	cis	rs11997175	0.603	rs7386384	chr8:33782471	C/T	cg04338863	chr8:33670619	NA	0.4	5.04	0.31	8.92e-7	Body mass index;
KIRP	cis	rs787274	1.000	rs9409123	chr9:115507165	G/A	cg13803584	chr9:115635662	SNX30	0.78	7.92	0.45	8.2e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg20387954	chr3:183756860	HTR3D	0.44	6.21	0.37	2.24e-9	Anterior chamber depth;
KIRP	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.69	-0.44	3.51e-13	Type 2 diabetes;
KIRP	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.64	9.52	0.52	1.7e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.5	-7.9	-0.45	9.6e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.39	9.6	0.52	9.95e-19	Corneal astigmatism;
KIRP	cis	rs2742417	1.000	rs2742447	chr3:45763977	C/T	cg04037228	chr3:45636386	LIMD1	0.34	4.89	0.3	1.82e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.78	-9.35	-0.51	5.47e-18	Osteoporosis;
KIRP	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg24375607	chr4:120327624	NA	-0.59	-6.73	-0.39	1.17e-10	Corneal astigmatism;
KIRP	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.51	6.67	0.39	1.68e-10	HDL cholesterol;
KIRP	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.56	5.99	0.36	7.44e-9	Ulcerative colitis;
KIRP	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs35000415	0.938	rs12535158	chr7:128625019	C/T	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.77	8.66	0.48	6.24e-16	Corneal astigmatism;
KIRP	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.4	-0.38	7.62e-10	Total body bone mineral density;
KIRP	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.3	-0.32	2.57e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs6738627	1.000	rs9653282	chr2:165554658	A/T	cg03182029	chr2:165697222	COBLL1	0.42	5.43	0.33	1.32e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	7.54	0.43	9.16e-13	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24471922	chr4:1217755	CTBP1	-0.59	-7.6	-0.44	6.33e-13	Parkinson's disease;
KIRP	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg26831259	chr4:1366826	KIAA1530	0.37	4.89	0.3	1.8e-6	Obesity-related traits;
KIRP	cis	rs300890	0.513	rs12640698	chr4:144104094	T/C	cg01719995	chr4:144104893	USP38	0.43	5.52	0.33	8.64e-8	Nasopharyngeal carcinoma;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00389713	chr6:43138877	SRF	1.05	6.88	0.4	4.99e-11	P wave terminal force;
KIRP	cis	rs136211	0.619	rs9607337	chr22:36758849	A/T	cg16924664	chr22:36878180	TXN2	0.44	5.08	0.31	7.44e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.35	0.32	1.98e-7	Cognitive test performance;
KIRP	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.46	5.42	0.33	1.43e-7	White matter hyperintensity burden;
KIRP	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg00677455	chr12:58241039	CTDSP2	-0.66	-7.89	-0.45	9.86e-14	Multiple sclerosis;
KIRP	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.7	7.92	0.45	8.32e-14	High light scatter reticulocyte count;
KIRP	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21545522	chr1:205238299	TMCC2	0.54	7.25	0.42	5.34e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs8084125	0.938	rs62105163	chr18:74943673	C/T	cg05528293	chr18:74961138	GALR1	0.5	4.91	0.3	1.63e-6	Obesity-related traits;
KIRP	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs6968419	0.674	rs1918912	chr7:115906373	C/T	cg02561103	chr7:115862891	TES	-0.42	-5.92	-0.35	1.08e-8	Intraocular pressure;
KIRP	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.47	6.43	0.38	6.45e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	8.49	0.48	1.98e-15	Post bronchodilator FEV1;
KIRP	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.81	7.36	0.42	2.78e-12	Methadone dose in opioid dependence;
KIRP	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg26149184	chr10:133730230	NA	0.43	5.08	0.31	7.3e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.7	7.2	0.42	7.32e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg04702396	chr17:15466718	FAM18B2	0.53	6.84	0.4	6.29e-11	Educational attainment (years of education);
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg26207909	chr14:103986467	CKB	-0.45	-5.57	-0.33	6.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg08283408	chr3:49949060	MON1A	0.42	5.56	0.33	7.19e-8	Body mass index;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.45	0.43	1.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.71	8.43	0.47	2.97e-15	Corneal astigmatism;
KIRP	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.46	-0.43	1.52e-12	Neuroticism;
KIRP	cis	rs6499755	0.734	rs31117	chr16:55380843	A/G	cg05099576	chr16:55362342	IRX6	0.28	5.63	0.34	4.81e-8	Hypospadias;
KIRP	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	5.47	0.33	1.09e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg26441486	chr22:50317300	CRELD2	-0.52	-7.68	-0.44	3.69e-13	Schizophrenia;
KIRP	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg22117172	chr7:91764530	CYP51A1	0.5	6.88	0.4	4.99e-11	Breast cancer;
KIRP	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg13736514	chr6:26305472	NA	0.52	6.45	0.38	5.73e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.89	-0.4	4.52e-11	Height;
KIRP	cis	rs859767	0.540	rs13424016	chr2:135406395	A/G	cg25422880	chr2:135218333	TMEM163	0.42	6.05	0.36	5.29e-9	Neuroticism;
KIRP	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg19610905	chr11:61596333	FADS2	-0.51	-5.75	-0.34	2.68e-8	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg16497661	chr14:103986332	CKB	-0.51	-6.47	-0.38	5.22e-10	Coronary artery disease;
KIRP	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.01	0.36	6.48e-9	Bipolar disorder;
KIRP	cis	rs501120	0.929	rs605425	chr10:44750669	T/C	cg09554077	chr10:44749378	NA	0.75	12.45	0.62	6.35e-28	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.46	0.38	5.56e-10	Bipolar disorder;
KIRP	cis	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg22496380	chr5:211416	CCDC127	-1.15	-7.23	-0.42	5.93e-12	Breast cancer;
KIRP	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg04691961	chr3:161091175	C3orf57	-0.57	-8.97	-0.5	7.6e-17	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg09455208	chr3:40491958	NA	0.35	6.04	0.36	5.57e-9	Renal cell carcinoma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22637834	chr1:244007281	AKT3	-0.48	-7.66	-0.44	4.15e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-7.98	-0.45	5.62e-14	Platelet count;
KIRP	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-6.19	-0.37	2.53e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.08e-6	Calcium levels;
KIRP	cis	rs6840360	0.516	rs6535794	chr4:152302783	G/T	cg25486957	chr4:152246857	NA	-0.41	-4.84	-0.3	2.26e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg21523564	chr15:75251491	NA	-0.35	-5.9	-0.35	1.17e-8	Caffeine consumption;
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg26354017	chr1:205819088	PM20D1	0.77	10.76	0.57	2.23e-22	Monocyte percentage of white cells;
KIRP	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	5.57	0.33	6.52e-8	Educational attainment;
KIRP	cis	rs2637030	0.515	rs439552	chr5:52978517	G/A	cg06476337	chr5:52856530	NDUFS4	0.57	6.44	0.38	6.26e-10	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.37	-7.77	-0.44	2.11e-13	Body mass index;
KIRP	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.88	0.35	1.31e-8	Motion sickness;
KIRP	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-7.67	-0.44	4e-13	Waist circumference;Body mass index;
KIRP	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.57	7.13	0.41	1.11e-11	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25729257	chr5:178157792	ZNF354A	0.53	6.18	0.37	2.61e-9	Smoking initiation;
KIRP	cis	rs3026101	0.671	rs62072674	chr17:5317806	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs13095912	1.000	rs6762208	chr3:185331165	A/C	cg11274856	chr3:185301563	NA	-0.47	-6.08	-0.36	4.54e-9	Systolic blood pressure;
KIRP	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg24699146	chr1:24152579	HMGCL	0.42	5.42	0.33	1.39e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6580649	0.574	rs7964359	chr12:48410566	T/A	cg26205652	chr12:48591994	NA	0.43	5.96	0.36	8.47e-9	Lung cancer;
KIRP	cis	rs6547631	0.592	rs2070966	chr2:85922860	G/T	cg24620635	chr2:85921963	GNLY	0.32	5.02	0.31	9.74e-7	Blood protein levels;
KIRP	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg03026011	chr10:45641679	LOC100133308	0.59	6.35	0.38	1.01e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07899794	chr17:19266098	B9D1	0.5	6.46	0.38	5.62e-10	Parkinson's disease;
KIRP	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg05361325	chr10:32636312	EPC1	0.62	5.91	0.35	1.12e-8	Sexual dysfunction (female);
KIRP	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg11235152	chr1:67600687	NA	0.71	10.52	0.56	1.3e-21	Psoriasis;
KIRP	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.54	5.66	0.34	4.16e-8	Schizophrenia;
KIRP	cis	rs228437	1.000	rs228436	chr6:134896913	A/T	cg24504307	chr6:134963096	NA	-0.45	-6.3	-0.37	1.36e-9	Melanoma;
KIRP	cis	rs62344088	1.000	rs13436694	chr5:122882	A/T	cg22857025	chr5:266934	NA	-0.77	-4.95	-0.3	1.41e-6	Asthma (childhood onset);
KIRP	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg00846425	chr4:957561	DGKQ	-0.51	-5.28	-0.32	2.78e-7	Type 2 diabetes;
KIRP	cis	rs6466055	0.661	rs6979284	chr7:104935730	A/T	cg04380332	chr7:105027541	SRPK2	0.35	4.91	0.3	1.65e-6	Schizophrenia;
KIRP	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg05418105	chr22:50981406	NA	-0.72	-7.41	-0.43	1.97e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1497828	0.956	rs2810782	chr1:217544443	C/G	cg04411442	chr1:217543379	NA	0.41	6.21	0.37	2.22e-9	Dialysis-related mortality;
KIRP	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg18944383	chr4:111397179	ENPEP	-0.53	-9.11	-0.5	3.05e-17	Coronary artery disease;
KIRP	cis	rs9303542	0.559	rs12939811	chr17:46607958	A/T	cg04904318	chr17:46607828	HOXB1	-0.61	-6.57	-0.39	2.99e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg07827796	chr19:33622959	WDR88	0.41	4.9	0.3	1.77e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.1e-7	Life satisfaction;
KIRP	cis	rs9372498	0.505	rs17427284	chr6:118991953	A/T	cg18833306	chr6:118973337	C6orf204	-0.48	-4.88	-0.3	1.9e-6	Diastolic blood pressure;
KIRP	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.43	-0.33	1.34e-7	Chronic sinus infection;
KIRP	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.02	10.99	0.57	3.99e-23	Vitiligo;
KIRP	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg18833306	chr6:118973337	C6orf204	-0.47	-4.97	-0.3	1.23e-6	Diastolic blood pressure;
KIRP	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	8.73	0.49	3.95e-16	Neuroticism;
KIRP	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs9309473	1.000	rs2140195	chr2:73702344	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.39	-0.38	8.2e-10	Metabolite levels;
KIRP	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	1.11	8.27	0.47	8.6e-15	Skin colour saturation;
KIRP	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-20.03	-0.79	1.4e-53	Height;
KIRP	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg23387468	chr7:139079360	LUC7L2	0.33	5.59	0.34	6.16e-8	Diisocyanate-induced asthma;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11389618	chr2:144712819	GTDC1	0.44	7.11	0.41	1.29e-11	C-reactive protein;
KIRP	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-0.93	-9.62	-0.52	8.62e-19	Mitochondrial DNA levels;
KIRP	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.21	0.51	1.49e-17	Prudent dietary pattern;
KIRP	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs448720	0.811	rs399408	chr15:68183851	G/A	cg24579218	chr15:68104479	NA	-0.34	-4.89	-0.3	1.78e-6	Cognitive performance;
KIRP	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-6.83	-0.4	6.8e-11	Mean platelet volume;
KIRP	cis	rs8053891	0.756	rs35259348	chr16:72003952	G/C	cg16558253	chr16:72132732	DHX38	-0.45	-4.85	-0.3	2.2e-6	Coronary artery disease;
KIRP	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15664640	chr17:80829946	TBCD	0.58	7.29	0.42	4.1e-12	Breast cancer;
KIRP	cis	rs17221829	0.733	rs10830304	chr11:89366754	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg25902810	chr10:99078978	FRAT1	0.59	7.38	0.43	2.47e-12	Monocyte count;
KIRP	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.85	-0.35	1.58e-8	Schizophrenia;
KIRP	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg08975724	chr8:8085496	FLJ10661	0.65	9.03	0.5	5.2e-17	Mood instability;
KIRP	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.58e-11	Cannabis dependence symptom count;
KIRP	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.59	-9.24	-0.51	1.18e-17	Sense of smell;
KIRP	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg27205649	chr11:78285834	NARS2	-0.68	-8.45	-0.47	2.51e-15	Alzheimer's disease (survival time);
KIRP	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.38e-10	Diabetic retinopathy;
KIRP	cis	rs9535307	0.696	rs9535305	chr13:50290415	A/T	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg10755058	chr3:40428713	ENTPD3	0.45	6.34	0.38	1.06e-9	Renal cell carcinoma;
KIRP	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.88	-11.5	-0.59	8.64e-25	Cognitive function;
KIRP	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.67	8.29	0.47	7.3e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg08648136	chr8:956695	NA	0.45	6.83	0.4	6.61e-11	Schizophrenia;
KIRP	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg01304814	chr3:48885189	PRKAR2A	0.55	5.06	0.31	8.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.5	0.33	9.67e-8	Height;
KIRP	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg19554555	chr3:13937349	NA	-0.47	-6.41	-0.38	7.25e-10	Ovarian reserve;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01168328	chr4:2304673	ZFYVE28	-0.46	-6.14	-0.36	3.28e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.61	4.99	0.3	1.13e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	cg21523751	chr1:182988639	NA	0.44	6.86	0.4	5.5e-11	Colorectal cancer;
KIRP	cis	rs6442310	0.534	rs1151998	chr3:12446492	A/G	cg02700894	chr3:12045449	SYN2	0.41	5.59	0.34	5.9e-8	Hematocrit;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26522792	chr2:128049136	ERCC3	0.59	7.14	0.41	1.07e-11	Interleukin-4 levels;
KIRP	trans	rs13170463	0.579	rs13183364	chr5:8039107	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg08134877	chr2:44394819	PPM1B	0.48	5.14	0.31	5.61e-7	Height;
KIRP	cis	rs7945718	0.870	rs3890065	chr11:12758767	C/G	ch.11.340609R	chr11:12831013	TEAD1	-0.4	-5.05	-0.31	8.79e-7	Educational attainment (years of education);
KIRP	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg20243544	chr17:37824526	PNMT	-0.38	-5.01	-0.3	1.06e-6	Self-reported allergy;
KIRP	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.53	7.81	0.45	1.61e-13	Bipolar disorder;
KIRP	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg24375607	chr4:120327624	NA	0.55	6.08	0.36	4.63e-9	Educational attainment;
KIRP	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.49	-5.62	-0.34	5.08e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg19592336	chr6:28129416	ZNF389	0.46	5.08	0.31	7.34e-7	Parkinson's disease;
KIRP	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.07	0.46	3.14e-14	Lung cancer;
KIRP	cis	rs504918	0.588	rs1444761	chr3:123974876	G/A	cg05766129	chr3:123988013	KALRN	-0.44	-5.46	-0.33	1.19e-7	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-7.76	-0.44	2.26e-13	Platelet count;
KIRP	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg00686598	chr14:53173677	PSMC6	-0.67	-6.04	-0.36	5.53e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6504950	0.854	rs244322	chr17:53224759	C/T	cg26251398	chr17:52985966	TOM1L1	0.38	4.96	0.3	1.32e-6	Breast cancer;
KIRP	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.39	-0.43	2.34e-12	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.5	6.0	0.36	7.02e-9	Longevity;Endometriosis;
KIRP	cis	rs42235	0.683	rs2282982	chr7:92277030	T/C	cg15732164	chr7:92237376	CDK6	-0.43	-5.9	-0.35	1.2e-8	Hip circumference adjusted for BMI;Height;
KIRP	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg24488311	chr11:68621650	NA	0.41	5.07	0.31	7.71e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14563868	chr15:52043951	LYSMD2;TMOD2	0.45	6.04	0.36	5.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.65	9.49	0.52	2.09e-18	Menarche (age at onset);
KIRP	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg25600027	chr14:23388339	RBM23	-0.52	-6.43	-0.38	6.42e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.79	-6.51	-0.38	4.13e-10	Putamen volume;
KIRP	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21643547	chr1:205240462	TMCC2	0.82	12.7	0.63	9.54e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.93	15.79	0.71	2.92e-39	Ulcerative colitis;
KIRP	cis	rs494562	0.892	rs498289	chr6:86116721	A/G	cg27039625	chr6:86159096	NT5E	0.42	5.34	0.32	2.07e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.4	0.43	2.15e-12	Neuroticism;
KIRP	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.85	13.57	0.65	1.08e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg18501202	chr6:125855421	NA	-0.34	-5.14	-0.31	5.65e-7	Brugada syndrome;
KIRP	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.7	-6.42	-0.38	7.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg22469141	chr19:14640373	MIR639;TECR	-0.48	-6.18	-0.37	2.63e-9	Blood metabolite levels;
KIRP	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg02023728	chr11:77925099	USP35	0.32	5.03	0.31	9.34e-7	Testicular germ cell tumor;
KIRP	trans	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.77	12.02	0.61	1.69e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs394563	0.839	rs584916	chr6:149790319	A/C	cg11245181	chr6:149772854	ZC3H12D	-0.32	-4.99	-0.3	1.14e-6	Dupuytren's disease;
KIRP	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.15	14.86	0.69	4.46e-36	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.77	11.56	0.59	5.83e-25	Metabolite levels;
KIRP	cis	rs7335046	0.614	rs72651412	chr13:100088038	G/T	cg25919922	chr13:100150906	NA	-0.64	-4.92	-0.3	1.57e-6	Basal cell carcinoma;
KIRP	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg01338139	chr15:38987640	C15orf53	-0.56	-6.34	-0.37	1.12e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.65	-6.86	-0.4	5.52e-11	Bipolar disorder;
KIRP	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.93	10.88	0.57	8.9e-23	Menarche (age at onset);
KIRP	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg23625390	chr15:77176239	SCAPER	0.52	7.2	0.42	7.19e-12	Blood metabolite levels;
KIRP	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.89	11.77	0.6	1.12e-25	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg18225595	chr11:63971243	STIP1	0.7	8.74	0.49	3.82e-16	Platelet count;
KIRP	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	4.92	0.3	1.56e-6	Bipolar disorder;
KIRP	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg18016565	chr1:150552671	MCL1	-0.38	-5.74	-0.34	2.83e-8	Melanoma;
KIRP	trans	rs587242	1.000	rs61786494	chr1:96905987	A/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg24488311	chr11:68621650	NA	0.44	5.21	0.32	3.91e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4663866	0.901	rs76312449	chr2:239190906	A/G	cg17283117	chr2:239148619	HES6	0.71	5.08	0.31	7.33e-7	Irritable bowel syndrome;
KIRP	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-12.7	-0.63	9.69e-29	Exhaled nitric oxide output;
KIRP	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.97e-8	Motion sickness;
KIRP	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18798372	chr8:124557975	NA	0.46	6.09	0.36	4.25e-9	Survival in pancreatic cancer;
KIRP	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.83	0.45	1.46e-13	Morning vs. evening chronotype;
KIRP	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg18944383	chr4:111397179	ENPEP	-0.6	-10.61	-0.56	6.68e-22	Coronary artery disease;
KIRP	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.06	23.72	0.83	1.7e-65	Multiple myeloma;
KIRP	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg15083037	chr5:83017644	HAPLN1	-0.61	-8.56	-0.48	1.27e-15	Prostate cancer;
KIRP	cis	rs7225151	0.710	rs79970806	chr17:5200232	C/T	cg24500398	chr17:5266808	RABEP1	-0.58	-5.71	-0.34	3.33e-8	Alzheimer's disease (late onset);
KIRP	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.7	8.8	0.49	2.44e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17456994	chr10:6130864	RBM17	-0.48	-6.26	-0.37	1.68e-9	Myopia;
KIRP	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07167872	chr1:205819463	PM20D1	0.74	10.23	0.55	1.08e-20	Monocyte percentage of white cells;
KIRP	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.78	6.75	0.4	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg05315796	chr3:52349193	DNAH1	0.46	7.11	0.41	1.26e-11	Bipolar disorder;
KIRP	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.62	8.22	0.46	1.15e-14	Prostate cancer;
KIRP	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg21132104	chr15:45694354	SPATA5L1	0.59	7.14	0.41	1.08e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.31	0.7	1.33e-37	Menarche (age at onset);
KIRP	cis	rs806215	1.000	rs712697	chr7:127247132	T/A	cg25922125	chr7:127225783	GCC1	0.47	5.05	0.31	8.61e-7	Type 2 diabetes;
KIRP	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05665937	chr4:1216051	CTBP1	0.44	6.08	0.36	4.65e-9	Obesity-related traits;
KIRP	cis	rs2213920	0.915	rs980176	chr9:118260408	T/G	cg13918206	chr9:118159781	DEC1	0.87	8.62	0.48	8.44e-16	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg23335576	chr14:104009727	NA	0.4	5.79	0.35	2.15e-8	Body mass index;
KIRP	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg08313168	chr12:7315531	NA	0.69	6.26	0.37	1.74e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg09408571	chr1:101003634	GPR88	-0.34	-7.89	-0.45	1.02e-13	Breast cancer;
KIRP	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg24324837	chr19:49891574	CCDC155	0.6	5.67	0.34	4.05e-8	Multiple sclerosis;
KIRP	cis	rs10129255	0.500	rs6576226	chr14:107186374	G/A	cg23076370	chr14:107095027	NA	-0.4	-4.93	-0.3	1.53e-6	Kawasaki disease;
KIRP	cis	rs7246657	0.712	rs4803263	chr19:38066782	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs12022452	0.591	rs12042242	chr1:40993873	A/G	cg25568243	chr1:40974465	DEM1	-0.53	-5.98	-0.36	7.67e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.84	13.17	0.64	2.41e-30	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.5	-0.38	4.32e-10	Monocyte percentage of white cells;
KIRP	cis	rs7594645	1.000	rs115889150	chr2:207597807	A/G	cg17160730	chr2:207629934	MDH1B;FASTKD2	-0.86	-5.11	-0.31	6.4e-7	Episodic memory;
KIRP	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg00147788	chr6:125855365	NA	-0.32	-5.06	-0.31	8.08e-7	Brugada syndrome;
KIRP	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.6	0.44	6.1e-13	White blood cell count;
KIRP	cis	rs7077164	1.000	rs7077164	chr10:71583198	C/T	cg20696214	chr10:71583771	COL13A1	0.49	6.75	0.4	1.03e-10	Non-alcoholic fatty liver disease histology (lobular);
KIRP	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	8.07	0.46	3.09e-14	Triglycerides;
KIRP	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	9.19	0.51	1.69e-17	Bone mineral density;
KIRP	cis	rs4478858	0.709	rs937786	chr1:31857869	G/A	cg00250761	chr1:31883323	NA	0.33	5.52	0.33	8.57e-8	Alcohol dependence;
KIRP	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg14675211	chr2:100938903	LONRF2	0.56	7.13	0.41	1.14e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs367943	0.673	rs7708084	chr5:112732692	G/T	cg12552261	chr5:112820674	MCC	0.58	6.88	0.4	4.98e-11	Type 2 diabetes;
KIRP	cis	rs1371614	0.589	rs471905	chr2:27111651	A/G	cg00617064	chr2:27272375	NA	0.45	5.46	0.33	1.19e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg00074818	chr8:8560427	CLDN23	-0.42	-6.71	-0.39	1.33e-10	Obesity-related traits;
KIRP	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.83	-8.95	-0.5	8.76e-17	Asthma;
KIRP	cis	rs4748857	0.898	rs4747462	chr10:23601892	T/G	cg12804278	chr10:23633326	C10orf67	0.44	5.3	0.32	2.55e-7	Systemic lupus erythematosus;
KIRP	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg04691961	chr3:161091175	C3orf57	0.47	6.93	0.4	3.63e-11	Morning vs. evening chronotype;
KIRP	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.31	0.32	2.48e-7	Lung cancer;
KIRP	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	13.59	0.65	9.1e-32	Cognitive ability;
KIRP	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.28	-0.47	7.96e-15	Neuroticism;
KIRP	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	1.1	12.0	0.61	1.94e-26	Corneal structure;
KIRP	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg08807101	chr21:30365312	RNF160	-0.64	-7.7	-0.44	3.25e-13	Selective IgA deficiency;
KIRP	cis	rs4236601	0.745	rs11983864	chr7:116142460	A/C	cg12739419	chr7:116140593	CAV2	0.48	5.97	0.36	8.03e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10703506	chr12:109576250	ACACB	0.45	6.37	0.38	9.34e-10	Survival in pancreatic cancer;
KIRP	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.73	5.88	0.35	1.35e-8	Diabetic retinopathy;
KIRP	cis	rs1829883	0.775	rs2461953	chr5:98821072	C/T	cg08333243	chr5:99726346	NA	0.39	4.95	0.3	1.38e-6	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27590541	chr16:10449708	NA	0.46	6.22	0.37	2.1e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg26587870	chr6:27730563	NA	-0.68	-5.48	-0.33	1.06e-7	Breast cancer;
KIRP	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg20701182	chr2:24300061	SF3B14	1.02	10.9	0.57	7.95e-23	Lymphocyte counts;
KIRP	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.52	-6.7	-0.39	1.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.28e-7	Red blood cell count;
KIRP	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.68	-7.53	-0.43	9.42e-13	DNA methylation (variation);
KIRP	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg20140201	chr2:241835670	C2orf54	-0.34	-5.34	-0.32	2.1e-7	Urinary metabolites;
KIRP	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.45	7.56	0.43	8.15e-13	Heart rate;
KIRP	cis	rs10773046	0.740	rs1922258	chr12:124353657	T/C	cg18594669	chr12:124364423	DNAH10	0.37	5.04	0.31	9.21e-7	Osteoarthritis (hip);
KIRP	cis	rs1448094	1.000	rs10083080	chr12:86348579	G/C	cg00310523	chr12:86230176	RASSF9	0.39	5.96	0.36	8.52e-9	Major depressive disorder;
KIRP	cis	rs10875746	0.903	rs886588	chr12:48477422	A/G	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.8	0.57	1.62e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg16396542	chr1:89473148	GBP3	0.41	5.68	0.34	3.73e-8	Carotid intima media thickness;
KIRP	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg05623727	chr3:50126028	RBM5	0.34	4.9	0.3	1.7e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs9409565	0.793	rs2486632	chr9:97196979	A/G	cg05679027	chr9:99775184	HIATL2	-0.56	-6.71	-0.39	1.33e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg26876637	chr1:152193138	HRNR	0.72	9.79	0.53	2.54e-19	Atopic dermatitis;
KIRP	cis	rs1143633	0.577	rs6745746	chr2:113610044	G/A	cg03712744	chr2:113669835	IL1F7	-0.42	-6.22	-0.37	2.16e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.77	0.6	1.13e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg27205649	chr11:78285834	NARS2	0.64	8.04	0.46	3.72e-14	Alzheimer's disease (survival time);
KIRP	cis	rs7520050	0.966	rs11211241	chr1:46452683	T/A	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.15e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs57338032	0.891	rs57839482	chr15:78757892	T/C	cg06917634	chr15:78832804	PSMA4	0.56	4.95	0.3	1.41e-6	CTACK levels;
KIRP	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg16111737	chr12:117408163	FBXW8	0.56	5.3	0.32	2.55e-7	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg20636351	chr8:55087400	NA	-0.58	-7.3	-0.42	3.94e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7923609	0.902	rs10740136	chr10:65329622	A/C	cg01631684	chr10:65280961	REEP3	-0.46	-5.45	-0.33	1.19e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs889398	0.741	rs6499269	chr16:69908918	T/C	cg09409435	chr16:70099608	PDXDC2	0.43	5.29	0.32	2.69e-7	Body mass index;
KIRP	cis	rs17641971	0.708	rs974781	chr8:49931055	T/A	cg00325661	chr8:49890786	NA	0.38	4.86	0.3	2.06e-6	Blood metabolite levels;
KIRP	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg16917193	chr12:54089295	NA	1.03	22.13	0.82	1.92e-60	Height;
KIRP	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.35	-0.42	2.96e-12	Red cell distribution width;
KIRP	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	6.83	0.4	6.6e-11	Initial pursuit acceleration;
KIRP	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg08999081	chr20:33150536	PIGU	-0.39	-5.04	-0.31	8.85e-7	Height;
KIRP	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	1.07	15.79	0.71	2.96e-39	Blood protein levels;
KIRP	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg17218026	chr1:154582156	ADAR	0.35	5.76	0.34	2.54e-8	Blood protein levels;
KIRP	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg20560298	chr2:73613845	ALMS1	0.46	5.76	0.34	2.48e-8	Schizophrenia;
KIRP	cis	rs911119	0.818	rs67862677	chr20:23591086	A/C	cg09631192	chr20:23583594	CST9	-0.62	-5.83	-0.35	1.69e-8	Chronic kidney disease;
KIRP	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg02461776	chr11:598696	PHRF1	0.73	7.66	0.44	4.15e-13	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8077577	0.895	rs1563371	chr17:18111793	C/T	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs2820315	1.000	rs2820309	chr1:201834944	A/G	cg11586189	chr1:201857591	SHISA4	-0.43	-6.34	-0.37	1.08e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9398803	0.650	rs9401874	chr6:126625617	A/C	cg19875578	chr6:126661172	C6orf173	-0.39	-4.96	-0.3	1.3e-6	Male-pattern baldness;
KIRP	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg06742321	chr12:123595122	PITPNM2	-0.45	-5.55	-0.33	7.2e-8	Platelet count;
KIRP	cis	rs11083475	0.557	rs2368519	chr19:39259241	C/T	cg26703956	chr19:39260304	NA	-0.46	-7.17	-0.42	8.92e-12	Heart rate;
KIRP	cis	rs6681460	1.000	rs6681460	chr1:67123057	C/T	cg02459107	chr1:67143332	SGIP1	-0.49	-7.17	-0.42	8.92e-12	Presence of antiphospholipid antibodies;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18891090	chr8:68167394	ARFGEF1	0.41	6.27	0.37	1.6e-9	Interleukin-4 levels;
KIRP	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.57	-6.51	-0.38	4.22e-10	Menarche (age at onset);
KIRP	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.49	-0.33	1.02e-7	Metabolite levels;
KIRP	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.71	-0.39	1.32e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.66	-0.44	4.2e-13	Neuroticism;
KIRP	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs3736485	0.934	rs8036904	chr15:51861438	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6001982	0.584	rs12158872	chr22:40832501	G/C	cg07138101	chr22:40742427	ADSL	0.68	5.42	0.33	1.43e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15209934	chr19:52800385	ZNF480	0.47	6.5	0.38	4.32e-10	Parkinson's disease;
KIRP	cis	rs7615316	0.902	rs6440092	chr3:142313987	T/A	cg20824294	chr3:142316082	PLS1	0.22	4.97	0.3	1.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.41	-0.38	7.19e-10	Uric acid levels;
KIRP	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.67	9.02	0.5	5.39e-17	Aortic root size;
KIRP	cis	rs2997447	0.637	rs2000403	chr1:26410161	A/G	cg19633962	chr1:26362018	EXTL1	-0.7	-5.96	-0.36	8.67e-9	QRS complex (12-leadsum);
KIRP	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.18	-0.37	2.59e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11987759	chr7:65425863	GUSB	0.58	7.79	0.44	1.89e-13	Aortic root size;
KIRP	cis	rs55788414	0.932	rs9921666	chr16:81181669	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.29	-0.47	7.58e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.3	0.37	1.4e-9	Height;
KIRP	cis	rs7507204	0.767	rs62125962	chr19:3410852	A/G	cg08380311	chr19:3435252	NFIC	0.71	6.65	0.39	1.87e-10	Height;
KIRP	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.58	7.72	0.44	2.83e-13	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	0.85	12.59	0.63	2.25e-28	Body mass index;
KIRP	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.74	8.8	0.49	2.54e-16	Triglycerides;
KIRP	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	1.04	18.98	0.77	4.29e-50	Heart rate;
KIRP	cis	rs4006360	0.614	rs6416914	chr17:39262850	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.62	-8.11	-0.46	2.45e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg01097406	chr16:89675127	NA	0.35	5.59	0.34	6.08e-8	Vitiligo;
KIRP	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg05802129	chr4:122689817	NA	-0.69	-9.22	-0.51	1.36e-17	Type 2 diabetes;
KIRP	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg13736514	chr6:26305472	NA	-0.6	-7.69	-0.44	3.53e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.21	0.37	2.25e-9	Retinal vascular caliber;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg23665729	chr3:49977591	RBM6	-0.49	-6.48	-0.38	4.89e-10	Morning vs. evening chronotype;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27189623	chr16:705930	WDR90	0.42	5.77	0.35	2.33e-8	Height;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg20164915	chr1:149871167	BOLA1	-0.45	-6.1	-0.36	4.17e-9	Metabolite levels (MHPG);
KIRP	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-0.97	-14.01	-0.67	3.5e-33	Blood trace element (Zn levels);
KIRP	cis	rs7989336	0.605	rs9516661	chr13:96975031	C/G	cg02571835	chr13:96230311	CLDN10	0.38	5.16	0.31	5.11e-7	Obesity;
KIRP	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg08313168	chr12:7315531	NA	0.7	6.28	0.37	1.56e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg12173498	chr6:36355764	ETV7	0.3	4.96	0.3	1.34e-6	Platelet distribution width;
KIRP	cis	rs250677	0.524	rs40521	chr5:148439639	C/T	cg12140854	chr5:148520817	ABLIM3	0.4	5.1	0.31	6.87e-7	Breast cancer;
KIRP	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg08126542	chr6:37504118	NA	-0.84	-13.31	-0.65	8.07e-31	Cognitive performance;
KIRP	cis	rs7827545	0.545	rs6578228	chr8:135562422	G/A	cg17885191	chr8:135476712	NA	0.68	6.36	0.38	9.62e-10	Hypertension (SNP x SNP interaction);
KIRP	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.69	-0.53	5.14e-19	Retinal vascular caliber;
KIRP	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.62	7.14	0.41	1.06e-11	Iron status biomarkers;
KIRP	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg18350739	chr11:68623251	NA	-0.48	-7.65	-0.44	4.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1873147	1.000	rs2130165	chr15:63314519	C/T	cg12160578	chr15:63334699	TPM1	-0.46	-5.61	-0.34	5.33e-8	Orofacial clefts;
KIRP	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg00277334	chr10:82204260	NA	-0.47	-5.28	-0.32	2.85e-7	Post bronchodilator FEV1;
KIRP	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg01943577	chr7:158741284	NA	-0.4	-5.46	-0.33	1.19e-7	Height;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs5762813	0.561	rs5752811	chr22:29225592	C/G	cg02153584	chr22:29168773	CCDC117	-0.54	-4.94	-0.3	1.41e-6	Hematocrit;Hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14527148	chr15:80216341	C15orf37;ST20	0.47	6.56	0.39	3.13e-10	Parkinson's disease;
KIRP	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg04374321	chr14:90722782	PSMC1	0.99	17.94	0.75	1.34e-46	Mortality in heart failure;
KIRP	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.44	-0.43	1.71e-12	Triglycerides;
KIRP	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs2120243	0.565	rs13087207	chr3:157099638	G/A	cg24825693	chr3:157122686	VEPH1	-0.56	-9.04	-0.5	4.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs28573326	0.563	rs35394221	chr4:166348182	A/C	cg13437084	chr2:26467494	HADHB;HADHA	-0.48	-6.71	-0.39	1.3e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs35123781	1.000	rs589153	chr5:139057548	A/G	cg10513866	chr5:139070639	NA	0.35	4.96	0.3	1.33e-6	Schizophrenia;
KIRP	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.3	11.5	0.59	8.91e-25	Diabetic retinopathy;
KIRP	cis	rs865483	0.895	rs2522965	chr17:35816318	C/G	cg06716730	chr17:35851459	DUSP14	0.25	6.06	0.36	5.03e-9	Monocyte count;
KIRP	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.87	0.88	5.78e-81	Chronic sinus infection;
KIRP	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	9.63	0.52	7.61e-19	Cognitive test performance;
KIRP	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.55	5.44	0.33	1.26e-7	Gut microbiome composition (summer);
KIRP	cis	rs944722	0.839	rs8073631	chr17:26104547	C/T	cg07704981	chr17:26127537	NOS2	-0.46	-5.66	-0.34	4.24e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Body mass index;
KIRP	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg18261050	chr1:119551319	NA	0.51	6.64	0.39	1.95e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs448720	0.811	rs383041	chr15:68184481	C/G	cg24579218	chr15:68104479	NA	-0.38	-5.42	-0.33	1.44e-7	Cognitive performance;
KIRP	trans	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.91	-0.4	4.07e-11	Myopia (pathological);
KIRP	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-5.31	-0.32	2.42e-7	Blood metabolite levels;
KIRP	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg14673194	chr17:80132900	CCDC57	-0.77	-8.66	-0.48	6.54e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg00076555	chr3:49705435	BSN	-0.29	-4.87	-0.3	1.99e-6	Body mass index;
KIRP	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.74	-6.6	-0.39	2.49e-10	Obesity-related traits;
KIRP	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg00405596	chr8:11794950	NA	0.47	5.85	0.35	1.57e-8	Retinal vascular caliber;
KIRP	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.5	-6.72	-0.39	1.27e-10	Blood metabolite levels;
KIRP	cis	rs918629	0.567	rs3777194	chr5:95245384	C/T	cg16656078	chr5:95278638	ELL2	-0.36	-5.6	-0.34	5.62e-8	IgG glycosylation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00419759	chr1:114301964	PHTF1	0.54	6.45	0.38	6.03e-10	Smoking initiation;
KIRP	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg02297831	chr4:17616191	MED28	0.56	6.55	0.39	3.39e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.9	-10.89	-0.57	8.71e-23	Response to antipsychotic treatment;
KIRP	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.75	9.49	0.52	2.12e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2481665	0.765	rs2481678	chr1:62634020	T/C	cg18591186	chr1:62594603	INADL	-0.55	-8.23	-0.46	1.08e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.45	-5.78	-0.35	2.31e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.91	-0.35	1.12e-8	LDL cholesterol levels;
KIRP	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg04087571	chr11:116723030	SIK3	-0.27	-5.66	-0.34	4.16e-8	Subjective well-being;
KIRP	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg00792783	chr2:198669748	PLCL1	0.45	4.94	0.3	1.47e-6	Dermatomyositis;
KIRP	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.84	-12.58	-0.63	2.36e-28	Systemic lupus erythematosus;
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs981844	0.689	rs6835372	chr4:154682056	T/C	cg14289246	chr4:154710475	SFRP2	-0.5	-6.59	-0.39	2.69e-10	Response to statins (LDL cholesterol change);
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22618164	chr12:122356400	WDR66	0.67	8.95	0.5	8.82e-17	Mean corpuscular volume;
KIRP	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg04287289	chr16:89883240	FANCA	-0.42	-5.33	-0.32	2.26e-7	Vitiligo;
KIRP	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11584989	chr19:19387371	SF4	0.57	6.09	0.36	4.34e-9	Bipolar disorder;
KIRP	cis	rs7923609	0.967	rs2393986	chr10:65320006	A/T	cg08743896	chr10:65200160	JMJD1C	-0.34	-5.03	-0.31	9.66e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-5.11	-0.31	6.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg12718519	chr1:2058417	PRKCZ	0.23	5.17	0.31	4.82e-7	Height;
KIRP	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg14541582	chr5:601475	NA	-0.55	-6.12	-0.36	3.63e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.89	0.45	1.02e-13	Coffee consumption (cups per day);
KIRP	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.7	-11.45	-0.59	1.28e-24	Menopause (age at onset);
KIRP	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.71	-8.05	-0.46	3.48e-14	Corneal astigmatism;
KIRP	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg00129232	chr17:37814104	STARD3	0.5	6.17	0.37	2.78e-9	Self-reported allergy;
KIRP	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.49	5.98	0.36	7.76e-9	Height;
KIRP	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.57	5.28	0.32	2.87e-7	Major depressive disorder;
KIRP	cis	rs62158211	0.826	rs62158168	chr2:114078381	C/G	cg17784749	chr2:114082611	LOC440839	0.79	8.6	0.48	9.23e-16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg10047753	chr17:41438598	NA	1.14	18.05	0.75	5.9e-47	Menopause (age at onset);
KIRP	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-0.96	-15.63	-0.71	1.02e-38	Height;
KIRP	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg11569703	chr11:65557185	OVOL1	0.42	7.09	0.41	1.43e-11	Systemic lupus erythematosus;
KIRP	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	6.02	0.36	6.43e-9	Motion sickness;
KIRP	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26378065	chr17:18585709	ZNF286B	0.51	6.61	0.39	2.34e-10	Educational attainment (years of education);
KIRP	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg24315340	chr6:146058215	EPM2A	-0.4	-4.88	-0.3	1.87e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11197563	chr11:129872003	NCRNA00167;PRDM10	0.51	6.46	0.38	5.51e-10	Parkinson's disease;
KIRP	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.77	-8.91	-0.49	1.2e-16	Colorectal cancer;
KIRP	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs7714584	1.000	rs4579248	chr5:150268151	C/T	cg22134413	chr5:150180641	NA	0.92	7.0	0.41	2.42e-11	Crohn's disease;
KIRP	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg00647317	chr7:50633725	DDC	0.4	5.79	0.35	2.09e-8	Systemic sclerosis;
KIRP	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg03128945	chr5:622914	CEP72	-0.48	-6.86	-0.4	5.51e-11	Obesity-related traits;
KIRP	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.86	-9.07	-0.5	3.95e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg10381502	chr11:71823885	C11orf51	1.13	7.83	0.45	1.47e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg02487422	chr3:49467188	NICN1	0.37	5.18	0.31	4.72e-7	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs367615	0.959	rs2201016	chr5:108947287	T/C	cg17395555	chr5:108820864	NA	0.51	5.36	0.32	1.94e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs4132509	1.000	rs6659180	chr1:243995348	C/T	cg21452805	chr1:244014465	NA	0.52	4.94	0.3	1.45e-6	RR interval (heart rate);
KIRP	cis	rs965513	1.000	rs7028661	chr9:100538470	A/G	cg13688889	chr9:100608707	NA	-0.58	-7.35	-0.42	2.94e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.51	-6.74	-0.4	1.09e-10	Blood metabolite levels;
KIRP	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg00631329	chr6:26305371	NA	-0.57	-7.43	-0.43	1.83e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.22	12.06	0.61	1.23e-26	Chin dimples;
KIRP	cis	rs394563	0.559	rs7753269	chr6:149671360	G/A	cg03678062	chr6:149772716	ZC3H12D	0.31	4.98	0.3	1.21e-6	Dupuytren's disease;
KIRP	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg13611997	chr5:233750	SDHA	0.43	5.11	0.31	6.5e-7	Breast cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07481194	chr14:23398747	PRMT5	0.55	6.5	0.38	4.44e-10	Smoking initiation;
KIRP	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.85	-8.68	-0.48	5.45e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.58	-11.74	-0.6	1.41e-25	Diabetic kidney disease;
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg02462569	chr6:150064036	NUP43	-0.33	-4.9	-0.3	1.78e-6	Lung cancer;
KIRP	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.54	8.27	0.47	8.56e-15	Coronary artery disease;
KIRP	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.39	0.47	3.93e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1165472	0.755	rs67461420	chr1:56154764	A/G	cg11523071	chr1:56160889	NA	-0.6	-7.9	-0.45	9.3e-14	Paclitaxel-induced neuropathy;
KIRP	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.72	-6.68	-0.39	1.59e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.71	8.99	0.5	6.71e-17	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.63	7.68	0.44	3.81e-13	Corneal astigmatism;
KIRP	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21659725	chr3:3221576	CRBN	0.59	6.89	0.4	4.78e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg04691961	chr3:161091175	C3orf57	-0.4	-5.91	-0.35	1.16e-8	Morning vs. evening chronotype;
KIRP	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.64	-8.13	-0.46	2.14e-14	Body mass index;
KIRP	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg18154014	chr19:37997991	ZNF793	0.63	5.35	0.32	2.02e-7	Coronary artery calcification;
KIRP	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg05315796	chr3:52349193	DNAH1	0.44	6.81	0.4	7.64e-11	Bipolar disorder;
KIRP	cis	rs918629	0.724	rs3734131	chr5:95278679	G/A	cg16656078	chr5:95278638	ELL2	-0.51	-7.54	-0.43	8.96e-13	IgG glycosylation;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03771185	chr4:775700	NA	-0.48	-6.11	-0.36	3.78e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-5.92	-0.35	1.07e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs911119	0.913	rs13037490	chr20:23583725	T/C	cg09631192	chr20:23583594	CST9	-0.67	-6.34	-0.37	1.08e-9	Chronic kidney disease;
KIRP	cis	rs6669919	0.553	rs12733443	chr1:211667751	C/T	cg10512769	chr1:211675356	NA	-0.76	-10.7	-0.56	3.55e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg10104683	chr2:20424989	SDC1	0.52	6.13	0.36	3.48e-9	Obesity-related traits;
KIRP	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg02376097	chr19:46275166	DMPK	-0.39	-4.99	-0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.82	-0.4	6.89e-11	Aortic root size;
KIRP	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.84	-7.89	-0.45	9.68e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.5	6.6	0.39	2.56e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg06935464	chr4:38784597	TLR10	0.52	5.23	0.32	3.67e-7	Breast cancer;
KIRP	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg16586182	chr3:47516702	SCAP	-0.73	-10.06	-0.54	3.65e-20	Colorectal cancer;
KIRP	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.96	-16.4	-0.72	2.38e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.61	8.96	0.5	8.55e-17	Mean corpuscular volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23557426	chr14:65944637	FUT8	0.44	6.81	0.4	7.27e-11	Interleukin-4 levels;
KIRP	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg07701084	chr6:150067640	NUP43	0.71	9.93	0.54	9.11e-20	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04582539	chr19:9938647	UBL5	0.54	6.79	0.4	8.55e-11	Parkinson's disease;
KIRP	cis	rs4908768	0.579	rs12137865	chr1:8868406	A/G	cg25722041	chr1:8623473	RERE	0.56	7.3	0.42	3.9e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs10489525	0.599	rs2335724	chr1:115608444	T/C	cg01522456	chr1:115632236	TSPAN2	0.53	6.99	0.41	2.55e-11	Autism;
KIRP	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12893428	chr3:195717962	SDHAP1	0.48	6.32	0.37	1.22e-9	Pancreatic cancer;
KIRP	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg12235144	chr12:48398329	COL2A1	0.46	4.88	0.3	1.92e-6	Lung cancer;
KIRP	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg10223061	chr2:219282414	VIL1	-0.33	-5.48	-0.33	1.03e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg19849509	chr2:175204996	NA	-0.54	-6.4	-0.38	7.67e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg24296786	chr1:45957014	TESK2	0.51	5.63	0.34	4.98e-8	Homocysteine levels;
KIRP	cis	rs36715	1.000	rs2617621	chr5:127546266	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.86	0.49	1.63e-16	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23651146	chr3:57261829	APPL1	0.51	6.26	0.37	1.7e-9	Parkinson's disease;
KIRP	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.66	0.71	8.46e-39	Chronic sinus infection;
KIRP	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg14689365	chr7:158441557	NCAPG2	-0.4	-4.94	-0.3	1.46e-6	Height;
KIRP	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.36	5.12	0.31	6.23e-7	Calcium levels;
KIRP	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.02	12.5	0.62	4.3e-28	Testicular germ cell tumor;
KIRP	cis	rs2224391	0.628	rs2753243	chr6:5256261	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-6.07	-0.36	4.71e-9	Height;
KIRP	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.7	-10.27	-0.55	7.95e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1864585	0.520	rs17776404	chr8:10672829	A/G	cg26278703	chr11:58910052	FAM111A	0.63	6.33	0.37	1.18e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2997447	0.846	rs3008420	chr1:26401403	C/T	cg19633962	chr1:26362018	EXTL1	-0.48	-4.84	-0.3	2.27e-6	QRS complex (12-leadsum);
KIRP	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg24747557	chr10:131355152	MGMT	0.45	6.15	0.36	3.14e-9	Response to temozolomide;
KIRP	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04530015	chr2:215796436	ABCA12	0.45	6.54	0.39	3.44e-10	Neuroblastoma (high-risk);
KIRP	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.58	-7.28	-0.42	4.35e-12	Uric acid clearance;
KIRP	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg15556689	chr8:8085844	FLJ10661	0.53	7.11	0.41	1.27e-11	Acne (severe);
KIRP	cis	rs11191270	1.000	rs4919626	chr10:104079818	T/C	cg15320455	chr10:103880129	LDB1	0.55	4.86	0.3	2.13e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg00405596	chr8:11794950	NA	0.42	5.35	0.32	2.04e-7	Retinal vascular caliber;
KIRP	cis	rs1699337	0.930	rs2938398	chr3:12404490	T/C	cg02700894	chr3:12045449	SYN2	0.38	4.88	0.3	1.95e-6	Cholesterol, total;
KIRP	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.12	-0.31	6.12e-7	Life satisfaction;
KIRP	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-5.32	-0.32	2.33e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.92	12.27	0.62	2.58e-27	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.42	-0.38	6.93e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7719624	0.840	rs916951	chr5:135384443	A/G	cg16684184	chr5:135415129	NA	-0.34	-4.86	-0.3	2.06e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs2916247	1.000	rs7833370	chr8:93066653	C/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9896052	0.625	rs11656558	chr17:73440437	T/C	cg25649188	chr17:73499917	CASKIN2	0.6	5.82	0.35	1.87e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg01721255	chr8:58191610	C8orf71	0.52	5.14	0.31	5.57e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6855629	0.740	rs10461139	chr4:106105299	A/G	cg08924430	chr4:106067052	TET2	0.36	5.18	0.31	4.57e-7	Height;
KIRP	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4765905	0.550	rs4765667	chr12:2312820	A/C	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.94	-0.4	3.36e-11	Schizophrenia;
KIRP	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.48	5.81	0.35	1.93e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9816784	0.525	rs41301371	chr3:195799567	C/T	cg01351295	chr3:195700735	SDHAP1	-0.45	-5.06	-0.31	8.02e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	6.54	0.38	3.61e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.08	0.5	3.61e-17	Bladder cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15921797	chr8:133797018	PHF20L1	0.44	6.42	0.38	7.14e-10	Interleukin-4 levels;
KIRP	trans	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.39	-0.43	2.29e-12	Mood instability;
KIRP	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.72	8.61	0.48	8.65e-16	Schizophrenia;
KIRP	cis	rs62355272	0.580	rs1010599	chr5:35908474	A/G	cg13894535	chr5:35919491	CAPSL	-0.37	-4.9	-0.3	1.77e-6	Lymphocyte counts;
KIRP	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg14375499	chr17:6899207	ALOX12	0.38	5.9	0.35	1.17e-8	Tonsillectomy;
KIRP	cis	rs8177876	0.658	rs2278022	chr16:81076821	T/C	cg08591886	chr16:81111003	C16orf46	-0.71	-5.32	-0.32	2.31e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23161317	chr6:28129485	ZNF389	0.41	4.93	0.3	1.49e-6	Depression;
KIRP	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.31	0.37	1.28e-9	Aortic root size;
KIRP	cis	rs2273669	0.833	rs1364450	chr6:109389508	A/C	cg05315195	chr6:109294784	ARMC2	-0.46	-4.88	-0.3	1.89e-6	Prostate cancer;
KIRP	cis	rs12200782	0.932	rs72844476	chr6:26574150	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg13736514	chr6:26305472	NA	-0.68	-8.46	-0.47	2.37e-15	Educational attainment;
KIRP	cis	rs564148	0.872	rs664727	chr1:34157328	G/C	cg25772827	chr1:34632573	C1orf94;CSMD2	0.44	5.0	0.3	1.07e-6	Response to amphetamines;
KIRP	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.45	-6.06	-0.36	4.97e-9	Melanoma;
KIRP	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg00666640	chr1:248458726	OR2T12	0.44	5.27	0.32	3.06e-7	Common traits (Other);
KIRP	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.43	-0.38	6.76e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6732160	0.624	rs10865397	chr2:73358292	C/T	cg01422370	chr2:73384389	NA	0.37	4.89	0.3	1.79e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.81	-10.18	-0.54	1.5e-20	Blood protein levels;
KIRP	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	11.59	0.59	4.53e-25	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-1.21	-10.24	-0.55	1e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.92	-0.45	8.06e-14	Homocysteine levels;
KIRP	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.36	-0.42	2.69e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs963731	0.571	rs4670270	chr2:39230351	G/A	cg04010122	chr2:39346883	SOS1	-0.88	-5.84	-0.35	1.67e-8	Corticobasal degeneration;
KIRP	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg07148914	chr20:33460835	GGT7	0.42	5.16	0.31	5.11e-7	Height;
KIRP	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.65	8.29	0.47	7.54e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs13401104	0.716	rs1377443	chr2:237129648	G/T	cg19324714	chr2:237145437	ASB18	0.52	5.41	0.33	1.47e-7	Educational attainment;
KIRP	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.28	-0.37	1.52e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.31	8.0	0.45	4.97e-14	Crohn's disease;
KIRP	cis	rs62413470	1.000	rs61200368	chr6:55943942	G/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs7903847	0.642	rs10882908	chr10:99134970	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.86	-0.35	1.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.6	-7.57	-0.43	7.44e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09256517	chr2:42396442	EML4	-0.57	-6.23	-0.37	1.98e-9	Menopause (age at onset);
KIRP	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.81	-13.3	-0.65	8.88e-31	Brugada syndrome;
KIRP	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg05791153	chr7:19748676	TWISTNB	0.67	6.15	0.37	3.12e-9	Thyroid stimulating hormone;
KIRP	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.42	-6.1	-0.36	4.09e-9	Height;
KIRP	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	9.11	0.5	3e-17	Bipolar disorder;
KIRP	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.12	-0.31	6.11e-7	Tonsillectomy;
KIRP	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.02	-0.3	1.01e-6	Pulmonary function;
KIRP	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.77	9.71	0.53	4.6e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	7.13	0.41	1.1e-11	Iron status biomarkers;
KIRP	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.08e-11	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09084106	chr17:20904603	USP22	-0.42	-6.05	-0.36	5.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg15660573	chr17:549704	VPS53	-0.95	-15.04	-0.69	1.04e-36	Prostate cancer;
KIRP	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.73	7.02	0.41	2.09e-11	Gut microbiome composition (summer);
KIRP	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg10117171	chr1:25599238	RHD	-0.37	-5.03	-0.31	9.51e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.43e-33	Primary sclerosing cholangitis;
KIRP	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.46e-9	Obesity-related traits;
KIRP	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg25039879	chr17:56429692	SUPT4H1	0.53	4.84	0.3	2.26e-6	Cognitive test performance;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg00343986	chr7:65444356	GUSB	0.5	6.18	0.37	2.63e-9	Aortic root size;
KIRP	cis	rs13014235	0.532	rs3731709	chr2:202246034	G/C	cg06431681	chr2:202330990	STRADB	0.38	5.1	0.31	6.89e-7	Basal cell carcinoma;
KIRP	cis	rs914615	0.508	rs4971079	chr1:155130391	C/T	cg02153340	chr1:155202674	NA	-0.48	-7.3	-0.42	4.02e-12	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs10073892	0.625	rs59648644	chr5:101618975	A/T	cg19774478	chr5:101632501	SLCO4C1	0.61	6.11	0.36	3.82e-9	Cognitive decline (age-related);
KIRP	cis	rs2979489	0.841	rs2015311	chr8:30306989	A/G	cg26383811	chr8:30366931	RBPMS	0.38	5.13	0.31	6e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08693600	chr19:58978543	ZNF324	0.49	6.07	0.36	4.75e-9	Parkinson's disease;
KIRP	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.31	-5.16	-0.31	4.99e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	14.25	0.67	5.17e-34	IgG glycosylation;
KIRP	cis	rs72627123	0.867	rs73303135	chr14:74495090	C/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.22	0.32	3.87e-7	Morning vs. evening chronotype;
KIRP	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.84	-12.27	-0.62	2.61e-27	Systemic lupus erythematosus;
KIRP	cis	rs4776059	0.959	rs4548810	chr15:52943814	C/T	cg25063058	chr15:52860530	ARPP19	0.48	5.25	0.32	3.37e-7	Schizophrenia;
KIRP	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.45e-22	Neuroticism;
KIRP	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg17366294	chr4:99064904	C4orf37	0.44	6.38	0.38	8.94e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06716807	chr2:27632449	PPM1G	0.5	6.4	0.38	7.61e-10	Parkinson's disease;
KIRP	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.73	-9.74	-0.53	3.71e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.34	0.32	2.07e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg24826892	chr11:71159390	DHCR7	0.44	4.89	0.3	1.81e-6	Vitamin D levels;
KIRP	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.85	8.77	0.49	3.1e-16	Body mass index;
KIRP	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15369054	chr17:80825471	TBCD	0.63	5.52	0.33	8.79e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg13206674	chr6:150067644	NUP43	0.64	8.69	0.48	5.1e-16	Lung cancer;
KIRP	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4664293	1.000	rs10193402	chr2:160507782	A/G	cg08347373	chr2:160653686	CD302	-0.39	-5.95	-0.35	9e-9	Monocyte percentage of white cells;
KIRP	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg16141378	chr3:129829833	LOC729375	-0.58	-7.73	-0.44	2.78e-13	Joint mobility (Beighton score);
KIRP	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg17554472	chr22:41940697	POLR3H	0.59	6.23	0.37	1.97e-9	Vitiligo;
KIRP	cis	rs13095912	0.752	rs13092283	chr3:185338005	T/C	cg11274856	chr3:185301563	NA	0.65	8.31	0.47	6.4e-15	Systolic blood pressure;
KIRP	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.14	-0.31	5.51e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.64	10.17	0.54	1.61e-20	HDL cholesterol levels;
KIRP	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg26681399	chr22:41777847	TEF	-0.44	-5.03	-0.31	9.32e-7	Vitiligo;
KIRP	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.72	0.34	3.1e-8	Putamen volume;
KIRP	cis	rs75804782	0.521	rs72982598	chr2:239455052	G/A	cg18131467	chr2:239335373	ASB1	-0.7	-5.42	-0.33	1.39e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg07884673	chr3:53033167	SFMBT1	0.92	6.97	0.41	2.9100000000000002e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg23533926	chr12:111358616	MYL2	-0.47	-6.14	-0.36	3.35e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs362296	0.698	rs362279	chr4:3260072	G/A	cg06533319	chr4:3265114	C4orf44	0.56	6.46	0.38	5.48e-10	Parental longevity (mother's age at death);
KIRP	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.4	-5.61	-0.34	5.56e-8	Blood metabolite levels;
KIRP	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.97	16.45	0.72	1.66e-41	Breast cancer;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.5	6.9	0.4	4.43e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg20744362	chr22:50050164	C22orf34	0.31	4.88	0.3	1.91e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.15	15.1	0.69	6.59e-37	Gut microbiome composition (summer);
KIRP	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg03609598	chr5:56110824	MAP3K1	-0.46	-5.17	-0.31	4.78e-7	Coronary artery disease;
KIRP	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg22549504	chr19:17448937	GTPBP3	-0.47	-5.09	-0.31	7.1e-7	Systemic lupus erythematosus;
KIRP	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.46	5.28	0.32	2.82e-7	Schizophrenia;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg24874828	chr4:187887005	NA	-0.57	-9.36	-0.51	5.25e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11235843	0.636	rs1464908	chr11:73402679	A/C	cg18195628	chr11:73498948	MRPL48	-0.48	-5.01	-0.3	1.05e-6	Hand grip strength;
KIRP	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.72	-0.34	3.02e-8	Aortic root size;
KIRP	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg27624424	chr6:160112604	SOD2	0.53	6.18	0.37	2.71e-9	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.89	9.73	0.53	3.8e-19	Gut microbiome composition (summer);
KIRP	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.5	-5.64	-0.34	4.56e-8	Testicular germ cell tumor;
KIRP	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg15252951	chr6:33757062	LEMD2	0.48	5.74	0.34	2.76e-8	Crohn's disease;
KIRP	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.5	-7.8	-0.45	1.75e-13	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01129751	chr2:42796040	MTA3	0.5	6.3	0.37	1.36e-9	Parkinson's disease;
KIRP	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg21535247	chr6:8435926	SLC35B3	-0.51	-6.63	-0.39	2.13e-10	Motion sickness;
KIRP	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.21	0.51	1.49e-17	Prudent dietary pattern;
KIRP	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.45	7.89	0.45	9.65e-14	Systemic lupus erythematosus;
KIRP	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.55	7.24	0.42	5.75e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.2	0.42	7.43e-12	Height;
KIRP	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.58	-6.6	-0.39	2.54e-10	Hypospadias;
KIRP	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	4.9	0.3	1.7e-6	Height;
KIRP	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.12e-8	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg24315340	chr6:146058215	EPM2A	0.47	6.29	0.37	1.43e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7903847	0.527	rs11189221	chr10:99198217	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.36	-0.32	1.93e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	8.18	0.46	1.48e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.62e-11	Lung cancer;
KIRP	cis	rs2274273	0.686	rs66531545	chr14:55587460	T/C	cg04306507	chr14:55594613	LGALS3	0.42	5.58	0.33	6.46e-8	Protein biomarker;
KIRP	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg11965913	chr1:205819406	PM20D1	-0.57	-5.74	-0.34	2.72e-8	Menarche (age at onset);
KIRP	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.4	-6.3	-0.37	1.35e-9	Body mass index;
KIRP	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.07e-11	Bipolar disorder;
KIRP	cis	rs748404	0.578	rs1058298	chr15:43700930	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	6.92	0.4	4.01e-11	Lung cancer;
KIRP	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.45	-5.13	-0.31	5.92e-7	Lung cancer in ever smokers;
KIRP	cis	rs654950	0.875	rs2759248	chr1:41990795	T/C	cg06885757	chr1:42089581	HIVEP3	-0.5	-7.19	-0.42	7.7e-12	Airway imaging phenotypes;
KIRP	cis	rs8054556	1.000	rs10871451	chr16:29986205	C/G	cg06326092	chr16:30034487	C16orf92	0.34	4.88	0.3	1.89e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg06386533	chr2:46925753	SOCS5	0.51	5.12	0.31	6.29e-7	Height;
KIRP	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.85	13.29	0.65	9.31e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.78e-9	Motion sickness;
KIRP	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.77	11.61	0.6	3.77e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.44	0.38	6.29e-10	Colorectal cancer;
KIRP	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.73	11.58	0.59	4.85e-25	Resting heart rate;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10865936	chr17:26989239	SUPT6H;SDF2	-0.47	-6.26	-0.37	1.71e-9	Metabolic traits;
KIRP	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17554472	chr22:41940697	POLR3H	0.66	6.86	0.4	5.45e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg03808351	chr9:123631620	PHF19	0.43	5.88	0.35	1.31e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.79	10.63	0.56	5.78e-22	Menarche (age at onset);
KIRP	trans	rs12043259	1.000	rs61642896	chr1:204827657	T/C	cg11485465	chr5:54518469	NA	0.42	6.39	0.38	8.06e-10	Addiction;
KIRP	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.66	-12.57	-0.63	2.51e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg00262122	chr8:11665843	FDFT1	-0.45	-5.25	-0.32	3.24e-7	Triglycerides;
KIRP	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg14349672	chr11:133703707	NA	-0.4	-4.89	-0.3	1.82e-6	Childhood ear infection;
KIRP	cis	rs2979489	0.945	rs11988541	chr8:30334273	G/A	cg26383811	chr8:30366931	RBPMS	-0.39	-5.34	-0.32	2.1e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.95	16.34	0.72	3.97e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.69	10.3	0.55	6.31e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg21926883	chr2:100939477	LONRF2	-0.44	-5.32	-0.32	2.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.43	6.13	0.36	3.4e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07570687	chr10:102243282	WNT8B	0.51	6.64	0.39	1.98e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-9.61	-0.52	8.77e-19	Longevity;Endometriosis;
KIRP	cis	rs10267417	0.603	rs10258555	chr7:19868344	T/G	cg05791153	chr7:19748676	TWISTNB	0.54	5.24	0.32	3.44e-7	Night sleep phenotypes;
KIRP	cis	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg04607699	chr11:48328132	OR4S1	-0.37	-5.1	-0.31	6.71e-7	HDL cholesterol;
KIRP	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.31	-5.23	-0.32	3.63e-7	Height;
KIRP	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.81	10.39	0.55	3.46e-21	Mean platelet volume;
KIRP	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg23594656	chr7:65796392	TPST1	0.53	8.32	0.47	6.19e-15	Aortic root size;
KIRP	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg05555928	chr11:63887634	MACROD1	-0.6	-5.38	-0.32	1.72e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs970548	0.955	rs11239551	chr10:46026107	G/A	cg01246622	chr10:115141827	NA	0.49	6.18	0.37	2.66e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.1	0.31	6.74e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-6.41	-0.38	7.51e-10	Dilated cardiomyopathy;
KIRP	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.55	6.92	0.4	3.83e-11	Monocyte count;
KIRP	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg05973401	chr12:123451056	ABCB9	0.54	6.28	0.37	1.52e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.5	6.3	0.37	1.38e-9	Alzheimer's disease biomarkers;
KIRP	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg07962218	chr7:65219954	SNORA22;CCT6P1	-0.36	-5.61	-0.34	5.41e-8	Calcium levels;
KIRP	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.46	-6.99	-0.41	2.58e-11	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.92	0.4	3.93e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.73	6.48	0.38	4.92e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7589728	0.516	rs79815126	chr2:88488270	G/A	cg04511125	chr2:88470314	THNSL2	0.87	6.05	0.36	5.38e-9	Plasma clusterin levels;
KIRP	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.78	7.15	0.41	1.02e-11	Mean platelet volume;
KIRP	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.78	-0.49	2.86e-16	Coronary artery disease;
KIRP	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg24009623	chr19:33667908	NA	-0.48	-6.32	-0.37	1.24e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.73	-9.68	-0.53	5.58e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg24110177	chr3:50126178	RBM5	-0.44	-5.59	-0.34	6.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg22771759	chr13:24902376	NA	0.45	5.61	0.34	5.33e-8	Obesity-related traits;
KIRP	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-7.87	-0.45	1.15e-13	Morning vs. evening chronotype;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08887933	chr16:71601037	TAT	0.54	6.18	0.37	2.62e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00268518	chr11:71164106	NADSYN1	-0.51	-6.62	-0.39	2.22e-10	Myopia;
KIRP	trans	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.42	-0.43	1.91e-12	Atopic dermatitis;
KIRP	cis	rs11718455	0.585	rs11710794	chr3:43930119	T/G	cg21419209	chr3:44054225	NA	-0.63	-7.37	-0.43	2.66e-12	Coronary artery disease;
KIRP	cis	rs300890	0.664	rs13137362	chr4:144199974	C/T	cg19876092	chr4:144208277	NA	0.41	6.63	0.39	2.16e-10	Nasopharyngeal carcinoma;
KIRP	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg22800045	chr5:56110881	MAP3K1	0.53	5.96	0.36	8.51e-9	Coronary artery disease;
KIRP	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.74	8.55	0.48	1.32e-15	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.84	-0.4	6.4e-11	Aortic root size;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	8.89e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg21905437	chr5:178450457	ZNF879	0.56	6.54	0.38	3.48e-10	Pubertal anthropometrics;
KIRP	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs11610422	1.000	rs12823902	chr12:31414290	A/G	cg14306366	chr12:31406441	NA	-0.58	-5.95	-0.35	9.35e-9	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg12486944	chr17:80159399	CCDC57	-0.41	-5.49	-0.33	1e-7	Life satisfaction;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09379601	chr19:12992224	DNASE2	-0.48	-6.4	-0.38	7.86e-10	Neuroticism;
KIRP	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.66	7.07	0.41	1.59e-11	Vitiligo;
KIRP	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg05669848	chr5:237993	SDHA	-0.5	-5.19	-0.31	4.39e-7	Breast cancer;
KIRP	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.74	9.41	0.51	3.76e-18	Renal function-related traits (BUN);
KIRP	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.51	-0.33	9.22e-8	Metabolite levels;
KIRP	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.41	-0.51	3.59e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6967385	0.560	rs34130399	chr7:12356746	T/A	cg20607287	chr7:12443886	VWDE	0.38	4.98	0.3	1.2e-6	Response to taxane treatment (placlitaxel);
KIRP	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg26681399	chr22:41777847	TEF	-0.44	-4.95	-0.3	1.36e-6	Vitiligo;
KIRP	cis	rs6430538	0.671	rs1942050	chr2:135574583	C/T	cg12500956	chr2:135428796	TMEM163	-0.39	-4.86	-0.3	2.14e-6	Parkinson's disease;
KIRP	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24703757	chr4:183838736	DCTD	0.46	6.2	0.37	2.32e-9	Parkinson's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24682316	chr20:35808040	C20orf132;RPN2	-0.47	-6.29	-0.37	1.47e-9	Metabolic traits;
KIRP	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.59	6.03	0.36	6.06e-9	Height;
KIRP	cis	rs16970672	0.824	rs8080086	chr17:75977988	A/G	cg08969274	chr17:75848810	NA	0.35	5.25	0.32	3.28e-7	Psychosis and Alzheimer's disease;
KIRP	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs16957091	0.738	rs1705356	chr15:42922656	C/T	cg24196017	chr15:43021976	CDAN1	-0.44	-5.58	-0.34	6.3e-8	MGMT methylation in smokers;
KIRP	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg00310523	chr12:86230176	RASSF9	-0.57	-8.86	-0.49	1.64e-16	Major depressive disorder;
KIRP	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg20312557	chr2:97357134	FER1L5	-0.76	-5.95	-0.35	9.22e-9	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.46	7.04	0.41	1.88e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.49	7.15	0.42	9.6e-12	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.66	6.9	0.4	4.45e-11	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.54	6.98	0.41	2.65e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs427941	0.703	rs201446	chr7:101738323	C/G	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.24e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-6.44	-0.38	6.06e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.53	-7.38	-0.43	2.46e-12	Prostate cancer;
KIRP	cis	rs8014252	0.803	rs74062769	chr14:71070576	A/C	cg11204974	chr14:71022665	NA	-0.68	-7.12	-0.41	1.21e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	5.22	0.32	3.86e-7	Educational attainment;
KIRP	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.03e-8	Motion sickness;
KIRP	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg10189774	chr4:17578691	LAP3	0.51	6.18	0.37	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.76	10.9	0.57	8.11e-23	Colorectal or endometrial cancer;
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.53	-8.15	-0.46	1.89e-14	Lung cancer;
KIRP	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.41	5.24	0.32	3.46e-7	Multiple sclerosis;
KIRP	cis	rs4908768	0.906	rs10492965	chr1:8598127	G/A	cg25722041	chr1:8623473	RERE	0.8	9.87	0.53	1.4e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs6601327	0.898	rs1458942	chr8:9406602	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.45	-0.38	5.78e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1620921	0.840	rs783178	chr6:161169739	C/T	cg01280913	chr6:161186852	NA	-0.41	-5.73	-0.34	2.95e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-0.82	-14.91	-0.69	2.97e-36	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26807935	chr5:139028606	CXXC5	0.49	6.02	0.36	6.44e-9	Parkinson's disease;
KIRP	cis	rs60154123	0.730	rs58366398	chr1:210471924	G/A	cg09074223	chr1:210466472	NA	0.6	6.26	0.37	1.73e-9	Coronary artery disease;
KIRP	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	1.03	20.25	0.79	2.49e-54	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg26134248	chr17:3907702	NA	0.55	8.19	0.46	1.4e-14	Type 2 diabetes;
KIRP	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg19077165	chr18:44547161	KATNAL2	0.47	5.77	0.35	2.37e-8	Personality dimensions;
KIRP	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.41e-8	Schizophrenia;
KIRP	cis	rs7646881	0.812	rs7636023	chr3:158460059	T/C	cg19483011	chr3:158453295	NA	-0.56	-5.89	-0.35	1.23e-8	Tetralogy of Fallot;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00711596	chr19:2115281	AP3D1	0.46	6.06	0.36	5.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.93	0.53	9.31e-20	Monocyte percentage of white cells;
KIRP	cis	rs8014252	0.711	rs59044667	chr14:71043704	A/G	cg11204974	chr14:71022665	NA	-0.73	-7.18	-0.42	8.16e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07638797	chr21:38792116	DYRK1A	-0.43	-7.0	-0.41	2.48e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg27205649	chr11:78285834	NARS2	-0.67	-7.39	-0.43	2.25e-12	Alzheimer's disease (survival time);
KIRP	cis	rs965513	1.000	rs7030280	chr9:100535267	C/T	cg13688889	chr9:100608707	NA	-0.59	-7.31	-0.42	3.77e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-6.11	-0.36	3.96e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.04	0.5	4.75e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	0.92	10.2	0.55	1.29e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs6738627	1.000	rs6752978	chr2:165552942	G/T	cg03182029	chr2:165697222	COBLL1	0.44	5.55	0.33	7.36e-8	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs4787491	0.704	rs35605010	chr16:30033428	A/G	cg06326092	chr16:30034487	C16orf92	0.49	7.59	0.44	6.49e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10267417	0.603	rs13241328	chr7:19939232	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	5.12	0.31	6.02e-7	Night sleep phenotypes;
KIRP	cis	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg26585981	chr11:48327164	OR4S1	-0.42	-5.36	-0.32	1.91e-7	HDL cholesterol;
KIRP	cis	rs651907	0.935	rs2929922	chr3:101587934	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.11	0.31	6.4e-7	Colorectal cancer;
KIRP	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg04824913	chr4:887549	GAK	-0.41	-5.3	-0.32	2.52e-7	Systemic sclerosis;
KIRP	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg23594656	chr7:65796392	TPST1	-0.41	-5.82	-0.35	1.84e-8	Aortic root size;
KIRP	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg00585698	chr12:123750864	CDK2AP1	0.53	6.62	0.39	2.19e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.81	-8.98	-0.5	7.34e-17	Neuroblastoma;
KIRP	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg14517863	chr17:44321492	NA	0.53	5.97	0.36	8.29e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg12559939	chr2:27858050	GPN1	0.4	5.06	0.31	8.22e-7	Oral cavity cancer;
KIRP	trans	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08382705	chr11:45687319	CHST1	-0.53	-6.5	-0.38	4.46e-10	Height;
KIRP	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg23587288	chr2:27483067	SLC30A3	-0.64	-6.91	-0.4	4.07e-11	Blood metabolite levels;
KIRP	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg00277334	chr10:82204260	NA	-0.44	-4.89	-0.3	1.79e-6	Post bronchodilator FEV1;
KIRP	cis	rs6968419	0.755	rs4730720	chr7:115895235	C/T	cg02561103	chr7:115862891	TES	0.42	6.08	0.36	4.6e-9	Intraocular pressure;
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	13.15	0.64	2.93e-30	Platelet count;
KIRP	cis	rs2034088	0.931	rs7217763	chr17:421437	A/G	cg06217071	chr17:408420	NA	0.74	11.18	0.58	1e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.13	-0.41	1.11e-11	Menopause (age at onset);
KIRP	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.7	-7.88	-0.45	1.06e-13	Menarche (age at onset);
KIRP	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg04935436	chr20:30431758	NA	0.49	6.59	0.39	2.59e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs963731	0.649	rs2373495	chr2:39254627	C/G	cg04010122	chr2:39346883	SOS1	-0.95	-6.56	-0.39	3.24e-10	Corticobasal degeneration;
KIRP	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.79	-10.11	-0.54	2.48e-20	Gut microbiome composition (winter);
KIRP	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.66	-9.24	-0.51	1.24e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7712401	0.623	rs30057	chr5:122298118	C/T	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14182563	chr22:51039000	MAPK8IP2	0.48	6.11	0.36	3.82e-9	Parkinson's disease;
KIRP	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-10.12	-0.54	2.29e-20	Exhaled nitric oxide output;
KIRP	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21643547	chr1:205240462	TMCC2	-0.85	-14.11	-0.67	1.65e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.07	0.5	3.86e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg23205692	chr1:25664452	TMEM50A	0.36	5.11	0.31	6.4e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.59	-6.84	-0.4	6.3e-11	Corneal astigmatism;
KIRP	cis	rs10121009	0.587	rs2281999	chr9:35381504	C/T	cg15271616	chr9:35490515	RUSC2	0.35	4.86	0.3	2.1e-6	Parkinson's disease;
KIRP	cis	rs459571	0.796	rs10993894	chr9:136884511	C/T	cg13789015	chr9:136890014	NCRNA00094	0.87	10.97	0.57	4.71e-23	Platelet distribution width;
KIRP	cis	rs7751419	0.651	rs10947778	chr6:39093606	T/C	cg08089693	chr6:39098871	NA	-0.7	-9.96	-0.54	7.39e-20	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00338735	chr4:53728038	RASL11B	0.5	5.72	0.34	3.03e-8	Optic nerve measurement (cup area);
KIRP	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.44	-0.38	6.21e-10	Daytime sleep phenotypes;
KIRP	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg09795085	chr6:101329169	ASCC3	-0.52	-6.35	-0.38	1.02e-9	Neuroticism;
KIRP	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg24804195	chr5:87968844	LOC645323	-0.47	-6.21	-0.37	2.22e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17860381	chr5:142783569	NR3C1	0.42	6.03	0.36	5.9e-9	Parkinson's disease;
KIRP	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs2862064	1.000	rs9313405	chr5:156447750	T/C	cg12943317	chr5:156479607	HAVCR1	-0.69	-6.67	-0.39	1.66e-10	Platelet count;
KIRP	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg04691961	chr3:161091175	C3orf57	-0.39	-6.27	-0.37	1.59e-9	Morning vs. evening chronotype;
KIRP	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg10128416	chr1:75198403	TYW3;CRYZ	0.47	5.93	0.35	1.03e-8	Resistin levels;
KIRP	cis	rs12120353	0.529	rs55956326	chr1:4623889	C/T	cg02837536	chr1:4771682	AJAP1	-0.5	-5.0	-0.3	1.09e-6	Anxiety disorder;
KIRP	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.81	-12.28	-0.62	2.43e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.22e-9	Breast cancer;
KIRP	cis	rs10203711	0.966	rs10184252	chr2:239598164	A/G	cg14580085	chr2:239553406	NA	0.4	5.33	0.32	2.18e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34339938	1	rs34339938	chr12:123678364	GAC/G	cg00376283	chr12:123451042	ABCB9	0.68	8.13	0.46	2.14e-14	Plateletcrit;
KIRP	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-8.0	-0.45	5.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.78	-0.44	2.04e-13	Homocysteine levels;
KIRP	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.42	5.44	0.33	1.28e-7	Body mass index;
KIRP	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg22951263	chr5:87985283	NA	-0.48	-6.83	-0.4	6.68e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs11676348	0.703	rs6737563	chr2:218945674	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-6.49	-0.38	4.71e-10	Ulcerative colitis;
KIRP	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.27	0.32	2.98e-7	Renal cell carcinoma;
KIRP	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg01721255	chr8:58191610	C8orf71	0.55	5.68	0.34	3.72e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg06212747	chr3:49208901	KLHDC8B	0.67	6.25	0.37	1.81e-9	Menarche (age at onset);
KIRP	cis	rs939574	0.676	rs12694457	chr2:220134010	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.67	-7.44	-0.43	1.67e-12	Platelet distribution width;
KIRP	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg23594656	chr7:65796392	TPST1	-0.49	-7.57	-0.43	7.38e-13	Aortic root size;
KIRP	trans	rs12517041	0.938	rs34072953	chr5:23269936	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.58	-6.17	-0.37	2.81e-9	Calcium levels;
KIRP	cis	rs11166927	0.935	rs12541565	chr8:140794689	C/A	cg16909799	chr8:140841666	TRAPPC9	0.72	10.4	0.55	3.22e-21	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg01631408	chr1:248437212	OR2T33	-0.65	-8.35	-0.47	5.06e-15	Common traits (Other);
KIRP	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg01689657	chr7:91764605	CYP51A1	-0.42	-5.96	-0.36	8.67e-9	Breast cancer;
KIRP	cis	rs4704187	0.687	rs67065524	chr5:74534309	A/G	cg03227963	chr5:74354835	NA	0.39	5.71	0.34	3.17e-8	Response to amphetamines;
KIRP	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.59	-9.67	-0.52	6.04e-19	Total body bone mineral density;
KIRP	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg17376030	chr22:41985996	PMM1	0.59	6.22	0.37	2.08e-9	Vitiligo;
KIRP	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	5.23	0.32	3.59e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11628318	0.538	rs1190339	chr14:103103876	C/T	cg01864069	chr14:103024347	NA	-0.42	-5.19	-0.31	4.35e-7	Platelet count;
KIRP	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.7	-7.14	-0.41	1.04e-11	Vitiligo;
KIRP	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-7.5	-0.43	1.19e-12	Total cholesterol levels;
KIRP	trans	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27627127	chr4:39062784	KLHL5	0.45	6.56	0.39	3.22e-10	Survival in pancreatic cancer;
KIRP	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg19913688	chr11:428466	ANO9	0.76	6.16	0.37	2.99e-9	Body mass index;
KIRP	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.65	7.94	0.45	7.27e-14	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05778739	chr2:96676295	LOC729234	0.54	6.43	0.38	6.69e-10	Smoking initiation;
KIRP	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.4	0.38	7.89e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.3	5.13	0.31	5.78e-7	Calcium levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20080079	chr12:85430174	TSPAN19;LRRIQ1	0.45	6.6	0.39	2.45e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.35	7.27	0.42	4.73e-12	Body mass index;
KIRP	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.99	10.28	0.55	7.37e-21	Eosinophilic esophagitis;
KIRP	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg18944383	chr4:111397179	ENPEP	0.62	11.38	0.59	2.23e-24	Height;
KIRP	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.63	-9.38	-0.51	4.67e-18	IgG glycosylation;
KIRP	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-8.44	-0.47	2.78e-15	Bipolar disorder;
KIRP	cis	rs11044737	0.530	rs73080884	chr12:19836422	G/T	cg21450381	chr12:19836352	NA	0.45	4.89	0.3	1.82e-6	Lifetime average cigarettes per day in chronic obstructive pulmonary disease;
KIRP	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.63	-8.22	-0.46	1.14e-14	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25862684	chr15:101142576	LINS1;ASB7	0.49	6.51	0.38	4.28e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.73	10.82	0.57	1.4e-22	Prostate cancer;
KIRP	cis	rs16976116	0.851	rs28784096	chr15:55503312	C/T	cg11288833	chr15:55489084	RSL24D1	0.66	7.37	0.43	2.54e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.87	13.57	0.65	1.11e-31	Blood protein levels;
KIRP	cis	rs34779708	0.766	rs7913451	chr10:35551525	T/C	cg03585969	chr10:35415529	CREM	0.59	6.75	0.4	1.05e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.16	0.37	2.91e-9	Primary sclerosing cholangitis;
KIRP	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.44	5.11	0.31	6.42e-7	Metabolite levels;
KIRP	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.61	8.89	0.49	1.3e-16	Resting heart rate;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03940137	chr1:200708937	CAMSAP1L1	-0.48	-6.58	-0.39	2.81e-10	Metabolic traits;
KIRP	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.74	11.12	0.58	1.57e-23	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05986781	chr7:127291658	SND1	0.51	6.06	0.36	5.2e-9	Smoking initiation;
KIRP	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg21747090	chr2:27597821	SNX17	-0.47	-6.22	-0.37	2.08e-9	Total body bone mineral density;
KIRP	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.89	0.49	1.38e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg05072774	chr3:49840536	C3orf54	-0.41	-5.1	-0.31	6.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.81	6.73	0.39	1.19e-10	Major depressive disorder;
KIRP	cis	rs9488822	0.623	rs195518	chr6:116241693	A/G	cg05304507	chr6:116381966	FRK	0.21	5.61	0.34	5.37e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs17401966	0.540	rs58014725	chr1:10474457	T/A	cg17425144	chr1:10567563	PEX14	-0.32	-5.35	-0.32	1.97e-7	Hepatocellular carcinoma;
KIRP	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.78	11.61	0.6	3.82e-25	Height;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.57	-7.4	-0.43	2.13e-12	Diastolic blood pressure;
KIRP	cis	rs1971762	0.545	rs10876466	chr12:53981426	G/C	cg16917193	chr12:54089295	NA	0.68	11.06	0.58	2.41e-23	Height;
KIRP	cis	rs6541297	0.645	rs2296065	chr1:230301776	G/A	cg20703242	chr1:230279135	GALNT2	0.31	5.05	0.31	8.42e-7	Coronary artery disease;
KIRP	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.73	10.56	0.56	9.57e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg01097406	chr16:89675127	NA	0.48	8.44	0.47	2.67e-15	Vitiligo;
KIRP	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	8.42	0.47	3.08e-15	Migraine;Coronary artery disease;
KIRP	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg23307798	chr14:103986281	CKB	-0.38	-4.92	-0.3	1.61e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.83	13.69	0.66	4.26e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg05754148	chr16:3507555	NAT15	0.49	4.89	0.3	1.78e-6	Tuberculosis;
KIRP	cis	rs8067545	0.532	rs35915823	chr17:19973397	A/G	cg04132472	chr17:19861366	AKAP10	0.44	5.13	0.31	5.9e-7	Schizophrenia;
KIRP	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg01973587	chr1:228161476	NA	0.38	4.97	0.3	1.27e-6	Diastolic blood pressure;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11987759	chr7:65425863	GUSB	0.69	9.64	0.52	7.53e-19	Aortic root size;
KIRP	trans	rs1941687	0.702	rs10460050	chr18:31413671	G/T	cg27147174	chr7:100797783	AP1S1	-0.51	-6.15	-0.37	3.15e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg03806693	chr22:41940476	POLR3H	-0.49	-5.58	-0.34	6.41e-8	Neuroticism;
KIRP	cis	rs7147624	0.532	rs72716459	chr14:66260654	C/T	cg03016385	chr14:66212404	NA	0.76	6.69	0.39	1.5e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg16268157	chr7:99778414	STAG3	-0.52	-6.0	-0.36	6.85e-9	Lung function (FEV1/FVC);
KIRP	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4664293	0.967	rs7559127	chr2:160515935	T/C	cg08347373	chr2:160653686	CD302	-0.38	-5.83	-0.35	1.75e-8	Monocyte percentage of white cells;
KIRP	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-5.57	-0.33	6.75e-8	Fear of minor pain;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08917092	chr7:16566261	NA	-0.43	-6.26	-0.37	1.69e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4073221	0.520	rs66659472	chr3:18196527	G/A	cg07694806	chr3:18168406	NA	-0.82	-7.08	-0.41	1.46e-11	Parkinson's disease;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg26521784	chr1:161129188	USP21	-0.46	-6.31	-0.37	1.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs42648	0.869	rs12374728	chr7:89941884	T/C	cg25739043	chr7:89950458	NA	-0.45	-7.11	-0.41	1.29e-11	Homocysteine levels;
KIRP	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06028808	chr11:68637592	NA	0.69	7.68	0.44	3.77e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg26876637	chr1:152193138	HRNR	0.73	9.83	0.53	1.95e-19	Atopic dermatitis;
KIRP	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.86	13.06	0.64	5.87e-30	Height;
KIRP	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.39	0.38	8.14e-10	Monocyte percentage of white cells;
KIRP	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	1.01	18.06	0.76	5.54e-47	Leprosy;
KIRP	cis	rs4765905	0.610	rs79475344	chr12:2317010	C/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.85	-0.4	6.04e-11	Schizophrenia;
KIRP	cis	rs7523273	0.597	rs11118612	chr1:207979577	T/A	cg22525895	chr1:207977042	MIR29B2	-0.58	-5.42	-0.33	1.41e-7	Schizophrenia;
KIRP	cis	rs689449	0.756	rs10934683	chr3:124453383	A/G	cg05980111	chr3:124395277	KALRN	-0.37	-5.1	-0.31	6.68e-7	Mean platelet volume;
KIRP	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg10117171	chr1:25599238	RHD	-0.38	-5.21	-0.32	4.01e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6601327	0.635	rs28828176	chr8:9663453	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.09	-0.31	7.12e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.74	-8.94	-0.5	9.25e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.95	11.07	0.58	2.15e-23	Corneal astigmatism;
KIRP	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4356932	1.000	rs4417995	chr4:76945999	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.54	7.5	0.43	1.13e-12	Schizophrenia;
KIRP	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.14	15.08	0.69	8.12e-37	Gut microbiome composition (summer);
KIRP	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg23307798	chr14:103986281	CKB	-0.51	-6.83	-0.4	6.61e-11	Coronary artery disease;
KIRP	cis	rs2625529	0.730	rs982752	chr15:72145937	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-6.51	-0.38	4.08e-10	Red blood cell count;
KIRP	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.12	-0.5	2.81e-17	Triglycerides;
KIRP	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.53	5.25	0.32	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09400194	chr10:81107848	PPIF	-0.4	-4.99	-0.3	1.14e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3026101	0.671	rs1806249	chr17:5311143	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg13409248	chr3:40428643	ENTPD3	0.4	5.3	0.32	2.57e-7	Renal cell carcinoma;
KIRP	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.85	12.83	0.63	3.42e-29	Menarche (age at onset);
KIRP	cis	rs6969780	0.915	rs3807597	chr7:27189195	C/T	cg17457637	chr7:27170717	HOXA4	-0.37	-4.87	-0.3	1.96e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.55	6.38	0.38	8.57e-10	Aortic root size;
KIRP	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg07884673	chr3:53033167	SFMBT1	0.74	5.71	0.34	3.25e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg26893134	chr6:116381904	FRK	0.2	5.45	0.33	1.2e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs12995849	0.905	rs12712218	chr2:106451751	G/T	cg16077055	chr2:106428750	NCK2	0.24	5.11	0.31	6.6e-7	Addiction;
KIRP	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs963731	0.649	rs6713281	chr2:39235330	G/T	cg04010122	chr2:39346883	SOS1	-0.88	-6.15	-0.37	3.11e-9	Corticobasal degeneration;
KIRP	cis	rs239198	0.568	rs979122	chr6:101332215	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-5.64	-0.34	4.59e-8	Menarche (age at onset);
KIRP	cis	rs55962025	0.711	rs2071655	chr4:3118116	A/C	cg06533319	chr4:3265114	C4orf44	0.4	5.08	0.31	7.6e-7	Parental longevity (mother's age at death);
KIRP	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.62	0.34	5.19e-8	Lung cancer;
KIRP	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg11965913	chr1:205819406	PM20D1	0.5	5.37	0.32	1.82e-7	Parkinson's disease;
KIRP	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg20936604	chr3:58311152	NA	-0.68	-5.58	-0.34	6.31e-8	Cholesterol, total;
KIRP	cis	rs2223471	0.719	rs9296640	chr6:50764274	C/G	cg03432817	chr6:50765336	NA	0.42	6.74	0.4	1.09e-10	Subcutaneous adipose tissue;
KIRP	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.42	-5.23	-0.32	3.6e-7	Schizophrenia;
KIRP	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg13736514	chr6:26305472	NA	-0.66	-8.43	-0.47	2.94e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.66	9.15	0.5	2.26e-17	Lymphocyte counts;
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg01798813	chr17:3906674	NA	-0.53	-7.43	-0.43	1.76e-12	Type 2 diabetes;
KIRP	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg04287289	chr16:89883240	FANCA	-0.39	-5.03	-0.31	9.61e-7	Vitiligo;
KIRP	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.63	-0.44	5.12e-13	Initial pursuit acceleration;
KIRP	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.61e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-9.2	-0.51	1.58e-17	Renal function-related traits (BUN);
KIRP	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.99	-0.45	5.32e-14	Monocyte percentage of white cells;
KIRP	cis	rs4356932	1.000	rs6532157	chr4:76974373	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.29	-0.32	2.77e-7	Menarche (age at onset);
KIRP	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg22974920	chr21:40686053	BRWD1	0.49	5.86	0.35	1.47e-8	Cognitive function;
KIRP	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.67	-7.42	-0.43	1.96e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7188697	0.922	rs2090727	chr16:58604161	A/G	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.44	-0.43	1.67e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.46	-6.99	-0.41	2.6e-11	Bipolar disorder;
KIRP	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg23594656	chr7:65796392	TPST1	0.45	7.12	0.41	1.17e-11	Aortic root size;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.53	-7.14	-0.41	1.04e-11	Longevity;Endometriosis;
KIRP	cis	rs11074306	0.541	rs8035334	chr15:28080367	C/T	cg26402630	chr15:28053930	OCA2	-0.32	-5.17	-0.31	4.79e-7	Uveal melanoma;
KIRP	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg01557791	chr16:72042693	DHODH	-0.49	-6.15	-0.36	3.15e-9	Fibrinogen levels;
KIRP	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.57	7.63	0.44	5.01e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4959799	0.557	rs9501971	chr6:3272565	G/A	cg03657281	chr6:3270030	SLC22A23	0.78	6.03	0.36	6.04e-9	Survival in rectal cancer;
KIRP	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.65	-9.63	-0.52	7.7e-19	Educational attainment;
KIRP	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs6568686	0.786	rs6568682	chr6:111814177	G/A	cg15721981	chr6:111408429	SLC16A10	-0.7	-6.25	-0.37	1.8e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.84	9.59	0.52	1.07e-18	Pulmonary function decline;
KIRP	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	6.29	0.37	1.48e-9	Mean platelet volume;
KIRP	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg18586891	chr4:952366	TMEM175	0.6	5.42	0.33	1.43e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs963731	0.649	rs1947432	chr2:39227063	C/T	cg04010122	chr2:39346883	SOS1	0.82	5.5	0.33	9.69e-8	Corticobasal degeneration;
KIRP	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-7.14	-0.41	1.05e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs883565	0.696	rs6599007	chr3:39114445	A/C	cg01426195	chr3:39028469	NA	-0.67	-11.05	-0.58	2.59e-23	Handedness;
KIRP	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.9	-13.19	-0.64	2.18e-30	Height;
KIRP	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg09373727	chr1:32405360	PTP4A2	-0.35	-4.89	-0.3	1.83e-6	Alcohol dependence;
KIRP	cis	rs959260	1.000	rs959260	chr17:73369422	C/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.94	16.33	0.72	4.34e-41	Breast cancer;
KIRP	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	6.09	0.36	4.34e-9	Neuranatomic and neurocognitive phenotypes;
KIRP	trans	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.31	0.42	3.83e-12	Exhaled nitric oxide output;
KIRP	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.82	0.35	1.81e-8	Melanoma;
KIRP	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg20312557	chr2:97357134	FER1L5	-0.73	-5.34	-0.32	2.06e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.13	-0.36	3.56e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg27532560	chr4:187881888	NA	-0.68	-10.89	-0.57	8.25e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11608355	0.521	rs1119271	chr12:109819727	A/T	cg19025524	chr12:109796872	NA	-0.51	-7.05	-0.41	1.84e-11	Neuroticism;
KIRP	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-6.29	-0.37	1.43e-9	Obesity (extreme);
KIRP	cis	rs911555	0.547	rs8006994	chr14:103841296	C/T	cg16497661	chr14:103986332	CKB	0.39	5.07	0.31	8.01e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.33	0.32	2.2e-7	Lung cancer;
KIRP	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	8.2	0.46	1.38e-14	Blood protein levels;
KIRP	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg27121462	chr16:89883253	FANCA	0.54	7.48	0.43	1.32e-12	Vitiligo;
KIRP	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	5.2	0.31	4.23e-7	Renal cell carcinoma;
KIRP	cis	rs7011507	0.945	rs80092837	chr8:49156418	G/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21545522	chr1:205238299	TMCC2	0.42	5.69	0.34	3.69e-8	Red blood cell count;
KIRP	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14169450	chr9:139327907	INPP5E	0.61	6.99	0.41	2.57e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.68	7.29	0.42	4.34e-12	Lymphocyte counts;
KIRP	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg07116693	chr15:90310901	NA	-0.23	-5.03	-0.31	9.63e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg18279126	chr7:2041391	MAD1L1	0.47	5.08	0.31	7.54e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg01798813	chr17:3906674	NA	0.41	5.1	0.31	6.78e-7	Type 2 diabetes;
KIRP	cis	rs16973500	0.808	rs1049794	chr16:71950450	C/T	cg09427745	chr16:71932006	KIAA0174	-0.59	-5.1	-0.31	6.74e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7209700	0.889	rs11079769	chr17:45349731	A/T	cg08085267	chr17:45401833	C17orf57	0.46	5.66	0.34	4.1e-8	IgG glycosylation;
KIRP	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-4.9	-0.3	1.78e-6	IFN-related cytopenia;
KIRP	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.82	-14.67	-0.68	1.96e-35	Body mass index;
KIRP	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.53	5.59	0.34	6.13e-8	Coronary artery disease;
KIRP	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg21775007	chr8:11205619	TDH	-0.42	-5.29	-0.32	2.66e-7	Monocyte count;
KIRP	cis	rs1190552	0.846	rs4906212	chr14:102981595	A/G	cg18135206	chr14:102964638	TECPR2	-0.47	-5.2	-0.31	4.15e-7	Blood protein levels;
KIRP	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	13.56	0.65	1.2e-31	Tonsillectomy;
KIRP	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.38	-5.41	-0.33	1.5e-7	Plateletcrit;
KIRP	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.1	-0.31	6.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg26681399	chr22:41777847	TEF	0.52	5.23	0.32	3.6e-7	Vitiligo;
KIRP	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.92	-0.4	3.9e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg12437481	chr16:420112	MRPL28	-0.55	-6.87	-0.4	5.14e-11	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.71	9.29	0.51	8.76e-18	Sudden cardiac arrest;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24575065	chr7:72972219	BCL7B	0.49	6.52	0.38	3.89e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12973672	0.812	rs10419959	chr19:35764705	G/A	cg12095397	chr19:35769544	USF2	0.68	6.3	0.37	1.36e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7106204	0.609	rs12785699	chr11:24280489	C/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.37	0.32	1.79e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg00933542	chr6:150070202	PCMT1	0.25	4.86	0.3	2.13e-6	Lung cancer;
KIRP	cis	rs4660306	0.744	rs11211115	chr1:45926438	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.37	0.38	9.46e-10	Homocysteine levels;
KIRP	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.5	-7.0	-0.41	2.36e-11	Schizophrenia;
KIRP	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg02100629	chr10:71892760	AIFM2	-0.39	-5.05	-0.31	8.58e-7	Blood protein levels;
KIRP	cis	rs7542091	0.704	rs12022221	chr1:210046178	A/C	cg05527609	chr1:210001259	C1orf107	-0.38	-5.08	-0.31	7.43e-7	Monobrow;
KIRP	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.2e-23	Prudent dietary pattern;
KIRP	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg25512537	chr17:76250053	NA	0.38	6.48	0.38	5.02e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-6.25	-0.37	1.79e-9	Morning vs. evening chronotype;
KIRP	cis	rs7027203	0.521	rs9299412	chr9:96523268	G/T	cg14598338	chr9:96623480	NA	-0.44	-6.69	-0.39	1.49e-10	DNA methylation (variation);
KIRP	cis	rs12135191	0.711	rs56176877	chr1:236491088	A/T	cg21399712	chr1:236511386	NA	-0.47	-6.09	-0.36	4.35e-9	Urate levels (BMI interaction);
KIRP	cis	rs72730918	0.618	rs1531157	chr15:51990058	A/T	cg14296394	chr15:51910925	DMXL2	0.78	10.2	0.55	1.29e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg06066596	chr15:83166174	LOC80154	-0.51	-5.87	-0.35	1.38e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.11	0.31	6.32e-7	Smoking behavior;
KIRP	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg20090143	chr19:45452003	APOC2	0.33	5.24	0.32	3.39e-7	Blood protein levels;
KIRP	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg22437258	chr11:111473054	SIK2	0.59	6.97	0.41	2.86e-11	Primary sclerosing cholangitis;
KIRP	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg00310523	chr12:86230176	RASSF9	0.42	6.45	0.38	5.83e-10	Major depressive disorder;
KIRP	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.45	0.33	1.2e-7	Thyroid stimulating hormone;
KIRP	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	5.18	0.31	4.6e-7	Obesity-related traits;
KIRP	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.75	11.05	0.58	2.6e-23	Prudent dietary pattern;
KIRP	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg07274523	chr3:49395745	GPX1	0.72	8.53	0.48	1.49e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs460214	0.553	rs9976546	chr21:40028193	C/G	cg05519781	chr21:40033154	ERG	-0.46	-5.07	-0.31	7.7e-7	Response to cognitive-behavioural therapy in anxiety disorder;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg04301623	chr19:5681171	HSD11B1L;C19orf70	-1.19	-6.66	-0.39	1.83e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.83	-10.74	-0.57	2.5e-22	Breast cancer;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg14042879	chr19:8478143	MARCH2	-1.11	-6.13	-0.36	3.45e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-7.11	-0.41	1.26e-11	Menarche (age at onset);
KIRP	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg23815491	chr16:72088622	HP	0.49	7.99	0.45	5.1e-14	Fibrinogen levels;
KIRP	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.84	13.51	0.65	1.73e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg18132916	chr6:79620363	NA	-0.42	-5.73	-0.34	2.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.57	7.12	0.41	1.16e-11	Arsenic metabolism;
KIRP	cis	rs9815354	0.812	rs73071307	chr3:41798699	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.35	0.47	4.88e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6693567	0.586	rs875514	chr1:150484555	C/G	cg07843065	chr1:150265600	MRPS21	0.43	5.6	0.34	5.6e-8	Migraine;
KIRP	cis	rs6568686	0.786	rs6568682	chr6:111814177	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.53	-4.96	-0.3	1.33e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs10214930	0.697	rs2080246	chr7:27569704	G/A	cg22168087	chr7:27702803	HIBADH	0.47	4.9	0.3	1.73e-6	Hypospadias;
KIRP	cis	rs661054	0.784	rs73016119	chr11:114422967	G/A	cg19465033	chr11:114479364	NA	0.42	5.08	0.31	7.41e-7	Ulcerative colitis;
KIRP	cis	rs60871478	1.000	rs62432223	chr7:787959	A/G	cg04727924	chr7:799746	HEATR2	-0.79	-8.69	-0.48	5.31e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7224685	0.530	rs36019144	chr17:3987499	T/C	cg11204139	chr17:3907470	NA	0.58	5.56	0.33	7.05e-8	Type 2 diabetes;
KIRP	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	1.33	9.88	0.53	1.36e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1215050	0.755	rs811479	chr4:98727398	A/T	cg05340658	chr4:99064831	C4orf37	0.54	6.55	0.39	3.39e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18364779	chr6:26104403	HIST1H4C	0.61	8.04	0.46	3.79e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	4.99	0.3	1.14e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-6.09	-0.36	4.22e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg21858823	chr1:15850916	CASP9	-0.52	-5.16	-0.31	5.18e-7	Systolic blood pressure;
KIRP	cis	rs3791406	0.654	rs3752804	chr2:240029490	C/T	cg13090969	chr2:240043331	HDAC4	-0.43	-4.89	-0.3	1.86e-6	Skin aging (microtopography measurement);
KIRP	cis	rs2671245	0.901	rs2767508	chr1:56155589	A/T	cg11523071	chr1:56160889	NA	0.41	6.74	0.39	1.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.94	12.18	0.61	5e-27	Breast cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25339552	chr19:33165499	ANKRD27;RGS9BP	-0.47	-6.02	-0.36	6.24e-9	Myopia;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.5	5.94	0.35	9.83e-9	Longevity;Endometriosis;
KIRP	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg02023728	chr11:77925099	USP35	-0.3	-5.25	-0.32	3.32e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.57	6.06	0.36	5.1e-9	Type 2 diabetes;
KIRP	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.71	9.97	0.54	7.04e-20	Mean corpuscular volume;
KIRP	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg18350739	chr11:68623251	NA	-0.51	-7.76	-0.44	2.33e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	16.0	0.71	5.47e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.58	6.75	0.4	1.05e-10	Pancreatic cancer;
KIRP	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg25486957	chr4:152246857	NA	-0.51	-5.54	-0.33	7.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	9.05	0.5	4.53e-17	Red cell distribution width;
KIRP	cis	rs4789452	1.000	rs11658815	chr17:75375881	G/A	cg02320862	chr17:75370284	SEPT9	-0.36	-5.01	-0.3	1.04e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs34779708	0.931	rs1926556	chr10:35344907	T/C	cg03585969	chr10:35415529	CREM	0.79	9.51	0.52	1.78e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.69	0.53	4.96e-19	Prudent dietary pattern;
KIRP	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.23	0.46	1.12e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs17123764	0.710	rs2278069	chr12:49944508	A/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.97	0.3	1.23e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg05220968	chr6:146057943	EPM2A	0.43	5.48	0.33	1.05e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg19847130	chr8:10466454	RP1L1	0.35	5.32	0.32	2.39e-7	Triglycerides;
KIRP	cis	rs8060686	0.516	rs4567701	chr16:68163662	T/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.42	-0.43	1.89e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7119038	0.730	rs10790269	chr11:118729456	C/T	cg19308663	chr11:118741387	NA	-0.55	-9.65	-0.52	6.88e-19	Sjögren's syndrome;
KIRP	cis	rs12911832	0.727	rs2604454	chr15:59098732	C/A	cg05156742	chr15:59063176	FAM63B	0.63	8.19	0.46	1.41e-14	Schizophrenia;
KIRP	cis	rs9943753	0.508	rs7138357	chr12:109832303	A/G	cg19025524	chr12:109796872	NA	-0.46	-6.27	-0.37	1.61e-9	HDL cholesterol;
KIRP	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.48	-7.97	-0.45	6.12e-14	Height;
KIRP	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.99	-0.3	1.12e-6	Inflammatory skin disease;
KIRP	cis	rs7700895	0.737	rs6556893	chr5:95226655	A/G	cg16656078	chr5:95278638	ELL2	-0.4	-6.0	-0.36	7.01e-9	IgG glycosylation;
KIRP	cis	rs8060686	0.516	rs11075670	chr16:68288393	C/G	cg26727032	chr16:67993705	SLC12A4	-0.72	-7.92	-0.45	8.41e-14	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.54	-6.04	-0.36	5.8e-9	Menopause (age at onset);
KIRP	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.47	6.14	0.36	3.32e-9	Gout;
KIRP	cis	rs72772090	0.539	rs56395748	chr5:96176893	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.7	-5.99	-0.36	7.36e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.48	6.6	0.39	2.51e-10	Testicular germ cell tumor;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.87	13.75	0.66	2.78e-32	Menarche (age at onset);
KIRP	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	trans	rs17834760	0.955	rs62424078	chr6:62087671	T/C	cg08476511	chr6:168435923	KIF25	0.52	6.05	0.36	5.31e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.05	0.5	4.46e-17	Lung cancer;
KIRP	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs7937612	1.000	rs11217852	chr11:120261187	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.74	-0.39	1.11e-10	Intraocular pressure;
KIRP	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.53	6.82	0.4	6.85e-11	Coronary heart disease;
KIRP	cis	rs12580194	0.593	rs61957884	chr12:55720177	A/G	cg11794356	chr12:55725991	OR6C3	-0.6	-8.41	-0.47	3.31e-15	Cancer;
KIRP	cis	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg12315302	chr6:26189340	HIST1H4D	1.07	6.09	0.36	4.22e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1962073	0.529	rs13258627	chr8:10274578	T/C	cg08975724	chr8:8085496	FLJ10661	0.55	6.74	0.39	1.11e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg12756093	chr1:115239321	AMPD1	0.55	7.49	0.43	1.22e-12	Autism;
KIRP	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg08603382	chr10:743973	NA	0.63	9.54	0.52	1.49e-18	Psychosis in Alzheimer's disease;
KIRP	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.73	7.3	0.42	4.06e-12	Menarche (age at onset);
KIRP	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg18478394	chr8:109455254	TTC35	0.53	6.33	0.37	1.14e-9	Dupuytren's disease;
KIRP	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.16	-0.31	5.14e-7	Menarche (age at onset);
KIRP	cis	rs4704187	0.687	rs6453112	chr5:74389901	A/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	cis	rs7851660	0.809	rs7866436	chr9:100650096	G/A	cg13688889	chr9:100608707	NA	-0.65	-8.23	-0.46	1.13e-14	Strep throat;
KIRP	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg13607699	chr17:42295918	UBTF	0.46	5.11	0.31	6.51e-7	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs8067287	0.688	rs58928848	chr17:16844876	G/A	cg26910001	chr17:16838321	NA	-0.47	-5.5	-0.33	9.29e-8	Diabetic kidney disease;
KIRP	cis	rs1978968	0.717	rs34740481	chr22:18401620	G/C	cg03078520	chr22:18463400	MICAL3	-0.52	-6.28	-0.37	1.51e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6539267	0.516	rs17218455	chr12:106716441	C/T	cg00173435	chr12:106696525	TCP11L2	0.71	6.75	0.4	1.05e-10	Tourette syndrome;
KIRP	cis	rs867371	0.502	rs28610286	chr15:82525655	C/T	cg00614314	chr15:82944287	LOC80154	0.41	5.31	0.32	2.49e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06725760	chr10:1102461	WDR37	0.52	6.69	0.39	1.52e-10	Parkinson's disease;
KIRP	cis	rs12973672	0.812	rs113185571	chr19:35758929	C/T	cg12095397	chr19:35769544	USF2	0.67	6.18	0.37	2.71e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg11130432	chr3:121712080	ILDR1	-0.45	-5.02	-0.3	9.9e-7	Multiple sclerosis;
KIRP	cis	rs6669384	0.826	rs4844393	chr1:207994429	T/C	cg22525895	chr1:207977042	MIR29B2	-0.62	-5.94	-0.35	9.83e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
KIRP	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.71	7.79	0.44	1.85e-13	Corneal astigmatism;
KIRP	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg00080972	chr5:178986291	RUFY1	0.36	5.41	0.33	1.49e-7	Lung cancer;
KIRP	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.47	-0.52	2.36e-18	Personality dimensions;
KIRP	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg11382394	chr1:2564504	MMEL1	-0.39	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg00310523	chr12:86230176	RASSF9	0.46	7.39	0.43	2.24e-12	Major depressive disorder;
KIRP	cis	rs711830	0.576	rs72916141	chr2:177069364	G/T	cg13092806	chr2:177043255	NA	-0.55	-5.69	-0.34	3.55e-8	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	0.83	9.05	0.5	4.46e-17	Gut microbiome composition (summer);
KIRP	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.73	-9.56	-0.52	1.33e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg25204440	chr1:209979598	IRF6	0.45	4.9	0.3	1.72e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.73	9.24	0.51	1.18e-17	Coronary artery disease;
KIRP	cis	rs9581857	0.615	rs61622854	chr13:28023194	T/A	cg22138327	chr13:27999177	GTF3A	0.77	6.17	0.37	2.86e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.77	-10.97	-0.57	4.52e-23	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.49	-6.35	-0.38	1.01e-9	Systolic blood pressure;
KIRP	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.97	-9.66	-0.52	6.16e-19	Multiple sclerosis;
KIRP	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs7224685	0.569	rs34377654	chr17:3990201	G/A	cg09695851	chr17:3907499	NA	0.58	5.45	0.33	1.2e-7	Type 2 diabetes;
KIRP	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	Myopia (pathological);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.56	6.58	0.39	2.86e-10	Smoking initiation;
KIRP	cis	rs490234	0.841	rs13285366	chr9:128375047	G/A	cg14078157	chr9:128172775	NA	-0.56	-6.54	-0.38	3.62e-10	Mean arterial pressure;
KIRP	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg26876637	chr1:152193138	HRNR	-0.49	-6.33	-0.37	1.17e-9	Atopic dermatitis;
KIRP	cis	rs11264213	0.901	rs2791961	chr1:36371419	C/G	cg27506609	chr1:36549197	TEKT2	-0.97	-10.12	-0.54	2.45e-20	Schizophrenia;
KIRP	cis	rs1800813	0.515	rs34148754	chr4:55057049	G/A	cg17187183	chr4:55093834	PDGFRA	0.49	5.93	0.35	1.04e-8	Corneal curvature;
KIRP	cis	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.22	-0.32	3.76e-7	Leprosy;
KIRP	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg22875332	chr1:76189707	ACADM	-0.34	-5.01	-0.3	1.06e-6	Daytime sleep phenotypes;
KIRP	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.74	-8.17	-0.46	1.63e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	-0.59	-7.27	-0.42	4.77e-12	Inflammatory bowel disease;
KIRP	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	1.13	9.05	0.5	4.61e-17	Parkinson's disease;
KIRP	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg19507638	chr5:93509721	C5orf36	-0.56	-4.85	-0.3	2.15e-6	Diabetic retinopathy;
KIRP	cis	rs4908768	0.582	rs12410893	chr1:8878885	A/G	cg03610117	chr1:8450231	RERE	-0.47	-5.22	-0.32	3.86e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg02733842	chr7:1102375	C7orf50	0.53	5.55	0.33	7.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7119038	0.629	rs10892271	chr11:118598544	G/A	cg19308663	chr11:118741387	NA	0.47	7.48	0.43	1.29e-12	Sjögren's syndrome;
KIRP	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.73	10.22	0.55	1.17e-20	Plateletcrit;Platelet count;
KIRP	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.93e-10	Colorectal cancer;
KIRP	cis	rs7116495	1.000	rs3750908	chr11:71822401	A/G	cg26138937	chr11:71823887	C11orf51	0.7	5.55	0.33	7.4e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.67	7.75	0.44	2.36e-13	Corneal astigmatism;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18350866	chr20:39766189	PLCG1	0.53	7.63	0.44	5.08e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-0.91	-13.35	-0.65	6.04e-31	Dupuytren's disease;
KIRP	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg09184832	chr6:79620586	NA	-0.39	-5.0	-0.3	1.09e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.71	8.62	0.48	8.36e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.23	-0.32	3.55e-7	Electroencephalogram traits;
KIRP	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg13206674	chr6:150067644	NUP43	0.55	7.83	0.45	1.44e-13	Testicular germ cell tumor;
KIRP	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg24009623	chr19:33667908	NA	0.47	5.71	0.34	3.18e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	1.07	13.54	0.65	1.36e-31	Response to antineoplastic agents;
KIRP	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.17	0.37	2.82e-9	Educational attainment;
KIRP	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg17133734	chr15:86042851	AKAP13	-0.45	-5.64	-0.34	4.61e-8	Interstitial lung disease;
KIRP	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg09307838	chr4:120376055	NA	0.78	9.29	0.51	8.28e-18	Corneal astigmatism;
KIRP	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.94	-0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.62	9.41	0.51	3.74e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg13939156	chr17:80058883	NA	-0.48	-5.5	-0.33	9.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-5.01	-0.3	1.06e-6	Schizophrenia;
KIRP	cis	rs921943	1.000	rs6877621	chr5:78314379	G/A	cg26802063	chr5:78281964	ARSB	0.5	6.19	0.37	2.47e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.64	10.07	0.54	3.37e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs112458284	0.557	rs4905135	chr14:94461601	A/G	cg17928799	chr2:174267362	NA	0.63	6.07	0.36	4.73e-9	Chronic obstructive pulmonary disease;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs9815354	1.000	rs9840532	chr3:41885697	A/G	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6662572	1.000	rs41310432	chr1:46083706	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.47	0.33	1.1e-7	Blood protein levels;
KIRP	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-0.78	-9.08	-0.5	3.54e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6001982	0.667	rs10483205	chr22:40883599	C/T	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.5	-0.38	4.52e-10	Mean corpuscular volume;
KIRP	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	1.02	10.64	0.56	5.45e-22	Eosinophilic esophagitis;
KIRP	cis	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg10761708	chr20:43804764	PI3	0.52	5.12	0.31	6.06e-7	Blood protein levels;
KIRP	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	7.26	0.42	5.06e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs8077577	0.945	rs11656035	chr17:18086025	T/C	cg09161412	chr17:18057145	MYO15A	-0.38	-5.04	-0.31	9.23e-7	Obesity-related traits;
KIRP	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.75	7.55	0.43	8.37e-13	Lung function (FEV1/FVC);
KIRP	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg16077055	chr2:106428750	NCK2	-0.31	-6.22	-0.37	2.1e-9	Addiction;
KIRP	trans	rs13170463	0.579	rs35970526	chr5:8048084	C/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.43e-13	Corneal astigmatism;
KIRP	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.14	0.36	3.36e-9	Educational attainment;
KIRP	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.6	-0.39	2.48e-10	Coronary artery disease;
KIRP	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.73	10.22	0.55	1.17e-20	Plateletcrit;Platelet count;
KIRP	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.77	8.58	0.48	1.1e-15	Corneal astigmatism;
KIRP	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.64	-0.39	2e-10	Coronary artery disease;
KIRP	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.52	6.29	0.37	1.48e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.64	-7.48	-0.43	1.28e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.82	-9.13	-0.5	2.63e-17	Blood pressure (smoking interaction);
KIRP	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.47	6.21	0.37	2.22e-9	Response to temozolomide;
KIRP	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs9943753	0.508	rs2075433	chr12:109833920	A/G	cg19025524	chr12:109796872	NA	-0.46	-6.27	-0.37	1.61e-9	HDL cholesterol;
KIRP	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.85	-0.63	2.87e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	1.09	14.21	0.67	7.22e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.78e-11	Bipolar disorder;
KIRP	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.69	-9.89	-0.53	1.26e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.49	-7.34	-0.42	3.12e-12	Electroencephalogram traits;
KIRP	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.83	-0.57	1.34e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg10560079	chr2:191398806	TMEM194B	-0.65	-7.77	-0.44	2.17e-13	Diastolic blood pressure;
KIRP	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.53	0.38	3.8e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.42	-6.47	-0.38	5.39e-10	Fractional excretion of uric acid;
KIRP	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05220968	chr6:146057943	EPM2A	0.39	5.0	0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg21858823	chr1:15850916	CASP9	0.55	5.91	0.35	1.15e-8	Systolic blood pressure;
KIRP	cis	rs9513627	0.834	rs73556197	chr13:100128479	A/G	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg13072238	chr3:49761600	GMPPB	0.56	5.18	0.31	4.52e-7	Menarche (age at onset);
KIRP	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg11271282	chr2:238384023	NA	0.51	5.9	0.35	1.19e-8	Prostate cancer;
KIRP	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.37	0.32	1.82e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.95e-15	Aortic root size;
KIRP	cis	rs15676	0.947	rs2293968	chr9:131587240	G/A	cg00228799	chr9:131580591	ENDOG	0.58	6.58	0.39	2.89e-10	Blood metabolite levels;
KIRP	cis	rs2273156	1.000	rs7145608	chr14:35463497	G/T	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.41	-0.33	1.48e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.75	-4.89	-0.3	1.81e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.57	-8.71	-0.49	4.51e-16	Longevity;
KIRP	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14159672	chr1:205819179	PM20D1	0.47	5.2	0.31	4.26e-7	Parkinson's disease;
KIRP	cis	rs7612445	0.878	rs11922153	chr3:179172593	A/G	cg01750654	chr3:179170617	GNB4	-0.57	-6.71	-0.39	1.34e-10	Resting heart rate;Heart rate;
KIRP	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg05721485	chr17:44071124	MAPT	0.56	7.42	0.43	1.85e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg00585698	chr12:123750864	CDK2AP1	0.47	5.6	0.34	5.61e-8	Neutrophil percentage of white cells;
KIRP	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.85	13.89	0.66	8.65e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg16797656	chr11:68205561	LRP5	0.37	4.87	0.3	2.01e-6	Total body bone mineral density;
KIRP	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.58	7.77	0.44	2.1e-13	Blood protein levels;
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13939156	chr17:80058883	NA	-0.5	-7.51	-0.43	1.08e-12	Life satisfaction;
KIRP	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-9.46	-0.52	2.67e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13143525	chr6:3068570	NA	0.46	6.18	0.37	2.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7615316	0.659	rs6440083	chr3:142124287	G/A	cg20824294	chr3:142316082	PLS1	0.27	5.39	0.32	1.67e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	1.18	9.92	0.53	9.73e-20	Economic and political preferences (immigration/crime);
KIRP	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.65	-5.77	-0.35	2.34e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs12210905	1.000	rs6917419	chr6:27243480	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.57	-5.46	-0.33	1.17e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg10503236	chr1:231470652	EXOC8	-0.54	-7.48	-0.43	1.35e-12	Hemoglobin concentration;
KIRP	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.44	5.29	0.32	2.71e-7	Body mass index;
KIRP	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg21775007	chr8:11205619	TDH	0.49	6.75	0.4	1.03e-10	Mood instability;
KIRP	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.19	21.48	0.81	2.29e-58	Cognitive function;
KIRP	cis	rs35740288	0.862	rs11637444	chr15:86311188	G/A	cg17133734	chr15:86042851	AKAP13	-0.5	-5.53	-0.33	8.24e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10924970	0.870	rs7531130	chr1:235440556	C/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.0	0.3	1.11e-6	Asthma;
KIRP	cis	rs10411936	0.750	rs8112401	chr19:16593012	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	5.07	0.31	7.88e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs5756391	0.546	rs4821561	chr22:37311877	A/G	cg16356956	chr22:37317934	CSF2RB	-0.46	-6.41	-0.38	7.47e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg18932078	chr1:2524107	MMEL1	0.39	5.29	0.32	2.65e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg23505145	chr19:12996616	KLF1	0.55	7.95	0.45	6.81e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1619661	0.505	rs10899997	chr10:44683841	T/G	cg09554077	chr10:44749378	NA	0.44	6.5	0.38	4.49e-10	QT interval (ambient particulate matter interaction);
KIRP	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.66	9.02	0.5	5.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.54	-5.77	-0.35	2.43e-8	Subjective well-being;
KIRP	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs3857536	0.813	rs6903678	chr6:66931208	C/T	cg07460842	chr6:66804631	NA	0.49	6.31	0.37	1.26e-9	Blood trace element (Cu levels);
KIRP	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg27411982	chr8:10470053	RP1L1	-0.38	-4.91	-0.3	1.63e-6	Neuroticism;
KIRP	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7010267	0.935	rs6469788	chr8:119952750	A/C	cg01975934	chr8:119970761	NA	-0.42	-5.5	-0.33	9.31e-8	Total body bone mineral density (age 45-60);
KIRP	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg04662567	chr6:169592167	NA	-0.83	-6.65	-0.39	1.92e-10	Pulse pressure;
KIRP	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg18306943	chr3:40428807	ENTPD3	0.42	5.6	0.34	5.58e-8	Renal cell carcinoma;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.36	-4.88	-0.3	1.94e-6	Renal function-related traits (BUN);
KIRP	cis	rs793571	0.590	rs618684	chr15:59115922	A/G	cg05156742	chr15:59063176	FAM63B	0.58	7.31	0.42	3.63e-12	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg01689657	chr7:91764605	CYP51A1	0.35	4.96	0.3	1.34e-6	Breast cancer;
KIRP	cis	rs11650494	0.710	rs2165701	chr17:47475822	A/G	cg08112188	chr17:47440006	ZNF652	1.18	7.6	0.44	6.22e-13	Prostate cancer;
KIRP	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-5.59	-0.34	5.92e-8	Colorectal cancer;
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	12.79	0.63	4.54e-29	Platelet count;
KIRP	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg13628971	chr7:2884303	GNA12	0.58	6.69	0.39	1.48e-10	Height;
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg24972876	chr7:65420302	NA	0.37	4.88	0.3	1.9e-6	Aortic root size;
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.52	6.68	0.39	1.59e-10	Testicular germ cell tumor;
KIRP	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg20243544	chr17:37824526	PNMT	0.47	6.46	0.38	5.59e-10	Asthma;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14008834	chr4:24472254	NA	-0.42	-6.19	-0.37	2.53e-9	Metabolic traits;
KIRP	cis	rs6681460	0.649	rs1415974	chr1:67005503	C/T	cg13052034	chr1:66999238	SGIP1	-0.42	-6.1	-0.36	4.05e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg23978390	chr7:1156363	C7orf50	0.49	5.8	0.35	2.07e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg01119278	chr6:110721349	DDO	-0.44	-6.5	-0.38	4.45e-10	Platelet distribution width;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg04803843	chr15:28351906	NA	-0.43	-6.19	-0.37	2.45e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.64	-0.39	1.96e-10	Lung cancer;
KIRP	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg06742321	chr12:123595122	PITPNM2	0.44	5.36	0.32	1.95e-7	Platelet count;
KIRP	cis	rs7103411	0.637	rs6416056	chr11:27646745	A/G	cg18117895	chr11:27722066	BDNF	0.42	4.92	0.3	1.59e-6	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.97	0.3	1.28e-6	Leprosy;
KIRP	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.45	0.55	2.15e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-6.23	-0.37	2.03e-9	Vitiligo;
KIRP	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg25281562	chr12:121454272	C12orf43	0.47	5.19	0.31	4.46e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg13206674	chr6:150067644	NUP43	0.51	7.22	0.42	6.37e-12	Lung cancer;
KIRP	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9972944	0.756	rs7218844	chr17:63768289	G/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.08e-13	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.96	11.38	0.59	2.27e-24	Corneal astigmatism;
KIRP	cis	rs61160187	0.522	rs2045356	chr5:59947354	C/T	cg02684056	chr5:59996105	DEPDC1B	0.5	5.59	0.34	5.92e-8	Educational attainment (years of education);Educational attainment (college completion);
KIRP	cis	rs7621025	0.500	rs16844241	chr3:136635171	A/G	cg15507776	chr3:136538369	TMEM22	-0.77	-9.79	-0.53	2.55e-19	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg05714579	chr10:131428358	MGMT	0.41	5.12	0.31	6.2e-7	Response to temozolomide;
KIRP	cis	rs13361707	0.726	rs11956019	chr5:40812231	G/A	cg01087697	chr5:40835557	RPL37	-0.43	-5.01	-0.3	1.05e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg25039879	chr17:56429692	SUPT4H1	0.59	5.17	0.31	4.82e-7	Cognitive test performance;
KIRP	cis	rs35740288	0.822	rs17636864	chr15:86234589	A/C	cg17133734	chr15:86042851	AKAP13	-0.49	-5.38	-0.32	1.78e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.02	0.31	9.74e-7	Schizophrenia;
KIRP	cis	rs6840360	0.642	rs7684462	chr4:152348422	T/G	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.34	-4.96	-0.3	1.33e-6	Coronary artery disease;
KIRP	cis	rs7523050	0.730	rs12729728	chr1:109431110	C/A	cg08274380	chr1:109419600	GPSM2	1.21	10.14	0.54	2.03e-20	Fat distribution (HIV);
KIRP	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg06637938	chr14:75390232	RPS6KL1	0.49	6.91	0.4	4.1e-11	Height;
KIRP	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg27087555	chr16:88793112	FAM38A	-1.49	-10.69	-0.56	3.84e-22	Plateletcrit;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.49	-6.71	-0.39	1.3100000000000001e-10	Renal function-related traits (BUN);
KIRP	cis	rs12519773	0.611	rs6873704	chr5:92490864	A/C	cg18783429	chr5:92414398	NA	0.28	4.91	0.3	1.64e-6	Migraine;
KIRP	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.85	12.78	0.63	5.02e-29	Height;
KIRP	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.75	-11.7	-0.6	2.01e-25	Prostate cancer;
KIRP	cis	rs2151522	0.603	rs11752287	chr6:127177879	A/G	cg21431617	chr6:127135037	NA	-0.32	-5.7	-0.34	3.44e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.59	-6.55	-0.39	3.39e-10	Aortic root size;
KIRP	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.62	8.25	0.47	9.36e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.69	10.25	0.55	9.05e-21	Dupuytren's disease;
KIRP	cis	rs8018808	1.000	rs8018808	chr14:77858336	A/G	cg20045696	chr14:77926864	AHSA1	-0.42	-5.19	-0.31	4.43e-7	Myeloid white cell count;
KIRP	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.74	0.39	1.15e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg07884673	chr3:53033167	SFMBT1	0.96	7.1	0.41	1.36e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3925075	0.531	rs9673519	chr16:31347557	T/C	cg02846316	chr16:31340340	ITGAM	0.47	5.63	0.34	4.82e-8	IgA nephropathy;
KIRP	cis	rs9843304	0.528	rs9880421	chr3:149183359	C/T	cg08667024	chr3:149219783	TM4SF4	0.56	8.41	0.47	3.35e-15	Gallstone disease;
KIRP	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg22713356	chr15:30763199	NA	1.25	12.41	0.62	9.05e-28	Uric acid levels;
KIRP	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.73	0.53	3.79e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg04691961	chr3:161091175	C3orf57	0.55	8.18	0.46	1.49e-14	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-1.0	-16.64	-0.73	3.67e-42	Height;
KIRP	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.71	10.5	0.56	1.49e-21	Eosinophilic esophagitis;
KIRP	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.77	7.04	0.41	1.86e-11	Cognitive function;
KIRP	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs798766	1.000	rs2166580	chr4:1743169	G/A	cg07775547	chr4:1625484	NA	-0.44	-5.34	-0.32	2.11e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs6580649	0.883	rs879242	chr12:48503301	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg03894339	chr8:19674705	INTS10	0.53	6.31	0.37	1.28e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg07511668	chr11:68622177	NA	0.43	5.76	0.34	2.54e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs13401104	0.716	rs11687393	chr2:237143805	G/C	cg19324714	chr2:237145437	ASB18	0.54	5.5	0.33	9.37e-8	Educational attainment;
KIRP	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.46	7.52	0.43	9.99e-13	Testicular germ cell tumor;
KIRP	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.46	-0.33	1.15e-7	Total body bone mineral density;
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg22325292	chr17:80708367	FN3K	0.36	4.86	0.3	2.1e-6	Glycated hemoglobin levels;
KIRP	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg22089800	chr15:90895588	ZNF774	0.61	8.33	0.47	5.74e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg08885076	chr2:99613938	TSGA10	0.53	9.27	0.51	9.88e-18	Chronic sinus infection;
KIRP	cis	rs6563210	0.789	rs9531181	chr13:36487547	C/A	cg19801062	chr13:36872135	C13orf38	-0.45	-4.95	-0.3	1.35e-6	Height;
KIRP	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg08533674	chr1:46993347	NA	-0.41	-5.09	-0.31	7.18e-7	Monobrow;
KIRP	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg05044414	chr3:183734942	ABCC5	0.38	5.84	0.35	1.65e-8	Anterior chamber depth;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18760276	chr1:36863421	LSM10	0.47	6.35	0.38	1.02e-9	Survival in pancreatic cancer;
KIRP	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-7.39	-0.43	2.25e-12	Menopause (age at onset);
KIRP	cis	rs4742903	0.904	rs7029970	chr9:107006565	G/A	cg14250997	chr9:106856677	SMC2	0.38	5.04	0.31	8.97e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs2733310	1.000	rs2703595	chr15:57490290	A/G	cg13626582	chr15:57592083	LOC283663	-0.31	-7.13	-0.41	1.1e-11	Mean platelet volume;
KIRP	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.4	-5.78	-0.35	2.31e-8	Height;
KIRP	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.61	-0.52	8.82e-19	Total body bone mineral density;
KIRP	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg18367735	chr17:79674897	NA	0.7	6.57	0.39	2.92e-10	Dental caries;
KIRP	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.78	-0.44	2.02e-13	Triglycerides;
KIRP	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04558112	chr16:69788908	NOB1	0.44	6.1	0.36	4.08e-9	Survival in pancreatic cancer;
KIRP	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-11.7	-0.6	1.96e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.58	-7.82	-0.45	1.5700000000000001e-13	Morning vs. evening chronotype;
KIRP	cis	rs1476670	0.710	rs753637	chr1:44508927	A/G	cg09470012	chr1:44509516	NA	0.37	5.8	0.35	2.08e-8	Eotaxin levels;
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg09699651	chr6:150184138	LRP11	0.46	6.22	0.37	2.1e-9	Lung cancer;
KIRP	cis	rs7009516	0.669	rs13280953	chr8:24250161	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.31	-6.41	-0.38	7.46e-10	Hair greying;
KIRP	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg14359292	chr7:27170892	HOXA4	-0.41	-5.77	-0.35	2.38e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6430538	0.671	rs6716734	chr2:135561141	T/C	cg25422880	chr2:135218333	TMEM163	-0.44	-6.12	-0.36	3.62e-9	Parkinson's disease;
KIRP	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs11731606	0.508	rs9307140	chr4:95288670	G/C	cg00507259	chr4:95128692	SMARCAD1	0.62	6.05	0.36	5.36e-9	Mean platelet volume;
KIRP	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.62	-6.56	-0.39	3.1e-10	Gut microbiome composition (summer);
KIRP	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.91	7.29	0.42	4.22e-12	Breast cancer;
KIRP	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.96	0.41	3.1e-11	Neuroticism;
KIRP	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.57	6.79	0.4	8.32e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg18882449	chr10:104885122	NT5C2	-0.39	-4.92	-0.3	1.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg01616529	chr11:638424	DRD4	-0.51	-6.72	-0.39	1.26e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg16141378	chr3:129829833	LOC729375	0.63	8.55	0.48	1.36e-15	Neuroticism;
KIRP	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.27	0.42	4.66e-12	Arsenic metabolism;
KIRP	trans	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Bladder cancer;
KIRP	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg16255804	chr6:135334527	HBS1L	-0.33	-5.34	-0.32	2.12e-7	Red blood cell count;
KIRP	cis	rs858239	0.509	rs57611130	chr7:23184552	C/A	cg23682824	chr7:23144976	KLHL7	0.54	6.35	0.38	1.01e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.7	5.43	0.33	1.36e-7	Facial emotion recognition (sad faces);
KIRP	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.47	6.48	0.38	4.94e-10	Testicular germ cell tumor;
KIRP	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-6.49	-0.38	4.71e-10	Vitamin D levels;
KIRP	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-8.08	-0.46	2.94e-14	Personality dimensions;
KIRP	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg17644776	chr2:200775616	C2orf69	0.55	5.93	0.35	1.04e-8	Schizophrenia;
KIRP	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg06647332	chr5:131281008	NA	0.45	5.11	0.31	6.58e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg14972814	chr11:95582409	MTMR2	-0.29	-4.95	-0.3	1.36e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17818399	0.781	rs13024534	chr2:46859386	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.65	0.34	4.43e-8	Height;
KIRP	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg09264619	chr17:80180166	NA	-0.52	-6.18	-0.37	2.64e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09082480	chr16:83997636	OSGIN1	-0.43	-6.42	-0.38	7.13e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	9.0	0.5	6.38e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.36	-0.38	9.9e-10	Lung cancer;
KIRP	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	trans	rs1568657	0.779	rs2167602	chr15:83649292	C/T	cg27496793	chr2:46926433	SOCS5	-0.42	-6.08	-0.36	4.6e-9	Kawasaki disease;
KIRP	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-9.19	-0.51	1.7e-17	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.03	-0.31	9.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.65	-0.39	1.87e-10	Neuroticism;
KIRP	cis	rs258892	0.843	rs11950068	chr5:72032998	T/C	cg21869765	chr5:72125136	TNPO1	-0.52	-5.83	-0.35	1.71e-8	Small cell lung carcinoma;
KIRP	cis	rs10214930	0.671	rs9639553	chr7:27578167	C/G	cg22168087	chr7:27702803	HIBADH	-0.44	-4.86	-0.3	2.13e-6	Hypospadias;
KIRP	cis	rs2625529	0.667	rs16956381	chr15:72193237	A/C	cg16672083	chr15:72433130	SENP8	-0.49	-6.1	-0.36	4.07e-9	Red blood cell count;
KIRP	cis	rs986417	0.818	rs10139251	chr14:60959958	A/C	cg27398547	chr14:60952738	C14orf39	0.66	6.66	0.39	1.82e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg14829360	chr17:73884958	NA	-0.46	-6.16	-0.37	2.88e-9	White matter hyperintensity burden;
KIRP	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg21427119	chr20:30132790	HM13	-0.42	-5.0	-0.3	1.07e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg14092571	chr14:90743983	NA	-0.41	-5.47	-0.33	1.12e-7	Mortality in heart failure;
KIRP	cis	rs7394190	0.748	rs11000772	chr10:75533988	T/G	cg04833713	chr10:74871078	NUDT13	0.43	4.86	0.3	2.1e-6	Incident atrial fibrillation;
KIRP	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.71	-0.39	1.34e-10	Neuroticism;
KIRP	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.54	0.39	3.47e-10	Height;
KIRP	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg27087555	chr16:88793112	FAM38A	0.67	7.36	0.42	2.81e-12	Autism spectrum disorder-related traits;
KIRP	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05472934	chr7:22766657	IL6	0.81	10.45	0.55	2.1e-21	Lung cancer;
KIRP	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-1.06	-9.9	-0.53	1.15e-19	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs72634030	0.609	rs7214522	chr17:5239575	T/G	cg20802942	chr17:5185005	RABEP1	0.54	5.32	0.32	2.34e-7	Rheumatoid arthritis;
KIRP	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.04	0.46	3.89e-14	Aortic root size;
KIRP	cis	rs2274273	0.967	rs10147667	chr14:55570849	C/T	cg04306507	chr14:55594613	LGALS3	-0.43	-6.31	-0.37	1.29e-9	Protein biomarker;
KIRP	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03060546	chr3:49711283	APEH	-0.64	-5.8	-0.35	1.99e-8	Menarche (age at onset);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18012350	chr15:74753669	UBL7	0.87	6.04	0.36	5.58e-9	P wave terminal force;
KIRP	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg06634786	chr22:41940651	POLR3H	-0.46	-5.06	-0.31	8.08e-7	Neuroticism;
KIRP	cis	rs427941	0.703	rs201448	chr7:101738860	T/C	cg06246474	chr7:101738831	CUX1	0.56	6.94	0.4	3.37e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.86	0.45	1.2e-13	Coffee consumption (cups per day);
KIRP	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.72	0.44	2.91e-13	Calcium levels;
KIRP	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.6	5.11	0.31	6.48e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.81	-12.38	-0.62	1.08e-27	Educational attainment;
KIRP	trans	rs593982	1.000	rs593982	chr11:65513107	T/C	cg16063989	chr7:139929855	NA	0.46	6.41	0.38	7.2e-10	Atopic dermatitis;
KIRP	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.18	-0.37	2.6e-9	Triglycerides;
KIRP	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	5.05	0.31	8.56e-7	Iron status biomarkers;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09549240	chr15:75250560	RPP25	0.27	4.89	0.3	1.81e-6	Breast cancer;
KIRP	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.63	-0.34	4.95e-8	Coronary artery disease;
KIRP	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.56	8.98	0.5	7e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.94	15.48	0.7	3.47e-38	Ulcerative colitis;
KIRP	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.24e-10	Colorectal cancer;
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.78	0.49	2.81e-16	Life satisfaction;
KIRP	cis	rs2976388	0.935	rs2978978	chr8:143756530	T/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.53	-0.38	3.83e-10	Urinary tract infection frequency;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20364594	chr6:158981615	TMEM181	0.49	6.61	0.39	2.42e-10	Parkinson's disease;
KIRP	cis	rs9810890	1.000	rs78675391	chr3:128472470	C/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg14932796	chr17:55038330	COIL	0.59	6.8	0.4	7.89e-11	Sleep duration;
KIRP	cis	rs921943	1.000	rs16876336	chr5:78323482	G/C	cg26802063	chr5:78281964	ARSB	0.49	6.1	0.36	4.13e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.19	-0.31	4.36e-7	Metabolite levels;
KIRP	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.74	8.62	0.48	8.48e-16	High light scatter reticulocyte count;
KIRP	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.79	11.36	0.59	2.6e-24	Monocyte count;
KIRP	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.96	0.41	3.05e-11	Educational attainment;
KIRP	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg26617929	chr16:1858877	NA	0.63	5.29	0.32	2.69e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.54	-7.34	-0.42	3.16e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04486305	chr16:22207248	NA	-0.47	-6.15	-0.37	3.17e-9	Survival in pancreatic cancer;
KIRP	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs7551222	0.752	rs885012	chr1:204544001	C/A	cg20240347	chr1:204465584	NA	-0.44	-8.36	-0.47	4.62e-15	Schizophrenia;
KIRP	cis	rs35883536	0.647	rs2809795	chr1:101038345	A/G	cg06223162	chr1:101003688	GPR88	0.44	9.06	0.5	4.13e-17	Monocyte count;
KIRP	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs4750440	0.706	rs10796148	chr10:14016900	G/A	cg27542038	chr10:14027202	FRMD4A	-0.48	-6.38	-0.38	8.8e-10	Adiponectin levels;
KIRP	cis	rs448720	0.584	rs8025526	chr15:68076483	A/T	cg24579218	chr15:68104479	NA	-0.48	-7.73	-0.44	2.73e-13	Cognitive performance;
KIRP	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg21475434	chr5:93447410	FAM172A	0.43	4.98	0.3	1.21e-6	Diabetic retinopathy;
KIRP	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.79	-0.53	2.5e-19	Schizophrenia;
KIRP	cis	rs6504950	0.800	rs35647022	chr17:53008071	C/T	cg26251398	chr17:52985966	TOM1L1	0.42	5.07	0.31	7.86e-7	Breast cancer;
KIRP	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.4	-0.33	1.6e-7	Bladder cancer;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-5.58	-0.34	6.21e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg01721255	chr8:58191610	C8orf71	0.54	5.55	0.33	7.41e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.58	-6.71	-0.39	1.33e-10	Red cell distribution width;
KIRP	cis	rs698833	0.547	rs1067355	chr2:44663152	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.56	-5.75	-0.34	2.65e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.53	-0.43	9.55e-13	Initial pursuit acceleration;
KIRP	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg04310649	chr10:35416472	CREM	-0.59	-6.93	-0.4	3.67e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.54	-6.16	-0.37	2.9e-9	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs12210905	0.920	rs6911234	chr6:27086859	T/A	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.6	-7.99	-0.45	5.34e-14	Neuroticism;
KIRP	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.5	-6.19	-0.37	2.51e-9	Coronary artery disease;
KIRP	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.82	-13.14	-0.64	2.99e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.5	8.35	0.47	4.88e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg11970804	chr8:8084126	NA	-0.38	-4.91	-0.3	1.67e-6	Mood instability;
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.39	0.65	4.62e-31	Platelet count;
KIRP	cis	rs2574975	0.531	rs1203398	chr10:52200340	A/G	cg10034176	chr10:52120283	SGMS1	0.4	5.74	0.34	2.71e-8	Response to amphetamines;
KIRP	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.72	6.41	0.38	7.36e-10	RR interval (heart rate);
KIRP	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg02631126	chr6:28058918	ZSCAN12L1	0.47	5.1	0.31	6.74e-7	Depression;
KIRP	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg20578329	chr17:80767326	TBCD	0.47	5.59	0.34	5.99e-8	Glycated hemoglobin levels;
KIRP	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.76	9.9	0.53	1.13e-19	N-glycan levels;
KIRP	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.66	8.53	0.48	1.51e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.78	-11.76	-0.6	1.25e-25	Dental caries;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25671651	chr2:203776787	ALS2CR8;WDR12	0.56	6.32	0.37	1.22e-9	Lung cancer in ever smokers;
KIRP	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg25482853	chr8:67687455	SGK3	0.79	6.99	0.41	2.64e-11	Obesity-related traits;
KIRP	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg19847130	chr8:10466454	RP1L1	-0.34	-5.02	-0.3	9.95e-7	Retinal vascular caliber;
KIRP	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.28	-0.37	1.53e-9	QT interval;
KIRP	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg13010199	chr12:38710504	ALG10B	0.62	7.68	0.44	3.73e-13	Morning vs. evening chronotype;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22753607	chr9:37120306	ZCCHC7	0.46	6.28	0.37	1.48e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6500395	0.890	rs11861666	chr16:48679914	G/T	cg04672837	chr16:48644449	N4BP1	0.48	6.43	0.38	6.56e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.74	-7.87	-0.45	1.11e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg06637938	chr14:75390232	RPS6KL1	0.7	9.58	0.52	1.09e-18	Height;
KIRP	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg15068132	chr12:102092402	CHPT1	-0.39	-5.09	-0.31	7.05e-7	Blood protein levels;
KIRP	trans	rs13170463	0.579	rs74781622	chr5:8041656	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs4006360	0.522	rs11871050	chr17:39236997	A/T	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	1.03e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs12019136	1	rs12019136	chr19:5835677	G/A	cg25387410	chr19:5844109	FUT3	-1.27	-10.1	-0.54	2.71e-20	Advanced age-related macular degeneration;IgG N-glycosylation phenotypes (multivariate analysis);
KIRP	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.49	0.52	2.07e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.78	7.6	0.44	6.39e-13	Neuroblastoma;
KIRP	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg25019033	chr10:957182	NA	0.38	5.19	0.31	4.47e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.87	-10.32	-0.55	5.55e-21	Vitiligo;
KIRP	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg01320579	chr17:75405842	SEPT9	0.49	7.85	0.45	1.29e-13	Airflow obstruction;
KIRP	cis	rs365132	0.846	rs353470	chr5:176444861	C/T	cg16309518	chr5:176445507	NA	-0.8	-12.02	-0.61	1.79e-26	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs12210905	0.687	rs72843622	chr6:27161152	C/T	cg11502198	chr6:26597334	ABT1	-0.74	-4.91	-0.3	1.66e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12496230	0.794	rs4856826	chr3:66858576	C/T	cg17646820	chr3:66848679	NA	0.4	6.64	0.39	2.01e-10	Type 2 diabetes;
KIRP	cis	rs290986	0.857	rs158509	chr9:93546449	C/G	cg02608019	chr9:93564028	SYK	0.61	5.72	0.34	3.13e-8	Multiple sclerosis;
KIRP	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-8.01	-0.45	4.66e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10788972	0.903	rs7537946	chr1:54538700	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.28	-4.88	-0.3	1.95e-6	Parkinson disease and lewy body pathology;
KIRP	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg27490568	chr2:178487706	NA	0.48	6.52	0.38	3.86e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-11.07	-0.58	2.24e-23	Dental caries;
KIRP	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.06	-0.36	5.15e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg05220968	chr6:146057943	EPM2A	0.4	5.15	0.31	5.37e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg22974920	chr21:40686053	BRWD1	0.45	5.11	0.31	6.53e-7	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26766005	chr2:171571941	SP5;LOC440925	0.46	6.45	0.38	5.76e-10	Parkinson's disease;
KIRP	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.13e-6	Bladder cancer;
KIRP	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.6	-0.34	5.58e-8	Height;
KIRP	cis	rs6751744	0.513	rs7563368	chr2:160457075	C/T	cg08347373	chr2:160653686	CD302	0.37	5.52	0.33	8.55e-8	Dysphagia;
KIRP	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.5	-6.57	-0.39	3.01e-10	Response to temozolomide;
KIRP	cis	rs11718455	0.585	rs11710794	chr3:43930119	T/G	cg08738300	chr3:44038990	NA	0.58	7.51	0.43	1.08e-12	Coronary artery disease;
KIRP	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.14	0.31	5.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg08603382	chr10:743973	NA	-0.53	-7.59	-0.44	6.74e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg12405258	chr13:114927641	NA	0.47	6.87	0.4	5.12e-11	Schizophrenia;
KIRP	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.4	5.47	0.33	1.09e-7	Red blood cell count;
KIRP	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05359518	chr15:57508437	TCF12	0.44	6.09	0.36	4.35e-9	C-reactive protein;
KIRP	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg00129232	chr17:37814104	STARD3	-0.52	-6.42	-0.38	7.15e-10	Self-reported allergy;
KIRP	cis	rs732716	0.853	rs62129349	chr19:4385659	A/G	cg21720385	chr19:4455239	UBXN6	0.7	8.57	0.48	1.14e-15	Mean corpuscular volume;
KIRP	trans	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg19274270	chr17:78178856	CARD14	-0.35	-6.12	-0.36	3.62e-9	Morning vs. evening chronotype;
KIRP	trans	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg26043149	chr18:55253948	FECH	-0.79	-8.74	-0.49	3.79e-16	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.73	-10.77	-0.57	2e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg10556349	chr10:835070	NA	0.62	5.74	0.34	2.85e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.23	0.32	3.66e-7	Asthma;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	1.04	11.27	0.58	4.88e-24	Alzheimer's disease;
KIRP	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.8	9.75	0.53	3.41e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9473924	0.542	rs4294001	chr6:50850065	G/A	cg14470998	chr6:50812995	TFAP2B	0.8	7.57	0.43	7.68e-13	Body mass index;
KIRP	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.56	7.35	0.42	2.96e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2997447	0.846	rs3008430	chr1:26390328	A/G	cg19633962	chr1:26362018	EXTL1	-0.54	-5.18	-0.31	4.66e-7	QRS complex (12-leadsum);
KIRP	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16265552	chr3:113667068	ZDHHC23	0.53	6.05	0.36	5.24e-9	Smoking initiation;
KIRP	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.95e-10	Subjective well-being;
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-5.75	-0.34	2.65e-8	Lung cancer;
KIRP	cis	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg27411982	chr8:10470053	RP1L1	-0.42	-5.21	-0.32	3.95e-7	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg17885191	chr8:135476712	NA	0.56	6.92	0.4	3.96e-11	Hypertension (SNP x SNP interaction);
KIRP	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg08761264	chr16:28874980	SH2B1	-0.44	-4.87	-0.3	2.01e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.65	-6.74	-0.39	1.14e-10	Breast cancer;
KIRP	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg12559939	chr2:27858050	GPN1	-0.42	-5.2	-0.31	4.27e-7	Oral cavity cancer;
KIRP	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg13409248	chr3:40428643	ENTPD3	0.35	4.87	0.3	2.03e-6	Renal cell carcinoma;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00314771	chr11:102963272	DCUN1D5	0.56	6.2	0.37	2.41e-9	Lung cancer in ever smokers;
KIRP	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg03060546	chr3:49711283	APEH	-0.58	-5.24	-0.32	3.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9972944	0.756	rs6504343	chr17:63755458	C/T	cg07283582	chr17:63770753	CCDC46	-0.44	-7.23	-0.42	5.91e-12	Total body bone mineral density;
KIRP	cis	rs11776767	0.597	rs2292369	chr8:10716028	A/G	cg12568669	chr8:11666485	FDFT1	0.24	5.36	0.32	1.88e-7	Triglycerides;
KIRP	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg03714773	chr7:91764589	CYP51A1	0.41	6.23	0.37	2.05e-9	Breast cancer;
KIRP	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.39e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.1	12.35	0.62	1.41e-27	Vitiligo;
KIRP	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.67	-5.25	-0.32	3.32e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.18	0.31	4.7e-7	Bipolar disorder;
KIRP	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.32	0.32	2.37e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs151997	0.777	rs3846499	chr5:50254200	G/A	cg06027927	chr5:50259733	NA	0.6	7.88	0.45	1.08e-13	Callous-unemotional behaviour;
KIRP	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.61	-7.9	-0.45	9.06e-14	Iron status biomarkers;
KIRP	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg17218026	chr1:154582156	ADAR	0.35	5.8	0.35	2.01e-8	Blood protein levels;
KIRP	cis	rs9815354	1.000	rs11923562	chr3:41760331	G/T	cg03022575	chr3:42003672	ULK4	0.54	5.89	0.35	1.28e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg25482853	chr8:67687455	SGK3	0.8	7.01	0.41	2.32e-11	Obesity-related traits;
KIRP	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.6	0.81	1e-58	Prudent dietary pattern;
KIRP	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg08975724	chr8:8085496	FLJ10661	0.53	6.74	0.39	1.13e-10	Neuroticism;
KIRP	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg06115741	chr20:33292138	TP53INP2	0.47	6.44	0.38	6.38e-10	Coronary artery disease;
KIRP	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg15083037	chr5:83017644	HAPLN1	-0.56	-8.06	-0.46	3.29e-14	Prostate cancer;
KIRP	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.87	-0.35	1.37e-8	Breast cancer;
KIRP	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg00922110	chr4:57842668	C4orf14	-0.42	-5.52	-0.33	8.78e-8	Response to bleomycin (chromatid breaks);
KIRP	cis	rs882732	1.000	rs882732	chr14:95027722	G/A	cg08495878	chr14:95027859	SERPINA4	-0.43	-5.24	-0.32	3.48e-7	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	11.36	0.59	2.49e-24	Platelet count;
KIRP	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg00982548	chr2:198649783	BOLL	-0.55	-5.52	-0.33	8.69e-8	Ulcerative colitis;
KIRP	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg21523564	chr15:75251491	NA	0.37	6.26	0.37	1.67e-9	Breast cancer;
KIRP	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg10761708	chr20:43804764	PI3	0.5	5.19	0.31	4.45e-7	Blood protein levels;
KIRP	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.8	6.68	0.39	1.56e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.9	0.45	9.11e-14	Coffee consumption (cups per day);
KIRP	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11987759	chr7:65425863	GUSB	0.49	6.39	0.38	8.39e-10	Aortic root size;
KIRP	cis	rs155346	0.625	rs264348	chr5:139360864	C/T	cg24724630	chr5:139362307	NRG2	-0.39	-5.25	-0.32	3.32e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	trans	rs12043259	0.615	rs7551936	chr1:204799816	G/A	cg11485465	chr5:54518469	NA	0.34	6.21	0.37	2.22e-9	Addiction;
KIRP	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg25007680	chr1:8021821	PARK7	0.65	9.07	0.5	3.92e-17	Response to antidepressants and depression;
KIRP	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg12940439	chr1:67600707	NA	0.43	6.41	0.38	7.48e-10	Psoriasis;
KIRP	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.05	-0.41	1.82e-11	Joint mobility (Beighton score);
KIRP	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg07843065	chr1:150265600	MRPS21	0.47	6.41	0.38	7.28e-10	Migraine;
KIRP	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg03342759	chr3:160939853	NMD3	-0.61	-8.0	-0.45	4.78e-14	Morning vs. evening chronotype;
KIRP	cis	rs743757	0.878	rs9867588	chr3:50526880	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.46	5.38	0.32	1.71e-7	Diastolic blood pressure;
KIRP	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs950776	0.612	rs8038920	chr15:78974545	A/G	cg22563815	chr15:78856949	CHRNA5	-0.41	-5.84	-0.35	1.63e-8	Sudden cardiac arrest;
KIRP	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.45	-0.47	2.65e-15	Colorectal cancer;
KIRP	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs8033133	0.602	rs1549477	chr15:25332118	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.56	-6.94	-0.4	3.53e-11	Blood osmolality (transformed sodium);
KIRP	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.89	-0.4	4.66e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg16898833	chr6:26189333	HIST1H4D	0.98	5.83	0.35	1.72e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.69	11.88	0.6	5.19e-26	Lung cancer;
KIRP	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.67	-0.34	4e-8	Parkinson's disease;
KIRP	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg13319975	chr6:146136371	FBXO30	0.43	5.83	0.35	1.74e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg11693508	chr17:37793320	STARD3	0.79	8.28	0.47	8.11e-15	Bipolar disorder;
KIRP	cis	rs73086581	1.000	rs6107386	chr20:3972756	A/C	cg02187196	chr20:3869020	PANK2	0.49	4.92	0.3	1.6e-6	Response to antidepressants in depression;
KIRP	cis	rs7011507	1.000	rs74516664	chr8:49176617	G/A	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.56	7.41	0.43	2e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg13147721	chr7:65941812	NA	-1.01	-6.75	-0.4	1.03e-10	Diabetic kidney disease;
KIRP	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg10189774	chr4:17578691	LAP3	0.51	5.86	0.35	1.47e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg06204229	chr3:52865917	ITIH4	0.51	7.5	0.43	1.16e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00906976	chr1:231664136	TSNAX-DISC1;TSNAX	0.45	6.43	0.38	6.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg12573674	chr2:1569213	NA	-0.57	-5.03	-0.31	9.32e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg13010199	chr12:38710504	ALG10B	0.64	7.97	0.45	5.77e-14	Morning vs. evening chronotype;
KIRP	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.67	-0.39	1.72e-10	Total cholesterol levels;
KIRP	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg05082376	chr22:42548792	NA	-0.46	-5.8	-0.35	2.01e-8	Schizophrenia;
KIRP	cis	rs7601312	0.967	rs13000938	chr2:229322311	G/C	cg02542817	chr2:229291442	NA	-0.38	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.42	-5.11	-0.31	6.62e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.79	-0.53	2.53e-19	Aortic root size;
KIRP	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.44	-6.41	-0.38	7.51e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.61	-7.03	-0.41	1.97e-11	DNA methylation (variation);
KIRP	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-0.88	-10.8	-0.57	1.67e-22	Blood protein levels;
KIRP	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.74	6.03	0.36	6e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.88	-11.74	-0.6	1.42e-25	Prostate cancer;
KIRP	cis	rs9469913	0.799	rs16894959	chr6:34825662	T/C	cg17674042	chr6:34482479	PACSIN1	-0.4	-5.42	-0.33	1.45e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.1	-0.36	4.02e-9	Obesity-related traits;
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.4	6.13	0.36	3.55e-9	Lung cancer;
KIRP	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.92e-31	Eye color traits;
KIRP	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.82e-7	Cognitive function;
KIRP	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.66	-9.83	-0.53	1.88e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17376030	chr22:41985996	PMM1	0.85	9.05	0.5	4.33e-17	Vitiligo;
KIRP	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.81	0.66	1.72e-32	Electrocardiographic conduction measures;
KIRP	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.68	9.19	0.51	1.71e-17	Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs524023	0.874	rs492175	chr11:64433078	A/G	cg09231725	chr11:64357281	SLC22A12	-0.61	-8.03	-0.46	3.98e-14	Urate levels in obese individuals;
KIRP	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.34	7.2	0.42	7.25e-12	Corneal astigmatism;
KIRP	cis	rs7737355	0.738	rs3776016	chr5:130855352	C/T	cg06307176	chr5:131281290	NA	0.42	5.02	0.31	9.69e-7	Life satisfaction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14168002	chr9:130656861	ST6GALNAC6	0.46	6.67	0.39	1.65e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7870753	0.838	rs10122900	chr9:99207540	C/T	cg25260653	chr9:99212216	HABP4	0.57	6.05	0.36	5.37e-9	Height;
KIRP	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.54	-5.96	-0.36	8.57e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-11.64	-0.6	3.2e-25	Dental caries;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01911186	chr12:12765398	CREBL2	0.54	6.61	0.39	2.4e-10	Smoking initiation;
KIRP	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg18132916	chr6:79620363	NA	-0.42	-5.66	-0.34	4.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.64	-0.63	1.48e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg08662619	chr6:150070041	PCMT1	0.34	5.25	0.32	3.23e-7	Lung cancer;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg03714773	chr7:91764589	CYP51A1	0.36	5.22	0.32	3.73e-7	Breast cancer;
KIRP	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.86	12.62	0.63	1.75e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.53	6.69	0.39	1.5e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21214613	chr1:16344536	HSPB7	0.36	4.98	0.3	1.18e-6	Dilated cardiomyopathy;
KIRP	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg02487422	chr3:49467188	NICN1	0.39	5.08	0.31	7.44e-7	Resting heart rate;
KIRP	trans	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg24644049	chr4:85504048	CDS1	0.91	6.19	0.37	2.55e-9	Skin colour saturation;
KIRP	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg06742321	chr12:123595122	PITPNM2	0.45	5.52	0.33	8.55e-8	Platelet count;
KIRP	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.77	11.65	0.6	2.93e-25	Caffeine consumption;
KIRP	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3741489	1.000	rs10781661	chr12:133431979	G/A	cg15275758	chr12:133412815	NA	0.52	5.4	0.33	1.57e-7	Cognitive function;
KIRP	cis	rs6466055	0.589	rs56251298	chr7:104956516	G/T	cg04380332	chr7:105027541	SRPK2	0.36	5.03	0.31	9.53e-7	Schizophrenia;
KIRP	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg18350739	chr11:68623251	NA	-0.48	-7.72	-0.44	2.96e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.88	10.1	0.54	2.79e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg17120908	chr11:65337727	SSSCA1	-0.5	-4.93	-0.3	1.54e-6	Plateletcrit;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14103574	chr5:162932455	MAT2B	-0.53	-6.76	-0.4	9.78e-11	Neuroticism;
KIRP	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg00122941	chr17:4613640	ARRB2	0.76	8.18	0.46	1.5e-14	Lymphocyte counts;
KIRP	cis	rs11264213	0.786	rs72659695	chr1:36311143	T/G	cg27506609	chr1:36549197	TEKT2	0.98	5.49	0.33	1e-7	Schizophrenia;
KIRP	trans	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg10756647	chr7:56101905	PSPH	1.0	7.17	0.42	8.86e-12	Diabetic kidney disease;
KIRP	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg18016565	chr1:150552671	MCL1	-0.48	-7.46	-0.43	1.47e-12	Tonsillectomy;
KIRP	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-5.49	-0.33	9.8e-8	Parkinson's disease;
KIRP	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.56	-6.8	-0.4	7.87e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07650554	chr16:30457408	SEPHS2	0.69	6.37	0.38	9.11e-10	Lung function (FEV1);
KIRP	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg21184320	chr1:21044207	KIF17	-0.35	-5.3	-0.32	2.62e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.83	9.07	0.5	3.91e-17	Alzheimer's disease;
KIRP	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg24803719	chr17:45855879	NA	-0.45	-5.85	-0.35	1.53e-8	IgG glycosylation;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	7.54	0.43	8.91e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg01566213	chr4:1579287	NA	-0.37	-5.44	-0.33	1.31e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.43	5.11	0.31	6.44e-7	Aortic root size;
KIRP	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	5.72	0.34	3.09e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.38	4.96	0.3	1.31e-6	Blood protein levels;
KIRP	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.21	0.61	4.19e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1971762	0.509	rs1247955	chr12:53964133	G/T	cg16917193	chr12:54089295	NA	-0.84	-14.0	-0.67	3.82e-33	Height;
KIRP	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.37	-5.39	-0.32	1.68e-7	Body mass index;
KIRP	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.56	4.89	0.3	1.8e-6	Initial pursuit acceleration;
KIRP	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16338060	chr14:50863307	CDKL1	0.51	6.45	0.38	5.86e-10	Parkinson's disease;
KIRP	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg17644776	chr2:200775616	C2orf69	0.56	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.79	12.99	0.64	9.64e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg10756647	chr7:56101905	PSPH	0.94	7.12	0.41	1.19e-11	Diabetic kidney disease;
KIRP	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.28	-5.43	-0.33	1.32e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg07382826	chr16:28625726	SULT1A1	0.47	5.22	0.32	3.82e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26306683	chr17:18585705	ZNF286B	0.59	7.49	0.43	1.25e-12	Educational attainment (years of education);
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07308232	chr7:1071921	C7orf50	-0.68	-8.25	-0.47	9.49e-15	Longevity;Endometriosis;
KIRP	cis	rs11191270	1.000	rs4919624	chr10:104021085	A/G	cg15320455	chr10:103880129	LDB1	0.54	4.88	0.3	1.95e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.85	-12.99	-0.64	1e-29	Height;
KIRP	cis	rs897080	0.515	rs786401	chr2:44712069	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.71	0.34	3.27e-8	Height;
KIRP	cis	rs12532214	1.000	rs12532214	chr7:3169890	C/G	cg19214707	chr7:3157722	NA	-0.63	-5.77	-0.35	2.35e-8	Itch intensity from mosquito bite;
KIRP	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg02696742	chr7:106810147	HBP1	-0.78	-8.65	-0.48	6.58e-16	Coronary artery disease;
KIRP	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.66	-9.53	-0.52	1.55e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.65	8.72	0.49	4.33e-16	Prostate cancer;
KIRP	cis	rs3779635	0.713	rs4733063	chr8:27302885	A/G	cg23736307	chr8:27182930	PTK2B	0.4	4.94	0.3	1.44e-6	Neuroticism;
KIRP	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.4	6.86	0.4	5.45e-11	Heart rate;
KIRP	cis	rs6466055	0.624	rs67162771	chr7:104951038	C/T	cg04380332	chr7:105027541	SRPK2	0.37	5.08	0.31	7.62e-7	Schizophrenia;
KIRP	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.63	7.68	0.44	3.64e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4805272	0.924	rs1363326	chr19:29325650	A/G	cg15000279	chr19:29285009	NA	-0.41	-6.08	-0.36	4.44e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2033732	0.706	rs7839360	chr8:85069719	G/T	cg05716166	chr8:85095498	RALYL	0.52	5.96	0.36	8.53e-9	Body mass index;
KIRP	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.92	-13.8	-0.66	1.84e-32	Lung cancer;
KIRP	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2223471	0.719	rs17608920	chr6:50773860	G/A	cg14470998	chr6:50812995	TFAP2B	-0.37	-4.85	-0.3	2.24e-6	Subcutaneous adipose tissue;
KIRP	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.81	9.71	0.53	4.42e-19	Multiple system atrophy;
KIRP	trans	rs10435719	0.746	rs58007588	chr8:11794969	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.52	0.43	1.02e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3857747	0.861	rs9648486	chr7:40420032	A/G	cg00420559	chr7:40367873	C7orf10	0.64	8.25	0.47	9.78e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.45e-8	Schizophrenia;
KIRP	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg19683494	chr5:74908142	NA	0.44	5.09	0.31	7.06e-7	Age-related disease endophenotypes;
KIRP	cis	rs365132	0.517	rs3762974	chr5:176328336	G/A	cg06783121	chr5:176314628	HK3	-0.49	-5.63	-0.34	4.8e-8	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg13354988	chr2:263656	ACP1;SH3YL1	0.37	4.91	0.3	1.69e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg13798780	chr7:105162888	PUS7	0.66	6.11	0.36	3.83e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg20387954	chr3:183756860	HTR3D	-0.47	-5.87	-0.35	1.39e-8	Anterior chamber depth;
KIRP	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.81	-0.35	1.9e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs62151617	1.000	rs71414824	chr2:70787029	A/T	cg24334149	chr2:71175539	ATP6V1B1	0.52	5.26	0.32	3.1e-7	Hair shape;
KIRP	cis	rs66987842	1	rs66987842	chr22:40904707	CT/C	cg07138101	chr22:40742427	ADSL	0.72	5.78	0.35	2.28e-8	Breast cancer;
KIRP	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg00405596	chr8:11794950	NA	-0.45	-5.67	-0.34	3.94e-8	Retinal vascular caliber;
KIRP	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.49	6.82	0.4	7.07e-11	Height;
KIRP	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg24375607	chr4:120327624	NA	0.58	6.67	0.39	1.69e-10	Corneal astigmatism;
KIRP	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg18764771	chr6:116381957	FRK	0.19	5.24	0.32	3.45e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07145255	chr5:59995354	DEPDC1B	0.65	6.02	0.36	6.2e-9	Lung function (FEV1);
KIRP	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.68	-12.41	-0.62	8.99e-28	White blood cell count (basophil);
KIRP	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.74	9.88	0.53	1.37e-19	Tonsillectomy;
KIRP	cis	rs17641971	0.645	rs341806	chr8:50034028	A/C	cg00325661	chr8:49890786	NA	0.47	5.87	0.35	1.39e-8	Blood metabolite levels;
KIRP	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.61	6.69	0.39	1.54e-10	Corneal astigmatism;
KIRP	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.57	0.33	6.63e-8	Alzheimer's disease;
KIRP	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.67	-6.46	-0.38	5.45e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg16141378	chr3:129829833	LOC729375	0.58	7.92	0.45	7.95e-14	Triglycerides;
KIRP	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	ch.11.340609R	chr11:12831013	TEAD1	-0.42	-5.41	-0.33	1.5e-7	Educational attainment (years of education);
KIRP	cis	rs6445967	1.000	rs6791748	chr3:58308519	G/A	cg16569813	chr3:58235849	ABHD6	-0.33	-4.95	-0.3	1.38e-6	Platelet count;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18389845	chr14:71199562	MAP3K9	0.49	6.19	0.37	2.49e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg17554472	chr22:41940697	POLR3H	-0.55	-6.03	-0.36	5.98e-9	Neuroticism;
KIRP	cis	rs687432	0.774	rs930703	chr11:57898493	A/T	cg19752551	chr11:57585705	CTNND1	-0.66	-8.63	-0.48	7.72e-16	Parkinson's disease;
KIRP	cis	rs9815354	0.812	rs114034165	chr3:41823297	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.57	6.98	0.41	2.75e-11	Blood metabolite levels;
KIRP	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.86	-0.3	2.07e-6	Pulmonary function;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26422975	chr1:231473532	EXOC8;C1orf124	0.46	6.43	0.38	6.56e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg05043794	chr9:111880884	C9orf5	-0.24	-5.02	-0.3	1.01e-6	Menarche (age at onset);
KIRP	cis	rs6959887	0.962	rs17606602	chr7:35281575	G/T	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00013569	chr17:80615692	RAB40B	0.44	6.02	0.36	6.46e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6831352	0.569	rs4140388	chr4:100065734	G/C	cg12011299	chr4:100065546	ADH4	0.46	6.26	0.37	1.66e-9	Alcohol dependence;
KIRP	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg02002194	chr4:3960332	NA	0.43	6.38	0.38	8.92e-10	Mood instability;
KIRP	cis	rs9325144	0.747	rs34246358	chr12:39179841	A/G	cg26384229	chr12:38710491	ALG10B	-0.55	-5.83	-0.35	1.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18252515	chr7:66147081	NA	0.43	5.09	0.31	7.17e-7	Aortic root size;
KIRP	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.04e-7	Putamen volume;
KIRP	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg04370829	chr17:406249	NA	0.39	4.89	0.3	1.86e-6	Prostate cancer;
KIRP	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg19507638	chr5:93509721	C5orf36	-0.59	-5.07	-0.31	7.92e-7	Diabetic retinopathy;
KIRP	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.69	10.07	0.54	3.45e-20	Lymphocyte counts;
KIRP	cis	rs662064	0.852	rs617728	chr1:10566522	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-5.11	-0.31	6.5e-7	Asthma;
KIRP	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg12081754	chr8:22256438	SLC39A14	0.78	9.3	0.51	8.1e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg13906792	chr15:75199810	C15orf17	-0.37	-5.4	-0.33	1.56e-7	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22271113	chr17:8370397	NDEL1	0.47	6.33	0.37	1.17e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-4.9	-0.3	1.7e-6	Testicular germ cell tumor;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.62	-8.36	-0.47	4.72e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.93	-0.4	3.57e-11	Systemic lupus erythematosus;
KIRP	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg26875233	chr11:93583750	C11orf90	-0.41	-7.7	-0.44	3.4e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.82	-7.32	-0.42	3.41e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.83	12.48	0.62	5.02e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.58	-6.67	-0.39	1.65e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.77	-8.91	-0.49	1.13e-16	Adiposity;
KIRP	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg07701084	chr6:150067640	NUP43	-0.66	-7.5	-0.43	1.14e-12	Lung cancer;
KIRP	cis	rs11169552	0.510	rs10506294	chr12:51070554	C/T	cg12884762	chr12:50931848	DIP2B	0.44	5.06	0.31	8.04e-7	Colorectal cancer;
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26207909	chr14:103986467	CKB	0.72	10.18	0.54	1.51e-20	Body mass index;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg24734643	chr22:39898247	SMCR7L	-0.52	-5.65	-0.34	4.44e-8	Menopause (age at onset);
KIRP	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.48	-0.79	4.47e-55	Height;
KIRP	cis	rs785830	0.749	rs543379	chr9:265469	T/G	cg14500300	chr9:211689	NA	0.57	7.8	0.45	1.76e-13	Platelet distribution width;
KIRP	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.78	0.4	9.06e-11	Lung cancer;
KIRP	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.64	-8.89	-0.49	1.33e-16	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08472978	chr3:11888455	C3orf31	0.49	6.03	0.36	5.99e-9	Parkinson's disease;
KIRP	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.05	-0.36	5.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg14458575	chr2:238380390	NA	0.6	8.13	0.46	2.09e-14	Prostate cancer;
KIRP	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11987759	chr7:65425863	GUSB	-0.46	-5.56	-0.33	6.95e-8	Aortic root size;
KIRP	cis	rs1620921	1.000	rs1740442	chr6:161197558	A/G	cg01280913	chr6:161186852	NA	-0.41	-5.76	-0.34	2.5e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.65	9.14	0.5	2.41e-17	Height;
KIRP	cis	rs909341	0.909	rs2236510	chr20:62368804	C/T	cg11503966	chr20:62272292	STMN3	-0.42	-5.77	-0.35	2.32e-8	Atopic dermatitis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12639422	chr2:64069082	UGP2	0.51	6.05	0.36	5.39e-9	Smoking initiation;
KIRP	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	0.8	7.01	0.41	2.26e-11	Obesity-related traits;
KIRP	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.61	-0.34	5.51e-8	IgG glycosylation;
KIRP	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.62	-7.5	-0.43	1.19e-12	Systemic lupus erythematosus;
KIRP	cis	rs55962025	0.842	rs2269477	chr4:3184464	G/T	cg13731523	chr4:3047190	NA	0.33	5.11	0.31	6.56e-7	Parental longevity (mother's age at death);
KIRP	trans	rs7710178	0.938	rs11750620	chr5:155969162	A/G	cg23165310	chr3:181422217	SOX2OT	0.74	6.11	0.36	3.8e-9	Airway responsiveness in chronic obstructive pulmonary disease;
KIRP	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg00504896	chr12:9437009	LOC642846	-0.6	-8.06	-0.46	3.27e-14	Breast size;
KIRP	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.3	-0.58	4.15e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.55	8.26	0.47	8.91e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.92	12.51	0.62	4.17e-28	Vitamin D levels;
KIRP	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.89	0.45	9.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg11906718	chr8:101322791	RNF19A	0.49	6.52	0.38	4.01e-10	Atrioventricular conduction;
KIRP	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg16512390	chr1:228756714	NA	0.45	5.03	0.31	9.27e-7	Diastolic blood pressure;
KIRP	cis	rs4950322	0.547	rs6660507	chr1:146620153	T/C	cg22381352	chr1:146742008	CHD1L	-0.38	-5.07	-0.31	7.76e-7	Protein quantitative trait loci;
KIRP	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg00647317	chr7:50633725	DDC	0.56	8.22	0.46	1.19e-14	Systemic sclerosis;
KIRP	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs2151522	0.688	rs9388537	chr6:127198630	A/G	cg21431617	chr6:127135037	NA	0.28	4.92	0.3	1.57e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06627077	chr19:47617100	ZC3H4	0.46	6.29	0.37	1.42e-9	Parkinson's disease;
KIRP	cis	rs9815354	0.812	rs59583650	chr3:41809063	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.32	0.47	6.13e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7623687	0.786	rs34759087	chr3:49162284	C/T	cg19401529	chr3:49056140	DALRD3	0.98	5.48	0.33	1.06e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.29	7.38	0.43	2.42e-12	Crohn's disease;
KIRP	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg08717414	chr16:71523259	ZNF19	-0.46	-5.0	-0.3	1.1e-6	Post bronchodilator FEV1;
KIRP	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	0.87	12.29	0.62	2.22e-27	Homoarginine levels;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02359409	chr6:42947317	PEX6	-0.52	-7.27	-0.42	4.64e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7116495	0.609	rs2276396	chr11:71823905	G/C	cg07596299	chr11:71824057	C11orf51	0.93	5.88	0.35	1.36e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs920590	0.918	rs11777075	chr8:19655666	G/A	cg03894339	chr8:19674705	INTS10	0.53	6.39	0.38	8.26e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	0.95	16.74	0.73	1.62e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.48	-0.48	2.13e-15	Blood metabolite levels;
KIRP	cis	rs1978968	0.869	rs5992931	chr22:18455914	G/A	cg02610425	chr22:18483192	MICAL3	0.37	5.0	0.3	1.1e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.79	9.01	0.5	6.04e-17	High light scatter reticulocyte count;
KIRP	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg13206674	chr6:150067644	NUP43	0.59	8.0	0.45	4.98e-14	Lung cancer;
KIRP	cis	rs2625529	0.730	rs7403191	chr15:72160964	C/T	cg16672083	chr15:72433130	SENP8	-0.47	-6.49	-0.38	4.76e-10	Red blood cell count;
KIRP	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	9.91	0.53	1.04e-19	Coffee consumption (cups per day);
KIRP	cis	rs714027	0.585	rs3958027	chr22:30244835	A/T	cg27665648	chr22:30112403	NA	0.47	6.05	0.36	5.49e-9	Lymphocyte counts;
KIRP	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg10932868	chr11:921992	NA	0.68	9.1	0.5	3.16e-17	Alzheimer's disease (late onset);
KIRP	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg04455712	chr21:45112962	RRP1B	0.51	6.84	0.4	6.27e-11	Mean corpuscular volume;
KIRP	cis	rs729982	1	rs729982	chr22:40810946	T/C	cg07138101	chr22:40742427	ADSL	0.76	6.09	0.36	4.26e-9	Number of common colds;
KIRP	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23281280	chr6:28129359	ZNF389	0.45	4.93	0.3	1.53e-6	Depression;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03074424	chr2:183989067	NUP35	0.44	6.19	0.37	2.55e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg15655495	chr12:38532458	NA	-0.25	-4.84	-0.3	2.26e-6	Heart rate;
KIRP	trans	rs1864585	0.619	rs73209922	chr8:10708509	A/G	cg26278703	chr11:58910052	FAM111A	0.62	6.07	0.36	4.93e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.48	-4.89	-0.3	1.8e-6	Pubertal anthropometrics;
KIRP	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg10932868	chr11:921992	NA	0.58	7.33	0.42	3.21e-12	Alzheimer's disease (late onset);
KIRP	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.79	-9.71	-0.53	4.38e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.66	8.27	0.47	8.72e-15	Red blood cell count;
KIRP	cis	rs9583531	0.660	rs34523940	chr13:111350205	C/T	cg24331049	chr13:111365604	ING1	-0.82	-5.57	-0.33	6.58e-8	Coronary artery disease;
KIRP	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg13482628	chr17:19912719	NA	0.68	10.34	0.55	4.76e-21	Schizophrenia;
KIRP	cis	rs12476592	0.602	rs2592388	chr2:63896096	A/C	cg17519650	chr2:63277830	OTX1	-0.46	-4.89	-0.3	1.79e-6	Childhood ear infection;
KIRP	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg26876637	chr1:152193138	HRNR	0.71	9.4	0.51	3.93e-18	Atopic dermatitis;
KIRP	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.59	7.76	0.44	2.23e-13	Height;
KIRP	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg23625390	chr15:77176239	SCAPER	0.53	7.03	0.41	2.09e-11	Blood metabolite levels;
KIRP	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.58	7.35	0.42	2.99e-12	Cognitive test performance;
KIRP	cis	rs992157	0.932	rs4672884	chr2:219182481	G/A	cg04731861	chr2:219085781	ARPC2	0.23	5.64	0.34	4.78e-8	Colorectal cancer;
KIRP	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.52	7.53	0.43	9.34e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg19592336	chr6:28129416	ZNF389	0.46	5.14	0.31	5.48e-7	Parkinson's disease;
KIRP	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.6	-7.36	-0.43	2.68e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs17023223	0.537	rs12081585	chr1:119615956	A/C	cg05756136	chr1:119680316	WARS2	-0.52	-6.42	-0.38	6.85e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg01620082	chr3:125678407	NA	-1.18	-7.63	-0.44	5.19e-13	Depression;
KIRP	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.62	-0.39	2.21e-10	Mood instability;
KIRP	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg12046867	chr14:103022105	NA	-0.54	-6.87	-0.4	5.29e-11	Platelet count;
KIRP	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg13072238	chr3:49761600	GMPPB	0.57	5.3	0.32	2.61e-7	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00810945	chr16:21964237	UQCRC2	0.53	6.23	0.37	2.03e-9	Smoking initiation;
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg11204139	chr17:3907470	NA	-0.81	-14.58	-0.68	3.97e-35	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07028821	chr7:140773905	NA	0.5	6.72	0.39	1.22e-10	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs661054	0.956	rs11215064	chr11:114446104	G/A	cg19465033	chr11:114479364	NA	0.42	5.66	0.34	4.1e-8	Ulcerative colitis;
KIRP	cis	rs6832769	1.000	rs10002541	chr4:56395011	T/C	cg05960024	chr4:56376020	CLOCK	-0.73	-9.48	-0.52	2.34e-18	Personality dimensions;
KIRP	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.43	-7.0	-0.41	2.37e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.29	-0.32	2.68e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.59	-6.08	-0.36	4.62e-9	Urinary tract infection frequency;
KIRP	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.02	-17.32	-0.74	1.76e-44	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17497419	chr2:24346215	PFN4;LOC375190	0.49	6.45	0.38	5.87e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00166722	chr3:10149974	C3orf24	0.48	4.88	0.3	1.92e-6	Alzheimer's disease;
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg11204139	chr17:3907470	NA	-0.85	-16.47	-0.72	1.37e-41	Type 2 diabetes;
KIRP	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg01872077	chr2:219646372	CYP27A1	0.39	5.08	0.31	7.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22052291	chr13:24153096	TNFRSF19	0.47	6.23	0.37	2.03e-9	Parkinson's disease;
KIRP	cis	rs17539620	0.624	rs62432752	chr6:154841074	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	5.98	0.36	7.62e-9	Lipoprotein (a) levels;
KIRP	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.46	-0.33	1.15e-7	Neutrophil percentage of white cells;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09562240	chr19:44100382	ZNF576;IRGQ	-0.45	-6.06	-0.36	5.12e-9	Metabolic traits;
KIRP	cis	rs35740288	0.770	rs62022867	chr15:86173281	A/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.13e-12	Uric acid levels;
KIRP	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg23752985	chr2:85803571	VAMP8	0.45	5.29	0.32	2.66e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22618164	chr12:122356400	WDR66	0.53	7.07	0.41	1.59e-11	Mean corpuscular volume;
KIRP	trans	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.12	0.41	1.21e-11	Retinal vascular caliber;
KIRP	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.66	-8.24	-0.47	1.03e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9815354	0.767	rs73079350	chr3:41876310	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.87	0.45	1.11e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg25650185	chr19:21324782	ZNF431	0.48	5.19	0.31	4.46e-7	Pain;
KIRP	cis	rs2980439	0.729	rs2955585	chr8:8093511	A/G	cg11608241	chr8:8085544	FLJ10661	0.57	7.11	0.41	1.24e-11	Neuroticism;
KIRP	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.68	5.47	0.33	1.1e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08761248	chr12:56615735	RNF41	0.5	6.25	0.37	1.78e-9	Parkinson's disease;
KIRP	cis	rs9596863	0.898	rs9316655	chr13:54319640	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	5.45	0.33	1.22e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs1035491	0.715	rs10080155	chr5:63926534	G/T	cg01791865	chr5:63954708	NA	0.32	5.02	0.3	9.88e-7	Body mass index;
KIRP	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg25039879	chr17:56429692	SUPT4H1	0.7	6.35	0.38	1.01e-9	Cognitive test performance;
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	-0.47	-5.5	-0.33	9.55e-8	Glycated hemoglobin levels;
KIRP	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.77	9.67	0.52	6e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12586317	0.532	rs2415268	chr14:35638753	C/T	cg07166546	chr14:35805898	NA	-0.28	-6.63	-0.39	2.06e-10	Psoriasis;
KIRP	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg21366198	chr4:185655624	MLF1IP	0.41	5.55	0.33	7.55e-8	Kawasaki disease;
KIRP	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg02570527	chr1:10970165	NA	0.41	5.01	0.3	1.04e-6	Body mass index;
KIRP	cis	rs6684428	0.536	rs4927276	chr1:56396569	G/A	cg11651538	chr1:56320950	NA	0.55	8.09	0.46	2.76e-14	Airflow obstruction;
KIRP	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.03	0.54	4.6e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	0.92	12.02	0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.52	-7.23	-0.42	6.16e-12	Asthma;
KIRP	cis	rs4664293	0.867	rs12692564	chr2:160617837	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs1465370	0.720	rs1558917	chr7:130028723	C/T	cg03229158	chr7:130009420	NA	0.35	5.04	0.31	8.9e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg02336718	chr17:17403227	NA	0.33	5.22	0.32	3.87e-7	Total body bone mineral density;
KIRP	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2131877	0.645	rs903310	chr3:194875944	C/T	cg21937377	chr3:194868750	C3orf21	0.21	5.24	0.32	3.47e-7	Non-small cell lung cancer;
KIRP	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.38	7.61	0.44	5.67e-13	Diastolic blood pressure;
KIRP	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.24	-0.42	5.82e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs4700695	0.925	rs6878011	chr5:65392465	G/A	cg21114390	chr5:65439923	SFRS12	-0.54	-5.31	-0.32	2.49e-7	Facial morphology (factor 19);
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.78	7.49	0.43	1.2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg18882449	chr10:104885122	NT5C2	0.51	6.59	0.39	2.61e-10	Arsenic metabolism;
KIRP	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg27205649	chr11:78285834	NARS2	0.68	9.04	0.5	4.71e-17	Alzheimer's disease (survival time);
KIRP	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.94	-0.35	9.53e-9	Breast cancer;
KIRP	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.83	11.88	0.6	5.09e-26	Monocyte count;
KIRP	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.75	-10.99	-0.57	4.07e-23	Waist circumference;Body mass index;
KIRP	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-6.27	-0.37	1.6e-9	Schizophrenia;
KIRP	cis	rs4953911	0.793	rs13014122	chr2:135050622	G/A	cg18482303	chr2:135041380	MGAT5	0.28	4.89	0.3	1.84e-6	Multiple sclerosis (severity);
KIRP	cis	rs68092024	0.704	rs704575	chr3:99486075	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-4.94	-0.3	1.42e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg12826209	chr6:26865740	GUSBL1	-0.79	-5.37	-0.32	1.84e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.58	7.85	0.45	1.29e-13	Coronary artery disease;
KIRP	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.84	10.86	0.57	1.04e-22	Platelet distribution width;
KIRP	cis	rs16976116	0.901	rs8031949	chr15:55492724	A/G	cg11288833	chr15:55489084	RSL24D1	0.6	6.67	0.39	1.72e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.78	10.35	0.55	4.6e-21	Resting heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03324578	chr3:46887918	NA	0.42	6.2	0.37	2.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7011049	0.915	rs11997706	chr8:53833202	T/G	cg26025543	chr8:53854495	NA	0.7	7.31	0.42	3.64e-12	Systolic blood pressure;
KIRP	cis	rs9309473	0.500	rs4852308	chr2:73834035	T/G	cg20560298	chr2:73613845	ALMS1	0.48	5.88	0.35	1.3e-8	Metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07689503	chr2:74426200	MTHFD2	0.57	7.03	0.41	2.02e-11	Parkinson's disease;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07402062	chr16:89894098	SPIRE2	0.32	6.7	0.39	1.41e-10	Vitiligo;
KIRP	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.94	8.93	0.49	9.85e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.82	-8.27	-0.47	8.38e-15	QRS complex (12-leadsum);
KIRP	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.82e-10	Protein C levels;
KIRP	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg00455402	chr19:21769736	NA	-0.39	-4.98	-0.3	1.21e-6	Pain;
KIRP	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg23594656	chr7:65796392	TPST1	-0.45	-6.89	-0.4	4.73e-11	Aortic root size;
KIRP	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg00800038	chr16:89945340	TCF25	-0.75	-5.26	-0.32	3.08e-7	Skin colour saturation;
KIRP	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg25019033	chr10:957182	NA	-0.64	-7.94	-0.45	7.34e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	6.48	0.38	4.87e-10	Eotaxin levels;
KIRP	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	0.95	12.31	0.62	1.83e-27	Blood protein levels;
KIRP	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.34	18.42	0.76	3.29e-48	Corneal structure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10355708	chr8:145618298	ADCK5	0.57	7.0	0.41	2.35e-11	Interleukin-4 levels;
KIRP	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.23	-0.42	5.9e-12	Type 2 diabetes;
KIRP	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.4e-11	Aortic root size;
KIRP	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	1.02	14.82	0.69	5.98e-36	Menopause (age at onset);
KIRP	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg25173405	chr17:45401733	C17orf57	-0.45	-6.24	-0.37	1.88e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg26248373	chr2:1572462	NA	-0.65	-6.28	-0.37	1.51e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10214930	0.813	rs10486548	chr7:27672695	C/T	cg22168087	chr7:27702803	HIBADH	0.5	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.91	10.99	0.57	4.07e-23	Post bronchodilator FEV1;
KIRP	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg18093559	chr17:18951025	GRAP	0.55	6.77	0.4	9.4e-11	Schizophrenia;
KIRP	trans	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.58	-0.39	2.8e-10	Joint mobility (Beighton score);
KIRP	cis	rs2236918	1.000	rs2526701	chr1:242018427	T/C	cg17736920	chr1:242011382	EXO1	0.71	9.1	0.5	3.17e-17	Menopause (age at onset);
KIRP	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg17470723	chr8:74884337	TCEB1	0.64	8.25	0.47	9.45e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg08648136	chr8:956695	NA	0.45	7.02	0.41	2.12e-11	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14913676	chr19:46234055	FBXO46	0.51	6.68	0.39	1.55e-10	Parkinson's disease;
KIRP	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7010267	0.773	rs4355801	chr8:119923873	A/G	cg01975934	chr8:119970761	NA	0.41	5.26	0.32	3.18e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs7719624	0.756	rs13168506	chr5:135396452	A/G	cg00308130	chr5:135415190	NA	0.32	5.11	0.31	6.58e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.45	-7.34	-0.42	3.13e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg19752551	chr11:57585705	CTNND1	-0.68	-11.44	-0.59	1.41e-24	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg09597638	chr17:3907349	NA	0.45	5.38	0.32	1.74e-7	Type 2 diabetes;
KIRP	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg13939156	chr17:80058883	NA	0.51	5.94	0.35	9.82e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21747090	chr2:27597821	SNX17	-0.44	-6.09	-0.36	4.28e-9	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26207909	chr14:103986467	CKB	0.76	11.78	0.6	1.09e-25	Body mass index;
KIRP	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.91	-0.3	1.66e-6	Pulmonary function;
KIRP	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg05527609	chr1:210001259	C1orf107	-0.48	-5.23	-0.32	3.69e-7	Red blood cell count;
KIRP	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg09491104	chr22:46646882	C22orf40	-0.52	-5.99	-0.36	7.41e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-7.86	-0.45	1.18e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7740706	1	rs7740706	chr6:141022536	T/G	cg24154271	chr6:140957775	NA	0.36	4.94	0.3	1.41e-6	Night sleep phenotypes;
KIRP	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.79	-12.81	-0.63	4.12e-29	Corneal structure;
KIRP	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9880406	0.833	rs938389	chr3:126058762	C/T	cg15490784	chr3:126061950	KLF15	0.5	5.2	0.31	4.28e-7	Macular telangiectasia type 2;
KIRP	cis	rs57561814	0.655	rs58879058	chr7:22741822	T/C	cg01770232	chr7:22766155	IL6	0.69	5.64	0.34	4.61e-8	Tonsillectomy;
KIRP	cis	rs7508	0.573	rs10107663	chr8:17899515	T/G	cg01800426	chr8:17659068	MTUS1	-0.41	-5.08	-0.31	7.61e-7	Atrial fibrillation;
KIRP	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.47	-0.43	1.4e-12	Pulmonary function;
KIRP	cis	rs10859871	0.760	rs11107973	chr12:95702385	T/C	cg07737802	chr12:95537812	FGD6	0.4	5.51	0.33	8.95e-8	Endometriosis;
KIRP	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.82	8.34	0.47	5.19e-15	Methadone dose in opioid dependence;
KIRP	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.53	-7.11	-0.41	1.27e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg11204139	chr17:3907470	NA	-0.81	-14.58	-0.68	3.91e-35	Type 2 diabetes;
KIRP	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.72	-11.22	-0.58	7.29e-24	Prostate cancer;
KIRP	cis	rs73058052	0.597	rs7249925	chr19:50093572	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.56	6.82	0.4	7.17e-11	Fibrinogen levels;
KIRP	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.53	-4.93	-0.3	1.51e-6	Yeast infection;
KIRP	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.52	6.84	0.4	6.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg02030672	chr11:45687055	CHST1	-0.57	-6.99	-0.41	2.51e-11	Obesity-related traits;
KIRP	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.04	-0.46	3.71e-14	Retinal vascular caliber;
KIRP	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.88	12.26	0.62	2.79e-27	Breast cancer;
KIRP	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.46	-5.11	-0.31	6.57e-7	Neuroticism;
KIRP	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	6.13	0.36	3.48e-9	Personality dimensions;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10361659	chr13:51482542	RNASEH2B	0.41	6.04	0.36	5.65e-9	Survival in pancreatic cancer;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg23736307	chr8:27182930	PTK2B	0.54	6.79	0.4	8.56e-11	Neuroticism;
KIRP	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.93	15.31	0.7	1.29e-37	Menopause (age at onset);
KIRP	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg24631222	chr15:78858424	CHRNA5	-0.81	-9.6	-0.52	1e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10045504	0.502	rs17352751	chr5:38737836	G/A	cg15396434	chr5:38725168	NA	-0.95	-9.53	-0.52	1.58e-18	Night sleep phenotypes;
KIRP	cis	rs12044355	0.964	rs12045144	chr1:231844248	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.43	5.25	0.32	3.27e-7	Alzheimer's disease;
KIRP	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.9	-14.96	-0.69	1.95e-36	Urate levels in lean individuals;
KIRP	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.79	-0.35	2.18e-8	Type 2 diabetes;
KIRP	cis	rs17057718	1.000	rs77543785	chr3:57148271	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.36	-4.85	-0.3	2.23e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.94	-15.19	-0.7	3.24e-37	Prudent dietary pattern;
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg11204139	chr17:3907470	NA	0.85	16.24	0.72	8.71e-41	Type 2 diabetes;
KIRP	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.47	0.38	5.27e-10	Major depressive disorder;
KIRP	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg11502198	chr6:26597334	ABT1	-0.43	-5.05	-0.31	8.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg13798912	chr7:905769	UNC84A	-0.7	-7.0	-0.41	2.48e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6594713	0.679	rs71577448	chr5:112768874	C/T	cg12552261	chr5:112820674	MCC	0.6	5.35	0.32	2.04e-7	Brain cytoarchitecture;
KIRP	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.55	7.06	0.41	1.7e-11	Eye color traits;
KIRP	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.89	-0.63	2.12e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg18944383	chr4:111397179	ENPEP	-0.43	-6.97	-0.41	2.96e-11	Coronary artery disease;
KIRP	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.55	-0.43	8.38e-13	Morning vs. evening chronotype;
KIRP	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.66	-8.72	-0.49	4.14e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs2273669	0.588	rs11153151	chr6:109316754	C/G	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs1950626	0.705	rs34991312	chr14:101435167	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.82	0.4	7.2e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	0.8	8.36	0.47	4.66e-15	Pediatric areal bone mineral density (radius);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03811519	chr9:134001305	NUP214	0.5	6.72	0.39	1.23e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2963155	0.518	rs10515522	chr5:142758394	A/G	cg17617527	chr5:142782415	NR3C1	0.69	6.33	0.37	1.17e-9	Breast cancer;
KIRP	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg16141378	chr3:129829833	LOC729375	0.49	6.38	0.38	8.84e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.65	10.27	0.55	7.79e-21	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg21734707	chr17:3908241	ZZEF1	-0.44	-4.96	-0.3	1.31e-6	Type 2 diabetes;
KIRP	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	9.21	0.51	1.44e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.63	0.44	5.31e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg19507638	chr5:93509721	C5orf36	0.54	5.04	0.31	9.15e-7	Diabetic retinopathy;
KIRP	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.7	9.02	0.5	5.63e-17	Bladder cancer;
KIRP	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg07541023	chr7:19748670	TWISTNB	0.65	5.83	0.35	1.69e-8	Thyroid stimulating hormone;
KIRP	cis	rs6064045	0.510	rs462083	chr20:52680021	A/G	cg23682609	chr20:52687365	BCAS1	0.36	5.74	0.34	2.75e-8	IgG glycosylation;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15791105	chr12:48367161	COL2A1	0.48	6.07	0.36	4.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg03585969	chr10:35415529	CREM	0.78	9.51	0.52	1.88e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13939156	chr17:80058883	NA	0.49	7.26	0.42	5.2e-12	Life satisfaction;
KIRP	cis	rs1832871	0.672	rs9456286	chr6:158734315	A/G	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.82	12.2	0.61	4.38e-27	IgG glycosylation;
KIRP	cis	rs17818399	0.815	rs17768132	chr2:46863249	G/T	cg06386533	chr2:46925753	SOCS5	-0.49	-4.98	-0.3	1.21e-6	Height;
KIRP	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-7.82	-0.45	1.52e-13	Bipolar disorder;
KIRP	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg14675211	chr2:100938903	LONRF2	0.48	6.71	0.39	1.3e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.67	-5.04	-0.31	9.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs812925	0.519	rs1186696	chr2:61660483	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-5.64	-0.34	4.63e-8	Immature fraction of reticulocytes;
KIRP	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	10.49	0.56	1.59e-21	Lung cancer in ever smokers;
KIRP	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.52	-6.63	-0.39	2.17e-10	Prudent dietary pattern;
KIRP	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.2	0.42	7.27e-12	Aortic root size;
KIRP	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg17145862	chr1:211918768	LPGAT1	0.62	6.9	0.4	4.27e-11	Crohn's disease;
KIRP	cis	rs7714584	1.000	rs61530785	chr5:150261364	A/G	cg22134413	chr5:150180641	NA	0.78	6.35	0.38	1.05e-9	Crohn's disease;
KIRP	cis	rs7404928	0.645	rs67922443	chr16:23929583	G/A	cg21745164	chr16:23765304	CHP2	-0.57	-6.24	-0.37	1.91e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs4713675	0.584	rs6938056	chr6:33669577	C/T	cg15676125	chr6:33679581	C6orf125	0.41	5.41	0.33	1.5e-7	Plateletcrit;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.94	0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.21	0.51	1.49e-17	Lymphocyte counts;
KIRP	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.6	6.8	0.4	7.67e-11	Cocaine dependence;
KIRP	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg19567339	chr10:100142640	NA	0.44	4.91	0.3	1.66e-6	Metabolite levels;
KIRP	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg26811252	chr16:29126840	RRN3P2	0.64	8.46	0.47	2.47e-15	Menopause (age at onset);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08749122	chr1:150459996	TARS2	0.55	6.13	0.36	3.57e-9	Lung cancer in ever smokers;
KIRP	cis	rs6563210	0.789	rs9545656	chr13:36474137	C/T	cg19801062	chr13:36872135	C13orf38	-0.48	-5.11	-0.31	6.33e-7	Height;
KIRP	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.35	-0.32	2.04e-7	Colorectal cancer;
KIRP	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg18190219	chr22:46762943	CELSR1	-0.76	-7.26	-0.42	5.16e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.51	6.35	0.38	1.04e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.27	-0.32	2.95e-7	Pulmonary function;
KIRP	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.76	-11.1	-0.58	1.73e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg05692746	chr2:100937584	LONRF2	0.39	4.9	0.3	1.72e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.64	-8.33	-0.47	5.54e-15	Age at first birth;
KIRP	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-5.98	-0.36	7.95e-9	Personality dimensions;
KIRP	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.84	-0.35	1.66e-8	Breast cancer;
KIRP	cis	rs9398803	0.865	rs9375441	chr6:126778600	G/A	cg19875578	chr6:126661172	C6orf173	0.51	6.63	0.39	2.1e-10	Male-pattern baldness;
KIRP	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.46	-6.92	-0.4	3.8e-11	Coronary artery disease;
KIRP	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.42	6.15	0.37	3.05e-9	Lipoprotein (a) levels;
KIRP	cis	rs77956314	0.901	rs12310299	chr12:117335487	C/G	cg02017074	chr12:117425053	FBXW8	-0.54	-4.88	-0.3	1.93e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.71	-7.79	-0.44	1.93e-13	Menarche (age at onset);
KIRP	cis	rs7770628	0.682	rs2144723	chr6:161121390	A/G	cg14663533	chr6:160955178	LPA	-0.47	-6.52	-0.38	3.95e-10	Protein quantitative trait loci;Lipoprotein (a) levels;
KIRP	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.63	6.57	0.39	2.94e-10	Gut microbiome composition (summer);
KIRP	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.57	-0.33	6.74e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg08662619	chr6:150070041	PCMT1	0.39	6.58	0.39	2.87e-10	Lung cancer;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15631343	chr1:8090712	NA	0.56	6.4	0.38	7.58e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg14416269	chr4:6271139	WFS1	0.33	4.9	0.3	1.77e-6	Cisplatin-induced ototoxicity;
KIRP	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.7	7.42	0.43	1.87e-12	Initial pursuit acceleration;
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22168489	chr12:122356033	WDR66	-0.63	-9.68	-0.53	5.46e-19	Mean corpuscular volume;
KIRP	cis	rs7766436	0.885	rs4712699	chr6:22592884	C/A	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.58	6.42	0.38	7.16e-10	Alcohol dependence;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.87	-0.6	5.24e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08280861	chr8:58055591	NA	0.74	6.07	0.36	4.86e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.81	-0.4	7.44e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg24531977	chr5:56204891	C5orf35	-0.39	-5.04	-0.31	9.13e-7	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.84	-10.39	-0.55	3.26e-21	Menarche (age at onset);
KIRP	cis	rs7680126	0.644	rs62288518	chr4:10087464	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-4.92	-0.3	1.56e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.12	-0.46	2.22e-14	Mood instability;
KIRP	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.53	7.35	0.42	2.93e-12	Kawasaki disease;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs6987853	0.787	rs2923436	chr8:42425298	G/A	cg09913449	chr8:42400586	C8orf40	0.4	5.37	0.32	1.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg17724175	chr1:150552817	MCL1	0.33	5.52	0.33	8.7e-8	Melanoma;
KIRP	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.76	-0.63	5.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs883565	0.528	rs4428122	chr3:38972603	C/A	cg01426195	chr3:39028469	NA	0.56	8.95	0.5	8.69e-17	Handedness;
KIRP	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg04374321	chr14:90722782	PSMC1	-0.83	-11.85	-0.6	6.35e-26	Mortality in heart failure;
KIRP	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg04034577	chr2:241836375	C2orf54	-0.29	-5.48	-0.33	1.03e-7	Urinary metabolites;
KIRP	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-6.92	-0.4	3.85e-11	Blood metabolite levels;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.35	-0.32	2.02e-7	Life satisfaction;
KIRP	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg18357526	chr6:26021779	HIST1H4A	0.47	5.69	0.34	3.57e-8	Blood metabolite levels;
KIRP	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	9.39	0.51	4.38e-18	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	1.05	13.54	0.65	1.4e-31	Exhaled nitric oxide output;
KIRP	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg02931644	chr1:25747376	RHCE	0.37	6.57	0.39	2.92e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs2152924	0.539	rs1765756	chr1:110007652	G/A	cg02175308	chr1:109941060	SORT1	-0.33	-5.14	-0.31	5.72e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.61	-0.34	5.3e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-0.62	-6.92	-0.4	3.91e-11	Initial pursuit acceleration;
KIRP	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg11608241	chr8:8085544	FLJ10661	-0.46	-5.39	-0.32	1.69e-7	Recombination measurement;
KIRP	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.42	-5.78	-0.35	2.21e-8	Total body bone mineral density;
KIRP	cis	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg27411982	chr8:10470053	RP1L1	0.41	4.96	0.3	1.31e-6	Neuroticism;
KIRP	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs367943	0.712	rs9326887	chr5:112728581	T/A	cg12552261	chr5:112820674	MCC	0.58	6.88	0.4	4.98e-11	Type 2 diabetes;
KIRP	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.04	16.2	0.72	1.15e-40	Subjective well-being;
KIRP	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	11.17	0.58	1.03e-23	Monocyte percentage of white cells;
KIRP	cis	rs858239	0.539	rs4504540	chr7:23186198	C/G	cg23682824	chr7:23144976	KLHL7	0.53	6.21	0.37	2.22e-9	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.6	8.22	0.46	1.18e-14	Triglycerides;
KIRP	cis	rs4702718	0.748	rs2918398	chr5:10693896	G/A	cg14521931	chr5:10832172	NA	0.41	5.28	0.32	2.9e-7	Obesity-related traits;
KIRP	cis	rs7542091	0.704	rs1883331	chr1:210043483	A/G	cg05527609	chr1:210001259	C1orf107	-0.37	-4.95	-0.3	1.41e-6	Monobrow;
KIRP	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.58	-0.39	2.75e-10	Menopause (age at onset);
KIRP	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.8	6.82	0.4	7.16e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg14851346	chr12:38532713	NA	-0.39	-4.85	-0.3	2.22e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10083777	0.551	rs79378252	chr16:81048159	T/A	cg08591886	chr16:81111003	C16orf46	-0.71	-5.22	-0.32	3.88e-7	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs7615316	0.836	rs6768093	chr3:142298200	A/T	cg20824294	chr3:142316082	PLS1	0.22	4.97	0.3	1.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs3789045	1.000	rs61817485	chr1:204595592	G/A	cg08641003	chr1:204589008	LRRN2	-0.52	-6.69	-0.39	1.54e-10	Educational attainment (college completion);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00557709	chr1:82268801	LPHN2	-0.46	-6.31	-0.37	1.32e-9	Survival in pancreatic cancer;
KIRP	cis	rs7584330	0.504	rs6712927	chr2:238427808	G/A	cg14458575	chr2:238380390	NA	0.51	6.13	0.36	3.4e-9	Prostate cancer;
KIRP	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.13	-0.5	2.54e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18122200	chr1:230203994	GALNT2	0.49	6.32	0.37	1.23e-9	Parkinson's disease;
KIRP	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg17507749	chr15:85114479	UBE2QP1	0.83	9.29	0.51	8.28e-18	Schizophrenia;
KIRP	cis	rs10814247	0.592	rs10972496	chr9:35496478	A/C	cg15271616	chr9:35490515	RUSC2	0.45	5.59	0.34	6.12e-8	Psoriasis;
KIRP	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.66	-8.4	-0.47	3.5e-15	Menopause (age at onset);
KIRP	cis	rs5753618	0.509	rs5749224	chr22:31558549	C/T	cg22777020	chr22:31556080	RNF185	-0.47	-4.91	-0.3	1.63e-6	Colorectal cancer;
KIRP	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg18882449	chr10:104885122	NT5C2	-0.5	-6.37	-0.38	9.23e-10	Arsenic metabolism;
KIRP	cis	rs2172802	0.693	rs10025823	chr4:62487743	T/C	cg04118610	chr4:62707027	LPHN3	-0.51	-5.97	-0.36	8.43e-9	Partial epilepsies;
KIRP	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg14440974	chr22:39074834	NA	-0.38	-4.95	-0.3	1.4e-6	Menopause (age at onset);
KIRP	cis	rs11169552	0.510	rs4768892	chr12:50960308	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-4.91	-0.3	1.66e-6	Colorectal cancer;
KIRP	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg27633287	chr12:130766243	NA	-0.39	-4.92	-0.3	1.58e-6	Menopause (age at onset);
KIRP	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.61	8.77	0.49	3.09e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg05347473	chr6:146136440	FBXO30	0.51	7.02	0.41	2.21e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.48	6.05	0.36	5.46e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.13	-0.36	3.56e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg08662619	chr6:150070041	PCMT1	0.36	5.72	0.34	3.03e-8	Lung cancer;
KIRP	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.41e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7084402	0.967	rs1649038	chr10:60330439	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.52	-6.32	-0.37	1.2e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.79	14.8	0.69	7.32e-36	Lymphocyte counts;
KIRP	cis	rs375066	0.592	rs10401203	chr19:44299666	C/T	cg11993925	chr19:44307056	LYPD5	-0.36	-5.0	-0.3	1.09e-6	Breast cancer;
KIRP	cis	rs12153243	1.000	rs12153243	chr5:142899801	A/T	cg13907255	chr5:142895549	NA	-0.38	-5.09	-0.31	7.04e-7	Migraine;
KIRP	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg26207909	chr14:103986467	CKB	0.44	5.28	0.32	2.86e-7	Coronary artery disease;
KIRP	cis	rs7404928	1.000	rs2023669	chr16:23905013	A/G	cg21745164	chr16:23765304	CHP2	-0.36	-5.16	-0.31	4.99e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg17652424	chr22:38574118	PLA2G6	-0.25	-5.04	-0.31	9.19e-7	Cutaneous nevi;
KIRP	cis	rs9816226	0.591	rs74607912	chr3:185818559	G/A	cg00760338	chr3:185826511	ETV5	-0.79	-6.83	-0.4	6.64e-11	Obesity;Body mass index;
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.69	0.34	3.64e-8	Lung cancer;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.39	-5.18	-0.31	4.69e-7	Renal function-related traits (BUN);
KIRP	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg01403660	chr11:68851641	TPCN2	0.68	6.64	0.39	2.02e-10	Blond vs. brown hair color;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07402800	chr8:145582003	FBXL6;GPR172A	-0.47	-6.24	-0.37	1.85e-9	Bladder cancer;
KIRP	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05776053	chr2:74358815	NA	0.52	5.44	0.33	1.27e-7	Gestational age at birth (maternal effect);
KIRP	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11987759	chr7:65425863	GUSB	0.44	5.28	0.32	2.85e-7	Aortic root size;
KIRP	cis	rs9581857	0.547	rs74518675	chr13:27972180	A/G	cg22138327	chr13:27999177	GTF3A	1.0	7.3	0.42	4e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.01	0.69	1.39e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.53	6.45	0.38	5.92e-10	Lymphocyte counts;
KIRP	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.51	6.39	0.38	8.14e-10	Alzheimer's disease (late onset);
KIRP	cis	rs17739794	0.517	rs34109064	chr8:772796	T/C	cg11667643	chr8:748456	NA	-0.43	-5.47	-0.33	1.1e-7	Clozapine-induced cytotoxicity;
KIRP	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.14	-0.46	1.96e-14	Acne (severe);
KIRP	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg26811252	chr16:29126840	RRN3P2	-0.66	-9.11	-0.5	2.88e-17	Menopause (age at onset);
KIRP	cis	rs981844	1.000	rs10517579	chr4:154666321	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs526231	0.697	rs253759	chr5:102615675	G/A	cg23492399	chr5:102201601	PAM	-0.5	-4.93	-0.3	1.55e-6	Primary biliary cholangitis;
KIRP	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg25036284	chr2:26402008	FAM59B	0.55	5.46	0.33	1.15e-7	Gut microbiome composition (summer);
KIRP	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg14541582	chr5:601475	NA	-0.55	-6.22	-0.37	2.12e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.51	5.09	0.31	7.12e-7	Alzheimer's disease;
KIRP	cis	rs4148660	1.000	rs4148657	chr12:22062348	A/T	cg14669847	chr12:22099120	NA	0.35	5.98	0.36	7.7e-9	Gout;
KIRP	cis	rs12210905	1.000	rs12209393	chr6:27085073	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs6504622	0.557	rs10853085	chr17:44995070	G/A	cg16759221	chr17:45003025	GOSR2	0.35	5.25	0.32	3.36e-7	Orofacial clefts;
KIRP	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.26	-0.42	5.05e-12	Body mass index;
KIRP	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg10760299	chr15:45669010	GATM	0.34	5.09	0.31	7.02e-7	Homoarginine levels;
KIRP	cis	rs6466055	0.661	rs67154126	chr7:104934281	A/G	cg04380332	chr7:105027541	SRPK2	0.37	5.03	0.31	9.53e-7	Schizophrenia;
KIRP	cis	rs74181299	0.855	rs2723066	chr2:65279321	T/G	cg05010058	chr2:65284262	CEP68	0.43	5.88	0.35	1.3e-8	Pulse pressure;
KIRP	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05347473	chr6:146136440	FBXO30	0.57	8.12	0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7614311	0.681	rs3774708	chr3:63881549	A/C	cg22134162	chr3:63841271	THOC7	-0.44	-5.55	-0.33	7.47e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.88	13.75	0.66	2.63e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	9.14	0.5	2.33e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.4	0.38	7.88e-10	Bipolar disorder;
KIRP	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.38	5.02	0.31	9.74e-7	Type 2 diabetes;
KIRP	trans	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg00938859	chr5:1591904	SDHAP3	0.55	6.38	0.38	8.81e-10	Breast cancer;
KIRP	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.59	-9.65	-0.52	6.76e-19	Total body bone mineral density;
KIRP	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg18904891	chr8:8559673	CLDN23	0.71	7.94	0.45	7.4e-14	Obesity-related traits;
KIRP	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg07308232	chr7:1071921	C7orf50	-0.54	-6.68	-0.39	1.61e-10	Longevity;Endometriosis;
KIRP	cis	rs684232	0.522	rs11247555	chr17:517419	G/A	cg15660573	chr17:549704	VPS53	0.43	4.89	0.3	1.84e-6	Prostate cancer;
KIRP	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.56	-6.65	-0.39	1.89e-10	Aortic root size;
KIRP	cis	rs17092148	1.000	rs6060017	chr20:33313042	G/T	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.6	-0.34	5.78e-8	Neuroticism;
KIRP	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs5747327	0.874	rs3788279	chr22:18200386	G/A	cg19898043	chr22:18121309	BCL2L13	-0.43	-5.43	-0.33	1.33e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg07395648	chr5:131743802	NA	-0.56	-7.83	-0.45	1.42e-13	Breast cancer;
KIRP	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.81	11.47	0.59	1.11e-24	Schizophrenia;
KIRP	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.5	-6.11	-0.36	3.93e-9	Iron status biomarkers;
KIRP	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg12661370	chr5:149340060	SLC26A2	0.45	5.54	0.33	7.82e-8	HIV-1 control;
KIRP	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.74	-9.67	-0.52	5.74e-19	Childhood ear infection;
KIRP	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.44	-5.19	-0.31	4.4e-7	Neuroticism;
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg26134248	chr17:3907702	NA	0.55	8.18	0.46	1.49e-14	Type 2 diabetes;
KIRP	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.82	-0.35	1.83e-8	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.569	rs12942513	chr17:4016721	C/A	cg11204139	chr17:3907470	NA	0.54	4.92	0.3	1.61e-6	Type 2 diabetes;
KIRP	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.75	-0.53	3.34e-19	Response to antipsychotic treatment;
KIRP	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg26116260	chr4:7069785	GRPEL1	-1.16	-7.06	-0.41	1.65e-11	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-1.16	-10.77	-0.57	2.07e-22	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13064457	chr3:142315224	PLS1	0.53	6.74	0.39	1.11e-10	Parkinson's disease;
KIRP	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11316940	chr10:69524027	NA	0.92	6.18	0.37	2.59e-9	P wave terminal force;
KIRP	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg23791538	chr6:167370224	RNASET2	0.45	5.43	0.33	1.33e-7	Primary biliary cholangitis;
KIRP	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs11955175	1.000	rs11955175	chr5:40626753	C/T	cg05478818	chr5:40835740	RPL37	-0.7	-5.58	-0.33	6.47e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg12658694	chr1:38397304	INPP5B	0.64	8.3	0.47	7.04e-15	Coronary artery disease;
KIRP	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	13.57	0.65	1.12e-31	Platelet count;
KIRP	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	5.52	0.33	8.45e-8	Bipolar disorder;
KIRP	cis	rs16973500	0.711	rs2878491	chr16:71981218	T/G	cg00732059	chr16:71740210	PHLPP2	-0.6	-5.58	-0.34	6.41e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.0	0.69	1.45e-36	Platelet count;
KIRP	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Bladder cancer;
KIRP	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.49	-0.48	2.03e-15	Coronary artery disease;
KIRP	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.91	-0.45	8.73e-14	Neuroticism;
KIRP	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg25019722	chr6:37503610	NA	-1.01	-16.4	-0.72	2.33e-41	Cognitive performance;
KIRP	trans	rs9534288	0.797	rs2404729	chr13:46617368	C/T	cg15268200	chr15:90904599	ZNF774	-0.41	-6.34	-0.37	1.11e-9	Blood protein levels;
KIRP	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.79	-11.81	-0.6	8.31e-26	Hip circumference;
KIRP	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-1.05	-14.44	-0.68	1.2e-34	Platelet distribution width;
KIRP	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.88	-0.3	1.88e-6	Longevity;
KIRP	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg11833968	chr6:79620685	NA	0.45	7.05	0.41	1.81e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.19	0.31	4.34e-7	Smoking behavior;
KIRP	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.75	7.2	0.42	7.32e-12	Mean platelet volume;
KIRP	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.04	-0.41	1.94e-11	Alzheimer's disease;
KIRP	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.64	-6.23	-0.37	2.06e-9	Menarche (age at onset);
KIRP	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg27165867	chr14:105738592	BRF1	0.4	4.92	0.3	1.61e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2398893	0.960	rs7849645	chr9:96744232	A/T	cg14459158	chr9:96720562	NA	0.29	5.09	0.31	7.24e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs220324	0.683	rs468947	chr21:43589930	C/T	cg08841829	chr21:43638893	ABCG1	0.45	5.2	0.31	4.18e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs11874712	1.000	rs11082510	chr18:43656620	T/A	cg26436583	chr18:43649176	PSTPIP2	-0.4	-5.68	-0.34	3.76e-8	Migraine - clinic-based;
KIRP	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-0.84	-9.41	-0.51	3.71e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-7.0	-0.41	2.36e-11	Monocyte percentage of white cells;
KIRP	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg04111992	chr7:158790115	NA	-0.41	-4.91	-0.3	1.64e-6	Facial morphology (factor 20);
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg07414643	chr4:187882934	NA	0.4	5.37	0.32	1.8e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7246760	1.000	rs10425775	chr19:9912917	G/A	cg02900749	chr2:68251473	NA	-0.89	-8.03	-0.46	4.03e-14	Pursuit maintenance gain;
KIRP	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg13263691	chr18:77568018	NA	0.51	6.81	0.4	7.47e-11	Schizophrenia;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg26513180	chr16:89883248	FANCA	0.88	14.78	0.69	8.4e-36	Vitiligo;
KIRP	cis	rs1832871	0.619	rs262826	chr6:158680567	C/T	cg07215822	chr6:158701037	NA	-0.6	-8.88	-0.49	1.43e-16	Height;
KIRP	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg01689657	chr7:91764605	CYP51A1	-0.42	-6.05	-0.36	5.45e-9	Breast cancer;
KIRP	cis	rs7537052	0.669	rs4652903	chr1:36642858	C/T	cg24686825	chr1:36642396	MAP7D1	-0.72	-9.59	-0.52	1.06e-18	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.69	-0.63	9.74e-29	Headache;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg21858823	chr1:15850916	CASP9	0.53	5.66	0.34	4.11e-8	Systolic blood pressure;
KIRP	trans	rs4362360	0.647	rs4482250	chr15:86972609	C/T	cg05694164	chr1:226496911	LIN9	-0.49	-6.19	-0.37	2.45e-9	Neuroticism;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg15117754	chr3:10150083	C3orf24	0.54	5.15	0.31	5.25e-7	Alzheimer's disease;
KIRP	cis	rs9473924	0.657	rs9473945	chr6:50890575	T/G	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.8	0.45	1.72e-13	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-4.91	-0.3	1.65e-6	Lung cancer;
KIRP	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg02487422	chr3:49467188	NICN1	-0.41	-5.43	-0.33	1.33e-7	Resting heart rate;
KIRP	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg10397082	chr2:1609832	NA	0.57	5.16	0.31	5.13e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg11845111	chr2:191398756	TMEM194B	0.94	10.25	0.55	9.37e-21	Diastolic blood pressure;
KIRP	trans	rs1620921	0.840	rs783177	chr6:161169815	C/T	cg01090089	chr7:6570974	GRID2IP	0.38	6.04	0.36	5.77e-9	Lipoprotein (a) - cholesterol levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06745235	chr1:180471494	ACBD6	0.51	6.07	0.36	4.82e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg09075522	chr1:92031145	NA	-0.41	-5.04	-0.31	9.15e-7	Breast cancer;
KIRP	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg02151108	chr14:50098012	C14orf104	-0.6	-8.36	-0.47	4.66e-15	Carotid intima media thickness;
KIRP	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg05347473	chr6:146136440	FBXO30	-0.57	-8.04	-0.46	3.74e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.14	-0.36	3.27e-9	Obesity-related traits;
KIRP	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.81	0.66	1.62e-32	Alzheimer's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12089204	chr11:1318605	TOLLIP	0.46	6.38	0.38	8.56e-10	Survival in pancreatic cancer;
KIRP	cis	rs9654415	0.536	rs10070847	chr5:72532422	C/G	cg14879418	chr5:72571312	NA	-0.46	-5.53	-0.33	8.23e-8	Eyebrow thickness;
KIRP	cis	rs9393777	0.668	rs16897515	chr6:27278020	A/C	cg12292205	chr6:26970375	C6orf41	0.49	5.26	0.32	3.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg06671706	chr8:8559999	CLDN23	0.52	6.07	0.36	4.72e-9	Obesity-related traits;
KIRP	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.63	-6.95	-0.41	3.27e-11	DNA methylation (variation);
KIRP	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.6	7.83	0.45	1.43e-13	Schizophrenia;
KIRP	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.79	-0.49	2.62e-16	Monocyte percentage of white cells;
KIRP	cis	rs7808935	0.628	rs9791862	chr7:27950760	G/A	cg05786569	chr7:27702416	HIBADH	0.51	4.98	0.3	1.19e-6	Prostate cancer;
KIRP	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg07382826	chr16:28625726	SULT1A1	-0.48	-5.6	-0.34	5.78e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs4262150	0.764	rs4478308	chr5:151936869	A/G	cg12297329	chr5:152029980	NA	-0.61	-7.62	-0.44	5.41e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg09491104	chr22:46646882	C22orf40	-0.58	-6.57	-0.39	2.99e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.65	7.98	0.45	5.64e-14	Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07871636	chr19:14017192	CC2D1A;C19orf57	0.51	6.75	0.4	1.05e-10	Parkinson's disease;
KIRP	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.5	-0.38	4.32e-10	Monocyte percentage of white cells;
KIRP	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg04310649	chr10:35416472	CREM	-0.59	-7.06	-0.41	1.66e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2916247	1.000	rs6987763	chr8:93028518	G/C	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.94	-0.45	7.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.59	7.44	0.43	1.73e-12	Tonsillectomy;
KIRP	cis	rs4561483	0.583	rs1029285	chr16:11987118	G/A	cg08843971	chr16:11963173	GSPT1	0.54	7.57	0.43	7.61e-13	Testicular germ cell tumor;
KIRP	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.58	-6.09	-0.36	4.26e-9	Obesity-related traits;
KIRP	cis	rs10875746	0.669	rs17122812	chr12:48597053	A/G	cg26205652	chr12:48591994	NA	0.81	10.73	0.56	2.7e-22	Longevity (90 years and older);
KIRP	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.58	-9.46	-0.52	2.59e-18	Prostate cancer;
KIRP	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg01304814	chr3:48885189	PRKAR2A	0.52	4.85	0.3	2.15e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg18367735	chr17:79674897	NA	0.75	6.81	0.4	7.56e-11	Dental caries;
KIRP	cis	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs12190007	1.000	rs12193198	chr6:169734411	G/A	cg15038512	chr6:170123185	PHF10	-0.41	-5.84	-0.35	1.68e-8	Obesity-related traits;
KIRP	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg22963979	chr7:1858916	MAD1L1	0.44	5.34	0.32	2.08e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4789452	0.967	rs7217986	chr17:75369578	T/C	cg12985929	chr17:75370611	SEPT9	-0.37	-5.19	-0.31	4.34e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7999699	0.902	rs12429882	chr13:48322475	T/C	cg23237801	chr1:16476620	EPHA2	0.52	6.56	0.39	3.19e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg05562828	chr17:3906858	NA	0.49	6.59	0.39	2.6e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2150410	0.831	rs1541100	chr21:40641052	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg16497277	chr3:49208875	KLHDC8B	-0.46	-6.0	-0.36	7.04e-9	Menarche (age at onset);
KIRP	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg03465714	chr1:152285911	FLG	-0.44	-5.28	-0.32	2.81e-7	Atopic dermatitis;
KIRP	cis	rs2415984	0.622	rs1955262	chr14:46940639	A/G	cg14871534	chr14:47121158	RPL10L	-0.45	-5.37	-0.32	1.85e-7	Number of children ever born;
KIRP	cis	rs7481311	0.956	rs7127239	chr11:27547379	A/C	cg18117895	chr11:27722066	BDNF	0.47	5.18	0.31	4.55e-7	Body mass index;Weight;
KIRP	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg11635098	chr7:100497156	NA	-0.68	-7.3	-0.42	3.92e-12	Resting heart rate;
KIRP	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00149659	chr3:10157352	C3orf10	0.83	9.02	0.5	5.55e-17	Alzheimer's disease;
KIRP	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg24807547	chr6:37504484	NA	-0.59	-9.09	-0.5	3.43e-17	Cognitive performance;
KIRP	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.02	0.3	9.97e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg18225595	chr11:63971243	STIP1	0.62	5.64	0.34	4.75e-8	Mean platelet volume;
KIRP	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg23815491	chr16:72088622	HP	-0.36	-5.9	-0.35	1.22e-8	Prostate cancer;
KIRP	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06544989	chr22:39130855	UNC84B	0.5	8.99	0.5	6.76e-17	Menopause (age at onset);
KIRP	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	trans	rs12449568	0.839	rs7222986	chr17:54406369	A/C	cg04456437	chr3:119217424	C3orf1	0.48	6.13	0.36	3.49e-9	Height;
KIRP	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.66	0.39	1.81e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.54	7.23	0.42	6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg19847130	chr8:10466454	RP1L1	-0.36	-5.23	-0.32	3.55e-7	Retinal vascular caliber;
KIRP	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	7.04	0.41	1.86e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg21919602	chr1:242011447	EXO1	-0.47	-5.98	-0.36	7.87e-9	Menopause (age at onset);
KIRP	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-9.39	-0.51	4.36e-18	Hemoglobin concentration;
KIRP	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg15448220	chr1:150897856	SETDB1	-0.39	-5.04	-0.31	8.88e-7	Tonsillectomy;
KIRP	cis	rs2151522	0.563	rs1105956	chr6:127146879	A/G	cg21431617	chr6:127135037	NA	-0.31	-5.52	-0.33	8.61e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.67	-7.86	-0.45	1.24e-13	Menopause (age at onset);
KIRP	cis	rs8067287	0.762	rs11651352	chr17:16824909	A/G	cg26910001	chr17:16838321	NA	0.57	5.73	0.34	2.86e-8	Diabetic kidney disease;
KIRP	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg24315340	chr6:146058215	EPM2A	0.42	5.04	0.31	8.93e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg13047869	chr3:10149882	C3orf24	0.57	5.23	0.32	3.55e-7	Alzheimer's disease;
KIRP	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg08501292	chr6:25962987	TRIM38	0.91	6.48	0.38	5.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg02462569	chr6:150064036	NUP43	-0.42	-6.37	-0.38	9e-10	Lung cancer;
KIRP	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.09	-8.5	-0.48	1.91e-15	Mitochondrial DNA levels;
KIRP	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.86	-12.29	-0.62	2.2e-27	Coronary artery disease;
KIRP	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg17401720	chr7:158221031	PTPRN2	0.35	5.41	0.33	1.51e-7	Obesity-related traits;
KIRP	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.84	11.29	0.58	4.29e-24	Morning vs. evening chronotype;
KIRP	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg10381502	chr11:71823885	C11orf51	1.19	7.76	0.44	2.34e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs7582180	1.000	rs4851286	chr2:100915629	T/C	cg21926883	chr2:100939477	LONRF2	-0.41	-4.89	-0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs62413470	1.000	rs62404863	chr6:55943202	T/C	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.71e-31	Diabetic retinopathy;
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg12486944	chr17:80159399	CCDC57	-0.41	-5.54	-0.33	7.74e-8	Life satisfaction;
KIRP	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs1476679	1.000	rs1476679	chr7:100004446	C/T	cg19116668	chr7:99932089	PMS2L1	-0.77	-9.58	-0.52	1.12e-18	Alzheimer's disease (late onset);
KIRP	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg02569458	chr12:86230093	RASSF9	0.54	7.99	0.45	5.38e-14	Major depressive disorder;
KIRP	cis	rs600806	0.778	rs4970761	chr1:109995398	C/T	cg02175308	chr1:109941060	SORT1	-0.29	-5.68	-0.34	3.7e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg15469184	chr8:337539	NA	0.62	7.05	0.41	1.79e-11	Obesity-related traits;
KIRP	cis	rs7221595	0.825	rs12601931	chr17:3986097	T/C	cg09695851	chr17:3907499	NA	0.6	5.78	0.35	2.22e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7221595	0.825	rs8078629	chr17:3983964	A/C	cg11204139	chr17:3907470	NA	0.58	5.78	0.35	2.24e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg15269541	chr15:43626905	ADAL	-0.39	-4.89	-0.3	1.85e-6	Lung cancer in ever smokers;
KIRP	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.56	12.27	0.62	2.62e-27	Diabetic kidney disease;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg02696790	chr15:75250997	RPP25	0.32	5.59	0.34	6.01e-8	Breast cancer;
KIRP	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.21	0.55	1.22e-20	Dupuytren's disease;
KIRP	cis	rs10463316	0.894	rs6579860	chr5:150752338	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-7.03	-0.41	2.07e-11	Metabolite levels (Pyroglutamine);
KIRP	trans	rs9944715	0.954	rs9675387	chr18:43798023	G/A	cg01718231	chr17:29326311	RNF135	-0.5	-6.04	-0.36	5.53e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg06307176	chr5:131281290	NA	-0.55	-5.99	-0.36	7.44e-9	Life satisfaction;
KIRP	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg07395648	chr5:131743802	NA	0.57	7.85	0.45	1.24e-13	Breast cancer;
KIRP	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.56	7.57	0.43	7.57e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12893428	chr3:195717962	SDHAP1	0.43	5.23	0.32	3.64e-7	Pancreatic cancer;
KIRP	cis	rs73195822	0.506	rs61440260	chr12:111142855	G/T	cg12870014	chr12:110450643	ANKRD13A	0.5	4.92	0.3	1.58e-6	Itch intensity from mosquito bite;
KIRP	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.79	10.54	0.56	1.12e-21	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg06521331	chr12:34319734	NA	-0.44	-5.28	-0.32	2.88e-7	Morning vs. evening chronotype;
KIRP	cis	rs10958369	0.541	rs1477956	chr8:54435227	T/G	cg12485204	chr8:54507357	NA	0.42	5.38	0.32	1.75e-7	Response to antineoplastic agents;
KIRP	cis	rs4683142	0.518	rs4682801	chr3:46021218	G/T	cg18004856	chr3:46029278	FYCO1	0.5	6.79	0.4	8.12e-11	Methadone dose in opioid dependence;
KIRP	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg11196788	chr11:71737549	NUMA1	0.55	4.88	0.3	1.94e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.79	10.35	0.55	4.44e-21	Gut microbiota (bacterial taxa);
KIRP	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.87	-0.4	5.38e-11	Daytime sleep phenotypes;
KIRP	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.95e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.22	-0.37	2.09e-9	Neuroticism;
KIRP	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg12501888	chr15:85177176	SCAND2	-0.42	-5.35	-0.32	2e-7	P wave terminal force;
KIRP	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13754255	chr15:65426202	PDCD7	0.44	6.2	0.37	2.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.4	0.33	1.59e-7	Lung cancer;
KIRP	cis	rs357618	1.000	rs357628	chr5:150850352	A/G	cg22672639	chr5:150884813	FAT2	0.35	5.35	0.32	1.98e-7	Basophil percentage of white cells;
KIRP	cis	rs4148660	1.000	rs7136887	chr12:22072339	A/T	cg14669847	chr12:22099120	NA	0.34	5.79	0.35	2.17e-8	Gout;
KIRP	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg08885076	chr2:99613938	TSGA10	-0.47	-6.35	-0.38	1.04e-9	Chronic sinus infection;
KIRP	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	0.98	17.57	0.75	2.44e-45	Heart rate;
KIRP	cis	rs77861329	1.000	rs352147	chr3:52208285	A/G	cg08692210	chr3:52188851	WDR51A	0.94	7.49	0.43	1.24e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.52	-6.23	-0.37	2.03e-9	Ulcerative colitis;
KIRP	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	8.1	0.46	2.53e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs17121403	0.661	rs12137325	chr1:100577906	T/G	cg24955406	chr1:100503596	HIAT1	0.78	5.09	0.31	7.19e-7	Pulmonary function decline;
KIRP	cis	rs4478037	0.558	rs55980934	chr3:33081696	C/T	cg19404215	chr3:33155277	CRTAP	0.92	6.03	0.36	5.9e-9	Major depressive disorder;
KIRP	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.75	-0.34	2.59e-8	Testicular germ cell tumor;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg03797768	chr13:24040813	NA	0.56	7.22	0.42	6.32e-12	Sleep duration;
KIRP	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.21	0.51	1.49e-17	Lymphocyte counts;
KIRP	cis	rs7009516	0.692	rs9650408	chr8:24240670	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.3	-6.17	-0.37	2.74e-9	Hair greying;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08748207	chr12:46777589	NA	0.65	6.28	0.37	1.53e-9	Lung function (FEV1);
KIRP	cis	rs6504950	0.830	rs35097996	chr17:53021923	T/C	cg26251398	chr17:52985966	TOM1L1	0.42	5.2	0.31	4.12e-7	Breast cancer;
KIRP	cis	rs8070740	0.841	rs2189337	chr17:5326178	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	7.5	0.43	1.14e-12	Menopause (age at onset);
KIRP	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.69	-0.39	1.48e-10	Mood instability;
KIRP	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.73	-0.53	3.86e-19	Response to antipsychotic treatment;
KIRP	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg04166393	chr7:2884313	GNA12	0.63	7.43	0.43	1.78e-12	Height;
KIRP	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg13660082	chr14:53194042	PSMC6	-0.59	-5.55	-0.33	7.45e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6973256	0.897	rs1041621	chr7:133353965	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.36	0.32	1.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11644362	1.000	rs35325771	chr16:12985138	A/C	cg06890432	chr16:12997467	SHISA9	-0.39	-6.03	-0.36	6.13e-9	Positive affect;Subjective well-being;
KIRP	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.74	-8.54	-0.48	1.41e-15	Ulcerative colitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10177748	chr19:41770160	HNRNPUL1	0.46	6.15	0.37	3.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.71	9.18	0.51	1.85e-17	Huntington's disease progression;
KIRP	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg00376283	chr12:123451042	ABCB9	-0.67	-6.35	-0.38	1.04e-9	Neutrophil percentage of white cells;
KIRP	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg17764715	chr19:33622953	WDR88	0.68	8.32	0.47	5.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4262150	0.810	rs4958562	chr5:151964590	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.05e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg09314803	chr17:79180344	AZI1	0.5	7.48	0.43	1.31e-12	Frontotemporal dementia;
KIRP	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.36	0.32	1.88e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg04896959	chr15:78267971	NA	0.49	6.53	0.38	3.67e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs4494114	1.000	rs7547273	chr1:39372590	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-5.14	-0.31	5.61e-7	Blood protein levels;
KIRP	cis	rs287982	0.935	rs287978	chr2:9970534	T/C	cg10881225	chr2:9984929	TAF1B	-0.4	-4.86	-0.3	2.05e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.76	9.36	0.51	5.11e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.6	-6.71	-0.39	1.3100000000000001e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs3820881	0.516	rs62279292	chr2:201246400	G/A	cg23516759	chr2:201153734	NA	-0.79	-7.15	-0.41	9.67e-12	Chickenpox;
KIRP	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg18765565	chr5:669397	TPPP	-0.39	-4.87	-0.3	1.98e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg18461458	chr19:21324796	ZNF431	-0.5	-5.07	-0.31	7.72e-7	Pain;
KIRP	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.25	-0.32	3.31e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg10047753	chr17:41438598	NA	1.12	18.32	0.76	7.35e-48	Menopause (age at onset);
KIRP	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg23594656	chr7:65796392	TPST1	-0.45	-6.34	-0.37	1.11e-9	Aortic root size;
KIRP	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg06766960	chr11:133703094	NA	-0.71	-9.83	-0.53	1.89e-19	Childhood ear infection;
KIRP	cis	rs2071426	0.793	rs7098376	chr10:96824738	A/T	cg09036531	chr10:96991505	NA	-0.56	-6.52	-0.38	3.89e-10	Blood metabolite levels;
KIRP	cis	rs12786942	0.502	rs11532049	chr11:101292217	C/T	cg03942599	chr11:101341554	TRPC6	-0.4	-5.02	-0.3	1.02e-6	Facial depth;
KIRP	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.5	6.85	0.4	5.87e-11	Total body bone mineral density;
KIRP	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg00981070	chr1:2046702	PRKCZ	0.42	6.0	0.36	6.89e-9	Height;
KIRP	cis	rs812925	0.892	rs4672440	chr2:61616653	T/G	cg15711740	chr2:61764176	XPO1	0.48	5.47	0.33	1.08e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg21475434	chr5:93447410	FAM172A	0.72	6.34	0.37	1.08e-9	Diabetic retinopathy;
KIRP	cis	rs3774830	0.714	rs7685158	chr4:5462776	C/T	cg26943120	chr4:5472116	STK32B	0.27	6.31	0.37	1.3e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg16590910	chr6:42928470	GNMT	0.43	6.1	0.36	4.15e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.69	-9.29	-0.51	8.59e-18	Glomerular filtration rate;
KIRP	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg03563238	chr19:33554763	RHPN2	-0.34	-5.81	-0.35	1.91e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg00129232	chr17:37814104	STARD3	-0.63	-5.91	-0.35	1.15e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs1011018	0.955	rs6464220	chr7:139454258	A/G	cg03224163	chr7:139420300	HIPK2	-0.46	-4.89	-0.3	1.81e-6	Systolic blood pressure;
KIRP	cis	rs12615966	1.000	rs12615966	chr2:105378957	A/G	cg16465502	chr2:105461796	NA	-0.62	-5.68	-0.34	3.7e-8	Pancreatic cancer;
KIRP	cis	rs11955175	1.000	rs112239156	chr5:40649478	A/C	cg05478818	chr5:40835740	RPL37	0.69	5.29	0.32	2.7e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs8177876	0.731	rs12448806	chr16:81138202	G/T	cg08591886	chr16:81111003	C16orf46	-0.66	-4.85	-0.3	2.18e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg10840412	chr1:235813424	GNG4	-0.69	-6.24	-0.37	1.93e-9	Bipolar disorder;
KIRP	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.84	8.97	0.5	7.55e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.58	4.94	0.3	1.45e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg13180566	chr4:1052158	NA	-0.51	-5.13	-0.31	5.75e-7	Recombination rate (females);
KIRP	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.94	8.21	0.46	1.28e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20985617	chr6:126964779	NA	-0.48	-6.55	-0.39	3.28e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg14829360	chr17:73884958	NA	-0.6	-8.53	-0.48	1.47e-15	Psoriasis;
KIRP	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg19468946	chr17:37922297	IKZF3	-0.46	-6.73	-0.39	1.16e-10	Asthma;
KIRP	cis	rs9644630	1.000	rs9644628	chr8:19369134	G/A	cg01280390	chr8:19363452	CSGALNACT1	-0.38	-4.95	-0.3	1.41e-6	Oropharynx cancer;
KIRP	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.81	-10.6	-0.56	6.96e-22	Platelet count;
KIRP	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.79	12.14	0.61	6.73e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg23899408	chr19:12877188	HOOK2	-0.45	-5.3	-0.32	2.57e-7	Mean corpuscular volume;
KIRP	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.34	0.42	3.2e-12	Height;
KIRP	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.75	9.62	0.52	8.32e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg03060546	chr3:49711283	APEH	0.54	5.86	0.35	1.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.88	0.35	1.31e-8	Motion sickness;
KIRP	cis	rs35995292	0.963	rs2392609	chr7:38952595	C/T	cg19327137	chr7:38886074	VPS41	0.47	5.43	0.33	1.33e-7	Subjective well-being (multi-trait analysis);
KIRP	cis	rs2594989	0.779	rs61275424	chr3:11595585	G/C	cg01796438	chr3:11312864	ATG7	0.43	5.7	0.34	3.39e-8	Circulating chemerin levels;
KIRP	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.96	15.11	0.69	6.07e-37	Systemic lupus erythematosus;
KIRP	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-11.78	-0.6	1.07e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs559928	0.502	rs7127926	chr11:64190767	G/T	cg05555928	chr11:63887634	MACROD1	-0.42	-5.02	-0.3	9.79e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs61935443	0.832	rs11107773	chr12:95282000	C/T	cg21533806	chr12:95267307	NA	0.66	6.63	0.39	2.12e-10	Schizophrenia;
KIRP	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.66	-6.04	-0.36	5.55e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01870903	chr8:104427655	DCAF13;SLC25A32	0.41	6.02	0.36	6.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4389656	0.857	rs5001282	chr5:6757668	T/C	cg10857441	chr5:6722123	POLS	-0.43	-6.01	-0.36	6.77e-9	Coronary artery disease;
KIRP	cis	rs939574	0.790	rs72955452	chr2:220101783	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.85	6.24	0.37	1.89e-9	Platelet distribution width;
KIRP	cis	rs4356975	0.563	rs12513195	chr4:69972086	T/G	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23688420	chr17:26879359	UNC119	-0.54	-6.53	-0.38	3.84e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.11	-0.64	3.87e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	4.03e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-5.8	-0.35	2e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14231369	chr9:113792896	LPAR1	-0.42	-6.11	-0.36	3.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.67	8.43	0.47	2.85e-15	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06028808	chr11:68637592	NA	0.71	8.56	0.48	1.25e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.68	-0.34	3.81e-8	Breast cancer;Mosquito bite size;
KIRP	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.66	0.34	4.1e-8	Total cholesterol levels;
KIRP	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.79	-12.56	-0.63	2.72e-28	Idiopathic membranous nephropathy;
KIRP	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.62	9.32	0.51	6.96e-18	Height;
KIRP	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg01620082	chr3:125678407	NA	-1.03	-6.53	-0.38	3.72e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.74	11.68	0.6	2.29e-25	Resting heart rate;
KIRP	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11208039	chr11:19138753	ZDHHC13	0.47	6.28	0.37	1.54e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7771547	0.642	rs605684	chr6:36493265	T/C	cg04289385	chr6:36355825	ETV7	0.44	6.82	0.4	7.01e-11	Platelet distribution width;
KIRP	cis	rs11077998	0.840	rs9910991	chr17:80481193	G/A	cg10255544	chr17:80519551	FOXK2	0.58	8.51	0.48	1.75e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.88	0.35	1.32e-8	Total cholesterol levels;
KIRP	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg00204512	chr16:28754710	NA	0.43	5.48	0.33	1.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00950418	chr7:105029125	SRPK2	-0.52	-6.47	-0.38	5.3e-10	Height;
KIRP	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.42	0.47	3.09e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs912330	0.500	rs9556967	chr13:99186751	G/T	cg07423050	chr13:99094983	FARP1	-0.33	-4.98	-0.3	1.21e-6	Alzheimer's disease;
KIRP	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-7.68	-0.44	3.81e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17001868	0.892	rs117667045	chr22:40736961	C/T	cg07138101	chr22:40742427	ADSL	0.71	6.02	0.36	6.4e-9	Mammographic density (dense area);
KIRP	cis	rs13102973	0.933	rs7656595	chr4:135875693	G/A	cg14419869	chr4:135874104	NA	0.56	9.41	0.51	3.64e-18	Subjective well-being;
KIRP	cis	rs2275565	0.748	rs4659736	chr1:237034784	A/C	cg17297354	chr1:237056641	MTR	0.54	6.11	0.36	3.84e-9	Homocysteine levels;
KIRP	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg21419209	chr3:44054225	NA	0.7	8.94	0.5	9.78e-17	Coronary artery disease;
KIRP	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg05156742	chr15:59063176	FAM63B	0.54	6.85	0.4	5.96e-11	Asperger disorder;
KIRP	trans	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg14791747	chr16:20752902	THUMPD1	0.63	6.73	0.39	1.16e-10	Cognitive test performance;
KIRP	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.25	-0.55	9.34e-21	Neuroticism;
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.75	-11.0	-0.57	3.69e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.14	9.52	0.52	1.74e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs31771	0.524	rs2644730	chr5:165519771	C/T	cg13976338	chr5:165423657	NA	-0.45	-5.07	-0.31	7.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6691722	0.503	rs6692646	chr1:24707629	C/T	cg18323236	chr1:24743029	NIPAL3	0.44	6.24	0.37	1.94e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs6681460	0.649	rs967325	chr1:67003722	C/T	cg02459107	chr1:67143332	SGIP1	0.4	5.55	0.33	7.46e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg05861140	chr6:150128134	PCMT1	-0.39	-5.24	-0.32	3.45e-7	Lung cancer;
KIRP	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.34	-5.01	-0.3	1.03e-6	Monocyte count;
KIRP	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg23460707	chr10:133558971	NA	0.36	5.48	0.33	1.05e-7	Survival in rectal cancer;
KIRP	cis	rs4654899	0.643	rs2053981	chr1:21227083	G/A	cg05370193	chr1:21551575	ECE1	0.42	5.87	0.35	1.42e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9467160	0.651	rs9393558	chr6:24454196	G/T	cg20631270	chr6:24437470	GPLD1	0.46	5.6	0.34	5.82e-8	Liver enzyme levels;
KIRP	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg16917193	chr12:54089295	NA	0.9	17.29	0.74	2.28e-44	Height;
KIRP	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.76	10.53	0.56	1.2e-21	Eye color traits;
KIRP	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.54	0.65	1.4e-31	Bladder cancer;
KIRP	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.8	-8.66	-0.48	6.21e-16	Coronary artery disease;
KIRP	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg15893493	chr8:124194847	FAM83A	0.86	7.55	0.43	8.52e-13	Urinary uromodulin levels;
KIRP	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.76	-0.44	2.29e-13	Total cholesterol levels;
KIRP	cis	rs17428704	0.571	rs10866507	chr5:14378088	C/T	cg26595256	chr5:14380529	TRIO	-0.9	-6.82	-0.4	7.02e-11	Electroencephalogram traits;
KIRP	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.29	0.37	1.41e-9	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.28	24.76	0.84	9.44e-69	IgG glycosylation;
KIRP	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-5.01	-0.3	1.04e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs4930103	0.682	rs217714	chr11:2011512	C/T	cg23202291	chr11:1979235	NA	0.44	5.61	0.34	5.51e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.49	-0.59	9.72e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.5	11.86	0.6	5.93e-26	Ewing sarcoma;
KIRP	cis	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg07460842	chr6:66804631	NA	-0.56	-7.25	-0.42	5.33e-12	Blood trace element (Cu levels);
KIRP	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.95	16.49	0.72	1.15e-41	Coronary artery disease;
KIRP	trans	rs2048656	0.523	rs7825286	chr8:9648541	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	6.6	0.39	2.54e-10	Schizophrenia;
KIRP	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-5.11	-0.31	6.54e-7	Neuroticism;
KIRP	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.63	-7.93	-0.45	7.58e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12935694	chr11:10823751	EIF4G2;SNORD97	0.48	6.74	0.39	1.09e-10	Survival in pancreatic cancer;
KIRP	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.64	8.6	0.48	9.48e-16	Motion sickness;
KIRP	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg26769984	chr7:1090371	C7orf50	0.88	6.77	0.4	9.29e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs6940638	0.606	rs6456771	chr6:27232395	G/A	cg12292205	chr6:26970375	C6orf41	-0.45	-5.47	-0.33	1.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg00933542	chr6:150070202	PCMT1	0.27	5.34	0.32	2.13e-7	Lung cancer;
KIRP	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg12131826	chr15:77904385	NA	-0.42	-5.78	-0.35	2.28e-8	Type 2 diabetes;
KIRP	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.02	-0.36	6.39e-9	Breast cancer;
KIRP	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.16	-0.37	2.89e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg04369109	chr6:150039330	LATS1	-0.53	-6.72	-0.39	1.25e-10	Lung cancer;
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg20790798	chr5:1857306	NA	-0.41	-5.02	-0.3	9.78e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9815354	1.000	rs9864217	chr3:41762206	G/A	cg03022575	chr3:42003672	ULK4	0.65	6.63	0.39	2.16e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.85	0.3	2.21e-6	Menopause (age at onset);
KIRP	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.68	6.74	0.39	1.15e-10	Menarche (age at onset);
KIRP	cis	rs1355223	0.902	rs704744	chr11:34736561	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07343429	chr11:1785120	HCCA2;CTSD	0.51	6.57	0.39	3e-10	Parkinson's disease;
KIRP	cis	rs4132509	0.895	rs7556516	chr1:243782009	G/A	cg21452805	chr1:244014465	NA	0.54	5.49	0.33	9.85e-8	RR interval (heart rate);
KIRP	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg02336718	chr17:17403227	NA	0.32	5.07	0.31	7.7300000000000005e-07	Total body bone mineral density;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.79	0.4	8.48e-11	Electroencephalogram traits;
KIRP	cis	rs10518128	1.000	rs9998442	chr4:75706141	T/C	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg26320410	chr3:9851826	TTLL3	-0.46	-6.24	-0.37	1.86e-9	Myopia;
KIRP	cis	rs988913	0.957	rs9296771	chr6:54782274	T/A	cg03513858	chr6:54763001	FAM83B	-0.39	-5.41	-0.33	1.5e-7	Menarche (age at onset);
KIRP	cis	rs7129556	0.906	rs72945508	chr11:77267537	G/C	cg12586386	chr11:77299805	AQP11	0.47	6.24	0.37	1.92e-9	Weight loss (gastric bypass surgery);
KIRP	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg02297831	chr4:17616191	MED28	0.62	7.9	0.45	9.15e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4889855	0.530	rs4889872	chr17:78621306	G/A	cg09596252	chr17:78655493	RPTOR	-0.49	-5.42	-0.33	1.46e-7	Fractional excretion of uric acid;
KIRP	cis	rs16976116	0.806	rs28466870	chr15:55495113	C/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg19847130	chr8:10466454	RP1L1	-0.4	-5.65	-0.34	4.46e-8	Retinal vascular caliber;
KIRP	trans	rs7178375	1.000	rs35162264	chr15:31200683	T/A	cg04373760	chr16:53404718	NA	0.63	6.6	0.39	2.55e-10	Hypertriglyceridemia;
KIRP	cis	rs12360000	0.770	rs12573442	chr10:1910626	T/C	cg26364871	chr10:1889757	NA	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg19000871	chr14:103996768	TRMT61A	-0.45	-4.88	-0.3	1.89e-6	Reticulocyte count;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00689492	chr4:1303491	MAEA	0.3	5.18	0.31	4.69e-7	Obesity-related traits;
KIRP	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg06027949	chr8:82754900	SNX16	-0.54	-6.89	-0.4	4.78e-11	Diastolic blood pressure;
KIRP	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg07803811	chr1:43423981	SLC2A1	-0.43	-4.93	-0.3	1.53e-6	Red cell distribution width;
KIRP	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.64	7.77	0.44	2.13e-13	Age at first birth;
KIRP	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg08890418	chr1:21044141	KIF17	0.35	5.16	0.31	5e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg27121462	chr16:89883253	FANCA	0.53	7.0	0.41	2.45e-11	Vitiligo;
KIRP	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.61	7.68	0.44	3.8e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg03929089	chr4:120376271	NA	0.75	6.8	0.4	7.83e-11	Axial length;
KIRP	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.53	7.1	0.41	1.31e-11	HDL cholesterol;
KIRP	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.75	-10.63	-0.56	5.74e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg13010199	chr12:38710504	ALG10B	0.41	5.25	0.32	3.37e-7	Bladder cancer;
KIRP	cis	rs754423	0.568	rs1540702	chr14:52521436	A/G	cg10149976	chr14:52535953	NID2	-0.4	-5.34	-0.32	2.07e-7	Craniofacial microsomia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04232466	chr8:21988724	HR	0.44	6.38	0.38	8.69e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg03808351	chr9:123631620	PHF19	0.46	6.42	0.38	6.99e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs10129255	0.500	rs6576230	chr14:107186778	C/A	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.31	5.09e-7	Kawasaki disease;
KIRP	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.73	7.49	0.43	1.24e-12	Prostate cancer;
KIRP	cis	rs2882667	0.858	rs13177503	chr5:138432759	G/C	cg04439458	chr5:138467593	SIL1	-0.52	-7.64	-0.44	4.85e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-8.32	-0.47	6.26e-15	Parkinson's disease;
KIRP	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.73	-9.8	-0.53	2.38e-19	Childhood ear infection;
KIRP	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.78	-10.58	-0.56	8.56e-22	Aortic root size;
KIRP	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg13010199	chr12:38710504	ALG10B	0.62	7.68	0.44	3.73e-13	Morning vs. evening chronotype;
KIRP	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.87	-9.99	-0.54	5.93e-20	Osteoarthritis;
KIRP	cis	rs796364	0.616	rs2689762	chr2:200687204	G/T	cg23649088	chr2:200775458	C2orf69	0.53	5.08	0.31	7.37e-7	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs807029	0.533	rs2863095	chr10:102746503	C/T	cg04662943	chr10:102668895	NA	0.45	4.84	0.3	2.25e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26837479	chr8:146228149	ZNF252;C8orf77	0.46	6.43	0.38	6.65e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.56	-6.06	-0.36	5.16e-9	Initial pursuit acceleration;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27492874	chr19:5680956	HSD11B1L;C19orf70	-0.54	-6.06	-0.36	5.02e-9	Menopause (age at onset);
KIRP	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.62	6.86	0.4	5.5e-11	Aortic root size;
KIRP	cis	rs76051363	0.500	rs73070422	chr4:1016645	C/G	cg03414932	chr4:1008425	FGFRL1	-0.63	-6.5	-0.38	4.54e-10	Total body bone mineral density;
KIRP	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-8.36	-0.47	4.82e-15	Bipolar disorder;
KIRP	trans	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg26043149	chr18:55253948	FECH	0.5	6.19	0.37	2.52e-9	Bone mineral density;
KIRP	cis	rs6772849	0.930	rs4467479	chr3:128369055	C/G	cg08795948	chr3:128337044	NA	0.46	5.92	0.35	1.06e-8	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs654384	0.933	rs588123	chr7:4164277	G/A	cg04612959	chr7:4183976	SDK1	-0.32	-5.01	-0.3	1.03e-6	Positive affect;
KIRP	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.93	0.49	1.05e-16	Motion sickness;
KIRP	cis	rs17095355	1.000	rs921351	chr10:111704715	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.99	-0.36	7.41e-9	Biliary atresia;
KIRP	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.7	8.71	0.49	4.66e-16	Neutrophil percentage of white cells;
KIRP	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.842	rs12977993	chr19:33580453	T/A	cg27124370	chr19:33622961	WDR88	0.59	7.27	0.42	4.72e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	5.66	0.34	4.21e-8	Schizophrenia;
KIRP	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-1.18	-10.14	-0.54	1.99e-20	Hip circumference adjusted for BMI;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01608045	chr19:3532665	FZR1	-0.44	-6.09	-0.36	4.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26306683	chr17:18585705	ZNF286B	0.57	7.31	0.42	3.73e-12	Educational attainment (years of education);
KIRP	cis	rs11638815	0.581	rs783535	chr15:83250425	T/A	cg06066596	chr15:83166174	LOC80154	-0.41	-4.87	-0.3	1.97e-6	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg13674574	chr14:64971270	ZBTB25;ZBTB1	0.5	6.19	0.37	2.43e-9	Plasma plasminogen activator levels;
KIRP	cis	rs2016266	0.784	rs6421176	chr12:53654052	A/G	cg16917193	chr12:54089295	NA	0.41	5.08	0.31	7.63e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.78	10.92	0.57	6.59e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.26	-0.37	1.68e-9	Response to antipsychotic treatment;
KIRP	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg02487422	chr3:49467188	NICN1	0.41	5.63	0.34	4.93e-8	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg00666640	chr1:248458726	OR2T12	0.36	4.87	0.3	2.02e-6	Common traits (Other);
KIRP	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.42	-6.59	-0.39	2.71e-10	Testicular germ cell tumor;
KIRP	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	7.9	0.45	9.47e-14	Personality dimensions;
KIRP	cis	rs8179	0.700	rs42041	chr7:92246744	C/G	cg15732164	chr7:92237376	CDK6	-0.52	-6.68	-0.39	1.57e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs72627123	0.582	rs62005101	chr14:74500585	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	5.12	0.31	6.04e-7	Morning vs. evening chronotype;
KIRP	cis	rs4849845	0.584	rs3896630	chr2:121037018	A/G	cg24070213	chr2:121070622	NA	0.39	5.94	0.35	9.73e-9	Mean platelet volume;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18918831	chr3:195489782	MUC4	-0.79	-7.0	-0.41	2.4e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg11941060	chr3:133502564	NA	-0.48	-5.9	-0.35	1.23e-8	Iron status biomarkers;
KIRP	cis	rs10214930	0.697	rs6947731	chr7:27638695	C/A	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00338735	chr4:53728038	RASL11B	0.5	5.91	0.35	1.11e-8	Optic nerve measurement (cup area);
KIRP	cis	rs4262150	0.667	rs11746423	chr5:152257512	G/T	cg12297329	chr5:152029980	NA	0.46	6.52	0.38	4.02e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg25547332	chr5:131281432	NA	0.5	5.78	0.35	2.22e-8	Life satisfaction;
KIRP	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.65	0.39	1.84e-10	Cannabis dependence symptom count;
KIRP	cis	rs10899021	1.000	rs11236201	chr11:74375633	A/G	cg25880958	chr11:74394337	NA	-0.64	-5.02	-0.3	9.88e-7	Response to metformin (IC50);
KIRP	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	7.26	0.42	4.95e-12	Height;
KIRP	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg24851858	chr13:114927579	NA	0.41	4.93	0.3	1.48e-6	Schizophrenia;
KIRP	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.39	0.33	1.61e-7	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14923438	chr8:11182872	MTMR9	0.45	6.69	0.39	1.48e-10	Interleukin-4 levels;
KIRP	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7923609	0.967	rs7082470	chr10:65277026	G/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.97	-0.36	8.31e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs860295	0.702	rs11264375	chr1:155424065	C/T	cg02153340	chr1:155202674	NA	0.51	7.1	0.41	1.35e-11	Body mass index;
KIRP	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	7.04	0.41	1.92e-11	Platelet count;
KIRP	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg21475434	chr5:93447410	FAM172A	0.43	5.01	0.3	1.05e-6	Diabetic retinopathy;
KIRP	trans	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg08400319	chr2:242004533	SNED1	0.44	6.05	0.36	5.4e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.42	0.33	1.43e-7	Coronary artery disease;
KIRP	cis	rs889398	0.742	rs12446197	chr16:69854869	A/G	cg09409435	chr16:70099608	PDXDC2	-0.44	-5.24	-0.32	3.41e-7	Body mass index;
KIRP	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.74	6.78	0.4	9.08e-11	Mean platelet volume;
KIRP	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06481639	chr22:41940642	POLR3H	0.71	7.12	0.41	1.15e-11	Vitiligo;
KIRP	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7945071	0.507	rs2853000	chr11:110295227	T/G	cg04157658	chr11:110243994	NA	0.36	5.72	0.34	3.03e-8	Cognitive function;
KIRP	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg24060327	chr5:131705240	SLC22A5	0.6	6.09	0.36	4.25e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	9.54	0.52	1.45e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.6	-8.19	-0.46	1.42e-14	High light scatter reticulocyte count;
KIRP	cis	rs921943	1.000	rs731123	chr5:78317728	G/A	cg26802063	chr5:78281964	ARSB	0.47	5.89	0.35	1.23e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs3931020	0.705	rs28482086	chr1:75226252	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.46	5.68	0.34	3.73e-8	Resistin levels;
KIRP	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.49	-6.77	-0.4	9.2e-11	Birth weight;
KIRP	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg22437258	chr11:111473054	SIK2	0.64	7.67	0.44	4.06e-13	Primary sclerosing cholangitis;
KIRP	cis	rs13108043	0.543	rs62306480	chr4:87922069	C/A	cg11209507	chr4:87813803	C4orf36	0.47	4.99	0.3	1.15e-6	Red blood cell count;
KIRP	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.78	-0.4	8.82e-11	Capecitabine sensitivity;
KIRP	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	1.07	17.12	0.74	8.34e-44	Cognitive function;
KIRP	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	cg04338863	chr8:33670619	NA	0.47	6.22	0.37	2.17e-9	Body mass index;
KIRP	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg15880211	chr22:50250494	ZBED4	0.52	5.62	0.34	5.1e-8	Schizophrenia;
KIRP	cis	rs4728302	0.869	rs889826	chr7:133595871	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.49	6.02	0.36	6.15e-9	Initial pursuit acceleration;
KIRP	cis	rs7083	0.967	rs558590	chr11:117139121	G/A	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs73198271	0.586	rs3789850	chr8:8686845	G/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-5.43	-0.33	1.32e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg18200150	chr17:30822561	MYO1D	0.48	5.94	0.35	9.86e-9	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27286337	chr10:134555280	INPP5A	0.86	10.25	0.55	9.19e-21	Migraine;
KIRP	cis	rs7851660	0.935	rs12347191	chr9:100619719	C/T	cg13688889	chr9:100608707	NA	-0.83	-12.51	-0.62	4.03e-28	Strep throat;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg01765077	chr12:122356316	WDR66	0.61	8.29	0.47	7.64e-15	Mean corpuscular volume;
KIRP	cis	rs9603616	1.000	rs7320598	chr13:40345466	C/T	cg26701198	chr13:40229707	COG6	-0.46	-5.14	-0.31	5.62e-7	Rheumatoid arthritis;
KIRP	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.82	11.91	0.6	3.85e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs1440410	0.830	rs1470130	chr4:144178902	A/G	cg01719995	chr4:144104893	USP38	0.43	5.67	0.34	4.06e-8	Ischemic stroke;
KIRP	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	11.02	0.58	3.12e-23	Bone mineral density;
KIRP	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg22117172	chr7:91764530	CYP51A1	-0.41	-5.85	-0.35	1.54e-8	Breast cancer;
KIRP	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-9.55	-0.52	1.39e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.56	5.59	0.34	6.09e-8	Initial pursuit acceleration;
KIRP	cis	rs15676	0.947	rs2997922	chr9:131580744	C/T	cg00228799	chr9:131580591	ENDOG	0.56	6.55	0.39	3.24e-10	Blood metabolite levels;
KIRP	cis	rs6450176	1.000	rs12654393	chr5:53302620	A/C	ch.5.1024479R	chr5:53302184	ARL15	0.88	11.51	0.59	8.17e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs12949688	0.682	rs1476729	chr17:55838708	C/T	cg12582317	chr17:55822272	NA	-0.45	-6.77	-0.4	9.31e-11	Schizophrenia;
KIRP	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-1.0	-16.36	-0.72	3.38e-41	Height;
KIRP	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg08619932	chr19:49200058	FUT2	0.38	5.92	0.35	1.06e-8	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs6991838	0.584	rs35941313	chr8:66499733	G/T	cg13398993	chr8:66546079	ARMC1	-0.47	-5.44	-0.33	1.31e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg16141378	chr3:129829833	LOC729375	0.49	6.23	0.37	2.02e-9	Mood instability;
KIRP	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.6	9.8	0.53	2.29e-19	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09059988	chr1:150693299	HORMAD1	0.52	6.82	0.4	7.06e-11	Interleukin-4 levels;
KIRP	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.44	6.0	0.36	6.84e-9	Sitting height ratio;
KIRP	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.85	-11.26	-0.58	5.56e-24	Type 2 diabetes;
KIRP	cis	rs12995491	0.731	rs56188884	chr2:88508657	G/A	cg04511125	chr2:88470314	THNSL2	-0.45	-5.64	-0.34	4.7e-8	Response to metformin (IC50);
KIRP	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.7	8.21	0.46	1.26e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7017914	0.935	rs6472551	chr8:71781849	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.4	-4.99	-0.3	1.16e-6	Bone mineral density;
KIRP	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg09699651	chr6:150184138	LRP11	0.58	7.94	0.45	7.04e-14	Lung cancer;
KIRP	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs12208915	0.945	rs10455354	chr6:79566230	C/T	cg18132916	chr6:79620363	NA	-0.57	-5.05	-0.31	8.76e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs654128	0.506	rs339298	chr6:117222067	C/T	cg12892004	chr6:117198278	RFX6	-0.41	-5.26	-0.32	3.07e-7	Telomere length;
KIRP	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.75	7.68	0.44	3.66e-13	Mean corpuscular hemoglobin;
KIRP	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg08501292	chr6:25962987	TRIM38	0.97	7.62	0.44	5.49e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6662572	0.737	rs7413189	chr1:46254330	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.47	-5.77	-0.35	2.36e-8	Blood protein levels;
KIRP	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.3	11.5	0.59	8.91e-25	Diabetic retinopathy;
KIRP	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.69	-7.6	-0.44	6.07e-13	Gut microbiome composition (summer);
KIRP	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.38	-5.35	-0.32	2.06e-7	Coronary artery disease;
KIRP	trans	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg13565492	chr6:43139072	SRF	-0.87	-8.04	-0.46	3.8e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6026990	1	rs6026990	chr20:58177615	T/A	cg07607922	chr3:121903644	CASR	-0.59	-6.32	-0.37	1.21e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.44	15.08	0.69	7.77e-37	Schizophrenia;
KIRP	cis	rs11264213	0.901	rs116757422	chr1:36349560	G/A	cg27506609	chr1:36549197	TEKT2	1.17	6.78	0.4	8.95e-11	Schizophrenia;
KIRP	cis	rs75920871	1.000	rs75920871	chr11:116780095	A/T	cg23684410	chr11:116897558	SIK3	0.48	5.24	0.32	3.44e-7	Subjective well-being;
KIRP	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg07701084	chr6:150067640	NUP43	0.6	6.5	0.38	4.35e-10	Lung cancer;
KIRP	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.33	-0.42	3.21e-12	Type 2 diabetes;
KIRP	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg01304814	chr3:48885189	PRKAR2A	0.71	5.64	0.34	4.61e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2970992	0.728	rs1543103	chr2:101326223	G/T	cg01042948	chr2:101319752	NA	0.41	5.79	0.35	2.17e-8	Educational attainment;
KIRP	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg18164611	chr1:46958628	NA	-0.45	-5.43	-0.33	1.35e-7	Monobrow;
KIRP	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.39	8.09	0.46	2.79e-14	IgG glycosylation;
KIRP	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg04865290	chr3:52927548	TMEM110	-0.67	-6.96	-0.41	2.98e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg23594656	chr7:65796392	TPST1	-0.45	-7.06	-0.41	1.74e-11	Aortic root size;
KIRP	cis	rs11583043	0.708	rs17123647	chr1:101529018	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.48	4.97	0.3	1.23e-6	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.5	6.2	0.37	2.42e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-5.37	-0.32	1.79e-7	Vitiligo;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg21607453	chr9:98783545	NCRNA00092	0.49	6.29	0.37	1.43e-9	Sleep duration;
KIRP	cis	rs7202877	0.706	rs247434	chr16:75445304	G/A	cg03315344	chr16:75512273	CHST6	-0.57	-5.16	-0.31	5.09e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.6	7.73	0.44	2.69e-13	Total body bone mineral density;
KIRP	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg00677455	chr12:58241039	CTDSP2	0.74	8.84	0.49	1.91e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg23995753	chr2:160760732	LY75	-0.43	-5.77	-0.35	2.42e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.8200000000000003e-11	Hypertriglyceridemia;
KIRP	cis	rs12780845	1.000	rs7082376	chr10:17232223	C/T	cg01003015	chr10:17271136	VIM	0.46	4.96	0.3	1.32e-6	Homocysteine levels;
KIRP	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11987759	chr7:65425863	GUSB	0.49	6.28	0.37	1.51e-9	Aortic root size;
KIRP	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.33	-0.7	1.09e-37	Headache;
KIRP	cis	rs12476592	0.602	rs7576316	chr2:63741122	G/A	cg17519650	chr2:63277830	OTX1	-0.42	-4.88	-0.3	1.93e-6	Childhood ear infection;
KIRP	cis	rs13401104	0.796	rs56338351	chr2:237119104	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg05251000	chr9:132935664	FREQ	0.52	8.81	0.49	2.28e-16	Alzheimer's disease (cognitive decline);
KIRP	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.46	-5.17	-0.31	4.83e-7	Squamous cell lung carcinoma;
KIRP	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg02297831	chr4:17616191	MED28	0.62	7.9	0.45	9.1e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.59	5.49	0.33	9.94e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.31	17.35	0.74	1.41e-44	Corneal structure;
KIRP	cis	rs282587	0.569	rs7987086	chr13:113409889	G/A	cg04656015	chr13:113407548	ATP11A	0.66	7.71	0.44	3.16e-13	Glycated hemoglobin levels;
KIRP	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg21775007	chr8:11205619	TDH	0.44	6.12	0.36	3.59e-9	Neuroticism;
KIRP	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.31	0.55	6.12e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg00800038	chr16:89945340	TCF25	-0.62	-5.99	-0.36	7.36e-9	Skin colour saturation;
KIRP	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.53	6.2	0.37	2.34e-9	Aortic root size;
KIRP	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.92	14.28	0.67	4.12e-34	Testicular germ cell tumor;
KIRP	cis	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-5.36	-0.32	1.88e-7	HDL cholesterol;
KIRP	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.91	-0.3	1.64e-6	Breast cancer;
KIRP	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18364779	chr6:26104403	HIST1H4C	0.52	6.01	0.36	6.81e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-1.0	-11.78	-0.6	1.03e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1010254	0.510	rs723427	chr5:151695769	G/A	cg12297329	chr5:152029980	NA	-0.65	-6.6	-0.39	2.56e-10	Optic nerve measurement (cup area);
KIRP	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg14004847	chr7:1930337	MAD1L1	-0.45	-5.02	-0.3	9.95e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg07274523	chr3:49395745	GPX1	0.56	5.28	0.32	2.89e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1345301	0.518	rs12468355	chr2:102861250	T/G	cg12451869	chr2:102867685	NA	0.47	6.77	0.4	9.63e-11	Waist circumference;
KIRP	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	6.44	0.38	6.11e-10	Schizophrenia;
KIRP	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.15	0.31	5.4e-7	Educational attainment;
KIRP	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg06521331	chr12:34319734	NA	-0.53	-6.54	-0.38	3.56e-10	Morning vs. evening chronotype;
KIRP	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.52	-5.86	-0.35	1.45e-8	Multiple sclerosis;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-5.63	-0.34	4.88e-8	Lung cancer;
KIRP	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.73	-13.09	-0.64	4.57e-30	Body mass index;
KIRP	cis	rs6466055	0.669	rs10808141	chr7:104715490	T/G	cg04380332	chr7:105027541	SRPK2	-0.63	-9.67	-0.52	6.1e-19	Schizophrenia;
KIRP	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.58	-8.03	-0.46	4.08e-14	Migraine;
KIRP	cis	rs13108043	0.511	rs72874293	chr4:87764384	T/A	cg11209507	chr4:87813803	C4orf36	0.48	5.31	0.32	2.43e-7	Red blood cell count;
KIRP	cis	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg04607699	chr11:48328132	OR4S1	-0.39	-5.54	-0.33	7.88e-8	Migraine - clinic-based;
KIRP	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.95	-0.5	9.09e-17	Coronary artery disease;
KIRP	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg15436174	chr10:43711423	RASGEF1A	0.85	9.42	0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	1.03	13.37	0.65	5.01e-31	Bipolar disorder and schizophrenia;
KIRP	cis	rs7919006	0.793	rs57982505	chr10:76766960	C/G	cg01390419	chr10:76803856	DUPD1	0.5	5.83	0.35	1.75e-8	Weight;
KIRP	cis	rs9391997	0.568	rs2048698	chr6:433962	C/T	cg13299325	chr6:447777	NA	0.25	4.94	0.3	1.43e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg08847533	chr14:75593920	NEK9	0.41	4.99	0.3	1.15e-6	Caffeine consumption;
KIRP	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.71	0.34	3.33e-8	Lung cancer;
KIRP	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.74	-7.87	-0.45	1.14e-13	Gout;
KIRP	trans	rs3741489	1.000	rs4758915	chr12:133477147	A/G	cg24132527	chr5:140019269	TMCO6	1.0	6.17	0.37	2.77e-9	Cognitive function;
KIRP	trans	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg06521331	chr12:34319734	NA	-0.6	-7.06	-0.41	1.65e-11	Bladder cancer;
KIRP	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs6580649	0.941	rs7312326	chr12:48480643	G/A	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs4728302	0.869	rs13231079	chr7:133604373	C/G	cg10665199	chr7:133106180	EXOC4	0.46	5.61	0.34	5.51e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs11650494	0.710	rs61427980	chr17:47473580	A/G	cg08112188	chr17:47440006	ZNF652	1.11	7.26	0.42	5.04e-12	Prostate cancer;
KIRP	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.95	0.45	6.58e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs526821	0.553	rs510095	chr11:55289154	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-6.3	-0.37	1.36e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg22532475	chr10:104410764	TRIM8	-0.31	-5.04	-0.31	9.23e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg05717871	chr11:638507	DRD4	-0.37	-5.52	-0.33	8.48e-8	Systemic lupus erythematosus;
KIRP	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg15440763	chr7:158190612	PTPRN2	0.42	5.24	0.32	3.42e-7	Obesity-related traits;
KIRP	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.02	0.64	7.74e-30	Bladder cancer;
KIRP	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-6.18	-0.37	2.69e-9	Asthma;
KIRP	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg07309820	chr7:148901717	ZNF282	-0.39	-4.91	-0.3	1.68e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.6	-9.77	-0.53	2.82e-19	Itch intensity from mosquito bite;
KIRP	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.06	-0.36	5.19e-9	Response to antipsychotic treatment;
KIRP	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.43	-4.93	-0.3	1.49e-6	Metabolite levels;
KIRP	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	1.08	15.98	0.71	6.61e-40	Menopause (age at onset);
KIRP	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.84	9.32	0.51	7.05e-18	Response to diuretic therapy;
KIRP	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg09184832	chr6:79620586	NA	-0.39	-4.98	-0.3	1.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.512	rs4925071	chr17:19954499	T/C	cg04132472	chr17:19861366	AKAP10	0.42	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.88	11.79	0.6	9.9e-26	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg24807547	chr6:37504484	NA	-0.6	-8.96	-0.5	8.16e-17	Cognitive performance;
KIRP	trans	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg26043149	chr18:55253948	FECH	0.51	6.19	0.37	2.5e-9	Bone mineral density;
KIRP	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.26	-0.32	3.12e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.6	-7.26	-0.42	4.92e-12	Breast cancer;
KIRP	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.55	8.05	0.46	3.52e-14	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25789201	chr7:72395803	POM121	0.57	6.68	0.39	1.54e-10	Smoking initiation;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25789201	chr7:72395803	POM121	-0.51	-6.65	-0.39	1.87e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg00931491	chr16:28608288	SULT1A2	-0.25	-5.0	-0.3	1.11e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12141179	chr2:172016663	TLK1	0.48	6.34	0.37	1.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-0.48	-6.2	-0.37	2.43e-9	Systemic lupus erythematosus;
KIRP	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg12756093	chr1:115239321	AMPD1	0.57	7.91	0.45	8.97e-14	Autism;
KIRP	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-7.43	-0.43	1.74e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02318596	chr3:88188181	ZNF654	0.37	6.06	0.36	5.07e-9	C-reactive protein;
KIRP	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-5.67	-0.34	4.07e-8	Parkinson's disease;
KIRP	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs7590368	0.640	rs12472302	chr2:10941301	G/A	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg05791153	chr7:19748676	TWISTNB	0.68	6.05	0.36	5.43e-9	Thyroid stimulating hormone;
KIRP	trans	rs933360	0.585	rs10281065	chr7:50829973	G/T	cg20003124	chr12:4557277	NA	-0.54	-6.58	-0.39	2.84e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.48e-9	Menopause (age at onset);
KIRP	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.71	-0.34	3.24e-8	Height;
KIRP	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7615316	0.603	rs7644451	chr3:141957076	A/G	cg20824294	chr3:142316082	PLS1	0.21	4.89	0.3	1.83e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9596863	0.898	rs13378524	chr13:54372390	G/A	ch.13.53330881F	chr13:54432880	NA	0.61	5.97	0.36	8.03e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg12598211	chr12:123634384	NA	0.44	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9972944	0.756	rs7223214	chr17:63761473	C/T	cg07283582	chr17:63770753	CCDC46	-0.44	-7.18	-0.42	8.41e-12	Total body bone mineral density;
KIRP	cis	rs62355272	1.000	rs57545288	chr5:35850629	C/T	cg13894535	chr5:35919491	CAPSL	-0.52	-6.07	-0.36	4.85e-9	Lymphocyte counts;
KIRP	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg18882449	chr10:104885122	NT5C2	-0.5	-6.47	-0.38	5.22e-10	Arsenic metabolism;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg26134248	chr17:3907702	NA	-0.55	-8.21	-0.46	1.28e-14	Type 2 diabetes;
KIRP	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.83	-6.72	-0.39	1.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.65	12.2	0.61	4.37e-27	Blood protein levels;
KIRP	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.99	-13.88	-0.66	9.5e-33	Response to antipsychotic treatment;
KIRP	cis	rs6438504	0.922	rs7612800	chr3:118915327	C/T	cg25372693	chr3:118959985	B4GALT4	0.35	5.97	0.36	8.35e-9	Clozapine-induced cytotoxicity;
KIRP	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.5	6.82	0.4	6.88e-11	Migraine;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02454982	chr1:3689201	LOC388588	0.47	6.28	0.37	1.5e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.08	-0.41	1.48e-11	Response to antipsychotic treatment;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.5	6.38	0.38	8.88e-10	Resistin levels;
KIRP	cis	rs240764	0.583	rs6905113	chr6:101209368	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.25	-0.32	3.32e-7	Neuroticism;
KIRP	cis	rs34779708	0.649	rs34421369	chr10:35550275	G/C	cg03585969	chr10:35415529	CREM	0.56	6.6	0.39	2.49e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs62413470	0.935	rs12192012	chr6:55972758	G/T	cg13327911	chr6:55965977	COL21A1	0.55	5.05	0.31	8.43e-7	Joint mobility (Beighton score);
KIRP	cis	rs60871478	1.000	rs62432224	chr7:788284	G/A	cg04727924	chr7:799746	HEATR2	-0.79	-8.73	-0.49	3.91e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2273156	1.000	rs12050447	chr14:35461965	A/G	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.39	-0.33	1.64e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	11.87	0.6	5.61e-26	Bipolar disorder;
KIRP	cis	rs2916247	0.954	rs28625919	chr8:93030325	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.94	-0.45	7.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg11845111	chr2:191398756	TMEM194B	0.94	10.45	0.55	2.24e-21	Diastolic blood pressure;
KIRP	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg06050784	chr16:88016603	BANP	0.41	5.15	0.31	5.26e-7	Menopause (age at onset);
KIRP	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.34	5.28	0.32	2.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-8.83	-0.49	1.95e-16	Hypospadias;
KIRP	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg19169023	chr15:41853346	TYRO3	-0.69	-7.95	-0.45	6.78e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.4	5.18	0.31	4.58e-7	Leprosy;
KIRP	cis	rs7766436	0.848	rs16901663	chr6:22598054	T/C	cg13666174	chr6:22585274	NA	-0.48	-6.49	-0.38	4.78e-10	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.7	-0.56	3.46e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.55	7.61	0.44	5.67e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.75	-0.34	2.58e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg08603382	chr10:743973	NA	-0.57	-8.07	-0.46	3.18e-14	Psychosis in Alzheimer's disease;
KIRP	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.83	11.27	0.58	4.86e-24	Morning vs. evening chronotype;
KIRP	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg25182066	chr10:30743637	MAP3K8	-0.58	-7.21	-0.42	6.79e-12	Inflammatory bowel disease;
KIRP	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2742417	0.935	rs2673028	chr3:45759654	A/G	cg04037228	chr3:45636386	LIMD1	0.36	5.26	0.32	3.11e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4664304	0.714	rs66496937	chr2:160738509	A/G	cg23995753	chr2:160760732	LY75	-0.42	-5.49	-0.33	1.01e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.56	7.17	0.42	8.63e-12	Longevity;
KIRP	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.4	4.87	0.3	2.04e-6	Renal cell carcinoma;
KIRP	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs6964587	1.000	rs7781597	chr7:91588194	T/C	cg22117172	chr7:91764530	CYP51A1	0.42	5.63	0.34	4.78e-8	Breast cancer;
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg18234130	chr8:27182889	PTK2B	0.53	6.88	0.4	4.81e-11	Neuroticism;
KIRP	cis	rs4356932	1.000	rs4359936	chr4:76971976	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg05625103	chr10:2543513	NA	0.48	5.82	0.35	1.86e-8	Age-related hearing impairment;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg24972876	chr7:65420302	NA	-0.4	-5.48	-0.33	1.04e-7	Aortic root size;
KIRP	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg18944383	chr4:111397179	ENPEP	0.71	13.3	0.65	9.3e-31	Coronary artery disease;
KIRP	cis	rs17321999	1.000	rs4952115	chr2:30478386	G/T	cg05247661	chr2:30472410	LBH	0.69	7.82	0.45	1.52e-13	Systemic lupus erythematosus;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15684290	chr8:6263623	MCPH1	0.49	7.5	0.43	1.18e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.81	13.08	0.64	4.93e-30	Menarche (age at onset);
KIRP	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg16497661	chr14:103986332	CKB	0.81	13.69	0.66	4.18e-32	Body mass index;
KIRP	cis	rs4742903	1.000	rs4743687	chr9:106856910	C/T	cg14250997	chr9:106856677	SMC2	0.39	5.14	0.31	5.56e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs687432	0.774	rs921445	chr11:57895573	C/T	cg19752551	chr11:57585705	CTNND1	-0.67	-8.52	-0.48	1.66e-15	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg26134248	chr17:3907702	NA	0.57	8.53	0.48	1.56e-15	Type 2 diabetes;
KIRP	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.95	-15.06	-0.69	9.2e-37	Systemic lupus erythematosus;
KIRP	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg15979348	chr13:112237479	NA	-0.39	-5.34	-0.32	2.13e-7	Menarche (age at onset);
KIRP	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg06521331	chr12:34319734	NA	-0.63	-7.56	-0.43	8.15e-13	Morning vs. evening chronotype;
KIRP	cis	rs6457821	1.000	rs73411722	chr6:35296056	G/T	cg06087101	chr6:35551932	FKBP5	0.55	5.04	0.31	9.12e-7	Height;
KIRP	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.79	7.92	0.45	8.17e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26151740	chr19:54641525	CNOT3	0.57	7.34	0.42	3.09e-12	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.19	-0.31	4.34e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.8	9.17	0.5	1.92e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg11266682	chr4:10021025	SLC2A9	0.41	5.08	0.31	7.54e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.52	5.98	0.36	7.84e-9	Aortic root size;
KIRP	cis	rs7225151	0.520	rs55993740	chr17:5231412	G/A	cg24500398	chr17:5266808	RABEP1	-0.58	-5.71	-0.34	3.23e-8	Alzheimer's disease (late onset);
KIRP	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg13271783	chr10:134563150	INPP5A	-0.6	-7.77	-0.44	2.08e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs3857747	0.759	rs4640968	chr7:40450451	G/A	cg00420559	chr7:40367873	C7orf10	-0.57	-7.78	-0.44	2.02e-13	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg23978390	chr7:1156363	C7orf50	0.39	5.18	0.31	4.61e-7	Longevity;Endometriosis;
KIRP	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg01097406	chr16:89675127	NA	0.38	6.46	0.38	5.61e-10	Hemoglobin concentration;
KIRP	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg07541023	chr7:19748670	TWISTNB	0.66	5.95	0.35	8.96e-9	Thyroid stimulating hormone;
KIRP	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg06026331	chr20:60912101	LAMA5	-0.48	-6.37	-0.38	8.98e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4737010	0.501	rs2032736	chr8:41639266	C/A	cg17182837	chr8:41585554	ANK1	0.53	5.5	0.33	9.65e-8	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1635	0.574	rs7757215	chr6:28212489	A/C	cg24848467	chr6:28134517	ZNF389	0.71	5.32	0.32	2.32e-7	Schizophrenia;
KIRP	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg18964960	chr10:1102726	WDR37	-0.55	-6.11	-0.36	3.87e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.71	8.62	0.48	8.36e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs55863869	0.748	rs922984	chr2:179615887	T/C	cg02880032	chr2:179629472	TTN	-0.59	-6.16	-0.37	2.96e-9	QT interval;
KIRP	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.74	11.26	0.58	5.32e-24	Type 2 diabetes;
KIRP	trans	rs12517041	1.000	rs16899396	chr5:23304911	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg17691542	chr6:26056736	HIST1H1C	0.65	7.46	0.43	1.49e-12	Iron status biomarkers;
KIRP	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg03609598	chr5:56110824	MAP3K1	0.48	5.43	0.33	1.35e-7	Initial pursuit acceleration;
KIRP	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.37	7.35	0.42	2.86e-12	Height;
KIRP	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-5.99	-0.36	7.59e-9	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg07382826	chr16:28625726	SULT1A1	0.51	5.99	0.36	7.44e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.18	0.72	1.4e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.39	5.91	0.35	1.15e-8	Platelet distribution width;
KIRP	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg19847130	chr8:10466454	RP1L1	0.39	5.68	0.34	3.79e-8	Systolic blood pressure;
KIRP	cis	rs3857067	0.806	rs4693002	chr4:95115302	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.27	-0.37	1.59e-9	QT interval;
KIRP	cis	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg21546286	chr11:48923668	NA	0.43	5.4	0.33	1.57e-7	HDL cholesterol;
KIRP	trans	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg24644049	chr4:85504048	CDS1	1.03	7.2	0.42	7.16e-12	Skin colour saturation;
KIRP	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-5.99	-0.36	7.54e-9	Prudent dietary pattern;
KIRP	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25833597	chr17:30823145	MYO1D	0.43	5.55	0.33	7.52e-8	Schizophrenia;
KIRP	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.48	-5.72	-0.34	3.04e-8	Tonsillectomy;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg20972416	chr2:220025218	NHEJ1	0.52	6.28	0.37	1.53e-9	Educational attainment;
KIRP	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.69	-0.44	3.53e-13	Joint mobility (Beighton score);
KIRP	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg09596252	chr17:78655493	RPTOR	-0.56	-7.38	-0.43	2.5e-12	Obesity;
KIRP	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.96	-10.17	-0.54	1.61e-20	IgG glycosylation;
KIRP	cis	rs997295	0.556	rs10468041	chr15:67773203	G/T	cg24579218	chr15:68104479	NA	0.36	5.2	0.31	4.16e-7	Motion sickness;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg11971027	chr1:153651147	NPR1	-0.41	-6.29	-0.37	1.46e-9	Hippocampal sclerosis of aging;
KIRP	cis	rs2929278	0.588	rs688009	chr15:44156302	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.46	5.39	0.32	1.66e-7	Schizophrenia;
KIRP	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg02807482	chr3:125708958	NA	-0.5	-4.86	-0.3	2.08e-6	Blood pressure (smoking interaction);
KIRP	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.35	6.22	0.37	2.12e-9	Renal cell carcinoma;
KIRP	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg25767906	chr1:53392781	SCP2	-0.39	-5.41	-0.33	1.48e-7	Monocyte count;
KIRP	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	5.24	0.32	3.39e-7	Schizophrenia;
KIRP	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg01879488	chr11:35160498	CD44	0.44	6.16	0.37	2.87e-9	Plasma plasminogen activator levels;
KIRP	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	0.74	10.84	0.57	1.21e-22	Prudent dietary pattern;
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg19875535	chr5:140030758	IK	0.57	7.17	0.42	8.94e-12	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.16	-0.37	2.98e-9	Systolic blood pressure;
KIRP	cis	rs71597109	0.681	rs11944577	chr4:102718658	A/G	cg14855874	chr4:102712397	BANK1	0.36	4.84	0.3	2.26e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs9905704	0.627	rs6503867	chr17:56621359	T/C	cg12560992	chr17:57184187	TRIM37	-0.56	-5.21	-0.32	3.97e-7	Testicular germ cell tumor;
KIRP	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.83	8.66	0.48	6.45e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg21851534	chr17:3907994	ZZEF1	0.5	7.27	0.42	4.72e-12	Type 2 diabetes;
KIRP	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg06937882	chr20:24974362	C20orf3	-0.43	-4.89	-0.3	1.86e-6	Blood protein levels;
KIRP	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg11235152	chr1:67600687	NA	0.68	9.96	0.54	7.29e-20	Psoriasis;
KIRP	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg24565620	chr2:194026	NA	-0.61	-6.6	-0.39	2.53e-10	Blood protein levels;
KIRP	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg08992911	chr2:238395768	MLPH	0.5	5.23	0.32	3.63e-7	Prostate cancer;
KIRP	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg25457927	chr22:38595422	NA	-0.31	-6.5	-0.38	4.39e-10	Breast cancer;
KIRP	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg18404041	chr3:52824283	ITIH1	-0.47	-5.75	-0.34	2.59e-8	Schizophrenia;
KIRP	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg26727032	chr16:67993705	SLC12A4	-0.65	-5.12	-0.31	6.24e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	9.36	0.51	5.39e-18	Cognitive test performance;
KIRP	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg08999081	chr20:33150536	PIGU	0.41	5.13	0.31	6.01e-7	Height;
KIRP	cis	rs960902	0.764	rs7582204	chr2:37729801	G/T	cg25341268	chr2:37734390	NA	-0.58	-8.09	-0.46	2.77e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11858474	chr10:81107246	PPIF	0.46	6.58	0.39	2.8e-10	Survival in pancreatic cancer;
KIRP	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs1147199	0.585	rs1837305	chr9:87247694	G/A	cg22402007	chr9:87282823	NTRK2	0.4	4.99	0.3	1.13e-6	Body mass index;
KIRP	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.43	7.1	0.41	1.32e-11	Hemoglobin concentration;
KIRP	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg01843034	chr6:37503916	NA	-0.96	-14.61	-0.68	3.22e-35	Cognitive performance;
KIRP	cis	rs447921	0.861	rs12951513	chr17:74455069	C/T	cg16776035	chr17:74542680	NA	-0.6	-4.9	-0.3	1.77e-6	Mitochondrial DNA levels;
KIRP	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg08017634	chr8:144659831	NAPRT1	0.78	5.0	0.3	1.11e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10214930	0.813	rs6954905	chr7:27664825	C/T	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg13293535	chr8:11597251	GATA4	-0.5	-7.59	-0.44	6.61e-13	Neuroticism;
KIRP	cis	rs9398803	0.687	rs9491653	chr6:126943630	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs2733310	0.895	rs1660951	chr15:57113407	G/A	cg13626582	chr15:57592083	LOC283663	-0.23	-5.03	-0.31	9.57e-7	Mean platelet volume;
KIRP	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg07395648	chr5:131743802	NA	0.37	5.21	0.32	4.01e-7	Acylcarnitine levels;
KIRP	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.79	10.82	0.57	1.44e-22	Aortic root size;
KIRP	cis	rs4128725	0.673	rs4625277	chr1:159372283	A/T	cg25076881	chr1:159409836	OR10J1	0.4	5.09	0.31	6.98e-7	Select biomarker traits;
KIRP	cis	rs4972806	0.668	rs2072588	chr2:177042930	G/C	cg14324370	chr2:177042789	NA	0.77	10.66	0.56	4.77e-22	IgG glycosylation;
KIRP	cis	rs4356975	0.522	rs62296942	chr4:69959119	T/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.41	7.03	0.41	2.07e-11	Heart rate;
KIRP	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.48	-0.33	1.06e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.5	6.22	0.37	2.1e-9	Birth weight;
KIRP	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg06742321	chr12:123595122	PITPNM2	0.46	5.37	0.32	1.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7215564	0.908	rs59254087	chr17:78665278	A/C	cg06153925	chr17:78755379	RPTOR	0.33	5.31	0.32	2.45e-7	Myopia (pathological);
KIRP	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg19847130	chr8:10466454	RP1L1	0.36	5.28	0.32	2.89e-7	Neuroticism;
KIRP	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg00919237	chr7:87102261	ABCB4	-0.73	-9.04	-0.5	4.79e-17	Gallbladder cancer;
KIRP	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg04546413	chr19:29218101	NA	0.6	5.72	0.34	3.07e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg04306507	chr14:55594613	LGALS3	0.53	8.45	0.47	2.55e-15	Protein biomarker;
KIRP	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.66	8.81	0.49	2.28e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.66	12.59	0.63	2.27e-28	Bone mineral density;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05098233	chr16:475948	RAB11FIP3	0.52	6.16	0.37	2.95e-9	Myopia (pathological);
KIRP	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.2	0.31	4.15e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.26	-0.47	9.13e-15	Monocyte percentage of white cells;
KIRP	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.46	-0.43	1.49e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7127900	1.000	rs7481129	chr11:2230460	A/C	cg25635251	chr11:2234043	NA	0.53	7.98	0.45	5.72e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg11608241	chr8:8085544	FLJ10661	0.44	5.42	0.33	1.41e-7	Mood instability;
KIRP	cis	rs965513	1.000	rs965513	chr9:100556109	A/G	cg13688889	chr9:100608707	NA	-0.59	-7.45	-0.43	1.53e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.74	6.51	0.38	4.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07473023	chr5:72921899	RGNEF	-0.47	-6.12	-0.36	3.58e-9	Myopia;
KIRP	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg03709012	chr19:19516395	GATAD2A	0.94	13.91	0.66	7.51e-33	Tonsillectomy;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg06815112	chr8:27182871	PTK2B	0.51	6.55	0.39	3.34e-10	Neuroticism;
KIRP	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg12756686	chr19:29218302	NA	0.55	4.97	0.3	1.26e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs13132184	0.507	rs67733859	chr4:38042347	G/A	cg14409701	chr4:38048871	TBC1D1	-0.79	-7.49	-0.43	1.21e-12	Verbal declarative memory;
KIRP	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7215564	0.908	rs8074870	chr17:78684132	T/C	cg06153925	chr17:78755379	RPTOR	0.34	5.51	0.33	9.25e-8	Myopia (pathological);
KIRP	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg15893493	chr8:124194847	FAM83A	0.88	7.31	0.42	3.73e-12	Urinary uromodulin levels;
KIRP	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg10047753	chr17:41438598	NA	1.0	15.07	0.69	8.65e-37	Menopause (age at onset);
KIRP	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.51	-6.82	-0.4	6.94e-11	Heart rate;
KIRP	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg07701084	chr6:150067640	NUP43	0.57	7.32	0.42	3.6e-12	Testicular germ cell tumor;
KIRP	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.82	-11.92	-0.6	3.81e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg14541582	chr5:601475	NA	-0.55	-6.11	-0.36	3.97e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg17554472	chr22:41940697	POLR3H	0.64	6.59	0.39	2.58e-10	Vitiligo;
KIRP	cis	rs6545883	0.929	rs10200055	chr2:61628017	T/A	cg15711740	chr2:61764176	XPO1	0.61	8.1	0.46	2.52e-14	Tuberculosis;
KIRP	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg01557791	chr16:72042693	DHODH	-0.75	-10.01	-0.54	5.27e-20	Fibrinogen levels;
KIRP	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-9.02	-0.5	5.63e-17	Brugada syndrome;
KIRP	cis	rs829661	0.947	rs4952147	chr2:30776270	G/A	cg10949345	chr2:30726833	LCLAT1	0.73	10.48	0.56	1.7e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16346588	chr10:242978	ZMYND11	0.47	5.75	0.34	2.62e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.57	-0.33	6.69e-8	Life satisfaction;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02756545	chr1:94884060	ABCD3	0.47	6.14	0.36	3.21e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs4143844	0.867	rs11555593	chr15:62145399	A/G	cg04814990	chr13:111957387	ARHGEF7	0.95	6.02	0.36	6.36e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg05784532	chr1:230284198	GALNT2	0.47	6.08	0.36	4.49e-9	Coronary artery disease;
KIRP	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg27398547	chr14:60952738	C14orf39	0.54	5.06	0.31	8.1e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.71	8.39	0.47	3.92e-15	Schizophrenia;
KIRP	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06544989	chr22:39130855	UNC84B	0.49	7.41	0.43	1.97e-12	Menopause (age at onset);
KIRP	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	5.1	0.31	6.66e-7	Height;
KIRP	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	0.86	10.28	0.55	7.65e-21	Corneal structure;
KIRP	trans	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg10756647	chr7:56101905	PSPH	1.02	7.73	0.44	2.72e-13	Diabetic kidney disease;
KIRP	cis	rs1434579	0.865	rs12980701	chr19:44948014	C/A	cg15540054	chr19:45004280	ZNF180	0.52	5.43	0.33	1.32e-7	Tuberculosis;
KIRP	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg01988459	chr11:68622903	NA	-0.37	-5.4	-0.33	1.57e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.97	0.3	1.26e-6	Lung cancer;
KIRP	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.44	5.35	0.32	2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2882667	0.964	rs12108892	chr5:138299630	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-6.53	-0.38	3.64e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg17554472	chr22:41940697	POLR3H	-0.56	-6.27	-0.37	1.58e-9	Vitiligo;
KIRP	cis	rs72960926	0.744	rs6923498	chr6:74913523	C/T	cg03266952	chr6:74778945	NA	-0.61	-5.49	-0.33	9.96e-8	Metabolite levels (MHPG);
KIRP	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg03808351	chr9:123631620	PHF19	0.42	5.53	0.33	8.14e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs6963495	0.818	rs6943132	chr7:105166776	C/T	cg13798780	chr7:105162888	PUS7	0.59	5.04	0.31	9.09e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg23127183	chr11:57508653	C11orf31	0.45	6.19	0.37	2.56e-9	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	8.13	0.46	2.16e-14	Prudent dietary pattern;
KIRP	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12667521	chr19:29218732	NA	0.6	5.24	0.32	3.4e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.75	10.99	0.57	3.91e-23	Prudent dietary pattern;
KIRP	cis	rs6973256	0.828	rs4731974	chr7:133344010	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.38	-0.38	8.55e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.62	8.72	0.49	4.32e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg03315344	chr16:75512273	CHST6	0.68	9.89	0.53	1.2e-19	Dupuytren's disease;
KIRP	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.32	8.36	0.47	4.73e-15	Crohn's disease;
KIRP	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg18944383	chr4:111397179	ENPEP	0.5	8.63	0.48	7.69e-16	Height;
KIRP	cis	rs13006833	0.634	rs1876877	chr2:191145274	G/A	cg21644426	chr2:191273491	MFSD6	0.45	5.43	0.33	1.35e-7	Urinary metabolites;
KIRP	cis	rs42648	0.935	rs42644	chr7:89974864	G/A	cg25739043	chr7:89950458	NA	-0.47	-7.46	-0.43	1.46e-12	Homocysteine levels;
KIRP	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg11584989	chr19:19387371	SF4	0.4	5.1	0.31	6.88e-7	Tonsillectomy;
KIRP	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	5.37	0.32	1.81e-7	Homoarginine levels;
KIRP	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg00484396	chr16:3507460	NAT15	0.53	5.35	0.32	2.06e-7	Tuberculosis;
KIRP	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg26116260	chr4:7069785	GRPEL1	1.14	16.93	0.73	3.68e-43	Monocyte percentage of white cells;
KIRP	cis	rs4664304	0.511	rs7606160	chr2:160693906	G/A	cg03641300	chr2:160917029	PLA2R1	-0.35	-4.92	-0.3	1.57e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06847283	chr2:217277082	SMARCAL1	0.49	6.29	0.37	1.46e-9	Parkinson's disease;
KIRP	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.88	-14.57	-0.68	4.28e-35	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg25486957	chr4:152246857	NA	-0.5	-5.29	-0.32	2.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.75	10.8	0.57	1.65e-22	Lung cancer;
KIRP	cis	rs2071426	0.959	rs1934983	chr10:96801929	A/G	cg09036531	chr10:96991505	NA	-0.56	-6.34	-0.37	1.12e-9	Blood metabolite levels;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09123484	chr1:15853263	DNAJC16	-0.45	-6.11	-0.36	3.87e-9	Electrocardiographic conduction measures;
KIRP	cis	rs2562456	0.833	rs55790393	chr19:21506184	A/T	cg18461458	chr19:21324796	ZNF431	-0.52	-5.04	-0.31	8.96e-7	Pain;
KIRP	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10433594	chr6:139696771	CITED2	-0.5	-6.84	-0.4	6.23e-11	Metabolic traits;
KIRP	cis	rs6438504	0.883	rs1584398	chr3:118967571	A/T	cg25372693	chr3:118959985	B4GALT4	0.34	5.65	0.34	4.5e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg01877450	chr7:97915802	BRI3	-0.55	-7.02	-0.41	2.2e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg00343986	chr7:65444356	GUSB	0.49	6.01	0.36	6.57e-9	Aortic root size;
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.05e-8	Lung cancer;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg23698023	chr8:27181813	PTK2B	0.33	5.02	0.3	1e-6	Neuroticism;
KIRP	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.67	5.54	0.33	7.92e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.19	0.42	7.97e-12	Lung cancer;
KIRP	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.4	-10.96	-0.57	4.91e-23	Gout;
KIRP	cis	rs7614311	0.689	rs73120898	chr3:63828780	G/A	cg22134162	chr3:63841271	THOC7	-0.44	-5.18	-0.31	4.61e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-1.04	-13.87	-0.66	1.05e-32	Body mass index;
KIRP	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg26207909	chr14:103986467	CKB	-0.45	-5.4	-0.33	1.56e-7	Coronary artery disease;
KIRP	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg13180566	chr4:1052158	NA	0.53	5.4	0.33	1.6e-7	Recombination rate (females);
KIRP	cis	rs397969	0.621	rs203449	chr17:19824621	C/T	cg13482628	chr17:19912719	NA	0.53	6.43	0.38	6.66e-10	Platelet count;
KIRP	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg10360139	chr7:1886902	MAD1L1	-0.53	-5.91	-0.35	1.13e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9943753	0.525	rs7952909	chr12:109808573	A/T	cg19025524	chr12:109796872	NA	0.49	6.79	0.4	8.27e-11	HDL cholesterol;
KIRP	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg22676075	chr6:135203613	NA	0.49	6.95	0.41	3.3e-11	Red blood cell count;
KIRP	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-7.89	-0.45	9.85e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg23601095	chr6:26197514	HIST1H3D	0.97	8.23	0.46	1.08e-14	Gout;Renal underexcretion gout;
KIRP	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.31	-0.37	1.29e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.74	-0.34	2.83e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg00405596	chr8:11794950	NA	-0.48	-6.22	-0.37	2.13e-9	Triglycerides;
KIRP	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.86	-0.63	2.83e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs17331151	0.505	rs34182518	chr3:52743854	G/A	cg04865290	chr3:52927548	TMEM110	-0.56	-4.85	-0.3	2.17e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9815354	0.859	rs9822288	chr3:41954588	C/T	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.54	7.2	0.42	7.43e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.74	0.49	3.75e-16	Bipolar disorder;
KIRP	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg17385448	chr1:15911702	AGMAT	0.25	4.92	0.3	1.57e-6	Systolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08646051	chr12:26205524	RASSF8	0.48	6.67	0.39	1.7e-10	Interleukin-4 levels;
KIRP	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.35	0.38	1.04e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02359409	chr6:42947317	PEX6	-0.37	-4.93	-0.3	1.49e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.5	-0.52	2.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.12	-0.41	1.17e-11	Menopause (age at onset);
KIRP	cis	rs4474465	0.541	rs11237527	chr11:78219664	C/A	cg27205649	chr11:78285834	NARS2	0.62	7.85	0.45	1.24e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9659323	0.931	rs113197996	chr1:119522426	G/A	cg18261050	chr1:119551319	NA	0.39	5.47	0.33	1.12e-7	Body mass index;
KIRP	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg02549819	chr16:58548995	SETD6	0.82	4.9	0.3	1.73e-6	Schizophrenia;
KIRP	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.63	-8.12	-0.46	2.29e-14	Colorectal cancer;
KIRP	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Colorectal cancer;
KIRP	cis	rs1010254	0.510	rs17113105	chr5:151712287	A/G	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs10073892	0.828	rs1393625	chr5:101876929	A/G	cg19774478	chr5:101632501	SLCO4C1	0.58	6.05	0.36	5.38e-9	Cognitive decline (age-related);
KIRP	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.57	0.43	7.72e-13	Lung cancer;
KIRP	trans	rs6919346	0.625	rs7453836	chr6:160942891	T/A	cg01413548	chr6:11656844	NA	0.37	6.12	0.36	3.61e-9	Lp (a) levels;
KIRP	cis	rs7508	0.619	rs483159	chr8:17911838	A/T	cg01800426	chr8:17659068	MTUS1	-0.72	-6.42	-0.38	6.92e-10	Atrial fibrillation;
KIRP	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg08975724	chr8:8085496	FLJ10661	0.54	6.78	0.4	8.83e-11	Triglycerides;
KIRP	cis	rs9409565	0.826	rs4612412	chr9:97208627	C/G	cg04523069	chr9:97136363	HIATL1	0.48	6.47	0.38	5.3e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.38	-0.43	2.43e-12	Response to antipsychotic treatment;
KIRP	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-1.03	-9.53	-0.52	1.58e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg20731937	chr12:48336164	NA	0.41	5.19	0.31	4.32e-7	Longevity (90 years and older);
KIRP	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg07274523	chr3:49395745	GPX1	0.72	8.75	0.49	3.35e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg01763666	chr17:80159506	CCDC57	0.37	5.04	0.31	9.19e-7	Life satisfaction;
KIRP	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	trans	rs1620921	0.901	rs783165	chr6:161177842	A/C	cg01090089	chr7:6570974	GRID2IP	0.39	6.09	0.36	4.42e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.08	-0.31	7.31e-7	Pulmonary function;
KIRP	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.47	7.26	0.42	5.14e-12	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg07884673	chr3:53033167	SFMBT1	1.04	7.92	0.45	8.18e-14	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs5995756	0.666	rs926231	chr22:40006986	C/G	cg10455938	chr22:40058150	CACNA1I	0.38	5.28	0.32	2.81e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg10018233	chr7:150070692	REPIN1	0.55	6.08	0.36	4.56e-9	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg00442670	chr17:47406777	ZNF652	-0.43	-6.14	-0.36	3.33e-9	Inflammatory biomarkers;
KIRP	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg13414629	chr9:132935646	FREQ	0.54	7.04	0.41	1.94e-11	Alzheimer's disease (cognitive decline);
KIRP	cis	rs754423	0.703	rs2101919	chr14:52520368	C/T	cg10149976	chr14:52535953	NID2	-0.4	-5.41	-0.33	1.51e-7	Craniofacial microsomia;
KIRP	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	17.38	0.74	1.14e-44	Homoarginine levels;
KIRP	cis	rs494562	0.892	rs550499	chr6:86115602	G/C	cg27039625	chr6:86159096	NT5E	0.42	5.31	0.32	2.45e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs11997175	0.766	rs4733176	chr8:33685334	A/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.77	0.35	2.36e-8	Body mass index;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.9	-0.3	1.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.41	7.13	0.41	1.1e-11	Heart rate;
KIRP	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.5	0.52	1.99e-18	Cognitive test performance;
KIRP	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-7.18	-0.42	8.3e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg24253500	chr15:84953950	NA	0.7	7.79	0.44	1.84e-13	Schizophrenia;
KIRP	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.26	-0.37	1.68e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.65	0.44	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg06636001	chr8:8085503	FLJ10661	0.67	9.03	0.5	5.05e-17	Retinal vascular caliber;
KIRP	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-10.06	-0.54	3.58e-20	Coffee consumption (cups per day);
KIRP	cis	rs2859741	0.587	rs516139	chr1:37471617	C/G	cg09363841	chr1:37513479	NA	-0.49	-7.64	-0.44	4.77e-13	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04147372	chr14:60337617	RTN1	-0.51	-6.17	-0.37	2.85e-9	Interleukin-4 levels;
KIRP	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg11784071	chr10:104629166	AS3MT	-0.39	-5.47	-0.33	1.11e-7	Arsenic metabolism;
KIRP	cis	rs4774899	0.966	rs12898327	chr15:57363937	G/T	cg13626582	chr15:57592083	LOC283663	-0.2	-4.91	-0.3	1.68e-6	Urinary tract infection frequency;
KIRP	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg01320579	chr17:75405842	SEPT9	0.49	7.77	0.44	2.13e-13	Airflow obstruction;
KIRP	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg20737812	chr15:86336631	KLHL25	-0.52	-6.45	-0.38	5.8e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3026101	0.624	rs11869800	chr17:5307781	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg12802720	chr12:52467448	C12orf44	0.55	6.23	0.37	2.02e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.34e-11	Aortic root size;
KIRP	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	1.03	11.56	0.59	5.65e-25	Post bronchodilator FEV1;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09658342	chr2:70476000	TIA1	0.63	7.34	0.42	3.1e-12	Lung cancer in ever smokers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08862778	chr1:11322643	MTOR	-0.47	-6.34	-0.37	1.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2573652	1.000	rs2581359	chr15:100513707	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.76	-12.47	-0.62	5.66e-28	Height;
KIRP	cis	rs4481887	0.538	rs6697831	chr1:248392205	C/T	cg01631408	chr1:248437212	OR2T33	-0.45	-5.17	-0.31	4.85e-7	Common traits (Other);
KIRP	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg05347473	chr6:146136440	FBXO30	-0.63	-9.26	-0.51	1.05e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.56	-15.56	-0.7	1.74e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.03e-11	Morning vs. evening chronotype;
KIRP	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.57	-6.88	-0.4	4.83e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg06204229	chr3:52865917	ITIH4	0.43	5.09	0.31	7.02e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03245229	chr8:26436527	DPYSL2	0.48	7.04	0.41	1.86e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.33	5.35	0.32	1.96e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.93	12.05	0.61	1.42e-26	Menopause (age at onset);
KIRP	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.71	8.43	0.47	2.97e-15	Corneal astigmatism;
KIRP	cis	rs155346	0.571	rs264340	chr5:139354551	A/G	cg24724630	chr5:139362307	NRG2	-0.38	-5.02	-0.3	9.98e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs2017305	0.834	rs2246974	chr10:70783324	T/C	cg01024728	chr10:70782572	NA	0.6	4.87	0.3	2.02e-6	Depression (quantitative trait);
KIRP	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg00405596	chr8:11794950	NA	-0.42	-4.99	-0.3	1.17e-6	Retinal vascular caliber;
KIRP	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06544989	chr22:39130855	UNC84B	0.5	8.85	0.49	1.72e-16	Menopause (age at onset);
KIRP	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.41	8.38	0.47	4.23e-15	Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.94e-8	Life satisfaction;
KIRP	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.22	0.72	1.01e-40	Electrocardiographic conduction measures;
KIRP	cis	rs17608059	0.545	rs9915045	chr17:13902636	G/T	cg11395062	chr17:14139857	CDRT15	0.59	7.75	0.44	2.44e-13	Temperament;
KIRP	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg17646820	chr3:66848679	NA	-0.73	-9.72	-0.53	4.15e-19	Type 2 diabetes;
KIRP	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	0.9	8.29	0.47	7.48e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg14829360	chr17:73884958	NA	-0.55	-7.62	-0.44	5.64e-13	Psoriasis;
KIRP	trans	rs3935996	0.767	rs12058859	chr1:56302126	C/T	cg21647170	chr7:56119546	CCT6A;PSPH	0.46	6.14	0.36	3.21e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
KIRP	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg01620082	chr3:125678407	NA	-1.13	-7.31	-0.42	3.7e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg05315796	chr3:52349193	DNAH1	-0.39	-6.12	-0.36	3.6e-9	Bipolar disorder;
KIRP	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg08822215	chr16:89438651	ANKRD11	-0.52	-6.68	-0.39	1.56e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-7.22	-0.42	6.58e-12	Brugada syndrome;
KIRP	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12908607	chr1:44402522	ARTN	-0.45	-6.46	-0.38	5.47e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg21253087	chr9:139290292	SNAPC4	0.4	5.21	0.32	3.99e-7	Monocyte percentage of white cells;
KIRP	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg17294928	chr15:75287854	SCAMP5	-0.78	-5.02	-0.3	1.02e-6	Lung cancer;
KIRP	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.59	8.14	0.46	1.95e-14	Prostate cancer;
KIRP	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	8.56	0.48	1.23e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg05315796	chr3:52349193	DNAH1	0.4	6.32	0.37	1.22e-9	Bipolar disorder;
KIRP	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03934478	chr11:495069	RNH1	0.83	6.78	0.4	8.78e-11	Body mass index;
KIRP	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03576123	chr11:487126	PTDSS2	-1.11	-9.55	-0.52	1.42e-18	Body mass index;
KIRP	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.61	-0.39	2.39e-10	Mean platelet volume;
KIRP	cis	rs6540559	0.611	rs6540563	chr1:210019858	C/G	cg22029157	chr1:209979665	IRF6	0.46	5.0	0.3	1.11e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.83	0.4	6.49e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg04691961	chr3:161091175	C3orf57	-0.36	-5.32	-0.32	2.39e-7	Kawasaki disease;
KIRP	cis	rs75920871	0.841	rs77250716	chr11:116877353	T/C	cg23684410	chr11:116897558	SIK3	0.57	6.16	0.37	2.98e-9	Subjective well-being;
KIRP	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.73	-8.89	-0.49	1.34e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg27624424	chr6:160112604	SOD2	0.46	4.92	0.3	1.61e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1440410	0.804	rs28470858	chr4:144108161	A/T	cg01719995	chr4:144104893	USP38	0.39	5.25	0.32	3.32e-7	Ischemic stroke;
KIRP	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg21775007	chr8:11205619	TDH	-0.43	-5.6	-0.34	5.82e-8	Monocyte count;
KIRP	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg00129232	chr17:37814104	STARD3	-0.53	-6.57	-0.39	2.94e-10	Self-reported allergy;
KIRP	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.62	6.84	0.4	6.33e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2742234	0.541	rs1879310	chr10:43734775	A/G	cg15436174	chr10:43711423	RASGEF1A	0.79	8.5	0.48	1.79e-15	Hirschsprung disease;
KIRP	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg26681399	chr22:41777847	TEF	-0.51	-4.9	-0.3	1.76e-6	Vitiligo;
KIRP	cis	rs9638182	0.638	rs6946689	chr7:72977637	T/A	cg07452164	chr7:72993570	TBL2	0.52	5.86	0.35	1.47e-8	Triglycerides;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.58	-9.17	-0.5	2.01e-17	Lung cancer;
KIRP	cis	rs7246657	0.722	rs10403173	chr19:38078680	G/A	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg04070771	chr13:27998621	GTF3A	0.54	5.52	0.33	8.79e-8	Schizophrenia;
KIRP	cis	rs2398893	0.774	rs10993047	chr9:96846500	C/T	cg14459158	chr9:96720562	NA	-0.3	-5.4	-0.33	1.57e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.51	-5.47	-0.33	1.11e-7	Subjective well-being;
KIRP	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.08	-13.84	-0.66	1.28e-32	Corneal structure;
KIRP	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs1134634	0.520	rs11943107	chr4:15574665	T/C	cg16509355	chr4:15471240	CC2D2A	-0.31	-5.24	-0.32	3.44e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-5.66	-0.34	4.22e-8	Subjective well-being;
KIRP	cis	rs933688	0.509	rs2941895	chr5:90520510	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.53	-5.87	-0.35	1.39e-8	Smoking behavior;
KIRP	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg06740227	chr12:86229804	RASSF9	0.43	5.4	0.33	1.61e-7	Major depressive disorder;
KIRP	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.63	8.12	0.46	2.32e-14	Mood instability;
KIRP	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.43	7.32	0.42	3.61e-12	Renal cell carcinoma;
KIRP	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	5.06e-7	Parkinson's disease;
KIRP	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs11264213	0.792	rs709309	chr1:36441148	G/T	cg27506609	chr1:36549197	TEKT2	0.98	10.25	0.55	9.42e-21	Schizophrenia;
KIRP	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.55	7.77	0.44	2.19e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg05362011	chr13:21860987	NA	-0.47	-5.02	-0.31	9.77e-7	White matter hyperintensity burden;
KIRP	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.58	0.34	6.4e-8	Parkinson's disease;
KIRP	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg00405596	chr8:11794950	NA	-0.43	-5.25	-0.32	3.32e-7	Neuroticism;
KIRP	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg08222618	chr4:941054	TMEM175	-0.48	-7.17	-0.42	8.55e-12	Systemic sclerosis;
KIRP	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.24	0.58	6.25e-24	Morning vs. evening chronotype;
KIRP	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg23477460	chr3:66848765	NA	0.71	8.49	0.48	2e-15	Type 2 diabetes;
KIRP	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.45	-5.84	-0.35	1.63e-8	Refractive error;
KIRP	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	0.64	5.78	0.35	2.29e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.85	12.49	0.62	4.66e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11069349	0.608	rs9585056	chr13:100081766	A/G	cg15490075	chr13:100150979	NA	-0.51	-5.61	-0.34	5.55e-8	Self-reported allergy;
KIRP	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.96	12.78	0.63	4.97e-29	Menopause (age at onset);
KIRP	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.12	15.75	0.71	4.13e-39	Breast cancer;
KIRP	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.24	0.58	6.25e-24	Morning vs. evening chronotype;
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.68	7.69	0.44	3.49e-13	Schizophrenia;
KIRP	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs142472947	1	rs142472947	chr1:8520487	AAAG/A	cg03610117	chr1:8450231	RERE	-0.48	-5.13	-0.31	5.75e-7	White blood cell count;
KIRP	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.88	0.3	1.88e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2278796	1.000	rs12124296	chr1:204945618	G/A	cg04862289	chr1:204966208	NFASC	0.65	9.07	0.5	3.86e-17	Mean platelet volume;
KIRP	trans	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.4e-20	Pursuit maintenance gain;
KIRP	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg22903471	chr2:27725779	GCKR	0.39	5.22	0.32	3.78e-7	Oral cavity cancer;
KIRP	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.84	-13.42	-0.65	3.38e-31	Breast cancer;
KIRP	cis	rs6832769	0.961	rs10009593	chr4:56436681	C/A	cg09317128	chr4:56265301	TMEM165	-0.52	-6.7	-0.39	1.39e-10	Personality dimensions;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.2.189776559R	chr2:190068314	NA	0.47	7.1	0.41	1.33e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.74	0.34	2.79e-8	Menopause (age at onset);
KIRP	trans	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.49	-0.38	4.73e-10	Glioblastoma;
KIRP	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	4.88	0.3	1.94e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg07511668	chr11:68622177	NA	0.4	5.27	0.32	2.99e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	9.72	0.53	4.29e-19	Response to antipsychotic treatment;
KIRP	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.39	-5.46	-0.33	1.14e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg10935138	chr17:73851978	WBP2	0.45	5.34	0.32	2.09e-7	White matter hyperintensity burden;
KIRP	cis	rs1011018	0.910	rs12673068	chr7:139434215	T/G	cg03224163	chr7:139420300	HIPK2	-0.46	-4.89	-0.3	1.8e-6	Systolic blood pressure;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.62	-5.97	-0.36	8.44e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg03060546	chr3:49711283	APEH	-0.69	-5.11	-0.31	6.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.72	-10.32	-0.55	5.49e-21	Cancer;
KIRP	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.75	8.54	0.48	1.44e-15	Sudden cardiac arrest;
KIRP	trans	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg25042112	chr7:64838748	ZNF92	-0.59	-6.02	-0.36	6.19e-9	Pain;
KIRP	cis	rs35892873	0.959	rs9877710	chr3:126091223	A/G	cg15490784	chr3:126061950	KLF15	0.51	6.53	0.38	3.8e-10	Male-pattern baldness;
KIRP	cis	rs4356932	1.000	rs4241580	chr4:76956188	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.54	5.74	0.34	2.72e-8	Hypospadias;
KIRP	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	7.17	0.42	8.74e-12	Menarche (age at onset);
KIRP	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08439880	chr3:133502540	NA	-0.53	-6.57	-0.39	2.98e-10	Iron status biomarkers;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg08662619	chr6:150070041	PCMT1	0.37	6.2	0.37	2.43e-9	Lung cancer;
KIRP	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.65	-7.11	-0.41	1.27e-11	DNA methylation (variation);
KIRP	cis	rs8014252	0.803	rs17108264	chr14:71066484	A/G	cg19730268	chr14:71022823	NA	-0.72	-6.4	-0.38	7.89e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06466757	chr4:1255808	NA	-0.44	-6.61	-0.39	2.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9488822	0.662	rs195534	chr6:116254834	T/C	cg18764771	chr6:116381957	FRK	0.19	5.02	0.3	1.01e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22509189	chr2:225307070	NA	0.44	5.13	0.31	5.93e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg17757837	chr7:157058334	UBE3C	0.78	10.52	0.56	1.31e-21	Body mass index;
KIRP	cis	rs16958440	1.000	rs61316646	chr18:44610670	G/C	cg17192377	chr18:44677553	HDHD2	0.73	6.61	0.39	2.32e-10	Sitting height ratio;
KIRP	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg16255804	chr6:135334527	HBS1L	0.32	5.08	0.31	7.55e-7	Red blood cell count;
KIRP	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.46	6.46	0.38	5.48e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2816062	0.786	rs2816059	chr1:18902977	G/A	cg18795169	chr1:18902165	NA	-0.86	-13.39	-0.65	4.47e-31	Urate levels in lean individuals;
KIRP	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	5.86	0.35	1.48e-8	Bipolar disorder;
KIRP	cis	rs3112255	0.935	rs1467130	chr2:101306319	T/C	cg01042948	chr2:101319752	NA	0.43	6.15	0.36	3.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	7.12	0.41	1.18e-11	Refractive astigmatism;
KIRP	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.72	-10.15	-0.54	1.95e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6956675	1.000	rs1609527	chr7:62599257	C/T	cg08930214	chr7:62859557	LOC100287834	0.51	5.84	0.35	1.67e-8	Obesity-related traits;
KIRP	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	1.16	14.34	0.67	2.67e-34	Type 2 diabetes nephropathy;
KIRP	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg18240653	chr6:144019428	PHACTR2	-0.46	-4.87	-0.3	2.04e-6	Obesity-related traits;
KIRP	cis	rs4664304	0.620	rs1828480	chr2:160720384	G/A	cg03641300	chr2:160917029	PLA2R1	0.35	5.22	0.32	3.77e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1823913	0.599	rs10497713	chr2:192144038	C/T	cg12404831	chr2:192114017	MYO1B	0.53	7.35	0.42	2.88e-12	Obesity-related traits;
KIRP	cis	rs4356975	0.522	rs34386959	chr4:69966555	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg15655495	chr12:38532458	NA	-0.27	-5.13	-0.31	5.85e-7	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11714341	chr5:158605914	RNF145	0.44	6.61	0.39	2.3e-10	C-reactive protein;
KIRP	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-8.18	-0.46	1.52e-14	Total body bone mineral density;
KIRP	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-6.18	-0.37	2.65e-9	Inflammatory skin disease;
KIRP	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs62070183	0.595	rs4605221	chr17:31251098	C/T	cg05781649	chr17:31146240	MYO1D	-0.5	-4.89	-0.3	1.82e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs11249608	0.744	rs4701025	chr5:178444474	G/A	cg21905437	chr5:178450457	ZNF879	-0.49	-5.77	-0.35	2.36e-8	Pubertal anthropometrics;
KIRP	cis	rs960902	0.710	rs2192943	chr2:37731460	A/C	cg25341268	chr2:37734390	NA	-0.58	-7.92	-0.45	8.21e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg23815491	chr16:72088622	HP	0.44	6.01	0.36	6.61e-9	Blood protein levels;
KIRP	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg16586182	chr3:47516702	SCAP	-0.77	-11.17	-0.58	1.02e-23	Colorectal cancer;
KIRP	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.57	0.39	3e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.87	-0.4	5.28e-11	Aortic root size;
KIRP	cis	rs4790333	0.653	rs2447103	chr17:2262997	A/C	cg02569219	chr17:2266849	SGSM2	0.43	5.48	0.33	1.07e-7	Proinsulin levels;
KIRP	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.86	9.78	0.53	2.71e-19	High light scatter reticulocyte count;
KIRP	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg00922110	chr4:57842668	C4orf14	-0.43	-5.73	-0.34	2.85e-8	Response to bleomycin (chromatid breaks);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12588256	chr13:77601659	FBXL3	-0.45	-6.02	-0.36	6.39e-9	Warfarin maintenance dose;
KIRP	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg23335576	chr14:104009727	NA	0.39	5.43	0.33	1.33e-7	Body mass index;
KIRP	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs6580649	0.941	rs72644845	chr12:48503881	G/A	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg04317338	chr11:64019027	PLCB3	0.54	6.35	0.38	1.06e-9	Platelet count;
KIRP	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.57	-6.43	-0.38	6.54e-10	Menarche (age at onset);
KIRP	cis	rs7951870	1.000	rs7109698	chr11:46673344	A/G	cg19486271	chr11:47235900	DDB2	-0.45	-5.17	-0.31	4.78e-7	Schizophrenia;
KIRP	cis	rs687432	0.924	rs7950003	chr11:57759936	C/T	cg19752551	chr11:57585705	CTNND1	-0.65	-8.39	-0.47	3.82e-15	Parkinson's disease;
KIRP	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.86	9.71	0.53	4.46e-19	High light scatter reticulocyte count;
KIRP	trans	rs61440199	1.000	rs73818811	chr3:20144715	G/A	cg08354614	chr10:80673607	NA	0.56	6.19	0.37	2.54e-9	Staphylococcus aureus nasal carriage (intermittent);
KIRP	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg00405596	chr8:11794950	NA	0.51	6.38	0.38	8.86e-10	Neuroticism;
KIRP	cis	rs829661	0.948	rs829619	chr2:30749567	C/T	cg10949345	chr2:30726833	LCLAT1	0.72	10.35	0.55	4.45e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.09	0.54	3.04e-20	Total body bone mineral density;
KIRP	cis	rs1712517	0.771	rs7074749	chr10:105116056	C/T	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.41e-9	Migraine;
KIRP	cis	rs7127900	0.583	rs11043142	chr11:2234042	A/G	cg25635251	chr11:2234043	NA	0.44	6.97	0.41	2.85e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.83	-9.36	-0.51	5.13e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs6901004	0.771	rs6900781	chr6:111422856	T/A	cg15721981	chr6:111408429	SLC16A10	-0.52	-6.95	-0.41	3.27e-11	Blood metabolite levels;
KIRP	trans	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.07	0.36	4.74e-9	Mean corpuscular volume;
KIRP	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.74	-10.66	-0.56	4.5e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs17023223	0.581	rs12064109	chr1:119642296	T/C	cg05756136	chr1:119680316	WARS2	-0.55	-7.29	-0.42	4.23e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.63	6.75	0.4	1.03e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.11	12.04	0.61	1.53e-26	Vitiligo;
KIRP	cis	rs3540	0.513	rs1072879	chr15:90922038	C/T	cg22089800	chr15:90895588	ZNF774	0.62	8.49	0.48	2.02e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05854894	chr18:9475337	RALBP1	0.47	6.5	0.38	4.46e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7712401	0.601	rs246320	chr5:122308581	A/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.27	-0.37	1.65e-9	Monocyte percentage of white cells;
KIRP	cis	rs7524258	0.900	rs4908611	chr1:7313861	G/A	cg07173049	chr1:7289937	CAMTA1	0.72	11.01	0.57	3.48e-23	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg13798912	chr7:905769	UNC84A	0.52	5.22	0.32	3.8e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1823913	0.599	rs17414109	chr2:192175401	T/A	cg12404831	chr2:192114017	MYO1B	0.51	7.02	0.41	2.11e-11	Obesity-related traits;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg09015484	chr9:96929106	NA	0.6	7.05	0.41	1.8e-11	Sleep duration;
KIRP	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	10.24	0.55	9.95e-21	Triglycerides;
KIRP	cis	rs10267417	0.673	rs10242012	chr7:19938249	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.87	0.3	1.96e-6	Night sleep phenotypes;
KIRP	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.65	8.44	0.47	2.67e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg22643751	chr7:855365	UNC84A	0.38	5.14	0.31	5.5e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg00852783	chr1:26633632	UBXN11	-0.51	-5.19	-0.31	4.42e-7	Obesity-related traits;
KIRP	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-5.2	-0.31	4.21e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg14675211	chr2:100938903	LONRF2	-0.47	-6.02	-0.36	6.41e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6800768	0.633	rs57144868	chr3:24144965	G/C	cg10674438	chr3:24145617	LOC152024	-0.52	-6.8	-0.4	7.79e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.71	0.39	1.36e-10	Colorectal cancer;
KIRP	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.68	9.95	0.54	8.01e-20	Lymphocyte counts;
KIRP	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg08885076	chr2:99613938	TSGA10	0.53	9.27	0.51	9.88e-18	Chronic sinus infection;
KIRP	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	8.1e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs71403859	0.554	rs12373065	chr16:71870032	T/A	cg08717414	chr16:71523259	ZNF19	-0.68	-5.24	-0.32	3.42e-7	Post bronchodilator FEV1;
KIRP	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.72	0.53	4.15e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11605924	0.901	rs7105751	chr11:45856973	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.48	-5.82	-0.35	1.84e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg08496016	chr9:99181722	ZNF367	0.72	6.21	0.37	2.2e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs17023223	0.537	rs6662165	chr1:119614071	T/G	cg05756136	chr1:119680316	WARS2	-0.58	-7.65	-0.44	4.54e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg10729496	chr3:10149963	C3orf24	0.54	4.89	0.3	1.85e-6	Alzheimer's disease;
KIRP	cis	rs2979489	0.891	rs4449748	chr8:30304402	A/G	cg26383811	chr8:30366931	RBPMS	0.39	5.3	0.32	2.61e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.88	-0.4	4.96e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs12230513	0.793	rs10783756	chr12:55920314	A/G	cg03330747	chr12:56361238	CDK2;SILV	-0.37	-4.97	-0.3	1.27e-6	Contrast sensitivity;
KIRP	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-7.51	-0.43	1.07e-12	Response to antipsychotic treatment;
KIRP	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.35	5.23	0.32	3.63e-7	Eye color traits;
KIRP	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg04602081	chr1:16498086	NA	0.39	4.96	0.3	1.34e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.2	-0.8	1.87e-57	Ulcerative colitis;
KIRP	cis	rs9653442	0.564	rs10185510	chr2:100790581	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.29	-0.32	2.68e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg21475434	chr5:93447410	FAM172A	0.43	4.99	0.3	1.12e-6	Diabetic retinopathy;
KIRP	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg08085267	chr17:45401833	C17orf57	-0.51	-6.33	-0.37	1.13e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.69	10.26	0.55	8.36e-21	Prostate cancer;
KIRP	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.42	-4.92	-0.3	1.61e-6	Blood metabolite levels;
KIRP	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-7.32	-0.42	3.47e-12	Resting heart rate;
KIRP	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs858239	0.539	rs2390757	chr7:23191492	A/G	cg23682824	chr7:23144976	KLHL7	0.5	5.73	0.34	2.9e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.62	5.93	0.35	1.01e-8	Breast cancer;
KIRP	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.13	-0.36	3.53e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg06121193	chr1:90282411	NA	-0.46	-6.49	-0.38	4.62e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.8	12.69	0.63	1.04e-28	Breast cancer;
KIRP	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.6	8.06	0.46	3.23e-14	White matter hyperintensity burden;
KIRP	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg00405596	chr8:11794950	NA	0.52	6.25	0.37	1.8e-9	Mood instability;
KIRP	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.83	12.55	0.62	3.08e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.82	-12.82	-0.63	3.81e-29	Asthma;
KIRP	cis	rs10193935	0.579	rs62142594	chr2:42524531	G/A	cg27598129	chr2:42591480	NA	-0.79	-5.55	-0.33	7.26e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg17507749	chr15:85114479	UBE2QP1	0.86	9.81	0.53	2.25e-19	Schizophrenia;
KIRP	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg10207240	chr12:122356781	WDR66	0.58	7.91	0.45	8.74e-14	Mean corpuscular volume;
KIRP	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.57e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2151522	0.563	rs6908014	chr6:127145083	C/T	cg21431617	chr6:127135037	NA	0.33	5.87	0.35	1.44e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.31	-0.37	1.29e-9	Monocyte count;
KIRP	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.62	-7.68	-0.44	3.81e-13	Breast cancer;
KIRP	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06544989	chr22:39130855	UNC84B	0.49	8.65	0.48	6.86e-16	Menopause (age at onset);
KIRP	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.31	8.19	0.46	1.44e-14	Primary biliary cholangitis;
KIRP	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.42	8.05	0.46	3.47e-14	Educational attainment (years of education);
KIRP	cis	rs17092148	0.943	rs4911160	chr20:33349940	G/A	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	cis	rs7595037	0.663	rs7421075	chr2:68656342	T/C	cg12452813	chr2:68675892	NA	-0.43	-5.29	-0.32	2.77e-7	Multiple sclerosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01651660	chr14:101452433	SNORD114-25;SNORD114-26	-0.44	-6.93	-0.4	3.65e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-5.58	-0.34	6.41e-8	Bipolar disorder;
KIRP	cis	rs9913156	0.515	rs11658808	chr17:4577112	C/T	cg23387401	chr17:4582204	PELP1	-0.4	-5.21	-0.32	3.93e-7	Lymphocyte counts;
KIRP	cis	rs3755132	0.929	rs16862823	chr2:15775210	T/C	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs714027	0.626	rs7287570	chr22:30507358	G/C	cg27665648	chr22:30112403	NA	-0.45	-6.3	-0.37	1.38e-9	Lymphocyte counts;
KIRP	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg17376030	chr22:41985996	PMM1	-0.7	-8.04	-0.46	3.69e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1144	0.537	rs2470949	chr7:104590780	C/T	cg04380332	chr7:105027541	SRPK2	-0.55	-8.08	-0.46	2.84e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.91	10.48	0.56	1.73e-21	Menopause (age at onset);
KIRP	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg02023728	chr11:77925099	USP35	-0.31	-5.25	-0.32	3.23e-7	Alzheimer's disease (survival time);
KIRP	cis	rs8084125	1.000	rs871830	chr18:74953607	G/C	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.65	-9.37	-0.51	4.77e-18	Retinal vascular caliber;
KIRP	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	0.94	10.32	0.55	5.53e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2637030	0.559	rs549131	chr5:52902238	T/C	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg13010199	chr12:38710504	ALG10B	0.58	7.38	0.43	2.37e-12	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.86e-11	Retinal vascular caliber;
KIRP	cis	rs80282103	0.618	rs2279256	chr10:1132852	G/A	cg08668510	chr10:1095578	IDI1	0.79	5.41	0.33	1.52e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg18357526	chr6:26021779	HIST1H4A	0.47	5.5	0.33	9.28e-8	Blood metabolite levels;
KIRP	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.93	10.3	0.55	6.26e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6102059	0.692	rs2865504	chr20:39203614	T/A	cg06665391	chr20:39312290	NA	0.39	5.0	0.3	1.09e-6	LDL cholesterol;
KIRP	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1978968	0.956	rs1110661	chr22:18444734	C/T	cg03078520	chr22:18463400	MICAL3	-0.66	-7.88	-0.45	1.04e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs986417	0.901	rs1950310	chr14:60988526	T/A	cg27398547	chr14:60952738	C14orf39	0.72	7.1	0.41	1.37e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03734322	chr17:1532856	SLC43A2	0.53	6.75	0.4	1.03e-10	Smoking initiation;
KIRP	cis	rs3857536	0.904	rs4336428	chr6:66901840	C/T	cg07460842	chr6:66804631	NA	-0.4	-5.33	-0.32	2.2e-7	Blood trace element (Cu levels);
KIRP	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg02297831	chr4:17616191	MED28	0.51	6.22	0.37	2.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.29	12.33	0.62	1.61e-27	Diabetic retinopathy;
KIRP	cis	rs1832871	0.672	rs7750011	chr6:158746802	A/C	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.42	5.16	0.31	5.05e-7	Diabetic retinopathy;
KIRP	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg10047753	chr17:41438598	NA	1.13	18.71	0.77	3.64e-49	Menopause (age at onset);
KIRP	cis	rs12049351	0.631	rs11810108	chr1:229668671	C/T	cg11742688	chr1:229674241	ABCB10	0.39	6.46	0.38	5.58e-10	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg24826892	chr11:71159390	DHCR7	0.44	5.06	0.31	8.04e-7	Vitamin D levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20696214	chr10:71583771	COL13A1	0.52	6.83	0.4	6.46e-11	Interleukin-4 levels;
KIRP	cis	rs6088813	0.925	rs4353719	chr20:33977349	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-6.83	-0.4	6.58e-11	Height;
KIRP	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-21.84	-0.81	1.65e-59	Height;
KIRP	cis	rs9309473	1.000	rs7584575	chr2:73666402	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.24	-0.37	1.89e-9	Metabolite levels;
KIRP	trans	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg20528838	chr20:57427730	GNAS	-0.47	-6.28	-0.37	1.54e-9	Height;
KIRP	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg24060327	chr5:131705240	SLC22A5	0.61	6.23	0.37	1.98e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.66	0.39	1.76e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg16497661	chr14:103986332	CKB	0.49	6.58	0.39	2.83e-10	Body mass index;
KIRP	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg04546413	chr19:29218101	NA	0.89	8.99	0.5	6.98e-17	Methadone dose in opioid dependence;
KIRP	cis	rs56161922	0.915	rs12563415	chr1:207856666	G/T	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.55	-4.94	-0.3	1.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs580438	0.707	rs473030	chr3:13350085	C/G	cg10657019	chr3:13328039	NA	0.65	8.58	0.48	1.11e-15	Myringotomy;
KIRP	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-6.44	-0.38	6.15e-10	Aortic root size;
KIRP	cis	rs11673344	0.566	rs2385181	chr19:37886330	C/A	cg14683738	chr19:37701593	ZNF585B	0.43	4.93	0.3	1.5e-6	Obesity-related traits;
KIRP	trans	rs3935996	0.767	rs12058859	chr1:56302126	C/T	cg00920043	chr1:11333412	UBIAD1	0.45	6.05	0.36	5.3e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.49	7.24	0.42	5.87e-12	Lymphocyte counts;
KIRP	cis	rs2625529	0.617	rs2128112	chr15:72186286	A/T	cg16672083	chr15:72433130	SENP8	0.45	6.31	0.37	1.32e-9	Red blood cell count;
KIRP	cis	rs2219968	0.962	rs6995342	chr8:78951749	A/T	cg00738934	chr8:78996279	NA	0.41	5.28	0.32	2.79e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1823913	0.599	rs12994212	chr2:192171636	C/T	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.65e-12	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs75920871	0.623	rs56016514	chr11:116961588	G/A	cg04087571	chr11:116723030	SIK3	-0.28	-5.55	-0.33	7.25e-8	Subjective well-being;
KIRP	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11987759	chr7:65425863	GUSB	-0.69	-9.71	-0.53	4.37e-19	Aortic root size;
KIRP	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg22705602	chr4:152727874	NA	-0.56	-9.89	-0.53	1.22e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23172579	chr4:141677235	TBC1D9	-0.51	-7.44	-0.43	1.64e-12	Metabolic traits;
KIRP	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.75	-8.17	-0.46	1.61e-14	Vitiligo;
KIRP	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg18016565	chr1:150552671	MCL1	0.36	5.53	0.33	8.37e-8	Tonsillectomy;
KIRP	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.31	5.11	0.31	6.32e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg11382394	chr1:2564504	MMEL1	0.38	4.86	0.3	2.14e-6	Ulcerative colitis;
KIRP	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18364779	chr6:26104403	HIST1H4C	0.41	5.32	0.32	2.33e-7	Schizophrenia;
KIRP	cis	rs9815354	0.812	rs17214945	chr3:41808660	A/C	cg03022575	chr3:42003672	ULK4	0.76	8.08	0.46	2.83e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg13010199	chr12:38710504	ALG10B	-0.57	-7.76	-0.44	2.21e-13	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.53	-6.96	-0.41	3.12e-11	Longevity;Endometriosis;
KIRP	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg01689657	chr7:91764605	CYP51A1	0.41	5.86	0.35	1.45e-8	Breast cancer;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.94	16.96	0.73	2.99e-43	Longevity;Endometriosis;
KIRP	trans	rs78049276	0.651	rs59415853	chr4:148378225	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.78	-10.48	-0.56	1.7e-21	Pulse pressure;
KIRP	trans	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg21775007	chr8:11205619	TDH	-0.46	-6.03	-0.36	6.11e-9	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01892346	chr16:25026828	ARHGAP17	0.54	6.66	0.39	1.77e-10	Parkinson's disease;
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg06654118	chr4:1303317	MAEA	0.26	4.96	0.3	1.31e-6	Longevity;
KIRP	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.5	-0.48	1.85e-15	Vitiligo;
KIRP	cis	rs12643440	0.960	rs12641746	chr4:17206822	A/G	cg22650099	chr4:17144496	NA	0.49	5.81	0.35	1.91e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4805272	1.000	rs10423704	chr19:29323777	A/G	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg15128208	chr22:42549153	NA	0.55	6.1	0.36	4.17e-9	Birth weight;
KIRP	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.6	8.27	0.47	8.48e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs7078012	0.504	rs17886602	chr10:81697177	G/C	cg24613050	chr10:81743128	NA	-0.54	-5.03	-0.31	9.62e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg26893134	chr6:116381904	FRK	0.2	5.61	0.34	5.39e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.15	-0.31	5.45e-7	Metabolite levels;
KIRP	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg06742321	chr12:123595122	PITPNM2	0.43	5.48	0.33	1.04e-7	Platelet count;
KIRP	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-8.74	-0.49	3.59e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs981844	0.712	rs1350189	chr4:154744951	A/T	cg14289246	chr4:154710475	SFRP2	-0.54	-6.98	-0.41	2.67e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6681460	0.565	rs1536112	chr1:67107225	C/T	cg13052034	chr1:66999238	SGIP1	-0.39	-5.48	-0.33	1.05e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.4	9.48e-11	Red blood cell count;
KIRP	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg08975724	chr8:8085496	FLJ10661	0.64	8.76	0.49	3.3e-16	Neuroticism;
KIRP	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg26695010	chr11:65641043	EFEMP2	-0.44	-5.48	-0.33	1.08e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.6	6.62	0.39	2.22e-10	Interstitial lung disease;
KIRP	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.75	-9.89	-0.53	1.24e-19	Coronary artery disease;
KIRP	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.65	9.82	0.53	2.07e-19	Fibrinogen levels;
KIRP	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg09264619	chr17:80180166	NA	0.42	4.86	0.3	2.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-5.09	-0.31	6.95e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg20936604	chr3:58311152	NA	-0.7	-6.12	-0.36	3.64e-9	Cholesterol, total;
KIRP	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg02415014	chr8:143852576	LYNX1	0.33	5.21	0.32	3.94e-7	Urinary tract infection frequency;
KIRP	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg26408565	chr15:76604113	ETFA	-0.43	-5.78	-0.35	2.24e-8	Blood metabolite levels;
KIRP	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg23231163	chr10:75533350	FUT11	0.33	4.9	0.3	1.72e-6	Inflammatory bowel disease;
KIRP	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07685180	chr8:600429	NA	0.7	4.91	0.3	1.66e-6	IgG glycosylation;
KIRP	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.14	-10.14	-0.54	2.12e-20	Body mass index;
KIRP	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21545522	chr1:205238299	TMCC2	0.49	6.78	0.4	9.01e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.95	16.61	0.73	4.62e-42	Breast cancer;
KIRP	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg16497661	chr14:103986332	CKB	-0.49	-6.23	-0.37	1.98e-9	Coronary artery disease;
KIRP	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.12	0.31	6.05e-7	Parkinson's disease;
KIRP	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.58	6.94	0.4	3.48e-11	Mosquito bite size;
KIRP	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.42	0.51	3.43e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6818397	1.000	rs6818397	chr4:3434885	A/C	cg08741688	chr4:3415352	RGS12	0.39	5.19	0.31	4.41e-7	LDL cholesterol levels;Total cholesterol levels;
KIRP	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.48	5.95	0.35	8.96e-9	Initial pursuit acceleration;
KIRP	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.8	8.83	0.49	2e-16	Obesity-related traits;
KIRP	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.53	-5.09	-0.31	7.01e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.39	-5.32	-0.32	2.36e-7	Coronary artery disease;
KIRP	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-9.45	-0.52	2.87e-18	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14563868	chr15:52043951	LYSMD2;TMOD2	0.52	6.63	0.39	2.16e-10	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03172341	chr8:141577150	EIF2C2	0.47	6.05	0.36	5.34e-9	Interleukin-4 levels;
KIRP	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg19875535	chr5:140030758	IK	-0.72	-10.41	-0.55	2.81e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	1.35	10.84	0.57	1.19e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs253959	0.814	rs2221676	chr5:115458887	C/T	cg23108291	chr5:115420582	COMMD10	0.41	4.95	0.3	1.39e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.26	0.42	5.16e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.3	6.02	0.36	6.34e-9	Schizophrenia;
KIRP	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.66	-8.11	-0.46	2.46e-14	Aortic root size;
KIRP	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs16858210	0.874	rs11918588	chr3:183601715	C/A	cg01324343	chr3:183735012	ABCC5	0.4	5.29	0.32	2.72e-7	Menopause (age at onset);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00500167	chr6:100841663	SIM1	0.49	6.77	0.4	9.24e-11	Pancreatic cancer;
KIRP	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg23166289	chr1:210001082	C1orf107	0.4	4.94	0.3	1.47e-6	Orofacial clefts;
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.2	-0.37	2.41e-9	Lung cancer;
KIRP	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg01411142	chr8:19674711	INTS10	0.51	5.56	0.33	7.17e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.68	-9.3	-0.51	8.12e-18	Huntington's disease progression;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg24633833	chr3:10029261	TMEM111	0.57	5.31	0.32	2.48e-7	Alzheimer's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18369257	chr11:61520258	C11orf9	-0.49	-6.16	-0.37	2.97e-9	Myopia;
KIRP	cis	rs4663866	1.000	rs34897410	chr2:239182123	T/C	cg17283117	chr2:239148619	HES6	0.68	4.96	0.3	1.3e-6	Irritable bowel syndrome;
KIRP	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg11266682	chr4:10021025	SLC2A9	0.41	5.36	0.32	1.92e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg27170947	chr2:26402098	FAM59B	0.63	7.04	0.41	1.94e-11	Gut microbiome composition (summer);
KIRP	cis	rs6681460	0.932	rs4655640	chr1:67089220	T/C	cg02459107	chr1:67143332	SGIP1	0.48	6.78	0.4	9.05e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs4664293	0.867	rs4664301	chr2:160623366	C/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11735605	chr2:214016230	IKZF2	0.52	6.54	0.38	3.62e-10	Lung cancer in ever smokers;
KIRP	trans	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.71	-0.39	1.32e-10	Heart rate;
KIRP	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg21231944	chr12:82153410	PPFIA2	-0.4	-5.09	-0.31	7.14e-7	Resting heart rate;
KIRP	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.43	-0.38	6.75e-10	Height;
KIRP	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.96	-0.41	3.1e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs17125944	0.615	rs8003334	chr14:53374967	C/T	cg00686598	chr14:53173677	PSMC6	0.72	6.67	0.39	1.68e-10	Alzheimer's disease (late onset);
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg27170947	chr2:26402098	FAM59B	-0.59	-6.53	-0.38	3.69e-10	Gut microbiome composition (summer);
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg09695851	chr17:3907499	NA	0.86	16.73	0.73	1.87e-42	Type 2 diabetes;
KIRP	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg25801113	chr15:45476975	SHF	-0.44	-8.11	-0.46	2.41e-14	Uric acid levels;
KIRP	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.68	-0.44	3.82e-13	Neuroticism;
KIRP	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.42	0.43	1.92e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7808935	0.768	rs739704	chr7:27989768	G/A	cg22168087	chr7:27702803	HIBADH	0.67	7.23	0.42	5.92e-12	Prostate cancer;
KIRP	trans	rs2048656	0.569	rs35300296	chr8:9653697	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.02	0.41	2.17e-11	Schizophrenia;
KIRP	cis	rs77633900	0.614	rs7162982	chr15:76961559	G/A	cg21673338	chr15:77095150	SCAPER	0.5	6.46	0.38	5.61e-10	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs1424233	1.000	rs1424234	chr16:79682703	T/C	cg11120865	chr14:21853037	SUPT16H	0.37	6.3	0.37	1.37e-9	Obesity;
KIRP	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.82	8.66	0.48	6.2e-16	Prostate cancer;
KIRP	cis	rs7523050	0.730	rs72984612	chr1:109434826	T/C	cg08274380	chr1:109419600	GPSM2	1.16	10.22	0.55	1.14e-20	Fat distribution (HIV);
KIRP	cis	rs1656402	0.906	rs1656401	chr2:233426601	A/G	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg21186296	chr8:27182909	PTK2B	0.51	6.55	0.39	3.43e-10	Neuroticism;
KIRP	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	4.92	0.3	1.55e-6	Total cholesterol levels;
KIRP	cis	rs897080	0.515	rs1067334	chr2:44626633	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.02	0.36	6.29e-9	Height;
KIRP	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25517755	chr10:38738941	LOC399744	-0.51	-7.03	-0.41	2.07e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19386714	chr18:71825760	C18orf55	-0.41	-6.28	-0.37	1.52e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	11.42	0.59	1.64e-24	Ileal carcinoids;
KIRP	cis	rs72627123	0.656	rs75646425	chr14:74529433	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	5.26	0.32	3.09e-7	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.79	7.57	0.43	7.53e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.71	7.14	0.41	1.04e-11	Chronic kidney disease;
KIRP	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.58	-7.04	-0.41	1.89e-11	Aortic root size;
KIRP	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-4.99	-0.3	1.14e-6	Educational attainment;
KIRP	cis	rs12460243	0.938	rs78806879	chr19:8131883	C/G	cg06488775	chr19:8115360	NA	0.52	5.16	0.31	5.17e-7	Neurocognitive impairment in HIV-1 infection (continuous);
KIRP	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.37	-5.47	-0.33	1.09e-7	Survival in rectal cancer;
KIRP	cis	rs7404928	0.526	rs2575382	chr16:23833644	G/A	cg05497750	chr16:23765381	CHP2	-0.59	-6.69	-0.39	1.53e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12337011	chr2:28002424	MRPL33	0.44	6.06	0.36	5e-9	Interleukin-4 levels;
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg10254082	chr7:997346	NA	0.61	5.1	0.31	6.83e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg21573476	chr21:45109991	RRP1B	-0.65	-9.77	-0.53	2.96e-19	Mean corpuscular volume;
KIRP	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20307385	chr11:47447363	PSMC3	-0.53	-5.51	-0.33	9.13e-8	Subjective well-being;
KIRP	cis	rs12949688	0.570	rs12600654	chr17:55834916	G/A	cg12582317	chr17:55822272	NA	0.44	6.26	0.37	1.71e-9	Schizophrenia;
KIRP	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg11707556	chr5:10655725	ANKRD33B	0.69	8.99	0.5	6.97e-17	Height;
KIRP	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.67	10.07	0.54	3.39e-20	Dupuytren's disease;
KIRP	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.91	0.45	8.88e-14	Aortic root size;
KIRP	trans	rs17834760	0.955	rs62423557	chr6:62046190	G/T	cg08476511	chr6:168435923	KIF25	0.52	6.09	0.36	4.37e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.41	5.26	0.32	3.07e-7	Aortic root size;
KIRP	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.6	-5.98	-0.36	7.67e-9	Body mass index;
KIRP	cis	rs3134353	0.675	rs3019261	chr8:101978163	A/G	cg07585502	chr8:101912084	NA	-0.41	-5.11	-0.31	6.62e-7	Body mass index;
KIRP	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg07274523	chr3:49395745	GPX1	0.72	8.51	0.48	1.74e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14315341	chr12:97346526	NEDD1	-0.44	-7.07	-0.41	1.56e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08521655	chr17:3749512	C17orf85	-0.45	-6.05	-0.36	5.44e-9	Myopia;
KIRP	cis	rs17065868	0.764	rs60806722	chr13:45021236	A/G	cg10246903	chr13:45222710	NA	0.52	5.0	0.3	1.09e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.43	5.11	0.31	6.44e-7	Aortic root size;
KIRP	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.65	-0.48	6.89e-16	Total cholesterol levels;
KIRP	cis	rs9810259	0.508	rs6442309	chr3:12301166	A/G	cg02700894	chr3:12045449	SYN2	-0.37	-5.26	-0.32	3.08e-7	Platelet count;
KIRP	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg12315302	chr6:26189340	HIST1H4D	0.88	6.14	0.36	3.23e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.73	9.47	0.52	2.37e-18	Crohn's disease;
KIRP	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.49	5.95	0.35	8.98e-9	Common traits (Other);
KIRP	cis	rs2904967	1.000	rs636928	chr11:65093484	A/C	cg09225861	chr11:65069680	NA	0.43	5.23	0.32	3.63e-7	Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.25	0.32	3.33e-7	Alzheimer's disease;
KIRP	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg07537917	chr2:241836409	C2orf54	-0.33	-6.8	-0.4	7.79e-11	Urinary metabolites;
KIRP	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.69	6.0	0.36	7.13e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.5	7.22	0.42	6.63e-12	Urate levels in overweight individuals;
KIRP	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.93	-14.06	-0.67	2.41e-33	Lung cancer;
KIRP	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.47	-6.22	-0.37	2.13e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11252926	0.603	rs17293419	chr10:537014	G/A	cg03684893	chr10:554711	DIP2C	0.43	6.37	0.38	8.99e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg23933602	chr10:16859644	RSU1	0.57	6.73	0.39	1.16e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.82	9.91	0.53	1.08e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.8	-9.99	-0.54	5.9e-20	Response to antineoplastic agents;
KIRP	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	6.64	0.39	1.96e-10	Personality dimensions;
KIRP	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	3.98e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.69	8.07	0.46	3.05e-14	Smoking initiation;
KIRP	cis	rs2464469	0.526	rs2899612	chr15:58335867	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.85	-0.3	2.23e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
KIRP	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.58	-6.52	-0.38	4.06e-10	Coronary artery disease;
KIRP	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	1.05	14.74	0.68	1.11e-35	Menopause (age at onset);
KIRP	cis	rs9815354	1.000	rs9865127	chr3:41807448	C/T	cg03022575	chr3:42003672	ULK4	0.5	5.74	0.34	2.81e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-6.76	-0.4	1.02e-10	Neuroticism;
KIRP	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg05072774	chr3:49840536	C3orf54	-0.41	-5.14	-0.31	5.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8077059	1.000	rs8067868	chr17:55824949	C/T	cg12582317	chr17:55822272	NA	-0.4	-5.43	-0.33	1.33e-7	Sex hormone-binding globulin levels;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.56	8.62	0.48	8.21e-16	Lung cancer;
KIRP	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.34	5.13	0.31	5.79e-7	Psoriasis;
KIRP	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.75	-9.89	-0.53	1.21e-19	Blood metabolite levels;
KIRP	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	1.23	11.07	0.58	2.25e-23	Lymphocyte counts;
KIRP	cis	rs365132	0.905	rs353463	chr5:176403170	A/C	cg16309518	chr5:176445507	NA	-0.8	-12.17	-0.61	5.62e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	cg04338863	chr8:33670619	NA	0.49	6.41	0.38	7.51e-10	Body mass index;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg08901578	chr4:187885870	NA	-0.45	-6.82	-0.4	7.02e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg10047753	chr17:41438598	NA	0.92	12.69	0.63	1.01e-28	Menopause (age at onset);
KIRP	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg16388071	chr6:169726476	NA	-0.41	-5.67	-0.34	3.92e-8	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-1.05	-20.8	-0.8	3.81e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.78	10.74	0.56	2.58e-22	Response to antipsychotic treatment;
KIRP	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.76	-10.87	-0.57	9.66e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg06953865	chr19:18549723	ISYNA1	-0.42	-6.44	-0.38	6.17e-10	Breast cancer;
KIRP	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.95	-14.7	-0.68	1.58e-35	Height;
KIRP	cis	rs2150410	0.915	rs2272576	chr21:40684389	C/G	cg11890956	chr21:40555474	PSMG1	0.83	5.8	0.35	2.02e-8	Temperament (bipolar disorder);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg08118159	chr19:41055208	SPTBN4	0.46	6.09	0.36	4.26e-9	DNA methylation (variation);
KIRP	cis	rs6838801	0.752	rs13138237	chr4:77616562	C/G	cg17476223	chr4:77663285	SHROOM3	0.52	7.16	0.42	9.08e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs62355272	0.828	rs11958811	chr5:35823883	C/T	cg13894535	chr5:35919491	CAPSL	-0.49	-5.5	-0.33	9.55e-8	Lymphocyte counts;
KIRP	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.71	8.51	0.48	1.78e-15	Breast cancer;
KIRP	cis	rs6893300	0.745	rs6639	chr5:179156782	G/T	cg14593053	chr5:179126677	CANX	-0.58	-6.95	-0.41	3.25e-11	Resting heart rate;
KIRP	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-7.87	-0.45	1.13e-13	Body mass index;
KIRP	cis	rs7127900	0.904	rs7123180	chr11:2232272	A/G	cg25635251	chr11:2234043	NA	0.52	7.86	0.45	1.22e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg10223061	chr2:219282414	VIL1	-0.35	-5.84	-0.35	1.65e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.79	7.91	0.45	8.49e-14	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.46	6.79	0.4	8.2e-11	Urate levels in lean individuals;
KIRP	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.43	0.65	3.14e-31	Eye color traits;
KIRP	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.43	-5.04	-0.31	9.11e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg05187965	chr10:45406764	TMEM72	0.32	7.59	0.44	6.61e-13	Mean corpuscular volume;
KIRP	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.4	-0.55	3.23e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.68	6.33	0.37	1.14e-9	Schizophrenia;
KIRP	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.54	-6.58	-0.39	2.76e-10	Eosinophil percentage of white cells;
KIRP	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.01	-7.57	-0.43	7.63e-13	Mitochondrial DNA levels;
KIRP	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg24881330	chr22:46731750	TRMU	0.82	5.7	0.34	3.38e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.09	-12.53	-0.62	3.52e-28	Vitiligo;
KIRP	cis	rs7395581	0.797	rs10742801	chr11:47342220	A/C	cg26139080	chr11:47293733	MADD	-0.43	-5.27	-0.32	2.95e-7	HDL cholesterol;
KIRP	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35000415	0.938	rs12539476	chr7:128657483	T/C	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-7.09	-0.41	1.4e-11	Systemic lupus erythematosus;
KIRP	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.49	-6.18	-0.37	2.6e-9	IgG glycosylation;
KIRP	trans	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.03	-0.36	6.13e-9	Neuroticism;
KIRP	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.59	7.9	0.45	9.03e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.21e-7	Red blood cell count;
KIRP	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	12.6	0.63	2.02e-28	Personality dimensions;
KIRP	cis	rs4356932	1.000	rs6532157	chr4:76974373	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs9815354	1.000	rs1716668	chr3:41907850	T/C	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg13939156	chr17:80058883	NA	-0.49	-7.48	-0.43	1.33e-12	Life satisfaction;
KIRP	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg00629941	chr15:75287862	SCAMP5	-0.49	-5.22	-0.32	3.79e-7	Blood trace element (Zn levels);
KIRP	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.73	-10.91	-0.57	7.24e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.22	-5.25	-0.32	3.37e-7	Coronary artery disease;
KIRP	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg26876637	chr1:152193138	HRNR	-0.7	-8.81	-0.49	2.34e-16	Atopic dermatitis;
KIRP	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.76	6.66	0.39	1.78e-10	Body mass index;
KIRP	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	11.04	0.58	2.86e-23	Post bronchodilator FEV1;
KIRP	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.6	-0.39	2.48e-10	Retinal vascular caliber;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.53	0.33	8.19e-8	Life satisfaction;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs1440410	0.520	rs4629391	chr4:144046874	A/G	cg01719995	chr4:144104893	USP38	0.44	5.66	0.34	4.31e-8	Ischemic stroke;
KIRP	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.76	-12.01	-0.61	1.92e-26	Rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.81	11.0	0.57	3.62e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg15038512	chr6:170123185	PHF10	-0.56	-8.59	-0.48	9.9e-16	Obesity-related traits;
KIRP	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.18	-0.37	2.59e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	1.09	12.24	0.62	3.1e-27	Post bronchodilator FEV1;
KIRP	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg18586891	chr4:952366	TMEM175	0.62	5.11	0.31	6.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg22117172	chr7:91764530	CYP51A1	0.4	5.71	0.34	3.2e-8	Breast cancer;
KIRP	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.72	-6.19	-0.37	2.51e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6840360	0.582	rs6813735	chr4:152326990	T/G	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.44e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg02696790	chr15:75250997	RPP25	0.32	5.42	0.33	1.46e-7	Breast cancer;
KIRP	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg18190219	chr22:46762943	CELSR1	-0.93	-6.96	-0.41	3.01e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582180	0.629	rs11895772	chr2:100938917	G/C	cg05692746	chr2:100937584	LONRF2	-0.41	-5.37	-0.32	1.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.53	0.38	3.8e-10	Breast cancer;
KIRP	cis	rs11608355	0.538	rs7305165	chr12:109804222	G/A	cg19025524	chr12:109796872	NA	-0.52	-7.39	-0.43	2.32e-12	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06509239	chr2:19558569	OSR1	0.45	6.11	0.36	3.84e-9	Smoking initiation;
KIRP	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11987759	chr7:65425863	GUSB	-0.53	-7.1	-0.41	1.3e-11	Aortic root size;
KIRP	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.51	7.5	0.43	1.16e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.43	0.33	1.37e-7	Total cholesterol levels;
KIRP	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.99	-15.57	-0.7	1.66e-38	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg04025307	chr7:1156635	C7orf50	0.81	8.33	0.47	5.63e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg22117172	chr7:91764530	CYP51A1	0.48	6.8	0.4	7.77e-11	Breast cancer;
KIRP	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.39	-5.69	-0.34	3.65e-8	Sitting height ratio;
KIRP	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg13736514	chr6:26305472	NA	-0.68	-8.23	-0.46	1.09e-14	Educational attainment;
KIRP	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.59	8.19	0.46	1.45e-14	Coronary artery disease;
KIRP	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.28	-5.6	-0.34	5.83e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.41	5.36	0.32	1.87e-7	Aortic root size;
KIRP	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06481639	chr22:41940642	POLR3H	-0.51	-5.86	-0.35	1.49e-8	Vitiligo;
KIRP	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.51	7.13	0.41	1.1e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.04	16.04	0.71	4.24e-40	Subjective well-being;
KIRP	cis	rs7584330	0.554	rs6729415	chr2:238429943	C/G	cg08992911	chr2:238395768	MLPH	0.41	4.86	0.3	2.13e-6	Prostate cancer;
KIRP	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg02023728	chr11:77925099	USP35	0.35	5.51	0.33	8.95e-8	Alzheimer's disease (survival time);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10034028	chr2:151457153	NA	0.38	6.46	0.38	5.56e-10	C-reactive protein;
KIRP	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	1.15	14.89	0.69	3.57e-36	Response to hepatitis C treatment;
KIRP	cis	rs14168	1.000	rs7078445	chr10:53461562	T/G	cg18823846	chr10:53459691	PRKG1;CSTF2T	0.6	5.39	0.32	1.65e-7	Mammographic density (non-dense area);
KIRP	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.38	0.55	3.57e-21	Cognitive test performance;
KIRP	cis	rs12753569	0.837	rs1251490	chr1:76518693	T/C	cg00791851	chr1:76518896	NA	-0.32	-5.64	-0.34	4.77e-8	Personality dimensions;
KIRP	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.47e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.55	7.13	0.41	1.13e-11	Aortic root size;
KIRP	cis	rs2387326	0.717	rs12266400	chr10:129944536	C/G	cg16087940	chr10:129947807	NA	0.36	4.94	0.3	1.47e-6	Select biomarker traits;
KIRP	cis	rs12580194	0.593	rs11171430	chr12:55755254	A/G	cg11794356	chr12:55725991	OR6C3	-0.55	-7.7	-0.44	3.25e-13	Cancer;
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.67	11.36	0.59	2.52e-24	Cardiovascular disease risk factors;
KIRP	cis	rs9488822	0.662	rs536160	chr6:116267166	T/C	cg26893134	chr6:116381904	FRK	-0.19	-5.14	-0.31	5.72e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.61	-7.65	-0.44	4.62e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs34286592	1.000	rs13332078	chr16:29850705	C/T	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	4.91	0.3	1.64e-6	Multiple sclerosis;
KIRP	cis	rs6681460	0.649	rs6691033	chr1:67007429	C/T	cg02459107	chr1:67143332	SGIP1	0.39	5.37	0.32	1.81e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	5.15	0.31	5.36e-7	Menopause (age at onset);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18828365	chr5:78281819	ARSB	-0.49	-6.05	-0.36	5.23e-9	Obesity-related traits;
KIRP	cis	rs1620921	0.935	rs783171	chr6:161173610	A/G	cg01280913	chr6:161186852	NA	-0.44	-6.13	-0.36	3.49e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs4262150	0.810	rs4958320	chr5:151964215	G/A	cg12297329	chr5:152029980	NA	-0.65	-8.1	-0.46	2.52e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs8028182	0.636	rs11637586	chr15:75791112	G/C	cg20655648	chr15:75932815	IMP3	0.53	6.53	0.38	3.77e-10	Sudden cardiac arrest;
KIRP	cis	rs10875746	0.669	rs10875772	chr12:48609553	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-5.05	-0.31	8.57e-7	Longevity (90 years and older);
KIRP	trans	rs12517041	1.000	rs35561495	chr5:23309925	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg17724175	chr1:150552817	MCL1	0.35	5.81	0.35	1.92e-8	Melanoma;
KIRP	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg12435725	chr3:58293450	RPP14	-0.54	-5.67	-0.34	4e-8	Cholesterol, total;
KIRP	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.74	11.47	0.59	1.15e-24	Neuroticism;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg25858983	chr17:42295711	UBTF	-0.45	-6.07	-0.36	4.73e-9	Blood metabolite levels;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.13e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg05485520	chr3:45883628	LZTFL1	0.76	6.49	0.38	4.73e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	7.71	0.44	3.12e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-5.75	-0.34	2.59e-8	Bipolar disorder;
KIRP	cis	rs4073416	0.542	rs7147536	chr14:65874698	C/T	cg03016385	chr14:66212404	NA	-0.52	-6.4	-0.38	7.8e-10	N-glycan levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07046186	chr1:161861378	ATF6	0.41	6.18	0.37	2.61e-9	Interleukin-4 levels;
KIRP	cis	rs7209700	0.889	rs16941801	chr17:45354543	G/C	cg08085267	chr17:45401833	C17orf57	0.44	5.29	0.32	2.71e-7	IgG glycosylation;
KIRP	cis	rs5753618	0.509	rs5749229	chr22:31587218	T/C	cg22777020	chr22:31556080	RNF185	-0.5	-5.25	-0.32	3.32e-7	Colorectal cancer;
KIRP	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg13010199	chr12:38710504	ALG10B	0.4	5.34	0.32	2.13e-7	Heart rate;
KIRP	cis	rs11628318	0.614	rs12588817	chr14:103089210	G/A	cg01864069	chr14:103024347	NA	-0.42	-5.19	-0.31	4.35e-7	Platelet count;
KIRP	cis	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.32	4.86	0.3	2.09e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.01	-0.3	1.02e-6	Arsenic metabolism;
KIRP	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	9.13	0.5	2.64e-17	Bone mineral density;
KIRP	trans	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg10756647	chr7:56101905	PSPH	0.99	6.8	0.4	8.08e-11	Diabetic kidney disease;
KIRP	cis	rs1538970	0.924	rs4660858	chr1:45936351	G/A	cg05343316	chr1:45956843	TESK2	0.73	8.37	0.47	4.46e-15	Platelet count;
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg10318148	chr7:1024673	CYP2W1	-0.35	-5.12	-0.31	6.13e-7	Longevity;Endometriosis;
KIRP	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.93	-15.0	-0.69	1.5e-36	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-5.43	-0.33	1.35e-7	Testicular germ cell tumor;
KIRP	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg22906224	chr7:99728672	NA	-0.64	-7.85	-0.45	1.31e-13	Coronary artery disease;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.72	-10.49	-0.56	1.57e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg26384229	chr12:38710491	ALG10B	0.56	7.17	0.42	8.65e-12	Morning vs. evening chronotype;
KIRP	cis	rs7172677	0.737	rs7179426	chr15:75441488	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	0.69	11.47	0.59	1.15e-24	Carotid intima media thickness;
KIRP	cis	rs2213920	0.568	rs6478166	chr9:118213548	T/C	cg13918206	chr9:118159781	DEC1	0.96	9.97	0.54	6.87e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg14458575	chr2:238380390	NA	0.74	6.9	0.4	4.27e-11	Prostate cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg10556830	chr5:68462986	CCNB1	0.72	6.11	0.36	3.82e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.88	-11.71	-0.6	1.84e-25	Menopause (age at onset);
KIRP	cis	rs3829109	0.564	rs11145889	chr9:139293843	A/G	cg14169450	chr9:139327907	INPP5E	0.47	5.76	0.34	2.48e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs9815354	0.680	rs73073291	chr3:42028004	G/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10858047	0.883	rs12040800	chr1:115108577	T/C	cg12756093	chr1:115239321	AMPD1	0.64	6.15	0.37	3.05e-9	Autism;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.33	0.51	6.55e-18	Lung cancer;
KIRP	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg27462398	chr1:86174642	ZNHIT6	0.53	7.32	0.42	3.59e-12	Urate levels in overweight individuals;
KIRP	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.74	10.49	0.56	1.66e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs5753618	0.583	rs5753601	chr22:31798259	G/T	cg02404636	chr22:31891804	SFI1	0.51	5.79	0.35	2.17e-8	Colorectal cancer;
KIRP	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs4849845	0.886	rs1137385	chr2:121052268	A/T	cg24070213	chr2:121070622	NA	0.4	5.37	0.32	1.83e-7	Mean platelet volume;
KIRP	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.44	-0.33	1.29e-7	Bipolar disorder;
KIRP	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.55	8.74	0.49	3.79e-16	Obesity-related traits;
KIRP	cis	rs1009170	0.794	rs12589375	chr14:92584380	T/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.43	0.33	1.37e-7	Dialysis-related mortality;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02895995	chr19:7554069	PEX11G	0.56	6.87	0.4	5.3e-11	Smoking initiation;
KIRP	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Educational attainment;
KIRP	cis	rs16957091	0.821	rs7163030	chr15:42971620	A/G	cg24196017	chr15:43021976	CDAN1	-0.42	-5.42	-0.33	1.39e-7	MGMT methylation in smokers;
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg08662619	chr6:150070041	PCMT1	0.37	5.91	0.35	1.12e-8	Lung cancer;
KIRP	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.63	8.1	0.46	2.56e-14	Response to diuretic therapy;
KIRP	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg16255804	chr6:135334527	HBS1L	-0.31	-4.89	-0.3	1.8e-6	Red blood cell count;
KIRP	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg00579200	chr11:133705235	NA	-0.39	-4.85	-0.3	2.22e-6	Childhood ear infection;
KIRP	cis	rs9469913	0.867	rs9469907	chr6:34810799	T/C	cg17674042	chr6:34482479	PACSIN1	-0.39	-5.34	-0.32	2.13e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg18402987	chr7:1209562	NA	0.46	5.28	0.32	2.87e-7	Longevity;Endometriosis;
KIRP	cis	rs7923609	0.934	rs10761756	chr10:65172328	C/T	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7712401	0.715	rs13164161	chr5:122346897	G/A	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.07	-0.41	1.57e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.73	0.44	2.69e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3755605	0.520	rs1705602	chr3:169932915	A/G	cg02973263	chr3:169940162	PRKCI	0.42	4.85	0.3	2.19e-6	Testicular germ cell tumor;
KIRP	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.58e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg27203200	chr16:67193754	TRADD;FBXL8	0.49	6.06	0.36	4.95e-9	DNA methylation (variation);
KIRP	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.81	-12.01	-0.61	1.84e-26	Ulcerative colitis;
KIRP	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg05347473	chr6:146136440	FBXO30	0.44	5.88	0.35	1.36e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.52	6.34	0.37	1.09e-9	Smoking initiation;
KIRP	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	1.02	15.9	0.71	1.19e-39	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15661337	chr18:61034655	KDSR	0.5	6.35	0.38	1.03e-9	Parkinson's disease;
KIRP	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.47	6.48	0.38	4.94e-10	Testicular germ cell tumor;
KIRP	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg20913747	chr6:44695427	NA	-0.39	-4.95	-0.3	1.35e-6	Total body bone mineral density;
KIRP	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.68	-0.34	3.87e-8	Morning vs. evening chronotype;
KIRP	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.58	-0.39	2.76e-10	Diastolic blood pressure;
KIRP	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.69	-8.21	-0.46	1.26e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.86	11.45	0.59	1.27e-24	Cognitive function;
KIRP	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg07661805	chr8:143867942	LY6D	-0.28	-4.98	-0.3	1.2e-6	Urinary tract infection frequency;
KIRP	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	1.11	16.42	0.72	2.13e-41	Breast cancer;
KIRP	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs5753037	0.809	rs140150	chr22:30185719	C/G	cg01021169	chr22:30184971	ASCC2	-0.42	-5.23	-0.32	3.65e-7	Type 1 diabetes;
KIRP	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.43	-6.26	-0.37	1.72e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.44	-6.18	-0.37	2.67e-9	Height;
KIRP	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.63	6.57	0.39	2.94e-10	Gut microbiome composition (summer);
KIRP	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg26207909	chr14:103986467	CKB	-0.45	-5.54	-0.33	7.77e-8	Coronary artery disease;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg08575399	chr20:60719638	PSMA7;SS18L1	0.48	6.31	0.37	1.3e-9	Asthma;
KIRP	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg19338460	chr6:170058176	WDR27	-0.66	-7.71	-0.44	3.16e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7520050	0.966	rs6695809	chr1:46285461	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.55e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.41	-5.14	-0.31	5.7e-7	Leprosy;
KIRP	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg04780086	chr2:111875790	ACOXL	0.44	6.11	0.36	3.77e-9	Chronic lymphocytic leukemia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19864851	chr10:75503847	SEC24C	-0.47	-6.09	-0.36	4.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.84	10.13	0.54	2.17e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	0.79	6.98	0.41	2.79e-11	Obesity-related traits;
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.64	-10.05	-0.54	3.95e-20	Immature fraction of reticulocytes;
KIRP	cis	rs838147	0.844	rs8104897	chr19:49249814	C/A	cg08619932	chr19:49200058	FUT2	-0.34	-5.19	-0.31	4.41e-7	Dietary macronutrient intake;
KIRP	trans	rs6734238	0.966	rs12328766	chr2:113846738	A/G	cg11332951	chr1:2396472	NA	-0.41	-6.09	-0.36	4.29e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	cis	rs1209950	0.866	rs1734588	chr21:40180889	A/G	cg01359822	chr21:40176597	ETS2	0.36	5.73	0.34	2.95e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg16586182	chr3:47516702	SCAP	-0.52	-5.77	-0.35	2.38e-8	Birth weight;
KIRP	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg16497661	chr14:103986332	CKB	0.82	13.94	0.66	5.99e-33	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03757145	chr4:76555832	CDKL2	0.49	6.43	0.38	6.53e-10	Parkinson's disease;
KIRP	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg09163369	chr1:210001066	C1orf107	0.51	6.52	0.38	3.98e-10	Orofacial clefts;
KIRP	cis	rs501120	0.584	rs11595946	chr10:44685695	C/T	cg09554077	chr10:44749378	NA	0.58	6.02	0.36	6.44e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg23985595	chr17:80112537	CCDC57	-0.37	-5.5	-0.33	9.65e-8	Life satisfaction;
KIRP	cis	rs9584850	0.609	rs17574495	chr13:99155113	C/T	cg20750642	chr13:99100586	FARP1	-0.55	-5.78	-0.35	2.26e-8	Neuroticism;
KIRP	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.77	11.18	0.58	9.56e-24	Total body bone mineral density;
KIRP	cis	rs490234	0.934	rs10119068	chr9:128424508	A/G	cg14078157	chr9:128172775	NA	-0.53	-6.36	-0.38	9.58e-10	Mean arterial pressure;
KIRP	cis	rs13385	0.769	rs13353859	chr5:139620455	A/G	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg18833306	chr6:118973337	C6orf204	0.41	5.11	0.31	6.42e-7	Electrocardiographic conduction measures;
KIRP	cis	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg03511173	chr18:77590860	NA	0.46	5.09	0.31	7e-7	Opioid sensitivity;
KIRP	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.54	-7.09	-0.41	1.4e-11	Response to temozolomide;
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg12486944	chr17:80159399	CCDC57	-0.39	-5.3	-0.32	2.61e-7	Life satisfaction;
KIRP	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.38	5.14	0.31	5.72e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-0.87	-11.93	-0.61	3.36e-26	Urate levels;
KIRP	cis	rs2290402	0.536	rs2335172	chr4:855282	G/A	cg14517359	chr4:903473	GAK	-0.57	-6.19	-0.37	2.49e-9	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg00738919	chr7:1100172	C7orf50	0.42	4.97	0.3	1.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2862064	0.932	rs1553317	chr5:156479424	A/C	cg12943317	chr5:156479607	HAVCR1	-0.91	-8.2	-0.46	1.36e-14	Platelet count;
KIRP	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg14972814	chr11:95582409	MTMR2	0.29	5.04	0.31	9.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.83	9.97	0.54	6.87e-20	Corneal astigmatism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11653675	chr2:46811648	RHOQ;PIGF	0.36	6.38	0.38	8.64e-10	C-reactive protein;
KIRP	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs698813	0.851	rs698807	chr2:44701659	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.9	0.35	1.22e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg02336718	chr17:17403227	NA	-0.31	-4.89	-0.3	1.8e-6	Total body bone mineral density;
KIRP	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.72	11.24	0.58	6.33e-24	Menarche (age at onset);
KIRP	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.45	-0.59	1.29e-24	Idiopathic membranous nephropathy;
KIRP	cis	rs4478037	1.000	rs59622575	chr3:33162249	A/C	cg19404215	chr3:33155277	CRTAP	0.7	6.49	0.38	4.64e-10	Major depressive disorder;
KIRP	cis	rs2562456	0.876	rs2562413	chr19:21602886	G/C	cg18461458	chr19:21324796	ZNF431	-0.54	-5.15	-0.31	5.22e-7	Pain;
KIRP	cis	rs829661	0.948	rs829675	chr2:30710447	A/G	cg10949345	chr2:30726833	LCLAT1	0.69	9.71	0.53	4.45e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9290877	0.704	rs7356019	chr3:188459597	C/T	cg17392043	chr3:188495102	LPP	-0.49	-6.34	-0.37	1.1e-9	IgE levels;
KIRP	cis	rs7555523	0.887	rs2251768	chr1:165738311	A/T	cg24409356	chr1:165738333	TMCO1	0.73	6.23	0.37	1.97e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.84	11.89	0.6	4.72e-26	Neuroticism;
KIRP	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg19875535	chr5:140030758	IK	0.64	8.39	0.47	3.84e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.73	-9.21	-0.51	1.46e-17	Dilated cardiomyopathy;
KIRP	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.52	-5.61	-0.34	5.4e-8	Aortic root size;
KIRP	cis	rs1712517	0.524	rs1712509	chr10:105013870	G/T	cg04362960	chr10:104952993	NT5C2	-0.6	-7.37	-0.43	2.6e-12	Migraine;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.6	8.7	0.48	4.95e-16	Lung cancer;
KIRP	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.88	-0.35	1.34e-8	Parkinson's disease;
KIRP	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.0	-0.61	2.05e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.62	-6.19	-0.37	2.52e-9	Body mass index;
KIRP	cis	rs6545883	0.894	rs12620105	chr2:61512321	A/T	cg15711740	chr2:61764176	XPO1	0.6	7.69	0.44	3.62e-13	Tuberculosis;
KIRP	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	9.24	0.51	1.23e-17	Menarche (age at onset);
KIRP	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	cg12689670	chr1:183009347	LAMC1	-0.45	-6.56	-0.39	3.22e-10	Colorectal cancer;
KIRP	cis	rs1345301	1.000	rs11686567	chr2:102876609	A/G	cg12451869	chr2:102867685	NA	0.39	5.7	0.34	3.37e-8	Waist circumference;
KIRP	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.71	-0.49	4.58e-16	Coronary artery disease;
KIRP	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.51	6.24	0.37	1.88e-9	Urinary tract infection frequency;
KIRP	cis	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.81	0.35	1.92e-8	Neuroticism;
KIRP	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.48	-6.39	-0.38	8.43e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.43	-5.29	-0.32	2.66e-7	Neuroticism;
KIRP	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg21698718	chr17:80085957	CCDC57	0.33	4.98	0.3	1.18e-6	Life satisfaction;
KIRP	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.58	-0.33	6.47e-8	Colorectal cancer;
KIRP	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.39	8.22	0.46	1.21e-14	Type 2 diabetes;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg17082953	chr2:12856844	TRIB2	-0.48	-6.26	-0.37	1.71e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs77372450	0.636	rs6877434	chr5:157028947	A/C	cg05585991	chr5:157099197	C5orf52	-0.45	-5.26	-0.32	3.08e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7523050	0.908	rs12036331	chr1:109398707	A/T	cg08274380	chr1:109419600	GPSM2	0.7	6.64	0.39	1.95e-10	Fat distribution (HIV);
KIRP	cis	rs4663866	1.000	rs4663868	chr2:239161091	C/T	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg13628971	chr7:2884303	GNA12	0.41	5.14	0.31	5.66e-7	Height;
KIRP	cis	rs8018808	0.967	rs12889722	chr14:77850267	T/C	cg20045696	chr14:77926864	AHSA1	-0.42	-5.19	-0.31	4.43e-7	Myeloid white cell count;
KIRP	cis	rs5752326	0.510	rs1045523	chr22:26887829	A/G	cg20819150	chr22:26891497	TFIP11	0.58	5.09	0.31	7.2e-7	Ischemic stroke;
KIRP	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg12292205	chr6:26970375	C6orf41	0.48	6.96	0.41	3.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.83	0.35	1.74e-8	Depressive symptoms;
KIRP	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06850241	chr22:41845214	NA	-0.44	-5.15	-0.31	5.38e-7	Vitiligo;
KIRP	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.12e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg04226714	chr8:49833948	SNAI2	-0.51	-6.82	-0.4	7.14e-11	Life satisfaction;
KIRP	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-10.16	-0.54	1.72e-20	Total body bone mineral density;
KIRP	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg16141378	chr3:129829833	LOC729375	0.62	8.43	0.47	2.95e-15	Neuroticism;
KIRP	cis	rs6968419	0.755	rs6966770	chr7:115895718	A/G	cg02561103	chr7:115862891	TES	-0.36	-5.39	-0.32	1.67e-7	Intraocular pressure;
KIRP	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg14541582	chr5:601475	NA	-0.56	-6.07	-0.36	4.82e-9	Obesity-related traits;
KIRP	trans	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.76e-11	Diabetic kidney disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08640790	chr15:91498075	RCCD1	0.48	6.23	0.37	1.96e-9	Parkinson's disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg21558508	chr5:133968566	SAR1B	0.48	6.29	0.37	1.47e-9	DNA methylation (variation);
KIRP	cis	rs11645898	0.511	rs72787023	chr16:72031105	T/C	cg14768367	chr16:72042858	DHODH	-0.8	-8.03	-0.46	4.16e-14	Blood protein levels;
KIRP	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.64	-9.64	-0.52	7.35e-19	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg03808351	chr9:123631620	PHF19	0.44	6.02	0.36	6.23e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg21040759	chr13:24153478	TNFRSF19	0.5	6.38	0.38	8.95e-10	Colorectal cancer;
KIRP	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.57e-14	Height;
KIRP	cis	rs9325144	1.000	rs7963123	chr12:38976617	C/T	cg26384229	chr12:38710491	ALG10B	-0.54	-6.45	-0.38	6.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.99	-15.34	-0.7	1.04e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.35	-0.38	1.02e-9	Lung cancer;
KIRP	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.41	6.35	0.38	1.05e-9	Neuroticism;
KIRP	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg23533926	chr12:111358616	MYL2	-0.48	-6.12	-0.36	3.6e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.57	6.27	0.37	1.57e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.46	6.38	0.38	8.85e-10	Testicular germ cell tumor;
KIRP	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.47	6.64	0.39	1.97e-10	Sitting height ratio;
KIRP	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg11245181	chr6:149772854	ZC3H12D	-0.33	-5.03	-0.31	9.44e-7	Dupuytren's disease;
KIRP	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.54	-0.62	3.12e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10737909	1.000	rs10803369	chr1:15550525	G/T	cg21012057	chr1:15538911	TMEM51	-0.53	-7.21	-0.42	6.8e-12	Migraine;
KIRP	cis	rs2415984	0.622	rs2817568	chr14:46940986	C/G	cg14871534	chr14:47121158	RPL10L	0.39	4.98	0.3	1.17e-6	Number of children ever born;
KIRP	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg23985595	chr17:80112537	CCDC57	-0.34	-5.08	-0.31	7.52e-7	Life satisfaction;
KIRP	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg09137382	chr11:130731461	NA	0.56	8.28	0.47	7.78e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	10.32	0.55	5.54e-21	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10619411	chr15:101514474	LRRK1	-0.46	-6.77	-0.4	9.43e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23281280	chr6:28129359	ZNF389	0.5	5.35	0.32	2.04e-7	Depression;
KIRP	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg16558253	chr16:72132732	DHX38	-0.37	-4.98	-0.3	1.17e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg16497661	chr14:103986332	CKB	0.49	6.53	0.38	3.74e-10	Body mass index;
KIRP	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.71	-9.47	-0.52	2.41e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.59	-5.64	-0.34	4.7e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg06521331	chr12:34319734	NA	-0.6	-7.14	-0.41	1.02e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.67	-10.17	-0.54	1.67e-20	Hepatocellular carcinoma;
KIRP	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.66	7.89	0.45	9.77e-14	Type 2 diabetes;
KIRP	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg25124228	chr12:125621409	AACS	-0.59	-6.62	-0.39	2.22e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.61	0.56	6.59e-22	Personality dimensions;
KIRP	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	7.35	0.42	2.93e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.557	rs4077531	chr11:1013167	G/A	cg10932868	chr11:921992	NA	0.5	5.68	0.34	3.84e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2594989	0.943	rs9836989	chr3:11463637	G/A	cg01796438	chr3:11312864	ATG7	-0.56	-7.25	-0.42	5.47e-12	Circulating chemerin levels;
KIRP	cis	rs1823913	0.592	rs1349939	chr2:192164805	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg00784671	chr22:46762841	CELSR1	-0.52	-5.76	-0.34	2.54e-8	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg10756647	chr7:56101905	PSPH	0.9	7.06	0.41	1.65e-11	Diabetic kidney disease;
KIRP	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.56	5.88	0.35	1.3e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.72	10.08	0.54	3.18e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs6993449	0.740	rs1954733	chr8:108246315	A/G	cg10353870	chr2:127864778	BIN1	0.58	6.07	0.36	4.73e-9	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11855526	chr11:30607068	MPPED2	0.49	7.1	0.41	1.32e-11	Parkinson's disease;
KIRP	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg25008857	chr14:105974488	NA	0.44	5.0	0.3	1.11e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.42e-11	Schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10230308	chr17:61678218	TACO1	-0.6	-6.23	-0.37	1.97e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.0	-0.41	2.37e-11	Joint mobility (Beighton score);
KIRP	cis	rs10982256	0.905	rs10982255	chr9:117255744	C/T	cg13636371	chr9:117264095	DFNB31	0.59	8.16	0.46	1.74e-14	Bipolar disorder;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg07341007	chr3:195489909	MUC4	0.72	6.69	0.39	1.49e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.69	7.22	0.42	6.34e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg04455712	chr21:45112962	RRP1B	0.47	6.3	0.37	1.36e-9	Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg07701084	chr6:150067640	NUP43	0.71	9.95	0.54	7.98e-20	Lung cancer;
KIRP	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	4.94	0.3	1.47e-6	Personality dimensions;
KIRP	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	cg04338863	chr8:33670619	NA	0.41	5.24	0.32	3.42e-7	Body mass index;
KIRP	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg05805236	chr11:65401703	PCNXL3	-0.62	-8.36	-0.47	4.77e-15	Acne (severe);
KIRP	cis	rs2290402	0.536	rs3775129	chr4:875155	G/A	cg14517359	chr4:903473	GAK	-0.54	-5.64	-0.34	4.66e-8	Type 2 diabetes;
KIRP	cis	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.69	-0.39	1.53e-10	Morning vs. evening chronotype;
KIRP	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	1.09	9.73	0.53	3.91e-19	Pulse pressure;
KIRP	trans	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg24644049	chr4:85504048	CDS1	1.0	6.97	0.41	2.88e-11	Skin colour saturation;
KIRP	cis	rs526231	0.511	rs55896090	chr5:102362004	G/C	cg23492399	chr5:102201601	PAM	-0.47	-5.17	-0.31	4.83e-7	Primary biliary cholangitis;
KIRP	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg05768032	chr16:30646687	NA	0.48	5.77	0.35	2.35e-8	Multiple myeloma;
KIRP	cis	rs7188697	0.922	rs9923491	chr16:58603176	T/G	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg27205649	chr11:78285834	NARS2	-0.67	-7.64	-0.44	4.76e-13	Alzheimer's disease (survival time);
KIRP	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.62	7.77	0.44	2.09e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.34	-0.32	2.12e-7	Autism;
KIRP	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.95e-7	Total body bone mineral density;
KIRP	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg01629716	chr15:45996671	NA	0.37	6.7	0.39	1.39e-10	Waist circumference;Weight;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg05552183	chr6:42928497	GNMT	0.82	13.51	0.65	1.8e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.59	-0.39	2.65e-10	QT interval;
KIRP	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg03735888	chr19:58951602	ZNF132	0.46	5.51	0.33	9e-8	Uric acid clearance;
KIRP	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.71	10.53	0.56	1.22e-21	Height;
KIRP	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.41	0.38	7.47e-10	Bipolar disorder;
KIRP	cis	rs6539288	0.589	rs1037013	chr12:107219308	A/G	cg21360079	chr12:107162445	NA	-0.55	-7.83	-0.45	1.47e-13	Total body bone mineral density;
KIRP	cis	rs12995491	0.731	rs55705009	chr2:88500718	T/G	cg04511125	chr2:88470314	THNSL2	-0.49	-6.09	-0.36	4.32e-9	Response to metformin (IC50);
KIRP	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.48	-7.16	-0.42	9.15e-12	Schizophrenia;
KIRP	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg10556349	chr10:835070	NA	-0.4	-5.1	-0.31	6.73e-7	Survival in rectal cancer;
KIRP	cis	rs981844	0.617	rs4077965	chr4:154710520	G/C	cg14289246	chr4:154710475	SFRP2	0.58	7.19	0.42	7.55e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs7688540	0.771	rs61795007	chr4:255264	G/A	cg17891759	chr4:299121	NA	-0.44	-5.12	-0.31	6.03e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs5747327	0.874	rs5747329	chr22:18170207	A/G	cg19898043	chr22:18121309	BCL2L13	-0.4	-4.91	-0.3	1.69e-6	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	13.06	0.64	5.98e-30	Alzheimer's disease;
KIRP	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.62	0.34	5.16e-8	Lung cancer;
KIRP	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg11821147	chr12:72057762	ZFC3H1;THAP2	-0.54	-6.12	-0.36	3.73e-9	Corneal astigmatism;
KIRP	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.4	-6.34	-0.37	1.07e-9	Body mass index;
KIRP	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	4.98	0.3	1.22e-6	Rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.86	-12.29	-0.62	2.16e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg02696742	chr7:106810147	HBP1	-0.75	-6.93	-0.4	3.69e-11	Coronary artery disease;
KIRP	cis	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg26585981	chr11:48327164	OR4S1	-0.47	-5.67	-0.34	4.09e-8	HDL cholesterol;
KIRP	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg23933602	chr10:16859644	RSU1	0.56	6.27	0.37	1.58e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg06212747	chr3:49208901	KLHDC8B	0.69	8.26	0.47	8.86e-15	Menarche (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22317668	chr19:42772446	NA	0.48	6.43	0.38	6.67e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11191270	1.000	rs55970842	chr10:104171094	C/A	cg15320455	chr10:103880129	LDB1	0.59	5.2	0.31	4.21e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.719	rs6664823	chr1:152933424	A/C	cg07796016	chr1:152779584	LCE1C	-0.41	-4.89	-0.3	1.8e-6	Inflammatory skin disease;
KIRP	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6988636	0.818	rs1713733	chr8:124199458	A/G	cg23067535	chr8:124195133	FAM83A	0.58	5.56	0.33	6.96e-8	Urinary uromodulin levels;
KIRP	cis	rs11203032	0.831	rs12250945	chr10:90935206	A/G	cg16672925	chr10:90967113	CH25H	0.44	5.13	0.31	5.92e-7	Heart failure;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07898084	chr13:53029385	CKAP2	0.69	6.43	0.38	6.62e-10	Lung function (FEV1);
KIRP	trans	rs61884328	0.866	rs12575721	chr11:46823681	T/C	cg10758369	chr1:48459236	NA	0.53	6.6	0.39	2.56e-10	Total body bone mineral density (age over 60);
KIRP	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	6.22	0.37	2.11e-9	Breast cancer;
KIRP	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg18944383	chr4:111397179	ENPEP	0.54	9.46	0.52	2.52e-18	Height;
KIRP	cis	rs17221829	0.733	rs10765227	chr11:89385116	A/G	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs6430538	0.621	rs6725916	chr2:135564058	T/A	cg12500956	chr2:135428796	TMEM163	0.38	4.99	0.3	1.14e-6	Parkinson's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03114442	chr13:52378179	DHRS12	0.48	6.18	0.37	2.7e-9	Myopia (pathological);
KIRP	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg02336718	chr17:17403227	NA	0.34	5.15	0.31	5.32e-7	Total body bone mineral density;
KIRP	cis	rs55728055	0.661	rs7285893	chr22:32010042	A/G	cg01338084	chr22:32026380	PISD	0.89	6.37	0.38	9.12e-10	Age-related hearing impairment;
KIRP	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.49	6.27	0.37	1.64e-9	Total body bone mineral density;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg02733842	chr7:1102375	C7orf50	0.49	4.9	0.3	1.75e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.09	-0.36	4.35e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9815354	0.767	rs11917248	chr3:41885723	T/C	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg07068956	chr7:100330872	ZAN	0.39	5.22	0.32	3.75e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg08501292	chr6:25962987	TRIM38	0.81	5.5	0.33	9.56e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg26695010	chr11:65641043	EFEMP2	0.45	5.45	0.33	1.22e-7	Eosinophil percentage of white cells;
KIRP	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.96	8.6	0.48	9.55e-16	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.83	-9.16	-0.5	2.1e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg02487422	chr3:49467188	NICN1	0.42	5.43	0.33	1.35e-7	Resting heart rate;
KIRP	cis	rs7188697	0.922	rs7199856	chr16:58584772	A/C	cg21335942	chr16:58549945	SETD6	0.45	5.16	0.31	5.01e-7	QT interval;
KIRP	cis	rs10782582	0.668	rs7516477	chr1:76204502	C/G	cg22875332	chr1:76189707	ACADM	-0.35	-5.38	-0.32	1.75e-7	Daytime sleep phenotypes;
KIRP	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg15979348	chr13:112237479	NA	0.38	4.89	0.3	1.83e-6	Menarche (age at onset);
KIRP	cis	rs6540559	0.673	rs17015218	chr1:209967915	A/G	cg22029157	chr1:209979665	IRF6	0.52	5.87	0.35	1.38e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.62	5.52	0.33	8.54e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs2554380	0.628	rs2401130	chr15:84470735	A/C	cg14598478	chr15:84363061	ADAMTSL3	-0.32	-4.96	-0.3	1.34e-6	Height;
KIRP	cis	rs240764	0.817	rs11155610	chr6:101170233	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-5.43	-0.33	1.32e-7	Neuroticism;
KIRP	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg17724175	chr1:150552817	MCL1	0.29	4.87	0.3	1.98e-6	Melanoma;
KIRP	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.33	8.71	0.49	4.51e-16	Crohn's disease;
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg05627522	chr15:75251581	NA	0.4	6.39	0.38	8.16e-10	Breast cancer;
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07256732	chr16:621771	PIGQ	-0.47	-6.53	-0.38	3.68e-10	Height;
KIRP	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg23602478	chr1:26503979	CNKSR1	0.45	6.49	0.38	4.71e-10	Height;
KIRP	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.39	-4.87	-0.3	2e-6	Birth weight;
KIRP	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.41	-7.39	-0.43	2.29e-12	Refractive error;
KIRP	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	9.65	0.52	6.61e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	cis	rs9297994	0.883	rs7826120	chr8:59371725	T/C	cg05237114	chr8:58905672	FAM110B	0.35	4.84	0.3	2.27e-6	LDL cholesterol;
KIRP	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg27490568	chr2:178487706	NA	0.48	6.43	0.38	6.66e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs35740288	0.545	rs11637283	chr15:86316103	C/T	cg20737812	chr15:86336631	KLHL25	-0.48	-5.82	-0.35	1.82e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.07	-0.5	3.93e-17	Platelet count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22106847	chr5:118584299	DMXL1	-0.5	-7.78	-0.44	2.02e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg23188430	chr6:125850052	NA	-0.32	-4.92	-0.3	1.62e-6	Brugada syndrome;
KIRP	trans	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg06521331	chr12:34319734	NA	-0.56	-7.0	-0.41	2.44e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs259842	0.759	rs7597666	chr2:180683394	A/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.36	-5.23	-0.32	3.64e-7	Blood protein levels;
KIRP	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.39	-6.45	-0.38	5.81e-10	Dupuytren's disease;
KIRP	cis	rs4561483	0.583	rs17236573	chr16:11994655	G/C	cg08843971	chr16:11963173	GSPT1	0.53	7.54	0.43	9.09e-13	Testicular germ cell tumor;
KIRP	cis	rs2441986	0.894	rs2443440	chr11:57933122	T/C	cg19752551	chr11:57585705	CTNND1	0.4	4.9	0.3	1.7e-6	Systolic blood pressure;
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg11641102	chr8:27183873	PTK2B	0.42	5.52	0.33	8.81e-8	Neuroticism;
KIRP	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg24315340	chr6:146058215	EPM2A	-0.46	-6.14	-0.36	3.3e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg23625390	chr15:77176239	SCAPER	0.53	6.93	0.4	3.72e-11	Blood metabolite levels;
KIRP	cis	rs830233	0.649	rs6868887	chr5:165422715	A/T	cg13976338	chr5:165423657	NA	-0.71	-7.6	-0.44	6.23e-13	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	cg12689670	chr1:183009347	LAMC1	0.46	6.72	0.39	1.25e-10	Hypertriglyceridemia;
KIRP	cis	rs75920871	0.528	rs3886960	chr11:116924990	G/T	cg04087571	chr11:116723030	SIK3	-0.26	-5.56	-0.33	6.84e-8	Subjective well-being;
KIRP	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.42	11.13	0.58	1.42e-23	Prostate cancer;
KIRP	cis	rs5753037	0.702	rs5752961	chr22:30188084	C/T	cg27665648	chr22:30112403	NA	0.33	4.9	0.3	1.75e-6	Type 1 diabetes;
KIRP	cis	rs9436747	0.605	rs11587159	chr1:65987205	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.56	-5.86	-0.35	1.5e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs4700695	0.925	rs6449799	chr5:65394476	A/G	cg21114390	chr5:65439923	SFRS12	-0.5	-5.57	-0.33	6.66e-8	Facial morphology (factor 19);
KIRP	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.11e-7	Breast cancer;
KIRP	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.64	-0.39	1.99e-10	Monocyte percentage of white cells;
KIRP	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.69	9.38	0.51	4.62e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs57590327	0.503	rs7618973	chr3:81619588	C/T	cg07356753	chr3:81810745	GBE1	0.57	7.21	0.42	6.79e-12	Extraversion;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22555675	chr19:17799230	UNC13A	0.51	6.34	0.37	1.12e-9	Parkinson's disease;
KIRP	cis	rs4722404	0.768	rs10265027	chr7:3135770	T/C	cg19214707	chr7:3157722	NA	0.42	5.14	0.31	5.48e-7	Atopic dermatitis;
KIRP	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.79	7.79	0.44	1.89e-13	Bipolar disorder;
KIRP	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg02367723	chr1:46378857	MAST2	0.42	4.86	0.3	2.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg19743168	chr1:23544995	NA	0.48	6.43	0.38	6.44e-10	Height;
KIRP	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg12560992	chr17:57184187	TRIM37	0.59	5.4	0.33	1.55e-7	Cognitive test performance;
KIRP	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs8067545	0.532	rs12943904	chr17:20007567	G/C	cg13482628	chr17:19912719	NA	0.45	5.01	0.3	1.03e-6	Schizophrenia;
KIRP	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10002088	chr19:9271911	ZNF317	0.54	6.18	0.37	2.58e-9	Interleukin-4 levels;
KIRP	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg18154014	chr19:37997991	ZNF793	0.87	6.87	0.4	5.33e-11	Coronary artery calcification;
KIRP	cis	rs7529073	0.815	rs1431984	chr1:214148628	A/G	cg24083324	chr1:214162604	PROX1	-0.4	-5.79	-0.35	2.09e-8	Schizophrenia;
KIRP	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	10.51	0.56	1.42e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.05	-21.67	-0.81	5.83e-59	Myeloid white cell count;
KIRP	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.42	4.89	0.3	1.85e-6	Resistin levels;
KIRP	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-5.29	-0.32	2.68e-7	Schizophrenia;
KIRP	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.4	5.95	0.35	9.33e-9	Platelet distribution width;
KIRP	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg04733989	chr22:42467013	NAGA	0.58	7.86	0.45	1.18e-13	Cognitive function;
KIRP	trans	rs2797160	0.547	rs9401837	chr6:125956853	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.16	-0.37	2.9e-9	Endometrial cancer;
KIRP	cis	rs3105593	1.000	rs4509958	chr15:50894175	T/C	cg08437265	chr15:50716283	USP8	0.39	4.94	0.3	1.48e-6	QT interval;
KIRP	cis	rs4356932	1.000	rs7674409	chr4:76958334	C/G	cg00809888	chr4:76862425	NAAA	-0.44	-6.18	-0.37	2.71e-9	Blood protein levels;
KIRP	cis	rs12282928	0.917	rs1503175	chr11:48269192	A/G	cg26585981	chr11:48327164	OR4S1	-0.52	-6.29	-0.37	1.44e-9	Migraine - clinic-based;
KIRP	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg09455208	chr3:40491958	NA	-0.3	-5.35	-0.32	2.04e-7	Renal cell carcinoma;
KIRP	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg04935436	chr20:30431758	NA	-0.49	-5.73	-0.34	2.91e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.48	-6.93	-0.4	3.71e-11	Schizophrenia;
KIRP	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.81	0.4	7.24e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.76	-7.67	-0.44	4.05e-13	Platelet count;
KIRP	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg00405596	chr8:11794950	NA	0.47	6.13	0.36	3.48e-9	Retinal vascular caliber;
KIRP	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.81	8.18	0.46	1.52e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.76	5.62	0.34	5.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4729127	1.000	rs7799378	chr7:94007546	C/G	cg20814616	chr7:94014465	NA	0.38	5.01	0.3	1.04e-6	Intelligence;
KIRP	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.71	-10.06	-0.54	3.66e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.67	-8.09	-0.46	2.7e-14	Blood metabolite levels;
KIRP	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-7.5	-0.43	1.19e-12	Fear of minor pain;
KIRP	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg16141378	chr3:129829833	LOC729375	-0.51	-6.31	-0.37	1.27e-9	Neuroticism;
KIRP	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs3109167	0.623	rs2723006	chr7:83121863	T/C	cg14519356	chr7:83097669	SEMA3E	0.37	5.03	0.31	9.51e-7	Blood protein levels;
KIRP	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.81	8.55	0.48	1.31e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg10818794	chr15:86012489	AKAP13	-0.53	-7.61	-0.44	5.78e-13	Interstitial lung disease;
KIRP	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg22563815	chr15:78856949	CHRNA5	0.52	7.4	0.43	2.2e-12	Sudden cardiac arrest;
KIRP	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg04935436	chr20:30431758	NA	0.56	6.86	0.4	5.47e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs4302748	0.862	rs11973172	chr7:36183435	A/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs7180079	0.620	rs685068	chr15:64889129	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs597583	0.806	rs4938397	chr11:117392337	G/T	cg27161313	chr11:117392002	DSCAML1	-0.54	-5.98	-0.36	7.85e-9	Putamen volume;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12548088	chr19:12777567	MORG1;MAN2B1	0.55	6.86	0.4	5.41e-11	Myopia (pathological);
KIRP	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg19899395	chr1:46959349	NA	0.4	4.87	0.3	2.01e-6	Monobrow;
KIRP	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	11.55	0.59	5.94e-25	Schizophrenia;
KIRP	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	11.66	0.6	2.74e-25	Lung cancer in ever smokers;
KIRP	cis	rs4750440	0.585	rs35982189	chr10:14029875	T/C	cg27542038	chr10:14027202	FRMD4A	-0.59	-7.67	-0.44	4.09e-13	Adiponectin levels;
KIRP	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg06654118	chr4:1303317	MAEA	0.31	5.77	0.35	2.43e-8	Obesity-related traits;
KIRP	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.4	-0.51	3.99e-18	Chronic sinus infection;
KIRP	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg01631408	chr1:248437212	OR2T33	-0.63	-8.16	-0.46	1.75e-14	Common traits (Other);
KIRP	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.66	8.83	0.49	1.94e-16	Breast cancer;
KIRP	cis	rs4414128	0.832	rs1573	chr10:5680896	A/G	cg12223502	chr10:5658492	NA	0.48	5.43	0.33	1.38e-7	Breast cancer;
KIRP	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.14	-0.5	2.37e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.77	11.31	0.58	3.63e-24	Hip circumference;
KIRP	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg11846333	chr4:119757529	SEC24D	1.12	6.33	0.37	1.17e-9	Cannabis dependence symptom count;
KIRP	trans	rs301901	0.796	rs11742177	chr5:37504165	G/T	cg01568846	chr3:179281462	ACTL6A	0.49	6.04	0.36	5.71e-9	Height;
KIRP	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg04362960	chr10:104952993	NT5C2	0.51	6.23	0.37	1.97e-9	Arsenic metabolism;
KIRP	cis	rs612683	0.518	rs10875287	chr1:100812908	T/C	cg06223162	chr1:101003688	GPR88	-0.32	-6.2	-0.37	2.39e-9	Breast cancer;
KIRP	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg10495392	chr1:46806563	NSUN4	0.49	5.6	0.34	5.63e-8	Menopause (age at onset);
KIRP	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.56	6.96	0.41	3.05e-11	Breast cancer;
KIRP	cis	rs6546886	0.956	rs6546885	chr2:74245492	G/A	cg14702570	chr2:74259524	NA	-0.31	-6.14	-0.36	3.32e-9	Dialysis-related mortality;
KIRP	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg13334819	chr7:99746414	C7orf59	-0.49	-5.6	-0.34	5.7e-8	Coronary artery disease;
KIRP	cis	rs2124969	0.548	rs7586751	chr2:160958145	T/C	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.12	-0.36	3.62e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs12049351	0.774	rs11805194	chr1:229631734	T/C	cg11742688	chr1:229674241	ABCB10	-0.39	-6.03	-0.36	6.13e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.75	10.5	0.56	1.52e-21	Body mass index;
KIRP	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.65	-6.12	-0.36	3.65e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2224391	0.518	rs11757927	chr6:5282573	A/C	cg13962347	chr6:5174647	LYRM4	0.66	6.13	0.36	3.56e-9	Height;
KIRP	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23422044	chr7:1970798	MAD1L1	-0.7	-7.25	-0.42	5.53e-12	Bipolar disorder;
KIRP	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg11608241	chr8:8085544	FLJ10661	-0.4	-4.85	-0.3	2.21e-6	Joint mobility (Beighton score);
KIRP	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg06917634	chr15:78832804	PSMA4	-0.67	-7.32	-0.42	3.46e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17675882	chr20:35374068	NDRG3	-0.49	-6.36	-0.38	9.71e-10	Neuroticism;
KIRP	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.83	12.43	0.62	7.71e-28	Body mass index;
KIRP	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.83	-10.38	-0.55	3.57e-21	Diastolic blood pressure;
KIRP	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.57	-6.6	-0.39	2.52e-10	Childhood ear infection;
KIRP	cis	rs261532	0.906	rs355162	chr5:138956241	T/C	cg12205435	chr5:138714322	SLC23A1	-0.37	-4.95	-0.3	1.39e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.27	25.05	0.85	1.2e-69	IgG glycosylation;
KIRP	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.55	-0.39	3.27e-10	Joint mobility (Beighton score);
KIRP	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.78	-12.16	-0.61	5.79e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs6585424	1.000	rs12777867	chr10:81935530	C/T	cg27417294	chr10:81904244	PLAC9	0.53	5.06	0.31	8.29e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.59	-0.44	6.48e-13	Bladder cancer;
KIRP	cis	rs4481887	0.752	rs12046632	chr1:248479995	A/G	cg01631408	chr1:248437212	OR2T33	-0.62	-6.78	-0.4	8.79e-11	Common traits (Other);
KIRP	cis	rs3007729	1.000	rs3007729	chr1:18795255	A/G	cg05040210	chr1:18807594	KLHDC7A	-0.28	-5.16	-0.31	5.09e-7	Diabetic retinopathy;
KIRP	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.47	-5.62	-0.34	5.14e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.53	-0.43	9.89e-13	Height;
KIRP	cis	rs7852872	0.965	rs11794318	chr9:119254123	G/C	cg13792444	chr9:119245443	ASTN2	0.44	6.29	0.37	1.41e-9	Hippocampal volume;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04579211	chr15:41221939	DLL4	0.78	7.18	0.42	8.15e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07157834	chr1:205819609	PM20D1	-0.42	-4.92	-0.3	1.58e-6	Parkinson's disease;
KIRP	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg01721255	chr8:58191610	C8orf71	0.54	5.56	0.33	7.13e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg26681399	chr22:41777847	TEF	-0.49	-5.07	-0.31	7.86e-7	Vitiligo;
KIRP	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.51	6.13	0.36	3.4e-9	Parkinson's disease;
KIRP	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.7	-0.34	3.38e-8	Mood instability;
KIRP	cis	rs714027	0.605	rs193476	chr22:30450521	G/A	cg27665648	chr22:30112403	NA	-0.43	-5.89	-0.35	1.26e-8	Lymphocyte counts;
KIRP	cis	rs4523957	0.620	rs1565764	chr17:2074303	G/A	cg16513277	chr17:2031491	SMG6	-0.85	-12.43	-0.62	7.25e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.44	-5.79	-0.35	2.17e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.36	6.22	0.37	2.1e-9	Lipoprotein (a) levels;
KIRP	cis	rs860295	0.702	rs56675301	chr1:155364327	T/C	cg02153340	chr1:155202674	NA	-0.55	-7.48	-0.43	1.33e-12	Body mass index;
KIRP	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.93	-15.99	-0.71	6.2e-40	Height;
KIRP	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg08885076	chr2:99613938	TSGA10	-0.37	-4.99	-0.3	1.16e-6	Chronic sinus infection;
KIRP	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.15e-6	Parkinson's disease;
KIRP	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22857025	chr5:266934	NA	-0.85	-7.11	-0.41	1.28e-11	Asthma (childhood onset);
KIRP	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg01444801	chr10:135216882	MTG1	-0.56	-6.24	-0.37	1.9e-9	Systemic lupus erythematosus;
KIRP	cis	rs2219968	1.000	rs13260890	chr8:78970064	G/A	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs687432	0.924	rs12802044	chr11:57760683	T/C	cg19752551	chr11:57585705	CTNND1	-0.65	-8.25	-0.47	9.76e-15	Parkinson's disease;
KIRP	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.58	-0.8	2.03e-55	Height;
KIRP	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.78	-9.13	-0.5	2.52e-17	Corneal astigmatism;
KIRP	cis	rs16857609	1.000	rs57481445	chr2:218296374	A/G	cg15335768	chr2:218268053	DIRC3	-0.47	-6.88	-0.4	4.8e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs13161895	0.938	rs594202	chr5:179417335	C/T	cg02702477	chr5:179499311	RNF130	0.65	5.04	0.31	9.08e-7	LDL cholesterol;
KIRP	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	5.85	0.35	1.55e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg02527881	chr3:46936655	PTH1R	-0.37	-5.22	-0.32	3.72e-7	Colorectal cancer;
KIRP	cis	rs10073892	0.620	rs7730106	chr5:101965043	C/G	cg19774478	chr5:101632501	SLCO4C1	0.47	4.9	0.3	1.74e-6	Cognitive decline (age-related);
KIRP	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg08603382	chr10:743973	NA	0.45	6.47	0.38	5.32e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.44	-5.06	-0.31	8.13e-7	Schizophrenia;
KIRP	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.82	12.2	0.61	4.53e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.0	-0.3	1.07e-6	Iron status biomarkers;
KIRP	cis	rs7617773	1.000	rs6442106	chr3:48190815	G/A	cg11946769	chr3:48343235	NME6	-0.49	-5.93	-0.35	1.03e-8	Coronary artery disease;
KIRP	cis	rs698833	0.926	rs1067339	chr2:44624448	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.57	0.39	3.01e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs12282928	0.959	rs4980427	chr11:48296486	T/C	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg05692746	chr2:100937584	LONRF2	-0.46	-5.41	-0.33	1.51e-7	Educational attainment;
KIRP	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg14851346	chr12:38532713	NA	-0.4	-4.9	-0.3	1.76e-6	Bladder cancer;
KIRP	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.15	14.79	0.69	7.6e-36	Type 2 diabetes nephropathy;
KIRP	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.48	5.08	0.31	7.37e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs5752773	0.513	rs134489	chr22:28729767	A/T	cg21537212	chr22:29075247	TTC28	-0.47	-5.32	-0.32	2.3e-7	Vertical cup-disc ratio;
KIRP	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg10047753	chr17:41438598	NA	0.81	11.01	0.57	3.43e-23	Menopause (age at onset);
KIRP	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.57	-7.26	-0.42	5.11e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs12545912	0.770	rs4841196	chr8:9555092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.45	-0.38	5.82e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.48	5.8	0.35	2.06e-8	Diastolic blood pressure;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03762994	chr17:6899332	ALOX12	0.3	5.46	0.33	1.17e-7	Tonsillectomy;
KIRP	cis	rs1710354	0.872	rs7260113	chr19:51801624	A/G	cg04944904	chr19:51845941	VSIG10L	0.35	5.12	0.31	6.23e-7	Blood protein levels;
KIRP	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.7	7.06	0.41	1.67e-11	Menarche (age at onset);
KIRP	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.5	-7.2	-0.42	7.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg26924012	chr15:45694286	SPATA5L1	0.85	12.36	0.62	1.3e-27	Homoarginine levels;
KIRP	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9912468	0.528	rs9897002	chr17:64286494	A/G	cg19474267	chr17:64306194	PRKCA	-0.45	-5.78	-0.35	2.3e-8	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs7808935	0.628	rs72598552	chr7:27939961	G/A	cg22168087	chr7:27702803	HIBADH	0.73	7.29	0.42	4.25e-12	Prostate cancer;
KIRP	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg00806126	chr19:22604979	ZNF98	-0.56	-5.82	-0.35	1.8e-8	Pain;
KIRP	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	7.83	0.45	1.46e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9326248	0.515	rs2727793	chr11:116683374	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.42	4.91	0.3	1.67e-6	Blood protein levels;
KIRP	cis	rs2057178	0.745	rs12280757	chr11:32353264	G/A	cg06489367	chr11:32355509	NA	0.42	5.06	0.31	8.1e-7	Tuberculosis;
KIRP	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19005763	chr3:58225528	ABHD6	0.49	6.15	0.37	3.19e-9	Interleukin-4 levels;
KIRP	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.5	-4.9	-0.3	1.78e-6	IFN-related cytopenia;
KIRP	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-9.44	-0.52	3.07e-18	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg17554472	chr22:41940697	POLR3H	0.67	6.96	0.41	3.16e-11	Vitiligo;
KIRP	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg08822215	chr16:89438651	ANKRD11	-0.52	-6.46	-0.38	5.71e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.41	-0.38	7.33e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg02073558	chr3:44770973	ZNF501	0.59	8.23	0.46	1.08e-14	Depressive symptoms;
KIRP	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	5.05	0.31	8.75e-7	Resting heart rate;
KIRP	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.67	-8.58	-0.48	1.11e-15	Iron status biomarkers;
KIRP	cis	rs3026101	0.624	rs1065483	chr17:5284770	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.54	7.34	0.42	3.12e-12	Body mass index;
KIRP	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.02	0.3	1.02e-6	Retinal vascular caliber;
KIRP	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-6.1	-0.36	3.98e-9	Prudent dietary pattern;
KIRP	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.06	-20.06	-0.79	1.11e-53	Testicular germ cell tumor;
KIRP	cis	rs6968419	0.755	rs1141470	chr7:115898442	G/C	cg02561103	chr7:115862891	TES	-0.41	-5.93	-0.35	1e-8	Intraocular pressure;
KIRP	cis	rs6723108	0.738	rs10928512	chr2:135451302	A/C	cg12500956	chr2:135428796	TMEM163	0.48	6.21	0.37	2.28e-9	Type 2 diabetes;
KIRP	cis	rs9393813	0.516	rs4713099	chr6:27405202	T/G	cg03332623	chr6:27441972	ZNF184	-0.38	-5.28	-0.32	2.78e-7	Bipolar disorder;
KIRP	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg25356066	chr3:128598488	ACAD9	-0.53	-6.39	-0.38	8.36e-10	IgG glycosylation;
KIRP	cis	rs4953911	0.893	rs6430506	chr2:135061348	T/C	cg18482303	chr2:135041380	MGAT5	-0.28	-5.33	-0.32	2.19e-7	Multiple sclerosis (severity);
KIRP	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-8.61	-0.48	9.08e-16	Mean corpuscular volume;
KIRP	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.59	7.29	0.42	4.22e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.9	-0.45	9.06e-14	Homocysteine levels;
KIRP	cis	rs3821902	0.646	rs55955229	chr3:64015425	T/C	cg09006292	chr3:64049408	NA	-0.48	-5.0	-0.3	1.07e-6	Breast cancer;
KIRP	cis	rs6142102	0.625	rs4911381	chr20:32550345	C/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.74	-0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.64	-0.34	4.64e-8	Longevity;Endometriosis;
KIRP	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-5.8	-0.35	2.02e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs34057264	1	rs34057264	chr8:23372787	T/TTTTG	cg00472375	chr8:23315376	ENTPD4	0.59	4.93	0.3	1.48e-6	Mean corpuscular hemoglobin;Hemoglobin concentration;
KIRP	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.43	5.45	0.33	1.21e-7	Resistin levels;
KIRP	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	7.51	0.43	1.09e-12	Neuroticism;
KIRP	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	7.65	0.44	4.51e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15557168	chr22:42548783	NA	-0.45	-5.84	-0.35	1.64e-8	Cognitive function;
KIRP	cis	rs151997	0.537	rs11746939	chr5:50268856	G/A	cg06027927	chr5:50259733	NA	0.53	6.61	0.39	2.34e-10	Callous-unemotional behaviour;
KIRP	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.63	9.38	0.51	4.49e-18	Body mass index;
KIRP	trans	rs35607894	0.500	rs12884777	chr14:72461160	C/T	cg09954251	chr8:1278972	NA	0.56	6.2	0.37	2.41e-9	Schizophrenia;
KIRP	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg17385448	chr1:15911702	AGMAT	0.26	5.14	0.31	5.67e-7	Systolic blood pressure;
KIRP	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.45	6.32	0.37	1.19e-9	Dupuytren's disease;
KIRP	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01341218	chr17:43662625	NA	0.84	8.9	0.49	1.25e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.56	-0.48	1.23e-15	Retinal vascular caliber;
KIRP	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.19	-0.61	4.69e-27	Alzheimer's disease;
KIRP	cis	rs7819412	0.560	rs3021497	chr8:10996089	A/G	cg21775007	chr8:11205619	TDH	-0.41	-4.99	-0.3	1.16e-6	Triglycerides;
KIRP	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg23024343	chr7:107201750	COG5	0.4	4.86	0.3	2.06e-6	Coronary artery disease;
KIRP	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27297192	chr10:134578999	INPP5A	0.61	7.5	0.43	1.16e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs16828019	0.704	rs12024115	chr1:41534357	C/T	cg08144172	chr1:41849203	NA	0.62	5.05	0.31	8.68e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.62	-8.34	-0.47	5.39e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg12598211	chr12:123634384	NA	-0.44	-5.37	-0.32	1.8e-7	Neutrophil percentage of white cells;
KIRP	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg18944383	chr4:111397179	ENPEP	0.47	7.1	0.41	1.32e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg12559939	chr2:27858050	GPN1	-0.4	-4.86	-0.3	2.07e-6	Total body bone mineral density;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.4	6.15	0.36	3.15e-9	Lung cancer;
KIRP	cis	rs11583043	0.708	rs3861735	chr1:101530191	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	5.67	0.34	3.99e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17301259	0.509	rs10232993	chr7:88407594	T/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-4.98	-0.3	1.21e-6	Heschl's gyrus morphology;
KIRP	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg24596788	chr1:163392923	NA	-0.43	-5.92	-0.35	1.06e-8	Motion sickness;
KIRP	cis	rs8028182	0.636	rs8034317	chr15:75764343	G/A	cg20655648	chr15:75932815	IMP3	0.55	7.06	0.41	1.7e-11	Sudden cardiac arrest;
KIRP	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.73	10.02	0.54	4.83e-20	Multiple sclerosis;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg12547667	chr10:1132739	WDR37	-0.47	-6.78	-0.4	8.91e-11	Select biomarker traits;
KIRP	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.91	13.63	0.66	6.66e-32	Mean platelet volume;
KIRP	cis	rs7105934	1.000	rs10908176	chr11:69241453	T/C	cg24478926	chr11:69237550	NA	-0.58	-5.63	-0.34	4.82e-8	Renal cell carcinoma;
KIRP	cis	rs11945232	1.000	rs10027786	chr4:88347512	A/G	cg23841344	chr4:88312519	HSD17B11	-0.59	-7.55	-0.43	8.26e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs828999	0.688	rs12047867	chr1:108726907	G/A	cg06207961	chr1:108661230	NA	0.37	4.96	0.3	1.3e-6	Monocyte percentage of white cells;
KIRP	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.56	-6.82	-0.4	7.02e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg14664628	chr15:75095509	CSK	0.51	5.53	0.33	8.33e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6545883	0.895	rs796597	chr2:61681060	A/G	cg15711740	chr2:61764176	XPO1	-0.61	-7.78	-0.44	1.97e-13	Tuberculosis;
KIRP	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg21573476	chr21:45109991	RRP1B	-0.63	-8.76	-0.49	3.25e-16	Mean corpuscular volume;
KIRP	cis	rs16857609	0.628	rs2568154	chr2:218336054	A/G	cg15335768	chr2:218268053	DIRC3	-0.37	-5.55	-0.33	7.21e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.49	5.95	0.35	8.98e-9	Common traits (Other);
KIRP	cis	rs9990333	0.562	rs75681503	chr3:195822285	G/A	cg01351295	chr3:195700735	SDHAP1	-0.43	-4.86	-0.3	2.14e-6	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
KIRP	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg00629928	chr5:358741	AHRR	0.5	4.86	0.3	2.09e-6	Breast cancer;
KIRP	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.49	-0.33	1.01e-7	Height;
KIRP	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.58	-8.8	-0.49	2.53e-16	Height;
KIRP	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	6.3	0.37	1.38e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.21	-0.32	3.97e-7	Alcohol dependence;
KIRP	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	trans	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg24644049	chr4:85504048	CDS1	1.01	6.59	0.39	2.61e-10	Skin colour saturation;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01261044	chr14:35451962	SRP54	0.53	6.27	0.37	1.62e-9	Smoking initiation;
KIRP	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-9.86	-0.53	1.5700000000000001e-19	Gut microbiome composition (summer);
KIRP	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg15448220	chr1:150897856	SETDB1	0.43	5.53	0.33	8.12e-8	Tonsillectomy;
KIRP	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg05347473	chr6:146136440	FBXO30	0.57	8.12	0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1062746	0.786	rs11649550	chr16:87366770	G/A	cg02258303	chr16:87377426	FBXO31	-0.52	-6.27	-0.37	1.62e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg23307798	chr14:103986281	CKB	-0.44	-6.01	-0.36	6.67e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg10755058	chr3:40428713	ENTPD3	0.48	6.6	0.39	2.52e-10	Renal cell carcinoma;
KIRP	cis	rs17092148	1.000	rs57131731	chr20:33392739	C/T	cg16810054	chr20:33298113	TP53INP2	0.45	5.6	0.34	5.78e-8	Neuroticism;
KIRP	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.35	-5.19	-0.31	4.34e-7	Monocyte count;
KIRP	cis	rs17023223	0.537	rs2645305	chr1:119561365	A/G	cg18261050	chr1:119551319	NA	0.53	7.01	0.41	2.34e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.64	8.82	0.49	2.13e-16	Ulcerative colitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19027571	chr12:133463885	CHFR	0.43	6.13	0.36	3.42e-9	Survival in pancreatic cancer;
KIRP	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	1.06	14.35	0.68	2.42e-34	Alzheimer's disease;
KIRP	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.41	0.33	1.52e-7	Schizophrenia;
KIRP	trans	rs7692299	0.584	rs4833291	chr4:124700389	C/T	cg06476693	chr11:130283454	ADAMTS8	-0.37	-6.14	-0.36	3.23e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.74	-9.05	-0.5	4.42e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7017914	0.967	rs13271442	chr8:71585169	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.01	-0.3	1.06e-6	Bone mineral density;
KIRP	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.36	-0.38	9.69e-10	Daytime sleep phenotypes;
KIRP	cis	rs11967485	0.609	rs62435816	chr6:157153186	C/T	cg23222435	chr6:157204239	ARID1B	-0.68	-4.91	-0.3	1.67e-6	Calcium levels;
KIRP	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06544989	chr22:39130855	UNC84B	0.49	8.13	0.46	2.17e-14	Menopause (age at onset);
KIRP	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.77	9.89	0.53	1.21e-19	Aortic root size;
KIRP	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg21926883	chr2:100939477	LONRF2	-0.51	-6.75	-0.4	1.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-0.78	-11.33	-0.59	3.23e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs2398893	0.960	rs11788176	chr9:96829243	C/T	cg14459158	chr9:96720562	NA	0.32	5.5	0.33	9.37e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	8.32	0.47	6.06e-15	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg08600765	chr20:34638493	LOC647979	-0.66	-6.55	-0.39	3.34e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.62	-5.1	-0.31	6.87e-7	Yeast infection;
KIRP	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg11859384	chr17:80120422	CCDC57	0.45	6.08	0.36	4.47e-9	Life satisfaction;
KIRP	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.51	-0.33	9.23e-8	Neuroticism;
KIRP	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-6.9	-0.4	4.43e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-5.06	-0.31	8.07e-7	Colorectal cancer;
KIRP	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.63	7.62	0.44	5.57e-13	Systemic lupus erythematosus;
KIRP	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.34	0.37	1.11e-9	Aortic root size;
KIRP	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	1.11	14.6	0.68	3.48e-35	Pulmonary function decline;
KIRP	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.8	-11.26	-0.58	5.23e-24	Lung cancer in ever smokers;
KIRP	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg01420254	chr6:26195488	NA	1.24	11.27	0.58	4.85e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg13939156	chr17:80058883	NA	-0.49	-7.4	-0.43	2.2e-12	Life satisfaction;
KIRP	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg17554472	chr22:41940697	POLR3H	0.44	5.24	0.32	3.4e-7	Vitiligo;
KIRP	cis	rs77861329	1.000	rs13314125	chr3:52115398	C/T	cg08692210	chr3:52188851	WDR51A	0.84	5.87	0.35	1.39e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg18183042	chr17:80733038	TBCD	-0.37	-4.96	-0.3	1.33e-6	Glycated hemoglobin levels;
KIRP	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.03	-0.64	7.39e-30	Height;
KIRP	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg08807101	chr21:30365312	RNF160	0.54	5.51	0.33	8.97e-8	Cognitive test performance;
KIRP	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg00204512	chr16:28754710	NA	0.42	5.61	0.34	5.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.5	6.77	0.4	9.51e-11	High light scatter reticulocyte count;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg02733842	chr7:1102375	C7orf50	0.57	5.87	0.35	1.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg22705602	chr4:152727874	NA	-0.55	-9.7	-0.53	4.68e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08122544	chr19:14629215	DNAJB1	0.47	6.18	0.37	2.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg04733989	chr22:42467013	NAGA	0.45	5.39	0.32	1.68e-7	Cognitive function;
KIRP	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.74	-9.05	-0.5	4.42e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.55	6.96	0.41	3.09e-11	Phospholipid levels (plasma);
KIRP	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13409248	chr3:40428643	ENTPD3	0.37	5.08	0.31	7.62e-7	Renal cell carcinoma;
KIRP	cis	rs501120	0.657	rs1619661	chr10:44733383	T/C	cg09554077	chr10:44749378	NA	0.7	7.78	0.44	2.03e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg04998671	chr14:104000505	TRMT61A	-0.7	-6.9	-0.4	4.3e-11	Coronary artery disease;
KIRP	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg19847130	chr8:10466454	RP1L1	0.33	4.88	0.3	1.91e-6	Morning vs. evening chronotype;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg04854794	chr4:164415804	C4orf43	0.49	6.14	0.36	3.2e-9	DNA methylation (variation);
KIRP	cis	rs732716	0.785	rs34080966	chr19:4417845	C/T	cg21720385	chr19:4455239	UBXN6	-0.69	-8.62	-0.48	8.09e-16	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23046897	chr19:55851104	SUV420H2	0.45	6.02	0.36	6.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.37	8.49	0.48	2.03e-15	Asthma (sex interaction);
KIRP	cis	rs12144044	0.869	rs3806441	chr1:113249524	G/C	cg22162597	chr1:113214053	CAPZA1	0.44	4.88	0.3	1.93e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg01872077	chr2:219646372	CYP27A1	0.42	5.45	0.33	1.24e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs55675132	0.548	rs79783412	chr1:115373478	G/A	cg12756093	chr1:115239321	AMPD1	0.51	5.1	0.31	6.86e-7	Schizophrenia;
KIRP	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.71	11.08	0.58	2.12e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.33	-0.42	3.21e-12	Type 2 diabetes;
KIRP	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.68	-7.11	-0.41	1.28e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg07274523	chr3:49395745	GPX1	0.71	8.5	0.48	1.89e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.76	7.9	0.45	9.46e-14	Psoriasis;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg20568497	chr10:133558893	NA	0.32	4.93	0.3	1.54e-6	Survival in rectal cancer;
KIRP	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.43	6.62	0.39	2.3e-10	Schizophrenia;
KIRP	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.11	12.35	0.62	1.34e-27	Vitiligo;
KIRP	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg04725166	chr1:7887271	PER3	-0.33	-5.16	-0.31	5.17e-7	Crohn's disease;
KIRP	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	0.73	6.06	0.36	5.11e-9	Fat distribution (HIV);
KIRP	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.64	10.56	0.56	9.77e-22	Coronary artery disease;
KIRP	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	10.44	0.55	2.29e-21	Bone mineral density;
KIRP	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.67	8.65	0.48	6.57e-16	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.88	0.45	1.04e-13	Acne (severe);
KIRP	trans	rs7157940	0.692	rs4905163	chr14:94570770	A/G	cg22312127	chr12:132628967	NOC4L;DDX51	0.59	6.31	0.37	1.32e-9	Anthropometric traits;
KIRP	cis	rs2882667	0.822	rs11738376	chr5:138398172	G/A	cg04439458	chr5:138467593	SIL1	-0.52	-7.82	-0.45	1.5700000000000001e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	1.08	21.56	0.81	1.27e-58	Height;
KIRP	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	6.88	0.4	4.99e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	0.89	11.26	0.58	5.58e-24	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg07747251	chr5:1868357	NA	0.43	5.51	0.33	8.82e-8	Cardiovascular disease risk factors;
KIRP	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg11211951	chr8:145729740	GPT	-0.36	-5.9	-0.35	1.22e-8	Age at first birth;
KIRP	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg01420254	chr6:26195488	NA	1.16	8.65	0.48	6.56e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs6504950	0.800	rs7209926	chr17:53006324	C/T	cg26251398	chr17:52985966	TOM1L1	-0.43	-5.9	-0.35	1.23e-8	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02326534	chr10:30722736	MAP3K8	0.55	7.2	0.42	7.29e-12	Parkinson's disease;
KIRP	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg00129232	chr17:37814104	STARD3	-0.69	-9.04	-0.5	4.66e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs950881	0.932	rs10173081	chr2:102957348	C/T	cg01254707	chr2:102953421	IL1RL1	-0.51	-5.15	-0.31	5.25e-7	Allergy;
KIRP	cis	rs4953911	1.000	rs1257200	chr2:135036696	G/T	cg18482303	chr2:135041380	MGAT5	-0.28	-5.4	-0.33	1.61e-7	Multiple sclerosis (severity);
KIRP	cis	rs4664304	0.764	rs2063440	chr2:160800102	A/C	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.15	-0.31	5.26e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.94	-0.61	3.15e-26	Eye color traits;
KIRP	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg22903471	chr2:27725779	GCKR	0.38	5.24	0.32	3.41e-7	Oral cavity cancer;
KIRP	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.87	11.33	0.59	3.28e-24	Eotaxin levels;
KIRP	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.55	0.43	8.57e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	5.49	0.33	9.87e-8	Longevity;
KIRP	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs904251	0.600	rs2270687	chr6:37418263	A/G	cg11522683	chr6:37501428	NA	-0.37	-4.92	-0.3	1.62e-6	Cognitive performance;
KIRP	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg20750642	chr13:99100586	FARP1	-0.42	-4.89	-0.3	1.8e-6	Longevity;
KIRP	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.7	-0.34	3.4e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19346786	chr7:2764209	NA	-0.39	-6.44	-0.38	6.29e-10	Height;
KIRP	cis	rs4073582	0.964	rs801742	chr11:65914766	C/A	cg16950941	chr11:66035639	RAB1B	0.41	4.99	0.3	1.15e-6	Gout;
KIRP	cis	rs2371030	1.000	rs10211086	chr2:211575748	C/G	cg18417063	chr2:211583084	NA	-0.52	-7.79	-0.44	1.92e-13	Non-small cell lung cancer;
KIRP	cis	rs3105593	0.933	rs2414059	chr15:50873344	T/A	cg05456662	chr15:50716270	USP8	0.38	5.03	0.31	9.3e-7	QT interval;
KIRP	cis	rs28655083	0.913	rs7190129	chr16:77071456	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-5.56	-0.33	7.09e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg18998321	chr18:7038943	LAMA1	0.32	6.74	0.39	1.1e-10	Schizophrenia;
KIRP	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg21775007	chr8:11205619	TDH	-0.38	-4.91	-0.3	1.65e-6	Morning vs. evening chronotype;
KIRP	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-0.67	-5.53	-0.33	8.22e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	12.07	0.61	1.16e-26	Smoking behavior;
KIRP	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg05082376	chr22:42548792	NA	0.46	5.55	0.33	7.46e-8	Schizophrenia;
KIRP	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg09408571	chr1:101003634	GPR88	-0.24	-5.51	-0.33	9.19e-8	Monocyte count;
KIRP	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg10326726	chr10:51549505	MSMB	0.54	7.65	0.44	4.6e-13	Prostate-specific antigen levels;
KIRP	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.66	-8.6	-0.48	9.33e-16	Calcium levels;
KIRP	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.7	9.73	0.53	3.93e-19	Lymphocyte counts;
KIRP	cis	rs2916247	1.000	rs11779617	chr8:93034215	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.55	-6.94	-0.4	3.37e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.62	6.55	0.39	3.42e-10	Coronary artery calcification;
KIRP	cis	rs6442310	1.000	rs4135247	chr3:12396588	G/A	cg22839075	chr3:12045461	SYN2	-0.4	-5.62	-0.34	5.2100000000000003e-08	Hematocrit;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg13453750	chr1:205783389	SLC41A1	-0.45	-6.92	-0.4	4e-11	Menarche (age at onset);
KIRP	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg04539111	chr16:67997858	SLC12A4	-0.53	-5.1	-0.31	6.86e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg25042112	chr7:64838748	ZNF92	0.58	6.06	0.36	5.19e-9	Pain;
KIRP	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg14972814	chr11:95582409	MTMR2	0.36	5.96	0.36	8.54e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.71	9.33	0.51	6.33e-18	Cognitive function;
KIRP	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07409897	chr20:13619336	TASP1	0.49	6.79	0.4	8.22e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.28	-0.32	2.87e-7	Bladder cancer;
KIRP	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.55	-6.24	-0.37	1.88e-9	Alzheimer's disease (late onset);
KIRP	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.37	0.43	2.66e-12	Lung cancer;
KIRP	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.14	-0.31	5.7e-7	Post bronchodilator FEV1;
KIRP	cis	rs4786125	0.581	rs7194903	chr16:6918194	A/G	cg03623568	chr16:6915990	A2BP1	-0.4	-4.96	-0.3	1.29e-6	Heart rate variability traits (SDNN);
KIRP	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	0.83	7.41	0.43	2.07e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7534824	0.860	rs17450841	chr1:101606071	G/T	cg17443007	chr1:101659419	NA	0.63	5.27	0.32	2.96e-7	Refractive astigmatism;
KIRP	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg08999081	chr20:33150536	PIGU	0.48	6.43	0.38	6.72e-10	Coronary artery disease;
KIRP	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-11.92	-0.6	3.79e-26	Mortality in heart failure;
KIRP	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-5.47	-0.33	1.1e-7	Height;
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-7.44	-0.43	1.63e-12	Glycated hemoglobin levels;
KIRP	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg22676075	chr6:135203613	NA	0.47	6.51	0.38	4.15e-10	Red blood cell count;
KIRP	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg02375832	chr11:62437615	C11orf48	-0.52	-6.4	-0.38	7.8e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg11584989	chr19:19387371	SF4	0.42	5.3	0.32	2.57e-7	Tonsillectomy;
KIRP	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.45	5.3	0.32	2.53e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.63	3.22e-29	Morning vs. evening chronotype;
KIRP	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg05526886	chr2:227700861	RHBDD1	0.44	5.15	0.31	5.24e-7	Pulmonary function;
KIRP	cis	rs2964802	0.505	rs11957751	chr5:10819973	A/G	cg14521931	chr5:10832172	NA	0.7	10.77	0.57	2.04e-22	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.89	-9.11	-0.5	3.03e-17	Obesity-related traits;
KIRP	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.61	-7.2	-0.42	7.43e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.6	6.58	0.39	2.79e-10	Vitiligo;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13150344	chr11:67889062	CHKA	0.47	6.51	0.38	4.18e-10	Survival in pancreatic cancer;
KIRP	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg18753928	chr3:113234510	CCDC52	-0.6	-5.76	-0.34	2.49e-8	Dental caries;
KIRP	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	6.39	0.38	8.11e-10	Menarche (age at onset);
KIRP	cis	rs7116495	0.867	rs662649	chr11:71578875	C/T	cg11196788	chr11:71737549	NUMA1	-0.5	-4.95	-0.3	1.36e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.53e-7	Plateletcrit;
KIRP	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.49	5.72	0.34	3.14e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.45	0.38	6.02e-10	Menarche (age at onset);
KIRP	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg16512390	chr1:228756714	NA	0.72	5.72	0.34	3.14e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17240275	chr15:75500943	C15orf39	0.47	6.1	0.36	4.01e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg25356066	chr3:128598488	ACAD9	0.56	6.43	0.38	6.48e-10	IgG glycosylation;
KIRP	cis	rs6684428	0.610	rs10888940	chr1:56315779	C/T	cg11651538	chr1:56320950	NA	-0.74	-7.3	-0.42	4.09e-12	Airflow obstruction;
KIRP	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg05347473	chr6:146136440	FBXO30	0.54	7.78	0.44	2e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs56104184	0.830	rs73061622	chr19:49358111	C/T	cg12181417	chr19:49337499	HSD17B14	-0.48	-5.2	-0.31	4.13e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-7.87	-0.45	1.14e-13	Longevity;
KIRP	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9815354	1.000	rs6763829	chr3:41897046	A/G	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9972944	0.622	rs1895033	chr17:63777493	A/C	cg07283582	chr17:63770753	CCDC46	0.52	8.57	0.48	1.2e-15	Total body bone mineral density;
KIRP	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.77	8.04	0.46	3.67e-14	Psoriasis;
KIRP	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.63	8.78	0.49	2.89e-16	Blood protein levels;
KIRP	cis	rs4700695	0.764	rs251301	chr5:65300017	G/C	cg21114390	chr5:65439923	SFRS12	0.54	5.07	0.31	7.69e-7	Facial morphology (factor 19);
KIRP	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.42	5.03	0.31	9.5e-7	Refractive astigmatism;
KIRP	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-7.92	-0.45	8.15e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg10818794	chr15:86012489	AKAP13	-0.5	-7.1	-0.41	1.32e-11	Coronary artery disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg20645649	chr9:127624485	RPL35	-0.5	-6.34	-0.37	1.07e-9	Neuroticism;
KIRP	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.92	14.83	0.69	5.43e-36	Blood protein levels;
KIRP	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg19847130	chr8:10466454	RP1L1	-0.38	-5.59	-0.34	5.93e-8	Retinal vascular caliber;
KIRP	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.84	7.68	0.44	3.75e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.68	0.53	5.45e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14103574	chr5:162932455	MAT2B	0.67	6.24	0.37	1.93e-9	Lung function (FEV1);
KIRP	cis	rs7017914	0.967	rs1477944	chr8:71615600	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	Neuroticism;
KIRP	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.8	-11.64	-0.6	3.05e-25	Height;
KIRP	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.43	-0.43	1.78e-12	Systolic blood pressure;
KIRP	cis	rs2963155	0.518	rs33389	chr5:142700499	C/T	cg17617527	chr5:142782415	NR3C1	0.77	7.91	0.45	8.5e-14	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14407075	chr12:50794574	LARP4	0.49	6.33	0.37	1.17e-9	Parkinson's disease;
KIRP	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.54	7.06	0.41	1.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.7	10.55	0.56	1.03e-21	Dupuytren's disease;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg26233468	chr1:155145786	TRIM46;KRTCAP2	0.48	6.04	0.36	5.67e-9	Educational attainment;
KIRP	cis	rs17776563	0.919	rs1348005	chr15:89113482	A/G	cg05013243	chr15:89149849	MIR1179	0.41	5.39	0.32	1.67e-7	Thyroid hormone levels;
KIRP	cis	rs6681460	1.000	rs1536115	chr1:67121001	A/T	cg13052034	chr1:66999238	SGIP1	0.45	6.28	0.37	1.54e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.22	0.42	6.53e-12	Prudent dietary pattern;
KIRP	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg09873164	chr1:152488093	CRCT1	0.56	7.45	0.43	1.6e-12	Hair morphology;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.55	-7.15	-0.41	9.77e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17608500	chr1:154955711	FLAD1	0.73	6.19	0.37	2.48e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.71	-7.83	-0.45	1.41e-13	Blood protein levels;
KIRP	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg17644776	chr2:200775616	C2orf69	-0.6	-6.22	-0.37	2.18e-9	Schizophrenia;
KIRP	cis	rs7246657	0.722	rs11083432	chr19:38182633	A/G	cg14683738	chr19:37701593	ZNF585B	-0.45	-4.97	-0.3	1.25e-6	Coronary artery calcification;
KIRP	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg09873164	chr1:152488093	CRCT1	0.56	7.09	0.41	1.46e-11	Hair morphology;
KIRP	cis	rs3026101	0.671	rs2285746	chr17:5311742	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.57	-0.56	8.87e-22	Chronic sinus infection;
KIRP	trans	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg10756647	chr7:56101905	PSPH	-0.88	-7.7	-0.44	3.34e-13	Diabetic kidney disease;
KIRP	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg02187348	chr16:89574699	SPG7	0.48	5.9	0.35	1.19e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs7572644	0.656	rs12463914	chr2:28057359	C/T	cg27432699	chr2:27873401	GPN1	0.49	5.08	0.31	7.63e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.88	-0.45	1.07e-13	Platelet count;
KIRP	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.85	6.78	0.4	8.71e-11	Major depressive disorder;
KIRP	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-9.15	-0.5	2.31e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-11.75	-0.6	1.35e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs865483	0.895	rs853229	chr17:35800919	A/G	cg06716730	chr17:35851459	DUSP14	0.25	5.99	0.36	7.52e-9	Monocyte count;
KIRP	trans	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg12486944	chr17:80159399	CCDC57	0.38	5.17	0.31	4.74e-7	Life satisfaction;
KIRP	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs9654415	0.560	rs4540159	chr5:72546478	C/T	cg14879418	chr5:72571312	NA	0.47	6.13	0.36	3.5e-9	Eyebrow thickness;
KIRP	cis	rs6466055	0.777	rs11765045	chr7:104922115	T/A	cg04380332	chr7:105027541	SRPK2	0.64	9.69	0.53	5.05e-19	Schizophrenia;
KIRP	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.44	5.44	0.33	1.27e-7	Aortic root size;
KIRP	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.54	7.55	0.43	8.48e-13	Blood metabolite levels;
KIRP	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-7.15	-0.41	1e-11	Response to antipsychotic treatment;
KIRP	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg20243544	chr17:37824526	PNMT	0.47	6.48	0.38	4.95e-10	Asthma;
KIRP	cis	rs7225151	0.710	rs56125028	chr17:5230867	G/A	cg24500398	chr17:5266808	RABEP1	-0.58	-5.71	-0.34	3.23e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-0.72	-6.35	-0.38	1.01e-9	Obesity-related traits;
KIRP	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-8.98	-0.5	7.13e-17	Body mass index;
KIRP	trans	rs6601327	0.635	rs7844461	chr8:9653055	T/A	cg15556689	chr8:8085844	FLJ10661	0.54	6.86	0.4	5.62e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11245990	chr11:68621969	NA	0.41	5.58	0.34	6.22e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-6.87	-0.4	5.2e-11	Vitiligo;
KIRP	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg03806693	chr22:41940476	POLR3H	-0.47	-5.68	-0.34	3.7e-8	Neuroticism;
KIRP	cis	rs2151522	0.603	rs6941106	chr6:127191280	C/T	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.42	5.6	0.34	5.79e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.42	6.49	0.38	4.63e-10	Multiple sclerosis;
KIRP	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg25319279	chr11:5960081	NA	-0.54	-5.99	-0.36	7.57e-9	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07497264	chr14:94547434	DDX24;IFI27L1	0.5	6.1	0.36	4.11e-9	Parkinson's disease;
KIRP	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg13877915	chr19:58951672	ZNF132	0.6	5.85	0.35	1.54e-8	Mean platelet volume;
KIRP	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.43	-8.52	-0.48	1.62e-15	Urinary metabolites;
KIRP	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.82	-11.33	-0.59	3.14e-24	Height;
KIRP	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.52	-8.22	-0.46	1.18e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs13065560	0.593	rs9818630	chr3:38930307	T/G	cg01426195	chr3:39028469	NA	-0.44	-7.01	-0.41	2.31e-11	Interleukin-18 levels;
KIRP	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg21433313	chr16:3507492	NAT15	0.63	7.17	0.42	8.49e-12	Tuberculosis;
KIRP	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.59	-6.1	-0.36	4.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs367943	0.688	rs10063452	chr5:112734165	C/T	cg12552261	chr5:112820674	MCC	0.56	6.69	0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs7582720	1.000	rs72932765	chr2:203679183	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.31	0.55	5.8e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg02600515	chr11:62521696	ZBTB3	0.47	5.0	0.3	1.11e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16447950	chr5:562315	NA	-0.5	-6.03	-0.36	5.89e-9	Obesity-related traits;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.8	-14.17	-0.67	1.03e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1978968	0.731	rs9605468	chr22:18461180	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.79	-11.2	-0.58	8.59e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs4500972	1	rs4500972	chr2:73767897	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.14	-0.31	5.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7688540	0.771	rs77078697	chr4:252048	T/C	cg17891759	chr4:299121	NA	-0.44	-5.12	-0.31	6.03e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs17767294	0.708	rs9380018	chr6:27740646	A/G	cg08851530	chr6:28072375	NA	0.85	4.97	0.3	1.23e-6	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.31	-0.32	2.45e-7	Educational attainment (years of education);
KIRP	cis	rs860295	0.702	rs11264381	chr1:155522572	C/T	cg02153340	chr1:155202674	NA	0.55	7.37	0.43	2.57e-12	Body mass index;
KIRP	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.58	-0.34	6.36e-8	Colorectal cancer;
KIRP	cis	rs7779181	0.812	rs7779130	chr7:32346958	G/T	cg13207630	chr7:32358064	NA	0.46	5.59	0.34	6.13e-8	Body mass index;
KIRP	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg09455208	chr3:40491958	NA	0.32	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.73	-0.39	1.19e-10	Response to antipsychotic treatment;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03611007	chr10:85954336	PCDH21	-0.51	-6.22	-0.37	2.16e-9	Menopause (age at onset);
KIRP	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg17252645	chr8:143867129	LY6D	-0.31	-4.94	-0.3	1.44e-6	Urinary tract infection frequency;
KIRP	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	trans	rs7246760	0.867	rs8107594	chr19:9835957	G/C	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.4e-20	Pursuit maintenance gain;
KIRP	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg22617819	chr1:44378782	ST3GAL3	0.33	5.4	0.33	1.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6540556	0.723	rs12138452	chr1:209886578	T/A	cg05527609	chr1:210001259	C1orf107	-0.49	-5.2	-0.31	4.17e-7	Red blood cell count;
KIRP	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg27205649	chr11:78285834	NARS2	0.68	9.02	0.5	5.33e-17	Alzheimer's disease (survival time);
KIRP	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-6.02	-0.36	6.39e-9	Longevity;Endometriosis;
KIRP	cis	rs2274459	1.000	rs729376	chr6:33704823	C/T	cg06253072	chr6:33679850	C6orf125	0.49	4.87	0.3	2.01e-6	Obesity (extreme);
KIRP	cis	rs3925075	0.531	rs7206295	chr16:31336519	T/C	cg02846316	chr16:31340340	ITGAM	0.45	5.26	0.32	3.19e-7	IgA nephropathy;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.86	7.87	0.45	1.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-8.0	-0.45	4.74e-14	Total body bone mineral density;
KIRP	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	0.83	8.88	0.49	1.44e-16	Gut microbiome composition (summer);
KIRP	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.73	-0.39	1.18e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	trans	rs2048656	0.634	rs13259344	chr8:9652000	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.37	0.38	9.15e-10	Schizophrenia;
KIRP	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.59	7.73	0.44	2.8e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg18837035	chr15:81426597	C15orf26	-0.46	-4.89	-0.3	1.83e-6	QT interval (drug interaction);
KIRP	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.81	-12.48	-0.62	5.25e-28	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg11189052	chr15:85197271	WDR73	0.54	5.1	0.31	6.76e-7	Schizophrenia;
KIRP	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	cg21523751	chr1:182988639	NA	0.36	5.23	0.32	3.71e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.54	-4.93	-0.3	1.52e-6	Other erythrocyte phenotypes;
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.46	6.04	0.36	5.66e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg05370193	chr1:21551575	ECE1	-0.36	-4.99	-0.3	1.13e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg18016565	chr1:150552671	MCL1	-0.47	-7.4	-0.43	2.21e-12	Tonsillectomy;
KIRP	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg20090143	chr19:45452003	APOC2	0.34	5.47	0.33	1.12e-7	Blood protein levels;
KIRP	cis	rs7582720	1.000	rs72932767	chr2:203679306	T/C	cg08076091	chr2:203926405	NBEAL1	0.83	8.63	0.48	7.67e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg13753209	chr17:57696993	CLTC	-0.57	-5.67	-0.34	3.91e-8	Obesity-related traits;
KIRP	cis	rs10214930	0.697	rs12668430	chr7:27633518	A/G	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.8	8.07	0.46	3.14e-14	Migraine;Coronary artery disease;
KIRP	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg26384229	chr12:38710491	ALG10B	-0.52	-7.01	-0.41	2.23e-11	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg16141378	chr3:129829833	LOC729375	0.48	6.28	0.37	1.54e-9	Neuroticism;
KIRP	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg25866889	chr13:114914595	NA	-0.4	-5.58	-0.33	6.46e-8	Schizophrenia;
KIRP	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	cg21523751	chr1:182988639	NA	0.41	6.36	0.38	9.61e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.64	6.43	0.38	6.68e-10	Eotaxin levels;
KIRP	cis	rs684232	0.712	rs2955626	chr17:618100	C/G	cg15660573	chr17:549704	VPS53	0.85	12.99	0.64	9.65e-30	Prostate cancer;
KIRP	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg22307297	chr20:60903441	LAMA5	0.42	4.95	0.3	1.36e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11987759	chr7:65425863	GUSB	0.51	6.86	0.4	5.64e-11	Aortic root size;
KIRP	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.68	0.53	5.49e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.24	-0.32	3.41e-7	Myopia (pathological);
KIRP	cis	rs11593576	0.579	rs1313056	chr10:80996351	A/C	cg18737081	chr10:80999807	ZMIZ1	-0.29	-5.01	-0.3	1.02e-6	Vitiligo;
KIRP	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg04310649	chr10:35416472	CREM	0.54	6.23	0.37	2.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.45	6.04	0.36	5.76e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02705487	chr16:704060	WDR90	0.48	6.6	0.39	2.53e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.84	-0.35	1.62e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.62	-5.7	-0.34	3.37e-8	Narcolepsy;
KIRP	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	9.95	0.54	8.15e-20	Total body bone mineral density;
KIRP	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.81	10.88	0.57	9.18e-23	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.48	-6.11	-0.36	3.95e-9	Neutrophil percentage of white cells;
KIRP	cis	rs600806	0.713	rs10745305	chr1:110012148	A/G	cg02175308	chr1:109941060	SORT1	-0.27	-4.96	-0.3	1.32e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.17	-0.31	4.75e-7	Retinal vascular caliber;
KIRP	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05025164	chr4:1340916	KIAA1530	-0.42	-5.21	-0.32	3.93e-7	Obesity-related traits;
KIRP	cis	rs13424612	0.839	rs7577635	chr2:240901290	T/C	cg19172429	chr2:240878313	NA	0.3	5.01	0.3	1.06e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.74	10.85	0.57	1.15e-22	Neurofibrillary tangles;
KIRP	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12963246	chr6:28129442	ZNF389	0.48	6.01	0.36	6.64e-9	Depression;
KIRP	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-7.65	-0.44	4.67e-13	Alzheimer's disease (survival time);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19449227	chr15:34501904	C15orf29	0.5	6.48	0.38	4.94e-10	Parkinson's disease;
KIRP	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg00122941	chr17:4613640	ARRB2	0.76	8.18	0.46	1.5e-14	Lymphocyte counts;
KIRP	cis	rs3741489	1.000	rs2062162	chr12:133432744	C/T	cg01499426	chr12:133417423	CHFR	0.74	5.71	0.34	3.18e-8	Cognitive function;
KIRP	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg02461776	chr11:598696	PHRF1	0.47	5.01	0.3	1.05e-6	Systemic lupus erythematosus;
KIRP	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.74	-0.44	2.55e-13	Retinal vascular caliber;
KIRP	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-1.13	-19.22	-0.77	7e-51	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg21775007	chr8:11205619	TDH	-0.47	-6.19	-0.37	2.47e-9	Mood instability;
KIRP	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg06766960	chr11:133703094	NA	-0.57	-7.22	-0.42	6.49e-12	Childhood ear infection;
KIRP	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.83	-8.78	-0.49	2.84e-16	Exhaled nitric oxide output;
KIRP	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg26248373	chr2:1572462	NA	-0.69	-7.26	-0.42	4.99e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.65	-9.56	-0.52	1.25e-18	Obesity-related traits;
KIRP	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.49	-6.43	-0.38	6.72e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg23307798	chr14:103986281	CKB	-0.53	-6.99	-0.41	2.61e-11	Coronary artery disease;
KIRP	cis	rs3120667	0.720	rs11579266	chr1:152411813	G/A	cg26876637	chr1:152193138	HRNR	-0.6	-5.5	-0.33	9.64e-8	Eating disorders;
KIRP	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg05370193	chr1:21551575	ECE1	0.42	5.95	0.35	9.1e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.68	8.7	0.48	4.91e-16	Post bronchodilator FEV1;
KIRP	cis	rs1318772	1.000	rs67767339	chr5:112679491	C/T	cg12552261	chr5:112820674	MCC	0.81	5.09	0.31	7.13e-7	F-cell distribution;
KIRP	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg00042356	chr1:8021962	PARK7	-0.49	-4.93	-0.3	1.49e-6	Inflammatory bowel disease;
KIRP	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.79	-0.49	2.63e-16	Monocyte percentage of white cells;
KIRP	cis	rs714027	0.605	rs2412976	chr22:30567907	C/G	cg01021169	chr22:30184971	ASCC2	-0.44	-5.59	-0.34	6.05e-8	Lymphocyte counts;
KIRP	cis	rs4589502	1.000	rs7170743	chr15:67126339	T/G	cg12317470	chr15:67143691	NA	0.69	5.52	0.33	8.43e-8	Lung cancer (smoking interaction);
KIRP	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg06636001	chr8:8085503	FLJ10661	0.69	8.53	0.48	1.53e-15	Systemic lupus erythematosus;
KIRP	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg02612397	chr6:125855124	NA	0.34	4.99	0.3	1.16e-6	Brugada syndrome;
KIRP	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13293650	chr15:28341193	OCA2	0.51	6.31	0.37	1.29e-9	Lung cancer in ever smokers;
KIRP	cis	rs10073892	0.743	rs1584714	chr5:101653357	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs9640161	0.658	rs57888387	chr7:150004244	G/A	cg10018233	chr7:150070692	REPIN1	0.61	6.96	0.41	3.04e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	6.73	0.39	1.16e-10	Schizophrenia;
KIRP	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg19898043	chr22:18121309	BCL2L13	0.62	7.04	0.41	1.93e-11	Sum neutrophil eosinophil counts;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.26	-5.34	-0.32	2.14e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.38	8.0	0.45	5.05e-14	Asthma (sex interaction);
KIRP	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg06671706	chr8:8559999	CLDN23	0.52	6.28	0.37	1.55e-9	Obesity-related traits;
KIRP	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg21231944	chr12:82153410	PPFIA2	-0.41	-4.98	-0.3	1.21e-6	Resting heart rate;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02083528	chr1:78280850	FAM73A	0.44	6.38	0.38	8.7e-10	C-reactive protein;
KIRP	cis	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.56	-0.33	6.93e-8	HDL cholesterol;
KIRP	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-6.11	-0.36	3.89e-9	Colorectal cancer;
KIRP	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	trans	rs656319	0.513	rs688541	chr8:9818000	T/A	cg08975724	chr8:8085496	FLJ10661	-0.6	-6.62	-0.39	2.26e-10	Myopia (pathological);
KIRP	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26002218	chr14:103986227	CKB	0.26	4.95	0.3	1.36e-6	Body mass index;
KIRP	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg16497661	chr14:103986332	CKB	0.52	7.22	0.42	6.38e-12	Body mass index;
KIRP	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg07777115	chr5:623756	CEP72	-0.59	-6.04	-0.36	5.56e-9	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23855257	chr13:27746147	USP12	0.43	6.02	0.36	6.2e-9	Survival in pancreatic cancer;
KIRP	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg22974920	chr21:40686053	BRWD1	0.45	5.3	0.32	2.56e-7	Cognitive function;
KIRP	cis	rs12693043	0.817	rs10930673	chr2:175375315	G/A	cg11778734	chr2:175439522	WIPF1	-0.45	-6.05	-0.36	5.39e-9	Urate levels (BMI interaction);
KIRP	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg07167872	chr1:205819463	PM20D1	0.48	4.96	0.3	1.31e-6	Parkinson's disease;
KIRP	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg00857998	chr1:205179979	DSTYK	-0.49	-5.88	-0.35	1.35e-8	Platelet count;
KIRP	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg07395648	chr5:131743802	NA	-0.57	-8.38	-0.47	4.17e-15	Blood metabolite levels;
KIRP	trans	rs4938303	0.633	rs35963862	chr11:116549897	T/C	cg13754915	chr9:140174272	C9orf167	-0.73	-6.17	-0.37	2.79e-9	Triglycerides;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07792427	chr1:100985005	CDC14A	-0.42	-6.24	-0.37	1.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.65	-0.48	6.77e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9323205	0.723	rs55980461	chr14:51737434	G/A	cg23942311	chr14:51606299	NA	-0.53	-5.06	-0.31	8.06e-7	Cancer;
KIRP	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.87	9.93	0.53	9.62e-20	Vitamin D levels;
KIRP	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2786098	1.000	rs1337167	chr1:197316435	C/T	cg10106095	chr16:3025755	PKMYT1	0.61	6.12	0.36	3.76e-9	Asthma;
KIRP	cis	rs4765905	0.610	rs758173	chr12:2315228	G/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.87	-0.4	5.37e-11	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2273156	1.000	rs7141292	chr14:35462906	T/A	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.42	-0.33	1.45e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs6504950	0.800	rs72829484	chr17:53009280	G/T	cg26251398	chr17:52985966	TOM1L1	0.46	5.68	0.34	3.74e-8	Breast cancer;
KIRP	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs4664304	0.620	rs11675085	chr2:160713352	C/G	cg03641300	chr2:160917029	PLA2R1	0.37	5.55	0.33	7.44e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.36	-5.71	-0.34	3.26e-8	Colorectal cancer;
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.73	7.8	0.45	1.75e-13	Platelet count;
KIRP	cis	rs4908768	0.555	rs4908777	chr1:8804237	A/G	cg25722041	chr1:8623473	RERE	0.63	7.58	0.43	7.24e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.63	10.04	0.54	4.2e-20	Neuroticism;
KIRP	cis	rs279910	0.763	rs279896	chr9:966685	T/A	cg13952963	chr9:998547	NA	0.48	5.38	0.32	1.74e-7	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs9467160	0.581	rs2760144	chr6:24479197	A/G	cg20631270	chr6:24437470	GPLD1	0.41	4.98	0.3	1.21e-6	Liver enzyme levels;
KIRP	cis	rs8014252	0.708	rs74062750	chr14:71026052	C/G	cg11204974	chr14:71022665	NA	-0.71	-6.99	-0.41	2.61e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs11074306	0.508	rs12438618	chr15:28045534	A/G	cg26402630	chr15:28053930	OCA2	0.29	4.87	0.3	1.99e-6	Uveal melanoma;
KIRP	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	cis	rs675026	0.659	rs628648	chr6:154450985	C/A	cg07813322	chr6:154414604	OPRM1	-0.45	-5.9	-0.35	1.21e-8	Hypertension;
KIRP	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.7	-7.76	-0.44	2.21e-13	Obesity;Body mass index;
KIRP	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.48	-6.39	-0.38	8.02e-10	Response to temozolomide;
KIRP	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.56e-8	Colorectal cancer;
KIRP	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.58	-5.26	-0.32	3.17e-7	Obesity (extreme);
KIRP	cis	rs7582720	1.000	rs80087860	chr2:203673072	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.63e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	1.0	17.43	0.74	7.3e-45	Breast cancer;
KIRP	cis	rs9905704	0.681	rs2531730	chr17:56545069	T/G	cg12560992	chr17:57184187	TRIM37	-0.54	-5.15	-0.31	5.29e-7	Testicular germ cell tumor;
KIRP	cis	rs7555523	0.887	rs4657477	chr1:165736175	C/T	cg24409356	chr1:165738333	TMCO1	0.72	6.05	0.36	5.25e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.8e-6	Alzheimer's disease;
KIRP	cis	rs4776059	0.959	rs12898644	chr15:52905233	A/G	cg22715398	chr15:52968154	KIAA1370	-0.69	-8.51	-0.48	1.72e-15	Schizophrenia;
KIRP	cis	rs2273669	0.831	rs11153152	chr6:109343340	A/T	cg05315195	chr6:109294784	ARMC2	-0.5	-5.69	-0.34	3.52e-8	Prostate cancer;
KIRP	cis	rs526231	0.543	rs26258	chr5:102549721	A/C	cg23492399	chr5:102201601	PAM	-0.52	-5.65	-0.34	4.53e-8	Primary biliary cholangitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10296688	chr13:52598408	UTP14C;ALG11	0.63	8.11	0.46	2.47e-14	Interleukin-4 levels;
KIRP	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.68	5.73	0.34	2.95e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg09579323	chr1:150459698	TARS2	0.4	5.0	0.3	1.11e-6	Migraine;
KIRP	cis	rs10875746	0.859	rs11558768	chr12:48577789	C/T	cg26205652	chr12:48591994	NA	0.8	10.88	0.57	8.84e-23	Longevity (90 years and older);
KIRP	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.83	9.81	0.53	2.18e-19	Corneal astigmatism;
KIRP	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg08648136	chr8:956695	NA	0.39	5.44	0.33	1.28e-7	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg03060546	chr3:49711283	APEH	0.44	5.81	0.35	1.9e-8	Parkinson's disease;
KIRP	cis	rs7546668	1.000	rs3795758	chr1:15853551	C/T	cg21858823	chr1:15850916	CASP9	0.46	5.13	0.31	5.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6708331	0.517	rs10496178	chr2:70342815	A/G	cg05298696	chr2:70188691	ASPRV1	-0.48	-6.35	-0.38	1.02e-9	Obesity-related traits;
KIRP	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-9.05	-0.5	4.45e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg19847130	chr8:10466454	RP1L1	-0.35	-4.93	-0.3	1.52e-6	Retinal vascular caliber;
KIRP	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.81	10.98	0.57	4.33e-23	Platelet count;
KIRP	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg16497661	chr14:103986332	CKB	0.47	4.93	0.3	1.55e-6	Coronary artery disease;
KIRP	cis	rs6921919	0.609	rs36018474	chr6:28385529	C/G	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.38	-0.38	8.49e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.63	9.62	0.52	8.47e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg18850127	chr7:39170497	POU6F2	-0.27	-5.18	-0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.84	11.45	0.59	1.3e-24	Selective IgA deficiency;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.77	12.71	0.63	8.76e-29	Vitiligo;
KIRP	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.58	-0.59	4.79e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.27	-0.37	1.59e-9	Body mass index;
KIRP	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.72	7.41	0.43	2.04e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg01872077	chr2:219646372	CYP27A1	0.4	5.27	0.32	3.01e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.88	13.74	0.66	2.93e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20135002	chr11:47629003	NA	-0.48	-5.76	-0.34	2.56e-8	Subjective well-being;
KIRP	cis	rs2223471	0.602	rs9381891	chr6:50695502	T/C	cg03432817	chr6:50765336	NA	-0.36	-5.45	-0.33	1.23e-7	Subcutaneous adipose tissue;
KIRP	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.53	0.56	1.24e-21	Monocyte percentage of white cells;
KIRP	cis	rs2882667	0.894	rs10054478	chr5:138354075	G/A	cg04439458	chr5:138467593	SIL1	-0.44	-7.38	-0.43	2.41e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg02725872	chr8:58115012	NA	-0.53	-6.02	-0.36	6.19e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.73	8.93	0.49	1.04e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg08890418	chr1:21044141	KIF17	-0.34	-5.12	-0.31	6.27e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.89	11.39	0.59	2.07e-24	Schizophrenia;
KIRP	cis	rs13102973	0.965	rs13126242	chr4:135860948	T/C	cg14419869	chr4:135874104	NA	0.54	9.05	0.5	4.58e-17	Subjective well-being;
KIRP	cis	rs9462846	0.688	rs116255295	chr6:42906241	G/A	cg05552183	chr6:42928497	GNMT	0.61	6.98	0.41	2.71e-11	Blood protein levels;
KIRP	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg20636351	chr8:55087400	NA	-0.63	-7.86	-0.45	1.17e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg07395648	chr5:131743802	NA	0.55	7.7	0.44	3.33e-13	Breast cancer;
KIRP	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.55	0.39	3.31e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.92	15.15	0.69	4.56e-37	Metabolic syndrome;
KIRP	cis	rs76693355	0.512	rs1812974	chr11:120221068	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.41	-5.19	-0.31	4.49e-7	Intraocular pressure;
KIRP	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.4	7.83	0.45	1.48e-13	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18967534	chr4:2795345	SH3BP2	0.49	6.36	0.38	9.85e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg06640241	chr16:89574553	SPG7	0.63	8.14	0.46	2e-14	Multiple myeloma (IgH translocation);
KIRP	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06850241	chr22:41845214	NA	-0.5	-6.03	-0.36	5.85e-9	Vitiligo;
KIRP	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.36	5.3	0.32	2.51e-7	Survival in rectal cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg27552081	chr17:25621774	WSB1	0.78	6.63	0.39	2.12e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7336332	0.527	rs1475219	chr13:28037415	A/G	cg22138327	chr13:27999177	GTF3A	0.64	6.37	0.38	9.01e-10	Weight;
KIRP	cis	rs10203711	1.000	rs907103	chr2:239564541	A/G	cg14580085	chr2:239553406	NA	0.37	4.96	0.3	1.29e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.71e-7	Life satisfaction;
KIRP	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	8.29	0.47	7.43e-15	LDL cholesterol;
KIRP	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg08975724	chr8:8085496	FLJ10661	0.71	9.29	0.51	8.61e-18	Mood instability;
KIRP	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg21395723	chr22:39101663	GTPBP1	-0.38	-5.1	-0.31	6.89e-7	Menopause (age at onset);
KIRP	trans	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17712092	chr4:129076599	LARP1B	-0.56	-6.95	-0.41	3.19e-11	Eosinophil percentage of white cells;
KIRP	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7084402	0.967	rs7094882	chr10:60276829	C/T	cg05938607	chr10:60274200	BICC1	0.47	11.45	0.59	1.29e-24	Refractive error;
KIRP	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06850241	chr22:41845214	NA	0.43	4.88	0.3	1.91e-6	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	1.06	13.55	0.65	1.27e-31	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg08648136	chr8:956695	NA	0.46	6.45	0.38	5.72e-10	Schizophrenia;
KIRP	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg11952622	chr19:58962976	ZNF324B	0.43	5.03	0.31	9.38e-7	Uric acid clearance;
KIRP	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.78	9.94	0.54	8.86e-20	Corneal astigmatism;
KIRP	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.42	5.39	0.33	1.63e-7	Aortic root size;
KIRP	trans	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg11878675	chr2:74211845	NA	-0.43	-6.28	-0.37	1.54e-9	Breast cancer;
KIRP	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.84	-14.23	-0.67	6.18e-34	Heart rate;
KIRP	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.74e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4761097	0.516	rs7964825	chr12:85229690	A/G	cg00765312	chr12:85674694	ALX1	0.52	6.07	0.36	4.76e-9	Behavioural disinhibition (generation interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18276145	chr4:72052432	SLC4A4	0.48	6.26	0.37	1.74e-9	Parkinson's disease;
KIRP	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.19	0.37	2.55e-9	Aortic root size;
KIRP	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.64	-9.07	-0.5	3.79e-17	Dental caries;
KIRP	cis	rs2223471	0.624	rs1923523	chr6:50679081	G/T	cg03432817	chr6:50765336	NA	-0.41	-6.38	-0.38	8.89e-10	Subcutaneous adipose tissue;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09920427	chr19:12777674	MORG1;MAN2B1	0.58	7.0	0.41	2.38e-11	Smoking initiation;
KIRP	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	7.1	0.41	1.36e-11	Neuroticism;
KIRP	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg25039879	chr17:56429692	SUPT4H1	0.62	6.21	0.37	2.29e-9	Cognitive test performance;
KIRP	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	5.08	0.31	7.3e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.57	-6.62	-0.39	2.23e-10	DNA methylation (variation);
KIRP	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-14.19	-0.67	8.79e-34	Heart rate;
KIRP	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-5.23	-0.32	3.59e-7	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.73	6.47	0.38	5.27e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.72	10.08	0.54	3.18e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs988913	0.678	rs4712096	chr6:54978214	C/G	cg03513858	chr6:54763001	FAM83B	-0.36	-5.0	-0.3	1.07e-6	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.12	-0.31	6.04e-7	Life satisfaction;
KIRP	trans	rs7999699	0.902	rs9534797	chr13:48318163	G/A	cg23237801	chr1:16476620	EPHA2	0.51	6.34	0.37	1.1e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs75920871	1.000	rs1473325	chr11:116822034	C/T	cg23684410	chr11:116897558	SIK3	0.55	6.02	0.36	6.32e-9	Subjective well-being;
KIRP	cis	rs13361707	0.920	rs4957342	chr5:40694154	T/C	cg01087697	chr5:40835557	RPL37	-0.5	-5.71	-0.34	3.19e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10382410	chr7:100084527	C7orf51	0.47	6.03	0.36	5.85e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9400467	0.537	rs584937	chr6:111481577	T/G	cg15721981	chr6:111408429	SLC16A10	0.77	7.12	0.41	1.16e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	ch.11.42038R	chr11:967971	AP2A2	0.43	5.73	0.34	2.97e-8	Alzheimer's disease (late onset);
KIRP	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.6	-7.9	-0.45	9.12e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.51	6.28	0.37	1.5e-9	HIV-1 control;
KIRP	cis	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg11503966	chr20:62272292	STMN3	0.46	6.41	0.38	7.43e-10	Atopic dermatitis;
KIRP	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg23625390	chr15:77176239	SCAPER	0.47	6.1	0.36	4.04e-9	Blood metabolite levels;
KIRP	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08704250	chr15:31115839	NA	0.51	6.55	0.39	3.35e-10	Huntington's disease progression;
KIRP	cis	rs10211205	0.945	rs10186625	chr2:236617112	G/A	cg02339850	chr2:236586191	AGAP1	-0.53	-5.43	-0.33	1.33e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	14.85	0.69	4.63e-36	Platelet count;
KIRP	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.79	-8.68	-0.48	5.4e-16	Obesity-related traits;
KIRP	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg23307798	chr14:103986281	CKB	-0.51	-6.83	-0.4	6.61e-11	Coronary artery disease;
KIRP	cis	rs62380364	0.602	rs610217	chr5:88065263	G/A	cg22951263	chr5:87985283	NA	-0.46	-6.31	-0.37	1.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.54	7.89	0.45	1.01e-13	Immature fraction of reticulocytes;
KIRP	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.74	10.94	0.57	5.95e-23	Hip circumference;
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	17.02	0.74	1.92e-43	Platelet count;
KIRP	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg23920097	chr1:209922102	NA	0.47	5.41	0.33	1.53e-7	Red blood cell count;
KIRP	trans	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg06521331	chr12:34319734	NA	-0.52	-6.48	-0.38	4.86e-10	Heart rate;
KIRP	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	6.49	0.38	4.6e-10	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.59	-7.42	-0.43	1.93e-12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17345786	0.602	rs11923273	chr3:101337863	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	8.16	0.46	1.69e-14	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg16141378	chr3:129829833	LOC729375	0.57	7.72	0.44	2.99e-13	Neuroticism;
KIRP	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg13978929	chr19:21580086	ZNF493	-0.52	-5.1	-0.31	6.94e-7	Pain;
KIRP	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg09264619	chr17:80180166	NA	-0.51	-6.07	-0.36	4.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.56	-6.0	-0.36	7.11e-9	Breast cancer;
KIRP	cis	rs4908768	0.657	rs10492963	chr1:8810341	A/G	cg25722041	chr1:8623473	RERE	-0.65	-8.28	-0.47	8.01e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.57	-6.4	-0.38	7.98e-10	Menarche (age at onset);
KIRP	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.16	-0.42	9.06e-12	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.62	8.76	0.49	3.2e-16	Schizophrenia;
KIRP	cis	rs11225247	1.000	rs11225244	chr11:102278334	A/T	cg06323957	chr11:102217781	BIRC2	0.95	5.81	0.35	1.91e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.45	6.92	0.4	3.97e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg23682824	chr7:23144976	KLHL7	0.56	6.82	0.4	7.06e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs10875746	0.669	rs17122812	chr12:48597053	A/G	cg20731937	chr12:48336164	NA	0.46	5.85	0.35	1.58e-8	Longevity (90 years and older);
KIRP	cis	rs2411233	0.935	rs7180259	chr15:39302724	C/A	cg02291532	chr15:39874776	THBS1	0.36	4.9	0.3	1.78e-6	Platelet count;
KIRP	cis	rs62051538	0.524	rs72789314	chr16:31419703	G/A	cg13439730	chr16:31146999	PRSS8	0.33	4.98	0.3	1.23e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.02	-0.41	2.09e-11	Joint mobility (Beighton score);
KIRP	cis	rs7119038	0.818	rs73003215	chr11:118649512	G/A	cg19308663	chr11:118741387	NA	0.42	7.04	0.41	1.95e-11	Sjögren's syndrome;
KIRP	cis	rs6988636	0.534	rs73337894	chr8:124123010	T/C	cg15893493	chr8:124194847	FAM83A	0.61	5.09	0.31	6.99e-7	Urinary uromodulin levels;
KIRP	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-9.64	-0.52	7.2e-19	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15008879	chr10:22292810	DNAJC1	0.65	7.7	0.44	3.36e-13	Smoking initiation;
KIRP	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs2273669	0.667	rs112319185	chr6:109305318	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05025164	chr4:1340916	KIAA1530	0.56	7.55	0.43	8.65e-13	Obesity-related traits;
KIRP	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.3	0.37	1.33e-9	Retinal vascular caliber;
KIRP	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg19610905	chr11:61596333	FADS2	-0.62	-5.88	-0.35	1.34e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs9913711	1.000	rs9913711	chr17:70098161	C/G	cg11350586	chr17:70115862	SOX9	0.37	5.02	0.3	1.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg11362935	chr11:111250201	POU2AF1	0.41	6.49	0.38	4.67e-10	Primary biliary cholangitis;
KIRP	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg10318148	chr7:1024673	CYP2W1	0.39	5.94	0.35	9.78e-9	Longevity;Endometriosis;
KIRP	cis	rs17401966	0.597	rs56221672	chr1:10247313	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-6.88	-0.4	5.04e-11	Hepatocellular carcinoma;
KIRP	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg13939156	chr17:80058883	NA	0.48	5.58	0.34	6.19e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26617929	chr16:1858877	NA	-0.67	-5.68	-0.34	3.89e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.44	-0.33	1.3e-7	Life satisfaction;
KIRP	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.91	15.53	0.7	2.26e-38	Menarche (age at onset);
KIRP	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.64	-7.83	-0.45	1.44e-13	Coronary artery disease;
KIRP	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.84	-0.35	1.68e-8	Educational attainment;
KIRP	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg18132916	chr6:79620363	NA	0.45	4.98	0.3	1.21e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg27532560	chr4:187881888	NA	-0.8	-14.8	-0.69	7.01e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6142102	0.961	rs4911389	chr20:32565041	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	6.41	0.38	7.27e-10	Skin pigmentation;
KIRP	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6540559	1.000	rs742215	chr1:209961023	A/T	cg22029157	chr1:209979665	IRF6	0.54	6.6	0.39	2.48e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.91	10.4	0.55	3.1e-21	Corneal astigmatism;
KIRP	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg27147174	chr7:100797783	AP1S1	0.61	8.13	0.46	2.15e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	7.24	0.42	5.84e-12	Menarche (age at onset);
KIRP	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg21747090	chr2:27597821	SNX17	-0.43	-5.66	-0.34	4.26e-8	Total body bone mineral density;
KIRP	cis	rs944802	0.684	rs10811664	chr9:22142907	G/A	cg00491127	chr9:22154101	NA	-0.46	-5.09	-0.31	7.17e-7	White blood cell count;
KIRP	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.54	-0.62	3.12e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg00919237	chr7:87102261	ABCB4	-0.75	-9.54	-0.52	1.49e-18	Gallbladder cancer;
KIRP	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.55	6.36	0.38	9.61e-10	Aortic root size;
KIRP	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.26	-0.47	9.25e-15	Blood protein levels;
KIRP	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg26338869	chr17:61819248	STRADA	0.42	4.9	0.3	1.72e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11264213	0.901	rs581459	chr1:36375110	C/T	cg27506609	chr1:36549197	TEKT2	0.91	9.23	0.51	1.25e-17	Schizophrenia;
KIRP	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-11.67	-0.6	2.53e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7601312	0.875	rs3922231	chr2:229328281	T/C	cg02542817	chr2:229291442	NA	-0.37	-5.24	-0.32	3.45e-7	Schizophrenia;
KIRP	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.52	-0.33	8.38e-8	Headache;
KIRP	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	0.8	7.04	0.41	1.92e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	trans	rs17221829	0.733	rs11018668	chr11:89356178	C/T	cg26841156	chr19:7913922	EVI5L	-0.47	-6.43	-0.38	6.67e-10	Anxiety in major depressive disorder;
KIRP	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.79e-34	Airflow obstruction;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05993854	chr4:90032464	NA	-0.49	-6.8	-0.4	7.81e-11	Myopia;
KIRP	cis	rs2481665	0.902	rs1013293	chr1:62570321	G/A	cg18591186	chr1:62594603	INADL	-0.69	-10.75	-0.57	2.47e-22	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg21926883	chr2:100939477	LONRF2	-0.59	-7.89	-0.45	9.81e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1829883	0.775	rs2682144	chr5:98904162	A/G	cg08333243	chr5:99726346	NA	-0.43	-5.45	-0.33	1.22e-7	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.48	-6.34	-0.37	1.1e-9	Endometrial cancer;
KIRP	cis	rs9346649	0.616	rs7740995	chr6:168492221	G/A	cg09211372	chr6:168490623	NA	-0.37	-6.27	-0.37	1.59e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg27201679	chr10:1120794	WDR37	-0.45	-6.48	-0.38	5.1e-10	Select biomarker traits;
KIRP	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.51	-5.58	-0.33	6.48e-8	Schizophrenia;
KIRP	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.57	-7.77	-0.44	2.15e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg23594656	chr7:65796392	TPST1	0.53	8.32	0.47	6.29e-15	Aortic root size;
KIRP	cis	rs367943	0.688	rs1464163	chr5:112691815	A/G	cg12552261	chr5:112820674	MCC	0.52	6.15	0.37	3.13e-9	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	5.18	0.31	4.52e-7	Schizophrenia;
KIRP	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.42	5.46	0.33	1.19e-7	Childhood ear infection;
KIRP	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg07636037	chr3:49044803	WDR6	-0.71	-6.48	-0.38	4.91e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg02475777	chr4:1388615	CRIPAK	0.51	4.91	0.3	1.67e-6	Recombination rate (females);
KIRP	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.51	6.27	0.37	1.65e-9	Menopause (age at onset);
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.86	14.62	0.68	2.86e-35	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.73	-10.57	-0.56	8.69e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.66	9.31	0.51	7.23e-18	Blood protein levels;
KIRP	cis	rs17123764	0.818	rs7975599	chr12:49944926	A/G	cg02054252	chr12:50078554	FMNL3	0.42	4.94	0.3	1.42e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10131728	0.881	rs12878339	chr14:81643692	A/C	cg01989461	chr14:81687754	GTF2A1	-0.69	-5.47	-0.33	1.1e-7	IgG glycosylation;
KIRP	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.65	-9.37	-0.51	4.77e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.87	14.05	0.67	2.58e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg17595323	chr11:93583763	C11orf90	-0.32	-5.36	-0.32	1.9e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4950322	0.570	rs72692914	chr1:146774637	T/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.4	-0.33	1.54e-7	Protein quantitative trait loci;
KIRP	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg07936489	chr17:37558343	FBXL20	-0.5	-6.44	-0.38	6.2e-10	Asthma;
KIRP	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg15848620	chr12:58087721	OS9	-0.46	-5.37	-0.32	1.81e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21545522	chr1:205238299	TMCC2	-0.43	-5.75	-0.34	2.68e-8	Red blood cell count;
KIRP	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs9654415	0.560	rs6891189	chr5:72549745	A/G	cg23303188	chr5:72570711	NA	-0.41	-5.3	-0.32	2.56e-7	Eyebrow thickness;
KIRP	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.93	16.64	0.73	3.56e-42	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.75	-8.21	-0.46	1.24e-14	Parkinson's disease;
KIRP	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.38	5.12	0.31	6.27e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.68	10.02	0.54	4.85e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2904967	0.866	rs506280	chr11:65069534	A/C	cg09225861	chr11:65069680	NA	0.44	5.81	0.35	1.91e-8	Mean corpuscular volume;
KIRP	cis	rs2151522	0.603	rs7746534	chr6:127196109	A/G	cg21431617	chr6:127135037	NA	0.3	5.16	0.31	4.98e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg12315302	chr6:26189340	HIST1H4D	0.77	5.39	0.32	1.66e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg10756647	chr7:56101905	PSPH	0.98	6.96	0.41	3.1e-11	Gout;
KIRP	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg16797656	chr11:68205561	LRP5	0.37	4.85	0.3	2.17e-6	Total body bone mineral density;
KIRP	cis	rs16857609	1.000	rs13388294	chr2:218295406	A/G	cg15335768	chr2:218268053	DIRC3	0.42	6.01	0.36	6.56e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs2230307	0.656	rs571697	chr1:100478755	T/C	cg24955406	chr1:100503596	HIAT1	0.56	5.6	0.34	5.65e-8	Carotid intima media thickness;
KIRP	cis	rs9400467	0.506	rs3204954	chr6:111628597	C/G	cg15721981	chr6:111408429	SLC16A10	0.77	7.11	0.41	1.29e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg18527119	chr7:66119851	NA	-0.45	-4.85	-0.3	2.22e-6	Aortic root size;
KIRP	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg19554555	chr3:13937349	NA	0.55	8.05	0.46	3.51e-14	Ovarian reserve;
KIRP	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg17279839	chr7:150038598	RARRES2	0.47	6.45	0.38	5.97e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs888194	0.677	rs2075431	chr12:109874621	C/T	cg19025524	chr12:109796872	NA	-0.37	-5.07	-0.31	7.75e-7	Neuroticism;
KIRP	cis	rs2346160	0.836	rs206991	chr6:167699378	A/G	cg27333441	chr6:167680455	NA	-0.42	-5.83	-0.35	1.72e-8	Parental extreme longevity (95 years and older);
KIRP	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg16105309	chr15:79090380	ADAMTS7	0.6	7.81	0.45	1.62e-13	Schizophrenia;
KIRP	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	trans	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg16141378	chr3:129829833	LOC729375	-0.59	-6.93	-0.4	3.72e-11	Neuroticism;
KIRP	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg15083037	chr5:83017644	HAPLN1	-0.57	-8.3	-0.47	6.73e-15	Prostate cancer;
KIRP	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg04990556	chr1:26633338	UBXN11	-0.59	-7.15	-0.41	9.66e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg14593290	chr7:50529359	DDC	-0.46	-6.11	-0.36	3.91e-9	Malaria;
KIRP	cis	rs4713118	0.629	rs172165	chr6:28020814	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-4.88	-0.3	1.92e-6	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13724220	chr2:3383413	TTC15	0.46	6.14	0.36	3.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23555592	chr10:91174309	IFIT5	0.47	6.26	0.37	1.7e-9	Inflammatory biomarkers;
KIRP	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg08501292	chr6:25962987	TRIM38	0.74	5.06	0.31	8.39e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg20387954	chr3:183756860	HTR3D	0.64	9.47	0.52	2.49e-18	Anterior chamber depth;
KIRP	trans	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	7.07	0.41	1.62e-11	Mean corpuscular volume;
KIRP	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.85	-13.22	-0.64	1.66e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg00076555	chr3:49705435	BSN	-0.29	-4.95	-0.3	1.39e-6	Body mass index;
KIRP	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	0.84	11.93	0.61	3.42e-26	Homoarginine levels;
KIRP	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg06042504	chr8:55087323	NA	-0.53	-6.42	-0.38	6.94e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.91	-0.4	4.04e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg01657329	chr11:68192670	LRP5	-0.51	-5.44	-0.33	1.29e-7	Total body bone mineral density;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22168489	chr12:122356033	WDR66	0.68	10.22	0.55	1.18e-20	Mean corpuscular volume;
KIRP	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.64	7.72	0.44	2.86e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg21734707	chr17:3908241	ZZEF1	0.63	9.61	0.52	9.05e-19	Type 2 diabetes;
KIRP	cis	rs2220004	0.642	rs4939019	chr11:55831189	T/C	cg01505312	chr11:56258856	OR5M8;OR8U8	0.53	5.81	0.35	1.95e-8	Odorant perception (&beta-damascenone);
KIRP	cis	rs2712184	0.967	rs11892032	chr2:217668981	G/A	cg05032264	chr2:217675019	NA	-0.52	-7.83	-0.45	1.43e-13	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg26138937	chr11:71823887	C11orf51	-1.19	-7.91	-0.45	8.91e-14	Severe influenza A (H1N1) infection;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25134683	chr6:90348509	LYRM2	-0.55	-6.27	-0.37	1.61e-9	Menopause (age at onset);
KIRP	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10703506	chr12:109576250	ACACB	0.49	6.29	0.37	1.41e-9	Interleukin-4 levels;
KIRP	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.53	7.9	0.45	9.38e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs960902	0.620	rs11694646	chr2:37738067	A/G	cg25341268	chr2:37734390	NA	0.56	7.31	0.42	3.66e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg17133734	chr15:86042851	AKAP13	-0.46	-5.84	-0.35	1.6e-8	Coronary artery disease;
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg05255149	chr17:80675120	FN3KRP	-0.54	-6.82	-0.4	7.01e-11	Glycated hemoglobin levels;
KIRP	cis	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg27411982	chr8:10470053	RP1L1	-0.38	-4.86	-0.3	2.06e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg27170947	chr2:26402098	FAM59B	-0.58	-6.51	-0.38	4.14e-10	Gut microbiome composition (summer);
KIRP	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.83	12.42	0.62	8.08e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg12315302	chr6:26189340	HIST1H4D	0.97	5.81	0.35	1.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23281280	chr6:28129359	ZNF389	-0.49	-5.47	-0.33	1.08e-7	Depression;
KIRP	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg11927738	chr11:68850580	TPCN2	0.45	4.92	0.3	1.6e-6	Blond vs. brown hair color;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15032638	chr10:51565035	NCOA4	0.93	6.08	0.36	4.46e-9	P wave terminal force;
KIRP	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.4	4.94	0.3	1.42e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg15128208	chr22:42549153	NA	0.59	6.73	0.39	1.22e-10	Birth weight;
KIRP	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg17524265	chr8:144659883	NAPRT1	0.75	5.01	0.3	1.04e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg24631222	chr15:78858424	CHRNA5	-0.75	-9.06	-0.5	4.2e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1823913	0.599	rs13399251	chr2:192133484	A/C	cg12404831	chr2:192114017	MYO1B	0.49	6.75	0.4	1.06e-10	Obesity-related traits;
KIRP	cis	rs2944591	0.505	rs747462	chr2:233790171	A/C	cg11972305	chr2:233791962	NGEF	-0.44	-6.45	-0.38	5.79e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg13293535	chr8:11597251	GATA4	-0.42	-5.45	-0.33	1.25e-7	Retinal vascular caliber;
KIRP	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	trans	rs4839604	1.000	rs13317029	chr3:142961223	C/T	cg26927190	chr17:76875678	TIMP2	0.3	6.05	0.36	5.28e-9	N-glycan levels;
KIRP	cis	rs220324	0.688	rs11700704	chr21:43564103	C/T	cg09727148	chr21:43560719	UMODL1	0.42	4.9	0.3	1.75e-6	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.31	-0.32	2.42e-7	Coronary artery disease;
KIRP	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg06795125	chr2:108905320	SULT1C2	0.37	6.36	0.38	9.93e-10	Blood pressure;
KIRP	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	10.93	0.57	6.27e-23	Coronary artery disease;
KIRP	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.74	6.82	0.4	7.22e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg24397884	chr7:158709396	WDR60	0.56	7.32	0.42	3.47e-12	Height;
KIRP	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.7	-0.39	1.42e-10	Dilated cardiomyopathy;
KIRP	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.69	5.95	0.35	9.16e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs28834970	0.928	rs17057043	chr8:27220310	C/T	cg07216194	chr8:27182965	PTK2B	-0.42	-5.23	-0.32	3.55e-7	Alzheimer's disease (late onset);
KIRP	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg00310523	chr12:86230176	RASSF9	0.38	5.8	0.35	2.07e-8	Major depressive disorder;
KIRP	cis	rs780094	0.500	rs12987055	chr2:27834152	T/C	cg05484376	chr2:27715224	FNDC4	-0.37	-5.16	-0.31	5.11e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg19875535	chr5:140030758	IK	-0.66	-9.48	-0.52	2.28e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00745463	chr17:30367425	LRRC37B	0.93	6.67	0.39	1.66e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg14458575	chr2:238380390	NA	0.57	5.88	0.35	1.32e-8	Prostate cancer;
KIRP	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.57	-8.31	-0.47	6.57e-15	Schizophrenia;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg21427119	chr20:30132790	HM13	-0.42	-5.01	-0.3	1.03e-6	Mean corpuscular hemoglobin;
KIRP	trans	rs76288851	0.799	rs73201779	chr3:126492424	G/T	cg13821433	chr2:26726535	OTOF	0.56	6.19	0.37	2.49e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs4972539	0.784	rs16861363	chr2:174086492	A/G	cg04505972	chr2:173508040	NA	0.39	5.23	0.32	3.63e-7	Parental longevity (mother's age at death);
KIRP	cis	rs66696671	0.516	rs3816145	chr10:121347329	T/C	cg06765389	chr10:121379685	NA	-0.4	-5.35	-0.32	1.97e-7	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.6	-7.65	-0.44	4.5e-13	Obesity-related traits;
KIRP	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg11833968	chr6:79620685	NA	-0.46	-6.91	-0.4	4.18e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg06521331	chr12:34319734	NA	-0.54	-6.84	-0.4	6.07e-11	Heart rate;
KIRP	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg21775007	chr8:11205619	TDH	0.48	6.63	0.39	2.16e-10	Mood instability;
KIRP	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.97	-0.45	6.08e-14	Retinal vascular caliber;
KIRP	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg09579323	chr1:150459698	TARS2	0.4	5.05	0.31	8.45e-7	Migraine;
KIRP	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.67	6.61	0.39	2.43e-10	Axial length;
KIRP	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg03929089	chr4:120376271	NA	0.7	6.16	0.37	2.87e-9	Axial length;
KIRP	cis	rs72730918	0.564	rs34532503	chr15:51753047	A/G	cg14296394	chr15:51910925	DMXL2	0.76	10.41	0.55	2.83e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.58	7.61	0.44	5.83e-13	Retinal vascular caliber;
KIRP	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.98	12.72	0.63	8.03e-29	Homoarginine levels;
KIRP	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg01879757	chr17:41196368	BRCA1	-0.74	-10.27	-0.55	7.95e-21	Menopause (age at onset);
KIRP	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.76	10.95	0.57	5.56e-23	Colorectal cancer;
KIRP	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.45	5.87	0.35	1.43e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01506492	chr2:219232590	C2orf62	0.48	6.9	0.4	4.33e-11	Parkinson's disease;
KIRP	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.88	0.35	1.34e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19524238	chr7:2802976	GNA12	-0.39	-5.53	-0.33	8.36e-8	Height;
KIRP	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg01620082	chr3:125678407	NA	-0.89	-6.42	-0.38	6.96e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-1.08	-21.33	-0.81	7.38e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35883536	1.000	rs1832123	chr1:101168196	A/G	cg06223162	chr1:101003688	GPR88	0.34	6.99	0.41	2.65e-11	Monocyte count;
KIRP	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	8.1	0.46	2.59e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs3849570	0.695	rs9830445	chr3:81508063	T/G	cg07356753	chr3:81810745	GBE1	0.49	6.19	0.37	2.46e-9	Waist circumference;Body mass index;
KIRP	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.37	0.38	9.01e-10	Aortic root size;
KIRP	trans	rs1941687	0.527	rs6507059	chr18:31303643	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-6.83	-0.4	6.61e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs4851254	0.626	rs115581542	chr2:100717725	T/A	cg17356467	chr2:100759845	AFF3	0.49	5.14	0.31	5.6e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10931423	chr5:172152245	NA	0.58	7.21	0.42	6.7e-12	Interleukin-4 levels;
KIRP	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.65	-0.44	4.55e-13	Resting heart rate;
KIRP	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg22356347	chr1:167427500	CD247	-0.45	-6.12	-0.36	3.6e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg10755058	chr3:40428713	ENTPD3	0.49	6.67	0.39	1.72e-10	Renal cell carcinoma;
KIRP	cis	rs11874712	1.000	rs9945606	chr18:43673325	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.16e-8	Migraine - clinic-based;
KIRP	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg07005078	chr4:17578674	LAP3	0.43	4.9	0.3	1.75e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02843535	chr17:18759628	NA	0.59	6.98	0.41	2.77e-11	Smoking initiation;
KIRP	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.77	11.02	0.57	3.19e-23	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12282928	1.000	rs10769345	chr11:48335164	C/G	cg26585981	chr11:48327164	OR4S1	0.52	6.22	0.37	2.1e-9	Migraine - clinic-based;
KIRP	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg24807547	chr6:37504484	NA	-0.6	-9.58	-0.52	1.15e-18	Cognitive performance;
KIRP	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg12623918	chr2:306882	NA	0.47	5.84	0.35	1.6e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs16828019	0.704	rs12024115	chr1:41534357	C/T	cg18742814	chr1:41828276	NA	0.57	5.04	0.31	9.01e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2151522	0.563	rs1592287	chr6:127121137	A/G	cg21431617	chr6:127135037	NA	0.32	5.76	0.34	2.44e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs13067260	0.655	rs13324792	chr3:123719830	T/C	cg19918027	chr3:123987645	KALRN	-0.62	-5.51	-0.33	9.2e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35740288	0.770	rs4843082	chr15:86153390	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs62109865	0.655	rs62111817	chr19:12601287	A/G	cg19721055	chr19:12753329	NA	-0.84	-4.94	-0.3	1.48e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.3	-0.32	2.61e-7	Bipolar disorder;
KIRP	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg18306943	chr3:40428807	ENTPD3	0.4	5.24	0.32	3.46e-7	Renal cell carcinoma;
KIRP	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs77633900	0.772	rs2078437	chr15:76669580	A/G	cg21673338	chr15:77095150	SCAPER	0.59	5.29	0.32	2.72e-7	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg09699651	chr6:150184138	LRP11	0.45	5.85	0.35	1.59e-8	Lung cancer;
KIRP	cis	rs57338032	0.891	rs8036042	chr15:78764324	G/A	cg06917634	chr15:78832804	PSMA4	0.56	4.95	0.3	1.41e-6	CTACK levels;
KIRP	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.35	12.29	0.62	2.19e-27	Diabetic retinopathy;
KIRP	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.67	-6.14	-0.36	3.28e-9	Schizophrenia;
KIRP	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	7.92	0.45	8.41e-14	Schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13456812	chr6:167369504	RNASET2	0.47	6.1	0.36	4.1e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg00376283	chr12:123451042	ABCB9	-0.63	-7.34	-0.42	3.04e-12	Neutrophil percentage of white cells;
KIRP	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	11.2	0.58	8.34e-24	Smoking behavior;
KIRP	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.64	6.51	0.38	4.12e-10	Gastritis;
KIRP	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg01620082	chr3:125678407	NA	-0.95	-6.3	-0.37	1.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg07382826	chr16:28625726	SULT1A1	-0.45	-4.87	-0.3	2.04e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3764563	1.000	rs602300	chr19:15693041	G/A	cg20725493	chr19:15740067	CYP4F8	0.89	6.37	0.38	9.25e-10	Inflammatory biomarkers;
KIRP	cis	rs11625487	0.609	rs74063206	chr14:77981045	C/T	cg20045696	chr14:77926864	AHSA1	-0.67	-5.62	-0.34	5.29e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs7009516	0.819	rs5012230	chr8:24208934	A/C	cg01759110	chr8:24241694	ADAMDEC1	0.32	6.58	0.39	2.81e-10	Hair greying;
KIRP	cis	rs2150410	0.915	rs4816619	chr21:40599876	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg18586891	chr4:952366	TMEM175	-0.63	-5.25	-0.32	3.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg08901578	chr4:187885870	NA	-0.44	-6.6	-0.39	2.45e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	0.84	7.56	0.43	8.18e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.51	7.2	0.42	7.45e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg17014757	chr1:203156097	CHI3L1	-0.63	-6.78	-0.4	8.76e-11	YKL-40 levels;
KIRP	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg14825094	chr17:61818420	STRADA	-0.44	-5.03	-0.31	9.37e-7	Height;
KIRP	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4666002	0.789	rs12998770	chr2:27913188	T/C	cg27432699	chr2:27873401	GPN1	0.57	5.57	0.33	6.74e-8	Phospholipid levels (plasma);
KIRP	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.59	7.32	0.42	3.45e-12	Aortic root size;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg27532560	chr4:187881888	NA	-0.77	-12.99	-0.64	9.67e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7215564	0.822	rs2340771	chr17:78752947	A/C	cg06153925	chr17:78755379	RPTOR	-0.38	-6.26	-0.37	1.67e-9	Myopia (pathological);
KIRP	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg21605333	chr4:119757512	SEC24D	1.53	10.51	0.56	1.43e-21	Cannabis dependence symptom count;
KIRP	cis	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.13e-6	Androgen levels;
KIRP	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg18461458	chr19:21324796	ZNF431	0.48	5.1	0.31	6.94e-7	Pain;
KIRP	cis	rs4783244	0.794	rs17247500	chr16:82645783	A/G	cg09415485	chr16:82663111	CDH13	-0.28	-5.2	-0.31	4.19e-7	Adiponectin levels;
KIRP	trans	rs1864585	0.520	rs56046029	chr8:10693803	A/C	cg26278703	chr11:58910052	FAM111A	0.63	6.27	0.37	1.59e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg18154014	chr19:37997991	ZNF793	0.62	6.67	0.39	1.72e-10	Coronary artery calcification;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13047869	chr3:10149882	C3orf24	0.67	6.21	0.37	2.18e-9	Alzheimer's disease;
KIRP	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.69	6.78	0.4	9.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-1.01	-9.05	-0.5	4.58e-17	Left atrial antero-posterior diameter;
KIRP	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg12131826	chr15:77904385	NA	0.46	6.05	0.36	5.46e-9	Type 2 diabetes;
KIRP	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.47	-7.1	-0.41	1.37e-11	Vitamin D levels;
KIRP	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg13482628	chr17:19912719	NA	0.52	6.76	0.4	9.83e-11	Schizophrenia;
KIRP	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14575983	chr5:99922152	FAM174A	0.4	6.11	0.36	3.86e-9	Migraine with aura;
KIRP	cis	rs7849270	0.959	rs2094704	chr9:131918294	A/G	cg13538475	chr9:131942899	NA	-0.34	-5.15	-0.31	5.22e-7	Blood metabolite ratios;
KIRP	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg16482183	chr6:26056742	HIST1H1C	0.59	6.76	0.4	1.01e-10	Iron status biomarkers;
KIRP	cis	rs2411233	1.000	rs8029263	chr15:39301246	A/G	cg19287857	chr15:39890699	NA	0.38	5.32	0.32	2.31e-7	Platelet count;
KIRP	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg24044564	chr13:99115944	STK24	0.57	6.14	0.36	3.37e-9	Obesity-related traits;
KIRP	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.86	-7.74	-0.44	2.65e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.25	-0.47	9.49e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg23188430	chr6:125850052	NA	-0.34	-5.28	-0.32	2.86e-7	Brugada syndrome;
KIRP	cis	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg00405596	chr8:11794950	NA	0.55	7.79	0.44	1.91e-13	Monocyte count;
KIRP	cis	rs10761482	0.601	rs7922622	chr10:62207523	C/T	cg01186212	chr10:62110162	ANK3	0.3	5.11	0.31	6.48e-7	Schizophrenia;
KIRP	trans	rs6126344	0.957	rs8184337	chr20:50403227	A/G	cg06829968	chr15:53076235	ONECUT1	-0.43	-6.03	-0.36	6.05e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg12756093	chr1:115239321	AMPD1	0.5	6.68	0.39	1.62e-10	Autism;
KIRP	cis	rs427941	0.804	rs12537077	chr7:101825367	C/T	cg06246474	chr7:101738831	CUX1	0.47	5.5	0.33	9.58e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg23127183	chr11:57508653	C11orf31	-0.55	-7.08	-0.41	1.47e-11	Schizophrenia;
KIRP	cis	rs944802	0.684	rs2065500	chr9:22145694	A/G	cg00491127	chr9:22154101	NA	-0.48	-5.15	-0.31	5.45e-7	White blood cell count;
KIRP	trans	rs13170463	0.579	rs13166741	chr5:8035078	C/G	cg03862380	chr20:43029895	HNF4A	0.39	6.11	0.36	3.79e-9	Colorectal cancer;
KIRP	cis	rs16828019	0.777	rs67450703	chr1:41460129	A/G	cg18742814	chr1:41828276	NA	0.67	5.69	0.34	3.62e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg17077180	chr1:38461687	NA	0.39	5.44	0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs4006360	0.506	rs8080177	chr17:39301645	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.52	-6.82	-0.4	6.84e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	0.9	9.72	0.53	4.22e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg13880726	chr7:1868755	MAD1L1	0.51	5.99	0.36	7.46e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs28489187	0.706	rs233108	chr1:85781720	C/T	cg16011679	chr1:85725395	C1orf52	0.49	5.94	0.35	9.83e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.81	11.15	0.58	1.25e-23	Longevity;
KIRP	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg05347473	chr6:146136440	FBXO30	0.57	8.04	0.46	3.74e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.63	7.07	0.41	1.62e-11	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00545759	chr19:39833510	SAMD4B	0.52	6.57	0.39	3.04e-10	Parkinson's disease;
KIRP	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg12405258	chr13:114927641	NA	0.46	6.47	0.38	5.19e-10	Schizophrenia;
KIRP	cis	rs812925	0.519	rs2694627	chr2:61625506	A/G	cg15711740	chr2:61764176	XPO1	0.47	5.93	0.35	1.04e-8	Immature fraction of reticulocytes;
KIRP	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.72	8.89	0.49	1.3e-16	Cognitive function;
KIRP	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg21361702	chr7:150065534	REPIN1	-0.59	-5.85	-0.35	1.6e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.94	15.5	0.7	2.77e-38	Menarche (age at onset);
KIRP	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg02297831	chr4:17616191	MED28	0.6	7.63	0.44	5.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg06558623	chr16:89946397	TCF25	1.04	7.78	0.44	1.94e-13	Skin colour saturation;
KIRP	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg20701182	chr2:24300061	SF3B14	0.49	5.12	0.31	6.02e-7	Asthma;
KIRP	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.84	0.4	6.16e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg02336718	chr17:17403227	NA	0.34	5.41	0.33	1.48e-7	Total body bone mineral density;
KIRP	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.74	9.92	0.53	9.91e-20	Coffee consumption (cups per day);
KIRP	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg24375607	chr4:120327624	NA	0.57	5.87	0.35	1.37e-8	Corneal astigmatism;
KIRP	cis	rs4356932	1.000	rs4859414	chr4:76949997	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs9443189	1.000	rs3822957	chr6:76607280	A/G	cg01950844	chr6:76311363	SENP6	-0.59	-5.91	-0.35	1.16e-8	Prostate cancer;
KIRP	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg01620082	chr3:125678407	NA	-0.87	-6.18	-0.37	2.69e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7119167	0.813	rs10898925	chr11:73248692	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.46	-4.91	-0.3	1.7e-6	Blood protein levels;
KIRP	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.64	6.42	0.38	6.89e-10	Gastritis;
KIRP	cis	rs17095355	0.892	rs7085888	chr10:111713930	A/G	cg00817464	chr10:111662876	XPNPEP1	0.36	5.03	0.31	9.56e-7	Biliary atresia;
KIRP	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg16926213	chr1:1841314	NA	0.32	5.43	0.33	1.34e-7	Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08785274	chr1:161068252	KLHDC9	0.52	6.11	0.36	3.83e-9	Smoking initiation;
KIRP	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6132905	0.590	rs4815454	chr20:2624376	G/A	cg24848351	chr20:2622020	TMC2	-0.65	-5.82	-0.35	1.82e-8	Mumps;
KIRP	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.84	10.12	0.54	2.41e-20	Multiple sclerosis;
KIRP	cis	rs73198271	1.000	rs11776513	chr8:8609057	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.61	-0.34	5.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.67	9.81	0.53	2.13e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13394060	chr9:140704065	EHMT1	0.44	6.06	0.36	5.2e-9	Survival in pancreatic cancer;
KIRP	trans	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg10756647	chr7:56101905	PSPH	1.06	8.2	0.46	1.36e-14	Diabetic kidney disease;
KIRP	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg00933542	chr6:150070202	PCMT1	0.26	4.88	0.3	1.87e-6	Testicular germ cell tumor;
KIRP	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.58	8.6	0.48	9.53e-16	Longevity;
KIRP	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	5.7	0.34	3.36e-8	Hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12803694	chr19:15443052	NA	0.5	6.17	0.37	2.73e-9	Parkinson's disease;
KIRP	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg10047753	chr17:41438598	NA	-1.08	-17.28	-0.74	2.48e-44	Menopause (age at onset);
KIRP	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.77	9.6	0.52	1e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg27624424	chr6:160112604	SOD2	0.54	6.44	0.38	6.09e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16386425	chr10:429943	DIP2C	-0.49	-6.72	-0.39	1.24e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.9	0.53	1.11e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.28	0.58	4.68e-24	Alzheimer's disease;
KIRP	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.06	12.74	0.63	6.91e-29	Vitiligo;
KIRP	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.82	11.68	0.6	2.33e-25	Age-related hearing impairment;
KIRP	cis	rs10924970	0.967	rs7512798	chr1:235356425	C/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.07	0.31	7.96e-7	Asthma;
KIRP	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg19849509	chr2:175204996	NA	-0.51	-6.14	-0.36	3.21e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10009056	chr4:187475841	MTNR1A	0.43	6.13	0.36	3.49e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg01721255	chr8:58191610	C8orf71	0.62	5.36	0.32	1.89e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10090774	0.760	rs13276886	chr8:141730890	T/C	cg26074100	chr8:141568712	EIF2C2	0.33	5.12	0.31	6.15e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.96	-0.41	3.11e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17818399	0.815	rs35837037	chr2:46861300	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.59	0.34	6.15e-8	Height;
KIRP	cis	rs4716602	0.596	rs12386634	chr7:156158373	G/A	cg16983916	chr7:156159713	NA	-0.43	-5.44	-0.33	1.26e-7	Anti-saccade response;
KIRP	trans	rs4942242	0.967	rs58325557	chr13:44217771	A/G	cg19169023	chr15:41853346	TYRO3	0.54	6.56	0.39	3.2e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg14820908	chr5:178986412	RUFY1	-0.35	-5.11	-0.31	6.49e-7	Lung cancer;
KIRP	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs16973500	1.000	rs16973500	chr16:71965196	C/T	cg00732059	chr16:71740210	PHLPP2	-0.53	-5.41	-0.33	1.49e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg00255919	chr5:131827918	IRF1	0.25	5.22	0.32	3.84e-7	Asthma (sex interaction);
KIRP	trans	rs9409565	0.826	rs4744338	chr9:97158965	C/T	cg05679027	chr9:99775184	HIATL2	0.55	6.78	0.4	8.65e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.29	5.51	0.33	9.18e-8	Monocyte percentage of white cells;
KIRP	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg16989719	chr2:238392110	NA	-0.51	-6.54	-0.38	3.56e-10	Prostate cancer;
KIRP	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg19468946	chr17:37922297	IKZF3	-0.47	-6.39	-0.38	8.14e-10	Self-reported allergy;
KIRP	trans	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg11693508	chr17:37793320	STARD3	0.82	9.68	0.53	5.67e-19	Neuroticism;
KIRP	trans	rs72700829	0.531	rs12070288	chr1:151009984	C/G	cg18403396	chr6:71666282	B3GAT2	0.89	6.17	0.37	2.82e-9	Schizophrenia;
KIRP	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs12580194	0.593	rs61956292	chr12:55803346	T/C	cg11794356	chr12:55725991	OR6C3	-0.55	-7.15	-0.42	9.58e-12	Cancer;
KIRP	cis	rs867371	1.000	rs2088858	chr15:82474749	C/T	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg17724175	chr1:150552817	MCL1	0.38	6.39	0.38	8.04e-10	Tonsillectomy;
KIRP	cis	rs1209950	0.536	rs464366	chr21:40225071	C/T	cg02119577	chr21:40195074	ETS2	-0.39	-5.68	-0.34	3.79e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.64	-0.39	1.95e-10	Morning vs. evening chronotype;
KIRP	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.91	13.77	0.66	2.24e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4849845	0.889	rs10188430	chr2:121033418	C/T	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg17810781	chr1:201082982	CACNA1S	0.4	6.29	0.37	1.42e-9	Permanent tooth development;
KIRP	cis	rs4073416	0.542	rs6573616	chr14:66046816	A/G	cg03016385	chr14:66212404	NA	-0.52	-6.3	-0.37	1.36e-9	N-glycan levels;
KIRP	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.62	-7.26	-0.42	5.08e-12	Longevity;Endometriosis;
KIRP	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg05714579	chr10:131428358	MGMT	0.39	4.86	0.3	2.13e-6	Response to temozolomide;
KIRP	cis	rs9467603	0.920	rs34493019	chr6:25714959	A/G	cg22865713	chr6:25779897	SLC17A4	0.57	4.91	0.3	1.63e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.47	-9.67	-0.52	5.89e-19	Longevity;
KIRP	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg25418670	chr11:30344373	C11orf46	-0.6	-5.02	-0.3	1e-6	Morning vs. evening chronotype;
KIRP	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs7246760	1.000	rs10418248	chr19:9938214	T/A	cg02900749	chr2:68251473	NA	-0.9	-8.31	-0.47	6.66e-15	Pursuit maintenance gain;
KIRP	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg05775895	chr3:12838266	CAND2	0.34	5.72	0.34	3.14e-8	QRS complex (12-leadsum);
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.88	-14.9	-0.69	3.3e-36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg17376030	chr22:41985996	PMM1	-0.83	-8.98	-0.5	7.47e-17	Vitiligo;
KIRP	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-7.51	-0.43	1.12e-12	Parkinson's disease;
KIRP	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.6	0.59	4.07e-25	Total body bone mineral density;
KIRP	cis	rs7712401	0.623	rs30032	chr5:122238387	G/T	cg19412675	chr5:122181750	SNX24	0.51	5.53	0.33	8.31e-8	Mean platelet volume;
KIRP	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg00409905	chr10:38381863	ZNF37A	-0.58	-6.74	-0.39	1.11e-10	Obesity (extreme);
KIRP	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	0.83	9.05	0.5	4.46e-17	Gut microbiome composition (summer);
KIRP	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg23307798	chr14:103986281	CKB	-0.51	-6.92	-0.4	3.86e-11	Coronary artery disease;
KIRP	cis	rs34779708	0.733	rs12240638	chr10:35542610	G/T	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2219968	1.000	rs12056577	chr8:78961915	A/C	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2274273	0.624	rs4580079	chr14:55780366	G/A	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.4e-7	Protein biomarker;
KIRP	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg04218760	chr10:45406644	TMEM72	0.23	6.15	0.37	3.11e-9	Mean corpuscular volume;
KIRP	cis	rs1800562	1	rs1800562	chr6:26093141	C/T	cg17691542	chr6:26056736	HIST1H1C	0.86	5.58	0.34	6.18e-8	Hematocrit;Iron status biomarkers (transferrin levels);Diastolic blood pressure;Hemoglobin;Red blood cell count;Cholesterol, total;Hematology traits;Alcohol consumption (transferrin glycosylation);Iron status biomarkers (ferritin levels);LDL cholesterol;Iron status biomarkers;Mean corpuscular hemoglobin;Iron status biomarkers (transferrin saturation);Mean corpuscular volume;Iron status biomarkers (iron levels);Red blood cell traits;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hematological parameters;Hepcidin levels;Cardiovascular disease risk factors;
KIRP	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.42	5.89	0.35	1.29e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.14	0.31	5.64e-7	Breast cancer;
KIRP	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.93	-15.99	-0.71	5.94e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.58	6.61	0.39	2.42e-10	Body mass index (adult);
KIRP	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.53	6.82	0.4	6.85e-11	Coronary heart disease;
KIRP	cis	rs9469913	0.740	rs2744964	chr6:34591320	G/C	cg17674042	chr6:34482479	PACSIN1	-0.48	-6.39	-0.38	8.36e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg13409248	chr3:40428643	ENTPD3	0.39	5.25	0.32	3.24e-7	Renal cell carcinoma;
KIRP	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.38	-7.82	-0.45	1.52e-13	Body mass index;
KIRP	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg17554472	chr22:41940697	POLR3H	-0.61	-6.86	-0.4	5.56e-11	Vitiligo;
KIRP	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15556689	chr8:8085844	FLJ10661	0.74	8.6	0.48	9.34e-16	Red cell distribution width;
KIRP	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg14993813	chr1:46806288	NSUN4	-0.6	-6.75	-0.4	1.06e-10	Menopause (age at onset);
KIRP	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16318349	chr1:154917307	PBXIP1	-0.35	-5.51	-0.33	8.9e-8	Prostate cancer;
KIRP	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg05527609	chr1:210001259	C1orf107	-0.37	-4.94	-0.3	1.47e-6	Monobrow;
KIRP	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-9.57	-0.52	1.17e-18	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4761097	0.516	rs7968026	chr12:85230056	A/G	cg00765312	chr12:85674694	ALX1	0.52	6.07	0.36	4.76e-9	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.02	0.46	4.26e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7700895	0.737	rs6879652	chr5:95227462	T/C	cg16656078	chr5:95278638	ELL2	-0.36	-5.55	-0.33	7.36e-8	IgG glycosylation;
KIRP	cis	rs6499755	0.901	rs4784522	chr16:55348749	C/T	cg05099576	chr16:55362342	IRX6	0.27	5.63	0.34	4.91e-8	Hypospadias;
KIRP	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.58	7.85	0.45	1.29e-13	Mean corpuscular volume;
KIRP	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg04218760	chr10:45406644	TMEM72	-0.25	-6.55	-0.39	3.25e-10	Mean corpuscular volume;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg14664628	chr15:75095509	CSK	-0.63	-8.05	-0.46	3.58e-14	Breast cancer;
KIRP	cis	rs2916247	0.954	rs1484564	chr8:93122508	G/A	cg10183463	chr8:93005414	RUNX1T1	0.41	5.06	0.31	8.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.75	-0.44	2.48e-13	Joint mobility (Beighton score);
KIRP	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.59	-7.17	-0.42	8.49e-12	Resting heart rate;
KIRP	cis	rs78487399	0.808	rs17030998	chr2:43758199	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.04	-0.31	8.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.93	-15.66	-0.71	8.08e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg08501292	chr6:25962987	TRIM38	0.7	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.27	-0.51	9.81e-18	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg19126889	chr10:131565313	MGMT	-0.57	-7.49	-0.43	1.23e-12	Inflammatory biomarkers;
KIRP	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg23894439	chr1:183413866	NA	0.4	5.21	0.32	3.93e-7	Systemic lupus erythematosus;
KIRP	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg08999081	chr20:33150536	PIGU	-0.4	-5.15	-0.31	5.41e-7	Height;
KIRP	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.66	7.84	0.45	1.32e-13	DNA methylation (variation);
KIRP	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Bipolar disorder;
KIRP	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg01251548	chr11:17372745	DKFZp686O24166	-0.39	-5.21	-0.32	4.07e-7	Type 2 diabetes;
KIRP	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	4.86	0.3	2.06e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg08873628	chr1:175162347	KIAA0040	-0.41	-6.04	-0.36	5.63e-9	Alcohol dependence;
KIRP	cis	rs6901250	0.655	rs1117046	chr6:117136978	G/C	cg05399210	chr6:117082661	FAM162B	-0.38	-5.14	-0.31	5.72e-7	C-reactive protein levels;
KIRP	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-8.41	-0.47	3.26e-15	Coffee consumption (cups per day);
KIRP	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.42	-0.33	1.41e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10129255	0.518	rs10136903	chr14:107187105	T/C	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.69	-10.78	-0.57	1.86e-22	Educational attainment;
KIRP	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.99	-10.25	-0.55	9.15e-21	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg10523679	chr1:76189770	ACADM	-0.47	-6.32	-0.37	1.24e-9	Daytime sleep phenotypes;
KIRP	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs7116495	0.881	rs6592449	chr11:71670222	C/T	cg26138937	chr11:71823887	C11orf51	-0.72	-5.83	-0.35	1.71e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7538876	0.935	rs4920607	chr1:17760098	A/G	cg01904812	chr1:17746340	RCC2	0.3	5.18	0.31	4.7e-7	Basal cell carcinoma;
KIRP	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg09788416	chr12:39539408	NA	0.38	5.17	0.31	4.79e-7	Morning vs. evening chronotype;
KIRP	cis	rs2290419	0.730	rs117478490	chr11:68944030	T/C	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs4523957	0.620	rs9906467	chr17:2069003	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-12.71	-0.63	8.87e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg15282417	chr9:129245246	FAM125B	0.45	8.0	0.45	4.89e-14	Intraocular pressure;
KIRP	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg05526886	chr2:227700861	RHBDD1	0.42	4.86	0.3	2.14e-6	Pulmonary function;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-1.08	-21.37	-0.81	5.39e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26207909	chr14:103986467	CKB	0.49	6.47	0.38	5.19e-10	Body mass index;
KIRP	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg16586182	chr3:47516702	SCAP	-0.84	-12.06	-0.61	1.31e-26	Colorectal cancer;
KIRP	cis	rs6800768	0.633	rs62255803	chr3:24149030	T/C	cg10674438	chr3:24145617	LOC152024	-0.52	-6.88	-0.4	4.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg10792982	chr14:105748885	BRF1	-0.75	-11.89	-0.6	4.82e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.67	-0.44	3.92e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.65	9.72	0.53	4.24e-19	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg00800038	chr16:89945340	TCF25	-0.76	-5.19	-0.31	4.41e-7	Skin colour saturation;
KIRP	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26314531	chr2:26401878	FAM59B	-0.48	-4.96	-0.3	1.32e-6	Gut microbiome composition (summer);
KIRP	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07623839	chr16:767530	NA	-0.67	-8.23	-0.46	1.07e-14	Height;
KIRP	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.47	5.74	0.34	2.78e-8	Common traits (Other);
KIRP	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg23594656	chr7:65796392	TPST1	-0.47	-7.5	-0.43	1.19e-12	Aortic root size;
KIRP	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.87	-0.3	2.01e-6	Blood metabolite levels;
KIRP	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg02336718	chr17:17403227	NA	0.37	5.6	0.34	5.81e-8	Total body bone mineral density;
KIRP	cis	rs2692947	0.759	rs1917890	chr2:96672001	C/T	cg23100626	chr2:96804247	ASTL	0.42	5.69	0.34	3.67e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg00684032	chr4:1343700	KIAA1530	0.79	11.46	0.59	1.23e-24	Obesity-related traits;
KIRP	cis	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg11502198	chr6:26597334	ABT1	-0.81	-5.66	-0.34	4.21e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg08283408	chr3:49949060	MON1A	-0.41	-5.54	-0.33	7.85e-8	Body mass index;
KIRP	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.31	-0.32	2.42e-7	Gut microbiome composition (summer);
KIRP	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.54	0.48	1.39e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.02	17.67	0.75	1.17e-45	Schizophrenia;
KIRP	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg02569458	chr12:86230093	RASSF9	0.42	6.29	0.37	1.4e-9	Major depressive disorder;
KIRP	cis	rs1440410	0.835	rs7684847	chr4:144054567	C/T	cg01719995	chr4:144104893	USP38	0.46	6.29	0.37	1.44e-9	Ischemic stroke;
KIRP	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.37	1.57e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16706631	chr6:26204823	HIST1H4E	0.95	6.36	0.38	9.97e-10	P wave terminal force;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-8.95	-0.5	9.1e-17	Platelet count;
KIRP	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg24631222	chr15:78858424	CHRNA5	-0.81	-9.6	-0.52	1e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.41	-0.59	1.76e-24	Monocyte count;
KIRP	cis	rs1847202	0.717	rs13063437	chr3:72952388	A/G	cg06781948	chr3:72941472	GXYLT2	0.43	5.83	0.35	1.77e-8	Motion sickness;
KIRP	cis	rs2882667	0.858	rs11949916	chr5:138396277	T/G	cg04439458	chr5:138467593	SIL1	-0.51	-7.8	-0.45	1.72e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg15841412	chr13:111365552	ING1	-0.52	-5.64	-0.34	4.59e-8	Coronary artery disease;
KIRP	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg26205652	chr12:48591994	NA	-0.49	-5.29	-0.32	2.67e-7	Lung cancer;
KIRP	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.71	-8.86	-0.49	1.64e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9826463	0.757	rs73240305	chr3:142222770	A/G	cg20824294	chr3:142316082	PLS1	0.41	6.45	0.38	5.9e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.94	16.38	0.72	2.81e-41	Metabolic syndrome;
KIRP	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.41	5.19	0.31	4.35e-7	Birth weight;
KIRP	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg25447019	chr17:19030144	GRAPL	0.6	8.4	0.47	3.55e-15	Schizophrenia;
KIRP	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg19847866	chr10:1019161	NA	-0.63	-5.79	-0.35	2.1e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-5.72	-0.34	3.01e-8	Schizophrenia;
KIRP	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.37	-5.49	-0.33	9.82e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12049351	0.774	rs34551512	chr1:229618888	C/G	cg11742688	chr1:229674241	ABCB10	-0.4	-5.64	-0.34	4.64e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6500550	1.000	rs6500550	chr16:3746241	A/G	cg07396092	chr16:3662230	BTBD12	-0.51	-6.0	-0.36	7e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.54	-6.93	-0.4	3.65e-11	Blood metabolite levels;
KIRP	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg17366294	chr4:99064904	C4orf37	-0.37	-5.03	-0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6568686	0.786	rs6910340	chr6:111863064	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.57	-5.46	-0.33	1.14e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg11833968	chr6:79620685	NA	-0.45	-7.05	-0.41	1.81e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs73191547	0.615	rs10089666	chr8:10083040	A/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.28	0.37	1.53e-9	Schizophrenia;
KIRP	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg19899395	chr1:46959349	NA	-0.39	-4.88	-0.3	1.9e-6	Monobrow;
KIRP	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.69	5.95	0.35	9.16e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg12962167	chr3:53033115	SFMBT1	0.64	4.94	0.3	1.42e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7656342	0.543	rs6448981	chr4:9740325	G/C	cg00071950	chr4:10020882	SLC2A9	0.37	5.1	0.31	6.87e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs17102423	0.964	rs11623603	chr14:65602287	T/A	cg11161011	chr14:65562177	MAX	-0.47	-5.91	-0.35	1.15e-8	Obesity-related traits;
KIRP	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	12.06	0.61	1.29e-26	Menarche (age at onset);
KIRP	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg19743168	chr1:23544995	NA	0.52	7.29	0.42	4.27e-12	Height;
KIRP	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-5.56	-0.33	6.89e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.42	5.26	0.32	3.13e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg11846333	chr4:119757529	SEC24D	0.96	5.72	0.34	3.04e-8	Cannabis dependence symptom count;
KIRP	cis	rs9962915	0.967	rs1785408	chr18:5594648	A/G	cg12967001	chr18:5544089	EPB41L3	-0.39	-4.98	-0.3	1.2e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.86	-17.27	-0.74	2.65e-44	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	6.33	0.37	1.13e-9	Depressive symptoms;
KIRP	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.55	0.59	6.19e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09332309	chr17:4890691	CAMTA2	0.46	6.11	0.36	3.82e-9	Parkinson's disease;
KIRP	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.5	-0.33	9.54e-8	Coronary artery disease;
KIRP	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.64	-6.61	-0.39	2.39e-10	Gut microbiome composition (summer);
KIRP	cis	rs9400467	0.528	rs445349	chr6:111662102	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.43	5.69	0.34	3.59e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.93	12.46	0.62	6.15e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs28489187	0.706	rs233074	chr1:85809065	T/C	cg16011679	chr1:85725395	C1orf52	0.52	6.14	0.36	3.28e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.62	-9.67	-0.52	5.83e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg27490568	chr2:178487706	NA	0.48	6.44	0.38	6.4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs10875746	0.855	rs10875730	chr12:48427875	A/T	cg26205652	chr12:48591994	NA	0.78	10.52	0.56	1.26e-21	Longevity (90 years and older);
KIRP	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.44	0.43	1.7e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs516946	1.000	rs28602970	chr8:41524505	A/G	cg19441908	chr8:41529140	ANK1	0.49	7.05	0.41	1.85e-11	Type 2 diabetes;
KIRP	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-13.53	-0.65	1.48e-31	Heart rate;
KIRP	cis	rs7255045	0.700	rs11085818	chr19:12952271	G/A	cg23899408	chr19:12877188	HOOK2	-0.43	-4.9	-0.3	1.78e-6	Mean corpuscular volume;
KIRP	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.98	0.36	7.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11987759	chr7:65425863	GUSB	-0.52	-6.91	-0.4	4.21e-11	Aortic root size;
KIRP	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-8.23	-0.46	1.1e-14	Blood protein levels;
KIRP	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg19507638	chr5:93509721	C5orf36	-0.59	-5.31	-0.32	2.47e-7	Diabetic retinopathy;
KIRP	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg05347473	chr6:146136440	FBXO30	-0.58	-8.38	-0.47	4.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.58	7.55	0.43	8.25e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.78	-0.4	8.82e-11	Capecitabine sensitivity;
KIRP	trans	rs979961	0.636	rs75836355	chr4:117839877	C/T	cg02574033	chr7:141398961	KIAA1147	0.98	6.26	0.37	1.68e-9	Ulcerative colitis;
KIRP	cis	rs7116495	1.000	rs4338555	chr11:71755696	T/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.83	-8.95	-0.5	9.15e-17	Asthma;
KIRP	cis	rs2637030	0.559	rs424955	chr5:52902895	A/G	cg06476337	chr5:52856530	NDUFS4	0.53	5.75	0.34	2.64e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	1.11	18.12	0.76	3.41e-47	Cognitive function;
KIRP	cis	rs1669338	0.588	rs3749360	chr3:3213775	G/A	cg16797762	chr3:3221439	CRBN	-0.63	-5.7	-0.34	3.33e-8	White matter integrity;
KIRP	cis	rs6973256	0.605	rs6467499	chr7:133348922	G/T	cg10665199	chr7:133106180	EXOC4	-0.5	-6.37	-0.38	9.3e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4453791	0.932	rs78329075	chr3:38868431	C/T	cg23654821	chr3:39188656	CSRNP1	0.52	5.21	0.32	4.06e-7	Social communication problems;
KIRP	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.41	7.98	0.45	5.44e-14	Height;
KIRP	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	5.49	0.33	1.01e-7	Schizophrenia;
KIRP	cis	rs7011507	1.000	rs55634172	chr8:49139092	T/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.38	-0.65	4.7e-31	Tonsillectomy;
KIRP	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4950322	0.570	rs116339673	chr1:146800654	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.81	-12.43	-0.62	7.52e-28	Breast cancer;
KIRP	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-10.01	-0.54	5.35e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.44	-0.38	6.22e-10	Alcohol dependence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12592965	chr5:177631661	HNRNPAB	0.48	6.07	0.36	4.88e-9	Parkinson's disease;
KIRP	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.25	7.45	0.43	1.54e-12	Type 2 diabetes;
KIRP	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg24169773	chr3:122142474	KPNA1	-0.57	-6.35	-0.38	1.02e-9	LDL cholesterol levels;
KIRP	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg10117171	chr1:25599238	RHD	-0.42	-5.86	-0.35	1.5e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs4975616	0.843	rs6866783	chr5:1312020	T/C	cg07493874	chr5:1342172	CLPTM1L	0.5	6.51	0.38	4.15e-10	Lung cancer;
KIRP	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.3	6.15	0.37	3.09e-9	Body mass index;
KIRP	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.79	9.61	0.52	8.9e-19	Blood protein levels;
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.78	13.01	0.64	8.25e-30	Longevity;Endometriosis;
KIRP	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg04370829	chr17:406249	NA	0.39	4.92	0.3	1.55e-6	Prostate cancer;
KIRP	cis	rs981844	0.712	rs921882	chr4:154752878	A/C	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.35	7.32	0.42	3.45e-12	IgG glycosylation;
KIRP	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.91	-13.05	-0.64	6.34e-30	Blood protein levels;
KIRP	cis	rs7106204	1.000	rs7106204	chr11:24236096	C/T	ch.11.24196551F	chr11:24239977	NA	-0.91	-9.47	-0.52	2.44e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1215050	0.791	rs2865943	chr4:98778449	C/T	cg17366294	chr4:99064904	C4orf37	0.37	4.88	0.3	1.95e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.79	-0.4	8.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	1.0	10.34	0.55	4.72e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.94	0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.65	-8.28	-0.47	7.7e-15	Age at first birth;
KIRP	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.31	-0.32	2.5e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1829883	0.775	rs1939400	chr5:98879015	C/T	cg08333243	chr5:99726346	NA	-0.43	-5.44	-0.33	1.29e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs75646498	0.677	rs12324606	chr15:29880078	G/T	cg08904058	chr15:29859427	FAM189A1	-0.45	-5.94	-0.35	9.78e-9	Diisocyanate-induced asthma;
KIRP	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-12.12	-0.61	7.96e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.79	6.87	0.4	5.2e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs735860	0.763	rs6458912	chr6:53147965	G/A	cg10236188	chr6:53219634	NA	-0.38	-5.09	-0.31	7.22e-7	Glaucoma;
KIRP	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs10875746	0.669	rs10875779	chr12:48629869	G/A	cg26205652	chr12:48591994	NA	0.81	10.54	0.56	1.12e-21	Longevity (90 years and older);
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	14.54	0.68	5.67e-35	Lymphocyte counts;
KIRP	cis	rs4288356	1	rs4288356	chr8:141055724	G/A	cg05910124	chr8:141057427	TRAPPC9	-0.27	-5.28	-0.32	2.84e-7	Pulse pressure;
KIRP	cis	rs10465746	0.714	rs12730621	chr1:84433745	C/G	cg10977910	chr1:84465055	TTLL7	0.57	7.26	0.42	5.17e-12	Obesity-related traits;
KIRP	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg05802129	chr4:122689817	NA	-0.45	-6.54	-0.38	3.55e-10	Type 2 diabetes;
KIRP	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17507749	chr15:85114479	UBE2QP1	0.71	7.86	0.45	1.23e-13	Schizophrenia;
KIRP	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg10241871	chr14:102965420	TECPR2	-0.56	-6.51	-0.38	4.13e-10	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg00745463	chr17:30367425	LRRC37B	0.71	6.16	0.37	2.99e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1816752	0.719	rs11843470	chr13:24997699	A/C	cg02811702	chr13:24901961	NA	0.46	6.1	0.36	4.06e-9	Obesity-related traits;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.9	0.49	1.28e-16	Vitiligo;
KIRP	cis	rs4073221	0.615	rs34648851	chr3:18234610	T/C	cg07694806	chr3:18168406	NA	-0.61	-5.54	-0.33	7.94e-8	Parkinson's disease;
KIRP	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.66	8.33	0.47	5.6e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.17	-0.31	4.87e-7	Tonsillectomy;
KIRP	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.6	0.8	1.79e-55	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17341933	chr17:79008687	BAIAP2;FLJ90757	0.51	6.21	0.37	2.19e-9	Parkinson's disease;
KIRP	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg21184320	chr1:21044207	KIF17	-0.36	-5.49	-0.33	9.9e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Bladder cancer;
KIRP	cis	rs12042938	0.622	rs12030517	chr1:231808385	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	5.4	0.33	1.58e-7	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg05025164	chr4:1340916	KIAA1530	0.57	7.66	0.44	4.22e-13	Longevity;
KIRP	trans	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.35	0.42	2.88e-12	Exhaled nitric oxide output;
KIRP	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	7.94	0.45	7.29e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg21419209	chr3:44054225	NA	-0.74	-9.21	-0.51	1.47e-17	Coronary artery disease;
KIRP	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	0.85	10.19	0.54	1.41e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.61	-7.68	-0.44	3.68e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.59	-7.28	-0.42	4.44e-12	Extraversion;
KIRP	cis	rs240764	0.658	rs11155673	chr6:101243283	A/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.09	-0.31	7.24e-7	Neuroticism;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.6	-8.08	-0.46	2.93e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.96	16.24	0.72	8.53e-41	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02545393	chr11:70244902	CTTN	0.51	6.34	0.37	1.07e-9	Parkinson's disease;
KIRP	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.04	-0.31	9.2e-7	Pulmonary function;
KIRP	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.75	-7.6	-0.44	6.22e-13	Gut microbiome composition (summer);
KIRP	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg23131131	chr22:24373011	LOC391322	-0.52	-5.79	-0.35	2.12e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg16141378	chr3:129829833	LOC729375	0.52	6.31	0.37	1.26e-9	Neuroticism;
KIRP	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg17470723	chr8:74884337	TCEB1	0.64	8.25	0.47	9.51e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs78487399	0.908	rs73925553	chr2:43810646	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.59	-0.34	6.02e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs8077059	1.000	rs9916043	chr17:55813260	C/T	cg12582317	chr17:55822272	NA	0.4	5.0	0.3	1.1e-6	Sex hormone-binding globulin levels;
KIRP	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.39	5.36	0.32	1.88e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26434101	chr3:138655338	NA	0.48	6.1	0.36	4.01e-9	Parkinson's disease;
KIRP	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg20090143	chr19:45452003	APOC2	0.34	5.36	0.32	1.87e-7	Blood protein levels;
KIRP	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg04672837	chr16:48644449	N4BP1	0.5	6.89	0.4	4.7e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg21546286	chr11:48923668	NA	-0.45	-5.73	-0.34	2.86e-8	HDL cholesterol;
KIRP	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.44	5.59	0.34	5.88e-8	Response to temozolomide;
KIRP	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg26354017	chr1:205819088	PM20D1	-0.59	-5.46	-0.33	1.17e-7	Menarche (age at onset);
KIRP	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg15247329	chr7:2764246	NA	-0.36	-5.09	-0.31	7.25e-7	Height;
KIRP	cis	rs1165472	0.627	rs12239569	chr1:56133361	T/A	cg11523071	chr1:56160889	NA	-0.6	-7.37	-0.43	2.59e-12	Paclitaxel-induced neuropathy;
KIRP	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.69	7.66	0.44	4.29e-13	Corneal astigmatism;
KIRP	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg07777115	chr5:623756	CEP72	-0.56	-5.68	-0.34	3.72e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg05861140	chr6:150128134	PCMT1	-0.51	-7.12	-0.41	1.17e-11	Lung cancer;
KIRP	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.48	-0.33	1.06e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.54	-7.11	-0.41	1.26e-11	Height;
KIRP	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.08	-0.31	7.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.75	-0.44	2.41e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.52	6.95	0.41	3.18e-11	Smooth-surface caries;
KIRP	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.09e-14	Lung cancer;
KIRP	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.59	-0.34	6.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg24633833	chr3:10029261	TMEM111	0.54	5.28	0.32	2.78e-7	Alzheimer's disease;
KIRP	cis	rs11690462	0.963	rs34918214	chr2:26628100	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.44	5.25	0.32	3.31e-7	Coronary artery disease;
KIRP	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.93	-0.49	1e-16	Total cholesterol levels;
KIRP	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg00409905	chr10:38381863	ZNF37A	0.58	6.1	0.36	4.09e-9	Obesity (extreme);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09920427	chr19:12777674	MORG1;MAN2B1	0.45	6.02	0.36	6.33e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.52	7.18	0.42	8.1e-12	Mean corpuscular volume;
KIRP	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg17143192	chr8:8559678	CLDN23	0.59	6.8	0.4	7.92e-11	Obesity-related traits;
KIRP	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.57	6.99	0.41	2.62e-11	Breast cancer;
KIRP	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	cg21523751	chr1:182988639	NA	0.33	4.89	0.3	1.86e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12292205	chr6:26970375	C6orf41	-0.6	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	7.63	0.44	5.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	13.09	0.64	4.43e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.78	10.55	0.56	1.05e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs41464348	0.934	rs6735659	chr2:33526382	T/G	cg16572410	chr2:33467199	LTBP1	0.37	4.9	0.3	1.74e-6	Height;
KIRP	cis	rs654950	0.875	rs586055	chr1:41999076	T/C	cg06885757	chr1:42089581	HIVEP3	0.45	6.5	0.38	4.32e-10	Airway imaging phenotypes;
KIRP	cis	rs4700695	0.841	rs152996	chr5:65256506	A/G	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.39	-5.46	-0.33	1.18e-7	Coronary artery disease;
KIRP	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg00405596	chr8:11794950	NA	0.48	6.07	0.36	4.71e-9	Neuroticism;
KIRP	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg00310523	chr12:86230176	RASSF9	0.47	7.47	0.43	1.36e-12	Major depressive disorder;
KIRP	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.36	0.32	1.94e-7	Coronary artery disease;
KIRP	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg19875535	chr5:140030758	IK	-0.57	-7.12	-0.41	1.18e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg27170947	chr2:26402098	FAM59B	-0.58	-6.5	-0.38	4.37e-10	Gut microbiome composition (summer);
KIRP	cis	rs17123764	0.892	rs7971369	chr12:50160056	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.9	0.35	1.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg22705602	chr4:152727874	NA	0.52	8.51	0.48	1.7e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg03957235	chr1:3512243	MEGF6	-0.38	-5.01	-0.3	1.05e-6	Plateletcrit;
KIRP	cis	rs6815814	0.808	rs7673348	chr4:38845198	G/A	cg06935464	chr4:38784597	TLR10	0.42	5.17	0.31	4.95e-7	Breast cancer;
KIRP	cis	rs2016266	0.819	rs7398228	chr12:53660285	T/C	cg16917193	chr12:54089295	NA	0.45	5.69	0.34	3.54e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	trans	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg06636001	chr8:8085503	FLJ10661	0.52	6.29	0.37	1.45e-9	Neuroticism;
KIRP	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg23387468	chr7:139079360	LUC7L2	0.3	5.21	0.32	4.02e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4638749	0.501	rs6708539	chr2:108745042	C/A	cg25838818	chr2:108905173	SULT1C2	-0.36	-5.62	-0.34	5.2100000000000003e-08	Blood pressure;
KIRP	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg17554472	chr22:41940697	POLR3H	-0.43	-5.31	-0.32	2.41e-7	Neuroticism;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg01287788	chr2:86362935	SNORD94;PTCD3	-0.46	-6.22	-0.37	2.13e-9	Bladder cancer;
KIRP	cis	rs7119167	0.686	rs7936102	chr11:73044215	T/C	cg17517138	chr11:73019481	ARHGEF17	0.46	4.96	0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg08807101	chr21:30365312	RNF160	-0.58	-5.8	-0.35	1.98e-8	Cognitive test performance;
KIRP	cis	rs55692468	1.000	rs55692468	chr2:153361375	T/G	cg04681845	chr2:153283485	FMNL2	0.42	5.29	0.32	2.67e-7	Intraocular pressure;
KIRP	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.59	7.52	0.43	1.02e-12	Aortic root size;
KIRP	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.99	-0.5	6.72e-17	Retinal vascular caliber;
KIRP	cis	rs10924309	0.889	rs10924307	chr1:245858125	C/T	cg00036263	chr1:245852353	KIF26B	-0.5	-6.56	-0.39	3.12e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs7712401	0.607	rs246270	chr5:122258649	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs731174	0.592	rs6699887	chr1:38192604	G/A	cg12658694	chr1:38397304	INPP5B	-0.44	-4.92	-0.3	1.61e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.0	-0.45	4.86e-14	Alzheimer's disease;
KIRP	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-5.1	-0.31	6.77e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.75	11.04	0.58	2.73e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg03647239	chr10:116582469	FAM160B1	0.52	5.95	0.35	9.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs16828019	0.852	rs12044539	chr1:41661732	A/C	cg18742814	chr1:41828276	NA	0.66	5.77	0.35	2.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.48	-5.19	-0.31	4.5e-7	Body mass index (adult);
KIRP	trans	rs10772939	0.574	rs12830791	chr12:16598167	A/G	cg20863947	chr2:120124202	DBI;C2orf76	0.56	6.59	0.39	2.73e-10	Economic and political preferences;
KIRP	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg20312557	chr2:97357134	FER1L5	-0.7	-4.91	-0.3	1.66e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg04289385	chr6:36355825	ETV7	0.45	7.18	0.42	8.11e-12	Platelet distribution width;
KIRP	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.19	-0.51	1.68e-17	Total body bone mineral density;
KIRP	cis	rs1185460	1.000	rs1799993	chr11:118958127	A/C	cg23280166	chr11:118938394	VPS11	-0.65	-8.49	-0.48	1.98e-15	Coronary artery disease;
KIRP	cis	rs6545883	0.783	rs7355640	chr2:61845485	C/T	cg15711740	chr2:61764176	XPO1	-0.53	-6.95	-0.41	3.22e-11	Tuberculosis;
KIRP	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs10782582	0.758	rs5745546	chr1:76378038	G/A	cg10523679	chr1:76189770	ACADM	-0.35	-5.06	-0.31	8.36e-7	Daytime sleep phenotypes;
KIRP	trans	rs3858145	0.588	rs736535	chr10:70043916	G/A	cg04882175	chr6:131122610	NA	-0.59	-6.87	-0.4	5.21e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs1014246	1.000	rs1014244	chr10:118466150	C/T	cg14919929	chr10:118506882	NA	0.57	7.09	0.41	1.43e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs7215564	0.908	rs34785514	chr17:78661166	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs9859260	0.961	rs34221479	chr3:195798600	T/C	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.98	-0.3	1.17e-6	Mean corpuscular volume;
KIRP	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg01721255	chr8:58191610	C8orf71	0.6	5.53	0.33	8.12e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg12119029	chr16:89752879	CDK10	-0.29	-6.49	-0.38	4.72e-10	Vitiligo;
KIRP	cis	rs4780355	0.619	rs918737	chr16:11439639	T/C	cg00044050	chr16:11439710	C16orf75	-0.58	-6.69	-0.39	1.51e-10	Crohn's disease and psoriasis;
KIRP	cis	rs4954585	0.683	rs4452212	chr2:137015991	G/A	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.14e-13	Colorectal cancer;
KIRP	cis	rs959260	1.000	rs4789185	chr17:73383368	C/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13409248	chr3:40428643	ENTPD3	0.39	5.05	0.31	8.79e-7	Renal cell carcinoma;
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg18350739	chr11:68623251	NA	-0.52	-7.79	-0.44	1.92e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-13.51	-0.65	1.69e-31	Body mass index;
KIRP	cis	rs1816854	0.572	rs12226960	chr12:44213124	G/T	cg20956634	chr12:44200518	TWF1	0.59	5.21	0.32	4.08e-7	Inflammatory bowel disease;
KIRP	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.89	-12.97	-0.64	1.13e-29	Tonsillectomy;
KIRP	cis	rs3735025	0.892	rs7804988	chr7:137059860	T/C	cg13839563	chr7:136910420	NA	-0.43	-5.03	-0.31	9.37e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20307385	chr11:47447363	PSMC3	-0.51	-5.35	-0.32	2e-7	Subjective well-being;
KIRP	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg20368463	chr18:77673604	PQLC1	0.64	5.16	0.31	5.08e-7	Opioid sensitivity;
KIRP	cis	rs4658101	0.815	rs11165013	chr1:92051419	G/A	cg09075522	chr1:92031145	NA	0.46	5.55	0.33	7.23e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15557168	chr22:42548783	NA	-0.42	-5.42	-0.33	1.44e-7	Cognitive function;
KIRP	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg07936489	chr17:37558343	FBXL20	-0.5	-6.31	-0.37	1.28e-9	Asthma;
KIRP	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg23788917	chr6:8435910	SLC35B3	-0.46	-5.6	-0.34	5.78e-8	Motion sickness;
KIRP	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.54	-6.75	-0.4	1.07e-10	Urate levels in overweight individuals;
KIRP	trans	rs6902257	1.000	rs2503730	chr6:81320601	A/G	cg06063519	chr15:99274532	IGF1R	0.61	6.03	0.36	5.85e-9	Obesity-related traits;
KIRP	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg02725872	chr8:58115012	NA	-0.47	-5.69	-0.34	3.54e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.79	0.4	8.17e-11	Menarche (age at onset);
KIRP	cis	rs2274273	0.870	rs10144345	chr14:55847737	T/C	cg04306507	chr14:55594613	LGALS3	0.52	8.24	0.47	1.01e-14	Protein biomarker;
KIRP	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg03128060	chr6:142623767	GPR126	-0.37	-5.35	-0.32	2.04e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs35123781	1.000	rs9687282	chr5:139065988	T/G	cg10513866	chr5:139070639	NA	0.35	4.93	0.3	1.48e-6	Schizophrenia;
KIRP	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27343660	chr5:116289441	NA	-0.39	-6.03	-0.36	5.87e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg22800045	chr5:56110881	MAP3K1	0.73	7.84	0.45	1.38e-13	Initial pursuit acceleration;
KIRP	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs7011049	0.908	rs113206545	chr8:53858648	A/G	cg26025543	chr8:53854495	NA	0.75	7.42	0.43	1.91e-12	Systolic blood pressure;
KIRP	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.88	12.39	0.62	9.98e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.82	9.25	0.51	1.16e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.01	14.1	0.67	1.74e-33	Corneal structure;
KIRP	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg14972814	chr11:95582409	MTMR2	0.3	5.15	0.31	5.35e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.03	-0.31	9.45e-7	Carotid intima media thickness;
KIRP	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	6.87	0.4	5.09e-11	Joint mobility (Beighton score);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05329982	chr11:62359210	TUT1	0.49	6.74	0.39	1.13e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2594989	0.943	rs4365605	chr3:11452793	G/A	cg01796438	chr3:11312864	ATG7	-0.56	-7.27	-0.42	4.67e-12	Circulating chemerin levels;
KIRP	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.51	6.28	0.37	1.5e-9	Birth weight;
KIRP	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg21709803	chr11:61594965	FADS2	-0.46	-5.14	-0.31	5.51e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.57	-5.58	-0.34	6.19e-8	Skin colour saturation;
KIRP	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg13393036	chr8:95962371	TP53INP1	0.29	5.15	0.31	5.46e-7	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.48	5.66	0.34	4.18e-8	Menopause (age at onset);
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg24874828	chr4:187887005	NA	-0.44	-6.29	-0.37	1.48e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg21573476	chr21:45109991	RRP1B	-0.56	-7.33	-0.42	3.34e-12	Mean corpuscular volume;
KIRP	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg22437258	chr11:111473054	SIK2	0.59	6.75	0.4	1.08e-10	Primary sclerosing cholangitis;
KIRP	cis	rs1950626	0.662	rs72700538	chr14:101441911	C/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.86	0.4	5.45e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg04656015	chr13:113407548	ATP11A	-0.52	-5.08	-0.31	7.44e-7	Glycated hemoglobin levels;
KIRP	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	8.92	0.49	1.06e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg21905437	chr5:178450457	ZNF879	0.56	6.42	0.38	6.93e-10	Pubertal anthropometrics;
KIRP	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.66	9.11	0.5	2.88e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2120243	0.533	rs34263112	chr3:157056048	A/G	cg24825693	chr3:157122686	VEPH1	-0.38	-5.85	-0.35	1.53e-8	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.37	0.43	2.51e-12	Neuroticism;
KIRP	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg00204512	chr16:28754710	NA	0.49	6.5	0.38	4.54e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.38	-0.32	1.72e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs427941	0.703	rs201453	chr7:101739788	T/C	cg06246474	chr7:101738831	CUX1	0.54	6.71	0.39	1.36e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6838801	0.927	rs4623033	chr4:77517357	A/G	cg17476223	chr4:77663285	SHROOM3	0.52	7.28	0.42	4.59e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs2072732	0.861	rs12048975	chr1:2962225	T/C	cg11731671	chr1:2995604	PRDM16	-0.51	-5.74	-0.34	2.71e-8	Plateletcrit;
KIRP	cis	rs66696671	0.516	rs7098960	chr10:121338702	G/A	cg06765389	chr10:121379685	NA	-0.4	-5.31	-0.32	2.46e-7	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs7614311	0.639	rs73119035	chr3:63993966	A/G	cg09006292	chr3:64049408	NA	-0.57	-5.34	-0.32	2.11e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11987759	chr7:65425863	GUSB	-0.53	-7.05	-0.41	1.81e-11	Aortic root size;
KIRP	cis	rs72781680	0.611	rs78861366	chr2:24354428	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	5.04	0.31	9.21e-7	Lymphocyte counts;
KIRP	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg08975724	chr8:8085496	FLJ10661	-0.63	-7.78	-0.44	2.06e-13	Neuroticism;
KIRP	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg10223061	chr2:219282414	VIL1	0.4	6.38	0.38	8.62e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05665937	chr4:1216051	CTBP1	-0.43	-5.35	-0.32	2.02e-7	Obesity-related traits;
KIRP	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.24	-0.32	3.45e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	5.55	0.33	7.52e-8	Breast cancer;
KIRP	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.81	-10.81	-0.57	1.59e-22	Prostate cancer;
KIRP	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs77861329	1.000	rs9868101	chr3:52138377	T/C	cg08692210	chr3:52188851	WDR51A	0.95	7.63	0.44	5.21e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.5	7.63	0.44	5.27e-13	Testicular germ cell tumor;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00873521	chr9:95056130	IARS;SNORA84	0.64	7.79	0.44	1.91e-13	Smoking initiation;
KIRP	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg16141378	chr3:129829833	LOC729375	0.52	6.64	0.39	2.04e-10	Triglycerides;
KIRP	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.43	-5.6	-0.34	5.73e-8	QT interval;
KIRP	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.67	7.11	0.41	1.23e-11	Lymphocyte counts;
KIRP	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23598886	chr18:12777645	NA	0.73	6.03	0.36	5.96e-9	Inflammatory skin disease;
KIRP	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.62	11.28	0.58	4.72e-24	Total body bone mineral density;
KIRP	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.74	7.82	0.45	1.51e-13	Asthma;
KIRP	cis	rs580438	0.529	rs6442374	chr3:13409107	G/A	cg10657019	chr3:13328039	NA	-0.52	-6.79	-0.4	8.22e-11	Myringotomy;
KIRP	cis	rs7582720	0.775	rs72938351	chr2:204151503	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	7.27	0.42	4.78e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs131805	1.000	rs131805	chr22:50964153	T/C	cg25309564	chr22:51001381	C22orf41	0.55	5.17	0.31	4.75e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6545883	0.965	rs12713439	chr2:61752154	G/A	cg15711740	chr2:61764176	XPO1	-0.61	-8.29	-0.47	7.56e-15	Tuberculosis;
KIRP	cis	rs6977660	0.714	rs9969171	chr7:19827328	T/C	cg05791153	chr7:19748676	TWISTNB	0.61	5.96	0.36	8.57e-9	Thyroid stimulating hormone;
KIRP	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg04731861	chr2:219085781	ARPC2	0.3	7.65	0.44	4.53e-13	Colorectal cancer;
KIRP	cis	rs2223471	0.719	rs17608920	chr6:50773860	G/A	cg03432817	chr6:50765336	NA	-0.5	-8.23	-0.46	1.11e-14	Subcutaneous adipose tissue;
KIRP	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg08501292	chr6:25962987	TRIM38	0.79	5.38	0.32	1.74e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg02297831	chr4:17616191	MED28	-0.46	-5.7	-0.34	3.35e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.73	8.92	0.49	1.1e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.8	-0.35	1.99e-8	Colorectal cancer;
KIRP	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg09873164	chr1:152488093	CRCT1	0.58	7.25	0.42	5.54e-12	Hair morphology;
KIRP	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg14972814	chr11:95582409	MTMR2	0.35	5.78	0.35	2.3e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12476592	0.602	rs262526	chr2:63899478	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.94	-0.3	1.41e-6	Childhood ear infection;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08307612	chr20:62526785	DNAJC5	-0.58	-6.68	-0.39	1.62e-10	Menopause (age at onset);
KIRP	cis	rs9972944	0.756	rs8076925	chr17:63764616	A/C	cg07283582	chr17:63770753	CCDC46	-0.42	-7.0	-0.41	2.43e-11	Total body bone mineral density;
KIRP	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.68	7.42	0.43	1.95e-12	Smoking initiation;
KIRP	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg25173405	chr17:45401733	C17orf57	0.42	5.37	0.32	1.79e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.58	9.41	0.51	3.62e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03076246	chr16:67906784	EDC4	0.44	6.09	0.36	4.41e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9488822	0.662	rs536160	chr6:116267166	T/C	cg15226275	chr6:116381976	FRK	-0.2	-5.4	-0.33	1.56e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs28493229	1.000	rs28493229	chr19:41224204	G/C	cg21869046	chr19:41225005	ITPKC	0.56	6.54	0.38	3.49e-10	Kawasaki disease;
KIRP	cis	rs7084402	0.967	rs1658440	chr10:60323933	T/A	cg05938607	chr10:60274200	BICC1	-0.45	-11.15	-0.58	1.21e-23	Refractive error;
KIRP	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	1.06	18.76	0.77	2.46e-49	Bone mineral density;
KIRP	trans	rs2048656	0.634	rs13259344	chr8:9652000	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.0	0.41	2.47e-11	Schizophrenia;
KIRP	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg04837898	chr3:45731254	SACM1L	-0.36	-4.93	-0.3	1.55e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7224685	0.569	rs8067427	chr17:3997517	C/T	cg11204139	chr17:3907470	NA	0.54	5.17	0.31	4.86e-7	Type 2 diabetes;
KIRP	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.38	6.9	0.4	4.47e-11	Refractive error;
KIRP	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg18367735	chr17:79674897	NA	0.77	7.43	0.43	1.82e-12	Dental caries;
KIRP	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.63	-7.73	-0.44	2.72e-13	Neuroticism;
KIRP	cis	rs67478160	0.634	rs2144080	chr14:104258761	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.61	-8.0	-0.45	4.9e-14	Schizophrenia;
KIRP	cis	rs12496230	0.794	rs12635628	chr3:66859035	C/A	cg17646820	chr3:66848679	NA	0.4	6.56	0.39	3.18e-10	Type 2 diabetes;
KIRP	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.43	-5.08	-0.31	7.57e-7	Educational attainment;
KIRP	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	0.89	11.95	0.61	3.02e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.3	-0.42	3.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.47	-0.38	5.26e-10	Type 2 diabetes;
KIRP	cis	rs11997175	0.624	rs7388511	chr8:33735582	C/G	ch.8.33884649F	chr8:33765107	NA	0.58	6.47	0.38	5.38e-10	Body mass index;
KIRP	cis	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.3	-0.32	2.54e-7	Leprosy;
KIRP	cis	rs7187994	0.790	rs16974508	chr16:84781075	G/A	cg11201751	chr16:85158047	NA	0.47	4.85	0.3	2.22e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg25110126	chr1:46999211	NA	-0.45	-5.66	-0.34	4.22e-8	Monobrow;
KIRP	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	14.23	0.67	6.15e-34	Tonsillectomy;
KIRP	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs7929679	0.551	rs11032840	chr11:34779464	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	5.53	0.33	8.02e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.27	-0.42	4.83e-12	Type 2 diabetes;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.81	12.59	0.63	2.13e-28	Menarche (age at onset);
KIRP	cis	rs6589219	0.954	rs4520624	chr11:111172210	A/G	cg25129781	chr11:111156908	C11orf53	-0.5	-6.5	-0.38	4.46e-10	Colorectal cancer;
KIRP	cis	rs1165472	0.760	rs4453085	chr1:56127819	T/C	cg11523071	chr1:56160889	NA	-0.6	-7.55	-0.43	8.46e-13	Paclitaxel-induced neuropathy;
KIRP	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.21	-0.42	6.71e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg21775007	chr8:11205619	TDH	0.48	6.38	0.38	8.84e-10	Systolic blood pressure;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19531713	chr17:41277059	BRCA1;NBR2	0.51	6.99	0.41	2.59e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg21361702	chr7:150065534	REPIN1	0.55	5.85	0.35	1.59e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.86	-0.45	1.2e-13	Bipolar disorder;
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.83	-14.14	-0.67	1.27e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10203711	0.966	rs4998694	chr2:239564713	C/T	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12496230	0.700	rs13078081	chr3:66852901	T/C	cg17646820	chr3:66848679	NA	0.44	5.82	0.35	1.84e-8	Type 2 diabetes;
KIRP	cis	rs1440410	0.830	rs4690781	chr4:144180206	T/C	cg01719995	chr4:144104893	USP38	0.38	4.94	0.3	1.45e-6	Ischemic stroke;
KIRP	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.67	-9.27	-0.51	9.6e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.52	-7.97	-0.45	6.06e-14	Bone mineral density;
KIRP	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg11945507	chr8:142233382	SLC45A4	-0.65	-9.45	-0.52	2.75e-18	Immature fraction of reticulocytes;
KIRP	cis	rs698813	0.763	rs1067335	chr2:44625958	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.11	0.36	3.84e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg16309518	chr5:176445507	NA	-0.89	-13.82	-0.66	1.57e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15496005	chr11:110167562	RDX	0.49	6.1	0.36	4.05e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06481639	chr22:41940642	POLR3H	0.45	5.38	0.32	1.77e-7	Vitiligo;
KIRP	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg23594656	chr7:65796392	TPST1	-0.49	-7.45	-0.43	1.57e-12	Aortic root size;
KIRP	cis	rs7709377	0.597	rs11241374	chr5:115519754	T/C	cg23108291	chr5:115420582	COMMD10	0.4	4.85	0.3	2.15e-6	Metabolite levels  (X-11787);
KIRP	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7546094	1.000	rs6666579	chr1:113132393	A/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg19257562	chr1:2043853	PRKCZ	0.38	6.3	0.37	1.38e-9	Height;
KIRP	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.9	-0.49	1.25e-16	Blood trace element (Zn levels);
KIRP	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg07828024	chr6:149772892	ZC3H12D	0.32	5.37	0.32	1.82e-7	Dupuytren's disease;
KIRP	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13409248	chr3:40428643	ENTPD3	0.39	5.09	0.31	7.13e-7	Renal cell carcinoma;
KIRP	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.48	-6.37	-0.38	9.04e-10	Tuberculosis;
KIRP	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.43	-0.38	6.59e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.37	0.47	4.32e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-8.86	-0.49	1.64e-16	Platelet count;
KIRP	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg00074818	chr8:8560427	CLDN23	0.43	6.49	0.38	4.82e-10	Obesity-related traits;
KIRP	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.62	11.2	0.58	8.53e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg23307798	chr14:103986281	CKB	-0.41	-5.59	-0.34	6.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7568498	0.517	rs11678856	chr2:161925443	C/T	cg08807892	chr2:162101083	NA	-0.46	-5.39	-0.32	1.66e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg06740227	chr12:86229804	RASSF9	0.44	5.59	0.34	5.9e-8	Major depressive disorder;
KIRP	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.13	-0.5	2.5e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.87	-12.78	-0.63	5.22e-29	Total body bone mineral density;
KIRP	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.7	-0.34	3.37e-8	Menarche (age at onset);
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.59	-8.12	-0.46	2.29e-14	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07400246	chr11:64083702	ESRRA	-0.4	-6.08	-0.36	4.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.04	-0.31	8.88e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1847505	0.609	rs79087755	chr13:61482054	C/T	cg25164009	chr13:61490935	NA	0.54	5.69	0.34	3.59e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.53	-0.52	1.56e-18	Total body bone mineral density;
KIRP	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg24807547	chr6:37504484	NA	-0.55	-8.28	-0.47	7.7e-15	Cognitive performance;
KIRP	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-14.3	-0.67	3.55e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	12.0	0.61	2.03e-26	Multiple sclerosis;
KIRP	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg24565620	chr2:194026	NA	0.78	8.73	0.49	3.89e-16	Blood protein levels;
KIRP	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg04660111	chr19:49199234	FUT2	0.35	5.37	0.32	1.81e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	4.87	0.3	2.02e-6	Height;
KIRP	cis	rs2625529	0.713	rs12903980	chr15:72165549	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.03	-0.36	5.98e-9	Red blood cell count;
KIRP	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.21	0.51	1.46e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg20243544	chr17:37824526	PNMT	0.51	7.34	0.42	3.13e-12	Asthma;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.44	-5.14	-0.31	5.68e-7	Longevity;Endometriosis;
KIRP	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.4	5.56	0.33	6.95e-8	Endometrial cancer;
KIRP	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.8	-10.26	-0.55	8.87e-21	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6663390	0.831	rs2267894	chr1:208085735	G/A	cg00387621	chr1:208086895	NA	0.62	5.47	0.33	1.11e-7	Facial morphology (factor 18);
KIRP	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.52	7.04	0.41	1.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22576055	chr19:12777359	MORG1;MAN2B1	0.48	6.05	0.36	5.5e-9	Parkinson's disease;
KIRP	cis	rs600806	0.778	rs4970731	chr1:109995459	T/C	cg02175308	chr1:109941060	SORT1	-0.26	-4.85	-0.3	2.23e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.21	16.9	0.73	4.93e-43	Type 1 diabetes nephropathy;
KIRP	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.67	9.64	0.52	7.12e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.83	9.74	0.53	3.56e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-5.99	-0.36	7.33e-9	Mood instability;
KIRP	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.66	6.45	0.38	5.77e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10782582	0.609	rs80059220	chr1:76279112	G/T	cg03433033	chr1:76189801	ACADM	-0.42	-6.13	-0.36	3.49e-9	Daytime sleep phenotypes;
KIRP	cis	rs6723108	0.846	rs998451	chr2:135429288	G/A	cg12500956	chr2:135428796	TMEM163	-0.47	-6.05	-0.36	5.45e-9	Type 2 diabetes;
KIRP	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.5	5.85	0.35	1.55e-8	Mean platelet volume;
KIRP	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg07775547	chr4:1625484	NA	-0.43	-5.25	-0.32	3.35e-7	Bladder cancer;Urinary bladder cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03900353	chr1:212732456	NA	0.59	6.05	0.36	5.37e-9	Lung function (FEV1);
KIRP	cis	rs10997517	0.537	rs10822957	chr10:68769550	A/G	cg25104868	chr10:69634168	NA	0.46	4.88	0.3	1.91e-6	Migraine without aura;
KIRP	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.81	8.33	0.47	5.63e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg16867584	chr19:49200180	FUT2	0.31	4.96	0.3	1.33e-6	Dietary macronutrient intake;
KIRP	cis	rs17030434	0.749	rs1125228	chr4:154769052	C/T	cg14289246	chr4:154710475	SFRP2	-0.58	-7.53	-0.43	9.81e-13	Electrocardiographic conduction measures;
KIRP	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.62	9.61	0.52	9.05e-19	Bone mineral density;
KIRP	cis	rs4141404	0.577	rs2413045	chr22:31665862	A/G	cg22777020	chr22:31556080	RNF185	-0.62	-5.15	-0.31	5.42e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.72	11.85	0.6	6.53e-26	Obesity (extreme);
KIRP	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	7.47	0.43	1.4e-12	Coronary artery disease;
KIRP	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg21926883	chr2:100939477	LONRF2	-0.57	-7.88	-0.45	1.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-6.86	-0.4	5.57e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.8	12.39	0.62	9.89e-28	Coronary artery disease;
KIRP	cis	rs830233	0.954	rs830234	chr5:165403967	C/T	cg13976338	chr5:165423657	NA	-0.6	-6.26	-0.37	1.66e-9	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs1978968	0.763	rs5992137	chr22:18457986	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.75	-10.52	-0.56	1.28e-21	Presence of antiphospholipid antibodies;
KIRP	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.48	-0.38	4.84e-10	Urinary tract infection frequency;
KIRP	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.51	-0.38	4.28e-10	Triglycerides;
KIRP	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs7015630	0.603	rs2189025	chr8:90849184	G/A	cg18493113	chr8:90847772	NA	-0.43	-4.96	-0.3	1.29e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg07870213	chr5:140052090	DND1	0.62	7.51	0.43	1.08e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09699651	chr6:150184138	LRP11	-0.59	-8.16	-0.46	1.79e-14	Testicular germ cell tumor;
KIRP	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.46	-0.38	5.42e-10	IgG glycosylation;
KIRP	cis	rs11997175	0.646	rs67480501	chr8:33736315	C/T	cg04338863	chr8:33670619	NA	0.49	6.4	0.38	7.76e-10	Body mass index;
KIRP	cis	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg00405596	chr8:11794950	NA	-0.53	-6.56	-0.39	3.14e-10	Triglycerides;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.5	-6.05	-0.36	5.23e-9	Longevity;Endometriosis;
KIRP	cis	rs6909279	0.522	rs7741872	chr6:151893946	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.39	-5.01	-0.3	1.03e-6	Bone mineral density;
KIRP	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg21775007	chr8:11205619	TDH	0.44	5.97	0.36	8.43e-9	Neuroticism;
KIRP	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.18	0.31	4.7e-7	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14199148	chr13:52158669	WDFY2	0.5	6.13	0.36	3.4e-9	Parkinson's disease;
KIRP	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.88	12.59	0.63	2.22e-28	Mean platelet volume;
KIRP	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	11.12	0.58	1.56e-23	Post bronchodilator FEV1;
KIRP	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg01529538	chr14:23388837	RBM23	0.41	5.14	0.31	5.64e-7	Cognitive ability (multi-trait analysis);
KIRP	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.3	25.75	0.85	8.84e-72	IgG glycosylation;
KIRP	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg13319975	chr6:146136371	FBXO30	0.49	7.14	0.41	1.03e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.2	-5.05	-0.31	8.49e-7	Primary biliary cholangitis;
KIRP	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg26338869	chr17:61819248	STRADA	0.54	6.47	0.38	5.26e-10	Prudent dietary pattern;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg12461364	chr10:12084985	UPF2	0.47	6.15	0.37	3.12e-9	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg18306943	chr3:40428807	ENTPD3	-0.39	-5.42	-0.33	1.39e-7	Renal cell carcinoma;
KIRP	cis	rs7534824	0.625	rs12569251	chr1:101372040	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.84	7.07	0.41	1.59e-11	Refractive astigmatism;
KIRP	cis	rs9400467	0.528	rs1989574	chr6:111728533	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.58	-0.34	6.32e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1408224	0.688	rs866376	chr13:47230865	A/G	cg04092803	chr13:47240378	LRCH1	-0.65	-6.06	-0.36	5.1e-9	QRS complex (12-leadsum);
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13939156	chr17:80058883	NA	-0.5	-7.55	-0.43	8.49e-13	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09660584	chr15:64388147	SNX1	0.55	6.9	0.4	4.43e-11	Parkinson's disease;
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.7	9.39	0.51	4.14e-18	Longevity;
KIRP	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	trans	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.98e-12	Bladder cancer;
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.15e-7	Life satisfaction;
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg25487775	chr2:162093969	NA	0.45	6.04	0.36	5.75e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.47	-0.43	1.41e-12	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.57	-7.41	-0.43	1.99e-12	Aortic root size;
KIRP	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg23587288	chr2:27483067	SLC30A3	-0.58	-7.01	-0.41	2.31e-11	Blood metabolite levels;
KIRP	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.42	-5.43	-0.33	1.38e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.75	9.21	0.51	1.44e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.78	9.87	0.53	1.38e-19	Corneal astigmatism;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.48	-6.55	-0.39	3.32e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg18306943	chr3:40428807	ENTPD3	-0.44	-6.01	-0.36	6.67e-9	Renal cell carcinoma;
KIRP	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.42	0.47	3.25e-15	Morning vs. evening chronotype;
KIRP	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.52	-6.75	-0.4	1.05e-10	Schizophrenia;
KIRP	cis	rs2729354	0.768	rs1001956	chr11:57266949	C/G	cg24343310	chr11:57249947	NA	0.28	5.18	0.31	4.64e-7	Blood protein levels;
KIRP	cis	rs2299587	0.554	rs3853531	chr8:17748920	C/T	cg01800426	chr8:17659068	MTUS1	0.44	5.24	0.32	3.39e-7	Economic and political preferences;
KIRP	cis	rs2299587	0.610	rs6987474	chr8:17773298	T/C	cg01800426	chr8:17659068	MTUS1	-0.62	-7.37	-0.43	2.62e-12	Economic and political preferences;
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.69	8.17	0.46	1.64e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.77	9.18	0.51	1.83e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.45	-0.38	5.76e-10	Aortic root size;
KIRP	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg07827796	chr19:33622959	WDR88	0.45	5.5	0.33	9.73e-8	Colorectal cancer;
KIRP	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg05370193	chr1:21551575	ECE1	0.5	6.81	0.4	7.42e-11	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.95	11.05	0.58	2.64e-23	Corneal astigmatism;
KIRP	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.62	8.24	0.47	1.02e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg06521331	chr12:34319734	NA	-0.48	-5.99	-0.36	7.26e-9	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14826516	chr22:50639351	SELO	0.48	6.69	0.39	1.47e-10	Survival in pancreatic cancer;
KIRP	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.24	-0.32	3.5e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.43	-6.05	-0.36	5.49e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg00405596	chr8:11794950	NA	0.45	5.84	0.35	1.61e-8	Retinal vascular caliber;
KIRP	cis	rs490234	0.966	rs631287	chr9:128412676	G/A	cg14078157	chr9:128172775	NA	0.39	4.94	0.3	1.45e-6	Mean arterial pressure;
KIRP	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg17644776	chr2:200775616	C2orf69	0.56	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.2	-0.42	7.37e-12	Morning vs. evening chronotype;
KIRP	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.91	-11.46	-0.59	1.19e-24	Response to antineoplastic agents;
KIRP	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg15038512	chr6:170123185	PHF10	0.46	5.02	0.3	9.95e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	4.98	0.3	1.19e-6	Diabetic retinopathy;
KIRP	cis	rs6001982	0.667	rs6001932	chr22:40877635	C/A	cg07138101	chr22:40742427	ADSL	0.81	7.25	0.42	5.54e-12	Breast cancer;
KIRP	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg04673462	chr1:38461896	NA	0.4	5.3	0.32	2.64e-7	Coronary artery disease;
KIRP	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg21475434	chr5:93447410	FAM172A	-0.44	-5.08	-0.31	7.44e-7	Diabetic retinopathy;
KIRP	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.23	0.42	5.93e-12	Mean corpuscular volume;
KIRP	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg17691542	chr6:26056736	HIST1H1C	0.43	5.62	0.34	5.03e-8	Schizophrenia;
KIRP	cis	rs6142102	0.886	rs6059583	chr20:32532114	T/G	cg08999081	chr20:33150536	PIGU	0.51	5.85	0.35	1.6e-8	Skin pigmentation;
KIRP	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.16	-0.37	2.87e-9	Breast cancer;
KIRP	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.03	14.12	0.67	1.48e-33	Response to antipsychotic treatment;
KIRP	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.64	7.86	0.45	1.21e-13	Vitiligo;
KIRP	cis	rs5753037	0.653	rs131265	chr22:30145591	C/T	cg01021169	chr22:30184971	ASCC2	-0.45	-6.25	-0.37	1.84e-9	Type 1 diabetes;
KIRP	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg01990225	chr2:97406019	LMAN2L	-0.99	-6.99	-0.41	2.53e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2797160	0.904	rs1739366	chr6:126007409	T/C	cg05901451	chr6:126070800	HEY2	0.41	5.78	0.35	2.26e-8	Endometrial cancer;
KIRP	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg16691251	chr5:66510806	NA	0.43	5.62	0.34	5.03e-8	Breast cancer;
KIRP	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg04539111	chr16:67997858	SLC12A4	-0.55	-5.5	-0.33	9.54e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.54	4.97	0.3	1.26e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14898223	chr2:190447407	NA	0.33	6.24	0.37	1.94e-9	Survival in pancreatic cancer;
KIRP	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.66	-9.09	-0.5	3.33e-17	Rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23130739	chr14:100563887	EVL	0.46	6.17	0.37	2.85e-9	Interleukin-4 levels;
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.73	-8.57	-0.48	1.14e-15	Longevity;Endometriosis;
KIRP	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg02002194	chr4:3960332	NA	-0.45	-6.73	-0.39	1.19e-10	Mood instability;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.78	12.59	0.63	2.25e-28	Longevity;Endometriosis;
KIRP	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg23803603	chr1:2058230	PRKCZ	0.4	5.69	0.34	3.64e-8	Height;
KIRP	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.47	6.09	0.36	4.25e-9	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg10729496	chr3:10149963	C3orf24	0.53	4.86	0.3	2.06e-6	Alzheimer's disease;
KIRP	cis	rs41308713	0.681	rs8116426	chr20:37034643	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.33	8.08	0.46	3.01e-14	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2625529	0.878	rs4777478	chr15:72279085	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-6.13	-0.36	3.48e-9	Red blood cell count;
KIRP	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.6	-9.33	-0.51	6.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20135002	chr11:47629003	NA	-0.44	-4.95	-0.3	1.37e-6	Subjective well-being;
KIRP	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.37	-5.42	-0.33	1.42e-7	Monocyte count;
KIRP	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg15327641	chr2:3715039	ALLC	0.42	5.19	0.31	4.42e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs8523	0.901	rs61624919	chr6:10997823	G/A	cg13562911	chr6:11044106	ELOVL2	0.41	5.35	0.32	2.01e-7	Red blood cell fatty acid levels;
KIRP	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.63	-6.58	-0.39	2.82e-10	Gut microbiome composition (summer);
KIRP	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02877538	chr11:3013651	NAP1L4	0.52	6.45	0.38	5.81e-10	Parkinson's disease;
KIRP	cis	rs7106204	0.920	rs7946615	chr11:24221036	T/C	ch.11.24196551F	chr11:24239977	NA	0.82	8.76	0.49	3.27e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4771122	0.697	rs1475220	chr13:28037448	G/C	cg22138327	chr13:27999177	GTF3A	-0.62	-6.24	-0.37	1.9e-9	Body mass index;
KIRP	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17691542	chr6:26056736	HIST1H1C	0.53	6.67	0.39	1.72e-10	Height;
KIRP	cis	rs73193808	0.590	rs9982010	chr21:30568176	G/A	cg03476357	chr21:30257390	N6AMT1	0.45	5.05	0.31	8.5e-7	Coronary artery disease;
KIRP	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg01988459	chr11:68622903	NA	-0.35	-4.84	-0.3	2.26e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg11204139	chr17:3907470	NA	0.6	8.34	0.47	5.36e-15	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.53	0.33	8.12e-8	Lung cancer;
KIRP	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.59	-7.22	-0.42	6.64e-12	Aortic root size;
KIRP	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.4	-0.55	3.23e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg13453750	chr1:205783389	SLC41A1	-0.49	-7.22	-0.42	6.38e-12	Menarche (age at onset);
KIRP	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg05315796	chr3:52349193	DNAH1	-0.4	-6.37	-0.38	9.39e-10	Bipolar disorder;
KIRP	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	15.41	0.7	5.67e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg13444842	chr1:152974279	SPRR3	-0.38	-5.56	-0.33	6.9e-8	Inflammatory skin disease;
KIRP	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs7007076	0.808	rs28585458	chr8:124718580	G/A	cg00283535	chr8:124749564	ANXA13	0.6	6.78	0.4	9.11e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs17102884	0.587	rs6574190	chr14:75167015	G/A	cg08847533	chr14:75593920	NEK9	0.44	5.06	0.31	8.02e-7	Neuroticism;
KIRP	cis	rs16912285	0.585	rs11027807	chr11:24346556	G/T	ch.11.24196551F	chr11:24239977	NA	0.65	5.83	0.35	1.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs2458413	0.500	rs2458418	chr8:105350851	A/G	cg08657449	chr8:105351661	TM7SF4	-0.37	-5.86	-0.35	1.48e-8	Paget's disease;
KIRP	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06481639	chr22:41940642	POLR3H	-0.44	-5.31	-0.32	2.42e-7	Vitiligo;
KIRP	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg26695010	chr11:65641043	EFEMP2	0.51	5.1	0.31	6.88e-7	Crohn's disease;
KIRP	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.93	-0.49	1.04e-16	Resting heart rate;
KIRP	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26002218	chr14:103986227	CKB	0.28	5.32	0.32	2.37e-7	Body mass index;
KIRP	cis	rs400736	0.859	rs379920	chr1:8028865	G/C	cg25007680	chr1:8021821	PARK7	0.64	8.65	0.48	6.92e-16	Response to antidepressants and depression;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02685901	chr6:43597772	MAD2L1BP;GTPBP2	0.54	6.35	0.38	1.03e-9	Smoking initiation;
KIRP	cis	rs33912345	0.695	rs1254288	chr14:60861885	C/G	cg27398547	chr14:60952738	C14orf39	-0.39	-5.12	-0.31	6.21e-7	Glaucoma (high intraocular pressure);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06808467	chr18:5237767	LOC339290;C18orf18	-0.5	-6.84	-0.4	6.42e-11	Myopia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13951862	chr9:139425582	NOTCH1	0.46	6.66	0.39	1.81e-10	Survival in pancreatic cancer;
KIRP	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg09873164	chr1:152488093	CRCT1	-0.48	-5.89	-0.35	1.28e-8	Hair morphology;
KIRP	cis	rs1021993	0.545	rs80311419	chr1:209547418	T/G	cg24446417	chr1:209558027	NA	-0.49	-5.27	-0.32	2.99e-7	Gut microbiome composition (winter);
KIRP	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.43	-5.21	-0.32	4.04e-7	IgG glycosylation;
KIRP	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg20368463	chr18:77673604	PQLC1	-0.6	-7.95	-0.45	6.62e-14	Schizophrenia;
KIRP	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg08738300	chr3:44038990	NA	0.68	9.55	0.52	1.34e-18	Coronary artery disease;
KIRP	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg23335576	chr14:104009727	NA	0.39	5.69	0.34	3.58e-8	Body mass index;
KIRP	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	1.0	14.59	0.68	3.71e-35	Cognitive function;
KIRP	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-0.66	-6.34	-0.37	1.1e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14169450	chr9:139327907	INPP5E	0.51	7.57	0.43	7.3e-13	Monocyte percentage of white cells;
KIRP	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg18806923	chr11:75486296	DGAT2	-0.47	-6.09	-0.36	4.35e-9	Protein C levels;
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-6.29	-0.37	1.47e-9	Lung cancer;
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.41	-0.33	1.46e-7	Longevity;
KIRP	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg19875535	chr5:140030758	IK	0.62	8.66	0.48	6.45e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	trans	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg06521331	chr12:34319734	NA	0.57	6.75	0.4	1.08e-10	Bladder cancer;
KIRP	cis	rs4727443	0.966	rs66748925	chr7:99589843	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.41	5.45	0.33	1.22e-7	Interstitial lung disease;
KIRP	cis	rs9308731	1.000	rs13396983	chr2:111900598	A/G	cg23466623	chr2:111982296	NA	-0.44	-5.51	-0.33	9e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-10.84	-0.57	1.24e-22	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg22437258	chr11:111473054	SIK2	0.66	7.99	0.45	5.16e-14	Primary sclerosing cholangitis;
KIRP	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg24253500	chr15:84953950	NA	0.49	5.38	0.32	1.74e-7	Schizophrenia;
KIRP	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.8	-10.59	-0.56	7.82e-22	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg24565620	chr2:194026	NA	0.72	7.71	0.44	3.05e-13	Blood protein levels;
KIRP	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-6.97	-0.41	2.94e-11	Tonsillectomy;
KIRP	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.6	-8.5	-0.48	1.81e-15	Total body bone mineral density;
KIRP	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	cis	rs6991838	0.584	rs1053085	chr8:66515988	C/T	cg13398993	chr8:66546079	ARMC1	-0.44	-5.08	-0.31	7.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs4447963	chr5:74376309	A/C	cg03227963	chr5:74354835	NA	0.4	5.76	0.34	2.53e-8	Response to amphetamines;
KIRP	cis	rs7017914	0.967	rs17688313	chr8:71683864	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	0.4	4.99	0.3	1.16e-6	Bone mineral density;
KIRP	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20135002	chr11:47629003	NA	-0.48	-5.82	-0.35	1.87e-8	Subjective well-being;
KIRP	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.81	7.79	0.44	1.83e-13	Menopause (age at onset);
KIRP	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	1.06	20.81	0.8	3.66e-56	Parkinson's disease;
KIRP	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg00129232	chr17:37814104	STARD3	-0.49	-6.19	-0.37	2.43e-9	Self-reported allergy;
KIRP	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.1	0.61	9.4e-27	Bladder cancer;
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg08807892	chr2:162101083	NA	0.64	8.8	0.49	2.5e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7221595	0.825	rs12450845	chr17:3972784	G/A	cg09597638	chr17:3907349	NA	0.57	5.81	0.35	1.92e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg01879757	chr17:41196368	BRCA1	-0.79	-11.25	-0.58	6e-24	Menopause (age at onset);
KIRP	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.65	-7.11	-0.41	1.27e-11	DNA methylation (variation);
KIRP	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg05709478	chr1:6581295	PLEKHG5	0.61	5.48	0.33	1.05e-7	Body mass index;
KIRP	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.55	-7.43	-0.43	1.74e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	1.21	8.69	0.48	5.34e-16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg03605463	chr16:89740564	NA	0.49	6.47	0.38	5.27e-10	Hemoglobin concentration;
KIRP	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14159672	chr1:205819179	PM20D1	-0.46	-5.09	-0.31	7.04e-7	Parkinson's disease;
KIRP	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.76	10.68	0.56	3.99e-22	Body mass index;
KIRP	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs12780845	0.558	rs7090965	chr10:17216803	A/G	cg01003015	chr10:17271136	VIM	0.47	6.16	0.37	2.97e-9	Homocysteine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23493127	chr6:144164392	LTV1	0.54	7.14	0.41	1.06e-11	Parkinson's disease;
KIRP	trans	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.18	0.37	2.66e-9	Mean corpuscular volume;
KIRP	cis	rs365132	0.870	rs2454949	chr5:176466011	G/A	cg16309518	chr5:176445507	NA	-0.88	-13.52	-0.65	1.67e-31	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs3789045	1.000	rs3789045	chr1:204586812	C/T	cg18185008	chr1:204589407	LRRN2	-0.67	-7.47	-0.43	1.36e-12	Educational attainment (college completion);
KIRP	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.41	5.1	0.31	6.85e-7	Neutrophil percentage of white cells;
KIRP	cis	rs11671005	0.611	rs56026876	chr19:59006157	G/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.55	-5.83	-0.35	1.72e-8	Mean platelet volume;
KIRP	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25517755	chr10:38738941	LOC399744	-0.52	-7.14	-0.41	1.05e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.99	-0.41	2.62e-11	Monocyte count;
KIRP	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17554472	chr22:41940697	POLR3H	0.62	6.78	0.4	9.12e-11	Vitiligo;
KIRP	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.9	12.09	0.61	1.05e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs867371	1.000	rs7166570	chr15:82466221	C/T	cg00614314	chr15:82944287	LOC80154	0.54	6.46	0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2224391	0.628	rs766340	chr6:5243521	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.11	-0.36	3.81e-9	Height;
KIRP	cis	rs2651899	0.902	rs1798246	chr1:3080855	A/C	cg01413848	chr1:3081226	PRDM16	0.4	5.48	0.33	1.03e-7	Migraine;
KIRP	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.54	6.63	0.39	2.14e-10	Height;
KIRP	cis	rs10782582	0.934	rs11161854	chr1:76369617	C/T	cg10523679	chr1:76189770	ACADM	-0.38	-5.63	-0.34	5.01e-8	Daytime sleep phenotypes;
KIRP	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.56	-6.84	-0.4	6.16e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.62	-6.44	-0.38	6.31e-10	Eotaxin levels;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.46	5.97	0.36	8.36e-9	Life satisfaction;
KIRP	cis	rs9810890	1.000	rs73196987	chr3:128453382	A/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg00864860	chr1:7907996	UTS2	-0.53	-6.06	-0.36	5.05e-9	Crohn's disease;
KIRP	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-6.51	-0.38	4.1e-10	Monocyte count;
KIRP	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.3	-0.32	2.53e-7	Neuroticism;
KIRP	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.61	7.93	0.45	7.49e-14	Vitiligo;
KIRP	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.35	-0.38	1.01e-9	Coronary artery disease;
KIRP	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.59	0.44	6.6e-13	Major depressive disorder;
KIRP	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.25	-0.47	9.38e-15	Retinal vascular caliber;
KIRP	cis	rs259842	0.584	rs1480706	chr2:180708907	G/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.43	-5.76	-0.34	2.56e-8	Blood protein levels;
KIRP	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg00806126	chr19:22604979	ZNF98	0.63	6.66	0.39	1.79e-10	Pain;
KIRP	cis	rs7258465	1.000	rs7251653	chr19:18608283	C/T	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.96	-0.35	8.91e-9	Breast cancer;
KIRP	trans	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.66	-0.39	1.8e-10	Neuroticism;
KIRP	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.02	0.46	4.34e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs35661897	0.920	rs12469727	chr2:227301483	A/G	cg03426602	chr2:227312417	NA	0.57	7.06	0.41	1.7e-11	Urinary tract infection frequency;
KIRP	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.44	-5.03	-0.31	9.66e-7	Initial pursuit acceleration;
KIRP	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	Neuroticism;
KIRP	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg10223061	chr2:219282414	VIL1	0.33	5.53	0.33	8.31e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg00405596	chr8:11794950	NA	-0.5	-6.59	-0.39	2.59e-10	Triglycerides;
KIRP	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg24253500	chr15:84953950	NA	0.64	7.08	0.41	1.55e-11	Schizophrenia;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg18661731	chr18:59854239	PIGN;KIAA1468	-0.44	-6.24	-0.37	1.88e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03934478	chr11:495069	RNH1	0.86	6.97	0.41	2.95e-11	Body mass index;
KIRP	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs2041895	0.565	rs10861679	chr12:107322915	T/C	cg21360079	chr12:107162445	NA	-0.44	-4.94	-0.3	1.46e-6	Glaucoma (low intraocular pressure);
KIRP	trans	rs2018683	0.932	rs4386882	chr7:28989270	C/T	cg19402173	chr7:128379420	CALU	-0.66	-8.9	-0.49	1.27e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.79	9.3	0.51	8.09e-18	Bronchopulmonary dysplasia;
KIRP	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.92	-0.4	3.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06481639	chr22:41940642	POLR3H	0.77	7.84	0.45	1.33e-13	Vitiligo;
KIRP	cis	rs13082711	0.911	rs7637211	chr3:27419868	C/T	cg02860705	chr3:27208620	NA	0.57	7.68	0.44	3.65e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9815354	0.812	rs73071222	chr3:41986896	C/T	cg03022575	chr3:42003672	ULK4	0.8	8.3	0.47	6.83e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg23682824	chr7:23144976	KLHL7	0.44	5.27	0.32	3e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07859478	chr19:808116	PTBP1	0.59	6.94	0.4	3.44e-11	Interleukin-4 levels;
KIRP	cis	rs7127900	0.500	rs67798996	chr11:2233603	A/G	cg25635251	chr11:2234043	NA	0.44	6.99	0.41	2.53e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs3748682	0.861	rs12563037	chr1:38258644	C/G	cg12658694	chr1:38397304	INPP5B	-0.54	-5.94	-0.35	9.77e-9	Hypothyroidism;
KIRP	cis	rs2594989	0.652	rs346089	chr3:11234717	C/T	cg01796438	chr3:11312864	ATG7	-0.51	-5.24	-0.32	3.43e-7	Circulating chemerin levels;
KIRP	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg13293535	chr8:11597251	GATA4	-0.42	-5.45	-0.33	1.25e-7	Retinal vascular caliber;
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.62e-9	Lung cancer;
KIRP	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg04289385	chr6:36355825	ETV7	0.39	5.24	0.32	3.51e-7	Platelet distribution width;
KIRP	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg09165964	chr15:75287851	SCAMP5	-0.88	-8.47	-0.48	2.24e-15	Lung cancer;
KIRP	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02359409	chr6:42947317	PEX6	0.39	5.4	0.33	1.58e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.02	-0.31	9.77e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs73200209	0.744	rs10507269	chr12:116560327	A/T	cg01776926	chr12:116560359	MED13L	-0.52	-5.92	-0.35	1.07e-8	Total body bone mineral density;
KIRP	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.3	4.98	0.3	1.19e-6	Electrocardiographic conduction measures;
KIRP	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg14673194	chr17:80132900	CCDC57	-0.64	-7.0	-0.41	2.47e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2742234	0.910	rs2505505	chr10:43648221	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.54	-6.72	-0.39	1.22e-10	Hirschsprung disease;
KIRP	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.33	0.32	2.25e-7	Menopause (age at onset);
KIRP	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Bladder cancer;
KIRP	cis	rs1018697	1.000	rs7909612	chr10:104561456	G/A	cg04362960	chr10:104952993	NT5C2	0.51	6.15	0.36	3.16e-9	Colorectal adenoma (advanced);
KIRP	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg19847130	chr8:10466454	RP1L1	0.36	5.33	0.32	2.24e-7	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23614835	chr12:91363837	EPYC	-0.41	-6.44	-0.38	6.25e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg03711944	chr11:47377212	SPI1	-0.3	-4.97	-0.3	1.28e-6	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7173743	0.967	rs28580532	chr15:79134724	C/T	cg00079375	chr15:79125835	NA	-0.41	-5.83	-0.35	1.7e-8	Coronary artery disease;
KIRP	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg15128208	chr22:42549153	NA	0.54	5.95	0.35	9.22e-9	Birth weight;
KIRP	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg25008857	chr14:105974488	NA	0.44	4.91	0.3	1.68e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg24579218	chr15:68104479	NA	-0.6	-9.98	-0.54	6.29e-20	Restless legs syndrome;
KIRP	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg20891283	chr12:69753455	YEATS4	0.64	6.71	0.39	1.32e-10	Response to diuretic therapy;
KIRP	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.89	0.4	4.52e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	10.06	0.54	3.6e-20	Total body bone mineral density;
KIRP	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg05220968	chr6:146057943	EPM2A	-0.43	-5.64	-0.34	4.74e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.15	-0.64	2.95e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg01346077	chr3:125931526	NA	0.5	7.94	0.45	7.38e-14	Plasma homocysteine levels (post-methionine load test);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg15629134	chr6:43027399	KLC4;MRPL2	0.49	6.18	0.37	2.57e-9	Colorectal cancer;
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg13939156	chr17:80058883	NA	-0.5	-7.51	-0.43	1.06e-12	Life satisfaction;
KIRP	cis	rs10114408	0.959	rs1890380	chr9:96665812	G/A	cg14598338	chr9:96623480	NA	-0.32	-4.86	-0.3	2.1e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs62229266	0.773	rs878606	chr21:37406692	G/A	cg12218747	chr21:37451666	NA	-0.44	-5.45	-0.33	1.23e-7	Mitral valve prolapse;
KIRP	cis	rs2120243	0.539	rs9990136	chr3:157075834	C/T	cg24825693	chr3:157122686	VEPH1	-0.54	-8.21	-0.46	1.28e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.69	-7.71	-0.44	3.09e-13	Obesity-related traits;
KIRP	cis	rs11158198	0.643	rs980468	chr14:58586031	C/T	cg15908186	chr14:58618357	C14orf37	0.44	5.61	0.34	5.42e-8	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.51	7.07	0.41	1.59e-11	Mean corpuscular volume;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.51	-0.43	1.08e-12	Platelet count;
KIRP	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.68	8.27	0.47	8.48e-15	Aortic root size;
KIRP	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.74	7.52	0.43	1.05e-12	Lymphocyte counts;
KIRP	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg11211951	chr8:145729740	GPT	0.45	7.47	0.43	1.35e-12	Age at first birth;
KIRP	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.11	0.36	3.95e-9	Retinal vascular caliber;
KIRP	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.03	-0.31	9.5e-7	Bipolar disorder;
KIRP	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.77	11.62	0.6	3.47e-25	Metabolite levels;
KIRP	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.47	-7.01	-0.41	2.32e-11	Vitamin D levels;
KIRP	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg25486957	chr4:152246857	NA	-0.55	-5.94	-0.35	9.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.77	9.83	0.53	1.84e-19	Aortic root size;
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.51	5.0	0.3	1.1e-6	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12210905	1.000	rs5030958	chr6:27214257	G/C	cg11502198	chr6:26597334	ABT1	-0.85	-5.32	-0.32	2.34e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs17030434	1.000	rs12651051	chr4:154722114	A/G	cg14289246	chr4:154710475	SFRP2	-0.8	-9.68	-0.53	5.45e-19	Electrocardiographic conduction measures;
KIRP	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.81	0.4	7.62e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4849845	0.889	rs17050090	chr2:121054868	G/C	cg24070213	chr2:121070622	NA	0.4	5.47	0.33	1.11e-7	Mean platelet volume;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.82	-0.35	1.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.03	0.41	2.04e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.61	-9.79	-0.53	2.44e-19	Sense of smell;
KIRP	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-6.9	-0.4	4.31e-11	Menopause (age at onset);
KIRP	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg08975724	chr8:8085496	FLJ10661	0.65	8.17	0.46	1.58e-14	Neuroticism;
KIRP	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	0.84	6.23	0.37	2e-9	IgG glycosylation;
KIRP	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	cis	rs240764	0.717	rs1039032	chr6:101161931	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-4.9	-0.3	1.77e-6	Neuroticism;
KIRP	cis	rs6016377	0.689	rs6029183	chr20:39181070	C/G	cg06665391	chr20:39312290	NA	0.41	5.04	0.31	8.92e-7	Birth weight;
KIRP	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.83	-10.08	-0.54	3.25e-20	Blood protein levels;
KIRP	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg12454167	chr3:186435060	KNG1	0.53	9.2	0.51	1.6e-17	Blood protein levels;
KIRP	cis	rs9290877	0.552	rs9832630	chr3:188474832	C/T	cg17392043	chr3:188495102	LPP	-0.54	-7.04	-0.41	1.95e-11	IgE levels;
KIRP	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg21573476	chr21:45109991	RRP1B	-0.53	-6.98	-0.41	2.71e-11	Mean corpuscular volume;
KIRP	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.58	-6.78	-0.4	9.04e-11	Aortic root size;
KIRP	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg23100626	chr2:96804247	ASTL	0.52	7.55	0.43	8.3e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg19752551	chr11:57585705	CTNND1	0.76	12.29	0.62	2.21e-27	Schizophrenia;
KIRP	cis	rs6681460	0.649	rs1856315	chr1:67005229	A/G	cg02459107	chr1:67143332	SGIP1	0.38	5.42	0.33	1.45e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.62	-7.5	-0.43	1.19e-12	Systemic lupus erythematosus;
KIRP	cis	rs13279522	0.536	rs11997605	chr8:66985624	C/T	cg04041976	chr8:67085823	TRIM55	-0.44	-5.51	-0.33	9.16e-8	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.55	7.08	0.41	1.54e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-6.4	-0.38	7.74e-10	Dilated cardiomyopathy;
KIRP	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg19847130	chr8:10466454	RP1L1	-0.33	-5.01	-0.3	1.05e-6	Retinal vascular caliber;
KIRP	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.45	6.39	0.38	8.16e-10	Testicular germ cell tumor;
KIRP	cis	rs2901656	0.640	rs4916258	chr1:172413526	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	6.19	0.37	2.51e-9	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs953387	1.000	rs4954566	chr2:136901513	A/G	cg05194412	chr2:137003533	NA	0.4	5.2	0.31	4.25e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg18190219	chr22:46762943	CELSR1	-0.86	-6.99	-0.41	2.61e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9457247	0.935	rs2769345	chr6:167366394	T/C	cg07741184	chr6:167504864	NA	-0.24	-6.39	-0.38	8.22e-10	Crohn's disease;
KIRP	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.8	8.38	0.47	4.13e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.68	5.14	0.31	5.53e-7	Schizophrenia;
KIRP	cis	rs5167	0.777	rs56784978	chr19:45499388	T/C	cg09555818	chr19:45449301	APOC2	0.39	5.06	0.31	8.27e-7	Blood protein levels;
KIRP	cis	rs4356932	1.000	rs7664354	chr4:76982068	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg26681399	chr22:41777847	TEF	-0.54	-5.44	-0.33	1.3e-7	Vitiligo;
KIRP	cis	rs787274	0.850	rs1324931	chr9:115634282	A/G	cg13803584	chr9:115635662	SNX30	0.63	6.32	0.37	1.2e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.87	-0.35	1.41e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	1.02	19.12	0.77	1.49e-50	Heart rate;
KIRP	cis	rs10924970	0.781	rs10754614	chr1:235493804	G/A	cg26050004	chr1:235667680	B3GALNT2	0.39	4.85	0.3	2.18e-6	Asthma;
KIRP	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg16141378	chr3:129829833	LOC729375	0.51	6.07	0.36	4.82e-9	Neuroticism;
KIRP	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg19338460	chr6:170058176	WDR27	-0.66	-7.71	-0.44	3.16e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg22654517	chr2:96458247	NA	0.34	4.99	0.3	1.13e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs2970992	0.624	rs2309905	chr2:101328575	T/A	cg01042948	chr2:101319752	NA	0.42	5.93	0.35	1.02e-8	Educational attainment;
KIRP	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.16	0.61	5.83e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.47	-7.1	-0.41	1.37e-11	Vitamin D levels;
KIRP	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs4356975	0.563	rs6600878	chr4:69958336	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs73206853	0.764	rs12311093	chr12:110978032	A/G	cg12870014	chr12:110450643	ANKRD13A	-0.52	-6.45	-0.38	5.78e-10	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.4	-0.38	7.82e-10	Response to antipsychotic treatment;
KIRP	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg22906224	chr7:99728672	NA	-0.5	-6.12	-0.36	3.58e-9	Coronary artery disease;
KIRP	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg00684032	chr4:1343700	KIAA1530	0.46	5.96	0.36	8.86e-9	Longevity;
KIRP	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg14092571	chr14:90743983	NA	0.41	5.01	0.3	1.03e-6	Mortality in heart failure;
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.73	0.53	3.9e-19	Lung cancer;
KIRP	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	cis	rs3087591	0.659	rs757376	chr17:29717909	A/G	cg24425628	chr17:29625626	OMG;NF1	0.67	9.76	0.53	3.05e-19	Hip circumference;
KIRP	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg03959625	chr15:84868606	LOC388152	0.64	7.79	0.44	1.93e-13	Schizophrenia;
KIRP	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg04672837	chr16:48644449	N4BP1	0.45	6.31	0.37	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.66	-12.31	-0.62	1.91e-27	Intelligence (multi-trait analysis);
KIRP	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.81	-9.07	-0.5	3.81e-17	Blood pressure (smoking interaction);
KIRP	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg21466736	chr12:48725269	NA	-0.44	-5.41	-0.33	1.47e-7	Glycated hemoglobin levels;
KIRP	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09217309	chr6:150244204	RAET1G	0.42	5.12	0.31	6.18e-7	Testicular germ cell tumor;
KIRP	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg24253500	chr15:84953950	NA	-0.44	-5.42	-0.33	1.43e-7	P wave terminal force;
KIRP	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg09788416	chr12:39539408	NA	0.42	5.37	0.32	1.78e-7	Morning vs. evening chronotype;
KIRP	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.11	0.36	3.95e-9	Neuroticism;
KIRP	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.74	7.17	0.42	8.67e-12	Eosinophil percentage of granulocytes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14140118	chr11:108423031	EXPH5	0.41	6.03	0.36	5.89e-9	Interleukin-4 levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg26592208	chr11:61477833	DAGLA	-0.5	-6.57	-0.39	2.9e-10	Inflammatory biomarkers;
KIRP	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg10503236	chr1:231470652	EXOC8	-0.49	-6.67	-0.39	1.64e-10	Hemoglobin concentration;
KIRP	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.61	0.39	2.38e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21545522	chr1:205238299	TMCC2	0.51	6.66	0.39	1.76e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6669919	0.553	rs7546343	chr1:211671801	C/T	cg10512769	chr1:211675356	NA	-0.78	-11.29	-0.58	4.16e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg27490568	chr2:178487706	NA	0.48	6.44	0.38	6.4e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.75	11.03	0.58	2.94e-23	Lewy body disease;
KIRP	cis	rs17321999	0.516	rs17322090	chr2:30494172	G/T	cg05247661	chr2:30472410	LBH	0.69	5.55	0.33	7.57e-8	Systemic lupus erythematosus;
KIRP	cis	rs8038465	0.615	rs11634399	chr15:73949210	A/G	cg15420318	chr15:73925796	NPTN	0.65	9.32	0.51	7.08e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg24476569	chr13:95954382	ABCC4	-0.59	-9.17	-0.5	2.02e-17	Blood metabolite levels;
KIRP	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.52	-7.29	-0.42	4.11e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg22284058	chr8:142237359	SLC45A4	0.51	6.54	0.38	3.54e-10	Immature fraction of reticulocytes;
KIRP	cis	rs11871801	0.517	rs684214	chr17:40696915	C/T	cg14558262	chr17:40713999	COASY	0.5	4.97	0.3	1.28e-6	Crohn's disease;
KIRP	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg04362960	chr10:104952993	NT5C2	0.45	5.62	0.34	5.17e-8	Waist circumference;Hip circumference;
KIRP	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.6	7.33	0.42	3.21e-12	Blood metabolite levels;
KIRP	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-6.83	-0.4	6.5e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.47	9.67	0.52	6.09e-19	Rheumatoid arthritis;
KIRP	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.81	-11.98	-0.61	2.31e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg19847130	chr8:10466454	RP1L1	0.35	5.09	0.31	7.06e-7	Systolic blood pressure;
KIRP	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.25	17.47	0.74	5.64e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12315302	chr6:26189340	HIST1H4D	0.61	5.07	0.31	7.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg05315796	chr3:52349193	DNAH1	-0.41	-6.55	-0.39	3.36e-10	Bipolar disorder;
KIRP	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg01557791	chr16:72042693	DHODH	-0.41	-5.1	-0.31	6.66e-7	Fibrinogen levels;
KIRP	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.55	7.17	0.42	8.88e-12	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9473924	0.632	rs717270	chr6:50914587	T/C	cg03432817	chr6:50765336	NA	0.35	5.4	0.33	1.59e-7	Body mass index;
KIRP	cis	rs9463078	0.547	rs4714819	chr6:44735285	G/C	cg25276700	chr6:44698697	NA	0.36	5.1	0.31	6.65e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg08477640	chr19:41863820	B9D2	0.62	7.2	0.42	7.39e-12	Colorectal cancer;
KIRP	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.85	-12.83	-0.63	3.38e-29	Colorectal cancer;
KIRP	cis	rs2016266	0.819	rs1976938	chr12:53661925	C/T	cg16917193	chr12:54089295	NA	0.45	5.69	0.34	3.54e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg19875535	chr5:140030758	IK	-0.56	-6.89	-0.4	4.65e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.9	9.11	0.5	2.98e-17	Eosinophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17527142	chr3:49027225	P4HTM	0.5	6.12	0.36	3.65e-9	Parkinson's disease;
KIRP	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.44	-5.5	-0.33	9.28e-8	Breast cancer;
KIRP	cis	rs7221595	0.756	rs9900661	chr17:3962450	A/G	cg11204139	chr17:3907470	NA	0.59	6.06	0.36	5.08e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.14e-8	Life satisfaction;
KIRP	cis	rs1629083	0.902	rs57495164	chr11:118095148	T/C	cg18857871	chr11:118064634	AMICA1	0.62	8.07	0.46	3.15e-14	Lung cancer;
KIRP	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg18964960	chr10:1102726	WDR37	-0.63	-7.14	-0.41	1.08e-11	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7221595	0.825	rs12939802	chr17:3933904	C/T	cg11204139	chr17:3907470	NA	0.49	4.97	0.3	1.26e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.58	-6.66	-0.39	1.8e-10	Response to antineoplastic agents;
KIRP	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.81	9.83	0.53	1.87e-19	Corneal astigmatism;
KIRP	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg12940923	chr8:10282607	MSRA	-0.37	-4.85	-0.3	2.15e-6	Neuroticism;
KIRP	cis	rs3849570	0.615	rs9817070	chr3:81982936	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-7.2	-0.42	7.17e-12	Waist circumference;Body mass index;
KIRP	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22509189	chr2:225307070	NA	-0.45	-5.32	-0.32	2.28e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.76	10.95	0.57	5.39e-23	Schizophrenia;
KIRP	cis	rs10782582	1.000	rs10782582	chr1:76383297	A/G	cg03433033	chr1:76189801	ACADM	0.35	5.39	0.33	1.61e-7	Daytime sleep phenotypes;
KIRP	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.43	6.38	0.38	8.56e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	cg12689670	chr1:183009347	LAMC1	0.58	8.07	0.46	3.21e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs2033732	0.913	rs733594	chr8:85077686	C/T	cg05716166	chr8:85095498	RALYL	0.54	6.14	0.36	3.31e-9	Body mass index;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg06740227	chr12:86229804	RASSF9	0.41	5.16	0.31	5.15e-7	Major depressive disorder;
KIRP	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.66	6.59	0.39	2.67e-10	Vitiligo;
KIRP	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.53	-8.14	-0.46	1.96e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs703980	1.000	rs810517	chr10:80942620	A/G	cg18737081	chr10:80999807	ZMIZ1	-0.26	-4.88	-0.3	1.92e-6	Type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11814370	chr10:105110944	PCGF6	-0.49	-6.85	-0.4	5.72e-11	Metabolic traits;
KIRP	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg24807547	chr6:37504484	NA	-0.6	-9.15	-0.5	2.19e-17	Cognitive performance;
KIRP	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg00310523	chr12:86230176	RASSF9	0.43	6.7	0.39	1.45e-10	Major depressive disorder;
KIRP	cis	rs10506328	0.509	rs17109902	chr12:54661102	A/G	cg04070651	chr12:54611596	NA	-0.26	-4.92	-0.3	1.57e-6	Mean platelet volume;
KIRP	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06771106	chr2:113671356	IL1F7	-0.41	-5.12	-0.31	6.25e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg13319975	chr6:146136371	FBXO30	0.48	6.34	0.37	1.1e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.38	0.47	4.18e-15	Personality dimensions;
KIRP	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.41	-6.1	-0.36	4.19e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1021993	0.545	rs17014396	chr1:209548885	C/T	cg24446417	chr1:209558027	NA	-0.51	-4.9	-0.3	1.75e-6	Gut microbiome composition (winter);
KIRP	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.45	0.38	5.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.72	-8.83	-0.49	1.99e-16	Height;
KIRP	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15208573	chr6:44041185	NA	0.47	6.39	0.38	8.04e-10	Myopia (pathological);
KIRP	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.59e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs4786125	0.665	rs1565633	chr16:6919428	G/C	cg03623568	chr16:6915990	A2BP1	-0.44	-5.31	-0.32	2.48e-7	Heart rate variability traits (SDNN);
KIRP	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.97	-0.45	5.94e-14	Neuroticism;
KIRP	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00166722	chr3:10149974	C3orf24	0.48	4.92	0.3	1.59e-6	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01726823	chr2:65454860	ACTR2	0.51	6.37	0.38	9.05e-10	Parkinson's disease;
KIRP	trans	rs2043599	1.000	rs7259764	chr19:56466227	C/T	cg25841159	chr17:74137454	FOXJ1	0.93	6.27	0.37	1.57e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs11874712	0.688	rs11659478	chr18:43650488	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.44	-6.02	-0.36	6.45e-9	Migraine - clinic-based;
KIRP	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.97	-0.5	7.77e-17	Total cholesterol levels;
KIRP	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.68	-9.31	-0.51	7.17e-18	Huntington's disease progression;
KIRP	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg09571762	chr12:39539558	NA	0.35	4.88	0.3	1.9e-6	Morning vs. evening chronotype;
KIRP	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	trans	rs76288851	0.799	rs55954409	chr3:126499473	G/A	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.79	-0.44	1.88e-13	Aortic root size;
KIRP	cis	rs67257959	0.708	rs1979261	chr19:17193518	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.51	-5.89	-0.35	1.28e-8	Selective IgA deficiency;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19280121	chr17:21117780	TMEM11	0.52	6.14	0.36	3.25e-9	Smoking initiation;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg25801113	chr15:45476975	SHF	0.48	9.32	0.51	6.96e-18	Uric acid levels;
KIRP	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.73	-11.32	-0.59	3.42e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.64	-0.39	2.04e-10	Lung cancer;
KIRP	cis	rs7590368	0.600	rs3856466	chr2:10916770	C/T	cg15705551	chr2:10952987	PDIA6	0.67	5.74	0.34	2.82e-8	Educational attainment (years of education);
KIRP	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg01119278	chr6:110721349	DDO	-0.45	-6.51	-0.38	4.22e-10	Platelet distribution width;
KIRP	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.48	8.25	0.47	9.4e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs6430585	0.592	rs2016636	chr2:136058820	G/A	cg07169764	chr2:136633963	MCM6	0.52	6.04	0.36	5.61e-9	Corneal structure;
KIRP	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.7	-6.54	-0.38	3.54e-10	Schizophrenia;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11997175	0.655	rs72630923	chr8:33662404	C/A	cg04338863	chr8:33670619	NA	0.41	5.39	0.33	1.62e-7	Body mass index;
KIRP	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg19847130	chr8:10466454	RP1L1	0.35	5.02	0.3	9.85e-7	Systolic blood pressure;
KIRP	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg12573674	chr2:1569213	NA	-0.52	-5.05	-0.31	8.77e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9616064	0.520	rs875557	chr22:47034722	C/T	cg05621596	chr22:47072043	GRAMD4	-0.72	-8.76	-0.49	3.33e-16	Urate levels in obese individuals;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.78	-13.17	-0.64	2.43e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.71	11.14	0.58	1.34e-23	Coronary artery disease;
KIRP	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg24110177	chr3:50126178	RBM5	0.44	5.67	0.34	4.02e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg26681399	chr22:41777847	TEF	-0.54	-5.39	-0.33	1.65e-7	Vitiligo;
KIRP	cis	rs2599510	0.783	rs2710626	chr2:32758754	G/C	cg02381751	chr2:32503542	YIPF4	0.48	5.42	0.33	1.45e-7	Interleukin-18 levels;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg02733842	chr7:1102375	C7orf50	0.58	5.96	0.36	8.68e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg19187155	chr2:232395269	NMUR1	0.72	10.53	0.56	1.16e-21	Height;
KIRP	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.41	0.68	1.54e-34	Alzheimer's disease;
KIRP	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg17764715	chr19:33622953	WDR88	0.82	12.0	0.61	2e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.86	0.45	1.23e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1712790	0.665	rs17117456	chr11:114635772	A/C	cg19465033	chr11:114479364	NA	0.39	5.17	0.31	4.89e-7	Urinary albumin excretion;
KIRP	cis	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg27487796	chr7:28973253	NA	-0.22	-5.34	-0.32	2.1e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.87	13.14	0.64	3.04e-30	Metabolite levels;
KIRP	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg03235661	chr20:60525775	NA	-0.35	-5.35	-0.32	2.03e-7	Body mass index;
KIRP	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	1.04	13.42	0.65	3.63e-31	Neutrophil percentage of white cells;
KIRP	cis	rs12134040	0.557	rs61835534	chr1:236521578	A/G	cg21399712	chr1:236511386	NA	-0.53	-7.36	-0.42	2.82e-12	Urate levels (BMI interaction);
KIRP	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.31	-0.42	3.63e-12	Colorectal cancer;
KIRP	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.26	-0.37	1.67e-9	Systolic blood pressure;
KIRP	cis	rs6466055	0.612	rs56281713	chr7:104913947	A/G	cg04380332	chr7:105027541	SRPK2	0.36	5.0	0.3	1.08e-6	Schizophrenia;
KIRP	cis	rs9381040	0.692	rs4714430	chr6:41157054	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.53	-6.6	-0.39	2.52e-10	Alzheimer's disease (late onset);
KIRP	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.54	7.35	0.42	2.98e-12	Colorectal cancer;
KIRP	cis	rs6832769	1.000	rs28463765	chr4:56412434	C/T	cg05960024	chr4:56376020	CLOCK	-0.7	-8.66	-0.48	6.43e-16	Personality dimensions;
KIRP	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg05370193	chr1:21551575	ECE1	-0.36	-4.92	-0.3	1.61e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14159672	chr1:205819179	PM20D1	-0.6	-5.86	-0.35	1.47e-8	Menarche (age at onset);
KIRP	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg21360079	chr12:107162445	NA	-0.68	-9.76	-0.53	3.02e-19	Heart rate;
KIRP	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg03060546	chr3:49711283	APEH	0.54	7.33	0.42	3.22e-12	Menarche (age at onset);
KIRP	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-7.61	-0.44	5.88e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4690686	0.500	rs17062801	chr4:177262381	G/A	cg17059388	chr4:177262070	NA	0.86	12.45	0.62	6.18e-28	Essential tremor;
KIRP	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.55e-13	IgG glycosylation;
KIRP	cis	rs1018697	1.000	rs7911528	chr10:104551567	A/G	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.22	-6.11	-0.36	3.78e-9	Coronary artery disease;
KIRP	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.66	-12.19	-0.61	4.87e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.51	7.36	0.43	2.67e-12	Schizophrenia;
KIRP	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.5	0.33	9.51e-8	Parkinson's disease;
KIRP	cis	rs2274273	0.623	rs1187877	chr14:55495161	T/C	cg04306507	chr14:55594613	LGALS3	-0.41	-6.12	-0.36	3.61e-9	Protein biomarker;
KIRP	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.41	-5.18	-0.31	4.51e-7	Testicular germ cell tumor;
KIRP	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.35	-4.9	-0.3	1.74e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg10932868	chr11:921992	NA	0.58	7.33	0.42	3.21e-12	Alzheimer's disease (late onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07077900	chr3:53916135	ACTR8	0.47	6.17	0.37	2.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6700559	0.703	rs10919993	chr1:200627312	C/A	cg07804481	chr1:200639085	DDX59	0.52	6.75	0.4	1.03e-10	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.66	0.71	8.46e-39	Chronic sinus infection;
KIRP	cis	rs2802372	0.587	rs1250542	chr10:81034670	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.42	-5.28	-0.32	2.83e-7	Granulocyte count;
KIRP	cis	rs2151522	0.714	rs13198897	chr6:127185096	C/T	cg21431617	chr6:127135037	NA	0.29	5.26	0.32	3.19e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4716602	0.609	rs12386633	chr7:156158232	G/C	cg16983916	chr7:156159713	NA	-0.43	-5.44	-0.33	1.26e-7	Anti-saccade response;
KIRP	cis	rs7590368	0.715	rs56025654	chr2:10960952	G/A	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.77	8.75	0.49	3.37e-16	Primary sclerosing cholangitis;
KIRP	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs1208285	0.564	rs9389112	chr6:134204996	G/T	cg06643013	chr6:134217242	NA	-0.44	-5.12	-0.31	6.29e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg06060754	chr5:176797920	RGS14	0.43	6.51	0.38	4.26e-10	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.45	5.45	0.33	1.23e-7	Longevity;
KIRP	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	9.98	0.54	6.29e-20	Mood instability;
KIRP	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.01	-11.31	-0.58	3.79e-24	Colorectal cancer;
KIRP	cis	rs7681423	1.000	rs2066865	chr4:155525276	G/A	cg20735720	chr4:155535218	FGG	-0.63	-8.24	-0.46	1.05e-14	Fibrinogen;
KIRP	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg16077055	chr2:106428750	NCK2	0.27	5.32	0.32	2.35e-7	Addiction;
KIRP	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg04398451	chr17:18023971	MYO15A	0.61	8.04	0.46	3.78e-14	Total body bone mineral density;
KIRP	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11987759	chr7:65425863	GUSB	-0.61	-8.13	-0.46	2.07e-14	Aortic root size;
KIRP	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.65	-6.6	-0.39	2.52e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs34779708	0.931	rs12268745	chr10:35305989	C/G	cg04310649	chr10:35416472	CREM	-0.59	-6.94	-0.4	3.39e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.56	7.15	0.41	9.94e-12	Primary sclerosing cholangitis;
KIRP	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.88	11.27	0.58	4.89e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24051350	chr1:77165461	NA	0.41	6.56	0.39	3.13e-10	Survival in pancreatic cancer;
KIRP	cis	rs865483	0.895	rs2107105	chr17:35835080	C/T	cg06716730	chr17:35851459	DUSP14	0.25	6.08	0.36	4.64e-9	Monocyte count;
KIRP	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg16586182	chr3:47516702	SCAP	0.77	9.57	0.52	1.17e-18	Colorectal cancer;
KIRP	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.83	-9.18	-0.51	1.81e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg04369109	chr6:150039330	LATS1	0.51	6.25	0.37	1.82e-9	Lung cancer;
KIRP	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.41e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg14851346	chr12:38532713	NA	-0.4	-4.96	-0.3	1.34e-6	Bladder cancer;
KIRP	cis	rs933360	0.503	rs757777	chr7:50877048	G/A	cg14997413	chr7:51384937	COBL	0.31	4.9	0.3	1.75e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs1185460	1.000	rs7938944	chr11:118954066	T/C	cg23280166	chr11:118938394	VPS11	0.64	7.94	0.45	7.11e-14	Coronary artery disease;
KIRP	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.78e-11	Bipolar disorder;
KIRP	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg18154014	chr19:37997991	ZNF793	0.86	8.9	0.49	1.24e-16	Coronary artery calcification;
KIRP	cis	rs2625529	0.730	rs6494975	chr15:72177825	T/A	cg16672083	chr15:72433130	SENP8	0.47	6.47	0.38	5.4e-10	Red blood cell count;
KIRP	cis	rs62413470	1.000	rs12208500	chr6:55933259	T/G	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.78	-0.53	2.73e-19	Aortic root size;
KIRP	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.36	-0.38	9.64e-10	Aortic root size;
KIRP	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.97	-0.64	1.17e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7127900	1.000	rs11043143	chr11:2234093	T/C	cg25635251	chr11:2234043	NA	0.52	7.86	0.45	1.23e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.73	-7.76	-0.44	2.33e-13	Blood pressure (smoking interaction);
KIRP	cis	rs748404	0.723	rs11853991	chr15:43557549	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.45	5.39	0.32	1.67e-7	Lung cancer;
KIRP	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg17366294	chr4:99064904	C4orf37	0.38	5.01	0.3	1.06e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.72	-7.08	-0.41	1.49e-11	Breast cancer;
KIRP	cis	rs2554380	0.800	rs2585068	chr15:84404457	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.45	-6.34	-0.37	1.08e-9	Height;
KIRP	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04374321	chr14:90722782	PSMC1	0.89	14.57	0.68	4.26e-35	Mortality in heart failure;
KIRP	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg25251562	chr2:3704773	ALLC	-0.39	-5.29	-0.32	2.76e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg22907277	chr7:1156413	C7orf50	0.71	4.99	0.3	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4789452	1.000	rs11659109	chr17:75375859	C/T	cg12985929	chr17:75370611	SEPT9	-0.39	-5.42	-0.33	1.41e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs35995292	0.500	rs1019065	chr7:38939775	C/T	cg19327137	chr7:38886074	VPS41	0.81	12.67	0.63	1.14e-28	Subjective well-being (multi-trait analysis);
KIRP	trans	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.43	-0.38	6.7e-10	Bladder cancer;
KIRP	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.57	-7.04	-0.41	1.88e-11	Aortic root size;
KIRP	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.64	7.95	0.45	6.55e-14	Colorectal cancer;
KIRP	cis	rs7945718	0.870	rs10831903	chr11:12758660	C/T	cg25843174	chr11:12811716	TEAD1	0.46	8.6	0.48	9.73e-16	Educational attainment (years of education);
KIRP	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg07856975	chr6:36356162	ETV7	0.42	5.38	0.32	1.69e-7	Platelet distribution width;
KIRP	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.9	14.03	0.67	3.06e-33	Height;
KIRP	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-12.29	-0.62	2.24e-27	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27431596	chr1:120190588	ZNF697	0.54	7.79	0.44	1.93e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-17.11	-0.74	9.19e-44	Intelligence (multi-trait analysis);
KIRP	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	6.98	0.41	2.71e-11	Lung cancer in ever smokers;
KIRP	cis	rs17681684	0.565	rs12150476	chr17:9763876	A/C	cg26853458	chr17:9805074	RCVRN	0.54	5.08	0.31	7.47e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs4523957	0.615	rs59207721	chr17:2070479	C/A	cg16513277	chr17:2031491	SMG6	-0.79	-11.34	-0.59	2.98e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs501120	1.000	rs487465	chr10:44758197	A/C	cg09554077	chr10:44749378	NA	0.7	10.63	0.56	5.74e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.41	-0.38	7.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2904967	0.929	rs482842	chr11:65045278	T/G	cg09225861	chr11:65069680	NA	0.41	4.91	0.3	1.67e-6	Mean corpuscular volume;
KIRP	cis	rs11673344	0.864	rs1879497	chr19:37632877	G/T	cg14683738	chr19:37701593	ZNF585B	-0.45	-4.95	-0.3	1.37e-6	Obesity-related traits;
KIRP	cis	rs12913538	0.962	rs4774442	chr15:62897853	G/A	cg09983546	chr15:62884068	NA	0.59	8.42	0.47	3.16e-15	Sleep depth;
KIRP	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg03711944	chr11:47377212	SPI1	-0.34	-5.48	-0.33	1.06e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.77	11.15	0.58	1.19e-23	Morning vs. evening chronotype;
KIRP	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7534824	0.543	rs61780317	chr1:101407139	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	6.48	0.38	5.1e-10	Refractive astigmatism;
KIRP	cis	rs6594713	0.642	rs6890874	chr5:112787813	C/A	cg12552261	chr5:112820674	MCC	0.61	5.42	0.33	1.45e-7	Brain cytoarchitecture;
KIRP	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.72	7.28	0.42	4.59e-12	Methadone dose in opioid dependence;
KIRP	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.75	-0.49	3.53e-16	Myopia (pathological);
KIRP	cis	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.2	-0.31	4.27e-7	Neuroticism;
KIRP	trans	rs2504916	1.000	rs2504938	chr6:160824754	C/T	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.57	-6.03	-0.36	5.98e-9	Response to hepatitis C treatment;
KIRP	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.84	11.7	0.6	2.03e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.7	12.03	0.61	1.65e-26	Cardiovascular disease risk factors;
KIRP	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-5.21	-0.32	3.93e-7	Opioid sensitivity;
KIRP	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.03	-0.31	9.66e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.8	10.69	0.56	3.85e-22	Longevity;
KIRP	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-14.3	-0.67	3.67e-34	Heart rate;
KIRP	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg21775007	chr8:11205619	TDH	-0.48	-6.6	-0.39	2.45e-10	Systolic blood pressure;
KIRP	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.95	-0.5	8.97e-17	Response to antipsychotic treatment;
KIRP	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg24747557	chr10:131355152	MGMT	0.38	5.29	0.32	2.64e-7	Response to temozolomide;
KIRP	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg16898833	chr6:26189333	HIST1H4D	0.92	5.66	0.34	4.26e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs787274	1.000	rs885387	chr9:115596390	G/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.54	-0.38	3.55e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12580194	0.593	rs12579408	chr12:55764348	G/A	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg06654118	chr4:1303317	MAEA	0.28	5.12	0.31	6.17e-7	Longevity;
KIRP	cis	rs4356975	0.563	rs11937683	chr4:69949820	A/T	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26366830	chr5:173043172	BOD1	0.48	6.35	0.38	1.04e-9	Parkinson's disease;
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg04804543	chr8:142233427	SLC45A4	1.02	17.81	0.75	3.78e-46	Immature fraction of reticulocytes;
KIRP	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.77	-0.35	2.41e-8	Type 2 diabetes;
KIRP	cis	rs11779988	0.543	rs415226	chr8:17896138	T/A	cg01800426	chr8:17659068	MTUS1	-0.47	-4.96	-0.3	1.33e-6	Breast cancer;
KIRP	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg19847866	chr10:1019161	NA	-0.64	-5.77	-0.35	2.41e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.59	-8.54	-0.48	1.37e-15	Urate levels in overweight individuals;
KIRP	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg12855166	chr17:30846586	MYO1D	0.37	4.97	0.3	1.25e-6	Schizophrenia;
KIRP	trans	rs2270927	0.510	rs67771044	chr5:75577819	A/G	cg13563193	chr19:33072644	PDCD5	0.88	6.7	0.39	1.42e-10	Mean corpuscular volume;
KIRP	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg24498760	chr8:49746867	NA	0.41	5.16	0.31	5.17e-7	Blood metabolite ratios;
KIRP	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.72	-9.55	-0.52	1.37e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.42	0.47	3.07e-15	Eosinophil percentage of white cells;
KIRP	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.59	7.32	0.42	3.49e-12	Arsenic metabolism;
KIRP	cis	rs7113874	0.545	rs2084187	chr11:8536941	G/C	cg08015107	chr11:8618950	NA	-0.51	-6.77	-0.4	9.37e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.47	6.29	0.37	1.45e-9	Dupuytren's disease;
KIRP	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-7.69	-0.44	3.52e-13	Alzheimer's disease;
KIRP	cis	rs72627123	0.656	rs117145347	chr14:74564164	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.91	0.3	1.7e-6	Morning vs. evening chronotype;
KIRP	cis	rs9815354	1.000	rs12639255	chr3:41861738	T/C	cg03022575	chr3:42003672	ULK4	0.6	6.9	0.4	4.36e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg07148914	chr20:33460835	GGT7	0.48	6.16	0.37	3.02e-9	Height;
KIRP	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.61	7.63	0.44	5.05e-13	Red cell distribution width;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.65	9.57	0.52	1.24e-18	Menarche (age at onset);
KIRP	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.71	11.2	0.58	8.65e-24	Metabolite levels;
KIRP	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.47	7.14	0.41	1.06e-11	Electroencephalogram traits;
KIRP	cis	rs17121403	0.661	rs11166403	chr1:100593738	G/C	cg24955406	chr1:100503596	HIAT1	0.75	4.99	0.3	1.12e-6	Pulmonary function decline;
KIRP	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.69	9.34	0.51	6.22e-18	Glomerular filtration rate;
KIRP	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	0.94	9.19	0.51	1.68e-17	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.74	8.62	0.48	8.48e-16	High light scatter reticulocyte count;
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg21285383	chr16:89894308	SPIRE2	0.32	5.87	0.35	1.4e-8	Vitiligo;
KIRP	cis	rs13095912	0.889	rs34765114	chr3:185335156	T/A	cg11274856	chr3:185301563	NA	0.55	7.16	0.42	9.3e-12	Systolic blood pressure;
KIRP	cis	rs4073416	0.542	rs7144971	chr14:66120650	A/G	cg03016385	chr14:66212404	NA	0.51	6.23	0.37	1.96e-9	N-glycan levels;
KIRP	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.88	11.96	0.61	2.79e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.52	-0.38	4e-10	Joint mobility (Beighton score);
KIRP	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg09427745	chr16:71932006	KIAA0174	-0.62	-5.44	-0.33	1.3e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg20568497	chr10:133558893	NA	0.33	5.1	0.31	6.74e-7	Survival in rectal cancer;
KIRP	cis	rs7615316	0.779	rs10935461	chr3:142079379	A/G	cg20824294	chr3:142316082	PLS1	0.24	5.48	0.33	1.05e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4664293	0.867	rs12617546	chr2:160623590	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg21919602	chr1:242011447	EXO1	-0.49	-6.42	-0.38	7.01e-10	Menopause (age at onset);
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg21724239	chr8:58056113	NA	0.72	6.11	0.36	3.95e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg03160526	chr17:80928410	B3GNTL1	0.38	4.87	0.3	1.96e-6	Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg01320579	chr17:75405842	SEPT9	-0.46	-7.6	-0.44	6.09e-13	Airflow obstruction;
KIRP	cis	rs6563943	0.857	rs2325958	chr16:83632018	C/G	cg01935413	chr16:83636749	CDH13	0.36	5.06	0.31	8.11e-7	Height;
KIRP	cis	rs7818345	0.640	rs3802329	chr8:19266727	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.53	6.85	0.4	5.8e-11	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.43	-0.43	1.74e-12	Bipolar disorder;
KIRP	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.6	-7.33	-0.42	3.4e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg03563238	chr19:33554763	RHPN2	-0.33	-6.13	-0.36	3.42e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.53	-5.53	-0.33	7.97e-8	Tourette syndrome;
KIRP	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-8.42	-0.47	3.21e-15	Platelet count;
KIRP	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs10875746	0.855	rs10875731	chr12:48432743	G/A	cg26205652	chr12:48591994	NA	0.78	10.54	0.56	1.09e-21	Longevity (90 years and older);
KIRP	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg05082376	chr22:42548792	NA	-0.45	-5.62	-0.34	5.28e-8	Schizophrenia;
KIRP	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg17986701	chr20:44574422	PCIF1	0.49	7.53	0.43	9.51e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.47	-0.33	1.12e-7	Obesity-related traits;
KIRP	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.59	-6.83	-0.4	6.71e-11	Menarche (age at onset);
KIRP	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.34	-0.37	1.08e-9	Response to antipsychotic treatment;
KIRP	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.62	-7.29	-0.42	4.21e-12	Mammographic density (dense area);
KIRP	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.28	0.32	2.84e-7	Smoking behavior;
KIRP	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.66	0.39	1.73e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9443189	0.855	rs2842554	chr6:76455557	C/A	cg01950844	chr6:76311363	SENP6	-0.59	-6.38	-0.38	8.83e-10	Prostate cancer;
KIRP	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.67	-7.96	-0.45	6.33e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg01864069	chr14:103024347	NA	0.91	10.17	0.54	1.64e-20	Platelet count;
KIRP	cis	rs1978968	0.763	rs9605475	chr22:18463306	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.78	-11.07	-0.58	2.19e-23	Presence of antiphospholipid antibodies;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25432992	chr2:121493541	NA	0.48	6.12	0.36	3.67e-9	Parkinson's disease;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg24488311	chr11:68621650	NA	0.44	5.22	0.32	3.86e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2411233	0.905	rs12899025	chr15:39297872	G/A	cg02291532	chr15:39874776	THBS1	0.4	5.27	0.32	3.02e-7	Platelet count;
KIRP	cis	rs72627123	0.749	rs10149956	chr14:74649106	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.86	-5.67	-0.34	3.92e-8	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.56	6.83	0.4	6.5e-11	Aortic root size;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.53	7.11	0.41	1.28e-11	Total body bone mineral density;
KIRP	cis	rs8027181	0.839	rs7176223	chr15:73077742	T/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.3	0.42	4.04e-12	Triglyceride levels;
KIRP	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg26207909	chr14:103986467	CKB	-0.44	-5.67	-0.34	4.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7243821	0.639	rs8090350	chr18:52665677	A/G	cg26630735	chr18:52626848	CCDC68	0.48	5.29	0.32	2.7e-7	Chin dimples;
KIRP	cis	rs6496667	0.779	rs6496673	chr15:90976106	C/T	cg10434728	chr15:90938212	IQGAP1	0.36	4.9	0.3	1.77e-6	Rheumatoid arthritis;
KIRP	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.72	10.69	0.56	3.65e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7116495	1.000	rs4945435	chr11:71759219	C/T	cg26138937	chr11:71823887	C11orf51	-0.67	-5.35	-0.32	2.03e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.83	-11.57	-0.59	5.35e-25	Total body bone mineral density;
KIRP	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg00343986	chr7:65444356	GUSB	0.39	4.87	0.3	2.02e-6	Aortic root size;
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.23	0.64	1.52e-30	Platelet count;
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.7	10.32	0.55	5.75e-21	Retinal vascular caliber;
KIRP	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg23752985	chr2:85803571	VAMP8	0.59	8.52	0.48	1.63e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg26681399	chr22:41777847	TEF	0.51	5.19	0.31	4.41e-7	Vitiligo;
KIRP	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.76	0.34	2.55e-8	Lung cancer;
KIRP	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg17441377	chr17:3906640	NA	0.52	7.77	0.44	2.07e-13	Type 2 diabetes;
KIRP	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg19743168	chr1:23544995	NA	-0.48	-6.35	-0.38	1.01e-9	Height;
KIRP	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg01028140	chr2:1542097	TPO	-0.69	-6.2	-0.37	2.35e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg13271783	chr10:134563150	INPP5A	0.59	7.8	0.45	1.73e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	0.95	17.6	0.75	2e-45	Dental caries;
KIRP	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg22532475	chr10:104410764	TRIM8	-0.29	-4.96	-0.3	1.3e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.57	7.05	0.41	1.75e-11	Height;
KIRP	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.65	-12.39	-0.62	1.03e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg00784671	chr22:46762841	CELSR1	-0.88	-8.39	-0.47	3.73e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.71	0.44	3.1e-13	Coffee consumption (cups per day);
KIRP	cis	rs3849570	0.673	rs9877408	chr3:81974558	A/G	cg07356753	chr3:81810745	GBE1	-0.55	-7.31	-0.42	3.64e-12	Waist circumference;Body mass index;
KIRP	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.61	6.38	0.38	8.5e-10	Gastritis;
KIRP	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.84	11.86	0.6	5.75e-26	Total body bone mineral density;
KIRP	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg06064525	chr11:970664	AP2A2	-0.37	-7.64	-0.44	4.81e-13	Alzheimer's disease (late onset);
KIRP	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg25801113	chr15:45476975	SHF	0.48	9.38	0.51	4.46e-18	Uric acid levels;
KIRP	cis	rs6708331	0.517	rs12999042	chr2:70366811	C/T	cg05298696	chr2:70188691	ASPRV1	-0.41	-5.47	-0.33	1.08e-7	Obesity-related traits;
KIRP	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-1.01	-18.68	-0.77	4.4e-49	Height;
KIRP	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg15691649	chr6:25882328	NA	-0.44	-5.42	-0.33	1.42e-7	Blood metabolite levels;
KIRP	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	0.66	5.85	0.35	1.55e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2048656	0.637	rs10107396	chr8:9673152	T/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.07	-0.36	4.8e-9	Schizophrenia;
KIRP	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg19338460	chr6:170058176	WDR27	-0.64	-7.54	-0.43	8.91e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	6.16	0.37	2.9e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7175404	0.730	rs8033537	chr15:94033412	A/T	cg23502883	chr15:93959149	NA	0.46	5.41	0.33	1.52e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	15.74	0.71	4.4e-39	Platelet count;
KIRP	trans	rs933360	0.585	rs757774	chr7:50823311	A/G	cg20003124	chr12:4557277	NA	-0.54	-6.75	-0.4	1.07e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg10381502	chr11:71823885	C11orf51	1.09	7.61	0.44	5.85e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs12282928	1.000	rs10838850	chr11:48285856	C/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22117172	chr7:91764530	CYP51A1	0.46	6.29	0.37	1.41e-9	Breast cancer;
KIRP	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg12315302	chr6:26189340	HIST1H4D	0.9	6.07	0.36	4.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	8.6	0.48	9.49e-16	Neuroticism;
KIRP	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.97	-15.38	-0.7	7.13e-38	Primary sclerosing cholangitis;
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.61	-5.89	-0.35	1.28e-8	Alzheimer's disease;
KIRP	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.44	-5.24	-0.32	3.42e-7	Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03120717	chr11:124670846	C11orf61	0.4	6.7	0.39	1.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17554472	chr22:41940697	POLR3H	-0.68	-6.91	-0.4	4.11e-11	Vitiligo;
KIRP	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.65	7.91	0.45	8.65e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs7712401	0.541	rs42537	chr5:122274688	A/G	cg19412675	chr5:122181750	SNX24	0.47	5.2	0.31	4.22e-7	Mean platelet volume;
KIRP	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.7	-8.58	-0.48	1.08e-15	Type 2 diabetes;
KIRP	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.96	16.1	0.72	2.65e-40	Breast cancer;
KIRP	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.02	-0.3	1.01e-6	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25315287	chr19:36103455	HAUS5	0.43	6.11	0.36	3.96e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08572966	chr11:67980803	SUV420H1	0.49	6.22	0.37	2.14e-9	Parkinson's disease;
KIRP	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.5	6.39	0.38	8.3e-10	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg01631408	chr1:248437212	OR2T33	-0.63	-8.38	-0.47	4.12e-15	Common traits (Other);
KIRP	cis	rs4356932	0.967	rs4859605	chr4:76965822	C/G	cg00809888	chr4:76862425	NAAA	0.43	5.93	0.35	1.02e-8	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg05861140	chr6:150128134	PCMT1	-0.47	-6.54	-0.39	3.45e-10	Lung cancer;
KIRP	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2712184	0.660	rs10164732	chr2:217645669	A/T	cg05032264	chr2:217675019	NA	0.4	5.59	0.34	6.09e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.15	-0.37	3.12e-9	Schizophrenia;
KIRP	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg26248373	chr2:1572462	NA	-0.65	-7.88	-0.45	1.08e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg13010199	chr12:38710504	ALG10B	0.6	7.61	0.44	5.77e-13	Morning vs. evening chronotype;
KIRP	cis	rs2398893	0.924	rs7047684	chr9:96792790	C/T	cg14459158	chr9:96720562	NA	0.28	4.92	0.3	1.59e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.62	-0.34	5.13e-8	Crohn's disease;
KIRP	cis	rs6466055	0.589	rs6466035	chr7:104646899	C/T	cg04380332	chr7:105027541	SRPK2	-0.4	-5.35	-0.32	2.04e-7	Schizophrenia;
KIRP	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg08501292	chr6:25962987	TRIM38	1.02	8.16	0.46	1.68e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg05340658	chr4:99064831	C4orf37	-0.45	-5.14	-0.31	5.66e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2625529	0.617	rs13858	chr15:72433144	C/T	cg16672083	chr15:72433130	SENP8	-0.4	-5.55	-0.33	7.19e-8	Red blood cell count;
KIRP	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg15327641	chr2:3715039	ALLC	0.51	6.54	0.38	3.58e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2273156	0.706	rs7155696	chr14:35496754	G/A	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.19	-0.31	4.35e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs7940866	0.738	rs10894308	chr11:130891895	G/A	cg12179176	chr11:130786555	SNX19	0.73	8.46	0.47	2.37e-15	Schizophrenia;
KIRP	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg10523679	chr1:76189770	ACADM	-0.44	-6.04	-0.36	5.61e-9	Daytime sleep phenotypes;
KIRP	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.35	-0.47	4.93e-15	Mean corpuscular volume;
KIRP	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-8.34	-0.47	5.26e-15	Body mass index;
KIRP	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.74	-7.21	-0.42	6.76e-12	Bipolar disorder;
KIRP	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	1.39	9.95	0.54	7.87e-20	Prostate cancer;
KIRP	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14159672	chr1:205819179	PM20D1	0.5	5.55	0.33	7.44e-8	Parkinson's disease;
KIRP	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.59	7.19	0.42	7.9e-12	Bone mineral density;
KIRP	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.9	-0.49	1.29e-16	Neuroticism;
KIRP	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg00656387	chr3:40428638	ENTPD3	0.39	4.87	0.3	2e-6	Renal cell carcinoma;
KIRP	cis	rs1440410	0.835	rs34342939	chr4:144161670	T/A	cg01719995	chr4:144104893	USP38	0.38	4.94	0.3	1.43e-6	Ischemic stroke;
KIRP	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg05991184	chr2:219186017	PNKD	-0.36	-5.07	-0.31	7.79e-7	Colorectal cancer;
KIRP	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.14	-0.31	5.56e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs78487399	0.710	rs6731998	chr2:43677273	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11997175	0.766	rs7387133	chr8:33727045	C/G	ch.8.33884649F	chr8:33765107	NA	-0.49	-6.31	-0.37	1.32e-9	Body mass index;
KIRP	cis	rs17608059	0.545	rs736261	chr17:13936404	A/G	cg11395062	chr17:14139857	CDRT15	0.59	7.7	0.44	3.32e-13	Temperament;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg23377693	chr6:43597122	MAD2L1BP;GTPBP2	0.57	6.5	0.38	4.41e-10	Sleep duration;
KIRP	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.61	-8.22	-0.46	1.21e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg08890418	chr1:21044141	KIF17	0.41	6.08	0.36	4.55e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.64	-8.4	-0.47	3.52e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4787491	0.729	rs4238960	chr16:30038648	G/C	cg06326092	chr16:30034487	C16orf92	0.49	7.6	0.44	6.24e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs783540	0.500	rs1313494	chr15:83274279	C/T	cg16105309	chr15:79090380	ADAMTS7	0.58	7.04	0.41	1.87e-11	Schizophrenia;
KIRP	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.5	6.42	0.38	6.97e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20285609	chr1:41622030	SCMH1	0.56	7.02	0.41	2.15e-11	Interleukin-4 levels;
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.49	-8.86	-0.49	1.63e-16	Lung cancer;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.3	-0.32	2.59e-7	Life satisfaction;
KIRP	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.56	-7.88	-0.45	1.05e-13	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.62	-8.3	-0.47	6.77e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg01721255	chr8:58191610	C8orf71	-0.49	-4.94	-0.3	1.43e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2273669	0.667	rs7759014	chr6:109351125	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.91	8.09	0.46	2.69e-14	Inflammatory bowel disease;
KIRP	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.13	-0.31	5.92e-7	Pulmonary function;
KIRP	cis	rs240764	0.782	rs239223	chr6:101112345	A/G	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs2916247	1.000	rs10092162	chr8:93062830	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.77	-0.49	2.96e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7666738	0.609	rs35214820	chr4:98864692	G/A	cg05340658	chr4:99064831	C4orf37	0.67	7.77	0.44	2.18e-13	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg02002194	chr4:3960332	NA	0.44	6.2	0.37	2.41e-9	Neuroticism;
KIRP	cis	rs6973256	0.583	rs6955530	chr7:133339511	T/C	cg10665199	chr7:133106180	EXOC4	0.5	6.3	0.37	1.34e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.22	16.99	0.73	2.32e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.5	6.67	0.39	1.66e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg10223061	chr2:219282414	VIL1	-0.4	-6.42	-0.38	7.08e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg18595228	chr15:67193261	NA	-0.61	-6.74	-0.39	1.14e-10	Lung cancer (smoking interaction);
KIRP	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg16049864	chr8:95962084	TP53INP1	-0.37	-5.77	-0.35	2.36e-8	Type 2 diabetes;
KIRP	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs754423	0.585	rs7157151	chr14:52571583	C/T	cg10149976	chr14:52535953	NID2	0.38	5.57	0.33	6.59e-8	Craniofacial microsomia;
KIRP	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.76	0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg18402987	chr7:1209562	NA	0.46	4.97	0.3	1.23e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg18016565	chr1:150552671	MCL1	0.4	6.03	0.36	6.03e-9	Melanoma;
KIRP	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg21890820	chr11:65308645	LTBP3	0.38	4.85	0.3	2.17e-6	Bone mineral density;
KIRP	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg24579218	chr15:68104479	NA	-0.44	-7.16	-0.42	9.33e-12	Restless legs syndrome;
KIRP	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.54	-8.73	-0.49	4.01e-16	Prostate cancer;
KIRP	cis	rs300890	0.513	rs72719173	chr4:144055881	T/C	cg01719995	chr4:144104893	USP38	-0.43	-5.48	-0.33	1.08e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.88	0.45	1.07e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg08992911	chr2:238395768	MLPH	0.4	5.09	0.31	7.08e-7	Prostate cancer;
KIRP	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs537626	0.848	rs624797	chr11:69308575	G/T	cg18498241	chr11:69286352	NA	0.46	6.56	0.39	3.16e-10	Breast cancer (early onset);
KIRP	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg06212747	chr3:49208901	KLHDC8B	0.47	5.44	0.33	1.27e-7	Resting heart rate;
KIRP	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg25447019	chr17:19030144	GRAPL	0.6	8.4	0.47	3.69e-15	Schizophrenia;
KIRP	cis	rs4903604	0.581	rs41347855	chr14:78037909	C/T	cg18872420	chr14:78023429	SPTLC2	0.32	5.1	0.31	6.91e-7	Gut microbiome composition (winter);
KIRP	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs7712401	0.601	rs154496	chr5:122221731	A/G	cg19412675	chr5:122181750	SNX24	0.49	5.36	0.32	1.96e-7	Mean platelet volume;
KIRP	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25517755	chr10:38738941	LOC399744	-0.52	-7.18	-0.42	8.46e-12	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23522862	chr17:79829415	ARHGDIA	-0.56	-6.37	-0.38	9.29e-10	Migraine with aura;
KIRP	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg01988459	chr11:68622903	NA	-0.35	-4.84	-0.3	2.26e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.46	-5.83	-0.35	1.74e-8	Blood metabolite levels;
KIRP	cis	rs986417	0.818	rs965455	chr14:60960314	A/C	cg27398547	chr14:60952738	C14orf39	0.73	7.28	0.42	4.38e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.47	-5.9	-0.35	1.2e-8	IgG glycosylation;
KIRP	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg01721255	chr8:58191610	C8orf71	0.65	5.46	0.33	1.17e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg22437258	chr11:111473054	SIK2	0.67	8.05	0.46	3.58e-14	Primary sclerosing cholangitis;
KIRP	cis	rs4664293	0.836	rs11687502	chr2:160616975	T/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs9314323	0.624	rs117982737	chr8:26241010	C/T	cg13160058	chr8:26243215	BNIP3L	0.43	5.07	0.31	7.75e-7	Red cell distribution width;
KIRP	cis	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg07585502	chr8:101912084	NA	-0.65	-8.86	-0.49	1.61e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.63	6.52	0.38	4.06e-10	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg17706604	chr8:67624734	SGK3	0.5	6.09	0.36	4.3e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.53	6.73	0.39	1.21e-10	Autism spectrum disorder-related traits;
KIRP	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg15704280	chr7:45808275	SEPT13	0.7	6.26	0.37	1.69e-9	Axial length;
KIRP	cis	rs812925	0.537	rs10208769	chr2:61605614	A/T	cg15711740	chr2:61764176	XPO1	0.46	5.8	0.35	1.98e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg07596299	chr11:71824057	C11orf51	-0.84	-5.63	-0.34	5.01e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.23	0.42	6.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	8.78e-22	Morning vs. evening chronotype;
KIRP	cis	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg27411982	chr8:10470053	RP1L1	-0.46	-5.92	-0.35	1.1e-8	Neuroticism;
KIRP	cis	rs4148883	0.898	rs4699726	chr4:100099513	T/C	cg12011299	chr4:100065546	ADH4	0.5	6.63	0.39	2.06e-10	Alcohol dependence;
KIRP	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.59	7.43	0.43	1.79e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-6.83	-0.4	6.66e-11	Gut microbiome composition (summer);
KIRP	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg10189774	chr4:17578691	LAP3	-0.49	-5.79	-0.35	2.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.54	-0.43	9.02e-13	Bipolar disorder;
KIRP	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.61	0.34	5.37e-8	Bipolar disorder;
KIRP	cis	rs7224685	0.722	rs12945048	chr17:4159244	C/A	cg09695851	chr17:3907499	NA	0.61	6.58	0.39	2.78e-10	Type 2 diabetes;
KIRP	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg22777020	chr22:31556080	RNF185	-0.5	-5.25	-0.32	3.32e-7	Paclitaxel-induced neuropathy;
KIRP	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.51	7.44	0.43	1.63e-12	Lewy body disease;
KIRP	cis	rs988913	0.957	rs9382396	chr6:54760686	G/T	cg03513858	chr6:54763001	FAM83B	-0.39	-5.64	-0.34	4.61e-8	Menarche (age at onset);
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg19893067	chr17:80732956	TBCD	-0.35	-4.96	-0.3	1.29e-6	Glycated hemoglobin levels;
KIRP	cis	rs17321999	1.000	rs9309678	chr2:30487198	A/G	cg05247661	chr2:30472410	LBH	0.63	6.95	0.4	3.34e-11	Systemic lupus erythematosus;
KIRP	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.61	7.65	0.44	4.57e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.68	-9.5	-0.52	1.92e-18	Gut microbiome composition (winter);
KIRP	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.61	8.89	0.49	1.3e-16	Resting heart rate;
KIRP	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg25319279	chr11:5960081	NA	0.41	5.09	0.31	7.05e-7	DNA methylation (variation);
KIRP	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.53	8.28	0.47	8.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg03808351	chr9:123631620	PHF19	0.42	5.76	0.34	2.52e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.68e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg06521331	chr12:34319734	NA	-0.49	-6.09	-0.36	4.38e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23281280	chr6:28129359	ZNF389	0.5	5.35	0.32	2.03e-7	Depression;
KIRP	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.49	6.38	0.38	8.67e-10	Response to temozolomide;
KIRP	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.1	-0.36	4e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1978968	0.717	rs35645198	chr22:18408322	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.56	-6.74	-0.39	1.12e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs2882667	0.931	rs10075893	chr5:138355871	A/G	cg04439458	chr5:138467593	SIL1	0.43	7.34	0.42	3.03e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6450176	0.909	rs3776720	chr5:53296158	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.09	-0.58	1.94e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.4e-11	Electroencephalogram traits;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22168489	chr12:122356033	WDR66	0.56	8.5	0.48	1.86e-15	Mean corpuscular volume;
KIRP	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg27170947	chr2:26402098	FAM59B	-0.69	-7.43	-0.43	1.74e-12	Gut microbiome composition (summer);
KIRP	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg04727924	chr7:799746	HEATR2	0.72	8.31	0.47	6.46e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.76	11.71	0.6	1.77e-25	Urinary electrolytes (magnesium/calcium ratio);
KIRP	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-8.16	-0.46	1.71e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.3	-5.03	-0.31	9.4e-7	Monocyte count;
KIRP	cis	rs6752107	0.967	rs56049444	chr2:234157688	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	9.05	0.5	4.61e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.63	-9.5	-0.52	1.92e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg00981070	chr1:2046702	PRKCZ	0.31	5.3	0.32	2.54e-7	Height;
KIRP	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-7.01	-0.41	2.29e-11	Body mass index;
KIRP	cis	rs7751419	0.651	rs10947779	chr6:39093617	A/G	cg08089693	chr6:39098871	NA	-0.69	-9.9	-0.53	1.11e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg19767477	chr5:127420684	SLC12A2	-0.36	-5.14	-0.31	5.7e-7	Ileal carcinoids;
KIRP	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-8.11	-0.46	2.34e-14	Homocysteine levels;
KIRP	cis	rs7903847	0.620	rs7923385	chr10:99117097	T/A	cg20016023	chr10:99160130	RRP12	-0.41	-5.64	-0.34	4.58e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06481639	chr22:41940642	POLR3H	0.75	7.51	0.43	1.06e-12	Vitiligo;
KIRP	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg15871215	chr5:81402204	ATG10	0.48	6.36	0.38	9.8e-10	Breast cancer;
KIRP	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg05527609	chr1:210001259	C1orf107	-0.42	-5.32	-0.32	2.38e-7	Red blood cell count;
KIRP	cis	rs17331151	0.505	rs35371456	chr3:52563462	C/T	cg04865290	chr3:52927548	TMEM110	-0.55	-4.84	-0.3	2.27e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg24874828	chr4:187887005	NA	-0.54	-8.79	-0.49	2.58e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6687430	0.532	rs2150038	chr1:10609973	G/T	cg19773385	chr1:10388646	KIF1B	-0.39	-5.15	-0.31	5.22e-7	Hand grip strength;
KIRP	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.17	0.37	2.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.25e-14	Aortic root size;
KIRP	cis	rs7011507	1.000	rs6997499	chr8:49190984	G/T	cg15325961	chr8:49183143	NA	-0.59	-5.15	-0.31	5.43e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	7.59	0.44	6.46e-13	Bone mineral density;
KIRP	trans	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	6.53	0.38	3.8e-10	Ulcerative colitis;
KIRP	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.1	-12.76	-0.63	5.98e-29	Vitiligo;
KIRP	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg12549451	chr6:135224345	NA	0.42	5.07	0.31	7.82e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.88	13.96	0.66	5.06e-33	IgG glycosylation;
KIRP	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.72	9.04	0.5	4.68e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.6	-6.4	-0.38	7.87e-10	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09082480	chr16:83997636	OSGIN1	0.53	6.13	0.36	3.53e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs838147	0.733	rs12975781	chr19:49249698	A/G	cg13540341	chr19:49222985	MAMSTR	-0.32	-5.2	-0.31	4.21e-7	Dietary macronutrient intake;
KIRP	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg04398451	chr17:18023971	MYO15A	0.69	9.58	0.52	1.15e-18	Total body bone mineral density;
KIRP	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.58	0.34	6.29e-8	Parkinson's disease;
KIRP	cis	rs4466137	0.868	rs1975801	chr5:83022127	A/G	cg16102102	chr5:83017553	HAPLN1	-0.82	-10.79	-0.57	1.73e-22	Prostate cancer;
KIRP	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.52	-0.48	1.62e-15	Blood trace element (Zn levels);
KIRP	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.14	-0.41	1.06e-11	Mood instability;
KIRP	cis	rs5753618	0.583	rs2899164	chr22:31790289	G/A	cg02404636	chr22:31891804	SFI1	0.51	5.78	0.35	2.27e-8	Colorectal cancer;
KIRP	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.26	-0.55	8.32e-21	Triglycerides;
KIRP	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-5.59	-0.34	5.88e-8	Neuroticism;
KIRP	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.5	6.87	0.4	5.1e-11	Obesity-related traits;
KIRP	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.8	12.01	0.61	1.93e-26	Bladder cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14458328	chr5:41925210	FBXO4	0.41	6.14	0.36	3.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg03351412	chr1:154909251	PMVK	0.43	5.66	0.34	4.12e-8	Prostate cancer;
KIRP	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg15028436	chr7:37888078	TXNDC3	-0.48	-5.44	-0.33	1.28e-7	Alzheimer's disease (late onset);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22854549	chr19:5904785	VMAC;NDUFA11	-0.5	-6.8	-0.4	7.99e-11	Myopia;
KIRP	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.59	-6.84	-0.4	6.32e-11	Obesity (extreme);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12232835	chr3:183979215	ECE2;CAMK2N2	0.53	6.69	0.39	1.48e-10	Parkinson's disease;
KIRP	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06505273	chr16:24850292	NA	0.43	5.6	0.34	5.86e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.93	-10.88	-0.57	9.43e-23	Diastolic blood pressure;
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg21523564	chr15:75251491	NA	0.43	6.78	0.4	8.67e-11	Caffeine consumption;
KIRP	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17376030	chr22:41985996	PMM1	0.72	7.69	0.44	3.59e-13	Vitiligo;
KIRP	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg16512390	chr1:228756714	NA	0.46	5.16	0.31	5.18e-7	Diastolic blood pressure;
KIRP	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs7770628	0.653	rs1009124	chr6:161117913	G/A	cg14663533	chr6:160955178	LPA	0.42	5.66	0.34	4.29e-8	Protein quantitative trait loci;Lipoprotein (a) levels;
KIRP	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	1.24	11.24	0.58	6.13e-24	Lymphocyte counts;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19446589	chr2:63268631	EHBP1	0.42	6.18	0.37	2.6e-9	C-reactive protein;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.51	0.38	4.3e-10	Vitiligo;
KIRP	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg18132916	chr6:79620363	NA	-0.42	-5.66	-0.34	4.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs911119	0.908	rs12624424	chr20:23601878	C/T	cg09631192	chr20:23583594	CST9	-0.62	-5.83	-0.35	1.69e-8	Chronic kidney disease;
KIRP	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg22974920	chr21:40686053	BRWD1	-0.5	-6.06	-0.36	5.19e-9	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09309913	chr8:134583413	ST3GAL1	0.51	6.36	0.38	9.81e-10	Parkinson's disease;
KIRP	cis	rs7119038	0.629	rs11217000	chr11:118604984	A/G	cg19308663	chr11:118741387	NA	0.52	8.08	0.46	2.88e-14	Sjögren's syndrome;
KIRP	cis	rs1978968	0.763	rs9605478	chr22:18464410	G/A	cg03078520	chr22:18463400	MICAL3	-0.83	-11.74	-0.6	1.43e-25	Presence of antiphospholipid antibodies;
KIRP	cis	rs7560272	0.538	rs7370393	chr2:73925636	A/C	cg20560298	chr2:73613845	ALMS1	0.5	6.14	0.36	3.33e-9	Schizophrenia;
KIRP	cis	rs273218	1.000	rs273218	chr5:53380555	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.72	7.74	0.44	2.5e-13	Migraine;
KIRP	cis	rs7665939	1.000	rs7665190	chr4:190123040	A/G	cg09826759	chr4:190284978	NA	-0.67	-4.91	-0.3	1.65e-6	Amyotrophic lateral sclerosis;
KIRP	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg16141378	chr3:129829833	LOC729375	-0.47	-6.1	-0.36	4.08e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.51	0.56	1.39e-21	Exhaled nitric oxide output;
KIRP	cis	rs7707921	0.752	rs2406910	chr5:81308719	C/T	cg15871215	chr5:81402204	ATG10	0.47	5.84	0.35	1.67e-8	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9322225	chr6:150184882	G/C	cg09699651	chr6:150184138	LRP11	0.57	7.57	0.43	7.71e-13	Lung cancer;
KIRP	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg01028140	chr2:1542097	TPO	-0.53	-6.12	-0.36	3.71e-9	IgG glycosylation;
KIRP	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.48	6.18	0.37	2.62e-9	Menopause (age at onset);
KIRP	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.65	-10.04	-0.54	4.09e-20	Menopause (age at onset);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03480535	chr4:87856849	AFF1	0.56	6.4	0.38	7.68e-10	Lung cancer in ever smokers;
KIRP	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.17	-0.31	4.84e-7	Pulmonary function;
KIRP	cis	rs7919006	0.590	rs12249049	chr10:76786047	C/T	cg01390419	chr10:76803856	DUPD1	0.5	6.04	0.36	5.64e-9	Weight;
KIRP	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.35	-0.42	2.84e-12	Aortic root size;
KIRP	cis	rs4762326	1.000	rs10859856	chr12:95631276	T/C	cg07737802	chr12:95537812	FGD6	0.45	6.27	0.37	1.58e-9	Endometriosis;
KIRP	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg10326726	chr10:51549505	MSMB	-0.59	-8.99	-0.5	6.91e-17	Prostate-specific antigen levels;
KIRP	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-9.91	-0.53	1.09e-19	Eye color traits;
KIRP	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.46	-0.43	1.52e-12	Bipolar disorder;
KIRP	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.27	-0.32	2.98e-7	Electroencephalogram traits;
KIRP	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg00631329	chr6:26305371	NA	0.56	7.1	0.41	1.33e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-5.26	-0.32	3.08e-7	Skin colour saturation;
KIRP	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.5	-8.36	-0.47	4.75e-15	Height;
KIRP	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.89	13.29	0.65	9.68e-31	Coronary artery disease;
KIRP	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.55	-0.39	3.36e-10	Daytime sleep phenotypes;
KIRP	cis	rs16828019	0.777	rs67460888	chr1:41469337	T/C	cg24596898	chr1:41849189	NA	0.64	4.86	0.3	2.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.56	-9.03	-0.5	5.23e-17	Glomerular filtration rate (creatinine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05043032	chr1:95583073	TMEM56	0.51	6.93	0.4	3.58e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13995319	chr18:813013	YES1	0.55	6.72	0.39	1.23e-10	Lung cancer in ever smokers;
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg03289416	chr15:75166202	SCAMP2	0.58	8.25	0.47	9.6e-15	Breast cancer;
KIRP	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg10434728	chr15:90938212	IQGAP1	0.44	8.41	0.47	3.28e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs7712401	0.601	rs2164773	chr5:122338917	T/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.39e-7	Mean platelet volume;
KIRP	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.67	-7.36	-0.42	2.8e-12	Corneal structure;
KIRP	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg24826892	chr11:71159390	DHCR7	0.44	5.04	0.31	9.01e-7	Vitamin D levels;
KIRP	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.5	5.79	0.35	2.18e-8	Uric acid levels;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.69	-0.39	1.46e-10	Lung cancer;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg03547245	chr17:55335015	MSI2	-0.48	-6.33	-0.37	1.19e-9	Obesity-related traits;
KIRP	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.5	6.77	0.4	9.34e-11	Pulmonary function;
KIRP	cis	rs9479482	0.686	rs13199618	chr6:150384648	C/A	cg25797454	chr6:150327115	RAET1K	0.31	5.64	0.34	4.6e-8	Alopecia areata;
KIRP	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg05472934	chr7:22766657	IL6	0.85	11.01	0.57	3.41e-23	Lung cancer;
KIRP	cis	rs7523273	0.597	rs11118580	chr1:207959070	T/C	cg22525895	chr1:207977042	MIR29B2	-0.56	-4.9	-0.3	1.72e-6	Schizophrenia;
KIRP	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg02187348	chr16:89574699	SPG7	0.4	4.99	0.3	1.12e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.67	6.46	0.38	5.68e-10	Schizophrenia;
KIRP	cis	rs17592366	0.517	rs60007157	chr14:35312272	A/G	cg09327582	chr14:35236912	BAZ1A	0.55	5.8	0.35	2.04e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg26084005	chr2:241760190	KIF1A	0.48	5.82	0.35	1.82e-8	Urinary metabolites;
KIRP	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20135002	chr11:47629003	NA	-0.48	-5.7	-0.34	3.42e-8	Subjective well-being;
KIRP	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22168489	chr12:122356033	WDR66	0.66	9.67	0.52	5.73e-19	Mean corpuscular volume;
KIRP	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.8	11.93	0.61	3.38e-26	Ulcerative colitis;
KIRP	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.73	-8.98	-0.5	7.11e-17	Obesity-related traits;
KIRP	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.34	5.28	0.32	2.9e-7	Testicular germ cell tumor;
KIRP	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.61	-8.77	-0.49	3e-16	Multiple system atrophy;
KIRP	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs741677	0.963	rs8064649	chr17:472610	T/C	cg06217071	chr17:408420	NA	0.52	7.52	0.43	1.02e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.67	9.58	0.52	1.1e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg25512537	chr17:76250053	NA	0.33	5.75	0.34	2.62e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7215564	0.908	rs35646299	chr17:78653506	T/G	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg07382826	chr16:28625726	SULT1A1	-0.45	-5.04	-0.31	9.01e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11971779	0.590	rs11762145	chr7:138922666	G/A	cg07862535	chr7:139043722	LUC7L2	0.79	6.69	0.39	1.48e-10	Diisocyanate-induced asthma;
KIRP	cis	rs7818345	0.967	rs13258090	chr8:19285726	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.42	-6.17	-0.37	2.72e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	4.93	0.3	1.54e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09755102	chr1:33283495	S100PBP;YARS	-0.53	-6.73	-0.39	1.21e-10	Neuroticism;
KIRP	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg10189774	chr4:17578691	LAP3	0.51	6.23	0.37	2.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7577696	0.597	rs34197800	chr2:32389646	C/A	cg02381751	chr2:32503542	YIPF4	-0.53	-5.47	-0.33	1.12e-7	Inflammatory biomarkers;
KIRP	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.67	-10.21	-0.55	1.22e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07570687	chr10:102243282	WNT8B	0.48	5.77	0.35	2.42e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15828085	chr19:30302476	CCNE1	-0.57	-6.22	-0.37	2.12e-9	Menopause (age at onset);
KIRP	cis	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg19847130	chr8:10466454	RP1L1	-0.36	-5.7	-0.34	3.43e-8	Neuroticism;
KIRP	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg08648136	chr8:956695	NA	0.41	6.07	0.36	4.75e-9	Schizophrenia;
KIRP	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.4e-11	Electroencephalogram traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10267855	chr11:67121112	POLD4;LOC100130987	0.52	6.35	0.38	1.05e-9	Parkinson's disease;
KIRP	cis	rs4363385	0.510	rs6693927	chr1:153044009	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-6.19	-0.37	2.46e-9	Inflammatory skin disease;
KIRP	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg01559446	chr3:44596178	ZNF167	-0.36	-5.14	-0.31	5.7e-7	Depressive symptoms;
KIRP	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.28	0.32	2.88e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.64	-8.94	-0.5	9.73e-17	Breast cancer;
KIRP	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07167872	chr1:205819463	PM20D1	0.47	5.49	0.33	1.01e-7	Parkinson's disease;
KIRP	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg04013166	chr16:89971882	TCF25	0.67	5.63	0.34	4.83e-8	Skin colour saturation;
KIRP	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg17644776	chr2:200775616	C2orf69	0.62	5.67	0.34	4.01e-8	Schizophrenia;
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22168489	chr12:122356033	WDR66	0.65	9.89	0.53	1.25e-19	Mean corpuscular volume;
KIRP	cis	rs6500550	0.598	rs9989424	chr16:3672587	C/G	cg07396092	chr16:3662230	BTBD12	0.48	5.85	0.35	1.58e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg02462569	chr6:150064036	NUP43	-0.37	-5.6	-0.34	5.69e-8	Lung cancer;
KIRP	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg18709589	chr6:96969512	KIAA0776	0.34	5.08	0.31	7.63e-7	Headache;
KIRP	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	15.68	0.71	6.76e-39	Platelet count;
KIRP	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg11650704	chr1:154556575	ADAR	-0.42	-5.24	-0.32	3.43e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs16828019	0.852	rs12022978	chr1:41554088	A/G	cg18742814	chr1:41828276	NA	0.6	5.44	0.33	1.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.73	8.94	0.5	9.3e-17	DNA methylation (variation);
KIRP	cis	rs7527798	1.000	rs35823863	chr1:207873901	C/G	cg09232269	chr1:207846808	CR1L	-0.42	-5.07	-0.31	7.68e-7	Erythrocyte sedimentation rate;
KIRP	trans	rs763014	0.931	rs3752568	chr16:628302	A/G	cg00950418	chr7:105029125	SRPK2	-0.51	-6.34	-0.37	1.09e-9	Height;
KIRP	cis	rs17123764	0.605	rs73305098	chr12:50072997	G/A	cg02054252	chr12:50078554	FMNL3	0.43	4.87	0.3	2.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.7	9.97	0.54	7.06e-20	Mood instability;
KIRP	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg01950434	chr2:97203154	ARID5A	-0.5	-6.48	-0.38	4.9e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.47	-0.33	1.12e-7	Schizophrenia (age at onset);
KIRP	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.05e-17	Retinal vascular caliber;
KIRP	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg21360079	chr12:107162445	NA	-0.67	-9.34	-0.51	5.91e-18	Heart rate;
KIRP	trans	rs72634258	0.519	rs35267144	chr1:7934258	G/A	cg26848524	chr8:55294566	NA	-0.41	-6.12	-0.36	3.69e-9	Inflammatory bowel disease;
KIRP	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.75	8.3	0.47	7.01e-15	Cholesterol, total;
KIRP	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg06618935	chr21:46677482	NA	-0.36	-4.9	-0.3	1.76e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg14703610	chr5:56206110	C5orf35	0.49	6.77	0.4	9.56e-11	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20887711	chr4:1340912	KIAA1530	-0.47	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.49	-0.65	1.97e-31	Tonsillectomy;
KIRP	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.6	-8.05	-0.46	3.52e-14	Total body bone mineral density;
KIRP	cis	rs7246657	0.525	rs1667359	chr19:37486172	G/A	cg23950597	chr19:37808831	NA	-0.66	-5.88	-0.35	1.35e-8	Coronary artery calcification;
KIRP	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg20965017	chr5:231967	SDHA	-0.53	-6.11	-0.36	3.91e-9	Breast cancer;
KIRP	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg01620082	chr3:125678407	NA	-0.89	-6.48	-0.38	5.06e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.7	10.44	0.55	2.37e-21	Prostate cancer;
KIRP	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.84	-12.93	-0.64	1.62e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.52	7.31	0.42	3.71e-12	Coronary artery disease;
KIRP	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-7.17	-0.42	8.92e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-11.81	-0.6	8.38e-26	Height;
KIRP	cis	rs4356975	0.563	rs4508963	chr4:69984488	A/C	cg27372994	chr4:70080453	UGT2B11	0.36	4.85	0.3	2.2e-6	Obesity-related traits;
KIRP	cis	rs9826463	0.527	rs73238170	chr3:142100311	T/A	cg20824294	chr3:142316082	PLS1	0.39	5.86	0.35	1.47e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2916247	0.909	rs11785983	chr8:93049466	A/T	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.97	-0.45	5.94e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs8079658	0.904	rs62065065	chr17:63780029	G/A	cg18091269	chr17:63822838	CCDC46	-0.53	-6.56	-0.39	3.18e-10	Post bronchodilator FEV1;
KIRP	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.63	-6.34	-0.37	1.11e-9	Schizophrenia;
KIRP	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg10253484	chr15:75165896	SCAMP2	0.55	6.24	0.37	1.9e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.5	-7.12	-0.41	1.18e-11	Birth weight;
KIRP	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg09699651	chr6:150184138	LRP11	0.47	6.09	0.36	4.27e-9	Lung cancer;
KIRP	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-6.33	-0.37	1.16e-9	Blood metabolite levels;
KIRP	cis	rs72792276	0.818	rs57249773	chr5:127463166	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	7.21	0.42	6.83e-12	Red cell distribution width;
KIRP	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-0.97	-9.35	-0.51	5.51e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.57	-0.33	6.56e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01798499	chr12:123450932	ABCB9	0.47	6.23	0.37	2.04e-9	Parkinson's disease;
KIRP	cis	rs7582720	1.000	rs72932770	chr2:203680954	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.63e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.65	12.39	0.62	1e-27	Bone mineral density;
KIRP	cis	rs10924970	0.967	rs10754588	chr1:235438205	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg13173536	chr2:3403300	TTC15	-0.37	-4.97	-0.3	1.26e-6	Obesity-related traits;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04371633	chr14:65381025	CHURC1	0.47	6.24	0.37	1.87e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.76	10.12	0.54	2.39e-20	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.87	9.47	0.52	2.45e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.83	10.21	0.55	1.27e-20	Blood trace element (Cu levels);
KIRP	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg08738300	chr3:44038990	NA	0.66	8.83	0.49	1.99e-16	Coronary artery disease;
KIRP	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-6.6	-0.39	2.57e-10	Aortic root size;
KIRP	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.67	8.67	0.48	5.77e-16	Red blood cell count;
KIRP	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.89	0.45	9.98e-14	Lung cancer in ever smokers;
KIRP	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.23e-7	Obesity-related traits;
KIRP	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg14593290	chr7:50529359	DDC	0.8	9.99	0.54	5.94e-20	Malaria;
KIRP	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08975724	chr8:8085496	FLJ10661	0.65	8.21	0.46	1.24e-14	Mood instability;
KIRP	cis	rs56079296	0.929	rs7715363	chr5:121283915	G/C	cg01191064	chr5:121408893	LOX	-0.46	-5.06	-0.31	8.39e-7	Coronary artery disease;
KIRP	cis	rs735539	0.521	rs2818996	chr13:21428271	A/T	cg04906043	chr13:21280425	IL17D	-0.44	-5.2	-0.31	4.18e-7	Dental caries;
KIRP	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.43	8.11	0.46	2.4e-14	Educational attainment (years of education);
KIRP	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs282587	0.530	rs282602	chr13:113392644	G/A	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.82e-12	Glycated hemoglobin levels;
KIRP	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.71	-8.54	-0.48	1.46e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.62	-0.48	8.35e-16	Retinal vascular caliber;
KIRP	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg16497661	chr14:103986332	CKB	0.83	13.48	0.65	2.28e-31	Body mass index;
KIRP	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg16141378	chr3:129829833	LOC729375	0.54	7.07	0.41	1.62e-11	Retinal vascular caliber;
KIRP	cis	rs7534824	0.543	rs72734256	chr1:101390090	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.79	7.9	0.45	9.01e-14	Refractive astigmatism;
KIRP	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg17133734	chr15:86042851	AKAP13	-0.44	-5.58	-0.34	6.2e-8	Coronary artery disease;
KIRP	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9972944	0.691	rs10083837	chr17:63775311	C/G	cg07283582	chr17:63770753	CCDC46	0.52	8.55	0.48	1.32e-15	Total body bone mineral density;
KIRP	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.83	0.4	6.64e-11	Axial length;
KIRP	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.61	8.25	0.47	9.77e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7395581	0.918	rs326214	chr11:47298360	G/A	cg26139080	chr11:47293733	MADD	0.42	5.35	0.32	1.97e-7	HDL cholesterol;
KIRP	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.74	10.24	0.55	1.01e-20	Red blood cell count;
KIRP	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.72	-9.69	-0.53	5.02e-19	Glomerular filtration rate (creatinine);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00630453	chr20:2821369	FAM113A;VPS16	0.52	6.05	0.36	5.42e-9	Smoking initiation;
KIRP	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg22906224	chr7:99728672	NA	-0.65	-7.91	-0.45	9.01e-14	Coronary artery disease;
KIRP	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-8.73	-0.49	3.95e-16	Joint mobility (Beighton score);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05873124	chr14:61966719	PRKCH	0.4	6.16	0.37	2.88e-9	C-reactive protein;
KIRP	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg01320579	chr17:75405842	SEPT9	0.48	7.83	0.45	1.48e-13	Airflow obstruction;
KIRP	cis	rs7173743	0.935	rs12232282	chr15:79136525	T/C	cg00079375	chr15:79125835	NA	-0.41	-5.87	-0.35	1.37e-8	Coronary artery disease;
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.6	10.03	0.54	4.59e-20	Lymphocyte counts;
KIRP	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg16988262	chr1:15930761	NA	0.36	4.87	0.3	2.03e-6	Systolic blood pressure;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-9.41	-0.51	3.79e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.11	0.58	1.66e-23	Bipolar disorder;
KIRP	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.68	9.87	0.53	1.4e-19	Dupuytren's disease;
KIRP	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs7923609	1.000	rs12355784	chr10:65121565	G/T	cg08743896	chr10:65200160	JMJD1C	-0.41	-6.11	-0.36	3.8e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.62	-7.52	-0.43	1.01e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg18882449	chr10:104885122	NT5C2	0.47	6.04	0.36	5.6e-9	Arsenic metabolism;
KIRP	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-7.3	-0.42	3.87e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17694495	chr10:88281103	WAPAL	-0.45	-6.22	-0.37	2.08e-9	Metabolic traits;
KIRP	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.07	0.36	4.82e-9	Height;
KIRP	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg06742321	chr12:123595122	PITPNM2	0.45	5.6	0.34	5.61e-8	Platelet count;
KIRP	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg24881330	chr22:46731750	TRMU	0.66	4.98	0.3	1.19e-6	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12736937	chr8:144329131	ZFP41	-0.45	-6.4	-0.38	7.72e-10	Metabolic traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04774559	chr10:81965498	ANXA11	0.46	6.14	0.36	3.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	1.19	15.17	0.7	3.77e-37	Left atrial antero-posterior diameter;
KIRP	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	5.68	0.34	3.75e-8	Menarche (age at onset);
KIRP	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.51e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.27	0.65	1.12e-30	Eye color traits;
KIRP	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg16497661	chr14:103986332	CKB	-0.89	-15.52	-0.7	2.39e-38	Body mass index;
KIRP	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.7	-6.39	-0.38	8.45e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.93	14.18	0.67	8.93e-34	Mean platelet volume;
KIRP	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg25664220	chr3:72788482	NA	-0.39	-5.75	-0.34	2.68e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.68	-9.93	-0.54	8.98e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.55	6.33	0.37	1.16e-9	Aortic root size;
KIRP	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.88	-13.74	-0.66	2.93e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg14169450	chr9:139327907	INPP5E	0.57	6.93	0.4	3.66e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs6708331	0.517	rs13017427	chr2:70381531	G/A	cg05298696	chr2:70188691	ASPRV1	-0.46	-6.1	-0.36	4.14e-9	Obesity-related traits;
KIRP	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.61	7.41	0.43	2e-12	IgG glycosylation;
KIRP	trans	rs629535	0.954	rs559245	chr8:70009238	T/A	cg21567404	chr3:27674614	NA	-0.92	-13.28	-0.65	1.06e-30	Dupuytren's disease;
KIRP	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg08662619	chr6:150070041	PCMT1	0.37	5.96	0.36	8.74e-9	Lung cancer;
KIRP	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-0.38	-7.04	-0.41	1.9e-11	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.18	-23.62	-0.83	3.33e-65	Chronic sinus infection;
KIRP	cis	rs13394619	0.562	rs34532804	chr2:11746003	G/A	cg07314298	chr2:11723111	GREB1	0.48	6.5	0.38	4.39e-10	Endometriosis;
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg01721255	chr8:58191610	C8orf71	0.63	5.61	0.34	5.55e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07276078	chr15:39873206	THBS1	-0.52	-6.4	-0.38	7.66e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.69	10.51	0.56	1.42e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg06074448	chr4:187884817	NA	-0.75	-12.64	-0.63	1.53e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.76	11.12	0.58	1.58e-23	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.59	-6.91	-0.4	4.04e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.59	-0.39	2.66e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11997175	0.545	rs7839592	chr8:33666662	T/C	ch.8.33884649F	chr8:33765107	NA	0.5	6.01	0.36	6.81e-9	Body mass index;
KIRP	cis	rs7395581	0.842	rs2301216	chr11:47356870	A/T	cg26139080	chr11:47293733	MADD	-0.42	-5.12	-0.31	6.27e-7	HDL cholesterol;
KIRP	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14893161	chr1:205819251	PM20D1	-0.41	-4.86	-0.3	2.08e-6	Prostate-specific antigen levels;
KIRP	cis	rs12595433	0.895	rs12440897	chr15:63291484	C/T	cg03196360	chr15:63270641	NA	0.29	5.46	0.33	1.19e-7	Obesity-related traits;
KIRP	cis	rs9400467	0.537	rs12210707	chr6:111538387	C/T	cg15721981	chr6:111408429	SLC16A10	0.81	7.38	0.43	2.43e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10861342	1.000	rs7305712	chr12:105519188	A/T	cg23923672	chr12:105501055	KIAA1033	-0.85	-9.1	-0.5	3.24e-17	IgG glycosylation;
KIRP	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg07701084	chr6:150067640	NUP43	0.56	6.94	0.4	3.5e-11	Lung cancer;
KIRP	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.98	-0.36	7.64e-9	IgG glycosylation;
KIRP	trans	rs7619833	1.000	rs7646785	chr3:27482503	A/T	cg22620680	chr3:122920514	SEC22A	-0.46	-6.27	-0.37	1.64e-9	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10718078	chr1:201951076	RNPEP	0.46	6.15	0.37	3.12e-9	Interleukin-4 levels;
KIRP	trans	rs12659622	0.850	rs77611788	chr5:15639700	C/T	cg09887955	chr1:202129854	PTPN7	-0.54	-6.16	-0.37	2.88e-9	Obesity-related traits;
KIRP	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	1.0	16.14	0.72	1.93e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17524854	chr12:67663046	CAND1	0.52	7.2	0.42	7.35e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.58	7.03	0.41	1.99e-11	Blood metabolite levels;
KIRP	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg23307798	chr14:103986281	CKB	0.76	13.19	0.64	2.09e-30	Body mass index;
KIRP	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.49	-6.99	-0.41	2.58e-11	Height;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01765077	chr12:122356316	WDR66	0.45	6.12	0.36	3.74e-9	Mean corpuscular volume;
KIRP	cis	rs55986470	0.817	rs11883735	chr2:239407644	G/A	cg18131467	chr2:239335373	ASB1	-0.71	-5.37	-0.32	1.79e-7	Chronotype;
KIRP	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg00806126	chr19:22604979	ZNF98	0.68	7.23	0.42	6e-12	Pain;
KIRP	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.22	0.61	3.77e-27	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12366960	chr10:23122421	NA	0.55	7.79	0.44	1.86e-13	Interleukin-4 levels;
KIRP	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-6.48	-0.38	5.1e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1355223	0.902	rs680727	chr11:34704446	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.49	5.79	0.35	2.15e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.77	11.15	0.58	1.19e-23	Resting heart rate;
KIRP	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs7215564	0.908	rs7501544	chr17:78660946	T/A	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg22284058	chr8:142237359	SLC45A4	0.53	6.52	0.38	4.07e-10	Immature fraction of reticulocytes;
KIRP	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg12131826	chr15:77904385	NA	0.48	5.76	0.34	2.54e-8	Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.18e-7	Aortic root size;
KIRP	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.57	0.52	1.22e-18	Corneal astigmatism;
KIRP	cis	rs9394841	0.646	rs9369313	chr6:41847065	C/T	cg08135965	chr6:41755394	TOMM6	0.52	5.47	0.33	1.1e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs9859260	0.961	rs11185506	chr3:195797576	G/C	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.89	-0.3	1.79e-6	Mean corpuscular volume;
KIRP	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.99	-0.3	1.15e-6	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs882300	0.903	rs12472432	chr2:136919236	T/C	cg05194412	chr2:137003533	NA	-0.39	-5.3	-0.32	2.6e-7	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs4006360	0.575	rs6503607	chr17:39315344	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.38	-5.06	-0.31	8.3e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg07395648	chr5:131743802	NA	-0.44	-6.29	-0.37	1.4e-9	Blood metabolite levels;
KIRP	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26306683	chr17:18585705	ZNF286B	0.59	7.69	0.44	3.63e-13	Educational attainment (years of education);
KIRP	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9513627	1.000	rs7322368	chr13:100213990	T/C	cg25919922	chr13:100150906	NA	0.68	4.89	0.3	1.82e-6	Obesity-related traits;
KIRP	cis	rs2120243	0.565	rs1500919	chr3:157079048	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-8.41	-0.47	3.38e-15	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.57	-6.83	-0.4	6.59e-11	Monocyte count;
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg25347419	chr2:177043501	NA	0.38	5.23	0.32	3.59e-7	IgG glycosylation;
KIRP	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08392591	chr16:89556376	ANKRD11	0.4	5.2	0.31	4.27e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.55	-6.5	-0.38	4.44e-10	Bone mineral density;
KIRP	cis	rs56146971	0.703	rs76533089	chr14:91863973	G/T	cg16433844	chr14:91963127	SMEK1	-0.59	-5.35	-0.32	2.01e-7	Alzheimer disease and age of onset;
KIRP	cis	rs6539288	0.677	rs1348565	chr12:107329104	G/T	cg15890332	chr12:107067104	RFX4	0.35	5.61	0.34	5.34e-8	Total body bone mineral density;
KIRP	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg06042504	chr8:55087323	NA	-0.53	-6.49	-0.38	4.62e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20321375	chr12:8185526	FOXJ2	0.67	6.1	0.36	3.98e-9	Lung function (FEV1);
KIRP	cis	rs62355272	0.931	rs16902573	chr5:35907372	G/T	cg13894535	chr5:35919491	CAPSL	-0.55	-6.47	-0.38	5.38e-10	Lymphocyte counts;
KIRP	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg18944383	chr4:111397179	ENPEP	0.42	6.71	0.39	1.34e-10	Height;
KIRP	cis	rs4141404	0.673	rs1968023	chr22:31942770	A/G	cg02404636	chr22:31891804	SFI1	-0.57	-6.1	-0.36	4.04e-9	Paclitaxel-induced neuropathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09818691	chr1:12226143	TNFRSF1B	0.49	6.61	0.39	2.42e-10	Interleukin-4 levels;
KIRP	cis	rs9372498	0.536	rs9489394	chr6:118758234	T/C	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs7851660	0.809	rs7034648	chr9:100654093	C/A	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	5.2	0.31	4.22e-7	Leprosy;
KIRP	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.64	-8.42	-0.47	3.17e-15	Metabolic syndrome;
KIRP	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05025164	chr4:1340916	KIAA1530	0.4	4.99	0.3	1.14e-6	Obesity-related traits;
KIRP	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg18132916	chr6:79620363	NA	-0.36	-4.88	-0.3	1.89e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1050631	0.592	rs1539823	chr18:33736261	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.93	0.35	1.02e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg09184832	chr6:79620586	NA	-0.54	-7.34	-0.42	3.16e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.65	-7.3	-0.42	4.04e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs9309473	0.500	rs1528169	chr2:73669186	T/C	cg20560298	chr2:73613845	ALMS1	0.47	5.76	0.34	2.48e-8	Metabolite levels;
KIRP	cis	rs7919006	0.793	rs4746254	chr10:76803117	G/A	cg01390419	chr10:76803856	DUPD1	0.51	6.02	0.36	6.44e-9	Weight;
KIRP	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.85	-0.4	6.05e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.45	-6.98	-0.41	2.68e-11	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg07701084	chr6:150067640	NUP43	0.64	8.1	0.46	2.6e-14	Lung cancer;
KIRP	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg24826892	chr11:71159390	DHCR7	-0.44	-4.93	-0.3	1.51e-6	Vitamin D levels;
KIRP	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs4805834	0.719	rs12151363	chr19:33309030	A/T	cg07201929	chr19:33182834	NUDT19	-0.59	-4.95	-0.3	1.39e-6	Creatinine levels;
KIRP	cis	rs787274	1.000	rs4549852	chr9:115584223	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-6.66	-0.39	1.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg22903657	chr4:1355424	KIAA1530	0.35	4.86	0.3	2.05e-6	Obesity-related traits;
KIRP	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.49	-6.04	-0.36	5.57e-9	Dilated cardiomyopathy;
KIRP	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.65	-8.25	-0.47	9.55e-15	Tonsillectomy;
KIRP	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg24315340	chr6:146058215	EPM2A	-0.47	-5.89	-0.35	1.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg18016565	chr1:150552671	MCL1	-0.46	-7.18	-0.42	8.19e-12	Tonsillectomy;
KIRP	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg26513180	chr16:89883248	FANCA	-0.39	-4.88	-0.3	1.94e-6	Vitiligo;
KIRP	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	13.4	0.65	3.99e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg03161606	chr19:29218774	NA	0.83	8.02	0.46	4.43e-14	Methadone dose in opioid dependence;
KIRP	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg20913747	chr6:44695427	NA	-0.39	-4.94	-0.3	1.47e-6	Total body bone mineral density;
KIRP	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.71	0.49	4.44e-16	Lymphocyte counts;
KIRP	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg12218747	chr21:37451666	NA	-0.44	-5.33	-0.32	2.21e-7	Mitral valve prolapse;
KIRP	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11987759	chr7:65425863	GUSB	-0.45	-5.4	-0.33	1.58e-7	Aortic root size;
KIRP	cis	rs988913	0.837	rs9475109	chr6:54861913	T/C	cg03513858	chr6:54763001	FAM83B	-0.37	-5.11	-0.31	6.36e-7	Menarche (age at onset);
KIRP	trans	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg10756647	chr7:56101905	PSPH	1.02	7.45	0.43	1.61e-12	Diabetic kidney disease;
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg08662619	chr6:150070041	PCMT1	0.37	5.96	0.36	8.6e-9	Lung cancer;
KIRP	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg26149184	chr10:133730230	NA	0.42	4.97	0.3	1.24e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.19	0.31	4.34e-7	Smoking behavior;
KIRP	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-7.49	-0.43	1.22e-12	Educational attainment;
KIRP	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.5	6.46	0.38	5.58e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-1.02	-12.48	-0.62	5.06e-28	Breast cancer;
KIRP	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.68	10.03	0.54	4.38e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg08501292	chr6:25962987	TRIM38	0.78	5.32	0.32	2.39e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9488822	0.614	rs195529	chr6:116251893	T/C	cg26893134	chr6:116381904	FRK	0.19	5.01	0.3	1.05e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-9.87	-0.53	1.4e-19	Gut microbiome composition (summer);
KIRP	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg00405596	chr8:11794950	NA	0.58	7.95	0.45	6.8e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10875746	0.517	rs12721420	chr12:48358794	C/T	cg20731937	chr12:48336164	NA	0.71	8.78	0.49	2.81e-16	Longevity (90 years and older);
KIRP	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg01270228	chr10:1369114	ADARB2	0.53	6.91	0.4	4.16e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs7712401	0.715	rs436160	chr5:122355953	G/A	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs75920871	0.640	rs61903395	chr11:116931907	A/G	cg04087571	chr11:116723030	SIK3	-0.26	-5.03	-0.31	9.37e-7	Subjective well-being;
KIRP	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg02503808	chr4:7069936	GRPEL1	0.92	12.52	0.62	3.83e-28	Monocyte percentage of white cells;
KIRP	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg15507776	chr3:136538369	TMEM22	0.52	7.47	0.43	1.37e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.73	7.11	0.41	1.22e-11	Vitiligo;
KIRP	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg04691961	chr3:161091175	C3orf57	-0.53	-8.19	-0.46	1.43e-14	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.05	-0.41	1.76e-11	Joint mobility (Beighton score);
KIRP	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg00334542	chr7:100209784	MOSPD3	-0.78	-6.57	-0.39	3e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.57	7.7	0.44	3.23e-13	Bladder cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06128612	chr12:123868427	SETD8	0.43	6.01	0.36	6.51e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9359856	0.564	rs1179902	chr6:90321545	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-8.25	-0.47	9.8e-15	Bipolar disorder;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg10211518	chr19:633735	POLRMT	0.5	6.24	0.37	1.85e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg25486957	chr4:152246857	NA	-0.42	-4.85	-0.3	2.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10114408	0.921	rs1890374	chr9:96661146	A/G	cg14598338	chr9:96623480	NA	-0.32	-4.92	-0.3	1.56e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.38	17.54	0.75	3.17e-45	Uric acid levels;
KIRP	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.03	-0.58	3e-23	Height;
KIRP	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.74	8.29	0.47	7.54e-15	Corneal astigmatism;
KIRP	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg25486957	chr4:152246857	NA	-0.41	-4.96	-0.3	1.33e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13784276	chr9:139103646	QSOX2	0.45	6.07	0.36	4.8e-9	Pancreatic cancer;
KIRP	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12292205	chr6:26970375	C6orf41	-0.71	-7.58	-0.44	7e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg20003494	chr4:90757398	SNCA	-0.4	-5.15	-0.31	5.38e-7	Neuroticism;
KIRP	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg24060327	chr5:131705240	SLC22A5	-0.46	-5.85	-0.35	1.55e-8	Breast cancer;
KIRP	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7909791	0.606	rs3814219	chr10:105647095	A/G	cg11005552	chr10:105648138	OBFC1	-0.46	-5.22	-0.32	3.87e-7	White matter hyperintensity burden;
KIRP	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg27494647	chr7:150038898	RARRES2	0.41	6.34	0.37	1.09e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg09699651	chr6:150184138	LRP11	0.49	6.54	0.38	3.51e-10	Lung cancer;
KIRP	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.84	-14.04	-0.67	2.8e-33	Brugada syndrome;
KIRP	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg02811702	chr13:24901961	NA	0.41	5.39	0.33	1.63e-7	Obesity-related traits;
KIRP	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg24826892	chr11:71159390	DHCR7	0.45	5.01	0.3	1.06e-6	Vitamin D levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg24475210	chr4:6642433	MRFAP1	1.09	7.5	0.43	1.17e-12	P wave terminal force;
KIRP	cis	rs2012796	0.957	rs8016255	chr14:81816121	C/G	cg02996355	chr14:81879375	NA	0.43	5.76	0.34	2.44e-8	Night sleep phenotypes;
KIRP	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.54	-7.3	-0.42	3.94e-12	Schizophrenia;
KIRP	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg11859384	chr17:80120422	CCDC57	-0.4	-5.05	-0.31	8.5e-7	Life satisfaction;
KIRP	cis	rs7712401	0.580	rs42536	chr5:122276423	T/C	cg19412675	chr5:122181750	SNX24	0.47	5.2	0.31	4.22e-7	Mean platelet volume;
KIRP	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.95	12.44	0.62	6.68e-28	Menopause (age at onset);
KIRP	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg09137382	chr11:130731461	NA	0.56	8.2	0.46	1.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	7.98	0.45	5.45e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.22	-0.58	7.38e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.44	-0.38	6.36e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07192243	chr13:40233555	COG6	-0.42	-6.21	-0.37	2.3e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg03188948	chr7:1209495	NA	0.49	5.47	0.33	1.09e-7	Longevity;Endometriosis;
KIRP	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12292205	chr6:26970375	C6orf41	0.64	7.1	0.41	1.36e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg19116668	chr7:99932089	PMS2L1	0.43	4.9	0.3	1.73e-6	Coronary artery disease;
KIRP	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg14593290	chr7:50529359	DDC	0.8	10.02	0.54	5e-20	Malaria;
KIRP	cis	rs6545883	0.708	rs2518936	chr2:61792342	T/C	cg15711740	chr2:61764176	XPO1	-0.54	-7.07	-0.41	1.56e-11	Tuberculosis;
KIRP	cis	rs6991838	0.584	rs4737747	chr8:66519259	C/T	cg13398993	chr8:66546079	ARMC1	-0.44	-5.08	-0.31	7.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8022179	0.580	rs6575977	chr14:103823348	G/T	cg16497661	chr14:103986332	CKB	-0.53	-5.68	-0.34	3.88e-8	Monocyte count;
KIRP	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg02980000	chr4:1222292	CTBP1	0.75	8.89	0.49	1.37e-16	Systolic blood pressure;
KIRP	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.59	-11.51	-0.59	8.26e-25	Diabetic kidney disease;
KIRP	cis	rs9972944	0.756	rs2318868	chr17:63767592	G/T	cg07283582	chr17:63770753	CCDC46	-0.48	-7.95	-0.45	6.9e-14	Total body bone mineral density;
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg06057666	chr1:227327429	CDC42BPA	-0.35	-6.2	-0.37	2.4e-9	Suicide attempts in major depressive disorder;
KIRP	cis	rs7927997	0.965	rs7927894	chr11:76301316	A/G	cg17647271	chr11:76299819	NA	0.38	5.1	0.31	6.76e-7	Gut microbiota (functional units);Crohn's disease;
KIRP	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg07309820	chr7:148901717	ZNF282	-0.4	-5.2	-0.31	4.18e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg06917634	chr15:78832804	PSMA4	-0.67	-7.69	-0.44	3.49e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg19077165	chr18:44547161	KATNAL2	-0.55	-6.76	-0.4	1.02e-10	Educational attainment;
KIRP	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.59	7.37	0.43	2.53e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7998202	0.614	rs668967	chr13:113369948	G/A	cg04656015	chr13:113407548	ATP11A	-0.57	-6.19	-0.37	2.51e-9	Glycated hemoglobin levels;
KIRP	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs4262150	0.846	rs4958574	chr5:152091901	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.1	-0.46	2.54e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.49	6.88	0.4	5.01e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11225247	1.000	rs11225242	chr11:102274181	G/C	cg06323957	chr11:102217781	BIRC2	0.93	5.95	0.35	9.21e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-4.92	-0.3	1.57e-6	Platelet distribution width;
KIRP	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	7.97	0.45	5.95e-14	Neuroticism;
KIRP	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.49	-0.43	1.2e-12	Response to antipsychotic treatment;
KIRP	cis	rs10073892	0.830	rs10479214	chr5:101737869	C/A	cg19774478	chr5:101632501	SLCO4C1	0.67	6.49	0.38	4.73e-10	Cognitive decline (age-related);
KIRP	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12210905	1.000	rs5030955	chr6:27213867	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.39	-0.38	8.31e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	1.04	12.21	0.61	4.13e-27	Breast cancer;
KIRP	cis	rs501120	0.564	rs61855758	chr10:44684854	T/C	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.46	5.82	0.35	1.84e-8	Life satisfaction;
KIRP	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg21775007	chr8:11205619	TDH	0.48	6.72	0.39	1.28e-10	Mood instability;
KIRP	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.93e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.7	9.46	0.52	2.53e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.87	-12.15	-0.61	6.21e-27	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.34	-0.37	1.09e-9	Aortic root size;
KIRP	cis	rs4908768	1.000	rs11121203	chr1:8648240	T/C	cg03610117	chr1:8450231	RERE	-0.49	-5.08	-0.31	7.41e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6546886	0.826	rs13030414	chr2:74255284	T/A	cg14702570	chr2:74259524	NA	-0.27	-5.14	-0.31	5.67e-7	Dialysis-related mortality;
KIRP	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.51	-6.39	-0.38	8.34e-10	Iron status biomarkers;
KIRP	cis	rs7712401	0.562	rs30053	chr5:122303643	C/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg06521331	chr12:34319734	NA	-0.45	-5.28	-0.32	2.77e-7	Resting heart rate;
KIRP	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	1.21	12.77	0.63	5.49e-29	Alzheimer's disease;
KIRP	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg00343986	chr7:65444356	GUSB	-0.43	-4.99	-0.3	1.12e-6	Aortic root size;
KIRP	cis	rs7551222	0.749	rs6594018	chr1:204568152	A/G	cg20240347	chr1:204465584	NA	-0.4	-7.59	-0.44	6.48e-13	Schizophrenia;
KIRP	trans	rs7939886	0.920	rs4489763	chr11:55944474	G/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.62	-7.21	-0.42	6.77e-12	DNA methylation (variation);
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg01391022	chr12:122360665	WDR66	-0.37	-5.26	-0.32	3.12e-7	Mean corpuscular volume;
KIRP	cis	rs714027	0.605	rs41176	chr22:30432403	G/T	cg27665648	chr22:30112403	NA	-0.42	-5.85	-0.35	1.53e-8	Lymphocyte counts;
KIRP	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.93	12.86	0.63	2.77e-29	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	1.08	17.6	0.75	1.99e-45	Homoarginine levels;
KIRP	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.42	-0.33	1.41e-7	Dupuytren's disease;
KIRP	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.43	-5.17	-0.31	4.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg07402062	chr16:89894098	SPIRE2	0.34	7.24	0.42	5.64e-12	Vitiligo;
KIRP	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19717773	chr7:2847554	GNA12	-0.44	-6.49	-0.38	4.78e-10	Height;
KIRP	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg24296786	chr1:45957014	TESK2	0.55	6.83	0.4	6.75e-11	High light scatter reticulocyte count;
KIRP	cis	rs2860975	1.000	rs2860975	chr10:96766934	G/T	cg09036531	chr10:96991505	NA	0.54	6.94	0.4	3.55e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	9.41	0.51	3.57e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.17	0.31	4.77e-7	Cognitive test performance;
KIRP	cis	rs6693295	0.536	rs6656404	chr1:246255288	A/T	cg11798871	chr1:246315928	SMYD3	-0.68	-7.45	-0.43	1.61e-12	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs17221829	0.703	rs10830336	chr11:89406461	G/A	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.23	-0.32	3.55e-7	Anxiety in major depressive disorder;
KIRP	cis	rs2594989	0.943	rs9830784	chr3:11434605	A/G	cg01796438	chr3:11312864	ATG7	-0.72	-8.24	-0.47	1.03e-14	Circulating chemerin levels;
KIRP	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.63	-8.94	-0.5	9.58e-17	Total body bone mineral density;
KIRP	cis	rs2213920	0.619	rs6478174	chr9:118252779	C/T	cg13918206	chr9:118159781	DEC1	1.01	10.09	0.54	2.97e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg14343924	chr8:8086146	FLJ10661	0.43	5.16	0.31	5.15e-7	Mood instability;
KIRP	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.18	-0.31	4.67e-7	Personality dimensions;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg06061049	chr2:17934875	GEN1;SMC6	0.51	6.09	0.36	4.4e-9	Educational attainment;
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg22753607	chr9:37120306	ZCCHC7	0.46	6.28	0.37	1.5e-9	Plasma plasminogen activator levels;
KIRP	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.53	7.82	0.45	1.56e-13	Bipolar disorder;
KIRP	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.83	10.63	0.56	5.99e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs12973672	0.812	rs35497966	chr19:35764965	A/C	cg12095397	chr19:35769544	USF2	0.63	6.14	0.36	3.33e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4748857	0.947	rs7082900	chr10:23595533	G/A	cg12804278	chr10:23633326	C10orf67	0.42	5.18	0.31	4.53e-7	Systemic lupus erythematosus;
KIRP	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.33	-0.59	3.27e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg01798813	chr17:3906674	NA	0.55	7.66	0.44	4.17e-13	Type 2 diabetes;
KIRP	cis	rs1629083	0.846	rs605560	chr11:118067187	C/G	cg18857871	chr11:118064634	AMICA1	0.67	9.41	0.51	3.7e-18	Lung cancer;
KIRP	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg02463440	chr8:22132932	PIWIL2	0.38	4.87	0.3	1.97e-6	Hypertriglyceridemia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25571197	chr14:23298904	MRPL52	-0.46	-6.08	-0.36	4.55e-9	Interleukin-4 levels;
KIRP	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg09547025	chr6:142721804	GPR126	-0.38	-4.88	-0.3	1.94e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.5	-6.2	-0.37	2.33e-9	Red blood cell count;
KIRP	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00684032	chr4:1343700	KIAA1530	0.43	5.62	0.34	5.05e-8	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg10760299	chr15:45669010	GATM	0.35	5.11	0.31	6.47e-7	Homoarginine levels;
KIRP	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg06289844	chr6:126071538	HEY2	-0.36	-5.24	-0.32	3.45e-7	Brugada syndrome;
KIRP	cis	rs7010267	0.805	rs6992497	chr8:119980069	A/G	cg01975934	chr8:119970761	NA	-0.41	-5.19	-0.31	4.49e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.33	11.83	0.6	7.39e-26	Diabetic retinopathy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26419941	chr12:49183133	ADCY6	0.52	6.25	0.37	1.81e-9	Smoking initiation;
KIRP	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.87	11.46	0.59	1.17e-24	Orofacial clefts;
KIRP	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.78	0.6	1.04e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg22467129	chr15:76604101	ETFA	-0.38	-5.42	-0.33	1.42e-7	Blood metabolite levels;
KIRP	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.53	7.34	0.42	3.03e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-6.78	-0.4	8.81e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs33912345	0.695	rs1033732	chr14:60829564	A/G	cg27398547	chr14:60952738	C14orf39	0.41	5.46	0.33	1.14e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs6442310	0.534	rs1151999	chr3:12447153	G/T	cg02700894	chr3:12045449	SYN2	-0.39	-5.31	-0.32	2.45e-7	Hematocrit;
KIRP	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg24011408	chr12:48396354	COL2A1	-0.44	-6.11	-0.36	3.93e-9	Plateletcrit;
KIRP	cis	rs9653442	0.545	rs4850921	chr2:100762699	G/T	cg17356467	chr2:100759845	AFF3	0.48	6.31	0.37	1.3e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs28655083	1.000	rs1843455	chr16:77072343	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-5.61	-0.34	5.38e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.32	5.1	0.31	6.65e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg18709589	chr6:96969512	KIAA0776	0.34	5.04	0.31	8.89e-7	Headache;
KIRP	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg07001201	chr5:642380	CEP72	0.69	6.52	0.38	4.03e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7561273	0.609	rs3795953	chr2:24345707	C/G	cg20701182	chr2:24300061	SF3B14	0.49	6.04	0.36	5.67e-9	Quantitative traits;
KIRP	cis	rs74181299	0.571	rs2302647	chr2:65283174	G/A	cg05010058	chr2:65284262	CEP68	0.44	5.54	0.33	7.78e-8	Pulse pressure;
KIRP	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg08662619	chr6:150070041	PCMT1	0.33	5.16	0.31	5.13e-7	Lung cancer;
KIRP	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	6.33	0.37	1.14e-9	Height;
KIRP	cis	rs76793172	1.000	rs16980027	chr19:46313105	C/T	cg00442267	chr19:46317840	RSPH6A	-0.76	-6.06	-0.36	5.19e-9	Eosinophil counts;
KIRP	cis	rs1010254	0.559	rs72808324	chr5:151742995	T/C	cg12297329	chr5:152029980	NA	-0.61	-6.23	-0.37	1.98e-9	Optic nerve measurement (cup area);
KIRP	cis	rs1971256	0.500	rs9479050	chr6:151806338	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-5.94	-0.35	9.79e-9	Endometriosis;
KIRP	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.73	10.76	0.57	2.25e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg03959625	chr15:84868606	LOC388152	0.7	8.55	0.48	1.28e-15	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.73	5.87	0.35	1.41e-8	Diabetic retinopathy;
KIRP	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg12756093	chr1:115239321	AMPD1	-0.68	-9.76	-0.53	3.04e-19	Autism;
KIRP	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg10755058	chr3:40428713	ENTPD3	0.45	6.33	0.37	1.14e-9	Renal cell carcinoma;
KIRP	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg24488311	chr11:68621650	NA	0.47	5.42	0.33	1.41e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.4	-4.9	-0.3	1.77e-6	Asthma;
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg11204139	chr17:3907470	NA	0.61	8.24	0.47	1.04e-14	Type 2 diabetes;
KIRP	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg01864069	chr14:103024347	NA	-0.97	-13.06	-0.64	5.98e-30	Platelet count;
KIRP	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.55	-0.48	1.35e-15	Monocyte percentage of white cells;
KIRP	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-8.06	-0.46	3.41e-14	Homocysteine levels;
KIRP	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06481639	chr22:41940642	POLR3H	0.74	7.88	0.45	1.05e-13	Vitiligo;
KIRP	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg06307176	chr5:131281290	NA	0.55	6.21	0.37	2.25e-9	Life satisfaction;
KIRP	trans	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg25042112	chr7:64838748	ZNF92	0.58	6.14	0.36	3.34e-9	Pain;
KIRP	cis	rs11997175	0.545	rs67960786	chr8:33668770	G/A	cg04338863	chr8:33670619	NA	0.44	5.58	0.34	6.29e-8	Body mass index;
KIRP	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.02	-0.57	3.22e-23	Height;
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg22907277	chr7:1156413	C7orf50	0.84	7.99	0.45	5.26e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.38	-0.32	1.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4148660	1.000	rs10770867	chr12:22071795	G/C	cg14669847	chr12:22099120	NA	0.34	5.79	0.35	2.17e-8	Gout;
KIRP	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg05973401	chr12:123451056	ABCB9	0.51	5.45	0.33	1.2e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7246657	0.722	rs2909105	chr19:38167906	A/G	cg18154014	chr19:37997991	ZNF793	-0.64	-6.96	-0.41	3.02e-11	Coronary artery calcification;
KIRP	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg11945507	chr8:142233382	SLC45A4	-0.47	-6.24	-0.37	1.94e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg11130432	chr3:121712080	ILDR1	-0.48	-5.84	-0.35	1.63e-8	Multiple sclerosis;
KIRP	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg20290983	chr6:43655470	MRPS18A	1.0	11.22	0.58	7.25e-24	IgG glycosylation;
KIRP	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.22	-0.37	2.12e-9	Arsenic metabolism;
KIRP	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.55	-6.0	-0.36	6.95e-9	Body mass index;
KIRP	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.58	0.52	1.12e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs783540	0.521	rs28719490	chr15:83389440	A/G	cg18393722	chr15:85113863	UBE2QP1	0.54	6.43	0.38	6.68e-10	Schizophrenia;
KIRP	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.34	5.08	0.31	7.54e-7	Type 2 diabetes;
KIRP	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.32	-5.85	-0.35	1.53e-8	Educational attainment (years of education);
KIRP	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.28	-0.32	2.77e-7	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04091209	chr15:75744113	SIN3A	0.47	6.67	0.39	1.67e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.47	-0.33	1.09e-7	Menarche (age at onset);
KIRP	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg20750642	chr13:99100586	FARP1	0.42	5.24	0.32	3.39e-7	Longevity;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09963654	chr16:2806322	SRRM2	0.56	6.77	0.4	9.24e-11	Interleukin-4 levels;
KIRP	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23346625	chr5:146619708	STK32A	-0.45	-6.12	-0.36	3.71e-9	Inflammatory biomarkers;
KIRP	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg16479474	chr6:28041457	NA	0.45	4.87	0.3	2.02e-6	Depression;
KIRP	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.49	-0.38	4.75e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4332428	1.000	rs66885174	chr10:4975650	C/A	cg19648686	chr10:5044992	AKR1C2	-1.03	-8.53	-0.48	1.49e-15	Height;
KIRP	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	5.15	0.31	5.47e-7	Schizophrenia;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.71	10.77	0.57	2.12e-22	Menarche (age at onset);
KIRP	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs6987853	0.787	rs2974314	chr8:42457043	C/T	cg09913449	chr8:42400586	C8orf40	0.39	5.18	0.31	4.63e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg01689657	chr7:91764605	CYP51A1	0.36	5.34	0.32	2.1e-7	Breast cancer;
KIRP	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.63	-8.14	-0.46	1.92e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.65	8.37	0.47	4.31e-15	Height;
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-5.94	-0.35	9.77e-9	Lung cancer;
KIRP	cis	rs601339	1.000	rs11059384	chr12:123170301	C/A	cg18578876	chr12:123200353	GPR109B	0.5	4.9	0.3	1.72e-6	Adiponectin levels;
KIRP	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg25547332	chr5:131281432	NA	0.46	5.16	0.31	5.1e-7	Life satisfaction;
KIRP	cis	rs5750854	0.503	rs5750862	chr22:40026309	G/A	cg21377881	chr22:40064566	CACNA1I	-0.42	-5.75	-0.34	2.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17001868	0.892	rs12483888	chr22:40801312	A/G	cg07138101	chr22:40742427	ADSL	0.73	6.09	0.36	4.3e-9	Mammographic density (dense area);
KIRP	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg20387954	chr3:183756860	HTR3D	0.42	5.53	0.33	8.22e-8	Anterior chamber depth;
KIRP	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg23594656	chr7:65796392	TPST1	0.47	7.4	0.43	2.14e-12	Aortic root size;
KIRP	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26314531	chr2:26401878	FAM59B	-0.47	-5.01	-0.3	1.02e-6	Gut microbiome composition (summer);
KIRP	cis	rs10114408	0.959	rs10761304	chr9:96656982	A/G	cg14598338	chr9:96623480	NA	-0.33	-4.94	-0.3	1.46e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs2856321	0.874	rs1009951	chr12:11892896	C/T	cg06610204	chr17:21030148	DHRS7B	0.46	6.05	0.36	5.45e-9	Height;
KIRP	cis	rs1465370	0.800	rs62471721	chr7:130016470	G/A	cg03229158	chr7:130009420	NA	0.34	4.86	0.3	2.07e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14971439	chr5:122297244	SNX24	-0.39	-6.22	-0.37	2.12e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-5.24	-0.32	3.53e-7	Ulcerative colitis;
KIRP	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.74	9.4	0.51	4.08e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.36	-0.38	9.62e-10	Total body bone mineral density;
KIRP	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.95	-16.66	-0.73	3.17e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.59	0.34	6.03e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-8.02	-0.46	4.42e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg23894439	chr1:183413866	NA	-0.4	-5.22	-0.32	3.85e-7	Systemic lupus erythematosus;
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg05627522	chr15:75251581	NA	0.33	5.04	0.31	9.05e-7	Breast cancer;
KIRP	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.96	11.66	0.6	2.58e-25	Corneal astigmatism;
KIRP	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.15	-0.31	5.33e-7	Pulmonary function;
KIRP	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	0.95	8.07	0.46	3.05e-14	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.89	0.3	1.84e-6	Renal cell carcinoma;
KIRP	cis	rs7221595	0.825	rs8074860	chr17:3986657	C/G	cg09695851	chr17:3907499	NA	0.59	5.69	0.34	3.62e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg06453172	chr10:134556979	INPP5A	-0.6	-6.73	-0.39	1.19e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg16524733	chr11:117070046	TAGLN	0.38	4.95	0.3	1.39e-6	Blood protein levels;
KIRP	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.94	11.0	0.57	3.73e-23	Neuroticism;
KIRP	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg24130564	chr14:104152367	KLC1	-0.45	-5.21	-0.32	3.91e-7	Reticulocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16678602	chr10:85954331	PCDH21	0.45	6.16	0.37	3e-9	Parkinson's disease;
KIRP	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.6	6.22	0.37	2.18e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.48	6.44	0.38	6.18e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-1.05	-10.68	-0.56	4.06e-22	Post bronchodilator FEV1;
KIRP	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.32	-0.37	1.21e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	15.93	0.71	9.6e-40	Height;
KIRP	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg16586182	chr3:47516702	SCAP	-0.73	-10.2	-0.55	1.32e-20	Colorectal cancer;
KIRP	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	trans	rs6601327	0.600	rs7828039	chr8:9654757	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.83	-0.4	6.54e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg08761264	chr16:28874980	SH2B1	-0.51	-5.89	-0.35	1.29e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6991838	0.584	rs7463740	chr8:66486185	G/A	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.26	4.97	0.3	1.26e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	1.01	14.37	0.68	2.09e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.43	-6.45	-0.38	6.01e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.56	-7.84	-0.45	1.33e-13	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	10.29	0.55	6.74e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.62	-8.32	-0.47	6.13e-15	Rheumatoid arthritis;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20814179	chr4:940893	TMEM175	0.57	9.34	0.51	6.2e-18	Sjögren's syndrome;
KIRP	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.37	-5.48	-0.33	1.07e-7	Height;
KIRP	cis	rs2033732	0.826	rs2196618	chr8:85089437	A/G	cg05716166	chr8:85095498	RALYL	0.5	5.73	0.34	2.96e-8	Body mass index;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg11310756	chr17:8012578	ALOXE3	0.43	6.41	0.38	7.49e-10	Serum protein levels (sST2);
KIRP	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs6016377	0.737	rs6016380	chr20:39179975	A/G	cg22477343	chr20:39312069	NA	0.48	6.32	0.37	1.24e-9	Birth weight;
KIRP	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.62	7.06	0.41	1.66e-11	Caffeine consumption;
KIRP	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.91	-12.39	-0.62	9.98e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg06204229	chr3:52865917	ITIH4	-0.38	-5.7	-0.34	3.47e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.7	-9.11	-0.5	3.04e-17	Iron status biomarkers;
KIRP	cis	rs28489187	0.617	rs233061	chr1:85799282	G/A	cg16011679	chr1:85725395	C1orf52	0.44	5.51	0.33	8.94e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs4660531	1.000	rs4660532	chr1:41840197	C/T	cg08462924	chr1:41848221	NA	0.4	5.73	0.34	2.94e-8	Bipolar disorder;
KIRP	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg02023728	chr11:77925099	USP35	0.35	5.51	0.33	8.95e-8	Alzheimer's disease (survival time);
KIRP	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.79	-9.84	-0.53	1.74e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4849845	0.889	rs7557096	chr2:121032043	A/T	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs9462846	0.959	rs6937172	chr6:42884375	A/T	cg02353165	chr6:42928485	GNMT	0.49	5.55	0.33	7.22e-8	Blood protein levels;
KIRP	cis	rs1062177	0.950	rs59580263	chr5:151269577	T/A	cg00977110	chr5:151150581	G3BP1	0.6	6.04	0.36	5.6e-9	Preschool internalizing problems;
KIRP	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg19767477	chr5:127420684	SLC12A2	-0.37	-5.22	-0.32	3.72e-7	Ileal carcinoids;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.89	-0.53	1.28e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2554380	0.843	rs2562783	chr15:84387926	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.5	-7.12	-0.41	1.21e-11	Height;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg15117754	chr3:10150083	C3orf24	0.54	5.34	0.32	2.08e-7	Alzheimer's disease;
KIRP	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.51	0.38	4.28e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.48	6.42	0.38	6.84e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg01877450	chr7:97915802	BRI3	-0.57	-7.27	-0.42	4.64e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1620921	0.967	rs1247570	chr6:161208957	T/C	cg01280913	chr6:161186852	NA	-0.41	-5.6	-0.34	5.64e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.65	-6.99	-0.41	2.64e-11	DNA methylation (variation);
KIRP	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg15655495	chr12:38532458	NA	-0.27	-5.26	-0.32	3.1e-7	Bladder cancer;
KIRP	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.55	0.39	3.31e-10	Rheumatoid arthritis;
KIRP	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.84	-0.4	6.34e-11	Diastolic blood pressure;
KIRP	cis	rs11264213	0.892	rs6661867	chr1:36195809	C/A	cg27506609	chr1:36549197	TEKT2	0.76	6.83	0.4	6.74e-11	Schizophrenia;
KIRP	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg10223061	chr2:219282414	VIL1	0.32	5.3	0.32	2.52e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	trans	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.36	3.81e-9	Mean corpuscular volume;
KIRP	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.59	-6.74	-0.39	1.15e-10	Blood trace element (Cu levels);
KIRP	cis	rs282587	0.569	rs378432	chr13:113398048	A/C	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.64e-12	Glycated hemoglobin levels;
KIRP	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg06243866	chr13:111019493	COL4A2	-0.67	-9.99	-0.54	6.03e-20	White matter hyperintensity burden;
KIRP	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.53	-0.43	9.78e-13	Aortic root size;
KIRP	trans	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg19274270	chr17:78178856	CARD14	0.35	6.23	0.37	2.03e-9	Morning vs. evening chronotype;
KIRP	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg15340874	chr1:174969621	CACYBP	-0.47	-6.28	-0.37	1.53e-9	Thyroid cancer;
KIRP	cis	rs151997	0.893	rs27607	chr5:50228977	A/G	cg06027927	chr5:50259733	NA	-0.57	-7.18	-0.42	8.25e-12	Callous-unemotional behaviour;
KIRP	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.34	-4.85	-0.3	2.16e-6	Monocyte count;
KIRP	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg18404041	chr3:52824283	ITIH1	0.37	5.28	0.32	2.9e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4654899	0.865	rs6691824	chr1:21417577	T/G	cg05370193	chr1:21551575	ECE1	0.46	6.16	0.37	2.88e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs45544231	0.521	rs1477074	chr16:52578548	T/C	cg09051775	chr16:52580266	TOX3	-0.37	-5.06	-0.31	8.09e-7	Restless legs syndrome;
KIRP	trans	rs4620914	0.566	rs72723044	chr15:38234301	T/C	cg23637354	chr6:167809876	NA	-0.58	-6.18	-0.37	2.58e-9	Urate levels in overweight individuals;
KIRP	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg03735888	chr19:58951602	ZNF132	0.45	5.33	0.32	2.2e-7	Uric acid clearance;
KIRP	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.7	-9.95	-0.54	7.99e-20	Lymphocyte counts;
KIRP	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg25801113	chr15:45476975	SHF	-0.44	-8.15	-0.46	1.87e-14	Uric acid levels;
KIRP	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg18364779	chr6:26104403	HIST1H4C	-0.42	-4.98	-0.3	1.2e-6	Educational attainment;
KIRP	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.9	0.4	4.49e-11	Bladder cancer;
KIRP	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg01304814	chr3:48885189	PRKAR2A	0.84	5.92	0.35	1.09e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.59	7.53	0.43	9.46e-13	Monocyte count;
KIRP	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.46	-5.52	-0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.5	-6.5	-0.38	4.47e-10	Blood metabolite levels;
KIRP	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.54	-4.86	-0.3	2.11e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3540	0.538	rs2074585	chr15:91009484	G/A	cg22089800	chr15:90895588	ZNF774	0.45	5.68	0.34	3.86e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg06307176	chr5:131281290	NA	0.56	6.37	0.38	9.09e-10	Life satisfaction;
KIRP	cis	rs7536201	0.905	rs7525903	chr1:25294573	G/A	cg23273869	chr1:25296894	NA	-0.36	-4.93	-0.3	1.53e-6	Psoriasis vulgaris;
KIRP	cis	rs4664304	0.710	rs9636280	chr2:160717852	C/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.77	-0.35	2.34e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	0.87	10.37	0.55	3.94e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs12200782	0.722	rs12194095	chr6:26364520	C/T	cg11502198	chr6:26597334	ABT1	-0.89	-5.01	-0.3	1.03e-6	Small cell lung carcinoma;
KIRP	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.54	6.52	0.38	3.95e-10	AIDS;
KIRP	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.67	-7.59	-0.44	6.65e-13	Vitiligo;
KIRP	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-6.1	-0.36	4.18e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.64	7.96	0.45	6.37e-14	Height;
KIRP	cis	rs2120243	0.539	rs9857875	chr3:157078897	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-8.41	-0.47	3.38e-15	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.62	8.24	0.46	1.04e-14	Response to antidepressants and depression;
KIRP	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6973256	0.828	rs2016876	chr7:133395492	T/G	cg10665199	chr7:133106180	EXOC4	-0.52	-6.09	-0.36	4.4e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02578673	chr19:50379958	AKT1S1;TBC1D17	0.48	6.15	0.37	3.16e-9	Parkinson's disease;
KIRP	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.86	11.75	0.6	1.37e-25	Monocyte count;
KIRP	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.82	-12.29	-0.62	2.15e-27	Body mass index;
KIRP	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.73	8.2	0.46	1.31e-14	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.14	9.76	0.53	3.11e-19	Diabetic kidney disease;
KIRP	cis	rs2000999	0.573	rs34682685	chr16:72096227	G/A	cg04254540	chr16:71951199	KIAA0174	-0.88	-6.47	-0.38	5.12e-10	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs785830	0.600	rs618810	chr9:242529	T/A	cg14500300	chr9:211689	NA	0.41	5.29	0.32	2.68e-7	Platelet distribution width;
KIRP	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs10834997	0.680	rs293940	chr11:26555296	A/G	cg23885809	chr8:10469370	RP1L1	-0.48	-6.23	-0.37	1.96e-9	Tumor necrosis factor alpha levels;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.8	6.31	0.37	1.3e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg09597638	chr17:3907349	NA	-0.75	-14.17	-0.67	1e-33	Type 2 diabetes;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.55	5.57	0.33	6.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.15	-0.64	2.95e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg02367723	chr1:46378857	MAST2	0.42	4.92	0.3	1.58e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg05692746	chr2:100937584	LONRF2	-0.46	-5.41	-0.33	1.51e-7	Educational attainment;
KIRP	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.55	-5.78	-0.35	2.2e-8	Total cholesterol levels;
KIRP	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	1.12	18.9	0.77	7.77e-50	Cognitive function;
KIRP	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.95	12.32	0.62	1.8e-27	Homoarginine levels;
KIRP	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs17407555	0.657	rs1558488	chr4:10327414	A/G	cg11266682	chr4:10021025	SLC2A9	0.34	5.56	0.33	7.11e-8	Schizophrenia (age at onset);
KIRP	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.02	0.31	9.74e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9653442	0.564	rs12992234	chr2:100767886	G/A	cg22139774	chr2:100720529	AFF3	-0.3	-5.07	-0.31	7.8e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.4	5.44	0.33	1.3e-7	Atrioventricular conduction;
KIRP	cis	rs2120243	0.539	rs2168430	chr3:157120408	T/C	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19635580	chr1:220441596	RAB3GAP2;AURKAPS1	-0.44	-7.16	-0.42	9.34e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs16828019	0.777	rs35044078	chr1:41474400	C/G	cg03387723	chr1:41708464	SCMH1	-0.72	-6.19	-0.37	2.44e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.61	-9.07	-0.5	3.96e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1832871	0.711	rs9456266	chr6:158714422	A/G	cg07215822	chr6:158701037	NA	-0.65	-7.43	-0.43	1.84e-12	Height;
KIRP	cis	rs7712401	0.601	rs30048	chr5:122270393	A/G	cg19412675	chr5:122181750	SNX24	0.45	5.07	0.31	7.96e-7	Mean platelet volume;
KIRP	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.52	-0.33	8.38e-8	Obesity-related traits;
KIRP	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.09	-0.31	7.17e-7	Pulmonary function;
KIRP	cis	rs3105593	0.563	rs476733	chr15:50887630	C/T	cg05456662	chr15:50716270	USP8	0.38	4.89	0.3	1.84e-6	QT interval;
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.24	-0.32	3.47e-7	Longevity;Endometriosis;
KIRP	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.02	0.3	1.01e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg05861140	chr6:150128134	PCMT1	-0.45	-6.21	-0.37	2.28e-9	Lung cancer;
KIRP	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg03060546	chr3:49711283	APEH	0.46	6.22	0.37	2.16e-9	Parkinson's disease;
KIRP	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg23625390	chr15:77176239	SCAPER	0.48	6.32	0.37	1.2e-9	Blood metabolite levels;
KIRP	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.2	-0.37	2.39e-9	QT interval;
KIRP	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.9	11.14	0.58	1.31e-23	Homoarginine levels;
KIRP	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.89	-11.25	-0.58	5.84e-24	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.99	-0.3	1.14e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.42	-5.61	-0.34	5.47e-8	Dilated cardiomyopathy;
KIRP	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg16261398	chr11:1410750	BRSK2	-0.36	-5.56	-0.33	7.07e-8	Breast cancer;
KIRP	cis	rs9547996	0.879	rs7333205	chr13:38187458	A/T	cg13634560	chr13:38173852	POSTN	-0.4	-5.55	-0.33	7.2e-8	Diastolic blood pressure;
KIRP	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-0.71	-9.67	-0.52	5.81e-19	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25539644	chr5:41925386	FBXO4	0.46	6.27	0.37	1.6e-9	Myopia (pathological);
KIRP	cis	rs258892	0.842	rs11956081	chr5:72020287	T/G	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs6746896	0.762	rs878919	chr2:97437990	T/C	cg01990225	chr2:97406019	LMAN2L	-0.57	-7.12	-0.41	1.19e-11	Bipolar disorder;
KIRP	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg05639522	chr1:247681581	NA	0.59	5.65	0.34	4.4e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.54	-6.94	-0.4	3.43e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs2300206	1	rs2300206	chr20:32589808	G/C	cg24642439	chr20:33292090	TP53INP2	0.59	6.59	0.39	2.7e-10	Cancer;Cancer (pleiotropy);
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg27121462	chr16:89883253	FANCA	0.62	9.16	0.5	2.14e-17	Vitiligo;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.78	12.47	0.62	5.31e-28	Menarche (age at onset);
KIRP	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg16886403	chr8:143471632	TSNARE1	0.51	5.47	0.33	1.11e-7	Schizophrenia;
KIRP	cis	rs11603020	0.950	rs28362949	chr11:57371911	G/T	cg23127183	chr11:57508653	C11orf31	-0.47	-5.54	-0.33	7.62e-8	Blood protein levels;
KIRP	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg02002194	chr4:3960332	NA	-0.46	-6.78	-0.4	8.91e-11	Mood instability;
KIRP	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-0.94	-9.82	-0.53	2.02e-19	Blood protein levels;
KIRP	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.73	8.96	0.5	8.52e-17	Mammographic density (dense area);
KIRP	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.39	-5.01	-0.3	1.03e-6	Blood protein levels;
KIRP	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.28	-0.51	8.92e-18	Mood instability;
KIRP	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg08134877	chr2:44394819	PPM1B	0.49	4.97	0.3	1.26e-6	Height;
KIRP	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.41	4.97	0.3	1.24e-6	Body mass index;
KIRP	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.78	-9.51	-0.52	1.8e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7243821	0.544	rs55653518	chr18:52570377	A/G	cg26630735	chr18:52626848	CCDC68	0.47	4.98	0.3	1.22e-6	Chin dimples;
KIRP	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg00204512	chr16:28754710	NA	0.48	6.25	0.37	1.77e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13102973	0.899	rs4643872	chr4:135901432	A/G	cg14419869	chr4:135874104	NA	0.48	7.52	0.43	1.02e-12	Subjective well-being;
KIRP	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.53	6.16	0.37	3.03e-9	Blood metabolite levels;
KIRP	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg22117172	chr7:91764530	CYP51A1	0.46	6.42	0.38	7.04e-10	Breast cancer;
KIRP	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.72	-0.34	3.03e-8	Bladder cancer;
KIRP	cis	rs745080	0.651	rs12588286	chr14:52964654	C/T	cg23333723	chr14:53022898	GPR137C	-0.4	-5.56	-0.33	6.99e-8	Orofacial clefts;
KIRP	cis	rs75920871	0.920	rs61907594	chr11:116801811	C/T	cg23684410	chr11:116897558	SIK3	0.55	5.99	0.36	7.49e-9	Subjective well-being;
KIRP	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg07972983	chr1:205091412	RBBP5	0.43	5.1	0.31	6.71e-7	Red blood cell count;
KIRP	cis	rs7520050	0.966	rs6668284	chr1:46354510	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.31	-0.32	2.42e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.67	8.03	0.46	4.05e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.38	-5.04	-0.31	8.89e-7	Schizophrenia;
KIRP	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg24375607	chr4:120327624	NA	0.52	6.13	0.36	3.51e-9	Corneal astigmatism;
KIRP	cis	rs8113308	1.000	rs8105440	chr19:52451900	T/C	cg24732339	chr19:52471368	ZNF350	-0.49	-5.86	-0.35	1.47e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg14952266	chr13:112191215	NA	0.46	6.77	0.4	9.5e-11	Hepatitis;
KIRP	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.5	-8.36	-0.47	4.75e-15	Height;
KIRP	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-0.91	-8.8	-0.49	2.53e-16	Obesity-related traits;
KIRP	cis	rs300890	0.642	rs3828514	chr4:144296149	T/G	cg01719995	chr4:144104893	USP38	-0.41	-5.16	-0.31	5.12e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.85	9.08	0.5	3.62e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs732716	0.785	rs56272533	chr19:4420042	T/C	cg19820705	chr19:4455316	UBXN6	0.65	7.99	0.45	5.35e-14	Mean corpuscular volume;
KIRP	cis	rs9308731	0.966	rs36018702	chr2:111928373	G/T	cg23466623	chr2:111982296	NA	0.46	5.77	0.35	2.34e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs3858145	0.505	rs12765827	chr10:70046578	G/A	cg04882175	chr6:131122610	NA	0.52	6.03	0.36	6.01e-9	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs28489187	0.683	rs12047422	chr1:85848830	T/G	cg16011679	chr1:85725395	C1orf52	0.55	6.66	0.39	1.77e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9290877	0.667	rs17671666	chr3:188454664	T/C	cg17392043	chr3:188495102	LPP	-0.53	-6.89	-0.4	4.57e-11	IgE levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23385248	chr15:93579332	NA	-0.43	-6.08	-0.36	4.64e-9	Survival in pancreatic cancer;
KIRP	cis	rs3741151	0.686	rs12285885	chr11:73294478	A/G	cg17517138	chr11:73019481	ARHGEF17	0.65	5.61	0.34	5.3e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13198984	chr17:80129470	CCDC57	0.56	8.71	0.49	4.65e-16	Life satisfaction;
KIRP	trans	rs9556711	0.681	rs76417103	chr13:97968415	C/T	cg24049888	chr11:111250129	POU2AF1	-0.64	-6.47	-0.38	5.19e-10	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score);
KIRP	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	9.35	0.51	5.63e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.46	6.3	0.37	1.4e-9	Red blood cell count;
KIRP	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.16	0.5	2.08e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg02996583	chr8:142237188	SLC45A4	0.49	5.86	0.35	1.52e-8	Immature fraction of reticulocytes;
KIRP	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.69	-9.44	-0.52	2.93e-18	Colorectal cancer;
KIRP	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg24375607	chr4:120327624	NA	0.55	5.6	0.34	5.71e-8	Corneal astigmatism;
KIRP	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.78	-0.35	2.3e-8	Schizophrenia;
KIRP	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg19743168	chr1:23544995	NA	-0.49	-6.79	-0.4	8.49e-11	Height;
KIRP	cis	rs2271404	0.506	rs4848426	chr2:112002130	T/G	cg23466623	chr2:111982296	NA	-0.7	-9.49	-0.52	2.08e-18	Atopic dermatitis;
KIRP	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.34	0.55	4.65e-21	Cognitive test performance;
KIRP	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.49	-5.99	-0.36	7.33e-9	P wave terminal force;
KIRP	cis	rs2458413	0.500	rs2458415	chr8:105351998	A/C	cg15172053	chr8:105342214	NA	-0.38	-4.88	-0.3	1.88e-6	Paget's disease;
KIRP	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.76	-0.44	2.28e-13	Mood instability;
KIRP	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg04317338	chr11:64019027	PLCB3	0.55	6.38	0.38	8.84e-10	Platelet count;
KIRP	cis	rs2273669	0.667	rs75942063	chr6:109352545	G/A	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg20243544	chr17:37824526	PNMT	0.52	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg08738300	chr3:44038990	NA	0.7	9.81	0.53	2.11e-19	Coronary artery disease;
KIRP	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.42	5.54	0.33	7.61e-8	Hypertriglyceridemia;
KIRP	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.69	0.39	1.47e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23544223	chr18:12777786	NA	0.68	5.77	0.35	2.42e-8	Inflammatory skin disease;
KIRP	cis	rs9596863	1.000	rs7995218	chr13:54427874	C/G	ch.13.53330881F	chr13:54432880	NA	0.7	6.96	0.41	3.05e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg16586182	chr3:47516702	SCAP	0.64	8.59	0.48	1.02e-15	Colorectal cancer;
KIRP	cis	rs585287	0.539	rs675044	chr11:114051525	C/T	cg01914181	chr11:114070210	ZBTB16	0.5	5.31	0.32	2.42e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
KIRP	cis	rs6448317	1.000	rs11938296	chr4:24938861	A/G	cg21108841	chr4:24914750	CCDC149	-0.46	-5.38	-0.32	1.69e-7	Heschl's gyrus morphology;
KIRP	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.02	0.31	9.71e-7	Iron status biomarkers;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg05025164	chr4:1340916	KIAA1530	0.44	5.37	0.32	1.84e-7	Obesity-related traits;
KIRP	cis	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg21546286	chr11:48923668	NA	-0.47	-6.04	-0.36	5.53e-9	HDL cholesterol;
KIRP	cis	rs4908768	0.906	rs78110809	chr1:8573008	C/T	cg25722041	chr1:8623473	RERE	0.7	9.38	0.51	4.43e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2415984	0.600	rs2415958	chr14:46806262	C/G	cg14871534	chr14:47121158	RPL10L	-0.44	-5.23	-0.32	3.67e-7	Number of children ever born;
KIRP	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg25664220	chr3:72788482	NA	-0.47	-6.75	-0.4	1.08e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.38	-0.47	4.21e-15	Bone mineral density;
KIRP	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs6496667	0.779	rs7175440	chr15:90949403	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	5.25	0.32	3.35e-7	Rheumatoid arthritis;
KIRP	cis	rs9986765	1.000	rs28672333	chr7:142826798	G/A	cg11323483	chr7:142828068	PIP	-0.54	-4.98	-0.3	1.2e-6	Cancer;Dermatomyositis;
KIRP	cis	rs7737355	0.812	rs28610	chr5:130832382	T/C	cg25547332	chr5:131281432	NA	0.39	4.87	0.3	2.01e-6	Life satisfaction;
KIRP	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.42	5.77	0.35	2.39e-8	Coronary artery disease;
KIRP	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg18490616	chr2:88469792	THNSL2	0.66	5.33	0.32	2.22e-7	Plasma clusterin levels;
KIRP	cis	rs4253311	0.543	rs1053094	chr4:187133031	A/T	cg24794857	chr4:187113578	CYP4V2	0.36	4.98	0.3	1.18e-6	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
KIRP	cis	rs10875595	0.732	rs62378370	chr5:140679460	T/C	cg24830062	chr5:140700576	TAF7	-0.56	-5.47	-0.33	1.08e-7	Pulmonary function decline;
KIRP	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg23108931	chr8:105342351	NA	-0.35	-4.94	-0.3	1.46e-6	Paget's disease;
KIRP	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg23625390	chr15:77176239	SCAPER	-0.5	-6.52	-0.38	3.93e-10	Blood metabolite levels;
KIRP	cis	rs4728302	0.631	rs12707126	chr7:133584271	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.0	0.3	1.1e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1318772	0.866	rs13161969	chr5:112865809	A/C	cg12552261	chr5:112820674	MCC	0.76	5.35	0.32	1.98e-7	F-cell distribution;
KIRP	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.87	-0.63	2.55e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg25173405	chr17:45401733	C17orf57	-0.46	-6.1	-0.36	4.09e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12318506	0.510	rs35181956	chr12:75980022	C/T	cg04728562	chr12:75699417	CAPS2	-1.27	-7.42	-0.43	1.88e-12	Coronary artery calcification;
KIRP	cis	rs7941030	0.902	rs10790519	chr11:122535408	A/G	cg20555462	chr11:122535518	UBASH3B	-0.42	-5.25	-0.32	3.23e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.27	-0.42	4.72e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.78	7.44	0.43	1.64e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.47	6.68	0.39	1.59e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12591125	chr7:1885375	MAD1L1	-0.49	-5.07	-0.31	7.69e-7	Bipolar disorder;
KIRP	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.8	8.3	0.47	6.76e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.6	7.56	0.43	8.11e-13	Resistin levels;
KIRP	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-1.0	-15.52	-0.7	2.38e-38	Coronary artery disease;
KIRP	cis	rs526231	0.543	rs34809	chr5:102430117	C/A	cg23492399	chr5:102201601	PAM	-0.54	-5.93	-0.35	1.05e-8	Primary biliary cholangitis;
KIRP	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.58	7.85	0.45	1.29e-13	Mean corpuscular volume;
KIRP	cis	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.52	-0.33	8.61e-8	HDL cholesterol;
KIRP	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.58	7.99	0.45	5.26e-14	Tuberculosis;
KIRP	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.7	7.79	0.45	1.82e-13	Neutrophil percentage of white cells;
KIRP	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.77	-9.11	-0.5	2.87e-17	Blood protein levels;
KIRP	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg27539214	chr16:67997921	SLC12A4	-0.55	-5.15	-0.31	5.23e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg11584989	chr19:19387371	SF4	0.42	5.37	0.32	1.82e-7	Tonsillectomy;
KIRP	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.92	14.65	0.68	2.36e-35	Testicular germ cell tumor;
KIRP	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg14675211	chr2:100938903	LONRF2	0.48	6.48	0.38	5.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.83	11.49	0.59	9.54e-25	Lung cancer in ever smokers;
KIRP	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg17764715	chr19:33622953	WDR88	0.66	8.29	0.47	7.25e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.55	8.04	0.46	3.74e-14	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4523957	0.890	rs216191	chr17:2188639	C/T	cg16513277	chr17:2031491	SMG6	0.61	8.48	0.48	2.18e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	7.71	0.44	3.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.18	-0.31	4.66e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-6.77	-0.4	9.65e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.72	-6.91	-0.4	4.02e-11	Menarche (age at onset);
KIRP	cis	rs16857609	0.628	rs2568153	chr2:218339504	A/C	cg15335768	chr2:218268053	DIRC3	0.41	5.98	0.36	7.61e-9	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10512498	chr4:176986333	WDR17	-0.44	-6.51	-0.38	4.22e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25584080	chr5:205656	CCDC127	0.49	6.04	0.36	5.64e-9	Interleukin-4 levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18576335	chr17:8110165	AURKB	-0.49	-6.98	-0.41	2.8e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs78579285	0.545	rs79311053	chr16:88785206	C/T	cg09786329	chr16:88821445	FAM38A	-0.57	-4.89	-0.3	1.82e-6	Joint mobility (Beighton score);
KIRP	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.69	-8.34	-0.47	5.18e-15	Vitiligo;
KIRP	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg21017887	chr14:105400489	NA	-0.53	-8.84	-0.49	1.82e-16	Rheumatoid arthritis;
KIRP	cis	rs8010715	0.771	rs2277481	chr14:24587545	A/G	cg23112188	chr14:24563095	PCK2	-0.35	-5.07	-0.31	7.76e-7	IgG glycosylation;
KIRP	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg23533926	chr12:111358616	MYL2	-0.47	-6.21	-0.37	2.19e-9	Extrinsic epigenetic age acceleration;
KIRP	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg11846333	chr4:119757529	SEC24D	1.14	7.06	0.41	1.73e-11	Cannabis dependence symptom count;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg06074448	chr4:187884817	NA	-0.77	-12.68	-0.63	1.06e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-7.34	-0.42	3.06e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	1.1	10.96	0.57	5.02e-23	Psoriasis;
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.47	-0.62	5.53e-28	Primary sclerosing cholangitis;
KIRP	cis	rs13102973	0.965	rs11730310	chr4:135861925	A/G	cg14419869	chr4:135874104	NA	0.53	8.8	0.49	2.48e-16	Subjective well-being;
KIRP	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.76	9.22	0.51	1.42e-17	Response to antipsychotic treatment;
KIRP	cis	rs9644630	0.804	rs11783263	chr8:19371674	C/G	cg01280390	chr8:19363452	CSGALNACT1	-0.37	-5.09	-0.31	7.21e-7	Oropharynx cancer;
KIRP	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg03653399	chr8:142233436	SLC45A4	0.89	13.46	0.65	2.67e-31	Immature fraction of reticulocytes;
KIRP	cis	rs11907546	1	rs11907546	chr20:32719797	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	6.41	0.38	7.33e-10	Cancer;Cancer (pleiotropy);
KIRP	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.94	-0.4	3.54e-11	Initial pursuit acceleration;
KIRP	trans	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg11693508	chr17:37793320	STARD3	0.52	7.03	0.41	2e-11	Neuroticism;
KIRP	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	1.05	17.14	0.74	7.31e-44	Gut microbiome composition (winter);
KIRP	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.46	-0.43	1.49e-12	Electroencephalogram traits;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.9	15.12	0.69	5.94e-37	Menarche (age at onset);
KIRP	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.89	-11.97	-0.61	2.56e-26	Coronary artery disease;
KIRP	trans	rs7819412	0.582	rs2409685	chr8:10909193	C/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.97	-0.45	5.82e-14	Triglycerides;
KIRP	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.39	0.38	8.39e-10	Menarche (age at onset);
KIRP	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.98	17.17	0.74	5.57e-44	Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-7.2	-0.42	7.08e-12	Personality dimensions;
KIRP	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	1.01	12.31	0.62	1.91e-27	Post bronchodilator FEV1;
KIRP	cis	rs2733954	0.836	rs437786	chr16:85819373	C/T	cg03249995	chr16:85819513	COX4NB	0.42	4.9	0.3	1.71e-6	Leprosy;
KIRP	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.41	-5.26	-0.32	3.2e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg02574844	chr11:5959923	NA	-0.57	-5.91	-0.35	1.16e-8	DNA methylation (variation);
KIRP	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.42	-7.46	-0.43	1.53e-12	Refractive error;
KIRP	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06647332	chr5:131281008	NA	-0.44	-4.9	-0.3	1.74e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg19025524	chr12:109796872	NA	-0.38	-5.06	-0.31	8.06e-7	Neuroticism;
KIRP	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.46	6.81	0.4	7.61e-11	Lymphocyte counts;
KIRP	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.77	8.66	0.48	6.43e-16	Corneal astigmatism;
KIRP	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.08	0.36	4.44e-9	Height;
KIRP	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.31	17.35	0.74	1.41e-44	Corneal structure;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg23693289	chr8:27183097	PTK2B	0.55	7.09	0.41	1.41e-11	Neuroticism;
KIRP	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg11906718	chr8:101322791	RNF19A	-0.65	-8.3	-0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.53	6.55	0.39	3.43e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.53	8.1	0.46	2.52e-14	Itch intensity from mosquito bite;
KIRP	cis	rs10861342	0.579	rs77585712	chr12:105482251	T/C	cg23923672	chr12:105501055	KIAA1033	0.83	6.36	0.38	9.66e-10	IgG glycosylation;
KIRP	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg00745463	chr17:30367425	LRRC37B	0.72	6.27	0.37	1.61e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg09264619	chr17:80180166	NA	-0.41	-5.92	-0.35	1.05e-8	Life satisfaction;
KIRP	cis	rs11997175	0.902	rs7009022	chr8:33700404	A/G	cg04338863	chr8:33670619	NA	0.41	5.48	0.33	1.07e-7	Body mass index;
KIRP	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg00074818	chr8:8560427	CLDN23	0.41	6.61	0.39	2.42e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.48	-0.33	1.07e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.65	7.4	0.43	2.16e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.24	-0.37	1.87e-9	Myopia (pathological);
KIRP	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs62247992	0.698	rs11719573	chr3:43125190	A/G	cg12239580	chr3:43073058	FAM198A	-0.39	-5.2	-0.31	4.22e-7	Facial morphology (factor 15, philtrum width);
KIRP	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	4.95	0.3	1.37e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6733011	0.582	rs2280256	chr2:99449174	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.35	-0.32	1.97e-7	Bipolar disorder;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11245990	chr11:68621969	NA	0.37	5.02	0.3	1e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6991838	0.556	rs7846527	chr8:66498757	A/G	cg13398993	chr8:66546079	ARMC1	-0.47	-5.44	-0.33	1.31e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.84	10.11	0.54	2.52e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-5.55	-0.33	7.3900000000000007e-08	Total body bone mineral density;
KIRP	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.43	-15.45	-0.7	4.23e-38	Schizophrenia;
KIRP	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg13482628	chr17:19912719	NA	0.63	9.2	0.51	1.62e-17	Schizophrenia;
KIRP	cis	rs4671458	0.656	rs72806010	chr2:63753802	C/A	cg17519650	chr2:63277830	OTX1	-0.49	-4.97	-0.3	1.27e-6	Subjective well-being;
KIRP	cis	rs7715811	1.000	rs1502052	chr5:13774908	G/A	cg07548982	chr5:13769939	DNAH5	-0.54	-6.68	-0.39	1.55e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs4664304	0.658	rs2667016	chr2:160868855	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.49	-0.43	1.22e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs16936870	0.543	rs2926703	chr8:71166994	G/A	cg14232793	chr8:71155543	NCOA2	-0.57	-6.59	-0.39	2.61e-10	QT interval;
KIRP	trans	rs1106684	1.000	rs60381542	chr7:131460610	C/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	6.55	0.39	3.28e-10	Initial pursuit acceleration;
KIRP	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.56	7.41	0.43	2e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg13198984	chr17:80129470	CCDC57	0.56	8.41	0.47	3.4e-15	Life satisfaction;
KIRP	cis	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.65	4.97	0.3	1.24e-6	Childhood ear infection;
KIRP	cis	rs1983891	0.955	rs4714479	chr6:41518807	A/G	cg20194872	chr6:41519635	FOXP4	0.55	7.15	0.41	1.01e-11	Prostate cancer;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.62	8.64	0.48	7.06e-16	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18070394	chr4:2470786	RNF4	0.45	6.25	0.37	1.77e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.3	0.32	2.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2380205	0.967	rs907685	chr10:5900332	A/G	cg27141509	chr10:5886111	NA	-0.35	-5.1	-0.31	6.69e-7	Breast cancer;
KIRP	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.57	-0.33	6.83e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6838801	0.892	rs12647024	chr4:77575503	T/C	cg17476223	chr4:77663285	SHROOM3	0.55	8.02	0.46	4.42e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06481639	chr22:41940642	POLR3H	0.63	6.99	0.41	2.61e-11	Vitiligo;
KIRP	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.76	8.89	0.49	1.31e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.72	9.7	0.53	4.63e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.48	5.92	0.35	1.09e-8	Height;
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.64	8.59	0.48	9.92e-16	Longevity;Endometriosis;
KIRP	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg00800038	chr16:89945340	TCF25	-0.83	-6.22	-0.37	2.14e-9	Skin colour saturation;
KIRP	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.99	-16.13	-0.72	1.97e-40	Monocyte count;
KIRP	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg18944383	chr4:111397179	ENPEP	0.55	9.55	0.52	1.36e-18	Height;
KIRP	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg23032129	chr1:109941072	SORT1	-0.28	-4.92	-0.3	1.58e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.17	0.37	2.74e-9	Menopause (age at onset);
KIRP	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.65	-7.33	-0.42	3.33e-12	Height;
KIRP	cis	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	4.89	0.3	1.84e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs860295	0.812	rs11264413	chr1:155788656	G/A	cg02153340	chr1:155202674	NA	-0.41	-5.5	-0.33	9.54e-8	Body mass index;
KIRP	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.5	-0.33	9.63e-8	Neutrophil percentage of white cells;
KIRP	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.79	10.8	0.57	1.67e-22	Monocyte count;
KIRP	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.34	12.2	0.61	4.31e-27	Diabetic retinopathy;
KIRP	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.21	14.04	0.67	2.88e-33	Sexual dysfunction (female);
KIRP	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg06640241	chr16:89574553	SPG7	0.53	6.87	0.4	5.26e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.75	10.4	0.55	3e-21	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2151522	0.724	rs2077111	chr6:127135075	A/G	cg21431617	chr6:127135037	NA	0.31	5.66	0.34	4.27e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg26516362	chr5:178986906	RUFY1	0.34	5.66	0.34	4.1e-8	Lung cancer;
KIRP	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	0.9	10.11	0.54	2.5e-20	Triglycerides;
KIRP	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	trans	rs13170463	0.522	rs71606022	chr5:8051986	T/C	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.46	5.7	0.34	3.42e-8	Common traits (Other);
KIRP	cis	rs4774899	1.000	rs12899036	chr15:57476452	C/A	cg13626582	chr15:57592083	LOC283663	-0.2	-4.86	-0.3	2.05e-6	Urinary tract infection frequency;
KIRP	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg07936489	chr17:37558343	FBXL20	-0.48	-5.92	-0.35	1.1e-8	Asthma;
KIRP	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg20652464	chr8:752313	NA	-0.38	-5.48	-0.33	1.04e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg24747557	chr10:131355152	MGMT	0.44	5.67	0.34	4.06e-8	Response to temozolomide;
KIRP	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	ch.8.33884649F	chr8:33765107	NA	-0.59	-6.77	-0.4	9.61e-11	Body mass index;
KIRP	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	1.08	17.53	0.75	3.39e-45	Cognitive function;
KIRP	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.91	14.62	0.68	2.95e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1147199	0.585	rs1147197	chr9:87274148	G/A	cg22402007	chr9:87282823	NTRK2	-0.4	-4.98	-0.3	1.22e-6	Body mass index;
KIRP	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.45	-6.24	-0.37	1.9e-9	Coronary artery disease;
KIRP	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg12560992	chr17:57184187	TRIM37	0.52	6.26	0.37	1.71e-9	Primary tooth development (time to first tooth eruption);
KIRP	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.77	10.18	0.54	1.54e-20	Aortic root size;
KIRP	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg05527609	chr1:210001259	C1orf107	-0.5	-7.0	-0.41	2.39e-11	Monobrow;
KIRP	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg05347473	chr6:146136440	FBXO30	0.5	6.98	0.41	2.72e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7590368	0.640	rs72779433	chr2:10946986	C/T	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.8e-10	Cognitive function;
KIRP	cis	rs71403859	0.730	rs12446333	chr16:71752157	T/C	cg08717414	chr16:71523259	ZNF19	-1.03	-8.53	-0.48	1.52e-15	Post bronchodilator FEV1;
KIRP	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.35	0.51	5.76e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs244293	0.795	rs12940239	chr17:53068930	A/G	cg07707039	chr17:53042137	COX11	-0.42	-5.09	-0.31	6.99e-7	Menarche (age at onset);
KIRP	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.65	-7.09	-0.41	1.4e-11	Corneal structure;
KIRP	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Parkinson's disease;
KIRP	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg23262073	chr20:60523788	NA	-0.59	-5.86	-0.35	1.51e-8	Body mass index;
KIRP	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.62	-10.1	-0.54	2.75e-20	Pulse pressure;
KIRP	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg16141378	chr3:129829833	LOC729375	-0.61	-8.03	-0.46	4.06e-14	Mood instability;
KIRP	cis	rs7091068	0.671	rs588912	chr10:95402929	T/C	cg20715218	chr10:95462985	C10orf4	-0.48	-4.85	-0.3	2.18e-6	Urinary tract infection frequency;
KIRP	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg00405596	chr8:11794950	NA	-0.39	-4.96	-0.3	1.33e-6	Neuroticism;
KIRP	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg21890820	chr11:65308645	LTBP3	-0.38	-4.91	-0.3	1.62e-6	Bone mineral density;
KIRP	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.46	5.12	0.31	6.15e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08439880	chr3:133502540	NA	0.47	6.04	0.36	5.57e-9	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27347932	chr18:60987098	BCL2	0.51	6.38	0.38	8.53e-10	Parkinson's disease;
KIRP	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg04995300	chr3:66848608	NA	0.68	8.74	0.49	3.58e-16	Type 2 diabetes;
KIRP	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.58	-7.07	-0.41	1.59e-11	Coronary artery disease;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg18234130	chr8:27182889	PTK2B	0.54	7.03	0.41	2.05e-11	Neuroticism;
KIRP	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg18404041	chr3:52824283	ITIH1	0.46	5.78	0.35	2.22e-8	Schizophrenia;
KIRP	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	1.06	19.43	0.78	1.33e-51	Bone mineral density;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.76	0.49	3.26e-16	Prudent dietary pattern;
KIRP	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.8	-0.4	7.88e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.58	8.47	0.48	2.22e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.87	-13.79	-0.66	1.9e-32	Ulcerative colitis;
KIRP	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.52	8.68	0.48	5.46e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.78	7.99	0.45	5.14e-14	Diisocyanate-induced asthma;
KIRP	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06998765	chr14:75389618	RPS6KL1	0.25	5.05	0.31	8.41e-7	Caffeine consumption;
KIRP	cis	rs981844	1.000	rs2251994	chr4:154654097	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.52	0.43	1.01e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19385386	chr19:34012736	PEPD	-0.47	-6.15	-0.37	3.07e-9	Myopia;
KIRP	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg07827796	chr19:33622959	WDR88	0.41	4.96	0.3	1.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.92	-0.35	1.07e-8	Schizophrenia;
KIRP	cis	rs2219968	1.000	rs28551624	chr8:78957333	A/G	cg00738934	chr8:78996279	NA	0.49	6.81	0.4	7.29e-11	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs195204	0.542	rs4839426	chr1:115784029	T/C	cg11818615	chr15:98711013	NA	-0.5	-6.08	-0.36	4.54e-9	Alcoholism (heaviness of drinking);
KIRP	cis	rs6696239	1.000	rs7549475	chr1:227774700	A/G	cg27395484	chr1:227557617	NA	-0.45	-4.97	-0.3	1.27e-6	Height;
KIRP	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg21605333	chr4:119757512	SEC24D	1.66	10.42	0.55	2.7e-21	Cannabis dependence symptom count;
KIRP	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.76	-0.34	2.5e-8	Bladder cancer;
KIRP	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.29	-0.32	2.64e-7	Renal cell carcinoma;
KIRP	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.54	5.71	0.34	3.31e-8	White matter hyperintensity burden;
KIRP	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.95	-0.3	1.37e-6	Inflammatory bowel disease;
KIRP	cis	rs7729447	0.776	rs4867472	chr5:32693566	C/T	cg16267343	chr5:32710456	NPR3	0.53	6.0	0.36	6.86e-9	Blood pressure;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg05628107	chr10:89419384	PAPSS2	0.47	6.08	0.36	4.67e-9	Colorectal cancer;
KIRP	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	1.03	11.21	0.58	8e-24	Response to hepatitis C treatment;
KIRP	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.54	-6.32	-0.37	1.24e-9	Aortic root size;
KIRP	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.87	-0.49	1.54e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.39	0.32	1.68e-7	Coronary artery disease;
KIRP	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.39	-0.33	1.64e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.93	16.23	0.72	9.54e-41	Menarche (age at onset);
KIRP	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.13	-0.41	1.09e-11	Systolic blood pressure;
KIRP	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg03474202	chr17:45855739	NA	-0.38	-5.47	-0.33	1.1e-7	IgG glycosylation;
KIRP	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-5.19	-0.31	4.46e-7	IgG glycosylation;
KIRP	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.08	-0.36	4.53e-9	Daytime sleep phenotypes;
KIRP	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg09238746	chr17:78121135	EIF4A3	-0.48	-6.05	-0.36	5.37e-9	Yeast infection;
KIRP	cis	rs4950322	0.570	rs4950316	chr1:146745375	G/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg24579218	chr15:68104479	NA	0.44	7.14	0.41	1.02e-11	Restless legs syndrome;
KIRP	cis	rs2120243	0.508	rs12492874	chr3:157113227	C/A	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg06871246	chr4:1363661	KIAA1530	-0.53	-6.78	-0.4	8.78e-11	Longevity;
KIRP	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.78	10.07	0.54	3.3e-20	Tonsillectomy;
KIRP	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.42	-5.39	-0.32	1.68e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg20936604	chr3:58311152	NA	-0.66	-5.04	-0.31	9.16e-7	Cholesterol, total;
KIRP	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.1	0.5	3.22e-17	Morning vs. evening chronotype;
KIRP	cis	rs9815354	0.812	rs76966288	chr3:41825055	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.5	6.49	0.38	4.75e-10	Glycated hemoglobin levels;
KIRP	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.05	0.46	3.62e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs918629	0.716	rs3777178	chr5:95273915	G/C	cg16656078	chr5:95278638	ELL2	-0.47	-6.7	-0.39	1.4e-10	IgG glycosylation;
KIRP	cis	rs7923609	0.967	rs2393986	chr10:65320006	A/T	cg01631684	chr10:65280961	REEP3	-0.49	-5.73	-0.34	2.91e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10858047	0.883	rs41312702	chr1:115118622	A/G	cg12756093	chr1:115239321	AMPD1	0.69	6.52	0.38	4.07e-10	Autism;
KIRP	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.53	-7.49	-0.43	1.27e-12	Asthma;
KIRP	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.59	-7.93	-0.45	7.82e-14	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg16141378	chr3:129829833	LOC729375	0.62	8.4	0.47	3.51e-15	Triglycerides;
KIRP	cis	rs35740288	0.787	rs2291047	chr15:86225805	A/G	cg17133734	chr15:86042851	AKAP13	-0.48	-5.23	-0.32	3.58e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.83	11.42	0.59	1.69e-24	Morning vs. evening chronotype;
KIRP	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg19468946	chr17:37922297	IKZF3	-0.38	-5.14	-0.31	5.65e-7	Asthma;
KIRP	trans	rs12517041	1.000	rs115818285	chr5:23291449	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.96	-0.5	8.24e-17	Calcium levels;
KIRP	cis	rs7215564	0.908	rs901066	chr17:78659617	C/G	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg13147721	chr7:65941812	NA	0.97	7.1	0.41	1.32e-11	Gout;
KIRP	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.27	0.62	2.59e-27	Bone mineral density;
KIRP	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.25	-0.42	5.5e-12	Retinal vascular caliber;
KIRP	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-5.63	-0.34	4.87e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2625529	0.824	rs16956452	chr15:72284092	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.12e-9	Red blood cell count;
KIRP	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.32	-0.37	1.24e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg18932078	chr1:2524107	MMEL1	0.39	5.27	0.32	2.94e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg01320579	chr17:75405842	SEPT9	0.45	7.22	0.42	6.36e-12	Airflow obstruction;
KIRP	trans	rs1462872	0.736	rs364902	chr8:31791432	C/T	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs1440410	0.835	rs7663762	chr4:144049172	T/C	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs7224685	0.569	rs7212168	chr17:4024640	G/A	cg09695851	chr17:3907499	NA	0.55	5.16	0.31	5.13e-7	Type 2 diabetes;
KIRP	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg04362960	chr10:104952993	NT5C2	0.44	5.16	0.31	4.98e-7	Colorectal cancer;
KIRP	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.56	-6.49	-0.38	4.65e-10	White matter hyperintensity burden;
KIRP	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.48	-6.01	-0.36	6.7e-9	Refractive error;
KIRP	cis	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg21680719	chr1:38466677	FHL3	-0.23	-5.25	-0.32	3.26e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs10463316	0.817	rs7709507	chr5:150783349	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.14	-0.36	3.23e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20203792	chr4:20701925	PACRGL	0.65	7.91	0.45	8.63e-14	Smoking initiation;
KIRP	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	cis	rs698833	0.926	rs1067399	chr2:44678648	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.2	0.31	4.28e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.05	-21.5	-0.81	2.05e-58	Myeloid white cell count;
KIRP	cis	rs9815354	1.000	rs1717020	chr3:41981490	A/C	cg03022575	chr3:42003672	ULK4	0.52	5.85	0.35	1.6e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.8	-8.62	-0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02029091	chr6:166756042	SFT2D1	0.48	6.46	0.38	5.58e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08555112	chr17:48942811	TOB1	0.55	6.83	0.4	6.43e-11	Smoking initiation;
KIRP	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	cis	rs2737618	0.551	rs2816989	chr1:200070765	G/T	cg21825944	chr1:200113062	NR5A2	0.52	6.67	0.39	1.66e-10	Uric acid levels;
KIRP	cis	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg19171272	chr22:38449367	NA	-0.66	-9.61	-0.52	8.98e-19	Glioblastoma;Glioma;
KIRP	cis	rs9687846	0.877	rs9687833	chr5:55861601	G/A	cg15001016	chr5:55860904	NA	-0.29	-5.29	-0.32	2.69e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.79	-11.79	-0.6	9.73e-26	Hip circumference;
KIRP	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.89	-11.86	-0.6	5.79e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg07884673	chr3:53033167	SFMBT1	0.98	7.6	0.44	6.35e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.63	7.04	0.41	1.91e-11	Gut microbiome composition (summer);
KIRP	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg17269277	chr4:1796142	FGFR3	0.73	6.52	0.38	4.05e-10	Hirschsprung disease;
KIRP	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.97	-0.45	5.81e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1620921	0.505	rs4708881	chr6:161203159	C/T	cg01280913	chr6:161186852	NA	-0.57	-7.58	-0.44	7.04e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg04539111	chr16:67997858	SLC12A4	-0.52	-5.03	-0.31	9.56e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg00800569	chr2:239229395	TRAF3IP1	-0.42	-5.04	-0.31	9.19e-7	Multiple system atrophy;
KIRP	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg09427745	chr16:71932006	KIAA0174	-0.59	-5.17	-0.31	4.89e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg17691542	chr6:26056736	HIST1H1C	0.65	7.45	0.43	1.57e-12	Height;
KIRP	cis	rs9611198	0.846	rs4820383	chr22:39961286	C/A	cg03390717	chr22:39966585	CACNA1I	0.4	7.05	0.41	1.84e-11	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.96	-0.5	8.41e-17	Platelet count;
KIRP	cis	rs4319547	0.688	rs10744287	chr12:123077485	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.51	-6.63	-0.39	2.09e-10	Body mass index;
KIRP	cis	rs4356932	1.000	rs9884374	chr4:76946718	A/T	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg06521331	chr12:34319734	NA	0.46	5.68	0.34	3.72e-8	Morning vs. evening chronotype;
KIRP	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg15128208	chr22:42549153	NA	0.65	5.46	0.33	1.17e-7	Birth weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26803184	chr10:94333922	IDE	0.49	6.22	0.37	2.08e-9	Parkinson's disease;
KIRP	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.29	0.42	4.3e-12	Prudent dietary pattern;
KIRP	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.33	0.47	5.66e-15	Motion sickness;
KIRP	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-4.98	-0.3	1.17e-6	Initial pursuit acceleration;
KIRP	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.67	8.65	0.48	6.64e-16	Red blood cell count;
KIRP	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs9547692	0.793	rs556429	chr13:37487021	C/A	cg01493522	chr13:37497338	NA	-0.47	-5.69	-0.34	3.55e-8	Coronary artery disease;
KIRP	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.06	0.36	5.01e-9	Total cholesterol levels;
KIRP	cis	rs17065868	1.000	rs9525981	chr13:45123937	G/A	cg10246903	chr13:45222710	NA	0.7	6.56	0.39	3.23e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07008701	chr21:47552112	COL6A2	0.51	6.07	0.36	4.89e-9	Interleukin-4 levels;
KIRP	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.86	-9.31	-0.51	7.52e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.62	-6.65	-0.39	1.88e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.29	0.37	1.41e-9	Red blood cell count;
KIRP	cis	rs2281603	0.951	rs10133243	chr14:64981525	T/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg15089892	chr3:101568188	NFKBIZ	-0.52	-6.09	-0.36	4.37e-9	Brain structure;
KIRP	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.67	0.71	7.37e-39	Chronic sinus infection;
KIRP	cis	rs10861342	1.000	rs11112390	chr12:105542200	A/C	cg23923672	chr12:105501055	KIAA1033	0.87	9.02	0.5	5.61e-17	IgG glycosylation;
KIRP	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.2	0.64	1.92e-30	Eye color traits;
KIRP	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17467752	chr17:38218738	THRA	-0.56	-7.77	-0.44	2.17e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.38	-0.38	8.56e-10	Monocyte percentage of white cells;
KIRP	cis	rs6456156	0.904	rs2021033	chr6:167524239	C/T	cg07741184	chr6:167504864	NA	-0.22	-5.41	-0.33	1.46e-7	Primary biliary cholangitis;
KIRP	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg23719950	chr11:63933701	MACROD1	-0.68	-6.55	-0.39	3.26e-10	Mean platelet volume;
KIRP	trans	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg10756647	chr7:56101905	PSPH	-0.96	-6.72	-0.39	1.25e-10	Diabetic kidney disease;
KIRP	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg04310649	chr10:35416472	CREM	-0.6	-7.12	-0.41	1.22e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg13319975	chr6:146136371	FBXO30	-0.38	-5.05	-0.31	8.6e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23634678	chr11:102963104	DCUN1D5	0.51	6.32	0.37	1.19e-9	Smoking initiation;
KIRP	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.91	11.36	0.59	2.6e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg11189052	chr15:85197271	WDR73	-0.43	-5.33	-0.32	2.27e-7	P wave terminal force;
KIRP	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	6.66	0.39	1.75e-10	Aortic root size;
KIRP	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.91	10.34	0.55	4.95e-21	Triglycerides;
KIRP	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	1.08	15.74	0.71	4.28e-39	Menopause (age at onset);
KIRP	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg14972814	chr11:95582409	MTMR2	0.35	5.7	0.34	3.45e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.5e-9	Schizophrenia;
KIRP	cis	rs60154123	0.504	rs4844997	chr1:210486895	A/G	cg09074223	chr1:210466472	NA	0.52	5.34	0.32	2.14e-7	Coronary artery disease;
KIRP	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	0.54	6.51	0.38	4.14e-10	Prudent dietary pattern;
KIRP	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.95	-0.41	3.18e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-6.75	-0.4	1.07e-10	Menarche (age at onset);
KIRP	cis	rs9323205	0.862	rs11629399	chr14:51612814	T/C	cg23942311	chr14:51606299	NA	-0.58	-6.33	-0.37	1.17e-9	Cancer;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.71	-10.51	-0.56	1.42e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg01522456	chr1:115632236	TSPAN2	-0.46	-5.79	-0.35	2.16e-8	Autism;
KIRP	cis	rs7202877	0.706	rs247450	chr16:75490017	C/A	cg03315344	chr16:75512273	CHST6	-0.58	-5.35	-0.32	2.04e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.93	11.15	0.58	1.26e-23	Post bronchodilator FEV1;
KIRP	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg09571762	chr12:39539558	NA	0.34	5.07	0.31	7.78e-7	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16292851	chr18:29710780	RNF138	-0.45	-6.63	-0.39	2.1e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7106204	0.534	rs79475764	chr11:24278384	C/A	ch.11.24196551F	chr11:24239977	NA	0.71	4.93	0.3	1.52e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.41	-0.38	7.2e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2599510	0.934	rs2710634	chr2:32808804	T/C	cg02381751	chr2:32503542	YIPF4	0.46	5.08	0.31	7.56e-7	Interleukin-18 levels;
KIRP	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.98	-0.36	7.98e-9	Breast cancer;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg21698718	chr17:80085957	CCDC57	0.34	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	0.86	10.84	0.57	1.21e-22	Prostate cancer;
KIRP	cis	rs7520050	0.933	rs11211203	chr1:46315592	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7374004	0.967	rs4073103	chr3:38620442	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.41	4.91	0.3	1.63e-6	PR interval;
KIRP	cis	rs865483	0.929	rs853214	chr17:35860964	T/C	cg06716730	chr17:35851459	DUSP14	0.23	5.66	0.34	4.12e-8	Monocyte count;
KIRP	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg10818794	chr15:86012489	AKAP13	-0.49	-7.01	-0.41	2.33e-11	Coronary artery disease;
KIRP	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.52	7.16	0.42	9.33e-12	Mean corpuscular volume;
KIRP	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	9.88	0.53	1.31e-19	Lung cancer in ever smokers;
KIRP	cis	rs2380220	0.574	rs9374322	chr6:95998994	G/A	cg15832292	chr6:96025679	MANEA	0.71	6.8	0.4	7.88e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6956675	1.000	rs6968327	chr7:62574489	A/G	cg08930214	chr7:62859557	LOC100287834	0.47	5.41	0.33	1.5e-7	Obesity-related traits;
KIRP	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-11.11	-0.58	1.71e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg24253500	chr15:84953950	NA	0.49	5.7	0.34	3.42e-8	Schizophrenia;
KIRP	trans	rs7999699	0.902	rs11148083	chr13:48322139	A/G	cg23237801	chr1:16476620	EPHA2	0.52	6.67	0.39	1.68e-10	Colorectal cancer (diet interaction);
KIRP	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg18944383	chr4:111397179	ENPEP	0.47	7.63	0.44	5.02e-13	Coronary artery disease;
KIRP	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.5	-6.48	-0.38	4.91e-10	Schizophrenia;
KIRP	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.71	-7.88	-0.45	1.06e-13	Coronary artery disease or large artery stroke;
KIRP	trans	rs7618501	0.699	rs9862795	chr3:49915506	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.61	8.0	0.45	4.84e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.3	-0.47	6.95e-15	Platelet count;
KIRP	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.59	7.59	0.44	6.58e-13	Inhibitory control;
KIRP	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	trans	rs4111	0.500	rs9817480	chr3:56004422	G/A	cg26769435	chr8:53397932	NA	-0.43	-6.07	-0.36	4.84e-9	Sense of smell;
KIRP	cis	rs460214	0.564	rs458465	chr21:40024644	A/T	cg05519781	chr21:40033154	ERG	-0.44	-5.37	-0.32	1.78e-7	Response to cognitive-behavioural therapy in anxiety disorder;
KIRP	cis	rs2979489	0.786	rs2915595	chr8:30402817	A/G	cg26383811	chr8:30366931	RBPMS	0.39	5.52	0.33	8.76e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	0.92	11.74	0.6	1.44e-25	Blood protein levels;
KIRP	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	14.58	0.68	3.91e-35	Body mass index (adult);
KIRP	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21545522	chr1:205238299	TMCC2	-0.48	-6.63	-0.39	2.11e-10	Platelet count;
KIRP	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.18e-7	Red blood cell count;
KIRP	cis	rs35955747	0.934	rs5997966	chr22:31776246	C/T	cg02404636	chr22:31891804	SFI1	-0.37	-4.91	-0.3	1.63e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs8084125	0.765	rs72981159	chr18:74945042	A/G	cg26065057	chr18:74961000	GALR1	0.61	6.15	0.37	3.07e-9	Obesity-related traits;
KIRP	cis	rs7084402	0.967	rs1658495	chr10:60280153	C/A	cg05938607	chr10:60274200	BICC1	0.45	10.84	0.57	1.22e-22	Refractive error;
KIRP	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg11569703	chr11:65557185	OVOL1	-0.63	-9.15	-0.5	2.3e-17	Glomerular filtration rate (creatinine);Chronic kidney disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16868751	chr10:96162146	TBC1D12	0.55	6.73	0.39	1.21e-10	Smoking initiation;
KIRP	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg17554472	chr22:41940697	POLR3H	0.46	5.71	0.34	3.19e-8	Vitiligo;
KIRP	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-9.0	-0.5	6.4e-17	Platelet count;
KIRP	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg27398817	chr8:82754497	SNX16	-0.74	-8.0	-0.45	4.93e-14	Diastolic blood pressure;
KIRP	cis	rs11169552	0.510	rs4768907	chr12:51119307	A/G	cg12884762	chr12:50931848	DIP2B	-0.44	-5.21	-0.32	3.96e-7	Colorectal cancer;
KIRP	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.54	7.47	0.43	1.36e-12	IgG glycosylation;
KIRP	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg03563238	chr19:33554763	RHPN2	-0.3	-5.28	-0.32	2.82e-7	Colorectal cancer;
KIRP	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg26876637	chr1:152193138	HRNR	-0.76	-8.59	-0.48	1.03e-15	Atopic dermatitis;
KIRP	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.57	15.49	0.7	3.14e-38	Airflow obstruction;
KIRP	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.55	-5.57	-0.33	6.63e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg03146154	chr1:46216737	IPP	0.56	5.9	0.35	1.23e-8	Platelet count;
KIRP	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg08822215	chr16:89438651	ANKRD11	-0.53	-7.11	-0.41	1.29e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg07274523	chr3:49395745	GPX1	0.72	8.71	0.49	4.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.43	-5.35	-0.32	1.99e-7	Acne (severe);
KIRP	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.68	-11.84	-0.6	6.6e-26	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs2278796	0.639	rs6661192	chr1:204971413	A/G	cg17947172	chr1:204966197	NFASC	0.66	8.74	0.49	3.75e-16	Mean platelet volume;
KIRP	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg23307798	chr14:103986281	CKB	0.76	13.18	0.64	2.21e-30	Body mass index;
KIRP	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.72	-8.67	-0.48	6.04e-16	Cognitive function;
KIRP	cis	rs2019216	0.521	rs9807074	chr17:21930856	T/C	cg22648282	chr17:21454238	C17orf51	-0.57	-7.07	-0.41	1.56e-11	Pelvic organ prolapse;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg09264619	chr17:80180166	NA	-0.38	-5.59	-0.34	6.17e-8	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9303542	0.559	rs62066693	chr17:46617530	G/C	cg04904318	chr17:46607828	HOXB1	-0.61	-6.66	-0.39	1.73e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	12.57	0.63	2.55e-28	Bone mineral density;
KIRP	cis	rs7224685	0.569	rs3760471	chr17:4069735	C/A	cg05562828	chr17:3906858	NA	0.5	5.14	0.31	5.54e-7	Type 2 diabetes;
KIRP	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg03684893	chr10:554711	DIP2C	0.36	5.04	0.31	8.98e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.51	-0.43	1.12e-12	Life satisfaction;
KIRP	cis	rs7011192	0.793	rs11774104	chr8:10526434	C/G	cg04501334	chr8:10513686	RP1L1	-0.77	-6.08	-0.36	4.45e-9	Suicide;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs71277158	0.688	rs7615039	chr3:169806170	G/A	cg04067573	chr3:169899625	PHC3	0.65	6.14	0.36	3.29e-9	Prostate cancer;
KIRP	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	10.29	0.55	6.89e-21	Exhaled nitric oxide output;
KIRP	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.79	10.37	0.55	3.75e-21	Bipolar disorder;
KIRP	cis	rs1978968	1.000	rs5013012	chr22:18450149	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.69	-0.39	1.46e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg02023728	chr11:77925099	USP35	0.36	6.08	0.36	4.66e-9	Alzheimer's disease (survival time);
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg07317062	chr7:27170388	HOXA4	-0.39	-5.45	-0.33	1.25e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.74	-9.66	-0.52	6.46e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs6601327	0.586	rs6601340	chr8:9461315	A/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.48	-0.43	1.34e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg24203234	chr3:128598194	ACAD9	0.44	5.0	0.3	1.09e-6	IgG glycosylation;
KIRP	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg26876637	chr1:152193138	HRNR	-0.7	-8.81	-0.49	2.34e-16	Atopic dermatitis;
KIRP	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.53	-6.44	-0.38	6.07e-10	Iron status biomarkers;
KIRP	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.72	-8.31	-0.47	6.4e-15	Obesity-related traits;
KIRP	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	11.56	0.59	5.83e-25	Personality dimensions;
KIRP	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg23307798	chr14:103986281	CKB	-0.48	-6.51	-0.38	4.21e-10	Coronary artery disease;
KIRP	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.52	-7.74	-0.44	2.53e-13	IgG glycosylation;
KIRP	cis	rs4728302	0.607	rs10271671	chr7:133588413	G/A	cg10665199	chr7:133106180	EXOC4	0.43	5.05	0.31	8.75e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg22508957	chr16:3507546	NAT15	0.59	7.17	0.42	8.66e-12	Tuberculosis;
KIRP	trans	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg06521331	chr12:34319734	NA	-0.52	-6.46	-0.38	5.64e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.37e-6	Obesity-related traits;
KIRP	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.9	-0.35	1.17e-8	Diastolic blood pressure;
KIRP	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.52	8.41	0.47	3.28e-15	Monocyte count;
KIRP	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.02	-0.3	1e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.91	9.27	0.51	9.64e-18	Schizophrenia;
KIRP	cis	rs7274811	0.744	rs6120309	chr20:32169600	A/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.39	-4.91	-0.3	1.65e-6	Height;
KIRP	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.54	0.39	3.45e-10	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.41	4.99	0.3	1.13e-6	Asthma;
KIRP	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs6723108	0.654	rs520449	chr2:135295619	C/T	cg12500956	chr2:135428796	TMEM163	0.43	5.3	0.32	2.52e-7	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg19847130	chr8:10466454	RP1L1	-0.36	-5.36	-0.32	1.88e-7	Triglycerides;
KIRP	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.34	5.28	0.32	2.86e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg24315340	chr6:146058215	EPM2A	0.41	5.1	0.31	6.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.39	-7.37	-0.43	2.52e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg05775895	chr3:12838266	CAND2	0.33	5.47	0.33	1.09e-7	P wave duration;
KIRP	cis	rs12230513	0.732	rs59438785	chr12:55811665	A/G	cg11794356	chr12:55725991	OR6C3	-0.48	-5.9	-0.35	1.2e-8	Contrast sensitivity;
KIRP	cis	rs4073221	0.789	rs67392505	chr3:18217031	G/C	cg07694806	chr3:18168406	NA	-0.72	-6.29	-0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg08890418	chr1:21044141	KIF17	-0.43	-6.54	-0.38	3.57e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg04663916	chr13:50265991	EBPL	0.71	8.76	0.49	3.34e-16	Obesity-related traits;
KIRP	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	6.33	0.37	1.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.66	0.39	1.8e-10	Diabetic retinopathy;
KIRP	cis	rs2425143	1.000	rs2378409	chr20:34392464	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-4.9	-0.3	1.73e-6	Blood protein levels;
KIRP	cis	rs12282928	0.918	rs6485815	chr11:48243186	A/C	cg26585981	chr11:48327164	OR4S1	-0.51	-5.76	-0.34	2.54e-8	Migraine - clinic-based;
KIRP	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg01028140	chr2:1542097	TPO	-0.64	-6.52	-0.38	4.03e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-5.11	-0.31	6.46e-7	Colorectal cancer;
KIRP	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.6	9.86	0.53	1.48e-19	Total body bone mineral density;
KIRP	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg26681399	chr22:41777847	TEF	-0.5	-5.11	-0.31	6.35e-7	Vitiligo;
KIRP	cis	rs9513627	1.000	rs4285989	chr13:100132342	A/G	cg25919922	chr13:100150906	NA	0.7	5.5	0.33	9.4e-8	Obesity-related traits;
KIRP	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg09517075	chr8:22133004	PIWIL2	0.44	5.93	0.35	1.02e-8	Hypertriglyceridemia;
KIRP	cis	rs9611519	0.567	rs8141730	chr22:41473061	A/G	cg03806693	chr22:41940476	POLR3H	-0.41	-4.84	-0.3	2.26e-6	Neuroticism;
KIRP	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.24	0.42	5.65e-12	Aortic root size;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21404792	chr18:12433117	NA	0.47	6.21	0.37	2.22e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00149659	chr3:10157352	C3orf10	0.6	7.02	0.41	2.14e-11	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07040405	chr2:174828875	SP3	0.52	6.56	0.39	3.13e-10	Parkinson's disease;
KIRP	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.11	-0.46	2.39e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.62	0.39	2.29e-10	Height;
KIRP	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-8.42	-0.47	3.09e-15	Bipolar disorder;
KIRP	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.51	-7.75	-0.44	2.44e-13	Sudden cardiac arrest;
KIRP	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg20813462	chr7:2646259	IQCE	-0.64	-6.1	-0.36	4.07e-9	Urate levels in lean individuals;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14492773	chr5:56469900	GPBP1	-0.49	-6.2	-0.37	2.39e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6546324	0.625	rs6752799	chr2:67858503	G/A	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.66	8.46	0.47	2.43e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-6.6	-0.39	2.54e-10	Bladder cancer;
KIRP	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-9.98	-0.54	6.52e-20	Coffee consumption (cups per day);
KIRP	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.73	8.94	0.5	9.7e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg22800045	chr5:56110881	MAP3K1	0.73	7.84	0.45	1.38e-13	Initial pursuit acceleration;
KIRP	cis	rs490234	0.934	rs7865246	chr9:128269511	T/C	cg14078157	chr9:128172775	NA	-0.42	-5.27	-0.32	2.94e-7	Mean arterial pressure;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.54	6.89	0.4	4.75e-11	Menarche (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07643762	chr4:75174080	EPGN	-0.37	-6.03	-0.36	5.87e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg26597838	chr10:835615	NA	-0.54	-6.72	-0.39	1.25e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs17739794	0.537	rs7816826	chr8:814492	C/G	cg01971667	chr8:817044	NA	0.4	5.63	0.34	5.02e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.59	-7.54	-0.43	8.97e-13	Diastolic blood pressure;
KIRP	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg15436174	chr10:43711423	RASGEF1A	0.8	9.04	0.5	4.65e-17	Hirschsprung disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.5	6.65	0.39	1.89e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg27189623	chr16:705930	WDR90	0.48	6.74	0.39	1.14e-10	Height;
KIRP	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.05	-0.41	1.83e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.46	6.55	0.39	3.33e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.15	-0.54	1.94e-20	Total body bone mineral density;
KIRP	cis	rs754423	0.515	rs10150755	chr14:52545019	T/C	cg05884192	chr14:52515736	NID2	0.47	5.2	0.31	4.29e-7	Craniofacial microsomia;
KIRP	cis	rs2230307	0.536	rs629340	chr1:100538621	A/T	cg24955406	chr1:100503596	HIAT1	0.58	6.27	0.37	1.58e-9	Carotid intima media thickness;
KIRP	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.55	7.73	0.44	2.78e-13	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg01097406	chr16:89675127	NA	-0.33	-5.36	-0.32	1.91e-7	Vitiligo;
KIRP	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	8.91	0.49	1.2e-16	Resting heart rate;
KIRP	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg19773385	chr1:10388646	KIF1B	-0.73	-11.48	-0.59	1.03e-24	Hepatocellular carcinoma;
KIRP	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.96	-0.41	3.13e-11	Initial pursuit acceleration;
KIRP	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg22705602	chr4:152727874	NA	-0.54	-9.44	-0.52	2.91e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs8014252	0.803	rs73282153	chr14:71002310	C/T	cg19730268	chr14:71022823	NA	-0.62	-5.86	-0.35	1.48e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs13067260	0.655	rs16835002	chr3:123743646	A/G	cg19918027	chr3:123987645	KALRN	-0.65	-5.86	-0.35	1.45e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.55	6.69	0.39	1.5e-10	Alzheimer's disease (late onset);
KIRP	cis	rs6929812	0.934	rs7772160	chr6:27412386	C/T	cg03332623	chr6:27441972	ZNF184	-0.37	-5.32	-0.32	2.38e-7	Neuroticism (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg08501292	chr6:25962987	TRIM38	-0.8	-5.6	-0.34	5.64e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg07775675	chr17:74379922	SPHK1	0.43	6.08	0.36	4.61e-9	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg16898833	chr6:26189333	HIST1H4D	0.79	5.78	0.35	2.3e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.6	-0.39	2.47e-10	Lung cancer;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.6	8.7	0.48	4.97e-16	Menarche (age at onset);
KIRP	cis	rs9475752	0.793	rs55952713	chr6:56815307	A/G	cg22880620	chr6:56820808	BEND6;DST	0.5	5.17	0.31	4.96e-7	Menarche (age at onset);
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.47	-6.84	-0.4	6.15e-11	Electroencephalogram traits;
KIRP	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg24375607	chr4:120327624	NA	0.57	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs965513	1.000	rs7030256	chr9:100535203	C/G	cg13688889	chr9:100608707	NA	-0.58	-7.25	-0.42	5.42e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg21734707	chr17:3908241	ZZEF1	0.5	6.17	0.37	2.75e-9	Type 2 diabetes;
KIRP	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg20991723	chr1:152506922	NA	-0.45	-5.3	-0.32	2.6e-7	Hair morphology;
KIRP	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	1.08	9.79	0.53	2.49e-19	Pulse pressure;
KIRP	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.46	-6.3	-0.37	1.37e-9	Red blood cell count;
KIRP	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-7.29	-0.42	4.26e-12	Educational attainment;
KIRP	trans	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	8.7	0.49	4.76e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg01721255	chr8:58191610	C8orf71	0.5	4.89	0.3	1.85e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-7.81	-0.45	1.62e-13	Tonsillectomy;
KIRP	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-5.54	-0.33	7.71e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs5753618	0.583	rs7285619	chr22:31842554	C/T	cg02404636	chr22:31891804	SFI1	0.54	6.33	0.37	1.14e-9	Colorectal cancer;
KIRP	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.87	14.37	0.68	2.06e-34	Prostate cancer;
KIRP	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg05234568	chr11:5960015	NA	-0.6	-6.21	-0.37	2.28e-9	DNA methylation (variation);
KIRP	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	1.06	20.81	0.8	3.58e-56	Parkinson's disease;
KIRP	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg10117171	chr1:25599238	RHD	-0.42	-5.66	-0.34	4.21e-8	Erythrocyte sedimentation rate;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15190354	chr11:125494874	CHEK1	-0.49	-6.16	-0.37	2.89e-9	Inflammatory biomarkers;
KIRP	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg08999081	chr20:33150536	PIGU	-0.47	-6.2	-0.37	2.42e-9	Height;
KIRP	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.58	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17376030	chr22:41985996	PMM1	0.74	7.75	0.44	2.38e-13	Vitiligo;
KIRP	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.56	0.33	6.98e-8	Total cholesterol levels;
KIRP	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.09	-0.54	3.03e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs2281597	0.696	rs3856129	chr1:34279742	A/T	cg19991458	chr15:67417651	SMAD3	0.46	6.09	0.36	4.38e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09800235	chr12:133250183	POLE	0.58	7.17	0.42	8.61e-12	Interleukin-4 levels;
KIRP	cis	rs2671245	0.933	rs2255776	chr1:56156803	G/A	cg11523071	chr1:56160889	NA	0.41	6.71	0.39	1.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg21605333	chr4:119757512	SEC24D	1.66	11.8	0.6	8.89e-26	Cannabis dependence symptom count;
KIRP	cis	rs10751667	0.558	rs12276666	chr11:1022119	G/A	cg06064525	chr11:970664	AP2A2	-0.32	-5.8	-0.35	2.08e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg00784671	chr22:46762841	CELSR1	-0.76	-8.25	-0.47	9.37e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg07451762	chr16:28383216	NA	0.39	4.86	0.3	2.08e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3762637	0.941	rs9289192	chr3:122076115	C/G	cg24169773	chr3:122142474	KPNA1	-0.58	-5.86	-0.35	1.47e-8	LDL cholesterol levels;
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs11209185	0.509	rs12130147	chr1:68446944	G/A	cg22082780	chr1:68452167	NA	0.38	5.5	0.33	9.36e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.47	-5.89	-0.35	1.26e-8	Neutrophil percentage of white cells;
KIRP	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg13736514	chr6:26305472	NA	-0.65	-7.92	-0.45	8.28e-14	Height;
KIRP	cis	rs10203711	0.673	rs9677610	chr2:239621531	G/A	cg14580085	chr2:239553406	NA	0.38	4.88	0.3	1.93e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.72	8.75	0.49	3.51e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11731606	0.701	rs699861	chr4:95420163	G/A	cg20625393	chr4:95128694	SMARCAD1	-0.5	-4.86	-0.3	2.1e-6	Mean platelet volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06527153	chr1:109289113	STXBP3	0.56	6.6	0.39	2.56e-10	Smoking initiation;
KIRP	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs9596863	0.861	rs4088520	chr13:54441906	C/T	ch.13.53330881F	chr13:54432880	NA	-0.53	-5.71	-0.34	3.3e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7116495	0.609	rs949323	chr11:71714528	T/G	cg07596299	chr11:71824057	C11orf51	-0.83	-5.6	-0.34	5.72e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.63	-6.29	-0.37	1.42e-9	Schizophrenia;
KIRP	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg08885076	chr2:99613938	TSGA10	-0.54	-9.12	-0.5	2.79e-17	Chronic sinus infection;
KIRP	cis	rs8084125	1.000	rs72978662	chr18:74951872	G/A	cg26065057	chr18:74961000	GALR1	0.8	7.74	0.44	2.58e-13	Obesity-related traits;
KIRP	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.68	8.02	0.46	4.38e-14	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17040068	chr7:102715209	ARMC10;FBXL13	0.65	7.76	0.44	2.2e-13	Smoking initiation;
KIRP	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.59	-8.77	-0.49	3.02e-16	Urate levels in overweight individuals;
KIRP	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg14703610	chr5:56206110	C5orf35	0.51	5.63	0.34	4.91e-8	Type 2 diabetes;
KIRP	cis	rs6973256	0.897	rs2911495	chr7:133331405	T/C	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.55e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2625529	0.627	rs1037680	chr15:72514319	T/C	cg16672083	chr15:72433130	SENP8	-0.45	-5.42	-0.33	1.41e-7	Red blood cell count;
KIRP	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.21	0.42	6.84e-12	Lung cancer;
KIRP	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg13010199	chr12:38710504	ALG10B	-0.56	-7.05	-0.41	1.85e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg21204522	chr6:27730016	NA	-0.75	-5.53	-0.33	7.99e-8	Breast cancer;
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.79	13.4	0.65	4.13e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg01872077	chr2:219646372	CYP27A1	0.41	5.31	0.32	2.48e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg24060327	chr5:131705240	SLC22A5	-0.55	-6.88	-0.4	4.8e-11	Acylcarnitine levels;
KIRP	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg22875332	chr1:76189707	ACADM	0.57	7.46	0.43	1.53e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg17385448	chr1:15911702	AGMAT	0.26	5.12	0.31	6.28e-7	Systolic blood pressure;
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-5.55	-0.33	7.24e-8	Lung cancer;
KIRP	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.2	0.7	2.96e-37	Lymphocyte percentage of white cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10467997	chr4:156296145	MAP9	-0.43	-6.64	-0.39	1.96e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3784262	0.507	rs1992231	chr15:58190937	A/G	cg12031962	chr15:58353849	ALDH1A2	0.38	5.05	0.31	8.66e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.16	-0.46	1.7e-14	Response to antipsychotic treatment;
KIRP	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-1.06	-14.82	-0.69	5.92e-36	Alopecia areata;
KIRP	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg06654118	chr4:1303317	MAEA	0.27	5.09	0.31	6.98e-7	Obesity-related traits;
KIRP	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-8.1	-0.46	2.49e-14	Diastolic blood pressure;
KIRP	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg00262122	chr8:11665843	FDFT1	0.44	5.44	0.33	1.27e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.62	6.63	0.39	2.1e-10	Cognitive ability;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11111859	chr10:97686634	C10orf131	0.43	6.59	0.39	2.61e-10	Survival in pancreatic cancer;
KIRP	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg24209194	chr3:40518798	ZNF619	-0.42	-5.39	-0.33	1.65e-7	Renal cell carcinoma;
KIRP	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.08	0.36	4.61e-9	Height;
KIRP	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.5	-7.02	-0.41	2.17e-11	Schizophrenia;
KIRP	cis	rs12230513	1.000	rs12230513	chr12:55916780	A/G	cg19537932	chr12:55886519	OR6C68	-0.47	-5.09	-0.31	7.14e-7	Contrast sensitivity;
KIRP	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	1.11	10.8	0.57	1.68e-22	Blood protein levels;
KIRP	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg13319975	chr6:146136371	FBXO30	0.43	5.85	0.35	1.54e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.81	-0.45	1.62e-13	Aortic root size;
KIRP	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.65	-7.53	-0.43	9.49e-13	Mean platelet volume;
KIRP	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05665937	chr4:1216051	CTBP1	0.57	7.93	0.45	7.67e-14	Obesity-related traits;
KIRP	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.81	7.23	0.42	6.03e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs629922	1.000	rs670728	chr11:114064733	G/T	cg25009965	chr11:114031120	ZBTB16	-0.42	-5.51	-0.33	9.15e-8	Paneth cell defects in Crohn's disease;
KIRP	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg16141378	chr3:129829833	LOC729375	0.5	6.31	0.37	1.28e-9	Retinal vascular caliber;
KIRP	cis	rs9611198	0.765	rs5757721	chr22:39947574	A/G	cg03390717	chr22:39966585	CACNA1I	0.37	6.66	0.39	1.75e-10	Schizophrenia;
KIRP	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.9	-10.75	-0.57	2.46e-22	Vitiligo;
KIRP	cis	rs258892	0.895	rs155432	chr5:72138608	G/T	cg21869765	chr5:72125136	TNPO1	0.57	6.33	0.37	1.15e-9	Small cell lung carcinoma;
KIRP	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg14675211	chr2:100938903	LONRF2	0.49	6.38	0.38	8.59e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12765878	1.000	rs34300861	chr10:105643332	A/C	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs714031	0.934	rs4820387	chr22:40070446	A/G	cg21377881	chr22:40064566	CACNA1I	-0.66	-10.13	-0.54	2.21e-20	Schizophrenia;
KIRP	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg04202892	chr2:111875749	ACOXL	0.46	6.39	0.38	8.18e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs8060686	0.516	rs7197756	chr16:68275516	A/C	cg26727032	chr16:67993705	SLC12A4	-0.75	-8.93	-0.49	1.01e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg01304814	chr3:48885189	PRKAR2A	0.78	5.88	0.35	1.36e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.47	3.67e-15	Motion sickness;
KIRP	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	0.73	10.72	0.56	2.91e-22	Height;
KIRP	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.99	14.01	0.67	3.51e-33	Cognitive function;
KIRP	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg07636037	chr3:49044803	WDR6	-0.71	-7.46	-0.43	1.48e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14924176	chr2:69614462	GFPT1	0.52	6.45	0.38	5.98e-10	Parkinson's disease;
KIRP	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.07	-0.46	3.15e-14	Mean corpuscular volume;
KIRP	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg04865290	chr3:52927548	TMEM110	-0.6	-6.94	-0.4	3.38e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1669338	0.588	rs4684375	chr3:3170966	T/C	cg16797762	chr3:3221439	CRBN	-0.68	-6.43	-0.38	6.57e-10	White matter integrity;
KIRP	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.59	-7.28	-0.42	4.38e-12	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg09263875	chr16:632152	PIGQ	0.7	10.93	0.57	6.11e-23	Height;
KIRP	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg26681399	chr22:41777847	TEF	-0.51	-5.27	-0.32	2.98e-7	Vitiligo;
KIRP	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	7.32	0.42	3.55e-12	Bipolar disorder;
KIRP	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.53	-0.43	9.55e-13	Initial pursuit acceleration;
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg05627522	chr15:75251581	NA	0.4	6.41	0.38	7.22e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.76	-0.44	2.24e-13	Joint mobility (Beighton score);
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg11814155	chr7:99998594	ZCWPW1	0.6	5.59	0.34	6.02e-8	Platelet count;
KIRP	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.78	-11.2	-0.58	8.6e-24	Total body bone mineral density;
KIRP	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.12	-0.31	6.13e-7	Metabolite levels;
KIRP	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.94	15.44	0.7	4.46e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.86	-0.35	1.44e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.81	0.45	1.66e-13	Neuroticism;
KIRP	cis	rs6867032	0.527	rs4975790	chr5:2010376	C/T	cg26168224	chr5:2018326	NA	0.74	10.67	0.56	4.25e-22	Gut microbiome composition (winter);
KIRP	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.48	6.47	0.38	5.38e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7870753	0.578	rs10990558	chr9:99093945	T/C	cg25260653	chr9:99212216	HABP4	0.54	4.99	0.3	1.15e-6	Height;
KIRP	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg21684588	chr1:67600265	NA	0.42	4.92	0.3	1.56e-6	Psoriasis;
KIRP	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.23	0.46	1.07e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.66	9.02	0.5	5.56e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-6.89	-0.4	4.71e-11	Self-reported allergy;
KIRP	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg00262122	chr8:11665843	FDFT1	0.4	4.9	0.3	1.78e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7546094	0.967	rs1032312	chr1:113112746	G/A	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.45	6.2	0.37	2.33e-9	Sitting height ratio;
KIRP	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg22777020	chr22:31556080	RNF185	0.52	5.36	0.32	1.9e-7	Colorectal cancer;
KIRP	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg24110177	chr3:50126178	RBM5	0.55	7.19	0.42	7.73e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg08999081	chr20:33150536	PIGU	0.46	4.91	0.3	1.7e-6	Protein C levels;
KIRP	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg20607798	chr8:58055168	NA	0.58	5.13	0.31	5.82e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11264213	1.000	rs11264203	chr1:36239234	C/T	cg27506609	chr1:36549197	TEKT2	0.73	6.84	0.4	6.18e-11	Schizophrenia;
KIRP	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.54	4.9	0.3	1.76e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23855257	chr13:27746147	USP12	0.48	6.17	0.37	2.86e-9	Myopia (pathological);
KIRP	cis	rs6882046	0.513	rs187270	chr5:88026870	C/T	cg22951263	chr5:87985283	NA	-0.45	-6.39	-0.38	8.41e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.65	6.24	0.37	1.85e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.06	0.36	4.97e-9	Major depressive disorder;
KIRP	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-6.9	-0.4	4.26e-11	Menopause (age at onset);
KIRP	cis	rs2273669	0.585	rs11153159	chr6:109376647	C/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.13	-0.36	3.45e-9	Prostate cancer;
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg18234130	chr8:27182889	PTK2B	0.53	7.0	0.41	2.42e-11	Neuroticism;
KIRP	cis	rs7945718	0.621	rs6485992	chr11:12697359	C/T	cg25843174	chr11:12811716	TEAD1	0.3	5.41	0.33	1.53e-7	Educational attainment (years of education);
KIRP	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg26566898	chr11:117069891	TAGLN	0.38	4.91	0.3	1.68e-6	Blood protein levels;
KIRP	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.6	9.54	0.52	1.51e-18	Birth weight;
KIRP	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.82e-10	Protein C levels;
KIRP	cis	rs9815354	1.000	rs1629460	chr3:41927449	T/G	cg03022575	chr3:42003672	ULK4	-0.46	-5.25	-0.32	3.36e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.74	10.45	0.55	2.19e-21	Body mass index;
KIRP	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg16497661	chr14:103986332	CKB	0.81	13.39	0.65	4.36e-31	Body mass index;
KIRP	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.93	-0.45	7.56e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7481584	0.847	rs1468102	chr11:3004526	C/G	cg25174290	chr11:3078921	CARS	-0.55	-6.09	-0.36	4.41e-9	Calcium levels;
KIRP	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg08132940	chr7:1081526	C7orf50	-0.46	-5.28	-0.32	2.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17165284	chr19:10829165	MIR638;DNM2	0.53	6.82	0.4	7.12e-11	Parkinson's disease;
KIRP	cis	rs2273669	0.667	rs12214567	chr6:109317330	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg18306943	chr3:40428807	ENTPD3	0.41	5.39	0.33	1.65e-7	Renal cell carcinoma;
KIRP	cis	rs6859018	1.000	rs2082412	chr5:158717789	A/G	cg26646896	chr5:158686746	NA	0.37	5.45	0.33	1.23e-7	Serum sulfate level;
KIRP	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.82	-14.68	-0.68	1.8e-35	Body mass index;
KIRP	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.76	0.34	2.44e-8	Aortic root size;
KIRP	cis	rs10214930	0.813	rs6946305	chr7:27681195	A/G	cg22168087	chr7:27702803	HIBADH	0.5	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg15655495	chr12:38532458	NA	-0.27	-5.28	-0.32	2.79e-7	Bladder cancer;
KIRP	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.89	-0.4	4.64e-11	Joint mobility (Beighton score);
KIRP	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-9.01	-0.5	5.85e-17	Monocyte percentage of white cells;
KIRP	cis	rs10465746	0.780	rs7529293	chr1:84331981	A/G	cg10977910	chr1:84465055	TTLL7	0.55	6.93	0.4	3.64e-11	Obesity-related traits;
KIRP	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.21	0.32	4.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg04607699	chr11:48328132	OR4S1	-0.35	-4.9	-0.3	1.73e-6	HDL cholesterol;
KIRP	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg26876637	chr1:152193138	HRNR	-0.7	-8.28	-0.47	7.75e-15	Atopic dermatitis;
KIRP	cis	rs9473924	0.632	rs6924593	chr6:50926154	T/C	cg03432817	chr6:50765336	NA	0.35	5.4	0.33	1.59e-7	Body mass index;
KIRP	cis	rs601339	1.000	rs4759361	chr12:123178280	T/A	cg18578876	chr12:123200353	GPR109B	0.52	4.92	0.3	1.57e-6	Adiponectin levels;
KIRP	cis	rs8038465	0.904	rs11852484	chr15:73988652	G/A	cg15420318	chr15:73925796	NPTN	0.48	5.89	0.35	1.27e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg14091149	chr1:16273971	ZBTB17	0.38	5.79	0.35	2.14e-8	Dilated cardiomyopathy;
KIRP	cis	rs981844	0.712	rs4525952	chr4:154746606	G/T	cg14289246	chr4:154710475	SFRP2	0.55	7.06	0.41	1.73e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.09	-0.46	2.75e-14	Aortic root size;
KIRP	cis	rs9815354	1.000	rs7648357	chr3:41849670	A/G	cg03022575	chr3:42003672	ULK4	0.54	6.2	0.37	2.33e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4780401	0.755	rs2868981	chr16:11765518	T/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.16	-0.31	4.99e-7	Rheumatoid arthritis;
KIRP	cis	rs16936870	0.543	rs16936790	chr8:71086468	C/T	cg14232793	chr8:71155543	NCOA2	-0.53	-6.17	-0.37	2.78e-9	QT interval;
KIRP	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.49	-0.33	1.02e-7	Coronary artery disease;
KIRP	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg03959625	chr15:84868606	LOC388152	0.52	6.09	0.36	4.37e-9	Schizophrenia;
KIRP	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Body mass index;
KIRP	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.77	5.59	0.34	5.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg23698023	chr8:27181813	PTK2B	0.33	5.1	0.31	6.84e-7	Neuroticism;
KIRP	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg18190219	chr22:46762943	CELSR1	-0.72	-7.58	-0.44	7.01e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg21466736	chr12:48725269	NA	0.45	5.55	0.33	7.25e-8	Glycated hemoglobin levels;
KIRP	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg05347473	chr6:146136440	FBXO30	0.5	7.16	0.42	9.05e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.99	-16.75	-0.73	1.52e-42	Breast cancer;
KIRP	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-5.57	-0.33	6.55e-8	Lung cancer;
KIRP	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.62	-0.39	2.2e-10	Aortic root size;
KIRP	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.55	6.64	0.39	2e-10	Arsenic metabolism;
KIRP	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.75	10.32	0.55	5.75e-21	Red blood cell count;
KIRP	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.5	6.34	0.37	1.11e-9	Asthma (sex interaction);
KIRP	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	8.09	0.46	2.66e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1538970	0.962	rs2153607	chr1:45813820	G/A	cg05343316	chr1:45956843	TESK2	0.62	7.26	0.42	4.95e-12	Platelet count;
KIRP	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.43	5.9	0.35	1.22e-8	Total body bone mineral density;
KIRP	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.75	-12.34	-0.62	1.45e-27	Prostate cancer;
KIRP	cis	rs9583531	0.891	rs9521911	chr13:111370615	A/G	cg24331049	chr13:111365604	ING1	-0.8	-6.89	-0.4	4.56e-11	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00933542	chr6:150070202	PCMT1	0.31	6.01	0.36	6.59e-9	Lung cancer;
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.5	-6.5	-0.38	4.38e-10	Testicular germ cell tumor;
KIRP	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg03714773	chr7:91764589	CYP51A1	0.4	5.89	0.35	1.24e-8	Breast cancer;
KIRP	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs758324	0.947	rs253943	chr5:131320730	C/T	cg06307176	chr5:131281290	NA	0.48	5.15	0.31	5.32e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.19	-0.37	2.54e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg02980000	chr4:1222292	CTBP1	0.83	8.28	0.47	7.78e-15	Systolic blood pressure;
KIRP	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg18944383	chr4:111397179	ENPEP	-0.42	-6.73	-0.39	1.21e-10	Coronary artery disease;
KIRP	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.78	-0.35	2.27e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7126328	1	rs7126328	chr11:120244577	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.1	-0.41	1.29e-11	Intraocular pressure;
KIRP	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.03	-0.36	6.02e-9	Neuroticism;
KIRP	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg13165212	chr22:42675999	NA	0.35	5.93	0.35	1.01e-8	Cognitive function;
KIRP	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg00361562	chr2:198649771	BOLL	-0.54	-5.28	-0.32	2.83e-7	Ulcerative colitis;
KIRP	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	cg07049167	chr1:166818506	POGK	0.56	6.11	0.36	3.88e-9	Refractive astigmatism;
KIRP	trans	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.41	-0.38	7.32e-10	Triglycerides;
KIRP	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg09699651	chr6:150184138	LRP11	0.48	6.19	0.37	2.47e-9	Lung cancer;
KIRP	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg21419209	chr3:44054225	NA	-0.73	-8.98	-0.5	7.14e-17	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14251936	chr19:44417025	ZNF45	0.54	6.76	0.4	1.01e-10	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20149937	chr19:3465709	NA	-0.45	-6.11	-0.36	3.82e-9	Parkinson's disease;
KIRP	trans	rs2975734	0.680	rs10503406	chr8:10108972	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.8	-0.4	7.8e-11	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg22800045	chr5:56110881	MAP3K1	0.45	5.0	0.3	1.1e-6	Coronary artery disease;
KIRP	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.47	-0.33	1.1e-7	Subjective well-being;
KIRP	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg11608241	chr8:8085544	FLJ10661	-0.53	-6.56	-0.39	3.23e-10	Joint mobility (Beighton score);
KIRP	cis	rs9392653	0.655	rs1265351	chr6:5080904	A/G	cg13207534	chr6:5087447	PPP1R3G	-0.51	-5.93	-0.35	1.03e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs883565	0.543	rs784488	chr3:39173135	C/G	cg01426195	chr3:39028469	NA	0.52	8.27	0.47	8.67e-15	Handedness;
KIRP	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs17750015	0.733	rs12454362	chr18:54396186	G/A	cg18434998	chr18:54306185	TXNL1	-0.45	-5.63	-0.34	4.94e-8	Depression and alcohol dependence;
KIRP	cis	rs9715521	0.775	rs56957240	chr4:59847774	C/A	cg11281224	chr4:60001000	NA	-0.4	-4.96	-0.3	1.33e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2281603	0.570	rs10145013	chr14:64941591	C/T	cg01860774	chr14:64969374	ZBTB25	0.34	5.34	0.32	2.12e-7	Lymphocyte counts;
KIRP	cis	rs780094	0.500	rs12467476	chr2:27825715	T/C	cg05484376	chr2:27715224	FNDC4	-0.38	-5.21	-0.32	3.94e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs7903847	0.642	rs11189182	chr10:99144186	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg21775007	chr8:11205619	TDH	-0.51	-6.52	-0.38	3.93e-10	Joint mobility (Beighton score);
KIRP	cis	rs1866706	1.000	rs2165283	chr11:12873035	G/A	cg25843174	chr11:12811716	TEAD1	-0.3	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6448317	0.539	rs13113895	chr4:24932077	T/C	cg21108841	chr4:24914750	CCDC149	-0.52	-6.99	-0.41	2.62e-11	Heschl's gyrus morphology;
KIRP	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.45	-0.52	2.84e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg14458575	chr2:238380390	NA	0.82	7.5	0.43	1.15e-12	Prostate cancer;
KIRP	cis	rs62413470	1.000	rs12195340	chr6:55967008	A/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.69	0.34	3.58e-8	Bipolar disorder;
KIRP	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.38	-0.32	1.72e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13958324	chr10:63845528	ARID5B	0.43	6.19	0.37	2.44e-9	Interleukin-4 levels;
KIRP	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg08648136	chr8:956695	NA	0.38	5.24	0.32	3.43e-7	Schizophrenia;
KIRP	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.56	7.52	0.43	1.04e-12	Blood metabolite levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg04297258	chr16:88772664	RNF166;CTU2	-0.49	-6.1	-0.36	4.13e-9	Neuroticism;
KIRP	cis	rs17123764	0.818	rs3815832	chr12:49948105	A/G	cg02054252	chr12:50078554	FMNL3	0.43	5.23	0.32	3.54e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10861661	0.963	rs7977765	chr12:107205390	A/G	cg21360079	chr12:107162445	NA	-0.59	-6.7	-0.39	1.42e-10	Triglyceride levels;
KIRP	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.97	0.3	1.23e-6	Educational attainment;
KIRP	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	9.11	0.5	3.05e-17	Systemic lupus erythematosus;
KIRP	cis	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg07585502	chr8:101912084	NA	0.64	9.1	0.5	3.21e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4523957	0.855	rs11078883	chr17:2138828	C/G	cg16513277	chr17:2031491	SMG6	-0.57	-7.84	-0.45	1.33e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14169450	chr9:139327907	INPP5E	0.41	5.26	0.32	3.18e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg00024416	chr22:24240387	NA	0.42	5.1	0.31	6.82e-7	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg13611997	chr5:233750	SDHA	-0.44	-5.26	-0.32	3.15e-7	Breast cancer;
KIRP	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.93	-10.44	-0.55	2.26e-21	Blood protein levels;
KIRP	cis	rs4845875	0.535	rs198408	chr1:11898130	T/A	cg24844545	chr1:11908347	NPPA	-0.36	-5.06	-0.31	8.4e-7	Midregional pro atrial natriuretic peptide levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03768007	chr19:55851064	SUV420H2	0.51	6.64	0.39	2.04e-10	Parkinson's disease;
KIRP	cis	rs17221829	0.829	rs11018737	chr11:89427132	A/G	cg02982614	chr11:89391479	FOLH1B	-0.32	-4.93	-0.3	1.54e-6	Anxiety in major depressive disorder;
KIRP	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg08885076	chr2:99613938	TSGA10	-0.68	-12.14	-0.61	6.97e-27	Chronic sinus infection;
KIRP	cis	rs6585424	1.000	rs10466228	chr10:81924373	A/G	cg27417294	chr10:81904244	PLAC9	0.55	5.26	0.32	3.07e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.94	12.28	0.62	2.32e-27	Menopause (age at onset);
KIRP	cis	rs9888739	0.800	rs1143683	chr16:31336888	A/G	cg15817542	chr16:31343056	ITGAM	0.46	4.93	0.3	1.51e-6	Systemic lupus erythematosus;
KIRP	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg01872077	chr2:219646372	CYP27A1	0.38	4.92	0.3	1.59e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	1.22	13.42	0.65	3.63e-31	Uric acid levels;
KIRP	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg15556689	chr8:8085844	FLJ10661	0.52	7.02	0.41	2.19e-11	Neuroticism;
KIRP	cis	rs8084125	1.000	rs7230071	chr18:74955482	A/G	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.8	-12.83	-0.63	3.3e-29	Prostate cancer;
KIRP	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	cg04338863	chr8:33670619	NA	0.48	6.31	0.37	1.31e-9	Body mass index;
KIRP	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.46	0.33	1.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13361707	0.685	rs11957736	chr5:40819753	C/T	cg01087697	chr5:40835557	RPL37	-0.41	-4.95	-0.3	1.38e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg16141378	chr3:129829833	LOC729375	0.58	7.23	0.42	5.98e-12	Morning vs. evening chronotype;
KIRP	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.91e-9	Response to antipsychotic treatment;
KIRP	cis	rs9921338	0.961	rs7199821	chr16:11425011	T/G	cg00044050	chr16:11439710	C16orf75	-0.54	-5.69	-0.34	3.63e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	cis	rs4560672	0.938	rs71563797	chr6:158619948	G/C	cg14029994	chr6:158589857	SERAC1;GTF2H5	-0.62	-5.33	-0.32	2.19e-7	Smoking quantity;
KIRP	cis	rs4474465	0.688	rs4457782	chr11:78284733	A/G	cg27205649	chr11:78285834	NARS2	0.87	11.78	0.6	1.08e-25	Alzheimer's disease (survival time);
KIRP	cis	rs9815354	1.000	rs10865914	chr3:41919499	C/T	cg03022575	chr3:42003672	ULK4	-0.47	-5.31	-0.32	2.42e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg10047753	chr17:41438598	NA	1.17	19.27	0.78	4.52e-51	Menopause (age at onset);
KIRP	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3741798	1.000	rs78028836	chr12:12485448	G/A	cg08615371	chr12:12503544	MANSC1	0.94	8.28	0.47	7.84e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg22325292	chr17:80708367	FN3K	0.39	5.26	0.32	3.06e-7	Glycated hemoglobin levels;
KIRP	cis	rs7033996	1.000	rs16932790	chr9:35938274	C/G	cg00918944	chr9:35908117	LOC158376	0.38	5.23	0.32	3.62e-7	Urate levels (BMI interaction);
KIRP	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.45	-6.82	-0.4	7.19e-11	Lymphocyte counts;
KIRP	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.72	-9.44	-0.52	3.04e-18	Pancreatic cancer;
KIRP	trans	rs263156	0.967	rs605790	chr6:142879589	T/C	cg01789478	chr2:182545485	NEUROD1	-0.36	-6.28	-0.37	1.54e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05724965	chr11:122753715	C11orf63	0.45	6.03	0.36	6.03e-9	Parkinson's disease;
KIRP	cis	rs5750854	0.503	rs5750862	chr22:40026309	G/A	cg10455938	chr22:40058150	CACNA1I	0.42	5.96	0.36	8.48e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg23533419	chr12:54090519	NA	-0.32	-5.13	-0.31	5.78e-7	Height;
KIRP	cis	rs526231	0.511	rs45518833	chr5:102342990	T/C	cg23492399	chr5:102201601	PAM	-0.45	-5.04	-0.31	9.02e-7	Primary biliary cholangitis;
KIRP	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg09137382	chr11:130731461	NA	0.55	8.07	0.46	3.14e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9843304	0.529	rs34895718	chr3:149205217	A/G	cg08667024	chr3:149219783	TM4SF4	-0.39	-5.73	-0.34	2.88e-8	Gallstone disease;
KIRP	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg10169327	chr19:45448959	APOC2	-0.33	-5.0	-0.3	1.07e-6	Blood protein levels;
KIRP	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg23163573	chr2:108905468	SULT1C2	-0.31	-5.35	-0.32	1.97e-7	Blood pressure;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg24874828	chr4:187887005	NA	0.46	6.83	0.4	6.67e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg26681399	chr22:41777847	TEF	-0.51	-5.21	-0.32	3.99e-7	Vitiligo;
KIRP	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.33	0.42	3.34e-12	Schizophrenia;
KIRP	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.59	7.32	0.42	3.61e-12	Resting heart rate;
KIRP	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg17724175	chr1:150552817	MCL1	0.32	5.41	0.33	1.51e-7	Melanoma;
KIRP	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.96	12.68	0.63	1.12e-28	Homoarginine levels;
KIRP	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17219203	chr10:38645113	HSD17B7P2	0.42	4.94	0.3	1.46e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.81	0.49	2.36e-16	Coronary artery disease;
KIRP	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg24488311	chr11:68621650	NA	0.41	5.07	0.31	7.72e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs714027	1.000	rs2412970	chr22:30486826	C/T	cg27665648	chr22:30112403	NA	0.42	6.04	0.36	5.76e-9	Lymphocyte counts;
KIRP	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg26875233	chr11:93583750	C11orf90	-0.41	-7.7	-0.44	3.4e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25354744	chr6:24775480	GMNN	-0.44	-6.03	-0.36	5.93e-9	Metabolic traits;
KIRP	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.68	8.62	0.48	8.03e-16	Blood metabolite levels;
KIRP	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.6	-7.32	-0.42	3.44e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11673344	0.864	rs56208574	chr19:37498745	C/T	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.12	-0.31	6.16e-7	Obesity-related traits;
KIRP	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg15655495	chr12:38532458	NA	-0.28	-5.09	-0.31	6.99e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Parkinson's disease;
KIRP	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	1.03	13.23	0.64	1.54e-30	Post bronchodilator FEV1;
KIRP	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg19257562	chr1:2043853	PRKCZ	0.37	5.25	0.32	3.26e-7	Height;
KIRP	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg24807547	chr6:37504484	NA	-0.52	-7.71	-0.44	3.2e-13	Cognitive performance;
KIRP	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	1.03	10.75	0.57	2.46e-22	Alzheimer's disease;
KIRP	cis	rs405956	1.000	rs923405	chr6:105618017	T/C	cg22580625	chr6:105627791	POPDC3	-0.52	-4.86	-0.3	2.12e-6	QT interval;
KIRP	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17507749	chr15:85114479	UBE2QP1	0.56	6.55	0.39	3.33e-10	Schizophrenia;
KIRP	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.46	5.11	0.31	6.58e-7	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs12043259	0.892	rs4950969	chr1:204823961	G/C	cg11485465	chr5:54518469	NA	0.41	6.53	0.38	3.76e-10	Addiction;
KIRP	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs6601327	0.603	rs28634186	chr8:9669335	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-4.99	-0.3	1.12e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg10761708	chr20:43804764	PI3	0.5	5.24	0.32	3.47e-7	Blood protein levels;
KIRP	cis	rs12230513	0.732	rs60683621	chr12:55863224	C/G	cg19537932	chr12:55886519	OR6C68	-0.63	-7.64	-0.44	4.9e-13	Contrast sensitivity;
KIRP	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.75	-11.16	-0.58	1.16e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs35160687	0.814	rs7563887	chr2:86516121	C/T	cg10973622	chr2:86423274	IMMT	0.52	6.7	0.39	1.44e-10	Night sleep phenotypes;
KIRP	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg22681709	chr2:178499509	PDE11A	0.46	4.9	0.3	1.74e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.67	-9.3	-0.51	8.17e-18	Asthma;
KIRP	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.72	-7.51	-0.43	1.08e-12	Body mass index;
KIRP	cis	rs11997175	0.646	rs67480501	chr8:33736315	C/T	ch.8.33884649F	chr8:33765107	NA	0.62	7.79	0.45	1.82e-13	Body mass index;
KIRP	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.08	0.61	1.08e-26	Ulcerative colitis;
KIRP	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00864171	chr11:67383662	NA	0.39	5.13	0.31	5.8e-7	Mean corpuscular volume;
KIRP	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg17133734	chr15:86042851	AKAP13	-0.48	-5.97	-0.36	8.23e-9	Coronary artery disease;
KIRP	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.85	-7.86	-0.45	1.2e-13	Lung cancer in ever smokers;
KIRP	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg26174226	chr8:58114915	NA	-0.6	-7.2	-0.42	7.15e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20592691	chr13:60447453	DIAPH3	0.49	7.0	0.41	2.48e-11	Interleukin-4 levels;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.54	6.86	0.4	5.58e-11	Menarche (age at onset);
KIRP	cis	rs629922	0.507	rs623418	chr11:114068474	G/A	cg01914181	chr11:114070210	ZBTB16	-0.56	-5.65	-0.34	4.52e-8	Paneth cell defects in Crohn's disease;
KIRP	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.18	0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs4400599	1.000	rs4845364	chr1:154141908	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.49	-0.33	9.75e-8	Platelet distribution width;
KIRP	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg04317338	chr11:64019027	PLCB3	0.43	5.12	0.31	6.2e-7	Platelet count;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.22	-0.32	3.78e-7	Lung cancer;
KIRP	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg26138937	chr11:71823887	C11orf51	-1.11	-7.13	-0.41	1.1e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs7173743	0.935	rs11857877	chr15:79140838	G/C	cg00079375	chr15:79125835	NA	-0.37	-5.18	-0.31	4.52e-7	Coronary artery disease;
KIRP	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06481639	chr22:41940642	POLR3H	0.65	6.72	0.39	1.29e-10	Vitiligo;
KIRP	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.39	-0.33	1.63e-7	Homoarginine levels;
KIRP	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg07701084	chr6:150067640	NUP43	0.61	8.04	0.46	3.87e-14	Lung cancer;
KIRP	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	1.12	8.33	0.47	5.66e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg06217071	chr17:408420	NA	0.39	5.1	0.31	6.68e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.53	5.71	0.34	3.26e-8	Vitiligo;
KIRP	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg23682824	chr7:23144976	KLHL7	0.54	6.5	0.38	4.48e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6125597	0.967	rs6063378	chr20:47866411	C/T	cg03212862	chr20:47662828	CSE1L	-0.41	-5.22	-0.32	3.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78487399	0.908	rs10186441	chr2:43840048	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.9	-0.3	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg09137382	chr11:130731461	NA	0.51	6.83	0.4	6.5500000000000006e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16414030	chr3:133502952	NA	0.49	5.58	0.34	6.36e-8	Iron status biomarkers;
KIRP	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.47	-5.37	-0.32	1.85e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs78487399	0.908	rs6712944	chr2:43834118	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.06	-0.31	8.09e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg17133734	chr15:86042851	AKAP13	-0.44	-5.4	-0.33	1.57e-7	Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.71	-0.78	1.55e-52	Height;
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.06	0.36	5.14e-9	Lung cancer;
KIRP	trans	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg00938859	chr5:1591904	SDHAP3	0.59	7.9	0.45	9.59e-14	Breast cancer;
KIRP	cis	rs1440410	0.798	rs11100783	chr4:144162200	T/A	cg01719995	chr4:144104893	USP38	0.43	5.92	0.35	1.09e-8	Ischemic stroke;
KIRP	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg21573476	chr21:45109991	RRP1B	-0.7	-10.69	-0.56	3.72e-22	Mean corpuscular volume;
KIRP	cis	rs787274	0.557	rs7040954	chr9:115666959	C/T	cg13803584	chr9:115635662	SNX30	-0.64	-5.61	-0.34	5.54e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8179	1.000	rs4272	chr7:92236829	C/T	cg15732164	chr7:92237376	CDK6	0.56	6.87	0.4	5.38e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.59	-9.15	-0.5	2.24e-17	Longevity;
KIRP	cis	rs7635838	0.859	rs9875414	chr3:11453559	A/G	cg00170343	chr3:11313890	ATG7	0.47	5.94	0.35	9.73e-9	HDL cholesterol;
KIRP	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs2742234	0.955	rs2503849	chr10:43672776	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.63	-7.45	-0.43	1.55e-12	Hirschsprung disease;
KIRP	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.01	0.3	1.04e-6	Menopause (age at onset);
KIRP	cis	rs1318772	1.000	rs35568473	chr5:112734881	T/A	cg12552261	chr5:112820674	MCC	0.78	4.97	0.3	1.26e-6	F-cell distribution;
KIRP	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-7.03	-0.41	2.09e-11	Daytime sleep phenotypes;
KIRP	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg16325326	chr1:53192061	ZYG11B	0.81	11.47	0.59	1.12e-24	Monocyte count;
KIRP	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.63	-7.11	-0.41	1.27e-11	Coronary artery disease;
KIRP	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg04132472	chr17:19861366	AKAP10	-0.41	-5.33	-0.32	2.19e-7	Schizophrenia;
KIRP	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	5.42	0.33	1.41e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs2213920	0.679	rs10759780	chr9:118196088	A/C	cg13918206	chr9:118159781	DEC1	1.01	10.46	0.55	2e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg16141378	chr3:129829833	LOC729375	-0.52	-7.16	-0.42	9.21e-12	Neuroticism;
KIRP	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg08700190	chr5:6636046	SRD5A1	-0.48	-5.94	-0.35	9.51e-9	Response to amphetamines;
KIRP	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13409248	chr3:40428643	ENTPD3	0.4	5.16	0.31	5.11e-7	Renal cell carcinoma;
KIRP	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.85	0.4	5.87e-11	Colorectal cancer;
KIRP	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg15358701	chr1:161410459	NA	-0.63	-5.87	-0.35	1.43e-8	Rheumatoid arthritis;
KIRP	cis	rs9400467	0.537	rs12212282	chr6:111524838	T/C	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.85	-13.31	-0.65	8.17e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs12496230	0.909	rs13075691	chr3:66857626	T/A	cg04995300	chr3:66848608	NA	0.58	7.92	0.45	7.95e-14	Type 2 diabetes;
KIRP	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg21573476	chr21:45109991	RRP1B	-0.62	-8.78	-0.49	2.84e-16	Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07570687	chr10:102243282	WNT8B	0.49	6.07	0.36	4.7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs56161922	0.915	rs12562739	chr1:207856658	T/A	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg25019722	chr6:37503610	NA	-0.91	-12.87	-0.63	2.44e-29	Cognitive performance;
KIRP	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.72	-9.95	-0.54	7.81e-20	Plateletcrit;Platelet count;
KIRP	trans	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg16141378	chr3:129829833	LOC729375	0.57	7.83	0.45	1.47e-13	Mood instability;
KIRP	cis	rs60311166	1.000	rs6780005	chr3:52636615	C/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.91	5.6	0.34	5.58e-8	CTACK levels;
KIRP	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg21100191	chr22:23484243	RTDR1	1.05	17.7	0.75	9.26e-46	Bone mineral density;
KIRP	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg16386425	chr10:429943	DIP2C	0.46	6.04	0.36	5.67e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.73	10.74	0.56	2.59e-22	Hip circumference;
KIRP	cis	rs12044355	0.929	rs1954175	chr1:231855410	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.4	4.87	0.3	2.04e-6	Alzheimer's disease;
KIRP	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg03171003	chr2:111875934	NA	0.45	6.3	0.37	1.38e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg08989290	chr16:615782	NHLRC4	0.41	5.9	0.35	1.23e-8	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22539390	chr13:95227018	TGDS	0.53	7.59	0.44	6.64e-13	Interleukin-4 levels;
KIRP	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-6.63	-0.39	2.15e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9398803	0.687	rs9491652	chr6:126943620	G/C	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs3820928	0.709	rs2894627	chr2:227910171	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.08	-0.31	7.34e-7	Pulmonary function;
KIRP	cis	rs1318772	0.800	rs13172774	chr5:112925439	G/A	cg12552261	chr5:112820674	MCC	0.87	5.04	0.31	9.12e-7	F-cell distribution;
KIRP	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.17	22.57	0.82	7.36e-62	Primary sclerosing cholangitis;
KIRP	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg07384165	chr1:10488281	NA	-0.44	-5.63	-0.34	5.02e-8	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18932008	chr1:85426586	MCOLN2	0.44	6.04	0.36	5.73e-9	Interleukin-4 levels;
KIRP	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.32	-0.47	5.98e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-7.7	-0.44	3.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs77688320	0.553	rs2540331	chr2:202252873	A/C	cg06431681	chr2:202330990	STRADB	-0.46	-5.41	-0.33	1.51e-7	Breast cancer;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15686105	chr7:23623273	NA	0.54	6.38	0.38	8.79e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9398803	0.723	rs853969	chr6:127061318	C/T	cg19875578	chr6:126661172	C6orf173	0.39	5.08	0.31	7.45e-7	Male-pattern baldness;
KIRP	cis	rs735539	0.521	rs2818990	chr13:21388724	A/G	cg04906043	chr13:21280425	IL17D	0.42	5.07	0.31	7.72e-7	Dental caries;
KIRP	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.47	5.77	0.35	2.4e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17023223	0.537	rs10802075	chr1:119627227	C/T	cg18261050	chr1:119551319	NA	0.56	7.38	0.43	2.38e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07256732	chr16:621771	PIGQ	-0.45	-6.27	-0.37	1.59e-9	Height;
KIRP	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.31	-6.64	-0.39	2.02e-10	Diastolic blood pressure;
KIRP	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-8.02	-0.46	4.25e-14	Myopia (pathological);
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg03289416	chr15:75166202	SCAMP2	0.51	6.89	0.4	4.74e-11	Breast cancer;
KIRP	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	9.16	0.5	2.09e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.46	0.43	1.49e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg22676075	chr6:135203613	NA	0.47	6.76	0.4	9.78e-11	Red blood cell count;
KIRP	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.5	-0.33	9.58e-8	Metabolite levels;
KIRP	cis	rs16976116	0.901	rs28864456	chr15:55503092	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg09184832	chr6:79620586	NA	-0.51	-7.24	-0.42	5.65e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6676180	0.555	rs947430	chr1:119778734	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-6.7	-0.39	1.39e-10	Monobrow;
KIRP	cis	rs2594989	1.000	rs2594989	chr3:11316143	C/T	cg01796438	chr3:11312864	ATG7	-0.77	-8.73	-0.49	3.84e-16	Circulating chemerin levels;
KIRP	cis	rs7523050	0.643	rs36052234	chr1:109402943	C/T	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg09596252	chr17:78655493	RPTOR	0.59	7.83	0.45	1.43e-13	Obesity;
KIRP	cis	rs28489187	0.706	rs233062	chr1:85800385	T/G	cg16011679	chr1:85725395	C1orf52	0.5	6.24	0.37	1.93e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg19729930	chr2:74357872	NA	0.93	13.44	0.65	3.07e-31	Gestational age at birth (maternal effect);
KIRP	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.59	-0.34	6.13e-8	Aortic root size;
KIRP	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg04132472	chr17:19861366	AKAP10	0.42	5.81	0.35	1.97e-8	Schizophrenia;
KIRP	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.78	-0.35	2.3e-8	Schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg18093693	chr15:72668265	HEXA;C15orf34	0.48	6.29	0.37	1.46e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9914544	0.545	rs7212905	chr17:18774271	A/G	cg26378065	chr17:18585709	ZNF286B	0.38	4.85	0.3	2.17e-6	Educational attainment (years of education);
KIRP	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	0.84	7.56	0.43	8.1e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg15507776	chr3:136538369	TMEM22	0.53	7.37	0.43	2.62e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.44	6.16	0.37	2.87e-9	Coronary artery disease;
KIRP	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs7851660	0.874	rs13299924	chr9:100627562	C/T	cg13688889	chr9:100608707	NA	-0.67	-8.83	-0.49	1.97e-16	Strep throat;
KIRP	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg06671706	chr8:8559999	CLDN23	0.47	5.44	0.33	1.29e-7	Obesity-related traits;
KIRP	cis	rs12973672	1.000	rs12975284	chr19:35770962	G/C	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.7	9.04	0.5	4.91e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	-0.44	-6.2	-0.37	2.31e-9	Interleukin-4 levels;
KIRP	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg24315340	chr6:146058215	EPM2A	-0.39	-4.92	-0.3	1.6e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg27462398	chr1:86174642	ZNHIT6	-0.58	-8.39	-0.47	3.72e-15	Urate levels in overweight individuals;
KIRP	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg23032965	chr3:12705835	RAF1	0.74	8.02	0.46	4.33e-14	Cholesterol, total;
KIRP	cis	rs580438	0.529	rs7628051	chr3:13421150	C/T	cg10657019	chr3:13328039	NA	-0.53	-6.84	-0.4	6.14e-11	Myringotomy;
KIRP	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.63	-6.59	-0.39	2.61e-10	Axial length;
KIRP	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6442310	0.534	rs709150	chr3:12451337	C/G	cg02700894	chr3:12045449	SYN2	-0.4	-5.57	-0.33	6.74e-8	Hematocrit;
KIRP	trans	rs11023787	1.000	rs12293688	chr11:15928404	A/T	cg19973338	chr17:76141249	C17orf99	0.49	6.26	0.37	1.73e-9	Bone mineral density (wrist);
KIRP	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg26531700	chr6:26746687	NA	0.43	6.0	0.36	6.88e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg10503236	chr1:231470652	EXOC8	-0.48	-6.64	-0.39	2.01e-10	Hemoglobin concentration;
KIRP	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs732716	0.785	rs34080966	chr19:4417845	C/T	cg19820705	chr19:4455316	UBXN6	-0.65	-8.12	-0.46	2.24e-14	Mean corpuscular volume;
KIRP	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05220968	chr6:146057943	EPM2A	0.41	5.26	0.32	3.14e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.55	-7.6	-0.44	6.16e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.54	-5.38	-0.32	1.71e-7	Alzheimer's disease;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.79	6.91	0.4	4.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg00898013	chr13:113819073	PROZ	-0.55	-5.32	-0.32	2.37e-7	Platelet distribution width;
KIRP	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg05340658	chr4:99064831	C4orf37	0.64	7.01	0.41	2.22e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.89e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg00507259	chr4:95128692	SMARCAD1	0.41	5.24	0.32	3.37e-7	QT interval;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg13453750	chr1:205783389	SLC41A1	-0.46	-7.04	-0.41	1.93e-11	Menarche (age at onset);
KIRP	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.81	7.74	0.44	2.64e-13	Methadone dose in opioid dependence;
KIRP	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg05802129	chr4:122689817	NA	-0.58	-7.32	-0.42	3.42e-12	Type 2 diabetes;
KIRP	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.68	-0.34	3.76e-8	Testicular germ cell tumor;
KIRP	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs2574704	0.886	rs13078952	chr3:11630963	T/A	cg07643000	chr3:11666825	VGLL4	0.35	4.92	0.3	1.57e-6	Body mass index;
KIRP	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg19507638	chr5:93509721	C5orf36	-0.55	-5.13	-0.31	5.79e-7	Diabetic retinopathy;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg25937148	chr3:43147320	C3orf39	-0.46	-6.31	-0.37	1.27e-9	Morning vs. evening chronotype;
KIRP	cis	rs933360	0.585	rs6951356	chr7:50829767	C/G	cg14240098	chr7:50518052	FIGNL1	0.43	4.89	0.3	1.8e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-1.08	-10.52	-0.56	1.34e-21	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6545883	0.524	rs2463101	chr2:61574422	G/C	cg15711740	chr2:61764176	XPO1	0.43	5.2	0.31	4.16e-7	Tuberculosis;
KIRP	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.63	10.25	0.55	9.13e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6991838	0.612	rs12335276	chr8:66531903	A/G	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	0.638	rs12634670	chr3:41875299	G/C	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	5.81	0.35	1.9e-8	Birth weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13132716	chr1:249132749	ZNF672	0.58	7.25	0.42	5.34e-12	Parkinson's disease;
KIRP	cis	rs9826463	0.757	rs73240323	chr3:142294803	T/A	cg20824294	chr3:142316082	PLS1	0.41	6.47	0.38	5.22e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06699275	chr11:68518961	MTL5	0.46	6.59	0.39	2.64e-10	Parkinson's disease;
KIRP	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.68	-8.03	-0.46	4.08e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg11632617	chr15:75315747	PPCDC	-0.57	-4.89	-0.3	1.78e-6	Lung cancer;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs4654899	0.865	rs61779120	chr1:21481230	T/C	cg05370193	chr1:21551575	ECE1	0.46	5.77	0.35	2.43e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11987759	chr7:65425863	GUSB	-0.47	-5.62	-0.34	5.13e-8	Aortic root size;
KIRP	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00889227	chr1:205173544	DSTYK	-0.39	-5.42	-0.33	1.44e-7	Red blood cell count;
KIRP	cis	rs4711350	0.765	rs756138	chr6:33755711	G/C	cg25922239	chr6:33757077	LEMD2	0.58	6.17	0.37	2.87e-9	Schizophrenia;
KIRP	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-35.4	-0.91	1.61e-98	Myeloid white cell count;
KIRP	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg06026331	chr20:60912101	LAMA5	0.54	5.76	0.34	2.57e-8	Colorectal cancer;
KIRP	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg04727924	chr7:799746	HEATR2	0.65	5.95	0.35	9.02e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg23517279	chr6:96025343	MANEA	0.52	5.21	0.32	3.98e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-12.47	-0.62	5.69e-28	Height;
KIRP	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg05555928	chr11:63887634	MACROD1	0.53	4.94	0.3	1.46e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.44	5.86	0.35	1.48e-8	Homoarginine levels;
KIRP	cis	rs73200209	0.744	rs7136498	chr12:116483993	T/G	cg01776926	chr12:116560359	MED13L	-0.55	-6.09	-0.36	4.27e-9	Total body bone mineral density;
KIRP	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6662572	0.737	rs1355641	chr1:46599143	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.78	0.35	2.21e-8	Blood protein levels;
KIRP	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06481639	chr22:41940642	POLR3H	0.66	6.32	0.37	1.22e-9	Vitiligo;
KIRP	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg05998816	chr21:47859926	PCNT	0.54	6.02	0.36	6.45e-9	Lymphocyte counts;
KIRP	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg15485101	chr11:133734466	NA	0.51	6.79	0.4	8.18e-11	Childhood ear infection;
KIRP	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.88	-0.45	1.08e-13	Height;
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg09597638	chr17:3907349	NA	-0.74	-13.81	-0.66	1.68e-32	Type 2 diabetes;
KIRP	cis	rs4395908	0.559	rs13259195	chr8:4019695	T/G	cg01921437	chr8:3974145	CSMD1	-0.46	-5.73	-0.34	2.86e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	20.06	0.79	1.12e-53	Chronic sinus infection;
KIRP	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs12230513	0.732	rs60643523	chr12:55842928	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	1.11	20.59	0.8	1.9e-55	Bone mineral density;
KIRP	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs595982	0.661	rs606400	chr19:49371498	T/C	cg21252483	chr19:49399788	TULP2	-0.31	-5.8	-0.35	2.06e-8	Red cell distribution width;
KIRP	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.58	-6.17	-0.37	2.81e-9	Obesity-related traits;
KIRP	cis	rs11638352	1.000	rs2930528	chr15:44270531	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	5.59	0.34	6.03e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26526719	chr5:1949144	NA	0.44	5.04	0.31	8.91e-7	Gut microbiome composition (winter);
KIRP	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg03887218	chr1:16534349	ARHGEF19	0.58	7.8	0.45	1.79e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.56	-4.94	-0.3	1.42e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs662064	0.748	rs2506889	chr1:10596022	C/T	cg19773385	chr1:10388646	KIF1B	-0.4	-5.19	-0.31	4.46e-7	Asthma;
KIRP	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.7	-11.68	-0.6	2.3e-25	Lung function (FVC);
KIRP	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg01721255	chr8:58191610	C8orf71	0.51	5.44	0.33	1.28e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7870753	1.000	rs7870753	chr9:99201585	A/G	cg25260653	chr9:99212216	HABP4	0.53	5.96	0.36	8.49e-9	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08265812	chr1:85132464	SSX2IP	0.46	6.25	0.37	1.8e-9	Interleukin-4 levels;
KIRP	cis	rs1950626	0.532	rs61991120	chr14:101455222	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.53	6.14	0.36	3.37e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.68	7.88	0.45	1.07e-13	Corneal astigmatism;
KIRP	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	cis	rs7621025	0.662	rs3856637	chr3:136391195	C/T	cg15507776	chr3:136538369	TMEM22	0.39	5.02	0.3	1.01e-6	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg06815112	chr8:27182871	PTK2B	0.47	6.17	0.37	2.85e-9	Neuroticism;
KIRP	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.83	11.2	0.58	8.63e-24	Morning vs. evening chronotype;
KIRP	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.35	19.06	0.77	2.43e-50	Corneal structure;
KIRP	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05665937	chr4:1216051	CTBP1	0.55	7.65	0.44	4.62e-13	Obesity-related traits;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.48	-5.99	-0.36	7.32e-9	Life satisfaction;
KIRP	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16318349	chr1:154917307	PBXIP1	-0.33	-5.79	-0.35	2.18e-8	Prostate cancer;
KIRP	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	16.79	0.73	1.09e-42	Homoarginine levels;
KIRP	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.55	7.28	0.42	4.5e-12	Menarche (age at onset);
KIRP	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	4.96	0.3	1.31e-6	Tonsillectomy;
KIRP	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg07274523	chr3:49395745	GPX1	0.51	4.9	0.3	1.74e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18094961	chr10:45155744	NA	-0.57	-6.15	-0.37	3.15e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs72960926	0.590	rs11754945	chr6:74732673	A/C	cg03266952	chr6:74778945	NA	0.84	6.34	0.37	1.09e-9	Metabolite levels (MHPG);
KIRP	cis	rs17221829	0.733	rs10765222	chr11:89372109	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg15181151	chr6:150070149	PCMT1	0.31	5.29	0.32	2.76e-7	Lung cancer;
KIRP	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.64	10.68	0.56	4.01e-22	Coronary artery disease;
KIRP	cis	rs4356932	1.000	rs7688306	chr4:76982046	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg22437258	chr11:111473054	SIK2	0.56	6.57	0.39	2.97e-10	Primary sclerosing cholangitis;
KIRP	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg10755058	chr3:40428713	ENTPD3	0.37	5.3	0.32	2.58e-7	Renal cell carcinoma;
KIRP	cis	rs10861342	0.892	rs12322134	chr12:105646804	G/C	cg23923672	chr12:105501055	KIAA1033	0.69	6.2	0.37	2.32e-9	IgG glycosylation;
KIRP	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg13939156	chr17:80058883	NA	0.47	5.54	0.33	7.83e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg03060546	chr3:49711283	APEH	0.52	6.85	0.4	5.78e-11	Menarche (age at onset);
KIRP	cis	rs212524	0.544	rs9426748	chr1:21558490	C/A	cg21184320	chr1:21044207	KIF17	0.34	5.04	0.31	8.83e-7	Height;
KIRP	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.57	0.52	1.22e-18	Corneal astigmatism;
KIRP	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.64	-12.15	-0.61	6.43e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg19052272	chr2:3704530	ALLC	0.5	5.4	0.33	1.54e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.79	13.37	0.65	5.08e-31	Corneal structure;
KIRP	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09826364	chr7:158789723	NA	-0.39	-5.03	-0.31	9.38e-7	Facial morphology (factor 20);
KIRP	cis	rs7180079	0.620	rs650399	chr15:64802691	C/G	cg15337035	chr15:64978493	NA	-0.47	-5.18	-0.31	4.72e-7	Monocyte count;
KIRP	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.66	-10.21	-0.55	1.28e-20	Airway imaging phenotypes;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg25958857	chr12:53448399	TENC1	0.45	6.03	0.36	5.9e-9	DNA methylation (variation);
KIRP	cis	rs1497828	0.956	rs2815250	chr1:217573979	C/T	cg04411442	chr1:217543379	NA	-0.33	-5.3	-0.32	2.57e-7	Dialysis-related mortality;
KIRP	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.53	0.52	1.59e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7923609	1.000	rs7923609	chr10:65133822	A/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.62	-0.34	5.22e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05896465	chr22:45560692	NUP50	0.51	6.37	0.38	9.07e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.29	-0.37	1.44e-9	Response to antipsychotic treatment;
KIRP	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.41	-0.38	7.19e-10	Uric acid levels;
KIRP	trans	rs225245	0.817	rs225299	chr17:33922742	T/C	cg19694781	chr19:47549865	TMEM160	-0.51	-6.2	-0.37	2.35e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs735539	0.609	rs7332034	chr13:21214943	T/C	cg04906043	chr13:21280425	IL17D	-0.48	-5.54	-0.33	7.69e-8	Dental caries;
KIRP	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg09491104	chr22:46646882	C22orf40	-0.53	-5.32	-0.32	2.35e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12973672	0.855	rs7256866	chr19:35771257	A/G	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs514024	0.637	rs569227	chr9:130496076	A/G	cg13643465	chr9:130375613	STXBP1	0.46	5.95	0.35	8.97e-9	Eating disorders (purging via substances);
KIRP	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.57	-4.9	-0.3	1.77e-6	Schizophrenia;
KIRP	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg03433033	chr1:76189801	ACADM	0.75	10.48	0.56	1.68e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg27532560	chr4:187881888	NA	0.53	8.14	0.46	2.03e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg21827317	chr3:136751795	NA	0.38	5.28	0.32	2.8e-7	Neuroticism;
KIRP	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24110177	chr3:50126178	RBM5	-0.66	-7.52	-0.43	1.01e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02656441	chr13:111367915	ING1	1.0	7.1	0.41	1.37e-11	P wave terminal force;
KIRP	cis	rs737693	0.527	rs72983552	chr11:102764093	T/G	cg19620758	chr11:102826565	MMP13	0.78	6.95	0.41	3.2e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.84	7.93	0.45	7.91e-14	Methadone dose in opioid dependence;
KIRP	cis	rs6888304	0.589	rs13168878	chr5:31054210	C/A	cg10919204	chr5:31193340	CDH6	0.37	4.97	0.3	1.25e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg04289385	chr6:36355825	ETV7	0.45	7.04	0.41	1.93e-11	Platelet distribution width;
KIRP	trans	rs76288851	0.799	rs73203698	chr3:126580210	T/G	cg13821433	chr2:26726535	OTOF	0.58	6.41	0.38	7.31e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-5.23	-0.32	3.71e-7	Longevity;Endometriosis;
KIRP	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-9.71	-0.53	4.6e-19	Coronary artery disease;
KIRP	cis	rs6969780	1.000	rs73071550	chr7:27149099	T/C	cg26364809	chr7:27145159	NA	-0.64	-5.83	-0.35	1.75e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.69	-0.44	3.59e-13	Resting heart rate;
KIRP	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.51	-8.56	-0.48	1.24e-15	Height;
KIRP	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	7.95	0.45	6.7e-14	Ileal carcinoids;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01642168	chr19:55791471	HSPBP1	0.45	6.45	0.38	5.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06745235	chr1:180471494	ACBD6	0.69	6.46	0.38	5.42e-10	Lung function (FEV1);
KIRP	cis	rs3741151	0.773	rs7934218	chr11:73206729	C/T	cg17517138	chr11:73019481	ARHGEF17	0.64	5.66	0.34	4.26e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg09264619	chr17:80180166	NA	-0.41	-5.99	-0.36	7.52e-9	Life satisfaction;
KIRP	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg15436174	chr10:43711423	RASGEF1A	0.78	8.37	0.47	4.24e-15	Hirschsprung disease;
KIRP	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.56	-7.84	-0.45	1.37e-13	Coronary artery disease;
KIRP	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg16497661	chr14:103986332	CKB	0.52	7.08	0.41	1.47e-11	Body mass index;
KIRP	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.32	0.59	3.52e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	0.95	10.16	0.54	1.76e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg20534287	chr10:135191450	PAOX	0.48	5.89	0.35	1.28e-8	Lifespan;
KIRP	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.3	0.47	6.76e-15	IgG glycosylation;
KIRP	cis	rs2271404	0.506	rs12989775	chr2:111998827	C/G	cg23466623	chr2:111982296	NA	-0.68	-9.29	-0.51	8.29e-18	Atopic dermatitis;
KIRP	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.53	-0.38	3.69e-10	Retinal vascular caliber;
KIRP	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg23594656	chr7:65796392	TPST1	0.35	5.19	0.31	4.36e-7	Aortic root size;
KIRP	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg12962167	chr3:53033115	SFMBT1	0.76	5.68	0.34	3.71e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18252515	chr7:66147081	NA	-0.46	-5.5	-0.33	9.6e-8	Aortic root size;
KIRP	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs7615316	0.934	rs7651071	chr3:142243850	T/A	cg20824294	chr3:142316082	PLS1	0.22	4.86	0.3	2.06e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs829883	0.624	rs829881	chr12:98881228	T/G	cg25150519	chr12:98850993	NA	0.57	7.74	0.44	2.64e-13	Colorectal adenoma (advanced);
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg17441377	chr17:3906640	NA	0.53	7.89	0.45	1.02e-13	Type 2 diabetes;
KIRP	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg18944383	chr4:111397179	ENPEP	0.52	9.12	0.5	2.8e-17	Height;
KIRP	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.78	-10.76	-0.57	2.15e-22	Neuroticism;
KIRP	cis	rs6088813	1.000	rs2425065	chr20:33926268	A/T	cg14752227	chr20:34000481	UQCC	0.51	6.87	0.4	5.22e-11	Height;
KIRP	cis	rs7614311	0.636	rs77639204	chr3:64005452	C/T	cg22134162	chr3:63841271	THOC7	-0.41	-5.33	-0.32	2.24e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs10189230	0.935	rs3755029	chr2:222345820	T/C	cg14652038	chr2:222343519	EPHA4	0.52	7.43	0.43	1.75e-12	Urate levels in lean individuals;
KIRP	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.44	5.55	0.33	7.36e-8	Monobrow;
KIRP	cis	rs7010876	0.568	rs13264048	chr8:89227918	C/T	cg08624180	chr8:89339080	MMP16	0.53	5.16	0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg25288420	chr1:78511713	GIPC2	0.49	6.44	0.38	6.18e-10	Obesity-related traits;
KIRP	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.62	-7.0	-0.41	2.41e-11	Menarche (age at onset);
KIRP	trans	rs12517041	1.000	rs1428620	chr5:23283138	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08280861	chr8:58055591	NA	0.79	6.36	0.38	9.54e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Morning vs. evening chronotype;
KIRP	cis	rs78487399	0.803	rs75275342	chr2:43762885	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.93	-0.3	1.48e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08359192	chr2:61194733	PUS10	0.39	6.43	0.38	6.62e-10	C-reactive protein;
KIRP	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg08999081	chr20:33150536	PIGU	0.45	5.73	0.34	2.92e-8	Height;
KIRP	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.57	-0.33	6.55e-8	Chronic sinus infection;
KIRP	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg04691961	chr3:161091175	C3orf57	-0.5	-7.61	-0.44	5.98e-13	Morning vs. evening chronotype;
KIRP	cis	rs4523957	0.651	rs4790315	chr17:2070529	T/C	cg16513277	chr17:2031491	SMG6	-0.8	-11.63	-0.6	3.45e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg08662619	chr6:150070041	PCMT1	0.33	4.86	0.3	2.12e-6	Lung cancer;
KIRP	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-6.69	-0.39	1.48e-10	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg18190219	chr22:46762943	CELSR1	-0.73	-7.17	-0.42	8.9e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.67	7.41	0.43	1.97e-12	Tuberculosis;
KIRP	cis	rs8070740	0.898	rs4605225	chr17:5324136	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.24	0.42	5.68e-12	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09427374	chr2:86095320	ST3GAL5	0.51	6.35	0.38	1.06e-9	Interleukin-4 levels;
KIRP	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.59	6.95	0.41	3.29e-11	Corneal astigmatism;
KIRP	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.7	8.94	0.5	9.64e-17	Blood metabolite levels;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10307595	chr11:70330927	SHANK2	0.56	6.05	0.36	5.35e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.12	-0.36	3.62e-9	Personality dimensions;
KIRP	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	1.05	10.15	0.54	1.87e-20	Thyroid stimulating hormone;
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg04369109	chr6:150039330	LATS1	-0.49	-6.33	-0.37	1.17e-9	Lung cancer;
KIRP	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.86	-0.3	2.05e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs9381040	0.869	rs9357347	chr6:41150591	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.65	-6.63	-0.39	2.07e-10	Alzheimer's disease (late onset);
KIRP	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.76	0.34	2.51e-8	Breast cancer;
KIRP	cis	rs4073416	0.518	rs11158595	chr14:65906369	A/G	cg03016385	chr14:66212404	NA	-0.57	-6.91	-0.4	4.17e-11	N-glycan levels;
KIRP	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.06	-0.36	5.14e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs34779708	0.832	rs12764283	chr10:35530460	G/A	cg03585969	chr10:35415529	CREM	0.86	9.89	0.53	1.27e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6429082	0.511	rs12748957	chr1:235426133	T/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.06	0.31	8.3e-7	Adiposity;
KIRP	cis	rs7395581	0.918	rs4752825	chr11:47352409	G/A	cg26139080	chr11:47293733	MADD	-0.42	-5.12	-0.31	6.13e-7	HDL cholesterol;
KIRP	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.66	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg04398451	chr17:18023971	MYO15A	0.73	10.26	0.55	8.43e-21	Total body bone mineral density;
KIRP	cis	rs35740288	0.770	rs11634177	chr15:86148390	A/G	cg17133734	chr15:86042851	AKAP13	0.53	5.75	0.34	2.57e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg23920097	chr1:209922102	NA	-0.48	-5.63	-0.34	4.96e-8	Red blood cell count;
KIRP	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg11569703	chr11:65557185	OVOL1	0.32	4.89	0.3	1.8e-6	Eosinophil percentage of white cells;
KIRP	trans	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.5	-0.43	1.14e-12	Endometrial cancer;
KIRP	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs7236492	0.872	rs78226032	chr18:77230822	G/A	cg15644404	chr18:77186268	NFATC1	-0.91	-7.03	-0.41	1.98e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2625529	0.529	rs7183055	chr15:72377048	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.26	0.37	1.73e-9	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24558718	chr10:853215	NA	0.5	6.32	0.37	1.22e-9	Interleukin-4 levels;
KIRP	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs12986413	0.789	rs12980348	chr19:2181607	T/G	cg09261902	chr19:2140048	AP3D1	0.44	5.34	0.32	2.1e-7	Height;
KIRP	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-9.22	-0.51	1.42e-17	Colorectal cancer;
KIRP	cis	rs1971762	1.000	rs10876480	chr12:54066271	C/G	cg09709951	chr12:54017699	ATF7	0.45	5.65	0.34	4.31e-8	Height;
KIRP	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg16797656	chr11:68205561	LRP5	0.62	8.46	0.47	2.37e-15	Total body bone mineral density (age 45-60);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18050194	chr3:42623358	SEC22C	0.6	7.7	0.44	3.4e-13	Parkinson's disease;
KIRP	cis	rs7870753	0.786	rs10820629	chr9:99207032	T/A	cg25260653	chr9:99212216	HABP4	0.53	5.08	0.31	7.56e-7	Height;
KIRP	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17554472	chr22:41940697	POLR3H	-0.65	-6.45	-0.38	5.91e-10	Vitiligo;
KIRP	cis	rs17065868	1.000	rs61948036	chr13:45210487	G/T	cg10246903	chr13:45222710	NA	0.72	6.36	0.38	9.83e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4332428	0.649	rs80261559	chr10:4982212	C/T	cg19648686	chr10:5044992	AKR1C2	-0.93	-8.02	-0.46	4.4e-14	Height;
KIRP	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg01879757	chr17:41196368	BRCA1	-0.54	-7.31	-0.42	3.78e-12	Menopause (age at onset);
KIRP	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.72	6.69	0.39	1.47e-10	Schizophrenia;
KIRP	cis	rs698833	0.892	rs698797	chr2:44689905	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.75	0.4	1.03e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs12580194	1.000	rs12308286	chr12:55707326	C/T	cg11794356	chr12:55725991	OR6C3	-0.46	-6.34	-0.37	1.08e-9	Cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01924320	chr4:147364608	SLC10A7	-0.4	-6.13	-0.36	3.56e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg00129232	chr17:37814104	STARD3	0.68	7.48	0.43	1.32e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs9815354	0.812	rs17215183	chr3:41812334	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs17428704	0.571	rs16903428	chr5:14373437	C/T	cg26595256	chr5:14380529	TRIO	-0.85	-6.45	-0.38	5.78e-10	Electroencephalogram traits;
KIRP	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.59	-7.15	-0.41	9.72e-12	Mosquito bite size;
KIRP	cis	rs73086581	1.000	rs73086510	chr20:3922131	T/C	cg02187196	chr20:3869020	PANK2	0.5	4.9	0.3	1.7e-6	Response to antidepressants in depression;
KIRP	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.2	16.09	0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10338232	chr14:42683574	NA	0.43	6.9	0.4	4.38e-11	C-reactive protein;
KIRP	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.13	-0.31	5.83e-7	Inflammatory skin disease;
KIRP	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.22	0.37	2.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7224685	0.569	rs68060817	chr17:3995188	T/C	cg05562828	chr17:3906858	NA	0.52	5.37	0.32	1.83e-7	Type 2 diabetes;
KIRP	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.49	6.58	0.39	2.83e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.25	-0.47	9.49e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg02461776	chr11:598696	PHRF1	0.67	6.91	0.4	4.22e-11	Systemic lupus erythematosus;
KIRP	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs963731	0.649	rs378698	chr2:39316301	T/C	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.83	-0.63	3.46e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs6901004	0.688	rs34151782	chr6:111574537	T/A	cg15721981	chr6:111408429	SLC16A10	0.49	6.24	0.37	1.93e-9	Blood metabolite levels;
KIRP	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	1.16	16.44	0.72	1.8e-41	Breast cancer;
KIRP	cis	rs950881	0.932	rs3771180	chr2:102953617	G/T	cg01254707	chr2:102953421	IL1RL1	-0.5	-5.05	-0.31	8.6e-7	Allergy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00846340	chr4:2470860	RNF4	0.5	6.2	0.37	2.31e-9	Parkinson's disease;
KIRP	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02725872	chr8:58115012	NA	-0.72	-7.11	-0.41	1.25e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.54	7.58	0.44	6.95e-13	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14769792	chr4:89629747	FAM13AOS	-0.43	-6.3	-0.37	1.4e-9	Inflammatory biomarkers;
KIRP	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg11569703	chr11:65557185	OVOL1	-0.5	-8.99	-0.5	6.69e-17	Acne (severe);
KIRP	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-9.63	-0.52	7.85e-19	Total body bone mineral density;
KIRP	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.32	0.32	2.3e-7	Tonsillectomy;
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg23698023	chr8:27181813	PTK2B	0.34	4.99	0.3	1.15e-6	Neuroticism;
KIRP	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs4363385	0.510	rs11590369	chr1:152903603	G/C	cg25856811	chr1:152973957	SPRR3	-0.37	-5.12	-0.31	6.06e-7	Inflammatory skin disease;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.38e-8	Life satisfaction;
KIRP	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.51	7.18	0.42	8.16e-12	Mean corpuscular volume;
KIRP	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11987759	chr7:65425863	GUSB	0.49	6.23	0.37	1.96e-9	Aortic root size;
KIRP	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.45	6.08	0.36	4.5e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.41	-0.51	3.57e-18	Gut microbiome composition (summer);
KIRP	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg24315340	chr6:146058215	EPM2A	0.4	5.1	0.31	6.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10129255	0.556	rs8010005	chr14:107186226	A/G	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.31	5.07e-7	Kawasaki disease;
KIRP	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.42	-6.18	-0.37	2.64e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs6708331	0.517	rs12617812	chr2:70359471	A/G	cg01613454	chr2:70366299	NA	0.4	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg13397359	chr6:42928475	GNMT	0.43	4.89	0.3	1.83e-6	Blood protein levels;
KIRP	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.34	0.47	5.51e-15	Asthma (sex interaction);
KIRP	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.27	0.37	1.58e-9	Electroencephalogram traits;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00522316	chr19:6425042	KHSRP	-0.51	-6.06	-0.36	5.08e-9	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18377446	chr1:100335651	AGL	-0.46	-7.03	-0.41	2.03e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg14092571	chr14:90743983	NA	-0.38	-4.95	-0.3	1.39e-6	Mortality in heart failure;
KIRP	trans	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg18187862	chr3:45730750	SACM1L	-0.58	-6.35	-0.38	1.04e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg14458575	chr2:238380390	NA	0.55	5.9	0.35	1.2e-8	Prostate cancer;
KIRP	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg07856975	chr6:36356162	ETV7	0.39	5.87	0.35	1.43e-8	Platelet distribution width;
KIRP	cis	rs72792276	0.908	rs10478797	chr5:127442066	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	7.43	0.43	1.73e-12	Red cell distribution width;
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg11814155	chr7:99998594	ZCWPW1	0.56	5.57	0.33	6.78e-8	Platelet count;
KIRP	cis	rs494562	0.892	rs547052	chr6:86118840	G/A	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.57	-5.76	-0.34	2.52e-8	Subjective well-being;
KIRP	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.88	-10.36	-0.55	4.32e-21	Orofacial clefts;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg21938523	chr19:16222446	RAB8A	-0.56	-6.05	-0.36	5.41e-9	Menopause (age at onset);
KIRP	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.74	10.15	0.54	1.85e-20	Multiple sclerosis;
KIRP	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg09137382	chr11:130731461	NA	0.58	8.53	0.48	1.5e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06360820	chr2:242988706	NA	-0.83	-8.38	-0.47	4.14e-15	Obesity-related traits;
KIRP	cis	rs3026101	0.624	rs60116755	chr17:5303215	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.87	0.35	1.38e-8	Body mass index;
KIRP	cis	rs10073892	0.633	rs62372163	chr5:101618518	T/C	cg19774478	chr5:101632501	SLCO4C1	0.56	6.05	0.36	5.38e-9	Cognitive decline (age-related);
KIRP	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	0.99	15.3	0.7	1.38e-37	Primary sclerosing cholangitis;
KIRP	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.91	-9.16	-0.5	2.11e-17	Multiple sclerosis;
KIRP	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26207909	chr14:103986467	CKB	-0.81	-12.52	-0.62	3.79e-28	Body mass index;
KIRP	cis	rs7220401	0.542	rs55644350	chr17:27913368	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	5.52	0.33	8.59e-8	Coronary artery disease;
KIRP	cis	rs3762637	0.941	rs79493664	chr3:122109546	T/A	cg24169773	chr3:122142474	KPNA1	-0.55	-5.57	-0.33	6.51e-8	LDL cholesterol levels;
KIRP	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg23625390	chr15:77176239	SCAPER	0.48	6.23	0.37	2.03e-9	Blood metabolite levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16101101	chr1:153643504	ILF2	0.48	6.38	0.38	8.65e-10	Survival in pancreatic cancer;
KIRP	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.29	0.37	1.42e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg10760299	chr15:45669010	GATM	-0.34	-5.14	-0.31	5.69e-7	Homoarginine levels;
KIRP	cis	rs2802372	0.542	rs1272633	chr10:81065508	C/T	cg18688392	chr10:81059414	ZMIZ1	-0.65	-8.0	-0.45	4.98e-14	Granulocyte count;
KIRP	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs7615316	1.000	rs7615316	chr3:142355926	G/A	cg20824294	chr3:142316082	PLS1	0.24	5.29	0.32	2.71e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs12449568	0.844	rs759108	chr17:54409179	A/G	cg04456437	chr3:119217424	C3orf1	0.48	6.12	0.36	3.66e-9	Height;
KIRP	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg07596299	chr11:71824057	C11orf51	0.9	5.93	0.35	1.03e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.13	0.31	5.82e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.87	-0.53	1.39e-19	Response to antipsychotic treatment;
KIRP	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.9	14.26	0.67	4.82e-34	IgG glycosylation;
KIRP	cis	rs72925845	0.519	rs1623869	chr17:76426074	T/G	cg03830375	chr17:76426088	DNAH17	0.5	5.16	0.31	5.07e-7	Triglycerides;
KIRP	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg08890418	chr1:21044141	KIF17	0.65	9.94	0.54	8.62e-20	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	cg12689670	chr1:183009347	LAMC1	0.46	6.6	0.39	2.45e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-7.98	-0.45	5.71e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-10.56	-0.56	9.41e-22	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.61	6.91	0.4	4.22e-11	Aortic root size;
KIRP	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.9e-8	Glomerular filtration rate;
KIRP	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.72	8.08	0.46	2.96e-14	Corneal astigmatism;
KIRP	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg22356347	chr1:167427500	CD247	0.5	6.83	0.4	6.43e-11	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg27147174	chr7:100797783	AP1S1	0.56	7.17	0.42	8.62e-12	Life satisfaction;
KIRP	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg18478394	chr8:109455254	TTC35	0.6	7.47	0.43	1.4e-12	Dupuytren's disease;
KIRP	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg25019722	chr6:37503610	NA	-0.72	-8.34	-0.47	5.51e-15	Cognitive performance;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22036894	chr1:198850158	NA	-0.42	-6.4	-0.38	7.62e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.62	-0.34	5.11e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg23594656	chr7:65796392	TPST1	0.44	6.0	0.36	6.87e-9	Aortic root size;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18827097	chr2:3522506	ADI1	0.71	6.72	0.39	1.28e-10	Lung function (FEV1);
KIRP	cis	rs830124	0.673	rs529736	chr12:122384457	A/C	cg22618164	chr12:122356400	WDR66	0.48	4.89	0.3	1.83e-6	Urinary metabolites;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19072251	chr7:148787821	ZNF786	0.51	6.56	0.39	3.12e-10	Parkinson's disease;
KIRP	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	6.91	0.4	4.15e-11	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.44	-5.11	-0.31	6.41e-7	Aortic root size;
KIRP	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.94	11.33	0.59	3.1e-24	Exhaled nitric oxide levels;
KIRP	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.06	0.58	2.33e-23	Morning vs. evening chronotype;
KIRP	cis	rs12765878	0.675	rs3752946	chr10:105670849	A/T	cg11005552	chr10:105648138	OBFC1	0.35	4.88	0.3	1.95e-6	Coronary artery disease;
KIRP	cis	rs9381107	0.591	rs71561170	chr6:9512043	A/G	cg14735645	chr6:9486422	NA	-0.58	-5.65	-0.34	4.42e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg05973401	chr12:123451056	ABCB9	0.56	6.49	0.38	4.58e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.77	-13.51	-0.65	1.69e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg19875578	chr6:126661172	C6orf173	0.46	6.09	0.36	4.25e-9	Male-pattern baldness;
KIRP	cis	rs5753037	0.835	rs737908	chr22:30388302	G/A	cg27665648	chr22:30112403	NA	0.37	5.27	0.32	2.97e-7	Type 1 diabetes;
KIRP	cis	rs2224391	0.628	rs2773307	chr6:5244290	G/A	cg13962347	chr6:5174647	LYRM4	-0.72	-10.02	-0.54	4.91e-20	Height;
KIRP	cis	rs7771547	0.573	rs621796	chr6:36472259	A/T	cg07856975	chr6:36356162	ETV7	0.36	5.19	0.31	4.36e-7	Platelet distribution width;
KIRP	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.82	10.83	0.57	1.37e-22	N-glycan levels;
KIRP	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg09408571	chr1:101003634	GPR88	0.26	5.77	0.35	2.32e-8	Monocyte count;
KIRP	cis	rs7523273	0.626	rs2466572	chr1:207934487	A/C	cg22525895	chr1:207977042	MIR29B2	0.57	5.67	0.34	4.09e-8	Schizophrenia;
KIRP	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Body mass index;
KIRP	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg03235661	chr20:60525775	NA	-0.32	-5.27	-0.32	3e-7	Body mass index;
KIRP	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22117172	chr7:91764530	CYP51A1	0.48	6.86	0.4	5.66e-11	Breast cancer;
KIRP	cis	rs7520050	1.000	rs785511	chr1:46534498	T/C	cg03146154	chr1:46216737	IPP	-0.41	-5.39	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg26874164	chr19:58962979	ZNF324B	0.46	5.36	0.32	1.89e-7	Uric acid clearance;
KIRP	cis	rs4006360	0.628	rs34859541	chr17:39226322	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.47	-7.29	-0.42	4.13e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg00147788	chr6:125855365	NA	-0.32	-5.07	-0.31	7.97e-7	Brugada syndrome;
KIRP	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.65	0.48	6.88e-16	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg26384229	chr12:38710491	ALG10B	0.62	7.89	0.45	9.65e-14	Resting heart rate;
KIRP	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.69	-9.15	-0.5	2.18e-17	Motion sickness;
KIRP	cis	rs10924970	0.967	rs12741262	chr1:235406849	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.01	0.3	1.06e-6	Asthma;
KIRP	cis	rs7870753	0.730	rs7020954	chr9:99144913	G/A	cg25260653	chr9:99212216	HABP4	0.48	5.04	0.31	8.98e-7	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14576681	chr2:42588304	COX7A2L	0.46	6.15	0.37	3.07e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.77	0.35	2.4e-8	Menopause (age at onset);
KIRP	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-5.87	-0.35	1.4e-8	IgG glycosylation;
KIRP	trans	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.5	-0.38	4.32e-10	Neuroticism;
KIRP	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.5	7.91	0.45	8.86e-14	Height;
KIRP	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.9	13.28	0.65	1.01e-30	Triglycerides;
KIRP	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.71	-8.47	-0.48	2.26e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg13615516	chr5:77269221	NA	0.51	7.87	0.45	1.1e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg15605315	chr1:45957053	TESK2	0.41	5.11	0.31	6.38e-7	High light scatter reticulocyte count;
KIRP	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.64	-9.67	-0.52	6.06e-19	Educational attainment;
KIRP	cis	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg07460842	chr6:66804631	NA	-0.48	-5.83	-0.35	1.76e-8	Blood trace element (Cu levels);
KIRP	cis	rs55962025	0.883	rs3121419	chr4:3232257	C/T	cg06533319	chr4:3265114	C4orf44	0.49	5.2	0.31	4.28e-7	Parental longevity (mother's age at death);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg12882476	chr5:114632168	CCDC112	0.56	7.12	0.41	1.2e-11	DNA methylation (variation);
KIRP	cis	rs5753037	0.702	rs9614055	chr22:30187702	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.73	-0.34	2.96e-8	Type 1 diabetes;
KIRP	cis	rs597583	0.715	rs7936795	chr11:117391736	A/G	cg27161313	chr11:117392002	DSCAML1	-0.71	-7.16	-0.42	9.46e-12	Putamen volume;
KIRP	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.67	-0.44	4.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs28830936	0.966	rs8025714	chr15:42120157	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.64	-0.39	1.96e-10	Diastolic blood pressure;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg09695851	chr17:3907499	NA	0.81	14.83	0.69	5.4e-36	Type 2 diabetes;
KIRP	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.99	18.38	0.76	4.59e-48	Parkinson's disease;
KIRP	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-6.77	-0.4	9.18e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs708547	0.647	rs781666	chr4:57830981	A/G	cg12819144	chr4:165953018	TRIM60	0.4	6.2	0.37	2.4e-9	Response to bleomycin (chromatid breaks);
KIRP	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.61	8.13	0.46	2.13e-14	Aortic root size;
KIRP	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg21231944	chr12:82153410	PPFIA2	-0.41	-5.01	-0.3	1.03e-6	Resting heart rate;
KIRP	cis	rs3829109	0.564	rs12378717	chr9:139286060	G/C	cg14169450	chr9:139327907	INPP5E	0.59	6.84	0.4	6.34e-11	Peak insulin response;Acute insulin response;
KIRP	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	11.13	0.58	1.4e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg02002194	chr4:3960332	NA	0.43	6.15	0.37	3.17e-9	Neuroticism;
KIRP	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.64	8.06	0.46	3.37e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05165339	chr4:1420672	NA	-0.34	-5.12	-0.31	6.32e-7	Longevity;
KIRP	cis	rs9810890	1.000	rs73207986	chr3:128579806	A/G	cg15033153	chr3:128514015	RAB7A	0.69	5.03	0.31	9.52e-7	Dental caries;
KIRP	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.66	9.27	0.51	9.8e-18	Brugada syndrome;
KIRP	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg05998816	chr21:47859926	PCNT	0.54	5.97	0.36	8.08e-9	Lymphocyte counts;
KIRP	cis	rs11955175	1.000	rs78426328	chr5:40673176	G/T	cg17351974	chr5:40835760	RPL37	0.54	4.9	0.3	1.73e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg17372223	chr3:52568218	NT5DC2	0.33	5.08	0.31	7.32e-7	Electroencephalogram traits;
KIRP	cis	rs4595586	0.644	rs10437944	chr12:39308786	A/C	cg26384229	chr12:38710491	ALG10B	0.49	6.37	0.38	9.2e-10	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg06740227	chr12:86229804	RASSF9	0.47	6.05	0.36	5.4e-9	Major depressive disorder;
KIRP	cis	rs10875595	0.836	rs6889723	chr5:140676524	C/T	cg24830062	chr5:140700576	TAF7	-0.61	-5.6	-0.34	5.8e-8	Pulmonary function decline;
KIRP	cis	rs9328573	1.000	rs10468183	chr15:100512047	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.46	-6.43	-0.38	6.68e-10	Urate levels in lean individuals;
KIRP	cis	rs73198271	0.628	rs11783457	chr8:8588842	G/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg14343924	chr8:8086146	FLJ10661	-0.49	-6.05	-0.36	5.41e-9	Schizophrenia;
KIRP	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg11150807	chr10:43354902	NA	0.6	6.73	0.39	1.15e-10	Blood protein levels;
KIRP	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.38	-0.32	1.71e-7	Metabolite levels;
KIRP	trans	rs399593	0.767	rs2814637	chr10:30902048	C/T	cg02831383	chr1:3329820	PRDM16	-0.58	-6.07	-0.36	4.89e-9	Dental caries;
KIRP	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.35	5.12	0.31	6.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg18162783	chr1:1795891	GNB1	-0.38	-6.25	-0.37	1.8e-9	Body mass index;
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg05564831	chr3:52568323	NT5DC2	0.32	4.88	0.3	1.88e-6	Electroencephalogram traits;
KIRP	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg23752985	chr2:85803571	VAMP8	0.6	9.15	0.5	2.19e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	1.08	19.94	0.79	2.67e-53	Gut microbiome composition (winter);
KIRP	cis	rs74181299	0.819	rs2723086	chr2:65297686	C/T	cg05010058	chr2:65284262	CEP68	0.44	6.23	0.37	2.02e-9	Pulse pressure;
KIRP	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg16586182	chr3:47516702	SCAP	-0.7	-9.37	-0.51	4.86e-18	Colorectal cancer;
KIRP	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg23649088	chr2:200775458	C2orf69	0.67	5.84	0.35	1.68e-8	Schizophrenia;
KIRP	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.47	5.96	0.36	8.82e-9	Height;
KIRP	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.48	-6.09	-0.36	4.31e-9	Multiple sclerosis;
KIRP	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg10130564	chr11:117069849	TAGLN	0.43	5.37	0.32	1.79e-7	Blood protein levels;
KIRP	cis	rs2456568	0.778	rs7944194	chr11:93682413	C/G	cg26875233	chr11:93583750	C11orf90	0.32	5.86	0.35	1.5e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7236492	0.748	rs76617579	chr18:77200655	C/T	cg15644404	chr18:77186268	NFATC1	-0.91	-6.97	-0.41	2.88e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.96	-17.39	-0.74	1.03e-44	Breast cancer;
KIRP	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg04374321	chr14:90722782	PSMC1	0.9	15.31	0.7	1.27e-37	Mortality in heart failure;
KIRP	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg17376030	chr22:41985996	PMM1	0.52	5.86	0.35	1.47e-8	Vitiligo;
KIRP	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.61	-7.43	-0.43	1.81e-12	Glomerular filtration rate;
KIRP	cis	rs2274273	0.624	rs10129505	chr14:55776375	C/T	cg04306507	chr14:55594613	LGALS3	0.39	5.42	0.33	1.44e-7	Protein biomarker;
KIRP	cis	rs2929278	0.617	rs2955969	chr15:44114527	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.5	-6.03	-0.36	5.9e-9	Schizophrenia;
KIRP	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.75	11.28	0.58	4.63e-24	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.59	6.79	0.4	8.21e-11	Height;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg00684032	chr4:1343700	KIAA1530	0.45	5.32	0.32	2.35e-7	Longevity;
KIRP	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg14132834	chr19:41945861	ATP5SL	0.53	7.16	0.42	9.05e-12	Height;
KIRP	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg05347473	chr6:146136440	FBXO30	0.57	7.82	0.45	1.5e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg04362960	chr10:104952993	NT5C2	0.53	5.98	0.36	7.96e-9	Waist circumference;Hip circumference;
KIRP	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg16989719	chr2:238392110	NA	-0.53	-5.96	-0.36	8.68e-9	Prostate cancer;
KIRP	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.72	-0.34	3.01e-8	Pulmonary function;
KIRP	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.55	0.33	7.45e-8	Total cholesterol levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03899609	chr16:29911630	SEZ6L2;ASPHD1	0.44	6.2	0.37	2.38e-9	Survival in pancreatic cancer;
KIRP	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs524023	0.957	rs561193	chr11:64353029	A/G	cg09231725	chr11:64357281	SLC22A12	-0.58	-7.58	-0.44	6.87e-13	Urate levels in obese individuals;
KIRP	cis	rs2072732	0.861	rs2993479	chr1:2967039	A/T	cg03957235	chr1:3512243	MEGF6	-0.37	-5.03	-0.31	9.51e-7	Plateletcrit;
KIRP	cis	rs9378796	0.518	rs13196649	chr6:3435568	C/T	cg00476032	chr6:3446245	SLC22A23	-0.56	-5.3	-0.32	2.59e-7	Mean platelet volume;
KIRP	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg13978929	chr19:21580086	ZNF493	0.51	5.07	0.31	7.88e-7	Pain;
KIRP	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.51	6.97	0.41	2.83e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.92	14.12	0.67	1.48e-33	Bladder cancer;
KIRP	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.49	-5.83	-0.35	1.7e-8	Body mass index;
KIRP	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg05861140	chr6:150128134	PCMT1	-0.55	-7.85	-0.45	1.25e-13	Lung cancer;
KIRP	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06915872	chr16:87998081	BANP	0.56	5.75	0.34	2.69e-8	Menopause (age at onset);
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.95	-0.3	1.35e-6	Life satisfaction;
KIRP	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg12292205	chr6:26970375	C6orf41	-0.36	-5.39	-0.32	1.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	5.08	0.31	7.39e-7	Menarche (age at onset);
KIRP	cis	rs10214930	0.697	rs759269	chr7:27592347	C/T	cg22168087	chr7:27702803	HIBADH	0.46	4.91	0.3	1.68e-6	Hypospadias;
KIRP	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.55	-7.82	-0.45	1.59e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs889398	0.802	rs8050414	chr16:69886813	T/A	cg09409435	chr16:70099608	PDXDC2	0.43	5.29	0.32	2.74e-7	Body mass index;
KIRP	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs6545883	0.783	rs12713442	chr2:61848078	G/A	cg15711740	chr2:61764176	XPO1	-0.52	-6.78	-0.4	8.79e-11	Tuberculosis;
KIRP	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.62	-8.46	-0.47	2.41e-15	Breast cancer;
KIRP	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-7.11	-0.41	1.22e-11	Bone mineral density;
KIRP	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg25650185	chr19:21324782	ZNF431	0.47	4.92	0.3	1.6e-6	Pain;
KIRP	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.89	11.9	0.6	4.33e-26	Gestational age at birth (maternal effect);
KIRP	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.33	-5.97	-0.36	8.44e-9	Renal cell carcinoma;
KIRP	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.78	12.71	0.63	8.72e-29	Breast cancer;
KIRP	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg14541582	chr5:601475	NA	-0.53	-6.27	-0.37	1.57e-9	Obesity-related traits;
KIRP	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg10932868	chr11:921992	NA	0.59	7.34	0.42	3.06e-12	Alzheimer's disease (late onset);
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg14221460	chr8:27183342	PTK2B	0.5	6.52	0.38	3.89e-10	Neuroticism;
KIRP	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.96	0.57	4.96e-23	Cognitive test performance;
KIRP	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-1.08	-10.52	-0.56	1.34e-21	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.48	0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.43	-0.38	6.71e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7011049	1.000	rs72640850	chr8:53836681	A/C	cg26025543	chr8:53854495	NA	0.75	7.87	0.45	1.11e-13	Systolic blood pressure;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17940200	chr2:19170947	NA	0.35	6.04	0.36	5.63e-9	C-reactive protein;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-0.83	-12.48	-0.62	4.91e-28	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-8.24	-0.47	1.03e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs12900413	0.562	rs12898229	chr15:90295960	C/T	cg24650279	chr15:90327240	NA	-0.43	-5.36	-0.32	1.95e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	1.08	19.66	0.78	2.32e-52	Systemic lupus erythematosus;
KIRP	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.73	10.15	0.54	1.95e-20	Schizophrenia;
KIRP	cis	rs1298908	1.000	rs1298908	chr10:82013134	A/G	cg13429435	chr10:81271195	EIF5AL1	0.33	4.97	0.3	1.25e-6	Diabetic kidney disease;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-1.02	-18.23	-0.76	1.42e-47	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.42	-0.33	1.45e-7	Lung cancer;
KIRP	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg09455208	chr3:40491958	NA	0.36	6.32	0.37	1.21e-9	Renal cell carcinoma;
KIRP	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.76	-9.09	-0.5	3.38e-17	Pancreatic cancer;
KIRP	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg19407955	chr1:165599744	MGST3	-0.48	-5.42	-0.33	1.45e-7	Total ventricular volume;
KIRP	cis	rs16828019	0.789	rs34216154	chr1:41670907	G/A	cg24596898	chr1:41849189	NA	0.63	4.94	0.3	1.45e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg00405596	chr8:11794950	NA	0.55	7.4	0.43	2.21e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12580194	0.593	rs60774348	chr12:55757717	A/G	cg11794356	chr12:55725991	OR6C3	-0.53	-7.02	-0.41	2.15e-11	Cancer;
KIRP	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg27205649	chr11:78285834	NARS2	-0.52	-5.69	-0.34	3.69e-8	Testicular germ cell tumor;
KIRP	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg02297831	chr4:17616191	MED28	0.52	6.57	0.39	2.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7939886	0.920	rs7936219	chr11:55977335	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.43	5.65	0.34	4.49e-8	Testicular germ cell tumor;
KIRP	cis	rs10267417	0.603	rs13243056	chr7:19894101	A/C	cg05791153	chr7:19748676	TWISTNB	0.56	5.14	0.31	5.64e-7	Night sleep phenotypes;
KIRP	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.24e-6	Menopause (age at onset);
KIRP	cis	rs4478137	1.000	rs4478137	chr4:164238385	G/A	cg06758707	chr4:164254230	NPY1R	0.76	10.13	0.54	2.14e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7870753	0.838	rs10820741	chr9:99267553	T/C	cg25260653	chr9:99212216	HABP4	0.52	5.54	0.33	7.94e-8	Height;
KIRP	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-9.22	-0.51	1.36e-17	Coronary artery disease;
KIRP	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08822215	chr16:89438651	ANKRD11	0.41	5.52	0.33	8.79e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05665937	chr4:1216051	CTBP1	-0.47	-6.36	-0.38	9.64e-10	Obesity-related traits;
KIRP	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.44	-6.16	-0.37	3e-9	Dementia with Lewy bodies;
KIRP	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.45	8.02	0.46	4.26e-14	Height;
KIRP	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	1.13	16.94	0.73	3.44e-43	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg18209359	chr17:80159595	CCDC57	-0.41	-5.42	-0.33	1.41e-7	Life satisfaction;
KIRP	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg08968635	chr6:28129556	ZNF389	0.44	4.9	0.3	1.76e-6	Depression;
KIRP	cis	rs12210905	1.000	rs12209393	chr6:27085073	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg26384229	chr12:38710491	ALG10B	0.68	9.1	0.5	3.11e-17	Morning vs. evening chronotype;
KIRP	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04004882	chr2:215674386	BARD1	-0.81	-9.0	-0.5	6.36e-17	Neuroblastoma;
KIRP	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.76	7.84	0.45	1.39e-13	Uric acid levels;
KIRP	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg01631408	chr1:248437212	OR2T33	-0.54	-7.27	-0.42	4.68e-12	Common traits (Other);
KIRP	cis	rs13223928	0.542	rs12540595	chr7:3131792	G/A	cg19214707	chr7:3157722	NA	-0.67	-8.16	-0.46	1.7e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs73200209	0.703	rs17498942	chr12:116686117	C/G	cg01776926	chr12:116560359	MED13L	-0.55	-6.19	-0.37	2.54e-9	Total body bone mineral density;
KIRP	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.99	10.72	0.56	3e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.83	12.42	0.62	8.08e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg06307176	chr5:131281290	NA	0.53	5.85	0.35	1.53e-8	Life satisfaction;
KIRP	cis	rs12220238	0.722	rs4745749	chr10:76393742	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.53	6.06	0.36	4.99e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7923609	0.934	rs2893919	chr10:65134778	G/A	cg01631684	chr10:65280961	REEP3	-0.48	-5.61	-0.34	5.47e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22995356	chr3:184081109	POLR2H	-0.49	-6.48	-0.38	4.87e-10	Myopia;
KIRP	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg15764593	chr10:829463	NA	-0.83	-8.94	-0.5	9.39e-17	Uric acid levels;
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs13272623	0.502	rs268594	chr8:71513130	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.57	7.31	0.42	3.75e-12	IgG glycosylation;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg09596239	chr2:130940036	SMPD4;FAM128B	0.52	6.46	0.38	5.65e-10	Educational attainment;
KIRP	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.51	6.36	0.38	9.71e-10	Total body bone mineral density;
KIRP	cis	rs9398235	0.673	rs2073210	chr6:110729973	A/C	cg19196401	chr6:110721138	DDO	-0.43	-5.23	-0.32	3.6e-7	Systemic lupus erythematosus;
KIRP	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg08999081	chr20:33150536	PIGU	0.44	5.54	0.33	7.58e-8	Height;
KIRP	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg00629928	chr5:358741	AHRR	0.5	4.86	0.3	2.09e-6	Breast cancer;
KIRP	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg04731861	chr2:219085781	ARPC2	0.3	7.65	0.44	4.53e-13	Colorectal cancer;
KIRP	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.92	12.96	0.64	1.22e-29	Bladder cancer;
KIRP	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg18306943	chr3:40428807	ENTPD3	0.39	5.55	0.33	7.25e-8	Renal cell carcinoma;
KIRP	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	14.73	0.68	1.24e-35	Platelet count;
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.58	-7.45	-0.43	1.56e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	8.75	0.49	3.52e-16	Cognitive ability;
KIRP	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg16898833	chr6:26189333	HIST1H4D	0.83	5.9	0.35	1.17e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.62	7.66	0.44	4.19e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7688540	0.771	rs78343340	chr4:267437	G/A	cg17891759	chr4:299121	NA	-0.49	-5.13	-0.31	5.79e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.97	0.88	2.9e-81	Chronic sinus infection;
KIRP	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg18154014	chr19:37997991	ZNF793	0.63	5.35	0.32	2.02e-7	Coronary artery calcification;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.9	-13.66	-0.66	5.43e-32	Longevity;Endometriosis;
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.79e-8	Lung cancer;
KIRP	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.57	-0.39	3e-10	Blood pressure;
KIRP	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs963731	0.649	rs1454227	chr2:39249328	T/C	cg04010122	chr2:39346883	SOS1	-0.82	-5.98	-0.36	8.01e-9	Corticobasal degeneration;
KIRP	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg19610905	chr11:61596333	FADS2	-0.57	-7.77	-0.44	2.07e-13	Red cell distribution width;Mean platelet volume;
KIRP	trans	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	6.05	0.36	5.23e-9	Metabolite levels;
KIRP	cis	rs7009516	0.669	rs13251418	chr8:24246832	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.32	-6.6	-0.39	2.55e-10	Hair greying;
KIRP	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg03609598	chr5:56110824	MAP3K1	0.45	5.08	0.31	7.54e-7	Type 2 diabetes;
KIRP	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.32	0.51	7.11e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg05527609	chr1:210001259	C1orf107	-0.47	-5.17	-0.31	4.87e-7	Red blood cell count;
KIRP	cis	rs4363385	0.588	rs12082627	chr1:153023650	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-6.34	-0.37	1.1e-9	Inflammatory skin disease;
KIRP	cis	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg21546286	chr11:48923668	NA	0.43	5.36	0.32	1.89e-7	HDL cholesterol;
KIRP	cis	rs17023223	0.537	rs10923741	chr1:119604473	A/T	cg05756136	chr1:119680316	WARS2	-0.54	-7.17	-0.42	8.73e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg05973401	chr12:123451056	ABCB9	0.63	7.4	0.43	2.16e-12	Platelet count;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03042113	chr11:65430511	RELA	0.51	6.67	0.39	1.68e-10	Myopia (pathological);
KIRP	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg21926883	chr2:100939477	LONRF2	-0.56	-7.53	-0.43	9.86e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12282928	0.959	rs12290629	chr11:48298901	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs6684514	1.000	rs2270291	chr1:156244992	G/C	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg23479056	chr15:41276147	INO80	-0.42	-6.18	-0.37	2.69e-9	Menopause (age at onset);
KIRP	cis	rs10861342	1.000	rs2888841	chr12:105493750	C/T	cg23923672	chr12:105501055	KIAA1033	0.84	6.41	0.38	7.33e-10	IgG glycosylation;
KIRP	cis	rs2219968	1.000	rs13266678	chr8:78958272	T/C	cg00738934	chr8:78996279	NA	0.5	6.88	0.4	4.83e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.72	-10.3	-0.55	6.39e-21	Breast size;
KIRP	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.57	7.57	0.43	7.63e-13	Schizophrenia;
KIRP	cis	rs9630089	0.622	rs7906782	chr10:98961596	C/T	cg25902810	chr10:99078978	FRAT1	0.43	5.07	0.31	7.71e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	8.35	0.47	5.07e-15	HIV-1 control;
KIRP	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg03808351	chr9:123631620	PHF19	0.44	5.96	0.36	8.53e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs12190007	0.508	rs6605538	chr6:169731432	G/A	cg16388071	chr6:169726476	NA	0.54	7.85	0.45	1.27e-13	Obesity-related traits;
KIRP	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.63	-0.39	2.1e-10	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	1.0	8.13	0.46	2.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg13264159	chr8:625131	ERICH1	0.71	4.85	0.3	2.2e-6	IgG glycosylation;
KIRP	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.89	-0.35	1.29e-8	Neutrophil percentage of white cells;
KIRP	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.61	5.66	0.34	4.16e-8	Schizophrenia;
KIRP	cis	rs755109	1.000	rs7030907	chr9:100688577	C/T	cg13688889	chr9:100608707	NA	-0.42	-4.9	-0.3	1.73e-6	Quantitative traits;
KIRP	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg01843034	chr6:37503916	NA	-0.96	-14.51	-0.68	7.13e-35	Cognitive performance;
KIRP	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.91	0.66	7.43e-33	Smoking behavior;
KIRP	trans	rs13100616	1.000	rs7433215	chr3:178411190	T/C	cg26530345	chr2:220312410	SPEG	0.49	6.02	0.36	6.17e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.63	-0.34	4.89e-8	Type 2 diabetes;
KIRP	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.83	-0.45	1.48e-13	Retinal vascular caliber;
KIRP	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg15068132	chr12:102092402	CHPT1	-0.39	-5.12	-0.31	6.31e-7	Blood protein levels;
KIRP	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.81	6.36	0.38	9.71e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2061333	0.557	rs28446946	chr19:44607619	T/C	cg21636353	chr19:44617292	ZNF225	-0.49	-5.14	-0.31	5.62e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13939156	chr17:80058883	NA	0.5	7.51	0.43	1.11e-12	Life satisfaction;
KIRP	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg03351412	chr1:154909251	PMVK	0.43	5.66	0.34	4.12e-8	Prostate cancer;
KIRP	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-9.27	-0.51	9.82e-18	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25135922	chr1:226497286	LIN9	0.49	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.4	-0.33	1.6e-7	Pulmonary function;
KIRP	cis	rs72627123	0.867	rs3815331	chr14:74482948	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.87	5.68	0.34	3.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg21734707	chr17:3908241	ZZEF1	0.68	10.39	0.55	3.27e-21	Type 2 diabetes;
KIRP	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.4	-5.26	-0.32	3.15e-7	Type 2 diabetes;
KIRP	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-6.15	-0.37	3.12e-9	Schizophrenia;
KIRP	cis	rs7113874	0.802	rs11042029	chr11:8688125	C/A	cg08015107	chr11:8618950	NA	-0.42	-5.71	-0.34	3.23e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4849845	0.886	rs13412677	chr2:121029517	C/G	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.07	-0.36	4.89e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.62	8.56	0.48	1.24e-15	Rheumatoid arthritis;
KIRP	cis	rs447921	0.861	rs12950218	chr17:74409547	G/A	cg17201438	chr17:74438067	UBE2O	0.45	4.93	0.3	1.54e-6	Mitochondrial DNA levels;
KIRP	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	1.04	14.34	0.67	2.7200000000000002e-34	Menopause (age at onset);
KIRP	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.44	-6.17	-0.37	2.82e-9	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-5.75	-0.34	2.62e-8	Renal cell carcinoma;
KIRP	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.46	-9.36	-0.51	5.25e-18	Rheumatoid arthritis;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20069020	chr7:108166782	PNPLA8	0.52	6.54	0.38	3.49e-10	Myopia (pathological);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17293641	chr8:119964144	TNFRSF11B	0.54	6.11	0.36	3.82e-9	Lung cancer in ever smokers;
KIRP	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	9.29	0.51	8.26e-18	Retinal vascular caliber;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27144592	chr16:783916	NARFL	0.35	4.97	0.3	1.25e-6	Height;
KIRP	cis	rs3774830	0.869	rs11737487	chr4:5446673	G/A	cg26943120	chr4:5472116	STK32B	0.25	5.92	0.35	1.06e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.79	11.28	0.58	4.57e-24	Bladder cancer;
KIRP	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.22	19.77	0.78	1.01e-52	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.77	11.19	0.58	9.08e-24	Lung cancer;
KIRP	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07570687	chr10:102243282	WNT8B	0.49	5.84	0.35	1.65e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.59	-8.17	-0.46	1.61e-14	IgG glycosylation;
KIRP	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.64	-7.28	-0.42	4.36e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.61	7.16	0.42	9.02e-12	Smoking initiation;
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg08662619	chr6:150070041	PCMT1	0.35	5.6	0.34	5.72e-8	Lung cancer;
KIRP	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.41	5.85	0.35	1.52e-8	Endometrial cancer;
KIRP	cis	rs62413470	1.000	rs12205653	chr6:55960169	C/T	cg13327911	chr6:55965977	COL21A1	0.55	5.01	0.3	1.04e-6	Joint mobility (Beighton score);
KIRP	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.33	5.42	0.33	1.45e-7	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.29	-0.42	4.28e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg03934478	chr11:495069	RNH1	0.42	4.89	0.3	1.85e-6	Systemic lupus erythematosus;
KIRP	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.78	-0.4	8.94e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg23682824	chr7:23144976	KLHL7	0.57	6.97	0.41	2.88e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.58	-7.15	-0.41	1.01e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.96	15.85	0.71	1.79e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg02820901	chr13:113351484	ATP11A	0.68	6.34	0.37	1.08e-9	Glycated hemoglobin levels;
KIRP	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg03735888	chr19:58951602	ZNF132	0.48	5.9	0.35	1.2e-8	Uric acid clearance;
KIRP	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg08975724	chr8:8085496	FLJ10661	0.67	9.14	0.5	2.41e-17	Mood instability;
KIRP	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.44	6.0	0.36	6.92e-9	Total body bone mineral density;
KIRP	cis	rs2591576	0.753	rs1445715	chr5:165419631	T/C	cg13976338	chr5:165423657	NA	-0.79	-12.44	-0.62	6.77e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs10267417	0.535	rs12530927	chr7:19949960	T/C	cg05791153	chr7:19748676	TWISTNB	0.5	4.94	0.3	1.47e-6	Night sleep phenotypes;
KIRP	cis	rs13279522	0.536	rs6472248	chr8:67013291	T/C	cg04041976	chr8:67085823	TRIM55	-0.43	-5.34	-0.32	2.1e-7	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25517755	chr10:38738941	LOC399744	-0.52	-7.18	-0.42	8.46e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12580194	0.593	rs61957924	chr12:55744100	T/C	cg19537932	chr12:55886519	OR6C68	-0.48	-6.36	-0.38	9.58e-10	Cancer;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06238864	chr22:39078174	TOMM22	-0.44	-4.87	-0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.31	0.32	2.46e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.94	12.66	0.63	1.27e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg13798912	chr7:905769	UNC84A	0.67	6.51	0.38	4.27e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg08742575	chr21:47604166	C21orf56	0.39	4.95	0.3	1.37e-6	Testicular germ cell tumor;
KIRP	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.96	10.39	0.55	3.33e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg24375607	chr4:120327624	NA	0.57	6.44	0.38	6.14e-10	Corneal astigmatism;
KIRP	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-20.03	-0.79	1.4e-53	Height;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.78	7.49	0.43	1.2e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg17736920	chr1:242011382	EXO1	0.45	5.46	0.33	1.15e-7	Menopause (age at onset);
KIRP	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.27	-0.32	3.02e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs883565	0.655	rs7629839	chr3:39115294	G/A	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.31e-29	Handedness;
KIRP	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg04132472	chr17:19861366	AKAP10	0.43	5.51	0.33	8.88e-8	Schizophrenia;
KIRP	cis	rs7011507	1.000	rs7012852	chr8:49118849	T/C	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs3857536	0.730	rs2214126	chr6:66969162	G/A	cg07460842	chr6:66804631	NA	-0.46	-5.48	-0.33	1.07e-7	Blood trace element (Cu levels);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27312071	chr1:113008965	WNT2B	-0.55	-6.17	-0.37	2.83e-9	Menopause (age at onset);
KIRP	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.89	12.0	0.61	1.95e-26	Coronary artery disease;
KIRP	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg05457628	chr5:178986728	RUFY1	0.53	8.28	0.47	8.12e-15	Lung cancer;
KIRP	cis	rs7719624	0.869	rs6893691	chr5:135395433	A/G	cg16684184	chr5:135415129	NA	0.35	5.25	0.32	3.23e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.37	-0.38	9.3e-10	QT interval;
KIRP	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg21905437	chr5:178450457	ZNF879	0.56	6.54	0.38	3.59e-10	Pubertal anthropometrics;
KIRP	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.64	7.65	0.44	4.66e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9658691	0.920	rs36206197	chr10:90748602	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.8	-4.89	-0.3	1.78e-6	Mosquito bite size;
KIRP	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.81	10.02	0.54	4.87e-20	Phospholipid levels (plasma);
KIRP	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg02811702	chr13:24901961	NA	0.43	5.72	0.34	3.03e-8	Obesity-related traits;
KIRP	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-6.89	-0.4	4.75e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1270639	0.722	rs6950817	chr7:157439636	A/G	cg13357408	chr7:157437802	PTPRN2	0.66	6.45	0.38	5.86e-10	Colorectal cancer;
KIRP	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg07511934	chr16:89386912	ANKRD11	0.43	5.45	0.33	1.24e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs1569175	0.522	rs3094771	chr2:200886058	A/G	cg17644776	chr2:200775616	C2orf69	-0.62	-5.6	-0.34	5.63e-8	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs7870753	0.853	rs10761022	chr9:99224746	A/T	cg25260653	chr9:99212216	HABP4	0.54	6.03	0.36	6.07e-9	Height;
KIRP	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	1.09	8.56	0.48	1.21e-15	Plateletcrit;
KIRP	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-5.49	-0.33	9.77e-8	Schizophrenia;
KIRP	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21659725	chr3:3221576	CRBN	-0.6	-7.34	-0.42	3.1e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9810890	1.000	rs73198847	chr3:128507476	C/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs2479724	0.776	rs12523672	chr6:41749692	T/G	cg17623882	chr6:41773611	USP49	0.56	7.54	0.43	8.99e-13	Menarche (age at onset);
KIRP	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg23950597	chr19:37808831	NA	-0.86	-8.59	-0.48	1.01e-15	Coronary artery calcification;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20074142	chr15:56035371	PRTG	0.55	7.49	0.43	1.24e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08439880	chr3:133502540	NA	-0.43	-5.14	-0.31	5.55e-7	Iron status biomarkers;
KIRP	trans	rs264162	0.687	rs264188	chr18:10957974	C/T	cg19813362	chr1:956108	AGRN	0.48	6.1	0.36	4.01e-9	Stem cell growth factor beta levels;
KIRP	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.31	-5.09	-0.31	7.07e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg05861140	chr6:150128134	PCMT1	-0.48	-6.26	-0.37	1.7e-9	Lung cancer;
KIRP	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg15247329	chr7:2764246	NA	-0.41	-5.86	-0.35	1.5e-8	Height;
KIRP	cis	rs4742903	0.765	rs4743700	chr9:107005468	C/T	cg14250997	chr9:106856677	SMC2	0.38	5.07	0.31	7.77e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-6.04	-0.36	5.66e-9	Fear of minor pain;
KIRP	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.58	-7.15	-0.42	9.59e-12	Diastolic blood pressure;
KIRP	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.45	0.52	2.72e-18	Bipolar disorder;
KIRP	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-1.07	-19.83	-0.78	6.26e-53	Height;
KIRP	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg00376283	chr12:123451042	ABCB9	0.82	11.0	0.57	3.86e-23	Platelet count;
KIRP	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs35995292	0.534	rs28460817	chr7:38921917	T/C	cg19327137	chr7:38886074	VPS41	0.82	12.97	0.64	1.14e-29	Subjective well-being (multi-trait analysis);
KIRP	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.94	-0.4	3.5e-11	Height;
KIRP	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg10790698	chr19:18539756	SSBP4	-0.33	-7.43	-0.43	1.76e-12	Breast cancer;
KIRP	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg27539214	chr16:67997921	SLC12A4	-0.56	-5.3	-0.32	2.64e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.67	9.78	0.53	2.66e-19	Dupuytren's disease;
KIRP	cis	rs61160187	0.503	rs755077	chr5:60000608	C/T	cg02684056	chr5:59996105	DEPDC1B	0.4	4.86	0.3	2.12e-6	Educational attainment (years of education);Educational attainment (college completion);
KIRP	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.53	-0.38	3.79e-10	Menopause (age at onset);
KIRP	cis	rs4700695	0.764	rs152941	chr5:65241446	A/G	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.76	8.4	0.47	3.51e-15	Cholesterol, total;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11368438	chr3:142751654	SR140	0.45	6.4	0.38	7.98e-10	Interleukin-4 levels;
KIRP	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg13939156	chr17:80058883	NA	-0.48	-5.49	-0.33	1.02e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg03834567	chr2:218808745	TNS1	0.45	5.47	0.33	1.08e-7	Ulcerative colitis;
KIRP	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg00310523	chr12:86230176	RASSF9	-0.49	-7.74	-0.44	2.56e-13	Major depressive disorder;
KIRP	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	9.13	0.5	2.59e-17	Coffee consumption (cups per day);
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	5.6	0.34	5.75e-8	Longevity;
KIRP	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.97	14.9	0.69	3.21e-36	Diastolic blood pressure;
KIRP	cis	rs11605275	0.581	rs11606785	chr11:20030430	A/C	cg14835545	chr11:20032148	NAV2	-0.71	-4.9	-0.3	1.71e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21643547	chr1:205240462	TMCC2	-0.82	-12.71	-0.63	8.37e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs35661897	0.920	rs62190939	chr2:227336387	C/T	cg03426602	chr2:227312417	NA	-0.53	-6.8	-0.4	8.11e-11	Urinary tract infection frequency;
KIRP	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.08	-0.31	7.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1629083	0.902	rs11216827	chr11:118110202	A/T	cg18857871	chr11:118064634	AMICA1	0.62	8.17	0.46	1.62e-14	Lung cancer;
KIRP	cis	rs796825	0.530	rs34014378	chr3:119946506	T/A	cg21790991	chr3:120137480	FSTL1	-0.3	-5.23	-0.32	3.6e-7	HIV-1 susceptibility;
KIRP	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.13	14.03	0.67	2.93e-33	Gut microbiome composition (summer);
KIRP	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.42	4.86	0.3	2.14e-6	Osteoporosis;
KIRP	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.79	0.71	2.92e-39	Bipolar disorder;
KIRP	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	0.77	8.42	0.47	3.06e-15	Initial pursuit acceleration;
KIRP	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.46	5.89	0.35	1.29e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.47	0.48	2.25e-15	Motion sickness;
KIRP	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-1.09	-11.98	-0.61	2.39e-26	Corneal structure;
KIRP	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs77372450	0.636	rs6879084	chr5:157029188	C/T	cg23851860	chr5:157002805	ADAM19	0.45	4.91	0.3	1.68e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9990333	0.562	rs55970879	chr3:195821966	G/A	cg01351295	chr3:195700735	SDHAP1	-0.43	-4.86	-0.3	2.14e-6	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
KIRP	cis	rs56079296	0.929	rs73795207	chr5:121357759	A/C	cg05256605	chr5:121412184	LOX	-0.53	-5.86	-0.35	1.51e-8	Coronary artery disease;
KIRP	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg08126542	chr6:37504118	NA	-0.83	-13.14	-0.64	3.21e-30	Cognitive performance;
KIRP	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs72634258	0.945	rs3766606	chr1:8022197	G/T	cg00042356	chr1:8021962	PARK7	0.76	6.85	0.4	5.98e-11	Inflammatory bowel disease;
KIRP	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg24459738	chr19:57751996	ZNF805	-0.58	-7.21	-0.42	6.96e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.0	-0.41	2.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1843834	0.755	rs10192196	chr2:225577135	C/T	cg22509189	chr2:225307070	NA	-0.46	-5.63	-0.34	4.88e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg17304646	chr3:125932534	NA	0.3	5.29	0.32	2.72e-7	Metabolite levels;
KIRP	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.65	-0.56	4.85e-22	Menopause (age at onset);
KIRP	cis	rs13006833	0.739	rs291430	chr2:191198727	A/C	cg27211696	chr2:191398769	TMEM194B	0.4	5.63	0.34	4.82e-8	Urinary metabolites;
KIRP	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26526719	chr5:1949144	NA	0.44	5.26	0.32	3.19e-7	Gut microbiome composition (winter);
KIRP	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg01320579	chr17:75405842	SEPT9	-0.43	-7.11	-0.41	1.28e-11	Airflow obstruction;
KIRP	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg03342759	chr3:160939853	NMD3	0.44	5.29	0.32	2.74e-7	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.64	8.5	0.48	1.85e-15	Aortic root size;
KIRP	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.57	7.19	0.42	7.65e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.63	8.3	0.47	6.89e-15	Personality dimensions;
KIRP	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg18501202	chr6:125855421	NA	-0.34	-5.12	-0.31	6.26e-7	Brugada syndrome;
KIRP	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.95	15.46	0.7	3.9e-38	Menarche (age at onset);
KIRP	cis	rs9513627	1.000	rs7317126	chr13:100119739	T/A	cg25919922	chr13:100150906	NA	-0.65	-5.63	-0.34	4.79e-8	Obesity-related traits;
KIRP	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.64	-6.46	-0.38	5.64e-10	Blood trace element (Zn levels);
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.97	-0.3	1.28e-6	Life satisfaction;
KIRP	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs1961637	0.603	rs895772	chr2:223892964	C/T	cg02552189	chr2:223891284	NA	0.42	6.19	0.37	2.53e-9	Oropharynx cancer;
KIRP	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.46	8.02	0.46	4.29e-14	Height;
KIRP	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.81e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7212590	0.618	rs7217337	chr17:58023417	C/T	cg10252138	chr17:58120427	NA	-0.67	-5.48	-0.33	1.05e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs2916247	0.954	rs4506267	chr8:93079246	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.53	-6.89	-0.4	4.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.08	-0.31	7.52e-7	Pulmonary function;
KIRP	cis	rs12615966	1.000	rs61424916	chr2:105390188	C/A	cg16465502	chr2:105461796	NA	0.55	5.38	0.32	1.77e-7	Pancreatic cancer;
KIRP	cis	rs3857067	0.967	rs1509942	chr4:95013440	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg10755058	chr3:40428713	ENTPD3	0.37	5.23	0.32	3.62e-7	Renal cell carcinoma;
KIRP	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg07636037	chr3:49044803	WDR6	-0.58	-5.43	-0.33	1.34e-7	Menarche (age at onset);
KIRP	cis	rs7646881	0.812	rs61387735	chr3:158456161	G/A	cg19483011	chr3:158453295	NA	-0.56	-5.94	-0.35	9.55e-9	Tetralogy of Fallot;
KIRP	cis	rs3774830	1.000	rs3774830	chr4:5440083	A/G	cg26943120	chr4:5472116	STK32B	-0.25	-6.14	-0.36	3.25e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg24375607	chr4:120327624	NA	0.61	6.62	0.39	2.24e-10	Corneal astigmatism;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12379940	chr13:44947923	SERP2	-0.5	-6.27	-0.37	1.63e-9	Menopause (age at onset);
KIRP	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.65	-0.44	4.45e-13	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14071496	chr9:14322503	NA	0.5	6.86	0.4	5.49e-11	Parkinson's disease;
KIRP	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg22633769	chr20:60982531	CABLES2	0.57	7.31	0.42	3.75e-12	Colorectal cancer;
KIRP	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.21	-0.32	4e-7	Alcohol dependence;
KIRP	trans	rs74233809	0.901	rs4409766	chr10:104616663	A/G	cg17301223	chr8:145106438	OPLAH	-0.39	-6.47	-0.38	5.17e-10	Birth weight;
KIRP	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.57	10.93	0.57	6.47e-23	Bone mineral density;
KIRP	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.51	-0.48	1.68e-15	Neuroticism;
KIRP	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg08875078	chr22:50639485	SELO	-0.37	-4.88	-0.3	1.93e-6	Obesity-related traits;
KIRP	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.88	10.67	0.56	4.39e-22	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs16857609	0.550	rs1351163	chr2:218267992	A/G	cg15335768	chr2:218268053	DIRC3	-0.58	-7.24	-0.42	5.79e-12	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.64	7.38	0.43	2.44e-12	Mosquito bite size;
KIRP	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg02375832	chr11:62437615	C11orf48	-0.42	-5.22	-0.32	3.81e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	1.03	19.36	0.78	2.41e-51	Height;
KIRP	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg16558253	chr16:72132732	DHX38	-0.39	-5.34	-0.32	2.08e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.42	5.54	0.33	7.66e-8	Cardiovascular disease risk factors;
KIRP	cis	rs1816854	1.000	rs1816854	chr12:44205018	A/G	cg20956634	chr12:44200518	TWF1	0.51	5.47	0.33	1.11e-7	Inflammatory bowel disease;
KIRP	cis	rs11644362	1.000	rs3843707	chr16:12996788	G/A	cg06890432	chr16:12997467	SHISA9	-0.42	-6.56	-0.39	3.2e-10	Positive affect;Subjective well-being;
KIRP	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.63	6.74	0.39	1.1e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg15556689	chr8:8085844	FLJ10661	0.6	7.46	0.43	1.49e-12	Neuroticism;
KIRP	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	0.99	7.51	0.43	1.08e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	1.02	10.82	0.57	1.45e-22	Blood protein levels;
KIRP	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg13206674	chr6:150067644	NUP43	0.55	7.89	0.45	1.02e-13	Lung cancer;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg15778745	chr13:88324570	SLITRK5	-0.54	-6.14	-0.36	3.37e-9	Response to statin therapy;
KIRP	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.72	-0.49	4.2e-16	Mood instability;
KIRP	cis	rs2294369	1.000	rs4821913	chr22:40089308	C/T	cg10455938	chr22:40058150	CACNA1I	-0.52	-6.04	-0.36	5.68e-9	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs6496667	0.779	rs6496670	chr15:90949480	A/G	cg10434728	chr15:90938212	IQGAP1	0.4	5.13	0.31	5.78e-7	Rheumatoid arthritis;
KIRP	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	1.04	13.47	0.65	2.39e-31	Exhaled nitric oxide output;
KIRP	cis	rs597583	0.951	rs599411	chr11:117422262	T/G	cg27161313	chr11:117392002	DSCAML1	-0.45	-5.19	-0.31	4.31e-7	Putamen volume;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg01657329	chr11:68192670	LRP5	-0.47	-5.0	-0.3	1.1e-6	Total body bone mineral density;
KIRP	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg23625390	chr15:77176239	SCAPER	0.52	6.89	0.4	4.64e-11	Blood metabolite levels;
KIRP	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg20469991	chr17:27169893	C17orf63	0.54	5.59	0.34	5.93e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6445967	1.000	rs12633655	chr3:58306321	T/C	cg16569813	chr3:58235849	ABHD6	-0.33	-4.95	-0.3	1.38e-6	Platelet count;
KIRP	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.61	0.44	5.8e-13	Tonsillectomy;
KIRP	cis	rs9381107	0.932	rs34030781	chr6:9451449	C/T	cg14735645	chr6:9486422	NA	-0.44	-5.3	-0.32	2.57e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.7	-7.37	-0.43	2.65e-12	Gut microbiome composition (summer);
KIRP	cis	rs1629083	0.875	rs4938489	chr11:118079867	G/T	cg18857871	chr11:118064634	AMICA1	0.65	8.77	0.49	2.98e-16	Lung cancer;
KIRP	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg01559446	chr3:44596178	ZNF167	-0.38	-5.42	-0.33	1.41e-7	Depressive symptoms;
KIRP	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.21e-7	Red blood cell count;
KIRP	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.61	-0.34	5.55e-8	Electroencephalogram traits;
KIRP	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg24253500	chr15:84953950	NA	0.53	6.1	0.36	4.19e-9	Schizophrenia;
KIRP	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.45	9.68	0.53	5.52e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7215564	0.749	rs7217825	chr17:78733901	C/T	cg06153925	chr17:78755379	RPTOR	-0.34	-5.84	-0.35	1.64e-8	Myopia (pathological);
KIRP	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg09264619	chr17:80180166	NA	0.51	6.07	0.36	4.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg07856975	chr6:36356162	ETV7	0.45	5.86	0.35	1.46e-8	Platelet distribution width;
KIRP	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg04369109	chr6:150039330	LATS1	-0.5	-6.02	-0.36	6.44e-9	Lung cancer;
KIRP	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg24503407	chr1:205819492	PM20D1	0.47	5.14	0.31	5.52e-7	Parkinson's disease;
KIRP	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg08313168	chr12:7315531	NA	0.67	6.12	0.36	3.7e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06747863	chr12:118810789	TAOK3	0.54	6.2	0.37	2.42e-9	Smoking initiation;
KIRP	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.35	-0.42	2.89e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25470419	chr5:52907653	NDUFS4	-0.45	-6.86	-0.4	5.68e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3126085	0.560	rs12568784	chr1:152323132	G/T	cg26876637	chr1:152193138	HRNR	-0.58	-6.38	-0.38	8.79e-10	Atopic dermatitis;
KIRP	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.76e-6	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.44	-5.68	-0.34	3.85e-8	Renal cell carcinoma;
KIRP	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg14440974	chr22:39074834	NA	-0.38	-4.95	-0.3	1.4e-6	Menopause (age at onset);
KIRP	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg19539972	chr4:7069911	GRPEL1	0.4	5.18	0.31	4.56e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs367943	0.712	rs7731465	chr5:112687385	A/G	cg12552261	chr5:112820674	MCC	-0.54	-6.44	-0.38	6.33e-10	Type 2 diabetes;
KIRP	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg00409905	chr10:38381863	ZNF37A	0.48	5.38	0.32	1.76e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.68	-0.44	3.88e-13	Type 2 diabetes;
KIRP	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg17764715	chr19:33622953	WDR88	0.66	8.29	0.47	7.25e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.47	-6.09	-0.36	4.37e-9	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08949428	chr13:98451284	NA	0.5	7.26	0.42	5e-12	Survival in pancreatic cancer;
KIRP	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05220968	chr6:146057943	EPM2A	0.42	5.32	0.32	2.35e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12134245	0.874	rs61798047	chr1:92016934	C/T	cg21854759	chr1:92012499	NA	-0.47	-5.66	-0.34	4.24e-8	Breast cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18789337	chr6:114180353	MARCKS	0.51	6.51	0.38	4.17e-10	Smoking initiation;
KIRP	cis	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg05779272	chr9:33168018	B4GALT1	0.37	4.88	0.3	1.9e-6	IgG glycosylation;
KIRP	cis	rs2205829	0.563	rs4413607	chr6:27475120	A/C	cg03332623	chr6:27441972	ZNF184	-0.39	-5.54	-0.33	7.58e-8	Bipolar disorder;
KIRP	cis	rs35934224	0.710	rs56298833	chr22:19852438	A/G	cg11182965	chr22:19864308	TXNRD2	-0.41	-4.98	-0.3	1.21e-6	Glaucoma (primary open-angle);
KIRP	cis	rs7010876	0.568	rs13261169	chr8:89225076	C/T	cg08624180	chr8:89339080	MMP16	-0.55	-5.1	-0.31	6.95e-7	Schizophrenia;
KIRP	cis	rs909341	0.678	rs2738778	chr20:62291830	C/T	cg03999872	chr20:62272968	STMN3	-0.69	-7.61	-0.44	5.94e-13	Atopic dermatitis;
KIRP	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg05791153	chr7:19748676	TWISTNB	0.72	6.54	0.39	3.47e-10	Thyroid stimulating hormone;
KIRP	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.3e-12	Morning vs. evening chronotype;
KIRP	cis	rs17401966	0.597	rs2180185	chr1:10246129	C/G	cg19773385	chr1:10388646	KIF1B	-0.47	-7.14	-0.41	1.07e-11	Hepatocellular carcinoma;
KIRP	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.93	-15.53	-0.7	2.32e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg09873164	chr1:152488093	CRCT1	0.53	6.44	0.38	6.27e-10	Hair morphology;
KIRP	cis	rs7252981	0.632	rs8101679	chr19:19733877	T/C	cg11584989	chr19:19387371	SF4	-0.48	-5.61	-0.34	5.45e-8	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg25797454	chr6:150327115	RAET1K	0.31	5.9	0.35	1.21e-8	Alopecia areata;
KIRP	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg05347473	chr6:146136440	FBXO30	0.64	9.34	0.51	6.22e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg16988262	chr1:15930761	NA	0.36	4.89	0.3	1.85e-6	Systolic blood pressure;
KIRP	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs12580194	0.593	rs7960719	chr12:55722035	G/A	cg19537932	chr12:55886519	OR6C68	-0.48	-6.39	-0.38	8.44e-10	Cancer;
KIRP	cis	rs17023223	0.509	rs7542832	chr1:119762729	T/C	cg18261050	chr1:119551319	NA	0.45	5.87	0.35	1.43e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.44	0.33	1.3e-7	Cognitive test performance;
KIRP	cis	rs472402	0.580	rs7706809	chr5:6635971	G/T	cg08700190	chr5:6636046	SRD5A1	-0.42	-5.44	-0.33	1.31e-7	Response to amphetamines;
KIRP	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.85	12.76	0.63	6.09e-29	Diastolic blood pressure;
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09256448	chr16:638327	NA	0.35	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg10755058	chr3:40428713	ENTPD3	0.37	5.34	0.32	2.07e-7	Renal cell carcinoma;
KIRP	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg07621104	chr11:117668040	DSCAML1	0.48	6.01	0.36	6.66e-9	Myopia;
KIRP	cis	rs6459788	0.630	rs11977865	chr7:157234112	G/A	cg22987457	chr7:157211561	NA	0.43	5.37	0.32	1.85e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs12474201	0.851	rs36071056	chr2:47020976	C/T	cg06386533	chr2:46925753	SOCS5	1.05	13.95	0.66	5.76e-33	Height;
KIRP	cis	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg08501292	chr6:25962987	TRIM38	0.91	6.48	0.38	5.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.71	-6.52	-0.38	4.05e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1134634	0.520	rs4698403	chr4:15629827	T/G	cg16509355	chr4:15471240	CC2D2A	-0.35	-5.98	-0.36	7.81e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg06521331	chr12:34319734	NA	-0.58	-6.9	-0.4	4.43e-11	Morning vs. evening chronotype;
KIRP	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg27490568	chr2:178487706	NA	0.64	8.65	0.48	6.65e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	4.83e-8	Lung cancer;
KIRP	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.11	-0.36	3.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg25281562	chr12:121454272	C12orf43	0.59	7.04	0.41	1.96e-11	N-glycan levels;
KIRP	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.92	10.7	0.56	3.42e-22	Corneal astigmatism;
KIRP	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.61	7.66	0.44	4.13e-13	Body mass index;
KIRP	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.46	6.65	0.39	1.87e-10	Sitting height ratio;
KIRP	cis	rs7523273	0.568	rs1318653	chr1:208014922	C/T	cg22525895	chr1:207977042	MIR29B2	0.54	5.23	0.32	3.58e-7	Schizophrenia;
KIRP	cis	rs4253772	0.515	rs9615969	chr22:46773592	C/G	cg18190219	chr22:46762943	CELSR1	-0.82	-6.12	-0.36	3.6e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.61	9.74	0.53	3.67e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.12e-8	Life satisfaction;
KIRP	cis	rs2071426	0.959	rs7913269	chr10:96813932	T/C	cg09036531	chr10:96991505	NA	-0.56	-6.47	-0.38	5.31e-10	Blood metabolite levels;
KIRP	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.67	-10.37	-0.55	3.75e-21	Calcium levels;
KIRP	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg06640241	chr16:89574553	SPG7	0.66	8.7	0.48	4.91e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg10434728	chr15:90938212	IQGAP1	0.42	7.99	0.45	5.1e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.81	7.4	0.43	2.2e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.55	7.46	0.43	1.49e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22591889	chr10:93828960	CPEB3	-0.41	-6.02	-0.36	6.19e-9	Inflammatory biomarkers;
KIRP	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg21747090	chr2:27597821	SNX17	-0.44	-5.84	-0.35	1.69e-8	Total body bone mineral density;
KIRP	cis	rs7707921	0.505	rs12516434	chr5:81428072	T/A	cg15871215	chr5:81402204	ATG10	0.41	4.94	0.3	1.47e-6	Breast cancer;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg23693289	chr8:27183097	PTK2B	0.56	7.12	0.41	1.18e-11	Neuroticism;
KIRP	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.92e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs55986470	0.670	rs6704902	chr2:239417161	G/C	cg08773314	chr2:239334832	ASB1	-0.33	-4.84	-0.3	2.26e-6	Chronotype;
KIRP	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg04132472	chr17:19861366	AKAP10	0.44	6.21	0.37	2.25e-9	Schizophrenia;
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.26	-0.37	1.68e-9	Lung cancer;
KIRP	cis	rs507080	0.769	rs571001	chr11:118500173	C/T	cg04173919	chr11:118528438	PHLDB1	0.35	5.0	0.3	1.08e-6	Serum metabolite levels;
KIRP	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.44	5.92	0.35	1.05e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2733310	0.895	rs7359253	chr15:57114071	C/T	cg13626582	chr15:57592083	LOC283663	0.23	5.14	0.31	5.59e-7	Mean platelet volume;
KIRP	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.4	-4.93	-0.3	1.53e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg14893161	chr1:205819251	PM20D1	-0.55	-5.06	-0.31	8.36e-7	Menarche (age at onset);
KIRP	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-6.23	-0.37	1.98e-9	Lung cancer;
KIRP	cis	rs447921	0.861	rs12949638	chr17:74444758	C/T	cg16776035	chr17:74542680	NA	-0.61	-4.93	-0.3	1.5e-6	Mitochondrial DNA levels;
KIRP	cis	rs3947	0.951	rs1692814	chr8:11704298	T/C	cg21775007	chr8:11205619	TDH	-0.47	-5.03	-0.31	9.65e-7	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.56	0.33	7.12e-8	Breast cancer;
KIRP	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.03	-0.31	9.64e-7	Coronary artery disease;
KIRP	cis	rs9972944	0.756	rs6416948	chr17:63767131	T/G	cg07283582	chr17:63770753	CCDC46	-0.48	-7.95	-0.45	6.9e-14	Total body bone mineral density;
KIRP	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg26554054	chr8:600488	NA	0.66	5.22	0.32	3.86e-7	IgG glycosylation;
KIRP	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.42	0.33	1.46e-7	Blood protein levels;
KIRP	trans	rs6601327	0.665	rs10107992	chr8:9653287	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.43	-0.38	6.7e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	13.89	0.66	9.15e-33	Alzheimer's disease;
KIRP	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.04	-0.46	3.75e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.7	-10.02	-0.54	4.91e-20	Brugada syndrome;
KIRP	cis	rs997295	0.675	rs12902804	chr15:67988658	G/A	cg24579218	chr15:68104479	NA	0.36	5.05	0.31	8.48e-7	Motion sickness;
KIRP	cis	rs12580194	0.593	rs13377995	chr12:55757380	C/G	cg11794356	chr12:55725991	OR6C3	-0.55	-7.7	-0.44	3.25e-13	Cancer;
KIRP	cis	rs3741798	0.908	rs61922046	chr12:12495675	A/T	cg08615371	chr12:12503544	MANSC1	1.01	9.01	0.5	5.8e-17	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg16141378	chr3:129829833	LOC729375	0.46	6.09	0.36	4.27e-9	Mood instability;
KIRP	cis	rs77688320	0.553	rs2540449	chr2:202315759	T/C	cg06431681	chr2:202330990	STRADB	-0.44	-5.15	-0.31	5.22e-7	Breast cancer;
KIRP	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg06243866	chr13:111019493	COL4A2	0.6	7.99	0.45	5.21e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.96	12.86	0.63	2.67e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.85	0.45	1.25e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.71	10.31	0.55	6.03e-21	Oral cavity cancer;
KIRP	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Dermatomyositis;
KIRP	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg06121193	chr1:90282411	NA	-0.51	-7.36	-0.42	2.77e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.13	-0.31	5.81e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.97	-9.68	-0.53	5.39e-19	Multiple sclerosis;
KIRP	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-5.21	-0.31	4.09e-7	Schizophrenia;
KIRP	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.62	8.47	0.48	2.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.66	-9.96	-0.54	7.26e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs883565	0.771	rs1053516	chr3:39137883	G/A	cg01426195	chr3:39028469	NA	-0.67	-10.76	-0.57	2.15e-22	Handedness;
KIRP	cis	rs1538970	0.962	rs9429072	chr1:45810091	C/T	cg05343316	chr1:45956843	TESK2	-0.64	-7.45	-0.43	1.62e-12	Platelet count;
KIRP	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg03060546	chr3:49711283	APEH	0.53	7.17	0.42	8.49e-12	Menarche (age at onset);
KIRP	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg06212747	chr3:49208901	KLHDC8B	0.59	5.54	0.33	7.63e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg21827317	chr3:136751795	NA	0.37	5.18	0.31	4.61e-7	Neuroticism;
KIRP	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.46	6.34	0.37	1.09e-9	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11282895	chr21:34914652	SON;GART	0.48	6.63	0.39	2.06e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26770187	chr3:14693171	C3orf19	0.59	7.24	0.42	5.7e-12	Smoking initiation;
KIRP	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.93	-0.77	6.21e-50	Schizophrenia;
KIRP	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg14196790	chr5:131705035	SLC22A5	0.32	4.87	0.3	2.03e-6	Blood metabolite levels;
KIRP	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs151997	0.962	rs27936	chr5:50181418	T/A	cg06027927	chr5:50259733	NA	0.59	7.41	0.43	2.02e-12	Callous-unemotional behaviour;
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg07051648	chr19:49177693	NTN5;SEC1	-0.44	-5.62	-0.34	5.29e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg04080417	chr5:1859792	NA	-0.53	-6.54	-0.38	3.55e-10	Cardiovascular disease risk factors;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg22907277	chr7:1156413	C7orf50	0.67	6.86	0.4	5.58e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg09408571	chr1:101003634	GPR88	0.27	6.01	0.36	6.49e-9	Monocyte count;
KIRP	trans	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg03225520	chr7:72437350	NA	0.53	6.48	0.38	5.05e-10	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10861342	1.000	rs11112374	chr12:105510285	G/T	cg23923672	chr12:105501055	KIAA1033	0.92	9.36	0.51	5.18e-18	IgG glycosylation;
KIRP	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg07167872	chr1:205819463	PM20D1	-0.53	-5.11	-0.31	6.46e-7	Menarche (age at onset);
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.62	9.44	0.52	3.01e-18	Immature fraction of reticulocytes;
KIRP	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg00629941	chr15:75287862	SCAMP5	-0.52	-5.43	-0.33	1.33e-7	Blood trace element (Zn levels);
KIRP	cis	rs1823913	0.637	rs2883912	chr2:192149016	A/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.32	-0.37	1.22e-9	Obesity-related traits;
KIRP	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.18	0.37	2.68e-9	Height;
KIRP	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	14.04	0.67	2.78e-33	Alzheimer's disease;
KIRP	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg04727924	chr7:799746	HEATR2	0.67	6.08	0.36	4.46e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg07148914	chr20:33460835	GGT7	-0.57	-7.45	-0.43	1.58e-12	Height;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.77	11.67	0.6	2.47e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.13	0.31	5.94e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg21698718	chr17:80085957	CCDC57	0.36	5.17	0.31	4.96e-7	Life satisfaction;
KIRP	cis	rs988913	0.706	rs9382445	chr6:54937974	T/C	cg03513858	chr6:54763001	FAM83B	-0.35	-4.96	-0.3	1.29e-6	Menarche (age at onset);
KIRP	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg09579323	chr1:150459698	TARS2	0.41	5.19	0.31	4.39e-7	Migraine;
KIRP	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg07827796	chr19:33622959	WDR88	0.42	4.92	0.3	1.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg06521331	chr12:34319734	NA	-0.49	-5.88	-0.35	1.36e-8	Morning vs. evening chronotype;
KIRP	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.67	8.89	0.49	1.3e-16	Neuroticism;
KIRP	cis	rs1555895	0.622	rs7703	chr10:858394	C/T	cg10556349	chr10:835070	NA	-0.39	-5.13	-0.31	5.81e-7	Survival in rectal cancer;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg23995744	chr1:43824609	CDC20	-0.58	-6.47	-0.38	5.36e-10	Menopause (age at onset);
KIRP	cis	rs4971059	0.654	rs4971078	chr1:155129023	A/G	cg02153340	chr1:155202674	NA	-0.44	-6.25	-0.37	1.79e-9	Breast cancer;
KIRP	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.48	5.68	0.34	3.77e-8	Uric acid levels;
KIRP	cis	rs10426930	0.607	rs2613768	chr19:5074637	G/A	cg18473234	chr19:5097819	KDM4B	-0.57	-6.31	-0.37	1.31e-9	Monocyte percentage of white cells;
KIRP	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.41	0.38	7.46e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.92	7.57	0.43	7.5e-13	Major depressive disorder;
KIRP	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.05	0.31	8.41e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19269027	chr10:104262383	ACTR1A;SUFU	0.51	6.31	0.37	1.28e-9	Parkinson's disease;
KIRP	cis	rs7178572	0.625	rs12905285	chr15:77845812	T/C	cg12131826	chr15:77904385	NA	0.38	5.17	0.31	4.91e-7	Type 2 diabetes;
KIRP	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.61	-7.16	-0.42	9.41e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg05347473	chr6:146136440	FBXO30	0.61	8.69	0.48	5.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg15432903	chr11:17409602	KCNJ11	0.44	6.2	0.37	2.32e-9	Body mass index;Social communication problems;
KIRP	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.51	6.54	0.38	3.53e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg03929089	chr4:120376271	NA	0.75	6.83	0.4	6.46e-11	Intraocular pressure;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg00024416	chr22:24240387	NA	-0.35	-4.97	-0.3	1.23e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg23950597	chr19:37808831	NA	-0.62	-6.79	-0.4	8.19e-11	Coronary artery calcification;
KIRP	cis	rs4664293	0.836	rs2556102	chr2:160655122	C/T	cg08347373	chr2:160653686	CD302	-0.46	-6.76	-0.4	1.01e-10	Monocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09944325	chr14:75593969	NEK9	0.5	6.24	0.37	1.88e-9	Parkinson's disease;
KIRP	cis	rs8141529	0.600	rs16986838	chr22:29312578	C/T	cg15103426	chr22:29168792	CCDC117	0.52	5.09	0.31	7.27e-7	Lymphocyte counts;
KIRP	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg00262122	chr8:11665843	FDFT1	0.4	5.07	0.31	7.98e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs860295	0.702	rs10908465	chr1:155389688	C/T	cg02153340	chr1:155202674	NA	-0.55	-7.45	-0.43	1.56e-12	Body mass index;
KIRP	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-9.79	-0.53	2.52e-19	Total body bone mineral density;
KIRP	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg14345882	chr6:26364793	BTN3A2	0.66	4.89	0.3	1.81e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg21775007	chr8:11205619	TDH	0.47	6.5	0.38	4.37e-10	Neuroticism;
KIRP	cis	rs1800469	1.000	rs2317130	chr19:41861674	C/T	cg09537434	chr19:41945824	ATP5SL	-0.58	-6.86	-0.4	5.48e-11	Colorectal cancer;
KIRP	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg23307798	chr14:103986281	CKB	-0.51	-6.85	-0.4	6.03e-11	Coronary artery disease;
KIRP	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7737355	1.000	rs798416	chr5:130693100	T/C	cg06307176	chr5:131281290	NA	-0.53	-5.78	-0.35	2.21e-8	Life satisfaction;
KIRP	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg01620082	chr3:125678407	NA	-1.02	-6.59	-0.39	2.65e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6563943	1.000	rs9934700	chr16:83638734	C/T	cg01935413	chr16:83636749	CDH13	0.4	5.58	0.34	6.25e-8	Height;
KIRP	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.543	rs4968095	chr17:507539	A/G	cg15660573	chr17:549704	VPS53	-0.87	-13.35	-0.65	5.93e-31	Prostate cancer;
KIRP	cis	rs3741798	1.000	rs61922023	chr12:12485555	G/A	cg08615371	chr12:12503544	MANSC1	0.94	8.28	0.47	7.84e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	cg07049167	chr1:166818506	POGK	0.45	4.86	0.3	2.05e-6	Refractive astigmatism;
KIRP	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg24110177	chr3:50126178	RBM5	-0.49	-5.94	-0.35	9.78e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6580649	0.831	rs4760620	chr12:48559642	A/G	cg26205652	chr12:48591994	NA	0.5	5.89	0.35	1.24e-8	Lung cancer;
KIRP	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	10.49	0.56	1.56e-21	Electrocardiographic conduction measures;
KIRP	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	4.93	0.3	1.51e-6	Rheumatoid arthritis;
KIRP	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.16	0.61	5.99e-27	Cannabis dependence symptom count;
KIRP	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg05044414	chr3:183734942	ABCC5	0.36	5.4	0.33	1.59e-7	Anterior chamber depth;
KIRP	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.95	14.5	0.68	7.56e-35	Multiple system atrophy;
KIRP	cis	rs12311304	1.000	rs11056409	chr12:15382567	T/C	cg08258403	chr12:15378311	NA	0.38	5.59	0.34	6.15e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.56	7.29	0.42	4.17e-12	Multiple sclerosis;
KIRP	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.53	7.2	0.42	7.19e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.74	10.67	0.56	4.26e-22	Parkinson's disease;
KIRP	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.54	-0.38	3.54e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.54	-0.33	7.77e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08052428	chr9:135996421	RALGDS	0.69	6.66	0.39	1.77e-10	Lung function (FEV1);
KIRP	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	0.84	10.34	0.55	4.85e-21	Prostate cancer;
KIRP	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg00129232	chr17:37814104	STARD3	-0.8	-11.77	-0.6	1.13e-25	Asthma;
KIRP	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	1.04	13.73	0.66	3.07e-32	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.3	-6.89	-0.4	4.68e-11	Mean corpuscular volume;
KIRP	cis	rs13401104	0.680	rs11680714	chr2:237142605	A/G	cg26422059	chr2:237146110	ASB18	0.51	5.22	0.32	3.77e-7	Educational attainment;
KIRP	trans	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg00405596	chr8:11794950	NA	-0.47	-6.13	-0.36	3.46e-9	Joint mobility (Beighton score);
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.6	9.31	0.51	7.23e-18	Lung cancer;
KIRP	cis	rs6910061	1.000	rs13214777	chr6:11103597	C/G	cg27233058	chr6:11094804	LOC221710	0.57	5.76	0.34	2.46e-8	Diabetic kidney disease;
KIRP	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg23442198	chr4:187126114	CYP4V2	0.77	7.07	0.41	1.6e-11	Blood protein levels;
KIRP	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Corneal astigmatism;
KIRP	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg10253484	chr15:75165896	SCAMP2	-0.52	-6.03	-0.36	6.05e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg08975724	chr8:8085496	FLJ10661	0.58	7.68	0.44	3.86e-13	Neuroticism;
KIRP	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg07701084	chr6:150067640	NUP43	0.54	6.97	0.41	2.87e-11	Lung cancer;
KIRP	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg15880211	chr22:50250494	ZBED4	-0.49	-5.53	-0.33	8.03e-8	Schizophrenia;
KIRP	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.44	6.31	0.37	1.28e-9	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.75	-0.34	2.6e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.64	8.3	0.47	7.09e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs34779708	0.733	rs12254018	chr10:35550641	T/A	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.54	-10.21	-0.55	1.21e-20	Iron status biomarkers (transferrin levels);
KIRP	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.52	-7.12	-0.41	1.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	0.72	10.47	0.56	1.93e-21	Height;
KIRP	cis	rs2151522	0.603	rs9375464	chr6:127167231	A/G	cg21431617	chr6:127135037	NA	0.31	5.44	0.33	1.29e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.81	0.53	2.12e-19	Monocyte percentage of white cells;
KIRP	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.45	-0.55	2.24e-21	Chronic sinus infection;
KIRP	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.86	10.16	0.54	1.75e-20	Corneal astigmatism;
KIRP	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.83	-6.72	-0.39	1.28e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7737355	1.000	rs76753180	chr5:130763701	A/T	cg25547332	chr5:131281432	NA	-0.49	-5.47	-0.33	1.13e-7	Life satisfaction;
KIRP	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-12.63	-0.63	1.57e-28	Alzheimer's disease;
KIRP	trans	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg03929089	chr4:120376271	NA	0.84	6.18	0.37	2.6e-9	Axial length;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06665941	chr21:34602869	IFNAR2	0.52	7.1	0.41	1.36e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.92	-10.53	-0.56	1.16e-21	White matter hyperintensity burden;
KIRP	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg08648136	chr8:956695	NA	0.43	6.61	0.39	2.31e-10	Schizophrenia;
KIRP	cis	rs72730918	0.590	rs2606138	chr15:51967093	C/G	cg14296394	chr15:51910925	DMXL2	-0.76	-10.69	-0.56	3.7e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.509	rs11576882	chr1:152918785	T/G	cg13444842	chr1:152974279	SPRR3	-0.47	-6.72	-0.39	1.28e-10	Inflammatory skin disease;
KIRP	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg06740227	chr12:86229804	RASSF9	0.44	5.53	0.33	8.21e-8	Major depressive disorder;
KIRP	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg21184320	chr1:21044207	KIF17	0.5	7.05	0.41	1.82e-11	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg00857998	chr1:205179979	DSTYK	0.64	7.9	0.45	9.33e-14	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.67	7.27	0.42	4.82e-12	Vitiligo;
KIRP	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.49	6.12	0.36	3.68e-9	Type 2 diabetes;
KIRP	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg05163923	chr11:71159392	DHCR7	1.0	13.38	0.65	4.71e-31	Vitamin D levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12951224	chr8:38126910	PPAPDC1B	0.56	6.47	0.38	5.26e-10	Smoking initiation;
KIRP	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg18190219	chr22:46762943	CELSR1	-0.93	-7.41	-0.43	2.06e-12	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg05059571	chr16:84539110	KIAA1609	0.58	7.84	0.45	1.39e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg20585916	chr4:186081460	KIAA1430	0.38	6.04	0.36	5.56e-9	C-reactive protein;
KIRP	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg25767906	chr1:53392781	SCP2	-0.35	-4.97	-0.3	1.23e-6	Monocyte count;
KIRP	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg21775007	chr8:11205619	TDH	0.43	5.42	0.33	1.43e-7	Monocyte count;
KIRP	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.41	-0.43	2.01e-12	Retinal vascular caliber;
KIRP	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	5.31	0.32	2.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	0.94	6.67	0.39	1.71e-10	IgG glycosylation;
KIRP	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05220968	chr6:146057943	EPM2A	-0.4	-5.07	-0.31	7.68e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.61	-7.27	-0.42	4.9e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.65	-9.32	-0.51	7.09e-18	Retinal vascular caliber;
KIRP	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg23649088	chr2:200775458	C2orf69	-0.59	-6.33	-0.37	1.15e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.16	0.31	5.08e-7	Smoking behavior;
KIRP	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg13395646	chr4:1353034	KIAA1530	-0.37	-5.05	-0.31	8.6e-7	Obesity-related traits;
KIRP	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg10755058	chr3:40428713	ENTPD3	-0.39	-5.82	-0.35	1.81e-8	Renal cell carcinoma;
KIRP	cis	rs6575793	0.967	rs11845605	chr14:101037726	C/T	cg18516195	chr14:101012996	BEGAIN	-0.5	-7.19	-0.42	7.82e-12	Menarche (age at onset);
KIRP	cis	rs2224391	0.628	rs2773317	chr6:5254509	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.52	-0.38	4e-10	Height;
KIRP	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.2	27.29	0.87	2.22e-76	Schizophrenia;
KIRP	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.72	-10.6	-0.56	7.44e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg05802129	chr4:122689817	NA	0.55	7.15	0.41	9.78e-12	Type 2 diabetes;
KIRP	cis	rs7520050	0.966	rs12144263	chr1:46352446	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.44	-0.65	3.06e-31	Height;
KIRP	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-6.3	-0.37	1.38e-9	Initial pursuit acceleration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13921570	chr2:74730534	LOC151534;LBX2	0.52	6.83	0.4	6.73e-11	Smoking initiation;
KIRP	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg21918786	chr6:109611834	NA	-0.38	-5.65	-0.34	4.5e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg15068132	chr12:102092402	CHPT1	0.38	4.88	0.3	1.89e-6	Blood protein levels;
KIRP	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.66	-10.14	-0.54	2.02e-20	Menopause (age at onset);
KIRP	cis	rs12145833	0.538	rs10926977	chr1:243411367	T/G	cg02356786	chr1:243265016	LOC731275	0.91	6.47	0.38	5.21e-10	Obesity (early onset extreme);
KIRP	cis	rs7224685	0.569	rs7215798	chr17:4007666	C/G	cg05562828	chr17:3906858	NA	-0.53	-5.59	-0.34	5.87e-8	Type 2 diabetes;
KIRP	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	8.0	0.45	4.9e-14	Multiple sclerosis;
KIRP	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg02297831	chr4:17616191	MED28	0.59	7.56	0.43	7.92e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-4.88	-0.3	1.92e-6	Breast cancer;Mosquito bite size;
KIRP	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg02753203	chr1:228287806	NA	0.7	9.4	0.51	4e-18	Diastolic blood pressure;
KIRP	cis	rs6450176	0.909	rs11742688	chr5:53291081	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-10.87	-0.57	9.56e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg08400319	chr2:242004533	SNED1	0.46	6.39	0.38	8.1e-10	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg21851534	chr17:3907994	ZZEF1	0.66	10.58	0.56	8.25e-22	Type 2 diabetes;
KIRP	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg02696742	chr7:106810147	HBP1	-0.75	-7.69	-0.44	3.51e-13	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22368307	chr11:75110460	SNORD15A;RPS3	-0.46	-6.19	-0.37	2.45e-9	Survival in pancreatic cancer;
KIRP	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg09873164	chr1:152488093	CRCT1	-0.51	-6.43	-0.38	6.44e-10	Hair morphology;
KIRP	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.77	-8.34	-0.47	5.4e-15	Asthma;
KIRP	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.57	8.16	0.46	1.78e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg15038512	chr6:170123185	PHF10	0.47	5.24	0.32	3.39e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	9.59	0.52	1.03e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg09873164	chr1:152488093	CRCT1	0.52	6.54	0.38	3.5e-10	Hair morphology;
KIRP	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	1.0	17.39	0.74	1.03e-44	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16976116	0.901	rs28714578	chr15:55491121	G/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.33e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg02725872	chr8:58115012	NA	-0.53	-5.87	-0.35	1.42e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.65	-7.22	-0.42	6.35e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg08975724	chr8:8085496	FLJ10661	0.58	7.03	0.41	2.08e-11	Retinal vascular caliber;
KIRP	cis	rs11731606	0.508	rs28623728	chr4:95290861	C/T	cg20625393	chr4:95128694	SMARCAD1	0.53	5.09	0.31	7.06e-7	Mean platelet volume;
KIRP	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.54	-0.43	8.86e-13	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13343549	chr17:80983747	B3GNTL1	0.46	6.32	0.37	1.24e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.55	7.58	0.44	6.99e-13	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03120789	chr1:20208808	OTUD3	0.53	6.34	0.37	1.08e-9	Smoking initiation;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23535261	chr10:93038124	PCGF5	0.46	7.28	0.42	4.39e-12	Migraine with aura;
KIRP	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.62	-5.93	-0.35	9.99e-9	Breast cancer;
KIRP	cis	rs10875746	0.903	rs725454	chr12:48502100	A/G	cg26205652	chr12:48591994	NA	0.77	10.32	0.55	5.62e-21	Longevity (90 years and older);
KIRP	cis	rs11710088	0.740	rs10935760	chr3:149193423	C/G	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.49	-0.33	9.76e-8	QRS duration;
KIRP	cis	rs11628318	0.901	rs4900545	chr14:103051132	C/T	cg01864069	chr14:103024347	NA	-0.8	-10.7	-0.56	3.56e-22	Platelet count;
KIRP	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg24631222	chr15:78858424	CHRNA5	0.95	13.19	0.64	2.05e-30	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs258892	0.793	rs56762233	chr5:72056882	A/G	cg21869765	chr5:72125136	TNPO1	-0.52	-5.66	-0.34	4.17e-8	Small cell lung carcinoma;
KIRP	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.75	-9.0	-0.5	6.14e-17	Response to antipsychotic treatment;
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg03188948	chr7:1209495	NA	0.76	5.06	0.31	8.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.64	0.71	9.78e-39	Platelet count;
KIRP	trans	rs7246760	1.000	rs7246772	chr19:9886283	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.06	-0.54	3.62e-20	Pursuit maintenance gain;
KIRP	cis	rs10214930	0.697	rs1524532	chr7:27625686	G/T	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.04	-13.22	-0.64	1.67e-30	Exhaled nitric oxide output;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.84	12.7	0.63	9.61e-29	Menarche (age at onset);
KIRP	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg13482628	chr17:19912719	NA	0.53	6.82	0.4	6.89e-11	Schizophrenia;
KIRP	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg05673287	chr15:77411982	SGK269	-0.38	-4.89	-0.3	1.78e-6	Type 2 diabetes;
KIRP	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg03959625	chr15:84868606	LOC388152	0.71	8.47	0.48	2.22e-15	Schizophrenia;
KIRP	cis	rs593254	0.771	rs6455931	chr6:164392453	C/T	cg00040411	chr6:164393165	NA	-0.48	-5.42	-0.33	1.45e-7	Gestational age at birth in labor-initiated deliveries (maternal effect);
KIRP	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs2425143	1.000	rs57963833	chr20:34344225	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-4.98	-0.3	1.18e-6	Blood protein levels;
KIRP	cis	rs6977660	0.660	rs12531296	chr7:19816450	A/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs8133932	0.654	rs420386	chr21:47364816	G/A	cg11214348	chr21:47283868	PCBP3	-0.47	-5.38	-0.32	1.71e-7	Schizophrenia;
KIRP	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00300879	chr1:26503847	CNKSR1	0.46	6.63	0.39	2.15e-10	Height;
KIRP	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg03702533	chr15:77830579	NA	0.32	4.88	0.3	1.91e-6	Type 2 diabetes;
KIRP	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.1	0.36	4.12e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	9.75	0.53	3.47e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	6.71	0.39	1.35e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2652822	0.967	rs1472631	chr15:63423739	A/G	cg02713581	chr15:63449717	RPS27L	0.62	7.26	0.42	5.16e-12	Metabolic traits;
KIRP	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.84	10.35	0.55	4.49e-21	Sudden cardiac arrest;
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg04080417	chr5:1859792	NA	-0.64	-8.19	-0.46	1.46e-14	Cardiovascular disease risk factors;
KIRP	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1050631	0.960	rs3826603	chr18:33688370	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	6.25	0.37	1.8e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg27189623	chr16:705930	WDR90	0.44	6.1	0.36	4.15e-9	Height;
KIRP	cis	rs12096438	1.000	rs4603124	chr1:25893243	G/A	cg21452808	chr1:25900135	NA	0.37	5.7	0.34	3.47e-8	Platelet count;Mean platelet volume;
KIRP	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.46	5.22	0.32	3.76e-7	Schizophrenia;
KIRP	cis	rs8084125	0.832	rs56301307	chr18:74942711	A/G	cg18461021	chr18:74961002	GALR1	0.53	5.33	0.32	2.21e-7	Obesity-related traits;
KIRP	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06481639	chr22:41940642	POLR3H	-0.62	-5.72	-0.34	3.06e-8	Vitiligo;
KIRP	cis	rs6684514	0.922	rs12022657	chr1:156314147	A/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.9	-0.35	1.19e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg19847130	chr8:10466454	RP1L1	-0.39	-5.81	-0.35	1.93e-8	Neuroticism;
KIRP	cis	rs35264875	1.000	rs72919415	chr11:68827082	G/A	cg01403660	chr11:68851641	TPCN2	0.65	6.09	0.36	4.23e-9	Blond vs. brown hair color;
KIRP	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	8.27	0.47	8.36e-15	Lung cancer in ever smokers;
KIRP	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.52	-6.93	-0.4	3.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1978968	1.000	rs1076541	chr22:18440026	C/T	cg02610425	chr22:18483192	MICAL3	0.41	5.44	0.33	1.28e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.66	8.98	0.5	7.22e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.02	0.41	2.19e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg26248373	chr2:1572462	NA	-0.62	-5.82	-0.35	1.86e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg23307798	chr14:103986281	CKB	0.74	11.56	0.59	5.47e-25	Body mass index;
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg19893067	chr17:80732956	TBCD	-0.36	-4.94	-0.3	1.42e-6	Glycated hemoglobin levels;
KIRP	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg00852783	chr1:26633632	UBXN11	-0.44	-5.14	-0.31	5.73e-7	Obesity-related traits;
KIRP	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.5	7.03	0.41	2.01e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.45	-6.79	-0.4	8.33e-11	Coronary artery disease;
KIRP	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg09699651	chr6:150184138	LRP11	0.59	8.17	0.46	1.6e-14	Testicular germ cell tumor;
KIRP	cis	rs17095355	1.000	rs1376111	chr10:111707255	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.44	-6.42	-0.38	6.93e-10	Biliary atresia;
KIRP	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg13978929	chr19:21580086	ZNF493	-0.51	-5.05	-0.31	8.53e-7	Pain;
KIRP	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg02336718	chr17:17403227	NA	0.3	4.86	0.3	2.14e-6	Total body bone mineral density;
KIRP	cis	rs12431939	1.000	rs67113863	chr14:51653103	G/C	cg23942311	chr14:51606299	NA	-0.6	-5.22	-0.32	3.8e-7	Cancer;
KIRP	cis	rs7633770	0.735	rs12491236	chr3:46688481	C/T	cg11219411	chr3:46661640	NA	-0.42	-5.56	-0.33	6.9e-8	Coronary artery disease;
KIRP	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg27205649	chr11:78285834	NARS2	-0.5	-5.59	-0.34	6.12e-8	Testicular germ cell tumor;
KIRP	cis	rs2860975	1.000	rs10882514	chr10:96782898	T/C	cg09036531	chr10:96991505	NA	-0.52	-6.59	-0.39	2.65e-10	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	0.43	5.01	0.3	1.06e-6	Resistin levels;
KIRP	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-7.01	-0.41	2.32e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg19847866	chr10:1019161	NA	-0.61	-5.52	-0.33	8.64e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg03647239	chr10:116582469	FAM160B1	0.5	5.94	0.35	9.7e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4523957	0.614	rs7217108	chr17:2059408	G/C	cg16513277	chr17:2031491	SMG6	-0.78	-11.0	-0.57	3.82e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg07068956	chr7:100330872	ZAN	-0.57	-6.23	-0.37	2.01e-9	Other erythrocyte phenotypes;
KIRP	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg03609598	chr5:56110824	MAP3K1	0.47	5.4	0.33	1.57e-7	Initial pursuit acceleration;
KIRP	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg15841412	chr13:111365552	ING1	0.49	5.61	0.34	5.41e-8	Coronary artery disease;
KIRP	cis	rs13401104	0.796	rs1073463	chr2:237118096	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs2019216	0.500	rs12946184	chr17:21944675	A/C	cg22648282	chr17:21454238	C17orf51	-0.46	-4.99	-0.3	1.17e-6	Pelvic organ prolapse;
KIRP	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.6	-0.34	5.8e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg26513180	chr16:89883248	FANCA	0.75	5.3	0.32	2.58e-7	Skin colour saturation;
KIRP	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25359666	chr3:32544162	CMTM6	0.52	6.78	0.4	8.71e-11	Parkinson's disease;
KIRP	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.36	5.4	0.33	1.55e-7	Eye color traits;
KIRP	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg27205649	chr11:78285834	NARS2	0.82	10.44	0.55	2.28e-21	Alzheimer's disease (survival time);
KIRP	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg19847130	chr8:10466454	RP1L1	0.36	5.51	0.33	9.13e-8	Retinal vascular caliber;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg06815112	chr8:27182871	PTK2B	0.51	6.62	0.39	2.27e-10	Neuroticism;
KIRP	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.81	-8.33	-0.47	5.59e-15	Schizophrenia;
KIRP	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.12	-0.31	6.14e-7	Breast cancer;
KIRP	cis	rs6991838	0.584	rs3812412	chr8:66547092	G/A	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg06223162	chr1:101003688	GPR88	0.45	9.36	0.51	5.06e-18	Monocyte count;
KIRP	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.97	11.72	0.6	1.63e-25	Corneal astigmatism;
KIRP	cis	rs6681460	1.000	rs7521123	chr1:67121663	T/C	cg13052034	chr1:66999238	SGIP1	0.44	6.21	0.37	2.19e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs739496	0.518	rs10744775	chr12:112096215	T/C	cg19993006	chr12:111807180	FAM109A	0.43	4.88	0.3	1.87e-6	Platelet count;
KIRP	cis	rs2278796	0.752	rs6677763	chr1:204951540	A/G	cg17947172	chr1:204966197	NFASC	0.4	5.56	0.33	6.9e-8	Mean platelet volume;
KIRP	cis	rs4862307	0.836	rs4643860	chr4:184997945	T/C	cg06737308	chr4:185021514	ENPP6	-0.53	-6.74	-0.39	1.1e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-6.81	-0.4	7.57e-11	Fear of minor pain;
KIRP	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg00677455	chr12:58241039	CTDSP2	-0.53	-5.85	-0.35	1.54e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg02375832	chr11:62437615	C11orf48	-0.42	-5.3	-0.32	2.55e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg24009623	chr19:33667908	NA	0.48	5.85	0.35	1.55e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg17366294	chr4:99064904	C4orf37	0.45	5.4	0.33	1.55e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg12315302	chr6:26189340	HIST1H4D	1.09	6.04	0.36	5.66e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.62	8.83	0.49	2.01e-16	Bladder cancer;
KIRP	cis	rs3784262	0.669	rs4646555	chr15:58355345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.85	-0.3	2.2e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg07395648	chr5:131743802	NA	0.54	7.72	0.44	2.99e-13	Breast cancer;
KIRP	cis	rs2574975	0.509	rs1203404	chr10:52199096	C/T	cg10034176	chr10:52120283	SGMS1	0.4	5.74	0.34	2.71e-8	Response to amphetamines;
KIRP	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.09	0.36	4.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.84	10.22	0.55	1.12e-20	Homoarginine levels;
KIRP	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs742134	1.000	rs2413748	chr22:43530982	C/T	cg26453588	chr22:43506021	BIK	-0.37	-5.31	-0.32	2.48e-7	Prostate cancer;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg08298555	chr16:1260656	CACNA1H	0.47	6.43	0.38	6.41e-10	Morning vs. evening chronotype;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19531713	chr17:41277059	BRCA1;NBR2	0.58	7.04	0.41	1.89e-11	Smoking initiation;
KIRP	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.86	-12.28	-0.62	2.39e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.9	10.55	0.56	1.06e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs1318772	0.932	rs13171273	chr5:112907809	A/G	cg12552261	chr5:112820674	MCC	0.87	5.02	0.31	9.77e-7	F-cell distribution;
KIRP	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg08885076	chr2:99613938	TSGA10	-0.42	-6.1	-0.36	4.11e-9	Fear of minor pain;
KIRP	cis	rs7221595	0.825	rs62072392	chr17:3910125	A/G	cg09597638	chr17:3907349	NA	0.6	6.13	0.36	3.56e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2273669	0.667	rs1424479	chr6:109355790	G/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg02160872	chr5:212506	CCDC127	-0.46	-5.15	-0.31	5.41e-7	Breast cancer;
KIRP	cis	rs9761603	0.570	rs61326094	chr4:138412210	C/T	cg12033966	chr4:138453416	PCDH18	0.43	5.8	0.35	2.08e-8	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19234591	chr1:26632948	UBXN11	0.55	7.19	0.42	7.73e-12	Parkinson's disease;
KIRP	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg24826892	chr11:71159390	DHCR7	0.44	4.87	0.3	1.99e-6	Vitamin D levels;
KIRP	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg08313168	chr12:7315531	NA	0.72	6.59	0.39	2.71e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4704187	0.687	rs1600074	chr5:74436574	C/T	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg10645314	chr2:3704589	ALLC	-0.42	-5.36	-0.32	1.92e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs4690686	0.808	rs6553945	chr4:177270965	T/C	cg17059388	chr4:177262070	NA	0.57	8.05	0.46	3.57e-14	Essential tremor;
KIRP	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.54	-8.7	-0.49	4.73e-16	Schizophrenia;
KIRP	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg22117172	chr7:91764530	CYP51A1	-0.39	-5.54	-0.33	7.58e-8	Breast cancer;
KIRP	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.5	7.05	0.41	1.75e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.86	-0.57	1.06e-22	Height;
KIRP	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg13165212	chr22:42675999	NA	0.29	5.06	0.31	8.09e-7	Cognitive function;
KIRP	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.64	0.52	7.35e-19	Bipolar disorder;
KIRP	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg08700190	chr5:6636046	SRD5A1	-0.43	-5.22	-0.32	3.88e-7	Response to amphetamines;
KIRP	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs55986470	0.630	rs67981771	chr2:239402647	C/T	cg18131467	chr2:239335373	ASB1	-0.56	-5.72	-0.34	3.09e-8	Chronotype;
KIRP	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.81	-13.24	-0.65	1.38e-30	Idiopathic membranous nephropathy;
KIRP	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg15691649	chr6:25882328	NA	-0.42	-5.13	-0.31	5.92e-7	Blood metabolite levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10163397	chr8:41909456	MYST3	-0.45	-6.05	-0.36	5.38e-9	Metabolic traits;
KIRP	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-4.95	-0.3	1.38e-6	Menarche (age at onset);
KIRP	cis	rs11225247	0.881	rs11603677	chr11:102259992	A/T	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg04080417	chr5:1859792	NA	-0.63	-8.09	-0.46	2.77e-14	Cardiovascular disease risk factors;
KIRP	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05665937	chr4:1216051	CTBP1	0.5	7.11	0.41	1.28e-11	Obesity-related traits;
KIRP	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg20493526	chr2:3714936	ALLC	0.4	4.99	0.3	1.12e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05601917	chr6:125855416	NA	-0.33	-4.84	-0.3	2.26e-6	Brugada syndrome;
KIRP	trans	rs10874322	0.867	rs11587975	chr1:83047290	C/G	cg12753787	chr1:3239712	PRDM16	0.66	6.53	0.38	3.83e-10	Response to taxane treatment (docetaxel);
KIRP	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.64	7.56	0.43	8.09e-13	Type 2 diabetes;
KIRP	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg18032289	chr17:61959525	GH2	-0.39	-5.01	-0.3	1.03e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2742234	0.614	rs3026750	chr10:43607756	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.61	-7.24	-0.42	5.67e-12	Hirschsprung disease;
KIRP	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.68	-0.34	3.84e-8	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23043205	chr1:164699955	PBX1	0.44	6.38	0.38	8.83e-10	Interleukin-4 levels;
KIRP	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.94	-15.88	-0.71	1.47e-39	Height;
KIRP	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg12861170	chr19:19639553	YJEFN3	-0.45	-4.86	-0.3	2.06e-6	Bipolar disorder;
KIRP	cis	rs72843166	0.617	rs17760362	chr17:61418667	T/A	cg19683800	chr17:61518354	CYB561	-0.42	-5.26	-0.32	3.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.83	11.27	0.58	4.86e-24	Morning vs. evening chronotype;
KIRP	cis	rs2057178	0.860	rs7123725	chr11:32355336	G/T	cg05837727	chr11:32355149	NA	0.43	5.2	0.31	4.16e-7	Tuberculosis;
KIRP	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.54	6.77	0.4	9.63e-11	Cognitive test performance;
KIRP	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg08885076	chr2:99613938	TSGA10	-0.42	-6.36	-0.38	9.85e-10	Fear of minor pain;
KIRP	cis	rs7267005	0.661	rs2425099	chr20:34309643	T/C	cg17201900	chr20:34330562	RBM39	0.96	6.0	0.36	7.12e-9	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.53	-0.38	3.72e-10	Mood instability;
KIRP	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg20578329	chr17:80767326	TBCD	0.68	7.57	0.43	7.28e-13	Breast cancer;
KIRP	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.6	-6.74	-0.39	1.13e-10	Hypertension (SNP x SNP interaction);
KIRP	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.22	-0.58	7.37e-24	Body mass index;
KIRP	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg18154014	chr19:37997991	ZNF793	0.68	6.1	0.36	4.08e-9	Coronary artery calcification;
KIRP	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.4	-0.33	1.56e-7	Personality dimensions;
KIRP	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg18477163	chr1:228402036	OBSCN	0.29	5.44	0.33	1.28e-7	Diastolic blood pressure;
KIRP	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg27426351	chr10:43362370	NA	0.45	6.27	0.37	1.63e-9	Blood protein levels;
KIRP	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.62	12.13	0.61	7.46e-27	Bone mineral density;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg23719950	chr11:63933701	MACROD1	-0.63	-5.39	-0.32	1.67e-7	Mean platelet volume;
KIRP	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18364779	chr6:26104403	HIST1H4C	0.62	8.05	0.46	3.58e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.85	-0.63	3.04e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs6142102	1.000	rs6059672	chr20:32705468	A/G	cg08999081	chr20:33150536	PIGU	0.49	5.78	0.35	2.21e-8	Skin pigmentation;
KIRP	cis	rs4713118	0.696	rs2394002	chr6:27748015	G/A	cg20933634	chr6:27740509	NA	0.37	4.88	0.3	1.9e-6	Parkinson's disease;
KIRP	cis	rs580438	0.530	rs9850371	chr3:13425999	A/C	cg10657019	chr3:13328039	NA	-0.6	-7.95	-0.45	6.79e-14	Myringotomy;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.76	-0.4	9.75e-11	Longevity;
KIRP	cis	rs9309473	0.898	rs11126403	chr2:73796923	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-4.93	-0.3	1.5e-6	Metabolite levels;
KIRP	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.51	-7.73	-0.44	2.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs57590327	0.516	rs66665538	chr3:81796391	T/A	cg07356753	chr3:81810745	GBE1	-0.71	-7.33	-0.42	3.31e-12	Extraversion;
KIRP	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg20965017	chr5:231967	SDHA	-0.54	-6.23	-0.37	1.96e-9	Breast cancer;
KIRP	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.68	-0.34	3.72e-8	Bipolar disorder;
KIRP	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg22771759	chr13:24902376	NA	-0.45	-5.67	-0.34	3.97e-8	Obesity-related traits;
KIRP	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.57	-7.69	-0.44	3.52e-13	Glycated hemoglobin levels;
KIRP	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg08700190	chr5:6636046	SRD5A1	-0.49	-6.36	-0.38	9.61e-10	Response to amphetamines;
KIRP	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.71	-0.44	3.05e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.48	0.33	1.03e-7	Coronary artery disease;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg01391022	chr12:122360665	WDR66	-0.36	-5.23	-0.32	3.63e-7	Mean corpuscular volume;
KIRP	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.49	4.28e-16	Retinal vascular caliber;
KIRP	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.48	7.08	0.41	1.49e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.41	-0.78	1.56e-51	Schizophrenia;
KIRP	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.47	0.48	2.25e-15	Bipolar disorder;
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg21698718	chr17:80085957	CCDC57	-0.34	-4.93	-0.3	1.52e-6	Life satisfaction;
KIRP	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg11707556	chr5:10655725	ANKRD33B	0.56	7.1	0.41	1.32e-11	Coronary artery disease;
KIRP	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg06115741	chr20:33292138	TP53INP2	0.42	5.75	0.34	2.63e-8	Coronary artery disease;
KIRP	cis	rs6088813	1.000	rs6142370	chr20:33973378	G/A	cg14752227	chr20:34000481	UQCC	-0.52	-6.86	-0.4	5.42e-11	Height;
KIRP	cis	rs73198271	0.710	rs11779565	chr8:8680020	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.44	-0.38	6.07e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.78	-13.08	-0.64	5.02e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4664293	0.867	rs6760485	chr2:160579690	T/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs7116495	1.000	rs2511076	chr11:71783827	A/G	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg01877450	chr7:97915802	BRI3	-0.55	-7.15	-0.42	9.61e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.73	7.98	0.45	5.66e-14	Corneal astigmatism;
KIRP	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg00334542	chr7:100209784	MOSPD3	-0.79	-6.42	-0.38	7.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6681460	0.932	rs523956	chr1:67188276	A/G	cg02459107	chr1:67143332	SGIP1	-0.4	-5.86	-0.35	1.49e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13370754	chr5:80795179	SSBP2	-0.46	-7.42	-0.43	1.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.46	6.08	0.36	4.45e-9	Testicular germ cell tumor;
KIRP	cis	rs11209185	0.563	rs4655763	chr1:68438400	G/A	cg22082780	chr1:68452167	NA	-0.34	-5.15	-0.31	5.28e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06175825	chr1:55007736	NA	0.41	6.02	0.36	6.29e-9	Survival in pancreatic cancer;
KIRP	trans	rs12286929	0.651	rs12274772	chr11:115098768	C/T	cg06535942	chr6:107435516	BEND3	-0.48	-6.03	-0.36	6.02e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.9	15.89	0.71	1.33e-39	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.36	0.47	4.78e-15	IgG glycosylation;
KIRP	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02034447	chr16:89574710	SPG7	0.38	4.87	0.3	1.96e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.3	13.31	0.65	8.57e-31	Diabetic retinopathy;
KIRP	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.8	9.0	0.5	6.31e-17	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg02733842	chr7:1102375	C7orf50	0.58	5.92	0.35	1.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.67	-9.52	-0.52	1.73e-18	Facial morphology (factor 21, depth of nasal alae);
KIRP	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg18944383	chr4:111397179	ENPEP	0.6	10.85	0.57	1.16e-22	Height;
KIRP	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.83	-0.45	1.45e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg06219351	chr7:158114137	PTPRN2	0.56	7.96	0.45	6.18e-14	Calcium levels;
KIRP	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg00122941	chr17:4613640	ARRB2	-0.56	-6.39	-0.38	8.3e-10	Lymphocyte counts;
KIRP	cis	rs6838801	0.675	rs13125913	chr4:77535836	A/G	cg17476223	chr4:77663285	SHROOM3	0.41	5.8	0.35	1.98e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs7246657	0.508	rs10419845	chr19:37491192	G/T	cg23950597	chr19:37808831	NA	-0.69	-5.5	-0.33	9.52e-8	Coronary artery calcification;
KIRP	cis	rs4849845	0.889	rs7574745	chr2:121020802	C/T	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs11203032	0.831	rs7902290	chr10:90931602	T/C	cg16672925	chr10:90967113	CH25H	0.43	5.12	0.31	6.19e-7	Heart failure;
KIRP	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg06115741	chr20:33292138	TP53INP2	0.38	5.17	0.31	4.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg14338887	chr6:42928500	GNMT	-0.5	-7.54	-0.43	9.01e-13	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9436747	0.566	rs112314233	chr1:65973295	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.45	-0.33	1.23e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.81	-11.7	-0.6	1.96e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg23625390	chr15:77176239	SCAPER	0.46	6.03	0.36	5.82e-9	Blood metabolite levels;
KIRP	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg08133631	chr1:26527909	CATSPER4	-0.44	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.37	-5.53	-0.33	8.11e-8	Coronary artery disease;
KIRP	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg00800038	chr16:89945340	TCF25	-0.68	-5.0	-0.3	1.1e-6	Skin colour saturation;
KIRP	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.67	8.56	0.48	1.2e-15	Gestational age at birth (maternal effect);
KIRP	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.42	-5.97	-0.36	8.17e-9	Height;
KIRP	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.47	-7.96	-0.45	6.52e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.65	9.27	0.51	1.01e-17	Alcohol dependence;
KIRP	cis	rs12318506	0.826	rs35933860	chr12:75731821	A/G	cg04728562	chr12:75699417	CAPS2	-1.31	-8.78	-0.49	2.76e-16	Coronary artery calcification;
KIRP	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.63	-10.14	-0.54	2.1e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-4.85	-0.3	2.17e-6	Platelet distribution width;
KIRP	cis	rs96067	0.805	rs4653160	chr1:36599547	C/T	cg27506609	chr1:36549197	TEKT2	-0.49	-5.99	-0.36	7.28e-9	Corneal structure;
KIRP	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.15	-0.42	9.62e-12	Longevity;
KIRP	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg10189774	chr4:17578691	LAP3	-0.44	-5.32	-0.32	2.34e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6893300	0.542	rs3797774	chr5:179193970	C/T	cg14593053	chr5:179126677	CANX	0.75	11.54	0.59	6.49e-25	Resting heart rate;
KIRP	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.63e-13	IgG glycosylation;
KIRP	cis	rs10899021	1.000	rs11236202	chr11:74376692	A/G	cg25880958	chr11:74394337	NA	-0.64	-5.02	-0.3	9.88e-7	Response to metformin (IC50);
KIRP	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05776053	chr2:74358815	NA	0.47	4.9	0.3	1.76e-6	Gestational age at birth (maternal effect);
KIRP	cis	rs853679	0.546	rs200989	chr6:27816442	A/G	cg21204522	chr6:27730016	NA	-0.73	-5.36	-0.32	1.95e-7	Depression;
KIRP	cis	rs662064	0.926	rs589400	chr1:10561282	A/G	cg19773385	chr1:10388646	KIF1B	-0.44	-5.72	-0.34	3e-8	Asthma;
KIRP	cis	rs10929159	0.928	rs3738993	chr2:236918671	C/T	cg20128773	chr2:236923534	AGAP1	0.3	5.18	0.31	4.66e-7	Parkinson's disease;
KIRP	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg27432699	chr2:27873401	GPN1	-0.59	-7.61	-0.44	5.81e-13	Total body bone mineral density;
KIRP	cis	rs27434	0.607	rs34753	chr5:96150911	C/T	cg16492584	chr5:96139282	ERAP1	-0.41	-5.55	-0.33	7.28e-8	Ankylosing spondylitis;
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	8.87	0.49	1.48e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg00125455	chr20:44574271	PCIF1	0.45	9.03	0.5	5.05e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg11814155	chr7:99998594	ZCWPW1	0.52	4.95	0.3	1.36e-6	Platelet count;
KIRP	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg07068956	chr7:100330872	ZAN	-0.54	-5.66	-0.34	4.19e-8	Other erythrocyte phenotypes;
KIRP	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.56	-7.29	-0.42	4.27e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8070740	0.838	rs8072363	chr17:5335752	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.57	6.94	0.4	3.44e-11	Menopause (age at onset);
KIRP	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.74	-9.95	-0.54	8.05e-20	Fibrinogen levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23205092	chr13:73005899	NA	-0.43	-6.33	-0.37	1.15e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.73	7.38	0.43	2.48e-12	Methadone dose in opioid dependence;
KIRP	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.87	-8.8	-0.49	2.39e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs78579285	0.545	rs113385327	chr16:88785242	A/C	cg09054528	chr16:88821542	FAM38A	-0.56	-5.03	-0.31	9.67e-7	Joint mobility (Beighton score);
KIRP	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg13482628	chr17:19912719	NA	0.57	8.08	0.46	2.97e-14	Schizophrenia;
KIRP	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.36	5.65	0.34	4.37e-8	Electroencephalogram traits;
KIRP	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.22	-0.37	2.09e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4237845	0.591	rs10431506	chr12:58311524	G/A	cg02175503	chr12:58329896	NA	0.84	10.01	0.54	5.23e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg02175503	chr12:58329896	NA	0.64	7.87	0.45	1.15e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg04369109	chr6:150039330	LATS1	-0.48	-6.09	-0.36	4.22e-9	Lung cancer;
KIRP	cis	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg02972257	chr16:68554789	NA	-0.57	-6.1	-0.36	4e-9	Ulcerative colitis;
KIRP	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.56	-5.92	-0.35	1.05e-8	Ulcerative colitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07989678	chr2:172543677	DYNC1I2	-0.39	-6.31	-0.37	1.3e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	cg04338863	chr8:33670619	NA	0.41	5.32	0.32	2.34e-7	Body mass index;
KIRP	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.92	-12.35	-0.62	1.4e-27	Cognitive function;
KIRP	cis	rs6681460	0.800	rs485543	chr1:67194372	C/T	cg13052034	chr1:66999238	SGIP1	-0.36	-5.05	-0.31	8.67e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.63	8.05	0.46	3.51e-14	Lymphocyte percentage of white cells;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg21685750	chr2:37193358	STRN	-0.52	-6.96	-0.41	3.15e-11	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19856749	chr10:124316636	NA	-0.48	-6.21	-0.37	2.21e-9	Parkinson's disease;
KIRP	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	6.18	0.37	2.62e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.91	-0.66	7.57e-33	Primary sclerosing cholangitis;
KIRP	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.55	-0.43	8.59e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.21	0.37	2.29e-9	Hypertriglyceridemia;
KIRP	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg27519958	chr1:161735129	ATF6	-0.68	-8.25	-0.47	9.68e-15	IgG glycosylation;
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.75	10.67	0.56	4.2e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg23307798	chr14:103986281	CKB	0.76	12.8	0.63	4.17e-29	Body mass index;
KIRP	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.55	5.51	0.33	9.17e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.69	10.73	0.56	2.72e-22	Blood metabolite ratios;
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg05025164	chr4:1340916	KIAA1530	0.53	6.95	0.41	3.22e-11	Longevity;
KIRP	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg04037228	chr3:45636386	LIMD1	0.36	5.31	0.32	2.5e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs2898857	0.636	rs75323127	chr17:47325664	G/T	cg11430096	chr6:110968061	CDK19	0.79	6.33	0.37	1.15e-9	Cancer;
KIRP	trans	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.25	-0.42	5.54e-12	Bladder cancer;
KIRP	cis	rs45544231	0.569	rs12443621	chr16:52548037	A/G	cg09051775	chr16:52580266	TOX3	-0.36	-5.01	-0.3	1.02e-6	Restless legs syndrome;
KIRP	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.19	-0.31	4.33e-7	Educational attainment;
KIRP	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg13198984	chr17:80129470	CCDC57	0.57	8.79	0.49	2.68e-16	Life satisfaction;
KIRP	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	6.33	0.37	1.14e-9	Height;
KIRP	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-8.18	-0.46	1.56e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg02524346	chr8:600233	NA	-0.91	-5.67	-0.34	4.03e-8	IgG glycosylation;
KIRP	trans	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.74	-0.39	1.1e-10	Heart rate;
KIRP	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.72	0.49	4.29e-16	Morning vs. evening chronotype;
KIRP	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg11150807	chr10:43354902	NA	0.61	6.87	0.4	5.15e-11	Blood protein levels;
KIRP	cis	rs73198271	0.710	rs11779565	chr8:8680020	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.19	-0.37	2.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg25650185	chr19:21324782	ZNF431	0.47	4.96	0.3	1.33e-6	Pain;
KIRP	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg03711944	chr11:47377212	SPI1	-0.3	-5.06	-0.31	8.12e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs9584850	0.718	rs6491427	chr13:99113166	A/G	cg20750642	chr13:99100586	FARP1	-0.47	-5.45	-0.33	1.25e-7	Neuroticism;
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07648498	chr16:89883185	FANCA	0.39	4.94	0.3	1.42e-6	Vitiligo;
KIRP	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg02175503	chr12:58329896	NA	0.49	5.44	0.33	1.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.4	5.53	0.33	7.97e-8	Blood metabolite levels;
KIRP	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.67	-9.0	-0.5	6.19e-17	Personality dimensions;
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.51	0.33	9.16e-8	Life satisfaction;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13916398	chr11:76814824	CAPN5	-0.45	-6.16	-0.37	2.97e-9	Inflammatory biomarkers;
KIRP	cis	rs1629083	0.875	rs17121879	chr11:118080133	G/T	cg18857871	chr11:118064634	AMICA1	0.65	8.8	0.49	2.51e-16	Lung cancer;
KIRP	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.67	-8.49	-0.48	2.04e-15	Longevity;
KIRP	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg09555818	chr19:45449301	APOC2	0.41	5.33	0.32	2.25e-7	Blood protein levels;
KIRP	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg02038168	chr22:39784481	NA	-0.41	-4.94	-0.3	1.46e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	10.41	0.55	2.87e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7607369	0.596	rs56304256	chr2:219276138	T/C	cg10223061	chr2:219282414	VIL1	0.53	7.84	0.45	1.32e-13	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-22.63	-0.82	4.55e-62	Ulcerative colitis;
KIRP	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.63	-6.46	-0.38	5.58e-10	Platelet distribution width;
KIRP	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.55	-8.83	-0.49	2.04e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.56	0.33	6.93e-8	Putamen volume;
KIRP	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg18305652	chr10:134549665	INPP5A	0.49	7.49	0.43	1.23e-12	Migraine;
KIRP	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs11997175	0.692	rs6468202	chr8:33747720	C/A	cg04338863	chr8:33670619	NA	0.49	6.37	0.38	9.15e-10	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06770877	chr13:31897247	B3GALTL	0.43	6.04	0.36	5.56e-9	Survival in pancreatic cancer;
KIRP	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.73	-0.39	1.17e-10	Coronary artery disease;
KIRP	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg11833968	chr6:79620685	NA	-0.47	-7.1	-0.41	1.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg00405596	chr8:11794950	NA	0.57	7.87	0.45	1.15e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.1	0.5	3.21e-17	Morning vs. evening chronotype;
KIRP	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.99	-0.3	1.13e-6	Metabolite levels;
KIRP	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.56	-6.29	-0.37	1.44e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs6032067	0.852	rs2233882	chr20:43835683	T/A	cg10761708	chr20:43804764	PI3	0.52	5.34	0.32	2.08e-7	Blood protein levels;
KIRP	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.82	-0.45	1.51e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.57	-7.14	-0.41	1.04e-11	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg23387468	chr7:139079360	LUC7L2	0.32	5.46	0.33	1.14e-7	Diisocyanate-induced asthma;
KIRP	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg18944383	chr4:111397179	ENPEP	0.61	11.17	0.58	1.03e-23	Height;
KIRP	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.47	5.48	0.33	1.08e-7	Bipolar disorder;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg16261398	chr11:1410750	BRSK2	-0.44	-6.23	-0.37	1.96e-9	Blood metabolite levels;
KIRP	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.11	0.61	8.95e-27	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04633058	chr17:48474099	LRRC59	0.6	7.38	0.43	2.4e-12	Smoking initiation;
KIRP	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg18898632	chr2:242989856	NA	-0.53	-5.13	-0.31	5.8e-7	Obesity-related traits;
KIRP	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.47	6.5	0.38	4.51e-10	Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.92	-0.69	2.74e-36	Alzheimer's disease;
KIRP	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.79	-9.0	-0.5	6.31e-17	Diastolic blood pressure;
KIRP	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.26	-0.47	8.74e-15	Coronary artery disease;
KIRP	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	1.26	9.13	0.5	2.52e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19983818	chr5:10441822	ROPN1L	0.51	6.75	0.4	1.06e-10	Parkinson's disease;
KIRP	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg24154853	chr7:158122151	PTPRN2	0.38	5.55	0.33	7.46e-8	Calcium levels;
KIRP	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg04719120	chr6:96025338	MANEA	0.59	5.07	0.31	7.76e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg02807482	chr3:125708958	NA	0.53	5.29	0.32	2.66e-7	Blood pressure (smoking interaction);
KIRP	cis	rs1784581	0.722	rs1619122	chr6:162400198	G/T	cg17173639	chr6:162384350	PARK2	-0.59	-9.25	-0.51	1.15e-17	Itch intensity from mosquito bite;
KIRP	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.5	6.91	0.4	4.07e-11	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10437825	chr8:68334606	CPA6	0.52	7.84	0.45	1.34e-13	Interleukin-4 levels;
KIRP	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg16049864	chr8:95962084	TP53INP1	-0.35	-5.58	-0.34	6.3e-8	Type 2 diabetes;
KIRP	cis	rs2777491	0.874	rs1655556	chr15:41777935	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.9	-13.39	-0.65	4.43e-31	Ulcerative colitis;
KIRP	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4638749	0.501	rs9917180	chr2:108747645	A/C	cg25838818	chr2:108905173	SULT1C2	0.35	5.38	0.32	1.7e-7	Blood pressure;
KIRP	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.48e-10	Coronary artery disease;
KIRP	cis	rs2268667	0.597	rs1403954	chr1:85940157	C/T	cg16011679	chr1:85725395	C1orf52	0.41	5.21	0.32	4e-7	Asymmetrical dimethylarginine levels;
KIRP	cis	rs10982256	0.774	rs10817623	chr9:117244937	G/A	cg13636371	chr9:117264095	DFNB31	-0.5	-6.97	-0.41	2.95e-11	Bipolar disorder;
KIRP	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.71	0.44	3.07e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-10.77	-0.57	2.09e-22	Colorectal cancer;
KIRP	cis	rs8050907	1.000	rs8050907	chr16:4646878	G/A	cg09164920	chr16:4526354	HMOX2;NMRAL1	0.85	5.15	0.31	5.36e-7	Obesity-related traits;
KIRP	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg09344028	chr17:70110421	NA	0.4	7.91	0.45	8.74e-14	Thyroid hormone levels;
KIRP	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg20387954	chr3:183756860	HTR3D	-0.84	-11.7	-0.6	1.93e-25	Anterior chamber depth;
KIRP	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.56	8.85	0.49	1.7e-16	Bone mineral density;
KIRP	cis	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg06521331	chr12:34319734	NA	-0.62	-7.37	-0.43	2.51e-12	Morning vs. evening chronotype;
KIRP	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-4.95	-0.3	1.41e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs41264869	0.663	rs1062715	chr1:205129319	G/A	cg21214746	chr1:205091277	RBBP5	0.52	6.69	0.39	1.46e-10	Blood protein levels;
KIRP	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg07862535	chr7:139043722	LUC7L2	0.48	5.41	0.33	1.46e-7	Diisocyanate-induced asthma;
KIRP	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.18	14.01	0.67	3.48e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.68	7.62	0.44	5.62e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs1978968	0.763	rs9605473	chr22:18463266	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	0.76	10.66	0.56	4.68e-22	Presence of antiphospholipid antibodies;
KIRP	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.61	-9.06	-0.5	4.16e-17	Bipolar disorder;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13181291	chr1:151089582	GABPB2	-0.43	-6.02	-0.36	6.14e-9	Inflammatory biomarkers;
KIRP	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01645753	chr15:83316734	CPEB1	0.47	6.27	0.37	1.62e-9	Parkinson's disease;
KIRP	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18252515	chr7:66147081	NA	-0.46	-5.26	-0.32	3.11e-7	Aortic root size;
KIRP	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg21851534	chr17:3907994	ZZEF1	0.47	5.61	0.34	5.52e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs741677	0.963	rs9907102	chr17:464832	C/T	cg06217071	chr17:408420	NA	0.48	6.98	0.41	2.71e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2071403	0.966	rs13400534	chr2:1411883	A/G	cg07083862	chr2:1417248	TPO	-0.33	-5.27	-0.32	2.93e-7	Thyroid peroxidase antibody positivity;
KIRP	trans	rs1106684	1.000	rs61245739	chr7:131460915	C/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	1.04	11.37	0.59	2.45e-24	Alzheimer's disease;
KIRP	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.24e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.08	0.41	1.5e-11	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg16691251	chr5:66510806	NA	0.56	7.76	0.44	2.32e-13	Breast cancer;
KIRP	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg07541023	chr7:19748670	TWISTNB	0.68	6.1	0.36	4.03e-9	Thyroid stimulating hormone;
KIRP	trans	rs7246760	0.867	rs35416342	chr19:9779058	A/G	cg02900749	chr2:68251473	NA	-1.16	-9.53	-0.52	1.56e-18	Pursuit maintenance gain;
KIRP	trans	rs57602752	1.000	rs7920901	chr10:120648450	C/T	cg02768671	chr6:169470822	NA	0.51	6.43	0.38	6.61e-10	Cannabis dependence;
KIRP	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.55	0.43	8.37e-13	Gout;Renal underexcretion gout;
KIRP	cis	rs9815354	1.000	rs1716692	chr3:41983786	G/A	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.1e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg01763666	chr17:80159506	CCDC57	0.36	4.94	0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9321453	1.000	rs9376037	chr6:134775037	C/G	cg08754004	chr6:134775465	NA	-0.43	-4.95	-0.3	1.36e-6	Urate levels;
KIRP	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24110177	chr3:50126178	RBM5	0.42	5.5	0.33	9.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.67	-8.69	-0.48	5.03e-16	Longevity;Endometriosis;
KIRP	cis	rs6102059	0.692	rs62211684	chr20:39230467	T/C	cg06665391	chr20:39312290	NA	0.42	5.32	0.32	2.31e-7	LDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17084299	chr6:3259239	PSMG4	0.52	6.54	0.38	3.45e-10	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23281280	chr6:28129359	ZNF389	0.47	5.15	0.31	5.31e-7	Depression;
KIRP	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.6	0.39	2.56e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13361707	0.920	rs57806386	chr5:40699186	A/C	cg01087697	chr5:40835557	RPL37	-0.48	-5.44	-0.33	1.29e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg17133734	chr15:86042851	AKAP13	-0.46	-5.88	-0.35	1.36e-8	Coronary artery disease;
KIRP	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg02415014	chr8:143852576	LYNX1	0.32	5.02	0.3	9.79e-7	Urinary tract infection frequency;
KIRP	cis	rs2377585	0.524	rs11616092	chr12:8845493	A/G	cg03761649	chr12:8850719	RIMKLB	0.51	5.12	0.31	6.06e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs4073416	0.542	rs6573611	chr14:65865255	G/T	cg03016385	chr14:66212404	NA	-0.44	-5.71	-0.34	3.17e-8	N-glycan levels;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.63	8.06	0.46	3.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6669919	0.622	rs10863907	chr1:211685066	G/A	cg10512769	chr1:211675356	NA	-0.56	-8.05	-0.46	3.45e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg13395646	chr4:1353034	KIAA1530	-0.37	-5.03	-0.31	9.25e-7	Longevity;
KIRP	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg23479056	chr15:41276147	INO80	-0.41	-5.96	-0.35	8.92e-9	Menopause (age at onset);
KIRP	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg04310649	chr10:35416472	CREM	-0.59	-6.94	-0.4	3.43e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.67	-7.11	-0.41	1.28e-11	Lymphocyte counts;
KIRP	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.63	-7.77	-0.44	2.11e-13	Longevity;
KIRP	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg16111737	chr12:117408163	FBXW8	-0.58	-5.95	-0.35	9.34e-9	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.64	-7.29	-0.42	4.19e-12	Menarche (age at onset);
KIRP	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.87	9.79	0.53	2.46e-19	Corneal astigmatism;
KIRP	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	5.7	0.34	3.38e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7404928	0.645	rs10852255	chr16:23850580	C/T	cg05497750	chr16:23765381	CHP2	-0.53	-5.89	-0.35	1.25e-8	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs3008870	0.585	rs2815382	chr1:67515228	G/A	cg02640540	chr1:67518911	SLC35D1	0.59	7.28	0.42	4.43e-12	Lymphocyte percentage of white cells;
KIRP	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg17376030	chr22:41985996	PMM1	-0.83	-8.83	-0.49	1.98e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.79	12.82	0.63	3.75e-29	Schizophrenia;
KIRP	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg23601095	chr6:26197514	HIST1H3D	0.98	8.28	0.47	8.02e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg06204229	chr3:52865917	ITIH4	-0.41	-6.03	-0.36	6.1e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg10760299	chr15:45669010	GATM	0.32	4.87	0.3	1.98e-6	Homoarginine levels;
KIRP	cis	rs4363506	0.966	rs10830091	chr10:129273728	A/G	cg07804728	chr10:129284050	NA	0.41	5.83	0.35	1.76e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs11718455	0.526	rs67553643	chr3:43928130	C/T	cg08738300	chr3:44038990	NA	0.58	7.51	0.43	1.08e-12	Coronary artery disease;
KIRP	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08280861	chr8:58055591	NA	0.76	5.25	0.32	3.27e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.36	0.62	1.28e-27	Smoking behavior;
KIRP	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg08885076	chr2:99613938	TSGA10	0.53	9.28	0.51	9.4e-18	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04360313	chr19:10828869	DNM2;MIR638	0.54	6.65	0.39	1.85e-10	Parkinson's disease;
KIRP	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg13034073	chr7:2769681	GNA12	0.3	5.11	0.31	6.4e-7	Height;
KIRP	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.73	10.89	0.57	8.76e-23	Oral cavity cancer;
KIRP	cis	rs7116495	1.000	rs2511076	chr11:71783827	A/G	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg27068330	chr11:65405492	SIPA1	0.38	5.13	0.31	5.8e-7	Acne (severe);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02802062	chr3:172428840	NCEH1	0.49	6.3	0.37	1.35e-9	Parkinson's disease;
KIRP	cis	rs4765905	0.610	rs10774032	chr12:2309393	T/C	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.93	-0.4	3.58e-11	Schizophrenia;
KIRP	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs6674970	0.541	rs2902811	chr1:151010521	G/C	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.52	-6.16	-0.37	2.91e-9	Childhood ear infection;
KIRP	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs220519	0.681	rs220505	chr20:37293131	A/G	cg24308336	chr20:37270989	C20orf95	0.23	4.87	0.3	2.02e-6	Schizophrenia;
KIRP	cis	rs1594829	0.553	rs1564577	chr8:26164723	G/A	cg11498726	chr8:26250323	BNIP3L	-0.32	-4.94	-0.3	1.43e-6	Height;
KIRP	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.68	-9.31	-0.51	7.57e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-1.28	-12.57	-0.63	2.53e-28	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.55	-5.02	-0.3	9.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.83	12.32	0.62	1.69e-27	Systemic lupus erythematosus;
KIRP	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.8	8.9	0.49	1.25e-16	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.04	-0.31	8.91e-7	Triglycerides;
KIRP	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.73	7.67	0.44	3.93e-13	Lymphocyte counts;
KIRP	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.13	23.17	0.83	8.84e-64	Schizophrenia;
KIRP	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg05802129	chr4:122689817	NA	-0.7	-9.91	-0.53	1.07e-19	Type 2 diabetes;
KIRP	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.13	-9.57	-0.52	1.2e-18	Body mass index;
KIRP	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg07451762	chr16:28383216	NA	0.4	5.04	0.31	8.85e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7712401	0.645	rs154497	chr5:122221420	T/C	cg19412675	chr5:122181750	SNX24	0.5	5.49	0.33	1.01e-7	Mean platelet volume;
KIRP	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.73	8.26	0.47	9.22e-15	High light scatter reticulocyte count;
KIRP	cis	rs6546324	0.959	rs2861694	chr2:67845739	A/G	cg15745817	chr2:67799979	NA	-0.46	-6.1	-0.36	4.18e-9	Endometriosis;
KIRP	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg01721255	chr8:58191610	C8orf71	0.56	5.76	0.34	2.5e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1642645	0.597	rs702225	chr1:42373900	C/T	cg26038582	chr1:42384390	HIVEP3	-0.29	-5.59	-0.34	5.99e-8	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	0.5	8.9	0.49	1.21e-16	QRS complex (12-leadsum);
KIRP	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg12756093	chr1:115239321	AMPD1	0.55	7.49	0.43	1.22e-12	Autism;
KIRP	cis	rs73086581	0.947	rs67356712	chr20:3892886	A/G	cg02187196	chr20:3869020	PANK2	0.5	4.85	0.3	2.19e-6	Response to antidepressants in depression;
KIRP	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.53	-0.38	3.66e-10	Parkinson's disease;
KIRP	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Colorectal cancer;
KIRP	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg00631329	chr6:26305371	NA	-0.72	-8.98	-0.5	7.02e-17	Educational attainment;
KIRP	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	ch.8.33884649F	chr8:33765107	NA	0.5	6.0	0.36	6.91e-9	Body mass index;
KIRP	cis	rs4595586	0.679	rs7131749	chr12:39405462	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.21	-0.37	2.27e-9	Morning vs. evening chronotype;
KIRP	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	1.04	19.61	0.78	3.48e-52	Heart rate;
KIRP	cis	rs829661	0.793	rs829637	chr2:30737910	A/G	cg10949345	chr2:30726833	LCLAT1	1.14	13.67	0.66	4.84e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs73071352	0.588	rs55744136	chr3:41812293	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
KIRP	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg10434728	chr15:90938212	IQGAP1	-0.37	-7.01	-0.41	2.23e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.46	5.39	0.33	1.61e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg15556689	chr8:8085844	FLJ10661	0.54	7.2	0.42	7.43e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.03	-0.36	6.04e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg02931644	chr1:25747376	RHCE	0.38	6.81	0.4	7.54e-11	Erythrocyte sedimentation rate;
KIRP	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.48	-8.18	-0.46	1.48e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg07395648	chr5:131743802	NA	0.55	7.74	0.44	2.58e-13	Breast cancer;
KIRP	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.81	-0.35	1.93e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.34	-6.54	-0.38	3.63e-10	Lymphocyte counts;
KIRP	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg14092571	chr14:90743983	NA	-0.4	-5.44	-0.33	1.26e-7	Mortality in heart failure;
KIRP	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.95	11.04	0.58	2.71e-23	Corneal astigmatism;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.28e-16	Life satisfaction;
KIRP	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.53	6.44	0.38	6.19e-10	Monocyte count;
KIRP	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.23	-0.32	3.66e-7	Pulmonary function;
KIRP	trans	rs12517041	0.679	rs2356718	chr5:23313406	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.81	-7.14	-0.41	1.06e-11	Calcium levels;
KIRP	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.8	0.4	7.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.69	-0.39	1.46e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg22437258	chr11:111473054	SIK2	-0.55	-6.09	-0.36	4.35e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7712401	0.525	rs2910150	chr5:122296745	G/T	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.03	0.36	6.08e-9	Putamen volume;
KIRP	cis	rs1497828	0.956	rs2646799	chr1:217522196	T/C	cg04411442	chr1:217543379	NA	-0.42	-6.48	-0.38	5e-10	Dialysis-related mortality;
KIRP	cis	rs516946	1.000	rs10109812	chr8:41524899	A/G	cg19441908	chr8:41529140	ANK1	0.49	6.93	0.4	3.75e-11	Type 2 diabetes;
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	1.07	23.81	0.84	8.88e-66	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs42648	0.693	rs3747800	chr7:89899488	G/T	cg25739043	chr7:89950458	NA	-0.43	-6.84	-0.4	6.1e-11	Homocysteine levels;
KIRP	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.86	12.11	0.61	8.97e-27	Longevity;
KIRP	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg02336718	chr17:17403227	NA	-0.34	-5.35	-0.32	2e-7	Total body bone mineral density;
KIRP	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg17470723	chr8:74884337	TCEB1	0.62	7.77	0.44	2.1e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg23594656	chr7:65796392	TPST1	0.39	5.62	0.34	5.16e-8	Aortic root size;
KIRP	cis	rs7665939	1.000	rs72727639	chr4:190107992	G/C	cg09826759	chr4:190284978	NA	-0.75	-5.09	-0.31	7.17e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg18306943	chr3:40428807	ENTPD3	0.43	6.03	0.36	5.97e-9	Renal cell carcinoma;
KIRP	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg10755058	chr3:40428713	ENTPD3	0.47	6.58	0.39	2.78e-10	Renal cell carcinoma;
KIRP	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	0.84	6.53	0.38	3.66e-10	Mitochondrial DNA levels;
KIRP	cis	rs77861329	1.000	rs72964044	chr3:52092670	G/C	cg08692210	chr3:52188851	WDR51A	0.82	5.5	0.33	9.39e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg01877450	chr7:97915802	BRI3	-0.53	-6.84	-0.4	6.35e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.74	11.73	0.6	1.55e-25	Resting heart rate;
KIRP	cis	rs7175404	1.000	rs7175404	chr15:94036688	C/T	cg23502883	chr15:93959149	NA	-0.53	-5.74	-0.34	2.71e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8135828	1.000	rs16987832	chr22:29978749	C/G	cg23204276	chr22:29729285	AP1B1;SNORD125	0.46	5.14	0.31	5.48e-7	Lipid traits;
KIRP	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg07169764	chr2:136633963	MCM6	0.53	6.15	0.37	3.13e-9	Mosquito bite size;
KIRP	cis	rs9394169	0.818	rs1547671	chr6:33777260	C/T	cg25922239	chr6:33757077	LEMD2	0.4	4.88	0.3	1.93e-6	Essential tremor;
KIRP	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.6	7.39	0.43	2.33e-12	Age-related hearing impairment;
KIRP	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg07274523	chr3:49395745	GPX1	0.71	8.55	0.48	1.31e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg20701182	chr2:24300061	SF3B14	0.47	4.94	0.3	1.47e-6	Asthma;
KIRP	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg15704280	chr7:45808275	SEPT13	0.86	6.2	0.37	2.32e-9	Myopia (pathological);
KIRP	trans	rs6499188	0.510	rs9923262	chr16:68613106	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	6.16	0.37	2.98e-9	Ulcerative colitis;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.73	6.47	0.38	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.26e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs412050	0.793	rs74576380	chr22:22283280	A/G	cg17089214	chr22:22089827	YPEL1	0.58	5.62	0.34	5.23e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.46	-0.7	3.86e-38	Chronic sinus infection;
KIRP	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg20936604	chr3:58311152	NA	-0.66	-5.01	-0.3	1.03e-6	Cholesterol, total;
KIRP	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.75	-7.43	-0.43	1.83e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07169764	chr2:136633963	MCM6	0.58	6.99	0.41	2.52e-11	Mosquito bite size;
KIRP	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.44	-0.43	1.73e-12	Breast cancer;
KIRP	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.24	0.42	5.56e-12	Bipolar disorder;
KIRP	cis	rs2224391	0.628	rs2773311	chr6:5250866	A/T	cg13962347	chr6:5174647	LYRM4	-0.69	-9.72	-0.53	4.17e-19	Height;
KIRP	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg23978390	chr7:1156363	C7orf50	0.5	5.29	0.32	2.71e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs7119038	0.818	rs10892288	chr11:118644694	A/G	cg19308663	chr11:118741387	NA	0.55	8.59	0.48	1.01e-15	Sjögren's syndrome;
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.5	-0.38	4.56e-10	Lung cancer;
KIRP	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11987759	chr7:65425863	GUSB	-0.48	-6.16	-0.37	2.98e-9	Aortic root size;
KIRP	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg24296786	chr1:45957014	TESK2	0.43	5.45	0.33	1.21e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg02297831	chr4:17616191	MED28	0.61	7.77	0.44	2.09e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4132509	1.000	rs7514984	chr1:243965623	C/T	cg25706552	chr1:244017396	NA	0.57	7.17	0.42	8.66e-12	RR interval (heart rate);
KIRP	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.52	6.17	0.37	2.83e-9	Ulcerative colitis;
KIRP	cis	rs4699052	0.963	rs6816055	chr4:104143160	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-5.19	-0.31	4.3e-7	Testicular germ cell tumor;
KIRP	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.77	-0.4	9.2e-11	Neuroticism;
KIRP	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg22800045	chr5:56110881	MAP3K1	0.58	6.3	0.37	1.37e-9	Type 2 diabetes;
KIRP	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.83	-12.72	-0.63	8.17e-29	Asthma;
KIRP	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00495681	chr13:53174319	NA	0.37	4.92	0.3	1.62e-6	Lewy body disease;
KIRP	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.11	-0.61	8.57e-27	Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09299307	chr5:86709023	CCNH	0.59	7.3	0.42	3.99e-12	Smoking initiation;
KIRP	cis	rs796364	0.616	rs6718118	chr2:200691852	G/T	cg17644776	chr2:200775616	C2orf69	-0.58	-5.43	-0.33	1.32e-7	Schizophrenia;
KIRP	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg00931491	chr16:28608288	SULT1A2	-0.26	-4.85	-0.3	2.16e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4959799	0.557	rs9501970	chr6:3271509	T/C	cg03657281	chr6:3270030	SLC22A23	0.78	6.03	0.36	6.04e-9	Survival in rectal cancer;
KIRP	cis	rs7590368	0.715	rs72779470	chr2:10964057	C/T	cg15705551	chr2:10952987	PDIA6	0.6	5.41	0.33	1.48e-7	Educational attainment (years of education);
KIRP	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.14	-0.31	5.74e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.67	-7.65	-0.44	4.65e-13	Gut microbiome composition (summer);
KIRP	cis	rs13132184	0.507	rs933821	chr4:38026389	C/T	cg19090437	chr4:38080799	TBC1D1	-0.57	-5.39	-0.32	1.66e-7	Verbal declarative memory;
KIRP	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.95	-14.08	-0.67	2.08e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs2034650	0.544	rs8034416	chr15:40703339	C/T	cg08996748	chr15:40651036	DISP2	-0.34	-4.96	-0.3	1.34e-6	Interstitial lung disease;
KIRP	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-8.27	-0.47	8.71e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs199950	0.826	rs3905010	chr1:181598217	C/G	cg04237608	chr1:18659049	IGSF21	-0.37	-6.15	-0.37	3.06e-9	Body mass index (change over time);
KIRP	cis	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg21546286	chr11:48923668	NA	0.43	5.39	0.32	1.68e-7	HDL cholesterol;
KIRP	cis	rs2274273	0.624	rs1972221	chr14:55785381	C/A	cg04306507	chr14:55594613	LGALS3	0.39	5.38	0.32	1.77e-7	Protein biomarker;
KIRP	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.86	-14.07	-0.67	2.27e-33	Itch intensity from mosquito bite;
KIRP	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg19592336	chr6:28129416	ZNF389	0.49	5.57	0.33	6.54e-8	Depression;
KIRP	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.28	-0.42	4.42e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12826942	1.000	rs12826942	chr12:42796300	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	4.9	0.3	1.77e-6	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05223675	chr11:118888923	RPS25;TRAPPC4	0.47	6.08	0.36	4.48e-9	Parkinson's disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06074314	chr2:70475575	TIA1	-0.54	-6.87	-0.4	5.35e-11	Neuroticism;
KIRP	trans	rs75790006	0.546	rs28792075	chr4:42886045	A/T	cg16885725	chr6:167511486	NA	0.71	6.22	0.37	2.08e-9	Multiple keratinocyte cancers;
KIRP	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.76	-12.41	-0.62	8.79e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.81	0.66	1.62e-32	Alzheimer's disease;
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg14004847	chr7:1930337	MAD1L1	-0.45	-4.85	-0.3	2.19e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6142102	0.961	rs6059596	chr20:32557119	C/T	cg08999081	chr20:33150536	PIGU	0.5	5.96	0.36	8.62e-9	Skin pigmentation;
KIRP	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.36	0.32	1.93e-7	Menopause (age at onset);
KIRP	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg09264619	chr17:80180166	NA	-0.41	-5.99	-0.36	7.52e-9	Life satisfaction;
KIRP	cis	rs4663866	1.000	rs71426509	chr2:239175334	A/C	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.09	13.33	0.65	6.82e-31	Platelet count;
KIRP	cis	rs240764	0.658	rs10457849	chr6:101245591	A/G	cg09795085	chr6:101329169	ASCC3	0.49	5.77	0.35	2.32e-8	Neuroticism;
KIRP	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.94	12.21	0.61	4.11e-27	Cognitive function;
KIRP	cis	rs7948661	1.000	rs7113959	chr11:118379096	T/A	cg06090739	chr11:118230722	UBE4A	0.74	5.12	0.31	6.25e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg14952266	chr13:112191215	NA	-0.44	-6.45	-0.38	5.87e-10	Hepatitis;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.57	7.39	0.43	2.33e-12	Longevity;Endometriosis;
KIRP	cis	rs3857067	1.000	rs28876091	chr4:95000394	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.89e-7	QT interval;
KIRP	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.48	-7.28	-0.42	4.54e-12	Daytime sleep phenotypes;
KIRP	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	5.28	0.32	2.84e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25391681	chr5:128930873	ADAMTS19	-0.39	-6.02	-0.36	6.16e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-11.94	-0.61	3.29e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.54	7.18	0.42	8.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg03235661	chr20:60525775	NA	-0.36	-4.94	-0.3	1.44e-6	Body mass index;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15258722	chr13:110802573	COL4A1	0.55	6.67	0.39	1.69e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06658637	chr5:466542	EXOC3	0.43	6.17	0.37	2.84e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg05779272	chr9:33168018	B4GALT1	0.37	4.88	0.3	1.9e-6	IgG glycosylation;
KIRP	cis	rs9660180	0.967	rs66701417	chr1:1698092	A/G	cg03396347	chr1:1875803	NA	-0.62	-8.91	-0.49	1.18e-16	Body mass index;
KIRP	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.48	6.78	0.4	8.94e-11	Red blood cell count;
KIRP	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg15448220	chr1:150897856	SETDB1	0.43	5.3	0.32	2.62e-7	Melanoma;
KIRP	cis	rs9659323	0.622	rs6689568	chr1:119502961	A/G	cg05756136	chr1:119680316	WARS2	-0.38	-4.96	-0.3	1.3e-6	Body mass index;
KIRP	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg12549451	chr6:135224345	NA	0.44	5.2	0.31	4.2e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg01798813	chr17:3906674	NA	0.57	7.96	0.45	6.27e-14	Type 2 diabetes;
KIRP	cis	rs12579753	0.719	rs12369450	chr12:82266940	A/G	cg07988820	chr12:82153109	PPFIA2	-0.48	-6.12	-0.36	3.59e-9	Resting heart rate;
KIRP	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.65	7.58	0.44	7.05e-13	Platelet count;
KIRP	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.71	11.08	0.58	2.12e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs7760949	0.963	rs9382681	chr6:13915051	A/G	cg27413430	chr6:13925136	RNF182	0.38	4.96	0.3	1.33e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.25	-0.47	9.64e-15	Total cholesterol levels;
KIRP	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.79	-13.02	-0.64	8.08e-30	Prostate cancer;
KIRP	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg19610905	chr11:61596333	FADS2	-0.56	-8.43	-0.47	2.91e-15	Trans fatty acid levels;
KIRP	cis	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg21546286	chr11:48923668	NA	-0.47	-6.16	-0.37	3e-9	HDL cholesterol;
KIRP	cis	rs13034020	0.522	rs72809436	chr2:61251145	C/T	cg18625361	chr2:61244694	PEX13;PUS10	0.65	6.25	0.37	1.78e-9	Hodgkin's lymphoma;
KIRP	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01171360	chr6:293285	DUSP22	-0.54	-6.25	-0.37	1.83e-9	Menopause (age at onset);
KIRP	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg14558114	chr2:88469736	THNSL2	0.65	5.32	0.32	2.38e-7	Plasma clusterin levels;
KIRP	trans	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg15469184	chr8:337539	NA	0.5	6.27	0.37	1.62e-9	Obesity-related traits;
KIRP	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.83	12.68	0.63	1.06e-28	Height;
KIRP	trans	rs921874	0.554	rs2512499	chr11:86753948	A/G	cg22937172	chr2:240168862	HDAC4	0.5	6.45	0.38	5.81e-10	Total body bone mineral density;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.76	0.44	2.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg11815991	chr20:30193098	ID1	-0.5	-5.07	-0.31	7.7e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs838147	0.537	rs485073	chr19:49207255	A/G	cg21064579	chr19:49206444	FUT2	0.59	8.79	0.49	2.68e-16	Dietary macronutrient intake;
KIRP	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg02931644	chr1:25747376	RHCE	0.41	7.49	0.43	1.2e-12	Erythrocyte sedimentation rate;
KIRP	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.52	-7.2	-0.42	7.09e-12	Ulcerative colitis;
KIRP	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.17	13.24	0.64	1.48e-30	Platelet count;
KIRP	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.63	10.57	0.56	9.29e-22	Coronary artery disease;
KIRP	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.83e-7	Bipolar disorder;
KIRP	cis	rs9309473	0.500	rs6757996	chr2:73772251	G/A	cg20560298	chr2:73613845	ALMS1	-0.42	-5.21	-0.31	4.09e-7	Metabolite levels;
KIRP	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg25019033	chr10:957182	NA	-0.58	-5.96	-0.36	8.65e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs448720	0.811	rs1996120	chr15:68181534	G/A	cg24579218	chr15:68104479	NA	-0.4	-5.7	-0.34	3.43e-8	Cognitive performance;
KIRP	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	trans	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg08400319	chr2:242004533	SNED1	0.44	6.05	0.36	5.4e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg00677455	chr12:58241039	CTDSP2	0.97	12.61	0.63	1.88e-28	Multiple sclerosis;
KIRP	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg18833306	chr6:118973337	C6orf204	0.41	5.13	0.31	5.87e-7	Electrocardiographic conduction measures;
KIRP	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg26827852	chr1:89887630	LOC400759	0.45	6.3	0.37	1.38e-9	Carotid intima media thickness;
KIRP	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.09	0.41	1.41e-11	Morning vs. evening chronotype;
KIRP	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	11.97	0.61	2.55e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12379764	chr21:47803548	PCNT	0.43	5.18	0.31	4.72e-7	Testicular germ cell tumor;
KIRP	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg03235661	chr20:60525775	NA	-0.3	-4.97	-0.3	1.25e-6	Body mass index;
KIRP	trans	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.4	6.18	0.37	2.61e-9	Hypertriglyceridemia;
KIRP	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg16989719	chr2:238392110	NA	-0.67	-6.77	-0.4	9.62e-11	Prostate cancer;
KIRP	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg07936489	chr17:37558343	FBXL20	-0.57	-7.61	-0.44	5.83e-13	Asthma;
KIRP	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.04	-17.36	-0.74	1.32e-44	Dilated cardiomyopathy;
KIRP	cis	rs6466055	0.661	rs6466051	chr7:104897225	A/G	cg04380332	chr7:105027541	SRPK2	-0.36	-5.06	-0.31	8.22e-7	Schizophrenia;
KIRP	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.71	9.88	0.53	1.32e-19	Schizophrenia;
KIRP	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19717773	chr7:2847554	GNA12	-0.35	-5.22	-0.32	3.88e-7	Height;
KIRP	cis	rs1712790	0.535	rs12421720	chr11:114609108	A/G	cg19465033	chr11:114479364	NA	0.5	6.04	0.36	5.72e-9	Urinary albumin excretion;
KIRP	cis	rs11264213	0.901	rs620956	chr1:36362162	T/C	cg27506609	chr1:36549197	TEKT2	0.96	9.92	0.53	1.03e-19	Schizophrenia;
KIRP	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg17757837	chr7:157058334	UBE3C	-0.81	-11.27	-0.58	5.08e-24	Body mass index;
KIRP	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.92	-0.4	3.94e-11	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.15	0.41	9.81e-12	Prudent dietary pattern;
KIRP	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg11584989	chr19:19387371	SF4	0.44	5.57	0.33	6.66e-8	Tonsillectomy;
KIRP	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14169450	chr9:139327907	INPP5E	0.54	6.26	0.37	1.68e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs778371	0.749	rs2675965	chr2:233793736	C/T	cg11972305	chr2:233791962	NGEF	-0.42	-5.43	-0.33	1.34e-7	Schizophrenia;
KIRP	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	9.21	0.51	1.45e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg10189774	chr4:17578691	LAP3	0.5	6.03	0.36	5.99e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.55	7.77	0.44	2.12e-13	Huntington's disease progression;
KIRP	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.52	-6.96	-0.41	3.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-9.71	-0.53	4.41e-19	Hemoglobin concentration;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-5.92	-0.35	1.06e-8	Aortic root size;
KIRP	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-9.57	-0.52	1.16e-18	Coronary artery disease;
KIRP	cis	rs728616	0.614	rs35395602	chr10:81906770	A/G	cg27417294	chr10:81904244	PLAC9	0.56	5.05	0.31	8.68e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	9.98	0.54	6.29e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg18350739	chr11:68623251	NA	-0.48	-7.43	-0.43	1.78e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg03554702	chr20:43595206	STK4	0.52	6.45	0.38	5.81e-10	DNA methylation (variation);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25505605	chr20:45035867	ELMO2	0.55	6.16	0.37	2.97e-9	Lung cancer in ever smokers;
KIRP	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.68	-8.48	-0.48	2.17e-15	Smoking behavior;
KIRP	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	15.48	0.7	3.44e-38	Colorectal cancer;
KIRP	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs4664304	0.620	rs10186586	chr2:160715334	T/C	cg03641300	chr2:160917029	PLA2R1	0.35	5.21	0.32	3.99e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.43	0.52	3.18e-18	IgG glycosylation;
KIRP	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	0.74	6.95	0.41	3.29e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.42	-6.75	-0.4	1.07e-10	Refractive error;
KIRP	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg12560992	chr17:57184187	TRIM37	0.63	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs4765905	0.580	rs758174	chr12:2315706	T/C	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.87	-0.4	5.37e-11	Schizophrenia;
KIRP	cis	rs4363385	0.693	rs6656812	chr1:152930254	C/T	cg07796016	chr1:152779584	LCE1C	0.41	4.96	0.3	1.31e-6	Inflammatory skin disease;
KIRP	cis	rs7674212	0.541	rs2623070	chr4:104037388	A/G	cg16532752	chr4:104119610	CENPE	0.43	5.31	0.32	2.5e-7	Type 2 diabetes;
KIRP	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.77	-8.63	-0.48	7.88e-16	Platelet count;
KIRP	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	1.05	14.72	0.68	1.29e-35	Menopause (age at onset);
KIRP	cis	rs1134634	0.520	rs28419165	chr4:15589345	C/T	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.85	-0.35	1.58e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs12545912	0.739	rs6601344	chr8:9548145	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.35	-0.38	1.03e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.55	-8.83	-0.49	2.04e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs1021993	0.545	rs55684110	chr1:209541832	A/T	cg24446417	chr1:209558027	NA	-0.52	-5.66	-0.34	4.19e-8	Gut microbiome composition (winter);
KIRP	cis	rs7849270	0.879	rs10739741	chr9:131855160	G/C	cg13538475	chr9:131942899	NA	-0.36	-5.59	-0.34	6.16e-8	Blood metabolite ratios;
KIRP	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.77	0.35	2.31e-8	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg09699651	chr6:150184138	LRP11	0.45	5.96	0.36	8.48e-9	Lung cancer;
KIRP	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.75	9.92	0.53	1e-19	Selective IgA deficiency;
KIRP	cis	rs17021463	0.844	rs17311008	chr4:95274653	A/G	cg11021082	chr4:95130006	SMARCAD1	0.41	5.19	0.31	4.39e-7	Testicular germ cell tumor;
KIRP	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18357526	chr6:26021779	HIST1H4A	0.53	7.13	0.41	1.1e-11	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01328190	chr16:14529714	PARN	-0.43	-6.1	-0.36	4.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2077654	0.822	rs7932122	chr11:17431361	A/G	cg25308976	chr11:17434268	ABCC8	-1.04	-10.84	-0.57	1.2e-22	Gout;
KIRP	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.26	-0.37	1.74e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11603020	0.950	rs3824988	chr11:57377968	C/T	cg23127183	chr11:57508653	C11orf31	0.47	5.47	0.33	1.1e-7	Blood protein levels;
KIRP	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.41	4.98	0.3	1.22e-6	Diabetic retinopathy;
KIRP	cis	rs7258465	0.965	rs271628	chr19:18624333	A/G	cg10790698	chr19:18539756	SSBP4	-0.34	-7.41	-0.43	2.02e-12	Breast cancer;
KIRP	cis	rs11264213	0.901	rs72661608	chr1:36333850	C/G	cg27506609	chr1:36549197	TEKT2	1.19	7.29	0.42	4.33e-12	Schizophrenia;
KIRP	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg05973401	chr12:123451056	ABCB9	0.57	6.58	0.39	2.74e-10	Neutrophil percentage of white cells;
KIRP	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg10053473	chr17:62856997	LRRC37A3	0.65	8.03	0.46	3.96e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.1	-0.31	6.73e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.57	-6.9	-0.4	4.42e-11	Mosquito bite size;
KIRP	cis	rs4906332	1.000	rs11541718	chr14:103852164	C/G	cg26207909	chr14:103986467	CKB	-0.43	-5.14	-0.31	5.56e-7	Coronary artery disease;
KIRP	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.33	-0.37	1.15e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.8	-11.33	-0.59	3.19e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg21775007	chr8:11205619	TDH	-0.41	-5.02	-0.3	1.01e-6	Neuroticism;
KIRP	cis	rs2072732	0.821	rs12034573	chr1:2948020	C/T	cg11731671	chr1:2995604	PRDM16	-0.39	-5.03	-0.31	9.4e-7	Plateletcrit;
KIRP	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.97	17.82	0.75	3.45e-46	Colorectal adenoma (advanced);
KIRP	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.74	10.18	0.54	1.59e-20	Height;
KIRP	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-8.25	-0.47	9.73e-15	Neuroticism;
KIRP	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.21	0.37	2.21e-9	Ovarian reserve;
KIRP	cis	rs2281603	0.951	rs3783723	chr14:64983539	T/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs6907629	0.704	rs879840	chr6:167558739	C/T	cg13805183	chr6:167554790	NA	-0.38	-5.94	-0.35	9.88e-9	Asthma (childhood onset);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00712289	chr14:81130611	C14orf145	0.38	6.07	0.36	4.91e-9	C-reactive protein;
KIRP	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg18882449	chr10:104885122	NT5C2	-0.38	-4.89	-0.3	1.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg03188948	chr7:1209495	NA	0.84	7.79	0.44	1.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1190552	0.846	rs4906212	chr14:102981595	A/G	cg10241871	chr14:102965420	TECPR2	0.5	5.46	0.33	1.14e-7	Blood protein levels;
KIRP	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg17376030	chr22:41985996	PMM1	0.59	6.39	0.38	8.33e-10	Vitiligo;
KIRP	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.44	-5.68	-0.34	3.84e-8	Coronary artery disease;
KIRP	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.41	-4.92	-0.3	1.6e-6	Coronary artery disease;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-0.59	-7.9	-0.45	9.46e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-11.96	-0.61	2.77e-26	Vitiligo;
KIRP	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.68	10.12	0.54	2.33e-20	Dupuytren's disease;
KIRP	cis	rs9815354	0.812	rs73081370	chr3:41916258	G/C	cg03022575	chr3:42003672	ULK4	0.83	8.62	0.48	8.35e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15459742	chr9:111775564	CTNNAL1	0.61	7.17	0.42	8.61e-12	Smoking initiation;
KIRP	cis	rs12519773	0.555	rs2578490	chr5:92389236	C/T	cg18783429	chr5:92414398	NA	0.33	5.62	0.34	5.11e-8	Migraine;
KIRP	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs745821	0.701	rs73959982	chr18:48130202	T/C	cg18923635	chr18:48083994	NA	0.48	5.51	0.33	9.19e-8	Diastolic blood pressure;
KIRP	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.16e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.36	0.42	2.7e-12	Myopia (pathological);
KIRP	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg01529538	chr14:23388837	RBM23	0.42	5.29	0.32	2.68e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7937612	1.000	rs10892582	chr11:120347715	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.2	-0.42	7.09e-12	Intraocular pressure;
KIRP	cis	rs12580194	0.593	rs7485991	chr12:55789129	T/C	cg11794356	chr12:55725991	OR6C3	-0.53	-6.95	-0.4	3.32e-11	Cancer;
KIRP	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26002218	chr14:103986227	CKB	0.29	5.96	0.36	8.87e-9	Body mass index;
KIRP	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05220968	chr6:146057943	EPM2A	0.39	5.0	0.3	1.11e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.0	10.97	0.57	4.69e-23	HIV-1 control;
KIRP	cis	rs9400467	0.506	rs10457238	chr6:111762593	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs362296	0.698	rs3135171	chr4:3261127	A/G	cg06533319	chr4:3265114	C4orf44	0.55	6.34	0.37	1.09e-9	Parental longevity (mother's age at death);
KIRP	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.15	21.62	0.81	8.11e-59	Exhaled nitric oxide output;
KIRP	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg24955955	chr5:415729	AHRR	0.81	6.34	0.37	1.11e-9	Fat distribution (HIV);
KIRP	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg25418670	chr11:30344373	C11orf46	-0.6	-5.02	-0.3	1e-6	Morning vs. evening chronotype;
KIRP	cis	rs3126085	0.932	rs11204949	chr1:152219797	A/C	cg26876637	chr1:152193138	HRNR	-0.86	-8.84	-0.49	1.94e-16	Atopic dermatitis;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg14073663	chr11:33722324	C11orf91	-0.43	-6.3	-0.37	1.36e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg25486957	chr4:152246857	NA	0.57	6.12	0.36	3.62e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.67	10.25	0.55	9.34e-21	Blood metabolite ratios;
KIRP	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.01	-0.3	1.02e-6	Reticulocyte count;
KIRP	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg17366294	chr4:99064904	C4orf37	0.36	4.98	0.3	1.2e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.73	-0.44	2.72e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.58	-6.33	-0.37	1.15e-9	Body mass index;
KIRP	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg00656387	chr3:40428638	ENTPD3	-0.37	-5.02	-0.3	1.01e-6	Renal cell carcinoma;
KIRP	cis	rs7923609	0.967	rs7076310	chr10:65135672	C/A	cg01631684	chr10:65280961	REEP3	-0.48	-5.61	-0.34	5.47e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg21479132	chr6:26055353	NA	0.81	5.66	0.34	4.13e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.64	9.42	0.52	3.34e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7666738	0.546	rs13148080	chr4:98680947	A/G	cg05340658	chr4:99064831	C4orf37	0.65	7.52	0.43	1.04e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2671245	1.000	rs2819473	chr1:56156428	C/T	cg11523071	chr1:56160889	NA	0.4	6.16	0.37	2.91e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.64	8.09	0.46	2.71e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12461345	chr1:218519565	TGFB2	0.47	6.27	0.37	1.59e-9	Myopia (pathological);
KIRP	cis	rs1620921	0.505	rs4708878	chr6:161203026	A/G	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs5758511	0.817	rs133291	chr22:42269628	C/T	cg15128208	chr22:42549153	NA	0.54	5.71	0.34	3.17e-8	Birth weight;
KIRP	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg05315796	chr3:52349193	DNAH1	0.4	4.91	0.3	1.64e-6	Schizophrenia;
KIRP	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg24315340	chr6:146058215	EPM2A	0.39	5.0	0.3	1.09e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7808935	0.628	rs12666442	chr7:27937203	C/T	cg22168087	chr7:27702803	HIBADH	0.75	7.21	0.42	7.03e-12	Prostate cancer;
KIRP	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.16	0.54	1.76e-20	Cognitive test performance;
KIRP	cis	rs2916247	0.954	rs6471319	chr8:93090594	G/A	cg10183463	chr8:93005414	RUNX1T1	0.51	6.23	0.37	2.03e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.966	rs7077242	chr10:35481965	A/C	cg04310649	chr10:35416472	CREM	0.59	6.89	0.4	4.67e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs981844	0.961	rs6827685	chr4:154662227	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.67	0.44	3.99e-13	Response to statins (LDL cholesterol change);
KIRP	trans	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg25288420	chr1:78511713	GIPC2	-0.45	-6.05	-0.36	5.42e-9	Obesity-related traits;
KIRP	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.86	0.45	1.19e-13	Coffee consumption (cups per day);
KIRP	cis	rs490234	0.676	rs13299008	chr9:128213966	T/G	cg14078157	chr9:128172775	NA	-0.65	-7.43	-0.43	1.76e-12	Mean arterial pressure;
KIRP	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.43	0.52	3.11e-18	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.52	7.24	0.42	5.87e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.73	-10.57	-0.56	8.77e-22	Migraine;
KIRP	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.48e-12	Prudent dietary pattern;
KIRP	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.75	-9.98	-0.54	6.6e-20	Platelet count;
KIRP	cis	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg04691961	chr3:161091175	C3orf57	0.47	6.91	0.4	4.21e-11	Morning vs. evening chronotype;
KIRP	cis	rs77688320	0.535	rs2241118	chr2:202253716	G/C	cg06431681	chr2:202330990	STRADB	0.51	6.78	0.4	8.81e-11	Breast cancer;
KIRP	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg03959625	chr15:84868606	LOC388152	0.65	7.93	0.45	7.78e-14	Schizophrenia;
KIRP	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.75	11.36	0.59	2.5e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg19875535	chr5:140030758	IK	0.65	9.21	0.51	1.53e-17	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10733616	chr4:2845331	ADD1	0.5	6.18	0.37	2.66e-9	Parkinson's disease;
KIRP	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.92	13.65	0.66	5.86e-32	Personality dimensions;
KIRP	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg10167378	chr1:228756711	NA	0.88	7.37	0.43	2.63e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.72	9.17	0.5	1.9e-17	Coronary artery disease;
KIRP	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	5.4	0.33	1.59e-7	Personality dimensions;
KIRP	trans	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg25898076	chr12:131559071	GPR133	0.37	6.03	0.36	5.86e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs9400467	0.537	rs449308	chr6:111480395	A/C	cg22127309	chr6:111907043	TRAF3IP2	-0.54	-5.14	-0.31	5.67e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg24110177	chr3:50126178	RBM5	0.71	9.5	0.52	2.01e-18	Menarche (age at onset);
KIRP	cis	rs1010254	0.510	rs56019388	chr5:151706225	T/G	cg12297329	chr5:152029980	NA	-0.65	-6.6	-0.39	2.56e-10	Optic nerve measurement (cup area);
KIRP	cis	rs6754311	0.684	rs11681248	chr2:136820076	C/T	cg05194412	chr2:137003533	NA	0.4	4.89	0.3	1.85e-6	Mosquito bite size;
KIRP	cis	rs3206736	0.803	rs329578	chr7:35094194	A/G	cg06685737	chr7:35301730	NA	0.44	6.83	0.4	6.8e-11	Diastolic blood pressure;
KIRP	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg21361702	chr7:150065534	REPIN1	0.67	6.73	0.39	1.17e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.45	0.33	1.21e-7	Bipolar disorder;
KIRP	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg27462398	chr1:86174642	ZNHIT6	-0.68	-10.71	-0.56	3.18e-22	Urate levels in overweight individuals;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg27532560	chr4:187881888	NA	-0.75	-12.68	-0.63	1.13e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.76	0.34	2.54e-8	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.48	-5.99	-0.36	7.23e-9	Longevity;Endometriosis;
KIRP	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	1.02	9.45	0.52	2.77e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4700695	0.841	rs251300	chr5:65299715	C/G	cg21114390	chr5:65439923	SFRS12	-0.58	-6.18	-0.37	2.67e-9	Facial morphology (factor 19);
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg14338887	chr6:42928500	GNMT	0.39	5.42	0.33	1.45e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2717559	0.568	rs35093407	chr8:143885501	G/A	cg17252645	chr8:143867129	LY6D	-0.38	-6.01	-0.36	6.7e-9	Urinary tract infection frequency;
KIRP	cis	rs9596863	0.898	rs8000553	chr13:54344501	C/T	ch.13.53330881F	chr13:54432880	NA	0.58	5.57	0.33	6.67e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.56	-7.33	-0.42	3.35e-12	Aortic root size;
KIRP	cis	rs7106204	0.514	rs7123539	chr11:24272000	G/A	ch.11.24196551F	chr11:24239977	NA	-0.78	-6.98	-0.41	2.75e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.8	-10.35	-0.55	4.36e-21	Neutrophil percentage of white cells;
KIRP	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg13319975	chr6:146136371	FBXO30	0.4	5.48	0.33	1.04e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00852783	chr1:26633632	UBXN11	0.58	7.74	0.44	2.63e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg22875332	chr1:76189707	ACADM	-0.35	-5.07	-0.31	7.71e-7	Daytime sleep phenotypes;
KIRP	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg05791153	chr7:19748676	TWISTNB	-0.49	-5.72	-0.34	3.11e-8	Thyroid stimulating hormone;
KIRP	trans	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg06311355	chr22:24577269	SUSD2	-0.3	-6.19	-0.37	2.56e-9	Prostate cancer;
KIRP	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.85	-10.99	-0.57	4.1000000000000003e-23	Cognitive function;
KIRP	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.7	7.06	0.41	1.67e-11	Menarche (age at onset);
KIRP	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg27398547	chr14:60952738	C14orf39	0.68	6.7	0.39	1.42e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg01422370	chr2:73384389	NA	0.44	5.87	0.35	1.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1451375	0.698	rs10899748	chr7:50646089	G/A	cg14593290	chr7:50529359	DDC	0.56	6.9	0.4	4.33e-11	Malaria;
KIRP	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.07	-0.31	7.97e-7	Schizophrenia;
KIRP	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.29	-6.05	-0.36	5.27e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.69	-0.66	4.32e-32	Primary sclerosing cholangitis;
KIRP	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.71	9.34	0.51	5.87e-18	Morning vs. evening chronotype;
KIRP	cis	rs4356932	0.967	rs6835736	chr4:76962494	A/T	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9311676	0.632	rs56398717	chr3:58404355	G/A	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg09408571	chr1:101003634	GPR88	0.24	5.56	0.33	6.87e-8	Monocyte count;
KIRP	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg26139080	chr11:47293733	MADD	-0.42	-5.12	-0.31	6.13e-7	HDL cholesterol;
KIRP	cis	rs6693567	0.565	rs832621	chr1:150392909	G/C	cg07843065	chr1:150265600	MRPS21	0.47	6.61	0.39	2.43e-10	Migraine;
KIRP	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg21573476	chr21:45109991	RRP1B	0.64	8.62	0.48	8.02e-16	Mean corpuscular volume;
KIRP	trans	rs970548	0.909	rs55665473	chr10:46022005	G/A	cg01246622	chr10:115141827	NA	0.5	6.37	0.38	9e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg17554472	chr22:41940697	POLR3H	0.43	5.15	0.31	5.23e-7	Cannabis dependence symptom count;
KIRP	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg16497661	chr14:103986332	CKB	-0.52	-6.44	-0.38	6.36e-10	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00001245	chr3:15106710	MRPS25	0.47	6.61	0.39	2.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg21775007	chr8:11205619	TDH	0.74	11.33	0.59	3.22e-24	Retinal vascular caliber;
KIRP	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg09455208	chr3:40491958	NA	0.34	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg18882449	chr10:104885122	NT5C2	-0.51	-6.51	-0.38	4.12e-10	Arsenic metabolism;
KIRP	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.32	-0.32	2.29e-7	Tonsillectomy;
KIRP	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs9790314	0.589	rs4679662	chr3:160603024	T/C	cg19274270	chr17:78178856	CARD14	0.35	6.23	0.37	2.05e-9	Morning vs. evening chronotype;
KIRP	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.65	-0.48	6.71e-16	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6832769	1.000	rs9998146	chr4:56397977	C/T	cg09317128	chr4:56265301	TMEM165	-0.55	-6.98	-0.41	2.74e-11	Personality dimensions;
KIRP	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg05775895	chr3:12838266	CAND2	0.4	6.98	0.41	2.77e-11	QRS complex (12-leadsum);
KIRP	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09826364	chr7:158789723	NA	-0.44	-5.56	-0.33	6.95e-8	Facial morphology (factor 20);
KIRP	cis	rs77688320	0.535	rs10460403	chr2:202342737	A/G	cg06431681	chr2:202330990	STRADB	0.55	7.42	0.43	1.93e-12	Breast cancer;
KIRP	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.14	-9.79	-0.53	2.48e-19	Body mass index;
KIRP	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.53	6.96	0.41	3.05e-11	HDL cholesterol;
KIRP	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.65	-8.81	-0.49	2.28e-16	Ear protrusion;
KIRP	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg01475377	chr6:109611718	NA	-0.4	-5.66	-0.34	4.27e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg01941274	chr14:50234650	KLHDC2	0.4	4.94	0.3	1.47e-6	Carotid intima media thickness;
KIRP	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg19773385	chr1:10388646	KIF1B	-0.67	-9.12	-0.5	2.75e-17	Hepatocellular carcinoma;
KIRP	cis	rs1440410	0.830	rs6816223	chr4:144181711	T/C	cg01719995	chr4:144104893	USP38	0.39	5.02	0.3	1.01e-6	Ischemic stroke;
KIRP	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg00852783	chr1:26633632	UBXN11	-0.5	-4.93	-0.3	1.51e-6	Obesity-related traits;
KIRP	cis	rs2120243	0.510	rs10936087	chr3:157106628	T/G	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs3762637	0.941	rs9810999	chr3:122074391	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.7	-0.34	3.39e-8	LDL cholesterol levels;
KIRP	cis	rs6132905	0.590	rs74765630	chr20:2606745	C/T	cg24848351	chr20:2622020	TMC2	-0.61	-5.84	-0.35	1.67e-8	Mumps;
KIRP	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.64	-8.32	-0.47	5.99e-15	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.13	-0.5	2.52e-17	Response to antipsychotic treatment;
KIRP	cis	rs9400467	0.537	rs12214550	chr6:111505499	C/T	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	-0.77	-10.41	-0.55	2.84e-21	Inflammatory bowel disease;
KIRP	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg26134248	chr17:3907702	NA	-0.54	-7.94	-0.45	7.28e-14	Type 2 diabetes;
KIRP	cis	rs10875746	0.669	rs10875772	chr12:48609553	C/T	cg20731937	chr12:48336164	NA	0.47	5.75	0.34	2.66e-8	Longevity (90 years and older);
KIRP	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg25182066	chr10:30743637	MAP3K8	0.6	5.31	0.32	2.4e-7	Itch intensity from mosquito bite;
KIRP	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.53	6.92	0.4	3.96e-11	Prudent dietary pattern;
KIRP	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs684232	0.649	rs838369	chr17:578180	T/C	cg15660573	chr17:549704	VPS53	-0.8	-11.98	-0.61	2.37e-26	Prostate cancer;
KIRP	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.45	6.32	0.37	1.19e-9	Dupuytren's disease;
KIRP	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03138863	chr12:10978947	TAS2R10	-0.42	-6.58	-0.39	2.78e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs244899	0.904	rs168647	chr5:167912404	G/A	cg06604206	chr5:167912465	RARS	-0.53	-7.67	-0.44	3.98e-13	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs9912789	0.875	rs9892075	chr17:79186737	T/C	cg25342872	chr17:79175132	AZI1	-0.61	-8.33	-0.47	5.75e-15	Frontotemporal dementia;
KIRP	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.82	11.43	0.59	1.51e-24	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg08975724	chr8:8085496	FLJ10661	0.52	6.43	0.38	6.57e-10	Retinal vascular caliber;
KIRP	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg07661805	chr8:143867942	LY6D	-0.28	-4.98	-0.3	1.21e-6	Urinary tract infection frequency;
KIRP	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg27462398	chr1:86174642	ZNHIT6	0.48	5.79	0.35	2.13e-8	Urate levels in overweight individuals;
KIRP	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.7	-10.22	-0.55	1.13e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs3087591	0.683	rs757375	chr17:29717879	C/G	cg24425628	chr17:29625626	OMG;NF1	0.64	9.35	0.51	5.45e-18	Hip circumference;
KIRP	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg00981070	chr1:2046702	PRKCZ	0.4	5.85	0.35	1.58e-8	Height;
KIRP	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.09	-0.46	2.82e-14	Systemic lupus erythematosus;
KIRP	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg08885076	chr2:99613938	TSGA10	0.53	9.29	0.51	8.38e-18	Chronic sinus infection;
KIRP	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg02367723	chr1:46378857	MAST2	0.43	5.05	0.31	8.74e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs13170463	0.579	rs80224259	chr5:8043844	G/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs748404	0.697	rs471122	chr15:43558574	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-7.39	-0.43	2.27e-12	Lung cancer;
KIRP	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13126279	chr21:47581558	C21orf56	-0.42	-4.97	-0.3	1.24e-6	Testicular germ cell tumor;
KIRP	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.36	8.09	0.46	2.8e-14	Cutaneous nevi;
KIRP	cis	rs240764	0.658	rs9322181	chr6:101221630	C/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg16606324	chr3:10149918	C3orf24	0.56	5.26	0.32	3.19e-7	Alzheimer's disease;
KIRP	cis	rs4748857	0.947	rs4603206	chr10:23607192	C/T	cg12804278	chr10:23633326	C10orf67	0.45	5.41	0.33	1.48e-7	Systemic lupus erythematosus;
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg17441377	chr17:3906640	NA	0.46	5.99	0.36	7.59e-9	Type 2 diabetes;
KIRP	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg06565975	chr8:143823917	SLURP1	-0.34	-4.92	-0.3	1.58e-6	Urinary tract infection frequency;
KIRP	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.6	-6.87	-0.4	5.2e-11	Menarche (age at onset);
KIRP	cis	rs789859	0.965	rs789858	chr3:194405966	C/T	cg02072170	chr3:194406190	FAM43A	0.39	5.93	0.35	1e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg16691251	chr5:66510806	NA	-0.38	-5.15	-0.31	5.44e-7	Breast cancer;
KIRP	cis	rs2050392	0.792	rs9338188	chr10:30721963	G/C	cg25182066	chr10:30743637	MAP3K8	-0.64	-8.75	-0.49	3.51e-16	Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04793916	chr14:71275942	MAP3K9	0.49	6.23	0.37	1.97e-9	Parkinson's disease;
KIRP	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.25	-0.32	3.3e-7	Hip geometry;
KIRP	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.72	-0.39	1.26e-10	Systolic blood pressure;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00699235	chr12:49962218	MCRS1	-0.49	-6.39	-0.38	8.36e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg00405596	chr8:11794950	NA	0.44	5.65	0.34	4.54e-8	Retinal vascular caliber;
KIRP	trans	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg10756647	chr7:56101905	PSPH	1.08	8.58	0.48	1.08e-15	Diabetic kidney disease;
KIRP	cis	rs554111	0.637	rs529162	chr1:21063311	T/A	cg21184320	chr1:21044207	KIF17	0.4	5.91	0.35	1.15e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg08999081	chr20:33150536	PIGU	-0.39	-5.11	-0.31	6.36e-7	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14589563	chr11:63438716	ATL3	0.48	6.17	0.37	2.84e-9	Parkinson's disease;
KIRP	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.18	-0.77	9.19e-51	Schizophrenia;
KIRP	cis	rs5753037	0.869	rs5997546	chr22:30259342	A/G	cg27665648	chr22:30112403	NA	0.34	4.86	0.3	2.1e-6	Type 1 diabetes;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.88	8.37	0.47	4.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.29	0.42	4.1e-12	Rheumatoid arthritis;
KIRP	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.59	-7.0	-0.41	2.4e-11	Cognitive test performance;
KIRP	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg16255804	chr6:135334527	HBS1L	-0.31	-4.91	-0.3	1.69e-6	Red blood cell count;
KIRP	cis	rs745080	0.674	rs4088516	chr14:52947062	C/T	cg23333723	chr14:53022898	GPR137C	-0.4	-5.51	-0.33	9.02e-8	Orofacial clefts;
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg05562828	chr17:3906858	NA	-0.72	-14.33	-0.67	2.91e-34	Type 2 diabetes;
KIRP	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.43	0.52	3.15e-18	Hirschsprung disease;
KIRP	cis	rs1408799	0.830	rs10960752	chr9:12675284	G/A	cg05274944	chr9:12693694	TYRP1	0.35	4.98	0.3	1.22e-6	Eye color;Blue vs. green eyes;
KIRP	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg19847130	chr8:10466454	RP1L1	-0.42	-6.14	-0.36	3.26e-9	Retinal vascular caliber;
KIRP	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.29	0.37	1.44e-9	Homocysteine levels;
KIRP	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.57	-6.48	-0.38	4.97e-10	Hypospadias;
KIRP	cis	rs17121403	0.661	rs12138063	chr1:100505721	G/T	cg24955406	chr1:100503596	HIAT1	0.76	5.01	0.3	1.05e-6	Pulmonary function decline;
KIRP	cis	rs9900062	0.546	rs2676294	chr17:62710764	A/G	cg02097616	chr17:62675921	NA	-0.52	-6.45	-0.38	5.76e-10	QT interval;
KIRP	cis	rs10849893	0.595	rs10444490	chr12:121876385	G/C	cg01154721	chr12:121881891	KDM2B	-0.42	-5.48	-0.33	1.05e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-4.93	-0.3	1.52e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7106204	0.686	rs12790317	chr11:24254405	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	7.71	0.44	3.19e-13	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.07	0.8	5.15e-57	Prudent dietary pattern;
KIRP	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.21	-0.67	7.22e-34	Alzheimer's disease;
KIRP	cis	rs6681460	1.000	rs2872078	chr1:67127367	C/A	cg02459107	chr1:67143332	SGIP1	0.52	7.42	0.43	1.86e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg00262122	chr8:11665843	FDFT1	0.44	5.51	0.33	8.86e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.6	12.59	0.63	2.18e-28	Diabetic kidney disease;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg05316006	chr10:114879619	TCF7L2	-0.42	-6.11	-0.36	3.79e-9	Select biomarker traits;
KIRP	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg25019033	chr10:957182	NA	-0.6	-6.65	-0.39	1.9e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	0.73	6.54	0.38	3.57e-10	Skin colour saturation;
KIRP	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg00262122	chr8:11665843	FDFT1	-0.42	-5.21	-0.32	4.04e-7	Myopia (pathological);
KIRP	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.31	-5.15	-0.31	5.27e-7	Height;
KIRP	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg04306507	chr14:55594613	LGALS3	0.53	8.43	0.47	2.92e-15	Protein biomarker;
KIRP	cis	rs7601312	1.000	rs2194554	chr2:229322868	G/A	cg02542817	chr2:229291442	NA	-0.38	-5.45	-0.33	1.23e-7	Schizophrenia;
KIRP	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg23166289	chr1:210001082	C1orf107	0.53	5.91	0.35	1.13e-8	Orofacial clefts;
KIRP	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg01181863	chr3:195395398	SDHAP2	-0.47	-5.47	-0.33	1.08e-7	Pancreatic cancer;
KIRP	trans	rs6741892	1.000	rs13012704	chr2:38918793	T/C	cg07212940	chr3:62304165	C3orf14	0.8	6.24	0.37	1.9e-9	5-HTT brain serotonin transporter levels;
KIRP	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05025164	chr4:1340916	KIAA1530	0.41	5.14	0.31	5.64e-7	Obesity-related traits;
KIRP	cis	rs4656940	0.574	rs2769587	chr1:160761451	G/A	cg17331569	chr1:160788135	LY9	0.45	5.2	0.31	4.17e-7	Crohn's disease;
KIRP	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.61	-0.34	5.37e-8	Recombination measurement;
KIRP	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg04166393	chr7:2884313	GNA12	0.46	6.02	0.36	6.3e-9	Height;
KIRP	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.05e-8	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07811113	chr19:1408140	DAZAP1	0.58	7.22	0.42	6.35e-12	Parkinson's disease;
KIRP	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.16e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.54	5.71	0.34	3.22e-8	Response to diuretic therapy;
KIRP	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.4	-15.12	-0.69	5.88e-37	Plateletcrit;
KIRP	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.93	15.23	0.7	2.33e-37	Height;
KIRP	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	1.12	8.24	0.47	1.03e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg03714773	chr7:91764589	CYP51A1	-0.34	-4.86	-0.3	2.12e-6	Breast cancer;
KIRP	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.57	-6.96	-0.41	3.15e-11	Uric acid clearance;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg25703541	chr22:24373054	LOC391322	0.58	6.4	0.38	7.69e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg21333033	chr2:241827789	C2orf54	-0.36	-4.91	-0.3	1.66e-6	Urinary metabolites;
KIRP	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.78	11.69	0.6	2.11e-25	Total body bone mineral density;
KIRP	cis	rs7011049	0.908	rs72640860	chr8:53840500	G/A	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg10169327	chr19:45448959	APOC2	0.33	5.06	0.31	8.25e-7	Blood protein levels;
KIRP	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	0.96	10.5	0.56	1.53e-21	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg16989719	chr2:238392110	NA	-0.55	-6.29	-0.37	1.41e-9	Prostate cancer;
KIRP	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.28	-0.65	1.01e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.37	0.51	4.73e-18	Coffee consumption (cups per day);
KIRP	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.75	-8.11	-0.46	2.33e-14	Diastolic blood pressure;
KIRP	cis	rs7017914	0.967	rs6993115	chr8:71699183	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14505161	chr7:30544458	GGCT	-0.49	-6.08	-0.36	4.55e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-0.72	-6.64	-0.39	2.03e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg09788416	chr12:39539408	NA	0.4	5.37	0.32	1.85e-7	Morning vs. evening chronotype;
KIRP	cis	rs539514	0.614	rs598500	chr13:76370564	A/G	cg04757411	chr13:76259545	LMO7	0.38	5.35	0.32	2.05e-7	Type 1 diabetes;
KIRP	cis	rs6807915	0.603	rs7611617	chr3:12289142	C/T	cg02700894	chr3:12045449	SYN2	-0.35	-5.01	-0.3	1.05e-6	Leprosy;
KIRP	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg19847130	chr8:10466454	RP1L1	-0.36	-5.39	-0.33	1.61e-7	Triglycerides;
KIRP	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.64	8.37	0.47	4.33e-15	Body mass index;
KIRP	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	cis	rs7766436	0.961	rs6922960	chr6:22570189	T/C	cg13666174	chr6:22585274	NA	-0.4	-5.69	-0.34	3.59e-8	Coronary artery disease;
KIRP	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.72	0.39	1.23e-10	Aortic root size;
KIRP	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.5	-5.34	-0.32	2.08e-7	Body mass index;
KIRP	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.19	0.67	8.48e-34	Cognitive function;
KIRP	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg15655495	chr12:38532458	NA	0.27	5.33	0.32	2.25e-7	Bladder cancer;
KIRP	cis	rs1829883	0.668	rs4099249	chr5:98987121	C/A	cg08333243	chr5:99726346	NA	0.41	5.23	0.32	3.57e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23903597	chr17:61704154	MAP3K3	-0.6	-6.65	-0.39	1.84e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1829883	0.798	rs1403669	chr5:98794713	A/G	cg08333243	chr5:99726346	NA	-0.41	-5.3	-0.32	2.59e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg23594656	chr7:65796392	TPST1	-0.45	-7.15	-0.41	9.88e-12	Aortic root size;
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	14.81	0.69	6.35e-36	Platelet count;
KIRP	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.27	-0.37	1.65e-9	Monocyte percentage of white cells;
KIRP	cis	rs6977660	0.943	rs10270447	chr7:19849823	C/G	cg05791153	chr7:19748676	TWISTNB	-0.49	-5.29	-0.32	2.64e-7	Thyroid stimulating hormone;
KIRP	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg19746982	chr18:77552568	NA	0.29	5.01	0.3	1.02e-6	Schizophrenia;
KIRP	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.49	-0.33	1.01e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.95	-0.41	3.27e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg12384639	chr17:618140	VPS53	0.48	5.94	0.35	9.82e-9	Prostate cancer;
KIRP	cis	rs12580194	0.556	rs58780687	chr12:55736498	A/C	cg11794356	chr12:55725991	OR6C3	-0.54	-7.16	-0.42	9.37e-12	Cancer;
KIRP	trans	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.07	-0.41	1.61e-11	Bladder cancer;
KIRP	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg23127183	chr11:57508653	C11orf31	-0.54	-6.98	-0.41	2.79e-11	Schizophrenia;
KIRP	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.66	-7.44	-0.43	1.67e-12	Lung cancer;
KIRP	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.9	-14.94	-0.69	2.41e-36	Prostate cancer;
KIRP	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.58	8.02	0.46	4.37e-14	Heart rate;
KIRP	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.49	-0.48	2.03e-15	Coronary artery disease;
KIRP	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.47	6.01	0.36	6.57e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.66	-8.17	-0.46	1.6e-14	Aortic root size;
KIRP	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.63	0.39	2.11e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12930096	1.000	rs12929430	chr16:11679467	C/T	cg07439791	chr16:11680400	LITAF	0.65	5.72	0.34	3.06e-8	QT interval;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16910805	chr2:62081285	FAM161A	0.48	6.51	0.38	4.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg04154034	chr17:28927549	LRRC37B2	-0.49	-4.92	-0.3	1.6e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06647332	chr5:131281008	NA	-0.45	-4.92	-0.3	1.58e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9653442	0.545	rs4490209	chr2:100766711	C/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.48	-0.33	1.08e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs12517041	1.000	rs6879916	chr5:23312603	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	trans	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg24644049	chr4:85504048	CDS1	0.85	6.6	0.39	2.53e-10	Skin colour saturation;
KIRP	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg03929089	chr4:120376271	NA	0.68	6.09	0.36	4.34e-9	Axial length;
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg02462569	chr6:150064036	NUP43	-0.41	-6.13	-0.36	3.46e-9	Lung cancer;
KIRP	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg14847009	chr1:175162515	KIAA0040	-0.24	-5.09	-0.31	7.24e-7	Alcohol dependence;
KIRP	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.46	5.6	0.34	5.79e-8	Asthma (sex interaction);
KIRP	cis	rs6545883	0.524	rs811871	chr2:61577949	C/T	cg15711740	chr2:61764176	XPO1	0.45	5.4	0.33	1.54e-7	Tuberculosis;
KIRP	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.69	6.7	0.39	1.4e-10	Axial length;
KIRP	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg06917634	chr15:78832804	PSMA4	-0.47	-4.86	-0.3	2.07e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs17209837	1.000	rs12673662	chr7:87110351	C/G	cg00919237	chr7:87102261	ABCB4	0.64	6.6	0.39	2.53e-10	Gallbladder cancer;
KIRP	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg16497277	chr3:49208875	KLHDC8B	0.39	4.97	0.3	1.23e-6	Menarche (age at onset);
KIRP	cis	rs2562456	0.754	rs62109226	chr19:21536913	T/C	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg23032965	chr3:12705835	RAF1	0.73	8.02	0.46	4.27e-14	Cholesterol, total;
KIRP	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg03959625	chr15:84868606	LOC388152	-0.63	-7.06	-0.41	1.74e-11	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg23587288	chr2:27483067	SLC30A3	-0.62	-6.87	-0.4	5.2e-11	Blood metabolite levels;
KIRP	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.85	-0.3	2.24e-6	Pulmonary function;
KIRP	cis	rs4851266	0.765	rs11123821	chr2:100871189	A/C	cg05692746	chr2:100937584	LONRF2	-0.46	-5.35	-0.32	1.99e-7	Educational attainment;
KIRP	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.51	7.22	0.42	6.37e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg03289416	chr15:75166202	SCAMP2	-0.44	-6.19	-0.37	2.48e-9	Caffeine consumption;
KIRP	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.75	10.01	0.54	5.27e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-1.01	-12.41	-0.62	8.42e-28	Breast cancer;
KIRP	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.55	0.62	2.88e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.29	-0.32	2.7e-7	Gut microbiome composition (summer);
KIRP	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs10421328	0.784	rs28635562	chr19:19769690	C/T	cg03709012	chr19:19516395	GATAD2A	0.49	5.68	0.34	3.88e-8	Parental longevity (combined parental age at death);
KIRP	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	13.77	0.66	2.29e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-7.71	-0.44	3.13e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9470366	0.816	rs7742159	chr6:36619452	A/C	cg08179530	chr6:36648295	CDKN1A	0.53	6.44	0.38	6.13e-10	QRS duration;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg11859384	chr17:80120422	CCDC57	-0.41	-5.19	-0.31	4.3e-7	Life satisfaction;
KIRP	cis	rs7009516	0.819	rs11986557	chr8:24221339	G/A	cg01759110	chr8:24241694	ADAMDEC1	-0.29	-5.96	-0.36	8.49e-9	Hair greying;
KIRP	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.48	5.03	0.31	9.31e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs12579753	0.719	rs4418884	chr12:82277006	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.18	-0.37	2.57e-9	Resting heart rate;
KIRP	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg17279839	chr7:150038598	RARRES2	0.47	6.25	0.37	1.84e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.56	0.59	5.59e-25	Alzheimer's disease;
KIRP	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.18	0.31	4.58e-7	Smoking behavior;
KIRP	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-8.05	-0.46	3.43e-14	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20382932	chr2:71357258	MCEE;MPHOSPH10	0.44	6.4	0.38	7.96e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2505998	0.868	rs2505991	chr10:43566360	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.49	-4.92	-0.3	1.6e-6	Hirschsprung disease;
KIRP	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.59	7.44	0.43	1.73e-12	Tonsillectomy;
KIRP	cis	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg02336718	chr17:17403227	NA	-0.38	-5.88	-0.35	1.3e-8	Total body bone mineral density;
KIRP	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.39	-6.1	-0.36	4.15e-9	Lung cancer;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.05e-8	Lung cancer;
KIRP	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg14675211	chr2:100938903	LONRF2	0.5	6.63	0.39	2.16e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2548003	0.541	rs2014310	chr5:28723589	T/C	cg23224356	chr2:98206733	ANKRD36B	0.62	6.08	0.36	4.48e-9	Hip geometry;
KIRP	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg08501292	chr6:25962987	TRIM38	1.03	8.19	0.46	1.42e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg02336718	chr17:17403227	NA	0.35	5.43	0.33	1.35e-7	Total body bone mineral density;
KIRP	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg06050784	chr16:88016603	BANP	0.41	5.18	0.31	4.69e-7	Menopause (age at onset);
KIRP	cis	rs580438	0.510	rs6442382	chr3:13432581	C/T	cg10657019	chr3:13328039	NA	0.58	7.57	0.43	7.35e-13	Myringotomy;
KIRP	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg15605315	chr1:45957053	TESK2	0.4	5.09	0.31	7.28e-7	High light scatter reticulocyte count;
KIRP	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	1.1	21.85	0.81	1.46e-59	Height;
KIRP	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.13e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg25797454	chr6:150327115	RAET1K	0.32	5.95	0.35	9.39e-9	Alopecia areata;
KIRP	cis	rs904251	0.507	rs11756941	chr6:37416219	C/G	cg25019722	chr6:37503610	NA	-0.56	-5.19	-0.31	4.37e-7	Cognitive performance;
KIRP	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg16141378	chr3:129829833	LOC729375	0.62	8.4	0.47	3.51e-15	Triglycerides;
KIRP	cis	rs8077577	0.895	rs62072465	chr17:18114494	C/G	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.28	-0.55	7.63e-21	Coronary artery disease;
KIRP	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs986417	0.818	rs10142842	chr14:61085205	C/T	cg27398547	chr14:60952738	C14orf39	-0.56	-5.36	-0.32	1.92e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg01411142	chr8:19674711	INTS10	0.51	5.56	0.33	7.17e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg24846343	chr22:24311635	DDTL	0.46	4.91	0.3	1.64e-6	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg10755058	chr3:40428713	ENTPD3	0.39	5.39	0.32	1.67e-7	Renal cell carcinoma;
KIRP	trans	rs10487112	0.625	rs714498	chr7:90167839	A/T	cg27660165	chr1:156784036	SH2D2A	0.39	6.31	0.37	1.31e-9	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.55	7.25	0.42	5.45e-12	Breast cancer;
KIRP	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.97	9.63	0.52	7.88e-19	Lymphocyte counts;
KIRP	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05220968	chr6:146057943	EPM2A	0.4	5.13	0.31	5.88e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.67	7.32	0.42	3.46e-12	Smoking initiation;
KIRP	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.72	10.59	0.56	7.54e-22	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg09473613	chr1:24152604	HMGCL	-0.45	-5.93	-0.35	1.04e-8	Immature fraction of reticulocytes;
KIRP	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg14768367	chr16:72042858	DHODH	0.44	5.35	0.32	2.05e-7	Fibrinogen levels;
KIRP	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.5	6.26	0.37	1.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.62	11.97	0.61	2.45e-26	Bone mineral density;
KIRP	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.65	-0.34	4.33e-8	Coronary artery disease;
KIRP	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.36	4.94	0.3	1.48e-6	Coronary artery disease;
KIRP	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	1.04	20.17	0.79	4.8e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs41264869	0.628	rs12048453	chr1:205134987	T/C	cg21214746	chr1:205091277	RBBP5	0.5	6.4	0.38	7.8e-10	Blood protein levels;
KIRP	cis	rs12143943	0.834	rs34812029	chr1:204546987	A/G	cg20240347	chr1:204465584	NA	-0.35	-6.46	-0.38	5.48e-10	Cognitive performance;
KIRP	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	7.94	0.45	7.11e-14	Post bronchodilator FEV1;
KIRP	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.47	-5.05	-0.31	8.75e-7	Psoriasis;
KIRP	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.61	7.73	0.44	2.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg08822215	chr16:89438651	ANKRD11	-0.49	-6.58	-0.39	2.77e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.61	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.11	-0.41	1.28e-11	Myopia (pathological);
KIRP	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg03609598	chr5:56110824	MAP3K1	-0.44	-4.89	-0.3	1.78e-6	Coronary artery disease;
KIRP	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01171360	chr6:293285	DUSP22	-0.54	-6.19	-0.37	2.45e-9	Menopause (age at onset);
KIRP	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.84	-0.35	1.67e-8	Type 2 diabetes;
KIRP	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.64	0.44	4.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs516243	0.703	rs284313	chr1:10736434	A/G	cg02903756	chr1:10750680	CASZ1	-0.39	-5.93	-0.35	1.01e-8	Migraine - clinic-based;
KIRP	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg05220968	chr6:146057943	EPM2A	0.39	4.93	0.3	1.53e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8067545	0.640	rs17759083	chr17:19963605	T/A	cg13482628	chr17:19912719	NA	0.59	7.6	0.44	6.41e-13	Schizophrenia;
KIRP	cis	rs2671245	1.000	rs2671242	chr1:56163388	A/G	cg11523071	chr1:56160889	NA	0.4	6.16	0.37	2.91e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073221	0.654	rs35110494	chr3:18290188	C/A	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.81	-7.14	-0.41	1.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg08807101	chr21:30365312	RNF160	-0.55	-5.38	-0.32	1.72e-7	Cognitive test performance;
KIRP	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.02	0.41	2.19e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8018808	0.935	rs2242619	chr14:77895119	C/T	cg18872420	chr14:78023429	SPTLC2	-0.33	-4.88	-0.3	1.91e-6	Myeloid white cell count;
KIRP	cis	rs73198271	1.000	rs73198279	chr8:8608504	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.94	-0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg16736954	chr20:23401023	NAPB	0.62	4.87	0.3	2.03e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16301890	chr10:119301464	EMX2;EMX2OS	0.93	6.7	0.39	1.43e-10	P wave terminal force;
KIRP	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.59	7.37	0.43	2.59e-12	Corneal astigmatism;
KIRP	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21747090	chr2:27597821	SNX17	-0.48	-6.57	-0.39	2.99e-10	Total body bone mineral density;
KIRP	cis	rs580438	0.548	rs3773302	chr3:13379400	C/T	cg10657019	chr3:13328039	NA	-0.48	-6.33	-0.37	1.13e-9	Myringotomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14849639	chr18:12948029	SEH1L	0.52	6.63	0.39	2.13e-10	Parkinson's disease;
KIRP	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg08975724	chr8:8085496	FLJ10661	0.57	7.6	0.44	6.4e-13	Mean corpuscular hemoglobin;
KIRP	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.74	-0.39	1.13e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.78	12.8	0.63	4.47e-29	Menarche (age at onset);
KIRP	cis	rs2625529	0.526	rs10851850	chr15:72486509	A/G	cg16672083	chr15:72433130	SENP8	0.42	5.81	0.35	1.94e-8	Red blood cell count;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg00738919	chr7:1100172	C7orf50	0.42	4.97	0.3	1.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.83	0.35	1.77e-8	Motion sickness;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg23034840	chr1:205782522	SLC41A1	0.53	6.31	0.37	1.3e-9	Menarche (age at onset);
KIRP	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.67	-10.21	-0.55	1.22e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg26681399	chr22:41777847	TEF	0.42	4.84	0.3	2.26e-6	Vitiligo;
KIRP	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg23601095	chr6:26197514	HIST1H3D	0.94	8.33	0.47	5.88e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg23920097	chr1:209922102	NA	-0.48	-5.63	-0.34	4.96e-8	Red blood cell count;
KIRP	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs2274273	1.000	rs72718804	chr14:55630610	G/A	cg04306507	chr14:55594613	LGALS3	0.44	6.78	0.4	8.74e-11	Protein biomarker;
KIRP	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-7.24	-0.42	5.88e-12	Lung cancer;
KIRP	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.62	8.19	0.46	1.47e-14	Lymphocyte counts;
KIRP	cis	rs10045504	0.502	rs17352898	chr5:38745498	C/T	cg15396434	chr5:38725168	NA	-0.96	-9.57	-0.52	1.21e-18	Night sleep phenotypes;
KIRP	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.18	0.58	9.56e-24	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18514344	chr10:95242156	MYOF	-0.49	-6.06	-0.36	5.08e-9	Interleukin-4 levels;
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.26	-5.33	-0.32	2.17e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-1.2	-10.38	-0.55	3.59e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs7534824	0.625	rs6676834	chr1:101463788	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.14	0.41	1.05e-11	Refractive astigmatism;
KIRP	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2019216	0.542	rs1987424	chr17:21874036	G/A	cg22648282	chr17:21454238	C17orf51	-0.51	-6.54	-0.38	3.6e-10	Pelvic organ prolapse;
KIRP	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.36	-0.47	4.53e-15	Myopia (pathological);
KIRP	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.75	8.44	0.47	2.76e-15	Response to diuretic therapy;
KIRP	cis	rs10518128	1.000	rs7686578	chr4:75712726	A/G	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.87	14.08	0.67	2e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7578199	0.924	rs10172060	chr2:242325381	T/A	cg01632474	chr2:242799312	PDCD1	0.38	4.88	0.3	1.93e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg07423050	chr13:99094983	FARP1	-0.57	-8.49	-0.48	1.95e-15	Longevity;
KIRP	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07570687	chr10:102243282	WNT8B	0.52	6.84	0.4	6.22e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.39	9.56	0.52	1.29e-18	Corneal astigmatism;
KIRP	cis	rs7760535	0.811	rs464401	chr6:111669007	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Metabolic traits;
KIRP	cis	rs4006360	0.604	rs3843964	chr17:39227984	C/T	cg15015397	chr17:39261100	KRTAP4-9	0.52	8.07	0.46	3.18e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg17554472	chr22:41940697	POLR3H	0.67	6.94	0.4	3.55e-11	Vitiligo;
KIRP	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.54	6.59	0.39	2.64e-10	Monocyte count;
KIRP	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-6.77	-0.4	9.56e-11	Chronic sinus infection;
KIRP	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg06521331	chr12:34319734	NA	-0.6	-7.25	-0.42	5.47e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10214930	0.813	rs12700825	chr7:27672571	G/A	cg22168087	chr7:27702803	HIBADH	0.51	5.07	0.31	7.97e-7	Hypospadias;
KIRP	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.76	8.69	0.48	5.16e-16	Platelet count;
KIRP	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.98	-15.1	-0.69	6.55e-37	Height;
KIRP	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.65	0.52	6.73e-19	Corneal astigmatism;
KIRP	cis	rs787274	1.000	rs10759584	chr9:115554736	T/G	cg13803584	chr9:115635662	SNX30	-0.74	-8.38	-0.47	4e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs16858210	0.520	rs12633858	chr3:183549395	C/T	cg03417191	chr3:183542750	MAP6D1	-0.61	-5.4	-0.33	1.57e-7	Menopause (age at onset);
KIRP	cis	rs9381107	1.000	rs11754173	chr6:9455664	T/G	cg14735645	chr6:9486422	NA	-0.44	-5.23	-0.32	3.71e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg10117171	chr1:25599238	RHD	-0.44	-6.16	-0.37	2.99e-9	Erythrocyte sedimentation rate;
KIRP	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.22	-0.58	7.52e-24	Chronic sinus infection;
KIRP	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.53	0.65	1.49e-31	Bladder cancer;
KIRP	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12560992	chr17:57184187	TRIM37	0.6	6.98	0.41	2.66e-11	Testicular germ cell tumor;
KIRP	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.81	0.49	2.28e-16	Bladder cancer;
KIRP	cis	rs4971059	0.629	rs11264333	chr1:155108287	G/A	cg02153340	chr1:155202674	NA	-0.43	-6.2	-0.37	2.37e-9	Breast cancer;
KIRP	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg21972741	chr5:435613	AHRR	0.5	6.07	0.36	4.68e-9	Cystic fibrosis severity;
KIRP	cis	rs2278796	0.881	rs11240325	chr1:204955329	A/G	cg17947172	chr1:204966197	NFASC	0.57	7.66	0.44	4.2e-13	Mean platelet volume;
KIRP	cis	rs6807915	0.603	rs7632481	chr3:12293966	A/G	cg15873301	chr3:12045459	SYN2	-0.4	-5.27	-0.32	3.04e-7	Leprosy;
KIRP	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg12549451	chr6:135224345	NA	0.44	5.45	0.33	1.21e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.41	0.38	7.33e-10	Mean corpuscular volume;
KIRP	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.67	-0.34	4.07e-8	Depression;
KIRP	trans	rs656319	0.513	rs17746245	chr8:9981686	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.47	0.43	1.43e-12	Myopia (pathological);
KIRP	cis	rs6752107	0.936	rs13411660	chr2:234208258	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	7.91	0.45	8.92e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7395581	1.000	rs830085	chr11:47251199	G/A	cg26139080	chr11:47293733	MADD	0.4	4.91	0.3	1.64e-6	HDL cholesterol;
KIRP	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-4.89	-0.3	1.81e-6	Morning vs. evening chronotype;
KIRP	cis	rs7221595	0.825	rs8078629	chr17:3983964	A/C	cg21851534	chr17:3907994	ZZEF1	0.55	5.46	0.33	1.18e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.42e-6	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.08e-7	Breast cancer;
KIRP	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.82	9.72	0.53	4.18e-19	Pulmonary function decline;
KIRP	trans	rs17079247	0.841	rs9602694	chr13:85807464	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs7072216	0.555	rs2296432	chr10:100184063	C/G	cg11203827	chr10:100175560	PYROXD2	-0.37	-4.87	-0.3	1.96e-6	Metabolite levels;
KIRP	cis	rs1511802	0.666	rs2292424	chr4:187120625	G/A	cg24794857	chr4:187113578	CYP4V2	0.38	5.26	0.32	3.08e-7	Blood protein levels;
KIRP	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.84	0.53	1.76e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.81	-8.54	-0.48	1.46e-15	Hair shape;
KIRP	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.48	-5.85	-0.35	1.59e-8	P wave terminal force;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24321113	chr3:165513382	BCHE	-0.44	-6.62	-0.39	2.2e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg18032289	chr17:61959525	GH2	-0.4	-5.41	-0.33	1.47e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12282928	1.000	rs10838872	chr11:48336147	C/G	cg26585981	chr11:48327164	OR4S1	0.48	5.53	0.33	8.08e-8	Migraine - clinic-based;
KIRP	cis	rs12681963	0.688	rs2341177	chr8:30004493	C/T	cg04374813	chr8:30012889	DCTN6	0.47	4.85	0.3	2.15e-6	Migraine;
KIRP	cis	rs6832769	0.890	rs1522107	chr4:56380773	A/T	cg05960024	chr4:56376020	CLOCK	0.71	9.17	0.5	2.02e-17	Personality dimensions;
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.69	6.28	0.37	1.49e-9	Lung function (FEV1/FVC);
KIRP	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.66	9.4	0.51	3.87e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	8.79	0.49	2.58e-16	Neuroticism;
KIRP	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg08461772	chr7:95026248	PON3	0.4	5.76	0.34	2.51e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs62380364	0.613	rs254781	chr5:88000636	C/T	cg24804195	chr5:87968844	LOC645323	-0.49	-6.51	-0.38	4.23e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7894051	1.000	rs7894051	chr10:135184421	C/G	cg14353649	chr10:135191496	PAOX	-0.44	-5.04	-0.31	9.01e-7	Lifespan;
KIRP	cis	rs16936870	0.571	rs2977985	chr8:71142714	T/C	cg14232793	chr8:71155543	NCOA2	-0.59	-7.2	-0.42	7.33e-12	QT interval;
KIRP	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.09	-0.5	3.43e-17	Retinal vascular caliber;
KIRP	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.36	5.28	0.32	2.85e-7	Eye color traits;
KIRP	cis	rs12579753	0.574	rs7488890	chr12:82293300	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.49	-0.33	9.85e-8	Resting heart rate;
KIRP	cis	rs12200782	1.000	rs12211201	chr6:26461461	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.17	-0.37	2.73e-9	Small cell lung carcinoma;
KIRP	cis	rs66561647	0.661	rs7387614	chr8:128929353	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.42	5.3	0.32	2.52e-7	Hemoglobin concentration;
KIRP	cis	rs8523	0.804	rs7752895	chr6:11064780	C/T	cg13562911	chr6:11044106	ELOVL2	0.41	5.52	0.33	8.56e-8	Red blood cell fatty acid levels;
KIRP	cis	rs7709377	0.570	rs10079903	chr5:115435153	A/T	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.63	9.21	0.51	1.49e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.88	11.13	0.58	1.39e-23	Coronary artery disease;
KIRP	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.83	-8.32	-0.47	5.9e-15	Gut microbiome composition (summer);
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24011228	chr18:11908772	MPPE1	0.41	5.26	0.32	3.13e-7	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7819412	0.502	rs34440473	chr8:10906841	A/T	cg21775007	chr8:11205619	TDH	0.39	4.85	0.3	2.21e-6	Triglycerides;
KIRP	cis	rs13102973	0.538	rs13140134	chr4:135912595	C/T	cg14419869	chr4:135874104	NA	0.38	5.71	0.34	3.29e-8	Subjective well-being;
KIRP	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg12315302	chr6:26189340	HIST1H4D	1.05	6.41	0.38	7.21e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg02569458	chr12:86230093	RASSF9	0.37	5.3	0.32	2.58e-7	Major depressive disorder;
KIRP	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg19743168	chr1:23544995	NA	0.61	8.73	0.49	4.01e-16	Height;
KIRP	cis	rs10864907	0.935	rs2708919	chr2:113641631	T/C	cg03712744	chr2:113669835	IL1F7	-0.34	-4.98	-0.3	1.18e-6	Pulmonary function;
KIRP	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.87	12.44	0.62	6.79e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.12	0.31	6.3e-7	Bipolar disorder;
KIRP	cis	rs10214930	0.671	rs12534603	chr7:27652653	C/T	cg22168087	chr7:27702803	HIBADH	0.47	5.07	0.31	7.74e-7	Hypospadias;
KIRP	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	cg21523751	chr1:182988639	NA	-0.44	-6.95	-0.41	3.23e-11	Colorectal cancer;
KIRP	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg16988262	chr1:15930761	NA	0.4	5.13	0.31	6.02e-7	Systolic blood pressure;
KIRP	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.2	-0.8	1.87e-57	Ulcerative colitis;
KIRP	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.55	7.57	0.43	7.64e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13939156	chr17:80058883	NA	0.49	7.25	0.42	5.43e-12	Life satisfaction;
KIRP	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-9.06	-0.5	4.21e-17	Morning vs. evening chronotype;
KIRP	cis	rs4132509	0.793	rs6694738	chr1:243715210	C/A	cg21452805	chr1:244014465	NA	0.72	6.2	0.37	2.32e-9	RR interval (heart rate);
KIRP	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg17644776	chr2:200775616	C2orf69	0.58	6.17	0.37	2.86e-9	Schizophrenia;
KIRP	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg01988459	chr11:68622903	NA	-0.37	-5.25	-0.32	3.29e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2411233	0.967	rs1824494	chr15:39284763	G/A	cg02291532	chr15:39874776	THBS1	0.39	5.16	0.31	5.04e-7	Platelet count;
KIRP	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg13147721	chr7:65941812	NA	-0.9	-6.43	-0.38	6.58e-10	Diabetic kidney disease;
KIRP	cis	rs17065868	0.881	rs9525979	chr13:45118207	T/C	cg10246903	chr13:45222710	NA	0.69	6.47	0.38	5.38e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs12580194	0.556	rs61957898	chr12:55730423	T/C	cg19537932	chr12:55886519	OR6C68	-0.48	-6.38	-0.38	8.78e-10	Cancer;
KIRP	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg12311346	chr5:56204834	C5orf35	-0.39	-5.35	-0.32	1.97e-7	Coronary artery disease;
KIRP	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg07689907	chr11:61582574	FADS1	0.59	7.08	0.41	1.49e-11	Trans fatty acid levels;
KIRP	cis	rs12549025	0.530	rs11135740	chr8:23367757	A/G	cg00472375	chr8:23315376	ENTPD4	-0.45	-4.88	-0.3	1.91e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg13798780	chr7:105162888	PUS7	0.56	4.86	0.3	2.1e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs258892	0.895	rs463250	chr5:72144463	G/C	cg21869765	chr5:72125136	TNPO1	0.57	6.33	0.37	1.15e-9	Small cell lung carcinoma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07454192	chr8:74888262	TMEM70	0.56	6.55	0.39	3.33e-10	Smoking initiation;
KIRP	cis	rs11593576	0.861	rs10824731	chr10:81009237	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.4	-5.83	-0.35	1.76e-8	Vitiligo;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg05941025	chr16:89927596	SPIRE2	0.36	5.98	0.36	7.76e-9	Vitiligo;
KIRP	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.97	0.36	8.44e-9	Schizophrenia;
KIRP	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg03806693	chr22:41940476	POLR3H	-0.45	-5.37	-0.32	1.86e-7	Neuroticism;
KIRP	cis	rs236907	0.859	rs35631282	chr1:171760682	C/T	cg01410279	chr1:171621941	MYOC	-0.51	-4.92	-0.3	1.6e-6	Mean platelet volume;
KIRP	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg13206674	chr6:150067644	NUP43	0.5	7.05	0.41	1.85e-11	Testicular germ cell tumor;
KIRP	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg25866889	chr13:114914595	NA	-0.4	-5.58	-0.33	6.46e-8	Schizophrenia;
KIRP	cis	rs2273669	1.000	rs2273669	chr6:109285189	A/G	cg05315195	chr6:109294784	ARMC2	-0.47	-5.3	-0.32	2.58e-7	Prostate cancer;
KIRP	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.57	-6.6	-0.39	2.46e-10	Bipolar disorder;
KIRP	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.5	0.38	4.37e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.71	7.78	0.44	1.95e-13	Corneal astigmatism;
KIRP	cis	rs7078219	0.965	rs11190134	chr10:101282200	C/T	cg07044859	chr10:101282883	NA	-0.33	-5.54	-0.33	7.57e-8	Dental caries;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.58	-7.82	-0.45	1.52e-13	Testicular germ cell tumor;
KIRP	cis	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg21775007	chr8:11205619	TDH	0.4	5.13	0.31	5.84e-7	Triglycerides;
KIRP	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg20991723	chr1:152506922	NA	-0.48	-5.86	-0.35	1.51e-8	Hair morphology;
KIRP	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.38	-0.43	2.5e-12	Aortic root size;
KIRP	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg06042504	chr8:55087323	NA	-0.61	-7.48	-0.43	1.34e-12	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg16141378	chr3:129829833	LOC729375	0.59	7.75	0.44	2.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.95	-14.04	-0.67	2.79e-33	Longevity;Endometriosis;
KIRP	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.43	8.47	0.48	2.31e-15	Coronary artery disease;
KIRP	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-0.51	-6.33	-0.37	1.16e-9	Acne (severe);
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16524936	chr4:1340807	KIAA1530	-0.42	-5.12	-0.31	6.07e-7	Longevity;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-1.01	-11.84	-0.6	6.66e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.38	14.37	0.68	2.05e-34	Schizophrenia;
KIRP	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.71	7.98	0.45	5.63e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Hypertriglyceridemia;
KIRP	cis	rs714027	0.585	rs41168	chr22:30418161	A/C	cg27665648	chr22:30112403	NA	-0.38	-5.17	-0.31	4.8e-7	Lymphocyte counts;
KIRP	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg25319279	chr11:5960081	NA	-0.58	-5.84	-0.35	1.65e-8	DNA methylation (variation);
KIRP	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs889398	0.802	rs9940315	chr16:69876164	A/G	cg09409435	chr16:70099608	PDXDC2	0.44	5.23	0.32	3.66e-7	Body mass index;
KIRP	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.78	0.35	2.26e-8	Breast cancer;
KIRP	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg16989719	chr2:238392110	NA	-0.47	-5.6	-0.34	5.73e-8	Prostate cancer;
KIRP	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-5.18	-0.31	4.73e-7	Platelet distribution width;
KIRP	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11987759	chr7:65425863	GUSB	0.44	5.8	0.35	2.03e-8	Aortic root size;
KIRP	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg23894439	chr1:183413866	NA	0.42	5.52	0.33	8.5e-8	Systemic lupus erythematosus;
KIRP	cis	rs4006360	0.579	rs6416910	chr17:39235562	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.88	-0.45	1.06e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2916247	1.000	rs34711026	chr8:93029914	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.57	-6.99	-0.41	2.51e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg06521331	chr12:34319734	NA	-0.45	-5.28	-0.32	2.77e-7	Resting heart rate;
KIRP	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-8.11	-0.46	2.41e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.59	6.76	0.4	1.02e-10	Cystic fibrosis severity;
KIRP	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.61	8.56	0.48	1.22e-15	Gait speed in old age;
KIRP	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.71	-10.8	-0.57	1.66e-22	Hepatocellular carcinoma;
KIRP	cis	rs2230307	0.536	rs57637634	chr1:100447467	G/A	cg24955406	chr1:100503596	HIAT1	0.6	6.63	0.39	2.09e-10	Carotid intima media thickness;
KIRP	cis	rs7223966	0.655	rs9906924	chr17:61634538	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.95	0.35	9.27e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9309473	0.950	rs2947860	chr2:73855386	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.38	-0.32	1.69e-7	Metabolite levels;
KIRP	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.7	9.86	0.53	1.5700000000000001e-19	Retinal vascular caliber;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg11418813	chr15:70203031	NA	1.05	6.16	0.37	2.87e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs6540559	0.543	rs664097	chr1:210422179	C/T	cg09074223	chr1:210466472	NA	0.59	5.8	0.35	2.06e-8	Cleft lip with or without cleft palate;
KIRP	trans	rs17834760	0.909	rs62423544	chr6:62041376	A/C	cg08476511	chr6:168435923	KIF25	0.53	6.11	0.36	3.77e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs13385	0.769	rs17118739	chr5:139597910	C/T	cg01860693	chr5:139557145	C5orf32	0.48	5.25	0.32	3.33e-7	Atrial fibrillation;
KIRP	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	7.89	0.45	9.64e-14	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18523979	chr3:13009124	IQSEC1	0.5	6.24	0.37	1.87e-9	Parkinson's disease;
KIRP	cis	rs2279817	0.780	rs71644065	chr1:18001669	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.7	-8.61	-0.48	8.82e-16	Neuroticism;
KIRP	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.4	5.33	0.32	2.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg02527881	chr3:46936655	PTH1R	-0.37	-5.32	-0.32	2.36e-7	Colorectal cancer;
KIRP	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg13165212	chr22:42675999	NA	-0.37	-6.22	-0.37	2.15e-9	Cognitive function;
KIRP	cis	rs2273156	1.000	rs12897612	chr14:35471147	C/T	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.39	-0.33	1.62e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg11211951	chr8:145729740	GPT	0.43	7.05	0.41	1.82e-11	Age at first birth;
KIRP	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.7	-8.47	-0.48	2.3e-15	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24727343	chr7:121418840	NA	-0.38	-6.38	-0.38	8.63e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	1.02	15.96	0.71	7.68e-40	Vitamin D levels;
KIRP	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	trans	rs10819937	0.895	rs477578	chr9:104202537	A/T	cg24374857	chr1:41158439	NFYC;LOC100130557	-0.5	-6.74	-0.39	1.09e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6782228	0.606	rs9828893	chr3:128332925	T/C	cg18648031	chr3:128330563	NA	0.28	5.83	0.35	1.7e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg26384229	chr12:38710491	ALG10B	-0.62	-7.86	-0.45	1.19e-13	Resting heart rate;
KIRP	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.63	9.14	0.5	2.41e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.62	-7.53	-0.43	9.61e-13	Mosquito bite size;
KIRP	cis	rs11250097	0.501	rs2409665	chr8:10736233	G/C	cg21625330	chr8:9911636	MSRA	0.38	4.95	0.3	1.38e-6	Neuroticism;
KIRP	cis	rs7937612	0.931	rs61898351	chr11:120199924	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.14	-0.41	1.07e-11	Intraocular pressure;
KIRP	cis	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg08501292	chr6:25962987	TRIM38	1.13	6.38	0.38	8.94e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg06026331	chr20:60912101	LAMA5	0.87	8.71	0.49	4.41e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.46	5.85	0.35	1.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12579753	0.667	rs10862391	chr12:82307080	A/G	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.49	-0.33	9.85e-8	Resting heart rate;
KIRP	cis	rs5752326	0.510	rs4822723	chr22:26873397	C/A	cg20819150	chr22:26891497	TFIP11	0.53	5.0	0.3	1.11e-6	Ischemic stroke;
KIRP	cis	rs4774899	0.966	rs12904321	chr15:57507579	A/T	cg13626582	chr15:57592083	LOC283663	-0.21	-5.04	-0.31	8.88e-7	Urinary tract infection frequency;
KIRP	cis	rs7221595	0.778	rs36054194	chr17:3900280	C/T	cg21851534	chr17:3907994	ZZEF1	0.47	5.0	0.3	1.1e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs12496230	0.794	rs7638818	chr3:66860600	T/A	cg17646820	chr3:66848679	NA	0.38	6.18	0.37	2.68e-9	Type 2 diabetes;
KIRP	cis	rs2573652	1.000	rs2581346	chr15:100514178	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.68	-10.23	-0.55	1.05e-20	Height;
KIRP	cis	rs931812	0.895	rs965625	chr8:101909749	T/C	cg07585502	chr8:101912084	NA	-0.66	-8.76	-0.49	3.24e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg12486944	chr17:80159399	CCDC57	-0.39	-5.15	-0.31	5.22e-7	Life satisfaction;
KIRP	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.3	-0.32	2.57e-7	Neutrophil percentage of white cells;
KIRP	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.46	8.56	0.48	1.24e-15	Lipoprotein (a) levels;
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg12950624	chr19:46000154	RTN2	0.57	6.35	0.38	1.06e-9	QT interval;
KIRP	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg24531977	chr5:56204891	C5orf35	-0.38	-4.88	-0.3	1.91e-6	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2738048	0.545	rs2978950	chr8:6825284	C/G	cg24860332	chr8:6827800	DEFA10P	-0.4	-5.18	-0.31	4.55e-7	IgA nephropathy;
KIRP	trans	rs921874	0.553	rs1968742	chr11:86781426	C/T	cg22937172	chr2:240168862	HDAC4	0.5	6.44	0.38	6.08e-10	Total body bone mineral density;
KIRP	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.47	-0.38	5.12e-10	Morning vs. evening chronotype;
KIRP	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.92	-0.4	3.94e-11	Neuroticism;
KIRP	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.59	5.26	0.32	3.08e-7	Initial pursuit acceleration;
KIRP	cis	rs72730918	0.590	rs2606143	chr15:51942455	C/T	cg14296394	chr15:51910925	DMXL2	-0.78	-11.08	-0.58	2.04e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs10924309	0.686	rs4658796	chr1:245854680	A/G	cg00036263	chr1:245852353	KIF26B	-0.46	-6.29	-0.37	1.45e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs2904967	1.000	rs509303	chr11:65093190	A/C	cg09225861	chr11:65069680	NA	-0.45	-5.98	-0.36	7.7e-9	Mean corpuscular volume;
KIRP	cis	rs4595586	0.655	rs11170269	chr12:39387077	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.2	0.37	2.37e-9	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.12	0.41	1.2e-11	Bipolar disorder;
KIRP	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	6.63	0.39	2.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg10756647	chr7:56101905	PSPH	0.92	6.5	0.38	4.32e-10	Diabetic kidney disease;
KIRP	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg27205649	chr11:78285834	NARS2	0.82	11.43	0.59	1.51e-24	Alzheimer's disease (survival time);
KIRP	cis	rs9400467	0.506	rs75819068	chr6:111722487	A/C	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4006360	0.514	rs1588393	chr17:39247900	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.52	-7.94	-0.45	7.19e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.55	7.25	0.42	5.26e-12	Mean corpuscular volume;
KIRP	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.51	-6.17	-0.37	2.74e-9	Neurofibrillary tangles;
KIRP	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.78	-0.35	2.26e-8	Educational attainment;
KIRP	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg13409248	chr3:40428643	ENTPD3	0.39	5.03	0.31	9.53e-7	Renal cell carcinoma;
KIRP	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg11752832	chr7:134001865	SLC35B4	0.43	5.67	0.34	4e-8	Mean platelet volume;
KIRP	cis	rs3026101	0.671	rs1065482	chr17:5284719	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.97	0.36	8.03e-9	Body mass index;
KIRP	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.69	10.7	0.56	3.37e-22	Blood metabolite ratios;
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg16590910	chr6:42928470	GNMT	0.43	5.99	0.36	7.22e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-8.44	-0.47	2.78e-15	Bipolar disorder;
KIRP	cis	rs12210905	1.000	rs9348758	chr6:27255238	T/G	cg11502198	chr6:26597334	ABT1	-0.85	-4.85	-0.3	2.22e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg07395648	chr5:131743802	NA	-0.57	-8.54	-0.48	1.4e-15	Blood metabolite levels;
KIRP	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-8.5	-0.48	1.9e-15	Response to antipsychotic treatment;
KIRP	cis	rs4761097	0.537	rs1452251	chr12:85198515	C/A	cg00765312	chr12:85674694	ALX1	0.43	5.31	0.32	2.51e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg07068956	chr7:100330872	ZAN	-0.57	-5.88	-0.35	1.31e-8	Other erythrocyte phenotypes;
KIRP	cis	rs13279522	0.536	rs7843077	chr8:67036573	A/G	cg04041976	chr8:67085823	TRIM55	0.47	6.02	0.36	6.3e-9	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.69	-8.97	-0.5	7.99e-17	Obesity-related traits;
KIRP	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg11130432	chr3:121712080	ILDR1	0.44	5.14	0.31	5.59e-7	Multiple sclerosis;
KIRP	cis	rs4778581	0.569	rs1983414	chr15:80383337	G/A	cg08257866	chr15:80351198	ZFAND6	0.48	5.24	0.32	3.44e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.51	-6.41	-0.38	7.44e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg22764044	chr5:178986830	RUFY1	0.46	6.62	0.39	2.22e-10	Lung cancer;
KIRP	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.45	4.98	0.3	1.19e-6	Schizophrenia;
KIRP	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.42e-13	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611198	1.000	rs9611198	chr22:39955873	A/C	cg10455938	chr22:40058150	CACNA1I	0.53	7.45	0.43	1.55e-12	Schizophrenia;
KIRP	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	0.63	6.86	0.4	5.47e-11	Crohn's disease;
KIRP	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.61	7.39	0.43	2.34e-12	Mosquito bite size;
KIRP	cis	rs1971762	0.545	rs876252	chr12:54071422	A/G	cg23533419	chr12:54090519	NA	-0.37	-5.6	-0.34	5.71e-8	Height;
KIRP	cis	rs2377585	0.524	rs11612882	chr12:8843133	A/G	cg03761649	chr12:8850719	RIMKLB	-0.49	-4.88	-0.3	1.92e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.17e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.4	-0.47	3.57e-15	Total cholesterol levels;
KIRP	cis	rs7692976	0.579	rs6533482	chr4:110866717	G/A	cg06981781	chr4:110842888	EGF	-0.25	-5.47	-0.33	1.12e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs14403	0.913	rs884328	chr1:243654278	A/G	cg21452805	chr1:244014465	NA	0.54	5.38	0.32	1.76e-7	Schizophrenia;
KIRP	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg00376283	chr12:123451042	ABCB9	0.63	7.41	0.43	2.05e-12	Neutrophil percentage of white cells;
KIRP	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10308265	chr17:42290028	UBTF	0.45	5.01	0.3	1.02e-6	Total body bone mineral density;
KIRP	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg02725872	chr8:58115012	NA	-0.47	-5.69	-0.34	3.64e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.57	-7.77	-0.44	2.11e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.59	-7.13	-0.41	1.12e-11	Colorectal cancer;
KIRP	trans	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg06521331	chr12:34319734	NA	-0.49	-6.15	-0.37	3.05e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg20312557	chr2:97357134	FER1L5	-0.73	-5.27	-0.32	2.91e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.12	-0.46	2.19e-14	Neuroticism;
KIRP	cis	rs6684514	0.961	rs12126696	chr1:156241348	C/T	cg16558208	chr1:156270281	VHLL	-0.43	-5.59	-0.34	5.89e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg22349387	chr12:9600060	DDX12	0.32	4.86	0.3	2.11e-6	Breast size;
KIRP	cis	rs10203711	0.966	rs6713626	chr2:239566896	C/T	cg14580085	chr2:239553406	NA	0.39	5.16	0.31	5.18e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.27	-0.32	2.95e-7	Calcium levels;
KIRP	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.24	-0.32	3.49e-7	Morning vs. evening chronotype;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25618513	chr4:153456716	FBXW7	-0.47	-6.34	-0.37	1.1e-9	Myopia;
KIRP	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.62	8.42	0.47	3.18e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2742417	0.532	rs62242234	chr3:45772228	A/G	cg04037228	chr3:45636386	LIMD1	0.4	5.0	0.3	1.09e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.97	12.53	0.62	3.37e-28	Homoarginine levels;
KIRP	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.46	5.23	0.32	3.66e-7	Schizophrenia;
KIRP	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg02344993	chr17:57696989	CLTC	0.59	5.67	0.34	3.96e-8	Hemoglobin concentration;
KIRP	cis	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg27411982	chr8:10470053	RP1L1	0.41	4.92	0.3	1.62e-6	Neuroticism;
KIRP	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg25600027	chr14:23388339	RBM23	-0.51	-6.26	-0.37	1.74e-9	Cognitive ability (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03636082	chr8:104344711	FZD6	-0.43	-6.74	-0.39	1.1e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg27121462	chr16:89883253	FANCA	0.55	7.28	0.42	4.38e-12	Vitiligo;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25320221	chr1:183440909	SMG7	-0.51	-7.21	-0.42	6.99e-12	Survival in pancreatic cancer;
KIRP	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg14092571	chr14:90743983	NA	-0.41	-5.38	-0.32	1.75e-7	Mortality in heart failure;
KIRP	cis	rs2882667	0.931	rs10068237	chr5:138337960	T/A	cg04439458	chr5:138467593	SIL1	-0.44	-7.29	-0.42	4.27e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg08313168	chr12:7315531	NA	0.7	6.28	0.37	1.56e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.7	-8.56	-0.48	1.28e-15	Cognitive function;
KIRP	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.15	0.31	5.44e-7	Alzheimer's disease;
KIRP	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg24203234	chr3:128598194	ACAD9	0.43	4.94	0.3	1.47e-6	IgG glycosylation;
KIRP	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.45	-0.38	5.74e-10	Type 2 diabetes;
KIRP	cis	rs7614311	0.636	rs3733126	chr3:63988171	C/T	cg22134162	chr3:63841271	THOC7	-0.35	-4.91	-0.3	1.68e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg14784868	chr12:69753453	YEATS4	0.51	5.27	0.32	3.05e-7	Response to diuretic therapy;
KIRP	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.23	-0.42	5.9e-12	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15886017	chr9:96278586	FAM120A	-0.49	-7.88	-0.45	1.08e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs959260	0.858	rs2053156	chr17:73378440	G/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs57994353	0.600	rs4400499	chr9:139305041	C/T	cg21253087	chr9:139290292	SNAPC4	0.57	5.84	0.35	1.61e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08216050	chr16:704013	WDR90	0.53	6.86	0.4	5.66e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.95	-13.42	-0.65	3.58e-31	Schizophrenia;
KIRP	cis	rs7577696	0.554	rs34835885	chr2:32325414	G/A	cg02381751	chr2:32503542	YIPF4	-0.61	-5.97	-0.36	8.1e-9	Inflammatory biomarkers;
KIRP	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.33	-0.32	2.24e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.79	8.58	0.48	1.07e-15	Gastritis;
KIRP	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.71	9.73	0.53	3.99e-19	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg20701182	chr2:24300061	SF3B14	0.49	5.61	0.34	5.3e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.13e-6	Height;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg08807101	chr21:30365312	RNF160	0.6	7.26	0.42	5.01e-12	Pancreatic cancer;
KIRP	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-7.55	-0.43	8.28e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg02297831	chr4:17616191	MED28	0.57	7.1	0.41	1.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	7.38	0.43	2.4e-12	Iron status biomarkers;
KIRP	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.7	-0.39	1.4e-10	Diabetic kidney disease;
KIRP	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg00792783	chr2:198669748	PLCL1	0.47	5.4	0.33	1.6e-7	Intracranial aneurysm;
KIRP	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.77	9.77	0.53	2.93e-19	Corneal astigmatism;
KIRP	cis	rs7714584	1.000	rs73282234	chr5:150195924	G/C	cg22134413	chr5:150180641	NA	1.07	8.77	0.49	3.01e-16	Crohn's disease;
KIRP	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00889227	chr1:205173544	DSTYK	-0.37	-4.92	-0.3	1.55e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.61	-7.06	-0.41	1.73e-11	Menarche (age at onset);
KIRP	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.79	-6.59	-0.39	2.73e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg17376030	chr22:41985996	PMM1	-0.53	-6.05	-0.36	5.3e-9	Vitiligo;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02268410	chr3:101280546	RG9MTD1	0.57	6.15	0.37	3.2e-9	Lung cancer in ever smokers;
KIRP	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.59	7.9	0.45	9.03e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg17646820	chr3:66848679	NA	0.67	8.85	0.49	1.76e-16	Type 2 diabetes;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg22903657	chr4:1355424	KIAA1530	-0.41	-5.95	-0.35	9.26e-9	Obesity-related traits;
KIRP	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.78	9.94	0.54	8.75e-20	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs33912345	0.643	rs1313238	chr14:60848475	C/T	cg27398547	chr14:60952738	C14orf39	-0.41	-5.56	-0.33	6.91e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.58	7.63	0.44	5.06e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg14703610	chr5:56206110	C5orf35	0.49	6.38	0.38	8.8e-10	Coronary artery disease;
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg08163220	chr3:31574309	STT3B	-0.44	-6.1	-0.36	4.17e-9	Type 1 diabetes;
KIRP	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.83	13.2	0.64	1.98e-30	Monocyte percentage of white cells;
KIRP	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg22903471	chr2:27725779	GCKR	-0.67	-9.45	-0.52	2.86e-18	Total body bone mineral density;
KIRP	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg09455208	chr3:40491958	NA	0.41	7.02	0.41	2.2e-11	Renal cell carcinoma;
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.7	9.49	0.52	2.13e-18	Longevity;
KIRP	cis	rs9583531	0.660	rs61971611	chr13:111335319	C/T	cg24331049	chr13:111365604	ING1	-0.84	-5.85	-0.35	1.59e-8	Coronary artery disease;
KIRP	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.05	-0.36	5.27e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.67	7.42	0.43	1.91e-12	Hair shape;
KIRP	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg14132834	chr19:41945861	ATP5SL	-0.62	-8.45	-0.47	2.6e-15	Height;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.65	8.04	0.46	3.67e-14	Aortic root size;
KIRP	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg06742321	chr12:123595122	PITPNM2	-0.44	-5.61	-0.34	5.43e-8	Platelet count;
KIRP	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	1.0	17.4	0.74	9.29e-45	Breast cancer;
KIRP	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.32	-0.42	3.52e-12	Retinal vascular caliber;
KIRP	cis	rs6032067	0.929	rs6032070	chr20:43869795	A/T	cg10761708	chr20:43804764	PI3	0.48	5.01	0.3	1.02e-6	Blood protein levels;
KIRP	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.75	10.28	0.55	7.46e-21	Mood instability;
KIRP	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.31	-0.42	3.85e-12	Body mass index;
KIRP	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs56775891	0.559	rs11664298	chr18:77578986	G/A	cg24058013	chr18:77568902	NA	-0.6	-6.86	-0.4	5.65e-11	Schizophrenia;
KIRP	cis	rs7651039	0.846	rs2174267	chr3:15645835	T/C	cg16303742	chr3:15540471	COLQ	0.51	6.64	0.39	1.96e-10	Coronary heart disease;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs7221595	0.756	rs12603448	chr17:3949934	A/G	cg05562828	chr17:3906858	NA	0.49	5.39	0.32	1.67e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07955424	chr1:53905934	FLJ40434	-0.43	-6.55	-0.39	3.28e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.3	-4.95	-0.3	1.37e-6	Lymphocyte counts;
KIRP	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.3	-0.51	7.89e-18	Aortic root size;
KIRP	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.68	7.84	0.45	1.39e-13	IgG glycosylation;
KIRP	cis	rs258892	0.841	rs266426	chr5:72131255	A/G	cg21869765	chr5:72125136	TNPO1	0.58	6.37	0.38	9.1e-10	Small cell lung carcinoma;
KIRP	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg13160058	chr8:26243215	BNIP3L	-0.5	-7.35	-0.42	2.85e-12	Red cell distribution width;
KIRP	cis	rs539514	0.690	rs504273	chr13:76310850	C/T	cg04757411	chr13:76259545	LMO7	-0.37	-5.18	-0.31	4.7e-7	Type 1 diabetes;
KIRP	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg04132472	chr17:19861366	AKAP10	0.38	4.95	0.3	1.37e-6	Schizophrenia;
KIRP	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.79	-9.65	-0.52	6.96e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23903597	chr17:61704154	MAP3K3	-0.61	-7.97	-0.45	5.99e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs11786541	0.521	rs4841261	chr8:9817299	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.27	-0.37	1.6e-9	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg00094735	chr5:1949198	NA	-0.48	-5.73	-0.34	2.98e-8	Gut microbiome composition (winter);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg20300129	chr6:35058181	ANKS1A	-0.89	-6.35	-0.38	1.02e-9	Thrombomodulin levels in ischemic stroke;
KIRP	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg17788362	chr6:86352627	SYNCRIP	0.49	6.42	0.38	6.78e-10	Smooth-surface caries;
KIRP	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg22676075	chr6:135203613	NA	0.52	7.47	0.43	1.36e-12	Red blood cell count;
KIRP	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	cis	rs9535307	0.719	rs1198322	chr13:50380404	G/A	cg04663916	chr13:50265991	EBPL	-0.56	-6.05	-0.36	5.39e-9	Obesity-related traits;
KIRP	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.66	-6.15	-0.36	3.17e-9	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06705435	chr4:187025886	NA	0.43	6.69	0.39	1.47e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg08975724	chr8:8085496	FLJ10661	0.6	7.58	0.44	7.06e-13	Retinal vascular caliber;
KIRP	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2963155	0.518	rs56150733	chr5:142765099	T/C	cg17617527	chr5:142782415	NR3C1	0.76	6.59	0.39	2.71e-10	Breast cancer;
KIRP	cis	rs911119	1.000	rs6036476	chr20:23610308	C/G	cg09631192	chr20:23583594	CST9	-0.5	-4.9	-0.3	1.71e-6	Chronic kidney disease;
KIRP	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg11693508	chr17:37793320	STARD3	-0.74	-8.44	-0.47	2.74e-15	Bipolar disorder;
KIRP	cis	rs4494114	0.967	rs11211566	chr1:39354700	G/C	cg25970120	chr1:39325951	RRAGC	-0.4	-5.1	-0.31	6.75e-7	Blood protein levels;
KIRP	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.69	0.34	3.68e-8	Lung cancer;
KIRP	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg17507749	chr15:85114479	UBE2QP1	0.85	8.87	0.49	1.52e-16	Schizophrenia;
KIRP	cis	rs2411233	1.000	rs8029263	chr15:39301246	A/G	cg02291532	chr15:39874776	THBS1	0.41	5.49	0.33	1.01e-7	Platelet count;
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.88	8.37	0.47	4.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.87	-0.4	5.31e-11	Daytime sleep phenotypes;
KIRP	cis	rs7520050	1.000	rs785473	chr1:46516863	T/C	cg03146154	chr1:46216737	IPP	-0.42	-5.48	-0.33	1.05e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24115818	chr17:41150318	RPL27	-0.47	-6.01	-0.36	6.49e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22998749	chr13:94288693	GPC6	0.42	6.32	0.37	1.22e-9	Survival in pancreatic cancer;
KIRP	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg19847130	chr8:10466454	RP1L1	0.38	5.61	0.34	5.52e-8	Retinal vascular caliber;
KIRP	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg13628971	chr7:2884303	GNA12	0.58	6.95	0.41	3.3e-11	Height;
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	1.08	21.59	0.81	1.02e-58	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22455660	chr9:128509791	PBX3	0.53	6.11	0.36	3.9e-9	Smoking initiation;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8084125	0.832	rs62105171	chr18:74945663	G/A	cg26065057	chr18:74961000	GALR1	0.6	6.1	0.36	4.15e-9	Obesity-related traits;
KIRP	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.8	-0.35	2e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.57	-0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs1823913	0.637	rs4853569	chr2:192131696	T/A	cg12404831	chr2:192114017	MYO1B	-0.47	-6.36	-0.38	9.61e-10	Obesity-related traits;
KIRP	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg00012203	chr2:219082015	ARPC2	-0.44	-5.38	-0.32	1.71e-7	Ulcerative colitis;
KIRP	cis	rs6693295	0.752	rs2787999	chr1:246233630	A/G	cg11798871	chr1:246315928	SMYD3	-0.38	-4.85	-0.3	2.2e-6	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.69	-0.39	1.51e-10	Alcohol dependence;
KIRP	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.47	6.45	0.38	5.77e-10	Coronary artery disease;
KIRP	cis	rs7553864	0.966	rs1886635	chr1:87614950	G/A	cg17420885	chr1:87600446	LOC339524	-0.47	-6.22	-0.37	2.17e-9	Smoking behavior;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09267708	chr1:155883625	KIAA0907	0.46	6.39	0.38	8.19e-10	Interleukin-4 levels;
KIRP	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.41	0.38	7.34e-10	Bipolar disorder;
KIRP	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg04517722	chr19:17905589	B3GNT3	0.34	4.99	0.3	1.15e-6	Tumor biomarkers;
KIRP	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg09006292	chr3:64049408	NA	-0.54	-4.94	-0.3	1.43e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6088813	0.677	rs941665	chr20:33943281	C/T	cg14752227	chr20:34000481	UQCC	-0.46	-5.19	-0.31	4.5e-7	Height;
KIRP	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05776053	chr2:74358815	NA	0.53	5.5	0.33	9.61e-8	Gestational age at birth (maternal effect);
KIRP	cis	rs4908768	0.906	rs55860300	chr1:8596335	G/A	cg03610117	chr1:8450231	RERE	-0.45	-5.0	-0.3	1.07e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg26727032	chr16:67993705	SLC12A4	-0.69	-8.19	-0.46	1.42e-14	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01427869	chr13:113580562	NA	0.53	6.61	0.39	2.41e-10	Interleukin-4 levels;
KIRP	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.89	0.45	9.98e-14	Lung cancer in ever smokers;
KIRP	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg16102102	chr5:83017553	HAPLN1	-0.8	-10.31	-0.55	5.86e-21	Prostate cancer;
KIRP	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.66	7.99	0.45	5.25e-14	Height;
KIRP	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.69	10.33	0.55	5.26e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1106684	1.000	rs73163158	chr7:131463462	T/A	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.78	5.92	0.35	1.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg12560992	chr17:57184187	TRIM37	0.6	6.36	0.38	1e-9	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg01721255	chr8:58191610	C8orf71	0.54	5.24	0.32	3.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12230513	0.732	rs61957760	chr12:55859957	G/T	cg11794356	chr12:55725991	OR6C3	-0.52	-6.4	-0.38	7.8e-10	Contrast sensitivity;
KIRP	cis	rs7084402	0.967	rs1658452	chr10:60311114	A/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.89	-0.57	8.19e-23	Refractive error;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02487851	chr16:67260913	LRRC29;TMEM208	0.5	6.46	0.38	5.56e-10	Parkinson's disease;
KIRP	cis	rs7084402	0.967	rs1658422	chr10:60331758	G/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs10267417	0.603	rs10267511	chr7:19896924	A/G	cg05791153	chr7:19748676	TWISTNB	0.56	5.16	0.31	5.07e-7	Night sleep phenotypes;
KIRP	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.58	7.24	0.42	5.83e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg07930552	chr6:133119739	C6orf192	1.07	9.54	0.52	1.51e-18	Type 2 diabetes nephropathy;
KIRP	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg01620082	chr3:125678407	NA	-1.22	-7.76	-0.44	2.22e-13	Depression;
KIRP	trans	rs76288851	0.733	rs73199899	chr3:126453724	A/G	cg13821433	chr2:26726535	OTOF	0.58	6.41	0.38	7.46e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg12091567	chr17:66097778	LOC651250	0.68	8.31	0.47	6.63e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg02807482	chr3:125708958	NA	-0.5	-4.86	-0.3	2.08e-6	Blood pressure (smoking interaction);
KIRP	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg03605463	chr16:89740564	NA	0.41	4.87	0.3	2.01e-6	Vitiligo;
KIRP	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03352830	chr11:487213	PTDSS2	0.77	6.49	0.38	4.61e-10	Body mass index;
KIRP	cis	rs6669384	0.774	rs4844621	chr1:208030303	A/G	cg22525895	chr1:207977042	MIR29B2	-0.49	-4.88	-0.3	1.87e-6	Immune response to measles vaccine (measles-specific neutralising antibody titre);
KIRP	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg10818794	chr15:86012489	AKAP13	-0.49	-6.97	-0.41	2.85e-11	Interstitial lung disease;
KIRP	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.83	0.63	3.35e-29	Exhaled nitric oxide output;
KIRP	cis	rs2131877	0.763	rs2279630	chr3:194869342	C/T	cg21937377	chr3:194868750	C3orf21	0.21	4.99	0.3	1.14e-6	Non-small cell lung cancer;
KIRP	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg24747557	chr10:131355152	MGMT	-0.4	-5.39	-0.32	1.67e-7	Response to temozolomide;
KIRP	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.81	0.35	1.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.57	-6.06	-0.36	4.97e-9	Obesity-related traits;
KIRP	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.92e-14	Coffee consumption (cups per day);
KIRP	cis	rs12973672	1.000	rs1052033	chr19:35770471	C/T	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.04	-0.41	1.88e-11	Initial pursuit acceleration;
KIRP	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.53	0.52	1.58e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06115851	chr18:34408868	C18orf10;KIAA1328	0.55	6.79	0.4	8.53e-11	Parkinson's disease;
KIRP	cis	rs7582720	1.000	rs72934535	chr2:203968973	T/C	cg08076091	chr2:203926405	NBEAL1	0.9	7.88	0.45	1.06e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg23594656	chr7:65796392	TPST1	0.39	5.75	0.34	2.66e-8	Aortic root size;
KIRP	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg13319975	chr6:146136371	FBXO30	-0.44	-6.4	-0.38	7.87e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11987759	chr7:65425863	GUSB	0.51	6.93	0.4	3.73e-11	Aortic root size;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg26138937	chr11:71823887	C11orf51	-1.15	-8.03	-0.46	3.95e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-11.89	-0.6	4.5e-26	Glomerular filtration rate (creatinine);
KIRP	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.51	-0.43	1.06e-12	Neuroticism;
KIRP	cis	rs7215564	0.730	rs76584516	chr17:78549237	A/G	cg06153925	chr17:78755379	RPTOR	0.47	6.12	0.36	3.68e-9	Myopia (pathological);
KIRP	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg00405596	chr8:11794950	NA	-0.45	-5.91	-0.35	1.16e-8	Retinal vascular caliber;
KIRP	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.47	-5.51	-0.33	9.19e-8	Urate levels in overweight individuals;
KIRP	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg14675211	chr2:100938903	LONRF2	0.55	7.45	0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs273218	1.000	rs156437	chr5:53376454	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.66	7.28	0.42	4.35e-12	Migraine;
KIRP	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.54	5.34	0.32	2.08e-7	Initial pursuit acceleration;
KIRP	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.71	10.67	0.56	4.18e-22	Height;
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg01097406	chr16:89675127	NA	0.31	5.17	0.31	4.84e-7	Vitiligo;
KIRP	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.52	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.3	-0.47	6.85e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs300774	0.764	rs300756	chr2:233416	G/A	cg21211680	chr2:198530	NA	0.55	5.86	0.35	1.47e-8	Suicide attempts in bipolar disorder;
KIRP	trans	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg07393940	chr7:158741817	NA	0.45	6.17	0.37	2.79e-9	Life satisfaction;
KIRP	cis	rs2273156	1.000	rs2383689	chr14:35404020	C/G	cg09327582	chr14:35236912	BAZ1A	-0.55	-5.98	-0.36	7.65e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg23920097	chr1:209922102	NA	-0.48	-6.44	-0.38	6.36e-10	Red blood cell count;
KIRP	cis	rs7246657	0.722	rs1975937	chr19:38091932	A/T	cg18154014	chr19:37997991	ZNF793	0.61	6.68	0.39	1.57e-10	Coronary artery calcification;
KIRP	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg09695851	chr17:3907499	NA	-0.54	-5.18	-0.31	4.68e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11987759	chr7:65425863	GUSB	-0.58	-7.79	-0.44	1.87e-13	Aortic root size;
KIRP	cis	rs7119167	0.616	rs7115605	chr11:73084433	C/T	cg17517138	chr11:73019481	ARHGEF17	0.5	5.34	0.32	2.12e-7	Blood protein levels;
KIRP	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg11465639	chr17:19241549	NA	0.39	4.92	0.3	1.59e-6	Schizophrenia;
KIRP	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg18461021	chr18:74961002	GALR1	-0.53	-5.61	-0.34	5.3e-8	Obesity-related traits;
KIRP	cis	rs9807841	0.555	rs6511708	chr19:10788813	A/G	cg09936142	chr19:10668400	KRI1	-0.46	-5.21	-0.32	4.03e-7	Inflammatory skin disease;
KIRP	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.59	-8.41	-0.47	3.46e-15	Monobrow;
KIRP	cis	rs7084921	0.809	rs12415923	chr10:101797945	C/T	cg23247504	chr10:101824920	CPN1	-0.41	-5.16	-0.31	4.98e-7	Bone mineral density;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22168489	chr12:122356033	WDR66	0.57	8.68	0.48	5.44e-16	Mean corpuscular volume;
KIRP	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.6	-5.43	-0.33	1.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.99	13.34	0.65	6.56e-31	Menopause (age at onset);
KIRP	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.39	3.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg26354017	chr1:205819088	PM20D1	0.52	5.66	0.34	4.3e-8	Parkinson's disease;
KIRP	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	1.0	14.36	0.68	2.23e-34	Height;
KIRP	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.56	7.53	0.43	9.89e-13	Red blood cell count;
KIRP	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg25309564	chr22:51001381	C22orf41	0.74	5.12	0.31	6.22e-7	Narcolepsy;
KIRP	trans	rs10152811	0.714	rs11855031	chr15:86815101	C/T	cg09774649	chr4:8476536	C4orf23	-0.53	-6.04	-0.36	5.51e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.65	0.48	7e-16	Bipolar disorder;
KIRP	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.83	12.65	0.63	1.37e-28	Height;
KIRP	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7766436	0.648	rs7757111	chr6:22591154	C/A	cg13666174	chr6:22585274	NA	-0.37	-5.21	-0.31	4.08e-7	Coronary artery disease;
KIRP	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.37e-10	Subjective well-being;
KIRP	cis	rs42648	1.000	rs42649	chr7:89977789	A/T	cg25739043	chr7:89950458	NA	-0.45	-7.12	-0.41	1.16e-11	Homocysteine levels;
KIRP	cis	rs593531	0.592	rs598869	chr11:74046975	C/T	cg18195628	chr11:73498948	MRPL48	-0.41	-5.01	-0.3	1.04e-6	Neuroticism;
KIRP	cis	rs959260	1.000	rs2385264	chr17:73364992	C/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.51	0.43	1.09e-12	Major depressive disorder;
KIRP	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.8	0.66	1.85e-32	Cognitive function;
KIRP	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.35	5.54	0.33	7.95e-8	Childhood ear infection;
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.55	-6.21	-0.37	2.26e-9	Menopause (age at onset);
KIRP	cis	rs10982256	0.701	rs10982238	chr9:117237250	G/A	cg13636371	chr9:117264095	DFNB31	-0.38	-5.03	-0.31	9.55e-7	Bipolar disorder;
KIRP	cis	rs9494145	0.667	rs1331309	chr6:135406178	T/G	cg22676075	chr6:135203613	NA	0.43	4.96	0.3	1.34e-6	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02359409	chr6:42947317	PEX6	-0.47	-6.34	-0.38	1.06e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg00684032	chr4:1343700	KIAA1530	0.42	5.44	0.33	1.27e-7	Longevity;
KIRP	cis	rs2574975	0.679	rs2842107	chr10:52131485	A/G	cg10034176	chr10:52120283	SGMS1	0.54	7.3	0.42	4.03e-12	Response to amphetamines;
KIRP	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.65	7.15	0.41	9.91e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.62	-7.1	-0.41	1.35e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg00599163	chr2:162100495	NA	0.62	8.11	0.46	2.48e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs17030434	1.000	rs12646124	chr4:154718084	G/T	cg14289246	chr4:154710475	SFRP2	-0.81	-9.54	-0.52	1.46e-18	Electrocardiographic conduction measures;
KIRP	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg05973401	chr12:123451056	ABCB9	0.58	6.75	0.4	1.04e-10	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg13385521	chr17:29058706	SUZ12P	0.77	6.52	0.38	3.96e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.35	-5.02	-0.3	1.01e-6	Mean corpuscular volume;
KIRP	cis	rs6546886	0.913	rs12713805	chr2:74243380	C/T	cg14702570	chr2:74259524	NA	-0.33	-6.59	-0.39	2.61e-10	Dialysis-related mortality;
KIRP	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05220968	chr6:146057943	EPM2A	0.38	4.89	0.3	1.8e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.64	5.19	0.31	4.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	1.05	12.44	0.62	6.75e-28	Breast cancer;
KIRP	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.35	-0.32	2.01e-7	Breast cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg20261243	chr20:44718728	NCOA5	0.6	7.35	0.42	2.97e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg04132472	chr17:19861366	AKAP10	0.67	10.49	0.56	1.57e-21	Schizophrenia;
KIRP	cis	rs4414128	0.832	rs2386649	chr10:5680842	A/G	cg12223502	chr10:5658492	NA	-0.51	-5.83	-0.35	1.78e-8	Breast cancer;
KIRP	trans	rs9650657	0.812	rs11250073	chr8:10632236	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.37	-0.38	9.07e-10	Neuroticism;
KIRP	cis	rs7404928	0.526	rs2575384	chr16:23837694	C/T	cg05497750	chr16:23765381	CHP2	-0.59	-6.52	-0.38	4e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.18	-0.46	1.54e-14	Mood instability;
KIRP	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.78	6.43	0.38	6.45e-10	Bipolar disorder;
KIRP	cis	rs714031	1.000	rs714031	chr22:40070234	C/T	cg21377881	chr22:40064566	CACNA1I	0.66	10.13	0.54	2.16e-20	Schizophrenia;
KIRP	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg06636001	chr8:8085503	FLJ10661	0.56	6.98	0.41	2.68e-11	Schizophrenia;
KIRP	cis	rs4900069	0.872	rs7146000	chr14:91593248	C/T	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.43	-5.11	-0.31	6.37e-7	Resting heart rate;
KIRP	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	trans	rs1395804	0.935	rs7017641	chr8:132470314	C/A	cg02693607	chr7:27150598	HOXA3	0.72	6.22	0.37	2.13e-9	Visceral adipose tissue;
KIRP	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.75	6.4	0.38	7.94e-10	Body mass index;
KIRP	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg10504392	chr12:110044639	NA	0.25	5.05	0.31	8.56e-7	Neuroticism;
KIRP	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	9.52	0.52	1.68e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.51	-5.94	-0.35	9.52e-9	Osteoporosis;
KIRP	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.35	-5.03	-0.31	9.28e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg10047753	chr17:41438598	NA	1.15	18.7	0.77	3.85e-49	Menopause (age at onset);
KIRP	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg10189774	chr4:17578691	LAP3	0.41	5.02	0.3	9.96e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg16672083	chr15:72433130	SENP8	0.46	6.32	0.37	1.22e-9	Red blood cell count;
KIRP	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg07596299	chr11:71824057	C11orf51	-0.93	-5.89	-0.35	1.29e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.8	0.45	1.78e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg18882449	chr10:104885122	NT5C2	-0.51	-6.47	-0.38	5.27e-10	Arsenic metabolism;
KIRP	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.43	8.52	0.48	1.65e-15	Coronary artery disease;
KIRP	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg23306229	chr2:178417860	TTC30B	0.48	5.02	0.3	1.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.67	9.46	0.52	2.65e-18	Cognitive test performance;
KIRP	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.25	-0.32	3.34e-7	Mean platelet volume;
KIRP	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-4.88	-0.3	1.87e-6	Neuroticism;
KIRP	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.44	0.33	1.27e-7	Breast cancer;
KIRP	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.27	-0.55	7.94e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs4865169	0.811	rs6841086	chr4:57903268	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.55	7.03	0.41	2.02e-11	Breast cancer;
KIRP	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.9	13.05	0.64	6.4e-30	Morning vs. evening chronotype;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21211053	chr19:49496578	GYS1;RUVBL2	-0.45	-6.19	-0.37	2.48e-9	Electrocardiographic conduction measures;
KIRP	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10077468	chr15:91498367	RCCD1	0.52	6.57	0.39	3.05e-10	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26421169	chr11:104781259	NA	-0.44	-7.45	-0.43	1.55e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.92e-34	Menopause (age at onset);
KIRP	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.07	0.46	3.05e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16338060	chr14:50863307	CDKL1	0.46	6.22	0.37	2.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.84	-0.4	6.08e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg08847533	chr14:75593920	NEK9	0.49	6.02	0.36	6.38e-9	Neuroticism;
KIRP	trans	rs7939778	1.000	rs7939778	chr11:100507047	G/A	cg25416319	chr17:37080373	NA	0.47	6.13	0.36	3.42e-9	Lymphocyte counts;
KIRP	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.65	-9.23	-0.51	1.33e-17	Colorectal cancer;
KIRP	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg06115741	chr20:33292138	TP53INP2	0.46	6.13	0.36	3.5e-9	Coronary artery disease;
KIRP	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg11150807	chr10:43354902	NA	0.61	6.87	0.4	5.15e-11	Blood protein levels;
KIRP	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg18877969	chr2:232395326	NMUR1	-0.37	-5.23	-0.32	3.63e-7	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14237711	chr19:56826044	NA	0.46	6.38	0.38	8.61e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs684232	0.933	rs2474694	chr17:618039	G/A	cg15660573	chr17:549704	VPS53	0.46	5.86	0.35	1.49e-8	Prostate cancer;
KIRP	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	9.05	0.5	4.38e-17	Total body bone mineral density;
KIRP	cis	rs6753739	0.784	rs7578383	chr2:219930851	T/G	cg01749213	chr2:219906749	CCDC108	0.43	5.43	0.33	1.36e-7	Height;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.71	-9.33	-0.51	6.41e-18	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg05340658	chr4:99064831	C4orf37	0.67	7.81	0.45	1.6e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.35e-7	Life satisfaction;
KIRP	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.38	-0.38	8.61e-10	Response to antipsychotic treatment;
KIRP	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg15128208	chr22:42549153	NA	0.68	7.84	0.45	1.4e-13	Birth weight;
KIRP	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.87	-10.66	-0.56	4.68e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.39	-4.89	-0.3	1.8e-6	Personality dimensions;
KIRP	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.65e-9	Neuroticism;
KIRP	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-5.52	-0.33	8.78e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg13256891	chr4:100009986	ADH5	0.52	6.64	0.39	1.98e-10	Alcohol dependence;
KIRP	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	10.95	0.57	5.28e-23	Mood instability;
KIRP	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.83	0.35	1.71e-8	Total cholesterol levels;
KIRP	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg25173405	chr17:45401733	C17orf57	-0.46	-5.99	-0.36	7.28e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg07317062	chr7:27170388	HOXA4	0.37	5.28	0.32	2.82e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.67	8.53	0.48	1.52e-15	Prudent dietary pattern;
KIRP	trans	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg19274270	chr17:78178856	CARD14	0.35	6.34	0.37	1.07e-9	Morning vs. evening chronotype;
KIRP	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.96	-0.35	8.92e-9	IgG glycosylation;
KIRP	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg09555818	chr19:45449301	APOC2	0.52	7.56	0.43	7.83e-13	Blood protein levels;
KIRP	cis	rs17221829	0.733	rs72971005	chr11:89358412	G/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg04306507	chr14:55594613	LGALS3	0.53	8.46	0.47	2.37e-15	Protein biomarker;
KIRP	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg16988262	chr1:15930761	NA	0.39	5.13	0.31	5.8e-7	Systolic blood pressure;
KIRP	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-4.93	-0.3	1.5e-6	Tonsillectomy;
KIRP	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg24631222	chr15:78858424	CHRNA5	-0.44	-5.33	-0.32	2.27e-7	Sudden cardiac arrest;
KIRP	cis	rs2179367	0.959	rs4895789	chr6:149764654	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-4.99	-0.3	1.17e-6	Dupuytren's disease;
KIRP	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg07796016	chr1:152779584	LCE1C	-0.45	-5.73	-0.34	2.87e-8	Inflammatory skin disease;
KIRP	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg11783602	chr8:55087084	NA	-0.48	-5.82	-0.35	1.8e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	1.05	14.11	0.67	1.58e-33	Menopause (age at onset);
KIRP	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	1.03	14.16	0.67	1.11e-33	Menopause (age at onset);
KIRP	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.55	0.48	1.33e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.93	0.4	3.64e-11	Menarche (age at onset);
KIRP	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg05717871	chr11:638507	DRD4	-0.37	-5.32	-0.32	2.33e-7	Systemic lupus erythematosus;
KIRP	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg00042356	chr1:8021962	PARK7	-0.49	-4.91	-0.3	1.65e-6	Inflammatory bowel disease;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg20790798	chr5:1857306	NA	-0.41	-5.12	-0.31	6.06e-7	Cardiovascular disease risk factors;
KIRP	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07509240	chr7:65420297	NA	0.35	4.87	0.3	2.01e-6	Calcium levels;
KIRP	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg03714773	chr7:91764589	CYP51A1	-0.36	-5.26	-0.32	3.09e-7	Breast cancer;
KIRP	cis	rs116979167	0.514	rs1706915	chr7:105196437	A/G	cg19920283	chr7:105172520	RINT1	0.49	5.53	0.33	8.17e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg20936604	chr3:58311152	NA	-0.68	-5.23	-0.32	3.64e-7	Cholesterol, total;
KIRP	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23791690	chr10:43904038	HNRNPF	0.5	6.31	0.37	1.27e-9	Parkinson's disease;
KIRP	cis	rs6466055	0.748	rs10266871	chr7:104812129	G/A	cg04380332	chr7:105027541	SRPK2	-0.64	-9.61	-0.52	9.25e-19	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14868550	chr12:8185339	FOXJ2	0.54	6.67	0.39	1.68e-10	Parkinson's disease;
KIRP	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-5.64	-0.34	4.55e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg00666640	chr1:248458726	OR2T12	-0.46	-6.17	-0.37	2.8e-9	Common traits (Other);
KIRP	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.06	0.5	4.31e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.93	-0.35	1e-8	Breast cancer;
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg16268157	chr7:99778414	STAG3	-0.51	-5.29	-0.32	2.72e-7	Lung function (FEV1/FVC);
KIRP	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg10950524	chr7:2139216	MAD1L1	0.32	5.1	0.31	6.71e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg12756093	chr1:115239321	AMPD1	0.59	7.55	0.43	8.29e-13	Autism;
KIRP	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg08822215	chr16:89438651	ANKRD11	-0.46	-6.11	-0.36	3.93e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.92	0.4	3.87e-11	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17168820	chr19:51014340	JOSD2	0.53	6.82	0.4	6.97e-11	Parkinson's disease;
KIRP	cis	rs12143943	0.966	rs2369246	chr1:204567762	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.45	-0.38	5.9e-10	Cognitive performance;
KIRP	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.66	-7.76	-0.44	2.32e-13	IgG glycosylation;
KIRP	cis	rs6539288	0.677	rs10778515	chr12:107332481	A/G	cg15890332	chr12:107067104	RFX4	0.35	5.6	0.34	5.66e-8	Total body bone mineral density;
KIRP	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.7	8.46	0.47	2.41e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18654971	chr5:54469363	MIR449C;CDC20B	0.71	6.93	0.4	3.75e-11	Lung function (FEV1);
KIRP	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.66	-6.69	-0.39	1.53e-10	Pediatric areal bone mineral density (radius);
KIRP	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.43	6.06	0.36	5.07e-9	Sitting height ratio;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg13453750	chr1:205783389	SLC41A1	-0.47	-7.49	-0.43	1.26e-12	Menarche (age at onset);
KIRP	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg09658497	chr7:2847517	GNA12	-0.37	-5.11	-0.31	6.58e-7	Height;
KIRP	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.35	5.34	0.32	2.14e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7589728	0.688	rs76734941	chr2:88530454	T/C	cg04511125	chr2:88470314	THNSL2	0.84	5.12	0.31	6.17e-7	Plasma clusterin levels;
KIRP	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg11995313	chr8:8860691	ERI1	0.41	5.38	0.32	1.77e-7	Joint mobility (Beighton score);
KIRP	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.66	9.77	0.53	2.87e-19	Retinal vascular caliber;
KIRP	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg24579218	chr15:68104479	NA	-0.6	-9.98	-0.54	6.29e-20	Restless legs syndrome;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07028821	chr7:140773905	NA	-0.47	-6.55	-0.39	3.38e-10	Myopia;
KIRP	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.87	-9.05	-0.5	4.4e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.75	6.72	0.39	1.27e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4262150	0.883	rs72804766	chr5:152273887	C/T	cg12297329	chr5:152029980	NA	-0.62	-7.62	-0.44	5.39e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.7	-0.39	1.43e-10	Neuroticism;
KIRP	cis	rs8077577	0.945	rs997315	chr17:18085286	A/G	cg18869244	chr17:18121946	NA	0.5	5.74	0.34	2.74e-8	Obesity-related traits;
KIRP	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg18944383	chr4:111397179	ENPEP	-0.79	-16.82	-0.73	8.83e-43	Height;
KIRP	cis	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg00614314	chr15:82944287	LOC80154	-0.51	-6.1	-0.36	4.17e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.44e-11	Diabetic kidney disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21703056	chr20:60697448	LSM14B	-0.44	-6.4	-0.38	7.71e-10	Metabolic traits;
KIRP	trans	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.68	-0.39	1.55e-10	Heart rate;
KIRP	cis	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg04607699	chr11:48328132	OR4S1	-0.35	-4.88	-0.3	1.9e-6	HDL cholesterol;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05522046	chr3:52931664	TMEM110	0.56	6.51	0.38	4.13e-10	Smoking initiation;
KIRP	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.78	-7.63	-0.44	5.09e-13	Neuroblastoma;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs17286411	0.836	rs9936965	chr16:71900064	T/C	cg04254540	chr16:71951199	KIAA0174	-0.39	-5.17	-0.31	4.92e-7	Blood protein levels;
KIRP	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.39	-5.14	-0.31	5.51e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.38	0.38	8.78e-10	Hemoglobin concentration;
KIRP	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.59	7.36	0.42	2.79e-12	Tonsillectomy;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg01763666	chr17:80159506	CCDC57	0.36	4.98	0.3	1.21e-6	Life satisfaction;
KIRP	cis	rs3755132	0.929	rs2302931	chr2:15737480	C/A	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.81	8.98	0.5	7.3e-17	Alzheimer's disease;
KIRP	cis	rs8077577	0.747	rs8081155	chr17:18191948	C/G	cg18869244	chr17:18121946	NA	0.46	5.16	0.31	5.07e-7	Obesity-related traits;
KIRP	cis	rs8060686	0.516	rs2290699	chr16:68289059	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-6.97	-0.41	2.95e-11	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.64	-8.48	-0.48	2.05e-15	Calcium levels;
KIRP	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg05721485	chr17:44071124	MAPT	-0.36	-5.1	-0.31	6.74e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg23649088	chr2:200775458	C2orf69	-0.41	-5.34	-0.32	2.1e-7	QT interval;
KIRP	cis	rs1448094	0.654	rs7133797	chr12:86294184	G/C	cg02569458	chr12:86230093	RASSF9	0.37	5.38	0.32	1.76e-7	Major depressive disorder;
KIRP	cis	rs4950322	0.515	rs11239954	chr1:146717699	C/T	cg22381352	chr1:146742008	CHD1L	-0.4	-4.91	-0.3	1.65e-6	Protein quantitative trait loci;
KIRP	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.91	12.71	0.63	8.73e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg23335576	chr14:104009727	NA	0.4	5.48	0.33	1.05e-7	Body mass index;
KIRP	cis	rs4006360	0.579	rs1510075	chr17:39236452	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.55	-8.56	-0.48	1.28e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2071426	0.622	rs34946089	chr10:96765227	A/C	cg09036531	chr10:96991505	NA	-0.46	-5.34	-0.32	2.1e-7	Blood metabolite levels;
KIRP	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.13	0.69	5.33e-37	Platelet count;
KIRP	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.82	11.19	0.58	9.34e-24	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.68	0.48	5.55e-16	Motion sickness;
KIRP	trans	rs11809524	0.539	rs115269203	chr1:103403746	C/A	cg26941476	chr5:137790999	NA	0.75	6.12	0.36	3.76e-9	Bone mineral density;
KIRP	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg02375832	chr11:62437615	C11orf48	-0.52	-6.38	-0.38	8.96e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.9	-10.9	-0.57	8.11e-23	Parkinson's disease;
KIRP	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg26531700	chr6:26746687	NA	0.39	5.0	0.3	1.11e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg00360474	chr6:37504404	NA	-0.47	-6.38	-0.38	8.56e-10	Cognitive performance;
KIRP	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg08514558	chr10:81106712	PPIF	0.39	5.41	0.33	1.52e-7	Height;
KIRP	cis	rs644148	0.867	rs2571060	chr19:44971647	C/G	cg15540054	chr19:45004280	ZNF180	-0.65	-7.29	-0.42	4.23e-12	Personality dimensions;
KIRP	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.61e-7	Ulcerative colitis;
KIRP	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg00310523	chr12:86230176	RASSF9	0.39	5.99	0.36	7.23e-9	Major depressive disorder;
KIRP	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg21573476	chr21:45109991	RRP1B	-0.65	-9.56	-0.52	1.29e-18	Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.25	-5.31	-0.32	2.4e-7	Menarche (age at onset);
KIRP	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg17554472	chr22:41940697	POLR3H	0.65	6.61	0.39	2.39e-10	Vitiligo;
KIRP	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg07395648	chr5:131743802	NA	-0.56	-6.5	-0.38	4.47e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.31	-0.37	1.29e-9	Obesity-related traits;
KIRP	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-5.74	-0.34	2.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg10046767	chr12:53297693	KRT8	0.52	6.41	0.38	7.24e-10	Cancer (pleiotropy);
KIRP	cis	rs4812048	0.793	rs62205397	chr20:57597011	C/T	cg14073986	chr20:57617431	SLMO2	0.55	5.14	0.31	5.5e-7	Mean platelet volume;
KIRP	cis	rs6686643	1.000	rs957644	chr1:165616157	C/T	cg16553119	chr1:165599451	MGST3	-0.43	-5.12	-0.31	6.22e-7	Total ventricular volume;
KIRP	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg03171003	chr2:111875934	NA	0.41	5.75	0.34	2.64e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.75	8.3	0.47	7.01e-15	Cholesterol, total;
KIRP	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.39	0.59	2.09e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	12.4	0.62	9.44e-28	Platelet count;
KIRP	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.9	11.72	0.6	1.71e-25	Glomerular filtration rate (creatinine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19305147	chr1:232765605	NA	0.5	6.8	0.4	7.73e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3744061	0.557	rs2098093	chr17:74646469	G/C	cg27546012	chr17:74684504	MXRA7	-0.43	-5.13	-0.31	5.84e-7	Retinal arteriolar caliber;
KIRP	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg16989719	chr2:238392110	NA	-0.57	-5.72	-0.34	3.05e-8	Prostate cancer;
KIRP	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.43	0.55	2.43e-21	Bone mineral density;
KIRP	trans	rs4073416	0.712	rs4899179	chr14:65926748	A/C	cg13275176	chr2:97534450	SEMA4C	-0.46	-6.09	-0.36	4.24e-9	N-glycan levels;
KIRP	trans	rs6741892	0.793	rs12469458	chr2:38911819	G/C	cg07212940	chr3:62304165	C3orf14	0.84	6.34	0.37	1.07e-9	5-HTT brain serotonin transporter levels;
KIRP	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-1.05	-14.62	-0.68	2.89e-35	Platelet distribution width;
KIRP	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.82	9.79	0.53	2.52e-19	Corneal astigmatism;
KIRP	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.14	19.88	0.79	4.25e-53	Exhaled nitric oxide output;
KIRP	cis	rs7011507	1.000	rs7845258	chr8:49132224	T/C	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6684428	0.536	rs12119831	chr1:56392010	A/G	cg11651538	chr1:56320950	NA	0.56	7.89	0.45	9.82e-14	Airflow obstruction;
KIRP	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg09873164	chr1:152488093	CRCT1	0.56	7.09	0.41	1.46e-11	Hair morphology;
KIRP	cis	rs7665939	1.000	rs11942826	chr4:190109362	C/T	cg14840187	chr4:190284988	NA	-0.73	-6.04	-0.36	5.6e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg18709589	chr6:96969512	KIAA0776	0.37	4.86	0.3	2.08e-6	Migraine;Coronary artery disease;
KIRP	cis	rs2411233	0.967	rs7180968	chr15:39288527	C/G	cg02291532	chr15:39874776	THBS1	0.39	5.25	0.32	3.27e-7	Platelet count;
KIRP	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg08126542	chr6:37504118	NA	-0.72	-10.06	-0.54	3.75e-20	Cognitive performance;
KIRP	cis	rs10875746	0.517	rs12721420	chr12:48358794	C/T	cg26205652	chr12:48591994	NA	0.65	7.11	0.41	1.24e-11	Longevity (90 years and older);
KIRP	cis	rs4765905	0.675	rs2283288	chr12:2299048	C/T	cg10668781	chr12:2307325	CACNA1C	-0.29	-5.67	-0.34	4.02e-8	Schizophrenia;
KIRP	cis	rs7246865	0.859	rs12461874	chr19:17180358	C/A	cg18440316	chr19:18077727	KCNN1	-0.4	-5.61	-0.34	5.32e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.83	-0.35	1.71e-8	Triglycerides;
KIRP	trans	rs62056376	0.736	rs1233651	chr17:32639361	C/T	cg17487170	chr5:133451259	TCF7	0.51	6.03	0.36	6.1e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.64	-8.79	-0.49	2.65e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.06	-20.02	-0.79	1.46e-53	Prudent dietary pattern;
KIRP	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	7.71	0.44	3.12e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs5995756	0.600	rs5757748	chr22:40010636	T/A	cg21377881	chr22:40064566	CACNA1I	-0.37	-4.94	-0.3	1.46e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.52	6.29	0.37	1.41e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.65	0.44	4.4e-13	Height;
KIRP	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.87	11.29	0.58	4.47e-24	Monocyte count;
KIRP	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg20415053	chr1:26527928	CATSPER4	-0.43	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg05043794	chr9:111880884	C9orf5	-0.27	-5.41	-0.33	1.53e-7	Menarche (age at onset);
KIRP	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.6	6.57	0.39	2.99e-10	Exhaled nitric oxide output;
KIRP	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	5.95	0.35	9.26e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg02023728	chr11:77925099	USP35	0.3	4.92	0.3	1.59e-6	Alzheimer's disease (survival time);
KIRP	cis	rs4073221	0.654	rs34904734	chr3:18306892	G/A	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.86	-8.16	-0.46	1.72e-14	Fibroblast growth factor basic levels;
KIRP	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg26384229	chr12:38710491	ALG10B	0.63	7.98	0.45	5.42e-14	Resting heart rate;
KIRP	trans	rs7939886	0.920	rs11227849	chr11:56081413	A/T	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs71403859	0.502	rs8053720	chr16:71456142	C/G	cg08717414	chr16:71523259	ZNF19	-0.91	-8.91	-0.49	1.15e-16	Post bronchodilator FEV1;
KIRP	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg16388071	chr6:169726476	NA	-0.41	-5.67	-0.34	3.92e-8	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.95	12.25	0.62	3.01e-27	Homoarginine levels;
KIRP	cis	rs3007729	1.000	rs3007729	chr1:18795255	A/G	cg20200200	chr1:18807388	KLHDC7A	-0.18	-4.94	-0.3	1.47e-6	Diabetic retinopathy;
KIRP	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg07052231	chr12:7363540	PEX5	0.38	5.08	0.31	7.34e-7	IgG glycosylation;
KIRP	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs7814319	0.966	rs2319603	chr8:97270991	G/A	cg20787634	chr8:97240163	UQCRB	-0.67	-10.77	-0.57	2e-22	Lung function (FVC);
KIRP	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.41	-6.8	-0.4	7.73e-11	Attention deficit hyperactivity disorder;
KIRP	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.61	7.66	0.44	4.15e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.71	-7.22	-0.42	6.44e-12	Vitiligo;
KIRP	cis	rs7106204	0.541	rs78630920	chr11:24291192	C/A	ch.11.24196551F	chr11:24239977	NA	0.71	4.93	0.3	1.52e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.35	-0.32	2.03e-7	Red blood cell count;
KIRP	cis	rs883565	0.740	rs10510698	chr3:39107993	A/C	cg01426195	chr3:39028469	NA	-0.69	-11.89	-0.6	4.59e-26	Handedness;
KIRP	cis	rs960902	1.000	rs2192944	chr2:37731294	C/T	cg25341268	chr2:37734390	NA	0.55	7.6	0.44	6.07e-13	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.67	9.34	0.51	6.11e-18	Red blood cell count;
KIRP	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg18709589	chr6:96969512	KIAA0776	-0.4	-5.27	-0.32	3.06e-7	Migraine;Coronary artery disease;
KIRP	cis	rs1014246	0.848	rs58568639	chr10:118456886	C/G	cg14919929	chr10:118506882	NA	0.75	9.61	0.52	9.24e-19	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg03060546	chr3:49711283	APEH	-0.73	-5.66	-0.34	4.27e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.44	-5.46	-0.33	1.14e-7	Iron status biomarkers;
KIRP	cis	rs10073892	1.000	rs1901519	chr5:101754473	A/G	cg19774478	chr5:101632501	SLCO4C1	0.6	6.31	0.37	1.25e-9	Cognitive decline (age-related);
KIRP	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg00982548	chr2:198649783	BOLL	-0.52	-4.88	-0.3	1.91e-6	Ulcerative colitis;
KIRP	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.45	5.99	0.36	7.42e-9	IgG glycosylation;
KIRP	cis	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg00868766	chr15:40364524	NA	0.35	5.49	0.33	9.95e-8	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg18162783	chr1:1795891	GNB1	0.34	5.47	0.33	1.09e-7	Body mass index;
KIRP	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.59	-0.44	6.67e-13	Triglycerides;
KIRP	trans	rs7246760	0.737	rs60584926	chr19:9797014	C/T	cg02900749	chr2:68251473	NA	-1.2	-9.9	-0.53	1.13e-19	Pursuit maintenance gain;
KIRP	cis	rs6681460	0.899	rs499263	chr1:67179937	T/C	cg13052034	chr1:66999238	SGIP1	0.38	5.35	0.32	2e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.38	-5.09	-0.31	7.16e-7	Neuroticism;
KIRP	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg15038512	chr6:170123185	PHF10	0.62	7.28	0.42	4.39e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7215564	0.818	rs34929663	chr17:78617212	C/T	cg06153925	chr17:78755379	RPTOR	0.43	5.79	0.35	2.14e-8	Myopia (pathological);
KIRP	cis	rs651907	0.935	rs2926538	chr3:101587585	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.11	0.31	6.4e-7	Colorectal cancer;
KIRP	cis	rs7224685	0.569	rs965515	chr17:4038149	G/A	cg05562828	chr17:3906858	NA	0.51	5.34	0.32	2.13e-7	Type 2 diabetes;
KIRP	cis	rs57590327	0.503	rs6764261	chr3:81620370	T/G	cg07356753	chr3:81810745	GBE1	-0.57	-7.22	-0.42	6.57e-12	Extraversion;
KIRP	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-5.73	-0.34	2.92e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-7.85	-0.45	1.31e-13	Dental caries;
KIRP	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	0.85	7.56	0.43	7.75e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06850241	chr22:41845214	NA	-0.42	-4.92	-0.3	1.57e-6	Vitiligo;
KIRP	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.57	0.52	1.2e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.36	6.36e-9	Morning vs. evening chronotype;
KIRP	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg16303742	chr3:15540471	COLQ	-0.39	-5.06	-0.31	8.31e-7	Mean platelet volume;
KIRP	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.78	0.44	2.03e-13	IgG glycosylation;
KIRP	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.48	0.81	2.45e-58	Prudent dietary pattern;
KIRP	cis	rs8756	0.967	rs1038196	chr12:66343400	G/C	cg06712651	chr12:66351869	HMGA2	-0.76	-12.59	-0.63	2.27e-28	Height;
KIRP	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14893161	chr1:205819251	PM20D1	0.59	5.83	0.35	1.74e-8	Menarche (age at onset);
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.48	5.64	0.34	4.71e-8	Lung cancer;
KIRP	cis	rs1712790	0.614	rs1945525	chr11:114633098	C/T	cg19465033	chr11:114479364	NA	0.4	5.31	0.32	2.41e-7	Urinary albumin excretion;
KIRP	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg22117172	chr7:91764530	CYP51A1	-0.39	-5.52	-0.33	8.7e-8	Breast cancer;
KIRP	cis	rs7129556	0.638	rs11604207	chr11:77367542	C/T	cg12586386	chr11:77299805	AQP11	0.47	5.07	0.31	7.82e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-16.72	-0.73	2.01e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.47	-6.23	-0.37	2e-9	Bipolar disorder;
KIRP	cis	rs397969	0.573	rs203475	chr17:19850975	A/G	cg04132472	chr17:19861366	AKAP10	0.56	6.73	0.39	1.2e-10	Platelet count;
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22168489	chr12:122356033	WDR66	-0.61	-9.39	-0.51	4.36e-18	Mean corpuscular volume;
KIRP	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.75	0.44	2.37e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.59	-6.34	-0.37	1.1e-9	Carotid intima media thickness;
KIRP	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.31	-0.37	1.29e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12143943	0.934	rs1870551	chr1:204581014	A/G	cg20240347	chr1:204465584	NA	-0.35	-6.4	-0.38	7.7e-10	Cognitive performance;
KIRP	cis	rs4638749	0.677	rs12712018	chr2:108853505	A/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-6.65	-0.39	1.91e-10	Blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02155829	chr1:39325484	RRAGC	0.53	6.56	0.39	3.06e-10	Parkinson's disease;
KIRP	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.08	13.35	0.65	6.08e-31	Platelet count;
KIRP	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	5.13	0.31	5.83e-7	Schizophrenia;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg16178625	chr17:56609274	SEPT4	0.47	6.39	0.38	8.19e-10	DNA methylation (variation);
KIRP	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-1.03	-9.94	-0.54	8.92e-20	Blood pressure (smoking interaction);
KIRP	cis	rs7665939	1.000	rs11942826	chr4:190109362	C/T	cg09826759	chr4:190284978	NA	-0.64	-4.98	-0.3	1.17e-6	Amyotrophic lateral sclerosis;
KIRP	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.91e-25	Vitiligo;
KIRP	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	1.01	17.67	0.75	1.13e-45	Breast cancer;
KIRP	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.02	-13.28	-0.65	1.07e-30	Exhaled nitric oxide output;
KIRP	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.18	0.31	4.7e-7	Bipolar disorder;
KIRP	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.01	-14.1	-0.67	1.67e-33	Response to antipsychotic treatment;
KIRP	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs9479482	0.648	rs912557	chr6:150385977	C/T	cg25797454	chr6:150327115	RAET1K	0.31	5.56	0.33	7.11e-8	Alopecia areata;
KIRP	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.35	-0.38	1.03e-9	Morning vs. evening chronotype;
KIRP	trans	rs9914544	0.628	rs67053020	chr17:18680061	G/C	cg04702396	chr17:15466718	FAM18B2	0.67	9.71	0.53	4.56e-19	Educational attainment (years of education);
KIRP	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg24315340	chr6:146058215	EPM2A	0.41	5.07	0.31	7.92e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg26876637	chr1:152193138	HRNR	-0.82	-8.34	-0.47	5.26e-15	Atopic dermatitis;
KIRP	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.64	-9.08	-0.5	3.75e-17	Red cell distribution width;
KIRP	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.83	9.95	0.54	8.22e-20	Corneal astigmatism;
KIRP	cis	rs4849845	0.925	rs4100690	chr2:121027361	T/G	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg04733989	chr22:42467013	NAGA	0.59	7.82	0.45	1.52e-13	Cognitive function;
KIRP	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.6	-7.58	-0.43	7.19e-13	Diastolic blood pressure;
KIRP	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-10.05	-0.54	3.8e-20	Total body bone mineral density;
KIRP	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-10.87	-0.57	9.82e-23	Morning vs. evening chronotype;
KIRP	cis	rs41264869	0.628	rs16855154	chr1:205111275	T/C	cg21214746	chr1:205091277	RBBP5	0.51	6.64	0.39	1.97e-10	Blood protein levels;
KIRP	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.59	7.42	0.43	1.9e-12	Longevity;Endometriosis;
KIRP	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	5.9	0.35	1.18e-8	Educational attainment;
KIRP	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg20701182	chr2:24300061	SF3B14	0.97	10.56	0.56	9.8e-22	Lymphocyte counts;
KIRP	trans	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg01620082	chr3:125678407	NA	-1.24	-7.57	-0.43	7.7e-13	Depression;
KIRP	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.7	-9.2	-0.51	1.58e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.68	10.69	0.56	3.6e-22	Cancer;
KIRP	cis	rs9488822	0.585	rs390255	chr6:116237680	A/G	cg18764771	chr6:116381957	FRK	0.19	5.1	0.31	6.75e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs11134338	0.606	rs2962705	chr5:8997304	G/C	cg18330338	chr5:9047211	SEMA5A	0.37	5.0	0.3	1.1e-6	Obesity-related traits;
KIRP	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg16989719	chr2:238392110	NA	0.56	6.79	0.4	8.41e-11	Prostate cancer;
KIRP	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.51	-0.33	9.12e-8	Body mass index;
KIRP	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg05335186	chr13:53173507	NA	0.37	5.78	0.35	2.2e-8	Lewy body disease;
KIRP	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg18944383	chr4:111397179	ENPEP	0.52	9.2	0.51	1.6e-17	Height;
KIRP	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg13147721	chr7:65941812	NA	-0.93	-6.55	-0.39	3.4e-10	Diabetic kidney disease;
KIRP	cis	rs2737618	0.674	rs2249150	chr1:200083654	G/A	cg21825944	chr1:200113062	NR5A2	-0.55	-7.87	-0.45	1.14e-13	Uric acid levels;
KIRP	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg27144592	chr16:783916	NARFL	0.35	4.86	0.3	2.08e-6	Height;
KIRP	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.83	9.72	0.53	4.12e-19	Neutrophil percentage of white cells;
KIRP	cis	rs11710088	0.895	rs4321472	chr3:149195738	C/A	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.64	-0.34	4.74e-8	QRS duration;
KIRP	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	7.53	0.43	9.73e-13	Height;
KIRP	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.57	-9.31	-0.51	7.36e-18	Prostate cancer;
KIRP	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	1.13	13.25	0.65	1.36e-30	Eosinophil percentage of granulocytes;
KIRP	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.53	-6.54	-0.38	3.63e-10	Platelet distribution width;
KIRP	cis	rs9308433	0.529	rs4655332	chr1:214490756	G/A	cg06198575	chr1:214491504	SMYD2	0.54	6.95	0.4	3.33e-11	IgG glycosylation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19276371	chr2:74590743	DCTN1	0.45	6.14	0.36	3.26e-9	Survival in pancreatic cancer;
KIRP	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.48	0.48	2.14e-15	Bipolar disorder;
KIRP	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.24	13.26	0.65	1.25e-30	Uric acid levels;
KIRP	cis	rs4319547	0.662	rs35417323	chr12:123090572	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.39	-0.38	8.27e-10	Body mass index;
KIRP	cis	rs6670533	0.571	rs72884439	chr1:24867063	T/C	cg07475527	chr1:24864545	NA	-0.68	-4.96	-0.3	1.35e-6	Fasting blood insulin (BMI interaction);
KIRP	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs4664304	0.652	rs2221808	chr2:160870944	T/C	cg23995753	chr2:160760732	LY75	-0.38	-4.89	-0.3	1.86e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.7	-0.48	4.97e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg16255804	chr6:135334527	HBS1L	-0.33	-5.19	-0.31	4.32e-7	Red blood cell count;
KIRP	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.49	-6.84	-0.4	6.36e-11	Colorectal cancer;
KIRP	cis	rs13161895	1.000	rs34674199	chr5:179473900	G/A	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28834970	0.928	rs17057043	chr8:27220310	C/T	cg14221460	chr8:27183342	PTK2B	-0.45	-5.93	-0.35	1.04e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg19847130	chr8:10466454	RP1L1	0.37	5.46	0.33	1.13e-7	Retinal vascular caliber;
KIRP	cis	rs6909279	0.933	rs9479068	chr6:151872448	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.52	-6.81	-0.4	7.42e-11	Bone mineral density;
KIRP	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	9.21	0.51	1.46e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.91	10.4	0.55	3.1e-21	Corneal astigmatism;
KIRP	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-12.68	-0.63	1.07e-28	Alzheimer's disease;
KIRP	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg01874867	chr7:94954059	PON1	-0.43	-5.03	-0.31	9.59e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.72	6.47	0.38	5.29e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs17023223	0.537	rs10923754	chr1:119668640	T/C	cg18261050	chr1:119551319	NA	0.52	6.66	0.39	1.76e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.78	-10.61	-0.56	6.76e-22	Aortic root size;
KIRP	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.53	6.62	0.39	2.18e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2301573	1.000	rs11708809	chr3:129297478	C/T	cg15504747	chr3:129312979	PLXND1	-0.47	-5.04	-0.31	9.19e-7	Hip circumference;
KIRP	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.61	0.34	5.5e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.87	-13.79	-0.66	2.03e-32	Prudent dietary pattern;
KIRP	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	1.04	14.64	0.68	2.53e-35	Menopause (age at onset);
KIRP	cis	rs9948	1.000	rs2276654	chr2:97492479	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.31	-0.32	2.46e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6832769	1.000	rs1522106	chr4:56307214	A/C	cg09317128	chr4:56265301	TMEM165	-0.52	-6.42	-0.38	6.92e-10	Personality dimensions;
KIRP	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg10761708	chr20:43804764	PI3	0.5	5.19	0.31	4.45e-7	Blood protein levels;
KIRP	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg02151108	chr14:50098012	C14orf104	-0.45	-5.82	-0.35	1.81e-8	Carotid intima media thickness;
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg02996583	chr8:142237188	SLC45A4	0.47	5.7	0.34	3.43e-8	Immature fraction of reticulocytes;
KIRP	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.56	-5.38	-0.32	1.75e-7	Narcolepsy;
KIRP	cis	rs7359257	1.000	rs11071952	chr15:67694780	A/T	cg24579218	chr15:68104479	NA	0.36	5.36	0.32	1.87e-7	Menarche (age at onset);
KIRP	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg22681709	chr2:178499509	PDE11A	-0.48	-5.84	-0.35	1.63e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26314531	chr2:26401878	FAM59B	-0.48	-5.07	-0.31	7.87e-7	Gut microbiome composition (summer);
KIRP	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	7.1	0.41	1.32e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	15.56	0.7	1.79e-38	Platelet count;
KIRP	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg00079375	chr15:79125835	NA	-0.37	-5.31	-0.32	2.46e-7	Coronary artery disease;
KIRP	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	1.07	13.2	0.64	1.92e-30	Type 2 diabetes nephropathy;
KIRP	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.9	-13.53	-0.65	1.54e-31	Height;
KIRP	cis	rs17401966	0.522	rs10864450	chr1:10333959	G/T	cg17425144	chr1:10567563	PEX14	-0.32	-5.54	-0.33	7.57e-8	Hepatocellular carcinoma;
KIRP	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.61	9.95	0.54	7.82e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg23100626	chr2:96804247	ASTL	0.52	8.0	0.45	5.03e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg10223061	chr2:219282414	VIL1	-0.37	-6.09	-0.36	4.34e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17209837	0.920	rs17149652	chr7:87087187	G/T	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs9549260	0.753	rs9549243	chr13:41217205	G/A	cg21288729	chr13:41239152	FOXO1	0.51	5.33	0.32	2.18e-7	Red blood cell count;
KIRP	cis	rs282587	0.592	rs378694	chr13:113417199	G/A	cg04656015	chr13:113407548	ATP11A	0.58	5.61	0.34	5.55e-8	Glycated hemoglobin levels;
KIRP	cis	rs806215	0.826	rs712699	chr7:127250597	G/A	cg25922125	chr7:127225783	GCC1	0.46	4.92	0.3	1.57e-6	Type 2 diabetes;
KIRP	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg10169327	chr19:45448959	APOC2	0.33	4.93	0.3	1.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-7.39	-0.43	2.24e-12	Height;
KIRP	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg12559939	chr2:27858050	GPN1	-0.41	-4.96	-0.3	1.31e-6	Total body bone mineral density;
KIRP	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	10.04	0.54	4.14e-20	Cognitive test performance;
KIRP	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.5	6.57	0.39	2.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7660760	0.763	rs6810584	chr4:177497213	T/G	cg11970806	chr17:56066485	VEZF1	-0.42	-6.57	-0.39	2.97e-10	Left ventricle wall thickness;
KIRP	cis	rs7481584	0.886	rs4758621	chr11:3009640	C/T	cg25174290	chr11:3078921	CARS	0.55	6.14	0.36	3.32e-9	Calcium levels;
KIRP	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.58	-5.87	-0.35	1.42e-8	Platelet distribution width;
KIRP	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.45	10.17	0.54	1.67e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.93	13.68	0.66	4.8e-32	Height;
KIRP	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.72	9.69	0.53	5.15e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.03	-13.27	-0.65	1.17e-30	Corneal structure;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.71	10.04	0.54	4.11e-20	Caffeine consumption;
KIRP	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.99	0.54	5.94e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.35	-5.31	-0.32	2.43e-7	Headache;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20586607	chr14:50235780	KLHDC2	0.51	6.27	0.37	1.6e-9	Smoking initiation;
KIRP	cis	rs2230307	0.656	rs6662945	chr1:100584746	A/C	cg24955406	chr1:100503596	HIAT1	0.58	5.5	0.33	9.4e-8	Carotid intima media thickness;
KIRP	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.26	0.55	8.73e-21	Dupuytren's disease;
KIRP	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.88	-15.25	-0.7	2.1e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg06060754	chr5:176797920	RGS14	0.63	7.38	0.43	2.49e-12	Urate levels in lean individuals;
KIRP	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs714027	0.534	rs140124	chr22:30143693	G/C	cg01021169	chr22:30184971	ASCC2	-0.39	-4.92	-0.3	1.55e-6	Lymphocyte counts;
KIRP	cis	rs6681460	0.866	rs1856318	chr1:67024215	T/C	cg13052034	chr1:66999238	SGIP1	0.45	6.18	0.37	2.6e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg01557791	chr16:72042693	DHODH	-0.41	-5.01	-0.3	1.05e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2274273	0.840	rs28493647	chr14:55824463	T/C	cg04306507	chr14:55594613	LGALS3	0.46	7.31	0.42	3.7e-12	Protein biomarker;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg08901578	chr4:187885870	NA	-0.5	-7.83	-0.45	1.48e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11690462	0.963	rs6731447	chr2:26590118	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.43	5.12	0.31	6.31e-7	Coronary artery disease;
KIRP	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-0.96	-7.85	-0.45	1.24e-13	Body mass index;
KIRP	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg00491522	chr10:135256596	NA	0.62	6.42	0.38	7.03e-10	Systemic lupus erythematosus;
KIRP	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.35	0.38	1.04e-9	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg18944383	chr4:111397179	ENPEP	0.65	11.15	0.58	1.24e-23	Coronary artery disease;
KIRP	cis	rs981844	0.816	rs62325151	chr4:154730595	A/G	cg14289246	chr4:154710475	SFRP2	0.65	7.55	0.43	8.59e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg10932868	chr11:921992	NA	0.52	5.94	0.35	9.91e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg21643547	chr1:205240462	TMCC2	-0.54	-7.86	-0.45	1.23e-13	Red blood cell count;
KIRP	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg21360079	chr12:107162445	NA	-0.63	-8.86	-0.49	1.66e-16	Heart rate;
KIRP	cis	rs2470135	1	rs2470135	chr15:43995789	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	5.94	0.35	9.67e-9	Diastolic blood pressure;
KIRP	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.67	-9.57	-0.52	1.23e-18	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg04398451	chr17:18023971	MYO15A	-0.73	-10.1	-0.54	2.82e-20	Total body bone mineral density;
KIRP	cis	rs77861329	1.000	rs17051977	chr3:52182944	A/G	cg08692210	chr3:52188851	WDR51A	0.94	7.37	0.43	2.58e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg13385521	chr17:29058706	SUZ12P	0.55	5.4	0.33	1.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg02775129	chr4:119771670	NA	-0.84	-5.18	-0.31	4.61e-7	Cannabis dependence symptom count;
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg11641102	chr8:27183873	PTK2B	0.45	5.83	0.35	1.73e-8	Neuroticism;
KIRP	cis	rs9653442	0.527	rs10176782	chr2:100782827	C/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.27	-0.32	2.99e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg21224049	chr4:668623	ATP5I	0.47	6.09	0.36	4.3e-9	Lung adenocarcinoma;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.93	0.53	9.33e-20	Schizophrenia;
KIRP	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.95	11.06	0.58	2.44e-23	Corneal astigmatism;
KIRP	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg24565620	chr2:194026	NA	-0.62	-6.54	-0.38	3.55e-10	Blood protein levels;
KIRP	cis	rs10129255	0.500	rs6576231	chr14:107191930	T/C	cg23076370	chr14:107095027	NA	-0.4	-4.87	-0.3	2e-6	Kawasaki disease;
KIRP	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-0.86	-10.0	-0.54	5.64e-20	Pediatric areal bone mineral density (radius);
KIRP	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.78	9.37	0.51	4.83e-18	Corneal astigmatism;
KIRP	cis	rs6693567	0.565	rs12093148	chr1:150265173	G/A	cg07843065	chr1:150265600	MRPS21	-0.42	-5.8	-0.35	1.99e-8	Migraine;
KIRP	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-5.17	-0.31	4.84e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1978968	1.000	rs7291169	chr22:18449038	A/G	cg02610425	chr22:18483192	MICAL3	0.36	5.04	0.31	8.99e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs10486722	0.607	rs6463038	chr7:41768105	G/A	cg07952040	chr12:110562126	IFT81	-0.59	-6.16	-0.37	2.99e-9	Pit-and-Fissure caries;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06740354	chr17:40265795	KAT2A;DHX58	0.48	6.39	0.38	8.41e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08463715	chr5:60050299	ELOVL7	-0.4	-6.42	-0.38	6.78e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg21573476	chr21:45109991	RRP1B	-0.63	-8.46	-0.47	2.44e-15	Mean corpuscular volume;
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.73	-0.44	2.69e-13	Platelet count;
KIRP	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.4	-0.43	2.11e-12	Body mass index;
KIRP	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg23565292	chr14:50234668	KLHDC2	-0.45	-5.36	-0.32	1.87e-7	Carotid intima media thickness;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg23698023	chr8:27181813	PTK2B	0.36	5.39	0.32	1.65e-7	Neuroticism;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01180513	chr20:3388407	C20orf194	-0.55	-6.04	-0.36	5.56e-9	Menopause (age at onset);
KIRP	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.92	10.62	0.56	6.27e-22	Neuroticism;
KIRP	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.96	13.06	0.64	5.88e-30	Breast cancer;
KIRP	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg24169773	chr3:122142474	KPNA1	-0.58	-6.47	-0.38	5.27e-10	LDL cholesterol levels;
KIRP	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	15.89	0.71	1.31e-39	Electrocardiographic conduction measures;
KIRP	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7909074	1.000	rs7079573	chr10:45400406	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-7.54	-0.43	8.94e-13	Mean corpuscular volume;
KIRP	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	8.28	0.47	8.1e-15	Blood protein levels;
KIRP	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg04691961	chr3:161091175	C3orf57	-0.5	-7.92	-0.45	8.39e-14	Morning vs. evening chronotype;
KIRP	trans	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.62	0.39	2.28e-10	Mean corpuscular volume;
KIRP	cis	rs7520050	0.966	rs1085244	chr1:46563680	C/A	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.82	10.15	0.54	1.94e-20	Platelet distribution width;
KIRP	cis	rs3789045	0.779	rs12043569	chr1:204560004	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.5	-5.19	-0.31	4.34e-7	Educational attainment (college completion);
KIRP	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.1	0.67	1.79e-33	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26933691	chr19:36139020	COX6B1	0.5	6.14	0.36	3.23e-9	Parkinson's disease;
KIRP	trans	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg16141378	chr3:129829833	LOC729375	-0.58	-7.32	-0.42	3.41e-12	Systolic blood pressure;
KIRP	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.5	-7.85	-0.45	1.29e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs4262150	0.883	rs72799188	chr5:152186304	A/T	cg12297329	chr5:152029980	NA	-0.66	-8.52	-0.48	1.61e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.58	-7.12	-0.41	1.17e-11	Aortic root size;
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.61	8.42	0.47	3.05e-15	Menarche (age at onset);
KIRP	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg07384165	chr1:10488281	NA	0.46	5.9	0.35	1.19e-8	Prostate cancer;
KIRP	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.0	-16.44	-0.72	1.78e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs6749447	1.000	rs7558963	chr2:169026081	A/T	cg10223061	chr2:219282414	VIL1	-0.37	-6.07	-0.36	4.88e-9	Blood pressure;
KIRP	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.84	-0.35	1.65e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	11.97	0.61	2.46e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg01631408	chr1:248437212	OR2T33	0.55	7.47	0.43	1.39e-12	Common traits (Other);
KIRP	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg24250549	chr1:154909240	PMVK	0.75	9.95	0.54	7.92e-20	Prostate cancer;
KIRP	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.44	-0.55	2.26e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10789491	1.000	rs7516616	chr1:47186274	A/G	cg15501359	chr1:47185051	KIAA0494	-1.15	-12.43	-0.62	7.72e-28	Response to hepatitis C treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08993582	chr3:57678673	FAM116A	0.55	6.87	0.4	5.33e-11	Parkinson's disease;
KIRP	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg23594656	chr7:65796392	TPST1	0.39	5.75	0.34	2.66e-8	Aortic root size;
KIRP	cis	rs73198271	0.628	rs74433718	chr8:8591546	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg06204229	chr3:52865917	ITIH4	0.44	5.11	0.31	6.41e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18252515	chr7:66147081	NA	0.46	5.51	0.33	9.21e-8	Aortic root size;
KIRP	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg02151108	chr14:50098012	C14orf104	-0.46	-5.94	-0.35	9.87e-9	Carotid intima media thickness;
KIRP	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.59	-6.46	-0.38	5.56e-10	Menarche (age at onset);
KIRP	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg26695010	chr11:65641043	EFEMP2	0.56	6.95	0.41	3.27e-11	Eosinophil percentage of white cells;
KIRP	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg04691961	chr3:161091175	C3orf57	-0.47	-7.08	-0.41	1.54e-11	Morning vs. evening chronotype;
KIRP	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg21095983	chr6:86352623	SYNCRIP	0.53	7.1	0.41	1.32e-11	Smooth-surface caries;
KIRP	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.79	8.85	0.49	1.79e-16	Corneal astigmatism;
KIRP	cis	rs10203711	1.000	rs4994756	chr2:239567125	T/C	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg03808351	chr9:123631620	PHF19	0.43	5.94	0.35	9.87e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs3748682	0.821	rs12751325	chr1:38289383	T/C	cg12658694	chr1:38397304	INPP5B	0.54	5.94	0.35	9.48e-9	Hypothyroidism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16631698	chr10:3500383	NA	-0.47	-6.88	-0.4	5.08e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg11833968	chr6:79620685	NA	-0.45	-6.88	-0.4	5e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.48e-12	Prudent dietary pattern;
KIRP	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.26	13.43	0.65	3.21e-31	Eosinophil percentage of granulocytes;
KIRP	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.63	-7.26	-0.42	4.99e-12	Prudent dietary pattern;
KIRP	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-6.83	-0.4	6.74e-11	Vitiligo;
KIRP	cis	rs16854884	0.837	rs4380409	chr3:143800896	A/G	cg06585982	chr3:143692056	C3orf58	0.45	5.49	0.33	9.81e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	1.08	8.09	0.46	2.72e-14	Skin colour saturation;
KIRP	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.76	0.44	2.32e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs7594645	1.000	rs73985728	chr2:207668245	G/A	cg17543123	chr19:30155994	PLEKHF1	-0.9	-6.44	-0.38	6.18e-10	Episodic memory;
KIRP	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg01721255	chr8:58191610	C8orf71	-0.53	-5.24	-0.32	3.46e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs8114671	0.967	rs12481169	chr20:33794510	T/C	cg07148914	chr20:33460835	GGT7	-0.41	-5.13	-0.31	5.87e-7	Height;
KIRP	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04374321	chr14:90722782	PSMC1	0.88	14.29	0.67	3.75e-34	Mortality in heart failure;
KIRP	cis	rs17095355	1.000	rs3862006	chr10:111750764	A/G	cg00817464	chr10:111662876	XPNPEP1	0.37	5.07	0.31	7.85e-7	Biliary atresia;
KIRP	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.45e-8	Schizophrenia;
KIRP	cis	rs12210905	1.000	rs12209456	chr6:27085225	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs6438504	0.885	rs12632242	chr3:118916627	T/G	cg25372693	chr3:118959985	B4GALT4	0.35	5.93	0.35	1.01e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs7903847	0.673	rs3818908	chr10:99132701	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-5.65	-0.34	4.39e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.69	10.91	0.57	7.45e-23	Cancer;
KIRP	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	7.55	0.43	8.52e-13	Chronic sinus infection;
KIRP	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.95	0.35	9.03e-9	Total cholesterol levels;
KIRP	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.47	-0.52	2.38e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17123764	0.818	rs57916875	chr12:49989336	G/A	cg02054252	chr12:50078554	FMNL3	0.49	5.17	0.31	4.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-1.21	-12.72	-0.63	7.72e-29	Schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11079969	chr15:82339920	NA	0.4	6.22	0.37	2.14e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9653442	0.564	rs4850924	chr2:100782273	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-4.92	-0.3	1.59e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07570687	chr10:102243282	WNT8B	0.52	6.64	0.39	1.94e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.81	-0.4	7.52e-11	Blood metabolite levels;
KIRP	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg01444801	chr10:135216882	MTG1	-0.56	-6.24	-0.37	1.9e-9	Systemic lupus erythematosus;
KIRP	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	1.07	20.94	0.8	1.39e-56	Bone mineral density;
KIRP	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg06521852	chr22:38141419	TRIOBP	0.44	6.08	0.36	4.45e-9	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.08	14.7	0.68	1.57e-35	Corneal structure;
KIRP	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.97	-15.04	-0.69	1.12e-36	Height;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg06419568	chr12:46776835	NA	0.48	6.09	0.36	4.27e-9	Asthma;
KIRP	cis	rs2594989	0.708	rs2594997	chr3:11365739	A/T	cg01796438	chr3:11312864	ATG7	-0.67	-7.84	-0.45	1.33e-13	Circulating chemerin levels;
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg17441377	chr17:3906640	NA	0.4	5.36	0.32	1.93e-7	Type 2 diabetes;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg13645296	chr15:64275810	DAPK2	0.43	6.3	0.37	1.37e-9	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.34	-0.37	1.09e-9	Triglycerides;
KIRP	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.7	9.44	0.52	3.01e-18	Parkinson's disease;
KIRP	cis	rs8060686	0.920	rs2271293	chr16:67902070	A/G	cg04539111	chr16:67997858	SLC12A4	0.62	5.84	0.35	1.61e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg10223061	chr2:219282414	VIL1	0.49	7.41	0.43	2.08e-12	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs4356932	0.935	rs6532155	chr4:76974097	G/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.61e-9	Blood protein levels;
KIRP	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	9.3	0.51	7.73e-18	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11158559	0.865	rs911001	chr14:65240485	C/T	cg22797773	chr14:65239943	SPTB	-0.33	-5.27	-0.32	2.97e-7	Obesity-related traits;
KIRP	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	1.01	10.08	0.54	3.11e-20	Psoriasis;
KIRP	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg01097406	chr16:89675127	NA	0.33	5.14	0.31	5.54e-7	Vitiligo;
KIRP	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg16558253	chr16:72132732	DHX38	-0.47	-6.68	-0.39	1.57e-10	Fibrinogen levels;
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.34	-0.32	2.1e-7	Obesity-related traits;
KIRP	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.72	8.66	0.48	6.42e-16	Alcohol dependence;
KIRP	cis	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg08773314	chr2:239334832	ASB1	-0.55	-5.71	-0.34	3.29e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.79	9.66	0.52	6.15e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.76	11.56	0.59	5.7e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	7.05	0.41	1.83e-11	Prudent dietary pattern;
KIRP	cis	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg06307176	chr5:131281290	NA	0.55	6.3	0.37	1.33e-9	Life satisfaction;
KIRP	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.81	11.14	0.58	1.37e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.66	11.32	0.59	3.53e-24	Anterior chamber depth;
KIRP	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.61	-8.9	-0.49	1.29e-16	Monocyte percentage of white cells;
KIRP	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg09137382	chr11:130731461	NA	0.57	8.21	0.46	1.28e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs5753037	0.653	rs131266	chr22:30145717	G/T	cg01021169	chr22:30184971	ASCC2	-0.46	-6.31	-0.37	1.32e-9	Type 1 diabetes;
KIRP	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg07384165	chr1:10488281	NA	-0.4	-5.15	-0.31	5.22e-7	Breast cancer;
KIRP	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.43	-6.46	-0.38	5.52e-10	Schizophrenia;
KIRP	trans	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg11693508	chr17:37793320	STARD3	0.55	7.07	0.41	1.58e-11	Neuroticism;
KIRP	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.54	-6.1	-0.36	4.13e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg03342759	chr3:160939853	NMD3	0.45	5.45	0.33	1.21e-7	Morning vs. evening chronotype;
KIRP	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg04731861	chr2:219085781	ARPC2	0.22	5.77	0.35	2.37e-8	Colorectal cancer;
KIRP	cis	rs2120243	0.592	rs4640513	chr3:157115950	A/G	cg24825693	chr3:157122686	VEPH1	-0.49	-8.1	-0.46	2.56e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg23127183	chr11:57508653	C11orf31	0.5	6.09	0.36	4.22e-9	Schizophrenia;
KIRP	cis	rs4692589	0.581	rs62344679	chr4:170963591	G/A	cg19918862	chr4:170955249	NA	0.57	6.16	0.37	2.99e-9	Anxiety disorder;
KIRP	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.23	-6.51	-0.38	4.09e-10	Type 2 diabetes;
KIRP	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.69	-7.39	-0.43	2.29e-12	Gut microbiome composition (summer);
KIRP	cis	rs6838801	0.823	rs28583649	chr4:77591712	T/A	cg17476223	chr4:77663285	SHROOM3	0.56	8.06	0.46	3.4e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.54	-6.93	-0.4	3.65e-11	Blood metabolite levels;
KIRP	cis	rs75064307	0.734	rs1870011	chr3:108101323	G/T	cg14703454	chr3:108065259	HHLA2	0.54	6.18	0.37	2.69e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7005380	0.556	rs11984866	chr8:120936725	G/A	cg21645572	chr8:120931649	DEPDC6	-0.43	-5.2	-0.31	4.13e-7	Interstitial lung disease;
KIRP	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.73	7.98	0.45	5.66e-14	Corneal astigmatism;
KIRP	cis	rs62413470	1.000	rs62404895	chr6:55961427	A/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	trans	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-8.16	-0.46	1.76e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12476592	0.571	rs262475	chr2:63869045	A/T	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.91	-0.35	1.12e-8	LDL cholesterol levels;
KIRP	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg02404636	chr22:31891804	SFI1	-0.43	-5.1	-0.31	6.83e-7	Paclitaxel-induced neuropathy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10096405	chr4:1208301	CTBP1	-0.43	-6.48	-0.38	4.91e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg05791153	chr7:19748676	TWISTNB	0.65	5.82	0.35	1.86e-8	Thyroid stimulating hormone;
KIRP	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.05	0.5	4.45e-17	Bipolar disorder;
KIRP	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.54	6.81	0.4	7.53e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs698833	0.886	rs698775	chr2:44588941	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.61	0.39	2.35e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15554466	chr19:39936040	SUPT5H	-0.44	-6.08	-0.36	4.49e-9	Metabolic traits;
KIRP	cis	rs4791746	1.000	rs7208014	chr17:8619029	G/C	cg03115937	chr17:8649504	CCDC42	-0.52	-6.29	-0.37	1.43e-9	Heroin dependence;
KIRP	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.08	-0.36	4.67e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.65	6.48	0.38	5.07e-10	Eotaxin levels;
KIRP	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg06636001	chr8:8085503	FLJ10661	0.7	8.86	0.49	1.69e-16	Retinal vascular caliber;
KIRP	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.65	-7.47	-0.43	1.38e-12	IgG glycosylation;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.61	8.94	0.5	9.42e-17	Lung cancer;
KIRP	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.61	7.61	0.44	5.78e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg21427119	chr20:30132790	HM13	0.53	6.0	0.36	6.93e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.47	-6.16	-0.37	2.87e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg19923238	chr8:142232952	SLC45A4	-0.41	-4.88	-0.3	1.95e-6	Immature fraction of reticulocytes;
KIRP	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg15655495	chr12:38532458	NA	0.26	5.05	0.31	8.76e-7	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27324075	chr5:68856062	GTF2H2C;GTF2H2D	0.52	6.71	0.39	1.34e-10	Parkinson's disease;
KIRP	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg19636519	chr7:99541626	NA	0.28	4.88	0.3	1.91e-6	Coronary artery disease;
KIRP	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	1.33	10.0	0.54	5.72e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.5	7.2	0.42	7.28e-12	Schizophrenia;
KIRP	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.32	-6.74	-0.4	1.09e-10	Diastolic blood pressure;
KIRP	cis	rs4561483	0.582	rs3850997	chr16:12043512	G/T	cg08843971	chr16:11963173	GSPT1	-0.5	-6.0	-0.36	7.1e-9	Testicular germ cell tumor;
KIRP	cis	rs17030434	0.834	rs6843172	chr4:154760600	T/C	cg14289246	chr4:154710475	SFRP2	-0.66	-8.26	-0.47	9.23e-15	Electrocardiographic conduction measures;
KIRP	cis	rs4073416	0.518	rs10148529	chr14:66104703	A/T	cg03016385	chr14:66212404	NA	-0.54	-6.58	-0.39	2.73e-10	N-glycan levels;
KIRP	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.79	0.35	2.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11874712	1.000	rs7235373	chr18:43653763	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.5	-0.33	9.35e-8	Migraine - clinic-based;
KIRP	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.52	7.7	0.44	3.35e-13	Blood protein levels;
KIRP	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.05	0.31	8.42e-7	Smoking behavior;
KIRP	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.84	10.18	0.54	1.54e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.47	-5.9	-0.35	1.22e-8	Longevity;Endometriosis;
KIRP	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg02336718	chr17:17403227	NA	-0.33	-5.09	-0.31	7.05e-7	Total body bone mineral density;
KIRP	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.59	-7.79	-0.44	1.86e-13	Body mass index;
KIRP	trans	rs972578	0.765	rs4822213	chr22:43270819	A/G	cg15321293	chr3:36422198	STAC	-0.48	-6.24	-0.37	1.94e-9	Mean platelet volume;
KIRP	cis	rs7712401	0.601	rs446782	chr5:122341868	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.41	-0.33	1.48e-7	Mean platelet volume;
KIRP	cis	rs745821	0.598	rs73959977	chr18:48116645	T/A	cg18923635	chr18:48083994	NA	0.42	4.91	0.3	1.64e-6	Diastolic blood pressure;
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13939156	chr17:80058883	NA	0.5	7.54	0.43	9.21e-13	Life satisfaction;
KIRP	cis	rs7011049	1.000	rs72640868	chr8:53843812	C/A	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12893428	chr3:195717962	SDHAP1	0.47	6.22	0.37	2.06e-9	Pancreatic cancer;
KIRP	cis	rs7011049	0.915	rs78887309	chr8:53860016	A/C	cg26025543	chr8:53854495	NA	0.75	7.43	0.43	1.75e-12	Systolic blood pressure;
KIRP	cis	rs3126085	0.560	rs45541239	chr1:152346391	T/G	cg26876637	chr1:152193138	HRNR	-0.73	-7.22	-0.42	6.6e-12	Atopic dermatitis;
KIRP	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.46	-7.05	-0.41	1.78e-11	Coronary artery disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24993990	chr2:166428802	CSRNP3	0.41	6.14	0.36	3.26e-9	C-reactive protein;
KIRP	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg04317338	chr11:64019027	PLCB3	0.82	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg07884673	chr3:53033167	SFMBT1	-0.85	-7.26	-0.42	5.06e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-8.73	-0.49	3.98e-16	Personality dimensions;
KIRP	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.36	-6.67	-0.39	1.72e-10	Renal cell carcinoma;
KIRP	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.96	12.93	0.64	1.57e-29	Breast cancer;
KIRP	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg24253500	chr15:84953950	NA	0.53	6.1	0.36	4.19e-9	Schizophrenia;
KIRP	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.4	-0.47	3.57e-15	Total cholesterol levels;
KIRP	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-1.0	-18.42	-0.76	3.28e-48	Heart rate;
KIRP	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	9.19	0.51	1.71e-17	IgG glycosylation;
KIRP	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.39	-0.59	2.09e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.19	0.31	4.32e-7	Lung cancer;
KIRP	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.6	-7.87	-0.45	1.11e-13	Bladder cancer;
KIRP	trans	rs7939886	0.920	rs11227449	chr11:55949409	A/G	cg03929089	chr4:120376271	NA	0.98	6.29	0.37	1.46e-9	Myopia (pathological);
KIRP	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg21427119	chr20:30132790	HM13	0.41	4.97	0.3	1.26e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg02297831	chr4:17616191	MED28	0.53	6.54	0.39	3.46e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11650175	0.727	rs35233670	chr17:63750903	C/T	cg18091269	chr17:63822838	CCDC46	0.32	5.03	0.31	9.57e-7	Chin dimples;
KIRP	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.51	-7.24	-0.42	5.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg21573476	chr21:45109991	RRP1B	0.55	7.32	0.42	3.61e-12	Mean corpuscular volume;
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg21851534	chr17:3907994	ZZEF1	0.4	5.31	0.32	2.44e-7	Type 2 diabetes;
KIRP	cis	rs17121403	0.661	rs12129713	chr1:100489128	T/G	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs9400467	0.508	rs12211763	chr6:111787156	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.56	-0.33	7.03e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg24634471	chr8:143751801	JRK	-0.44	-5.05	-0.31	8.44e-7	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg24848339	chr3:12840334	CAND2	0.34	4.96	0.3	1.33e-6	QRS complex (12-leadsum);
KIRP	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	1.1	8.66	0.48	6.19e-16	Severe influenza A (H1N1) infection;
KIRP	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg04374321	chr14:90722782	PSMC1	-0.83	-11.56	-0.59	5.77e-25	Mortality in heart failure;
KIRP	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.46	0.52	2.56e-18	Multiple sclerosis;
KIRP	trans	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.24	-0.37	1.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20364594	chr6:158981615	TMEM181	-0.45	-6.61	-0.39	2.32e-10	Metabolic traits;
KIRP	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.11	-0.31	6.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg11970804	chr8:8084126	NA	0.37	4.88	0.3	1.91e-6	Joint mobility (Beighton score);
KIRP	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg21419209	chr3:44054225	NA	-0.77	-9.41	-0.51	3.76e-18	Coronary artery disease;
KIRP	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-5.03	-0.31	9.62e-7	Lung cancer;
KIRP	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.81	-10.23	-0.55	1.05e-20	Vitamin D levels;
KIRP	cis	rs1823913	0.614	rs4853576	chr2:192161344	T/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.18	-0.37	2.6e-9	Obesity-related traits;
KIRP	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg19468946	chr17:37922297	IKZF3	-0.48	-6.55	-0.39	3.34e-10	Self-reported allergy;
KIRP	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.5	-6.7	-0.39	1.4e-10	Hip circumference;Waist circumference;
KIRP	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.52	6.88	0.4	4.94e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11637445	0.677	rs10152422	chr15:68102929	C/T	cg24579218	chr15:68104479	NA	0.44	6.28	0.37	1.49e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2281603	0.570	rs73265641	chr14:64949864	G/A	cg01860774	chr14:64969374	ZBTB25	0.34	5.41	0.33	1.46e-7	Lymphocyte counts;
KIRP	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg05043794	chr9:111880884	C9orf5	0.21	5.01	0.3	1.02e-6	Menarche (age at onset);
KIRP	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg24253500	chr15:84953950	NA	0.51	5.84	0.35	1.61e-8	Schizophrenia;
KIRP	cis	rs1620921	0.505	rs9458025	chr6:161203435	T/C	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	1.04	13.46	0.65	2.55e-31	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.41	8.63	0.48	7.5e-16	IgG glycosylation;
KIRP	cis	rs62355272	0.861	rs7733008	chr5:35833623	G/A	cg13894535	chr5:35919491	CAPSL	-0.47	-5.33	-0.32	2.24e-7	Lymphocyte counts;
KIRP	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12924262	chr12:102091054	CHPT1	0.45	5.87	0.35	1.37e-8	Blood protein levels;
KIRP	cis	rs9813712	0.571	rs9824426	chr3:129944958	A/G	cg13799772	chr3:129800573	ALG1L2	-0.34	-4.98	-0.3	1.2e-6	Response to amphetamines;
KIRP	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.98	8.71	0.49	4.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9843304	0.616	rs4681177	chr3:149203000	G/T	cg08667024	chr3:149219783	TM4SF4	-0.44	-6.07	-0.36	4.86e-9	Gallstone disease;
KIRP	cis	rs7116495	1.000	rs12283462	chr11:71835406	T/G	cg26138937	chr11:71823887	C11orf51	0.7	5.51	0.33	9.27e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-12.64	-0.63	1.54e-28	Alzheimer's disease;
KIRP	cis	rs5753037	0.809	rs2074706	chr22:30200893	G/C	cg27665648	chr22:30112403	NA	0.46	6.36	0.38	9.95e-10	Type 1 diabetes;
KIRP	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.66	-0.44	4.13e-13	Type 2 diabetes;
KIRP	cis	rs228437	0.586	rs6920152	chr6:134947520	G/T	cg24504307	chr6:134963096	NA	-0.3	-5.09	-0.31	6.97e-7	Melanoma;
KIRP	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.94	12.99	0.64	9.58e-30	Response to antipsychotic treatment;
KIRP	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6959887	0.962	rs17675148	chr7:35288276	T/C	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg04132472	chr17:19861366	AKAP10	0.67	10.51	0.56	1.42e-21	Schizophrenia;
KIRP	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg24253500	chr15:84953950	NA	-0.43	-5.38	-0.32	1.72e-7	P wave terminal force;
KIRP	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.61	5.79	0.35	2.12e-8	Vitiligo;
KIRP	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg18198730	chr1:247681584	NA	-0.63	-6.86	-0.4	5.61e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg24044776	chr19:53454761	ZNF816A	-0.48	-7.12	-0.41	1.17e-11	Psoriasis;
KIRP	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	5.96	0.36	8.57e-9	Putamen volume;
KIRP	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.88	10.02	0.54	4.95e-20	Coronary artery disease;
KIRP	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-11.42	-0.59	1.64e-24	Alzheimer's disease;
KIRP	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.93	14.95	0.69	2.18e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10170310	0.872	rs62161711	chr2:139259222	A/G	cg10095539	chr2:139258744	SPOPL	0.36	5.71	0.34	3.26e-8	Response to antipsychotic treatment;
KIRP	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.47	-0.52	2.49e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.55	0.48	1.33e-15	Motion sickness;
KIRP	cis	rs7656342	0.686	rs10031303	chr4:9841690	A/T	cg00071950	chr4:10020882	SLC2A9	0.36	4.97	0.3	1.26e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22117172	chr7:91764530	CYP51A1	0.48	6.69	0.39	1.46e-10	Breast cancer;
KIRP	cis	rs5753037	0.809	rs5997530	chr22:30203599	C/G	cg27665648	chr22:30112403	NA	0.46	6.4	0.38	7.7e-10	Type 1 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17169043	chr6:170863845	PSMB1;TBP	0.5	6.34	0.37	1.07e-9	Parkinson's disease;
KIRP	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27297192	chr10:134578999	INPP5A	0.66	8.08	0.46	2.83e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg17294928	chr15:75287854	SCAMP5	0.58	7.75	0.44	2.4e-13	Breast cancer;
KIRP	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.97	17.08	0.74	1.18e-43	Breast cancer;
KIRP	cis	rs7903847	0.642	rs11189178	chr10:99143272	T/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.56	7.21	0.42	6.87e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg16232979	chr19:16187631	TPM4	-0.49	-6.3	-0.37	1.37e-9	Myopia;
KIRP	trans	rs1937787	0.522	rs12070989	chr1:80841004	G/T	cg02324974	chr12:132413779	PUS1	-0.49	-6.39	-0.38	8.13e-10	Stroke;
KIRP	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.9	-0.3	1.76e-6	Pulmonary function;
KIRP	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.85	-11.31	-0.58	3.78e-24	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg24848339	chr3:12840334	CAND2	0.34	5.37	0.32	1.86e-7	P wave duration;
KIRP	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg02696742	chr7:106810147	HBP1	-0.75	-7.73	-0.44	2.76e-13	Coronary artery disease;
KIRP	trans	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.5	-6.71	-0.39	1.3100000000000001e-10	Mean corpuscular volume;
KIRP	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg16342193	chr10:102329863	NA	-0.38	-4.97	-0.3	1.28e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.66	9.71	0.53	4.61e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg19847130	chr8:10466454	RP1L1	0.38	5.62	0.34	5.06e-8	Triglycerides;
KIRP	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.12	14.29	0.67	3.78e-34	Gut microbiome composition (summer);
KIRP	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24706213	chr1:109633347	TMEM167B	0.47	6.27	0.37	1.63e-9	Survival in pancreatic cancer;
KIRP	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg24253500	chr15:84953950	NA	0.51	5.75	0.34	2.67e-8	Schizophrenia;
KIRP	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.33	5.07	0.31	7.92e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2997447	0.761	rs61776575	chr1:26429844	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.58	-0.34	6.24e-8	QRS complex (12-leadsum);
KIRP	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg23815491	chr16:72088622	HP	-0.36	-5.29	-0.32	2.66e-7	Blood protein levels;
KIRP	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.36	0.32	1.9e-7	Blood protein levels;
KIRP	cis	rs6772849	0.930	rs6768344	chr3:128373556	G/A	cg08795948	chr3:128337044	NA	0.48	6.03	0.36	5.95e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg23307798	chr14:103986281	CKB	0.78	13.47	0.65	2.42e-31	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07121980	chr15:45879310	PLDN	0.43	6.15	0.37	3.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg21546286	chr11:48923668	NA	-0.47	-6.15	-0.36	3.17e-9	HDL cholesterol;
KIRP	cis	rs12693043	0.525	rs1010027	chr2:175418869	A/G	cg11778734	chr2:175439522	WIPF1	-0.47	-6.34	-0.37	1.12e-9	Urate levels (BMI interaction);
KIRP	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.63	8.63	0.48	7.96e-16	Alcohol dependence;
KIRP	cis	rs7119167	0.686	rs12275766	chr11:73048755	A/G	cg17517138	chr11:73019481	ARHGEF17	0.48	5.02	0.3	1.01e-6	Blood protein levels;
KIRP	cis	rs960902	0.818	rs60691585	chr2:37714428	A/G	cg25341268	chr2:37734390	NA	0.66	8.8	0.49	2.54e-16	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.38	0.38	8.55e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.11	-0.36	3.81e-9	Cutaneous nevi;
KIRP	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg13615516	chr5:77269221	NA	-0.47	-7.43	-0.43	1.78e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4787491	0.658	rs11647753	chr16:29928115	C/T	cg05445914	chr16:30134068	MAPK3	-0.42	-5.54	-0.33	7.82e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.86	-0.6	5.78e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg25019722	chr6:37503610	NA	-0.98	-14.95	-0.69	2.13e-36	Cognitive performance;
KIRP	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg20476274	chr7:133979776	SLC35B4	0.74	10.4	0.55	3.03e-21	Mean platelet volume;
KIRP	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10465746	0.653	rs11163877	chr1:84441848	T/A	cg10977910	chr1:84465055	TTLL7	0.55	7.13	0.41	1.14e-11	Obesity-related traits;
KIRP	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg00745463	chr17:30367425	LRRC37B	-0.65	-6.44	-0.38	6.06e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs4580973	1	rs4580973	chr7:104903659	A/G	cg04380332	chr7:105027541	SRPK2	0.38	5.29	0.32	2.64e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg00857998	chr1:205179979	DSTYK	0.63	7.48	0.43	1.29e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9826463	0.582	rs73238145	chr3:142060559	G/A	cg20824294	chr3:142316082	PLS1	0.43	6.22	0.37	2.16e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.92	12.4	0.62	9.52e-28	Homoarginine levels;
KIRP	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.51	-7.27	-0.42	4.82e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg04154034	chr17:28927549	LRRC37B2	0.53	5.06	0.31	8.11e-7	Body mass index;
KIRP	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg08885076	chr2:99613938	TSGA10	-0.4	-5.66	-0.34	4.11e-8	Fear of minor pain;
KIRP	cis	rs2671245	0.624	rs1182821	chr1:56170806	G/T	cg11523071	chr1:56160889	NA	0.35	4.86	0.3	2.1e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.16	25.03	0.85	1.38e-69	Schizophrenia;
KIRP	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.87	10.92	0.57	6.93e-23	Coronary artery disease;
KIRP	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg16141378	chr3:129829833	LOC729375	0.49	6.48	0.38	4.87e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs73198271	0.586	rs3789850	chr8:8686845	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.28	-0.32	2.89e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.99	-10.54	-0.56	1.13e-21	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17200737	chr14:92198536	CATSPERB	0.44	6.37	0.38	9.16e-10	Survival in pancreatic cancer;
KIRP	cis	rs7224314	1.000	rs62085810	chr17:65372855	G/A	cg01507342	chr17:65387096	PITPNC1	-0.48	-6.09	-0.36	4.26e-9	Diisocyanate-induced asthma;
KIRP	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00857998	chr1:205179979	DSTYK	0.67	8.64	0.48	7.49e-16	Red blood cell count;
KIRP	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.74e-11	Vitiligo;
KIRP	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	1.05	18.98	0.77	4.38e-50	Height;
KIRP	cis	rs6973256	0.865	rs2991230	chr7:133332086	A/C	cg10665199	chr7:133106180	EXOC4	-0.49	-6.18	-0.37	2.6e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.82	-10.55	-0.56	1.04e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	trans	rs16867225	1.000	rs16867225	chr2:181041286	G/A	cg18179931	chr3:194119058	GP5	-0.4	-6.35	-0.38	1.01e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.43	5.46	0.33	1.17e-7	Aortic root size;
KIRP	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg14664628	chr15:75095509	CSK	-0.65	-8.12	-0.46	2.3e-14	Breast cancer;
KIRP	cis	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg00262122	chr8:11665843	FDFT1	-0.44	-5.24	-0.32	3.53e-7	Joint mobility (Beighton score);
KIRP	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs77861329	1.000	rs17051957	chr3:52099441	A/G	cg08692210	chr3:52188851	WDR51A	0.9	7.13	0.41	1.13e-11	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	11.52	0.59	7.85e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.62	-8.19	-0.46	1.41e-14	Aortic root size;
KIRP	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.34	5.02	0.3	1.01e-6	Lymphocyte counts;
KIRP	cis	rs7523050	0.730	rs77425121	chr1:109417677	C/A	cg08274380	chr1:109419600	GPSM2	1.18	10.17	0.54	1.6e-20	Fat distribution (HIV);
KIRP	cis	rs6939532	0.522	rs9379870	chr6:26374410	A/G	cg12826209	chr6:26865740	GUSBL1	0.44	5.17	0.31	4.82e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10172253	chr1:84420145	TTLL7	-0.45	-6.7	-0.39	1.43e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg25019722	chr6:37503610	NA	-0.94	-15.13	-0.69	5.47e-37	Cognitive performance;
KIRP	cis	rs7027203	0.538	rs10125195	chr9:96523224	T/C	cg14598338	chr9:96623480	NA	-0.44	-6.69	-0.39	1.49e-10	DNA methylation (variation);
KIRP	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.02	0.3	1.01e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg19000871	chr14:103996768	TRMT61A	-0.52	-5.6	-0.34	5.65e-8	Reticulocyte count;
KIRP	cis	rs12449964	0.524	rs4925093	chr17:17568946	G/T	cg01246520	chr17:17644344	RAI1	0.29	4.86	0.3	2.07e-6	Coronary artery disease or ischemic stroke;
KIRP	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.77	-8.28	-0.47	7.87e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg09137382	chr11:130731461	NA	0.51	7.36	0.42	2.71e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4700695	0.925	rs12657113	chr5:65396959	A/C	cg21114390	chr5:65439923	SFRS12	-0.48	-5.71	-0.34	3.28e-8	Facial morphology (factor 19);
KIRP	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.76	0.81	2.97e-59	Prudent dietary pattern;
KIRP	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	5.29	0.32	2.75e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.95	14.5	0.68	7.62e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.78	-12.03	-0.61	1.64e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.72	-0.39	1.29e-10	Triglycerides;
KIRP	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg23505145	chr19:12996616	KLF1	0.55	8.09	0.46	2.71e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.6	-7.14	-0.41	1.05e-11	Initial pursuit acceleration;
KIRP	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.22	0.32	3.75e-7	Educational attainment;
KIRP	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.97	11.26	0.58	5.49e-24	Corneal astigmatism;
KIRP	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg22705602	chr4:152727874	NA	0.52	8.75	0.49	3.52e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.52	-7.51	-0.43	1.1e-12	Daytime sleep phenotypes;
KIRP	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg02073558	chr3:44770973	ZNF501	-0.62	-8.78	-0.49	2.82e-16	Depressive symptoms;
KIRP	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.78	-8.35	-0.47	4.99e-15	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25563233	chr19:11529396	RGL3	0.5	6.54	0.38	3.47e-10	Parkinson's disease;
KIRP	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg15655495	chr12:38532458	NA	0.25	4.93	0.3	1.49e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.75	-0.4	1.05e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12549025	0.516	rs13257250	chr8:23342959	G/A	cg00472375	chr8:23315376	ENTPD4	0.57	5.46	0.33	1.17e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs73200209	0.744	rs17498452	chr12:116538854	C/T	cg01776926	chr12:116560359	MED13L	0.57	6.29	0.37	1.4e-9	Total body bone mineral density;
KIRP	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg26061582	chr7:22766209	IL6	0.39	4.95	0.3	1.37e-6	Lung cancer;
KIRP	cis	rs6894268	0.722	rs6601058	chr5:179032187	A/G	cg22014891	chr5:179071901	C5orf60	-0.39	-4.91	-0.3	1.69e-6	Eating disorders;
KIRP	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-6.72	-0.39	1.22e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.55	-0.39	3.39e-10	IgG glycosylation;
KIRP	cis	rs4950322	0.570	rs4950400	chr1:146791101	C/G	cg22381352	chr1:146742008	CHD1L	0.47	5.6	0.34	5.65e-8	Protein quantitative trait loci;
KIRP	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-8.06	-0.46	3.39e-14	Coronary artery disease;
KIRP	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs829883	0.659	rs11109528	chr12:98951362	G/A	cg25150519	chr12:98850993	NA	-0.77	-9.3	-0.51	8.05e-18	Colorectal adenoma (advanced);
KIRP	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg01689657	chr7:91764605	CYP51A1	0.47	6.98	0.41	2.81e-11	Breast cancer;
KIRP	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-7.02	-0.41	2.18e-11	Lymphocyte counts;
KIRP	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-5.51	-0.33	8.82e-8	Ulcerative colitis;
KIRP	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.53	7.14	0.41	1.04e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-15.62	-0.71	1.15e-38	Electrocardiographic conduction measures;
KIRP	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.57	-7.98	-0.45	5.45e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg21258169	chr6:138661523	KIAA1244	0.43	6.53	0.38	3.67e-10	Migraine with aura;
KIRP	cis	rs9815354	0.812	rs113772069	chr3:41933389	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.99	0.45	5.18e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.49	5.98	0.36	7.99e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	10.1	0.54	2.72e-20	Alzheimer's disease;
KIRP	cis	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg21775007	chr8:11205619	TDH	-0.48	-5.96	-0.36	8.84e-9	Triglycerides;
KIRP	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg08885076	chr2:99613938	TSGA10	-0.33	-5.01	-0.3	1.04e-6	Bipolar disorder;
KIRP	trans	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00950418	chr7:105029125	SRPK2	-0.53	-6.54	-0.38	3.6e-10	Height;
KIRP	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-13.32	-0.65	7.41e-31	Blood trace element (Zn levels);
KIRP	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.5	-7.06	-0.41	1.68e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs617219	0.889	rs4466139	chr5:78430058	T/C	cg22188827	chr5:78429774	NA	-0.44	-4.99	-0.3	1.13e-6	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.54	8.37	0.47	4.4e-15	Coronary artery disease;
KIRP	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg24253500	chr15:84953950	NA	-0.62	-6.53	-0.38	3.73e-10	Schizophrenia;
KIRP	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.64	-7.76	-0.44	2.2e-13	Blood protein levels;
KIRP	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.64	8.57	0.48	1.17e-15	Calcium levels;
KIRP	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.78	-10.61	-0.56	6.76e-22	Aortic root size;
KIRP	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.44	4.87	0.3	1.99e-6	Schizophrenia;
KIRP	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg05973401	chr12:123451056	ABCB9	0.49	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14159672	chr1:205819179	PM20D1	-0.61	-5.93	-0.35	1.01e-8	Menarche (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17105737	chr19:639777	FGF22	0.42	6.57	0.39	2.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10858047	0.941	rs116185978	chr1:115118982	C/T	cg12756093	chr1:115239321	AMPD1	0.69	6.52	0.38	4.07e-10	Autism;
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13198984	chr17:80129470	CCDC57	-0.58	-8.78	-0.49	2.83e-16	Life satisfaction;
KIRP	cis	rs2120243	1.000	rs9289982	chr3:157144444	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.51	7.0	0.41	2.49e-11	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.7	9.37	0.51	4.86e-18	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.97	13.31	0.65	8.26e-31	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23279887	chr19:19249481	TMEM161A	-0.56	-6.83	-0.4	6.76e-11	Interleukin-4 levels;
KIRP	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg03465714	chr1:152285911	FLG	-0.41	-4.92	-0.3	1.57e-6	Atopic dermatitis;
KIRP	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.51	-5.88	-0.35	1.33e-8	Schizophrenia;
KIRP	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.68	-7.76	-0.44	2.33e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.55	-6.76	-0.4	1.02e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg11584989	chr19:19387371	SF4	0.43	5.46	0.33	1.16e-7	Tonsillectomy;
KIRP	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg13939156	chr17:80058883	NA	-0.5	-7.51	-0.43	1.06e-12	Life satisfaction;
KIRP	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.93	0.35	1.04e-8	Motion sickness;
KIRP	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.26	-7.88	-0.45	1.06e-13	Type 2 diabetes;
KIRP	cis	rs2131877	0.573	rs4300953	chr3:194846903	A/G	cg16306870	chr3:194868790	C3orf21	0.21	4.92	0.3	1.58e-6	Non-small cell lung cancer;
KIRP	cis	rs7033996	1.000	rs16932756	chr9:35921694	A/G	cg00918944	chr9:35908117	LOC158376	0.36	5.21	0.32	3.96e-7	Urate levels (BMI interaction);
KIRP	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21545522	chr1:205238299	TMCC2	0.39	5.15	0.31	5.37e-7	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	8.71	0.49	4.68e-16	Mood instability;
KIRP	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.86	-9.69	-0.53	5.3e-19	Blood pressure (smoking interaction);
KIRP	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	1.09	20.03	0.79	1.36e-53	Gut microbiome composition (winter);
KIRP	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.3	-0.51	7.9e-18	Personality dimensions;
KIRP	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg16989719	chr2:238392110	NA	-0.56	-6.04	-0.36	5.79e-9	Prostate cancer;
KIRP	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg17133734	chr15:86042851	AKAP13	-0.44	-5.41	-0.33	1.47e-7	Coronary artery disease;
KIRP	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	10.67	0.56	4.21e-22	Smoking behavior;
KIRP	cis	rs57590327	0.503	rs898763	chr3:81513408	T/C	cg07356753	chr3:81810745	GBE1	0.49	6.19	0.37	2.46e-9	Extraversion;
KIRP	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs10181042	0.528	rs2564118	chr2:61233289	A/G	cg10580144	chr2:61372316	C2orf74	0.39	4.96	0.3	1.34e-6	Crohn's disease;
KIRP	cis	rs7520050	0.966	rs7522601	chr1:46419021	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs62229266	1.000	rs62229266	chr21:37460271	A/T	cg12218747	chr21:37451666	NA	-0.41	-5.03	-0.31	9.49e-7	Mitral valve prolapse;
KIRP	cis	rs7714584	1.000	rs57406211	chr5:150170966	C/T	cg22134413	chr5:150180641	NA	1.06	7.56	0.43	8.2e-13	Crohn's disease;
KIRP	cis	rs2594989	0.831	rs7356051	chr3:11566288	A/C	cg01796438	chr3:11312864	ATG7	0.6	7.47	0.43	1.42e-12	Circulating chemerin levels;
KIRP	cis	rs7870753	0.782	rs6477496	chr9:99256412	C/T	cg25260653	chr9:99212216	HABP4	0.54	5.64	0.34	4.56e-8	Height;
KIRP	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.59	7.95	0.45	6.82e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6545883	0.894	rs7566035	chr2:61520815	C/T	cg15711740	chr2:61764176	XPO1	0.6	7.66	0.44	4.3e-13	Tuberculosis;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg26601039	chr13:36788722	SOHLH2	-0.43	-6.47	-0.38	5.36e-10	Bladder cancer;
KIRP	trans	rs12517041	1.000	rs10520889	chr5:23280920	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.31	-0.47	6.31e-15	Calcium levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13573980	chr1:223963249	CAPN2	0.49	6.14	0.36	3.32e-9	Interleukin-4 levels;
KIRP	cis	rs228437	1.000	rs450801	chr6:134905309	T/C	cg24504307	chr6:134963096	NA	-0.5	-6.98	-0.41	2.67e-11	Melanoma;
KIRP	trans	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg08400319	chr2:242004533	SNED1	0.44	6.04	0.36	5.69e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7523273	0.565	rs1998539	chr1:207886596	G/A	cg22525895	chr1:207977042	MIR29B2	0.45	5.79	0.35	2.14e-8	Schizophrenia;
KIRP	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-0.66	-7.69	-0.44	3.61e-13	Initial pursuit acceleration;
KIRP	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg14003231	chr6:33640908	ITPR3	0.28	5.07	0.31	7.74e-7	Plateletcrit;
KIRP	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.61	-7.78	-0.44	1.99e-13	Breast size;
KIRP	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.21e-6	Blood protein levels;
KIRP	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.88	-14.42	-0.68	1.37e-34	Prostate cancer;
KIRP	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg19116668	chr7:99932089	PMS2L1	-0.45	-5.24	-0.32	3.49e-7	Coronary artery disease;
KIRP	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15664640	chr17:80829946	TBCD	-0.74	-6.59	-0.39	2.59e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg01378222	chr16:28622494	SULT1A1	-0.62	-5.34	-0.32	2.06e-7	Platelet distribution width;
KIRP	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	1.08	13.74	0.66	2.83e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.31	-0.37	1.26e-9	QT interval;
KIRP	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.36	5.51	0.33	9.12e-8	P wave duration;
KIRP	cis	rs7520050	0.801	rs6703960	chr1:46232723	C/T	cg03146154	chr1:46216737	IPP	-0.42	-5.18	-0.31	4.68e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg16650896	chr7:64838774	ZNF92	0.52	6.05	0.36	5.46e-9	Sleep duration;
KIRP	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	6.51	0.38	4.2e-10	Menarche (age at onset);
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg01798813	chr17:3906674	NA	0.52	6.58	0.39	2.74e-10	Type 2 diabetes;
KIRP	cis	rs789859	0.965	rs812583	chr3:194406505	C/G	cg02072170	chr3:194406190	FAM43A	0.36	5.52	0.33	8.48e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03429512	chr2:203140700	NOP58;SNORD70	0.42	6.26	0.37	1.7e-9	Survival in pancreatic cancer;
KIRP	cis	rs11645898	0.630	rs72791135	chr16:72259718	G/C	cg14768367	chr16:72042858	DHODH	-0.7	-6.78	-0.4	8.68e-11	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14412733	chr9:116172785	POLE3;C9orf43	0.45	6.09	0.36	4.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.97	0.3	1.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg26248373	chr2:1572462	NA	0.64	6.09	0.36	4.25e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg07169764	chr2:136633963	MCM6	0.53	6.19	0.37	2.46e-9	Mosquito bite size;
KIRP	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.49	5.82	0.35	1.86e-8	Uric acid levels;
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	12.86	0.63	2.69e-29	Platelet count;
KIRP	trans	rs6601327	0.670	rs4128198	chr8:9433499	T/G	cg16141378	chr3:129829833	LOC729375	-0.47	-6.19	-0.37	2.55e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.73	-8.27	-0.47	8.64e-15	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.75e-13	Life satisfaction;
KIRP	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06544989	chr22:39130855	UNC84B	0.5	9.02	0.5	5.63e-17	Menopause (age at onset);
KIRP	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg06217071	chr17:408420	NA	0.73	11.31	0.58	3.78e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg00806126	chr19:22604979	ZNF98	0.68	7.0	0.41	2.39e-11	Pain;
KIRP	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg16141378	chr3:129829833	LOC729375	0.57	7.85	0.45	1.27e-13	Neuroticism;
KIRP	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-5.28	-0.32	2.88e-7	Height;
KIRP	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg25457927	chr22:38595422	NA	-0.31	-6.38	-0.38	8.71e-10	Breast cancer;
KIRP	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	cg21523751	chr1:182988639	NA	0.44	6.87	0.4	5.3e-11	Hypertriglyceridemia;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg13453750	chr1:205783389	SLC41A1	-0.49	-7.67	-0.44	4.08e-13	Menarche (age at onset);
KIRP	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.76	10.57	0.56	8.95e-22	Eye color traits;
KIRP	cis	rs10073892	0.830	rs13355136	chr5:101607291	A/G	cg19774478	chr5:101632501	SLCO4C1	0.66	6.38	0.38	8.87e-10	Cognitive decline (age-related);
KIRP	trans	rs1864585	0.520	rs7009920	chr8:10585162	C/T	cg26278703	chr11:58910052	FAM111A	-0.57	-6.16	-0.37	2.89e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.82	-12.2	-0.61	4.27e-27	Breast cancer;
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg05562828	chr17:3906858	NA	-0.7	-13.58	-0.65	1.02e-31	Type 2 diabetes;
KIRP	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg21191810	chr6:118973309	C6orf204	0.39	5.51	0.33	8.96e-8	Electrocardiographic conduction measures;
KIRP	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg24579218	chr15:68104479	NA	-0.45	-6.59	-0.39	2.65e-10	Obesity;
KIRP	cis	rs4664293	0.867	rs7566584	chr2:160584795	A/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg15556689	chr8:8085844	FLJ10661	0.53	7.07	0.41	1.58e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6495367	0.966	rs745029	chr15:79381779	C/T	cg17916960	chr15:79447300	NA	0.34	5.8	0.35	1.99e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10073892	0.703	rs62372166	chr5:101629644	C/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.34	0.37	1.11e-9	Cognitive decline (age-related);
KIRP	cis	rs8112211	0.598	rs4802351	chr19:38848796	A/G	cg14299480	chr19:38876666	GGN	-0.39	-4.99	-0.3	1.15e-6	Blood protein levels;
KIRP	cis	rs9815354	0.812	rs73073323	chr3:41834051	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg07541023	chr7:19748670	TWISTNB	0.66	5.96	0.36	8.68e-9	Thyroid stimulating hormone;
KIRP	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg23216685	chr1:86174607	ZNHIT6	-0.55	-7.34	-0.42	3.06e-12	Urate levels in overweight individuals;
KIRP	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.22	-0.32	3.9e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-11.99	-0.61	2.23e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg08662619	chr6:150070041	PCMT1	0.33	5.2	0.31	4.2e-7	Testicular germ cell tumor;
KIRP	cis	rs6496667	1.000	rs7178663	chr15:90897058	C/T	cg10434728	chr15:90938212	IQGAP1	0.38	4.96	0.3	1.32e-6	Rheumatoid arthritis;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg05569124	chr11:125495582	CHEK1	0.5	6.14	0.36	3.24e-9	Educational attainment;
KIRP	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg02297831	chr4:17616191	MED28	0.57	6.96	0.41	3.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-8.07	-0.46	3.03e-14	Alzheimer's disease;
KIRP	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	5.44	0.33	1.27e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs600806	0.713	rs10857786	chr1:110010110	C/G	cg02175308	chr1:109941060	SORT1	-0.26	-4.87	-0.3	2.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg17182837	chr8:41585554	ANK1	-0.49	-6.93	-0.4	3.78e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg24110177	chr3:50126178	RBM5	-0.67	-9.1	-0.5	3.28e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-0.85	-6.5	-0.38	4.52e-10	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.48	0.38	4.91e-10	Axial length;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10462643	chr6:127296973	NA	0.41	6.56	0.39	3.09e-10	C-reactive protein;
KIRP	cis	rs1270639	0.778	rs2530403	chr7:157445639	C/T	cg13357408	chr7:157437802	PTPRN2	0.61	6.1	0.36	4.12e-9	Colorectal cancer;
KIRP	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25353054	chr22:39101979	GTPBP1	0.5	6.07	0.36	4.8e-9	Myopia (pathological);
KIRP	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg15252951	chr6:33757062	LEMD2	0.42	4.99	0.3	1.13e-6	Crohn's disease;
KIRP	cis	rs77688320	0.535	rs10804115	chr2:202280233	C/T	cg06431681	chr2:202330990	STRADB	0.5	6.74	0.39	1.14e-10	Breast cancer;
KIRP	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	ch.11.340609R	chr11:12831013	TEAD1	0.43	5.48	0.33	1.04e-7	Educational attainment (years of education);
KIRP	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.79	8.41	0.47	3.26e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.58	7.35	0.42	2.98e-12	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00387117	chr3:105105844	ALCAM	-0.44	-6.79	-0.4	8.12e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	1.04	8.88	0.49	1.43e-16	Lung cancer in ever smokers;
KIRP	cis	rs1448094	0.967	rs10779222	chr12:86330775	G/A	cg00310523	chr12:86230176	RASSF9	0.38	5.84	0.35	1.66e-8	Major depressive disorder;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13515998	chr14:71581031	PCNX	0.45	6.85	0.4	5.79e-11	C-reactive protein;
KIRP	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.83	11.01	0.57	3.6e-23	Coronary artery disease;
KIRP	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg14650228	chr8:144573510	ZC3H3	-0.69	-4.93	-0.3	1.5e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs6142102	0.538	rs6142058	chr20:32542801	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-10.98	-0.57	4.32e-23	Morning vs. evening chronotype;
KIRP	cis	rs6577655	0.517	rs6996991	chr8:135589255	G/A	cg17885191	chr8:135476712	NA	0.66	6.66	0.39	1.79e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg07701084	chr6:150067640	NUP43	0.7	9.59	0.52	1.03e-18	Lung cancer;
KIRP	cis	rs259842	0.699	rs56008592	chr2:180729224	G/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.44	-6.2	-0.37	2.41e-9	Blood protein levels;
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg16867584	chr19:49200180	FUT2	0.31	4.93	0.3	1.52e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	5.98	0.36	7.85e-9	Height;
KIRP	cis	rs2573652	1.000	rs2581358	chr15:100513725	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.69	-10.69	-0.56	3.64e-22	Height;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg14221460	chr8:27183342	PTK2B	0.52	6.84	0.4	6.3e-11	Neuroticism;
KIRP	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.5	-7.79	-0.44	1.91e-13	IgG glycosylation;
KIRP	cis	rs17428704	0.571	rs57640930	chr5:14405231	C/T	cg26595256	chr5:14380529	TRIO	-0.85	-6.65	-0.39	1.93e-10	Electroencephalogram traits;
KIRP	cis	rs10875746	0.903	rs11168418	chr12:48515754	C/A	cg20731937	chr12:48336164	NA	0.41	5.34	0.32	2.16e-7	Longevity (90 years and older);
KIRP	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg18404041	chr3:52824283	ITIH1	-0.47	-5.82	-0.35	1.83e-8	Schizophrenia;
KIRP	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.17	0.42	8.91e-12	Electroencephalogram traits;
KIRP	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.39e-10	Bipolar disorder;
KIRP	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	Schizophrenia;
KIRP	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.32	-0.42	3.54e-12	Retinal vascular caliber;
KIRP	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg07395648	chr5:131743802	NA	-0.36	-4.96	-0.3	1.32e-6	Blood metabolite levels;
KIRP	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg21605333	chr4:119757512	SEC24D	0.54	5.76	0.34	2.51e-8	Cannabis dependence symptom count;
KIRP	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-14.22	-0.67	6.92e-34	Alzheimer's disease;
KIRP	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.39	6.0	0.36	7.14e-9	Hypertriglyceridemia;
KIRP	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.42	6.24	0.37	1.9e-9	Schizophrenia;
KIRP	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.81	9.86	0.53	1.54e-19	Corneal astigmatism;
KIRP	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.53	6.29	0.37	1.41e-9	Macular telangiectasia type 2;
KIRP	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-4.97	-0.3	1.24e-6	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.86	13.57	0.65	1.06e-31	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.42	-5.41	-0.33	1.5e-7	Alzheimer's disease (late onset);
KIRP	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.64	8.47	0.48	2.2e-15	Corneal astigmatism;
KIRP	cis	rs11608355	0.521	rs6606704	chr12:109814036	T/C	cg19025524	chr12:109796872	NA	-0.51	-7.03	-0.41	2.06e-11	Neuroticism;
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg15117754	chr3:10150083	C3orf24	0.53	4.96	0.3	1.31e-6	Alzheimer's disease;
KIRP	cis	rs6832769	1.000	rs10016506	chr4:56396674	G/T	cg05960024	chr4:56376020	CLOCK	-0.73	-9.41	-0.51	3.8e-18	Personality dimensions;
KIRP	cis	rs7221595	0.825	rs12951359	chr17:3921731	T/A	cg09695851	chr17:3907499	NA	0.6	6.08	0.36	4.59e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg07777115	chr5:623756	CEP72	-0.6	-6.02	-0.36	6.19e-9	Obesity-related traits;
KIRP	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	trans	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg19857564	chr1:92545888	BTBD8	-0.53	-6.03	-0.36	6.02e-9	Lung cancer;
KIRP	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg19468946	chr17:37922297	IKZF3	-0.51	-7.02	-0.41	2.09e-11	Self-reported allergy;
KIRP	cis	rs16986825	0.546	rs9625612	chr22:29258140	T/A	cg02153584	chr22:29168773	CCDC117	0.51	5.06	0.31	8.09e-7	Pancreatic cancer;
KIRP	cis	rs4926611	0.931	rs1526909	chr1:54084347	G/C	cg08927728	chr1:54059983	GLIS1	-0.25	-5.29	-0.32	2.74e-7	Hand grip strength;
KIRP	cis	rs9311676	0.656	rs7647184	chr3:58370046	C/T	cg06643156	chr3:58380774	PXK	0.35	4.92	0.3	1.56e-6	Systemic lupus erythematosus;
KIRP	cis	rs7221595	0.756	rs35102999	chr17:3892700	G/A	cg11204139	chr17:3907470	NA	0.56	5.57	0.33	6.62e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.93	0.45	7.68e-14	Aortic root size;
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.51	5.05	0.31	8.45e-7	Alzheimer's disease;
KIRP	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.16	0.54	1.79e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6815814	0.699	rs11730390	chr4:38881414	T/C	cg06935464	chr4:38784597	TLR10	0.53	5.38	0.32	1.72e-7	Breast cancer;
KIRP	cis	rs136211	0.577	rs9607339	chr22:36768932	G/T	cg21778268	chr22:36877729	TXN2	-0.45	-6.01	-0.36	6.71e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg07395648	chr5:131743802	NA	-0.36	-5.29	-0.32	2.65e-7	Blood metabolite levels;
KIRP	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.64	9.13	0.5	2.64e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.45	-0.47	2.55e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.51	6.03	0.36	5.88e-9	White matter hyperintensity burden;
KIRP	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.41e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20430773	chr1:16534157	ARHGEF19	0.59	7.06	0.41	1.65e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12579753	0.692	rs11115064	chr12:82278683	G/A	cg07988820	chr12:82153109	PPFIA2	-0.5	-6.2	-0.37	2.41e-9	Resting heart rate;
KIRP	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01256987	chr12:42539512	GXYLT1	-0.46	-6.14	-0.36	3.37e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs10982256	0.870	rs1408525	chr9:117274994	C/T	cg13636371	chr9:117264095	DFNB31	0.52	7.28	0.42	4.43e-12	Bipolar disorder;
KIRP	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26617929	chr16:1858877	NA	-0.67	-5.68	-0.34	3.89e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	trans	rs330048	0.545	rs719409	chr8:9151226	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	6.6	0.39	2.47e-10	Systemic lupus erythematosus;
KIRP	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.59	-12.41	-0.62	8.59e-28	Diabetic kidney disease;
KIRP	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.15	-15.92	-0.71	1.07e-39	Lymphocyte percentage of white cells;
KIRP	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24229701	chr12:130821962	PIWIL1	-0.4	-5.7	-0.34	3.48e-8	Menopause (age at onset);
KIRP	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.5	6.08	0.36	4.65e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3733418	0.860	rs13141887	chr4:165950921	C/T	cg10852876	chr4:165953100	TRIM60	-0.5	-5.39	-0.32	1.68e-7	Obesity-related traits;
KIRP	cis	rs7172677	1.000	rs4886658	chr15:75414536	A/C	cg14082893	chr15:75400931	NA	0.37	5.38	0.32	1.76e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.67	-0.52	6.1e-19	Coronary artery disease;
KIRP	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg09555818	chr19:45449301	APOC2	0.52	7.56	0.43	7.83e-13	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24634408	chr4:177250214	SPCS3	-0.4	-6.04	-0.36	5.77e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg21775007	chr8:11205619	TDH	0.7	9.83	0.53	1.86e-19	Retinal vascular caliber;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg16103275	chr6:290800	DUSP22	0.46	6.04	0.36	5.57e-9	Menopause (age at onset);
KIRP	cis	rs3026101	0.671	rs3026145	chr17:5316742	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.83	0.35	1.72e-8	Body mass index;
KIRP	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg26695010	chr11:65641043	EFEMP2	0.47	5.68	0.34	3.76e-8	Eosinophil percentage of white cells;
KIRP	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.65	-8.28	-0.47	7.94e-15	Motion sickness;
KIRP	cis	rs13053308	0.934	rs4820197	chr22:35939369	A/G	cg17807448	chr22:35932140	NA	-0.33	-5.14	-0.31	5.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4851266	0.898	rs12053126	chr2:100864646	A/T	cg05692746	chr2:100937584	LONRF2	-0.43	-5.13	-0.31	5.9e-7	Educational attainment;
KIRP	cis	rs7027203	0.557	rs2490997	chr9:96522109	C/T	cg14598338	chr9:96623480	NA	-0.44	-6.69	-0.39	1.49e-10	DNA methylation (variation);
KIRP	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.63	8.11	0.46	2.33e-14	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00089353	chr3:160473693	PPM1L	0.44	6.14	0.36	3.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg25182066	chr10:30743637	MAP3K8	-0.61	-8.14	-0.46	1.95e-14	Inflammatory bowel disease;
KIRP	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs7709377	0.597	rs11241371	chr5:115493530	C/T	cg23108291	chr5:115420582	COMMD10	0.42	4.95	0.3	1.37e-6	Metabolite levels  (X-11787);
KIRP	cis	rs2071403	0.933	rs11685159	chr2:1412282	A/C	cg07083862	chr2:1417248	TPO	0.33	5.27	0.32	2.93e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs897080	0.515	rs1085486	chr2:44617324	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.57	0.39	3.05e-10	Height;
KIRP	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.87	-0.53	1.45e-19	Height;
KIRP	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13198984	chr17:80129470	CCDC57	-0.55	-8.53	-0.48	1.48e-15	Life satisfaction;
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.25	-5.27	-0.32	3e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs11648785	0.661	rs870856	chr16:90089463	C/G	cg26114043	chr4:128544375	NA	-0.45	-6.5	-0.38	4.33e-10	Tanning;
KIRP	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08822215	chr16:89438651	ANKRD11	-0.45	-6.08	-0.36	4.57e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-9.55	-0.52	1.43e-18	Longevity;Endometriosis;
KIRP	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg24631222	chr15:78858424	CHRNA5	0.4	5.1	0.31	6.63e-7	Sudden cardiac arrest;
KIRP	trans	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.18	-0.37	2.63e-9	Neuroticism;
KIRP	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.71	-7.99	-0.45	5.1e-14	Height;
KIRP	cis	rs73206853	0.764	rs7314552	chr12:110618890	C/T	cg12870014	chr12:110450643	ANKRD13A	0.53	5.61	0.34	5.46e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02376269	chr15:43398346	UBR1	0.5	6.44	0.38	6.32e-10	Parkinson's disease;
KIRP	cis	rs1067327	1	rs1067327	chr2:44628529	C/G	cg04920474	chr2:44395004	PPM1B	0.37	5.09	0.31	7.19e-7	Anxiety disorder (factor score);
KIRP	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-4.95	-0.3	1.38e-6	Tonsillectomy;
KIRP	cis	rs4654899	1.000	rs10916937	chr1:21439785	A/G	cg05370193	chr1:21551575	ECE1	0.44	6.12	0.36	3.6e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.63	7.1	0.41	1.32e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.94	17.19	0.74	5.05e-44	Breast cancer;
KIRP	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.53	0.52	1.56e-18	Colorectal cancer;
KIRP	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg01422370	chr2:73384389	NA	0.46	6.14	0.36	3.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.16	-0.31	4.99e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg07972983	chr1:205091412	RBBP5	0.43	5.2	0.31	4.11e-7	Red blood cell count;
KIRP	cis	rs12643440	0.538	rs6818238	chr4:17140193	C/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.37	6.34	0.37	1.06e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.53	-6.95	-0.4	3.31e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.73	7.88	0.45	1.04e-13	Diastolic blood pressure;
KIRP	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg03146154	chr1:46216737	IPP	-0.41	-5.27	-0.32	2.93e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.6	7.73	0.44	2.71e-13	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07570687	chr10:102243282	WNT8B	0.52	6.72	0.39	1.29e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg18806716	chr10:30721971	MAP3K8	-0.34	-5.17	-0.31	4.78e-7	Inflammatory bowel disease;
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg19723775	chr5:179050963	HNRNPH1	0.45	5.1	0.31	6.67e-7	Lung cancer;
KIRP	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4662750	0.619	rs2244042	chr2:128404998	A/G	cg00597225	chr2:128649830	NA	0.35	4.88	0.3	1.88e-6	Renal cell carcinoma;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg16721257	chr8:130954845	NA	0.57	6.39	0.38	8.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg13319975	chr6:146136371	FBXO30	-0.37	-4.98	-0.3	1.19e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg17595323	chr11:93583763	C11orf90	-0.32	-5.36	-0.32	1.9e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.48	-0.38	4.88e-10	Neuroticism;
KIRP	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg09408571	chr1:101003634	GPR88	0.24	5.18	0.31	4.71e-7	Breast cancer;
KIRP	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg26681399	chr22:41777847	TEF	-0.53	-5.11	-0.31	6.38e-7	Vitiligo;
KIRP	trans	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16357287	chr18:12947517	SEH1L	0.4	5.68	0.34	3.74e-8	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg11569703	chr11:65557185	OVOL1	0.81	15.54	0.7	2.11e-38	Acne (severe);
KIRP	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	12.0	0.61	2e-26	Alzheimer's disease;
KIRP	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.45	-5.7	-0.34	3.49e-8	Menarche (age at onset);
KIRP	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg23803603	chr1:2058230	PRKCZ	-0.39	-5.75	-0.34	2.59e-8	Height;
KIRP	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.88	13.83	0.66	1.45e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.72	11.59	0.59	4.54e-25	Mean corpuscular volume;
KIRP	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.91	-0.45	8.54e-14	Mean corpuscular volume;
KIRP	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg19875535	chr5:140030758	IK	-0.7	-9.74	-0.53	3.55e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg10326726	chr10:51549505	MSMB	0.59	9.12	0.5	2.79e-17	Prostate-specific antigen levels;
KIRP	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg04673462	chr1:38461896	NA	0.48	6.62	0.39	2.27e-10	Coronary artery disease;
KIRP	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg21926883	chr2:100939477	LONRF2	-0.57	-7.67	-0.44	3.96e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03036057	chr6:72806828	RIMS1	-0.39	-6.13	-0.36	3.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06152496	chr10:95462325	C10orf4	-0.55	-6.05	-0.36	5.37e-9	Menopause (age at onset);
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg17014757	chr1:203156097	CHI3L1	0.61	6.78	0.4	8.97e-11	YKL-40 levels;
KIRP	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg19773385	chr1:10388646	KIF1B	-0.69	-9.78	-0.53	2.8e-19	Hepatocellular carcinoma;
KIRP	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	7.29	0.42	4.17e-12	Height;
KIRP	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.09	16.13	0.72	2.09e-40	Cognitive ability;
KIRP	cis	rs10488172	0.618	rs4731987	chr7:133638308	G/A	cg10665199	chr7:133106180	EXOC4	-0.45	-4.88	-0.3	1.94e-6	Tonometry;
KIRP	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg21926883	chr2:100939477	LONRF2	-0.53	-7.16	-0.42	9.16e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.722	rs2927739	chr19:38149330	C/A	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.46	-6.06	-0.36	5.2e-9	Body mass index;
KIRP	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.64	8.99	0.5	6.58e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.58	8.41	0.47	3.36e-15	Colorectal cancer;
KIRP	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.94	-15.35	-0.7	9.59e-38	Breast cancer;
KIRP	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.66	9.68	0.53	5.43e-19	Dupuytren's disease;
KIRP	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg16497661	chr14:103986332	CKB	0.44	6.05	0.36	5.25e-9	Body mass index;
KIRP	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg18306943	chr3:40428807	ENTPD3	0.4	5.47	0.33	1.11e-7	Renal cell carcinoma;
KIRP	cis	rs6594499	1.000	rs6594499	chr5:110470137	A/C	cg04022379	chr5:110408740	TSLP	-0.43	-6.2	-0.37	2.31e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	7.02	0.41	2.12e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg15352829	chr14:105391018	PLD4	-0.45	-9.05	-0.5	4.38e-17	Systemic lupus erythematosus;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06338299	chr10:98591780	LCOR	0.45	6.05	0.36	5.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.99	-0.41	2.63e-11	Blood pressure;
KIRP	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg03060546	chr3:49711283	APEH	-0.63	-5.05	-0.31	8.6e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.37	0.43	2.62e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02672962	chr16:3665541	NA	-0.44	-6.13	-0.36	3.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.48	-0.78	9.45e-52	Height;
KIRP	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.13	0.46	2.12e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.88	13.49	0.65	2e-31	Height;
KIRP	cis	rs965513	1.000	rs1443438	chr9:100550028	T/C	cg13688889	chr9:100608707	NA	-0.61	-7.73	-0.44	2.73e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.42	-0.38	7.03e-10	Joint mobility (Beighton score);
KIRP	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.11	-0.36	3.81e-9	Cutaneous nevi;
KIRP	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-5.7	-0.34	3.38e-8	Mood instability;
KIRP	cis	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg20368463	chr18:77673604	PQLC1	-0.46	-5.81	-0.35	1.92e-8	Schizophrenia;
KIRP	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.15	-0.31	5.35e-7	Joint mobility (Beighton score);
KIRP	cis	rs10858047	0.883	rs7539721	chr1:115171649	C/T	cg12756093	chr1:115239321	AMPD1	-0.67	-6.46	-0.38	5.42e-10	Autism;
KIRP	cis	rs1950626	0.623	rs35947256	chr14:101460366	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.5	5.57	0.33	6.73e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs112591243	0.685	rs2839362	chr21:48024626	G/A	cg26904215	chr21:47823096	PCNT	-0.69	-5.36	-0.32	1.93e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs96067	0.805	rs2296268	chr1:36603165	G/A	cg27506609	chr1:36549197	TEKT2	-0.49	-5.91	-0.35	1.16e-8	Corneal structure;
KIRP	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.92	14.88	0.69	3.93e-36	Blood protein levels;
KIRP	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	4.89	0.3	1.86e-6	Personality dimensions;
KIRP	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.02	18.0	0.75	8.69e-47	Testicular germ cell tumor;
KIRP	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-5.75	-0.34	2.68e-8	Body mass index;
KIRP	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	1.16	9.29	0.51	8.59e-18	LDL cholesterol;
KIRP	cis	rs4950322	0.570	rs3737855	chr1:146742918	G/A	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.11	-0.36	3.85e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	6.9	0.4	4.48e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.65	-0.34	4.32e-8	Height;
KIRP	cis	rs7224685	0.569	rs8070737	chr17:3981066	G/T	cg05562828	chr17:3906858	NA	0.58	6.21	0.37	2.22e-9	Type 2 diabetes;
KIRP	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg07001201	chr5:642380	CEP72	0.68	6.39	0.38	8.43e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12292205	chr6:26970375	C6orf41	0.66	7.65	0.44	4.52e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7932354	0.666	rs6485696	chr11:46842045	C/T	cg16389345	chr11:46697382	NA	0.44	5.39	0.32	1.69e-7	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs4660306	0.672	rs534534	chr1:46024701	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.86	-0.35	1.48e-8	Homocysteine levels;
KIRP	cis	rs10782582	0.668	rs1250880	chr1:76196602	T/C	cg10523679	chr1:76189770	ACADM	0.4	5.82	0.35	1.86e-8	Daytime sleep phenotypes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18504358	chr14:23340787	LRP10	0.62	7.79	0.44	1.88e-13	Smoking initiation;
KIRP	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	0.75	9.53	0.52	1.62e-18	Prostate cancer;
KIRP	cis	rs9478638	0.507	rs2184406	chr6:155629678	T/C	cg06694381	chr6:155569200	TIAM2	-0.45	-4.98	-0.3	1.2e-6	Electroencephalogram traits;
KIRP	cis	rs10773046	0.740	rs7297429	chr12:124367578	A/C	cg18594669	chr12:124364423	DNAH10	0.4	5.46	0.33	1.16e-7	Osteoarthritis (hip);
KIRP	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.4	4.86	0.3	2.14e-6	Systemic lupus erythematosus;
KIRP	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	9.64	0.52	7.31e-19	Lung cancer in ever smokers;
KIRP	cis	rs17021463	0.872	rs34181160	chr4:95275157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.41	5.19	0.31	4.39e-7	Testicular germ cell tumor;
KIRP	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	trans	rs11165623	0.740	rs11165638	chr1:96921357	C/A	cg10631902	chr5:14652156	NA	-0.65	-10.08	-0.54	3.16e-20	Hip circumference;Waist circumference;
KIRP	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.98	-14.39	-0.68	1.71e-34	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.32	0.37	1.22e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg09264619	chr17:80180166	NA	0.39	5.53	0.33	8.11e-8	Life satisfaction;
KIRP	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-10.63	-0.56	5.93e-22	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg15880211	chr22:50250494	ZBED4	-0.49	-5.86	-0.35	1.51e-8	Schizophrenia;
KIRP	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.64	9.21	0.51	1.53e-17	Resting heart rate;
KIRP	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg16989719	chr2:238392110	NA	-0.55	-7.81	-0.45	1.7e-13	Prostate cancer;
KIRP	cis	rs12210905	0.688	rs72839479	chr6:27332910	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.86	-6.22	-0.37	2.09e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs501120	1.000	rs671765	chr10:44752976	A/G	cg09554077	chr10:44749378	NA	0.74	12.06	0.61	1.24e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.5	-6.12	-0.36	3.63e-9	P wave terminal force;
KIRP	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.8	10.91	0.57	7.3e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg00405596	chr8:11794950	NA	-0.47	-6.12	-0.36	3.64e-9	Retinal vascular caliber;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg13453750	chr1:205783389	SLC41A1	-0.46	-7.13	-0.41	1.12e-11	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05329982	chr11:62359210	TUT1	0.6	7.37	0.43	2.51e-12	Smoking initiation;
KIRP	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.91	-13.25	-0.65	1.32e-30	Tonsillectomy;
KIRP	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.62	7.06	0.41	1.73e-11	Initial pursuit acceleration;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13800542	chr6:137113325	MAP3K5	0.49	6.09	0.36	4.21e-9	Myopia (pathological);
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.89	-0.53	1.28e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.82	-8.6	-0.48	9.31e-16	Hair shape;
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.81	12.53	0.62	3.55e-28	Longevity;Endometriosis;
KIRP	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg08975724	chr8:8085496	FLJ10661	0.55	7.48	0.43	1.29e-12	Neuroticism;
KIRP	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.6	-7.79	-0.44	1.92e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.47e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.73	7.29	0.42	4.16e-12	Menarche (age at onset);
KIRP	cis	rs7539542	0.556	rs6686801	chr1:202874730	C/T	cg08940984	chr1:202857613	RABIF	0.46	5.7	0.34	3.4e-8	Mean platelet volume;
KIRP	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.2	-0.42	7.26e-12	Morning vs. evening chronotype;
KIRP	cis	rs12823128	0.967	rs1900941	chr12:26868322	T/C	cg14081884	chr12:26986758	ITPR2	0.39	4.86	0.3	2.1e-6	Birth weight;
KIRP	cis	rs867371	1.000	rs7180584	chr15:82455834	A/G	cg06066596	chr15:83166174	LOC80154	-0.47	-5.49	-0.33	9.96e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg04702396	chr17:15466718	FAM18B2	0.49	6.35	0.38	1.01e-9	Educational attainment (years of education);
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg03653399	chr8:142233436	SLC45A4	-0.94	-14.67	-0.68	2.05e-35	Immature fraction of reticulocytes;
KIRP	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.47e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	cg21523751	chr1:182988639	NA	-0.43	-6.67	-0.39	1.66e-10	Colorectal cancer;
KIRP	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg16586182	chr3:47516702	SCAP	-0.68	-9.47	-0.52	2.35e-18	Colorectal cancer;
KIRP	cis	rs17121403	0.661	rs12136795	chr1:100582306	T/C	cg24955406	chr1:100503596	HIAT1	0.78	5.08	0.31	7.35e-7	Pulmonary function decline;
KIRP	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg05623727	chr3:50126028	RBM5	0.35	5.3	0.32	2.61e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1864585	0.520	rs17776622	chr8:10676497	T/C	cg26278703	chr11:58910052	FAM111A	0.66	6.42	0.38	6.89e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2249694	0.520	rs10857730	chr10:135326822	T/G	cg20169779	chr10:135381914	SYCE1	-0.57	-6.31	-0.37	1.3e-9	Obesity-related traits;
KIRP	cis	rs9420	0.528	rs73480556	chr11:57400462	G/C	cg19752551	chr11:57585705	CTNND1	-0.59	-8.37	-0.47	4.35e-15	Schizophrenia;
KIRP	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.41	4.88	0.3	1.92e-6	Monocyte count;
KIRP	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.96	-13.65	-0.66	5.7e-32	Schizophrenia;
KIRP	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.65	-12.4	-0.62	9.44e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg18882449	chr10:104885122	NT5C2	0.49	6.25	0.37	1.8e-9	Arsenic metabolism;
KIRP	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	cis	rs6840360	0.515	rs11099811	chr4:152320532	C/A	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.44e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.54	7.45	0.43	1.55e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg11584989	chr19:19387371	SF4	-0.41	-5.12	-0.31	6.05e-7	Tonsillectomy;
KIRP	cis	rs3007168	1.000	rs2999365	chr14:51600192	A/G	cg23942311	chr14:51606299	NA	0.49	5.23	0.32	3.59e-7	Cancer;
KIRP	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.99	-0.45	5.32e-14	Monocyte percentage of white cells;
KIRP	cis	rs6993770	0.661	rs16873231	chr8:106518235	C/G	cg12797828	chr8:106520928	ZFPM2	-0.33	-4.92	-0.3	1.58e-6	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20572926	chr12:114404130	RBM19	-0.52	-7.63	-0.44	4.99e-13	Myopia;
KIRP	cis	rs2737618	0.722	rs2737673	chr1:200081710	T/C	cg21825944	chr1:200113062	NR5A2	-0.57	-7.75	-0.44	2.47e-13	Uric acid levels;
KIRP	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18252515	chr7:66147081	NA	0.46	5.43	0.33	1.32e-7	Aortic root size;
KIRP	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.98	13.38	0.65	4.75e-31	Vitamin D levels;
KIRP	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.47	-6.27	-0.37	1.65e-9	Monocyte count;
KIRP	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.45	1.59e-13	Morning vs. evening chronotype;
KIRP	cis	rs56146971	0.763	rs77450079	chr14:91863924	A/C	cg10511902	chr14:91842949	CCDC88C	0.48	5.11	0.31	6.56e-7	Alzheimer disease and age of onset;
KIRP	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg07741184	chr6:167504864	NA	-0.2	-5.26	-0.32	3.21e-7	Crohn's disease;
KIRP	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-9.2	-0.51	1.6e-17	Bladder cancer;
KIRP	cis	rs698833	0.886	rs786613	chr2:44590066	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-6.31	-0.37	1.32e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.51	-6.67	-0.39	1.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9323205	0.906	rs11629336	chr14:51686620	A/C	cg23942311	chr14:51606299	NA	0.54	5.93	0.35	9.97e-9	Cancer;
KIRP	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs7833787	0.868	rs34629387	chr8:18704917	A/G	cg17701159	chr8:18705777	PSD3	-0.32	-6.06	-0.36	5.05e-9	Obesity-related traits;
KIRP	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg15128208	chr22:42549153	NA	0.74	8.05	0.46	3.49e-14	Birth weight;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.64	10.03	0.54	4.61e-20	Lung cancer;
KIRP	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg08741688	chr4:3415352	RGS12	-0.44	-5.29	-0.32	2.71e-7	Serum sulfate level;
KIRP	cis	rs7119	0.717	rs62007348	chr15:77804501	C/T	cg12131826	chr15:77904385	NA	0.51	6.03	0.36	6.01e-9	Type 2 diabetes;
KIRP	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7.01e-8	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12617598	chr1:193222046	CDC73	-0.48	-7.55	-0.43	8.58e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.26	-0.47	9.13e-15	Neuroticism;
KIRP	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.69	7.72	0.44	2.87e-13	Corneal astigmatism;
KIRP	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.12	0.41	1.2e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg20243544	chr17:37824526	PNMT	0.48	6.7	0.39	1.38e-10	Asthma;
KIRP	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.57	4.93	0.3	1.53e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.66	7.21	0.42	6.76e-12	Cardiac Troponin-T levels;
KIRP	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.69	8.19	0.46	1.38e-14	Type 2 diabetes;
KIRP	cis	rs228437	1.000	rs228448	chr6:134903308	C/T	cg24504307	chr6:134963096	NA	-0.45	-6.3	-0.37	1.36e-9	Melanoma;
KIRP	cis	rs6743226	0.840	rs10933549	chr2:242240702	A/G	cg10021735	chr2:242295487	FARP2	0.5	6.15	0.36	3.18e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	7.11	0.41	1.26e-11	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg00405596	chr8:11794950	NA	0.56	7.63	0.44	5.11e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7534824	0.582	rs61780297	chr1:101400855	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.25	0.42	5.24e-12	Refractive astigmatism;
KIRP	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg06521331	chr12:34319734	NA	-0.63	-7.52	-0.43	1.03e-12	Morning vs. evening chronotype;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg14338887	chr6:42928500	GNMT	0.46	6.78	0.4	8.65e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4671458	0.626	rs4567921	chr2:63847114	G/A	cg17519650	chr2:63277830	OTX1	-0.49	-5.1	-0.31	6.77e-7	Subjective well-being;
KIRP	cis	rs9469913	0.740	rs2744939	chr6:34548206	T/A	cg14254433	chr6:34482411	PACSIN1	-0.49	-5.7	-0.34	3.42e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.64	-8.08	-0.46	2.96e-14	Inflammatory bowel disease;
KIRP	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg10326726	chr10:51549505	MSMB	0.62	8.87	0.49	1.52e-16	Prostate-specific antigen levels;
KIRP	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg08917208	chr2:24149416	ATAD2B	0.67	6.08	0.36	4.66e-9	Lymphocyte counts;
KIRP	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs28834970	0.928	rs17057043	chr8:27220310	C/T	cg23736307	chr8:27182930	PTK2B	-0.47	-6.03	-0.36	5.97e-9	Alzheimer's disease (late onset);
KIRP	cis	rs35961285	0.614	rs34466548	chr1:246034622	A/C	cg00351750	chr1:246038775	SMYD3	0.43	4.87	0.3	2e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg01849466	chr14:104193079	ZFYVE21	0.42	5.1	0.31	6.92e-7	Schizophrenia;
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.06e-7	Life satisfaction;
KIRP	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	1.09	19.98	0.79	2.05e-53	Bone mineral density;
KIRP	cis	rs78487399	0.808	rs13405776	chr2:43739121	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.86	-0.3	2.11e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg24315340	chr6:146058215	EPM2A	-0.45	-5.66	-0.34	4.24e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg10047753	chr17:41438598	NA	1.15	18.22	0.76	1.51e-47	Menopause (age at onset);
KIRP	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-0.89	-6.23	-0.37	2.06e-9	Inflammatory biomarkers;
KIRP	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg19875535	chr5:140030758	IK	0.52	6.64	0.39	1.99e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9948	0.881	rs7580942	chr2:97468276	C/G	cg01990225	chr2:97406019	LMAN2L	-0.61	-5.66	-0.34	4.18e-8	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19278809	chr4:6785080	KIAA0232	0.56	7.01	0.41	2.24e-11	Parkinson's disease;
KIRP	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.22	-0.32	3.88e-7	Blood metabolite levels;
KIRP	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.62	10.99	0.57	3.93e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs3744061	0.557	rs9907925	chr17:74646293	G/A	cg27546012	chr17:74684504	MXRA7	-0.43	-5.2	-0.31	4.26e-7	Retinal arteriolar caliber;
KIRP	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-0.97	-7.7	-0.44	3.23e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.73	10.86	0.57	1.04e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.55	8.15	0.46	1.89e-14	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.93	13.5	0.65	1.86e-31	Bladder cancer;
KIRP	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.17	0.64	2.54e-30	Eye color traits;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.48	5.54	0.33	7.85e-8	Glycated hemoglobin levels;
KIRP	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-9.3	-0.51	8.04e-18	Response to antipsychotic treatment;
KIRP	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.27	-0.47	8.39e-15	Type 2 diabetes;
KIRP	cis	rs56079296	0.929	rs4425539	chr5:121272524	G/T	cg05256605	chr5:121412184	LOX	0.53	5.64	0.34	4.55e-8	Coronary artery disease;
KIRP	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg00800038	chr16:89945340	TCF25	-0.7	-4.9	-0.3	1.71e-6	Skin colour saturation;
KIRP	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg11650704	chr1:154556575	ADAR	0.4	4.99	0.3	1.14e-6	Blood protein levels;
KIRP	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-8.69	-0.48	5.29e-16	Total body bone mineral density;
KIRP	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.55	6.68	0.39	1.57e-10	Asthma;
KIRP	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.31	-0.32	2.41e-7	Neuroticism;
KIRP	cis	rs72829446	0.530	rs2302761	chr17:7358520	C/T	cg02795151	chr17:7402630	POLR2A	0.75	7.62	0.44	5.55e-13	Androgen levels;
KIRP	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg18657303	chr4:1051139	NA	0.54	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.94	0.45	7.04e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	cg21523751	chr1:182988639	NA	0.35	4.96	0.3	1.34e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg26695010	chr11:65641043	EFEMP2	-0.43	-5.31	-0.32	2.42e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.92	11.67	0.6	2.48e-25	Cognitive function;
KIRP	cis	rs698833	0.532	rs698809	chr2:44702978	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.55	-5.88	-0.35	1.31e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.78	9.18	0.51	1.81e-17	Smoking behavior;
KIRP	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg18478394	chr8:109455254	TTC35	0.51	6.26	0.37	1.71e-9	Dupuytren's disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04826516	chr16:1401898	C16orf42;GNPTG	-0.57	-6.28	-0.37	1.54e-9	Menopause (age at onset);
KIRP	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.73	-8.76	-0.49	3.13e-16	Breast size;
KIRP	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg13660082	chr14:53194042	PSMC6	-0.53	-5.16	-0.31	5.14e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.73	-7.44	-0.43	1.67e-12	Bipolar disorder;
KIRP	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-11.65	-0.6	2.92e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.56	-0.52	1.28e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-7.98	-0.45	5.72e-14	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg01721255	chr8:58191610	C8orf71	0.62	5.5	0.33	9.61e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.86	-11.43	-0.59	1.55e-24	Cocaine dependence;
KIRP	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-13.56	-0.65	1.16e-31	Vitiligo;
KIRP	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg08313168	chr12:7315531	NA	0.68	6.17	0.37	2.76e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs904251	0.686	rs931649	chr6:37466079	T/C	cg01843034	chr6:37503916	NA	-0.64	-6.65	-0.39	1.91e-10	Cognitive performance;
KIRP	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg25019033	chr10:957182	NA	-0.58	-6.06	-0.36	4.95e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs9330264	0.508	rs7364869	chr1:155087188	A/G	cg02153340	chr1:155202674	NA	-0.36	-5.14	-0.31	5.55e-7	1,5-anhydroglucitol levels;
KIRP	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg08975724	chr8:8085496	FLJ10661	0.51	6.3	0.37	1.33e-9	Retinal vascular caliber;
KIRP	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.56	8.02	0.46	4.24e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2120243	0.874	rs2316706	chr3:157160061	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.57	7.75	0.44	2.44e-13	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg25922239	chr6:33757077	LEMD2	0.57	7.25	0.42	5.33e-12	Crohn's disease;
KIRP	cis	rs7520050	0.778	rs3013597	chr1:46128356	C/A	cg15605315	chr1:45957053	TESK2	-0.4	-5.02	-0.3	1e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg11569703	chr11:65557185	OVOL1	0.44	7.49	0.43	1.2e-12	Systemic lupus erythematosus;
KIRP	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.76	-9.79	-0.53	2.53e-19	Aortic root size;
KIRP	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.7	10.5	0.56	1.52e-21	Blood metabolite ratios;
KIRP	cis	rs7395662	0.963	rs2089209	chr11:48987120	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.8	-0.35	2.05e-8	HDL cholesterol;
KIRP	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.79	-12.72	-0.63	7.78e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs11637445	0.677	rs4539549	chr15:68070619	C/T	cg24579218	chr15:68104479	NA	-0.42	-6.34	-0.37	1.11e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6191	0.901	rs33383	chr5:142709986	C/T	cg08845721	chr5:142780693	NR3C1	-0.38	-5.25	-0.32	3.28e-7	Night sleep phenotypes;
KIRP	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.95	14.09	0.67	1.94e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7011049	0.673	rs72640836	chr8:53828023	G/T	cg26025543	chr8:53854495	NA	0.48	4.97	0.3	1.25e-6	Systolic blood pressure;
KIRP	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13315871	1.000	rs13317835	chr3:58383275	C/T	cg12435725	chr3:58293450	RPP14	-0.48	-5.12	-0.31	6.19e-7	Cholesterol, total;
KIRP	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg16141378	chr3:129829833	LOC729375	0.62	7.97	0.45	6.1e-14	Neuroticism;
KIRP	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg18882449	chr10:104885122	NT5C2	-0.38	-4.88	-0.3	1.88e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg12131826	chr15:77904385	NA	-0.44	-5.92	-0.35	1.1e-8	Type 2 diabetes;
KIRP	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	0.73	6.49	0.38	4.58e-10	Skin colour saturation;
KIRP	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg07810366	chr2:100720526	AFF3	-0.31	-5.66	-0.34	4.3e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9532580	0.656	rs2721068	chr13:41139712	T/C	cg21288729	chr13:41239152	FOXO1	0.69	9.14	0.5	2.48e-17	Mean corpuscular hemoglobin;
KIRP	cis	rs72960926	0.744	rs114317207	chr6:74955867	C/T	cg03266952	chr6:74778945	NA	-0.61	-5.16	-0.31	5.09e-7	Metabolite levels (MHPG);
KIRP	cis	rs13108043	0.605	rs35653846	chr4:87922823	A/G	cg11209507	chr4:87813803	C4orf36	0.47	4.99	0.3	1.15e-6	Red blood cell count;
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.64	-9.48	-0.52	2.22e-18	Vitiligo;
KIRP	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.72	9.91	0.53	1.1e-19	Parkinson's disease;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23978390	chr7:1156363	C7orf50	0.47	6.47	0.38	5.26e-10	Longevity;Endometriosis;
KIRP	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg10503236	chr1:231470652	EXOC8	-0.48	-6.78	-0.4	8.82e-11	Hemoglobin concentration;
KIRP	cis	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg21775007	chr8:11205619	TDH	-0.41	-5.35	-0.32	2.02e-7	Monocyte count;
KIRP	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.89	-11.97	-0.61	2.56e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs830233	0.565	rs190387	chr5:165510163	C/T	cg13976338	chr5:165423657	NA	0.57	5.42	0.33	1.41e-7	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg03060546	chr3:49711283	APEH	-0.74	-5.57	-0.33	6.54e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.8	-11.95	-0.61	2.87e-26	Height;
KIRP	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg11131117	chr7:1891496	MAD1L1	0.42	5.16	0.31	4.98e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs367943	0.712	rs7734061	chr5:112700175	A/G	cg12552261	chr5:112820674	MCC	0.56	6.65	0.39	1.92e-10	Type 2 diabetes;
KIRP	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg10360139	chr7:1886902	MAD1L1	-0.44	-4.9	-0.3	1.7e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.51	-6.66	-0.39	1.77e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg06953865	chr19:18549723	ISYNA1	-0.4	-6.01	-0.36	6.7e-9	Breast cancer;
KIRP	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg03098644	chr7:100410630	EPHB4	0.52	5.3	0.32	2.59e-7	Other erythrocyte phenotypes;
KIRP	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg15485101	chr11:133734466	NA	0.44	5.88	0.35	1.35e-8	Childhood ear infection;
KIRP	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg24011408	chr12:48396354	COL2A1	-0.41	-5.81	-0.35	1.89e-8	Plateletcrit;
KIRP	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	0.94	11.41	0.59	1.74e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg23352942	chr3:46931381	PTH1R	-0.45	-5.79	-0.35	2.09e-8	Birth weight;
KIRP	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg12315302	chr6:26189340	HIST1H4D	0.98	6.84	0.4	6.15e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.24	-0.32	3.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10861342	0.892	rs77479670	chr12:105516631	C/T	cg23923672	chr12:105501055	KIAA1033	0.85	6.54	0.39	3.44e-10	IgG glycosylation;
KIRP	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg17644776	chr2:200775616	C2orf69	0.56	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg17133734	chr15:86042851	AKAP13	-0.45	-5.69	-0.34	3.52e-8	Interstitial lung disease;
KIRP	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.4	5.35	0.32	2.01e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg16989719	chr2:238392110	NA	0.51	5.95	0.35	9.01e-9	Prostate cancer;
KIRP	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg13611997	chr5:233750	SDHA	-0.41	-4.92	-0.3	1.58e-6	Breast cancer;
KIRP	cis	rs10982256	0.870	rs998547	chr9:117275012	G/A	cg13636371	chr9:117264095	DFNB31	0.52	7.28	0.42	4.43e-12	Bipolar disorder;
KIRP	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg13409248	chr3:40428643	ENTPD3	0.38	5.12	0.31	6.14e-7	Renal cell carcinoma;
KIRP	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.57	-5.99	-0.36	7.36e-9	Schizophrenia;
KIRP	cis	rs3112255	1.000	rs2137674	chr2:101305228	C/A	cg01042948	chr2:101319752	NA	0.42	5.93	0.35	1.02e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg23752985	chr2:85803571	VAMP8	0.49	5.94	0.35	9.64e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6001982	0.588	rs17001977	chr22:40880213	G/A	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.68	0.34	3.88e-8	Platelet count;
KIRP	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg25356066	chr3:128598488	ACAD9	0.52	5.97	0.36	8.35e-9	IgG glycosylation;
KIRP	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg26338869	chr17:61819248	STRADA	-0.46	-5.51	-0.33	9.2e-8	Prudent dietary pattern;
KIRP	cis	rs6466055	0.661	rs12532134	chr7:104922603	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.03	0.31	9.68e-7	Schizophrenia;
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.54	7.25	0.42	5.46e-12	Menarche (age at onset);
KIRP	cis	rs7715811	0.913	rs10513154	chr5:13780601	T/C	cg07548982	chr5:13769939	DNAH5	-0.56	-6.77	-0.4	9.29e-11	Subclinical atherosclerosis traits (other);
KIRP	cis	rs9649213	0.574	rs34817002	chr7:97887051	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.66	0.34	4.28e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.88	9.8	0.53	2.43e-19	Corneal astigmatism;
KIRP	cis	rs6142102	0.961	rs4911144	chr20:32614371	A/G	cg08999081	chr20:33150536	PIGU	0.49	5.86	0.35	1.44e-8	Skin pigmentation;
KIRP	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg04374321	chr14:90722782	PSMC1	0.99	18.13	0.76	3.17e-47	Mortality in heart failure;
KIRP	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg20243544	chr17:37824526	PNMT	0.46	6.17	0.37	2.76e-9	Asthma;
KIRP	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg06654118	chr4:1303317	MAEA	0.26	4.96	0.3	1.32e-6	Longevity;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03647317	chr4:187891568	NA	-0.81	-13.45	-0.65	2.85e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs244899	0.967	rs2445785	chr5:167924928	A/G	cg06604206	chr5:167912465	RARS	0.53	7.56	0.43	8.01e-13	Response to platinum-based chemotherapy (carboplatin);
KIRP	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg04226714	chr8:49833948	SNAI2	-0.57	-7.83	-0.45	1.5e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22353495	chr1:100326811	AGL	-0.43	-6.63	-0.39	2.16e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.76	9.29	0.51	8.48e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.74	8.78	0.49	2.87e-16	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg19507638	chr5:93509721	C5orf36	0.55	5.22	0.32	3.74e-7	Diabetic retinopathy;
KIRP	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-7.6	-0.44	6.2800000000000005e-13	Cognitive function;
KIRP	cis	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.8	-0.4	8.05e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.65	-9.42	-0.51	3.45e-18	Schizophrenia;
KIRP	cis	rs73193808	0.639	rs2832242	chr21:30552185	G/T	cg03476357	chr21:30257390	N6AMT1	0.43	4.95	0.3	1.39e-6	Coronary artery disease;
KIRP	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg11189052	chr15:85197271	WDR73	0.54	5.11	0.31	6.33e-7	Schizophrenia;
KIRP	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	11.8	0.6	8.9e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.77	8.32	0.47	6.23e-15	Lung function (FEV1/FVC);
KIRP	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.4	9.92	0.53	9.65e-20	Corneal astigmatism;
KIRP	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg01843034	chr6:37503916	NA	-0.84	-12.08	-0.61	1.13e-26	Cognitive performance;
KIRP	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-6.9	-0.4	4.42e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14461570	chr2:170683907	UBR3	0.53	6.65	0.39	1.87e-10	Myopia (pathological);
KIRP	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs7760535	0.711	rs240965	chr6:111644524	C/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.5	-0.33	9.73e-8	Metabolic traits;
KIRP	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.35	0.32	2.06e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	7.74	0.44	2.52e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.62	7.07	0.41	1.61e-11	Schizophrenia;
KIRP	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.55	-7.93	-0.45	7.86e-14	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09507697	chr7:130037985	TSGA14	0.43	6.51	0.38	4.28e-10	Survival in pancreatic cancer;
KIRP	cis	rs1883415	0.553	rs760907	chr6:24479873	T/C	cg20631270	chr6:24437470	GPLD1	0.39	4.99	0.3	1.13e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.42	5.88	0.35	1.32e-8	Lewy body disease;
KIRP	cis	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg11015470	chr5:28928158	NA	-0.47	-5.2	-0.31	4.29e-7	Hip geometry;
KIRP	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	1.08	14.07	0.67	2.22e-33	Post bronchodilator FEV1;
KIRP	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.79	-8.88	-0.49	1.48e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-4.87	-0.3	2.02e-6	Neuroticism;
KIRP	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg05604800	chr16:89913972	SPIRE2	-0.44	-5.31	-0.32	2.45e-7	Vitiligo;
KIRP	cis	rs12580194	0.556	rs61957898	chr12:55730423	T/C	cg11794356	chr12:55725991	OR6C3	-0.61	-8.75	-0.49	3.44e-16	Cancer;
KIRP	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.33	-0.37	1.14e-9	Morning vs. evening chronotype;
KIRP	trans	rs1493916	0.592	rs1389068	chr18:31312738	G/T	cg27147174	chr7:100797783	AP1S1	-0.55	-6.64	-0.39	2e-10	Life satisfaction;
KIRP	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.18	9.45	0.52	2.69e-18	Plateletcrit;
KIRP	cis	rs2574704	1.000	rs2616561	chr3:11652417	G/A	cg07643000	chr3:11666825	VGLL4	-0.41	-5.92	-0.35	1.09e-8	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12756303	chr2:74692479	MOGS	0.51	6.49	0.38	4.63e-10	Parkinson's disease;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.96	-0.3	1.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11645453	chr3:52864694	ITIH4	0.33	4.85	0.3	2.16e-6	Bipolar disorder;
KIRP	cis	rs4919044	0.808	rs835274	chr10:94796534	A/G	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs61935443	0.720	rs10859780	chr12:95282601	T/C	cg21533806	chr12:95267307	NA	0.66	6.63	0.39	2.12e-10	Schizophrenia;
KIRP	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.09	0.64	4.49e-30	Tonsillectomy;
KIRP	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg24203234	chr3:128598194	ACAD9	0.44	5.06	0.31	8.3e-7	IgG glycosylation;
KIRP	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.84	-12.46	-0.62	5.75e-28	Height;
KIRP	cis	rs9931543	0.504	rs9922112	chr16:56314687	A/C	cg02433656	chr16:56322654	GNAO1	0.45	5.23	0.32	3.59e-7	Subjective well-being;
KIRP	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.38	13.83	0.66	1.49e-32	Schizophrenia;
KIRP	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg10792982	chr14:105748885	BRF1	0.93	14.76	0.69	9.58e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.36	0.59	2.52e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.59	-6.66	-0.39	1.77e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9372498	0.908	rs4551203	chr6:118693502	G/A	cg18833306	chr6:118973337	C6orf204	-0.61	-4.98	-0.3	1.2e-6	Diastolic blood pressure;
KIRP	cis	rs4523957	0.893	rs11078019	chr17:2162121	G/A	cg16513277	chr17:2031491	SMG6	-0.58	-8.01	-0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs72634030	0.536	rs72634018	chr17:5197752	A/G	cg20802942	chr17:5185005	RABEP1	0.51	5.09	0.31	7.12e-7	Rheumatoid arthritis;
KIRP	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg03342759	chr3:160939853	NMD3	-0.43	-5.24	-0.32	3.44e-7	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03045425	chr18:31803633	NOL4	-0.41	-6.07	-0.36	4.85e-9	Interleukin-4 levels;
KIRP	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	6.12	0.36	3.7e-9	Height;
KIRP	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	6.26	0.37	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12431939	0.626	rs7160810	chr14:51716467	G/A	cg23942311	chr14:51606299	NA	0.46	5.16	0.31	5.06e-7	Cancer;
KIRP	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg07511934	chr16:89386912	ANKRD11	0.42	5.41	0.33	1.51e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.23e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg02297831	chr4:17616191	MED28	0.49	6.07	0.36	4.7e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11888757	chr16:87799687	KLHDC4	0.49	6.22	0.37	2.17e-9	Parkinson's disease;
KIRP	cis	rs1413885	0.549	rs9436725	chr1:65852870	A/G	cg13202122	chr1:65886182	LEPROT;LEPR	0.41	4.87	0.3	2.04e-6	Anticoagulant levels;
KIRP	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg04944784	chr2:26401820	FAM59B	-0.72	-8.02	-0.46	4.32e-14	Gut microbiome composition (summer);
KIRP	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.69	8.87	0.49	1.48e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg17294928	chr15:75287854	SCAMP5	0.58	7.86	0.45	1.2e-13	Breast cancer;
KIRP	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg26531700	chr6:26746687	NA	0.52	7.27	0.42	4.83e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg15832292	chr6:96025679	MANEA	0.71	5.7	0.34	3.38e-8	Behavioural disinhibition (generation interaction);
KIRP	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.13	0.64	3.44e-30	Exhaled nitric oxide output;
KIRP	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.88	12.87	0.63	2.43e-29	Bladder cancer;
KIRP	cis	rs6995541	0.518	rs13254592	chr8:10707271	T/A	cg12568669	chr8:11666485	FDFT1	0.25	5.53	0.33	8.16e-8	Triglyceride levels;
KIRP	cis	rs9962915	0.967	rs1785418	chr18:5601403	A/G	cg06550462	chr18:5544208	EPB41L3	0.38	4.87	0.3	2.03e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs2018683	0.691	rs4722881	chr7:29001560	A/G	cg19402173	chr7:128379420	CALU	0.63	8.17	0.46	1.59e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg23484912	chr5:273055	PDCD6	0.63	7.86	0.45	1.2e-13	Pancreatic cancer;
KIRP	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.75	9.99	0.54	5.89e-20	Breast cancer;
KIRP	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.46	-0.38	5.64e-10	Bipolar disorder;
KIRP	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.79	7.89	0.45	1.01e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg02524346	chr8:600233	NA	0.73	5.66	0.34	4.1e-8	IgG glycosylation;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05954817	chr1:27248333	NUDC	-0.5	-6.3	-0.37	1.39e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4236601	0.720	rs3779511	chr7:116141778	T/G	cg12739419	chr7:116140593	CAV2	0.47	5.9	0.35	1.21e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	0.72	6.88	0.4	5.01e-11	Breast cancer;
KIRP	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg11344533	chr11:111475393	SIK2	-0.29	-4.97	-0.3	1.24e-6	Primary sclerosing cholangitis;
KIRP	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	1.0	17.43	0.74	7.3e-45	Breast cancer;
KIRP	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg10047753	chr17:41438598	NA	0.79	11.05	0.58	2.58e-23	Menopause (age at onset);
KIRP	cis	rs4845459	0.967	rs6700158	chr1:152592828	T/G	cg07796016	chr1:152779584	LCE1C	-0.49	-5.99	-0.36	7.39e-9	Psoriasis;
KIRP	cis	rs35740288	0.539	rs4843101	chr15:86339661	G/T	cg20737812	chr15:86336631	KLHL25	-0.48	-5.51	-0.33	8.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7429990	0.932	rs11720151	chr3:48140634	G/A	cg11946769	chr3:48343235	NME6	-0.5	-5.79	-0.35	2.18e-8	Educational attainment (years of education);
KIRP	cis	rs9715521	0.746	rs57464801	chr4:59851169	C/G	cg11281224	chr4:60001000	NA	-0.42	-5.26	-0.32	3.08e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.8	9.66	0.52	6.57e-19	Corneal astigmatism;
KIRP	trans	rs909341	0.868	rs2315009	chr20:62344140	C/G	cg01311341	chr22:25575246	KIAA1671	-0.63	-7.64	-0.44	4.95e-13	Atopic dermatitis;
KIRP	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg04166393	chr7:2884313	GNA12	0.65	7.72	0.44	2.94e-13	Height;
KIRP	cis	rs6737205	0.522	rs6547829	chr2:28323869	C/T	cg05484376	chr2:27715224	FNDC4	-0.55	-4.99	-0.3	1.16e-6	RR interval (tricyclic/tetracyclic antidepressant use interaction);
KIRP	cis	rs9948	1.000	rs2276654	chr2:97492479	G/A	cg01990225	chr2:97406019	LMAN2L	-1.07	-7.64	-0.44	4.8e-13	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2061333	1.000	rs2061333	chr19:44614208	A/G	cg21636353	chr19:44617292	ZNF225	0.5	5.34	0.32	2.09e-7	Alzheimer's disease;
KIRP	cis	rs7715811	1.000	rs9688222	chr5:13760906	C/A	cg07548982	chr5:13769939	DNAH5	-0.53	-6.47	-0.38	5.39e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg23307798	chr14:103986281	CKB	0.53	5.86	0.35	1.46e-8	Monocyte count;
KIRP	cis	rs8018808	1.000	rs11844594	chr14:77843814	T/C	cg20045696	chr14:77926864	AHSA1	-0.42	-5.12	-0.31	6.09e-7	Myeloid white cell count;
KIRP	cis	rs78487399	0.808	rs111812200	chr2:43674278	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.82	-14.41	-0.68	1.47e-34	Post bronchodilator FEV1;
KIRP	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.49	7.35	0.42	2.84e-12	Resting heart rate;
KIRP	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.67	-9.34	-0.51	6.2e-18	QRS duration;
KIRP	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.98	-0.36	7.76e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.32	-0.32	2.32e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.34e-15	Bone mineral density;
KIRP	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24549020	chr5:56110836	MAP3K1	0.52	5.12	0.31	6.28e-7	Initial pursuit acceleration;
KIRP	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg27121462	chr16:89883253	FANCA	-0.51	-6.11	-0.36	3.91e-9	Vitiligo;
KIRP	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-5.65	-0.34	4.46e-8	Renal function-related traits (BUN);
KIRP	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.7	-0.49	4.87e-16	Neuroticism;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.75	9.39	0.51	4.22e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4356932	0.811	rs68156651	chr4:76972468	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.05	0.36	5.3e-9	Blood protein levels;
KIRP	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg17554472	chr22:41940697	POLR3H	-0.67	-7.22	-0.42	6.46e-12	Vitiligo;
KIRP	cis	rs9487051	0.676	rs9386780	chr6:109584410	A/G	cg21918786	chr6:109611834	NA	-0.41	-5.74	-0.34	2.78e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg10326726	chr10:51549505	MSMB	0.54	7.51	0.43	1.07e-12	Prostate-specific antigen levels;
KIRP	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	1.03	14.21	0.67	7.51e-34	Menopause (age at onset);
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg14789911	chr21:47582049	C21orf56	-0.4	-4.98	-0.3	1.2e-6	Testicular germ cell tumor;
KIRP	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg09936400	chr10:82049201	MAT1A	0.33	5.41	0.33	1.51e-7	Diabetic kidney disease;
KIRP	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.8	-11.53	-0.59	7.17e-25	Total body bone mineral density;
KIRP	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	1.08	7.68	0.44	3.75e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3733606	0.775	rs66514314	chr4:6827238	C/T	cg05012661	chr4:6891264	NA	0.51	6.36	0.38	9.68e-10	Platelet count;
KIRP	cis	rs7246657	0.722	rs4802029	chr19:38055612	A/T	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	trans	rs35100037	0.803	rs13186509	chr5:128606522	T/C	cg23338408	chr14:31289523	NA	-0.61	-6.23	-0.37	2.02e-9	Ankle injury;
KIRP	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.05	0.61	1.38e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7692976	0.578	rs2282784	chr4:110869246	G/A	cg06981781	chr4:110842888	EGF	-0.24	-5.29	-0.32	2.76e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg20673091	chr1:2541236	MMEL1	0.42	5.87	0.35	1.38e-8	Ulcerative colitis;
KIRP	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg17264618	chr3:40429014	ENTPD3	0.32	4.98	0.3	1.18e-6	Renal cell carcinoma;
KIRP	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	0.5	8.9	0.49	1.21e-16	QRS complex (12-leadsum);
KIRP	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.71	0.49	4.66e-16	Motion sickness;
KIRP	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.85	-0.63	2.87e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.55	7.25	0.42	5.54e-12	Menarche (age at onset);
KIRP	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg13206674	chr6:150067644	NUP43	0.48	5.55	0.33	7.3900000000000007e-08	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24714147	chr19:14629240	DNAJB1	0.54	6.77	0.4	9.48e-11	Parkinson's disease;
KIRP	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-5.09	-0.31	6.97e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs12200782	1.000	rs41267923	chr6:26452947	C/T	cg11502198	chr6:26597334	ABT1	-0.73	-4.96	-0.3	1.3e-6	Small cell lung carcinoma;
KIRP	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg27608139	chr16:2294856	DCI	0.5	6.02	0.36	6.14e-9	Height;
KIRP	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.56	-8.04	-0.46	3.79e-14	Airway imaging phenotypes;
KIRP	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg26681399	chr22:41777847	TEF	0.42	4.88	0.3	1.93e-6	Vitiligo;
KIRP	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.23	0.7	2.45e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.75e-10	Red blood cell count;
KIRP	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.69	9.7	0.53	4.74e-19	Post bronchodilator FEV1;
KIRP	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.83	12.61	0.63	1.82e-28	Mean corpuscular volume;
KIRP	cis	rs4262150	0.883	rs72799143	chr5:152100749	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.4	-0.47	3.61e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20573562	chr11:18034664	SERGEF	0.59	7.66	0.44	4.22e-13	Parkinson's disease;
KIRP	cis	rs62413470	0.935	rs62404861	chr6:55943101	C/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12921961	chr14:75078834	LTBP2	0.5	7.03	0.41	2.06e-11	Parkinson's disease;
KIRP	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.55	-7.45	-0.43	1.53e-12	Mean corpuscular volume;
KIRP	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.41	-4.94	-0.3	1.43e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10128264	0.934	rs1250589	chr10:80980304	C/G	cg20744163	chr10:80999841	ZMIZ1	-0.34	-5.68	-0.34	3.81e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.6	-0.66	8.76e-32	Height;
KIRP	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.82	11.98	0.61	2.43e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg04662567	chr6:169592167	NA	0.6	8.19	0.46	1.4e-14	Pulse pressure;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg00405596	chr8:11794950	NA	-0.48	-6.35	-0.38	1.05e-9	Retinal vascular caliber;
KIRP	cis	rs7178909	0.872	rs57715404	chr15:90433958	T/C	cg19708238	chr15:90437601	AP3S2	0.57	7.82	0.45	1.59e-13	Common traits (Other);
KIRP	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1950626	0.716	rs34572720	chr14:101447150	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.63	6.89	0.4	4.67e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.62	-8.23	-0.46	1.13e-14	Resting heart rate;
KIRP	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg12559939	chr2:27858050	GPN1	0.41	5.35	0.32	2.01e-7	Oral cavity cancer;
KIRP	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.58	0.34	6.35e-8	Bipolar disorder;
KIRP	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.75	-0.44	2.48e-13	Morning vs. evening chronotype;
KIRP	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg17279839	chr7:150038598	RARRES2	0.4	5.11	0.31	6.51e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6102059	0.503	rs6029178	chr20:39178557	A/G	cg22477343	chr20:39312069	NA	-0.46	-6.08	-0.36	4.66e-9	LDL cholesterol;
KIRP	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.6	7.66	0.44	4.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.84	12.21	0.61	3.91e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.85	-0.3	2.15e-6	Pulmonary function;
KIRP	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.23	0.46	1.11e-14	IgG glycosylation;
KIRP	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.34	-4.91	-0.3	1.64e-6	Coronary artery disease;
KIRP	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg06243866	chr13:111019493	COL4A2	0.73	11.04	0.58	2.84e-23	White matter hyperintensity burden;
KIRP	cis	rs698833	0.532	rs2616444	chr2:44605518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.42	0.38	7.12e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg19731401	chr7:2775893	GNA12	0.68	6.41	0.38	7.37e-10	Childhood ear infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14905166	chr10:44052448	ZNF239	0.52	6.76	0.4	9.73e-11	Interleukin-4 levels;
KIRP	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.62	8.61	0.48	8.65e-16	Bladder cancer;
KIRP	cis	rs6539288	0.901	rs11113143	chr12:107303859	T/A	cg16260113	chr12:107380972	MTERFD3	0.4	5.03	0.31	9.53e-7	Total body bone mineral density;
KIRP	cis	rs16828019	0.852	rs34979067	chr1:41543084	G/A	cg18742814	chr1:41828276	NA	0.61	5.55	0.33	7.25e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7173389	0.530	rs6495063	chr15:73682708	G/T	cg01796676	chr15:73680284	NA	0.51	5.64	0.34	4.66e-8	Resting heart rate;
KIRP	cis	rs11650494	0.710	rs76305536	chr17:47488913	G/A	cg08112188	chr17:47440006	ZNF652	1.43	8.06	0.46	3.32e-14	Prostate cancer;
KIRP	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03934478	chr11:495069	RNH1	0.83	6.78	0.4	8.78e-11	Body mass index;
KIRP	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.36	7.44	0.43	1.7e-12	IgG glycosylation;
KIRP	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	cis	rs742614	0.576	rs2747537	chr20:32405217	A/G	cg06304546	chr20:32448765	NA	-0.76	-11.32	-0.59	3.53e-24	Stearic acid (18:0) levels;
KIRP	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-11.83	-0.6	7.28e-26	Glomerular filtration rate (creatinine);
KIRP	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	16.09	0.72	2.7e-40	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg11632617	chr15:75315747	PPCDC	-0.44	-5.02	-0.3	9.92e-7	Blood trace element (Zn levels);
KIRP	cis	rs28489187	0.558	rs1146382	chr1:85918101	C/T	cg16011679	chr1:85725395	C1orf52	-0.41	-4.97	-0.3	1.27e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.54	8.16	0.46	1.68e-14	Lung cancer;
KIRP	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg10223061	chr2:219282414	VIL1	0.43	6.74	0.39	1.11e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6959887	0.962	rs4720170	chr7:35287484	A/T	cg06685737	chr7:35301730	NA	0.42	6.13	0.36	3.43e-9	Birth weight;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02845365	chr2:58468581	FANCL	-0.46	-6.26	-0.37	1.66e-9	Migraine with aura;
KIRP	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21643547	chr1:205240462	TMCC2	-0.78	-12.0	-0.61	2.02e-26	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.68	5.47	0.33	1.1e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg18944383	chr4:111397179	ENPEP	0.49	8.14	0.46	1.98e-14	Coronary artery disease;
KIRP	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg16988262	chr1:15930761	NA	0.36	4.96	0.3	1.29e-6	Systolic blood pressure;
KIRP	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg05802129	chr4:122689817	NA	-0.51	-7.14	-0.41	1.02e-11	Type 2 diabetes;
KIRP	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.71	-11.25	-0.58	5.64e-24	Hepatocellular carcinoma;
KIRP	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.04	-0.36	5.58e-9	Coronary artery disease;
KIRP	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.55	-0.39	3.36e-10	Response to antipsychotic treatment;
KIRP	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.29	0.51	8.51e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-4.85	-0.3	2.16e-6	Myopia (pathological);
KIRP	cis	rs2223471	1.000	rs2223471	chr6:50733648	A/T	cg03432817	chr6:50765336	NA	-0.51	-8.09	-0.46	2.82e-14	Subcutaneous adipose tissue;
KIRP	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.44	6.3	0.37	1.37e-9	Endometrial cancer;
KIRP	cis	rs1497828	0.956	rs2646834	chr1:217545202	G/C	cg04411442	chr1:217543379	NA	0.41	6.21	0.37	2.22e-9	Dialysis-related mortality;
KIRP	cis	rs7404928	0.629	rs6497688	chr16:23850836	C/T	cg21745164	chr16:23765304	CHP2	0.57	7.33	0.42	3.36e-12	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.39	4.84	0.3	2.25e-6	Blood protein levels;
KIRP	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.63	0.44	5.21e-13	Neuroticism;
KIRP	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.7	-7.44	-0.43	1.66e-12	DNA methylation (variation);
KIRP	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg06740227	chr12:86229804	RASSF9	0.41	5.15	0.31	5.27e-7	Major depressive disorder;
KIRP	cis	rs496547	0.520	rs11216963	chr11:118580814	G/A	cg19308663	chr11:118741387	NA	0.41	6.4	0.38	7.8e-10	Hip minimal joint space width;
KIRP	cis	rs73058052	0.569	rs2116922	chr19:50103252	G/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.52	6.3	0.37	1.38e-9	Fibrinogen levels;
KIRP	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	1.09	19.27	0.78	4.81e-51	Schizophrenia;
KIRP	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.55	-0.33	7.54e-8	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.76	8.67	0.48	5.93e-16	Adiposity;
KIRP	cis	rs7714584	1.000	rs11748553	chr5:150184553	A/G	cg22134413	chr5:150180641	NA	1.05	7.58	0.44	6.99e-13	Crohn's disease;
KIRP	cis	rs2882667	0.931	rs6596457	chr5:138323379	T/C	cg04439458	chr5:138467593	SIL1	-0.45	-7.38	-0.43	2.48e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg02733842	chr7:1102375	C7orf50	0.56	5.81	0.35	1.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg06223162	chr1:101003688	GPR88	-0.43	-8.75	-0.49	3.38e-16	Monocyte count;
KIRP	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-5.88	-0.35	1.31e-8	HDL cholesterol;
KIRP	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.76	10.57	0.56	9e-22	Colorectal cancer;
KIRP	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.66	-8.14	-0.46	2.03e-14	Aortic root size;
KIRP	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg12315302	chr6:26189340	HIST1H4D	0.98	6.84	0.4	6.15e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg13736514	chr6:26305472	NA	-0.67	-9.08	-0.5	3.76e-17	Educational attainment;
KIRP	cis	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg06521331	chr12:34319734	NA	-0.63	-7.46	-0.43	1.49e-12	Morning vs. evening chronotype;
KIRP	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg21132104	chr15:45694354	SPATA5L1	0.76	9.33	0.51	6.44e-18	Homoarginine levels;
KIRP	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.2e-8	Aortic root size;
KIRP	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg00149659	chr3:10157352	C3orf10	0.56	6.64	0.39	2e-10	Alzheimer's disease;
KIRP	cis	rs1847505	0.562	rs79109903	chr13:61453746	A/T	cg25164009	chr13:61490935	NA	0.47	5.18	0.31	4.67e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg18877969	chr2:232395326	NMUR1	-0.37	-5.45	-0.33	1.24e-7	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12315590	chr3:128997497	C3orf37	0.53	6.36	0.38	9.73e-10	Smoking initiation;
KIRP	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-10.38	-0.55	3.72e-21	Pancreatic cancer;
KIRP	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg05347473	chr6:146136440	FBXO30	-0.64	-9.4	-0.51	4.06e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4478858	0.839	rs10798834	chr1:31708977	G/A	cg00250761	chr1:31883323	NA	-0.3	-5.36	-0.32	1.87e-7	Alcohol dependence;
KIRP	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.81	10.9	0.57	7.97e-23	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg08662619	chr6:150070041	PCMT1	0.34	5.53	0.33	8.06e-8	Lung cancer;
KIRP	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Retinal vascular caliber;
KIRP	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg23307798	chr14:103986281	CKB	0.77	13.51	0.65	1.75e-31	Body mass index;
KIRP	cis	rs311392	0.525	rs366276	chr8:55100181	T/C	cg06042504	chr8:55087323	NA	-0.54	-6.69	-0.39	1.5e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.69	8.35	0.47	4.96e-15	Height;
KIRP	cis	rs4938534	0.533	rs1806397	chr11:111264915	T/C	cg18316498	chr11:111250196	POU2AF1	0.38	6.02	0.36	6.34e-9	Primary biliary cholangitis;
KIRP	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg22563815	chr15:78856949	CHRNA5	-0.41	-6.48	-0.38	5.05e-10	Sudden cardiac arrest;
KIRP	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.78	10.35	0.55	4.6e-21	Resting heart rate;
KIRP	cis	rs2554380	0.600	rs6602986	chr15:84447099	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.34	-5.11	-0.31	6.5e-7	Height;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg27315239	chr1:53593711	SLC1A7	0.56	6.05	0.36	5.36e-9	Response to statin therapy;
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg08662619	chr6:150070041	PCMT1	0.34	5.48	0.33	1.03e-7	Lung cancer;
KIRP	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.64	6.78	0.4	8.86e-11	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2120243	0.539	rs2305622	chr3:157122504	C/T	cg24825693	chr3:157122686	VEPH1	-0.56	-9.37	-0.51	4.81e-18	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.26	-0.62	2.69e-27	Blood trace element (Zn levels);
KIRP	cis	rs17592366	0.713	rs77368305	chr14:35324383	A/G	cg09327582	chr14:35236912	BAZ1A	0.69	5.25	0.32	3.32e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg14580859	chr9:123691850	NA	0.36	5.12	0.31	6.31e-7	Rheumatoid arthritis;
KIRP	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg25566285	chr7:158114605	PTPRN2	0.79	13.2	0.64	1.89e-30	Calcium levels;
KIRP	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-7.56	-0.43	7.78e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.58	-0.34	6.19e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	1.19	13.9	0.66	8.52e-33	Monocyte percentage of white cells;
KIRP	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.07	0.5	3.9e-17	Morning vs. evening chronotype;
KIRP	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg07001201	chr5:642380	CEP72	-0.68	-6.47	-0.38	5.2400000000000005e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.66	-0.34	4.13e-8	Life satisfaction;
KIRP	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-4.92	-0.3	1.6e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2929278	0.736	rs2412823	chr15:44227270	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.44	-5.22	-0.32	3.74e-7	Schizophrenia;
KIRP	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.49	-6.8	-0.4	8.09e-11	Schizophrenia;
KIRP	trans	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg19694781	chr19:47549865	TMEM160	-0.52	-6.34	-0.37	1.08e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg08250444	chr1:155100078	EFNA1	0.56	7.32	0.42	3.49e-12	Educational attainment;
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.69	10.79	0.57	1.8e-22	Lung cancer;
KIRP	cis	rs6910061	0.956	rs9468419	chr6:11102576	T/C	cg27233058	chr6:11094804	LOC221710	0.58	5.91	0.35	1.16e-8	Diabetic kidney disease;
KIRP	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg21972741	chr5:435613	AHRR	0.52	6.88	0.4	4.84e-11	Cystic fibrosis severity;
KIRP	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.45	5.84	0.35	1.62e-8	Brain structure;
KIRP	cis	rs1468333	1.000	rs2906124	chr5:137528835	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	5.3	0.32	2.61e-7	Resting heart rate;
KIRP	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.45	5.23	0.32	3.7e-7	Schizophrenia;
KIRP	cis	rs12425451	0.544	rs7961302	chr12:3146436	G/C	cg05389053	chr12:3131226	TEAD4	-0.5	-5.97	-0.36	8.07e-9	Narcolepsy with cataplexy;
KIRP	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg18190219	chr22:46762943	CELSR1	-0.64	-7.15	-0.42	9.59e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg17441377	chr17:3906640	NA	0.53	7.13	0.41	1.14e-11	Type 2 diabetes;
KIRP	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg06637938	chr14:75390232	RPS6KL1	0.51	7.39	0.43	2.22e-12	Height;
KIRP	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.49	6.9	0.4	4.29e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.79	-0.35	2.16e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg21858823	chr1:15850916	CASP9	0.51	5.5	0.33	9.5e-8	Systolic blood pressure;
KIRP	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.83	10.38	0.55	3.64e-21	Neutrophil percentage of white cells;
KIRP	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.28	-0.32	2.82e-7	Primary biliary cholangitis;
KIRP	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-0.4	-5.0	-0.3	1.07e-6	Type 2 diabetes;
KIRP	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg21174375	chr14:64681225	SYNE2	0.7	9.64	0.52	7.25e-19	Atrial fibrillation;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg24874828	chr4:187887005	NA	-0.47	-7.02	-0.41	2.21e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg13962466	chr20:25176127	ENTPD6	-0.44	-5.53	-0.33	8.11e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3736485	0.934	rs17609693	chr15:51868000	T/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20135002	chr11:47629003	NA	-0.48	-5.77	-0.35	2.42e-8	Neuroticism;
KIRP	cis	rs10267417	0.603	rs10227497	chr7:19917006	A/G	cg05791153	chr7:19748676	TWISTNB	0.52	4.96	0.3	1.3e-6	Night sleep phenotypes;
KIRP	cis	rs5753037	0.543	rs131284	chr22:30157589	T/C	cg01021169	chr22:30184971	ASCC2	-0.52	-7.0	-0.41	2.43e-11	Type 1 diabetes;
KIRP	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.87	0.35	1.42e-8	Tonsillectomy;
KIRP	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs1941687	0.831	rs55671114	chr18:31386284	C/A	cg27147174	chr7:100797783	AP1S1	-0.55	-6.82	-0.4	7.17e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg21174375	chr14:64681225	SYNE2	0.43	4.85	0.3	2.15e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg03563238	chr19:33554763	RHPN2	-0.29	-4.85	-0.3	2.17e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg17372223	chr3:52568218	NT5DC2	0.31	5.1	0.31	6.82e-7	Bipolar disorder;
KIRP	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg16309518	chr5:176445507	NA	-0.84	-13.03	-0.64	7.31e-30	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20887711	chr4:1340912	KIAA1530	0.46	5.79	0.35	2.09e-8	Obesity-related traits;
KIRP	cis	rs6430538	0.621	rs2156003	chr2:135569248	C/A	cg25422880	chr2:135218333	TMEM163	-0.44	-6.19	-0.37	2.54e-9	Parkinson's disease;
KIRP	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.12	-0.31	6.19e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs55962025	0.711	rs17780797	chr4:3117579	T/C	cg06533319	chr4:3265114	C4orf44	0.4	5.09	0.31	7.24e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.35	1.16e-8	Total cholesterol levels;
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg10729496	chr3:10149963	C3orf24	0.55	5.01	0.3	1.04e-6	Alzheimer's disease;
KIRP	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	11.79	0.6	1e-25	Bipolar disorder;
KIRP	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg10047753	chr17:41438598	NA	1.03	12.92	0.64	1.6800000000000001e-29	Menopause (age at onset);
KIRP	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.746	rs4841441	chr8:10630898	C/A	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.84	-0.4	6.14e-11	Neuroticism;
KIRP	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18252515	chr7:66147081	NA	0.43	5.02	0.3	1.01e-6	Aortic root size;
KIRP	cis	rs7394190	0.748	rs34163229	chr10:75406912	G/T	cg04833713	chr10:74871078	NUDT13	0.51	5.91	0.35	1.11e-8	Incident atrial fibrillation;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg04305134	chr10:75173374	ANXA7	0.94	6.47	0.38	5.4e-10	P wave terminal force;
KIRP	cis	rs6578185	0.568	rs13248753	chr8:142464967	C/T	cg07762003	chr8:142452454	FLJ43860	0.4	5.39	0.33	1.64e-7	Endometriosis;
KIRP	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg21452805	chr1:244014465	NA	-0.71	-5.9	-0.35	1.18e-8	RR interval (heart rate);
KIRP	cis	rs7175404	0.793	rs6497078	chr15:94033245	C/T	cg23502883	chr15:93959149	NA	0.47	5.55	0.33	7.28e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs1014246	0.826	rs4752004	chr10:118473209	A/G	cg14919929	chr10:118506882	NA	0.58	7.68	0.44	3.66e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs6594713	0.603	rs6879257	chr5:112845803	C/T	cg12552261	chr5:112820674	MCC	0.55	4.94	0.3	1.48e-6	Brain cytoarchitecture;
KIRP	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00908189	chr16:619842	PIGQ	0.86	11.85	0.6	6.4e-26	Height;
KIRP	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg04166393	chr7:2884313	GNA12	0.7	8.46	0.47	2.46e-15	Height;
KIRP	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.41	0.68	1.57e-34	Cognitive function;
KIRP	cis	rs539514	0.627	rs9544034	chr13:76293764	G/A	cg04757411	chr13:76259545	LMO7	-0.37	-5.19	-0.31	4.41e-7	Type 1 diabetes;
KIRP	trans	rs2208049	0.947	rs3092156	chr20:41685152	G/A	cg10074813	chr8:144637872	GSDMD	0.47	6.18	0.37	2.63e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.59	-6.87	-0.4	5.38e-11	Corneal astigmatism;
KIRP	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.72	-0.39	1.26e-10	Menopause (age at onset);
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg13206674	chr6:150067644	NUP43	0.52	7.38	0.43	2.42e-12	Lung cancer;
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg10729496	chr3:10149963	C3orf24	0.54	5.02	0.31	9.71e-7	Alzheimer's disease;
KIRP	cis	rs12780845	0.505	rs973307	chr10:17246333	C/T	cg01003015	chr10:17271136	VIM	-0.4	-4.95	-0.3	1.38e-6	Homocysteine levels;
KIRP	cis	rs17030434	0.784	rs10032475	chr4:154674748	C/T	cg14289246	chr4:154710475	SFRP2	-0.48	-6.3	-0.37	1.33e-9	Electrocardiographic conduction measures;
KIRP	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs1511802	0.666	rs4862663	chr4:187119228	T/A	cg24794857	chr4:187113578	CYP4V2	0.41	5.8	0.35	2.06e-8	Blood protein levels;
KIRP	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg19592336	chr6:28129416	ZNF389	0.48	5.51	0.33	8.85e-8	Depression;
KIRP	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.35	6.04	0.36	5.74e-9	Pursuit maintenance gain;
KIRP	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg22437258	chr11:111473054	SIK2	0.63	7.67	0.44	4.08e-13	Primary sclerosing cholangitis;
KIRP	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.73	8.8	0.49	2.4e-16	Pulmonary function decline;
KIRP	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.82	9.79	0.53	2.57e-19	Corneal astigmatism;
KIRP	cis	rs6753739	0.745	rs1378640	chr2:219917632	C/T	cg01749213	chr2:219906749	CCDC108	0.44	5.26	0.32	3.15e-7	Height;
KIRP	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.41	-11.61	-0.6	3.75e-25	Diabetic kidney disease;
KIRP	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.6	7.86	0.45	1.18e-13	Lymphocyte counts;
KIRP	trans	rs3013648	0.777	rs11149322	chr13:85388136	A/T	cg21827674	chr12:133007847	NA	-0.73	-6.55	-0.39	3.36e-10	Huntington's disease progression;
KIRP	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg07274523	chr3:49395745	GPX1	0.71	8.69	0.48	5.04e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg02696790	chr15:75250997	RPP25	0.29	5.32	0.32	2.33e-7	Breast cancer;
KIRP	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.88	-0.35	1.3e-8	Response to antipsychotic treatment;
KIRP	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs55863869	0.748	rs2291312	chr2:179631214	A/G	cg02880032	chr2:179629472	TTN	0.64	5.53	0.33	7.96e-8	QT interval;
KIRP	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg07777115	chr5:623756	CEP72	-0.58	-5.86	-0.35	1.5e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg21698718	chr17:80085957	CCDC57	0.35	5.11	0.31	6.52e-7	Life satisfaction;
KIRP	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.92	13.59	0.65	9.55e-32	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.63	-0.39	2.14e-10	Axial length;
KIRP	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Urinary tract infection frequency;
KIRP	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.51	-0.38	4.07e-10	Coronary artery disease;
KIRP	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.63	7.12	0.41	1.19e-11	Alcohol dependence;
KIRP	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg00857998	chr1:205179979	DSTYK	0.64	7.59	0.44	6.77e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg18944383	chr4:111397179	ENPEP	-0.52	-6.2	-0.37	2.32e-9	Axial length;
KIRP	cis	rs6450176	0.909	rs2448	chr5:53302354	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.2	-0.58	8.68e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg12560992	chr17:57184187	TRIM37	0.7	6.76	0.4	9.88e-11	Cognitive test performance;
KIRP	cis	rs4851254	0.660	rs114552491	chr2:100709533	C/T	cg17356467	chr2:100759845	AFF3	0.53	5.43	0.33	1.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	1.11	15.6	0.71	1.31e-38	Multiple sclerosis;
KIRP	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.42	0.33	1.43e-7	Total cholesterol levels;
KIRP	cis	rs9810890	1.000	rs73198822	chr3:128480061	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16754643	chr12:133518353	ZNF605	-0.43	-6.02	-0.36	6.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg07212818	chr11:638076	DRD4	-0.44	-5.41	-0.33	1.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.65	-10.81	-0.57	1.51e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.75	-8.77	-0.49	3.1e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9400467	0.528	rs11153291	chr6:111720130	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.71	-0.34	3.22e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12496230	0.794	rs1867409	chr3:66860178	G/A	cg17646820	chr3:66848679	NA	0.39	6.34	0.37	1.06e-9	Type 2 diabetes;
KIRP	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-16.66	-0.73	3.11e-42	Height;
KIRP	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.45	-6.33	-0.37	1.16e-9	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00850501	chr19:14530371	DDX39	0.45	6.37	0.38	9.08e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1699337	0.930	rs1373641	chr3:12402474	C/T	cg02700894	chr3:12045449	SYN2	0.37	4.87	0.3	2.04e-6	Cholesterol, total;
KIRP	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.9	11.14	0.58	1.31e-23	Homoarginine levels;
KIRP	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.48	5.84	0.35	1.62e-8	Subjective well-being;
KIRP	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.0	-0.41	2.38e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg00204512	chr16:28754710	NA	0.43	5.39	0.33	1.61e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1318772	1.000	rs26980	chr5:112770027	T/G	cg12552261	chr5:112820674	MCC	0.83	5.31	0.32	2.49e-7	F-cell distribution;
KIRP	cis	rs259282	0.583	rs3760938	chr19:33106907	C/T	cg02997394	chr19:33096574	ANKRD27	-0.42	-4.93	-0.3	1.54e-6	Schizophrenia;
KIRP	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg15839431	chr19:19639596	YJEFN3	-0.55	-5.72	-0.34	3.13e-8	Bipolar disorder;
KIRP	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.83	11.98	0.61	2.41e-26	Heart rate;
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.56	6.71	0.39	1.32e-10	Menopause (age at onset);
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg24777315	chr12:66135734	NA	0.55	6.52	0.38	3.95e-10	Response to statin therapy;
KIRP	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	1.23	12.74	0.63	6.73e-29	Red blood cell traits;
KIRP	cis	rs2072732	0.861	rs2993510	chr1:2956666	C/T	cg11731671	chr1:2995604	PRDM16	0.38	5.17	0.31	4.86e-7	Plateletcrit;
KIRP	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs6959887	0.926	rs12538515	chr7:35297958	C/A	cg06685737	chr7:35301730	NA	0.45	6.44	0.38	6.39e-10	Birth weight;
KIRP	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.68	-0.34	3.86e-8	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg09264619	chr17:80180166	NA	0.37	5.37	0.32	1.81e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs714027	0.605	rs5753025	chr22:30542157	T/C	cg27665648	chr22:30112403	NA	-0.45	-6.4	-0.38	7.73e-10	Lymphocyte counts;
KIRP	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.58	5.43	0.33	1.35e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.72	-0.39	1.26e-10	Longevity;Endometriosis;
KIRP	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.91	11.09	0.58	1.86e-23	Response to antineoplastic agents;
KIRP	cis	rs1978968	0.763	rs9605480	chr22:18465105	G/A	cg02610425	chr22:18483192	MICAL3	0.36	5.39	0.33	1.64e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg11569703	chr11:65557185	OVOL1	0.75	13.3	0.65	8.7e-31	Acne (severe);
KIRP	cis	rs6589219	0.954	rs3802841	chr11:111171672	G/T	cg25129781	chr11:111156908	C11orf53	-0.49	-6.33	-0.37	1.12e-9	Colorectal cancer;
KIRP	cis	rs514024	0.520	rs836333	chr9:130486384	C/T	cg13643465	chr9:130375613	STXBP1	0.41	5.57	0.33	6.63e-8	Eating disorders (purging via substances);
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg09597638	chr17:3907349	NA	-0.74	-13.81	-0.66	1.68e-32	Type 2 diabetes;
KIRP	cis	rs597583	0.755	rs562422	chr11:117428278	G/A	cg27161313	chr11:117392002	DSCAML1	-0.56	-5.92	-0.35	1.07e-8	Putamen volume;
KIRP	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.34	12.31	0.62	1.86e-27	Diabetic retinopathy;
KIRP	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg16141378	chr3:129829833	LOC729375	0.51	6.8	0.4	7.68e-11	Systolic blood pressure;
KIRP	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.67	-0.52	5.88e-19	Response to antipsychotic treatment;
KIRP	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.56	7.95	0.45	6.75e-14	Breast cancer;
KIRP	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.51	-0.43	1.1e-12	Triglycerides;
KIRP	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13047869	chr3:10149882	C3orf24	0.52	4.91	0.3	1.69e-6	Alzheimer's disease;
KIRP	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.36	5.08	0.31	7.6e-7	Coronary artery disease;
KIRP	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.3	-0.37	1.39e-9	Migraine - clinic-based;
KIRP	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg10760299	chr15:45669010	GATM	0.35	5.13	0.31	5.78e-7	Homoarginine levels;
KIRP	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs4234798	1.000	rs4689653	chr4:7223319	T/G	cg18431297	chr4:7219810	SORCS2	0.68	8.96	0.5	8.07e-17	Insulin-like growth factors;
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.36	0.32	1.95e-7	Lung cancer;
KIRP	cis	rs8141529	0.529	rs5762814	chr22:29203964	G/A	cg02153584	chr22:29168773	CCDC117	0.52	4.89	0.3	1.84e-6	Lymphocyte counts;
KIRP	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg04166393	chr7:2884313	GNA12	0.4	5.26	0.32	3.19e-7	Height;
KIRP	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg23899408	chr19:12877188	HOOK2	-0.45	-5.07	-0.31	7.7300000000000005e-07	Mean corpuscular volume;
KIRP	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.78	-11.17	-0.58	1.09e-23	Blood metabolite levels;
KIRP	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.41	4.95	0.3	1.36e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.15	21.04	0.8	6.57e-57	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs2150410	0.833	rs4818011	chr21:40648595	C/T	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs11677416	1.000	rs4848304	chr2:113552737	T/C	cg23974023	chr2:113544294	IL1A	-0.35	-5.45	-0.33	1.25e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs3099143	0.901	rs76101229	chr15:77134975	C/T	cg21673338	chr15:77095150	SCAPER	-0.6	-6.02	-0.36	6.44e-9	Recalcitrant atopic dermatitis;
KIRP	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4356932	1.000	rs6532156	chr4:76974351	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg06815112	chr8:27182871	PTK2B	0.5	6.46	0.38	5.72e-10	Neuroticism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg25844216	chr1:226333792	ACBD3	0.54	8.34	0.47	5.38e-15	C-reactive protein;
KIRP	cis	rs73105738	0.590	rs73120114	chr5:73286033	C/T	cg26653990	chr5:72510846	NA	-0.49	-5.37	-0.32	1.86e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg18190219	chr22:46762943	CELSR1	-0.87	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.92	-0.4	3.79e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13401104	0.716	rs11685999	chr2:237143226	G/A	cg19324714	chr2:237145437	ASB18	0.54	5.5	0.33	9.37e-8	Educational attainment;
KIRP	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.41	-6.73	-0.39	1.21e-10	Height;
KIRP	trans	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg06521331	chr12:34319734	NA	-0.6	-7.15	-0.41	9.86e-12	Bladder cancer;
KIRP	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.62	7.88	0.45	1.03e-13	Alcohol dependence;
KIRP	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.74	-6.9	-0.4	4.5e-11	Cerebrospinal P-tau181p levels;
KIRP	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21659725	chr3:3221576	CRBN	-0.6	-7.18	-0.42	8.3e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1659258	0.527	rs1258391	chr2:88615224	C/T	cg00685853	chr2:88648947	NA	0.53	6.12	0.36	3.76e-9	Visceral fat;
KIRP	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs12543645	0.598	rs35338507	chr8:10277982	G/A	cg08975724	chr8:8085496	FLJ10661	0.53	6.29	0.37	1.47e-9	Schizophrenia;
KIRP	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg01777586	chr17:80163174	CCDC57	0.46	4.9	0.3	1.76e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.7	7.55	0.43	8.39e-13	Corneal astigmatism;
KIRP	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.59	5.45	0.33	1.23e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.36e-7	Bipolar disorder;
KIRP	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.65	-0.44	4.57e-13	Type 2 diabetes;
KIRP	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.5	-5.1	-0.31	6.85e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg00277334	chr10:82204260	NA	-0.45	-4.95	-0.3	1.41e-6	Post bronchodilator FEV1;
KIRP	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg04025307	chr7:1156635	C7orf50	0.52	5.69	0.34	3.6e-8	Bronchopulmonary dysplasia;
KIRP	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.85	-12.66	-0.63	1.26e-28	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15527401	chr19:59071099	UBE2M;LOC100131691	0.61	7.36	0.42	2.77e-12	Smoking initiation;
KIRP	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	0.81	8.38	0.47	4.23e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07732421	chr5:74633253	HMGCR	-0.47	-6.14	-0.36	3.25e-9	Pancreatic cancer;
KIRP	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg02151108	chr14:50098012	C14orf104	-0.57	-8.15	-0.46	1.79e-14	Carotid intima media thickness;
KIRP	cis	rs4262150	0.544	rs72795336	chr5:151903469	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.79	-0.49	2.7e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.69	8.07	0.46	3.18e-14	Smoking initiation;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg05562828	chr17:3906858	NA	0.71	14.09	0.67	1.85e-33	Type 2 diabetes;
KIRP	cis	rs35740288	0.929	rs11556865	chr15:86303180	C/G	cg17133734	chr15:86042851	AKAP13	-0.5	-5.44	-0.33	1.3e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17408923	chr2:109335769	RANBP2	0.66	6.08	0.36	4.68e-9	Lung function (FEV1);
KIRP	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg00800569	chr2:239229395	TRAF3IP1	0.42	4.92	0.3	1.56e-6	Multiple system atrophy;
KIRP	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.7	10.49	0.56	1.58e-21	Hip circumference;
KIRP	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-7.12	-0.41	1.2e-11	Vitiligo;
KIRP	cis	rs4851254	0.618	rs35300735	chr2:100667829	G/A	cg17356467	chr2:100759845	AFF3	0.55	5.69	0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-5.61	-0.34	5.43e-8	Morning vs. evening chronotype;
KIRP	trans	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg15469184	chr8:337539	NA	0.59	6.68	0.39	1.58e-10	Obesity-related traits;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00012762	chr17:72744649	SLC9A3R1	-0.43	-6.08	-0.36	4.56e-9	Morning vs. evening chronotype;
KIRP	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.82	13.41	0.65	3.93e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23281280	chr6:28129359	ZNF389	0.49	5.41	0.33	1.53e-7	Depression;
KIRP	cis	rs17381785	0.835	rs11725063	chr4:14913852	G/A	cg12377275	chr4:15005593	CPEB2	0.54	6.09	0.36	4.21e-9	Urate levels in overweight individuals;
KIRP	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.97	11.09	0.58	1.96e-23	Pulmonary function decline;
KIRP	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg08313168	chr12:7315531	NA	0.68	6.08	0.36	4.5e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7258465	1.000	rs76194	chr19:18630580	T/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.45	-0.43	1.62e-12	Breast cancer;
KIRP	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg00677455	chr12:58241039	CTDSP2	0.6	7.35	0.42	3e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12565681	chr17:74497418	RHBDF2	0.48	6.18	0.37	2.71e-9	Parkinson's disease;
KIRP	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg21573476	chr21:45109991	RRP1B	-0.63	-8.45	-0.47	2.51e-15	Mean corpuscular volume;
KIRP	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.74	-10.08	-0.54	3.25e-20	Childhood ear infection;
KIRP	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg16606324	chr3:10149918	C3orf24	0.69	5.83	0.35	1.7e-8	Alzheimer's disease;
KIRP	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.62	8.58	0.48	1.08e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg02389323	chr16:88786976	FAM38A	0.79	5.53	0.33	8.23e-8	Plateletcrit;
KIRP	cis	rs12780845	1.000	rs10490958	chr10:17233450	A/G	cg01003015	chr10:17271136	VIM	-0.45	-4.89	-0.3	1.83e-6	Homocysteine levels;
KIRP	cis	rs11874712	1.000	rs11874712	chr18:43688576	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.38	-5.24	-0.32	3.44e-7	Migraine - clinic-based;
KIRP	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg18646521	chr2:111875858	NA	0.41	5.8	0.35	2e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs6110278	0.685	rs6135144	chr20:14412500	C/G	cg17696268	chr20:14319035	FLRT3;MACROD2	-0.36	-5.02	-0.3	9.86e-7	Mean platelet volume;
KIRP	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21640587	chr11:117668038	DSCAML1	0.52	6.48	0.38	4.96e-10	Myopia;
KIRP	cis	rs405956	1.000	rs9404601	chr6:105568685	G/A	cg22580625	chr6:105627791	POPDC3	-0.61	-6.46	-0.38	5.68e-10	QT interval;
KIRP	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.78	9.21	0.51	1.5e-17	Corneal astigmatism;
KIRP	cis	rs2299587	0.689	rs1847154	chr8:17780338	A/G	cg01800426	chr8:17659068	MTUS1	-0.56	-6.74	-0.39	1.15e-10	Economic and political preferences;
KIRP	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.64	-0.66	6.42e-32	Response to antipsychotic treatment;
KIRP	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.81	0.35	1.96e-8	Menopause (age at onset);
KIRP	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.61	-9.95	-0.54	7.96e-20	Prostate cancer;
KIRP	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.57	-0.39	3.05e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.69	-8.86	-0.49	1.6e-16	Vitiligo;
KIRP	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg13482628	chr17:19912719	NA	-0.53	-7.0	-0.41	2.49e-11	Schizophrenia;
KIRP	cis	rs7852872	0.812	rs1885234	chr9:119252277	T/G	cg13792444	chr9:119245443	ASTN2	0.42	6.51	0.38	4.24e-10	Hippocampal volume;
KIRP	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg13731523	chr4:3047190	NA	-0.35	-6.22	-0.37	2.1e-9	Serum sulfate level;
KIRP	cis	rs77669868	0.703	rs61904685	chr11:114072659	G/A	cg01914181	chr11:114070210	ZBTB16	0.55	4.98	0.3	1.19e-6	Monocyte percentage of white cells;
KIRP	cis	rs12282928	0.959	rs7124318	chr11:48338030	C/T	cg26585981	chr11:48327164	OR4S1	0.5	6.09	0.36	4.28e-9	Migraine - clinic-based;
KIRP	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.66	8.5	0.48	1.86e-15	Tonsillectomy;
KIRP	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.74	6.81	0.4	7.33e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg05941025	chr16:89927596	SPIRE2	0.35	5.5	0.33	9.39e-8	Vitiligo;
KIRP	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.44	0.52	2.95e-18	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	0.53	6.26	0.37	1.68e-9	Prudent dietary pattern;
KIRP	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg05072774	chr3:49840536	C3orf54	0.43	5.51	0.33	9.17e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	26.46	0.86	6.51e-74	Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20187825	chr17:79895070	PYCR1	-0.54	-6.1	-0.36	4.03e-9	Menopause (age at onset);
KIRP	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.18	12.61	0.63	1.83e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg20368463	chr18:77673604	PQLC1	-0.47	-5.84	-0.35	1.66e-8	Schizophrenia;
KIRP	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.13	0.31	5.89e-7	Melanoma;
KIRP	cis	rs1577917	0.545	rs9450325	chr6:86475814	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.4	4.88	0.3	1.93e-6	Response to antipsychotic treatment;
KIRP	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.75	9.03	0.5	5e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg00024416	chr22:24240387	NA	-0.42	-5.97	-0.36	8.17e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7945718	0.621	rs7931351	chr11:12692162	A/T	cg25843174	chr11:12811716	TEAD1	0.32	5.67	0.34	4.06e-8	Educational attainment (years of education);
KIRP	cis	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg21546286	chr11:48923668	NA	0.42	5.05	0.31	8.62e-7	HDL cholesterol;
KIRP	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.56	10.26	0.55	8.59e-21	Iron status biomarkers (transferrin levels);
KIRP	cis	rs9815354	0.638	rs73073258	chr3:42017894	G/A	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg03959625	chr15:84868606	LOC388152	0.69	8.46	0.47	2.38e-15	Schizophrenia;
KIRP	cis	rs986417	0.818	rs767603	chr14:61098683	T/C	cg27398547	chr14:60952738	C14orf39	0.62	5.64	0.34	4.76e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.33	0.62	1.56e-27	Bone mineral density;
KIRP	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg00225070	chr15:80189496	MTHFS	0.61	7.03	0.41	2e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs13082711	0.911	rs34316374	chr3:27437385	G/C	cg02860705	chr3:27208620	NA	0.58	8.42	0.47	3.15e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg26681399	chr22:41777847	TEF	-0.47	-5.28	-0.32	2.85e-7	Vitiligo;
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.05	0.41	1.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs472402	0.560	rs10037161	chr5:6624294	C/A	cg08700190	chr5:6636046	SRD5A1	-0.4	-5.07	-0.31	7.85e-7	Response to amphetamines;
KIRP	cis	rs10822145	1	rs10822145	chr10:64934548	C/T	cg08743896	chr10:65200160	JMJD1C	-0.36	-5.37	-0.32	1.79e-7	Triglycerides;
KIRP	cis	rs9900972	0.918	rs4789942	chr17:76877495	T/C	cg20937029	chr17:76870563	TIMP2	0.44	5.15	0.31	5.24e-7	Obesity-related traits;
KIRP	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.42	0.59	1.65e-24	Morning vs. evening chronotype;
KIRP	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.36	5.7	0.34	3.39e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7011049	0.778	rs6981132	chr8:53866250	T/C	cg26025543	chr8:53854495	NA	0.59	6.54	0.38	3.57e-10	Systolic blood pressure;
KIRP	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.96e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.83	-10.35	-0.55	4.38e-21	Cognitive function;
KIRP	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.49	-0.48	2.03e-15	Coronary artery disease;
KIRP	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg00129232	chr17:37814104	STARD3	0.7	7.73	0.44	2.69e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg18016565	chr1:150552671	MCL1	0.38	5.85	0.35	1.58e-8	Melanoma;
KIRP	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.81	9.77	0.53	2.91e-19	Multiple system atrophy;
KIRP	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.24	0.58	6.14e-24	Bladder cancer;
KIRP	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.72	-9.11	-0.5	2.92e-17	Aortic root size;
KIRP	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.74	-8.51	-0.48	1.77e-15	Triglycerides;
KIRP	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.6	8.06	0.46	3.41e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	trans	rs7999699	0.967	rs4119502	chr13:48332418	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	6.84e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs79149102	0.737	rs75128970	chr15:75181397	C/T	cg09165964	chr15:75287851	SCAMP5	-0.86	-5.35	-0.32	2.01e-7	Lung cancer;
KIRP	cis	rs6589964	1.000	rs6589964	chr11:122870683	A/C	cg27398637	chr11:122830231	C11orf63	-0.44	-5.49	-0.33	9.99e-8	Menarche (age at onset);
KIRP	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg06640241	chr16:89574553	SPG7	0.8	11.83	0.6	7.47e-26	Multiple myeloma (IgH translocation);
KIRP	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg19404215	chr3:33155277	CRTAP	0.71	5.47	0.33	1.08e-7	Major depressive disorder;
KIRP	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.6	-9.43	-0.52	3.31e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.99	10.51	0.56	1.44e-21	Exhaled nitric oxide output;
KIRP	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	0.9	11.62	0.6	3.66e-25	Primary sclerosing cholangitis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16261398	chr11:1410750	BRSK2	-0.42	-6.24	-0.37	1.86e-9	Metabolic traits;
KIRP	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.67	6.48	0.38	4.87e-10	Eotaxin levels;
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.55	0.33	7.2e-8	Lung cancer;
KIRP	cis	rs2223471	0.719	rs9381901	chr6:50765751	A/G	cg03432817	chr6:50765336	NA	-0.42	-6.61	-0.39	2.43e-10	Subcutaneous adipose tissue;
KIRP	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05347473	chr6:146136440	FBXO30	0.6	8.73	0.49	3.99e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829661	0.793	rs1470533	chr2:30868678	G/A	cg10949345	chr2:30726833	LCLAT1	1.03	12.65	0.63	1.38e-28	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05315796	chr3:52349193	DNAH1	0.38	6.01	0.36	6.74e-9	Bipolar disorder;
KIRP	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg24972876	chr7:65420302	NA	0.4	5.46	0.33	1.19e-7	Aortic root size;
KIRP	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.1	-0.31	6.65e-7	Mood instability;
KIRP	cis	rs4563143	0.647	rs61378972	chr19:29218742	C/T	cg04546413	chr19:29218101	NA	1.04	10.82	0.57	1.42e-22	Methadone dose in opioid dependence;
KIRP	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.88	10.12	0.54	2.42e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs12541635	0.677	rs6999580	chr8:107018254	C/T	cg10147462	chr8:107024639	NA	0.36	5.45	0.33	1.2e-7	Age of smoking initiation;
KIRP	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg05347473	chr6:146136440	FBXO30	-0.59	-8.4	-0.47	3.6e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1823913	0.538	rs13432697	chr2:192210670	G/A	cg12404831	chr2:192114017	MYO1B	0.48	6.35	0.38	1.05e-9	Obesity-related traits;
KIRP	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg23594656	chr7:65796392	TPST1	-0.48	-7.33	-0.42	3.25e-12	Aortic root size;
KIRP	cis	rs10875746	0.903	rs725454	chr12:48502100	A/G	cg20731937	chr12:48336164	NA	0.41	5.3	0.32	2.63e-7	Longevity (90 years and older);
KIRP	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.71	-7.08	-0.41	1.47e-11	Vitiligo;
KIRP	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-1.34	-11.2	-0.58	8.66e-24	Plateletcrit;
KIRP	cis	rs6001982	0.667	rs73167098	chr22:40895810	C/A	cg07138101	chr22:40742427	ADSL	0.72	5.81	0.35	1.9e-8	Breast cancer;
KIRP	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.9	-0.71	1.23e-39	Chronic sinus infection;
KIRP	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.71	10.85	0.57	1.17e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg24498760	chr8:49746867	NA	-0.41	-5.07	-0.31	7.81e-7	Blood metabolite ratios;
KIRP	cis	rs11605275	0.892	rs16937352	chr11:20032010	G/C	cg14835545	chr11:20032148	NAV2	-0.8	-6.14	-0.36	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg19680485	chr15:31195859	MTMR15	0.52	4.88	0.3	1.93e-6	Hypertriglyceridemia;
KIRP	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.81	-0.35	1.97e-8	Morning vs. evening chronotype;
KIRP	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.59	7.36	0.42	2.79e-12	Tonsillectomy;
KIRP	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs7172677	1.000	rs4886658	chr15:75414536	A/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-6.15	-0.36	3.14e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.97	-15.55	-0.7	1.92e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.46	5.88	0.35	1.32e-8	Iron status biomarkers;
KIRP	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg14131526	chr19:38747285	PPP1R14A	0.46	6.52	0.38	4e-10	Prostate cancer;Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg26681399	chr22:41777847	TEF	-0.48	-5.09	-0.31	7.08e-7	Vitiligo;
KIRP	cis	rs78761021	0.720	rs55735457	chr17:9796710	C/T	cg26853458	chr17:9805074	RCVRN	0.52	5.04	0.31	8.9e-7	Type 2 diabetes;
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg12705353	chr12:122356852	WDR66	0.39	5.12	0.31	6.1e-7	Mean corpuscular volume;
KIRP	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	6.85	0.4	5.86e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01340089	chr12:22199200	CMAS	0.54	6.71	0.39	1.33e-10	Parkinson's disease;
KIRP	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg10760299	chr15:45669010	GATM	0.34	4.93	0.3	1.54e-6	Homoarginine levels;
KIRP	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.44	5.61	0.34	5.42e-8	Crohn's disease;
KIRP	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.52	6.53	0.38	3.67e-10	Resistin levels;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.86	13.54	0.65	1.42e-31	Menarche (age at onset);
KIRP	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02479904	chr11:47429944	SLC39A13	0.53	6.81	0.4	7.47e-11	Parkinson's disease;
KIRP	cis	rs57338032	0.891	rs61388072	chr15:78760344	G/A	cg06917634	chr15:78832804	PSMA4	0.56	4.95	0.3	1.41e-6	CTACK levels;
KIRP	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.57	-6.87	-0.4	5.27e-11	Mosquito bite size;
KIRP	cis	rs7116495	1.000	rs4945426	chr11:71748146	A/C	cg26138937	chr11:71823887	C11orf51	0.68	5.32	0.32	2.29e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg01616529	chr11:638424	DRD4	-0.37	-5.03	-0.31	9.48e-7	Systemic lupus erythematosus;
KIRP	cis	rs5747327	0.839	rs2024230	chr22:18132930	C/T	cg19898043	chr22:18121309	BCL2L13	-0.41	-4.91	-0.3	1.62e-6	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	0.95	8.19	0.46	1.46e-14	Arsenic metabolism;
KIRP	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.44	0.33	1.29e-7	Breast cancer;
KIRP	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21545522	chr1:205238299	TMCC2	0.46	6.31	0.37	1.3e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2882667	0.756	rs11957953	chr5:138479377	G/T	cg04439458	chr5:138467593	SIL1	-0.52	-7.72	-0.44	2.9e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs986417	1.000	rs1254318	chr14:60902549	T/C	cg27398547	chr14:60952738	C14orf39	-0.64	-5.86	-0.35	1.44e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1729407	0.647	rs2727791	chr11:116684562	C/G	cg26566898	chr11:117069891	TAGLN	0.41	5.48	0.33	1.05e-7	Apolipoprotein A-IV levels;
KIRP	trans	rs2270927	0.834	rs4496693	chr5:75576729	T/C	cg13563193	chr19:33072644	PDCD5	0.87	7.82	0.45	1.59e-13	Mean corpuscular volume;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg05450262	chr10:3371481	NA	0.52	6.4	0.38	7.74e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18894666	chr14:77495072	C14orf4	-0.53	-6.65	-0.39	1.86e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs73200209	0.744	rs17426239	chr12:116438287	A/G	cg01776926	chr12:116560359	MED13L	0.58	5.84	0.35	1.66e-8	Total body bone mineral density;
KIRP	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg04166393	chr7:2884313	GNA12	0.39	5.16	0.31	5.21e-7	Height;
KIRP	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-4.99	-0.3	1.13e-6	Large artery stroke;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14084312	chr14:88459488	GALC	0.51	6.52	0.38	4.02e-10	Smoking initiation;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.71	7.14	0.41	1.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg07701084	chr6:150067640	NUP43	0.61	7.87	0.45	1.11e-13	Lung cancer;
KIRP	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg20243544	chr17:37824526	PNMT	0.47	6.49	0.38	4.76e-10	Asthma;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-1.09	-22.07	-0.82	2.89e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs787274	1.000	rs813101	chr9:115532907	C/G	cg13803584	chr9:115635662	SNX30	-0.73	-8.22	-0.46	1.2e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19400545	chr4:124319236	SPRY1	0.44	6.54	0.38	3.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11613427	chr3:52932208	TMEM110	-0.3	-5.01	-0.3	1.06e-6	Schizophrenia;
KIRP	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.46	5.38	0.32	1.73e-7	Glycated hemoglobin levels;
KIRP	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg26513180	chr16:89883248	FANCA	0.59	7.91	0.45	8.67e-14	Vitiligo;
KIRP	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Immature fraction of reticulocytes;
KIRP	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-12.02	-0.61	1.73e-26	Exhaled nitric oxide output;
KIRP	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg13047869	chr3:10149882	C3orf24	0.53	5.26	0.32	3.18e-7	Alzheimer's disease;
KIRP	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg03714773	chr7:91764589	CYP51A1	0.37	5.39	0.33	1.63e-7	Breast cancer;
KIRP	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17123764	0.892	rs12317778	chr12:50105637	T/C	cg20471783	chr12:50157085	TMBIM6	0.38	5.49	0.33	1.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10121009	0.567	rs10814226	chr9:35324818	T/C	cg15271616	chr9:35490515	RUSC2	0.38	4.94	0.3	1.46e-6	Parkinson's disease;
KIRP	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg05347473	chr6:146136440	FBXO30	0.57	8.14	0.46	1.94e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.68	-8.85	-0.49	1.78e-16	Bladder cancer;
KIRP	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-12.36	-0.62	1.24e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.91	-13.57	-0.65	1.08e-31	Coronary artery disease;
KIRP	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg05342945	chr12:48394962	COL2A1	-0.45	-4.97	-0.3	1.23e-6	Lung cancer;
KIRP	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg02569458	chr12:86230093	RASSF9	0.35	4.98	0.3	1.21e-6	Major depressive disorder;
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs7849270	1.000	rs932833	chr9:131884041	T/A	cg13538475	chr9:131942899	NA	-0.31	-5.04	-0.31	9.09e-7	Blood metabolite ratios;
KIRP	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-9.64	-0.52	7.49e-19	Primary sclerosing cholangitis;
KIRP	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.56	8.48	0.48	2.17e-15	Bone mineral density;
KIRP	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg03929089	chr4:120376271	NA	0.76	6.73	0.39	1.17e-10	Axial length;
KIRP	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.39	-6.93	-0.4	3.69e-11	Refractive error;
KIRP	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.56	-9.8	-0.53	2.42e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg24747557	chr10:131355152	MGMT	-0.43	-5.92	-0.35	1.06e-8	Response to temozolomide;
KIRP	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.29	26.77	0.86	7.72e-75	IgG glycosylation;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	cis	rs7766436	0.885	rs3734215	chr6:22571323	T/C	cg13666174	chr6:22585274	NA	-0.43	-5.95	-0.35	9.06e-9	Coronary artery disease;
KIRP	cis	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg24110177	chr3:50126178	RBM5	-0.67	-9.1	-0.5	3.28e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.53	-6.92	-0.4	3.85e-11	Body mass index;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg25650185	chr19:21324782	ZNF431	-0.48	-5.13	-0.31	5.95e-7	Pain;
KIRP	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.47	0.33	1.12e-7	Tonsillectomy;
KIRP	cis	rs2916247	1.000	rs28716374	chr8:93030411	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.64	-8.83	-0.49	2.03e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6504950	0.830	rs17817877	chr17:53034628	T/A	cg26251398	chr17:52985966	TOM1L1	0.43	5.21	0.32	3.96e-7	Breast cancer;
KIRP	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg01631408	chr1:248437212	OR2T33	-0.63	-8.34	-0.47	5.31e-15	Common traits (Other);
KIRP	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg20744362	chr22:50050164	C22orf34	0.31	5.02	0.3	9.85e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	9.82	0.53	2.07e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs860295	0.557	rs12035524	chr1:155667102	C/T	cg02153340	chr1:155202674	NA	-0.51	-6.59	-0.39	2.58e-10	Body mass index;
KIRP	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg00491522	chr10:135256596	NA	0.56	5.98	0.36	7.67e-9	Systemic lupus erythematosus;
KIRP	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.8	9.83	0.53	1.94e-19	Corneal astigmatism;
KIRP	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg09754948	chr16:28834200	ATXN2L	-0.44	-4.97	-0.3	1.25e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs27434	0.583	rs34756	chr5:96152383	C/T	cg16492584	chr5:96139282	ERAP1	0.42	5.57	0.33	6.83e-8	Ankylosing spondylitis;
KIRP	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg02725872	chr8:58115012	NA	0.43	5.25	0.32	3.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.85	0.35	1.59e-8	Breast cancer;
KIRP	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg23100626	chr2:96804247	ASTL	0.44	5.56	0.33	7.09e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg08283408	chr3:49949060	MON1A	0.42	5.54	0.33	7.78e-8	Body mass index;
KIRP	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-5.48	-0.33	1.06e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs12586317	0.576	rs72664862	chr14:35641572	C/T	cg07166546	chr14:35805898	NA	-0.27	-6.46	-0.38	5.52e-10	Psoriasis;
KIRP	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.57	-7.08	-0.41	1.51e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2882667	0.931	rs11955952	chr5:138329119	A/G	cg04439458	chr5:138467593	SIL1	-0.42	-6.94	-0.4	3.47e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs496547	0.654	rs688161	chr11:118677710	G/A	cg19308663	chr11:118741387	NA	-0.29	-5.18	-0.31	4.71e-7	Hip minimal joint space width;
KIRP	cis	rs988913	0.957	rs1503147	chr6:54759483	A/G	cg03513858	chr6:54763001	FAM83B	-0.38	-5.53	-0.33	8.1e-8	Menarche (age at onset);
KIRP	cis	rs4654899	0.865	rs1472831	chr1:21435940	C/T	cg05370193	chr1:21551575	ECE1	0.47	5.97	0.36	8.36e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.57	-11.84	-0.6	6.67e-26	Diabetic kidney disease;
KIRP	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.5	7.0	0.41	2.39e-11	Glioblastoma;Glioma;
KIRP	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.96	0.3	1.34e-6	Lymphocyte counts;
KIRP	trans	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg04373760	chr16:53404718	NA	-0.58	-6.29	-0.37	1.46e-9	Hypertriglyceridemia;
KIRP	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg06026331	chr20:60912101	LAMA5	0.52	5.46	0.33	1.17e-7	Colorectal cancer;
KIRP	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg06212747	chr3:49208901	KLHDC8B	0.58	6.4	0.38	7.75e-10	Menarche (age at onset);
KIRP	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07570687	chr10:102243282	WNT8B	0.5	6.48	0.38	5.07e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-6.72	-0.39	1.24e-10	Aortic root size;
KIRP	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg26769984	chr7:1090371	C7orf50	0.73	6.03	0.36	5.93e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.46e-8	Life satisfaction;
KIRP	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.34	5.38	0.32	1.72e-7	QRS complex (12-leadsum);
KIRP	cis	rs7246657	0.638	rs7246461	chr19:38196581	C/G	cg23950597	chr19:37808831	NA	0.49	5.42	0.33	1.42e-7	Coronary artery calcification;
KIRP	trans	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg18555811	chr3:193852889	HES1	-0.48	-6.1	-0.36	4.02e-9	Atopic dermatitis;
KIRP	cis	rs73416724	0.544	rs79306700	chr6:43234901	T/C	cg02694972	chr6:43249501	TTBK1	-0.56	-4.91	-0.3	1.64e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg25664220	chr3:72788482	NA	-0.48	-7.18	-0.42	8.29e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg06481639	chr22:41940642	POLR3H	-0.42	-4.86	-0.3	2.08e-6	Neuroticism;
KIRP	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg02378861	chr5:212933	CCDC127	-0.62	-5.26	-0.32	3.1e-7	Fat distribution (HIV);
KIRP	cis	rs258892	0.895	rs7737643	chr5:72058445	G/T	cg21869765	chr5:72125136	TNPO1	-0.52	-5.66	-0.34	4.17e-8	Small cell lung carcinoma;
KIRP	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg25173405	chr17:45401733	C17orf57	-0.47	-6.71	-0.39	1.36e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.75	9.76	0.53	3.11e-19	Monocyte count;
KIRP	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg17366294	chr4:99064904	C4orf37	0.36	4.88	0.3	1.92e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg03929089	chr4:120376271	NA	0.76	6.75	0.4	1.05e-10	Axial length;
KIRP	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg19913688	chr11:428466	ANO9	0.94	8.62	0.48	8.44e-16	Body mass index;
KIRP	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.73	-0.39	1.19e-10	Capecitabine sensitivity;
KIRP	cis	rs72960926	0.744	rs55867620	chr6:75038763	G/A	cg03266952	chr6:74778945	NA	-0.7	-5.22	-0.32	3.76e-7	Metabolite levels (MHPG);
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	-0.38	-5.9	-0.35	1.18e-8	Lymphocyte counts;
KIRP	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.76	0.81	2.97e-59	Prudent dietary pattern;
KIRP	cis	rs7551222	0.752	rs10900593	chr1:204470096	G/T	cg20240347	chr1:204465584	NA	-0.43	-8.06	-0.46	3.36e-14	Schizophrenia;
KIRP	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg06742321	chr12:123595122	PITPNM2	0.42	5.13	0.31	5.86e-7	Neutrophil percentage of white cells;
KIRP	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.45	-5.31	-0.32	2.48e-7	Reticulocyte count;
KIRP	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg21187068	chr8:144659627	NAPRT1	0.74	4.99	0.3	1.14e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17507749	chr15:85114479	UBE2QP1	0.78	8.71	0.49	4.6e-16	Schizophrenia;
KIRP	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg10761708	chr20:43804764	PI3	0.5	5.02	0.3	1e-6	Blood protein levels;
KIRP	cis	rs920590	0.704	rs6586867	chr8:19653050	A/G	cg03894339	chr8:19674705	INTS10	0.4	4.87	0.3	2e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12620999	1.000	rs12620999	chr2:238036367	C/T	cg23555395	chr2:238036564	NA	-0.57	-6.72	-0.39	1.27e-10	Systemic lupus erythematosus;
KIRP	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.39	4.98	0.3	1.22e-6	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.06	0.61	1.27e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg07596299	chr11:71824057	C11orf51	0.89	5.94	0.35	9.61e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.62	6.78	0.4	8.64e-11	Multiple sclerosis;
KIRP	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg08885076	chr2:99613938	TSGA10	0.53	9.06	0.5	4.22e-17	Chronic sinus infection;
KIRP	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg23307798	chr14:103986281	CKB	0.83	14.73	0.68	1.26e-35	Body mass index;
KIRP	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg04662567	chr6:169592167	NA	0.63	8.68	0.48	5.59e-16	Pulse pressure;
KIRP	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg19468946	chr17:37922297	IKZF3	-0.37	-5.24	-0.32	3.38e-7	Asthma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14609960	chr10:3180273	PITRM1	0.49	6.75	0.4	1.05e-10	Interleukin-4 levels;
KIRP	cis	rs61990749	0.511	rs10146144	chr14:78325300	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.78	5.86	0.35	1.52e-8	Fibroblast growth factor basic levels;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4252707	1	rs4252707	chr1:204508147	G/A	cg18185008	chr1:204589407	LRRN2	-0.6	-6.71	-0.39	1.34e-10	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg06815112	chr8:27182871	PTK2B	0.51	6.59	0.39	2.73e-10	Neuroticism;
KIRP	cis	rs300890	0.729	rs11100787	chr4:144312292	A/G	cg19876092	chr4:144208277	NA	-0.31	-4.85	-0.3	2.19e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg21452805	chr1:244014465	NA	0.7	6.02	0.36	6.42e-9	RR interval (heart rate);
KIRP	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg16584676	chr17:46985605	UBE2Z	-0.5	-6.09	-0.36	4.27e-9	Type 2 diabetes;
KIRP	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.78	9.06	0.5	4.26e-17	Cognitive ability;
KIRP	cis	rs7566780	0.630	rs4364023	chr2:16687496	A/G	cg09580478	chr2:16689509	NA	0.48	5.18	0.31	4.57e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs1215050	0.791	rs7688942	chr4:98832048	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.12	0.31	6.3e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.42	0.7	5.45e-38	Bipolar disorder;
KIRP	cis	rs17092148	0.790	rs6087602	chr20:33170689	G/A	cg16810054	chr20:33298113	TP53INP2	-0.42	-4.84	-0.3	2.25e-6	Neuroticism;
KIRP	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.61	-7.89	-0.45	9.63e-14	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.74	9.51	0.52	1.86e-18	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs11874712	1.000	rs1800639	chr18:43671240	G/T	cg26436583	chr18:43649176	PSTPIP2	-0.45	-6.45	-0.38	5.73e-10	Migraine - clinic-based;
KIRP	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg18646521	chr2:111875858	NA	0.41	5.92	0.35	1.09e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg00405596	chr8:11794950	NA	0.46	5.84	0.35	1.68e-8	Retinal vascular caliber;
KIRP	cis	rs2281603	0.570	rs10150781	chr14:64955859	G/A	cg01860774	chr14:64969374	ZBTB25	0.33	5.4	0.33	1.58e-7	Lymphocyte counts;
KIRP	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.71	9.52	0.52	1.66e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg21775007	chr8:11205619	TDH	0.43	5.84	0.35	1.65e-8	Triglycerides;
KIRP	trans	rs1106684	1.000	rs67654455	chr7:131463481	A/G	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg07803811	chr1:43423981	SLC2A1	0.54	7.5	0.43	1.18e-12	Red cell distribution width;
KIRP	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.61	0.59	4e-25	Total body bone mineral density;
KIRP	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg24579218	chr15:68104479	NA	-0.48	-7.89	-0.45	1.02e-13	Restless legs syndrome;
KIRP	cis	rs15676	0.783	rs7044955	chr9:131567152	C/T	cg00228799	chr9:131580591	ENDOG	-0.49	-4.98	-0.3	1.21e-6	Blood metabolite levels;
KIRP	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.94	14.12	0.67	1.48e-33	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.59	8.85	0.49	1.79e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Body mass index;
KIRP	cis	rs600806	0.676	rs2781553	chr1:110026989	G/T	cg02175308	chr1:109941060	SORT1	0.28	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg18709589	chr6:96969512	KIAA0776	0.34	5.07	0.31	8.01e-7	Headache;
KIRP	cis	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg19847130	chr8:10466454	RP1L1	-0.33	-5.17	-0.31	4.84e-7	Neuroticism;
KIRP	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.05	11.19	0.58	9.2e-24	Cognitive test performance;
KIRP	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.72	10.13	0.54	2.14e-20	Obesity-related traits;
KIRP	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.47	-5.0	-0.3	1.1e-6	Initial pursuit acceleration;
KIRP	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg05973401	chr12:123451056	ABCB9	0.51	5.45	0.33	1.2e-7	Neutrophil percentage of white cells;
KIRP	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.77	0.49	3.04e-16	Eosinophil percentage of white cells;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11905131	chr22:24372483	LOC391322	0.54	5.74	0.34	2.77e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.61	-0.34	5.43e-8	Aortic root size;
KIRP	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg16586182	chr3:47516702	SCAP	0.75	9.98	0.54	6.33e-20	Colorectal cancer;
KIRP	trans	rs1864585	0.520	rs73208757	chr8:10658716	G/T	cg26278703	chr11:58910052	FAM111A	0.65	6.45	0.38	5.75e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.65	8.85	0.49	1.81e-16	Alcohol dependence;
KIRP	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg03808351	chr9:123631620	PHF19	0.37	5.27	0.32	2.92e-7	Rheumatoid arthritis;
KIRP	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-12.59	-0.63	2.24e-28	Vitiligo;
KIRP	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg22903471	chr2:27725779	GCKR	0.45	6.32	0.37	1.21e-9	Oral cavity cancer;
KIRP	cis	rs12549025	0.729	rs11784090	chr8:23377161	C/T	cg08322043	chr8:23340750	NA	-0.55	-5.22	-0.32	3.8e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.73e-8	Life satisfaction;
KIRP	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.22	-0.42	6.48e-12	Gut microbiome composition (summer);
KIRP	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg00922110	chr4:57842668	C4orf14	-0.4	-5.22	-0.32	3.75e-7	Response to bleomycin (chromatid breaks);
KIRP	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg25036284	chr2:26402008	FAM59B	0.52	4.91	0.3	1.69e-6	Gut microbiome composition (summer);
KIRP	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg21775007	chr8:11205619	TDH	0.44	5.88	0.35	1.3e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg08076091	chr2:203926405	NBEAL1	0.83	8.85	0.49	1.78e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs42648	0.790	rs42637	chr7:89969831	A/G	cg25739043	chr7:89950458	NA	-0.37	-5.6	-0.34	5.68e-8	Homocysteine levels;
KIRP	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.71	-0.44	3.19e-13	Response to antipsychotic treatment;
KIRP	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7508	0.711	rs3810	chr8:17914117	T/G	cg01800426	chr8:17659068	MTUS1	-0.43	-5.04	-0.31	9e-7	Atrial fibrillation;
KIRP	cis	rs1440410	0.798	rs11100772	chr4:144054088	T/G	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.26e-10	Ischemic stroke;
KIRP	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	7.73	0.44	2.77e-13	Coronary artery disease;
KIRP	cis	rs1050631	0.564	rs1785904	chr18:33713132	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.58	-0.34	6.37e-8	Response to antipsychotic treatment;
KIRP	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg12963246	chr6:28129442	ZNF389	0.53	6.47	0.38	5.28e-10	Depression;
KIRP	cis	rs55728055	0.661	rs62239169	chr22:32042514	G/A	cg01338084	chr22:32026380	PISD	1.02	6.35	0.38	1.01e-9	Age-related hearing impairment;
KIRP	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg27398547	chr14:60952738	C14orf39	-0.61	-5.38	-0.32	1.73e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs787274	1.000	rs787292	chr9:115508529	A/G	cg13803584	chr9:115635662	SNX30	0.77	7.75	0.44	2.38e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	7.94	0.45	7.23e-14	Schizophrenia;
KIRP	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg05791153	chr7:19748676	TWISTNB	0.69	6.13	0.36	3.45e-9	Thyroid stimulating hormone;
KIRP	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg19743168	chr1:23544995	NA	0.56	7.76	0.44	2.32e-13	Height;
KIRP	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg11941060	chr3:133502564	NA	-0.44	-5.34	-0.32	2.11e-7	Iron status biomarkers;
KIRP	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg05709478	chr1:6581295	PLEKHG5	0.61	5.45	0.33	1.23e-7	Body mass index;
KIRP	cis	rs4845459	0.967	rs6677595	chr1:152590187	C/T	cg07796016	chr1:152779584	LCE1C	-0.49	-6.04	-0.36	5.63e-9	Psoriasis;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-0.64	-8.73	-0.49	3.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9359856	0.517	rs17506515	chr6:90507332	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.74	-0.44	2.65e-13	Bipolar disorder;
KIRP	cis	rs2071403	0.509	rs17786733	chr2:1410929	T/A	cg07083862	chr2:1417248	TPO	0.35	5.39	0.32	1.67e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.43	5.36	0.32	1.9e-7	Melanoma;
KIRP	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-9.14	-0.5	2.46e-17	Resting heart rate;
KIRP	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.24	0.62	3.34e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.63	-5.55	-0.33	7.56e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08677398	chr8:58056175	NA	0.6	5.02	0.3	9.82e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg01879757	chr17:41196368	BRCA1	-0.7	-8.47	-0.48	2.2e-15	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg01689657	chr7:91764605	CYP51A1	0.41	5.91	0.35	1.15e-8	Breast cancer;
KIRP	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg00079169	chr19:2811669	THOP1	0.51	5.45	0.33	1.25e-7	Total cholesterol levels;
KIRP	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg13611997	chr5:233750	SDHA	-0.43	-5.14	-0.31	5.49e-7	Breast cancer;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg23736307	chr8:27182930	PTK2B	0.54	6.81	0.4	7.5e-11	Neuroticism;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01398415	chr1:226309536	NA	0.46	6.35	0.38	1.02e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.65	-0.34	4.44e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.51	8.07	0.46	3.06e-14	Major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15579888	chr18:48722878	MEX3C	0.52	6.55	0.39	3.34e-10	Parkinson's disease;
KIRP	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.78	9.88	0.53	1.34e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg10326726	chr10:51549505	MSMB	-0.59	-8.94	-0.5	9.22e-17	Prostate-specific antigen levels;
KIRP	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3755132	0.929	rs4668937	chr2:15736029	G/A	cg12888861	chr2:15731646	DDX1	0.42	5.47	0.33	1.09e-7	Wilms tumor;
KIRP	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.21	0.31	4.09e-7	Lung cancer;
KIRP	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg02336718	chr17:17403227	NA	-0.35	-5.49	-0.33	9.91e-8	Total body bone mineral density;
KIRP	cis	rs6973256	0.637	rs12539993	chr7:133418799	C/T	cg10665199	chr7:133106180	EXOC4	0.49	6.18	0.37	2.68e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.71	10.45	0.55	2.17e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.56	7.26	0.42	5.09e-12	Longevity;Endometriosis;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.48	-0.38	5.01e-10	Longevity;
KIRP	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.31	8.21	0.46	1.25e-14	Primary biliary cholangitis;
KIRP	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.81	-10.26	-0.55	8.78e-21	Menarche (age at onset);
KIRP	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.88	9.88	0.53	1.32e-19	Corneal astigmatism;
KIRP	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg05335186	chr13:53173507	NA	0.34	5.29	0.32	2.67e-7	Lewy body disease;
KIRP	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.63	6.43	0.38	6.76e-10	Eotaxin levels;
KIRP	cis	rs1355223	1.000	rs11607300	chr11:34759319	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.5	-5.81	-0.35	1.88e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17030434	0.954	rs11724154	chr4:154753108	G/T	cg14289246	chr4:154710475	SFRP2	-0.76	-9.42	-0.51	3.44e-18	Electrocardiographic conduction measures;
KIRP	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.79	8.76	0.49	3.17e-16	Diastolic blood pressure;
KIRP	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg02336718	chr17:17403227	NA	0.32	4.94	0.3	1.47e-6	Total body bone mineral density;
KIRP	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.76	10.42	0.55	2.77e-21	Sudden cardiac arrest;
KIRP	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg15704280	chr7:45808275	SEPT13	0.71	6.35	0.38	1.04e-9	Intraocular pressure;
KIRP	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.05	0.31	8.41e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.94	13.89	0.66	9.06e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.45	-6.69	-0.39	1.47e-10	Coronary artery disease;
KIRP	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	0.93	14.45	0.68	1.13e-34	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg09473613	chr1:24152604	HMGCL	0.46	5.98	0.36	7.84e-9	Immature fraction of reticulocytes;
KIRP	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	9.04	0.5	4.87e-17	Neuroticism;
KIRP	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg03647239	chr10:116582469	FAM160B1	0.52	6.01	0.36	6.8e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg06713675	chr4:122721982	EXOSC9	-0.64	-6.43	-0.38	6.5e-10	Type 2 diabetes;
KIRP	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg18944383	chr4:111397179	ENPEP	0.54	9.53	0.52	1.55e-18	Height;
KIRP	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	0.81	8.49	0.48	1.98e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg00919237	chr7:87102261	ABCB4	0.71	9.41	0.51	3.74e-18	Gallbladder cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26251401	chr19:36236539	PSENEN;U2AF1L4	-0.53	-6.48	-0.38	4.98e-10	Interleukin-4 levels;
KIRP	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-1.04	-9.43	-0.52	3.21e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg12940439	chr1:67600707	NA	0.39	5.93	0.35	1.02e-8	Psoriasis;
KIRP	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.72	9.43	0.52	3.11e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg12559939	chr2:27858050	GPN1	0.42	5.1	0.31	6.7e-7	Oral cavity cancer;
KIRP	cis	rs2274273	1.000	rs57970196	chr14:55600405	C/T	cg04306507	chr14:55594613	LGALS3	0.46	7.08	0.41	1.53e-11	Protein biomarker;
KIRP	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.75	-9.7	-0.53	4.8e-19	Multiple sclerosis;
KIRP	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26207909	chr14:103986467	CKB	0.78	12.23	0.61	3.41e-27	Body mass index;
KIRP	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.84	-12.83	-0.63	3.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.8	-13.52	-0.65	1.68e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg26816564	chr1:7831052	VAMP3	1.03	9.12	0.5	2.71e-17	Inflammatory bowel disease;
KIRP	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.38	-4.85	-0.3	2.23e-6	Carotid intima media thickness;
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.49	5.71	0.34	3.29e-8	Glycated hemoglobin levels;
KIRP	cis	rs7011507	1.000	rs79844130	chr8:49178852	G/A	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs16976116	0.855	rs28522816	chr15:55495114	C/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.6	-0.39	2.51e-10	Recombination measurement;
KIRP	cis	rs62109865	0.655	rs56133960	chr19:12593878	T/C	cg19721055	chr19:12753329	NA	-0.84	-4.96	-0.3	1.31e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.49	-5.06	-0.31	8.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7737355	1.000	rs30736	chr5:130724240	A/G	cg25547332	chr5:131281432	NA	-0.48	-5.4	-0.33	1.53e-7	Life satisfaction;
KIRP	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg02297831	chr4:17616191	MED28	0.61	7.68	0.44	3.72e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg09699651	chr6:150184138	LRP11	0.45	5.9	0.35	1.17e-8	Lung cancer;
KIRP	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.64	7.22	0.42	6.41e-12	Schizophrenia;
KIRP	trans	rs972578	0.677	rs7287107	chr22:43262513	A/G	cg15321293	chr3:36422198	STAC	-0.47	-6.13	-0.36	3.47e-9	Mean platelet volume;
KIRP	cis	rs654384	0.507	rs4723420	chr7:4174889	A/T	cg04612959	chr7:4183976	SDK1	0.29	4.86	0.3	2.11e-6	Positive affect;
KIRP	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg25547332	chr5:131281432	NA	0.47	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.6	0.44	6.19e-13	Educational attainment;
KIRP	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg04990556	chr1:26633338	UBXN11	0.68	6.39	0.38	8.31e-10	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.61	7.68	0.44	3.8e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.66	-12.44	-0.62	6.87e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.51	-5.8	-0.35	1.98e-8	Neuroticism;
KIRP	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg15252951	chr6:33757062	LEMD2	0.41	4.94	0.3	1.47e-6	Crohn's disease;
KIRP	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.65	9.67	0.52	6.12e-19	Neuroticism;
KIRP	cis	rs7267005	1.000	rs59740766	chr20:34453142	G/A	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg24874828	chr4:187887005	NA	0.49	7.19	0.42	7.7e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg20607798	chr8:58055168	NA	0.67	5.25	0.32	3.29e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	1.01	17.67	0.75	1.13e-45	Breast cancer;
KIRP	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-16.57	-0.73	6.43e-42	Height;
KIRP	cis	rs714515	0.934	rs2227198	chr1:172360164	A/G	cg01573306	chr1:172330400	DNM3	0.43	5.58	0.34	6.22e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs3540	0.513	rs2601182	chr15:90925430	A/T	cg22089800	chr15:90895588	ZNF774	0.61	8.4	0.47	3.53e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg20965017	chr5:231967	SDHA	-0.55	-6.3	-0.37	1.36e-9	Breast cancer;
KIRP	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg12549451	chr6:135224345	NA	-0.44	-5.41	-0.33	1.48e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg03433033	chr1:76189801	ACADM	-0.61	-8.41	-0.47	3.44e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg12292205	chr6:26970375	C6orf41	0.33	4.92	0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg05714579	chr10:131428358	MGMT	0.49	6.39	0.38	8.02e-10	Response to temozolomide;
KIRP	cis	rs930036	0.655	rs35381957	chr2:171937873	C/T	cg12801329	chr2:171670795	NA	0.43	4.89	0.3	1.85e-6	Menopause (age at onset);
KIRP	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24123712	chr3:49967161	MON1A	0.44	6.09	0.36	4.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9815354	1.000	rs1716683	chr3:41923074	A/G	cg03022575	chr3:42003672	ULK4	-0.48	-5.34	-0.32	2.09e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.77	-11.35	-0.59	2.76e-24	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.84	0.49	1.89e-16	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	cis	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg15590007	chr10:45870220	ALOX5	-0.57	-5.13	-0.31	5.88e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs12200782	1.000	rs41267923	chr6:26452947	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.14	-0.36	3.25e-9	Small cell lung carcinoma;
KIRP	cis	rs2273156	1.000	rs12888272	chr14:35425602	G/C	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.69	-0.34	3.54e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg24315340	chr6:146058215	EPM2A	0.43	5.46	0.33	1.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg03999872	chr20:62272968	STMN3	-0.56	-6.49	-0.38	4.57e-10	Atopic dermatitis;
KIRP	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.24	-4.98	-0.3	1.22e-6	Menarche (age at onset);
KIRP	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg13332499	chr17:408570	NA	0.59	8.78	0.49	2.87e-16	Hip circumference adjusted for BMI;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24859484	chr2:174830050	SP3	0.52	7.49	0.43	1.21e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg07843065	chr1:150265600	MRPS21	0.47	6.61	0.39	2.43e-10	Migraine;
KIRP	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg05791153	chr7:19748676	TWISTNB	0.64	5.9	0.35	1.21e-8	Thyroid stimulating hormone;
KIRP	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.51	5.22	0.32	3.81e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.9	11.65	0.6	2.82e-25	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.04	14.87	0.69	4.14e-36	Cognitive ability;
KIRP	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg15660573	chr17:549704	VPS53	0.57	7.2	0.42	7.33e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	5.58	0.34	6.39e-8	Longevity;
KIRP	cis	rs2281603	0.570	rs10133848	chr14:64948489	T/A	cg01860774	chr14:64969374	ZBTB25	0.33	5.49	0.33	1e-7	Lymphocyte counts;
KIRP	cis	rs7551222	0.614	rs4951385	chr1:204454165	C/T	cg20240347	chr1:204465584	NA	-0.42	-7.54	-0.43	8.86e-13	Schizophrenia;
KIRP	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg04132472	chr17:19861366	AKAP10	-0.38	-4.97	-0.3	1.25e-6	Schizophrenia;
KIRP	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.81	12.51	0.62	4.09e-28	Height;
KIRP	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg15252951	chr6:33757062	LEMD2	0.48	5.74	0.34	2.76e-8	Crohn's disease;
KIRP	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	6.02	0.36	6.31e-9	Motion sickness;
KIRP	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.24	13.65	0.66	5.98e-32	Uric acid levels;
KIRP	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.31	-0.7	1.29e-37	Alzheimer's disease;
KIRP	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg05717871	chr11:638507	DRD4	-0.39	-5.59	-0.34	6.04e-8	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3768617	0.811	rs10911200	chr1:182998377	T/C	cg12689670	chr1:183009347	LAMC1	0.58	8.08	0.46	2.87e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.5	6.59	0.39	2.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12667521	chr19:29218732	NA	0.56	5.37	0.32	1.84e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7539542	0.529	rs66898765	chr1:202867769	A/G	cg19681188	chr1:202830198	LOC148709	-0.47	-5.08	-0.31	7.35e-7	Mean platelet volume;
KIRP	trans	rs6601327	0.665	rs4841218	chr8:9653902	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.16	-0.42	9.57e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7215564	0.818	rs1531946	chr17:78630807	G/A	cg06153925	chr17:78755379	RPTOR	0.49	6.45	0.38	5.99e-10	Myopia (pathological);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07001901	chr16:81813363	PLCG2	0.45	6.03	0.36	6.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg07884673	chr3:53033167	SFMBT1	0.98	7.6	0.44	6.35e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7715806	0.500	rs17563995	chr5:75007556	A/G	cg19683494	chr5:74908142	NA	0.52	5.24	0.32	3.37e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.71	-10.51	-0.56	1.41e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7225151	0.710	rs112888134	chr17:5247732	C/A	cg24500398	chr17:5266808	RABEP1	-0.6	-5.94	-0.35	9.81e-9	Alzheimer's disease (late onset);
KIRP	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	5.05e-11	Aortic root size;
KIRP	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.79	12.08	0.61	1.07e-26	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.27	24.92	0.85	2.98e-69	IgG glycosylation;
KIRP	cis	rs7113874	1.000	rs7113874	chr11:8688016	C/T	cg08015107	chr11:8618950	NA	-0.35	-4.87	-0.3	1.96e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.78	-9.4	-0.51	4.03e-18	Morning vs. evening chronotype;
KIRP	cis	rs1881396	0.945	rs1881397	chr2:27832285	A/G	cg27432699	chr2:27873401	GPN1	0.55	6.62	0.39	2.28e-10	Nonalcoholic fatty liver disease;
KIRP	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11622362	chr11:34938112	PDHX;APIP	-0.46	-5.77	-0.35	2.41e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.58	-0.39	2.79e-10	Diastolic blood pressure;
KIRP	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg21360079	chr12:107162445	NA	-0.64	-9.03	-0.5	5.1e-17	Heart rate;
KIRP	cis	rs427941	0.595	rs6465851	chr7:101827463	A/C	cg06246474	chr7:101738831	CUX1	0.51	6.13	0.36	3.49e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2290402	0.536	rs56253935	chr4:853871	A/T	cg00846425	chr4:957561	DGKQ	-0.5	-5.38	-0.32	1.76e-7	Type 2 diabetes;
KIRP	cis	rs6450176	0.564	rs381024	chr5:53326234	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-8.69	-0.48	5.24e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg00738919	chr7:1100172	C7orf50	0.42	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	5.58	0.34	6.18e-8	Platelet count;
KIRP	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.79	-9.04	-0.5	4.78e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.44	5.61	0.34	5.42e-8	Crohn's disease;
KIRP	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.37e-10	Subjective well-being;
KIRP	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.26	0.47	9.01e-15	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25485084	chr12:118809325	TAOK3	0.5	6.72	0.39	1.25e-10	Smoking initiation;
KIRP	cis	rs2315504	0.509	rs3760335	chr17:39026061	T/A	cg05063374	chr17:38953512	KRT28	-0.38	-5.14	-0.31	5.54e-7	Height;
KIRP	cis	rs6893807	1.000	rs1422191	chr5:87949158	G/A	cg24804195	chr5:87968844	LOC645323	0.53	5.59	0.34	5.96e-8	Body mass index;
KIRP	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.47	0.48	2.24e-15	Morning vs. evening chronotype;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg03190020	chr2:202645957	ALS2	0.52	6.03	0.36	6.07e-9	Educational attainment;
KIRP	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.74	-10.41	-0.55	2.9e-21	Fibrinogen levels;
KIRP	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.43	-5.47	-0.33	1.11e-7	Schizophrenia;
KIRP	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.61	-9.8	-0.53	2.43e-19	Vitamin D levels;
KIRP	cis	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20621674	chr13:56188634	NA	0.32	5.18	0.31	4.62e-7	Warfarin maintenance dose;
KIRP	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-9.45	-0.52	2.84e-18	Morning vs. evening chronotype;
KIRP	cis	rs78487399	0.908	rs61271889	chr2:43825436	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.14	-0.31	5.5e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs12431939	1.000	rs60593258	chr14:51662280	T/A	cg23942311	chr14:51606299	NA	-0.57	-5.62	-0.34	5.23e-8	Cancer;
KIRP	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg01990225	chr2:97406019	LMAN2L	-1.08	-7.22	-0.42	6.36e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7751419	0.675	rs6458096	chr6:39107698	C/T	cg08089693	chr6:39098871	NA	-0.68	-9.76	-0.53	3.22e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg02487422	chr3:49467188	NICN1	0.4	5.2	0.31	4.24e-7	Resting heart rate;
KIRP	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg26681399	chr22:41777847	TEF	-0.49	-5.49	-0.33	1.02e-7	Vitiligo;
KIRP	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg24399712	chr22:39784796	NA	0.5	7.24	0.42	5.76e-12	IgG glycosylation;
KIRP	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.49	-0.78	8.58e-52	Height;
KIRP	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg23172400	chr8:95962367	TP53INP1	-0.27	-5.26	-0.32	3.17e-7	Type 2 diabetes;
KIRP	cis	rs7534824	0.625	rs58234233	chr1:101510440	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.94	7.46	0.43	1.46e-12	Refractive astigmatism;
KIRP	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.76	9.66	0.52	6.35e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg21698718	chr17:80085957	CCDC57	0.37	5.4	0.33	1.58e-7	Life satisfaction;
KIRP	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.83	13.38	0.65	4.83e-31	Metabolic syndrome;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16139199	chr18:19180362	ESCO1	0.58	6.91	0.4	4.09e-11	Smoking initiation;
KIRP	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg02297831	chr4:17616191	MED28	0.61	7.82	0.45	1.54e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.5	8.88	0.49	1.41e-16	Vitiligo;
KIRP	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.5	-6.21	-0.37	2.23e-9	Post bronchodilator FEV1;
KIRP	cis	rs600806	0.745	rs12136063	chr1:110014170	A/G	cg02175308	chr1:109941060	SORT1	0.28	5.22	0.32	3.72e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7542091	0.669	rs7540534	chr1:210044824	A/T	cg05527609	chr1:210001259	C1orf107	-0.37	-4.94	-0.3	1.47e-6	Monobrow;
KIRP	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1866706	0.896	rs6486062	chr11:12860618	C/T	cg25843174	chr11:12811716	TEAD1	-0.31	-5.11	-0.31	6.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.52	-0.62	3.73e-28	Alzheimer's disease;
KIRP	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.1	0.36	4.12e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4430311	1.000	rs2953328	chr1:244023680	C/T	cg25706552	chr1:244017396	NA	-0.59	-9.42	-0.51	3.5e-18	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	cis	rs2411233	1.000	rs2117207	chr15:39289254	C/T	cg02291532	chr15:39874776	THBS1	0.37	5.08	0.31	7.43e-7	Platelet count;
KIRP	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg26531700	chr6:26746687	NA	0.47	6.69	0.39	1.47e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3857536	0.654	rs9342541	chr6:66977595	G/A	cg07460842	chr6:66804631	NA	-0.46	-5.42	-0.33	1.4e-7	Blood trace element (Cu levels);
KIRP	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg00409905	chr10:38381863	ZNF37A	0.46	4.88	0.3	1.88e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg19695335	chr20:25604759	NANP	1.03	6.89	0.4	4.61e-11	P wave terminal force;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00605358	chr12:89747739	DUSP6	0.59	6.8	0.4	7.77e-11	Smoking initiation;
KIRP	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.85	0.4	5.8200000000000003e-11	Aortic root size;
KIRP	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.88	12.59	0.63	2.22e-28	Mean platelet volume;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.67	10.26	0.55	8.37e-21	Monocyte percentage of white cells;
KIRP	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	6.05	0.36	5.39e-9	Response to antipsychotic treatment;
KIRP	cis	rs7523050	0.730	rs12079547	chr1:109469314	A/C	cg08274380	chr1:109419600	GPSM2	0.81	7.35	0.42	2.89e-12	Fat distribution (HIV);
KIRP	cis	rs12431939	1.000	rs58225416	chr14:51662196	C/T	cg23942311	chr14:51606299	NA	-0.57	-4.99	-0.3	1.16e-6	Cancer;
KIRP	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.7	9.21	0.51	1.52e-17	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.74	-10.21	-0.55	1.28e-20	Dental caries;
KIRP	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-8.05	-0.46	3.43e-14	Height;
KIRP	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	7.11	0.41	1.26e-11	Eye color traits;
KIRP	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.0	-0.41	2.47e-11	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg19274270	chr17:78178856	CARD14	0.36	6.68	0.39	1.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg05072774	chr3:49840536	C3orf54	-0.42	-4.9	-0.3	1.74e-6	Resting heart rate;
KIRP	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05220968	chr6:146057943	EPM2A	0.38	4.87	0.3	2.03e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg10523679	chr1:76189770	ACADM	-0.53	-7.62	-0.44	5.64e-13	Daytime sleep phenotypes;
KIRP	cis	rs8084125	1.000	rs871830	chr18:74953607	G/C	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.6	-9.83	-0.53	1.83e-19	Prostate cancer;
KIRP	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.68	9.81	0.53	2.16e-19	Multiple myeloma (IgH translocation);
KIRP	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg19507638	chr5:93509721	C5orf36	-0.59	-5.31	-0.32	2.47e-7	Diabetic retinopathy;
KIRP	cis	rs240764	0.817	rs239249	chr6:101087081	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.55	0.33	7.22e-8	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09246302	chr7:112121036	C7orf53	0.47	6.16	0.37	3.01e-9	Interleukin-4 levels;
KIRP	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-6.86	-0.4	5.56e-11	Body mass index;
KIRP	cis	rs16912285	0.892	rs75859717	chr11:24346313	G/A	ch.11.24196551F	chr11:24239977	NA	0.71	4.87	0.3	2e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7923609	0.902	rs4633333	chr10:65328539	C/G	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.19	-0.31	4.39e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.5	6.88	0.4	4.87e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg06223162	chr1:101003688	GPR88	-0.42	-8.67	-0.48	6.04e-16	Monocyte count;
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.5	-0.33	9.37e-8	Life satisfaction;
KIRP	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.51e-10	Aortic root size;
KIRP	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg01028140	chr2:1542097	TPO	-0.71	-6.99	-0.41	2.55e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs490234	0.702	rs1339499	chr9:128406453	T/C	cg14078157	chr9:128172775	NA	-0.63	-7.3	-0.42	4e-12	Mean arterial pressure;
KIRP	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg01631408	chr1:248437212	OR2T33	-0.72	-9.56	-0.52	1.25e-18	Common traits (Other);
KIRP	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.45	-0.33	1.2e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9761603	0.774	rs9685307	chr4:138411527	C/G	cg12033966	chr4:138453416	PCDH18	0.43	5.63	0.34	4.98e-8	Diastolic blood pressure;
KIRP	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.6	-0.34	5.78e-8	Bipolar disorder;
KIRP	cis	rs7116495	0.609	rs949324	chr11:71714526	G/C	cg10381502	chr11:71823885	C11orf51	-1.06	-7.41	-0.43	1.97e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	11.17	0.58	1.06e-23	Body mass index (adult);
KIRP	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.07e-9	Schizophrenia;
KIRP	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.91	-0.35	1.12e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2882667	1.000	rs10064130	chr5:138309307	C/T	cg04439458	chr5:138467593	SIL1	-0.46	-7.12	-0.41	1.22e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1345301	0.518	rs1558624	chr2:102862233	A/G	cg12451869	chr2:102867685	NA	0.46	6.8	0.4	7.97e-11	Waist circumference;
KIRP	cis	rs42648	0.564	rs39284	chr7:89791981	T/C	cg25739043	chr7:89950458	NA	-0.39	-6.04	-0.36	5.69e-9	Homocysteine levels;
KIRP	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg11965913	chr1:205819406	PM20D1	0.49	5.63	0.34	4.97e-8	Parkinson's disease;
KIRP	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg10224037	chr5:178157518	ZNF354A	0.87	10.32	0.55	5.75e-21	Neutrophil percentage of white cells;
KIRP	cis	rs12765878	0.756	rs6584579	chr10:105645725	A/G	cg11005552	chr10:105648138	OBFC1	-0.39	-5.35	-0.32	2.01e-7	Coronary artery disease;
KIRP	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.08	-0.36	4.67e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.78	-0.44	2.05e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg11693508	chr17:37793320	STARD3	0.49	6.67	0.39	1.68e-10	Neuroticism;
KIRP	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg27205649	chr11:78285834	NARS2	0.68	9.11	0.5	3.05e-17	Alzheimer's disease (survival time);
KIRP	cis	rs6832769	0.961	rs13128582	chr4:56328944	C/G	cg09317128	chr4:56265301	TMEM165	0.55	7.44	0.43	1.63e-12	Personality dimensions;
KIRP	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg21132104	chr15:45694354	SPATA5L1	0.59	7.29	0.42	4.32e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.32	5.77	0.35	2.36e-8	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
KIRP	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.62	7.09	0.41	1.4e-11	Height;
KIRP	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg13318129	chr22:45737514	FAM118A	0.59	6.69	0.39	1.49e-10	Tonsillectomy;
KIRP	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.69	-8.12	-0.46	2.2e-14	Blood protein levels;
KIRP	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.61	8.25	0.47	9.95e-15	Total body bone mineral density;
KIRP	cis	rs10465746	0.746	rs12749350	chr1:84456948	T/A	cg10977910	chr1:84465055	TTLL7	0.58	7.19	0.42	7.59e-12	Obesity-related traits;
KIRP	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.32	-0.32	2.28e-7	Neuroticism;
KIRP	cis	rs710987	1.000	rs710985	chr5:3529983	C/T	cg14530963	chr5:3489551	NA	0.41	5.02	0.3	1.01e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs1978968	1.000	rs13053667	chr22:18443404	G/A	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs12476592	0.602	rs262482	chr2:63877042	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs42648	0.564	rs11563340	chr7:89809579	A/G	cg25739043	chr7:89950458	NA	-0.39	-6.04	-0.36	5.57e-9	Homocysteine levels;
KIRP	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.28e-7	Schizophrenia;
KIRP	cis	rs8133932	0.554	rs11089028	chr21:47298312	T/C	cg11214348	chr21:47283868	PCBP3	0.46	5.27	0.32	3.04e-7	Schizophrenia;
KIRP	cis	rs16828019	0.929	rs8179465	chr1:41701747	C/T	cg03387723	chr1:41708464	SCMH1	-0.77	-6.81	-0.4	7.41e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-9.02	-0.5	5.47e-17	Morning vs. evening chronotype;
KIRP	trans	rs972578	0.715	rs4820491	chr22:43261065	C/G	cg15321293	chr3:36422198	STAC	-0.49	-6.31	-0.37	1.26e-9	Mean platelet volume;
KIRP	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.48	8.26	0.47	9.13e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs397969	0.646	rs203467	chr17:19809749	C/T	cg13482628	chr17:19912719	NA	0.5	5.49	0.33	9.95e-8	Platelet count;
KIRP	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg21918786	chr6:109611834	NA	-0.39	-5.41	-0.33	1.51e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs13401104	0.755	rs55787207	chr2:237106584	A/T	cg19324714	chr2:237145437	ASB18	0.47	4.87	0.3	1.99e-6	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18021506	chr2:219271208	NA	0.51	6.2	0.37	2.42e-9	Parkinson's disease;
KIRP	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs5756391	0.546	rs4821560	chr22:37311806	G/T	cg16356956	chr22:37317934	CSF2RB	-0.4	-5.52	-0.33	8.51e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs11955175	1.000	rs11953977	chr5:40674690	G/C	cg05478818	chr5:40835740	RPL37	0.7	5.44	0.33	1.32e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12476592	0.602	rs6708804	chr2:63807269	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-4.95	-0.3	1.39e-6	Childhood ear infection;
KIRP	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-0.98	-9.56	-0.52	1.25e-18	Hip circumference adjusted for BMI;
KIRP	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.42	-0.43	1.92e-12	Triglycerides;
KIRP	cis	rs6142102	0.625	rs6142051	chr20:32533018	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.36	0.32	1.96e-7	Skin pigmentation;
KIRP	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.52	4.85	0.3	2.14e-6	Height;
KIRP	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.7	-13.0	-0.64	9.4e-30	Body mass index;
KIRP	cis	rs9400467	0.528	rs465796	chr6:111619725	T/G	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-5.15	-0.31	5.37e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9533799	1.000	rs2282064	chr13:44805870	G/A	cg19190762	chr13:44806055	NA	0.62	8.41	0.47	3.45e-15	Amyotrophic lateral sclerosis;
KIRP	trans	rs12431410	0.536	rs10148598	chr14:60147659	C/T	cg20601314	chr10:104179541	FBXL15;PSD	-0.58	-6.16	-0.37	2.91e-9	Schizophrenia;
KIRP	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg25486957	chr4:152246857	NA	-0.43	-5.01	-0.3	1.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg24315340	chr6:146058215	EPM2A	-0.43	-5.35	-0.32	2e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.63	5.19	0.31	4.44e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg25486957	chr4:152246857	NA	-0.5	-5.44	-0.33	1.3e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg16650896	chr7:64838774	ZNF92	-0.54	-6.89	-0.4	4.75e-11	Neuroticism;
KIRP	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.92	13.55	0.65	1.25e-31	Menopause (age at onset);
KIRP	cis	rs9311676	0.656	rs11130632	chr3:58369324	C/T	cg06643156	chr3:58380774	PXK	0.35	4.97	0.3	1.24e-6	Systemic lupus erythematosus;
KIRP	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg25390334	chr2:241827778	C2orf54	-0.34	-4.86	-0.3	2.08e-6	Urinary metabolites;
KIRP	cis	rs7487075	0.751	rs10880947	chr12:46677284	A/T	cg09050775	chr12:46762708	SLC38A2	0.38	5.0	0.3	1.11e-6	Itch intensity from mosquito bite;
KIRP	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.73	0.44	2.75e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.55	-0.33	7.34e-8	Neuroticism;
KIRP	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.7	10.19	0.54	1.45e-20	Lymphocyte counts;
KIRP	cis	rs41563	0.557	rs17777642	chr7:104599208	G/A	cg04380332	chr7:105027541	SRPK2	-0.47	-7.08	-0.41	1.52e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs710913	0.618	rs11206437	chr1:40078711	A/C	cg27567593	chr1:39956653	BMP8A	-0.36	-5.0	-0.3	1.09e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.63	6.3	0.37	1.37e-9	Eotaxin levels;
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg09264619	chr17:80180166	NA	-0.37	-5.42	-0.33	1.45e-7	Life satisfaction;
KIRP	trans	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	1.02	15.78	0.71	3.14e-39	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.61	-6.92	-0.4	3.84e-11	Hypertension (SNP x SNP interaction);
KIRP	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg06521331	chr12:34319734	NA	-0.47	-6.01	-0.36	6.8e-9	Morning vs. evening chronotype;
KIRP	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg26875233	chr11:93583750	C11orf90	-0.4	-7.56	-0.43	8.21e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs4938303	0.633	rs61906104	chr11:116550115	A/G	cg13754915	chr9:140174272	C9orf167	-0.73	-6.17	-0.37	2.79e-9	Triglycerides;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19429466	chr4:87515395	PTPN13	0.44	6.01	0.36	6.5e-9	Survival in pancreatic cancer;
KIRP	cis	rs501120	0.810	rs607592	chr10:44750215	A/G	cg09554077	chr10:44749378	NA	0.74	12.39	0.62	1.01e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19524238	chr7:2802976	GNA12	-0.36	-5.04	-0.31	8.92e-7	Height;
KIRP	cis	rs2970992	0.728	rs1543104	chr2:101326226	T/C	cg01042948	chr2:101319752	NA	0.41	5.79	0.35	2.17e-8	Educational attainment;
KIRP	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.5	12.13	0.61	7.45e-27	Airflow obstruction;
KIRP	cis	rs62109865	0.529	rs62111791	chr19:12588501	C/G	cg19721055	chr19:12753329	NA	-0.84	-4.96	-0.3	1.31e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg07395648	chr5:131743802	NA	-0.38	-5.26	-0.32	3.18e-7	Acylcarnitine levels;
KIRP	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg26412358	chr1:26503933	CNKSR1	0.42	5.71	0.34	3.22e-8	Height;
KIRP	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg01028140	chr2:1542097	TPO	-0.6	-6.09	-0.36	4.31e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg10617943	chr7:1981403	MAD1L1	-0.36	-4.97	-0.3	1.28e-6	Neuroticism;
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07402062	chr16:89894098	SPIRE2	0.31	6.62	0.39	2.28e-10	Vitiligo;
KIRP	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.34	-0.37	1.1e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10782582	0.609	rs112205173	chr1:76310100	C/T	cg10523679	chr1:76189770	ACADM	-0.47	-6.28	-0.37	1.51e-9	Daytime sleep phenotypes;
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.81	13.09	0.64	4.61e-30	Vitiligo;
KIRP	cis	rs258892	1.000	rs258892	chr5:72305846	A/C	cg21869765	chr5:72125136	TNPO1	-0.51	-6.3	-0.37	1.4e-9	Small cell lung carcinoma;
KIRP	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	1e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.52	5.73	0.34	2.94e-8	Lung cancer;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg23594656	chr7:65796392	TPST1	-0.33	-4.85	-0.3	2.23e-6	Aortic root size;
KIRP	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	7.58	0.43	7.22e-13	Lung cancer;
KIRP	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.08	0.36	4.57e-9	Educational attainment;
KIRP	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.78	0.4	9.1e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.72	12.63	0.63	1.62e-28	Lung cancer;
KIRP	cis	rs28834970	0.925	rs6987305	chr8:27208126	G/A	cg07216194	chr8:27182965	PTK2B	-0.43	-5.37	-0.32	1.85e-7	Alzheimer's disease (late onset);
KIRP	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07343612	chr16:622815	PIGQ	-0.51	-5.81	-0.35	1.88e-8	Height;
KIRP	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg03757805	chr13:111521981	C13orf29	-0.37	-6.2	-0.37	2.41e-9	Sitting height ratio;
KIRP	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg17644776	chr2:200775616	C2orf69	0.63	5.66	0.34	4.12e-8	Schizophrenia;
KIRP	cis	rs73200209	0.744	rs17426718	chr12:116599676	A/C	cg01776926	chr12:116560359	MED13L	-0.52	-5.87	-0.35	1.37e-8	Total body bone mineral density;
KIRP	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.58e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.86	-0.4	5.64e-11	Height;
KIRP	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs4950322	0.570	rs80270233	chr1:146734978	C/G	cg22381352	chr1:146742008	CHD1L	-0.47	-5.51	-0.33	9.25e-8	Protein quantitative trait loci;
KIRP	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg01988459	chr11:68622903	NA	-0.43	-5.82	-0.35	1.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.36	-0.42	2.76e-12	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.26e-15	Motion sickness;
KIRP	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg27124370	chr19:33622961	WDR88	0.6	7.43	0.43	1.84e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.77	14.58	0.68	3.87e-35	Lymphocyte counts;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.0	0.36	6.88e-9	Height;
KIRP	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.65	6.33	0.37	1.18e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.69	-8.57	-0.48	1.15e-15	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08652369	chr3:66429805	LRIG1	0.52	6.38	0.38	8.85e-10	Interleukin-4 levels;
KIRP	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.79	9.05	0.5	4.5e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.84	10.08	0.54	3.21e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg21361702	chr7:150065534	REPIN1	0.61	5.89	0.35	1.29e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg10756647	chr7:56101905	PSPH	0.97	7.2	0.42	7.51e-12	Diabetic kidney disease;
KIRP	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.44	-6.13	-0.36	3.5e-9	Lung cancer;
KIRP	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg10189774	chr4:17578691	LAP3	0.45	5.4	0.33	1.6e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.43	5.3	0.32	2.58e-7	IgG glycosylation;
KIRP	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.61	-7.56	-0.43	8.1e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06481639	chr22:41940642	POLR3H	0.71	7.25	0.42	5.26e-12	Vitiligo;
KIRP	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05220968	chr6:146057943	EPM2A	0.41	5.28	0.32	2.9e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs963731	0.649	rs2924714	chr2:39333288	A/G	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.35	0.7	9.06e-38	Chronic sinus infection;
KIRP	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs8038465	0.874	rs2291013	chr15:74000506	T/G	cg15420318	chr15:73925796	NPTN	0.51	6.52	0.38	4.02e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-6.75	-0.4	1.04e-10	Response to antipsychotic treatment;
KIRP	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.51	-0.33	9.05e-8	Bipolar disorder;
KIRP	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.56	6.49	0.38	4.75e-10	Myopia (pathological);
KIRP	cis	rs3736485	0.966	rs11070852	chr15:51782294	G/T	cg14296394	chr15:51910925	DMXL2	-0.39	-5.91	-0.35	1.16e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.73	9.28	0.51	8.88e-18	Resting heart rate;
KIRP	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.26	-0.47	8.74e-15	Response to antipsychotic treatment;
KIRP	cis	rs933360	0.585	rs7785908	chr7:50833567	T/C	cg14240098	chr7:50518052	FIGNL1	0.43	4.92	0.3	1.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs2273669	0.667	rs12208578	chr6:109369745	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-6.05	-0.36	5.5e-9	Prostate cancer;
KIRP	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-6.12	-0.36	3.64e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14052593	chr10:75490264	BMS1P4	-0.42	-6.07	-0.36	4.82e-9	Survival in pancreatic cancer;
KIRP	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg13414629	chr9:132935646	FREQ	0.53	7.0	0.41	2.36e-11	Alzheimer's disease (cognitive decline);
KIRP	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.14	-0.31	5.47e-7	Fear of minor pain;
KIRP	trans	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.76e-11	Diabetic kidney disease;
KIRP	trans	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg06521331	chr12:34319734	NA	-0.54	-6.59	-0.39	2.69e-10	Heart rate;
KIRP	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.67	-7.42	-0.43	1.87e-12	Gut microbiome composition (summer);
KIRP	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.65	8.37	0.47	4.31e-15	Height;
KIRP	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.98	0.36	7.94e-9	Depressive symptoms;
KIRP	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.64	-7.68	-0.44	3.76e-13	Metabolic traits;
KIRP	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg04034577	chr2:241836375	C2orf54	-0.27	-5.25	-0.32	3.31e-7	Urinary metabolites;
KIRP	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.51	-6.21	-0.37	2.19e-9	Iron status biomarkers;
KIRP	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-8.05	-0.46	3.59e-14	Morning vs. evening chronotype;
KIRP	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg25182066	chr10:30743637	MAP3K8	0.61	7.44	0.43	1.67e-12	Inflammatory bowel disease;
KIRP	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.8	-0.53	2.34e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-7.72	-0.44	3e-13	Bipolar disorder;
KIRP	cis	rs7714584	1.000	rs75071288	chr5:150224379	C/T	cg22134413	chr5:150180641	NA	0.57	5.08	0.31	7.4e-7	Crohn's disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg19729279	chr5:133861951	PHF15	-0.49	-6.29	-0.37	1.45e-9	Neuroticism;
KIRP	cis	rs9815354	1.000	rs73069392	chr3:41787009	C/T	cg03022575	chr3:42003672	ULK4	0.63	6.84	0.4	6.38e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.41	-0.38	7.33e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-4.93	-0.3	1.54e-6	Ulcerative colitis;
KIRP	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg08501292	chr6:25962987	TRIM38	0.77	5.36	0.32	1.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12643440	0.585	rs601517	chr4:17167630	T/C	cg22650099	chr4:17144496	NA	0.49	5.94	0.35	9.8e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg22906224	chr7:99728672	NA	0.47	5.63	0.34	5.02e-8	Coronary artery disease;
KIRP	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.69	10.3	0.55	6.31e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.58	4.94	0.3	1.44e-6	Initial pursuit acceleration;
KIRP	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg02187348	chr16:89574699	SPG7	0.45	5.58	0.34	6.27e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg21698718	chr17:80085957	CCDC57	-0.34	-4.88	-0.3	1.89e-6	Life satisfaction;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg20913106	chr8:38324522	FGFR1	-0.53	-6.91	-0.4	4.08e-11	Type 1 diabetes nephropathy;
KIRP	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	5.22	0.32	3.77e-7	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01363902	chr12:121022439	NA	0.51	6.58	0.39	2.75e-10	Smoking initiation;
KIRP	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg13293535	chr8:11597251	GATA4	-0.41	-5.11	-0.31	6.32e-7	Retinal vascular caliber;
KIRP	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg02023728	chr11:77925099	USP35	0.3	4.91	0.3	1.69e-6	Alzheimer's disease (survival time);
KIRP	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg01529538	chr14:23388837	RBM23	0.42	5.29	0.32	2.68e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs3858145	0.588	rs4142048	chr10:70044031	T/C	cg04882175	chr6:131122610	NA	-0.61	-6.96	-0.41	3.12e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.72	8.66	0.48	6.42e-16	Alcohol dependence;
KIRP	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.7	-11.12	-0.58	1.51e-23	Hepatocellular carcinoma;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg17294928	chr15:75287854	SCAMP5	0.58	7.75	0.44	2.4e-13	Breast cancer;
KIRP	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.55	-6.32	-0.37	1.25e-9	Initial pursuit acceleration;
KIRP	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs4132509	0.947	rs10927039	chr1:243721726	C/T	cg25706552	chr1:244017396	NA	-0.52	-6.81	-0.4	7.25e-11	RR interval (heart rate);
KIRP	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.42	5.36	0.32	1.91e-7	Aortic root size;
KIRP	cis	rs1629083	0.654	rs648682	chr11:118066582	T/C	cg18857871	chr11:118064634	AMICA1	0.74	10.66	0.56	4.67e-22	Lung cancer;
KIRP	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg21972741	chr5:435613	AHRR	0.5	6.09	0.36	4.42e-9	Cystic fibrosis severity;
KIRP	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.57	0.39	3.03e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25471413	chr8:103424494	UBR5	-0.49	-6.07	-0.36	4.7e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4389656	1.000	rs11951576	chr5:6731413	C/T	cg10857441	chr5:6722123	POLS	0.46	5.81	0.35	1.95e-8	Coronary artery disease;
KIRP	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.4	-6.43	-0.38	6.44e-10	Body mass index;
KIRP	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	1.19	11.06	0.58	2.47e-23	Lymphocyte counts;
KIRP	cis	rs7221595	0.825	rs8076743	chr17:3916537	A/T	cg11204139	chr17:3907470	NA	0.63	6.24	0.37	1.94e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	8.28	0.47	7.76e-15	Lymphocyte percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22112179	chr15:66084820	DENND4A	0.48	7.12	0.41	1.17e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.66	7.91	0.45	8.9e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2411233	0.967	rs1347270	chr15:39286543	C/T	cg02291532	chr15:39874776	THBS1	0.36	4.85	0.3	2.21e-6	Platelet count;
KIRP	cis	rs6484504	0.625	rs1535741	chr11:31375072	T/C	cg26647111	chr11:31128758	NA	0.44	5.1	0.31	6.66e-7	Red blood cell count;
KIRP	cis	rs12580194	0.593	rs74844018	chr12:55766871	G/A	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg23594656	chr7:65796392	TPST1	0.46	7.27	0.42	4.84e-12	Aortic root size;
KIRP	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.82	10.31	0.55	5.85e-21	Blood protein levels;
KIRP	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg14541582	chr5:601475	NA	-0.55	-6.12	-0.36	3.63e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.65	8.35	0.47	5.02e-15	Red blood cell count;
KIRP	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-6.08	-0.36	4.58e-9	Bipolar disorder;
KIRP	cis	rs860295	0.702	rs10796945	chr1:155427688	G/A	cg02153340	chr1:155202674	NA	-0.52	-7.48	-0.43	1.32e-12	Body mass index;
KIRP	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.14	19.27	0.78	4.68e-51	Cognitive function;
KIRP	cis	rs6893300	0.785	rs58386410	chr5:179205704	T/C	cg14593053	chr5:179126677	CANX	-0.57	-7.19	-0.42	7.81e-12	Resting heart rate;
KIRP	cis	rs17065868	1.000	rs9533924	chr13:45169705	C/T	cg10246903	chr13:45222710	NA	0.77	6.71	0.39	1.3100000000000001e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.36	-0.47	4.71e-15	Total cholesterol levels;
KIRP	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.74	10.69	0.56	3.61e-22	Schizophrenia;
KIRP	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	1.06	12.23	0.61	3.54e-27	Vitiligo;
KIRP	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.4	6.6	0.39	2.46e-10	Electroencephalogram traits;
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg07701084	chr6:150067640	NUP43	0.75	10.3	0.55	6.55e-21	Lung cancer;
KIRP	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg21775007	chr8:11205619	TDH	-0.39	-5.15	-0.31	5.4e-7	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-5.6	-0.34	5.85e-8	Aortic root size;
KIRP	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	8.76	0.49	3.3e-16	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs1699337	0.502	rs796290	chr3:12449683	C/G	cg02700894	chr3:12045449	SYN2	-0.37	-5.06	-0.31	8.19e-7	Cholesterol, total;
KIRP	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg13147721	chr7:65941812	NA	-0.99	-6.77	-0.4	9.56e-11	Diabetic kidney disease;
KIRP	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.49	5.39	0.33	1.65e-7	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg08662619	chr6:150070041	PCMT1	0.39	6.61	0.39	2.35e-10	Lung cancer;
KIRP	cis	rs12476592	0.571	rs68183503	chr2:63802888	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.27	-16.27	-0.72	6.67e-41	Breast cancer;
KIRP	trans	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg24644049	chr4:85504048	CDS1	0.95	6.94	0.4	3.4e-11	Skin colour saturation;
KIRP	cis	rs2041895	0.527	rs10861681	chr12:107334262	C/T	cg15890332	chr12:107067104	RFX4	0.35	5.07	0.31	7.7300000000000005e-07	Glaucoma (low intraocular pressure);
KIRP	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg24375607	chr4:120327624	NA	-0.58	-6.82	-0.4	6.89e-11	Corneal astigmatism;
KIRP	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.51	5.36	0.32	1.87e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg05347473	chr6:146136440	FBXO30	-0.56	-7.76	-0.44	2.34e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.67	0.66	4.91e-32	Smoking behavior;
KIRP	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg09795085	chr6:101329169	ASCC3	0.51	6.27	0.37	1.57e-9	Neuroticism;
KIRP	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg05562828	chr17:3906858	NA	0.49	6.38	0.38	8.87e-10	Type 2 diabetes;
KIRP	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.75	-9.86	-0.53	1.54e-19	Huntington's disease progression;
KIRP	cis	rs1570884	0.767	rs3751384	chr13:50123622	G/C	cg08779649	chr13:50194554	NA	0.49	6.9	0.4	4.36e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.1	0.46	2.56e-14	Aortic root size;
KIRP	cis	rs282587	0.542	rs282563	chr13:113374551	C/T	cg04656015	chr13:113407548	ATP11A	-0.63	-7.16	-0.42	9.08e-12	Glycated hemoglobin levels;
KIRP	cis	rs6546886	0.912	rs7587991	chr2:74297288	C/T	cg14702570	chr2:74259524	NA	-0.27	-5.32	-0.32	2.36e-7	Dialysis-related mortality;
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.8	-10.8	-0.57	1.66e-22	Longevity;
KIRP	cis	rs9393813	0.528	rs9468141	chr6:27474527	C/T	cg03332623	chr6:27441972	ZNF184	-0.34	-5.01	-0.3	1.05e-6	Bipolar disorder;
KIRP	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.58	7.82	0.45	1.55e-13	White matter hyperintensity burden;
KIRP	cis	rs12330322	0.521	rs9832668	chr3:72399093	G/A	cg05607079	chr3:72387937	NA	0.39	5.16	0.31	5.11e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg04804543	chr8:142233427	SLC45A4	-0.75	-9.47	-0.52	2.43e-18	Immature fraction of reticulocytes;
KIRP	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.91	11.64	0.6	3.13e-25	Homoarginine levels;
KIRP	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.41	-0.47	3.42e-15	Coronary artery disease;
KIRP	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.57	-7.1	-0.41	1.32e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg02023728	chr11:77925099	USP35	-0.29	-5.12	-0.31	6.31e-7	Alzheimer's disease (survival time);
KIRP	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg09355771	chr2:177043147	NA	-0.42	-4.89	-0.3	1.83e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.2	-0.51	1.54e-17	Mood instability;
KIRP	cis	rs3736485	0.932	rs4775966	chr15:51913788	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg10047753	chr17:41438598	NA	1.11	17.87	0.75	2.31e-46	Menopause (age at onset);
KIRP	cis	rs9367716	0.868	rs9396267	chr6:57110411	C/G	cg03371099	chr6:57305889	PRIM2	0.44	5.7	0.34	3.35e-8	Coronary artery disease;
KIRP	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg03653399	chr8:142233436	SLC45A4	-0.48	-5.91	-0.35	1.11e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.63	-8.04	-0.46	3.78e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs4704187	0.687	rs2112874	chr5:74525165	G/A	cg03227963	chr5:74354835	NA	0.4	5.82	0.35	1.84e-8	Response to amphetamines;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25338766	chr19:36500444	ALKBH6;C19orf46	0.49	7.01	0.41	2.33e-11	Parkinson's disease;
KIRP	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.9	14.25	0.67	5.27e-34	Mean corpuscular volume;
KIRP	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.56	-0.48	1.23e-15	Blood metabolite levels;
KIRP	trans	rs3809095	0.521	rs11024008	chr11:16667834	A/G	cg15531249	chr16:85744077	C16orf74	-0.44	-6.22	-0.37	2.08e-9	Total body bone mineral density;
KIRP	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg27426351	chr10:43362370	NA	0.46	6.19	0.37	2.49e-9	Blood protein levels;
KIRP	cis	rs7814319	1.000	rs6468495	chr8:97259953	C/A	cg20787634	chr8:97240163	UQCRB	-0.59	-9.29	-0.51	8.68e-18	Lung function (FVC);
KIRP	cis	rs9644630	1.000	rs9644629	chr8:19369290	T/C	cg01280390	chr8:19363452	CSGALNACT1	-0.38	-4.9	-0.3	1.72e-6	Oropharynx cancer;
KIRP	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	1.08	8.25	0.47	9.62e-15	Skin colour saturation;
KIRP	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg02073558	chr3:44770973	ZNF501	0.72	11.31	0.58	3.63e-24	Depressive symptoms;
KIRP	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg08126542	chr6:37504118	NA	-0.86	-13.55	-0.65	1.29e-31	Cognitive performance;
KIRP	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	1.14	16.36	0.72	3.37e-41	Breast cancer;
KIRP	cis	rs8133932	0.654	rs425232	chr21:47346525	G/T	cg11214348	chr21:47283868	PCBP3	-0.44	-5.13	-0.31	5.89e-7	Schizophrenia;
KIRP	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.67	6.65	0.39	1.87e-10	Axial length;
KIRP	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg17366294	chr4:99064904	C4orf37	-0.35	-4.92	-0.3	1.57e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.29	-6.25	-0.37	1.76e-9	Asthma (sex interaction);
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs11710088	0.895	rs34897827	chr3:149198330	G/A	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.43	-0.33	1.36e-7	QRS duration;
KIRP	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg23479056	chr15:41276147	INO80	0.36	5.01	0.3	1.03e-6	Menopause (age at onset);
KIRP	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.48	-5.7	-0.34	3.41e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	0.75	7.23	0.42	6.13e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.96	-0.36	8.76e-9	Cardiac Troponin-T levels;
KIRP	cis	rs728478	0.967	rs7221245	chr17:57455602	G/C	cg16535752	chr17:57448097	YPEL2	-0.22	-5.26	-0.32	3.16e-7	QT interval;
KIRP	cis	rs1978968	0.717	rs34263881	chr22:18401597	G/C	cg03078520	chr22:18463400	MICAL3	-0.52	-6.23	-0.37	2.03e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.82	0.63	3.63e-29	Platelet count;
KIRP	cis	rs4700695	0.841	rs152994	chr5:65262989	A/G	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs1863824	0.625	rs10887599	chr10:88168780	G/A	cg07322936	chr10:88137208	NA	-0.52	-5.13	-0.31	5.83e-7	Schizophrenia;
KIRP	cis	rs35740288	0.520	rs56183577	chr15:86319706	A/G	cg20737812	chr15:86336631	KLHL25	-0.5	-5.92	-0.35	1.06e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3736485	0.934	rs1902593	chr15:51882080	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.66	8.63	0.48	7.72e-16	Longevity;Endometriosis;
KIRP	trans	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg11693508	chr17:37793320	STARD3	0.82	8.36	0.47	4.61e-15	Neuroticism;
KIRP	cis	rs2979489	0.891	rs2915592	chr8:30396417	C/T	cg26383811	chr8:30366931	RBPMS	-0.43	-6.09	-0.36	4.33e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg07570687	chr10:102243282	WNT8B	0.52	6.25	0.37	1.8e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4363385	0.530	rs6663448	chr1:152894627	C/T	cg07796016	chr1:152779584	LCE1C	-0.45	-5.72	-0.34	3.04e-8	Inflammatory skin disease;
KIRP	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.78	7.52	0.43	1.01e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35740288	0.822	rs17636864	chr15:86234589	A/C	cg10818794	chr15:86012489	AKAP13	-0.41	-4.86	-0.3	2.09e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.48	6.29	0.37	1.48e-9	Testicular germ cell tumor;
KIRP	trans	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.24	-0.37	1.94e-9	Neuroticism;
KIRP	cis	rs10129255	0.556	rs9324093	chr14:107139910	C/T	cg23076370	chr14:107095027	NA	-0.41	-5.27	-0.32	2.94e-7	Kawasaki disease;
KIRP	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.29	-0.32	2.66e-7	Coronary artery disease;
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.72	0.34	3.03e-8	Lung cancer;
KIRP	cis	rs2797685	0.898	rs697693	chr1:7886424	C/T	cg00864860	chr1:7907996	UTS2	-0.49	-5.86	-0.35	1.47e-8	Crohn's disease;
KIRP	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg01559446	chr3:44596178	ZNF167	-0.35	-5.06	-0.31	8.04e-7	Depressive symptoms;
KIRP	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg08847533	chr14:75593920	NEK9	-0.5	-6.05	-0.36	5.45e-9	IgG glycosylation;
KIRP	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.52	7.56	0.43	8.15e-13	Huntington's disease progression;
KIRP	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.12	8.48	0.48	2.08e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6433857	0.505	rs1542036	chr2:181350009	A/C	cg23363182	chr2:181467187	NA	-0.38	-5.32	-0.32	2.28e-7	Body mass index;
KIRP	cis	rs1014246	0.826	rs11197801	chr10:118471693	C/T	cg14919929	chr10:118506882	NA	-0.57	-7.46	-0.43	1.47e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.63	-9.24	-0.51	1.23e-17	Heart rate;
KIRP	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg08662619	chr6:150070041	PCMT1	0.33	5.14	0.31	5.48e-7	Lung cancer;
KIRP	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.31	-0.32	2.51e-7	Aortic root size;
KIRP	cis	rs193541	0.530	rs6595405	chr5:122084745	C/T	cg19412675	chr5:122181750	SNX24	0.51	5.43	0.33	1.33e-7	Glucose homeostasis traits;
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg09695851	chr17:3907499	NA	-0.81	-14.69	-0.68	1.7000000000000001e-35	Type 2 diabetes;
KIRP	cis	rs12049351	0.774	rs12117468	chr1:229671361	G/T	cg11742688	chr1:229674241	ABCB10	-0.42	-6.83	-0.4	6.49e-11	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7737355	0.947	rs6895586	chr5:130588008	C/A	cg06647332	chr5:131281008	NA	0.46	5.09	0.31	7.22e-7	Life satisfaction;
KIRP	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg18854424	chr1:2615690	NA	0.34	5.32	0.32	2.32e-7	Ulcerative colitis;
KIRP	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.64	6.29	0.37	1.41e-9	Eotaxin levels;
KIRP	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg13482628	chr17:19912719	NA	0.54	7.43	0.43	1.75e-12	Schizophrenia;
KIRP	trans	rs12517041	1.000	rs113660280	chr5:23302289	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.6	0.52	9.84e-19	Prudent dietary pattern;
KIRP	cis	rs732765	0.734	rs7153812	chr14:75173490	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.4	-4.95	-0.3	1.4e-6	Non-small cell lung cancer;
KIRP	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg13165212	chr22:42675999	NA	0.39	6.52	0.38	3.92e-10	Cognitive function;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00020052	chr2:68546899	CNRIP1	0.61	6.29	0.37	1.44e-9	Lung function (FEV1);
KIRP	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.53	7.03	0.41	2.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.94	-0.54	8.61e-20	Response to antipsychotic treatment;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.64	7.99	0.45	5.35e-14	Corneal astigmatism;
KIRP	cis	rs72949976	0.584	rs12467619	chr2:214022933	T/C	cg08319019	chr2:214017104	IKZF2	0.52	6.45	0.38	6.04e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs28595532	0.641	rs72670213	chr4:119281608	G/T	cg21605333	chr4:119757512	SEC24D	0.92	6.29	0.37	1.41e-9	Cannabis dependence symptom count;
KIRP	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg20637307	chr2:213403960	ERBB4	-0.51	-6.93	-0.4	3.74e-11	Symmetrical dimethylarginine levels;
KIRP	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.69	5.95	0.35	9.16e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.59	-9.32	-0.51	6.84e-18	C-reactive protein levels;
KIRP	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.78	-11.92	-0.61	3.74e-26	Hip circumference;
KIRP	cis	rs28655083	1.000	rs28655083	chr16:77061214	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-5.65	-0.34	4.39e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	-0.68	-8.76	-0.49	3.2e-16	Itch intensity from mosquito bite;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05528533	chr6:35310264	PPARD	0.47	6.26	0.37	1.69e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10813644	chr19:2271093	OAZ1	0.57	7.16	0.42	9.4e-12	Parkinson's disease;
KIRP	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg21775007	chr8:11205619	TDH	0.45	6.11	0.36	3.83e-9	Mood instability;
KIRP	cis	rs876084	0.505	rs10955953	chr8:121106381	C/T	cg22335954	chr8:121166405	COL14A1	0.36	4.86	0.3	2.13e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	1.1	17.04	0.74	1.55e-43	Homoarginine levels;
KIRP	cis	rs9796	0.774	rs28866311	chr15:41442195	T/G	cg23479056	chr15:41276147	INO80	-0.42	-5.82	-0.35	1.78e-8	Menopause (age at onset);
KIRP	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg05220968	chr6:146057943	EPM2A	0.39	5.09	0.31	7.06e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3925075	1.000	rs9673404	chr16:31347592	A/T	cg02846316	chr16:31340340	ITGAM	0.61	9.65	0.52	6.7e-19	IgA nephropathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15065069	chr1:154974120	ZBTB7B	0.49	6.06	0.36	5.21e-9	Interleukin-4 levels;
KIRP	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg17133734	chr15:86042851	AKAP13	-0.45	-5.67	-0.34	3.94e-8	Coronary artery disease;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg24874828	chr4:187887005	NA	-0.48	-7.06	-0.41	1.66e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg07843065	chr1:150265600	MRPS21	0.41	5.7	0.34	3.39e-8	Migraine;
KIRP	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.5	0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg23067535	chr8:124195133	FAM83A	-0.66	-6.51	-0.38	4.3e-10	Urinary uromodulin levels;
KIRP	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.77	-11.91	-0.6	3.96e-26	Prostate cancer;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg26531700	chr6:26746687	NA	0.46	6.12	0.36	3.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.38	5.66	0.34	4.23e-8	Platelet distribution width;
KIRP	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.54	0.33	7.58e-8	Menarche (age at onset);
KIRP	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs3843585	0.870	rs3793814	chr10:71710583	A/G	cg07081753	chr10:71718679	COL13A1	-0.33	-5.18	-0.31	4.63e-7	Middle childhood and early adolescence aggressive behavior;
KIRP	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4750440	0.702	rs7922870	chr10:14030921	C/T	cg27542038	chr10:14027202	FRMD4A	-0.48	-6.44	-0.38	6.24e-10	Adiponectin levels;
KIRP	cis	rs1971762	0.563	rs4759279	chr12:54064888	C/T	cg23533419	chr12:54090519	NA	-0.35	-5.52	-0.33	8.54e-8	Height;
KIRP	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-10.27	-0.55	7.97e-21	Total body bone mineral density;
KIRP	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs2274273	0.624	rs78205412	chr14:55781250	G/A	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.4e-7	Protein biomarker;
KIRP	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Colorectal cancer;
KIRP	cis	rs4262150	0.767	rs55786399	chr5:151945469	A/T	cg12297329	chr5:152029980	NA	-0.66	-8.13	-0.46	2.15e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02018176	chr4:1364513	KIAA1530	-0.38	-4.9	-0.3	1.77e-6	Obesity-related traits;
KIRP	cis	rs742614	1.000	rs742614	chr20:32482632	A/G	cg06304546	chr20:32448765	NA	-0.51	-6.73	-0.39	1.18e-10	Stearic acid (18:0) levels;
KIRP	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg01557791	chr16:72042693	DHODH	-0.66	-7.33	-0.42	3.4e-12	Blood protein levels;
KIRP	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg16725984	chr16:89735184	C16orf55	0.2	5.25	0.32	3.26e-7	Vitiligo;
KIRP	cis	rs1497828	0.956	rs2818965	chr1:217569776	T/A	cg04411442	chr1:217543379	NA	0.44	6.48	0.38	5.04e-10	Dialysis-related mortality;
KIRP	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs1816752	0.811	rs9507337	chr13:24984945	A/T	cg02811702	chr13:24901961	NA	0.39	5.04	0.31	8.88e-7	Obesity-related traits;
KIRP	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs6669919	0.655	rs6540686	chr1:211683025	G/T	cg10512769	chr1:211675356	NA	-0.6	-8.43	-0.47	2.97e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg12705353	chr12:122356852	WDR66	0.53	6.89	0.4	4.62e-11	Mean corpuscular volume;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20301340	chr19:41815941	CCDC97	0.54	6.12	0.36	3.63e-9	Lung cancer in ever smokers;
KIRP	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.71	-6.2	-0.37	2.33e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2742234	0.915	rs2742233	chr10:43610558	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.63	-7.56	-0.43	8.11e-13	Hirschsprung disease;
KIRP	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.11	-12.54	-0.62	3.3e-28	Vitiligo;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01769749	chr2:68813121	NA	0.39	6.42	0.38	7.05e-10	C-reactive protein;
KIRP	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.43	-0.33	1.36e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.66	5.56	0.33	6.93e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.29	0.37	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.63	-7.13	-0.41	1.13e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9815354	0.951	rs6793520	chr3:41865289	C/G	cg03022575	chr3:42003672	ULK4	0.54	5.94	0.35	9.53e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.77	-9.95	-0.54	7.92e-20	Ulcerative colitis;
KIRP	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg12560992	chr17:57184187	TRIM37	0.54	5.75	0.34	2.65e-8	Cognitive test performance;
KIRP	cis	rs4560672	1.000	rs80155944	chr6:158584328	T/C	cg14029994	chr6:158589857	SERAC1;GTF2H5	-0.56	-4.96	-0.3	1.33e-6	Smoking quantity;
KIRP	cis	rs9815354	1.000	rs4973991	chr3:41927273	C/T	cg03022575	chr3:42003672	ULK4	-0.46	-5.25	-0.32	3.36e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.42	5.28	0.32	2.78e-7	Birth weight;
KIRP	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.45e-9	Breast cancer;
KIRP	cis	rs4664293	1.000	rs10184034	chr2:160505427	A/G	cg08347373	chr2:160653686	CD302	-0.39	-5.95	-0.35	9e-9	Monocyte percentage of white cells;
KIRP	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.45	-6.01	-0.36	6.6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs42648	0.869	rs42609	chr7:89949855	A/T	cg25739043	chr7:89950458	NA	-0.46	-7.29	-0.42	4.28e-12	Homocysteine levels;
KIRP	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg16586182	chr3:47516702	SCAP	-0.66	-8.9	-0.49	1.25e-16	Colorectal cancer;
KIRP	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.13	-0.54	2.19e-20	Colorectal cancer;
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg27144592	chr16:783916	NARFL	0.36	4.98	0.3	1.19e-6	Height;
KIRP	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.36	3.85e-9	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.62	-9.08	-0.5	3.59e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-7.36	-0.42	2.8e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.97	16.57	0.73	6.18e-42	Breast cancer;
KIRP	cis	rs2574975	0.679	rs2688879	chr10:52133698	T/C	cg10034176	chr10:52120283	SGMS1	-0.53	-7.01	-0.41	2.22e-11	Response to amphetamines;
KIRP	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.22	6.19	0.37	2.51e-9	Type 2 diabetes;
KIRP	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	7.7	0.44	3.31e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg01631684	chr10:65280961	REEP3	-0.49	-5.74	-0.34	2.77e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs13014235	0.934	rs10202963	chr2:202241907	T/G	cg06431681	chr2:202330990	STRADB	0.41	5.55	0.33	7.43e-8	Basal cell carcinoma;
KIRP	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.77	10.76	0.57	2.24e-22	Morning vs. evening chronotype;
KIRP	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg20387954	chr3:183756860	HTR3D	0.62	9.13	0.5	2.63e-17	Anterior chamber depth;
KIRP	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.74	-10.31	-0.55	5.91e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg00405596	chr8:11794950	NA	-0.48	-6.19	-0.37	2.56e-9	Mood instability;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg05360402	chr5:110848191	STARD4	-0.51	-6.52	-0.38	4.03e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	15.05	0.69	1e-36	Chronic sinus infection;
KIRP	cis	rs4776059	0.798	rs10851520	chr15:52912978	C/G	cg25063058	chr15:52860530	ARPP19	-0.5	-4.93	-0.3	1.54e-6	Schizophrenia;
KIRP	cis	rs7113850	0.541	rs7107940	chr11:24233228	G/A	ch.11.24196551F	chr11:24239977	NA	0.88	8.1	0.46	2.56e-14	Bone fracture in osteoporosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15688980	chr3:156975045	NA	0.53	6.75	0.4	1.05e-10	Interleukin-4 levels;
KIRP	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	6.68	0.39	1.62e-10	Cognitive test performance;
KIRP	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg06742321	chr12:123595122	PITPNM2	-0.41	-5.02	-0.31	9.75e-7	Neutrophil percentage of white cells;
KIRP	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg11189052	chr15:85197271	WDR73	0.54	5.77	0.35	2.42e-8	Schizophrenia;
KIRP	cis	rs830233	0.657	rs1096225	chr5:165397947	C/T	cg13976338	chr5:165423657	NA	-0.74	-10.55	-0.56	1.02e-21	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.64	-7.99	-0.45	5.26e-14	Breast size;
KIRP	cis	rs838147	0.844	rs8108468	chr19:49247786	G/A	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.27e-7	Dietary macronutrient intake;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg01097406	chr16:89675127	NA	-0.33	-5.54	-0.33	7.63e-8	Vitiligo;
KIRP	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg27631724	chr1:11040367	C1orf127	0.45	9.27	0.51	9.61e-18	Ewing sarcoma;
KIRP	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg24315340	chr6:146058215	EPM2A	-0.47	-6.22	-0.37	2.17e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg00405596	chr8:11794950	NA	0.52	6.85	0.4	5.75e-11	Joint mobility (Beighton score);
KIRP	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg08999081	chr20:33150536	PIGU	-0.43	-5.6	-0.34	5.85e-8	Height;
KIRP	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	cg12689670	chr1:183009347	LAMC1	0.46	6.41	0.38	7.42e-10	Colorectal cancer;
KIRP	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11622362	chr11:34938112	PDHX;APIP	-0.44	-5.38	-0.32	1.77e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	5.54	0.33	7.58e-8	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.43	-0.47	2.88e-15	Neuroticism;
KIRP	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg05785598	chr3:49045655	WDR6	0.28	5.06	0.31	8.4e-7	Parkinson's disease;
KIRP	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.12	-0.46	2.31e-14	Monocyte percentage of white cells;
KIRP	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg02574844	chr11:5959923	NA	-0.63	-6.72	-0.39	1.26e-10	DNA methylation (variation);
KIRP	trans	rs10435719	0.746	rs58007588	chr8:11794969	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.24	0.37	1.88e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg00360474	chr6:37504404	NA	-0.43	-6.15	-0.36	3.2e-9	Cognitive performance;
KIRP	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.6	-7.39	-0.43	2.34e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02232531	chr16:699316	WDR90	0.5	6.33	0.37	1.14e-9	Parkinson's disease;
KIRP	cis	rs745821	0.701	rs77310792	chr18:48101746	A/G	cg18923635	chr18:48083994	NA	0.43	4.87	0.3	1.96e-6	Diastolic blood pressure;
KIRP	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.34	6.12	0.36	3.74e-9	Renal cell carcinoma;
KIRP	cis	rs6732160	0.588	rs10192654	chr2:73370882	A/T	cg01422370	chr2:73384389	NA	-0.5	-6.8	-0.4	7.77e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg03465714	chr1:152285911	FLG	0.47	5.3	0.32	2.6e-7	Atopic dermatitis;
KIRP	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg04731861	chr2:219085781	ARPC2	0.22	5.31	0.32	2.47e-7	Colorectal cancer;
KIRP	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg27462398	chr1:86174642	ZNHIT6	-0.6	-8.83	-0.49	1.95e-16	Urate levels in overweight individuals;
KIRP	cis	rs11718455	0.563	rs6809096	chr3:43902494	G/C	cg21419209	chr3:44054225	NA	-0.55	-6.46	-0.38	5.45e-10	Coronary artery disease;
KIRP	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.27	9.18	0.51	1.77e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg05802129	chr4:122689817	NA	-0.5	-6.66	-0.39	1.73e-10	Type 2 diabetes;
KIRP	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg16068336	chr17:48637367	CACNA1G	-0.41	-5.24	-0.32	3.43e-7	Type 2 diabetes;
KIRP	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.92	14.63	0.68	2.69e-35	Testicular germ cell tumor;
KIRP	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.51	8.79	0.49	2.55e-16	Pneumonia;
KIRP	trans	rs12517041	1.000	rs4701363	chr5:23301008	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.7	-0.44	3.35e-13	Calcium levels;
KIRP	cis	rs6545883	0.542	rs2593628	chr2:61573287	T/A	cg15711740	chr2:61764176	XPO1	0.45	5.43	0.33	1.33e-7	Tuberculosis;
KIRP	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.62	-7.51	-0.43	1.1e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2387326	0.717	rs10829336	chr10:129943532	T/C	cg16087940	chr10:129947807	NA	-0.36	-5.01	-0.3	1.05e-6	Select biomarker traits;
KIRP	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.69	0.34	3.68e-8	Renal cell carcinoma;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2412208	0.796	rs4287204	chr1:7076184	G/A	cg20434152	chr1:7120926	CAMTA1	-0.39	-4.88	-0.3	1.94e-6	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.65	-6.81	-0.4	7.31e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.27	0.47	8.32e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-5.62	-0.34	5.2100000000000003e-08	Height;
KIRP	cis	rs859767	0.812	rs842358	chr2:135345109	C/T	cg12500956	chr2:135428796	TMEM163	0.37	4.85	0.3	2.21e-6	Neuroticism;
KIRP	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg01620082	chr3:125678407	NA	-1.33	-8.35	-0.47	5.13e-15	Depression;
KIRP	cis	rs4704187	0.687	rs4627970	chr5:74528776	G/A	cg03227963	chr5:74354835	NA	0.4	5.82	0.35	1.84e-8	Response to amphetamines;
KIRP	cis	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg12315302	chr6:26189340	HIST1H4D	0.74	5.19	0.31	4.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	9.53	0.52	1.61e-18	Cognitive test performance;
KIRP	cis	rs7224685	0.569	rs12453798	chr17:4017079	C/T	cg05562828	chr17:3906858	NA	0.51	5.35	0.32	1.97e-7	Type 2 diabetes;
KIRP	cis	rs7172677	0.737	rs7178625	chr15:75441017	A/G	cg14664628	chr15:75095509	CSK	-0.55	-6.1	-0.36	4.02e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10814247	0.592	rs12380141	chr9:35509200	T/C	cg15271616	chr9:35490515	RUSC2	0.45	5.59	0.34	6.12e-8	Psoriasis;
KIRP	cis	rs7870753	0.945	rs6477489	chr9:99239841	A/C	cg25260653	chr9:99212216	HABP4	0.54	6.05	0.36	5.3e-9	Height;
KIRP	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg16141378	chr3:129829833	LOC729375	0.53	6.99	0.41	2.62e-11	Retinal vascular caliber;
KIRP	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.53	5.65	0.34	4.44e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9383929	0.556	rs6909279	chr6:151895456	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.51	-6.69	-0.39	1.47e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-8.26	-0.47	8.95e-15	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15416064	chr12:49209402	NA	0.52	6.38	0.38	8.93e-10	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11166927	0.870	rs11166930	chr8:140824621	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.55	-7.64	-0.44	4.77e-13	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.74	8.17	0.46	1.61e-14	Corneal astigmatism;
KIRP	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.77e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.68	7.63	0.44	5.27e-13	Exhaled nitric oxide output;
KIRP	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg25173405	chr17:45401733	C17orf57	0.41	5.28	0.32	2.79e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg17788362	chr6:86352627	SYNCRIP	0.47	6.5	0.38	4.53e-10	Smooth-surface caries;
KIRP	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.47	-5.8	-0.35	2.08e-8	Initial pursuit acceleration;
KIRP	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg21605333	chr4:119757512	SEC24D	1.67	11.88	0.6	5.17e-26	Cannabis dependence symptom count;
KIRP	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.86	0.53	1.53e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19882132	chr14:106167949	NA	-0.42	-5.2	-0.31	4.19e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-6.24	-0.37	1.95e-9	Menarche (age at onset);
KIRP	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05585630	chr7:157510462	PTPRN2	-0.55	-8.25	-0.47	9.38e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.42	5.36	0.32	1.94e-7	Blood metabolite levels;
KIRP	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.6	-7.83	-0.45	1.44e-13	Diastolic blood pressure;
KIRP	cis	rs9840812	0.637	rs667920	chr3:136069472	G/T	cg15507776	chr3:136538369	TMEM22	0.42	5.16	0.31	5.01e-7	Fibrinogen levels;
KIRP	cis	rs1823913	0.599	rs12994236	chr2:192171717	A/G	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.65e-12	Obesity-related traits;
KIRP	cis	rs55962025	0.883	rs3121419	chr4:3232257	C/T	cg13731523	chr4:3047190	NA	0.33	5.14	0.31	5.69e-7	Parental longevity (mother's age at death);
KIRP	cis	rs494562	0.892	rs4624841	chr6:86130251	G/A	cg27039625	chr6:86159096	NT5E	0.44	5.75	0.34	2.67e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg07541023	chr7:19748670	TWISTNB	0.66	6.46	0.38	5.43e-10	Thyroid stimulating hormone;
KIRP	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05025164	chr4:1340916	KIAA1530	0.66	9.09	0.5	3.45e-17	Longevity;
KIRP	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg11569703	chr11:65557185	OVOL1	0.34	5.16	0.31	5.14e-7	Urate levels;
KIRP	cis	rs743757	1.000	rs2282752	chr3:50433967	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.31	0.32	2.47e-7	Diastolic blood pressure;
KIRP	cis	rs1978968	0.700	rs10854521	chr22:18482600	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.57	-0.39	2.98e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.46	5.28	0.32	2.88e-7	Fear of minor pain;
KIRP	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04398451	chr17:18023971	MYO15A	-0.91	-14.25	-0.67	5.36e-34	Total body bone mineral density;
KIRP	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg02820901	chr13:113351484	ATP11A	0.68	6.34	0.37	1.08e-9	Glycated hemoglobin levels;
KIRP	cis	rs13185784	0.667	rs62406986	chr5:179644055	G/A	cg02891314	chr5:179741120	GFPT2	0.52	5.1	0.31	6.72e-7	TRAIL levels;
KIRP	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.42	5.51	0.33	8.87e-8	Birth weight;
KIRP	cis	rs2213920	0.679	rs4978638	chr9:118232778	G/C	cg13918206	chr9:118159781	DEC1	1.01	10.16	0.54	1.72e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs2901460	0.509	rs12463815	chr2:62087165	C/T	cg02183531	chr2:62113199	CCT4	-0.49	-5.07	-0.31	7.69e-7	Mean corpuscular volume;
KIRP	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.45	-5.7	-0.34	3.46e-8	Bipolar disorder;
KIRP	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg25486957	chr4:152246857	NA	-0.52	-5.73	-0.34	2.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2425143	1.000	rs2425078	chr20:34298163	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-5.82	-0.35	1.84e-8	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26530971	chr8:110552297	EBAG9	0.44	6.27	0.37	1.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10771695	chr14:103800476	EIF5	-0.59	-6.49	-0.38	4.7e-10	Menopause (age at onset);
KIRP	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg06521852	chr22:38141419	TRIOBP	0.48	6.81	0.4	7.24e-11	Optic cup area;Vertical cup-disc ratio;
KIRP	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.19	-0.37	2.46e-9	Morning vs. evening chronotype;
KIRP	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.79	-9.79	-0.53	2.47e-19	Iron status biomarkers;
KIRP	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.93	-0.57	6.32e-23	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04141141	chr5:54777774	PPAP2A	-0.42	-6.45	-0.38	5.98e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6901004	0.803	rs354529	chr6:111504655	G/A	cg15721981	chr6:111408429	SLC16A10	-0.49	-6.44	-0.38	6.24e-10	Blood metabolite levels;
KIRP	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.58	9.09	0.5	3.39e-17	Vitamin D levels;
KIRP	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg21775007	chr8:11205619	TDH	0.48	6.53	0.38	3.72e-10	Neuroticism;
KIRP	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.7	-0.63	9.07e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12136737	0.826	rs17576899	chr1:184346241	A/G	cg25595908	chr1:184386875	C1orf21	0.71	4.94	0.3	1.45e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3736594	0.513	rs56725354	chr2:27824168	G/C	cg27432699	chr2:27873401	GPN1	0.55	6.14	0.36	3.34e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.59	0.39	2.6200000000000003e-10	Educational attainment;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg25341789	chr19:3506185	FZR1	0.76	6.61	0.39	2.3e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg05347473	chr6:146136440	FBXO30	0.6	8.58	0.48	1.11e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg04315214	chr1:2043799	PRKCZ	0.49	8.54	0.48	1.44e-15	Height;
KIRP	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg08501292	chr6:25962987	TRIM38	1.03	8.19	0.46	1.42e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	-0.69	-4.86	-0.3	2.05e-6	Childhood ear infection;
KIRP	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08439880	chr3:133502540	NA	-0.43	-5.13	-0.31	5.95e-7	Iron status biomarkers;
KIRP	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.71	-9.93	-0.54	8.97e-20	Educational attainment;
KIRP	trans	rs7939886	0.920	rs10431119	chr11:55977069	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs7635838	0.892	rs9852530	chr3:11466469	C/T	cg00170343	chr3:11313890	ATG7	0.46	5.87	0.35	1.37e-8	HDL cholesterol;
KIRP	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13047869	chr3:10149882	C3orf24	0.56	5.55	0.33	7.49e-8	Alzheimer's disease;
KIRP	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	10.24	0.55	1.02e-20	Nonalcoholic fatty liver disease;
KIRP	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.14	-0.31	5.67e-7	Bipolar disorder;
KIRP	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.39	-5.54	-0.33	7.68e-8	Monocyte count;
KIRP	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg16751203	chr2:127950803	CYP27C1	0.37	4.9	0.3	1.76e-6	Protein C levels;
KIRP	cis	rs7975161	1.000	rs7975161	chr12:104645405	C/T	cg25273343	chr12:104657179	TXNRD1	0.57	5.34	0.32	2.13e-7	Toenail selenium levels;
KIRP	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-7.97	-0.45	5.87e-14	Personality dimensions;
KIRP	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.62	5.93	0.35	1.01e-8	Breast cancer;
KIRP	cis	rs11673344	0.526	rs8101610	chr19:38057506	A/C	cg14683738	chr19:37701593	ZNF585B	0.44	5.35	0.32	2e-7	Obesity-related traits;
KIRP	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.91	-7.8	-0.45	1.71e-13	Smoking behavior;
KIRP	cis	rs55863869	0.748	rs7585334	chr2:179620951	C/T	cg02880032	chr2:179629472	TTN	-0.68	-6.14	-0.36	3.28e-9	QT interval;
KIRP	cis	rs73206853	0.697	rs16934006	chr12:110527907	T/A	cg12870014	chr12:110450643	ANKRD13A	0.56	5.74	0.34	2.72e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs2535633	0.631	rs2257216	chr3:52968726	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-12.09	-0.61	1.04e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.72	7.95	0.45	6.85e-14	Corneal astigmatism;
KIRP	cis	rs12541635	0.677	rs1496181	chr8:107027141	C/T	cg10147462	chr8:107024639	NA	0.33	4.96	0.3	1.3e-6	Age of smoking initiation;
KIRP	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg24315340	chr6:146058215	EPM2A	-0.39	-4.9	-0.3	1.71e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19613905	chr15:56757180	MNS1	0.49	6.58	0.39	2.74e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg05791153	chr7:19748676	TWISTNB	0.64	5.72	0.34	3.08e-8	Thyroid stimulating hormone;
KIRP	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23903597	chr17:61704154	MAP3K3	-0.63	-8.11	-0.46	2.4e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.98	13.61	0.66	8.14e-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.75	7.27	0.42	4.73e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-5.55	-0.33	7.45e-8	HDL cholesterol;
KIRP	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg21918786	chr6:109611834	NA	-0.39	-5.41	-0.33	1.51e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	14.65	0.68	2.32e-35	Alzheimer's disease;
KIRP	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	7.87	0.45	1.14e-13	Mood instability;
KIRP	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.26	-21.74	-0.81	3.4e-59	Breast cancer;
KIRP	cis	rs9815354	1.000	rs9815354	chr3:41912651	G/A	cg03022575	chr3:42003672	ULK4	0.63	6.57	0.39	2.95e-10	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg05369268	chr19:18092781	KCNN1	0.43	6.95	0.41	3.17e-11	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs6973256	0.828	rs10247014	chr7:133431038	A/C	cg10665199	chr7:133106180	EXOC4	0.47	5.83	0.35	1.69e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28669119	0.778	rs159950	chr5:88116319	C/T	cg18498987	chr5:88179539	MEF2C	0.53	6.62	0.39	2.22e-10	Schizophrenia;
KIRP	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	9.64	0.52	7.31e-19	Lung cancer in ever smokers;
KIRP	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	6.06	0.36	5.11e-9	Motion sickness;
KIRP	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg16141378	chr3:129829833	LOC729375	0.57	7.66	0.44	4.19e-13	Retinal vascular caliber;
KIRP	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.78	0.49	2.77e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.6	8.36	0.47	4.52e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19144769	chr2:39298958	SOS1	-0.39	-6.3	-0.37	1.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2013441	0.613	rs888424	chr17:19985427	C/T	cg13482628	chr17:19912719	NA	0.49	6.48	0.38	4.84e-10	Obesity-related traits;
KIRP	cis	rs494562	0.892	rs7767626	chr6:86124394	G/A	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs62109865	0.748	rs62111824	chr19:12612530	A/C	cg19721055	chr19:12753329	NA	-0.84	-4.94	-0.3	1.48e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg18806716	chr10:30721971	MAP3K8	-0.45	-6.98	-0.41	2.66e-11	Inflammatory bowel disease;
KIRP	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.56	7.61	0.44	5.78e-13	Gout;
KIRP	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg13482628	chr17:19912719	NA	0.53	6.9	0.4	4.32e-11	Schizophrenia;
KIRP	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.69	-9.0	-0.5	6.19e-17	Morning vs. evening chronotype;
KIRP	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.7	-11.92	-0.61	3.67e-26	Lung function (FVC);
KIRP	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15320075	chr8:145703422	NA	-0.57	-7.43	-0.43	1.78e-12	Age at first birth;
KIRP	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.67	-9.68	-0.53	5.54e-19	Brugada syndrome;
KIRP	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg25547332	chr5:131281432	NA	-0.47	-5.26	-0.32	3.15e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-12.09	-0.61	1.03e-26	Alzheimer's disease;
KIRP	trans	rs12517041	1.000	rs4701365	chr5:23315034	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.55	-0.43	8.27e-13	Calcium levels;
KIRP	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.55e-13	Life satisfaction;
KIRP	cis	rs1867631	0.585	rs11208940	chr1:67127242	A/G	cg13052034	chr1:66999238	SGIP1	-0.45	-6.85	-0.4	5.75e-11	Menopause (age at onset);
KIRP	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.73	-7.82	-0.45	1.59e-13	Blood pressure (smoking interaction);
KIRP	cis	rs7481584	0.717	rs3759025	chr11:3017377	G/A	cg08508325	chr11:3079039	CARS	0.31	5.54	0.33	7.87e-8	Calcium levels;
KIRP	cis	rs12476592	0.602	rs2604613	chr2:63832776	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.15	-0.31	5.47e-7	Childhood ear infection;
KIRP	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-8.74	-0.49	3.68e-16	Gut microbiome composition (summer);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08203824	chr5:126365785	MARCH3	-0.46	-6.02	-0.36	6.47e-9	Myopia;
KIRP	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.82	12.56	0.63	2.79e-28	Body mass index;
KIRP	cis	rs13395090	0.967	rs12105179	chr2:3721729	C/T	cg15327641	chr2:3715039	ALLC	-0.63	-8.53	-0.48	1.52e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg23594656	chr7:65796392	TPST1	-0.47	-7.53	-0.43	9.78e-13	Aortic root size;
KIRP	cis	rs57590327	0.612	rs820272	chr3:81554345	T/C	cg07356753	chr3:81810745	GBE1	0.51	5.8	0.35	2e-8	Extraversion;
KIRP	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg09184832	chr6:79620586	NA	-0.52	-7.34	-0.42	3.07e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.71	-0.34	3.22e-8	Mood instability;
KIRP	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg18225595	chr11:63971243	STIP1	0.64	5.79	0.35	2.09e-8	Mean platelet volume;
KIRP	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.75	8.04	0.46	3.66e-14	Bipolar disorder;
KIRP	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.24	6.96	0.41	3.13e-11	Type 2 diabetes;
KIRP	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.16	-0.42	9.15e-12	Vitiligo;
KIRP	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.69	10.26	0.55	8.36e-21	Prostate cancer;
KIRP	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg18190219	chr22:46762943	CELSR1	-0.71	-7.4	-0.43	2.15e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs883115	0.743	rs1002130	chr1:224800929	C/T	cg01808320	chr1:224927238	CNIH3	-0.35	-5.2	-0.31	4.28e-7	Cancer;
KIRP	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg09890400	chr1:26503858	CNKSR1	0.42	5.79	0.35	2.13e-8	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18752774	chr11:7060500	NLRP14	0.42	6.14	0.36	3.21e-9	Interleukin-4 levels;
KIRP	cis	rs2274273	0.638	rs9919921	chr14:55695505	A/G	cg04306507	chr14:55594613	LGALS3	0.43	5.65	0.34	4.38e-8	Protein biomarker;
KIRP	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg03929089	chr4:120376271	NA	0.69	6.11	0.36	3.84e-9	Axial length;
KIRP	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg06042504	chr8:55087323	NA	0.6	7.32	0.42	3.58e-12	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00292435	chr9:91925643	CKS2	0.47	6.42	0.38	6.88e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2411233	1.000	rs11070163	chr15:39277151	A/G	cg02291532	chr15:39874776	THBS1	-0.36	-4.91	-0.3	1.64e-6	Platelet count;
KIRP	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs6746082	0.519	rs508262	chr2:25761044	G/A	cg23192403	chr2:25781496	DTNB	-0.26	-5.25	-0.32	3.21e-7	Multiple myeloma;
KIRP	cis	rs7429990	0.965	rs62260764	chr3:47990500	G/C	cg11946769	chr3:48343235	NME6	0.55	5.61	0.34	5.45e-8	Educational attainment (years of education);
KIRP	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08822215	chr16:89438651	ANKRD11	-0.46	-6.22	-0.37	2.08e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg19912559	chr1:40204330	PPIE	0.41	5.11	0.31	6.45e-7	Blood protein levels;
KIRP	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg08076091	chr2:203926405	NBEAL1	0.82	8.23	0.46	1.11e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.09	0.54	2.93e-20	Dupuytren's disease;
KIRP	cis	rs7692976	0.578	rs12506702	chr4:110845763	A/G	cg06981781	chr4:110842888	EGF	-0.24	-5.4	-0.33	1.54e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00781540	chr3:50396681	TMEM115	0.56	6.89	0.4	4.55e-11	Parkinson's disease;
KIRP	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg10223061	chr2:219282414	VIL1	0.43	7.0	0.41	2.43e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg18932078	chr1:2524107	MMEL1	0.46	6.28	0.37	1.49e-9	Ulcerative colitis;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.13	-0.41	1.11e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg22089800	chr15:90895588	ZNF774	0.45	5.36	0.32	1.87e-7	Rheumatoid arthritis;
KIRP	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.34	5.34	0.32	2.15e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.55	-7.13	-0.41	1.11e-11	Obesity-related traits;
KIRP	cis	rs28830936	0.966	rs2277535	chr15:42119711	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.64	-0.39	1.96e-10	Diastolic blood pressure;
KIRP	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs7903847	0.642	rs10882909	chr10:99137998	G/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.36	6.25	0.37	1.82e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.77	8.34	0.47	5.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg01631408	chr1:248437212	OR2T33	-0.64	-8.08	-0.46	2.9e-14	Common traits (Other);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10452333	chr10:81444403	LOC650623	0.43	6.54	0.38	3.5e-10	Survival in pancreatic cancer;
KIRP	cis	rs13102973	0.640	rs11099303	chr4:135887709	C/A	cg14419869	chr4:135874104	NA	-0.48	-7.18	-0.42	8.06e-12	Subjective well-being;
KIRP	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.92	14.93	0.69	2.65e-36	Metabolic syndrome;
KIRP	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg07827796	chr19:33622959	WDR88	0.41	4.94	0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg25019033	chr10:957182	NA	-0.61	-6.43	-0.38	6.75e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg16606324	chr3:10149918	C3orf24	0.56	5.25	0.32	3.27e-7	Alzheimer's disease;
KIRP	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.85	10.24	0.55	1.02e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs7180079	0.544	rs4777594	chr15:65076993	A/G	cg15337035	chr15:64978493	NA	-0.45	-4.91	-0.3	1.67e-6	Monocyte count;
KIRP	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.61	-7.53	-0.43	9.4e-13	Red cell distribution width;
KIRP	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-7.32	-0.42	3.6e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg24579218	chr15:68104479	NA	-0.57	-9.27	-0.51	9.49e-18	Restless legs syndrome;
KIRP	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-6.9	-0.4	4.33e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2737618	0.651	rs2249172	chr1:200082955	A/G	cg21825944	chr1:200113062	NR5A2	0.51	6.84	0.4	6.13e-11	Uric acid levels;
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.61	9.51	0.52	1.78e-18	Lung cancer;
KIRP	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	cg04338863	chr8:33670619	NA	0.49	6.43	0.38	6.64e-10	Body mass index;
KIRP	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	0.82	9.64	0.52	7.14e-19	Neutrophil percentage of white cells;
KIRP	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg08885076	chr2:99613938	TSGA10	-0.47	-5.8	-0.35	1.99e-8	Chronic sinus infection;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.93	-12.89	-0.64	2.11e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20701983	chr7:135194361	CNOT4	0.48	6.04	0.36	5.55e-9	Parkinson's disease;
KIRP	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg09455208	chr3:40491958	NA	-0.38	-7.02	-0.41	2.19e-11	Renal cell carcinoma;
KIRP	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.77	12.28	0.62	2.41e-27	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-1.1	-23.21	-0.83	6.86e-64	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.21	0.37	2.21e-9	Ovarian reserve;
KIRP	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg10818794	chr15:86012489	AKAP13	-0.48	-6.71	-0.39	1.35e-10	Interstitial lung disease;
KIRP	cis	rs13401104	0.716	rs11677595	chr2:237140651	A/G	cg19324714	chr2:237145437	ASB18	0.54	5.5	0.33	9.37e-8	Educational attainment;
KIRP	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.65	-9.28	-0.51	9.24e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.83	-7.44	-0.43	1.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	0.95	10.68	0.56	3.88e-22	Triglycerides;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg26247618	chr15:44119245	WDR76	-0.47	-6.48	-0.38	5.07e-10	Morning vs. evening chronotype;
KIRP	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.64	7.92	0.45	8.08e-14	Alcohol dependence;
KIRP	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.99	14.85	0.69	4.79e-36	Menopause (age at onset);
KIRP	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg23387468	chr7:139079360	LUC7L2	-0.28	-5.1	-0.31	6.86e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	0.64	5.18	0.31	4.64e-7	Major depressive disorder;
KIRP	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.79	9.18	0.51	1.85e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7113850	0.541	rs56732861	chr11:24234333	C/G	ch.11.24196551F	chr11:24239977	NA	0.9	8.37	0.47	4.29e-15	Bone fracture in osteoporosis;
KIRP	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.32	-0.32	2.36e-7	Colorectal cancer;
KIRP	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg14650228	chr8:144573510	ZC3H3	-0.68	-4.9	-0.3	1.74e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.55	7.02	0.41	2.17e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.56	6.89	0.4	4.57e-11	Aortic root size;
KIRP	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.51	-7.99	-0.45	5.14e-14	Platelet distribution width;
KIRP	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg26754761	chr2:177040938	NA	-0.46	-7.77	-0.44	2.15e-13	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	trans	rs9970896	0.522	rs10926960	chr1:236043410	G/T	cg02281038	chr19:14139137	RLN3	-0.66	-6.07	-0.36	4.71e-9	Monocyte percentage of white cells;
KIRP	cis	rs9426935	0.527	rs7537213	chr1:154072287	G/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.34	4.91	0.3	1.68e-6	Lentiform nucleus volume;
KIRP	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg21466736	chr12:48725269	NA	-0.5	-6.38	-0.38	8.92e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.0	-10.89	-0.57	8.4e-23	Gut microbiome composition (summer);
KIRP	cis	rs812925	0.893	rs1186705	chr2:61673278	A/C	cg15711740	chr2:61764176	XPO1	-0.48	-5.51	-0.33	9.26e-8	Immature fraction of reticulocytes;
KIRP	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg17845761	chr1:175162550	KIAA0040	-0.27	-4.91	-0.3	1.68e-6	Diastolic blood pressure;
KIRP	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg22717608	chr11:34937665	PDHX;APIP	-0.4	-5.03	-0.31	9.26e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.02	-0.3	9.82e-7	Educational attainment;
KIRP	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg04976154	chr16:1532411	NA	-0.63	-9.26	-0.51	1.03e-17	Bone mineral density;
KIRP	cis	rs73200209	0.701	rs61939684	chr12:116509365	G/A	cg01776926	chr12:116560359	MED13L	-0.56	-6.13	-0.36	3.38e-9	Total body bone mineral density;
KIRP	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg20291162	chr17:40259547	DHX58	-0.33	-4.86	-0.3	2.1e-6	Fibrinogen levels;
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg13206674	chr6:150067644	NUP43	0.62	8.52	0.48	1.6e-15	Lung cancer;
KIRP	cis	rs2302729	0.578	rs11062298	chr12:2771709	A/C	cg19945202	chr12:2788847	CACNA1C	-0.75	-10.89	-0.57	8.71e-23	Sleep quality;
KIRP	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.46	5.05	0.31	8.5e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs4959799	0.557	rs9503514	chr6:3271703	A/G	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.25	-0.32	3.34e-7	Survival in rectal cancer;
KIRP	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg20636351	chr8:55087400	NA	-0.54	-6.62	-0.39	2.2e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg21523564	chr15:75251491	NA	0.41	6.57	0.39	3.02e-10	Breast cancer;
KIRP	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.8	11.04	0.58	2.81e-23	Aortic root size;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18936378	chr17:41847161	DUSP3	0.51	7.07	0.41	1.63e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4332428	1.000	rs6650153	chr10:5019320	C/T	cg19648686	chr10:5044992	AKR1C2	-0.93	-7.98	-0.45	5.55e-14	Height;
KIRP	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg08807101	chr21:30365312	RNF160	-0.64	-7.86	-0.45	1.18e-13	Pancreatic cancer;
KIRP	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg06740227	chr12:86229804	RASSF9	0.47	5.73	0.34	2.96e-8	Major depressive disorder;
KIRP	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg26516362	chr5:178986906	RUFY1	0.39	6.55	0.39	3.25e-10	Lung cancer;
KIRP	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	7.9	0.45	9.47e-14	Personality dimensions;
KIRP	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.09	-20.73	-0.8	6.93e-56	Chronic sinus infection;
KIRP	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.43e-11	Response to antipsychotic treatment;
KIRP	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.16	-0.31	5.17e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.8	-10.0	-0.54	5.58e-20	Blood protein levels;
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg09695851	chr17:3907499	NA	0.82	15.01	0.69	1.31e-36	Type 2 diabetes;
KIRP	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	7.46	0.43	1.48e-12	Height;
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg24488311	chr11:68621650	NA	0.43	5.0	0.3	1.11e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.76	-7.73	-0.44	2.74e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20456954	chr8:68178729	ARFGEF1	-0.41	-6.48	-0.38	4.85e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg26513180	chr16:89883248	FANCA	0.75	5.27	0.32	2.99e-7	Skin colour saturation;
KIRP	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg11584989	chr19:19387371	SF4	0.41	5.27	0.32	2.99e-7	Tonsillectomy;
KIRP	cis	rs6142102	0.961	rs6088355	chr20:32545887	A/G	cg08999081	chr20:33150536	PIGU	0.5	5.89	0.35	1.26e-8	Skin pigmentation;
KIRP	cis	rs4595586	0.679	rs7312898	chr12:39346833	T/C	cg26384229	chr12:38710491	ALG10B	0.5	6.37	0.38	8.97e-10	Morning vs. evening chronotype;
KIRP	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.44	-7.2	-0.42	7.41e-12	Blood protein levels;
KIRP	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.89	13.02	0.64	7.97e-30	Bladder cancer;
KIRP	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.79	10.99	0.57	4.14e-23	Breast cancer;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs12580194	0.554	rs12578577	chr12:55716443	C/T	cg11794356	chr12:55725991	OR6C3	-0.58	-8.1	-0.46	2.55e-14	Cancer;
KIRP	cis	rs2048656	0.578	rs925610	chr8:9681836	G/C	cg27411982	chr8:10470053	RP1L1	-0.41	-5.39	-0.32	1.65e-7	Schizophrenia;
KIRP	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-5.04	-0.31	9.2e-7	Fear of minor pain;
KIRP	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg15507776	chr3:136538369	TMEM22	0.54	7.63	0.44	5.18e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7616330	0.836	rs6780338	chr3:71029408	C/T	cg23830205	chr3:71127516	FOXP1	-0.44	-4.98	-0.3	1.22e-6	QT interval;
KIRP	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg14972814	chr11:95582409	MTMR2	0.37	6.2	0.37	2.32e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17023223	0.509	rs56195272	chr1:119713997	A/T	cg05756136	chr1:119680316	WARS2	-0.62	-8.36	-0.47	4.76e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs330048	0.545	rs719409	chr8:9151226	C/T	cg08975724	chr8:8085496	FLJ10661	0.62	7.36	0.42	2.68e-12	Systemic lupus erythematosus;
KIRP	cis	rs4919044	0.866	rs55661575	chr10:94825108	C/T	cg05127821	chr10:94822908	CYP26C1	-0.91	-6.16	-0.37	2.97e-9	Coronary artery disease;
KIRP	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.84	-0.45	1.39e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg13395646	chr4:1353034	KIAA1530	-0.36	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-7.53	-0.43	9.68e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03831869	chr16:3508546	NAT15	0.58	6.39	0.38	8.15e-10	Lung cancer in ever smokers;
KIRP	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.46	-0.33	1.18e-7	Metabolite levels;
KIRP	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.61	6.79	0.4	8.5e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.15	-0.31	5.3e-7	Coronary artery disease;
KIRP	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg21605333	chr4:119757512	SEC24D	1.56	10.56	0.56	9.77e-22	Cannabis dependence symptom count;
KIRP	cis	rs28489187	0.706	rs233113	chr1:85786299	T/A	cg16011679	chr1:85725395	C1orf52	0.5	6.11	0.36	3.9e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.86	-0.35	1.46e-8	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.45	-0.33	1.2e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.63	7.38	0.43	2.39e-12	Schizophrenia;
KIRP	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12900413	0.687	rs8034777	chr15:90313057	C/T	cg07116693	chr15:90310901	NA	0.23	4.94	0.3	1.43e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs909341	0.909	rs1291210	chr20:62335293	A/C	cg03999872	chr20:62272968	STMN3	-0.56	-6.62	-0.39	2.25e-10	Atopic dermatitis;
KIRP	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs4650994	0.550	rs11581618	chr1:178572720	G/A	cg12486710	chr1:178512616	C1orf220	-0.25	-5.13	-0.31	6.01e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg16386425	chr10:429943	DIP2C	-0.38	-5.1	-0.31	6.68e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.54	8.08	0.46	3e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7083	1.000	rs2509210	chr11:117136070	T/C	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs10073892	0.828	rs10214392	chr5:101659642	A/T	cg19774478	chr5:101632501	SLCO4C1	0.65	7.14	0.41	1.04e-11	Cognitive decline (age-related);
KIRP	cis	rs6001982	0.748	rs28419341	chr22:40854456	G/T	cg07138101	chr22:40742427	ADSL	0.78	7.04	0.41	1.92e-11	Breast cancer;
KIRP	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg03474202	chr17:45855739	NA	-0.44	-6.24	-0.37	1.9e-9	IgG glycosylation;
KIRP	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-1.0	-12.29	-0.62	2.24e-27	Breast cancer;
KIRP	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.41	-5.81	-0.35	1.9e-8	Endometrial cancer;
KIRP	cis	rs501120	0.584	rs7902040	chr10:44695308	A/G	cg09554077	chr10:44749378	NA	0.49	5.31	0.32	2.46e-7	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.47	7.81	0.45	1.69e-13	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
KIRP	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	trans	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.25	-0.42	5.25e-12	Heart rate;
KIRP	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.52	6.36	0.38	9.75e-10	Subjective well-being;
KIRP	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs12580194	0.593	rs12296692	chr12:55756851	A/G	cg11794356	chr12:55725991	OR6C3	-0.53	-7.47	-0.43	1.43e-12	Cancer;
KIRP	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg07169764	chr2:136633963	MCM6	0.53	6.18	0.37	2.63e-9	Mosquito bite size;
KIRP	cis	rs7737355	0.947	rs6596007	chr5:130588550	A/G	cg06647332	chr5:131281008	NA	-0.47	-5.24	-0.32	3.5e-7	Life satisfaction;
KIRP	cis	rs3821902	0.646	rs73120951	chr3:64058005	T/G	cg09006292	chr3:64049408	NA	-0.5	-5.08	-0.31	7.3e-7	Breast cancer;
KIRP	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg01475377	chr6:109611718	NA	-0.38	-5.27	-0.32	2.99e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg27129171	chr3:47204927	SETD2	0.39	4.92	0.3	1.6e-6	Birth weight;
KIRP	cis	rs40363	1.000	rs37839	chr16:3510310	T/C	cg21433313	chr16:3507492	NAT15	0.65	7.18	0.42	8.35e-12	Tuberculosis;
KIRP	cis	rs1712517	0.844	rs4918003	chr10:105044157	C/T	cg05636881	chr10:105038444	INA	0.42	6.02	0.36	6.37e-9	Migraine;
KIRP	cis	rs2241685	0.834	rs11127299	chr2:1961787	A/G	cg22511877	chr2:1942942	MYT1L	-0.62	-5.58	-0.34	6.26e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.79e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs28595532	0.660	rs11933762	chr4:119307126	A/G	cg26518628	chr1:97050305	NA	-0.82	-8.84	-0.49	1.88e-16	Cannabis dependence symptom count;
KIRP	cis	rs75216060	0.906	rs9657227	chr8:13817839	T/G	cg12665059	chr8:13787749	NA	0.31	4.89	0.3	1.85e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-6.8	-0.4	7.89e-11	Pulmonary function;
KIRP	cis	rs712039	0.652	rs712038	chr17:35762557	G/A	cg16670864	chr17:35848621	DUSP14	0.42	5.03	0.31	9.52e-7	Tuberculosis;
KIRP	cis	rs78761021	0.720	rs56086072	chr17:9798412	C/T	cg26853458	chr17:9805074	RCVRN	0.51	4.93	0.3	1.49e-6	Type 2 diabetes;
KIRP	cis	rs8084125	0.832	rs62105171	chr18:74945663	G/A	cg18461021	chr18:74961002	GALR1	0.52	5.3	0.32	2.59e-7	Obesity-related traits;
KIRP	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.31	-0.55	6.07e-21	Hypospadias;
KIRP	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.44	7.07	0.41	1.61e-11	Testicular germ cell tumor;
KIRP	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.42	5.51	0.33	9.1e-8	IgG glycosylation;
KIRP	cis	rs883565	0.543	rs784496	chr3:39179536	A/G	cg01426195	chr3:39028469	NA	0.51	8.22	0.46	1.18e-14	Handedness;
KIRP	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.78	-0.4	8.89e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.63	7.49	0.43	1.27e-12	Mean platelet volume;
KIRP	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07308232	chr7:1071921	C7orf50	-0.59	-7.47	-0.43	1.44e-12	Longevity;Endometriosis;
KIRP	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg18016565	chr1:150552671	MCL1	0.37	5.88	0.35	1.32e-8	Melanoma;
KIRP	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg11266682	chr4:10021025	SLC2A9	0.34	4.93	0.3	1.54e-6	Blood metabolite levels;
KIRP	cis	rs7224685	0.569	rs8070737	chr17:3981066	G/T	cg21734707	chr17:3908241	ZZEF1	0.53	4.86	0.3	2.09e-6	Type 2 diabetes;
KIRP	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.84	11.37	0.59	2.43e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.68	-10.06	-0.54	3.66e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg07636037	chr3:49044803	WDR6	-0.81	-7.64	-0.44	4.86e-13	Cognitive function;
KIRP	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.71	-0.56	3.22e-22	Menopause (age at onset);
KIRP	cis	rs7395581	0.798	rs10769252	chr11:47343955	A/G	cg25783544	chr11:47291846	MADD	0.44	4.95	0.3	1.36e-6	HDL cholesterol;
KIRP	cis	rs4478858	0.735	rs12134484	chr1:31823741	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.52	-0.33	8.49e-8	Alcohol dependence;
KIRP	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05956132	chr10:46091449	MARCH8	0.45	6.61	0.39	2.37e-10	Interleukin-4 levels;
KIRP	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	-0.43	-5.31	-0.32	2.44e-7	Resistin levels;
KIRP	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08439880	chr3:133502540	NA	-0.5	-6.09	-0.36	4.22e-9	Iron status biomarkers;
KIRP	cis	rs6662572	0.703	rs55641506	chr1:46580708	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.75	0.34	2.69e-8	Blood protein levels;
KIRP	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg10755058	chr3:40428713	ENTPD3	-0.37	-5.36	-0.32	1.94e-7	Renal cell carcinoma;
KIRP	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg01843034	chr6:37503916	NA	-0.72	-8.38	-0.47	4.02e-15	Cognitive performance;
KIRP	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg07777115	chr5:623756	CEP72	-0.6	-6.02	-0.36	6.19e-9	Obesity-related traits;
KIRP	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-9.72	-0.53	4.07e-19	Coronary artery disease;
KIRP	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg22771759	chr13:24902376	NA	0.38	5.05	0.31	8.6e-7	Obesity-related traits;
KIRP	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.76	-0.34	2.51e-8	Breast cancer;
KIRP	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.65	9.14	0.5	2.33e-17	Migraine;Coronary artery disease;
KIRP	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.92	-0.35	1.05e-8	Breast cancer;
KIRP	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg02023728	chr11:77925099	USP35	0.46	7.52	0.43	1.02e-12	Testicular germ cell tumor;
KIRP	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.87	12.24	0.62	3.17e-27	Schizophrenia;
KIRP	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg27205649	chr11:78285834	NARS2	-0.63	-7.06	-0.41	1.68e-11	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02314835	chr15:51914292	DMXL2	0.47	6.04	0.36	5.71e-9	Parkinson's disease;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg01097406	chr16:89675127	NA	-0.3	-4.98	-0.3	1.21e-6	Vitiligo;
KIRP	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.18	-0.64	2.26e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.54	-0.38	3.54e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.75	9.47	0.52	2.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.69	7.94	0.45	7.27e-14	Smoking initiation;
KIRP	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.07	-7.75	-0.44	2.42e-13	Mitochondrial DNA levels;
KIRP	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.23	12.16	0.61	5.79e-27	Diabetic retinopathy;
KIRP	cis	rs56079296	0.929	rs7715363	chr5:121283915	G/C	cg05256605	chr5:121412184	LOX	0.53	5.74	0.34	2.81e-8	Coronary artery disease;
KIRP	cis	rs5750854	0.503	rs5757752	chr22:40025237	G/C	cg10455938	chr22:40058150	CACNA1I	0.43	6.11	0.36	3.92e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14295958	chr14:24025576	THTPA	0.5	6.76	0.4	9.84e-11	Parkinson's disease;
KIRP	cis	rs77688320	0.535	rs7597850	chr2:202261402	A/G	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs16912285	0.688	rs12801480	chr11:24270146	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	9.7	0.53	4.77e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.81	0.53	2.23e-19	Prudent dietary pattern;
KIRP	cis	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.17e-11	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26319343	chr19:5623198	SAFB2;SAFB	0.48	6.49	0.38	4.57e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6450176	1.000	rs3776707	chr5:53304873	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.4	-0.59	1.95e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg20302533	chr7:39170763	POU6F2	0.26	5.29	0.32	2.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12560992	chr17:57184187	TRIM37	0.62	7.15	0.41	9.94e-12	Testicular germ cell tumor;
KIRP	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.57	-0.33	6.83e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg17507749	chr15:85114479	UBE2QP1	0.75	7.14	0.41	1.02e-11	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06202686	chr2:170336108	BBS5	0.51	6.01	0.36	6.49e-9	Smoking initiation;
KIRP	cis	rs80215559	0.661	rs115740542	chr6:26123502	T/C	cg16482183	chr6:26056742	HIST1H1C	0.94	5.64	0.34	4.75e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg17133734	chr15:86042851	AKAP13	-0.47	-5.93	-0.35	1e-8	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	15.6	0.71	1.27e-38	Platelet count;
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg06145435	chr7:1022769	CYP2W1	0.36	5.14	0.31	5.74e-7	Longevity;Endometriosis;
KIRP	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-1.05	-14.17	-0.67	1e-33	Blood pressure (smoking interaction);
KIRP	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.57	-7.52	-0.43	1e-12	Male sexual orientation;
KIRP	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg02696790	chr15:75250997	RPP25	0.28	5.17	0.31	4.95e-7	Breast cancer;
KIRP	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.51	7.06	0.41	1.71e-11	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.65	0.48	6.69e-16	Prudent dietary pattern;
KIRP	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.53	-8.04	-0.46	3.74e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg23649088	chr2:200775458	C2orf69	-0.56	-4.99	-0.3	1.14e-6	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26734620	chr12:56694298	CS	-0.86	-7.95	-0.45	6.74e-14	Psoriasis vulgaris;
KIRP	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg08501292	chr6:25962987	TRIM38	1.1	8.13	0.46	2.09e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.74	-12.06	-0.61	1.25e-26	Prostate cancer;
KIRP	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.32	0.32	2.34e-7	Height;
KIRP	cis	rs4638749	0.501	rs2101357	chr2:108748974	G/A	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.92	-0.3	1.57e-6	Blood pressure;
KIRP	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg13010199	chr12:38710504	ALG10B	0.54	6.52	0.38	4.04e-10	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg24009623	chr19:33667908	NA	0.47	6.23	0.37	2.03e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25860425	chr11:64684671	ATG2A	-0.5	-6.54	-0.38	3.45e-10	Metabolic traits;
KIRP	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg03128534	chr1:43423976	SLC2A1	-0.51	-5.82	-0.35	1.79e-8	Red cell distribution width;
KIRP	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.68	9.95	0.54	8.26e-20	Dupuytren's disease;
KIRP	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.15	0.37	3.08e-9	Hypertriglyceridemia;
KIRP	cis	rs7534824	0.625	rs17409422	chr1:101502386	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	6.75	0.4	1.03e-10	Refractive astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17103051	chr17:17184692	COPS3	0.44	6.04	0.36	5.78e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	cis	rs12580194	0.630	rs60586348	chr12:55745151	A/T	cg19537932	chr12:55886519	OR6C68	-0.5	-6.47	-0.38	5.14e-10	Cancer;
KIRP	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.53	7.14	0.41	1.04e-11	Tuberculosis;
KIRP	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-7.24	-0.42	5.7e-12	Monocyte count;
KIRP	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-0.84	-11.99	-0.61	2.11e-26	Total body bone mineral density;
KIRP	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg27205649	chr11:78285834	NARS2	0.67	8.95	0.5	8.9e-17	Alzheimer's disease (survival time);
KIRP	cis	rs67385638	0.962	rs2071348	chr11:5264146	T/G	cg12559170	chr11:5275217	HBG2	0.45	6.41	0.38	7.37e-10	Hemoglobin levels;
KIRP	trans	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg11693508	chr17:37793320	STARD3	0.8	8.01	0.45	4.48e-14	Neuroticism;
KIRP	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg09699651	chr6:150184138	LRP11	0.48	6.49	0.38	4.69e-10	Lung cancer;
KIRP	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg20362242	chr5:692897	TPPP	0.56	4.86	0.3	2.14e-6	Obesity-related traits;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg19936614	chr4:187627811	FAT1	0.39	6.12	0.36	3.67e-9	Warfarin maintenance dose;
KIRP	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.63	-7.7	-0.44	3.39e-13	Eosinophil percentage of white cells;
KIRP	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.67	9.76	0.53	3.23e-19	Dupuytren's disease;
KIRP	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg18709589	chr6:96969512	KIAA0776	0.34	5.18	0.31	4.59e-7	Headache;
KIRP	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7709377	0.597	rs1396481	chr5:115475187	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.02	0.3	9.97e-7	Metabolite levels  (X-11787);
KIRP	cis	rs11250464	0.724	rs4614361	chr10:1410394	A/G	cg08668359	chr10:1443807	ADARB2	0.49	6.1	0.36	4.09e-9	Radiation response;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg12933314	chr7:4815160	KIAA0415	0.54	6.24	0.37	1.85e-9	Sleep duration;
KIRP	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs9469913	0.740	rs2814943	chr6:34552736	C/T	cg17674042	chr6:34482479	PACSIN1	-0.46	-6.28	-0.37	1.55e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.97	-13.89	-0.66	9.19e-33	Cognitive function;
KIRP	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.65	7.89	0.45	1e-13	Aortic root size;
KIRP	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.61	-0.48	9.01e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.46	8.1	0.46	2.65e-14	Height;
KIRP	cis	rs6963495	0.556	rs818481	chr7:105158467	G/C	cg19920283	chr7:105172520	RINT1	0.54	6.13	0.36	3.5e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4722404	0.840	rs4236317	chr7:3134593	C/T	cg06416929	chr7:3127028	NA	-0.34	-5.09	-0.31	7.09e-7	Atopic dermatitis;
KIRP	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.95	14.11	0.67	1.65e-33	Response to bleomycin (chromatid breaks);
KIRP	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.63	-8.45	-0.47	2.64e-15	Glaucoma (primary open-angle);
KIRP	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs448720	0.811	rs4776382	chr15:68179651	C/T	cg24579218	chr15:68104479	NA	-0.39	-5.49	-0.33	1e-7	Cognitive performance;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21902014	chr5:90076292	GPR98	-0.41	-6.41	-0.38	7.4e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.48	-5.65	-0.34	4.41e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.57	-7.79	-0.44	1.84e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.95	10.93	0.57	6.13e-23	Corneal astigmatism;
KIRP	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.87	0.4	5.2e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9311676	0.632	rs11130643	chr3:58423288	G/A	cg06643156	chr3:58380774	PXK	0.35	4.89	0.3	1.8e-6	Systemic lupus erythematosus;
KIRP	trans	rs12517041	1.000	rs2081951	chr5:23287576	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.68	-0.48	5.57e-16	Calcium levels;
KIRP	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.53	-6.96	-0.41	3.06e-11	Pulse pressure;
KIRP	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.99	11.89	0.6	4.52e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs427941	0.632	rs201505	chr7:101760287	T/C	cg06246474	chr7:101738831	CUX1	0.56	6.87	0.4	5.12e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.57	-7.2	-0.42	7.35e-12	Metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08020574	chr16:89557182	ANKRD11	0.48	6.55	0.39	3.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.42	5.47	0.33	1.1e-7	Cardiovascular disease risk factors;
KIRP	cis	rs13088645	0.652	rs13074557	chr3:134153526	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.54	7.71	0.44	3.03e-13	Coronary artery disease;
KIRP	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.69	-7.8	-0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg09408571	chr1:101003634	GPR88	-0.24	-5.53	-0.33	8.06e-8	Monocyte count;
KIRP	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.83	15.52	0.7	2.44e-38	Anterior chamber depth;
KIRP	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.95	-0.35	9.4e-9	Glomerular filtration rate;
KIRP	cis	rs533123	0.818	rs204051	chr1:29166578	A/G	cg08366446	chr1:29138936	OPRD1	0.91	7.58	0.43	7.21e-13	Schizophrenia;
KIRP	cis	rs9535307	0.860	rs1127021	chr13:50296115	C/T	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs2412208	0.755	rs10864263	chr1:7068025	C/T	cg20434152	chr1:7120926	CAMTA1	-0.37	-4.93	-0.3	1.5e-6	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.53	7.29	0.42	4.14e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg26876637	chr1:152193138	HRNR	0.77	10.13	0.54	2.27e-20	Atopic dermatitis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02106828	chr1:236959224	MTR	-0.93	-6.31	-0.37	1.27e-9	P wave terminal force;
KIRP	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13047869	chr3:10149882	C3orf24	-0.53	-4.89	-0.3	1.85e-6	Alzheimer's disease;
KIRP	cis	rs7119038	0.818	rs76704408	chr11:118683327	G/T	cg19308663	chr11:118741387	NA	0.53	9.1	0.5	3.26e-17	Sjögren's syndrome;
KIRP	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg18882449	chr10:104885122	NT5C2	-0.49	-6.33	-0.37	1.16e-9	Arsenic metabolism;
KIRP	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg25600027	chr14:23388339	RBM23	-0.5	-6.23	-0.37	2.04e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg00931491	chr16:28608288	SULT1A2	0.27	5.44	0.33	1.27e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg03929089	chr4:120376271	NA	0.67	6.49	0.38	4.61e-10	Axial length;
KIRP	cis	rs860295	0.756	rs7546258	chr1:155698645	T/A	cg02153340	chr1:155202674	NA	-0.42	-5.71	-0.34	3.28e-8	Body mass index;
KIRP	trans	rs10181042	0.565	rs2564117	chr2:61233022	A/T	cg26882419	chr1:227751228	ZNF678	-0.48	-6.08	-0.36	4.5e-9	Crohn's disease;
KIRP	cis	rs7215564	0.818	rs4075782	chr17:78556325	A/G	cg06153925	chr17:78755379	RPTOR	-0.46	-5.84	-0.35	1.68e-8	Myopia (pathological);
KIRP	cis	rs2882877	0.735	rs994227	chr2:190432467	T/C	cg10752008	chr2:190445175	SLC40A1	0.46	5.25	0.32	3.34e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg27506609	chr1:36549197	TEKT2	0.46	5.68	0.34	3.76e-8	Corneal structure;
KIRP	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.05	-0.31	8.47e-7	Educational attainment (years of education);
KIRP	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg17691542	chr6:26056736	HIST1H1C	0.65	7.63	0.44	5.28e-13	Iron status biomarkers;
KIRP	cis	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg21546286	chr11:48923668	NA	-0.47	-6.16	-0.37	3e-9	HDL cholesterol;
KIRP	cis	rs11024102	0.962	rs34927905	chr11:17001427	C/T	cg15378786	chr11:17036137	PLEKHA7	0.49	4.94	0.3	1.42e-6	Glaucoma (primary angle closure);
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-4.85	-0.3	2.2e-6	Electroencephalogram traits;
KIRP	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg00076555	chr3:49705435	BSN	-0.29	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg04132472	chr17:19861366	AKAP10	0.67	10.57	0.56	8.77e-22	Schizophrenia;
KIRP	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.97	9.91	0.53	1.11e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.68	10.24	0.55	9.67e-21	Blood metabolite levels;
KIRP	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg16586182	chr3:47516702	SCAP	0.81	11.65	0.6	2.79e-25	Colorectal cancer;
KIRP	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	11.61	0.6	3.81e-25	Smoking behavior;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06697094	chr17:54911185	DGKE	-0.45	-6.33	-0.37	1.12e-9	Metabolic traits;
KIRP	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg26354017	chr1:205819088	PM20D1	-0.61	-6.0	-0.36	7.06e-9	Menarche (age at onset);
KIRP	cis	rs7224685	0.569	rs12940782	chr17:3992712	T/C	cg09597638	chr17:3907349	NA	0.54	5.36	0.32	1.93e-7	Type 2 diabetes;
KIRP	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg09699651	chr6:150184138	LRP11	0.48	6.26	0.37	1.74e-9	Lung cancer;
KIRP	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg08885076	chr2:99613938	TSGA10	-0.37	-4.85	-0.3	2.23e-6	Chronic sinus infection;
KIRP	cis	rs1829883	0.898	rs2963578	chr5:98785417	C/T	cg08333243	chr5:99726346	NA	-0.41	-5.45	-0.33	1.24e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs1950626	0.833	rs72700524	chr14:101417309	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.83	0.4	6.72e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs735539	0.555	rs2762990	chr13:21371427	T/C	cg04906043	chr13:21280425	IL17D	-0.43	-5.12	-0.31	6.05e-7	Dental caries;
KIRP	cis	rs4363506	0.625	rs1931733	chr10:129281605	T/G	cg07804728	chr10:129284050	NA	0.41	5.51	0.33	9.07e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg17845761	chr1:175162550	KIAA0040	0.33	6.47	0.38	5.15e-10	Alcohol dependence;
KIRP	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.5	-5.16	-0.31	5.15e-7	Huntington's disease progression;
KIRP	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg27205649	chr11:78285834	NARS2	-0.66	-8.54	-0.48	1.46e-15	Alzheimer's disease (survival time);
KIRP	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg04727924	chr7:799746	HEATR2	-0.76	-8.55	-0.48	1.3e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg03060546	chr3:49711283	APEH	0.57	6.08	0.36	4.48e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7565981	1.000	rs6722013	chr2:101429196	A/G	cg02232089	chr2:101440696	NPAS2	-0.57	-5.23	-0.32	3.63e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.47	6.55	0.39	3.28e-10	Red blood cell count;
KIRP	cis	rs2273156	0.587	rs8014377	chr14:35531057	C/T	cg09327582	chr14:35236912	BAZ1A	-0.47	-4.84	-0.3	2.24e-6	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg01849789	chr22:41697279	ZC3H7B	-0.45	-5.36	-0.32	1.88e-7	Vitiligo;
KIRP	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.79	10.77	0.57	2.04e-22	Aortic root size;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25059436	chr11:47574990	CUGBP1	0.47	6.15	0.37	3.08e-9	Myopia (pathological);
KIRP	cis	rs3815308	0.530	rs2240129	chr19:2197734	C/T	cg09261902	chr19:2140048	AP3D1	0.57	7.96	0.45	6.47e-14	Breast cancer;
KIRP	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg18350739	chr11:68623251	NA	-0.48	-7.75	-0.44	2.36e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.68	-8.76	-0.49	3.32e-16	Cognitive test performance;
KIRP	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.47	0.38	5.25e-10	Lung cancer;
KIRP	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg04995300	chr3:66848608	NA	-0.67	-9.01	-0.5	5.81e-17	Type 2 diabetes;
KIRP	cis	rs9346649	0.654	rs35453512	chr6:168491906	C/G	cg09211372	chr6:168490623	NA	-0.37	-6.49	-0.38	4.72e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs882732	1.000	rs910342	chr14:95038047	G/T	cg05186455	chr14:95027692	SERPINA4	-0.39	-5.29	-0.32	2.68e-7	Blood protein levels;
KIRP	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.98	15.64	0.71	9.62e-39	Uric acid clearance;
KIRP	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.75	8.25	0.47	9.7e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	5.94	0.35	9.62e-9	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03160445	chr3:100120349	LNP1;TOMM70A	0.54	6.15	0.37	3.06e-9	Smoking initiation;
KIRP	cis	rs4700695	0.925	rs4700693	chr5:65399078	A/G	cg21114390	chr5:65439923	SFRS12	-0.5	-4.85	-0.3	2.23e-6	Facial morphology (factor 19);
KIRP	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg11789530	chr4:8429930	ACOX3	-0.88	-10.1	-0.54	2.71e-20	Response to antineoplastic agents;
KIRP	cis	rs6693295	0.877	rs10924530	chr1:246337719	G/A	cg11798871	chr1:246315928	SMYD3	-0.56	-6.46	-0.38	5.63e-10	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02359409	chr6:42947317	PEX6	-0.37	-4.93	-0.3	1.49e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg05802129	chr4:122689817	NA	-0.46	-6.71	-0.39	1.32e-10	Type 2 diabetes;
KIRP	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg06481639	chr22:41940642	POLR3H	-0.45	-4.99	-0.3	1.15e-6	Neuroticism;
KIRP	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17366294	chr4:99064904	C4orf37	-0.39	-5.53	-0.33	8.02e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.0	0.3	1.12e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.4	-5.75	-0.34	2.6e-8	Dementia with Lewy bodies;
KIRP	cis	rs35740288	0.857	rs3803506	chr15:86290940	A/C	cg17133734	chr15:86042851	AKAP13	-0.51	-5.64	-0.34	4.78e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3736485	0.932	rs10519313	chr15:51915812	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.16	-0.31	5.12e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg00495681	chr13:53174319	NA	0.37	4.92	0.3	1.59e-6	Lewy body disease;
KIRP	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs1010254	0.510	rs72791425	chr5:151770646	A/G	cg12297329	chr5:152029980	NA	-0.67	-6.63	-0.39	2.08e-10	Optic nerve measurement (cup area);
KIRP	cis	rs6088813	1.000	rs6142358	chr20:33960308	A/G	cg14752227	chr20:34000481	UQCC	0.53	7.03	0.41	2.08e-11	Height;
KIRP	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14893161	chr1:205819251	PM20D1	-0.58	-5.68	-0.34	3.86e-8	Menarche (age at onset);
KIRP	cis	rs8113308	0.810	rs11879040	chr19:52450109	A/C	cg24732339	chr19:52471368	ZNF350	-0.46	-5.18	-0.31	4.72e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs787274	1.000	rs7030795	chr9:115558962	G/A	cg13803584	chr9:115635662	SNX30	-0.73	-6.61	-0.39	2.33e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.81	-12.44	-0.62	7.01e-28	Blood metabolite levels;
KIRP	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg08885076	chr2:99613938	TSGA10	-0.61	-10.98	-0.57	4.51e-23	Chronic sinus infection;
KIRP	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg24747557	chr10:131355152	MGMT	-0.38	-5.05	-0.31	8.69e-7	Response to temozolomide;
KIRP	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2929278	0.617	rs524908	chr15:44187991	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.47	-5.79	-0.35	2.19e-8	Schizophrenia;
KIRP	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.55	-6.28	-0.37	1.53e-9	Smoking behavior;
KIRP	trans	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	trans	rs6851508	0.573	rs309705	chr4:177427340	G/T	cg10644361	chr14:37667230	MIPOL1	0.49	6.05	0.36	5.3e-9	Left ventricle wall thickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07121640	chr3:185303828	SENP2	0.57	7.04	0.41	1.86e-11	Parkinson's disease;
KIRP	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg23172400	chr8:95962367	TP53INP1	0.39	8.24	0.46	1.05e-14	Type 2 diabetes;
KIRP	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg21361702	chr7:150065534	REPIN1	0.51	5.51	0.33	9.01e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.75	-10.37	-0.55	3.87e-21	Plateletcrit;Platelet count;
KIRP	cis	rs4790312	0.846	rs2131704	chr17:1970898	C/T	cg24156229	chr17:1948635	NA	-0.41	-5.15	-0.31	5.39e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs4704846	0.614	rs6420075	chr5:156486120	C/G	cg12943317	chr5:156479607	HAVCR1	0.52	4.89	0.3	1.83e-6	Blood protein levels;
KIRP	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg04837898	chr3:45731254	SACM1L	-0.35	-4.87	-0.3	1.99e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.94	-0.3	1.41e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.9	0.64	2.05e-29	Exhaled nitric oxide output;
KIRP	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11987759	chr7:65425863	GUSB	-0.48	-6.19	-0.37	2.47e-9	Aortic root size;
KIRP	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.52	5.49	0.33	1.01e-7	Obesity-related traits;
KIRP	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.62	8.25	0.47	9.95e-15	Prostate cancer;
KIRP	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.93	0.53	9.33e-20	Schizophrenia;
KIRP	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg17724175	chr1:150552817	MCL1	0.35	5.81	0.35	1.92e-8	Melanoma;
KIRP	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.24	-0.32	3.44e-7	Fear of minor pain;
KIRP	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg07843065	chr1:150265600	MRPS21	0.43	5.89	0.35	1.28e-8	Migraine;
KIRP	trans	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg25214090	chr10:38739885	LOC399744	-0.58	-6.83	-0.4	6.5500000000000006e-11	Corneal astigmatism;
KIRP	cis	rs77861329	1.000	rs352151	chr3:52210272	C/G	cg08692210	chr3:52188851	WDR51A	0.92	7.34	0.42	3.05e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs281408	0.559	rs281386	chr19:49217305	A/G	cg21064579	chr19:49206444	FUT2	-0.35	-4.88	-0.3	1.87e-6	Urinary metabolites (H-NMR features);
KIRP	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.83	12.96	0.64	1.23e-29	Testicular germ cell tumor;
KIRP	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.09	-0.61	9.94e-27	Chronic sinus infection;
KIRP	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.38	-0.47	3.97e-15	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21950493	chr12:110907285	GPN3;C12orf24	1.07	7.17	0.42	8.6e-12	P wave terminal force;
KIRP	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.54	7.68	0.44	3.85e-13	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.75	-8.79	-0.49	2.69e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg23594656	chr7:65796392	TPST1	0.42	5.8	0.35	2.02e-8	Aortic root size;
KIRP	cis	rs76533333	0.646	rs71446625	chr13:113390285	G/T	cg04656015	chr13:113407548	ATP11A	0.72	5.99	0.36	7.34e-9	Red cell distribution width;
KIRP	cis	rs4262150	0.767	rs17453481	chr5:151949017	A/C	cg12297329	chr5:152029980	NA	-0.67	-8.16	-0.46	1.76e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.83	-13.32	-0.65	7.72e-31	Blood metabolite levels;
KIRP	cis	rs7760535	0.763	rs10457240	chr6:111848874	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.65	-0.34	4.4e-8	Metabolic traits;
KIRP	cis	rs2046867	0.908	rs2322610	chr3:72793651	C/A	cg25664220	chr3:72788482	NA	-0.41	-5.97	-0.36	8.3e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.68	-8.23	-0.46	1.1e-14	Blood protein levels;
KIRP	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.63	-0.34	4.98e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1365505	0.600	rs1648350	chr15:50486400	G/A	cg26188685	chr15:50540269	HDC	-0.33	-5.45	-0.33	1.22e-7	Blood metabolite ratios;
KIRP	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02187348	chr16:89574699	SPG7	0.51	6.51	0.38	4.24e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg02367723	chr1:46378857	MAST2	0.44	5.04	0.31	8.85e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs10858047	0.943	rs9729280	chr1:115076994	G/A	cg12756093	chr1:115239321	AMPD1	0.55	5.3	0.32	2.52e-7	Autism;
KIRP	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg13482628	chr17:19912719	NA	0.53	6.85	0.4	5.99e-11	Schizophrenia;
KIRP	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.61	-8.66	-0.48	6.51e-16	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.58	-6.51	-0.38	4.09e-10	Bipolar disorder;
KIRP	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg06219351	chr7:158114137	PTPRN2	0.58	8.36	0.47	4.68e-15	Calcium levels;
KIRP	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs1894292	0.715	rs6827519	chr4:74466409	G/A	cg12566645	chr4:74483141	RASSF6	0.36	4.99	0.3	1.12e-6	Prostate cancer;
KIRP	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg21452805	chr1:244014465	NA	0.7	6.55	0.39	3.33e-10	RR interval (heart rate);
KIRP	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	5.94	0.35	9.49e-9	Iron status biomarkers;
KIRP	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.96	-14.47	-0.68	9.72e-35	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4849845	0.889	rs2278505	chr2:121050560	A/G	cg24070213	chr2:121070622	NA	0.41	5.66	0.34	4.22e-8	Mean platelet volume;
KIRP	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.69	9.97	0.54	6.77e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.51	-13.5	-0.65	1.93e-31	Cutaneous nevi;
KIRP	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.46	-11.07	-0.58	2.28e-23	Diabetic kidney disease;
KIRP	cis	rs986417	0.901	rs12886086	chr14:61042091	A/G	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2548003	0.541	rs2014310	chr5:28723589	T/C	cg11015470	chr5:28928158	NA	0.52	5.71	0.34	3.23e-8	Hip geometry;
KIRP	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg18709589	chr6:96969512	KIAA0776	0.34	5.15	0.31	5.29e-7	Headache;
KIRP	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg01721255	chr8:58191610	C8orf71	0.61	5.48	0.33	1.08e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2456568	0.695	rs7942055	chr11:93691063	A/C	cg26875233	chr11:93583750	C11orf90	0.35	6.62	0.39	2.23e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.59	7.35	0.42	2.99e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg22384356	chr8:124195192	FAM83A	-0.55	-4.99	-0.3	1.16e-6	Urinary uromodulin levels;
KIRP	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg00241281	chr14:105779794	PACS2	-0.36	-5.19	-0.31	4.3e-7	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg06521331	chr12:34319734	NA	-0.6	-7.09	-0.41	1.39e-11	Bladder cancer;
KIRP	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.75	-0.34	2.59e-8	Breast cancer;
KIRP	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.59e-18	Corneal astigmatism;
KIRP	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	6.16	0.37	2.92e-9	Breast cancer;
KIRP	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg04132472	chr17:19861366	AKAP10	0.43	5.93	0.35	1e-8	Schizophrenia;
KIRP	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg07701084	chr6:150067640	NUP43	0.68	8.9	0.49	1.26e-16	Lung cancer;
KIRP	cis	rs13088645	0.532	rs12695612	chr3:134161824	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.47	6.2	0.37	2.31e-9	Coronary artery disease;
KIRP	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg24154853	chr7:158122151	PTPRN2	0.39	5.56	0.33	7.17e-8	Calcium levels;
KIRP	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7209700	0.821	rs4634	chr17:45369789	G/A	cg25173405	chr17:45401733	C17orf57	0.41	4.89	0.3	1.8e-6	IgG glycosylation;
KIRP	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.83	0.35	1.73e-8	Breast cancer;
KIRP	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg21573476	chr21:45109991	RRP1B	-0.54	-7.33	-0.42	3.41e-12	Mean corpuscular volume;
KIRP	cis	rs829661	0.948	rs829662	chr2:30726551	G/C	cg10949345	chr2:30726833	LCLAT1	0.69	9.68	0.53	5.44e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7551222	0.681	rs4245739	chr1:204518842	G/T	cg20240347	chr1:204465584	NA	-0.37	-6.29	-0.37	1.45e-9	Schizophrenia;
KIRP	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21984481	chr17:79567631	NPLOC4	0.38	6.05	0.36	5.47e-9	Eye color traits;
KIRP	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg17554472	chr22:41940697	POLR3H	-0.46	-5.51	-0.33	9.14e-8	Neuroticism;
KIRP	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.81	11.29	0.58	4.41e-24	Aortic root size;
KIRP	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.56	8.83	0.49	1.99e-16	Coronary artery disease;
KIRP	cis	rs17293817	1.000	rs17293817	chr10:1452786	C/T	cg02851212	chr10:1451418	ADARB2	0.41	5.2	0.31	4.11e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21426303	chr8:123945740	ZHX2	0.45	6.23	0.37	1.98e-9	Interleukin-4 levels;
KIRP	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.86	-0.53	1.51e-19	Triglycerides;
KIRP	cis	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg08773314	chr2:239334832	ASB1	-0.55	-5.68	-0.34	3.84e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg12292205	chr6:26970375	C6orf41	0.34	4.86	0.3	2.09e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18314121	chr1:225726360	ENAH	0.4	6.46	0.38	5.67e-10	Survival in pancreatic cancer;
KIRP	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.28	0.37	1.56e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs42648	0.569	rs110360	chr7:89856608	C/T	cg25739043	chr7:89950458	NA	-0.39	-6.05	-0.36	5.24e-9	Homocysteine levels;
KIRP	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg10223061	chr2:219282414	VIL1	-0.29	-4.85	-0.3	2.19e-6	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg02367723	chr1:46378857	MAST2	0.43	5.01	0.3	1.02e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs13185784	0.703	rs62406991	chr5:179658323	A/G	cg23248424	chr5:179741104	GFPT2	0.54	5.33	0.32	2.26e-7	TRAIL levels;
KIRP	cis	rs4302748	0.862	rs4720196	chr7:36183300	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs7766436	0.553	rs62391069	chr6:22610835	C/T	cg13666174	chr6:22585274	NA	-0.45	-5.11	-0.31	6.56e-7	Coronary artery disease;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.65	-9.65	-0.52	6.58e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg26875233	chr11:93583750	C11orf90	0.42	7.9	0.45	9.5e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.56	-7.0	-0.41	2.42e-11	Coronary artery disease;
KIRP	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg16497661	chr14:103986332	CKB	0.84	14.64	0.68	2.59e-35	Body mass index;
KIRP	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.39	-5.09	-0.31	7.13e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs925946	0.518	rs10767647	chr11:27567392	A/G	cg18117895	chr11:27722066	BDNF	-0.45	-4.87	-0.3	1.96e-6	Body mass index;Weight;
KIRP	trans	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.53	0.38	3.82e-10	Mood instability;
KIRP	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.44	0.43	1.63e-12	Lung cancer;
KIRP	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.52	5.77	0.35	2.31e-8	Birth weight;
KIRP	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-5.52	-0.33	8.67e-8	Caffeine consumption;
KIRP	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00300879	chr1:26503847	CNKSR1	0.48	6.56	0.39	3.2e-10	Height;
KIRP	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg17143192	chr8:8559678	CLDN23	0.72	8.33	0.47	5.53e-15	Obesity-related traits;
KIRP	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg25650185	chr19:21324782	ZNF431	0.47	4.96	0.3	1.33e-6	Pain;
KIRP	cis	rs13006833	0.634	rs1876877	chr2:191145274	G/A	cg27211696	chr2:191398769	TMEM194B	0.4	5.56	0.33	6.89e-8	Urinary metabolites;
KIRP	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg26354017	chr1:205819088	PM20D1	0.45	5.0	0.3	1.11e-6	Parkinson's disease;
KIRP	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-19.03	-0.77	3.04e-50	Height;
KIRP	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg26876637	chr1:152193138	HRNR	-0.7	-8.75	-0.49	3.4e-16	Atopic dermatitis;
KIRP	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg23845249	chr11:68861649	NA	0.6	8.76	0.49	3.31e-16	Blond vs. brown hair color;
KIRP	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.95	0.3	1.4e-6	Bipolar disorder;
KIRP	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.32	-0.37	1.2e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	1.0	17.46	0.74	6.01e-45	Breast cancer;
KIRP	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg16346588	chr10:242978	ZMYND11	0.45	5.58	0.34	6.37e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs6546886	0.912	rs10200470	chr2:74284687	A/G	cg14702570	chr2:74259524	NA	-0.33	-6.78	-0.4	8.87e-11	Dialysis-related mortality;
KIRP	trans	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.47	-0.38	5.33e-10	Neuroticism;
KIRP	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.66	-8.51	-0.48	1.73e-15	Extraversion;
KIRP	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg06634786	chr22:41940651	POLR3H	-0.48	-5.8	-0.35	2.04e-8	Neuroticism;
KIRP	cis	rs78487399	0.808	rs7599781	chr2:43678726	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10892173	0.846	rs2298647	chr11:117671641	A/T	cg21640587	chr11:117668038	DSCAML1	0.45	6.62	0.39	2.18e-10	Myopia;
KIRP	cis	rs11138902	0.649	rs13283450	chr9:72164094	C/G	cg14397918	chr9:72078829	APBA1	0.35	5.59	0.34	6.15e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.39	4.93	0.3	1.52e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.49	6.0	0.36	7.15e-9	Glycated hemoglobin levels;
KIRP	cis	rs17092148	1.000	rs11699062	chr20:33400379	A/T	cg16810054	chr20:33298113	TP53INP2	0.47	5.71	0.34	3.17e-8	Neuroticism;
KIRP	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.52	-6.32	-0.37	1.23e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.88	-14.85	-0.69	4.83e-36	Prostate cancer;
KIRP	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg02725872	chr8:58115012	NA	-0.44	-5.09	-0.31	7.13e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2213920	0.679	rs7860135	chr9:118242257	G/A	cg13918206	chr9:118159781	DEC1	0.81	8.44	0.47	2.72e-15	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.74	10.53	0.56	1.24e-21	Schizophrenia;
KIRP	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg21858823	chr1:15850916	CASP9	0.55	5.88	0.35	1.36e-8	Systolic blood pressure;
KIRP	cis	rs9435341	0.762	rs72697623	chr1:107554269	G/A	cg09367891	chr1:107599246	PRMT6	0.67	9.01	0.5	5.85e-17	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg26874229	chr2:105853672	NA	-0.41	-5.64	-0.34	4.54e-8	Type 2 diabetes;
KIRP	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg18404041	chr3:52824283	ITIH1	0.41	5.19	0.31	4.49e-7	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.06	-0.31	8.37e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1978968	0.788	rs12169946	chr22:18468105	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.56	-6.65	-0.39	1.83e-10	Presence of antiphospholipid antibodies;
KIRP	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.76	-9.33	-0.51	6.67e-18	Corneal astigmatism;
KIRP	cis	rs405956	0.932	rs9654624	chr6:105584895	G/C	cg22580625	chr6:105627791	POPDC3	-0.63	-6.58	-0.39	2.84e-10	QT interval;
KIRP	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg13334819	chr7:99746414	C7orf59	-0.54	-6.1	-0.36	4.16e-9	Coronary artery disease;
KIRP	cis	rs4852324	0.536	rs17009553	chr2:74220035	A/G	cg05890377	chr2:74357713	NA	-0.65	-4.87	-0.3	2.01e-6	Systemic lupus erythematosus;
KIRP	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.48	-5.84	-0.35	1.6e-8	P wave terminal force;
KIRP	cis	rs16828019	0.789	rs34216154	chr1:41670907	G/A	cg18742814	chr1:41828276	NA	0.66	5.74	0.34	2.73e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg23682824	chr7:23144976	KLHL7	0.57	6.9	0.4	4.33e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.35	-0.38	1.02e-9	Metabolite levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25964984	chr22:30783371	RNF215	-0.45	-6.16	-0.37	3e-9	Metabolic traits;
KIRP	cis	rs2505998	0.879	rs2435358	chr10:43580215	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.52	-5.42	-0.33	1.43e-7	Hirschsprung disease;
KIRP	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg07382826	chr16:28625726	SULT1A1	0.51	6.02	0.36	6.42e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.6	-7.53	-0.43	9.77e-13	Iron status biomarkers;
KIRP	cis	rs4711350	0.765	rs2182658	chr6:33748831	G/T	cg25922239	chr6:33757077	LEMD2	-0.56	-6.06	-0.36	5.03e-9	Schizophrenia;
KIRP	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-5.07	-0.31	7.84e-7	Height;
KIRP	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg21132104	chr15:45694354	SPATA5L1	-0.9	-10.76	-0.57	2.16e-22	Homoarginine levels;
KIRP	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7011507	1.000	rs7829764	chr8:49164981	C/T	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.43	-5.14	-0.31	5.52e-7	IgG glycosylation;
KIRP	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.38	-0.38	8.68e-10	Systemic lupus erythematosus;
KIRP	cis	rs6500550	0.599	rs2379220	chr16:3694299	G/C	cg07396092	chr16:3662230	BTBD12	0.44	5.12	0.31	6.27e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg01065977	chr19:18549689	ISYNA1	0.39	5.82	0.35	1.85e-8	Breast cancer;
KIRP	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs15676	0.812	rs10819447	chr9:131576416	T/G	cg00228799	chr9:131580591	ENDOG	0.59	6.8	0.4	7.76e-11	Blood metabolite levels;
KIRP	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.47	-6.91	-0.4	4.15e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.36	-0.32	1.88e-7	Red blood cell count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23097696	chr1:156308121	CCT3;C1orf182	-0.45	-6.28	-0.37	1.55e-9	Survival in pancreatic cancer;
KIRP	cis	rs10875746	0.768	rs12305182	chr12:48421407	G/T	cg20731937	chr12:48336164	NA	0.44	5.78	0.35	2.2e-8	Longevity (90 years and older);
KIRP	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.94	-0.4	3.49e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.09	21.46	0.81	2.85e-58	Testicular germ cell tumor;
KIRP	cis	rs5756391	0.546	rs9607397	chr22:37315988	C/T	cg16356956	chr22:37317934	CSF2RB	0.37	5.09	0.31	7.1e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7252505	0.892	rs8111153	chr19:33606056	C/T	cg17764715	chr19:33622953	WDR88	0.69	5.98	0.36	7.75e-9	Colorectal cancer;
KIRP	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.47	7.22	0.42	6.29e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs6578185	0.810	rs7816220	chr8:142453585	T/C	cg15142913	chr8:142440250	PTP4A3	0.36	4.91	0.3	1.63e-6	Endometriosis;
KIRP	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.23	17.17	0.74	5.89e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg01864069	chr14:103024347	NA	-0.96	-12.71	-0.63	8.72e-29	Platelet count;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-6.41	-0.38	7.24e-10	Lung cancer;
KIRP	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.29	-0.78	4.04e-51	Schizophrenia;
KIRP	cis	rs4783244	0.794	rs17175173	chr16:82645892	G/A	cg09415485	chr16:82663111	CDH13	-0.29	-5.3	-0.32	2.59e-7	Adiponectin levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00650088	chr1:227169808	CABC1	0.45	6.2	0.37	2.37e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08280861	chr8:58055591	NA	0.79	6.36	0.38	9.52e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.45	-5.32	-0.32	2.31e-7	Testicular germ cell tumor;Testicular germ cell cancer;
KIRP	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg06781948	chr3:72941472	GXYLT2	0.47	6.17	0.37	2.85e-9	Motion sickness;
KIRP	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg00629941	chr15:75287862	SCAMP5	-0.48	-5.16	-0.31	5.16e-7	Blood trace element (Zn levels);
KIRP	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg05973401	chr12:123451056	ABCB9	0.62	7.25	0.42	5.46e-12	Platelet count;
KIRP	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.24e-7	Lung cancer;
KIRP	cis	rs6541297	0.645	rs4846919	chr1:230301451	A/G	cg20703242	chr1:230279135	GALNT2	0.31	5.08	0.31	7.53e-7	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.47	6.06	0.36	5e-9	Red cell distribution width;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12267933	chr2:228176991	COL4A3	0.43	6.04	0.36	5.6e-9	Interleukin-4 levels;
KIRP	cis	rs7692976	0.608	rs1860129	chr4:110886343	G/C	cg06981781	chr4:110842888	EGF	-0.24	-5.27	-0.32	3.04e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg05973401	chr12:123451056	ABCB9	0.6	7.05	0.41	1.84e-11	Platelet count;
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg15181151	chr6:150070149	PCMT1	0.3	5.11	0.31	6.61e-7	Lung cancer;
KIRP	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.65	6.47	0.38	5.14e-10	Height;
KIRP	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg00334542	chr7:100209784	MOSPD3	-0.79	-6.42	-0.38	7.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg18357526	chr6:26021779	HIST1H4A	0.47	5.44	0.33	1.26e-7	Blood metabolite levels;
KIRP	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-8.57	-0.48	1.19e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2637030	0.559	rs187659	chr5:52916018	G/A	cg06476337	chr5:52856530	NDUFS4	0.55	6.2	0.37	2.33e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.73	8.93	0.49	1.04e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs300890	0.642	rs3805256	chr4:144282390	C/T	cg01719995	chr4:144104893	USP38	-0.42	-5.23	-0.32	3.66e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg11833968	chr6:79620685	NA	-0.48	-7.23	-0.42	6.17e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.81	10.51	0.56	1.35e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	9.63	0.52	8.07e-19	Alzheimer's disease;
KIRP	cis	rs1712517	1.000	rs1163084	chr10:105039048	T/C	cg05636881	chr10:105038444	INA	0.44	6.25	0.37	1.82e-9	Migraine;
KIRP	cis	rs7178909	0.872	rs2165070	chr15:90408976	C/A	cg19708238	chr15:90437601	AP3S2	0.56	7.49	0.43	1.26e-12	Common traits (Other);
KIRP	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg16346588	chr10:242978	ZMYND11	-0.41	-4.88	-0.3	1.88e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg27411982	chr8:10470053	RP1L1	0.43	5.74	0.34	2.79e-8	Neuroticism;
KIRP	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.77	12.22	0.61	3.62e-27	Schizophrenia;
KIRP	cis	rs8018808	0.902	rs176773	chr14:77882456	C/T	cg18872420	chr14:78023429	SPTLC2	0.34	4.92	0.3	1.6e-6	Myeloid white cell count;
KIRP	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.85	-13.31	-0.65	8.17e-31	Intelligence (multi-trait analysis);
KIRP	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.55	-6.26	-0.37	1.66e-9	Breast cancer;
KIRP	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg23750338	chr8:142222470	SLC45A4	-0.38	-5.46	-0.33	1.19e-7	Birth weight;
KIRP	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	1.04	14.46	0.68	1.05e-34	Menopause (age at onset);
KIRP	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.61	-0.34	5.41e-8	Height;
KIRP	cis	rs4699052	1.000	rs4699052	chr4:104137790	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-5.13	-0.31	5.85e-7	Testicular germ cell tumor;
KIRP	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs193541	0.632	rs6595413	chr5:122156949	G/A	cg19412675	chr5:122181750	SNX24	0.57	5.98	0.36	7.94e-9	Glucose homeostasis traits;
KIRP	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg08392591	chr16:89556376	ANKRD11	0.48	6.0	0.36	7.1e-9	Multiple myeloma (IgH translocation);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	0.5	6.29	0.37	1.48e-9	Asthma;
KIRP	cis	rs7113874	0.659	rs67320655	chr11:8519209	G/A	cg08015107	chr11:8618950	NA	-0.72	-8.72	-0.49	4.22e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.72	-0.34	3.16e-8	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17971531	chr1:24882680	C1orf130	0.45	6.24	0.37	1.91e-9	Parkinson's disease;
KIRP	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.67	9.49	0.52	2.17e-18	Colorectal cancer;
KIRP	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.76	10.64	0.56	5.57e-22	Type 2 diabetes;
KIRP	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.75	11.17	0.58	1.07e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7572644	0.640	rs13027427	chr2:28021043	G/T	cg27432699	chr2:27873401	GPN1	0.51	5.67	0.34	3.97e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	trans	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg00405596	chr8:11794950	NA	-0.46	-6.12	-0.36	3.57e-9	Mood instability;
KIRP	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.77	7.0	0.41	2.47e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg14768367	chr16:72042858	DHODH	0.5	6.24	0.37	1.88e-9	Fibrinogen levels;
KIRP	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.29	0.37	1.45e-9	Morning vs. evening chronotype;
KIRP	cis	rs4722585	0.533	rs2049843	chr7:26196963	G/A	cg07876897	chr7:26191696	NFE2L3	0.38	4.85	0.3	2.22e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg11317459	chr13:21872234	NA	1.26	17.29	0.74	2.24e-44	White matter hyperintensity burden;
KIRP	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.86	0.53	1.53e-19	Schizophrenia;
KIRP	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg00814883	chr7:100076585	TSC22D4	-0.53	-5.16	-0.31	5e-7	Lung function (FEV1/FVC);
KIRP	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs2380205	0.967	rs2203196	chr10:5908209	G/A	cg27141509	chr10:5886111	NA	-0.36	-5.15	-0.31	5.33e-7	Breast cancer;
KIRP	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-13.06	-0.64	5.97e-30	Vitiligo;
KIRP	cis	rs7656342	0.636	rs4697902	chr4:9863936	T/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-5.13	-0.31	5.78e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg25173405	chr17:45401733	C17orf57	0.47	6.38	0.38	8.75e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.91	15.5	0.7	2.82e-38	Menarche (age at onset);
KIRP	cis	rs4794202	0.534	rs10428	chr17:45915086	G/A	cg02219949	chr17:45927392	SP6	0.61	7.05	0.41	1.82e-11	Alzheimer's disease (cognitive decline);
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs35740288	0.822	rs2016517	chr15:86229618	C/T	cg17133734	chr15:86042851	AKAP13	-0.48	-5.23	-0.32	3.58e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg00800038	chr16:89945340	TCF25	-0.76	-5.28	-0.32	2.78e-7	Skin colour saturation;
KIRP	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg03351412	chr1:154909251	PMVK	0.58	7.48	0.43	1.33e-12	Prostate cancer;
KIRP	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg19116668	chr7:99932089	PMS2L1	-0.42	-4.89	-0.3	1.79e-6	Coronary artery disease;
KIRP	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.04	0.54	4.36e-20	Total body bone mineral density;
KIRP	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg00852783	chr1:26633632	UBXN11	-0.44	-5.23	-0.32	3.64e-7	Obesity-related traits;
KIRP	cis	rs2224391	0.534	rs2773308	chr6:5246833	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.59	-0.39	2.61e-10	Height;
KIRP	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	1.08	16.95	0.73	3.21e-43	Cognitive function;
KIRP	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.59	-6.7	-0.39	1.44e-10	Menarche (age at onset);
KIRP	cis	rs9816226	0.591	rs6809651	chr3:185814642	G/A	cg00760338	chr3:185826511	ETV5	-0.76	-6.56	-0.39	3.18e-10	Obesity;Body mass index;
KIRP	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg00784671	chr22:46762841	CELSR1	-0.88	-8.4	-0.47	3.53e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1847202	0.859	rs11923247	chr3:72923306	A/G	cg06781948	chr3:72941472	GXYLT2	0.46	5.88	0.35	1.34e-8	Motion sickness;
KIRP	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-1.01	-17.13	-0.74	8.12e-44	Height;
KIRP	cis	rs829661	0.901	rs829663	chr2:30726536	T/A	cg10949345	chr2:30726833	LCLAT1	0.69	9.68	0.53	5.44e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg13010199	chr12:38710504	ALG10B	0.63	8.29	0.47	7.55e-15	Heart rate;
KIRP	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-5.27	-0.32	2.96e-7	Morning vs. evening chronotype;
KIRP	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg22732515	chr19:44031385	ETHE1	0.64	9.33	0.51	6.26e-18	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs11955175	1.000	rs75929994	chr5:40821816	T/C	cg17351974	chr5:40835760	RPL37	0.64	5.23	0.32	3.66e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg17145862	chr1:211918768	LPGAT1	1.03	17.41	0.74	8.66e-45	Leprosy;
KIRP	cis	rs2273669	0.504	rs79374607	chr6:109398257	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-5.44	-0.33	1.31e-7	Prostate cancer;
KIRP	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.47	5.37	0.32	1.79e-7	Schizophrenia;
KIRP	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	1.13	12.06	0.61	1.23e-26	Psoriasis;
KIRP	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07080220	chr10:102295463	HIF1AN	0.73	7.0	0.41	2.44e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg01620082	chr3:125678407	NA	-1.16	-7.26	-0.42	4.96e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6545883	0.826	rs1186697	chr2:61661417	G/A	cg15711740	chr2:61764176	XPO1	-0.61	-7.86	-0.45	1.21e-13	Tuberculosis;
KIRP	cis	rs1417569	0.517	rs2994625	chr10:31195319	G/A	cg00428179	chr10:31322131	ZNF438	-0.37	-5.54	-0.33	7.83e-8	Tuberculosis;
KIRP	cis	rs17092148	0.945	rs6060009	chr20:33303974	T/G	cg16810054	chr20:33298113	TP53INP2	-0.46	-5.72	-0.34	3.03e-8	Neuroticism;
KIRP	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.83	11.01	0.57	3.59e-23	Menarche (age at onset);
KIRP	cis	rs1847505	0.837	rs3127054	chr13:61413908	A/G	cg25164009	chr13:61490935	NA	0.48	5.45	0.33	1.25e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs2733201	1.000	rs2162365	chr15:44433142	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-5.22	-0.32	3.89e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg27490568	chr2:178487706	NA	-0.42	-5.48	-0.33	1.06e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.8	12.0	0.61	2.05e-26	IgG glycosylation;
KIRP	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	1.14	8.92	0.49	1.07e-16	Parkinson's disease;
KIRP	cis	rs2522056	0.808	rs2706373	chr5:131804256	C/T	cg07395648	chr5:131743802	NA	0.53	6.38	0.38	8.7e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg23625390	chr15:77176239	SCAPER	0.52	6.75	0.4	1.06e-10	Blood metabolite levels;
KIRP	cis	rs4791746	1.000	rs7215874	chr17:8628632	C/T	cg03115937	chr17:8649504	CCDC42	0.43	5.51	0.33	9.05e-8	Heroin dependence;
KIRP	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.12	14.79	0.69	7.71e-36	Lymphocyte percentage of white cells;
KIRP	cis	rs244293	0.657	rs4829	chr17:53039315	C/T	cg07707039	chr17:53042137	COX11	-0.4	-5.07	-0.31	7.86e-7	Menarche (age at onset);
KIRP	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg23166289	chr1:210001082	C1orf107	0.41	5.05	0.31	8.43e-7	Orofacial clefts;
KIRP	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	0.66	5.7	0.34	3.42e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.6	-8.67	-0.48	5.88e-16	Brugada syndrome;
KIRP	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.53	0.38	3.73e-10	Mean platelet volume;
KIRP	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg18404041	chr3:52824283	ITIH1	0.36	5.21	0.32	4.01e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2273669	0.667	rs12206834	chr6:109303967	T/G	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	9.94	0.54	8.82e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg18132916	chr6:79620363	NA	-0.4	-5.55	-0.33	7.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg05370193	chr1:21551575	ECE1	0.42	5.91	0.35	1.13e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9309473	0.519	rs2421667	chr2:73832459	T/C	cg20560298	chr2:73613845	ALMS1	0.45	5.66	0.34	4.1e-8	Metabolite levels;
KIRP	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.91	15.26	0.7	1.9e-37	Headache;
KIRP	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg13206674	chr6:150067644	NUP43	0.48	5.6	0.34	5.59e-8	Lung cancer;
KIRP	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg00405596	chr8:11794950	NA	-0.49	-6.45	-0.38	5.86e-10	Retinal vascular caliber;
KIRP	cis	rs981844	1.000	rs2405430	chr4:154658391	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.81	-9.5	-0.52	1.92e-18	Coronary artery disease;
KIRP	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.6	7.27	0.42	4.69e-12	Platelet count;
KIRP	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.81	-0.35	1.92e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18867708	chr6:26865862	GUSBL1	-0.5	-6.28	-0.37	1.55e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg03585969	chr10:35415529	CREM	0.84	10.16	0.54	1.78e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.69	-13.0	-0.64	9.36e-30	White blood cell count (basophil);
KIRP	cis	rs687432	0.924	rs34534719	chr11:57700867	C/A	cg19752551	chr11:57585705	CTNND1	-0.7	-9.24	-0.51	1.2e-17	Parkinson's disease;
KIRP	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.99	-0.45	5.32e-14	Monocyte percentage of white cells;
KIRP	cis	rs526231	0.543	rs34765	chr5:102506864	G/C	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.21e-8	Primary biliary cholangitis;
KIRP	trans	rs61931739	0.614	rs6488172	chr12:33745669	A/G	cg26384229	chr12:38710491	ALG10B	0.5	6.31	0.37	1.28e-9	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00357671	chr12:124809516	NCOR2	0.5	6.22	0.37	2.17e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04579211	chr15:41221939	DLL4	0.44	6.16	0.37	2.93e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.69	0.48	5.01e-16	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.89	-11.26	-0.58	5.48e-24	Vitamin D levels;
KIRP	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.19	0.31	4.34e-7	Total cholesterol levels;
KIRP	cis	rs8053891	0.708	rs8055242	chr16:72006882	C/T	cg04254540	chr16:71951199	KIAA0174	-0.5	-5.37	-0.32	1.85e-7	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-6.25	-0.37	1.82e-9	Lung cancer;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	13.71	0.66	3.61e-32	Platelet count;
KIRP	cis	rs28489187	0.706	rs233120	chr1:85788490	A/C	cg16011679	chr1:85725395	C1orf52	0.5	6.22	0.37	2.12e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	1.02	18.12	0.76	3.34e-47	Height;
KIRP	cis	rs7395581	0.877	rs10838690	chr11:47335075	A/G	cg25783544	chr11:47291846	MADD	0.43	4.95	0.3	1.35e-6	HDL cholesterol;
KIRP	cis	rs11783469	0.524	rs2235116	chr8:23337410	C/T	cg08322043	chr8:23340750	NA	0.46	5.35	0.32	2.06e-7	Reticulocyte count;
KIRP	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.8	-11.17	-0.58	1.07e-23	Height;
KIRP	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg01028140	chr2:1542097	TPO	-0.67	-6.21	-0.37	2.18e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg02151108	chr14:50098012	C14orf104	0.57	7.95	0.45	6.59e-14	Carotid intima media thickness;
KIRP	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg05347473	chr6:146136440	FBXO30	0.5	7.01	0.41	2.31e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs740160	0.558	rs73395508	chr7:98901894	A/C	cg12290671	chr7:99195819	NA	-0.53	-5.04	-0.31	8.85e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.79	10.59	0.56	7.86e-22	Longevity;
KIRP	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg16512390	chr1:228756714	NA	0.74	6.08	0.36	4.55e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14895029	chr7:2775587	GNA12	-0.43	-5.06	-0.31	8.37e-7	Height;
KIRP	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	1.24	10.77	0.57	2.05e-22	Gut microbiota (bacterial taxa);
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg10505658	chr17:80084571	CCDC57	-0.26	-4.85	-0.3	2.19e-6	Life satisfaction;
KIRP	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg24747557	chr10:131355152	MGMT	0.5	6.28	0.37	1.55e-9	Response to temozolomide;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14126091	chr2:105946410	TGFBRAP1	-0.47	-6.28	-0.37	1.5e-9	Metabolic traits;
KIRP	cis	rs7122257	0.563	rs2403460	chr11:11146438	A/G	cg16931664	chr11:11169707	NA	-0.41	-5.4	-0.33	1.58e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3120667	0.790	rs4285700	chr1:152387628	C/A	cg26876637	chr1:152193138	HRNR	-0.56	-5.48	-0.33	1.04e-7	Eating disorders;
KIRP	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.78	-11.0	-0.57	3.66e-23	Coronary artery disease;
KIRP	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00958927	chr1:175162553	KIAA0040	0.28	4.89	0.3	1.8e-6	Alcohol dependence;
KIRP	cis	rs7561273	0.609	rs10197527	chr2:24352398	A/C	cg20701182	chr2:24300061	SF3B14	0.48	5.94	0.35	9.91e-9	Quantitative traits;
KIRP	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs17095355	0.818	rs6584970	chr10:111847820	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.36	-4.98	-0.3	1.2e-6	Biliary atresia;
KIRP	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg07274523	chr3:49395745	GPX1	0.72	8.81	0.49	2.29e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6690583	0.623	rs11588160	chr1:85444226	T/G	cg22153463	chr1:85462885	MCOLN2	0.62	5.13	0.31	5.95e-7	Serum sulfate level;
KIRP	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.48	8.09	0.46	2.72e-14	Pneumonia;
KIRP	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.51	6.38	0.38	8.59e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	15.57	0.7	1.65e-38	Chronic sinus infection;
KIRP	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg10755058	chr3:40428713	ENTPD3	0.48	6.66	0.39	1.82e-10	Renal cell carcinoma;
KIRP	trans	rs12043259	1.000	rs6674756	chr1:204825974	A/G	cg11485465	chr5:54518469	NA	0.41	6.51	0.38	4.24e-10	Addiction;
KIRP	cis	rs7180079	0.620	rs12899738	chr15:65060028	C/G	cg15337035	chr15:64978493	NA	-0.51	-5.46	-0.33	1.16e-7	Monocyte count;
KIRP	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7903847	0.620	rs11189168	chr10:99125769	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-5.66	-0.34	4.2e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.6	6.77	0.4	9.65e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.79	-0.4	8.42e-11	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03462096	chr14:56157197	NA	0.44	6.85	0.4	5.97e-11	Interleukin-4 levels;
KIRP	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.24	0.51	1.22e-17	Colorectal cancer;
KIRP	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.77	7.96	0.45	6.35e-14	Cerebrospinal P-tau181p levels;
KIRP	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.45e-9	Depression;
KIRP	cis	rs2916247	0.954	rs7004515	chr8:93119689	G/A	cg10183463	chr8:93005414	RUNX1T1	0.4	4.85	0.3	2.16e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs986417	0.818	rs2882601	chr14:61096879	A/T	cg27398547	chr14:60952738	C14orf39	0.55	5.26	0.32	3.08e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.81	11.14	0.58	1.37e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.56	0.48	1.27e-15	Electroencephalogram traits;
KIRP	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	9.56	0.52	1.32e-18	Total body bone mineral density;
KIRP	cis	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg19847130	chr8:10466454	RP1L1	0.32	4.85	0.3	2.2e-6	Neuroticism;
KIRP	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg15893493	chr8:124194847	FAM83A	-0.87	-6.98	-0.41	2.71e-11	Urinary uromodulin levels;
KIRP	trans	rs61931739	0.592	rs61927752	chr12:33697205	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.12	-0.36	3.67e-9	Morning vs. evening chronotype;
KIRP	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.7	-8.82	-0.49	2.18e-16	Monocyte count;
KIRP	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.85	11.21	0.58	7.87e-24	Menarche (age at onset);
KIRP	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-0.8	-10.5	-0.56	1.49e-21	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg11707556	chr5:10655725	ANKRD33B	0.54	6.83	0.4	6.56e-11	Coronary artery disease;
KIRP	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg00647317	chr7:50633725	DDC	0.44	6.44	0.38	6.33e-10	Systemic sclerosis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18250916	chr5:612533	CEP72	-0.48	-6.58	-0.39	2.74e-10	Myopia;
KIRP	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05025164	chr4:1340916	KIAA1530	0.4	4.99	0.3	1.14e-6	Obesity-related traits;
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg14664628	chr15:75095509	CSK	-0.62	-7.68	-0.44	3.7e-13	Breast cancer;
KIRP	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	4.92	0.3	1.58e-6	Schizophrenia;
KIRP	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg27068330	chr11:65405492	SIPA1	0.37	5.08	0.31	7.32e-7	Acne (severe);
KIRP	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg16650896	chr7:64838774	ZNF92	0.54	6.87	0.4	5.27e-11	Asthma;
KIRP	cis	rs9303542	0.559	rs35621842	chr17:46606222	C/T	cg04904318	chr17:46607828	HOXB1	-0.62	-6.72	-0.39	1.28e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg22705602	chr4:152727874	NA	0.55	9.76	0.53	3.11e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.72	7.75	0.44	2.39e-13	Initial pursuit acceleration;
KIRP	cis	rs11078597	0.671	rs1310	chr17:1641715	G/T	cg17514665	chr17:1657533	SERPINF2	0.46	5.68	0.34	3.84e-8	Serum albumin level;
KIRP	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-5.89	-0.35	1.23e-8	Educational attainment (years of education);
KIRP	trans	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg21775007	chr8:11205619	TDH	-0.45	-6.06	-0.36	5.07e-9	Mood instability;
KIRP	cis	rs11264213	0.901	rs11263830	chr1:36345798	C/T	cg27506609	chr1:36549197	TEKT2	1.0	10.47	0.56	1.86e-21	Schizophrenia;
KIRP	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.84	12.21	0.61	3.91e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.74e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7084402	0.967	rs10826198	chr10:60274182	C/T	cg05938607	chr10:60274200	BICC1	0.42	10.22	0.55	1.15e-20	Refractive error;
KIRP	cis	rs2668423	1.000	rs2526136	chr19:1368398	A/G	cg02639931	chr19:1387894	NDUFS7	-0.75	-9.64	-0.52	7.27e-19	Nonalcoholic fatty liver disease;
KIRP	cis	rs7429990	0.930	rs13072132	chr3:47866161	A/G	cg11946769	chr3:48343235	NME6	0.54	5.42	0.33	1.41e-7	Educational attainment (years of education);
KIRP	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.52	-6.0	-0.36	7e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.722	rs16958861	chr19:38124179	G/A	cg18154014	chr19:37997991	ZNF793	0.61	6.69	0.39	1.52e-10	Coronary artery calcification;
KIRP	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg00042356	chr1:8021962	PARK7	0.6	4.85	0.3	2.22e-6	Inflammatory bowel disease;
KIRP	trans	rs927821	0.532	rs11594302	chr10:104186829	A/G	cg06646780	chr6:130182053	C6orf191	-0.65	-6.04	-0.36	5.79e-9	Social autistic-like traits;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg05956132	chr10:46091449	MARCH8	-0.41	-6.31	-0.37	1.3e-9	Inflammatory biomarkers;
KIRP	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs16828019	0.640	rs1140227	chr1:41493811	C/T	cg03387723	chr1:41708464	SCMH1	-0.77	-6.23	-0.37	2.01e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg01864069	chr14:103024347	NA	-0.86	-10.0	-0.54	5.54e-20	Platelet count;
KIRP	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg06092702	chr1:163392909	NA	0.37	5.65	0.34	4.44e-8	Motion sickness;
KIRP	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg05347473	chr6:146136440	FBXO30	0.41	5.66	0.34	4.23e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2692947	0.673	rs584811	chr2:97069879	A/G	cg23100626	chr2:96804247	ASTL	-0.43	-5.83	-0.35	1.71e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.89	0.4	4.61e-11	Bipolar disorder;
KIRP	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.16	12.23	0.61	3.53e-27	Nonalcoholic fatty liver disease;
KIRP	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	cg12689670	chr1:183009347	LAMC1	0.57	7.81	0.45	1.7e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.41	5.86	0.35	1.51e-8	Endometrial cancer;
KIRP	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg00074818	chr8:8560427	CLDN23	-0.42	-6.3	-0.37	1.38e-9	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15874048	chr14:45369753	C14orf28	0.42	6.12	0.36	3.72e-9	Interleukin-4 levels;
KIRP	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.12	-0.31	6.16e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6545883	0.560	rs11677775	chr2:61503110	T/C	cg15711740	chr2:61764176	XPO1	0.47	5.77	0.35	2.4e-8	Tuberculosis;
KIRP	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-0.79	-7.7	-0.44	3.32e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12476592	0.602	rs1255	chr2:63825934	T/C	cg17519650	chr2:63277830	OTX1	-0.46	-5.15	-0.31	5.47e-7	Childhood ear infection;
KIRP	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.89	10.66	0.56	4.78e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg00599163	chr2:162100495	NA	0.63	8.23	0.46	1.13e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs1829883	0.737	rs2548105	chr5:98905292	T/C	cg08333243	chr5:99726346	NA	0.39	5.01	0.3	1.02e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.81	8.28	0.47	7.94e-15	Educational attainment;
KIRP	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05180771	chr4:6576736	MAN2B2	-0.49	-6.12	-0.36	3.69e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.78	-0.53	2.64e-19	Hemoglobin concentration;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg07414643	chr4:187882934	NA	0.39	5.11	0.31	6.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.55	7.3	0.42	4.04e-12	Red blood cell count;
KIRP	cis	rs2274273	0.870	rs10139083	chr14:55782735	C/A	cg04306507	chr14:55594613	LGALS3	0.44	6.56	0.39	3.08e-10	Protein biomarker;
KIRP	cis	rs13424612	0.764	rs2887406	chr2:240923147	C/T	cg19172429	chr2:240878313	NA	0.3	4.99	0.3	1.14e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.57	-6.63	-0.39	2.12e-10	Initial pursuit acceleration;
KIRP	cis	rs372883	0.967	rs2832290	chr21:30728863	C/T	cg24692254	chr21:30365293	RNF160	-0.43	-5.55	-0.33	7.47e-8	Pancreatic cancer;
KIRP	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg18646521	chr2:111875858	NA	0.39	5.68	0.34	3.78e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs7927592	0.645	rs7936582	chr11:68292930	T/C	cg16797656	chr11:68205561	LRP5	0.4	6.38	0.38	8.78e-10	Total body bone mineral density;
KIRP	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	0.76	6.45	0.38	5.98e-10	Fat distribution (HIV);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14448850	chr7:22860191	TOMM7	0.52	6.89	0.4	4.65e-11	Survival in pancreatic cancer;
KIRP	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg02487422	chr3:49467188	NICN1	0.4	5.6	0.34	5.71e-8	Menarche (age at onset);
KIRP	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-10.63	-0.56	5.82e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-7.18	-0.42	8.28e-12	Platelet count;
KIRP	trans	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.36	3.81e-9	Mean corpuscular volume;
KIRP	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.46	5.28	0.32	2.82e-7	Schizophrenia;
KIRP	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.19	-0.31	4.39e-7	Alcohol dependence;
KIRP	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg14650228	chr8:144573510	ZC3H3	-0.71	-5.03	-0.31	9.56e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6753739	0.745	rs6436104	chr2:219915767	A/G	cg01749213	chr2:219906749	CCDC108	0.44	5.2	0.31	4.24e-7	Height;
KIRP	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg05484376	chr2:27715224	FNDC4	0.32	5.29	0.32	2.74e-7	Oral cavity cancer;
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.6	7.3	0.42	3.98e-12	Menopause (age at onset);
KIRP	cis	rs11225247	0.881	rs11604008	chr11:102259744	T/A	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs1823913	0.599	rs6736071	chr2:192151991	C/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.24	-0.37	1.87e-9	Obesity-related traits;
KIRP	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.71	10.19	0.54	1.42e-20	Body mass index;
KIRP	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg18404041	chr3:52824283	ITIH1	0.35	4.9	0.3	1.71e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.44	0.55	2.39e-21	Monocyte percentage of white cells;
KIRP	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.36	-4.95	-0.3	1.37e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14769373	chr6:40998127	UNC5CL	0.62	6.56	0.39	3.08e-10	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs7630877	0.886	rs59018122	chr3:179602512	C/A	cg18765712	chr3:179670323	PEX5L	0.56	6.57	0.39	2.99e-10	Type 2 diabetes;
KIRP	cis	rs4740619	0.711	rs10756730	chr9:15975069	T/C	cg14451791	chr9:16040625	NA	-0.38	-4.89	-0.3	1.86e-6	Body mass index;
KIRP	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.31	0.37	1.27e-9	Mood instability;
KIRP	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.06	0.64	5.78e-30	Exhaled nitric oxide output;
KIRP	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.51	5.36	0.32	1.87e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.71	0.53	4.59e-19	Lung cancer;
KIRP	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.15	-0.31	5.37e-7	Life satisfaction;
KIRP	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs1971762	0.762	rs7976793	chr12:54073069	G/T	cg09709951	chr12:54017699	ATF7	0.4	5.09	0.31	7.11e-7	Height;
KIRP	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.37	7.34	0.42	3.14e-12	IgG glycosylation;
KIRP	cis	rs58649573	0.509	rs917782	chr9:126790666	T/C	cg14112217	chr9:126806003	NA	0.35	5.13	0.31	5.87e-7	Post-traumatic stress disorder;
KIRP	cis	rs9921338	0.961	rs72773834	chr16:11413293	G/A	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs199950	0.911	rs199941	chr1:181597047	G/T	cg04237608	chr1:18659049	IGSF21	0.39	6.54	0.38	3.43e-10	Body mass index (change over time);
KIRP	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.84	-0.35	1.66e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.5	-0.78	7.7e-52	Height;
KIRP	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.49	0.38	4.65e-10	Platelet count;
KIRP	cis	rs11731606	0.508	rs28497379	chr4:95283789	G/T	cg00507259	chr4:95128692	SMARCAD1	0.68	6.01	0.36	6.62e-9	Mean platelet volume;
KIRP	cis	rs7147624	1.000	rs2411349	chr14:66214426	T/C	cg03016385	chr14:66212404	NA	-0.94	-9.88	-0.53	1.37e-19	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.5	7.7	0.44	3.41e-13	Bone mineral density;
KIRP	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.4	-0.33	1.58e-7	Coronary artery disease;
KIRP	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg27494647	chr7:150038898	RARRES2	0.45	6.55	0.39	3.3e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg05901451	chr6:126070800	HEY2	0.38	4.92	0.3	1.59e-6	Endometrial cancer;
KIRP	cis	rs7614311	0.636	rs67944903	chr3:63871195	A/T	cg22134162	chr3:63841271	THOC7	-0.4	-5.63	-0.34	4.96e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.88	8.37	0.47	4.36e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.72	10.16	0.54	1.75e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.67	9.69	0.53	5.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-0.91	-8.95	-0.5	9.07e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg04132472	chr17:19861366	AKAP10	0.43	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.87	10.47	0.56	1.82e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg10818794	chr15:86012489	AKAP13	-0.49	-6.94	-0.4	3.41e-11	Coronary artery disease;
KIRP	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.44	-6.14	-0.36	3.33e-9	Bone mineral density (spine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24255728	chr3:150804063	MED12L	0.53	6.69	0.39	1.47e-10	Parkinson's disease;
KIRP	cis	rs13315871	1.000	rs13071688	chr3:58398730	G/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg08992911	chr2:238395768	MLPH	0.45	5.22	0.32	3.83e-7	Prostate cancer;
KIRP	cis	rs75920871	0.623	rs7928320	chr11:116942753	C/T	cg04087571	chr11:116723030	SIK3	-0.28	-5.77	-0.35	2.32e-8	Subjective well-being;
KIRP	cis	rs986417	0.748	rs8019541	chr14:60929145	A/G	cg27398547	chr14:60952738	C14orf39	0.74	7.43	0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs35000415	0.938	rs12706861	chr7:128616582	C/T	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.61	-8.48	-0.48	2.18e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1983891	0.826	rs4714476	chr6:41513740	T/C	cg20194872	chr6:41519635	FOXP4	0.49	6.22	0.37	2.15e-9	Prostate cancer;
KIRP	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.51	-7.19	-0.42	7.7e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.83	-11.32	-0.59	3.37e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg23102388	chr7:1867652	MAD1L1	0.42	5.21	0.32	4.07e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14249877	chr10:32322959	KIF5B	0.48	6.91	0.4	4.25e-11	Interleukin-4 levels;
KIRP	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10038092	chr1:33502309	AK2	-0.49	-6.08	-0.36	4.46e-9	Myopia;
KIRP	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	0.66	7.61	0.44	5.91e-13	Dental caries;
KIRP	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg18944383	chr4:111397179	ENPEP	0.6	11.15	0.58	1.25e-23	Height;
KIRP	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg06740227	chr12:86229804	RASSF9	0.49	6.32	0.37	1.21e-9	Major depressive disorder;
KIRP	cis	rs9783347	1.000	rs4150610	chr11:18364140	A/G	cg15585147	chr11:18324498	HPS5	0.44	5.95	0.35	9.4e-9	Pancreatic cancer;
KIRP	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.63	7.47	0.43	1.37e-12	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs12984174	1.000	rs403439	chr19:18142075	A/G	cg21649277	chr19:18117794	ARRDC2	-0.66	-5.58	-0.34	6.36e-8	Pulmonary function in asthmatics;
KIRP	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg13293535	chr8:11597251	GATA4	-0.42	-5.45	-0.33	1.25e-7	Retinal vascular caliber;
KIRP	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.73	8.91	0.49	1.15e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11671005	0.656	rs11671092	chr19:59009109	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.6	-6.02	-0.36	6.4e-9	Mean platelet volume;
KIRP	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg06634786	chr22:41940651	POLR3H	-0.43	-5.22	-0.32	3.84e-7	Neuroticism;
KIRP	cis	rs7011507	1.000	rs7830222	chr8:49165313	C/T	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs5753037	0.774	rs140118	chr22:30135806	G/A	cg27665648	chr22:30112403	NA	0.47	6.67	0.39	1.72e-10	Type 1 diabetes;
KIRP	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.36	-0.32	1.91e-7	Cholesterol, total;
KIRP	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.61	-0.34	5.55e-8	Electroencephalogram traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03067574	chr19:47767875	CCDC9	-0.52	-6.71	-0.39	1.3e-10	Survival in pancreatic cancer;
KIRP	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg21360079	chr12:107162445	NA	-0.66	-9.34	-0.51	6.03e-18	Heart rate;
KIRP	cis	rs17123764	0.892	rs17123927	chr12:50149347	A/G	cg20471783	chr12:50157085	TMBIM6	0.42	6.02	0.36	6.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-1.05	-10.83	-0.57	1.29e-22	Blood protein levels;
KIRP	cis	rs17533156	0.612	rs62078287	chr17:75128493	C/T	cg11416367	chr17:75137675	SEC14L1	0.52	5.11	0.31	6.62e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.41	0.51	3.77e-18	Morning vs. evening chronotype;
KIRP	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.7	-0.39	1.42e-10	Response to antipsychotic treatment;
KIRP	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14893161	chr1:205819251	PM20D1	0.51	5.71	0.34	3.26e-8	Prostate-specific antigen levels;
KIRP	cis	rs6540559	0.543	rs650728	chr1:210433351	C/T	cg09074223	chr1:210466472	NA	0.58	5.61	0.34	5.47e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.41	-4.94	-0.3	1.48e-6	Educational attainment;
KIRP	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg22617819	chr1:44378782	ST3GAL3	-0.39	-6.41	-0.38	7.25e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-7.78	-0.44	2.01e-13	Platelet distribution width;
KIRP	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.53	7.17	0.42	8.8e-12	Night sleep phenotypes;
KIRP	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg16898833	chr6:26189333	HIST1H4D	0.83	5.89	0.35	1.23e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg07414643	chr4:187882934	NA	0.4	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.72	-10.69	-0.56	3.79e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2798269	0.586	rs1199949	chr13:22076091	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.4	-4.89	-0.3	1.86e-6	PR segment;
KIRP	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13047869	chr3:10149882	C3orf24	0.54	5.4	0.33	1.58e-7	Alzheimer's disease;
KIRP	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-14.72	-0.68	1.3e-35	Alzheimer's disease;
KIRP	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg24747557	chr10:131355152	MGMT	-0.39	-5.13	-0.31	5.75e-7	Response to temozolomide;
KIRP	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	17.23	0.74	3.71e-44	Height;
KIRP	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.79	-10.18	-0.54	1.56e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs651907	0.512	rs771324	chr3:101610365	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.07	0.31	7.99e-7	Colorectal cancer;
KIRP	cis	rs7903847	0.619	rs10786336	chr10:99134953	A/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.86	-0.35	1.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.57	-6.24	-0.37	1.88e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg07511934	chr16:89386912	ANKRD11	0.42	5.29	0.32	2.69e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	11.91	0.6	4.01e-26	Monocyte count;
KIRP	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.15	9.34	0.51	5.98e-18	Cognitive function;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10529812	chr17:80350324	C17orf101	0.48	6.58	0.39	2.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	6.33	0.37	1.16e-9	Ulcerative colitis;
KIRP	cis	rs624899	0.655	rs1671825	chr19:11588405	A/G	cg08680689	chr19:11670216	ELOF1	-0.72	-5.45	-0.33	1.25e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.54	-7.39	-0.43	2.27e-12	Gut microbiome composition (summer);
KIRP	cis	rs6882046	0.513	rs601942	chr5:88031820	T/C	cg22951263	chr5:87985283	NA	-0.47	-6.66	-0.39	1.79e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg09184832	chr6:79620586	NA	-0.43	-5.96	-0.36	8.57e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.75	-7.63	-0.44	5.18e-13	Gut microbiome composition (summer);
KIRP	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg26138937	chr11:71823887	C11orf51	-1.16	-7.98	-0.45	5.51e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs290986	0.857	rs167080	chr9:93553577	T/C	cg02608019	chr9:93564028	SYK	-0.6	-5.47	-0.33	1.08e-7	Multiple sclerosis;
KIRP	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.47	-5.97	-0.36	8.29e-9	Parkinson's disease;
KIRP	cis	rs13315871	1.000	rs13063504	chr3:58409854	A/G	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	trans	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.26	-0.37	1.72e-9	Obesity-related traits;
KIRP	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg12131826	chr15:77904385	NA	0.4	5.34	0.32	2.11e-7	Type 2 diabetes;
KIRP	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg05315796	chr3:52349193	DNAH1	0.42	6.79	0.4	8.36e-11	Bipolar disorder;
KIRP	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	0.8	13.19	0.64	2.07e-30	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg01126855	chr4:183727586	NA	0.71	6.07	0.36	4.84e-9	Hirschsprung disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06332666	chr2:128521022	WDR33	0.38	6.14	0.36	3.24e-9	Migraine with aura;
KIRP	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.35	0.65	6.19e-31	Personality dimensions;
KIRP	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs400736	0.602	rs4573544	chr1:8165247	C/T	cg25007680	chr1:8021821	PARK7	-0.43	-5.54	-0.33	7.83e-8	Response to antidepressants and depression;
KIRP	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-5.03	-0.31	9.53e-7	Aortic root size;
KIRP	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg11266682	chr4:10021025	SLC2A9	0.34	4.9	0.3	1.71e-6	Blood metabolite levels;
KIRP	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-9.35	-0.51	5.67e-18	Coffee consumption (cups per day);
KIRP	cis	rs17384381	0.861	rs2300640	chr1:85823795	C/G	cg16011679	chr1:85725395	C1orf52	0.86	8.54	0.48	1.43e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4728302	0.869	rs958405	chr7:133597151	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-8.82	-0.49	2.21e-16	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.6	0.81	1e-58	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs9810890	1.000	rs73196993	chr3:128456755	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.04	0.31	8.95e-7	Parkinson's disease;
KIRP	cis	rs7010876	0.568	rs10110977	chr8:89214009	A/G	cg08624180	chr8:89339080	MMP16	-0.53	-4.97	-0.3	1.25e-6	Schizophrenia;
KIRP	trans	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg10756647	chr7:56101905	PSPH	0.93	9.48	0.52	2.2e-18	Diabetic kidney disease;
KIRP	cis	rs2213920	0.679	rs4979523	chr9:118177550	G/A	cg13918206	chr9:118159781	DEC1	1.0	10.45	0.55	2.2e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs17507216	0.718	rs7165690	chr15:83323555	A/G	cg19175742	chr15:83331452	AP3B2	0.44	4.95	0.3	1.35e-6	Excessive daytime sleepiness;
KIRP	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.64	7.92	0.45	8.11e-14	Vitiligo;
KIRP	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg13736514	chr6:26305472	NA	-0.67	-8.54	-0.48	1.4e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2708977	0.637	rs597420	chr2:97070353	T/C	cg01950434	chr2:97203154	ARID5A	-0.4	-4.86	-0.3	2.06e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7635838	0.785	rs7427412	chr3:11535020	G/A	cg00170343	chr3:11313890	ATG7	0.46	5.78	0.35	2.25e-8	HDL cholesterol;
KIRP	cis	rs2882667	0.898	rs2043272	chr5:138390631	A/C	cg04439458	chr5:138467593	SIL1	-0.44	-7.39	-0.43	2.35e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.74	-10.37	-0.55	3.91e-21	Response to temozolomide;
KIRP	cis	rs6693295	0.877	rs12060229	chr1:246296666	T/A	cg11798871	chr1:246315928	SMYD3	-0.46	-5.62	-0.34	5.08e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7113850	0.541	rs76005477	chr11:24233322	G/A	ch.11.24196551F	chr11:24239977	NA	0.93	7.72	0.44	2.99e-13	Bone fracture in osteoporosis;
KIRP	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.65	-7.74	-0.44	2.64e-13	Iron status biomarkers;
KIRP	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.51	0.38	4.13e-10	Atrioventricular conduction;
KIRP	cis	rs9426935	0.899	rs7415004	chr1:153865461	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	0.29	5.0	0.3	1.11e-6	Lentiform nucleus volume;
KIRP	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.76	-0.63	5.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs897080	0.516	rs1067361	chr2:44661217	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.04	0.36	5.56e-9	Height;
KIRP	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.18	12.59	0.63	2.24e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs16828019	0.704	rs34486565	chr1:41522510	C/T	cg18742814	chr1:41828276	NA	0.69	5.91	0.35	1.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg07677296	chr16:1877182	HAGH;FAHD1	-0.61	-5.38	-0.32	1.73e-7	Ankle injury;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06394476	chr2:65454602	ACTR2	0.49	6.28	0.37	1.52e-9	Parkinson's disease;
KIRP	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg18944383	chr4:111397179	ENPEP	0.53	9.45	0.52	2.86e-18	Height;
KIRP	cis	rs2273669	0.667	rs78714994	chr6:109350351	G/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg22437258	chr11:111473054	SIK2	0.57	6.55	0.39	3.25e-10	Primary sclerosing cholangitis;
KIRP	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05220968	chr6:146057943	EPM2A	0.39	5.0	0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg25182066	chr10:30743637	MAP3K8	0.61	7.67	0.44	3.97e-13	Inflammatory bowel disease;
KIRP	cis	rs6968419	0.755	rs3807982	chr7:115898885	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.93	-0.35	1e-8	Intraocular pressure;
KIRP	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg25173405	chr17:45401733	C17orf57	0.43	5.62	0.34	5.29e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19719311	chr1:51443992	NA	-0.6	-7.95	-0.45	6.79e-14	Migraine with aura;
KIRP	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg25039879	chr17:56429692	SUPT4H1	0.56	5.02	0.3	1.01e-6	Cognitive test performance;
KIRP	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.48	6.65	0.39	1.89e-10	Red blood cell count;
KIRP	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-9.82	-0.53	2.06e-19	Morning vs. evening chronotype;
KIRP	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg23682824	chr7:23144976	KLHL7	0.58	6.93	0.4	3.77e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.81	10.49	0.56	1.59e-21	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.36	-0.72	3.22e-41	Height;
KIRP	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.61	-9.0	-0.5	6.26e-17	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12963246	chr6:28129442	ZNF389	-0.53	-6.42	-0.38	6.94e-10	Depression;
KIRP	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.9	12.13	0.61	7.28e-27	Cognitive function;
KIRP	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.8	10.84	0.57	1.19e-22	Systemic lupus erythematosus;
KIRP	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.56	-15.48	-0.7	3.24e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.62	5.35	0.32	1.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg01721255	chr8:58191610	C8orf71	0.51	5.02	0.31	9.71e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2688419	0.527	rs1355740	chr3:23070957	C/T	cg00327796	chr3:23032191	NA	0.45	6.17	0.37	2.75e-9	Type 2 diabetes;
KIRP	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg24169773	chr3:122142474	KPNA1	-0.58	-6.43	-0.38	6.7e-10	LDL cholesterol levels;
KIRP	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.68	9.3	0.51	8.18e-18	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.63	6.61	0.39	2.3e-10	Gut microbiome composition (summer);
KIRP	cis	rs1829883	0.804	rs1608435	chr5:98817492	A/G	cg08333243	chr5:99726346	NA	-0.37	-5.14	-0.31	5.65e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs17030434	0.784	rs8180349	chr4:154657038	T/C	cg14289246	chr4:154710475	SFRP2	-0.56	-6.85	-0.4	6e-11	Electrocardiographic conduction measures;
KIRP	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	18.82	0.77	1.47e-49	Height;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-4.88	-0.3	1.94e-6	Longevity;
KIRP	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg23335576	chr14:104009727	NA	0.4	5.53	0.33	8.17e-8	Body mass index;
KIRP	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg20578329	chr17:80767326	TBCD	0.47	6.13	0.36	3.52e-9	Breast cancer;
KIRP	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.62e-7	Life satisfaction;
KIRP	cis	rs4843185	0.699	rs2029	chr16:85708846	C/A	cg26571870	chr16:85723150	GINS2	-0.49	-5.24	-0.32	3.44e-7	Platelet distribution width;
KIRP	cis	rs838147	0.844	rs8108136	chr19:49247693	C/T	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.27e-7	Dietary macronutrient intake;
KIRP	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.28	0.67	4.17e-34	Platelet count;
KIRP	cis	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg19847130	chr8:10466454	RP1L1	0.34	4.88	0.3	1.94e-6	Neuroticism;
KIRP	cis	rs911119	0.913	rs12710327	chr20:23569689	C/T	cg09631192	chr20:23583594	CST9	-0.47	-4.98	-0.3	1.21e-6	Chronic kidney disease;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg08021120	chr3:195498017	MUC4	0.53	4.96	0.3	1.29e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg18461458	chr19:21324796	ZNF431	-0.46	-4.95	-0.3	1.38e-6	Pain;
KIRP	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg26248373	chr2:1572462	NA	-0.61	-5.98	-0.36	7.66e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg22828804	chr20:3140466	UBOX5;FASTKD5	0.53	7.0	0.41	2.43e-11	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21768436	chr8:67341108	RRS1	0.53	7.04	0.41	1.91e-11	Parkinson's disease;
KIRP	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg05347473	chr6:146136440	FBXO30	0.56	8.1	0.46	2.62e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs867371	1.000	rs2867579	chr15:82475384	G/C	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-6.09	-0.36	4.33e-9	Gut microbiome composition (summer);
KIRP	cis	rs1832871	0.711	rs12525147	chr6:158683509	A/G	cg07215822	chr6:158701037	NA	-0.65	-7.36	-0.42	2.79e-12	Height;
KIRP	cis	rs2071426	0.959	rs1592037	chr10:96792328	A/G	cg09036531	chr10:96991505	NA	0.65	7.25	0.42	5.48e-12	Blood metabolite levels;
KIRP	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06481639	chr22:41940642	POLR3H	-0.43	-4.88	-0.3	1.9e-6	Neuroticism;
KIRP	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.83	11.91	0.6	4.01e-26	Monocyte count;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg21698718	chr17:80085957	CCDC57	0.38	5.55	0.33	7.53e-8	Life satisfaction;
KIRP	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.67	9.58	0.52	1.08e-18	Retinal vascular caliber;
KIRP	cis	rs6540556	0.723	rs6672256	chr1:209894043	A/T	cg23920097	chr1:209922102	NA	0.45	5.38	0.32	1.76e-7	Red blood cell count;
KIRP	trans	rs16939607	0.822	rs2128019	chr8:78994159	G/T	cg22617002	chr13:112275633	NA	-0.65	-6.18	-0.37	2.59e-9	White blood cell count;
KIRP	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.94	0.54	8.77e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs584438	0.837	rs35103116	chr17:38594806	C/T	cg09213124	chr17:38599508	IGFBP4	-0.3	-5.07	-0.31	7.93e-7	Height;
KIRP	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.3	0.37	1.36e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs490234	0.812	rs2900229	chr9:128466312	A/G	cg14078157	chr9:128172775	NA	-0.42	-5.15	-0.31	5.31e-7	Mean arterial pressure;
KIRP	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg06611532	chr13:114900021	NA	0.23	5.42	0.33	1.44e-7	Schizophrenia;
KIRP	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg00361562	chr2:198649771	BOLL	-0.49	-5.04	-0.31	9.11e-7	Ulcerative colitis;
KIRP	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg15841412	chr13:111365552	ING1	-0.49	-5.58	-0.34	6.21e-8	Coronary artery disease;
KIRP	cis	rs4786125	0.519	rs1388805	chr16:6929947	C/T	cg03623568	chr16:6915990	A2BP1	-0.44	-5.26	-0.32	3.11e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.71	-9.7	-0.53	4.64e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg24642439	chr20:33292090	TP53INP2	0.56	6.66	0.39	1.77e-10	Height;
KIRP	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	5.81	0.35	1.94e-8	Mean platelet volume;
KIRP	cis	rs7656342	0.622	rs13119059	chr4:9847860	G/C	cg11266682	chr4:10021025	SLC2A9	0.33	5.03	0.31	9.6e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-0.78	-10.15	-0.54	1.96e-20	Post bronchodilator FEV1;
KIRP	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-7.9	-0.45	9.46e-14	Prudent dietary pattern;
KIRP	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg06697600	chr4:7070879	GRPEL1	-0.4	-5.29	-0.32	2.64e-7	Monocyte percentage of white cells;
KIRP	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg26138937	chr11:71823887	C11orf51	0.98	6.63	0.39	2.13e-10	Severe influenza A (H1N1) infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08393828	chr14:102228221	PPP2R5C	0.57	6.47	0.38	5.15e-10	Smoking initiation;
KIRP	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg12369402	chr1:90227771	NA	-0.34	-4.85	-0.3	2.16e-6	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs7937612	1.000	rs9633950	chr11:120248249	T/G	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.13	-0.41	1.11e-11	Intraocular pressure;
KIRP	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22117172	chr7:91764530	CYP51A1	0.45	6.18	0.37	2.63e-9	Breast cancer;
KIRP	cis	rs2562456	0.793	rs7258473	chr19:21514597	A/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.64	-7.43	-0.43	1.75e-12	Lung cancer;
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg09597638	chr17:3907349	NA	0.75	14.28	0.67	4.36e-34	Type 2 diabetes;
KIRP	trans	rs7939886	0.841	rs11227583	chr11:55995737	C/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	13.43	0.65	3.24e-31	Platelet count;
KIRP	cis	rs75920871	0.920	rs7128071	chr11:116968798	G/A	cg23684410	chr11:116897558	SIK3	0.51	4.99	0.3	1.12e-6	Subjective well-being;
KIRP	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	0.85	7.65	0.44	4.68e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.74	-8.39	-0.47	3.81e-15	Osteoarthritis;
KIRP	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.76	6.58	0.39	2.76e-10	Diabetic retinopathy;
KIRP	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg02344993	chr17:57696989	CLTC	0.54	5.21	0.32	3.98e-7	Hemoglobin concentration;
KIRP	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.52	-5.75	-0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs6838801	0.927	rs28716539	chr4:77512012	T/C	cg17476223	chr4:77663285	SHROOM3	0.55	7.58	0.43	7.17e-13	Cleft lip with or without cleft palate;
KIRP	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.73	8.82	0.49	2.11e-16	Corneal astigmatism;
KIRP	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.59	-0.39	2.66e-10	Neuroticism;
KIRP	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg14952266	chr13:112191215	NA	0.47	6.94	0.4	3.53e-11	Hepatitis;
KIRP	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.89	11.87	0.6	5.31e-26	Cognitive function;
KIRP	cis	rs35955747	0.871	rs5994392	chr22:31783906	T/A	cg02404636	chr22:31891804	SFI1	-0.37	-5.12	-0.31	6.04e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.9	14.21	0.67	7.47e-34	Dental caries;
KIRP	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.67	6.25	0.37	1.77e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.75	11.49	0.59	9.86e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.55	-6.79	-0.4	8.6e-11	Type 2 diabetes;
KIRP	cis	rs6973256	0.897	rs12530581	chr7:133342955	A/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.38	-0.38	8.55e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.6	7.24	0.42	5.82e-12	Aortic root size;
KIRP	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.19	13.83	0.66	1.44e-32	Sexual dysfunction (female);
KIRP	trans	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00950418	chr7:105029125	SRPK2	-0.55	-6.78	-0.4	8.99e-11	Height;
KIRP	cis	rs2294369	0.906	rs136855	chr22:40061683	A/G	cg10455938	chr22:40058150	CACNA1I	0.41	4.96	0.3	1.29e-6	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg20368463	chr18:77673604	PQLC1	-0.51	-5.12	-0.31	6.18e-7	Opioid sensitivity;
KIRP	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.84	-0.45	1.34e-13	Total cholesterol levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03660451	chr17:73664606	RECQL5;SAP30BP	0.47	6.12	0.36	3.75e-9	Interleukin-4 levels;
KIRP	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.5	6.29	0.37	1.43e-9	Iron status biomarkers;
KIRP	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg11833968	chr6:79620685	NA	-0.37	-5.12	-0.31	6.06e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.72	-0.34	3.11e-8	Height;
KIRP	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.77	-6.92	-0.4	3.8e-11	Prostate cancer;
KIRP	cis	rs11264213	0.901	rs67641270	chr1:36413329	T/C	cg27506609	chr1:36549197	TEKT2	0.97	10.14	0.54	2.03e-20	Schizophrenia;
KIRP	trans	rs78438709	1.000	rs2421015	chr10:124183091	C/T	cg08224212	chr11:34196093	ABTB2	1.01	6.52	0.38	3.95e-10	Headache;
KIRP	cis	rs7429990	0.965	rs17785248	chr3:47672915	A/G	cg11946769	chr3:48343235	NME6	0.53	5.29	0.32	2.73e-7	Educational attainment (years of education);
KIRP	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg03060546	chr3:49711283	APEH	-0.71	-5.51	-0.33	9.16e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg14346243	chr4:90757452	SNCA	-0.38	-4.85	-0.3	2.15e-6	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07859478	chr19:808116	PTBP1	0.49	6.33	0.37	1.18e-9	Survival in pancreatic cancer;
KIRP	cis	rs6496044	1.000	rs6496044	chr15:86067306	G/A	cg17133734	chr15:86042851	AKAP13	-0.46	-5.45	-0.33	1.2e-7	Interstitial lung disease;
KIRP	cis	rs16828019	0.777	rs11209363	chr1:41485077	T/C	cg03387723	chr1:41708464	SCMH1	-0.73	-6.28	-0.37	1.55e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg18178197	chr22:50098317	NA	0.58	6.92	0.4	3.98e-11	Natriuretic peptide levels;
KIRP	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.29	0.42	4.13e-12	Retinal vascular caliber;
KIRP	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.44	-6.01	-0.36	6.8e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs787274	1.000	rs787278	chr9:115473531	C/A	cg13803584	chr9:115635662	SNX30	0.72	6.38	0.38	8.8e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17554472	chr22:41940697	POLR3H	0.74	7.53	0.43	9.76e-13	Vitiligo;
KIRP	cis	rs16937956	0.597	rs72852616	chr11:8406886	T/C	cg08015107	chr11:8618950	NA	-0.53	-6.93	-0.4	3.73e-11	Body mass index;
KIRP	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs6453429	0.536	rs673834	chr5:78367139	T/G	cg06501366	chr5:78365687	BHMT2;DMGDH	-0.33	-5.82	-0.35	1.84e-8	Urinary metabolites;
KIRP	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	1.0	17.59	0.75	2.19e-45	Breast cancer;
KIRP	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.78	12.44	0.62	7.12e-28	Coronary artery disease;
KIRP	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.66	5.61	0.34	5.49e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13006833	0.634	rs1876877	chr2:191145274	G/A	cg25963032	chr2:191064776	C2orf88	0.37	4.91	0.3	1.69e-6	Urinary metabolites;
KIRP	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.66	-7.06	-0.41	1.69e-11	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14166846	chr1:220268091	IARS2	0.55	7.0	0.41	2.41e-11	Smoking initiation;
KIRP	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.85	-0.3	2.24e-6	Pulmonary function;
KIRP	cis	rs17221829	0.673	rs4491227	chr11:89403759	G/A	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.15	-0.31	5.42e-7	Anxiety in major depressive disorder;
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	12.78	0.63	4.91e-29	Platelet count;
KIRP	trans	rs12986445	0.711	rs3845682	chr2:26110064	A/T	cg18516150	chr3:148614668	CPA3	0.42	6.02	0.36	6.45e-9	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
KIRP	cis	rs7737355	0.945	rs245801	chr5:130666955	T/C	cg25547332	chr5:131281432	NA	-0.48	-5.29	-0.32	2.73e-7	Life satisfaction;
KIRP	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.39	4.96	0.3	1.29e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23396286	chr10:99258505	UBTD1;MMS19	0.72	6.72	0.39	1.29e-10	Lung function (FEV1);
KIRP	cis	rs9372498	0.536	rs9489458	chr6:118920503	G/A	cg18833306	chr6:118973337	C6orf204	-0.47	-4.97	-0.3	1.23e-6	Diastolic blood pressure;
KIRP	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs75920871	0.528	rs7108912	chr11:116925996	G/A	cg04087571	chr11:116723030	SIK3	-0.26	-5.56	-0.33	6.84e-8	Subjective well-being;
KIRP	cis	rs75920871	0.925	rs17120237	chr11:116891046	T/C	cg23684410	chr11:116897558	SIK3	0.55	5.97	0.36	8.33e-9	Subjective well-being;
KIRP	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.56	8.51	0.48	1.68e-15	Itch intensity from mosquito bite;
KIRP	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.73	10.26	0.55	8.35e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.6	-8.2	-0.46	1.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.3	-0.32	2.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.951	rs58865997	chr12:48566873	G/A	cg20731937	chr12:48336164	NA	0.42	5.41	0.33	1.46e-7	Longevity (90 years and older);
KIRP	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26207909	chr14:103986467	CKB	-0.81	-12.59	-0.63	2.19e-28	Body mass index;
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.47	-5.58	-0.33	6.48e-8	Longevity;Endometriosis;
KIRP	cis	rs75920871	1.000	rs1473324	chr11:116821918	T/G	cg23684410	chr11:116897558	SIK3	0.55	6.02	0.36	6.32e-9	Subjective well-being;
KIRP	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.91	0.3	1.63e-6	Tonsillectomy;
KIRP	cis	rs986417	0.818	rs7144656	chr14:61032909	A/G	cg27398547	chr14:60952738	C14orf39	0.61	5.2	0.31	4.28e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6663390	0.510	rs12095775	chr1:208091310	C/T	cg00387621	chr1:208086895	NA	0.6	5.08	0.31	7.44e-7	Facial morphology (factor 18);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10001378	chr17:54674212	NA	-0.48	-7.03	-0.41	2.05e-11	Morning vs. evening chronotype;
KIRP	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.67	-8.45	-0.47	2.63e-15	Morning vs. evening chronotype;
KIRP	trans	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.44	0.38	6.36e-10	Mean corpuscular volume;
KIRP	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg22029157	chr1:209979665	IRF6	0.43	6.82	0.4	7.15e-11	Monobrow;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.61	-12.19	-0.61	4.74e-27	Diabetic kidney disease;
KIRP	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg06611532	chr13:114900021	NA	0.21	4.89	0.3	1.83e-6	Schizophrenia;
KIRP	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.64	-0.44	4.97e-13	Breast cancer;
KIRP	trans	rs4742903	0.509	rs4743697	chr9:106959800	G/C	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.09	-0.36	4.36e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg26384229	chr12:38710491	ALG10B	0.57	7.61	0.44	6.01e-13	Morning vs. evening chronotype;
KIRP	cis	rs3774830	0.967	rs1004375	chr4:5438478	G/A	cg26943120	chr4:5472116	STK32B	0.25	6.07	0.36	4.9e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21790344	chr1:212004782	LPGAT1	-0.42	-6.34	-0.37	1.09e-9	Inflammatory biomarkers;
KIRP	cis	rs743757	1.000	rs2236964	chr3:50449062	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.52	-5.77	-0.35	2.35e-8	Diastolic blood pressure;
KIRP	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.52	0.62	3.89e-28	Menopause (age at onset);
KIRP	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.7	-11.45	-0.59	1.28e-24	Menopause (age at onset);
KIRP	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.53	6.86	0.4	5.51e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.82	-12.32	-0.62	1.71e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs72730918	0.564	rs34929849	chr15:51800385	G/T	cg14296394	chr15:51910925	DMXL2	0.82	10.98	0.57	4.41e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7119038	0.818	rs11217040	chr11:118680648	C/A	cg19308663	chr11:118741387	NA	0.52	8.69	0.48	5.05e-16	Sjögren's syndrome;
KIRP	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.06	-0.36	5.11e-9	Neuroticism;
KIRP	cis	rs329674	0.556	rs61910566	chr11:133735545	A/G	cg06766960	chr11:133703094	NA	-0.65	-4.93	-0.3	1.52e-6	Bipolar disorder;
KIRP	cis	rs35995292	0.963	rs10242978	chr7:38898823	A/G	cg19327137	chr7:38886074	VPS41	0.51	6.18	0.37	2.63e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg16524733	chr11:117070046	TAGLN	0.41	5.45	0.33	1.2e-7	Blood protein levels;
KIRP	cis	rs155346	0.625	rs264350	chr5:139362321	T/C	cg24724630	chr5:139362307	NRG2	-0.41	-5.49	-0.33	1.02e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg09699651	chr6:150184138	LRP11	0.49	6.24	0.37	1.95e-9	Lung cancer;
KIRP	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.99	16.59	0.73	5.63e-42	Bone mineral density;
KIRP	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.68	4.95	0.3	1.38e-6	Childhood ear infection;
KIRP	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg05163923	chr11:71159392	DHCR7	-0.82	-8.24	-0.47	1.01e-14	Vitamin D levels;
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg01631408	chr1:248437212	OR2T33	0.43	5.62	0.34	5.27e-8	Common traits (Other);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10222474	chr8:103822809	NA	-0.43	-6.26	-0.37	1.7e-9	Metabolic traits;
KIRP	cis	rs1144	0.537	rs2470940	chr7:104581974	A/C	cg04380332	chr7:105027541	SRPK2	-0.52	-7.7	-0.44	3.29e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.53	6.67	0.39	1.64e-10	Height;
KIRP	cis	rs3789045	1.000	rs45501495	chr1:204596454	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.43	-5.1	-0.31	6.65e-7	Educational attainment (college completion);
KIRP	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs6840360	0.901	rs1946999	chr4:152455339	T/C	cg25486957	chr4:152246857	NA	-0.47	-5.47	-0.33	1.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.6	7.79	0.44	1.92e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.55	6.73	0.39	1.2e-10	Multiple sclerosis;
KIRP	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.5	0.74	4.43e-45	Chronic sinus infection;
KIRP	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26314531	chr2:26401878	FAM59B	-0.49	-5.03	-0.31	9.45e-7	Gut microbiome composition (summer);
KIRP	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.47	5.78	0.35	2.29e-8	Longevity;
KIRP	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.61	-0.39	2.33e-10	Systolic blood pressure;
KIRP	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-4.93	-0.3	1.53e-6	Tonsillectomy;
KIRP	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.62	-9.37	-0.51	4.88e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg25036284	chr2:26402008	FAM59B	-0.53	-5.59	-0.34	5.95e-8	Gut microbiome composition (summer);
KIRP	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.98	-15.83	-0.71	2.13e-39	Uric acid clearance;
KIRP	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.42	-6.2	-0.37	2.39e-9	Coronary artery disease;
KIRP	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-6.84	-0.4	6.16e-11	Body mass index;
KIRP	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	1.0	7.15	0.41	9.9e-12	IgG glycosylation;
KIRP	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.45	-5.55	-0.33	7.5e-8	P wave terminal force;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23889086	chr19:47731562	BBC3	0.49	6.61	0.39	2.3e-10	Parkinson's disease;
KIRP	trans	rs815815	0.943	rs815811	chr2:47377472	A/G	cg26632776	chr21:45875534	LRRC3	0.64	6.08	0.36	4.52e-9	Dialysis-related mortality;
KIRP	trans	rs12345625	0.590	rs16917077	chr9:31532212	A/G	cg05270381	chr1:202976926	TMEM183A;TMEM183B	0.9	6.02	0.36	6.22e-9	Classic bladder exstrophy;
KIRP	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg26769984	chr7:1090371	C7orf50	0.55	5.69	0.34	3.69e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26002218	chr14:103986227	CKB	-0.33	-6.85	-0.4	5.83e-11	Body mass index;
KIRP	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg25801113	chr15:45476975	SHF	0.43	7.93	0.45	7.77e-14	Uric acid levels;
KIRP	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg22974920	chr21:40686053	BRWD1	0.52	6.2	0.37	2.43e-9	Cognitive function;
KIRP	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg20701182	chr2:24300061	SF3B14	0.5	4.96	0.3	1.34e-6	Lymphocyte counts;
KIRP	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg19507638	chr5:93509721	C5orf36	-0.53	-5.01	-0.3	1.02e-6	Diabetic retinopathy;
KIRP	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg11608241	chr8:8085544	FLJ10661	0.42	5.44	0.33	1.25e-7	Mood instability;
KIRP	cis	rs9896933	0.943	rs6502023	chr17:80909608	T/G	cg15664640	chr17:80829946	TBCD	0.57	5.37	0.32	1.8e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.62	-0.34	5.15e-8	Lung cancer;
KIRP	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.71	8.13	0.46	2.14e-14	Pancreatic cancer;
KIRP	cis	rs7766436	0.885	rs7773749	chr6:22587190	C/G	cg13666174	chr6:22585274	NA	-0.46	-6.59	-0.39	2.69e-10	Coronary artery disease;
KIRP	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.18	-15.81	-0.71	2.53e-39	Gut microbiome composition (summer);
KIRP	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg05621596	chr22:47072043	GRAMD4	-0.53	-7.4	-0.43	2.18e-12	Urate levels in obese individuals;
KIRP	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08439880	chr3:133502540	NA	-0.54	-6.47	-0.38	5.2e-10	Iron status biomarkers;
KIRP	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.06	-0.46	3.26e-14	Bone mineral density;
KIRP	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg14345882	chr6:26364793	BTN3A2	0.53	5.04	0.31	8.83e-7	Urinary tract infection frequency;
KIRP	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg01528321	chr10:82214614	TSPAN14	-0.99	-9.13	-0.5	2.57e-17	Post bronchodilator FEV1;
KIRP	cis	rs6442310	0.534	rs1151999	chr3:12447153	G/T	cg22839075	chr3:12045461	SYN2	-0.37	-5.2	-0.31	4.27e-7	Hematocrit;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg01988459	chr11:68622903	NA	-0.41	-5.85	-0.35	1.54e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12210905	1.000	rs12203728	chr6:27051750	G/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	8.23	0.46	1.11e-14	Lymphocyte percentage of white cells;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg00020052	chr2:68546899	CNRIP1	0.47	6.1	0.36	4.09e-9	Sleep duration;
KIRP	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg12573791	chr2:3828286	NA	0.41	5.67	0.34	3.97e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg25214090	chr10:38739885	LOC399744	0.57	6.74	0.39	1.09e-10	Corneal astigmatism;
KIRP	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.36	5.19	0.31	4.33e-7	Calcium levels;
KIRP	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg17207736	chr8:142237307	SLC45A4	-0.4	-5.0	-0.3	1.11e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg21851534	chr17:3907994	ZZEF1	0.72	12.04	0.61	1.5e-26	Type 2 diabetes;
KIRP	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.6	-6.62	-0.39	2.26e-10	Prostate cancer;
KIRP	cis	rs6987853	0.933	rs2974352	chr8:42408483	C/T	cg09913449	chr8:42400586	C8orf40	0.38	4.9	0.3	1.78e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg06565975	chr8:143823917	SLURP1	0.47	7.42	0.43	1.88e-12	Urinary tract infection frequency;
KIRP	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg14391382	chr7:866102	UNC84A	0.54	6.75	0.4	1.05e-10	Subjective well-being;
KIRP	cis	rs11078597	0.671	rs34599286	chr17:1645747	C/A	cg17514665	chr17:1657533	SERPINF2	0.45	5.5	0.33	9.51e-8	Serum albumin level;
KIRP	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg26876637	chr1:152193138	HRNR	0.72	9.73	0.53	4e-19	Atopic dermatitis;
KIRP	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.29	-0.32	2.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	5.06	0.31	8.2e-7	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.74	-0.49	3.76e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg21625330	chr8:9911636	MSRA	0.37	4.88	0.3	1.95e-6	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11955762	chr13:111268705	CARKD	0.45	6.27	0.37	1.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21852761	chr6:130340620	L3MBTL3	0.46	6.18	0.37	2.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg19847130	chr8:10466454	RP1L1	0.35	5.13	0.31	5.86e-7	Triglycerides;
KIRP	cis	rs244731	0.920	rs67008484	chr5:176735383	T/C	cg06060754	chr5:176797920	RGS14	0.65	7.39	0.43	2.28e-12	Urate levels in lean individuals;
KIRP	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.65	-7.6	-0.44	6.31e-13	Height;
KIRP	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg03808351	chr9:123631620	PHF19	0.41	5.58	0.34	6.33e-8	Rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg15117754	chr3:10150083	C3orf24	0.55	5.2	0.31	4.22e-7	Alzheimer's disease;
KIRP	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg08975724	chr8:8085496	FLJ10661	0.62	8.68	0.48	5.69e-16	Mood instability;
KIRP	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	14.12	0.67	1.47e-33	Electrocardiographic conduction measures;
KIRP	cis	rs7534824	0.860	rs6685428	chr1:101619780	G/C	cg17443007	chr1:101659419	NA	0.66	5.09	0.31	7.25e-7	Refractive astigmatism;
KIRP	cis	rs595982	0.726	rs607356	chr19:49371241	T/C	cg21252483	chr19:49399788	TULP2	-0.35	-6.6	-0.39	2.54e-10	Red cell distribution width;
KIRP	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.41	5.69	0.34	3.55e-8	Endometrial cancer;
KIRP	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.76	10.41	0.55	2.85e-21	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	7.45	0.43	1.53e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10982256	0.875	rs1535962	chr9:117259062	T/C	cg13636371	chr9:117264095	DFNB31	0.58	7.94	0.45	7.01e-14	Bipolar disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08157672	chr2:68547141	CNRIP1	0.48	6.21	0.37	2.23e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14770000	chr3:127872147	EEFSEC	0.53	6.83	0.4	6.68e-11	Parkinson's disease;
KIRP	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg25039879	chr17:56429692	SUPT4H1	0.62	5.44	0.33	1.31e-7	Cognitive test performance;
KIRP	cis	rs77688320	0.529	rs2540438	chr2:202350556	C/A	cg06431681	chr2:202330990	STRADB	-0.44	-5.17	-0.31	4.84e-7	Breast cancer;
KIRP	cis	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg23134075	chr14:61517513	SLC38A6	-0.39	-5.03	-0.31	9.52e-7	Select biomarker traits;
KIRP	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg25356066	chr3:128598488	ACAD9	0.56	6.42	0.38	7.09e-10	IgG glycosylation;
KIRP	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.69	9.77	0.53	2.94e-19	Post bronchodilator FEV1;
KIRP	cis	rs2839627	0.638	rs73366794	chr21:44269180	C/T	cg03543861	chr21:44258195	NA	0.6	6.32	0.37	1.19e-9	Information processing speed;
KIRP	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg08975724	chr8:8085496	FLJ10661	0.56	6.84	0.4	6.34e-11	Parkinson's disease;
KIRP	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg24747557	chr10:131355152	MGMT	-0.46	-6.28	-0.37	1.56e-9	Response to temozolomide;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07400628	chr1:6761934	DNAJC11	0.44	6.34	0.37	1.07e-9	Survival in pancreatic cancer;
KIRP	cis	rs240764	0.658	rs2050549	chr6:101216645	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.26	-0.32	3.14e-7	Neuroticism;
KIRP	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.0	0.3	1.12e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg15691649	chr6:25882328	NA	-0.43	-5.16	-0.31	5.02e-7	Blood metabolite levels;
KIRP	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg14768367	chr16:72042858	DHODH	-1.06	-11.38	-0.59	2.25e-24	Blood protein levels;
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg21734707	chr17:3908241	ZZEF1	0.63	9.58	0.52	1.15e-18	Type 2 diabetes;
KIRP	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg26248373	chr2:1572462	NA	-0.69	-7.38	-0.43	2.48e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.88	-0.3	1.88e-6	Lung cancer;
KIRP	cis	rs2400749	0.739	rs4545740	chr14:100035249	A/G	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.3	-0.32	2.55e-7	Alzheimer's disease (survival time);
KIRP	cis	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg06521331	chr12:34319734	NA	-0.63	-7.51	-0.43	1.08e-12	Morning vs. evening chronotype;
KIRP	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.65	-7.84	-0.45	1.35e-13	Calcium levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg22244076	chr20:33872703	EIF6	0.52	6.61	0.39	2.4e-10	Myopia (pathological);
KIRP	cis	rs6466055	0.867	rs10241415	chr7:104948076	A/G	cg04380332	chr7:105027541	SRPK2	0.64	9.61	0.52	8.81e-19	Schizophrenia;
KIRP	cis	rs6681460	1.000	rs2872078	chr1:67127367	C/A	cg13052034	chr1:66999238	SGIP1	0.44	5.94	0.35	9.45e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg08461772	chr7:95026248	PON3	0.4	5.69	0.34	3.58e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.6	9.22	0.51	1.38e-17	Height;
KIRP	cis	rs6570726	0.967	rs441364	chr6:145853662	G/C	cg23711669	chr6:146136114	FBXO30	0.7	10.55	0.56	1.08e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg22681709	chr2:178499509	PDE11A	-0.63	-9.24	-0.51	1.2e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg24253500	chr15:84953950	NA	0.54	6.03	0.36	5.98e-9	Schizophrenia;
KIRP	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.91	-14.73	-0.68	1.24e-35	Breast cancer;
KIRP	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.48	7.32	0.42	3.61e-12	Resting heart rate;
KIRP	cis	rs1832871	0.541	rs56182595	chr6:158895680	T/A	cg07215822	chr6:158701037	NA	-0.53	-5.77	-0.35	2.41e-8	Height;
KIRP	cis	rs8014252	0.803	rs56922268	chr14:71052171	A/C	cg19730268	chr14:71022823	NA	-0.72	-6.4	-0.38	7.9e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg10729496	chr3:10149963	C3orf24	0.54	4.89	0.3	1.85e-6	Alzheimer's disease;
KIRP	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg26138937	chr11:71823887	C11orf51	-1.1	-7.81	-0.45	1.62e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.92	-8.79	-0.49	2.65e-16	Fibroblast growth factor basic levels;
KIRP	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.3	7.41	0.43	2.03e-12	Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04085025	chr7:30029442	SCRN1	0.46	6.41	0.38	7.32e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg24503407	chr1:205819492	PM20D1	0.53	5.53	0.33	8.31e-8	Basophil percentage of granulocytes;
KIRP	trans	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg08975724	chr8:8085496	FLJ10661	0.54	6.75	0.4	1.07e-10	Retinal vascular caliber;
KIRP	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg07636037	chr3:49044803	WDR6	0.56	5.3	0.32	2.59e-7	Menarche (age at onset);
KIRP	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	1.0	18.51	0.76	1.64e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg24488311	chr11:68621650	NA	0.47	5.64	0.34	4.76e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.47	-5.75	-0.34	2.62e-8	Testicular germ cell tumor;
KIRP	cis	rs11169552	0.510	rs10459235	chr12:51096183	G/A	cg12884762	chr12:50931848	DIP2B	-0.44	-5.21	-0.32	3.96e-7	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27340350	chr19:49559583	CGB7	0.42	6.4	0.38	7.76e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00950418	chr7:105029125	SRPK2	-0.53	-6.51	-0.38	4.19e-10	Height;
KIRP	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.89	-14.4	-0.68	1.69e-34	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs798766	1.000	rs798767	chr4:1734281	A/G	cg07775547	chr4:1625484	NA	-0.44	-5.32	-0.32	2.28e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.72	10.39	0.55	3.3e-21	High light scatter reticulocyte count;
KIRP	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg22437258	chr11:111473054	SIK2	-0.57	-6.55	-0.39	3.28e-10	Primary sclerosing cholangitis;
KIRP	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.8	9.68	0.53	5.65e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4356932	0.967	rs13111790	chr4:76972402	G/C	cg00809888	chr4:76862425	NAAA	0.43	6.05	0.36	5.3e-9	Blood protein levels;
KIRP	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12900413	0.603	rs12905689	chr15:90301343	G/A	cg24650279	chr15:90327240	NA	-0.43	-5.37	-0.32	1.84e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs3925075	0.833	rs11641202	chr16:31330161	A/G	cg02846316	chr16:31340340	ITGAM	0.59	8.45	0.47	2.54e-15	IgA nephropathy;
KIRP	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg10852876	chr4:165953100	TRIM60	-0.47	-5.08	-0.31	7.32e-7	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06715928	chr10:112257500	DUSP5	-0.46	-6.38	-0.38	8.87e-10	Metabolic traits;
KIRP	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.74	0.44	2.62e-13	Vitiligo;
KIRP	cis	rs4682868	0.583	rs10865925	chr3:42913610	T/C	cg21365077	chr3:42922735	NA	0.43	4.99	0.3	1.13e-6	Monocyte percentage of white cells;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.5	-6.61	-0.39	2.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.72	5.93	0.35	1.03e-8	Diabetic retinopathy;
KIRP	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.54	0.52	1.49e-18	Prudent dietary pattern;
KIRP	cis	rs1697139	0.710	rs6866416	chr5:66517476	A/G	cg16691251	chr5:66510806	NA	0.44	5.21	0.32	4e-7	Breast cancer;
KIRP	cis	rs7707921	0.690	rs6870335	chr5:81590070	A/T	cg07807695	chr5:81608485	ATP6AP1L	0.45	5.85	0.35	1.53e-8	Breast cancer;
KIRP	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.01	-7.57	-0.43	7.63e-13	Mitochondrial DNA levels;
KIRP	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-5.3	-0.32	2.55e-7	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.99	0.3	1.13e-6	Renal cell carcinoma;
KIRP	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.46	-6.21	-0.37	2.26e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.8	12.12	0.61	7.85e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg08989290	chr16:615782	NHLRC4	0.4	5.86	0.35	1.45e-8	Height;
KIRP	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	4.98e-9	Depression;
KIRP	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs311392	0.867	rs367108	chr8:55093142	G/A	cg11783602	chr8:55087084	NA	-0.57	-7.07	-0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.95	13.28	0.65	1.08e-30	Cognitive function;
KIRP	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg08992911	chr2:238395768	MLPH	0.64	5.75	0.34	2.63e-8	Prostate cancer;
KIRP	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.81e-19	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14406005	chr8:67589135	C8orf44	0.53	6.58	0.39	2.74e-10	Interleukin-4 levels;
KIRP	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16318349	chr1:154917307	PBXIP1	-0.29	-5.14	-0.31	5.72e-7	Prostate cancer;
KIRP	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs17092148	1.000	rs910871	chr20:33333208	C/A	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg27205649	chr11:78285834	NARS2	0.55	5.33	0.32	2.26e-7	Testicular germ cell tumor;
KIRP	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.84e-11	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21788624	chr2:20251350	LAPTM4A	0.47	6.74	0.39	1.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17344932	chr17:38183730	MED24;SNORD124	0.49	7.79	0.44	1.86e-13	White blood cell count (neutrophil);
KIRP	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.29e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg08133631	chr1:26527909	CATSPER4	-0.46	-5.15	-0.31	5.36e-7	Obesity-related traits;
KIRP	cis	rs17739794	0.517	rs34109064	chr8:772796	T/C	cg01971667	chr8:817044	NA	-0.43	-5.79	-0.35	2.17e-8	Clozapine-induced cytotoxicity;
KIRP	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72730918	0.564	rs1902595	chr15:51905715	T/C	cg14296394	chr15:51910925	DMXL2	-0.77	-10.81	-0.57	1.55e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg06521331	chr12:34319734	NA	-0.63	-7.44	-0.43	1.68e-12	Morning vs. evening chronotype;
KIRP	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.44	5.13	0.31	5.91e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg23752985	chr2:85803571	VAMP8	0.61	9.13	0.5	2.51e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14161477	chr13:114192847	TMCO3	0.5	6.7	0.39	1.41e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17123764	0.681	rs74086911	chr12:50015942	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.67	0.34	3.93e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.06	-0.31	8.25e-7	Iron status biomarkers;
KIRP	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg24459738	chr19:57751996	ZNF805	-0.59	-7.23	-0.42	6.06e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs2795502	0.873	rs2795527	chr10:43270240	T/C	cg11150807	chr10:43354902	NA	-0.62	-5.38	-0.32	1.74e-7	Blood protein levels;
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg18679886	chr7:107531975	DLD	0.52	6.13	0.36	3.46e-9	Body mass index in non-asthmatics;
KIRP	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg16141378	chr3:129829833	LOC729375	0.59	8.26	0.47	9.27e-15	Neuroticism;
KIRP	cis	rs1345301	1.000	rs12474199	chr2:102868980	G/A	cg12451869	chr2:102867685	NA	0.38	5.71	0.34	3.32e-8	Waist circumference;
KIRP	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.68	7.9	0.45	9.02e-14	Blood metabolite levels;
KIRP	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.6	-7.3	-0.42	4.08e-12	Schizophrenia;
KIRP	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg16141378	chr3:129829833	LOC729375	0.57	6.99	0.41	2.54e-11	Retinal vascular caliber;
KIRP	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.41	6.97	0.41	2.83e-11	Heart rate;
KIRP	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg18016565	chr1:150552671	MCL1	0.38	5.84	0.35	1.65e-8	Melanoma;
KIRP	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.58	-9.23	-0.51	1.26e-17	Longevity;
KIRP	cis	rs478607	0.831	rs3825074	chr11:64415767	G/A	cg09231725	chr11:64357281	SLC22A12	-0.66	-5.19	-0.31	4.41e-7	Urate levels;
KIRP	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg03235661	chr20:60525775	NA	-0.36	-5.41	-0.33	1.46e-7	Body mass index;
KIRP	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg00806126	chr19:22604979	ZNF98	-0.69	-7.28	-0.42	4.61e-12	Pain;
KIRP	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg25036284	chr2:26402008	FAM59B	0.53	5.47	0.33	1.08e-7	Gut microbiome composition (summer);
KIRP	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.57	7.93	0.45	7.8500000000000006e-14	Vitiligo;
KIRP	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.68	-8.92	-0.49	1.07e-16	Hepatocellular carcinoma;
KIRP	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.59	7.72	0.44	2.99e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.57	-7.07	-0.41	1.59e-11	Coronary artery disease;
KIRP	cis	rs73200209	0.744	rs61937384	chr12:116698606	G/C	cg01776926	chr12:116560359	MED13L	-0.55	-6.16	-0.37	2.89e-9	Total body bone mineral density;
KIRP	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg19645103	chr12:69753606	YEATS4	-0.46	-5.29	-0.32	2.65e-7	Response to diuretic therapy;
KIRP	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.7	-6.6	-0.39	2.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.54	7.4	0.43	2.11e-12	Colorectal cancer;
KIRP	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg23587288	chr2:27483067	SLC30A3	-0.55	-6.93	-0.4	3.64e-11	Blood metabolite levels;
KIRP	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.77	9.83	0.53	1.84e-19	Aortic root size;
KIRP	cis	rs7779181	1.000	rs12531858	chr7:32340099	G/T	cg27532318	chr7:32358331	NA	0.42	5.0	0.3	1.1e-6	Body mass index;
KIRP	cis	rs829661	0.793	rs2602767	chr2:30853300	A/G	cg10949345	chr2:30726833	LCLAT1	-1.07	-13.19	-0.64	2.11e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg20673091	chr1:2541236	MMEL1	-0.66	-9.86	-0.53	1.54e-19	Ulcerative colitis;
KIRP	cis	rs7221595	0.825	rs2290437	chr17:3923115	G/A	cg09695851	chr17:3907499	NA	0.63	6.76	0.4	1.02e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg25512537	chr17:76250053	NA	0.41	6.72	0.39	1.24e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.43	5.37	0.32	1.79e-7	Longevity;
KIRP	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg19338460	chr6:170058176	WDR27	-0.68	-7.94	-0.45	7.1e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	5.54	0.33	7.84e-8	Height;
KIRP	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	5.41	0.33	1.5e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg12549451	chr6:135224345	NA	0.38	4.87	0.3	2.04e-6	Red blood cell count;
KIRP	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.09	-12.09	-0.61	1.04e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12143943	0.866	rs4252726	chr1:204513402	G/A	cg20240347	chr1:204465584	NA	-0.35	-6.43	-0.38	6.64e-10	Cognitive performance;
KIRP	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg17710535	chr19:10819994	QTRT1	0.42	5.34	0.32	2.07e-7	Inflammatory skin disease;
KIRP	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg05072774	chr3:49840536	C3orf54	-0.41	-5.37	-0.32	1.86e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg23307798	chr14:103986281	CKB	0.42	5.6	0.34	5.77e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06544989	chr22:39130855	UNC84B	0.44	7.78	0.44	2.05e-13	Menopause (age at onset);
KIRP	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.61	6.69	0.39	1.54e-10	Corneal astigmatism;
KIRP	cis	rs13343954	0.756	rs2042190	chr19:33532716	T/C	cg17764715	chr19:33622953	WDR88	0.67	7.63	0.44	5.09e-13	Colorectal cancer;
KIRP	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.19	-22.05	-0.81	3.48e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24371114	chr4:24913973	CCDC149	0.31	6.22	0.37	2.15e-9	Parkinson's disease;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg14789911	chr21:47582049	C21orf56	0.4	4.96	0.3	1.35e-6	Testicular germ cell tumor;
KIRP	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg09549813	chr16:4587862	C16orf5	0.33	5.03	0.31	9.35e-7	Schizophrenia;
KIRP	cis	rs1843834	0.721	rs6715655	chr2:225582284	C/T	cg22509189	chr2:225307070	NA	0.45	5.53	0.33	8.19e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs1440410	0.536	rs11100779	chr4:144104764	C/T	cg01719995	chr4:144104893	USP38	0.43	5.52	0.33	8.64e-8	Ischemic stroke;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05660570	chr19:50432873	NUP62;IL4I1;ATF5	0.49	6.43	0.38	6.5e-10	Parkinson's disease;
KIRP	cis	rs6977660	1.000	rs10260527	chr7:19801930	G/A	cg07541023	chr7:19748670	TWISTNB	0.51	5.4	0.33	1.54e-7	Thyroid stimulating hormone;
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg04369109	chr6:150039330	LATS1	-0.5	-6.36	-0.38	9.72e-10	Lung cancer;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.75	11.84	0.6	6.63e-26	Longevity;Endometriosis;
KIRP	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg11262906	chr1:85462892	MCOLN2	-0.48	-5.34	-0.32	2.07e-7	Serum sulfate level;
KIRP	cis	rs1050631	1.000	rs1785919	chr18:33691964	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.5	6.14	0.36	3.23e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.59	-7.53	-0.43	9.54e-13	Cotinine glucuronidation;
KIRP	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg20469991	chr17:27169893	C17orf63	-0.53	-5.7	-0.34	3.36e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg21395723	chr22:39101663	GTPBP1	0.42	5.51	0.33	8.97e-8	Menopause (age at onset);
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-6.13	-0.36	3.53e-9	Longevity;
KIRP	cis	rs282587	0.569	rs432522	chr13:113400015	A/G	cg04656015	chr13:113407548	ATP11A	0.65	7.73	0.44	2.75e-13	Glycated hemoglobin levels;
KIRP	trans	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19894588	chr14:64061835	NA	0.51	6.97	0.41	2.98e-11	Glioblastoma;Glioma;
KIRP	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg25902810	chr10:99078978	FRAT1	0.58	7.31	0.42	3.68e-12	Monocyte count;
KIRP	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.23	-0.42	6.24e-12	Neuroticism;
KIRP	cis	rs9815354	0.761	rs57638657	chr3:41809238	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.32	0.47	6.13e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15525503	chr1:3773166	DFFB;KIAA0562	0.44	6.07	0.36	4.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.55	5.58	0.34	6.23e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg15979348	chr13:112237479	NA	0.4	5.12	0.31	6.06e-7	Menarche (age at onset);
KIRP	cis	rs11577318	0.626	rs11806568	chr1:26686837	C/A	cg00852783	chr1:26633632	UBXN11	-0.46	-5.24	-0.32	3.46e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.91	10.65	0.56	4.83e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.23	-21.13	-0.8	3.28e-57	Breast cancer;
KIRP	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg00204512	chr16:28754710	NA	0.45	5.94	0.35	9.66e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.86	0.53	1.5e-19	Multiple sclerosis;
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-6.3	-0.37	1.34e-9	Lung function (FEV1/FVC);
KIRP	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg21253087	chr9:139290292	SNAPC4	0.45	4.91	0.3	1.69e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg18154014	chr19:37997991	ZNF793	-0.61	-6.68	-0.39	1.57e-10	Coronary artery calcification;
KIRP	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg14003231	chr6:33640908	ITPR3	0.28	4.94	0.3	1.42e-6	Height;
KIRP	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg04998671	chr14:104000505	TRMT61A	0.56	6.63	0.39	2.15e-10	Coronary artery disease;
KIRP	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg12463550	chr7:65579703	CRCP	0.44	5.07	0.31	7.84e-7	Aortic root size;
KIRP	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg25204440	chr1:209979598	IRF6	0.44	4.92	0.3	1.6e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg18882449	chr10:104885122	NT5C2	-0.51	-6.57	-0.39	3.03e-10	Arsenic metabolism;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05477027	chr19:46295590	DMWD	0.51	6.79	0.4	8.13e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.27	0.47	8.19e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.57	0.33	6.58e-8	Putamen volume;
KIRP	cis	rs6725041	0.547	rs1505353	chr2:213203057	C/A	cg16329650	chr2:213403929	ERBB4	-0.38	-4.96	-0.3	1.32e-6	QT interval (ambient particulate matter interaction);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg02664216	chr12:19592651	AEBP2	0.53	6.23	0.37	2.01e-9	Sleep duration;
KIRP	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg10047753	chr17:41438598	NA	0.86	11.85	0.6	6.25e-26	Menopause (age at onset);
KIRP	cis	rs2712184	0.756	rs2712164	chr2:217659916	G/A	cg05032264	chr2:217675019	NA	-0.49	-7.15	-0.42	9.61e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00907473	chr1:90459283	ZNF326;LOC492303	0.4	6.22	0.37	2.18e-9	Warfarin maintenance dose;
KIRP	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg25547332	chr5:131281432	NA	-0.47	-5.29	-0.32	2.68e-7	Life satisfaction;
KIRP	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg20387954	chr3:183756860	HTR3D	0.64	9.53	0.52	1.55e-18	Anterior chamber depth;
KIRP	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.44	5.17	0.31	4.74e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.17	13.24	0.64	1.48e-30	Platelet count;
KIRP	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs240110	0.570	rs966741	chr6:101218375	A/G	cg09795085	chr6:101329169	ASCC3	-0.44	-5.26	-0.32	3.17e-7	Neuroticism;
KIRP	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.54	-0.38	3.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg06740227	chr12:86229804	RASSF9	0.45	5.79	0.35	2.14e-8	Major depressive disorder;
KIRP	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.69	9.37	0.51	5.03e-18	Body mass index;
KIRP	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.82	-8.25	-0.47	9.95e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-7.21	-0.42	7.01e-12	Gut microbiome composition (summer);
KIRP	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg21014159	chr11:117668035	DSCAML1	0.38	5.64	0.34	4.68e-8	Myopia;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg18209359	chr17:80159595	CCDC57	0.44	5.61	0.34	5.56e-8	Life satisfaction;
KIRP	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-8.82	-0.49	2.16e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs61935443	0.666	rs11107781	chr12:95301086	T/A	cg21533806	chr12:95267307	NA	0.59	5.24	0.32	3.44e-7	Schizophrenia;
KIRP	cis	rs2692947	0.794	rs2692949	chr2:96673525	G/A	cg23100626	chr2:96804247	ASTL	0.43	5.66	0.34	4.28e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg24296786	chr1:45957014	TESK2	-0.42	-5.27	-0.32	2.93e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.97	0.36	8.09e-9	Platelet count;
KIRP	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs6681460	0.901	rs1570815	chr1:67139667	C/T	cg02459107	chr1:67143332	SGIP1	0.52	7.4	0.43	2.12e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.88	-0.57	8.82e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.52	-5.15	-0.31	5.42e-7	Diastolic blood pressure;
KIRP	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg05887092	chr17:76393375	PGS1	0.54	7.49	0.43	1.22e-12	HDL cholesterol levels;
KIRP	cis	rs4400599	0.569	rs10797058	chr1:154200704	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.98	-0.36	7.67e-9	Platelet distribution width;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02047359	chr10:75174015	ANXA7	0.46	6.09	0.36	4.4e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.22	-17.14	-0.74	7.12e-44	Breast cancer;
KIRP	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg07395648	chr5:131743802	NA	-0.38	-5.39	-0.32	1.65e-7	Blood metabolite levels;
KIRP	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06481639	chr22:41940642	POLR3H	-0.71	-7.02	-0.41	2.13e-11	Vitiligo;
KIRP	cis	rs4728302	0.869	rs7792546	chr7:133595502	G/T	cg10665199	chr7:133106180	EXOC4	0.46	5.7	0.34	3.41e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs8018808	0.935	rs12433766	chr14:77930293	C/T	cg18872420	chr14:78023429	SPTLC2	0.36	5.24	0.32	3.52e-7	Myeloid white cell count;
KIRP	cis	rs8177876	0.822	rs9933184	chr16:81111176	G/A	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.42	6.17	0.37	2.73e-9	Information processing speed;
KIRP	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg10189774	chr4:17578691	LAP3	-0.46	-5.44	-0.33	1.27e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20887711	chr4:1340912	KIAA1530	-0.45	-5.59	-0.34	6.05e-8	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11799589	chr1:44443270	ATP6V0B	0.4	6.3	0.37	1.35e-9	Survival in pancreatic cancer;
KIRP	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.47	-6.46	-0.38	5.72e-10	Lung function (FVC);Lung function (FEV1);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10267855	chr11:67121112	POLD4;LOC100130987	-0.47	-6.18	-0.37	2.61e-9	Metabolic traits;
KIRP	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.66	9.03	0.5	4.97e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.73	10.09	0.54	2.85e-20	Plateletcrit;Platelet count;
KIRP	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg08499158	chr17:42289980	UBTF	-0.67	-8.8	-0.49	2.39e-16	Total body bone mineral density;
KIRP	cis	rs12594515	0.694	rs2068294	chr15:45985548	G/T	cg01629716	chr15:45996671	NA	0.36	6.28	0.37	1.51e-9	Waist circumference;Weight;
KIRP	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.89	10.99	0.57	3.9e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.66	8.79	0.49	2.62e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-4.94	-0.3	1.45e-6	Life satisfaction;
KIRP	cis	rs10089	0.680	rs3805616	chr5:127520897	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	5.53	0.33	8.08e-8	Ileal carcinoids;
KIRP	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg17182837	chr8:41585554	ANK1	-0.48	-6.64	-0.39	1.98e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.94	-0.54	8.37e-20	Total body bone mineral density;
KIRP	cis	rs501120	0.584	rs12355852	chr10:44704280	G/T	cg09554077	chr10:44749378	NA	0.56	5.95	0.35	9.34e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg06050784	chr16:88016603	BANP	0.4	5.03	0.31	9.36e-7	Menopause (age at onset);
KIRP	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.7	7.63	0.44	5.08e-13	Corneal astigmatism;
KIRP	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.98	16.53	0.73	8.43e-42	Prudent dietary pattern;
KIRP	trans	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg04373760	chr16:53404718	NA	0.62	7.06	0.41	1.67e-11	Hypertriglyceridemia;
KIRP	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg21605333	chr4:119757512	SEC24D	1.67	11.86	0.6	5.89e-26	Cannabis dependence symptom count;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.16e-8	Life satisfaction;
KIRP	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.41	-0.33	1.47e-7	Neuroticism;
KIRP	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg18132916	chr6:79620363	NA	-0.4	-5.5	-0.33	9.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg19554555	chr3:13937349	NA	0.56	8.47	0.48	2.22e-15	Ovarian reserve;
KIRP	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.8	11.03	0.58	2.99e-23	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1373549	1.000	rs10880906	chr12:46477878	A/G	cg21957191	chr20:1960655	PDYN	-0.46	-6.24	-0.37	1.85e-9	Hippocampal atrophy;
KIRP	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.97e-16	Morning vs. evening chronotype;
KIRP	cis	rs2235544	0.554	rs7540270	chr1:54484682	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.32	-5.87	-0.35	1.4e-8	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg11522683	chr6:37501428	NA	-0.38	-4.98	-0.3	1.19e-6	Cognitive performance;
KIRP	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.46	-5.32	-0.32	2.38e-7	Parkinson's disease;
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.87	14.67	0.68	1.96e-35	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.56	-5.64	-0.34	4.68e-8	Type 2 diabetes;
KIRP	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03934478	chr11:495069	RNH1	0.87	7.06	0.41	1.67e-11	Body mass index;
KIRP	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg02503808	chr4:7069936	GRPEL1	-1.05	-10.75	-0.57	2.46e-22	Monocyte percentage of white cells;
KIRP	trans	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg25288420	chr1:78511713	GIPC2	0.58	7.83	0.45	1.47e-13	Obesity-related traits;
KIRP	cis	rs7833787	0.832	rs12546229	chr8:18701879	C/T	cg17701159	chr8:18705777	PSD3	-0.39	-7.27	-0.42	4.82e-12	Obesity-related traits;
KIRP	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	trans	rs587242	1.000	rs7551466	chr1:96892427	G/T	cg10631902	chr5:14652156	NA	0.52	6.02	0.36	6.46e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.69	-0.39	1.49e-10	Lymphocyte counts;
KIRP	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.44	2.75e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6125597	0.967	rs6122779	chr20:47893014	T/C	cg03212862	chr20:47662828	CSE1L	-0.41	-5.24	-0.32	3.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.86	12.87	0.63	2.52e-29	Longevity;
KIRP	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.42	5.32	0.32	2.37e-7	Cystic fibrosis severity;
KIRP	cis	rs3096299	0.646	rs918722	chr16:89415081	C/G	cg06640241	chr16:89574553	SPG7	0.53	6.6	0.39	2.5e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.15	0.54	1.85e-20	Cognitive test performance;
KIRP	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg17595323	chr11:93583763	C11orf90	-0.37	-6.28	-0.37	1.51e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.03	-0.36	5.96e-9	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12584590	chr12:120078537	TMEM233	-0.47	-7.48	-0.43	1.29e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs1823913	0.599	rs7598639	chr2:192132684	A/G	cg12404831	chr2:192114017	MYO1B	0.49	6.75	0.4	1.06e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg18209359	chr17:80159595	CCDC57	0.4	5.36	0.32	1.91e-7	Life satisfaction;
KIRP	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.8	-11.59	-0.59	4.4e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg25356066	chr3:128598488	ACAD9	0.5	5.82	0.35	1.81e-8	IgG glycosylation;
KIRP	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.45	0.43	1.59e-12	Prudent dietary pattern;
KIRP	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.85	-0.45	1.25e-13	Neuroticism;
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs11264213	0.901	rs12031138	chr1:36407806	C/T	cg27506609	chr1:36549197	TEKT2	-0.97	-10.16	-0.54	1.81e-20	Schizophrenia;
KIRP	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg02527881	chr3:46936655	PTH1R	-0.37	-5.15	-0.31	5.45e-7	Colorectal cancer;
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg15117754	chr3:10150083	C3orf24	0.55	5.24	0.32	3.5e-7	Alzheimer's disease;
KIRP	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07530022	chr16:431628	TMEM8A;LOC100134368	-0.5	-6.38	-0.38	8.7e-10	Myopia;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg04628465	chr16:85015467	ZDHHC7	-0.47	-6.03	-0.36	6.04e-9	Bladder cancer;
KIRP	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg04369109	chr6:150039330	LATS1	-0.46	-5.68	-0.34	3.88e-8	Lung cancer;
KIRP	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg04369109	chr6:150039330	LATS1	-0.52	-6.05	-0.36	5.49e-9	Lung cancer;
KIRP	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg12963246	chr6:28129442	ZNF389	0.5	6.13	0.36	3.55e-9	Depression;
KIRP	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.85	12.17	0.61	5.34e-27	Coronary artery disease;
KIRP	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs921968	0.565	rs2059717	chr2:219600316	A/T	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.27	-0.32	3.03e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19603966	chr10:22292833	DNAJC1	0.51	6.74	0.39	1.14e-10	Survival in pancreatic cancer;
KIRP	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.63	8.26	0.47	8.88e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8077577	0.895	rs62072498	chr17:18125951	C/G	cg18869244	chr17:18121946	NA	0.49	5.56	0.33	7.12e-8	Obesity-related traits;
KIRP	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg11382394	chr1:2564504	MMEL1	-0.43	-5.54	-0.33	7.75e-8	Ulcerative colitis;
KIRP	cis	rs67385638	0.862	rs11036641	chr11:5310578	A/G	cg12559170	chr11:5275217	HBG2	0.47	6.43	0.38	6.42e-10	Hemoglobin levels;
KIRP	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.41	-0.47	3.32e-15	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06728437	chr2:208031766	KLF7	0.46	6.31	0.37	1.31e-9	Parkinson's disease;
KIRP	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	1.33	9.88	0.53	1.36e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs829661	0.843	rs1096109	chr2:30759655	A/G	cg10949345	chr2:30726833	LCLAT1	1.13	14.2	0.67	8.2e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs1355223	0.902	rs1901831	chr11:34725175	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.75e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg17372223	chr3:52568218	NT5DC2	0.34	5.59	0.34	5.95e-8	Bipolar disorder;
KIRP	cis	rs258892	0.895	rs34658	chr5:72148496	A/G	cg21869765	chr5:72125136	TNPO1	0.57	6.26	0.37	1.7e-9	Small cell lung carcinoma;
KIRP	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.8	9.61	0.52	8.87e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs5753037	0.653	rs131285	chr22:30157940	T/C	cg01021169	chr22:30184971	ASCC2	-0.43	-5.86	-0.35	1.5e-8	Type 1 diabetes;
KIRP	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.94	13.68	0.66	4.57e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3849570	0.533	rs6809793	chr3:81990089	C/T	cg07356753	chr3:81810745	GBE1	-0.52	-6.77	-0.4	9.65e-11	Waist circumference;Body mass index;
KIRP	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs804280	0.535	rs10435719	chr8:11776904	C/T	cg21775007	chr8:11205619	TDH	0.47	6.34	0.38	1.06e-9	Myopia (pathological);
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.95	-0.3	1.35e-6	Life satisfaction;
KIRP	trans	rs7157940	0.692	rs4905163	chr14:94570770	A/G	cg24708831	chr14:100070564	CCDC85C	0.52	6.03	0.36	6.08e-9	Anthropometric traits;
KIRP	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.7	0.34	3.37e-8	Total cholesterol levels;
KIRP	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.71	-11.22	-0.58	7.51e-24	Hepatocellular carcinoma;
KIRP	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.46	5.97	0.36	8.17e-9	Gout;
KIRP	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2635047	0.638	rs55730206	chr18:44608230	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.24	0.37	1.85e-9	Educational attainment;
KIRP	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.48	6.1	0.36	4.11e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-5.43	-0.33	1.33e-7	Neuroticism;
KIRP	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg16473166	chr22:50639996	SELO	0.82	9.28	0.51	9.07e-18	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.52	-6.35	-0.38	1.01e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs4750440	0.637	rs2447010	chr10:14032115	T/C	cg27542038	chr10:14027202	FRMD4A	-0.39	-5.27	-0.32	2.96e-7	Adiponectin levels;
KIRP	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.43	-6.49	-0.38	4.56e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.03e-9	Depression;
KIRP	cis	rs16828019	0.777	rs12023079	chr1:41470111	G/A	cg03387723	chr1:41708464	SCMH1	-0.75	-6.08	-0.36	4.5e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.22	22.44	0.82	1.93e-61	Cognitive function;
KIRP	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.01	0.45	4.48e-14	Height;
KIRP	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.24	0.58	6.31e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	7.57	0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.74	8.45	0.47	2.5e-15	Adiposity;
KIRP	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg04087571	chr11:116723030	SIK3	-0.26	-5.44	-0.33	1.26e-7	Subjective well-being;
KIRP	cis	rs7688540	0.771	rs17164747	chr4:260587	G/T	cg17891759	chr4:299121	NA	-0.49	-4.99	-0.3	1.15e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg04727924	chr7:799746	HEATR2	-0.66	-6.61	-0.39	2.39e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.54	13.6	0.66	8.49e-32	Airflow obstruction;
KIRP	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.46	-5.29	-0.32	2.75e-7	Total body bone mineral density;
KIRP	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.11	-0.31	6.35e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3017493	0.786	rs59579317	chr11:70684569	A/G	cg10362475	chr11:70507825	SHANK2	0.37	5.58	0.34	6.33e-8	Renal transplant outcome;
KIRP	cis	rs874426	0.528	rs7110926	chr11:19574469	A/G	cg13922121	chr11:19575262	NAV2	0.46	5.65	0.34	4.4e-8	Attention deficit hyperactivity disorder (time to onset);
KIRP	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg26587870	chr6:27730563	NA	-0.65	-4.92	-0.3	1.56e-6	Breast cancer;
KIRP	cis	rs1076160	0.846	rs10793944	chr9:135707903	C/T	cg04648087	chr9:135819397	TSC1	-0.39	-4.85	-0.3	2.21e-6	Psoriasis;
KIRP	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg12573791	chr2:3828286	NA	0.35	4.85	0.3	2.2e-6	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg26751094	chr13:95954534	ABCC4	-0.55	-7.56	-0.43	7.83e-13	Blood metabolite levels;
KIRP	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.48	5.96	0.36	8.89e-9	Radiation response;
KIRP	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg16141378	chr3:129829833	LOC729375	0.57	6.85	0.4	5.8e-11	Neuroticism;
KIRP	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg14003231	chr6:33640908	ITPR3	0.3	5.4	0.33	1.57e-7	Plateletcrit;
KIRP	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.63	7.73	0.44	2.72e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg12131826	chr15:77904385	NA	-0.44	-5.86	-0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.39e-10	Aortic root size;
KIRP	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg26513180	chr16:89883248	FANCA	0.58	7.17	0.42	8.53e-12	Vitiligo;
KIRP	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.53	-6.8	-0.4	7.8e-11	Type 2 diabetes;
KIRP	cis	rs72634258	0.519	rs744001	chr1:7934557	G/A	cg26816564	chr1:7831052	VAMP3	0.6	5.25	0.32	3.28e-7	Inflammatory bowel disease;
KIRP	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg03714773	chr7:91764589	CYP51A1	0.34	5.07	0.31	7.93e-7	Breast cancer;
KIRP	cis	rs35000415	0.938	rs12536266	chr7:128611035	G/A	cg19972273	chr7:128594194	NA	0.85	6.19	0.37	2.45e-9	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06481639	chr22:41940642	POLR3H	-0.72	-7.28	-0.42	4.36e-12	Vitiligo;
KIRP	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	1.0	17.85	0.75	2.88e-46	Parkinson's disease;
KIRP	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg04691961	chr3:161091175	C3orf57	-0.37	-5.0	-0.3	1.07e-6	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00149659	chr3:10157352	C3orf10	0.83	8.87	0.49	1.55e-16	Alzheimer's disease;
KIRP	cis	rs6191	0.935	rs258747	chr5:142656813	A/G	cg08845721	chr5:142780693	NR3C1	0.38	5.2	0.31	4.28e-7	Night sleep phenotypes;
KIRP	cis	rs80282103	0.618	rs57514701	chr10:1146169	G/A	cg08668510	chr10:1095578	IDI1	0.96	6.43	0.38	6.45e-10	Glomerular filtration rate (creatinine);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27497285	chr9:95432195	IPPK	0.53	6.04	0.36	5.51e-9	Smoking initiation;
KIRP	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs925255	0.810	rs1396733	chr2:28642747	A/C	cg01273330	chr2:28605224	NA	0.37	6.29	0.37	1.41e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs427941	0.773	rs420437	chr7:101819315	C/T	cg06246474	chr7:101738831	CUX1	0.52	5.91	0.35	1.14e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	5.51	0.33	9.13e-8	Schizophrenia;
KIRP	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg01631408	chr1:248437212	OR2T33	-0.41	-5.44	-0.33	1.27e-7	Common traits (Other);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20573562	chr11:18034664	SERGEF	0.45	6.06	0.36	5.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg14458575	chr2:238380390	NA	0.46	5.23	0.32	3.55e-7	Prostate cancer;
KIRP	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.68	9.05	0.5	4.5e-17	Inflammatory bowel disease;
KIRP	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00338735	chr4:53728038	RASL11B	0.56	5.03	0.31	9.28e-7	Optic nerve measurement (cup area);
KIRP	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg08851530	chr6:28072375	NA	0.87	5.04	0.31	9.17e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg04865290	chr3:52927548	TMEM110	-0.65	-6.85	-0.4	6.05e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs1950626	0.569	rs4143956	chr14:101434356	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.54	6.1	0.36	4.03e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	4.9	0.3	1.78e-6	Schizophrenia;
KIRP	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg18164611	chr1:46958628	NA	0.43	5.4	0.33	1.56e-7	Monobrow;
KIRP	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.74	0.44	2.55e-13	Coffee consumption (cups per day);
KIRP	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.5	-0.48	1.81e-15	Neuroticism;
KIRP	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg14353649	chr10:135191496	PAOX	0.48	5.33	0.32	2.23e-7	Lifespan;
KIRP	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.47	0.52	2.48e-18	Colorectal cancer;
KIRP	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg02775129	chr4:119771670	NA	-0.87	-4.92	-0.3	1.55e-6	Cannabis dependence symptom count;
KIRP	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	9.89	0.53	1.21e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2916247	1.000	rs6988317	chr8:93042221	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.57	-7.36	-0.42	2.76e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs35883536	1.000	rs35883536	chr1:101106534	G/A	cg06223162	chr1:101003688	GPR88	0.32	6.58	0.39	2.73e-10	Monocyte count;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg07476944	chr4:39978140	PDS5A	-0.43	-6.03	-0.36	5.96e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15369054	chr17:80825471	TBCD	0.66	5.75	0.34	2.65e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg00800038	chr16:89945340	TCF25	0.68	5.05	0.31	8.43e-7	Skin colour saturation;
KIRP	cis	rs4889855	0.530	rs11654265	chr17:78602697	G/A	cg09596252	chr17:78655493	RPTOR	-0.48	-5.4	-0.33	1.56e-7	Fractional excretion of uric acid;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13198984	chr17:80129470	CCDC57	0.59	8.79	0.49	2.58e-16	Life satisfaction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06398150	chr16:1021062	LMF1	-0.57	-7.21	-0.42	7.06e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg14345882	chr6:26364793	BTN3A2	0.66	4.88	0.3	1.95e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg17376030	chr22:41985996	PMM1	-0.76	-8.44	-0.47	2.84e-15	Vitiligo;
KIRP	cis	rs6062509	0.811	rs6062498	chr20:62339059	C/G	cg11503966	chr20:62272292	STMN3	0.33	5.04	0.31	8.89e-7	Prostate cancer;
KIRP	cis	rs4900538	0.827	rs3742444	chr14:102971050	T/G	cg18135206	chr14:102964638	TECPR2	0.89	12.9	0.64	2.03e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.58	7.72	0.44	2.99e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-7.96	-0.45	6.25e-14	Migraine;Coronary artery disease;
KIRP	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.83	9.9	0.53	1.19e-19	Corneal astigmatism;
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg03724423	chr7:27170755	HOXA4	-0.37	-5.46	-0.33	1.15e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg22138327	chr13:27999177	GTF3A	-0.88	-7.01	-0.41	2.26e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg20887711	chr4:1340912	KIAA1530	0.53	6.89	0.4	4.54e-11	Longevity;
KIRP	cis	rs7221595	0.673	rs115725560	chr17:3980493	T/A	cg11204139	chr17:3907470	NA	0.58	5.67	0.34	3.98e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.66	-8.01	-0.45	4.54e-14	Aortic root size;
KIRP	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03934478	chr11:495069	RNH1	0.83	6.78	0.4	8.78e-11	Body mass index;
KIRP	cis	rs920590	0.879	rs67391684	chr8:19654642	A/T	cg03894339	chr8:19674705	INTS10	0.53	6.42	0.38	6.88e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs71277158	0.688	rs3772178	chr3:169773833	T/C	cg04067573	chr3:169899625	PHC3	0.52	4.96	0.3	1.35e-6	Prostate cancer;
KIRP	cis	rs2411233	0.837	rs12907480	chr15:39250334	C/T	cg05886626	chr15:39873553	THBS1	0.35	5.16	0.31	5.03e-7	Platelet count;
KIRP	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.68	-7.63	-0.44	5.07e-13	Recalcitrant atopic dermatitis;
KIRP	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.88e-13	Bipolar disorder;
KIRP	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg19257562	chr1:2043853	PRKCZ	0.39	6.45	0.38	5.91e-10	Height;
KIRP	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.71	10.84	0.57	1.2e-22	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.53	0.48	1.55e-15	Prudent dietary pattern;
KIRP	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg11130432	chr3:121712080	ILDR1	-0.45	-5.45	-0.33	1.22e-7	Multiple sclerosis;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs12311304	0.901	rs9788111	chr12:15417254	T/C	cg08258403	chr12:15378311	NA	0.38	5.53	0.33	7.97e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6438504	0.883	rs4603947	chr3:118943552	A/G	cg25372693	chr3:118959985	B4GALT4	-0.32	-5.55	-0.33	7.41e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg21640587	chr11:117668038	DSCAML1	0.49	6.71	0.39	1.37e-10	Myopia;
KIRP	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg24747557	chr10:131355152	MGMT	-0.4	-5.44	-0.33	1.25e-7	Response to temozolomide;
KIRP	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs7929679	0.545	rs2421740	chr11:34796754	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.36e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.61	8.06	0.46	3.38e-14	Schizophrenia;
KIRP	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg13010199	chr12:38710504	ALG10B	0.65	7.94	0.45	7.21e-14	Morning vs. evening chronotype;
KIRP	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.56	7.31	0.42	3.84e-12	Breast cancer;
KIRP	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg02700894	chr3:12045449	SYN2	0.46	6.59	0.39	2.68e-10	Plateletcrit;Lymphocyte counts;White blood cell count;
KIRP	cis	rs4716602	0.674	rs10244637	chr7:156157853	G/A	cg16983916	chr7:156159713	NA	-0.39	-5.3	-0.32	2.56e-7	Anti-saccade response;
KIRP	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg04865290	chr3:52927548	TMEM110	-0.62	-6.92	-0.4	3.85e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.06	0.64	5.78e-30	Exhaled nitric oxide output;
KIRP	cis	rs7805747	0.961	rs10224002	chr7:151415041	C/T	cg17611936	chr7:151411526	PRKAG2	-0.52	-6.8	-0.4	7.86e-11	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
KIRP	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.16	-10.75	-0.57	2.31e-22	Body mass index;
KIRP	cis	rs7572263	0.724	rs6704765	chr2:209054267	C/G	cg23998903	chr2:209048830	C2orf80	-0.36	-5.25	-0.32	3.22e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.72	-10.65	-0.56	4.96e-22	Lung cancer;
KIRP	cis	rs56313388	0.521	rs62039274	chr16:56328813	G/T	cg02433656	chr16:56322654	GNAO1	0.47	5.52	0.33	8.66e-8	Pulse pressure;
KIRP	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.71	9.97	0.54	7.2e-20	Plateletcrit;Platelet count;
KIRP	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs6942756	0.531	rs2896415	chr7:128904523	G/A	cg15488143	chr7:128924101	AHCYL2	-0.47	-6.05	-0.36	5.47e-9	White matter hyperintensity burden;
KIRP	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.83	-0.4	6.6e-11	Morning vs. evening chronotype;
KIRP	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg11522683	chr6:37501428	NA	-0.37	-4.94	-0.3	1.46e-6	Cognitive performance;
KIRP	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs10802346	0.636	rs12141086	chr1:246366287	C/G	cg15962031	chr1:246363574	SMYD3	0.8	5.69	0.34	3.6e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.8	-0.35	2.05e-8	HDL cholesterol;
KIRP	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-8.84	-0.49	1.88e-16	Bipolar disorder;
KIRP	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg14593290	chr7:50529359	DDC	0.47	6.01	0.36	6.54e-9	Malaria;
KIRP	cis	rs4523957	0.651	rs898748	chr17:2085475	G/T	cg16513277	chr17:2031491	SMG6	-0.8	-11.62	-0.6	3.67e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg03808351	chr9:123631620	PHF19	0.55	8.23	0.46	1.09e-14	Birth weight;
KIRP	cis	rs9920506	0.536	rs12441998	chr15:78929372	G/A	cg24631222	chr15:78858424	CHRNA5	-0.45	-5.09	-0.31	7.28e-7	Post bronchodilator FEV1;
KIRP	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg24579218	chr15:68104479	NA	-0.35	-5.0	-0.3	1.11e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg27121462	chr16:89883253	FANCA	-0.5	-6.49	-0.38	4.8e-10	Vitiligo;
KIRP	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.57	5.28	0.32	2.9e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10267417	0.673	rs2892955	chr7:19933486	A/G	cg05791153	chr7:19748676	TWISTNB	0.47	4.93	0.3	1.49e-6	Night sleep phenotypes;
KIRP	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.44	5.29	0.32	2.71e-7	Body mass index;
KIRP	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.24e-8	Lung cancer;
KIRP	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.64	-7.28	-0.42	4.6e-12	Menarche (age at onset);
KIRP	cis	rs6578185	0.810	rs7816220	chr8:142453585	T/C	cg07762003	chr8:142452454	FLJ43860	-0.67	-10.31	-0.55	6.07e-21	Endometriosis;
KIRP	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.74	-9.57	-0.52	1.24e-18	Breast size;
KIRP	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.8	10.97	0.57	4.66e-23	Colorectal cancer;
KIRP	cis	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg08773314	chr2:239334832	ASB1	-0.55	-5.7	-0.34	3.39e-8	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13051728	chr14:68086375	ARG2	0.49	6.09	0.36	4.27e-9	Parkinson's disease;
KIRP	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.53	7.98	0.45	5.53e-14	Itch intensity from mosquito bite;
KIRP	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.92	-11.81	-0.6	8.56e-26	Blood protein levels;
KIRP	trans	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg11693508	chr17:37793320	STARD3	0.81	8.18	0.46	1.54e-14	Neuroticism;
KIRP	cis	rs918629	0.724	rs55841351	chr5:95278019	A/G	cg16656078	chr5:95278638	ELL2	-0.45	-6.65	-0.39	1.84e-10	IgG glycosylation;
KIRP	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.48	0.33	1.03e-7	Resting heart rate;
KIRP	cis	rs2862064	1.000	rs905211	chr5:156447218	A/T	cg12943317	chr5:156479607	HAVCR1	-0.73	-6.8	-0.4	7.86e-11	Platelet count;
KIRP	cis	rs2274273	0.712	rs6572999	chr14:55527374	T/C	cg04306507	chr14:55594613	LGALS3	0.42	6.37	0.38	9e-10	Protein biomarker;
KIRP	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.85	12.25	0.62	3e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.55	-0.56	1.08e-21	Triglycerides;
KIRP	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	1.11	10.39	0.55	3.27e-21	Lymphocyte counts;
KIRP	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.56	-0.48	1.22e-15	Lung cancer;
KIRP	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs752010	0.543	rs7545381	chr1:42044183	T/A	cg06885757	chr1:42089581	HIVEP3	0.46	6.63	0.39	2.16e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg01245423	chr9:98080212	FANCC	0.54	7.24	0.42	5.64e-12	Educational attainment;
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg07701084	chr6:150067640	NUP43	0.71	10.0	0.54	5.74e-20	Lung cancer;
KIRP	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.98	13.95	0.66	5.68e-33	Cognitive function;
KIRP	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.62	9.97	0.54	7.02e-20	HDL cholesterol levels;
KIRP	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg06640241	chr16:89574553	SPG7	0.46	5.99	0.36	7.59e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.32	-0.42	3.54e-12	Uric acid levels;
KIRP	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg16898833	chr6:26189333	HIST1H4D	0.85	5.99	0.36	7.46e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs714027	0.565	rs2285667	chr22:30384104	T/A	cg27665648	chr22:30112403	NA	0.41	5.62	0.34	5.2e-8	Lymphocyte counts;
KIRP	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.39	-5.14	-0.31	5.65e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	10.8	0.57	1.62e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7590368	0.673	rs17365209	chr2:10939117	C/T	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.55e-9	Educational attainment (years of education);
KIRP	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg09936400	chr10:82049201	MAT1A	0.35	4.88	0.3	1.93e-6	Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg05220968	chr6:146057943	EPM2A	-0.39	-5.0	-0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.5	-7.2	-0.42	7.45e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs3109167	0.666	rs6976446	chr7:83108019	T/C	cg14519356	chr7:83097669	SEMA3E	-0.47	-6.52	-0.38	3.86e-10	Blood protein levels;
KIRP	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg07395648	chr5:131743802	NA	-0.33	-4.85	-0.3	2.17e-6	Breast cancer;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.31	0.37	1.31e-9	Coronary artery disease;
KIRP	cis	rs8044868	0.530	rs7185840	chr16:72102112	A/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.4	-0.33	1.54e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4748857	1.000	rs4748857	chr10:23599558	C/T	cg12804278	chr10:23633326	C10orf67	0.43	5.23	0.32	3.61e-7	Systemic lupus erythematosus;
KIRP	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.37	0.43	2.55e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4722404	0.533	rs2396960	chr7:3110933	A/G	cg06416929	chr7:3127028	NA	0.35	5.0	0.3	1.08e-6	Atopic dermatitis;
KIRP	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.56	7.16	0.42	9.12e-12	Personality dimensions;
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg22718636	chr4:961658	DGKQ	0.36	5.77	0.35	2.36e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.74	11.14	0.58	1.3e-23	Colorectal cancer;
KIRP	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg05234568	chr11:5960015	NA	-0.61	-6.27	-0.37	1.62e-9	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12484686	chr17:14204340	HS3ST3B1	0.51	6.4	0.38	7.84e-10	Parkinson's disease;
KIRP	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.4	0.43	2.16e-12	Aortic root size;
KIRP	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg25486957	chr4:152246857	NA	-0.41	-5.0	-0.3	1.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.48	-6.28	-0.37	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg08975724	chr8:8085496	FLJ10661	-0.67	-9.16	-0.5	2.03e-17	Triglycerides;
KIRP	trans	rs13170463	0.579	rs11742306	chr5:8038634	A/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg00990874	chr7:1149470	C7orf50	-0.65	-7.09	-0.41	1.43e-11	Bronchopulmonary dysplasia;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg19948974	chr18:23671311	SS18	-0.44	-6.51	-0.38	4.28e-10	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs7507204	0.906	rs62125968	chr19:3422261	G/A	cg08380311	chr19:3435252	NFIC	0.66	6.57	0.39	2.99e-10	Height;
KIRP	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg07701084	chr6:150067640	NUP43	0.75	10.26	0.55	8.45e-21	Lung cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00990635	chr19:19745667	GMIP	0.51	6.95	0.41	3.35e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	8.27	0.47	8.31e-15	Retinal vascular caliber;
KIRP	cis	rs7712401	0.623	rs426877	chr5:122314635	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.79	10.54	0.56	1.09e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.3	-4.89	-0.3	1.84e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.49	6.66	0.39	1.81e-10	Cardiovascular disease risk factors;
KIRP	trans	rs2997105	1.000	rs9591688	chr13:56357242	T/A	cg08528735	chr3:184428879	MAGEF1	0.57	6.19	0.37	2.54e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs2708977	1.000	rs10184209	chr2:97337491	G/T	cg01950434	chr2:97203154	ARID5A	0.52	6.32	0.37	1.23e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10875746	0.587	rs9788082	chr12:48752056	C/A	cg26205652	chr12:48591994	NA	0.78	9.41	0.51	3.75e-18	Longevity (90 years and older);
KIRP	cis	rs7737355	0.773	rs3776006	chr5:130875538	C/T	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.85e-6	Life satisfaction;
KIRP	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg01522456	chr1:115632236	TSPAN2	-0.37	-5.0	-0.3	1.07e-6	Autism;
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg24633833	chr3:10029261	TMEM111	0.53	5.11	0.31	6.38e-7	Alzheimer's disease;
KIRP	cis	rs282587	0.569	rs282594	chr13:113379640	A/G	cg04656015	chr13:113407548	ATP11A	0.66	7.97	0.45	5.83e-14	Glycated hemoglobin levels;
KIRP	cis	rs986417	0.901	rs2351172	chr14:61008687	A/G	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-1.24	-8.33	-0.47	5.83e-15	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
KIRP	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg00933542	chr6:150070202	PCMT1	0.28	5.39	0.33	1.65e-7	Lung cancer;
KIRP	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.57	-0.33	6.64e-8	Chronic sinus infection;
KIRP	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.77	-10.8	-0.57	1.65e-22	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg08017634	chr8:144659831	NAPRT1	0.77	5.11	0.31	6.48e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.66	8.42	0.47	3.17e-15	Breast cancer;
KIRP	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg07636037	chr3:49044803	WDR6	-0.76	-7.68	-0.44	3.8e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06050784	chr16:88016603	BANP	0.44	5.36	0.32	1.92e-7	Menopause (age at onset);
KIRP	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg26874229	chr2:105853672	NA	-0.38	-5.52	-0.33	8.59e-8	Type 2 diabetes;
KIRP	cis	rs1832871	0.619	rs262825	chr6:158678631	C/T	cg07215822	chr6:158701037	NA	0.45	6.46	0.38	5.58e-10	Height;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.39	6.13	0.36	3.4e-9	Renal function-related traits (BUN);
KIRP	cis	rs8067287	0.640	rs62065424	chr17:16828650	A/G	cg26910001	chr17:16838321	NA	-0.61	-5.98	-0.36	7.62e-9	Diabetic kidney disease;
KIRP	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg06740227	chr12:86229804	RASSF9	0.53	6.68	0.39	1.54e-10	Major depressive disorder;
KIRP	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg05721485	chr17:44071124	MAPT	0.58	7.46	0.43	1.48e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs873917	0.577	rs784599	chr1:40138507	A/G	cg18438793	chr1:40149837	HPCAL4	0.45	6.11	0.36	3.83e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg18306943	chr3:40428807	ENTPD3	0.37	5.12	0.31	6.23e-7	Renal cell carcinoma;
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	trans	rs12517041	1.000	rs10520888	chr5:23280539	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.36	-0.47	4.82e-15	Calcium levels;
KIRP	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg12310025	chr6:25882481	NA	-0.39	-5.35	-0.32	2.05e-7	Height;
KIRP	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.01	-0.5	5.69e-17	Chronic sinus infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18800827	chr17:42633783	FZD2	0.4	6.13	0.36	3.51e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07628558	chr20:56964831	VAPB	0.62	6.07	0.36	4.83e-9	Lung function (FEV1);
KIRP	trans	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg26043149	chr18:55253948	FECH	0.5	6.11	0.36	3.89e-9	Bone mineral density;
KIRP	cis	rs13202913	0.779	rs9383896	chr6:151768495	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.58	4.86	0.3	2.11e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.78	12.65	0.63	1.41e-28	Menarche (age at onset);
KIRP	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs4006360	0.575	rs404154	chr17:39315341	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.35	-5.09	-0.31	7.18e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.97	11.76	0.6	1.24e-25	Corneal astigmatism;
KIRP	cis	rs7224685	0.569	rs34859684	chr17:3982628	G/C	cg11204139	chr17:3907470	NA	0.56	5.59	0.34	5.91e-8	Type 2 diabetes;
KIRP	cis	rs11671005	0.735	rs11084544	chr19:58940127	C/G	cg13877915	chr19:58951672	ZNF132	0.6	5.86	0.35	1.51e-8	Mean platelet volume;
KIRP	cis	rs7849270	1.000	rs7020708	chr9:131885131	A/G	cg13538475	chr9:131942899	NA	-0.31	-5.04	-0.31	9.09e-7	Blood metabolite ratios;
KIRP	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-7.03	-0.41	2.01e-11	Personality dimensions;
KIRP	cis	rs9843304	0.616	rs67576825	chr3:149202683	A/C	cg08667024	chr3:149219783	TM4SF4	-0.42	-6.19	-0.37	2.54e-9	Gallstone disease;
KIRP	cis	rs17428704	0.571	rs35373258	chr5:14398531	G/C	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.62	5.57	0.33	6.53e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.75	-10.89	-0.57	8.29e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg06027949	chr8:82754900	SNX16	-0.51	-5.5	-0.33	9.28e-8	Diastolic blood pressure;
KIRP	cis	rs838147	0.844	rs8105137	chr19:49249888	G/A	cg08619932	chr19:49200058	FUT2	-0.34	-5.27	-0.32	2.97e-7	Dietary macronutrient intake;
KIRP	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.52	-7.12	-0.41	1.21e-11	Menarche (age at onset);
KIRP	cis	rs6546886	1.000	rs6546886	chr2:74245777	A/G	cg14702570	chr2:74259524	NA	-0.33	-6.65	-0.39	1.86e-10	Dialysis-related mortality;
KIRP	trans	rs10874322	1.000	rs10874322	chr1:83054799	A/G	cg12753787	chr1:3239712	PRDM16	-0.51	-6.01	-0.36	6.48e-9	Response to taxane treatment (docetaxel);
KIRP	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.52e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14598338	chr9:96623480	NA	-0.67	-11.49	-0.59	9.4e-25	DNA methylation (variation);
KIRP	cis	rs918629	0.567	rs11741590	chr5:95241127	A/G	cg16656078	chr5:95278638	ELL2	0.35	5.34	0.32	2.09e-7	IgG glycosylation;
KIRP	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg08773314	chr2:239334832	ASB1	0.39	7.05	0.41	1.82e-11	Multiple system atrophy;
KIRP	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg24826892	chr11:71159390	DHCR7	0.44	4.86	0.3	2.07e-6	Vitamin D levels;
KIRP	cis	rs735860	0.726	rs209510	chr6:53202035	T/C	cg10236188	chr6:53219634	NA	0.42	5.58	0.34	6.22e-8	Glaucoma;
KIRP	cis	rs6504950	0.813	rs244321	chr17:53223998	T/A	cg26251398	chr17:52985966	TOM1L1	0.38	4.96	0.3	1.32e-6	Breast cancer;
KIRP	cis	rs6969780	0.630	rs10238095	chr7:27196643	A/G	cg19142026	chr7:27170394	HOXA4	-0.34	-5.12	-0.31	6.25e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-9.76	-0.53	3.23e-19	Colorectal cancer;
KIRP	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	9.76	0.53	3.04e-19	Ileal carcinoids;
KIRP	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg19636519	chr7:99541626	NA	0.32	6.0	0.36	7.1e-9	Coronary artery disease;
KIRP	cis	rs9783347	1.000	rs4150575	chr11:18356466	C/T	cg15585147	chr11:18324498	HPS5	0.37	4.97	0.3	1.27e-6	Pancreatic cancer;
KIRP	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-10.27	-0.55	7.9e-21	Chronic sinus infection;
KIRP	trans	rs17079247	0.722	rs1907007	chr13:85808644	A/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.43	-0.38	6.53e-10	Bipolar disorder (mania);
KIRP	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.58	7.56	0.43	8.16e-13	Total body bone mineral density;
KIRP	cis	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg21546286	chr11:48923668	NA	-0.48	-5.95	-0.35	8.99e-9	HDL cholesterol;
KIRP	cis	rs13401104	0.587	rs62190973	chr2:237145231	T/A	cg19324714	chr2:237145437	ASB18	0.56	6.52	0.38	3.97e-10	Educational attainment;
KIRP	cis	rs35740288	0.731	rs11634651	chr15:86093926	A/C	cg17133734	chr15:86042851	AKAP13	-0.49	-5.43	-0.33	1.34e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.33	0.42	3.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg12486944	chr17:80159399	CCDC57	0.38	5.09	0.31	7.18e-7	Life satisfaction;
KIRP	cis	rs9473924	0.542	rs2857514	chr6:50811283	C/T	cg14470998	chr6:50812995	TFAP2B	1.07	8.69	0.48	5.18e-16	Body mass index;
KIRP	cis	rs7106204	1.000	rs35876423	chr11:24214859	G/T	ch.11.24196551F	chr11:24239977	NA	0.84	8.9	0.49	1.28e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg07216194	chr8:27182965	PTK2B	0.45	5.6	0.34	5.73e-8	Neuroticism;
KIRP	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	7.47	0.43	1.36e-12	Iron status biomarkers;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg01506766	chr13:46626746	ZC3H13	-0.45	-6.03	-0.36	5.83e-9	Blood metabolite levels;
KIRP	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.2	-0.42	7.41e-12	Type 2 diabetes;
KIRP	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg09408571	chr1:101003634	GPR88	0.26	5.97	0.36	8.04e-9	Breast cancer;
KIRP	cis	rs11710088	0.931	rs4630883	chr3:149199160	A/G	cg08667024	chr3:149219783	TM4SF4	0.39	5.63	0.34	4.96e-8	QRS duration;
KIRP	cis	rs787274	1.000	rs7041965	chr9:115598341	T/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.55	-0.39	3.31e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	14.36	0.68	2.25e-34	Platelet count;
KIRP	cis	rs2070997	0.756	rs3808820	chr9:133726956	A/T	cg13397898	chr9:133768931	QRFP	0.32	5.14	0.31	5.63e-7	Response to amphetamines;
KIRP	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg18225595	chr11:63971243	STIP1	0.66	6.06	0.36	5.08e-9	Mean platelet volume;
KIRP	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg00981070	chr1:2046702	PRKCZ	-0.37	-5.45	-0.33	1.21e-7	Height;
KIRP	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg21253087	chr9:139290292	SNAPC4	0.5	6.96	0.41	3.03e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7534824	0.860	rs17450806	chr1:101605109	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.88	-5.49	-0.33	1.01e-7	Refractive astigmatism;
KIRP	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg10503236	chr1:231470652	EXOC8	-0.52	-7.14	-0.41	1.06e-11	Hemoglobin concentration;
KIRP	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.52	6.94	0.4	3.47e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2637030	0.559	rs6881928	chr5:52988609	C/A	cg06476337	chr5:52856530	NDUFS4	0.56	6.3	0.37	1.34e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.91	-0.45	8.48e-14	Neuroticism;
KIRP	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.91	-11.83	-0.6	7.07e-26	Schizophrenia;
KIRP	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.48	-5.07	-0.31	7.66e-7	Breast cancer;
KIRP	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	6.34	0.37	1.07e-9	Coronary artery disease;
KIRP	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12776902	chr4:144452479	SMARCA5	-0.38	-6.1	-0.36	4.01e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg15181151	chr6:150070149	PCMT1	0.3	5.12	0.31	6.1e-7	Lung cancer;
KIRP	trans	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg23960684	chr11:61559964	C11orf10;FEN1	-0.52	-6.09	-0.36	4.41e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26361754	chr2:206790750	NA	0.53	7.02	0.41	2.11e-11	Parkinson's disease;
KIRP	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.74	-7.39	-0.43	2.36e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg25319279	chr11:5960081	NA	-0.6	-6.17	-0.37	2.87e-9	DNA methylation (variation);
KIRP	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.61	-6.73	-0.39	1.2e-10	Urate levels in lean individuals;
KIRP	trans	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg24644049	chr4:85504048	CDS1	1.04	7.22	0.42	6.41e-12	Skin colour saturation;
KIRP	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg14458575	chr2:238380390	NA	0.55	5.81	0.35	1.97e-8	Prostate cancer;
KIRP	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs11955175	1.000	rs11956741	chr5:40677576	G/C	cg05478818	chr5:40835740	RPL37	0.68	5.09	0.31	7.26e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2916247	0.908	rs2339457	chr8:93103628	A/G	cg10183463	chr8:93005414	RUNX1T1	0.5	5.76	0.34	2.55e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg00094735	chr5:1949198	NA	0.45	5.45	0.33	1.21e-7	Gut microbiome composition (winter);
KIRP	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg24747557	chr10:131355152	MGMT	-0.37	-4.91	-0.3	1.7e-6	Response to temozolomide;
KIRP	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg19847130	chr8:10466454	RP1L1	-0.42	-6.15	-0.37	3.13e-9	Retinal vascular caliber;
KIRP	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs6120849	0.951	rs6120848	chr20:33728678	T/C	cg24642439	chr20:33292090	TP53INP2	0.73	7.69	0.44	3.51e-13	Protein C levels;
KIRP	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	0.53	6.31	0.37	1.3e-9	Prudent dietary pattern;
KIRP	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg13264159	chr8:625131	ERICH1	-0.7	-5.8	-0.35	2.05e-8	IgG glycosylation;
KIRP	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	11.65	0.6	2.82e-25	Electrocardiographic conduction measures;
KIRP	cis	rs10073892	0.743	rs62372222	chr5:101651505	T/C	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs62413470	1.000	rs12196526	chr6:55955754	C/G	cg13327911	chr6:55965977	COL21A1	-0.55	-5.14	-0.31	5.72e-7	Joint mobility (Beighton score);
KIRP	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg07636037	chr3:49044803	WDR6	-0.77	-7.61	-0.44	5.67e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.36	-5.02	-0.3	1.01e-6	Birth weight;
KIRP	cis	rs2456568	0.557	rs2456566	chr11:93698272	A/C	cg26875233	chr11:93583750	C11orf90	-0.27	-4.95	-0.3	1.4e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.65	-0.39	1.89e-10	Lung cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07422560	chr12:82752315	C12orf26;CCDC59	0.45	6.21	0.37	2.25e-9	Survival in pancreatic cancer;
KIRP	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.54	0.48	1.44e-15	Motion sickness;
KIRP	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg06885757	chr1:42089581	HIVEP3	0.65	10.09	0.54	3.02e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.85	10.46	0.55	1.95e-21	Multiple sclerosis;
KIRP	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg03605463	chr16:89740564	NA	-0.45	-5.21	-0.32	4e-7	Vitiligo;
KIRP	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.83	9.11	0.5	2.94e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs4523957	0.583	rs903159	chr17:2055109	C/T	cg16513277	chr17:2031491	SMG6	-0.85	-12.15	-0.61	6.32e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg00204512	chr16:28754710	NA	-0.49	-6.64	-0.39	1.97e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7766436	0.885	rs1954272	chr6:22586499	A/G	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.77	-6.66	-0.39	1.83e-10	Body mass index;
KIRP	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.04	0.31	9.09e-7	Lung cancer;
KIRP	cis	rs56079296	0.929	rs79742050	chr5:121379775	C/T	cg05256605	chr5:121412184	LOX	-0.54	-5.9	-0.35	1.17e-8	Coronary artery disease;
KIRP	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.64	-0.52	7.11e-19	Hemoglobin concentration;
KIRP	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg20362242	chr5:692897	TPPP	0.59	5.05	0.31	8.81e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.37	0.65	5.32e-31	Personality dimensions;
KIRP	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg12369402	chr1:90227771	NA	-0.44	-6.44	-0.38	6.38e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1978968	1.000	rs1110662	chr22:18444908	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7011049	0.778	rs7823580	chr8:53870595	C/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10011647	chr11:58892585	FAM111B	0.42	6.14	0.36	3.25e-9	Survival in pancreatic cancer;
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg11641102	chr8:27183873	PTK2B	0.47	6.11	0.36	3.89e-9	Neuroticism;
KIRP	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.26	-21.84	-0.81	1.57e-59	Breast cancer;
KIRP	cis	rs554111	0.660	rs1985278	chr1:21091861	G/T	cg21184320	chr1:21044207	KIF17	-0.41	-5.87	-0.35	1.41e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.61	8.87	0.49	1.52e-16	Mean corpuscular volume;
KIRP	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg21361702	chr7:150065534	REPIN1	0.62	6.03	0.36	6e-9	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	0.97	11.51	0.59	8.25e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15553848	chr2:39664346	MAP4K3	0.5	6.22	0.37	2.1e-9	Parkinson's disease;
KIRP	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19717773	chr7:2847554	GNA12	-0.37	-5.42	-0.33	1.43e-7	Height;
KIRP	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26378065	chr17:18585709	ZNF286B	0.55	6.83	0.4	6.62e-11	Educational attainment (years of education);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20704247	chr8:144409764	TOP1MT	-0.49	-6.67	-0.39	1.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	6.94	0.4	3.45e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	trans	rs6601327	0.635	rs7844461	chr8:9653055	T/A	cg08975724	chr8:8085496	FLJ10661	0.49	6.14	0.36	3.25e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-5.65	-0.34	4.45e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7546094	0.846	rs55675817	chr1:113166876	C/A	cg22162597	chr1:113214053	CAPZA1	-0.46	-5.84	-0.35	1.68e-8	Platelet distribution width;
KIRP	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.29	0.32	2.7e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.41	-6.36	-0.38	9.96e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs714027	0.837	rs713875	chr22:30592487	C/G	cg27665648	chr22:30112403	NA	-0.42	-6.28	-0.37	1.52e-9	Lymphocyte counts;
KIRP	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-8.6	-0.48	9.5e-16	Cognitive function;
KIRP	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg03647239	chr10:116582469	FAM160B1	0.5	5.99	0.36	7.46e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.54	-5.93	-0.35	1.04e-8	LDL cholesterol to HDL cholesterol ratio;
KIRP	cis	rs838721	0.574	rs34332006	chr2:234257452	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.47	5.27	0.32	2.91e-7	Total body bone mineral density;
KIRP	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	0.98	7.45	0.43	1.6e-12	Arsenic metabolism;
KIRP	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23903597	chr17:61704154	MAP3K3	-0.64	-6.97	-0.41	2.94e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs7521681	1.000	rs7521681	chr1:108322535	C/T	cg21202240	chr1:109285050	FNDC7	0.47	5.19	0.31	4.41e-7	Asthma and hay fever;
KIRP	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg25486957	chr4:152246857	NA	0.53	5.88	0.35	1.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4926611	0.863	rs2141083	chr1:54082352	C/T	cg08927728	chr1:54059983	GLIS1	0.25	5.32	0.32	2.33e-7	Hand grip strength;
KIRP	trans	rs11945798	1.000	rs16887512	chr4:12734271	C/T	cg17431079	chr1:39607710	MACF1	-0.78	-6.21	-0.37	2.21e-9	Word reading;
KIRP	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.18	0.37	2.7e-9	Menarche (age at onset);
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg03653399	chr8:142233436	SLC45A4	-0.95	-14.97	-0.69	1.89e-36	Immature fraction of reticulocytes;
KIRP	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg24049888	chr11:111250129	POU2AF1	0.4	6.66	0.39	1.79e-10	Primary biliary cholangitis;
KIRP	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	1.17	13.32	0.65	7.4e-31	Red blood cell traits;
KIRP	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg00852783	chr1:26633632	UBXN11	-0.54	-5.59	-0.34	6.09e-8	Obesity-related traits;
KIRP	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.62	7.82	0.45	1.58e-13	Resting heart rate;
KIRP	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg24955406	chr1:100503596	HIAT1	0.59	6.33	0.37	1.14e-9	Carotid intima media thickness;
KIRP	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.43	-0.47	2.87e-15	Common traits (Other);
KIRP	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.07	-0.31	7.88e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.62	-7.18	-0.42	8.25e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg05362011	chr13:21860987	NA	-0.46	-4.96	-0.3	1.3e-6	White matter hyperintensity burden;
KIRP	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg01304814	chr3:48885189	PRKAR2A	0.61	5.41	0.33	1.51e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.46	-6.97	-0.41	2.97e-11	Huntington's disease progression;
KIRP	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.7	-9.42	-0.51	3.37e-18	Waist circumference;Body mass index;
KIRP	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma (childhood onset);
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.41	0.74	8.46e-45	Platelet count;
KIRP	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg03714773	chr7:91764589	CYP51A1	0.37	5.39	0.33	1.63e-7	Breast cancer;
KIRP	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21788624	chr2:20251350	LAPTM4A	-0.52	-6.39	-0.38	8.2e-10	Interleukin-4 levels;
KIRP	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.55	-9.31	-0.51	7.4e-18	Height;
KIRP	cis	rs4689642	0.709	rs4689090	chr4:7226751	G/T	cg21353189	chr4:7228343	SORCS2	0.41	5.46	0.33	1.14e-7	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.85	13.29	0.65	9.31e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08280861	chr8:58055591	NA	0.68	4.97	0.3	1.25e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07570687	chr10:102243282	WNT8B	0.38	4.87	0.3	2.01e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.73	-9.64	-0.52	7.44e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.73	-9.18	-0.51	1.84e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.45	-5.24	-0.32	3.53e-7	Reticulocyte count;
KIRP	cis	rs4713118	0.824	rs7759217	chr6:27730463	A/G	cg20933634	chr6:27740509	NA	0.39	5.15	0.31	5.24e-7	Parkinson's disease;
KIRP	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.51	-11.59	-0.59	4.46e-25	Diabetic kidney disease;
KIRP	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg21427119	chr20:30132790	HM13	-0.56	-6.33	-0.37	1.14e-9	Mean corpuscular hemoglobin;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25204742	chr7:6448933	DAGLB	0.51	7.06	0.41	1.66e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.55	6.4	0.38	7.89e-10	Aortic root size;
KIRP	cis	rs6445967	1.000	rs3796215	chr3:58316657	A/G	cg16569813	chr3:58235849	ABHD6	-0.34	-4.92	-0.3	1.58e-6	Platelet count;
KIRP	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs8018808	0.875	rs7250	chr14:77935520	G/A	cg18872420	chr14:78023429	SPTLC2	0.37	5.39	0.33	1.61e-7	Myeloid white cell count;
KIRP	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg00981070	chr1:2046702	PRKCZ	0.3	5.17	0.31	4.96e-7	Height;
KIRP	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.65	-7.54	-0.43	8.92e-13	Platelet count;
KIRP	trans	rs1995809	0.793	rs76328771	chr4:147945270	T/C	cg23682866	chr10:43858278	NA	0.6	6.12	0.36	3.6e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.5	-6.25	-0.37	1.76e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg16255804	chr6:135334527	HBS1L	-0.31	-4.9	-0.3	1.75e-6	Red blood cell count;
KIRP	cis	rs4345220	0.585	rs6831658	chr4:41642581	T/C	cg15232654	chr4:41643107	LIMCH1	0.45	5.95	0.35	8.98e-9	Migraine with aura;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10659575	chr11:102188233	BIRC3	0.63	7.71	0.44	3.07e-13	Smoking initiation;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg01721255	chr8:58191610	C8orf71	-0.56	-5.24	-0.32	3.5e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.84	9.56	0.52	1.29e-18	Iron status biomarkers;
KIRP	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.3	-5.88	-0.35	1.34e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.41	0.33	1.5e-7	Putamen volume;
KIRP	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.55	6.43	0.38	6.43e-10	Height;
KIRP	cis	rs6466055	0.720	rs1204056	chr7:104957761	G/A	cg04380332	chr7:105027541	SRPK2	0.62	9.1	0.5	3.19e-17	Schizophrenia;
KIRP	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-0.73	-7.7	-0.44	3.23e-13	Gout;
KIRP	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.65	0.39	1.87e-10	Retinal vascular caliber;
KIRP	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg26205652	chr12:48591994	NA	-0.49	-5.29	-0.32	2.67e-7	Lung cancer;
KIRP	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs9400271	0.632	rs9384703	chr6:109586803	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.51	-0.33	9.07e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.46	5.74	0.34	2.78e-8	Asthma;
KIRP	cis	rs6832769	1.000	rs4865008	chr4:56410855	T/G	cg05960024	chr4:56376020	CLOCK	-0.72	-9.24	-0.51	1.18e-17	Personality dimensions;
KIRP	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.87	9.77	0.53	2.86e-19	Large artery stroke;
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg23693289	chr8:27183097	PTK2B	0.54	6.98	0.41	2.76e-11	Neuroticism;
KIRP	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.17	0.42	8.63e-12	Bipolar disorder;
KIRP	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.77	7.83	0.45	1.44e-13	Exhaled nitric oxide output;
KIRP	cis	rs10214930	0.697	rs12537499	chr7:27591595	A/G	cg22168087	chr7:27702803	HIBADH	-0.46	-4.9	-0.3	1.74e-6	Hypospadias;
KIRP	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg17410650	chr12:54324560	NA	-0.48	-6.54	-0.38	3.57e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
KIRP	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.77	9.95	0.54	8.22e-20	Height;
KIRP	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	0.99	7.71	0.44	3.02e-13	Arsenic metabolism;
KIRP	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg15282417	chr9:129245246	FAM125B	0.43	7.34	0.42	3.03e-12	Intraocular pressure;
KIRP	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg27432699	chr2:27873401	GPN1	-0.43	-5.48	-0.33	1.04e-7	Total body bone mineral density;
KIRP	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.26	0.47	8.97e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg25801113	chr15:45476975	SHF	0.41	7.43	0.43	1.82e-12	Uric acid levels;
KIRP	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.6	-7.71	-0.44	3.02e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.86	-11.4	-0.59	1.93e-24	Cognitive function;
KIRP	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.13e-6	Bladder cancer;
KIRP	cis	rs981844	0.696	rs7695605	chr4:154635436	C/G	cg14289246	chr4:154710475	SFRP2	0.57	6.49	0.38	4.82e-10	Response to statins (LDL cholesterol change);
KIRP	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg03098644	chr7:100410630	EPHB4	-0.65	-8.7	-0.48	4.98e-16	Plasminogen activator inhibitor type 1 levels (PAI-1);
KIRP	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.38	5.16	0.31	5.07e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.22	0.46	1.17e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06544989	chr22:39130855	UNC84B	0.48	7.54	0.43	8.79e-13	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.45	-0.52	2.82e-18	Aortic root size;
KIRP	cis	rs9659323	1.000	rs12073056	chr1:119508400	C/T	cg18261050	chr1:119551319	NA	0.35	4.86	0.3	2.12e-6	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02962892	chr19:16989384	SIN3B	-0.54	-6.49	-0.38	4.64e-10	Parkinson's disease;
KIRP	cis	rs1629083	0.935	rs2051480	chr11:118094513	A/G	cg18857871	chr11:118064634	AMICA1	0.62	8.07	0.46	3.15e-14	Lung cancer;
KIRP	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg25173405	chr17:45401733	C17orf57	0.51	6.66	0.39	1.79e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.47	7.1	0.41	1.29e-11	Resting heart rate;
KIRP	cis	rs60871478	0.635	rs4725122	chr7:785318	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.58	5.48	0.33	1.04e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg06453172	chr10:134556979	INPP5A	-0.6	-7.12	-0.41	1.18e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1043099	0.549	rs9608904	chr22:30808761	A/G	cg03868770	chr22:30783737	RNF215	-0.47	-4.87	-0.3	1.95e-6	Rheumatoid arthritis;
KIRP	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	1.03	10.16	0.54	1.79e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg17218026	chr1:154582156	ADAR	0.35	5.8	0.35	2.01e-8	Blood protein levels;
KIRP	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg18350739	chr11:68623251	NA	-0.46	-7.24	-0.42	5.63e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.4	0.47	3.49e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.29	0.37	1.41e-9	Total body bone mineral density;
KIRP	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.52	-5.98	-0.36	7.85e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs708547	0.723	rs35982175	chr4:57841365	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	9.06	0.5	4.26e-17	Response to bleomycin (chromatid breaks);
KIRP	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.51	7.83	0.45	1.41e-13	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.77	-0.4	9.42e-11	Type 2 diabetes;
KIRP	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg18190219	chr22:46762943	CELSR1	-0.88	-7.09	-0.41	1.43e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1656402	1.000	rs1656402	chr2:233426526	C/T	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-6.09	-0.36	4.37e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6893300	0.524	rs12522926	chr5:179214818	G/A	cg14593053	chr5:179126677	CANX	0.74	11.36	0.59	2.48e-24	Resting heart rate;
KIRP	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-0.39	-4.88	-0.3	1.94e-6	Type 2 diabetes;
KIRP	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg08799069	chr10:126477246	METTL10	-0.49	-6.46	-0.38	5.45e-10	Asthma;
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.76	11.52	0.59	7.59e-25	Menarche (age at onset);
KIRP	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg21573476	chr21:45109991	RRP1B	-0.59	-7.94	-0.45	7.41e-14	Mean corpuscular volume;
KIRP	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg07828024	chr6:149772892	ZC3H12D	-0.32	-5.49	-0.33	9.84e-8	Dupuytren's disease;
KIRP	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.58	-0.63	2.29e-28	Alzheimer's disease;
KIRP	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.83e-8	Bipolar disorder;
KIRP	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs240764	0.711	rs240148	chr6:101076767	C/T	cg09795085	chr6:101329169	ASCC3	0.44	5.29	0.32	2.71e-7	Neuroticism;
KIRP	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg18016565	chr1:150552671	MCL1	0.41	6.05	0.36	5.28e-9	Melanoma;
KIRP	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-6.87	-0.4	5.27e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.12e-11	Blood metabolite levels;
KIRP	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.51	-6.01	-0.36	6.7e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2274273	0.686	rs2296489	chr14:55624977	T/C	cg04306507	chr14:55594613	LGALS3	0.42	5.54	0.33	7.86e-8	Protein biomarker;
KIRP	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs7560272	0.513	rs7558546	chr2:73937732	A/T	cg20560298	chr2:73613845	ALMS1	0.46	5.5	0.33	9.63e-8	Schizophrenia;
KIRP	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.47	5.99	0.36	7.56e-9	Type 2 diabetes;
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg02696790	chr15:75250997	RPP25	0.3	5.1	0.31	6.63e-7	Breast cancer;
KIRP	cis	rs9309473	0.500	rs12472502	chr2:73859184	C/T	cg20560298	chr2:73613845	ALMS1	0.45	5.58	0.34	6.35e-8	Metabolite levels;
KIRP	cis	rs77688320	0.535	rs7575721	chr2:202256778	C/T	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs4972539	0.784	rs10497402	chr2:174088266	G/A	cg04505972	chr2:173508040	NA	-0.45	-5.95	-0.35	9.39e-9	Parental longevity (mother's age at death);
KIRP	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg16797656	chr11:68205561	LRP5	0.37	4.96	0.3	1.34e-6	Total body bone mineral density;
KIRP	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.81	-11.48	-0.59	1.04e-24	Body mass index;
KIRP	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg24112000	chr20:60950667	NA	-0.65	-8.21	-0.46	1.25e-14	Colorectal cancer;
KIRP	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg02297831	chr4:17616191	MED28	0.63	7.89	0.45	1.02e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.64	-6.59	-0.39	2.61e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.02	0.64	7.74e-30	Bladder cancer;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg02297831	chr4:17616191	MED28	0.55	6.89	0.4	4.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg14541582	chr5:601475	NA	-0.58	-6.61	-0.39	2.42e-10	Obesity-related traits;
KIRP	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.75	10.87	0.57	9.89e-23	Body mass index;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg20887711	chr4:1340912	KIAA1530	0.42	4.88	0.3	1.94e-6	Obesity-related traits;
KIRP	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg25486957	chr4:152246857	NA	-0.5	-5.29	-0.32	2.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4776059	0.724	rs11633933	chr15:52948357	T/C	cg25063058	chr15:52860530	ARPP19	0.52	5.54	0.33	7.7e-8	Schizophrenia;
KIRP	cis	rs77688320	0.517	rs2270315	chr2:202317265	C/A	cg06431681	chr2:202330990	STRADB	0.54	6.81	0.4	7.3e-11	Breast cancer;
KIRP	cis	rs2882667	0.858	rs11956159	chr5:138408568	T/C	cg04439458	chr5:138467593	SIL1	-0.51	-7.8	-0.45	1.81e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg18882449	chr10:104885122	NT5C2	-0.39	-5.03	-0.31	9.53e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg26384229	chr12:38710491	ALG10B	0.57	7.63	0.44	5.18e-13	Morning vs. evening chronotype;
KIRP	cis	rs6844506	0.607	rs2136758	chr4:185226060	T/A	cg12654155	chr4:185238627	NA	-0.39	-5.18	-0.31	4.66e-7	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
KIRP	cis	rs258892	0.895	rs253169	chr5:72118987	G/A	cg21869765	chr5:72125136	TNPO1	-0.56	-6.18	-0.37	2.57e-9	Small cell lung carcinoma;
KIRP	cis	rs12900413	0.562	rs28450767	chr15:90298228	A/G	cg24650279	chr15:90327240	NA	-0.42	-5.25	-0.32	3.32e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs4664304	0.754	rs17829052	chr2:160821067	G/A	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.15	-0.31	5.21e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.54	-6.22	-0.37	2.13e-9	Pulse pressure;
KIRP	trans	rs10969557	0.600	rs7028627	chr9:315394	G/T	cg13711394	chr13:37004737	CCNA1	0.37	6.04	0.36	5.67e-9	Lung cancer;
KIRP	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.37	-5.59	-0.34	5.88e-8	Insulin-like growth factors;
KIRP	cis	rs77633900	0.772	rs283802	chr15:76791270	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-5.9	-0.35	1.23e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14182563	chr22:51039000	MAPK8IP2	0.48	6.78	0.4	8.65e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6558530	0.625	rs7459507	chr8:1698192	A/G	cg08198773	chr8:1697536	NA	0.46	5.47	0.33	1.1e-7	Systolic blood pressure;
KIRP	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg04025307	chr7:1156635	C7orf50	0.53	5.99	0.36	7.54e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg20578329	chr17:80767326	TBCD	-0.42	-5.48	-0.33	1.07e-7	Breast cancer;
KIRP	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.75	11.31	0.58	3.75e-24	Blood metabolite ratios;
KIRP	cis	rs35740288	0.770	rs4843081	chr15:86153044	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs77688320	0.500	rs4129010	chr2:202308325	G/T	cg06431681	chr2:202330990	STRADB	0.56	7.66	0.44	4.34e-13	Breast cancer;
KIRP	cis	rs56399783	0.901	rs73051469	chr7:2877811	A/G	cg19731401	chr7:2775893	GNA12	0.7	6.79	0.4	8.44e-11	Childhood ear infection;
KIRP	cis	rs2591576	0.809	rs1445716	chr5:165419506	T/C	cg13976338	chr5:165423657	NA	-0.79	-12.29	-0.62	2.25e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg22138327	chr13:27999177	GTF3A	0.75	6.77	0.4	9.66e-11	Weight;
KIRP	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.77	0.49	3.01e-16	Retinal vascular caliber;
KIRP	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.8	-0.45	1.77e-13	Gut microbiome composition (summer);
KIRP	cis	rs6005807	0.719	rs60693420	chr22:29045930	T/C	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg15534755	chr11:117069859	TAGLN	0.4	4.96	0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-4.96	-0.3	1.34e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1697938	0.875	rs323561	chr5:40871745	T/G	cg01087697	chr5:40835557	RPL37	-0.48	-5.3	-0.32	2.58e-7	Multiple system atrophy;
KIRP	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg23594656	chr7:65796392	TPST1	0.37	5.28	0.32	2.86e-7	Aortic root size;
KIRP	cis	rs1546924	0.570	rs197412	chr1:112308953	T/C	cg23955903	chr1:112298873	DDX20;C1orf183	0.46	5.76	0.34	2.53e-8	Body mass index;
KIRP	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg19913688	chr11:428466	ANO9	-0.8	-6.01	-0.36	6.57e-9	Body mass index;
KIRP	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.59	0.65	9.23e-32	Mean platelet volume;
KIRP	cis	rs73198271	1.000	rs11775821	chr8:8609153	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.96	-0.3	1.34e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25971741	chr6:15343116	JARID2	-0.47	-6.77	-0.4	9.23e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7106204	0.748	rs7122986	chr11:24224634	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	10.87	0.57	1.01e-22	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg18461458	chr19:21324796	ZNF431	-0.47	-4.89	-0.3	1.85e-6	Pain;
KIRP	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.49	5.66	0.34	4.19e-8	Glycated hemoglobin levels;
KIRP	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.0	0.61	2.06e-26	Bladder cancer;
KIRP	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.8	7.67	0.44	3.97e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	1.11	11.28	0.58	4.49e-24	Psoriasis;
KIRP	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.87	-0.3	2.02e-6	Breast cancer;
KIRP	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.98	12.9	0.64	2.02e-29	Homoarginine levels;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16524936	chr4:1340807	KIAA1530	-0.46	-5.73	-0.34	2.94e-8	Longevity;
KIRP	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.83	10.03	0.54	4.38e-20	Triglycerides;
KIRP	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg14703610	chr5:56206110	C5orf35	0.48	6.23	0.37	2.05e-9	Coronary artery disease;
KIRP	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.45	-0.52	2.82e-18	Rheumatoid arthritis;
KIRP	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.5	-6.0	-0.36	6.98e-9	P wave terminal force;
KIRP	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.9	12.93	0.64	1.6e-29	Tonsillectomy;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg12118915	chr15:94774775	NA	-0.69	-6.04	-0.36	5.74e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.74	10.81	0.57	1.56e-22	Orofacial clefts;
KIRP	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	4.98e-9	Depression;
KIRP	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.64	-0.34	4.68e-8	Type 2 diabetes;
KIRP	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg00310523	chr12:86230176	RASSF9	-0.47	-7.49	-0.43	1.26e-12	Major depressive disorder;
KIRP	cis	rs7916697	0.578	rs61854799	chr10:70006659	T/C	cg06988349	chr10:69991859	ATOH7	0.43	5.18	0.31	4.72e-7	Optic disc area;
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.56	0.52	1.3e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8126001	0.573	rs7271530	chr20:62727915	A/G	cg17454746	chr20:62716485	OPRL1;C20orf201	-0.29	-4.99	-0.3	1.14e-6	Pulse pressure;Mean corpuscular volume;
KIRP	cis	rs61935443	0.562	rs11107791	chr12:95316374	G/A	cg21533806	chr12:95267307	NA	0.58	5.29	0.32	2.69e-7	Schizophrenia;
KIRP	cis	rs780094	0.500	rs13022873	chr2:27815510	A/C	cg05484376	chr2:27715224	FNDC4	-0.37	-5.48	-0.33	1.06e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs6546886	0.917	rs11884748	chr2:74248451	A/C	cg14702570	chr2:74259524	NA	-0.33	-6.57	-0.39	2.89e-10	Dialysis-related mortality;
KIRP	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg18261050	chr1:119551319	NA	0.51	6.7	0.39	1.4e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7221595	0.778	rs12946045	chr17:3904307	G/C	cg11204139	chr17:3907470	NA	0.6	6.53	0.38	3.66e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs76693355	0.512	rs11827818	chr11:120198728	C/T	cg24566217	chr11:120254723	ARHGEF12	0.4	5.0	0.3	1.07e-6	Intraocular pressure;
KIRP	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.55	7.1	0.41	1.3e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.69	9.12	0.5	2.85e-17	Bladder cancer;
KIRP	cis	rs8523	0.804	rs6900220	chr6:11065138	T/C	cg13562911	chr6:11044106	ELOVL2	0.38	5.02	0.3	9.93e-7	Red blood cell fatty acid levels;
KIRP	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.64	5.49	0.33	9.78e-8	Schizophrenia;
KIRP	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.61	-6.11	-0.36	3.95e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.54	0.39	3.46e-10	Mood instability;
KIRP	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.62	8.41	0.47	3.26e-15	Height;
KIRP	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.57	-9.31	-0.51	7.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6725041	0.750	rs1402764	chr2:213096345	T/C	cg16329650	chr2:213403929	ERBB4	-0.36	-5.02	-0.31	9.77e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	0.9	10.58	0.56	8.24e-22	Testicular germ cell tumor;
KIRP	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg04218760	chr10:45406644	TMEM72	-0.23	-6.17	-0.37	2.8e-9	Mean corpuscular volume;
KIRP	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg04691961	chr3:161091175	C3orf57	-0.66	-10.55	-0.56	1.04e-21	Morning vs. evening chronotype;
KIRP	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.57	-7.96	-0.45	6.32e-14	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	6.6	0.39	2.54e-10	Systolic blood pressure;
KIRP	cis	rs6973256	0.897	rs7780456	chr7:133328782	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.49	-0.38	4.7e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.2	0.46	1.34e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg13010199	chr12:38710504	ALG10B	0.44	5.77	0.35	2.38e-8	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.43	0.47	2.99e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg23625390	chr15:77176239	SCAPER	0.53	6.92	0.4	3.81e-11	Blood metabolite levels;
KIRP	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-1.03	-18.82	-0.77	1.49e-49	Height;
KIRP	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12311346	chr5:56204834	C5orf35	-0.44	-6.16	-0.37	2.93e-9	Coronary artery disease;
KIRP	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.73	10.21	0.55	1.23e-20	Plateletcrit;Platelet count;
KIRP	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06115741	chr20:33292138	TP53INP2	0.44	5.82	0.35	1.86e-8	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.17	-0.37	2.84e-9	Lung cancer;
KIRP	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.33	0.42	3.31e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg11642891	chr2:3452563	TTC15	-0.54	-6.92	-0.4	3.84e-11	Obesity-related traits;
KIRP	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg13819577	chr1:248512075	OR14C36	-0.35	-4.95	-0.3	1.37e-6	Common traits (Other);
KIRP	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg11234688	chr2:1609660	NA	0.62	4.9	0.3	1.73e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg24642844	chr7:1081250	C7orf50	-0.8	-8.5	-0.48	1.81e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9311676	0.632	rs11130637	chr3:58405573	C/G	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.57	8.48	0.48	2.07e-15	Bone mineral density;
KIRP	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg26338869	chr17:61819248	STRADA	0.54	6.48	0.38	5.05e-10	Prudent dietary pattern;
KIRP	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	trans	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs1056053	0.514	rs1056051	chr6:166571579	T/G	cg11088901	chr6:166572345	T	-0.51	-7.11	-0.41	1.26e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs3733418	0.929	rs13149062	chr4:165905360	T/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.5	-4.96	-0.3	1.3e-6	Obesity-related traits;
KIRP	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.57	6.95	0.41	3.2e-11	Diastolic blood pressure;
KIRP	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.47	4.89	0.3	1.79e-6	Smoking behavior;
KIRP	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg08822215	chr16:89438651	ANKRD11	-0.5	-6.63	-0.39	2.09e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.43	-0.47	2.88e-15	Joint mobility (Beighton score);
KIRP	cis	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.18	0.31	4.64e-7	Leprosy;
KIRP	cis	rs4900538	0.827	rs1046651	chr14:102971016	T/C	cg18135206	chr14:102964638	TECPR2	0.89	12.9	0.64	2.03e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.42	-5.35	-0.32	1.99e-7	Menarche (age at onset);
KIRP	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg10189774	chr4:17578691	LAP3	0.51	5.99	0.36	7.47e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg10434728	chr15:90938212	IQGAP1	0.3	5.07	0.31	7.86e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.5	-6.85	-0.4	5.78e-11	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.75	-0.34	2.6e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg15128208	chr22:42549153	NA	0.71	7.97	0.45	5.84e-14	Birth weight;
KIRP	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	7.34	0.42	3.09e-12	Lung cancer;
KIRP	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg13482628	chr17:19912719	NA	0.5	6.42	0.38	6.81e-10	Schizophrenia;
KIRP	trans	rs4688759	0.764	rs2023953	chr3:50103917	G/A	cg00383909	chr3:49044727	WDR6	0.93	7.65	0.44	4.43e-13	Blood protein levels;
KIRP	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.34	-0.32	2.07e-7	Pulmonary function;
KIRP	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.31	-5.49	-0.33	9.8e-8	Monocyte count;
KIRP	cis	rs6732160	0.588	rs2043099	chr2:73374156	G/A	cg01422370	chr2:73384389	NA	0.51	6.92	0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg00149659	chr3:10157352	C3orf10	0.78	6.38	0.38	8.83e-10	Alzheimer's disease;
KIRP	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.36	5.74	0.34	2.8e-8	Colorectal cancer;
KIRP	cis	rs754423	0.582	rs1390968	chr14:52517629	A/G	cg10149976	chr14:52535953	NID2	-0.38	-5.1	-0.31	6.66e-7	Craniofacial microsomia;
KIRP	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.9	0.45	9.13e-14	Neuroticism;
KIRP	cis	rs7172677	0.691	rs12901092	chr15:75374145	C/A	cg14664628	chr15:75095509	CSK	0.46	5.65	0.34	4.53e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg11693508	chr17:37793320	STARD3	0.57	7.32	0.42	3.54e-12	Neuroticism;
KIRP	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.39	5.92	0.35	1.07e-8	Body mass index;
KIRP	cis	rs72820985	1.000	rs1544804	chr16:80842824	A/G	cg04448709	chr16:81349954	GAN	-0.49	-5.03	-0.31	9.3e-7	Breast cancer;
KIRP	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.48	-7.88	-0.45	1.03e-13	Height;
KIRP	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	1.06	19.21	0.77	7.28e-51	Leprosy;
KIRP	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg27205649	chr11:78285834	NARS2	0.51	5.51	0.33	8.85e-8	Testicular germ cell tumor;
KIRP	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg05785598	chr3:49045655	WDR6	0.32	5.89	0.35	1.29e-8	Parkinson's disease;
KIRP	cis	rs13006833	0.668	rs2582746	chr2:191163784	T/C	cg27211696	chr2:191398769	TMEM194B	0.39	5.44	0.33	1.27e-7	Urinary metabolites;
KIRP	cis	rs3936840	0.565	rs8011721	chr14:102986388	C/G	cg10241871	chr14:102965420	TECPR2	0.42	5.19	0.31	4.32e-7	Plateletcrit;
KIRP	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.38	-7.42	-0.43	1.95e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.22	-0.37	2.13e-9	Retinal vascular caliber;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg19990977	chr19:10654446	ATG4D	0.49	6.11	0.36	3.93e-9	Educational attainment;
KIRP	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg18944383	chr4:111397179	ENPEP	0.61	11.1	0.58	1.78e-23	Height;
KIRP	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.4	4.87	0.3	1.96e-6	Menopause (age at onset);
KIRP	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg27205649	chr11:78285834	NARS2	-0.54	-5.16	-0.31	5.15e-7	Testicular germ cell tumor;
KIRP	cis	rs13190036	0.748	rs28395268	chr5:176710547	C/G	cg06733329	chr5:176740039	MXD3	-0.41	-5.13	-0.31	5.78e-7	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg19507638	chr5:93509721	C5orf36	-0.62	-5.78	-0.35	2.24e-8	Diabetic retinopathy;
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	5.06e-7	Parkinson's disease;
KIRP	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs859767	0.812	rs842360	chr2:135347885	T/C	cg12500956	chr2:135428796	TMEM163	0.38	4.85	0.3	2.23e-6	Neuroticism;
KIRP	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.28e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg24642844	chr7:1081250	C7orf50	-0.88	-7.43	-0.43	1.78e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.16e-51	Leprosy;
KIRP	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.64	-0.44	4.78e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.65	0.34	4.5e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg20578329	chr17:80767326	TBCD	-0.67	-7.59	-0.44	6.81e-13	Breast cancer;
KIRP	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.75	-6.7	-0.39	1.38e-10	Schizophrenia;
KIRP	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg17145862	chr1:211918768	LPGAT1	-0.91	-12.93	-0.64	1.61e-29	Leprosy;
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg04374321	chr14:90722782	PSMC1	-0.83	-11.89	-0.6	4.48e-26	Mortality in heart failure;
KIRP	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.4	9.16e-11	Red blood cell count;
KIRP	cis	rs494562	0.892	rs4624841	chr6:86130251	G/A	cg21730993	chr6:86159210	NT5E	0.51	5.19	0.31	4.35e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs2172802	0.570	rs2343526	chr4:62521386	T/C	cg04118610	chr4:62707027	LPHN3	0.44	5.46	0.33	1.14e-7	Partial epilepsies;
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg04025307	chr7:1156635	C7orf50	0.9	14.2	0.67	8.15e-34	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg02285715	chr20:61493179	TCFL5	0.49	6.19	0.37	2.52e-9	Educational attainment;
KIRP	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.79	12.76	0.63	5.82e-29	Vitiligo;
KIRP	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.86	13.18	0.64	2.29e-30	Menarche (age at onset);
KIRP	cis	rs7246657	0.891	rs7253114	chr19:37988725	G/A	cg18154014	chr19:37997991	ZNF793	0.69	7.78	0.44	1.94e-13	Coronary artery calcification;
KIRP	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.61	-6.78	-0.4	9.02e-11	Menarche (age at onset);
KIRP	cis	rs1298062	0.717	rs74176110	chr19:50995568	G/C	cg11430371	chr19:50961752	MYBPC2	0.36	4.98	0.3	1.21e-6	Age of smoking initiation;
KIRP	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	14.87	0.69	4.22e-36	Platelet count;
KIRP	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.51	-6.49	-0.38	4.64e-10	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg06521331	chr12:34319734	NA	-0.47	-6.01	-0.36	6.8e-9	Morning vs. evening chronotype;
KIRP	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-7.02	-0.41	2.21e-11	Coronary artery disease;
KIRP	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.67	-7.24	-0.42	5.59e-12	DNA methylation (variation);
KIRP	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-7.79	-0.44	1.92e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg09184832	chr6:79620586	NA	-0.39	-4.98	-0.3	1.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.69	-7.97	-0.45	5.85e-14	Resting heart rate;
KIRP	trans	rs800082	0.690	rs2575191	chr3:144279228	G/A	cg24215973	chr2:240111563	HDAC4	0.51	7.03	0.41	2.02e-11	Smoking behavior;
KIRP	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg19402173	chr7:128379420	CALU	-0.62	-8.05	-0.46	3.59e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs2882667	0.628	rs13162420	chr5:138174759	T/C	cg04439458	chr5:138467593	SIL1	-0.42	-5.39	-0.32	1.66e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9596863	0.851	rs9568923	chr13:54357573	G/A	ch.13.53330881F	chr13:54432880	NA	0.6	5.84	0.35	1.63e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg07068956	chr7:100330872	ZAN	0.55	5.91	0.35	1.11e-8	Other erythrocyte phenotypes;
KIRP	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-10.98	-0.57	4.51e-23	Height;
KIRP	cis	rs12900413	0.687	rs8035472	chr15:90313432	T/C	cg07116693	chr15:90310901	NA	-0.23	-4.94	-0.3	1.43e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs240764	0.658	rs10872628	chr6:101176349	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-5.47	-0.33	1.12e-7	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23564559	chr14:60632100	DHRS7	0.5	6.16	0.37	2.99e-9	Parkinson's disease;
KIRP	cis	rs4523957	0.614	rs2316512	chr17:2064710	A/T	cg16513277	chr17:2031491	SMG6	-0.79	-11.25	-0.58	5.73e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3931020	0.566	rs1327086	chr1:75271032	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.75	0.34	2.67e-8	Resistin levels;
KIRP	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg05709478	chr1:6581295	PLEKHG5	0.67	7.23	0.42	6.26e-12	Body mass index;
KIRP	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.15e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13279522	0.536	rs13264487	chr8:67008429	A/G	cg04041976	chr8:67085823	TRIM55	-0.44	-5.43	-0.33	1.34e-7	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg21775007	chr8:11205619	TDH	-0.52	-6.56	-0.39	3.07e-10	Systolic blood pressure;
KIRP	cis	rs1823913	0.895	rs10931491	chr2:192120813	G/A	cg12404831	chr2:192114017	MYO1B	-0.5	-6.74	-0.39	1.14e-10	Obesity-related traits;
KIRP	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.58	6.79	0.4	8.54e-11	Corneal astigmatism;
KIRP	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.06	0.64	5.82e-30	Menopause (age at onset);
KIRP	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.27	0.55	7.94e-21	Coffee consumption (cups per day);
KIRP	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.58	-6.14	-0.36	3.37e-9	Ulcerative colitis;
KIRP	trans	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg24644049	chr4:85504048	CDS1	0.93	6.86	0.4	5.65e-11	Skin colour saturation;
KIRP	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.8	10.92	0.57	6.81e-23	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg07870213	chr5:140052090	DND1	-0.62	-7.69	-0.44	3.44e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg04306507	chr14:55594613	LGALS3	0.53	8.26	0.47	8.87e-15	Protein biomarker;
KIRP	cis	rs796364	0.616	rs7589545	chr2:200676102	T/A	cg17644776	chr2:200775616	C2orf69	0.57	5.28	0.32	2.89e-7	Schizophrenia;
KIRP	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg21419209	chr3:44054225	NA	-0.74	-9.43	-0.52	3.17e-18	Coronary artery disease;
KIRP	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05601917	chr6:125855416	NA	-0.38	-5.81	-0.35	1.92e-8	Brugada syndrome;
KIRP	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.69	-5.83	-0.35	1.74e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.81	12.71	0.63	8.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.35	6.75	0.4	1.08e-10	Educational attainment (years of education);
KIRP	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg21523564	chr15:75251491	NA	-0.35	-5.94	-0.35	9.57e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.88	-0.45	1.05e-13	Migraine;Coronary artery disease;
KIRP	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg15038512	chr6:170123185	PHF10	0.49	5.55	0.33	7.45e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg26769984	chr7:1090371	C7orf50	0.8	7.45	0.43	1.61e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.23	-0.42	5.97e-12	Type 2 diabetes;
KIRP	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.52	-0.33	8.68e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.27	0.32	3.01e-7	Educational attainment;
KIRP	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg02475777	chr4:1388615	CRIPAK	0.56	5.24	0.32	3.52e-7	Recombination rate (females);
KIRP	cis	rs78487399	0.808	rs77791126	chr2:43744050	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-4.84	-0.3	2.24e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2479106	0.591	rs10283413	chr9:126395188	A/T	cg16191174	chr9:126692580	DENND1A	0.37	5.04	0.31	9.16e-7	Polycystic ovary syndrome;
KIRP	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	9.45	0.52	2.7e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4308124	1.000	rs57874285	chr2:112012672	C/A	cg23466623	chr2:111982296	NA	0.4	5.56	0.33	6.85e-8	Vitiligo;
KIRP	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg03714773	chr7:91764589	CYP51A1	-0.38	-5.52	-0.33	8.67e-8	Breast cancer;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.87	10.12	0.54	2.31e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg20818283	chr2:191399100	TMEM194B	-0.52	-6.54	-0.38	3.58e-10	Pulse pressure;
KIRP	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.72	-8.23	-0.46	1.08e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.69	8.23	0.46	1.1e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs258892	0.843	rs4560525	chr5:72031768	G/A	cg21869765	chr5:72125136	TNPO1	-0.53	-6.06	-0.36	4.98e-9	Small cell lung carcinoma;
KIRP	cis	rs7937612	1.000	rs7939137	chr11:120343271	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.95	-0.41	3.24e-11	Intraocular pressure;
KIRP	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.56	-7.7	-0.44	3.39e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6835098	0.692	rs28701033	chr4:174079376	T/A	cg08422745	chr4:174089978	GALNT7	-0.69	-9.31	-0.51	7.65e-18	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs755249	0.701	rs1180342	chr1:39992878	T/G	cg27567593	chr1:39956653	BMP8A	0.35	4.95	0.3	1.4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.42	5.04	0.31	9.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg12253828	chr6:101329408	ASCC3	0.96	7.72	0.44	2.89e-13	Economic and political preferences (immigration/crime);
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.26	0.47	9.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg04731861	chr2:219085781	ARPC2	-0.23	-5.64	-0.34	4.76e-8	Colorectal cancer;
KIRP	cis	rs2230307	0.536	rs482466	chr1:100488177	C/T	cg24955406	chr1:100503596	HIAT1	0.58	6.36	0.38	9.91e-10	Carotid intima media thickness;
KIRP	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.83	10.8	0.57	1.68e-22	N-glycan levels;
KIRP	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg15556689	chr8:8085844	FLJ10661	0.64	8.27	0.47	8.5e-15	Retinal vascular caliber;
KIRP	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg05714579	chr10:131428358	MGMT	0.42	5.3	0.32	2.57e-7	Response to temozolomide;
KIRP	cis	rs8060686	0.623	rs12599178	chr16:68128104	A/G	cg26727032	chr16:67993705	SLC12A4	-0.74	-9.03	-0.5	5.14e-17	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs9784649	1.000	rs55806673	chr5:24957298	A/G	cg08600765	chr20:34638493	LOC647979	-0.6	-6.08	-0.36	4.47e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg09408571	chr1:101003634	GPR88	-0.24	-5.47	-0.33	1.09e-7	Monocyte count;
KIRP	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg08501292	chr6:25962987	TRIM38	0.79	5.43	0.33	1.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.59	8.7	0.49	4.71e-16	Itch intensity from mosquito bite;
KIRP	cis	rs11138902	0.673	rs10867682	chr9:72118619	C/T	cg14397918	chr9:72078829	APBA1	0.34	5.39	0.33	1.61e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.78	-0.49	2.86e-16	Coronary artery disease;
KIRP	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg12908607	chr1:44402522	ARTN	-0.38	-5.63	-0.34	5.02e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4356932	0.967	rs4407534	chr4:76979326	G/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.54	5.54	0.33	7.71e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9990333	0.544	rs11915082	chr3:195809139	G/A	cg01351295	chr3:195700735	SDHAP1	-0.43	-4.98	-0.3	1.2e-6	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);
KIRP	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg21775007	chr8:11205619	TDH	0.43	5.43	0.33	1.38e-7	Neuroticism;
KIRP	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26207909	chr14:103986467	CKB	0.76	11.83	0.6	7.21e-26	Body mass index;
KIRP	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg20891283	chr12:69753455	YEATS4	0.49	5.51	0.33	9.13e-8	Response to diuretic therapy;
KIRP	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.69	-9.07	-0.5	3.82e-17	Huntington's disease progression;
KIRP	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.74	0.81	3.44e-59	Prudent dietary pattern;
KIRP	cis	rs42648	0.935	rs2188233	chr7:89958315	G/A	cg25739043	chr7:89950458	NA	-0.47	-7.3	-0.42	3.92e-12	Homocysteine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09063859	chr10:1086904	IDI1;C10orf110	0.51	7.43	0.43	1.81e-12	Interleukin-4 levels;
KIRP	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg18850127	chr7:39170497	POU6F2	0.26	5.31	0.32	2.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.49	0.52	2.17e-18	Parkinson's disease;
KIRP	cis	rs3748682	0.861	rs28625842	chr1:38310786	G/A	cg12658694	chr1:38397304	INPP5B	0.55	6.05	0.36	5.39e-9	Hypothyroidism;
KIRP	cis	rs6991838	0.530	rs6472217	chr8:66547731	A/G	cg13398993	chr8:66546079	ARMC1	0.45	5.2	0.31	4.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.76	-11.45	-0.59	1.29e-24	Height;
KIRP	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg12756093	chr1:115239321	AMPD1	0.58	7.42	0.43	1.91e-12	Autism;
KIRP	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.8	-0.4	7.98e-11	Diabetic kidney disease;
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.17	0.31	4.75e-7	Life satisfaction;
KIRP	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg05861140	chr6:150128134	PCMT1	-0.55	-7.99	-0.45	5.37e-14	Lung cancer;
KIRP	cis	rs2072732	0.861	rs67919793	chr1:2954230	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	cis	rs7572644	0.713	rs4666021	chr2:28055881	A/G	cg27432699	chr2:27873401	GPN1	0.49	5.26	0.32	3.07e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-8.1	-0.46	2.6e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9504361	0.808	rs2277096	chr6:564515	G/T	cg13471009	chr6:564609	EXOC2	-0.33	-4.88	-0.3	1.95e-6	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
KIRP	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.84	0.35	1.61e-8	Personality dimensions;
KIRP	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.38	-0.43	2.44e-12	Body mass index;
KIRP	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg07777115	chr5:623756	CEP72	-0.56	-5.71	-0.34	3.33e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9549260	0.564	rs4941989	chr13:41299687	T/C	cg21288729	chr13:41239152	FOXO1	0.56	7.35	0.42	2.85e-12	Red blood cell count;
KIRP	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06377993	chr1:196624484	CFH	-0.43	-6.78	-0.4	8.69e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg21546286	chr11:48923668	NA	-0.47	-5.97	-0.36	8.44e-9	HDL cholesterol;
KIRP	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.13	0.31	5.87e-7	Rheumatoid arthritis;
KIRP	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.79	-11.35	-0.59	2.66e-24	Blood metabolite levels;
KIRP	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	9.93	0.53	9.17e-20	Lung cancer in ever smokers;
KIRP	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-6.09	-0.36	4.41e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg00405596	chr8:11794950	NA	0.48	6.32	0.37	1.24e-9	Joint mobility (Beighton score);
KIRP	cis	rs58688157	0.960	rs61877856	chr11:617378	C/T	cg16486109	chr11:613632	IRF7	0.41	4.94	0.3	1.47e-6	Systemic lupus erythematosus;
KIRP	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.66	-9.04	-0.5	4.65e-17	Total body bone mineral density;
KIRP	cis	rs3126085	0.935	rs72696975	chr1:152206090	A/G	cg26876637	chr1:152193138	HRNR	-0.82	-8.89	-0.49	1.38e-16	Atopic dermatitis;
KIRP	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14895029	chr7:2775587	GNA12	-0.41	-4.9	-0.3	1.75e-6	Height;
KIRP	cis	rs9914544	0.545	rs34417974	chr17:18773636	T/C	cg26378065	chr17:18585709	ZNF286B	0.39	5.06	0.31	8.27e-7	Educational attainment (years of education);
KIRP	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.26	0.42	5.01e-12	Retinal vascular caliber;
KIRP	trans	rs2997105	1.000	rs2935462	chr13:56418447	C/A	cg08528735	chr3:184428879	MAGEF1	-0.56	-6.18	-0.37	2.67e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg26681399	chr22:41777847	TEF	-0.52	-4.94	-0.3	1.42e-6	Vitiligo;
KIRP	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.31	4.99	0.3	1.14e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs9815354	0.812	rs58360908	chr3:41839837	A/G	cg03022575	chr3:42003672	ULK4	0.8	8.23	0.46	1.09e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9912468	0.535	rs2013785	chr17:64236477	A/G	cg19474267	chr17:64306194	PRKCA	-0.4	-5.13	-0.31	5.96e-7	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.85	-10.73	-0.56	2.77e-22	Longevity;Endometriosis;
KIRP	cis	rs6001982	0.584	rs73167039	chr22:40833146	A/G	cg07138101	chr22:40742427	ADSL	0.68	5.27	0.32	2.98e-7	Breast cancer;
KIRP	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg18129178	chr5:148520854	ABLIM3	0.46	5.07	0.31	7.7e-7	Breast cancer;
KIRP	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	13.07	0.64	5.42e-30	Tonsillectomy;
KIRP	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg17724175	chr1:150552817	MCL1	0.35	5.93	0.35	1.05e-8	Melanoma;
KIRP	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.52	6.66	0.39	1.81e-10	Monocyte count;
KIRP	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg08992911	chr2:238395768	MLPH	0.42	4.95	0.3	1.35e-6	Prostate cancer;
KIRP	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.73	0.39	1.16e-10	Height;
KIRP	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	0.86	10.12	0.54	2.39e-20	Pediatric areal bone mineral density (radius);
KIRP	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.52	7.67	0.44	4.11e-13	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.75	-10.92	-0.57	6.9e-23	Waist circumference;Body mass index;
KIRP	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.26	17.21	0.74	4.16e-44	Corneal structure;
KIRP	cis	rs4690686	0.836	rs10003662	chr4:177258951	C/G	cg17059388	chr4:177262070	NA	0.54	7.61	0.44	5.98e-13	Essential tremor;
KIRP	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.56	-7.48	-0.43	1.3e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19524238	chr7:2802976	GNA12	-0.35	-4.87	-0.3	2.01e-6	Height;
KIRP	cis	rs7929679	0.521	rs7122506	chr11:34786853	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.45	5.5	0.33	9.71e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs1883415	0.853	rs2760141	chr6:24480897	C/T	cg20631270	chr6:24437470	GPLD1	0.41	4.97	0.3	1.23e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2274273	0.624	rs7152390	chr14:55811701	C/T	cg04306507	chr14:55594613	LGALS3	0.39	5.32	0.32	2.35e-7	Protein biomarker;
KIRP	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg24747557	chr10:131355152	MGMT	0.4	5.45	0.33	1.22e-7	Response to temozolomide;
KIRP	cis	rs4700695	0.841	rs251325	chr5:65269618	A/G	cg21114390	chr5:65439923	SFRS12	0.58	5.92	0.35	1.06e-8	Facial morphology (factor 19);
KIRP	cis	rs2275620	0.526	rs4110516	chr10:96643976	G/C	cg09036531	chr10:96991505	NA	-0.48	-5.79	-0.35	2.18e-8	Gout;
KIRP	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg19610905	chr11:61596333	FADS2	-0.46	-6.66	-0.39	1.78e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg21775007	chr8:11205619	TDH	0.54	6.91	0.4	4.2e-11	Systolic blood pressure;
KIRP	cis	rs12693043	0.727	rs3087907	chr2:175424779	T/G	cg11778734	chr2:175439522	WIPF1	-0.54	-7.43	-0.43	1.83e-12	Urate levels (BMI interaction);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg26614578	chr12:113623930	C12orf52;DDX54	-0.48	-6.13	-0.36	3.47e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs981844	0.775	rs62323979	chr4:154752935	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.68	0.44	3.66e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.73	-0.49	3.85e-16	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19024381	chr2:242626441	DTYMK	0.53	6.86	0.4	5.61e-11	Parkinson's disease;
KIRP	cis	rs6662572	0.737	rs10890356	chr1:46317924	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.49	0.33	1.01e-7	Coronary artery disease;
KIRP	cis	rs9815354	0.680	rs17218936	chr3:42019392	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs12043259	0.730	rs11801633	chr1:204807723	G/A	cg11485465	chr5:54518469	NA	0.35	6.2	0.37	2.39e-9	Addiction;
KIRP	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.29	0.32	2.77e-7	Menopause (age at onset);
KIRP	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg07636037	chr3:49044803	WDR6	-0.66	-6.72	-0.39	1.27e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10517025	0.673	rs73235559	chr4:42419622	G/C	cg13587180	chr4:42403248	SHISA3	0.43	5.03	0.31	9.43e-7	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg01475377	chr6:109611718	NA	-0.41	-5.76	-0.34	2.54e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.73	-0.63	7.38e-29	Exhaled nitric oxide output;
KIRP	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg08657492	chr7:27170832	HOXA4	-0.29	-4.85	-0.3	2.24e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg11731671	chr1:2995604	PRDM16	-0.39	-5.04	-0.31	8.83e-7	Plateletcrit;
KIRP	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.57	7.45	0.43	1.57e-12	Systemic lupus erythematosus;
KIRP	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg25019033	chr10:957182	NA	-0.61	-7.2	-0.42	7.49e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs9488822	0.662	rs195521	chr6:116244114	T/C	cg18764771	chr6:116381957	FRK	0.18	4.9	0.3	1.77e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.24	0.51	1.22e-17	Colorectal cancer;
KIRP	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.71	9.4	0.51	3.91e-18	Obesity-related traits;
KIRP	cis	rs8018808	0.935	rs11627016	chr14:77881138	T/C	cg18872420	chr14:78023429	SPTLC2	0.34	4.92	0.3	1.6e-6	Myeloid white cell count;
KIRP	cis	rs77688320	0.535	rs6751543	chr2:202264933	T/C	cg06431681	chr2:202330990	STRADB	0.52	6.92	0.4	3.96e-11	Breast cancer;
KIRP	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.34	6.12	0.36	3.63e-9	Renal cell carcinoma;
KIRP	cis	rs55962025	0.686	rs6844859	chr4:3190486	T/C	cg06533319	chr4:3265114	C4orf44	0.39	4.9	0.3	1.76e-6	Parental longevity (mother's age at death);
KIRP	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg04289385	chr6:36355825	ETV7	0.38	5.08	0.31	7.62e-7	Platelet distribution width;
KIRP	cis	rs240764	0.817	rs240145	chr6:101079610	A/C	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.9	-0.35	1.22e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg08975724	chr8:8085496	FLJ10661	0.67	8.97	0.5	7.6e-17	Mood instability;
KIRP	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.66	0.34	4.22e-8	Menopause (age at onset);
KIRP	cis	rs1215050	0.791	rs165241	chr4:98681112	C/T	cg05340658	chr4:99064831	C4orf37	0.49	6.02	0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7010267	0.583	rs1485302	chr8:119976144	A/G	cg13268132	chr8:119964037	TNFRSF11B	-0.41	-5.16	-0.31	5.05e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg05347473	chr6:146136440	FBXO30	0.61	8.51	0.48	1.79e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1712517	0.904	rs7905968	chr10:105135319	C/T	cg05636881	chr10:105038444	INA	0.43	6.11	0.36	3.8e-9	Migraine;
KIRP	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.46	-5.55	-0.33	7.22e-8	Initial pursuit acceleration;
KIRP	cis	rs9372498	0.536	rs9489442	chr6:118885950	A/C	cg18833306	chr6:118973337	C6orf204	-0.45	-4.85	-0.3	2.24e-6	Diastolic blood pressure;
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs11779988	0.545	rs208764	chr8:17806270	G/A	cg01800426	chr8:17659068	MTUS1	-0.64	-6.51	-0.38	4.29e-10	Breast cancer;
KIRP	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09713475	chr16:1961667	HS3ST6	0.38	5.17	0.31	4.73e-7	Insulin-like growth factors;
KIRP	cis	rs6466055	0.720	rs13239067	chr7:105011629	T/A	cg04380332	chr7:105027541	SRPK2	-0.64	-9.49	-0.52	2.09e-18	Schizophrenia;
KIRP	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3806701	0.619	rs6442008	chr3:46645753	C/T	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.6	-6.99	-0.41	2.65e-11	Blood protein levels;
KIRP	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg16386425	chr10:429943	DIP2C	0.39	5.15	0.31	5.45e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg02503808	chr4:7069936	GRPEL1	0.89	11.53	0.59	6.95e-25	Monocyte percentage of white cells;
KIRP	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.61	-6.21	-0.37	2.23e-9	Tuberculosis;
KIRP	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	0.98	11.74	0.6	1.4e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20786246	chr2:72377174	NA	0.41	6.1	0.36	4.03e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-5.01	-0.3	1.03e-6	Smoking behavior;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-7.65	-0.44	4.62e-13	Electroencephalogram traits;
KIRP	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.88	-10.07	-0.54	3.33e-20	Gut microbiome composition (summer);
KIRP	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg25182066	chr10:30743637	MAP3K8	-0.64	-8.78	-0.49	2.74e-16	Inflammatory bowel disease;
KIRP	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.85	0.35	1.58e-8	Total cholesterol levels;
KIRP	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-1.13	-21.15	-0.8	2.73e-57	Monocyte count;
KIRP	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg18944383	chr4:111397179	ENPEP	0.68	12.66	0.63	1.32e-28	Height;
KIRP	trans	rs7554547	0.667	rs2336377	chr1:11949970	A/G	cg03536846	chr8:120886254	DEPDC6	0.55	6.51	0.38	4.24e-10	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.64	0.34	4.55e-8	Life satisfaction;
KIRP	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.56	-6.55	-0.39	3.4e-10	Psoriasis;
KIRP	trans	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.04	0.36	5.52e-9	Neuroticism;
KIRP	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.09	-0.64	4.49e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg02297831	chr4:17616191	MED28	0.6	7.66	0.44	4.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.91	-0.49	1.13e-16	Mean corpuscular volume;
KIRP	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg05555928	chr11:63887634	MACROD1	-0.54	-5.13	-0.31	5.91e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.5	-0.38	4.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg10890403	chr12:132336407	NA	0.41	5.2	0.31	4.13e-7	Migraine;
KIRP	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	7.9	0.45	9.22e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6901004	0.716	rs35312643	chr6:111574536	C/A	cg15721981	chr6:111408429	SLC16A10	0.49	6.24	0.37	1.93e-9	Blood metabolite levels;
KIRP	trans	rs9463078	0.585	rs9472451	chr6:45198796	A/C	cg09952002	chr17:46640774	HOXB3	-0.43	-6.17	-0.37	2.79e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7172677	0.960	rs11072526	chr15:75432517	T/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-5.61	-0.34	5.41e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	9.5	0.52	2e-18	Renal function-related traits (BUN);
KIRP	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-13.61	-0.66	7.84e-32	Chronic sinus infection;
KIRP	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg03468072	chr12:39539422	NA	0.44	5.98	0.36	7.98e-9	Morning vs. evening chronotype;
KIRP	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.93	-14.07	-0.67	2.24e-33	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06597049	chr2:102313888	MAP4K4	0.47	6.04	0.36	5.65e-9	Parkinson's disease;
KIRP	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.75	0.4	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7224685	0.569	rs12950310	chr17:4001980	T/C	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.72e-7	Type 2 diabetes;
KIRP	cis	rs963731	0.579	rs1454220	chr2:39277108	G/A	cg04010122	chr2:39346883	SOS1	-0.84	-5.96	-0.36	8.81e-9	Corticobasal degeneration;
KIRP	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.22	-20.6	-0.8	1.81e-55	Breast cancer;
KIRP	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg11833968	chr6:79620685	NA	-0.47	-6.94	-0.4	3.4e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg26248373	chr2:1572462	NA	-0.82	-11.04	-0.58	2.77e-23	IgG glycosylation;
KIRP	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18357526	chr6:26021779	HIST1H4A	0.81	9.16	0.5	2.05e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.09e-11	Hypertriglyceridemia;
KIRP	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg22437258	chr11:111473054	SIK2	-0.59	-6.56	-0.39	3.07e-10	Primary sclerosing cholangitis;
KIRP	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.71	-8.15	-0.46	1.81e-14	Colorectal cancer;
KIRP	cis	rs9815354	1.000	rs61744388	chr3:41756965	C/T	cg03022575	chr3:42003672	ULK4	0.55	6.1	0.36	4.02e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg04132472	chr17:19861366	AKAP10	0.64	9.48	0.52	2.3e-18	Schizophrenia;
KIRP	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg17764715	chr19:33622953	WDR88	0.68	8.27	0.47	8.27e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg14558114	chr2:88469736	THNSL2	-0.42	-5.53	-0.33	8.37e-8	Response to metformin (IC50);
KIRP	trans	rs1462872	0.669	rs327353	chr8:31799648	G/C	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg16434002	chr17:42200994	HDAC5	-0.52	-6.47	-0.38	5.12e-10	Total body bone mineral density;
KIRP	cis	rs4664304	0.629	rs62175466	chr2:160852308	C/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.46	-0.33	1.17e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg18135206	chr14:102964638	TECPR2	0.46	5.24	0.32	3.45e-7	Blood protein levels;
KIRP	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	5.33	0.32	2.25e-7	Homoarginine levels;
KIRP	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.58	7.52	0.43	1.01e-12	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03228824	chr1:160313057	COPA;NCSTN	0.48	6.45	0.38	5.75e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs62413470	0.872	rs9382577	chr6:55914850	A/T	cg13327911	chr6:55965977	COL21A1	0.57	5.13	0.31	5.89e-7	Joint mobility (Beighton score);
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg16341495	chr8:142228727	SLC45A4	-0.39	-4.87	-0.3	1.97e-6	Immature fraction of reticulocytes;
KIRP	cis	rs9583531	0.660	rs80030913	chr13:111336866	G/C	cg07595035	chr13:111291582	CARKD	0.68	5.03	0.31	9.34e-7	Coronary artery disease;
KIRP	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05220968	chr6:146057943	EPM2A	0.39	4.85	0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2522056	1.000	rs2522050	chr5:131796609	C/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.23	0.37	2.02e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs13279522	0.536	rs10957366	chr8:67029940	C/G	cg04041976	chr8:67085823	TRIM55	-0.45	-5.67	-0.34	4.06e-8	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs2275565	0.810	rs17599657	chr1:237017076	A/C	cg17297354	chr1:237056641	MTR	-0.53	-5.82	-0.35	1.84e-8	Homocysteine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19726179	chr10:71813353	H2AFY2	0.5	6.47	0.38	5.29e-10	Parkinson's disease;
KIRP	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg06935464	chr4:38784597	TLR10	0.51	5.15	0.31	5.27e-7	Breast cancer;
KIRP	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg07511668	chr11:68622177	NA	0.38	4.97	0.3	1.28e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.04	0.31	9.01e-7	Retinal vascular caliber;
KIRP	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg10617943	chr7:1981403	MAD1L1	-0.37	-5.19	-0.31	4.48e-7	Neuroticism;
KIRP	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.28	-0.55	7.6e-21	Coffee consumption (cups per day);
KIRP	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.79	13.11	0.64	3.93e-30	Calcium levels;
KIRP	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-5.04	-0.31	8.89e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7615316	1.000	rs9882763	chr3:142341308	T/G	cg20824294	chr3:142316082	PLS1	0.23	5.14	0.31	5.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.67	-10.13	-0.54	2.21e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg18815343	chr6:28367644	ZSCAN12	0.38	5.49	0.33	1.01e-7	Pubertal anthropometrics;
KIRP	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg22009923	chr11:832065	CD151	-0.33	-4.96	-0.3	1.33e-6	Mean platelet volume;
KIRP	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg05802129	chr4:122689817	NA	-0.46	-6.77	-0.4	9.43e-11	Type 2 diabetes;
KIRP	cis	rs9815354	1.000	rs6802340	chr3:41894034	T/C	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg06634786	chr22:41940651	POLR3H	-0.48	-5.94	-0.35	9.74e-9	Neuroticism;
KIRP	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.51	-0.43	1.06e-12	Neuroticism;
KIRP	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.8	11.41	0.59	1.76e-24	Menopause (age at onset);
KIRP	cis	rs4481887	0.604	rs6694598	chr1:248409490	A/G	cg01631408	chr1:248437212	OR2T33	-0.48	-5.78	-0.35	2.25e-8	Common traits (Other);
KIRP	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs6973256	0.865	rs11771373	chr7:133334842	A/G	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.75	-11.53	-0.59	7.06e-25	Neuroticism;
KIRP	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.81	12.72	0.63	7.96e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg13271783	chr10:134563150	INPP5A	-0.53	-7.08	-0.41	1.54e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4363385	0.776	rs2879490	chr1:152947163	A/G	cg07796016	chr1:152779584	LCE1C	-0.45	-5.2	-0.31	4.22e-7	Inflammatory skin disease;
KIRP	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-4.97	-0.3	1.28e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.47	5.09	0.31	6.97e-7	Alzheimer's disease;
KIRP	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.41	-0.43	2.05e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs524023	0.874	rs504915	chr11:64464085	T/A	cg09231725	chr11:64357281	SLC22A12	0.58	7.67	0.44	4.09e-13	Urate levels in obese individuals;
KIRP	cis	rs11955175	1.000	rs11951044	chr5:40671189	G/A	cg05478818	chr5:40835740	RPL37	0.69	5.36	0.32	1.94e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg18306943	chr3:40428807	ENTPD3	0.42	5.89	0.35	1.28e-8	Renal cell carcinoma;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25785679	chr19:49496701	GYS1;RUVBL2	0.5	6.07	0.36	4.82e-9	Myopia (pathological);
KIRP	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.1	0.36	4.04e-9	Breast cancer;
KIRP	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg20936604	chr3:58311152	NA	-0.6	-5.07	-0.31	7.92e-7	Cholesterol, total;
KIRP	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg20243544	chr17:37824526	PNMT	0.38	4.92	0.3	1.59e-6	Self-reported allergy;
KIRP	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg02487422	chr3:49467188	NICN1	-0.39	-5.4	-0.33	1.54e-7	Parkinson's disease;
KIRP	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.39	-4.92	-0.3	1.58e-6	Blood metabolite levels;
KIRP	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.77	-11.66	-0.6	2.66e-25	Breast cancer;
KIRP	cis	rs6832769	1.000	rs6824057	chr4:56367278	G/C	cg05960024	chr4:56376020	CLOCK	0.7	8.77	0.49	3.08e-16	Personality dimensions;
KIRP	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-15.73	-0.71	4.8e-39	Primary sclerosing cholangitis;
KIRP	cis	rs5753037	0.838	rs5763688	chr22:30393503	C/G	cg27665648	chr22:30112403	NA	-0.36	-5.1	-0.31	6.7e-7	Type 1 diabetes;
KIRP	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg05220968	chr6:146057943	EPM2A	-0.39	-4.93	-0.3	1.54e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9462846	1.000	rs9462846	chr6:42861581	A/C	cg02353165	chr6:42928485	GNMT	0.44	4.96	0.3	1.35e-6	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.64	0.44	4.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs9652601	0.959	rs9931397	chr16:11177394	G/C	cg04616529	chr16:11181986	CLEC16A	0.37	4.91	0.3	1.63e-6	Systemic lupus erythematosus;
KIRP	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg15128208	chr22:42549153	NA	0.72	8.06	0.46	3.27e-14	Birth weight;
KIRP	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.55	-6.8	-0.4	7.81e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg05342945	chr12:48394962	COL2A1	0.47	5.12	0.31	6.17e-7	Lung cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05935374	chr11:82782929	RAB30	0.46	6.27	0.37	1.59e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6841333	0.539	rs4859592	chr4:76948664	A/G	cg00809888	chr4:76862425	NAAA	0.42	5.89	0.35	1.28e-8	Monokine induced by gamma interferon levels;
KIRP	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg21905437	chr5:178450457	ZNF879	0.58	6.77	0.4	9.64e-11	Pubertal anthropometrics;
KIRP	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg00310523	chr12:86230176	RASSF9	0.55	8.6	0.48	9.5e-16	Major depressive disorder;
KIRP	cis	rs755109	1.000	rs10760021	chr9:100697648	T/A	cg13688889	chr9:100608707	NA	-0.41	-4.9	-0.3	1.77e-6	Quantitative traits;
KIRP	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg01338139	chr15:38987640	C15orf53	-0.53	-5.64	-0.34	4.66e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.02	0.36	6.47e-9	Depression;
KIRP	cis	rs7709377	0.595	rs13179593	chr5:115440772	A/G	cg23108291	chr5:115420582	COMMD10	0.43	5.16	0.31	5.2e-7	Metabolite levels  (X-11787);
KIRP	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.72	-8.86	-0.49	1.62e-16	Coronary artery disease;
KIRP	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg23477460	chr3:66848765	NA	0.76	7.84	0.45	1.4e-13	Type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-5.65	-0.34	4.51e-8	Chronic sinus infection;
KIRP	trans	rs10242455	0.702	rs28753399	chr7:98997259	C/T	cg09045935	chr12:6379348	NA	0.87	6.11	0.36	3.81e-9	Blood metabolite levels;
KIRP	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg12311346	chr5:56204834	C5orf35	-0.4	-5.46	-0.33	1.19e-7	Coronary artery disease;
KIRP	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg25600027	chr14:23388339	RBM23	-0.52	-6.43	-0.38	6.42e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg20651018	chr11:3035856	CARS	-0.36	-4.96	-0.3	1.31e-6	Longevity;
KIRP	cis	rs66530629	0.874	rs6667299	chr1:25158500	T/C	cg22509179	chr1:25234806	RUNX3	-0.38	-5.07	-0.31	7.7300000000000005e-07	Plateletcrit;
KIRP	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.03	-0.31	9.57e-7	Triglycerides;
KIRP	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg04731861	chr2:219085781	ARPC2	-0.2	-4.97	-0.3	1.27e-6	Colorectal cancer;
KIRP	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.76	-0.53	3.16e-19	Morning vs. evening chronotype;
KIRP	cis	rs12210905	1.000	rs6917419	chr6:27243480	C/T	cg11502198	chr6:26597334	ABT1	-0.66	-4.91	-0.3	1.68e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg02657892	chr1:62190594	TM2D1	0.51	6.22	0.37	2.1e-9	Educational attainment;
KIRP	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg26876637	chr1:152193138	HRNR	-0.84	-8.29	-0.47	7.52e-15	Atopic dermatitis;
KIRP	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	0.99	10.76	0.57	2.17e-22	Blood protein levels;
KIRP	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	trans	rs6601327	0.600	rs7828039	chr8:9654757	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.26	-0.42	5.17e-12	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs17079247	0.841	rs9566052	chr13:85808028	T/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	6.5	0.38	4.36e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.48	-6.02	-0.36	6.27e-9	Refractive error;
KIRP	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.47	6.3	0.37	1.37e-9	Red cell distribution width;
KIRP	cis	rs13034020	0.522	rs62150970	chr2:61244410	C/G	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.71	0.39	1.35e-10	Hodgkin's lymphoma;
KIRP	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01171360	chr6:293285	DUSP22	-0.54	-6.25	-0.37	1.83e-9	Menopause (age at onset);
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	4.96	0.3	1.29e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs793108	0.901	rs1771641	chr10:31434499	C/T	cg00428179	chr10:31322131	ZNF438	-0.33	-4.89	-0.3	1.86e-6	Multiple sclerosis;Rheumatoid arthritis;
KIRP	cis	rs8084125	1.000	rs7237781	chr18:74953527	C/T	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs2880765	0.525	rs2062234	chr15:86054490	A/G	cg15340431	chr15:86040528	AKAP13	-0.46	-5.9	-0.35	1.18e-8	Coronary artery disease;
KIRP	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.51e-15	Mortality in heart failure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16211055	chr1:228594250	TRIM11	0.56	6.67	0.39	1.65e-10	Smoking initiation;
KIRP	cis	rs1215050	1.000	rs1215050	chr4:98849826	A/G	cg17366294	chr4:99064904	C4orf37	-0.38	-5.01	-0.3	1.04e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.74	7.25	0.42	5.49e-12	Obesity-related traits;
KIRP	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg16141378	chr3:129829833	LOC729375	-0.48	-6.27	-0.37	1.59e-9	Schizophrenia;
KIRP	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg12658694	chr1:38397304	INPP5B	0.63	8.16	0.46	1.75e-14	Coronary artery disease;
KIRP	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.73	-0.34	2.94e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.62	0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4740619	0.565	rs10756736	chr9:16032225	T/C	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15812903	chr14:100912065	WDR25	0.56	6.25	0.37	1.84e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg11783602	chr8:55087084	NA	-0.61	-7.7	-0.44	3.24e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.55	0.39	3.34e-10	Height;
KIRP	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg15660573	chr17:549704	VPS53	-0.82	-12.08	-0.61	1.05e-26	Prostate cancer;
KIRP	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.43	-0.43	1.74e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg26065057	chr18:74961000	GALR1	0.62	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs4849845	0.889	rs6542577	chr2:121013832	G/C	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs7116495	0.609	rs595062	chr11:71809635	C/T	cg10381502	chr11:71823885	C11orf51	1.15	7.55	0.43	8.26e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-1.08	-14.73	-0.68	1.23e-35	Strep throat;
KIRP	cis	rs77861329	1.000	rs352150	chr3:52209995	A/G	cg08692210	chr3:52188851	WDR51A	0.95	7.5	0.43	1.16e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.38	-5.29	-0.32	2.7e-7	Lung cancer;
KIRP	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg15832292	chr6:96025679	MANEA	0.77	7.05	0.41	1.79e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg05669848	chr5:237993	SDHA	-0.5	-5.08	-0.31	7.37e-7	Breast cancer;
KIRP	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06481639	chr22:41940642	POLR3H	-0.75	-7.85	-0.45	1.32e-13	Vitiligo;
KIRP	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg00631329	chr6:26305371	NA	0.66	8.88	0.49	1.44e-16	Educational attainment;
KIRP	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03352830	chr11:487213	PTDSS2	0.75	5.16	0.31	5.18e-7	Body mass index;
KIRP	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg05484376	chr2:27715224	FNDC4	0.36	6.22	0.37	2.14e-9	Total body bone mineral density;
KIRP	cis	rs35000415	0.938	rs13227075	chr7:128643297	T/C	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs4700695	0.764	rs251327	chr5:65269464	A/G	cg21114390	chr5:65439923	SFRS12	0.58	5.92	0.35	1.06e-8	Facial morphology (factor 19);
KIRP	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg19752551	chr11:57585705	CTNND1	-0.68	-11.48	-0.59	1.05e-24	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg26513180	chr16:89883248	FANCA	0.83	5.54	0.33	7.84e-8	Skin colour saturation;
KIRP	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg03609598	chr5:56110824	MAP3K1	-0.5	-5.14	-0.31	5.58e-7	Type 2 diabetes;
KIRP	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg04990556	chr1:26633338	UBXN11	0.68	6.54	0.38	3.52e-10	Obesity-related traits;
KIRP	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.68	0.44	3.69e-13	Aortic root size;
KIRP	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg20476274	chr7:133979776	SLC35B4	0.55	6.56	0.39	3.21e-10	Mean platelet volume;
KIRP	cis	rs1760803	0.754	rs3762339	chr1:154208877	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.58	-0.33	6.46e-8	Nicotine dependence;
KIRP	cis	rs9547996	0.959	rs9548003	chr13:38233206	A/G	cg13634560	chr13:38173852	POSTN	-0.35	-4.98	-0.3	1.18e-6	Diastolic blood pressure;
KIRP	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.9	0.35	1.19e-8	Birth weight;
KIRP	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg12661370	chr5:149340060	SLC26A2	0.49	5.21	0.32	4.02e-7	HIV-1 control;
KIRP	cis	rs9972944	0.692	rs6504346	chr17:63757175	C/A	cg07283582	chr17:63770753	CCDC46	-0.46	-7.48	-0.43	1.29e-12	Total body bone mineral density;
KIRP	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg05872129	chr22:39784769	NA	-0.67	-9.84	-0.53	1.79e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.65	-7.74	-0.44	2.5e-13	Cotinine glucuronidation;
KIRP	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg21161173	chr5:140098174	VTRNA1-2	-0.38	-4.93	-0.3	1.53e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg02524346	chr8:600233	NA	0.74	5.78	0.35	2.24e-8	IgG glycosylation;
KIRP	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg19045956	chr2:200819837	C2orf60;C2orf47	0.47	5.8	0.35	2.06e-8	Osteoporosis;
KIRP	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg24110177	chr3:50126178	RBM5	0.44	5.69	0.34	3.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs897504	0.500	rs6756985	chr2:33686786	G/A	cg17598334	chr2:33700917	RASGRP3	-0.6	-6.03	-0.36	5.99e-9	Multiple system atrophy (pathologically confirmed);
KIRP	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg01689657	chr7:91764605	CYP51A1	-0.38	-5.42	-0.33	1.43e-7	Breast cancer;
KIRP	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.42	5.62	0.34	5.03e-8	Childhood ear infection;
KIRP	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.73	-9.25	-0.51	1.16e-17	Primary biliary cholangitis;
KIRP	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.73	-9.21	-0.51	1.45e-17	Height;
KIRP	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-7.15	-0.41	9.9e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.43	5.41	0.33	1.52e-7	Aortic root size;
KIRP	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs6684514	1.000	rs66965793	chr1:156285814	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-5.95	-0.35	9.29e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.45e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.9	6.49	0.38	4.67e-10	Putamen volume;
KIRP	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.58	7.83	0.45	1.43e-13	Height;
KIRP	cis	rs9426935	0.966	rs9427232	chr1:153792958	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	0.28	4.88	0.3	1.94e-6	Lentiform nucleus volume;
KIRP	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.49	-0.33	1.02e-7	Metabolite levels;
KIRP	cis	rs4919044	0.866	rs11187247	chr10:94794319	G/T	cg05127821	chr10:94822908	CYP26C1	-0.99	-7.26	-0.42	5.16e-12	Coronary artery disease;
KIRP	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg07962218	chr7:65219954	SNORA22;CCT6P1	-0.35	-5.28	-0.32	2.85e-7	Calcium levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26744308	chr2:7909341	NA	-0.45	-6.05	-0.36	5.35e-9	Myopia (pathological);
KIRP	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg11972305	chr2:233791962	NGEF	0.35	4.91	0.3	1.69e-6	Schizophrenia;
KIRP	cis	rs6681460	0.932	rs2483705	chr1:67191180	C/G	cg02459107	chr1:67143332	SGIP1	-0.39	-5.75	-0.34	2.67e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	13.23	0.64	1.54e-30	Post bronchodilator FEV1;
KIRP	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg12855166	chr17:30846586	MYO1D	0.43	5.95	0.35	9.34e-9	Schizophrenia;
KIRP	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02725872	chr8:58115012	NA	-0.66	-6.51	-0.38	4.09e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg06640241	chr16:89574553	SPG7	0.66	8.91	0.49	1.17e-16	Multiple myeloma (IgH translocation);
KIRP	trans	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg09872104	chr7:134855509	C7orf49	-0.79	-6.22	-0.37	2.11e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg03647239	chr10:116582469	FAM160B1	0.51	5.71	0.34	3.21e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg11970804	chr8:8084126	NA	-0.34	-4.91	-0.3	1.69e-6	Mood instability;
KIRP	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.27	-0.42	4.88e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs35740288	0.703	rs10520598	chr15:86173381	T/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg26207909	chr14:103986467	CKB	-0.48	-6.25	-0.37	1.8e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.45	6.76	0.4	1.01e-10	Major depressive disorder;
KIRP	cis	rs7107174	0.901	rs2450126	chr11:77916279	A/G	cg02023728	chr11:77925099	USP35	0.39	5.2	0.31	4.27e-7	Testicular germ cell tumor;
KIRP	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg16497661	chr14:103986332	CKB	-0.51	-6.44	-0.38	6.06e-10	Coronary artery disease;
KIRP	cis	rs78487399	0.710	rs17334919	chr2:43707385	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.6	5.09	0.31	7.23e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.79	-9.35	-0.51	5.74e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.63	-8.75	-0.49	3.53e-16	Breast cancer;
KIRP	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-0.87	-11.58	-0.59	4.8e-25	Gut microbiota (bacterial taxa);
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg06871246	chr4:1363661	KIAA1530	-0.56	-6.99	-0.41	2.52e-11	Longevity;
KIRP	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.34	-0.59	2.93e-24	Diabetic kidney disease;
KIRP	cis	rs7312774	0.881	rs12320167	chr12:107310167	G/A	cg16260113	chr12:107380972	MTERFD3	0.72	6.55	0.39	3.28e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.45	-6.79	-0.4	8.22e-11	Platelet distribution width;
KIRP	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg08885076	chr2:99613938	TSGA10	-0.42	-6.16	-0.37	2.88e-9	Bipolar disorder;
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg09597638	chr17:3907349	NA	0.8	15.98	0.71	6.8e-40	Type 2 diabetes;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-1.04	-20.26	-0.79	2.37e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg24058013	chr18:77568902	NA	-0.73	-10.89	-0.57	8.7e-23	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.68	-0.34	3.81e-8	Life satisfaction;
KIRP	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.26	-0.32	3.18e-7	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.58	-6.81	-0.4	7.31e-11	Aortic root size;
KIRP	trans	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.36	-0.38	9.8e-10	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09240793	chr17:79465311	NA	0.47	6.32	0.37	1.19e-9	Interleukin-4 levels;
KIRP	cis	rs231513	0.911	rs231515	chr17:41964083	A/G	cg26893861	chr17:41843967	DUSP3	-0.48	-4.93	-0.3	1.54e-6	Cognitive function;
KIRP	cis	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg21546286	chr11:48923668	NA	-0.48	-6.11	-0.36	3.97e-9	HDL cholesterol;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14776943	chr17:42201167	HDAC5	0.57	6.51	0.38	4.3e-10	Smoking initiation;
KIRP	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.44	-7.01	-0.41	2.22e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs11161851	0.839	rs12120668	chr1:75321017	G/C	cg11196437	chr1:75593865	LHX8	-0.41	-5.94	-0.35	9.56e-9	Visceral fat;
KIRP	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.51	6.63	0.39	2.12e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs4666002	0.956	rs3749147	chr2:27851918	G/A	cg05484376	chr2:27715224	FNDC4	-0.42	-5.51	-0.33	9.19e-8	Phospholipid levels (plasma);
KIRP	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.77	-11.43	-0.59	1.51e-24	Height;
KIRP	cis	rs10465746	0.682	rs882897	chr1:84426049	A/T	cg10977910	chr1:84465055	TTLL7	0.57	7.11	0.41	1.27e-11	Obesity-related traits;
KIRP	cis	rs6504950	0.830	rs12951542	chr17:53041965	T/C	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	cis	rs1555895	0.576	rs7071801	chr10:854011	T/C	cg10017260	chr10:834428	NA	-0.48	-7.18	-0.42	8.33e-12	Survival in rectal cancer;
KIRP	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg01620082	chr3:125678407	NA	-1.03	-6.53	-0.38	3.72e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.68	8.76	0.49	3.18e-16	Bladder cancer;
KIRP	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	1.22	10.06	0.54	3.69e-20	Gut microbiota (bacterial taxa);
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg27590781	chr2:152266272	RIF1	0.48	6.14	0.36	3.28e-9	Metabolite levels (MHPG);
KIRP	cis	rs2278796	0.693	rs2794859	chr1:204967256	A/G	cg17947172	chr1:204966197	NFASC	0.58	7.99	0.45	5.12e-14	Mean platelet volume;
KIRP	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg08501292	chr6:25962987	TRIM38	0.98	5.89	0.35	1.25e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg23601095	chr6:26197514	HIST1H3D	0.91	7.47	0.43	1.36e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs7084402	0.967	rs1649041	chr10:60328782	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7851660	0.809	rs1561961	chr9:100667599	C/T	cg13688889	chr9:100608707	NA	-0.68	-8.65	-0.48	6.59e-16	Strep throat;
KIRP	cis	rs77688320	0.573	rs2714480	chr2:202351009	T/C	cg06431681	chr2:202330990	STRADB	-0.44	-5.17	-0.31	4.84e-7	Breast cancer;
KIRP	cis	rs6563210	0.789	rs9545699	chr13:36485112	C/A	cg19801062	chr13:36872135	C13orf38	-0.5	-5.47	-0.33	1.12e-7	Height;
KIRP	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs8028182	0.549	rs7402293	chr15:75636137	A/G	cg20655648	chr15:75932815	IMP3	-0.54	-6.9	-0.4	4.49e-11	Sudden cardiac arrest;
KIRP	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg00806126	chr19:22604979	ZNF98	0.64	6.74	0.39	1.14e-10	Pain;
KIRP	trans	rs78049276	0.736	rs10305838	chr4:148400256	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.75	-9.08	-0.5	3.52e-17	Pulse pressure;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12489322	chr5:60628376	ZSWIM6	0.49	6.18	0.37	2.7e-9	Myopia (pathological);
KIRP	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg23625390	chr15:77176239	SCAPER	0.5	6.52	0.38	3.92e-10	Blood metabolite levels;
KIRP	cis	rs4262150	0.726	rs9324734	chr5:152012795	G/A	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.18e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-0.73	-10.28	-0.55	7.56e-21	White blood cell count;
KIRP	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg24972876	chr7:65420302	NA	0.41	5.61	0.34	5.38e-8	Calcium levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04407853	chr18:33878230	FHOD3	0.53	6.8	0.4	7.74e-11	Parkinson's disease;
KIRP	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-1.02	-12.35	-0.62	1.39e-27	Exhaled nitric oxide output;
KIRP	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg09699651	chr6:150184138	LRP11	-0.46	-6.0	-0.36	6.85e-9	Lung cancer;
KIRP	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-7.04	-0.41	1.96e-11	Systemic lupus erythematosus;
KIRP	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg01616529	chr11:638424	DRD4	-0.44	-5.72	-0.34	3.12e-8	Systemic lupus erythematosus;
KIRP	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg10932868	chr11:921992	NA	0.55	6.9	0.4	4.3e-11	Alzheimer's disease (late onset);
KIRP	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg27411982	chr8:10470053	RP1L1	-0.48	-6.12	-0.36	3.61e-9	Neuroticism;
KIRP	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.44	-5.99	-0.36	7.42e-9	Monocyte count;
KIRP	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.01	12.55	0.62	2.91e-28	Testicular germ cell tumor;
KIRP	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.66	0.48	6.17e-16	Motion sickness;
KIRP	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg08992911	chr2:238395768	MLPH	0.5	4.93	0.3	1.49e-6	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11616701	chr5:122950706	CSNK1G3	0.48	6.25	0.37	1.84e-9	Interleukin-4 levels;
KIRP	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.83	10.24	0.55	1.02e-20	Corneal astigmatism;
KIRP	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.42	6.15	0.37	3.07e-9	Carotid intima media thickness;
KIRP	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg05562828	chr17:3906858	NA	-0.52	-5.58	-0.34	6.2e-8	Type 2 diabetes;
KIRP	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	5.44	0.33	1.3e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.42	-0.47	3.1e-15	Morning vs. evening chronotype;
KIRP	cis	rs698833	0.926	rs1085449	chr2:44653432	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.03	0.31	9.66e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs12532214	0.595	rs74409671	chr7:3119182	A/G	cg19214707	chr7:3157722	NA	-0.71	-6.06	-0.36	5.13e-9	Itch intensity from mosquito bite;
KIRP	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg10932868	chr11:921992	NA	0.65	8.79	0.49	2.62e-16	Alzheimer's disease (late onset);
KIRP	cis	rs12195424	0.558	rs74408362	chr6:56294480	T/G	cg20782286	chr6:56298173	NA	-0.72	-4.95	-0.3	1.37e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg15068132	chr12:102092402	CHPT1	-0.4	-5.15	-0.31	5.26e-7	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.06e-8	Motion sickness;
KIRP	cis	rs1497828	0.956	rs2818976	chr1:217548956	A/C	cg04411442	chr1:217543379	NA	0.31	5.02	0.3	1e-6	Dialysis-related mortality;
KIRP	cis	rs57561814	1.000	rs6949149	chr7:22749157	G/T	cg01770232	chr7:22766155	IL6	0.65	5.35	0.32	2.06e-7	Tonsillectomy;
KIRP	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.08	12.8	0.63	4.4e-29	Lymphocyte percentage of white cells;
KIRP	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20135002	chr11:47629003	NA	-0.46	-5.48	-0.33	1.04e-7	Subjective well-being;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11207507	chr13:80915118	SPRY2	0.64	6.02	0.36	6.46e-9	Lung function (FEV1);
KIRP	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.82	0.4	6.91e-11	Height;
KIRP	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.03	0.41	2.07e-11	Electroencephalogram traits;
KIRP	cis	rs11779988	0.571	rs208053	chr8:17825327	G/A	cg01800426	chr8:17659068	MTUS1	-0.61	-6.1	-0.36	4.12e-9	Breast cancer;
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.94	-14.94	-0.69	2.32e-36	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs931127	0.554	rs11227261	chr11:65462843	C/G	cg11569703	chr11:65557185	OVOL1	0.32	4.97	0.3	1.28e-6	Systemic lupus erythematosus;
KIRP	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.96	0.36	8.66e-9	Renal cell carcinoma;
KIRP	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.79	-11.72	-0.6	1.64e-25	Hip circumference;
KIRP	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.63	8.86	0.49	1.66e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9398803	0.713	rs1490384	chr6:126851160	C/T	cg19875578	chr6:126661172	C6orf173	0.44	5.53	0.33	8.24e-8	Male-pattern baldness;
KIRP	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.68	-0.39	1.62e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg06521331	chr12:34319734	NA	-0.45	-5.17	-0.31	4.94e-7	Resting heart rate;
KIRP	trans	rs4742903	0.509	rs1605445	chr9:106958484	C/A	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.09	-0.36	4.22e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.84	10.17	0.54	1.68e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6568686	0.577	rs174395	chr6:111919007	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.55	5.15	0.31	5.33e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg12131826	chr15:77904385	NA	0.46	6.2	0.37	2.4e-9	Type 2 diabetes;
KIRP	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.71	10.29	0.55	6.77e-21	Lymphocyte counts;
KIRP	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	9.31	0.51	7.42e-18	Smoking behavior;
KIRP	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg26811252	chr16:29126840	RRN3P2	0.76	10.19	0.54	1.4e-20	Menopause (age at onset);
KIRP	cis	rs300703	0.810	rs72772835	chr2:134554	C/T	cg21211680	chr2:198530	NA	-0.99	-8.35	-0.47	4.92e-15	Blood protein levels;
KIRP	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.92	-0.35	1.1e-8	Breast cancer;
KIRP	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.4	6.78	0.4	8.85e-11	Heart rate;
KIRP	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg13798912	chr7:905769	UNC84A	-0.5	-5.22	-0.32	3.85e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg23950597	chr19:37808831	NA	-0.76	-6.6	-0.39	2.54e-10	Coronary artery calcification;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06666157	chr19:4791552	FEM1A	0.54	7.22	0.42	6.52e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-9.54	-0.52	1.49e-18	Response to antipsychotic treatment;
KIRP	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.35e-8	Blood protein levels;
KIRP	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.62	8.37	0.47	4.52e-15	Testicular germ cell tumor;
KIRP	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	trans	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg25042112	chr7:64838748	ZNF92	0.59	6.37	0.38	9e-10	Pain;
KIRP	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg24375607	chr4:120327624	NA	-0.46	-4.97	-0.3	1.23e-6	Corneal astigmatism;
KIRP	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.83	-0.35	1.72e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21530026	chr6:57049329	BAG2	0.36	6.09	0.36	4.37e-9	C-reactive protein;
KIRP	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg27124370	chr19:33622961	WDR88	0.72	10.3	0.55	6.29e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6681460	0.966	rs2025595	chr1:67152499	G/A	cg13052034	chr1:66999238	SGIP1	0.44	5.92	0.35	1.06e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg20731937	chr12:48336164	NA	0.41	5.19	0.31	4.32e-7	Longevity (90 years and older);
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg01391022	chr12:122360665	WDR66	0.41	6.07	0.36	4.72e-9	Mean corpuscular volume;
KIRP	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg27462398	chr1:86174642	ZNHIT6	0.49	5.68	0.34	3.87e-8	Urate levels in overweight individuals;
KIRP	cis	rs1891275	0.515	rs10881957	chr10:93501876	C/T	cg07889827	chr10:93443413	NA	-0.45	-7.63	-0.44	5.23e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1656402	1.000	rs1190437	chr2:233423796	C/G	cg03852847	chr2:233439513	NA	0.7	11.59	0.59	4.5e-25	Non-small cell lung cancer (survival);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg02860732	chr16:12995292	SHISA9	-0.45	-6.07	-0.36	4.79e-9	Blood metabolite levels;
KIRP	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.92	-0.45	8.34e-14	Neuroticism;
KIRP	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21545522	chr1:205238299	TMCC2	0.42	5.64	0.34	4.77e-8	Red blood cell count;
KIRP	cis	rs42648	0.564	rs13224065	chr7:89802363	G/A	cg25739043	chr7:89950458	NA	-0.39	-6.04	-0.36	5.57e-9	Homocysteine levels;
KIRP	cis	rs7119038	0.818	rs10892279	chr11:118611781	G/A	cg19308663	chr11:118741387	NA	0.46	7.51	0.43	1.07e-12	Sjögren's syndrome;
KIRP	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.71	9.35	0.51	5.79e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg08668510	chr10:1095578	IDI1	0.82	5.6	0.34	5.59e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	5.21	0.32	3.95e-7	Menarche (age at onset);
KIRP	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.16	-0.31	5.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.79	14.45	0.68	1.13e-34	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07697672	chr16:30825951	NA	0.44	6.43	0.38	6.56e-10	Parkinson's disease;
KIRP	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.34	-6.13	-0.36	3.47e-9	Renal cell carcinoma;
KIRP	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	0.76	7.68	0.44	3.67e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs859767	0.519	rs6707326	chr2:135357705	G/A	cg12500956	chr2:135428796	TMEM163	-0.46	-6.05	-0.36	5.31e-9	Neuroticism;
KIRP	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg05775895	chr3:12838266	CAND2	0.4	6.98	0.41	2.77e-11	QRS complex (12-leadsum);
KIRP	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.27	12.8	0.63	4.22e-29	Diabetic retinopathy;
KIRP	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg14825094	chr17:61818420	STRADA	-0.42	-4.85	-0.3	2.23e-6	Height;
KIRP	cis	rs367943	0.712	rs7734304	chr5:112730165	G/A	cg12552261	chr5:112820674	MCC	0.58	6.88	0.4	4.98e-11	Type 2 diabetes;
KIRP	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg12591125	chr7:1885375	MAD1L1	0.63	6.09	0.36	4.36e-9	Bipolar disorder;
KIRP	cis	rs62413470	1.000	rs62404894	chr6:55961287	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9311676	0.656	rs34579268	chr3:58410554	C/T	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.69	7.81	0.45	1.7e-13	Corneal astigmatism;
KIRP	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.43	-6.2	-0.37	2.33e-9	Vitamin D levels;
KIRP	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.91	10.99	0.57	3.93e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.48	7.13	0.41	1.11e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13648088	chr10:124768538	ACADSB;IKZF5	0.5	6.57	0.39	2.97e-10	Parkinson's disease;
KIRP	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg06219351	chr7:158114137	PTPRN2	0.58	8.37	0.47	4.45e-15	Calcium levels;
KIRP	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.52	6.64	0.39	1.94e-10	Myeloid white cell count;
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg09355771	chr2:177043147	NA	0.43	5.58	0.34	6.37e-8	IgG glycosylation;
KIRP	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs6670533	0.571	rs72884438	chr1:24866637	T/C	cg07475527	chr1:24864545	NA	-0.68	-4.96	-0.3	1.35e-6	Fasting blood insulin (BMI interaction);
KIRP	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg25319279	chr11:5960081	NA	-0.53	-5.49	-0.33	9.81e-8	DNA methylation (variation);
KIRP	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.56	5.7	0.34	3.38e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.66	-0.34	4.14e-8	Schizophrenia;
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg12486944	chr17:80159399	CCDC57	0.38	5.11	0.31	6.56e-7	Life satisfaction;
KIRP	cis	rs11825064	0.562	rs80265266	chr11:134509727	A/G	cg06603561	chr11:134479413	NA	-0.97	-7.24	-0.42	5.88e-12	Seasonality;
KIRP	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.47	-7.1	-0.41	1.37e-11	Vitamin D levels;
KIRP	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.84	11.23	0.58	6.63e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.62	-0.39	2.23e-10	Response to antipsychotic treatment;
KIRP	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg08975724	chr8:8085496	FLJ10661	0.49	6.09	0.36	4.43e-9	Retinal vascular caliber;
KIRP	cis	rs7119167	0.722	rs60700454	chr11:73057511	A/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.17	0.31	4.78e-7	Blood protein levels;
KIRP	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.78	-11.24	-0.58	6.22e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18252515	chr7:66147081	NA	0.42	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs62380364	0.602	rs448809	chr5:88005828	G/T	cg22951263	chr5:87985283	NA	-0.44	-6.17	-0.37	2.76e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg10047753	chr17:41438598	NA	1.11	17.71	0.75	8.21e-46	Menopause (age at onset);
KIRP	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.06	18.96	0.77	4.92e-50	Triglycerides;
KIRP	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg05717871	chr11:638507	DRD4	-0.39	-5.58	-0.33	6.48e-8	Systemic lupus erythematosus;
KIRP	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.85	-7.74	-0.44	2.52e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2070997	0.756	rs3824400	chr9:133734075	A/G	cg13397898	chr9:133768931	QRFP	-0.3	-5.06	-0.31	8.32e-7	Response to amphetamines;
KIRP	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	8.1e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12619656	chr10:103345347	POLL	0.43	6.22	0.37	2.16e-9	Interleukin-4 levels;
KIRP	cis	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg03342759	chr3:160939853	NMD3	0.43	5.29	0.32	2.72e-7	Morning vs. evening chronotype;
KIRP	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg14580859	chr9:123691850	NA	0.35	5.06	0.31	8.23e-7	Rheumatoid arthritis;
KIRP	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-7.84	-0.45	1.37e-13	Bipolar disorder;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23708337	chr7:1209742	NA	0.41	5.06	0.31	8.05e-7	Longevity;Endometriosis;
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg12705353	chr12:122356852	WDR66	0.52	6.99	0.41	2.58e-11	Mean corpuscular volume;
KIRP	cis	rs10267417	0.535	rs10272487	chr7:19862415	A/T	cg05791153	chr7:19748676	TWISTNB	0.56	5.53	0.33	8.34e-8	Night sleep phenotypes;
KIRP	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	8.73	0.49	4.03e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7737355	1.000	rs2549018	chr5:130698949	C/T	cg06647332	chr5:131281008	NA	-0.46	-5.15	-0.31	5.41e-7	Life satisfaction;
KIRP	cis	rs4690686	0.538	rs7436387	chr4:177257723	T/G	cg17059388	chr4:177262070	NA	0.83	10.84	0.57	1.23e-22	Essential tremor;
KIRP	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.69	-8.56	-0.48	1.25e-15	Schizophrenia;
KIRP	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.92	13.38	0.65	4.65e-31	Bladder cancer;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg20366603	chr17:7218821	GPS2	0.47	6.73	0.39	1.21e-10	Ischemic stroke;
KIRP	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg17986701	chr20:44574422	PCIF1	-0.49	-7.56	-0.43	7.85e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg02712587	chr15:40268421	EIF2AK4	-0.48	-5.7	-0.34	3.5e-8	Response to haloperidol in psychosis;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	7.3	0.42	3.85e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01954957	chr14:38263617	NA	-0.47	-6.23	-0.37	1.99e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.62	8.26	0.47	9e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg10047753	chr17:41438598	NA	1.15	18.14	0.76	2.88e-47	Menopause (age at onset);
KIRP	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg04310649	chr10:35416472	CREM	-0.55	-6.16	-0.37	2.89e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg15655495	chr12:38532458	NA	-0.31	-5.33	-0.32	2.21e-7	Bladder cancer;
KIRP	trans	rs1973993	0.561	rs4127308	chr1:96990754	G/C	cg10631902	chr5:14652156	NA	-0.52	-6.51	-0.38	4.27e-10	Weight;
KIRP	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.7	7.32	0.42	3.48e-12	Bipolar disorder;
KIRP	trans	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg19955956	chr7:72299837	SBDSP;TYW1B	0.44	6.16	0.37	2.89e-9	Blood metabolite levels;
KIRP	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg19116668	chr7:99932089	PMS2L1	0.44	5.11	0.31	6.48e-7	Coronary artery disease;
KIRP	cis	rs10823500	0.549	rs10999204	chr10:72007306	G/A	cg02100629	chr10:71892760	AIFM2	-0.36	-4.93	-0.3	1.55e-6	Blood protein levels;
KIRP	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-0.8	-10.01	-0.54	5.35e-20	Blood trace element (Zn levels);
KIRP	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.86	10.02	0.54	4.71e-20	Neutrophil percentage of white cells;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.31	-0.32	2.47e-7	Obesity-related traits;
KIRP	cis	rs9309473	0.607	rs1522927	chr2:73556155	T/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.41	-0.38	7.4e-10	Metabolite levels;
KIRP	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.51	7.89	0.45	9.75e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2154427	0.872	rs76549663	chr21:34099768	G/A	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.67	-5.67	-0.34	3.93e-8	Bilirubin levels;
KIRP	cis	rs61884328	0.733	rs57012996	chr11:47194924	T/G	cg23433285	chr11:47201945	PACSIN3	0.68	5.27	0.32	2.99e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs17681684	0.541	rs12150176	chr17:9764547	C/T	cg26853458	chr17:9805074	RCVRN	0.54	5.1	0.31	6.85e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg18016565	chr1:150552671	MCL1	0.37	5.61	0.34	5.38e-8	Melanoma;
KIRP	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.62	8.24	0.47	1.03e-14	Menarche (age at onset);
KIRP	cis	rs7809950	0.599	rs2237658	chr7:106837866	T/G	cg23024343	chr7:107201750	COG5	-0.49	-6.57	-0.39	2.94e-10	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04996355	chr5:148206108	ADRB2	0.45	6.22	0.37	2.16e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02725872	chr8:58115012	NA	-0.63	-5.68	-0.34	3.7e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.3	5.97	0.36	8.06e-9	Schizophrenia;
KIRP	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg15691649	chr6:25882328	NA	-0.42	-5.11	-0.31	6.32e-7	Blood metabolite levels;
KIRP	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg07701084	chr6:150067640	NUP43	0.56	7.14	0.41	1.07e-11	Lung cancer;
KIRP	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg10645314	chr2:3704589	ALLC	-0.52	-6.43	-0.38	6.73e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.66	6.71	0.39	1.29e-10	Vitiligo;
KIRP	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-6.2	-0.37	2.4e-9	Monocyte percentage of white cells;
KIRP	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-1.09	-21.45	-0.81	3.05e-58	Height;
KIRP	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg06647332	chr5:131281008	NA	-0.46	-5.01	-0.3	1.06e-6	Life satisfaction;
KIRP	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg22138327	chr13:27999177	GTF3A	0.89	7.04	0.41	1.88e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs2270927	0.510	rs35764719	chr5:75573550	G/T	cg13563193	chr19:33072644	PDCD5	0.93	6.84	0.4	6.38e-11	Mean corpuscular volume;
KIRP	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs4886920	0.894	rs4587942	chr15:78119345	G/T	cg10461261	chr15:78109450	NA	-0.37	-6.07	-0.36	4.7e-9	Neuroticism;
KIRP	cis	rs2898681	0.614	rs4864680	chr4:53708421	T/G	cg00338735	chr4:53728038	RASL11B	0.44	5.57	0.33	6.76e-8	Optic nerve measurement (cup area);
KIRP	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg00977110	chr5:151150581	G3BP1	0.63	6.43	0.38	6.5e-10	Preschool internalizing problems;
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.29	0.37	1.47e-9	Lung cancer;
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.17	0.37	2.8e-9	Platelet count;
KIRP	cis	rs10266483	0.739	rs2692099	chr7:63767762	G/C	cg04636841	chr7:63768139	NA	-0.39	-5.27	-0.32	2.93e-7	Response to statin therapy;
KIRP	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.1	0.41	1.37e-11	IgG glycosylation;
KIRP	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg23495837	chr4:3480318	DOK7	-0.43	-5.67	-0.34	3.93e-8	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.4e-8	Life satisfaction;
KIRP	cis	rs255758	0.600	rs255753	chr5:53320095	A/T	cg22592108	chr5:53304441	ARL15	0.4	5.58	0.34	6.25e-8	Rheumatoid arthritis;
KIRP	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg24324837	chr19:49891574	CCDC155	0.6	5.63	0.34	4.81e-8	Multiple sclerosis;
KIRP	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.6	5.09	0.31	7.17e-7	Bipolar disorder;
KIRP	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.53	-5.88	-0.35	1.37e-8	Coronary artery disease;
KIRP	cis	rs2415984	0.622	rs7156466	chr14:46933384	A/G	cg14871534	chr14:47121158	RPL10L	-0.45	-5.4	-0.33	1.56e-7	Number of children ever born;
KIRP	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg03388025	chr16:89894329	SPIRE2	0.34	6.47	0.38	5.39e-10	Vitiligo;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-4.89	-0.3	1.79e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.63	8.92	0.49	1.13e-16	Lymphocyte counts;
KIRP	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg01338139	chr15:38987640	C15orf53	-0.57	-6.32	-0.37	1.21e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg23188430	chr6:125850052	NA	-0.33	-5.21	-0.32	4.08e-7	Brugada syndrome;
KIRP	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg24154853	chr7:158122151	PTPRN2	0.36	5.22	0.32	3.74e-7	Calcium levels;
KIRP	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.02	-0.36	6.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.84	-9.11	-0.5	3.01e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.49	-5.08	-0.31	7.48e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.48	6.05	0.36	5.47e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18867708	chr6:26865862	GUSBL1	0.47	5.82	0.35	1.84e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.61	7.03	0.41	1.97e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.6e-6	Total body bone mineral density;
KIRP	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg13482628	chr17:19912719	NA	-0.53	-7.02	-0.41	2.17e-11	Schizophrenia;
KIRP	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.76	10.2	0.55	1.3e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-10.44	-0.55	2.25e-21	Hypospadias;
KIRP	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.83	9.66	0.52	6.27e-19	Osteoarthritis;
KIRP	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg24807547	chr6:37504484	NA	-0.42	-5.91	-0.35	1.15e-8	Cognitive performance;
KIRP	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.99	15.84	0.71	2.02e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.64	-5.81	-0.35	1.89e-8	Schizophrenia;
KIRP	cis	rs6142102	1.000	rs12480839	chr20:32727430	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	6.4	0.38	7.6e-10	Skin pigmentation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11657970	chr5:148521075	ABLIM3	0.44	6.07	0.36	4.69e-9	Parkinson's disease;
KIRP	cis	rs11779988	0.538	rs12541567	chr8:17920077	T/A	cg01800426	chr8:17659068	MTUS1	-0.43	-5.15	-0.31	5.29e-7	Breast cancer;
KIRP	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg04906043	chr13:21280425	IL17D	-0.56	-6.73	-0.39	1.21e-10	Dental caries;
KIRP	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.43	-0.43	1.8e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg21573476	chr21:45109991	RRP1B	0.63	8.3	0.47	6.86e-15	Mean corpuscular volume;
KIRP	trans	rs62056376	0.736	rs758293	chr17:32640523	A/T	cg06688323	chr4:4858340	NA	0.59	6.23	0.37	2.02e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.43	5.41	0.33	1.53e-7	Melanoma;
KIRP	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.53	0.48	1.55e-15	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg07701084	chr6:150067640	NUP43	0.63	8.17	0.46	1.62e-14	Lung cancer;
KIRP	cis	rs56079296	0.866	rs7736099	chr5:121280216	G/A	cg05256605	chr5:121412184	LOX	0.51	5.41	0.33	1.46e-7	Coronary artery disease;
KIRP	cis	rs62355272	0.931	rs3866449	chr5:35919343	C/T	cg13894535	chr5:35919491	CAPSL	-0.52	-6.16	-0.37	2.97e-9	Lymphocyte counts;
KIRP	cis	rs9596863	0.898	rs68039282	chr13:54389435	C/A	ch.13.53330881F	chr13:54432880	NA	0.6	5.81	0.35	1.88e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7680126	0.596	rs4698031	chr4:10315921	A/G	cg20640774	chr4:10143053	NA	0.47	4.89	0.3	1.83e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14893161	chr1:205819251	PM20D1	-0.59	-5.75	-0.34	2.67e-8	Menarche (age at onset);
KIRP	cis	rs7894051	1.000	rs77189950	chr10:135126722	A/T	cg17833184	chr10:135191291	PAOX	0.79	5.44	0.33	1.32e-7	Lifespan;
KIRP	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg23307798	chr14:103986281	CKB	0.72	11.23	0.58	6.81e-24	Body mass index;
KIRP	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	1.05	14.99	0.69	1.64e-36	Alzheimer's disease;
KIRP	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.71	-8.37	-0.47	4.34e-15	Resting heart rate;
KIRP	cis	rs539514	0.664	rs1323712	chr13:76300085	C/G	cg04757411	chr13:76259545	LMO7	-0.35	-5.04	-0.31	9.05e-7	Type 1 diabetes;
KIRP	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.28e-6	Menopause (age at onset);
KIRP	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.88	8.31	0.47	6.67e-15	Type 2 diabetes;
KIRP	cis	rs7084402	0.967	rs1658434	chr10:60328756	G/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.26	-0.55	8.6e-21	Refractive error;
KIRP	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	8.82	0.49	2.21e-16	Lymphocyte counts;
KIRP	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg03146154	chr1:46216737	IPP	0.55	5.79	0.35	2.16e-8	Platelet count;
KIRP	cis	rs3789045	0.866	rs11584700	chr1:204576983	C/T	cg08641003	chr1:204589008	LRRN2	0.57	6.08	0.36	4.49e-9	Educational attainment (college completion);
KIRP	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.64	-7.2	-0.42	7.49e-12	Platelet distribution width;
KIRP	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg02820901	chr13:113351484	ATP11A	0.68	6.34	0.37	1.08e-9	Glycated hemoglobin levels;
KIRP	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.35	6.2	0.37	2.4e-9	Renal cell carcinoma;
KIRP	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg14092571	chr14:90743983	NA	0.41	5.58	0.33	6.46e-8	Mortality in heart failure;
KIRP	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	7.1	0.41	1.32e-11	Height;
KIRP	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-10.17	-0.54	1.65e-20	Body mass index;
KIRP	cis	rs13424612	0.965	rs34789127	chr2:240952002	C/T	cg01812947	chr2:240904978	NDUFA10	0.5	6.35	0.38	1.02e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26002218	chr14:103986227	CKB	0.28	5.75	0.34	2.58e-8	Body mass index;
KIRP	cis	rs9361491	0.534	rs10943568	chr6:79404207	G/T	cg09184832	chr6:79620586	NA	-0.38	-4.92	-0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07080220	chr10:102295463	HIF1AN	0.73	7.02	0.41	2.16e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.52	-0.38	3.86e-10	Joint mobility (Beighton score);
KIRP	cis	rs7719624	0.846	rs2237066	chr5:135367603	C/T	cg16684184	chr5:135415129	NA	-0.34	-5.1	-0.31	6.84e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs6142102	0.625	rs6141432	chr20:32548597	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05220968	chr6:146057943	EPM2A	-0.42	-5.27	-0.32	2.95e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.69	9.35	0.51	5.79e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	5.51	0.33	9.11e-8	Bipolar disorder;
KIRP	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg25566285	chr7:158114605	PTPRN2	-0.73	-10.64	-0.56	5.32e-22	Calcium levels;
KIRP	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08048268	chr3:133502702	NA	-0.45	-5.36	-0.32	1.91e-7	Iron status biomarkers;
KIRP	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg26441486	chr22:50317300	CRELD2	-0.47	-7.18	-0.42	8.16e-12	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.99	7.84	0.45	1.38e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg23484912	chr5:273055	PDCD6	0.65	7.69	0.44	3.5e-13	Pancreatic cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22332910	chr11:35641226	FJX1	0.48	6.13	0.36	3.5e-9	Smoking initiation;
KIRP	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13047869	chr3:10149882	C3orf24	0.53	5.04	0.31	8.87e-7	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14291194	chr7:33149114	RP9	0.47	6.57	0.39	2.97e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg06064525	chr11:970664	AP2A2	-0.29	-5.31	-0.32	2.43e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-0.59	-8.15	-0.46	1.86e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg12962167	chr3:53033115	SFMBT1	0.71	5.19	0.31	4.44e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.86	0.35	1.5e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs526231	0.511	rs10515341	chr5:102317117	G/A	cg23492399	chr5:102201601	PAM	-0.49	-5.56	-0.33	7.01e-8	Primary biliary cholangitis;
KIRP	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.12e-11	Bipolar disorder;
KIRP	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg12718519	chr1:2058417	PRKCZ	-0.19	-5.34	-0.32	2.14e-7	Height;
KIRP	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	1.05	11.43	0.59	1.55e-24	Height;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20187825	chr17:79895070	PYCR1	-0.46	-6.07	-0.36	4.75e-9	Myopia;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06976994	chr3:190929946	OSTN	0.42	6.44	0.38	6.12e-10	Migraine with aura;
KIRP	cis	rs4588572	0.779	rs3088102	chr5:77654679	G/A	cg11547950	chr5:77652471	NA	0.53	5.52	0.33	8.71e-8	Triglycerides;
KIRP	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.47	0.43	1.36e-12	Major depressive disorder;
KIRP	cis	rs858239	0.539	rs2178139	chr7:23191636	A/G	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.8	11.73	0.6	1.55e-25	Bladder cancer;
KIRP	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.76	-8.03	-0.46	4.14e-14	Asthma;
KIRP	cis	rs7737355	0.947	rs10067982	chr5:130835940	C/G	cg06307176	chr5:131281290	NA	0.5	5.47	0.33	1.13e-7	Life satisfaction;
KIRP	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg07451762	chr16:28383216	NA	0.42	5.48	0.33	1.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg08847533	chr14:75593920	NEK9	-0.51	-6.26	-0.37	1.71e-9	IgG glycosylation;
KIRP	cis	rs9826463	1.000	rs28709617	chr3:142332635	C/G	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.84	-12.76	-0.63	5.73e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg23594656	chr7:65796392	TPST1	-0.48	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs7520050	0.807	rs28647556	chr1:46206399	G/A	cg24296786	chr1:45957014	TESK2	-0.42	-5.28	-0.32	2.79e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg10756647	chr7:56101905	PSPH	0.99	7.16	0.42	9.02e-12	Diabetic kidney disease;
KIRP	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs4132509	1.000	rs10754807	chr1:243804158	G/A	cg25706552	chr1:244017396	NA	0.58	7.77	0.44	2.16e-13	RR interval (heart rate);
KIRP	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg26531700	chr6:26746687	NA	0.41	5.58	0.34	6.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28489187	0.730	rs12121675	chr1:85798484	A/G	cg16011679	chr1:85725395	C1orf52	0.54	6.52	0.38	3.99e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs240764	0.717	rs10872622	chr6:101165017	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.17	-0.31	4.74e-7	Neuroticism;
KIRP	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15448220	chr1:150897856	SETDB1	0.38	4.93	0.3	1.54e-6	Melanoma;
KIRP	cis	rs4664293	0.836	rs73967923	chr2:160658265	G/A	cg08347373	chr2:160653686	CD302	-0.42	-6.17	-0.37	2.74e-9	Monocyte percentage of white cells;
KIRP	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg19052272	chr2:3704530	ALLC	-0.42	-5.28	-0.32	2.86e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9217	0.841	rs56226499	chr17:7398223	C/T	cg02795151	chr17:7402630	POLR2A	-0.57	-7.03	-0.41	2.05e-11	Height;
KIRP	cis	rs1011018	0.955	rs4132077	chr7:139420225	T/C	cg03224163	chr7:139420300	HIPK2	-0.47	-4.91	-0.3	1.69e-6	Systolic blood pressure;
KIRP	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	14.64	0.68	2.56e-35	Platelet count;
KIRP	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.86	13.02	0.64	7.98e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9815354	1.000	rs1716664	chr3:41948378	G/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.27	-0.32	3.04e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6058796	0.892	rs35103329	chr20:31238139	G/A	cg13636640	chr20:31349939	DNMT3B	0.56	4.85	0.3	2.2e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg16988262	chr1:15930761	NA	0.39	5.16	0.31	5.1e-7	Systolic blood pressure;
KIRP	cis	rs7580658	0.545	rs13001184	chr2:127952206	A/G	cg16751203	chr2:127950803	CYP27C1	0.4	5.62	0.34	5.24e-8	Protein C levels;
KIRP	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.5	5.83	0.35	1.73e-8	Uric acid levels;
KIRP	cis	rs877282	0.898	rs11253353	chr10:766862	C/A	cg17470449	chr10:769945	NA	0.76	7.19	0.42	7.71e-12	Uric acid levels;
KIRP	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.5	7.94	0.45	7.38e-14	Testicular germ cell tumor;
KIRP	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.63	6.93	0.4	3.77e-11	Aortic root size;
KIRP	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.39	-4.89	-0.3	1.82e-6	Coronary artery disease;
KIRP	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg21926883	chr2:100939477	LONRF2	-0.55	-7.58	-0.44	7.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00585698	chr12:123750864	CDK2AP1	0.52	5.52	0.33	8.38e-8	Neutrophil percentage of white cells;
KIRP	cis	rs60871478	0.853	rs62432222	chr7:787194	T/C	cg04727924	chr7:799746	HEATR2	-0.74	-7.7	-0.44	3.38e-13	Cerebrospinal P-tau181p levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01629058	chr22:46692853	CN5H6.4;GTSE1	-0.5	-6.08	-0.36	4.64e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg24315340	chr6:146058215	EPM2A	0.46	5.87	0.35	1.38e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.61	0.6	3.79e-25	Alzheimer's disease;
KIRP	cis	rs4656940	0.574	rs546669	chr1:160768471	C/A	cg17331569	chr1:160788135	LY9	0.43	5.04	0.31	9.1e-7	Crohn's disease;
KIRP	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.42	-4.95	-0.3	1.41e-6	Diabetic retinopathy;
KIRP	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.78	9.68	0.53	5.38e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4638749	0.501	rs3919943	chr2:108758865	G/A	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.04	-0.31	9.07e-7	Blood pressure;
KIRP	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg04013166	chr16:89971882	TCF25	0.67	5.63	0.34	4.83e-8	Skin colour saturation;
KIRP	cis	rs11735612	0.604	rs11939202	chr4:138527880	T/C	cg12033966	chr4:138453416	PCDH18	0.36	4.97	0.3	1.28e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-5.1	-0.31	6.75e-7	Response to bleomycin (chromatid breaks);
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.84	-15.01	-0.69	1.36e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg23594656	chr7:65796392	TPST1	0.47	7.37	0.43	2.61e-12	Aortic root size;
KIRP	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.72	10.47	0.56	1.8e-21	Alcohol dependence;
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19723775	chr5:179050963	HNRNPH1	0.53	6.12	0.36	3.58e-9	Lung cancer;
KIRP	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg06550200	chr5:1325588	CLPTM1L	0.83	11.47	0.59	1.13e-24	Lung cancer;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg03188948	chr7:1209495	NA	0.47	5.52	0.33	8.53e-8	Longevity;Endometriosis;
KIRP	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.14	0.31	5.56e-7	Tonsillectomy;
KIRP	cis	rs6750047	0.546	rs2082255	chr2:38273758	C/A	cg07380506	chr2:38303506	CYP1B1	0.43	5.64	0.34	4.62e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg26875233	chr11:93583750	C11orf90	-0.36	-6.66	-0.39	1.75e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.09	0.31	6.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs1363578	chr5:74510341	C/T	cg03227963	chr5:74354835	NA	0.41	6.0	0.36	6.9e-9	Response to amphetamines;
KIRP	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-8.04	-0.46	3.78e-14	Glomerular filtration rate;
KIRP	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg01620082	chr3:125678407	NA	-0.59	-6.69	-0.39	1.52e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs911119	0.954	rs2254635	chr20:23622758	G/T	cg16589663	chr20:23618590	CST3	0.53	5.75	0.34	2.68e-8	Chronic kidney disease;
KIRP	cis	rs4073416	0.542	rs2898814	chr14:66023961	T/C	cg03016385	chr14:66212404	NA	-0.53	-6.47	-0.38	5.35e-10	N-glycan levels;
KIRP	cis	rs2275565	0.872	rs7527957	chr1:237022870	T/C	cg17297354	chr1:237056641	MTR	-0.4	-5.13	-0.31	5.9e-7	Homocysteine levels;
KIRP	cis	rs10510057	0.614	rs10787981	chr10:121324768	A/G	cg06765389	chr10:121379685	NA	-0.48	-7.51	-0.43	1.07e-12	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg26876637	chr1:152193138	HRNR	0.72	9.37	0.51	4.87e-18	Atopic dermatitis;
KIRP	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.36	0.62	1.28e-27	Smoking behavior;
KIRP	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs72960926	0.590	rs56343698	chr6:74749564	C/T	cg03266952	chr6:74778945	NA	-0.88	-6.0	-0.36	6.85e-9	Metabolite levels (MHPG);
KIRP	cis	rs2904967	0.703	rs541829	chr11:64997737	A/G	cg12562828	chr11:65076843	NA	-0.74	-9.03	-0.5	5.09e-17	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16452678	chr20:10015688	ANKRD5	0.48	6.64	0.39	1.99e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.93e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	1.000	rs2551036	chr5:130648994	G/A	cg25547332	chr5:131281432	NA	0.47	5.26	0.32	3.1e-7	Life satisfaction;
KIRP	cis	rs9653442	0.545	rs11681966	chr2:100759457	A/C	cg22139774	chr2:100720529	AFF3	0.34	5.54	0.33	7.61e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-10.33	-0.55	5.15e-21	Colorectal cancer;
KIRP	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.77	10.31	0.55	6.11e-21	Crohn's disease;
KIRP	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg02038168	chr22:39784481	NA	-0.42	-5.24	-0.32	3.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.65	-9.05	-0.5	4.49e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg05370193	chr1:21551575	ECE1	0.45	6.26	0.37	1.67e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9890032	0.570	rs8068504	chr17:29112070	C/A	cg13385521	chr17:29058706	SUZ12P	0.44	5.16	0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.51	-6.89	-0.4	4.71e-11	Dilated cardiomyopathy;
KIRP	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg25358565	chr5:93447407	FAM172A	-0.59	-6.77	-0.4	9.21e-11	Diabetic retinopathy;
KIRP	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.77	9.93	0.53	9.17e-20	Aortic root size;
KIRP	trans	rs73439953	0.770	rs4496254	chr18:56616346	C/T	cg16116321	chr2:225244609	FAM124B	-0.46	-6.36	-0.38	1e-9	Triptolide cytotoxicity;
KIRP	cis	rs6722613	0.900	rs12104791	chr2:25531207	T/G	cg10614445	chr2:25526696	DNMT3A	-0.32	-5.26	-0.32	3.12e-7	Ossification of the posterior longitudinal ligament of the spine;
KIRP	cis	rs17592366	0.793	rs8010444	chr14:35303630	C/A	cg09327582	chr14:35236912	BAZ1A	0.66	4.99	0.3	1.15e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.89	-0.35	1.29e-8	Pulmonary function;
KIRP	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25951256	chr10:38645740	HSD17B7P2	0.41	4.89	0.3	1.82e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.91	14.14	0.67	1.28e-33	Testicular germ cell tumor;
KIRP	cis	rs1978968	1.000	rs11704827	chr22:18450287	A/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.57	-0.43	7.33e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs9354308	0.753	rs10944854	chr6:66604806	T/A	cg07460842	chr6:66804631	NA	0.43	5.43	0.33	1.33e-7	Metabolite levels;
KIRP	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg14541582	chr5:601475	NA	-0.57	-6.5	-0.38	4.44e-10	Obesity-related traits;
KIRP	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.47	-5.58	-0.34	6.37e-8	Body mass index;
KIRP	cis	rs11967485	0.534	rs72998909	chr6:157167848	G/A	cg23222435	chr6:157204239	ARID1B	-0.66	-5.25	-0.32	3.27e-7	Calcium levels;
KIRP	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.53	7.9	0.45	9.35e-14	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg02836325	chr17:76403955	PGS1	0.38	6.45	0.38	5.95e-10	HDL cholesterol levels;
KIRP	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.9	-10.47	-0.56	1.87e-21	White matter hyperintensity burden;
KIRP	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg12292205	chr6:26970375	C6orf41	0.33	4.87	0.3	2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.68	-7.22	-0.42	6.59e-12	DNA methylation (variation);
KIRP	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg14580859	chr9:123691850	NA	0.35	5.0	0.3	1.08e-6	Rheumatoid arthritis;
KIRP	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12444845	chr8:56685709	TMEM68;TGS1	0.48	6.09	0.36	4.29e-9	Parkinson's disease;
KIRP	cis	rs13359291	1.000	rs13359291	chr5:122476457	G/A	cg16368670	chr5:122501738	PRDM6	-0.51	-6.28	-0.37	1.54e-9	Systolic blood pressure;
KIRP	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.76	9.78	0.53	2.67e-19	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg20623943	chr1:47799834	CMPK1	0.49	6.2	0.37	2.35e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	9.54	0.52	1.45e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs7122257	0.507	rs11043112	chr11:11151583	C/T	cg16931664	chr11:11169707	NA	-0.45	-6.32	-0.37	1.23e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.2	0.31	4.26e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg22117172	chr7:91764530	CYP51A1	0.41	5.76	0.34	2.5e-8	Breast cancer;
KIRP	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg15083037	chr5:83017644	HAPLN1	-0.64	-8.98	-0.5	7.18e-17	Prostate cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00172189	chr18:45364325	SMAD2	-0.42	-6.24	-0.37	1.87e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg07274523	chr3:49395745	GPX1	0.69	8.34	0.47	5.4e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg19592336	chr6:28129416	ZNF389	-0.52	-5.96	-0.36	8.78e-9	Depression;
KIRP	cis	rs12435908	1.000	rs74611500	chr14:66009789	C/T	cg23373153	chr14:65346875	NA	-0.53	-4.89	-0.3	1.8e-6	Ischemic stroke;
KIRP	cis	rs5743618	0.537	rs10019853	chr4:38765291	T/C	cg06935464	chr4:38784597	TLR10	0.4	4.96	0.3	1.34e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2387326	1.000	rs12252465	chr10:129932395	G/A	cg16087940	chr10:129947807	NA	-0.46	-6.05	-0.36	5.48e-9	Select biomarker traits;
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg25487775	chr2:162093969	NA	0.44	5.93	0.35	1.04e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs4356932	1.000	rs4859415	chr4:76956528	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.83	-12.11	-0.61	8.38e-27	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.71	8.94	0.5	9.63e-17	Red blood cell count;
KIRP	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-4.99	-0.3	1.12e-6	Pulmonary function;
KIRP	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	0.87	9.87	0.53	1.47e-19	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4908768	0.906	rs12401496	chr1:8600401	C/T	cg25722041	chr1:8623473	RERE	0.8	9.87	0.53	1.4e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg16141378	chr3:129829833	LOC729375	0.61	8.25	0.47	9.73e-15	Retinal vascular caliber;
KIRP	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	5.73	0.34	2.94e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13108043	0.605	rs35886751	chr4:87935533	T/G	cg11209507	chr4:87813803	C4orf36	0.45	4.87	0.3	2e-6	Red blood cell count;
KIRP	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg04218760	chr10:45406644	TMEM72	-0.24	-6.28	-0.37	1.56e-9	Mean corpuscular volume;
KIRP	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	11.22	0.58	7.42e-24	Monocyte percentage of white cells;
KIRP	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg05709478	chr1:6581295	PLEKHG5	-0.64	-6.33	-0.37	1.16e-9	Body mass index;
KIRP	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-8.67	-0.48	6.12e-16	Morning vs. evening chronotype;
KIRP	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.35	-11.02	-0.57	3.23e-23	Alzheimer's disease (late onset);
KIRP	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.41	-5.67	-0.34	4.06e-8	Endometrial cancer;
KIRP	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg14789911	chr21:47582049	C21orf56	-0.4	-4.99	-0.3	1.16e-6	Testicular germ cell tumor;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14984066	chr15:22946914	CYFIP1	0.44	6.31	0.37	1.3e-9	Survival in pancreatic cancer;
KIRP	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.9	-0.35	1.18e-8	Breast cancer;
KIRP	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.98	-11.15	-0.58	1.22e-23	Colorectal cancer;
KIRP	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg26929925	chr5:138714136	SLC23A1	0.38	5.35	0.32	2.03e-7	Esophageal squamous cell carcinoma;
KIRP	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	7.24	0.42	5.89e-12	Caffeine consumption;
KIRP	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs12230513	0.732	rs61956300	chr12:55812640	T/G	cg11794356	chr12:55725991	OR6C3	-0.51	-6.26	-0.37	1.72e-9	Contrast sensitivity;
KIRP	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.42	5.11	0.31	6.32e-7	Diastolic blood pressure;
KIRP	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg15212455	chr7:39170539	POU6F2	0.26	5.95	0.35	9.05e-9	IgG glycosylation;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg07701084	chr6:150067640	NUP43	0.7	9.88	0.53	1.33e-19	Lung cancer;
KIRP	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.27	-22.09	-0.82	2.59e-60	Breast cancer;
KIRP	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-0.39	-4.96	-0.3	1.33e-6	Type 2 diabetes;
KIRP	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg14458575	chr2:238380390	NA	0.55	5.9	0.35	1.2e-8	Prostate cancer;
KIRP	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg22778903	chr21:42741698	MX2	-0.6	-7.95	-0.45	6.94e-14	Melanoma;
KIRP	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg15893493	chr8:124194847	FAM83A	0.87	7.64	0.44	4.81e-13	Urinary uromodulin levels;
KIRP	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.35	5.41	0.33	1.46e-7	Calcium levels;
KIRP	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-7.42	-0.43	1.85e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.6	0.66	8.93e-32	Electrocardiographic conduction measures;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13763729	chr18:5294883	ZFP161	0.47	6.06	0.36	4.96e-9	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.69	0.48	5.25e-16	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00020052	chr2:68546899	CNRIP1	0.5	6.49	0.38	4.7e-10	Smoking initiation;
KIRP	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.59	7.16	0.42	9.16e-12	Colorectal cancer;
KIRP	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg02378861	chr5:212933	CCDC127	-0.75	-5.84	-0.35	1.64e-8	Fat distribution (HIV);
KIRP	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg07382826	chr16:28625726	SULT1A1	0.51	5.82	0.35	1.87e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg10047753	chr17:41438598	NA	1.16	18.5	0.76	1.75e-48	Menopause (age at onset);
KIRP	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.46	5.99	0.36	7.6e-9	Hypertriglyceridemia;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.8	14.29	0.67	4.04e-34	Height;
KIRP	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg10223061	chr2:219282414	VIL1	-0.33	-5.4	-0.33	1.54e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19853194	chr18:9913725	VAPA	-0.52	-6.86	-0.4	5.42e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-5.26	-0.32	3.1e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9815354	1.000	rs9869440	chr3:41763155	G/C	cg03022575	chr3:42003672	ULK4	0.48	5.29	0.32	2.67e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg17554472	chr22:41940697	POLR3H	0.41	4.94	0.3	1.44e-6	Vitiligo;
KIRP	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.84	-9.7	-0.53	4.76e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	7.37	0.43	2.55e-12	Height;
KIRP	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-8.04	-0.46	3.86e-14	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs2562456	0.916	rs1967182	chr19:21603139	C/G	cg18461458	chr19:21324796	ZNF431	-0.54	-5.15	-0.31	5.22e-7	Pain;
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.94	-0.35	9.58e-9	Obesity-related traits;
KIRP	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.13	0.31	6e-7	Parkinson's disease;
KIRP	cis	rs3204270	0.639	rs62080199	chr17:79627906	T/G	cg18367735	chr17:79674897	NA	0.69	6.29	0.37	1.46e-9	Dental caries;
KIRP	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.1	0.31	6.76e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg25418670	chr11:30344373	C11orf46	0.6	5.07	0.31	7.92e-7	Morning vs. evening chronotype;
KIRP	cis	rs2742417	1.000	rs2742454	chr3:45766222	T/A	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	2.97e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg15590007	chr10:45870220	ALOX5	-0.55	-5.36	-0.32	1.9e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg07001201	chr5:642380	CEP72	0.7	6.58	0.39	2.74e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2230307	0.572	rs514090	chr1:100563186	C/G	cg24955406	chr1:100503596	HIAT1	0.66	7.52	0.43	1.01e-12	Carotid intima media thickness;
KIRP	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs1891275	0.515	rs2421694	chr10:93516104	A/G	cg07889827	chr10:93443413	NA	-0.44	-7.43	-0.43	1.8e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06544989	chr22:39130855	UNC84B	0.52	8.31	0.47	6.32e-15	Menopause (age at onset);
KIRP	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.87	0.3	2.04e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9473924	0.542	rs6901576	chr6:50926064	G/T	cg14470998	chr6:50812995	TFAP2B	-0.81	-7.66	-0.44	4.17e-13	Body mass index;
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.67	0.34	3.96e-8	Lung cancer;
KIRP	cis	rs1629083	0.875	rs1617182	chr11:118068949	C/T	cg18857871	chr11:118064634	AMICA1	0.68	9.48	0.52	2.26e-18	Lung cancer;
KIRP	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.69	-0.34	3.59e-8	Life satisfaction;
KIRP	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg20243544	chr17:37824526	PNMT	-0.4	-4.96	-0.3	1.3e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09149974	chr10:94754429	EXOC6	-0.41	-6.2	-0.37	2.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.76	9.65	0.52	6.9e-19	Neutrophil percentage of white cells;
KIRP	cis	rs9381107	0.932	rs9380836	chr6:9441421	A/G	cg14735645	chr6:9486422	NA	-0.44	-5.45	-0.33	1.19e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17376030	chr22:41985996	PMM1	-0.79	-7.89	-0.45	9.98e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-6.63	-0.39	2.15e-10	Menarche (age at onset);
KIRP	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.64	-6.26	-0.37	1.72e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.74	6.79	0.4	8.5e-11	Mean platelet volume;
KIRP	cis	rs74181299	0.684	rs1420183	chr2:65309988	A/G	cg05010058	chr2:65284262	CEP68	-0.42	-5.7	-0.34	3.35e-8	Pulse pressure;
KIRP	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.48	-6.15	-0.36	3.15e-9	IgG glycosylation;
KIRP	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.42	-0.51	3.4e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg01656853	chr19:49199172	FUT2	0.34	4.86	0.3	2.08e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs4765905	1.000	rs4765905	chr12:2349584	C/G	cg10668781	chr12:2307325	CACNA1C	-0.28	-5.14	-0.31	5.67e-7	Schizophrenia;
KIRP	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	0.96	8.2	0.46	1.3e-14	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6959887	1.000	rs7797172	chr7:35295831	A/G	cg06685737	chr7:35301730	NA	0.45	6.66	0.39	1.78e-10	Birth weight;
KIRP	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg12315302	chr6:26189340	HIST1H4D	0.87	6.22	0.37	2.15e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1420338	0.867	rs7795950	chr7:34161715	A/G	cg01275685	chr7:34179230	BMPER	-0.51	-7.39	-0.43	2.35e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.37	2e-9	Aortic root size;
KIRP	cis	rs447921	0.773	rs11077821	chr17:74455579	C/T	cg16776035	chr17:74542680	NA	-0.58	-5.99	-0.36	7.36e-9	Mitochondrial DNA levels;
KIRP	cis	rs4356932	0.656	rs6826085	chr4:76870229	C/T	cg00809888	chr4:76862425	NAAA	-0.5	-7.14	-0.41	1.06e-11	Blood protein levels;
KIRP	cis	rs9815354	0.812	rs73077373	chr3:41852887	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7213347	0.581	rs7209460	chr17:2048713	C/T	cg15816464	chr17:2026533	SMG6	0.44	6.59	0.39	2.66e-10	Total body bone mineral density;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06348081	chr3:182511312	ATP11B	0.53	6.38	0.38	8.69e-10	Myopia (pathological);
KIRP	cis	rs4764487	0.685	rs740839	chr12:6338637	C/T	cg08284733	chr12:6341482	CD9	0.58	9.55	0.52	1.35e-18	Mean platelet volume;
KIRP	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg16586182	chr3:47516702	SCAP	-0.63	-8.75	-0.49	3.37e-16	Colorectal cancer;
KIRP	cis	rs9535307	0.584	rs61961501	chr13:50392956	A/G	cg04663916	chr13:50265991	EBPL	-0.64	-6.13	-0.36	3.38e-9	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19586698	chr8:92097851	OTUD6B	-0.48	-7.72	-0.44	2.99e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg18154014	chr19:37997991	ZNF793	0.58	5.27	0.32	3.06e-7	Coronary artery calcification;
KIRP	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.74	8.0	0.45	4.78e-14	Gut microbiome composition (summer);
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	13.83	0.66	1.43e-32	Platelet count;
KIRP	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.96	15.27	0.7	1.8e-37	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg23594656	chr7:65796392	TPST1	0.51	7.88	0.45	1.04e-13	Aortic root size;
KIRP	cis	rs12580194	0.593	rs61957887	chr12:55721734	C/T	cg19537932	chr12:55886519	OR6C68	-0.5	-6.68	-0.39	1.62e-10	Cancer;
KIRP	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.48	5.79	0.35	2.11e-8	Alzheimer's disease (late onset);
KIRP	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.71	6.11	0.36	3.88e-9	Diabetic retinopathy;
KIRP	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg05861140	chr6:150128134	PCMT1	-0.51	-7.15	-0.41	9.93e-12	Lung cancer;
KIRP	cis	rs4654899	0.714	rs12123093	chr1:21114416	C/T	cg08890418	chr1:21044141	KIF17	0.33	4.85	0.3	2.17e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1894292	0.645	rs13142786	chr4:74477135	T/A	cg12566645	chr4:74483141	RASSF6	0.37	5.06	0.31	8.2e-7	Prostate cancer;
KIRP	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.67	8.82	0.49	2.11e-16	Longevity;
KIRP	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.44	2.77e-13	Neuroticism;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg15365367	chr14:20811805	PARP2;RPPH1	0.51	6.34	0.37	1.1e-9	Colorectal cancer;
KIRP	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.6	-7.01	-0.41	2.3e-11	Menarche (age at onset);
KIRP	cis	rs494562	0.892	rs683218	chr6:86118584	A/G	cg27039625	chr6:86159096	NT5E	0.44	5.75	0.34	2.67e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.26e-18	Bladder cancer;
KIRP	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg04369109	chr6:150039330	LATS1	-0.64	-7.65	-0.44	4.46e-13	Lung cancer;
KIRP	cis	rs829661	0.793	rs2121600	chr2:30842625	T/C	cg10949345	chr2:30726833	LCLAT1	1.08	12.88	0.63	2.28e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs9928842	0.540	rs8051363	chr16:75255217	A/G	cg09066997	chr16:75300724	BCAR1	0.45	5.1	0.31	6.72e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs145445141	1	rs145445141	chr1:67489169	ATT/A	cg02640540	chr1:67518911	SLC35D1	0.7	5.91	0.35	1.13e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9323205	0.765	rs2999386	chr14:51652628	G/T	cg23942311	chr14:51606299	NA	0.64	8.9	0.49	1.25e-16	Cancer;
KIRP	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg14675211	chr2:100938903	LONRF2	0.44	5.42	0.33	1.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9584850	0.834	rs17574378	chr13:99116384	T/C	cg20750642	chr13:99100586	FARP1	-0.49	-5.93	-0.35	1.02e-8	Neuroticism;
KIRP	cis	rs7084402	0.967	rs1649043	chr10:60328209	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg06212747	chr3:49208901	KLHDC8B	0.87	13.23	0.64	1.48e-30	Menarche (age at onset);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg06649899	chr16:67261154	TMEM208;LRRC29	0.48	6.08	0.36	4.51e-9	Asthma;
KIRP	cis	rs2274273	0.934	rs10137307	chr14:55845185	T/C	cg04306507	chr14:55594613	LGALS3	0.4	5.95	0.35	9.01e-9	Protein biomarker;
KIRP	cis	rs4523957	0.890	rs9908888	chr17:2102453	G/C	cg16513277	chr17:2031491	SMG6	-0.68	-9.59	-0.52	1.02e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.65	-0.34	4.45e-8	Bipolar disorder;
KIRP	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.49	0.62	4.56e-28	Ileal carcinoids;
KIRP	cis	rs12643440	1.000	rs12643440	chr4:17221233	C/T	cg22650099	chr4:17144496	NA	-0.51	-6.15	-0.37	3.06e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg23601095	chr6:26197514	HIST1H3D	1.03	8.43	0.47	2.95e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12924262	chr12:102091054	CHPT1	0.49	6.32	0.37	1.23e-9	Blood protein levels;
KIRP	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.51	-7.61	-0.44	5.88e-13	IgG glycosylation;
KIRP	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.61	-9.6	-0.52	9.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg08989290	chr16:615782	NHLRC4	0.4	5.92	0.35	1.07e-8	Height;
KIRP	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg18404041	chr3:52824283	ITIH1	-0.38	-4.92	-0.3	1.56e-6	Bipolar disorder;
KIRP	cis	rs17023223	0.537	rs1325940	chr1:119586687	G/A	cg05756136	chr1:119680316	WARS2	-0.56	-7.56	-0.43	7.93e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	9.7	0.53	4.85e-19	Post bronchodilator FEV1;
KIRP	cis	rs7923609	0.934	rs7923544	chr10:65182256	T/G	cg01631684	chr10:65280961	REEP3	-0.5	-5.77	-0.35	2.35e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13047869	chr3:10149882	C3orf24	0.52	4.91	0.3	1.69e-6	Alzheimer's disease;
KIRP	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.67	5.79	0.35	2.18e-8	Cognitive function;
KIRP	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.74	7.71	0.44	3.19e-13	Uric acid levels;
KIRP	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	1.04	14.23	0.67	6.33e-34	Menopause (age at onset);
KIRP	cis	rs1010254	0.510	rs55726523	chr5:151756407	C/T	cg12297329	chr5:152029980	NA	-0.71	-6.88	-0.4	4.98e-11	Optic nerve measurement (cup area);
KIRP	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.42	-0.38	6.96e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg17554472	chr22:41940697	POLR3H	-0.44	-5.05	-0.31	8.62e-7	Neuroticism;
KIRP	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg20701182	chr2:24300061	SF3B14	0.93	10.43	0.55	2.46e-21	Lymphocyte counts;
KIRP	cis	rs1215050	0.846	rs1839903	chr4:98791414	C/T	cg17366294	chr4:99064904	C4orf37	0.38	5.01	0.3	1.06e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg27068330	chr11:65405492	SIPA1	0.38	5.18	0.31	4.67e-7	Acne (severe);
KIRP	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg15893493	chr8:124194847	FAM83A	0.83	7.09	0.41	1.38e-11	Urinary uromodulin levels;
KIRP	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.56	7.61	0.44	5.78e-13	Gout;
KIRP	cis	rs8044868	0.548	rs12930702	chr16:72077000	C/G	cg16558253	chr16:72132732	DHX38	-0.41	-5.45	-0.33	1.21e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg02175503	chr12:58329896	NA	0.68	7.9	0.45	9.08e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.7	-8.93	-0.49	1e-16	Menopause (age at onset);
KIRP	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.53	13.51	0.65	1.69e-31	Airflow obstruction;
KIRP	trans	rs194045	0.609	rs252344	chr16:29184882	G/A	cg17334114	chr3:133646504	NA	0.57	6.63	0.39	2.14e-10	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.0	-0.41	2.45e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg05802129	chr4:122689817	NA	-0.58	-7.33	-0.42	3.27e-12	Type 2 diabetes;
KIRP	cis	rs7246657	0.722	rs2927747	chr19:38159530	C/T	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs1043515	0.748	rs11653487	chr17:36942631	A/G	cg20826740	chr17:37024042	NA	-0.35	-4.87	-0.3	1.95e-6	Height;
KIRP	cis	rs6142102	0.961	rs4911393	chr20:32570926	A/G	cg08999081	chr20:33150536	PIGU	0.49	6.37	0.38	8.99e-10	Skin pigmentation;
KIRP	cis	rs2274273	0.840	rs2009291	chr14:55838230	A/C	cg04306507	chr14:55594613	LGALS3	-0.51	-7.99	-0.45	5.33e-14	Protein biomarker;
KIRP	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.04	0.36	5.77e-9	Morning vs. evening chronotype;
KIRP	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.69	-6.58	-0.39	2.86e-10	Opioid sensitivity;
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.6	0.52	1e-18	Lung cancer;
KIRP	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.64	0.56	5.51e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg24565620	chr2:194026	NA	0.78	8.42	0.47	3.11e-15	Blood protein levels;
KIRP	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg19847130	chr8:10466454	RP1L1	-0.4	-6.27	-0.37	1.59e-9	Neuroticism;
KIRP	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00958927	chr1:175162553	KIAA0040	-0.29	-4.96	-0.3	1.31e-6	Alcohol dependence;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg22975147	chr17:8021903	ALOXE3	-0.49	-6.22	-0.37	2.15e-9	Neuroticism;
KIRP	cis	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg21546286	chr11:48923668	NA	-0.44	-5.63	-0.34	4.85e-8	HDL cholesterol;
KIRP	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg19468946	chr17:37922297	IKZF3	-0.46	-6.66	-0.39	1.74e-10	Asthma;
KIRP	trans	rs4775041	0.961	rs11858759	chr15:58676821	G/A	cg21369679	chr16:47007757	DNAJA2	0.56	6.38	0.38	8.81e-10	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.41	-6.35	-0.38	1.03e-9	Colorectal cancer;
KIRP	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg02151108	chr14:50098012	C14orf104	-0.47	-6.14	-0.36	3.32e-9	Carotid intima media thickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07742499	chr19:55851016	SUV420H2	0.54	6.86	0.4	5.62e-11	Parkinson's disease;
KIRP	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg10047753	chr17:41438598	NA	1.16	18.75	0.77	2.5e-49	Menopause (age at onset);
KIRP	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg09873164	chr1:152488093	CRCT1	0.56	7.11	0.41	1.24e-11	Hair morphology;
KIRP	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.77	-10.35	-0.55	4.5e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.91	-0.45	8.82e-14	Personality dimensions;
KIRP	cis	rs12586317	0.576	rs10146445	chr14:35631553	C/T	cg07166546	chr14:35805898	NA	-0.27	-6.4	-0.38	7.89e-10	Psoriasis;
KIRP	cis	rs4006360	0.542	rs9900575	chr17:39307675	C/T	cg15015397	chr17:39261100	KRTAP4-9	0.39	5.24	0.32	3.51e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg18501202	chr6:125855421	NA	-0.35	-5.39	-0.33	1.62e-7	Brugada syndrome;
KIRP	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.67	-8.59	-0.48	1.03e-15	Extraversion;
KIRP	cis	rs62024995	0.735	rs35223575	chr15:98705084	G/C	cg16735875	chr15:99367484	IGF1R	0.58	5.49	0.33	1.01e-7	White matter hyperintensity burden;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23104823	chr14:45553408	PRPF39	0.53	7.06	0.41	1.73e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.78	-9.91	-0.53	1.06e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.11e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg08999081	chr20:33150536	PIGU	-0.41	-5.29	-0.32	2.68e-7	Height;
KIRP	cis	rs4851254	0.550	rs13402299	chr2:100659409	C/T	cg17356467	chr2:100759845	AFF3	0.55	5.91	0.35	1.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23281280	chr6:28129359	ZNF389	0.5	5.35	0.32	2.04e-7	Depression;
KIRP	cis	rs7904368	0.754	rs12253908	chr10:16853358	T/C	cg14835575	chr10:16859367	RSU1	0.77	9.32	0.51	6.89e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.03	0.5	5.24e-17	Colorectal cancer;
KIRP	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg16865965	chr2:85811662	VAMP5	0.34	5.1	0.31	6.91e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.89	-14.98	-0.69	1.71e-36	Height;
KIRP	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg26898376	chr11:64110657	CCDC88B	0.52	6.39	0.38	8.11e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs13014235	0.532	rs13029007	chr2:202264877	G/T	cg06431681	chr2:202330990	STRADB	0.39	5.26	0.32	3.17e-7	Basal cell carcinoma;
KIRP	cis	rs687432	0.688	rs12804808	chr11:57892312	C/G	cg19752551	chr11:57585705	CTNND1	-0.6	-8.05	-0.46	3.63e-14	Parkinson's disease;
KIRP	cis	rs11997175	0.575	rs56942690	chr8:33820308	G/A	cg04338863	chr8:33670619	NA	0.4	5.15	0.31	5.26e-7	Body mass index;
KIRP	cis	rs1511802	0.666	rs62350519	chr4:187119701	G/A	cg24794857	chr4:187113578	CYP4V2	0.38	5.3	0.32	2.61e-7	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07832834	chr1:2457954	PANK4	0.51	6.64	0.39	1.95e-10	Parkinson's disease;
KIRP	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.41	-0.33	1.49e-7	Aortic root size;
KIRP	cis	rs477895	0.582	rs71456310	chr11:64128494	C/T	cg04317338	chr11:64019027	PLCB3	0.76	5.41	0.33	1.51e-7	Mean platelet volume;
KIRP	cis	rs918629	0.679	rs58921760	chr5:95270865	A/C	cg16656078	chr5:95278638	ELL2	-0.47	-6.78	-0.4	8.86e-11	IgG glycosylation;
KIRP	cis	rs7129556	0.859	rs11237215	chr11:77247515	G/A	cg12586386	chr11:77299805	AQP11	0.41	5.48	0.33	1.07e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02359409	chr6:42947317	PEX6	-0.51	-7.04	-0.41	1.88e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs45430	0.928	rs398206	chr21:42742036	C/A	cg22778903	chr21:42741698	MX2	0.61	7.92	0.45	8.2e-14	Melanoma;
KIRP	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs757110	1.000	rs757110	chr11:17418477	C/A	cg15432903	chr11:17409602	KCNJ11	0.74	11.03	0.58	3.11e-23	Type 2 diabetes;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.85	8.02	0.46	4.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.56	7.03	0.41	2.03e-11	Arsenic metabolism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03052760	chr1:35738702	ZMYM4	-0.41	-6.21	-0.37	2.24e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1712517	0.740	rs11191663	chr10:105118462	C/T	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.41e-9	Migraine;
KIRP	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg11833968	chr6:79620685	NA	-0.46	-6.94	-0.4	3.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs3136516	0.537	rs752850	chr11:47175150	A/G	cg16389345	chr11:46697382	NA	0.5	6.21	0.37	2.29e-9	Venous thromboembolism;
KIRP	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg04609801	chr16:28609176	SULT1A2	-0.57	-5.61	-0.34	5.57e-8	Platelet distribution width;
KIRP	cis	rs7104764	0.507	rs7111364	chr11:258542	G/C	cg00562011	chr11:252351	PSMD13	-0.52	-6.55	-0.39	3.36e-10	Menarche (age at onset);
KIRP	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.05	-0.46	3.61e-14	Aortic root size;
KIRP	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.62	8.69	0.48	5.34e-16	Menarche (age at onset);
KIRP	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg02002194	chr4:3960332	NA	-0.46	-7.05	-0.41	1.83e-11	Mood instability;
KIRP	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg06885757	chr1:42089581	HIVEP3	0.64	9.94	0.54	8.72e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg13319975	chr6:146136371	FBXO30	-0.4	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg09455208	chr3:40491958	NA	-0.36	-6.66	-0.39	1.81e-10	Renal cell carcinoma;
KIRP	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg23950597	chr19:37808831	NA	-0.64	-6.61	-0.39	2.42e-10	Coronary artery calcification;
KIRP	cis	rs8103278	0.826	rs11669442	chr19:46374557	A/G	cg11657440	chr19:46296263	DMWD	-0.54	-6.45	-0.38	5.84e-10	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.51e-16	Life satisfaction;
KIRP	trans	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	7.8	0.45	1.77e-13	Hemoglobin concentration;
KIRP	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.66	-8.17	-0.46	1.6e-14	Aortic root size;
KIRP	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.36	0.38	9.6e-10	Educational attainment;
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs13223928	0.631	rs12531881	chr7:3156842	C/T	cg19214707	chr7:3157722	NA	-0.7	-8.78	-0.49	2.75e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	cg12689670	chr1:183009347	LAMC1	0.41	5.9	0.35	1.21e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg21680719	chr1:38466677	FHL3	-0.22	-4.91	-0.3	1.69e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs2172802	0.570	rs4860424	chr4:62537309	A/G	cg04118610	chr4:62707027	LPHN3	-0.45	-5.54	-0.33	7.95e-8	Partial epilepsies;
KIRP	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg19077165	chr18:44547161	KATNAL2	0.5	6.5	0.38	4.39e-10	Educational attainment;
KIRP	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.16	-0.5	2.15e-17	Neuroticism;
KIRP	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.62	6.89	0.4	4.52e-11	Aortic root size;
KIRP	cis	rs3825932	0.961	rs10400877	chr15:79234378	A/T	cg25744700	chr15:79237217	CTSH	0.43	5.28	0.32	2.86e-7	Type 1 diabetes;
KIRP	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10468482	0.615	rs7221716	chr17:8159232	A/G	cg06726167	chr17:8076949	TMEM107	0.6	5.73	0.34	2.85e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg25547332	chr5:131281432	NA	0.47	5.41	0.33	1.52e-7	Life satisfaction;
KIRP	cis	rs6968419	0.755	rs17138486	chr7:115894403	C/G	cg02561103	chr7:115862891	TES	-0.41	-5.82	-0.35	1.83e-8	Intraocular pressure;
KIRP	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.54	13.36	0.65	5.67e-31	Airflow obstruction;
KIRP	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg03161606	chr19:29218774	NA	0.65	6.27	0.37	1.57e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-5.96	-0.36	8.64e-9	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs17123764	0.818	rs17123808	chr12:49979413	C/T	cg20471783	chr12:50157085	TMBIM6	0.32	5.02	0.3	9.88e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg22715398	chr15:52968154	KIAA1370	0.63	6.93	0.4	3.77e-11	Schizophrenia;
KIRP	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg13819577	chr1:248512075	OR14C36	-0.39	-5.25	-0.32	3.24e-7	Common traits (Other);
KIRP	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg21187068	chr8:144659627	NAPRT1	0.74	5.05	0.31	8.51e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.69	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg10756647	chr7:56101905	PSPH	0.99	7.25	0.42	5.45e-12	Diabetic kidney disease;
KIRP	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.92	10.1	0.54	2.67e-20	Menarche (age at onset);
KIRP	trans	rs2826891	0.603	rs2739379	chr21:23021849	G/A	cg18742814	chr1:41828276	NA	-0.39	-6.04	-0.36	5.71e-9	Longevity;
KIRP	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg09873164	chr1:152488093	CRCT1	0.5	6.25	0.37	1.84e-9	Hair morphology;
KIRP	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.48	4.84	0.3	2.26e-6	Alzheimer's disease;
KIRP	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg24972876	chr7:65420302	NA	0.41	5.58	0.34	6.44e-8	Calcium levels;
KIRP	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-6.37	-0.38	9.04e-10	Aortic root size;
KIRP	cis	rs397969	0.646	rs17604987	chr17:19867331	A/T	cg13482628	chr17:19912719	NA	-0.43	-5.0	-0.3	1.09e-6	Platelet count;
KIRP	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.98	-15.98	-0.71	6.79e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.22	-0.37	2.15e-9	Neuroticism;
KIRP	cis	rs743757	1.000	rs743857	chr3:50493550	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	5.62	0.34	5.23e-8	Diastolic blood pressure;
KIRP	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg05347473	chr6:146136440	FBXO30	0.44	5.94	0.35	9.66e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg21573476	chr21:45109991	RRP1B	-0.67	-9.83	-0.53	1.95e-19	Mean corpuscular volume;
KIRP	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg03289416	chr15:75166202	SCAMP2	0.43	6.05	0.36	5.26e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.82	-0.4	7.2e-11	Immature fraction of reticulocytes;
KIRP	cis	rs9815354	0.904	rs4621303	chr3:41839370	T/A	cg03022575	chr3:42003672	ULK4	0.48	5.42	0.33	1.42e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9398803	0.865	rs2152876	chr6:126761228	A/G	cg19875578	chr6:126661172	C6orf173	-0.5	-6.55	-0.39	3.36e-10	Male-pattern baldness;
KIRP	cis	rs17033621	0.967	rs1524294	chr2:107612295	G/A	cg17818308	chr2:107502146	ST6GAL2	-0.37	-4.88	-0.3	1.88e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg05973401	chr12:123451056	ABCB9	0.57	6.57	0.39	2.94e-10	Neutrophil percentage of white cells;
KIRP	trans	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg00938859	chr5:1591904	SDHAP3	-0.59	-7.86	-0.45	1.19e-13	Breast cancer;
KIRP	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21385522	chr1:16154831	NA	0.43	5.45	0.33	1.21e-7	Systolic blood pressure;
KIRP	cis	rs719152	0.836	rs10770135	chr11:10707740	T/C	cg07356130	chr11:10772521	CTR9	0.45	4.86	0.3	2.06e-6	Mean platelet volume;
KIRP	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.52	0.33	8.48e-8	Total cholesterol levels;
KIRP	cis	rs12208915	0.848	rs7774691	chr6:79505798	C/G	cg18132916	chr6:79620363	NA	0.53	4.98	0.3	1.22e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs17453880	0.781	rs17113485	chr5:151978353	A/G	cg12297329	chr5:152029980	NA	-0.68	-10.16	-0.54	1.77e-20	Subjective well-being;
KIRP	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg10017260	chr10:834428	NA	-0.5	-4.88	-0.3	1.87e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs8077577	0.747	rs62072540	chr17:18225228	G/A	cg18869244	chr17:18121946	NA	0.44	4.99	0.3	1.15e-6	Obesity-related traits;
KIRP	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg01294253	chr9:136912663	BRD3	-0.39	-5.26	-0.32	3.17e-7	Platelet distribution width;
KIRP	cis	rs7849270	1.000	rs10819471	chr9:131896325	A/C	cg13538475	chr9:131942899	NA	-0.34	-5.39	-0.33	1.63e-7	Blood metabolite ratios;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09529150	chr10:22615839	BMI1	-0.39	-6.45	-0.38	5.83e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs787274	0.850	rs10733598	chr9:115615329	G/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.69	-0.39	1.53e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.76	10.23	0.55	1.09e-20	Menarche (age at onset);
KIRP	cis	rs2014572	0.904	rs10412465	chr19:57753931	T/C	cg12963866	chr19:57752005	ZNF805	-0.48	-6.0	-0.36	7.16e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs10924970	0.967	rs10925270	chr1:235425875	C/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11200358	chr6:24719988	C6orf62	0.48	6.91	0.4	4.04e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg20991723	chr1:152506922	NA	-0.45	-5.43	-0.33	1.34e-7	Hair morphology;
KIRP	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	0.73	9.26	0.51	1.08e-17	Vitiligo;
KIRP	cis	rs4664293	0.867	rs7566802	chr2:160584991	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15481429	chr15:94945799	MCTP2	-0.47	-6.09	-0.36	4.22e-9	Inflammatory biomarkers;
KIRP	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	0.5	6.55	0.39	3.34e-10	Systemic lupus erythematosus;
KIRP	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.53	-7.34	-0.42	3.2e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	6.34	0.37	1.08e-9	Total cholesterol levels;
KIRP	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.84	16.09	0.72	2.76e-40	Anterior chamber depth;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg15105011	chr4:940614	TMEM175	0.52	8.41	0.47	3.3e-15	Sjögren's syndrome;
KIRP	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.79	11.45	0.59	1.26e-24	Parkinson's disease;
KIRP	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg16950941	chr11:66035639	RAB1B	0.4	4.98	0.3	1.22e-6	Gout;
KIRP	cis	rs7766436	0.848	rs11759474	chr6:22580980	G/T	cg13666174	chr6:22585274	NA	-0.45	-5.75	-0.34	2.64e-8	Coronary artery disease;
KIRP	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.59	-8.39	-0.47	3.89e-15	Testicular germ cell tumor;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14121472	chr12:2934143	ITFG2	0.54	6.27	0.37	1.62e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.68	10.53	0.56	1.24e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	8.69	0.48	5.3e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6732160	0.774	rs1367291	chr2:73374865	A/T	cg01422370	chr2:73384389	NA	0.41	5.51	0.33	8.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg15117754	chr3:10150083	C3orf24	0.62	5.09	0.31	7.01e-7	Alzheimer's disease;
KIRP	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.59	-7.44	-0.43	1.7e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.61	8.23	0.46	1.13e-14	Blood protein levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15840638	chr15:79298691	RASGRF1	0.53	6.46	0.38	5.56e-10	Interleukin-4 levels;
KIRP	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg00360474	chr6:37504404	NA	-0.46	-6.24	-0.37	1.88e-9	Cognitive performance;
KIRP	cis	rs2997447	0.501	rs2783635	chr1:26434527	T/C	cg19633962	chr1:26362018	EXTL1	-0.49	-4.88	-0.3	1.92e-6	QRS complex (12-leadsum);
KIRP	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.81	10.46	0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg18478394	chr8:109455254	TTC35	0.52	6.05	0.36	5.25e-9	Dupuytren's disease;
KIRP	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg02297831	chr4:17616191	MED28	0.53	6.6	0.39	2.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4234798	0.933	rs7678751	chr4:7219035	A/G	cg18431297	chr4:7219810	SORCS2	0.59	8.01	0.45	4.51e-14	Insulin-like growth factors;
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg23693289	chr8:27183097	PTK2B	-0.56	-7.19	-0.42	7.98e-12	Neuroticism;
KIRP	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02972257	chr16:68554789	NA	-0.72	-7.06	-0.41	1.68e-11	Ulcerative colitis;
KIRP	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-1.07	-7.75	-0.44	2.41e-13	Obesity-related traits;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.89	-9.64	-0.52	7.22e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	6.9	0.4	4.43e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg20701182	chr2:24300061	SF3B14	1.01	10.81	0.57	1.59e-22	Lymphocyte counts;
KIRP	cis	rs10782582	0.758	rs5745559	chr1:76379517	A/C	cg10523679	chr1:76189770	ACADM	-0.36	-5.12	-0.31	6.27e-7	Daytime sleep phenotypes;
KIRP	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.43	0.33	1.36e-7	Educational attainment (years of education);
KIRP	cis	rs28669119	0.778	rs585950	chr5:88099671	C/T	cg18498987	chr5:88179539	MEF2C	-0.53	-6.5	-0.38	4.54e-10	Schizophrenia;
KIRP	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.44	-6.06	-0.36	5.05e-9	Monocyte count;
KIRP	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.65	7.78	0.44	1.97e-13	Type 2 diabetes;
KIRP	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg01097406	chr16:89675127	NA	-0.32	-5.17	-0.31	4.95e-7	Vitiligo;
KIRP	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg00631329	chr6:26305371	NA	0.54	6.76	0.4	1e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.45	0.33	1.2e-7	Bipolar disorder;
KIRP	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg16388071	chr6:169726476	NA	-0.38	-5.16	-0.31	5.08e-7	Obesity-related traits;
KIRP	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.19	0.37	2.47e-9	Red blood cell count;
KIRP	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.72	0.49	4.31e-16	Prudent dietary pattern;
KIRP	cis	rs7395581	0.877	rs7127907	chr11:47324472	A/C	cg25783544	chr11:47291846	MADD	0.44	5.07	0.31	7.94e-7	HDL cholesterol;
KIRP	cis	rs507080	0.961	rs1784298	chr11:118548665	T/C	cg04173919	chr11:118528438	PHLDB1	0.33	4.87	0.3	1.98e-6	Serum metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17070338	chr13:111268441	CARKD	0.45	6.04	0.36	5.55e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg01097406	chr16:89675127	NA	-0.29	-4.93	-0.3	1.53e-6	Vitiligo;
KIRP	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.62	6.64	0.39	1.95e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.67	9.0	0.5	6.27e-17	Total body bone mineral density;
KIRP	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.91	13.28	0.65	1.08e-30	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs675026	0.927	rs544205	chr6:154425290	G/A	cg07813322	chr6:154414604	OPRM1	-0.45	-5.92	-0.35	1.07e-8	Hypertension;
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.25	-0.32	3.29e-7	Life satisfaction;
KIRP	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.73	11.0	0.57	3.86e-23	Blood metabolite ratios;
KIRP	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.55	6.95	0.41	3.19e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-7.77	-0.44	2.1e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.71	-7.22	-0.42	6.44e-12	Vitiligo;
KIRP	cis	rs4742903	0.527	rs1349375	chr9:106969043	T/C	cg14250997	chr9:106856677	SMC2	0.37	4.89	0.3	1.85e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg01763666	chr17:80159506	CCDC57	0.46	5.04	0.31	9.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg18833306	chr6:118973337	C6orf204	-0.46	-4.91	-0.3	1.68e-6	Diastolic blood pressure;
KIRP	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.75	11.53	0.59	6.95e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13082711	0.911	rs35605663	chr3:27515754	C/T	cg02860705	chr3:27208620	NA	0.48	6.61	0.39	2.37e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs3755132	0.929	rs3755133	chr2:15731583	C/T	cg12888861	chr2:15731646	DDX1	0.41	5.51	0.33	9.2e-8	Wilms tumor;
KIRP	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9309473	0.898	rs11126404	chr2:73796924	T/A	cg20560298	chr2:73613845	ALMS1	-0.43	-4.93	-0.3	1.5e-6	Metabolite levels;
KIRP	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.84	0.35	1.65e-8	Aortic root size;
KIRP	cis	rs7818345	0.935	rs7016259	chr8:19277530	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.38	0.38	8.95e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.9	-12.41	-0.62	9.06e-28	Schizophrenia;
KIRP	cis	rs56161922	1.000	rs74692669	chr1:207818120	G/C	cg09557387	chr1:207818395	CR1L	1.08	6.51	0.38	4.2e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs4560672	1.000	rs78146749	chr6:158591288	C/G	cg14029994	chr6:158589857	SERAC1;GTF2H5	-0.56	-4.96	-0.3	1.33e-6	Smoking quantity;
KIRP	cis	rs4523957	0.553	rs2131703	chr17:2025360	G/T	cg16513277	chr17:2031491	SMG6	-0.84	-12.62	-0.63	1.8e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12431939	0.948	rs12435444	chr14:51656071	C/T	cg23942311	chr14:51606299	NA	-0.6	-5.46	-0.33	1.18e-7	Cancer;
KIRP	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05025164	chr4:1340916	KIAA1530	0.53	6.94	0.4	3.56e-11	Obesity-related traits;
KIRP	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.81	-8.46	-0.47	2.41e-15	Gut microbiome composition (summer);
KIRP	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg11062466	chr8:58055876	NA	0.62	5.64	0.34	4.61e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.18e-11	Blood metabolite levels;
KIRP	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.6	-7.61	-0.44	6e-13	Corneal astigmatism;
KIRP	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg26422059	chr2:237146110	ASB18	0.46	5.19	0.31	4.42e-7	Educational attainment;
KIRP	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.55	0.39	3.43e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9815354	1.000	rs73081353	chr3:41906448	T/A	cg03022575	chr3:42003672	ULK4	0.64	6.79	0.4	8.29e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	1.04	19.56	0.78	4.84e-52	Height;
KIRP	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.29	7.75	0.44	2.39e-13	Crohn's disease;
KIRP	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg22903471	chr2:27725779	GCKR	-0.52	-7.38	-0.43	2.37e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.48	-4.87	-0.3	2.03e-6	Neutrophil percentage of white cells;
KIRP	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg04731861	chr2:219085781	ARPC2	-0.28	-7.16	-0.42	9.28e-12	Colorectal cancer;
KIRP	cis	rs10484885	0.588	rs9344947	chr6:90304789	A/G	cg13799429	chr6:90582589	CASP8AP2	0.56	6.01	0.36	6.66e-9	QRS interval (sulfonylurea treatment interaction);
KIRP	trans	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg24644049	chr4:85504048	CDS1	0.97	6.49	0.38	4.75e-10	Skin colour saturation;
KIRP	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05472934	chr7:22766657	IL6	0.47	6.78	0.4	9.11e-11	Lung cancer;
KIRP	cis	rs7656342	0.755	rs6810736	chr4:9879728	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.91	0.3	1.63e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.2	-0.55	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.76	10.56	0.56	9.48e-22	Leprosy;
KIRP	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.48	7.36	0.42	2.83e-12	Resting heart rate;
KIRP	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.66	-7.19	-0.42	7.72e-12	Vitiligo;
KIRP	cis	rs7119	0.700	rs4886519	chr15:77893885	A/G	cg12131826	chr15:77904385	NA	-0.49	-6.27	-0.37	1.61e-9	Type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.49	6.76	0.4	9.81e-11	Red blood cell count;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs2273669	0.667	rs11153139	chr6:109279381	C/T	cg05315195	chr6:109294784	ARMC2	-0.56	-5.93	-0.35	9.98e-9	Prostate cancer;
KIRP	cis	rs911119	0.866	rs2405393	chr20:23569392	G/C	cg09631192	chr20:23583594	CST9	-0.48	-5.1	-0.31	6.85e-7	Chronic kidney disease;
KIRP	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.36	0.42	2.69e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs10761482	0.566	rs7092863	chr10:62180882	C/T	cg01186212	chr10:62110162	ANK3	-0.32	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.32	-0.42	3.45e-12	Response to antipsychotic treatment;
KIRP	cis	rs2591576	1.000	rs2591576	chr5:165408059	A/G	cg13976338	chr5:165423657	NA	0.75	10.3	0.55	6.63e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.53	5.84	0.35	1.65e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.56	-7.38	-0.43	2.44e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3818717	0.539	rs12950737	chr17:17678573	G/A	cg01246520	chr17:17644344	RAI1	-0.33	-5.23	-0.32	3.55e-7	Lymphocyte counts;
KIRP	cis	rs12210905	1.000	rs9368498	chr6:27254006	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.8	-5.91	-0.35	1.13e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9584850	0.834	rs2031239	chr13:99111560	C/T	cg20750642	chr13:99100586	FARP1	-0.52	-6.27	-0.37	1.63e-9	Neuroticism;
KIRP	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg24315340	chr6:146058215	EPM2A	0.39	4.93	0.3	1.53e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.53	-7.1	-0.41	1.35e-11	Post bronchodilator FEV1;
KIRP	cis	rs72634030	0.536	rs72634029	chr17:5268113	G/T	cg20802942	chr17:5185005	RABEP1	0.5	5.02	0.3	9.88e-7	Rheumatoid arthritis;
KIRP	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg17108064	chr15:78857060	CHRNA5	0.37	5.25	0.32	3.33e-7	Sudden cardiac arrest;
KIRP	cis	rs16828019	0.777	rs67460888	chr1:41469337	T/C	cg18742814	chr1:41828276	NA	0.68	5.71	0.34	3.29e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7011049	1.000	rs72648403	chr8:53854848	T/C	cg26025543	chr8:53854495	NA	0.75	7.77	0.44	2.19e-13	Systolic blood pressure;
KIRP	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.24	0.51	1.21e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg21523564	chr15:75251491	NA	0.47	8.1	0.46	2.52e-14	Breast cancer;
KIRP	cis	rs8060686	0.920	rs16942887	chr16:67928042	G/A	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.01	-0.3	1.03e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.37	7.36	0.42	2.74e-12	IgG glycosylation;
KIRP	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg17888390	chr10:101282816	NA	-0.27	-4.84	-0.3	2.24e-6	Dental caries;
KIRP	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.61	6.03	0.36	5.99e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.35	0.38	1.03e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.51	7.15	0.41	9.81e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg13206674	chr6:150067644	NUP43	0.51	7.23	0.42	6.17e-12	Testicular germ cell tumor;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg26465743	chr13:77901232	MYCBP2	0.54	6.9	0.4	4.36e-11	Educational attainment;
KIRP	cis	rs7709377	0.595	rs253959	chr5:115568757	T/C	cg23108291	chr5:115420582	COMMD10	0.44	5.29	0.32	2.75e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg17833184	chr10:135191291	PAOX	0.69	4.85	0.3	2.17e-6	Lifespan;
KIRP	cis	rs1147199	0.585	rs7468983	chr9:87247277	C/T	cg22402007	chr9:87282823	NTRK2	0.4	4.96	0.3	1.33e-6	Body mass index;
KIRP	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.97	-14.55	-0.68	5.24e-35	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.61	-7.56	-0.43	8.1e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.4	-5.57	-0.33	6.58e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06659073	chr6:158589307	SERAC1;GTF2H5	0.47	6.08	0.36	4.62e-9	Parkinson's disease;
KIRP	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	7.29	0.42	4.29e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02725872	chr8:58115012	NA	-0.76	-9.15	-0.5	2.26e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.77	12.19	0.61	4.68e-27	Coronary artery disease;
KIRP	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.55	5.43	0.33	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9810890	1.000	rs73208001	chr3:128602864	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.65	-9.82	-0.53	1.99e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.65	9.35	0.51	5.64e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08492202	chr8:42911315	FNTA	-0.49	-6.66	-0.39	1.79e-10	Survival in pancreatic cancer;
KIRP	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.42	-6.05	-0.36	5.42e-9	Height;
KIRP	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs882732	1.000	rs882732	chr14:95027722	G/A	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.57	-0.33	6.63e-8	Blood protein levels;
KIRP	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	1.06	14.88	0.69	3.66e-36	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20913106	chr8:38324522	FGFR1	0.53	6.56	0.39	3.22e-10	Smoking initiation;
KIRP	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg20026190	chr17:76395443	PGS1	0.51	6.6	0.39	2.48e-10	HDL cholesterol levels;
KIRP	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21545522	chr1:205238299	TMCC2	0.41	5.54	0.33	7.91e-8	Red blood cell count;
KIRP	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.51	8.16	0.46	1.69e-14	IgG glycosylation;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg27261837	chr1:146714163	CHD1L	-0.52	-6.59	-0.39	2.68e-10	Neuroticism;
KIRP	trans	rs1840108	0.733	rs36093148	chr2:181442277	T/G	cg25649188	chr17:73499917	CASKIN2	0.74	6.14	0.36	3.22e-9	Anti-saccade response;
KIRP	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg15432903	chr11:17409602	KCNJ11	0.44	6.2	0.37	2.32e-9	Body mass index;Social communication problems;
KIRP	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.55	0.33	7.49e-8	Alzheimer's disease;
KIRP	trans	rs1106684	1.000	rs58010278	chr7:131460787	T/C	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs9900972	0.918	rs8065102	chr17:76876735	T/C	cg00961940	chr17:76876995	TIMP2	0.53	6.76	0.4	9.99e-11	Obesity-related traits;
KIRP	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg17554472	chr22:41940697	POLR3H	0.68	6.94	0.4	3.5e-11	Vitiligo;
KIRP	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-6.28	-0.37	1.49e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg03060546	chr3:49711283	APEH	-0.6	-5.26	-0.32	3.13e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12826209	chr6:26865740	GUSBL1	0.67	6.04	0.36	5.6e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.63	-8.01	-0.46	4.46e-14	Iron status biomarkers;
KIRP	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.93	-12.78	-0.63	4.88e-29	Cognitive function;
KIRP	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.46	7.62	0.44	5.36e-13	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg07701084	chr6:150067640	NUP43	0.7	8.64	0.48	7.2e-16	Lung cancer;
KIRP	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg23594656	chr7:65796392	TPST1	-0.44	-6.04	-0.36	5.67e-9	Aortic root size;
KIRP	cis	rs926392	0.640	rs2867899	chr20:37694622	C/A	cg16355469	chr20:37678765	NA	0.59	7.13	0.41	1.14e-11	Dialysis-related mortality;
KIRP	trans	rs17834760	0.955	rs6920752	chr6:62059244	T/C	cg08476511	chr6:168435923	KIF25	0.51	6.09	0.36	4.25e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg08890418	chr1:21044141	KIF17	0.35	5.29	0.32	2.67e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.65	5.99	0.36	7.31e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.91	0.35	1.15e-8	Menopause (age at onset);
KIRP	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-5.9	-0.35	1.22e-8	LDL cholesterol levels;
KIRP	cis	rs3790645	1.000	rs369385	chr1:26893229	C/T	cg23229016	chr1:26872525	RPS6KA1	0.23	6.15	0.37	3.1e-9	Glucose homeostasis traits;
KIRP	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg24253500	chr15:84953950	NA	0.55	6.11	0.36	3.94e-9	Schizophrenia;
KIRP	trans	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.43	-0.43	1.75e-12	Atopic dermatitis;
KIRP	trans	rs13170463	0.579	rs34585271	chr5:8046796	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs6539288	0.745	rs2041895	chr12:107350088	C/G	cg21360079	chr12:107162445	NA	-0.39	-5.06	-0.31	8.07e-7	Total body bone mineral density;
KIRP	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.53	-6.16	-0.37	2.97e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg02023728	chr11:77925099	USP35	-0.29	-4.89	-0.3	1.79e-6	Alzheimer's disease (survival time);
KIRP	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-11.69	-0.6	2.16e-25	Glomerular filtration rate (creatinine);
KIRP	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg16141378	chr3:129829833	LOC729375	-0.57	-6.9	-0.4	4.41e-11	Mood instability;
KIRP	cis	rs9788682	0.792	rs2869032	chr15:78714561	C/T	cg24631222	chr15:78858424	CHRNA5	-0.95	-10.7	-0.56	3.57e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg13010199	chr12:38710504	ALG10B	-0.67	-8.83	-0.49	1.95e-16	Morning vs. evening chronotype;
KIRP	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.56	15.11	0.69	6.22e-37	Airflow obstruction;
KIRP	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.46	-9.36	-0.51	5.25e-18	Rheumatoid arthritis;
KIRP	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.45	5.66	0.34	4.22e-8	Lymphocyte counts;
KIRP	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.68	10.29	0.55	7.09e-21	Blood metabolite ratios;
KIRP	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	6.99	0.41	2.65e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg00938859	chr5:1591904	SDHAP3	0.59	7.83	0.45	1.45e-13	Breast cancer;
KIRP	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.03	0.54	4.49e-20	Coffee consumption (cups per day);
KIRP	cis	rs4356932	1.000	rs6848603	chr4:76973521	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.67	8.3	0.47	6.87e-15	Blood metabolite levels;
KIRP	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.68	7.3	0.42	4.06e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-5.86	-0.35	1.51e-8	Fear of minor pain;
KIRP	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.73	9.28	0.51	8.99e-18	Coronary artery disease;
KIRP	trans	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs9303542	0.694	rs4793854	chr17:46572133	A/G	cg04904318	chr17:46607828	HOXB1	0.41	5.07	0.31	7.7300000000000005e-07	Ovarian cancer;Epithelial ovarian cancer;
KIRP	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg13010199	chr12:38710504	ALG10B	0.62	7.59	0.44	6.47e-13	Morning vs. evening chronotype;
KIRP	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	1.05	9.13	0.5	2.65e-17	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06869039	chr8:12838022	C8orf79	-0.41	-6.42	-0.38	7.07e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.17	0.5	1.91e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg26585981	chr11:48327164	OR4S1	-0.42	-5.32	-0.32	2.32e-7	Height;
KIRP	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.35	-0.32	2.02e-7	Post bronchodilator FEV1;
KIRP	cis	rs240764	0.817	rs240146	chr6:101078718	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.39	0.38	8.19e-10	Breast cancer;
KIRP	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.61	8.17	0.46	1.68e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4936894	0.500	rs11219502	chr11:124084433	A/G	cg27160556	chr11:124181099	OR8D1	-0.46	-6.59	-0.39	2.59e-10	Aging (time to death);
KIRP	cis	rs33912345	0.695	rs1254314	chr14:60896434	G/C	cg27398547	chr14:60952738	C14orf39	-0.41	-5.59	-0.34	6.13e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.38	-0.47	4.06e-15	Platelet count;
KIRP	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg14403583	chr14:105418241	AHNAK2	0.68	9.31	0.51	7.64e-18	Rheumatoid arthritis;
KIRP	cis	rs4273100	0.790	rs60606605	chr17:19277144	G/A	cg18093559	chr17:18951025	GRAP	-0.54	-5.05	-0.31	8.49e-7	Schizophrenia;
KIRP	cis	rs6504950	0.679	rs9897646	chr17:52985351	G/C	cg26251398	chr17:52985966	TOM1L1	0.44	5.85	0.35	1.54e-8	Breast cancer;
KIRP	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.88	12.59	0.63	2.22e-28	Mean platelet volume;
KIRP	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.95	0.5	8.59e-17	Colorectal cancer;
KIRP	cis	rs58688157	0.921	rs35600572	chr11:617214	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.64	-7.73	-0.44	2.71e-13	Systemic lupus erythematosus;
KIRP	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg24009623	chr19:33667908	NA	0.48	6.27	0.37	1.61e-9	Bone properties (heel);
KIRP	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.71	0.44	3.1e-13	Coffee consumption (cups per day);
KIRP	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.32	-0.37	1.2e-9	Response to antipsychotic treatment;
KIRP	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03375212	chr4:39368138	RFC1	-0.54	-6.79	-0.4	8.4e-11	Interleukin-4 levels;
KIRP	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7033996	1.000	rs16932791	chr9:35946784	A/G	cg00918944	chr9:35908117	LOC158376	0.38	5.34	0.32	2.12e-7	Urate levels (BMI interaction);
KIRP	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.86	9.01	0.5	5.77e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14598338	chr9:96623480	NA	-0.68	-11.7	-0.6	1.96e-25	DNA methylation (variation);
KIRP	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.77	10.45	0.55	2.19e-21	Response to bleomycin (chromatid breaks);
KIRP	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg11234688	chr2:1609660	NA	0.61	5.44	0.33	1.28e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg02073558	chr3:44770973	ZNF501	0.73	11.73	0.6	1.51e-25	Depressive symptoms;
KIRP	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg22189786	chr22:42395067	WBP2NL	0.46	5.83	0.35	1.75e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg12435725	chr3:58293450	RPP14	-0.5	-5.18	-0.31	4.68e-7	Cholesterol, total;
KIRP	cis	rs2223471	0.546	rs548180	chr6:50584306	C/A	cg03432817	chr6:50765336	NA	-0.36	-5.29	-0.32	2.73e-7	Subcutaneous adipose tissue;
KIRP	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.15	0.46	1.89e-14	Schizophrenia;
KIRP	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg02023728	chr11:77925099	USP35	0.43	6.16	0.37	2.97e-9	Testicular germ cell tumor;
KIRP	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.68	0.48	5.45e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg23307798	chr14:103986281	CKB	-0.5	-6.77	-0.4	9.26e-11	Coronary artery disease;
KIRP	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05472934	chr7:22766657	IL6	0.82	10.54	0.56	1.15e-21	Lung cancer;
KIRP	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.49	5.72	0.34	3.14e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs7551222	0.752	rs11240756	chr1:204482594	C/T	cg20240347	chr1:204465584	NA	-0.46	-8.75	-0.49	3.42e-16	Schizophrenia;
KIRP	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg06064525	chr11:970664	AP2A2	-0.37	-7.59	-0.44	6.45e-13	Alzheimer's disease (late onset);
KIRP	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.29	0.37	1.43e-9	Educational attainment;
KIRP	cis	rs6725041	0.571	rs4619547	chr2:213052177	G/T	cg20637307	chr2:213403960	ERBB4	-0.4	-5.26	-0.32	3.13e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg25811766	chr13:21894605	NA	-0.62	-6.39	-0.38	8.08e-10	White matter hyperintensity burden;
KIRP	cis	rs1620921	0.505	rs13199812	chr6:161201960	T/C	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs42648	0.755	rs1557650	chr7:89971556	A/C	cg25739043	chr7:89950458	NA	-0.44	-6.92	-0.4	3.92e-11	Homocysteine levels;
KIRP	cis	rs7923609	0.967	rs10509186	chr10:65207018	C/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02413627	chr15:66313056	MEGF11	0.55	6.5	0.38	4.44e-10	Interleukin-4 levels;
KIRP	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.34	0.65	6.59e-31	Electrocardiographic conduction measures;
KIRP	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05351357	chr22:49932778	NA	-0.36	-5.0	-0.3	1.07e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	trans	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg06521331	chr12:34319734	NA	-0.59	-7.1	-0.41	1.34e-11	Bladder cancer;
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg08901578	chr4:187885870	NA	0.55	9.24	0.51	1.23e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	5.44	0.33	1.25e-7	Platelet count;
KIRP	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.51	5.37	0.32	1.81e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.63	0.34	4.97e-8	Aortic root size;
KIRP	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs4862307	0.754	rs6846208	chr4:184991703	C/T	cg06737308	chr4:185021514	ENPP6	0.54	6.92	0.4	3.93e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg13409248	chr3:40428643	ENTPD3	-0.37	-5.21	-0.32	4.06e-7	Renal cell carcinoma;
KIRP	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg18190219	chr22:46762943	CELSR1	-0.88	-7.29	-0.42	4.27e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19700328	chr14:106028568	NA	-0.61	-6.73	-0.39	1.2e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg12756686	chr19:29218302	NA	0.57	5.36	0.32	1.9e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg00079375	chr15:79125835	NA	0.39	5.62	0.34	5.2100000000000003e-08	Coronary artery disease;
KIRP	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.81	-10.03	-0.54	4.61e-20	Blood protein levels;
KIRP	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12595433	0.522	rs2035713	chr15:63287273	T/C	cg03196360	chr15:63270641	NA	-0.29	-5.45	-0.33	1.22e-7	Obesity-related traits;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg21734707	chr17:3908241	ZZEF1	0.66	10.19	0.54	1.4e-20	Type 2 diabetes;
KIRP	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.56	7.15	0.41	1e-11	Aortic root size;
KIRP	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg13736514	chr6:26305472	NA	-0.7	-8.63	-0.48	7.81e-16	Educational attainment;
KIRP	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg11707556	chr5:10655725	ANKRD33B	0.69	8.58	0.48	1.12e-15	Coronary artery disease;
KIRP	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.45	-6.37	-0.38	9.08e-10	Coronary artery disease;
KIRP	cis	rs6088813	0.961	rs6088791	chr20:33907909	A/G	cg14752227	chr20:34000481	UQCC	0.47	6.01	0.36	6.58e-9	Height;
KIRP	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.68	9.24	0.51	1.19e-17	Coronary artery disease;
KIRP	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.64	-0.34	4.73e-8	Parkinson's disease;
KIRP	cis	rs1971762	0.712	rs7302232	chr12:53965423	A/T	cg16917193	chr12:54089295	NA	0.67	10.86	0.57	1.08e-22	Height;
KIRP	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg03647239	chr10:116582469	FAM160B1	0.51	5.92	0.35	1.05e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg05973401	chr12:123451056	ABCB9	0.64	7.76	0.44	2.33e-13	Platelet count;
KIRP	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.29	25.15	0.85	6.24e-70	IgG glycosylation;
KIRP	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.51	-7.61	-0.44	5.88e-13	IgG glycosylation;
KIRP	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg23982607	chr1:1823379	GNB1	-0.84	-14.85	-0.69	4.68e-36	Body mass index;
KIRP	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg04731861	chr2:219085781	ARPC2	0.27	6.88	0.4	5.06e-11	Colorectal cancer;
KIRP	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg25922239	chr6:33757077	LEMD2	0.65	8.39	0.47	3.78e-15	Crohn's disease;
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg01763666	chr17:80159506	CCDC57	0.37	5.03	0.31	9.4e-7	Life satisfaction;
KIRP	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.98	-11.21	-0.58	7.71e-24	Exhaled nitric oxide output;
KIRP	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.6	-7.48	-0.43	1.33e-12	Prudent dietary pattern;
KIRP	cis	rs10131728	0.892	rs12891586	chr14:81712844	C/G	cg01989461	chr14:81687754	GTF2A1	-0.76	-6.01	-0.36	6.81e-9	IgG glycosylation;
KIRP	cis	rs7737355	0.738	rs3776001	chr5:130957992	T/A	cg25547332	chr5:131281432	NA	0.4	4.98	0.3	1.19e-6	Life satisfaction;
KIRP	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg03235661	chr20:60525775	NA	-0.29	-4.92	-0.3	1.62e-6	Body mass index;
KIRP	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs35771425	1.000	rs12740755	chr1:211591669	C/G	cg10512769	chr1:211675356	NA	-0.51	-5.1	-0.31	6.66e-7	Educational attainment (years of education);
KIRP	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg17133734	chr15:86042851	AKAP13	-0.41	-5.13	-0.31	5.97e-7	Interstitial lung disease;
KIRP	cis	rs7010267	1.000	rs7010267	chr8:119946656	A/C	cg01975934	chr8:119970761	NA	-0.43	-5.78	-0.35	2.3e-8	Total body bone mineral density (age 45-60);
KIRP	cis	rs644148	0.933	rs565819	chr19:44967714	A/G	cg15540054	chr19:45004280	ZNF180	0.65	7.26	0.42	5.02e-12	Personality dimensions;
KIRP	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.76	-11.93	-0.61	3.48e-26	Rheumatoid arthritis;
KIRP	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg23093090	chr10:104574429	C10orf26	0.37	5.91	0.35	1.12e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.59	7.36	0.42	2.79e-12	Tonsillectomy;
KIRP	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg01559446	chr3:44596178	ZNF167	-0.35	-4.93	-0.3	1.53e-6	Depressive symptoms;
KIRP	cis	rs6504950	0.745	rs12603899	chr17:53010098	T/C	cg26251398	chr17:52985966	TOM1L1	0.45	6.06	0.36	5.11e-9	Breast cancer;
KIRP	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.88	0.49	1.46e-16	Bipolar disorder;
KIRP	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg13373371	chr19:49828787	SLC6A16	0.43	5.24	0.32	3.44e-7	Multiple sclerosis;
KIRP	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg23533926	chr12:111358616	MYL2	-0.48	-6.35	-0.38	1.01e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.71	-10.44	-0.55	2.34e-21	Orofacial clefts;
KIRP	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.93	12.48	0.62	5.27e-28	Coronary artery disease;
KIRP	cis	rs6545883	0.860	rs777589	chr2:61425621	T/C	cg15711740	chr2:61764176	XPO1	-0.57	-7.44	-0.43	1.66e-12	Tuberculosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15676371	chr5:176518013	FGFR4	-0.43	-6.15	-0.37	3.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4959799	0.557	rs9503514	chr6:3271703	A/G	cg03657281	chr6:3270030	SLC22A23	0.78	6.03	0.36	6.04e-9	Survival in rectal cancer;
KIRP	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.52	-6.2	-0.37	2.37e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.44	6.19	0.37	2.45e-9	Testicular germ cell tumor;
KIRP	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.99	16.34	0.72	3.74e-41	Menopause (age at onset);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg15980914	chr19:28297092	NA	-0.62	-6.28	-0.37	1.55e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs12752838	0.777	rs11121246	chr1:8917102	T/G	cg06972019	chr1:8937448	ENO1	-0.34	-4.99	-0.3	1.14e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg14930904	chr10:32216787	ARHGAP12	0.38	4.94	0.3	1.47e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.53	-6.8	-0.4	7.8e-11	Type 2 diabetes;
KIRP	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2273669	0.504	rs3813499	chr6:109497085	G/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.04	-0.31	9e-7	Prostate cancer;
KIRP	trans	rs2048656	0.524	rs12543959	chr8:9539000	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.55	-0.39	3.26e-10	Schizophrenia;
KIRP	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.4	-0.47	3.57e-15	Total cholesterol levels;
KIRP	cis	rs7923609	0.967	rs7912893	chr10:65162000	T/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg20243544	chr17:37824526	PNMT	0.54	7.99	0.45	5.31e-14	Asthma;
KIRP	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg13456812	chr6:167369504	RNASET2	0.53	6.26	0.37	1.66e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs501120	0.584	rs1746042	chr10:44731897	C/T	cg09554077	chr10:44749378	NA	0.7	7.78	0.44	2.03e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7172677	0.737	rs12910348	chr15:75437642	A/G	cg14664628	chr15:75095509	CSK	-0.55	-6.08	-0.36	4.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg03160526	chr17:80928410	B3GNTL1	0.42	5.21	0.32	3.99e-7	Glycated hemoglobin levels;
KIRP	cis	rs2997447	0.846	rs3008418	chr1:26403098	G/A	cg19633962	chr1:26362018	EXTL1	-0.49	-4.88	-0.3	1.91e-6	QRS complex (12-leadsum);
KIRP	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg25233709	chr10:116636983	FAM160B1	0.34	5.23	0.32	3.59e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg08131204	chr22:41487073	MIR1281	-0.43	-4.98	-0.3	1.2e-6	Neuroticism;
KIRP	cis	rs6466055	0.501	rs6965384	chr7:104603112	A/G	cg04380332	chr7:105027541	SRPK2	-0.62	-9.17	-0.5	2e-17	Schizophrenia;
KIRP	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7870753	0.838	rs10991367	chr9:99253933	T/C	cg25260653	chr9:99212216	HABP4	0.54	5.92	0.35	1.05e-8	Height;
KIRP	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg17691542	chr6:26056736	HIST1H1C	0.96	10.47	0.56	1.88e-21	Iron status biomarkers;
KIRP	cis	rs12230513	0.732	rs60643523	chr12:55842928	A/G	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs68170813	0.522	rs12154818	chr7:107074515	G/C	cg02696742	chr7:106810147	HBP1	-0.49	-5.05	-0.31	8.64e-7	Coronary artery disease;
KIRP	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.71	10.06	0.54	3.74e-20	Caffeine consumption;
KIRP	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	13.1	0.64	4.08e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.42	9.15	0.5	2.26e-17	Mean corpuscular volume;
KIRP	cis	rs4742903	0.935	rs10120101	chr9:107000909	C/T	cg14250997	chr9:106856677	SMC2	0.37	4.97	0.3	1.28e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7127900	0.561	rs7115232	chr11:2229361	G/A	cg25635251	chr11:2234043	NA	0.44	6.98	0.41	2.73e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg26695010	chr11:65641043	EFEMP2	0.45	5.21	0.32	4.06e-7	Eosinophil percentage of white cells;
KIRP	cis	rs35955747	0.633	rs5998012	chr22:31889844	G/A	cg02404636	chr22:31891804	SFI1	-0.41	-5.45	-0.33	1.22e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.04	-0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.82	0.45	1.53e-13	Aortic root size;
KIRP	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.56	8.82	0.49	2.13e-16	Coronary artery disease;
KIRP	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg24579218	chr15:68104479	NA	-0.54	-7.81	-0.45	1.66e-13	Restless legs syndrome;
KIRP	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg09571762	chr12:39539558	NA	-0.33	-4.91	-0.3	1.64e-6	Morning vs. evening chronotype;
KIRP	cis	rs16974263	1.000	rs16974263	chr19:40913539	A/G	cg14588209	chr19:40950453	SERTAD3	-0.53	-5.76	-0.34	2.51e-8	Otitis media;Otitis media (chronic);Otitis media (recurrent);
KIRP	cis	rs7534824	0.543	rs6693339	chr1:101424431	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.69	-6.79	-0.4	8.32e-11	Refractive astigmatism;
KIRP	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.66	-0.39	1.75e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02475777	chr4:1388615	CRIPAK	-0.53	-6.8	-0.4	7.91e-11	Obesity-related traits;
KIRP	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.75	-7.96	-0.45	6.43e-14	Asthma;
KIRP	cis	rs4129585	1.000	rs4129585	chr8:143312933	A/C	cg16886403	chr8:143471632	TSNARE1	0.47	5.04	0.31	9.12e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6102059	0.598	rs4812443	chr20:39198836	T/G	cg06665391	chr20:39312290	NA	0.44	5.43	0.33	1.33e-7	LDL cholesterol;
KIRP	cis	rs4783244	0.862	rs736718	chr16:82656425	A/C	cg09415485	chr16:82663111	CDH13	0.29	5.59	0.34	5.88e-8	Adiponectin levels;
KIRP	cis	rs9547996	0.879	rs9547940	chr13:38129403	A/G	cg13634560	chr13:38173852	POSTN	-0.41	-5.7	-0.34	3.35e-8	Diastolic blood pressure;
KIRP	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.66	-8.35	-0.47	5.02e-15	Extraversion;
KIRP	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.67	7.91	0.45	8.98e-14	Corneal astigmatism;
KIRP	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg21361702	chr7:150065534	REPIN1	0.61	6.16	0.37	2.9e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg00360474	chr6:37504404	NA	-0.5	-7.41	-0.43	2.01e-12	Cognitive performance;
KIRP	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.44	-5.1	-0.31	6.65e-7	Schizophrenia;
KIRP	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg14664628	chr15:75095509	CSK	-0.64	-7.71	-0.44	3.1400000000000003e-13	Caffeine consumption;
KIRP	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02034447	chr16:89574710	SPG7	0.4	5.09	0.31	7.04e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs11790131	0.742	rs12336917	chr9:19471205	A/G	cg21157465	chr1:11020631	C1orf127	-0.51	-6.17	-0.37	2.82e-9	Liver fibrosis severity in HIV/hepatitis C co-infection;
KIRP	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg11569703	chr11:65557185	OVOL1	0.57	9.88	0.53	1.34e-19	Acne (severe);
KIRP	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.91	13.43	0.65	3.33e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.64	-8.33	-0.47	5.77e-15	Prudent dietary pattern;
KIRP	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13728813	chr4:110634374	PLA2G12A	-0.46	-6.96	-0.41	3.13e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.76	-10.65	-0.56	4.88e-22	Waist circumference;Body mass index;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.63	9.2	0.51	1.62e-17	Longevity;Endometriosis;
KIRP	cis	rs1355223	0.902	rs1578622	chr11:34725915	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.03	-0.31	9.44e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26513850	chr22:51038720	MAPK8IP2	-0.57	-6.67	-0.39	1.72e-10	Menopause (age at onset);
KIRP	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg00982548	chr2:198649783	BOLL	-0.54	-5.57	-0.33	6.7e-8	Ulcerative colitis;
KIRP	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg17376030	chr22:41985996	PMM1	-0.52	-6.32	-0.37	1.2e-9	Vitiligo;
KIRP	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.46	-6.6	-0.39	2.44e-10	Coronary artery disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16029838	chr7:44530503	NUDCD3	-0.89	-6.29	-0.37	1.47e-9	P wave terminal force;
KIRP	cis	rs17095355	1.000	rs975442	chr10:111705895	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.98	-0.36	7.88e-9	Biliary atresia;
KIRP	cis	rs4851254	0.920	rs13011874	chr2:100752497	C/T	cg17356467	chr2:100759845	AFF3	0.61	7.33	0.42	3.26e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg19743168	chr1:23544995	NA	0.51	7.17	0.42	8.74e-12	Height;
KIRP	cis	rs981844	1.000	rs72731672	chr4:154664925	G/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.26e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs11168351	0.927	rs11168342	chr12:48383797	G/T	cg21466736	chr12:48725269	NA	-0.4	-5.02	-0.3	9.86e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.35	0.42	2.88e-12	Exhaled nitric oxide output;
KIRP	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.79	-0.45	1.83e-13	Total cholesterol levels;
KIRP	cis	rs885389	0.924	rs7957882	chr12:131617417	G/T	cg06374807	chr12:131606857	GPR133	-0.44	-5.84	-0.35	1.63e-8	RR interval (heart rate);
KIRP	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.33	5.96	0.35	8.92e-9	Migraine;
KIRP	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.84	10.54	0.56	1.12e-21	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13939156	chr17:80058883	NA	0.52	7.74	0.44	2.57e-13	Life satisfaction;
KIRP	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.48	-5.97	-0.36	8.02e-9	Prudent dietary pattern;
KIRP	trans	rs7729273	0.913	rs12515060	chr5:7191601	G/C	cg13850847	chr9:136131739	ABO	0.51	6.45	0.38	5.77e-10	Cognitive performance;
KIRP	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-4.93	-0.3	1.54e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04260516	chr14:24630327	IRF9	0.56	6.5	0.38	4.46e-10	Smoking initiation;
KIRP	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg21827317	chr3:136751795	NA	-0.37	-5.22	-0.32	3.81e-7	Neuroticism;
KIRP	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg01988459	chr11:68622903	NA	-0.4	-5.63	-0.34	4.87e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	7.29	0.42	4.15e-12	Height;
KIRP	cis	rs12903563	0.505	rs12898861	chr15:77983802	A/G	cg25212270	chr15:78015279	NA	0.44	5.72	0.34	3.11e-8	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs4566357	1.000	rs1917129	chr2:227927951	A/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.13	-0.31	5.91e-7	Coronary artery disease;
KIRP	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21545522	chr1:205238299	TMCC2	0.42	5.64	0.34	4.75e-8	Red blood cell count;
KIRP	cis	rs4262150	0.920	rs67988891	chr5:152204741	C/G	cg12297329	chr5:152029980	NA	-0.49	-6.8	-0.4	8.1e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.84	0.45	1.34e-13	Morning vs. evening chronotype;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12400556	chr7:5085482	RBAK	0.54	6.36	0.38	9.52e-10	Myopia (pathological);
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.79	-8.9	-0.49	1.26e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.73	9.46	0.52	2.63e-18	Breast cancer;
KIRP	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	trans	rs7947761	0.563	rs11824432	chr11:100618979	G/A	cg20593887	chr7:2106784	MAD1L1	-0.43	-6.05	-0.36	5.49e-9	Coronary artery disease;
KIRP	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.41	-0.51	3.73e-18	Morning vs. evening chronotype;
KIRP	cis	rs5762813	0.614	rs59203761	chr22:29293369	C/T	cg02153584	chr22:29168773	CCDC117	0.59	5.09	0.31	7.15e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs17539620	0.565	rs9918393	chr6:154843268	G/A	cg20019720	chr6:154832845	CNKSR3	0.44	5.81	0.35	1.98e-8	Lipoprotein (a) levels;
KIRP	trans	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg10756647	chr7:56101905	PSPH	1.01	7.35	0.42	2.93e-12	Diabetic kidney disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06807593	chr18:51795886	POLI	0.49	6.23	0.37	1.97e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25902460	chr9:126030596	STRBP	0.49	6.11	0.36	3.85e-9	Parkinson's disease;
KIRP	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg06565975	chr8:143823917	SLURP1	-0.33	-4.9	-0.3	1.72e-6	Urinary tract infection frequency;
KIRP	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-6.5	-0.38	4.37e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2562456	0.833	rs62107539	chr19:21517712	T/C	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg18806716	chr10:30721971	MAP3K8	-0.44	-7.01	-0.41	2.35e-11	Inflammatory bowel disease;
KIRP	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg00857998	chr1:205179979	DSTYK	0.52	6.48	0.38	5.02e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg13147721	chr7:65941812	NA	-1.01	-6.94	-0.4	3.44e-11	Diabetic kidney disease;
KIRP	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-5.77	-0.35	2.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg21918786	chr6:109611834	NA	-0.39	-5.43	-0.33	1.32e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs11123406	0.723	rs60665449	chr2:111959687	G/A	cg23466623	chr2:111982296	NA	0.51	6.86	0.4	5.47e-11	Type 2 diabetes;
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.45	-6.38	-0.38	8.5e-10	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.66	5.13	0.31	6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12780845	1.000	rs33993216	chr10:17204139	G/A	cg01003015	chr10:17271136	VIM	0.46	4.97	0.3	1.28e-6	Homocysteine levels;
KIRP	cis	rs216013	0.866	rs98545	chr12:2737295	A/G	cg19945202	chr12:2788847	CACNA1C	-0.45	-4.84	-0.3	2.26e-6	Warfarin maintenance dose;
KIRP	cis	rs10751667	0.600	rs1128419	chr11:1010750	G/A	cg06064525	chr11:970664	AP2A2	-0.32	-5.93	-0.35	1.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg18132916	chr6:79620363	NA	-0.43	-5.92	-0.35	1.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.548	rs4254751	chr4:152322571	C/T	cg25486957	chr4:152246857	NA	-0.42	-5.03	-0.31	9.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.54	-5.07	-0.31	7.82e-7	Narcolepsy;
KIRP	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.37	11.83	0.6	7.07e-26	Alzheimer's disease (late onset);
KIRP	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg12923728	chr3:195709715	SDHAP1	-0.61	-7.76	-0.44	2.29e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg27572855	chr1:25598939	RHD	0.49	8.14	0.46	1.92e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg14784868	chr12:69753453	YEATS4	0.5	5.15	0.31	5.22e-7	Response to diuretic therapy;
KIRP	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg07741184	chr6:167504864	NA	0.22	5.87	0.35	1.39e-8	Crohn's disease;
KIRP	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg07596299	chr11:71824057	C11orf51	-0.89	-5.94	-0.35	9.61e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.59	5.47	0.33	1.08e-7	Alzheimer's disease;
KIRP	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg24296786	chr1:45957014	TESK2	0.4	5.05	0.31	8.55e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.39	0.33	1.64e-7	Menopause (age at onset);
KIRP	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg21475434	chr5:93447410	FAM172A	0.44	5.11	0.31	6.56e-7	Diabetic retinopathy;
KIRP	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.81	-0.49	2.37e-16	Response to antipsychotic treatment;
KIRP	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26617929	chr16:1858877	NA	-0.63	-5.52	-0.33	8.77e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4704187	0.687	rs10050948	chr5:74484275	C/T	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.47	-5.88	-0.35	1.33e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs7870753	0.578	rs10820386	chr9:99097310	C/A	cg25260653	chr9:99212216	HABP4	0.53	4.87	0.3	2e-6	Height;
KIRP	cis	rs11874712	1.000	rs7244921	chr18:43667528	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.45	-9.27	-0.51	1.01e-17	Rheumatoid arthritis;
KIRP	cis	rs12476592	0.543	rs10170988	chr2:63650582	T/C	cg17519650	chr2:63277830	OTX1	-0.44	-4.89	-0.3	1.85e-6	Childhood ear infection;
KIRP	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.86	9.7	0.53	4.77e-19	High light scatter reticulocyte count;
KIRP	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-7.61	-0.44	5.98e-13	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.33	-0.32	2.22e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.52	5.3	0.32	2.58e-7	Alzheimer's disease;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22903657	chr4:1355424	KIAA1530	-0.35	-4.93	-0.3	1.5e-6	Longevity;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12042864	chr7:99066260	NA	0.46	6.05	0.36	5.44e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg05973401	chr12:123451056	ABCB9	0.58	6.8	0.4	7.73e-11	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17082953	chr2:12856844	TRIB2	0.48	6.26	0.37	1.69e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.19	0.31	4.41e-7	Menopause (age at onset);
KIRP	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.56	8.0	0.45	5.01e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs6601327	0.665	rs9286060	chr8:9653145	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.95	-0.45	6.87e-14	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg09699651	chr6:150184138	LRP11	0.47	6.19	0.37	2.44e-9	Lung cancer;
KIRP	cis	rs9535307	0.929	rs9535310	chr13:50296026	T/C	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.45	7.99	0.45	5.39e-14	Height;
KIRP	cis	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg26585981	chr11:48327164	OR4S1	-0.51	-6.3	-0.37	1.39e-9	Migraine - clinic-based;
KIRP	cis	rs4908768	0.657	rs4908510	chr1:8806345	C/G	cg25722041	chr1:8623473	RERE	-0.51	-6.61	-0.39	2.43e-10	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.3	-0.42	3.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2671245	0.933	rs748284	chr1:56174303	A/T	cg11523071	chr1:56160889	NA	0.39	6.24	0.37	1.9e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.7	8.36	0.47	4.66e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.12	-0.36	3.57e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.49	6.45	0.38	5.8e-10	Aortic root size;
KIRP	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.45	-6.4	-0.38	7.98e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.71	-9.14	-0.5	2.44e-17	Childhood ear infection;
KIRP	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg10254082	chr7:997346	NA	0.57	4.94	0.3	1.45e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-6.59	-0.39	2.73e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4740619	0.617	rs7873925	chr9:16027483	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.58	-0.34	6.19e-8	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12588256	chr13:77601659	FBXL3	-0.53	-6.43	-0.38	6.43e-10	Interleukin-4 levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01727434	chr2:152118530	RBM43	0.52	6.53	0.38	3.65e-10	Smoking initiation;
KIRP	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.82	12.01	0.61	1.92e-26	Eye color traits;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg23939001	chr4:940644	TMEM175	0.71	12.58	0.63	2.3e-28	Sjögren's syndrome;
KIRP	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.52	4.99	0.3	1.15e-6	Recombination rate (females);
KIRP	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.65	0.34	4.39e-8	Aortic root size;
KIRP	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.47	5.53	0.33	8.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.702	rs55981733	chr4:119306600	G/A	cg21605333	chr4:119757512	SEC24D	0.87	7.04	0.41	1.88e-11	Cannabis dependence symptom count;
KIRP	cis	rs735539	0.645	rs9550662	chr13:21141552	C/T	cg04906043	chr13:21280425	IL17D	-0.48	-5.5	-0.33	9.7e-8	Dental caries;
KIRP	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.43	0.52	3.15e-18	Hirschsprung disease;
KIRP	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg19052272	chr2:3704530	ALLC	-0.38	-5.24	-0.32	3.53e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg25486957	chr4:152246857	NA	-0.55	-5.96	-0.36	8.86e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10536264	chr5:132158346	SHROOM1	0.98	6.08	0.36	4.5e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.41	5.19	0.31	4.48e-7	Testicular germ cell tumor;
KIRP	cis	rs6681460	0.966	rs10789214	chr1:67146817	C/T	cg13052034	chr1:66999238	SGIP1	0.47	6.41	0.38	7.43e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-12.21	-0.61	4.02e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.88	-11.19	-0.58	9.35e-24	Vitamin D levels;
KIRP	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg02570527	chr1:10970165	NA	0.43	5.22	0.32	3.81e-7	Body mass index;
KIRP	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	11.55	0.59	5.94e-25	Schizophrenia;
KIRP	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.95	-16.64	-0.73	3.52e-42	Height;
KIRP	trans	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg10756647	chr7:56101905	PSPH	1.01	7.32	0.42	3.41e-12	Diabetic kidney disease;
KIRP	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg17644776	chr2:200775616	C2orf69	0.6	5.71	0.34	3.2e-8	Schizophrenia;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.74	-10.2	-0.55	1.36e-20	Longevity;Endometriosis;
KIRP	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg04865290	chr3:52927548	TMEM110	-0.44	-5.6	-0.34	5.72e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs12210905	0.688	rs115030474	chr6:27512220	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-5.88	-0.35	1.32e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg19847130	chr8:10466454	RP1L1	0.33	4.96	0.3	1.29e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.85	-0.53	1.59e-19	Menopause (age at onset);
KIRP	trans	rs4938303	0.671	rs35352977	chr11:116552473	A/T	cg13754915	chr9:140174272	C9orf167	-0.73	-6.17	-0.37	2.79e-9	Triglycerides;
KIRP	cis	rs7215564	0.908	rs34333328	chr17:78683420	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.39e-7	Myopia (pathological);
KIRP	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg12315302	chr6:26189340	HIST1H4D	0.73	5.07	0.31	7.96e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs2151522	0.564	rs6920370	chr6:127191126	T/A	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg15896084	chr13:114927664	NA	0.47	6.31	0.37	1.32e-9	Schizophrenia;
KIRP	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	1.02	10.65	0.56	4.83e-22	Lung cancer in ever smokers;
KIRP	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg25019033	chr10:957182	NA	-0.73	-9.82	-0.53	2.03e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg14703610	chr5:56206110	C5orf35	0.5	6.89	0.4	4.59e-11	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs501120	0.584	rs58540467	chr10:44705170	T/C	cg09554077	chr10:44749378	NA	0.63	6.95	0.41	3.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6088813	0.702	rs2425060	chr20:33914701	T/C	cg14752227	chr20:34000481	UQCC	0.49	6.08	0.36	4.57e-9	Height;
KIRP	cis	rs7221595	0.825	rs2290437	chr17:3923115	G/A	cg09597638	chr17:3907349	NA	0.6	6.81	0.4	7.52e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.46	-6.22	-0.37	2.15e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2289681	0.525	rs12451394	chr17:42979592	G/A	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.5	-4.93	-0.3	1.54e-6	Cognitive function;
KIRP	cis	rs2481665	0.772	rs6661862	chr1:62534854	A/C	cg18591186	chr1:62594603	INADL	0.64	9.42	0.51	3.44e-18	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9596863	1.000	rs9316669	chr13:54401836	C/G	ch.13.53330881F	chr13:54432880	NA	0.63	6.54	0.38	3.53e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19717773	chr7:2847554	GNA12	-0.37	-5.47	-0.33	1.08e-7	Height;
KIRP	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-1.05	-19.11	-0.77	1.55e-50	Height;
KIRP	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.25	-0.42	5.38e-12	Type 2 diabetes;
KIRP	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg17376030	chr22:41985996	PMM1	0.82	8.97	0.5	7.81e-17	Vitiligo;
KIRP	cis	rs631288	0.793	rs4950386	chr1:146675551	A/G	cg25205988	chr1:146714368	CHD1L	1.0	5.47	0.33	1.09e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg24503407	chr1:205819492	PM20D1	0.45	4.92	0.3	1.57e-6	Parkinson's disease;
KIRP	cis	rs6732160	0.517	rs10189791	chr2:73397699	G/A	cg01422370	chr2:73384389	NA	0.51	6.47	0.38	5.4e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg02297831	chr4:17616191	MED28	0.61	7.7	0.44	3.31e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.67	8.7	0.49	4.83e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg19901468	chr14:105411992	AHNAK2	-0.81	-13.07	-0.64	5.26e-30	Rheumatoid arthritis;
KIRP	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.25	-0.47	9.72e-15	Monocyte percentage of white cells;
KIRP	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.27	0.55	8.22e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03961580	chr8:62589300	ASPH	0.46	6.34	0.37	1.07e-9	Interleukin-4 levels;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-1.03	-12.18	-0.61	5.14e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.54	-4.9	-0.3	1.75e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-10.1	-0.54	2.69e-20	Height;
KIRP	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs11997175	0.646	rs28785323	chr8:33736104	C/G	cg04338863	chr8:33670619	NA	0.49	6.4	0.38	7.76e-10	Body mass index;
KIRP	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.13	22.57	0.82	6.99e-62	Schizophrenia;
KIRP	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.94	-0.35	9.75e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.39	0.38	8.33e-10	Mean platelet volume;
KIRP	cis	rs9815354	0.812	rs73073337	chr3:41837497	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.52	-0.33	8.49e-8	Subjective well-being;
KIRP	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.13	-0.41	1.14e-11	Neuroticism;
KIRP	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg12435725	chr3:58293450	RPP14	0.52	5.68	0.34	3.75e-8	Cholesterol, total;
KIRP	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg25797454	chr6:150327115	RAET1K	0.32	5.96	0.36	8.78e-9	Alopecia areata;
KIRP	trans	rs2898857	0.545	rs12602382	chr17:47356805	C/A	cg11430096	chr6:110968061	CDK19	0.52	6.52	0.38	3.9e-10	Cancer;
KIRP	cis	rs72843166	0.509	rs75195552	chr17:61524225	G/A	cg19683800	chr17:61518354	CYB561	-0.45	-5.83	-0.35	1.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg13206674	chr6:150067644	NUP43	0.48	6.81	0.4	7.58e-11	Lung cancer;
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.64	-8.28	-0.47	7.88e-15	Longevity;Endometriosis;
KIRP	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-5.7	-0.34	3.5e-8	Vitiligo;
KIRP	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.5	7.24	0.42	5.58e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.49	6.49	0.38	4.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs111342015	0.667	rs76187039	chr6:43233990	G/T	cg02694972	chr6:43249501	TTBK1	-0.53	-4.89	-0.3	1.85e-6	Breast cancer;
KIRP	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26207909	chr14:103986467	CKB	0.74	10.53	0.56	1.19e-21	Body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10538929	chr1:22149812	LDLRAD2;HSPG2	0.52	6.85	0.4	5.72e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg26605046	chr4:2439731	NA	-0.37	-5.93	-0.35	1.04e-8	Cognitive function;
KIRP	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05347473	chr6:146136440	FBXO30	0.47	6.34	0.37	1.1e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2625529	0.824	rs4411469	chr15:72421689	A/G	cg16672083	chr15:72433130	SENP8	-0.49	-6.01	-0.36	6.58e-9	Red blood cell count;
KIRP	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.35	-0.42	2.89e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs11586313	0.507	rs3856026	chr1:152869763	T/C	cg07796016	chr1:152779584	LCE1C	-0.48	-6.02	-0.36	6.19e-9	Vitamin D levels;
KIRP	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg18527119	chr7:66119851	NA	0.49	5.24	0.32	3.38e-7	Aortic root size;
KIRP	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.68	-9.54	-0.52	1.45e-18	Coronary artery disease;
KIRP	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg16497661	chr14:103986332	CKB	-0.83	-14.0	-0.67	3.79e-33	Body mass index;
KIRP	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.91	0.3	1.64e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.65	-6.83	-0.4	6.63e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.51	-7.27	-0.42	4.74e-12	Daytime sleep phenotypes;
KIRP	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.59	5.47	0.33	1.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg07884673	chr3:53033167	SFMBT1	0.99	7.42	0.43	1.88e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs116095464	0.850	rs10057272	chr5:340188	T/C	cg22496380	chr5:211416	CCDC127	-1.21	-7.49	-0.43	1.23e-12	Breast cancer;
KIRP	cis	rs16912285	0.688	rs59797575	chr11:24315536	A/T	ch.11.24196551F	chr11:24239977	NA	0.81	9.16	0.5	2.08e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs580438	0.548	rs11707261	chr3:13422683	T/C	cg10657019	chr3:13328039	NA	-0.51	-6.68	-0.39	1.59e-10	Myringotomy;
KIRP	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg14343924	chr8:8086146	FLJ10661	0.49	5.71	0.34	3.18e-8	Systolic blood pressure;
KIRP	cis	rs1538970	0.962	rs9429160	chr1:45827968	G/T	cg05343316	chr1:45956843	TESK2	0.64	7.39	0.43	2.36e-12	Platelet count;
KIRP	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.72	9.77	0.53	2.84e-19	Red blood cell count;
KIRP	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.85	12.74	0.63	6.8e-29	Longevity;
KIRP	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg00495681	chr13:53174319	NA	0.43	5.93	0.35	1.04e-8	Lewy body disease;
KIRP	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-7.0	-0.41	2.48e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1971762	0.545	rs7297461	chr12:54047178	A/T	cg16917193	chr12:54089295	NA	0.88	15.92	0.71	1.03e-39	Height;
KIRP	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.64	-8.13	-0.46	2.14e-14	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1448094	0.522	rs12313658	chr12:86271063	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.52	0.38	3.88e-10	Major depressive disorder;
KIRP	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg05636881	chr10:105038444	INA	0.63	5.43	0.33	1.35e-7	Arsenic metabolism;
KIRP	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07570687	chr10:102243282	WNT8B	0.51	6.26	0.37	1.74e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.53	5.61	0.34	5.42e-8	Adiposity;
KIRP	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-4.86	-0.3	2.08e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-0.96	-8.43	-0.47	2.9e-15	Plateletcrit;
KIRP	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-8.38	-0.47	3.99e-15	Gut microbiome composition (summer);
KIRP	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg27170947	chr2:26402098	FAM59B	0.63	6.76	0.4	9.83e-11	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.63e-9	Life satisfaction;
KIRP	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg03235661	chr20:60525775	NA	-0.39	-5.94	-0.35	9.45e-9	Body mass index;
KIRP	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.83	7.68	0.44	3.79e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.45	5.92	0.35	1.07e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18357526	chr6:26021779	HIST1H4A	0.52	6.71	0.39	1.32e-10	Height;
KIRP	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg21475434	chr5:93447410	FAM172A	0.44	5.11	0.31	6.56e-7	Diabetic retinopathy;
KIRP	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-6.08	-0.36	4.6e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs778371	0.748	rs1878287	chr2:233790649	G/T	cg11972305	chr2:233791962	NGEF	-0.44	-5.6	-0.34	5.86e-8	Schizophrenia;
KIRP	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg07596299	chr11:71824057	C11orf51	-0.91	-6.11	-0.36	3.79e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.84	-11.2	-0.58	8.58e-24	Prostate cancer;
KIRP	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.13	0.41	1.12e-11	Height;
KIRP	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg07424592	chr7:64974309	NA	0.75	4.93	0.3	1.51e-6	Diabetic kidney disease;
KIRP	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.76	-9.25	-0.51	1.14e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg12940439	chr1:67600707	NA	0.34	5.23	0.32	3.58e-7	Psoriasis;
KIRP	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	8.92	0.49	1.08e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg19847130	chr8:10466454	RP1L1	0.38	5.74	0.34	2.71e-8	Retinal vascular caliber;
KIRP	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg11621586	chr10:70884670	VPS26A	1.19	15.17	0.7	3.77e-37	Left atrial antero-posterior diameter;
KIRP	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.73	7.75	0.44	2.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.38	-4.85	-0.3	2.22e-6	Mean platelet volume;
KIRP	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15077376	chr3:159943308	LOC401097	0.41	5.27	0.32	3.04e-7	Parkinson's disease;
KIRP	cis	rs2034650	0.525	rs11790	chr15:40712737	T/C	cg08996748	chr15:40651036	DISP2	-0.36	-5.15	-0.31	5.41e-7	Interstitial lung disease;
KIRP	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.74	-9.42	-0.51	3.52e-18	Aortic root size;
KIRP	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.6	-7.57	-0.43	7.67e-13	Hyperactive-impulsive symptoms;
KIRP	cis	rs9928842	0.771	rs4888363	chr16:75277344	A/T	cg09066997	chr16:75300724	BCAR1	0.54	5.16	0.31	5.03e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs12476592	0.602	rs262484	chr2:63878015	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg04935436	chr20:30431758	NA	0.49	6.31	0.37	1.3e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	6.44	0.38	6.37e-10	Personality dimensions;
KIRP	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg16570157	chr11:829783	EFCAB4A	-0.46	-6.04	-0.36	5.75e-9	Subjective well-being;
KIRP	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.76	10.55	0.56	1.04e-21	Parkinson's disease;
KIRP	cis	rs533123	0.668	rs414491	chr1:29170159	C/G	cg08366446	chr1:29138936	OPRD1	0.91	7.55	0.43	8.47e-13	Schizophrenia;
KIRP	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg01304814	chr3:48885189	PRKAR2A	0.73	5.61	0.34	5.33e-8	Cognitive function;
KIRP	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg08992911	chr2:238395768	MLPH	0.7	6.12	0.36	3.65e-9	Prostate cancer;
KIRP	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.56	-11.93	-0.61	3.47e-26	Diabetic kidney disease;
KIRP	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05665937	chr4:1216051	CTBP1	0.56	7.84	0.45	1.34e-13	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22352273	chr2:238969464	SCLY	0.45	6.19	0.37	2.56e-9	Parkinson's disease;
KIRP	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.69	-9.58	-0.52	1.09e-18	Blood protein levels;
KIRP	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg16989719	chr2:238392110	NA	-0.59	-6.06	-0.36	5.08e-9	Prostate cancer;
KIRP	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg08992911	chr2:238395768	MLPH	0.43	5.2	0.31	4.21e-7	Prostate cancer;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.49	0.33	1.02e-7	Life satisfaction;
KIRP	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg25706552	chr1:244017396	NA	0.58	6.65	0.39	1.93e-10	RR interval (heart rate);
KIRP	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg08890418	chr1:21044141	KIF17	-0.43	-6.52	-0.38	4.01e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg24130564	chr14:104152367	KLC1	-0.38	-4.97	-0.3	1.27e-6	Body mass index;
KIRP	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.62	8.92	0.49	1.12e-16	Resting heart rate;
KIRP	trans	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg16141378	chr3:129829833	LOC729375	0.48	6.1	0.36	4.17e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.99	0.45	5.14e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.0	0.36	7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.44	-6.46	-0.38	5.43e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03934478	chr11:495069	RNH1	0.87	7.01	0.41	2.26e-11	Body mass index;
KIRP	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg18209359	chr17:80159595	CCDC57	0.36	4.91	0.3	1.69e-6	Life satisfaction;
KIRP	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg27631724	chr1:11040367	C1orf127	0.38	7.67	0.44	3.98e-13	Ewing sarcoma;
KIRP	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg06204229	chr3:52865917	ITIH4	0.52	5.81	0.35	1.94e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4774899	1.000	rs3803454	chr15:57241042	T/C	cg13626582	chr15:57592083	LOC283663	-0.2	-4.91	-0.3	1.65e-6	Urinary tract infection frequency;
KIRP	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.87	-0.57	1.02e-22	Height;
KIRP	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	4.92	0.3	1.6e-6	Coronary artery disease;
KIRP	cis	rs28655083	0.956	rs7184167	chr16:77069451	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.55	-5.94	-0.35	9.6e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg19116668	chr7:99932089	PMS2L1	-0.77	-9.97	-0.54	7.2e-20	Alzheimer's disease (late onset);
KIRP	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.43	0.43	1.75e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.64	7.79	0.44	1.91e-13	Obesity-related traits;
KIRP	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.75	-0.34	2.63e-8	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg21698718	chr17:80085957	CCDC57	0.33	4.87	0.3	2.01e-6	Life satisfaction;
KIRP	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg26149184	chr10:133730230	NA	0.43	5.08	0.31	7.3e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.52	-0.48	1.63e-15	Monocyte percentage of white cells;
KIRP	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	0.91	6.36	0.38	9.87e-10	Arsenic metabolism;
KIRP	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.27	0.47	8.42e-15	Menopause (age at onset);
KIRP	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg03128060	chr6:142623767	GPR126	0.35	5.07	0.31	7.93e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg00745463	chr17:30367425	LRRC37B	-0.94	-8.35	-0.47	5.1e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg21851534	chr17:3907994	ZZEF1	-0.64	-10.2	-0.55	1.32e-20	Type 2 diabetes;
KIRP	cis	rs2011503	0.509	rs73006705	chr19:19781917	A/G	cg11584989	chr19:19387371	SF4	0.51	5.12	0.31	6.1e-7	Bipolar disorder;
KIRP	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.65	8.75	0.49	3.55e-16	Mosquito bite size;
KIRP	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.74	-9.13	-0.5	2.67e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg05973401	chr12:123451056	ABCB9	0.64	6.13	0.36	3.38e-9	Neutrophil percentage of white cells;
KIRP	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg23505145	chr19:12996616	KLF1	0.55	8.09	0.46	2.71e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7225151	0.710	rs77318561	chr17:5184467	T/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.88	-0.35	1.35e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.45	5.86	0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs2281603	0.570	rs12050238	chr14:64964875	C/G	cg01860774	chr14:64969374	ZBTB25	0.33	5.37	0.32	1.8e-7	Lymphocyte counts;
KIRP	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.43	7.29	0.42	4.32e-12	Heart rate;
KIRP	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.31	5.74	0.34	2.74e-8	Renal cell carcinoma;
KIRP	cis	rs2637030	0.559	rs372006	chr5:52875859	T/A	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.05	-0.41	1.83e-11	Bladder cancer;
KIRP	cis	rs7709377	0.620	rs10079466	chr5:115477636	C/A	cg23108291	chr5:115420582	COMMD10	0.44	5.34	0.32	2.14e-7	Metabolite levels  (X-11787);
KIRP	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12095067	chr19:9929835	FBXL12	0.52	6.62	0.39	2.24e-10	Parkinson's disease;
KIRP	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg17347104	chr14:75034677	LTBP2	-0.41	-4.93	-0.3	1.53e-6	Caffeine consumption;
KIRP	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.15	14.79	0.69	7.6e-36	Type 2 diabetes nephropathy;
KIRP	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg11584989	chr19:19387371	SF4	0.41	5.28	0.32	2.81e-7	Tonsillectomy;
KIRP	cis	rs8133932	0.654	rs10854475	chr21:47332749	A/G	cg11214348	chr21:47283868	PCBP3	0.47	5.41	0.33	1.51e-7	Schizophrenia;
KIRP	cis	rs10056811	0.510	rs10058171	chr5:74407991	C/T	cg19683494	chr5:74908142	NA	0.55	4.93	0.3	1.5e-6	Coronary artery disease;
KIRP	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.56	6.23	0.37	2e-9	Height;
KIRP	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs4774830	0.661	rs12443357	chr15:56305980	C/T	cg24530489	chr15:56299380	NA	-0.79	-4.88	-0.3	1.88e-6	Delta-5 desaturase activity;
KIRP	cis	rs11038871	1.000	rs1317826	chr11:46387868	A/G	cg16389345	chr11:46697382	NA	-0.51	-7.02	-0.41	2.15e-11	Immunoglobulin A;
KIRP	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-4.87	-0.3	1.97e-6	IgG glycosylation;
KIRP	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.44	6.11	0.36	3.96e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs516946	0.950	rs508419	chr8:41522991	A/G	cg19441908	chr8:41529140	ANK1	-0.5	-7.2	-0.42	7.37e-12	Type 2 diabetes;
KIRP	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.69	-9.99	-0.54	5.84e-20	Educational attainment;
KIRP	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.86	-8.6	-0.48	9.56e-16	Subcortical brain region volumes;Hippocampal volume;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg06099646	chr16:51174768	SALL1	-0.51	-6.61	-0.39	2.43e-10	Inflammatory biomarkers;
KIRP	cis	rs3018712	0.522	rs4930595	chr11:68435827	A/G	cg23009355	chr11:68451396	GAL	-0.37	-4.86	-0.3	2.09e-6	Total body bone mineral density;
KIRP	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.43	5.6	0.34	5.8e-8	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19139691	chr2:86668469	KDM3A	-0.45	-6.22	-0.37	2.13e-9	Migraine with aura;
KIRP	trans	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg06521331	chr12:34319734	NA	-0.51	-6.49	-0.38	4.69e-10	Bladder cancer;
KIRP	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.44	-0.47	2.8e-15	Mood instability;
KIRP	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg23324259	chr8:82754387	SNX16	0.44	4.88	0.3	1.9e-6	Diastolic blood pressure;
KIRP	cis	rs6832769	0.961	rs11133382	chr4:56316980	T/G	cg09317128	chr4:56265301	TMEM165	0.52	6.99	0.41	2.56e-11	Personality dimensions;
KIRP	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg02975922	chr3:195473998	MUC4	-0.54	-6.3	-0.37	1.33e-9	Pancreatic cancer;
KIRP	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08439880	chr3:133502540	NA	0.42	5.0	0.3	1.09e-6	Iron status biomarkers;
KIRP	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg14346243	chr4:90757452	SNCA	-0.39	-4.92	-0.3	1.62e-6	Neuroticism;
KIRP	cis	rs654950	0.783	rs640688	chr1:42001831	A/G	cg06885757	chr1:42089581	HIVEP3	-0.45	-6.48	-0.38	4.89e-10	Airway imaging phenotypes;
KIRP	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg23920097	chr1:209922102	NA	-0.4	-5.36	-0.32	1.92e-7	Red blood cell count;
KIRP	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs112591243	0.685	rs117450955	chr21:47990916	T/A	cg26904215	chr21:47823096	PCNT	-0.8	-5.96	-0.36	8.78e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs9653442	0.564	rs7601892	chr2:100789490	G/A	cg17356467	chr2:100759845	AFF3	0.38	5.35	0.32	2.01e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	ch.11.42038R	chr11:967971	AP2A2	0.46	5.97	0.36	8.32e-9	Alzheimer's disease (late onset);
KIRP	cis	rs2964802	0.505	rs2083232	chr5:10812811	G/A	cg14521931	chr5:10832172	NA	-0.75	-11.56	-0.59	5.79e-25	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg00361562	chr2:198649771	BOLL	-0.48	-5.06	-0.31	8.27e-7	Ulcerative colitis;
KIRP	trans	rs7403037	0.517	rs71461546	chr15:24797295	G/C	cg00996262	chr17:7554930	ATP1B2	0.62	6.29	0.37	1.41e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg19875535	chr5:140030758	IK	0.65	9.21	0.51	1.52e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg00310523	chr12:86230176	RASSF9	-0.47	-7.53	-0.43	9.4e-13	Major depressive disorder;
KIRP	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.13	0.41	1.08e-11	Height;
KIRP	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.17	-0.37	2.86e-9	Subjective well-being;
KIRP	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg08392591	chr16:89556376	ANKRD11	-0.43	-5.32	-0.32	2.3e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.85	-12.92	-0.64	1.72e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-0.52	-7.41	-0.43	1.97e-12	Coronary artery disease;
KIRP	cis	rs9921338	0.961	rs11545336	chr16:11439496	G/A	cg00044050	chr16:11439710	C16orf75	-0.56	-6.01	-0.36	6.75e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01126855	chr4:183727586	NA	0.51	6.29	0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs2594989	0.673	rs9855241	chr3:11602910	C/T	cg01796438	chr3:11312864	ATG7	0.51	5.81	0.35	1.97e-8	Circulating chemerin levels;
KIRP	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg08603382	chr10:743973	NA	-0.63	-10.08	-0.54	3.1e-20	Psychosis in Alzheimer's disease;
KIRP	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.71	-0.53	4.34e-19	Morning vs. evening chronotype;
KIRP	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.93	-12.54	-0.62	3.12e-28	Multiple sclerosis;
KIRP	cis	rs7635838	0.964	rs7624086	chr3:11412620	C/G	cg00170343	chr3:11313890	ATG7	0.44	5.6	0.34	5.63e-8	HDL cholesterol;
KIRP	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg25356066	chr3:128598488	ACAD9	0.47	5.43	0.33	1.34e-7	IgG glycosylation;
KIRP	cis	rs8060686	0.920	rs58588228	chr16:67802010	C/T	cg04539111	chr16:67997858	SLC12A4	-0.61	-6.01	-0.36	6.64e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg17691542	chr6:26056736	HIST1H1C	0.78	8.28	0.47	7.7e-15	Iron status biomarkers;
KIRP	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg02591564	chr12:125578355	AACS	-0.43	-4.98	-0.3	1.2e-6	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg05914723	chr15:78953907	NA	0.43	5.01	0.3	1.05e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg13319975	chr6:146136371	FBXO30	0.45	5.93	0.35	9.97e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.23	13.01	0.64	8.44e-30	Alzheimer's disease;
KIRP	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.88	0.35	1.32e-8	Motion sickness;
KIRP	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg24747557	chr10:131355152	MGMT	-0.44	-6.11	-0.36	3.88e-9	Response to temozolomide;
KIRP	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.55	-7.21	-0.42	6.87e-12	Total body bone mineral density;
KIRP	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg24060327	chr5:131705240	SLC22A5	-0.48	-6.3	-0.37	1.37e-9	Breast cancer;
KIRP	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.53	6.35	0.38	1.05e-9	Eosinophil percentage of white cells;
KIRP	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg10397082	chr2:1609832	NA	0.57	5.15	0.31	5.36e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2223471	0.501	rs1161372	chr6:50607519	A/T	cg03432817	chr6:50765336	NA	-0.37	-5.63	-0.34	4.85e-8	Subcutaneous adipose tissue;
KIRP	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg13206674	chr6:150067644	NUP43	0.53	7.33	0.42	3.26e-12	Lung cancer;
KIRP	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.49	-0.33	9.77e-8	Coronary artery disease;
KIRP	cis	rs198389	0.589	rs198401	chr1:11888384	A/G	cg24844545	chr1:11908347	NPPA	-0.37	-5.1	-0.31	6.82e-7	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
KIRP	cis	rs4689642	0.709	rs13133665	chr4:7226157	G/A	cg21353189	chr4:7228343	SORCS2	0.41	5.46	0.33	1.14e-7	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg15485101	chr11:133734466	NA	0.44	5.81	0.35	1.9e-8	Childhood ear infection;
KIRP	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg25036284	chr2:26402008	FAM59B	-0.54	-5.54	-0.33	7.71e-8	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.24e-8	Lung cancer;
KIRP	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18364779	chr6:26104403	HIST1H4C	0.41	5.32	0.32	2.33e-7	Schizophrenia;
KIRP	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.58	-7.16	-0.42	9.08e-12	Iron status biomarkers;
KIRP	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.41	0.47	3.44e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs12210905	1.000	rs12192320	chr6:27090305	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.68	-0.39	1.6e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs12208915	0.848	rs12213359	chr6:79534027	C/A	cg18132916	chr6:79620363	NA	0.55	5.04	0.31	9.05e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.53	-7.1	-0.41	1.32e-11	Mean corpuscular volume;
KIRP	cis	rs5753037	0.639	rs5997534	chr22:30220190	G/A	cg01021169	chr22:30184971	ASCC2	-0.48	-6.22	-0.37	2.14e-9	Type 1 diabetes;
KIRP	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg01631408	chr1:248437212	OR2T33	-0.7	-9.36	-0.51	5.3e-18	Common traits (Other);
KIRP	trans	rs73017364	0.605	rs4657163	chr1:162160856	C/G	cg13533616	chr9:131889368	PPP2R4	0.62	6.22	0.37	2.14e-9	QT interval;
KIRP	cis	rs201798	0.866	rs149875	chr13:50953036	G/T	cg10393508	chr13:50950265	NA	0.36	4.94	0.3	1.47e-6	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
KIRP	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17507749	chr15:85114479	UBE2QP1	0.73	8.33	0.47	5.62e-15	Schizophrenia;
KIRP	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg22974920	chr21:40686053	BRWD1	0.49	5.85	0.35	1.57e-8	Cognitive function;
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg18234130	chr8:27182889	PTK2B	0.55	7.17	0.42	8.9e-12	Neuroticism;
KIRP	cis	rs6594713	0.642	rs17389165	chr5:112796598	A/C	cg12552261	chr5:112820674	MCC	-0.61	-5.48	-0.33	1.05e-7	Brain cytoarchitecture;
KIRP	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg05805236	chr11:65401703	PCNXL3	-0.56	-7.05	-0.41	1.75e-11	Acne (severe);
KIRP	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg04374321	chr14:90722782	PSMC1	0.99	18.13	0.76	3.17e-47	Mortality in heart failure;
KIRP	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.95	9.68	0.53	5.57e-19	Blood protein levels;
KIRP	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.49	-8.35	-0.47	4.99e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.27	0.42	4.77e-12	Prudent dietary pattern;
KIRP	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.39	-0.55	3.23e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg23517279	chr6:96025343	MANEA	0.6	5.38	0.32	1.77e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-6.64	-0.39	2.04e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.15	9.57	0.52	1.16e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg19636519	chr7:99541626	NA	0.38	7.02	0.41	2.17e-11	Coronary artery disease;
KIRP	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg00334542	chr7:100209784	MOSPD3	-0.58	-5.2	-0.31	4.29e-7	Other erythrocyte phenotypes;
KIRP	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.56	7.31	0.42	3.63e-12	Coronary artery disease;
KIRP	cis	rs684232	0.933	rs866304	chr17:587729	T/C	cg15660573	chr17:549704	VPS53	-0.5	-6.29	-0.37	1.43e-9	Prostate cancer;
KIRP	cis	rs2230307	0.536	rs11166407	chr1:100637708	C/T	cg24955406	chr1:100503596	HIAT1	0.6	6.23	0.37	2.04e-9	Carotid intima media thickness;
KIRP	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.45	-6.1	-0.36	4.05e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.44	-0.47	2.8e-15	Mood instability;
KIRP	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.15	0.37	3.09e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6988985	0.765	rs4736359	chr8:143987427	T/G	cg10324643	chr8:143916377	GML	0.43	4.99	0.3	1.14e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	trans	rs921874	0.553	rs2077594	chr11:86772166	G/A	cg20852851	chr2:240168848	HDAC4	0.46	6.21	0.37	2.22e-9	Total body bone mineral density;
KIRP	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.81	-7.89	-0.45	9.71e-14	Menopause (age at onset);
KIRP	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg00982548	chr2:198649783	BOLL	-0.55	-5.04	-0.31	9.05e-7	Ulcerative colitis;
KIRP	cis	rs12049351	0.774	rs1444727	chr1:229616758	T/C	cg11742688	chr1:229674241	ABCB10	-0.38	-6.12	-0.36	3.7e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg14664628	chr15:75095509	CSK	-1.11	-17.63	-0.75	1.51e-45	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.34	0.42	3.03e-12	Bipolar disorder;
KIRP	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.82	-12.51	-0.62	4.11e-28	Breast cancer;
KIRP	cis	rs2011503	0.509	rs76347963	chr19:19780145	C/T	cg11584989	chr19:19387371	SF4	0.51	5.12	0.31	6.1e-7	Bipolar disorder;
KIRP	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.47	-0.33	1.12e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	13.15	0.64	2.9e-30	Mean corpuscular hemoglobin;
KIRP	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.49	5.36	0.32	1.91e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg10434728	chr15:90938212	IQGAP1	0.42	7.29	0.42	4.31e-12	Rheumatoid arthritis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03903247	chr3:197477068	FYTTD1;KIAA0226	-0.5	-6.06	-0.36	5.02e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg09455208	chr3:40491958	NA	0.3	4.98	0.3	1.17e-6	Renal cell carcinoma;
KIRP	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-0.72	-6.35	-0.38	1.01e-9	Obesity-related traits;
KIRP	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg13165212	chr22:42675999	NA	0.3	5.29	0.32	2.73e-7	Cognitive function;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11228876	chr1:236227653	NID1	0.41	6.19	0.37	2.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg22437258	chr11:111473054	SIK2	0.6	7.05	0.41	1.78e-11	Primary sclerosing cholangitis;
KIRP	cis	rs2303759	0.507	rs1465696	chr19:49837439	G/A	cg22590775	chr19:49891494	CCDC155	0.65	6.04	0.36	5.64e-9	Multiple sclerosis;
KIRP	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg22974920	chr21:40686053	BRWD1	-0.42	-4.89	-0.3	1.81e-6	Cognitive function;
KIRP	cis	rs7909074	1.000	rs6593447	chr10:45400235	G/A	cg05187965	chr10:45406764	TMEM72	-0.32	-7.55	-0.43	8.32e-13	Mean corpuscular volume;
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg09355771	chr2:177043147	NA	0.49	6.47	0.38	5.21e-10	IgG glycosylation;
KIRP	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-0.66	-5.71	-0.34	3.19e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	6.01	0.36	6.65e-9	Response to antipsychotic treatment;
KIRP	cis	rs1816752	0.870	rs73469543	chr13:24998970	T/C	cg02811702	chr13:24901961	NA	0.43	5.6	0.34	5.71e-8	Obesity-related traits;
KIRP	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg10223061	chr2:219282414	VIL1	0.42	6.62	0.39	2.21e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.71	9.02	0.5	5.51e-17	Coronary artery disease;
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-13.19	-0.64	2.14e-30	Alzheimer's disease;
KIRP	cis	rs698833	0.538	rs1067396	chr2:44637738	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.43	0.38	6.47e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08280861	chr8:58055591	NA	0.69	6.52	0.38	3.97e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.69	0.48	5.25e-16	Motion sickness;
KIRP	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.36	0.38	9.58e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg07395648	chr5:131743802	NA	-0.57	-8.38	-0.47	4.17e-15	Blood metabolite levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04297686	chr5:93643309	C5orf36	0.4	6.33	0.37	1.17e-9	Survival in pancreatic cancer;
KIRP	cis	rs367943	0.698	rs9326900	chr5:112972859	A/G	cg12552261	chr5:112820674	MCC	0.43	4.85	0.3	2.23e-6	Type 2 diabetes;
KIRP	cis	rs3109167	0.623	rs2723009	chr7:83116749	A/C	cg14519356	chr7:83097669	SEMA3E	0.38	5.23	0.32	3.67e-7	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16701655	chr10:51826695	FAM21A	-0.45	-6.13	-0.36	3.5e-9	Survival in pancreatic cancer;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.93	-10.82	-0.57	1.43e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9479482	0.686	rs2184452	chr6:150384827	T/C	cg25797454	chr6:150327115	RAET1K	0.33	5.84	0.35	1.61e-8	Alopecia areata;
KIRP	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.68	-0.48	5.37e-16	Type 2 diabetes;
KIRP	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	8.19	0.46	1.39e-14	Blood protein levels;
KIRP	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.95	-0.57	5.48e-23	Colorectal cancer;
KIRP	cis	rs35740288	0.787	rs2291047	chr15:86225805	A/G	cg10818794	chr15:86012489	AKAP13	-0.42	-5.0	-0.3	1.1e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg14972814	chr11:95582409	MTMR2	0.34	5.66	0.34	4.11e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg20991723	chr1:152506922	NA	-0.45	-5.48	-0.33	1.04e-7	Hair morphology;
KIRP	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.44	-0.38	6.1e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2274273	0.837	rs8011329	chr14:55677255	G/A	cg04306507	chr14:55594613	LGALS3	0.5	7.67	0.44	4.11e-13	Protein biomarker;
KIRP	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Smoking initiation;
KIRP	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg09549813	chr16:4587862	C16orf5	-0.32	-4.86	-0.3	2.09e-6	Schizophrenia;
KIRP	cis	rs6992848	0.727	rs13251796	chr8:141169168	G/A	cg13911501	chr8:141220320	TRAPPC9	0.43	5.11	0.31	6.42e-7	Response to amphetamines;
KIRP	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.71	-10.33	-0.55	5.24e-21	Morning vs. evening chronotype;
KIRP	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	7.3	0.42	3.99e-12	Iron status biomarkers;
KIRP	cis	rs2400749	0.830	rs4905855	chr14:100032246	T/G	cg19965031	chr14:100038389	CCDC85C	-0.43	-5.3	-0.32	2.6e-7	Alzheimer's disease (survival time);
KIRP	cis	rs13385	0.769	rs7707814	chr5:139583728	C/G	cg01860693	chr5:139557145	C5orf32	0.49	5.38	0.32	1.75e-7	Atrial fibrillation;
KIRP	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.81	9.74	0.53	3.65e-19	Corneal astigmatism;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.79	0.4	8.41e-11	Electroencephalogram traits;
KIRP	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.61	-7.69	-0.44	3.5e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.53	7.04	0.41	1.88e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg01304814	chr3:48885189	PRKAR2A	0.55	5.06	0.31	8.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2224391	0.628	rs2773310	chr6:5250828	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.57	-0.39	3.06e-10	Height;
KIRP	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.48	6.37	0.38	9.42e-10	Mean corpuscular volume;
KIRP	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.6	0.44	6.4e-13	White blood cell count;
KIRP	cis	rs4812048	0.846	rs151361	chr20:57614002	A/G	cg14073986	chr20:57617431	SLMO2	0.44	4.95	0.3	1.38e-6	Mean platelet volume;
KIRP	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.26	0.47	9.07e-15	Personality dimensions;
KIRP	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.14	24.3	0.84	2.54e-67	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17554472	chr22:41940697	POLR3H	0.69	7.08	0.41	1.48e-11	Vitiligo;
KIRP	cis	rs6001982	0.831	rs73167080	chr22:40885498	C/G	cg07138101	chr22:40742427	ADSL	0.73	5.5	0.33	9.28e-8	Breast cancer;
KIRP	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.97	10.23	0.55	1.08e-20	Blood protein levels;
KIRP	cis	rs754423	0.548	rs7154428	chr14:52569722	A/C	cg05884192	chr14:52515736	NID2	-0.48	-5.37	-0.32	1.81e-7	Craniofacial microsomia;
KIRP	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.38	-0.38	8.61e-10	Response to antipsychotic treatment;
KIRP	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.96	-0.36	8.82e-9	Morning vs. evening chronotype;
KIRP	cis	rs7582720	1.000	rs74675536	chr2:203673073	G/A	cg08076091	chr2:203926405	NBEAL1	0.83	8.63	0.48	7.67e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg05861140	chr6:150128134	PCMT1	-0.49	-6.95	-0.41	3.21e-11	Lung cancer;
KIRP	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.76e-6	Bipolar disorder;
KIRP	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.05	-0.46	3.52e-14	Total cholesterol levels;
KIRP	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg24972876	chr7:65420302	NA	0.41	5.6	0.34	5.64e-8	Aortic root size;
KIRP	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg24747557	chr10:131355152	MGMT	0.52	7.31	0.42	3.8e-12	Response to temozolomide;
KIRP	cis	rs10858047	0.883	rs6537842	chr1:115204467	C/T	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	12.21	0.61	4.01e-27	Monocyte percentage of white cells;
KIRP	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.53	6.43	0.38	6.76e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg15247329	chr7:2764246	NA	-0.34	-4.85	-0.3	2.19e-6	Height;
KIRP	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs8018808	0.935	rs8005759	chr14:77880493	C/T	cg20045696	chr14:77926864	AHSA1	0.46	5.53	0.33	8.11e-8	Myeloid white cell count;
KIRP	cis	rs4356932	0.905	rs7679394	chr4:76985890	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	1.02	10.08	0.54	3.24e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05220968	chr6:146057943	EPM2A	-0.41	-5.4	-0.33	1.55e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16603964	chr6:111803680	REV3L	0.5	6.74	0.39	1.15e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.73	7.35	0.42	2.91e-12	Bipolar disorder;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.78	12.58	0.63	2.32e-28	Longevity;Endometriosis;
KIRP	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.56	10.39	0.55	3.44e-21	Iron status biomarkers (transferrin levels);
KIRP	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	16.82	0.73	8.57e-43	Height;
KIRP	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg18404041	chr3:52824283	ITIH1	0.45	5.49	0.33	1e-7	Schizophrenia;
KIRP	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	6.11	0.36	3.86e-9	Neuroticism;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19698099	chr2:189897254	COL5A2	0.39	6.28	0.37	1.51e-9	Migraine with aura;
KIRP	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg05082376	chr22:42548792	NA	-0.46	-5.31	-0.32	2.49e-7	Schizophrenia;
KIRP	cis	rs7572644	0.699	rs898032	chr2:28202936	C/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.3	-0.32	2.57e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg08992911	chr2:238395768	MLPH	0.4	5.09	0.31	7.08e-7	Prostate cancer;
KIRP	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg02378861	chr5:212933	CCDC127	-0.73	-5.78	-0.35	2.21e-8	Fat distribution (HIV);
KIRP	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.51	-6.23	-0.37	1.96e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.28	-0.37	1.55e-9	Hemoglobin concentration;
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg05025164	chr4:1340916	KIAA1530	0.45	5.49	0.33	9.95e-8	Obesity-related traits;
KIRP	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg09344028	chr17:70110421	NA	0.4	8.17	0.46	1.67e-14	Thyroid hormone levels;
KIRP	cis	rs9912468	1.000	rs4328478	chr17:64307982	C/T	cg19474267	chr17:64306194	PRKCA	-0.66	-9.34	-0.51	5.98e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.47	6.94	0.4	3.53e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.64	8.5	0.48	1.81e-15	Calcium levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08002746	chr8:19961386	NA	-0.4	-6.07	-0.36	4.75e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg27542767	chr6:40253980	NA	0.41	6.09	0.36	4.35e-9	Breast size;
KIRP	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.5e-39	Headache;
KIRP	cis	rs5746492	0.568	rs73151057	chr22:18397913	T/G	cg03078520	chr22:18463400	MICAL3	0.44	5.92	0.35	1.1e-8	Eotaxin levels;
KIRP	cis	rs10266483	0.774	rs642909	chr7:63770321	T/C	cg04636841	chr7:63768139	NA	-0.39	-5.08	-0.31	7.44e-7	Response to statin therapy;
KIRP	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	20.06	0.79	1.12e-53	Chronic sinus infection;
KIRP	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06634786	chr22:41940651	POLR3H	-0.41	-4.87	-0.3	2e-6	Vitiligo;
KIRP	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-0.82	-9.57	-0.52	1.17e-18	Pediatric areal bone mineral density (radius);
KIRP	cis	rs234043	1.000	rs234043	chr3:172313367	T/C	cg22572614	chr3:172241975	TNFSF10	-0.3	-5.39	-0.32	1.67e-7	Renal cell carcinoma;
KIRP	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1978968	0.830	rs11089210	chr22:18445692	A/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.91	-0.4	4.07e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.65	-7.26	-0.42	5.18e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.75	-0.34	2.68e-8	Parkinson's disease;
KIRP	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00509281	chr10:62554092	CDC2;CDK1	-0.44	-6.59	-0.39	2.67e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7553864	0.966	rs11161935	chr1:87614191	G/A	cg17420885	chr1:87600446	LOC339524	-0.48	-6.39	-0.38	8.3e-10	Smoking behavior;
KIRP	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.86e-15	Prudent dietary pattern;
KIRP	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.66	9.06	0.5	4.23e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-4.87	-0.3	2.02e-6	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18907495	chr17:53828548	PCTP	0.59	7.13	0.41	1.11e-11	Smoking initiation;
KIRP	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg15556689	chr8:8085844	FLJ10661	0.65	8.29	0.47	7.43e-15	Retinal vascular caliber;
KIRP	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.34	0.42	3.09e-12	Rheumatoid arthritis;
KIRP	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.8	10.89	0.57	8.67e-23	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg23985595	chr17:80112537	CCDC57	0.37	5.52	0.33	8.41e-8	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.49	-7.15	-0.41	9.88e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs580438	0.548	rs184930	chr3:13360513	C/T	cg10657019	chr3:13328039	NA	0.59	7.77	0.44	2.16e-13	Myringotomy;
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg05025164	chr4:1340916	KIAA1530	0.46	5.56	0.33	6.85e-8	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02835003	chr19:36234764	U2AF1L4;TMEM149	-0.4	-6.17	-0.37	2.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg00806126	chr19:22604979	ZNF98	0.64	6.75	0.4	1.04e-10	Pain;
KIRP	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.15	20.44	0.79	6.03e-55	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs11203032	0.831	rs10788635	chr10:90927063	A/G	cg16672925	chr10:90967113	CH25H	0.41	4.87	0.3	2e-6	Heart failure;
KIRP	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.71	8.34	0.47	5.37e-15	Corneal astigmatism;
KIRP	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg05315796	chr3:52349193	DNAH1	0.51	7.86	0.45	1.23e-13	Electroencephalogram traits;
KIRP	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.48	-0.33	1.05e-7	Cognitive function;
KIRP	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.95	-0.4	3.35e-11	Aortic root size;
KIRP	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11874712	1.000	rs28699609	chr18:43674879	A/T	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.16e-8	Migraine - clinic-based;
KIRP	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg11366901	chr6:160182831	ACAT2	1.13	14.04	0.67	2.81e-33	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.74	9.19	0.51	1.65e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4776059	1.000	rs4776058	chr15:52880263	A/G	cg25063058	chr15:52860530	ARPP19	0.63	6.92	0.4	3.83e-11	Schizophrenia;
KIRP	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.63	-8.87	-0.49	1.54e-16	Schizophrenia;
KIRP	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg04865290	chr3:52927548	TMEM110	-0.67	-6.92	-0.4	4e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.51	0.38	4.12e-10	Retinal vascular caliber;
KIRP	cis	rs2072732	0.861	rs72630909	chr1:2968979	C/T	cg11731671	chr1:2995604	PRDM16	-0.54	-5.84	-0.35	1.62e-8	Plateletcrit;
KIRP	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.43	-6.13	-0.36	3.49e-9	Schizophrenia;
KIRP	trans	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg16141378	chr3:129829833	LOC729375	0.52	6.54	0.38	3.57e-10	Mood instability;
KIRP	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.61	-7.63	-0.44	5.04e-13	Iron status biomarkers;
KIRP	cis	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg27487796	chr7:28973253	NA	-0.22	-5.08	-0.31	7.33e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19828298	chr1:3713105	LRRC47	0.72	6.74	0.39	1.11e-10	Lung function (FEV1);
KIRP	cis	rs2367563	0.930	rs7957253	chr12:96054414	G/A	cg19013339	chr12:96052514	NTN4	0.34	5.39	0.33	1.62e-7	Allergic dermatitis (nickel);
KIRP	cis	rs10267417	0.603	rs10229973	chr7:19894778	G/A	cg05791153	chr7:19748676	TWISTNB	0.56	5.16	0.31	5.07e-7	Night sleep phenotypes;
KIRP	cis	rs10435719	0.746	rs58007588	chr8:11794969	A/G	cg21775007	chr8:11205619	TDH	0.45	6.02	0.36	6.2e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7180079	0.620	rs2414856	chr15:65072461	A/G	cg15337035	chr15:64978493	NA	-0.47	-5.14	-0.31	5.7e-7	Monocyte count;
KIRP	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.58	8.78	0.49	2.87e-16	Height;
KIRP	cis	rs2279817	0.863	rs11203439	chr1:18026328	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.62	9.05	0.5	4.53e-17	Neuroticism;
KIRP	cis	rs1985732	1	rs1985732	chr6:26376161	A/G	cg12826209	chr6:26865740	GUSBL1	0.48	5.47	0.33	1.11e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs748404	0.697	rs574065	chr15:43550655	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-7.38	-0.43	2.4e-12	Lung cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18462168	chr15:22892545	CYFIP1	0.72	6.06	0.36	5.09e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02334926	chr5:63802741	RGS7BP	0.53	6.51	0.38	4.21e-10	Smoking initiation;
KIRP	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg01338084	chr22:32026380	PISD	1.03	7.65	0.44	4.68e-13	Age-related hearing impairment;
KIRP	cis	rs9302635	0.640	rs9933009	chr16:72190650	G/A	cg16558253	chr16:72132732	DHX38	-0.45	-5.98	-0.36	7.83e-9	Blood protein levels;
KIRP	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.49	0.33	1.02e-7	Lung cancer;
KIRP	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.38	5.33	0.32	2.22e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg19539972	chr4:7069911	GRPEL1	0.74	9.04	0.5	4.92e-17	Monocyte percentage of white cells;
KIRP	cis	rs6499255	1.000	rs73579458	chr16:69804764	G/C	cg15192750	chr16:69999425	NA	0.48	4.87	0.3	1.99e-6	IgE levels;
KIRP	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg06647332	chr5:131281008	NA	0.43	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.74	-0.78	1.24e-52	Height;
KIRP	cis	rs514024	0.700	rs554160	chr9:130491633	T/C	cg13643465	chr9:130375613	STXBP1	0.46	5.94	0.35	9.71e-9	Eating disorders (purging via substances);
KIRP	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg12559939	chr2:27858050	GPN1	-0.45	-5.62	-0.34	5.07e-8	Oral cavity cancer;
KIRP	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg15226275	chr6:116381976	FRK	0.22	5.85	0.35	1.57e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.32	-0.32	2.38e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg02187348	chr16:89574699	SPG7	-0.46	-5.56	-0.33	6.91e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-7.5	-0.43	1.15e-12	Lymphocyte counts;
KIRP	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg23995753	chr2:160760732	LY75	-0.43	-5.78	-0.35	2.25e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07127945	chr18:45688278	NA	0.6	8.06	0.46	3.23e-14	Parkinson's disease;
KIRP	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09699651	chr6:150184138	LRP11	0.6	8.07	0.46	3.03e-14	Testicular germ cell tumor;
KIRP	cis	rs8018808	0.935	rs958463	chr14:77886721	G/T	cg20045696	chr14:77926864	AHSA1	0.46	5.68	0.34	3.71e-8	Myeloid white cell count;
KIRP	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg22549504	chr19:17448937	GTPBP3	0.46	5.05	0.31	8.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs7017914	0.902	rs35893260	chr8:71620073	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs6991838	0.584	rs7836349	chr8:66503563	A/G	cg13398993	chr8:66546079	ARMC1	-0.45	-5.1	-0.31	6.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs881375	0.902	rs7021880	chr9:123673890	G/C	cg03808351	chr9:123631620	PHF19	-0.41	-5.22	-0.32	3.88e-7	Rheumatoid arthritis;
KIRP	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.01	14.16	0.67	1.11e-33	Cognitive ability;
KIRP	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg16606324	chr3:10149918	C3orf24	0.56	5.25	0.32	3.27e-7	Alzheimer's disease;
KIRP	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg07606381	chr6:8435919	SLC35B3	-0.65	-8.49	-0.48	2.04e-15	Motion sickness;
KIRP	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.63	8.72	0.49	4.13e-16	Autism;
KIRP	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg25457927	chr22:38595422	NA	-0.31	-6.26	-0.37	1.75e-9	Breast cancer;
KIRP	cis	rs860295	0.580	rs867550	chr1:155880391	T/C	cg02153340	chr1:155202674	NA	-0.38	-4.88	-0.3	1.92e-6	Body mass index;
KIRP	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg08885076	chr2:99613938	TSGA10	-0.47	-7.27	-0.42	4.64e-12	Fear of minor pain;
KIRP	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.32	7.34	0.42	3.05e-12	Cutaneous nevi;
KIRP	cis	rs2710642	0.927	rs6705798	chr2:63259881	C/T	cg17519650	chr2:63277830	OTX1	0.43	4.86	0.3	2.08e-6	LDL cholesterol levels;LDL cholesterol;
KIRP	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-6.41	-0.38	7.19e-10	Uric acid levels;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg10254082	chr7:997346	NA	0.47	4.96	0.3	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	8.98	0.5	7.3e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4273100	0.541	rs7501702	chr17:19293727	C/T	cg25447019	chr17:19030144	GRAPL	0.55	7.65	0.44	4.5e-13	Schizophrenia;
KIRP	cis	rs4006360	1.000	rs4006360	chr17:39250639	A/G	cg15015397	chr17:39261100	KRTAP4-9	0.56	8.66	0.48	6.25e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.34	6.12	0.36	3.63e-9	Renal cell carcinoma;
KIRP	cis	rs1656402	1.000	rs2077930	chr2:233425867	G/A	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.61	8.33	0.47	5.75e-15	Blood protein levels;
KIRP	cis	rs3857067	0.934	rs1509941	chr4:95018784	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.85	-0.3	2.16e-6	QT interval;
KIRP	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	8.36	0.47	4.82e-15	Body mass index;
KIRP	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.76	-9.79	-0.53	2.53e-19	Aortic root size;
KIRP	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.74	5.96	0.36	8.49e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9815354	1.000	rs1716669	chr3:41908681	A/G	cg03022575	chr3:42003672	ULK4	0.51	5.87	0.35	1.37e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg17554472	chr22:41940697	POLR3H	-0.41	-4.95	-0.3	1.38e-6	Neuroticism;
KIRP	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.71	9.34	0.51	5.87e-18	Morning vs. evening chronotype;
KIRP	cis	rs8179	0.645	rs17766836	chr7:92258961	C/T	cg15732164	chr7:92237376	CDK6	-0.48	-6.19	-0.37	2.49e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg05973401	chr12:123451056	ABCB9	0.57	6.58	0.39	2.74e-10	Neutrophil percentage of white cells;
KIRP	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg24110177	chr3:50126178	RBM5	-0.48	-5.86	-0.35	1.48e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.44	5.25	0.32	3.27e-7	Melanoma;
KIRP	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg00931491	chr16:28608288	SULT1A2	-0.25	-5.04	-0.31	9.19e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.52	-4.85	-0.3	2.16e-6	Narcolepsy;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg09379601	chr19:12992224	DNASE2	0.68	6.05	0.36	5.48e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-6.25	-0.37	1.84e-9	Response to antipsychotic treatment;
KIRP	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.57	0.39	2.99e-10	Lung cancer;
KIRP	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.86	-0.35	1.51e-8	Multiple sclerosis;
KIRP	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.59	-7.14	-0.41	1.07e-11	Aortic root size;
KIRP	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.54	-0.48	1.45e-15	Calcium levels;
KIRP	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg13397359	chr6:42928475	GNMT	-0.61	-6.58	-0.39	2.8e-10	Blood protein levels;
KIRP	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg00629928	chr5:358741	AHRR	0.53	5.4	0.33	1.53e-7	Breast cancer;
KIRP	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.1	-0.31	6.9e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.69	-8.22	-0.46	1.18e-14	Blood protein levels;
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg07747251	chr5:1868357	NA	0.43	5.58	0.34	6.18e-8	Cardiovascular disease risk factors;
KIRP	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg00656387	chr3:40428638	ENTPD3	-0.39	-5.33	-0.32	2.17e-7	Renal cell carcinoma;
KIRP	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg07843065	chr1:150265600	MRPS21	0.45	6.25	0.37	1.75e-9	Migraine;
KIRP	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg02725872	chr8:58115012	NA	-0.43	-5.09	-0.31	7.19e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg21475434	chr5:93447410	FAM172A	-0.45	-5.27	-0.32	3.04e-7	Diabetic retinopathy;
KIRP	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	1.06	18.68	0.77	4.33e-49	Bone mineral density;
KIRP	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.22	-0.55	1.14e-20	Height;
KIRP	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.49	6.09	0.36	4.26e-9	Menopause (age at onset);
KIRP	cis	rs9815354	0.951	rs17060961	chr3:41763711	A/G	cg03022575	chr3:42003672	ULK4	0.48	5.29	0.32	2.67e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.85	-0.35	1.56e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs12912251	0.591	rs3104150	chr15:39003585	T/C	cg10631289	chr15:39006617	NA	-0.73	-8.12	-0.46	2.3e-14	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-4.87	-0.3	1.96e-6	Mean platelet volume;
KIRP	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.71	9.83	0.53	1.97e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2790457	0.833	rs1265843	chr10:28925017	T/C	cg05705492	chr10:28955341	NA	-0.54	-8.09	-0.46	2.7e-14	Multiple myeloma;
KIRP	cis	rs580438	0.529	rs4684133	chr3:13435095	G/A	cg10657019	chr3:13328039	NA	-0.5	-6.39	-0.38	8.35e-10	Myringotomy;
KIRP	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.85	10.08	0.54	3.18e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg20891558	chr2:74357851	NA	0.91	12.23	0.62	3.36e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg11814155	chr7:99998594	ZCWPW1	0.54	4.98	0.3	1.2e-6	Lung function (FEV1/FVC);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15740357	chr19:57791795	ZNF460	0.53	6.45	0.38	5.91e-10	Parkinson's disease;
KIRP	cis	rs7923609	0.905	rs7092784	chr10:65214749	C/T	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.52	-0.33	8.61e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs13720	0.722	rs163801	chr20:57578614	A/G	cg23907860	chr20:57583709	CTSZ	-0.47	-5.27	-0.32	2.96e-7	Platelet distribution width;
KIRP	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.01e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg15147215	chr3:52552868	STAB1	-0.29	-4.97	-0.3	1.25e-6	Electroencephalogram traits;
KIRP	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.45	-5.75	-0.34	2.61e-8	Initial pursuit acceleration;
KIRP	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.97	14.61	0.68	3.07e-35	Sudden cardiac arrest;
KIRP	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.83	11.24	0.58	6.25e-24	Morning vs. evening chronotype;
KIRP	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.95	-0.35	9e-9	Parkinson's disease;
KIRP	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg20240347	chr1:204465584	NA	-0.41	-7.93	-0.45	7.57e-14	Schizophrenia;
KIRP	cis	rs860295	0.702	rs10752611	chr1:155509107	C/T	cg02153340	chr1:155202674	NA	-0.56	-7.68	-0.44	3.7e-13	Body mass index;
KIRP	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.4	-5.45	-0.33	1.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.34	18.42	0.76	3.29e-48	Corneal structure;
KIRP	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.87	-0.57	1.02e-22	Height;
KIRP	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg02038168	chr22:39784481	NA	-0.42	-5.24	-0.32	3.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg06740227	chr12:86229804	RASSF9	0.44	5.59	0.34	5.9e-8	Major depressive disorder;
KIRP	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.81	-11.11	-0.58	1.69e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg01872077	chr2:219646372	CYP27A1	0.39	5.07	0.31	7.67e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.67	-11.6	-0.59	4.19e-25	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	11.44	0.59	1.43e-24	Total body bone mineral density;
KIRP	cis	rs6546886	0.957	rs4416242	chr2:74259894	A/T	cg14702570	chr2:74259524	NA	-0.33	-6.74	-0.39	1.1e-10	Dialysis-related mortality;
KIRP	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07570687	chr10:102243282	WNT8B	0.43	4.9	0.3	1.7e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg11204139	chr17:3907470	NA	0.61	8.33	0.47	5.62e-15	Type 2 diabetes;
KIRP	cis	rs2635047	0.615	rs2571005	chr18:44714365	A/G	cg19077165	chr18:44547161	KATNAL2	0.43	5.18	0.31	4.69e-7	Educational attainment;
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.6	-7.53	-0.43	9.42e-13	Aortic root size;
KIRP	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	1.16	9.05	0.5	4.39e-17	Economic and political preferences (immigration/crime);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg12404745	chr1:89846031	GBP6	0.38	6.18	0.37	2.63e-9	C-reactive protein;
KIRP	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	1.02	8.92	0.49	1.11e-16	Pulse pressure;
KIRP	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg03627880	chr6:151815985	C6orf97	-0.42	-5.16	-0.31	4.98e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.6	-6.69	-0.39	1.48e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.65	7.03	0.41	2.07e-11	Gut microbiome composition (summer);
KIRP	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.58	-7.13	-0.41	1.08e-11	Aortic root size;
KIRP	cis	rs73086581	1.000	rs17215529	chr20:3975402	A/G	cg02187196	chr20:3869020	PANK2	0.48	5.02	0.31	9.7e-7	Response to antidepressants in depression;
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.19	-0.37	2.48e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs12643440	0.538	rs16894418	chr4:17141112	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	6.2	0.37	2.42e-9	Multiple sclerosis;
KIRP	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg00784671	chr22:46762841	CELSR1	-0.66	-8.01	-0.46	4.46e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs13108043	0.511	rs13149938	chr4:87768517	G/T	cg11209507	chr4:87813803	C4orf36	-0.46	-5.16	-0.31	5.09e-7	Red blood cell count;
KIRP	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs883565	0.655	rs4676670	chr3:39049594	A/C	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	cis	rs9381107	0.932	rs13219694	chr6:9422441	T/G	cg14735645	chr6:9486422	NA	-0.45	-5.35	-0.32	2e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs3784262	0.669	rs4646554	chr15:58355437	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.97	-0.3	1.25e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2625529	0.689	rs8178	chr15:72114747	G/A	cg16672083	chr15:72433130	SENP8	-0.47	-6.64	-0.39	1.96e-10	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10263684	chr2:46520913	NA	0.54	6.82	0.4	7.01e-11	Interleukin-4 levels;
KIRP	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.71	7.82	0.45	1.56e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg02175503	chr12:58329896	NA	0.64	7.9	0.45	9.2e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-5.32	-0.32	2.39e-7	Electroencephalogram traits;
KIRP	trans	rs7246760	1.000	rs56357664	chr19:9903399	C/T	cg02900749	chr2:68251473	NA	-1.0	-8.2	-0.46	1.3e-14	Pursuit maintenance gain;
KIRP	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.03	-0.36	5.86e-9	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.52	5.89	0.35	1.24e-8	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.4e-11	Aortic root size;
KIRP	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.21	-0.32	3.93e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg18944383	chr4:111397179	ENPEP	0.51	8.41	0.47	3.3e-15	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03328750	chr5:142150401	ARHGAP26	0.56	6.59	0.39	2.58e-10	Smoking initiation;
KIRP	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.44	-5.22	-0.32	3.79e-7	Crohn's disease;
KIRP	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.58	-7.22	-0.42	6.6e-12	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4950322	0.570	rs72692963	chr1:146802821	G/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.52	1.73e-18	Colorectal cancer;
KIRP	cis	rs6504950	0.830	rs12936860	chr17:53030226	C/T	cg26251398	chr17:52985966	TOM1L1	0.42	5.19	0.31	4.5e-7	Breast cancer;
KIRP	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg18764771	chr6:116381957	FRK	0.19	5.35	0.32	2.06e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg24296786	chr1:45957014	TESK2	0.63	8.39	0.47	3.79e-15	High light scatter reticulocyte count;
KIRP	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg08975724	chr8:8085496	FLJ10661	0.6	8.37	0.47	4.36e-15	Neuroticism;
KIRP	cis	rs988913	0.957	rs2397177	chr6:54834133	A/G	cg03513858	chr6:54763001	FAM83B	-0.37	-5.37	-0.32	1.8e-7	Menarche (age at onset);
KIRP	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg23594656	chr7:65796392	TPST1	-0.44	-6.04	-0.36	5.67e-9	Aortic root size;
KIRP	cis	rs10465746	0.905	rs34274953	chr1:84415011	G/A	cg10977910	chr1:84465055	TTLL7	0.47	5.8	0.35	1.99e-8	Obesity-related traits;
KIRP	cis	rs6681460	0.649	rs7540195	chr1:67002406	C/T	cg13052034	chr1:66999238	SGIP1	-0.44	-6.0	-0.36	7.2e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.24	-0.42	5.64e-12	Colorectal cancer;
KIRP	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg21573476	chr21:45109991	RRP1B	-0.54	-7.47	-0.43	1.42e-12	Mean corpuscular volume;
KIRP	cis	rs253959	0.774	rs254151	chr5:115642097	C/G	cg23108291	chr5:115420582	COMMD10	-0.5	-5.76	-0.34	2.53e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg11130432	chr3:121712080	ILDR1	-0.46	-5.63	-0.34	5.03e-8	Multiple sclerosis;
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg23985595	chr17:80112537	CCDC57	-0.34	-5.08	-0.31	7.52e-7	Life satisfaction;
KIRP	cis	rs4302748	0.862	rs11981777	chr7:36184753	G/A	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.44	-6.68	-0.39	1.55e-10	Platelet distribution width;
KIRP	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.47	-11.68	-0.6	2.3e-25	Diabetic kidney disease;
KIRP	cis	rs78487399	0.710	rs7590220	chr2:43702151	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.02	-0.3	9.94e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.51	0.33	9.14e-8	Educational attainment;
KIRP	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.82e-7	Cognitive function;
KIRP	cis	rs6882046	0.513	rs254779	chr5:88019629	T/C	cg22951263	chr5:87985283	NA	-0.47	-6.53	-0.38	3.74e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs7113874	0.802	rs885114	chr11:8678756	G/A	cg08015107	chr11:8618950	NA	-0.41	-5.79	-0.35	2.12e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	12.13	0.61	7.24e-27	Smoking behavior;
KIRP	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13606994	chr1:44402422	ARTN	-0.28	-5.39	-0.33	1.64e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs73086581	0.945	rs6052219	chr20:3970307	A/G	cg02187196	chr20:3869020	PANK2	0.47	4.9	0.3	1.72e-6	Response to antidepressants in depression;
KIRP	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg07862535	chr7:139043722	LUC7L2	0.44	4.91	0.3	1.66e-6	Diisocyanate-induced asthma;
KIRP	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg18806716	chr10:30721971	MAP3K8	-0.45	-7.03	-0.41	2.08e-11	Inflammatory bowel disease;
KIRP	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.58	-7.82	-0.45	1.58e-13	Vitiligo;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.95	16.33	0.72	4.11e-41	Menarche (age at onset);
KIRP	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.45	5.78	0.35	2.24e-8	IgG glycosylation;
KIRP	cis	rs7615316	0.671	rs62276437	chr3:142210992	T/C	cg20824294	chr3:142316082	PLS1	-0.26	-5.21	-0.32	3.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg12560992	chr17:57184187	TRIM37	0.54	5.83	0.35	1.74e-8	Cognitive test performance;
KIRP	cis	rs13361707	0.612	rs10043245	chr5:40819088	C/T	cg01087697	chr5:40835557	RPL37	-0.4	-4.94	-0.3	1.42e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.59	7.99	0.45	5.27e-14	Height;
KIRP	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg16511985	chr3:153974050	SGEF	0.38	5.21	0.32	3.97e-7	Coronary artery disease;
KIRP	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.96	-14.87	-0.69	4.18e-36	Height;
KIRP	cis	rs667920	0.500	rs34738913	chr3:136437884	T/A	cg15507776	chr3:136538369	TMEM22	-0.68	-5.96	-0.36	8.5e-9	Coronary artery disease;
KIRP	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.06	12.58	0.63	2.35e-28	Vitiligo;
KIRP	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	6.07	0.36	4.86e-9	Response to antipsychotic treatment;
KIRP	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.6	8.13	0.46	2.09e-14	Blood protein levels;
KIRP	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.15	0.41	9.81e-12	Prudent dietary pattern;
KIRP	cis	rs7903847	0.667	rs10882931	chr10:99165794	C/A	cg20016023	chr10:99160130	RRP12	-0.41	-5.57	-0.33	6.58e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg14580859	chr9:123691850	NA	0.36	5.05	0.31	8.62e-7	Rheumatoid arthritis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg05210886	chr1:245133216	EFCAB2	0.87	6.53	0.38	3.7e-10	P wave terminal force;
KIRP	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.59	7.73	0.44	2.66e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg06740227	chr12:86229804	RASSF9	-0.42	-5.2	-0.31	4.24e-7	Major depressive disorder;
KIRP	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12311346	chr5:56204834	C5orf35	-0.48	-6.47	-0.38	5.16e-10	Coronary artery disease;
KIRP	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.57	-7.31	-0.42	3.85e-12	Prudent dietary pattern;
KIRP	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.46	-0.47	2.34e-15	Neuroticism;
KIRP	cis	rs3736594	0.840	rs57238885	chr2:27974260	C/G	cg27432699	chr2:27873401	GPN1	0.56	6.93	0.4	3.71e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.6	0.44	6.31e-13	Asthma;
KIRP	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg07541023	chr7:19748670	TWISTNB	0.64	5.74	0.34	2.72e-8	Thyroid stimulating hormone;
KIRP	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg25486957	chr4:152246857	NA	-0.58	-6.17	-0.37	2.76e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.96	-0.61	2.63e-26	Eye color traits;
KIRP	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.6	5.12	0.31	6.22e-7	Bipolar disorder;
KIRP	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg18882449	chr10:104885122	NT5C2	0.47	5.89	0.35	1.29e-8	Arsenic metabolism;
KIRP	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg26441486	chr22:50317300	CRELD2	0.55	8.41	0.47	3.3e-15	Schizophrenia;
KIRP	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.65	-7.72	-0.44	2.92e-13	Mean platelet volume;
KIRP	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg01763666	chr17:80159506	CCDC57	0.34	4.88	0.3	1.89e-6	Life satisfaction;
KIRP	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-6.45	-0.38	5.8e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-7.18	-0.42	8.3e-12	Vitiligo;
KIRP	cis	rs11628318	0.906	rs2403064	chr14:103053483	G/A	cg01864069	chr14:103024347	NA	-0.72	-9.46	-0.52	2.66e-18	Platelet count;
KIRP	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-0.78	-9.26	-0.51	1.08e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6901250	0.569	rs621486	chr6:117089143	T/C	cg12892004	chr6:117198278	RFX6	0.37	6.05	0.36	5.5e-9	C-reactive protein levels;
KIRP	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.64	-9.26	-0.51	1.02e-17	Retinal vascular caliber;
KIRP	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.8e-8	Schizophrenia;
KIRP	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg03585969	chr10:35415529	CREM	0.81	9.52	0.52	1.71e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12282928	0.921	rs7933408	chr11:48246824	G/A	cg26585981	chr11:48327164	OR4S1	-0.52	-6.24	-0.37	1.92e-9	Migraine - clinic-based;
KIRP	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.51	6.62	0.39	2.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	10.01	0.54	5.36e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10073892	0.830	rs11746537	chr5:101593522	C/T	cg19774478	chr5:101632501	SLCO4C1	0.66	6.39	0.38	8.11e-10	Cognitive decline (age-related);
KIRP	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg23625390	chr15:77176239	SCAPER	0.53	7.01	0.41	2.27e-11	Blood metabolite levels;
KIRP	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.65	7.28	0.42	4.49e-12	Tuberculosis;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19734201	chr4:39699603	UBE2K	0.47	6.3	0.37	1.35e-9	Myopia (pathological);
KIRP	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.75	-10.63	-0.56	5.65e-22	Colorectal cancer;
KIRP	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg18198730	chr1:247681584	NA	0.82	5.4	0.33	1.61e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg27624424	chr6:160112604	SOD2	-0.46	-4.94	-0.3	1.44e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4740619	0.587	rs1328274	chr9:16023669	G/T	cg14451791	chr9:16040625	NA	-0.41	-5.27	-0.32	3.06e-7	Body mass index;
KIRP	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7937612	0.802	rs36011588	chr11:120196433	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.18	-0.42	8.27e-12	Intraocular pressure;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.77	-0.35	2.36e-8	Life satisfaction;
KIRP	cis	rs17739794	0.557	rs35400327	chr8:808789	A/G	cg01971667	chr8:817044	NA	0.42	5.86	0.35	1.46e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.89	11.93	0.61	3.36e-26	Bipolar disorder;
KIRP	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	0.73	10.22	0.55	1.14e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15204119	chr19:10613180	KEAP1	0.49	6.78	0.4	8.84e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	cg04338863	chr8:33670619	NA	0.42	5.41	0.33	1.49e-7	Body mass index;
KIRP	cis	rs3736594	0.513	rs62138965	chr2:27816593	T/C	cg27432699	chr2:27873401	GPN1	0.57	6.01	0.36	6.55e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.93	14.18	0.67	8.93e-34	Mean platelet volume;
KIRP	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg09904177	chr6:26538194	HMGN4	0.43	5.83	0.35	1.74e-8	Schizophrenia;
KIRP	cis	rs793571	0.590	rs4775094	chr15:59115995	A/G	cg05156742	chr15:59063176	FAM63B	0.52	6.45	0.38	6.01e-10	Schizophrenia;
KIRP	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg19468946	chr17:37922297	IKZF3	0.46	6.66	0.39	1.74e-10	Asthma;
KIRP	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.48	7.38	0.43	2.41e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.6	7.56	0.43	8.06e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg16141378	chr3:129829833	LOC729375	0.49	6.33	0.37	1.16e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13401104	0.680	rs11894606	chr2:237114834	T/G	cg19324714	chr2:237145437	ASB18	0.47	5.02	0.3	9.92e-7	Educational attainment;
KIRP	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg05347473	chr6:146136440	FBXO30	-0.49	-6.86	-0.4	5.49e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.56	7.41	0.43	2e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.94	11.21	0.58	7.75e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg16989719	chr2:238392110	NA	-0.53	-6.99	-0.41	2.54e-11	Prostate cancer;
KIRP	trans	rs933360	0.585	rs7785914	chr7:50833576	T/C	cg20003124	chr12:4557277	NA	0.53	6.46	0.38	5.69e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg16473166	chr22:50639996	SELO	-0.65	-8.04	-0.46	3.82e-14	Obesity-related traits;
KIRP	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.36	-0.47	4.67e-15	Inflammatory bowel disease;
KIRP	trans	rs6775745	0.600	rs9289416	chr3:131800249	A/G	cg08905652	chr6:74161099	C6orf150	-0.48	-6.2	-0.37	2.4e-9	Neutrophil count;
KIRP	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg22541963	chr20:60982533	CABLES2	-0.41	-5.09	-0.31	7.18e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.68	6.57	0.39	3.01e-10	Eotaxin levels;
KIRP	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg19847130	chr8:10466454	RP1L1	0.35	5.31	0.32	2.43e-7	Retinal vascular caliber;
KIRP	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs6662572	0.703	rs72690847	chr1:46256929	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.6	0.34	5.75e-8	Blood protein levels;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.56	-7.02	-0.41	2.17e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs8049040	0.521	rs12935725	chr16:71569388	T/C	cg08717414	chr16:71523259	ZNF19	-0.54	-6.21	-0.37	2.28e-9	Blood protein levels;
KIRP	cis	rs7553864	0.667	rs4656143	chr1:87605208	G/A	cg17420885	chr1:87600446	LOC339524	-0.58	-7.47	-0.43	1.36e-12	Smoking behavior;
KIRP	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg05418105	chr22:50981406	NA	-0.58	-6.28	-0.37	1.55e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10021731	0.597	rs12508215	chr4:115620259	C/T	cg22609233	chr4:115518992	UGT8	0.38	5.07	0.31	7.92e-7	Optic disc area;
KIRP	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.46	-6.11	-0.36	3.84e-9	Blood metabolite levels;
KIRP	cis	rs13343954	0.825	rs2216595	chr19:33533292	C/T	cg27124370	chr19:33622961	WDR88	0.62	6.92	0.4	3.86e-11	Colorectal cancer;
KIRP	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg05966235	chr16:28915196	ATP2A1	-0.45	-4.93	-0.3	1.5e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg24315340	chr6:146058215	EPM2A	0.42	5.22	0.32	3.83e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-0.53	-7.41	-0.43	2.02e-12	Coronary artery disease;
KIRP	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	7.39	0.43	2.27e-12	Joint mobility (Beighton score);
KIRP	cis	rs7534824	0.625	rs17525507	chr1:101430504	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.16	0.42	9.39e-12	Refractive astigmatism;
KIRP	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.61	-8.51	-0.48	1.72e-15	Menarche (age at onset);
KIRP	cis	rs3741151	0.773	rs12274057	chr11:73283937	A/T	cg17517138	chr11:73019481	ARHGEF17	0.67	5.38	0.32	1.73e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.34	-0.32	2.11e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23544223	chr18:12777786	NA	0.76	6.42	0.38	6.9e-10	Inflammatory skin disease;
KIRP	cis	rs1461503	0.934	rs930983	chr11:122834414	A/G	cg27398637	chr11:122830231	C11orf63	-0.66	-8.32	-0.47	5.95e-15	Menarche (age at onset);
KIRP	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.93	14.24	0.67	5.94e-34	Coronary artery disease;
KIRP	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.58	-7.1	-0.41	1.35e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9311676	0.632	rs62258078	chr3:58363432	G/A	cg06643156	chr3:58380774	PXK	0.36	5.14	0.31	5.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.58	7.54	0.43	9.22e-13	Breast cancer;
KIRP	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.35	-0.38	1.01e-9	Coronary artery disease;
KIRP	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg21827317	chr3:136751795	NA	0.36	4.93	0.3	1.49e-6	Neuroticism;
KIRP	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.82	-13.51	-0.65	1.7e-31	Longevity;
KIRP	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.55	7.39	0.43	2.26e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs57338032	0.891	rs61299530	chr15:78760287	G/A	cg06917634	chr15:78832804	PSMA4	0.56	4.95	0.3	1.41e-6	CTACK levels;
KIRP	cis	rs17125944	0.686	rs55685925	chr14:53334546	A/G	cg00686598	chr14:53173677	PSMC6	-0.7	-6.74	-0.39	1.12e-10	Alzheimer's disease (late onset);
KIRP	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.48	0.33	1.03e-7	Diastolic blood pressure;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-1.16	-22.29	-0.82	5.8e-61	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.05	-0.36	5.47e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.97	-0.45	5.81e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6545883	0.524	rs778159	chr2:61556744	T/C	cg15711740	chr2:61764176	XPO1	0.46	5.73	0.34	2.95e-8	Tuberculosis;
KIRP	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2299587	0.932	rs13279395	chr8:17852036	T/G	cg01800426	chr8:17659068	MTUS1	-0.41	-4.86	-0.3	2.1e-6	Economic and political preferences;
KIRP	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.63	-8.29	-0.47	7.59e-15	Iron status biomarkers;
KIRP	cis	rs11191270	0.554	rs11191275	chr10:104142800	C/T	cg15320455	chr10:103880129	LDB1	0.88	6.79	0.4	8.5e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18317022	chr19:48017995	NAPA	0.48	6.05	0.36	5.45e-9	Parkinson's disease;
KIRP	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	0.85	7.7	0.44	3.29e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg04289385	chr6:36355825	ETV7	0.43	6.85	0.4	5.85e-11	Platelet distribution width;
KIRP	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs9826463	0.757	rs79576118	chr3:142244645	A/C	cg20824294	chr3:142316082	PLS1	0.39	6.25	0.37	1.84e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.74	-0.44	2.65e-13	Colorectal cancer;
KIRP	cis	rs11871801	0.517	rs6963	chr17:40731597	A/T	cg14558262	chr17:40713999	COASY	-0.5	-5.37	-0.32	1.85e-7	Crohn's disease;
KIRP	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg08717414	chr16:71523259	ZNF19	-0.45	-4.85	-0.3	2.18e-6	Post bronchodilator FEV1;
KIRP	cis	rs8077577	0.708	rs4925151	chr17:18130132	G/C	cg18869244	chr17:18121946	NA	-0.48	-5.42	-0.33	1.43e-7	Obesity-related traits;
KIRP	cis	rs2131877	0.573	rs4645095	chr3:194846894	C/T	cg19775763	chr3:194786989	NA	-0.43	-5.23	-0.32	3.66e-7	Non-small cell lung cancer;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.25	-0.32	3.29e-7	Life satisfaction;
KIRP	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.46	-5.89	-0.35	1.24e-8	Blood metabolite levels;
KIRP	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg11569703	chr11:65557185	OVOL1	-0.36	-5.69	-0.34	3.6e-8	Eosinophil percentage of white cells;
KIRP	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.63	0.39	2.11e-10	Colorectal cancer;
KIRP	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg08662619	chr6:150070041	PCMT1	0.31	4.87	0.3	2.02e-6	Testicular germ cell tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00111333	chr1:198828249	MIR181B1;MIR181A1	0.5	6.77	0.4	9.57e-11	Interleukin-4 levels;
KIRP	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.5	0.43	1.15e-12	Obesity-related traits;
KIRP	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.89	-10.04	-0.54	4.07e-20	Exhaled nitric oxide output;
KIRP	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg19592336	chr6:28129416	ZNF389	0.48	5.35	0.32	1.97e-7	Depression;
KIRP	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg13264159	chr8:625131	ERICH1	-0.66	-5.68	-0.34	3.84e-8	IgG glycosylation;
KIRP	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg06598544	chr20:61472147	COL9A3	-0.74	-6.46	-0.38	5.57e-10	Obesity-related traits;
KIRP	cis	rs6774721	1.000	rs6774721	chr3:49381898	G/A	cg19401529	chr3:49056140	DALRD3	0.91	6.71	0.39	1.36e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg00149659	chr3:10157352	C3orf10	0.62	7.19	0.42	7.66e-12	Alzheimer's disease;
KIRP	cis	rs1434579	0.966	rs7246892	chr19:44928668	A/G	cg15540054	chr19:45004280	ZNF180	0.53	5.81	0.35	1.91e-8	Tuberculosis;
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg15181151	chr6:150070149	PCMT1	0.3	5.06	0.31	8.25e-7	Lung cancer;
KIRP	cis	rs830233	0.649	rs62383296	chr5:165432070	T/C	cg13976338	chr5:165423657	NA	-0.71	-7.81	-0.45	1.65e-13	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg16497661	chr14:103986332	CKB	-0.49	-6.31	-0.37	1.26e-9	Coronary artery disease;
KIRP	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg18586891	chr4:952366	TMEM175	0.62	5.1	0.31	6.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10186029	0.509	rs1122846	chr2:213939354	C/G	cg08319019	chr2:214017104	IKZF2	0.44	5.32	0.32	2.35e-7	Systemic sclerosis;
KIRP	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.65	9.62	0.52	8.17e-19	Schizophrenia;
KIRP	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.39	-5.2	-0.31	4.24e-7	Social autistic-like traits;
KIRP	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg20302533	chr7:39170763	POU6F2	0.26	5.18	0.31	4.7e-7	IgG glycosylation;
KIRP	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.53	-6.26	-0.37	1.67e-9	Bone mineral density;
KIRP	cis	rs77633900	0.772	rs284902	chr15:76745687	G/C	cg21673338	chr15:77095150	SCAPER	-0.63	-5.5	-0.33	9.74e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs10875746	0.855	rs17122620	chr12:48464475	A/G	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs2224391	0.590	rs2145372	chr6:5245070	T/C	cg13962347	chr6:5174647	LYRM4	-0.72	-10.01	-0.54	5.16e-20	Height;
KIRP	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg26965718	chr17:79658957	HGS	-0.62	-5.8	-0.35	1.98e-8	Dental caries;
KIRP	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.21e-7	Red blood cell count;
KIRP	cis	rs2057178	1.000	rs11031728	chr11:32363616	C/G	cg06489367	chr11:32355509	NA	0.44	4.97	0.3	1.23e-6	Tuberculosis;
KIRP	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg12435725	chr3:58293450	RPP14	-0.47	-5.07	-0.31	7.85e-7	Cholesterol, total;
KIRP	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.8	10.78	0.57	1.97e-22	Morning vs. evening chronotype;
KIRP	cis	rs9652601	0.959	rs9888908	chr16:11181244	C/A	cg04616529	chr16:11181986	CLEC16A	0.37	4.85	0.3	2.15e-6	Systemic lupus erythematosus;
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.6	8.94	0.5	9.27e-17	Menarche (age at onset);
KIRP	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-7.54	-0.43	8.77e-13	Coronary artery disease;
KIRP	cis	rs7599312	0.586	rs4404217	chr2:213385817	G/A	cg20637307	chr2:213403960	ERBB4	0.43	4.99	0.3	1.12e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2797160	0.547	rs1418645	chr6:125946476	T/A	cg05901451	chr6:126070800	HEY2	-0.37	-5.12	-0.31	6.04e-7	Endometrial cancer;
KIRP	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.7	0.39	1.44e-10	Height;
KIRP	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.43	0.33	1.36e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.57	9.32	0.51	6.69e-18	Lung cancer;
KIRP	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.68	4.89	0.3	1.79e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.71	7.19	0.42	7.79e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg26876637	chr1:152193138	HRNR	-0.69	-9.02	-0.5	5.6e-17	Atopic dermatitis;
KIRP	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.68	-6.26	-0.37	1.72e-9	Schizophrenia;
KIRP	cis	rs2046867	0.862	rs28632160	chr3:72800690	T/C	cg25664220	chr3:72788482	NA	-0.45	-6.89	-0.4	4.73e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg02038168	chr22:39784481	NA	-0.41	-4.89	-0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.57	-0.33	6.6e-8	Subjective well-being;
KIRP	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.34	-7.5	-0.43	1.16e-12	Cutaneous nevi;
KIRP	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg14250997	chr9:106856677	SMC2	0.44	6.15	0.36	3.19e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg27532560	chr4:187881888	NA	-0.77	-12.99	-0.64	9.67e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17123764	0.710	rs12320556	chr12:49973011	A/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.67	-7.28	-0.42	4.5e-12	Gut microbiome composition (summer);
KIRP	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.81	9.94	0.54	8.69e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg09117114	chr16:67998030	SLC12A4	-0.47	-4.94	-0.3	1.44e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7635838	0.819	rs4684781	chr3:11516299	G/A	cg00170343	chr3:11313890	ATG7	0.48	6.19	0.37	2.54e-9	HDL cholesterol;
KIRP	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg03959625	chr15:84868606	LOC388152	0.71	8.47	0.48	2.22e-15	Schizophrenia;
KIRP	cis	rs8077577	0.895	rs735960	chr17:18057301	G/A	cg09161412	chr17:18057145	MYO15A	-0.4	-5.08	-0.31	7.59e-7	Obesity-related traits;
KIRP	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06915872	chr16:87998081	BANP	0.57	5.96	0.36	8.83e-9	Menopause (age at onset);
KIRP	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg08773314	chr2:239334832	ASB1	0.42	7.36	0.42	2.73e-12	Multiple system atrophy;
KIRP	cis	rs17123764	0.818	rs75222486	chr12:50009762	T/G	cg20471783	chr12:50157085	TMBIM6	0.4	5.65	0.34	4.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg10547527	chr2:198650123	BOLL	-0.54	-4.86	-0.3	2.08e-6	Ulcerative colitis;
KIRP	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.23	-6.1	-0.36	4.1e-9	Mean corpuscular volume;
KIRP	cis	rs6832769	0.922	rs6825994	chr4:56390411	C/A	cg05960024	chr4:56376020	CLOCK	-0.63	-8.09	-0.46	2.69e-14	Personality dimensions;
KIRP	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg24375607	chr4:120327624	NA	0.55	6.33	0.37	1.12e-9	Corneal astigmatism;
KIRP	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.97	0.41	2.93e-11	Coffee consumption (cups per day);
KIRP	trans	rs7939886	0.920	rs11227868	chr11:56083905	C/T	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.34	6.11	0.36	3.77e-9	Renal cell carcinoma;
KIRP	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg17595323	chr11:93583763	C11orf90	-0.37	-6.14	-0.36	3.36e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.55	-6.79	-0.4	8.5e-11	Schizophrenia;
KIRP	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.51	6.58	0.39	2.77e-10	Aortic root size;
KIRP	cis	rs9815354	0.767	rs79323474	chr3:42000973	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.78	6.55	0.39	3.3e-10	Fat distribution (HIV);
KIRP	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.77	-12.38	-0.62	1.06e-27	Resting heart rate;
KIRP	cis	rs365132	1.000	rs353467	chr5:176445698	T/C	cg16309518	chr5:176445507	NA	-0.88	-13.64	-0.66	6.2e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg13711144	chr7:107218933	BCAP29;DUS4L	0.54	6.7	0.39	1.41e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg12071656	chr20:44642570	MMP9	0.43	6.02	0.36	6.31e-9	Colorectal cancer;
KIRP	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.99	-16.75	-0.73	1.52e-42	Breast cancer;
KIRP	cis	rs7584330	0.626	rs2271809	chr2:238449107	A/G	cg16989719	chr2:238392110	NA	-0.39	-5.19	-0.31	4.4e-7	Prostate cancer;
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg17294928	chr15:75287854	SCAMP5	0.57	7.2	0.42	7.17e-12	Caffeine consumption;
KIRP	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.97	11.48	0.59	1.04e-24	Iron status biomarkers;
KIRP	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.89	0.35	1.25e-8	Motion sickness;
KIRP	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg00106254	chr7:1943704	MAD1L1	-0.57	-6.33	-0.37	1.14e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.12	-0.31	6.19e-7	Skin colour saturation;
KIRP	cis	rs9517302	0.578	rs2274054	chr13:99098470	C/T	cg24044564	chr13:99115944	STK24	0.55	6.29	0.37	1.42e-9	Obesity-related traits;
KIRP	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-1.05	-20.13	-0.79	6.38e-54	Height;
KIRP	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.05	11.79	0.6	9.77e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.37	0.32	1.8e-7	Ovarian reserve;
KIRP	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	1.03	11.57	0.59	5.15e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg09873164	chr1:152488093	CRCT1	0.56	7.09	0.41	1.46e-11	Hair morphology;
KIRP	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.78	12.27	0.62	2.57e-27	Bladder cancer;
KIRP	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	8.72	0.49	4.31e-16	Coronary artery disease;
KIRP	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.66	9.73	0.53	3.81e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.64	-0.44	4.92e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg12403142	chr1:92012408	NA	-0.39	-4.9	-0.3	1.74e-6	Breast cancer;
KIRP	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.59	6.91	0.4	4.15e-11	Blood protein levels;
KIRP	cis	rs1056053	0.514	rs3127329	chr6:166572362	G/A	cg11088901	chr6:166572345	T	-0.51	-7.28	-0.42	4.46e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.31	5.24	0.32	3.52e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs2916247	1.000	rs11775644	chr8:93042425	C/A	cg10183463	chr8:93005414	RUNX1T1	-0.58	-7.09	-0.41	1.42e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg04374321	chr14:90722782	PSMC1	-0.89	-13.29	-0.65	9.44e-31	Mortality in heart failure;
KIRP	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	6.73	0.39	1.19e-10	Height;
KIRP	trans	rs1928295	0.786	rs7038943	chr9:120377178	T/C	cg04204072	chr16:20752857	THUMPD1	-0.5	-6.29	-0.37	1.42e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12311304	0.901	rs7132337	chr12:15416115	A/G	cg08258403	chr12:15378311	NA	0.38	5.5	0.33	9.5e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg02336718	chr17:17403227	NA	-0.38	-5.73	-0.34	2.91e-8	Total body bone mineral density;
KIRP	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-9.85	-0.53	1.68e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.74	-10.73	-0.56	2.67e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-1.0	-16.86	-0.73	6.58e-43	Height;
KIRP	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg13482628	chr17:19912719	NA	0.61	8.7	0.48	4.9e-16	Schizophrenia;
KIRP	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg01097406	chr16:89675127	NA	-0.31	-4.93	-0.3	1.54e-6	Vitiligo;
KIRP	cis	rs9761603	0.662	rs9761827	chr4:138416511	G/A	cg12033966	chr4:138453416	PCDH18	0.43	5.69	0.34	3.61e-8	Diastolic blood pressure;
KIRP	cis	rs7178909	0.872	rs17241560	chr15:90429202	T/A	cg19708238	chr15:90437601	AP3S2	0.54	7.37	0.43	2.66e-12	Common traits (Other);
KIRP	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg23682824	chr7:23144976	KLHL7	0.49	5.88	0.35	1.34e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs62238980	0.520	rs62238975	chr22:32569545	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.79	5.37	0.32	1.85e-7	Childhood ear infection;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10355708	chr8:145618298	ADCK5	0.56	6.02	0.36	6.24e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg21775007	chr8:11205619	TDH	-0.39	-4.9	-0.3	1.72e-6	Neuroticism;
KIRP	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12315302	chr6:26189340	HIST1H4D	0.65	5.08	0.31	7.55e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg06740227	chr12:86229804	RASSF9	0.4	5.01	0.3	1.04e-6	Major depressive disorder;
KIRP	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.51	6.68	0.39	1.61e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	1.13	10.82	0.57	1.45e-22	Left atrial antero-posterior diameter;
KIRP	cis	rs9549328	0.670	rs2873372	chr13:113613383	A/G	cg17524180	chr13:113633600	MCF2L	-0.28	-5.32	-0.32	2.37e-7	Systolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18397137	chr19:59055873	TRIM28	0.46	6.09	0.36	4.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	0.77	7.94	0.45	6.98e-14	Breast cancer;
KIRP	cis	rs9463078	0.547	rs4711798	chr6:44750777	A/G	cg25276700	chr6:44698697	NA	-0.35	-4.92	-0.3	1.58e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.23	-0.32	3.56e-7	Retinal vascular caliber;
KIRP	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.44	5.16	0.31	5e-7	Schizophrenia;
KIRP	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.62	8.37	0.47	4.49e-15	Total body bone mineral density;
KIRP	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.53	8.33	0.47	5.59e-15	Lung cancer;
KIRP	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	8.96	0.5	8.21e-17	Motion sickness;
KIRP	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.56	0.33	6.93e-8	Breast cancer;
KIRP	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.5	-7.39	-0.43	2.29e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.02e-14	Lung cancer;
KIRP	cis	rs712039	0.652	rs853197	chr17:35848716	T/C	cg16670864	chr17:35848621	DUSP14	0.46	5.69	0.34	3.64e-8	Tuberculosis;
KIRP	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.66	-9.05	-0.5	4.39e-17	Huntington's disease progression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24763094	chr2:160569157	MARCH7	0.42	6.11	0.36	3.97e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.6	-0.39	2.55e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg26373071	chr5:1325741	CLPTM1L	0.56	7.44	0.43	1.67e-12	Lung cancer;
KIRP	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg17644776	chr2:200775616	C2orf69	0.57	5.26	0.32	3.09e-7	Schizophrenia;
KIRP	cis	rs965513	0.901	rs7045465	chr9:100534823	A/T	cg13688889	chr9:100608707	NA	-0.43	-5.3	-0.32	2.51e-7	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	9.96	0.54	7.32e-20	Coffee consumption (cups per day);
KIRP	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.99	-13.68	-0.66	4.79e-32	Ulcerative colitis;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg10253484	chr15:75165896	SCAMP2	-0.53	-6.39	-0.38	8.07e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs2554380	0.943	rs2562776	chr15:84368163	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-8.96	-0.5	8.23e-17	Height;
KIRP	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-11.78	-0.6	1.1e-25	Chronic sinus infection;
KIRP	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg12560992	chr17:57184187	TRIM37	0.6	5.5	0.33	9.69e-8	Cognitive test performance;
KIRP	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.54	6.71	0.39	1.3100000000000001e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.7	-10.14	-0.54	2.11e-20	Brugada syndrome;
KIRP	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.15	-15.09	-0.69	7.49e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.7	9.79	0.53	2.59e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs12049351	0.774	rs12039754	chr1:229644896	G/A	cg11742688	chr1:229674241	ABCB10	-0.37	-5.4	-0.33	1.57e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.7	10.14	0.54	2.05e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg26338869	chr17:61819248	STRADA	0.53	6.28	0.37	1.52e-9	Prudent dietary pattern;
KIRP	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg02570527	chr1:10970165	NA	-0.4	-4.98	-0.3	1.18e-6	Body mass index;
KIRP	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-0.67	-7.72	-0.44	3e-13	Initial pursuit acceleration;
KIRP	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg07636037	chr3:49044803	WDR6	-0.75	-5.63	-0.34	4.84e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02666008	chr1:110880366	NA	0.43	6.24	0.37	1.93e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.19	-0.37	2.43e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60311166	1.000	rs12107484	chr3:52632093	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.91	5.6	0.34	5.58e-8	CTACK levels;
KIRP	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00149659	chr3:10157352	C3orf10	0.76	6.74	0.39	1.13e-10	Alzheimer's disease;
KIRP	cis	rs1559088	0.576	rs4805852	chr19:33609441	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-6.33	-0.37	1.15e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg06521331	chr12:34319734	NA	-0.54	-6.82	-0.4	7.05e-11	Bladder cancer;
KIRP	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.6	0.39	2.54e-10	Height;
KIRP	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.65	5.48	0.33	1.03e-7	Facial emotion recognition (sad faces);
KIRP	cis	rs5756391	0.546	rs1807546	chr22:37311425	A/C	cg16356956	chr22:37317934	CSF2RB	0.42	5.76	0.34	2.55e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs11638352	0.661	rs2555384	chr15:44420900	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.08	-0.36	4.49e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.72	7.05	0.41	1.79e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05315796	chr3:52349193	DNAH1	0.4	6.2	0.37	2.36e-9	Bipolar disorder;
KIRP	trans	rs62056376	0.736	rs758293	chr17:32640523	A/T	cg04960603	chr2:119604313	EN1	0.55	6.17	0.37	2.84e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	1.02	15.96	0.71	7.68e-40	Vitamin D levels;
KIRP	cis	rs745821	0.701	rs11873631	chr18:48100404	C/T	cg18923635	chr18:48083994	NA	0.43	5.12	0.31	6.19e-7	Diastolic blood pressure;
KIRP	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.89	-11.75	-0.6	1.36e-25	Menopause (age at onset);
KIRP	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	1.03	13.01	0.64	8.2e-30	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11397581	chr15:22955729	CYFIP1	0.48	6.13	0.36	3.52e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4132509	1.000	rs9782883	chr1:243892532	A/G	cg25706552	chr1:244017396	NA	0.58	7.5	0.43	1.17e-12	RR interval (heart rate);
KIRP	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13876462	chr9:103236040	TMEFF1	-0.44	-6.49	-0.38	4.65e-10	Myopia;
KIRP	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.62e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.16	-0.37	2.92e-9	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg15181151	chr6:150070149	PCMT1	0.31	5.32	0.32	2.38e-7	Lung cancer;
KIRP	cis	rs12210905	1.000	rs12201498	chr6:27030084	C/T	cg11502198	chr6:26597334	ABT1	-0.78	-4.98	-0.3	1.18e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.66	-8.05	-0.46	3.61e-14	Aortic root size;
KIRP	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.16	0.31	5.15e-7	Lung cancer;
KIRP	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25517755	chr10:38738941	LOC399744	-0.52	-7.14	-0.41	1.05e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.83	0.6	7.21e-26	Ileal carcinoids;
KIRP	cis	rs1165472	0.588	rs1514135	chr1:56116232	C/G	cg11523071	chr1:56160889	NA	-0.41	-6.06	-0.36	4.98e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs6499755	0.739	rs31099	chr16:55370907	G/A	cg05099576	chr16:55362342	IRX6	0.33	6.63	0.39	2.05e-10	Hypospadias;
KIRP	cis	rs7709377	0.620	rs7734295	chr5:115432208	G/A	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01023714	chr4:10084725	WDR1	0.58	6.96	0.41	3.01e-11	Interleukin-4 levels;
KIRP	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.76	-12.65	-0.63	1.33e-28	Calcium levels;
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.75	10.8	0.57	1.65e-22	Lung cancer;
KIRP	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	0.94	15.52	0.7	2.46e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-7.96	-0.45	6.43e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6974574	0.961	rs1717720	chr7:38112615	A/G	cg10754659	chr7:38110151	NA	-0.37	-5.0	-0.3	1.1e-6	Height;
KIRP	cis	rs6681460	1.000	rs4655636	chr1:67068537	A/G	cg02459107	chr1:67143332	SGIP1	0.47	6.64	0.39	2.02e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.69	8.53	0.48	1.53e-15	Multiple sclerosis;
KIRP	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1420338	0.837	rs17753041	chr7:34176925	G/A	cg01275685	chr7:34179230	BMPER	-0.61	-9.3	-0.51	8.07e-18	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.68	9.7	0.53	4.69e-19	Retinal vascular caliber;
KIRP	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.7	9.95	0.54	8.22e-20	Caffeine consumption;
KIRP	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.43	5.57	0.33	6.68e-8	Blood metabolite levels;
KIRP	cis	rs427941	0.668	rs201438	chr7:101735236	G/A	cg06246474	chr7:101738831	CUX1	0.55	6.8	0.4	7.91e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	0.94	6.34	0.37	1.07e-9	P wave terminal force;
KIRP	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg09788416	chr12:39539408	NA	0.43	5.25	0.32	3.22e-7	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2573652	0.674	rs11630583	chr15:100543355	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.23	-0.42	6.15e-12	Height;
KIRP	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.66	-8.25	-0.47	9.45e-15	Corneal astigmatism;
KIRP	cis	rs11209002	0.614	rs7552205	chr1:67551741	C/A	cg02640540	chr1:67518911	SLC35D1	0.59	6.54	0.38	3.62e-10	Crohn's disease;
KIRP	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg24110177	chr3:50126178	RBM5	-0.67	-7.62	-0.44	5.42e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.44	-5.1	-0.31	6.79e-7	P wave terminal force;
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.97	-14.1	-0.67	1.79e-33	Longevity;Endometriosis;
KIRP	cis	rs9616064	0.520	rs875559	chr22:47034838	T/C	cg22689280	chr22:47017522	NA	0.44	4.96	0.3	1.29e-6	Urate levels in obese individuals;
KIRP	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg09029085	chr17:47094198	IGF2BP1	0.24	5.59	0.34	6.01e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs12913538	0.747	rs7167910	chr15:62888516	C/T	cg09983546	chr15:62884068	NA	-0.56	-7.58	-0.43	7.17e-13	Sleep depth;
KIRP	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg11130432	chr3:121712080	ILDR1	0.42	5.05	0.31	8.69e-7	Multiple sclerosis;
KIRP	cis	rs2067615	0.831	rs1922437	chr12:107058045	C/T	cg21360079	chr12:107162445	NA	-0.44	-5.51	-0.33	8.9e-8	Heart rate;
KIRP	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg20673091	chr1:2541236	MMEL1	0.6	8.47	0.48	2.19e-15	Multiple sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10325536	chr4:3512392	NA	-0.47	-6.27	-0.37	1.6e-9	Parkinson's disease;
KIRP	cis	rs7523273	0.606	rs1474742	chr1:207976666	A/C	cg22525895	chr1:207977042	MIR29B2	0.7	9.37	0.51	5.05e-18	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.74	-10.31	-0.55	6.09e-21	Childhood ear infection;
KIRP	cis	rs4262150	0.667	rs4533947	chr5:152260682	A/G	cg12297329	chr5:152029980	NA	-0.47	-6.69	-0.39	1.47e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs1345301	0.587	rs12464251	chr2:102867208	C/G	cg12451869	chr2:102867685	NA	0.49	7.06	0.41	1.72e-11	Waist circumference;
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg14664628	chr15:75095509	CSK	-0.67	-8.06	-0.46	3.25e-14	Caffeine consumption;
KIRP	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25223263	chr11:119020168	ABCG4	0.4	6.02	0.36	6.14e-9	Survival in pancreatic cancer;
KIRP	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.4	-5.9	-0.35	1.17e-8	Coronary artery disease;
KIRP	cis	rs2737618	0.674	rs2260033	chr1:200086074	G/A	cg21825944	chr1:200113062	NR5A2	-0.54	-7.68	-0.44	3.72e-13	Uric acid levels;
KIRP	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.79	9.95	0.54	8.25e-20	Corneal astigmatism;
KIRP	trans	rs6601327	0.665	rs10113186	chr8:9655426	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.15	-0.41	9.73e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg16077055	chr2:106428750	NCK2	0.31	6.06	0.36	4.97e-9	Addiction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20415529	chr4:57845134	POLR2B;C4orf14	0.53	7.01	0.41	2.33e-11	Parkinson's disease;
KIRP	trans	rs6881634	0.524	rs9293750	chr5:77754138	C/T	cg02919814	chr21:37666008	DOPEY2	-0.41	-6.03	-0.36	5.87e-9	Hippocampal atrophy;
KIRP	cis	rs4700695	0.925	rs796728	chr5:65382500	C/T	cg21114390	chr5:65439923	SFRS12	-0.55	-6.0	-0.36	7e-9	Facial morphology (factor 19);
KIRP	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.55	-11.49	-0.59	9.75e-25	Diabetic kidney disease;
KIRP	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg17143192	chr8:8559678	CLDN23	0.61	7.17	0.42	9e-12	Obesity-related traits;
KIRP	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.88	-11.94	-0.61	3.26e-26	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg01256987	chr12:42539512	GXYLT1	-0.45	-5.87	-0.35	1.43e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg12427896	chr2:111880694	BCL2L11	0.77	6.51	0.38	4.31e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs11779988	0.545	rs436506	chr8:17798243	A/G	cg01800426	chr8:17659068	MTUS1	0.58	5.55	0.33	7.48e-8	Breast cancer;
KIRP	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg27490568	chr2:178487706	NA	0.49	6.63	0.39	2.11e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.5	6.39	0.38	8.35e-10	Menopause (age at onset);
KIRP	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg23594656	chr7:65796392	TPST1	0.53	8.19	0.46	1.41e-14	Aortic root size;
KIRP	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.77	10.32	0.55	5.61e-21	Morning vs. evening chronotype;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.78	11.96	0.61	2.65e-26	Menarche (age at onset);
KIRP	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.32	0.37	1.22e-9	Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.84	9.04	0.5	4.94e-17	Phospholipid levels (plasma);
KIRP	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.49	-6.21	-0.37	2.21e-9	Post bronchodilator FEV1;
KIRP	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg08847533	chr14:75593920	NEK9	0.46	5.49	0.33	1.02e-7	IgG glycosylation;
KIRP	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-5.08	-0.31	7.5e-7	Axial length;
KIRP	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19524238	chr7:2802976	GNA12	-0.37	-5.08	-0.31	7.56e-7	Height;
KIRP	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-10.26	-0.55	8.43e-21	Total body bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08714311	chr1:62311238	INADL	-0.47	-7.04	-0.41	1.96e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6466055	0.661	rs67180946	chr7:104828926	T/A	cg04380332	chr7:105027541	SRPK2	0.36	4.85	0.3	2.18e-6	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.35	-6.35	-0.38	1.02e-9	Renal cell carcinoma;
KIRP	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.74	11.57	0.59	5.3e-25	Prostate cancer;
KIRP	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg02023728	chr11:77925099	USP35	-0.35	-5.46	-0.33	1.16e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.44	5.43	0.33	1.37e-7	Blood protein levels;
KIRP	trans	rs593982	0.925	rs585272	chr11:65505289	A/G	cg16063989	chr7:139929855	NA	0.45	6.19	0.37	2.5e-9	Atopic dermatitis;
KIRP	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg07148914	chr20:33460835	GGT7	0.41	5.2	0.31	4.2e-7	Height;
KIRP	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg08807101	chr21:30365312	RNF160	-0.65	-7.73	-0.44	2.69e-13	Pancreatic cancer;
KIRP	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.81	9.93	0.53	9.32e-20	Corneal astigmatism;
KIRP	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.39	5.65	0.34	4.35e-8	Testicular germ cell tumor;
KIRP	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg02175503	chr12:58329896	NA	-0.54	-6.06	-0.36	4.95e-9	Multiple sclerosis;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg00738919	chr7:1100172	C7orf50	0.43	5.11	0.31	6.5e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6256	1.000	rs78828031	chr11:13574150	T/A	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.64	-7.77	-0.44	2.11e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	1.01	11.21	0.58	8.01e-24	Blood protein levels;
KIRP	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.67	8.05	0.46	3.62e-14	Neutrophil percentage of white cells;
KIRP	cis	rs1978968	1.000	rs1076539	chr22:18439598	A/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.78	-0.44	2e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs62355272	0.861	rs1603071	chr5:35846278	C/T	cg13894535	chr5:35919491	CAPSL	-0.51	-5.67	-0.34	4.05e-8	Lymphocyte counts;
KIRP	cis	rs742614	0.875	rs3888736	chr20:32479793	C/A	cg06304546	chr20:32448765	NA	-0.47	-5.79	-0.35	2.12e-8	Stearic acid (18:0) levels;
KIRP	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.27	-5.6	-0.34	5.6e-8	Menarche (age at onset);
KIRP	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.97	15.75	0.71	4.02e-39	Uric acid clearance;
KIRP	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.58	6.95	0.41	3.3e-11	Height;
KIRP	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg20243544	chr17:37824526	PNMT	0.54	7.94	0.45	7.1e-14	Asthma;
KIRP	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2862064	0.932	rs2221267	chr5:156401533	G/C	cg12943317	chr5:156479607	HAVCR1	-0.84	-6.55	-0.39	3.35e-10	Platelet count;
KIRP	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.03	-0.36	5.89e-9	Height;
KIRP	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.78	9.23	0.51	1.31e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.95	-15.66	-0.71	7.99e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.71	9.4	0.51	4.03e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.6	-7.66	-0.44	4.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7654585	0.962	rs2309289	chr4:25947094	T/A	cg10409131	chr4:25915609	C4orf52	0.51	5.83	0.35	1.74e-8	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg12486944	chr17:80159399	CCDC57	-0.38	-5.09	-0.31	6.98e-7	Life satisfaction;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10446143	chr21:44394730	PKNOX1	0.47	6.2	0.37	2.34e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26682510	chr14:32546457	ARHGAP5;C14orf128	0.53	7.68	0.44	3.72e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs33912345	0.695	rs1254282	chr14:60855623	C/T	cg27398547	chr14:60952738	C14orf39	0.38	5.07	0.31	7.72e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs7116495	0.867	rs601865	chr11:71581938	G/A	cg11196788	chr11:71737549	NUMA1	-0.5	-4.98	-0.3	1.2e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.53	9.3	0.51	8.08e-18	Vitiligo;
KIRP	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg23601095	chr6:26197514	HIST1H3D	0.92	7.55	0.43	8.37e-13	Gout;Renal underexcretion gout;
KIRP	cis	rs208520	0.909	rs58958359	chr6:67021381	A/C	cg07460842	chr6:66804631	NA	0.89	7.62	0.44	5.55e-13	Exhaled nitric oxide output;
KIRP	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.78	-0.35	2.3e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14374504	chr9:86322725	UBQLN1	0.52	6.49	0.38	4.7e-10	Parkinson's disease;
KIRP	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	6.93	0.4	3.69e-11	Systemic lupus erythematosus;
KIRP	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg04691961	chr3:161091175	C3orf57	-0.43	-5.61	-0.34	5.32e-8	Parkinson's disease;
KIRP	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.88	8.92	0.49	1.06e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg06223162	chr1:101003688	GPR88	0.45	9.36	0.51	5.06e-18	Monocyte count;
KIRP	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.7	-10.76	-0.57	2.21e-22	Glomerular filtration rate (creatinine);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03790189	chr16:89977815	NA	0.47	6.06	0.36	5.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.32	6.03	0.36	6.02e-9	Monocyte percentage of white cells;
KIRP	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.81	-8.46	-0.47	2.41e-15	Gut microbiome composition (summer);
KIRP	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	6.42	0.38	7.02e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	6.01	0.36	6.58e-9	HIV-1 control;
KIRP	cis	rs7173743	0.525	rs7403442	chr15:79136123	A/G	cg00079375	chr15:79125835	NA	0.4	5.61	0.34	5.33e-8	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10002088	chr19:9271911	ZNF317	-0.46	-6.09	-0.36	4.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg09172766	chr16:89788316	C16orf7;ZNF276	0.49	6.13	0.36	3.4e-9	DNA methylation (variation);
KIRP	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-6.59	-0.39	2.72e-10	Menarche (age at onset);
KIRP	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.29	6.74	0.39	1.11e-10	IgG glycosylation;
KIRP	cis	rs6700559	0.654	rs12061556	chr1:200650239	G/C	cg07804481	chr1:200639085	DDX59	0.5	6.6	0.39	2.52e-10	Coronary artery disease;
KIRP	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.65	7.44	0.43	1.7e-12	Orofacial clefts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15529703	chr5:17187054	LOC285696	-0.46	-6.16	-0.37	2.95e-9	Parkinson's disease;
KIRP	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg17757837	chr7:157058334	UBE3C	0.79	10.66	0.56	4.5e-22	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09174674	chr1:9884042	CLSTN1	0.5	6.55	0.39	3.38e-10	Parkinson's disease;
KIRP	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg21466736	chr12:48725269	NA	-0.42	-5.46	-0.33	1.17e-7	Glycated hemoglobin levels;
KIRP	cis	rs1823913	0.637	rs10931495	chr2:192164173	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.26	-0.37	1.67e-9	Obesity-related traits;
KIRP	cis	rs12519773	1.000	rs4470752	chr5:92460541	C/T	cg18783429	chr5:92414398	NA	0.29	5.2	0.31	4.18e-7	Migraine;
KIRP	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14159672	chr1:205819179	PM20D1	0.47	5.21	0.32	4.01e-7	Parkinson's disease;
KIRP	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg06345736	chr22:50966936	TYMP	-0.65	-9.76	-0.53	3.07e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	8.01e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.56	-7.27	-0.42	4.7e-12	Aortic root size;
KIRP	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.37e-13	Neuroticism;
KIRP	cis	rs2839627	0.564	rs2839595	chr21:44298966	G/A	cg03543861	chr21:44258195	NA	0.57	6.06	0.36	5.21e-9	Information processing speed;
KIRP	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.16	0.31	4.97e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.76	8.68	0.48	5.71e-16	Diastolic blood pressure;
KIRP	cis	rs3779635	0.844	rs56330356	chr8:27278847	A/G	cg23693289	chr8:27183097	PTK2B	0.45	5.7	0.34	3.39e-8	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21656685	chr18:2947843	LPIN2;LOC727896	0.42	6.77	0.4	9.45e-11	Survival in pancreatic cancer;
KIRP	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.85	-13.29	-0.65	9.96e-31	Breast cancer;
KIRP	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.83	-13.14	-0.64	3.06e-30	Systemic lupus erythematosus;
KIRP	cis	rs17373728	0.526	rs13275074	chr8:76159360	C/A	cg07016329	chr8:76221503	NA	0.45	5.95	0.35	9.02e-9	Diabetic kidney disease;
KIRP	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg13482628	chr17:19912719	NA	0.57	7.96	0.45	6.25e-14	Schizophrenia;
KIRP	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg22029157	chr1:209979665	IRF6	0.38	5.88	0.35	1.35e-8	Monobrow;
KIRP	cis	rs7635838	0.892	rs7372723	chr3:11466511	G/A	cg00170343	chr3:11313890	ATG7	0.46	5.87	0.35	1.37e-8	HDL cholesterol;
KIRP	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg26373071	chr5:1325741	CLPTM1L	0.55	7.46	0.43	1.46e-12	Lung cancer;
KIRP	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg26022315	chr17:47021804	SNF8	0.41	5.12	0.31	6.1e-7	Type 2 diabetes;
KIRP	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg05315796	chr3:52349193	DNAH1	0.54	8.83	0.49	2.01e-16	Electroencephalogram traits;
KIRP	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22022881	chr2:105853494	NA	-0.39	-5.8	-0.35	2.06e-8	Type 2 diabetes;
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg27144592	chr16:783916	NARFL	0.37	5.14	0.31	5.7e-7	Height;
KIRP	cis	rs2072732	0.861	rs67872056	chr1:2954165	C/T	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16373769	chr10:30024815	SVIL	0.49	6.08	0.36	4.53e-9	Parkinson's disease;
KIRP	cis	rs6585424	1.000	rs2304410	chr10:81921810	T/C	cg27417294	chr10:81904244	PLAC9	0.56	5.46	0.33	1.14e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07305506	chr3:152058521	MBNL1;TMEM14E	-0.41	-6.15	-0.37	3.19e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.44	8.42	0.47	3.14e-15	Educational attainment (years of education);
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg14338887	chr6:42928500	GNMT	0.47	6.8	0.4	8.05e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1891275	0.515	rs10786010	chr10:93443773	G/A	cg07889827	chr10:93443413	NA	-0.41	-7.06	-0.41	1.73e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.47e-7	Life satisfaction;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg08901578	chr4:187885870	NA	0.49	7.51	0.43	1.07e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg06781948	chr3:72941472	GXYLT2	0.49	6.21	0.37	2.29e-9	Motion sickness;
KIRP	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.44	5.97	0.36	8.35e-9	Red blood cell count;
KIRP	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.46	0.33	1.15e-7	Breast cancer;
KIRP	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.76e-9	Breast cancer;
KIRP	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg10326726	chr10:51549505	MSMB	-0.54	-7.9	-0.45	9.15e-14	Prostate-specific antigen levels;
KIRP	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.5	6.57	0.39	2.9e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7715811	1.000	rs1502042	chr5:13758344	G/A	cg07548982	chr5:13769939	DNAH5	-0.52	-6.35	-0.38	1.01e-9	Subclinical atherosclerosis traits (other);
KIRP	cis	rs1891498	0.625	rs11552588	chr1:147245383	T/C	cg27546670	chr1:147246839	GJA5	-0.8	-11.22	-0.58	7.14e-24	Cognitive performance;
KIRP	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg23602478	chr1:26503979	CNKSR1	0.45	6.48	0.38	4.84e-10	Height;
KIRP	cis	rs12643440	0.538	rs2041441	chr4:17136036	C/T	cg22650099	chr4:17144496	NA	-0.7	-8.78	-0.49	2.83e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg12384639	chr17:618140	VPS53	0.49	5.96	0.36	8.84e-9	Prostate cancer;
KIRP	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.57	-0.39	3.03e-10	Glioblastoma;
KIRP	cis	rs597583	0.806	rs11605509	chr11:117396433	T/C	cg27161313	chr11:117392002	DSCAML1	-0.53	-5.86	-0.35	1.46e-8	Putamen volume;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23979876	chr4:141299001	SCOC	0.39	6.12	0.36	3.74e-9	C-reactive protein;
KIRP	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.61	-6.62	-0.39	2.28e-10	DNA methylation (variation);
KIRP	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg21926883	chr2:100939477	LONRF2	-0.57	-7.9	-0.45	9.53e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg05973401	chr12:123451056	ABCB9	0.53	6.06	0.36	5.03e-9	Neutrophil percentage of white cells;
KIRP	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg10169327	chr19:45448959	APOC2	0.33	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.47	6.0	0.36	6.84e-9	Initial pursuit acceleration;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04294412	chr4:7045720	CCDC96;TADA2B	0.58	6.35	0.38	1.04e-9	Lung cancer in ever smokers;
KIRP	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	trans	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg05926928	chr17:57297772	GDPD1	1.53	13.52	0.65	1.58e-31	Opioid sensitivity;
KIRP	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg16497661	chr14:103986332	CKB	0.84	14.42	0.68	1.3600000000000001e-34	Body mass index;
KIRP	cis	rs2150410	0.833	rs6517524	chr21:40572531	A/C	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg13409248	chr3:40428643	ENTPD3	0.38	5.16	0.31	5.05e-7	Renal cell carcinoma;
KIRP	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9810890	1.000	rs73198861	chr3:128516182	A/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs7688540	0.771	rs11726829	chr4:224948	T/C	cg11678896	chr4:568514	NA	-0.44	-5.09	-0.31	7.11e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs4236601	0.720	rs1052990	chr7:116148370	T/G	cg05166801	chr7:116143459	CAV2	0.48	5.87	0.35	1.44e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14324927	chr4:48343333	SLAIN2	0.46	6.15	0.37	3.1e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20652787	chr6:41863119	USP49	-0.55	-6.26	-0.37	1.72e-9	Menopause (age at onset);
KIRP	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs7116495	1.000	rs949325	chr11:71729656	A/G	cg26138937	chr11:71823887	C11orf51	-0.72	-5.8	-0.35	1.99e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.52	0.33	8.59e-8	Breast cancer;
KIRP	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.11	0.41	1.27e-11	Mean corpuscular volume;
KIRP	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.42	0.33	1.44e-7	Melanoma;
KIRP	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg21433313	chr16:3507492	NAT15	0.58	4.95	0.3	1.39e-6	Tuberculosis;
KIRP	cis	rs2494938	0.692	rs1771309	chr6:40542187	C/T	cg14084896	chr6:40530702	LRFN2	-0.45	-5.71	-0.34	3.26e-8	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg26617929	chr16:1858877	NA	0.63	5.44	0.33	1.29e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26242888	chr14:89629141	FOXN3	0.45	6.08	0.36	4.62e-9	Gut microbiome composition (summer);
KIRP	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg26531700	chr6:26746687	NA	0.47	6.79	0.4	8.35e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06481639	chr22:41940642	POLR3H	0.68	6.9	0.4	4.29e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.73	0.34	2.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg10434728	chr15:90938212	IQGAP1	-0.43	-8.2	-0.46	1.31e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.43	-5.16	-0.31	4.99e-7	IgG glycosylation;
KIRP	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg21905437	chr5:178450457	ZNF879	0.56	6.43	0.38	6.52e-10	Pubertal anthropometrics;
KIRP	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.18e-7	Red blood cell count;
KIRP	cis	rs9815354	1.000	rs1716642	chr3:41965865	A/C	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg01559446	chr3:44596178	ZNF167	-0.36	-5.06	-0.31	8.25e-7	Depressive symptoms;
KIRP	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg25173405	chr17:45401733	C17orf57	-0.46	-6.0	-0.36	6.85e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg04025307	chr7:1156635	C7orf50	0.76	7.74	0.44	2.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12137294	0.866	rs1172151	chr1:205221659	A/C	cg21643547	chr1:205240462	TMCC2	-0.48	-6.71	-0.39	1.33e-10	Red cell distribution width;
KIRP	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg13271783	chr10:134563150	INPP5A	-0.62	-7.92	-0.45	8.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.65	0.39	1.87e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2274273	0.529	rs7149965	chr14:55508191	G/A	cg04306507	chr14:55594613	LGALS3	0.39	5.69	0.34	3.64e-8	Protein biomarker;
KIRP	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24229701	chr12:130821962	PIWIL1	0.43	5.45	0.33	1.22e-7	Menopause (age at onset);
KIRP	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.45	-6.88	-0.4	4.82e-11	Coronary artery disease;
KIRP	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.97	0.36	8.07e-9	Type 2 diabetes;
KIRP	trans	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg24644049	chr4:85504048	CDS1	0.96	6.84	0.4	6.3e-11	Skin colour saturation;
KIRP	cis	rs1832871	0.965	rs861179	chr6:158712720	A/G	cg07215822	chr6:158701037	NA	-0.49	-6.28	-0.37	1.55e-9	Height;
KIRP	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.43	7.28	0.42	4.48e-12	Heart rate;
KIRP	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-7.9	-0.45	9.13e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs71636778	0.722	rs35650645	chr1:27169484	T/C	cg12203394	chr1:27248618	NUDC	0.76	5.93	0.35	1.05e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10988449	0.941	rs11788781	chr9:132372719	G/C	cg18327994	chr9:132372705	NA	-0.57	-5.42	-0.33	1.39e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.51	-5.97	-0.36	8.38e-9	Colorectal cancer;
KIRP	cis	rs11603020	0.950	rs28362948	chr11:57369013	A/C	cg19752551	chr11:57585705	CTNND1	-0.67	-9.2	-0.51	1.61e-17	Blood protein levels;
KIRP	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.6	6.27	0.37	1.57e-9	Gut microbiome composition (summer);
KIRP	cis	rs6831352	0.704	rs1800759	chr4:100065509	T/G	cg13256891	chr4:100009986	ADH5	0.56	6.9	0.4	4.49e-11	Alcohol dependence;
KIRP	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.57	0.48	1.13e-15	Eosinophil percentage of white cells;
KIRP	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-5.17	-0.31	4.92e-7	Eosinophil percentage of white cells;
KIRP	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.4	-5.54	-0.33	7.9e-8	Monocyte count;
KIRP	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.62	-5.28	-0.32	2.79e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.4	5.75	0.34	2.69e-8	Testicular germ cell tumor;
KIRP	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.45	-5.48	-0.33	1.04e-7	Iron status biomarkers;
KIRP	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg27211696	chr2:191398769	TMEM194B	-0.76	-9.21	-0.51	1.46e-17	Diastolic blood pressure;
KIRP	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.95	0.35	9.08e-9	Motion sickness;
KIRP	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg21366198	chr4:185655624	MLF1IP	0.39	5.29	0.32	2.74e-7	Kawasaki disease;
KIRP	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27403822	chr1:179050983	TOR3A	0.54	6.37	0.38	9.24e-10	Smoking initiation;
KIRP	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.98	-0.45	5.55e-14	Retinal vascular caliber;
KIRP	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg17133734	chr15:86042851	AKAP13	0.46	5.7	0.34	3.39e-8	Interstitial lung disease;
KIRP	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06544989	chr22:39130855	UNC84B	0.5	8.92	0.49	1.13e-16	Menopause (age at onset);
KIRP	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.54	0.33	7.82e-8	Melanoma;
KIRP	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg08668510	chr10:1095578	IDI1	0.79	5.22	0.32	3.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	8.98	0.5	7.03e-17	Hemoglobin concentration;
KIRP	cis	rs1476670	0.661	rs10157253	chr1:44505646	C/G	cg09470012	chr1:44509516	NA	0.32	5.16	0.31	5.01e-7	Eotaxin levels;
KIRP	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.46	-0.33	1.14e-7	Pulmonary function;
KIRP	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg08499158	chr17:42289980	UBTF	0.46	5.95	0.35	8.94e-9	Total body bone mineral density;
KIRP	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.55	-4.91	-0.3	1.63e-6	Other erythrocyte phenotypes;
KIRP	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.14e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.98	-11.62	-0.6	3.56e-25	Colorectal cancer;
KIRP	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg16586182	chr3:47516702	SCAP	-0.41	-5.03	-0.31	9.41e-7	Birth weight;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg10117171	chr1:25599238	RHD	-0.4	-5.39	-0.33	1.64e-7	Erythrocyte sedimentation rate;
KIRP	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.18	-0.46	1.57e-14	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17376030	chr22:41985996	PMM1	0.69	7.54	0.43	8.89e-13	Vitiligo;
KIRP	cis	rs9815354	0.812	rs7652506	chr3:42060235	C/T	cg03022575	chr3:42003672	ULK4	0.7	7.63	0.44	5.06e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.26	-16.91	-0.73	4.36e-43	Breast cancer;
KIRP	cis	rs17453880	0.963	rs57358310	chr5:151948242	A/T	cg12297329	chr5:152029980	NA	-0.71	-10.03	-0.54	4.49e-20	Subjective well-being;
KIRP	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.53	-5.25	-0.32	3.23e-7	DNA methylation (variation);
KIRP	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg16306078	chr6:126000798	NA	0.27	4.99	0.3	1.16e-6	Endometrial cancer;
KIRP	cis	rs7712401	0.601	rs371604	chr5:122318432	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg03647239	chr10:116582469	FAM160B1	0.49	5.61	0.34	5.32e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs11997175	1.000	rs6468200	chr8:33745191	A/T	cg04338863	chr8:33670619	NA	0.42	5.52	0.33	8.78e-8	Body mass index;
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07308232	chr7:1071921	C7orf50	-0.82	-10.09	-0.54	2.9e-20	Longevity;Endometriosis;
KIRP	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.43	5.43	0.33	1.37e-7	IgG glycosylation;
KIRP	cis	rs6499255	0.951	rs75815213	chr16:69702854	C/T	cg15192750	chr16:69999425	NA	0.47	4.92	0.3	1.62e-6	IgE levels;
KIRP	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg07827796	chr19:33622959	WDR88	-0.53	-6.94	-0.4	3.37e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.49	-6.84	-0.4	6.17e-11	Motion sickness;
KIRP	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.87	-14.18	-0.67	9.12e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2017305	0.834	rs12242235	chr10:70782556	A/T	cg01024728	chr10:70782572	NA	0.63	5.22	0.32	3.78e-7	Depression (quantitative trait);
KIRP	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.6	5.75	0.34	2.61e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg26513180	chr16:89883248	FANCA	0.79	5.3	0.32	2.64e-7	Skin colour saturation;
KIRP	cis	rs77972171	0.558	rs2215555	chr7:123352307	T/C	cg03229431	chr7:123269106	ASB15	-0.57	-4.92	-0.3	1.57e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs77633900	0.772	rs8031378	chr15:76657874	A/G	cg21673338	chr15:77095150	SCAPER	-0.55	-5.18	-0.31	4.56e-7	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.83	-15.06	-0.69	8.88e-37	Body mass index;
KIRP	cis	rs17321999	0.859	rs72787718	chr2:30474351	G/A	cg05247661	chr2:30472410	LBH	0.59	6.76	0.4	9.8e-11	Systemic lupus erythematosus;
KIRP	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.35	-0.32	2.01e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs234043	1.000	rs234051	chr3:172311712	C/T	cg03055671	chr3:172231528	TNFSF10	0.4	5.78	0.35	2.24e-8	Renal cell carcinoma;
KIRP	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.71	8.93	0.49	1.01e-16	Platelet count;
KIRP	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.81	12.56	0.63	2.8e-28	Breast cancer;
KIRP	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.48	5.13	0.31	5.96e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg06766960	chr11:133703094	NA	-0.66	-8.36	-0.47	4.78e-15	Childhood ear infection;
KIRP	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.57	-6.5	-0.38	4.33e-10	Schizophrenia;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11039808	chr5:77591002	AP3B1	0.95	6.38	0.38	8.89e-10	P wave terminal force;
KIRP	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.5	-0.43	1.16e-12	Triglycerides;
KIRP	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.72	8.44	0.47	2.83e-15	High light scatter reticulocyte count;
KIRP	cis	rs16986825	0.570	rs5752822	chr22:29266025	A/G	cg02153584	chr22:29168773	CCDC117	0.49	5.38	0.32	1.69e-7	Pancreatic cancer;
KIRP	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.49	-0.52	2.05e-18	Height;
KIRP	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg24315340	chr6:146058215	EPM2A	0.41	5.27	0.32	3.03e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg03128060	chr6:142623767	GPR126	0.37	5.35	0.32	2.06e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.82	-12.23	-0.62	3.4e-27	Asthma;
KIRP	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg05025164	chr4:1340916	KIAA1530	-0.53	-7.29	-0.42	4.17e-12	Obesity-related traits;
KIRP	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.65	-12.55	-0.62	2.91e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg02336718	chr17:17403227	NA	-0.33	-5.35	-0.32	2.04e-7	Total body bone mineral density;
KIRP	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg25019033	chr10:957182	NA	-0.6	-6.65	-0.39	1.9e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg00405596	chr8:11794950	NA	-0.47	-5.9	-0.35	1.22e-8	Systolic blood pressure;
KIRP	cis	rs10861342	0.786	rs12309135	chr12:105599596	G/C	cg23923672	chr12:105501055	KIAA1033	0.81	5.04	0.31	9.04e-7	IgG glycosylation;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg17719053	chr1:75198211	TYW3;CRYZ	0.43	6.25	0.37	1.79e-9	Resistin levels;
KIRP	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.47	-6.74	-0.39	1.11e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.51	8.28	0.47	7.69e-15	Height;
KIRP	cis	rs7951870	1.000	rs12578042	chr11:46515004	C/G	cg16389345	chr11:46697382	NA	0.49	5.58	0.34	6.18e-8	Schizophrenia;
KIRP	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg23422044	chr7:1970798	MAD1L1	-0.67	-6.2	-0.37	2.39e-9	Neuroticism;
KIRP	cis	rs7589728	1.000	rs6720809	chr2:88528943	T/C	cg04511125	chr2:88470314	THNSL2	0.67	5.18	0.31	4.66e-7	Plasma clusterin levels;
KIRP	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.97	16.46	0.72	1.52e-41	Monocyte count;
KIRP	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg04804543	chr8:142233427	SLC45A4	-0.76	-10.48	-0.56	1.68e-21	Immature fraction of reticulocytes;
KIRP	cis	rs7106204	0.534	rs16912411	chr11:24320444	A/T	ch.11.24196551F	chr11:24239977	NA	0.71	4.87	0.3	2.04e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg07274523	chr3:49395745	GPX1	0.58	5.86	0.35	1.44e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.37	-0.32	1.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.7	-8.64	-0.48	7.4e-16	Height;
KIRP	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.49	7.33	0.42	3.27e-12	Lung cancer;
KIRP	cis	rs1468333	0.964	rs2967786	chr5:137547675	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	5.19	0.31	4.5e-7	Resting heart rate;
KIRP	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.94	-0.4	3.5e-11	Joint mobility (Beighton score);
KIRP	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.25e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.11e-7	Breast cancer;
KIRP	cis	rs1760803	0.754	rs2879788	chr1:154204310	A/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.46	-0.33	1.17e-7	Nicotine dependence;
KIRP	cis	rs17125944	0.686	rs12884504	chr14:53360494	G/A	cg00686598	chr14:53173677	PSMC6	-0.67	-6.32	-0.37	1.25e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.46	8.96	0.5	8.36e-17	Educational attainment (years of education);
KIRP	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08822215	chr16:89438651	ANKRD11	-0.42	-5.64	-0.34	4.75e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.87	-8.13	-0.46	2.05e-14	Monocyte percentage of white cells;
KIRP	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg15192750	chr16:69999425	NA	-0.43	-5.41	-0.33	1.48e-7	Sjögren's syndrome;
KIRP	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	5.95	0.35	9.11e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.98	-9.74	-0.53	3.65e-19	Multiple sclerosis;
KIRP	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg11569703	chr11:65557185	OVOL1	0.42	7.22	0.42	6.51e-12	Systemic lupus erythematosus;
KIRP	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg08131204	chr22:41487073	MIR1281	-0.45	-5.21	-0.32	4.04e-7	Neuroticism;
KIRP	cis	rs45544231	0.544	rs1420535	chr16:52578215	C/A	cg09051775	chr16:52580266	TOX3	-0.37	-5.06	-0.31	8.09e-7	Restless legs syndrome;
KIRP	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg00857998	chr1:205179979	DSTYK	0.5	6.34	0.37	1.11e-9	Red blood cell count;
KIRP	cis	rs7712401	0.601	rs246271	chr5:122212822	A/G	cg19412675	chr5:122181750	SNX24	0.51	5.55	0.33	7.52e-8	Mean platelet volume;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg07747251	chr5:1868357	NA	0.42	5.53	0.33	8.19e-8	Cardiovascular disease risk factors;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.38	-0.32	1.76e-7	Life satisfaction;
KIRP	cis	rs2548003	0.565	rs2554894	chr5:28762951	A/G	cg22863700	chr5:28928346	NA	0.59	6.09	0.36	4.2e-9	Hip geometry;
KIRP	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg22974920	chr21:40686053	BRWD1	0.49	5.55	0.33	7.3900000000000007e-08	Cognitive function;
KIRP	cis	rs10203711	1.000	rs10207724	chr2:239566705	G/C	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2411233	0.837	rs12911780	chr15:39250617	A/G	cg02291532	chr15:39874776	THBS1	0.49	6.5	0.38	4.41e-10	Platelet count;
KIRP	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg05220968	chr6:146057943	EPM2A	-0.38	-4.85	-0.3	2.24e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17121403	0.661	rs12130121	chr1:100490692	A/G	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs6558530	0.666	rs7005699	chr8:1700620	A/T	cg08198773	chr8:1697536	NA	0.52	6.24	0.37	1.9e-9	Systolic blood pressure;
KIRP	cis	rs8063160	0.561	rs12922197	chr16:89744809	G/C	cg07984980	chr16:89898383	SPIRE2	0.86	5.17	0.31	4.8e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.48	-0.33	1.06e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg04398451	chr17:18023971	MYO15A	-0.65	-8.67	-0.48	5.79e-16	Total body bone mineral density;
KIRP	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.83	12.07	0.61	1.16e-26	Mean platelet volume;
KIRP	cis	rs7587476	0.906	rs16852750	chr2:215646683	A/G	cg04004882	chr2:215674386	BARD1	0.83	7.76	0.44	2.24e-13	Neuroblastoma;
KIRP	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.94	13.34	0.65	6.45e-31	Gestational age at birth (maternal effect);
KIRP	cis	rs4262150	0.846	rs72799138	chr5:152096515	G/T	cg12297329	chr5:152029980	NA	-0.66	-8.1	-0.46	2.48e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg16141378	chr3:129829833	LOC729375	-0.55	-6.72	-0.39	1.26e-10	Mood instability;
KIRP	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	9.9	0.53	1.12e-19	Mean platelet volume;
KIRP	cis	rs57786342	0.539	rs4902652	chr14:69280309	A/G	cg03189333	chr14:69283534	NA	0.42	5.21	0.31	4.08e-7	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	5.82	0.35	1.83e-8	Mean platelet volume;
KIRP	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg17554472	chr22:41940697	POLR3H	-0.66	-7.38	-0.43	2.45e-12	Vitiligo;
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.78	12.24	0.62	3.32e-27	Menarche (age at onset);
KIRP	cis	rs6893300	0.785	rs11738720	chr5:179154998	A/G	cg14593053	chr5:179126677	CANX	-0.58	-7.08	-0.41	1.47e-11	Resting heart rate;
KIRP	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08280861	chr8:58055591	NA	0.72	5.92	0.35	1.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	0.92	12.02	0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9393813	0.626	rs2235232	chr6:27326863	G/A	cg18711553	chr6:27366782	ZNF391	0.39	5.31	0.32	2.44e-7	Bipolar disorder;
KIRP	cis	rs68170813	1.000	rs34273277	chr7:107249020	A/G	cg02696742	chr7:106810147	HBP1	-0.62	-6.14	-0.36	3.31e-9	Coronary artery disease;
KIRP	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.47	0.38	5.4e-10	Lung cancer;
KIRP	cis	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg16898833	chr6:26189333	HIST1H4D	0.95	5.52	0.33	8.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9921338	0.961	rs8056282	chr16:11407236	T/C	cg00044050	chr16:11439710	C16orf75	-0.56	-5.55	-0.33	7.34e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.54	-6.97	-0.41	2.84e-11	Crohn's disease;
KIRP	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg05220968	chr6:146057943	EPM2A	0.39	5.09	0.31	7.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg26876637	chr1:152193138	HRNR	0.72	9.72	0.53	4.25e-19	Atopic dermatitis;
KIRP	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.63	7.6	0.44	6.08e-13	Height;
KIRP	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg09555818	chr19:45449301	APOC2	0.5	7.26	0.42	4.94e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.67	6.48	0.38	4.87e-10	Eotaxin levels;
KIRP	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs11971779	0.700	rs11763942	chr7:139005795	A/T	cg07862535	chr7:139043722	LUC7L2	0.66	6.8	0.4	8.1e-11	Diisocyanate-induced asthma;
KIRP	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.55	-6.37	-0.38	9.2e-10	Coronary artery disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14425843	chr7:92729833	SAMD9	0.56	6.36	0.38	9.53e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg23587288	chr2:27483067	SLC30A3	-0.58	-7.19	-0.42	7.85e-12	Blood metabolite levels;
KIRP	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06529343	chr6:153324256	MTRF1L	-0.53	-6.52	-0.38	3.96e-10	Migraine with aura;
KIRP	cis	rs580438	0.569	rs1048637	chr3:13358171	T/G	cg10657019	chr3:13328039	NA	0.52	6.79	0.4	8.48e-11	Myringotomy;
KIRP	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.68	-8.4	-0.47	3.58e-15	Schizophrenia;
KIRP	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	6.26	0.37	1.67e-9	Bipolar disorder;
KIRP	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg16926213	chr1:1841314	NA	0.31	5.23	0.32	3.64e-7	Body mass index;
KIRP	cis	rs1832871	0.711	rs9459904	chr6:158700982	C/T	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	7.92	0.45	8.17e-14	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg12369402	chr1:90227771	NA	-0.37	-5.3	-0.32	2.56e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-8.87	-0.49	1.54e-16	Myopia (pathological);
KIRP	cis	rs798766	0.514	rs798750	chr4:1717171	G/A	cg24119469	chr4:1625181	NA	-0.41	-5.45	-0.33	1.23e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg14458575	chr2:238380390	NA	0.58	5.68	0.34	3.8e-8	Prostate cancer;
KIRP	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg07930552	chr6:133119739	C6orf192	0.87	8.9	0.49	1.26e-16	Type 2 diabetes nephropathy;
KIRP	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.75	-10.34	-0.55	4.96e-21	Blood metabolite levels;
KIRP	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.7	-10.13	-0.54	2.23e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19671926	chr4:122722719	EXOSC9	0.5	6.07	0.36	4.72e-9	Type 2 diabetes;
KIRP	cis	rs365132	0.875	rs353477	chr5:176418927	C/T	cg16309518	chr5:176445507	NA	-0.81	-12.38	-0.62	1.06e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.06	0.36	4.97e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg19875535	chr5:140030758	IK	0.56	6.97	0.41	2.85e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1050631	0.592	rs1789548	chr18:33724296	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.93	0.35	1.02e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.8	9.01	0.5	5.79e-17	Corneal astigmatism;
KIRP	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg12591125	chr7:1885375	MAD1L1	0.64	6.16	0.37	2.96e-9	Bipolar disorder;
KIRP	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-7.0	-0.41	2.45e-11	Type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10556830	chr5:68462986	CCNB1	0.6	7.05	0.41	1.76e-11	Smoking initiation;
KIRP	cis	rs7737355	0.812	rs7731773	chr5:130973943	A/G	cg06307176	chr5:131281290	NA	0.42	4.93	0.3	1.48e-6	Life satisfaction;
KIRP	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg00792783	chr2:198669748	PLCL1	0.46	5.19	0.31	4.34e-7	Dermatomyositis;
KIRP	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg17356467	chr2:100759845	AFF3	0.54	5.7	0.34	3.5e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg14061069	chr19:46274453	DMPK	0.67	11.68	0.6	2.2e-25	Coronary artery disease;
KIRP	cis	rs6832769	1.000	rs9997288	chr4:56347227	A/G	cg09317128	chr4:56265301	TMEM165	0.52	6.41	0.38	7.53e-10	Personality dimensions;
KIRP	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg20368463	chr18:77673604	PQLC1	0.73	7.01	0.41	2.32e-11	Opioid sensitivity;
KIRP	cis	rs7520050	0.966	rs12049588	chr1:46472422	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.26	-0.32	3.06e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21545522	chr1:205238299	TMCC2	0.42	5.68	0.34	3.87e-8	Red blood cell count;
KIRP	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg21605333	chr4:119757512	SEC24D	1.48	9.55	0.52	1.36e-18	Cannabis dependence symptom count;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg08132940	chr7:1081526	C7orf50	-0.53	-5.5	-0.33	9.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.49	-0.33	9.98e-8	Depression;
KIRP	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.93	10.69	0.56	3.63e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg26354017	chr1:205819088	PM20D1	-0.5	-5.76	-0.34	2.44e-8	Parkinson's disease;
KIRP	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.95	0.4	3.36e-11	Platelet count;
KIRP	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg23307798	chr14:103986281	CKB	0.73	11.33	0.59	3.22e-24	Body mass index;
KIRP	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.91	-11.72	-0.6	1.69e-25	Breast cancer;
KIRP	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.41	-5.26	-0.32	3.09e-7	Mean platelet volume;
KIRP	trans	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.2	-0.37	2.41e-9	Triglycerides;
KIRP	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.65	-7.38	-0.43	2.42e-12	Menarche (age at onset);
KIRP	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg14829360	chr17:73884958	NA	-0.47	-6.39	-0.38	8.39e-10	White matter hyperintensity burden;
KIRP	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg17764715	chr19:33622953	WDR88	0.8	11.48	0.59	1.04e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs714027	0.585	rs41156	chr22:30404653	T/C	cg27665648	chr22:30112403	NA	-0.39	-5.33	-0.32	2.22e-7	Lymphocyte counts;
KIRP	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-7.0	-0.41	2.49e-11	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg10381502	chr11:71823885	C11orf51	1.11	7.63	0.44	5.04e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.26	-0.37	1.71e-9	Cardiac Troponin-T levels;
KIRP	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.44	2.78e-13	Neuroticism;
KIRP	cis	rs2746347	0.722	rs2796516	chr1:57131323	C/T	cg09935045	chr1:57111199	PRKAA2	0.53	5.43	0.33	1.37e-7	Lymphocyte counts;
KIRP	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.65	-12.4	-0.62	9.36e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.76	-0.71	3.66e-39	Immature fraction of reticulocytes;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.69	11.32	0.59	3.55e-24	Mean corpuscular volume;
KIRP	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg05784532	chr1:230284198	GALNT2	0.43	6.46	0.38	5.47e-10	Coronary artery disease;
KIRP	cis	rs7215564	0.730	rs7214653	chr17:78581450	A/G	cg06153925	chr17:78755379	RPTOR	-0.31	-5.36	-0.32	1.91e-7	Myopia (pathological);
KIRP	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg07424592	chr7:64974309	NA	0.75	4.92	0.3	1.59e-6	Diabetic kidney disease;
KIRP	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg11031976	chr2:198649780	BOLL	-0.54	-5.18	-0.31	4.72e-7	Ulcerative colitis;
KIRP	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg05669848	chr5:237993	SDHA	-0.5	-5.19	-0.31	4.39e-7	Breast cancer;
KIRP	cis	rs34339938	1	rs34339938	chr12:123678364	GAC/G	cg00585698	chr12:123750864	CDK2AP1	-0.5	-6.31	-0.37	1.27e-9	Plateletcrit;
KIRP	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.75	11.06	0.58	2.41e-23	Hip circumference;
KIRP	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.86e-11	Retinal vascular caliber;
KIRP	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Melanoma;
KIRP	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.69	9.89	0.53	1.23e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.52	-8.78	-0.49	2.91e-16	Height;
KIRP	cis	rs965469	0.652	rs6051837	chr20:3388994	G/T	cg25506879	chr20:3388711	C20orf194	-0.46	-4.91	-0.3	1.68e-6	IFN-related cytopenia;
KIRP	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.51	-7.16	-0.42	9.2e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg07856975	chr6:36356162	ETV7	0.42	5.38	0.32	1.69e-7	Platelet distribution width;
KIRP	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.61	7.79	0.44	1.86e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11638352	0.661	rs1834641	chr15:44434312	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-5.22	-0.32	3.89e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg05555928	chr11:63887634	MACROD1	-0.59	-5.36	-0.32	1.94e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg08807892	chr2:162101083	NA	0.44	5.3	0.32	2.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg16558253	chr16:72132732	DHX38	-0.45	-5.6	-0.34	5.85e-8	Blood protein levels;
KIRP	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg24154853	chr7:158122151	PTPRN2	0.39	5.56	0.33	7.17e-8	Calcium levels;
KIRP	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.73	-9.1	-0.5	3.12e-17	Height;
KIRP	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg09579323	chr1:150459698	TARS2	0.43	5.42	0.33	1.4e-7	Migraine;
KIRP	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg09137382	chr11:130731461	NA	0.51	6.83	0.4	6.5500000000000006e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.48	6.57	0.39	2.98e-10	Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs7633770	0.735	rs12491294	chr3:46688498	G/T	cg11219411	chr3:46661640	NA	-0.42	-5.56	-0.33	6.9e-8	Coronary artery disease;
KIRP	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.34	5.48	0.33	1.03e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.29	-0.47	7.33e-15	Retinal vascular caliber;
KIRP	cis	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.2	0.31	4.22e-7	Leprosy;
KIRP	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg14004847	chr7:1930337	MAD1L1	-0.57	-6.39	-0.38	8.36e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg21395723	chr22:39101663	GTPBP1	0.44	5.94	0.35	9.86e-9	Menopause (age at onset);
KIRP	cis	rs7582720	1.000	rs72934535	chr2:203968973	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.04	7.62	0.44	5.53e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.29	0.32	2.77e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19346786	chr7:2764209	NA	-0.45	-7.33	-0.42	3.22e-12	Height;
KIRP	cis	rs1562975	0.722	rs17583662	chr4:109461985	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.4	4.93	0.3	1.53e-6	Height;
KIRP	cis	rs12976411	0.575	rs59552401	chr19:32827401	A/C	cg02282382	chr19:32836354	ZNF507	0.71	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg18500431	chr7:1709489	NA	0.49	6.42	0.38	7.09e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg27170947	chr2:26402098	FAM59B	-0.68	-7.23	-0.42	6.1e-12	Gut microbiome composition (summer);
KIRP	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs12580194	0.593	rs61957878	chr12:55716754	G/T	cg19537932	chr12:55886519	OR6C68	-0.47	-6.07	-0.36	4.76e-9	Cancer;
KIRP	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg24796726	chr7:884288	UNC84A	-0.49	-4.85	-0.3	2.15e-6	Initial pursuit acceleration;
KIRP	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg12826209	chr6:26865740	GUSBL1	-0.79	-5.41	-0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.77	-9.22	-0.51	1.36e-17	Pancreatic cancer;
KIRP	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.48	-5.81	-0.35	1.95e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs6594499	0.872	rs7732974	chr5:110455381	T/C	cg04022379	chr5:110408740	TSLP	0.48	7.2	0.42	7.26e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.17	-0.31	4.95e-7	Height;
KIRP	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.82	10.05	0.54	3.91e-20	Pulse pressure;
KIRP	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg23920097	chr1:209922102	NA	-0.49	-5.65	-0.34	4.45e-8	Red blood cell count;
KIRP	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.17	-16.12	-0.72	2.23e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs11250464	0.517	rs2387668	chr10:1432003	C/T	cg08668359	chr10:1443807	ADARB2	0.44	5.52	0.33	8.78e-8	Radiation response;
KIRP	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg15128208	chr22:42549153	NA	0.54	5.75	0.34	2.64e-8	Birth weight;
KIRP	cis	rs494562	0.892	rs619299	chr6:86121482	A/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg05785598	chr3:49045655	WDR6	0.29	5.26	0.32	3.21e-7	Parkinson's disease;
KIRP	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00889227	chr1:205173544	DSTYK	-0.38	-5.03	-0.31	9.55e-7	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2371030	1.000	rs2193616	chr2:211573706	C/A	cg18417063	chr2:211583084	NA	-0.5	-7.12	-0.41	1.22e-11	Non-small cell lung cancer;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg23985595	chr17:80112537	CCDC57	-0.34	-5.19	-0.31	4.45e-7	Life satisfaction;
KIRP	cis	rs9549367	0.588	rs9549360	chr13:113893032	C/G	cg18105134	chr13:113819100	PROZ	-0.9	-8.88	-0.49	1.42e-16	Platelet distribution width;
KIRP	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg10523679	chr1:76189770	ACADM	-0.47	-6.28	-0.37	1.51e-9	Daytime sleep phenotypes;
KIRP	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg16988262	chr1:15930761	NA	0.38	5.03	0.31	9.66e-7	Systolic blood pressure;
KIRP	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs829661	0.947	rs829682	chr2:30708430	G/T	cg10949345	chr2:30726833	LCLAT1	0.73	10.24	0.55	1.01e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.56	-0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg21734707	chr17:3908241	ZZEF1	0.63	9.51	0.52	1.82e-18	Type 2 diabetes;
KIRP	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.47	8.44	0.47	2.78e-15	Superior crus of antihelix expression;
KIRP	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13198984	chr17:80129470	CCDC57	0.54	8.04	0.46	3.7e-14	Life satisfaction;
KIRP	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-6.81	-0.4	7.36e-11	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23346107	chr14:69864717	ERH;SLC39A9	0.49	6.21	0.37	2.27e-9	Parkinson's disease;
KIRP	trans	rs933360	0.585	rs6593164	chr7:50824401	C/T	cg20003124	chr12:4557277	NA	0.54	6.57	0.39	2.92e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26367730	chr8:41386454	GINS4	0.46	6.07	0.36	4.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs17079247	0.841	rs1907006	chr13:85808725	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg13264159	chr8:625131	ERICH1	-0.67	-4.93	-0.3	1.5e-6	IgG glycosylation;
KIRP	cis	rs4356932	0.902	rs28548768	chr4:76972755	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.17	0.37	2.77e-9	Blood protein levels;
KIRP	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.46	-6.26	-0.37	1.7e-9	Monocyte count;
KIRP	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg04733989	chr22:42467013	NAGA	0.55	7.49	0.43	1.25e-12	Cognitive function;
KIRP	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.59	-8.92	-0.49	1.1e-16	Fat distribution (HIV);
KIRP	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.63	-6.88	-0.4	4.96e-11	Vitiligo;
KIRP	cis	rs75920871	1.000	rs7934763	chr11:116792357	T/G	cg23684410	chr11:116897558	SIK3	0.54	5.89	0.35	1.28e-8	Subjective well-being;
KIRP	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	cis	rs2151522	0.724	rs62426324	chr6:127142458	C/T	cg21431617	chr6:127135037	NA	0.3	5.45	0.33	1.24e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.24e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg23100626	chr2:96804247	ASTL	-0.48	-6.59	-0.39	2.58e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs72634258	0.786	rs4268374	chr1:8174083	G/T	cg00042356	chr1:8021962	PARK7	-0.51	-5.17	-0.31	4.92e-7	Inflammatory bowel disease;
KIRP	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg12160578	chr15:63334699	TPM1	0.64	6.78	0.4	8.89e-11	Orofacial clefts;
KIRP	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.32	-0.37	1.2e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2929278	0.546	rs686666	chr15:44161550	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.38	0.38	8.63e-10	Schizophrenia;
KIRP	cis	rs6942756	0.531	rs4731569	chr7:128930828	C/T	cg15488143	chr7:128924101	AHCYL2	-0.45	-6.11	-0.36	3.85e-9	White matter hyperintensity burden;
KIRP	cis	rs55675132	0.510	rs55953277	chr1:115270907	T/A	cg12756093	chr1:115239321	AMPD1	0.65	6.31	0.37	1.27e-9	Schizophrenia;
KIRP	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.27e-21	Educational attainment;
KIRP	cis	rs10865541	0.902	rs7558487	chr2:3425514	G/C	cg11642891	chr2:3452563	TTC15	-0.55	-6.99	-0.41	2.57e-11	Obesity-related traits;
KIRP	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg23625390	chr15:77176239	SCAPER	-0.65	-9.56	-0.52	1.32e-18	Blood metabolite levels;
KIRP	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg04374321	chr14:90722782	PSMC1	0.48	5.19	0.31	4.47e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.08	0.41	1.47e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg17554472	chr22:41940697	POLR3H	0.56	6.17	0.37	2.78e-9	Vitiligo;
KIRP	cis	rs732716	0.853	rs62129349	chr19:4385659	A/G	cg19820705	chr19:4455316	UBXN6	0.67	8.28	0.47	8.17e-15	Mean corpuscular volume;
KIRP	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg03806693	chr22:41940476	POLR3H	1.06	12.02	0.61	1.74e-26	Cannabis dependence symptom count;
KIRP	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg08125733	chr17:73851984	WBP2	0.53	6.58	0.39	2.79e-10	White matter hyperintensity burden;
KIRP	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.95	-8.68	-0.48	5.59e-16	Rheumatoid arthritis;
KIRP	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-8.85	-0.49	1.79e-16	Eye color traits;
KIRP	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg20573242	chr4:122745356	CCNA2	0.41	4.97	0.3	1.26e-6	Type 2 diabetes;
KIRP	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.92	14.28	0.67	4.32e-34	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs58649573	0.609	rs1327292	chr9:126768210	A/T	cg14112217	chr9:126806003	NA	0.37	5.23	0.32	3.54e-7	Post-traumatic stress disorder;
KIRP	cis	rs1359582	0.881	rs2901950	chr10:90362099	A/G	cg15661332	chr10:90342814	RNLS	0.59	6.04	0.36	5.57e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.08	-0.31	7.61e-7	Depression;
KIRP	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg25566285	chr7:158114605	PTPRN2	0.74	9.28	0.51	9.27e-18	Response to amphetamines;
KIRP	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.88	9.38	0.51	4.52e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg03641300	chr2:160917029	PLA2R1	-0.45	-6.89	-0.4	4.69e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2970818	0.614	rs11063213	chr12:4632967	A/G	cg14576962	chr12:4671597	NA	-0.42	-5.04	-0.31	9.14e-7	Phosphorus levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25043643	chr14:102609274	WDR20	0.55	6.73	0.39	1.2e-10	Interleukin-4 levels;
KIRP	cis	rs7737355	0.773	rs4706023	chr5:130882379	T/C	cg25547332	chr5:131281432	NA	0.4	4.92	0.3	1.62e-6	Life satisfaction;
KIRP	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.74	10.29	0.55	7.06e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg24585782	chr17:78113791	EIF4A3	-0.48	-5.53	-0.33	8.27e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.61	8.75	0.49	3.57e-16	Resting heart rate;
KIRP	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg26681399	chr22:41777847	TEF	0.51	5.17	0.31	4.8e-7	Vitiligo;
KIRP	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.71	6.22	0.37	2.11e-9	Inflammatory bowel disease;
KIRP	cis	rs9346649	0.630	rs4235913	chr6:168491697	T/C	cg09211372	chr6:168490623	NA	-0.37	-6.49	-0.38	4.8e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs2803122	0.502	rs7873489	chr9:19384787	A/T	cg13469590	chr9:19229767	NA	0.35	5.09	0.31	7.14e-7	Pulse pressure;
KIRP	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.67	9.69	0.53	5.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs71277158	0.624	rs16854848	chr3:169822201	T/C	cg04067573	chr3:169899625	PHC3	0.59	5.67	0.34	3.99e-8	Prostate cancer;
KIRP	cis	rs7215564	0.908	rs7501497	chr17:78660738	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs10875746	0.855	rs10875729	chr12:48426726	A/G	cg26205652	chr12:48591994	NA	0.69	9.28	0.51	9.45e-18	Longevity (90 years and older);
KIRP	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg00982548	chr2:198649783	BOLL	-0.6	-5.5	-0.33	9.46e-8	Ulcerative colitis;
KIRP	cis	rs4936894	0.500	rs11599947	chr11:124124483	A/G	cg27160556	chr11:124181099	OR8D1	-0.46	-6.67	-0.39	1.65e-10	Aging (time to death);
KIRP	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.65	7.83	0.45	1.47e-13	Height;
KIRP	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.2	-0.37	2.37e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.91	-8.93	-0.49	1.05e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.71	9.3	0.51	8.06e-18	Cognitive function;
KIRP	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg15896084	chr13:114927664	NA	0.44	5.62	0.34	5.11e-8	Schizophrenia;
KIRP	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg06917634	chr15:78832804	PSMA4	0.56	5.97	0.36	8.24e-9	Sudden cardiac arrest;
KIRP	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.9e-8	Depression;
KIRP	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.51	-6.6	-0.39	2.56e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg26585981	chr11:48327164	OR4S1	-0.44	-5.54	-0.33	7.9e-8	HDL cholesterol;
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.63	-8.85	-0.49	1.76e-16	Obesity-related traits;
KIRP	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.91	-11.58	-0.59	4.79e-25	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21813591	chr1:147071537	BCL9	0.52	6.6	0.39	2.51e-10	Parkinson's disease;
KIRP	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.12	0.36	3.59e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg06204229	chr3:52865917	ITIH4	0.53	5.83	0.35	1.71e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	0.83	12.49	0.62	4.86e-28	Body mass index;
KIRP	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.17	0.31	4.87e-7	Schizophrenia;
KIRP	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg21890820	chr11:65308645	LTBP3	0.4	5.07	0.31	7.78e-7	Bone mineral density;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg15181151	chr6:150070149	PCMT1	0.32	5.47	0.33	1.12e-7	Lung cancer;
KIRP	cis	rs2387326	0.767	rs11016096	chr10:129942734	G/A	cg16087940	chr10:129947807	NA	-0.36	-4.84	-0.3	2.26e-6	Select biomarker traits;
KIRP	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.21	0.51	1.47e-17	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23717686	chr20:44044727	PIGT	0.52	6.51	0.38	4.15e-10	Parkinson's disease;
KIRP	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg15997130	chr1:24165203	NA	0.42	5.61	0.34	5.43e-8	Immature fraction of reticulocytes;
KIRP	cis	rs13082711	0.911	rs34422761	chr3:27513366	C/A	cg02860705	chr3:27208620	NA	0.47	6.61	0.39	2.37e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7523050	0.643	rs35438081	chr1:109402831	G/T	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.58	0.52	1.12e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4713675	0.565	rs4711343	chr6:33714548	G/A	cg14003231	chr6:33640908	ITPR3	0.29	5.1	0.31	6.94e-7	Plateletcrit;
KIRP	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.8	9.74	0.53	3.51e-19	Corneal astigmatism;
KIRP	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.79	10.74	0.56	2.58e-22	Aortic root size;
KIRP	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.58	-6.08	-0.36	4.52e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.15	-0.37	3.07e-9	Small cell lung carcinoma;
KIRP	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg21419209	chr3:44054225	NA	-0.71	-8.83	-0.49	2.07e-16	Coronary artery disease;
KIRP	cis	rs853679	0.546	rs200990	chr6:27815823	T/G	cg21204522	chr6:27730016	NA	-0.69	-5.21	-0.32	3.93e-7	Depression;
KIRP	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.7	8.28	0.47	7.75e-15	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg22437258	chr11:111473054	SIK2	0.58	6.79	0.4	8.51e-11	Primary sclerosing cholangitis;
KIRP	cis	rs539514	0.587	rs689418	chr13:76322977	G/A	cg04757411	chr13:76259545	LMO7	-0.42	-5.85	-0.35	1.52e-8	Type 1 diabetes;
KIRP	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.45	5.81	0.35	1.9e-8	Asthma (bronchodilator response);
KIRP	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.75	11.06	0.58	2.38e-23	Prudent dietary pattern;
KIRP	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg02462569	chr6:150064036	NUP43	-0.38	-5.68	-0.34	3.76e-8	Lung cancer;
KIRP	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	13.3	0.65	9.17e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg17646820	chr3:66848679	NA	0.67	9.51	0.52	1.78e-18	Type 2 diabetes;
KIRP	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.66	9.01	0.5	6.09e-17	Mosquito bite size;
KIRP	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg08885076	chr2:99613938	TSGA10	0.65	11.63	0.6	3.39e-25	Chronic sinus infection;
KIRP	cis	rs6901004	0.803	rs354544	chr6:111531159	T/C	cg15721981	chr6:111408429	SLC16A10	-0.57	-7.81	-0.45	1.64e-13	Blood metabolite levels;
KIRP	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg26248373	chr2:1572462	NA	-0.62	-5.67	-0.34	4.06e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs2048656	0.578	rs10095236	chr8:9684925	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.48	-0.38	4.92e-10	Schizophrenia;
KIRP	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.19	-0.31	4.32e-7	Vitiligo;
KIRP	trans	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg19274270	chr17:78178856	CARD14	-0.34	-6.2	-0.37	2.41e-9	Morning vs. evening chronotype;
KIRP	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.75	-12.28	-0.62	2.35e-27	Cancer;
KIRP	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg10047753	chr17:41438598	NA	1.14	17.86	0.75	2.59e-46	Menopause (age at onset);
KIRP	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg17145862	chr1:211918768	LPGAT1	0.64	7.27	0.42	4.89e-12	Crohn's disease;
KIRP	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.47e-19	Glomerular filtration rate (creatinine);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10327801	chr3:151801977	NA	0.38	6.09	0.36	4.42e-9	C-reactive protein;
KIRP	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg24253500	chr15:84953950	NA	0.69	7.76	0.44	2.21e-13	Schizophrenia;
KIRP	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.28	-22.17	-0.82	1.38e-60	Breast cancer;
KIRP	cis	rs7215564	0.908	rs35361366	chr17:78684751	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.39e-7	Myopia (pathological);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04120428	chr1:59369810	NA	-0.44	-6.12	-0.36	3.64e-9	Myopia;
KIRP	cis	rs72634258	0.945	rs161800	chr1:8042402	A/T	cg00042356	chr1:8021962	PARK7	0.53	4.98	0.3	1.18e-6	Inflammatory bowel disease;
KIRP	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg20744362	chr22:50050164	C22orf34	0.34	5.02	0.31	9.74e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs2652822	0.525	rs17828874	chr15:63516266	C/G	cg02713581	chr15:63449717	RPS27L	-0.48	-5.44	-0.33	1.32e-7	Metabolic traits;
KIRP	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.82	11.02	0.57	3.2e-23	Body mass index;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24532400	chr5:64064502	SDCCAG10;SFRS12IP1	-0.47	-6.06	-0.36	5.05e-9	Migraine with aura;
KIRP	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-7.98	-0.45	5.53e-14	Glomerular filtration rate;
KIRP	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-9.78	-0.53	2.65e-19	Chronic sinus infection;
KIRP	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg11764359	chr7:65958608	NA	0.82	4.85	0.3	2.2e-6	Diabetic kidney disease;
KIRP	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.94	13.06	0.64	5.9e-30	Menopause (age at onset);
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.29	5.28	0.32	2.91e-7	Tonsillectomy;
KIRP	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.02	-0.57	3.31e-23	Height;
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.3	-0.32	2.59e-7	Life satisfaction;
KIRP	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.67	9.32	0.51	6.68e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.41	6.81	0.4	7.28e-11	Type 2 diabetes;
KIRP	cis	rs780094	0.500	rs12995461	chr2:27778167	A/C	cg05484376	chr2:27715224	FNDC4	-0.38	-5.24	-0.32	3.4e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs6450176	0.904	rs6889847	chr5:53303452	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.46	-0.59	1.19e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.43	5.32	0.32	2.31e-7	Aortic root size;
KIRP	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg07384165	chr1:10488281	NA	-0.41	-5.38	-0.32	1.7e-7	Breast cancer;
KIRP	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.23e-7	Obesity-related traits;
KIRP	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg22643751	chr7:855365	UNC84A	0.35	4.9	0.3	1.74e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs11225247	0.881	rs11225235	chr11:102247361	G/A	cg06323957	chr11:102217781	BIRC2	0.92	5.66	0.34	4.25e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02443818	chr7:155437108	RBM33	0.53	6.69	0.39	1.46e-10	Parkinson's disease;
KIRP	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.56	-0.33	7.04e-8	Platelet count;
KIRP	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg10381502	chr11:71823885	C11orf51	-1.19	-8.0	-0.45	4.75e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.73e-8	Melanoma;
KIRP	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.45	-0.43	1.57e-12	Menopause (age at onset);
KIRP	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.71	8.32	0.47	6.11e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg11031976	chr2:198649780	BOLL	-0.54	-5.18	-0.31	4.72e-7	Ulcerative colitis;
KIRP	cis	rs13315871	1.000	rs71311869	chr3:58398922	C/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.11	-14.13	-0.67	1.32e-33	Alzheimer's disease;
KIRP	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg18016565	chr1:150552671	MCL1	0.37	5.83	0.35	1.73e-8	Melanoma;
KIRP	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.47	-5.63	-0.34	4.96e-8	Carotid intima media thickness;
KIRP	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	15.95	0.71	8.01e-40	Homoarginine levels;
KIRP	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg18755752	chr8:142205143	DENND3	-0.47	-6.22	-0.37	2.1e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Colorectal cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15716185	chr18:60190644	ZCCHC2	0.57	6.54	0.38	3.55e-10	Smoking initiation;
KIRP	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.99	-0.41	2.54e-11	Monocyte count;
KIRP	cis	rs882732	0.576	rs2070777	chr14:95034342	T/A	cg08495878	chr14:95027859	SERPINA4	-0.49	-6.34	-0.37	1.1e-9	Blood protein levels;
KIRP	trans	rs10863681	0.764	rs12038701	chr1:222242777	A/G	cg27628854	chr8:121823482	SNTB1	0.54	6.27	0.37	1.57e-9	Metabolite levels (HVA-5-HIAA Factor score);
KIRP	cis	rs4132509	0.744	rs10803146	chr1:243709454	T/G	cg25706552	chr1:244017396	NA	0.6	6.58	0.39	2.77e-10	RR interval (heart rate);
KIRP	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2625529	0.668	rs8192431	chr15:72492352	G/A	cg16672083	chr15:72433130	SENP8	-0.46	-5.46	-0.33	1.17e-7	Red blood cell count;
KIRP	cis	rs78487399	0.908	rs6544675	chr2:43835952	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.39	-0.33	1.61e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg01879757	chr17:41196368	BRCA1	-0.74	-9.01	-0.5	5.9e-17	Menopause (age at onset);
KIRP	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.78	-13.16	-0.64	2.74e-30	Calcium levels;
KIRP	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.74	10.41	0.55	2.89e-21	Parkinson's disease;
KIRP	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg26384229	chr12:38710491	ALG10B	0.66	8.86	0.49	1.63e-16	Morning vs. evening chronotype;
KIRP	trans	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg17822266	chr1:2720087	NA	-0.46	-6.32	-0.37	1.19e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg08179530	chr6:36648295	CDKN1A	-0.65	-8.85	-0.49	1.71e-16	QRS duration;
KIRP	cis	rs8012	0.517	rs8113575	chr19:13030280	G/A	cg11738485	chr19:12877000	HOOK2	0.44	5.39	0.32	1.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
KIRP	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg12559939	chr2:27858050	GPN1	-0.42	-5.28	-0.32	2.89e-7	Oral cavity cancer;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.2	-0.55	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.5	-11.64	-0.6	3.16e-25	Diabetic kidney disease;
KIRP	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.45	6.47	0.38	5.22e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	trans	rs7939886	0.920	rs7107736	chr11:55987980	C/G	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.77	10.65	0.56	5.12e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs6499755	0.712	rs31111	chr16:55378686	C/A	cg05099576	chr16:55362342	IRX6	0.32	6.46	0.38	5.59e-10	Hypospadias;
KIRP	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.5	6.54	0.38	3.5e-10	Blood protein levels;
KIRP	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-7.91	-0.45	8.88e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.84	13.29	0.65	9.61e-31	Blood metabolite levels;
KIRP	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	0.83	9.74	0.53	3.51e-19	Post bronchodilator FEV1;
KIRP	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-6.87	-0.4	5.22e-11	Schizophrenia;
KIRP	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08802203	chr2:233415465	TIGD1;EIF4E2	0.54	6.6	0.39	2.48e-10	Parkinson's disease;
KIRP	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg24296786	chr1:45957014	TESK2	0.42	5.12	0.31	6.24e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.6	8.09	0.46	2.68e-14	Bladder cancer;
KIRP	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.83	0.49	2.03e-16	Electroencephalogram traits;
KIRP	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.62	7.31	0.42	3.82e-12	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs397969	0.646	rs8079923	chr17:19869544	C/T	cg04132472	chr17:19861366	AKAP10	0.56	6.66	0.39	1.74e-10	Platelet count;
KIRP	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-4.95	-0.3	1.41e-6	Coronary artery disease;
KIRP	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.57	6.0	0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg21475434	chr5:93447410	FAM172A	-0.43	-5.04	-0.31	9.06e-7	Diabetic retinopathy;
KIRP	cis	rs12200782	1.000	rs72843802	chr6:26517515	C/T	cg11502198	chr6:26597334	ABT1	-0.76	-5.19	-0.31	4.44e-7	Small cell lung carcinoma;
KIRP	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	12.45	0.62	6.32e-28	Lung cancer in ever smokers;
KIRP	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg23202291	chr11:1979235	NA	0.49	6.33	0.37	1.16e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs8044868	0.586	rs3844425	chr16:72194325	T/C	cg16558253	chr16:72132732	DHX38	-0.42	-5.64	-0.34	4.69e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.51	0.48	1.76e-15	Motion sickness;
KIRP	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.29	15.56	0.7	1.78e-38	Eosinophil percentage of granulocytes;
KIRP	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg13072238	chr3:49761600	GMPPB	-0.62	-5.46	-0.33	1.17e-7	Menarche (age at onset);
KIRP	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.32	5.29	0.32	2.69e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs9900972	0.918	rs8065599	chr17:76877073	T/C	cg00961940	chr17:76876995	TIMP2	0.54	6.99	0.41	2.54e-11	Obesity-related traits;
KIRP	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg19507638	chr5:93509721	C5orf36	-0.55	-5.1	-0.31	6.64e-7	Diabetic retinopathy;
KIRP	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	0.9	14.42	0.68	1.39e-34	Ewing sarcoma;
KIRP	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg17470723	chr8:74884337	TCEB1	0.64	8.17	0.46	1.6e-14	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23348161	chr2:240964931	NDUFA10	0.56	7.31	0.42	3.71e-12	Parkinson's disease;
KIRP	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.29	7.75	0.44	2.39e-13	Crohn's disease;
KIRP	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg14228332	chr4:119757509	SEC24D	0.78	4.87	0.3	2.02e-6	Cannabis dependence symptom count;
KIRP	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg04287289	chr16:89883240	FANCA	0.61	5.09	0.31	7.22e-7	Skin colour saturation;
KIRP	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg25866889	chr13:114914595	NA	-0.38	-5.23	-0.32	3.68e-7	Schizophrenia;
KIRP	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg12560992	chr17:57184187	TRIM37	0.47	5.49	0.33	9.9e-8	Cognitive test performance;
KIRP	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-5.56	-0.33	7.07e-8	Blood metabolite levels;
KIRP	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg21415424	chr6:37503074	NA	-0.35	-5.1	-0.31	6.83e-7	Cognitive performance;
KIRP	cis	rs6142102	0.602	rs6141433	chr20:32548862	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs6429082	0.967	rs704709	chr1:235620964	C/T	cg26050004	chr1:235667680	B3GALNT2	0.47	6.03	0.36	5.93e-9	Adiposity;
KIRP	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.11	13.13	0.64	3.38e-30	White matter hyperintensity burden;
KIRP	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.58	7.78	0.44	2.04e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00864171	chr11:67383662	NA	0.38	5.08	0.31	7.32e-7	Mean corpuscular volume;
KIRP	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.66	-0.52	6.31e-19	Aortic root size;
KIRP	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.71	6.51	0.38	4.07e-10	Gut microbiome composition (summer);
KIRP	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.39e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.56	0.33	7.05e-8	Putamen volume;
KIRP	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.65	-5.7	-0.34	3.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1440410	0.560	rs4395451	chr4:144077025	T/G	cg01719995	chr4:144104893	USP38	0.43	5.51	0.33	9.16e-8	Ischemic stroke;
KIRP	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.69	8.43	0.47	2.9e-15	Neutrophil percentage of white cells;
KIRP	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	8.19	0.46	1.4e-14	Type 2 diabetes;
KIRP	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg09936142	chr19:10668400	KRI1	-0.43	-5.12	-0.31	6.1e-7	Inflammatory skin disease;
KIRP	cis	rs253959	0.545	rs712597	chr5:115658182	A/G	cg23108291	chr5:115420582	COMMD10	-0.51	-5.69	-0.34	3.66e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.37	-5.5	-0.33	9.31e-8	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg16497661	chr14:103986332	CKB	-0.52	-6.52	-0.38	4e-10	Coronary artery disease;
KIRP	cis	rs10073892	0.703	rs9327825	chr5:101638179	C/T	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs981844	0.712	rs1456398	chr4:154738266	G/A	cg14289246	chr4:154710475	SFRP2	-0.54	-7.06	-0.41	1.74e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg24558204	chr6:135376177	HBS1L	-0.47	-6.0	-0.36	6.93e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7808935	0.768	rs757137	chr7:27989343	T/C	cg05786569	chr7:27702416	HIBADH	0.46	5.28	0.32	2.85e-7	Prostate cancer;
KIRP	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg01338139	chr15:38987640	C15orf53	-0.57	-6.32	-0.37	1.21e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.18	0.37	2.65e-9	Platelet count;
KIRP	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	cis	rs7246657	0.943	rs10404945	chr19:38022358	T/C	cg23950597	chr19:37808831	NA	-0.56	-6.16	-0.37	3.02e-9	Coronary artery calcification;
KIRP	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.43	-5.82	-0.35	1.8e-8	Dementia with Lewy bodies;
KIRP	trans	rs7246760	1.000	rs113915533	chr19:9881379	A/C	cg02900749	chr2:68251473	NA	-1.19	-10.06	-0.54	3.62e-20	Pursuit maintenance gain;
KIRP	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg00262263	chr6:170184901	NA	0.53	7.31	0.42	3.64e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7105934	1.000	rs10908174	chr11:69241293	G/A	cg24478926	chr11:69237550	NA	-0.59	-5.3	-0.32	2.53e-7	Renal cell carcinoma;
KIRP	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.72	-0.44	2.92e-13	Breast cancer;
KIRP	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07234876	chr8:600039	NA	1.0	7.08	0.41	1.52e-11	IgG glycosylation;
KIRP	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg05528293	chr18:74961138	GALR1	0.54	6.05	0.36	5.3300000000000004e-09	Obesity-related traits;
KIRP	cis	rs1843834	0.755	rs10192196	chr2:225577135	C/T	cg22455342	chr2:225449267	CUL3	0.49	5.74	0.34	2.8e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg14593290	chr7:50529359	DDC	-0.8	-10.0	-0.54	5.52e-20	Malaria;
KIRP	cis	rs10073892	0.620	rs13163706	chr5:102002777	T/C	cg19774478	chr5:101632501	SLCO4C1	0.58	5.71	0.34	3.31e-8	Cognitive decline (age-related);
KIRP	cis	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg21546286	chr11:48923668	NA	-0.44	-5.57	-0.33	6.59e-8	HDL cholesterol;
KIRP	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.34	0.37	1.1e-9	Educational attainment;
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg10207240	chr12:122356781	WDR66	0.47	6.14	0.36	3.23e-9	Mean corpuscular volume;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg14221460	chr8:27183342	PTK2B	0.53	6.77	0.4	9.26e-11	Neuroticism;
KIRP	cis	rs737693	1.000	rs72983508	chr11:102727409	C/A	cg19620758	chr11:102826565	MMP13	0.71	5.65	0.34	4.42e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	1.01	12.91	0.64	1.8e-29	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.29	-0.47	7.54e-15	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-4.95	-0.3	1.4e-6	Life satisfaction;
KIRP	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.47	6.43	0.38	6.53e-10	Age-related hearing impairment;
KIRP	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.66	7.37	0.43	2.55e-12	Height;
KIRP	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16318349	chr1:154917307	PBXIP1	-0.29	-5.01	-0.3	1.05e-6	Prostate cancer;
KIRP	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg03684893	chr10:554711	DIP2C	0.36	4.94	0.3	1.41e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-6.68	-0.39	1.54e-10	Morning vs. evening chronotype;
KIRP	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg07395648	chr5:131743802	NA	-0.45	-5.88	-0.35	1.33e-8	Breast cancer;
KIRP	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.47	-5.23	-0.32	3.58e-7	Plasminogen activator inhibitor type 1 levels (PAI-1);
KIRP	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.53	-0.38	3.75e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-10.81	-0.57	1.5e-22	Hepatocellular carcinoma;
KIRP	cis	rs1983891	0.651	rs4714489	chr6:41552429	G/A	cg20194872	chr6:41519635	FOXP4	0.53	6.68	0.39	1.59e-10	Prostate cancer;
KIRP	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.91	13.95	0.66	5.81e-33	Selective IgA deficiency;
KIRP	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.66	5.54	0.33	7.79e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11138902	0.666	rs11139274	chr9:72161136	C/T	cg14123607	chr9:72164709	APBA1	-0.4	-5.07	-0.31	7.93e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.47	-0.33	1.12e-7	Dupuytren's disease;
KIRP	cis	rs7188697	0.922	rs37056	chr16:58560877	G/A	cg21335942	chr16:58549945	SETD6	0.47	5.16	0.31	5e-7	QT interval;
KIRP	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg09699651	chr6:150184138	LRP11	0.5	6.37	0.38	9.3e-10	Lung cancer;
KIRP	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.54	-0.33	7.74e-8	IgG glycosylation;
KIRP	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	5.47	0.33	1.1e-7	Coronary artery disease;
KIRP	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	0.84	7.53	0.43	9.78e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.73	-11.42	-0.59	1.67e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-12.21	-0.61	4.17e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs16975963	0.644	rs1478462	chr19:38147025	A/G	cg18030218	chr19:38865513	PSMD8	0.54	4.89	0.3	1.85e-6	Longevity;
KIRP	cis	rs6005807	0.719	rs58049055	chr22:29007850	A/G	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.42	-0.43	1.88e-12	Colorectal cancer;
KIRP	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.06	-0.5	4.19e-17	Blood metabolite levels;
KIRP	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg14343924	chr8:8086146	FLJ10661	0.51	5.95	0.35	9.07e-9	Neuroticism;
KIRP	cis	rs17095355	0.901	rs9783184	chr10:111760499	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.09	-0.36	4.33e-9	Biliary atresia;
KIRP	cis	rs4959799	0.655	rs1127473	chr6:3270578	C/T	cg03657281	chr6:3270030	SLC22A23	0.79	6.02	0.36	6.29e-9	Survival in rectal cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12506373	chr2:27440548	CAD	0.45	6.12	0.36	3.76e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-0.81	-8.35	-0.47	4.88e-15	Left ventricular obstructive tract defect (inherited effect);
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.43	0.38	6.64e-10	Bipolar disorder;
KIRP	cis	rs17221829	0.764	rs6483020	chr11:89386384	A/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs11581903	0.568	rs34087138	chr1:53083567	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.89	7.04	0.41	1.96e-11	Joint mobility (Beighton score);
KIRP	cis	rs2908197	0.806	rs6465098	chr7:75972947	T/C	cg10167463	chr7:75959203	YWHAG	-0.37	-5.01	-0.3	1.03e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	6.93	0.4	3.59e-11	Breast cancer;
KIRP	cis	rs1497828	0.956	rs2646803	chr1:217522466	A/G	cg04411442	chr1:217543379	NA	0.4	6.11	0.36	3.78e-9	Dialysis-related mortality;
KIRP	trans	rs263156	0.868	rs6924380	chr6:142965680	C/T	cg01789478	chr2:182545485	NEUROD1	-0.34	-6.07	-0.36	4.79e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26314531	chr2:26401878	FAM59B	0.49	4.96	0.3	1.33e-6	Gut microbiome composition (summer);
KIRP	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.55	7.33	0.42	3.36e-12	Height;
KIRP	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.57	0.73	6.1e-42	Electrocardiographic conduction measures;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14534967	chr7:73153139	ABHD11	0.58	6.69	0.39	1.47e-10	Smoking initiation;
KIRP	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.6	-6.84	-0.4	6.1e-11	Alzheimer's disease (late onset);
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg10351095	chr21:47802916	PCNT	0.43	5.43	0.33	1.35e-7	Testicular germ cell tumor;
KIRP	cis	rs220519	0.783	rs220512	chr20:37286121	A/G	cg24308336	chr20:37270989	C20orf95	0.23	4.99	0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg05156742	chr15:59063176	FAM63B	0.53	6.49	0.38	4.74e-10	Asperger disorder;
KIRP	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.25	0.32	3.22e-7	Vitiligo;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg05628496	chr17:17991167	DRG2	-0.47	-6.02	-0.36	6.19e-9	Neuroticism;
KIRP	cis	rs2294369	1.000	rs2294369	chr22:40075400	G/A	cg10455938	chr22:40058150	CACNA1I	0.53	6.02	0.36	6.3e-9	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.41	6.28	0.37	1.55e-9	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs861318	0.838	rs855866	chr1:159052720	A/G	cg05529816	chr17:4802735	CHRNE;C17orf107	0.51	6.14	0.36	3.24e-9	Obesity-related traits;
KIRP	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.63	-7.82	-0.45	1.55e-13	Mean platelet volume;
KIRP	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.86	-9.07	-0.5	3.95e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg06060754	chr5:176797920	RGS14	-0.61	-7.06	-0.41	1.74e-11	Urate levels in lean individuals;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg11087736	chr15:51200195	AP4E1	0.53	6.29	0.37	1.42e-9	Plasma plasminogen activator levels;
KIRP	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10152523	chr3:50374932	RASSF1	0.56	6.91	0.4	4.17e-11	Parkinson's disease;
KIRP	cis	rs1559088	0.847	rs2287679	chr19:33600764	T/C	cg27124370	chr19:33622961	WDR88	0.56	6.98	0.41	2.77e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg00579200	chr11:133705235	NA	-0.44	-5.83	-0.35	1.72e-8	Childhood ear infection;
KIRP	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg06596689	chr7:139875956	LOC100134229;JHDM1D	-0.43	-6.05	-0.36	5.44e-9	Serum protein levels (sST2);
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg01798813	chr17:3906674	NA	0.52	7.15	0.42	9.58e-12	Type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.64	-7.15	-0.41	9.9e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.17	0.37	2.78e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.28e-6	Menopause (age at onset);
KIRP	trans	rs4322600	0.963	rs34332718	chr14:88287016	C/A	cg19030814	chr1:232600205	SIPA1L2	0.44	6.13	0.36	3.56e-9	Breast cancer;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg23693289	chr8:27183097	PTK2B	-0.58	-7.25	-0.42	5.36e-12	Neuroticism;
KIRP	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg03929089	chr4:120376271	NA	-0.62	-6.56	-0.39	3.1e-10	D-dimer levels;
KIRP	trans	rs12517041	1.000	rs10054160	chr5:23297609	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs6539288	0.513	rs7977247	chr12:107259470	T/C	cg15890332	chr12:107067104	RFX4	0.34	6.0	0.36	7.12e-9	Total body bone mineral density;
KIRP	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.7	0.34	3.39e-8	Lung cancer;
KIRP	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg08076091	chr2:203926405	NBEAL1	-0.88	-9.55	-0.52	1.33e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg08975724	chr8:8085496	FLJ10661	0.61	7.54	0.43	8.87e-13	Retinal vascular caliber;
KIRP	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.4	5.84	0.35	1.67e-8	Multiple sclerosis;
KIRP	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.17	-0.42	8.82e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2348418	0.715	rs4931083	chr12:28721885	A/G	cg13890972	chr12:28721907	NA	0.33	5.17	0.31	4.74e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg20673841	chr7:107026890	COG5	0.41	4.94	0.3	1.46e-6	Coronary artery disease;
KIRP	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.58	7.78	0.44	2.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg17376030	chr22:41985996	PMM1	0.53	5.85	0.35	1.56e-8	Vitiligo;
KIRP	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.86	12.36	0.62	1.25e-27	Menopause (age at onset);
KIRP	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg17133734	chr15:86042851	AKAP13	-0.47	-6.02	-0.36	6.2e-9	Coronary artery disease;
KIRP	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg23625390	chr15:77176239	SCAPER	0.51	6.74	0.39	1.12e-10	Blood metabolite levels;
KIRP	cis	rs11874712	0.931	rs35507656	chr18:43652541	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.51	-0.33	9.06e-8	Migraine - clinic-based;
KIRP	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg05043794	chr9:111880884	C9orf5	-0.27	-5.41	-0.33	1.53e-7	Menarche (age at onset);
KIRP	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.72	8.25	0.47	9.94e-15	Cognitive ability;
KIRP	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg25486957	chr4:152246857	NA	-0.48	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4233802	1.000	rs7563730	chr2:151132697	A/G	cg25300694	chr2:151184358	NA	0.87	6.81	0.4	7.38e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4919044	0.534	rs7918909	chr10:94660689	G/A	cg05127821	chr10:94822908	CYP26C1	-0.97	-7.53	-0.43	9.59e-13	Coronary artery disease;
KIRP	cis	rs7553864	1.000	rs4514217	chr1:87614094	G/A	cg17420885	chr1:87600446	LOC339524	-0.48	-6.4	-0.38	7.97e-10	Smoking behavior;
KIRP	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	cis	rs2742417	1.000	rs2673047	chr3:45743113	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg06468920	chr17:61613267	KCNH6	-0.52	-6.42	-0.38	6.96e-10	Body mass index;
KIRP	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.73	-9.84	-0.53	1.73e-19	Blood metabolite levels;
KIRP	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.43	5.18	0.31	4.51e-7	Dialysis-related mortality;
KIRP	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.83	-0.63	3.46e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.48	5.65	0.34	4.5e-8	Uric acid levels;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg27338695	chr8:41435702	AGPAT6	0.49	6.32	0.37	1.24e-9	DNA methylation (variation);
KIRP	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg17554472	chr22:41940697	POLR3H	0.43	5.23	0.32	3.56e-7	Vitiligo;
KIRP	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23544223	chr18:12777786	NA	0.76	6.46	0.38	5.61e-10	Inflammatory skin disease;
KIRP	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.92	12.27	0.62	2.58e-27	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	0.9	12.08	0.61	1.11e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg13880726	chr7:1868755	MAD1L1	0.48	5.53	0.33	8.08e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg06521331	chr12:34319734	NA	0.55	6.96	0.41	3.06e-11	Heart rate;
KIRP	cis	rs6032067	1.000	rs13041304	chr20:43811697	G/A	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.49e-8	Blood protein levels;
KIRP	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7219021	0.705	rs962273	chr17:46978353	T/C	cg16584676	chr17:46985605	UBE2Z	0.44	5.19	0.31	4.38e-7	Schizophrenia or bipolar disorder;
KIRP	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	6.69	0.39	1.53e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	0.92	10.71	0.56	3.32e-22	Corneal structure;
KIRP	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg07972983	chr1:205091412	RBBP5	0.42	4.99	0.3	1.12e-6	Red blood cell count;
KIRP	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.75	11.05	0.58	2.58e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg06307176	chr5:131281290	NA	0.51	5.5	0.33	9.45e-8	Life satisfaction;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.42	6.43	0.38	6.58e-10	Renal function-related traits (BUN);
KIRP	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.56	6.9	0.4	4.3e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg08975724	chr8:8085496	FLJ10661	0.66	8.97	0.5	7.8e-17	Systolic blood pressure;
KIRP	cis	rs13053308	0.864	rs2413353	chr22:35926968	A/G	cg04636920	chr22:35946739	RASD2	0.3	4.97	0.3	1.28e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg24399712	chr22:39784796	NA	0.57	6.73	0.39	1.21e-10	IgG glycosylation;
KIRP	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.54	-7.36	-0.42	2.8e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.85	-11.72	-0.6	1.64e-25	Lung cancer;
KIRP	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.73	7.23	0.42	5.94e-12	Cannabis dependence symptom count;
KIRP	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.49	-6.2	-0.37	2.34e-9	Schizophrenia;
KIRP	trans	rs3858145	0.588	rs55888445	chr10:70036456	C/T	cg04882175	chr6:131122610	NA	-0.59	-6.99	-0.41	2.63e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg01721255	chr8:58191610	C8orf71	0.54	5.59	0.34	6.14e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.18	0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-5.91	-0.35	1.13e-8	Height;
KIRP	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.69	7.98	0.45	5.57e-14	Obesity-related traits;
KIRP	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.41	-0.38	7.33e-10	Joint mobility (Beighton score);
KIRP	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg07741184	chr6:167504864	NA	0.22	5.99	0.36	7.34e-9	Crohn's disease;
KIRP	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg01843524	chr15:80216276	C15orf37;ST20	0.41	5.24	0.32	3.38e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26314531	chr2:26401878	FAM59B	-0.52	-5.75	-0.34	2.6e-8	Gut microbiome composition (summer);
KIRP	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg02175503	chr12:58329896	NA	-0.43	-4.85	-0.3	2.2e-6	Multiple sclerosis;
KIRP	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.59	-5.09	-0.31	7.25e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg16083429	chr3:49237500	CCDC36	-0.39	-5.07	-0.31	7.9e-7	Menarche (age at onset);
KIRP	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	8.37	0.47	4.35e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg18154014	chr19:37997991	ZNF793	-0.61	-6.68	-0.39	1.57e-10	Coronary artery calcification;
KIRP	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-5.57	-0.33	6.71e-8	Neuroticism;
KIRP	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.41	0.33	1.5e-7	Total cholesterol levels;
KIRP	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.45	5.25	0.32	3.23e-7	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs6991838	0.557	rs7012578	chr8:66504827	A/C	cg13398993	chr8:66546079	ARMC1	-0.45	-5.11	-0.31	6.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.75	-9.69	-0.53	5.2e-19	Total body bone mineral density;
KIRP	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs9652601	0.959	rs12928537	chr16:11191400	G/A	cg04616529	chr16:11181986	CLEC16A	0.38	4.89	0.3	1.79e-6	Systemic lupus erythematosus;
KIRP	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg26384229	chr12:38710491	ALG10B	-0.61	-7.36	-0.42	2.75e-12	Morning vs. evening chronotype;
KIRP	cis	rs2791713	0.591	rs12747843	chr1:207161610	A/T	cg24040043	chr1:207224982	YOD1	0.28	4.99	0.3	1.16e-6	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	cis	rs3736485	0.966	rs8028017	chr15:51912708	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.6	-5.24	-0.32	3.53e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.72	-10.38	-0.55	3.59e-21	Longevity;
KIRP	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.37	5.48	0.33	1.04e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg00684032	chr4:1343700	KIAA1530	0.46	5.53	0.33	8.08e-8	Longevity;
KIRP	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.65	7.66	0.44	4.15e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg26681399	chr22:41777847	TEF	-0.49	-5.09	-0.31	7.25e-7	Vitiligo;
KIRP	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg22974920	chr21:40686053	BRWD1	0.51	6.09	0.36	4.27e-9	Cognitive function;
KIRP	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.62	-8.64	-0.48	7.47e-16	Breast cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg07551545	chr19:39466313	FBXO17	-0.61	-6.73	-0.39	1.16e-10	Menopause (age at onset);
KIRP	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg03128060	chr6:142623767	GPR126	0.35	5.06	0.31	8.13e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08280861	chr8:58055591	NA	0.73	5.86	0.35	1.47e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8060686	0.546	rs8047978	chr16:68143598	T/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.67	-0.44	3.96e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg19468946	chr17:37922297	IKZF3	0.49	6.79	0.4	8.18e-11	Self-reported allergy;
KIRP	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.71	-9.73	-0.53	3.88e-19	Body mass index;
KIRP	cis	rs9815354	0.812	rs17218264	chr3:41975847	C/T	cg03022575	chr3:42003672	ULK4	-0.79	-8.42	-0.47	3.22e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg03929089	chr4:120376271	NA	0.67	6.7	0.39	1.4e-10	Axial length;
KIRP	trans	rs972578	0.692	rs4822217	chr22:43278162	T/C	cg15321293	chr3:36422198	STAC	-0.48	-6.19	-0.37	2.56e-9	Mean platelet volume;
KIRP	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.79	0.53	2.49e-19	Corneal astigmatism;
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg00717297	chr12:122170156	TMEM120B	0.95	6.5	0.38	4.41e-10	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.46	-0.43	1.52e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.45	9.03	0.5	5.31e-17	Multiple system atrophy;
KIRP	cis	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg27411982	chr8:10470053	RP1L1	-0.39	-4.92	-0.3	1.6e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg22681709	chr2:178499509	PDE11A	0.55	5.27	0.32	3.05e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13634501	chr15:60690026	ANXA2	-0.45	-6.04	-0.36	5.6e-9	Metabolic traits;
KIRP	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg01475377	chr6:109611718	NA	-0.42	-5.89	-0.35	1.26e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg19554555	chr3:13937349	NA	-0.47	-6.49	-0.38	4.64e-10	Ovarian reserve;
KIRP	cis	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.91e-9	Leprosy;
KIRP	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.38	5.66	0.34	4.23e-8	Platelet distribution width;
KIRP	cis	rs2658782	0.724	rs2658769	chr11:93252030	T/C	cg15737290	chr11:93063684	CCDC67	0.66	7.69	0.44	3.45e-13	Pulmonary function decline;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg00777555	chr3:57583074	ARF4	0.79	6.85	0.4	5.72e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.95	-16.37	-0.72	2.97e-41	Height;
KIRP	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.95	15.99	0.71	5.95e-40	Mortality in heart failure;
KIRP	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23903597	chr17:61704154	MAP3K3	-0.59	-6.56	-0.39	3.12e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.74	-7.85	-0.45	1.32e-13	Blood pressure (smoking interaction);
KIRP	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.68	8.29	0.47	7.57e-15	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg07701084	chr6:150067640	NUP43	0.63	8.27	0.47	8.28e-15	Lung cancer;
KIRP	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg26207909	chr14:103986467	CKB	0.44	5.41	0.33	1.49e-7	Coronary artery disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27007178	chr17:4634690	MED11	-0.48	-6.05	-0.36	5.45e-9	Migraine with aura;
KIRP	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg00405596	chr8:11794950	NA	0.48	5.95	0.35	8.98e-9	Neuroticism;
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.26	-5.44	-0.33	1.29e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg06808227	chr14:105710500	BRF1	-0.78	-9.36	-0.51	5.21e-18	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.87	12.68	0.63	1.12e-28	Ileal carcinoids;
KIRP	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.89	0.4	4.66e-11	Height;
KIRP	trans	rs800082	0.690	rs2717392	chr3:144280080	T/C	cg24215973	chr2:240111563	HDAC4	0.47	6.33	0.37	1.14e-9	Smoking behavior;
KIRP	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg01877450	chr7:97915802	BRI3	-0.55	-7.08	-0.41	1.54e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg09117114	chr16:67998030	SLC12A4	-0.49	-5.2	-0.31	4.27e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg04369109	chr6:150039330	LATS1	-0.45	-5.57	-0.33	6.54e-8	Lung cancer;
KIRP	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg08885076	chr2:99613938	TSGA10	-0.42	-6.42	-0.38	7.06e-10	Fear of minor pain;
KIRP	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg23594656	chr7:65796392	TPST1	0.49	7.65	0.44	4.65e-13	Aortic root size;
KIRP	cis	rs11203032	0.908	rs11812888	chr10:90957546	G/T	cg16672925	chr10:90967113	CH25H	0.43	5.3	0.32	2.58e-7	Heart failure;
KIRP	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.77	12.25	0.62	2.97e-27	Menarche (age at onset);
KIRP	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.93	-12.58	-0.63	2.44e-28	Cognitive function;
KIRP	cis	rs1978968	0.763	rs35276871	chr22:18459040	C/T	cg02610425	chr22:18483192	MICAL3	0.38	5.33	0.32	2.18e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg26248373	chr2:1572462	NA	-0.61	-5.98	-0.36	7.66e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03385696	chr7:75988425	YWHAG	0.48	6.31	0.37	1.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.02	-0.36	6.18e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06481639	chr22:41940642	POLR3H	0.71	7.18	0.42	8.11e-12	Vitiligo;
KIRP	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg23594656	chr7:65796392	TPST1	0.46	7.27	0.42	4.84e-12	Aortic root size;
KIRP	cis	rs6893300	0.776	rs56396231	chr5:179157298	T/G	cg14593053	chr5:179126677	CANX	-0.58	-7.05	-0.41	1.84e-11	Resting heart rate;
KIRP	cis	rs2395909	1	rs2395909	chr7:107292663	G/A	cg23024343	chr7:107201750	COG5	0.39	5.76	0.34	2.47e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.48	-6.1	-0.36	4.08e-9	Paraoxonase activity;
KIRP	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.67	7.47	0.43	1.37e-12	Height;
KIRP	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg10818794	chr15:86012489	AKAP13	-0.51	-7.17	-0.42	8.59e-12	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01595830	chr7:154799705	NA	0.45	6.05	0.36	5.49e-9	Interleukin-4 levels;
KIRP	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.44	-0.52	3e-18	Coronary artery disease;
KIRP	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.93	10.55	0.56	1.06e-21	Breast cancer;
KIRP	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.77	7.83	0.45	1.44e-13	Exhaled nitric oxide output;
KIRP	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.93	13.62	0.66	7.34e-32	Glomerular filtration rate (creatinine);
KIRP	cis	rs1355223	0.573	rs1361646	chr11:34746360	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.57	-6.56	-0.39	3.07e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg17264618	chr3:40429014	ENTPD3	0.31	4.9	0.3	1.78e-6	Renal cell carcinoma;
KIRP	cis	rs35995292	1.000	rs56098802	chr7:38913730	T/C	cg19327137	chr7:38886074	VPS41	0.52	6.14	0.36	3.32e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg16898833	chr6:26189333	HIST1H4D	0.74	5.28	0.32	2.88e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs75229567	0.541	rs775443	chr12:70122623	C/T	cg10114359	chr12:70132523	RAB3IP	-0.55	-5.01	-0.3	1.02e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs7582720	0.832	rs116426890	chr2:204196618	C/T	cg08076091	chr2:203926405	NBEAL1	0.82	7.65	0.44	4.44e-13	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg01283332	chr5:1856932	NA	-0.48	-6.15	-0.37	3.05e-9	Cardiovascular disease risk factors;
KIRP	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.71	9.73	0.53	3.74e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.52	-6.94	-0.4	3.54e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11625487	0.609	rs74063385	chr14:77966859	C/T	cg20045696	chr14:77926864	AHSA1	-0.73	-5.8	-0.35	2.02e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg25412594	chr2:56152003	EFEMP1	0.4	6.18	0.37	2.61e-9	C-reactive protein;
KIRP	cis	rs6445967	1.000	rs13325699	chr3:58286870	T/C	cg16569813	chr3:58235849	ABHD6	-0.33	-4.94	-0.3	1.46e-6	Platelet count;
KIRP	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg21775007	chr8:11205619	TDH	-0.39	-5.08	-0.31	7.32e-7	Morning vs. evening chronotype;
KIRP	cis	rs494562	0.892	rs617483	chr6:86124008	C/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg23693289	chr8:27183097	PTK2B	0.58	7.34	0.42	3.04e-12	Neuroticism;
KIRP	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg20243544	chr17:37824526	PNMT	0.47	6.56	0.39	3.24e-10	Asthma;
KIRP	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.74	10.29	0.55	7.06e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7714584	1.000	rs77698001	chr5:150250367	C/T	cg22134413	chr5:150180641	NA	0.74	6.56	0.39	3.22e-10	Crohn's disease;
KIRP	cis	rs17209837	0.915	rs17149637	chr7:87085209	G/A	cg00919237	chr7:87102261	ABCB4	-0.78	-8.58	-0.48	1.1e-15	Gallbladder cancer;
KIRP	cis	rs151997	0.925	rs27270	chr5:50183712	A/G	cg06027927	chr5:50259733	NA	-0.59	-7.54	-0.43	9.27e-13	Callous-unemotional behaviour;
KIRP	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs13170463	0.579	rs6896921	chr5:8047148	T/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7709377	0.620	rs10066081	chr5:115488569	A/G	cg23108291	chr5:115420582	COMMD10	0.43	5.24	0.32	3.45e-7	Metabolite levels  (X-11787);
KIRP	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11987759	chr7:65425863	GUSB	0.47	5.97	0.36	8.36e-9	Aortic root size;
KIRP	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.43	-5.48	-0.33	1.06e-7	Menarche (age at onset);
KIRP	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	0.41	5.77	0.35	2.32e-8	Coronary artery disease;
KIRP	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg21858823	chr1:15850916	CASP9	0.56	5.9	0.35	1.17e-8	Systolic blood pressure;
KIRP	cis	rs11650494	0.516	rs2233660	chr17:47492366	C/T	cg08112188	chr17:47440006	ZNF652	-0.93	-6.23	-0.37	2.01e-9	Prostate cancer;
KIRP	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg10760299	chr15:45669010	GATM	0.34	5.27	0.32	3.04e-7	Homoarginine levels;
KIRP	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.39	5.09	0.31	7.27e-7	Blood protein levels;
KIRP	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.4	6.85	0.4	5.95e-11	QRS complex (12-leadsum);
KIRP	cis	rs365132	0.875	rs2962842	chr5:176338955	A/G	cg16309518	chr5:176445507	NA	-0.8	-12.66	-0.63	1.26e-28	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11576217	chr1:204381098	PPP1R15B	0.56	6.68	0.39	1.56e-10	Smoking initiation;
KIRP	cis	rs8077577	0.945	rs11871039	chr17:18078904	C/G	cg09161412	chr17:18057145	MYO15A	-0.42	-5.32	-0.32	2.38e-7	Obesity-related traits;
KIRP	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg16141378	chr3:129829833	LOC729375	-0.59	-7.51	-0.43	1.11e-12	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22178861	chr4:83294886	HNRNPD	0.44	6.19	0.37	2.51e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21206266	chr8:98656243	MTDH	0.46	6.47	0.38	5.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.57	-6.52	-0.38	3.96e-10	Breast cancer;
KIRP	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg03887218	chr1:16534349	ARHGEF19	0.57	7.71	0.44	3.13e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4474465	0.850	rs7111004	chr11:78269961	G/A	cg27205649	chr11:78285834	NARS2	0.62	6.88	0.4	4.81e-11	Alzheimer's disease (survival time);
KIRP	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.83	13.45	0.65	2.85e-31	Prostate cancer;
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.5	-0.38	4.53e-10	Lung cancer;
KIRP	cis	rs3739821	0.793	rs7023663	chr9:130714930	T/C	cg17308606	chr9:130706144	FAM102A	0.33	5.47	0.33	1.08e-7	Glaucoma (primary angle closure);
KIRP	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg12131826	chr15:77904385	NA	0.42	5.67	0.34	3.97e-8	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg01879757	chr17:41196368	BRCA1	-0.77	-10.54	-0.56	1.12e-21	Menopause (age at onset);
KIRP	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.03	-0.5	5.06e-17	Blood metabolite levels;
KIRP	cis	rs17030434	0.953	rs12639885	chr4:154700374	G/A	cg14289246	chr4:154710475	SFRP2	-0.8	-9.6	-0.52	9.6e-19	Electrocardiographic conduction measures;
KIRP	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg05526886	chr2:227700861	RHBDD1	0.43	5.06	0.31	8.23e-7	Pulmonary function;
KIRP	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg18478394	chr8:109455254	TTC35	0.52	6.54	0.38	3.52e-10	Dupuytren's disease;
KIRP	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.49	6.17	0.37	2.76e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg02151108	chr14:50098012	C14orf104	-0.51	-7.1	-0.41	1.3e-11	Carotid intima media thickness;
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.77	11.19	0.58	9.08e-24	Lung cancer;
KIRP	cis	rs365132	0.846	rs184784	chr5:176440229	G/T	cg16309518	chr5:176445507	NA	-0.77	-11.61	-0.6	3.78e-25	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.28	-0.32	2.85e-7	Life satisfaction;
KIRP	cis	rs12580194	0.593	rs66516917	chr12:55749131	T/G	cg11794356	chr12:55725991	OR6C3	-0.54	-7.47	-0.43	1.39e-12	Cancer;
KIRP	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.68	-8.87	-0.49	1.52e-16	Prudent dietary pattern;
KIRP	cis	rs7429990	0.965	rs35012836	chr3:47711490	G/A	cg11946769	chr3:48343235	NME6	0.51	4.99	0.3	1.14e-6	Educational attainment (years of education);
KIRP	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.81	7.83	0.45	1.41e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.72	-9.17	-0.5	1.9e-17	Endometriosis;
KIRP	cis	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.49	6.65	0.39	1.84e-10	Leprosy;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg24888944	chr8:67525724	MYBL1	-0.42	-6.14	-0.36	3.2e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg03315344	chr16:75512273	CHST6	0.55	5.47	0.33	1.12e-7	Advanced age-related macular degeneration;
KIRP	cis	rs2273156	0.673	rs12878219	chr14:35381137	G/A	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.73	-0.34	2.89e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.21	0.32	4.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.41	-8.62	-0.48	8.45e-16	Vitiligo;
KIRP	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.51	0.38	4.12e-10	Aortic root size;
KIRP	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg26754761	chr2:177040938	NA	-0.47	-7.82	-0.45	1.59e-13	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.71	10.91	0.57	7.41e-23	Blood metabolite ratios;
KIRP	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg08076091	chr2:203926405	NBEAL1	0.86	8.81	0.49	2.24e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.68	8.1	0.46	2.57e-14	Diabetic retinopathy;
KIRP	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg06647332	chr5:131281008	NA	0.46	5.23	0.32	3.6e-7	Life satisfaction;
KIRP	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.65	-0.34	4.41e-8	Recombination measurement;
KIRP	cis	rs6466055	0.932	rs2057884	chr7:104930250	T/C	cg04380332	chr7:105027541	SRPK2	0.51	7.86	0.45	1.2e-13	Schizophrenia;
KIRP	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.67	8.91	0.49	1.2e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06481639	chr22:41940642	POLR3H	-0.66	-7.53	-0.43	9.49e-13	Vitiligo;
KIRP	cis	rs1712517	0.844	rs1163081	chr10:105029840	G/C	cg05636881	chr10:105038444	INA	0.42	6.3	0.37	1.34e-9	Migraine;
KIRP	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg22305516	chr19:4391533	SH3GL1	0.36	5.14	0.31	5.56e-7	Mean corpuscular volume;
KIRP	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	trans	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01349053	chr4:153255985	FBXW7	-0.4	-6.1	-0.36	3.99e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg07701084	chr6:150067640	NUP43	0.71	9.84	0.53	1.74e-19	Lung cancer;
KIRP	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	6.87	0.4	5.33e-11	Systemic lupus erythematosus;
KIRP	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.47	-5.78	-0.35	2.22e-8	Diastolic blood pressure;
KIRP	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.6	0.44	6.31e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.32	0.42	3.57e-12	Mean corpuscular volume;
KIRP	cis	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg05639522	chr1:247681581	NA	0.55	4.94	0.3	1.41e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-6.22	-0.37	2.17e-9	Bone mineral density;
KIRP	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.36	-0.42	2.69e-12	Glomerular filtration rate (creatinine);
KIRP	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-0.84	-9.25	-0.51	1.13e-17	Blood pressure (smoking interaction);
KIRP	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg26205652	chr12:48591994	NA	0.45	4.86	0.3	2.09e-6	Lung cancer;
KIRP	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg16989719	chr2:238392110	NA	-0.46	-5.92	-0.35	1.08e-8	Prostate cancer;
KIRP	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg03468072	chr12:39539422	NA	0.41	5.76	0.34	2.46e-8	Morning vs. evening chronotype;
KIRP	cis	rs7903847	0.602	rs7916665	chr10:99157573	T/G	cg20016023	chr10:99160130	RRP12	-0.44	-6.12	-0.36	3.64e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg27189623	chr16:705930	WDR90	0.46	6.08	0.36	4.46e-9	Height;
KIRP	cis	rs732765	0.734	rs7152804	chr14:75164008	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.4	-4.96	-0.3	1.32e-6	Non-small cell lung cancer;
KIRP	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg19731401	chr7:2775893	GNA12	0.57	5.88	0.35	1.35e-8	Childhood ear infection;
KIRP	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-4.9	-0.3	1.71e-6	Skin colour saturation;
KIRP	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13456812	chr6:167369504	RNASET2	-0.49	-6.27	-0.37	1.62e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg05234568	chr11:5960015	NA	-0.6	-6.23	-0.37	2.01e-9	DNA methylation (variation);
KIRP	trans	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg17145862	chr1:211918768	LPGAT1	-0.54	-6.92	-0.4	3.86e-11	Leprosy;
KIRP	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.16	-21.67	-0.81	5.63e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-6.85	-0.4	5.74e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg00262122	chr8:11665843	FDFT1	0.43	5.41	0.33	1.52e-7	Myopia (pathological);
KIRP	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	1.06	15.22	0.7	2.63e-37	Menopause (age at onset);
KIRP	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.53	-0.38	3.7e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg02023728	chr11:77925099	USP35	0.35	5.46	0.33	1.17e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.19	-0.51	1.73e-17	Response to antipsychotic treatment;
KIRP	cis	rs4654899	0.802	rs57351360	chr1:21229538	T/A	cg05370193	chr1:21551575	ECE1	0.4	5.2	0.31	4.23e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg15252951	chr6:33757062	LEMD2	0.44	5.2	0.31	4.15e-7	Crohn's disease;
KIRP	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg00981070	chr1:2046702	PRKCZ	0.4	5.67	0.34	3.97e-8	Height;
KIRP	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.68	-11.8	-0.6	9.51e-26	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.47	6.71	0.39	1.36e-10	Sitting height ratio;
KIRP	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-7.07	-0.41	1.59e-11	Vitiligo;
KIRP	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-5.84	-0.35	1.66e-8	Schizophrenia;
KIRP	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.33	0.47	5.8e-15	Lung cancer in ever smokers;
KIRP	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.5	-6.51	-0.38	4.19e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs61884328	0.852	rs61896120	chr11:47071900	G/A	cg23433285	chr11:47201945	PACSIN3	0.77	6.26	0.37	1.67e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.55	-6.9	-0.4	4.3e-11	White blood cell count (neutrophil);
KIRP	cis	rs16828019	0.852	rs3820090	chr1:41573652	A/G	cg18742814	chr1:41828276	NA	0.59	5.19	0.31	4.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs981844	0.857	rs72731698	chr4:154716353	T/C	cg14289246	chr4:154710475	SFRP2	0.65	7.88	0.45	1.03e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs240764	0.817	rs239189	chr6:101128787	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.65	0.34	4.34e-8	Neuroticism;
KIRP	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.41	5.0	0.3	1.08e-6	Common traits (Other);
KIRP	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.95	11.24	0.58	6.42e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.15	0.31	5.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	1.000	rs9874513	chr3:41909508	G/A	cg03022575	chr3:42003672	ULK4	0.64	6.79	0.4	8.29e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	0.75	10.88	0.57	9.2e-23	Prudent dietary pattern;
KIRP	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.94	-14.61	-0.68	3.24e-35	Height;
KIRP	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.9	14.25	0.67	5.4e-34	Coronary artery disease;
KIRP	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07234876	chr8:600039	NA	0.8	6.21	0.37	2.22e-9	IgG glycosylation;
KIRP	cis	rs2790457	0.771	rs2800737	chr10:28943072	T/C	cg05705492	chr10:28955341	NA	-0.52	-7.14	-0.41	1.08e-11	Multiple myeloma;
KIRP	cis	rs239198	0.602	rs9390698	chr6:101296389	G/A	cg09795085	chr6:101329169	ASCC3	0.49	5.78	0.35	2.29e-8	Menarche (age at onset);
KIRP	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg21918786	chr6:109611834	NA	-0.41	-5.76	-0.34	2.51e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24867478	chr11:67029151	NA	0.42	6.15	0.37	3.13e-9	Parkinson's disease;
KIRP	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg19338460	chr6:170058176	WDR27	-0.69	-8.04	-0.46	3.75e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg20560298	chr2:73613845	ALMS1	0.44	5.43	0.33	1.36e-7	Metabolite levels;
KIRP	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-6.02	-0.36	6.41e-9	Subjective well-being;
KIRP	cis	rs7301016	0.652	rs2270732	chr12:62965149	T/C	cg01804193	chr12:63026212	NA	0.44	5.44	0.33	1.26e-7	IgG glycosylation;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.73	-10.4	-0.55	3.13e-21	Menarche (age at onset);
KIRP	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	7.17	0.42	9e-12	Lung function (FEV1/FVC);
KIRP	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.51e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg09323728	chr8:95962352	TP53INP1	0.24	4.89	0.3	1.82e-6	Type 2 diabetes;
KIRP	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg08975724	chr8:8085496	FLJ10661	0.68	7.79	0.44	1.93e-13	Red cell distribution width;
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-9.34	-0.51	5.86e-18	Platelet count;
KIRP	cis	rs73206853	0.764	rs67828368	chr12:110546298	C/T	cg12870014	chr12:110450643	ANKRD13A	0.53	5.4	0.33	1.55e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg12369402	chr1:90227771	NA	-0.36	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg11965913	chr1:205819406	PM20D1	-0.43	-5.44	-0.33	1.31e-7	Menarche (age at onset);
KIRP	trans	rs1864585	0.520	rs56122299	chr8:10662773	C/A	cg26278703	chr11:58910052	FAM111A	0.64	6.42	0.38	7.12e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4783244	0.862	rs17260630	chr16:82654035	C/T	cg09415485	chr16:82663111	CDH13	-0.28	-5.39	-0.32	1.69e-7	Adiponectin levels;
KIRP	cis	rs714027	0.605	rs5753037	chr22:30581722	C/T	cg01021169	chr22:30184971	ASCC2	-0.46	-5.75	-0.34	2.62e-8	Lymphocyte counts;
KIRP	cis	rs11997175	0.766	rs4733176	chr8:33685334	A/T	cg04338863	chr8:33670619	NA	0.4	5.3	0.32	2.55e-7	Body mass index;
KIRP	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg18306943	chr3:40428807	ENTPD3	0.4	5.65	0.34	4.34e-8	Renal cell carcinoma;
KIRP	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.8	7.98	0.45	5.67e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg19650706	chr5:140594406	PCDHB13	-0.45	-4.99	-0.3	1.16e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1832871	0.711	rs9457248	chr6:158681204	C/T	cg07215822	chr6:158701037	NA	-0.61	-7.05	-0.41	1.75e-11	Height;
KIRP	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.84	-11.0	-0.57	3.62e-23	Cognitive function;
KIRP	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.64	0.39	1.95e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs76288851	0.799	rs73193179	chr3:126681825	G/C	cg13821433	chr2:26726535	OTOF	0.57	6.2	0.37	2.38e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg26138937	chr11:71823887	C11orf51	-1.04	-7.1	-0.41	1.3e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	5.6	0.34	5.62e-8	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.35	-0.32	2.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg07274523	chr3:49395745	GPX1	0.56	5.14	0.31	5.69e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg07382826	chr16:28625726	SULT1A1	0.45	5.4	0.33	1.61e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.59	-8.68	-0.48	5.43e-16	Itch intensity from mosquito bite;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg26240231	chr7:1148101	C7orf50	-0.42	-5.08	-0.31	7.54e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs71597109	0.681	rs67800004	chr4:102717916	A/T	cg14855874	chr4:102712397	BANK1	0.38	5.05	0.31	8.47e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg15655495	chr12:38532458	NA	0.26	4.98	0.3	1.19e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.46	5.22	0.32	3.78e-7	Osteoporosis;
KIRP	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs1050631	0.592	rs1789527	chr18:33712229	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.48	6.05	0.36	5.45e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	9.07	0.5	4.02e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg21014159	chr11:117668035	DSCAML1	0.41	6.21	0.37	2.19e-9	Myopia;
KIRP	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02034447	chr16:89574710	SPG7	0.39	4.95	0.3	1.36e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg20578329	chr17:80767326	TBCD	-0.66	-7.58	-0.43	7.18e-13	Breast cancer;
KIRP	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg11038491	chr20:34638489	LOC647979	-0.76	-8.12	-0.46	2.26e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs4363385	0.510	rs61811886	chr1:153035743	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-6.04	-0.36	5.62e-9	Inflammatory skin disease;
KIRP	cis	rs6681460	0.966	rs10889644	chr1:67145322	C/A	cg02459107	chr1:67143332	SGIP1	0.51	7.34	0.42	3.03e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg27487796	chr7:28973253	NA	0.22	5.1	0.31	6.86e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg07701084	chr6:150067640	NUP43	0.7	9.33	0.51	6.38e-18	Lung cancer;
KIRP	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.04	-0.36	5.78e-9	IgG glycosylation;
KIRP	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	1.0	15.87	0.71	1.6e-39	Vitamin D levels;
KIRP	cis	rs2644899	0.859	rs2604893	chr19:41293543	A/G	cg24958765	chr19:41283667	RAB4B	-0.6	-6.53	-0.38	3.71e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg07451762	chr16:28383216	NA	0.42	5.41	0.33	1.51e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	cis	rs4478858	0.735	rs6679393	chr1:31770944	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.48	-0.33	1.07e-7	Alcohol dependence;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10898856	chr6:155154782	RBM16	0.4	6.22	0.37	2.14e-9	Migraine with aura;
KIRP	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.67	-0.44	4.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.36	0.47	4.78e-15	IgG glycosylation;
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.81	-10.32	-0.55	5.4e-21	Longevity;Endometriosis;
KIRP	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg20636351	chr8:55087400	NA	-0.53	-6.6	-0.39	2.54e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg17133734	chr15:86042851	AKAP13	-0.41	-4.97	-0.3	1.24e-6	Interstitial lung disease;
KIRP	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13047869	chr3:10149882	C3orf24	0.49	4.87	0.3	2e-6	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14081859	chr6:56954773	ZNF451	0.45	6.3	0.37	1.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg19847130	chr8:10466454	RP1L1	0.45	6.6	0.39	2.46e-10	Joint mobility (Beighton score);
KIRP	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg10504392	chr12:110044639	NA	0.26	5.2	0.31	4.21e-7	Neuroticism;
KIRP	cis	rs6430538	0.671	rs1942050	chr2:135574583	C/T	cg25422880	chr2:135218333	TMEM163	0.39	5.32	0.32	2.29e-7	Parkinson's disease;
KIRP	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.47	-0.52	2.44e-18	Mean corpuscular volume;
KIRP	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.7	-0.39	1.42e-10	Obesity-related traits;
KIRP	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.67	-7.26	-0.42	4.99e-12	Corneal structure;
KIRP	cis	rs2635047	0.604	rs1434527	chr18:44742868	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-5.28	-0.32	2.87e-7	Educational attainment;
KIRP	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg06637938	chr14:75390232	RPS6KL1	0.57	7.63	0.44	5.02e-13	Caffeine consumption;
KIRP	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.78	0.44	2.06e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.26	-0.37	1.69e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs7582720	1.000	rs3845800	chr2:203734365	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.89	-8.34	-0.47	5.17e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg10397082	chr2:1609832	NA	0.6	5.42	0.33	1.45e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.53	8.81	0.49	2.36e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.68	-0.44	3.69e-13	Aortic root size;
KIRP	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.95	14.65	0.68	2.35e-35	Triglycerides;
KIRP	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg02158880	chr13:53174818	NA	0.39	5.15	0.31	5.32e-7	Lewy body disease;
KIRP	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs10875746	0.903	rs10875735	chr12:48463806	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg15841412	chr13:111365552	ING1	0.5	5.79	0.35	2.12e-8	Coronary artery disease;
KIRP	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg09754948	chr16:28834200	ATXN2L	0.46	5.31	0.32	2.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.65	0.48	6.69e-16	Prudent dietary pattern;
KIRP	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.63	7.3	0.42	3.99e-12	Gestational age at birth (maternal effect);
KIRP	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg18306943	chr3:40428807	ENTPD3	0.48	6.11	0.36	3.86e-9	Renal cell carcinoma;
KIRP	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.39	-0.38	8.05e-10	Coronary artery disease;
KIRP	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.48	5.63	0.34	4.95e-8	Monocyte count;
KIRP	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg07884673	chr3:53033167	SFMBT1	0.81	6.38	0.38	8.86e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.47	-10.43	-0.55	2.55e-21	Alzheimer's disease (late onset);
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg02733842	chr7:1102375	C7orf50	0.56	5.76	0.34	2.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs399593	0.848	rs7896682	chr10:30909392	A/G	cg19508823	chr2:116315952	DPP10	-0.52	-6.16	-0.37	2.9e-9	Dental caries;
KIRP	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	1.96e-14	Testicular germ cell tumor;
KIRP	trans	rs13170463	0.522	rs13190277	chr5:8035272	A/G	cg03862380	chr20:43029895	HNF4A	0.42	6.42	0.38	6.85e-10	Colorectal cancer;
KIRP	trans	rs921874	0.553	rs2445580	chr11:86785635	C/A	cg20852851	chr2:240168848	HDAC4	0.47	6.08	0.36	4.54e-9	Total body bone mineral density;
KIRP	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00149659	chr3:10157352	C3orf10	0.52	6.18	0.37	2.59e-9	Alzheimer's disease;
KIRP	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.82	0.81	1.91e-59	Prudent dietary pattern;
KIRP	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg16586182	chr3:47516702	SCAP	0.64	8.89	0.49	1.29e-16	Colorectal cancer;
KIRP	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.24	-4.99	-0.3	1.14e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg00277334	chr10:82204260	NA	-0.5	-5.76	-0.34	2.53e-8	Post bronchodilator FEV1;
KIRP	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	26.33	0.86	1.65e-73	Schizophrenia;
KIRP	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg08885076	chr2:99613938	TSGA10	-0.48	-8.21	-0.46	1.24e-14	Chronic sinus infection;
KIRP	cis	rs58649573	0.552	rs7049157	chr9:126787006	A/G	cg14112217	chr9:126806003	NA	0.36	5.15	0.31	5.34e-7	Post-traumatic stress disorder;
KIRP	trans	rs1962073	0.667	rs11250004	chr8:10270958	T/G	cg16141378	chr3:129829833	LOC729375	0.53	6.68	0.39	1.6e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs6959887	0.962	rs2270222	chr7:35281155	A/G	cg06685737	chr7:35301730	NA	-0.42	-6.24	-0.37	1.9e-9	Birth weight;
KIRP	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg27432699	chr2:27873401	GPN1	-0.54	-6.98	-0.41	2.75e-11	Total body bone mineral density;
KIRP	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.75	-8.7	-0.49	4.82e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs11731606	0.712	rs28502775	chr4:95401945	A/G	cg20625393	chr4:95128694	SMARCAD1	0.56	4.99	0.3	1.13e-6	Mean platelet volume;
KIRP	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-7.76	-0.44	2.2e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg06521331	chr12:34319734	NA	-0.57	-7.0	-0.41	2.46e-11	Morning vs. evening chronotype;
KIRP	cis	rs6594713	0.642	rs13171630	chr5:112837037	C/T	cg12552261	chr5:112820674	MCC	0.59	5.26	0.32	3.07e-7	Brain cytoarchitecture;
KIRP	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg12861170	chr19:19639553	YJEFN3	-0.49	-5.07	-0.31	8e-7	Bipolar disorder;
KIRP	cis	rs4851254	0.961	rs11677607	chr2:100751150	C/T	cg17356467	chr2:100759845	AFF3	0.54	6.87	0.4	5.37e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-6.13	-0.36	3.47e-9	Longevity;
KIRP	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.91	0.4	4.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	6.28	0.37	1.53e-9	Renal cell carcinoma;
KIRP	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.83	12.59	0.63	2.26e-28	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs12431939	1.000	rs66806841	chr14:51670524	G/C	cg23942311	chr14:51606299	NA	-0.57	-5.65	-0.34	4.32e-8	Cancer;
KIRP	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.77	9.86	0.53	1.52e-19	Coronary artery disease;
KIRP	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.97	15.75	0.71	3.89e-39	Systemic lupus erythematosus;
KIRP	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg09184832	chr6:79620586	NA	-0.52	-7.42	-0.43	1.86e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg01244601	chr4:120671846	NA	-0.4	-5.21	-0.32	3.97e-7	Corneal astigmatism;
KIRP	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.44	-0.47	2.83e-15	Mean corpuscular volume;
KIRP	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.66	0.48	6.33e-16	Exhaled nitric oxide output;
KIRP	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.97	14.76	0.69	9.42e-36	Coronary artery disease;
KIRP	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.59	-0.44	6.54e-13	Type 2 diabetes;
KIRP	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-0.55	-7.95	-0.45	6.64e-14	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.75	5.7	0.34	3.48e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.6	7.68	0.44	3.87e-13	Alcohol dependence;
KIRP	cis	rs1978968	1.000	rs5992917	chr22:18443699	G/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.78	-0.44	1.94e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-7.72	-0.44	2.83e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg01988459	chr11:68622903	NA	-0.36	-5.04	-0.31	9.11e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs300890	1.000	rs300905	chr4:144240473	C/T	cg19876092	chr4:144208277	NA	-0.44	-7.18	-0.42	8.23e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-7.75	-0.44	2.4e-13	Morning vs. evening chronotype;
KIRP	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.52	-0.33	8.57e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg17644776	chr2:200775616	C2orf69	0.46	5.22	0.32	3.81e-7	Osteoporosis;
KIRP	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.58	5.42	0.33	1.43e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4728302	0.838	rs755664	chr7:133596671	C/G	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.72	-8.56	-0.48	1.2e-15	Neuroticism;
KIRP	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-8.37	-0.47	4.26e-15	Alzheimer's disease;
KIRP	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg00745463	chr17:30367425	LRRC37B	-0.67	-6.31	-0.37	1.29e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg13165212	chr22:42675999	NA	0.28	5.05	0.31	8.78e-7	Cognitive function;
KIRP	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.42	-5.36	-0.32	1.94e-7	Aortic root size;
KIRP	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-1.02	-17.35	-0.74	1.44e-44	Height;
KIRP	cis	rs7520050	0.966	rs10890363	chr1:46356148	C/T	cg03146154	chr1:46216737	IPP	0.43	5.31	0.32	2.39e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	0.89	14.79	0.69	7.73e-36	Vitiligo;
KIRP	cis	rs13082711	0.911	rs36101969	chr3:27438181	G/A	cg02860705	chr3:27208620	NA	0.58	8.18	0.46	1.52e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2625529	0.618	rs6494992	chr15:72420750	G/C	cg16672083	chr15:72433130	SENP8	0.42	5.91	0.35	1.13e-8	Red blood cell count;
KIRP	cis	rs17209837	1.000	rs45607141	chr7:87087025	A/G	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg00585698	chr12:123750864	CDK2AP1	0.53	6.59	0.39	2.6200000000000003e-10	Neutrophil percentage of white cells;
KIRP	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg21775007	chr8:11205619	TDH	0.5	6.59	0.39	2.61e-10	Systolic blood pressure;
KIRP	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg24296786	chr1:45957014	TESK2	0.52	6.7	0.39	1.45e-10	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4704187	0.687	rs1903839	chr5:74421397	A/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.12e-11	Blood metabolite levels;
KIRP	cis	rs6888304	0.589	rs13160294	chr5:31042829	C/T	cg10919204	chr5:31193340	CDH6	0.38	4.95	0.3	1.35e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	11.82	0.6	7.78e-26	Platelet count;
KIRP	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs10979	0.644	rs12527367	chr6:143918718	C/T	cg25407410	chr6:143891975	LOC285740	-0.45	-5.51	-0.33	9.08e-8	Hypospadias;
KIRP	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	5.82	0.35	1.81e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.87	14.14	0.67	1.23e-33	Prudent dietary pattern;
KIRP	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg06598544	chr20:61472147	COL9A3	-0.82	-7.05	-0.41	1.79e-11	Obesity-related traits;
KIRP	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg08029281	chr1:67600428	NA	-0.36	-5.23	-0.32	3.7e-7	Psoriasis;
KIRP	cis	rs1215050	0.765	rs588851	chr4:98678247	C/T	cg05340658	chr4:99064831	C4orf37	0.49	6.02	0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6500550	0.599	rs73505446	chr16:3694206	A/G	cg07396092	chr16:3662230	BTBD12	0.44	5.12	0.31	6.27e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;White blood cell count;Neutrophil count;
KIRP	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26207909	chr14:103986467	CKB	0.75	11.31	0.58	3.81e-24	Body mass index;
KIRP	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.72	10.08	0.54	3.18e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg15147215	chr3:52552868	STAB1	-0.31	-5.52	-0.33	8.58e-8	Electroencephalogram traits;
KIRP	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.25	-0.32	3.36e-7	Parkinson's disease;
KIRP	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.83e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4400599	0.618	rs1194600	chr1:154236009	G/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.58	-0.33	6.49e-8	Platelet distribution width;
KIRP	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg05507819	chr15:63340323	TPM1	0.5	6.05	0.36	5.44e-9	Platelet count;
KIRP	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg22676075	chr6:135203613	NA	0.51	7.3	0.42	3.87e-12	Red blood cell count;
KIRP	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.62	-6.76	-0.4	1.01e-10	DNA methylation (variation);
KIRP	trans	rs7531932	0.713	rs12044128	chr1:72169559	T/A	cg20667729	chr19:43691878	PSG5	-0.43	-6.18	-0.37	2.61e-9	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00629928	chr5:358741	AHRR	0.5	4.86	0.3	2.09e-6	Breast cancer;
KIRP	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.51	-6.55	-0.39	3.39e-10	IgG glycosylation;
KIRP	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg02073558	chr3:44770973	ZNF501	0.59	8.54	0.48	1.43e-15	Depressive symptoms;
KIRP	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg25173405	chr17:45401733	C17orf57	-0.56	-7.98	-0.45	5.6e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg18944383	chr4:111397179	ENPEP	0.68	12.51	0.62	3.91e-28	Height;
KIRP	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg17507749	chr15:85114479	UBE2QP1	0.87	9.95	0.54	8.19e-20	Schizophrenia;
KIRP	cis	rs2274273	0.840	rs72715769	chr14:55762429	C/G	cg04306507	chr14:55594613	LGALS3	0.44	6.56	0.39	3.08e-10	Protein biomarker;
KIRP	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg05347473	chr6:146136440	FBXO30	0.6	8.77	0.49	3.12e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.44	-10.68	-0.56	4.05e-22	Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.62	9.57	0.52	1.17e-18	Lung cancer;
KIRP	cis	rs732716	0.785	rs56033249	chr19:4369447	C/T	cg03719555	chr19:4455413	UBXN6	0.5	7.39	0.43	2.34e-12	Mean corpuscular volume;
KIRP	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.47	5.94	0.35	9.73e-9	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs1440410	0.830	rs300939	chr4:144173212	A/G	cg01719995	chr4:144104893	USP38	0.44	6.02	0.36	6.43e-9	Ischemic stroke;
KIRP	cis	rs6690583	0.623	rs1371143	chr1:85455532	C/T	cg22153463	chr1:85462885	MCOLN2	0.6	5.72	0.34	3.1e-8	Serum sulfate level;
KIRP	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11645453	chr3:52864694	ITIH4	0.33	4.89	0.3	1.81e-6	Bipolar disorder;
KIRP	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	13.88	0.66	9.79e-33	Alzheimer's disease;
KIRP	cis	rs6847149	0.929	rs10857002	chr4:110773433	A/C	cg07850274	chr4:110748770	RRH	0.44	5.14	0.31	5.6e-7	Exercise treadmill test traits;
KIRP	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Life satisfaction;
KIRP	cis	rs815815	0.608	rs815809	chr2:47380203	T/C	cg27223769	chr2:47403360	CALM2	-0.7	-8.37	-0.47	4.32e-15	Dialysis-related mortality;
KIRP	cis	rs988913	0.957	rs10485136	chr6:54756495	A/G	cg03513858	chr6:54763001	FAM83B	0.38	5.45	0.33	1.24e-7	Menarche (age at onset);
KIRP	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg11502198	chr6:26597334	ABT1	-0.8	-5.42	-0.33	1.39e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.85	-9.56	-0.52	1.3e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.54	-6.35	-0.38	1.05e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg11031976	chr2:198649780	BOLL	-0.52	-4.99	-0.3	1.15e-6	Ulcerative colitis;
KIRP	cis	rs5766691	0.966	rs5767526	chr22:47532591	T/C	cg15757745	chr22:47558489	TBC1D22A	-0.42	-5.09	-0.31	7.01e-7	Longevity;
KIRP	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.49	-6.13	-0.36	3.4e-9	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg01620082	chr3:125678407	NA	-1.09	-6.86	-0.4	5.53e-11	Depression;
KIRP	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.51	5.91	0.35	1.11e-8	Aortic root size;
KIRP	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.53	7.93	0.45	7.75e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.69	8.48	0.48	2.07e-15	Neutrophil percentage of white cells;
KIRP	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.54	8.23	0.46	1.08e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg06223162	chr1:101003688	GPR88	0.41	8.16	0.46	1.69e-14	Monocyte count;
KIRP	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18932078	chr1:2524107	MMEL1	0.45	6.27	0.37	1.58e-9	Multiple sclerosis;
KIRP	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.6	-0.44	6.23e-13	Breast cancer;
KIRP	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg16396542	chr1:89473148	GBP3	0.4	5.61	0.34	5.57e-8	Carotid intima media thickness;
KIRP	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.51	6.12	0.36	3.71e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2916247	0.954	rs7003305	chr8:93101992	T/C	cg10183463	chr8:93005414	RUNX1T1	0.49	5.61	0.34	5.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg19507638	chr5:93509721	C5orf36	-0.56	-5.07	-0.31	7.91e-7	Diabetic retinopathy;
KIRP	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg02297831	chr4:17616191	MED28	0.58	7.17	0.42	8.97e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.95	-11.83	-0.6	7.47e-26	Body mass index;
KIRP	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.48	-5.49	-0.33	1.02e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg04691961	chr3:161091175	C3orf57	-0.38	-5.65	-0.34	4.53e-8	Morning vs. evening chronotype;
KIRP	cis	rs10875746	0.669	rs11168499	chr12:48662670	A/G	cg24011408	chr12:48396354	COL2A1	-0.47	-5.22	-0.32	3.81e-7	Longevity (90 years and older);
KIRP	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg25182066	chr10:30743637	MAP3K8	-0.63	-7.98	-0.45	5.49e-14	Inflammatory bowel disease;
KIRP	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.78	0.4	9.06e-11	Lung cancer;
KIRP	cis	rs9815354	0.812	rs113300894	chr3:41984243	G/C	cg03022575	chr3:42003672	ULK4	0.78	8.06	0.46	3.31e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26240231	chr7:1148101	C7orf50	-0.42	-5.24	-0.32	3.52e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg01721255	chr8:58191610	C8orf71	0.49	5.24	0.32	3.47e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.8	8.04	0.46	3.77e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.82	-0.63	3.79e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs9400467	0.506	rs12209969	chr6:111668167	G/A	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13046164	chr2:99224758	UNC50;C2orf64	0.45	6.13	0.36	3.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6580649	0.941	rs11613485	chr12:48462455	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.19e-13	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.23	0.42	6.09e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs5753618	0.583	rs7287267	chr22:31748415	C/T	cg02404636	chr22:31891804	SFI1	0.47	5.03	0.31	9.34e-7	Colorectal cancer;
KIRP	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.91	15.67	0.71	7.62e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9972944	0.756	rs7221131	chr17:63764848	G/A	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs9905704	0.914	rs2611777	chr17:56826958	A/G	cg12560992	chr17:57184187	TRIM37	0.57	6.35	0.38	1.03e-9	Testicular germ cell tumor;
KIRP	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.54	-6.24	-0.37	1.89e-9	Coronary artery disease;
KIRP	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg11693508	chr17:37793320	STARD3	0.69	7.29	0.42	4.31e-12	Bipolar disorder;
KIRP	cis	rs11074306	0.503	rs7169607	chr15:28062978	C/T	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.59e-6	Uveal melanoma;
KIRP	cis	rs11967485	0.614	rs72998928	chr6:157192225	C/T	cg23222435	chr6:157204239	ARID1B	-0.75	-4.9	-0.3	1.72e-6	Calcium levels;
KIRP	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.8	11.78	0.6	1.04e-25	Bladder cancer;
KIRP	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg11941060	chr3:133502564	NA	-0.51	-6.27	-0.37	1.6e-9	Iron status biomarkers;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.8	-11.41	-0.59	1.74e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg00677455	chr12:58241039	CTDSP2	-0.52	-5.81	-0.35	1.96e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs58649573	0.552	rs1042486	chr9:126783433	G/C	cg14112217	chr9:126806003	NA	0.36	5.19	0.31	4.37e-7	Post-traumatic stress disorder;
KIRP	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.58	-11.75	-0.6	1.36e-25	Diabetic kidney disease;
KIRP	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	6.23	0.37	2e-9	Eosinophil percentage of white cells;
KIRP	cis	rs10073892	0.830	rs57977588	chr5:101634545	A/G	cg19774478	chr5:101632501	SLCO4C1	0.65	6.4	0.38	7.8e-10	Cognitive decline (age-related);
KIRP	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.53	5.72	0.34	3.11e-8	Obesity-related traits;
KIRP	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg06636001	chr8:8085503	FLJ10661	0.68	8.44	0.47	2.77e-15	Neuroticism;
KIRP	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg13010199	chr12:38710504	ALG10B	-0.38	-4.95	-0.3	1.41e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.16	-0.31	5.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3779635	1.000	rs3779635	chr8:27284692	C/T	cg14221460	chr8:27183342	PTK2B	0.44	5.73	0.34	2.95e-8	Neuroticism;
KIRP	cis	rs12153243	0.714	rs3901620	chr5:142911019	C/A	cg13907255	chr5:142895549	NA	-0.38	-4.85	-0.3	2.15e-6	Migraine;
KIRP	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-20.21	-0.79	3.37e-54	Height;
KIRP	cis	rs7849270	1.000	rs746489	chr9:131910093	G/T	cg13538475	chr9:131942899	NA	-0.33	-5.32	-0.32	2.34e-7	Blood metabolite ratios;
KIRP	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.98	-0.3	1.19e-6	Breast cancer;
KIRP	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg20626144	chr17:157107	RPH3AL	-0.85	-6.03	-0.36	5.83e-9	Lymphocyte counts;
KIRP	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.73	9.27	0.51	9.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg03734322	chr17:1532856	SLC43A2	-0.48	-6.6	-0.39	2.5e-10	Neuroticism;
KIRP	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg16339924	chr4:17578868	LAP3	-0.53	-7.0	-0.41	2.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg05973401	chr12:123451056	ABCB9	0.63	7.53	0.43	9.88e-13	Platelet count;
KIRP	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19524238	chr7:2802976	GNA12	-0.35	-4.91	-0.3	1.69e-6	Height;
KIRP	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg06223162	chr1:101003688	GPR88	-0.43	-8.89	-0.49	1.31e-16	Monocyte count;
KIRP	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-14.83	-0.69	5.8e-36	Coronary artery disease;
KIRP	cis	rs367943	0.712	rs1120091	chr5:112684229	C/A	cg12552261	chr5:112820674	MCC	0.5	5.71	0.34	3.24e-8	Type 2 diabetes;
KIRP	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg06307176	chr5:131281290	NA	0.55	5.96	0.36	8.77e-9	Life satisfaction;
KIRP	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg05721485	chr17:44071124	MAPT	0.57	7.52	0.43	9.93e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.85	-13.31	-0.65	8.2e-31	Urate levels in lean individuals;
KIRP	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg19197139	chr17:4613644	ARRB2	0.74	7.74	0.44	2.49e-13	Lymphocyte counts;
KIRP	cis	rs496547	0.719	rs598373	chr11:118664377	T/C	cg19308663	chr11:118741387	NA	-0.28	-4.97	-0.3	1.26e-6	Hip minimal joint space width;
KIRP	cis	rs1448094	0.967	rs7312144	chr12:86328256	T/C	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.8e-7	Major depressive disorder;
KIRP	cis	rs8177876	0.658	rs75422577	chr16:81088166	G/A	cg08591886	chr16:81111003	C16orf46	-0.66	-5.36	-0.32	1.88e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.58	-0.39	2.78e-10	Triglycerides;
KIRP	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-5.68	-0.34	3.82e-8	Lung cancer;
KIRP	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.42	-0.51	3.52e-18	Response to antipsychotic treatment;
KIRP	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.83	0.49	2.03e-16	Menopause (age at onset);
KIRP	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg15691649	chr6:25882328	NA	0.42	5.18	0.31	4.57e-7	Blood metabolite levels;
KIRP	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg26681399	chr22:41777847	TEF	0.54	5.14	0.31	5.59e-7	Vitiligo;
KIRP	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.45	-0.38	5.74e-10	Type 2 diabetes;
KIRP	trans	rs12043259	0.730	rs12044625	chr1:204794737	T/G	cg11485465	chr5:54518469	NA	0.38	6.31	0.37	1.26e-9	Addiction;
KIRP	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg05535760	chr7:792225	HEATR2	1.05	10.17	0.54	1.7e-20	Cerebrospinal P-tau181p levels;
KIRP	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg05714579	chr10:131428358	MGMT	0.49	6.39	0.38	8.02e-10	Response to temozolomide;
KIRP	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.91	-14.66	-0.68	2.07e-35	Height;
KIRP	cis	rs1577917	0.883	rs2782263	chr6:86791307	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.47	-5.83	-0.35	1.72e-8	Response to antipsychotic treatment;
KIRP	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.36	0.32	1.87e-7	Menopause (age at onset);
KIRP	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.56	-6.14	-0.36	3.37e-9	Blood pressure (smoking interaction);
KIRP	cis	rs62413470	1.000	rs12209464	chr6:55985189	A/T	cg13327911	chr6:55965977	COL21A1	0.59	5.05	0.31	8.43e-7	Joint mobility (Beighton score);
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg27532560	chr4:187881888	NA	-0.77	-12.68	-0.63	1.06e-28	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.41	-0.47	3.35e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg10645314	chr2:3704589	ALLC	-0.63	-6.97	-0.41	2.95e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9475752	0.793	rs71564869	chr6:56814575	A/C	cg22880620	chr6:56820808	BEND6;DST	0.5	5.17	0.31	4.96e-7	Menarche (age at onset);
KIRP	cis	rs27434	0.529	rs42443	chr5:96156224	G/A	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1.01e-7	Ankylosing spondylitis;
KIRP	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg01849789	chr22:41697279	ZC3H7B	-0.45	-5.14	-0.31	5.47e-7	Neuroticism;
KIRP	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg02836325	chr17:76403955	PGS1	0.4	6.82	0.4	6.85e-11	HDL cholesterol levels;
KIRP	cis	rs6466055	0.589	rs12534212	chr7:104641241	C/G	cg04380332	chr7:105027541	SRPK2	-0.4	-5.36	-0.32	1.94e-7	Schizophrenia;
KIRP	cis	rs27434	0.529	rs34757	chr5:96152588	T/C	cg16492584	chr5:96139282	ERAP1	-0.41	-5.55	-0.33	7.28e-8	Ankylosing spondylitis;
KIRP	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.53	7.18	0.42	8.02e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg26220594	chr1:19110978	NA	-0.48	-5.18	-0.31	4.52e-7	Drug-induced liver injury (nitrofurantoin);
KIRP	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.65	8.16	0.46	1.72e-14	Pancreatic cancer;
KIRP	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg15252951	chr6:33757062	LEMD2	0.42	5.0	0.3	1.09e-6	Crohn's disease;
KIRP	cis	rs6901250	0.569	rs686708	chr6:117091683	A/G	cg05399210	chr6:117082661	FAM162B	-0.47	-6.64	-0.39	1.95e-10	C-reactive protein levels;
KIRP	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg11031976	chr2:198649780	BOLL	-0.48	-4.94	-0.3	1.43e-6	Ulcerative colitis;
KIRP	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.95	-14.35	-0.68	2.46e-34	Height;
KIRP	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.31	-0.42	3.77e-12	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg07827796	chr19:33622959	WDR88	0.53	6.98	0.41	2.73e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg06647332	chr5:131281008	NA	-0.44	-4.88	-0.3	1.9e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6832769	0.925	rs6554292	chr4:56451110	G/T	cg05960024	chr4:56376020	CLOCK	-0.61	-7.95	-0.45	6.67e-14	Personality dimensions;
KIRP	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.69	9.7	0.53	4.74e-19	Post bronchodilator FEV1;
KIRP	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.4	-0.33	1.6e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg05562828	chr17:3906858	NA	0.79	16.93	0.73	3.73e-43	Type 2 diabetes;
KIRP	cis	rs6088813	1.000	rs6088816	chr20:33982435	G/A	cg14752227	chr20:34000481	UQCC	-0.51	-6.61	-0.39	2.37e-10	Height;
KIRP	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	9.18	0.51	1.78e-17	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs1547374	0.694	rs225349	chr21:43776890	C/T	cg09521743	chr10:75415752	SYNPO2L	0.44	6.31	0.37	1.29e-9	Pancreatic cancer;
KIRP	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06850241	chr22:41845214	NA	-0.47	-5.88	-0.35	1.31e-8	Vitiligo;
KIRP	cis	rs9311676	0.618	rs12152336	chr3:58365146	T/A	cg06643156	chr3:58380774	PXK	0.36	5.1	0.31	6.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg15068132	chr12:102092402	CHPT1	-0.41	-5.37	-0.32	1.82e-7	Blood protein levels;
KIRP	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.75	-10.64	-0.56	5.4e-22	Height;
KIRP	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-6.64	-0.39	2.01e-10	Self-reported allergy;
KIRP	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.31	17.35	0.74	1.41e-44	Corneal structure;
KIRP	cis	rs9937943	0.720	rs112685216	chr16:74609517	G/A	cg01733217	chr16:74700730	RFWD3	0.61	5.73	0.34	2.89e-8	Neutrophil percentage of white cells;
KIRP	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	7.37	0.43	2.6e-12	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.36	5.31	0.32	2.41e-7	Lymphocyte counts;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18877309	chr1:2105343	PRKCZ	0.46	6.17	0.37	2.72e-9	Survival in pancreatic cancer;
KIRP	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.26	-0.42	4.94e-12	Mean corpuscular volume;
KIRP	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.9	-0.35	1.17e-8	Breast cancer;
KIRP	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.44	-0.33	1.26e-7	Body mass index;
KIRP	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-10.99	-0.57	4.05e-23	Menarche (age at onset);
KIRP	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.5	-7.9	-0.45	9.16e-14	Huntington's disease progression;
KIRP	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.51	5.99	0.36	7.42e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs5747327	0.770	rs5746460	chr22:18178393	A/T	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.11	-0.31	6.57e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs8084125	1.000	rs7237781	chr18:74953527	C/T	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs7215564	0.818	rs78905718	chr17:78604278	G/A	cg06153925	chr17:78755379	RPTOR	0.38	5.41	0.33	1.49e-7	Myopia (pathological);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05400618	chr7:2128721	MAD1L1	-0.46	-6.22	-0.37	2.14e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.78	-10.25	-0.55	9.6e-21	Coffee consumption (cups per day);
KIRP	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.51	5.83	0.35	1.71e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1355223	1.000	rs35365094	chr11:34767790	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-5.87	-0.35	1.42e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs986417	0.688	rs965454	chr14:60960251	T/C	cg27398547	chr14:60952738	C14orf39	0.65	6.5	0.38	4.34e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg00800038	chr16:89945340	TCF25	-0.9	-7.32	-0.42	3.41e-12	Skin colour saturation;
KIRP	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg01843034	chr6:37503916	NA	-0.83	-10.91	-0.57	7.18e-23	Cognitive performance;
KIRP	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg07661805	chr8:143867942	LY6D	-0.29	-5.17	-0.31	4.96e-7	Urinary tract infection frequency;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.55	6.93	0.4	3.63e-11	Longevity;Endometriosis;
KIRP	cis	rs6988636	0.710	rs62521797	chr8:124134321	A/T	cg23067535	chr8:124195133	FAM83A	-0.67	-5.51	-0.33	9e-8	Urinary uromodulin levels;
KIRP	cis	rs10904887	1.000	rs10904887	chr10:17188641	T/C	cg01003015	chr10:17271136	VIM	-0.4	-4.85	-0.3	2.24e-6	Telomere length;
KIRP	cis	rs9311474	0.652	rs411457	chr3:52228150	A/T	cg05315796	chr3:52349193	DNAH1	-0.4	-5.82	-0.35	1.86e-8	Electroencephalogram traits;
KIRP	cis	rs2273669	0.667	rs12212402	chr6:109306681	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs12311304	0.965	rs16910692	chr12:15370010	T/C	cg08258403	chr12:15378311	NA	0.36	5.32	0.32	2.32e-7	Behavioural disinhibition (generation interaction);
KIRP	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg00405596	chr8:11794950	NA	0.53	7.03	0.41	2.08e-11	Mood instability;
KIRP	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.32	5.54	0.33	7.95e-8	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10776057	chr1:178307554	RASAL2	-0.4	-6.18	-0.37	2.72e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8014252	0.803	rs60555424	chr14:71041502	T/C	cg11204974	chr14:71022665	NA	-0.63	-6.58	-0.39	2.8e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00585698	chr12:123750864	CDK2AP1	-0.52	-5.42	-0.33	1.42e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg09597638	chr17:3907349	NA	-0.75	-13.89	-0.66	9.07e-33	Type 2 diabetes;
KIRP	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.25	5.32	0.32	2.38e-7	Menarche (age at onset);
KIRP	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.92	12.96	0.64	1.22e-29	Bladder cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27365115	chr2:103353231	MFSD9	-0.47	-6.21	-0.37	2.29e-9	Metabolic traits;
KIRP	cis	rs73198271	0.960	rs73198286	chr8:8612022	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-5.6	-0.34	5.83e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6708331	0.517	rs9989836	chr2:70342727	G/A	cg01613454	chr2:70366299	NA	0.39	5.21	0.32	4.07e-7	Obesity-related traits;
KIRP	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg04804543	chr8:142233427	SLC45A4	-0.54	-6.99	-0.41	2.6e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02475777	chr4:1388615	CRIPAK	0.39	5.19	0.31	4.31e-7	Longevity;
KIRP	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.67	9.5	0.52	1.96e-18	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg05861140	chr6:150128134	PCMT1	0.45	6.1	0.36	4.08e-9	Lung cancer;
KIRP	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07648498	chr16:89883185	FANCA	0.39	5.12	0.31	6.28e-7	Vitiligo;
KIRP	cis	rs240764	0.746	rs240156	chr6:101063149	C/G	cg09795085	chr6:101329169	ASCC3	0.44	5.12	0.31	6.12e-7	Neuroticism;
KIRP	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.01	-0.3	1.04e-6	Blood metabolite levels;
KIRP	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.6	-5.3	-0.32	2.61e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg07862535	chr7:139043722	LUC7L2	0.49	5.45	0.33	1.24e-7	Diisocyanate-induced asthma;
KIRP	cis	rs13385	0.769	rs269782	chr5:139545302	G/A	cg01860693	chr5:139557145	C5orf32	0.49	5.36	0.32	1.95e-7	Atrial fibrillation;
KIRP	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg05295671	chr13:79234353	RNF219	0.61	5.95	0.35	9.1e-9	Large artery stroke;
KIRP	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	6.25	0.37	1.83e-9	Schizophrenia;
KIRP	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.58	7.17	0.42	8.93e-12	Arsenic metabolism;
KIRP	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-1.07	-13.61	-0.66	8.24e-32	Lymphocyte counts;
KIRP	trans	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg16141378	chr3:129829833	LOC729375	-0.55	-7.08	-0.41	1.51e-11	Neuroticism;
KIRP	trans	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg06521331	chr12:34319734	NA	-0.54	-6.65	-0.39	1.88e-10	Heart rate;
KIRP	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.47	0.38	5.2e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg04727924	chr7:799746	HEATR2	0.73	8.19	0.46	1.44e-14	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.82	-12.23	-0.62	3.4e-27	Asthma;
KIRP	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-8.98	-0.5	7.31e-17	Total body bone mineral density;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25504222	chr19:4639508	TNFAIP8L1	0.55	7.61	0.44	5.96e-13	Myopia (pathological);
KIRP	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06481639	chr22:41940642	POLR3H	-0.69	-7.6	-0.44	6.06e-13	Vitiligo;
KIRP	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.62	7.77	0.44	2.09e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.54	-7.12	-0.41	1.2e-11	Longevity;
KIRP	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.95	-0.35	9.01e-9	IgG glycosylation;
KIRP	cis	rs55675132	0.548	rs17274753	chr1:115379546	G/A	cg12756093	chr1:115239321	AMPD1	0.54	5.25	0.32	3.31e-7	Schizophrenia;
KIRP	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.75	-8.42	-0.47	3.2e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg00981070	chr1:2046702	PRKCZ	-0.31	-5.52	-0.33	8.61e-8	Height;
KIRP	cis	rs2371030	1.000	rs10184528	chr2:211575134	A/T	cg18417063	chr2:211583084	NA	-0.52	-7.6	-0.44	6.12e-13	Non-small cell lung cancer;
KIRP	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg00343986	chr7:65444356	GUSB	0.45	5.58	0.34	6.23e-8	Aortic root size;
KIRP	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg00647317	chr7:50633725	DDC	0.52	7.5	0.43	1.18e-12	Systemic sclerosis;
KIRP	cis	rs7714584	1.000	rs59531858	chr5:150247063	T/G	cg22134413	chr5:150180641	NA	0.95	7.46	0.43	1.52e-12	Crohn's disease;
KIRP	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg07274523	chr3:49395745	GPX1	0.71	8.75	0.49	3.41e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs745821	0.659	rs8098724	chr18:48125899	G/A	cg18923635	chr18:48083994	NA	0.48	4.87	0.3	1.97e-6	Diastolic blood pressure;
KIRP	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg02570527	chr1:10970165	NA	-0.44	-5.42	-0.33	1.42e-7	Body mass index;
KIRP	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg25486957	chr4:152246857	NA	-0.52	-5.69	-0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-9.4	-0.51	3.99e-18	Total body bone mineral density;
KIRP	cis	rs7172677	0.960	rs8026273	chr15:75413766	T/A	cg10253484	chr15:75165896	SCAMP2	-0.56	-6.15	-0.36	3.14e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg25506127	chr15:74907002	CLK3	-0.58	-6.7	-0.39	1.4e-10	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.64	-8.84	-0.49	1.92e-16	Colorectal cancer;
KIRP	trans	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	8.11	0.46	2.4e-14	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.16	-21.08	-0.8	4.81e-57	Ulcerative colitis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17935304	chr21:40555523	PSMG1	-0.5	-6.18	-0.37	2.69e-9	Myopia;
KIRP	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.31	17.35	0.74	1.41e-44	Corneal structure;
KIRP	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.7	9.14	0.5	2.44e-17	Morning vs. evening chronotype;
KIRP	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg20092376	chr4:56023423	NA	0.42	5.22	0.32	3.79e-7	Endometriosis;
KIRP	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.61	-0.44	5.84e-13	Mood instability;
KIRP	cis	rs2071403	0.901	rs56217611	chr2:1400070	T/C	cg06500727	chr2:1417164	TPO	0.35	5.07	0.31	7.85e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs9584850	0.507	rs59704350	chr13:99160430	T/A	cg20750642	chr13:99100586	FARP1	-0.53	-5.69	-0.34	3.53e-8	Neuroticism;
KIRP	cis	rs9469913	0.866	rs2744942	chr6:34643752	T/C	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.13	-0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	1.08	24.09	0.84	1.1e-66	Breast cancer;
KIRP	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.55	0.33	7.22e-8	Coronary artery disease;
KIRP	cis	rs876084	0.966	rs876083	chr8:121101533	C/T	cg22335954	chr8:121166405	COL14A1	-0.4	-5.17	-0.31	4.79e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg15769724	chr15:89787113	FANCI	0.51	6.16	0.37	2.95e-9	Beard thickness;
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg10207240	chr12:122356781	WDR66	0.5	6.75	0.4	1.07e-10	Mean corpuscular volume;
KIRP	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg13798912	chr7:905769	UNC84A	0.78	7.38	0.43	2.4e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.76	6.99	0.41	2.53e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.68	-9.43	-0.52	3.16e-18	Retinal vascular caliber;
KIRP	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6102059	0.518	rs4812444	chr20:39216286	G/T	cg22477343	chr20:39312069	NA	0.42	5.15	0.31	5.33e-7	LDL cholesterol;
KIRP	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1973993	0.717	rs55650017	chr1:96952142	G/A	cg10631902	chr5:14652156	NA	-0.59	-8.31	-0.47	6.62e-15	Weight;
KIRP	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.3	18.85	0.77	1.15e-49	Corneal structure;
KIRP	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18252515	chr7:66147081	NA	0.46	5.51	0.33	9.21e-8	Aortic root size;
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.7	-0.39	1.4e-10	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.15	-0.36	3.18e-9	Lung cancer;
KIRP	trans	rs13170463	0.579	rs13164870	chr5:8034734	G/T	cg03862380	chr20:43029895	HNF4A	0.39	6.03	0.36	6.1e-9	Colorectal cancer;
KIRP	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2119480	0.731	rs369788	chr13:111305787	C/T	cg24331049	chr13:111365604	ING1	-0.45	-5.35	-0.32	1.98e-7	Diastolic blood pressure;
KIRP	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg11518657	chr1:67396239	MIER1	0.49	5.02	0.3	9.89e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg20302533	chr7:39170763	POU6F2	0.27	5.66	0.34	4.12e-8	IgG glycosylation;
KIRP	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.0	-0.3	1.11e-6	Carotid intima media thickness;
KIRP	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg01304814	chr3:48885189	PRKAR2A	0.58	5.1	0.31	6.92e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.57	-6.94	-0.4	3.44e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.78	-7.95	-0.45	6.95e-14	Inflammatory bowel disease;
KIRP	cis	rs6840360	0.582	rs59714108	chr4:152325939	G/A	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.44e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2562456	0.833	rs2154302	chr19:21490411	G/A	cg18461458	chr19:21324796	ZNF431	-0.53	-5.15	-0.31	5.23e-7	Pain;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg06654118	chr4:1303317	MAEA	0.27	5.12	0.31	6.12e-7	Longevity;
KIRP	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	9.61	0.52	8.78e-19	Renal function-related traits (BUN);
KIRP	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.72	9.84	0.53	1.79e-19	Red blood cell count;
KIRP	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.81	9.6	0.52	9.51e-19	Corneal astigmatism;
KIRP	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18252515	chr7:66147081	NA	0.46	5.39	0.32	1.67e-7	Aortic root size;
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.59	-0.34	6.17e-8	Life satisfaction;
KIRP	cis	rs4523957	0.928	rs441750	chr17:2190767	T/C	cg16513277	chr17:2031491	SMG6	0.6	8.27	0.47	8.38e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.53	0.38	3.71e-10	Educational attainment;
KIRP	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg19847130	chr8:10466454	RP1L1	0.37	5.46	0.33	1.16e-7	Triglycerides;
KIRP	cis	rs829883	0.898	rs249834	chr12:98827544	T/C	cg25150519	chr12:98850993	NA	-0.91	-13.51	-0.65	1.71e-31	Colorectal adenoma (advanced);
KIRP	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-5.48	-0.33	1.07e-7	Personality dimensions;
KIRP	cis	rs2011503	0.739	rs10412176	chr19:19689164	T/C	cg11584989	chr19:19387371	SF4	-0.55	-5.81	-0.35	1.94e-8	Bipolar disorder;
KIRP	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg02336718	chr17:17403227	NA	0.36	5.45	0.33	1.2e-7	Total body bone mineral density;
KIRP	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg26811252	chr16:29126840	RRN3P2	-0.76	-10.48	-0.56	1.75e-21	Menopause (age at onset);
KIRP	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	11.16	0.58	1.18e-23	Cognitive test performance;
KIRP	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-4.99	-0.3	1.14e-6	Educational attainment;
KIRP	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.49	-0.33	1e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7221595	0.825	rs12450845	chr17:3972784	G/A	cg05562828	chr17:3906858	NA	0.57	6.19	0.37	2.47e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7267005	0.661	rs76093771	chr20:34460677	C/G	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03114244	chr11:61560355	FEN1;C11orf10;MIR611	0.51	6.25	0.37	1.75e-9	Parkinson's disease;
KIRP	trans	rs61884328	0.777	rs61897784	chr11:47154514	A/G	cg10758369	chr1:48459236	NA	0.48	6.35	0.38	1.04e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs12580194	0.593	rs55898514	chr12:55736238	G/A	cg19537932	chr12:55886519	OR6C68	-0.49	-6.4	-0.38	7.84e-10	Cancer;
KIRP	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	0.94	12.11	0.61	8.95e-27	Blood protein levels;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg13495038	chr10:134582338	INPP5A	0.43	6.06	0.36	5.1e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs7584330	0.504	rs61213635	chr2:238428132	A/G	cg08992911	chr2:238395768	MLPH	0.46	5.25	0.32	3.36e-7	Prostate cancer;
KIRP	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	1.08	15.25	0.7	2.12e-37	Multiple sclerosis;
KIRP	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.43	5.38	0.32	1.71e-7	Aortic root size;
KIRP	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs13185784	0.569	rs6877489	chr5:179677545	C/T	cg23248424	chr5:179741104	GFPT2	-0.53	-5.65	-0.34	4.36e-8	TRAIL levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25174615	chr18:43684699	ATP5A1;HAUS1	0.52	6.74	0.39	1.12e-10	Parkinson's disease;
KIRP	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	1.16	14.34	0.67	2.67e-34	Type 2 diabetes nephropathy;
KIRP	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg01620082	chr3:125678407	NA	-1.02	-6.59	-0.39	2.65e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-5.98	-0.36	7.7e-9	Colorectal cancer;
KIRP	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg12560992	chr17:57184187	TRIM37	0.61	5.62	0.34	5.09e-8	Cognitive test performance;
KIRP	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg19610905	chr11:61596333	FADS2	-0.52	-6.11	-0.36	3.92e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs1832871	0.711	rs7770047	chr6:158685696	A/G	cg07215822	chr6:158701037	NA	-0.64	-7.51	-0.43	1.1e-12	Height;
KIRP	cis	rs9362426	1.000	rs1203156	chr6:88079694	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	6.04	0.36	5.54e-9	Depressive episodes in bipolar disorder;
KIRP	cis	rs6466055	0.661	rs2079341	chr7:104904235	A/C	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.59	7.79	0.45	1.82e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.93	-13.17	-0.64	2.4e-30	Coronary artery disease;
KIRP	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg15733309	chr7:157513707	PTPRN2	0.42	6.28	0.37	1.54e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg10818794	chr15:86012489	AKAP13	0.49	6.89	0.4	4.78e-11	Interstitial lung disease;
KIRP	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.76e-9	Breast cancer;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.75	-0.34	2.66e-8	Life satisfaction;
KIRP	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.5	0.43	1.17e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg06050784	chr16:88016603	BANP	0.43	5.46	0.33	1.16e-7	Menopause (age at onset);
KIRP	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.53	-0.48	1.49e-15	Menarche (age at onset);
KIRP	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.03	-13.14	-0.64	2.99e-30	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22933469	chr3:11888149	C3orf31	0.52	6.52	0.38	3.96e-10	Parkinson's disease;
KIRP	cis	rs6690583	0.623	rs12042018	chr1:85436937	T/C	cg22153463	chr1:85462885	MCOLN2	0.61	5.07	0.31	7.91e-7	Serum sulfate level;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21233506	chr2:148653986	ACVR2A	-0.46	-6.9	-0.4	4.25e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.49	-0.33	1.02e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.19	-0.37	2.45e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6753739	0.784	rs437512	chr2:219926168	T/C	cg01749213	chr2:219906749	CCDC108	0.41	4.96	0.3	1.31e-6	Height;
KIRP	cis	rs113084984	0.538	rs11686574	chr2:11684007	C/G	cg07314298	chr2:11723111	GREB1	0.41	5.51	0.33	9.01e-8	Breast cancer;
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg17294928	chr15:75287854	SCAMP5	0.58	7.72	0.44	2.97e-13	Breast cancer;
KIRP	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg26174226	chr8:58114915	NA	-0.61	-7.19	-0.42	7.64e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg18225595	chr11:63971243	STIP1	0.66	6.06	0.36	5.08e-9	Mean platelet volume;
KIRP	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-8.79	-0.49	2.62e-16	Osteoarthritis;
KIRP	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-8.08	-0.46	2.83e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1712517	0.771	rs7921655	chr10:105113701	C/T	cg05636881	chr10:105038444	INA	0.43	6.27	0.37	1.65e-9	Migraine;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08204369	chr17:73150733	HN1	0.65	7.75	0.44	2.35e-13	Smoking initiation;
KIRP	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.73	9.1	0.5	3.17e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.81	0.53	2.24e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.76	8.8	0.49	2.46e-16	Reticulocyte fraction of red cells;
KIRP	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.91	-10.74	-0.56	2.58e-22	Vitiligo;
KIRP	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.73	5.91	0.35	1.11e-8	Diabetic retinopathy;
KIRP	cis	rs6832769	0.696	rs7660054	chr4:56268507	T/C	cg09317128	chr4:56265301	TMEM165	0.53	7.09	0.41	1.39e-11	Personality dimensions;
KIRP	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.83	-12.05	-0.61	1.35e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22318304	chr11:124543788	SIAE;SPA17	0.39	6.3	0.37	1.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg26207909	chr14:103986467	CKB	-0.48	-6.16	-0.37	2.93e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1891275	0.508	rs7099557	chr10:93445364	C/G	cg07889827	chr10:93443413	NA	-0.41	-7.03	-0.41	2.04e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6723108	0.651	rs6724866	chr2:135407310	C/A	cg25422880	chr2:135218333	TMEM163	0.34	5.04	0.31	8.92e-7	Type 2 diabetes;
KIRP	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg15436174	chr10:43711423	RASGEF1A	0.79	8.24	0.47	1.04e-14	Hirschsprung disease;
KIRP	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg02751453	chr18:77725136	HSBP1L1	0.4	5.2	0.31	4.14e-7	Opioid sensitivity;
KIRP	cis	rs2033732	0.673	rs10808858	chr8:85070841	C/T	cg05716166	chr8:85095498	RALYL	0.55	6.26	0.37	1.66e-9	Body mass index;
KIRP	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.42	0.43	1.87e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs55788414	0.932	rs8043592	chr16:81182537	A/G	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.29	-0.47	7.58e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	1.11	22.17	0.82	1.39e-60	Height;
KIRP	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.59	0.34	5.88e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2837828	0.967	rs11702668	chr21:42176277	G/A	cg05777962	chr1:247614860	OR2B11	-0.39	-6.08	-0.36	4.48e-9	Neutrophil count;
KIRP	cis	rs6142102	0.602	rs932388	chr20:32657378	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	5.76	0.34	2.5e-8	Skin pigmentation;
KIRP	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	10.46	0.55	2.05e-21	Nonalcoholic fatty liver disease;
KIRP	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.28e-7	Reticulocyte count;High light scatter reticulocyte count;
KIRP	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg20673091	chr1:2541236	MMEL1	-0.67	-10.36	-0.55	4.12e-21	Ulcerative colitis;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg10534938	chr5:1868639	NA	0.36	4.87	0.3	2.04e-6	Cardiovascular disease risk factors;
KIRP	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	7.15	0.41	9.97e-12	Neuroticism;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg12843872	chr7:90894352	FZD1	-0.55	-6.69	-0.39	1.5e-10	Type 1 diabetes nephropathy;
KIRP	trans	rs199950	1.000	rs199950	chr1:181590858	C/T	cg04237608	chr1:18659049	IGSF21	0.33	6.02	0.36	6.42e-9	Body mass index (change over time);
KIRP	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg06042504	chr8:55087323	NA	-0.61	-7.48	-0.43	1.34e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg08807101	chr21:30365312	RNF160	-0.57	-6.92	-0.4	3.98e-11	Pancreatic cancer;
KIRP	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg11833968	chr6:79620685	NA	-0.48	-7.22	-0.42	6.43e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	11.51	0.59	8.19e-25	Smoking behavior;
KIRP	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg26384229	chr12:38710491	ALG10B	0.72	9.38	0.51	4.51e-18	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18156551	chr11:63991917	TRPT1	-0.47	-6.72	-0.39	1.29e-10	Parkinson's disease;
KIRP	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.9	14.01	0.67	3.44e-33	Height;
KIRP	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg21905437	chr5:178450457	ZNF879	0.51	5.91	0.35	1.14e-8	Pubertal anthropometrics;
KIRP	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	6.61	0.39	2.33e-10	Height;
KIRP	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs7113850	0.541	rs78363992	chr11:24232126	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.34	0.47	5.17e-15	Bone fracture in osteoporosis;
KIRP	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg07116693	chr15:90310901	NA	-0.23	-4.99	-0.3	1.14e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.52	-6.09	-0.36	4.2e-9	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg16717723	chr8:2172215	NA	-0.49	-6.75	-0.4	1.07e-10	Inflammatory biomarkers;
KIRP	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg02367723	chr1:46378857	MAST2	0.45	5.24	0.32	3.47e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg25418670	chr11:30344373	C11orf46	-0.6	-5.15	-0.31	5.43e-7	Morning vs. evening chronotype;
KIRP	cis	rs1971762	0.542	rs12303370	chr12:54091807	A/C	cg16917193	chr12:54089295	NA	0.84	16.51	0.73	1e-41	Height;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg00976509	chr11:130184046	ZBTB44	0.56	7.05	0.41	1.76e-11	Educational attainment;
KIRP	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.97	-0.5	7.51e-17	Total cholesterol levels;
KIRP	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.42	-5.14	-0.31	5.73e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.18e-7	Aortic root size;
KIRP	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12311346	chr5:56204834	C5orf35	-0.45	-5.67	-0.34	3.97e-8	Coronary artery disease;
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg00106254	chr7:1943704	MAD1L1	-0.44	-5.01	-0.3	1.05e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	0.43	6.04	0.36	5.59e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.8	12.97	0.64	1.16e-29	Dupuytren's disease;
KIRP	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg18357645	chr12:58087776	OS9	0.43	5.32	0.32	2.29e-7	Multiple sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03439086	chr11:64085030	PRDX5;TRMT112	0.55	7.1	0.41	1.35e-11	Parkinson's disease;
KIRP	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.84	-13.37	-0.65	5.05e-31	Coronary artery disease;
KIRP	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.97	-0.5	7.62e-17	Mood instability;
KIRP	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21643547	chr1:205240462	TMCC2	-0.87	-13.89	-0.66	9.11e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2213920	0.679	rs4979534	chr9:118211159	T/C	cg13918206	chr9:118159781	DEC1	0.96	9.97	0.54	6.87e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05220968	chr6:146057943	EPM2A	-0.37	-5.03	-0.31	9.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.69	-0.44	3.55e-13	Platelet count;
KIRP	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg07972983	chr1:205091412	RBBP5	-0.43	-5.23	-0.32	3.7e-7	Red blood cell count;
KIRP	cis	rs15676	0.783	rs2977998	chr9:131580570	A/G	cg00228799	chr9:131580591	ENDOG	0.58	6.53	0.38	3.75e-10	Blood metabolite levels;
KIRP	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.86	-13.4	-0.65	4e-31	Height;
KIRP	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.44	-0.43	1.67e-12	Bone mineral density;
KIRP	cis	rs2862064	0.932	rs1809941	chr5:156482459	G/T	cg12943317	chr5:156479607	HAVCR1	-0.91	-8.05	-0.46	3.54e-14	Platelet count;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2692947	0.800	rs4332959	chr2:96549121	C/T	cg23100626	chr2:96804247	ASTL	0.45	6.21	0.37	2.28e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.64	-0.39	1.98e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg19116668	chr7:99932089	PMS2L1	0.45	5.06	0.31	8.17e-7	Coronary artery disease;
KIRP	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg04398451	chr17:18023971	MYO15A	-0.87	-12.61	-0.63	1.83e-28	Total body bone mineral density;
KIRP	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-6.17	-0.37	2.76e-9	Chronic sinus infection;
KIRP	cis	rs3017493	0.786	rs78344725	chr11:70687830	G/A	cg03578926	chr11:70508032	SHANK2	0.29	4.93	0.3	1.55e-6	Renal transplant outcome;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg19338460	chr6:170058176	WDR27	-1.21	-9.51	-0.52	1.82e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06481639	chr22:41940642	POLR3H	0.49	5.85	0.35	1.59e-8	Vitiligo;
KIRP	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.65	10.34	0.55	4.66e-21	Coronary artery disease;
KIRP	trans	rs886716	0.835	rs10270775	chr7:26554620	A/G	cg06954677	chr8:39873708	IDO2	0.47	6.11	0.36	3.98e-9	Smoking behavior;
KIRP	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg24503407	chr1:205819492	PM20D1	0.49	5.31	0.32	2.5e-7	Parkinson's disease;
KIRP	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg13271783	chr10:134563150	INPP5A	-0.61	-7.74	-0.44	2.58e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4356932	0.935	rs4605683	chr4:76979327	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs7714584	1.000	rs10058943	chr5:150226586	A/G	cg22134413	chr5:150180641	NA	0.58	5.21	0.32	3.98e-7	Crohn's disease;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg21698718	chr17:80085957	CCDC57	0.35	5.11	0.31	6.51e-7	Life satisfaction;
KIRP	cis	rs9962915	0.900	rs1785381	chr18:5589721	C/T	cg12967001	chr18:5544089	EPB41L3	-0.4	-4.94	-0.3	1.42e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.38e-7	Oral cavity cancer;
KIRP	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg06871246	chr4:1363661	KIAA1530	0.44	5.47	0.33	1.09e-7	Obesity-related traits;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24367761	chr6:131908781	MED23	0.41	6.46	0.38	5.47e-10	C-reactive protein;
KIRP	cis	rs8135828	1.000	rs2530664	chr22:30038152	A/C	cg23204276	chr22:29729285	AP1B1;SNORD125	0.45	5.02	0.3	1e-6	Lipid traits;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-5.03	-0.31	9.43e-7	Life satisfaction;
KIRP	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg03714773	chr7:91764589	CYP51A1	0.37	5.39	0.33	1.63e-7	Breast cancer;
KIRP	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.68	7.99	0.45	5.06e-14	Cocaine dependence;
KIRP	cis	rs9584850	0.834	rs745638	chr13:99119307	C/G	cg20750642	chr13:99100586	FARP1	0.52	6.27	0.37	1.57e-9	Neuroticism;
KIRP	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg26513180	chr16:89883248	FANCA	0.83	5.53	0.33	8.06e-8	Skin colour saturation;
KIRP	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.91	12.45	0.62	6.33e-28	Coronary artery disease;
KIRP	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg16586182	chr3:47516702	SCAP	-0.8	-11.58	-0.59	4.75e-25	Colorectal cancer;
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg07701084	chr6:150067640	NUP43	0.62	8.02	0.46	4.39e-14	Lung cancer;
KIRP	trans	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg06521331	chr12:34319734	NA	-0.52	-6.36	-0.38	9.75e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.46	-5.41	-0.33	1.51e-7	Response to antidepressants in depression;
KIRP	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.83	0.66	1.47e-32	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.48	5.42	0.33	1.4e-7	Platelet distribution width;
KIRP	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.7	9.78	0.53	2.7e-19	Asperger disorder;
KIRP	cis	rs1971762	0.509	rs10783592	chr12:54037430	G/A	cg23533419	chr12:54090519	NA	-0.34	-5.08	-0.31	7.34e-7	Height;
KIRP	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.14	24.3	0.84	2.54e-67	Testicular germ cell tumor;
KIRP	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.95	14.61	0.68	3.11e-35	Orofacial clefts;
KIRP	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.65	8.08	0.46	2.97e-14	Breast cancer;
KIRP	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08048268	chr3:133502702	NA	-0.41	-4.92	-0.3	1.6e-6	Iron status biomarkers;
KIRP	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg17264618	chr3:40429014	ENTPD3	0.32	4.98	0.3	1.18e-6	Renal cell carcinoma;
KIRP	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	1.02	19.13	0.77	1.35e-50	Breast cancer;
KIRP	cis	rs4929949	0.565	rs11517718	chr11:8693405	G/A	cg08015107	chr11:8618950	NA	-0.35	-4.87	-0.3	1.96e-6	Body mass index;
KIRP	cis	rs1341267	1.000	rs1341267	chr13:95284980	A/C	cg09582042	chr13:95253676	GPR180	-0.3	-5.17	-0.31	4.92e-7	Triglyceride levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21887597	chr15:83419354	NA	0.53	6.2	0.37	2.4e-9	Smoking initiation;
KIRP	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-7.96	-0.45	6.22e-14	Schizophrenia;
KIRP	cis	rs6815814	0.861	rs6531663	chr4:38792340	T/C	cg06935464	chr4:38784597	TLR10	0.59	7.17	0.42	8.64e-12	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21817673	chr5:141736862	NA	0.47	6.1	0.36	4e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20553930	chr7:120590671	ING3	0.46	6.12	0.36	3.74e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.9e-20	Alzheimer's disease (late onset);
KIRP	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg01304814	chr3:48885189	PRKAR2A	0.55	5.12	0.31	6.23e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.78	-0.44	2e-13	Tonsillectomy;
KIRP	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.48	-5.88	-0.35	1.33e-8	Eosinophil percentage of white cells;
KIRP	cis	rs950881	0.932	rs13431828	chr2:102954653	C/T	cg01254707	chr2:102953421	IL1RL1	-0.5	-5.05	-0.31	8.6e-7	Allergy;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.5	6.28	0.37	1.54e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg27124370	chr19:33622961	WDR88	0.72	10.12	0.54	2.37e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg13271783	chr10:134563150	INPP5A	-0.63	-7.91	-0.45	8.75e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.2	0.46	1.3e-14	Personality dimensions;
KIRP	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg23479056	chr15:41276147	INO80	0.37	5.09	0.31	7.18e-7	Menopause (age at onset);
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.35	6.22	0.37	2.09e-9	Renal cell carcinoma;
KIRP	cis	rs494562	0.773	rs6919207	chr6:86129271	C/T	cg21730993	chr6:86159210	NT5E	0.57	5.64	0.34	4.56e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-4.96	-0.3	1.31e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.56	-8.59	-0.48	1.01e-15	Lung cancer;
KIRP	cis	rs7635838	0.785	rs904475	chr3:11535417	G/A	cg00170343	chr3:11313890	ATG7	0.47	5.73	0.34	2.97e-8	HDL cholesterol;
KIRP	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg07395648	chr5:131743802	NA	-0.61	-8.56	-0.48	1.2e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs2929278	0.617	rs693919	chr15:44102328	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.5	-5.92	-0.35	1.09e-8	Schizophrenia;
KIRP	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs7590368	0.640	rs56260452	chr2:10954843	C/G	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.42	5.65	0.34	4.5e-8	Melanoma;
KIRP	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg24375607	chr4:120327624	NA	0.65	7.53	0.43	9.34e-13	Corneal astigmatism;
KIRP	trans	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg12929700	chr20:62947519	NA	-0.59	-6.11	-0.36	3.9e-9	Refractive error;
KIRP	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg08916839	chr5:415575	AHRR	0.52	5.58	0.34	6.33e-8	Fat distribution (HIV);
KIRP	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.39	0.38	8.16e-10	Mean platelet volume;
KIRP	cis	rs4750440	0.702	rs7917812	chr10:14030067	G/A	cg27542038	chr10:14027202	FRMD4A	-0.47	-6.44	-0.38	6.38e-10	Adiponectin levels;
KIRP	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	1.12	8.23	0.46	1.13e-14	Skin colour saturation;
KIRP	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	1.15	14.54	0.68	5.7e-35	Response to hepatitis C treatment;
KIRP	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.32	5.6	0.34	5.84e-8	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15054260	chr8:90769710	RIPK2	0.68	6.52	0.38	3.96e-10	Lung function (FEV1);
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.54	-7.08	-0.41	1.51e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.37e-14	Aortic root size;
KIRP	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	10.28	0.55	7.47e-21	Smoking behavior;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.62	-0.39	2.29e-10	Response to antipsychotic treatment;
KIRP	cis	rs9394841	0.692	rs56215622	chr6:41892457	G/A	cg08135965	chr6:41755394	TOMM6	0.53	5.6	0.34	5.86e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs10267417	0.603	rs7796408	chr7:19945782	C/A	cg05791153	chr7:19748676	TWISTNB	0.51	5.12	0.31	6.3e-7	Night sleep phenotypes;
KIRP	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03264133	chr6:25882463	NA	0.41	5.31	0.32	2.46e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.65	7.98	0.45	5.7e-14	Corneal astigmatism;
KIRP	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.71	0.34	3.21e-8	Height;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27213352	chr17:32907731	TMEM132E;C17orf102	0.51	6.87	0.4	5.32e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg22563815	chr15:78856949	CHRNA5	0.53	7.51	0.43	1.06e-12	Sudden cardiac arrest;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21521454	chr19:48972670	CYTH2	0.49	7.01	0.41	2.26e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.94	-0.35	9.68e-9	Obesity-related traits;
KIRP	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg16141378	chr3:129829833	LOC729375	0.53	7.33	0.42	3.36e-12	Triglycerides;
KIRP	cis	rs3120667	0.929	rs3126099	chr1:152314219	A/G	cg26876637	chr1:152193138	HRNR	-0.56	-6.38	-0.38	8.83e-10	Eating disorders;
KIRP	cis	rs2273669	0.504	rs74421833	chr6:109409274	A/G	cg05315195	chr6:109294784	ARMC2	-0.59	-4.88	-0.3	1.95e-6	Prostate cancer;
KIRP	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.44	-0.43	1.7e-12	Neuroticism;
KIRP	cis	rs7737355	0.812	rs3776013	chr5:130867404	C/T	cg06307176	chr5:131281290	NA	0.42	5.02	0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs6545883	0.503	rs1665272	chr2:61379286	A/C	cg15711740	chr2:61764176	XPO1	-0.52	-6.65	-0.39	1.86e-10	Tuberculosis;
KIRP	trans	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-6.89	-0.4	4.65e-11	Obesity-related traits;
KIRP	cis	rs754423	0.703	rs1540700	chr14:52521773	G/A	cg05884192	chr14:52515736	NID2	-0.68	-7.99	-0.45	5.27e-14	Craniofacial microsomia;
KIRP	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12560992	chr17:57184187	TRIM37	0.63	7.29	0.42	4.29e-12	Testicular germ cell tumor;
KIRP	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.67	-9.28	-0.51	9.43e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg10117171	chr1:25599238	RHD	-0.37	-5.11	-0.31	6.35e-7	Erythrocyte sedimentation rate;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09625499	chr3:197384388	NA	0.39	6.06	0.36	4.97e-9	Pancreatic cancer;
KIRP	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	5.96	0.36	8.52e-9	Breast cancer;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg10254082	chr7:997346	NA	0.46	4.88	0.3	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28489187	0.706	rs761601	chr1:85797298	A/G	cg16011679	chr1:85725395	C1orf52	0.54	6.52	0.38	3.99e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg01238044	chr22:24384105	GSTT1	0.54	7.06	0.41	1.7e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg12315302	chr6:26189340	HIST1H4D	0.95	6.49	0.38	4.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg21698718	chr17:80085957	CCDC57	0.34	5.03	0.31	9.28e-7	Life satisfaction;
KIRP	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg10760299	chr15:45669010	GATM	0.34	5.09	0.31	6.96e-7	Homoarginine levels;
KIRP	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg03538708	chr1:25844672	NA	-0.38	-4.89	-0.3	1.8e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-7.79	-0.44	1.93e-13	Dental caries;
KIRP	cis	rs11264213	0.786	rs72659690	chr1:36291750	G/A	cg27506609	chr1:36549197	TEKT2	0.96	5.34	0.32	2.13e-7	Schizophrenia;
KIRP	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.08	12.51	0.62	3.95e-28	Uric acid levels;
KIRP	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg09990169	chr2:241835740	C2orf54	-0.45	-6.67	-0.39	1.64e-10	Urinary metabolites;
KIRP	cis	rs8014252	0.803	rs10135356	chr14:71030355	T/C	cg19730268	chr14:71022823	NA	-0.56	-5.3	-0.32	2.6e-7	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.8	-13.21	-0.64	1.75e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg05861140	chr6:150128134	PCMT1	-0.5	-7.06	-0.41	1.71e-11	Lung cancer;
KIRP	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg10189774	chr4:17578691	LAP3	0.45	5.25	0.32	3.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.36	-0.38	9.51e-10	Coronary artery disease;
KIRP	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg24879335	chr3:133465180	TF	0.33	4.86	0.3	2.09e-6	Iron status biomarkers;
KIRP	cis	rs6974574	0.961	rs1464712	chr7:38125584	A/G	cg10754659	chr7:38110151	NA	-0.37	-5.05	-0.31	8.42e-7	Height;
KIRP	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.12	-0.36	3.77e-9	Response to antipsychotic treatment;
KIRP	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.12e-22	Coronary artery disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg12055265	chr4:114285588	ANK2	0.4	6.22	0.37	2.15e-9	C-reactive protein;
KIRP	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg02175503	chr12:58329896	NA	0.5	5.38	0.32	1.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	5.22	0.32	3.77e-7	Parkinson's disease;
KIRP	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg09873164	chr1:152488093	CRCT1	0.53	6.66	0.39	1.76e-10	Hair morphology;
KIRP	cis	rs526231	0.543	rs26525	chr5:102464923	G/C	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	cis	rs3924048	0.574	rs11121925	chr1:12613130	A/C	cg00291366	chr1:12616550	NA	0.45	6.45	0.38	6.03e-10	Optic cup area;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01999652	chr6:28220110	ZKSCAN4	-0.48	-6.3	-0.37	1.37e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6450176	0.951	rs5013866	chr5:53300947	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-5.05	-0.31	8.53e-7	Skin colour saturation;
KIRP	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg16141378	chr3:129829833	LOC729375	0.57	7.44	0.43	1.68e-12	Mood instability;
KIRP	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.38	-5.11	-0.31	6.56e-7	Coronary artery disease;
KIRP	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg21918786	chr6:109611834	NA	0.35	5.24	0.32	3.41e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.67	-0.39	1.7e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.09	0.36	4.24e-9	Primary sclerosing cholangitis;
KIRP	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.69	-0.53	5.3e-19	Neuroticism;
KIRP	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.07	8.81	0.49	2.35e-16	Mitochondrial DNA levels;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.08e-8	Lung cancer;
KIRP	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg09873164	chr1:152488093	CRCT1	0.51	6.43	0.38	6.44e-10	Hair morphology;
KIRP	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.63	-0.34	4.88e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02186127	chr17:33914245	AP2B1	0.53	6.07	0.36	4.92e-9	Smoking initiation;
KIRP	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2637030	0.559	rs256116	chr5:52962251	C/T	cg06476337	chr5:52856530	NDUFS4	0.54	5.86	0.35	1.46e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs2120243	0.592	rs28638274	chr3:157124479	C/T	cg24825693	chr3:157122686	VEPH1	-0.49	-8.06	-0.46	3.42e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.69	8.69	0.48	5.2e-16	Height;
KIRP	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg08779649	chr13:50194554	NA	0.48	6.56	0.39	3.17e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg00684032	chr4:1343700	KIAA1530	0.52	6.8	0.4	8.06e-11	Longevity;
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg01081737	chr8:142238752	SLC45A4	0.33	4.96	0.3	1.29e-6	Immature fraction of reticulocytes;
KIRP	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg24565620	chr2:194026	NA	-0.67	-6.03	-0.36	5.86e-9	Blood protein levels;
KIRP	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg08499158	chr17:42289980	UBTF	-0.63	-8.59	-0.48	1.02e-15	Total body bone mineral density;
KIRP	cis	rs11955175	1.000	rs79132719	chr5:40668525	T/C	cg04002187	chr5:40835754	RPL37	0.66	5.31	0.32	2.51e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.57	7.23	0.42	5.91e-12	Lung cancer;
KIRP	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg08501292	chr6:25962987	TRIM38	0.79	5.43	0.33	1.32e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.37	0.68	2.16e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.3	-0.32	2.61e-7	Rheumatoid arthritis;
KIRP	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.3	-5.12	-0.31	6.25e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	5.58	0.34	6.29e-8	Depressive symptoms;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06950987	chr22:20255298	RTN4R	0.46	6.16	0.37	2.93e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	7.26	0.42	5e-12	Retinal vascular caliber;
KIRP	cis	rs8077577	0.945	rs34474249	chr17:18074525	T/C	cg09161412	chr17:18057145	MYO15A	-0.4	-5.21	-0.32	4.02e-7	Obesity-related traits;
KIRP	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.56	6.12	0.36	3.65e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22047825	chr15:99640892	NA	0.49	6.74	0.39	1.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-7.64	-0.44	4.7e-13	Vitiligo;
KIRP	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg16141378	chr3:129829833	LOC729375	0.53	7.08	0.41	1.52e-11	Morning vs. evening chronotype;
KIRP	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.6	9.1	0.5	3.2e-17	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs4926611	0.698	rs12072004	chr1:54060991	C/A	cg08927728	chr1:54059983	GLIS1	0.27	5.75	0.34	2.58e-8	Hand grip strength;
KIRP	cis	rs3806843	0.900	rs3756334	chr5:140213796	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.4	-0.38	7.83e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	1.08	7.89	0.45	9.99e-14	Skin colour saturation;
KIRP	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-7.02	-0.41	2.21e-11	Skin colour saturation;
KIRP	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	0.96	15.85	0.71	1.9e-39	Bone mineral density;
KIRP	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.53	6.61	0.39	2.39e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15781525	chr6:564561	EXOC2	-0.42	-6.29	-0.37	1.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.44	9.81	0.53	2.17e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg26516362	chr5:178986906	RUFY1	-0.45	-8.01	-0.45	4.54e-14	Lung cancer;
KIRP	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.77	-8.28	-0.47	7.87e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg14458575	chr2:238380390	NA	0.46	5.33	0.32	2.27e-7	Prostate cancer;
KIRP	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg02336718	chr17:17403227	NA	0.36	5.41	0.33	1.51e-7	Total body bone mineral density;
KIRP	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg11608241	chr8:8085544	FLJ10661	-0.46	-5.74	-0.34	2.83e-8	Joint mobility (Beighton score);
KIRP	cis	rs11877825	0.826	rs4643401	chr18:10579303	G/C	cg07277756	chr18:10589357	NA	0.5	6.07	0.36	4.87e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg08283408	chr3:49949060	MON1A	0.42	5.56	0.33	7.19e-8	Body mass index;
KIRP	cis	rs7179456	0.545	rs2250583	chr15:59050382	C/T	cg05156742	chr15:59063176	FAM63B	-0.54	-6.74	-0.39	1.11e-10	Asperger disorder;
KIRP	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-8.84	-0.49	1.92e-16	Personality dimensions;
KIRP	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.52	0.33	8.54e-8	Renal cell carcinoma;
KIRP	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.51	-7.21	-0.42	6.74e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4849845	0.760	rs55877687	chr2:121013675	A/G	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.58	5.92	0.35	1.1e-8	Height;
KIRP	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.75	0.44	2.41e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs10073892	0.664	rs10067911	chr5:101893255	C/T	cg19774478	chr5:101632501	SLCO4C1	0.6	5.86	0.35	1.49e-8	Cognitive decline (age-related);
KIRP	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg24881330	chr22:46731750	TRMU	0.72	6.5	0.38	4.32e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.64	9.57	0.52	1.19e-18	Vitiligo;
KIRP	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.7	9.39	0.51	4.38e-18	Mood instability;
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg07648498	chr16:89883185	FANCA	0.45	5.84	0.35	1.67e-8	Schizophrenia;
KIRP	cis	rs7523273	0.565	rs2796250	chr1:207903654	T/C	cg22525895	chr1:207977042	MIR29B2	-0.47	-5.99	-0.36	7.26e-9	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.06e-10	Prudent dietary pattern;
KIRP	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg18646521	chr2:111875858	NA	0.4	5.72	0.34	3.14e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-16.01	-0.71	5.21e-40	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.03	0.36	6e-9	Height;
KIRP	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.08	0.61	1.09e-26	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.76	-0.44	2.21e-13	Mood instability;
KIRP	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.32	12.04	0.61	1.45e-26	Diabetic retinopathy;
KIRP	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.78	9.31	0.51	7.29e-18	Corneal astigmatism;
KIRP	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.87	12.22	0.61	3.86e-27	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16905586	chr3:49761211	GMPPB	0.47	6.89	0.4	4.69e-11	Survival in pancreatic cancer;
KIRP	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg07274523	chr3:49395745	GPX1	0.72	8.48	0.48	2.11e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.91	14.4	0.68	1.62e-34	Dental caries;
KIRP	cis	rs7178909	0.872	rs28865973	chr15:90435178	T/G	cg19708238	chr15:90437601	AP3S2	0.57	7.9	0.45	9.08e-14	Common traits (Other);
KIRP	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.2e-6	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.41	0.51	3.62e-18	Morning vs. evening chronotype;
KIRP	cis	rs7221595	0.825	rs12951359	chr17:3921731	T/A	cg09597638	chr17:3907349	NA	0.56	6.02	0.36	6.23e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs8177876	0.822	rs76948085	chr16:81112804	G/A	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.13	-0.5	2.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7224685	0.569	rs34540447	chr17:3994413	T/C	cg09597638	chr17:3907349	NA	0.52	5.24	0.32	3.41e-7	Type 2 diabetes;
KIRP	cis	rs4132509	1.000	rs320320	chr1:243835186	A/G	cg25706552	chr1:244017396	NA	0.56	7.94	0.45	7.2e-14	RR interval (heart rate);
KIRP	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-1.13	-12.23	-0.61	3.59e-27	Response to hepatitis C treatment;
KIRP	cis	rs6504950	0.800	rs9891704	chr17:53010755	A/G	cg26251398	chr17:52985966	TOM1L1	0.45	6.06	0.36	5.02e-9	Breast cancer;
KIRP	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.2	12.91	0.64	1.82e-29	Uric acid levels;
KIRP	cis	rs11645898	0.625	rs8047930	chr16:72106024	C/T	cg14768367	chr16:72042858	DHODH	-0.66	-7.76	-0.44	2.31e-13	Blood protein levels;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg21186296	chr8:27182909	PTK2B	0.52	6.57	0.39	3.04e-10	Neuroticism;
KIRP	cis	rs9596863	0.898	rs114565044	chr13:54399897	C/T	ch.13.53330881F	chr13:54432880	NA	0.62	6.24	0.37	1.9e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-1.14	-14.06	-0.67	2.42e-33	Type 2 diabetes nephropathy;
KIRP	cis	rs829661	0.645	rs829695	chr2:30650152	G/A	cg10949345	chr2:30726833	LCLAT1	1.08	13.43	0.65	3.16e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs960902	0.713	rs6757678	chr2:37723610	A/G	cg25341268	chr2:37734390	NA	0.57	7.71	0.44	3.21e-13	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg15282417	chr9:129245246	FAM125B	0.43	7.2	0.42	7.41e-12	Intraocular pressure;
KIRP	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg15691649	chr6:25882328	NA	0.45	5.58	0.34	6.33e-8	Blood metabolite levels;
KIRP	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg12181417	chr19:49337499	HSD17B14	-0.47	-5.02	-0.3	1e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.67	7.27	0.42	4.82e-12	Vitiligo;
KIRP	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg11235152	chr1:67600687	NA	-0.74	-10.77	-0.57	2.1e-22	Psoriasis;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.83	-12.72	-0.63	7.97e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01302669	chr3:49824110	IP6K1	0.48	6.29	0.37	1.46e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.43	-5.83	-0.35	1.69e-8	Breast cancer;
KIRP	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.1	0.36	4.2e-9	Mean corpuscular volume;
KIRP	cis	rs13064411	0.542	rs7650671	chr3:113201216	C/T	cg18753928	chr3:113234510	CCDC52	-0.49	-6.26	-0.37	1.72e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-8.22	-0.46	1.14e-14	Morning vs. evening chronotype;
KIRP	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.48	6.91	0.4	4.13e-11	Coronary artery disease;
KIRP	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg07384080	chr1:156148190	NA	0.29	5.06	0.31	8.36e-7	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg08280861	chr8:58055591	NA	0.53	5.06	0.31	8.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.06	0.54	3.77e-20	Morning vs. evening chronotype;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14875093	chr19:38398164	WDR87;SIPA1L3	-0.49	-6.2	-0.37	2.35e-9	Neuroticism;
KIRP	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.68	8.23	0.46	1.1e-14	Smoking initiation;
KIRP	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.15	0.46	1.79e-14	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.91	-14.91	-0.69	2.98e-36	Urate levels in lean individuals;
KIRP	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.9e-11	Retinal vascular caliber;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17360330	chr4:4459401	STX18	0.53	7.15	0.41	9.93e-12	Interleukin-4 levels;
KIRP	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.54	6.68	0.39	1.62e-10	Monocyte count;
KIRP	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.29	0.51	8.51e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.47	-6.93	-0.4	3.7e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2067663	0.730	rs653444	chr5:88049341	C/T	cg18498987	chr5:88179539	MEF2C	-0.41	-5.2	-0.31	4.11e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.19	0.31	4.46e-7	Educational attainment;
KIRP	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.64	-0.39	2.03e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7551222	0.681	rs10900595	chr1:204511602	C/A	cg20240347	chr1:204465584	NA	-0.43	-8.21	-0.46	1.26e-14	Schizophrenia;
KIRP	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	ch.11.42038R	chr11:967971	AP2A2	-0.37	-4.87	-0.3	2.02e-6	Alzheimer's disease (late onset);
KIRP	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.71	11.04	0.58	2.85e-23	Coronary artery disease;
KIRP	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.58	0.48	1.07e-15	Bipolar disorder;
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	12.78	0.63	4.91e-29	Platelet count;
KIRP	cis	rs7916697	0.593	rs3740587	chr10:70020802	G/A	cg06988349	chr10:69991859	ATOH7	-0.39	-5.08	-0.31	7.57e-7	Optic disc area;
KIRP	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.99	14.19	0.67	8.78e-34	Cognitive function;
KIRP	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.34	-0.47	5.3e-15	Mean corpuscular volume;
KIRP	cis	rs6662572	1.000	rs11585275	chr1:46095989	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.23	0.32	3.62e-7	Blood protein levels;
KIRP	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.49	-5.24	-0.32	3.38e-7	Initial pursuit acceleration;
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg17207736	chr8:142237307	SLC45A4	0.53	6.78	0.4	8.78e-11	Immature fraction of reticulocytes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26690672	chr4:146031291	ABCE1	-0.4	-6.03	-0.36	5.98e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg22800045	chr5:56110881	MAP3K1	-0.7	-6.87	-0.4	5.22e-11	Initial pursuit acceleration;
KIRP	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.77	-0.6	1.11e-25	Total body bone mineral density;
KIRP	cis	rs9581857	0.579	rs76578450	chr13:27982656	C/A	cg22138327	chr13:27999177	GTF3A	0.97	7.48	0.43	1.35e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg16141378	chr3:129829833	LOC729375	-0.59	-7.68	-0.44	3.71e-13	Mood instability;
KIRP	cis	rs332034	0.546	rs28481744	chr8:8696346	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-5.01	-0.3	1.05e-6	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg21798802	chr22:38057573	PDXP	0.43	5.21	0.32	3.94e-7	Fat distribution (HIV);
KIRP	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.53	7.74	0.44	2.54e-13	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg27490568	chr2:178487706	NA	0.53	7.29	0.42	4.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.5	7.01	0.41	2.29e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1832871	0.640	rs262831	chr6:158691169	A/T	cg07215822	chr6:158701037	NA	-0.58	-8.6	-0.48	9.24e-16	Height;
KIRP	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.69	8.43	0.47	2.9e-15	Neutrophil percentage of white cells;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21171335	chr12:122356390	WDR66	0.63	8.38	0.47	4.1e-15	Mean corpuscular volume;
KIRP	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.44	5.14	0.31	5.53e-7	Aortic root size;
KIRP	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.98	-0.5	7.38e-17	Total cholesterol levels;
KIRP	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.43	5.63	0.34	4.92e-8	Height;
KIRP	cis	rs675026	0.927	rs544228	chr6:154425291	C/A	cg07813322	chr6:154414604	OPRM1	-0.47	-6.05	-0.36	5.25e-9	Hypertension;
KIRP	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.56	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs4363385	0.747	rs6668696	chr1:152964910	A/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.96	-0.3	1.29e-6	Inflammatory skin disease;
KIRP	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.01	-12.97	-0.64	1.15e-29	Exhaled nitric oxide output;
KIRP	cis	rs6062509	0.965	rs1056441	chr20:62370349	T/C	cg11503966	chr20:62272292	STMN3	0.35	4.97	0.3	1.28e-6	Prostate cancer;
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg14221460	chr8:27183342	PTK2B	-0.54	-6.76	-0.4	9.8e-11	Alzheimer's disease (late onset);
KIRP	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.73	-0.53	3.81e-19	Hemoglobin concentration;
KIRP	cis	rs17453880	0.853	rs60230149	chr5:151965041	G/A	cg12297329	chr5:152029980	NA	-0.68	-10.16	-0.54	1.74e-20	Subjective well-being;
KIRP	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.78	10.53	0.56	1.25e-21	Osteoporosis;
KIRP	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.79	-10.84	-0.57	1.24e-22	Calcium levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17213048	chr8:124332861	ATAD2	-0.42	-6.51	-0.38	4.29e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.61	-0.34	5.49e-8	Aortic root size;
KIRP	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.54	-5.23	-0.32	3.62e-7	Obesity (extreme);
KIRP	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg04539111	chr16:67997858	SLC12A4	-0.56	-5.41	-0.33	1.48e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.83	0.49	2.06e-16	Resting heart rate;
KIRP	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.93	0.61	3.38e-26	Ileal carcinoids;
KIRP	cis	rs11877825	0.826	rs9676146	chr18:10571489	A/T	cg07277756	chr18:10589357	NA	0.51	6.17	0.37	2.84e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg21523564	chr15:75251491	NA	0.48	8.15	0.46	1.91e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs35740288	0.822	rs1961601	chr15:86229606	T/C	cg10818794	chr15:86012489	AKAP13	-0.42	-5.0	-0.3	1.1e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	0.96	8.03	0.46	4.02e-14	Skin colour saturation;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07897831	chr17:73512512	CASKIN2;TSEN54	0.5	6.61	0.39	2.36e-10	Myopia (pathological);
KIRP	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg11234688	chr2:1609660	NA	0.58	5.28	0.32	2.79e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-5.05	-0.31	8.62e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25181236	chr4:56387275	CLOCK	-0.4	-6.06	-0.36	5.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg20701182	chr2:24300061	SF3B14	0.63	5.37	0.32	1.82e-7	Lymphocyte counts;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10146780	chr14:52897968	TXNDC16	0.48	6.71	0.39	1.3100000000000001e-10	Interleukin-4 levels;
KIRP	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-9.88	-0.53	1.28e-19	Gut microbiome composition (summer);
KIRP	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg09455208	chr3:40491958	NA	0.31	5.74	0.34	2.74e-8	Renal cell carcinoma;
KIRP	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.66	8.84	0.49	1.84e-16	Bladder cancer;
KIRP	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs13185784	0.667	rs35551113	chr5:179654221	T/C	cg13944838	chr5:179740914	GFPT2	0.54	5.25	0.32	3.34e-7	TRAIL levels;
KIRP	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg05315796	chr3:52349193	DNAH1	0.37	5.23	0.32	3.59e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg13798912	chr7:905769	UNC84A	0.53	5.39	0.33	1.64e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-1.05	-14.64	-0.68	2.43e-35	Orofacial clefts;
KIRP	cis	rs4262150	0.641	rs7379700	chr5:152325534	C/T	cg12297329	chr5:152029980	NA	0.49	7.19	0.42	7.9e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03967533	chr1:23378206	KDM1A	-0.44	-6.62	-0.39	2.24e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03536861	chr1:25071933	CLIC4	-0.5	-6.45	-0.38	5.95e-10	Myopia;
KIRP	cis	rs6840360	0.573	rs4696249	chr4:152264647	A/G	cg25486957	chr4:152246857	NA	-0.44	-5.57	-0.33	6.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6669919	0.653	rs12058879	chr1:211684876	G/A	cg10512769	chr1:211675356	NA	-0.56	-8.11	-0.46	2.38e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.83	-0.57	1.28e-22	Menopause (age at onset);
KIRP	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg23825301	chr11:1296823	TOLLIP	0.34	5.14	0.31	5.69e-7	Breast cancer;
KIRP	cis	rs367943	0.712	rs27567	chr5:112741798	C/T	cg12552261	chr5:112820674	MCC	0.56	6.69	0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05665937	chr4:1216051	CTBP1	0.46	6.35	0.38	1.04e-9	Obesity-related traits;
KIRP	cis	rs6539288	0.630	rs3759316	chr12:107370210	A/C	cg15890332	chr12:107067104	RFX4	0.32	5.22	0.32	3.77e-7	Total body bone mineral density;
KIRP	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21211367	chr2:162094118	NA	0.41	5.58	0.34	6.26e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.58e-7	Body mass index;
KIRP	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg09165964	chr15:75287851	SCAMP5	0.44	5.49	0.33	9.75e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg23649088	chr2:200775458	C2orf69	0.53	5.08	0.31	7.37e-7	Schizophrenia;
KIRP	trans	rs10107145	0.509	rs4310166	chr8:10763736	A/G	cg16141378	chr3:129829833	LOC729375	0.53	6.41	0.38	7.21e-10	Systolic blood pressure;
KIRP	cis	rs12210905	0.688	rs72845030	chr6:27532643	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-5.83	-0.35	1.72e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs8103278	0.507	rs10415988	chr19:46246704	C/T	cg02376097	chr19:46275166	DMPK	0.48	6.51	0.38	4.22e-10	Coronary artery disease;
KIRP	cis	rs1870805	0.630	rs2614755	chr8:141001882	C/T	cg15997020	chr8:140990656	TRAPPC9	-0.39	-5.36	-0.32	1.87e-7	Obesity-related traits;
KIRP	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg24203234	chr3:128598194	ACAD9	0.44	5.01	0.3	1.06e-6	IgG glycosylation;
KIRP	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-1.04	-10.86	-0.57	1.05e-22	Monocyte percentage of white cells;
KIRP	cis	rs4700695	1.000	rs4700696	chr5:65412634	G/C	cg21114390	chr5:65439923	SFRS12	-0.61	-5.82	-0.35	1.78e-8	Facial morphology (factor 19);
KIRP	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.47	-5.63	-0.34	4.86e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-6.24	-0.37	1.9e-9	Lung cancer;
KIRP	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.77	9.02	0.5	5.4e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	16.16	0.72	1.62e-40	Bipolar disorder;
KIRP	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg07167872	chr1:205819463	PM20D1	0.53	5.11	0.31	6.46e-7	Menarche (age at onset);
KIRP	cis	rs981844	0.683	rs1563462	chr4:154755051	G/A	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.46	5.91	0.35	1.15e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.67	10.2	0.55	1.33e-20	Monocyte percentage of white cells;
KIRP	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.01	-0.5	5.8e-17	Personality dimensions;
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg12463550	chr7:65579703	CRCP	-0.44	-4.94	-0.3	1.42e-6	Aortic root size;
KIRP	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.06	-0.54	3.54e-20	Coffee consumption (cups per day);
KIRP	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.43	6.44	0.38	6.09e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.52	7.09	0.41	1.41e-11	Gout;
KIRP	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.47	6.54	0.39	3.46e-10	Sitting height ratio;
KIRP	cis	rs17020663	0.713	rs2278721	chr2:101620990	C/G	cg12594615	chr2:101643137	TBC1D8	0.42	4.94	0.3	1.41e-6	Pulse pressure;
KIRP	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.45	-8.74	-0.49	3.63e-16	Longevity;
KIRP	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg09344028	chr17:70110421	NA	0.4	7.89	0.45	1.01e-13	Thyroid hormone levels;
KIRP	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg25706552	chr1:244017396	NA	0.56	6.31	0.37	1.26e-9	RR interval (heart rate);
KIRP	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg05991184	chr2:219186017	PNKD	0.39	5.39	0.32	1.65e-7	Colorectal cancer;
KIRP	trans	rs587242	1.000	rs722155	chr1:96906374	A/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.31	0.47	6.48e-15	Total body bone mineral density;
KIRP	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.56	-7.27	-0.42	4.71e-12	Aortic root size;
KIRP	cis	rs8084125	1.000	rs62105170	chr18:74945570	A/G	cg18461021	chr18:74961002	GALR1	0.62	5.9	0.35	1.19e-8	Obesity-related traits;
KIRP	cis	rs6725041	0.532	rs12623803	chr2:213201642	G/C	cg20637307	chr2:213403960	ERBB4	-0.48	-6.05	-0.36	5.42e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg15841412	chr13:111365552	ING1	0.52	5.77	0.35	2.38e-8	Coronary artery disease;
KIRP	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18364779	chr6:26104403	HIST1H4C	0.41	5.33	0.32	2.23e-7	Schizophrenia;
KIRP	cis	rs13064411	0.735	rs2614191	chr3:113269201	C/T	cg10517650	chr3:113235015	CCDC52	-0.35	-5.17	-0.31	4.8e-7	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.62	0.52	8.45e-19	Monocyte percentage of white cells;
KIRP	trans	rs10486722	0.607	rs6463036	chr7:41753786	G/A	cg07952040	chr12:110562126	IFT81	-0.59	-6.09	-0.36	4.21e-9	Pit-and-Fissure caries;
KIRP	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.62	-4.96	-0.3	1.3e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs2591576	0.691	rs1070024	chr5:165399771	C/T	cg13976338	chr5:165423657	NA	-0.7	-9.87	-0.53	1.43e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg14289246	chr4:154710475	SFRP2	-0.52	-6.84	-0.4	6.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs9815354	0.680	rs73073292	chr3:42028023	C/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20224016	chr19:56632746	ZNF787	0.44	6.06	0.36	4.99e-9	Cancer;
KIRP	cis	rs2688419	0.565	rs1817581	chr3:23078375	T/A	cg00327796	chr3:23032191	NA	-0.48	-6.48	-0.38	5.1e-10	Type 2 diabetes;
KIRP	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.61	-0.48	8.9e-16	Neuroticism;
KIRP	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.95	-0.3	1.37e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg25486957	chr4:152246857	NA	-0.52	-5.73	-0.34	2.89e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	1.0	17.46	0.74	6.01e-45	Breast cancer;
KIRP	cis	rs3733418	0.929	rs1401400	chr4:165927911	G/C	cg10852876	chr4:165953100	TRIM60	-0.44	-4.92	-0.3	1.56e-6	Obesity-related traits;
KIRP	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.51	7.8	0.45	1.76e-13	Total body bone mineral density;
KIRP	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.56	8.07	0.46	3.19e-14	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.68	8.13	0.46	2.08e-14	Breast cancer;
KIRP	cis	rs365132	0.875	rs353496	chr5:176429898	T/C	cg16309518	chr5:176445507	NA	-0.81	-12.38	-0.62	1.06e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16149437	chr2:39245178	SOS1	-0.38	-6.05	-0.36	5.34e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg01721255	chr8:58191610	C8orf71	0.56	4.87	0.3	1.97e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.87	8.56	0.48	1.25e-15	Methadone dose in opioid dependence;
KIRP	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg15605315	chr1:45957053	TESK2	0.42	5.27	0.32	3.04e-7	High light scatter reticulocyte count;
KIRP	cis	rs8070740	0.592	rs2189338	chr17:5326341	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.6	7.95	0.45	6.87e-14	Menopause (age at onset);
KIRP	cis	rs8070740	0.786	rs34856659	chr17:5327572	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.37	0.43	2.56e-12	Menopause (age at onset);
KIRP	cis	rs2415984	0.579	rs61993339	chr14:46969266	G/A	cg14871534	chr14:47121158	RPL10L	-0.41	-4.9	-0.3	1.74e-6	Number of children ever born;
KIRP	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg09238746	chr17:78121135	EIF4A3	-0.81	-9.31	-0.51	7.41e-18	Yeast infection;
KIRP	cis	rs787274	0.764	rs787287	chr9:115534245	T/C	cg13803584	chr9:115635662	SNX30	-0.74	-6.66	-0.39	1.8e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.05	-0.36	5.47e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12413816	1.000	rs12413816	chr10:13757765	G/T	cg16485048	chr10:13749193	FRMD4A	0.65	9.32	0.51	6.73e-18	Red cell distribution width;
KIRP	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg25801113	chr15:45476975	SHF	0.42	7.91	0.45	8.62e-14	Uric acid levels;
KIRP	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.23	-21.71	-0.81	4.28e-59	Breast cancer;
KIRP	cis	rs5756391	0.503	rs9607395	chr22:37315742	C/T	cg16356956	chr22:37317934	CSF2RB	0.37	5.04	0.31	8.94e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06544989	chr22:39130855	UNC84B	0.52	9.19	0.51	1.66e-17	Menopause (age at onset);
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg21285383	chr16:89894308	SPIRE2	0.33	6.29	0.37	1.48e-9	Vitiligo;
KIRP	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.44	-5.41	-0.33	1.52e-7	Diastolic blood pressure;
KIRP	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.87	12.64	0.63	1.49e-28	Bladder cancer;
KIRP	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.52	7.71	0.44	3.1e-13	Blood protein levels;
KIRP	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg24631222	chr15:78858424	CHRNA5	-0.81	-9.72	-0.53	4.27e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs240764	0.687	rs239248	chr6:101088315	T/A	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.66	-8.72	-0.49	4.17e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.35	-0.42	3e-12	Aortic root size;
KIRP	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.41	-0.43	2.01e-12	Neuroticism;
KIRP	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.81	0.4	7.36e-11	Neuroticism;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	1.06	21.29	0.81	9.81e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.79	-7.38	-0.43	2.38e-12	Chronic sinus infection;
KIRP	cis	rs9888739	0.641	rs67898294	chr16:31362711	C/T	cg15817542	chr16:31343056	ITGAM	-0.55	-5.76	-0.34	2.53e-8	Systemic lupus erythematosus;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14421829	chr9:117350234	ATP6V1G1	0.5	6.46	0.38	5.58e-10	Parkinson's disease;
KIRP	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-8.0	-0.45	4.89e-14	Cognitive function;
KIRP	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg07636037	chr3:49044803	WDR6	-0.71	-5.09	-0.31	7.19e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs997295	0.592	rs2899724	chr15:67760808	C/T	cg24579218	chr15:68104479	NA	0.36	5.21	0.32	3.97e-7	Motion sickness;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.86	11.8	0.6	9.41e-26	Height;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.71	8.66	0.48	6.33e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.62	6.43	0.38	6.56e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg05535760	chr7:792225	HEATR2	-0.84	-7.55	-0.43	8.23e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg08648136	chr8:956695	NA	0.52	7.72	0.44	2.85e-13	Schizophrenia;
KIRP	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.47	5.91	0.35	1.16e-8	Menopause (age at onset);
KIRP	cis	rs4073221	0.654	rs34741569	chr3:18284731	T/C	cg07694806	chr3:18168406	NA	-0.65	-5.9	-0.35	1.19e-8	Parkinson's disease;
KIRP	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	6.02	0.36	6.15e-9	Eotaxin levels;
KIRP	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.42	-0.43	1.86e-12	Triglycerides;
KIRP	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.7	9.58	0.52	1.1e-18	Red blood cell count;
KIRP	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs60871478	0.635	rs4725122	chr7:785318	A/G	cg04727924	chr7:799746	HEATR2	-0.6	-6.21	-0.37	2.19e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs13161895	0.646	rs77997852	chr5:179504925	T/C	cg06664874	chr5:179499304	RNF130	0.81	4.89	0.3	1.81e-6	LDL cholesterol;
KIRP	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.64	10.07	0.54	3.43e-20	Bone mineral density;
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg09699651	chr6:150184138	LRP11	0.47	6.13	0.36	3.55e-9	Lung cancer;
KIRP	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-6.26	-0.37	1.73e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.51	4.97	0.3	1.26e-6	Initial pursuit acceleration;
KIRP	cis	rs2591576	0.511	rs248552	chr5:165380979	G/A	cg13976338	chr5:165423657	NA	-0.71	-9.58	-0.52	1.11e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.55	-6.01	-0.36	6.62e-9	Body mass index;
KIRP	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.39	-0.43	2.27e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7523273	0.554	rs2761434	chr1:207917499	C/T	cg22525895	chr1:207977042	MIR29B2	-0.5	-5.03	-0.31	9.39e-7	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg01798813	chr17:3906674	NA	0.52	7.26	0.42	4.99e-12	Type 2 diabetes;
KIRP	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.3	-4.95	-0.3	1.38e-6	Height;
KIRP	cis	rs929596	0.564	rs2602362	chr2:234516548	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-5.45	-0.33	1.2e-7	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.78	-8.96	-0.5	8.06e-17	Schizophrenia;
KIRP	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg19554555	chr3:13937349	NA	-0.48	-6.43	-0.38	6.51e-10	Ovarian reserve;
KIRP	cis	rs6669919	0.967	rs894983	chr1:211675279	T/C	cg10512769	chr1:211675356	NA	-0.63	-10.08	-0.54	3.23e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs735539	0.645	rs6490601	chr13:21245897	G/A	cg27499820	chr13:21296301	IL17D	0.36	5.19	0.31	4.41e-7	Dental caries;
KIRP	cis	rs17092148	0.945	rs6060034	chr20:33351864	T/C	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg03959625	chr15:84868606	LOC388152	0.65	6.65	0.39	1.86e-10	Schizophrenia;
KIRP	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.42	-6.94	-0.4	3.49e-11	Body mass index;
KIRP	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.75	-10.87	-0.57	9.72e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.65	-6.96	-0.41	3.15e-11	Gut microbiome composition (summer);
KIRP	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	trans	rs4742903	0.509	rs1857984	chr9:106954979	A/G	cg06629767	chr10:72238406	KIAA1274	0.44	6.16	0.37	2.88e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs75920871	0.925	rs61903417	chr11:116956157	T/G	cg23684410	chr11:116897558	SIK3	0.57	5.82	0.35	1.79e-8	Subjective well-being;
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg05861140	chr6:150128134	PCMT1	-0.51	-7.35	-0.42	2.99e-12	Lung cancer;
KIRP	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.38	-5.05	-0.31	8.5e-7	Neuroticism;
KIRP	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs9659323	1.000	rs56897173	chr1:119515732	G/A	cg18261050	chr1:119551319	NA	0.35	4.9	0.3	1.75e-6	Body mass index;
KIRP	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.81	0.45	1.66e-13	Corneal astigmatism;
KIRP	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-4.94	-0.3	1.45e-6	Testicular germ cell tumor;
KIRP	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.64	8.12	0.46	2.23e-14	Tonsillectomy;
KIRP	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg06307176	chr5:131281290	NA	0.55	5.94	0.35	9.87e-9	Life satisfaction;
KIRP	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.12	-0.54	2.38e-20	Heart rate;
KIRP	cis	rs7602568	0.954	rs4666064	chr2:28586643	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-5.36	-0.32	1.95e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg26207909	chr14:103986467	CKB	-0.44	-5.35	-0.32	1.98e-7	Coronary artery disease;
KIRP	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-0.78	-6.92	-0.4	3.9e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2274459	0.841	rs13214874	chr6:33686368	G/A	cg06253072	chr6:33679850	C6orf125	0.52	5.53	0.33	8.2e-8	Obesity (extreme);
KIRP	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.71	11.05	0.58	2.56e-23	Resting heart rate;
KIRP	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.42	5.71	0.34	3.24e-8	Night sleep phenotypes;
KIRP	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.75e-10	Colorectal cancer;
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.51	5.19	0.31	4.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08280861	chr8:58055591	NA	0.78	6.34	0.37	1.07e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.43	-5.27	-0.32	2.94e-7	Aortic root size;
KIRP	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06634786	chr22:41940651	POLR3H	-0.49	-5.5	-0.33	9.4e-8	Vitiligo;
KIRP	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.38e-10	Diabetic retinopathy;
KIRP	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg08501292	chr6:25962987	TRIM38	0.75	5.31	0.32	2.44e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7394190	0.810	rs7394178	chr10:75421580	G/A	cg04833713	chr10:74871078	NUDT13	0.44	5.35	0.32	1.96e-7	Incident atrial fibrillation;
KIRP	cis	rs1823913	0.503	rs35282329	chr2:192208651	G/A	cg12404831	chr2:192114017	MYO1B	0.51	7.01	0.41	2.3e-11	Obesity-related traits;
KIRP	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.5	8.01	0.45	4.66e-14	Platelet distribution width;
KIRP	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-7.39	-0.43	2.3e-12	Bipolar disorder;
KIRP	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.54	-5.55	-0.33	7.34e-8	DNA methylation (variation);
KIRP	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg03060546	chr3:49711283	APEH	0.53	7.16	0.42	9.23e-12	Menarche (age at onset);
KIRP	cis	rs380904	0.926	rs7842979	chr8:144601896	T/G	cg20583945	chr8:144636462	GSDMD	0.47	5.89	0.35	1.24e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg11859384	chr17:80120422	CCDC57	-0.42	-5.28	-0.32	2.82e-7	Life satisfaction;
KIRP	cis	rs258892	0.895	rs34656	chr5:72148117	C/T	cg21869765	chr5:72125136	TNPO1	0.57	6.28	0.37	1.49e-9	Small cell lung carcinoma;
KIRP	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.7	-0.53	4.73e-19	Morning vs. evening chronotype;
KIRP	cis	rs35264875	1.000	rs72919415	chr11:68827082	G/A	cg23845249	chr11:68861649	NA	0.58	8.01	0.45	4.58e-14	Blond vs. brown hair color;
KIRP	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	8.23	0.46	1.12e-14	Myopia (pathological);
KIRP	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg06223162	chr1:101003688	GPR88	-0.43	-8.8	-0.49	2.41e-16	Monocyte count;
KIRP	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg14906510	chr12:7781169	NA	0.48	4.93	0.3	1.51e-6	HDL cholesterol levels;
KIRP	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg22508957	chr16:3507546	NAT15	0.44	6.58	0.39	2.74e-10	Tuberculosis;
KIRP	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.03e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.91	10.38	0.55	3.73e-21	Eosinophil percentage of granulocytes;
KIRP	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.7	-6.3	-0.37	1.39e-9	Intraocular pressure;
KIRP	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg08648136	chr8:956695	NA	0.43	6.62	0.39	2.23e-10	Schizophrenia;
KIRP	cis	rs3768617	0.811	rs4396114	chr1:183007441	C/T	cg21523751	chr1:182988639	NA	0.37	5.09	0.31	7.19e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg05347473	chr6:146136440	FBXO30	0.62	8.75	0.49	3.48e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.73	10.89	0.57	8.53e-23	Hip circumference;
KIRP	cis	rs1823913	0.637	rs12623156	chr2:192164387	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.26	-0.37	1.67e-9	Obesity-related traits;
KIRP	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg03887218	chr1:16534349	ARHGEF19	0.58	7.72	0.44	2.94e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs12949688	0.654	rs4793914	chr17:55834581	T/G	cg12582317	chr17:55822272	NA	0.44	6.2	0.37	2.35e-9	Schizophrenia;
KIRP	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-5.38	-0.32	1.76e-7	HDL cholesterol;
KIRP	cis	rs8054556	0.647	rs4787488	chr16:29995803	G/T	cg06326092	chr16:30034487	C16orf92	-0.4	-5.92	-0.35	1.06e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.67	9.15	0.5	2.19e-17	Red blood cell count;
KIRP	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.98	-0.36	7.94e-9	Obesity-related traits;
KIRP	cis	rs7766436	0.848	rs6931450	chr6:22582076	T/C	cg13666174	chr6:22585274	NA	-0.44	-6.1	-0.36	4.02e-9	Coronary artery disease;
KIRP	cis	rs1823913	0.525	rs7424440	chr2:192202645	A/T	cg12404831	chr2:192114017	MYO1B	0.51	7.02	0.41	2.18e-11	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg02569458	chr12:86230093	RASSF9	0.38	5.55	0.33	7.54e-8	Major depressive disorder;
KIRP	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg02319466	chr17:76381040	PGS1	0.45	6.31	0.37	1.31e-9	HDL cholesterol;
KIRP	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06481639	chr22:41940642	POLR3H	0.73	7.23	0.42	6.18e-12	Vitiligo;
KIRP	cis	rs5753037	0.702	rs131301	chr22:30185889	A/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.71	-0.34	3.16e-8	Type 1 diabetes;
KIRP	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg20003494	chr4:90757398	SNCA	-0.41	-5.31	-0.32	2.47e-7	Neuroticism;
KIRP	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	1.04	20.09	0.79	8.99e-54	Heart rate;
KIRP	trans	rs587242	1.000	rs12036050	chr1:96917491	T/C	cg10631902	chr5:14652156	NA	0.53	6.14	0.36	3.2e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.44	7.79	0.44	1.9e-13	Superior crus of antihelix expression;
KIRP	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.32	-0.32	2.3e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs6838801	0.823	rs7691621	chr4:77589959	A/G	cg17476223	chr4:77663285	SHROOM3	0.56	8.12	0.46	2.29e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg05639522	chr1:247681581	NA	0.59	5.65	0.34	4.4e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg27411982	chr8:10470053	RP1L1	-0.47	-5.7	-0.34	3.45e-8	Neuroticism;
KIRP	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	7.75	0.44	2.36e-13	Systemic lupus erythematosus;
KIRP	cis	rs2456568	0.695	rs55756119	chr11:93689909	A/G	cg26875233	chr11:93583750	C11orf90	0.33	6.24	0.37	1.92e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.24	-0.32	3.43e-7	Schizophrenia;
KIRP	cis	rs897080	0.515	rs786405	chr2:44710367	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.76	0.34	2.47e-8	Height;
KIRP	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg06212747	chr3:49208901	KLHDC8B	0.65	7.26	0.42	5.12e-12	Menarche (age at onset);
KIRP	cis	rs7104764	0.507	rs6598054	chr11:254010	C/T	cg00562011	chr11:252351	PSMD13	0.49	6.32	0.37	1.25e-9	Menarche (age at onset);
KIRP	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	8.95	0.5	8.69e-17	Cognitive test performance;
KIRP	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.32	5.49	0.33	9.77e-8	Dupuytren's disease;
KIRP	cis	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg07585502	chr8:101912084	NA	-0.65	-8.49	-0.48	1.95e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg23594656	chr7:65796392	TPST1	-0.47	-7.53	-0.43	9.42e-13	Aortic root size;
KIRP	cis	rs2997447	0.706	rs2783712	chr1:26429344	A/C	cg19633962	chr1:26362018	EXTL1	-0.49	-4.91	-0.3	1.69e-6	QRS complex (12-leadsum);
KIRP	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.87	-9.95	-0.54	7.92e-20	Gut microbiome composition (summer);
KIRP	cis	rs507080	0.769	rs570836	chr11:118512162	G/A	cg04173919	chr11:118528438	PHLDB1	0.35	5.01	0.3	1.06e-6	Serum metabolite levels;
KIRP	cis	rs858239	0.539	rs4377861	chr7:23185969	C/T	cg23682824	chr7:23144976	KLHL7	0.49	5.63	0.34	5.03e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg11234688	chr2:1609660	NA	0.64	5.72	0.34	3.06e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg01244601	chr4:120671846	NA	-0.4	-5.21	-0.32	3.97e-7	Corneal astigmatism;
KIRP	trans	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg13565492	chr6:43139072	SRF	-0.75	-7.46	-0.43	1.5e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs273218	0.724	rs392714	chr5:53382703	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.5	5.75	0.34	2.63e-8	Migraine;
KIRP	trans	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg24644049	chr4:85504048	CDS1	1.05	6.85	0.4	5.93e-11	Skin colour saturation;
KIRP	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.83	13.03	0.64	7.31e-30	Ulcerative colitis;
KIRP	cis	rs10073892	0.743	rs13358420	chr5:101651946	C/A	cg19774478	chr5:101632501	SLCO4C1	0.65	6.67	0.39	1.68e-10	Cognitive decline (age-related);
KIRP	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	1.13	15.4	0.7	6.5e-38	Post bronchodilator FEV1;
KIRP	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.88e-18	Height;
KIRP	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg02725872	chr8:58115012	NA	-0.56	-6.39	-0.38	8.33e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs867371	1.000	rs1392976	chr15:82446175	A/G	cg06066596	chr15:83166174	LOC80154	0.47	5.53	0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-8.67	-0.48	6.02e-16	Bipolar disorder;
KIRP	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.49	8.1	0.46	2.57e-14	Erythrocyte sedimentation rate;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02539911	chr17:58677246	PPM1D	0.53	6.12	0.36	3.58e-9	Smoking initiation;
KIRP	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.3	-6.96	-0.41	3.07e-11	Mean corpuscular volume;
KIRP	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg12963246	chr6:28129442	ZNF389	0.53	6.41	0.38	7.49e-10	Depression;
KIRP	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg12311346	chr5:56204834	C5orf35	-0.36	-4.96	-0.3	1.31e-6	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs1978968	1.000	rs5992926	chr22:18449876	A/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.59	-0.44	6.55e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg16794390	chr17:18148240	FLII	0.58	8.05	0.46	3.54e-14	Parental longevity (combined parental age at death);
KIRP	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23598886	chr18:12777645	NA	-0.66	-5.11	-0.31	6.46e-7	Inflammatory skin disease;
KIRP	cis	rs9608946	1.000	rs737942	chr22:30876835	A/G	cg23383138	chr22:30885012	SEC14L4	0.4	4.93	0.3	1.52e-6	Red cell distribution width;
KIRP	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.76	-8.65	-0.48	6.77e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.63	-7.27	-0.42	4.88e-12	Menarche (age at onset);
KIRP	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25214090	chr10:38739885	LOC399744	-0.57	-7.13	-0.41	1.13e-11	Corneal astigmatism;
KIRP	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.28	0.37	1.49e-9	Colorectal cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11696861	chr19:6739997	TRIP10	-0.46	-6.04	-0.36	5.79e-9	Myopia;
KIRP	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.38	5.58	0.33	6.47e-8	Survival in rectal cancer;
KIRP	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg02002194	chr4:3960332	NA	-0.47	-6.41	-0.38	7.37e-10	Mood instability;
KIRP	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-8.23	-0.46	1.08e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.66	10.1	0.54	2.66e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	6.74	0.4	1.09e-10	Lymphocyte counts;
KIRP	cis	rs731174	0.802	rs579908	chr1:38187447	A/G	cg14170840	chr1:38155120	C1orf109	-0.4	-5.0	-0.3	1.08e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.53	7.4	0.43	2.12e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs57994353	0.600	rs11145974	chr9:139316744	A/G	cg14169450	chr9:139327907	INPP5E	-0.52	-5.72	-0.34	3.08e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.97	12.89	0.64	2.08e-29	Breast cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg03837627	chr17:28443756	CCDC55;MIR423	1.05	7.16	0.42	9.3e-12	P wave terminal force;
KIRP	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-10.02	-0.54	5.04e-20	Triglycerides;
KIRP	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.35	-0.32	2.03e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.58	6.8	0.4	8.07e-11	Coronary artery disease;
KIRP	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	0.95	12.16	0.61	6e-27	Blood protein levels;
KIRP	cis	rs981844	0.712	rs878911	chr4:154755615	A/G	cg14289246	chr4:154710475	SFRP2	-0.55	-7.07	-0.41	1.59e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.45	5.81	0.35	1.93e-8	Crohn's disease;
KIRP	cis	rs9649213	0.593	rs1468338	chr7:97951118	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-7.13	-0.41	1.13e-11	Response to antipsychotic treatment;
KIRP	cis	rs7572644	0.699	rs6547814	chr2:28102998	G/A	cg27432699	chr2:27873401	GPN1	0.43	5.23	0.32	3.62e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Bladder cancer;
KIRP	cis	rs282587	0.569	rs282600	chr13:113391602	G/A	cg04656015	chr13:113407548	ATP11A	0.66	7.83	0.45	1.46e-13	Glycated hemoglobin levels;
KIRP	cis	rs2625529	0.775	rs4777484	chr15:72376543	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.96	-0.36	8.53e-9	Red blood cell count;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.64	-5.2	-0.31	4.1e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.67	-9.68	-0.53	5.37e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs4740619	0.556	rs1359954	chr9:16039223	A/G	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.07e-7	Body mass index;
KIRP	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	5.88	0.35	1.36e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10861661	0.963	rs10444533	chr12:107229705	A/G	cg21360079	chr12:107162445	NA	0.57	6.4	0.38	7.68e-10	Triglyceride levels;
KIRP	cis	rs4262150	0.739	rs17455800	chr5:152065789	T/A	cg12297329	chr5:152029980	NA	-0.67	-8.21	-0.46	1.27e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg10756647	chr7:56101905	PSPH	0.92	6.98	0.41	2.77e-11	Gout;
KIRP	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg10167378	chr1:228756711	NA	0.88	7.37	0.43	2.63e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg23307798	chr14:103986281	CKB	0.73	11.35	0.59	2.68e-24	Body mass index;
KIRP	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.4	4.87	0.3	1.97e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.55	-0.48	1.37e-15	Neuroticism;
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22168489	chr12:122356033	WDR66	0.65	9.46	0.52	2.52e-18	Mean corpuscular volume;
KIRP	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Melanoma;
KIRP	cis	rs829661	0.739	rs1470534	chr2:30868392	A/G	cg10949345	chr2:30726833	LCLAT1	1.03	12.65	0.63	1.38e-28	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs687432	0.887	rs11601663	chr11:57773306	T/C	cg19752551	chr11:57585705	CTNND1	-0.68	-8.88	-0.49	1.44e-16	Parkinson's disease;
KIRP	cis	rs9535307	0.727	rs7983303	chr13:50358053	T/A	cg04663916	chr13:50265991	EBPL	0.65	6.89	0.4	4.66e-11	Obesity-related traits;
KIRP	cis	rs9815354	0.812	rs73077359	chr3:41850016	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs830383	0.615	rs2861667	chr5:165511601	C/T	cg13976338	chr5:165423657	NA	0.44	5.31	0.32	2.51e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg04226714	chr8:49833948	SNAI2	-0.45	-6.19	-0.37	2.48e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg16080015	chr7:5085479	RBAK	0.57	6.74	0.39	1.12e-10	Electroencephalogram traits;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg02716799	chr4:52709203	DCUN1D4	0.52	6.61	0.39	2.32e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	1.04	9.32	0.51	6.99e-18	Left atrial antero-posterior diameter;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.81	11.26	0.58	5.43e-24	Height;
KIRP	cis	rs7520050	0.966	rs12409773	chr1:46358831	A/G	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.65e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg17376030	chr22:41985996	PMM1	0.84	9.04	0.5	4.91e-17	Vitiligo;
KIRP	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	8.35	0.47	4.98e-15	Menarche (age at onset);
KIRP	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.43	-10.87	-0.57	9.88e-23	Diabetic kidney disease;
KIRP	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.59	-0.34	5.87e-8	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06296570	chr7:130792605	FLJ43663	0.58	6.94	0.4	3.36e-11	Lung cancer in ever smokers;
KIRP	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.41	-0.43	1.99e-12	Bipolar disorder;
KIRP	cis	rs4148660	0.697	rs2131136	chr12:22042621	G/T	cg14669847	chr12:22099120	NA	-0.36	-5.65	-0.34	4.45e-8	Gout;
KIRP	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.87	-9.05	-0.5	4.4e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg04034577	chr2:241836375	C2orf54	-0.43	-8.09	-0.46	2.73e-14	Urinary metabolites;
KIRP	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.58	-7.84	-0.45	1.39e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1971762	0.545	rs4759280	chr12:54064958	C/A	cg16917193	chr12:54089295	NA	0.92	17.0	0.73	2.24e-43	Height;
KIRP	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg22800045	chr5:56110881	MAP3K1	0.61	7.07	0.41	1.63e-11	Initial pursuit acceleration;
KIRP	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg12131826	chr15:77904385	NA	0.43	5.8	0.35	1.98e-8	Type 2 diabetes;
KIRP	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.51	-0.43	1.11e-12	Response to antipsychotic treatment;
KIRP	cis	rs4332428	0.881	rs4531365	chr10:4984333	A/G	cg19648686	chr10:5044992	AKR1C2	-0.89	-8.12	-0.46	2.3e-14	Height;
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg09165964	chr15:75287851	SCAMP5	0.51	6.67	0.39	1.68e-10	Breast cancer;
KIRP	cis	rs7106204	0.609	rs10500976	chr11:24335921	A/G	ch.11.24196551F	chr11:24239977	NA	-0.62	-5.33	-0.32	2.27e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.61	-0.39	2.35e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2033732	1.000	rs2033732	chr8:85079709	T/C	cg05716166	chr8:85095498	RALYL	0.59	6.39	0.38	8.46e-10	Body mass index;
KIRP	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05315796	chr3:52349193	DNAH1	0.4	6.18	0.37	2.58e-9	Electroencephalogram traits;
KIRP	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.85e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg21186296	chr8:27182909	PTK2B	0.5	6.39	0.38	8.4e-10	Neuroticism;
KIRP	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg02725872	chr8:58115012	NA	-0.6	-7.42	-0.43	1.86e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22857025	chr5:266934	NA	-1.14	-8.27	-0.47	8.31e-15	Breast cancer;
KIRP	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.76	-11.78	-0.6	1.07e-25	Monocyte percentage of white cells;
KIRP	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.49	-7.3	-0.42	3.93e-12	IgG glycosylation;
KIRP	cis	rs55863869	0.892	rs2742347	chr2:179600648	C/T	cg02880032	chr2:179629472	TTN	0.66	5.3	0.32	2.51e-7	QT interval;
KIRP	cis	rs2274273	0.805	rs60972460	chr14:55571773	A/T	cg04306507	chr14:55594613	LGALS3	0.52	8.24	0.47	1.04e-14	Protein biomarker;
KIRP	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.2	-16.06	-0.72	3.56e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.15	0.67	1.14e-33	Platelet count;
KIRP	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs11638352	1.000	rs2412848	chr15:44269607	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	5.59	0.34	6.03e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg22517653	chr1:2918612	NA	-0.42	-5.01	-0.3	1.04e-6	Plateletcrit;
KIRP	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg08648136	chr8:956695	NA	0.52	8.05	0.46	3.62e-14	Schizophrenia;
KIRP	cis	rs4561483	0.583	rs11075027	chr16:11948895	T/C	cg08843971	chr16:11963173	GSPT1	0.54	7.64	0.44	4.89e-13	Testicular germ cell tumor;
KIRP	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg02848875	chr15:64387786	SNX1	0.5	5.29	0.32	2.76e-7	Monocyte count;
KIRP	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-0.73	-6.17	-0.37	2.76e-9	Diabetic retinopathy;
KIRP	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.51	0.43	1.09e-12	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.16	0.5	2.1e-17	Alzheimer's disease;
KIRP	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-8.37	-0.47	4.4e-15	Morning vs. evening chronotype;
KIRP	cis	rs12580194	0.593	rs67934812	chr12:55785591	T/G	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg21775007	chr8:11205619	TDH	0.45	6.03	0.36	5.86e-9	Myopia (pathological);
KIRP	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg17252645	chr8:143867129	LY6D	-0.31	-4.98	-0.3	1.22e-6	Urinary tract infection frequency;
KIRP	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg21479132	chr6:26055353	NA	0.76	4.88	0.3	1.95e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg22117172	chr7:91764530	CYP51A1	-0.39	-5.74	-0.34	2.78e-8	Breast cancer;
KIRP	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-14.02	-0.67	3.17e-33	Alzheimer's disease;
KIRP	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.37	-7.77	-0.44	2.16e-13	Body mass index;
KIRP	cis	rs10875746	0.903	rs61918806	chr12:48484433	G/A	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs7221595	0.778	rs12946045	chr17:3904307	G/C	cg09597638	chr17:3907349	NA	0.59	6.83	0.4	6.76e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.53	-6.55	-0.39	3.4e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10073892	0.620	rs36059004	chr5:101944008	C/A	cg19774478	chr5:101632501	SLCO4C1	0.49	5.24	0.32	3.4e-7	Cognitive decline (age-related);
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.81	-14.49	-0.68	8.16e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1434579	0.865	rs12978546	chr19:44945947	C/A	cg15540054	chr19:45004280	ZNF180	0.53	5.82	0.35	1.81e-8	Tuberculosis;
KIRP	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.84	10.58	0.56	8.09e-22	Gestational age at birth (maternal effect);
KIRP	trans	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg16141378	chr3:129829833	LOC729375	0.54	7.03	0.41	2.01e-11	Mood instability;
KIRP	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg15117754	chr3:10150083	C3orf24	0.57	5.38	0.32	1.73e-7	Alzheimer's disease;
KIRP	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.54	-6.83	-0.4	6.78e-11	Urate levels in overweight individuals;
KIRP	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg19680485	chr15:31195859	MTMR15	0.4	5.05	0.31	8.67e-7	Huntington's disease progression;
KIRP	cis	rs17301259	0.548	rs7785139	chr7:88401172	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-4.99	-0.3	1.14e-6	Heschl's gyrus morphology;
KIRP	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.6	0.34	5.84e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	8.58	0.48	1.07e-15	Motion sickness;
KIRP	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg07212818	chr11:638076	DRD4	-0.39	-4.89	-0.3	1.8e-6	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.38	-0.38	8.9e-10	Lung cancer;
KIRP	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg05527609	chr1:210001259	C1orf107	-0.46	-5.04	-0.31	9.24e-7	Red blood cell count;
KIRP	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.08	-0.41	1.49e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg16255804	chr6:135334527	HBS1L	-0.34	-5.46	-0.33	1.17e-7	Red blood cell count;
KIRP	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg25753631	chr6:25732923	NA	-0.28	-5.3	-0.32	2.53e-7	Iron status biomarkers;
KIRP	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.81	0.45	1.63e-13	Morning vs. evening chronotype;
KIRP	cis	rs7116495	1.000	rs11235440	chr11:71826644	A/G	cg26138937	chr11:71823887	C11orf51	0.66	5.34	0.32	2.1e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.61	6.25	0.37	1.85e-9	Axial length;
KIRP	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg20637307	chr2:213403960	ERBB4	0.9	15.64	0.71	9.52e-39	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.73	6.45	0.38	5.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.46	5.1	0.31	6.68e-7	Schizophrenia;
KIRP	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.54	8.12	0.46	2.32e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.56	-8.06	-0.46	3.24e-14	Coronary artery disease;
KIRP	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs12973672	1.000	rs2280747	chr19:35770064	C/T	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7301016	0.846	rs12367878	chr12:63027483	C/T	cg01804193	chr12:63026212	NA	0.57	6.18	0.37	2.71e-9	IgG glycosylation;
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00689492	chr4:1303491	MAEA	0.31	5.33	0.32	2.26e-7	Obesity-related traits;
KIRP	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-8.83	-0.49	2e-16	Platelet distribution width;
KIRP	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg03806693	chr22:41940476	POLR3H	-0.49	-5.59	-0.34	6.03e-8	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11225247	0.881	rs11225236	chr11:102250098	C/T	cg06323957	chr11:102217781	BIRC2	0.92	5.66	0.34	4.25e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4762326	0.584	rs1038652	chr12:95659012	C/T	cg07737802	chr12:95537812	FGD6	0.39	5.21	0.32	3.95e-7	Endometriosis;
KIRP	trans	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25954194	chr5:131879310	IL5	0.47	6.22	0.37	2.17e-9	Myopia (pathological);
KIRP	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.15	15.92	0.71	1.07e-39	Lymphocyte percentage of white cells;
KIRP	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.59	7.59	0.44	6.72e-13	Endometrial cancer;
KIRP	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg15676125	chr6:33679581	C6orf125	0.4	5.22	0.32	3.88e-7	Plateletcrit;
KIRP	cis	rs17065868	1.000	rs9533896	chr13:45106511	A/G	cg10246903	chr13:45222710	NA	0.7	6.85	0.4	5.96e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.71	7.47	0.43	1.37e-12	Diastolic blood pressure;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg21411534	chr10:93558674	TNKS2	0.67	6.25	0.37	1.77e-9	Lung function (FEV1);
KIRP	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg01320579	chr17:75405842	SEPT9	0.45	7.22	0.42	6.36e-12	Airflow obstruction;
KIRP	cis	rs9972944	0.756	rs12600343	chr17:63764721	G/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.82	-0.45	1.56e-13	Total body bone mineral density;
KIRP	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg21680719	chr1:38466677	FHL3	-0.22	-4.85	-0.3	2.16e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.53	0.65	1.46e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.72e-7	Type 2 diabetes;
KIRP	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg08648136	chr8:956695	NA	0.41	5.8	0.35	2.06e-8	Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg24679411	chr12:6876188	PTMS	-0.62	-6.78	-0.4	8.75e-11	Menopause (age at onset);
KIRP	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.31e-9	Schizophrenia;
KIRP	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg20140201	chr2:241835670	C2orf54	-0.35	-5.32	-0.32	2.31e-7	Urinary metabolites;
KIRP	cis	rs6832769	0.961	rs13152650	chr4:56357858	T/C	cg05960024	chr4:56376020	CLOCK	0.64	8.19	0.46	1.43e-14	Personality dimensions;
KIRP	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	6.99	0.41	2.59e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11987759	chr7:65425863	GUSB	0.58	7.73	0.44	2.69e-13	Aortic root size;
KIRP	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg02151108	chr14:50098012	C14orf104	-0.58	-8.27	-0.47	8.57e-15	Carotid intima media thickness;
KIRP	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg11189052	chr15:85197271	WDR73	0.48	4.99	0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs13108043	0.511	rs13106574	chr4:87769929	T/C	cg11209507	chr4:87813803	C4orf36	0.48	5.33	0.32	2.21e-7	Red blood cell count;
KIRP	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-1.0	-14.96	-0.69	1.99e-36	Gut microbiome composition (winter);
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14580600	chr22:39715786	SNORD43;RPL3	-0.49	-5.45	-0.33	1.2e-7	Menopause (age at onset);
KIRP	cis	rs2505998	0.912	rs2505994	chr10:43568887	C/T	cg15436174	chr10:43711423	RASGEF1A	0.5	5.02	0.3	1.01e-6	Hirschsprung disease;
KIRP	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.95	-14.7	-0.68	1.58e-35	Height;
KIRP	cis	rs4006360	0.560	rs3861283	chr17:39243940	C/G	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs745821	0.879	rs17742138	chr18:48144571	C/G	cg18923635	chr18:48083994	NA	-0.47	-5.41	-0.33	1.47e-7	Diastolic blood pressure;
KIRP	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.71	0.39	1.3e-10	Tonsillectomy;
KIRP	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg18441811	chr11:71824068	C11orf51	0.78	5.14	0.31	5.53e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg25019033	chr10:957182	NA	-0.69	-8.82	-0.49	2.11e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs59698941	0.527	rs1910075	chr5:132180089	A/T	cg14825688	chr5:132208181	LEAP2	-0.37	-4.88	-0.3	1.92e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.18	0.31	4.56e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.75	7.78	0.44	2.05e-13	Uric acid levels;
KIRP	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12893428	chr3:195717962	SDHAP1	-0.32	-4.9	-0.3	1.75e-6	Pancreatic cancer;
KIRP	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.65	-7.65	-0.44	4.64e-13	DNA methylation (variation);
KIRP	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	1.01	16.7	0.73	2.26e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs9905704	0.560	rs2632507	chr17:56530597	C/A	cg12560992	chr17:57184187	TRIM37	0.54	5.33	0.32	2.25e-7	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.6	9.0	0.5	6.48e-17	Facial morphology (factor 21, depth of nasal alae);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14110031	chr5:96372731	NA	-0.4	-6.32	-0.37	1.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.84	-13.09	-0.64	4.7e-30	Blood metabolite levels;
KIRP	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	9.56	0.52	1.3e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15356195	chr7:5569741	ACTB	-0.44	-6.2	-0.37	2.3e-9	Metabolic traits;
KIRP	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg24807547	chr6:37504484	NA	-0.52	-7.71	-0.44	3.2e-13	Cognitive performance;
KIRP	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-5.28	-0.32	2.82e-7	Recombination measurement;
KIRP	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	5.05e-11	Aortic root size;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg05520288	chr5:34929958	DNAJC21	-0.52	-6.19	-0.37	2.57e-9	Brain structure;
KIRP	cis	rs9217	0.870	rs3853821	chr17:7396327	G/T	cg02795151	chr17:7402630	POLR2A	-0.58	-7.25	-0.42	5.22e-12	Height;
KIRP	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg25922239	chr6:33757077	LEMD2	0.64	7.27	0.42	4.69e-12	Crohn's disease;
KIRP	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.81	-0.35	1.94e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.56	-7.73	-0.44	2.69e-13	Motion sickness;
KIRP	cis	rs7851660	0.809	rs7031386	chr9:100665669	G/T	cg13688889	chr9:100608707	NA	-0.68	-8.66	-0.48	6.18e-16	Strep throat;
KIRP	cis	rs5750854	0.503	rs5750861	chr22:40026141	C/A	cg10455938	chr22:40058150	CACNA1I	0.42	5.96	0.36	8.48e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg00745463	chr17:30367425	LRRC37B	0.67	5.22	0.32	3.83e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg02696742	chr7:106810147	HBP1	-0.81	-7.97	-0.45	6.05e-14	Coronary artery disease;
KIRP	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg05347473	chr6:146136440	FBXO30	0.5	7.05	0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17067123	0.614	rs56749262	chr4:180067592	C/A	cg26610307	chr4:180072759	NA	-0.47	-5.18	-0.31	4.67e-7	Response to hepatitis C treatment;
KIRP	cis	rs6594713	0.679	rs17388260	chr5:112764578	C/A	cg12552261	chr5:112820674	MCC	0.6	5.35	0.32	2.04e-7	Brain cytoarchitecture;
KIRP	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.95	15.84	0.71	2.03e-39	Adiposity;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11232610	chr5:140027381	NDUFA2;IK	0.93	6.11	0.36	3.97e-9	P wave terminal force;
KIRP	cis	rs3789045	0.729	rs12039968	chr1:204490674	C/T	cg18185008	chr1:204589407	LRRN2	-0.6	-6.56	-0.39	3.06e-10	Educational attainment (college completion);
KIRP	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4073221	0.929	rs35846759	chr3:18282821	A/G	cg07694806	chr3:18168406	NA	-0.84	-7.09	-0.41	1.4e-11	Parkinson's disease;
KIRP	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg02725872	chr8:58115012	NA	-0.56	-6.26	-0.37	1.69e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.42	-6.2	-0.37	2.38e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1577917	0.545	rs9344548	chr6:86487337	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	6.78	0.4	8.88e-11	Response to antipsychotic treatment;
KIRP	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg21573476	chr21:45109991	RRP1B	-0.64	-8.68	-0.48	5.61e-16	Mean corpuscular volume;
KIRP	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg01631408	chr1:248437212	OR2T33	-0.61	-8.0	-0.45	4.97e-14	Common traits (Other);
KIRP	cis	rs714031	0.934	rs5757768	chr22:40071322	G/A	cg21377881	chr22:40064566	CACNA1I	-0.69	-10.6	-0.56	7.09e-22	Schizophrenia;
KIRP	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-9.82	-0.53	1.97e-19	Glomerular filtration rate (creatinine);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11924518	chr12:48213110	HDAC7	-0.61	-6.5	-0.38	4.52e-10	Menopause (age at onset);
KIRP	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg09904177	chr6:26538194	HMGN4	-0.46	-5.67	-0.34	4.02e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06169648	chr16:85646832	KIAA0182	0.57	6.69	0.39	1.47e-10	Smoking initiation;
KIRP	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg06671706	chr8:8559999	CLDN23	0.57	6.6	0.39	2.52e-10	Obesity-related traits;
KIRP	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg26384229	chr12:38710491	ALG10B	0.74	9.84	0.53	1.76e-19	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-5.83	-0.35	1.71e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.53	-6.18	-0.37	2.69e-9	Urate levels in overweight individuals;
KIRP	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.53	6.42	0.38	6.9e-10	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg24081819	chr8:27348940	EPHX2	-0.44	-6.23	-0.37	2.04e-9	Type 1 diabetes nephropathy;
KIRP	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg26531700	chr6:26746687	NA	0.41	5.57	0.33	6.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13185784	0.667	rs35551113	chr5:179654221	T/C	cg23221052	chr5:179740743	GFPT2	0.53	5.14	0.31	5.64e-7	TRAIL levels;
KIRP	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-8.94	-0.5	9.46e-17	Longevity;Endometriosis;
KIRP	cis	rs1978968	1.000	rs1076540	chr22:18439958	C/T	cg02610425	chr22:18483192	MICAL3	0.36	5.0	0.3	1.1e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs4666360	1.000	rs6725416	chr2:20336773	C/T	cg07142377	chr2:20335552	NA	-0.28	-5.01	-0.3	1.02e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
KIRP	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.04	-0.41	1.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg00129232	chr17:37814104	STARD3	-0.66	-7.25	-0.42	5.26e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.7	8.7	0.48	4.98e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	0.75	6.72	0.39	1.27e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	8.19	0.46	1.42e-14	Mood instability;
KIRP	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg21573476	chr21:45109991	RRP1B	-0.56	-7.62	-0.44	5.41e-13	Mean corpuscular volume;
KIRP	cis	rs6681460	0.634	rs12143964	chr1:67010266	T/G	cg13052034	chr1:66999238	SGIP1	0.46	6.56	0.39	3.11e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs2742234	0.955	rs1800861	chr10:43613843	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.63	-7.59	-0.44	6.47e-13	Hirschsprung disease;
KIRP	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg01689657	chr7:91764605	CYP51A1	0.46	6.65	0.39	1.92e-10	Breast cancer;
KIRP	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.43	-0.38	6.5e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.47	6.73	0.39	1.2e-10	Sitting height ratio;
KIRP	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-6.11	-0.36	3.87e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.1	0.61	9.4e-27	Bladder cancer;
KIRP	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.5	-7.1	-0.41	1.32e-11	Systemic lupus erythematosus;
KIRP	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.91	-14.91	-0.69	2.98e-36	Urate levels in lean individuals;
KIRP	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.47	-5.2	-0.31	4.1e-7	Neuroticism;
KIRP	cis	rs6028335	0.674	rs66513266	chr20:37597410	G/T	cg16355469	chr20:37678765	NA	0.56	5.45	0.33	1.22e-7	Alcohol and nicotine co-dependence;
KIRP	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-5.35	-0.32	2.05e-7	Triglycerides;
KIRP	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.32	-6.33	-0.37	1.17e-9	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs76793172	1.000	rs28433213	chr19:46341168	C/T	cg00442267	chr19:46317840	RSPH6A	-0.7	-5.98	-0.36	7.61e-9	Eosinophil counts;
KIRP	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-0.61	-9.85	-0.53	1.6e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.67	-10.18	-0.54	1.58e-20	Coronary artery disease;
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg12288994	chr5:1860383	NA	0.64	10.12	0.54	2.34e-20	Cardiovascular disease risk factors;
KIRP	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6733011	0.628	rs6713991	chr2:99464384	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.38	-0.32	1.75e-7	Bipolar disorder;
KIRP	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg18132916	chr6:79620363	NA	-0.42	-5.75	-0.34	2.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.67	0.44	3.93e-13	Tonsillectomy;
KIRP	cis	rs526231	0.511	rs17154942	chr5:102352718	C/T	cg23492399	chr5:102201601	PAM	0.5	5.44	0.33	1.29e-7	Primary biliary cholangitis;
KIRP	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.84	13.71	0.66	3.53e-32	Multiple myeloma;
KIRP	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.53	7.35	0.42	2.97e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg26207909	chr14:103986467	CKB	-0.49	-6.19	-0.37	2.56e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.8	0.49	2.45e-16	Neuroticism;
KIRP	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-19.5	-0.78	7.85e-52	Schizophrenia;
KIRP	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg13444842	chr1:152974279	SPRR3	-0.48	-7.0	-0.41	2.38e-11	Inflammatory skin disease;
KIRP	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg06212747	chr3:49208901	KLHDC8B	0.66	7.53	0.43	9.83e-13	Menarche (age at onset);
KIRP	cis	rs2625529	0.823	rs11072332	chr15:72108307	G/T	cg16672083	chr15:72433130	SENP8	-0.57	-7.67	-0.44	3.94e-13	Red blood cell count;
KIRP	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.17	0.54	1.65e-20	Dupuytren's disease;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18475036	chr19:45873826	ERCC2	0.52	7.04	0.41	1.86e-11	Parkinson's disease;
KIRP	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17554472	chr22:41940697	POLR3H	-0.69	-7.06	-0.41	1.72e-11	Vitiligo;
KIRP	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.44	0.43	1.65e-12	Retinal vascular caliber;
KIRP	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	4.96	0.3	1.33e-6	Longevity;
KIRP	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.73	-9.23	-0.51	1.25e-17	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.56	-6.25	-0.37	1.82e-9	Menarche (age at onset);
KIRP	cis	rs6466055	0.661	rs12537196	chr7:104922624	A/G	cg04380332	chr7:105027541	SRPK2	0.38	5.11	0.31	6.45e-7	Schizophrenia;
KIRP	cis	rs2976388	1.000	rs2920282	chr8:143757763	T/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.51	-0.38	4.19e-10	Urinary tract infection frequency;
KIRP	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg26597838	chr10:835615	NA	-0.5	-5.96	-0.36	8.55e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4959799	0.557	rs1127466	chr6:3270937	G/C	cg03657281	chr6:3270030	SLC22A23	0.79	6.02	0.36	6.29e-9	Survival in rectal cancer;
KIRP	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.63	-0.63	1.55e-28	Chronic sinus infection;
KIRP	trans	rs7939886	0.920	rs7950386	chr11:55931513	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	14.75	0.69	1.01e-35	Platelet count;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg22328890	chr16:68298258	SLC7A6	0.54	6.19	0.37	2.47e-9	Sleep duration;
KIRP	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg03465714	chr1:152285911	FLG	0.49	5.26	0.32	3.19e-7	Atopic dermatitis;
KIRP	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-6.0	-0.36	7.04e-9	Monocyte count;
KIRP	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-6.04	-0.36	5.57e-9	Red blood cell count;
KIRP	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26913058	chr16:419975	MRPL28	-0.45	-5.65	-0.34	4.33e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs10411262	0.935	rs2312289	chr19:47175615	G/C	cg13467550	chr19:47212573	PRKD2	0.37	5.39	0.32	1.68e-7	Tonsillectomy;
KIRP	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-8.21	-0.46	1.23e-14	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13011713	chr3:132176123	DNAJC13	0.42	6.73	0.39	1.16e-10	Survival in pancreatic cancer;
KIRP	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.6	-0.48	9.23e-16	Retinal vascular caliber;
KIRP	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg21466736	chr12:48725269	NA	-0.48	-6.41	-0.38	7.58e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs7941030	0.871	rs7115089	chr11:122530591	C/G	cg20555462	chr11:122535518	UBASH3B	-0.43	-5.32	-0.32	2.38e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-4.99	-0.3	1.15e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg13206674	chr6:150067644	NUP43	0.56	7.87	0.45	1.11e-13	Lung cancer;
KIRP	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.69	-8.77	-0.49	2.94e-16	Aortic root size;
KIRP	cis	rs13387221	0.542	rs4952692	chr2:44147793	A/G	cg08750440	chr2:43447375	NA	-0.47	-4.9	-0.3	1.71e-6	Intelligence (childhood);
KIRP	cis	rs258892	0.793	rs61141607	chr5:72056883	T/A	cg21869765	chr5:72125136	TNPO1	-0.52	-5.66	-0.34	4.17e-8	Small cell lung carcinoma;
KIRP	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.99	-0.3	1.13e-6	Lung cancer;
KIRP	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.21	-5.63	-0.34	4.94e-8	Coronary artery disease;
KIRP	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg05579598	chr16:88989069	CBFA2T3	0.27	5.71	0.34	3.27e-8	Social autistic-like traits;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg00738919	chr7:1100172	C7orf50	0.42	4.96	0.3	1.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg01097406	chr16:89675127	NA	0.35	5.27	0.32	3.04e-7	Vitiligo;
KIRP	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.81	8.73	0.49	3.85e-16	Prostate cancer;
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Colorectal cancer;
KIRP	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.26	-0.62	2.69e-27	Blood trace element (Zn levels);
KIRP	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg24565620	chr2:194026	NA	-0.72	-5.42	-0.33	1.44e-7	Blood protein levels;
KIRP	cis	rs16828019	0.777	rs2300658	chr1:41505022	G/A	cg03387723	chr1:41708464	SCMH1	-0.77	-6.23	-0.37	1.99e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.04	-0.41	1.88e-11	Initial pursuit acceleration;
KIRP	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-5.7	-0.34	3.49e-8	Obesity (extreme);
KIRP	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18364779	chr6:26104403	HIST1H4C	-0.54	-5.73	-0.34	2.96e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07786668	chr16:73092391	ZFHX3	1.02	7.38	0.43	2.44e-12	P wave terminal force;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg09256448	chr16:638327	NA	0.35	4.91	0.3	1.66e-6	Height;
KIRP	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg02187348	chr16:89574699	SPG7	0.41	4.91	0.3	1.69e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs934734	0.967	rs702875	chr2:65614197	T/C	cg08085232	chr2:65598271	SPRED2	-0.44	-5.78	-0.35	2.26e-8	Rheumatoid arthritis;
KIRP	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg12131826	chr15:77904385	NA	0.48	5.75	0.34	2.67e-8	Type 2 diabetes;
KIRP	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg11995313	chr8:8860691	ERI1	0.38	5.2	0.31	4.12e-7	Joint mobility (Beighton score);
KIRP	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.66	-8.78	-0.49	2.77e-16	Total body bone mineral density;
KIRP	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.32	-0.32	2.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.55	-5.85	-0.35	1.56e-8	Schizophrenia;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13939156	chr17:80058883	NA	0.51	7.69	0.44	3.43e-13	Life satisfaction;
KIRP	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg11839771	chr15:80205821	ST20	0.39	5.56	0.33	6.94e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27658640	chr17:4843839	RNF167;SLC25A11	0.52	6.36	0.38	9.6e-10	Smoking initiation;
KIRP	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-5.63	-0.34	5.01e-8	Aortic root size;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg08662619	chr6:150070041	PCMT1	0.39	6.43	0.38	6.75e-10	Lung cancer;
KIRP	cis	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-5.57	-0.33	6.55e-8	HDL cholesterol;
KIRP	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.23	0.42	6.15e-12	Coffee consumption (cups per day);
KIRP	cis	rs13132184	0.510	rs55767827	chr4:38056537	A/G	cg14409701	chr4:38048871	TBC1D1	-0.78	-6.88	-0.4	5.02e-11	Verbal declarative memory;
KIRP	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.46	6.96	0.41	3.07e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.81	9.06	0.5	4.2e-17	Coronary artery disease;
KIRP	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.3	-6.04	-0.36	5.79e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg09699651	chr6:150184138	LRP11	0.45	6.08	0.36	4.61e-9	Lung cancer;
KIRP	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.81	-10.89	-0.57	8.25e-23	Blood trace element (Zn levels);
KIRP	cis	rs13385	0.769	rs28573694	chr5:139609951	T/G	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs17065868	0.764	rs12146905	chr13:45036020	G/A	cg10246903	chr13:45222710	NA	0.59	4.95	0.3	1.36e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2733310	0.947	rs1441235	chr15:57130462	G/A	cg13626582	chr15:57592083	LOC283663	-0.25	-5.63	-0.34	4.95e-8	Mean platelet volume;
KIRP	cis	rs675026	0.927	rs1323044	chr6:154421607	A/G	cg07813322	chr6:154414604	OPRM1	-0.5	-6.5	-0.38	4.39e-10	Hypertension;
KIRP	cis	rs4262150	0.810	rs4958565	chr5:152006087	T/C	cg12297329	chr5:152029980	NA	-0.67	-8.2	-0.46	1.38e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.9e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg00981070	chr1:2046702	PRKCZ	0.41	5.89	0.35	1.25e-8	Height;
KIRP	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.51	0.33	9.08e-8	Educational attainment;
KIRP	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.4	-5.04	-0.31	8.91e-7	Cystic fibrosis severity;
KIRP	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg18833306	chr6:118973337	C6orf204	-0.39	-5.11	-0.31	6.45e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9653442	0.527	rs11690905	chr2:100761473	C/T	cg22139774	chr2:100720529	AFF3	0.34	5.54	0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.8	10.91	0.57	7.4e-23	Response to antipsychotic treatment;
KIRP	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-1.1	-19.49	-0.78	8.33e-52	Monocyte count;
KIRP	cis	rs12580194	0.593	rs66902680	chr12:55724080	A/C	cg19537932	chr12:55886519	OR6C68	-0.51	-6.56	-0.39	3.15e-10	Cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26468049	chr16:4817196	ZNF500	0.55	7.15	0.41	9.59e-12	Parkinson's disease;
KIRP	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg08975724	chr8:8085496	FLJ10661	0.65	8.1	0.46	2.64e-14	Mood instability;
KIRP	cis	rs735539	0.593	rs4463942	chr13:21367434	C/T	cg04906043	chr13:21280425	IL17D	-0.42	-4.96	-0.3	1.34e-6	Dental caries;
KIRP	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.88	-13.94	-0.66	5.9e-33	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02031397	chr1:42383598	HIVEP3	0.4	6.05	0.36	5.4e-9	Parkinson's disease;
KIRP	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.4	4.95	0.3	1.4e-6	Diabetic retinopathy;
KIRP	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.75	11.26	0.58	5.25e-24	Lung cancer;
KIRP	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-6.37	-0.38	9.18e-10	Dilated cardiomyopathy;
KIRP	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg26893134	chr6:116381904	FRK	0.2	5.44	0.33	1.28e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.12	-0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg08131204	chr22:41487073	MIR1281	-0.44	-5.24	-0.32	3.52e-7	Neuroticism;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.83	-16.36	-0.72	3.39e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.7	0.49	4.78e-16	Motion sickness;
KIRP	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg00066239	chr17:78472159	NA	-0.27	-5.18	-0.31	4.72e-7	Fractional excretion of uric acid;
KIRP	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	0.99	13.08	0.64	4.96e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg27532560	chr4:187881888	NA	-0.77	-13.16	-0.64	2.67e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4478858	0.684	rs12725881	chr1:31736123	C/T	cg00250761	chr1:31883323	NA	0.3	4.97	0.3	1.23e-6	Alcohol dependence;
KIRP	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg00689492	chr4:1303491	MAEA	0.27	4.85	0.3	2.17e-6	Longevity;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg26004664	chr4:183794378	NA	0.37	6.07	0.36	4.75e-9	Warfarin maintenance dose;
KIRP	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.42	7.0	0.41	2.39e-11	Heart rate;
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg15181151	chr6:150070149	PCMT1	0.31	5.14	0.31	5.58e-7	Lung cancer;
KIRP	cis	rs1978968	0.763	rs9605480	chr22:18465105	G/A	cg03078520	chr22:18463400	MICAL3	-0.85	-12.01	-0.61	1.82e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg15655495	chr12:38532458	NA	0.27	5.39	0.32	1.68e-7	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00496914	chr19:44259188	C19orf61	0.52	6.77	0.4	9.63e-11	Parkinson's disease;
KIRP	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.73	9.08	0.5	3.67e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg25486957	chr4:152246857	NA	-0.48	-5.38	-0.32	1.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg18131467	chr2:239335373	ASB1	-0.76	-5.56	-0.33	6.89e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.81	-0.78	7.56e-53	Schizophrenia;
KIRP	cis	rs909341	0.909	rs2253823	chr20:62372956	C/T	cg11503966	chr20:62272292	STMN3	-0.41	-5.63	-0.34	4.95e-8	Atopic dermatitis;
KIRP	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	8.83	0.49	2.04e-16	Bipolar disorder;
KIRP	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.62	8.92	0.49	1.12e-16	Resting heart rate;
KIRP	cis	rs9658691	0.920	rs72809360	chr10:90746990	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.81	-4.92	-0.3	1.56e-6	Mosquito bite size;
KIRP	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.57	-0.68	4.3e-35	Primary sclerosing cholangitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01970906	chr13:113862960	PCID2;CUL4A	0.5	6.79	0.4	8.28e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs62355272	0.580	rs2361403	chr5:35905211	C/T	cg13894535	chr5:35919491	CAPSL	-0.38	-5.09	-0.31	7.1e-7	Lymphocyte counts;
KIRP	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg01657329	chr11:68192670	LRP5	-0.61	-8.14	-0.46	1.99e-14	Total body bone mineral density;
KIRP	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.96	10.39	0.55	3.33e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.48	-5.95	-0.35	9.1e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11581903	0.866	rs11591099	chr1:53056597	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.55	5.37	0.32	1.82e-7	Joint mobility (Beighton score);
KIRP	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg17863274	chr19:49399704	TULP2	-0.41	-5.82	-0.35	1.81e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs2668423	1.000	rs2668423	chr19:1370526	T/G	cg02639931	chr19:1387894	NDUFS7	-0.75	-9.53	-0.52	1.57e-18	Nonalcoholic fatty liver disease;
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.58	5.32	0.32	2.3e-7	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.53	6.27	0.37	1.58e-9	Aortic root size;
KIRP	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg12173498	chr6:36355764	ETV7	-0.3	-4.96	-0.3	1.33e-6	Platelet distribution width;
KIRP	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg25019033	chr10:957182	NA	-0.56	-6.87	-0.4	5.09e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26526719	chr5:1949144	NA	0.44	5.25	0.32	3.29e-7	Gut microbiome composition (winter);
KIRP	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.17	-0.31	4.75e-7	Retinal vascular caliber;
KIRP	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.65	-7.83	-0.45	1.44e-13	Iron status biomarkers;
KIRP	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.81	11.19	0.58	9.21e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg26879891	chr1:152191343	HRNR	-0.47	-6.71	-0.39	1.34e-10	Inflammatory skin disease;
KIRP	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg19554555	chr3:13937349	NA	-0.46	-6.16	-0.37	2.9e-9	Ovarian reserve;
KIRP	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.89	-0.35	1.28e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.68	8.95	0.5	8.72e-17	Migraine;Coronary artery disease;
KIRP	cis	rs8014252	0.803	rs74938470	chr14:71040022	T/C	cg19730268	chr14:71022823	NA	-0.69	-6.16	-0.37	2.95e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2072732	0.861	rs72629493	chr1:2951347	G/A	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.74	-8.8	-0.49	2.51e-16	Tonsillectomy;
KIRP	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.6	-8.4	-0.47	3.56e-15	Diastolic blood pressure;
KIRP	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg13703089	chr14:106090767	NA	-0.35	-4.87	-0.3	2.04e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg03929089	chr4:120376271	NA	0.68	6.64	0.39	2.05e-10	Axial length;
KIRP	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.65	-7.9	-0.45	9.48e-14	Height;
KIRP	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.49	7.01	0.41	2.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg13395646	chr4:1353034	KIAA1530	-0.38	-5.05	-0.31	8.48e-7	Longevity;
KIRP	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.52	-6.66	-0.39	1.76e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.72	7.94	0.45	7.18e-14	Corneal astigmatism;
KIRP	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg21466736	chr12:48725269	NA	0.45	5.56	0.33	6.93e-8	Glycated hemoglobin levels;
KIRP	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs73157695	0.521	rs55918937	chr21:47184033	C/T	cg11214348	chr21:47283868	PCBP3	-0.37	-4.89	-0.3	1.79e-6	Myopia;
KIRP	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.94	-0.4	3.46e-11	Acne (severe);
KIRP	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg00125455	chr20:44574271	PCIF1	-0.3	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2901460	0.509	rs56944298	chr2:62090001	A/G	cg02183531	chr2:62113199	CCT4	-0.49	-5.07	-0.31	7.69e-7	Mean corpuscular volume;
KIRP	trans	rs76288851	0.799	rs73203603	chr3:126540438	A/G	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.49	2.71e-16	Bladder cancer;
KIRP	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg13072238	chr3:49761600	GMPPB	0.58	5.38	0.32	1.73e-7	Menarche (age at onset);
KIRP	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.4	-5.05	-0.31	8.72e-7	Carotid intima media thickness;
KIRP	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.78	-13.16	-0.64	2.62e-30	Calcium levels;
KIRP	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.64	6.68	0.39	1.61e-10	Menarche (age at onset);
KIRP	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.24e-13	Total cholesterol levels;
KIRP	trans	rs3809095	0.521	rs4756856	chr11:16641718	T/G	cg15531249	chr16:85744077	C16orf74	0.43	6.05	0.36	5.3300000000000004e-09	Total body bone mineral density;
KIRP	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19524238	chr7:2802976	GNA12	-0.4	-5.63	-0.34	4.79e-8	Height;
KIRP	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg13165212	chr22:42675999	NA	0.35	5.84	0.35	1.61e-8	Cognitive function;
KIRP	cis	rs3931020	0.566	rs1327086	chr1:75271032	A/G	cg21535942	chr1:75199100	CRYZ;TYW3	0.4	5.06	0.31	8.24e-7	Resistin levels;
KIRP	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg26876637	chr1:152193138	HRNR	0.75	9.81	0.53	2.12e-19	Atopic dermatitis;
KIRP	cis	rs2013441	0.613	rs9901125	chr17:20008929	A/G	cg13482628	chr17:19912719	NA	0.51	6.74	0.39	1.11e-10	Obesity-related traits;
KIRP	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	5.71	0.34	3.26e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08508325	chr11:3079039	CARS	0.31	5.74	0.34	2.72e-8	Calcium levels;
KIRP	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.8	-0.4	7.81e-11	Joint mobility (Beighton score);
KIRP	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.55	7.03	0.41	2.03e-11	Coronary heart disease;
KIRP	cis	rs2071426	0.959	rs1341164	chr10:96800873	T/C	cg09036531	chr10:96991505	NA	-0.54	-6.04	-0.36	5.65e-9	Blood metabolite levels;
KIRP	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg06647332	chr5:131281008	NA	-0.44	-4.92	-0.3	1.56e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg26513180	chr16:89883248	FANCA	0.64	5.13	0.31	5.84e-7	Skin colour saturation;
KIRP	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23281280	chr6:28129359	ZNF389	0.49	5.47	0.33	1.08e-7	Depression;
KIRP	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg15832292	chr6:96025679	MANEA	-0.76	-6.8	-0.4	8e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.74	11.34	0.59	2.95e-24	Type 2 diabetes;
KIRP	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg09344028	chr17:70110421	NA	0.38	7.82	0.45	1.51e-13	Thyroid hormone levels;
KIRP	trans	rs10772939	0.513	rs7958668	chr12:16581315	G/A	cg20863947	chr2:120124202	DBI;C2orf76	0.55	6.39	0.38	8.3e-10	Economic and political preferences;
KIRP	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg13482628	chr17:19912719	NA	-0.57	-8.09	-0.46	2.78e-14	Schizophrenia;
KIRP	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-8.11	-0.46	2.34e-14	Homocysteine levels;
KIRP	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg16512390	chr1:228756714	NA	0.46	5.16	0.31	5.18e-7	Diastolic blood pressure;
KIRP	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-10.81	-0.57	1.54e-22	Chronic sinus infection;
KIRP	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs17065868	1.000	rs58838977	chr13:45222235	A/G	cg10246903	chr13:45222710	NA	0.72	7.06	0.41	1.73e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.47	0.52	2.34e-18	Total body bone mineral density;
KIRP	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.16	-0.37	2.98e-9	Alcohol dependence;
KIRP	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.67	6.32	0.37	1.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs11605924	1.000	rs11605924	chr11:45873091	A/C	ch.11.939596F	chr11:45881766	CRY2	-0.54	-6.8	-0.4	8.02e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.59	-12.45	-0.62	6.65e-28	Diabetic kidney disease;
KIRP	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.41	4.96	0.3	1.3e-6	Tonsillectomy;
KIRP	cis	rs6662572	0.686	rs59091734	chr1:46285809	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.62	0.34	5.05e-8	Blood protein levels;
KIRP	cis	rs4132509	1.000	rs10927051	chr1:243805936	G/C	cg21452805	chr1:244014465	NA	0.49	4.96	0.3	1.29e-6	RR interval (heart rate);
KIRP	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	8.4	0.47	3.57e-15	Lung cancer in ever smokers;
KIRP	cis	rs2019216	0.500	rs2169916	chr17:21884670	G/C	cg22648282	chr17:21454238	C17orf51	-0.54	-6.32	-0.37	1.2e-9	Pelvic organ prolapse;
KIRP	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.47	6.16	0.37	2.98e-9	IgG glycosylation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14291291	chr6:33656083	ITPR3	0.53	6.51	0.38	4.25e-10	Interleukin-4 levels;
KIRP	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.45	5.49	0.33	9.96e-8	Common traits (Other);
KIRP	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04008905	chr6:142644368	GPR126	-0.41	-6.37	-0.38	9.05e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg25801113	chr15:45476975	SHF	0.41	7.43	0.43	1.82e-12	Uric acid levels;
KIRP	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.87	-0.35	1.37e-8	Breast cancer;
KIRP	cis	rs78487399	0.908	rs12467420	chr2:43831150	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.06	-0.31	8.11e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg21523564	chr15:75251491	NA	-0.35	-5.94	-0.35	9.57e-9	Systemic lupus erythematosus;
KIRP	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg08917208	chr2:24149416	ATAD2B	0.67	5.93	0.35	1.05e-8	Lymphocyte counts;
KIRP	cis	rs55871839	0.684	rs7002967	chr8:59816806	T/A	cg07426533	chr8:59803705	TOX	-0.48	-7.94	-0.45	7.38e-14	Pneumonia;
KIRP	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.46	5.84	0.35	1.65e-8	Aortic root size;
KIRP	cis	rs4776059	0.916	rs4774636	chr15:52968193	A/C	cg25063058	chr15:52860530	ARPP19	0.53	5.46	0.33	1.15e-7	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22879515	chr11:111383515	MIR34B;BTG4;MIR34C	0.4	6.23	0.37	2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-21.7	-0.81	4.73e-59	Height;
KIRP	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.68	8.25	0.47	9.87e-15	Pulse pressure;
KIRP	cis	rs654950	0.875	rs687766	chr1:41998849	C/G	cg06885757	chr1:42089581	HIVEP3	0.45	6.42	0.38	7e-10	Airway imaging phenotypes;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.84	14.85	0.69	4.75e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9309473	0.528	rs7573275	chr2:73552542	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.49	-0.33	9.75e-8	Metabolite levels;
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg26174226	chr8:58114915	NA	-0.53	-4.91	-0.3	1.64e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs7638995	0.878	rs7620430	chr3:69169602	G/A	cg26574240	chr3:69171822	LMOD3	-0.71	-8.79	-0.49	2.61e-16	Alzheimer's disease (late onset);
KIRP	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg09873164	chr1:152488093	CRCT1	0.58	7.25	0.42	5.54e-12	Hair morphology;
KIRP	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg00405596	chr8:11794950	NA	0.57	7.94	0.45	7.26e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.21	-0.32	4.02e-7	Life satisfaction;
KIRP	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11987759	chr7:65425863	GUSB	-0.69	-9.67	-0.52	5.86e-19	Aortic root size;
KIRP	cis	rs494562	0.892	rs522915	chr6:86116321	A/G	cg27039625	chr6:86159096	NT5E	0.42	5.34	0.32	2.07e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	IgG glycosylation;
KIRP	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg22732515	chr19:44031385	ETHE1	0.62	8.83	0.49	1.98e-16	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.29	-6.65	-0.39	1.84e-10	Mean corpuscular volume;
KIRP	cis	rs1971762	0.545	rs7485472	chr12:54044438	T/C	cg16917193	chr12:54089295	NA	0.92	16.96	0.73	2.99e-43	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01351037	chr15:85525384	PDE8A	0.53	6.76	0.4	1.01e-10	Parkinson's disease;
KIRP	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg24642439	chr20:33292090	TP53INP2	-0.59	-7.04	-0.41	1.88e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.79	7.21	0.42	6.84e-12	Methadone dose in opioid dependence;
KIRP	cis	rs8049040	0.524	rs35331976	chr16:71427106	C/A	cg08717414	chr16:71523259	ZNF19	-0.59	-6.8	-0.4	7.72e-11	Blood protein levels;
KIRP	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.69	0.34	3.69e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7520050	0.966	rs10890361	chr1:46346234	A/T	cg03146154	chr1:46216737	IPP	-0.45	-5.46	-0.33	1.19e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4740619	0.711	rs4590533	chr9:15989766	C/G	cg14451791	chr9:16040625	NA	-0.38	-4.89	-0.3	1.78e-6	Body mass index;
KIRP	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.59	6.95	0.41	3.29e-11	Corneal astigmatism;
KIRP	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.92	-10.59	-0.56	7.62e-22	White matter hyperintensity burden;
KIRP	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg10326726	chr10:51549505	MSMB	-0.59	-8.56	-0.48	1.22e-15	Prostate-specific antigen levels;
KIRP	cis	rs4262150	0.544	rs72795351	chr5:151910821	G/A	cg12297329	chr5:152029980	NA	-0.65	-7.9	-0.45	9.04e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs17092148	0.848	rs6060030	chr20:33340313	C/T	cg16810054	chr20:33298113	TP53INP2	-0.43	-5.2	-0.31	4.15e-7	Neuroticism;
KIRP	cis	rs7809615	0.901	rs11761528	chr7:99118801	C/T	cg12290671	chr7:99195819	NA	-0.75	-6.99	-0.41	2.57e-11	Blood metabolite ratios;
KIRP	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.5	6.84	0.4	6.07e-11	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17636471	chr11:64851605	CDCA5;ZFPL1	0.51	6.4	0.38	7.96e-10	Parkinson's disease;
KIRP	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg02570527	chr1:10970165	NA	-0.41	-4.87	-0.3	1.98e-6	Body mass index;
KIRP	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg02725872	chr8:58115012	NA	-0.46	-5.46	-0.33	1.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg17401720	chr7:158221031	PTPRN2	-0.36	-5.66	-0.34	4.26e-8	Obesity-related traits;
KIRP	cis	rs2120243	0.539	rs6441127	chr3:157095507	T/C	cg24825693	chr3:157122686	VEPH1	-0.56	-9.04	-0.5	4.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.49	-0.52	2.17e-18	Gut microbiome composition (summer);
KIRP	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Parkinson's disease;
KIRP	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	7.79	0.44	1.85e-13	Systemic lupus erythematosus;
KIRP	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	1.08	10.45	0.55	2.16e-21	Psoriasis;
KIRP	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg15083037	chr5:83017644	HAPLN1	-0.58	-8.4	-0.47	3.55e-15	Prostate cancer;
KIRP	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.83	10.74	0.57	2.55e-22	Primary sclerosing cholangitis;
KIRP	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.49	-6.15	-0.37	3.03e-9	Neurofibrillary tangles;
KIRP	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.37	-0.32	1.83e-7	Metabolite levels;
KIRP	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.76	10.24	0.55	1.02e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg19476082	chr7:2414320	EIF3B	0.55	5.13	0.31	5.75e-7	Multiple sclerosis;
KIRP	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-10.01	-0.54	5.37e-20	Neuroticism;
KIRP	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg15445000	chr17:37608096	MED1	0.53	6.06	0.36	5.11e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs755109	1.000	rs3808894	chr9:100686129	A/G	cg13688889	chr9:100608707	NA	-0.42	-4.85	-0.3	2.19e-6	Quantitative traits;
KIRP	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg16141378	chr3:129829833	LOC729375	0.51	6.39	0.38	8.43e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7017914	0.967	rs7012404	chr8:71668698	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.54	6.43	0.38	6.46e-10	Diastolic blood pressure;
KIRP	cis	rs112591243	0.685	rs2839294	chr21:47917664	T/C	cg26904215	chr21:47823096	PCNT	-0.79	-5.78	-0.35	2.3e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.66	10.02	0.54	4.99e-20	Lung cancer;
KIRP	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg27171509	chr10:82033454	MAT1A	-0.42	-5.82	-0.35	1.87e-8	Borderline personality disorder;
KIRP	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg20387954	chr3:183756860	HTR3D	0.62	9.06	0.5	4.19e-17	Anterior chamber depth;
KIRP	cis	rs35883536	1.000	rs12724990	chr1:101137030	G/A	cg06223162	chr1:101003688	GPR88	0.33	6.69	0.39	1.45e-10	Monocyte count;
KIRP	cis	rs75920871	0.688	rs7109876	chr11:116848648	G/T	cg23684410	chr11:116897558	SIK3	0.52	5.33	0.32	2.25e-7	Subjective well-being;
KIRP	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg27147174	chr7:100797783	AP1S1	-0.68	-8.66	-0.48	6.37e-16	Life satisfaction;
KIRP	cis	rs4363385	0.510	rs61815707	chr1:152909018	T/C	cg13444842	chr1:152974279	SPRR3	-0.44	-6.3	-0.37	1.36e-9	Inflammatory skin disease;
KIRP	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.27	0.51	1e-17	Cognitive test performance;
KIRP	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	8.06	0.46	3.38e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19671926	chr4:122722719	EXOSC9	0.48	5.76	0.34	2.51e-8	Type 2 diabetes;
KIRP	cis	rs4356932	1.000	rs6846814	chr4:76952288	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.92	0.3	1.57e-6	Blood protein levels;
KIRP	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg05973401	chr12:123451056	ABCB9	0.6	7.27	0.42	4.72e-12	Platelet count;
KIRP	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.82	-12.36	-0.62	1.26e-27	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06898199	chr7:128502890	ATP6V1F	0.46	6.37	0.38	9.4e-10	Survival in pancreatic cancer;
KIRP	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-6.1	-0.36	4.05e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg23161317	chr6:28129485	ZNF389	0.46	5.3	0.32	2.62e-7	Depression;
KIRP	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg02807482	chr3:125708958	NA	-0.53	-5.13	-0.31	5.98e-7	Blood pressure (smoking interaction);
KIRP	cis	rs4132509	0.793	rs9428579	chr1:243690034	C/T	cg25706552	chr1:244017396	NA	0.59	7.3	0.42	3.9e-12	RR interval (heart rate);
KIRP	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.48	5.87	0.35	1.42e-8	Height;
KIRP	cis	rs78487399	0.908	rs73925552	chr2:43810564	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.46	-0.33	1.19e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg01631408	chr1:248437212	OR2T33	0.62	8.24	0.47	1.04e-14	Common traits (Other);
KIRP	cis	rs1978968	1.000	rs11704059	chr22:18449543	A/G	cg02610425	chr22:18483192	MICAL3	0.36	5.0	0.3	1.1e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.89	10.57	0.56	9.15e-22	Gut microbiome composition (summer);
KIRP	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.51	6.31	0.37	1.27e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.23	0.46	1.1e-14	Lung cancer;
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.73	10.26	0.55	8.38e-21	Lung cancer;
KIRP	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg07395648	chr5:131743802	NA	-0.36	-4.92	-0.3	1.55e-6	Blood metabolite levels;
KIRP	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-6.61	-0.39	2.31e-10	Gut microbiome composition (summer);
KIRP	cis	rs11264213	0.892	rs72659664	chr1:36185467	G/A	cg27506609	chr1:36549197	TEKT2	0.76	6.79	0.4	8.38e-11	Schizophrenia;
KIRP	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.75	-9.27	-0.51	9.85e-18	Personality dimensions;
KIRP	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg18306943	chr3:40428807	ENTPD3	-0.41	-5.52	-0.33	8.67e-8	Renal cell carcinoma;
KIRP	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17376030	chr22:41985996	PMM1	0.77	8.04	0.46	3.68e-14	Vitiligo;
KIRP	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg02487422	chr3:49467188	NICN1	-0.48	-6.44	-0.38	6.39e-10	Parkinson's disease;
KIRP	cis	rs5747327	0.874	rs5747333	chr22:18180567	G/C	cg19898043	chr22:18121309	BCL2L13	-0.43	-5.39	-0.32	1.66e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.49	0.52	2.16e-18	Total body bone mineral density;
KIRP	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg08890418	chr1:21044141	KIF17	0.69	10.61	0.56	6.64e-22	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg21191810	chr6:118973309	C6orf204	-0.42	-4.86	-0.3	2.14e-6	Diastolic blood pressure;
KIRP	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-5.46	-0.33	1.14e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg06050784	chr16:88016603	BANP	0.44	5.24	0.32	3.53e-7	Menopause (age at onset);
KIRP	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.8	10.98	0.57	4.52e-23	Aortic root size;
KIRP	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs9535307	0.719	rs9535341	chr13:50363304	C/T	cg04663916	chr13:50265991	EBPL	-0.64	-6.54	-0.39	3.45e-10	Obesity-related traits;
KIRP	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.92	-0.4	3.82e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg16268157	chr7:99778414	STAG3	-0.53	-5.78	-0.35	2.24e-8	Lung function (FEV1/FVC);
KIRP	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.57	4.97	0.3	1.26e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs654950	1.000	rs600401	chr1:41984658	C/T	cg06885757	chr1:42089581	HIVEP3	0.43	6.23	0.37	1.97e-9	Airway imaging phenotypes;
KIRP	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.41	6.2	0.37	2.35e-9	Neuroticism;
KIRP	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.36	0.38	9.69e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.43	-0.43	1.78e-12	Aortic root size;
KIRP	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg05802129	chr4:122689817	NA	-0.46	-6.72	-0.39	1.25e-10	Type 2 diabetes;
KIRP	cis	rs240764	0.669	rs846800	chr6:101270498	C/G	cg09795085	chr6:101329169	ASCC3	0.49	5.72	0.34	3.14e-8	Neuroticism;
KIRP	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg22139774	chr2:100720529	AFF3	0.34	5.51	0.33	8.99e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg19847130	chr8:10466454	RP1L1	-0.39	-5.67	-0.34	4.01e-8	Neuroticism;
KIRP	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg16898833	chr6:26189333	HIST1H4D	0.83	5.9	0.35	1.19e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.73	-0.44	2.71e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22618164	chr12:122356400	WDR66	0.59	7.98	0.45	5.57e-14	Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.64	-7.61	-0.44	5.94e-13	Iron status biomarkers;
KIRP	cis	rs735539	0.645	rs9552251	chr13:21180247	A/G	cg27499820	chr13:21296301	IL17D	-0.35	-5.01	-0.3	1.02e-6	Dental caries;
KIRP	cis	rs4460629	0.521	rs4361977	chr1:155076079	C/T	cg00103785	chr1:155043322	NA	-0.32	-5.68	-0.34	3.71e-8	Serum magnesium levels;
KIRP	cis	rs7751419	0.651	rs1864059	chr6:39105177	T/G	cg25014318	chr6:39016776	GLP1R	0.35	5.03	0.31	9.3e-7	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg26531700	chr6:26746687	NA	0.41	5.58	0.34	6.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.58	7.86	0.45	1.17e-13	Height;
KIRP	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg19507638	chr5:93509721	C5orf36	-0.61	-5.66	-0.34	4.28e-8	Diabetic retinopathy;
KIRP	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.43	-7.03	-0.41	2.08e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.37	-0.38	9.26e-10	Hemoglobin concentration;
KIRP	cis	rs6681460	1.000	rs6656550	chr1:67122552	C/T	cg13052034	chr1:66999238	SGIP1	0.43	5.94	0.35	9.61e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs4704187	0.687	rs4704197	chr5:74537751	C/T	cg03227963	chr5:74354835	NA	0.4	5.84	0.35	1.67e-8	Response to amphetamines;
KIRP	cis	rs597583	0.950	rs473343	chr11:117408156	G/C	cg27161313	chr11:117392002	DSCAML1	-0.51	-5.89	-0.35	1.26e-8	Putamen volume;
KIRP	cis	rs9659323	1.000	rs6680737	chr1:119521631	G/A	cg18261050	chr1:119551319	NA	0.38	5.41	0.33	1.5e-7	Body mass index;
KIRP	cis	rs9815354	0.680	rs114478966	chr3:42007050	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.82	0.49	2.15e-16	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08307766	chr12:70637393	CNOT2	0.46	6.06	0.36	5.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs921943	0.957	rs16876302	chr5:78311315	T/C	cg26802063	chr5:78281964	ARSB	0.5	6.28	0.37	1.54e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	2.97e-7	Tonsillectomy;
KIRP	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.67	-7.86	-0.45	1.2e-13	Cocaine dependence;
KIRP	cis	rs6088813	1.000	rs6087698	chr20:33948919	A/G	cg14752227	chr20:34000481	UQCC	-0.51	-6.87	-0.4	5.22e-11	Height;
KIRP	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg07777115	chr5:623756	CEP72	-0.56	-5.54	-0.33	7.77e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg09455208	chr3:40491958	NA	0.34	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14530259	chr9:133455155	LOC100272217;FUBP3	-0.49	-6.15	-0.37	3.17e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7729447	0.841	rs10941021	chr5:32691144	C/T	cg16267343	chr5:32710456	NPR3	0.51	5.88	0.35	1.36e-8	Blood pressure;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg19923238	chr8:142232952	SLC45A4	-0.42	-5.03	-0.31	9.26e-7	Immature fraction of reticulocytes;
KIRP	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg06671706	chr8:8559999	CLDN23	0.44	5.17	0.31	4.8e-7	Obesity-related traits;
KIRP	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.74	-0.63	6.73e-29	Alzheimer's disease;
KIRP	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg06627628	chr2:24431161	ITSN2	0.46	5.62	0.34	5.06e-8	Asthma;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg04677344	chr5:76326870	AGGF1	-0.47	-6.19	-0.37	2.56e-9	Obesity-related traits;
KIRP	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.49	6.73	0.39	1.18e-10	Red blood cell count;
KIRP	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg03388025	chr16:89894329	SPIRE2	-0.4	-8.12	-0.46	2.18e-14	Vitiligo;
KIRP	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg12573674	chr2:1569213	NA	-0.52	-5.05	-0.31	8.77e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs273573	0.643	rs10767883	chr11:30974203	A/T	cg14844989	chr11:31128820	NA	-0.34	-4.89	-0.3	1.78e-6	Total body bone mineral density;
KIRP	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg17724175	chr1:150552817	MCL1	0.35	5.93	0.35	1.03e-8	Melanoma;
KIRP	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.43	5.25	0.32	3.33e-7	Iron status biomarkers;
KIRP	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.51	-0.33	9.11e-8	Blood metabolite levels;
KIRP	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.65	7.97	0.45	5.97e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs5753037	0.869	rs5763650	chr22:30364224	T/C	cg27665648	chr22:30112403	NA	0.37	5.29	0.32	2.64e-7	Type 1 diabetes;
KIRP	cis	rs9296736	0.524	rs35307174	chr6:53938974	A/G	cg04374786	chr6:53939321	C6orf142	0.53	7.05	0.41	1.75e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.16	-0.37	2.98e-9	Breast cancer;
KIRP	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	11.34	0.59	3.04e-24	Menopause (age at onset);
KIRP	cis	rs6540556	0.608	rs2205985	chr1:209912100	A/G	cg23920097	chr1:209922102	NA	-0.38	-5.14	-0.31	5.67e-7	Red blood cell count;
KIRP	cis	rs12760731	0.720	rs10913560	chr1:178452629	A/G	cg00404053	chr1:178313656	RASAL2	0.67	5.37	0.32	1.87e-7	Obesity-related traits;
KIRP	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.71	10.22	0.55	1.14e-20	High light scatter reticulocyte count;
KIRP	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.58	-0.39	2.82e-10	Uric acid levels;
KIRP	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.44	5.53	0.33	8.36e-8	Platelet count;
KIRP	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.39	-0.47	3.75e-15	Neuroticism;
KIRP	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.78	-0.4	9.07e-11	Coronary artery disease;
KIRP	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.92	10.92	0.57	6.67e-23	Corneal astigmatism;
KIRP	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg00656387	chr3:40428638	ENTPD3	0.38	4.86	0.3	2.08e-6	Renal cell carcinoma;
KIRP	cis	rs7737355	0.812	rs11242084	chr5:130935777	T/C	cg06307176	chr5:131281290	NA	0.41	4.93	0.3	1.53e-6	Life satisfaction;
KIRP	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.13	-0.31	5.79e-7	Tonsillectomy;
KIRP	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12963246	chr6:28129442	ZNF389	0.52	6.1	0.36	4.06e-9	Depression;
KIRP	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18267131	chr3:71600114	FOXP1	-0.41	-6.37	-0.38	9.11e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.5	6.39	0.38	8.41e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg24112000	chr20:60950667	NA	-0.78	-10.16	-0.54	1.78e-20	Colorectal cancer;
KIRP	cis	rs4748857	0.782	rs1319250	chr10:23529098	C/T	cg12804278	chr10:23633326	C10orf67	0.42	5.23	0.32	3.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg03146154	chr1:46216737	IPP	0.67	6.33	0.37	1.15e-9	Platelet count;
KIRP	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.66	0.39	1.81e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.76	-0.57	2.26e-22	Triglycerides;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04559178	chr12:29301719	NA	0.43	6.25	0.37	1.83e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs714027	0.967	rs4823077	chr22:30545149	A/G	cg27665648	chr22:30112403	NA	-0.41	-5.9	-0.35	1.21e-8	Lymphocyte counts;
KIRP	cis	rs911119	0.913	rs6036465	chr20:23588003	G/T	cg09631192	chr20:23583594	CST9	-0.47	-5.04	-0.31	9.06e-7	Chronic kidney disease;
KIRP	cis	rs988913	0.957	rs9382397	chr6:54782893	A/G	cg03513858	chr6:54763001	FAM83B	-0.39	-5.41	-0.33	1.5e-7	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.6	-0.34	5.67e-8	Life satisfaction;
KIRP	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg26876637	chr1:152193138	HRNR	0.73	9.51	0.52	1.88e-18	Atopic dermatitis;
KIRP	trans	rs61440199	0.892	rs73818810	chr3:20143380	C/T	cg08354614	chr10:80673607	NA	0.56	6.19	0.37	2.54e-9	Staphylococcus aureus nasal carriage (intermittent);
KIRP	cis	rs11195062	0.521	rs6584977	chr10:111954970	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.34	-5.4	-0.33	1.58e-7	Multiple myeloma;
KIRP	trans	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.23	-0.37	1.97e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00533811	chr22:51021411	CHKB-CPT1B;CHKB;LOC100144603	0.54	6.95	0.41	3.33e-11	Parkinson's disease;
KIRP	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg17376030	chr22:41985996	PMM1	0.6	6.5	0.38	4.34e-10	Vitiligo;
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg09165964	chr15:75287851	SCAMP5	0.55	7.07	0.41	1.61e-11	Caffeine consumption;
KIRP	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg01620082	chr3:125678407	NA	-1.18	-7.43	-0.43	1.79e-12	Depression;
KIRP	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.18	-0.51	1.83e-17	Colorectal cancer;
KIRP	cis	rs2904967	0.852	rs1633466	chr11:65016173	C/G	cg09225861	chr11:65069680	NA	-0.41	-5.02	-0.3	1.01e-6	Mean corpuscular volume;
KIRP	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.54	6.77	0.4	9.34e-11	Obesity-related traits;
KIRP	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg05861140	chr6:150128134	PCMT1	-0.5	-7.03	-0.41	2.03e-11	Lung cancer;
KIRP	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg26681399	chr22:41777847	TEF	0.49	5.13	0.31	5.98e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.6	0.44	6.15e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.23	0.32	3.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.06	0.46	3.36e-14	Menopause (age at onset);
KIRP	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11987759	chr7:65425863	GUSB	0.58	7.77	0.44	2.11e-13	Aortic root size;
KIRP	cis	rs2411233	0.934	rs1824492	chr15:39284513	A/C	cg19287857	chr15:39890699	NA	0.37	5.22	0.32	3.81e-7	Platelet count;
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.79	0.63	4.79e-29	Platelet count;
KIRP	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg26876637	chr1:152193138	HRNR	-0.72	-9.53	-0.52	1.61e-18	Atopic dermatitis;
KIRP	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg06636001	chr8:8085503	FLJ10661	0.69	9.04	0.5	4.74e-17	Retinal vascular caliber;
KIRP	cis	rs684232	0.522	rs11247555	chr17:517419	G/A	cg04370829	chr17:406249	NA	-0.5	-6.13	-0.36	3.41e-9	Prostate cancer;
KIRP	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg21699342	chr2:239360505	ASB1	0.44	5.39	0.33	1.62e-7	Multiple system atrophy;
KIRP	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-9.97	-0.54	7.06e-20	Chronic sinus infection;
KIRP	cis	rs11123406	0.501	rs10864954	chr2:111966947	A/G	cg23466623	chr2:111982296	NA	-0.61	-7.47	-0.43	1.43e-12	Type 2 diabetes;
KIRP	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg08514558	chr10:81106712	PPIF	0.41	5.6	0.34	5.7e-8	Height;
KIRP	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg14835575	chr10:16859367	RSU1	0.78	10.21	0.55	1.28e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18746364	chr3:196669422	NCBP2;LOC152217	-0.46	-6.24	-0.37	1.85e-9	Metabolic traits;
KIRP	cis	rs35072154	0.825	rs58582591	chr14:52293872	C/T	cg24361212	chr14:51298003	NIN	-0.36	-4.89	-0.3	1.78e-6	Breast cancer;
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.15e-7	Life satisfaction;
KIRP	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.66	-11.03	-0.58	3.05e-23	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.44	5.21	0.32	4.05e-7	Systemic lupus erythematosus;
KIRP	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg25019033	chr10:957182	NA	-0.5	-5.31	-0.32	2.48e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs1712517	0.873	rs1712516	chr10:105033628	G/A	cg05636881	chr10:105038444	INA	0.46	6.89	0.4	4.65e-11	Migraine;
KIRP	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg01721255	chr8:58191610	C8orf71	0.53	5.32	0.32	2.31e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	7.9	0.45	9.47e-14	Personality dimensions;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11309039	chr5:133702676	CDKL3	-0.46	-6.11	-0.36	3.87e-9	Myopia;
KIRP	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.72	-8.77	-0.49	2.98e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg23594656	chr7:65796392	TPST1	-0.44	-6.3	-0.37	1.36e-9	Aortic root size;
KIRP	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg15655495	chr12:38532458	NA	-0.27	-4.85	-0.3	2.18e-6	Bladder cancer;
KIRP	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.62	-4.91	-0.3	1.69e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg11941060	chr3:133502564	NA	-0.54	-6.29	-0.37	1.43e-9	Iron status biomarkers;
KIRP	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg16434002	chr17:42200994	HDAC5	-0.46	-5.51	-0.33	8.97e-8	Total body bone mineral density;
KIRP	cis	rs714515	0.900	rs6697844	chr1:172308238	C/T	cg01573306	chr1:172330400	DNM3	-0.48	-6.22	-0.37	2.15e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.98	13.16	0.64	2.73e-30	Cognitive function;
KIRP	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	7.56	0.43	8.16e-13	Lymphocyte counts;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg09699651	chr6:150184138	LRP11	0.47	6.26	0.37	1.66e-9	Lung cancer;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg02238950	chr17:1505303	SLC43A2	-0.49	-6.31	-0.37	1.29e-9	Bladder cancer;
KIRP	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.74	11.7	0.6	1.91e-25	Calcium levels;
KIRP	cis	rs28595532	0.702	rs72670250	chr4:119337134	T/C	cg21605333	chr4:119757512	SEC24D	1.03	7.75	0.44	2.48e-13	Cannabis dependence symptom count;
KIRP	cis	rs11749327	0.719	rs72698510	chr5:464339	C/A	cg26850624	chr5:429559	AHRR	-0.48	-6.34	-0.37	1.08e-9	Hemoglobin concentration;Hypospadias;
KIRP	cis	rs11138902	0.649	rs13287758	chr9:72156599	T/C	cg14397918	chr9:72078829	APBA1	0.35	5.51	0.33	9e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15575222	chr20:1206255	RAD21L1	-0.47	-6.34	-0.37	1.12e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg22437258	chr11:111473054	SIK2	0.59	6.76	0.4	1.02e-10	Primary sclerosing cholangitis;
KIRP	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.82	10.6	0.56	7.42e-22	Menopause (age at onset);
KIRP	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.7	-0.63	9.44e-29	Extrinsic epigenetic age acceleration;
KIRP	trans	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg13565492	chr6:43139072	SRF	-0.94	-8.67	-0.48	5.79e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.82	9.15	0.5	2.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg06121193	chr1:90282411	NA	-0.53	-7.52	-0.43	1e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00376283	chr12:123451042	ABCB9	-0.67	-6.35	-0.38	1.04e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg26373071	chr5:1325741	CLPTM1L	0.55	7.39	0.43	2.23e-12	Lung cancer;
KIRP	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg03433033	chr1:76189801	ACADM	-0.46	-6.51	-0.38	4.18e-10	Daytime sleep phenotypes;
KIRP	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg16141378	chr3:129829833	LOC729375	0.52	7.01	0.41	2.34e-11	Joint mobility (Beighton score);
KIRP	cis	rs7712401	0.601	rs35334805	chr5:122335261	G/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.56	5.92	0.35	1.09e-8	Morning vs. evening chronotype;
KIRP	cis	rs981946	0.544	rs12204759	chr6:3352636	G/A	cg18842474	chr6:3356384	SLC22A23	0.48	6.03	0.36	6.02e-9	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
KIRP	cis	rs4262150	0.883	rs72799202	chr5:152193105	A/C	cg12297329	chr5:152029980	NA	-0.62	-8.03	-0.46	4.13e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg09904177	chr6:26538194	HMGN4	0.39	4.9	0.3	1.74e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg08888203	chr3:10149979	C3orf24	0.48	5.07	0.31	7.85e-7	Alzheimer's disease;
KIRP	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg21184320	chr1:21044207	KIF17	-0.35	-5.3	-0.32	2.52e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.58	7.18	0.42	8.24e-12	Cognitive test performance;
KIRP	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg24060327	chr5:131705240	SLC22A5	-0.75	-9.27	-0.51	9.65e-18	Acylcarnitine levels;
KIRP	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg14593290	chr7:50529359	DDC	0.47	6.01	0.36	6.54e-9	Malaria;
KIRP	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.36	-0.32	1.89e-7	Ovarian reserve;
KIRP	cis	rs2916247	0.954	rs7845971	chr8:93022095	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.6	-7.87	-0.45	1.15e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.75	-0.34	2.64e-8	Schizophrenia;
KIRP	cis	rs4654899	0.865	rs7532667	chr1:21438239	A/G	cg05370193	chr1:21551575	ECE1	0.48	6.56	0.39	3.15e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	0.88	10.12	0.54	2.42e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	12.82	0.63	3.75e-29	Personality dimensions;
KIRP	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06544989	chr22:39130855	UNC84B	-0.43	-7.51	-0.43	1.12e-12	Menopause (age at onset);
KIRP	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg01843524	chr15:80216276	C15orf37;ST20	0.39	4.9	0.3	1.71e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.11	-0.31	6.51e-7	Educational attainment;
KIRP	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg23100626	chr2:96804247	ASTL	-0.52	-7.54	-0.43	8.77e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14613607	chr9:139333683	INPP5E	0.61	7.55	0.43	8.59e-13	Parkinson's disease;
KIRP	cis	rs11166927	0.716	rs4736094	chr8:140802186	G/A	cg16909799	chr8:140841666	TRAPPC9	0.4	5.25	0.32	3.36e-7	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg07843065	chr1:150265600	MRPS21	0.42	5.71	0.34	3.21e-8	Migraine;
KIRP	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.57	-7.78	-0.44	2e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg01849789	chr22:41697279	ZC3H7B	-0.41	-4.86	-0.3	2.13e-6	Neuroticism;
KIRP	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg21395723	chr22:39101663	GTPBP1	0.4	5.32	0.32	2.32e-7	Menopause (age at onset);
KIRP	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.51	-0.33	9.16e-8	IgG glycosylation;
KIRP	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.48	0.33	1.07e-7	Breast cancer;
KIRP	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg26924012	chr15:45694286	SPATA5L1	0.47	5.73	0.34	2.86e-8	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.86	-10.97	-0.57	4.66e-23	Breast cancer;
KIRP	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg23594656	chr7:65796392	TPST1	-0.45	-6.26	-0.37	1.75e-9	Aortic root size;
KIRP	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.54	6.4	0.38	7.72e-10	Arsenic metabolism;
KIRP	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	1.1	10.44	0.55	2.28e-21	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg19468946	chr17:37922297	IKZF3	-0.46	-6.54	-0.38	3.6e-10	Asthma;
KIRP	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.75	-8.54	-0.48	1.4e-15	Platelet count;
KIRP	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.58	-8.55	-0.48	1.31e-15	Mean corpuscular volume;
KIRP	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg27572855	chr1:25598939	RHD	0.55	9.7	0.53	4.81e-19	Erythrocyte sedimentation rate;
KIRP	cis	rs10140922	0.931	rs4982258	chr14:35821891	G/A	cg07166546	chr14:35805898	NA	-0.24	-6.04	-0.36	5.6e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg13880726	chr7:1868755	MAD1L1	0.49	5.49	0.33	1.01e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg06935464	chr4:38784597	TLR10	0.5	5.17	0.31	4.74e-7	Breast cancer;
KIRP	cis	rs2273669	0.748	rs11759732	chr6:109370006	A/G	cg05315195	chr6:109294784	ARMC2	-0.49	-5.32	-0.32	2.3e-7	Prostate cancer;
KIRP	cis	rs11638352	1.000	rs6493092	chr15:44289418	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.84	-5.59	-0.34	6.03e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg11608241	chr8:8085544	FLJ10661	-0.5	-6.49	-0.38	4.74e-10	Triglycerides;
KIRP	cis	rs1823913	1.000	rs4853562	chr2:192118422	A/G	cg12404831	chr2:192114017	MYO1B	-0.5	-6.7	-0.39	1.39e-10	Obesity-related traits;
KIRP	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	10.26	0.55	8.62e-21	Hip circumference;
KIRP	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg07395648	chr5:131743802	NA	-0.55	-7.74	-0.44	2.65e-13	Blood metabolite levels;
KIRP	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-15.8	-0.71	2.74e-39	Coronary artery disease;
KIRP	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.29	7.78	0.44	1.95e-13	Crohn's disease;
KIRP	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg05756136	chr1:119680316	WARS2	-0.61	-8.06	-0.46	3.28e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs8018808	0.935	rs11159261	chr14:77921120	A/G	cg18872420	chr14:78023429	SPTLC2	0.33	4.93	0.3	1.49e-6	Myeloid white cell count;
KIRP	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg00677455	chr12:58241039	CTDSP2	-0.44	-5.01	-0.3	1.02e-6	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg05414235	chr15:100273828	LYSMD4	-1.11	-6.13	-0.36	3.48e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg00383909	chr3:49044727	WDR6	0.64	5.94	0.35	9.87e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4523957	0.533	rs170043	chr17:2200434	G/T	cg16513277	chr17:2031491	SMG6	-0.5	-5.62	-0.34	5.24e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg10096100	chr1:26503862	CNKSR1	0.42	5.94	0.35	9.75e-9	Height;
KIRP	cis	rs62229266	0.605	rs11701331	chr21:37458392	T/C	cg12218747	chr21:37451666	NA	-0.58	-8.24	-0.46	1.06e-14	Mitral valve prolapse;
KIRP	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.33	-5.12	-0.31	6.23e-7	Inflammatory bowel disease;
KIRP	trans	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.48	-6.39	-0.38	8.15e-10	Mean corpuscular volume;
KIRP	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.65	-0.39	1.85e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.17	-0.54	1.6e-20	Coffee consumption (cups per day);
KIRP	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.4	5.19	0.31	4.46e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.17	-0.31	4.77e-7	Life satisfaction;
KIRP	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.97	0.54	7.23e-20	Lung cancer in ever smokers;
KIRP	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.24	13.65	0.66	5.98e-32	Uric acid levels;
KIRP	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.74	-9.41	-0.51	3.74e-18	Aortic root size;
KIRP	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	trans	rs587242	1.000	rs2985639	chr1:96894735	C/T	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26526719	chr5:1949144	NA	0.41	4.94	0.3	1.41e-6	Gut microbiome composition (winter);
KIRP	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg07424592	chr7:64974309	NA	0.75	4.89	0.3	1.84e-6	Diabetic kidney disease;
KIRP	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.81e-8	Body mass index;
KIRP	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-5.44	-0.33	1.3e-7	Chronic sinus infection;
KIRP	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg25019722	chr6:37503610	NA	-0.94	-13.76	-0.66	2.41e-32	Cognitive performance;
KIRP	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.67	-8.24	-0.47	1.01e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7630877	0.924	rs1404271	chr3:179632209	T/C	cg18765712	chr3:179670323	PEX5L	0.51	6.09	0.36	4.28e-9	Type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg05233311	chr7:65670241	TPST1	-0.47	-6.43	-0.38	6.75e-10	Metabolic traits;
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-9.41	-0.51	3.57e-18	Platelet count;
KIRP	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg00647317	chr7:50633725	DDC	-0.43	-5.7	-0.34	3.38e-8	Malaria;
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.7	-0.39	1.4e-10	Immature fraction of reticulocytes;
KIRP	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg08603382	chr10:743973	NA	0.46	6.75	0.4	1.07e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.19	0.31	4.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs877282	0.853	rs7092805	chr10:756246	G/A	cg17470449	chr10:769945	NA	0.69	6.73	0.39	1.16e-10	Uric acid levels;
KIRP	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-9.34	-0.51	5.94e-18	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-0.97	-9.41	-0.51	3.72e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs7923609	0.967	rs4486511	chr10:65264266	C/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.18e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12643440	0.718	rs543525	chr4:17143562	C/T	cg22650099	chr4:17144496	NA	-0.5	-6.86	-0.4	5.47e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs8177876	0.822	rs4324141	chr16:81114825	A/G	cg08591886	chr16:81111003	C16orf46	0.6	5.86	0.35	1.51e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.59	7.47	0.43	1.43e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.18	0.54	1.54e-20	Coffee consumption (cups per day);
KIRP	cis	rs1050631	1.000	rs11081934	chr18:33705304	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.53	6.53	0.38	3.72e-10	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg18306943	chr3:40428807	ENTPD3	-0.41	-5.5	-0.33	9.49e-8	Renal cell carcinoma;
KIRP	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	15.82	0.71	2.28e-39	Post bronchodilator FEV1;
KIRP	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg00343986	chr7:65444356	GUSB	0.46	5.61	0.34	5.5e-8	Calcium levels;
KIRP	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.43e-13	Corneal astigmatism;
KIRP	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg13978929	chr19:21580086	ZNF493	0.5	4.87	0.3	2e-6	Pain;
KIRP	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.81	-10.82	-0.57	1.44e-22	Schizophrenia;
KIRP	cis	rs4950322	0.580	rs2083720	chr1:146593878	A/T	cg22381352	chr1:146742008	CHD1L	-0.44	-5.07	-0.31	7.85e-7	Protein quantitative trait loci;
KIRP	cis	rs10892173	0.818	rs7947524	chr11:117671091	C/T	cg21014159	chr11:117668035	DSCAML1	0.37	5.57	0.33	6.52e-8	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27498211	chr16:4588826	C16orf5	0.49	6.25	0.37	1.83e-9	Parkinson's disease;
KIRP	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11987759	chr7:65425863	GUSB	-0.45	-5.48	-0.33	1.05e-7	Aortic root size;
KIRP	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg17376030	chr22:41985996	PMM1	-0.54	-5.73	-0.34	2.93e-8	Vitiligo;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg16726947	chr2:178476124	NA	-0.47	-6.02	-0.36	6.18e-9	Inflammatory biomarkers;
KIRP	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg00701064	chr4:6280414	WFS1	0.46	10.17	0.54	1.67e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	0.66	5.88	0.35	1.31e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7923609	0.967	rs10761758	chr10:65172747	A/T	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03926050	chr12:111020225	PPTC7	0.46	6.29	0.37	1.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-1.04	-12.83	-0.63	3.43e-29	Breast cancer;
KIRP	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.4	-5.33	-0.32	2.26e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16416793	chr11:101981035	YAP1	0.49	6.06	0.36	5e-9	Parkinson's disease;
KIRP	cis	rs2012796	0.957	rs8011477	chr14:81815587	C/T	cg02996355	chr14:81879375	NA	0.43	5.81	0.35	1.94e-8	Night sleep phenotypes;
KIRP	cis	rs7527798	1.000	rs12738067	chr1:207858527	G/C	cg09232269	chr1:207846808	CR1L	-0.42	-5.01	-0.3	1.03e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.9	14.65	0.68	2.27e-35	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4711336	0.935	rs3818525	chr6:33660779	A/G	cg15676125	chr6:33679581	C6orf125	0.43	5.87	0.35	1.39e-8	Height;
KIRP	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg13770153	chr20:60521292	NA	-0.42	-5.0	-0.3	1.09e-6	Body mass index;
KIRP	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs73193808	0.614	rs11088112	chr21:30566236	T/A	cg03476357	chr21:30257390	N6AMT1	0.45	5.05	0.31	8.5e-7	Coronary artery disease;
KIRP	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs6546324	0.625	rs6546317	chr2:67828793	C/G	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.7e-13	Endometriosis;
KIRP	cis	rs7078219	0.580	rs10883361	chr10:101282968	T/C	cg07044859	chr10:101282883	NA	-0.33	-5.85	-0.35	1.52e-8	Dental caries;
KIRP	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.45	5.72	0.34	3e-8	Resistin levels;
KIRP	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.57	7.04	0.41	1.88e-11	Aortic root size;
KIRP	cis	rs911119	0.913	rs6048926	chr20:23580987	C/A	cg09631192	chr20:23583594	CST9	-0.48	-5.02	-0.3	9.97e-7	Chronic kidney disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24545466	chr11:33891541	LMO2	-0.48	-6.64	-0.39	1.97e-10	Survival in pancreatic cancer;
KIRP	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	0.92	10.85	0.57	1.13e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg06636001	chr8:8085503	FLJ10661	0.55	6.76	0.4	1.01e-10	Neuroticism;
KIRP	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.62	-0.34	5.13e-8	Crohn's disease;
KIRP	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg13819577	chr1:248512075	OR14C36	-0.37	-4.99	-0.3	1.16e-6	Common traits (Other);
KIRP	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg13482628	chr17:19912719	NA	0.69	10.65	0.56	5.09e-22	Schizophrenia;
KIRP	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.41	-0.33	1.46e-7	Personality dimensions;
KIRP	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg09264619	chr17:80180166	NA	-0.41	-5.92	-0.35	1.05e-8	Life satisfaction;
KIRP	cis	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg18478394	chr8:109455254	TTC35	0.6	7.55	0.43	8.66e-13	Dupuytren's disease;
KIRP	cis	rs2278796	0.639	rs6661266	chr1:204971452	C/T	cg17449235	chr1:204966235	NFASC	-0.57	-7.8	-0.45	1.79e-13	Mean platelet volume;
KIRP	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs1669338	0.588	rs73009149	chr3:3220473	G/C	cg16797762	chr3:3221439	CRBN	-0.61	-5.53	-0.33	8.32e-8	White matter integrity;
KIRP	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7799006	0.757	rs2398668	chr7:2298227	A/G	cg02951883	chr7:2050386	MAD1L1	0.44	5.32	0.32	2.37e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg15871215	chr5:81402204	ATG10	0.5	6.56	0.39	3.09e-10	Breast cancer;
KIRP	cis	rs687432	0.774	rs11601841	chr11:57889566	G/A	cg19752551	chr11:57585705	CTNND1	-0.64	-8.23	-0.46	1.09e-14	Parkinson's disease;
KIRP	cis	rs2860975	0.542	rs1926705	chr10:96818418	C/T	cg09036531	chr10:96991505	NA	-0.48	-5.94	-0.35	9.6e-9	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-1.02	-22.4	-0.82	2.55e-61	Breast cancer;
KIRP	cis	rs2594714	1.000	rs2607276	chr19:13954633	T/G	cg18576835	chr19:13944261	NA	-0.36	-5.15	-0.31	5.22e-7	Breast cancer;
KIRP	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg12855166	chr17:30846586	MYO1D	0.35	4.85	0.3	2.21e-6	Schizophrenia;
KIRP	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg00806126	chr19:22604979	ZNF98	-0.66	-6.9	-0.4	4.33e-11	Pain;
KIRP	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg15848620	chr12:58087721	OS9	0.43	5.09	0.31	7.17e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg21252483	chr19:49399788	TULP2	-0.47	-6.19	-0.37	2.5e-9	Red cell distribution width;
KIRP	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg22800045	chr5:56110881	MAP3K1	-0.75	-7.35	-0.42	2.98e-12	Initial pursuit acceleration;
KIRP	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg05370193	chr1:21551575	ECE1	0.43	6.01	0.36	6.77e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.56	-7.18	-0.42	8.02e-12	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs2371030	0.930	rs2371029	chr2:211568889	T/C	cg18417063	chr2:211583084	NA	-0.52	-7.52	-0.43	1.03e-12	Non-small cell lung cancer;
KIRP	cis	rs3736485	0.844	rs8041197	chr15:51865877	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.04	-0.31	8.82e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01507044	chr13:23949294	SACS	0.5	6.26	0.37	1.72e-9	Parkinson's disease;
KIRP	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	0.85	7.43	0.43	1.74e-12	Lung disease severity in cystic fibrosis;
KIRP	trans	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg06521331	chr12:34319734	NA	-0.54	-6.68	-0.39	1.55e-10	Heart rate;
KIRP	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg16414030	chr3:133502952	NA	-0.54	-6.22	-0.37	2.07e-9	Iron status biomarkers;
KIRP	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	15.92	0.71	1.09e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.83	11.83	0.6	7.12e-26	Blood metabolite ratios;
KIRP	cis	rs714515	0.868	rs7546252	chr1:172368310	A/G	cg01573306	chr1:172330400	DNM3	0.4	5.14	0.31	5.68e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg08133631	chr1:26527909	CATSPER4	-0.47	-5.2	-0.31	4.16e-7	Obesity-related traits;
KIRP	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg03808351	chr9:123631620	PHF19	0.43	5.86	0.35	1.5e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs2281603	0.571	rs59577187	chr14:64955671	C/T	cg01860774	chr14:64969374	ZBTB25	0.34	5.47	0.33	1.11e-7	Lymphocyte counts;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17177017	chr17:74668252	NA	0.45	6.37	0.38	9.21e-10	Survival in pancreatic cancer;
KIRP	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs504918	0.783	rs11717452	chr3:124120599	T/C	cg05766129	chr3:123988013	KALRN	-0.4	-4.9	-0.3	1.71e-6	Schizophrenia;
KIRP	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-5.95	-0.35	9.02e-9	Personality dimensions;
KIRP	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.96	0.35	8.89e-9	Morning vs. evening chronotype;
KIRP	cis	rs9962915	1.000	rs1719944	chr18:5596603	A/G	cg16304950	chr18:5543945	EPB41L3	-0.4	-4.93	-0.3	1.5e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Corneal astigmatism;
KIRP	cis	rs13401104	0.796	rs10929164	chr2:237110321	C/T	cg19324714	chr2:237145437	ASB18	0.47	4.89	0.3	1.84e-6	Educational attainment;
KIRP	cis	rs78487399	0.710	rs77620935	chr2:43673765	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.89	-0.3	1.85e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.74	-0.34	2.71e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.45	5.84	0.35	1.61e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.67	10.5	0.56	1.46e-21	Lung cancer;
KIRP	cis	rs7555523	0.887	rs4656461	chr1:165687205	G/A	cg24409356	chr1:165738333	TMCO1	0.52	4.95	0.3	1.39e-6	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs7998202	0.667	rs282576	chr13:113358864	A/G	cg04656015	chr13:113407548	ATP11A	-0.47	-4.89	-0.3	1.81e-6	Glycated hemoglobin levels;
KIRP	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	8.31	0.47	6.36e-15	Myopia (pathological);
KIRP	cis	rs4595586	0.679	rs4768473	chr12:39326256	A/G	cg26384229	chr12:38710491	ALG10B	0.49	6.31	0.37	1.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs7011507	0.945	rs78120406	chr8:49156086	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6840360	0.692	rs4479686	chr4:152399324	C/T	cg25486957	chr4:152246857	NA	-0.44	-5.03	-0.31	9.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.68	-0.34	3.84e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg22777020	chr22:31556080	RNF185	0.48	5.11	0.31	6.47e-7	Colorectal cancer;
KIRP	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg02903104	chr8:1507517	DLGAP2	0.38	5.74	0.34	2.82e-8	Lung cancer;
KIRP	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.81	-11.53	-0.59	7.03e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg03289416	chr15:75166202	SCAMP2	-0.41	-5.29	-0.32	2.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs12282928	0.876	rs7937826	chr11:48299348	T/G	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg00094735	chr5:1949198	NA	0.46	5.52	0.33	8.53e-8	Gut microbiome composition (winter);
KIRP	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	9.14	0.5	2.44e-17	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg06647332	chr5:131281008	NA	0.46	5.01	0.3	1.05e-6	Life satisfaction;
KIRP	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.38	5.76	0.34	2.44e-8	Multiple sclerosis;
KIRP	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg10560079	chr2:191398806	TMEM194B	-0.67	-8.01	-0.46	4.46e-14	Diastolic blood pressure;
KIRP	cis	rs9815354	0.812	rs73073230	chr3:42008263	G/A	cg03022575	chr3:42003672	ULK4	0.83	8.7	0.49	4.83e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.55e-23	Primary sclerosing cholangitis;
KIRP	cis	rs9649213	0.593	rs10953257	chr7:97960664	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-5.9	-0.35	1.17e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs74181299	0.712	rs2241160	chr2:65291546	A/G	cg05010058	chr2:65284262	CEP68	0.43	6.02	0.36	6.43e-9	Pulse pressure;
KIRP	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.48	7.32	0.42	3.61e-12	Resting heart rate;
KIRP	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg18709589	chr6:96969512	KIAA0776	0.34	5.18	0.31	4.59e-7	Headache;
KIRP	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.68	-8.98	-0.5	7.44e-17	Obesity-related traits;
KIRP	cis	rs4789452	1.000	rs11658815	chr17:75375881	G/A	cg05184938	chr17:75369939	SEPT9	-0.37	-5.06	-0.31	8.35e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.79	-7.13	-0.41	1.12e-11	Obesity-related traits;
KIRP	trans	rs1859156	0.812	rs6816886	chr4:95822524	C/A	cg24204951	chr2:239172084	PER2	0.28	6.58	0.39	2.77e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs2248020	0.501	rs2263368	chr11:93264680	A/C	cg15737290	chr11:93063684	CCDC67	0.47	5.38	0.32	1.72e-7	Insulin levels in response to oral glucose tolerance test (30 minutes);
KIRP	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg26207909	chr14:103986467	CKB	-0.52	-6.61	-0.39	2.37e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg09165964	chr15:75287851	SCAMP5	-0.99	-9.73	-0.53	3.92e-19	Lung cancer;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg22907277	chr7:1156413	C7orf50	0.83	8.23	0.46	1.13e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6499755	0.965	rs9889178	chr16:55353110	G/T	cg05099576	chr16:55362342	IRX6	0.28	5.83	0.35	1.78e-8	Hypospadias;
KIRP	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.94e-7	Aortic root size;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg09699651	chr6:150184138	LRP11	0.47	6.3	0.37	1.37e-9	Lung cancer;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg18404041	chr3:52824283	ITIH1	-0.48	-6.09	-0.36	4.21e-9	Bipolar disorder;
KIRP	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.65	8.79	0.49	2.58e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.31	-6.09	-0.36	4.25e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.76	-10.04	-0.54	4.09e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg17724175	chr1:150552817	MCL1	0.32	5.39	0.32	1.66e-7	Melanoma;
KIRP	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.68	-10.56	-0.56	9.87e-22	Educational attainment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.10.1909607F	chr10:91522494	KIF20B	0.49	7.14	0.41	1.03e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs66530629	0.874	rs4648878	chr1:25164113	A/G	cg22509179	chr1:25234806	RUNX3	-0.39	-5.13	-0.31	6e-7	Plateletcrit;
KIRP	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.45	-0.38	5.79e-10	Bone mineral density;
KIRP	cis	rs112908525	1	rs112908525	chr7:80305278	T/TGAGGGTTGA	cg21369886	chr7:80305251	CD36	-0.4	-5.68	-0.34	3.73e-8	Mean corpuscular volume;
KIRP	cis	rs17221829	0.703	rs1962258	chr11:89380687	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.23e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.29	4.96	0.3	1.33e-6	Electrocardiographic conduction measures;
KIRP	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg07395648	chr5:131743802	NA	-0.57	-8.48	-0.48	2.07e-15	Blood metabolite levels;
KIRP	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg18850127	chr7:39170497	POU6F2	0.28	5.15	0.31	5.23e-7	IgG glycosylation;
KIRP	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	cis	rs13102973	0.899	rs13127659	chr4:135900604	G/A	cg14419869	chr4:135874104	NA	0.48	7.52	0.43	1.02e-12	Subjective well-being;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05332869	chr20:39658073	TOP1	0.54	6.42	0.38	6.82e-10	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19932343	chr11:66610763	RCE1;C11orf80	0.51	6.21	0.37	2.19e-9	Parkinson's disease;
KIRP	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	8.16	0.46	1.78e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg12560992	chr17:57184187	TRIM37	0.6	5.2	0.31	4.14e-7	Cognitive test performance;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14512731	chr9:139378529	C9orf163;SEC16A	0.48	6.05	0.36	5.51e-9	Myopia (pathological);
KIRP	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg20651018	chr11:3035856	CARS	-0.4	-5.66	-0.34	4.16e-8	Longevity;
KIRP	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.55	-7.42	-0.43	1.88e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.5	6.45	0.38	5.89e-10	Asthma (bronchodilator response);
KIRP	cis	rs1165472	0.755	rs6669971	chr1:56155543	A/G	cg11523071	chr1:56160889	NA	-0.74	-11.54	-0.59	6.61e-25	Paclitaxel-induced neuropathy;
KIRP	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14169450	chr9:139327907	INPP5E	0.51	7.45	0.43	1.56e-12	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs6701037	0.555	rs10912898	chr1:175120469	A/G	cg17845761	chr1:175162550	KIAA0040	-0.26	-4.91	-0.3	1.67e-6	Alcohol dependence;
KIRP	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.88	-12.41	-0.62	8.82e-28	Cocaine dependence;
KIRP	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.15	-0.37	3.06e-9	Superior crus of antihelix expression;
KIRP	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg00576331	chr11:65640516	EFEMP2	0.43	5.45	0.33	1.25e-7	DNA methylation (variation);
KIRP	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg05425664	chr17:57184151	TRIM37	-0.39	-5.14	-0.31	5.57e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.57	-0.52	1.17e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs2594989	0.780	rs2443706	chr3:11550505	C/G	cg01796438	chr3:11312864	ATG7	-0.58	-7.04	-0.41	1.86e-11	Circulating chemerin levels;
KIRP	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-4.85	-0.3	2.17e-6	Initial pursuit acceleration;
KIRP	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.85	-0.45	1.28e-13	Triglycerides;
KIRP	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.58	-7.8	-0.45	1.75e-13	White matter hyperintensity burden;
KIRP	cis	rs8077059	1.000	rs8076475	chr17:55814749	C/T	cg12582317	chr17:55822272	NA	0.41	5.14	0.31	5.49e-7	Sex hormone-binding globulin levels;
KIRP	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.37e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.75	-8.89	-0.49	1.29e-16	Cognitive ability;
KIRP	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg00204512	chr16:28754710	NA	0.42	5.13	0.31	5.9e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg26513180	chr16:89883248	FANCA	0.69	5.48	0.33	1.07e-7	Interleukin-17 levels;
KIRP	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.73	9.6	0.52	9.91e-19	Blood metabolite levels;
KIRP	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.08	-0.31	7.41e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24323275	chr3:111694896	PHLDB2	0.4	6.14	0.36	3.22e-9	C-reactive protein;
KIRP	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg16553119	chr1:165599451	MGST3	-0.44	-5.36	-0.32	1.95e-7	Total ventricular volume;
KIRP	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg18190219	chr22:46762943	CELSR1	-0.53	-6.07	-0.36	4.83e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9815354	1.000	rs11928580	chr3:41885722	C/T	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1823913	0.927	rs13013390	chr2:192126727	A/G	cg12404831	chr2:192114017	MYO1B	0.48	6.93	0.4	3.71e-11	Obesity-related traits;
KIRP	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.93	-13.92	-0.66	7.23e-33	Body mass index;
KIRP	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg18904891	chr8:8559673	CLDN23	0.7	7.87	0.45	1.12e-13	Obesity-related traits;
KIRP	cis	rs11138902	0.673	rs13291843	chr9:72162011	C/T	cg14397918	chr9:72078829	APBA1	0.35	5.61	0.34	5.35e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.66	0.34	4.24e-8	Lung cancer;
KIRP	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-7.95	-0.45	6.71e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.22	0.32	3.88e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7897654	0.571	rs12767543	chr10:104631663	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-5.18	-0.31	4.51e-7	Schizophrenia;
KIRP	cis	rs60154123	1.000	rs60154123	chr1:210468999	C/T	cg09074223	chr1:210466472	NA	0.53	5.01	0.3	1.04e-6	Coronary artery disease;
KIRP	cis	rs662064	0.925	rs669701	chr1:10544725	A/G	cg19773385	chr1:10388646	KIF1B	0.37	5.11	0.31	6.55e-7	Asthma;
KIRP	cis	rs59197085	0.551	rs60384027	chr7:128437514	G/A	cg00734629	chr7:128471146	FLNC	0.47	5.04	0.31	8.82e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.53	6.52	0.38	4.03e-10	Total body bone mineral density;
KIRP	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-5.95	-0.35	9.14e-9	Bladder cancer;
KIRP	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg04989706	chr14:50066350	PPIL5	-0.49	-6.04	-0.36	5.66e-9	Carotid intima media thickness;
KIRP	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg15655495	chr12:38532458	NA	0.26	5.03	0.31	9.41e-7	Bladder cancer;
KIRP	cis	rs7246865	0.531	rs8103913	chr19:17166229	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.39	0.38	8.34e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.09	0.41	1.43e-11	Mean platelet volume;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.5	9.05	0.5	4.46e-17	Lung cancer;
KIRP	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg05072774	chr3:49840536	C3orf54	0.43	5.51	0.33	9.1e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19894588	chr14:64061835	NA	0.5	6.72	0.39	1.26e-10	Glioblastoma;Glioma;
KIRP	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.28	-0.32	2.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg06671706	chr8:8559999	CLDN23	0.57	6.56	0.39	3.1e-10	Obesity-related traits;
KIRP	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.78	9.64	0.52	7.15e-19	Iron status biomarkers;
KIRP	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg19847130	chr8:10466454	RP1L1	0.39	5.43	0.33	1.38e-7	Retinal vascular caliber;
KIRP	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00255919	chr5:131827918	IRF1	0.27	5.74	0.34	2.71e-8	Asthma (sex interaction);
KIRP	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.6	7.79	0.45	1.83e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.3	-0.37	1.39e-9	IgG glycosylation;
KIRP	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.41	-0.33	1.47e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7760535	0.656	rs1883136	chr6:111907023	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.7	-9.85	-0.53	1.6e-19	Metabolic traits;
KIRP	cis	rs9815354	0.951	rs17060938	chr3:41759191	T/C	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.31e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg27170947	chr2:26402098	FAM59B	-0.63	-6.38	-0.38	8.66e-10	Gut microbiome composition (summer);
KIRP	cis	rs57994353	0.663	rs4418446	chr9:139305024	G/A	cg21253087	chr9:139290292	SNAPC4	0.57	5.81	0.35	1.88e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.45	6.65	0.39	1.91e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg19847130	chr8:10466454	RP1L1	0.38	5.63	0.34	4.78e-8	Triglycerides;
KIRP	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg27205649	chr11:78285834	NARS2	-0.55	-6.2	-0.37	2.43e-9	Testicular germ cell tumor;
KIRP	cis	rs61332075	0.518	rs6749508	chr2:239456243	C/T	cg18131467	chr2:239335373	ASB1	-0.62	-5.78	-0.35	2.27e-8	Lung function (FEV1/FVC);
KIRP	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg19468946	chr17:37922297	IKZF3	-0.49	-6.77	-0.4	9.47e-11	Self-reported allergy;
KIRP	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.22	-0.32	3.72e-7	Bladder cancer;
KIRP	cis	rs3849570	0.533	rs6548784	chr3:81995889	G/A	cg07356753	chr3:81810745	GBE1	-0.49	-6.41	-0.38	7.49e-10	Waist circumference;Body mass index;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg07701084	chr6:150067640	NUP43	-0.65	-8.8	-0.49	2.5e-16	Lung cancer;
KIRP	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.78	-10.94	-0.57	5.82e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	5.14	0.31	5.47e-7	Renal cell carcinoma;
KIRP	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg02038168	chr22:39784481	NA	-0.41	-4.89	-0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg14517359	chr4:903473	GAK	-0.6	-6.12	-0.36	3.66e-9	Type 2 diabetes;
KIRP	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.66	0.6	2.75e-25	Menarche (age at onset);
KIRP	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.74	-9.4	-0.51	3.95e-18	Facial morphology (factor 19);
KIRP	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665630	0.522	rs114382704	chr2:23951810	G/T	cg08063864	chr2:24346004	PFN4;LOC375190	0.9	5.24	0.32	3.46e-7	Hypertension;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04297258	chr16:88772664	RNF166;CTU2	0.65	7.78	0.44	1.94e-13	Smoking initiation;
KIRP	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.6	5.72	0.34	3.02e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg09408571	chr1:101003634	GPR88	-0.22	-5.02	-0.3	9.87e-7	Monocyte count;
KIRP	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg02574844	chr11:5959923	NA	-0.6	-6.13	-0.36	3.39e-9	DNA methylation (variation);
KIRP	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-11.35	-0.59	2.71e-24	Body mass index;
KIRP	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.5	7.14	0.41	1.03e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.06	-0.46	3.38e-14	Body mass index;
KIRP	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.84	10.56	0.56	9.46e-22	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg25547332	chr5:131281432	NA	-0.47	-5.31	-0.32	2.5e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.36	-0.32	1.89e-7	Bipolar disorder;
KIRP	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.29	0.37	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.66	0.48	6.32e-16	Bladder cancer;
KIRP	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.38	7.42	0.43	1.87e-12	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18751573	chr3:16924903	NA	0.52	6.86	0.4	5.52e-11	Interleukin-4 levels;
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.5	-0.38	4.56e-10	Lung cancer;
KIRP	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.08	-0.41	1.46e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	0.89	13.96	0.66	5.15e-33	Breast cancer;
KIRP	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	7.79	0.44	1.88e-13	Lung cancer in ever smokers;
KIRP	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.72	5.87	0.35	1.4e-8	Body mass index;
KIRP	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg18944383	chr4:111397179	ENPEP	0.44	7.22	0.42	6.33e-12	Height;
KIRP	cis	rs785830	0.811	rs661356	chr9:244457	G/A	cg14500300	chr9:211689	NA	0.57	7.92	0.45	7.96e-14	Platelet distribution width;
KIRP	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-11.94	-0.61	3.09e-26	Cognitive function;
KIRP	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg16797656	chr11:68205561	LRP5	0.39	5.29	0.32	2.67e-7	Total body bone mineral density;
KIRP	cis	rs909341	0.818	rs2750483	chr20:62345470	A/G	cg03999872	chr20:62272968	STMN3	-0.56	-6.57	-0.39	2.93e-10	Atopic dermatitis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17157516	chr1:35332203	DLGAP3	0.63	6.34	0.37	1.09e-9	Lung function (FEV1);
KIRP	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs45544231	0.569	rs9302556	chr16:52543645	C/A	cg09051775	chr16:52580266	TOX3	-0.36	-5.01	-0.3	1.02e-6	Restless legs syndrome;
KIRP	cis	rs17023223	0.537	rs2361273	chr1:119603700	A/T	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	2.94e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2380205	0.651	rs6602312	chr10:5926931	A/C	cg27141509	chr10:5886111	NA	-0.34	-4.86	-0.3	2.07e-6	Breast cancer;
KIRP	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg06766960	chr11:133703094	NA	-0.58	-7.32	-0.42	3.44e-12	Childhood ear infection;
KIRP	cis	rs3947	0.951	rs1736086	chr8:11704897	C/T	cg21775007	chr8:11205619	TDH	-0.47	-5.03	-0.31	9.65e-7	Blood protein levels;
KIRP	cis	rs7945718	0.533	rs10765987	chr11:12705743	C/T	cg25843174	chr11:12811716	TEAD1	0.34	5.7	0.34	3.43e-8	Educational attainment (years of education);
KIRP	cis	rs3733418	0.929	rs2280325	chr4:165928254	C/T	cg10852876	chr4:165953100	TRIM60	-0.48	-5.64	-0.34	4.77e-8	Obesity-related traits;
KIRP	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg11608241	chr8:8085544	FLJ10661	-0.46	-5.72	-0.34	3.08e-8	Joint mobility (Beighton score);
KIRP	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.42e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg23985595	chr17:80112537	CCDC57	0.38	5.91	0.35	1.15e-8	Life satisfaction;
KIRP	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.86	14.65	0.68	2.3e-35	Intelligence (multi-trait analysis);
KIRP	trans	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.43	-0.43	1.82e-12	Neuroticism;
KIRP	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18364779	chr6:26104403	HIST1H4C	0.51	5.86	0.35	1.47e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.64	0.48	7.11e-16	IgG glycosylation;
KIRP	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04374321	chr14:90722782	PSMC1	0.93	15.78	0.71	3.23e-39	Mortality in heart failure;
KIRP	cis	rs16858210	0.520	rs10460892	chr3:183546124	C/T	cg03417191	chr3:183542750	MAP6D1	-0.57	-5.4	-0.33	1.56e-7	Menopause (age at onset);
KIRP	cis	rs16854884	0.657	rs35788195	chr3:143739311	C/T	cg06585982	chr3:143692056	C3orf58	0.58	7.53	0.43	9.84e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg08975724	chr8:8085496	FLJ10661	0.7	9.19	0.51	1.76e-17	Mood instability;
KIRP	cis	rs12362504	0.532	rs7948688	chr11:9927911	T/G	cg07197493	chr11:9884649	SBF2	-0.39	-5.09	-0.31	7.08e-7	Survival in pancreatic cancer;
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	4.9	0.3	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.98	15.46	0.7	3.9e-38	Chronic sinus infection;
KIRP	cis	rs16936870	0.543	rs34017261	chr8:71233273	A/G	cg14232793	chr8:71155543	NCOA2	0.56	6.47	0.38	5.27e-10	QT interval;
KIRP	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.69	-0.66	4.32e-32	Primary sclerosing cholangitis;
KIRP	trans	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17183009	chr3:120277827	NA	0.52	6.16	0.37	2.98e-9	Corneal astigmatism;
KIRP	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	4.95	0.3	1.37e-6	Educational attainment (years of education);
KIRP	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.56	0.33	6.86e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02252918	chr12:124458442	ZNF664;CCDC92	0.67	6.06	0.36	5.02e-9	Lung function (FEV1);
KIRP	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.0	-0.5	6.42e-17	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27498364	chr3:78922413	ROBO1	0.42	6.02	0.36	6.21e-9	Interleukin-4 levels;
KIRP	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.44	-0.43	1.7e-12	Gut microbiome composition (summer);
KIRP	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg22705602	chr4:152727874	NA	-0.52	-8.98	-0.5	7.23e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg23978390	chr7:1156363	C7orf50	0.53	7.31	0.42	3.72e-12	Longevity;Endometriosis;
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.61	5.5	0.33	9.67e-8	Alzheimer's disease;
KIRP	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg00684032	chr4:1343700	KIAA1530	0.5	6.67	0.39	1.65e-10	Obesity-related traits;
KIRP	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.42e-10	Major depressive disorder;
KIRP	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.69	-9.27	-0.51	1.01e-17	Lung cancer;
KIRP	cis	rs8054556	0.787	rs1140239	chr16:30021402	C/T	cg06326092	chr16:30034487	C16orf92	0.43	5.72	0.34	3.13e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg06995285	chr7:2418615	EIF3B	0.82	8.54	0.48	1.39e-15	Multiple sclerosis;
KIRP	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg07884673	chr3:53033167	SFMBT1	0.79	6.22	0.37	2.1e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs11638352	1.000	rs8037441	chr15:44311916	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-5.76	-0.34	2.49e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg11234688	chr2:1609660	NA	0.54	5.02	0.3	9.93e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.75	6.66	0.39	1.77e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6723108	0.738	rs7599054	chr2:135540546	A/G	cg12500956	chr2:135428796	TMEM163	0.51	6.66	0.39	1.81e-10	Type 2 diabetes;
KIRP	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg00405596	chr8:11794950	NA	0.38	4.92	0.3	1.59e-6	Retinal vascular caliber;
KIRP	trans	rs7830939	0.586	rs28734832	chr8:9321947	C/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.2	-0.37	2.34e-9	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03172996	chr2:152955498	CACNB4	0.44	6.23	0.37	2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.59	-6.83	-0.4	6.69e-11	Obesity-related traits;
KIRP	cis	rs6662572	0.737	rs7532388	chr1:46472734	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.64	0.34	4.72e-8	Blood protein levels;
KIRP	cis	rs981844	0.961	rs62325084	chr4:154662603	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08015590	chr7:2281924	NUDT1;FTSJ2	-0.55	-6.17	-0.37	2.84e-9	Menopause (age at onset);
KIRP	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.68	9.33	0.51	6.34e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.42	-7.01	-0.41	2.31e-11	Age at first birth;
KIRP	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg18646521	chr2:111875858	NA	0.41	5.85	0.35	1.53e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs829661	0.512	rs1113661	chr2:30805280	C/T	cg10949345	chr2:30726833	LCLAT1	0.48	7.09	0.41	1.4e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.53	-4.99	-0.3	1.17e-6	Alzheimer's disease;
KIRP	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg03051577	chr14:103366987	TRAF3	0.47	6.05	0.36	5.26e-9	Pancreatic cancer;
KIRP	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.97	-0.41	2.9100000000000002e-11	Response to antipsychotic treatment;
KIRP	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg13147721	chr7:65941812	NA	0.95	6.57	0.39	3.03e-10	Diabetic kidney disease;
KIRP	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.31	-0.32	2.4e-7	Headache;
KIRP	cis	rs7078219	0.965	rs11190126	chr10:101271789	A/C	cg07044859	chr10:101282883	NA	-0.31	-5.11	-0.31	6.35e-7	Dental caries;
KIRP	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23281280	chr6:28129359	ZNF389	0.44	4.87	0.3	2.01e-6	Depression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01546424	chr6:149721457	MAP3K7IP2;SUMO4	0.53	6.52	0.38	3.97e-10	Interleukin-4 levels;
KIRP	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.62	4.86	0.3	2.07e-6	Schizophrenia;
KIRP	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs73206853	0.764	rs56838584	chr12:110666136	A/G	cg12870014	chr12:110450643	ANKRD13A	0.53	5.62	0.34	5.16e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg09022993	chr4:52917875	SPATA18	-0.36	-6.05	-0.36	5.3e-9	Schizophrenia;
KIRP	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.98	15.69	0.71	6.25e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.29	-0.32	2.76e-7	Bipolar disorder;
KIRP	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.98	-15.78	-0.71	3.22e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg00405596	chr8:11794950	NA	-0.51	-6.86	-0.4	5.61e-11	Monocyte count;
KIRP	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.43	0.59	1.48e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg17443007	chr1:101659419	NA	0.39	5.49	0.33	9.93e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs981844	0.775	rs1020704	chr4:154736494	C/T	cg14289246	chr4:154710475	SFRP2	0.63	7.43	0.43	1.74e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs8141529	0.600	rs739196	chr22:29311271	G/A	cg15103426	chr22:29168792	CCDC117	0.52	5.09	0.31	7.27e-7	Lymphocyte counts;
KIRP	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg26061582	chr7:22766209	IL6	0.43	6.03	0.36	6e-9	Lung cancer;
KIRP	cis	rs8113308	0.810	rs8100541	chr19:52449695	A/G	cg25782003	chr19:52490127	ZNF350	0.54	5.11	0.31	6.44e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-8.42	-0.47	3.1e-15	Morning vs. evening chronotype;
KIRP	cis	rs17321999	0.810	rs58645306	chr2:30475074	T/C	cg05247661	chr2:30472410	LBH	0.6	7.02	0.41	2.14e-11	Systemic lupus erythematosus;
KIRP	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg01689657	chr7:91764605	CYP51A1	0.39	5.81	0.35	1.97e-8	Breast cancer;
KIRP	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.38	6.46	0.38	5.66e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.56	-6.87	-0.4	5.29e-11	Aortic root size;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25654301	chr17:73511699	TSEN54;CASKIN2	-0.43	-6.28	-0.37	1.56e-9	Metabolic traits;
KIRP	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg13409248	chr3:40428643	ENTPD3	0.4	5.3	0.32	2.57e-7	Renal cell carcinoma;
KIRP	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg19116668	chr7:99932089	PMS2L1	-0.82	-10.85	-0.57	1.13e-22	Alzheimer's disease (late onset);
KIRP	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.37	-5.03	-0.31	9.45e-7	Neuroticism;
KIRP	cis	rs7009516	0.587	rs2291577	chr8:24256470	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.31	-6.55	-0.39	3.24e-10	Hair greying;
KIRP	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.68	-12.63	-0.63	1.67e-28	White blood cell count (basophil);
KIRP	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.66	-8.98	-0.5	7.18e-17	Metabolic syndrome;
KIRP	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6681460	0.933	rs7554101	chr1:67156472	A/G	cg13052034	chr1:66999238	SGIP1	-0.37	-5.23	-0.32	3.59e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.74	-10.78	-0.57	1.94e-22	Educational attainment;
KIRP	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg05775895	chr3:12838266	CAND2	0.32	5.43	0.33	1.37e-7	P wave duration;
KIRP	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.46	5.6	0.34	5.59e-8	Common traits (Other);
KIRP	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg00334542	chr7:100209784	MOSPD3	-0.54	-5.11	-0.31	6.6e-7	Other erythrocyte phenotypes;
KIRP	cis	rs78761021	0.720	rs79348078	chr17:9795771	T/A	cg26853458	chr17:9805074	RCVRN	0.5	4.85	0.3	2.18e-6	Type 2 diabetes;
KIRP	cis	rs12731740	0.908	rs2294911	chr1:207988603	G/C	cg22525895	chr1:207977042	MIR29B2	-0.64	-4.9	-0.3	1.74e-6	Biomedical quantitative traits;
KIRP	cis	rs10924309	0.640	rs6700599	chr1:245854047	G/T	cg00036263	chr1:245852353	KIF26B	-0.54	-7.74	-0.44	2.63e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.55	6.39	0.38	8.18e-10	Dialysis-related mortality;
KIRP	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.33e-13	Life satisfaction;
KIRP	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.66	-0.39	1.8e-10	Joint mobility (Beighton score);
KIRP	cis	rs3126085	0.560	rs11204985	chr1:152333597	A/G	cg26876637	chr1:152193138	HRNR	0.56	6.36	0.38	9.64e-10	Atopic dermatitis;
KIRP	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg23216685	chr1:86174607	ZNHIT6	0.5	5.91	0.35	1.15e-8	Urate levels in overweight individuals;
KIRP	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg23202291	chr11:1979235	NA	0.42	5.43	0.33	1.38e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.51	-11.6	-0.59	4.35e-25	Diabetic kidney disease;
KIRP	cis	rs300774	0.841	rs2926788	chr2:199410	G/A	cg21211680	chr2:198530	NA	0.57	6.08	0.36	4.44e-9	Suicide attempts in bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.6.1297321R	chr6:55725979	BMP5	0.46	6.58	0.39	2.87e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg18850127	chr7:39170497	POU6F2	0.28	5.15	0.31	5.23e-7	IgG glycosylation;
KIRP	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg26893134	chr6:116381904	FRK	0.2	5.78	0.35	2.26e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	6.63	0.39	2.08e-10	Menarche (age at onset);
KIRP	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	11.81	0.6	8.86e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg24565620	chr2:194026	NA	0.72	7.79	0.44	1.93e-13	Blood protein levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg08204369	chr17:73150733	HN1	0.79	6.82	0.4	7.11e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg09873164	chr1:152488093	CRCT1	0.47	5.71	0.34	3.27e-8	Hair morphology;
KIRP	cis	rs4273100	0.512	rs7502682	chr17:19295450	G/T	cg25447019	chr17:19030144	GRAPL	0.57	7.71	0.44	3.17e-13	Schizophrenia;
KIRP	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.74	-10.58	-0.56	8.29e-22	Itch intensity from mosquito bite;
KIRP	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.63	0.39	2.1e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.58	8.72	0.49	4.31e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg21573476	chr21:45109991	RRP1B	0.63	8.65	0.48	6.9e-16	Mean corpuscular volume;
KIRP	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg11608241	chr8:8085544	FLJ10661	-0.38	-4.85	-0.3	2.24e-6	Mood instability;
KIRP	cis	rs2063714	0.967	rs9322586	chr6:157195220	T/C	cg23222435	chr6:157204239	ARID1B	-0.45	-6.77	-0.4	9.49e-11	Sitting height ratio;
KIRP	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.77	-10.47	-0.56	1.88e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.1	-0.31	6.81e-7	Neuroticism;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.81	14.05	0.67	2.49e-33	Vitiligo;
KIRP	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.59	-7.6	-0.44	6.14e-13	Vitiligo;
KIRP	cis	rs9488822	0.662	rs195520	chr6:116242740	A/G	cg15226275	chr6:116381976	FRK	0.2	5.2	0.31	4.21e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg17507749	chr15:85114479	UBE2QP1	0.7	7.57	0.43	7.68e-13	Schizophrenia;
KIRP	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg04166393	chr7:2884313	GNA12	0.47	6.2	0.37	2.33e-9	Height;
KIRP	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg04362960	chr10:104952993	NT5C2	0.47	5.87	0.35	1.39e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.74	-0.63	6.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs9309473	0.950	rs7596773	chr2:73846000	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.46	-0.33	1.19e-7	Metabolite levels;
KIRP	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.79	-11.05	-0.58	2.49e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.13	-0.31	5.99e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.25	-17.16	-0.74	6.08e-44	Corneal structure;
KIRP	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg27490568	chr2:178487706	NA	0.52	7.07	0.41	1.61e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.55	6.16	0.37	2.97e-9	Diisocyanate-induced asthma;
KIRP	cis	rs34421088	0.532	rs11782742	chr8:11165009	C/T	cg00405596	chr8:11794950	NA	0.39	5.04	0.31	9.21e-7	Neuroticism;
KIRP	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.89e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg03724423	chr7:27170755	HOXA4	0.35	5.26	0.32	3.06e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.7	9.36	0.51	5.38e-18	Neuroticism;
KIRP	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.44e-17	Retinal vascular caliber;
KIRP	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.5	7.08	0.41	1.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7523273	0.597	rs2724374	chr1:207941191	G/T	cg22525895	chr1:207977042	MIR29B2	0.57	5.67	0.34	4.09e-8	Schizophrenia;
KIRP	trans	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg00938859	chr5:1591904	SDHAP3	0.53	6.26	0.37	1.69e-9	Breast cancer;
KIRP	cis	rs2299587	0.554	rs13253029	chr8:17749622	C/T	cg01800426	chr8:17659068	MTUS1	-0.43	-5.0	-0.3	1.11e-6	Economic and political preferences;
KIRP	cis	rs3008706	0.920	rs3008708	chr9:16033356	A/G	cg14451791	chr9:16040625	NA	0.54	5.55	0.33	7.46e-8	Bilirubin levels;
KIRP	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.65	-8.23	-0.46	1.1e-14	Sudden cardiac arrest;
KIRP	cis	rs273218	1.000	rs156380	chr5:53378450	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.69	7.45	0.43	1.55e-12	Migraine;
KIRP	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.72	-8.51	-0.48	1.69e-15	Diastolic blood pressure;
KIRP	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	10.17	0.54	1.6e-20	Monocyte percentage of white cells;
KIRP	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.69	7.91	0.45	8.47e-14	Menarche (age at onset);
KIRP	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg00677455	chr12:58241039	CTDSP2	-0.66	-7.81	-0.45	1.67e-13	Multiple sclerosis;
KIRP	cis	rs11203032	0.831	rs10887926	chr10:90940358	G/A	cg16672925	chr10:90967113	CH25H	0.78	8.15	0.46	1.91e-14	Heart failure;
KIRP	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.6	-7.13	-0.41	1.12e-11	Mosquito bite size;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.78	9.85	0.53	1.65e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg27170947	chr2:26402098	FAM59B	-0.69	-7.43	-0.43	1.74e-12	Gut microbiome composition (summer);
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.94	16.56	0.73	6.76e-42	Longevity;Endometriosis;
KIRP	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg01990225	chr2:97406019	LMAN2L	-1.05	-7.07	-0.41	1.63e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg01251548	chr11:17372745	DKFZp686O24166	-0.4	-5.29	-0.32	2.68e-7	Type 2 diabetes;
KIRP	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.45	6.32	0.37	1.24e-9	Childhood ear infection;
KIRP	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.56	0.39	3.13e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs478607	0.749	rs2022050	chr11:64367651	G/A	cg09231725	chr11:64357281	SLC22A12	-0.65	-5.08	-0.31	7.61e-7	Urate levels;
KIRP	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg14082893	chr15:75400931	NA	0.36	5.29	0.32	2.7e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.94e-7	Neuroticism;
KIRP	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.52	-5.97	-0.36	8.29e-9	Inflammatory skin disease;
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.85	0.35	1.59e-8	Platelet count;
KIRP	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg01765077	chr12:122356316	WDR66	0.64	9.17	0.5	1.93e-17	Mean platelet volume;
KIRP	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg06212747	chr3:49208901	KLHDC8B	0.65	9.12	0.5	2.84e-17	Resting heart rate;
KIRP	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg14851346	chr12:38532713	NA	-0.4	-5.02	-0.3	9.9e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg07138768	chr7:917805	C7orf20	0.32	5.21	0.32	3.93e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.13	0.41	1.12e-11	Height;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.9	14.27	0.67	4.62e-34	IgG glycosylation;
KIRP	trans	rs2048656	0.605	rs13273565	chr8:9649146	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.67	0.39	1.7e-10	Schizophrenia;
KIRP	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.67	10.4	0.55	3.04e-21	Pulse pressure;
KIRP	cis	rs10128264	0.841	rs2790766	chr10:80960616	A/G	cg20744163	chr10:80999841	ZMIZ1	0.29	5.05	0.31	8.43e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-0.8	-8.96	-0.5	8.16e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg22284058	chr8:142237359	SLC45A4	-0.5	-6.31	-0.37	1.3e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7851660	0.874	rs10122541	chr9:100628268	G/A	cg13688889	chr9:100608707	NA	-0.67	-8.83	-0.49	1.97e-16	Strep throat;
KIRP	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.86	-11.78	-0.6	1.03e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.32	5.06	0.31	8.26e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.66	-9.14	-0.5	2.36e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg18441811	chr11:71824068	C11orf51	-0.63	-5.09	-0.31	7.11e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs3790645	1.000	rs657227	chr1:26892104	T/A	cg23229016	chr1:26872525	RPS6KA1	0.23	6.16	0.37	2.88e-9	Glucose homeostasis traits;
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg22105103	chr4:187893119	NA	0.71	10.36	0.55	4.23e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg08603382	chr10:743973	NA	-0.52	-8.07	-0.46	3.07e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg03647239	chr10:116582469	FAM160B1	0.52	6.02	0.36	6.41e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg23649088	chr2:200775458	C2orf69	-0.64	-6.81	-0.4	7.29e-11	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07142678	chr1:112162349	RAP1A	-0.49	-6.26	-0.37	1.67e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.5	-6.25	-0.37	1.79e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.7	9.01	0.5	5.7e-17	Dilated cardiomyopathy;
KIRP	cis	rs2273156	0.706	rs7153550	chr14:35501800	A/G	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.19	-0.31	4.35e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.58	-6.67	-0.39	1.63e-10	Schizophrenia;
KIRP	trans	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg03060546	chr3:49711283	APEH	-0.62	-6.1	-0.36	4.17e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg15234197	chr11:68924956	NA	0.34	4.92	0.3	1.59e-6	Blond vs. brown hair color;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27466766	chr8:144679319	EEF1D;TIGD5	0.46	6.34	0.37	1.1e-9	Parkinson's disease;
KIRP	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg06533319	chr4:3265114	C4orf44	0.58	6.87	0.4	5.26e-11	Parental longevity (mother's age at death);
KIRP	cis	rs4356975	0.527	rs4694645	chr4:69992918	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.06	0.31	8.15e-7	Obesity-related traits;
KIRP	cis	rs7539542	0.556	rs2275734	chr1:202887295	C/T	cg08940984	chr1:202857613	RABIF	0.51	6.23	0.37	1.99e-9	Mean platelet volume;
KIRP	cis	rs8018808	0.875	rs11159258	chr14:77880593	T/C	cg20045696	chr14:77926864	AHSA1	0.46	5.77	0.35	2.34e-8	Myeloid white cell count;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	7.34	0.42	3.17e-12	Lymphocyte counts;
KIRP	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.55	-7.35	-0.42	2.93e-12	Urate levels in overweight individuals;
KIRP	cis	rs7246657	0.722	rs10406379	chr19:38036725	G/A	cg18154014	chr19:37997991	ZNF793	0.61	6.66	0.39	1.79e-10	Coronary artery calcification;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26671183	chr1:207226604	PFKFB2	0.44	6.01	0.36	6.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.66	8.45	0.47	2.57e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.78e-12	Lung cancer;
KIRP	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.83	11.0	0.57	3.77e-23	Coronary artery disease;
KIRP	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	13.8	0.66	1.8e-32	Smoking behavior;
KIRP	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	1.05	19.44	0.78	1.3e-51	Height;
KIRP	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.11	-0.41	1.29e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg23920097	chr1:209922102	NA	-0.46	-5.35	-0.32	1.97e-7	Red blood cell count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21981481	chr7:127011849	ZNF800	-0.49	-7.42	-0.43	1.94e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Bladder cancer;
KIRP	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg10760299	chr15:45669010	GATM	0.34	5.09	0.31	7.02e-7	Homoarginine levels;
KIRP	cis	rs7215564	0.908	rs61707349	chr17:78665255	T/C	cg06153925	chr17:78755379	RPTOR	0.33	5.31	0.32	2.45e-7	Myopia (pathological);
KIRP	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg21361702	chr7:150065534	REPIN1	0.67	6.64	0.39	2.04e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg21573476	chr21:45109991	RRP1B	-0.65	-9.23	-0.51	1.29e-17	Mean corpuscular volume;
KIRP	cis	rs10465746	0.545	rs12145516	chr1:84480376	A/G	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	6.87e-8	Obesity-related traits;
KIRP	cis	rs72829446	0.530	rs2302761	chr17:7358520	C/T	cg17788227	chr17:7347145	FGF11;CHRNB1	0.49	5.08	0.31	7.41e-7	Androgen levels;
KIRP	cis	rs2191566	0.576	rs414402	chr19:44492568	A/G	cg18700516	chr19:44507157	ZNF230	0.42	4.85	0.3	2.2e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs76533333	0.915	rs71446622	chr13:113365480	G/A	cg04656015	chr13:113407548	ATP11A	0.63	5.29	0.32	2.67e-7	Red cell distribution width;
KIRP	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.56	0.48	1.23e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg08975724	chr8:8085496	FLJ10661	0.6	7.4	0.43	2.21e-12	Neuroticism;
KIRP	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs988913	0.874	rs12662124	chr6:54802336	A/G	cg03513858	chr6:54763001	FAM83B	-0.38	-5.34	-0.32	2.1e-7	Menarche (age at onset);
KIRP	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg05973401	chr12:123451056	ABCB9	0.57	6.58	0.39	2.74e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.11	-0.31	6.44e-7	Retinal vascular caliber;
KIRP	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.49	5.73	0.34	2.91e-8	Mean platelet volume;
KIRP	trans	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg00405596	chr8:11794950	NA	0.52	6.8	0.4	7.85e-11	Mood instability;
KIRP	cis	rs13161895	1.000	rs35973843	chr5:179466502	T/C	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19979107	chr2:175351956	GPR155	0.44	6.02	0.36	6.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4692589	1.000	rs4692783	chr4:170935407	G/A	cg19918862	chr4:170955249	NA	0.42	5.13	0.31	5.78e-7	Anxiety disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13591497	chr9:126129566	CRB2	0.46	6.03	0.36	5.87e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg05342682	chr7:94953680	PON1	0.6	8.59	0.48	9.85e-16	Paraoxonase activity;
KIRP	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg13072238	chr3:49761600	GMPPB	0.62	5.49	0.33	1.02e-7	Menarche (age at onset);
KIRP	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.9	0.49	1.21e-16	Resting heart rate;
KIRP	cis	rs9625935	0.685	rs131291	chr22:30169436	G/A	cg01021169	chr22:30184971	ASCC2	-0.47	-5.43	-0.33	1.32e-7	Tonsillectomy;
KIRP	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.64	-0.44	4.78e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12643440	0.718	rs612181	chr4:17143492	A/T	cg22650099	chr4:17144496	NA	0.51	7.05	0.41	1.78e-11	Metabolite levels (Pyroglutamine);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24394020	chr22:50354019	PIM3	-0.53	-7.1	-0.41	1.35e-11	Myopia;
KIRP	cis	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.19	-0.31	4.41e-7	Leprosy;
KIRP	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.75	6.77	0.4	9.66e-11	Weight;
KIRP	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	0.43	6.04	0.36	5.59e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg11833968	chr6:79620685	NA	-0.44	-6.76	-0.4	9.78e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.27	0.51	9.89e-18	Morning vs. evening chronotype;
KIRP	cis	rs2273669	0.915	rs1080945	chr6:109304694	A/G	cg05315195	chr6:109294784	ARMC2	-0.48	-5.48	-0.33	1.06e-7	Prostate cancer;
KIRP	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg22549504	chr19:17448937	GTPBP3	0.49	5.1	0.31	6.83e-7	Systemic lupus erythematosus;
KIRP	cis	rs655720	1	rs655720	chr3:136103267	C/T	cg15507776	chr3:136538369	TMEM22	0.4	5.2	0.31	4.24e-7	Coronary artery disease;
KIRP	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg05333889	chr7:157238977	NA	-0.53	-7.91	-0.45	8.8e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs1448094	0.817	rs10863108	chr12:86328249	C/T	cg06740227	chr12:86229804	RASSF9	0.44	5.58	0.34	6.37e-8	Major depressive disorder;
KIRP	cis	rs10751667	0.961	rs7479171	chr11:926809	G/A	cg10932868	chr11:921992	NA	0.59	7.47	0.43	1.4e-12	Alzheimer's disease (late onset);
KIRP	cis	rs828999	1.000	rs828999	chr1:108744934	A/G	cg06207961	chr1:108661230	NA	0.36	4.92	0.3	1.59e-6	Monocyte percentage of white cells;
KIRP	trans	rs6601327	0.600	rs4841219	chr8:9654185	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.64	-0.44	4.69e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-7.05	-0.41	1.84e-11	Self-reported allergy;
KIRP	cis	rs7173389	0.530	rs6495064	chr15:73682867	C/T	cg01796676	chr15:73680284	NA	-0.51	-6.14	-0.36	3.32e-9	Resting heart rate;
KIRP	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.64	9.16	0.5	2.07e-17	Dupuytren's disease;
KIRP	cis	rs6723108	0.651	rs6724866	chr2:135407310	C/A	cg12500956	chr2:135428796	TMEM163	-0.42	-5.68	-0.34	3.78e-8	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04211818	chr16:3661492	BTBD12	0.55	7.18	0.42	8.33e-12	Parkinson's disease;
KIRP	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.49e-6	Red blood cell count;
KIRP	cis	rs7216169	1	rs7216169	chr17:5219511	C/T	cg24500398	chr17:5266808	RABEP1	-0.6	-4.99	-0.3	1.12e-6	Red blood cell density in sickle cell anemia;
KIRP	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.57	-8.97	-0.5	7.96e-17	C-reactive protein levels;
KIRP	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg23188430	chr6:125850052	NA	-0.34	-5.39	-0.33	1.65e-7	Brugada syndrome;
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg06871246	chr4:1363661	KIAA1530	0.47	5.9	0.35	1.19e-8	Obesity-related traits;
KIRP	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.32	0.59	3.56e-24	Height;
KIRP	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.28	0.32	2.88e-7	Lung cancer;
KIRP	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.87	-12.81	-0.63	4.02e-29	Personality dimensions;
KIRP	cis	rs6783573	0.965	rs7650998	chr3:46607255	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	0.44	5.96	0.36	8.76e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.71e-36	Prostate cancer;
KIRP	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	0.93	16.28	0.72	6.22e-41	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10904908	1.000	rs7920002	chr10:17259766	T/A	cg01003015	chr10:17271136	VIM	-0.43	-5.22	-0.32	3.75e-7	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg23796481	chr11:64053134	BAD;GPR137	0.77	8.87	0.49	1.58e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1298062	0.756	rs2463241	chr19:50996961	C/T	cg11430371	chr19:50961752	MYBPC2	-0.36	-5.12	-0.31	6.05e-7	Age of smoking initiation;
KIRP	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.76	-0.34	2.49e-8	Huntington's disease progression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00818198	chr7:55001045	NA	0.45	6.71	0.39	1.3100000000000001e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs979961	0.568	rs114522298	chr4:117915311	T/C	cg02574033	chr7:141398961	KIAA1147	0.93	6.08	0.36	4.57e-9	Ulcerative colitis;
KIRP	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.14	-15.45	-0.7	4.18e-38	Lymphocyte percentage of white cells;
KIRP	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg22138327	chr13:27999177	GTF3A	0.77	8.64	0.48	7.27e-16	Weight;
KIRP	cis	rs17221829	0.645	rs9804648	chr11:89375840	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs16858868	0.964	rs1282944	chr3:111635403	A/G	cg27279460	chr3:111697713	ABHD10	-0.41	-4.93	-0.3	1.52e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.08	0.31	7.44e-7	Leprosy;
KIRP	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg10047753	chr17:41438598	NA	1.13	18.18	0.76	2.13e-47	Menopause (age at onset);
KIRP	cis	rs1978968	0.654	rs13056749	chr22:18402924	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.48	-5.9	-0.35	1.22e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21957399	chr18:11980981	IMPA2	0.52	6.57	0.39	3.02e-10	Parkinson's disease;
KIRP	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.1	0.58	1.82e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg16486109	chr11:613632	IRF7	0.45	5.3	0.32	2.58e-7	Systemic lupus erythematosus;
KIRP	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	10.11	0.54	2.6e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7923609	0.818	rs10822159	chr10:65096250	C/T	cg01631684	chr10:65280961	REEP3	-0.47	-5.38	-0.32	1.75e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs78545713	0.649	rs113407109	chr6:26224403	T/G	cg01420254	chr6:26195488	NA	1.21	7.59	0.44	6.71e-13	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07504864	chr6:88412167	NCRNA00120;AKIRIN2	0.93	6.29	0.37	1.41e-9	P wave terminal force;
KIRP	cis	rs17286411	0.769	rs34111614	chr16:71949163	C/T	cg04254540	chr16:71951199	KIAA0174	-0.38	-5.04	-0.31	8.92e-7	Blood protein levels;
KIRP	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.59	-7.21	-0.42	6.68e-12	Longevity;
KIRP	cis	rs6681460	0.625	rs6679568	chr1:67074177	C/T	cg13052034	chr1:66999238	SGIP1	0.38	5.29	0.32	2.65e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.77	-0.35	2.42e-8	Electroencephalogram traits;
KIRP	cis	rs959260	1.000	rs2117562	chr17:73369000	C/T	cg20590849	chr17:73267439	MIF4GD	-0.61	-6.54	-0.38	3.52e-10	Systemic lupus erythematosus;
KIRP	trans	rs6506900	0.692	rs1426311	chr18:28898567	A/G	cg10906284	chr12:63544430	AVPR1A	-0.38	-6.17	-0.37	2.74e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs12580194	0.593	rs61957899	chr12:55731971	C/T	cg19537932	chr12:55886519	OR6C68	-0.49	-6.41	-0.38	7.56e-10	Cancer;
KIRP	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.53	7.73	0.44	2.72e-13	Immature fraction of reticulocytes;
KIRP	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.65	-0.39	1.84e-10	Axial length;
KIRP	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.53	5.24	0.32	3.52e-7	Initial pursuit acceleration;
KIRP	trans	rs7819412	0.593	rs11778398	chr8:10974243	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.54	-0.38	3.47e-10	Triglycerides;
KIRP	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.52	-7.31	-0.42	3.67e-12	Hematocrit;
KIRP	cis	rs4595586	0.632	rs1356266	chr12:39403581	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.13	-0.36	3.41e-9	Morning vs. evening chronotype;
KIRP	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg18944383	chr4:111397179	ENPEP	0.52	8.56	0.48	1.24e-15	Coronary artery disease;
KIRP	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg13165212	chr22:42675999	NA	0.29	5.36	0.32	1.94e-7	Cognitive function;
KIRP	cis	rs4849845	0.889	rs7605557	chr2:121032732	G/A	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg10523679	chr1:76189770	ACADM	-0.49	-6.94	-0.4	3.55e-11	Daytime sleep phenotypes;
KIRP	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg19592336	chr6:28129416	ZNF389	-0.48	-5.56	-0.33	6.98e-8	Depression;
KIRP	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	1.07	22.78	0.82	1.54e-62	Parkinson's disease;
KIRP	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg00857998	chr1:205179979	DSTYK	0.62	7.44	0.43	1.68e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.9	-12.01	-0.61	1.92e-26	Platelet distribution width;
KIRP	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg09455208	chr3:40491958	NA	-0.32	-5.86	-0.35	1.45e-8	Renal cell carcinoma;
KIRP	cis	rs10751667	0.600	rs14346	chr11:1011829	T/C	cg10932868	chr11:921992	NA	0.5	5.84	0.35	1.67e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.73	-0.39	1.2e-10	Monocyte percentage of white cells;
KIRP	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-0.94	-11.17	-0.58	1.04e-23	Lymphocyte counts;
KIRP	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.93	12.05	0.61	1.42e-26	Menopause (age at onset);
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07308232	chr7:1071921	C7orf50	-0.64	-8.35	-0.47	5.04e-15	Longevity;Endometriosis;
KIRP	cis	rs16828019	0.852	rs3766324	chr1:41588653	A/G	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.77e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg19847130	chr8:10466454	RP1L1	0.34	5.13	0.31	5.81e-7	Triglycerides;
KIRP	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.02	-0.58	3.16e-23	Blood metabolite levels;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg01238044	chr22:24384105	GSTT1	0.46	5.69	0.34	3.61e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg04691961	chr3:161091175	C3orf57	-0.4	-5.91	-0.35	1.16e-8	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg08975724	chr8:8085496	FLJ10661	0.66	9.06	0.5	4.27e-17	Mood instability;
KIRP	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	0.87	12.35	0.62	1.43e-27	Homoarginine levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22105215	chr5:118309939	DTWD2	0.39	6.08	0.36	4.47e-9	Survival in pancreatic cancer;
KIRP	cis	rs10875469	1.000	rs10875469	chr8:142333425	A/G	cg17903548	chr8:142401534	NA	-0.51	-5.88	-0.35	1.3e-8	Discordance in emotional problems in monozygotic twins;
KIRP	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.65	12.42	0.62	8.31e-28	Bone mineral density;
KIRP	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg16989719	chr2:238392110	NA	-0.45	-5.81	-0.35	1.91e-8	Prostate cancer;
KIRP	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.66	-8.5	-0.48	1.88e-15	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.569	rs12942513	chr17:4016721	C/A	cg05562828	chr17:3906858	NA	0.5	5.05	0.31	8.46e-7	Type 2 diabetes;
KIRP	cis	rs16976116	0.855	rs7172289	chr15:55501705	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09585974	chr10:31076192	NA	0.55	6.19	0.37	2.43e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.52	5.51	0.33	9.25e-8	Tourette syndrome;
KIRP	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg25036284	chr2:26402008	FAM59B	-0.48	-5.07	-0.31	8.01e-7	Gut microbiome composition (summer);
KIRP	cis	rs3735025	0.963	rs56361933	chr7:137064062	A/G	cg13839563	chr7:136910420	NA	-0.43	-5.03	-0.31	9.37e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Bladder cancer;
KIRP	trans	rs4352251	0.591	rs2177996	chr2:101949911	A/G	cg01941881	chr14:105793310	PACS2	0.59	6.08	0.36	4.63e-9	Adiponectin levels (BMI-adjusted);Adiponectin levels;
KIRP	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg05347473	chr6:146136440	FBXO30	-0.59	-8.31	-0.47	6.3e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg04034577	chr2:241836375	C2orf54	-0.28	-5.41	-0.33	1.46e-7	Urinary metabolites;
KIRP	cis	rs858239	0.539	rs6955726	chr7:23186691	A/G	cg23682824	chr7:23144976	KLHL7	0.53	6.21	0.37	2.22e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.44	6.06	0.36	5.18e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13999143	chr4:6728799	NA	0.51	6.51	0.38	4.16e-10	Interleukin-4 levels;
KIRP	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg04398451	chr17:18023971	MYO15A	0.67	8.92	0.49	1.12e-16	Total body bone mineral density;
KIRP	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg22961513	chr11:14280813	SPON1	0.3	5.06	0.31	8.38e-7	Mitochondrial DNA levels;
KIRP	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg23594656	chr7:65796392	TPST1	0.38	5.61	0.34	5.54e-8	Aortic root size;
KIRP	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.7	-8.81	-0.49	2.28e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs62151617	1.000	rs881570	chr2:70817474	G/T	cg24334149	chr2:71175539	ATP6V1B1	0.5	4.84	0.3	2.27e-6	Hair shape;
KIRP	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg11707556	chr5:10655725	ANKRD33B	0.67	8.44	0.47	2.8e-15	Height;
KIRP	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.96	-0.57	4.94e-23	Refractive error;
KIRP	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.16	-0.72	1.56e-40	Height;
KIRP	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg02353165	chr6:42928485	GNMT	0.44	4.95	0.3	1.36e-6	Blood protein levels;
KIRP	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.79	-6.91	-0.4	4.02e-11	Body mass index;
KIRP	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg22951263	chr5:87985283	NA	-0.5	-7.09	-0.41	1.41e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	8.71	0.49	4.6e-16	Cognitive test performance;
KIRP	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg23100626	chr2:96804247	ASTL	0.45	5.92	0.35	1.08e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs13185784	0.703	rs35394934	chr5:179677555	T/C	cg23221052	chr5:179740743	GFPT2	0.53	5.12	0.31	6.18e-7	TRAIL levels;
KIRP	cis	rs959260	0.688	rs9302989	chr17:73359270	G/A	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.43	-0.33	1.33e-7	Systemic lupus erythematosus;
KIRP	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.02	0.46	4.26e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.4	7.29	0.42	4.33e-12	Refractive error;
KIRP	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg19052272	chr2:3704530	ALLC	0.37	4.95	0.3	1.37e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.54	-7.26	-0.42	5.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.42	6.33	0.37	1.17e-9	Neuroticism;
KIRP	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.44	-6.06	-0.36	5.05e-9	Monocyte count;
KIRP	cis	rs1847505	0.559	rs1475496	chr13:61566031	G/C	cg25164009	chr13:61490935	NA	-0.6	-7.57	-0.43	7.3e-13	Polychlorinated biphenyl levels;
KIRP	cis	rs72730918	0.618	rs1531156	chr15:51990057	G/T	cg14296394	chr15:51910925	DMXL2	0.78	10.51	0.56	1.38e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2862064	0.818	rs4704839	chr5:156484626	A/T	cg12943317	chr5:156479607	HAVCR1	-0.88	-7.46	-0.43	1.49e-12	Platelet count;
KIRP	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.71	10.29	0.55	6.77e-21	Lymphocyte counts;
KIRP	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	7.33	0.42	3.29e-12	Educational attainment;
KIRP	cis	rs5753037	0.838	rs140145	chr22:30178305	C/T	cg27665648	chr22:30112403	NA	0.44	6.23	0.37	1.96e-9	Type 1 diabetes;
KIRP	cis	rs11592657	0.715	rs7920765	chr10:128784637	T/A	cg05702161	chr10:128779687	DOCK1	-0.42	-5.71	-0.34	3.29e-8	Schizophrenia;
KIRP	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.64	-0.39	1.96e-10	Axial length;
KIRP	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.46	-5.88	-0.35	1.34e-8	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	1.01	20.02	0.79	1.42e-53	Parkinson's disease;
KIRP	cis	rs7666738	0.546	rs10026181	chr4:98814118	C/T	cg05340658	chr4:99064831	C4orf37	-0.67	-7.82	-0.45	1.5e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.3	-6.11	-0.36	3.91e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg09408571	chr1:101003634	GPR88	-0.22	-5.05	-0.31	8.54e-7	Monocyte count;
KIRP	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.81	-13.69	-0.66	4.14e-32	Brugada syndrome;
KIRP	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.69	9.33	0.51	6.29e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.5	6.89	0.4	4.75e-11	Mean corpuscular volume;
KIRP	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg09631939	chr20:60582478	TAF4	-0.4	-4.87	-0.3	2.01e-6	Body mass index;
KIRP	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.91	-0.64	1.86e-29	Exhaled nitric oxide output;
KIRP	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg18364779	chr6:26104403	HIST1H4C	0.38	4.99	0.3	1.13e-6	Schizophrenia;
KIRP	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg10189774	chr4:17578691	LAP3	0.53	6.4	0.38	7.71e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg12560992	chr17:57184187	TRIM37	0.61	5.47	0.33	1.11e-7	Cognitive test performance;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.48	5.61	0.34	5.56e-8	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5753618	0.561	rs2413047	chr22:31666026	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.37	-0.32	1.8e-7	Colorectal cancer;
KIRP	cis	rs2071403	0.933	rs1972113	chr2:1407046	T/C	cg07083862	chr2:1417248	TPO	0.32	5.06	0.31	8.33e-7	Thyroid peroxidase antibody positivity;
KIRP	trans	rs2698530	0.583	rs2698527	chr2:64499629	C/T	cg04647370	chr7:44613073	DDX56	0.5	6.12	0.36	3.6e-9	Iron status biomarkers;
KIRP	cis	rs7688540	0.771	rs4549329	chr4:239785	T/A	cg17891759	chr4:299121	NA	-0.45	-5.15	-0.31	5.29e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.44	5.55	0.33	7.47e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4631830	0.965	rs7070301	chr10:51543070	T/G	cg10326726	chr10:51549505	MSMB	-0.59	-8.57	-0.48	1.18e-15	Prostate-specific antigen levels;
KIRP	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.77	-0.35	2.34e-8	Type 2 diabetes;
KIRP	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19717773	chr7:2847554	GNA12	-0.4	-5.93	-0.35	1.02e-8	Height;
KIRP	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.69	8.06	0.46	3.32e-14	Cocaine dependence;
KIRP	cis	rs3736485	0.966	rs7177720	chr15:51890282	T/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.04	-0.31	8.88e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg21204522	chr6:27730016	NA	-0.68	-5.07	-0.31	7.9e-7	Depression;
KIRP	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg08648136	chr8:956695	NA	0.47	7.21	0.42	6.97e-12	Schizophrenia;
KIRP	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg17385448	chr1:15911702	AGMAT	0.25	4.85	0.3	2.24e-6	Systolic blood pressure;
KIRP	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg24154853	chr7:158122151	PTPRN2	-0.37	-5.33	-0.32	2.23e-7	Calcium levels;
KIRP	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs8179	0.593	rs7804722	chr7:92288106	C/T	cg15732164	chr7:92237376	CDK6	0.43	5.68	0.34	3.73e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.58	-7.41	-0.43	2.08e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg24296786	chr1:45957014	TESK2	0.5	6.38	0.38	8.83e-10	Red blood cell count;Reticulocyte count;
KIRP	cis	rs17592366	0.517	rs10148967	chr14:35283744	G/A	cg09327582	chr14:35236912	BAZ1A	0.58	5.92	0.35	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs7834588	0.736	rs72658314	chr8:63909412	G/A	cg04220482	chr8:63952370	GGH	0.55	5.8	0.35	1.99e-8	Response to Vitamin E supplementation;
KIRP	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg09754948	chr16:28834200	ATXN2L	0.5	5.61	0.34	5.54e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg18504358	chr14:23340787	LRP10	0.46	6.28	0.37	1.53e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-20.22	-0.79	3.34e-54	Height;
KIRP	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg00204512	chr16:28754710	NA	-0.41	-5.28	-0.32	2.84e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4356932	1.000	rs6825045	chr4:76957558	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11460331	chr2:39664131	MAP4K3	0.56	7.21	0.42	6.89e-12	Parkinson's disease;
KIRP	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.51	-6.22	-0.37	2.16e-9	HDL cholesterol;
KIRP	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.83	-14.69	-0.68	1.73e-35	Post bronchodilator FEV1;
KIRP	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.5	-0.38	4.55e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12579753	0.692	rs9943807	chr12:82279404	T/A	cg07988820	chr12:82153109	PPFIA2	-0.45	-5.35	-0.32	1.99e-7	Resting heart rate;
KIRP	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	8.35	0.47	4.88e-15	Eosinophil percentage of white cells;
KIRP	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.84	0.49	1.89e-16	Prudent dietary pattern;
KIRP	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.11	-0.31	6.38e-7	Bipolar disorder;
KIRP	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.17	0.37	2.73e-9	Aortic root size;
KIRP	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg25319279	chr11:5960081	NA	-0.53	-5.55	-0.33	7.38e-8	DNA methylation (variation);
KIRP	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg27205649	chr11:78285834	NARS2	0.82	11.3	0.58	3.9e-24	Alzheimer's disease (survival time);
KIRP	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.34	-0.32	2.1e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg17554472	chr22:41940697	POLR3H	-0.67	-6.88	-0.4	4.98e-11	Vitiligo;
KIRP	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.81	-12.89	-0.63	2.23e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs7221595	0.825	rs12938597	chr17:3961200	C/T	cg09695851	chr17:3907499	NA	0.54	5.2	0.31	4.27e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	trans	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.16	-0.42	9.5e-12	Bladder cancer;
KIRP	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.08	-13.26	-0.65	1.2e-30	Vitiligo;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09933375	chr10:70481015	CCAR1	0.44	6.38	0.38	8.72e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.17	-0.37	2.79e-9	Response to antipsychotic treatment;
KIRP	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-5.32	-0.32	2.3e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-0.9	-12.04	-0.61	1.47e-26	Blood protein levels;
KIRP	cis	rs7630877	0.924	rs17691911	chr3:179632808	C/G	cg18765712	chr3:179670323	PEX5L	0.52	6.21	0.37	2.21e-9	Type 2 diabetes;
KIRP	cis	rs8079658	0.762	rs7211723	chr17:63854425	A/C	cg18091269	chr17:63822838	CCDC46	0.37	5.07	0.31	7.92e-7	Post bronchodilator FEV1;
KIRP	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg24998770	chr7:37888106	TXNDC3	0.46	6.15	0.36	3.18e-9	Alzheimer's disease (late onset);
KIRP	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.76	6.77	0.4	9.4e-11	Diabetic retinopathy;
KIRP	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg19197139	chr17:4613644	ARRB2	0.72	7.34	0.42	3.06e-12	Lymphocyte counts;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg17381798	chr2:1761308	NA	0.41	6.33	0.37	1.17e-9	Pancreatic cancer;
KIRP	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.62	-6.65	-0.39	1.93e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg04317338	chr11:64019027	PLCB3	0.55	6.54	0.39	3.45e-10	Platelet count;
KIRP	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg10144569	chr3:42726640	KBTBD5	0.5	5.59	0.34	6.12e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.15	12.71	0.63	8.56e-29	Uric acid levels;
KIRP	cis	rs10073892	0.830	rs10078945	chr5:101623086	T/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.35	0.38	1e-9	Cognitive decline (age-related);
KIRP	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg04166393	chr7:2884313	GNA12	0.43	5.77	0.35	2.33e-8	Height;
KIRP	cis	rs6546886	0.912	rs4073048	chr2:74302498	C/T	cg14702570	chr2:74259524	NA	-0.29	-5.62	-0.34	5.23e-8	Dialysis-related mortality;
KIRP	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg08668510	chr10:1095578	IDI1	0.8	5.57	0.33	6.7e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg13147721	chr7:65941812	NA	-0.91	-6.45	-0.38	5.87e-10	Diabetic kidney disease;
KIRP	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	11.29	0.58	4.17e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.49	5.94	0.35	9.7e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16294570	chr8:16858909	FGF20	-0.41	-6.07	-0.36	4.71e-9	Interleukin-4 levels;
KIRP	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.7	9.82	0.53	1.97e-19	Obesity-related traits;
KIRP	cis	rs7808935	0.672	rs38507	chr7:28021193	A/G	cg22168087	chr7:27702803	HIBADH	-0.66	-6.2	-0.37	2.41e-9	Prostate cancer;
KIRP	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg24060327	chr5:131705240	SLC22A5	-0.55	-6.95	-0.4	3.33e-11	Blood metabolite levels;
KIRP	cis	rs7833787	0.770	rs4921966	chr8:18698418	G/T	cg17701159	chr8:18705777	PSD3	-0.29	-5.02	-0.3	9.79e-7	Obesity-related traits;
KIRP	cis	rs684232	0.623	rs117314378	chr17:521672	C/T	cg15660573	chr17:549704	VPS53	-0.93	-13.85	-0.66	1.22e-32	Prostate cancer;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.43	-5.37	-0.32	1.79e-7	Longevity;Endometriosis;
KIRP	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.84	8.98	0.5	7.47e-17	Alzheimer's disease;
KIRP	cis	rs2963155	0.518	rs6196	chr5:142661490	A/G	cg17617527	chr5:142782415	NR3C1	0.76	7.79	0.45	1.83e-13	Breast cancer;
KIRP	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg14440974	chr22:39074834	NA	-0.38	-4.94	-0.3	1.44e-6	Menopause (age at onset);
KIRP	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23161317	chr6:28129485	ZNF389	0.48	5.77	0.35	2.33e-8	Depression;
KIRP	cis	rs17592366	0.838	rs12434654	chr14:35339046	T/C	cg09327582	chr14:35236912	BAZ1A	0.68	5.19	0.31	4.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs2307121	0.700	rs10065298	chr5:64712210	A/T	cg11190754	chr5:64858552	CENPK;PPWD1	0.42	5.33	0.32	2.26e-7	Corneal structure;
KIRP	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg14829360	chr17:73884958	NA	-0.47	-6.32	-0.37	1.19e-9	White matter hyperintensity burden;
KIRP	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-22.14	-0.82	1.77e-60	Exhaled nitric oxide output;
KIRP	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.43	-0.52	3.2e-18	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15348799	chr3:170075452	SKIL	0.49	6.14	0.36	3.21e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg05347473	chr6:146136440	FBXO30	-0.55	-7.67	-0.44	3.92e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.95	12.34	0.62	1.5e-27	Menopause (age at onset);
KIRP	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18110333	chr6:292329	DUSP22	-0.59	-6.92	-0.4	3.78e-11	Menopause (age at onset);
KIRP	cis	rs12620999	0.941	rs7593758	chr2:237980920	G/T	cg23555395	chr2:238036564	NA	-0.44	-5.24	-0.32	3.5e-7	Systemic lupus erythematosus;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11208039	chr11:19138753	ZDHHC13	0.52	6.05	0.36	5.46e-9	Smoking initiation;
KIRP	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg01649584	chr22:38516149	PLA2G6	-0.44	-6.06	-0.36	5.13e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg17279839	chr7:150038598	RARRES2	0.53	6.8	0.4	7.88e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-14.01	-0.67	3.5e-33	Blood trace element (Zn levels);
KIRP	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-9.36	-0.51	5.34e-18	Total body bone mineral density;
KIRP	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.27e-11	Blood pressure;
KIRP	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg21419209	chr3:44054225	NA	-0.71	-8.9	-0.49	1.28e-16	Coronary artery disease;
KIRP	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-8.78	-0.49	2.92e-16	Alzheimer's disease (survival time);
KIRP	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg05255149	chr17:80675120	FN3KRP	0.45	4.88	0.3	1.92e-6	Glycated hemoglobin levels;
KIRP	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.86	13.04	0.64	6.53e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.18	-0.37	2.65e-9	Schizophrenia;
KIRP	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg18357645	chr12:58087776	OS9	0.52	6.8	0.4	7.79e-11	Multiple sclerosis;
KIRP	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg23719950	chr11:63933701	MACROD1	-0.66	-6.18	-0.37	2.67e-9	Mean platelet volume;
KIRP	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.9	0.35	1.2e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg25427524	chr10:38739819	LOC399744	0.43	5.31	0.32	2.42e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.27e-15	Motion sickness;
KIRP	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.23	0.61	3.58e-27	Bone mineral density;
KIRP	cis	rs258892	0.895	rs13182583	chr5:72051575	C/T	cg21869765	chr5:72125136	TNPO1	-0.51	-5.92	-0.35	1.08e-8	Small cell lung carcinoma;
KIRP	cis	rs78487399	0.808	rs79271345	chr2:43746094	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-4.96	-0.3	1.31e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1978968	0.826	rs5992946	chr22:18466111	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.67	-7.25	-0.42	5.32e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs35740288	0.694	rs17618909	chr15:86095462	A/C	cg17133734	chr15:86042851	AKAP13	-0.49	-5.48	-0.33	1.04e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg05484376	chr2:27715224	FNDC4	0.33	5.12	0.31	6.2e-7	Total body bone mineral density;
KIRP	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.82	-9.53	-0.52	1.6e-18	Multiple sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10625578	chr3:49893964	TRAIP	0.59	7.4	0.43	2.1e-12	Parkinson's disease;
KIRP	cis	rs7106204	0.858	rs2403889	chr11:24210226	T/C	ch.11.24196551F	chr11:24239977	NA	0.8	9.34	0.51	6.16e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.55	7.13	0.41	1.11e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg02367723	chr1:46378857	MAST2	0.42	4.9	0.3	1.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs4349753	0.904	rs3909840	chr5:144172448	G/A	cg16033277	chr17:80885358	TBCD	0.41	6.29	0.37	1.46e-9	Photic sneeze reflex;
KIRP	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.34	-0.32	2.12e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.53	-7.64	-0.44	4.98e-13	Bipolar disorder;
KIRP	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.18	15.97	0.71	7.39e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.44	5.11	0.31	6.41e-7	Schizophrenia;
KIRP	cis	rs5995756	0.761	rs6001639	chr22:40003309	C/A	cg10455938	chr22:40058150	CACNA1I	-0.56	-8.42	-0.47	3.08e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25517755	chr10:38738941	LOC399744	-0.5	-6.99	-0.41	2.56e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2154427	0.872	rs80141393	chr21:34098304	C/T	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.67	-5.69	-0.34	3.68e-8	Bilirubin levels;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg13699009	chr12:122356056	WDR66	0.72	12.08	0.61	1.13e-26	Mean corpuscular volume;
KIRP	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.92	8.99	0.5	6.97e-17	Methadone dose in opioid dependence;
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.41	6.46	0.38	5.52e-10	Renal function-related traits (BUN);
KIRP	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg05768032	chr16:30646687	NA	-0.45	-5.72	-0.34	3.05e-8	Dementia with Lewy bodies;
KIRP	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.76	-5.23	-0.32	3.6e-7	Blood protein levels;
KIRP	cis	rs9426935	0.604	rs2790685	chr1:154025193	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.35	-5.22	-0.32	3.88e-7	Lentiform nucleus volume;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15750102	chr4:107237686	AIMP1;TBCK	-0.46	-6.17	-0.37	2.79e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg17279839	chr7:150038598	RARRES2	0.42	5.2	0.31	4.12e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10773046	0.740	rs1882489	chr12:124364441	T/A	cg18594669	chr12:124364423	DNAH10	0.39	5.35	0.32	2e-7	Osteoarthritis (hip);
KIRP	cis	rs4356932	0.691	rs6532078	chr4:76920809	A/G	cg00809888	chr4:76862425	NAAA	0.49	6.94	0.4	3.44e-11	Blood protein levels;
KIRP	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.71	9.42	0.51	3.41e-18	Cognitive function;
KIRP	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.53	6.7	0.39	1.44e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6772849	0.930	rs9868579	chr3:128351054	C/T	cg08795948	chr3:128337044	NA	-0.5	-6.36	-0.38	9.57e-10	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00149659	chr3:10157352	C3orf10	0.84	9.19	0.51	1.69e-17	Alzheimer's disease;
KIRP	cis	rs7766436	0.885	rs13198323	chr6:22577065	C/T	cg13666174	chr6:22585274	NA	-0.43	-5.88	-0.35	1.33e-8	Coronary artery disease;
KIRP	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.47	-7.85	-0.45	1.28e-13	Erythrocyte sedimentation rate;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00252408	chr1:98389381	NA	-0.44	-6.4	-0.38	7.77e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.71	8.03	0.46	4.11e-14	Height;
KIRP	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg21252483	chr19:49399788	TULP2	-0.56	-7.16	-0.42	9.36e-12	Red cell distribution width;
KIRP	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg11429664	chr15:91260578	BLM	0.52	6.08	0.36	4.55e-9	Menopause (age at onset);
KIRP	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.2	0.31	4.22e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20832448	chr3:36418645	NA	0.5	6.37	0.38	9e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg05791153	chr7:19748676	TWISTNB	0.66	6.05	0.36	5.43e-9	Thyroid stimulating hormone;
KIRP	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.47	0.56	1.82e-21	Hip circumference;
KIRP	cis	rs787274	1.000	rs700122	chr9:115551847	A/G	cg13803584	chr9:115635662	SNX30	-0.71	-6.21	-0.37	2.23e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.49	-6.88	-0.4	4.82e-11	Daytime sleep phenotypes;
KIRP	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg09795085	chr6:101329169	ASCC3	-0.5	-6.01	-0.36	6.74e-9	Neuroticism;
KIRP	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-8.32	-0.47	6.17e-15	Morning vs. evening chronotype;
KIRP	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg14061069	chr19:46274453	DMPK	0.67	11.63	0.6	3.3e-25	Coronary artery disease;
KIRP	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg21100191	chr22:23484243	RTDR1	0.83	11.16	0.58	1.12e-23	Bone mineral density;
KIRP	cis	rs3857747	0.759	rs34398005	chr7:40399535	C/A	cg00420559	chr7:40367873	C7orf10	0.66	8.48	0.48	2.14e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10580397	chr3:23331228	UBE2E2	-0.4	-6.82	-0.4	7.02e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26002218	chr14:103986227	CKB	0.27	5.37	0.32	1.82e-7	Body mass index;
KIRP	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.5	-5.91	-0.35	1.16e-8	Bone mineral density;
KIRP	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.49	-0.65	1.97e-31	Tonsillectomy;
KIRP	trans	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.06	0.36	5.04e-9	Mean corpuscular volume;
KIRP	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-4.88	-0.3	1.9e-6	Testicular germ cell tumor;
KIRP	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.66	7.56	0.43	7.89e-13	Orofacial clefts;
KIRP	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg18646521	chr2:111875858	NA	0.36	5.11	0.31	6.32e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16447950	chr5:562315	NA	-0.47	-5.65	-0.34	4.45e-8	Obesity-related traits;
KIRP	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.35	-4.9	-0.3	1.71e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	0.76	7.97	0.45	5.94e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg05938607	chr10:60274200	BICC1	0.41	10.01	0.54	5.21e-20	Refractive error;
KIRP	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	-0.58	-6.72	-0.39	1.24e-10	IgG glycosylation;
KIRP	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-5.74	-0.34	2.71e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.53	5.42	0.33	1.4e-7	Height;
KIRP	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.72	10.18	0.54	1.49e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.76	7.79	0.44	1.91e-13	Uric acid levels;
KIRP	trans	rs4908760	0.899	rs6577496	chr1:8581227	C/A	cg04109822	chr20:50158057	NFATC2	0.36	6.01	0.36	6.49e-9	Vitiligo;
KIRP	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg10117171	chr1:25599238	RHD	0.4	5.41	0.33	1.5e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs988913	0.723	rs7761568	chr6:55005426	C/A	cg03513858	chr6:54763001	FAM83B	0.39	5.49	0.33	9.96e-8	Menarche (age at onset);
KIRP	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.75	-8.75	-0.49	3.4e-16	Longevity;
KIRP	cis	rs4409675	1.000	rs4313418	chr1:28255308	C/A	cg23691781	chr1:28212827	C1orf38	-0.32	-6.54	-0.38	3.6e-10	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2625529	0.824	rs12901886	chr15:72408069	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-6.07	-0.36	4.86e-9	Red blood cell count;
KIRP	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg26022315	chr17:47021804	SNF8	0.42	5.4	0.33	1.54e-7	Type 2 diabetes;
KIRP	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg18306943	chr3:40428807	ENTPD3	0.44	5.71	0.34	3.19e-8	Renal cell carcinoma;
KIRP	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg00361562	chr2:198649771	BOLL	-0.51	-4.92	-0.3	1.55e-6	Ulcerative colitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05019396	chr2:170870146	UBR3	-0.5	-7.17	-0.42	8.75e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.15	-0.5	2.3e-17	Personality dimensions;
KIRP	cis	rs13132184	0.507	rs933821	chr4:38026389	C/T	cg14409701	chr4:38048871	TBC1D1	-0.8	-7.51	-0.43	1.1e-12	Verbal declarative memory;
KIRP	cis	rs7719624	0.967	rs10463536	chr5:135362682	T/C	cg16684184	chr5:135415129	NA	0.34	5.14	0.31	5.67e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-7.56	-0.43	8.16e-13	Height;
KIRP	cis	rs6832769	1.000	rs9998146	chr4:56397977	C/T	cg05960024	chr4:56376020	CLOCK	-0.72	-9.24	-0.51	1.23e-17	Personality dimensions;
KIRP	cis	rs860295	0.580	rs867549	chr1:155880159	T/C	cg02153340	chr1:155202674	NA	-0.38	-4.88	-0.3	1.92e-6	Body mass index;
KIRP	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	6.31	0.37	1.29e-9	Menarche (age at onset);
KIRP	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	cg12689670	chr1:183009347	LAMC1	0.44	6.31	0.37	1.28e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg00204512	chr16:28754710	NA	0.43	5.39	0.32	1.65e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.77	8.6	0.48	9.41e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg07701084	chr6:150067640	NUP43	0.61	7.79	0.45	1.82e-13	Lung cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14935078	chr19:17414399	ABHD8	-0.51	-6.92	-0.4	3.87e-11	Myopia;
KIRP	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14163061	chr2:44223239	LRPPRC	0.46	6.39	0.38	8.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	1.0	17.43	0.74	7.3e-45	Breast cancer;
KIRP	cis	rs2273669	0.588	rs79465564	chr6:109350290	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	trans	rs9944715	0.911	rs7230995	chr18:43786822	G/A	cg01718231	chr17:29326311	RNF135	-0.51	-6.19	-0.37	2.53e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.78	-11.57	-0.59	5.44e-25	Height;
KIRP	cis	rs9603616	0.719	rs4492929	chr13:40237911	G/A	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg17644776	chr2:200775616	C2orf69	-0.6	-6.62	-0.39	2.25e-10	Schizophrenia;
KIRP	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-10.04	-0.54	4.32e-20	Total body bone mineral density;
KIRP	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.44	-15.64	-0.71	9.48e-39	Schizophrenia;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg23300368	chr8:68864908	PREX2	0.44	6.07	0.36	4.77e-9	Coronary artery disease;
KIRP	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg08890418	chr1:21044141	KIF17	0.34	5.14	0.31	5.48e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.89	12.13	0.61	7.25e-27	Ulcerative colitis;
KIRP	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg04087571	chr11:116723030	SIK3	0.26	5.56	0.33	6.84e-8	Subjective well-being;
KIRP	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.6	-9.46	-0.52	2.63e-18	C-reactive protein levels;
KIRP	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	11.54	0.59	6.79e-25	Total body bone mineral density;
KIRP	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg03060546	chr3:49711283	APEH	-0.73	-5.95	-0.35	9.16e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg25173405	chr17:45401733	C17orf57	0.51	6.66	0.39	1.79e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg17145862	chr1:211918768	LPGAT1	0.61	6.81	0.4	7.59e-11	Crohn's disease;
KIRP	cis	rs4903214	0.895	rs10130040	chr14:74713682	A/C	cg08255017	chr14:74727001	VSX2	-0.45	-5.79	-0.35	2.18e-8	Inflammatory bowel disease;
KIRP	cis	rs17253792	0.545	rs34719936	chr14:56015134	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.35	0.32	2.05e-7	Putamen volume;
KIRP	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg22029157	chr1:209979665	IRF6	0.39	5.98	0.36	7.66e-9	Monobrow;
KIRP	cis	rs7027203	0.576	rs7874836	chr9:96559370	C/T	cg14598338	chr9:96623480	NA	-0.49	-7.5	-0.43	1.14e-12	DNA methylation (variation);
KIRP	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.9	-0.3	1.72e-6	Pulmonary function;
KIRP	cis	rs7572644	0.662	rs12465103	chr2:28199736	G/C	cg27432699	chr2:27873401	GPN1	-0.44	-5.28	-0.32	2.83e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.62	-7.57	-0.43	7.32e-13	Waist circumference;Body mass index;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg15877295	chr7:138915876	UBN2	0.45	6.17	0.37	2.82e-9	Ischemic stroke;
KIRP	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.61	-7.42	-0.43	1.9e-12	Cognitive test performance;
KIRP	cis	rs10411262	0.935	rs314666	chr19:47176825	T/C	cg13467550	chr19:47212573	PRKD2	0.39	5.77	0.35	2.33e-8	Tonsillectomy;
KIRP	cis	rs7737355	0.947	rs6864145	chr5:130637861	C/T	cg06647332	chr5:131281008	NA	0.47	5.16	0.31	5.13e-7	Life satisfaction;
KIRP	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg27356188	chr5:637386	CEP72	0.37	4.85	0.3	2.24e-6	Obesity-related traits;
KIRP	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.8	8.82	0.49	2.13e-16	Bipolar disorder;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg27144592	chr16:783916	NARFL	0.37	5.13	0.31	5.89e-7	Height;
KIRP	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.48	5.97	0.36	8.15e-9	Height;
KIRP	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	0.99	13.27	0.65	1.09e-30	Neutrophil percentage of white cells;
KIRP	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.67	-8.72	-0.49	4.14e-16	Hypospadias;
KIRP	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.64	8.01	0.45	4.5e-14	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg01689657	chr7:91764605	CYP51A1	-0.38	-5.52	-0.33	8.74e-8	Breast cancer;
KIRP	cis	rs526231	0.511	rs3910557	chr5:102350471	T/A	cg23492399	chr5:102201601	PAM	-0.45	-5.04	-0.31	9.02e-7	Primary biliary cholangitis;
KIRP	cis	rs62344088	1.000	rs73022563	chr5:140813	G/T	cg22857025	chr5:266934	NA	-0.74	-5.02	-0.3	9.92e-7	Asthma (childhood onset);
KIRP	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.48	6.46	0.38	5.54e-10	Dupuytren's disease;
KIRP	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.11	23.11	0.83	1.38e-63	Testicular germ cell tumor;
KIRP	cis	rs7463659	0.512	rs7840196	chr8:135449371	A/C	cg13434034	chr8:135477110	NA	-0.46	-5.91	-0.35	1.15e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9840812	0.598	rs33999043	chr3:136100040	G/A	cg15507776	chr3:136538369	TMEM22	0.48	5.1	0.31	6.77e-7	Fibrinogen levels;
KIRP	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.83	-12.13	-0.61	7.26e-27	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-1.02	-11.97	-0.61	2.51e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.82	11.32	0.59	3.52e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8103278	0.793	rs59093775	chr19:46374037	G/A	cg11657440	chr19:46296263	DMWD	-0.54	-6.32	-0.37	1.19e-9	Coronary artery disease;
KIRP	cis	rs9583531	0.760	rs9521916	chr13:111385509	A/G	cg24331049	chr13:111365604	ING1	-0.68	-6.38	-0.38	8.94e-10	Coronary artery disease;
KIRP	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.06	-0.41	1.74e-11	Eye color traits;
KIRP	cis	rs2505998	1.000	rs1864410	chr10:43575625	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-5.21	-0.32	3.97e-7	Hirschsprung disease;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg15112475	chr7:1198522	ZFAND2A	0.43	4.94	0.3	1.45e-6	Longevity;Endometriosis;
KIRP	cis	rs7980687	0.527	rs1626703	chr12:123710835	A/C	cg05973401	chr12:123451056	ABCB9	0.63	7.34	0.42	3.09e-12	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.65	7.75	0.44	2.39e-13	Smoking initiation;
KIRP	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	1.23	12.74	0.63	6.73e-29	Red blood cell traits;
KIRP	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.11	0.61	8.95e-27	Blood protein levels;
KIRP	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg08885076	chr2:99613938	TSGA10	-0.42	-6.4	-0.38	7.63e-10	Fear of minor pain;
KIRP	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg16497661	chr14:103986332	CKB	0.38	4.91	0.3	1.69e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6662572	0.737	rs56316933	chr1:46266725	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.19	0.31	4.43e-7	Blood protein levels;
KIRP	cis	rs10858047	0.831	rs11102826	chr1:115181607	T/A	cg12756093	chr1:115239321	AMPD1	-0.67	-6.46	-0.38	5.42e-10	Autism;
KIRP	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.51	-11.28	-0.58	4.73e-24	Diabetic kidney disease;
KIRP	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.56	5.08	0.31	7.42e-7	Major depressive disorder;
KIRP	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg19025524	chr12:109796872	NA	-0.59	-8.45	-0.47	2.58e-15	Neuroticism;
KIRP	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4356975	0.563	rs6858558	chr4:69969543	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.34	0.32	2.09e-7	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.45	-5.71	-0.34	3.17e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10276623	chr14:94770592	SERPINA6	0.5	6.26	0.37	1.68e-9	Interleukin-4 levels;
KIRP	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-6.1	-0.36	3.98e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2115630	0.764	rs11073716	chr15:85335774	C/T	cg12501888	chr15:85177176	SCAND2	-0.38	-4.87	-0.3	1.97e-6	P wave terminal force;
KIRP	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg19338460	chr6:170058176	WDR27	-0.66	-7.7	-0.44	3.27e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg20813462	chr7:2646259	IQCE	0.66	6.25	0.37	1.79e-9	Urate levels in lean individuals;
KIRP	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg00405596	chr8:11794950	NA	0.51	6.79	0.4	8.22e-11	Mood instability;
KIRP	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg04865290	chr3:52927548	TMEM110	-0.41	-5.24	-0.32	3.4e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7845219	0.525	rs7820818	chr8:95919231	G/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.17	-0.37	2.73e-9	Type 2 diabetes;
KIRP	cis	rs12210905	1.000	rs9379970	chr6:27255231	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.8	-5.91	-0.35	1.12e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9653442	0.564	rs2309756	chr2:100780269	G/C	cg17356467	chr2:100759845	AFF3	0.42	5.39	0.33	1.61e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.36	-5.49	-0.33	1e-7	Body mass index;
KIRP	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.45	5.87	0.35	1.43e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.06	0.36	4.96e-9	Iron status biomarkers;
KIRP	cis	rs76917914	0.820	rs12554583	chr9:100812569	A/G	cg03040243	chr9:100819229	NANS	0.62	6.42	0.38	7.16e-10	Immature fraction of reticulocytes;
KIRP	cis	rs282587	0.569	rs7982564	chr13:113398930	G/A	cg04656015	chr13:113407548	ATP11A	0.6	6.88	0.4	4.86e-11	Glycated hemoglobin levels;
KIRP	cis	rs7404928	0.645	rs4592664	chr16:23890735	C/T	cg21745164	chr16:23765304	CHP2	0.6	6.94	0.4	3.47e-11	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs9596863	1.000	rs9568948	chr13:54437693	A/C	ch.13.53330881F	chr13:54432880	NA	0.68	6.92	0.4	3.98e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.23	-0.32	3.58e-7	Neutrophil percentage of white cells;
KIRP	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.46e-19	Colorectal cancer;
KIRP	cis	rs9653442	0.564	rs2164711	chr2:100775422	G/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg25547332	chr5:131281432	NA	0.48	5.37	0.32	1.84e-7	Life satisfaction;
KIRP	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg17182837	chr8:41585554	ANK1	-0.45	-6.32	-0.37	1.2e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg24476569	chr13:95954382	ABCC4	-0.59	-9.17	-0.5	2.02e-17	Blood metabolite levels;
KIRP	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg08501292	chr6:25962987	TRIM38	0.91	6.48	0.38	5.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7903847	0.642	rs9888026	chr10:99159869	G/T	cg20016023	chr10:99160130	RRP12	0.42	5.74	0.34	2.71e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7127900	0.583	rs71455921	chr11:2233635	A/C	cg25635251	chr11:2234043	NA	0.43	6.85	0.4	5.78e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs6835098	0.692	rs10520252	chr4:174070959	T/C	cg08422745	chr4:174089978	GALNT7	-0.7	-9.29	-0.51	8.56e-18	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs2904967	0.703	rs239257	chr11:64989071	G/A	cg12562828	chr11:65076843	NA	-0.74	-9.03	-0.5	5.09e-17	Mean corpuscular volume;
KIRP	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg15128208	chr22:42549153	NA	0.76	8.19	0.46	1.44e-14	Birth weight;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg08805041	chr16:621841	PIGQ	-0.39	-5.26	-0.32	3.09e-7	Height;
KIRP	cis	rs6032067	0.704	rs62205505	chr20:43874856	C/T	cg10761708	chr20:43804764	PI3	0.53	5.42	0.33	1.45e-7	Blood protein levels;
KIRP	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.71	-8.92	-0.49	1.1e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.45	-6.18	-0.37	2.68e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg00802000	chr16:706648	WDR90	-0.4	-5.09	-0.31	7.24e-7	Height;
KIRP	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.18	-0.54	1.54e-20	Response to antipsychotic treatment;
KIRP	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg06598544	chr20:61472147	COL9A3	-0.83	-6.62	-0.39	2.17e-10	Obesity-related traits;
KIRP	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.53	7.97	0.45	5.81e-14	Testicular germ cell tumor;
KIRP	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.69	8.06	0.46	3.32e-14	Cocaine dependence;
KIRP	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg13385521	chr17:29058706	SUZ12P	0.78	6.34	0.37	1.07e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9381040	1.000	rs9394767	chr6:41159905	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.64	-6.77	-0.4	9.33e-11	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg15436174	chr10:43711423	RASGEF1A	0.82	9.03	0.5	5.29e-17	Hirschsprung disease;
KIRP	cis	rs8012145	0.543	rs61976999	chr14:55186948	A/G	cg19913537	chr14:55186044	SAMD4A	0.32	4.93	0.3	1.5e-6	Plateletcrit;
KIRP	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.7	-10.74	-0.57	2.54e-22	Hepatocellular carcinoma;
KIRP	cis	rs28530674	1.000	rs1009971	chr1:19222020	A/G	cg26407146	chr1:19229049	ALDH4A1	1.02	7.42	0.43	1.85e-12	Eosinophilic esophagitis;
KIRP	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs7084783	0.500	rs9521	chr10:105358458	C/G	cg00126946	chr10:105363258	SH3PXD2A	-0.38	-4.98	-0.3	1.22e-6	Fear of pain;
KIRP	cis	rs10102274	1.000	rs80105881	chr8:91728835	C/T	cg16814680	chr8:91681699	NA	-0.81	-4.88	-0.3	1.92e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs554111	0.656	rs10753514	chr1:21492531	T/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.5	-0.38	4.5e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.76	-10.06	-0.54	3.55e-20	Dental caries;
KIRP	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.67	-0.44	4.03e-13	Response to antipsychotic treatment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14886640	chr14:50103224	C14orf104	-0.48	-7.36	-0.42	2.79e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10683054	chr6:132129037	ENPP1	0.49	6.27	0.37	1.6e-9	Parkinson's disease;
KIRP	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	10.15	0.54	1.88e-20	Exhaled nitric oxide levels;
KIRP	cis	rs883565	0.569	rs7613766	chr3:39152248	C/G	cg01426195	chr3:39028469	NA	-0.53	-8.34	-0.47	5.43e-15	Handedness;
KIRP	trans	rs13170463	0.579	rs4293881	chr5:8051611	T/C	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs113084984	0.718	rs4669747	chr2:11684315	C/T	cg07314298	chr2:11723111	GREB1	0.39	5.04	0.31	9.23e-7	Breast cancer;
KIRP	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.46	5.37	0.32	1.83e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	10.97	0.57	4.79e-23	Alzheimer's disease;
KIRP	cis	rs73206853	0.764	rs68087637	chr12:110619797	T/C	cg12870014	chr12:110450643	ANKRD13A	0.54	5.9	0.35	1.22e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs7215564	0.818	rs35059200	chr17:78661619	T/C	cg06153925	chr17:78755379	RPTOR	0.3	4.93	0.3	1.51e-6	Myopia (pathological);
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs6577655	0.517	rs2315835	chr8:135589854	A/G	cg17885191	chr8:135476712	NA	0.67	6.53	0.38	3.77e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs925255	0.713	rs9309662	chr2:28629892	A/G	cg01273330	chr2:28605224	NA	0.34	5.8	0.35	2e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs17023223	0.537	rs2794312	chr1:119591046	C/T	cg05756136	chr1:119680316	WARS2	-0.56	-7.64	-0.44	4.86e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg15226275	chr6:116381976	FRK	0.23	6.15	0.36	3.18e-9	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg05926928	chr17:57297772	GDPD1	-0.79	-7.53	-0.43	9.39e-13	Opioid sensitivity;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg06636001	chr8:8085503	FLJ10661	0.6	8.04	0.46	3.81e-14	Myopia (pathological);
KIRP	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs921943	1.000	rs3797538	chr5:78322671	A/G	cg26802063	chr5:78281964	ARSB	0.49	6.1	0.36	4.13e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.76	-9.76	-0.53	3.23e-19	Gut microbiome composition (winter);
KIRP	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg12560992	chr17:57184187	TRIM37	0.69	6.37	0.38	9.41e-10	Cognitive test performance;
KIRP	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.93e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg03714773	chr7:91764589	CYP51A1	0.4	5.81	0.35	1.9e-8	Breast cancer;
KIRP	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg19899395	chr1:46959349	NA	0.39	4.99	0.3	1.15e-6	Monobrow;
KIRP	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.76	9.02	0.5	5.61e-17	Platelet count;
KIRP	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.47e-13	Bipolar disorder;
KIRP	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	14.7	0.68	1.54e-35	Chronic sinus infection;
KIRP	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg21366198	chr4:185655624	MLF1IP	0.49	6.5	0.38	4.42e-10	Kawasaki disease;
KIRP	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.74	-9.67	-0.52	6.01e-19	Prudent dietary pattern;
KIRP	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg10852876	chr4:165953100	TRIM60	-0.46	-4.99	-0.3	1.14e-6	Obesity-related traits;
KIRP	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.3	-0.42	3.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg04132472	chr17:19861366	AKAP10	-0.4	-5.2	-0.31	4.29e-7	Schizophrenia;
KIRP	trans	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg01620082	chr3:125678407	NA	-1.01	-6.02	-0.36	6.31e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.59	-8.23	-0.46	1.1e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.23	-0.32	3.63e-7	Life satisfaction;
KIRP	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.95e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.82	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.68	-11.95	-0.61	2.94e-26	Neuroticism;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09567642	chr5:70751435	BDP1	1.03	6.31	0.37	1.26e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs7084402	0.967	rs1658425	chr10:60331547	G/C	cg05938607	chr10:60274200	BICC1	-0.37	-8.68	-0.48	5.51e-16	Refractive error;
KIRP	cis	rs7106204	0.609	rs12791360	chr11:24286239	T/G	ch.11.24196551F	chr11:24239977	NA	0.78	6.78	0.4	9.01e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs742115	0.563	rs7762842	chr6:11303695	G/A	cg25250968	chr6:11318770	NEDD9	-0.41	-5.95	-0.35	9.24e-9	Coronary artery disease;
KIRP	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.75	-10.77	-0.57	2.06e-22	Waist circumference;Body mass index;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.71	-6.14	-0.36	3.37e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.95	0.35	9.03e-9	Total cholesterol levels;
KIRP	cis	rs10089	0.552	rs56718459	chr5:127546214	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.6	0.48	9.64e-16	Ileal carcinoids;
KIRP	cis	rs12549025	0.530	rs28656888	chr8:23266209	C/T	cg00472375	chr8:23315376	ENTPD4	0.58	6.88	0.4	5.02e-11	Reticulocyte fraction of red cells;
KIRP	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23161317	chr6:28129485	ZNF389	-0.42	-5.0	-0.3	1.09e-6	Depression;
KIRP	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-6.65	-0.39	1.84e-10	Urinary tract infection frequency;
KIRP	trans	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.5	0.38	4.32e-10	Neuroticism;
KIRP	cis	rs4566357	1.000	rs7567789	chr2:227922104	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.04	-0.31	9.03e-7	Coronary artery disease;
KIRP	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg25600027	chr14:23388339	RBM23	-0.52	-6.43	-0.38	6.42e-10	Cognitive ability (multi-trait analysis);
KIRP	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.71	-0.39	1.3e-10	Myopia (pathological);
KIRP	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.73	8.82	0.49	2.11e-16	Corneal astigmatism;
KIRP	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.53	-15.52	-0.7	2.55e-38	Hip circumference adjusted for BMI;
KIRP	trans	rs12408261	0.525	rs1912923	chr1:189021988	A/G	cg15739309	chr8:1711235	CLN8	0.48	6.26	0.37	1.75e-9	Number of pregnancies;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17339956	chr3:44283355	C3orf77	0.52	6.9	0.4	4.5e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.61	-8.09	-0.46	2.67e-14	Smoking behavior;
KIRP	cis	rs6466055	0.661	rs7782673	chr7:104917508	G/C	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	6.96e-7	Schizophrenia;
KIRP	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg26248373	chr2:1572462	NA	-0.8	-10.84	-0.57	1.22e-22	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg09165964	chr15:75287851	SCAMP5	0.48	6.31	0.37	1.26e-9	Breast cancer;
KIRP	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg06115741	chr20:33292138	TP53INP2	0.45	5.74	0.34	2.73e-8	Coronary artery disease;
KIRP	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg13047869	chr3:10149882	C3orf24	0.56	5.48	0.33	1.04e-7	Alzheimer's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16522462	chr20:1875565	SIRPA	-0.44	-6.2	-0.37	2.38e-9	Metabolic traits;
KIRP	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg19875535	chr5:140030758	IK	0.64	9.0	0.5	6.19e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10267417	0.535	rs4275125	chr7:19911004	A/G	cg05791153	chr7:19748676	TWISTNB	0.5	5.14	0.31	5.58e-7	Night sleep phenotypes;
KIRP	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.53	-6.58	-0.39	2.85e-10	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	cg12689670	chr1:183009347	LAMC1	0.44	6.28	0.37	1.51e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	9.55	0.52	1.35e-18	Educational attainment;
KIRP	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg13482628	chr17:19912719	NA	-0.53	-6.93	-0.4	3.59e-11	Schizophrenia;
KIRP	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.61	-0.39	2.38e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs28834970	0.928	rs17057043	chr8:27220310	C/T	cg21186296	chr8:27182909	PTK2B	-0.42	-5.36	-0.32	1.96e-7	Alzheimer's disease (late onset);
KIRP	trans	rs2997105	1.000	rs9597260	chr13:56346286	G/A	cg08528735	chr3:184428879	MAGEF1	0.56	6.24	0.37	1.85e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg08890418	chr1:21044141	KIF17	0.71	10.28	0.55	7.41e-21	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg00806126	chr19:22604979	ZNF98	0.66	6.78	0.4	8.79e-11	Pain;
KIRP	trans	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg25214090	chr10:38739885	LOC399744	0.49	6.15	0.37	3.07e-9	Diastolic blood pressure;
KIRP	cis	rs16858210	0.874	rs6792309	chr3:183607661	C/T	cg01324343	chr3:183735012	ABCC5	0.4	5.28	0.32	2.89e-7	Menopause (age at onset);
KIRP	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.96	0.45	6.19e-14	Coffee consumption (cups per day);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg07254608	chr8:41997973	NA	-0.5	-6.51	-0.38	4.22e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07702853	chr1:150254280	C1orf51	0.56	7.03	0.41	2.02e-11	Parkinson's disease;
KIRP	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg08533674	chr1:46993347	NA	0.39	4.98	0.3	1.2e-6	Monobrow;
KIRP	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.54	-6.83	-0.4	6.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.71	-10.45	-0.55	2.11e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-4.95	-0.3	1.37e-6	IgG glycosylation;
KIRP	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.78	11.7	0.6	1.96e-25	Multiple myeloma (IgH translocation);
KIRP	cis	rs1678542	0.679	rs775251	chr12:57978740	A/G	cg00677455	chr12:58241039	CTDSP2	0.57	6.52	0.38	3.9e-10	Rheumatoid arthritis;
KIRP	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg16306078	chr6:126000798	NA	0.26	4.87	0.3	2.04e-6	Endometrial cancer;
KIRP	trans	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-7.03	-0.41	2.02e-11	Obesity-related traits;
KIRP	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05192639	chr6:26864778	GUSBL1	-0.23	-4.9	-0.3	1.72e-6	Educational attainment;
KIRP	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg01620082	chr3:125678407	NA	-1.15	-7.44	-0.43	1.65e-12	Depression;
KIRP	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg23950597	chr19:37808831	NA	-0.69	-6.17	-0.37	2.85e-9	Coronary artery calcification;
KIRP	cis	rs6580083	1.000	rs6580083	chr5:153865729	A/G	cg21964928	chr5:153872958	NA	0.41	5.5	0.33	9.46e-8	QRS duration;
KIRP	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg15556689	chr8:8085844	FLJ10661	0.43	5.58	0.34	6.21e-8	Mood instability;
KIRP	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.65	-5.93	-0.35	1.02e-8	Height;
KIRP	cis	rs7221595	0.825	rs62072392	chr17:3910125	A/G	cg21734707	chr17:3908241	ZZEF1	0.53	4.91	0.3	1.64e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg04607699	chr11:48328132	OR4S1	-0.33	-4.85	-0.3	2.2e-6	Height;
KIRP	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.66	-9.16	-0.5	2.09e-17	Plateletcrit;Platelet count;
KIRP	cis	rs853679	0.527	rs213228	chr6:28331252	A/C	cg09682330	chr6:28411287	ZSCAN23	-0.4	-4.91	-0.3	1.7e-6	Depression;
KIRP	cis	rs9535307	0.929	rs4942863	chr13:50314408	T/C	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.8.1136903F	chr8:51469395	SNTG1	0.51	7.22	0.42	6.33e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18879177	chr6:105854768	NA	0.47	6.89	0.4	4.66e-11	Survival in pancreatic cancer;
KIRP	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.75	-8.97	-0.5	7.63e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.83	-0.35	1.73e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22857025	chr5:266934	NA	-0.73	-6.42	-0.38	6.84e-10	Asthma (childhood onset);
KIRP	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg22437258	chr11:111473054	SIK2	0.63	7.68	0.44	3.81e-13	Primary sclerosing cholangitis;
KIRP	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.61	-7.67	-0.44	3.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7923609	0.869	rs9971352	chr10:65265108	A/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.14	-0.36	3.35e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.59	-0.48	1.04e-15	Response to antipsychotic treatment;
KIRP	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg16296679	chr22:42394374	WBP2NL	0.36	4.99	0.3	1.15e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.92	-13.94	-0.66	6.29e-33	Monocyte count;
KIRP	cis	rs6807915	0.603	rs9823123	chr3:12288569	A/C	cg02700894	chr3:12045449	SYN2	-0.43	-5.96	-0.36	8.66e-9	Leprosy;
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg05861140	chr6:150128134	PCMT1	0.45	6.35	0.38	1.01e-9	Lung cancer;
KIRP	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg02811702	chr13:24901961	NA	0.43	5.55	0.33	7.24e-8	Obesity-related traits;
KIRP	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.85	12.77	0.63	5.42e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	1.13	10.33	0.55	5.21e-21	Lymphocyte counts;
KIRP	cis	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg02972257	chr16:68554789	NA	-0.57	-6.01	-0.36	6.56e-9	Ulcerative colitis;
KIRP	cis	rs4908768	0.596	rs4908516	chr1:8879610	G/C	cg25722041	chr1:8623473	RERE	0.76	7.86	0.45	1.22e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs2625529	0.652	rs12148078	chr15:72300471	G/C	cg16672083	chr15:72433130	SENP8	0.46	6.43	0.38	6.55e-10	Red blood cell count;
KIRP	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	1.1	17.84	0.75	3.08e-46	Cognitive function;
KIRP	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.94	11.02	0.57	3.32e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.62	9.17	0.5	1.89e-17	Total body bone mineral density;
KIRP	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.35	-0.32	1.97e-7	Neuroticism;
KIRP	cis	rs394563	0.591	rs237029	chr6:149717425	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.33	-5.37	-0.32	1.86e-7	Dupuytren's disease;
KIRP	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg16988262	chr1:15930761	NA	0.38	4.86	0.3	2.09e-6	Systolic blood pressure;
KIRP	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.7	8.96	0.5	8.55e-17	Morning vs. evening chronotype;
KIRP	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg12405258	chr13:114927641	NA	-0.45	-6.52	-0.38	3.96e-10	Schizophrenia;
KIRP	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg21361702	chr7:150065534	REPIN1	0.58	5.72	0.34	3.13e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21747090	chr2:27597821	SNX17	-0.47	-6.59	-0.39	2.7e-10	Total body bone mineral density;
KIRP	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.78	9.85	0.53	1.65e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.51	-6.6	-0.39	2.52e-10	Height;
KIRP	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.4	-5.59	-0.34	5.91e-8	Height;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg27532560	chr4:187881888	NA	-0.76	-13.13	-0.64	3.47e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34779708	0.931	rs67976880	chr10:35372261	G/C	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-7.14	-0.41	1.08e-11	Recalcitrant atopic dermatitis;
KIRP	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.67	7.33	0.42	3.29e-12	Blood pressure (smoking interaction);
KIRP	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.4	9.16e-11	Red blood cell count;
KIRP	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.15	11.22	0.58	7.27e-24	Alzheimer's disease (late onset);
KIRP	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.57	7.75	0.44	2.42e-13	Prostate cancer;
KIRP	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.09	12.24	0.62	3.11e-27	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg07636037	chr3:49044803	WDR6	-0.55	-5.06	-0.31	8.26e-7	Menarche (age at onset);
KIRP	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg09238746	chr17:78121135	EIF4A3	0.47	5.74	0.34	2.71e-8	Yeast infection;
KIRP	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-5.71	-0.34	3.16e-8	Response to antipsychotic treatment;
KIRP	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.49	5.66	0.34	4.19e-8	Metabolite levels;
KIRP	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg17376030	chr22:41985996	PMM1	0.53	5.91	0.35	1.16e-8	Vitiligo;
KIRP	trans	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg25042112	chr7:64838748	ZNF92	0.58	6.08	0.36	4.45e-9	Pain;
KIRP	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg13266496	chr6:110720918	DDO	-0.35	-5.63	-0.34	4.88e-8	Platelet distribution width;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12580194	0.593	rs7313465	chr12:55736863	C/T	cg19537932	chr12:55886519	OR6C68	-0.48	-6.34	-0.37	1.12e-9	Cancer;
KIRP	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.81	7.95	0.45	6.87e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6793245	0.810	rs7429945	chr3:38591689	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.49	-6.2	-0.37	2.42e-9	QT interval;
KIRP	cis	rs7674212	0.512	rs2720462	chr4:104056210	T/G	cg16532752	chr4:104119610	CENPE	-0.42	-5.06	-0.31	8.29e-7	Type 2 diabetes;
KIRP	cis	rs2408955	0.561	rs11168365	chr12:48421772	A/G	cg21466736	chr12:48725269	NA	0.39	4.92	0.3	1.57e-6	Glycated hemoglobin levels;
KIRP	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg21775007	chr8:11205619	TDH	-0.4	-5.05	-0.31	8.49e-7	Triglycerides;
KIRP	cis	rs6834538	0.597	rs1486865	chr4:113465651	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.44	5.33	0.32	2.25e-7	Free thyroxine concentration;
KIRP	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg04310649	chr10:35416472	CREM	-0.58	-7.07	-0.41	1.6e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.32	5.18	0.31	4.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21147944	chr13:114264438	TFDP1	-0.42	-6.14	-0.36	3.26e-9	Inflammatory biomarkers;
KIRP	cis	rs17331151	0.505	rs7644763	chr3:52546487	C/T	cg04865290	chr3:52927548	TMEM110	0.55	4.84	0.3	2.27e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.63	-0.63	1.58e-28	Electrocardiographic conduction measures;
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.69	-9.9	-0.53	1.13e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg23803603	chr1:2058230	PRKCZ	-0.42	-6.0	-0.36	7.17e-9	Height;
KIRP	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.58	7.64	0.44	4.96e-13	White matter hyperintensity burden;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.06	0.46	3.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg02951883	chr7:2050386	MAD1L1	0.52	5.86	0.35	1.47e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs12282928	1.000	rs4752923	chr11:48288155	A/G	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.85	12.54	0.62	3.28e-28	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24422927	chr21:38640288	DSCR3	0.54	7.08	0.41	1.51e-11	Parkinson's disease;
KIRP	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg00504896	chr12:9437009	LOC642846	-0.51	-6.33	-0.37	1.18e-9	Breast size;
KIRP	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.74	-0.34	2.82e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.42	-0.47	3.18e-15	Mood instability;
KIRP	cis	rs35995292	0.963	rs2893567	chr7:38902934	A/G	cg19327137	chr7:38886074	VPS41	0.53	6.43	0.38	6.69e-10	Subjective well-being (multi-trait analysis);
KIRP	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.59	-11.43	-0.59	1.51e-24	Cancer (pleiotropy);
KIRP	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg20578329	chr17:80767326	TBCD	-0.48	-5.73	-0.34	2.94e-8	Glycated hemoglobin levels;
KIRP	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg12963246	chr6:28129442	ZNF389	0.51	6.24	0.37	1.85e-9	Depression;
KIRP	cis	rs55788414	0.932	rs4365300	chr16:81184460	C/T	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.78	0.35	2.2e-8	Total cholesterol levels;
KIRP	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg24579218	chr15:68104479	NA	-0.54	-8.56	-0.48	1.28e-15	Restless legs syndrome;
KIRP	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	13.83	0.66	1.44e-32	Cognitive ability;
KIRP	cis	rs1816752	0.819	rs7316961	chr13:24985177	C/T	cg02811702	chr13:24901961	NA	0.39	5.02	0.3	9.79e-7	Obesity-related traits;
KIRP	cis	rs11153147	0.649	rs10456863	chr6:109299092	A/T	cg05315195	chr6:109294784	ARMC2	-0.62	-6.19	-0.37	2.46e-9	Mean corpuscular volume;
KIRP	cis	rs7246657	0.722	rs8100646	chr19:38107943	T/C	cg23950597	chr19:37808831	NA	-0.59	-6.36	-0.38	9.51e-10	Coronary artery calcification;
KIRP	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg16584676	chr17:46985605	UBE2Z	0.47	5.91	0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02725872	chr8:58115012	NA	-0.66	-6.37	-0.38	9.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg15105011	chr4:940614	TMEM175	0.42	5.47	0.33	1.1e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.64	-0.39	2.02e-10	Bladder cancer;
KIRP	cis	rs9398803	0.865	rs9372839	chr6:126809870	G/A	cg19875578	chr6:126661172	C6orf173	0.51	6.6	0.39	2.47e-10	Male-pattern baldness;
KIRP	cis	rs7584330	0.554	rs57140815	chr2:238428330	A/G	cg14458575	chr2:238380390	NA	0.52	6.15	0.36	3.15e-9	Prostate cancer;
KIRP	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg08501292	chr6:25962987	TRIM38	1.13	6.63	0.39	2.15e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	13.69	0.66	4.41e-32	Platelet count;
KIRP	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-12.58	-0.63	2.37e-28	Height;
KIRP	trans	rs13170463	0.649	rs35530734	chr5:8045423	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs4926611	0.931	rs4927019	chr1:54085048	C/T	cg08927728	chr1:54059983	GLIS1	-0.24	-5.22	-0.32	3.78e-7	Hand grip strength;
KIRP	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg14664628	chr15:75095509	CSK	0.49	5.8	0.35	2.01e-8	Systemic lupus erythematosus;
KIRP	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	8.64	0.48	7.17e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10105999	chr11:65337913	SSSCA1	0.46	6.43	0.38	6.71e-10	Survival in pancreatic cancer;
KIRP	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.66	8.5	0.48	1.9e-15	Response to antipsychotic treatment;
KIRP	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-1.02	-17.35	-0.74	1.44e-44	Height;
KIRP	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-7.29	-0.42	4.1e-12	Dental caries;
KIRP	cis	rs7187994	0.848	rs35210690	chr16:84782857	C/G	cg07647771	chr16:84786436	USP10	-0.37	-5.22	-0.32	3.74e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs3735025	0.963	rs161337	chr7:137052616	G/C	cg13839563	chr7:136910420	NA	0.39	4.93	0.3	1.52e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg20936604	chr3:58311152	NA	-0.8	-5.99	-0.36	7.57e-9	Cholesterol, total;
KIRP	cis	rs950881	0.808	rs11679146	chr2:103009412	A/G	cg22835712	chr2:102737379	NA	0.47	4.95	0.3	1.37e-6	Allergy;
KIRP	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.84	11.95	0.61	2.92e-26	Monocyte count;
KIRP	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.6	6.99	0.41	2.57e-11	Height;
KIRP	cis	rs13102973	0.899	rs4541577	chr4:135901087	G/T	cg14419869	chr4:135874104	NA	0.48	7.39	0.43	2.24e-12	Subjective well-being;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10508349	chr16:68942231	TMCO7	0.52	7.24	0.42	5.9e-12	Survival in pancreatic cancer;
KIRP	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.41	-5.18	-0.31	4.51e-7	Testicular germ cell tumor;
KIRP	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.04	0.41	1.93e-11	Height;
KIRP	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13606994	chr1:44402422	ARTN	-0.33	-6.44	-0.38	6.34e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11997175	0.595	rs7386404	chr8:33762842	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.04	0.31	8.82e-7	Body mass index;
KIRP	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.6	-5.42	-0.33	1.4e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.55	4.98	0.3	1.2e-6	Alzheimer's disease;
KIRP	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg26531700	chr6:26746687	NA	0.38	5.11	0.31	6.53e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25875908	chr15:93442302	CHD2	0.39	6.21	0.37	2.23e-9	Survival in pancreatic cancer;
KIRP	cis	rs7808935	0.593	rs12671866	chr7:28005988	C/A	cg22168087	chr7:27702803	HIBADH	0.49	4.87	0.3	1.99e-6	Prostate cancer;
KIRP	cis	rs7246865	0.859	rs11086052	chr19:17169081	G/A	cg18440316	chr19:18077727	KCNN1	-0.37	-5.2	-0.31	4.13e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs62413470	1.000	rs4336432	chr6:55946490	C/G	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs986417	1.000	rs713336	chr14:60974958	T/G	cg27398547	chr14:60952738	C14orf39	0.76	7.5	0.43	1.13e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.3	-5.03	-0.31	9.4e-7	Monocyte count;
KIRP	cis	rs10203711	0.966	rs907105	chr2:239565052	A/G	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	1.07	22.47	0.82	1.56e-61	Parkinson's disease;
KIRP	cis	rs1903068	0.927	rs12331507	chr4:56011889	A/G	cg01777861	chr4:56023843	NA	-0.37	-4.86	-0.3	2.13e-6	Endometriosis;
KIRP	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.23	-0.32	3.69e-7	Pulmonary function;
KIRP	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.65	8.71	0.49	4.47e-16	Bladder cancer;
KIRP	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg02524346	chr8:600233	NA	0.88	6.64	0.39	1.97e-10	IgG glycosylation;
KIRP	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg13385521	chr17:29058706	SUZ12P	0.86	6.44	0.38	6.21e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.79	0.4	8.6e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4409675	1.000	rs12047897	chr1:28253307	C/T	cg23691781	chr1:28212827	C1orf38	0.33	6.39	0.38	8.02e-10	Corneal astigmatism;
KIRP	trans	rs1928295	0.786	rs10983720	chr9:120387487	A/T	cg04204072	chr16:20752857	THUMPD1	-0.5	-6.31	-0.37	1.29e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg13010199	chr12:38710504	ALG10B	0.46	5.89	0.35	1.26e-8	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.07	0.31	7.92e-7	Lung cancer;
KIRP	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.61	8.81	0.49	2.34e-16	Colorectal cancer;
KIRP	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.81	-0.4	7.22e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.89	14.02	0.67	3.3e-33	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.62	7.83	0.45	1.49e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.46	-5.43	-0.33	1.37e-7	Schizophrenia;
KIRP	cis	rs2980439	0.729	rs2955585	chr8:8093511	A/G	cg14343924	chr8:8086146	FLJ10661	0.53	6.44	0.38	6.39e-10	Neuroticism;
KIRP	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02617837	chr12:107349530	C12orf23	-0.57	-6.32	-0.37	1.2e-9	Menopause (age at onset);
KIRP	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.59	-9.42	-0.51	3.39e-18	C-reactive protein levels;
KIRP	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg23791538	chr6:167370224	RNASET2	-0.5	-5.92	-0.35	1.05e-8	Primary biliary cholangitis;
KIRP	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.28	-0.32	2.82e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	8.11	0.46	2.4e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs8053891	0.906	rs12926408	chr16:71994451	G/C	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.96	-0.3	1.29e-6	Coronary artery disease;
KIRP	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.04	-0.41	1.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg07843065	chr1:150265600	MRPS21	0.5	7.1	0.41	1.3e-11	Migraine;
KIRP	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-0.88	-11.85	-0.6	6.43e-26	Gut microbiota (bacterial taxa);
KIRP	cis	rs6580649	0.941	rs6580651	chr12:48429933	A/T	cg26205652	chr12:48591994	NA	-0.48	-5.59	-0.34	6.06e-8	Lung cancer;
KIRP	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg11518657	chr1:67396239	MIER1	0.48	4.92	0.3	1.55e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.16	0.37	2.91e-9	Personality dimensions;
KIRP	cis	rs9938149	0.674	rs7500824	chr16:88299491	C/T	cg05435882	chr16:88311214	NA	0.42	5.23	0.32	3.68e-7	Corneal structure;Central corneal thickness;
KIRP	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg06223162	chr1:101003688	GPR88	0.45	9.36	0.51	5.06e-18	Monocyte count;
KIRP	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.0	-0.45	4.97e-14	Mean corpuscular volume;
KIRP	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9515201	0.748	rs9583489	chr13:111032833	C/T	cg06243866	chr13:111019493	COL4A2	-0.64	-7.77	-0.44	2.19e-13	White matter hyperintensity burden;
KIRP	cis	rs9986765	1.000	rs73725075	chr7:142823479	C/A	cg11323483	chr7:142828068	PIP	-0.54	-4.98	-0.3	1.2e-6	Cancer;Dermatomyositis;
KIRP	cis	rs504918	0.525	rs920894	chr3:123987216	G/A	cg05766129	chr3:123988013	KALRN	0.51	7.3	0.42	3.97e-12	Schizophrenia;
KIRP	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.69	9.37	0.51	4.95e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.5	6.49	0.38	4.82e-10	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9403521	0.898	rs3924969	chr6:143979399	C/G	cg18240653	chr6:144019428	PHACTR2	-0.48	-5.14	-0.31	5.69e-7	Obesity-related traits;
KIRP	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.69	9.48	0.52	2.33e-18	Menarche (age at onset);
KIRP	cis	rs7542091	0.739	rs10863793	chr1:210037420	G/A	cg22029157	chr1:209979665	IRF6	0.38	5.28	0.32	2.85e-7	Monobrow;
KIRP	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg08280861	chr8:58055591	NA	0.58	5.46	0.33	1.15e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg12756093	chr1:115239321	AMPD1	0.59	7.55	0.43	8.29e-13	Autism;
KIRP	trans	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	trans	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg03735916	chr2:200715285	NA	-0.46	-6.21	-0.37	2.19e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25351996	chr5:131563782	P4HA2	-0.45	-6.05	-0.36	5.35e-9	Myopia;
KIRP	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg25811766	chr13:21894605	NA	-0.61	-5.95	-0.35	9.05e-9	White matter hyperintensity burden;
KIRP	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.57	-5.22	-0.32	3.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.61	-8.24	-0.47	9.97e-15	Height;
KIRP	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.68	-9.3	-0.51	8.22e-18	Colorectal cancer;
KIRP	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg09455208	chr3:40491958	NA	-0.29	-5.04	-0.31	9.08e-7	Renal cell carcinoma;
KIRP	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg26597838	chr10:835615	NA	-0.58	-7.08	-0.41	1.51e-11	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	8.19	0.46	1.45e-14	Bipolar disorder;
KIRP	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg24375607	chr4:120327624	NA	-0.39	-4.96	-0.3	1.29e-6	Diastolic blood pressure;
KIRP	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.07	0.72	3.3e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	0.77	8.42	0.47	3.06e-15	Initial pursuit acceleration;
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	9.78e-8	Lung cancer;
KIRP	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	9.01	0.5	5.69e-17	Personality dimensions;
KIRP	cis	rs7539542	0.556	rs6692075	chr1:202881302	C/T	cg08940984	chr1:202857613	RABIF	0.46	5.8	0.35	2.05e-8	Mean platelet volume;
KIRP	cis	rs42648	0.596	rs194524	chr7:89861832	G/A	cg25739043	chr7:89950458	NA	-0.41	-6.33	-0.37	1.13e-9	Homocysteine levels;
KIRP	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.63	-7.03	-0.41	1.98e-11	Menarche (age at onset);
KIRP	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg07636037	chr3:49044803	WDR6	0.44	5.19	0.31	4.45e-7	Resting heart rate;
KIRP	cis	rs7616215	0.519	rs2133664	chr3:46101774	T/A	cg08033130	chr3:45983597	CXCR6;FYCO1	0.36	5.21	0.32	4.01e-7	Behcet's disease;
KIRP	cis	rs2273669	0.504	rs75423558	chr6:109499130	T/C	cg05315195	chr6:109294784	ARMC2	-0.53	-5.03	-0.31	9.56e-7	Prostate cancer;
KIRP	cis	rs6578185	0.782	rs10109519	chr8:142453669	T/C	cg07762003	chr8:142452454	FLJ43860	-0.64	-9.46	-0.52	2.65e-18	Endometriosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25770397	chr18:61034583	KDSR	-0.55	-6.22	-0.37	2.07e-9	Interleukin-4 levels;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-1.05	-20.37	-0.79	1.02e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3857067	1.000	rs1509940	chr4:95018758	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.02	-0.3	9.95e-7	QT interval;
KIRP	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.71	-8.29	-0.47	7.5e-15	Obesity-related traits;
KIRP	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12963246	chr6:28129442	ZNF389	-0.49	-6.05	-0.36	5.45e-9	Depression;
KIRP	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.95	0.61	2.94e-26	Alzheimer's disease;
KIRP	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.87	-0.35	1.42e-8	IgG glycosylation;
KIRP	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg11752832	chr7:134001865	SLC35B4	0.44	5.68	0.34	3.82e-8	Mean platelet volume;
KIRP	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg16482183	chr6:26056742	HIST1H1C	0.64	7.21	0.42	6.98e-12	Iron status biomarkers;
KIRP	cis	rs11622475	1.000	rs7143936	chr14:104459452	A/C	cg20488157	chr14:104394430	TDRD9	0.76	10.74	0.56	2.64e-22	Bipolar disorder;
KIRP	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg18234130	chr8:27182889	PTK2B	0.55	7.12	0.41	1.18e-11	Neuroticism;
KIRP	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.82	-13.13	-0.64	3.41e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.58	7.13	0.41	1.1e-11	Arsenic metabolism;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg27568321	chr4:113152709	AP1AR	0.93	6.27	0.37	1.58e-9	P wave terminal force;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08346078	chr19:680592	FSTL3	0.49	6.16	0.37	2.93e-9	Parkinson's disease;
KIRP	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg25281562	chr12:121454272	C12orf43	-0.49	-5.32	-0.32	2.38e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.96	-16.64	-0.73	3.62e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg20243544	chr17:37824526	PNMT	0.52	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.24	-0.32	3.46e-7	Blood metabolite levels;
KIRP	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	1.06	19.48	0.78	9.28e-52	Systemic lupus erythematosus;
KIRP	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg17757837	chr7:157058334	UBE3C	-0.82	-11.24	-0.58	6.29e-24	Body mass index;
KIRP	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg11783602	chr8:55087084	NA	-0.57	-6.98	-0.41	2.78e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.06	0.5	4.31e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3112255	0.967	rs1606552	chr2:101304053	T/G	cg01042948	chr2:101319752	NA	0.43	6.15	0.36	3.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-6.82	-0.4	7.06e-11	Obesity (extreme);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg25292277	chr6:42186449	MRPS10	-0.47	-6.22	-0.37	2.14e-9	Inflammatory biomarkers;
KIRP	cis	rs732716	0.740	rs78869060	chr19:4444742	A/G	cg19820705	chr19:4455316	UBXN6	0.68	8.52	0.48	1.58e-15	Mean corpuscular volume;
KIRP	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	1.15	9.43	0.52	3.28e-18	Economic and political preferences (immigration/crime);
KIRP	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.81	-0.53	2.14e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg12315302	chr6:26189340	HIST1H4D	0.77	5.15	0.31	5.43e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.55	0.48	1.34e-15	Motion sickness;
KIRP	cis	rs2888674	1.000	rs717658	chr7:150503637	A/T	cg05726600	chr7:150498594	TMEM176B;TMEM176A	0.33	5.25	0.32	3.25e-7	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
KIRP	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.67	-5.73	-0.34	2.98e-8	Arsenic metabolism;
KIRP	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.39	-0.47	3.9e-15	Neuroticism;
KIRP	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.92	-0.3	1.56e-6	Crohn's disease;
KIRP	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.06	0.41	1.71e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12826209	chr6:26865740	GUSBL1	0.46	5.83	0.35	1.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7937612	0.931	rs11823300	chr11:120199080	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.74	-0.4	1.09e-10	Intraocular pressure;
KIRP	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.67	9.99	0.54	5.98e-20	Retinal vascular caliber;
KIRP	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.95e-7	Red blood cell count;
KIRP	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg13180566	chr4:1052158	NA	-0.53	-5.37	-0.32	1.8e-7	Recombination rate (females);
KIRP	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.78	8.59	0.48	1.05e-15	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17417193	chr6:45983110	CLIC5	-0.39	-6.12	-0.36	3.68e-9	Metabolic traits;
KIRP	cis	rs16958440	1.000	rs16958701	chr18:44655241	T/C	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg02569458	chr12:86230093	RASSF9	0.37	5.39	0.32	1.67e-7	Major depressive disorder;
KIRP	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25517755	chr10:38738941	LOC399744	-0.48	-6.79	-0.4	8.45e-11	Breast cancer;
KIRP	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.34	5.94	0.35	9.49e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7107174	0.901	rs1055250	chr11:77925708	C/G	cg02023728	chr11:77925099	USP35	0.51	8.06	0.46	3.33e-14	Testicular germ cell tumor;
KIRP	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.63	7.85	0.45	1.27e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07031243	chr17:40976230	BECN1	0.5	6.45	0.38	6.03e-10	Parkinson's disease;
KIRP	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg09788416	chr12:39539408	NA	0.37	5.05	0.31	8.81e-7	Morning vs. evening chronotype;
KIRP	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.8	-0.4	7.75e-11	Height;
KIRP	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.61	9.76	0.53	3.1400000000000002e-19	C-reactive protein levels;
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.77	10.43	0.55	2.5e-21	Longevity;
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg07402062	chr16:89894098	SPIRE2	0.3	6.24	0.37	1.89e-9	Vitiligo;
KIRP	cis	rs34779708	0.733	rs12249814	chr10:35542757	T/C	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.51e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs72781680	0.582	rs72783611	chr2:24291445	C/T	cg20701182	chr2:24300061	SF3B14	0.99	10.84	0.57	1.19e-22	Lymphocyte counts;
KIRP	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.11	0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.86	-0.4	5.43e-11	Coronary artery calcification;
KIRP	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00321850	chr1:175162397	KIAA0040	-0.34	-6.17	-0.37	2.77e-9	Alcohol dependence;
KIRP	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.08	-0.72	2.94e-40	Height;
KIRP	cis	rs35160687	0.814	rs1863063	chr2:86518249	A/C	cg23811061	chr2:86423046	IMMT	0.35	4.86	0.3	2.08e-6	Night sleep phenotypes;
KIRP	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg18461458	chr19:21324796	ZNF431	0.47	5.03	0.31	9.43e-7	Pain;
KIRP	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg08975724	chr8:8085496	FLJ10661	0.6	7.76	0.44	2.34e-13	Retinal vascular caliber;
KIRP	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.71	-9.76	-0.53	3.19e-19	Plateletcrit;Platelet count;
KIRP	trans	rs877282	0.583	rs11253428	chr10:823233	C/T	cg22713356	chr15:30763199	NA	0.9	8.85	0.49	1.8e-16	Uric acid levels;
KIRP	trans	rs3730682	0.641	rs665445	chr18:51842682	A/C	cg02273398	chr6:50817400	NA	-0.49	-6.04	-0.36	5.56e-9	Psoriasis;
KIRP	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.7	-0.44	3.26e-13	Mean corpuscular volume;
KIRP	cis	rs9463078	0.547	rs9472360	chr6:44747410	T/C	cg25276700	chr6:44698697	NA	0.34	4.94	0.3	1.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg16482183	chr6:26056742	HIST1H1C	0.62	7.14	0.41	1.06e-11	Iron status biomarkers;
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg13906792	chr15:75199810	C15orf17	-0.38	-5.47	-0.33	1.1e-7	Breast cancer;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg23693289	chr8:27183097	PTK2B	0.58	7.47	0.43	1.42e-12	Neuroticism;
KIRP	cis	rs60154123	0.730	rs11119455	chr1:210457762	C/T	cg09074223	chr1:210466472	NA	0.58	6.22	0.37	2.13e-9	Coronary artery disease;
KIRP	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.66	8.95	0.5	8.62e-17	Bone properties (heel);
KIRP	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.64	8.56	0.48	1.22e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15664462	chr3:151996146	MBNL1	0.39	6.13	0.36	3.51e-9	C-reactive protein;
KIRP	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.96	16.43	0.72	1.87e-41	Monocyte count;
KIRP	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg17757837	chr7:157058334	UBE3C	0.82	11.08	0.58	2.15e-23	Body mass index;
KIRP	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg05220968	chr6:146057943	EPM2A	-0.37	-5.03	-0.31	9.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7326068	0.557	rs4331211	chr13:21125299	T/C	cg04906043	chr13:21280425	IL17D	-0.52	-6.2	-0.37	2.31e-9	Schizophrenia, bipolar disorder and depression (combined);
KIRP	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.77	12.02	0.61	1.75e-26	Colorectal cancer;
KIRP	trans	rs6561151	1.000	rs6561151	chr13:44484706	G/A	cg12856521	chr11:46389249	DGKZ	0.5	6.83	0.4	6.44e-11	Crohn's disease;
KIRP	cis	rs72843166	0.842	rs12602745	chr17:61221773	T/C	cg19683800	chr17:61518354	CYB561	-0.41	-4.93	-0.3	1.53e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.39e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.71	-11.79	-0.6	9.76e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10864907	0.781	rs35978740	chr2:113609371	G/A	cg03712744	chr2:113669835	IL1F7	-0.4	-5.72	-0.34	3.09e-8	Pulmonary function;
KIRP	cis	rs6662572	0.737	rs55765474	chr1:46401170	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.52	0.33	8.75e-8	Blood protein levels;
KIRP	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	9.24	0.51	1.22e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs12643440	0.538	rs2314601	chr4:17139932	C/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.15e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.92	14.02	0.67	3.13e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9603616	0.719	rs7991151	chr13:40239139	G/A	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.65	-8.41	-0.47	3.41e-15	Obesity-related traits;
KIRP	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg08994789	chr17:28903642	LRRC37B2	0.76	8.94	0.5	9.24e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg18753928	chr3:113234510	CCDC52	-0.54	-6.9	-0.4	4.46e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	trans	rs9693857	0.505	rs2085640	chr8:9265464	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.86	0.4	5.55e-11	Systolic blood pressure;
KIRP	cis	rs4356932	1.000	rs4401475	chr4:76975924	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.95	17.55	0.75	2.85e-45	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg13628971	chr7:2884303	GNA12	0.45	5.81	0.35	1.88e-8	Height;
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg04369109	chr6:150039330	LATS1	-0.58	-7.43	-0.43	1.77e-12	Lung cancer;
KIRP	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.52	5.45	0.33	1.2e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2574704	0.962	rs11709778	chr3:11652034	C/T	cg07643000	chr3:11666825	VGLL4	0.41	5.92	0.35	1.09e-8	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21708767	chr2:25565514	DNMT3A	0.53	7.29	0.42	4.2e-12	Parkinson's disease;
KIRP	cis	rs1403694	1.000	rs2689197	chr3:186438346	C/T	cg12454167	chr3:186435060	KNG1	0.5	8.9	0.49	1.28e-16	Blood protein levels;
KIRP	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg13397359	chr6:42928475	GNMT	0.43	4.89	0.3	1.83e-6	Blood protein levels;
KIRP	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.79	8.03	0.46	4.12e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs7760949	0.963	rs1571565	chr6:13907185	A/G	cg27413430	chr6:13925136	RNF182	0.41	5.32	0.32	2.34e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg10223061	chr2:219282414	VIL1	0.38	5.97	0.36	8.35e-9	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.77	-7.14	-0.41	1.05e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.57	-4.95	-0.3	1.39e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg25319279	chr11:5960081	NA	-0.57	-5.78	-0.35	2.25e-8	DNA methylation (variation);
KIRP	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.57	6.08	0.36	4.58e-9	Schizophrenia;
KIRP	cis	rs7927370	0.558	rs55915740	chr11:55608874	G/C	cg07850316	chr11:56344833	OR5M10;OR8U8	0.66	5.1	0.31	6.95e-7	Systemic lupus erythematosus;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04238871	chr10:126431886	FAM53B	-0.45	-6.31	-0.37	1.29e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.78	-11.41	-0.59	1.74e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.08	0.41	1.48e-11	Lung cancer;
KIRP	cis	rs11638352	0.661	rs2555389	chr15:44431145	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-5.22	-0.32	3.89e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs490234	0.651	rs13301073	chr9:128284378	G/A	cg14078157	chr9:128172775	NA	-0.65	-7.89	-0.45	9.88e-14	Mean arterial pressure;
KIRP	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.77	-7.35	-0.42	2.95e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.75	-9.63	-0.52	7.74e-19	Aortic root size;
KIRP	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg00204512	chr16:28754710	NA	0.4	5.15	0.31	5.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg07308232	chr7:1071921	C7orf50	-0.49	-5.3	-0.32	2.57e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00950418	chr7:105029125	SRPK2	-0.54	-6.89	-0.4	4.62e-11	Height;
KIRP	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg16898833	chr6:26189333	HIST1H4D	0.87	5.38	0.32	1.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.6	-0.34	5.6e-8	Parkinson's disease;
KIRP	cis	rs7534824	0.543	rs61780299	chr1:101403471	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.83	0.35	1.7e-8	Refractive astigmatism;
KIRP	cis	rs7221595	0.825	rs7225453	chr17:3960620	T/C	cg05562828	chr17:3906858	NA	0.53	5.78	0.35	2.2e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4356932	1.000	rs4333205	chr4:76984795	A/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.64	0.71	9.35e-39	Bipolar disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05734877	chr13:111299462	CARS2	0.43	6.13	0.36	3.51e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs16828019	0.777	rs12739052	chr1:41464455	C/A	cg18742814	chr1:41828276	NA	0.68	5.73	0.34	2.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.42	-5.38	-0.32	1.72e-7	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.08	0.61	1.11e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg10755058	chr3:40428713	ENTPD3	0.48	6.66	0.39	1.79e-10	Renal cell carcinoma;
KIRP	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.63	-9.98	-0.54	6.41e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs17655565	0.581	rs1791625	chr12:52761679	A/G	cg07925835	chr12:52762777	KRT85	0.47	5.56	0.33	6.99e-8	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs7500321	1.000	rs7500321	chr16:28977020	G/A	cg07382826	chr16:28625726	SULT1A1	-0.47	-5.06	-0.31	8.23e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.78	10.35	0.55	4.6e-21	Resting heart rate;
KIRP	cis	rs734999	0.588	rs2764841	chr1:2529360	G/A	cg20673091	chr1:2541236	MMEL1	-0.78	-12.67	-0.63	1.21e-28	Ulcerative colitis;
KIRP	cis	rs4704187	0.687	rs10064409	chr5:74527134	A/G	cg03227963	chr5:74354835	NA	0.4	5.82	0.35	1.84e-8	Response to amphetamines;
KIRP	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20135002	chr11:47629003	NA	0.44	4.97	0.3	1.26e-6	Subjective well-being;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24242429	chr13:108867887	LIG4	-0.5	-6.6	-0.39	2.46e-10	Myopia;
KIRP	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	cis	rs853679	0.546	rs493161	chr6:27850714	A/T	cg21204522	chr6:27730016	NA	-0.69	-5.14	-0.31	5.56e-7	Depression;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08667777	chr3:51422532	MANF	0.63	7.68	0.44	3.82e-13	Smoking initiation;
KIRP	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.51	6.07	0.36	4.79e-9	Eosinophil percentage of white cells;
KIRP	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.57	0.39	2.93e-10	Neuroticism;
KIRP	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg27356188	chr5:637386	CEP72	-0.36	-4.9	-0.3	1.72e-6	Obesity-related traits;
KIRP	cis	rs732765	0.734	rs12882425	chr14:75189226	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.05	-0.31	8.51e-7	Non-small cell lung cancer;
KIRP	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.25e-10	Protein C levels;
KIRP	cis	rs12049351	0.774	rs3767327	chr1:229659310	C/G	cg11742688	chr1:229674241	ABCB10	-0.36	-5.36	-0.32	1.93e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg11965913	chr1:205819406	PM20D1	-0.57	-5.2	-0.31	4.15e-7	Menarche (age at onset);
KIRP	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg04025307	chr7:1156635	C7orf50	0.52	5.18	0.31	4.59e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs5753037	0.838	rs5752975	chr22:30274335	C/G	cg01021169	chr22:30184971	ASCC2	-0.39	-5.12	-0.31	6.11e-7	Type 1 diabetes;
KIRP	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.11	-0.31	6.34e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg17764715	chr19:33622953	WDR88	0.67	8.41	0.47	3.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9479482	0.686	rs2010259	chr6:150385475	C/T	cg03788504	chr6:150331562	NA	-0.35	-6.39	-0.38	8.11e-10	Alopecia areata;
KIRP	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14159672	chr1:205819179	PM20D1	-0.6	-5.79	-0.35	2.13e-8	Menarche (age at onset);
KIRP	cis	rs7666738	0.546	rs10018080	chr4:98758436	C/A	cg05340658	chr4:99064831	C4orf37	0.66	7.67	0.44	4.04e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.6	-7.33	-0.42	3.32e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs1355223	0.902	rs1258468	chr11:34729731	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.74	-10.13	-0.54	2.2e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg16590910	chr6:42928470	GNMT	0.42	5.89	0.35	1.27e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg23815491	chr16:72088622	HP	0.5	7.15	0.42	9.58e-12	Blood protein levels;
KIRP	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.63	-8.46	-0.47	2.48e-15	Glaucoma (primary open-angle);
KIRP	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg21890820	chr11:65308645	LTBP3	0.93	5.78	0.35	2.22e-8	Height;
KIRP	cis	rs193541	0.632	rs30063	chr5:122295693	G/A	cg19412675	chr5:122181750	SNX24	0.6	6.38	0.38	8.51e-10	Glucose homeostasis traits;
KIRP	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg09231725	chr11:64357281	SLC22A12	0.61	8.03	0.46	3.95e-14	Urate levels in obese individuals;
KIRP	cis	rs526231	0.543	rs34808	chr5:102429188	T/A	cg23492399	chr5:102201601	PAM	-0.54	-5.93	-0.35	1.05e-8	Primary biliary cholangitis;
KIRP	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-8.73	-0.49	3.92e-16	Alzheimer's disease (survival time);
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg07747251	chr5:1868357	NA	0.43	5.52	0.33	8.76e-8	Cardiovascular disease risk factors;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.57	-5.89	-0.35	1.28e-8	DNA methylation (variation);
KIRP	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17087759	chr2:220094168	ANKZF1;ATG9A	0.56	7.01	0.41	2.29e-11	Parkinson's disease;
KIRP	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg01721255	chr8:58191610	C8orf71	0.52	5.59	0.34	6.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2625529	0.668	rs12591313	chr15:72556746	T/C	cg16672083	chr15:72433130	SENP8	-0.44	-5.26	-0.32	3.14e-7	Red blood cell count;
KIRP	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg06453172	chr10:134556979	INPP5A	0.6	6.93	0.4	3.65e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27600766	chr18:21594250	TTC39C	-0.42	-6.03	-0.36	6.06e-9	Metabolic traits;
KIRP	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	5.67	0.34	3.94e-8	Menarche (age at onset);
KIRP	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	1.14	16.36	0.72	3.37e-41	Breast cancer;
KIRP	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs75804782	0.521	rs55915157	chr2:239424273	T/C	cg18131467	chr2:239335373	ASB1	-0.74	-5.36	-0.32	1.89e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg27490568	chr2:178487706	NA	0.48	6.66	0.39	1.8e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-5.24	-0.32	3.46e-7	Testicular germ cell tumor;
KIRP	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg11569703	chr11:65557185	OVOL1	0.73	13.19	0.64	2.08e-30	Acne (severe);
KIRP	cis	rs7945718	0.840	rs10741601	chr11:12735873	T/C	cg25843174	chr11:12811716	TEAD1	0.42	7.91	0.45	8.63e-14	Educational attainment (years of education);
KIRP	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.51	6.81	0.4	7.45e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	1.01	14.66	0.68	2.21e-35	Menopause (age at onset);
KIRP	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.81	-10.81	-0.57	1.55e-22	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs55675132	0.548	rs12136501	chr1:115366483	G/A	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs7582720	0.945	rs72932711	chr2:203639846	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	9.63	0.52	8.09e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs986417	0.818	rs2351173	chr14:61008755	C/T	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.8	-8.45	-0.47	2.51e-15	Systemic lupus erythematosus;
KIRP	cis	rs7011049	1.000	rs11995106	chr8:53834768	C/T	cg26025543	chr8:53854495	NA	0.72	7.58	0.44	6.99e-13	Systolic blood pressure;
KIRP	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.79	10.31	0.55	6.08e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.88	10.32	0.55	5.51e-21	Osteoarthritis;
KIRP	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg16497661	chr14:103986332	CKB	0.79	12.55	0.62	3.05e-28	Body mass index;
KIRP	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.57	-9.5	-0.52	1.98e-18	Prostate cancer;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs35740288	0.822	rs34734963	chr15:86217644	C/T	cg17133734	chr15:86042851	AKAP13	-0.48	-5.15	-0.31	5.32e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	1.01	12.37	0.62	1.23e-27	Post bronchodilator FEV1;
KIRP	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.57e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg24315340	chr6:146058215	EPM2A	-0.43	-5.3	-0.32	2.61e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17053845	chr2:74375133	BOLA3	0.48	6.44	0.38	6.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2658782	0.593	rs2243410	chr11:93255519	T/G	cg15737290	chr11:93063684	CCDC67	0.68	7.87	0.45	1.11e-13	Pulmonary function decline;
KIRP	cis	rs4730250	0.554	rs17428504	chr7:106914944	T/C	cg02696742	chr7:106810147	HBP1	-0.81	-7.97	-0.45	5.86e-14	Osteoarthritis;
KIRP	cis	rs17431357	1.000	rs73221378	chr12:120910521	G/A	cg25045489	chr12:120971538	RNF10	-0.65	-4.98	-0.3	1.2e-6	Insulin resistance/response;
KIRP	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.13	0.31	5.78e-7	Bipolar disorder;
KIRP	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.32	-0.37	1.25e-9	Response to antipsychotic treatment;
KIRP	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg15655495	chr12:38532458	NA	0.26	4.98	0.3	1.18e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-1.25	-12.79	-0.63	4.56e-29	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4478858	0.647	rs10798836	chr1:31709214	C/T	cg00250761	chr1:31883323	NA	-0.32	-5.56	-0.33	7e-8	Alcohol dependence;
KIRP	cis	rs689449	0.756	rs11706118	chr3:124464142	C/A	cg05980111	chr3:124395277	KALRN	0.37	5.07	0.31	7.79e-7	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00765428	chr21:34638638	IL10RB	0.5	6.66	0.39	1.75e-10	Parkinson's disease;
KIRP	cis	rs13065560	0.594	rs4398365	chr3:38878804	C/G	cg01426195	chr3:39028469	NA	-0.43	-6.89	-0.4	4.71e-11	Interleukin-18 levels;
KIRP	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	7.42	0.43	1.85e-12	Lung cancer;
KIRP	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.93	0.3	1.49e-6	Renal cell carcinoma;
KIRP	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.93	11.92	0.6	3.81e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg17182837	chr8:41585554	ANK1	-0.47	-6.52	-0.38	4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.63	0.56	5.86e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.73	0.44	2.79e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04035031	chr22:46067830	ATXN10	-0.45	-6.2	-0.37	2.38e-9	Metabolic traits;
KIRP	cis	rs193541	0.586	rs11241662	chr5:122181975	A/G	cg19412675	chr5:122181750	SNX24	-0.59	-6.3	-0.37	1.35e-9	Glucose homeostasis traits;
KIRP	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg21775007	chr8:11205619	TDH	0.45	6.03	0.36	5.86e-9	Myopia (pathological);
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.64	8.5	0.48	1.88e-15	Longevity;Endometriosis;
KIRP	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg23533419	chr12:54090519	NA	-0.32	-5.13	-0.31	5.78e-7	Height;
KIRP	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	trans	rs1106684	1.000	rs1477228	chr7:131455563	C/T	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	cis	rs6545883	0.524	rs2593631	chr2:61572286	A/G	cg15711740	chr2:61764176	XPO1	0.45	5.44	0.33	1.31e-7	Tuberculosis;
KIRP	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.63	-0.34	5e-8	Coronary artery disease;
KIRP	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.51	-6.55	-0.39	3.41e-10	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg18132916	chr6:79620363	NA	-0.42	-5.67	-0.34	4.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-0.85	-6.64	-0.39	2.03e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg14952266	chr13:112191215	NA	0.46	6.79	0.4	8.15e-11	Hepatitis;
KIRP	cis	rs17065868	1.000	rs9533920	chr13:45157394	G/A	cg10246903	chr13:45222710	NA	0.63	6.75	0.4	1.07e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.51	-0.38	4.17e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs68170813	0.652	rs17481621	chr7:107113852	G/C	cg02696742	chr7:106810147	HBP1	-0.69	-6.23	-0.37	2.05e-9	Coronary artery disease;
KIRP	cis	rs9654415	0.560	rs4540159	chr5:72546478	C/T	cg23303188	chr5:72570711	NA	0.4	5.33	0.32	2.24e-7	Eyebrow thickness;
KIRP	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-7.01	-0.41	2.25e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg18154014	chr19:37997991	ZNF793	0.73	7.81	0.45	1.69e-13	Coronary artery calcification;
KIRP	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.95	-0.5	8.85e-17	Platelet count;
KIRP	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.75	-0.34	2.59e-8	Neutrophil percentage of white cells;
KIRP	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-7.8	-0.45	1.71e-13	Acylcarnitine levels;
KIRP	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg08501292	chr6:25962987	TRIM38	1.04	7.49	0.43	1.23e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13088645	0.541	rs9842113	chr3:134192338	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.55	-7.56	-0.43	8.09e-13	Coronary artery disease;
KIRP	cis	rs17321999	1.000	rs72787724	chr2:30491746	T/C	cg05247661	chr2:30472410	LBH	0.78	7.32	0.42	3.48e-12	Systemic lupus erythematosus;
KIRP	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.54	-7.35	-0.42	2.94e-12	Response to temozolomide;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.8	-10.03	-0.54	4.45e-20	Longevity;Endometriosis;
KIRP	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.61	-6.96	-0.41	3.09e-11	Prudent dietary pattern;
KIRP	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-0.54	-7.47	-0.43	1.39e-12	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg15181151	chr6:150070149	PCMT1	0.31	5.33	0.32	2.27e-7	Lung cancer;
KIRP	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg18016565	chr1:150552671	MCL1	-0.35	-5.24	-0.32	3.41e-7	Tonsillectomy;
KIRP	cis	rs4523957	0.590	rs9899427	chr17:2063550	A/T	cg16513277	chr17:2031491	SMG6	-0.78	-11.0	-0.57	3.82e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg11833968	chr6:79620685	NA	-0.46	-6.97	-0.41	2.89e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.79	-13.01	-0.64	8.34e-30	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs6142102	0.778	rs6059555	chr20:32514324	G/C	cg08999081	chr20:33150536	PIGU	0.47	5.51	0.33	9.03e-8	Skin pigmentation;
KIRP	cis	rs9810890	1.000	rs73196996	chr3:128458416	G/A	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-7.28	-0.42	4.62e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.39	8.07	0.46	3.1e-14	IgG glycosylation;
KIRP	cis	rs1971762	1.000	rs1971762	chr12:54058238	C/T	cg16917193	chr12:54089295	NA	0.69	9.2	0.51	1.65e-17	Height;
KIRP	cis	rs9815354	0.951	rs1716679	chr3:41905339	T/C	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg03289416	chr15:75166202	SCAMP2	0.44	6.2	0.37	2.34e-9	Breast cancer;
KIRP	cis	rs13418717	0.793	rs10180994	chr2:127660075	C/G	cg25501666	chr2:127640322	NA	0.91	7.46	0.43	1.47e-12	Heart failure;
KIRP	cis	rs42648	0.748	rs6972119	chr7:89894008	T/C	cg25739043	chr7:89950458	NA	-0.43	-6.85	-0.4	5.99e-11	Homocysteine levels;
KIRP	cis	rs3733606	0.538	rs11734099	chr4:6891435	G/A	cg05012661	chr4:6891264	NA	0.56	7.43	0.43	1.76e-12	Platelet count;
KIRP	cis	rs897080	0.515	rs698767	chr2:44576417	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.24	0.37	1.89e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25339552	chr19:33165499	ANKRD27;RGS9BP	0.55	7.05	0.41	1.8e-11	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg04369109	chr6:150039330	LATS1	-0.64	-8.18	-0.46	1.53e-14	Lung cancer;
KIRP	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.29	28.07	0.87	1.16e-78	IgG glycosylation;
KIRP	cis	rs7572263	0.724	rs34082227	chr2:209055449	G/T	cg23998903	chr2:209048830	C2orf80	-0.37	-5.19	-0.31	4.39e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs1823913	1.000	rs4853462	chr2:192123804	C/A	cg12404831	chr2:192114017	MYO1B	-0.5	-6.77	-0.4	9.57e-11	Obesity-related traits;
KIRP	cis	rs8060686	0.764	rs73599521	chr16:67733322	G/A	cg04539111	chr16:67997858	SLC12A4	-0.59	-5.81	-0.35	1.88e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	1.02	15.74	0.71	4.23e-39	Menopause (age at onset);
KIRP	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.37	0.43	2.55e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.71	8.02	0.46	4.32e-14	Mammographic density (dense area);
KIRP	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.81	11.08	0.58	2.02e-23	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7078219	0.505	rs4129132	chr10:101284637	T/G	cg07044859	chr10:101282883	NA	-0.3	-5.2	-0.31	4.14e-7	Dental caries;
KIRP	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.0	0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs17101923	0.901	rs7966340	chr12:66331365	G/C	cg06712651	chr12:66351869	HMGA2	-0.59	-6.58	-0.39	2.84e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.44	6.18	0.37	2.67e-9	Testicular germ cell tumor;
KIRP	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.79	8.76	0.49	3.17e-16	Diastolic blood pressure;
KIRP	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.96	-9.72	-0.53	4.2e-19	QRS complex (12-leadsum);
KIRP	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs2976388	0.935	rs2976384	chr8:143752994	T/C	cg06565975	chr8:143823917	SLURP1	-0.45	-6.62	-0.39	2.27e-10	Urinary tract infection frequency;
KIRP	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.78	0.4	9.06e-11	Lung cancer;
KIRP	cis	rs9303542	0.625	rs9904760	chr17:46575031	C/T	cg04904318	chr17:46607828	HOXB1	-0.44	-5.45	-0.33	1.24e-7	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg16917193	chr12:54089295	NA	0.85	16.34	0.72	3.89e-41	Height;
KIRP	trans	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg25042112	chr7:64838748	ZNF92	0.6	6.32	0.37	1.22e-9	Pain;
KIRP	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.28	7.73	0.44	2.82e-13	Crohn's disease;
KIRP	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21659725	chr3:3221576	CRBN	0.66	8.9	0.49	1.27e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg06212747	chr3:49208901	KLHDC8B	0.7	8.25	0.47	9.68e-15	Menarche (age at onset);
KIRP	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.11	0.36	3.87e-9	Morning vs. evening chronotype;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10706069	chr10:112836688	ADRA2A	-0.59	-6.39	-0.38	8.27e-10	Menopause (age at onset);
KIRP	cis	rs28493229	0.881	rs10404911	chr19:41174903	A/T	cg21869046	chr19:41225005	ITPKC	0.4	5.25	0.32	3.31e-7	Kawasaki disease;
KIRP	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg26513180	chr16:89883248	FANCA	0.79	5.27	0.32	2.98e-7	Skin colour saturation;
KIRP	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.48	-7.21	-0.42	7.04e-12	Coronary artery disease;
KIRP	cis	rs1829883	1.000	rs2461991	chr5:98793332	C/G	cg08333243	chr5:99726346	NA	-0.36	-4.86	-0.3	2.09e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2071426	0.622	rs2211267	chr10:96781920	C/T	cg09036531	chr10:96991505	NA	-0.45	-5.24	-0.32	3.38e-7	Blood metabolite levels;
KIRP	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.51	-6.13	-0.36	3.45e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4356932	1.000	rs4543147	chr4:76976661	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.14	0.36	3.37e-9	Blood protein levels;
KIRP	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg13206674	chr6:150067644	NUP43	0.54	7.46	0.43	1.47e-12	Lung cancer;
KIRP	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg20991723	chr1:152506922	NA	-0.44	-5.21	-0.32	4.02e-7	Hair morphology;
KIRP	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg01879757	chr17:41196368	BRCA1	-0.58	-7.6	-0.44	6.26e-13	Menopause (age at onset);
KIRP	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg08992911	chr2:238395768	MLPH	0.42	5.19	0.31	4.3e-7	Prostate cancer;
KIRP	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	7.6	0.44	6.18e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.41	-5.91	-0.35	1.16e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg19847130	chr8:10466454	RP1L1	0.38	5.75	0.34	2.61e-8	Retinal vascular caliber;
KIRP	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.64	9.21	0.51	1.53e-17	Resting heart rate;
KIRP	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.8	0.53	2.39e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.74	-0.39	1.13e-10	Myopia (pathological);
KIRP	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg02792322	chr13:21280448	IL17D	-0.34	-4.91	-0.3	1.69e-6	Schizophrenia, bipolar disorder and depression (combined);
KIRP	trans	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg14791747	chr16:20752902	THUMPD1	0.65	6.93	0.4	3.57e-11	Cognitive test performance;
KIRP	cis	rs77372450	0.636	rs11749144	chr5:157026996	A/G	cg23851860	chr5:157002805	ADAM19	0.47	5.21	0.32	3.92e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6832769	1.000	rs4580704	chr4:56326707	C/G	cg09317128	chr4:56265301	TMEM165	-0.55	-7.04	-0.41	1.91e-11	Personality dimensions;
KIRP	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg14580859	chr9:123691850	NA	0.35	5.07	0.31	7.84e-7	Rheumatoid arthritis;
KIRP	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.74	-8.07	-0.46	3.11e-14	HIV-1 control;
KIRP	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.79	-13.91	-0.66	7.53e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg21573476	chr21:45109991	RRP1B	0.72	11.39	0.59	2.03e-24	Mean corpuscular volume;
KIRP	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.57	-5.73	-0.34	2.97e-8	Platelet distribution width;
KIRP	cis	rs2213920	0.749	rs6478172	chr9:118251281	C/T	cg13918206	chr9:118159781	DEC1	1.01	10.09	0.54	2.97e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	0.89	13.14	0.64	3.2e-30	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg24498760	chr8:49746867	NA	0.42	5.17	0.31	4.85e-7	Blood metabolite ratios;
KIRP	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-6.85	-0.4	5.84e-11	Menarche (age at onset);
KIRP	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-1.18	-10.01	-0.54	5.13e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.37	-10.44	-0.55	2.37e-21	Diabetic kidney disease;
KIRP	cis	rs4919044	0.641	rs7905234	chr10:94719384	A/G	cg05127821	chr10:94822908	CYP26C1	-0.94	-7.59	-0.44	6.5e-13	Coronary artery disease;
KIRP	trans	rs7980799	0.967	rs7971226	chr12:33586881	C/T	cg26384229	chr12:38710491	ALG10B	0.56	6.96	0.41	3.05e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs6568686	0.627	rs17539951	chr6:111664969	G/A	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs2738048	0.545	rs2738046	chr8:6823542	C/A	cg24860332	chr8:6827800	DEFA10P	-0.39	-5.1	-0.31	6.7e-7	IgA nephropathy;
KIRP	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.66	-8.46	-0.47	2.42e-15	Personality dimensions;
KIRP	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.91	0.3	1.67e-6	Parkinson's disease;
KIRP	cis	rs11825685	0.790	rs74733798	chr11:134538378	A/G	cg06603561	chr11:134479413	NA	-0.67	-5.81	-0.35	1.97e-8	IgG glycosylation;
KIRP	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg03959625	chr15:84868606	LOC388152	0.48	5.68	0.34	3.78e-8	Schizophrenia;
KIRP	cis	rs16936870	0.516	rs11785897	chr8:71134438	A/G	cg14232793	chr8:71155543	NCOA2	-0.53	-6.03	-0.36	5.87e-9	QT interval;
KIRP	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11971779	0.625	rs10260850	chr7:139003602	G/T	cg07862535	chr7:139043722	LUC7L2	0.43	5.07	0.31	7.92e-7	Diisocyanate-induced asthma;
KIRP	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg24796726	chr7:884288	UNC84A	-0.56	-5.31	-0.32	2.5e-7	Initial pursuit acceleration;
KIRP	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg15488143	chr7:128924101	AHCYL2	0.59	6.4	0.38	7.75e-10	White matter hyperintensity burden;
KIRP	cis	rs7172677	0.737	rs6495155	chr15:75437311	G/A	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.43	-0.38	6.72e-10	Lung cancer;
KIRP	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg16141378	chr3:129829833	LOC729375	0.48	6.2	0.37	2.33e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.73	6.44	0.38	6.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-11.82	-0.6	7.98e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.52e-7	Tonsillectomy;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg02619805	chr19:5623015	SAFB2;SAFB	0.53	6.68	0.39	1.54e-10	Educational attainment;
KIRP	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-0.66	-5.71	-0.34	3.19e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.55	-0.39	3.33e-10	Coronary artery disease;
KIRP	cis	rs28489187	0.617	rs233118	chr1:85787967	C/T	cg16011679	chr1:85725395	C1orf52	-0.44	-5.54	-0.33	7.93e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.03	0.31	9.42e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.44	-0.52	2.99e-18	Aortic root size;
KIRP	cis	rs4006360	0.579	rs2320223	chr17:39234769	G/T	cg15015397	chr17:39261100	KRTAP4-9	-0.55	-7.8	-0.45	1.76e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	1.03	14.51	0.68	6.68e-35	Menopause (age at onset);
KIRP	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg19913688	chr11:428466	ANO9	-0.73	-5.61	-0.34	5.44e-8	Body mass index;
KIRP	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.45	5.75	0.34	2.63e-8	Multiple sclerosis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14002172	chr7:99699610	MCM7;AP4M1	-0.49	-6.14	-0.36	3.24e-9	Myopia;
KIRP	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.69	-10.78	-0.57	1.86e-22	Educational attainment;
KIRP	cis	rs12580194	0.593	rs7960760	chr12:55722311	A/G	cg19537932	chr12:55886519	OR6C68	-0.5	-6.68	-0.39	1.62e-10	Cancer;
KIRP	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.83	-12.1	-0.61	9.11e-27	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7566780	0.575	rs4832645	chr2:16694736	C/G	cg09580478	chr2:16689509	NA	0.43	4.95	0.3	1.38e-6	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg06637938	chr14:75390232	RPS6KL1	0.49	6.91	0.4	4.1e-11	Height;
KIRP	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg17376030	chr22:41985996	PMM1	0.61	6.39	0.38	8.4e-10	Vitiligo;
KIRP	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-0.79	-7.68	-0.44	3.69e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.83	0.49	2.05e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg05220968	chr6:146057943	EPM2A	-0.42	-5.57	-0.33	6.53e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	0.75	10.9	0.57	7.82e-23	Prudent dietary pattern;
KIRP	trans	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.74	0.44	2.5e-13	Breast cancer;
KIRP	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg18755752	chr8:142205143	DENND3	-0.48	-6.31	-0.37	1.25e-9	Immature fraction of reticulocytes;
KIRP	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.34	-0.42	3.07e-12	Aortic root size;
KIRP	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg00982548	chr2:198649783	BOLL	-0.54	-5.07	-0.31	7.65e-7	Ulcerative colitis;
KIRP	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	7.54	0.43	9.18e-13	Post bronchodilator FEV1;
KIRP	cis	rs8018808	0.902	rs147316	chr14:77888664	C/T	cg20045696	chr14:77926864	AHSA1	0.46	5.52	0.33	8.52e-8	Myeloid white cell count;
KIRP	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg19554555	chr3:13937349	NA	-0.45	-6.06	-0.36	5.17e-9	Ovarian reserve;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15351736	chr11:111808104	DIXDC1	0.48	6.96	0.41	3.14e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.25	0.62	3.02e-27	Bladder cancer;
KIRP	cis	rs13315871	0.615	rs6789547	chr3:58426047	C/T	cg12435725	chr3:58293450	RPP14	-0.35	-4.99	-0.3	1.16e-6	Cholesterol, total;
KIRP	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg03563238	chr19:33554763	RHPN2	-0.32	-6.0	-0.36	7.1e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg13482628	chr17:19912719	NA	0.57	8.05	0.46	3.61e-14	Schizophrenia;
KIRP	cis	rs7837045	0.556	rs4907405	chr8:142567233	A/G	cg14233295	chr8:142517186	FLJ43860	0.49	5.06	0.31	8.28e-7	Breast size;
KIRP	cis	rs34929064	0.536	rs2961278	chr7:22634779	C/G	cg23521230	chr7:22704884	NA	0.45	5.22	0.32	3.89e-7	Major depression and alcohol dependence;
KIRP	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.72	10.64	0.56	5.35e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg21132104	chr15:45694354	SPATA5L1	0.77	9.78	0.53	2.69e-19	Homoarginine levels;
KIRP	cis	rs6142102	0.961	rs6057957	chr20:32549858	T/G	cg24642439	chr20:33292090	TP53INP2	0.58	6.38	0.38	8.48e-10	Skin pigmentation;
KIRP	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.35	0.62	1.34e-27	Ileal carcinoids;
KIRP	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg21775007	chr8:11205619	TDH	0.43	5.94	0.35	9.88e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2236918	1.000	rs1635515	chr1:242017009	A/G	cg17736920	chr1:242011382	EXO1	0.72	9.32	0.51	7.01e-18	Menopause (age at onset);
KIRP	cis	rs11123406	0.501	rs3747653	chr2:111966540	T/C	cg23466623	chr2:111982296	NA	0.58	7.3	0.42	3.94e-12	Type 2 diabetes;
KIRP	cis	rs1208285	0.564	rs9375992	chr6:134203345	G/A	cg06643013	chr6:134217242	NA	-0.44	-5.21	-0.31	4.09e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.82	-10.63	-0.56	5.69e-22	Height;
KIRP	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15369054	chr17:80825471	TBCD	-0.58	-5.2	-0.31	4.22e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg08773314	chr2:239334832	ASB1	-0.55	-5.71	-0.34	3.29e-8	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg24483002	chr8:22225017	SLC39A14	0.58	6.33	0.37	1.14e-9	Electroencephalogram traits;
KIRP	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.45	5.08	0.31	7.41e-7	Schizophrenia;
KIRP	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2979489	0.891	rs2915591	chr8:30395948	C/G	cg26383811	chr8:30366931	RBPMS	-0.47	-6.38	-0.38	8.77e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs6058796	1.000	rs6057614	chr20:31255800	C/T	cg13636640	chr20:31349939	DNMT3B	0.53	4.86	0.3	2.12e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg14703610	chr5:56206110	C5orf35	0.48	6.65	0.39	1.83e-10	Coronary artery disease;
KIRP	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.45	-6.33	-0.37	1.15e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.79	6.91	0.4	4.19e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs1983891	0.742	rs6920495	chr6:41554182	A/G	cg20194872	chr6:41519635	FOXP4	0.49	6.43	0.38	6.71e-10	Prostate cancer;
KIRP	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-11.4	-0.59	1.9e-24	Vitiligo;
KIRP	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.62	-7.63	-0.44	5.1e-13	Longevity;
KIRP	cis	rs1018697	0.966	rs11191396	chr10:104552865	A/G	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	cis	rs1555895	0.656	rs61831439	chr10:840244	A/G	cg10017260	chr10:834428	NA	-0.43	-6.3	-0.37	1.36e-9	Survival in rectal cancer;
KIRP	cis	rs2108622	1.000	rs55744319	chr19:15981821	G/A	cg19546583	chr19:16022523	NA	-0.43	-4.98	-0.3	1.21e-6	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
KIRP	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.36	0.47	4.66e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11245990	chr11:68621969	NA	0.41	5.62	0.34	5.28e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.72	-9.31	-0.51	7.36e-18	Coronary artery disease;
KIRP	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.22	0.51	1.43e-17	Morning vs. evening chronotype;
KIRP	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg09035930	chr12:129282057	SLC15A4	1.05	17.93	0.75	1.55e-46	Systemic lupus erythematosus;
KIRP	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.53	7.31	0.42	3.82e-12	Menarche (age at onset);
KIRP	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	7.71	0.44	3.21e-13	Height;
KIRP	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.65	-9.12	-0.5	2.68e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.81	-11.6	-0.59	4.29e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.46	-5.81	-0.35	1.89e-8	Schizophrenia;
KIRP	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	6.0	0.36	7.07e-9	Schizophrenia;
KIRP	cis	rs675026	0.926	rs681243	chr6:154427741	T/C	cg07813322	chr6:154414604	OPRM1	-0.5	-6.61	-0.39	2.37e-10	Hypertension;
KIRP	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg00504896	chr12:9437009	LOC642846	-0.6	-8.24	-0.47	1.03e-14	Breast size;
KIRP	cis	rs4356932	1.000	rs12510335	chr4:76980539	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.46	5.14	0.31	5.54e-7	Schizophrenia;
KIRP	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.71	-0.34	3.25e-8	Height;
KIRP	cis	rs918629	0.530	rs56156268	chr5:95240659	G/A	cg16656078	chr5:95278638	ELL2	-0.36	-5.32	-0.32	2.34e-7	IgG glycosylation;
KIRP	cis	rs7221595	0.778	rs2727072	chr17:3918585	C/G	cg09695851	chr17:3907499	NA	0.7	8.65	0.48	6.81e-16	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs748404	0.697	rs475261	chr15:43546456	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.54	7.31	0.42	3.83e-12	Lung cancer;
KIRP	cis	rs7107174	0.748	rs2458640	chr11:78035856	A/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.99	-0.36	7.42e-9	Testicular germ cell tumor;
KIRP	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.48	6.78	0.4	8.94e-11	Red blood cell count;
KIRP	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.63	8.12	0.46	2.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22491279	chr19:8008671	TIMM44	0.47	6.29	0.37	1.47e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06402602	chr16:87417326	FBXO31	0.5	6.18	0.37	2.69e-9	Parkinson's disease;
KIRP	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-5.56	-0.33	7.1e-8	Body mass index;
KIRP	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.42	5.09	0.31	6.99e-7	Common traits (Other);
KIRP	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.58	7.43	0.43	1.75e-12	Coronary artery disease;
KIRP	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.76	-10.77	-0.57	2.06e-22	Blood metabolite levels;
KIRP	cis	rs7224685	0.569	rs34356467	chr17:3978531	G/T	cg05562828	chr17:3906858	NA	0.57	6.15	0.36	3.19e-9	Type 2 diabetes;
KIRP	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-4.97	-0.3	1.25e-6	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09649134	chr3:155523747	C3orf33	0.49	6.25	0.37	1.78e-9	Parkinson's disease;
KIRP	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg25036284	chr2:26402008	FAM59B	0.55	5.47	0.33	1.11e-7	Gut microbiome composition (summer);
KIRP	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.57	7.49	0.43	1.25e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs13226913	0.869	rs10246303	chr7:7286445	A/T	cg04827551	chr7:7268805	C1GALT1	-0.36	-5.17	-0.31	4.93e-7	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs4356932	1.000	rs10017431	chr4:76955406	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.56	-7.12	-0.41	1.18e-11	Obesity-related traits;
KIRP	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.26e-10	Hypertriglyceridemia;
KIRP	cis	rs12579753	0.810	rs1343934	chr12:82123112	G/A	cg21231944	chr12:82153410	PPFIA2	-0.41	-4.9	-0.3	1.76e-6	Resting heart rate;
KIRP	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg00405596	chr8:11794950	NA	0.53	6.43	0.38	6.61e-10	Mood instability;
KIRP	cis	rs7534824	0.625	rs7545402	chr1:101321076	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	5.71	0.34	3.23e-8	Refractive astigmatism;
KIRP	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-11.44	-0.59	1.39e-24	Dental caries;
KIRP	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	IgG glycosylation;
KIRP	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.91	-11.56	-0.59	5.67e-25	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03033080	chr12:118454561	RFC5	0.6	7.53	0.43	9.53e-13	Parkinson's disease;
KIRP	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.56	7.32	0.42	3.48e-12	Aortic root size;
KIRP	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.56	7.78	0.44	2.02e-13	Mean corpuscular volume;
KIRP	cis	rs58785573	0.513	rs7678850	chr4:38592867	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.88	0.3	1.94e-6	Lymphocyte percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19030620	chr1:220922217	MOSC2	0.4	6.19	0.37	2.51e-9	Smoking initiation;
KIRP	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg21253087	chr9:139290292	SNAPC4	0.49	6.89	0.4	4.65e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg23460707	chr10:133558971	NA	-0.35	-5.32	-0.32	2.28e-7	Survival in rectal cancer;
KIRP	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.48	6.78	0.4	8.94e-11	Red blood cell count;
KIRP	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26002218	chr14:103986227	CKB	0.29	6.03	0.36	5.92e-9	Body mass index;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	14.65	0.68	2.37e-35	Lymphocyte counts;
KIRP	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.97	13.15	0.64	2.98e-30	Menopause (age at onset);
KIRP	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.88	-14.02	-0.67	3.28e-33	Height;
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg24101359	chr6:42928495	GNMT	0.64	9.54	0.52	1.44e-18	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.71	9.4	0.51	3.89e-18	Morning vs. evening chronotype;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20574550	chr3:125876169	ALDH1L1	0.43	6.02	0.36	6.29e-9	Pancreatic cancer;
KIRP	cis	rs1999930	0.527	rs12203739	chr6:116280356	C/T	cg15226275	chr6:116381976	FRK	0.22	4.9	0.3	1.72e-6	Age-related macular degeneration;
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg21698718	chr17:80085957	CCDC57	0.37	5.4	0.33	1.58e-7	Life satisfaction;
KIRP	cis	rs12580194	0.593	rs59466585	chr12:55722736	T/G	cg11794356	chr12:55725991	OR6C3	-0.59	-8.57	-0.48	1.13e-15	Cancer;
KIRP	cis	rs10782582	0.668	rs814897	chr1:76154273	G/A	cg03433033	chr1:76189801	ACADM	0.38	5.92	0.35	1.09e-8	Daytime sleep phenotypes;
KIRP	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg12315302	chr6:26189340	HIST1H4D	1.04	6.07	0.36	4.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.16	9.55	0.52	1.33e-18	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6442310	0.534	rs1822825	chr3:12449963	G/A	cg22839075	chr3:12045461	SYN2	-0.39	-5.53	-0.33	8.2e-8	Hematocrit;
KIRP	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.78	8.95	0.5	8.89e-17	Corneal astigmatism;
KIRP	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg07636037	chr3:49044803	WDR6	-0.74	-5.7	-0.34	3.5e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02196227	chr4:89080292	ABCG2	0.52	6.92	0.4	3.83e-11	Smoking initiation;
KIRP	trans	rs2531992	0.925	rs2531993	chr16:4014245	A/G	cg09155362	chr15:33487289	NA	-0.56	-6.79	-0.4	8.24e-11	Waist circumference;
KIRP	cis	rs6973256	0.583	rs2042000	chr7:133322697	T/C	cg10665199	chr7:133106180	EXOC4	0.52	6.68	0.39	1.58e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.04	0.36	5.77e-9	Systolic blood pressure;
KIRP	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-7.6	-0.44	6.11e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.79	0.35	2.14e-8	Lung cancer;
KIRP	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.92	-16.18	-0.72	1.32e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-0.74	-10.37	-0.55	3.77e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9596863	0.898	rs9316668	chr13:54400431	C/T	ch.13.53330881F	chr13:54432880	NA	0.64	6.44	0.38	6.11e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.53	6.49	0.38	4.73e-10	Monocyte count;
KIRP	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg03678062	chr6:149772716	ZC3H12D	-0.33	-5.43	-0.33	1.34e-7	Dupuytren's disease;
KIRP	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.77	9.94	0.54	8.83e-20	Aortic root size;
KIRP	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7590368	0.715	rs12463454	chr2:10958235	G/A	cg15705551	chr2:10952987	PDIA6	0.59	5.42	0.33	1.4e-7	Educational attainment (years of education);
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg11204139	chr17:3907470	NA	0.83	15.56	0.7	1.79e-38	Type 2 diabetes;
KIRP	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg05083358	chr7:2394359	EIF3B	-0.73	-7.13	-0.41	1.09e-11	Multiple sclerosis;
KIRP	cis	rs10046574	0.561	rs13438700	chr7:135207626	C/A	cg27474649	chr7:135195673	CNOT4	0.55	5.18	0.31	4.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.45	5.13	0.31	5.87e-7	Schizophrenia;
KIRP	cis	rs7646881	0.812	rs73017539	chr3:158460743	A/G	cg19483011	chr3:158453295	NA	-0.54	-5.64	-0.34	4.57e-8	Tetralogy of Fallot;
KIRP	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-6.03	-0.36	6.01e-9	Total body bone mineral density;
KIRP	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	6.95	0.41	3.26e-11	Response to antipsychotic treatment;
KIRP	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.53	13.51	0.65	1.69e-31	Airflow obstruction;
KIRP	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg18944383	chr4:111397179	ENPEP	0.63	11.49	0.59	9.6e-25	Height;
KIRP	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg05973401	chr12:123451056	ABCB9	0.55	6.26	0.37	1.69e-9	Neutrophil percentage of white cells;
KIRP	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg00990874	chr7:1149470	C7orf50	-0.46	-5.03	-0.31	9.48e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg18402987	chr7:1209562	NA	0.71	4.98	0.3	1.18e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13798912	chr7:905769	UNC84A	0.73	7.0	0.41	2.44e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg03702533	chr15:77830579	NA	0.33	4.96	0.3	1.3e-6	Type 2 diabetes;
KIRP	cis	rs6466055	1.000	rs6466055	chr7:104929064	A/C	cg04380332	chr7:105027541	SRPK2	0.51	7.77	0.44	2.07e-13	Schizophrenia;
KIRP	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.84	9.95	0.54	8.16e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.06	-0.46	3.39e-14	Migraine;Coronary artery disease;
KIRP	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg12435725	chr3:58293450	RPP14	-0.47	-5.07	-0.31	7.85e-7	Cholesterol, total;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13930136	chr10:134254845	NA	-0.42	-6.42	-0.38	7.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg16898833	chr6:26189333	HIST1H4D	0.64	4.91	0.3	1.68e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg24972876	chr7:65420302	NA	0.45	6.38	0.38	8.85e-10	Calcium levels;
KIRP	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	6.87	0.4	5.13e-11	Mean corpuscular hemoglobin;
KIRP	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23960561	chr4:40058360	N4BP2;LOC344967	0.5	6.17	0.37	2.87e-9	Parkinson's disease;
KIRP	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-6.96	-0.41	3.15e-11	Colorectal cancer;
KIRP	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Visceral adipose tissue adjusted for BMI;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg16489511	chr6:26659419	ZNF322A	-0.49	-6.15	-0.37	3.05e-9	Obesity-related traits;
KIRP	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs12780845	0.540	rs11254413	chr10:17204187	G/A	cg01003015	chr10:17271136	VIM	0.49	6.36	0.38	9.75e-10	Homocysteine levels;
KIRP	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg08514558	chr10:81106712	PPIF	0.39	5.32	0.32	2.28e-7	Height;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg27338695	chr8:41435702	AGPAT6	0.54	6.52	0.38	4.06e-10	Plasma plasminogen activator levels;
KIRP	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg06766960	chr11:133703094	NA	-0.65	-8.64	-0.48	7.22e-16	Childhood ear infection;
KIRP	cis	rs2898681	0.581	rs10003908	chr4:53681089	T/C	cg00338735	chr4:53728038	RASL11B	0.43	5.34	0.32	2.09e-7	Optic nerve measurement (cup area);
KIRP	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.34	0.32	2.09e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.14	-0.36	3.22e-9	Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.45e-16	Motion sickness;
KIRP	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.64	6.42	0.38	6.89e-10	Gastritis;
KIRP	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg00250761	chr1:31883323	NA	-0.31	-5.41	-0.33	1.47e-7	Alcohol dependence;
KIRP	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20135002	chr11:47629003	NA	-0.46	-4.97	-0.3	1.27e-6	Subjective well-being;
KIRP	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	ch.8.33884649F	chr8:33765107	NA	-0.52	-6.68	-0.39	1.54e-10	Body mass index;
KIRP	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.11	-0.31	6.48e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	1.06	19.9	0.79	3.78e-53	Heart rate;
KIRP	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13047869	chr3:10149882	C3orf24	-0.63	-5.33	-0.32	2.24e-7	Alzheimer's disease;
KIRP	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.62	-5.27	-0.32	3e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg09571762	chr12:39539558	NA	0.33	4.93	0.3	1.53e-6	Morning vs. evening chronotype;
KIRP	cis	rs9354308	0.771	rs2814100	chr6:66528107	A/G	cg07460842	chr6:66804631	NA	0.48	5.47	0.33	1.12e-7	Metabolite levels;
KIRP	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg17845761	chr1:175162550	KIAA0040	0.33	6.34	0.37	1.08e-9	Alcohol dependence;
KIRP	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg05714579	chr10:131428358	MGMT	-0.49	-6.39	-0.38	8.02e-10	Response to temozolomide;
KIRP	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg00129232	chr17:37814104	STARD3	-0.56	-6.94	-0.4	3.44e-11	Self-reported allergy;
KIRP	cis	rs4654899	0.802	rs76122612	chr1:21243059	C/T	cg05370193	chr1:21551575	ECE1	0.41	5.22	0.32	3.82e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.03	0.64	7.39e-30	Exhaled nitric oxide output;
KIRP	cis	rs6681460	0.932	rs2044399	chr1:67054080	T/C	cg13052034	chr1:66999238	SGIP1	0.4	5.56	0.33	7.01e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg05315796	chr3:52349193	DNAH1	0.46	7.0	0.41	2.41e-11	Bipolar disorder;
KIRP	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.57	-7.98	-0.45	5.47e-14	Height;
KIRP	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.42	-0.38	7.14e-10	Body mass index;
KIRP	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.34	-0.37	1.07e-9	Breast cancer;
KIRP	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.47	6.1	0.36	4e-9	Mean corpuscular volume;
KIRP	cis	rs4901847	0.509	rs10129164	chr14:58536728	C/T	cg15908186	chr14:58618357	C14orf37	0.41	5.19	0.31	4.48e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9815354	1.000	rs9855965	chr3:41860508	C/T	cg03022575	chr3:42003672	ULK4	0.59	6.86	0.4	5.69e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg05973401	chr12:123451056	ABCB9	0.55	6.2	0.37	2.35e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9372498	0.536	rs9489395	chr6:118758884	T/C	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	trans	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.37	-0.38	9.48e-10	Neuroticism;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg14706950	chr10:93169801	HECTD2;LOC100188947	0.55	6.19	0.37	2.52e-9	Electroencephalogram traits;
KIRP	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg13455623	chr4:3480656	DOK7	-0.36	-4.85	-0.3	2.19e-6	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
KIRP	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.63	8.55	0.48	1.3e-15	Total body bone mineral density;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-7.17	-0.42	8.52e-12	Longevity;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14821842	chr8:118532860	MED30	0.47	6.04	0.36	5.54e-9	Inflammatory biomarkers;
KIRP	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.91	-0.49	1.14e-16	Myopia (pathological);
KIRP	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.47	6.24	0.37	1.85e-9	Testicular germ cell tumor;
KIRP	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.53	7.05	0.41	1.79e-11	HDL cholesterol;
KIRP	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.2	0.72	1.18e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6832769	1.000	rs3805152	chr4:56359658	C/T	cg05960024	chr4:56376020	CLOCK	0.7	8.77	0.49	3.08e-16	Personality dimensions;
KIRP	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.89	14.08	0.67	2e-33	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23827867	chr20:306044	SOX12	0.53	6.49	0.38	4.81e-10	Smoking initiation;
KIRP	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.43e-9	Obesity-related traits;
KIRP	cis	rs3105593	0.965	rs8029073	chr15:50913148	T/A	cg05456662	chr15:50716270	USP8	0.44	5.32	0.32	2.36e-7	QT interval;
KIRP	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	13.51	0.65	1.69e-31	Platelet count;
KIRP	cis	rs2594989	1.000	rs346081	chr3:11329085	A/G	cg01796438	chr3:11312864	ATG7	-0.62	-7.0	-0.41	2.49e-11	Circulating chemerin levels;
KIRP	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15128208	chr22:42549153	NA	-0.42	-5.25	-0.32	3.36e-7	Cognitive function;
KIRP	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Educational attainment;
KIRP	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.92	10.86	0.57	1.05e-22	Exhaled nitric oxide levels;
KIRP	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.0	0.36	7e-9	Menopause (age at onset);
KIRP	cis	rs6102059	0.548	rs4812441	chr20:39187925	G/A	cg22477343	chr20:39312069	NA	0.45	5.98	0.36	7.83e-9	LDL cholesterol;
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.61	8.91	0.49	1.2e-16	Lung cancer;
KIRP	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.38	5.26	0.32	3.17e-7	Endometrial cancer;
KIRP	cis	rs4132509	1.000	rs10927043	chr1:243762208	C/T	cg25706552	chr1:244017396	NA	0.52	6.78	0.4	9.01e-11	RR interval (heart rate);
KIRP	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-1.1	-19.49	-0.78	8.33e-52	Monocyte count;
KIRP	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.58	-7.65	-0.44	4.58e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs933360	0.503	rs2329554	chr7:50875030	A/G	cg14997413	chr7:51384937	COBL	0.31	4.89	0.3	1.85e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs953387	1.000	rs12473760	chr2:136905697	C/A	cg05194412	chr2:137003533	NA	-0.4	-5.23	-0.32	3.58e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs6504622	0.599	rs197913	chr17:44990046	G/C	cg16759221	chr17:45003025	GOSR2	-0.33	-5.06	-0.31	8.3e-7	Orofacial clefts;
KIRP	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg00504896	chr12:9437009	LOC642846	0.51	7.13	0.41	1.13e-11	Breast size;
KIRP	trans	rs587242	1.000	rs12744194	chr1:96898486	T/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.92	10.48	0.56	1.74e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.68	8.62	0.48	8.03e-16	Blood metabolite levels;
KIRP	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.67	-7.76	-0.44	2.3e-13	DNA methylation (variation);
KIRP	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg13877915	chr19:58951672	ZNF132	0.91	13.49	0.65	2.1e-31	Uric acid clearance;
KIRP	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg04865290	chr3:52927548	TMEM110	-0.66	-7.01	-0.41	2.22e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg13198984	chr17:80129470	CCDC57	0.58	8.74	0.49	3.62e-16	Life satisfaction;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg09278885	chr1:2126389	C1orf86;LOC100128003	0.57	6.72	0.39	1.29e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg04865290	chr3:52927548	TMEM110	-0.61	-6.77	-0.4	9.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.73	0.49	4.08e-16	Prudent dietary pattern;
KIRP	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	0.44	6.03	0.36	6.07e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.08	-21.68	-0.81	5.22e-59	Myeloid white cell count;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18870258	chr20:9460935	PLCB4	0.44	6.44	0.38	6.34e-10	Migraine with aura;
KIRP	cis	rs6681460	0.966	rs7542924	chr1:67143055	C/T	cg13052034	chr1:66999238	SGIP1	0.46	6.44	0.38	6.36e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	8.74	0.49	3.67e-16	Cognitive test performance;
KIRP	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg16989719	chr2:238392110	NA	0.43	5.41	0.33	1.51e-7	Prostate cancer;
KIRP	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05665937	chr4:1216051	CTBP1	-0.48	-6.6	-0.39	2.46e-10	Obesity-related traits;
KIRP	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	9.08	0.5	3.68e-17	Personality dimensions;
KIRP	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03982820	chr1:40723960	ZMPSTE24	0.47	6.11	0.36	3.82e-9	Survival in pancreatic cancer;
KIRP	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg23307798	chr14:103986281	CKB	0.49	7.03	0.41	2.07e-11	Body mass index;
KIRP	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg22563815	chr15:78856949	CHRNA5	0.5	7.26	0.42	4.95e-12	Sudden cardiac arrest;
KIRP	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg11752832	chr7:134001865	SLC35B4	-0.41	-4.93	-0.3	1.49e-6	Mean platelet volume;
KIRP	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	6.41	0.38	7.28e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.75	-11.09	-0.58	1.97e-23	Hip circumference;
KIRP	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.76	9.66	0.52	6.27e-19	Mood instability;
KIRP	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.9	-13.44	-0.65	3.01e-31	Height;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg09695851	chr17:3907499	NA	-0.82	-15.0	-0.69	1.47e-36	Type 2 diabetes;
KIRP	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg26248373	chr2:1572462	NA	-0.62	-6.01	-0.36	6.48e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.2e-6	Blood protein levels;
KIRP	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.75	8.11	0.46	2.4e-14	Uric acid levels;
KIRP	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-7.76	-0.44	2.21e-13	Lung cancer;
KIRP	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.23	-0.42	6.08e-12	Retinal vascular caliber;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg08208917	chr15:42565872	GANC;TMEM87A	0.92	6.13	0.36	3.39e-9	P wave terminal force;
KIRP	cis	rs9584850	0.874	rs7988959	chr13:99104004	T/C	cg20750642	chr13:99100586	FARP1	-0.54	-6.2	-0.37	2.38e-9	Neuroticism;
KIRP	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg01843034	chr6:37503916	NA	-0.97	-14.71	-0.68	1.44e-35	Cognitive performance;
KIRP	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.45	-0.33	1.24e-7	Coronary artery disease;
KIRP	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg19847130	chr8:10466454	RP1L1	0.42	6.04	0.36	5.65e-9	Joint mobility (Beighton score);
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg25356066	chr3:128598488	ACAD9	0.54	6.2	0.37	2.35e-9	IgG glycosylation;
KIRP	trans	rs4396968	1.000	rs4396968	chr4:47089184	C/T	cg02639540	chr4:4855348	NA	-0.61	-6.11	-0.36	3.88e-9	Cervical cancer;
KIRP	cis	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg25390334	chr2:241827778	C2orf54	-0.34	-4.88	-0.3	1.95e-6	Urinary metabolites;
KIRP	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.45	6.4e-14	Aortic root size;
KIRP	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11225247	0.881	rs12277594	chr11:102257415	A/C	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs13006833	0.668	rs2582746	chr2:191163784	T/C	cg21644426	chr2:191273491	MFSD6	0.45	5.48	0.33	1.03e-7	Urinary metabolites;
KIRP	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.14e-11	Obesity-related traits;
KIRP	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-5.83	-0.35	1.73e-8	Educational attainment;
KIRP	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.2	-0.8	1.98e-57	Ulcerative colitis;
KIRP	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.84	-13.17	-0.64	2.49e-30	Blood metabolite levels;
KIRP	cis	rs7221595	0.778	rs2727072	chr17:3918585	C/G	cg21734707	chr17:3908241	ZZEF1	0.57	6.51	0.38	4.11e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6540559	0.546	rs59435160	chr1:210030730	C/A	cg22029157	chr1:209979665	IRF6	0.53	5.53	0.33	8.07e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg07451762	chr16:28383216	NA	0.42	5.5	0.33	9.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	0.41	5.76	0.34	2.5e-8	Coronary artery disease;
KIRP	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.73	9.23	0.51	1.29e-17	Response to hepatitis C treatment;
KIRP	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.81	-0.63	4.05e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg06636001	chr8:8085503	FLJ10661	0.51	6.42	0.38	6.88e-10	Recombination measurement;
KIRP	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg05926928	chr17:57297772	GDPD1	0.99	10.6	0.56	7.05e-22	Opioid sensitivity;
KIRP	trans	rs863345	0.526	rs857723	chr1:158604000	C/T	cg05360176	chr12:48357394	TMEM106C	0.46	6.05	0.36	5.32e-9	Pneumococcal bacteremia;
KIRP	cis	rs9807841	0.670	rs2010492	chr19:10803395	A/G	cg09936142	chr19:10668400	KRI1	-0.44	-4.92	-0.3	1.57e-6	Inflammatory skin disease;
KIRP	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg05941025	chr16:89927596	SPIRE2	0.33	5.16	0.31	5.01e-7	Vitiligo;
KIRP	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.03	-0.41	2.08e-11	Joint mobility (Beighton score);
KIRP	cis	rs1413885	0.516	rs1591364	chr1:65842364	T/G	cg13202122	chr1:65886182	LEPROT;LEPR	0.42	4.92	0.3	1.58e-6	Anticoagulant levels;
KIRP	cis	rs867371	1.000	rs8037224	chr15:82464530	G/A	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg02570527	chr1:10970165	NA	-0.41	-4.91	-0.3	1.69e-6	Body mass index;
KIRP	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg00677455	chr12:58241039	CTDSP2	-0.49	-5.54	-0.33	7.57e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.74	10.19	0.54	1.47e-20	Plateletcrit;Platelet count;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05485520	chr3:45883628	LZTFL1	0.51	6.14	0.36	3.32e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7998202	0.667	rs282577	chr13:113358838	G/A	cg02820901	chr13:113351484	ATP11A	0.52	4.97	0.3	1.23e-6	Glycated hemoglobin levels;
KIRP	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.74	10.99	0.57	3.99e-23	Resting heart rate;
KIRP	cis	rs1823913	0.637	rs10931497	chr2:192170980	G/A	cg12404831	chr2:192114017	MYO1B	-0.45	-6.1	-0.36	4.09e-9	Obesity-related traits;
KIRP	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg00677455	chr12:58241039	CTDSP2	-0.44	-5.01	-0.3	1.02e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	cis	rs2213920	0.679	rs9409160	chr9:118227046	G/A	cg13918206	chr9:118159781	DEC1	0.99	9.95	0.54	8.14e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05220968	chr6:146057943	EPM2A	0.39	5.05	0.31	8.58e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg22138327	chr13:27999177	GTF3A	0.7	6.49	0.38	4.64e-10	Weight;
KIRP	cis	rs240764	0.658	rs3811078	chr6:101247503	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-5.09	-0.31	7.14e-7	Neuroticism;
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.18	-0.31	4.69e-7	Lung cancer;
KIRP	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg11859384	chr17:80120422	CCDC57	0.45	6.16	0.37	2.92e-9	Life satisfaction;
KIRP	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.37	5.88	0.35	1.36e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg02153584	chr22:29168773	CCDC117	0.56	7.12	0.41	1.16e-11	Lymphocyte counts;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg26516362	chr5:178986906	RUFY1	0.47	8.48	0.48	2.12e-15	Lung cancer;
KIRP	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.61	7.13	0.41	1.15e-11	Height;
KIRP	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.55	0.33	7.49e-8	Alzheimer's disease;
KIRP	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.85	12.48	0.62	5e-28	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24679411	chr12:6876188	PTMS	0.51	6.22	0.37	2.09e-9	Parkinson's disease;
KIRP	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25517755	chr10:38738941	LOC399744	0.34	4.87	0.3	2e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs76533333	0.564	rs114940891	chr13:113419784	A/T	cg04656015	chr13:113407548	ATP11A	0.61	4.88	0.3	1.87e-6	Red cell distribution width;
KIRP	cis	rs7712401	0.601	rs30039	chr5:122277179	A/C	cg19412675	chr5:122181750	SNX24	-0.46	-5.14	-0.31	5.57e-7	Mean platelet volume;
KIRP	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.6	-8.6	-0.48	9.52e-16	Breast size;
KIRP	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg15448220	chr1:150897856	SETDB1	0.38	4.96	0.3	1.32e-6	Melanoma;
KIRP	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.54	-5.96	-0.36	8.61e-9	Platelet distribution width;
KIRP	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg18657303	chr4:1051139	NA	0.58	5.24	0.32	3.52e-7	Recombination rate (females);
KIRP	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg10755058	chr3:40428713	ENTPD3	0.44	6.3	0.37	1.39e-9	Renal cell carcinoma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25029022	chr1:185126088	C1orf25;C1orf26	-0.51	-6.78	-0.4	8.75e-11	Survival in pancreatic cancer;
KIRP	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg15038512	chr6:170123185	PHF10	0.46	5.31	0.32	2.45e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.84	-0.45	1.37e-13	Joint mobility (Beighton score);
KIRP	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.66	9.07	0.5	3.89e-17	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg23505145	chr19:12996616	KLF1	0.61	9.03	0.5	5.17e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-0.82	-8.08	-0.46	2.99e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06481639	chr22:41940642	POLR3H	-0.47	-5.71	-0.34	3.26e-8	Vitiligo;
KIRP	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg24253500	chr15:84953950	NA	0.64	7.08	0.41	1.55e-11	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs16936870	0.543	rs10504473	chr8:71260332	A/C	cg14232793	chr8:71155543	NCOA2	0.54	6.24	0.37	1.95e-9	QT interval;
KIRP	cis	rs6901004	0.803	rs1022092	chr6:111427286	G/A	cg15721981	chr6:111408429	SLC16A10	-0.61	-8.51	-0.48	1.7e-15	Blood metabolite levels;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.56	-7.57	-0.43	7.66e-13	Longevity;Endometriosis;
KIRP	cis	rs7149337	0.837	rs4296182	chr14:51662167	A/C	cg23942311	chr14:51606299	NA	0.76	12.64	0.63	1.45e-28	Cancer;
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg12705353	chr12:122356852	WDR66	0.54	7.13	0.41	1.1e-11	Mean corpuscular volume;
KIRP	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	1.13	10.59	0.56	7.94e-22	Red blood cell traits;
KIRP	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg10617943	chr7:1981403	MAD1L1	-0.38	-5.17	-0.31	4.88e-7	Neuroticism;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg03289416	chr15:75166202	SCAMP2	0.52	7.07	0.41	1.58e-11	Breast cancer;
KIRP	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.71	8.51	0.48	1.7e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7903847	0.642	rs7092499	chr10:99140313	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-5.64	-0.34	4.72e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6125597	0.967	rs1079661	chr20:47850614	A/T	cg03212862	chr20:47662828	CSE1L	-0.42	-5.38	-0.32	1.73e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg27205649	chr11:78285834	NARS2	0.68	9.04	0.5	4.74e-17	Alzheimer's disease (survival time);
KIRP	cis	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.2e-11	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.44	0.38	6.18e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2718058	0.515	rs1584611	chr7:37874039	T/C	cg15028436	chr7:37888078	TXNDC3	0.55	7.33	0.42	3.41e-12	Alzheimer's disease (late onset);
KIRP	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21747090	chr2:27597821	SNX17	-0.48	-6.64	-0.39	1.97e-10	Total body bone mineral density;
KIRP	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg11987759	chr7:65425863	GUSB	-0.43	-5.01	-0.3	1.06e-6	Corneal structure;
KIRP	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.61	0.34	5.4e-8	Blood protein levels;
KIRP	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-0.9	-9.94	-0.54	8.47e-20	Gut microbiome composition (summer);
KIRP	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg13147721	chr7:65941812	NA	1.04	7.24	0.42	5.57e-12	Diabetic kidney disease;
KIRP	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg10818794	chr15:86012489	AKAP13	-0.5	-7.19	-0.42	7.54e-12	Coronary artery disease;
KIRP	cis	rs4481887	0.790	rs6695468	chr1:248424596	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.2	0.31	4.21e-7	Common traits (Other);
KIRP	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg10755058	chr3:40428713	ENTPD3	0.48	6.65	0.39	1.89e-10	Renal cell carcinoma;
KIRP	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.63	-8.44	-0.47	2.81e-15	Motion sickness;
KIRP	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg08989290	chr16:615782	NHLRC4	0.41	6.07	0.36	4.9e-9	Height;
KIRP	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.7	-11.68	-0.6	2.3e-25	Lung function (FVC);
KIRP	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-8.73	-0.49	4e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg07148914	chr20:33460835	GGT7	0.67	8.44	0.47	2.77e-15	Height;
KIRP	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-4.87	-0.3	1.96e-6	Response to bleomycin (chromatid breaks);
KIRP	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.38	-0.38	8.61e-10	Systolic blood pressure;
KIRP	cis	rs600806	0.778	rs10857787	chr1:110010289	C/T	cg02175308	chr1:109941060	SORT1	-0.26	-4.85	-0.3	2.24e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg01631408	chr1:248437212	OR2T33	-0.68	-8.74	-0.49	3.75e-16	Common traits (Other);
KIRP	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.57	-6.24	-0.37	1.89e-9	Colorectal adenoma (advanced);
KIRP	cis	rs4073221	0.654	rs13065016	chr3:18291793	A/G	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.4e-9	Parkinson's disease;
KIRP	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.64	0.39	2.04e-10	Hypertriglyceridemia;
KIRP	cis	rs830383	0.584	rs13156877	chr5:165507699	T/C	cg13976338	chr5:165423657	NA	0.48	5.58	0.34	6.24e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg19847130	chr8:10466454	RP1L1	0.4	5.71	0.34	3.3e-8	Retinal vascular caliber;
KIRP	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg24324837	chr19:49891574	CCDC155	0.68	8.8	0.49	2.51e-16	Multiple sclerosis;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg04025307	chr7:1156635	C7orf50	0.73	7.46	0.43	1.48e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg15181151	chr6:150070149	PCMT1	0.31	5.24	0.32	3.39e-7	Lung cancer;
KIRP	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg11846333	chr4:119757529	SEC24D	1.14	6.8	0.4	7.75e-11	Cannabis dependence symptom count;
KIRP	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-7.01	-0.41	2.31e-11	Eye color traits;
KIRP	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.39	-5.12	-0.31	6.22e-7	Parkinson's disease;
KIRP	cis	rs1018697	1.000	rs7073114	chr10:104555651	C/T	cg04362960	chr10:104952993	NT5C2	0.48	5.82	0.35	1.85e-8	Colorectal adenoma (advanced);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02639808	chr4:77997188	CCNI	-0.57	-6.15	-0.37	3.12e-9	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18614379	chr15:64388188	SNX1	0.47	6.4	0.38	7.99e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg01689657	chr7:91764605	CYP51A1	0.39	5.78	0.35	2.25e-8	Breast cancer;
KIRP	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	7.57	0.43	7.49e-13	Bone mineral density;
KIRP	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.31	-0.32	2.51e-7	Neuroticism;
KIRP	cis	rs62413470	1.000	rs12196709	chr6:55941100	T/C	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg08204369	chr17:73150733	HN1	0.54	6.16	0.37	2.93e-9	Sleep duration;
KIRP	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg24009623	chr19:33667908	NA	0.47	6.3	0.37	1.39e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8028182	0.636	rs28737338	chr15:75768679	C/T	cg20655648	chr15:75932815	IMP3	0.55	7.06	0.41	1.7e-11	Sudden cardiac arrest;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.84	9.08	0.5	3.65e-17	Exhaled nitric oxide output;
KIRP	cis	rs3126085	0.935	rs3126088	chr1:152305785	A/G	cg26876637	chr1:152193138	HRNR	-0.7	-8.75	-0.49	3.4e-16	Atopic dermatitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13635455	chr14:91731012	NA	0.53	7.45	0.43	1.56e-12	Parkinson's disease;
KIRP	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg00094735	chr5:1949198	NA	-0.5	-5.73	-0.34	2.97e-8	Gut microbiome composition (winter);
KIRP	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg22633769	chr20:60982531	CABLES2	-0.43	-5.32	-0.32	2.31e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg08662619	chr6:150070041	PCMT1	0.38	6.34	0.37	1.07e-9	Lung cancer;
KIRP	cis	rs11024102	0.925	rs7127818	chr11:17004090	G/C	cg15378786	chr11:17036137	PLEKHA7	0.49	4.85	0.3	2.21e-6	Glaucoma (primary angle closure);
KIRP	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg22974920	chr21:40686053	BRWD1	0.51	6.21	0.37	2.29e-9	Cognitive function;
KIRP	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs7534824	0.625	rs61780285	chr1:101357627	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.71	0.34	3.31e-8	Refractive astigmatism;
KIRP	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.64	0.44	4.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.2	-0.37	2.36e-9	Lung cancer;
KIRP	cis	rs7221595	0.825	rs62072392	chr17:3910125	A/G	cg11204139	chr17:3907470	NA	0.6	5.82	0.35	1.81e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.09	0.36	4.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7011049	0.778	rs12375363	chr8:53868768	A/C	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.62	8.05	0.46	3.62e-14	Colorectal cancer;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg02923274	chr12:98987217	SLC25A3	0.44	6.03	0.36	5.89e-9	Coronary artery disease;
KIRP	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg07810366	chr2:100720526	AFF3	0.32	5.04	0.31	9.08e-7	Educational attainment;
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg10150615	chr22:24372951	LOC391322	-0.59	-6.3	-0.37	1.33e-9	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.78	0.35	2.2e-8	Lung cancer;
KIRP	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg14983838	chr19:29218262	NA	0.73	7.06	0.41	1.66e-11	Methadone dose in opioid dependence;
KIRP	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg13271783	chr10:134563150	INPP5A	-0.5	-6.4	-0.38	7.59e-10	Migraine;
KIRP	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.62	-7.57	-0.43	7.66e-13	Mosquito bite size;
KIRP	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.83	13.73	0.66	3.14e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs73206853	0.764	rs7299230	chr12:110618512	A/T	cg12870014	chr12:110450643	ANKRD13A	0.53	5.61	0.34	5.46e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs12220238	0.722	rs10762635	chr10:76403131	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.55	5.96	0.36	8.59e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.46	0.38	5.71e-10	Educational attainment;
KIRP	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg23950597	chr19:37808831	NA	-0.59	-6.35	-0.38	1.02e-9	Coronary artery calcification;
KIRP	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.47	-5.82	-0.35	1.83e-8	Menarche (age at onset);
KIRP	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg09699651	chr6:150184138	LRP11	0.45	6.08	0.36	4.61e-9	Lung cancer;
KIRP	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.57	-0.33	6.77e-8	Aortic root size;
KIRP	trans	rs615632	0.516	rs13279794	chr8:9684014	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.8	0.4	7.91e-11	Neuroticism;
KIRP	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg01097406	chr16:89675127	NA	0.31	5.1	0.31	6.71e-7	Vitiligo;
KIRP	cis	rs1847202	0.762	rs62249896	chr3:72949857	C/G	cg06781948	chr3:72941472	GXYLT2	0.48	6.2	0.37	2.39e-9	Motion sickness;
KIRP	cis	rs17221829	0.733	rs11018679	chr11:89362869	G/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.88	-0.3	1.89e-6	Anxiety in major depressive disorder;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-7.73	-0.44	2.71e-13	Lung cancer;
KIRP	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg02696790	chr15:75250997	RPP25	0.28	4.92	0.3	1.61e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.41	5.24	0.32	3.42e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg25174290	chr11:3078921	CARS	-0.57	-6.11	-0.36	3.92e-9	Calcium levels;
KIRP	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.58	-7.12	-0.41	1.18e-11	Aortic root size;
KIRP	cis	rs1144713	0.531	rs1716941	chr12:32255094	A/G	cg01321189	chr12:32259338	BICD1	0.43	5.19	0.31	4.33e-7	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs12135191	0.771	rs12749874	chr1:236503856	A/G	cg21399712	chr1:236511386	NA	-0.48	-6.02	-0.36	6.19e-9	Urate levels (BMI interaction);
KIRP	cis	rs1867631	1.000	rs10889636	chr1:67089924	A/G	cg13052034	chr1:66999238	SGIP1	-0.48	-6.85	-0.4	5.78e-11	Menopause (age at onset);
KIRP	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-0.43	-5.54	-0.33	7.81e-8	Acne (severe);
KIRP	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14169450	chr9:139327907	INPP5E	0.38	5.56	0.33	6.99e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4908768	0.594	rs11121227	chr1:8830640	C/T	cg03610117	chr1:8450231	RERE	-0.44	-4.88	-0.3	1.88e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg00079375	chr15:79125835	NA	0.38	5.4	0.33	1.54e-7	Coronary artery disease;
KIRP	trans	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg26043149	chr18:55253948	FECH	-0.5	-6.34	-0.37	1.1e-9	Bone mineral density;
KIRP	cis	rs4713675	0.565	rs942640	chr6:33686442	G/T	cg15676125	chr6:33679581	C6orf125	0.42	5.51	0.33	8.97e-8	Plateletcrit;
KIRP	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg08742575	chr21:47604166	C21orf56	0.41	5.33	0.32	2.18e-7	Testicular germ cell tumor;
KIRP	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg11783602	chr8:55087084	NA	-0.57	-7.07	-0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs904251	0.620	rs883372	chr6:37477605	A/C	cg24807547	chr6:37504484	NA	-0.49	-5.56	-0.33	7.01e-8	Cognitive performance;
KIRP	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.74	7.38	0.43	2.46e-12	Vitiligo;
KIRP	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.74	-6.95	-0.41	3.17e-11	Alzheimer's disease (late onset);
KIRP	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg16306078	chr6:126000798	NA	-0.27	-4.99	-0.3	1.14e-6	Endometrial cancer;
KIRP	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	13.47	0.65	2.45e-31	Platelet count;
KIRP	cis	rs975752	0.867	rs66728174	chr10:102020626	C/T	cg13817732	chr10:102046368	BLOC1S2	0.72	6.01	0.36	6.83e-9	Schizophrenia;
KIRP	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	0.93	13.51	0.65	1.7e-31	Dupuytren's disease;
KIRP	trans	rs1864585	0.520	rs7817252	chr8:10685932	C/A	cg26278703	chr11:58910052	FAM111A	0.64	6.08	0.36	4.64e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4262150	0.883	rs55918828	chr5:152187782	C/T	cg12297329	chr5:152029980	NA	-0.66	-8.53	-0.48	1.55e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2862064	0.872	rs2902132	chr5:156445525	C/T	cg12943317	chr5:156479607	HAVCR1	-0.89	-7.96	-0.45	6.21e-14	Platelet count;
KIRP	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.59	-8.54	-0.48	1.45e-15	Obesity-related traits;
KIRP	cis	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg21546286	chr11:48923668	NA	-0.48	-6.1	-0.36	4.19e-9	HDL cholesterol;
KIRP	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.65	10.21	0.55	1.27e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg26876637	chr1:152193138	HRNR	0.73	9.87	0.53	1.45e-19	Atopic dermatitis;
KIRP	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-1.01	-16.63	-0.73	4.1e-42	Height;
KIRP	cis	rs10484885	0.559	rs16881894	chr6:90192112	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.49	-5.09	-0.31	7.03e-7	QRS interval (sulfonylurea treatment interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01395402	chr3:63898123	ATXN7	0.55	6.99	0.41	2.6e-11	Parkinson's disease;
KIRP	cis	rs10426930	0.547	rs2054519	chr19:5059360	T/C	cg18473234	chr19:5097819	KDM4B	-0.59	-6.67	-0.39	1.64e-10	Monocyte percentage of white cells;
KIRP	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.59	-7.92	-0.45	8.25e-14	Asthma;
KIRP	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs3812049	0.532	rs251389	chr5:127541877	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	8.46	0.47	2.34e-15	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.57	-6.36	-0.38	1e-9	LDL cholesterol levels;
KIRP	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.65	7.71	0.44	3.02e-13	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7246760	0.867	rs59616842	chr19:9792245	G/A	cg02900749	chr2:68251473	NA	-1.16	-9.53	-0.52	1.56e-18	Pursuit maintenance gain;
KIRP	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg06307176	chr5:131281290	NA	0.56	6.23	0.37	2.04e-9	Life satisfaction;
KIRP	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.16e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.68	7.4	0.43	2.12e-12	Smoking initiation;
KIRP	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	1.17	9.65	0.52	6.88e-19	Lymphocyte counts;
KIRP	trans	rs12517041	0.748	rs16892375	chr5:23304111	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs2278796	1.000	rs12124296	chr1:204945618	G/A	cg17449235	chr1:204966235	NFASC	0.55	7.44	0.43	1.65e-12	Mean platelet volume;
KIRP	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-5.32	-0.32	2.37e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg26138937	chr11:71823887	C11orf51	1.01	6.25	0.37	1.76e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs7582720	1.000	rs72932745	chr2:203662888	A/C	cg08076091	chr2:203926405	NBEAL1	0.85	8.53	0.48	1.52e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg16479474	chr6:28041457	NA	0.44	4.93	0.3	1.5e-6	Depression;
KIRP	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg01557791	chr16:72042693	DHODH	-0.41	-5.02	-0.3	9.85e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs3736485	0.578	rs1456300	chr15:51982016	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.01	-0.3	1.02e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg10756647	chr7:56101905	PSPH	0.96	6.67	0.39	1.66e-10	Gout;
KIRP	trans	rs2270927	0.510	rs2937749	chr5:75571564	T/G	cg13563193	chr19:33072644	PDCD5	0.95	6.05	0.36	5.3e-9	Mean corpuscular volume;
KIRP	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg13798912	chr7:905769	UNC84A	0.55	5.58	0.34	6.41e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.83	11.91	0.6	4.01e-26	Monocyte count;
KIRP	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	9.05	0.5	4.5e-17	Mood instability;
KIRP	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg08888203	chr3:10149979	C3orf24	0.49	5.13	0.31	5.78e-7	Alzheimer's disease;
KIRP	cis	rs10214930	0.697	rs1980329	chr7:27630300	T/A	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.91	-0.49	1.16e-16	Coronary artery disease;
KIRP	cis	rs6681460	0.966	rs4655506	chr1:67150811	C/T	cg13052034	chr1:66999238	SGIP1	0.44	5.95	0.35	9.23e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.05	0.46	3.6e-14	Lung cancer;
KIRP	cis	rs17739794	0.557	rs7816977	chr8:814612	A/G	cg01971667	chr8:817044	NA	0.39	5.6	0.34	5.65e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs6838801	0.523	rs344123	chr4:77638013	T/C	cg17476223	chr4:77663285	SHROOM3	-0.58	-7.47	-0.43	1.41e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.15	-16.03	-0.71	4.27e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs1635	0.655	rs1416919	chr6:28302884	T/G	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	0.84	8.07	0.46	3.02e-14	Methadone dose in opioid dependence;
KIRP	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg12591125	chr7:1885375	MAD1L1	0.64	6.14	0.36	3.22e-9	Bipolar disorder;
KIRP	cis	rs9409565	0.826	rs4744338	chr9:97158965	C/T	cg04523069	chr9:97136363	HIATL1	-0.47	-6.36	-0.38	9.5e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg09904177	chr6:26538194	HMGN4	-0.45	-6.12	-0.36	3.61e-9	Schizophrenia;
KIRP	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.26	-0.62	2.85e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs1538970	1.000	rs1538970	chr1:45847562	G/A	cg05343316	chr1:45956843	TESK2	0.63	7.07	0.41	1.6e-11	Platelet count;
KIRP	trans	rs9371601	0.819	rs214946	chr6:152713812	G/A	cg05529123	chr2:66910386	NA	-0.46	-6.23	-0.37	2.02e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-1.02	-10.18	-0.54	1.57e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.72	11.11	0.58	1.68e-23	Cancer;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00585698	chr12:123750864	CDK2AP1	0.44	5.59	0.34	6.16e-8	Neutrophil percentage of white cells;
KIRP	cis	rs13401104	0.796	rs72620805	chr2:237113711	G/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg24585782	chr17:78113791	EIF4A3	-0.54	-6.3	-0.37	1.38e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg06766960	chr11:133703094	NA	-0.49	-6.35	-0.38	1.02e-9	Childhood ear infection;
KIRP	cis	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg06521331	chr12:34319734	NA	0.57	7.1	0.41	1.35e-11	Morning vs. evening chronotype;
KIRP	trans	rs7428850	0.803	rs1015922	chr3:24127267	C/G	cg08976554	chr12:124908112	NCOR2	-0.5	-6.04	-0.36	5.67e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg15660573	chr17:549704	VPS53	-0.85	-12.79	-0.63	4.66e-29	Prostate cancer;
KIRP	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.78	-9.47	-0.52	2.44e-18	Response to antipsychotic treatment;
KIRP	cis	rs4363385	0.510	rs10888528	chr1:153050516	A/G	cg07796016	chr1:152779584	LCE1C	0.46	5.78	0.35	2.28e-8	Inflammatory skin disease;
KIRP	cis	rs42648	0.935	rs2188232	chr7:89958314	A/C	cg25739043	chr7:89950458	NA	-0.47	-7.3	-0.42	3.92e-12	Homocysteine levels;
KIRP	cis	rs6662572	0.806	rs11211133	chr1:45991079	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.55	6.11	0.36	3.88e-9	Blood protein levels;
KIRP	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-5.27	-0.32	3e-7	Life satisfaction;
KIRP	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.83	12.65	0.63	1.36e-28	Prostate cancer;
KIRP	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	11.87	0.6	5.4e-26	Blood protein levels;
KIRP	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg11833968	chr6:79620685	NA	-0.41	-5.98	-0.36	7.67e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4663866	0.901	rs71426512	chr2:239187128	C/T	cg16914508	chr2:239161102	PER2	0.72	5.17	0.31	4.81e-7	Irritable bowel syndrome;
KIRP	cis	rs1440410	0.835	rs4594668	chr4:144050446	A/T	cg01719995	chr4:144104893	USP38	-0.5	-6.91	-0.4	4.13e-11	Ischemic stroke;
KIRP	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.8e-7	Major depressive disorder;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.83	7.44	0.43	1.7e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	9.06	0.5	4.09e-17	Motion sickness;
KIRP	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.46	-10.07	-0.54	3.33e-20	Mean corpuscular volume;
KIRP	cis	rs6585424	0.850	rs75804987	chr10:81932509	C/T	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg05785598	chr3:49045655	WDR6	0.29	5.26	0.32	3.21e-7	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.47	5.94	0.35	9.78e-9	Life satisfaction;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg03967431	chr4:99849653	EIF4E	0.52	6.08	0.36	4.46e-9	Plasma plasminogen activator levels;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.51	5.05	0.31	8.45e-7	Alzheimer's disease;
KIRP	cis	rs75920871	0.920	rs7924318	chr11:116816630	C/G	cg23684410	chr11:116897558	SIK3	0.55	6.02	0.36	6.32e-9	Subjective well-being;
KIRP	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.38	-0.68	1.86e-34	Primary sclerosing cholangitis;
KIRP	trans	rs2594989	0.887	rs7640360	chr3:11584889	T/G	cg02538783	chr10:35102505	PARD3	0.36	6.13	0.36	3.56e-9	Circulating chemerin levels;
KIRP	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg17133734	chr15:86042851	AKAP13	-0.41	-5.13	-0.31	5.97e-7	Interstitial lung disease;
KIRP	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg01620082	chr3:125678407	NA	-0.88	-6.35	-0.38	1.04e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg17764715	chr19:33622953	WDR88	0.68	8.32	0.47	5.91e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.41	-5.0	-0.3	1.09e-6	Neurofibrillary tangles;
KIRP	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg25039879	chr17:56429692	SUPT4H1	0.61	5.35	0.32	1.98e-7	Cognitive test performance;
KIRP	cis	rs77688320	0.573	rs2080327	chr2:202326218	G/A	cg06431681	chr2:202330990	STRADB	-0.42	-4.88	-0.3	1.94e-6	Breast cancer;
KIRP	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00300879	chr1:26503847	CNKSR1	0.48	6.85	0.4	5.88e-11	Height;
KIRP	cis	rs684232	0.835	rs12450003	chr17:519015	T/C	cg04370829	chr17:406249	NA	0.38	4.96	0.3	1.34e-6	Prostate cancer;
KIRP	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.95	0.41	3.26e-11	Vitiligo;
KIRP	cis	rs4740619	0.557	rs1328296	chr9:16046292	G/C	cg14451791	chr9:16040625	NA	-0.4	-5.09	-0.31	7.19e-7	Body mass index;
KIRP	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg14440974	chr22:39074834	NA	-0.38	-4.95	-0.3	1.4e-6	Menopause (age at onset);
KIRP	cis	rs6725041	0.819	rs10172672	chr2:213089291	C/A	cg20637307	chr2:213403960	ERBB4	-0.4	-5.14	-0.31	5.62e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	1.08	8.07	0.46	3.05e-14	Skin colour saturation;
KIRP	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg06064525	chr11:970664	AP2A2	-0.34	-6.68	-0.39	1.55e-10	Alzheimer's disease (late onset);
KIRP	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.56	8.09	0.46	2.71e-14	Bone mineral density;
KIRP	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg02297831	chr4:17616191	MED28	-0.51	-6.07	-0.36	4.71e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9596863	1.000	rs1977889	chr13:54442809	C/T	ch.13.53330881F	chr13:54432880	NA	-0.56	-5.75	-0.34	2.69e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.29	0.47	7.43e-15	Response to antipsychotic treatment;
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg11814155	chr7:99998594	ZCWPW1	0.62	5.83	0.35	1.73e-8	Platelet count;
KIRP	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg18478394	chr8:109455254	TTC35	0.48	5.95	0.35	8.93e-9	Dupuytren's disease;
KIRP	cis	rs7246657	0.943	rs7248733	chr19:37996361	A/C	cg23950597	chr19:37808831	NA	-0.62	-6.73	-0.39	1.2e-10	Coronary artery calcification;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06932451	chr19:36869880	NA	0.56	6.98	0.41	2.65e-11	Smoking initiation;
KIRP	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg06102954	chr21:42741788	MX2	0.53	7.43	0.43	1.78e-12	Melanoma;
KIRP	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg02297831	chr4:17616191	MED28	0.54	6.42	0.38	7.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg11846333	chr4:119757529	SEC24D	0.96	5.94	0.35	9.75e-9	Cannabis dependence symptom count;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.76	11.94	0.61	3.08e-26	Vitiligo;
KIRP	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg07827796	chr19:33622959	WDR88	0.43	5.1	0.31	6.78e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg11131117	chr7:1891496	MAD1L1	0.4	4.84	0.3	2.26e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg02023728	chr11:77925099	USP35	0.28	4.87	0.3	2.02e-6	Alzheimer's disease (survival time);
KIRP	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg05729581	chr11:3078854	CARS	0.41	5.19	0.31	4.5e-7	Longevity;
KIRP	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg08603382	chr10:743973	NA	-0.43	-6.22	-0.37	2.15e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.44	-5.68	-0.34	3.73e-8	Motion sickness;
KIRP	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.9	-0.35	1.17e-8	Height;
KIRP	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg04374321	chr14:90722782	PSMC1	-0.84	-11.86	-0.6	5.73e-26	Mortality in heart failure;
KIRP	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.73	11.13	0.58	1.44e-23	Type 2 diabetes;
KIRP	trans	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg06521331	chr12:34319734	NA	-0.52	-6.33	-0.37	1.13e-9	Bladder cancer;
KIRP	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg23625390	chr15:77176239	SCAPER	-0.51	-6.78	-0.4	8.95e-11	Blood metabolite levels;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-0.82	-14.9	-0.69	3.28e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg11657440	chr19:46296263	DMWD	-0.71	-8.97	-0.5	7.78e-17	Coronary artery disease;
KIRP	cis	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg00576331	chr11:65640516	EFEMP2	-0.43	-5.36	-0.32	1.89e-7	Breast cancer;
KIRP	cis	rs13006833	0.668	rs2136566	chr2:191141283	C/T	cg21644426	chr2:191273491	MFSD6	0.44	5.12	0.31	6.06e-7	Urinary metabolites;
KIRP	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.91	13.22	0.64	1.68e-30	Menopause (age at onset);
KIRP	cis	rs7173743	0.525	rs4341710	chr15:79140460	C/T	cg00079375	chr15:79125835	NA	-0.4	-5.59	-0.34	6.1e-8	Coronary artery disease;
KIRP	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg20701182	chr2:24300061	SF3B14	1.01	10.79	0.57	1.76e-22	Lymphocyte counts;
KIRP	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.68	-8.07	-0.46	3.17e-14	Blood protein levels;
KIRP	cis	rs1010254	0.510	rs17543421	chr5:151701350	T/C	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg05784532	chr1:230284198	GALNT2	0.43	6.43	0.38	6.51e-10	Coronary artery disease;
KIRP	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.7	-8.38	-0.47	4.21e-15	Facial morphology (factor 19);
KIRP	cis	rs282587	0.569	rs385990	chr13:113396575	A/G	cg04656015	chr13:113407548	ATP11A	0.64	7.52	0.43	1.01e-12	Glycated hemoglobin levels;
KIRP	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg19592336	chr6:28129416	ZNF389	0.5	5.65	0.34	4.5e-8	Depression;
KIRP	cis	rs405956	1.000	rs1338020	chr6:105577686	C/T	cg22580625	chr6:105627791	POPDC3	-0.6	-6.36	-0.38	9.7e-10	QT interval;
KIRP	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.93	10.99	0.57	4.05e-23	Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05647208	chr19:18527971	NA	0.49	6.99	0.41	2.6e-11	Parkinson's disease;
KIRP	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.51	6.99	0.41	2.62e-11	Night sleep phenotypes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.56	6.65	0.39	1.83e-10	Smoking initiation;
KIRP	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.67e-19	Prudent dietary pattern;
KIRP	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg22906224	chr7:99728672	NA	-0.5	-6.12	-0.36	3.58e-9	Coronary artery disease;
KIRP	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs16828019	0.852	rs12045171	chr1:41528805	G/A	cg18742814	chr1:41828276	NA	0.52	4.87	0.3	2.01e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10484885	0.878	rs1328018	chr6:90297847	A/G	cg13799429	chr6:90582589	CASP8AP2	0.77	7.31	0.42	3.66e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs1030268	0.667	rs12707111	chr7:133330144	C/T	cg10665199	chr7:133106180	EXOC4	0.58	5.9	0.35	1.17e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	1.02	10.21	0.55	1.22e-20	Psoriasis;
KIRP	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14893161	chr1:205819251	PM20D1	0.49	5.37	0.32	1.79e-7	Parkinson's disease;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.69	10.48	0.56	1.75e-21	Menarche (age at onset);
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.54e-8	Life satisfaction;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.72	6.11	0.36	3.83e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.83	12.27	0.62	2.56e-27	Eye color traits;
KIRP	cis	rs3105593	1.000	rs3105590	chr15:50864145	A/G	cg05456662	chr15:50716270	USP8	0.42	5.17	0.31	4.82e-7	QT interval;
KIRP	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.72	11.8	0.6	9.19e-26	Metabolite levels;
KIRP	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05472934	chr7:22766657	IL6	0.8	10.24	0.55	1.01e-20	Lung cancer;
KIRP	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-6.71	-0.39	1.36e-10	Body mass index;
KIRP	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg21775007	chr8:11205619	TDH	-0.49	-6.33	-0.37	1.17e-9	Systolic blood pressure;
KIRP	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03934478	chr11:495069	RNH1	0.84	6.61	0.39	2.36e-10	Body mass index;
KIRP	cis	rs7941600	1.000	rs7941600	chr11:9280284	G/A	cg19415743	chr11:9336845	TMEM41B	0.73	5.01	0.3	1.04e-6	Coronary artery disease;
KIRP	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.73	-0.77	3.02e-49	Schizophrenia;
KIRP	cis	rs9311676	0.656	rs6800514	chr3:58358717	C/T	cg06643156	chr3:58380774	PXK	0.36	5.07	0.31	7.93e-7	Systemic lupus erythematosus;
KIRP	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.18	0.31	4.62e-7	Body mass index;
KIRP	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg02487422	chr3:49467188	NICN1	0.35	4.93	0.3	1.5e-6	Parkinson's disease;
KIRP	cis	rs2882667	0.898	rs6867343	chr5:138374428	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-7.55	-0.43	8.73e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg14580859	chr9:123691850	NA	0.35	4.98	0.3	1.22e-6	Rheumatoid arthritis;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	7.65	0.44	4.59e-13	Lymphocyte counts;
KIRP	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.94	12.21	0.61	4e-27	Menopause (age at onset);
KIRP	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.46	-6.72	-0.39	1.27e-10	Obesity-related traits;
KIRP	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg18477163	chr1:228402036	OBSCN	-0.33	-6.61	-0.39	2.31e-10	Diastolic blood pressure;
KIRP	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	6.24	0.37	1.88e-9	Mean platelet volume;
KIRP	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg02527881	chr3:46936655	PTH1R	-0.44	-6.24	-0.37	1.91e-9	Colorectal cancer;
KIRP	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.49	0.38	4.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01391022	chr12:122360665	WDR66	-0.41	-6.13	-0.36	3.55e-9	Mean corpuscular volume;
KIRP	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	5.33	0.32	2.2e-7	Obesity-related traits;
KIRP	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg13482628	chr17:19912719	NA	0.55	7.79	0.44	1.89e-13	Schizophrenia;
KIRP	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg07395648	chr5:131743802	NA	-0.51	-6.43	-0.38	6.46e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs12130219	1.000	rs1552994	chr1:152171461	A/G	cg26879891	chr1:152191343	HRNR	0.5	6.12	0.36	3.71e-9	Inflammatory skin disease;
KIRP	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg07661805	chr8:143867942	LY6D	-0.29	-5.07	-0.31	7.67e-7	Urinary tract infection frequency;
KIRP	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg05785598	chr3:49045655	WDR6	0.29	5.25	0.32	3.3e-7	Parkinson's disease;
KIRP	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg04850286	chr10:81895943	PLAC9	0.27	5.07	0.31	7.87e-7	Sarcoidosis;
KIRP	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.95	-13.28	-0.65	1.06e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg21775007	chr8:11205619	TDH	0.39	5.32	0.32	2.28e-7	Monocyte count;
KIRP	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.62e-8	Neuroticism;
KIRP	trans	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg20528838	chr20:57427730	GNAS	-0.46	-6.17	-0.37	2.76e-9	Height;
KIRP	cis	rs4690686	0.836	rs10015351	chr4:177258952	A/G	cg17059388	chr4:177262070	NA	0.54	7.61	0.44	5.98e-13	Essential tremor;
KIRP	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs8014252	0.614	rs28612538	chr14:71025206	G/A	cg19730268	chr14:71022823	NA	-0.51	-4.93	-0.3	1.53e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg23845249	chr11:68861649	NA	0.37	5.91	0.35	1.11e-8	Blond vs. brown hair color;
KIRP	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-8.54	-0.48	1.46e-15	Response to antipsychotic treatment;
KIRP	cis	rs7580658	0.545	rs885275	chr2:127951095	T/C	cg16751203	chr2:127950803	CYP27C1	0.41	5.71	0.34	3.27e-8	Protein C levels;
KIRP	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.59	7.32	0.42	3.49e-12	Arsenic metabolism;
KIRP	cis	rs7792596	0.861	rs4729128	chr7:94014485	C/A	cg20814616	chr7:94014465	NA	-0.4	-6.81	-0.4	7.56e-11	Intelligence;
KIRP	cis	rs2882667	1.000	rs10515505	chr5:138313146	A/G	cg04439458	chr5:138467593	SIL1	-0.42	-6.39	-0.38	8.37e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9921338	0.961	rs7206017	chr16:11440861	C/T	cg00044050	chr16:11439710	C16orf75	-0.55	-5.87	-0.35	1.43e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.43	-5.31	-0.32	2.51e-7	Aortic root size;
KIRP	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.65	-5.0	-0.3	1.1e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.58	7.17	0.42	8.89e-12	Arsenic metabolism;
KIRP	cis	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg03016385	chr14:66212404	NA	-0.97	-10.01	-0.54	5.1e-20	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.53	-0.38	3.71e-10	Neuroticism;
KIRP	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.43	-5.02	-0.3	1.01e-6	Aortic root size;
KIRP	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg11764359	chr7:65958608	NA	-0.75	-4.86	-0.3	2.11e-6	Gout;
KIRP	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg00310523	chr12:86230176	RASSF9	-0.42	-6.19	-0.37	2.55e-9	Major depressive disorder;
KIRP	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.66	9.6	0.52	1e-18	Dupuytren's disease;
KIRP	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.62	6.82	0.4	6.85e-11	Response to antipsychotic treatment;
KIRP	cis	rs734999	0.505	rs4073285	chr1:2539796	C/T	cg20673091	chr1:2541236	MMEL1	0.67	10.4	0.55	3.14e-21	Ulcerative colitis;
KIRP	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.8	-11.18	-0.58	9.69e-24	Blood metabolite levels;
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg10253484	chr15:75165896	SCAMP2	-0.47	-5.56	-0.33	6.88e-8	Breast cancer;
KIRP	cis	rs9302690	1.000	rs74809791	chr16:57472860	G/T	cg27017172	chr16:57497170	POLR2C	1.05	8.54	0.48	1.42e-15	Blood protein levels;
KIRP	cis	rs12949688	0.601	rs10083839	chr17:55835623	C/T	cg12582317	chr17:55822272	NA	0.44	6.4	0.38	7.61e-10	Schizophrenia;
KIRP	cis	rs9533799	1.000	rs9533798	chr13:44802505	C/G	cg19190762	chr13:44806055	NA	-0.59	-7.98	-0.45	5.69e-14	Amyotrophic lateral sclerosis;
KIRP	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.61	-6.89	-0.4	4.68e-11	Mean platelet volume;
KIRP	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg02367723	chr1:46378857	MAST2	0.42	4.86	0.3	2.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00791764	chr4:53727839	RASL11B	0.45	6.35	0.38	1.05e-9	Optic nerve measurement (cup area);
KIRP	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg12573674	chr2:1569213	NA	-0.59	-5.29	-0.32	2.64e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2072732	0.904	rs56069604	chr1:2971452	T/C	cg11731671	chr1:2995604	PRDM16	-0.59	-6.46	-0.38	5.45e-10	Plateletcrit;
KIRP	cis	rs2236918	0.932	rs2488471	chr1:242019831	T/C	cg17736920	chr1:242011382	EXO1	0.75	9.86	0.53	1.54e-19	Menopause (age at onset);
KIRP	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg03465714	chr1:152285911	FLG	-0.42	-5.01	-0.3	1.03e-6	Atopic dermatitis;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22618164	chr12:122356400	WDR66	-0.62	-8.61	-0.48	9.13e-16	Mean corpuscular volume;
KIRP	cis	rs10181042	0.565	rs3108630	chr2:61268160	A/G	cg10580144	chr2:61372316	C2orf74	-0.39	-5.43	-0.33	1.33e-7	Crohn's disease;
KIRP	trans	rs587242	0.956	rs602272	chr1:96893914	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.46	5.24	0.32	3.47e-7	Schizophrenia;
KIRP	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg02640540	chr1:67518911	SLC35D1	0.4	4.94	0.3	1.44e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs1045714	1.000	rs1045713	chr7:2653579	G/A	cg20813462	chr7:2646259	IQCE	0.69	6.15	0.37	3.11e-9	Urate levels in lean individuals;
KIRP	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.94	0.5	9.35e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.6	7.05	0.41	1.75e-11	Vitiligo;
KIRP	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.59	8.59	0.48	1.02e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.23	-0.42	6.13e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2290419	0.730	rs59374155	chr11:68940308	G/C	cg17042914	chr11:68898666	NA	-0.7	-5.07	-0.31	7.93e-7	Cutaneous malignant melanoma;
KIRP	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-16.01	-0.71	5.08e-40	Coronary artery disease;
KIRP	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg00933542	chr6:150070202	PCMT1	0.26	4.98	0.3	1.2e-6	Testicular germ cell tumor;
KIRP	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg00277334	chr10:82204260	NA	-0.58	-6.08	-0.36	4.67e-9	Post bronchodilator FEV1;
KIRP	cis	rs7534824	0.625	rs17525507	chr1:101430504	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.51	0.33	9.04e-8	Refractive astigmatism;
KIRP	trans	rs708547	0.578	rs781665	chr4:57831461	G/A	cg12819144	chr4:165953018	TRIM60	0.4	6.23	0.37	2.05e-9	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg01798813	chr17:3906674	NA	0.46	5.66	0.34	4.28e-8	Type 2 diabetes;
KIRP	cis	rs6959887	0.962	rs4723405	chr7:35285977	C/T	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-11.55	-0.59	5.9e-25	Alzheimer's disease;
KIRP	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg23594656	chr7:65796392	TPST1	-0.44	-6.04	-0.36	5.67e-9	Aortic root size;
KIRP	cis	rs17030434	0.871	rs6847648	chr4:154729700	G/A	cg14289246	chr4:154710475	SFRP2	-0.7	-8.43	-0.47	2.88e-15	Electrocardiographic conduction measures;
KIRP	cis	rs4666002	0.789	rs6727215	chr2:27934731	G/A	cg27432699	chr2:27873401	GPN1	0.55	5.27	0.32	2.96e-7	Phospholipid levels (plasma);
KIRP	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.56	-6.56	-0.39	3.09e-10	Iron status biomarkers;
KIRP	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg09596252	chr17:78655493	RPTOR	0.58	7.65	0.44	4.54e-13	Obesity;
KIRP	cis	rs4389656	1.000	rs4389656	chr5:6753728	A/G	cg10857441	chr5:6722123	POLS	-0.4	-5.06	-0.31	8.35e-7	Coronary artery disease;
KIRP	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg02811702	chr13:24901961	NA	0.43	5.69	0.34	3.67e-8	Obesity-related traits;
KIRP	cis	rs3134353	0.863	rs4734500	chr8:101970119	C/T	cg07585502	chr8:101912084	NA	-0.4	-4.88	-0.3	1.88e-6	Body mass index;
KIRP	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg25036284	chr2:26402008	FAM59B	-0.6	-5.86	-0.35	1.51e-8	Gut microbiome composition (summer);
KIRP	cis	rs2598107	0.601	rs17171212	chr7:37964965	C/T	cg25225232	chr7:37962694	EPDR1	0.4	4.94	0.3	1.46e-6	Dupuytren's disease;
KIRP	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg01304814	chr3:48885189	PRKAR2A	0.82	6.02	0.36	6.33e-9	Blood protein levels;
KIRP	cis	rs11608355	0.521	rs7978210	chr12:109835990	A/G	cg19025524	chr12:109796872	NA	-0.47	-6.61	-0.39	2.41e-10	Neuroticism;
KIRP	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.72	0.44	2.84e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2415984	0.622	rs10131871	chr14:46931700	A/G	cg14871534	chr14:47121158	RPL10L	0.45	5.42	0.33	1.44e-7	Number of children ever born;
KIRP	cis	rs3126085	0.515	rs11204998	chr1:152365655	A/C	cg26876637	chr1:152193138	HRNR	-0.51	-6.39	-0.38	8.09e-10	Atopic dermatitis;
KIRP	cis	rs7712401	0.601	rs13155907	chr5:122334633	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs9815354	0.812	rs73073371	chr3:41843443	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs9790314	0.613	rs13092102	chr3:160598093	C/G	cg19274270	chr17:78178856	CARD14	0.35	6.1	0.36	4.2e-9	Morning vs. evening chronotype;
KIRP	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg14458575	chr2:238380390	NA	0.56	7.64	0.44	4.71e-13	Prostate cancer;
KIRP	cis	rs33912345	0.695	rs1254283	chr14:60856024	A/G	cg27398547	chr14:60952738	C14orf39	-0.41	-5.53	-0.33	8.29e-8	Glaucoma (high intraocular pressure);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23436918	chr7:16685595	BZW2;ANKMY2	0.71	6.57	0.39	2.98e-10	Lung function (FEV1);
KIRP	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg00656387	chr3:40428638	ENTPD3	-0.37	-5.1	-0.31	6.92e-7	Renal cell carcinoma;
KIRP	cis	rs7213347	0.780	rs216224	chr17:2156285	T/C	cg15816464	chr17:2026533	SMG6	-0.33	-5.02	-0.3	1.01e-6	Total body bone mineral density;
KIRP	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25517755	chr10:38738941	LOC399744	0.36	5.03	0.31	9.62e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.02	15.08	0.69	7.85e-37	Chronic sinus infection;
KIRP	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg01529538	chr14:23388837	RBM23	0.42	5.25	0.32	3.27e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg09788416	chr12:39539408	NA	0.42	5.25	0.32	3.22e-7	Morning vs. evening chronotype;
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg08901578	chr4:187885870	NA	-0.5	-7.7	-0.44	3.34e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.84	-0.35	1.66e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.22	-5.9	-0.35	1.21e-8	Type 2 diabetes;
KIRP	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11987759	chr7:65425863	GUSB	0.52	6.73	0.39	1.17e-10	Aortic root size;
KIRP	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg15128208	chr22:42549153	NA	0.38	4.91	0.3	1.62e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	0.95	12.49	0.62	4.82e-28	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs1538970	0.962	rs9429075	chr1:45818421	G/A	cg05343316	chr1:45956843	TESK2	0.65	7.55	0.43	8.67e-13	Platelet count;
KIRP	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06850241	chr22:41845214	NA	0.44	5.07	0.31	7.87e-7	Vitiligo;
KIRP	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.57	7.47	0.43	1.36e-12	Mean corpuscular volume;
KIRP	cis	rs4481887	0.508	rs4474292	chr1:248396646	G/A	cg01631408	chr1:248437212	OR2T33	-0.42	-5.34	-0.32	2.09e-7	Common traits (Other);
KIRP	cis	rs11877825	0.826	rs3911954	chr18:10569112	C/T	cg07277756	chr18:10589357	NA	0.48	6.11	0.36	3.89e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15664640	chr17:80829946	TBCD	-0.74	-6.63	-0.39	2.11e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.12	0.61	7.75e-27	Bipolar disorder;
KIRP	cis	rs7719624	0.967	rs2282790	chr5:135363875	A/G	cg16684184	chr5:135415129	NA	0.34	5.18	0.31	4.65e-7	Response to cytidine analogues (gemcitabine);
KIRP	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.87	-0.49	1.55e-16	Retinal vascular caliber;
KIRP	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	trans	rs9790314	0.613	rs55956394	chr3:160590693	C/T	cg19274270	chr17:78178856	CARD14	0.35	6.02	0.36	6.38e-9	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.96	11.16	0.58	1.1e-23	Corneal astigmatism;
KIRP	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.41	-5.14	-0.31	5.53e-7	Aortic root size;
KIRP	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12292205	chr6:26970375	C6orf41	-0.49	-6.16	-0.37	2.95e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25318301	chr1:228566560	OBSCN	0.43	6.2	0.37	2.32e-9	Parkinson's disease;
KIRP	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg21452805	chr1:244014465	NA	0.72	6.78	0.4	8.64e-11	RR interval (heart rate);
KIRP	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00684032	chr4:1343700	KIAA1530	0.44	5.79	0.35	2.19e-8	Obesity-related traits;
KIRP	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	7.13	0.41	1.12e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.14	11.99	0.61	2.16e-26	Platelet count;
KIRP	cis	rs6693295	0.887	rs12144716	chr1:246267566	C/T	cg11798871	chr1:246315928	SMYD3	-0.43	-5.26	-0.32	3.19e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.51	-7.37	-0.43	2.51e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	6.34	0.37	1.12e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.61e-21	Diabetic kidney disease;
KIRP	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg10144569	chr3:42726640	KBTBD5	-0.48	-5.01	-0.3	1.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg00647317	chr7:50633725	DDC	-0.44	-5.73	-0.34	2.89e-8	Malaria;
KIRP	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg00334542	chr7:100209784	MOSPD3	-0.55	-5.02	-0.3	1.01e-6	Other erythrocyte phenotypes;
KIRP	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.91	-13.06	-0.64	5.81e-30	Tonsillectomy;
KIRP	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.55	-8.54	-0.48	1.38e-15	Prostate cancer;
KIRP	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.42	-7.73	-0.44	2.83e-13	Urinary metabolites;
KIRP	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12681366	0.734	rs10102233	chr8:95401657	A/T	cg13257157	chr8:95487014	RAD54B	0.4	4.93	0.3	1.52e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs921943	1.000	rs2034899	chr5:78316188	T/G	cg26802063	chr5:78281964	ARSB	0.49	6.18	0.37	2.69e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17595386	chr2:11774474	GREB1	0.47	6.08	0.36	4.56e-9	Interleukin-4 levels;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.7	-8.73	-0.49	4.03e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg03959625	chr15:84868606	LOC388152	0.63	6.56	0.39	3.18e-10	Schizophrenia;
KIRP	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.97	14.9	0.69	3.21e-36	Diastolic blood pressure;
KIRP	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.71	6.52	0.38	4e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.36	0.38	1e-9	Aortic root size;
KIRP	cis	rs1978968	0.763	rs9605472	chr22:18463216	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.78	-11.07	-0.58	2.19e-23	Presence of antiphospholipid antibodies;
KIRP	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.5	-6.53	-0.38	3.78e-10	Calcium levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16435858	chr3:129158884	IFT122;MBD4	0.5	6.22	0.37	2.06e-9	Parkinson's disease;
KIRP	cis	rs12044355	0.929	rs6667123	chr1:231851991	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.56	0.33	6.89e-8	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.69	8.93	0.49	1.02e-16	Bladder cancer;
KIRP	cis	rs4363385	0.510	rs7541328	chr1:152894142	C/G	cg07796016	chr1:152779584	LCE1C	-0.46	-5.79	-0.35	2.13e-8	Inflammatory skin disease;
KIRP	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg18357526	chr6:26021779	HIST1H4A	0.48	5.61	0.34	5.41e-8	Blood metabolite levels;
KIRP	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg00319359	chr11:70116639	PPFIA1	0.81	7.0	0.41	2.39e-11	Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg13147721	chr7:65941812	NA	-1.01	-6.86	-0.4	5.43e-11	Diabetic kidney disease;
KIRP	cis	rs6005807	0.640	rs73432205	chr22:29028132	C/T	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	10.09	0.54	2.97e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.67	-9.02	-0.5	5.42e-17	Huntington's disease progression;
KIRP	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs11650494	0.516	rs9907942	chr17:47513891	C/T	cg08112188	chr17:47440006	ZNF652	0.78	5.07	0.31	7.9e-7	Prostate cancer;
KIRP	trans	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg08975724	chr8:8085496	FLJ10661	0.5	6.1	0.36	4.19e-9	Neuroticism;
KIRP	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	12.52	0.62	3.89e-28	Menopause (age at onset);
KIRP	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg06917634	chr15:78832804	PSMA4	-0.47	-4.91	-0.3	1.64e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs76693355	0.512	rs4938802	chr11:120228989	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.42	-5.43	-0.33	1.33e-7	Intraocular pressure;
KIRP	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs981844	0.775	rs1037656	chr4:154750786	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-7.17	-0.42	8.52e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs6545883	0.525	rs1729662	chr2:61391305	G/A	cg15711740	chr2:61764176	XPO1	-0.58	-7.42	-0.43	1.95e-12	Tuberculosis;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg26213368	chr11:62474978	BSCL2;GNG3	-0.45	-6.13	-0.36	3.42e-9	Bladder cancer;
KIRP	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg07395648	chr5:131743802	NA	-0.37	-5.06	-0.31	8.4e-7	Blood metabolite levels;
KIRP	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.68	-8.02	-0.46	4.38e-14	Blood protein levels;
KIRP	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.43	-0.47	2.96e-15	Mood instability;
KIRP	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.42	7.9	0.45	9.19e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.75	8.68	0.48	5.52e-16	Corneal astigmatism;
KIRP	cis	rs1014246	0.826	rs1900508	chr10:118470750	C/T	cg14919929	chr10:118506882	NA	-0.57	-7.52	-0.43	1e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg08761264	chr16:28874980	SH2B1	-0.49	-5.5	-0.33	9.74e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4654899	1.000	rs12126133	chr1:21456537	T/C	cg05370193	chr1:21551575	ECE1	0.43	5.94	0.35	9.84e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg24253500	chr15:84953950	NA	-0.41	-5.24	-0.32	3.49e-7	P wave terminal force;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.91	0.35	1.16e-8	Lung cancer;
KIRP	cis	rs17065868	0.892	rs35665055	chr13:45094501	T/C	cg10246903	chr13:45222710	NA	0.74	6.77	0.4	9.6e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23186104	chr11:72353587	PDE2A	0.5	6.89	0.4	4.61e-11	Parkinson's disease;
KIRP	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25517755	chr10:38738941	LOC399744	-0.38	-5.06	-0.31	8.12e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg10620530	chr9:139922595	C9orf139;ABCA2	0.76	6.43	0.38	6.67e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6684428	0.706	rs11206677	chr1:56335237	C/A	cg11651538	chr1:56320950	NA	-0.9	-11.73	-0.6	1.53e-25	Airflow obstruction;
KIRP	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.93	-15.94	-0.71	9e-40	Ulcerative colitis;
KIRP	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.42	5.13	0.31	5.84e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1355223	0.902	rs1773910	chr11:34741253	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9547996	0.842	rs56361602	chr13:38214916	T/C	cg13634560	chr13:38173852	POSTN	-0.4	-5.68	-0.34	3.82e-8	Diastolic blood pressure;
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg20607798	chr8:58055168	NA	0.71	5.72	0.34	3.01e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg13703089	chr14:106090767	NA	-0.35	-4.85	-0.3	2.17e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg07827796	chr19:33622959	WDR88	0.42	4.99	0.3	1.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg00990874	chr7:1149470	C7orf50	-0.73	-7.51	-0.43	1.1e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg10047753	chr17:41438598	NA	1.14	18.13	0.76	3.22e-47	Menopause (age at onset);
KIRP	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.44	-6.47	-0.38	5.4e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg11150807	chr10:43354902	NA	0.68	7.56	0.43	8.09e-13	Blood protein levels;
KIRP	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	5.5	0.33	9.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg07460842	chr6:66804631	NA	-0.49	-6.08	-0.36	4.46e-9	Blood trace element (Cu levels);
KIRP	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg07636037	chr3:49044803	WDR6	-0.69	-4.87	-0.3	2.04e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.61	8.6	0.48	9.4e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-4.99	-0.3	1.16e-6	Obesity-related traits;
KIRP	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	8.81	0.49	2.24e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs400736	0.729	rs9434948	chr1:8004963	A/C	cg25007680	chr1:8021821	PARK7	-0.56	-7.25	-0.42	5.33e-12	Response to antidepressants and depression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11618193	chr7:42951185	C7orf25	0.5	6.9	0.4	4.33e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs75920871	0.528	rs4388921	chr11:116976778	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-5.09	-0.31	7.21e-7	Subjective well-being;
KIRP	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.41	-0.43	1.99e-12	Colorectal cancer;
KIRP	trans	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.44	0.38	6.36e-10	Mean corpuscular volume;
KIRP	cis	rs6973256	0.897	rs10266435	chr7:133346081	C/T	cg10665199	chr7:133106180	EXOC4	-0.52	-6.36	-0.38	9.87e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs12517041	1.000	rs71611220	chr5:23281005	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.31	-0.47	6.31e-15	Calcium levels;
KIRP	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.64	10.4	0.55	3.1e-21	Morning vs. evening chronotype;
KIRP	cis	rs9473924	0.632	rs7751155	chr6:50863173	A/T	cg03432817	chr6:50765336	NA	0.35	5.41	0.33	1.52e-7	Body mass index;
KIRP	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg23422044	chr7:1970798	MAD1L1	-0.43	-5.57	-0.33	6.51e-8	Neuroticism;
KIRP	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.09	-0.36	4.37e-9	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13577493	chr3:50541078	CACNA2D2	0.52	6.63	0.39	2.06e-10	Parkinson's disease;
KIRP	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.64	-0.66	6.24e-32	Response to antipsychotic treatment;
KIRP	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	cg07049167	chr1:166818506	POGK	0.56	6.03	0.36	6.11e-9	Refractive astigmatism;
KIRP	trans	rs847851	1.000	rs2473615	chr6:34893910	C/G	cg00020474	chr1:8214963	NA	0.41	6.32	0.37	1.22e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs75920871	1.000	rs61905691	chr11:116880703	A/G	cg23684410	chr11:116897558	SIK3	0.54	5.81	0.35	1.97e-8	Subjective well-being;
KIRP	cis	rs13294100	0.929	rs8181077	chr9:17580616	A/T	cg11213383	chr9:17579734	SH3GL2	-0.53	-6.89	-0.4	4.58e-11	Parkinson's disease;
KIRP	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-4.91	-0.3	1.69e-6	P wave terminal force;
KIRP	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.94	-0.45	7.3e-14	Retinal vascular caliber;
KIRP	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg09904177	chr6:26538194	HMGN4	-0.45	-4.91	-0.3	1.69e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05025164	chr4:1340916	KIAA1530	0.39	5.02	0.31	9.74e-7	Obesity-related traits;
KIRP	cis	rs13102973	0.640	rs6829739	chr4:135835789	G/A	cg14419869	chr4:135874104	NA	0.5	8.24	0.46	1.06e-14	Subjective well-being;
KIRP	cis	rs3736485	0.934	rs4143723	chr15:51867172	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg20744362	chr22:50050164	C22orf34	0.33	5.09	0.31	7.03e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs9644630	0.841	rs7018210	chr8:19327643	G/A	cg01280390	chr8:19363452	CSGALNACT1	-0.4	-5.19	-0.31	4.33e-7	Oropharynx cancer;
KIRP	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg23335576	chr14:104009727	NA	0.39	5.7	0.34	3.5e-8	Body mass index;
KIRP	cis	rs66569888	0.710	rs67005606	chr2:106876277	T/C	cg16099169	chr2:106886729	NA	-0.74	-10.48	-0.56	1.78e-21	Facial morphology (factor 23);
KIRP	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg25838818	chr2:108905173	SULT1C2	-0.43	-6.5	-0.38	4.32e-10	Blood pressure;
KIRP	cis	rs7178909	0.835	rs7169019	chr15:90400364	T/G	cg19708238	chr15:90437601	AP3S2	0.58	7.77	0.44	2.13e-13	Common traits (Other);
KIRP	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.22	20.15	0.79	5.42e-54	Cognitive function;
KIRP	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.22	0.32	3.82e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg03115019	chr17:80708279	FN3K	0.51	6.79	0.4	8.12e-11	Glycated hemoglobin levels;
KIRP	cis	rs7838490	0.559	rs11988322	chr8:89581915	T/A	cg08624180	chr8:89339080	MMP16	-0.44	-5.13	-0.31	5.99e-7	Body mass index and cholesterol (psychopharmacological treatment);
KIRP	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.57	-6.47	-0.38	5.28e-10	Menarche (age at onset);
KIRP	cis	rs9972944	0.902	rs9972881	chr17:63771334	A/G	cg07283582	chr17:63770753	CCDC46	0.47	7.91	0.45	8.8e-14	Total body bone mineral density;
KIRP	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.4	0.72	2.5e-41	Electrocardiographic conduction measures;
KIRP	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.46	6.68	0.39	1.56e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9329221	0.585	rs12550717	chr8:10266706	G/A	cg27411982	chr8:10470053	RP1L1	0.44	5.51	0.33	9.15e-8	Neuroticism;
KIRP	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg05342945	chr12:48394962	COL2A1	-0.46	-5.04	-0.31	9.18e-7	Lung cancer;
KIRP	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-1.02	-17.28	-0.74	2.4e-44	Height;
KIRP	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.51	0.33	8.88e-8	Melanoma;
KIRP	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	5.8	0.35	2.04e-8	Educational attainment;
KIRP	cis	rs7572644	0.603	rs7580274	chr2:28266069	C/T	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9398803	0.830	rs1337735	chr6:126771024	T/A	cg19875578	chr6:126661172	C6orf173	0.51	6.63	0.39	2.15e-10	Male-pattern baldness;
KIRP	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.73	-0.44	2.73e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	5.3	0.32	2.56e-7	Leprosy;
KIRP	trans	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg19694781	chr19:47549865	TMEM160	-0.58	-7.63	-0.44	5.15e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg01843034	chr6:37503916	NA	-0.82	-11.5	-0.59	9.23e-25	Cognitive performance;
KIRP	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.22	-12.56	-0.63	2.71e-28	Atopic dermatitis;
KIRP	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.83	0.4	6.47e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg24253500	chr15:84953950	NA	0.62	6.62	0.39	2.2e-10	Schizophrenia;
KIRP	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg01214346	chr17:406501	NA	0.4	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-11.37	-0.59	2.4e-24	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	9.2	0.51	1.55e-17	Retinal vascular caliber;
KIRP	cis	rs6752107	0.500	rs11893210	chr2:234204672	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.41	4.94	0.3	1.42e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.54	9.07	0.5	3.88e-17	Bone mineral density;
KIRP	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg11161011	chr14:65562177	MAX	-0.61	-7.81	-0.45	1.68e-13	Obesity-related traits;
KIRP	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.09e-6	Bladder cancer;
KIRP	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg14993813	chr1:46806288	NSUN4	-0.62	-7.23	-0.42	5.97e-12	Menopause (age at onset);
KIRP	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg16506815	chr2:162101123	NA	-0.48	-5.69	-0.34	3.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08704250	chr15:31115839	NA	-0.53	-7.6	-0.44	6.32e-13	Huntington's disease progression;
KIRP	cis	rs4006360	0.575	rs7501893	chr17:39311411	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.43	-5.77	-0.35	2.38e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.61	-8.19	-0.46	1.44e-14	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg05555928	chr11:63887634	MACROD1	-0.68	-5.26	-0.32	3.19e-7	Body mass index;
KIRP	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg17351974	chr5:40835760	RPL37	0.62	5.1	0.31	6.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg00079375	chr15:79125835	NA	-0.36	-5.2	-0.31	4.19e-7	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12843872	chr7:90894352	FZD1	0.63	7.37	0.43	2.64e-12	Smoking initiation;
KIRP	cis	rs10073892	0.743	rs2895807	chr5:101653570	G/A	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.65	-8.1	-0.46	2.5e-14	Vitiligo;
KIRP	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04317338	chr11:64019027	PLCB3	0.43	5.24	0.32	3.49e-7	Platelet count;
KIRP	trans	rs17079247	0.841	rs1927721	chr13:85810939	T/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.07	-0.36	4.77e-9	Bipolar disorder (mania);
KIRP	cis	rs8062405	0.690	rs4787458	chr16:28531287	A/G	cg16576597	chr16:28551801	NUPR1	0.38	5.47	0.33	1.09e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	6.72	0.39	1.26e-10	Retinal vascular caliber;
KIRP	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg03735888	chr19:58951602	ZNF132	0.47	5.52	0.33	8.4e-8	Uric acid clearance;
KIRP	cis	rs9905704	0.718	rs8072379	chr17:56615997	C/A	cg12560992	chr17:57184187	TRIM37	-0.55	-5.18	-0.31	4.69e-7	Testicular germ cell tumor;
KIRP	cis	rs859767	0.540	rs6739706	chr2:135407409	A/C	cg12500956	chr2:135428796	TMEM163	-0.42	-5.69	-0.34	3.54e-8	Neuroticism;
KIRP	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.17	0.46	1.64e-14	Resting heart rate;
KIRP	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.0	0.36	6.88e-9	Ovarian reserve;
KIRP	cis	rs859767	0.501	rs10928507	chr2:135396631	C/T	cg25422880	chr2:135218333	TMEM163	-0.37	-5.6	-0.34	5.74e-8	Neuroticism;
KIRP	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg06598544	chr20:61472147	COL9A3	-0.74	-5.79	-0.35	2.16e-8	Obesity-related traits;
KIRP	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg18944383	chr4:111397179	ENPEP	0.52	8.55	0.48	1.29e-15	Coronary artery disease;
KIRP	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg23791538	chr6:167370224	RNASET2	-0.47	-5.71	-0.34	3.2e-8	Crohn's disease;
KIRP	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.46e-8	Crohn's disease;
KIRP	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg21775007	chr8:11205619	TDH	0.38	4.96	0.3	1.31e-6	Neuroticism;
KIRP	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.6	8.07	0.46	3.21e-14	White matter hyperintensity burden;
KIRP	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-4.92	-0.3	1.56e-6	Colorectal cancer;
KIRP	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.69	8.18	0.46	1.53e-14	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg00405596	chr8:11794950	NA	-0.4	-4.89	-0.3	1.81e-6	Neuroticism;
KIRP	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	12.4	0.62	9.63e-28	Smoking behavior;
KIRP	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg22437258	chr11:111473054	SIK2	0.66	7.98	0.45	5.44e-14	Primary sclerosing cholangitis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04489856	chr17:36861700	MLLT6	-0.48	-6.32	-0.37	1.23e-9	Myopia;
KIRP	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.47	-5.85	-0.35	1.6e-8	Iron status biomarkers;
KIRP	cis	rs5753037	0.702	rs9614055	chr22:30187702	C/T	cg27665648	chr22:30112403	NA	0.33	4.9	0.3	1.7e-6	Type 1 diabetes;
KIRP	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg09658497	chr7:2847517	GNA12	-0.35	-5.05	-0.31	8.6e-7	Height;
KIRP	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.09	14.44	0.68	1.22e-34	Gut microbiome composition (summer);
KIRP	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.74	-0.34	2.83e-8	IgG glycosylation;
KIRP	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg25174290	chr11:3078921	CARS	-0.54	-6.84	-0.4	6.09e-11	Calcium levels;
KIRP	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.17	-13.09	-0.64	4.5e-30	Eosinophil percentage of granulocytes;
KIRP	cis	rs4332428	0.881	rs72769971	chr10:5004295	C/T	cg19648686	chr10:5044992	AKR1C2	-0.91	-8.14	-0.46	2.01e-14	Height;
KIRP	cis	rs7017914	1.000	rs13252719	chr8:71734569	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs6499255	1.000	rs55863174	chr16:69819996	G/C	cg15192750	chr16:69999425	NA	0.46	4.86	0.3	2.1e-6	IgE levels;
KIRP	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg15507776	chr3:136538369	TMEM22	0.39	5.24	0.32	3.52e-7	Neuroticism;
KIRP	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.35	-0.38	1.02e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.84	0.49	1.9e-16	Motion sickness;
KIRP	cis	rs6662572	0.737	rs72692613	chr1:46399557	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.54	0.33	7.88e-8	Blood protein levels;
KIRP	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs13185784	0.703	rs62406991	chr5:179658323	A/G	cg02891314	chr5:179741120	GFPT2	0.52	5.05	0.31	8.46e-7	TRAIL levels;
KIRP	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.16	0.31	5.17e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.94	-15.04	-0.69	1.06e-36	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21211866	chr9:35111727	KIAA1539	0.53	6.21	0.37	2.27e-9	Smoking initiation;
KIRP	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg02678768	chr17:74002944	EVPL	-0.41	-5.4	-0.33	1.59e-7	White matter hyperintensity burden;
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg17294928	chr15:75287854	SCAMP5	0.57	7.34	0.42	3.11e-12	Caffeine consumption;
KIRP	cis	rs504918	0.502	rs76996118	chr3:124025129	C/A	cg05766129	chr3:123988013	KALRN	-0.45	-5.74	-0.34	2.85e-8	Schizophrenia;
KIRP	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg01268866	chr2:3683757	COLEC11	-0.42	-5.07	-0.31	7.67e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs56079296	0.929	rs73795205	chr5:121352305	A/G	cg05256605	chr5:121412184	LOX	-0.54	-5.81	-0.35	1.9e-8	Coronary artery disease;
KIRP	cis	rs6728642	0.831	rs10496325	chr2:97683329	C/T	cg26665480	chr2:98280029	ACTR1B	0.55	5.94	0.35	9.7e-9	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg00677455	chr12:58241039	CTDSP2	0.57	6.44	0.38	6.1e-10	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.1	0.41	1.32e-11	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14753042	chr7:55714413	LOC442308	0.46	6.09	0.36	4.26e-9	Survival in pancreatic cancer;
KIRP	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.92	11.37	0.59	2.29e-24	Diastolic blood pressure;
KIRP	cis	rs651907	0.640	rs771578	chr3:101613434	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.12	0.31	6.16e-7	Colorectal cancer;
KIRP	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06360820	chr2:242988706	NA	-0.82	-8.08	-0.46	2.86e-14	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg14593290	chr7:50529359	DDC	-0.59	-8.39	-0.47	3.78e-15	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg08901578	chr4:187885870	NA	-0.44	-6.6	-0.39	2.45e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg07701084	chr6:150067640	NUP43	0.75	10.26	0.55	8.45e-21	Lung cancer;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.41	6.15	0.37	3.04e-9	Lymphocyte counts;
KIRP	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg12549451	chr6:135224345	NA	0.42	5.17	0.31	4.76e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs17592366	0.517	rs4982219	chr14:35286483	A/T	cg09327582	chr14:35236912	BAZ1A	0.55	5.71	0.34	3.2e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.3	-6.15	-0.37	3.08e-9	Schizophrenia;
KIRP	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg04025307	chr7:1156635	C7orf50	0.5	5.0	0.3	1.08e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.83	0.63	3.35e-29	Exhaled nitric oxide output;
KIRP	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg24579218	chr15:68104479	NA	-0.54	-8.52	-0.48	1.66e-15	Restless legs syndrome;
KIRP	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.65	0.48	7e-16	Motion sickness;
KIRP	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.45	5.37	0.32	1.86e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.47	-5.13	-0.31	5.75e-7	Obesity (extreme);
KIRP	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.51	0.43	1.09e-12	Mean corpuscular volume;
KIRP	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.64	-9.71	-0.53	4.42e-19	Menopause (age at onset);
KIRP	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg13444842	chr1:152974279	SPRR3	0.44	6.02	0.36	6.43e-9	Inflammatory skin disease;
KIRP	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg11608241	chr8:8085544	FLJ10661	0.42	5.23	0.32	3.61e-7	Recombination measurement;
KIRP	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg08499158	chr17:42289980	UBTF	0.88	13.01	0.64	8.25e-30	Total body bone mineral density;
KIRP	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26314531	chr2:26401878	FAM59B	-0.49	-5.13	-0.31	5.97e-7	Gut microbiome composition (summer);
KIRP	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.46	-6.12	-0.36	3.64e-9	Retinal vascular caliber;
KIRP	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg14558114	chr2:88469736	THNSL2	0.66	5.08	0.31	7.48e-7	Plasma clusterin levels;
KIRP	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.55	-6.59	-0.39	2.64e-10	Mosquito bite size;
KIRP	cis	rs17221829	0.699	rs78403327	chr11:89384225	C/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.25e-6	Anxiety in major depressive disorder;
KIRP	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg17849569	chr6:28058911	ZSCAN12L1	0.41	5.16	0.31	4.99e-7	Cardiac Troponin-T levels;
KIRP	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg17376030	chr22:41985996	PMM1	0.58	6.6	0.39	2.44e-10	Vitiligo;
KIRP	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	10.7	0.56	3.42e-22	Leprosy;
KIRP	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.67	-10.3	-0.55	6.68e-21	Airway imaging phenotypes;
KIRP	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.2	-0.31	4.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7215564	0.818	rs76704328	chr17:78585954	T/G	cg06153925	chr17:78755379	RPTOR	0.42	5.85	0.35	1.55e-8	Myopia (pathological);
KIRP	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.61	0.48	8.74e-16	Bipolar disorder;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg11204139	chr17:3907470	NA	0.82	15.05	0.69	9.61e-37	Type 2 diabetes;
KIRP	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.87	-6.42	-0.38	7.11e-10	Putamen volume;
KIRP	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg24803719	chr17:45855879	NA	-0.45	-6.1	-0.36	4.15e-9	IgG glycosylation;
KIRP	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg03060546	chr3:49711283	APEH	-0.68	-5.25	-0.32	3.27e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.77	-6.5	-0.38	4.41e-10	Blood pressure (smoking interaction);
KIRP	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.51	6.17	0.37	2.76e-9	Schizophrenia;
KIRP	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.93	0.57	6.49e-23	Lung cancer in ever smokers;
KIRP	cis	rs2411233	1.000	rs7165634	chr15:39282648	G/C	cg02291532	chr15:39874776	THBS1	0.39	5.16	0.31	5.04e-7	Platelet count;
KIRP	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	5.21	0.32	3.98e-7	Renal cell carcinoma;
KIRP	cis	rs7221595	0.825	rs8074860	chr17:3986657	C/G	cg09597638	chr17:3907349	NA	0.55	5.7	0.34	3.4e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.16	-0.31	5.16e-7	Longevity;
KIRP	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg11608241	chr8:8085544	FLJ10661	0.38	4.89	0.3	1.86e-6	Mood instability;
KIRP	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg26681399	chr22:41777847	TEF	-0.43	-5.08	-0.31	7.46e-7	Vitiligo;
KIRP	cis	rs6499129	0.558	rs16957489	chr16:67651879	G/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.77	-0.4	9.52e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7395581	0.918	rs3847502	chr11:47333685	C/A	cg25783544	chr11:47291846	MADD	0.43	4.93	0.3	1.53e-6	HDL cholesterol;
KIRP	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg09699651	chr6:150184138	LRP11	0.46	5.57	0.33	6.69e-8	Lung cancer;
KIRP	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	0.85	11.22	0.58	7.12e-24	Primary sclerosing cholangitis;
KIRP	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.06	0.41	1.66e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg25356066	chr3:128598488	ACAD9	0.52	6.07	0.36	4.88e-9	IgG glycosylation;
KIRP	cis	rs2904967	0.866	rs676573	chr11:65026462	T/G	cg09225861	chr11:65069680	NA	-0.41	-4.91	-0.3	1.67e-6	Mean corpuscular volume;
KIRP	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	0.95	8.16	0.46	1.78e-14	Arsenic metabolism;
KIRP	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs6991838	0.584	rs35790435	chr8:66502523	G/A	cg13398993	chr8:66546079	ARMC1	-0.45	-5.18	-0.31	4.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.69	10.68	0.56	4.1e-22	Blood metabolite ratios;
KIRP	cis	rs4704187	0.663	rs6897274	chr5:74426103	T/A	cg03227963	chr5:74354835	NA	0.41	5.93	0.35	9.96e-9	Response to amphetamines;
KIRP	cis	rs11997175	0.646	rs6468197	chr8:33734894	G/T	cg04338863	chr8:33670619	NA	0.49	6.4	0.38	7.76e-10	Body mass index;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06745235	chr1:180471494	ACBD6	0.5	6.66	0.39	1.74e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg21285383	chr16:89894308	SPIRE2	0.32	6.18	0.37	2.71e-9	Vitiligo;
KIRP	cis	rs2415984	0.622	rs61993301	chr14:46949667	C/T	cg14871534	chr14:47121158	RPL10L	-0.45	-5.39	-0.33	1.62e-7	Number of children ever born;
KIRP	cis	rs62380364	0.602	rs588282	chr5:88032651	G/T	cg22951263	chr5:87985283	NA	-0.47	-6.66	-0.39	1.79e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs909341	0.909	rs914559	chr20:62369300	C/G	cg03999872	chr20:62272968	STMN3	0.59	6.6	0.39	2.48e-10	Atopic dermatitis;
KIRP	cis	rs7015630	0.657	rs13278954	chr8:90852058	G/A	cg18493113	chr8:90847772	NA	-0.55	-6.16	-0.37	2.94e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17134890	chr11:122753390	C11orf63	-0.4	-6.18	-0.37	2.6e-9	Breast cancer;
KIRP	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.97	-11.95	-0.61	2.85e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg21132104	chr15:45694354	SPATA5L1	0.77	9.73	0.53	3.73e-19	Homoarginine levels;
KIRP	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg03929089	chr4:120376271	NA	0.71	6.31	0.37	1.29e-9	Axial length;
KIRP	cis	rs9652601	1.000	rs9652601	chr16:11174365	G/A	cg04616529	chr16:11181986	CLEC16A	0.39	5.1	0.31	6.8e-7	Systemic lupus erythematosus;
KIRP	cis	rs2235544	0.565	rs928443	chr1:54473516	C/T	cg25741118	chr1:54482237	LDLRAD1	0.28	4.98	0.3	1.23e-6	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	cis	rs712039	0.687	rs11656455	chr17:35771885	G/A	cg16670864	chr17:35848621	DUSP14	0.42	4.95	0.3	1.35e-6	Tuberculosis;
KIRP	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg16586182	chr3:47516702	SCAP	0.56	6.72	0.39	1.23e-10	Birth weight;
KIRP	cis	rs10214930	0.752	rs2391454	chr7:27690624	A/G	cg22168087	chr7:27702803	HIBADH	0.51	5.13	0.31	5.91e-7	Hypospadias;
KIRP	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.35	-0.32	2.04e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7614311	1.000	rs7646324	chr3:63808118	T/C	cg22134162	chr3:63841271	THOC7	-0.37	-5.39	-0.32	1.67e-7	Lung function (FVC);Lung function (FEV1);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02047359	chr10:75174015	ANXA7	0.5	6.02	0.36	6.44e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.34	7.4	0.43	2.2e-12	Cutaneous nevi;
KIRP	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.39	6.69	0.39	1.46e-10	Heart rate;
KIRP	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg23887609	chr12:130822674	PIWIL1	-0.38	-4.91	-0.3	1.63e-6	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.85	13.29	0.65	9.31e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.24	-0.32	3.41e-7	Colorectal cancer;
KIRP	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg03563238	chr19:33554763	RHPN2	-0.35	-6.07	-0.36	4.84e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg18825076	chr15:78729989	IREB2	-0.43	-5.03	-0.31	9.5e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11176342	chr11:18344099	HPS5;GTF2H1	0.57	7.2	0.42	7.34e-12	Parkinson's disease;
KIRP	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.37	0.51	4.98e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg18932078	chr1:2524107	MMEL1	0.37	5.15	0.31	5.44e-7	Ulcerative colitis;
KIRP	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.73e-10	Subjective well-being;
KIRP	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	7.46	0.43	1.44e-12	Height;
KIRP	cis	rs4638749	0.501	rs6733637	chr2:108804564	A/G	cg25838818	chr2:108905173	SULT1C2	-0.36	-5.75	-0.34	2.65e-8	Blood pressure;
KIRP	cis	rs2371030	1.000	rs2111713	chr2:211576458	G/A	cg18417063	chr2:211583084	NA	-0.52	-7.67	-0.44	3.99e-13	Non-small cell lung cancer;
KIRP	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-7.24	-0.42	5.76e-12	Vitamin D levels;
KIRP	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg06640241	chr16:89574553	SPG7	0.54	7.02	0.41	2.13e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05220968	chr6:146057943	EPM2A	0.38	4.86	0.3	2.07e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6601327	0.670	rs9987266	chr8:9659346	T/C	cg27411982	chr8:10470053	RP1L1	-0.38	-4.87	-0.3	2e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg05072774	chr3:49840536	C3orf54	0.42	5.03	0.31	9.29e-7	Resting heart rate;
KIRP	cis	rs9815354	0.812	rs73073361	chr3:41842926	C/G	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg10977910	chr1:84465055	TTLL7	0.44	5.3	0.32	2.56e-7	Obesity-related traits;
KIRP	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg04287289	chr16:89883240	FANCA	-0.59	-7.82	-0.45	1.53e-13	Vitiligo;
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg09699651	chr6:150184138	LRP11	0.49	6.47	0.38	5.15e-10	Lung cancer;
KIRP	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.42	5.12	0.31	6.14e-7	Recombination rate (males);
KIRP	cis	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg01028140	chr2:1542097	TPO	-0.52	-5.89	-0.35	1.29e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.63	-0.39	2.11e-10	Bipolar disorder;
KIRP	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.4	4.98	0.3	1.17e-6	Blood protein levels;
KIRP	cis	rs7808935	0.589	rs38517	chr7:28030486	C/T	cg22168087	chr7:27702803	HIBADH	0.64	6.11	0.36	3.86e-9	Prostate cancer;
KIRP	cis	rs6547631	0.622	rs10180391	chr2:85926345	C/T	cg24620635	chr2:85921963	GNLY	0.32	5.05	0.31	8.64e-7	Blood protein levels;
KIRP	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.53e-11	Vitiligo;
KIRP	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg01304814	chr3:48885189	PRKAR2A	0.7	5.43	0.33	1.33e-7	Cognitive function;
KIRP	cis	rs7560272	0.538	rs12052539	chr2:73937153	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.62	-0.34	5.15e-8	Schizophrenia;
KIRP	cis	rs35934224	0.771	rs34820460	chr22:19869210	G/A	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.82	-0.35	1.85e-8	Glaucoma (primary open-angle);
KIRP	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.64	3.14e-30	Bladder cancer;
KIRP	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs6738627	0.931	rs13432797	chr2:165526587	C/G	cg03182029	chr2:165697222	COBLL1	-0.44	-5.7	-0.34	3.42e-8	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs829883	0.724	rs3168521	chr12:98908547	C/T	cg25150519	chr12:98850993	NA	-0.76	-9.4	-0.51	3.9e-18	Colorectal adenoma (advanced);
KIRP	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs6539288	0.677	rs7315989	chr12:107339788	A/G	cg21360079	chr12:107162445	NA	-0.45	-5.65	-0.34	4.49e-8	Total body bone mineral density;
KIRP	cis	rs6988636	0.818	rs10111810	chr8:124169565	G/A	cg15893493	chr8:124194847	FAM83A	0.86	6.6	0.39	2.54e-10	Urinary uromodulin levels;
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.77	10.49	0.56	1.65e-21	Longevity;
KIRP	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.58	-6.34	-0.37	1.12e-9	Menarche (age at onset);
KIRP	cis	rs1867631	0.585	rs4655642	chr1:67090083	A/G	cg13052034	chr1:66999238	SGIP1	0.42	6.17	0.37	2.8e-9	Menopause (age at onset);
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg12486944	chr17:80159399	CCDC57	0.4	5.37	0.32	1.78e-7	Life satisfaction;
KIRP	cis	rs2448490	0.629	rs7395672	chr11:65488982	G/A	cg11569703	chr11:65557185	OVOL1	-0.36	-5.65	-0.34	4.38e-8	Platelet count;
KIRP	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.57	0.33	6.68e-8	Skin colour saturation;
KIRP	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7224685	0.569	rs12942513	chr17:4016721	C/A	cg09695851	chr17:3907499	NA	0.53	4.85	0.3	2.23e-6	Type 2 diabetes;
KIRP	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg11569703	chr11:65557185	OVOL1	0.51	8.64	0.48	7.24e-16	Acne (severe);
KIRP	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-10.21	-0.55	1.2e-20	Colorectal cancer;
KIRP	cis	rs7017914	0.967	rs13258584	chr8:71671579	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	trans	rs1106684	1.000	rs67435826	chr7:131458662	A/G	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22906224	chr7:99728672	NA	0.55	6.97	0.41	2.95e-11	Coronary artery disease;
KIRP	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg01872077	chr2:219646372	CYP27A1	-0.38	-5.25	-0.32	3.23e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg25937216	chr8:58172855	NA	-0.49	-5.68	-0.34	3.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	9.71	0.53	4.44e-19	Cognitive test performance;
KIRP	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg20965017	chr5:231967	SDHA	0.57	6.68	0.39	1.59e-10	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05479791	chr8:146228139	ZNF252;C8orf77	0.47	6.33	0.37	1.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg10223061	chr2:219282414	VIL1	0.55	8.41	0.47	3.41e-15	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.39	0.38	8.15e-10	Joint mobility (Beighton score);
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.8	11.57	0.59	5.06e-25	Menarche (age at onset);
KIRP	cis	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg00852783	chr1:26633632	UBXN11	-0.56	-5.51	-0.33	8.98e-8	Obesity-related traits;
KIRP	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg02574844	chr11:5959923	NA	-0.58	-5.97	-0.36	8.15e-9	DNA methylation (variation);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg16869862	chr3:58509780	ACOX2	-0.5	-6.71	-0.39	1.33e-10	Inflammatory biomarkers;
KIRP	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg07395648	chr5:131743802	NA	-0.56	-7.8	-0.45	1.74e-13	Breast cancer;
KIRP	trans	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg25288420	chr1:78511713	GIPC2	0.51	6.97	0.41	2.92e-11	Obesity-related traits;
KIRP	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-6.8	-0.4	7.82e-11	Gut microbiome composition (summer);
KIRP	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.35	19.06	0.77	2.43e-50	Corneal structure;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg11909976	chr19:59055696	TRIM28	0.53	6.78	0.4	9.08e-11	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04567588	chr17:7387175	POLR2A;ZBTB4	0.53	7.0	0.41	2.43e-11	Parkinson's disease;
KIRP	cis	rs1816752	0.819	rs9511240	chr13:24985906	G/A	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg11518657	chr1:67396239	MIER1	0.6	5.89	0.35	1.29e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs9535307	0.929	rs9316474	chr13:50313345	C/A	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17376030	chr22:41985996	PMM1	0.82	8.84	0.49	1.82e-16	Vitiligo;
KIRP	cis	rs8067354	0.645	rs2102507	chr17:57875907	A/G	cg02344993	chr17:57696989	CLTC	0.61	5.85	0.35	1.57e-8	Hemoglobin concentration;
KIRP	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.71	9.5	0.52	1.98e-18	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg16898833	chr6:26189333	HIST1H4D	0.66	5.01	0.3	1.05e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06481639	chr22:41940642	POLR3H	-0.45	-5.47	-0.33	1.11e-7	Vitiligo;
KIRP	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg02023728	chr11:77925099	USP35	0.34	5.41	0.33	1.52e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1143633	0.515	rs2723167	chr2:113621210	C/T	cg03712744	chr2:113669835	IL1F7	-0.41	-6.02	-0.36	6.24e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.52	-7.27	-0.42	4.72e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg05347473	chr6:146136440	FBXO30	0.5	6.98	0.41	2.72e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.8	10.85	0.57	1.12e-22	Osteoporosis;
KIRP	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg23594656	chr7:65796392	TPST1	-0.48	-7.41	-0.43	2.07e-12	Aortic root size;
KIRP	cis	rs2594989	0.887	rs6442253	chr3:11474238	T/C	cg01796438	chr3:11312864	ATG7	-0.54	-6.59	-0.39	2.59e-10	Circulating chemerin levels;
KIRP	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg09137382	chr11:130731461	NA	-0.51	-7.13	-0.41	1.13e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.34	0.47	5.28e-15	Morning vs. evening chronotype;
KIRP	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19671926	chr4:122722719	EXOSC9	0.45	5.37	0.32	1.79e-7	Type 2 diabetes;
KIRP	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg04990556	chr1:26633338	UBXN11	0.67	6.49	0.38	4.59e-10	Obesity-related traits;
KIRP	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg17507749	chr15:85114479	UBE2QP1	0.83	9.27	0.51	1e-17	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13135637	chr7:117056487	ASZ1	0.44	6.37	0.38	9.23e-10	Interleukin-4 levels;
KIRP	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.74	10.16	0.54	1.74e-20	Mood instability;
KIRP	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg07402062	chr16:89894098	SPIRE2	0.36	7.71	0.44	3.1e-13	Vitiligo;
KIRP	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.19	21.62	0.81	8.42e-59	Cognitive function;
KIRP	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.5	0.48	1.8e-15	Bipolar disorder;
KIRP	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.32	-0.37	1.19e-9	Alcohol dependence;
KIRP	cis	rs1318772	1.000	rs72788641	chr5:112621327	T/G	cg12552261	chr5:112820674	MCC	0.82	5.09	0.31	6.97e-7	F-cell distribution;
KIRP	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg07777115	chr5:623756	CEP72	-0.57	-5.82	-0.35	1.86e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg06558623	chr16:89946397	TCF25	1.03	7.47	0.43	1.44e-12	Skin colour saturation;
KIRP	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.84	11.81	0.6	8.51e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg06521331	chr12:34319734	NA	-0.6	-6.99	-0.41	2.61e-11	Bladder cancer;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.53	7.04	0.41	1.88e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg20607764	chr19:44506953	ZNF230	0.47	5.57	0.33	6.61e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.71	8.13	0.46	2.05e-14	Mammographic density (dense area);
KIRP	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12379764	chr21:47803548	PCNT	-0.41	-5.08	-0.31	7.54e-7	Testicular germ cell tumor;
KIRP	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-9.01	-0.5	6.07e-17	Morning vs. evening chronotype;
KIRP	trans	rs12444979	0.507	rs8062735	chr16:19839538	C/T	cg02778551	chr7:1045947	C7orf50	-0.49	-6.23	-0.37	2.02e-9	Body mass index;
KIRP	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs11673344	0.526	rs2306201	chr19:38077474	G/A	cg14683738	chr19:37701593	ZNF585B	-0.44	-5.33	-0.32	2.27e-7	Obesity-related traits;
KIRP	cis	rs6545883	0.929	rs7606167	chr2:61742654	C/G	cg15711740	chr2:61764176	XPO1	-0.61	-8.27	-0.47	8.31e-15	Tuberculosis;
KIRP	cis	rs4936894	0.500	rs7111729	chr11:124093172	C/G	cg27160556	chr11:124181099	OR8D1	-0.46	-6.53	-0.38	3.73e-10	Aging (time to death);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23317907	chr2:222437071	EPHA4	0.46	6.24	0.37	1.93e-9	Parkinson's disease;
KIRP	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs77633900	0.772	rs284903	chr15:76744813	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-6.06	-0.36	5.03e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.88	8.92	0.49	1.06e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	cg12689670	chr1:183009347	LAMC1	0.44	6.32	0.37	1.25e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.52	-5.09	-0.31	7.25e-7	Recombination rate (females);
KIRP	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.51	-6.68	-0.39	1.59e-10	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg02462569	chr6:150064036	NUP43	-0.37	-5.72	-0.34	3.02e-8	Lung cancer;
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.64	-7.88	-0.45	1.09e-13	Aortic root size;
KIRP	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	cis	rs1816854	0.938	rs11182273	chr12:44202901	C/G	cg20956634	chr12:44200518	TWF1	0.45	5.0	0.3	1.07e-6	Inflammatory bowel disease;
KIRP	cis	rs8016982	0.662	rs1957546	chr14:81639984	C/T	cg01989461	chr14:81687754	GTF2A1	0.46	4.87	0.3	2e-6	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.16	0.37	2.88e-9	Diabetic retinopathy;
KIRP	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg25650185	chr19:21324782	ZNF431	0.48	5.06	0.31	8.12e-7	Pain;
KIRP	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg23594656	chr7:65796392	TPST1	-0.47	-7.53	-0.43	9.42e-13	Aortic root size;
KIRP	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.2	-0.55	1.3e-20	Hemoglobin concentration;
KIRP	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.32	-0.62	1.68e-27	Ulcerative colitis;
KIRP	cis	rs2072732	0.861	rs12040299	chr1:2951041	C/T	cg11731671	chr1:2995604	PRDM16	-0.46	-5.98	-0.36	7.65e-9	Plateletcrit;
KIRP	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.94	-13.41	-0.65	3.78e-31	Response to antipsychotic treatment;
KIRP	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.21	0.37	2.27e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs7507204	0.680	rs12975645	chr19:3419132	A/G	cg08380311	chr19:3435252	NFIC	0.66	6.57	0.39	2.98e-10	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06877599	chr19:39936212	SUPT5H	0.49	6.62	0.39	2.2e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-6.69	-0.39	1.5e-10	Parkinson's disease;
KIRP	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg16586182	chr3:47516702	SCAP	0.62	8.61	0.48	8.87e-16	Colorectal cancer;
KIRP	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.02	-0.3	1.01e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg17554472	chr22:41940697	POLR3H	-0.59	-6.69	-0.39	1.51e-10	Vitiligo;
KIRP	cis	rs963731	0.579	rs4643520	chr2:39229464	T/C	cg04010122	chr2:39346883	SOS1	-0.88	-5.83	-0.35	1.76e-8	Corticobasal degeneration;
KIRP	cis	rs508618	0.731	rs12033229	chr1:231545703	T/C	cg10503236	chr1:231470652	EXOC8	0.53	7.0	0.41	2.42e-11	Red blood cell count;
KIRP	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.26	-0.32	3.19e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	6.33	0.37	1.15e-9	Ulcerative colitis;
KIRP	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.67	8.19	0.46	1.44e-14	Obesity-related traits;
KIRP	cis	rs16828019	0.777	rs12739052	chr1:41464455	C/A	cg24596898	chr1:41849189	NA	0.64	4.93	0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg05941025	chr16:89927596	SPIRE2	0.35	5.52	0.33	8.74e-8	Vitiligo;
KIRP	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg13444842	chr1:152974279	SPRR3	-0.49	-7.18	-0.42	8.25e-12	Inflammatory skin disease;
KIRP	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.55	6.57	0.39	2.96e-10	HIV-1 control;
KIRP	cis	rs7624766	0.508	rs1598495	chr3:160497731	G/A	cg22637730	chr3:160473554	PPM1L	0.44	5.46	0.33	1.16e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs12643440	0.960	rs12650417	chr4:17206547	C/T	cg22650099	chr4:17144496	NA	0.47	5.2	0.31	4.19e-7	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg12315302	chr6:26189340	HIST1H4D	0.96	6.8	0.4	8.09e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg16917193	chr12:54089295	NA	-0.89	-17.54	-0.75	3.18e-45	Height;
KIRP	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg10523679	chr1:76189770	ACADM	-0.44	-6.05	-0.36	5.36e-9	Daytime sleep phenotypes;
KIRP	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs4852324	0.536	rs13387174	chr2:74206685	G/A	cg05890377	chr2:74357713	NA	0.66	4.88	0.3	1.87e-6	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.53	-0.33	8.25e-8	Lung cancer;
KIRP	cis	rs9303542	0.527	rs8074125	chr17:46610060	G/T	cg04904318	chr17:46607828	HOXB1	-0.62	-6.69	-0.39	1.46e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs6684514	1.000	rs10908502	chr1:156300082	A/G	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.67e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6448317	1.000	rs11934149	chr4:24938953	T/C	cg21108841	chr4:24914750	CCDC149	-0.46	-5.38	-0.32	1.69e-7	Heschl's gyrus morphology;
KIRP	cis	rs7595037	0.552	rs11126184	chr2:68652174	C/A	cg12452813	chr2:68675892	NA	-0.43	-5.29	-0.32	2.67e-7	Multiple sclerosis;
KIRP	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg10760299	chr15:45669010	GATM	0.35	5.09	0.31	7.03e-7	Homoarginine levels;
KIRP	cis	rs2273669	0.915	rs4992383	chr6:109292816	C/A	cg05315195	chr6:109294784	ARMC2	-0.49	-5.55	-0.33	7.33e-8	Prostate cancer;
KIRP	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.71	10.05	0.54	3.9e-20	Ear protrusion;
KIRP	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.55	-7.26	-0.42	5.22e-12	Vitiligo;
KIRP	cis	rs12476592	0.602	rs2604614	chr2:63894133	T/G	cg17519650	chr2:63277830	OTX1	-0.46	-4.89	-0.3	1.79e-6	Childhood ear infection;
KIRP	cis	rs10170310	1.000	rs6720716	chr2:139268802	A/G	cg10095539	chr2:139258744	SPOPL	0.37	5.88	0.35	1.35e-8	Response to antipsychotic treatment;
KIRP	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.17	-0.37	2.75e-9	Daytime sleep phenotypes;
KIRP	cis	rs8177876	0.749	rs754429	chr16:81096179	C/T	cg08591886	chr16:81111003	C16orf46	-0.7	-5.68	-0.34	3.77e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.42	0.55	2.77e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.63	7.09	0.41	1.39e-11	Childhood ear infection;
KIRP	cis	rs2882667	0.931	rs10077796	chr5:138356775	A/C	cg04439458	chr5:138467593	SIL1	0.42	6.75	0.4	1.03e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.78	-10.56	-0.56	9.67e-22	Aortic root size;
KIRP	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.88e-18	Height;
KIRP	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.68	-0.44	3.71e-13	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14575983	chr5:99922152	FAM174A	-0.48	-7.52	-0.43	1.05e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20454620	chr14:54863806	CDKN3	0.5	6.18	0.37	2.71e-9	Parkinson's disease;
KIRP	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.73	10.78	0.57	1.96e-22	Hip circumference;
KIRP	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.04	-0.31	8.89e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.52	5.31	0.32	2.49e-7	Initial pursuit acceleration;
KIRP	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.68	8.64	0.48	7.47e-16	Educational attainment;
KIRP	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.12	-0.61	7.81e-27	Exhaled nitric oxide output;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg07511668	chr11:68622177	NA	0.37	5.14	0.31	5.55e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9398803	0.678	rs4621655	chr6:126896107	G/A	cg19875578	chr6:126661172	C6orf173	0.38	4.89	0.3	1.81e-6	Male-pattern baldness;
KIRP	cis	rs7660760	0.606	rs17063303	chr4:177497111	C/T	cg26301788	chr4:177713423	VEGFC	0.36	4.91	0.3	1.66e-6	Left ventricle wall thickness;
KIRP	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.68	-8.99	-0.5	6.56e-17	Longevity;
KIRP	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg26441486	chr22:50317300	CRELD2	-0.39	-6.24	-0.37	1.94e-9	Schizophrenia;
KIRP	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg06219351	chr7:158114137	PTPRN2	0.48	6.08	0.36	4.47e-9	Calcium levels;
KIRP	cis	rs7082209	1.000	rs61856381	chr10:44811172	T/C	cg09554077	chr10:44749378	NA	0.44	5.38	0.32	1.73e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg26306683	chr17:18585705	ZNF286B	0.46	5.75	0.34	2.61e-8	Educational attainment (years of education);
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg26134248	chr17:3907702	NA	0.53	7.73	0.44	2.71e-13	Type 2 diabetes;
KIRP	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.26	17.15	0.74	6.68e-44	Type 1 diabetes nephropathy;
KIRP	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg01721255	chr8:58191610	C8orf71	0.6	5.42	0.33	1.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6001982	0.584	rs10483203	chr22:40829953	A/T	cg07138101	chr22:40742427	ADSL	0.7	4.88	0.3	1.92e-6	Breast cancer;
KIRP	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-5.99	-0.36	7.24e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7582720	0.731	rs934287	chr2:203708307	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.68	-7.06	-0.41	1.66e-11	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg08975724	chr8:8085496	FLJ10661	0.54	7.18	0.42	8.37e-12	Retinal vascular caliber;
KIRP	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.64	0.39	2.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.76	6.58	0.39	2.76e-10	Diabetic retinopathy;
KIRP	cis	rs12230513	0.732	rs4343668	chr12:55868936	G/T	cg11794356	chr12:55725991	OR6C3	-0.53	-6.34	-0.37	1.07e-9	Contrast sensitivity;
KIRP	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11987759	chr7:65425863	GUSB	0.49	6.51	0.38	4.12e-10	Aortic root size;
KIRP	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg15691649	chr6:25882328	NA	0.41	4.88	0.3	1.93e-6	Blood metabolite levels;
KIRP	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg01620082	chr3:125678407	NA	-0.88	-6.37	-0.38	9.11e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.96	15.11	0.69	6.07e-37	Systemic lupus erythematosus;
KIRP	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.53	-0.33	8.14e-8	Height;
KIRP	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg10189774	chr4:17578691	LAP3	0.49	6.03	0.36	5.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1497828	0.956	rs2646817	chr1:217525251	T/G	cg04411442	chr1:217543379	NA	-0.41	-6.17	-0.37	2.78e-9	Dialysis-related mortality;
KIRP	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.76	-8.16	-0.46	1.75e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7274811	0.744	rs209665	chr20:32128889	T/G	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.39	-4.91	-0.3	1.68e-6	Height;
KIRP	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg15839431	chr19:19639596	YJEFN3	-0.49	-4.92	-0.3	1.6e-6	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02666966	chr16:28857347	TUFM	0.52	6.42	0.38	6.96e-10	Parkinson's disease;
KIRP	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.83	-11.69	-0.6	2.09e-25	Platelet count;
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.81	-14.68	-0.68	1.77e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	-0.87	-6.39	-0.38	8.25e-10	Putamen volume;
KIRP	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.95	11.81	0.6	8.65e-26	Triglycerides;
KIRP	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.84	10.11	0.54	2.52e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg06219351	chr7:158114137	PTPRN2	-0.61	-8.71	-0.49	4.4e-16	Calcium levels;
KIRP	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.83	0.35	1.69e-8	Menopause (age at onset);
KIRP	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg16434002	chr17:42200994	HDAC5	-0.45	-5.34	-0.32	2.17e-7	Total body bone mineral density;
KIRP	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	cg07049167	chr1:166818506	POGK	-0.5	-5.35	-0.32	1.98e-7	Refractive astigmatism;
KIRP	cis	rs10214930	0.697	rs1851913	chr7:27585076	T/C	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.22e-6	Hypospadias;
KIRP	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg03511173	chr18:77590860	NA	-0.44	-4.95	-0.3	1.36e-6	Opioid sensitivity;
KIRP	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.62	9.41	0.51	3.74e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.67	0.71	7.37e-39	Chronic sinus infection;
KIRP	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00149659	chr3:10157352	C3orf10	0.56	6.74	0.39	1.13e-10	Alzheimer's disease;
KIRP	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.75	-10.17	-0.54	1.62e-20	Sleep quality;
KIRP	cis	rs11203032	0.831	rs11203011	chr10:90931178	A/C	cg16672925	chr10:90967113	CH25H	0.61	6.26	0.37	1.74e-9	Heart failure;
KIRP	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg14673194	chr17:80132900	CCDC57	0.77	8.66	0.48	6.54e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg25650185	chr19:21324782	ZNF431	0.47	4.96	0.3	1.33e-6	Pain;
KIRP	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg17376030	chr22:41985996	PMM1	0.82	8.74	0.49	3.6e-16	Vitiligo;
KIRP	cis	rs756777	0.878	rs7855899	chr9:136665308	C/T	cg14069709	chr9:136671979	VAV2	0.44	5.19	0.31	4.47e-7	IgG glycosylation;
KIRP	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.38	-0.32	1.78e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.76	9.62	0.52	8.26e-19	Menopause (age at onset);
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg08989290	chr16:615782	NHLRC4	0.4	5.77	0.35	2.35e-8	Height;
KIRP	trans	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.74	9.35	0.51	5.45e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-5.68	-0.34	3.84e-8	Lung cancer;
KIRP	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.56	8.0	0.45	4.83e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9393813	0.516	rs4713098	chr6:27403605	C/T	cg03332623	chr6:27441972	ZNF184	-0.38	-5.22	-0.32	3.84e-7	Bipolar disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12495676	chr15:76552683	ETFA;TYRO3P	0.53	6.28	0.37	1.56e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6688613	0.685	rs742048	chr1:166910145	A/C	cg07049167	chr1:166818506	POGK	-0.46	-5.06	-0.31	8.3e-7	Refractive astigmatism;
KIRP	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15254786	chr2:207630414	MDH1B;FASTKD2	0.52	6.09	0.36	4.31e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg07395648	chr5:131743802	NA	0.51	6.27	0.37	1.6e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.9	8.06	0.46	3.34e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	9.62	0.52	8.38e-19	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-6.1	-0.36	4.18e-9	Height;
KIRP	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.66	10.06	0.54	3.76e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.8	11.38	0.59	2.25e-24	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.79	-0.35	2.12e-8	Parkinson's disease;
KIRP	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.63	9.62	0.52	8.47e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7113874	0.592	rs12808779	chr11:8437827	C/T	cg08015107	chr11:8618950	NA	-0.65	-7.95	-0.45	6.56e-14	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.74	0.39	1.15e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-16.31	-0.72	5.07e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.27	0.32	2.98e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg07585502	chr8:101912084	NA	-0.65	-8.68	-0.48	5.6e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23903597	chr17:61704154	MAP3K3	-0.55	-6.56	-0.39	3.13e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg18225595	chr11:63971243	STIP1	0.65	5.86	0.35	1.45e-8	Mean platelet volume;
KIRP	cis	rs4523957	0.690	rs7213715	chr17:2093511	A/T	cg16513277	chr17:2031491	SMG6	-0.78	-11.01	-0.57	3.61e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2250402	0.510	rs75578790	chr15:40332440	A/G	cg01081584	chr15:40268610	EIF2AK4	0.45	5.35	0.32	2e-7	Corneal curvature;
KIRP	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.59	-8.39	-0.47	3.76e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.82	-12.99	-0.64	1.01e-29	Blood metabolite levels;
KIRP	cis	rs8133932	0.654	rs371587	chr21:47348512	G/A	cg11214348	chr21:47283868	PCBP3	-0.47	-5.32	-0.32	2.29e-7	Schizophrenia;
KIRP	cis	rs7078219	0.505	rs4409764	chr10:101284237	T/G	cg07044859	chr10:101282883	NA	-0.3	-5.2	-0.31	4.14e-7	Dental caries;
KIRP	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.59	7.36	0.42	2.8e-12	Arsenic metabolism;
KIRP	cis	rs1712517	0.771	rs59744322	chr10:105146692	G/T	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.31e-9	Migraine;
KIRP	cis	rs4716602	0.622	rs59109406	chr7:156167344	T/C	cg16983916	chr7:156159713	NA	-0.46	-6.05	-0.36	5.46e-9	Anti-saccade response;
KIRP	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg00806126	chr19:22604979	ZNF98	-0.67	-7.1	-0.41	1.36e-11	Pain;
KIRP	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.64	-9.25	-0.51	1.16e-17	Morning vs. evening chronotype;
KIRP	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg21573476	chr21:45109991	RRP1B	-0.86	-13.49	-0.65	2.1e-31	Mean corpuscular volume;
KIRP	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.66	0.39	1.81e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.85	0.3	2.21e-6	Menopause (age at onset);
KIRP	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.01	-0.3	1.03e-6	Cognitive function;
KIRP	cis	rs6088813	1.000	rs6141546	chr20:33949282	T/C	cg14752227	chr20:34000481	UQCC	-0.51	-6.87	-0.4	5.22e-11	Height;
KIRP	cis	rs17123764	0.892	rs61281663	chr12:50098005	A/G	cg20471783	chr12:50157085	TMBIM6	0.4	5.33	0.32	2.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.91	10.38	0.55	3.73e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.87	-15.8	-0.71	2.68e-39	Body mass index;
KIRP	cis	rs8038465	0.561	rs59104311	chr15:73845185	G/A	cg15420318	chr15:73925796	NPTN	0.66	9.26	0.51	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	1.03	15.06	0.69	8.98e-37	Menopause (age at onset);
KIRP	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.09	-15.11	-0.69	6.18e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.21	0.32	4.04e-7	Lung cancer;
KIRP	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg19906672	chr4:6918868	TBC1D14	0.51	5.23	0.32	3.65e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17851061	chr2:11758591	GREB1	0.45	6.4	0.38	7.94e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.39e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6684428	0.706	rs10493185	chr1:56321789	A/G	cg11651538	chr1:56320950	NA	-0.93	-12.86	-0.63	2.63e-29	Airflow obstruction;
KIRP	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.69	-0.39	1.53e-10	Retinal vascular caliber;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01933248	chr2:418573	NA	0.36	6.04	0.36	5.81e-9	Survival in pancreatic cancer;
KIRP	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs258892	0.895	rs10077575	chr5:72084557	A/C	cg21869765	chr5:72125136	TNPO1	-0.55	-5.99	-0.36	7.27e-9	Small cell lung carcinoma;
KIRP	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg02153584	chr22:29168773	CCDC117	0.58	5.91	0.35	1.15e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	trans	rs7999699	0.783	rs12584226	chr13:48307408	C/G	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.5	5.72	0.34	3.04e-8	Diastolic blood pressure;
KIRP	cis	rs1298062	0.763	rs921938	chr19:50982086	C/A	cg11430371	chr19:50961752	MYBPC2	0.37	5.04	0.31	8.96e-7	Age of smoking initiation;
KIRP	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.42	5.73	0.34	2.97e-8	Bipolar disorder;
KIRP	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.91	13.27	0.65	1.15e-30	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7017914	0.967	rs6472539	chr8:71629810	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.73	-10.77	-0.57	2.04e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.66	5.0	0.3	1.1e-6	Schizophrenia;
KIRP	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg18154014	chr19:37997991	ZNF793	0.61	6.68	0.39	1.57e-10	Coronary artery calcification;
KIRP	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg27490568	chr2:178487706	NA	0.71	8.78	0.49	2.89e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.26	0.37	1.68e-9	Menarche (age at onset);
KIRP	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.4	5.13	0.31	5.86e-7	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.6	0.48	9.28e-16	Motion sickness;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg11641102	chr8:27183873	PTK2B	0.42	5.61	0.34	5.34e-8	Neuroticism;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.76	11.49	0.59	9.41e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg22138327	chr13:27999177	GTF3A	0.85	6.53	0.38	3.77e-10	Weight;
KIRP	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.77	10.97	0.57	4.68e-23	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.63	8.12	0.46	2.24e-14	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs4646404	0.509	rs4646359	chr17:17470609	C/T	cg01246520	chr17:17644344	RAI1	-0.32	-5.5	-0.33	9.71e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg03929089	chr4:120376271	NA	0.98	7.25	0.42	5.41e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.16	-0.31	5.19e-7	Inflammatory bowel disease;
KIRP	cis	rs4936894	0.500	rs11219541	chr11:124130982	G/A	cg27160556	chr11:124181099	OR8D1	-0.39	-5.75	-0.34	2.66e-8	Aging (time to death);
KIRP	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg13198984	chr17:80129470	CCDC57	0.56	8.62	0.48	8.13e-16	Life satisfaction;
KIRP	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg04492858	chr10:133558786	NA	0.35	5.19	0.31	4.41e-7	Survival in rectal cancer;
KIRP	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	11.77	0.6	1.12e-25	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-0.61	-6.73	-0.39	1.19e-10	Initial pursuit acceleration;
KIRP	cis	rs6753739	0.745	rs1455836	chr2:219912866	T/G	cg01749213	chr2:219906749	CCDC108	0.41	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.83	0.35	1.74e-8	Lung cancer;
KIRP	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.44	-6.17	-0.37	2.82e-9	Schizophrenia;
KIRP	cis	rs6815814	0.808	rs7669329	chr4:38846719	T/C	cg06935464	chr4:38784597	TLR10	0.49	5.93	0.35	9.99e-9	Breast cancer;
KIRP	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.03	-0.41	2e-11	Initial pursuit acceleration;
KIRP	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-7.99	-0.45	5.37e-14	Eye color traits;
KIRP	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg26513180	chr16:89883248	FANCA	0.51	4.88	0.3	1.94e-6	Skin colour saturation;
KIRP	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg23649088	chr2:200775458	C2orf69	-0.39	-4.92	-0.3	1.58e-6	QT interval;
KIRP	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg03714773	chr7:91764589	CYP51A1	-0.38	-5.49	-0.33	1.02e-7	Breast cancer;
KIRP	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg09455208	chr3:40491958	NA	0.41	7.05	0.41	1.77e-11	Renal cell carcinoma;
KIRP	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.47	5.45	0.33	1.24e-7	Menarche (age at onset);
KIRP	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs7221595	0.756	rs9900661	chr17:3962450	A/G	cg09695851	chr17:3907499	NA	0.59	6.09	0.36	4.26e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.43	0.33	1.37e-7	Educational attainment;
KIRP	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.58	-7.12	-0.41	1.18e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7769051	0.522	rs77652453	chr6:133142421	A/G	cg22852734	chr6:133119734	C6orf192	1.05	5.67	0.34	3.9e-8	Type 2 diabetes nephropathy;
KIRP	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.62	7.23	0.42	5.93e-12	Obesity-related traits;
KIRP	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg08885076	chr2:99613938	TSGA10	0.52	8.95	0.5	9.03e-17	Chronic sinus infection;
KIRP	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg09526685	chr4:187126073	CYP4V2	0.67	6.38	0.38	8.79e-10	Blood protein levels;
KIRP	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg04691961	chr3:161091175	C3orf57	-0.46	-6.57	-0.39	2.98e-10	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg16606324	chr3:10149918	C3orf24	0.56	5.25	0.32	3.27e-7	Alzheimer's disease;
KIRP	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.49	-5.43	-0.33	1.35e-7	White matter hyperintensity burden;
KIRP	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg26207909	chr14:103986467	CKB	-0.44	-5.61	-0.34	5.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs501120	0.925	rs559469	chr10:44752118	C/T	cg09554077	chr10:44749378	NA	-0.75	-12.14	-0.61	6.69e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.86	-0.35	1.47e-8	Morning vs. evening chronotype;
KIRP	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	1.3	9.0	0.5	6.34e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg01864069	chr14:103024347	NA	-0.97	-12.44	-0.62	6.71e-28	Platelet count;
KIRP	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02737782	chr1:8014393	NA	-0.45	-6.02	-0.36	6.28e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13198984	chr17:80129470	CCDC57	-0.55	-8.25	-0.47	9.67e-15	Life satisfaction;
KIRP	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	12.0	0.61	2.03e-26	Multiple sclerosis;
KIRP	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.76	10.28	0.55	7.56e-21	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17165432	chr2:230222630	DNER	0.55	6.8	0.4	8.1e-11	Interleukin-4 levels;
KIRP	cis	rs12210905	1.000	rs114337870	chr6:27254937	A/C	cg11502198	chr6:26597334	ABT1	-0.85	-4.86	-0.3	2.09e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs838147	0.534	rs2638280	chr19:49209318	G/A	cg16867584	chr19:49200180	FUT2	0.34	5.44	0.33	1.28e-7	Dietary macronutrient intake;
KIRP	cis	rs155346	0.625	rs264345	chr5:139359139	G/A	cg24724630	chr5:139362307	NRG2	-0.38	-5.02	-0.3	1.01e-6	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg00405596	chr8:11794950	NA	0.48	5.99	0.36	7.35e-9	Retinal vascular caliber;
KIRP	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	0.89	8.99	0.5	6.98e-17	Methadone dose in opioid dependence;
KIRP	cis	rs10489525	0.530	rs11102884	chr1:115612947	A/G	cg01522456	chr1:115632236	TSPAN2	-0.53	-7.34	-0.42	3.07e-12	Autism;
KIRP	cis	rs9308731	0.583	rs2165107	chr2:111931350	C/G	cg04202892	chr2:111875749	ACOXL	0.48	6.58	0.39	2.82e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.58	-7.43	-0.43	1.84e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.75	-0.63	6.19e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs71597109	0.568	rs11940179	chr4:102727577	C/T	cg14855874	chr4:102712397	BANK1	0.4	5.2	0.31	4.14e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs6459788	1.000	rs6459788	chr7:157260190	G/A	cg06271696	chr7:157225062	NA	-0.5	-6.37	-0.38	9.08e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg00405596	chr8:11794950	NA	0.42	5.57	0.33	6.56e-8	Retinal vascular caliber;
KIRP	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg04438997	chr17:70115868	SOX9	0.36	5.31	0.32	2.5e-7	Thyroid hormone levels;
KIRP	cis	rs11250464	0.517	rs2387667	chr10:1430761	T/C	cg08668359	chr10:1443807	ADARB2	0.39	4.98	0.3	1.2e-6	Radiation response;
KIRP	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg13736514	chr6:26305472	NA	-0.67	-9.07	-0.5	3.86e-17	Educational attainment;
KIRP	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.6	7.63	0.44	5.07e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9400467	0.537	rs1150081	chr6:111479016	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.29	0.32	2.66e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg23594656	chr7:65796392	TPST1	0.33	4.9	0.3	1.74e-6	Calcium levels;
KIRP	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.09	0.5	3.44e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg00106254	chr7:1943704	MAD1L1	-0.52	-5.75	-0.34	2.62e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2019216	0.521	rs2175657	chr17:21908494	T/G	cg22648282	chr17:21454238	C17orf51	-0.52	-6.51	-0.38	4.26e-10	Pelvic organ prolapse;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.53	5.2	0.31	4.25e-7	Alzheimer's disease;
KIRP	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.66	8.74	0.49	3.6e-16	Joint mobility (Beighton score);
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg15181151	chr6:150070149	PCMT1	0.31	5.2	0.31	4.1e-7	Lung cancer;
KIRP	cis	rs11673344	0.734	rs1234250	chr19:37690420	C/T	cg14683738	chr19:37701593	ZNF585B	0.5	5.77	0.35	2.4e-8	Obesity-related traits;
KIRP	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg04166393	chr7:2884313	GNA12	0.43	5.39	0.32	1.69e-7	Height;
KIRP	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs67257959	0.903	rs7259285	chr19:17153149	A/G	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.44	-5.2	-0.31	4.15e-7	Selective IgA deficiency;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10263684	chr2:46520913	NA	0.44	6.17	0.37	2.84e-9	Survival in pancreatic cancer;
KIRP	cis	rs629922	0.855	rs512113	chr11:114049654	C/A	cg25009965	chr11:114031120	ZBTB16	0.41	5.35	0.32	2.01e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg06060754	chr5:176797920	RGS14	-0.61	-7.06	-0.41	1.74e-11	Urate levels in lean individuals;
KIRP	cis	rs501120	0.584	rs10900000	chr10:44694892	G/A	cg09554077	chr10:44749378	NA	0.6	6.44	0.38	6.07e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs6977660	1.000	rs10260527	chr7:19801930	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	5.62	0.34	5.24e-8	Thyroid stimulating hormone;
KIRP	cis	rs3925075	0.553	rs9888907	chr16:31349040	A/G	cg02846316	chr16:31340340	ITGAM	0.47	5.95	0.35	9.02e-9	IgA nephropathy;
KIRP	cis	rs113835537	0.529	rs4930378	chr11:66255515	T/C	cg24851651	chr11:66362959	CCS	0.43	5.1	0.31	6.77e-7	Airway imaging phenotypes;
KIRP	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08280861	chr8:58055591	NA	0.69	6.52	0.38	3.97e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs78545713	0.536	rs116337444	chr6:26208269	G/A	cg23601095	chr6:26197514	HIST1H3D	0.88	5.22	0.32	3.83e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs238295	0.846	rs6053528	chr20:5582598	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.48	-4.85	-0.3	2.2e-6	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.57	7.52	0.43	9.96e-13	Morning vs. evening chronotype;
KIRP	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg04727924	chr7:799746	HEATR2	-0.68	-7.11	-0.41	1.22e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.64	-9.19	-0.51	1.76e-17	Retinal vascular caliber;
KIRP	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg01475377	chr6:109611718	NA	-0.38	-5.28	-0.32	2.78e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9394169	0.709	rs6919321	chr6:33724004	G/A	cg25922239	chr6:33757077	LEMD2	0.43	5.24	0.32	3.53e-7	Essential tremor;
KIRP	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.84	0.4	6.27e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7119038	0.818	rs7942535	chr11:118681464	C/T	cg19308663	chr11:118741387	NA	-0.48	-7.98	-0.45	5.6e-14	Sjögren's syndrome;
KIRP	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg27494647	chr7:150038898	RARRES2	0.37	5.75	0.34	2.6e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg04287289	chr16:89883240	FANCA	0.47	5.97	0.36	8.04e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg17376030	chr22:41985996	PMM1	-0.83	-8.49	-0.48	1.94e-15	Vitiligo;
KIRP	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.26	11.87	0.6	5.43e-26	Diabetic retinopathy;
KIRP	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.43	6.56	0.39	3.08e-10	Schizophrenia;
KIRP	cis	rs1190552	0.846	rs11623570	chr14:102959277	G/T	cg18135206	chr14:102964638	TECPR2	0.46	5.18	0.31	4.55e-7	Blood protein levels;
KIRP	cis	rs10208940	0.920	rs7423646	chr2:68758180	A/G	cg12452813	chr2:68675892	NA	0.47	5.06	0.31	8.07e-7	Urate levels in lean individuals;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.64	8.87	0.49	1.53e-16	Menarche (age at onset);
KIRP	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg27494647	chr7:150038898	RARRES2	-0.44	-6.25	-0.37	1.76e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.8	10.31	0.55	6.12e-21	Mean corpuscular volume;
KIRP	cis	rs4281086	0.561	rs4997498	chr8:10352622	G/C	cg21775007	chr8:11205619	TDH	0.41	5.32	0.32	2.31e-7	Obesity-related traits;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg27333271	chr3:7268498	GRM7	-0.38	-6.02	-0.36	6.47e-9	Inflammatory biomarkers;
KIRP	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg06565975	chr8:143823917	SLURP1	-0.57	-7.82	-0.45	1.54e-13	Urinary tract infection frequency;
KIRP	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg12218747	chr21:37451666	NA	-0.43	-5.37	-0.32	1.8e-7	Mitral valve prolapse;
KIRP	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.87	8.66	0.48	6.53e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs12153243	1.000	rs59514002	chr5:142901014	T/A	cg13907255	chr5:142895549	NA	-0.37	-5.03	-0.31	9.69e-7	Migraine;
KIRP	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.96	12.57	0.63	2.6e-28	Breast cancer;
KIRP	cis	rs2669010	0.796	rs2632211	chr12:77045889	A/G	cg14998926	chr12:77026162	NA	-0.42	-5.66	-0.34	4.11e-8	Systemic lupus erythematosus;
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg17372223	chr3:52568218	NT5DC2	0.36	5.9	0.35	1.22e-8	Electroencephalogram traits;
KIRP	cis	rs17095355	1.000	rs9630102	chr10:111738662	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.06	-0.36	5e-9	Biliary atresia;
KIRP	cis	rs1322639	0.575	rs9294966	chr6:169565318	G/T	cg04662567	chr6:169592167	NA	-0.64	-5.45	-0.33	1.2e-7	Pulse pressure;
KIRP	cis	rs78487399	0.808	rs17039133	chr2:43694570	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.11	-0.31	6.42e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs34286592	0.929	rs9923649	chr16:29832138	G/A	cg08218971	chr16:29826754	C16orf53;PRRT2	0.36	5.24	0.32	3.42e-7	Multiple sclerosis;
KIRP	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23598886	chr18:12777645	NA	0.68	5.66	0.34	4.25e-8	Inflammatory skin disease;
KIRP	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg13256891	chr4:100009986	ADH5	0.5	6.15	0.37	3.04e-9	Alcohol dependence;
KIRP	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs12282928	0.918	rs11039656	chr11:48320705	T/G	cg26585981	chr11:48327164	OR4S1	0.5	6.01	0.36	6.51e-9	Migraine - clinic-based;
KIRP	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg26818010	chr10:134567672	INPP5A	-0.66	-7.2	-0.42	7.32e-12	Migraine;
KIRP	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	5.51	0.33	9.25e-8	Urinary tract infection frequency;
KIRP	trans	rs783540	0.521	rs28719490	chr15:83389440	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.64	-7.61	-0.44	5.9e-13	Schizophrenia;
KIRP	cis	rs2219968	1.000	rs11777219	chr8:78959566	A/T	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.79	10.93	0.57	6.22e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4356932	0.935	rs10031452	chr4:76924933	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.13	0.31	5.78e-7	Blood protein levels;
KIRP	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.74	-8.18	-0.46	1.49e-14	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.61	9.2	0.51	1.56e-17	Lung cancer;
KIRP	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg08992911	chr2:238395768	MLPH	0.49	5.28	0.32	2.88e-7	Prostate cancer;
KIRP	trans	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7124676	1.000	rs7124676	chr11:64313291	A/G	cg09127371	chr11:64313507	NA	-0.41	-5.71	-0.34	3.24e-8	Obesity-related traits;
KIRP	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	1.05	22.23	0.82	8.86e-61	Parkinson's disease;
KIRP	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg18833306	chr6:118973337	C6orf204	0.42	5.3	0.32	2.61e-7	Electrocardiographic conduction measures;
KIRP	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	13.91	0.66	7.44e-33	Cognitive ability;
KIRP	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.79	-11.39	-0.59	2.05e-24	Response to temozolomide;
KIRP	cis	rs8084125	1.000	rs72981154	chr18:74944135	C/T	cg05528293	chr18:74961138	GALR1	0.5	4.91	0.3	1.63e-6	Obesity-related traits;
KIRP	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15432903	chr11:17409602	KCNJ11	-0.45	-5.27	-0.32	3.05e-7	Glaucoma (primary angle closure);
KIRP	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg13147721	chr7:65941812	NA	-0.89	-6.36	-0.38	9.62e-10	Diabetic kidney disease;
KIRP	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg20169779	chr10:135381914	SYCE1	-0.63	-5.84	-0.35	1.64e-8	Gout;
KIRP	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.61	8.13	0.46	2.08e-14	Motion sickness;
KIRP	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.42	8.06	0.46	3.37e-14	Educational attainment (years of education);
KIRP	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.27	0.32	3.01e-7	Educational attainment;
KIRP	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg17470723	chr8:74884337	TCEB1	0.64	8.17	0.46	1.6e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7572263	0.724	rs7579275	chr2:209053080	A/C	cg23998903	chr2:209048830	C2orf80	-0.36	-5.25	-0.32	3.22e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.67	0.34	3.93e-8	Educational attainment;
KIRP	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg07044859	chr10:101282883	NA	-0.32	-5.85	-0.35	1.52e-8	Dental caries;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.76	7.21	0.42	6.85e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	1.08	21.52	0.81	1.75e-58	Height;
KIRP	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Melanoma;
KIRP	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs7246657	0.722	rs1564208	chr19:38041221	A/G	cg18154014	chr19:37997991	ZNF793	0.61	6.66	0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs7771547	0.855	rs1406945	chr6:36562441	C/G	cg04289385	chr6:36355825	ETV7	0.39	5.44	0.33	1.27e-7	Platelet distribution width;
KIRP	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg21918786	chr6:109611834	NA	0.41	5.86	0.35	1.49e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg10096100	chr1:26503862	CNKSR1	0.41	5.8	0.35	2.01e-8	Height;
KIRP	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.33	0.62	1.67e-27	Bone mineral density;
KIRP	cis	rs675026	0.963	rs582924	chr6:154446778	C/G	cg07813322	chr6:154414604	OPRM1	-0.52	-6.74	-0.39	1.11e-10	Hypertension;
KIRP	cis	rs4908768	0.906	rs114812780	chr1:8528854	G/T	cg03610117	chr1:8450231	RERE	-0.48	-5.15	-0.31	5.25e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg13409248	chr3:40428643	ENTPD3	-0.36	-5.02	-0.31	9.77e-7	Renal cell carcinoma;
KIRP	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs698813	0.789	rs2592195	chr2:44607707	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.14	0.36	3.37e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs2411233	0.837	rs1368803	chr15:39256705	C/T	cg19287857	chr15:39890699	NA	0.47	6.47	0.38	5.29e-10	Platelet count;
KIRP	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.86	-0.3	2.05e-6	Crohn's disease;
KIRP	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.04e-7	Putamen volume;
KIRP	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.73	-0.39	1.21e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9469913	0.799	rs2744947	chr6:34657809	A/T	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.28	-0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg04036182	chr15:45458818	NA	0.47	6.34	0.37	1.09e-9	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs16976116	0.901	rs28526269	chr15:55499190	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.33	5.28	0.32	2.86e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1978968	1.000	rs12158906	chr22:18437382	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.62	-7.94	-0.45	7.33e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs4965006	1.000	rs11246900	chr12:132506784	G/T	cg00588090	chr12:132412438	PUS1	0.57	5.6	0.34	5.7e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.22	-0.32	3.79e-7	Coronary artery disease;
KIRP	trans	rs1973993	0.662	rs2057427	chr1:96888897	C/G	cg10631902	chr5:14652156	NA	-0.57	-8.02	-0.46	4.3e-14	Weight;
KIRP	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg23100626	chr2:96804247	ASTL	-0.52	-7.78	-0.44	2.03e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.26	-0.32	3.11e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg27205649	chr11:78285834	NARS2	-0.53	-5.82	-0.35	1.81e-8	Testicular germ cell tumor;
KIRP	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.44	-5.06	-0.31	8.08e-7	Eosinophil percentage of white cells;
KIRP	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.44	6.3	0.37	1.36e-9	Endometrial cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08862778	chr1:11322643	MTOR	0.48	6.42	0.38	7.11e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.63	-8.01	-0.46	4.46e-14	Iron status biomarkers;
KIRP	cis	rs71636778	0.631	rs76133297	chr1:27154470	G/A	cg12203394	chr1:27248618	NUDC	0.82	6.2	0.37	2.34e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg06453172	chr10:134556979	INPP5A	-0.53	-5.82	-0.35	1.84e-8	Migraine;
KIRP	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.73	9.1	0.5	3.27e-17	Platelet distribution width;
KIRP	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.74	5.99	0.36	7.57e-9	Body mass index;
KIRP	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs253959	0.881	rs2416427	chr5:115437676	G/A	cg23108291	chr5:115420582	COMMD10	0.43	5.15	0.31	5.21e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.63	8.08	0.46	2.99e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.37	-5.73	-0.34	2.88e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg00579200	chr11:133705235	NA	-0.42	-5.62	-0.34	5.04e-8	Childhood ear infection;
KIRP	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.85	5.18	0.31	4.65e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.72	0.34	3.14e-8	Lung cancer;
KIRP	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.57	8.2	0.46	1.31e-14	Carotid intima media thickness;
KIRP	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.73	9.69	0.53	5e-19	Cognitive function;
KIRP	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg15128208	chr22:42549153	NA	0.67	5.79	0.35	2.15e-8	Birth weight;
KIRP	cis	rs4849845	0.925	rs4849842	chr2:121012666	T/A	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg22676075	chr6:135203613	NA	-0.48	-6.62	-0.39	2.19e-10	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08516262	chr3:101292886	PCNP	-0.51	-6.02	-0.36	6.16e-9	Interleukin-4 levels;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-10.74	-0.56	2.59e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.31	0.55	6.14e-21	Coffee consumption (cups per day);
KIRP	cis	rs504918	0.556	rs73188191	chr3:124016463	T/C	cg05766129	chr3:123988013	KALRN	-0.44	-5.64	-0.34	4.6e-8	Schizophrenia;
KIRP	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-5.02	-0.3	1.01e-6	Major depressive disorder;
KIRP	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg17554472	chr22:41940697	POLR3H	0.63	6.46	0.38	5.67e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg12560992	chr17:57184187	TRIM37	0.61	5.62	0.34	5.09e-8	Cognitive test performance;
KIRP	trans	rs1620921	0.901	rs783180	chr6:161168961	G/T	cg01090089	chr7:6570974	GRID2IP	0.39	6.25	0.37	1.77e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg08999081	chr20:33150536	PIGU	0.46	6.16	0.37	2.93e-9	Height;
KIRP	cis	rs6142102	0.961	rs6120487	chr20:32622608	A/G	cg08999081	chr20:33150536	PIGU	0.56	7.33	0.42	3.35e-12	Skin pigmentation;
KIRP	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.04	0.36	5.64e-9	Lung cancer;
KIRP	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg04731861	chr2:219085781	ARPC2	-0.21	-5.16	-0.31	5.02e-7	Colorectal cancer;
KIRP	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg11952622	chr19:58962976	ZNF324B	0.42	4.93	0.3	1.49e-6	Uric acid clearance;
KIRP	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-1.12	-14.81	-0.69	6.6e-36	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	1.02	16.59	0.73	5.38e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7737355	0.898	rs6864413	chr5:130637868	G/T	cg06307176	chr5:131281290	NA	0.54	5.84	0.35	1.61e-8	Life satisfaction;
KIRP	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg09676129	chr20:60540388	NA	-0.35	-4.99	-0.3	1.17e-6	Body mass index;
KIRP	cis	rs1322639	0.614	rs6925188	chr6:169563337	T/C	cg04662567	chr6:169592167	NA	-0.64	-5.39	-0.33	1.64e-7	Pulse pressure;
KIRP	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg25338242	chr13:114786047	RASA3	0.41	4.85	0.3	2.2e-6	Schizophrenia;
KIRP	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg05785598	chr3:49045655	WDR6	0.31	5.65	0.34	4.38e-8	Parkinson's disease;
KIRP	cis	rs112591243	0.685	rs78443123	chr21:47953331	G/T	cg26904215	chr21:47823096	PCNT	-0.82	-6.13	-0.36	3.44e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs7289126	1.000	rs5995558	chr22:38647639	A/G	cg25457927	chr22:38595422	NA	-0.31	-6.72	-0.39	1.24e-10	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.09e-16	Life satisfaction;
KIRP	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.64	-8.89	-0.49	1.33e-16	Breast cancer;
KIRP	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg03060546	chr3:49711283	APEH	0.53	7.09	0.41	1.41e-11	Menarche (age at onset);
KIRP	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-8.2	-0.46	1.3e-14	Neuroticism;
KIRP	cis	rs2274459	1.000	rs35445446	chr6:33716745	C/T	cg06253072	chr6:33679850	C6orf125	0.51	5.01	0.3	1.03e-6	Obesity (extreme);
KIRP	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.62	0.34	5.05e-8	Breast cancer;
KIRP	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg27205649	chr11:78285834	NARS2	-0.56	-6.31	-0.37	1.3e-9	Testicular germ cell tumor;
KIRP	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-6.96	-0.41	3.02e-11	Bone mineral density;
KIRP	cis	rs35740288	0.770	rs1382534	chr15:86142170	A/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs13385	0.769	rs3822739	chr5:139625743	A/G	cg01860693	chr5:139557145	C5orf32	0.46	5.09	0.31	7.01e-7	Atrial fibrillation;
KIRP	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.85	-0.35	1.53e-8	Breast cancer;
KIRP	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.73	11.4	0.59	1.9e-24	QRS duration;
KIRP	cis	rs17373728	0.710	rs2221810	chr8:76221468	C/G	cg07016329	chr8:76221503	NA	-0.51	-6.71	-0.39	1.35e-10	Diabetic kidney disease;
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.16	0.37	2.9e-9	Platelet count;
KIRP	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg24459738	chr19:57751996	ZNF805	-0.55	-6.85	-0.4	5.92e-11	Hyperactive-impulsive symptoms;
KIRP	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.53	6.63	0.39	2.15e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.54	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs11638352	1.000	rs11638352	chr15:44293137	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-5.91	-0.35	1.13e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.49	6.25	0.37	1.79e-9	Testicular germ cell tumor;
KIRP	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg11189052	chr15:85197271	WDR73	0.5	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg22676075	chr6:135203613	NA	0.51	7.51	0.43	1.06e-12	Red blood cell count;
KIRP	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg06223162	chr1:101003688	GPR88	0.44	9.15	0.5	2.22e-17	Monocyte count;
KIRP	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg22705602	chr4:152727874	NA	-0.52	-8.94	-0.5	9.31e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-9.16	-0.5	2.04e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.18	0.37	2.7e-9	Menopause (age at onset);
KIRP	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.81	-7.12	-0.41	1.17e-11	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00111333	chr1:198828249	MIR181B1;MIR181A1	0.41	6.02	0.36	6.2e-9	Survival in pancreatic cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00185336	chr7:73153699	ABHD11	0.45	6.05	0.36	5.28e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.5	-6.5	-0.38	4.54e-10	Schizophrenia;
KIRP	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.46	-5.19	-0.31	4.3e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	1.02	11.49	0.59	9.35e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.79	10.17	0.54	1.63e-20	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-4.95	-0.3	1.4e-6	Cognitive function;
KIRP	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.95	14.62	0.68	3e-35	Menopause (age at onset);
KIRP	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14963534	chr19:17420130	DDA1	0.54	7.02	0.41	2.18e-11	Parkinson's disease;
KIRP	cis	rs7615316	1.000	rs4413348	chr3:142333025	A/G	cg20824294	chr3:142316082	PLS1	-0.23	-5.1	-0.31	6.63e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1497828	0.956	rs2815233	chr1:217539236	T/C	cg04411442	chr1:217543379	NA	-0.43	-6.63	-0.39	2.06e-10	Dialysis-related mortality;
KIRP	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.57	7.51	0.43	1.1e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9715521	0.712	rs58171535	chr4:59847742	T/A	cg11281224	chr4:60001000	NA	-0.4	-4.96	-0.3	1.33e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg12119029	chr16:89752879	CDK10	0.23	5.01	0.3	1.05e-6	Hemoglobin concentration;
KIRP	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05601917	chr6:125855416	NA	-0.34	-5.03	-0.31	9.37e-7	Brugada syndrome;
KIRP	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.79	-10.14	-0.54	1.99e-20	Blood trace element (Zn levels);
KIRP	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg21186296	chr8:27182909	PTK2B	0.46	5.77	0.35	2.42e-8	Neuroticism;
KIRP	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	12.67	0.63	1.14e-28	Personality dimensions;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18794426	chr1:3563325	WDR8	0.46	6.11	0.36	3.98e-9	Survival in pancreatic cancer;
KIRP	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.67	7.49	0.43	1.2e-12	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.66	9.06	0.5	4.09e-17	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	5.32	0.32	2.38e-7	Renal cell carcinoma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00016718	chr6:49405490	MUT	0.39	6.17	0.37	2.82e-9	Interleukin-4 levels;
KIRP	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.73	0.34	2.97e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2346160	0.867	rs2989556	chr6:167704404	T/A	cg27333441	chr6:167680455	NA	-0.4	-5.42	-0.33	1.39e-7	Parental extreme longevity (95 years and older);
KIRP	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.89	0.35	1.26e-8	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04445214	chr22:31688300	PIK3IP1	0.48	6.02	0.36	6.2e-9	Smoking initiation;
KIRP	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.54	-6.61	-0.39	2.31e-10	Multiple sclerosis;
KIRP	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg00647317	chr7:50633725	DDC	0.45	6.79	0.4	8.16e-11	Body mass index;
KIRP	cis	rs13178130	0.515	rs4958190	chr5:133897000	C/T	cg06019726	chr5:133897654	PHF15	0.4	5.99	0.36	7.32e-9	Menarche (age at onset);
KIRP	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.96	15.76	0.71	3.75e-39	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg15744005	chr10:104629667	AS3MT	-0.38	-7.93	-0.45	7.91e-14	Arsenic metabolism;
KIRP	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.59	6.43	0.38	6.62e-10	Aortic root size;
KIRP	cis	rs4118325	0.562	rs61800177	chr1:107703530	C/T	cg01939741	chr1:107680714	NA	-0.56	-5.3	-0.32	2.58e-7	AIDS;
KIRP	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-8.66	-0.48	6.24e-16	Platelet count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04742505	chr7:72936528	BAZ1B	0.53	6.21	0.37	2.26e-9	Smoking initiation;
KIRP	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg01200585	chr1:228362443	C1orf69	0.53	6.84	0.4	6.29e-11	Diastolic blood pressure;
KIRP	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs75920871	0.800	rs59266239	chr11:116911077	C/T	cg04087571	chr11:116723030	SIK3	-0.26	-4.86	-0.3	2.11e-6	Subjective well-being;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09270366	chr10:134587114	INPP5A	0.51	6.72	0.39	1.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs61884328	0.852	rs60174717	chr11:47106994	G/A	cg23433285	chr11:47201945	PACSIN3	0.69	5.6	0.34	5.68e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.54	-8.56	-0.48	1.26e-15	Prostate cancer;
KIRP	cis	rs11779988	0.545	rs208759	chr8:17807929	G/C	cg01800426	chr8:17659068	MTUS1	-0.63	-6.51	-0.38	4.19e-10	Breast cancer;
KIRP	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.02	0.31	9.78e-7	Bipolar disorder;
KIRP	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg13978929	chr19:21580086	ZNF493	0.5	4.92	0.3	1.58e-6	Pain;
KIRP	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.44	-5.38	-0.32	1.72e-7	Migraine;Coronary artery disease;
KIRP	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13917712	chr19:38714681	DPF1	0.47	6.51	0.38	4.08e-10	Parkinson's disease;
KIRP	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	cis	rs6772849	0.896	rs9816260	chr3:128352083	A/T	cg08795948	chr3:128337044	NA	0.49	6.21	0.37	2.23e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	cg21523751	chr1:182988639	NA	0.44	6.84	0.4	6.08e-11	Colorectal cancer;
KIRP	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg16141378	chr3:129829833	LOC729375	-0.56	-7.39	-0.43	2.25e-12	Retinal vascular caliber;
KIRP	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	10.68	0.56	4.13e-22	Personality dimensions;
KIRP	cis	rs3112255	0.905	rs4850945	chr2:101287063	A/T	cg01042948	chr2:101319752	NA	-0.36	-5.23	-0.32	3.55e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1928295	0.786	rs28693508	chr9:120361418	C/G	cg04204072	chr16:20752857	THUMPD1	-0.51	-6.27	-0.37	1.58e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2061333	0.901	rs3172	chr19:44609846	C/G	cg21636353	chr19:44617292	ZNF225	-0.46	-4.91	-0.3	1.66e-6	Alzheimer's disease;
KIRP	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg02336718	chr17:17403227	NA	0.37	5.74	0.34	2.72e-8	Total body bone mineral density;
KIRP	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.69	11.08	0.58	2e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22332100	chr1:2000508	PRKCZ	0.5	6.47	0.38	5.36e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs728616	0.764	rs56196124	chr10:81902655	A/T	cg27417294	chr10:81904244	PLAC9	0.56	4.89	0.3	1.81e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.65	9.04	0.5	4.94e-17	Dental caries;
KIRP	cis	rs4728302	0.607	rs2042454	chr7:133580710	A/G	cg10665199	chr7:133106180	EXOC4	0.42	4.9	0.3	1.73e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.56	-6.36	-0.38	9.99e-10	Initial pursuit acceleration;
KIRP	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.38	-5.06	-0.31	8.31e-7	Oropharynx cancer;
KIRP	cis	rs1971762	0.527	rs784562	chr12:53919700	A/C	cg16917193	chr12:54089295	NA	-0.8	-13.24	-0.65	1.39e-30	Height;
KIRP	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg06289844	chr6:126071538	HEY2	-0.35	-4.93	-0.3	1.54e-6	Endometrial cancer;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.2e-8	Life satisfaction;
KIRP	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	9.65	0.52	6.82e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.66	-9.24	-0.51	1.17e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.84	-12.21	-0.61	3.9e-27	Longevity;
KIRP	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg01097406	chr16:89675127	NA	-0.33	-5.45	-0.33	1.23e-7	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12727462	chr1:108742820	SLC25A24	0.51	6.25	0.37	1.8e-9	Parkinson's disease;
KIRP	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.88	11.8	0.6	9.08e-26	Coronary artery disease;
KIRP	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg00262122	chr8:11665843	FDFT1	0.44	5.38	0.32	1.76e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.42	-0.38	7.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7973719	0.865	rs12820829	chr12:7347534	G/A	cg07052231	chr12:7363540	PEX5	0.4	5.3	0.32	2.61e-7	IgG glycosylation;
KIRP	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.99e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg09137382	chr11:130731461	NA	0.49	6.54	0.38	3.63e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.61	8.81	0.49	2.34e-16	Colorectal cancer;
KIRP	cis	rs75920871	0.528	rs723955	chr11:116925042	G/A	cg04087571	chr11:116723030	SIK3	-0.26	-5.56	-0.33	6.84e-8	Subjective well-being;
KIRP	cis	rs2279817	0.908	rs3766310	chr1:17977642	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.9	-0.45	9.2e-14	Neuroticism;
KIRP	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg02574844	chr11:5959923	NA	-0.64	-6.57	-0.39	2.94e-10	DNA methylation (variation);
KIRP	cis	rs1832871	0.512	rs28639499	chr6:158874950	A/G	cg07215822	chr6:158701037	NA	-0.52	-5.6	-0.34	5.84e-8	Height;
KIRP	cis	rs11203032	0.908	rs4282908	chr10:90943967	C/T	cg16672925	chr10:90967113	CH25H	0.45	5.46	0.33	1.15e-7	Heart failure;
KIRP	cis	rs74181299	0.684	rs2302631	chr2:65331659	T/G	cg05010058	chr2:65284262	CEP68	-0.43	-5.9	-0.35	1.18e-8	Pulse pressure;
KIRP	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.77	-0.35	2.43e-8	Educational attainment;
KIRP	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.39	0.43	2.26e-12	Retinal vascular caliber;
KIRP	cis	rs7903847	0.667	rs11189181	chr10:99144154	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-5.43	-0.33	1.35e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg18478394	chr8:109455254	TTC35	0.51	6.26	0.37	1.71e-9	Dupuytren's disease;
KIRP	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg08662619	chr6:150070041	PCMT1	0.34	5.29	0.32	2.75e-7	Lung cancer;
KIRP	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.35	5.08	0.31	7.33e-7	Coronary artery disease;
KIRP	cis	rs1018697	1.000	rs10748830	chr10:104548382	A/C	cg04362960	chr10:104952993	NT5C2	0.49	5.85	0.35	1.55e-8	Colorectal adenoma (advanced);
KIRP	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.68	8.03	0.46	4.06e-14	Diabetic retinopathy;
KIRP	cis	rs6832769	0.961	rs28445925	chr4:56435849	T/C	cg09317128	chr4:56265301	TMEM165	-0.53	-6.85	-0.4	5.95e-11	Personality dimensions;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25730356	chr1:154540159	CHRNB2	0.42	6.32	0.37	1.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16263701	chr12:48213605	HDAC7	0.57	6.63	0.39	2.08e-10	Smoking initiation;
KIRP	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.65	0.52	6.89e-19	Longevity;
KIRP	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg00158530	chr16:69966973	MIR140;WWP2	-0.41	-5.41	-0.33	1.5e-7	Menarche (age at onset);
KIRP	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	1.02	10.74	0.57	2.51e-22	Cerebrospinal P-tau181p levels;
KIRP	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	0.93	14.63	0.68	2.62e-35	Heart rate;
KIRP	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg06636001	chr8:8085503	FLJ10661	0.71	10.36	0.55	4.25e-21	Mood instability;
KIRP	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg09594475	chr20:60884601	LAMA5	0.37	5.63	0.34	4.86e-8	Pelvic organ prolapse;
KIRP	trans	rs9371601	0.859	rs492904	chr6:152720194	A/G	cg05529123	chr2:66910386	NA	-0.47	-6.49	-0.38	4.8e-10	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg23682824	chr7:23144976	KLHL7	0.54	6.5	0.38	4.48e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.85	13.22	0.64	1.66e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.47	5.94	0.35	9.73e-9	Schizophrenia (inflammation and infection response interaction);
KIRP	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.76	11.83	0.6	7.61e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg21401794	chr1:90099060	LRRC8C	0.66	9.04	0.5	4.72e-17	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.21	0.32	3.94e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg26408565	chr15:76604113	ETFA	0.48	6.69	0.39	1.47e-10	Blood metabolite levels;
KIRP	cis	rs6601327	0.603	rs13275545	chr8:9667914	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.01	-0.3	1.05e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg07636037	chr3:49044803	WDR6	-0.75	-5.63	-0.34	4.84e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg17105886	chr17:28927953	LRRC37B2	-0.51	-5.16	-0.31	5.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.34	0.47	5.19e-15	Motion sickness;
KIRP	cis	rs1978968	0.763	rs35276871	chr22:18459040	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.73	-9.19	-0.51	1.7e-17	Presence of antiphospholipid antibodies;
KIRP	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg11784071	chr10:104629166	AS3MT	-0.38	-5.31	-0.32	2.47e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs35995292	0.927	rs4720308	chr7:38914285	A/C	cg19327137	chr7:38886074	VPS41	0.52	6.14	0.36	3.32e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.68	8.03	0.46	3.92e-14	DNA methylation (variation);
KIRP	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg03714773	chr7:91764589	CYP51A1	0.41	6.23	0.37	2.05e-9	Breast cancer;
KIRP	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg23842812	chr7:76127459	DTX2	0.53	4.87	0.3	2.04e-6	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2120243	0.504	rs114107407	chr3:157062635	G/A	cg24825693	chr3:157122686	VEPH1	-0.37	-5.66	-0.34	4.22e-8	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs7187994	0.848	rs34139611	chr16:84772473	C/T	cg07647771	chr16:84786436	USP10	-0.51	-6.1	-0.36	4.17e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg19847130	chr8:10466454	RP1L1	-0.36	-5.67	-0.34	4.05e-8	Neuroticism;
KIRP	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.72	6.4	0.38	7.9e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11874712	1.000	rs2298787	chr18:43669980	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg00129232	chr17:37814104	STARD3	0.72	9.17	0.5	1.91e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.68	8.91	0.49	1.13e-16	Bladder cancer;
KIRP	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.68	-7.5	-0.43	1.15e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22906224	chr7:99728672	NA	-0.56	-7.38	-0.43	2.41e-12	Coronary artery disease;
KIRP	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg16497661	chr14:103986332	CKB	-0.49	-6.42	-0.38	6.98e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	8.01	0.45	4.7e-14	Retinal vascular caliber;
KIRP	cis	rs597583	0.951	rs636530	chr11:117421858	C/T	cg27161313	chr11:117392002	DSCAML1	0.5	5.74	0.34	2.75e-8	Putamen volume;
KIRP	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg26811252	chr16:29126840	RRN3P2	0.68	9.06	0.5	4.14e-17	Menopause (age at onset);
KIRP	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg23594656	chr7:65796392	TPST1	-0.49	-7.45	-0.43	1.57e-12	Aortic root size;
KIRP	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.21	0.32	3.97e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.89	8.46	0.47	2.42e-15	Body mass index;
KIRP	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg15655495	chr12:38532458	NA	-0.29	-5.03	-0.31	9.52e-7	Bladder cancer;
KIRP	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.88	8.53	0.48	1.54e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs909341	0.909	rs1758205	chr20:62355756	G/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.8	-0.4	7.85e-11	Atopic dermatitis;
KIRP	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.76	11.16	0.58	1.13e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.95	-0.69	2.12e-36	Alzheimer's disease;
KIRP	cis	rs71403859	0.667	rs12924650	chr16:71705908	C/T	cg08717414	chr16:71523259	ZNF19	-0.95	-8.19	-0.46	1.43e-14	Post bronchodilator FEV1;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg27532560	chr4:187881888	NA	0.72	11.87	0.6	5.36e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg04865290	chr3:52927548	TMEM110	-0.6	-6.86	-0.4	5.4e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg25457927	chr22:38595422	NA	-0.31	-6.57	-0.39	2.91e-10	Cutaneous nevi;
KIRP	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.02	0.3	1.01e-6	Diisocyanate-induced asthma;
KIRP	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.34	0.37	1.08e-9	Educational attainment;
KIRP	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.64	-9.37	-0.51	4.93e-18	Endometriosis;
KIRP	cis	rs11203032	0.831	rs7076185	chr10:90923524	G/A	cg16672925	chr10:90967113	CH25H	0.73	7.26	0.42	5.11e-12	Heart failure;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.79	14.36	0.68	2.19e-34	Height;
KIRP	cis	rs858239	0.539	rs4365988	chr7:23190871	T/C	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.58	0.44	7.22e-13	Retinal vascular caliber;
KIRP	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg13798912	chr7:905769	UNC84A	0.61	6.03	0.36	5.88e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.29	-0.42	4.2e-12	Joint mobility (Beighton score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06532611	chr19:58067858	ZNF550	-0.43	-6.22	-0.37	2.09e-9	Parkinson's disease;
KIRP	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.52	-6.82	-0.4	7.11e-11	Hip circumference;Waist circumference;
KIRP	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19524238	chr7:2802976	GNA12	-0.37	-4.95	-0.3	1.4e-6	Height;
KIRP	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.12	-0.41	1.16e-11	Response to antipsychotic treatment;
KIRP	cis	rs9435341	0.762	rs3861909	chr1:107544176	A/G	cg09367891	chr1:107599246	PRMT6	-0.56	-7.44	-0.43	1.64e-12	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs8054556	0.708	rs2278557	chr16:30093779	C/G	cg06326092	chr16:30034487	C16orf92	0.44	5.89	0.35	1.27e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.8	9.67	0.52	6.09e-19	Response to antipsychotic treatment;
KIRP	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.42	6.33	0.37	1.14e-9	Carotid intima media thickness;
KIRP	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	0.55	5.26	0.32	3.08e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs13315871	1.000	rs71311864	chr3:58372324	C/T	cg12435725	chr3:58293450	RPP14	-0.5	-5.29	-0.32	2.7e-7	Cholesterol, total;
KIRP	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg02574844	chr11:5959923	NA	0.57	5.77	0.35	2.42e-8	DNA methylation (variation);
KIRP	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg23594656	chr7:65796392	TPST1	0.5	7.69	0.44	3.45e-13	Aortic root size;
KIRP	cis	rs4132509	1.000	rs2291410	chr1:243716654	A/C	cg25706552	chr1:244017396	NA	-0.51	-7.09	-0.41	1.44e-11	RR interval (heart rate);
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg21851534	chr17:3907994	ZZEF1	0.5	7.28	0.42	4.37e-12	Type 2 diabetes;
KIRP	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	1.1	19.76	0.78	1.12e-52	Monocyte count;
KIRP	cis	rs11718455	0.767	rs6782500	chr3:43990260	A/G	cg08738300	chr3:44038990	NA	-0.66	-8.96	-0.5	8.42e-17	Coronary artery disease;
KIRP	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.88	-12.77	-0.63	5.44e-29	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg08648136	chr8:956695	NA	0.47	6.45	0.38	5.84e-10	Schizophrenia;
KIRP	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6707387	0.686	rs13020325	chr2:214489208	G/A	cg08319019	chr2:214017104	IKZF2	0.47	5.38	0.32	1.72e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03837750	chr1:74664160	LRRIQ3;TNNI3K;FPGT	0.48	6.21	0.37	2.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10073892	0.917	rs10214388	chr5:101659466	A/G	cg19774478	chr5:101632501	SLCO4C1	0.65	7.14	0.41	1.04e-11	Cognitive decline (age-related);
KIRP	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.62	9.19	0.51	1.69e-17	Coronary artery disease;
KIRP	cis	rs6568686	0.786	rs7450789	chr6:111816975	G/T	cg15721981	chr6:111408429	SLC16A10	-0.71	-6.07	-0.36	4.87e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg05861140	chr6:150128134	PCMT1	-0.4	-5.53	-0.33	8.16e-8	Lung cancer;
KIRP	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg16362232	chr11:430036	ANO9	0.63	5.06	0.31	8.4e-7	Body mass index;
KIRP	cis	rs10214930	0.647	rs7790498	chr7:27653207	A/G	cg22168087	chr7:27702803	HIBADH	0.47	5.07	0.31	7.74e-7	Hypospadias;
KIRP	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg18132916	chr6:79620363	NA	-0.41	-5.72	-0.34	3.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.52	6.9	0.4	4.39e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.11	-0.31	6.35e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg16586182	chr3:47516702	SCAP	0.64	8.59	0.48	1.02e-15	Colorectal cancer;
KIRP	cis	rs7520050	0.966	rs785485	chr1:46574424	C/T	cg03146154	chr1:46216737	IPP	-0.41	-5.41	-0.33	1.52e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg13332499	chr17:408570	NA	0.37	4.87	0.3	1.99e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs2236918	1.000	rs1635512	chr1:242024500	A/G	cg17736920	chr1:242011382	EXO1	-0.71	-9.31	-0.51	7.43e-18	Menopause (age at onset);
KIRP	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg03609598	chr5:56110824	MAP3K1	0.68	6.67	0.39	1.69e-10	Initial pursuit acceleration;
KIRP	cis	rs4716602	0.896	rs4716427	chr7:156166490	C/T	cg04090468	chr7:156181990	NA	-0.46	-5.52	-0.33	8.55e-8	Anti-saccade response;
KIRP	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-6.51	-0.38	4.1e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.84	-0.57	1.22e-22	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.6	9.05	0.5	4.47e-17	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13973351	chr11:60928923	VPS37C	0.53	7.05	0.41	1.75e-11	Parkinson's disease;
KIRP	cis	rs7601312	1.000	rs2216876	chr2:229317192	G/A	cg02542817	chr2:229291442	NA	-0.38	-5.66	-0.34	4.29e-8	Schizophrenia;
KIRP	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.35	-4.97	-0.3	1.24e-6	Tuberculosis;
KIRP	cis	rs644148	0.730	rs2571044	chr19:44985573	G/A	cg15540054	chr19:45004280	ZNF180	-0.64	-6.99	-0.41	2.63e-11	Personality dimensions;
KIRP	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg07930552	chr6:133119739	C6orf192	0.84	8.46	0.47	2.35e-15	Type 2 diabetes nephropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21018429	chr17:66032163	KPNA2	0.48	6.25	0.37	1.75e-9	Parkinson's disease;
KIRP	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg24699146	chr1:24152579	HMGCL	0.45	6.42	0.38	6.89e-10	Immature fraction of reticulocytes;
KIRP	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.53e-10	Aortic root size;
KIRP	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.83	-6.99	-0.41	2.5e-11	Obesity-related traits;
KIRP	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.43	5.01	0.3	1.02e-6	Blood protein levels;
KIRP	trans	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03602288	chr17:46641863	HOXB3	0.45	6.16	0.37	2.9e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg16141378	chr3:129829833	LOC729375	0.49	6.33	0.37	1.18e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg07402062	chr16:89894098	SPIRE2	0.35	7.45	0.43	1.58e-12	Vitiligo;
KIRP	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	6.5	0.38	4.41e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.47	-5.97	-0.36	8.29e-9	Parkinson's disease;
KIRP	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.5	-0.52	1.96e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.86	11.81	0.6	8.77e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.67	9.32	0.51	6.68e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg21401794	chr1:90099060	LRRC8C	0.7	9.8	0.53	2.4e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	0.97	8.19	0.46	1.39e-14	Arsenic metabolism;
KIRP	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.86	0.3	2.05e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs74181299	1.000	rs74181299	chr2:65283972	T/C	cg05010058	chr2:65284262	CEP68	0.51	7.61	0.44	5.85e-13	Pulse pressure;
KIRP	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg01677386	chr11:118938358	VPS11	-0.48	-5.37	-0.32	1.81e-7	Coronary artery disease;
KIRP	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg17757837	chr7:157058334	UBE3C	0.79	10.73	0.56	2.82e-22	Body mass index;
KIRP	cis	rs1318772	0.623	rs34077922	chr5:112975720	T/G	cg12552261	chr5:112820674	MCC	0.84	4.99	0.3	1.15e-6	F-cell distribution;
KIRP	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg21775007	chr8:11205619	TDH	0.44	6.11	0.36	3.97e-9	Neuroticism;
KIRP	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg24826892	chr11:71159390	DHCR7	-0.46	-5.13	-0.31	5.97e-7	Vitamin D levels;
KIRP	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs3120667	0.790	rs3829868	chr1:152382120	A/G	cg26876637	chr1:152193138	HRNR	0.54	5.27	0.32	2.96e-7	Eating disorders;
KIRP	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg16141378	chr3:129829833	LOC729375	0.53	7.03	0.41	1.98e-11	Retinal vascular caliber;
KIRP	cis	rs806321	0.548	rs1269268	chr13:50907290	T/A	cg10393508	chr13:50950265	NA	-0.46	-6.47	-0.38	5.39e-10	Multiple sclerosis;
KIRP	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg15848620	chr12:58087721	OS9	-0.51	-5.95	-0.35	8.94e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4849845	0.849	rs7588151	chr2:121020641	A/C	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.9	9.12	0.5	2.86e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg27205649	chr11:78285834	NARS2	-0.49	-5.39	-0.33	1.63e-7	Testicular germ cell tumor;
KIRP	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.66	7.17	0.42	8.85e-12	Initial pursuit acceleration;
KIRP	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.01	0.36	6.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg21475434	chr5:93447410	FAM172A	-0.44	-5.2	-0.31	4.21e-7	Diabetic retinopathy;
KIRP	trans	rs1106684	1.000	rs12534297	chr7:131464095	C/T	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg04369109	chr6:150039330	LATS1	-0.51	-6.35	-0.38	1.03e-9	Lung cancer;
KIRP	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg17691542	chr6:26056736	HIST1H1C	0.53	6.43	0.38	6.57e-10	Iron status biomarkers;
KIRP	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.81	-0.45	1.67e-13	Monocyte percentage of white cells;
KIRP	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg12384639	chr17:618140	VPS53	0.47	5.99	0.36	7.26e-9	Prostate cancer;
KIRP	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.64	0.39	2.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg00405596	chr8:11794950	NA	0.59	8.21	0.46	1.28e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg26531700	chr6:26746687	NA	0.52	7.24	0.42	5.76e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.641	rs34084719	chr7:107095227	A/G	cg02696742	chr7:106810147	HBP1	-0.67	-7.05	-0.41	1.78e-11	Coronary artery disease;
KIRP	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-5.82	-0.35	1.87e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg22951263	chr5:87985283	NA	-0.48	-6.79	-0.4	8.41e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24198953	chr19:18451444	PGPEP1	0.53	6.59	0.39	2.6200000000000003e-10	Parkinson's disease;
KIRP	cis	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.53	6.31	0.37	1.27e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.53	0.33	8.28e-8	Breast cancer;
KIRP	cis	rs6496667	0.779	rs7169787	chr15:91039929	C/T	cg10434728	chr15:90938212	IQGAP1	0.38	4.93	0.3	1.52e-6	Rheumatoid arthritis;
KIRP	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs12230513	0.938	rs4336160	chr12:55891377	C/T	cg19537932	chr12:55886519	OR6C68	-0.45	-4.94	-0.3	1.48e-6	Contrast sensitivity;
KIRP	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	1.0	14.35	0.68	2.35e-34	Cognitive function;
KIRP	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg13147721	chr7:65941812	NA	-0.93	-6.55	-0.39	3.4e-10	Diabetic kidney disease;
KIRP	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.36	-0.42	2.73e-12	Vitiligo;
KIRP	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	1.02	17.94	0.75	1.4300000000000001e-46	Diastolic blood pressure;
KIRP	cis	rs9309473	0.519	rs1083922	chr2:73704003	A/G	cg20560298	chr2:73613845	ALMS1	0.47	5.78	0.35	2.3e-8	Metabolite levels;
KIRP	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.82	-11.5	-0.59	9.21e-25	Eosinophil percentage of white cells;
KIRP	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.85e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg04727924	chr7:799746	HEATR2	-0.76	-8.55	-0.48	1.3e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg02775129	chr4:119771670	NA	-0.85	-5.0	-0.3	1.11e-6	Cannabis dependence symptom count;
KIRP	trans	rs17741873	0.722	rs10824045	chr10:75656543	A/G	cg04129911	chr4:79543134	NA	-0.39	-6.06	-0.36	4.97e-9	Paclitaxel disposition in epithelial ovarian cancer;
KIRP	cis	rs7221595	0.756	rs9900661	chr17:3962450	A/G	cg21851534	chr17:3907994	ZZEF1	0.58	6.09	0.36	4.42e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.85	13.34	0.65	6.77e-31	Height;
KIRP	cis	rs7737355	0.812	rs12514547	chr5:130973304	C/G	cg06307176	chr5:131281290	NA	0.41	4.9	0.3	1.76e-6	Life satisfaction;
KIRP	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.04	0.31	8.84e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.85	12.22	0.61	3.86e-27	Coronary artery disease;
KIRP	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg13180566	chr4:1052158	NA	-0.52	-5.24	-0.32	3.48e-7	Recombination rate (females);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02056921	chr1:901892	PLEKHN1	-0.51	-6.68	-0.39	1.61e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17935304	chr21:40555523	PSMG1	0.54	6.57	0.39	2.99e-10	Parkinson's disease;
KIRP	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg04034577	chr2:241836375	C2orf54	-0.4	-8.27	-0.47	8.33e-15	Urinary metabolites;
KIRP	cis	rs7027203	0.557	rs2263354	chr9:96511073	A/C	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.87e-10	DNA methylation (variation);
KIRP	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.99	-0.5	6.7e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg02725872	chr8:58115012	NA	-0.48	-5.25	-0.32	3.26e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25313289	chr16:2264884	PGP	-0.48	-6.16	-0.37	2.91e-9	Myopia;
KIRP	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg26513180	chr16:89883248	FANCA	0.61	5.56	0.33	7.13e-8	Skin colour saturation;
KIRP	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	9.75	0.53	3.26e-19	Cognitive test performance;
KIRP	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.91	-0.49	1.17e-16	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.18	0.31	4.58e-7	Breast cancer;
KIRP	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs79149102	0.649	rs1531163	chr15:75113083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.67	-5.32	-0.32	2.37e-7	Lung cancer;
KIRP	cis	rs1014246	0.848	rs758362	chr10:118457905	G/A	cg14919929	chr10:118506882	NA	0.69	9.42	0.51	3.5e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg06740227	chr12:86229804	RASSF9	0.4	5.02	0.3	1.02e-6	Major depressive disorder;
KIRP	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	0.83	10.29	0.55	6.74e-21	Prostate cancer;
KIRP	cis	rs17453880	0.895	rs4610448	chr5:152019865	A/T	cg12297329	chr5:152029980	NA	-0.72	-10.87	-0.57	9.78e-23	Subjective well-being;
KIRP	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.48	-6.51	-0.38	4.25e-10	Coronary artery disease;
KIRP	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.88	-13.2	-0.64	2.02e-30	Systemic lupus erythematosus;
KIRP	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.2	0.51	1.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg27165867	chr14:105738592	BRF1	-0.43	-5.24	-0.32	3.45e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.56	8.08	0.46	2.91e-14	Bone mineral density;
KIRP	cis	rs897080	0.515	rs2850290	chr2:44636055	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.6	0.34	5.71e-8	Height;
KIRP	cis	rs7215564	1.000	rs7215564	chr17:78737287	A/G	cg06153925	chr17:78755379	RPTOR	0.37	6.43	0.38	6.74e-10	Myopia (pathological);
KIRP	trans	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.81	-12.64	-0.63	1.43e-28	Breast cancer;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.1	-0.41	1.3e-11	Platelet count;
KIRP	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg07511668	chr11:68622177	NA	0.39	5.25	0.32	3.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.61	9.95	0.54	7.98e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg15147215	chr3:52552868	STAB1	-0.35	-6.11	-0.36	3.87e-9	Electroencephalogram traits;
KIRP	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	1.05	11.26	0.58	5.25e-24	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9381107	1.000	rs9349190	chr6:9462881	T/A	cg14735645	chr6:9486422	NA	-0.46	-5.91	-0.35	1.16e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9815354	1.000	rs9311288	chr3:41804581	C/G	cg03022575	chr3:42003672	ULK4	0.54	6.22	0.37	2.07e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.72	-7.48	-0.43	1.34e-12	Body mass index;
KIRP	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.96	12.43	0.62	7.38e-28	Cognitive function;
KIRP	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg18190219	chr22:46762943	CELSR1	-0.89	-7.14	-0.41	1.04e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.76	11.03	0.58	3.07e-23	Parkinson's disease;
KIRP	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.67	-11.3	-0.58	4.02e-24	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.95	-11.65	-0.6	2.85e-25	Bipolar disorder and schizophrenia;
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	cis	rs3736485	0.966	rs2414111	chr15:51901357	A/G	cg14296394	chr15:51910925	DMXL2	0.34	5.05	0.31	8.61e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg08392591	chr16:89556376	ANKRD11	0.48	5.98	0.36	7.84e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg19645103	chr12:69753606	YEATS4	0.48	4.87	0.3	1.98e-6	Response to diuretic therapy;
KIRP	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.41	-5.36	-0.32	1.96e-7	IgG glycosylation;
KIRP	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.69	7.23	0.42	6.12e-12	Uric acid levels;
KIRP	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14598338	chr9:96623480	NA	-0.68	-11.54	-0.59	6.74e-25	DNA methylation (variation);
KIRP	cis	rs526231	0.543	rs152134	chr5:102512447	C/G	cg23492399	chr5:102201601	PAM	-0.53	-5.91	-0.35	1.15e-8	Primary biliary cholangitis;
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	6.08	0.36	4.44e-9	Obesity-related traits;
KIRP	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg22800045	chr5:56110881	MAP3K1	0.73	7.84	0.45	1.38e-13	Initial pursuit acceleration;
KIRP	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-6.93	-0.4	3.65e-11	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18254147	chr5:131347582	ACSL6	0.46	6.42	0.38	7.04e-10	Parkinson's disease;
KIRP	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.74	9.75	0.53	3.41e-19	Cognitive function;
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg17441377	chr17:3906640	NA	0.54	8.19	0.46	1.39e-14	Type 2 diabetes;
KIRP	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.01	14.76	0.69	9.72e-36	Orofacial clefts;
KIRP	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-5.75	-0.34	2.59e-8	Testicular germ cell tumor;
KIRP	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-9.33	-0.51	6.56e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg00631329	chr6:26305371	NA	-0.67	-8.25	-0.47	9.41e-15	Educational attainment;
KIRP	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-6.2	-0.37	2.33e-9	Cognitive ability (multi-trait analysis);
KIRP	trans	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg00405596	chr8:11794950	NA	0.46	6.31	0.37	1.29e-9	Joint mobility (Beighton score);
KIRP	cis	rs112591243	0.685	rs73379602	chr21:48027317	G/A	cg10657630	chr21:48055338	PRMT2	0.57	5.13	0.31	5.83e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18932078	chr1:2524107	MMEL1	-0.47	-6.5	-0.38	4.51e-10	Ulcerative colitis;
KIRP	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.81	-0.45	1.63e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg15839431	chr19:19639596	YJEFN3	0.48	5.21	0.32	3.93e-7	Bipolar disorder;
KIRP	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg02993010	chr8:124780839	FAM91A1	-0.58	-6.08	-0.36	4.58e-9	Pancreatic cancer;
KIRP	cis	rs1978968	1.000	rs1110662	chr22:18444908	G/A	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg24488311	chr11:68621650	NA	0.43	5.41	0.33	1.48e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg20243544	chr17:37824526	PNMT	0.43	5.94	0.35	9.87e-9	Asthma;
KIRP	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg04896959	chr15:78267971	NA	-0.68	-6.35	-0.38	1.02e-9	Coronary artery disease or large artery stroke;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-9.21	-0.51	1.47e-17	Platelet count;
KIRP	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	6.7	0.39	1.45e-10	Breast cancer;
KIRP	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg01631408	chr1:248437212	OR2T33	-0.65	-8.24	-0.47	1.01e-14	Common traits (Other);
KIRP	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs6893300	0.961	rs62406223	chr5:179218361	C/T	cg14593053	chr5:179126677	CANX	-0.55	-6.11	-0.36	3.91e-9	Resting heart rate;
KIRP	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.37	0.43	2.54e-12	Bladder cancer;
KIRP	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg02527881	chr3:46936655	PTH1R	-0.37	-5.2	-0.31	4.25e-7	Colorectal cancer;
KIRP	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg20701182	chr2:24300061	SF3B14	0.53	5.22	0.32	3.72e-7	Lymphocyte counts;
KIRP	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg17554472	chr22:41940697	POLR3H	0.47	5.35	0.32	2.04e-7	Vitiligo;
KIRP	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg27205649	chr11:78285834	NARS2	0.61	7.2	0.42	7.41e-12	Alzheimer's disease (survival time);
KIRP	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.58	0.48	1.09e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7011049	0.778	rs6981481	chr8:53866409	T/C	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.26	-21.67	-0.81	5.75e-59	Breast cancer;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.57	-5.72	-0.34	3.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9815354	0.680	rs73073250	chr3:42016559	G/T	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg02297831	chr4:17616191	MED28	0.57	6.9	0.4	4.38e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7147624	0.572	rs72714446	chr14:65933144	G/A	cg03016385	chr14:66212404	NA	0.89	5.3	0.32	2.6e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1635	0.655	rs60698636	chr6:28316045	A/G	cg15743358	chr6:28303923	ZNF323	-0.75	-5.15	-0.31	5.22e-7	Schizophrenia;
KIRP	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.46	5.16	0.31	5.03e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg00262122	chr8:11665843	FDFT1	0.43	5.41	0.33	1.52e-7	Myopia (pathological);
KIRP	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-7.61	-0.44	5.76e-13	Personality dimensions;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg07648498	chr16:89883185	FANCA	0.41	5.34	0.32	2.09e-7	Vitiligo;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07213065	chr2:196642673	DNAH7	-0.42	-6.93	-0.4	3.62e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg04374321	chr14:90722782	PSMC1	-0.91	-13.49	-0.65	1.98e-31	Mortality in heart failure;
KIRP	cis	rs61884328	0.852	rs60335739	chr11:47148728	C/T	cg23433285	chr11:47201945	PACSIN3	0.61	5.0	0.3	1.11e-6	Total body bone mineral density (age over 60);
KIRP	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	0.78	8.44	0.47	2.83e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	trans	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.07	-0.5	4.01e-17	Blood metabolite levels;
KIRP	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg18944383	chr4:111397179	ENPEP	-0.44	-7.06	-0.41	1.66e-11	Coronary artery disease;
KIRP	trans	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg15469184	chr8:337539	NA	0.63	7.15	0.41	9.78e-12	Obesity-related traits;
KIRP	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg04362960	chr10:104952993	NT5C2	0.43	5.02	0.31	9.73e-7	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.12	-0.46	2.26e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	6.42	0.38	6.91e-10	Cognitive test performance;
KIRP	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg17724175	chr1:150552817	MCL1	0.36	5.98	0.36	7.95e-9	Melanoma;
KIRP	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.26	6.95	0.4	3.35e-11	Breast cancer;Mosquito bite size;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.43	4.9	0.3	1.72e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10128251	0.650	rs4469789	chr10:5712366	A/G	cg11519256	chr10:5708881	ASB13	0.45	5.92	0.35	1.08e-8	Childhood ear infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17397135	chr2:28789816	PLB1	0.47	6.45	0.38	5.8e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.44	-5.78	-0.35	2.31e-8	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.68	-8.54	-0.48	1.45e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.47	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	13.1	0.64	4.12e-30	Alzheimer's disease;
KIRP	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.61	7.73	0.44	2.73e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2334880	0.587	rs8058188	chr16:71675136	G/A	cg00732059	chr16:71740210	PHLPP2	0.39	5.24	0.32	3.51e-7	Malaria;
KIRP	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs7187994	0.848	rs60566983	chr16:84774799	A/G	cg07647771	chr16:84786436	USP10	-0.46	-5.75	-0.34	2.69e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.05	-21.67	-0.81	5.83e-59	Myeloid white cell count;
KIRP	cis	rs7119038	0.779	rs73005502	chr11:118697906	A/G	cg19308663	chr11:118741387	NA	0.6	9.33	0.51	6.46e-18	Sjögren's syndrome;
KIRP	cis	rs7267005	0.661	rs112742250	chr20:34410597	A/G	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-17.6	-0.75	2.02e-45	Schizophrenia;
KIRP	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg08501292	chr6:25962987	TRIM38	0.99	5.91	0.35	1.16e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg08975724	chr8:8085496	FLJ10661	0.69	9.25	0.51	1.12e-17	Mood instability;
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.57	5.09	0.31	7.08e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.61	5.76	0.34	2.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg10047753	chr17:41438598	NA	0.92	13.82	0.66	1.55e-32	Menopause (age at onset);
KIRP	cis	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.65	-7.1	-0.41	1.35e-11	Asthma;
KIRP	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg04362960	chr10:104952993	NT5C2	0.83	6.14	0.36	3.35e-9	Arsenic metabolism;
KIRP	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.72	8.44	0.47	2.83e-15	High light scatter reticulocyte count;
KIRP	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg24826892	chr11:71159390	DHCR7	0.44	5.2	0.31	4.27e-7	Vitamin D levels;
KIRP	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs6142618	0.533	rs242598	chr20:30664189	T/C	cg09796376	chr20:30640595	HCK	0.4	5.57	0.33	6.61e-8	Inflammatory bowel disease;
KIRP	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.19	0.51	1.69e-17	Bipolar disorder;
KIRP	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03517284	chr6:25882590	NA	0.39	5.2	0.31	4.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2820315	0.964	rs2820311	chr1:201841476	A/G	cg11586189	chr1:201857591	SHISA4	-0.39	-5.46	-0.33	1.17e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg27411982	chr8:10470053	RP1L1	0.44	5.23	0.32	3.55e-7	Neuroticism;
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02359409	chr6:42947317	PEX6	-0.38	-4.98	-0.3	1.22e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg12334488	chr2:20871173	GDF7	-0.4	-5.1	-0.31	6.7e-7	Abdominal aortic aneurysm;
KIRP	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs6496044	0.568	rs3743321	chr15:86064968	A/G	cg10818794	chr15:86012489	AKAP13	-0.5	-6.95	-0.41	3.17e-11	Interstitial lung disease;
KIRP	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.87	13.38	0.65	4.83e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs6662572	0.737	rs7525281	chr1:46267923	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.4e-8	Blood protein levels;
KIRP	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg18198730	chr1:247681584	NA	-0.65	-7.05	-0.41	1.83e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs78487399	0.808	rs6544666	chr2:43732234	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.06	-0.31	8.28e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.65	8.7	0.49	4.73e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-6.98	-0.41	2.75e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg27411982	chr8:10470053	RP1L1	-0.48	-6.24	-0.37	1.86e-9	Mood instability;
KIRP	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs734999	0.967	rs10797434	chr1:2511280	C/T	cg18854424	chr1:2615690	NA	0.38	5.89	0.35	1.25e-8	Ulcerative colitis;
KIRP	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19536664	chr17:6899085	ALOX12	-0.45	-6.75	-0.4	1.08e-10	Tonsillectomy;
KIRP	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg07395648	chr5:131743802	NA	-0.59	-8.44	-0.47	2.67e-15	Blood metabolite levels;
KIRP	cis	rs4805272	0.962	rs55811684	chr19:29319749	G/C	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11021305	chr6:36410485	PXT1;KCTD20	0.45	6.29	0.37	1.47e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.89	9.01	0.5	5.93e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.57	-7.75	-0.44	2.41e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14598338	chr9:96623480	NA	0.65	10.02	0.54	4.84e-20	DNA methylation (variation);
KIRP	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	13.8	0.66	1.86e-32	Platelet count;
KIRP	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg02574844	chr11:5959923	NA	-0.57	-5.9	-0.35	1.18e-8	DNA methylation (variation);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg25722142	chr6:139695762	CITED2	0.51	6.02	0.36	6.29e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg07460842	chr6:66804631	NA	-0.49	-6.0	-0.36	6.94e-9	Blood trace element (Cu levels);
KIRP	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg09526685	chr4:187126073	CYP4V2	0.94	7.92	0.45	8.16e-14	Blood protein levels;
KIRP	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.84	-11.39	-0.59	2.11e-24	Body mass index;
KIRP	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	5.07	0.31	7.69e-7	Menarche (age at onset);
KIRP	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg16989719	chr2:238392110	NA	-0.64	-6.31	-0.37	1.29e-9	Prostate cancer;
KIRP	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.67	-9.2	-0.51	1.64e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg08773314	chr2:239334832	ASB1	0.43	8.81	0.49	2.23e-16	Multiple system atrophy;
KIRP	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg01998806	chr11:64116279	CCDC88B	-0.4	-6.09	-0.36	4.26e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg07169764	chr2:136633963	MCM6	-0.53	-6.1	-0.36	4.08e-9	Mosquito bite size;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.59	9.25	0.51	1.1e-17	Mean corpuscular volume;
KIRP	cis	rs12208915	0.848	rs2174740	chr6:79536565	A/G	cg18132916	chr6:79620363	NA	-0.57	-5.38	-0.32	1.74e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg21775007	chr8:11205619	TDH	-0.39	-5.23	-0.32	3.59e-7	Monocyte count;
KIRP	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.42	-5.18	-0.31	4.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25517755	chr10:38738941	LOC399744	0.52	7.22	0.42	6.58e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4805272	0.962	rs8110833	chr19:29322794	A/G	cg15000279	chr19:29285009	NA	-0.4	-6.04	-0.36	5.53e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	4.89	0.3	1.79e-6	Eosinophil percentage of white cells;
KIRP	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs6725041	0.690	rs7581138	chr2:213101989	C/T	cg16329650	chr2:213403929	ERBB4	-0.36	-5.03	-0.31	9.28e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs12210905	1.000	rs12209429	chr6:27054867	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08989290	chr16:615782	NHLRC4	0.39	5.74	0.34	2.74e-8	Height;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg22434424	chr13:108868130	LIG4	0.52	6.66	0.39	1.81e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.71	10.44	0.55	2.39e-21	Multiple sclerosis;
KIRP	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.58	8.58	0.48	1.08e-15	Fat distribution (HIV);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15844609	chr19:38806846	YIF1B	-0.47	-6.2	-0.37	2.42e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6772849	0.930	rs13434160	chr3:128374770	T/C	cg08795948	chr3:128337044	NA	0.49	6.21	0.37	2.22e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg05775895	chr3:12838266	CAND2	-0.36	-6.16	-0.37	2.95e-9	QRS complex (12-leadsum);
KIRP	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.52	0.33	8.59e-8	Educational attainment;
KIRP	cis	rs12282928	1.000	rs1503183	chr11:48259296	C/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.21	-0.37	2.18e-9	Migraine - clinic-based;
KIRP	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-5.73	-0.34	2.97e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	8.92	0.49	1.08e-16	Resting heart rate;
KIRP	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.41	5.01	0.3	1.02e-6	Systemic lupus erythematosus;
KIRP	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.73	-10.5	-0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19524238	chr7:2802976	GNA12	-0.37	-5.06	-0.31	8.3e-7	Height;
KIRP	cis	rs412050	0.547	rs61763401	chr22:22139847	C/T	cg17089214	chr22:22089827	YPEL1	0.65	5.88	0.35	1.34e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs4006360	0.646	rs8080164	chr17:39292845	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.53	-8.15	-0.46	1.8e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.94	-0.54	8.61e-20	Response to antipsychotic treatment;
KIRP	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.17	-0.7	3.79e-37	Alzheimer's disease;
KIRP	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.22e-9	Breast cancer;
KIRP	cis	rs7113850	0.541	rs76671714	chr11:24231278	C/G	ch.11.24196551F	chr11:24239977	NA	0.93	7.68	0.44	3.79e-13	Bone fracture in osteoporosis;
KIRP	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.54	7.4	0.43	2.18e-12	IgG glycosylation;
KIRP	cis	rs2273669	0.667	rs74582170	chr6:109312689	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.27	-0.37	1.64e-9	Prostate cancer;
KIRP	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg00318621	chr2:106887213	NA	-0.47	-7.16	-0.42	9.44e-12	Facial morphology (factor 23);
KIRP	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	-0.46	-5.26	-0.32	3.09e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs921874	0.586	rs2513218	chr11:86754210	T/C	cg22937172	chr2:240168862	HDAC4	0.5	6.47	0.38	5.19e-10	Total body bone mineral density;
KIRP	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.43	-5.87	-0.35	1.37e-8	Red blood cell count;
KIRP	cis	rs9398803	0.698	rs1101563	chr6:127049198	T/C	cg19875578	chr6:126661172	C6orf173	-0.41	-5.34	-0.32	2.11e-7	Male-pattern baldness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04594618	chr12:8182145	NA	-0.41	-6.12	-0.36	3.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.63	5.31	0.32	2.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg00310523	chr12:86230176	RASSF9	-0.43	-6.63	-0.39	2.15e-10	Major depressive disorder;
KIRP	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.1	0.61	9.4e-27	Bladder cancer;
KIRP	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg26373071	chr5:1325741	CLPTM1L	0.56	7.41	0.43	2.02e-12	Lung cancer;
KIRP	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.92	10.42	0.55	2.77e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.75	-9.81	-0.53	2.25e-19	Dental caries;
KIRP	cis	rs7845219	0.544	rs4735331	chr8:95917958	C/T	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.25	-0.37	1.77e-9	Type 2 diabetes;
KIRP	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.89	11.78	0.6	1.06e-25	Orofacial clefts;
KIRP	cis	rs997295	1.000	rs35395156	chr15:67962763	A/G	cg14210607	chr15:68128175	NA	-0.3	-4.91	-0.3	1.66e-6	Motion sickness;
KIRP	cis	rs4073416	0.542	rs4902399	chr14:65956897	C/T	cg03016385	chr14:66212404	NA	0.51	6.2	0.37	2.35e-9	N-glycan levels;
KIRP	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.49	5.75	0.34	2.65e-8	Mean platelet volume;
KIRP	cis	rs7084402	0.967	rs1658429	chr10:60330422	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg17507749	chr15:85114479	UBE2QP1	0.81	8.71	0.49	4.51e-16	Schizophrenia;
KIRP	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg13206674	chr6:150067644	NUP43	-0.53	-6.48	-0.38	4.9e-10	Lung cancer;
KIRP	cis	rs12693043	0.525	rs1010028	chr2:175418960	C/T	cg11778734	chr2:175439522	WIPF1	-0.51	-6.73	-0.39	1.15e-10	Urate levels (BMI interaction);
KIRP	cis	rs4523957	0.928	rs216176	chr17:2168509	G/C	cg16513277	chr17:2031491	SMG6	0.58	8.04	0.46	3.84e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg04672837	chr16:48644449	N4BP1	0.5	6.77	0.4	9.65e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg17425144	chr1:10567563	PEX14	-0.3	-5.13	-0.31	5.75e-7	Hepatocellular carcinoma;
KIRP	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.75	-11.0	-0.57	3.62e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.15	9.34	0.51	5.98e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg08501292	chr6:25962987	TRIM38	0.79	5.44	0.33	1.31e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2224391	0.628	rs2753243	chr6:5256261	C/T	cg13962347	chr6:5174647	LYRM4	-0.68	-9.61	-0.52	8.8e-19	Height;
KIRP	cis	rs4356975	0.522	rs4642304	chr4:69951550	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.34	-4.92	-0.3	1.58e-6	Monocyte count;
KIRP	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg00012203	chr2:219082015	ARPC2	-0.42	-5.14	-0.31	5.62e-7	Ulcerative colitis;
KIRP	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.91	7.67	0.44	3.89e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.86	0.53	1.5e-19	Multiple sclerosis;
KIRP	cis	rs4786125	0.665	rs7201025	chr16:6920592	C/T	cg03623568	chr16:6915990	A2BP1	-0.44	-5.31	-0.32	2.48e-7	Heart rate variability traits (SDNN);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24313640	chr11:57425161	CLP1	-0.47	-6.02	-0.36	6.26e-9	Survival in pancreatic cancer;
KIRP	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.59	-6.35	-0.38	1.01e-9	Corneal astigmatism;
KIRP	cis	rs7246657	0.722	rs10412510	chr19:38075944	A/G	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg18305652	chr10:134549665	INPP5A	0.43	6.81	0.4	7.4e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10802521	chr3:52805072	NEK4	-0.36	-4.93	-0.3	1.53e-6	Bipolar disorder;
KIRP	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.75	12.01	0.61	1.93e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1461503	0.900	rs7110039	chr11:122834001	C/T	cg27398637	chr11:122830231	C11orf63	0.7	9.77	0.53	2.84e-19	Menarche (age at onset);
KIRP	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.54	7.12	0.41	1.15e-11	Colorectal cancer;
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	5.97	0.36	8.37e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.95	-12.59	-0.63	2.13e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9473924	0.505	rs9473949	chr6:50909659	T/A	cg14470998	chr6:50812995	TFAP2B	0.96	8.76	0.49	3.2e-16	Body mass index;
KIRP	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	cg21523751	chr1:182988639	NA	0.45	6.97	0.41	2.86e-11	Colorectal cancer;
KIRP	cis	rs7078219	0.714	rs11190139	chr10:101288099	C/G	cg07044859	chr10:101282883	NA	-0.34	-5.02	-0.3	9.83e-7	Dental caries;
KIRP	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg09137382	chr11:130731461	NA	0.59	8.54	0.48	1.45e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg23682824	chr7:23144976	KLHL7	0.55	6.68	0.39	1.59e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.47	5.24	0.32	3.42e-7	Systemic lupus erythematosus;
KIRP	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08439880	chr3:133502540	NA	-0.51	-6.31	-0.37	1.26e-9	Iron status biomarkers;
KIRP	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.78	7.24	0.42	5.81e-12	Mean platelet volume;
KIRP	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.43	-0.33	1.32e-7	P wave terminal force;
KIRP	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.98	9.31	0.51	7.46e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.74	-10.37	-0.55	3.75e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs860295	0.702	rs5005770	chr1:155345043	C/T	cg02153340	chr1:155202674	NA	0.55	7.47	0.43	1.43e-12	Body mass index;
KIRP	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg23920097	chr1:209922102	NA	-0.4	-5.36	-0.32	1.92e-7	Red blood cell count;
KIRP	cis	rs1838105	0.780	rs1623402	chr17:44994280	C/T	cg16759221	chr17:45003025	GOSR2	-0.39	-5.85	-0.35	1.54e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-7.15	-0.41	9.9e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.59	-6.15	-0.37	3.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.83	11.66	0.6	2.65e-25	Mean platelet volume;
KIRP	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	trans	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg10756647	chr7:56101905	PSPH	1.03	7.69	0.44	3.48e-13	Diabetic kidney disease;
KIRP	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg19567339	chr10:100142640	NA	0.44	4.95	0.3	1.36e-6	Metabolite levels;
KIRP	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.9	13.28	0.65	1.01e-30	Triglycerides;
KIRP	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg13072238	chr3:49761600	GMPPB	-0.56	-5.27	-0.32	2.95e-7	Menarche (age at onset);
KIRP	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg18110333	chr6:292329	DUSP22	-0.52	-6.22	-0.37	2.12e-9	Menopause (age at onset);
KIRP	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.41	5.77	0.35	2.37e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	0.75	7.56	0.43	8.2e-13	Bipolar disorder;
KIRP	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg12591125	chr7:1885375	MAD1L1	0.65	6.11	0.36	3.78e-9	Bipolar disorder;
KIRP	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2273669	0.588	rs6568555	chr6:109331777	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg12935359	chr14:103987150	CKB	-0.55	-6.9	-0.4	4.29e-11	Body mass index;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs1760803	0.701	rs6427509	chr1:154219718	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.58	-0.33	6.46e-8	Nicotine dependence;
KIRP	cis	rs4523957	0.890	rs12941836	chr17:2194874	C/G	cg16513277	chr17:2031491	SMG6	0.59	8.22	0.46	1.14e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7264396	1.000	rs224440	chr20:34159447	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-5.21	-0.32	3.94e-7	Total cholesterol levels;
KIRP	cis	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.45e-9	HDL cholesterol;
KIRP	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.65	5.02	0.3	1e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2591576	0.602	rs1120354	chr5:165354069	C/G	cg13976338	chr5:165423657	NA	-0.6	-7.98	-0.45	5.69e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg05347473	chr6:146136440	FBXO30	0.64	9.34	0.51	5.97e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg11584989	chr19:19387371	SF4	0.41	5.06	0.31	8.08e-7	Tonsillectomy;
KIRP	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.51	1.4e-17	Morning vs. evening chronotype;
KIRP	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs7180079	0.620	rs589690	chr15:64907406	C/T	cg15337035	chr15:64978493	NA	-0.47	-5.19	-0.31	4.49e-7	Monocyte count;
KIRP	cis	rs4789452	0.934	rs3987888	chr17:75370274	T/C	cg12985929	chr17:75370611	SEPT9	-0.39	-5.57	-0.33	6.6e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6752107	0.503	rs12997325	chr2:234237387	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	5.85	0.35	1.53e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10242455	0.702	rs17161726	chr7:99008395	C/G	cg18809830	chr7:99032528	PTCD1	-0.76	-4.99	-0.3	1.14e-6	Blood metabolite levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22110492	chr9:136283026	ADAMTS13;REXO4	0.43	6.82	0.4	6.9e-11	Cancer;
KIRP	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.81	8.61	0.48	9.11e-16	Phospholipid levels (plasma);
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	17.02	0.74	1.92e-43	Platelet count;
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg05941025	chr16:89927596	SPIRE2	-0.38	-6.02	-0.36	6.15e-9	Vitiligo;
KIRP	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg05717871	chr11:638507	DRD4	-0.39	-5.31	-0.32	2.45e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg12560992	chr17:57184187	TRIM37	0.55	5.1	0.31	6.92e-7	Cognitive test performance;
KIRP	cis	rs28834970	0.925	rs2322599	chr8:27211910	G/A	cg21186296	chr8:27182909	PTK2B	-0.44	-5.54	-0.33	7.75e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.44	7.25	0.42	5.41e-12	Testicular germ cell tumor;
KIRP	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-6.93	-0.4	3.65e-11	Tonsillectomy;
KIRP	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.71	-6.55	-0.39	3.32e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg16316519	chr12:8542756	LOC389634	-0.49	-7.02	-0.41	2.17e-11	Blood metabolite levels;
KIRP	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.71	9.97	0.54	6.95e-20	Caffeine consumption;
KIRP	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	20.54	0.79	2.91e-55	Colorectal cancer;
KIRP	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.55	7.41	0.43	1.97e-12	HDL cholesterol;
KIRP	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.03e-9	Depression;
KIRP	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg00579200	chr11:133705235	NA	-0.41	-5.51	-0.33	9.05e-8	Childhood ear infection;
KIRP	cis	rs9462846	0.652	rs77807794	chr6:42906242	C/T	cg02353165	chr6:42928485	GNMT	0.64	7.21	0.42	6.91e-12	Blood protein levels;
KIRP	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12923728	chr3:195709715	SDHAP1	-0.79	-8.94	-0.5	9.65e-17	Pancreatic cancer;
KIRP	cis	rs5753037	0.813	rs9614100	chr22:30288339	A/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.08	-0.31	7.49e-7	Type 1 diabetes;
KIRP	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.8	0.45	1.76e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.44	0.55	2.28e-21	Lung cancer in ever smokers;
KIRP	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.28	-0.37	1.51e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg06289844	chr6:126071538	HEY2	0.44	6.64	0.39	1.98e-10	Brugada syndrome;
KIRP	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.74	0.39	1.12e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12580194	0.593	rs58254871	chr12:55750281	G/A	cg11794356	chr12:55725991	OR6C3	-0.52	-6.95	-0.41	3.19e-11	Cancer;
KIRP	cis	rs7572644	0.662	rs6706209	chr2:28101938	C/T	cg27432699	chr2:27873401	GPN1	-0.41	-4.87	-0.3	2.04e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs2625529	0.878	rs16956302	chr15:72136243	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-6.28	-0.37	1.51e-9	Red blood cell count;
KIRP	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.39	-5.48	-0.33	1.06e-7	Mean corpuscular volume;
KIRP	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg00405596	chr8:11794950	NA	0.38	4.96	0.3	1.31e-6	Retinal vascular caliber;
KIRP	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg09163369	chr1:210001066	C1orf107	0.44	5.64	0.34	4.61e-8	Monobrow;
KIRP	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg08461772	chr7:95026248	PON3	0.4	5.76	0.34	2.51e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.91	-12.52	-0.62	3.76e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.9	14.26	0.67	4.82e-34	IgG glycosylation;
KIRP	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.96	13.36	0.65	5.71e-31	Cognitive function;
KIRP	cis	rs33912345	0.750	rs1254275	chr14:60845983	A/C	cg27398547	chr14:60952738	C14orf39	-0.4	-5.33	-0.32	2.21e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs7582720	0.832	rs116426890	chr2:204196618	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.04	8.2	0.46	1.36e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg15181151	chr6:150070149	PCMT1	0.31	5.21	0.32	4.07e-7	Lung cancer;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-1.05	-22.68	-0.82	3.14e-62	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg26043149	chr18:55253948	FECH	-0.52	-6.45	-0.38	6.04e-10	Bone mineral density;
KIRP	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.6	-6.8	-0.4	7.95e-11	Breast cancer;
KIRP	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg03235661	chr20:60525775	NA	-0.4	-6.23	-0.37	1.99e-9	Body mass index;
KIRP	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg03060546	chr3:49711283	APEH	-0.65	-5.9	-0.35	1.22e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.76e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.96	8.08	0.46	2.93e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg20003494	chr4:90757398	SNCA	-0.37	-4.9	-0.3	1.75e-6	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06105935	chr7:88265165	NA	-0.4	-6.43	-0.38	6.58e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.78	7.95	0.45	6.82e-14	Gut microbiome composition (summer);
KIRP	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-1.01	-11.28	-0.58	4.71e-24	Educational attainment;
KIRP	cis	rs12615966	0.929	rs9941698	chr2:105384717	G/A	cg16465502	chr2:105461796	NA	0.55	5.38	0.32	1.77e-7	Pancreatic cancer;
KIRP	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-9.12	-0.5	2.74e-17	Mood instability;
KIRP	cis	rs6142102	0.961	rs2377957	chr20:32554473	A/G	cg08999081	chr20:33150536	PIGU	0.54	6.84	0.4	6.15e-11	Skin pigmentation;
KIRP	cis	rs754423	0.515	rs2144983	chr14:52548843	C/T	cg10149976	chr14:52535953	NID2	-0.36	-5.16	-0.31	4.98e-7	Craniofacial microsomia;
KIRP	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg16309518	chr5:176445507	NA	-0.85	-13.11	-0.64	3.85e-30	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.51	7.0	0.41	2.41e-11	Glioblastoma;Glioma;
KIRP	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg05315796	chr3:52349193	DNAH1	0.5	7.13	0.41	1.14e-11	Bipolar disorder;
KIRP	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg24315340	chr6:146058215	EPM2A	-0.46	-5.96	-0.36	8.71e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.52	6.54	0.39	3.43e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg02187348	chr16:89574699	SPG7	0.44	5.25	0.32	3.31e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs494562	0.892	rs9294335	chr6:86126680	C/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg11859384	chr17:80120422	CCDC57	0.45	5.71	0.34	3.21e-8	Life satisfaction;
KIRP	cis	rs4944092	0.855	rs596339	chr11:75916507	T/C	cg04588336	chr11:75916460	WNT11	-0.42	-6.36	-0.38	9.56e-10	PR interval;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg09263875	chr16:632152	PIGQ	0.75	12.62	0.63	1.68e-28	Height;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11860616	chr5:158712539	UBLCP1	0.41	6.09	0.36	4.33e-9	Migraine with aura;
KIRP	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.41	4.92	0.3	1.61e-6	Menopause (age at onset);
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg14221460	chr8:27183342	PTK2B	-0.54	-6.92	-0.4	3.95e-11	Alzheimer's disease (late onset);
KIRP	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg17788227	chr17:7347145	FGF11;CHRNB1	0.49	5.08	0.31	7.45e-7	Androgen levels;
KIRP	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.18	-0.31	4.69e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17507749	chr15:85114479	UBE2QP1	0.72	8.03	0.46	3.98e-14	Schizophrenia;
KIRP	cis	rs2294693	0.945	rs9394755	chr6:41006680	C/T	cg14769373	chr6:40998127	UNC5CL	0.52	5.64	0.34	4.68e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg15147215	chr3:52552868	STAB1	-0.27	-4.89	-0.3	1.84e-6	Bipolar disorder;
KIRP	cis	rs986417	1.000	rs1950319	chr14:61048844	T/C	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg02795151	chr17:7402630	POLR2A	0.83	7.76	0.44	2.3e-13	Androgen levels;
KIRP	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg21643547	chr1:205240462	TMCC2	-0.72	-10.96	-0.57	5.23e-23	Red blood cell count;
KIRP	trans	rs28595532	0.623	rs11932674	chr4:119306807	A/C	cg26518628	chr1:97050305	NA	-0.82	-8.84	-0.49	1.88e-16	Cannabis dependence symptom count;
KIRP	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.01	0.3	1.06e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.48	-5.49	-0.33	1e-7	Aortic root size;
KIRP	cis	rs1413885	0.516	rs6588138	chr1:65838366	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	6.0	0.36	6.85e-9	Anticoagulant levels;
KIRP	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.58	7.43	0.43	1.84e-12	Aortic root size;
KIRP	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.41	-5.45	-0.33	1.24e-7	Tuberculosis;
KIRP	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.38	5.43	0.33	1.37e-7	Electrocardiographic conduction measures;
KIRP	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.75	-0.34	2.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs986417	1.000	rs10130255	chr14:60944435	C/T	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg19645103	chr12:69753606	YEATS4	-0.48	-5.0	-0.3	1.07e-6	Response to diuretic therapy;
KIRP	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24549020	chr5:56110836	MAP3K1	0.51	5.25	0.32	3.28e-7	Initial pursuit acceleration;
KIRP	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg01378222	chr16:28622494	SULT1A1	-0.66	-6.08	-0.36	4.52e-9	Platelet distribution width;
KIRP	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.45	-0.38	5.8e-10	Bladder cancer;
KIRP	cis	rs754423	0.515	rs12433236	chr14:52544615	G/A	cg05884192	chr14:52515736	NID2	0.47	5.2	0.31	4.29e-7	Craniofacial microsomia;
KIRP	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.99	10.28	0.55	7.37e-21	Eosinophilic esophagitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01696193	chr6:56819912	BEND6;DST	0.5	6.28	0.37	1.51e-9	Parkinson's disease;
KIRP	cis	rs6568686	0.786	rs6927920	chr6:111820382	A/T	cg15721981	chr6:111408429	SLC16A10	-0.69	-5.96	-0.36	8.63e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs9948	0.786	rs6756482	chr2:97458561	A/G	cg01990225	chr2:97406019	LMAN2L	-0.8	-6.83	-0.4	6.57e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg06815112	chr8:27182871	PTK2B	-0.5	-6.36	-0.38	9.77e-10	Neuroticism;
KIRP	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00585698	chr12:123750864	CDK2AP1	0.46	5.63	0.34	4.83e-8	Neutrophil percentage of white cells;
KIRP	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.17	-0.31	4.83e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg12598211	chr12:123634384	NA	-0.43	-5.17	-0.31	4.94e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg10189774	chr4:17578691	LAP3	0.51	6.23	0.37	2.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.03	-0.31	9.27e-7	Blood pressure;
KIRP	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg01721255	chr8:58191610	C8orf71	0.5	4.87	0.3	1.96e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.36	-5.92	-0.35	1.08e-8	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14263942	chr4:76555772	CDKL2	0.55	6.92	0.4	3.85e-11	Parkinson's disease;
KIRP	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.88	-14.36	-0.68	2.28e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6681460	0.932	rs602513	chr1:67177270	G/A	cg02459107	chr1:67143332	SGIP1	0.43	6.13	0.36	3.48e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg01620082	chr3:125678407	NA	-1.16	-7.36	-0.42	2.82e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17528648	chr5:38846100	OSMR	0.54	7.46	0.43	1.44e-12	Parkinson's disease;
KIRP	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	5.19	0.31	4.48e-7	Schizophrenia;
KIRP	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.67	9.39	0.51	4.26e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1864400	0.641	rs61845681	chr10:43733180	T/C	cg15436174	chr10:43711423	RASGEF1A	0.84	7.99	0.45	5.22e-14	Hirschsprung disease;
KIRP	cis	rs2154427	0.872	rs10446070	chr21:34010624	C/T	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.62	-5.2	-0.31	4.16e-7	Bilirubin levels;
KIRP	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.64	9.19	0.51	1.69e-17	Bladder cancer;
KIRP	cis	rs34779708	0.931	rs17583009	chr10:35320915	T/C	cg03585969	chr10:35415529	CREM	0.8	9.71	0.53	4.34e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.03	-8.7	-0.48	4.93e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.72	5.72	0.34	3.02e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10982256	0.870	rs10982248	chr9:117250903	G/A	cg13636371	chr9:117264095	DFNB31	0.6	8.55	0.48	1.29e-15	Bipolar disorder;
KIRP	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg03651054	chr13:50194643	NA	0.59	8.31	0.47	6.58e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg08885076	chr2:99613938	TSGA10	0.53	9.26	0.51	1.06e-17	Chronic sinus infection;
KIRP	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.38	-0.32	1.72e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg12826209	chr6:26865740	GUSBL1	0.8	5.49	0.33	9.81e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg14952266	chr13:112191215	NA	-0.45	-6.72	-0.39	1.25e-10	Hepatitis;
KIRP	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.63	6.85	0.4	5.91e-11	Smoking initiation;
KIRP	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg06637938	chr14:75390232	RPS6KL1	0.37	5.24	0.32	3.41e-7	Height;
KIRP	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.5	-5.03	-0.31	9.57e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4950322	0.570	rs4950404	chr1:146791552	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27333693	chr10:23002092	PIP4K2A	0.53	6.44	0.38	6.36e-10	Smoking initiation;
KIRP	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.92	-14.72	-0.68	1.38e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.79	-12.58	-0.63	2.4e-28	Paraoxonase activity;
KIRP	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.66	-7.93	-0.45	7.62e-14	Eosinophil percentage of white cells;
KIRP	cis	rs17767294	0.708	rs6908688	chr6:27886051	A/G	cg08851530	chr6:28072375	NA	0.83	4.85	0.3	2.14e-6	Parkinson's disease;
KIRP	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg05347473	chr6:146136440	FBXO30	0.5	7.15	0.41	1.02e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg24644049	chr4:85504048	CDS1	0.76	6.47	0.38	5.37e-10	Skin colour saturation;
KIRP	cis	rs7224685	0.569	rs35578550	chr17:3996470	A/G	cg05562828	chr17:3906858	NA	0.55	5.69	0.34	3.68e-8	Type 2 diabetes;
KIRP	trans	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.75	0.44	2.35e-13	Breast cancer;
KIRP	cis	rs34779708	0.733	rs4298846	chr10:35547380	A/G	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.68	9.74	0.53	3.63e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.52	-0.65	1.61e-31	Height;
KIRP	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Body mass index;
KIRP	cis	rs7534824	0.543	rs17408457	chr1:101385693	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	6.04	0.36	5.66e-9	Refractive astigmatism;
KIRP	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.73	-6.07	-0.36	4.88e-9	Major depressive disorder;
KIRP	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.52	6.42	0.38	6.82e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.96	-11.13	-0.58	1.44e-23	Alzheimer's disease;
KIRP	trans	rs2055729	0.614	rs17150693	chr8:9741652	C/G	cg06636001	chr8:8085503	FLJ10661	0.55	6.14	0.36	3.25e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.69	-8.71	-0.49	4.56e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06505273	chr16:24850292	NA	0.37	5.04	0.31	9.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.74	-8.14	-0.46	2.03e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg20243544	chr17:37824526	PNMT	0.49	6.5	0.38	4.4e-10	Asthma;
KIRP	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg09904177	chr6:26538194	HMGN4	-0.46	-5.69	-0.34	3.69e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.5	-6.66	-0.39	1.79e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13418717	1.000	rs12329197	chr2:127645411	A/G	cg25501666	chr2:127640322	NA	-1.05	-7.21	-0.42	6.82e-12	Heart failure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25643782	chr11:118978198	C2CD2L	0.54	7.08	0.41	1.48e-11	Parkinson's disease;
KIRP	cis	rs988913	0.723	rs4715520	chr6:54995995	A/G	cg03513858	chr6:54763001	FAM83B	0.39	5.68	0.34	3.72e-8	Menarche (age at onset);
KIRP	cis	rs6988636	0.818	rs10111810	chr8:124169565	G/A	cg23067535	chr8:124195133	FAM83A	-0.76	-6.74	-0.39	1.11e-10	Urinary uromodulin levels;
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.48	7.44	0.43	1.72e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.26	-0.37	1.74e-9	Joint mobility (Beighton score);
KIRP	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-0.85	-9.1	-0.5	3.23e-17	Gut microbiome composition (summer);
KIRP	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg15880211	chr22:50250494	ZBED4	0.6	5.28	0.32	2.83e-7	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg17105886	chr17:28927953	LRRC37B2	0.53	5.11	0.31	6.51e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7560272	0.538	rs2421575	chr2:73919522	G/A	cg20560298	chr2:73613845	ALMS1	0.52	6.27	0.37	1.57e-9	Schizophrenia;
KIRP	cis	rs427941	1.000	rs407943	chr7:101859050	G/A	cg06246474	chr7:101738831	CUX1	-0.52	-6.25	-0.37	1.75e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.83	10.48	0.56	1.68e-21	Total cholesterol levels;
KIRP	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.62	-7.04	-0.41	1.95e-11	Mean platelet volume;
KIRP	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.5e-21	Bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01691160	chr4:156340422	NA	-0.38	-6.04	-0.36	5.65e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg21775007	chr8:11205619	TDH	0.49	6.13	0.36	3.56e-9	Mood instability;
KIRP	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg21573476	chr21:45109991	RRP1B	-0.76	-10.64	-0.56	5.46e-22	Mean corpuscular volume;
KIRP	cis	rs10484885	0.757	rs12201016	chr6:90149275	C/T	cg13799429	chr6:90582589	CASP8AP2	0.66	6.4	0.38	7.81e-10	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.76e-9	Breast cancer;
KIRP	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg08501292	chr6:25962987	TRIM38	0.96	5.81	0.35	1.97e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.63	-9.58	-0.52	1.08e-18	Prostate cancer;
KIRP	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg06935464	chr4:38784597	TLR10	0.5	5.13	0.31	5.92e-7	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.43	-0.38	6.41e-10	Height;
KIRP	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.86	-12.45	-0.62	6.28e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs212524	0.544	rs2038089	chr1:21551457	C/T	cg08890418	chr1:21044141	KIF17	-0.39	-5.81	-0.35	1.88e-8	Height;
KIRP	cis	rs10267417	0.589	rs6960989	chr7:19869349	G/A	cg05791153	chr7:19748676	TWISTNB	0.57	5.5	0.33	9.27e-8	Night sleep phenotypes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14774995	chr8:128841050	PVT1	0.45	6.21	0.37	2.18e-9	Interleukin-4 levels;
KIRP	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg03834567	chr2:218808745	TNS1	0.46	5.57	0.33	6.83e-8	Ulcerative colitis;
KIRP	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg15103426	chr22:29168792	CCDC117	0.51	5.16	0.31	5.16e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg07493874	chr5:1342172	CLPTM1L	0.49	6.27	0.37	1.58e-9	Lung cancer;
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg08901578	chr4:187885870	NA	0.49	7.4	0.43	2.16e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04413180	chr2:236847057	AGAP1	-0.53	-6.2	-0.37	2.36e-9	Interleukin-4 levels;
KIRP	cis	rs9393813	1.000	rs1011665	chr6:27332298	T/C	cg18711553	chr6:27366782	ZNF391	0.36	5.25	0.32	3.27e-7	Bipolar disorder;
KIRP	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	1.01	13.83	0.66	1.39e-32	Cognitive ability;
KIRP	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg08499158	chr17:42289980	UBTF	0.51	6.41	0.38	7.31e-10	Total body bone mineral density;
KIRP	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23161317	chr6:28129485	ZNF389	0.42	4.92	0.3	1.57e-6	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.61	-0.34	5.47e-8	Life satisfaction;
KIRP	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.21	-0.64	1.79e-30	Alzheimer's disease;
KIRP	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22117172	chr7:91764530	CYP51A1	0.5	7.13	0.41	1.11e-11	Breast cancer;
KIRP	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg02336718	chr17:17403227	NA	-0.36	-5.6	-0.34	5.76e-8	Total body bone mineral density;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02999476	chr16:427684	TMEM8A	0.45	6.19	0.37	2.46e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.31	-6.05	-0.36	5.46e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.11	0.31	6.58e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15262992	chr20:61442882	OGFR	0.48	6.19	0.37	2.56e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	trans	rs9944715	1.000	rs4890320	chr18:43814124	T/C	cg01718231	chr17:29326311	RNF135	-0.5	-6.05	-0.36	5.32e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg10434728	chr15:90938212	IQGAP1	-0.37	-6.94	-0.4	3.48e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-7.69	-0.44	3.55e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9790314	0.670	rs9864752	chr3:160937591	A/C	cg04691961	chr3:161091175	C3orf57	-0.47	-6.93	-0.4	3.63e-11	Morning vs. evening chronotype;
KIRP	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.4	0.62	9.64e-28	Monocyte percentage of white cells;
KIRP	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg13119609	chr19:45449297	APOC2	-0.57	-8.17	-0.46	1.66e-14	Blood protein levels;
KIRP	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.92	-0.35	1.06e-8	Height;
KIRP	cis	rs2414059	0.548	rs3098177	chr15:50783777	A/G	cg05456662	chr15:50716270	USP8	-0.41	-5.58	-0.33	6.47e-8	QT interval;
KIRP	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.55	5.24	0.32	3.43e-7	Tuberculosis;
KIRP	cis	rs6832769	0.890	rs564762	chr4:56284631	C/T	cg05960024	chr4:56376020	CLOCK	0.64	8.32	0.47	6.11e-15	Personality dimensions;
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.85	-12.72	-0.63	8.34e-29	Height;
KIRP	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg02931644	chr1:25747376	RHCE	0.43	8.04	0.46	3.8e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg01304814	chr3:48885189	PRKAR2A	0.56	4.95	0.3	1.38e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg06935464	chr4:38784597	TLR10	0.54	5.37	0.32	1.8e-7	Breast cancer;
KIRP	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg09936142	chr19:10668400	KRI1	-0.41	-4.88	-0.3	1.87e-6	Inflammatory skin disease;
KIRP	trans	rs12043259	0.730	rs67020185	chr1:204816673	C/T	cg11485465	chr5:54518469	NA	0.39	6.76	0.4	9.86e-11	Addiction;
KIRP	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	7.14	0.41	1.07e-11	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02664216	chr12:19592651	AEBP2	0.63	7.6	0.44	6.36e-13	Smoking initiation;
KIRP	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg07596299	chr11:71824057	C11orf51	-0.84	-5.69	-0.34	3.65e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22603710	chr3:134514098	EPHB1	0.5	6.64	0.39	2.01e-10	Parkinson's disease;
KIRP	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg07930552	chr6:133119739	C6orf192	1.07	9.54	0.52	1.51e-18	Type 2 diabetes nephropathy;
KIRP	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg16141378	chr3:129829833	LOC729375	0.55	7.45	0.43	1.57e-12	Retinal vascular caliber;
KIRP	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg06453172	chr10:134556979	INPP5A	-0.55	-6.02	-0.36	6.18e-9	Migraine;
KIRP	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg16672083	chr15:72433130	SENP8	0.46	6.43	0.38	6.55e-10	Red blood cell count;
KIRP	cis	rs6693295	0.729	rs6680996	chr1:246214432	C/T	cg11798871	chr1:246315928	SMYD3	-0.42	-5.26	-0.32	3.17e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.47	-0.33	1.13e-7	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg11859384	chr17:80120422	CCDC57	-0.41	-5.19	-0.31	4.3e-7	Life satisfaction;
KIRP	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg23587288	chr2:27483067	SLC30A3	-0.64	-7.23	-0.42	6.19e-12	Blood metabolite levels;
KIRP	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.5	-5.63	-0.34	4.87e-8	Colorectal cancer;
KIRP	cis	rs3829109	0.534	rs563	chr9:139296485	C/T	cg14169450	chr9:139327907	INPP5E	-0.47	-5.81	-0.35	1.97e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs9473924	0.505	rs2817416	chr6:50809777	T/C	cg14470998	chr6:50812995	TFAP2B	1.01	9.07	0.5	3.83e-17	Body mass index;
KIRP	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22509189	chr2:225307070	NA	-0.44	-5.39	-0.32	1.69e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg06223162	chr1:101003688	GPR88	0.4	7.81	0.45	1.62e-13	Monocyte count;
KIRP	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg02487422	chr3:49467188	NICN1	0.49	7.33	0.42	3.29e-12	Resting heart rate;
KIRP	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg09455208	chr3:40491958	NA	0.34	5.75	0.34	2.65e-8	Renal cell carcinoma;
KIRP	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	1.0	10.19	0.54	1.48e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12476592	0.602	rs10865340	chr2:63824049	C/G	cg17519650	chr2:63277830	OTX1	-0.46	-5.06	-0.31	8.15e-7	Childhood ear infection;
KIRP	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.37	5.12	0.31	6.24e-7	Bipolar disorder;
KIRP	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg16497661	chr14:103986332	CKB	-0.52	-6.85	-0.4	5.9e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	7.12	0.41	1.15e-11	Neuroticism;
KIRP	cis	rs13401104	0.633	rs11679598	chr2:237112451	A/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.48	6.64	0.39	1.98e-10	Lewy body disease;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg23188430	chr6:125850052	NA	-0.34	-5.28	-0.32	2.91e-7	High light scatter reticulocyte count;
KIRP	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg21361702	chr7:150065534	REPIN1	0.62	6.52	0.38	3.99e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	10.14	0.54	2.04e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.67	-7.21	-0.42	7.02e-12	Neuroticism;
KIRP	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.61	7.14	0.41	1.05e-11	Pancreatic cancer;
KIRP	cis	rs9436747	0.546	rs10749753	chr1:65998467	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.45	-4.97	-0.3	1.26e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.14	19.27	0.78	4.68e-51	Cognitive function;
KIRP	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.55	-0.33	7.29e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs16828019	0.929	rs12029321	chr1:41682530	G/C	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg26043149	chr18:55253948	FECH	0.5	6.08	0.36	4.53e-9	Bone mineral density;
KIRP	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg03146154	chr1:46216737	IPP	0.43	5.35	0.32	1.98e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.89	-12.1	-0.61	9.59e-27	Menopause (age at onset);
KIRP	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg19752551	chr11:57585705	CTNND1	-0.8	-13.11	-0.64	4.07e-30	Schizophrenia;
KIRP	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.22	0.58	7.06e-24	Morning vs. evening chronotype;
KIRP	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.49	0.33	9.83e-8	Resistin levels;
KIRP	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg23565292	chr14:50234668	KLHDC2	-0.4	-4.86	-0.3	2.12e-6	Carotid intima media thickness;
KIRP	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.32	-5.38	-0.32	1.76e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.58	6.42	0.38	7.16e-10	Alcohol dependence;
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.69	10.96	0.57	4.9e-23	Lung cancer;
KIRP	cis	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg13293535	chr8:11597251	GATA4	0.47	6.98	0.41	2.66e-11	Neuroticism;
KIRP	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.65	-12.4	-0.62	9.44e-28	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	0.88	9.35	0.51	5.43e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.91	10.76	0.57	2.22e-22	Diastolic blood pressure;
KIRP	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.54	-0.43	8.86e-13	Neuroticism;
KIRP	cis	rs10872587	0.555	rs9497426	chr6:146234644	G/A	cg13319975	chr6:146136371	FBXO30	0.56	6.04	0.36	5.51e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg19274270	chr17:78178856	CARD14	-0.34	-6.2	-0.37	2.41e-9	Morning vs. evening chronotype;
KIRP	cis	rs4356932	1.000	rs7684461	chr4:76962996	G/T	cg19388996	chr4:76862389	NAAA	-0.4	-5.05	-0.31	8.66e-7	Blood protein levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22924838	chr2:200715629	NA	-0.47	-6.31	-0.37	1.3e-9	Myopia;
KIRP	cis	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg11015470	chr5:28928158	NA	0.46	5.08	0.31	7.56e-7	Hip geometry;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	14.18	0.67	9.18e-34	Platelet count;
KIRP	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.75	11.79	0.6	9.64e-26	Resting heart rate;
KIRP	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg22437258	chr11:111473054	SIK2	-0.61	-6.68	-0.39	1.62e-10	Primary sclerosing cholangitis;
KIRP	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg02344993	chr17:57696989	CLTC	0.55	5.25	0.32	3.33e-7	Hemoglobin concentration;
KIRP	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.46	-4.84	-0.3	2.26e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg00990874	chr7:1149470	C7orf50	-0.64	-5.45	-0.33	1.22e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.69	7.27	0.42	4.89e-12	Diastolic blood pressure;
KIRP	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	22.49	0.82	1.28e-61	Schizophrenia;
KIRP	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg24315340	chr6:146058215	EPM2A	0.42	5.2	0.31	4.1e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg04727924	chr7:799746	HEATR2	-0.79	-8.9	-0.49	1.21e-16	Cerebrospinal P-tau181p levels;
KIRP	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg16105309	chr15:79090380	ADAMTS7	0.6	7.78	0.44	2.02e-13	Schizophrenia;
KIRP	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.61	-8.59	-0.48	1.05e-15	Multiple system atrophy;
KIRP	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg18165381	chr3:44552316	NA	-0.39	-4.95	-0.3	1.36e-6	Depressive symptoms;
KIRP	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.64	-6.31	-0.37	1.3e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs7923609	0.936	rs10761779	chr10:65274927	A/G	cg01631684	chr10:65280961	REEP3	-0.52	-6.18	-0.37	2.71e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.31	-0.55	5.91e-21	Response to antipsychotic treatment;
KIRP	cis	rs710216	0.917	rs4660691	chr1:43417150	T/G	cg03128534	chr1:43423976	SLC2A1	-0.54	-5.56	-0.33	7.09e-8	Red cell distribution width;
KIRP	trans	rs71658797	0.505	rs12042177	chr1:77986638	A/G	cg23090529	chr1:51442133	NA	-0.47	-6.08	-0.36	4.56e-9	Lung cancer in ever smokers;Lung cancer;Lung adenocarcinoma;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09586080	chr16:86543543	FOXF1	-0.56	-6.21	-0.37	2.19e-9	Menopause (age at onset);
KIRP	cis	rs17321999	0.904	rs59693338	chr2:30473177	T/C	cg05247661	chr2:30472410	LBH	0.71	7.87	0.45	1.14e-13	Systemic lupus erythematosus;
KIRP	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg12826209	chr6:26865740	GUSBL1	0.46	5.31	0.32	2.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg12559939	chr2:27858050	GPN1	0.41	5.15	0.31	5.31e-7	Oral cavity cancer;
KIRP	cis	rs7267005	1.000	rs79599063	chr20:34504209	A/G	cg17201900	chr20:34330562	RBM39	0.87	4.9	0.3	1.71e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs56313388	0.757	rs3790093	chr16:56319850	C/T	cg02433656	chr16:56322654	GNAO1	0.45	5.12	0.31	6.25e-7	Pulse pressure;
KIRP	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.97	-16.74	-0.73	1.72e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg17356467	chr2:100759845	AFF3	0.55	5.65	0.34	4.5e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	24.1	0.84	1.03e-66	Chronic sinus infection;
KIRP	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs3105593	1.000	rs2630	chr15:50849399	T/C	cg05456662	chr15:50716270	USP8	0.41	5.05	0.31	8.48e-7	QT interval;
KIRP	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-6.53	-0.38	3.64e-10	Chronic sinus infection;
KIRP	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg16306078	chr6:126000798	NA	-0.27	-5.06	-0.31	8.23e-7	Endometrial cancer;
KIRP	cis	rs2929278	0.638	rs2016840	chr15:44211868	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.47	-5.67	-0.34	3.93e-8	Schizophrenia;
KIRP	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.6	7.27	0.42	4.7e-12	Obesity-related traits;
KIRP	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg21775007	chr8:11205619	TDH	-0.37	-4.96	-0.3	1.34e-6	Monocyte count;
KIRP	cis	rs35300120	0.757	rs7540816	chr1:233659142	A/G	cg23054119	chr1:233659267	NA	0.4	5.7	0.34	3.42e-8	Cognitive function;
KIRP	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg07378217	chr19:58662286	ZNF329	-0.59	-5.47	-0.33	1.11e-7	Cholesterol, total;
KIRP	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.81	10.51	0.56	1.44e-21	N-glycan levels;
KIRP	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg25486957	chr4:152246857	NA	-0.48	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg16296679	chr22:42394374	WBP2NL	0.36	4.95	0.3	1.37e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs1497828	0.956	rs2132993	chr1:217547640	A/G	cg04411442	chr1:217543379	NA	0.31	4.97	0.3	1.27e-6	Dialysis-related mortality;
KIRP	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1971762	1.000	rs10783594	chr12:54067135	A/C	cg09709951	chr12:54017699	ATF7	0.45	5.67	0.34	3.96e-8	Height;
KIRP	cis	rs9815354	1.000	rs1125203	chr3:41760895	T/C	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.2e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9596863	0.898	rs9568906	chr13:54335197	A/G	ch.13.53330881F	chr13:54432880	NA	0.6	5.79	0.35	2.16e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15174463	chr3:160118190	SMC4;IFT80	0.43	6.21	0.37	2.28e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14159672	chr1:205819179	PM20D1	-0.41	-4.99	-0.3	1.14e-6	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.44	0.43	1.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.75	9.98	0.54	6.66e-20	Mood instability;
KIRP	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.41	-5.36	-0.32	1.96e-7	IgG glycosylation;
KIRP	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg22974920	chr21:40686053	BRWD1	0.49	5.8	0.35	2.05e-8	Cognitive function;
KIRP	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.58	-9.46	-0.52	2.56e-18	Prostate cancer;
KIRP	cis	rs4595586	0.655	rs7958206	chr12:39329294	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.33	0.37	1.13e-9	Morning vs. evening chronotype;
KIRP	cis	rs8032158	0.963	rs11071231	chr15:56159118	A/C	cg02198044	chr15:56286336	NEDD4	-0.41	-4.89	-0.3	1.84e-6	Keloid;
KIRP	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.43	-6.19	-0.37	2.55e-9	Vitamin D levels;
KIRP	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	26.1	0.86	7.88e-73	Chronic sinus infection;
KIRP	cis	rs3736485	0.609	rs744039	chr15:51973373	T/C	cg14296394	chr15:51910925	DMXL2	-0.34	-4.99	-0.3	1.14e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.83	-12.02	-0.61	1.68e-26	Dental caries;
KIRP	cis	rs11638352	1.000	rs2615297	chr15:44406021	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-5.1	-0.31	6.83e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs16912285	0.535	rs7936178	chr11:24252515	G/T	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg07001201	chr5:642380	CEP72	0.64	5.81	0.35	1.89e-8	Lung disease severity in cystic fibrosis;
KIRP	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.09	-19.7	-0.78	1.7e-52	Exhaled nitric oxide output;
KIRP	cis	rs7113874	0.613	rs10840066	chr11:8532003	G/A	cg08015107	chr11:8618950	NA	-0.49	-6.42	-0.38	6.92e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13418717	0.793	rs4663053	chr2:127638990	A/G	cg25501666	chr2:127640322	NA	-1.09	-11.54	-0.59	6.44e-25	Heart failure;
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.14	12.25	0.62	3.04e-27	Platelet count;
KIRP	cis	rs12311304	0.965	rs7980227	chr12:15367715	T/A	cg08258403	chr12:15378311	NA	0.38	5.79	0.35	2.17e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03934478	chr11:495069	RNH1	0.87	6.97	0.41	2.9e-11	Body mass index;
KIRP	cis	rs4926611	0.730	rs6662142	chr1:54059368	T/C	cg08927728	chr1:54059983	GLIS1	0.29	6.11	0.36	3.93e-9	Hand grip strength;
KIRP	cis	rs7814319	0.674	rs2292835	chr8:97243720	G/A	cg20787634	chr8:97240163	UQCRB	-0.58	-7.79	-0.44	1.89e-13	Lung function (FVC);
KIRP	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg00717180	chr2:96193071	NA	-0.49	-6.07	-0.36	4.94e-9	Height;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg13453750	chr1:205783389	SLC41A1	-0.46	-6.91	-0.4	4.23e-11	Menarche (age at onset);
KIRP	cis	rs7870753	0.853	rs7870106	chr9:99210584	C/T	cg25260653	chr9:99212216	HABP4	0.47	5.25	0.32	3.31e-7	Height;
KIRP	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.77	-6.13	-0.36	3.45e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.44	-0.33	1.26e-7	Renal cell carcinoma;
KIRP	cis	rs12447804	0.871	rs2304488	chr16:58074210	A/G	cg03859792	chr16:58121049	NA	0.49	6.73	0.39	1.2e-10	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg00343986	chr7:65444356	GUSB	0.46	5.63	0.34	4.99e-8	Aortic root size;
KIRP	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.44	-8.53	-0.48	1.5e-15	Urinary metabolites;
KIRP	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.32	-0.32	2.32e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1021993	0.545	rs1006316	chr1:209550461	T/C	cg24446417	chr1:209558027	NA	-0.49	-5.26	-0.32	3.11e-7	Gut microbiome composition (winter);
KIRP	cis	rs9488822	0.650	rs195523	chr6:116246964	G/A	cg05304507	chr6:116381966	FRK	0.2	5.08	0.31	7.31e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.97	0.36	8.07e-9	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09287164	chr2:220462681	STK11IP	0.43	6.21	0.37	2.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs793571	0.637	rs7179456	chr15:59174539	G/T	cg05156742	chr15:59063176	FAM63B	-0.41	-4.87	-0.3	2e-6	Schizophrenia;
KIRP	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.73	9.08	0.5	3.71e-17	Huntington's disease progression;
KIRP	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	-0.68	-8.77	-0.49	3.04e-16	Inflammatory bowel disease;
KIRP	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg02475777	chr4:1388615	CRIPAK	-0.55	-5.24	-0.32	3.5e-7	Recombination rate (females);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg10352719	chr14:24769404	DHRS1;C14orf21	0.5	6.03	0.36	5.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1440410	0.798	rs7666785	chr4:144060464	A/G	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14500932	chr9:126534337	DENND1A	-0.43	-6.71	-0.39	1.36e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg09695851	chr17:3907499	NA	0.53	5.01	0.3	1.02e-6	Type 2 diabetes;
KIRP	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.42	9.38	0.51	4.49e-18	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg19554555	chr3:13937349	NA	-0.46	-6.27	-0.37	1.62e-9	Ovarian reserve;
KIRP	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg10756647	chr7:56101905	PSPH	0.99	6.8	0.4	8.08e-11	Diabetic kidney disease;
KIRP	cis	rs193541	0.642	rs42538	chr5:122292352	A/T	cg19412675	chr5:122181750	SNX24	0.61	6.48	0.38	5.06e-10	Glucose homeostasis traits;
KIRP	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-7.23	-0.42	6.14e-12	Response to antipsychotic treatment;
KIRP	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg10761708	chr20:43804764	PI3	0.45	4.89	0.3	1.86e-6	Blood protein levels;
KIRP	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg05340658	chr4:99064831	C4orf37	-0.55	-6.65	-0.39	1.84e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.23	-0.42	6.26e-12	Neuroticism;
KIRP	cis	rs2151522	0.762	rs11752314	chr6:127168910	T/A	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	12.52	0.62	3.75e-28	Eye color traits;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.46e-8	Life satisfaction;
KIRP	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.92	-14.1	-0.67	1.74e-33	Systemic lupus erythematosus;
KIRP	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.45	-5.87	-0.35	1.42e-8	Body mass index;
KIRP	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.6	8.1	0.46	2.54e-14	Longevity;Endometriosis;
KIRP	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17344932	chr17:38183730	MED24;SNORD124	0.44	6.84	0.4	6.24e-11	Myeloid white cell count;
KIRP	cis	rs3821902	0.569	rs17069797	chr3:64054348	T/C	cg09006292	chr3:64049408	NA	-0.51	-5.28	-0.32	2.81e-7	Breast cancer;
KIRP	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	13.09	0.64	4.43e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.64	7.86	0.45	1.21e-13	Vitiligo;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18484068	chr5:1509526	LPCAT1	0.47	6.05	0.36	5.49e-9	Pancreatic cancer;
KIRP	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	0.55	7.8	0.45	1.8e-13	Coronary artery disease;
KIRP	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.75	10.81	0.57	1.51e-22	Body mass index;
KIRP	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06481639	chr22:41940642	POLR3H	0.65	7.14	0.41	1.04e-11	Vitiligo;
KIRP	cis	rs7223966	0.655	rs7209961	chr17:61633705	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.02	0.36	6.24e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	ch.10.789016R	chr10:30833448	NA	-0.46	-6.05	-0.36	5.38e-9	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20163429	chr10:102046263	BLOC1S2	0.47	6.18	0.37	2.66e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg15038512	chr6:170123185	PHF10	-0.57	-8.59	-0.48	1.04e-15	Obesity-related traits;
KIRP	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg17376030	chr22:41985996	PMM1	0.44	5.41	0.33	1.47e-7	Vitiligo;
KIRP	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-5.75	-0.34	2.6e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.03	-0.31	9.61e-7	Neuroticism;
KIRP	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg27432699	chr2:27873401	GPN1	-0.45	-5.87	-0.35	1.38e-8	Total body bone mineral density;
KIRP	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-8.39	-0.47	3.82e-15	Alzheimer's disease;
KIRP	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.76	-10.0	-0.54	5.43e-20	QT interval;
KIRP	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.14	0.36	3.36e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.71	-6.11	-0.36	3.97e-9	Schizophrenia;
KIRP	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.49	6.95	0.4	3.33e-11	Immature fraction of reticulocytes;
KIRP	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.53	0.75	3.39e-45	Cognitive function;
KIRP	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.46	5.17	0.31	4.9e-7	Schizophrenia;
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg14338887	chr6:42928500	GNMT	0.48	7.16	0.42	9.33e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs41264869	0.628	rs6687271	chr1:205165322	A/C	cg21214746	chr1:205091277	RBBP5	0.5	6.44	0.38	6.37e-10	Blood protein levels;
KIRP	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg02711726	chr17:80685570	FN3KRP	0.5	7.17	0.42	8.63e-12	Glycated hemoglobin levels;
KIRP	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg06012730	chr15:75315579	PPCDC	-0.42	-5.22	-0.32	3.88e-7	Blood trace element (Zn levels);
KIRP	cis	rs7852872	0.965	rs4836726	chr9:119246425	C/T	cg13792444	chr9:119245443	ASTN2	-0.37	-5.46	-0.33	1.17e-7	Hippocampal volume;
KIRP	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.54	6.57	0.39	2.95e-10	Corneal astigmatism;
KIRP	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26306683	chr17:18585705	ZNF286B	0.59	7.5	0.43	1.15e-12	Educational attainment (years of education);
KIRP	cis	rs6466055	0.589	rs2299298	chr7:104745818	G/A	cg04380332	chr7:105027541	SRPK2	-0.4	-5.47	-0.33	1.1e-7	Schizophrenia;
KIRP	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.25	0.37	1.84e-9	Aortic root size;
KIRP	cis	rs4132509	1.000	rs2125230	chr1:243885848	A/G	cg21452805	chr1:244014465	NA	-0.57	-5.9	-0.35	1.17e-8	RR interval (heart rate);
KIRP	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.74	9.96	0.54	7.27e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg19592336	chr6:28129416	ZNF389	0.52	6.0	0.36	6.93e-9	Depression;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-13.19	-0.64	2.14e-30	Alzheimer's disease;
KIRP	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg10645314	chr2:3704589	ALLC	-0.64	-7.1	-0.41	1.32e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs1864585	0.520	rs56109041	chr8:10657154	G/C	cg26278703	chr11:58910052	FAM111A	0.65	6.48	0.38	4.88e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg08874788	chr8:98656259	MTDH	0.48	6.13	0.36	3.48e-9	Educational attainment;
KIRP	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.47	-6.24	-0.37	1.9e-9	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.05	-0.31	8.7e-7	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.95	12.32	0.62	1.8e-27	Homoarginine levels;
KIRP	cis	rs1788820	0.957	rs1652342	chr18:21099583	C/T	cg14672496	chr18:21087552	C18orf8	0.42	5.93	0.35	1.05e-8	Body mass index;
KIRP	cis	rs5753037	0.809	rs5997530	chr22:30203599	C/G	cg01021169	chr22:30184971	ASCC2	-0.39	-4.87	-0.3	1.97e-6	Type 1 diabetes;
KIRP	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	1.09	20.9	0.8	1.86e-56	Bone mineral density;
KIRP	cis	rs4563143	0.647	rs61378972	chr19:29218742	C/T	cg03161606	chr19:29218774	NA	1.01	10.07	0.54	3.39e-20	Methadone dose in opioid dependence;
KIRP	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	6.59	0.39	2.6e-10	Response to antipsychotic treatment;
KIRP	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg25547332	chr5:131281432	NA	0.47	5.17	0.31	4.87e-7	Life satisfaction;
KIRP	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs969348	0.611	rs2672093	chr15:81873237	G/A	cg08662227	chr15:81411066	NA	0.48	4.97	0.3	1.27e-6	Paclitaxel disposition in epithelial ovarian cancer;
KIRP	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg13514129	chr1:39547527	MACF1	0.52	7.54	0.43	9.16e-13	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs6546886	0.912	rs13006301	chr2:74291015	G/A	cg14702570	chr2:74259524	NA	-0.32	-6.28	-0.37	1.48e-9	Dialysis-related mortality;
KIRP	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.23	-0.42	5.96e-12	Alzheimer's disease (late onset);
KIRP	cis	rs11203032	0.831	rs4511206	chr10:90968759	C/T	cg16672925	chr10:90967113	CH25H	0.85	8.33	0.47	5.69e-15	Heart failure;
KIRP	cis	rs918629	0.530	rs6889029	chr5:95251238	A/G	cg16656078	chr5:95278638	ELL2	0.33	4.97	0.3	1.26e-6	IgG glycosylation;
KIRP	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.85	12.7	0.63	9.38e-29	Systolic blood pressure;
KIRP	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg05973401	chr12:123451056	ABCB9	0.61	7.3	0.42	3.93e-12	Platelet count;
KIRP	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg00012203	chr2:219082015	ARPC2	-0.41	-5.01	-0.3	1.06e-6	Ulcerative colitis;
KIRP	cis	rs654128	0.640	rs339335	chr6:117213995	A/G	cg12892004	chr6:117198278	RFX6	0.36	5.1	0.31	6.73e-7	Telomere length;
KIRP	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00933542	chr6:150070202	PCMT1	0.27	5.27	0.32	2.96e-7	Lung cancer;
KIRP	cis	rs12541635	0.677	rs12546875	chr8:107012915	C/T	cg10147462	chr8:107024639	NA	0.35	5.34	0.32	2.08e-7	Age of smoking initiation;
KIRP	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	8.53	0.48	1.56e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.88	0.35	1.32e-8	Schizophrenia;
KIRP	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.78	8.5	0.48	1.83e-15	Cholesterol, total;
KIRP	cis	rs7252505	0.892	rs10411921	chr19:33608500	C/T	cg17764715	chr19:33622953	WDR88	0.7	5.93	0.35	1.03e-8	Colorectal cancer;
KIRP	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg22563815	chr15:78856949	CHRNA5	0.51	7.87	0.45	1.1e-13	Sudden cardiac arrest;
KIRP	cis	rs1555895	0.576	rs2274376	chr10:850157	A/G	cg10017260	chr10:834428	NA	-0.47	-7.08	-0.41	1.5e-11	Survival in rectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23661306	chr3:57541993	PDE12	0.48	6.18	0.37	2.64e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.74	-8.02	-0.46	4.42e-14	Vitiligo;
KIRP	trans	rs6601327	0.613	rs12677507	chr8:9481687	G/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.49	-0.38	4.77e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07570687	chr10:102243282	WNT8B	0.51	6.26	0.37	1.74e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.47	5.14	0.31	5.52e-7	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10620530	chr9:139922595	C9orf139;ABCA2	0.59	6.9	0.4	4.45e-11	Smoking initiation;
KIRP	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.93	0.54	9.12e-20	Lung cancer;
KIRP	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.83	11.01	0.57	3.39e-23	N-glycan levels;
KIRP	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-7.54	-0.43	8.97e-13	Diastolic blood pressure;
KIRP	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.45	-5.55	-0.33	7.56e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg00405596	chr8:11794950	NA	-0.46	-5.7	-0.34	3.4e-8	Neuroticism;
KIRP	cis	rs2625529	0.526	rs7179942	chr15:72563074	C/G	cg16672083	chr15:72433130	SENP8	0.4	5.63	0.34	4.83e-8	Red blood cell count;
KIRP	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.46	6.63	0.39	2.14e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs732765	0.734	rs10133860	chr14:75186425	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.86	-0.3	2.08e-6	Non-small cell lung cancer;
KIRP	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	12.59	0.63	2.27e-28	Bone mineral density;
KIRP	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg14003231	chr6:33640908	ITPR3	0.28	4.94	0.3	1.46e-6	Plateletcrit;
KIRP	cis	rs7215564	0.908	rs57778244	chr17:78653798	T/G	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg21854759	chr1:92012499	NA	-0.47	-6.06	-0.36	5.04e-9	Breast cancer;
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.18	0.37	2.65e-9	Platelet count;
KIRP	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	1.01	13.09	0.64	4.62e-30	Post bronchodilator FEV1;
KIRP	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg25124228	chr12:125621409	AACS	-0.65	-9.0	-0.5	6.1e-17	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-8.56	-0.48	1.22e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11987759	chr7:65425863	GUSB	0.47	6.1	0.36	4.09e-9	Aortic root size;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05025164	chr4:1340916	KIAA1530	0.58	7.73	0.44	2.74e-13	Longevity;
KIRP	cis	rs9400467	0.506	rs17678681	chr6:111582038	T/A	cg15721981	chr6:111408429	SLC16A10	0.75	6.87	0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-5.33	-0.32	2.27e-7	Triglycerides;
KIRP	cis	rs13102973	0.965	rs13142779	chr4:135872841	G/T	cg14419869	chr4:135874104	NA	0.55	9.43	0.52	3.2e-18	Subjective well-being;
KIRP	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.77	-11.56	-0.59	5.58e-25	Obesity-related traits;
KIRP	cis	rs4671458	0.948	rs12466601	chr2:63556348	T/G	cg17519650	chr2:63277830	OTX1	-0.54	-5.39	-0.32	1.69e-7	Subjective well-being;
KIRP	cis	rs13315871	1.000	rs9849482	chr3:58422087	G/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.65	7.77	0.44	2.13e-13	Testicular germ cell tumor;
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.71	12.24	0.62	3.2e-27	Lung cancer;
KIRP	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg10763598	chr19:19431466	KIAA0892;SF4	0.62	5.17	0.31	4.78e-7	Nonalcoholic fatty liver disease;
KIRP	cis	rs11945232	0.624	rs35649088	chr4:88369786	C/T	cg23841344	chr4:88312519	HSD17B11	-0.6	-6.58	-0.39	2.78e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2282032	0.825	rs17799220	chr14:90739446	C/A	cg04374321	chr14:90722782	PSMC1	0.59	5.58	0.34	6.23e-8	Longevity;
KIRP	cis	rs55692468	0.848	rs12471183	chr2:153366827	T/C	cg04681845	chr2:153283485	FMNL2	0.45	5.61	0.34	5.35e-8	Intraocular pressure;
KIRP	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.53	6.91	0.4	4.21e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs1106684	1.000	rs12539540	chr7:131464280	A/G	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.72	-7.8	-0.45	1.82e-13	DNA methylation (variation);
KIRP	cis	rs4728302	0.630	rs1862873	chr7:133590287	T/A	cg10665199	chr7:133106180	EXOC4	0.43	5.06	0.31	8.08e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-10.11	-0.54	2.54e-20	Total body bone mineral density;
KIRP	cis	rs2562456	0.652	rs62110214	chr19:21775208	G/A	cg00806126	chr19:22604979	ZNF98	-0.67	-6.41	-0.38	7.32e-10	Pain;
KIRP	cis	rs3126085	0.560	rs6587668	chr1:152333958	A/G	cg26876637	chr1:152193138	HRNR	-0.74	-7.09	-0.41	1.37e-11	Atopic dermatitis;
KIRP	trans	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg00405596	chr8:11794950	NA	0.47	6.33	0.37	1.14e-9	Joint mobility (Beighton score);
KIRP	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.97	-0.41	2.95e-11	Monocyte count;
KIRP	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.39	-0.33	1.64e-7	Personality dimensions;
KIRP	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18255839	chr2:239335447	ASB1	0.43	5.11	0.31	6.4e-7	Multiple system atrophy;
KIRP	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.41	-5.08	-0.31	7.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg27494647	chr7:150038898	RARRES2	0.41	6.17	0.37	2.74e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1712517	0.771	rs61869827	chr10:105079439	T/C	cg05636881	chr10:105038444	INA	0.43	6.19	0.37	2.45e-9	Migraine;
KIRP	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs5753037	0.869	rs41155	chr22:30404547	A/C	cg27665648	chr22:30112403	NA	-0.36	-5.08	-0.31	7.54e-7	Type 1 diabetes;
KIRP	cis	rs911119	1.000	rs34374560	chr20:23609462	C/T	cg16589663	chr20:23618590	CST3	0.62	5.94	0.35	9.5e-9	Chronic kidney disease;
KIRP	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.59	-8.15	-0.46	1.9e-14	High light scatter reticulocyte count;
KIRP	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.56	-8.57	-0.48	1.17e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.69	7.9	0.45	9.31e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg25457927	chr22:38595422	NA	-0.24	-4.88	-0.3	1.91e-6	Cutaneous nevi;
KIRP	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.65	8.18	0.46	1.49e-14	Coronary artery disease;
KIRP	cis	rs7814319	0.966	rs10095443	chr8:97269738	C/T	cg20787634	chr8:97240163	UQCRB	-0.67	-10.77	-0.57	2e-22	Lung function (FVC);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14655101	chr9:140136205	TUBB2C	0.46	6.45	0.38	5.74e-10	Cancer;
KIRP	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.46	7.78	0.44	2.01e-13	Erythrocyte sedimentation rate;
KIRP	trans	rs11923600	0.652	rs16826766	chr3:175957413	A/G	cg00728300	chr16:87903283	SLC7A5	0.47	6.04	0.36	5.61e-9	Height;
KIRP	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg11498726	chr8:26250323	BNIP3L	-0.55	-8.11	-0.46	2.46e-14	Red cell distribution width;
KIRP	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	8.0	0.45	4.74e-14	Iron status biomarkers;
KIRP	cis	rs1829883	0.835	rs1464638	chr5:98785846	T/C	cg08333243	chr5:99726346	NA	-0.41	-5.31	-0.32	2.47e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.86	-11.79	-0.6	1.01e-25	Schizophrenia;
KIRP	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.41	-0.47	3.34e-15	Colorectal cancer;
KIRP	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.44	-0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs7221595	0.825	rs7225453	chr17:3960620	T/C	cg09695851	chr17:3907499	NA	0.55	5.37	0.32	1.81e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.96	16.51	0.72	1.05e-41	Menarche (age at onset);
KIRP	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg11569703	chr11:65557185	OVOL1	0.37	5.72	0.34	3.09e-8	Eosinophil percentage of white cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15159625	chr1:118042759	MAN1A2	-0.41	-6.15	-0.37	3.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg10790698	chr19:18539756	SSBP4	-0.34	-7.5	-0.43	1.14e-12	Breast cancer;
KIRP	cis	rs1656402	0.861	rs1729255	chr2:233429196	C/G	cg03852847	chr2:233439513	NA	0.68	9.06	0.5	4.17e-17	Non-small cell lung cancer (survival);
KIRP	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg19592336	chr6:28129416	ZNF389	0.48	5.51	0.33	8.85e-8	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg09699651	chr6:150184138	LRP11	0.43	5.14	0.31	5.53e-7	Lung cancer;
KIRP	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg12131826	chr15:77904385	NA	0.42	5.67	0.34	3.97e-8	Type 2 diabetes;
KIRP	trans	rs13170463	0.579	rs71606020	chr5:8046475	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9547996	0.879	rs9547964	chr13:38151202	A/C	cg13634560	chr13:38173852	POSTN	-0.41	-5.77	-0.35	2.39e-8	Diastolic blood pressure;
KIRP	cis	rs4919044	0.866	rs1475366	chr10:94781857	T/C	cg05127821	chr10:94822908	CYP26C1	-0.99	-7.26	-0.42	5.16e-12	Coronary artery disease;
KIRP	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.95	-0.57	5.65e-23	Breast cancer;
KIRP	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-6.15	-0.37	3.12e-9	Neuroticism;
KIRP	cis	rs7523050	0.730	rs34182354	chr1:109416340	C/T	cg08274380	chr1:109419600	GPSM2	1.18	10.3	0.55	6.6e-21	Fat distribution (HIV);
KIRP	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.83	-0.4	6.81e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6545883	0.929	rs7561229	chr2:61737990	A/T	cg15711740	chr2:61764176	XPO1	-0.59	-8.01	-0.45	4.64e-14	Tuberculosis;
KIRP	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg25039879	chr17:56429692	SUPT4H1	0.62	5.44	0.33	1.3e-7	Cognitive test performance;
KIRP	cis	rs1823913	0.637	rs4853575	chr2:192160875	C/T	cg12404831	chr2:192114017	MYO1B	-0.45	-6.04	-0.36	5.62e-9	Obesity-related traits;
KIRP	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	cis	rs7712401	0.645	rs246316	chr5:122266197	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.28	0.32	2.78e-7	Mean platelet volume;
KIRP	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.92	0.3	1.61e-6	Cognitive test performance;
KIRP	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg11189052	chr15:85197271	WDR73	-0.43	-5.13	-0.31	5.75e-7	P wave terminal force;
KIRP	cis	rs7011507	1.000	rs7814627	chr8:49128094	C/T	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20986655	chr6:170151393	TCTE3;C6orf70	0.45	6.34	0.37	1.1e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8077577	0.945	rs62073604	chr17:18065888	T/C	cg18869244	chr17:18121946	NA	0.48	5.38	0.32	1.78e-7	Obesity-related traits;
KIRP	cis	rs7737355	0.898	rs3775999	chr5:130970090	T/C	cg06307176	chr5:131281290	NA	0.56	5.97	0.36	8.14e-9	Life satisfaction;
KIRP	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg11569703	chr11:65557185	OVOL1	-0.38	-5.65	-0.34	4.49e-8	Urate levels;
KIRP	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.04	-0.5	4.65e-17	Retinal vascular caliber;
KIRP	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.53	7.23	0.42	6.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs300890	0.513	rs4277733	chr4:144048046	A/G	cg01719995	chr4:144104893	USP38	-0.41	-5.35	-0.32	1.99e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg04673462	chr1:38461896	NA	0.47	6.36	0.38	1e-9	Coronary artery disease;
KIRP	cis	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg03511173	chr18:77590860	NA	0.52	4.96	0.3	1.33e-6	Opioid sensitivity;
KIRP	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.85	-0.57	1.17e-22	Height;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17492891	chr22:41843204	TOB2	0.72	6.22	0.37	2.06e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.24	-15.65	-0.71	8.5e-39	Type 1 diabetes nephropathy;
KIRP	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.1	-0.31	6.81e-7	Pulmonary function;
KIRP	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.84	7.83	0.45	1.43e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg02462569	chr6:150064036	NUP43	-0.43	-6.54	-0.38	3.58e-10	Lung cancer;
KIRP	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	1.08	21.18	0.8	2.27e-57	Height;
KIRP	cis	rs10782582	0.609	rs2029682	chr1:76341619	T/C	cg03433033	chr1:76189801	ACADM	-0.42	-6.08	-0.36	4.53e-9	Daytime sleep phenotypes;
KIRP	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg10523679	chr1:76189770	ACADM	-0.46	-6.3	-0.37	1.35e-9	Daytime sleep phenotypes;
KIRP	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.99e-8	Lung cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26247263	chr6:118972830	C6orf204	-0.45	-6.21	-0.37	2.28e-9	Metabolic traits;
KIRP	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg00958927	chr1:175162553	KIAA0040	-0.29	-4.97	-0.3	1.23e-6	Alcohol dependence;
KIRP	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg05973401	chr12:123451056	ABCB9	0.63	7.61	0.44	5.79e-13	Platelet count;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg08662619	chr6:150070041	PCMT1	0.35	5.64	0.34	4.69e-8	Lung cancer;
KIRP	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.95	-8.68	-0.48	5.59e-16	Rheumatoid arthritis;
KIRP	cis	rs6662572	0.737	rs56368769	chr1:46451739	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.19	0.31	4.37e-7	Blood protein levels;
KIRP	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.32	-0.32	2.3e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs56146971	0.670	rs12590074	chr14:91867390	T/G	cg16433844	chr14:91963127	SMEK1	-0.56	-5.5	-0.33	9.57e-8	Alzheimer disease and age of onset;
KIRP	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.75	11.36	0.59	2.5e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7215564	0.730	rs34588273	chr17:78571465	C/T	cg06153925	chr17:78755379	RPTOR	0.45	5.87	0.35	1.37e-8	Myopia (pathological);
KIRP	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.56	-0.65	1.16e-31	Height;
KIRP	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg11621586	chr10:70884670	VPS26A	1.23	16.95	0.73	3.27e-43	Left atrial antero-posterior diameter;
KIRP	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.8	0.35	2.05e-8	Depressive symptoms;
KIRP	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs75920871	0.764	rs1473327	chr11:116823996	A/T	cg23684410	chr11:116897558	SIK3	0.55	6.02	0.36	6.32e-9	Subjective well-being;
KIRP	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.74	-9.12	-0.5	2.81e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg01620082	chr3:125678407	NA	-0.88	-6.35	-0.38	1.04e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg21775007	chr8:11205619	TDH	0.52	6.41	0.38	7.51e-10	Parkinson's disease;
KIRP	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg14517863	chr17:44321492	NA	0.49	5.63	0.34	5.02e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	9.72	0.53	4.12e-19	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs290268	0.874	rs290997	chr9:93559351	G/A	cg02608019	chr9:93564028	SYK	0.82	11.52	0.59	7.49e-25	Platelet count;
KIRP	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg04554929	chr8:105342491	NA	-0.41	-6.05	-0.36	5.24e-9	Paget's disease;
KIRP	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.91	-0.45	8.52e-14	Homocysteine levels;
KIRP	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	11.29	0.58	4.38e-24	Blood protein levels;
KIRP	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18932078	chr1:2524107	MMEL1	-0.39	-5.31	-0.32	2.42e-7	Ulcerative colitis;
KIRP	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg05973401	chr12:123451056	ABCB9	0.55	6.3	0.37	1.4e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10924970	0.776	rs72758049	chr1:235465045	G/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.0	0.3	1.1e-6	Asthma;
KIRP	cis	rs2165468	0.901	rs12571618	chr10:3502944	G/A	cg11503287	chr10:3498567	NA	0.76	5.17	0.31	4.78e-7	Bone mineral density;
KIRP	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.51e-25	Morning vs. evening chronotype;
KIRP	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	10.36	0.55	4.14e-21	Calcium levels;
KIRP	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.6	-9.63	-0.52	7.67e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.26	-0.32	3.06e-7	Inflammatory bowel disease;
KIRP	cis	rs9400467	0.537	rs78080415	chr6:111537016	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.57	5.38	0.32	1.72e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs62247992	0.698	rs17075162	chr3:43117917	T/C	cg12239580	chr3:43073058	FAM198A	0.37	4.96	0.3	1.31e-6	Facial morphology (factor 15, philtrum width);
KIRP	cis	rs7508	0.511	rs371922	chr8:17900003	T/C	cg01800426	chr8:17659068	MTUS1	-0.46	-4.93	-0.3	1.49e-6	Atrial fibrillation;
KIRP	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg07596299	chr11:71824057	C11orf51	-0.84	-5.63	-0.34	5.01e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg19000871	chr14:103996768	TRMT61A	-0.4	-4.94	-0.3	1.46e-6	Coronary artery disease;
KIRP	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg02569458	chr12:86230093	RASSF9	-0.52	-7.64	-0.44	4.79e-13	Major depressive disorder;
KIRP	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-12.0	-0.61	2.01e-26	Height;
KIRP	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg21573476	chr21:45109991	RRP1B	-0.67	-9.55	-0.52	1.4e-18	Mean corpuscular volume;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.66	10.03	0.54	4.65e-20	Monocyte percentage of white cells;
KIRP	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg19507638	chr5:93509721	C5orf36	0.61	5.29	0.32	2.77e-7	Diabetic retinopathy;
KIRP	cis	rs10518128	0.850	rs10009647	chr4:75711420	C/T	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs501120	1.000	rs620356	chr10:44761073	A/C	cg09554077	chr10:44749378	NA	0.7	10.73	0.56	2.84e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.52	7.01	0.41	2.33e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs539514	0.690	rs1092601	chr13:76309746	C/T	cg04757411	chr13:76259545	LMO7	-0.37	-5.23	-0.32	3.55e-7	Type 1 diabetes;
KIRP	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-8.45	-0.47	2.62e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg20362242	chr5:692897	TPPP	0.56	4.86	0.3	2.14e-6	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26500707	chr16:50100227	HEATR3	0.47	6.92	0.4	3.86e-11	Survival in pancreatic cancer;
KIRP	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	4.03e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.35	5.02	0.31	9.73e-7	Neuroticism;
KIRP	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15687780	chr3:184294839	EPHB3	-0.49	-6.6	-0.39	2.46e-10	Inflammatory biomarkers;
KIRP	cis	rs240764	0.697	rs846799	chr6:101270345	A/G	cg09795085	chr6:101329169	ASCC3	0.48	5.76	0.34	2.55e-8	Neuroticism;
KIRP	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-0.8	-10.96	-0.57	5.01e-23	IgG glycosylation;
KIRP	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg13206674	chr6:150067644	NUP43	0.47	6.57	0.39	3.03e-10	Testicular germ cell tumor;
KIRP	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14769373	chr6:40998127	UNC5CL	-0.63	-6.76	-0.4	9.77e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-0.58	-8.37	-0.47	4.27e-15	Coronary artery disease;
KIRP	cis	rs4671458	0.948	rs17348207	chr2:63460744	A/G	cg17519650	chr2:63277830	OTX1	-0.52	-5.52	-0.33	8.61e-8	Subjective well-being;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21607453	chr9:98783545	NCRNA00092	0.61	8.2	0.46	1.35e-14	Smoking initiation;
KIRP	cis	rs11955398	0.585	rs4524466	chr5:60020078	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7546094	0.935	rs3013439	chr1:113200671	T/G	cg22162597	chr1:113214053	CAPZA1	-0.5	-7.06	-0.41	1.67e-11	Platelet distribution width;
KIRP	cis	rs35771425	0.742	rs116456234	chr1:211635669	C/T	cg10512769	chr1:211675356	NA	-0.67	-6.16	-0.37	3.03e-9	Educational attainment (years of education);
KIRP	cis	rs12049351	0.774	rs6668018	chr1:229629053	T/C	cg11742688	chr1:229674241	ABCB10	-0.38	-5.58	-0.34	6.24e-8	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26321464	chr19:7968588	MAP2K7	-0.55	-6.07	-0.36	4.93e-9	Menopause (age at onset);
KIRP	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg21161173	chr5:140098174	VTRNA1-2	-0.37	-4.89	-0.3	1.81e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg19468946	chr17:37922297	IKZF3	-0.47	-6.43	-0.38	6.55e-10	Self-reported allergy;
KIRP	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg18811423	chr2:55921094	PNPT1	0.69	9.69	0.53	5.01e-19	Metabolic syndrome;
KIRP	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg01620082	chr3:125678407	NA	-1.14	-7.28	-0.42	4.53e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2274273	1.000	rs11621351	chr14:55616740	C/A	cg04306507	chr14:55594613	LGALS3	0.45	6.98	0.41	2.72e-11	Protein biomarker;
KIRP	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.72	-10.96	-0.57	5.06e-23	Hepatocellular carcinoma;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10666761	chr15:55909920	PRTG	0.41	6.58	0.39	2.83e-10	C-reactive protein;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.43	-6.77	-0.4	9.16e-11	Lung cancer;
KIRP	trans	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.19	-0.42	7.67e-12	Bladder cancer;
KIRP	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg17644776	chr2:200775616	C2orf69	0.57	5.26	0.32	3.09e-7	Schizophrenia;
KIRP	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg06740227	chr12:86229804	RASSF9	0.47	6.05	0.36	5.4e-9	Major depressive disorder;
KIRP	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	7.58	0.44	7.06e-13	Retinal vascular caliber;
KIRP	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.61	6.95	0.4	3.31e-11	Schizophrenia;
KIRP	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg27490568	chr2:178487706	NA	0.39	5.17	0.31	4.79e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg24110177	chr3:50126178	RBM5	-0.75	-10.23	-0.55	1.08e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs6743226	0.870	rs67652230	chr2:242235446	A/T	cg10021735	chr2:242295487	FARP2	0.5	6.2	0.37	2.42e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs62413470	1.000	rs12213571	chr6:55957493	A/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08280861	chr8:58055591	NA	0.74	5.86	0.35	1.46e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.53	8.06	0.46	3.41e-14	Itch intensity from mosquito bite;
KIRP	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.65	-9.98	-0.54	6.38e-20	Hepatocellular carcinoma;
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg03115019	chr17:80708279	FN3K	-0.55	-7.4	-0.43	2.18e-12	Glycated hemoglobin levels;
KIRP	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.47	-5.55	-0.33	7.25e-8	Iron status biomarkers;
KIRP	cis	rs787274	0.543	rs4979177	chr9:115644266	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-8.83	-0.49	1.98e-16	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg07234876	chr8:600039	NA	-1.03	-6.29	-0.37	1.47e-9	IgG glycosylation;
KIRP	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg07511934	chr16:89386912	ANKRD11	0.41	5.21	0.32	4.07e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs10751667	0.560	rs10902267	chr11:1007831	T/C	cg06064525	chr11:970664	AP2A2	-0.31	-5.68	-0.34	3.79e-8	Alzheimer's disease (late onset);
KIRP	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.57	-6.63	-0.39	2.09e-10	Aortic root size;
KIRP	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg10397082	chr2:1609832	NA	0.54	4.89	0.3	1.85e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.44	-0.43	1.68e-12	Neuroticism;
KIRP	cis	rs2048656	0.578	rs2090061	chr8:9680978	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-5.56	-0.33	7.06e-8	Schizophrenia;
KIRP	trans	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.89e-11	Bladder cancer;
KIRP	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg23307798	chr14:103986281	CKB	-0.82	-14.25	-0.67	5.24e-34	Body mass index;
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg07402062	chr16:89894098	SPIRE2	0.3	5.78	0.35	2.23e-8	Vitiligo;
KIRP	cis	rs785830	0.538	rs581500	chr9:259331	C/T	cg14500300	chr9:211689	NA	0.41	5.58	0.34	6.36e-8	Platelet distribution width;
KIRP	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.1	-0.36	4.01e-9	Height;
KIRP	cis	rs7546668	1.000	rs4646093	chr1:15821400	G/T	cg21858823	chr1:15850916	CASP9	0.47	5.15	0.31	5.39e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4594175	0.926	rs9323207	chr14:51621908	A/G	cg23942311	chr14:51606299	NA	-0.54	-7.13	-0.41	1.08e-11	Cancer;
KIRP	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.68	7.88	0.45	1.07e-13	Corneal astigmatism;
KIRP	cis	rs10267417	0.589	rs13239768	chr7:19951233	C/G	cg05791153	chr7:19748676	TWISTNB	0.49	4.85	0.3	2.16e-6	Night sleep phenotypes;
KIRP	cis	rs73198271	1.000	rs4841030	chr8:8607011	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-5.85	-0.35	1.58e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg00042356	chr1:8021962	PARK7	0.53	5.54	0.33	7.89e-8	Inflammatory bowel disease;
KIRP	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-8.97	-0.5	8.01e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg08890418	chr1:21044141	KIF17	0.34	5.1	0.31	6.85e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.8	0.6	8.89e-26	Cannabis dependence symptom count;
KIRP	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg01411142	chr8:19674711	INTS10	0.45	4.92	0.3	1.62e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.81	12.53	0.62	3.55e-28	Longevity;Endometriosis;
KIRP	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.58e-36	Height;
KIRP	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.55	-7.28	-0.42	4.56e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg15117754	chr3:10150083	C3orf24	0.51	5.11	0.31	6.46e-7	Alzheimer's disease;
KIRP	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs3026101	0.671	rs1806222	chr17:5289676	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.42	6.23	0.37	1.97e-9	Neuroticism;
KIRP	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg00800038	chr16:89945340	TCF25	-0.61	-5.86	-0.35	1.51e-8	Skin colour saturation;
KIRP	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg00262122	chr8:11665843	FDFT1	0.4	5.07	0.31	7.89e-7	Neuroticism;
KIRP	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg03188948	chr7:1209495	NA	0.66	4.97	0.3	1.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19440553	chr5:93486848	C5orf36	-0.4	-6.06	-0.36	5.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg11130432	chr3:121712080	ILDR1	-0.45	-5.37	-0.32	1.86e-7	Multiple sclerosis;
KIRP	cis	rs62070183	0.938	rs9911168	chr17:31036154	C/T	cg05781649	chr17:31146240	MYO1D	-0.55	-5.62	-0.34	5.18e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	trans	rs6738485	0.552	rs62146770	chr2:106854277	C/T	cg14715136	chr2:108537789	NA	0.38	6.14	0.36	3.21e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20135002	chr11:47629003	NA	-0.44	-4.99	-0.3	1.14e-6	Subjective well-being;
KIRP	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.88	13.76	0.66	2.51e-32	Height;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.66	9.99	0.54	6.24e-20	Monocyte percentage of white cells;
KIRP	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.69	-7.06	-0.41	1.65e-11	Vitiligo;
KIRP	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg12858261	chr2:113808755	IL1F8	0.46	5.34	0.32	2.16e-7	Protein quantitative trait loci;
KIRP	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs7017914	0.934	rs7830550	chr8:71570431	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.4	-4.99	-0.3	1.16e-6	Bone mineral density;
KIRP	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19671926	chr4:122722719	EXOSC9	0.45	5.37	0.32	1.79e-7	Type 2 diabetes;
KIRP	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg03714773	chr7:91764589	CYP51A1	-0.33	-5.15	-0.31	5.41e-7	Breast cancer;
KIRP	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.5	6.5	0.38	4.51e-10	HDL cholesterol levels;
KIRP	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12315302	chr6:26189340	HIST1H4D	0.86	6.07	0.36	4.77e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7116495	0.609	rs2503	chr11:71719403	C/T	cg07596299	chr11:71824057	C11orf51	0.82	5.32	0.32	2.32e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.06	-9.73	-0.53	3.74e-19	Hip circumference adjusted for BMI;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg25140501	chr14:23564641	ACIN1;C14orf119	0.49	6.22	0.37	2.13e-9	Educational attainment;
KIRP	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg13256891	chr4:100009986	ADH5	0.5	6.13	0.36	3.5e-9	Alcohol dependence;
KIRP	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg00852783	chr1:26633632	UBXN11	0.54	7.68	0.44	3.77e-13	Obesity-related traits;
KIRP	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.97	17.87	0.75	2.38e-46	Colorectal adenoma (advanced);
KIRP	cis	rs9488822	0.585	rs195517	chr6:116241584	G/A	cg05304507	chr6:116381966	FRK	0.21	5.39	0.33	1.63e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg06074448	chr4:187884817	NA	-0.77	-12.8	-0.63	4.27e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs200220	0.748	rs201803	chr13:50980202	A/G	cg03830680	chr5:158636697	NA	0.81	6.1	0.36	4.18e-9	Adiponectin levels (BMI-adjusted);
KIRP	cis	rs6782228	0.675	rs6806687	chr3:128391789	C/T	cg18648031	chr3:128330563	NA	-0.25	-5.22	-0.32	3.79e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05597270	chr3:87276383	CHMP2B	0.58	7.23	0.42	6.12e-12	Parkinson's disease;
KIRP	cis	rs17213078	0.602	rs4851926	chr2:106742660	A/G	cg16099169	chr2:106886729	NA	0.41	5.91	0.35	1.16e-8	Facial morphology (factor 23);
KIRP	cis	rs365132	1.000	rs402511	chr5:176434440	G/A	cg16309518	chr5:176445507	NA	-0.89	-13.8	-0.66	1.77e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg01689657	chr7:91764605	CYP51A1	0.44	6.46	0.38	5.65e-10	Breast cancer;
KIRP	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg14346243	chr4:90757452	SNCA	-0.38	-4.85	-0.3	2.14e-6	Neuroticism;
KIRP	cis	rs7116495	1.000	rs7948821	chr11:71652485	G/A	cg11196788	chr11:71737549	NUMA1	0.56	4.99	0.3	1.14e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.96	16.35	0.72	3.45e-41	Breast cancer;
KIRP	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg01831904	chr17:28903510	LRRC37B2	0.83	6.49	0.38	4.77e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg04731861	chr2:219085781	ARPC2	-0.23	-5.92	-0.35	1.08e-8	Colorectal cancer;
KIRP	cis	rs7870753	0.838	rs6477497	chr9:99256570	T/C	cg25260653	chr9:99212216	HABP4	0.55	5.87	0.35	1.44e-8	Height;
KIRP	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17376030	chr22:41985996	PMM1	0.7	7.58	0.43	7.19e-13	Vitiligo;
KIRP	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.79	0.35	2.15e-8	Tonsillectomy;
KIRP	cis	rs1468333	1.000	rs423258	chr5:137475787	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	5.14	0.31	5.67e-7	Resting heart rate;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg20069020	chr7:108166782	PNPLA8	0.49	6.21	0.37	2.28e-9	Educational attainment;
KIRP	cis	rs5753037	0.869	rs3788420	chr22:30376919	T/G	cg27665648	chr22:30112403	NA	0.38	5.29	0.32	2.66e-7	Type 1 diabetes;
KIRP	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-7.27	-0.42	4.9e-12	Longevity;Endometriosis;
KIRP	cis	rs4262150	0.920	rs4478368	chr5:152291650	C/T	cg12297329	chr5:152029980	NA	0.5	7.01	0.41	2.3e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs1465370	0.760	rs10263705	chr7:130027633	C/T	cg03229158	chr7:130009420	NA	-0.33	-4.88	-0.3	1.95e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs6681460	1.000	rs6659968	chr1:67123459	C/T	cg02459107	chr1:67143332	SGIP1	0.49	7.17	0.42	8.92e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11987759	chr7:65425863	GUSB	-0.62	-8.29	-0.47	7.24e-15	Aortic root size;
KIRP	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg16584676	chr17:46985605	UBE2Z	0.45	5.79	0.35	2.17e-8	Type 2 diabetes;
KIRP	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.88	15.86	0.71	1.63e-39	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.65	6.97	0.41	2.9e-11	Response to diuretic therapy;
KIRP	trans	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg24644049	chr4:85504048	CDS1	1.0	6.95	0.41	3.31e-11	Skin colour saturation;
KIRP	trans	rs13170463	0.579	rs6884115	chr5:8036513	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19882132	chr14:106167949	NA	-0.41	-4.88	-0.3	1.92e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.58	-7.34	-0.42	3.02e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg27490568	chr2:178487706	NA	0.47	6.23	0.37	1.98e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13606994	chr1:44402422	ARTN	-0.33	-6.52	-0.38	3.92e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.4	0.51	3.89e-18	Morning vs. evening chronotype;
KIRP	cis	rs16912285	0.688	rs1899541	chr11:24339624	T/C	ch.11.24196551F	chr11:24239977	NA	0.79	9.32	0.51	6.7e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10875746	0.669	rs11168496	chr12:48650855	G/A	cg20731937	chr12:48336164	NA	0.42	5.66	0.34	4.2e-8	Longevity (90 years and older);
KIRP	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.64	-0.52	7.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs554111	0.509	rs495522	chr1:21105994	C/T	cg08890418	chr1:21044141	KIF17	0.58	9.08	0.5	3.64e-17	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.92	12.65	0.63	1.39e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.48	-6.21	-0.37	2.21e-9	Schizophrenia;
KIRP	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.76	9.69	0.53	5.1e-19	Corneal astigmatism;
KIRP	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.99	-15.34	-0.7	1.05e-37	Ulcerative colitis;
KIRP	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.15	-0.37	3.13e-9	Total cholesterol levels;
KIRP	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.38	-5.03	-0.31	9.36e-7	Bipolar disorder;
KIRP	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg07395648	chr5:131743802	NA	0.36	5.25	0.32	3.28e-7	Breast cancer;
KIRP	cis	rs6028335	0.674	rs66486072	chr20:37647882	G/A	cg16355469	chr20:37678765	NA	0.51	5.04	0.31	8.86e-7	Alcohol and nicotine co-dependence;
KIRP	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs17030434	0.911	rs75822357	chr4:154738258	T/C	cg14289246	chr4:154710475	SFRP2	-0.77	-9.34	-0.51	5.92e-18	Electrocardiographic conduction measures;
KIRP	cis	rs35740288	0.752	rs11636138	chr15:86287547	T/A	cg17133734	chr15:86042851	AKAP13	-0.49	-5.24	-0.32	3.44e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg11707556	chr5:10655725	ANKRD33B	0.67	8.48	0.48	2.11e-15	Height;
KIRP	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.47	6.15	0.36	3.16e-9	Platelet count;
KIRP	cis	rs8053891	0.756	rs35259348	chr16:72003952	G/C	cg04254540	chr16:71951199	KIAA0174	-0.52	-5.61	-0.34	5.39e-8	Coronary artery disease;
KIRP	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.79	7.23	0.42	6.16e-12	Mean platelet volume;
KIRP	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-1.05	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.46	6.74	0.39	1.1e-10	Urate levels in lean individuals;
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.55	-6.21	-0.37	2.26e-9	Menopause (age at onset);
KIRP	cis	rs4253772	0.530	rs11090875	chr22:46785301	C/T	cg18190219	chr22:46762943	CELSR1	-0.79	-6.68	-0.39	1.59e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-5.46	-0.33	1.14e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs55675132	0.510	rs12136319	chr1:115298525	T/C	cg12756093	chr1:115239321	AMPD1	0.65	6.41	0.38	7.5e-10	Schizophrenia;
KIRP	cis	rs17321999	1.000	rs111597890	chr2:30492116	G/A	cg05247661	chr2:30472410	LBH	0.78	7.32	0.42	3.48e-12	Systemic lupus erythematosus;
KIRP	trans	rs6901152	0.525	rs4896651	chr6:143691393	A/G	cg19160975	chr7:72936186	BAZ1B	-0.46	-6.09	-0.36	4.39e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.63	0.52	8.12e-19	Lung cancer;
KIRP	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.47	-5.01	-0.3	1.05e-6	Psoriasis;
KIRP	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg02725872	chr8:58115012	NA	-0.45	-5.42	-0.33	1.42e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10849893	0.538	rs4980986	chr12:121914808	A/T	cg01154721	chr12:121881891	KDM2B	-0.44	-5.85	-0.35	1.55e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg07274523	chr3:49395745	GPX1	0.71	8.69	0.48	5.04e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19671926	chr4:122722719	EXOSC9	0.46	5.41	0.33	1.47e-7	Type 2 diabetes;
KIRP	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.77	10.27	0.55	8.25e-21	Menopause (age at onset);
KIRP	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	10.21	0.55	1.22e-20	Psoriasis;
KIRP	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-7.65	-0.44	4.68e-13	Menopause (age at onset);
KIRP	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg26207909	chr14:103986467	CKB	0.41	5.26	0.32	3.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs2718058	0.583	rs2722248	chr7:37845286	G/T	cg15028436	chr7:37888078	TXNDC3	0.5	5.26	0.32	3.07e-7	Alzheimer's disease (late onset);
KIRP	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs6669919	0.647	rs4951753	chr1:211671794	C/T	cg10512769	chr1:211675356	NA	-0.43	-6.06	-0.36	4.95e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.87	0.35	1.42e-8	Tonsillectomy;
KIRP	cis	rs73200209	0.912	rs11612304	chr12:116517704	C/T	cg01776926	chr12:116560359	MED13L	0.48	5.66	0.34	4.12e-8	Total body bone mineral density;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08989290	chr16:615782	NHLRC4	0.41	6.08	0.36	4.62e-9	Height;
KIRP	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg07884673	chr3:53033167	SFMBT1	0.81	6.35	0.38	1.02e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg18431297	chr4:7219810	SORCS2	-0.42	-4.97	-0.3	1.25e-6	Insulin-like growth factors;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15738916	chr2:102314495	MAP4K4	0.71	6.65	0.39	1.83e-10	Lung function (FEV1);
KIRP	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.47	6.49	0.38	4.82e-10	Schizophrenia;
KIRP	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg10253484	chr15:75165896	SCAMP2	-0.54	-6.36	-0.38	9.96e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	9.5	0.52	1.99e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1125355	0.589	rs11681670	chr2:159610292	G/A	cg02251393	chr2:159651559	DAPL1	0.41	4.93	0.3	1.54e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.59	-0.34	6.11e-8	Lung cancer;
KIRP	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg04733989	chr22:42467013	NAGA	0.5	5.96	0.36	8.7e-9	Cognitive function;
KIRP	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.79	-10.96	-0.57	4.99e-23	Osteoporosis;
KIRP	cis	rs7246657	0.722	rs1531549	chr19:38088009	T/C	cg23950597	chr19:37808831	NA	-0.61	-6.55	-0.39	3.33e-10	Coronary artery calcification;
KIRP	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg08975724	chr8:8085496	FLJ10661	0.59	7.29	0.42	4.1e-12	Neuroticism;
KIRP	cis	rs6662572	0.806	rs12047498	chr1:45954632	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.56	6.18	0.37	2.62e-9	Blood protein levels;
KIRP	cis	rs10465746	0.570	rs11163886	chr1:84473445	C/A	cg10977910	chr1:84465055	TTLL7	0.47	5.73	0.34	2.94e-8	Obesity-related traits;
KIRP	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg08992911	chr2:238395768	MLPH	0.56	5.43	0.33	1.38e-7	Prostate cancer;
KIRP	cis	rs6708331	0.517	rs9989836	chr2:70342727	G/A	cg05298696	chr2:70188691	ASPRV1	-0.44	-5.81	-0.35	1.91e-8	Obesity-related traits;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.73	10.98	0.57	4.29e-23	Menarche (age at onset);
KIRP	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.05	-0.36	5.26e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.62e-8	Aortic root size;
KIRP	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg23719950	chr11:63933701	MACROD1	-0.65	-6.26	-0.37	1.71e-9	Mean platelet volume;
KIRP	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg03289416	chr15:75166202	SCAMP2	0.47	6.46	0.38	5.59e-10	Breast cancer;
KIRP	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.44	-5.33	-0.32	2.26e-7	Testicular germ cell tumor;
KIRP	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	8.23	0.46	1.08e-14	Response to antipsychotic treatment;
KIRP	cis	rs290986	1.000	rs290986	chr9:93563536	A/G	cg02608019	chr9:93564028	SYK	0.63	6.1	0.36	4.17e-9	Multiple sclerosis;
KIRP	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.41	-0.51	3.79e-18	Asthma;
KIRP	cis	rs2494938	0.901	rs374337	chr6:40523971	C/G	cg14084896	chr6:40530702	LRFN2	-0.4	-5.08	-0.31	7.6e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21545522	chr1:205238299	TMCC2	0.42	5.65	0.34	4.53e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs2274273	0.588	rs9323285	chr14:55863829	A/C	cg04306507	chr14:55594613	LGALS3	-0.39	-5.38	-0.32	1.74e-7	Protein biomarker;
KIRP	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg07395648	chr5:131743802	NA	0.54	7.79	0.44	1.84e-13	Breast cancer;
KIRP	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17376030	chr22:41985996	PMM1	0.56	6.42	0.38	6.94e-10	Vitiligo;
KIRP	cis	rs7688540	0.771	rs10005733	chr4:292001	C/G	cg11678896	chr4:568514	NA	-0.41	-4.86	-0.3	2.06e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.75	6.75	0.4	1.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.38	6.84	0.4	6.39e-11	Refractive error;
KIRP	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.36	5.41	0.33	1.47e-7	Multiple sclerosis;
KIRP	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg02570527	chr1:10970165	NA	-0.43	-4.96	-0.3	1.32e-6	Body mass index;
KIRP	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.55	7.61	0.44	5.92e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg23682824	chr7:23144976	KLHL7	0.54	6.53	0.38	3.78e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-11.54	-0.59	6.57e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05776053	chr2:74358815	NA	0.48	5.01	0.3	1.05e-6	Gestational age at birth (maternal effect);
KIRP	cis	rs883115	0.846	rs6665204	chr1:224814765	T/C	cg01808320	chr1:224927238	CNIH3	-0.36	-5.14	-0.31	5.73e-7	Cancer;
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.49	-0.43	1.27e-12	Life satisfaction;
KIRP	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.05	-8.12	-0.46	2.22e-14	Mitochondrial DNA levels;
KIRP	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.24	0.42	5.79e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-10.65	-0.56	4.81e-22	Colorectal cancer;
KIRP	cis	rs7677751	0.806	rs4864847	chr4:55071953	G/A	cg17187183	chr4:55093834	PDGFRA	0.78	9.52	0.52	1.72e-18	Corneal astigmatism;
KIRP	cis	rs138229	0.506	rs138233	chr22:50559953	G/A	cg16473166	chr22:50639996	SELO	0.47	5.47	0.33	1.1e-7	Behavioural disinhibition (generation interaction);
KIRP	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.71	8.46	0.47	2.48e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.75	0.4	1.08e-10	Monocyte percentage of white cells;
KIRP	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg17252645	chr8:143867129	LY6D	-0.32	-5.03	-0.31	9.63e-7	Urinary tract infection frequency;
KIRP	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.84	-0.4	6.38e-11	Hemoglobin concentration;
KIRP	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg12405258	chr13:114927641	NA	0.49	7.27	0.42	4.82e-12	Schizophrenia;
KIRP	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg00495681	chr13:53174319	NA	0.45	6.16	0.37	2.98e-9	Lewy body disease;
KIRP	trans	rs1223629	0.826	rs61044747	chr10:96036405	C/A	cg03387497	chr20:17680945	BANF2	0.72	6.51	0.38	4.07e-10	Glucose homeostasis traits;
KIRP	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	5.83	0.35	1.7e-8	Total cholesterol levels;
KIRP	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.18e-8	Skin colour saturation;
KIRP	cis	rs1519814	0.956	rs11774123	chr8:121119274	C/T	cg22335954	chr8:121166405	COL14A1	0.61	6.09	0.36	4.24e-9	Breast cancer;
KIRP	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.6	-0.34	5.66e-8	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00624834	chr18:72163391	CNDP2	0.53	6.71	0.39	1.35e-10	Parkinson's disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08267002	chr2:74741573	TLX2	0.53	6.68	0.39	1.54e-10	Lung cancer in ever smokers;
KIRP	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-7.77	-0.44	2.1e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg08847533	chr14:75593920	NEK9	0.51	6.22	0.37	2.08e-9	IgG glycosylation;
KIRP	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-6.82	-0.4	6.82e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs76288851	0.733	rs11706866	chr3:126452377	G/A	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-4.88	-0.3	1.92e-6	Neuroticism;
KIRP	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg01721255	chr8:58191610	C8orf71	0.56	5.83	0.35	1.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6732160	0.845	rs10203718	chr2:73361515	G/C	cg01422370	chr2:73384389	NA	0.4	5.27	0.32	2.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.75	-9.22	-0.51	1.36e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.43	-0.43	1.8e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.94	0.4	3.51e-11	Platelet count;
KIRP	trans	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg11693508	chr17:37793320	STARD3	0.55	7.09	0.41	1.43e-11	Neuroticism;
KIRP	cis	rs1978968	0.956	rs35972244	chr22:18434038	C/G	cg03078520	chr22:18463400	MICAL3	-0.73	-8.19	-0.46	1.39e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs2235573	0.718	rs4373009	chr22:38490056	A/G	cg19171272	chr22:38449367	NA	-0.54	-7.61	-0.44	5.66e-13	Glioblastoma;Glioma;
KIRP	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-1.32	-10.96	-0.57	5.03e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs897080	0.515	rs1067351	chr2:44669907	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	5.95	0.35	9.07e-9	Height;
KIRP	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.78	-10.53	-0.56	1.18e-21	Aortic root size;
KIRP	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg16586182	chr3:47516702	SCAP	-0.54	-6.49	-0.38	4.63e-10	Birth weight;
KIRP	cis	rs13053817	1.000	rs7290684	chr22:29857664	C/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.43	-5.28	-0.32	2.84e-7	Carotid atherosclerosis in HIV infection;
KIRP	cis	rs13315871	1.000	rs12330157	chr3:58364562	C/T	cg12435725	chr3:58293450	RPP14	-0.5	-5.32	-0.32	2.35e-7	Cholesterol, total;
KIRP	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg08885076	chr2:99613938	TSGA10	-0.36	-5.93	-0.35	1.01e-8	Bipolar disorder;
KIRP	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg23163573	chr2:108905468	SULT1C2	-0.26	-5.01	-0.3	1.03e-6	Blood pressure;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.54	7.45	0.43	1.62e-12	Mean corpuscular volume;
KIRP	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-0.78	-9.95	-0.54	7.81e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.56	7.51	0.43	1.06e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.52	-7.68	-0.44	3.65e-13	IgG glycosylation;
KIRP	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.9	-13.34	-0.65	6.53e-31	Height;
KIRP	cis	rs9834373	0.853	rs9862616	chr3:78491944	A/G	cg06138941	chr3:78371609	NA	-0.37	-4.91	-0.3	1.69e-6	Protein quantitative trait loci;
KIRP	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg07382826	chr16:28625726	SULT1A1	0.45	5.24	0.32	3.46e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-8.52	-0.48	1.64e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.87	9.79	0.53	2.46e-19	Corneal astigmatism;
KIRP	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg24154853	chr7:158122151	PTPRN2	0.39	5.59	0.34	6e-8	Calcium levels;
KIRP	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg20813462	chr7:2646259	IQCE	0.65	6.21	0.37	2.3e-9	Urate levels in lean individuals;
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.81	-0.4	7.64e-11	Monocyte count;
KIRP	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg01522456	chr1:115632236	TSPAN2	0.38	5.04	0.31	8.86e-7	Autism;
KIRP	cis	rs4356932	1.000	rs6819597	chr4:76957171	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.71	10.44	0.55	2.35e-21	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg16586182	chr3:47516702	SCAP	-0.54	-6.59	-0.39	2.6200000000000003e-10	Birth weight;
KIRP	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.29	-0.32	2.66e-7	Coronary artery disease;
KIRP	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	5.6	0.34	5.64e-8	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-6.01	-0.36	6.57e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.16	22.39	0.82	2.78e-61	Exhaled nitric oxide output;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23696891	chr6:138187872	TNFAIP3	0.43	6.16	0.37	2.93e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9815354	1.000	rs9856633	chr3:42013850	C/T	cg03022575	chr3:42003672	ULK4	0.48	5.58	0.34	6.19e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg14703610	chr5:56206110	C5orf35	0.46	6.15	0.37	3.06e-9	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15664640	chr17:80829946	TBCD	0.82	9.58	0.52	1.09e-18	Breast cancer;
KIRP	cis	rs17253792	0.545	rs34446601	chr14:56010586	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.11	0.31	6.5e-7	Putamen volume;
KIRP	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg24488311	chr11:68621650	NA	0.49	5.52	0.33	8.47e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs12517041	1.000	rs6879795	chr5:23305275	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.75	-0.44	2.49e-13	Calcium levels;
KIRP	cis	rs600806	0.850	rs10776806	chr1:109952127	G/A	cg02175308	chr1:109941060	SORT1	-0.26	-4.92	-0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.8	-11.07	-0.58	2.27e-23	Mean corpuscular hemoglobin;
KIRP	cis	rs4650994	0.550	rs12047530	chr1:178543407	A/G	cg12486710	chr1:178512616	C1orf220	-0.25	-5.35	-0.32	1.99e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg13010199	chr12:38710504	ALG10B	0.48	6.38	0.38	8.55e-10	Morning vs. evening chronotype;
KIRP	cis	rs7945718	0.875	rs7105783	chr11:12719794	A/G	cg25843174	chr11:12811716	TEAD1	0.4	7.35	0.42	3e-12	Educational attainment (years of education);
KIRP	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.58	-0.34	6.36e-8	Colorectal cancer;
KIRP	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-7.98	-0.45	5.55e-14	Morning vs. evening chronotype;
KIRP	trans	rs12690897	0.609	rs62460995	chr7:85227412	T/C	cg25658385	chr6:35265341	DEF6	-0.32	-6.07	-0.36	4.78e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg00656387	chr3:40428638	ENTPD3	-0.38	-5.18	-0.31	4.7e-7	Renal cell carcinoma;
KIRP	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.89	14.53	0.68	5.84e-35	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16944159	chr2:62132759	COMMD1	0.57	6.55	0.39	3.41e-10	Smoking initiation;
KIRP	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs220324	0.657	rs2839474	chr21:43570482	T/C	cg08841829	chr21:43638893	ABCG1	-0.42	-4.91	-0.3	1.67e-6	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg03808351	chr9:123631620	PHF19	0.45	6.31	0.37	1.3e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs10865541	0.935	rs4971502	chr2:3414029	A/G	cg11642891	chr2:3452563	TTC15	-0.54	-6.89	-0.4	4.7e-11	Obesity-related traits;
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg22764044	chr5:178986830	RUFY1	0.46	6.58	0.39	2.73e-10	Lung cancer;
KIRP	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.87	-12.12	-0.61	7.88e-27	Platelet distribution width;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.24	-0.47	1.01e-14	Mean corpuscular volume;
KIRP	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg03855291	chr11:639423	DRD4	-0.34	-4.94	-0.3	1.47e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.04	-20.67	-0.8	1.09e-55	Prudent dietary pattern;
KIRP	cis	rs3947	0.906	rs709822	chr8:11702313	C/G	cg00262122	chr8:11665843	FDFT1	-0.47	-5.0	-0.3	1.1e-6	Blood protein levels;
KIRP	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg05305434	chr11:1874049	LSP1	0.4	8.63	0.48	7.54e-16	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.44	-5.84	-0.35	1.67e-8	Height;
KIRP	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg01403660	chr11:68851641	TPCN2	0.6	5.92	0.35	1.09e-8	Blond vs. brown hair color;
KIRP	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg08975724	chr8:8085496	FLJ10661	0.6	8.36	0.47	4.81e-15	Neuroticism;
KIRP	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.38	-0.32	1.76e-7	Breast cancer;
KIRP	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg03563238	chr19:33554763	RHPN2	-0.32	-5.67	-0.34	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.58	7.87	0.45	1.15e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17129028	chr17:74304023	QRICH2	0.52	6.57	0.39	2.96e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-8.2	-0.46	1.3e-14	Total body bone mineral density;
KIRP	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.76	-10.47	-0.56	1.82e-21	Blood metabolite levels;
KIRP	cis	rs2224391	1.000	rs9504369	chr6:5261575	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.93	-0.4	3.7e-11	Height;
KIRP	cis	rs11138902	0.649	rs13287758	chr9:72156599	T/C	cg14123607	chr9:72164709	APBA1	-0.41	-5.0	-0.3	1.11e-6	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-6.66	-0.39	1.76e-10	Obesity-related traits;
KIRP	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.05	0.31	8.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9810890	1.000	rs73196989	chr3:128454638	G/A	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs6545883	0.868	rs2441381	chr2:61798829	C/T	cg15711740	chr2:61764176	XPO1	-0.6	-8.24	-0.47	1.01e-14	Tuberculosis;
KIRP	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.81	-0.4	7.64e-11	Monocyte count;
KIRP	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.56	-5.6	-0.34	5.58e-8	DNA methylation (variation);
KIRP	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg18261050	chr1:119551319	NA	0.49	6.15	0.37	3.1e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.46	6.78	0.4	8.95e-11	Carotid intima media thickness;
KIRP	cis	rs6832769	0.857	rs28377791	chr4:56473181	T/C	cg05960024	chr4:56376020	CLOCK	-0.6	-7.16	-0.42	9.06e-12	Personality dimensions;
KIRP	cis	rs6142102	0.961	rs6120519	chr20:32688113	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	6.84	0.4	6.09e-11	Skin pigmentation;
KIRP	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	0.84	7.54	0.43	8.76e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg26335602	chr6:28129616	ZNF389	-0.43	-4.86	-0.3	2.08e-6	Depression;
KIRP	trans	rs7939886	0.841	rs11227809	chr11:56070386	A/G	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs10861342	1.000	rs12229846	chr12:105553066	A/C	cg23923672	chr12:105501055	KIAA1033	0.86	6.95	0.41	3.23e-11	IgG glycosylation;
KIRP	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.85	12.31	0.62	1.88e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.73	5.91	0.35	1.11e-8	Diabetic retinopathy;
KIRP	cis	rs11264213	0.901	rs636832	chr1:36363475	G/A	cg27506609	chr1:36549197	TEKT2	0.96	9.92	0.53	1.03e-19	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9394169	0.592	rs4304152	chr6:33723290	C/T	cg25922239	chr6:33757077	LEMD2	0.51	6.08	0.36	4.44e-9	Essential tremor;
KIRP	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.4	-5.41	-0.33	1.47e-7	IgG glycosylation;
KIRP	cis	rs643506	1.000	rs647080	chr11:111609174	A/G	cg09085632	chr11:111637200	PPP2R1B	0.53	5.92	0.35	1.08e-8	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14551251	chr3:15901281	ANKRD28	0.48	6.73	0.39	1.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg17143192	chr8:8559678	CLDN23	0.62	7.44	0.43	1.73e-12	Obesity-related traits;
KIRP	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-1.0	-16.64	-0.73	3.76e-42	Height;
KIRP	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg18709589	chr6:96969512	KIAA0776	0.34	5.12	0.31	6.27e-7	Headache;
KIRP	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs9815354	0.812	rs56983571	chr3:41994473	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.51	0.48	1.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.28	-0.32	2.87e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.75	10.88	0.57	9.4e-23	Schizophrenia;
KIRP	cis	rs7005380	0.581	rs869340	chr8:120932612	T/C	cg21645572	chr8:120931649	DEPDC6	-0.52	-7.24	-0.42	5.77e-12	Interstitial lung disease;
KIRP	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg13010199	chr12:38710504	ALG10B	0.5	6.25	0.37	1.79e-9	Morning vs. evening chronotype;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg26359216	chr10:14646455	FAM107B	0.52	6.58	0.39	2.86e-10	DNA methylation (variation);
KIRP	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.69	6.99	0.41	2.52e-11	Vitiligo;
KIRP	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg24459738	chr19:57751996	ZNF805	-0.58	-7.19	-0.42	7.56e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-11.81	-0.6	8.84e-26	Height;
KIRP	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.69	-9.98	-0.54	6.56e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	6.34	0.37	1.09e-9	Lymphocyte counts;
KIRP	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg15832292	chr6:96025679	MANEA	0.76	6.91	0.4	4.05e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg12369402	chr1:90227771	NA	-0.36	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.61	5.47	0.33	1.08e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.42	0.33	1.43e-7	Lung cancer;
KIRP	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.4	-5.6	-0.34	5.68e-8	Endometrial cancer;
KIRP	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.45	-4.99	-0.3	1.12e-6	Parkinson's disease;
KIRP	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.64	-8.39	-0.47	3.95e-15	Metabolic syndrome;
KIRP	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.66	8.76	0.49	3.24e-16	Schizophrenia;
KIRP	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg00343986	chr7:65444356	GUSB	0.49	6.06	0.36	5.03e-9	Aortic root size;
KIRP	trans	rs12043259	0.881	rs6677723	chr1:204826328	A/G	cg11485465	chr5:54518469	NA	0.41	6.46	0.38	5.59e-10	Addiction;
KIRP	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg16898833	chr6:26189333	HIST1H4D	1.07	6.34	0.37	1.11e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2273669	0.504	rs78885459	chr6:109439138	A/C	cg05315195	chr6:109294784	ARMC2	-0.53	-5.12	-0.31	6.11e-7	Prostate cancer;
KIRP	cis	rs7923609	0.846	rs7896518	chr10:65104500	A/G	cg08743896	chr10:65200160	JMJD1C	-0.34	-4.92	-0.3	1.59e-6	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2219968	0.746	rs10957878	chr8:78910939	A/C	cg00738934	chr8:78996279	NA	-0.38	-5.17	-0.31	4.76e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-18.51	-0.76	1.69e-48	Schizophrenia;
KIRP	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.49	-0.38	4.64e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.64	0.34	4.63e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg14847009	chr1:175162515	KIAA0040	-0.24	-5.02	-0.3	9.9e-7	Alcohol dependence;
KIRP	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.71	0.49	4.66e-16	Motion sickness;
KIRP	cis	rs3857067	1.000	rs1588385	chr4:95017161	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.5	-6.64	-0.39	1.95e-10	Breast cancer;
KIRP	cis	rs7221595	0.825	rs9905748	chr17:3968639	C/T	cg05562828	chr17:3906858	NA	0.57	6.55	0.39	3.32e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs2290402	0.536	rs2061846	chr4:852484	A/G	cg21249729	chr9:138392748	C9orf116;MRPS2	0.62	6.36	0.38	9.72e-10	Type 2 diabetes;
KIRP	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg18132916	chr6:79620363	NA	-0.43	-5.85	-0.35	1.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.47	-9.63	-0.52	7.64e-19	Longevity;
KIRP	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg13072238	chr3:49761600	GMPPB	-0.59	-5.62	-0.34	5.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.81	-10.58	-0.56	8.53e-22	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.97	-0.3	1.23e-6	Eosinophil percentage of white cells;
KIRP	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg10755058	chr3:40428713	ENTPD3	0.49	6.63	0.39	2.1e-10	Renal cell carcinoma;
KIRP	cis	rs3755132	0.929	rs3770471	chr2:15770775	C/T	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.62	-6.96	-0.41	3.14e-11	Neuroticism;
KIRP	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.55	-6.63	-0.39	2.09e-10	Monocyte count;
KIRP	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.07	0.46	3.05e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.28	-0.47	7.71e-15	Obesity-related traits;
KIRP	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg08662619	chr6:150070041	PCMT1	0.39	6.45	0.38	5.9e-10	Lung cancer;
KIRP	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg21433313	chr16:3507492	NAT15	0.66	6.92	0.4	3.94e-11	Tuberculosis;
KIRP	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.67	7.68	0.44	3.7e-13	Smoking initiation;
KIRP	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11987759	chr7:65425863	GUSB	-0.62	-8.15	-0.46	1.91e-14	Aortic root size;
KIRP	trans	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg25042112	chr7:64838748	ZNF92	0.58	6.08	0.36	4.54e-9	Pain;
KIRP	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg07777115	chr5:623756	CEP72	-0.52	-5.67	-0.34	3.89e-8	Obesity-related traits;
KIRP	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg20493526	chr2:3714936	ALLC	0.4	4.89	0.3	1.85e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.77	6.86	0.4	5.44e-11	Diabetic retinopathy;
KIRP	cis	rs267939	0.501	rs267959	chr5:10737802	A/G	cg14521931	chr5:10832172	NA	-0.54	-7.16	-0.42	9.03e-12	Gut microbiota (functional units);Ulcerative colitis;
KIRP	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.46	-0.33	1.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.83	-12.6	-0.63	2.05e-28	Body mass index;
KIRP	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.62	-8.44	-0.47	2.68e-15	Obesity-related traits;
KIRP	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg18357526	chr6:26021779	HIST1H4A	0.39	4.88	0.3	1.94e-6	Height;
KIRP	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.67	-6.93	-0.4	3.74e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11825685	0.790	rs80204957	chr11:134545553	A/T	cg06603561	chr11:134479413	NA	-0.64	-5.56	-0.33	6.86e-8	IgG glycosylation;
KIRP	cis	rs2072732	0.821	rs12037307	chr1:2947756	C/A	cg11731671	chr1:2995604	PRDM16	-0.5	-5.64	-0.34	4.55e-8	Plateletcrit;
KIRP	cis	rs494562	0.892	rs544403	chr6:86119116	G/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.75	0.71	4.13e-39	Chronic sinus infection;
KIRP	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg20060108	chr2:102954350	IL1RL1	-0.64	-5.67	-0.34	4.06e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs35740288	0.721	rs4843093	chr15:86237433	G/A	cg10818794	chr15:86012489	AKAP13	-0.41	-4.86	-0.3	2.1e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg23131131	chr22:24373011	LOC391322	0.59	6.96	0.41	3.07e-11	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.68	7.99	0.45	5.34e-14	Menopause (age at onset);
KIRP	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg18904891	chr8:8559673	CLDN23	0.6	6.78	0.4	9.08e-11	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg21775007	chr8:11205619	TDH	-0.48	-5.96	-0.36	8.62e-9	Triglycerides;
KIRP	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg18261050	chr1:119551319	NA	0.5	6.43	0.38	6.74e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.99	-18.4	-0.76	3.83e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg13263691	chr18:77568018	NA	0.52	6.97	0.41	2.94e-11	Schizophrenia;
KIRP	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.5	6.47	0.38	5.3e-10	HDL cholesterol levels;
KIRP	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.85	-11.52	-0.59	7.92e-25	Cognitive function;
KIRP	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.63	0.34	4.83e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg02023728	chr11:77925099	USP35	0.3	4.97	0.3	1.23e-6	Alzheimer's disease (survival time);
KIRP	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02807482	chr3:125708958	NA	-0.55	-5.19	-0.31	4.5e-7	Blood pressure (smoking interaction);
KIRP	cis	rs12049351	0.774	rs10916504	chr1:229655892	A/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.52	-0.33	8.56e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.53	6.85	0.4	5.97e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.71	10.81	0.57	1.52e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.96	13.58	0.65	1.01e-31	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	1.02	18.28	0.76	9.53e-48	Heart rate;
KIRP	cis	rs9309473	1.000	rs10186501	chr2:73697844	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.81	-0.35	1.96e-8	Metabolite levels;
KIRP	cis	rs6016377	0.604	rs1012167	chr20:39159119	C/T	cg22477343	chr20:39312069	NA	-0.39	-5.31	-0.32	2.4e-7	Birth weight;
KIRP	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-9.96	-0.54	7.25e-20	Breast cancer;
KIRP	trans	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.43	-0.52	3.11e-18	Neuroticism;
KIRP	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.65	-7.21	-0.42	6.91e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4740619	0.619	rs10810522	chr9:16031644	C/A	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs3736485	0.966	rs7173880	chr15:51785433	C/A	cg14296394	chr15:51910925	DMXL2	-0.36	-5.42	-0.33	1.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.53	5.65	0.34	4.39e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg24315340	chr6:146058215	EPM2A	-0.38	-4.85	-0.3	2.2e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg13565492	chr6:43139072	SRF	-0.84	-7.66	-0.44	4.16e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg10223061	chr2:219282414	VIL1	0.53	7.75	0.44	2.38e-13	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.51	5.59	0.34	6.15e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs55788414	1.000	rs9921827	chr16:81181869	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.29	-0.47	7.58e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs1056053	0.514	rs3127331	chr6:166572744	C/T	cg11088901	chr6:166572345	T	-0.53	-7.54	-0.43	9.17e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg18595228	chr15:67193261	NA	0.48	4.89	0.3	1.8e-6	Lung cancer (smoking interaction);
KIRP	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg15445000	chr17:37608096	MED1	0.47	5.59	0.34	6.01e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs2414059	0.518	rs3098171	chr15:50771511	C/G	cg08437265	chr15:50716283	USP8	-0.36	-5.12	-0.31	6.31e-7	QT interval;
KIRP	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.26	0.42	4.95e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.55	-5.86	-0.35	1.44e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.43	-0.38	6.77e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.47	0.33	1.12e-7	Melanoma;
KIRP	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.63	8.93	0.49	1.02e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-12.34	-0.62	1.44e-27	Chronic sinus infection;
KIRP	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg05082376	chr22:42548792	NA	0.45	5.62	0.34	5.28e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg09264619	chr17:80180166	NA	-0.4	-5.76	-0.34	2.56e-8	Life satisfaction;
KIRP	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.79	10.19	0.54	1.4e-20	Platelet count;
KIRP	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.76	0.66	2.39e-32	Cognitive function;
KIRP	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.46	5.09	0.31	7.11e-7	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08575122	chr10:33269417	NA	0.49	6.34	0.37	1.11e-9	Parkinson's disease;
KIRP	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg20578329	chr17:80767326	TBCD	0.68	8.12	0.46	2.22e-14	Breast cancer;
KIRP	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.72	-8.31	-0.47	6.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27462988	chr10:115594756	DCLRE1A	0.41	6.36	0.38	9.76e-10	Interleukin-4 levels;
KIRP	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.5	-0.38	4.37e-10	Lung cancer;
KIRP	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.68	-7.87	-0.45	1.1e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg09911534	chr15:67153556	NA	0.43	5.26	0.32	3.08e-7	Lung cancer (smoking interaction);
KIRP	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.44	-5.67	-0.34	4.03e-8	Aortic root size;
KIRP	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.11	0.31	6.32e-7	Smoking behavior;
KIRP	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg04691961	chr3:161091175	C3orf57	-0.44	-5.67	-0.34	4.08e-8	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg05669848	chr5:237993	SDHA	0.47	5.18	0.31	4.68e-7	Breast cancer;
KIRP	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg02023728	chr11:77925099	USP35	0.28	4.92	0.3	1.56e-6	Alzheimer's disease (survival time);
KIRP	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs7582720	1.000	rs78128841	chr2:203663975	C/T	cg08076091	chr2:203926405	NBEAL1	0.85	8.53	0.48	1.52e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs56079296	0.778	rs3805442	chr5:121404880	A/T	cg05256605	chr5:121412184	LOX	-0.48	-5.63	-0.34	4.8e-8	Coronary artery disease;
KIRP	trans	rs76288851	0.799	rs4456816	chr3:126682166	T/C	cg13821433	chr2:26726535	OTOF	0.55	6.37	0.38	9.23e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs6546324	0.625	rs11126138	chr2:67794476	C/T	cg15745817	chr2:67799979	NA	-0.63	-6.64	-0.39	1.99e-10	Endometriosis;
KIRP	cis	rs934734	0.563	rs11695373	chr2:65581200	A/G	cg08085232	chr2:65598271	SPRED2	-0.52	-6.56	-0.39	3.11e-10	Rheumatoid arthritis;
KIRP	cis	rs2273669	0.667	rs17070139	chr6:109358345	C/G	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	6.96	0.41	3.16e-11	Breast cancer;
KIRP	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.47	0.43	1.37e-12	Obesity-related traits;
KIRP	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.59	-7.23	-0.42	6.02e-12	Arsenic metabolism;
KIRP	cis	rs829661	0.793	rs7591110	chr2:30789904	A/G	cg10949345	chr2:30726833	LCLAT1	1.12	14.05	0.67	2.54e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-7.93	-0.45	7.84e-14	Glomerular filtration rate;
KIRP	cis	rs8027181	0.804	rs34661924	chr15:72994564	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.52	7.59	0.44	6.52e-13	Triglyceride levels;
KIRP	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg01346077	chr3:125931526	NA	0.48	7.83	0.45	1.46e-13	Metabolite levels;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.26	0.47	8.85e-15	Personality dimensions;
KIRP	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.7	8.84	0.49	1.84e-16	Height;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.88	15.97	0.71	6.87e-40	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	1.02	18.28	0.76	9.53e-48	Heart rate;
KIRP	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.83	10.45	0.55	2.15e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.89	15.12	0.69	5.55e-37	Mortality in heart failure;
KIRP	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	0.94	7.79	0.44	1.87e-13	Gut microbiota (bacterial taxa);
KIRP	cis	rs6028335	0.674	rs12625983	chr20:37603936	C/T	cg16355469	chr20:37678765	NA	-0.51	-5.0	-0.3	1.09e-6	Alcohol and nicotine co-dependence;
KIRP	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2599510	0.811	rs2754520	chr2:32810293	G/A	cg02381751	chr2:32503542	YIPF4	0.48	5.47	0.33	1.11e-7	Interleukin-18 levels;
KIRP	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg01294253	chr9:136912663	BRD3	0.4	5.27	0.32	2.99e-7	Platelet distribution width;
KIRP	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg08975724	chr8:8085496	FLJ10661	0.66	8.3	0.47	6.88e-15	Neuroticism;
KIRP	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.08	-0.31	7.64e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs59868192	0.850	rs76177165	chr15:42252488	C/T	cg20935245	chr15:42234343	EHD4	-0.55	-5.4	-0.33	1.58e-7	White blood cell count;
KIRP	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.63	8.41	0.47	3.3e-15	Joint mobility (Beighton score);
KIRP	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg09238746	chr17:78121135	EIF4A3	-0.6	-7.32	-0.42	3.58e-12	Yeast infection;
KIRP	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.57	-4.85	-0.3	2.15e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05601917	chr6:125855416	NA	0.33	4.93	0.3	1.48e-6	Brugada syndrome;
KIRP	cis	rs9398803	0.673	rs1262556	chr6:127054435	G/C	cg19875578	chr6:126661172	C6orf173	-0.42	-5.23	-0.32	3.61e-7	Male-pattern baldness;
KIRP	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg10381502	chr11:71823885	C11orf51	-1.2	-7.91	-0.45	8.61e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs1816752	0.774	rs2862895	chr13:24984466	T/A	cg02811702	chr13:24901961	NA	0.4	5.08	0.31	7.35e-7	Obesity-related traits;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16395911	chr14:57700568	EXOC5	0.41	6.53	0.38	3.79e-10	C-reactive protein;
KIRP	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg14703610	chr5:56206110	C5orf35	0.47	6.4	0.38	7.69e-10	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16386425	chr10:429943	DIP2C	0.48	6.6	0.39	2.54e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs4742903	0.904	rs10991187	chr9:106996271	C/T	cg14250997	chr9:106856677	SMC2	0.4	5.36	0.32	1.9e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.73	5.87	0.35	1.43e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7252505	0.892	rs3826907	chr19:33599246	C/T	cg17764715	chr19:33622953	WDR88	0.69	5.88	0.35	1.32e-8	Colorectal cancer;
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.6	5.59	0.34	6.03e-8	Alzheimer's disease;
KIRP	cis	rs1971762	0.527	rs9737721	chr12:54074696	A/T	cg16917193	chr12:54089295	NA	0.85	15.41	0.7	5.74e-38	Height;
KIRP	trans	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-6.89	-0.4	4.65e-11	Obesity-related traits;
KIRP	trans	rs9292195	0.764	rs2081106	chr5:58478599	G/T	cg02027429	chr5:135166467	NA	0.67	6.05	0.36	5.27e-9	Breast cancer;
KIRP	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	cis	rs9400467	0.537	rs17663278	chr6:111504881	A/C	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg23698023	chr8:27181813	PTK2B	0.34	5.0	0.3	1.09e-6	Neuroticism;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.52	6.21	0.37	2.24e-9	Longevity;Endometriosis;
KIRP	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	1.0	15.89	0.71	1.31e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.77	-11.04	-0.58	2.69e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg13332499	chr17:408570	NA	0.63	8.63	0.48	7.7e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.41	1.89e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.56	-0.65	1.18e-31	Monocyte count;
KIRP	trans	rs10851411	0.862	rs2595939	chr15:42791458	C/T	cg24009656	chr6:146759324	NA	0.47	6.19	0.37	2.49e-9	Glucose homeostasis traits;
KIRP	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.92	-12.94	-0.64	1.42e-29	Coronary artery disease;
KIRP	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg23719950	chr11:63933701	MACROD1	-0.67	-6.45	-0.38	5.96e-10	Mean platelet volume;
KIRP	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.76	11.3	0.58	4.04e-24	Monocyte percentage of white cells;
KIRP	cis	rs10073892	0.743	rs10077220	chr5:101652857	T/C	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg17436946	chr4:39699568	UBE2K	0.51	6.71	0.39	1.35e-10	Bladder cancer;
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.64	-0.34	4.64e-8	Longevity;Endometriosis;
KIRP	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.81	10.95	0.57	5.46e-23	Platelet count;
KIRP	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.86	13.48	0.65	2.24e-31	Menarche (age at onset);
KIRP	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.68	6.93	0.4	3.71e-11	Vitiligo;
KIRP	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.92	-13.34	-0.65	6.74e-31	Tonsillectomy;
KIRP	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.64	-8.55	-0.48	1.36e-15	Motion sickness;
KIRP	cis	rs3789045	0.826	rs12040520	chr1:204564762	G/A	cg08641003	chr1:204589008	LRRN2	-0.51	-5.31	-0.32	2.46e-7	Educational attainment (college completion);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11723795	chr14:91975931	SMEK1	0.57	7.17	0.42	8.75e-12	Parkinson's disease;
KIRP	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.68	5.21	0.32	3.99e-7	Major depressive disorder;
KIRP	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.57	7.64	0.44	4.94e-13	Red blood cell count;
KIRP	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.78	7.24	0.42	5.81e-12	Attention deficit hyperactivity disorder;
KIRP	cis	rs3925075	0.531	rs4608351	chr16:31348848	T/C	cg02846316	chr16:31340340	ITGAM	0.46	5.53	0.33	8.23e-8	IgA nephropathy;
KIRP	cis	rs7721647	0.853	rs1813756	chr5:90863382	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs12580194	0.593	rs7971053	chr12:55729947	A/C	cg11794356	chr12:55725991	OR6C3	-0.6	-8.78	-0.49	2.8e-16	Cancer;
KIRP	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.81	0.35	1.91e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs3743162	0.553	rs12915656	chr15:85415580	G/C	cg17507749	chr15:85114479	UBE2QP1	0.58	5.87	0.35	1.4e-8	Alzheimer's disease (age of onset);
KIRP	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg13628971	chr7:2884303	GNA12	0.4	5.18	0.31	4.68e-7	Height;
KIRP	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.46	-7.35	-0.42	2.91e-12	Lung cancer;
KIRP	cis	rs8044868	0.886	rs12325266	chr16:72214858	C/T	cg14768367	chr16:72042858	DHODH	-0.41	-4.91	-0.3	1.65e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.53	-0.56	1.18e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.95	-0.35	9.1e-9	Height;
KIRP	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.4	-5.15	-0.31	5.22e-7	Blood protein levels;
KIRP	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.3	-0.32	2.53e-7	Iron status biomarkers;
KIRP	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.67	8.91	0.49	1.2e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg06598544	chr20:61472147	COL9A3	-0.78	-6.75	-0.4	1.05e-10	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	5.72	0.34	3.08e-8	Renal cell carcinoma;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg07701084	chr6:150067640	NUP43	0.69	9.49	0.52	2.11e-18	Lung cancer;
KIRP	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg26531700	chr6:26746687	NA	0.41	5.57	0.33	6.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg20673091	chr1:2541236	MMEL1	0.68	10.14	0.54	2.01e-20	Ulcerative colitis;
KIRP	cis	rs9815354	0.680	rs73075231	chr3:42051694	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.25	0.42	5.43e-12	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10875746	0.855	rs10875729	chr12:48426726	A/G	cg20731937	chr12:48336164	NA	0.4	5.28	0.32	2.9e-7	Longevity (90 years and older);
KIRP	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.67	10.18	0.54	1.57e-20	Coronary artery disease;
KIRP	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg05347473	chr6:146136440	FBXO30	0.57	8.04	0.46	3.74e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.46	-6.51	-0.38	4.2e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6991838	0.584	rs16932245	chr8:66510045	A/C	cg13398993	chr8:66546079	ARMC1	-0.44	-5.05	-0.31	8.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.54	7.75	0.44	2.39e-13	Sudden cardiac arrest;
KIRP	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg05535760	chr7:792225	HEATR2	-0.43	-5.0	-0.3	1.08e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg13010199	chr12:38710504	ALG10B	0.6	7.9	0.45	9.21e-14	Bladder cancer;
KIRP	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	1.04	13.37	0.65	5.14e-31	Exhaled nitric oxide output;
KIRP	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08109568	chr15:31115862	NA	-0.65	-8.69	-0.48	5.33e-16	Huntington's disease progression;
KIRP	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg00784671	chr22:46762841	CELSR1	-0.8	-7.81	-0.45	1.65e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg23920097	chr1:209922102	NA	-0.46	-6.27	-0.37	1.64e-9	Red blood cell count;
KIRP	cis	rs17744121	0.584	rs17813106	chr21:30499897	A/C	cg23789846	chr21:30375227	NA	0.8	4.87	0.3	1.97e-6	Visceral fat;
KIRP	cis	rs17023223	0.537	rs2794310	chr1:119561930	C/G	cg05756136	chr1:119680316	WARS2	-0.54	-7.32	-0.42	3.55e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg20578329	chr17:80767326	TBCD	-0.47	-5.61	-0.34	5.55e-8	Glycated hemoglobin levels;
KIRP	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.31	0.55	6.2e-21	Parkinson's disease;
KIRP	cis	rs72634030	0.536	rs8073133	chr17:5211074	C/T	cg20802942	chr17:5185005	RABEP1	0.52	4.99	0.3	1.17e-6	Rheumatoid arthritis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14551251	chr3:15901281	ANKRD28	-0.47	-6.28	-0.37	1.48e-9	Myopia;
KIRP	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-7.69	-0.44	3.46e-13	Total body bone mineral density;
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-8.87	-0.49	1.56e-16	Platelet count;
KIRP	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg19468946	chr17:37922297	IKZF3	-0.38	-5.15	-0.31	5.47e-7	Asthma;
KIRP	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.92	-10.7	-0.56	3.58e-22	Body mass index;
KIRP	cis	rs55871839	0.533	rs7813733	chr8:59852429	C/T	cg07426533	chr8:59803705	TOX	0.38	5.33	0.32	2.21e-7	Pneumonia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15793244	chr4:71705590	GRSF1	0.56	7.34	0.42	3.16e-12	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs28489187	0.706	rs12124170	chr1:85811182	A/G	cg16011679	chr1:85725395	C1orf52	0.54	6.52	0.38	3.99e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.47	7.43	0.43	1.76e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.45	5.66	0.34	4.27e-8	Lymphocyte counts;
KIRP	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-7.63	-0.44	5.2e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg06521331	chr12:34319734	NA	-0.54	-6.63	-0.39	2.08e-10	Heart rate;
KIRP	cis	rs17818399	0.781	rs34449783	chr2:46863555	C/T	cg06386533	chr2:46925753	SOCS5	0.51	5.11	0.31	6.61e-7	Height;
KIRP	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.96	16.24	0.72	8.53e-41	Breast cancer;
KIRP	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg00262122	chr8:11665843	FDFT1	-0.42	-5.12	-0.31	6.05e-7	Neuroticism;
KIRP	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.24	11.64	0.6	3.02e-25	Diabetic retinopathy;
KIRP	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg00338735	chr4:53728038	RASL11B	0.43	5.53	0.33	8.27e-8	Optic nerve measurement (cup area);
KIRP	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.8	8.86	0.49	1.66e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg02297831	chr4:17616191	MED28	0.54	6.87	0.4	5.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09130556	chr2:38304030	CYP1B1	0.44	6.37	0.38	9.33e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.26	0.37	1.66e-9	Resistin levels;
KIRP	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg25204440	chr1:209979598	IRF6	0.5	5.08	0.31	7.51e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.17	-0.31	4.92e-7	Metabolite levels;
KIRP	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.48	-0.52	2.31e-18	Response to antipsychotic treatment;
KIRP	cis	rs5167	0.566	rs35080293	chr19:45496624	T/G	cg09555818	chr19:45449301	APOC2	0.39	5.02	0.3	9.86e-7	Blood protein levels;
KIRP	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.48	6.67	0.39	1.72e-10	Red blood cell count;
KIRP	cis	rs7084783	0.519	rs4917395	chr10:105351382	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.44	5.59	0.34	5.97e-8	Fear of pain;
KIRP	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	5.05	0.31	8.75e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg01843034	chr6:37503916	NA	-0.66	-8.35	-0.47	4.88e-15	Cognitive performance;
KIRP	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	cg04338863	chr8:33670619	NA	0.49	6.35	0.38	1.01e-9	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16047663	chr1:201975041	RNPEP	0.48	6.07	0.36	4.76e-9	Interleukin-4 levels;
KIRP	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	9.24	0.51	1.17e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7923609	0.967	rs4454603	chr10:65012750	C/T	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.67	-0.34	4.04e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg12430078	chr2:70121688	SNRNP27	0.46	6.03	0.36	6.07e-9	Inflammatory biomarkers;
KIRP	cis	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.2	0.31	4.22e-7	Leprosy;
KIRP	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg08501292	chr6:25962987	TRIM38	1.01	7.59	0.44	6.75e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.2e-6	Blood protein levels;
KIRP	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.55	0.39	3.31e-10	Rheumatoid arthritis;
KIRP	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg04731861	chr2:219085781	ARPC2	0.27	6.73	0.39	1.2e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs830383	0.584	rs31770	chr5:165496438	C/G	cg13976338	chr5:165423657	NA	0.56	7.22	0.42	6.3e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	1.15	11.06	0.58	2.46e-23	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23196670	chr19:59085019	MZF1;LOC100131691	0.44	6.15	0.37	3.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2150410	0.833	rs7282029	chr21:40570309	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24110177	chr3:50126178	RBM5	0.44	5.66	0.34	4.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	1.17	9.46	0.52	2.59e-18	Cognitive function;
KIRP	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.84	-9.77	-0.53	2.91e-19	White matter hyperintensity burden;
KIRP	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.67e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.61	6.74	0.39	1.13e-10	Red blood cell count;
KIRP	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.6	-9.61	-0.52	8.76e-19	Sense of smell;
KIRP	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.53	-7.36	-0.42	2.74e-12	Vitiligo;
KIRP	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg08822215	chr16:89438651	ANKRD11	-0.45	-5.42	-0.33	1.4e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.62	-8.51	-0.48	1.71e-15	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.81e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-1.15	-10.53	-0.56	1.2e-21	Body mass index;
KIRP	cis	rs6959887	0.962	rs17606698	chr7:35283756	C/T	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	1.97e-9	Birth weight;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg17768439	chr3:50273700	GNAI2	-0.59	-6.5	-0.38	4.46e-10	Menopause (age at onset);
KIRP	trans	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg07817883	chr1:32538562	TMEM39B	1.35	8.67	0.48	6.01e-16	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.67	-9.13	-0.5	2.65e-17	Lymphocyte counts;
KIRP	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg09754948	chr16:28834200	ATXN2L	0.47	5.44	0.33	1.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.46	-0.59	1.23e-24	Monocyte count;
KIRP	cis	rs4663866	0.901	rs35390666	chr2:239193578	C/T	cg16914508	chr2:239161102	PER2	0.72	5.19	0.31	4.37e-7	Irritable bowel syndrome;
KIRP	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.56	-6.36	-0.38	9.99e-10	Initial pursuit acceleration;
KIRP	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg09596252	chr17:78655493	RPTOR	-0.47	-5.47	-0.33	1.13e-7	Fractional excretion of uric acid;
KIRP	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.19	0.37	2.44e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.47	-0.48	2.21e-15	Retinal vascular caliber;
KIRP	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.71	-0.6	1.86e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg21395723	chr22:39101663	GTPBP1	-0.43	-5.36	-0.32	1.9e-7	Menopause (age at onset);
KIRP	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.64	8.51	0.48	1.69e-15	Multiple sclerosis;
KIRP	cis	rs8177876	0.822	rs1410	chr16:81115833	T/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.53	6.94	0.4	3.53e-11	Subjective well-being;Cardiovascular disease risk factors;
KIRP	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	0.6	5.05	0.31	8.68e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.52	-7.31	-0.42	3.7e-12	Asthma;
KIRP	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.45	-6.12	-0.36	3.73e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.72	-9.04	-0.5	4.71e-17	Aortic root size;
KIRP	cis	rs918629	0.761	rs3777165	chr5:95291425	A/G	cg16656078	chr5:95278638	ELL2	0.52	7.49	0.43	1.2e-12	IgG glycosylation;
KIRP	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.47	7.1	0.41	1.3e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-21.74	-0.81	3.43e-59	Prudent dietary pattern;
KIRP	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.66	9.43	0.52	3.23e-18	Colorectal cancer;
KIRP	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg09699651	chr6:150184138	LRP11	0.6	8.37	0.47	4.37e-15	Testicular germ cell tumor;
KIRP	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.43	6.42	0.38	6.78e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	1.17	11.65	0.6	2.78e-25	Red blood cell traits;
KIRP	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.62e-8	Aortic root size;
KIRP	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.19	15.87	0.71	1.58e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4936894	0.500	rs11606880	chr11:124125213	T/C	cg27160556	chr11:124181099	OR8D1	-0.46	-6.53	-0.38	3.8e-10	Aging (time to death);
KIRP	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11987759	chr7:65425863	GUSB	0.5	6.68	0.39	1.54e-10	Aortic root size;
KIRP	cis	rs7130144	0.534	rs74855511	chr11:130460751	G/A	cg26307797	chr11:130446613	NA	-0.63	-5.2	-0.31	4.19e-7	Urate levels in lean individuals;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.45	-0.38	5.87e-10	Lung cancer;
KIRP	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.75	-11.0	-0.57	3.62e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.81	12.21	0.61	4.03e-27	Body mass index;
KIRP	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg25547332	chr5:131281432	NA	0.49	5.41	0.33	1.49e-7	Life satisfaction;
KIRP	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.08	-0.36	4.66e-9	Obesity-related traits;
KIRP	cis	rs7666738	0.546	rs11097591	chr4:98910173	G/A	cg17366294	chr4:99064904	C4orf37	0.38	4.85	0.3	2.22e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg26068271	chr17:76253126	NA	0.56	7.66	0.44	4.26e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15726378	chr11:116643733	BUD13	0.48	6.16	0.37	2.87e-9	DNA methylation (variation);
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs918629	0.530	rs3777200	chr5:95234791	A/G	cg16656078	chr5:95278638	ELL2	0.39	5.72	0.34	3.01e-8	IgG glycosylation;
KIRP	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.43	5.92	0.35	1.08e-8	Total body bone mineral density;
KIRP	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg17120908	chr11:65337727	SSSCA1	-0.5	-4.93	-0.3	1.54e-6	Bone mineral density;
KIRP	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.15e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg01422370	chr2:73384389	NA	0.47	6.28	0.37	1.52e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs397969	0.646	rs1638526	chr17:19848450	T/C	cg13482628	chr17:19912719	NA	0.53	6.47	0.38	5.38e-10	Platelet count;
KIRP	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.45	5.66	0.34	4.19e-8	Childhood ear infection;
KIRP	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg08501292	chr6:25962987	TRIM38	0.9	7.09	0.41	1.46e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg01631408	chr1:248437212	OR2T33	-0.6	-7.68	-0.44	3.68e-13	Common traits (Other);
KIRP	cis	rs1971762	0.931	rs12818213	chr12:54072007	A/G	cg16917193	chr12:54089295	NA	0.69	9.32	0.51	7.05e-18	Height;
KIRP	trans	rs4352251	0.673	rs4851418	chr2:101939128	A/G	cg01941881	chr14:105793310	PACS2	-0.64	-6.43	-0.38	6.77e-10	Adiponectin levels (BMI-adjusted);Adiponectin levels;
KIRP	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg14092571	chr14:90743983	NA	-0.4	-5.37	-0.32	1.81e-7	Mortality in heart failure;
KIRP	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4953911	1.000	rs749048	chr2:135067289	T/G	cg18482303	chr2:135041380	MGAT5	-0.29	-5.57	-0.33	6.82e-8	Multiple sclerosis (severity);
KIRP	cis	rs867371	0.929	rs1045508	chr15:82449906	A/C	cg06066596	chr15:83166174	LOC80154	0.46	5.32	0.32	2.35e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14282407	chr17:7835499	TRAPPC1;CNTROB	0.42	6.24	0.37	1.86e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06544989	chr22:39130855	UNC84B	0.5	7.71	0.44	3.05e-13	Menopause (age at onset);
KIRP	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.73	7.16	0.42	9.06e-12	Menarche (age at onset);
KIRP	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.39	-5.12	-0.31	6.23e-7	Parkinson's disease;
KIRP	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.69	-5.38	-0.32	1.78e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg14338887	chr6:42928500	GNMT	0.37	5.32	0.32	2.34e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.59	6.95	0.4	3.33e-11	Alcohol dependence;
KIRP	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg27147174	chr7:100797783	AP1S1	-0.72	-9.1	-0.5	3.21e-17	Life satisfaction;
KIRP	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.21	-0.32	3.9e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3736485	0.578	rs11638106	chr15:51969295	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-4.98	-0.3	1.19e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs16828019	0.852	rs71648535	chr1:41613750	G/A	cg03387723	chr1:41708464	SCMH1	-0.81	-6.93	-0.4	3.57e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg00908189	chr16:619842	PIGQ	0.89	11.88	0.6	4.97e-26	Height;
KIRP	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg10434728	chr15:90938212	IQGAP1	0.42	7.99	0.45	5.08e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Schizophrenia;
KIRP	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg00495681	chr13:53174319	NA	-0.38	-5.07	-0.31	7.71e-7	Lewy body disease;
KIRP	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	9.8	0.53	2.35e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.55	-0.39	3.42e-10	Response to antipsychotic treatment;
KIRP	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.57	-8.72	-0.49	4.18e-16	Paraoxonase activity;
KIRP	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.45	-0.55	2.24e-21	Chronic sinus infection;
KIRP	cis	rs2241210	0.550	rs7486178	chr12:109980266	G/A	cg08884029	chr12:110012500	MVK;MMAB	-0.41	-5.98	-0.36	7.82e-9	HDL cholesterol levels;
KIRP	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	1.23	11.08	0.58	2.08e-23	Lymphocyte counts;
KIRP	cis	rs6725041	0.819	rs1521661	chr2:213083104	T/A	cg20637307	chr2:213403960	ERBB4	-0.41	-5.35	-0.32	1.99e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.8	9.6	0.52	9.54e-19	Corneal astigmatism;
KIRP	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg01251548	chr11:17372745	DKFZp686O24166	-0.37	-4.92	-0.3	1.6e-6	Type 2 diabetes;
KIRP	cis	rs4356932	1.000	rs4241579	chr4:76947284	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-5.2	-0.31	4.2e-7	Psoriasis;
KIRP	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg20090143	chr19:45452003	APOC2	0.33	5.34	0.32	2.06e-7	Blood protein levels;
KIRP	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.61	-8.54	-0.48	1.45e-15	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09981029	chr16:67943338	PSKH1	-0.49	-6.71	-0.39	1.33e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.4	5.21	0.32	4.06e-7	Melanoma;
KIRP	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	0.94	7.22	0.42	6.29e-12	Obesity-related traits;
KIRP	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00889227	chr1:205173544	DSTYK	-0.38	-5.45	-0.33	1.25e-7	Red blood cell count;
KIRP	cis	rs75804782	0.641	rs59499060	chr2:239341411	C/T	cg08773314	chr2:239334832	ASB1	-0.53	-5.27	-0.32	3.01e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.41	5.98	0.36	7.86e-9	Sitting height ratio;
KIRP	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.78	7.62	0.44	5.48e-13	Red blood cell traits;
KIRP	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg00106254	chr7:1943704	MAD1L1	0.47	5.35	0.32	2.01e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.5	-5.14	-0.31	5.49e-7	Blood metabolite levels;
KIRP	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg05991184	chr2:219186017	PNKD	0.36	5.2	0.31	4.2e-7	Colorectal cancer;
KIRP	cis	rs12210905	0.920	rs9348759	chr6:27290888	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.71	-0.39	1.35e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06381135	chr10:134505548	INPP5A	0.48	6.49	0.38	4.64e-10	Interleukin-4 levels;
KIRP	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg11189052	chr15:85197271	WDR73	-0.55	-5.17	-0.31	4.87e-7	Schizophrenia;
KIRP	cis	rs35300120	0.757	rs1553030	chr1:233652816	A/G	cg23054119	chr1:233659267	NA	-0.35	-5.03	-0.31	9.35e-7	Cognitive function;
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	13.93	0.66	6.54e-33	Platelet count;
KIRP	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg17294928	chr15:75287854	SCAMP5	-0.65	-5.79	-0.35	2.18e-8	Lung cancer;
KIRP	cis	rs367943	0.666	rs7703503	chr5:112962334	A/C	cg12552261	chr5:112820674	MCC	0.43	4.87	0.3	2.02e-6	Type 2 diabetes;
KIRP	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg23719950	chr11:63933701	MACROD1	-0.69	-6.71	-0.39	1.37e-10	Mean platelet volume;
KIRP	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.41	-0.33	1.47e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg22852734	chr6:133119734	C6orf192	1.21	11.18	0.58	9.66e-24	Type 2 diabetes nephropathy;
KIRP	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg09788416	chr12:39539408	NA	0.39	5.26	0.32	3.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs12913538	0.926	rs12438162	chr15:62884463	A/G	cg09983546	chr15:62884068	NA	0.5	6.75	0.4	1.05e-10	Sleep depth;
KIRP	cis	rs17023223	0.537	rs56708249	chr1:119593205	C/G	cg18261050	chr1:119551319	NA	0.52	6.98	0.41	2.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-6.81	-0.4	7.61e-11	Response to antipsychotic treatment;
KIRP	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.6	-6.27	-0.37	1.65e-9	Vitiligo;
KIRP	cis	rs6601327	0.670	rs13259398	chr8:9659935	T/A	cg27411982	chr8:10470053	RP1L1	-0.39	-4.9	-0.3	1.72e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.68	-0.53	5.64e-19	Response to antipsychotic treatment;
KIRP	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.35	-0.32	1.99e-7	Aortic root size;
KIRP	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.77	10.33	0.55	5.31e-21	Huntington's disease progression;
KIRP	cis	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg06521331	chr12:34319734	NA	-0.45	-5.15	-0.31	5.26e-7	Resting heart rate;
KIRP	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.72	7.23	0.42	5.94e-12	Vitiligo;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21515243	chr18:21033072	RIOK3	0.67	8.04	0.46	3.89e-14	Smoking initiation;
KIRP	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg13615516	chr5:77269221	NA	-0.5	-7.62	-0.44	5.65e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg08875078	chr22:50639485	SELO	0.39	5.15	0.31	5.22e-7	Obesity-related traits;
KIRP	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs12545912	0.770	rs12677313	chr8:9543120	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.46	-0.38	5.5e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.69	-0.39	1.52e-10	Menopause (age at onset);
KIRP	cis	rs5753037	0.801	rs1138120	chr22:30229954	T/C	cg27665648	chr22:30112403	NA	0.49	6.53	0.38	3.81e-10	Type 1 diabetes;
KIRP	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-5.86	-0.35	1.45e-8	Huntington's disease progression;
KIRP	cis	rs1476679	0.830	rs6971558	chr7:100079857	A/T	cg19116668	chr7:99932089	PMS2L1	-0.73	-8.75	-0.49	3.53e-16	Alzheimer's disease (late onset);
KIRP	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg04362960	chr10:104952993	NT5C2	0.54	6.52	0.38	3.93e-10	Arsenic metabolism;
KIRP	cis	rs830233	0.866	rs11134404	chr5:165416801	A/T	cg13976338	chr5:165423657	NA	-0.49	-5.54	-0.33	7.62e-8	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.56	4.91	0.3	1.65e-6	Bipolar disorder;
KIRP	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.94	0.45	7.42e-14	Height;
KIRP	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.05	0.41	1.83e-11	Mean platelet volume;
KIRP	cis	rs6991838	0.550	rs7817112	chr8:66537120	C/A	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs859767	0.501	rs1568121	chr2:135406606	G/A	cg25422880	chr2:135218333	TMEM163	0.35	5.17	0.31	4.91e-7	Neuroticism;
KIRP	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg16141378	chr3:129829833	LOC729375	0.6	7.96	0.45	6.5e-14	Neuroticism;
KIRP	trans	rs7160151	0.621	rs7154215	chr14:49809462	C/A	cg24274272	chr17:72278023	DNAI2	0.48	6.09	0.36	4.29e-9	C-reactive protein (red blood cell fatty acid level interaction);
KIRP	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg13256891	chr4:100009986	ADH5	0.5	6.13	0.36	3.5e-9	Alcohol dependence;
KIRP	cis	rs9815354	0.812	rs73069213	chr3:41940590	G/A	cg03022575	chr3:42003672	ULK4	0.78	7.95	0.45	6.91e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs662064	0.962	rs622623	chr1:10555257	C/T	cg19773385	chr1:10388646	KIF1B	0.36	4.93	0.3	1.48e-6	Asthma;
KIRP	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.59	-7.01	-0.41	2.24e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.52	5.58	0.33	6.48e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg20673841	chr7:107026890	COG5	-0.41	-5.07	-0.31	8.01e-7	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg01689657	chr7:91764605	CYP51A1	0.42	6.02	0.36	6.34e-9	Breast cancer;
KIRP	trans	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.78	-11.69	-0.6	2.06e-25	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg16497661	chr14:103986332	CKB	-0.89	-15.52	-0.7	2.39e-38	Body mass index;
KIRP	cis	rs2594989	0.887	rs2454513	chr3:11549596	C/T	cg01796438	chr3:11312864	ATG7	-0.67	-7.82	-0.45	1.53e-13	Circulating chemerin levels;
KIRP	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg15103426	chr22:29168792	CCDC117	0.54	7.01	0.41	2.29e-11	Lymphocyte counts;
KIRP	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.42	5.24	0.32	3.53e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs2072732	0.861	rs72629494	chr1:2951349	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs9687846	0.808	rs9686661	chr5:55861786	C/T	cg15001016	chr5:55860904	NA	-0.31	-5.43	-0.33	1.36e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg19847130	chr8:10466454	RP1L1	-0.37	-5.25	-0.32	3.29e-7	Retinal vascular caliber;
KIRP	cis	rs6939532	0.522	rs2073528	chr6:26375143	G/C	cg14345882	chr6:26364793	BTN3A2	0.32	4.91	0.3	1.67e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg11498726	chr8:26250323	BNIP3L	-0.53	-8.0	-0.45	4.77e-14	Red cell distribution width;
KIRP	cis	rs71403859	0.667	rs12920890	chr16:71787588	G/A	cg08717414	chr16:71523259	ZNF19	-0.86	-7.03	-0.41	2.03e-11	Post bronchodilator FEV1;
KIRP	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg26384229	chr12:38710491	ALG10B	0.48	6.21	0.37	2.27e-9	Morning vs. evening chronotype;
KIRP	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg04398451	chr17:18023971	MYO15A	-0.88	-12.89	-0.63	2.21e-29	Total body bone mineral density;
KIRP	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg12315302	chr6:26189340	HIST1H4D	0.7	5.16	0.31	5.07e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs904251	0.600	rs4714068	chr6:37455642	A/C	cg25019722	chr6:37503610	NA	-0.88	-12.83	-0.63	3.48e-29	Cognitive performance;
KIRP	trans	rs61931739	0.711	rs7968821	chr12:34318351	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.18	0.51	1.81e-17	Morning vs. evening chronotype;
KIRP	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg26022315	chr17:47021804	SNF8	0.41	5.45	0.33	1.23e-7	Type 2 diabetes;
KIRP	cis	rs7481584	0.962	rs11024708	chr11:2968809	A/G	cg25174290	chr11:3078921	CARS	-0.54	-6.09	-0.36	4.27e-9	Calcium levels;
KIRP	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg08126542	chr6:37504118	NA	-0.83	-13.22	-0.64	1.7e-30	Cognitive performance;
KIRP	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.67	-8.43	-0.47	2.85e-15	Age at first birth;
KIRP	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs11209185	0.509	rs9436789	chr1:68441456	G/A	cg22082780	chr1:68452167	NA	0.39	5.57	0.33	6.6e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg11266682	chr4:10021025	SLC2A9	0.39	5.81	0.35	1.92e-8	Blood metabolite levels;
KIRP	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06766273	chr11:62521983	ZBTB3	0.59	6.95	0.41	3.21e-11	Smoking initiation;
KIRP	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.42	7.04	0.41	1.92e-11	Heart rate;
KIRP	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-7.21	-0.42	7.07e-12	Response to antipsychotic treatment;
KIRP	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.66	8.07	0.46	3.08e-14	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs9948	0.521	rs61750875	chr2:97359364	A/G	cg01990225	chr2:97406019	LMAN2L	-0.79	-6.54	-0.38	3.48e-10	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg11752832	chr7:134001865	SLC35B4	0.43	4.91	0.3	1.64e-6	Mean platelet volume;
KIRP	cis	rs4356932	1.000	rs6814817	chr4:76951170	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs55871839	0.559	rs4737526	chr8:59823372	A/G	cg07426533	chr8:59803705	TOX	0.39	5.3	0.32	2.56e-7	Pneumonia;
KIRP	trans	rs12690897	0.704	rs10231543	chr7:85337016	G/T	cg25658385	chr6:35265341	DEF6	-0.35	-6.02	-0.36	6.34e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-5.89	-0.35	1.24e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23903597	chr17:61704154	MAP3K3	-0.61	-7.95	-0.45	6.59e-14	Height;
KIRP	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs4713675	0.604	rs791902	chr6:33702617	G/A	cg25922239	chr6:33757077	LEMD2	-0.42	-4.92	-0.3	1.57e-6	Plateletcrit;
KIRP	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.81	-13.06	-0.64	5.7e-30	Heart rate;
KIRP	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg02725872	chr8:58115012	NA	-0.53	-6.0	-0.36	6.98e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg21605333	chr4:119757512	SEC24D	1.36	9.38	0.51	4.61e-18	Cannabis dependence symptom count;
KIRP	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-4.94	-0.3	1.46e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2273669	0.667	rs11153153	chr6:109356104	A/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg24565620	chr2:194026	NA	-0.64	-7.59	-0.44	6.79e-13	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.97	-0.61	2.52e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg17960426	chr8:142067321	NA	0.49	5.94	0.35	9.44e-9	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.9	-10.87	-0.57	1e-22	Vitamin D levels;
KIRP	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.62	8.73	0.49	4.04e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs7909074	1.000	rs10736831	chr10:45402311	G/A	cg05187965	chr10:45406764	TMEM72	-0.3	-7.04	-0.41	1.9e-11	Mean corpuscular volume;
KIRP	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.51	0.52	1.87e-18	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg24110177	chr3:50126178	RBM5	-0.56	-6.79	-0.4	8.5e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg03808351	chr9:123631620	PHF19	0.39	5.35	0.32	2.03e-7	Rheumatoid arthritis;
KIRP	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg00922110	chr4:57842668	C4orf14	-0.43	-5.59	-0.34	5.96e-8	Response to bleomycin (chromatid breaks);
KIRP	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-5.68	-0.34	3.86e-8	Monocyte percentage of white cells;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05125455	chr11:115069145	CADM1	0.48	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg19875535	chr5:140030758	IK	-0.61	-8.69	-0.48	5.23e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6504950	0.800	rs17745183	chr17:53013595	G/T	cg26251398	chr17:52985966	TOM1L1	0.45	5.68	0.34	3.71e-8	Breast cancer;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.51e-6	Life satisfaction;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg06654118	chr4:1303317	MAEA	0.3	5.4	0.33	1.56e-7	Obesity-related traits;
KIRP	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16318349	chr1:154917307	PBXIP1	-0.34	-5.71	-0.34	3.18e-8	Prostate cancer;
KIRP	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs16828019	0.852	rs34979067	chr1:41543084	G/A	cg08144172	chr1:41849203	NA	0.62	5.13	0.31	5.76e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.56	-0.39	3.16e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.62	-6.38	-0.38	8.94e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7267005	1.000	rs7268813	chr20:34482863	G/C	cg17201900	chr20:34330562	RBM39	0.87	4.9	0.3	1.71e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7714584	1.000	rs73282209	chr5:150174959	G/A	cg22134413	chr5:150180641	NA	1.07	8.61	0.48	8.8e-16	Crohn's disease;
KIRP	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.34	-7.47	-0.43	1.38e-12	Cutaneous nevi;
KIRP	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg07777115	chr5:623756	CEP72	0.61	6.22	0.37	2.11e-9	Obesity-related traits;
KIRP	cis	rs17092148	1.000	rs6060043	chr20:33364584	C/T	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg19847130	chr8:10466454	RP1L1	0.35	5.02	0.3	9.85e-7	Systolic blood pressure;
KIRP	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.42	5.95	0.35	9.28e-9	Ovarian reserve;
KIRP	cis	rs12282928	1.000	rs1905285	chr11:48326024	A/G	cg26585981	chr11:48327164	OR4S1	0.5	6.04	0.36	5.75e-9	Migraine - clinic-based;
KIRP	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.43	7.54	0.43	9.11e-13	Renal cell carcinoma;
KIRP	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	ch.11.340609R	chr11:12831013	TEAD1	0.44	5.43	0.33	1.33e-7	Educational attainment (years of education);
KIRP	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg05484376	chr2:27715224	FNDC4	-0.3	-5.01	-0.3	1.04e-6	Oral cavity cancer;
KIRP	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.76	-9.25	-0.51	1.11e-17	Obesity-related traits;
KIRP	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.26	-0.42	5.06e-12	Aortic root size;
KIRP	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.65	-0.39	1.84e-10	Axial length;
KIRP	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.28	-0.37	1.51e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg13319975	chr6:146136371	FBXO30	0.43	5.73	0.34	2.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg18306943	chr3:40428807	ENTPD3	0.46	6.09	0.36	4.28e-9	Renal cell carcinoma;
KIRP	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg19592336	chr6:28129416	ZNF389	0.5	5.65	0.34	4.33e-8	Depression;
KIRP	cis	rs698813	0.805	rs804877	chr2:44702751	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.97	0.36	8.12e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	trans	rs2048656	0.540	rs55868514	chr8:9680400	T/C	cg16141378	chr3:129829833	LOC729375	0.49	6.39	0.38	8.06e-10	Schizophrenia;
KIRP	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg00409905	chr10:38381863	ZNF37A	-0.59	-7.56	-0.43	7.86e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08638512	chr10:120514811	C10orf46	0.52	6.5	0.38	4.48e-10	Parkinson's disease;
KIRP	cis	rs6142102	0.961	rs761235	chr20:32534408	A/G	cg08999081	chr20:33150536	PIGU	0.51	5.9	0.35	1.21e-8	Skin pigmentation;
KIRP	cis	rs17431357	1.000	rs17431446	chr12:120884291	C/T	cg25045489	chr12:120971538	RNF10	-0.65	-4.98	-0.3	1.2e-6	Insulin resistance/response;
KIRP	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	6.56	0.39	3.07e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.37	-4.92	-0.3	1.56e-6	Iron status biomarkers;
KIRP	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.8	-12.83	-0.63	3.3e-29	Prostate cancer;
KIRP	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg26727032	chr16:67993705	SLC12A4	-0.54	-4.89	-0.3	1.85e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg02023728	chr11:77925099	USP35	0.34	5.41	0.33	1.52e-7	Alzheimer's disease (survival time);
KIRP	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.65	0.44	4.49e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.92	9.69	0.53	4.97e-19	Corneal astigmatism;
KIRP	cis	rs12549025	0.836	rs11784870	chr8:23415524	G/A	cg00892891	chr8:23423734	SLC25A37	0.49	5.03	0.31	9.37e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7172677	1.000	rs11638746	chr15:75403108	A/C	cg14664628	chr15:75095509	CSK	0.53	5.78	0.35	2.25e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg03465714	chr1:152285911	FLG	-0.43	-5.15	-0.31	5.4e-7	Atopic dermatitis;
KIRP	cis	rs4474465	0.850	rs7111004	chr11:78269961	G/A	cg02023728	chr11:77925099	USP35	-0.36	-5.54	-0.33	7.65e-8	Alzheimer's disease (survival time);
KIRP	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.4	5.35	0.32	1.99e-7	Blood protein levels;
KIRP	cis	rs10128264	0.902	rs942797	chr10:80986432	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.34	-5.61	-0.34	5.39e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs12282928	1.000	rs7946076	chr11:48308318	A/G	cg26585981	chr11:48327164	OR4S1	0.51	6.24	0.37	1.9e-9	Migraine - clinic-based;
KIRP	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg21191810	chr6:118973309	C6orf204	-0.42	-4.89	-0.3	1.86e-6	Diastolic blood pressure;
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27144592	chr16:783916	NARFL	0.37	5.11	0.31	6.42e-7	Height;
KIRP	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.71	-10.38	-0.55	3.55e-21	Height;
KIRP	cis	rs4654899	0.571	rs1888759	chr1:21065167	G/A	cg08890418	chr1:21044141	KIF17	0.34	5.08	0.31	7.45e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10128264	0.841	rs2790766	chr10:80960616	A/G	cg18737081	chr10:80999807	ZMIZ1	0.28	5.52	0.33	8.77e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs4006360	0.601	rs7501863	chr17:39249898	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.6	-8.47	-0.48	2.26e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg03999872	chr20:62272968	STMN3	-0.56	-6.57	-0.39	2.91e-10	Atopic dermatitis;
KIRP	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.5	-7.15	-0.41	1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg21427119	chr20:30132790	HM13	-0.54	-6.19	-0.37	2.53e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg04727924	chr7:799746	HEATR2	-0.73	-8.28	-0.47	8.02e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9467160	0.734	rs35901848	chr6:24443640	G/A	cg20631270	chr6:24437470	GPLD1	0.44	5.22	0.32	3.85e-7	Liver enzyme levels;
KIRP	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.42	-5.0	-0.3	1.08e-6	Blood metabolite levels;
KIRP	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.8	9.2	0.51	1.57e-17	Post bronchodilator FEV1;
KIRP	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.93e-11	Neuroticism;
KIRP	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg21858823	chr1:15850916	CASP9	0.53	5.66	0.34	4.11e-8	Systolic blood pressure;
KIRP	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.6	6.34	0.37	1.07e-9	Schizophrenia;
KIRP	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.67	-7.23	-0.42	5.92e-12	Corneal structure;
KIRP	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.48	-5.89	-0.35	1.23e-8	Iron status biomarkers;
KIRP	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.62	-8.14	-0.46	1.92e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	5.81	0.35	1.91e-8	Homoarginine levels;
KIRP	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.22	0.42	6.6e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg19077165	chr18:44547161	KATNAL2	0.45	5.52	0.33	8.47e-8	Personality dimensions;
KIRP	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg18478394	chr8:109455254	TTC35	0.51	6.09	0.36	4.3e-9	Dupuytren's disease;
KIRP	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.32	-0.32	2.3e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.71	-8.84	-0.49	1.87e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg09264619	chr17:80180166	NA	-0.51	-6.07	-0.36	4.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.25	-0.47	9.36e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.25	35.65	0.92	3.67e-99	Myeloid white cell count;
KIRP	cis	rs13315871	1.000	rs6771073	chr3:58458043	G/A	cg12435725	chr3:58293450	RPP14	-0.48	-4.98	-0.3	1.19e-6	Cholesterol, total;
KIRP	cis	rs17453880	0.709	rs73284889	chr5:151928731	G/A	cg12297329	chr5:152029980	NA	-0.56	-8.09	-0.46	2.67e-14	Subjective well-being;
KIRP	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.92	13.42	0.65	3.47e-31	Bladder cancer;
KIRP	cis	rs10924309	0.737	rs6700721	chr1:245854173	C/T	cg00036263	chr1:245852353	KIF26B	-0.53	-7.73	-0.44	2.71e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg00981070	chr1:2046702	PRKCZ	0.45	6.48	0.38	5.02e-10	Height;
KIRP	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg00646381	chr17:77835854	NA	0.56	7.37	0.43	2.64e-12	Electroencephalogram traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24036612	chr5:101633158	SLCO4C1	-0.4	-6.48	-0.38	4.89e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.97	0.5	7.81e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.36	-4.93	-0.3	1.49e-6	Neuroticism;
KIRP	cis	rs365132	0.875	rs2454952	chr5:176376493	C/T	cg16309518	chr5:176445507	NA	-0.81	-12.45	-0.62	6.63e-28	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.43	7.15	0.41	9.7e-12	Heart rate;
KIRP	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.95e-10	Subjective well-being;
KIRP	cis	rs9612	1.000	rs1058	chr19:44268325	C/G	cg08581076	chr19:44259116	C19orf61	0.5	5.43	0.33	1.37e-7	Exhaled nitric oxide output;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09878408	chr6:145050022	UTRN	-0.4	-6.05	-0.36	5.41e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3026101	0.647	rs12603729	chr17:5320685	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.89	0.35	1.27e-8	Body mass index;
KIRP	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg00262122	chr8:11665843	FDFT1	-0.42	-5.17	-0.31	4.87e-7	Retinal vascular caliber;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19770116	chr3:57199524	IL17RD	0.5	7.05	0.41	1.76e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.03	0.41	1.98e-11	Bipolar disorder;
KIRP	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs6496667	0.779	rs8024110	chr15:90947453	A/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-5.07	-0.31	7.74e-7	Rheumatoid arthritis;
KIRP	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg00507259	chr4:95128692	SMARCAD1	0.39	5.02	0.3	9.93e-7	QT interval;
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.17	0.31	4.75e-7	Life satisfaction;
KIRP	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.35	-4.96	-0.3	1.29e-6	Dementia with Lewy bodies;
KIRP	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.49	-11.44	-0.59	1.39e-24	Diabetic kidney disease;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg16405210	chr4:1374714	KIAA1530	-0.43	-5.34	-0.32	2.1e-7	Obesity-related traits;
KIRP	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15645344	chr4:165109574	MARCH1	0.42	6.23	0.37	2e-9	Cancer;
KIRP	cis	rs7172677	0.711	rs8027552	chr15:75439393	A/G	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9612	1.000	rs346524	chr19:44260572	T/C	cg08581076	chr19:44259116	C19orf61	0.6	6.57	0.39	2.99e-10	Exhaled nitric oxide output;
KIRP	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs17221829	0.626	rs10830340	chr11:89413850	C/T	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.23	-0.32	3.68e-7	Anxiety in major depressive disorder;
KIRP	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-0.82	-9.18	-0.51	1.83e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.82	11.98	0.61	2.43e-26	Bladder cancer;
KIRP	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.66	8.99	0.5	6.83e-17	Coronary artery disease;
KIRP	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg18132916	chr6:79620363	NA	-0.42	-5.67	-0.34	4.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.35	5.52	0.33	8.53e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.71	-9.23	-0.51	1.31e-17	Life satisfaction;
KIRP	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg18657303	chr4:1051139	NA	0.53	4.89	0.3	1.86e-6	Recombination rate (females);
KIRP	cis	rs4654899	0.606	rs651085	chr1:21097783	A/G	cg08890418	chr1:21044141	KIF17	-0.34	-5.16	-0.31	5.11e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13326420	chr3:150173062	TSC22D2	0.38	6.07	0.36	4.7e-9	C-reactive protein;
KIRP	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.61	-0.39	2.37e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs16828019	0.852	rs35992757	chr1:41652862	C/T	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.65	8.53	0.48	1.47e-15	Aortic root size;
KIRP	cis	rs1823913	0.637	rs1349938	chr2:192164696	G/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg26681399	chr22:41777847	TEF	0.52	4.95	0.3	1.38e-6	Vitiligo;
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.49e-13	Life satisfaction;
KIRP	cis	rs17041941	1.000	rs35718992	chr2:111998256	A/C	cg23466623	chr2:111982296	NA	0.66	6.3	0.37	1.33e-9	Cognitive function;
KIRP	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.43	-0.38	6.48e-10	Aortic root size;
KIRP	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg10950524	chr7:2139216	MAD1L1	0.31	4.92	0.3	1.6e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.51	-0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs1950626	0.787	rs34857222	chr14:101391354	G/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.76	0.4	9.98e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9398803	0.965	rs9491624	chr6:126679106	A/T	cg19875578	chr6:126661172	C6orf173	0.49	6.46	0.38	5.66e-10	Male-pattern baldness;
KIRP	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg02570527	chr1:10970165	NA	-0.4	-4.92	-0.3	1.59e-6	Body mass index;
KIRP	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg19875535	chr5:140030758	IK	0.69	9.6	0.52	1e-18	Schizophrenia;
KIRP	cis	rs9547996	0.842	rs9547965	chr13:38153888	G/A	cg13634560	chr13:38173852	POSTN	-0.4	-5.57	-0.33	6.59e-8	Diastolic blood pressure;
KIRP	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg01559446	chr3:44596178	ZNF167	-0.36	-5.03	-0.31	9.67e-7	Depressive symptoms;
KIRP	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg06027949	chr8:82754900	SNX16	-0.45	-5.59	-0.34	6.1e-8	Diastolic blood pressure;
KIRP	cis	rs2346160	1.000	rs6937935	chr6:167670223	T/C	cg04673565	chr6:167680447	NA	0.41	5.32	0.32	2.31e-7	Parental extreme longevity (95 years and older);
KIRP	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg10503236	chr1:231470652	EXOC8	-0.52	-7.64	-0.44	4.93e-13	Hemoglobin concentration;
KIRP	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	trans	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg14011486	chr1:26737247	LIN28	0.69	7.4	0.43	2.12e-12	Atrial fibrillation;
KIRP	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.77	13.51	0.65	1.79e-31	Weight;
KIRP	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.85	-14.08	-0.67	1.97e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-7.03	-0.41	2.03e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.59	7.61	0.44	6.01e-13	Monocyte count;
KIRP	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.57	7.53	0.43	9.6e-13	HDL cholesterol;
KIRP	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg17145862	chr1:211918768	LPGAT1	0.68	8.34	0.47	5.37e-15	Crohn's disease;
KIRP	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-6.1	-0.36	4.05e-9	Bone properties (heel);
KIRP	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.43	6.91	0.4	4.07e-11	Testicular germ cell tumor;
KIRP	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.5	-5.91	-0.35	1.16e-8	Bone mineral density;
KIRP	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.55	7.06	0.41	1.67e-11	Corneal structure;
KIRP	cis	rs2479106	0.553	rs3739827	chr9:126690157	A/G	cg16191174	chr9:126692580	DENND1A	-0.55	-6.43	-0.38	6.58e-10	Polycystic ovary syndrome;
KIRP	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.07	0.41	1.58e-11	Height;
KIRP	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.94	16.55	0.73	7.33e-42	Metabolic syndrome;
KIRP	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg02903104	chr8:1507517	DLGAP2	0.35	5.23	0.32	3.66e-7	Lung cancer;
KIRP	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg02153340	chr1:155202674	NA	-0.37	-5.19	-0.31	4.38e-7	Breast cancer;
KIRP	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.61	-7.8	-0.45	1.78e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-6.29	-0.37	1.47e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.4	-0.55	3.11e-21	Monocyte percentage of white cells;
KIRP	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.93	13.81	0.66	1.62e-32	Tonsillectomy;
KIRP	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg18016565	chr1:150552671	MCL1	-0.48	-7.39	-0.43	2.31e-12	Tonsillectomy;
KIRP	cis	rs992157	0.764	rs2891079	chr2:219184691	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.15	0.36	3.18e-9	Colorectal cancer;
KIRP	cis	rs6901250	0.655	rs636252	chr6:117157774	A/G	cg12892004	chr6:117198278	RFX6	-0.39	-6.41	-0.38	7.18e-10	C-reactive protein levels;
KIRP	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.61	-0.34	5.39e-8	Aortic root size;
KIRP	cis	rs240764	0.658	rs4840155	chr6:101253942	G/T	cg09795085	chr6:101329169	ASCC3	-0.43	-5.1	-0.31	6.71e-7	Neuroticism;
KIRP	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.64	-0.34	4.56e-8	Pulmonary function;
KIRP	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg04013166	chr16:89971882	TCF25	0.68	5.7	0.34	3.41e-8	Skin colour saturation;
KIRP	cis	rs10203711	0.901	rs907101	chr2:239564458	T/A	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.49	6.0	0.36	6.99e-9	Multiple sclerosis;
KIRP	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.91	0.66	7.5e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4523957	0.548	rs11869619	chr17:2066150	G/C	cg16513277	chr17:2031491	SMG6	-0.83	-11.55	-0.59	5.93e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg23051811	chr6:44095108	MRPL14;TMEM63B	-0.6	-7.0	-0.41	2.49e-11	Menopause (age at onset);
KIRP	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.48	-5.89	-0.35	1.23e-8	Iron status biomarkers;
KIRP	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.57	-7.09	-0.41	1.4e-11	Uric acid levels;
KIRP	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg22117172	chr7:91764530	CYP51A1	-0.41	-5.76	-0.34	2.52e-8	Breast cancer;
KIRP	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.63	-0.39	2.14e-10	Breast cancer;
KIRP	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06818126	chr11:68850279	TPCN2	0.51	6.25	0.37	1.81e-9	Hair color;
KIRP	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-12.41	-0.62	8.55e-28	Dental caries;
KIRP	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.57	-7.65	-0.44	4.46e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.8	0.4	8.04e-11	Vitiligo;
KIRP	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.96	15.39	0.7	6.99e-38	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.44	6.18	0.37	2.67e-9	Testicular germ cell tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11419670	chr3:57310747	ASB14	0.42	6.18	0.37	2.62e-9	Interleukin-4 levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08551088	chr10:121631655	C10orf119	0.5	6.77	0.4	9.66e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6974574	1.000	rs1403987	chr7:38111941	A/G	cg10754659	chr7:38110151	NA	-0.36	-5.01	-0.3	1.03e-6	Height;
KIRP	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.52	-0.38	4.05e-10	Mood instability;
KIRP	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.35	-6.93	-0.4	3.59e-11	Type 2 diabetes;
KIRP	cis	rs12282928	0.959	rs960640	chr11:48290320	A/G	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.78	0.35	2.3e-8	Motion sickness;
KIRP	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg05220968	chr6:146057943	EPM2A	-0.38	-4.84	-0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13464717	chr19:2269532	OAZ1	0.54	6.86	0.4	5.58e-11	Parkinson's disease;
KIRP	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.48	6.51	0.38	4.09e-10	Testicular germ cell tumor;
KIRP	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg17595323	chr11:93583763	C11orf90	-0.32	-5.36	-0.32	1.9e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01225541	chr5:122110639	SNX2	0.49	6.29	0.37	1.46e-9	Myopia (pathological);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01524359	chr1:46049306	NASP	0.62	6.03	0.36	6.01e-9	Lung function (FEV1);
KIRP	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.34	12.3	0.62	2.1e-27	Diabetic retinopathy;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.52	7.23	0.42	6.19e-12	Testicular germ cell tumor;
KIRP	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg09184832	chr6:79620586	NA	0.57	8.01	0.45	4.64e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	0.763	rs5992137	chr22:18457986	T/C	cg02610425	chr22:18483192	MICAL3	0.37	5.57	0.33	6.79e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs80282103	0.618	rs11819230	chr10:1128812	A/G	cg08668510	chr10:1095578	IDI1	0.79	5.4	0.33	1.54e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	1.05	13.5	0.65	1.89e-31	Exhaled nitric oxide output;
KIRP	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg23484912	chr5:273055	PDCD6	0.59	7.37	0.43	2.66e-12	Pancreatic cancer;
KIRP	cis	rs6561750	1.000	rs9527143	chr13:54433563	C/A	ch.13.53330881F	chr13:54432880	NA	-0.37	-5.04	-0.31	9.08e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.25	0.47	9.45e-15	Eosinophil percentage of white cells;
KIRP	cis	rs9810259	0.508	rs9853146	chr3:12299313	C/T	cg15873301	chr3:12045459	SYN2	0.38	4.96	0.3	1.31e-6	Platelet count;
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg02375832	chr11:62437615	C11orf48	-0.42	-5.69	-0.34	3.61e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-7.21	-0.42	6.88e-12	Self-reported allergy;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg27532560	chr4:187881888	NA	-0.76	-12.94	-0.64	1.51e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08568561	chr7:42834498	NA	0.4	6.39	0.38	8.12e-10	Cancer;
KIRP	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg10017260	chr10:834428	NA	0.53	5.39	0.33	1.65e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs10486003	1.000	rs77457702	chr7:97225156	A/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.65	-5.2	-0.31	4.21e-7	Response to platinum-based agents;
KIRP	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg03714773	chr7:91764589	CYP51A1	-0.34	-5.11	-0.31	6.41e-7	Breast cancer;
KIRP	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	11.26	0.58	5.36e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-1.42	-14.44	-0.68	1.16e-34	Schizophrenia;
KIRP	cis	rs17123764	0.710	rs57191490	chr12:50064889	G/A	cg02054252	chr12:50078554	FMNL3	0.47	4.97	0.3	1.25e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.34	-0.32	2.15e-7	Aortic root size;
KIRP	cis	rs6453429	0.720	rs673752	chr5:78367092	C/T	cg06501366	chr5:78365687	BHMT2;DMGDH	0.31	5.22	0.32	3.8e-7	Urinary metabolites;
KIRP	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg07451762	chr16:28383216	NA	0.42	5.43	0.33	1.34e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	1.03	13.16	0.64	2.73e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.49	-0.33	9.99e-8	Colorectal cancer;
KIRP	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.48	6.15	0.37	3.13e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg17372223	chr3:52568218	NT5DC2	0.33	5.08	0.31	7.32e-7	Electroencephalogram traits;
KIRP	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.86	11.67	0.6	2.51e-25	Response to diuretic therapy;
KIRP	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.78	-10.98	-0.57	4.32e-23	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg08885076	chr2:99613938	TSGA10	-0.37	-5.22	-0.32	3.8e-7	Chronic sinus infection;
KIRP	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.6	-0.39	2.57e-10	Aortic root size;
KIRP	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.46	6.34	0.37	1.09e-9	Coronary artery disease;
KIRP	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg06271696	chr7:157225062	NA	-0.57	-7.61	-0.44	5.78e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs33912345	0.750	rs1254266	chr14:60841222	C/T	cg27398547	chr14:60952738	C14orf39	-0.4	-5.3	-0.32	2.61e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.56	0.52	1.27e-18	Morning vs. evening chronotype;
KIRP	cis	rs2637030	0.542	rs429384	chr5:52908205	A/G	cg06476337	chr5:52856530	NDUFS4	0.55	6.18	0.37	2.65e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg03342759	chr3:160939853	NMD3	0.42	5.0	0.3	1.09e-6	Morning vs. evening chronotype;
KIRP	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.57	-0.39	2.97e-10	Joint mobility (Beighton score);
KIRP	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg15733309	chr7:157513707	PTPRN2	0.54	8.42	0.47	3.16e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs12476592	0.602	rs262478	chr2:63872386	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-4.95	-0.3	1.37e-6	Childhood ear infection;
KIRP	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.48	-6.21	-0.37	2.21e-9	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.85	11.18	0.58	9.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	9.69	0.53	5.09e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.94	15.18	0.7	3.6e-37	Metabolite levels;
KIRP	trans	rs587242	0.866	rs12037267	chr1:96904093	C/T	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.77	11.39	0.59	1.99e-24	Height;
KIRP	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.71	7.14	0.41	1.04e-11	Chronic kidney disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10933691	chr10:28436499	MPP7	0.53	7.03	0.41	2.06e-11	Interleukin-4 levels;
KIRP	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	1.05	8.12	0.46	2.22e-14	Mitochondrial DNA levels;
KIRP	cis	rs8027181	0.839	rs62017600	chr15:73072236	T/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.37	0.43	2.53e-12	Triglyceride levels;
KIRP	cis	rs11673344	0.642	rs55926714	chr19:37798876	A/G	cg14683738	chr19:37701593	ZNF585B	-0.42	-4.89	-0.3	1.79e-6	Obesity-related traits;
KIRP	cis	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg21546286	chr11:48923668	NA	0.43	5.4	0.33	1.57e-7	HDL cholesterol;
KIRP	cis	rs2533291	0.541	rs1242784	chr7:157498516	C/T	cg20030024	chr7:157442494	PTPRN2	-0.58	-5.38	-0.32	1.72e-7	Inflammatory skin disease;
KIRP	cis	rs2970992	0.764	rs12712081	chr2:101329232	T/C	cg01042948	chr2:101319752	NA	0.42	5.91	0.35	1.15e-8	Educational attainment;
KIRP	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg00981070	chr1:2046702	PRKCZ	-0.42	-6.77	-0.4	9.61e-11	Height;
KIRP	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.41	-0.33	1.48e-7	Coronary artery disease;
KIRP	cis	rs7246657	0.722	rs2927747	chr19:38159530	C/T	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs1843834	0.624	rs2396110	chr2:225560219	A/G	cg22455342	chr2:225449267	CUL3	0.49	5.45	0.33	1.24e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg09699651	chr6:150184138	LRP11	0.46	5.87	0.35	1.42e-8	Lung cancer;
KIRP	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg00629928	chr5:358741	AHRR	0.47	5.06	0.31	8.37e-7	Breast cancer;
KIRP	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08280861	chr8:58055591	NA	0.69	6.26	0.37	1.74e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12057741	chr8:119964124	TNFRSF11B	0.45	6.34	0.37	1.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.62	7.0	0.41	2.48e-11	Neutrophil percentage of white cells;
KIRP	cis	rs17065868	0.764	rs73188717	chr13:45019390	G/C	cg10246903	chr13:45222710	NA	0.51	4.91	0.3	1.66e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21643547	chr1:205240462	TMCC2	-0.88	-14.11	-0.67	1.62e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.72	9.47	0.52	2.5e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg00784671	chr22:46762841	CELSR1	-0.82	-8.14	-0.46	2.02e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg24565620	chr2:194026	NA	-0.68	-7.61	-0.44	5.83e-13	Blood protein levels;
KIRP	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.86	-11.23	-0.58	6.91e-24	Cognitive function;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.59e-8	Life satisfaction;
KIRP	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	5.39	0.33	1.61e-7	Breast cancer;
KIRP	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs35000415	0.873	rs34748780	chr7:128700153	A/G	cg19972273	chr7:128594194	NA	0.8	6.14	0.36	3.35e-9	Systemic lupus erythematosus;
KIRP	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg11569703	chr11:65557185	OVOL1	0.37	5.69	0.34	3.54e-8	Eosinophil percentage of white cells;
KIRP	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg20636351	chr8:55087400	NA	-0.53	-6.35	-0.38	1.02e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg05041795	chr8:1365749	NA	-0.48	-5.02	-0.3	9.95e-7	Triglycerides;
KIRP	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.84	14.24	0.67	5.69e-34	Dental caries;
KIRP	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.35	-0.32	1.97e-7	Neuroticism;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13723693	chr17:80656731	RAB40B	-0.53	-6.9	-0.4	4.26e-11	Myopia;
KIRP	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.56	7.3	0.42	3.93e-12	Eye color traits;
KIRP	cis	rs11997175	0.692	rs6995075	chr8:33673816	G/A	ch.8.33884649F	chr8:33765107	NA	0.47	5.91	0.35	1.14e-8	Body mass index;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10457504	chr17:19281708	MAPK7	0.46	6.12	0.36	3.68e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg19773385	chr1:10388646	KIF1B	-0.69	-9.1	-0.5	3.13e-17	Hepatocellular carcinoma;
KIRP	cis	rs35995292	0.534	rs2392604	chr7:38918012	C/T	cg19327137	chr7:38886074	VPS41	0.82	13.15	0.64	2.77e-30	Subjective well-being (multi-trait analysis);
KIRP	cis	rs8044868	0.530	rs9924964	chr16:72085561	T/A	cg16558253	chr16:72132732	DHX38	-0.39	-5.11	-0.31	6.4e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.13	0.31	5.95e-7	Body mass index;
KIRP	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg06050784	chr16:88016603	BANP	0.42	5.19	0.31	4.35e-7	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs5753037	0.869	rs5997546	chr22:30259342	A/G	cg01021169	chr22:30184971	ASCC2	-0.39	-5.17	-0.31	4.89e-7	Type 1 diabetes;
KIRP	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.59	-0.56	7.83e-22	Menopause (age at onset);
KIRP	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.49	-6.25	-0.37	1.77e-9	Body mass index;
KIRP	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg13047869	chr3:10149882	C3orf24	0.54	5.26	0.32	3.14e-7	Alzheimer's disease;
KIRP	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg14580859	chr9:123691850	NA	0.34	5.04	0.31	9.1e-7	Rheumatoid arthritis;
KIRP	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.41	-6.39	-0.38	8.31e-10	Body mass index;
KIRP	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg24253500	chr15:84953950	NA	-0.62	-6.61	-0.39	2.35e-10	Schizophrenia;
KIRP	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs2554380	0.800	rs8032414	chr15:84395969	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.5	-7.15	-0.41	1.02e-11	Height;
KIRP	cis	rs7719624	0.756	rs6880837	chr5:135396669	A/G	cg16684184	chr5:135415129	NA	0.38	5.84	0.35	1.63e-8	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs12693043	0.727	rs10172858	chr2:175417011	C/T	cg11778734	chr2:175439522	WIPF1	0.56	8.22	0.46	1.21e-14	Urate levels (BMI interaction);
KIRP	cis	rs860295	0.702	rs12067371	chr1:155437669	C/T	cg02153340	chr1:155202674	NA	-0.52	-7.54	-0.43	9.27e-13	Body mass index;
KIRP	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg18225595	chr11:63971243	STIP1	0.59	5.34	0.32	2.07e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6686643	0.868	rs9333471	chr1:165619712	A/G	cg16553119	chr1:165599451	MGST3	-0.39	-4.99	-0.3	1.13e-6	Total ventricular volume;
KIRP	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.83	0.35	1.7e-8	Coronary artery disease;
KIRP	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.62	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15457276	chr19:4832024	TICAM1	-0.44	-6.34	-0.37	1.09e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4494114	1.000	rs9439082	chr1:39344055	G/A	cg25970120	chr1:39325951	RRAGC	-0.4	-5.03	-0.31	9.38e-7	Blood protein levels;
KIRP	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.06e-10	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.85	0.4	5.9e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.57	7.44	0.43	1.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg07138768	chr7:917805	C7orf20	0.32	5.26	0.32	3.17e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.28	-21.72	-0.81	3.87e-59	Breast cancer;
KIRP	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg06197360	chr20:60970103	CABLES2	-0.49	-5.54	-0.33	7.69e-8	Colorectal cancer;
KIRP	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg23601095	chr6:26197514	HIST1H3D	0.7	6.72	0.39	1.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg02527881	chr3:46936655	PTH1R	0.36	4.92	0.3	1.58e-6	Colorectal cancer;
KIRP	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.72	-8.57	-0.48	1.14e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.59	6.86	0.4	5.48e-11	Pancreatic cancer;
KIRP	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.61	-0.44	5.99e-13	Joint mobility (Beighton score);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00973424	chr1:164325910	NA	-0.41	-6.56	-0.39	3.13e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg25036284	chr2:26402008	FAM59B	-0.6	-5.98	-0.36	7.66e-9	Gut microbiome composition (summer);
KIRP	trans	rs1223629	0.826	rs74231354	chr10:96038457	C/A	cg03387497	chr20:17680945	BANF2	0.73	6.34	0.37	1.11e-9	Glucose homeostasis traits;
KIRP	cis	rs12210905	0.688	rs72845028	chr6:27528408	T/C	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.4e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.6	-6.52	-0.38	4.04e-10	Hypospadias;
KIRP	cis	rs4561483	0.583	rs9925010	chr16:11956668	A/G	cg08843971	chr16:11963173	GSPT1	0.54	7.65	0.44	4.41e-13	Testicular germ cell tumor;
KIRP	cis	rs12549025	0.782	rs11781222	chr8:23389571	A/G	cg00472375	chr8:23315376	ENTPD4	0.58	5.28	0.32	2.79e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs35740288	0.822	rs17574774	chr15:86233370	C/T	cg17133734	chr15:86042851	AKAP13	0.49	5.4	0.33	1.55e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.47	6.9	0.4	4.26e-11	Lymphocyte counts;
KIRP	cis	rs17123764	1.000	rs59261129	chr12:49951377	C/T	cg20471783	chr12:50157085	TMBIM6	0.4	5.4	0.33	1.53e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs12517041	1.000	rs6889753	chr5:23304559	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	0.82	7.48	0.43	1.35e-12	Calcium levels;
KIRP	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.73	8.6	0.48	9.58e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04559178	chr12:29301719	NA	0.5	6.49	0.38	4.59e-10	Smoking initiation;
KIRP	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs4262150	0.667	rs13160798	chr5:152276252	A/G	cg12297329	chr5:152029980	NA	0.46	6.41	0.38	7.27e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs258892	0.842	rs10060065	chr5:72065830	T/C	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg11970804	chr8:8084126	NA	0.39	5.11	0.31	6.56e-7	Neuroticism;
KIRP	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.55	17.71	0.75	8.22e-46	Opioid sensitivity;
KIRP	cis	rs4959270	0.869	rs55776749	chr6:452732	A/G	cg13299325	chr6:447777	NA	0.27	5.21	0.32	3.97e-7	Limited cutaneous systemic scleroderma;
KIRP	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.76	-12.01	-0.61	1.92e-26	Rheumatoid arthritis;
KIRP	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.91	-11.26	-0.58	5.36e-24	Menarche (age at onset);
KIRP	cis	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg06585982	chr3:143692056	C3orf58	-0.53	-6.65	-0.39	1.89e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.08	-0.41	1.47e-11	Vitiligo;
KIRP	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg17554472	chr22:41940697	POLR3H	-0.63	-7.04	-0.41	1.89e-11	Vitiligo;
KIRP	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg07884673	chr3:53033167	SFMBT1	-0.56	-5.27	-0.32	2.98e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg00360474	chr6:37504404	NA	-0.44	-6.28	-0.37	1.48e-9	Cognitive performance;
KIRP	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg17145862	chr1:211918768	LPGAT1	0.76	10.56	0.56	9.48e-22	Leprosy;
KIRP	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg21640587	chr11:117668038	DSCAML1	0.44	6.57	0.39	3.02e-10	Myopia;
KIRP	cis	rs35740288	0.770	rs17570529	chr15:86125607	A/T	cg17133734	chr15:86042851	AKAP13	-0.49	-5.31	-0.32	2.47e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg23131131	chr22:24373011	LOC391322	-0.69	-8.95	-0.5	9.13e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.71	-11.44	-0.59	1.39e-24	Itch intensity from mosquito bite;
KIRP	cis	rs10073892	0.789	rs7356787	chr5:101806886	A/G	cg19774478	chr5:101632501	SLCO4C1	-0.67	-6.49	-0.38	4.62e-10	Cognitive decline (age-related);
KIRP	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg12623918	chr2:306882	NA	0.43	5.38	0.32	1.77e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg25019033	chr10:957182	NA	-0.58	-7.19	-0.42	7.94e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.46	0.33	1.14e-7	Blood protein levels;
KIRP	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.77	-0.4	9.28e-11	Systolic blood pressure;
KIRP	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.47	9.75	0.53	3.36e-19	Schizophrenia;
KIRP	cis	rs4262150	0.544	rs4246030	chr5:151906048	C/T	cg12297329	chr5:152029980	NA	-0.71	-8.8	-0.49	2.53e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg14458575	chr2:238380390	NA	-0.54	-7.11	-0.41	1.23e-11	Prostate cancer;
KIRP	cis	rs662064	0.962	rs683864	chr1:10561954	T/C	cg19773385	chr1:10388646	KIF1B	-0.39	-5.06	-0.31	8.16e-7	Asthma;
KIRP	cis	rs7851660	0.809	rs7037324	chr9:100658318	A/G	cg13688889	chr9:100608707	NA	-0.67	-8.45	-0.47	2.66e-15	Strep throat;
KIRP	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.46	-5.88	-0.35	1.32e-8	Coronary artery disease;
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-9.07	-0.5	3.9e-17	Platelet count;
KIRP	cis	rs6988636	0.710	rs62521805	chr8:124159200	C/T	cg23067535	chr8:124195133	FAM83A	-0.61	-5.55	-0.33	7.5e-8	Urinary uromodulin levels;
KIRP	cis	rs7017914	0.967	rs6987007	chr8:71600942	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.65e-7	Bone mineral density;
KIRP	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg22549504	chr19:17448937	GTPBP3	0.49	5.36	0.32	1.92e-7	Systemic lupus erythematosus;
KIRP	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.45	-6.32	-0.37	1.2e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs8070740	0.836	rs4444392	chr17:5324588	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.31	0.42	3.65e-12	Menopause (age at onset);
KIRP	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18364779	chr6:26104403	HIST1H4C	0.39	5.17	0.31	4.92e-7	Schizophrenia;
KIRP	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.95	-0.35	9.15e-9	Pulmonary function;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg09597638	chr17:3907349	NA	0.82	16.53	0.73	9e-42	Type 2 diabetes;
KIRP	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs9443189	1.000	rs6905047	chr6:76498109	C/T	cg01950844	chr6:76311363	SENP6	0.53	5.22	0.32	3.86e-7	Prostate cancer;
KIRP	cis	rs7113874	0.578	rs35807094	chr11:8550345	T/C	cg08015107	chr11:8618950	NA	-0.72	-8.83	-0.49	1.99e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.88	-12.16	-0.61	6.02e-27	Obesity-related traits;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.59	-10.35	-0.55	4.51e-21	Lung cancer;
KIRP	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.57	7.19	0.42	7.65e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26413987	chr12:121124951	MLEC	0.52	6.48	0.38	5.08e-10	Parkinson's disease;
KIRP	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs12949688	0.601	rs4793573	chr17:55834533	C/T	cg12582317	chr17:55822272	NA	0.39	5.84	0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs2154427	0.655	rs844996	chr21:34041526	C/T	cg03746930	chr21:34165763	C21orf62;C21orf49	0.63	5.22	0.32	3.8e-7	Bilirubin levels;
KIRP	cis	rs3789045	1.000	rs12046747	chr1:204593696	G/A	cg08641003	chr1:204589008	LRRN2	-0.66	-7.09	-0.41	1.41e-11	Educational attainment (college completion);
KIRP	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.54	7.65	0.44	4.53e-13	Schizophrenia;
KIRP	cis	rs10510057	0.592	rs2917941	chr10:121328421	A/T	cg06765389	chr10:121379685	NA	0.48	7.55	0.43	8.41e-13	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs2733310	0.843	rs997683	chr15:57541904	A/C	cg13626582	chr15:57592083	LOC283663	-0.27	-6.18	-0.37	2.71e-9	Mean platelet volume;
KIRP	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.48	6.18	0.37	2.61e-9	Blood metabolite levels;
KIRP	cis	rs13102973	0.965	rs13106621	chr4:135854975	A/T	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.12e-16	Subjective well-being;
KIRP	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	8.29	0.47	7.19e-15	Bipolar disorder;
KIRP	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg07777115	chr5:623756	CEP72	-0.58	-5.72	-0.34	3.01e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.31	-0.47	6.39e-15	Coronary artery disease;
KIRP	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.54	7.16	0.42	9.43e-12	Primary sclerosing cholangitis;
KIRP	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg12560992	chr17:57184187	TRIM37	0.59	5.3	0.32	2.57e-7	Cognitive test performance;
KIRP	cis	rs2274273	0.624	rs66464079	chr14:55766164	G/T	cg04306507	chr14:55594613	LGALS3	0.42	5.71	0.34	3.27e-8	Protein biomarker;
KIRP	trans	rs2281597	0.605	rs2358511	chr1:34288232	A/G	cg19991458	chr15:67417651	SMAD3	-0.49	-6.31	-0.37	1.3e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg00405596	chr8:11794950	NA	0.54	7.24	0.42	5.65e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7808935	0.958	rs10486567	chr7:27976563	G/A	cg22168087	chr7:27702803	HIBADH	0.63	6.85	0.4	6.01e-11	Prostate cancer;
KIRP	trans	rs6919346	0.652	rs9365168	chr6:160940120	A/G	cg01413548	chr6:11656844	NA	0.38	6.27	0.37	1.62e-9	Lp (a) levels;
KIRP	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.14	-0.36	3.28e-9	Metabolite levels;
KIRP	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.55	-7.33	-0.42	3.38e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.48	6.24	0.37	1.89e-9	Childhood ear infection;
KIRP	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-4.85	-0.3	2.24e-6	Blood protein levels;
KIRP	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs911119	1.000	rs6048956	chr20:23609301	C/T	cg16589663	chr20:23618590	CST3	0.62	5.94	0.35	9.5e-9	Chronic kidney disease;
KIRP	cis	rs7011049	0.673	rs72640835	chr8:53828012	T/C	cg26025543	chr8:53854495	NA	0.48	4.97	0.3	1.25e-6	Systolic blood pressure;
KIRP	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg23594656	chr7:65796392	TPST1	0.53	8.32	0.47	6.29e-15	Aortic root size;
KIRP	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.23	-6.1	-0.36	4.1e-9	Mean corpuscular volume;
KIRP	cis	rs981844	0.775	rs17371468	chr4:154759826	G/C	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.72	-8.94	-0.5	9.63e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg04226714	chr8:49833948	SNAI2	-0.45	-6.29	-0.37	1.46e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.31	0.55	6.12e-21	Mean corpuscular hemoglobin;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14932796	chr17:55038330	COIL	0.47	6.12	0.36	3.69e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.62	-7.56	-0.43	7.83e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9323205	0.798	rs2999392	chr14:51655145	A/G	cg23942311	chr14:51606299	NA	-0.61	-7.84	-0.45	1.38e-13	Cancer;
KIRP	cis	rs8084125	1.000	rs62105183	chr18:74951589	C/T	cg18461021	chr18:74961002	GALR1	0.61	5.85	0.35	1.6e-8	Obesity-related traits;
KIRP	cis	rs6681460	0.866	rs996123	chr1:67025343	T/C	cg02459107	chr1:67143332	SGIP1	0.42	5.85	0.35	1.52e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.23	-0.37	1.98e-9	Lung cancer;
KIRP	cis	rs12900413	0.562	rs11631438	chr15:90300620	C/T	cg24650279	chr15:90327240	NA	-0.42	-5.2	-0.31	4.27e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1847505	0.609	rs9539004	chr13:61587049	T/C	cg25164009	chr13:61490935	NA	-0.58	-7.29	-0.42	4.1e-12	Polychlorinated biphenyl levels;
KIRP	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.91	13.43	0.65	3.34e-31	Mean platelet volume;
KIRP	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.88	0.4	4.98e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16282993	chr6:26204765	HIST1H4E	0.9	6.03	0.36	5.96e-9	P wave terminal force;
KIRP	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg05347473	chr6:146136440	FBXO30	0.61	8.74	0.49	3.82e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	0.94	12.26	0.62	2.8e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg26513180	chr16:89883248	FANCA	0.54	6.81	0.4	7.35e-11	Vitiligo;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	7.12	0.41	1.17e-11	Menarche (age at onset);
KIRP	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-0.91	-12.32	-0.62	1.72e-27	Blood trace element (Zn levels);
KIRP	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.53	6.79	0.4	8.31e-11	Coronary artery disease;
KIRP	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	-0.6	-7.38	-0.43	2.36e-12	Inflammatory bowel disease;
KIRP	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg03808351	chr9:123631620	PHF19	0.41	5.53	0.33	8.18e-8	Rheumatoid arthritis;
KIRP	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg20387954	chr3:183756860	HTR3D	0.64	9.47	0.52	2.49e-18	Anterior chamber depth;
KIRP	cis	rs55986470	0.817	rs10177049	chr2:239422169	G/T	cg18131467	chr2:239335373	ASB1	-0.65	-5.59	-0.34	6.07e-8	Chronotype;
KIRP	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-7.21	-0.42	6.88e-12	Self-reported allergy;
KIRP	trans	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7712401	0.601	rs417268	chr5:122345012	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.41	-0.33	1.48e-7	Mean platelet volume;
KIRP	cis	rs7923609	0.875	rs10822143	chr10:64887856	C/T	cg01631684	chr10:65280961	REEP3	-0.5	-5.89	-0.35	1.24e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg05805236	chr11:65401703	PCNXL3	-0.54	-6.93	-0.4	3.65e-11	Acne (severe);
KIRP	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2671245	0.565	rs80146477	chr1:56133399	C/G	cg11523071	chr1:56160889	NA	0.43	6.44	0.38	6.38e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.57	7.04	0.41	1.89e-11	Pancreatic cancer;
KIRP	cis	rs9488822	0.662	rs195532	chr6:116253765	T/G	cg18764771	chr6:116381957	FRK	0.18	5.08	0.31	7.52e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8084125	0.765	rs62105164	chr18:74944367	C/T	cg26065057	chr18:74961000	GALR1	0.74	7.55	0.43	8.25e-13	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs7809950	0.798	rs2701684	chr7:107299527	C/T	cg23024343	chr7:107201750	COG5	0.39	5.94	0.35	9.75e-9	Coronary artery disease;
KIRP	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.1	-0.41	1.31e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg23985595	chr17:80112537	CCDC57	-0.37	-5.5	-0.33	9.65e-8	Life satisfaction;
KIRP	cis	rs17065868	1.000	rs56208811	chr13:45067786	C/T	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.81	-10.39	-0.55	3.36e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg10189774	chr4:17578691	LAP3	0.49	5.69	0.34	3.63e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs72730918	0.590	rs6493514	chr15:51914778	T/G	cg14296394	chr15:51910925	DMXL2	-0.78	-10.91	-0.57	7.54e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	0.889	rs75609411	chr11:48951316	A/C	cg21546286	chr11:48923668	NA	-0.48	-5.92	-0.35	1.07e-8	HDL cholesterol;
KIRP	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg03289416	chr15:75166202	SCAMP2	0.4	5.51	0.33	9.09e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs1978968	0.763	rs8140977	chr22:18463608	C/T	cg02610425	chr22:18483192	MICAL3	0.37	5.6	0.34	5.79e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg13165212	chr22:42675999	NA	0.3	5.41	0.33	1.51e-7	Cognitive function;
KIRP	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26526719	chr5:1949144	NA	-0.43	-5.04	-0.31	8.93e-7	Gut microbiome composition (winter);
KIRP	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg20302533	chr7:39170763	POU6F2	0.29	6.27	0.37	1.57e-9	IgG glycosylation;
KIRP	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg17145862	chr1:211918768	LPGAT1	-0.92	-13.39	-0.65	4.31e-31	Leprosy;
KIRP	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	1.02	12.93	0.64	1.53e-29	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.73	-8.96	-0.5	8.25e-17	Cognitive function;
KIRP	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.51	-5.09	-0.31	7.07e-7	Pubertal anthropometrics;
KIRP	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.35	1.11e-8	Total cholesterol levels;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg27189623	chr16:705930	WDR90	0.44	6.12	0.36	3.73e-9	Height;
KIRP	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.58	-7.39	-0.43	2.3e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12681366	0.663	rs2919660	chr8:95470697	C/A	cg13257157	chr8:95487014	RAD54B	0.41	5.05	0.31	8.78e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs4959799	0.557	rs9503517	chr6:3272109	C/T	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.25	-0.32	3.34e-7	Survival in rectal cancer;
KIRP	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.55	-8.97	-0.5	7.59e-17	Prostate cancer;
KIRP	cis	rs6977660	0.652	rs10275246	chr7:19851059	G/A	cg05791153	chr7:19748676	TWISTNB	0.67	5.82	0.35	1.81e-8	Thyroid stimulating hormone;
KIRP	cis	rs12580194	0.556	rs11171433	chr12:55757797	A/T	cg11794356	chr12:55725991	OR6C3	-0.53	-7.02	-0.41	2.15e-11	Cancer;
KIRP	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.52	7.02	0.41	2.19e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.56	8.07	0.46	3.13e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.55	-6.9	-0.4	4.25e-11	White blood cell count;
KIRP	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg25664220	chr3:72788482	NA	0.35	5.22	0.32	3.82e-7	Motion sickness;
KIRP	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.68	-7.28	-0.42	4.55e-12	Body mass index;
KIRP	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg23594656	chr7:65796392	TPST1	0.44	5.99	0.36	7.26e-9	Aortic root size;
KIRP	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.88	-11.75	-0.6	1.36e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg27205649	chr11:78285834	NARS2	0.82	11.43	0.59	1.51e-24	Alzheimer's disease (survival time);
KIRP	cis	rs17209837	1.000	rs59616301	chr7:87118407	T/C	cg00919237	chr7:87102261	ABCB4	-0.66	-6.68	-0.39	1.54e-10	Gallbladder cancer;
KIRP	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-4.85	-0.3	2.16e-6	Cognitive function;
KIRP	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.85	-0.49	1.8e-16	Neuroticism;
KIRP	cis	rs714027	0.626	rs4336042	chr22:30552511	G/A	cg27665648	chr22:30112403	NA	-0.45	-6.4	-0.38	7.73e-10	Lymphocyte counts;
KIRP	cis	rs10073892	0.620	rs10068654	chr5:101979297	T/G	cg19774478	chr5:101632501	SLCO4C1	0.55	5.6	0.34	5.8e-8	Cognitive decline (age-related);
KIRP	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17554472	chr22:41940697	POLR3H	-0.68	-7.08	-0.41	1.51e-11	Vitiligo;
KIRP	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.41	-5.27	-0.32	2.95e-7	IgG glycosylation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09441348	chr3:126290635	TXNRD3IT1	0.47	6.41	0.38	7.27e-10	Interleukin-4 levels;
KIRP	cis	rs2387326	0.672	rs10829347	chr10:129947386	T/C	cg16087940	chr10:129947807	NA	-0.43	-5.83	-0.35	1.7e-8	Select biomarker traits;
KIRP	cis	rs9810890	1.000	rs73196974	chr3:128449006	A/C	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.23	0.32	3.71e-7	Cognitive test performance;
KIRP	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.61	-7.92	-0.45	8.25e-14	Uric acid clearance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08673532	chr16:87422913	FBXO31	0.53	6.96	0.41	3.03e-11	Interleukin-4 levels;
KIRP	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.34	0.42	3.17e-12	Bipolar disorder;
KIRP	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13198984	chr17:80129470	CCDC57	-0.49	-7.67	-0.44	3.9e-13	Life satisfaction;
KIRP	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg25019722	chr6:37503610	NA	-0.94	-14.87	-0.69	4.16e-36	Cognitive performance;
KIRP	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.5	-6.58	-0.39	2.74e-10	Schizophrenia;
KIRP	cis	rs944802	0.684	rs10811665	chr9:22146604	T/C	cg00491127	chr9:22154101	NA	-0.48	-5.16	-0.31	5e-7	White blood cell count;
KIRP	cis	rs9488822	0.623	rs195516	chr6:116241548	T/A	cg26893134	chr6:116381904	FRK	0.2	5.43	0.33	1.32e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg06121193	chr1:90282411	NA	-0.48	-6.94	-0.4	3.55e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg08975724	chr8:8085496	FLJ10661	-0.72	-9.73	-0.53	3.9e-19	Triglycerides;
KIRP	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.77	-8.93	-0.49	1.03e-16	Resting heart rate;
KIRP	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg05064044	chr6:292385	DUSP22	-0.55	-6.43	-0.38	6.54e-10	Menopause (age at onset);
KIRP	trans	rs6977660	0.770	rs10224061	chr7:19852619	C/G	cg01879488	chr11:35160498	CD44	0.49	6.3	0.37	1.35e-9	Thyroid stimulating hormone;
KIRP	cis	rs6450176	0.633	rs389525	chr5:53333075	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-8.71	-0.49	4.54e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.39	7.72	0.44	2.92e-13	Multiple system atrophy;
KIRP	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.78	10.79	0.57	1.83e-22	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg15655495	chr12:38532458	NA	-0.29	-5.05	-0.31	8.7e-7	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.79	0.44	1.89e-13	Morning vs. evening chronotype;
KIRP	cis	rs959260	1.000	rs4788889	chr17:73389126	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.09	-0.36	4.32e-9	Systemic lupus erythematosus;
KIRP	cis	rs997295	0.592	rs7162320	chr15:67766038	C/G	cg24579218	chr15:68104479	NA	0.34	4.94	0.3	1.45e-6	Motion sickness;
KIRP	cis	rs6841333	0.812	rs2869462	chr4:76934719	C/G	cg24176760	chr4:76958061	ART3;CXCL11	-0.45	-4.97	-0.3	1.24e-6	Monokine induced by gamma interferon levels;
KIRP	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.25	17.63	0.75	1.56e-45	White matter hyperintensity burden;
KIRP	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg16586182	chr3:47516702	SCAP	-0.49	-6.12	-0.36	3.72e-9	Birth weight;
KIRP	cis	rs4750440	0.670	rs7917314	chr10:14029682	G/A	cg27542038	chr10:14027202	FRMD4A	-0.48	-6.7	-0.39	1.41e-10	Adiponectin levels;
KIRP	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg24375607	chr4:120327624	NA	-0.46	-4.97	-0.3	1.23e-6	Corneal astigmatism;
KIRP	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.64	7.11	0.41	1.25e-11	Arsenic metabolism;
KIRP	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	7.85e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg12486944	chr17:80159399	CCDC57	0.38	5.1	0.31	6.65e-7	Life satisfaction;
KIRP	cis	rs6997458	0.785	rs13255540	chr8:86343581	T/C	cg02393479	chr8:86352350	CA3	-0.32	-4.95	-0.3	1.36e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.99	-0.64	9.85e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.56	7.95	0.45	6.75e-14	Breast cancer;
KIRP	trans	rs1106684	0.925	rs68017295	chr7:131458828	C/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs11166927	0.524	rs2035087	chr8:140831320	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.83	-12.91	-0.64	1.78e-29	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs3112255	0.512	rs11123843	chr2:101338023	A/T	cg01042948	chr2:101319752	NA	0.36	4.96	0.3	1.33e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs997295	1.000	rs938878	chr15:67993366	C/T	cg14210607	chr15:68128175	NA	-0.3	-4.98	-0.3	1.18e-6	Motion sickness;
KIRP	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg21798802	chr22:38057573	PDXP	0.34	4.89	0.3	1.83e-6	Fat distribution (HIV);
KIRP	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.42	-5.25	-0.32	3.32e-7	Neuroticism;
KIRP	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg08738300	chr3:44038990	NA	0.69	9.49	0.52	2.15e-18	Coronary artery disease;
KIRP	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18252515	chr7:66147081	NA	0.47	5.55	0.33	7.43e-8	Aortic root size;
KIRP	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.91	0.35	1.15e-8	Menopause (age at onset);
KIRP	cis	rs300890	0.729	rs11100786	chr4:144301054	T/C	cg19876092	chr4:144208277	NA	-0.31	-4.86	-0.3	2.09e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg23188430	chr6:125850052	NA	-0.34	-5.28	-0.32	2.9e-7	High light scatter reticulocyte count;
KIRP	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.33	-7.36	-0.42	2.81e-12	Cutaneous nevi;
KIRP	cis	rs4481887	0.800	rs28590733	chr1:248514978	T/C	cg01631408	chr1:248437212	OR2T33	-0.43	-6.05	-0.36	5.34e-9	Common traits (Other);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25253773	chr2:74942436	NA	0.46	6.25	0.37	1.82e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs57590327	0.679	rs35381070	chr3:81590374	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-6.45	-0.38	6.03e-10	Extraversion;
KIRP	cis	rs2562456	0.833	rs4359573	chr19:21542296	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg11130432	chr3:121712080	ILDR1	-0.45	-5.39	-0.33	1.62e-7	Multiple sclerosis;
KIRP	cis	rs6732160	0.588	rs13394018	chr2:73372605	C/T	cg01422370	chr2:73384389	NA	0.53	7.13	0.41	1.09e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg16898833	chr6:26189333	HIST1H4D	0.71	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06748934	chr4:175239475	KIAA1712	-0.46	-7.37	-0.43	2.66e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.33	-6.58	-0.39	2.78e-10	Breast cancer;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10361659	chr13:51482542	RNASEH2B	0.53	6.26	0.37	1.7e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs885389	1.000	rs867411	chr12:131621789	T/G	cg00260028	chr12:131606990	GPR133	-0.46	-5.66	-0.34	4.15e-8	RR interval (heart rate);
KIRP	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.53	6.68	0.39	1.59e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	6.31	0.37	1.26e-9	Axial length;
KIRP	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg18451016	chr1:38461880	NA	0.5	7.07	0.41	1.57e-11	Coronary artery disease;
KIRP	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.66	7.88	0.45	1.07e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.7	-0.39	1.39e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2295359	1.000	rs11465754	chr1:67631431	A/G	cg11235152	chr1:67600687	NA	0.64	9.5	0.52	1.9e-18	Psoriasis;
KIRP	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg05802129	chr4:122689817	NA	0.46	6.72	0.39	1.28e-10	Type 2 diabetes;
KIRP	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg05347473	chr6:146136440	FBXO30	0.65	9.33	0.51	6.35e-18	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02949340	chr10:102820489	KAZALD1	0.93	6.43	0.38	6.66e-10	P wave terminal force;
KIRP	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg26681399	chr22:41777847	TEF	-0.54	-5.18	-0.31	4.62e-7	Vitiligo;
KIRP	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg13180566	chr4:1052158	NA	0.56	5.74	0.34	2.81e-8	Recombination rate (females);
KIRP	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.27	-0.32	3.03e-7	Coronary artery disease;
KIRP	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg00530320	chr1:46809349	NSUN4	0.44	5.32	0.32	2.3e-7	Menopause (age at onset);
KIRP	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.52	-0.33	8.38e-8	Obesity-related traits;
KIRP	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-6.67	-0.39	1.69e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg18944383	chr4:111397179	ENPEP	0.44	7.21	0.42	6.72e-12	Height;
KIRP	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.86e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg13444842	chr1:152974279	SPRR3	-0.35	-4.93	-0.3	1.5e-6	Inflammatory skin disease;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg02996583	chr8:142237188	SLC45A4	-0.49	-6.05	-0.36	5.27e-9	Immature fraction of reticulocytes;
KIRP	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.47	5.93	0.35	1e-8	IgG glycosylation;
KIRP	cis	rs888194	0.690	rs7954144	chr12:110015893	A/G	cg05360138	chr12:110035743	NA	0.4	4.87	0.3	1.96e-6	Neuroticism;
KIRP	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg21427119	chr20:30132790	HM13	-0.52	-5.92	-0.35	1.05e-8	Mean corpuscular hemoglobin;
KIRP	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg03929089	chr4:120376271	NA	0.63	6.33	0.37	1.16e-9	Axial length;
KIRP	cis	rs7851660	0.809	rs10512255	chr9:100652582	C/T	cg13688889	chr9:100608707	NA	-0.71	-8.44	-0.47	2.75e-15	Strep throat;
KIRP	cis	rs10073892	0.789	rs72779972	chr5:101768044	C/T	cg19774478	chr5:101632501	SLCO4C1	0.6	5.59	0.34	6e-8	Cognitive decline (age-related);
KIRP	cis	rs11628318	0.614	rs12590775	chr14:103150623	A/G	cg01864069	chr14:103024347	NA	0.44	5.3	0.32	2.56e-7	Platelet count;
KIRP	cis	rs1943345	0.556	rs665714	chr11:82911261	A/C	cg07047830	chr11:82868014	PCF11	0.44	5.2	0.31	4.21e-7	Obesity-related traits;
KIRP	cis	rs2411233	0.804	rs12911790	chr15:39250642	A/G	cg19287857	chr15:39890699	NA	0.45	6.22	0.37	2.18e-9	Platelet count;
KIRP	cis	rs2411233	1.000	rs7168969	chr15:39271293	C/A	cg02291532	chr15:39874776	THBS1	0.4	5.42	0.33	1.39e-7	Platelet count;
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg19893067	chr17:80732956	TBCD	0.35	4.86	0.3	2.1e-6	Glycated hemoglobin levels;
KIRP	trans	rs72749603	0.643	rs16900905	chr5:31343671	A/G	cg00589006	chr16:70415864	ST3GAL2	0.64	6.12	0.36	3.6e-9	Large artery stroke;
KIRP	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg16988262	chr1:15930761	NA	0.37	4.98	0.3	1.21e-6	Systolic blood pressure;
KIRP	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg21775007	chr8:11205619	TDH	-0.43	-5.64	-0.34	4.59e-8	Monocyte count;
KIRP	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01213445	chr15:91537450	PRC1	-0.47	-6.55	-0.39	3.25e-10	Metabolic traits;
KIRP	trans	rs3935996	0.767	rs12058859	chr1:56302126	C/T	cg01078248	chr7:123197661	NDUFA5	0.44	6.15	0.37	3.08e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
KIRP	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	11.61	0.59	4e-25	Schizophrenia;
KIRP	cis	rs2880765	0.525	rs2062234	chr15:86054490	A/G	cg10818794	chr15:86012489	AKAP13	-0.52	-7.04	-0.41	1.87e-11	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.88	0.3	1.94e-6	Menopause (age at onset);
KIRP	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.89	-0.49	1.32e-16	Morning vs. evening chronotype;
KIRP	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg12292205	chr6:26970375	C6orf41	0.5	7.29	0.42	4.24e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7116495	0.609	rs2155145	chr11:71719619	G/T	cg07596299	chr11:71824057	C11orf51	-0.88	-5.45	-0.33	1.22e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs76288851	0.799	rs11717563	chr3:126573218	A/C	cg13821433	chr2:26726535	OTOF	0.6	6.64	0.39	1.95e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.2	0.46	1.34e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg02569458	chr12:86230093	RASSF9	-0.38	-5.19	-0.31	4.4e-7	Major depressive disorder;
KIRP	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.19	-0.31	4.36e-7	Colorectal cancer;
KIRP	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11645453	chr3:52864694	ITIH4	-0.34	-5.3	-0.32	2.54e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg09658497	chr7:2847517	GNA12	-0.31	-5.01	-0.3	1.02e-6	Height;
KIRP	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.42	5.59	0.34	6.17e-8	Educational attainment;
KIRP	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg23958373	chr8:599963	NA	0.87	6.83	0.4	6.74e-11	IgG glycosylation;
KIRP	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.67	6.3	0.37	1.38e-9	Eotaxin levels;
KIRP	cis	rs6968419	0.674	rs7459355	chr7:115906775	A/G	cg02561103	chr7:115862891	TES	-0.39	-5.48	-0.33	1.08e-7	Intraocular pressure;
KIRP	cis	rs6684428	1.000	rs12141666	chr1:56370556	T/C	cg11651538	chr1:56320950	NA	-0.86	-10.11	-0.54	2.52e-20	Airflow obstruction;
KIRP	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.4	5.03	0.31	9.52e-7	Childhood ear infection;
KIRP	cis	rs526231	0.578	rs6876278	chr5:102249546	A/G	cg23492399	chr5:102201601	PAM	-0.43	-4.86	-0.3	2.14e-6	Primary biliary cholangitis;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09952002	chr17:46640774	HOXB3	0.53	6.29	0.37	1.47e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.61	-8.22	-0.46	1.19e-14	Lymphocyte percentage of white cells;
KIRP	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	9.1	0.5	3.11e-17	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	8.03	0.46	4e-14	Systemic lupus erythematosus;
KIRP	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.77	12.2	0.61	4.45e-27	Longevity;
KIRP	cis	rs62355272	1.000	rs11567701	chr5:35859863	G/T	cg13894535	chr5:35919491	CAPSL	-0.54	-6.28	-0.37	1.49e-9	Lymphocyte counts;
KIRP	cis	rs1823913	0.614	rs4853466	chr2:192160669	A/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.18	-0.37	2.61e-9	Obesity-related traits;
KIRP	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg05692746	chr2:100937584	LONRF2	-0.38	-5.06	-0.31	8.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs838147	0.760	rs412712	chr19:49234299	A/T	cg08619932	chr19:49200058	FUT2	-0.34	-5.11	-0.31	6.45e-7	Dietary macronutrient intake;
KIRP	cis	rs4789452	0.655	rs2001613	chr17:75383679	C/T	cg12985929	chr17:75370611	SEPT9	-0.38	-5.33	-0.32	2.25e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6681460	0.800	rs481681	chr1:67194378	G/A	cg02459107	chr1:67143332	SGIP1	-0.4	-5.75	-0.34	2.64e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg09238746	chr17:78121135	EIF4A3	-0.56	-7.16	-0.42	9.16e-12	Yeast infection;
KIRP	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.9e-7	Aortic root size;
KIRP	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg05340658	chr4:99064831	C4orf37	-0.54	-6.51	-0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.99	-15.48	-0.7	3.47e-38	Ulcerative colitis;
KIRP	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	0.9	8.29	0.47	7.48e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.43	-9.47	-0.52	2.42e-18	Alzheimer's disease (late onset);
KIRP	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg00149659	chr3:10157352	C3orf10	0.92	9.81	0.53	2.19e-19	Alzheimer's disease;
KIRP	cis	rs7561273	0.586	rs11896092	chr2:24317827	G/A	cg20701182	chr2:24300061	SF3B14	0.49	5.89	0.35	1.28e-8	Quantitative traits;
KIRP	cis	rs745821	0.879	rs58693787	chr18:48141710	A/G	cg18923635	chr18:48083994	NA	0.46	5.27	0.32	3.04e-7	Diastolic blood pressure;
KIRP	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg06212747	chr3:49208901	KLHDC8B	0.63	8.84	0.49	1.9e-16	Resting heart rate;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11149743	chr17:46688419	HOXB7	-0.48	-6.04	-0.36	5.63e-9	Myopia;
KIRP	cis	rs580438	0.529	rs9866800	chr3:13421907	C/T	cg10657019	chr3:13328039	NA	-0.52	-6.82	-0.4	6.94e-11	Myringotomy;
KIRP	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.71	-6.15	-0.37	3.04e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01616529	chr11:638424	DRD4	-0.42	-5.59	-0.34	5.93e-8	Systemic lupus erythematosus;
KIRP	trans	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg19894588	chr14:64061835	NA	-0.62	-7.45	-0.43	1.56e-12	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg12292205	chr6:26970375	C6orf41	0.34	4.85	0.3	2.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	1.1	22.11	0.82	2.24e-60	Parkinson's disease;
KIRP	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	1.14	17.75	0.75	6.35e-46	Cognitive function;
KIRP	trans	rs7939886	0.920	rs76702940	chr11:55999305	G/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.72	8.56	0.48	1.22e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.18	20.45	0.79	5.46e-55	Cognitive function;
KIRP	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.65	8.86	0.49	1.59e-16	Coronary artery disease;
KIRP	cis	rs17101923	0.760	rs12812630	chr12:66322841	G/A	cg06712651	chr12:66351869	HMGA2	-0.55	-5.71	-0.34	3.26e-8	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	trans	rs9650657	0.740	rs12676417	chr8:10668634	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.23	0.37	1.99e-9	Neuroticism;
KIRP	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.7	-0.39	1.38e-10	Obesity-related traits;
KIRP	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.63	9.1	0.5	3.26e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.39	-4.99	-0.3	1.13e-6	IgG glycosylation;
KIRP	cis	rs2273669	0.667	rs7765732	chr6:109347057	A/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.59	-6.88	-0.4	5.04e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs9393813	1.000	rs13220817	chr6:27356527	T/C	cg18711553	chr6:27366782	ZNF391	-0.36	-5.36	-0.32	1.91e-7	Bipolar disorder;
KIRP	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.71	0.49	4.55e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.98	8.42	0.47	3.15e-15	Systolic blood pressure;
KIRP	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.05	-0.31	8.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg16917193	chr12:54089295	NA	0.86	16.52	0.73	9.65e-42	Height;
KIRP	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.91	0.45	8.59e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg19645103	chr12:69753606	YEATS4	-0.47	-4.93	-0.3	1.51e-6	Response to diuretic therapy;
KIRP	cis	rs2273669	0.588	rs2145767	chr6:109296185	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.26	-0.37	1.74e-9	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg26513180	chr16:89883248	FANCA	0.79	5.63	0.34	4.9e-8	Skin colour saturation;
KIRP	cis	rs6782228	0.527	rs7426806	chr3:128412930	G/A	cg18648031	chr3:128330563	NA	0.26	5.27	0.32	3.03e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs654950	0.875	rs600109	chr1:41998246	A/G	cg06885757	chr1:42089581	HIVEP3	-0.51	-7.49	-0.43	1.27e-12	Airway imaging phenotypes;
KIRP	cis	rs4740619	0.619	rs4741561	chr9:16045827	A/G	cg14451791	chr9:16040625	NA	-0.39	-5.05	-0.31	8.5e-7	Body mass index;
KIRP	cis	rs9859260	1.000	rs2239640	chr3:195789708	G/T	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	10.39	0.55	3.26e-21	Smoking behavior;
KIRP	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05776053	chr2:74358815	NA	-0.52	-5.57	-0.33	6.73e-8	Gestational age at birth (maternal effect);
KIRP	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg03468072	chr12:39539422	NA	0.41	5.88	0.35	1.34e-8	Morning vs. evening chronotype;
KIRP	cis	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.47	-6.11	-0.36	3.82e-9	Leprosy;
KIRP	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-17.3	-0.74	2.1e-44	Coronary artery disease;
KIRP	cis	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16997312	chr1:160314505	NCSTN;COPA	0.39	5.54	0.33	7.9e-8	C-reactive protein;
KIRP	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.72	11.36	0.59	2.59e-24	Retinal vascular caliber;
KIRP	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.78	10.28	0.55	7.65e-21	Menopause (age at onset);
KIRP	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.82	7.19	0.42	7.73e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg24851858	chr13:114927579	NA	0.42	5.04	0.31	8.88e-7	Schizophrenia;
KIRP	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	1.2	12.46	0.62	5.9e-28	Alzheimer's disease;
KIRP	cis	rs7221595	0.778	rs57625058	chr17:3914513	T/G	cg21851534	chr17:3907994	ZZEF1	0.56	5.43	0.33	1.35e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg06521331	chr12:34319734	NA	-0.58	-7.07	-0.41	1.61e-11	Bladder cancer;
KIRP	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06481639	chr22:41940642	POLR3H	-0.59	-6.37	-0.38	9.27e-10	Vitiligo;
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg05457628	chr5:178986728	RUFY1	-0.6	-9.83	-0.53	1.86e-19	Lung cancer;
KIRP	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg00495681	chr13:53174319	NA	-0.42	-5.81	-0.35	1.89e-8	Lewy body disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg13920838	chr9:35095103	PIGO	0.65	7.24	0.42	5.84e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs714027	0.585	rs5763670	chr22:30383758	C/G	cg01021169	chr22:30184971	ASCC2	-0.41	-4.99	-0.3	1.13e-6	Lymphocyte counts;
KIRP	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg27205649	chr11:78285834	NARS2	0.82	10.24	0.55	1.01e-20	Alzheimer's disease (survival time);
KIRP	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	5.1	0.31	6.91e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs72843166	0.562	rs72841395	chr17:61471046	C/T	cg19683800	chr17:61518354	CYB561	-0.41	-5.28	-0.32	2.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg02151108	chr14:50098012	C14orf104	-0.51	-6.88	-0.4	4.97e-11	Carotid intima media thickness;
KIRP	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg05082376	chr22:42548792	NA	0.35	4.85	0.3	2.24e-6	Cognitive function;
KIRP	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg00507259	chr4:95128692	SMARCAD1	0.39	4.86	0.3	2.11e-6	Type 2 diabetes;
KIRP	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.59	-7.4	-0.43	2.16e-12	Retinal vascular caliber;
KIRP	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg23594656	chr7:65796392	TPST1	0.51	7.92	0.45	8.25e-14	Aortic root size;
KIRP	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg05370193	chr1:21551575	ECE1	-0.42	-5.98	-0.36	7.74e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.68	6.92	0.4	3.8e-11	Vitiligo;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg11168104	chr5:1857477	NA	-0.42	-5.51	-0.33	9.23e-8	Cardiovascular disease risk factors;
KIRP	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg04374321	chr14:90722782	PSMC1	0.47	5.02	0.3	9.91e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs10214930	0.813	rs7779990	chr7:27671899	T/C	cg22168087	chr7:27702803	HIBADH	0.51	5.07	0.31	7.97e-7	Hypospadias;
KIRP	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.54	-7.32	-0.42	3.52e-12	Blood trace element (Cu levels);
KIRP	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg18478038	chr5:70751223	BDP1	0.44	6.2	0.37	2.34e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
KIRP	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.72	9.13	0.5	2.65e-17	Alcohol dependence;
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-1.1	-21.45	-0.81	3.03e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.42	6.24	0.37	1.9e-9	Schizophrenia;
KIRP	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg24199006	chr10:106089203	ITPRIP	0.36	5.19	0.31	4.48e-7	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg24955955	chr5:415729	AHRR	0.77	6.27	0.37	1.59e-9	Fat distribution (HIV);
KIRP	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg19257562	chr1:2043853	PRKCZ	0.39	6.38	0.38	8.73e-10	Height;
KIRP	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg03733263	chr8:22462867	KIAA1967	1.12	16.93	0.73	3.66e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg00241281	chr14:105779794	PACS2	-0.36	-5.04	-0.31	8.89e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg12140854	chr5:148520817	ABLIM3	0.44	4.87	0.3	1.97e-6	Breast cancer;
KIRP	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-5.84	-0.35	1.61e-8	Blood protein levels;
KIRP	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12049351	0.719	rs4925493	chr1:229623137	T/C	cg11742688	chr1:229674241	ABCB10	-0.41	-6.52	-0.38	3.89e-10	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.63	-0.34	4.97e-8	Aortic root size;
KIRP	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg03714773	chr7:91764589	CYP51A1	-0.36	-5.33	-0.32	2.24e-7	Breast cancer;
KIRP	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	1.06	19.5	0.78	7.74e-52	Monocyte count;
KIRP	cis	rs78579285	0.584	rs35353288	chr16:88800814	G/A	cg09054528	chr16:88821542	FAM38A	-0.65	-5.38	-0.32	1.77e-7	Joint mobility (Beighton score);
KIRP	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.26	0.37	1.68e-9	Menarche (age at onset);
KIRP	cis	rs6693295	0.938	rs10924478	chr1:246222572	T/G	cg11798871	chr1:246315928	SMYD3	-0.44	-5.21	-0.32	4.02e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs2425143	1.000	rs13038622	chr20:34319343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg02023728	chr11:77925099	USP35	-0.3	-5.2	-0.31	4.29e-7	Alzheimer's disease (survival time);
KIRP	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18252515	chr7:66147081	NA	0.46	5.51	0.33	9.21e-8	Aortic root size;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10774480	chr11:68191716	LRP5	0.5	6.9	0.4	4.49e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.08	0.46	2.94e-14	Height;
KIRP	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg08975724	chr8:8085496	FLJ10661	0.69	8.61	0.48	9.07e-16	Neuroticism;
KIRP	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.96	0.5	8.56e-17	Morning vs. evening chronotype;
KIRP	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.95	10.3	0.55	6.24e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.93	0.54	8.99e-20	Monocyte percentage of white cells;
KIRP	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg17691542	chr6:26056736	HIST1H1C	0.49	6.42	0.38	6.83e-10	Height;
KIRP	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg15507776	chr3:136538369	TMEM22	-0.39	-5.38	-0.32	1.76e-7	Neuroticism;
KIRP	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.58	7.0	0.41	2.45e-11	Blood metabolite levels;
KIRP	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.71e-36	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13939156	chr17:80058883	NA	-0.5	-7.65	-0.44	4.43e-13	Life satisfaction;
KIRP	cis	rs17125944	0.686	rs2357947	chr14:53345378	C/T	cg00686598	chr14:53173677	PSMC6	-0.74	-6.76	-0.4	9.9e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg19847130	chr8:10466454	RP1L1	0.36	5.31	0.32	2.49e-7	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs7560272	0.723	rs13386124	chr2:73771695	C/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.36	-0.32	1.9e-7	Schizophrenia;
KIRP	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11987759	chr7:65425863	GUSB	-0.54	-7.14	-0.41	1.04e-11	Aortic root size;
KIRP	cis	rs17453880	0.929	rs62398709	chr5:152055235	A/T	cg12297329	chr5:152029980	NA	-0.67	-9.97	-0.54	6.8e-20	Subjective well-being;
KIRP	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg00745463	chr17:30367425	LRRC37B	-0.65	-6.46	-0.38	5.7e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg09033563	chr22:24373618	LOC391322	-0.45	-5.71	-0.34	3.24e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg17470723	chr8:74884337	TCEB1	0.62	7.92	0.45	8.29e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg15691649	chr6:25882328	NA	-0.42	-5.04	-0.31	9.01e-7	Blood metabolite levels;
KIRP	cis	rs4148087	0.790	rs4148099	chr21:43639591	A/C	cg08841829	chr21:43638893	ABCG1	-0.58	-4.92	-0.3	1.58e-6	Eating disorder in bipolar disorder;
KIRP	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg19077165	chr18:44547161	KATNAL2	0.44	5.82	0.35	1.82e-8	Educational attainment;
KIRP	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg09201719	chr10:104596890	CYP17A1	0.35	5.02	0.3	9.92e-7	Arsenic metabolism;
KIRP	cis	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.09	0.31	7.11e-7	Leprosy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03712062	chr4:62359523	NA	-0.45	-6.87	-0.4	5.32e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs732716	0.785	rs56033249	chr19:4369447	C/T	cg19820705	chr19:4455316	UBXN6	0.67	7.86	0.45	1.21e-13	Mean corpuscular volume;
KIRP	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg07741184	chr6:167504864	NA	0.23	6.25	0.37	1.79e-9	Crohn's disease;
KIRP	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg09571762	chr12:39539558	NA	0.36	5.06	0.31	8.21e-7	Morning vs. evening chronotype;
KIRP	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg01529538	chr14:23388837	RBM23	0.42	5.27	0.32	2.92e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs2250402	0.655	rs2307101	chr15:40322460	C/T	cg16127683	chr15:40268777	EIF2AK4	0.5	5.04	0.31	8.92e-7	Corneal curvature;
KIRP	cis	rs7534824	0.543	rs61780317	chr1:101407139	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.84	7.88	0.45	1.07e-13	Refractive astigmatism;
KIRP	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg06289844	chr6:126071538	HEY2	0.36	5.1	0.31	6.86e-7	Brugada syndrome;
KIRP	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02359409	chr6:42947317	PEX6	-0.38	-4.98	-0.3	1.22e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg21395723	chr22:39101663	GTPBP1	-0.45	-5.92	-0.35	1.07e-8	Menopause (age at onset);
KIRP	cis	rs2151522	0.762	rs6569470	chr6:127158042	A/G	cg21431617	chr6:127135037	NA	-0.28	-5.09	-0.31	6.99e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg11235152	chr1:67600687	NA	0.77	11.46	0.59	1.22e-24	Psoriasis;
KIRP	cis	rs7536201	1.000	rs4649040	chr1:25293902	C/T	cg23273869	chr1:25296894	NA	-0.35	-4.88	-0.3	1.94e-6	Psoriasis vulgaris;
KIRP	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-7.86	-0.45	1.18e-13	Body mass index;
KIRP	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.47e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg24747557	chr10:131355152	MGMT	0.43	6.13	0.36	3.43e-9	Response to temozolomide;
KIRP	cis	rs2150410	0.604	rs6517520	chr21:40548898	A/C	cg11890956	chr21:40555474	PSMG1	0.7	5.08	0.31	7.44e-7	Temperament (bipolar disorder);
KIRP	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg17554472	chr22:41940697	POLR3H	0.68	7.24	0.42	5.82e-12	Vitiligo;
KIRP	cis	rs9581857	0.547	rs9581876	chr13:28101113	T/C	cg22138327	chr13:27999177	GTF3A	0.83	6.38	0.38	8.56e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.73	-7.55	-0.43	8.67e-13	Vitiligo;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg12290896	chr5:96038388	CAST	0.54	6.65	0.39	1.92e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg05802129	chr4:122689817	NA	-0.46	-6.77	-0.4	9.43e-11	Type 2 diabetes;
KIRP	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14169450	chr9:139327907	INPP5E	0.56	6.57	0.39	3.06e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9905704	0.633	rs8068455	chr17:56589381	C/T	cg12560992	chr17:57184187	TRIM37	-0.56	-5.19	-0.31	4.41e-7	Testicular germ cell tumor;
KIRP	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg23127183	chr11:57508653	C11orf31	-0.55	-7.1	-0.41	1.33e-11	Schizophrenia;
KIRP	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.62	0.71	1.08e-38	Bipolar disorder;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg22799860	chr5:98191055	CHD1	0.38	6.26	0.37	1.75e-9	C-reactive protein;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18800042	chr5:141238690	PCDH1	-0.43	-6.17	-0.37	2.86e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.65	8.8	0.49	2.42e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	7.16	0.42	9.13e-12	IgG glycosylation;
KIRP	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.75	-10.66	-0.56	4.54e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg27124370	chr19:33622961	WDR88	0.55	4.86	0.3	2.13e-6	Bone properties (heel);
KIRP	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg17294928	chr15:75287854	SCAMP5	-0.63	-5.34	-0.32	2.07e-7	Lung cancer;
KIRP	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.51e-25	Morning vs. evening chronotype;
KIRP	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg21017887	chr14:105400489	NA	-0.51	-8.49	-0.48	2.03e-15	Rheumatoid arthritis;
KIRP	cis	rs830233	0.565	rs31752	chr5:165509894	A/T	cg13976338	chr5:165423657	NA	0.59	5.35	0.32	2e-7	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.75	-9.49	-0.52	2.14e-18	Huntington's disease progression;
KIRP	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs6448317	1.000	rs7698504	chr4:24939386	A/T	cg21108841	chr4:24914750	CCDC149	-0.45	-5.39	-0.33	1.64e-7	Heschl's gyrus morphology;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07725658	chr4:71705655	GRSF1	0.47	6.09	0.36	4.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg14664628	chr15:75095509	CSK	0.56	6.09	0.36	4.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs4845875	0.626	rs11121828	chr1:11834454	C/T	cg24844545	chr1:11908347	NPPA	0.36	5.13	0.31	5.91e-7	Midregional pro atrial natriuretic peptide levels;
KIRP	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.95	-16.46	-0.72	1.47e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-1.16	-9.4	-0.51	3.83e-18	Prostate cancer;
KIRP	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg08873628	chr1:175162347	KIAA0040	0.44	6.54	0.39	3.46e-10	Alcohol dependence;
KIRP	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg08076091	chr2:203926405	NBEAL1	0.91	9.46	0.52	2.52e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg25356066	chr3:128598488	ACAD9	0.47	5.43	0.33	1.34e-7	IgG glycosylation;
KIRP	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-10.49	-0.56	1.57e-21	Chronic sinus infection;
KIRP	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg13939156	chr17:80058883	NA	0.47	5.54	0.33	7.83e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.61	6.81	0.4	7.29e-11	Tonsillectomy;
KIRP	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs2016266	0.502	rs7954558	chr12:53638137	G/A	cg04065151	chr12:53682969	ESPL1	-0.43	-5.38	-0.32	1.71e-7	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.96	-0.41	3.15e-11	Mood instability;
KIRP	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.82	11.71	0.6	1.87e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.75	-9.99	-0.54	6.08e-20	Sudden cardiac arrest;
KIRP	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg06026331	chr20:60912101	LAMA5	0.49	6.1	0.36	4.05e-9	Pelvic organ prolapse;
KIRP	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-6.7	-0.39	1.45e-10	Axial length;
KIRP	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg04865290	chr3:52927548	TMEM110	-0.42	-5.11	-0.31	6.58e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.55	7.39	0.43	2.28e-12	Menarche (age at onset);
KIRP	cis	rs714515	0.586	rs5029889	chr1:172451591	T/C	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.72	-9.64	-0.52	7.08e-19	Hypospadias;
KIRP	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg11130432	chr3:121712080	ILDR1	-0.45	-5.3	-0.32	2.63e-7	Multiple sclerosis;
KIRP	cis	rs16858210	0.648	rs79478990	chr3:183587094	C/T	cg25686905	chr3:183603175	PARL	-0.41	-4.88	-0.3	1.93e-6	Menopause (age at onset);
KIRP	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg04727924	chr7:799746	HEATR2	-0.75	-7.91	-0.45	8.58e-14	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-7.22	-0.42	6.48e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7937612	1.000	rs894839	chr11:120337705	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.8	-0.4	7.82e-11	Intraocular pressure;
KIRP	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13047869	chr3:10149882	C3orf24	0.52	4.91	0.3	1.69e-6	Alzheimer's disease;
KIRP	cis	rs16828019	0.852	rs71648534	chr1:41613747	G/T	cg03387723	chr1:41708464	SCMH1	-0.81	-6.93	-0.4	3.57e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs2048656	0.561	rs9650639	chr8:9542601	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.23	-0.37	2.04e-9	Schizophrenia;
KIRP	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.75	-9.14	-0.5	2.36e-17	Multiple sclerosis;
KIRP	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg24253500	chr15:84953950	NA	0.64	7.61	0.44	5.96e-13	Schizophrenia;
KIRP	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.02	0.3	1.01e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg12658694	chr1:38397304	INPP5B	0.67	9.2	0.51	1.61e-17	Coronary artery disease;
KIRP	cis	rs17407555	0.738	rs73212895	chr4:10121025	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-4.93	-0.3	1.5e-6	Schizophrenia (age at onset);
KIRP	cis	rs11203032	1.000	rs11203031	chr10:90964395	G/T	cg16672925	chr10:90967113	CH25H	0.83	8.63	0.48	8.01e-16	Heart failure;
KIRP	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.87	13.93	0.66	6.73e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg11843606	chr2:227700838	RHBDD1	0.4	5.13	0.31	5.92e-7	Pulmonary function;
KIRP	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.58	-7.12	-0.41	1.17e-11	Aortic root size;
KIRP	cis	rs7084402	0.902	rs3001715	chr10:60285509	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.8	-0.57	1.63e-22	Refractive error;
KIRP	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.54	7.15	0.41	1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs11264213	0.901	rs72661632	chr1:36420715	G/A	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg22676075	chr6:135203613	NA	-0.5	-6.55	-0.39	3.26e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg24581572	chr1:205197876	TMCC2	0.41	6.33	0.37	1.17e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6142102	1.000	rs6059673	chr20:32705561	T/C	cg08999081	chr20:33150536	PIGU	0.49	5.83	0.35	1.73e-8	Skin pigmentation;
KIRP	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.65	-6.92	-0.4	3.98e-11	Gut microbiome composition (summer);
KIRP	cis	rs12620999	0.941	rs10929215	chr2:238037456	G/A	cg15976283	chr2:238042351	NA	0.39	5.39	0.32	1.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-1.02	-11.02	-0.57	3.2e-23	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24181591	chr17:7211285	EIF5A	0.48	6.44	0.38	6.35e-10	Myopia (pathological);
KIRP	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg08885076	chr2:99613938	TSGA10	-0.45	-6.66	-0.39	1.78e-10	Fear of minor pain;
KIRP	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg24375607	chr4:120327624	NA	0.68	8.12	0.46	2.23e-14	Corneal astigmatism;
KIRP	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.82	-0.57	1.46e-22	Triglycerides;
KIRP	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg09137382	chr11:130731461	NA	0.53	7.75	0.44	2.37e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.41	-0.33	1.51e-7	Life satisfaction;
KIRP	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.33	-5.46	-0.33	1.19e-7	Dupuytren's disease;
KIRP	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.58	7.57	0.43	7.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.6	-9.39	-0.51	4.29e-18	Height;
KIRP	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.7	-0.39	1.43e-10	Allergy;
KIRP	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg13409248	chr3:40428643	ENTPD3	0.39	5.18	0.31	4.65e-7	Renal cell carcinoma;
KIRP	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg21926883	chr2:100939477	LONRF2	-0.55	-7.58	-0.44	7.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	0.83	8.63	0.48	7.66e-16	Methadone dose in opioid dependence;
KIRP	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg19875535	chr5:140030758	IK	0.64	8.73	0.49	3.83e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9517320	0.967	rs9517337	chr13:99181647	A/C	cg07423050	chr13:99094983	FARP1	0.32	5.25	0.32	3.21e-7	Longevity;
KIRP	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.47	5.2	0.31	4.25e-7	Smoking behavior;
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.42	0.33	1.45e-7	Lung cancer;
KIRP	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg15068132	chr12:102092402	CHPT1	-0.39	-5.05	-0.31	8.47e-7	Blood protein levels;
KIRP	cis	rs1555895	0.576	rs12413763	chr10:849454	A/G	cg10017260	chr10:834428	NA	-0.44	-6.35	-0.38	1.02e-9	Survival in rectal cancer;
KIRP	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.75	-9.23	-0.51	1.26e-17	Schizophrenia;
KIRP	cis	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg26367366	chr8:4980734	NA	0.62	6.86	0.4	5.48e-11	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12484590	chr1:156475177	NA	-0.46	-6.26	-0.37	1.73e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-6.77	-0.4	9.51e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2415984	0.622	rs11846013	chr14:46932291	A/C	cg14871534	chr14:47121158	RPL10L	0.45	5.43	0.33	1.38e-7	Number of children ever born;
KIRP	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7246657	0.722	rs10406379	chr19:38036725	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.66	-0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.73	9.96	0.54	7.49e-20	Red blood cell count;
KIRP	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg26022315	chr17:47021804	SNF8	0.41	5.37	0.32	1.79e-7	Type 2 diabetes;
KIRP	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg13147721	chr7:65941812	NA	-1.01	-6.71	-0.39	1.36e-10	Diabetic kidney disease;
KIRP	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.78	9.65	0.52	6.73e-19	Blood protein levels;
KIRP	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg27422857	chr2:105853526	NA	-0.43	-5.66	-0.34	4.23e-8	Type 2 diabetes;
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg05457628	chr5:178986728	RUFY1	0.64	10.44	0.55	2.28e-21	Lung cancer;
KIRP	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06634786	chr22:41940651	POLR3H	-0.41	-4.85	-0.3	2.21e-6	Vitiligo;
KIRP	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg23100626	chr2:96804247	ASTL	0.47	6.38	0.38	8.66e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.85	0.3	2.21e-6	Rheumatoid arthritis;
KIRP	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg00576331	chr11:65640516	EFEMP2	-0.5	-5.56	-0.33	6.98e-8	Crohn's disease;
KIRP	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs2997447	0.600	rs1335759	chr1:26471743	G/T	cg19633962	chr1:26362018	EXTL1	0.42	5.14	0.31	5.65e-7	QRS complex (12-leadsum);
KIRP	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.95	12.89	0.63	2.19e-29	Multiple sclerosis;
KIRP	cis	rs16958440	1.000	rs62096464	chr18:44629207	T/A	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs73086581	1.000	rs6052220	chr20:3970594	C/T	cg02187196	chr20:3869020	PANK2	0.5	5.19	0.31	4.44e-7	Response to antidepressants in depression;
KIRP	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg08761264	chr16:28874980	SH2B1	-0.48	-5.5	-0.33	9.62e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1440410	0.835	rs11722027	chr4:144050017	G/A	cg01719995	chr4:144104893	USP38	0.46	6.42	0.38	6.91e-10	Ischemic stroke;
KIRP	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg23719950	chr11:63933701	MACROD1	-0.67	-6.45	-0.38	5.96e-10	Mean platelet volume;
KIRP	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	11.72	0.6	1.72e-25	Bipolar disorder;
KIRP	cis	rs2733310	0.948	rs1841695	chr15:57450020	C/T	cg13626582	chr15:57592083	LOC283663	-0.26	-6.1	-0.36	4.1e-9	Mean platelet volume;
KIRP	cis	rs7709377	0.620	rs13180407	chr5:115478988	T/C	cg23108291	chr5:115420582	COMMD10	0.42	5.02	0.3	9.92e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg20534287	chr10:135191450	PAOX	-0.49	-5.64	-0.34	4.69e-8	Lifespan;
KIRP	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg07001201	chr5:642380	CEP72	0.68	6.21	0.37	2.29e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg04315214	chr1:2043799	PRKCZ	-0.35	-5.59	-0.34	6.12e-8	Height;
KIRP	cis	rs4262150	0.883	rs11167604	chr5:152282430	A/C	cg12297329	chr5:152029980	NA	0.45	6.18	0.37	2.58e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.66	-9.61	-0.52	8.91e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14460953	chr17:7835493	TRAPPC1;CNTROB	0.42	6.19	0.37	2.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.55	6.34	0.37	1.09e-9	Bone mineral density (spine);
KIRP	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.68	10.12	0.54	2.33e-20	Dupuytren's disease;
KIRP	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.71	9.19	0.51	1.69e-17	Body mass index;
KIRP	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-6.25	-0.37	1.83e-9	Daytime sleep phenotypes;
KIRP	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg22437258	chr11:111473054	SIK2	-0.56	-6.45	-0.38	5.85e-10	Primary sclerosing cholangitis;
KIRP	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg14345882	chr6:26364793	BTN3A2	0.49	5.14	0.31	5.56e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.37	-10.44	-0.55	2.37e-21	Diabetic kidney disease;
KIRP	cis	rs16976116	0.851	rs28699327	chr15:55500335	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7095944	0.614	rs2280450	chr10:126436279	C/T	cg08799069	chr10:126477246	METTL10	-0.47	-6.17	-0.37	2.78e-9	Asthma;
KIRP	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.95	12.06	0.61	1.27e-26	Homoarginine levels;
KIRP	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18252515	chr7:66147081	NA	-0.46	-5.55	-0.33	7.29e-8	Aortic root size;
KIRP	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg00277334	chr10:82204260	NA	-0.63	-6.51	-0.38	4.11e-10	Post bronchodilator FEV1;
KIRP	cis	rs6684514	1.000	rs12038481	chr1:156284815	T/C	cg16558208	chr1:156270281	VHLL	-0.44	-5.9	-0.35	1.21e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2880765	0.546	rs35316253	chr15:86065560	T/C	cg17133734	chr15:86042851	AKAP13	-0.6	-7.28	-0.42	4.6e-12	Coronary artery disease;
KIRP	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg25902810	chr10:99078978	FRAT1	0.59	7.39	0.43	2.34e-12	Monocyte count;
KIRP	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.65	-7.88	-0.45	1.08e-13	Height;
KIRP	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.39	-5.92	-0.35	1.09e-8	Height;
KIRP	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg03854865	chr6:26224070	HIST1H3E	0.67	5.03	0.31	9.66e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.67	-9.03	-0.5	5.24e-17	Motion sickness;
KIRP	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg14703610	chr5:56206110	C5orf35	0.51	5.96	0.36	8.53e-9	Initial pursuit acceleration;
KIRP	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg07777115	chr5:623756	CEP72	-0.59	-6.04	-0.36	5.7e-9	Obesity-related traits;
KIRP	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-10.83	-0.57	1.35e-22	Response to antipsychotic treatment;
KIRP	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg13173536	chr2:3403300	TTC15	-0.36	-4.89	-0.3	1.86e-6	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg21605333	chr4:119757512	SEC24D	1.45	11.06	0.58	2.4e-23	Cannabis dependence symptom count;
KIRP	cis	rs5753618	0.561	rs4603880	chr22:31744721	T/C	cg02404636	chr22:31891804	SFI1	0.49	5.55	0.33	7.46e-8	Colorectal cancer;
KIRP	cis	rs2057178	0.546	rs12361455	chr11:32334100	G/A	cg05837727	chr11:32355149	NA	0.43	4.85	0.3	2.14e-6	Tuberculosis;
KIRP	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg11945507	chr8:142233382	SLC45A4	-0.44	-5.94	-0.35	9.73e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10382060	chr16:4853033	ROGDI	-0.46	-6.1	-0.36	4.13e-9	Myopia;
KIRP	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs6467136	0.818	rs62481345	chr7:127165537	T/C	cg08586737	chr7:127225949	GCC1	-0.39	-5.26	-0.32	3.19e-7	Type 2 diabetes;
KIRP	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-4.95	-0.3	1.38e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.49	0.38	4.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.13	22.32	0.82	4.65e-61	Testicular germ cell tumor;
KIRP	cis	rs1832871	0.672	rs13437296	chr6:158762819	A/C	cg07215822	chr6:158701037	NA	-0.64	-7.4	-0.43	2.13e-12	Height;
KIRP	cis	rs2882667	0.931	rs10075039	chr5:138337854	A/G	cg04439458	chr5:138467593	SIL1	-0.44	-7.27	-0.42	4.91e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	0.81	11.39	0.59	2.05e-24	Breast cancer;
KIRP	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.54	7.25	0.42	5.38e-12	Mean corpuscular volume;
KIRP	cis	rs7520050	0.751	rs592214	chr1:46024505	G/A	cg15605315	chr1:45957053	TESK2	0.42	5.25	0.32	3.26e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2273669	0.915	rs6907937	chr6:109293898	T/G	cg05315195	chr6:109294784	ARMC2	-0.5	-5.69	-0.34	3.66e-8	Prostate cancer;
KIRP	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.86	8.64	0.48	7.34e-16	Fibroblast growth factor basic levels;
KIRP	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.91	12.01	0.61	1.87e-26	Alcohol dependence;
KIRP	cis	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.45e-9	HDL cholesterol;
KIRP	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.55	-6.41	-0.38	7.21e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg23262073	chr20:60523788	NA	0.57	5.6	0.34	5.58e-8	Body mass index;
KIRP	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg00262122	chr8:11665843	FDFT1	-0.44	-5.24	-0.32	3.43e-7	Neuroticism;
KIRP	cis	rs1318772	1.000	rs1318772	chr5:112723567	A/G	cg12552261	chr5:112820674	MCC	0.78	6.62	0.39	2.23e-10	F-cell distribution;
KIRP	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg11757124	chr7:157526947	PTPRN2	-0.51	-5.91	-0.35	1.11e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.2	0.61	4.21e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs745080	0.634	rs7157154	chr14:53064563	A/T	cg23333723	chr14:53022898	GPR137C	-0.42	-5.86	-0.35	1.47e-8	Orofacial clefts;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15305172	chr6:116892775	RWDD1	0.49	6.08	0.36	4.53e-9	C-reactive protein;
KIRP	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	0.78	7.14	0.41	1.04e-11	Cognitive function;
KIRP	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.22	-0.58	7.52e-24	Chronic sinus infection;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14231369	chr9:113792896	LPAR1	0.5	7.08	0.41	1.46e-11	Survival in pancreatic cancer;
KIRP	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg01616529	chr11:638424	DRD4	-0.49	-6.4	-0.38	7.78e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1434579	0.966	rs1062098	chr19:44930738	A/G	cg15540054	chr19:45004280	ZNF180	0.53	5.86	0.35	1.5e-8	Tuberculosis;
KIRP	cis	rs2151522	0.603	rs62439176	chr6:127205126	G/A	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.27	0.42	4.71e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs10465746	0.725	rs4907185	chr1:84336047	T/C	cg10977910	chr1:84465055	TTLL7	0.57	7.33	0.42	3.31e-12	Obesity-related traits;
KIRP	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.71	9.31	0.51	7.35e-18	Motion sickness;
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs6893300	1.000	rs62406178	chr5:179164218	T/C	cg14593053	chr5:179126677	CANX	-0.57	-6.28	-0.37	1.52e-9	Resting heart rate;
KIRP	cis	rs7870753	0.530	rs117847766	chr9:99191655	A/T	cg25260653	chr9:99212216	HABP4	0.56	5.72	0.34	3.06e-8	Height;
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg23034840	chr1:205782522	SLC41A1	0.53	6.22	0.37	2.12e-9	Menarche (age at onset);
KIRP	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.84	0.35	1.62e-8	Menopause (age at onset);
KIRP	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.03	-0.31	9.52e-7	Bladder cancer;
KIRP	cis	rs7187994	0.848	rs8044948	chr16:84749734	A/T	cg07647771	chr16:84786436	USP10	-0.38	-5.07	-0.31	7.67e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs57338032	0.883	rs72738757	chr15:78797307	C/T	cg06917634	chr15:78832804	PSMA4	0.57	4.94	0.3	1.46e-6	CTACK levels;
KIRP	cis	rs150986675	1	rs150986675	chr11:102777303	T/C	cg19620758	chr11:102826565	MMP13	0.8	6.39	0.38	8.31e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.68	9.04	0.5	4.89e-17	Eye color traits;
KIRP	trans	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg13565492	chr6:43139072	SRF	-0.82	-7.46	-0.43	1.53e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	7.79	0.44	1.9e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.56	8.09	0.46	2.71e-14	Bone mineral density;
KIRP	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	5.67	0.34	3.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg21191810	chr6:118973309	C6orf204	-0.44	-4.89	-0.3	1.84e-6	Diastolic blood pressure;
KIRP	cis	rs6137287	0.668	rs6082329	chr20:21100138	G/T	cg04219410	chr20:21106687	PLK1S1	-0.42	-5.19	-0.31	4.34e-7	Height;
KIRP	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	1.02	10.36	0.55	4.14e-21	Psoriasis;
KIRP	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.69	-6.84	-0.4	6.39e-11	Breast cancer;
KIRP	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.77	-0.49	2.98e-16	Total cholesterol levels;
KIRP	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg07395648	chr5:131743802	NA	-0.36	-4.85	-0.3	2.16e-6	Blood metabolite levels;
KIRP	cis	rs11138902	0.649	rs11139289	chr9:72164537	A/G	cg14397918	chr9:72078829	APBA1	0.31	4.98	0.3	1.2e-6	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs4262150	0.846	rs72799163	chr5:152132117	T/C	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2411233	0.935	rs2898672	chr15:39292434	C/T	cg19287857	chr15:39890699	NA	0.38	5.33	0.32	2.27e-7	Platelet count;
KIRP	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.61	9.26	0.51	1.06e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs559555	0.553	rs682895	chr2:31871583	G/T	cg02381751	chr2:32503542	YIPF4	-0.47	-4.93	-0.3	1.54e-6	Blood metabolite ratios;Blood metabolite levels;
KIRP	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.63	-8.53	-0.48	1.54e-15	Breast cancer;
KIRP	trans	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg25645199	chr5:171533681	STK10	-0.53	-6.06	-0.36	5.19e-9	Diabetic retinopathy;
KIRP	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.43	5.31	0.32	2.49e-7	Aortic root size;
KIRP	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg19847130	chr8:10466454	RP1L1	-0.32	-4.88	-0.3	1.87e-6	Retinal vascular caliber;
KIRP	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-6.84	-0.4	6.18e-11	Type 2 diabetes;
KIRP	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19717773	chr7:2847554	GNA12	-0.37	-5.52	-0.33	8.64e-8	Height;
KIRP	cis	rs2671245	0.865	rs2819472	chr1:56168510	A/G	cg11523071	chr1:56160889	NA	0.42	6.74	0.39	1.13e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7007076	0.516	rs6470179	chr8:124749610	C/T	cg00283535	chr8:124749564	ANXA13	-0.76	-8.35	-0.47	4.98e-15	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.36	-4.9	-0.3	1.77e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.47	6.18	0.37	2.68e-9	Red blood cell count;
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg09699651	chr6:150184138	LRP11	0.46	6.2	0.37	2.42e-9	Lung cancer;
KIRP	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg05082376	chr22:42548792	NA	0.45	5.79	0.35	2.18e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7572644	0.699	rs1902966	chr2:28189280	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-7.04	-0.41	1.88e-11	Gut microbiome composition (summer);
KIRP	cis	rs259842	0.693	rs2219670	chr2:180713209	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	0.39	5.24	0.32	3.5e-7	Blood protein levels;
KIRP	cis	rs11644362	0.966	rs12933348	chr16:12991081	C/T	cg06890432	chr16:12997467	SHISA9	-0.4	-6.12	-0.36	3.7e-9	Positive affect;Subjective well-being;
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs9659323	0.745	rs10923723	chr1:119544002	G/A	cg18261050	chr1:119551319	NA	0.41	5.78	0.35	2.27e-8	Body mass index;
KIRP	trans	rs35100037	0.803	rs6877820	chr5:128585430	A/G	cg23338408	chr14:31289523	NA	-0.59	-6.05	-0.36	5.47e-9	Ankle injury;
KIRP	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg18190219	chr22:46762943	CELSR1	-0.87	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7215564	0.908	rs80183474	chr17:78655070	T/A	cg06153925	chr17:78755379	RPTOR	0.33	5.31	0.32	2.43e-7	Myopia (pathological);
KIRP	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.94	0.4	3.49e-11	Bipolar disorder;
KIRP	cis	rs11955175	1.000	rs11956741	chr5:40677576	G/C	cg17351974	chr5:40835760	RPL37	0.61	5.32	0.32	2.29e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.73	8.31	0.47	6.64e-15	Mammographic density (dense area);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg23375190	chr22:25960673	ADRBK2	0.46	6.19	0.37	2.48e-9	DNA methylation (variation);
KIRP	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg23625390	chr15:77176239	SCAPER	0.54	7.08	0.41	1.47e-11	Blood metabolite levels;
KIRP	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.74	-9.44	-0.52	2.94e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg06640241	chr16:89574553	SPG7	0.78	11.81	0.6	8.7e-26	Multiple myeloma (IgH translocation);
KIRP	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-7.19	-0.42	7.54e-12	Vitiligo;
KIRP	cis	rs72960926	0.744	rs3897895	chr6:74917550	C/T	cg03266952	chr6:74778945	NA	-0.68	-4.85	-0.3	2.22e-6	Metabolite levels (MHPG);
KIRP	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14237958	chr9:74674159	C9orf57	0.44	6.62	0.39	2.27e-10	Survival in pancreatic cancer;
KIRP	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg10360139	chr7:1886902	MAD1L1	-0.53	-5.93	-0.35	1.02e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs746961	0.965	rs892098	chr19:31099589	G/T	cg21533331	chr19:31848049	NA	-0.36	-4.96	-0.3	1.29e-6	Select biomarker traits;
KIRP	cis	rs860295	0.702	rs10796943	chr1:155414729	T/C	cg02153340	chr1:155202674	NA	-0.56	-7.66	-0.44	4.32e-13	Body mass index;
KIRP	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.4	-0.38	7.91e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2242116	0.501	rs936184	chr3:46938247	A/C	cg02527881	chr3:46936655	PTH1R	-0.56	-6.28	-0.37	1.51e-9	Birth weight;
KIRP	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.5	7.61	0.44	5.93e-13	Resting heart rate;
KIRP	cis	rs8084125	1.000	rs72978668	chr18:74953748	A/C	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.46	5.27	0.32	2.96e-7	Schizophrenia;
KIRP	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg07796016	chr1:152779584	LCE1C	-0.47	-5.94	-0.35	9.46e-9	Inflammatory skin disease;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.79	6.85	0.4	5.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6088813	0.857	rs6142378	chr20:33997291	T/A	cg14752227	chr20:34000481	UQCC	-0.53	-6.84	-0.4	6.39e-11	Height;
KIRP	cis	rs253959	0.545	rs712595	chr5:115657498	A/G	cg23108291	chr5:115420582	COMMD10	-0.51	-5.69	-0.34	3.66e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg05484376	chr2:27715224	FNDC4	0.41	6.85	0.4	5.95e-11	Total body bone mineral density;
KIRP	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.82	11.33	0.59	3.17e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2249694	0.520	rs6537609	chr10:135323084	A/G	cg20169779	chr10:135381914	SYCE1	-0.6	-6.71	-0.39	1.34e-10	Obesity-related traits;
KIRP	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.66	8.15	0.46	1.84e-14	Calcium levels;
KIRP	cis	rs239198	0.555	rs9399695	chr6:101290415	A/C	cg09795085	chr6:101329169	ASCC3	0.56	6.32	0.37	1.23e-9	Menarche (age at onset);
KIRP	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.66e-11	Type 2 diabetes;
KIRP	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11987759	chr7:65425863	GUSB	-0.44	-5.57	-0.33	6.78e-8	Aortic root size;
KIRP	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.92	-13.13	-0.64	3.36e-30	Tonsillectomy;
KIRP	cis	rs12282928	0.921	rs7108931	chr11:48288626	C/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.85	13.22	0.64	1.66e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2625529	0.824	rs11072346	chr15:72400434	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-6.07	-0.36	4.86e-9	Red blood cell count;
KIRP	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.6	-0.39	2.47e-10	Glomerular filtration rate;
KIRP	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.65	-8.04	-0.46	3.89e-14	Aortic root size;
KIRP	cis	rs1697139	0.710	rs6888412	chr5:66526800	G/C	cg16691251	chr5:66510806	NA	0.43	5.13	0.31	5.88e-7	Breast cancer;
KIRP	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.54	-0.43	9.25e-13	Mood instability;
KIRP	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	8.15	0.46	1.82e-14	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg13482628	chr17:19912719	NA	0.62	8.84	0.49	1.84e-16	Schizophrenia;
KIRP	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.13	-0.46	2.16e-14	Response to antipsychotic treatment;
KIRP	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.16	-11.09	-0.58	1.88e-23	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg01200585	chr1:228362443	C1orf69	0.44	5.55	0.33	7.21e-8	Diastolic blood pressure;
KIRP	cis	rs988913	0.957	rs12525787	chr6:54789072	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.38	-0.32	1.77e-7	Menarche (age at onset);
KIRP	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg08134877	chr2:44394819	PPM1B	0.49	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-7.21	-0.42	6.78e-12	Daytime sleep phenotypes;
KIRP	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg00543991	chr22:32367038	NA	0.53	4.9	0.3	1.73e-6	Childhood ear infection;
KIRP	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg05370193	chr1:21551575	ECE1	0.47	6.26	0.37	1.71e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7215564	0.908	rs4243241	chr17:78660502	A/C	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg10792982	chr14:105748885	BRF1	0.88	13.42	0.65	3.64e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs9815354	1.000	rs7617397	chr3:41959037	T/C	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.7	-9.9	-0.53	1.13e-19	Caffeine consumption;
KIRP	cis	rs7809799	0.571	rs73163167	chr7:98943086	C/T	cg12290671	chr7:99195819	NA	-0.71	-5.37	-0.32	1.84e-7	Ulcerative colitis;
KIRP	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.54	7.22	0.42	6.54e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1341267	0.873	rs4296139	chr13:95275576	C/G	cg09582042	chr13:95253676	GPR180	0.27	4.85	0.3	2.17e-6	Triglyceride levels;
KIRP	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.43	-0.47	2.94e-15	Coronary artery disease;
KIRP	cis	rs2916247	0.954	rs7012562	chr8:93020557	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.94	-0.45	7.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4400599	0.618	rs9804045	chr1:154191691	C/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.41	5.93	0.35	1.04e-8	Platelet distribution width;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25334215	chr11:33163286	CSTF3	-0.44	-6.98	-0.41	2.78e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg07169764	chr2:136633963	MCM6	-0.53	-6.18	-0.37	2.69e-9	Mosquito bite size;
KIRP	cis	rs9815354	0.812	rs57209010	chr3:41854743	A/T	cg03022575	chr3:42003672	ULK4	0.79	8.52	0.48	1.62e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4959799	0.557	rs9503515	chr6:3272018	G/A	cg03657281	chr6:3270030	SLC22A23	0.78	6.03	0.36	6.04e-9	Survival in rectal cancer;
KIRP	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg00405596	chr8:11794950	NA	-0.6	-8.78	-0.49	2.78e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19171272	chr22:38449367	NA	-0.58	-8.89	-0.49	1.34e-16	Glioblastoma;Glioma;
KIRP	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg17554472	chr22:41940697	POLR3H	0.68	7.1	0.41	1.32e-11	Vitiligo;
KIRP	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg10657630	chr21:48055338	PRMT2	-0.41	-4.94	-0.3	1.46e-6	Testicular germ cell tumor;
KIRP	cis	rs62413470	1.000	rs62406156	chr6:55941887	A/G	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs10940138	0.830	rs4976136	chr5:67206148	G/C	ch.5.1281357F	chr5:67228439	NA	0.8	12.43	0.62	7.3e-28	Menarche (age at onset);
KIRP	cis	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg21546286	chr11:48923668	NA	0.45	5.45	0.33	1.24e-7	HDL cholesterol;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.74	10.61	0.56	6.52e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg02795151	chr17:7402630	POLR2A	0.78	8.0	0.45	4.88e-14	Androgen levels;
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg18350739	chr11:68623251	NA	-0.52	-7.79	-0.44	1.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	7.95	0.45	6.68e-14	Total body bone mineral density;
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.62	-8.46	-0.47	2.39e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-9.52	-0.52	1.65e-18	Heart rate;
KIRP	cis	rs11735612	0.624	rs35462921	chr4:138527290	T/C	cg12033966	chr4:138453416	PCDH18	0.36	5.01	0.3	1.04e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg00405596	chr8:11794950	NA	-0.5	-6.58	-0.39	2.87e-10	Retinal vascular caliber;
KIRP	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.68	7.92	0.45	8.05e-14	Breast cancer;
KIRP	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.65	-9.92	-0.53	9.7e-20	Coronary artery disease;
KIRP	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.04	0.31	8.84e-7	Menopause (age at onset);
KIRP	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.86	-13.49	-0.65	1.98e-31	Breast cancer;
KIRP	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.45	5.28	0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17818399	0.815	rs17768132	chr2:46863249	G/T	cg02822958	chr2:46747628	ATP6V1E2	-0.5	-5.44	-0.33	1.3e-7	Height;
KIRP	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.53	5.34	0.32	2.11e-7	Birth weight;
KIRP	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg04362960	chr10:104952993	NT5C2	0.55	6.58	0.39	2.82e-10	Arsenic metabolism;
KIRP	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.96	13.62	0.66	7.14e-32	Response to antipsychotic treatment;
KIRP	cis	rs7737355	1.000	rs27421	chr5:130743771	C/T	cg06647332	chr5:131281008	NA	-0.46	-5.0	-0.3	1.07e-6	Life satisfaction;
KIRP	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg04156418	chr7:157293606	NA	-0.36	-5.2	-0.31	4.29e-7	Inattentive symptoms;
KIRP	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg14893161	chr1:205819251	PM20D1	0.56	5.99	0.36	7.49e-9	Basophil percentage of granulocytes;
KIRP	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg13393036	chr8:95962371	TP53INP1	0.33	6.35	0.38	1.01e-9	Type 2 diabetes;
KIRP	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.66	-6.38	-0.38	8.57e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.43	-5.6	-0.34	5.72e-8	Refractive error;
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.26	-5.4	-0.33	1.55e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg24110177	chr3:50126178	RBM5	0.7	9.33	0.51	6.51e-18	Menarche (age at onset);
KIRP	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg01990225	chr2:97406019	LMAN2L	-0.9	-6.89	-0.4	4.54e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg22117172	chr7:91764530	CYP51A1	0.43	6.01	0.36	6.51e-9	Breast cancer;
KIRP	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.62	-7.04	-0.41	1.95e-11	Mean platelet volume;
KIRP	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.59	7.85	0.45	1.24e-13	Response to temozolomide;
KIRP	cis	rs2278796	0.608	rs6700069	chr1:204968945	A/G	cg17947172	chr1:204966197	NFASC	0.66	8.86	0.49	1.64e-16	Mean platelet volume;
KIRP	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.91	12.57	0.63	2.59e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14776894	chr11:120973197	TECTA	0.54	6.97	0.41	2.84e-11	Interleukin-4 levels;
KIRP	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.68	8.58	0.48	1.08e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg08761264	chr16:28874980	SH2B1	-0.48	-5.56	-0.33	7.17e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1891498	0.602	rs10793706	chr1:147243753	C/G	cg27546670	chr1:147246839	GJA5	-0.81	-11.24	-0.58	6.05e-24	Cognitive performance;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg01669482	chr16:25043131	NA	-0.51	-6.55	-0.39	3.39e-10	Neuroticism;
KIRP	cis	rs1514687	0.534	rs11694726	chr2:1460220	C/T	cg03133821	chr2:1513998	TPO	-0.56	-5.03	-0.31	9.57e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg09455208	chr3:40491958	NA	0.34	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	cis	rs7011507	1.000	rs79074709	chr8:49187254	T/G	cg15325961	chr8:49183143	NA	0.61	5.2	0.31	4.17e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.82	9.7	0.53	4.66e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg01864069	chr14:103024347	NA	-0.87	-9.89	-0.53	1.27e-19	Platelet count;
KIRP	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.71	10.32	0.55	5.41e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs80282103	0.618	rs11818314	chr10:1148157	G/C	cg08668510	chr10:1095578	IDI1	0.96	6.43	0.38	6.45e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs8177876	0.642	rs4324143	chr16:81114988	G/C	cg08591886	chr16:81111003	C16orf46	-0.59	-5.76	-0.34	2.45e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Bladder cancer;
KIRP	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs501916	0.833	rs59184310	chr15:48050205	A/T	cg16110827	chr15:48056943	SEMA6D	-0.37	-4.96	-0.3	1.31e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg16917193	chr12:54089295	NA	0.86	16.51	0.73	9.86e-42	Height;
KIRP	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg10117171	chr1:25599238	RHD	0.43	5.91	0.35	1.11e-8	Erythrocyte sedimentation rate;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13745593	chr4:135248186	NA	-0.43	-6.69	-0.39	1.48e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs9581857	0.546	rs9579082	chr13:27965763	C/T	cg22138327	chr13:27999177	GTF3A	1.03	7.44	0.43	1.72e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs501916	0.743	rs3743281	chr15:48056958	C/T	cg16110827	chr15:48056943	SEMA6D	-0.38	-5.02	-0.3	1e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-22.83	-0.82	1.04e-62	Exhaled nitric oxide output;
KIRP	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg07395648	chr5:131743802	NA	0.57	7.88	0.45	1.05e-13	Breast cancer;Mosquito bite size;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17524854	chr12:67663046	CAND1	0.66	6.3	0.37	1.4e-9	Lung function (FEV1);
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg10351095	chr21:47802916	PCNT	-0.41	-5.04	-0.31	8.9e-7	Testicular germ cell tumor;
KIRP	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg01559446	chr3:44596178	ZNF167	-0.37	-5.34	-0.32	2.08e-7	Depressive symptoms;
KIRP	cis	rs981844	0.712	rs6855093	chr4:154754050	A/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2224391	0.518	rs17140102	chr6:5288618	C/G	cg13962347	chr6:5174647	LYRM4	-0.66	-6.13	-0.36	3.47e-9	Height;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg20930514	chr14:77499758	NA	0.48	6.02	0.36	6.41e-9	Asthma;
KIRP	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.99	0.45	5.35e-14	Corneal astigmatism;
KIRP	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg05991184	chr2:219186017	PNKD	0.34	4.96	0.3	1.32e-6	Colorectal cancer;
KIRP	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg03468072	chr12:39539422	NA	0.41	5.48	0.33	1.07e-7	Morning vs. evening chronotype;
KIRP	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg14541582	chr5:601475	NA	-0.54	-6.08	-0.36	4.58e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg09640425	chr7:158790006	NA	-0.46	-5.91	-0.35	1.14e-8	Facial morphology (factor 20);
KIRP	cis	rs4356932	0.597	rs7679177	chr4:76853790	C/G	cg19388996	chr4:76862389	NAAA	-0.4	-5.09	-0.31	7.26e-7	Blood protein levels;
KIRP	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07636037	chr3:49044803	WDR6	0.71	8.18	0.46	1.52e-14	Menarche (age at onset);
KIRP	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg16434002	chr17:42200994	HDAC5	-0.55	-6.65	-0.39	1.87e-10	Total body bone mineral density;
KIRP	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21545522	chr1:205238299	TMCC2	0.41	5.66	0.34	4.27e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12560992	chr17:57184187	TRIM37	0.6	6.66	0.39	1.77e-10	Testicular germ cell tumor;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05671241	chr3:126373822	NA	0.49	7.17	0.42	8.61e-12	Survival in pancreatic cancer;
KIRP	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.78	11.24	0.58	6.37e-24	Blood metabolite ratios;
KIRP	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg02569458	chr12:86230093	RASSF9	0.36	5.16	0.31	5.03e-7	Major depressive disorder;
KIRP	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg01559446	chr3:44596178	ZNF167	-0.35	-5.09	-0.31	7.06e-7	Depressive symptoms;
KIRP	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg18132916	chr6:79620363	NA	-0.43	-5.92	-0.35	1.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.63	-7.84	-0.45	1.34e-13	P wave terminal force;
KIRP	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.79	-10.61	-0.56	6.7e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4919044	0.599	rs10882124	chr10:94665826	A/G	cg05127821	chr10:94822908	CYP26C1	-0.88	-7.07	-0.41	1.63e-11	Coronary artery disease;
KIRP	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.8	9.07	0.5	3.9e-17	Corneal astigmatism;
KIRP	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg18016565	chr1:150552671	MCL1	-0.47	-7.21	-0.42	6.95e-12	Blood protein levels;
KIRP	cis	rs8133932	0.654	rs382303	chr21:47349284	G/A	cg11214348	chr21:47283868	PCBP3	-0.47	-5.32	-0.32	2.29e-7	Schizophrenia;
KIRP	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-1.06	-18.72	-0.77	3.37e-49	Monocyte count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23672752	chr16:66785618	DYNC1LI2	0.44	6.1	0.36	4e-9	Survival in pancreatic cancer;
KIRP	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg13978929	chr19:21580086	ZNF493	0.5	4.89	0.3	1.83e-6	Pain;
KIRP	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-7.85	-0.45	1.26e-13	Fibrinogen levels;
KIRP	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs1843834	0.721	rs1434057	chr2:225606389	T/G	cg22455342	chr2:225449267	CUL3	0.48	5.47	0.33	1.11e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.78	-0.4	8.82e-11	Capecitabine sensitivity;
KIRP	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg03808351	chr9:123631620	PHF19	0.43	5.95	0.35	9.15e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg15841412	chr13:111365552	ING1	0.54	6.17	0.37	2.84e-9	Coronary artery disease;
KIRP	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.96	0.57	4.96e-23	Cognitive test performance;
KIRP	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.36e-14	Aortic root size;
KIRP	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg10818794	chr15:86012489	AKAP13	-0.5	-7.15	-0.41	9.9e-12	Coronary artery disease;
KIRP	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.75	9.21	0.51	1.44e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg11204139	chr17:3907470	NA	-0.62	-8.66	-0.48	6.47e-16	Type 2 diabetes;
KIRP	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.47	6.25	0.37	1.8e-9	Red blood cell count;
KIRP	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-16.08	-0.72	3.07e-40	Electrocardiographic conduction measures;
KIRP	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg07117364	chr1:16154769	NA	-0.4	-4.85	-0.3	2.18e-6	Dilated cardiomyopathy;
KIRP	cis	rs9815354	0.830	rs1624519	chr3:41984800	G/A	cg03022575	chr3:42003672	ULK4	-0.49	-5.58	-0.34	6.24e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.7	-0.39	1.41e-10	Glomerular filtration rate;
KIRP	cis	rs11016883	1.000	rs10829619	chr10:131491318	C/G	cg14312783	chr10:131504572	MGMT	0.4	5.08	0.31	7.64e-7	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg09873164	chr1:152488093	CRCT1	0.51	6.48	0.38	4.98e-10	Hair morphology;
KIRP	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	1.05	10.53	0.56	1.17e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21643547	chr1:205240462	TMCC2	-0.82	-12.76	-0.63	5.73e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.97	-0.41	2.92e-11	Acylcarnitine levels;
KIRP	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.69	7.66	0.44	4.29e-13	Corneal astigmatism;
KIRP	cis	rs876084	1.000	rs876084	chr8:121101522	A/G	cg22335954	chr8:121166405	COL14A1	-0.38	-5.06	-0.31	8.08e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg02487422	chr3:49467188	NICN1	0.39	5.51	0.33	9.24e-8	Menarche (age at onset);
KIRP	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg25173405	chr17:45401733	C17orf57	-0.48	-6.26	-0.37	1.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9625935	0.957	rs5763689	chr22:30394623	T/C	cg01021169	chr22:30184971	ASCC2	-0.43	-4.92	-0.3	1.6e-6	Tonsillectomy;
KIRP	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg00405596	chr8:11794950	NA	0.58	7.88	0.45	1.06e-13	Myopia (pathological);
KIRP	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.82	9.35	0.51	5.45e-18	Response to diuretic therapy;
KIRP	cis	rs6540559	0.673	rs6694552	chr1:209976459	A/C	cg22029157	chr1:209979665	IRF6	0.51	5.8	0.35	1.99e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11987759	chr7:65425863	GUSB	0.47	6.15	0.36	3.2e-9	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25126678	chr2:27274379	AGBL5	0.51	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg21698718	chr17:80085957	CCDC57	-0.34	-4.89	-0.3	1.84e-6	Life satisfaction;
KIRP	cis	rs1440410	0.835	rs11100771	chr4:144053881	A/G	cg01719995	chr4:144104893	USP38	-0.47	-6.51	-0.38	4.31e-10	Ischemic stroke;
KIRP	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.43	-5.14	-0.31	5.66e-7	Facial morphology (factor 20);
KIRP	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg18190219	chr22:46762943	CELSR1	-0.87	-7.46	-0.43	1.49e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1050631	0.592	rs1789547	chr18:33725705	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.48	6.03	0.36	6.1e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg08885076	chr2:99613938	TSGA10	0.53	9.26	0.51	1.06e-17	Chronic sinus infection;
KIRP	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.52	-6.76	-0.4	9.97e-11	Longevity;
KIRP	cis	rs7621025	0.505	rs34281413	chr3:136461860	C/T	cg15507776	chr3:136538369	TMEM22	-0.67	-5.96	-0.35	8.9e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs7520050	0.966	rs809775	chr1:46538040	A/T	cg03146154	chr1:46216737	IPP	-0.41	-5.39	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg26360961	chr12:7282931	CLSTN3;RBP5	0.53	6.19	0.37	2.45e-9	Electroencephalogram traits;
KIRP	cis	rs73200209	0.912	rs10507268	chr12:116540227	G/A	cg01776926	chr12:116560359	MED13L	-0.48	-5.75	-0.34	2.59e-8	Total body bone mineral density;
KIRP	cis	rs10211205	0.945	rs3754670	chr2:236617595	C/T	cg02339850	chr2:236586191	AGAP1	0.43	5.02	0.3	9.98e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.83	-11.29	-0.58	4.29e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6142102	0.961	rs1055857	chr20:32613873	A/G	cg08999081	chr20:33150536	PIGU	0.52	6.76	0.4	9.81e-11	Skin pigmentation;
KIRP	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg02696790	chr15:75250997	RPP25	0.29	5.34	0.32	2.07e-7	Breast cancer;
KIRP	cis	rs6782228	0.565	rs11719239	chr3:128419054	A/G	cg18648031	chr3:128330563	NA	0.25	4.93	0.3	1.52e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg01025720	chr13:113346439	ATP11A	0.52	5.02	0.31	9.76e-7	Glycated hemoglobin levels;
KIRP	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.91	0.4	4.19e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs2802372	0.620	rs1250544	chr10:81032885	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.41	-5.27	-0.32	2.92e-7	Granulocyte count;
KIRP	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.62	-8.17	-0.46	1.64e-14	Height;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.37	-0.32	1.78e-7	Life satisfaction;
KIRP	cis	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg19171272	chr22:38449367	NA	-0.65	-9.79	-0.53	2.52e-19	Glioblastoma;Glioma;
KIRP	cis	rs6832769	0.925	rs2412663	chr4:56455816	C/A	cg09317128	chr4:56265301	TMEM165	-0.5	-6.38	-0.38	8.57e-10	Personality dimensions;
KIRP	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.14	12.03	0.61	1.63e-26	Mitochondrial DNA levels;
KIRP	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.97	11.72	0.6	1.63e-25	Corneal astigmatism;
KIRP	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg12658694	chr1:38397304	INPP5B	0.64	8.2	0.46	1.32e-14	Coronary artery disease;
KIRP	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.48	0.59	1.06e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg24747557	chr10:131355152	MGMT	-0.46	-6.41	-0.38	7.41e-10	Response to temozolomide;
KIRP	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg09904177	chr6:26538194	HMGN4	-0.44	-5.81	-0.35	1.97e-8	Schizophrenia;
KIRP	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	trans	rs587242	0.911	rs80336582	chr1:96901001	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.55	-0.43	8.74e-13	Type 2 diabetes;
KIRP	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.69	9.99	0.54	6.07e-20	Lymphocyte counts;
KIRP	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.02	0.31	9.74e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-4.96	-0.3	1.31e-6	Metabolite levels;
KIRP	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg10932868	chr11:921992	NA	-0.62	-8.01	-0.45	4.52e-14	Alzheimer's disease (late onset);
KIRP	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.48	-0.33	1.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.26	6.27	0.37	1.57e-9	IgG glycosylation;
KIRP	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.5	7.18	0.42	8.21e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg07701084	chr6:150067640	NUP43	0.69	9.76	0.53	3.13e-19	Lung cancer;
KIRP	cis	rs600806	0.745	rs4970763	chr1:110006349	G/A	cg02175308	chr1:109941060	SORT1	-0.26	-4.88	-0.3	1.87e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.43	-5.65	-0.34	4.53e-8	Testicular germ cell tumor;
KIRP	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.02	0.3	9.8e-7	Menopause (age at onset);
KIRP	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.75	7.56	0.43	8.2e-13	Bipolar disorder;
KIRP	cis	rs2273156	0.570	rs79702597	chr14:35558856	G/A	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.03	-0.31	9.37e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.68	-0.34	3.87e-8	Parkinson's disease;
KIRP	cis	rs4713675	0.584	rs7759668	chr6:33670406	C/T	cg15676125	chr6:33679581	C6orf125	-0.44	-5.54	-0.33	7.81e-8	Plateletcrit;
KIRP	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.12	-0.5	2.85e-17	Neuroticism;
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.49e-13	Life satisfaction;
KIRP	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg21100191	chr22:23484243	RTDR1	1.0	17.31	0.74	1.91e-44	Bone mineral density;
KIRP	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg14593290	chr7:50529359	DDC	-0.65	-7.73	-0.44	2.73e-13	Malaria;
KIRP	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg06637938	chr14:75390232	RPS6KL1	0.7	9.46	0.52	2.65e-18	Height;
KIRP	cis	rs7119038	0.818	rs6589686	chr11:118612565	G/A	cg19308663	chr11:118741387	NA	0.45	7.16	0.42	9.28e-12	Sjögren's syndrome;
KIRP	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.52	7.3	0.42	3.89e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.6	7.94	0.45	7.31e-14	Alcohol dependence;
KIRP	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg14541582	chr5:601475	NA	-0.58	-6.65	-0.39	1.89e-10	Obesity-related traits;
KIRP	cis	rs832540	0.866	rs252894	chr5:56224339	A/C	cg14703610	chr5:56206110	C5orf35	-0.47	-6.22	-0.37	2.11e-9	Coronary artery disease;
KIRP	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.94	14.37	0.68	2.1e-34	Body mass index (adult);
KIRP	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg00343986	chr7:65444356	GUSB	0.39	4.86	0.3	2.12e-6	Aortic root size;
KIRP	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg08648136	chr8:956695	NA	0.41	6.12	0.36	3.6e-9	Schizophrenia;
KIRP	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.44	5.78	0.35	2.26e-8	Blood metabolite levels;
KIRP	cis	rs1376877	0.519	rs12466364	chr2:204226331	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.48	4.96	0.3	1.31e-6	Subclinical atherosclerosis traits (other);
KIRP	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.88	13.75	0.66	2.63e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10129255	0.500	rs6576229	chr14:107186773	G/A	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.31	5.09e-7	Kawasaki disease;
KIRP	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg08741688	chr4:3415352	RGS12	-0.47	-5.23	-0.32	3.67e-7	Serum sulfate level;
KIRP	cis	rs5753037	0.838	rs5763565	chr22:30271962	A/T	cg27665648	chr22:30112403	NA	0.37	5.2	0.31	4.22e-7	Type 1 diabetes;
KIRP	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-8.31	-0.47	6.32e-15	Mean corpuscular volume;
KIRP	cis	rs364477	0.762	rs9299103	chr9:1001231	G/T	cg13952963	chr9:998547	NA	-0.62	-5.38	-0.32	1.72e-7	Major depressive disorder;
KIRP	cis	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg21605333	chr4:119757512	SEC24D	0.78	6.35	0.38	1.04e-9	Cannabis dependence symptom count;
KIRP	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg27205649	chr11:78285834	NARS2	-0.62	-7.19	-0.42	7.96e-12	Testicular germ cell tumor;
KIRP	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg13092806	chr2:177043255	NA	0.66	7.06	0.41	1.67e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.1	-0.54	2.74e-20	Neuroticism;
KIRP	trans	rs9329221	0.539	rs35060302	chr8:10264771	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.12	0.41	1.21e-11	Neuroticism;
KIRP	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23291865	chr20:5093660	C20orf30	-0.48	-6.99	-0.41	2.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7113850	0.541	rs78652241	chr11:24234956	A/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.37	0.47	4.29e-15	Bone fracture in osteoporosis;
KIRP	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.52	0.52	1.7e-18	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg13660082	chr14:53194042	PSMC6	-0.67	-7.3	-0.42	3.88e-12	Alzheimer's disease (late onset);
KIRP	cis	rs10267417	0.657	rs16872411	chr7:19913562	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.05	0.31	8.55e-7	Night sleep phenotypes;
KIRP	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.28	25.3	0.85	2.09e-70	IgG glycosylation;
KIRP	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.5	0.33	9.41e-8	Coronary artery disease;
KIRP	trans	rs2048656	0.561	rs9650639	chr8:9542601	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.46	-0.38	5.5e-10	Schizophrenia;
KIRP	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg23100626	chr2:96804247	ASTL	0.49	7.06	0.41	1.7e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4243830	0.826	rs3908553	chr1:6621921	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.84	6.55	0.39	3.28e-10	Body mass index;
KIRP	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	1.08	19.91	0.79	3.31e-53	Gut microbiome composition (winter);
KIRP	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg12315302	chr6:26189340	HIST1H4D	0.99	6.87	0.4	5.11e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg25019033	chr10:957182	NA	-0.61	-7.44	-0.43	1.7e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg16606324	chr3:10149918	C3orf24	0.59	5.41	0.33	1.48e-7	Alzheimer's disease;
KIRP	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.6	-0.52	9.89e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	1.01	9.45	0.52	2.72e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08704250	chr15:31115839	NA	0.42	7.25	0.42	5.37e-12	Huntington's disease progression;
KIRP	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.56	7.0	0.41	2.4e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2281603	0.570	rs11626222	chr14:64953259	G/A	cg01860774	chr14:64969374	ZBTB25	0.33	5.4	0.33	1.58e-7	Lymphocyte counts;
KIRP	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.47	7.56	0.43	7.76e-13	Eye color traits;
KIRP	cis	rs7181230	1.000	rs28620926	chr15:40357171	A/G	cg20592017	chr15:40364740	NA	0.34	4.91	0.3	1.63e-6	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.95	-14.5	-0.68	7.37e-35	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg19197139	chr17:4613644	ARRB2	0.74	7.6	0.44	6.27e-13	Lymphocyte counts;
KIRP	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.71	9.65	0.52	7.03e-19	Schizophrenia;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg08132940	chr7:1081526	C7orf50	-0.7	-7.15	-0.41	1.01e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.75	-10.69	-0.56	3.81e-22	Neurofibrillary tangles;
KIRP	trans	rs1973993	0.561	rs56142427	chr1:96992318	A/G	cg10631902	chr5:14652156	NA	-0.56	-6.81	-0.4	7.34e-11	Weight;
KIRP	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.5	-7.32	-0.42	3.58e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg05255149	chr17:80675120	FN3KRP	-0.46	-5.26	-0.32	3.09e-7	Breast cancer;
KIRP	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.31	0.62	1.87e-27	Morning vs. evening chronotype;
KIRP	cis	rs1866706	0.896	rs7105759	chr11:12868817	T/A	cg25843174	chr11:12811716	TEAD1	-0.32	-5.59	-0.34	6.03e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg13736514	chr6:26305472	NA	-0.67	-8.12	-0.46	2.3e-14	Educational attainment;
KIRP	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.53	7.93	0.45	7.75e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10463316	0.894	rs1876619	chr5:150744773	G/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.47	-0.38	5.11e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.46	-7.12	-0.41	1.15e-11	Coronary artery disease;
KIRP	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg14673194	chr17:80132900	CCDC57	0.77	8.66	0.48	6.54e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2017305	0.834	rs79520726	chr10:70781956	T/C	cg01024728	chr10:70782572	NA	0.63	5.22	0.32	3.78e-7	Depression (quantitative trait);
KIRP	cis	rs9378796	0.518	rs13213207	chr6:3439065	C/T	cg00476032	chr6:3446245	SLC22A23	-0.53	-5.07	-0.31	7.91e-7	Mean platelet volume;
KIRP	cis	rs7078012	0.504	rs78496266	chr10:81686762	C/T	cg24613050	chr10:81743128	NA	-0.54	-5.14	-0.31	5.61e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.93	10.0	0.54	5.44e-20	Alzheimer's disease;
KIRP	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.85	0.49	1.7e-16	Bipolar disorder;
KIRP	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14893161	chr1:205819251	PM20D1	-0.45	-5.68	-0.34	3.72e-8	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg02725872	chr8:58115012	NA	-0.51	-6.09	-0.36	4.32e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7127129	0.503	rs1131715	chr11:70053487	C/T	cg06159181	chr11:70072977	NA	-0.34	-5.32	-0.32	2.33e-7	Aortic root size;
KIRP	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg07936489	chr17:37558343	FBXL20	-0.51	-6.5	-0.38	4.48e-10	Asthma;
KIRP	trans	rs6596140	0.620	rs10065215	chr5:133029538	A/G	cg08567913	chr11:114082594	ZBTB16	-0.43	-6.08	-0.36	4.55e-9	Hypertension;
KIRP	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg15655495	chr12:38532458	NA	-0.3	-5.29	-0.32	2.64e-7	Bladder cancer;
KIRP	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.24	0.42	5.86e-12	Retinal vascular caliber;
KIRP	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg17796960	chr10:135278976	LOC619207	-0.48	-5.51	-0.33	8.83e-8	Systemic lupus erythematosus;
KIRP	cis	rs745821	0.701	rs75376611	chr18:48099877	A/G	cg18923635	chr18:48083994	NA	0.43	5.12	0.31	6.19e-7	Diastolic blood pressure;
KIRP	cis	rs7766436	0.848	rs6903685	chr6:22605813	C/T	cg13666174	chr6:22585274	NA	-0.47	-6.3	-0.37	1.37e-9	Coronary artery disease;
KIRP	cis	rs2016266	0.859	rs11170506	chr12:53730759	G/T	cg16917193	chr12:54089295	NA	-0.51	-5.95	-0.35	9.37e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4805834	0.843	rs17206254	chr19:33356962	C/T	cg07201929	chr19:33182834	NUDT19	-0.62	-5.01	-0.3	1.05e-6	Creatinine levels;
KIRP	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.68	8.1	0.46	2.57e-14	Diabetic retinopathy;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg04025307	chr7:1156635	C7orf50	0.68	8.91	0.49	1.16e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1021993	0.545	rs4844820	chr1:209554465	G/A	cg24446417	chr1:209558027	NA	-0.5	-4.85	-0.3	2.2e-6	Gut microbiome composition (winter);
KIRP	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg13180566	chr4:1052158	NA	-0.54	-5.44	-0.33	1.29e-7	Recombination rate (females);
KIRP	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg13165212	chr22:42675999	NA	0.28	5.18	0.31	4.51e-7	Cognitive function;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17977556	chr15:69553073	GLCE	-0.42	-6.28	-0.37	1.51e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.76	10.88	0.57	8.91e-23	Height;
KIRP	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.52	-13.92	-0.66	7.27e-33	Airflow obstruction;
KIRP	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.43	5.9	0.35	1.19e-8	Total body bone mineral density;
KIRP	cis	rs911119	0.913	rs13043610	chr20:23586941	G/A	cg16589663	chr20:23618590	CST3	0.68	6.35	0.38	1.04e-9	Chronic kidney disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01758115	chr16:48357692	LONP2	0.53	7.25	0.42	5.31e-12	Interleukin-4 levels;
KIRP	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.97	-0.41	2.9e-11	Neutrophil percentage of white cells;
KIRP	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	1.08	19.25	0.78	5.36e-51	Monocyte count;
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg19536664	chr17:6899085	ALOX12	0.46	6.9	0.4	4.48e-11	Tonsillectomy;
KIRP	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg09137382	chr11:130731461	NA	0.57	7.99	0.45	5.24e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs74181299	0.964	rs2540948	chr2:65284623	T/C	cg05010058	chr2:65284262	CEP68	0.43	5.7	0.34	3.44e-8	Pulse pressure;
KIRP	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.8	10.75	0.57	2.32e-22	Triglycerides;
KIRP	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11987759	chr7:65425863	GUSB	0.52	6.94	0.4	3.36e-11	Aortic root size;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07178008	chr18:19445471	MIB1	0.44	6.58	0.39	2.78e-10	Migraine with aura;
KIRP	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	1.03	14.59	0.68	3.81e-35	Cognitive function;
KIRP	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11987759	chr7:65425863	GUSB	0.49	6.38	0.38	8.5e-10	Aortic root size;
KIRP	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg14689365	chr7:158441557	NCAPG2	0.46	5.73	0.34	2.88e-8	Height;
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg06815112	chr8:27182871	PTK2B	0.5	6.57	0.39	2.95e-10	Neuroticism;
KIRP	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.2	0.46	1.3e-14	Personality dimensions;
KIRP	cis	rs7116495	1.000	rs3793938	chr11:71823133	G/A	cg11196788	chr11:71737549	NUMA1	-0.57	-5.07	-0.31	7.72e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg05673287	chr15:77411982	SGK269	-0.39	-5.07	-0.31	7.66e-7	Type 2 diabetes;
KIRP	cis	rs10207628	1.000	rs1530047	chr2:127848936	A/C	cg06223080	chr2:127868745	NA	-0.58	-7.54	-0.43	9.29e-13	Psychosis and Alzheimer's disease;
KIRP	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg21858823	chr1:15850916	CASP9	0.54	5.81	0.35	1.92e-8	Systolic blood pressure;
KIRP	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00321850	chr1:175162397	KIAA0040	-0.33	-6.04	-0.36	5.76e-9	Alcohol dependence;
KIRP	cis	rs3821902	0.646	rs17344570	chr3:64014239	A/C	cg09006292	chr3:64049408	NA	0.54	5.88	0.35	1.32e-8	Breast cancer;
KIRP	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.28e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg04944784	chr2:26401820	FAM59B	0.7	7.52	0.43	1.01e-12	Gut microbiome composition (summer);
KIRP	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.48	-0.33	1.07e-7	Coronary artery disease;
KIRP	cis	rs12049351	0.774	rs2381108	chr1:229637881	T/G	cg11742688	chr1:229674241	ABCB10	-0.37	-5.52	-0.33	8.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg06307176	chr5:131281290	NA	0.55	6.03	0.36	6.12e-9	Life satisfaction;
KIRP	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.38	4.98	0.3	1.18e-6	Obesity-related traits;
KIRP	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.63	7.88	0.45	1.05e-13	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.61	-0.44	5.98e-13	Morning vs. evening chronotype;
KIRP	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg27211696	chr2:191398769	TMEM194B	-0.53	-6.43	-0.38	6.64e-10	Diastolic blood pressure;
KIRP	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.44	-5.34	-0.32	2.16e-7	Testicular germ cell tumor;
KIRP	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.71	9.76	0.53	3.07e-19	Colorectal cancer;
KIRP	cis	rs7119167	0.686	rs7933162	chr11:73044213	A/C	cg17517138	chr11:73019481	ARHGEF17	0.46	4.96	0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.87	-0.3	1.97e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs894344	0.572	rs16905168	chr8:135550179	C/T	cg04050898	chr8:135490694	ZFAT	-0.38	-5.26	-0.32	3.12e-7	Systolic blood pressure;
KIRP	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg00677455	chr12:58241039	CTDSP2	-0.5	-5.62	-0.34	5.05e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg02993010	chr8:124780839	FAM91A1	-0.59	-6.11	-0.36	3.8e-9	Pancreatic cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15738916	chr2:102314495	MAP4K4	0.6	7.08	0.41	1.51e-11	Smoking initiation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00983485	chr15:31284262	MTMR10	0.54	6.26	0.37	1.68e-9	Smoking initiation;
KIRP	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg25173405	chr17:45401733	C17orf57	0.43	5.55	0.33	7.46e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.4	4.95	0.3	1.4e-6	Diabetic retinopathy;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13570982	chr14:55596240	LGALS3	-0.49	-6.06	-0.36	5.19e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-6.77	-0.4	9.2e-11	Heart rate;
KIRP	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.59	-8.96	-0.5	8.41e-17	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg21573476	chr21:45109991	RRP1B	-0.54	-7.35	-0.42	2.99e-12	Mean corpuscular volume;
KIRP	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.53	0.52	1.54e-18	Colorectal cancer;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg14839134	chr8:61496287	RAB2A	-0.44	-6.12	-0.36	3.64e-9	Select biomarker traits;
KIRP	cis	rs4141404	0.851	rs9606833	chr22:31750013	T/C	cg22777020	chr22:31556080	RNF185	0.54	5.21	0.32	3.98e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.91	-13.4	-0.65	4e-31	Systemic lupus erythematosus;
KIRP	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.62	9.41	0.51	3.74e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	trans	rs587242	1.000	rs2011694	chr1:96884286	T/A	cg10631902	chr5:14652156	NA	0.53	6.11	0.36	3.91e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs7945718	0.621	rs10831887	chr11:12665436	A/C	cg25843174	chr11:12811716	TEAD1	0.34	6.28	0.37	1.56e-9	Educational attainment (years of education);
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08805041	chr16:621841	PIGQ	-0.37	-5.14	-0.31	5.62e-7	Height;
KIRP	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	1.08	20.53	0.79	3.08e-55	Height;
KIRP	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.53	-7.09	-0.41	1.42e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.63	-7.18	-0.42	8.33e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22752895	chr6:3118674	BPHL	0.52	6.97	0.41	2.87e-11	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.17	-0.37	2.8e-9	Lung cancer;
KIRP	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.44	-0.38	6.35e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg17441377	chr17:3906640	NA	0.55	8.32	0.47	6.06e-15	Type 2 diabetes;
KIRP	cis	rs13034020	0.522	rs4564760	chr2:61248575	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.59	6.5	0.38	4.34e-10	Hodgkin's lymphoma;
KIRP	cis	rs860295	0.836	rs35615695	chr1:155501014	T/C	cg02153340	chr1:155202674	NA	0.38	5.09	0.31	7.02e-7	Body mass index;
KIRP	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	1.12	16.11	0.72	2.43e-40	Multiple sclerosis;
KIRP	cis	rs6959887	0.962	rs6976630	chr7:35285562	A/G	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg16989719	chr2:238392110	NA	-0.55	-6.23	-0.37	1.95e-9	Prostate cancer;
KIRP	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26617929	chr16:1858877	NA	-0.62	-5.5	-0.33	9.66e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04884244	chr1:155448900	ASH1L	-0.41	-6.07	-0.36	4.94e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.77	9.43	0.52	3.15e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg26138937	chr11:71823887	C11orf51	-1.11	-7.13	-0.41	1.1e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs9581857	0.547	rs75085794	chr13:28095944	A/C	cg22138327	chr13:27999177	GTF3A	0.82	6.35	0.38	1e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.8	10.33	0.55	5.27e-21	Mean platelet volume;
KIRP	cis	rs6504622	0.537	rs197919	chr17:45003675	C/T	cg16759221	chr17:45003025	GOSR2	-0.39	-5.81	-0.35	1.88e-8	Orofacial clefts;
KIRP	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9815354	1.000	rs7624372	chr3:41881107	T/A	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg19752551	chr11:57585705	CTNND1	0.74	12.4	0.62	9.36e-28	Schizophrenia;
KIRP	cis	rs6450176	0.951	rs255757	chr5:53309371	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.1	-0.58	1.75e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.66	6.68	0.39	1.6e-10	Vitiligo;
KIRP	cis	rs654950	0.840	rs2810551	chr1:41995402	G/A	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.47	-0.38	5.23e-10	Airway imaging phenotypes;
KIRP	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg07870213	chr5:140052090	DND1	-0.62	-7.72	-0.44	2.99e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.79	-0.49	2.67e-16	Personality dimensions;
KIRP	cis	rs6594499	0.872	rs13178997	chr5:110444249	G/T	cg04022379	chr5:110408740	TSLP	0.48	7.28	0.42	4.37e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.51	-7.21	-0.42	6.69e-12	Schizophrenia;
KIRP	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.45	-6.82	-0.4	7.01e-11	Coronary artery disease;
KIRP	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg25301532	chr20:43378953	KCNK15	0.59	6.86	0.4	5.68e-11	Obesity-related traits;
KIRP	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17415451	chr5:11589049	CTNND2	0.4	6.19	0.37	2.55e-9	Inflammatory biomarkers;
KIRP	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.92	12.2	0.61	4.46e-27	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs13401104	0.531	rs12469569	chr2:237113376	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs4730250	0.554	rs76257331	chr7:106916279	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-7.62	-0.44	5.52e-13	Osteoarthritis;
KIRP	cis	rs6882076	1.000	rs9715911	chr5:156394441	G/A	cg12943317	chr5:156479607	HAVCR1	-0.66	-7.99	-0.45	5.2e-14	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg25566285	chr7:158114605	PTPRN2	-0.71	-9.92	-0.53	1.02e-19	Response to amphetamines;
KIRP	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg00806126	chr19:22604979	ZNF98	0.67	6.91	0.4	4.06e-11	Pain;
KIRP	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg13906792	chr15:75199810	C15orf17	-0.37	-5.41	-0.33	1.52e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg09658497	chr7:2847517	GNA12	-0.36	-4.97	-0.3	1.23e-6	Height;
KIRP	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.55	-5.79	-0.35	2.19e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	11.8	0.6	9.1e-26	Lung cancer in ever smokers;
KIRP	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.05	-20.71	-0.8	7.51e-56	Myeloid white cell count;
KIRP	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.79	12.07	0.61	1.14e-26	Multiple myeloma (IgH translocation);
KIRP	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.16	-0.31	5.2e-7	Dupuytren's disease;
KIRP	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.19	-0.46	1.39e-14	Monocyte percentage of white cells;
KIRP	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.42	-5.68	-0.34	3.85e-8	Homoarginine levels;
KIRP	cis	rs2594989	0.943	rs62245870	chr3:11439838	G/A	cg01796438	chr3:11312864	ATG7	-0.59	-7.54	-0.43	9.32e-13	Circulating chemerin levels;
KIRP	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.66	-8.05	-0.46	3.63e-14	Menarche (age at onset);
KIRP	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.44	-9.75	-0.53	3.36e-19	Alzheimer's disease (late onset);
KIRP	cis	rs2274273	0.745	rs748017	chr14:55542300	A/G	cg04306507	chr14:55594613	LGALS3	0.41	6.26	0.37	1.67e-9	Protein biomarker;
KIRP	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg26875233	chr11:93583750	C11orf90	-0.4	-7.56	-0.43	8.21e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs73200209	0.704	rs56258518	chr12:116596371	G/A	cg01776926	chr12:116560359	MED13L	-0.52	-5.84	-0.35	1.62e-8	Total body bone mineral density;
KIRP	cis	rs72960926	0.744	rs72957983	chr6:74968228	A/G	cg03266952	chr6:74778945	NA	-0.6	-5.29	-0.32	2.66e-7	Metabolite levels (MHPG);
KIRP	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	5.52	0.33	8.38e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.47	5.8	0.35	2.01e-8	Mean platelet volume;
KIRP	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg16083429	chr3:49237500	CCDC36	-0.39	-5.07	-0.31	7.9e-7	Menarche (age at onset);
KIRP	cis	rs10782582	0.609	rs5745547	chr1:76378275	G/C	cg03433033	chr1:76189801	ACADM	-0.47	-6.85	-0.4	5.97e-11	Daytime sleep phenotypes;
KIRP	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg24972876	chr7:65420302	NA	0.44	6.38	0.38	8.71e-10	Calcium levels;
KIRP	trans	rs12517041	1.000	rs4701360	chr5:23292240	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.92	-0.49	1.11e-16	Calcium levels;
KIRP	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg00677455	chr12:58241039	CTDSP2	-0.46	-5.43	-0.33	1.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg13939156	chr17:80058883	NA	0.5	5.92	0.35	1.06e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.23	-0.32	3.6e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.51	5.16	0.31	4.98e-7	Initial pursuit acceleration;
KIRP	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg11465639	chr17:19241549	NA	0.39	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.72	-0.34	3.03e-8	Non-small cell lung cancer;
KIRP	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg23335576	chr14:104009727	NA	0.4	5.88	0.35	1.32e-8	Body mass index;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg05315796	chr3:52349193	DNAH1	0.45	6.94	0.4	3.53e-11	Electroencephalogram traits;
KIRP	cis	rs6545883	0.507	rs4672427	chr2:61469250	A/G	cg15711740	chr2:61764176	XPO1	0.39	4.9	0.3	1.76e-6	Tuberculosis;
KIRP	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	1.0	17.68	0.75	1.05e-45	Breast cancer;
KIRP	cis	rs7178375	1.000	rs28693590	chr15:31195021	A/G	cg19680485	chr15:31195859	MTMR15	-0.54	-4.92	-0.3	1.58e-6	Hypertriglyceridemia;
KIRP	cis	rs6568686	0.527	rs174396	chr6:111919334	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.22	0.32	3.86e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs7215564	0.908	rs2316063	chr17:78663360	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	trans	rs13067306	0.748	rs17816812	chr3:94153867	C/T	cg22377486	chr17:41984018	MPP2	-0.51	-6.32	-0.37	1.24e-9	Blood pressure measurement (high sodium intervention);
KIRP	cis	rs10773046	0.740	rs11057382	chr12:124362889	C/T	cg18594669	chr12:124364423	DNAH10	0.37	5.01	0.3	1.05e-6	Osteoarthritis (hip);
KIRP	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	1.03	7.69	0.44	3.58e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs965604	1.000	rs12904234	chr15:78779384	C/T	cg24631222	chr15:78858424	CHRNA5	-0.39	-4.88	-0.3	1.94e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.88	-10.04	-0.54	4.08e-20	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.68	0.48	5.45e-16	Life satisfaction;
KIRP	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.96e-7	Body mass index;
KIRP	cis	rs6466055	0.777	rs3801278	chr7:104907017	C/T	cg04380332	chr7:105027541	SRPK2	0.64	9.72	0.53	4.08e-19	Schizophrenia;
KIRP	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg00745463	chr17:30367425	LRRC37B	0.53	5.0	0.3	1.08e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs554111	0.660	rs658851	chr1:21079425	T/C	cg21184320	chr1:21044207	KIF17	0.4	5.97	0.36	8.37e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2882667	0.898	rs10058347	chr5:138361358	G/A	cg04439458	chr5:138467593	SIL1	-0.44	-7.29	-0.42	4.2e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg23205692	chr1:25664452	TMEM50A	0.37	5.22	0.32	3.8e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg07701084	chr6:150067640	NUP43	-0.74	-10.06	-0.54	3.61e-20	Lung cancer;
KIRP	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg12560992	chr17:57184187	TRIM37	0.61	5.52	0.33	8.6e-8	Cognitive test performance;
KIRP	trans	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg25042112	chr7:64838748	ZNF92	-0.55	-6.07	-0.36	4.76e-9	Pain;
KIRP	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg19418458	chr7:158789849	NA	-0.43	-5.07	-0.31	7.66e-7	Facial morphology (factor 20);
KIRP	trans	rs78049276	0.736	rs73855814	chr4:148397751	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.66	-7.29	-0.42	4.26e-12	Pulse pressure;
KIRP	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg15893493	chr8:124194847	FAM83A	0.93	7.94	0.45	7.42e-14	Urinary uromodulin levels;
KIRP	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.58	8.02	0.46	4.37e-14	Heart rate;
KIRP	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg23565292	chr14:50234668	KLHDC2	-0.45	-5.36	-0.32	1.87e-7	Carotid intima media thickness;
KIRP	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.79	10.11	0.54	2.64e-20	Coronary artery disease;
KIRP	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg24488311	chr11:68621650	NA	0.48	5.54	0.33	7.77e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.5	-9.32	-0.51	6.7e-18	Cystic fibrosis severity;
KIRP	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg08499158	chr17:42289980	UBTF	-0.65	-8.36	-0.47	4.58e-15	Total body bone mineral density;
KIRP	cis	rs6959887	0.962	rs2024343	chr7:35297620	A/G	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg23533419	chr12:54090519	NA	-0.31	-4.88	-0.3	1.94e-6	Height;
KIRP	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.65	7.38	0.43	2.39e-12	Hair shape;
KIRP	cis	rs318719	1	rs318719	chr19:11496981	T/C	cg08680689	chr19:11670216	ELOF1	-0.55	-5.38	-0.32	1.76e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09529600	chr5:147651477	SPINK5L3	-0.44	-6.71	-0.39	1.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg25174290	chr11:3078921	CARS	-0.59	-6.54	-0.38	3.5e-10	Calcium levels;
KIRP	cis	rs554111	0.660	rs541464	chr1:21067095	C/T	cg08890418	chr1:21044141	KIF17	0.56	8.7	0.48	4.91e-16	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.42	0.51	3.53e-18	Height;
KIRP	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.11e-13	Uric acid levels;
KIRP	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.81	-11.86	-0.6	5.92e-26	Systemic lupus erythematosus;
KIRP	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.83	-12.94	-0.64	1.43e-29	Prostate cancer;
KIRP	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg11584989	chr19:19387371	SF4	-0.41	-5.23	-0.32	3.59e-7	Tonsillectomy;
KIRP	trans	rs11165623	0.585	rs55896436	chr1:96994162	G/A	cg10631902	chr5:14652156	NA	-0.51	-6.76	-0.4	1e-10	Hip circumference;Waist circumference;
KIRP	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.01	0.41	2.23e-11	Mean corpuscular volume;
KIRP	cis	rs62413470	0.938	rs12207662	chr6:55931147	G/A	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs983545	0.540	rs34059555	chr3:16892585	A/G	cg23220897	chr3:16924709	NA	-0.29	-4.89	-0.3	1.85e-6	Blood protein levels;
KIRP	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg25486957	chr4:152246857	NA	-0.52	-5.69	-0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7712401	0.601	rs374403	chr5:122341713	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.41	-0.33	1.48e-7	Mean platelet volume;
KIRP	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09497020	chr5:893046	TRIP13;BRD9	-0.48	-6.44	-0.38	6.32e-10	Myopia;
KIRP	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9398803	0.835	rs1602278	chr6:126838605	A/C	cg19875578	chr6:126661172	C6orf173	0.43	5.5	0.33	9.32e-8	Male-pattern baldness;
KIRP	trans	rs2270927	0.510	rs2358712	chr5:75580687	A/G	cg13563193	chr19:33072644	PDCD5	0.91	6.78	0.4	8.85e-11	Mean corpuscular volume;
KIRP	cis	rs62027291	0.654	rs11634136	chr15:77063039	A/G	cg23625390	chr15:77176239	SCAPER	-0.76	-5.49	-0.33	9.95e-8	Plateletcrit;
KIRP	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.95	-0.45	6.69e-14	Retinal vascular caliber;
KIRP	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg00383909	chr3:49044727	WDR6	0.45	4.97	0.3	1.24e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27297192	chr10:134578999	INPP5A	0.5	6.3	0.37	1.37e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8756	0.875	rs1042725	chr12:66358347	C/T	cg06712651	chr12:66351869	HMGA2	-0.73	-12.31	-0.62	1.92e-27	Height;
KIRP	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.51	6.52	0.38	3.9e-10	Menopause (age at onset);
KIRP	cis	rs9815354	0.680	rs114714860	chr3:41882905	G/C	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2014572	0.967	rs10418480	chr19:57755055	C/T	cg24459738	chr19:57751996	ZNF805	-0.54	-6.73	-0.39	1.17e-10	Hyperactive-impulsive symptoms;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02647388	chr6:7541868	DSP	0.45	6.09	0.36	4.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7523273	0.526	rs677715	chr1:208047284	A/G	cg22525895	chr1:207977042	MIR29B2	0.43	5.42	0.33	1.42e-7	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg22800045	chr5:56110881	MAP3K1	0.72	7.71	0.44	3.04e-13	Initial pursuit acceleration;
KIRP	trans	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg13565492	chr6:43139072	SRF	-0.93	-8.77	-0.49	3.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.46	6.8	0.4	7.67e-11	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs311392	0.554	rs377049	chr8:55097512	A/G	cg11783602	chr8:55087084	NA	-0.48	-5.82	-0.35	1.8e-8	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09368670	chr1:109234826	PRPF38B	-0.49	-6.03	-0.36	5.89e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6750047	0.625	rs336037	chr2:38261124	T/C	cg07380506	chr2:38303506	CYP1B1	-0.45	-5.86	-0.35	1.49e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.76	11.68	0.6	2.31e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.64	0.48	7.16e-16	Response to antipsychotic treatment;
KIRP	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07476653	chr7:5570327	ACTB	0.44	6.03	0.36	5.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.18	-0.31	4.68e-7	Ulcerative colitis;
KIRP	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.79	0.4	8.38e-11	Breast cancer;
KIRP	cis	rs490234	0.966	rs545900	chr9:128341278	C/T	cg14078157	chr9:128172775	NA	0.42	5.33	0.32	2.25e-7	Mean arterial pressure;
KIRP	cis	rs963731	0.649	rs297159	chr2:39328827	C/T	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs11209002	0.614	rs12140736	chr1:67586671	T/C	cg02640540	chr1:67518911	SLC35D1	0.6	6.73	0.39	1.22e-10	Crohn's disease;
KIRP	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg10503236	chr1:231470652	EXOC8	-0.5	-7.1	-0.41	1.31e-11	Hemoglobin concentration;
KIRP	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg18490616	chr2:88469792	THNSL2	0.67	5.4	0.33	1.56e-7	Plasma clusterin levels;
KIRP	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.51	-5.74	-0.34	2.74e-8	Neuroticism;
KIRP	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs11955398	0.542	rs2085413	chr5:60025379	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.33	-0.32	2.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.25	-0.47	9.95e-15	Blood protein levels;
KIRP	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg26207909	chr14:103986467	CKB	-0.44	-5.37	-0.32	1.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.74	9.12	0.5	2.73e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.72	8.25	0.47	9.94e-15	Cognitive ability;
KIRP	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg14159672	chr1:205819179	PM20D1	0.42	4.86	0.3	2.11e-6	White blood cell types;
KIRP	cis	rs732716	0.813	rs760369	chr19:4449287	C/T	cg21720385	chr19:4455239	UBXN6	-0.67	-8.46	-0.47	2.41e-15	Mean corpuscular volume;
KIRP	cis	rs9302635	0.513	rs9923575	chr16:72230112	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.66	-0.34	4.28e-8	Blood protein levels;
KIRP	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.56	-0.39	3.24e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.72	-7.08	-0.41	1.46e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.55	-6.88	-0.4	4.94e-11	Morning vs. evening chronotype;
KIRP	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.72	-8.51	-0.48	1.69e-15	Diastolic blood pressure;
KIRP	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.51	6.38	0.38	8.62e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg04733989	chr22:42467013	NAGA	0.49	5.9	0.35	1.23e-8	Cognitive function;
KIRP	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.65	-9.2	-0.51	1.61e-17	Retinal vascular caliber;
KIRP	cis	rs28595532	0.748	rs66615663	chr4:119336701	C/T	cg21605333	chr4:119757512	SEC24D	0.94	7.19	0.42	7.56e-12	Cannabis dependence symptom count;
KIRP	cis	rs10782582	0.609	rs1630302	chr1:76412090	A/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.42	-0.38	6.98e-10	Daytime sleep phenotypes;
KIRP	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.62	-7.0	-0.41	2.4e-11	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.79	8.08	0.46	2.95e-14	Hip geometry;
KIRP	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	13.02	0.64	8.06e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.48	6.67	0.39	1.71e-10	Mean corpuscular volume;
KIRP	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.35	-0.38	1.02e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg13010199	chr12:38710504	ALG10B	0.46	6.0	0.36	6.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.91	12.52	0.62	3.69e-28	Menopause (age at onset);
KIRP	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg13010199	chr12:38710504	ALG10B	0.64	7.95	0.45	6.68e-14	Morning vs. evening chronotype;
KIRP	cis	rs12362504	0.504	rs7131516	chr11:9893919	T/C	cg07197493	chr11:9884649	SBF2	-0.47	-6.47	-0.38	5.25e-10	Survival in pancreatic cancer;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.46	5.61	0.34	5.37e-8	Resistin levels;
KIRP	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg23422044	chr7:1970798	MAD1L1	-0.51	-6.78	-0.4	8.85e-11	Neuroticism;
KIRP	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg20991723	chr1:152506922	NA	-0.46	-5.47	-0.33	1.1e-7	Hair morphology;
KIRP	trans	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg24644049	chr4:85504048	CDS1	1.03	6.86	0.4	5.6e-11	Skin colour saturation;
KIRP	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg26207909	chr14:103986467	CKB	0.42	4.87	0.3	2.03e-6	Monocyte count;
KIRP	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.43	5.69	0.34	3.67e-8	Initial pursuit acceleration;
KIRP	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	9.89	0.53	1.21e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg06740227	chr12:86229804	RASSF9	-0.41	-5.3	-0.32	2.58e-7	Major depressive disorder;
KIRP	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.94	-14.9	-0.69	3.31e-36	Height;
KIRP	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg01973587	chr1:228161476	NA	-0.4	-5.01	-0.3	1.06e-6	Diastolic blood pressure;
KIRP	cis	rs7937612	0.965	rs4938799	chr11:120208257	T/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.54	-0.38	3.62e-10	Intraocular pressure;
KIRP	cis	rs7916697	0.947	rs1900004	chr10:70000881	C/T	cg18338521	chr10:69995036	NA	-0.4	-5.2	-0.31	4.27e-7	Optic disc area;
KIRP	cis	rs9921338	0.961	rs4781069	chr16:11428762	G/A	cg00044050	chr16:11439710	C16orf75	-0.55	-5.86	-0.35	1.51e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.65	-9.41	-0.51	3.64e-18	Retinal vascular caliber;
KIRP	cis	rs9900972	0.918	rs6501258	chr17:76877824	T/A	cg00961940	chr17:76876995	TIMP2	0.55	7.18	0.42	8.07e-12	Obesity-related traits;
KIRP	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg17145862	chr1:211918768	LPGAT1	0.77	10.56	0.56	9.49e-22	Leprosy;
KIRP	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.61	-0.39	2.34e-10	Neuroticism;
KIRP	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.35	-6.04	-0.36	5.52e-9	Height;
KIRP	cis	rs7246967	0.673	rs34726149	chr19:22952111	A/G	cg03230154	chr19:22817176	ZNF492	0.51	5.0	0.3	1.1e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.7	-0.34	3.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7119	0.671	rs11635226	chr15:77854678	C/T	cg12131826	chr15:77904385	NA	0.44	5.17	0.31	4.88e-7	Type 2 diabetes;
KIRP	cis	rs698833	0.509	rs1372080	chr2:44540241	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.1	0.31	6.86e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.4	5.75	0.34	2.69e-8	Testicular germ cell tumor;
KIRP	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	0.92	7.87	0.45	1.1e-13	Obesity-related traits;
KIRP	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg26875233	chr11:93583750	C11orf90	0.36	6.94	0.4	3.43e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8038465	0.874	rs11574488	chr15:73999379	T/A	cg15420318	chr15:73925796	NPTN	0.52	6.59	0.39	2.6e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg26681399	chr22:41777847	TEF	-0.51	-5.1	-0.31	6.77e-7	Vitiligo;
KIRP	trans	rs7999699	0.902	rs2406512	chr13:48320938	C/G	cg23237801	chr1:16476620	EPHA2	0.5	6.21	0.37	2.25e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg00405596	chr8:11794950	NA	0.5	6.3	0.37	1.36e-9	Neuroticism;
KIRP	cis	rs6714710	0.535	rs11686881	chr2:98353847	C/T	cg26665480	chr2:98280029	ACTR1B	0.55	6.47	0.38	5.11e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.53	-0.33	8.35e-8	Bipolar disorder;
KIRP	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.32	8.17	0.46	1.64e-14	Primary biliary cholangitis;
KIRP	cis	rs7534824	0.543	rs61780295	chr1:101400264	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	5.71	0.34	3.27e-8	Refractive astigmatism;
KIRP	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg16558253	chr16:72132732	DHX38	-0.6	-8.95	-0.5	8.84e-17	Fibrinogen levels;
KIRP	cis	rs3755132	0.852	rs6711424	chr2:15745333	T/G	cg12888861	chr2:15731646	DDX1	0.4	5.19	0.31	4.42e-7	Wilms tumor;
KIRP	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.89	-0.66	8.74e-33	Ulcerative colitis;
KIRP	cis	rs7870753	0.838	rs7849634	chr9:99256215	T/C	cg25260653	chr9:99212216	HABP4	0.55	5.87	0.35	1.44e-8	Height;
KIRP	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	8.1e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.25e-11	Diabetic kidney disease;
KIRP	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.27	-0.32	2.98e-7	Total body bone mineral density;
KIRP	trans	rs7980799	0.935	rs9888363	chr12:33529288	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-6.43	-0.38	6.74e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	9.27	0.51	9.49e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.42	-0.43	1.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg06818126	chr11:68850279	TPCN2	-0.46	-5.37	-0.32	1.85e-7	Hair color;
KIRP	cis	rs6991838	0.584	rs16932250	chr8:66511014	T/G	cg13398993	chr8:66546079	ARMC1	-0.44	-5.05	-0.31	8.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9900972	0.918	rs4789940	chr17:76877671	G/T	cg20937029	chr17:76870563	TIMP2	0.42	5.06	0.31	8.13e-7	Obesity-related traits;
KIRP	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.6	-5.98	-0.36	7.67e-9	Body mass index;
KIRP	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.2	-0.31	4.25e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg00701064	chr4:6280414	WFS1	0.35	7.01	0.41	2.32e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.81	-7.12	-0.41	1.17e-11	Body mass index;
KIRP	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.4	-5.3	-0.32	2.6e-7	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00405232	chr1:94311802	MIR760	0.52	6.24	0.37	1.93e-9	Smoking initiation;
KIRP	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.51	-0.33	8.85e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg08847533	chr14:75593920	NEK9	-0.55	-6.51	-0.38	4.2e-10	IgG glycosylation;
KIRP	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-1.0	-16.78	-0.73	1.23e-42	Height;
KIRP	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.77	-9.87	-0.53	1.47e-19	Chronic sinus infection;
KIRP	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.48	-11.64	-0.6	3.16e-25	Diabetic kidney disease;
KIRP	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg16497661	chr14:103986332	CKB	0.81	12.93	0.64	1.64e-29	Body mass index;
KIRP	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-6.44	-0.38	6.2e-10	Asthma;
KIRP	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.52	8.49	0.48	1.94e-15	Rheumatoid arthritis;
KIRP	cis	rs882732	1.000	rs875958	chr14:95028667	A/T	cg08495878	chr14:95027859	SERPINA4	-0.43	-5.24	-0.32	3.48e-7	Blood protein levels;
KIRP	cis	rs1318772	0.932	rs11953034	chr5:112909921	C/T	cg12552261	chr5:112820674	MCC	0.81	5.54	0.33	7.74e-8	F-cell distribution;
KIRP	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.9	-12.16	-0.61	5.81e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6545883	0.929	rs2463100	chr2:61659199	C/G	cg15711740	chr2:61764176	XPO1	-0.6	-7.61	-0.44	5.68e-13	Tuberculosis;
KIRP	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04541695	chr4:18023633	LCORL	-0.5	-6.75	-0.4	1.05e-10	Myopia;
KIRP	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg23594656	chr7:65796392	TPST1	-0.46	-6.36	-0.38	9.92e-10	Aortic root size;
KIRP	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg09455208	chr3:40491958	NA	-0.38	-7.02	-0.41	2.19e-11	Renal cell carcinoma;
KIRP	cis	rs1006703	0.544	rs10153291	chr17:3833740	G/A	cg06463185	chr17:3833770	ATP2A3	-0.64	-5.8	-0.35	1.99e-8	Glucose homeostasis traits;
KIRP	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg23649088	chr2:200775458	C2orf69	-0.39	-4.92	-0.3	1.58e-6	QT interval;
KIRP	cis	rs741677	0.927	rs2586117	chr17:483887	G/A	cg06217071	chr17:408420	NA	0.5	7.15	0.41	9.85e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg00262122	chr8:11665843	FDFT1	-0.43	-5.35	-0.32	2.04e-7	Triglycerides;
KIRP	cis	rs27434	0.583	rs28129	chr5:96155518	G/A	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1.01e-7	Ankylosing spondylitis;
KIRP	trans	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg19274270	chr17:78178856	CARD14	-0.36	-6.4	-0.38	7.87e-10	Morning vs. evening chronotype;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg14855657	chr8:10587604	SOX7	-0.53	-6.41	-0.38	7.37e-10	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs6901004	0.835	rs1150079	chr6:111471425	A/T	cg15721981	chr6:111408429	SLC16A10	-0.55	-7.46	-0.43	1.46e-12	Blood metabolite levels;
KIRP	cis	rs7630877	0.886	rs940523	chr3:179621954	A/T	cg18765712	chr3:179670323	PEX5L	-0.56	-6.65	-0.39	1.83e-10	Type 2 diabetes;
KIRP	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	4.07e-15	Protein biomarker;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06587054	chr3:183602662	PARL	0.5	6.32	0.37	1.23e-9	Parkinson's disease;
KIRP	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.02	0.5	5.61e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-5.13	-0.31	5.8e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs13170463	0.579	rs71606007	chr5:8041598	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.8	7.78	0.44	2e-13	Lung function (FEV1/FVC);
KIRP	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.58	-6.51	-0.38	4.12e-10	Fear of minor pain;
KIRP	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg06064525	chr11:970664	AP2A2	-0.29	-5.44	-0.33	1.28e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg15068132	chr12:102092402	CHPT1	0.4	5.11	0.31	6.39e-7	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11492041	chr2:139259481	SPOPL	-0.46	-6.02	-0.36	6.22e-9	Survival in pancreatic cancer;
KIRP	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	1.1	17.86	0.75	2.61e-46	Cognitive function;
KIRP	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.61	8.48	0.48	2.14e-15	Lymphocyte counts;
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.52	-0.33	8.71e-8	Lung cancer;
KIRP	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.91	-0.4	4.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.77	9.53	0.52	1.6e-18	Monocyte percentage of white cells;
KIRP	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.42	6.85	0.4	5.96e-11	Testicular germ cell tumor;
KIRP	cis	rs4356932	1.000	rs4550961	chr4:76978693	A/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-5.03	-0.31	9.44e-7	Breast cancer;
KIRP	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg11995313	chr8:8860691	ERI1	0.38	5.05	0.31	8.74e-7	Joint mobility (Beighton score);
KIRP	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg00647317	chr7:50633725	DDC	0.45	6.91	0.4	4.03e-11	Body mass index;
KIRP	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg26513180	chr16:89883248	FANCA	0.79	5.6	0.34	5.64e-8	Skin colour saturation;
KIRP	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.47e-7	Atopic dermatitis;
KIRP	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg05315796	chr3:52349193	DNAH1	0.4	6.36	0.38	9.55e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03045169	chr17:62503007	CCDC45;DDX5	0.6	7.0	0.41	2.36e-11	Smoking initiation;
KIRP	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg06815419	chr15:83735862	BTBD1	0.5	6.19	0.37	2.46e-9	Colorectal cancer;
KIRP	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.55	-6.81	-0.4	7.65e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.66	8.05	0.46	3.56e-14	Aortic root size;
KIRP	cis	rs9815354	0.680	rs115754309	chr3:42017246	A/G	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.99	-0.69	1.65e-36	Height;
KIRP	cis	rs6005807	0.719	rs73430189	chr22:29004881	C/A	cg12565055	chr22:29076175	TTC28	0.58	4.99	0.3	1.14e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.91	15.74	0.71	4.27e-39	Headache;
KIRP	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg18657303	chr4:1051139	NA	0.56	5.06	0.31	8.22e-7	Recombination rate (females);
KIRP	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.84	13.07	0.64	5.41e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.78	7.68	0.44	3.69e-13	Migraine;Coronary artery disease;
KIRP	cis	rs903263	0.897	rs1472243	chr1:84566165	T/A	cg09414863	chr1:85049548	NA	0.34	4.85	0.3	2.21e-6	Breast cancer (male);
KIRP	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.11	0.46	2.36e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9921338	0.961	rs66555362	chr16:11388833	G/T	cg00044050	chr16:11439710	C16orf75	-0.5	-5.3	-0.32	2.53e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs10832963	1.000	rs10832963	chr11:18664241	T/G	cg20219074	chr11:18656078	SPTY2D1	0.8	11.15	0.58	1.22e-23	Breast cancer;
KIRP	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg05484376	chr2:27715224	FNDC4	-0.31	-5.03	-0.31	9.29e-7	Oral cavity cancer;
KIRP	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs7714670	1.000	rs7714670	chr5:73072354	C/T	cg04480106	chr5:72934606	RGNEF	0.38	4.95	0.3	1.39e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg25019033	chr10:957182	NA	-0.55	-6.73	-0.39	1.22e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.27	0.51	9.89e-18	Morning vs. evening chronotype;
KIRP	cis	rs9400271	0.632	rs9400262	chr6:109591433	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.53	-8.83	-0.49	2.01e-16	Eye color traits;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg02696790	chr15:75250997	RPP25	0.29	5.03	0.31	9.28e-7	Breast cancer;
KIRP	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.61	7.87	0.45	1.11e-13	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg18306943	chr3:40428807	ENTPD3	0.39	5.48	0.33	1.05e-7	Renal cell carcinoma;
KIRP	cis	rs981844	0.961	rs62325108	chr4:154679767	G/A	cg14289246	chr4:154710475	SFRP2	0.65	7.2	0.42	7.17e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02678909	chr10:111767639	ADD3	0.52	6.46	0.38	5.55e-10	Parkinson's disease;
KIRP	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.38	13.83	0.66	1.49e-32	Schizophrenia;
KIRP	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg16558253	chr16:72132732	DHX38	-0.49	-7.0	-0.41	2.48e-11	Fibrinogen levels;
KIRP	cis	rs1829883	0.689	rs10055036	chr5:98884386	A/G	cg08333243	chr5:99726346	NA	-0.43	-5.44	-0.33	1.29e-7	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs5745687	0.558	rs11973414	chr7:81501570	G/A	cg09570573	chr2:10916250	ATP6V1C2	-0.76	-6.07	-0.36	4.83e-9	Hepatocyte growth factor levels;Endothelial growth factor levels;
KIRP	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg12310025	chr6:25882481	NA	-0.41	-5.85	-0.35	1.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs55675132	0.548	rs75733320	chr1:115373820	T/C	cg12756093	chr1:115239321	AMPD1	0.51	5.1	0.31	6.86e-7	Schizophrenia;
KIRP	cis	rs9513627	0.915	rs4324006	chr13:100122545	A/G	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs11203032	0.831	rs4417181	chr10:90967093	T/C	cg16672925	chr10:90967113	CH25H	0.86	8.44	0.47	2.67e-15	Heart failure;
KIRP	cis	rs1538970	0.924	rs4660851	chr1:45843810	A/T	cg05343316	chr1:45956843	TESK2	0.59	6.87	0.4	5.17e-11	Platelet count;
KIRP	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg08885076	chr2:99613938	TSGA10	0.48	8.21	0.46	1.27e-14	Chronic sinus infection;
KIRP	cis	rs35300120	0.757	rs6696955	chr1:233654929	G/A	cg23054119	chr1:233659267	NA	-0.41	-5.75	-0.34	2.63e-8	Cognitive function;
KIRP	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.68	5.0	0.3	1.11e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.77	10.01	0.54	5.15e-20	Schizophrenia;
KIRP	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	7.09	0.41	1.39e-11	Migraine;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.26	-5.26	-0.32	3.09e-7	Lymphocyte counts;
KIRP	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-5.24	-0.32	3.41e-7	Height;
KIRP	cis	rs78487399	0.908	rs72868628	chr2:43833039	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.32	-0.32	2.35e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs12367572	0.601	rs1495036	chr12:45410643	T/C	cg04608330	chr12:45269318	NELL2	-0.39	-5.3	-0.32	2.51e-7	Gut microbiome composition (summer);
KIRP	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg12131826	chr15:77904385	NA	0.5	5.91	0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg16255804	chr6:135334527	HBS1L	-0.31	-4.97	-0.3	1.26e-6	Red blood cell count;
KIRP	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg03609598	chr5:56110824	MAP3K1	-0.48	-5.55	-0.33	7.3e-8	Initial pursuit acceleration;
KIRP	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg14254433	chr6:34482411	PACSIN1	-0.71	-7.36	-0.42	2.68e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.46	-0.47	2.38e-15	Mood instability;
KIRP	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg25838818	chr2:108905173	SULT1C2	-0.65	-9.58	-0.52	1.15e-18	Lobe size;
KIRP	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.84	12.53	0.62	3.35e-28	Longevity;
KIRP	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.28	-0.37	1.51e-9	QT interval;
KIRP	cis	rs6499255	1.000	rs4078387	chr16:69814047	G/A	cg15192750	chr16:69999425	NA	0.46	4.86	0.3	2.1e-6	IgE levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01557147	chr5:100233130	ST8SIA4	-0.42	-6.21	-0.37	2.19e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.44	-7.2	-0.42	7.14e-12	Refractive error;
KIRP	cis	rs9549328	0.842	rs6577024	chr13:113634091	G/C	cg17524180	chr13:113633600	MCF2L	-0.3	-5.47	-0.33	1.13e-7	Systolic blood pressure;
KIRP	cis	rs9810890	1.000	rs73198855	chr3:128512664	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.04	-0.31	9.15e-7	Life satisfaction;
KIRP	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.16	-0.54	1.73e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg02733842	chr7:1102375	C7orf50	-0.69	-6.14	-0.36	3.29e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg26898376	chr11:64110657	CCDC88B	0.45	4.99	0.3	1.14e-6	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.6	-6.99	-0.41	2.5e-11	Menopause (age at onset);
KIRP	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.61	-0.34	5.39e-8	Schizophrenia;
KIRP	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg08992911	chr2:238395768	MLPH	0.48	4.9	0.3	1.7e-6	Prostate cancer;
KIRP	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.83	-0.4	6.58e-11	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24742294	chr1:247109025	NA	-0.41	-6.21	-0.37	2.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg08508325	chr11:3079039	CARS	0.33	5.94	0.35	9.74e-9	Calcium levels;
KIRP	cis	rs1045714	1.000	rs1045714	chr7:2653582	A/G	cg20813462	chr7:2646259	IQCE	0.69	6.15	0.37	3.11e-9	Urate levels in lean individuals;
KIRP	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs4262150	0.693	rs9285647	chr5:152279502	A/G	cg12297329	chr5:152029980	NA	0.45	6.33	0.37	1.14e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg06481639	chr22:41940642	POLR3H	0.45	5.36	0.32	1.92e-7	Vitiligo;
KIRP	cis	rs6893807	1.000	rs6893807	chr5:87965021	C/T	cg24804195	chr5:87968844	LOC645323	-0.59	-6.23	-0.37	2.02e-9	Body mass index;
KIRP	cis	rs35883536	0.528	rs1855800	chr1:101030641	G/A	cg06223162	chr1:101003688	GPR88	0.47	9.71	0.53	4.36e-19	Monocyte count;
KIRP	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg25019722	chr6:37503610	NA	-0.98	-14.65	-0.68	2.3e-35	Cognitive performance;
KIRP	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-4.9	-0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg00507259	chr4:95128692	SMARCAD1	0.39	5.0	0.3	1.09e-6	QT interval;
KIRP	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.26	0.55	8.5e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.63	8.36	0.47	4.75e-15	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs3124314	1.000	rs12033735	chr1:152140291	A/G	cg13071333	chr1:152595882	LCE3A	-0.35	-4.94	-0.3	1.43e-6	Hair morphology;
KIRP	cis	rs8177876	0.642	rs16954572	chr16:81112904	T/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.66	6.18	0.37	2.65e-9	Lung function (FEV1);
KIRP	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg27205649	chr11:78285834	NARS2	0.62	7.32	0.42	3.59e-12	Alzheimer's disease (survival time);
KIRP	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg16497661	chr14:103986332	CKB	0.48	5.71	0.34	3.16e-8	Monocyte count;
KIRP	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.3e-21	Educational attainment;
KIRP	cis	rs262150	0.788	rs2657389	chr7:158763795	G/A	cg04111992	chr7:158790115	NA	-0.44	-5.42	-0.33	1.44e-7	Facial morphology (factor 20);
KIRP	cis	rs240764	0.578	rs723743	chr6:101237504	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.22	0.32	3.85e-7	Neuroticism;
KIRP	cis	rs1829883	0.600	rs2948748	chr5:98742134	A/G	cg08333243	chr5:99726346	NA	0.38	5.11	0.31	6.41e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.65	8.75	0.49	3.41e-16	Systemic lupus erythematosus;
KIRP	cis	rs7172677	1.000	rs2029519	chr15:75415962	A/G	cg14082893	chr15:75400931	NA	0.38	5.53	0.33	8.27e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.65	-8.8	-0.49	2.53e-16	Mortality in heart failure;
KIRP	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.72	-10.44	-0.55	2.26e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg23305971	chr4:88379316	NUDT9	-0.4	-6.13	-0.36	3.52e-9	Select biomarker traits;
KIRP	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.9	-0.49	1.27e-16	Resting heart rate;
KIRP	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.84	9.91	0.53	1.11e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs12230513	0.732	rs61957764	chr12:55867916	G/A	cg19537932	chr12:55886519	OR6C68	-0.62	-7.46	-0.43	1.49e-12	Contrast sensitivity;
KIRP	cis	rs4638749	0.501	rs1872594	chr2:108746813	T/C	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.04	-0.31	8.97e-7	Blood pressure;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16652332	chr19:50104992	PRR12	0.52	6.78	0.4	8.64e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.83	-0.4	6.73e-11	Recombination measurement;
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg11814155	chr7:99998594	ZCWPW1	0.53	5.05	0.31	8.53e-7	Platelet count;
KIRP	cis	rs4728302	0.607	rs4422723	chr7:133606158	A/T	cg10665199	chr7:133106180	EXOC4	0.41	4.86	0.3	2.14e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1021993	0.545	rs76234951	chr1:209551226	A/T	cg24446417	chr1:209558027	NA	-0.51	-4.89	-0.3	1.78e-6	Gut microbiome composition (winter);
KIRP	cis	rs2712184	0.652	rs13000985	chr2:217644361	T/G	cg05032264	chr2:217675019	NA	0.41	5.69	0.34	3.58e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.93	-0.4	3.7e-11	Initial pursuit acceleration;
KIRP	cis	rs7605378	1.000	rs2689766	chr2:200697539	A/T	cg17644776	chr2:200775616	C2orf69	0.48	5.38	0.32	1.71e-7	Osteoporosis;
KIRP	cis	rs12580194	0.593	rs61956291	chr12:55797964	G/C	cg11794356	chr12:55725991	OR6C3	-0.53	-6.97	-0.41	2.9e-11	Cancer;
KIRP	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	1.06	11.27	0.58	4.9e-24	Nonalcoholic fatty liver disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27140938	chr4:25235459	PI4K2B	0.46	6.27	0.37	1.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.1	-0.41	1.31e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	0.68	6.5	0.38	4.33e-10	Breast cancer;
KIRP	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg01721255	chr8:58191610	C8orf71	0.59	5.14	0.31	5.66e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.53	6.69	0.39	1.47e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.31e-9	Depression;
KIRP	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.84	-14.43	-0.68	1.32e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	7.0	0.41	2.43e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27189623	chr16:705930	WDR90	0.45	6.26	0.37	1.68e-9	Height;
KIRP	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.79	-0.49	2.65e-16	Retinal vascular caliber;
KIRP	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.33	6.37	0.38	9.36e-10	Alcohol dependence;
KIRP	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	0.71	9.59	0.52	1.03e-18	Prostate cancer;
KIRP	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08280861	chr8:58055591	NA	0.72	5.64	0.34	4.56e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg18967534	chr4:2795345	SH3BP2	-0.47	-6.19	-0.37	2.46e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00857998	chr1:205179979	DSTYK	0.67	8.68	0.48	5.42e-16	Red blood cell count;
KIRP	cis	rs6142102	0.625	rs6142056	chr20:32541155	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs2014572	0.967	rs7259978	chr19:57756129	C/T	cg12963866	chr19:57752005	ZNF805	-0.48	-6.14	-0.36	3.27e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg19610905	chr11:61596333	FADS2	0.56	8.11	0.46	2.39e-14	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs7851660	0.809	rs7036589	chr9:100657720	A/T	cg13688889	chr9:100608707	NA	0.68	8.66	0.48	6.25e-16	Strep throat;
KIRP	cis	rs1816752	0.819	rs4770664	chr13:24988833	C/T	cg02811702	chr13:24901961	NA	0.42	5.49	0.33	9.95e-8	Obesity-related traits;
KIRP	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg24009623	chr19:33667908	NA	0.47	5.71	0.34	3.27e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7714584	1.000	rs12659118	chr5:150324622	T/C	cg22134413	chr5:150180641	NA	0.83	6.17	0.37	2.85e-9	Crohn's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15187882	chr19:6459536	SLC25A23	0.48	6.06	0.36	5.12e-9	Myopia (pathological);
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg12692727	chr7:1102344	C7orf50	0.48	5.12	0.31	6.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg24699146	chr1:24152579	HMGCL	0.43	5.56	0.33	6.97e-8	Immature fraction of reticulocytes;
KIRP	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.2	0.37	2.39e-9	Menopause (age at onset);
KIRP	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.47	-0.38	5.25e-10	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11226328	chr1:29213367	EPB41	0.57	7.1	0.41	1.33e-11	Smoking initiation;
KIRP	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	1.02	10.45	0.55	2.22e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18946802	chr3:14220310	LSM3;XPC	-0.56	-6.63	-0.39	2.16e-10	Interleukin-4 levels;
KIRP	cis	rs6977660	0.660	rs7357202	chr7:19817911	T/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg05861140	chr6:150128134	PCMT1	-0.52	-7.31	-0.42	3.71e-12	Lung cancer;
KIRP	cis	rs2921036	0.503	rs7817832	chr8:8380821	T/C	cg06636001	chr8:8085503	FLJ10661	0.52	5.48	0.33	1.04e-7	Neuroticism;
KIRP	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg26727032	chr16:67993705	SLC12A4	0.61	4.97	0.3	1.27e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.96e-9	Breast cancer;
KIRP	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.72	-8.42	-0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg25173405	chr17:45401733	C17orf57	-0.48	-6.42	-0.38	6.98e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10211205	1.000	rs10211205	chr2:236617466	C/T	cg13770573	chr2:236586376	AGAP1	-0.44	-5.05	-0.31	8.56e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg06521331	chr12:34319734	NA	-0.49	-6.21	-0.37	2.19e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1538970	0.962	rs2487442	chr1:45857176	C/G	cg05343316	chr1:45956843	TESK2	-0.61	-7.26	-0.42	5.22e-12	Platelet count;
KIRP	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.5	6.81	0.4	7.49e-11	Red blood cell count;
KIRP	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.63	-7.27	-0.42	4.88e-12	Menarche (age at onset);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg20099054	chr8:71581315	LACTB2;XKR9	-0.5	-6.41	-0.38	7.51e-10	Myopia;
KIRP	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.67	-7.87	-0.45	1.11e-13	Menarche (age at onset);
KIRP	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.79	-11.68	-0.6	2.24e-25	Retinal vascular caliber;
KIRP	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg04166393	chr7:2884313	GNA12	0.39	5.16	0.31	5.09e-7	Height;
KIRP	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.24e-13	Tonsillectomy;
KIRP	cis	rs4594175	0.707	rs12432912	chr14:51739395	T/C	cg23942311	chr14:51606299	NA	0.42	5.67	0.34	3.99e-8	Cancer;
KIRP	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22626663	chr17:4870301	SPAG7	0.49	6.61	0.39	2.3e-10	Parkinson's disease;
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg17294928	chr15:75287854	SCAMP5	0.58	7.83	0.45	1.47e-13	Breast cancer;
KIRP	cis	rs8018808	0.935	rs11159261	chr14:77921120	A/G	cg20045696	chr14:77926864	AHSA1	0.43	5.41	0.33	1.51e-7	Myeloid white cell count;
KIRP	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.49	-6.0	-0.36	6.99e-9	Schizophrenia;
KIRP	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.38	5.09	0.31	7e-7	Dupuytren's disease;
KIRP	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg18753928	chr3:113234510	CCDC52	-0.52	-6.66	-0.39	1.8e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.62	6.71	0.39	1.3100000000000001e-10	Gut microbiome composition (summer);
KIRP	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	1.1	14.62	0.68	2.89e-35	Post bronchodilator FEV1;
KIRP	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg20240347	chr1:204465584	NA	-0.43	-8.22	-0.46	1.16e-14	Schizophrenia;
KIRP	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05025164	chr4:1340916	KIAA1530	0.38	4.92	0.3	1.6e-6	Obesity-related traits;
KIRP	cis	rs853679	0.550	rs1150692	chr6:28173957	A/G	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg18944383	chr4:111397179	ENPEP	-0.61	-10.62	-0.56	6.08e-22	Coronary artery disease;
KIRP	cis	rs9625935	0.518	rs245008	chr22:30315736	T/C	cg01021169	chr22:30184971	ASCC2	-0.45	-6.34	-0.37	1.08e-9	Tonsillectomy;
KIRP	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.8	-0.4	7.84e-11	Aortic root size;
KIRP	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.4e-21	Alzheimer's disease (late onset);
KIRP	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.52	-11.48	-0.59	9.99e-25	Diabetic kidney disease;
KIRP	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	4.99	0.3	1.17e-6	Eosinophil percentage of white cells;
KIRP	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.25	11.86	0.6	6.01e-26	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22900224	chr3:52804907	NEK4	0.55	6.9	0.4	4.4e-11	Parkinson's disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06649520	chr4:153700671	ARFIP1;TIGD4	0.59	6.39	0.38	8.22e-10	Lung cancer in ever smokers;
KIRP	cis	rs4889855	0.556	rs4506961	chr17:78543182	G/A	cg09596252	chr17:78655493	RPTOR	-0.49	-5.56	-0.33	7.19e-8	Fractional excretion of uric acid;
KIRP	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg18016565	chr1:150552671	MCL1	-0.35	-5.36	-0.32	1.94e-7	Tonsillectomy;
KIRP	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17554472	chr22:41940697	POLR3H	0.62	6.78	0.4	9.12e-11	Vitiligo;
KIRP	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.61	-7.79	-0.44	1.86e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg14458575	chr2:238380390	NA	0.83	9.67	0.52	5.77e-19	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13435832	chr9:103065209	TEX10	0.54	7.05	0.41	1.8e-11	Interleukin-4 levels;
KIRP	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.6	0.39	2.52e-10	Renal cell carcinoma;
KIRP	cis	rs8014252	0.803	rs74062726	chr14:70986179	A/G	cg11204974	chr14:71022665	NA	-0.62	-6.59	-0.39	2.66e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg21605333	chr4:119757512	SEC24D	1.41	9.71	0.53	4.61e-19	Cannabis dependence symptom count;
KIRP	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.98	-11.19	-0.58	9.44e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.78	-0.4	8.94e-11	Hemoglobin concentration;
KIRP	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.53	6.18	0.37	2.71e-9	Aortic root size;
KIRP	cis	rs2929278	0.617	rs533143	chr15:44188854	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.49	5.91	0.35	1.15e-8	Schizophrenia;
KIRP	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15128208	chr22:42549153	NA	-0.44	-5.53	-0.33	8.11e-8	Cognitive function;
KIRP	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg17724175	chr1:150552817	MCL1	0.32	5.38	0.32	1.76e-7	Melanoma;
KIRP	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg12501888	chr15:85177176	SCAND2	-0.38	-4.88	-0.3	1.93e-6	P wave terminal force;
KIRP	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	1.05	19.0	0.77	3.6e-50	Monocyte count;
KIRP	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.6	8.45	0.47	2.65e-15	Endometrial cancer;
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg01765077	chr12:122356316	WDR66	0.58	8.0	0.45	4.75e-14	Mean corpuscular volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00811796	chr7:129073727	FAM40B	0.52	6.84	0.4	6.11e-11	Smoking initiation;
KIRP	cis	rs6545883	0.826	rs2694617	chr2:61537214	G/A	cg15711740	chr2:61764176	XPO1	0.61	8.12	0.46	2.3e-14	Tuberculosis;
KIRP	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00338735	chr4:53728038	RASL11B	0.42	5.18	0.31	4.64e-7	Optic nerve measurement (cup area);
KIRP	cis	rs4954585	0.683	rs10221893	chr2:137013606	C/T	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.14e-13	Colorectal cancer;
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-6.35	-0.38	1.02e-9	Longevity;Endometriosis;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg20034215	chr18:77724692	HSBP1L1	0.51	6.22	0.37	2.1e-9	Plasma plasminogen activator levels;
KIRP	cis	rs6545883	0.894	rs7602859	chr2:61458206	A/T	cg15711740	chr2:61764176	XPO1	0.57	7.31	0.42	3.85e-12	Tuberculosis;
KIRP	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.71	9.08	0.5	3.61e-17	Bladder cancer;
KIRP	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg25801113	chr15:45476975	SHF	0.41	7.66	0.44	4.26e-13	Uric acid levels;
KIRP	cis	rs4761097	0.537	rs10862936	chr12:85210030	T/A	cg00765312	chr12:85674694	ALX1	0.51	5.84	0.35	1.62e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg23517279	chr6:96025343	MANEA	-0.55	-5.09	-0.31	7.01e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.41	-6.34	-0.37	1.1e-9	Refractive error;
KIRP	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.27	7.37	0.43	2.51e-12	Crohn's disease;
KIRP	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg07001201	chr5:642380	CEP72	0.5	5.96	0.36	8.86e-9	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18780259	chr19:19006582	GDF1;LASS1	0.42	6.2	0.37	2.37e-9	Parkinson's disease;
KIRP	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg26531700	chr6:26746687	NA	0.4	5.47	0.33	1.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	trans	rs2270927	0.510	rs7730153	chr5:75579762	A/G	cg13563193	chr19:33072644	PDCD5	-0.86	-6.87	-0.4	5.09e-11	Mean corpuscular volume;
KIRP	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.62	8.13	0.46	2.08e-14	Birth weight;
KIRP	cis	rs490234	0.867	rs829181	chr9:128288002	A/G	cg14078157	chr9:128172775	NA	0.41	5.24	0.32	3.49e-7	Mean arterial pressure;
KIRP	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg06565975	chr8:143823917	SLURP1	0.47	7.4	0.43	2.21e-12	Urinary tract infection frequency;
KIRP	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.89	9.29	0.51	8.64e-18	Alzheimer's disease;
KIRP	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg09473613	chr1:24152604	HMGCL	0.39	4.86	0.3	2.12e-6	Immature fraction of reticulocytes;
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.65	-8.99	-0.5	6.95e-17	Longevity;
KIRP	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.37	0.43	2.6e-12	Height;
KIRP	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.46	5.32	0.32	2.36e-7	Schizophrenia;
KIRP	cis	rs10045504	0.502	rs17456198	chr5:38732005	A/G	cg15396434	chr5:38725168	NA	-0.92	-9.5	-0.52	2e-18	Night sleep phenotypes;
KIRP	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.11	0.31	6.46e-7	Educational attainment;
KIRP	cis	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg06521331	chr12:34319734	NA	-0.63	-7.59	-0.44	6.56e-13	Morning vs. evening chronotype;
KIRP	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg02336718	chr17:17403227	NA	-0.37	-5.45	-0.33	1.21e-7	Total body bone mineral density;
KIRP	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg21252483	chr19:49399788	TULP2	-0.43	-8.19	-0.46	1.46e-14	Red cell distribution width;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21289763	chr17:78868835	RPTOR	-0.51	-6.79	-0.4	8.57e-11	Survival in pancreatic cancer;
KIRP	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.53	7.36	0.42	2.83e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs775227	0.636	rs3773697	chr3:113023509	C/T	cg10517650	chr3:113235015	CCDC52	-0.49	-5.64	-0.34	4.75e-8	Dental caries;
KIRP	cis	rs904251	0.686	rs2776911	chr6:37439950	T/A	cg25019722	chr6:37503610	NA	-0.64	-6.57	-0.39	2.99e-10	Cognitive performance;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg08132940	chr7:1081526	C7orf50	-0.7	-7.04	-0.41	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.42e-6	Life satisfaction;
KIRP	trans	rs507506	0.712	rs1875673	chr17:7108506	T/G	cg15655154	chr3:113604241	GRAMD1C	-0.72	-10.14	-0.54	2.03e-20	Adiponectin levels;
KIRP	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.62	8.44	0.47	2.71e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.05e-6	Morning vs. evening chronotype;
KIRP	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.77	6.7	0.39	1.41e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs526231	0.543	rs257310	chr5:102418853	C/T	cg23492399	chr5:102201601	PAM	-0.54	-5.96	-0.36	8.85e-9	Primary biliary cholangitis;
KIRP	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.11	0.61	8.87e-27	Smoking behavior;
KIRP	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg10761708	chr20:43804764	PI3	0.48	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs16828019	0.777	rs13376450	chr1:41469043	A/G	cg03387723	chr1:41708464	SCMH1	-0.74	-6.12	-0.36	3.69e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-32.13	-0.9	5.1e-90	Myeloid white cell count;
KIRP	cis	rs9393813	0.529	rs7761966	chr6:27445703	C/T	cg18711553	chr6:27366782	ZNF391	-0.37	-4.87	-0.3	2.01e-6	Bipolar disorder;
KIRP	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.43	-5.1	-0.31	6.9e-7	Longevity;Endometriosis;
KIRP	cis	rs883115	0.791	rs4654060	chr1:224817330	A/G	cg01808320	chr1:224927238	CNIH3	-0.36	-5.26	-0.32	3.12e-7	Cancer;
KIRP	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg06640241	chr16:89574553	SPG7	0.65	8.72	0.49	4.37e-16	Multiple myeloma (IgH translocation);
KIRP	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.95	-14.13	-0.67	1.34e-33	Coronary artery disease;
KIRP	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg02570527	chr1:10970165	NA	-0.46	-5.51	-0.33	8.89e-8	Body mass index;
KIRP	cis	rs7651736	0.835	rs6439679	chr3:136757463	C/T	cg21827317	chr3:136751795	NA	-0.4	-5.53	-0.33	8.28e-8	Neuroticism;
KIRP	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.33	0.37	1.13e-9	Neuroticism;
KIRP	cis	rs6973256	0.865	rs2483509	chr7:133341162	G/A	cg10665199	chr7:133106180	EXOC4	-0.51	-6.38	-0.38	8.71e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.677	rs12712018	chr2:108853505	A/C	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.1	-0.36	4e-9	Blood pressure;
KIRP	cis	rs12986413	1.000	rs12459350	chr19:2176586	A/G	cg09261902	chr19:2140048	AP3D1	0.64	10.0	0.54	5.82e-20	Height;
KIRP	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg11204139	chr17:3907470	NA	0.49	5.11	0.31	6.53e-7	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg07701084	chr6:150067640	NUP43	0.68	9.36	0.51	5.08e-18	Lung cancer;
KIRP	cis	rs867371	1.000	rs7180584	chr15:82455834	A/G	cg00614314	chr15:82944287	LOC80154	0.55	6.51	0.38	4.08e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs8067287	0.634	rs17793572	chr17:16843992	A/G	cg26910001	chr17:16838321	NA	0.45	5.34	0.32	2.07e-7	Diabetic kidney disease;
KIRP	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.95	15.27	0.7	1.83e-37	Lung cancer in ever smokers;
KIRP	cis	rs13401104	0.796	rs1466206	chr2:237121221	G/C	cg19324714	chr2:237145437	ASB18	0.48	4.99	0.3	1.13e-6	Educational attainment;
KIRP	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.69	-7.69	-0.44	3.55e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.44	-6.94	-0.4	3.38e-11	Educational attainment;
KIRP	cis	rs3768617	0.811	rs12022720	chr1:183017223	A/G	cg21523751	chr1:182988639	NA	0.37	5.08	0.31	7.44e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.54	-6.69	-0.39	1.49e-10	Birth weight;
KIRP	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.58	-0.34	6.27e-8	Aortic root size;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07098314	chr17:39823360	NA	0.47	6.64	0.39	1.95e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg15488143	chr7:128924101	AHCYL2	0.41	4.89	0.3	1.85e-6	White matter hyperintensity burden;
KIRP	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg24565620	chr2:194026	NA	-0.72	-5.42	-0.33	1.44e-7	Blood protein levels;
KIRP	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-6.66	-0.39	1.79e-10	Colorectal cancer;
KIRP	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-8.46	-0.47	2.48e-15	Response to antipsychotic treatment;
KIRP	cis	rs35995292	0.889	rs10272767	chr7:38898819	G/C	cg19327137	chr7:38886074	VPS41	0.51	6.18	0.37	2.63e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg00792783	chr2:198669748	PLCL1	-0.45	-5.1	-0.31	6.83e-7	Dermatomyositis;
KIRP	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.97	-0.41	2.9100000000000002e-11	Monocyte count;
KIRP	cis	rs17428704	0.571	rs72748245	chr5:14408982	A/T	cg26595256	chr5:14380529	TRIO	-0.81	-6.12	-0.36	3.61e-9	Electroencephalogram traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13475699	chr20:60718362	PSMA7;SS18L1	-0.48	-6.06	-0.36	5.09e-9	Myopia;
KIRP	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.57	8.14	0.46	1.96e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg08283408	chr3:49949060	MON1A	-0.42	-5.45	-0.33	1.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg04691961	chr3:161091175	C3orf57	-0.39	-5.89	-0.35	1.27e-8	Morning vs. evening chronotype;
KIRP	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs55882075	0.765	rs34329357	chr5:179130408	G/C	cg14593053	chr5:179126677	CANX	0.76	11.27	0.58	4.87e-24	Monocyte percentage of white cells;
KIRP	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.97	0.3	1.26e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg23102388	chr7:1867652	MAD1L1	-0.43	-5.89	-0.35	1.29e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.44	-5.83	-0.35	1.74e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-0.56	-7.92	-0.45	8.01e-14	Coronary artery disease;
KIRP	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.76	12.02	0.61	1.7e-26	Vitiligo;
KIRP	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.67	8.82	0.49	2.2e-16	Motion sickness;
KIRP	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg00319359	chr11:70116639	PPFIA1	0.57	5.95	0.35	8.96e-9	Coronary artery disease;
KIRP	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.39	6.71	0.39	1.32e-10	QRS complex (12-leadsum);
KIRP	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.56	-7.7	-0.44	3.36e-13	Economic and political preferences (feminism/equality);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg08163220	chr3:31574309	STT3B	0.49	6.18	0.37	2.66e-9	Educational attainment;
KIRP	cis	rs6504622	0.905	rs9889741	chr17:45026333	G/A	cg24703533	chr17:45055318	NA	0.38	5.3	0.32	2.56e-7	Orofacial clefts;
KIRP	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-5.49	-0.33	9.86e-8	Asthma;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg09695851	chr17:3907499	NA	0.83	15.22	0.7	2.63e-37	Type 2 diabetes;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg26134248	chr17:3907702	NA	0.41	5.17	0.31	4.79e-7	Type 2 diabetes;
KIRP	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.47	-6.96	-0.41	3.04e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg12560992	chr17:57184187	TRIM37	-0.52	-5.79	-0.35	2.17e-8	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.42	-4.97	-0.3	1.23e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg21475434	chr5:93447410	FAM172A	-0.43	-5.0	-0.3	1.1e-6	Diabetic retinopathy;
KIRP	cis	rs4702	0.591	rs7183988	chr15:91428589	T/G	cg05469396	chr15:91419421	FURIN	0.37	4.89	0.3	1.81e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg27189623	chr16:705930	WDR90	0.44	6.04	0.36	5.64e-9	Height;
KIRP	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg07423050	chr13:99094983	FARP1	0.33	5.48	0.33	1.07e-7	Longevity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04504182	chr1:202777459	KDM5B	0.5	6.2	0.37	2.35e-9	Parkinson's disease;
KIRP	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg21926883	chr2:100939477	LONRF2	-0.62	-8.41	-0.47	3.35e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg01620082	chr3:125678407	NA	-0.86	-6.2	-0.37	2.38e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg14664628	chr15:75095509	CSK	-0.61	-7.48	-0.43	1.29e-12	Breast cancer;
KIRP	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.76	14.47	0.68	9.63e-35	Obesity-related traits;
KIRP	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11645453	chr3:52864694	ITIH4	0.46	6.3	0.37	1.33e-9	Bipolar disorder;
KIRP	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg18306943	chr3:40428807	ENTPD3	0.43	5.65	0.34	4.52e-8	Renal cell carcinoma;
KIRP	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg25482853	chr8:67687455	SGK3	0.82	7.16	0.42	9.55e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs367943	0.698	rs2217296	chr5:112973829	A/T	cg12552261	chr5:112820674	MCC	0.43	4.85	0.3	2.23e-6	Type 2 diabetes;
KIRP	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-1.07	-12.74	-0.63	6.86e-29	Exhaled nitric oxide output;
KIRP	cis	rs10208940	0.920	rs34366735	chr2:68771995	A/G	cg12452813	chr2:68675892	NA	0.47	5.06	0.31	8.07e-7	Urate levels in lean individuals;
KIRP	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.51	-6.36	-0.38	9.99e-10	Total body bone mineral density;
KIRP	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs960902	0.592	rs10865125	chr2:37737883	T/G	cg25341268	chr2:37734390	NA	-0.61	-8.61	-0.48	9.15e-16	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg07862535	chr7:139043722	LUC7L2	0.46	5.16	0.31	4.99e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.92	12.48	0.62	4.92e-28	Vitamin D levels;
KIRP	cis	rs9398803	0.865	rs1907067	chr6:126837663	A/C	cg19875578	chr6:126661172	C6orf173	0.49	6.3	0.37	1.39e-9	Male-pattern baldness;
KIRP	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs16975963	0.644	rs111319455	chr19:38162647	A/C	cg18030218	chr19:38865513	PSMD8	0.56	5.05	0.31	8.61e-7	Longevity;
KIRP	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg12062639	chr20:23401060	NAPB	0.85	7.39	0.43	2.33e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.61	-0.34	5.47e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.09	17.89	0.75	2.13e-46	Primary sclerosing cholangitis;
KIRP	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.04	-0.31	9.14e-7	Menarche (age at onset);
KIRP	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg16584290	chr5:462447	EXOC3	0.43	5.49	0.33	9.9e-8	Cystic fibrosis severity;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20962901	chr1:116681753	NA	-0.39	-6.34	-0.37	1.09e-9	Warfarin maintenance dose;
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg01721255	chr8:58191610	C8orf71	0.58	5.6	0.34	5.68e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7119038	0.818	rs10892286	chr11:118642085	A/C	cg19308663	chr11:118741387	NA	0.55	8.69	0.48	5.22e-16	Sjögren's syndrome;
KIRP	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg11970804	chr8:8084126	NA	-0.39	-5.66	-0.34	4.17e-8	Mood instability;
KIRP	cis	rs832187	0.704	rs704364	chr3:63874734	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.45	5.19	0.31	4.45e-7	Schizophrenia;
KIRP	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.98	14.12	0.67	1.47e-33	Cognitive function;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	-0.51	-6.82	-0.4	6.91e-11	Survival in pancreatic cancer;
KIRP	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.39	-5.12	-0.31	6.23e-7	Parkinson's disease;
KIRP	cis	rs59197085	0.515	rs17165198	chr7:128451741	C/T	cg00734629	chr7:128471146	FLNC	-0.39	-5.23	-0.32	3.66e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg03209412	chr4:183728196	NA	0.48	6.24	0.37	1.91e-9	Pediatric autoimmune diseases;
KIRP	cis	rs8028182	0.577	rs8023268	chr15:75814672	A/T	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs3825932	0.701	rs1036937	chr15:79237180	C/A	cg25744700	chr15:79237217	CTSH	0.42	5.22	0.32	3.8e-7	Type 1 diabetes;
KIRP	cis	rs8054556	0.647	rs11649149	chr16:30008644	C/T	cg06326092	chr16:30034487	C16orf92	0.42	6.18	0.37	2.64e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.33	5.2	0.31	4.11e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs61863818	0.557	rs7898743	chr10:99153540	T/G	cg08345082	chr10:99160200	RRP12	-0.37	-5.3	-0.32	2.55e-7	Monocyte percentage of white cells;
KIRP	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.67	-0.34	3.92e-8	Breast cancer;
KIRP	cis	rs6662572	0.737	rs74523130	chr1:46599619	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.78	0.35	2.21e-8	Blood protein levels;
KIRP	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.64	4.97	0.3	1.26e-6	Schizophrenia;
KIRP	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg20991723	chr1:152506922	NA	-0.45	-5.08	-0.31	7.4e-7	Hair morphology;
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg05255149	chr17:80675120	FN3KRP	0.45	4.86	0.3	2.08e-6	Glycated hemoglobin levels;
KIRP	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg18016565	chr1:150552671	MCL1	0.4	6.12	0.36	3.62e-9	Melanoma;
KIRP	trans	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg13565492	chr6:43139072	SRF	-1.01	-9.87	-0.53	1.38e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2882667	0.931	rs10077896	chr5:138356756	G/A	cg04439458	chr5:138467593	SIL1	-0.43	-7.39	-0.43	2.24e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs72627509	0.951	rs72606404	chr4:57841213	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-4.99	-0.3	1.12e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06481639	chr22:41940642	POLR3H	0.45	5.46	0.33	1.19e-7	Vitiligo;
KIRP	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.5	6.4	0.38	7.66e-10	HDL cholesterol levels;
KIRP	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg05130518	chr13:21295590	IL17D	0.4	5.13	0.31	5.76e-7	Dental caries;
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg04369109	chr6:150039330	LATS1	-0.43	-5.23	-0.32	3.69e-7	Lung cancer;
KIRP	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg10434728	chr15:90938212	IQGAP1	0.43	7.5	0.43	1.18e-12	Rheumatoid arthritis;
KIRP	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.78	9.46	0.52	2.68e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs76533333	0.646	rs71446911	chr13:113377528	G/T	cg04656015	chr13:113407548	ATP11A	0.71	5.84	0.35	1.67e-8	Red cell distribution width;
KIRP	trans	rs7246760	0.867	rs66464474	chr19:9795149	T/C	cg02900749	chr2:68251473	NA	-1.2	-9.9	-0.53	1.13e-19	Pursuit maintenance gain;
KIRP	cis	rs56399783	0.901	rs73033407	chr7:2878857	G/C	cg19731401	chr7:2775893	GNA12	0.74	6.21	0.37	2.3e-9	Childhood ear infection;
KIRP	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg24631222	chr15:78858424	CHRNA5	0.41	5.09	0.31	7.13e-7	Sudden cardiac arrest;
KIRP	cis	rs7903847	0.619	rs10882912	chr10:99138077	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.88	11.6	0.59	4.18e-25	Primary sclerosing cholangitis;
KIRP	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.59	-0.68	3.79e-35	Primary sclerosing cholangitis;
KIRP	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.91	10.43	0.55	2.45e-21	Corneal astigmatism;
KIRP	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-6.18	-0.37	2.62e-9	Breast cancer;
KIRP	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg04865290	chr3:52927548	TMEM110	-0.62	-6.84	-0.4	6.08e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11987759	chr7:65425863	GUSB	0.57	7.59	0.44	6.75e-13	Aortic root size;
KIRP	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.6	-9.1	-0.5	3.1e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.62	8.41	0.47	3.26e-15	Height;
KIRP	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.62	8.66	0.48	6.2e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs10463316	0.962	rs61647401	chr5:150743076	T/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.63	-0.34	4.95e-8	Metabolite levels (Pyroglutamine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04646113	chr15:75744117	SIN3A	0.53	7.47	0.43	1.41e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs732505	1.000	rs8111720	chr19:5585823	A/G	cg26242866	chr19:5711310	LONP1	0.68	5.22	0.32	3.89e-7	vWF and FVIII levels;
KIRP	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.48	-0.33	1.07e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.56	-7.77	-0.44	2.17e-13	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.7	-10.76	-0.57	2.18e-22	Monocyte percentage of white cells;
KIRP	cis	rs7709377	0.553	rs12332433	chr5:115465930	C/T	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.08	12.71	0.63	8.38e-29	White matter hyperintensity burden;
KIRP	cis	rs4852324	0.536	rs71418714	chr2:74219886	G/C	cg20891558	chr2:74357851	NA	0.65	4.86	0.3	2.1e-6	Systemic lupus erythematosus;
KIRP	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg20701182	chr2:24300061	SF3B14	0.58	5.17	0.31	4.74e-7	Lymphocyte counts;
KIRP	cis	rs55863869	0.748	rs2291309	chr2:179623577	G/T	cg02880032	chr2:179629472	TTN	0.67	5.49	0.33	9.95e-8	QT interval;
KIRP	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.74	-10.49	-0.56	1.65e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.73	5.37	0.32	1.79e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.2	-0.37	2.42e-9	Neuroticism;
KIRP	cis	rs1298062	0.689	rs12985344	chr19:50954750	T/C	cg11430371	chr19:50961752	MYBPC2	0.42	5.81	0.35	1.97e-8	Age of smoking initiation;
KIRP	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg17366294	chr4:99064904	C4orf37	0.44	6.38	0.38	8.94e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12431939	0.598	rs8012074	chr14:51732101	C/G	cg23942311	chr14:51606299	NA	0.41	4.91	0.3	1.66e-6	Cancer;
KIRP	cis	rs1555895	0.656	rs7919815	chr10:842062	C/G	cg10017260	chr10:834428	NA	-0.42	-6.12	-0.36	3.6e-9	Survival in rectal cancer;
KIRP	cis	rs1981331	1.000	rs75843712	chr21:47976115	A/G	cg23283320	chr21:48055893	PRMT2	1.39	8.63	0.48	7.88e-16	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg23335576	chr14:104009727	NA	0.39	5.69	0.34	3.58e-8	Body mass index;
KIRP	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.52	0.38	3.88e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-5.04	-0.31	8.87e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	1.07	20.35	0.79	1.17e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.78	-10.98	-0.57	4.32e-23	Morning vs. evening chronotype;
KIRP	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.11	0.41	1.23e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg12923728	chr3:195709715	SDHAP1	-0.54	-6.15	-0.37	3.08e-9	Mean corpuscular volume;
KIRP	cis	rs2219968	1.000	rs1073444	chr8:78959671	T/C	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14895029	chr7:2775587	GNA12	-0.42	-4.95	-0.3	1.39e-6	Height;
KIRP	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.26e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg09559047	chr8:10916868	XKR6	0.38	5.44	0.33	1.31e-7	Neuroticism;
KIRP	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-5.47	-0.33	1.09e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs933360	0.585	rs2286152	chr7:50827176	C/T	cg20003124	chr12:4557277	NA	0.55	6.75	0.4	1.07e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg26531700	chr6:26746687	NA	-0.37	-5.02	-0.3	9.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.515	rs7207986	chr17:3979949	G/A	cg05562828	chr17:3906858	NA	0.6	6.46	0.38	5.71e-10	Type 2 diabetes;
KIRP	trans	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg16141378	chr3:129829833	LOC729375	0.58	7.67	0.44	4.11e-13	Mood instability;
KIRP	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	9.43	0.52	3.25e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs35740288	0.587	rs4843089	chr15:86176136	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs11225247	0.764	rs78166284	chr11:102252087	A/G	cg06323957	chr11:102217781	BIRC2	0.91	5.65	0.34	4.4e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.83	11.88	0.6	5.09e-26	Monocyte count;
KIRP	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-6.03	-0.36	6e-9	Breast cancer;
KIRP	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.92	0.45	7.93e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.3	7.29	0.42	4.22e-12	IgG glycosylation;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.43	9.25	0.51	1.13e-17	Vitiligo;
KIRP	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.68	0.44	3.8e-13	Calcium levels;
KIRP	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.38	0.51	4.46e-18	Morning vs. evening chronotype;
KIRP	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg13264159	chr8:625131	ERICH1	-0.76	-6.31	-0.37	1.27e-9	IgG glycosylation;
KIRP	cis	rs7485210	0.673	rs78606016	chr12:131632805	T/A	cg13406893	chr12:131568647	GPR133	0.69	4.94	0.3	1.46e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.65	10.33	0.55	5.06e-21	Bone mineral density;
KIRP	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg26681399	chr22:41777847	TEF	-0.53	-5.52	-0.33	8.46e-8	Vitiligo;
KIRP	cis	rs6684428	1.000	rs12145137	chr1:56370557	A/T	cg11651538	chr1:56320950	NA	-0.86	-10.11	-0.54	2.52e-20	Airflow obstruction;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04392234	chr4:74608458	IL8	0.4	6.62	0.39	2.19e-10	C-reactive protein;
KIRP	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	5.28	0.32	2.88e-7	Renal cell carcinoma;
KIRP	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.07	0.67	2.12e-33	Tonsillectomy;
KIRP	cis	rs7757419	1.000	rs7773328	chr6:34435162	A/T	cg25473981	chr6:34433676	PACSIN1	0.42	5.21	0.31	4.09e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
KIRP	cis	rs17092148	1.000	rs6060047	chr20:33367400	G/T	cg16810054	chr20:33298113	TP53INP2	0.46	5.7	0.34	3.38e-8	Neuroticism;
KIRP	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg07636037	chr3:49044803	WDR6	-0.73	-5.64	-0.34	4.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg06795125	chr2:108905320	SULT1C2	0.37	6.96	0.41	3.16e-11	Blood pressure;
KIRP	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	5.55	0.33	7.22e-8	Iron status biomarkers;
KIRP	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs7129556	0.954	rs11823651	chr11:77253879	G/A	cg12586386	chr11:77299805	AQP11	0.47	6.14	0.36	3.32e-9	Weight loss (gastric bypass surgery);
KIRP	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg24375607	chr4:120327624	NA	-0.51	-5.95	-0.35	9.1e-9	Corneal astigmatism;
KIRP	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg07051648	chr19:49177693	NTN5;SEC1	-0.47	-5.98	-0.36	7.76e-9	Dietary macronutrient intake;
KIRP	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg07395648	chr5:131743802	NA	-0.36	-5.39	-0.32	1.68e-7	Blood metabolite levels;
KIRP	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg00576331	chr11:65640516	EFEMP2	0.58	7.73	0.44	2.8e-13	DNA methylation (variation);
KIRP	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-7.23	-0.42	5.94e-12	Vitiligo;
KIRP	trans	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg19694781	chr19:47549865	TMEM160	-0.5	-6.07	-0.36	4.69e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9815354	0.812	rs73071212	chr3:41981856	C/A	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.48	1.5e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2270927	0.510	rs2937748	chr5:75572032	T/G	cg13563193	chr19:33072644	PDCD5	0.8	6.2	0.37	2.34e-9	Mean corpuscular volume;
KIRP	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.44	5.86	0.35	1.45e-8	Homoarginine levels;
KIRP	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.89	-11.48	-0.59	1.01e-24	Homoarginine levels;
KIRP	cis	rs6708331	0.517	rs7599072	chr2:70360006	C/T	cg01613454	chr2:70366299	NA	0.4	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg16989719	chr2:238392110	NA	-0.38	-5.18	-0.31	4.59e-7	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14204415	chr9:131464988	PKN3	0.55	7.01	0.41	2.26e-11	Parkinson's disease;
KIRP	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg08847533	chr14:75593920	NEK9	0.62	6.97	0.41	2.84e-11	Caffeine consumption;
KIRP	cis	rs2395528	0.574	rs2670220	chr10:80125781	C/T	cg08356028	chr10:80217969	NA	0.36	5.42	0.33	1.45e-7	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs5753618	0.504	rs7284622	chr22:31907985	G/A	cg02404636	chr22:31891804	SFI1	0.56	6.55	0.39	3.35e-10	Colorectal cancer;
KIRP	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg01843524	chr15:80216276	C15orf37;ST20	0.44	5.37	0.32	1.84e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg13264159	chr8:625131	ERICH1	-0.74	-5.56	-0.33	7.16e-8	IgG glycosylation;
KIRP	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg24747557	chr10:131355152	MGMT	0.38	5.24	0.32	3.46e-7	Response to temozolomide;
KIRP	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.37	0.32	1.79e-7	Diisocyanate-induced asthma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00314741	chr10:22706255	SPAG6	-0.37	-6.04	-0.36	5.81e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.59	7.9	0.45	9.03e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg12559939	chr2:27858050	GPN1	0.42	5.35	0.32	2.02e-7	Oral cavity cancer;
KIRP	cis	rs1318772	1.000	rs34625553	chr5:112680073	C/A	cg12552261	chr5:112820674	MCC	0.8	5.06	0.31	8.05e-7	F-cell distribution;
KIRP	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-12.31	-0.62	1.86e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg08975724	chr8:8085496	FLJ10661	0.59	7.93	0.45	7.74e-14	Joint mobility (Beighton score);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02421824	chr12:89393249	NA	-0.44	-6.44	-0.38	6.39e-10	Select biomarker traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25212365	chr15:78441641	IDH3A	0.47	6.36	0.38	9.78e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6684428	1.000	rs12123418	chr1:56383394	C/T	cg11651538	chr1:56320950	NA	0.85	10.71	0.56	3.31e-22	Airflow obstruction;
KIRP	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg09029085	chr17:47094198	IGF2BP1	0.24	5.54	0.33	7.81e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-5.79	-0.35	2.1e-8	Total cholesterol levels;
KIRP	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.58	6.73	0.39	1.15e-10	Aortic root size;
KIRP	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-0.66	-8.89	-0.49	1.36e-16	Morning vs. evening chronotype;
KIRP	cis	rs79349575	0.756	rs62078385	chr17:47045009	C/T	cg26022315	chr17:47021804	SNF8	0.41	5.13	0.31	5.92e-7	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08280861	chr8:58055591	NA	0.62	5.28	0.32	2.81e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.18	-21.32	-0.81	7.6e-58	Ulcerative colitis;
KIRP	cis	rs10411936	0.712	rs8103486	chr19:16603107	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.35	0.32	2.04e-7	White blood cell count;Multiple sclerosis;
KIRP	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.78	-8.96	-0.5	8.2e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.69	8.39	0.47	3.79e-15	Type 2 diabetes;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg27189623	chr16:705930	WDR90	0.44	6.12	0.36	3.57e-9	Height;
KIRP	trans	rs909341	0.716	rs71325464	chr20:62363453	A/G	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.95	-0.41	3.29e-11	Atopic dermatitis;
KIRP	cis	rs10929159	0.964	rs10170434	chr2:236937578	G/A	cg20128773	chr2:236923534	AGAP1	0.28	4.89	0.3	1.8e-6	Parkinson's disease;
KIRP	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.5	-0.33	9.64e-8	Breast cancer;
KIRP	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg18527119	chr7:66119851	NA	-0.45	-4.92	-0.3	1.59e-6	Aortic root size;
KIRP	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg04998671	chr14:104000505	TRMT61A	-0.54	-6.38	-0.38	8.83e-10	Coronary artery disease;
KIRP	cis	rs9547996	0.842	rs11843893	chr13:38213738	C/T	cg13634560	chr13:38173852	POSTN	-0.39	-5.51	-0.33	9.08e-8	Diastolic blood pressure;
KIRP	cis	rs2067615	0.965	rs4964484	chr12:107113024	A/C	cg21360079	chr12:107162445	NA	0.48	6.16	0.37	3.01e-9	Heart rate;
KIRP	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-4.97	-0.3	1.26e-6	Neutrophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.49	-6.72	-0.39	1.28e-10	Colorectal cancer;
KIRP	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg20651018	chr11:3035856	CARS	-0.36	-4.97	-0.3	1.25e-6	Longevity;
KIRP	cis	rs1465370	0.644	rs1558919	chr7:130029508	A/T	cg03229158	chr7:130009420	NA	0.36	5.23	0.32	3.69e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs1440410	0.571	rs62331619	chr4:144028452	G/A	cg01719995	chr4:144104893	USP38	-0.46	-5.8	-0.35	2.02e-8	Ischemic stroke;
KIRP	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg00343986	chr7:65444356	GUSB	0.46	5.63	0.34	5.03e-8	Calcium levels;
KIRP	cis	rs9398235	0.598	rs9487402	chr6:110746545	T/G	cg02872426	chr6:110736772	DDO	-0.3	-4.95	-0.3	1.38e-6	Systemic lupus erythematosus;
KIRP	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.28	0.55	7.7e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	1.01	11.85	0.6	6.26e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg26876637	chr1:152193138	HRNR	-0.75	-8.84	-0.49	1.84e-16	Atopic dermatitis;
KIRP	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.45	-5.5	-0.33	9.33e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.95	16.26	0.72	7.27e-41	Breast cancer;
KIRP	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.62	-9.15	-0.5	2.18e-17	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14563115	chr1:14082215	PRDM2	-0.42	-6.55	-0.39	3.36e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg01843524	chr15:80216276	C15orf37;ST20	0.42	5.27	0.32	2.99e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs8060686	0.920	rs60990105	chr16:67680956	T/A	cg26727032	chr16:67993705	SLC12A4	-0.54	-5.14	-0.31	5.51e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8014252	0.803	rs60860517	chr14:71029919	A/C	cg19730268	chr14:71022823	NA	-0.56	-5.3	-0.32	2.6e-7	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs3026101	0.671	rs748486	chr17:5290824	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.08	0.41	1.48e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18252515	chr7:66147081	NA	0.43	4.99	0.3	1.14e-6	Aortic root size;
KIRP	cis	rs9409565	0.762	rs60964095	chr9:97175774	G/T	cg04523069	chr9:97136363	HIATL1	0.47	6.34	0.37	1.07e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs6088813	1.000	rs6088799	chr20:33934301	T/C	cg14752227	chr20:34000481	UQCC	-0.51	-6.88	-0.4	4.91e-11	Height;
KIRP	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.56	6.18	0.37	2.71e-9	Bipolar disorder;
KIRP	trans	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.8200000000000003e-11	Bladder cancer;
KIRP	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg00677455	chr12:58241039	CTDSP2	0.71	8.1	0.46	2.52e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg22283653	chr8:49824208	NA	0.53	7.7	0.44	3.33e-13	Sudden cardiac arrest;
KIRP	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.82	0.45	1.51e-13	Myopia (pathological);
KIRP	cis	rs9393692	0.578	rs806795	chr6:26205293	G/A	cg00631329	chr6:26305371	NA	-0.8	-11.61	-0.6	3.8e-25	Educational attainment;
KIRP	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.63	7.89	0.45	9.67e-14	Height;
KIRP	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg11161011	chr14:65562177	MAX	-0.69	-7.75	-0.44	2.39e-13	Obesity-related traits;
KIRP	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg13444842	chr1:152974279	SPRR3	-0.41	-5.94	-0.35	9.75e-9	Inflammatory skin disease;
KIRP	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg14972814	chr11:95582409	MTMR2	0.35	5.89	0.35	1.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.68	5.47	0.33	1.1e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09238106	chr11:64242796	NA	0.45	6.03	0.36	6.02e-9	Survival in pancreatic cancer;
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg02462569	chr6:150064036	NUP43	-0.39	-5.82	-0.35	1.83e-8	Lung cancer;
KIRP	cis	rs11153306	0.529	rs11153303	chr6:111937875	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-5.23	-0.32	3.54e-7	Tonsillectomy;
KIRP	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg07843065	chr1:150265600	MRPS21	0.42	5.67	0.34	3.96e-8	Migraine;
KIRP	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	5.27	0.32	2.93e-7	Menopause (age at onset);
KIRP	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg23752985	chr2:85803571	VAMP8	0.48	6.69	0.39	1.52e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg00094735	chr5:1949198	NA	0.46	5.52	0.33	8.53e-8	Gut microbiome composition (winter);
KIRP	cis	rs3755132	0.929	rs7579604	chr2:15746975	A/T	cg12888861	chr2:15731646	DDX1	0.4	5.25	0.32	3.32e-7	Wilms tumor;
KIRP	trans	rs6561151	0.957	rs7995004	chr13:44478820	C/T	cg17145862	chr1:211918768	LPGAT1	0.67	8.18	0.46	1.53e-14	Crohn's disease;
KIRP	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg08807101	chr21:30365312	RNF160	0.61	7.03	0.41	2.07e-11	Cognitive test performance;
KIRP	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	7.22	0.42	6.27e-12	Multiple sclerosis;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.06	0.36	5e-9	Lung cancer;
KIRP	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.13	0.36	3.54e-9	Menopause (age at onset);
KIRP	trans	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg21171335	chr12:122356390	WDR66	0.49	6.57	0.39	2.98e-10	Mean corpuscular volume;
KIRP	cis	rs3126085	0.515	rs12033221	chr1:152356113	A/G	cg26876637	chr1:152193138	HRNR	-0.66	-6.75	-0.4	1.03e-10	Atopic dermatitis;
KIRP	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg09890400	chr1:26503858	CNKSR1	0.42	5.79	0.35	2.13e-8	Height;
KIRP	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg25447019	chr17:19030144	GRAPL	-0.58	-8.29	-0.47	7.39e-15	Schizophrenia;
KIRP	trans	rs2856321	0.874	rs4763719	chr12:11877420	A/G	cg10155026	chr12:4553029	FGF6	0.42	6.29	0.37	1.45e-9	Height;
KIRP	cis	rs1538970	0.924	rs11211118	chr1:45930270	A/C	cg03146154	chr1:46216737	IPP	0.47	5.1	0.31	6.94e-7	Platelet count;
KIRP	cis	rs6546886	0.912	rs4574138	chr2:74294406	C/T	cg14702570	chr2:74259524	NA	-0.26	-4.97	-0.3	1.28e-6	Dialysis-related mortality;
KIRP	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.38	-5.18	-0.31	4.58e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26912984	chr6:111408745	SLC16A10	0.54	6.42	0.38	7.15e-10	Smoking initiation;
KIRP	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-12.66	-0.63	1.29e-28	Height;
KIRP	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.68	7.14	0.41	1.03e-11	Lymphocyte counts;
KIRP	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.58	7.52	0.43	1.01e-12	Aortic root size;
KIRP	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	6.11	0.36	3.81e-9	Height;
KIRP	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.39	5.07	0.31	7.77e-7	Breast cancer;
KIRP	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-7.07	-0.41	1.61e-11	Mood instability;
KIRP	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg17356467	chr2:100759845	AFF3	0.52	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17554472	chr22:41940697	POLR3H	0.69	7.08	0.41	1.48e-11	Vitiligo;
KIRP	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.42	-5.01	-0.3	1.06e-6	Longevity;Endometriosis;
KIRP	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.39	-0.32	1.68e-7	Subjective well-being;
KIRP	trans	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Bladder cancer;
KIRP	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg08761264	chr16:28874980	SH2B1	-0.47	-5.48	-0.33	1.03e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg12573674	chr2:1569213	NA	-0.52	-5.05	-0.31	8.77e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.23	-0.32	3.57e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-4.88	-0.3	1.89e-6	Ileal carcinoids;
KIRP	cis	rs4389656	0.857	rs274709	chr5:6726464	T/C	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-7.4	-0.43	2.1e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs12431939	0.948	rs12436364	chr14:51671320	T/C	cg23942311	chr14:51606299	NA	-0.57	-5.88	-0.35	1.35e-8	Cancer;
KIRP	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.95e-10	Subjective well-being;
KIRP	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.84	6.98	0.41	2.81e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.38	0.38	8.78e-10	Hypertriglyceridemia;
KIRP	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg10255544	chr17:80519551	FOXK2	0.56	8.3	0.47	6.84e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg19847130	chr8:10466454	RP1L1	0.33	4.92	0.3	1.59e-6	Morning vs. evening chronotype;
KIRP	cis	rs2395528	0.574	rs2253240	chr10:80110953	T/C	cg08356028	chr10:80217969	NA	0.38	5.67	0.34	3.93e-8	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg06121193	chr1:90282411	NA	-0.41	-5.7	-0.34	3.36e-8	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	0.75	7.23	0.42	6.13e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg03854865	chr6:26224070	HIST1H3E	0.62	4.85	0.3	2.16e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs12681963	1.000	rs12681963	chr8:29982518	T/C	cg10449087	chr8:29952694	LEPROTL1	-0.63	-5.64	-0.34	4.76e-8	Migraine;
KIRP	cis	rs1629083	0.935	rs1056562	chr11:118125625	T/C	cg18857871	chr11:118064634	AMICA1	0.69	10.07	0.54	3.38e-20	Lung cancer;
KIRP	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg00745463	chr17:30367425	LRRC37B	-0.72	-6.94	-0.4	3.41e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs7527798	0.592	rs2296159	chr1:207851760	G/A	cg09232269	chr1:207846808	CR1L	-0.37	-5.52	-0.33	8.78e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg07636037	chr3:49044803	WDR6	0.56	5.3	0.32	2.59e-7	Menarche (age at onset);
KIRP	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.68	9.01	0.5	5.8e-17	Colorectal cancer;
KIRP	cis	rs2380205	0.967	rs10905303	chr10:5894180	C/A	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.54e-8	Breast cancer;
KIRP	trans	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg19694781	chr19:47549865	TMEM160	-0.58	-7.63	-0.44	5.15e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.42	-5.37	-0.32	1.82e-7	Type 2 diabetes;
KIRP	cis	rs1635	0.826	rs742107	chr6:28290714	A/C	cg15743358	chr6:28303923	ZNF323	-0.78	-5.48	-0.33	1.07e-7	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.31	-0.42	3.85e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.4	-5.56	-0.33	6.99e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.83	0.53	1.94e-19	Morning vs. evening chronotype;
KIRP	cis	rs33912345	0.695	rs1314387	chr14:60877399	T/C	cg27398547	chr14:60952738	C14orf39	-0.4	-5.44	-0.33	1.3e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs2594989	0.837	rs2454497	chr3:11501597	T/C	cg01796438	chr3:11312864	ATG7	-0.67	-8.19	-0.46	1.45e-14	Circulating chemerin levels;
KIRP	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg12560992	chr17:57184187	TRIM37	0.63	5.66	0.34	4.22e-8	Cognitive test performance;
KIRP	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.44	0.47	2.84e-15	Lung cancer in ever smokers;
KIRP	cis	rs3924048	0.574	rs12096486	chr1:12616911	T/C	cg00291366	chr1:12616550	NA	0.45	6.37	0.38	9.43e-10	Optic cup area;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19269713	chr2:69969370	ANXA4	0.63	8.1	0.46	2.64e-14	Parkinson's disease;
KIRP	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg04609801	chr16:28609176	SULT1A2	-0.55	-5.26	-0.32	3.2e-7	Platelet distribution width;
KIRP	cis	rs35740288	0.787	rs35250181	chr15:86242662	T/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.55	-0.33	7.5e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4919087	0.810	rs1468069	chr10:98988759	A/C	cg25902810	chr10:99078978	FRAT1	0.48	5.77	0.35	2.4e-8	Monocyte count;
KIRP	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	6.22	0.37	2.17e-9	Caffeine consumption;
KIRP	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.68	-8.31	-0.47	6.42e-15	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19767339	chr1:63932041	ITGB3BP	-0.49	-7.66	-0.44	4.28e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2224391	0.628	rs11752747	chr6:5272671	A/G	cg13962347	chr6:5174647	LYRM4	-0.76	-9.86	-0.53	1.55e-19	Height;
KIRP	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg08514558	chr10:81106712	PPIF	0.38	5.18	0.31	4.67e-7	Height;
KIRP	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg24585782	chr17:78113791	EIF4A3	-0.5	-5.97	-0.36	8.03e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg00852783	chr1:26633632	UBXN11	0.54	7.6	0.44	6.18e-13	Obesity-related traits;
KIRP	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.71	-0.39	1.3e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg19592336	chr6:28129416	ZNF389	0.53	5.91	0.35	1.11e-8	Depression;
KIRP	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07570687	chr10:102243282	WNT8B	0.47	5.74	0.34	2.81e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg00677455	chr12:58241039	CTDSP2	-0.53	-6.26	-0.37	1.67e-9	Multiple sclerosis;
KIRP	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.87	11.02	0.57	3.18e-23	Coronary artery disease;
KIRP	cis	rs662064	0.925	rs669701	chr1:10544725	A/G	cg07384165	chr1:10488281	NA	-0.42	-5.3	-0.32	2.63e-7	Asthma;
KIRP	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	0.77	5.85	0.35	1.52e-8	IgG glycosylation;
KIRP	cis	rs96067	0.805	rs12033825	chr1:36600311	C/T	cg24686825	chr1:36642396	MAP7D1	-0.56	-6.2	-0.37	2.41e-9	Corneal structure;
KIRP	cis	rs3857067	1.000	rs7694820	chr4:95017026	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-4.89	-0.3	1.79e-6	QT interval;
KIRP	cis	rs2574975	0.531	rs1211496	chr10:52207314	T/C	cg10034176	chr10:52120283	SGMS1	0.4	5.63	0.34	4.81e-8	Response to amphetamines;
KIRP	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg26262840	chr14:90767686	C14orf102	-0.35	-4.89	-0.3	1.83e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.44	6.06	0.36	5.04e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs5753618	0.583	rs9606843	chr22:31853371	A/C	cg02404636	chr22:31891804	SFI1	0.53	6.18	0.37	2.64e-9	Colorectal cancer;
KIRP	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.9	14.59	0.68	3.63e-35	Dental caries;
KIRP	trans	rs12545912	0.770	rs4841196	chr8:9555092	A/G	cg16141378	chr3:129829833	LOC729375	0.48	6.06	0.36	5.06e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.52	-0.48	1.64e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg08999081	chr20:33150536	PIGU	0.46	6.16	0.37	2.91e-9	Height;
KIRP	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	1.02	10.66	0.56	4.48e-22	Exhaled nitric oxide output;
KIRP	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg05072774	chr3:49840536	C3orf54	0.43	5.54	0.33	7.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs33912345	0.695	rs1254313	chr14:60895686	A/T	cg27398547	chr14:60952738	C14orf39	-0.41	-5.59	-0.34	6.13e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.61	7.71	0.44	3.1e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg09873164	chr1:152488093	CRCT1	0.57	7.66	0.44	4.17e-13	Hair morphology;
KIRP	cis	rs687432	0.924	rs34563263	chr11:57698602	A/T	cg19752551	chr11:57585705	CTNND1	-0.56	-7.64	-0.44	4.86e-13	Parkinson's disease;
KIRP	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg21360079	chr12:107162445	NA	-0.68	-9.6	-0.52	1e-18	Heart rate;
KIRP	cis	rs9815354	1.000	rs56158380	chr3:41885588	G/A	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg01620082	chr3:125678407	NA	-1.19	-7.59	-0.44	6.51e-13	Depression;
KIRP	cis	rs580438	0.529	rs2062852	chr3:13434543	A/G	cg10657019	chr3:13328039	NA	-0.5	-6.39	-0.38	8.35e-10	Myringotomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25105066	chr7:70159340	AUTS2	0.5	6.14	0.36	3.23e-9	Parkinson's disease;
KIRP	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.48	-6.56	-0.39	3.07e-10	Asthma;
KIRP	cis	rs4704187	0.687	rs6879894	chr5:74498164	C/A	cg03227963	chr5:74354835	NA	0.4	5.79	0.35	2.13e-8	Response to amphetamines;
KIRP	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.47	5.03	0.31	9.64e-7	LDL cholesterol levels;LDL cholesterol;
KIRP	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.45	-5.65	-0.34	4.31e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg25566285	chr7:158114605	PTPRN2	0.79	13.16	0.64	2.71e-30	Calcium levels;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.8	6.31	0.37	1.3e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14039299	chr9:135251409	TTF1	-0.48	-6.95	-0.41	3.28e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg15896084	chr13:114927664	NA	-0.45	-6.42	-0.38	7.13e-10	Schizophrenia;
KIRP	cis	rs10463554	0.750	rs26257	chr5:102550531	C/T	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.24e-8	Parkinson's disease;
KIRP	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.88	-9.04	-0.5	4.94e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg20673091	chr1:2541236	MMEL1	-0.67	-10.12	-0.54	2.45e-20	Ulcerative colitis;
KIRP	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg10381502	chr11:71823885	C11orf51	-1.09	-7.61	-0.44	5.85e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.49	5.98	0.36	7.76e-9	Height;
KIRP	cis	rs6601327	0.665	rs11249949	chr8:9655612	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.12	-0.31	6.18e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.36	-0.32	1.93e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.75	9.71	0.53	4.61e-19	Response to antipsychotic treatment;
KIRP	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.16	0.31	5.01e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs240764	0.817	rs239206	chr6:101137332	T/G	cg09795085	chr6:101329169	ASCC3	0.46	5.51	0.33	8.82e-8	Neuroticism;
KIRP	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.51	6.64	0.39	1.98e-10	Response to temozolomide;
KIRP	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.52	-5.45	-0.33	1.24e-7	Corneal structure;
KIRP	cis	rs6743226	0.934	rs6705421	chr2:242212672	A/G	cg10021735	chr2:242295487	FARP2	0.51	6.19	0.37	2.56e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs684232	0.901	rs450289	chr17:629896	G/T	cg04370829	chr17:406249	NA	0.38	5.0	0.3	1.1e-6	Prostate cancer;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg20849121	chr1:12679951	NA	-0.43	-6.04	-0.36	5.66e-9	Neuroticism;
KIRP	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg00012203	chr2:219082015	ARPC2	-0.42	-5.23	-0.32	3.66e-7	Ulcerative colitis;
KIRP	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg12315302	chr6:26189340	HIST1H4D	0.7	5.19	0.31	4.51e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.74	-11.03	-0.58	2.97e-23	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.81	10.61	0.56	6.74e-22	Platelet distribution width;
KIRP	cis	rs2905347	0.964	rs2961270	chr7:22622138	C/A	cg23521230	chr7:22704884	NA	0.4	5.21	0.32	4.05e-7	Major depression and alcohol dependence;
KIRP	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.83	-10.42	-0.55	2.65e-21	Gut microbiome composition (summer);
KIRP	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs2279817	1.000	rs2279817	chr1:18021858	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-7.87	-0.45	1.15e-13	Neuroticism;
KIRP	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.49	6.43	0.38	6.42e-10	HDL cholesterol;
KIRP	cis	rs17065868	1.000	rs9525988	chr13:45172189	G/T	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs282587	0.597	rs12876520	chr13:113393566	C/G	cg04656015	chr13:113407548	ATP11A	0.61	6.59	0.39	2.7e-10	Glycated hemoglobin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21794428	chr13:21635420	LATS2	0.49	6.05	0.36	5.5e-9	Parkinson's disease;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg08132940	chr7:1081526	C7orf50	-0.46	-5.28	-0.32	2.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs427941	0.585	rs201511	chr7:101767653	A/G	cg06246474	chr7:101738831	CUX1	0.54	6.5	0.38	4.45e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg18586891	chr4:952366	TMEM175	0.64	5.76	0.34	2.51e-8	Parkinson's disease;
KIRP	cis	rs2151522	0.762	rs9375459	chr6:127147704	C/T	cg21431617	chr6:127135037	NA	0.3	5.34	0.32	2.16e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7560272	0.723	rs7562047	chr2:73725168	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.72	-0.34	3.03e-8	Schizophrenia;
KIRP	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18308176	chr2:242786266	NA	0.42	6.1	0.36	4.04e-9	Parkinson's disease;
KIRP	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19717773	chr7:2847554	GNA12	-0.35	-5.23	-0.32	3.64e-7	Height;
KIRP	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.27	-0.32	3.04e-7	Bladder cancer;
KIRP	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.35	0.38	1.05e-9	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11987759	chr7:65425863	GUSB	0.58	7.68	0.44	3.76e-13	Aortic root size;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25786640	chr7:1946447	MAD1L1	0.44	6.27	0.37	1.59e-9	Survival in pancreatic cancer;
KIRP	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg03605463	chr16:89740564	NA	0.58	7.49	0.43	1.25e-12	Vitiligo;
KIRP	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs1883415	0.534	rs2760145	chr6:24478813	T/C	cg20631270	chr6:24437470	GPLD1	0.39	4.99	0.3	1.13e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9309473	1.000	rs1534471	chr2:73647508	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.8	-0.35	1.99e-8	Metabolite levels;
KIRP	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg19610905	chr11:61596333	FADS2	-0.54	-6.29	-0.37	1.41e-9	Neutrophil count;Sum basophil neutrophil counts;
KIRP	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg08313168	chr12:7315531	NA	0.68	6.18	0.37	2.61e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs10411262	0.935	rs2871987	chr19:47175528	A/G	cg13467550	chr19:47212573	PRKD2	0.37	5.36	0.32	1.93e-7	Tonsillectomy;
KIRP	cis	rs4363385	0.574	rs4845505	chr1:152960943	T/A	cg13444842	chr1:152974279	SPRR3	-0.47	-6.89	-0.4	4.53e-11	Inflammatory skin disease;
KIRP	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	Myopia (pathological);
KIRP	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-8.12	-0.46	2.3e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6668534	1.000	rs6668534	chr1:161671995	C/T	cg07385423	chr1:161697574	FCRLB	0.43	4.96	0.3	1.34e-6	Blood protein levels;
KIRP	cis	rs3733418	0.929	rs72697952	chr4:165900928	A/G	cg10852876	chr4:165953100	TRIM60	-0.45	-4.94	-0.3	1.43e-6	Obesity-related traits;
KIRP	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.31	8.04	0.46	3.74e-14	Primary biliary cholangitis;
KIRP	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.33	-0.32	2.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.01	15.0	0.69	1.48e-36	Chronic sinus infection;
KIRP	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg08533674	chr1:46993347	NA	-0.46	-5.81	-0.35	1.91e-8	Monobrow;
KIRP	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg00933542	chr6:150070202	PCMT1	0.3	5.74	0.34	2.84e-8	Lung cancer;
KIRP	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg09455208	chr3:40491958	NA	0.3	5.01	0.3	1.04e-6	Renal cell carcinoma;
KIRP	cis	rs4262150	0.667	rs4958594	chr5:152298956	C/T	cg12297329	chr5:152029980	NA	0.47	6.64	0.39	2e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-12.94	-0.64	1.44e-29	Dental caries;
KIRP	cis	rs7523273	0.565	rs2796280	chr1:207889345	C/T	cg22525895	chr1:207977042	MIR29B2	-0.45	-5.79	-0.35	2.14e-8	Schizophrenia;
KIRP	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.67	-0.39	1.65e-10	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg02725872	chr8:58115012	NA	-0.56	-7.66	-0.44	4.2e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.81	-10.81	-0.57	1.59e-22	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02905663	chr8:119123707	EXT1	0.5	6.49	0.38	4.57e-10	Parkinson's disease;
KIRP	cis	rs4965359	0.700	rs28831142	chr15:101574403	T/G	cg18083008	chr15:101557551	LRRK1	-0.34	-4.94	-0.3	1.43e-6	Central corneal thickness;
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	5.57	0.33	6.68e-8	Longevity;
KIRP	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.35	-0.32	2.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg00319359	chr11:70116639	PPFIA1	0.64	6.25	0.37	1.76e-9	Coronary artery disease;
KIRP	cis	rs28735056	0.584	rs11664834	chr18:77644876	G/T	cg20368463	chr18:77673604	PQLC1	0.56	6.64	0.39	1.95e-10	Schizophrenia;
KIRP	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg17425144	chr1:10567563	PEX14	0.47	8.6	0.48	9.27e-16	Breast cancer;
KIRP	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg20744362	chr22:50050164	C22orf34	0.33	4.86	0.3	2.13e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg05347473	chr6:146136440	FBXO30	0.66	9.49	0.52	2.04e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.5	6.48	0.38	4.83e-10	White matter hyperintensity burden;
KIRP	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg04731861	chr2:219085781	ARPC2	0.3	7.54	0.43	8.96e-13	Colorectal cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00371891	chr19:4723959	DPP9	0.47	6.21	0.37	2.2e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg11031976	chr2:198649780	BOLL	-0.52	-4.99	-0.3	1.15e-6	Ulcerative colitis;
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.48	4.9	0.3	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg08076091	chr2:203926405	NBEAL1	0.83	8.85	0.49	1.78e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg21926883	chr2:100939477	LONRF2	-0.56	-7.5	-0.43	1.13e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg21573476	chr21:45109991	RRP1B	-0.61	-7.95	-0.45	6.93e-14	Mean corpuscular volume;
KIRP	cis	rs6832769	1.000	rs6853192	chr4:56409254	T/A	cg05960024	chr4:56376020	CLOCK	-0.62	-7.93	-0.45	7.46e-14	Personality dimensions;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25019777	chr4:53525403	USP46	-0.54	-6.13	-0.36	3.38e-9	Interleukin-4 levels;
KIRP	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.5	-5.56	-0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg12623918	chr2:306882	NA	-0.46	-5.83	-0.35	1.75e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23295637	chr19:1513399	ADAMTSL5	0.46	6.07	0.36	4.73e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg18209359	chr17:80159595	CCDC57	0.4	5.16	0.31	5.1e-7	Life satisfaction;
KIRP	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.35	5.31	0.32	2.42e-7	QRS complex (12-leadsum);
KIRP	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.38	-0.43	2.41e-12	Glomerular filtration rate (creatinine);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg21572997	chr11:68080756	LRP5	0.53	6.13	0.36	3.45e-9	Plasma plasminogen activator levels;
KIRP	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg15083037	chr5:83017644	HAPLN1	-0.51	-8.55	-0.48	1.35e-15	Prostate cancer;
KIRP	cis	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg08775375	chr8:10454154	NA	0.35	4.88	0.3	1.9e-6	Neuroticism;
KIRP	cis	rs7221595	0.673	rs115725560	chr17:3980493	T/A	cg21851534	chr17:3907994	ZZEF1	0.54	5.28	0.32	2.82e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs300890	0.642	rs719392	chr4:144281231	A/G	cg01719995	chr4:144104893	USP38	-0.42	-5.31	-0.32	2.49e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.44	5.86	0.35	1.48e-8	Homoarginine levels;
KIRP	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg17507749	chr15:85114479	UBE2QP1	0.86	9.84	0.53	1.8e-19	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg13147721	chr7:65941812	NA	-0.97	-6.86	-0.4	5.54e-11	Diabetic kidney disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg24859228	chr10:12391835	CAMK1D	0.47	6.41	0.38	7.58e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.61	8.77	0.49	3.09e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4919694	0.667	rs117927731	chr10:105112852	C/A	cg05636881	chr10:105038444	INA	0.7	5.69	0.34	3.66e-8	Arsenic metabolism;
KIRP	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg13679303	chr9:96623674	NA	-0.51	-7.22	-0.42	6.58e-12	DNA methylation (variation);
KIRP	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	0.61	6.9	0.4	4.29e-11	Initial pursuit acceleration;
KIRP	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.82	-13.48	-0.65	2.24e-31	Brugada syndrome;
KIRP	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.86	11.01	0.57	3.47e-23	Gestational age at birth (maternal effect);
KIRP	cis	rs1010254	0.510	rs2348421	chr5:151759901	T/C	cg12297329	chr5:152029980	NA	-0.71	-6.92	-0.4	3.85e-11	Optic nerve measurement (cup area);
KIRP	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.74	-10.35	-0.55	4.63e-21	Body mass index;
KIRP	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.04	-0.41	1.88e-11	Initial pursuit acceleration;
KIRP	cis	rs9826463	1.000	rs6797745	chr3:142345203	G/C	cg20824294	chr3:142316082	PLS1	0.33	5.5	0.33	9.64e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7116495	1.000	rs610041	chr11:71797968	A/G	cg26138937	chr11:71823887	C11orf51	-0.65	-5.06	-0.31	8.15e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg21696256	chr3:125484277	NA	-0.44	-4.84	-0.3	2.24e-6	Blood pressure (smoking interaction);
KIRP	trans	rs330071	0.549	rs11785593	chr8:9256324	A/G	cg16141378	chr3:129829833	LOC729375	-0.64	-7.22	-0.42	6.53e-12	Acne (severe);
KIRP	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg03711944	chr11:47377212	SPI1	-0.3	-5.05	-0.31	8.69e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-6.93	-0.4	3.62e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.76	-8.85	-0.49	1.79e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8028182	0.636	rs11638974	chr15:75799306	G/A	cg20655648	chr15:75932815	IMP3	0.52	6.32	0.37	1.24e-9	Sudden cardiac arrest;
KIRP	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs12220238	1.000	rs3812638	chr10:75896072	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.18	0.42	8.1e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.59	-8.31	-0.47	6.47e-15	Calcium levels;
KIRP	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.89	12.37	0.62	1.2e-27	Response to antipsychotic treatment;
KIRP	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.07	-0.36	4.88e-9	Height;
KIRP	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.8	12.72	0.63	7.96e-29	Blood metabolite levels;
KIRP	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.81	8.82	0.49	2.17e-16	HIV-1 control;
KIRP	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg03468072	chr12:39539422	NA	0.42	6.23	0.37	2.06e-9	Morning vs. evening chronotype;
KIRP	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.84	8.71	0.49	4.59e-16	Cerebrospinal P-tau181p levels;
KIRP	trans	rs972578	0.740	rs1983648	chr22:43255397	T/A	cg15321293	chr3:36422198	STAC	-0.48	-6.2	-0.37	2.43e-9	Mean platelet volume;
KIRP	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg06223162	chr1:101003688	GPR88	-0.43	-8.8	-0.49	2.5e-16	Monocyte count;
KIRP	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg06204229	chr3:52865917	ITIH4	0.49	6.68	0.39	1.55e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.66	9.4	0.51	3.87e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.21e-6	Morning vs. evening chronotype;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18404041	chr3:52824283	ITIH1	-0.36	-4.88	-0.3	1.89e-6	Electroencephalogram traits;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg20169779	chr10:135381914	SYCE1	0.43	5.03	0.31	9.55e-7	Obesity-related traits;
KIRP	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.07	-0.36	4.8e-9	IgG glycosylation;
KIRP	cis	rs7707921	0.767	rs226199	chr5:81572464	G/C	cg07807695	chr5:81608485	ATP6AP1L	-0.41	-5.16	-0.31	5.16e-7	Breast cancer;
KIRP	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg09904177	chr6:26538194	HMGN4	0.4	4.95	0.3	1.4e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.05e-17	Retinal vascular caliber;
KIRP	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg02336718	chr17:17403227	NA	-0.34	-5.23	-0.32	3.64e-7	Total body bone mineral density;
KIRP	cis	rs4664293	0.867	rs34795915	chr2:160588931	A/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.85	11.29	0.58	4.34e-24	N-glycan levels;
KIRP	cis	rs6752107	0.840	rs2119505	chr2:234154651	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.61	7.96	0.45	6.14e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg06521331	chr12:34319734	NA	-0.63	-7.44	-0.43	1.68e-12	Morning vs. evening chronotype;
KIRP	cis	rs698833	0.892	rs698796	chr2:44689669	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.62	0.39	2.29e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.75	11.33	0.59	3.18e-24	Hip circumference;
KIRP	cis	rs4658101	0.700	rs12048543	chr1:92050356	C/T	cg09075522	chr1:92031145	NA	0.45	5.54	0.33	7.94e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07402062	chr16:89894098	SPIRE2	0.33	6.94	0.4	3.38e-11	Vitiligo;
KIRP	trans	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	0.78	8.49	0.48	1.92e-15	Pediatric areal bone mineral density (radius);
KIRP	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg05528293	chr18:74961138	GALR1	0.52	5.73	0.34	2.96e-8	Obesity-related traits;
KIRP	cis	rs9788682	0.706	rs2656055	chr15:78720194	C/A	cg24631222	chr15:78858424	CHRNA5	-0.78	-9.11	-0.5	2.95e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg15832292	chr6:96025679	MANEA	0.71	5.7	0.34	3.38e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2997447	0.761	rs2802312	chr1:26430822	T/C	cg19633962	chr1:26362018	EXTL1	-0.56	-5.27	-0.32	3.05e-7	QRS complex (12-leadsum);
KIRP	cis	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg19847130	chr8:10466454	RP1L1	0.39	6.26	0.37	1.66e-9	Neuroticism;
KIRP	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.81	-13.13	-0.64	3.24e-30	Prostate cancer;
KIRP	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.45e-8	Crohn's disease;
KIRP	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg01294253	chr9:136912663	BRD3	0.44	5.74	0.34	2.84e-8	Platelet distribution width;
KIRP	cis	rs9972944	0.902	rs10512503	chr17:63772066	G/A	cg07283582	chr17:63770753	CCDC46	0.51	8.35	0.47	5.08e-15	Total body bone mineral density;
KIRP	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.91	-0.3	1.66e-6	Pulmonary function;
KIRP	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg00343986	chr7:65444356	GUSB	-0.4	-4.9	-0.3	1.72e-6	Aortic root size;
KIRP	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg27432699	chr2:27873401	GPN1	-0.45	-5.79	-0.35	2.12e-8	Total body bone mineral density;
KIRP	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg15534755	chr11:117069859	TAGLN	-0.41	-5.16	-0.31	5.19e-7	Blood protein levels;
KIRP	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.54	-6.16	-0.37	2.95e-9	Breast cancer;
KIRP	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg04132472	chr17:19861366	AKAP10	0.43	5.88	0.35	1.35e-8	Schizophrenia;
KIRP	cis	rs28834970	0.925	rs2322599	chr8:27211910	G/A	cg18234130	chr8:27182889	PTK2B	-0.46	-5.96	-0.36	8.84e-9	Alzheimer's disease (late onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12661088	chr5:43120934	ZNF131	0.53	6.14	0.36	3.37e-9	Smoking initiation;
KIRP	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.98	13.0	0.64	9.03e-30	Vitamin D levels;
KIRP	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg02153584	chr22:29168773	CCDC117	0.58	5.91	0.35	1.15e-8	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg16586182	chr3:47516702	SCAP	-0.73	-10.25	-0.55	9.28e-21	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	1.07	15.63	0.71	1.05e-38	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05645360	chr10:115614541	DCLRE1A;NHLRC2	0.43	6.19	0.37	2.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg16497661	chr14:103986332	CKB	-0.48	-6.16	-0.37	2.98e-9	Coronary artery disease;
KIRP	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	1.33	9.88	0.53	1.36e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.62	8.29	0.47	7.35e-15	Lymphocyte counts;
KIRP	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.51	-8.71	-0.49	4.55e-16	Pneumonia;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.76	11.73	0.6	1.56e-25	Menarche (age at onset);
KIRP	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.23	-0.42	6.24e-12	Joint mobility (Beighton score);
KIRP	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	8.76	0.49	3.31e-16	Cognitive test performance;
KIRP	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg04414720	chr1:150670196	GOLPH3L	0.37	4.9	0.3	1.72e-6	Tonsillectomy;
KIRP	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.83	-0.35	1.73e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.44	-5.99	-0.36	7.24e-9	Abdominal aortic aneurysm;
KIRP	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07570687	chr10:102243282	WNT8B	-0.53	-7.15	-0.41	9.69e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10824796	1.000	rs7096206	chr10:54531685	C/G	cg27418851	chr10:54531653	MBL2	0.45	5.19	0.31	4.39e-7	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24906519	chr6:53409386	GCLC	0.52	6.35	0.38	1.04e-9	Parkinson's disease;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg03125605	chr16:67236337	MIR328;ELMO3	0.43	6.18	0.37	2.71e-9	Beard thickness;
KIRP	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg11693508	chr17:37793320	STARD3	0.68	7.24	0.42	5.81e-12	Bipolar disorder;
KIRP	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg00666640	chr1:248458726	OR2T12	-0.38	-4.84	-0.3	2.25e-6	Common traits (Other);
KIRP	cis	rs9309473	0.950	rs7566364	chr2:73842889	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.5	-0.33	9.6e-8	Metabolite levels;
KIRP	cis	rs7180079	0.563	rs610700	chr15:64872537	A/G	cg15337035	chr15:64978493	NA	-0.46	-5.02	-0.3	9.8e-7	Monocyte count;
KIRP	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00889227	chr1:205173544	DSTYK	-0.37	-5.31	-0.32	2.5e-7	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19646445	chr1:215740697	KCTD3	0.43	6.1	0.36	4.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.75	8.94	0.5	9.79e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7856656	1.000	rs10973326	chr9:37419497	G/A	cg09233161	chr9:37079712	NA	0.43	4.9	0.3	1.73e-6	Cancer;
KIRP	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.51	-6.41	-0.38	7.43e-10	Dilated cardiomyopathy;
KIRP	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs4704187	0.687	rs6885887	chr5:74497842	A/C	cg03227963	chr5:74354835	NA	0.39	5.49	0.33	9.96e-8	Response to amphetamines;
KIRP	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg09795085	chr6:101329169	ASCC3	-0.51	-6.18	-0.37	2.61e-9	Neuroticism;
KIRP	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg16077055	chr2:106428750	NCK2	0.27	5.32	0.32	2.35e-7	Addiction;
KIRP	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	5.61	0.34	5.32e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.62	-6.9	-0.4	4.25e-11	Neuroticism;
KIRP	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg17425144	chr1:10567563	PEX14	0.44	7.46	0.43	1.49e-12	Hand grip strength;
KIRP	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg10253484	chr15:75165896	SCAMP2	0.56	6.39	0.38	8.29e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg09699651	chr6:150184138	LRP11	0.48	6.48	0.38	4.95e-10	Lung cancer;
KIRP	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.64	-11.21	-0.58	7.86e-24	White blood cell count (basophil);
KIRP	cis	rs8077577	0.789	rs62072546	chr17:18253839	C/T	cg18869244	chr17:18121946	NA	0.47	5.06	0.31	8.03e-7	Obesity-related traits;
KIRP	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.13e-6	Aortic root size;
KIRP	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg00262122	chr8:11665843	FDFT1	0.44	5.52	0.33	8.67e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.4	0.55	3.01e-21	Parkinson's disease;
KIRP	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	1.05	19.15	0.77	1.19e-50	Heart rate;
KIRP	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	0.56	8.26	0.47	8.91e-15	Diastolic blood pressure;
KIRP	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs2278796	0.528	rs4951151	chr1:204970302	T/C	cg17947172	chr1:204966197	NFASC	0.64	8.18	0.46	1.57e-14	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.9	0.3	1.74e-6	Lung cancer;
KIRP	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg21132104	chr15:45694354	SPATA5L1	0.58	7.0	0.41	2.44e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.74	-6.97	-0.41	2.84e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.3	0.47	6.72e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10162002	1.000	rs17078796	chr13:24043830	A/G	cg00158254	chr13:24040743	NA	-0.5	-4.97	-0.3	1.27e-6	Hypothyroidism;
KIRP	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	0.97	7.58	0.44	6.98e-13	Age-related hearing impairment;
KIRP	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg18904891	chr8:8559673	CLDN23	0.72	8.0	0.45	4.86e-14	Obesity-related traits;
KIRP	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg08890418	chr1:21044141	KIF17	0.35	5.31	0.32	2.43e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.61	-7.28	-0.42	4.54e-12	Mosquito bite size;
KIRP	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg20933634	chr6:27740509	NA	0.36	4.89	0.3	1.79e-6	Parkinson's disease;
KIRP	cis	rs8018808	0.967	rs4903579	chr14:77850940	T/A	cg20045696	chr14:77926864	AHSA1	-0.43	-5.37	-0.32	1.86e-7	Myeloid white cell count;
KIRP	cis	rs4700695	0.925	rs4700090	chr5:65412434	C/T	cg21114390	chr5:65439923	SFRS12	-0.59	-5.81	-0.35	1.94e-8	Facial morphology (factor 19);
KIRP	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg18135206	chr14:102964638	TECPR2	0.45	5.08	0.31	7.51e-7	Blood protein levels;
KIRP	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg25319279	chr11:5960081	NA	-0.52	-5.38	-0.32	1.71e-7	DNA methylation (variation);
KIRP	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg21475434	chr5:93447410	FAM172A	-0.62	-5.18	-0.31	4.66e-7	Diabetic retinopathy;
KIRP	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.7	9.3	0.51	8.09e-18	Eye color traits;
KIRP	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.47	-5.61	-0.34	5.44e-8	P wave terminal force;
KIRP	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.48	6.07	0.36	4.93e-9	Menopause (age at onset);
KIRP	cis	rs6448317	1.000	rs13105803	chr4:24940002	A/G	cg21108841	chr4:24914750	CCDC149	-0.46	-5.38	-0.32	1.69e-7	Heschl's gyrus morphology;
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.97	0.36	8.09e-9	Platelet count;
KIRP	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg24879335	chr3:133465180	TF	0.34	4.95	0.3	1.36e-6	Iron status biomarkers;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg07870486	chr7:56019566	MRPS17	0.51	6.34	0.37	1.08e-9	Educational attainment;
KIRP	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg04370829	chr17:406249	NA	0.4	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.78	0.53	2.63e-19	Prudent dietary pattern;
KIRP	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg14359292	chr7:27170892	HOXA4	-0.34	-4.99	-0.3	1.15e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.4	4.97	0.3	1.23e-6	Asthma;
KIRP	cis	rs6973256	0.865	rs763645	chr7:133343428	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.38	-0.38	8.55e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22173241	chr19:10764462	ILF3;LOC147727	0.5	6.77	0.4	9.56e-11	Parkinson's disease;
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.48	-6.6	-0.39	2.55e-10	Testicular germ cell tumor;
KIRP	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.48	6.65	0.39	1.86e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg20560298	chr2:73613845	ALMS1	0.4	4.94	0.3	1.46e-6	Schizophrenia;
KIRP	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09379601	chr19:12992224	DNASE2	0.71	6.95	0.41	3.3e-11	Lung function (FEV1);
KIRP	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	1.03	11.62	0.6	3.52e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.46	-9.36	-0.51	5.25e-18	Rheumatoid arthritis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24004959	chr3:189087191	NA	0.36	6.19	0.37	2.57e-9	C-reactive protein;
KIRP	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-8.33	-0.47	5.56e-15	Coffee consumption (cups per day);
KIRP	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.61	-8.23	-0.46	1.1e-14	Colorectal cancer;
KIRP	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg12218747	chr21:37451666	NA	-0.45	-5.54	-0.33	7.58e-8	Mitral valve prolapse;
KIRP	cis	rs904251	0.504	rs9380677	chr6:37480366	A/G	cg01843034	chr6:37503916	NA	-0.99	-15.8	-0.71	2.75e-39	Cognitive performance;
KIRP	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.41	5.92	0.35	1.08e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs829883	0.724	rs11109507	chr12:98904160	C/T	cg25150519	chr12:98850993	NA	0.75	9.81	0.53	2.16e-19	Colorectal adenoma (advanced);
KIRP	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg11952622	chr19:58962976	ZNF324B	0.46	5.57	0.33	6.65e-8	Uric acid clearance;
KIRP	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg01620082	chr3:125678407	NA	-0.94	-6.75	-0.4	1.08e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02725872	chr8:58115012	NA	-0.73	-7.64	-0.44	4.73e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06850241	chr22:41845214	NA	-0.46	-5.59	-0.34	5.96e-8	Vitiligo;
KIRP	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg20243544	chr17:37824526	PNMT	-0.4	-5.0	-0.3	1.11e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg25922239	chr6:33757077	LEMD2	0.64	7.27	0.42	4.69e-12	Crohn's disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg01252224	chr16:83841660	HSBP1	0.49	6.06	0.36	4.98e-9	DNA methylation (variation);
KIRP	cis	rs9815354	0.868	rs1716653	chr3:41975598	C/A	cg03022575	chr3:42003672	ULK4	-0.57	-6.68	-0.39	1.6e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs860295	0.702	rs475550	chr1:155652081	A/T	cg02153340	chr1:155202674	NA	-0.43	-5.77	-0.35	2.41e-8	Body mass index;
KIRP	cis	rs2742417	1.000	rs2742423	chr3:45733430	A/G	cg04037228	chr3:45636386	LIMD1	0.36	5.25	0.32	3.34e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.61	-8.5	-0.48	1.8e-15	Motion sickness;
KIRP	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.92	-11.32	-0.59	3.56e-24	Diastolic blood pressure;
KIRP	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.45	7.61	0.44	5.82e-13	Testicular germ cell tumor;
KIRP	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.97	11.37	0.59	2.28e-24	Corneal astigmatism;
KIRP	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	4.94	0.3	1.45e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.57	0.73	6.1e-42	Electrocardiographic conduction measures;
KIRP	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg10503236	chr1:231470652	EXOC8	-0.5	-7.05	-0.41	1.76e-11	Hemoglobin concentration;
KIRP	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06481639	chr22:41940642	POLR3H	-0.65	-7.05	-0.41	1.75e-11	Vitiligo;
KIRP	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg02023728	chr11:77925099	USP35	0.45	7.51	0.43	1.1e-12	Testicular germ cell tumor;
KIRP	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.97	14.61	0.68	3.11e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg21695830	chr1:89457462	RBMXL1;CCBL2	0.47	6.21	0.37	2.28e-9	Carotid intima media thickness;
KIRP	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg00857998	chr1:205179979	DSTYK	0.5	6.36	0.38	9.65e-10	Red blood cell count;
KIRP	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.66	7.64	0.44	4.82e-13	Schizophrenia;
KIRP	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg24881330	chr22:46731750	TRMU	0.84	7.29	0.42	4.34e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4132509	1.000	rs1458024	chr1:243937445	G/C	cg21452805	chr1:244014465	NA	0.47	4.9	0.3	1.75e-6	RR interval (heart rate);
KIRP	trans	rs2048656	0.578	rs925610	chr8:9681836	G/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.13	-0.41	1.14e-11	Schizophrenia;
KIRP	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.66	9.4	0.51	4e-18	Mood instability;
KIRP	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg16434002	chr17:42200994	HDAC5	-0.52	-6.29	-0.37	1.43e-9	Total body bone mineral density;
KIRP	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg01559446	chr3:44596178	ZNF167	-0.36	-5.14	-0.31	5.5e-7	Depressive symptoms;
KIRP	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.5	-6.3	-0.37	1.33e-9	Neutrophil percentage of white cells;
KIRP	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg01620082	chr3:125678407	NA	-1.03	-6.64	-0.39	1.97e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2548003	0.518	rs1157974	chr5:28765229	C/T	cg22863700	chr5:28928346	NA	-0.59	-6.09	-0.36	4.2e-9	Hip geometry;
KIRP	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.32	-0.32	2.34e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg05127821	chr10:94822908	CYP26C1	-1.1	-11.3	-0.58	3.95e-24	Coronary artery disease;
KIRP	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg07585502	chr8:101912084	NA	-0.66	-8.34	-0.47	5.23e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg20731937	chr12:48336164	NA	0.39	5.1	0.31	6.88e-7	Longevity (90 years and older);
KIRP	cis	rs12311304	0.965	rs73065457	chr12:15366321	C/T	cg08258403	chr12:15378311	NA	0.34	4.99	0.3	1.17e-6	Behavioural disinhibition (generation interaction);
KIRP	trans	rs587242	1.000	rs12045626	chr1:96917476	C/T	cg10631902	chr5:14652156	NA	0.53	6.14	0.36	3.2e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.69	0.34	3.53e-8	Educational attainment;
KIRP	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.12	-0.41	1.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.46	-6.2	-0.37	2.38e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg08501292	chr6:25962987	TRIM38	1.01	7.49	0.43	1.26e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3087591	0.639	rs734403	chr17:29723346	T/C	cg24425628	chr17:29625626	OMG;NF1	0.59	8.37	0.47	4.36e-15	Hip circumference;
KIRP	trans	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.6	0.39	2.55e-10	Retinal vascular caliber;
KIRP	cis	rs710913	0.816	rs1180341	chr1:39992808	A/G	cg27567593	chr1:39956653	BMP8A	0.33	4.95	0.3	1.38e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1712517	0.525	rs11191667	chr10:105128898	G/A	cg04362960	chr10:104952993	NT5C2	-0.58	-7.31	-0.42	3.79e-12	Migraine;
KIRP	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg03209412	chr4:183728196	NA	0.44	6.07	0.36	4.69e-9	Pediatric autoimmune diseases;
KIRP	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18252515	chr7:66147081	NA	0.44	5.16	0.31	4.98e-7	Aortic root size;
KIRP	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.6e-8	Colorectal cancer;
KIRP	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03352830	chr11:487213	PTDSS2	0.77	6.38	0.38	8.81e-10	Body mass index;
KIRP	cis	rs2574975	0.531	rs1203387	chr10:52206378	A/C	cg10034176	chr10:52120283	SGMS1	0.39	5.55	0.33	7.55e-8	Response to amphetamines;
KIRP	cis	rs12643440	0.538	rs879572	chr4:17148487	G/C	cg22650099	chr4:17144496	NA	-0.76	-8.98	-0.5	7.2e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.76	10.74	0.57	2.52e-22	Red blood cell count;
KIRP	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg20744362	chr22:50050164	C22orf34	0.34	5.14	0.31	5.72e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.12	14.43	0.68	1.34e-34	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.29	0.32	2.73e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.48	-5.62	-0.34	5.28e-8	Longevity;Endometriosis;
KIRP	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.57	-7.82	-0.45	1.54e-13	Migraine;
KIRP	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.97	-0.41	2.87e-11	Myopia (pathological);
KIRP	cis	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg21546286	chr11:48923668	NA	-0.46	-5.96	-0.36	8.68e-9	HDL cholesterol;
KIRP	cis	rs960902	0.620	rs6734373	chr2:37735241	C/T	cg25341268	chr2:37734390	NA	-0.52	-6.86	-0.4	5.52e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg09344028	chr17:70110421	NA	-0.49	-12.1	-0.61	9.43e-27	Thyroid hormone levels;
KIRP	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg17143192	chr8:8559678	CLDN23	0.68	7.75	0.44	2.45e-13	Obesity-related traits;
KIRP	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	1.09	8.9	0.49	1.26e-16	Plasma clusterin levels;
KIRP	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05665937	chr4:1216051	CTBP1	0.43	6.04	0.36	5.77e-9	Obesity-related traits;
KIRP	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.56	8.78	0.49	2.79e-16	Coronary artery disease;
KIRP	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.56	-6.84	-0.4	6.24e-11	Aortic root size;
KIRP	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11987759	chr7:65425863	GUSB	0.58	7.71	0.44	3.12e-13	Aortic root size;
KIRP	cis	rs2625529	0.938	rs8747	chr15:72115541	C/A	cg16672083	chr15:72433130	SENP8	-0.53	-6.49	-0.38	4.58e-10	Red blood cell count;
KIRP	cis	rs9972944	0.756	rs1421032	chr17:63766368	A/C	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg11234688	chr2:1609660	NA	0.61	5.41	0.33	1.46e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs11997175	0.838	rs10954934	chr8:33669637	T/C	cg04338863	chr8:33670619	NA	0.42	5.61	0.34	5.51e-8	Body mass index;
KIRP	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg20387954	chr3:183756860	HTR3D	0.64	9.42	0.51	3.55e-18	Anterior chamber depth;
KIRP	cis	rs4363506	1.000	rs4414136	chr10:129274778	C/T	cg07804728	chr10:129284050	NA	0.41	5.83	0.35	1.73e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Melanoma;
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg17294928	chr15:75287854	SCAMP5	-0.58	-7.87	-0.45	1.14e-13	Breast cancer;
KIRP	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg09788416	chr12:39539408	NA	0.42	5.37	0.32	1.78e-7	Morning vs. evening chronotype;
KIRP	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg23533926	chr12:111358616	MYL2	-0.52	-6.94	-0.4	3.5e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg15655495	chr12:38532458	NA	0.26	4.94	0.3	1.45e-6	Bladder cancer;
KIRP	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg18132916	chr6:79620363	NA	0.41	5.59	0.34	6.02e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg13206674	chr6:150067644	NUP43	0.59	8.63	0.48	7.86e-16	Lung cancer;
KIRP	cis	rs17592366	0.793	rs7143293	chr14:35318458	T/A	cg09327582	chr14:35236912	BAZ1A	0.66	5.14	0.31	5.49e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.16	-0.31	5.08e-7	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg05457628	chr5:178986728	RUFY1	0.48	7.09	0.41	1.38e-11	Lung cancer;
KIRP	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-0.77	-10.21	-0.55	1.26e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.79	14.93	0.69	2.59e-36	Lymphocyte counts;
KIRP	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.65	-9.38	-0.51	4.67e-18	Retinal vascular caliber;
KIRP	cis	rs7594645	0.661	rs12463410	chr2:207715608	C/T	cg06697829	chr2:208633331	FZD5	-0.84	-4.94	-0.3	1.43e-6	Episodic memory;
KIRP	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.56	0.33	6.98e-8	Breast cancer;
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.72	8.63	0.48	8.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12224898	chr2:96971451	SNRNP200	0.48	6.06	0.36	5.14e-9	Parkinson's disease;
KIRP	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.4	-4.98	-0.3	1.19e-6	Aortic root size;
KIRP	cis	rs7617773	0.780	rs9846818	chr3:48375685	C/T	cg11946769	chr3:48343235	NME6	0.61	7.72	0.44	2.86e-13	Coronary artery disease;
KIRP	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-6.47	-0.38	5.27e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.22	0.42	6.6e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.44	0.33	1.3e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2820315	1.000	rs2644122	chr1:201810407	A/G	cg11586189	chr1:201857591	SHISA4	-0.39	-5.49	-0.33	1e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.93	-0.53	9.5e-20	Hemoglobin concentration;
KIRP	cis	rs7852872	0.931	rs10759844	chr9:119249326	T/A	cg13792444	chr9:119245443	ASTN2	0.42	6.05	0.36	5.5e-9	Hippocampal volume;
KIRP	cis	rs2224391	0.534	rs2753228	chr6:5246623	G/T	cg13962347	chr6:5174647	LYRM4	-0.74	-10.1	-0.54	2.65e-20	Height;
KIRP	cis	rs4638749	0.501	rs9653451	chr2:108781858	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.22	-0.32	3.81e-7	Blood pressure;
KIRP	trans	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg14791747	chr16:20752902	THUMPD1	-0.59	-7.98	-0.45	5.51e-14	Cognitive test performance;
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg04369109	chr6:150039330	LATS1	0.49	5.99	0.36	7.35e-9	Lung cancer;
KIRP	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.47	-5.55	-0.33	7.4e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.16	-0.31	5.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg21411534	chr10:93558674	TNKS2	0.53	6.11	0.36	3.81e-9	Sleep duration;
KIRP	cis	rs2594989	0.673	rs9854573	chr3:11602577	C/T	cg01796438	chr3:11312864	ATG7	0.46	5.28	0.32	2.87e-7	Circulating chemerin levels;
KIRP	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg13397359	chr6:42928475	GNMT	0.65	9.55	0.52	1.4e-18	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-10.4	-0.55	3.18e-21	Colorectal cancer;
KIRP	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.55	7.61	0.44	5.83e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs909341	0.909	rs1758205	chr20:62355756	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.95	-0.41	3.29e-11	Atopic dermatitis;
KIRP	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg26384229	chr12:38710491	ALG10B	0.56	7.16	0.42	9.48e-12	Morning vs. evening chronotype;
KIRP	cis	rs7116495	1.000	rs17161991	chr11:71839960	T/C	cg11196788	chr11:71737549	NUMA1	-0.55	-4.92	-0.3	1.59e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs4789452	1.000	rs34596832	chr17:75373170	C/T	cg02320862	chr17:75370284	SEPT9	-0.37	-5.09	-0.31	6.99e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg23594656	chr7:65796392	TPST1	0.39	5.9	0.35	1.2e-8	Aortic root size;
KIRP	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg10047753	chr17:41438598	NA	1.12	17.92	0.75	1.57e-46	Menopause (age at onset);
KIRP	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg08501292	chr6:25962987	TRIM38	1.09	8.15	0.46	1.91e-14	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs3128341	0.639	rs6690399	chr1:72817099	A/T	cg16299813	chr17:79632380	C17orf90;CCDC137	-0.34	-6.1	-0.36	4.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.52	-6.39	-0.38	8.15e-10	Body mass index;
KIRP	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg09163369	chr1:210001066	C1orf107	0.53	5.75	0.34	2.67e-8	Orofacial clefts;
KIRP	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.79	-0.44	1.89e-13	Platelet count;
KIRP	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.57	8.37	0.47	4.28e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.44	-6.46	-0.38	5.45e-10	Refractive error;
KIRP	cis	rs1440410	0.798	rs13106497	chr4:144120680	C/T	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg15848620	chr12:58087721	OS9	-0.49	-5.67	-0.34	3.94e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9372498	0.536	rs9489409	chr6:118802721	A/G	cg21191810	chr6:118973309	C6orf204	-0.42	-4.88	-0.3	1.87e-6	Diastolic blood pressure;
KIRP	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg17554472	chr22:41940697	POLR3H	-0.55	-6.44	-0.38	6.18e-10	Vitiligo;
KIRP	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.91	13.4	0.65	3.98e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg07044859	chr10:101282883	NA	-0.28	-5.03	-0.31	9.38e-7	Dental caries;
KIRP	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.98	15.55	0.7	1.91e-38	Uric acid clearance;
KIRP	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	1.03	11.14	0.58	1.31e-23	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg17724175	chr1:150552817	MCL1	-0.34	-5.79	-0.35	2.11e-8	Tonsillectomy;
KIRP	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg10017260	chr10:834428	NA	-0.55	-5.41	-0.33	1.53e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs678170	1	rs678170	chr11:114431956	A/G	cg19465033	chr11:114479364	NA	0.4	5.6	0.34	5.81e-8	Ulcerative colitis;
KIRP	cis	rs554111	0.509	rs495522	chr1:21105994	C/T	cg21184320	chr1:21044207	KIF17	0.4	5.94	0.35	9.68e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7221595	0.877	rs35321558	chr17:3892909	G/A	cg21851534	chr17:3907994	ZZEF1	0.56	5.57	0.33	6.62e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.76	8.7	0.49	4.78e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	1.06	9.32	0.51	7.15e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.3	13.48	0.65	2.19e-31	Diabetic retinopathy;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.62	9.57	0.52	1.17e-18	Lung cancer;
KIRP	cis	rs33912345	0.750	rs1254319	chr14:60903757	G/A	cg27398547	chr14:60952738	C14orf39	-0.39	-5.11	-0.31	6.36e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs4950322	0.515	rs72691016	chr1:146717027	T/C	cg22381352	chr1:146742008	CHD1L	-0.43	-5.39	-0.32	1.68e-7	Protein quantitative trait loci;
KIRP	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg08501292	chr6:25962987	TRIM38	0.74	4.93	0.3	1.5e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg18709589	chr6:96969512	KIAA0776	0.34	5.04	0.31	8.89e-7	Headache;
KIRP	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg14673194	chr17:80132900	CCDC57	-0.74	-8.02	-0.46	4.22e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg27490568	chr2:178487706	NA	0.49	6.64	0.39	2.03e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.64	7.66	0.44	4.2e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs12949688	1.000	rs4793566	chr17:55815469	T/C	cg12582317	chr17:55822272	NA	0.6	10.0	0.54	5.66e-20	Schizophrenia;
KIRP	cis	rs4742903	0.935	rs10991166	chr9:106974096	T/C	cg14250997	chr9:106856677	SMC2	0.38	4.96	0.3	1.29e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg01677386	chr11:118938358	VPS11	-0.55	-6.75	-0.4	1.08e-10	Coronary artery disease;
KIRP	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.31	7.3	0.42	3.87e-12	IgG glycosylation;
KIRP	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.28	-0.37	1.56e-9	Migraine - clinic-based;
KIRP	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.69	0.44	3.45e-13	Personality dimensions;
KIRP	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg12923728	chr3:195709715	SDHAP1	-0.8	-9.19	-0.51	1.75e-17	Pancreatic cancer;
KIRP	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.68	-6.83	-0.4	6.44e-11	Vitiligo;
KIRP	trans	rs6601327	0.635	rs7821575	chr8:9665955	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.38	-0.38	8.55e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg01721255	chr8:58191610	C8orf71	0.53	5.46	0.33	1.14e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs981844	0.754	rs897608	chr4:154754960	C/T	cg14289246	chr4:154710475	SFRP2	0.54	6.86	0.4	5.65e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.22	-0.37	2.12e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13095912	0.962	rs7638853	chr3:185350706	G/A	cg11274856	chr3:185301563	NA	0.55	6.97	0.41	2.86e-11	Systolic blood pressure;
KIRP	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg23594656	chr7:65796392	TPST1	0.51	7.89	0.45	9.9e-14	Aortic root size;
KIRP	cis	rs4262150	0.883	rs72799186	chr5:152182121	G/T	cg12297329	chr5:152029980	NA	-0.66	-8.54	-0.48	1.43e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26207909	chr14:103986467	CKB	0.75	11.5	0.59	8.59e-25	Body mass index;
KIRP	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg27205649	chr11:78285834	NARS2	-0.66	-7.67	-0.44	3.96e-13	Alzheimer's disease (survival time);
KIRP	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg23920097	chr1:209922102	NA	-0.49	-5.65	-0.34	4.45e-8	Red blood cell count;
KIRP	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg03709012	chr19:19516395	GATAD2A	0.49	5.69	0.34	3.52e-8	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg07741184	chr6:167504864	NA	0.23	6.08	0.36	4.52e-9	Crohn's disease;
KIRP	trans	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg14791747	chr16:20752902	THUMPD1	0.58	6.35	0.38	1.03e-9	Cognitive test performance;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.72	-11.04	-0.58	2.74e-23	Hepatocellular carcinoma;
KIRP	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.85	-12.96	-0.64	1.26e-29	Eye color traits;
KIRP	cis	rs9921338	0.961	rs4780358	chr16:11374212	G/T	cg00044050	chr16:11439710	C16orf75	-0.48	-4.88	-0.3	1.95e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs1033962	0.865	rs4319409	chr10:25215953	T/C	cg04878152	chr3:148415960	AGTR1	0.4	6.16	0.37	2.93e-9	Post-traumatic stress disorder;
KIRP	trans	rs7246760	0.867	rs7259075	chr19:9778776	G/A	cg02900749	chr2:68251473	NA	-1.16	-9.53	-0.52	1.56e-18	Pursuit maintenance gain;
KIRP	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.66	-0.34	4.26e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs34779708	0.733	rs4391768	chr10:35547595	A/G	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg18944383	chr4:111397179	ENPEP	0.45	7.42	0.43	1.92e-12	Coronary artery disease;
KIRP	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.5	-6.17	-0.37	2.87e-9	Neurofibrillary tangles;
KIRP	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg06042504	chr8:55087323	NA	-0.6	-7.22	-0.42	6.32e-12	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	7.78	0.44	2.01e-13	Crohn's disease;
KIRP	cis	rs2191566	0.960	rs56171514	chr19:44506110	G/C	cg18700516	chr19:44507157	ZNF230	-0.48	-5.73	-0.34	3e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	5.21	0.32	3.91e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7945071	0.507	rs2853001	chr11:110286562	C/A	cg04157658	chr11:110243994	NA	0.36	5.65	0.34	4.42e-8	Cognitive function;
KIRP	trans	rs861318	0.838	rs855866	chr1:159052720	A/G	cg03797305	chr16:30209202	SULT1A3;SULT1A4	0.55	6.05	0.36	5.3e-9	Obesity-related traits;
KIRP	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg18586891	chr4:952366	TMEM175	0.63	5.11	0.31	6.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2916247	1.000	rs7830403	chr8:93008852	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.67	-9.25	-0.51	1.12e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg04132472	chr17:19861366	AKAP10	-0.39	-5.14	-0.31	5.65e-7	Schizophrenia;
KIRP	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	1.04	20.21	0.79	3.54e-54	Breast cancer;
KIRP	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg00857998	chr1:205179979	DSTYK	0.64	7.98	0.45	5.54e-14	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg24881330	chr22:46731750	TRMU	0.65	4.93	0.3	1.48e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg01097406	chr16:89675127	NA	0.31	5.24	0.32	3.39e-7	Hemoglobin concentration;
KIRP	cis	rs6496044	0.507	rs62022863	chr15:86162053	C/G	cg10818794	chr15:86012489	AKAP13	0.42	5.76	0.34	2.54e-8	Interstitial lung disease;
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.55	7.49	0.43	1.2e-12	Glycated hemoglobin levels;
KIRP	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.65	-6.7	-0.39	1.41e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs934734	0.563	rs11684155	chr2:65581300	C/T	cg08085232	chr2:65598271	SPRED2	-0.55	-6.97	-0.41	2.96e-11	Rheumatoid arthritis;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.84	12.46	0.62	5.88e-28	Menarche (age at onset);
KIRP	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.97	13.38	0.65	4.67e-31	Multiple sclerosis;
KIRP	cis	rs1465370	0.682	rs2268382	chr7:130027037	A/C	cg03229158	chr7:130009420	NA	0.34	5.07	0.31	7.93e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg10223061	chr2:219282414	VIL1	0.31	5.12	0.31	6.08e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.98	10.28	0.55	7.21e-21	Alzheimer's disease;
KIRP	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.77	9.06	0.5	4.08e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9931543	0.504	rs4784651	chr16:56311774	A/G	cg02433656	chr16:56322654	GNAO1	-0.42	-4.99	-0.3	1.14e-6	Subjective well-being;
KIRP	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06637938	chr14:75390232	RPS6KL1	-1.05	-18.5	-0.76	1.85e-48	Caffeine consumption;
KIRP	cis	rs12050794	0.671	rs62022788	chr15:72559326	T/G	cg16672083	chr15:72433130	SENP8	0.41	5.72	0.34	3.05e-8	Metabolite levels (HVA/MHPG ratio);
KIRP	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.56	-7.33	-0.42	3.35e-12	Aortic root size;
KIRP	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg23307798	chr14:103986281	CKB	0.73	11.44	0.59	1.4e-24	Body mass index;
KIRP	cis	rs4148660	0.596	rs7132834	chr12:22108595	G/T	cg14669847	chr12:22099120	NA	0.32	5.44	0.33	1.26e-7	Gout;
KIRP	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00938859	chr5:1591904	SDHAP3	0.59	8.0	0.45	5.05e-14	Breast cancer;
KIRP	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-15.97	-0.71	7.05e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg07843065	chr1:150265600	MRPS21	-0.51	-7.36	-0.42	2.76e-12	Migraine;
KIRP	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg15556689	chr8:8085844	FLJ10661	0.6	8.03	0.46	3.97e-14	Retinal vascular caliber;
KIRP	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.48	5.86	0.35	1.51e-8	Glycated hemoglobin levels;
KIRP	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2742234	0.910	rs2505513	chr10:43633537	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.53	-6.58	-0.39	2.75e-10	Hirschsprung disease;
KIRP	cis	rs6088813	0.635	rs2425054	chr20:33894091	A/G	cg14752227	chr20:34000481	UQCC	0.44	4.87	0.3	1.96e-6	Height;
KIRP	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.39	6.69	0.39	1.46e-10	Heart rate;
KIRP	cis	rs6901250	0.788	rs571296	chr6:117092558	A/G	cg12892004	chr6:117198278	RFX6	-0.57	-9.09	-0.5	3.37e-17	C-reactive protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16586093	chr2:203879653	NBEAL1	0.5	6.29	0.37	1.41e-9	Parkinson's disease;
KIRP	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-10.29	-0.55	6.74e-21	Hip circumference;
KIRP	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	8.59	0.48	1e-15	Pulse pressure;
KIRP	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg16989719	chr2:238392110	NA	-0.59	-8.33	-0.47	5.88e-15	Prostate cancer;
KIRP	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs300890	0.513	rs13151561	chr4:144136986	C/T	cg01719995	chr4:144104893	USP38	0.39	5.04	0.31	8.83e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.42	5.46	0.33	1.16e-7	Schizophrenia;
KIRP	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4132509	1.000	rs3766673	chr1:243720473	T/C	cg21452805	chr1:244014465	NA	0.56	5.81	0.35	1.89e-8	RR interval (heart rate);
KIRP	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.74	-0.39	1.11e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10207628	0.823	rs10166461	chr2:127859413	G/A	cg06223080	chr2:127868745	NA	-0.6	-7.93	-0.45	7.63e-14	Psychosis and Alzheimer's disease;
KIRP	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg04935436	chr20:30431758	NA	0.5	6.88	0.4	5.02e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg20701182	chr2:24300061	SF3B14	0.53	5.15	0.31	5.34e-7	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22794795	chr12:113623087	C12orf52;DDX54	0.48	6.4	0.38	7.72e-10	Parkinson's disease;
KIRP	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.11	-0.31	6.54e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.94	0.35	9.72e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.71	-7.85	-0.45	1.25e-13	Body mass index;
KIRP	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.45	-6.45	-0.38	5.91e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.08	-0.46	3.01e-14	Mean corpuscular volume;
KIRP	cis	rs16937956	0.597	rs12788830	chr11:8401976	G/A	cg08015107	chr11:8618950	NA	-0.57	-7.42	-0.43	1.96e-12	Body mass index;
KIRP	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.37	5.34	0.32	2.14e-7	Coronary artery disease;
KIRP	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.82	0.4	7.21e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.74	-9.45	-0.52	2.82e-18	Aortic root size;
KIRP	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg26384229	chr12:38710491	ALG10B	0.66	8.93	0.49	1.01e-16	Morning vs. evening chronotype;
KIRP	cis	rs4713675	0.584	rs7770465	chr6:33674156	G/C	cg15676125	chr6:33679581	C6orf125	0.42	5.48	0.33	1.07e-7	Plateletcrit;
KIRP	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.41	-4.92	-0.3	1.6e-6	Coronary artery disease;
KIRP	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg03060546	chr3:49711283	APEH	0.43	5.65	0.34	4.38e-8	Parkinson's disease;
KIRP	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.81	12.08	0.61	1.12e-26	Height;
KIRP	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.24	0.37	1.95e-9	Aortic root size;
KIRP	cis	rs2729354	0.817	rs2649667	chr11:57270509	A/C	cg24343310	chr11:57249947	NA	0.29	5.6	0.34	5.81e-8	Blood protein levels;
KIRP	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg25019033	chr10:957182	NA	-0.49	-5.23	-0.32	3.64e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.75	-10.87	-0.57	9.82e-23	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.7	11.26	0.58	5.5e-24	Lung cancer;
KIRP	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs1859156	0.767	rs13119758	chr4:95856397	A/G	cg24204951	chr2:239172084	PER2	0.3	6.27	0.37	1.63e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.44	-5.67	-0.34	4.09e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.48	-5.04	-0.31	8.96e-7	Schizophrenia;
KIRP	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.83	-11.19	-0.58	9.01e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02972257	chr16:68554789	NA	-0.65	-6.64	-0.39	2.05e-10	Ulcerative colitis;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.43e-6	Life satisfaction;
KIRP	cis	rs757081	0.667	rs34724588	chr11:17137581	T/C	cg15432903	chr11:17409602	KCNJ11	-0.51	-5.97	-0.36	8.26e-9	Systolic blood pressure;
KIRP	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg23307798	chr14:103986281	CKB	0.72	11.22	0.58	7.27e-24	Body mass index;
KIRP	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg20673091	chr1:2541236	MMEL1	-0.69	-10.69	-0.56	3.81e-22	Multiple sclerosis;
KIRP	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.64e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg13180566	chr4:1052158	NA	-0.5	-5.16	-0.31	4.99e-7	Recombination rate (females);
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg08662619	chr6:150070041	PCMT1	0.39	6.58	0.39	2.87e-10	Lung cancer;
KIRP	cis	rs9535307	0.929	rs1547623	chr13:50348187	G/A	cg04663916	chr13:50265991	EBPL	0.65	6.91	0.4	4.03e-11	Obesity-related traits;
KIRP	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg01879757	chr17:41196368	BRCA1	-0.5	-6.78	-0.4	8.66e-11	Menopause (age at onset);
KIRP	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.54	5.6	0.34	5.64e-8	Menarche (age at onset);
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.64	-9.08	-0.5	3.65e-17	Monocyte percentage of white cells;
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.66	9.43	0.52	3.14e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.91	11.58	0.59	5.03e-25	Vitamin D levels;
KIRP	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.65	9.64	0.52	7.16e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.24	-0.51	1.18e-17	Total body bone mineral density;
KIRP	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.9	16.36	0.72	3.37e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs28489187	0.683	rs2892888	chr1:85866147	A/G	cg16011679	chr1:85725395	C1orf52	-0.5	-6.17	-0.37	2.83e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs151997	1.000	rs152803	chr5:50212120	C/T	cg06027927	chr5:50259733	NA	0.59	7.49	0.43	1.24e-12	Callous-unemotional behaviour;
KIRP	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg04013166	chr16:89971882	TCF25	0.69	8.24	0.47	1.03e-14	Skin colour saturation;
KIRP	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg18132916	chr6:79620363	NA	-0.4	-5.5	-0.33	9.45e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs4657015	1.000	rs4657015	chr1:161272441	A/G	cg18430411	chr8:144873183	SCRIB	-0.69	-9.66	-0.52	6.4e-19	Visceral adipose tissue adjusted for BMI;
KIRP	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24229701	chr12:130821962	PIWIL1	-0.43	-5.43	-0.33	1.37e-7	Menopause (age at onset);
KIRP	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.79e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg15557168	chr22:42548783	NA	0.41	5.59	0.34	6.06e-8	Cognitive function;
KIRP	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg16586182	chr3:47516702	SCAP	-0.52	-6.4	-0.38	7.92e-10	Birth weight;
KIRP	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg23594656	chr7:65796392	TPST1	-0.41	-5.82	-0.35	1.84e-8	Aortic root size;
KIRP	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg16586182	chr3:47516702	SCAP	-0.43	-5.33	-0.32	2.19e-7	Birth weight;
KIRP	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.77	0.4	9.27e-11	Axial length;
KIRP	cis	rs7043114	0.525	rs7026361	chr9:95138564	A/C	cg13798575	chr9:95087839	CENPP;NOL8	0.41	5.04	0.31	8.85e-7	Height;
KIRP	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.96	-15.24	-0.7	2.23e-37	Intelligence (multi-trait analysis);
KIRP	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg08600765	chr20:34638493	LOC647979	-0.69	-6.18	-0.37	2.59e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.28	-0.42	4.6e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2073300	0.793	rs6048814	chr20:23448411	A/C	cg12480562	chr20:23434244	CST11	0.62	6.25	0.37	1.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-7.71	-0.44	3.15e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.56	-0.52	1.25e-18	Lung cancer;
KIRP	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs9479482	0.686	rs9397137	chr6:150382002	G/A	cg25797454	chr6:150327115	RAET1K	0.3	5.33	0.32	2.25e-7	Alopecia areata;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12805764	chr1:153631263	SNAPIN	0.48	6.23	0.37	2.05e-9	Parkinson's disease;
KIRP	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg22117172	chr7:91764530	CYP51A1	0.4	5.51	0.33	9.27e-8	Breast cancer;
KIRP	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.91	14.14	0.67	1.28e-33	Testicular germ cell tumor;
KIRP	cis	rs7116495	1.000	rs671681	chr11:71782812	T/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11488569	chr9:130186546	ZNF79	0.93	6.09	0.36	4.27e-9	P wave terminal force;
KIRP	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg19116668	chr7:99932089	PMS2L1	-0.51	-5.8	-0.35	2.05e-8	Coronary artery disease;
KIRP	cis	rs7737355	0.853	rs6596024	chr5:130769785	A/C	cg06307176	chr5:131281290	NA	0.42	5.0	0.3	1.11e-6	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs656319	0.513	rs3885723	chr8:9991661	A/C	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.74	-0.44	2.54e-13	Myopia (pathological);
KIRP	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.16	-0.31	5.11e-7	Electroencephalogram traits;
KIRP	cis	rs6466055	0.661	rs7805928	chr7:104934662	A/G	cg04380332	chr7:105027541	SRPK2	0.35	4.91	0.3	1.65e-6	Schizophrenia;
KIRP	cis	rs9398803	0.713	rs4621657	chr6:126896227	G/A	cg19875578	chr6:126661172	C6orf173	0.38	4.89	0.3	1.81e-6	Male-pattern baldness;
KIRP	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg03714773	chr7:91764589	CYP51A1	-0.34	-4.87	-0.3	2.01e-6	Breast cancer;
KIRP	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.57	-0.39	3e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.92	-12.53	-0.62	3.42e-28	Platelet distribution width;
KIRP	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.73	10.82	0.57	1.43e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg18478394	chr8:109455254	TTC35	-0.58	-7.27	-0.42	4.78e-12	Dupuytren's disease;
KIRP	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg22681709	chr2:178499509	PDE11A	-0.62	-9.11	-0.5	2.98e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.57	7.53	0.43	9.6e-13	HDL cholesterol;
KIRP	cis	rs10131728	1.000	rs12878477	chr14:81673091	T/C	cg01989461	chr14:81687754	GTF2A1	-0.71	-5.82	-0.35	1.87e-8	IgG glycosylation;
KIRP	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	14.64	0.68	2.53e-35	Alzheimer's disease;
KIRP	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg06115741	chr20:33292138	TP53INP2	0.39	5.25	0.32	3.32e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	7.11	0.41	1.24e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2224391	0.590	rs72813700	chr6:5275531	T/C	cg13962347	chr6:5174647	LYRM4	-0.79	-7.88	-0.45	1.09e-13	Height;
KIRP	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.6	-7.81	-0.45	1.6e-13	Cocaine dependence;
KIRP	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.76	-7.19	-0.42	7.57e-12	Psoriasis vulgaris;
KIRP	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg21695830	chr1:89457462	RBMXL1;CCBL2	0.47	6.33	0.37	1.14e-9	Carotid intima media thickness;
KIRP	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg16077055	chr2:106428750	NCK2	0.31	6.19	0.37	2.53e-9	Addiction;
KIRP	cis	rs1215050	0.660	rs3864229	chr4:98714323	A/G	cg17366294	chr4:99064904	C4orf37	0.41	5.24	0.32	3.49e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg16989719	chr2:238392110	NA	-0.52	-6.88	-0.4	4.8e-11	Prostate cancer;
KIRP	cis	rs2120243	1.000	rs2120243	chr3:157147568	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.49	7.22	0.42	6.59e-12	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03065383	chr2:96011964	KCNIP3	0.58	7.43	0.43	1.74e-12	Parkinson's disease;
KIRP	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg20387954	chr3:183756860	HTR3D	0.45	6.53	0.38	3.65e-10	Anterior chamber depth;
KIRP	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-33.96	-0.91	7.83e-95	Myeloid white cell count;
KIRP	trans	rs11148252	0.535	rs11616459	chr13:53076400	A/T	cg18335740	chr13:41363409	SLC25A15	0.5	7.34	0.42	3.02e-12	Lewy body disease;
KIRP	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.96	-0.57	5.1e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs151997	0.962	rs26088	chr5:50172670	T/G	cg06027927	chr5:50259733	NA	0.61	7.55	0.43	8.57e-13	Callous-unemotional behaviour;
KIRP	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg24565620	chr2:194026	NA	0.71	5.47	0.33	1.12e-7	Blood protein levels;
KIRP	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg14456004	chr13:21872349	NA	-1.09	-13.34	-0.65	6.73e-31	White matter hyperintensity burden;
KIRP	trans	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg19274270	chr17:78178856	CARD14	-0.39	-7.23	-0.42	6.05e-12	Morning vs. evening chronotype;
KIRP	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.02	0.36	6.46e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.57	-5.27	-0.32	2.96e-7	Body mass index;
KIRP	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.65e-30	Eye color traits;
KIRP	cis	rs1440410	0.536	rs10009906	chr4:144131357	G/A	cg01719995	chr4:144104893	USP38	0.39	5.04	0.31	8.83e-7	Ischemic stroke;
KIRP	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg07701084	chr6:150067640	NUP43	0.52	6.41	0.38	7.17e-10	Testicular germ cell tumor;
KIRP	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.63	-8.89	-0.49	1.37e-16	Colorectal cancer;
KIRP	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg04306507	chr14:55594613	LGALS3	0.46	7.02	0.41	2.16e-11	Protein biomarker;
KIRP	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.45	6.1	0.36	4.08e-9	Testicular germ cell tumor;
KIRP	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-0.84	-9.31	-0.51	7.33e-18	Gut microbiome composition (summer);
KIRP	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs28735056	0.584	rs11664834	chr18:77644876	G/T	cg05926928	chr17:57297772	GDPD1	0.61	6.72	0.39	1.27e-10	Schizophrenia;
KIRP	cis	rs12318506	0.536	rs35642656	chr12:76023244	C/G	cg04728562	chr12:75699417	CAPS2	-0.86	-5.65	-0.34	4.34e-8	Coronary artery calcification;
KIRP	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.94	-10.45	-0.55	2.09e-21	Blood protein levels;
KIRP	trans	rs12043259	0.730	rs10458593	chr1:204792384	G/C	cg11485465	chr5:54518469	NA	0.38	6.31	0.37	1.26e-9	Addiction;
KIRP	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.69e-10	Diabetic kidney disease;
KIRP	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg22437258	chr11:111473054	SIK2	0.61	7.13	0.41	1.11e-11	Primary sclerosing cholangitis;
KIRP	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.57	7.32	0.42	3.51e-12	Asthma (sex interaction);
KIRP	cis	rs10465746	0.780	rs11163865	chr1:84366917	C/T	cg10977910	chr1:84465055	TTLL7	0.53	6.68	0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.65	-9.09	-0.5	3.43e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.69	-9.1	-0.5	3.27e-17	Huntington's disease progression;
KIRP	cis	rs1355223	0.573	rs1597961	chr11:34727114	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.13	-0.36	3.42e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg16141378	chr3:129829833	LOC729375	0.53	6.96	0.41	3.12e-11	Retinal vascular caliber;
KIRP	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.82	13.93	0.66	6.55e-33	Longevity;
KIRP	cis	rs10463316	0.608	rs13360453	chr5:150769143	T/C	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.54	-0.38	3.57e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.96	-11.9	-0.6	4.32e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs4658101	0.815	rs10874794	chr1:92045585	C/T	cg09075522	chr1:92031145	NA	0.45	5.16	0.31	5.19e-7	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.85	6.44	0.38	6.14e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.52	-6.17	-0.37	2.76e-9	Prudent dietary pattern;
KIRP	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg02023728	chr11:77925099	USP35	0.36	5.55	0.33	7.38e-8	Alzheimer's disease (survival time);
KIRP	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg17133734	chr15:86042851	AKAP13	-0.41	-4.97	-0.3	1.24e-6	Interstitial lung disease;
KIRP	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg13147721	chr7:65941812	NA	-0.99	-6.75	-0.4	1.08e-10	Diabetic kidney disease;
KIRP	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg12861170	chr19:19639553	YJEFN3	-0.49	-5.09	-0.31	7.27e-7	Bipolar disorder;
KIRP	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.08	-0.31	7.38e-7	Pulmonary function;
KIRP	cis	rs7274811	0.652	rs149236	chr20:32023380	C/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.44	5.33	0.32	2.17e-7	Height;
KIRP	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.57	10.5	0.56	1.52e-21	Bone mineral density;
KIRP	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	9.04	0.5	4.85e-17	Resting heart rate;
KIRP	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg05938607	chr10:60274200	BICC1	-0.46	-11.23	-0.58	6.59e-24	Refractive error;
KIRP	cis	rs3739821	0.789	rs10987787	chr9:130729153	C/G	cg17308606	chr9:130706144	FAM102A	0.35	5.88	0.35	1.3e-8	Glaucoma (primary angle closure);
KIRP	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.86e-15	Prudent dietary pattern;
KIRP	cis	rs2964802	0.505	rs7715280	chr5:10809219	C/T	cg14521931	chr5:10832172	NA	-0.73	-10.97	-0.57	4.55e-23	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.86	10.64	0.56	5.51e-22	Obesity-related traits;
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.89	13.46	0.65	2.64e-31	Longevity;
KIRP	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.55	-7.02	-0.41	2.12e-11	Type 2 diabetes;
KIRP	cis	rs4132509	1.000	rs6429433	chr1:243857994	C/T	cg21452805	chr1:244014465	NA	0.6	5.99	0.36	7.36e-9	RR interval (heart rate);
KIRP	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.63	8.59	0.48	1.02e-15	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.2	0.31	4.22e-7	Leprosy;
KIRP	cis	rs394563	0.591	rs237028	chr6:149718650	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.32	-5.33	-0.32	2.17e-7	Dupuytren's disease;
KIRP	cis	rs6442310	0.534	rs2959272	chr3:12442833	T/G	cg22839075	chr3:12045461	SYN2	0.34	4.94	0.3	1.41e-6	Hematocrit;
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.28	-0.32	2.87e-7	Longevity;Endometriosis;
KIRP	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg25356066	chr3:128598488	ACAD9	0.46	5.33	0.32	2.25e-7	IgG glycosylation;
KIRP	cis	rs4356932	1.000	rs11097212	chr4:76952879	A/G	cg00809888	chr4:76862425	NAAA	0.45	6.3	0.37	1.39e-9	Blood protein levels;
KIRP	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg21096502	chr7:56174374	CHCHD2	-0.65	-6.17	-0.37	2.8e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg16144293	chr14:75469539	EIF2B2	-0.49	-5.6	-0.34	5.66e-8	Height;
KIRP	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg08917208	chr2:24149416	ATAD2B	1.17	10.32	0.55	5.49e-21	Lymphocyte counts;
KIRP	cis	rs75646498	0.571	rs77241922	chr15:29859371	T/A	cg08904058	chr15:29859427	FAM189A1	-0.43	-5.58	-0.34	6.34e-8	Diisocyanate-induced asthma;
KIRP	cis	rs7121756	0.515	rs1510418	chr11:57752099	A/G	cg19752551	chr11:57585705	CTNND1	0.37	5.67	0.34	4e-8	Fractures (vertebral);
KIRP	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.17e-37	Height;
KIRP	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg01879757	chr17:41196368	BRCA1	-0.78	-10.64	-0.56	5.55e-22	Menopause (age at onset);
KIRP	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.56	7.95	0.45	6.81e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.79	11.97	0.61	2.47e-26	Longevity;Endometriosis;
KIRP	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg26554054	chr8:600488	NA	0.74	5.99	0.36	7.39e-9	IgG glycosylation;
KIRP	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg07645718	chr20:61493192	TCFL5	0.76	6.1	0.36	4.02e-9	Obesity-related traits;
KIRP	cis	rs2587695	0.904	rs2579624	chr2:120303820	A/T	cg07176264	chr2:120281999	SCTR	0.32	5.02	0.31	9.75e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg09264619	chr17:80180166	NA	-0.51	-6.14	-0.36	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg18165381	chr3:44552316	NA	-0.4	-5.05	-0.31	8.45e-7	Depressive symptoms;
KIRP	cis	rs1983891	0.738	rs913075	chr6:41568906	G/A	cg20194872	chr6:41519635	FOXP4	0.52	5.57	0.33	6.71e-8	Prostate cancer;
KIRP	cis	rs2964802	0.505	rs6872243	chr5:10818337	C/T	cg14521931	chr5:10832172	NA	-0.74	-11.26	-0.58	5.45e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.57	-0.48	1.13e-15	Common traits (Other);
KIRP	cis	rs9826463	0.582	rs73238159	chr3:142078759	C/T	cg20824294	chr3:142316082	PLS1	0.5	6.95	0.41	3.2e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7916410	0.512	rs1900003	chr10:70004551	A/C	cg06988349	chr10:69991859	ATOH7	0.39	5.12	0.31	6.18e-7	Optic disc area;
KIRP	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.56	-7.18	-0.42	8.46e-12	Prostate cancer;
KIRP	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.48	5.86	0.35	1.44e-8	Diabetic kidney disease;
KIRP	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg22916017	chr11:64110731	CCDC88B	0.55	6.32	0.37	1.24e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs654128	0.640	rs2184343	chr6:117237584	T/G	cg12892004	chr6:117198278	RFX6	-0.41	-5.26	-0.32	3.14e-7	Telomere length;
KIRP	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.31	0.55	5.9e-21	Hip circumference;
KIRP	cis	rs78487399	0.808	rs6705351	chr2:43843137	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.52	-0.33	8.49e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.53	7.91	0.45	8.52e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.42	5.12	0.31	6.2e-7	Common traits (Other);
KIRP	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.72	10.18	0.54	1.49e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6102059	0.572	rs1001878	chr20:39197282	A/G	cg22477343	chr20:39312069	NA	0.44	5.69	0.34	3.54e-8	LDL cholesterol;
KIRP	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg16558253	chr16:72132732	DHX38	0.46	6.72	0.39	1.27e-10	Prostate cancer;
KIRP	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.44	-15.01	-0.69	1.4e-36	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4494114	0.967	rs7532880	chr1:39297734	T/C	cg25970120	chr1:39325951	RRAGC	-0.41	-4.94	-0.3	1.46e-6	Blood protein levels;
KIRP	cis	rs4523957	0.928	rs216202	chr17:2197387	T/C	cg16513277	chr17:2031491	SMG6	0.6	8.31	0.47	6.45e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs714027	0.585	rs41170	chr22:30421066	C/T	cg27665648	chr22:30112403	NA	0.4	5.39	0.32	1.66e-7	Lymphocyte counts;
KIRP	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.73	8.06	0.46	3.26e-14	Corneal astigmatism;
KIRP	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	1.06	11.73	0.6	1.56e-25	Red blood cell traits;
KIRP	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-7.84	-0.45	1.36e-13	Personality dimensions;
KIRP	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg01689657	chr7:91764605	CYP51A1	0.41	5.86	0.35	1.46e-8	Breast cancer;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg20774722	chr17:19551893	ALDH3A2	-0.44	-6.04	-0.36	5.54e-9	Blood metabolite levels;
KIRP	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2764980	1.000	rs2814925	chr10:3284061	A/G	cg11630169	chr10:3283847	NA	-0.46	-6.21	-0.37	2.26e-9	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4523957	0.820	rs2209073	chr17:2205664	G/A	cg16513277	chr17:2031491	SMG6	0.53	7.11	0.41	1.26e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg02569458	chr12:86230093	RASSF9	0.52	7.6	0.44	6.3e-13	Major depressive disorder;
KIRP	cis	rs62413470	1.000	rs17218770	chr6:55942956	C/G	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs7084402	0.967	rs1649048	chr10:60324282	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.77	-0.57	2.01e-22	Refractive error;
KIRP	cis	rs3026101	0.671	rs3944127	chr17:5297766	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.93	0.35	1.02e-8	Body mass index;
KIRP	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.52	-5.78	-0.35	2.22e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	5.2	0.31	4.21e-7	Menopause (age at onset);
KIRP	cis	rs73086581	0.787	rs68127408	chr20:3868447	T/C	cg02187196	chr20:3869020	PANK2	0.58	5.36	0.32	1.94e-7	Response to antidepressants in depression;
KIRP	cis	rs2839627	0.561	rs6586250	chr21:44270229	C/T	cg03543861	chr21:44258195	NA	0.53	6.01	0.36	6.65e-9	Information processing speed;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09517190	chr1:1492513	SSU72	-0.48	-6.52	-0.38	4e-10	Inflammatory biomarkers;
KIRP	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg25838818	chr2:108905173	SULT1C2	-0.43	-6.5	-0.38	4.51e-10	Blood pressure;
KIRP	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.91	10.85	0.57	1.13e-22	Exhaled nitric oxide levels;
KIRP	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg02931644	chr1:25747376	RHCE	-0.35	-6.35	-0.38	1.05e-9	Erythrocyte sedimentation rate;
KIRP	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	1.02	20.69	0.8	8.93e-56	Breast cancer;
KIRP	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg17595323	chr11:93583763	C11orf90	0.3	5.14	0.31	5.63e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg24642844	chr7:1081250	C7orf50	-0.38	-5.23	-0.32	3.63e-7	Longevity;Endometriosis;
KIRP	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg26513180	chr16:89883248	FANCA	0.7	5.5	0.33	9.64e-8	Skin colour saturation;
KIRP	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.68	9.78	0.53	2.67e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg05721485	chr17:44071124	MAPT	0.35	4.85	0.3	2.22e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg21887597	chr15:83419354	NA	-0.49	-6.19	-0.37	2.53e-9	Neuroticism;
KIRP	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.79	7.17	0.42	8.52e-12	Alzheimer's disease;
KIRP	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg25173405	chr17:45401733	C17orf57	0.42	5.39	0.32	1.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg15117754	chr3:10150083	C3orf24	0.52	5.02	0.3	9.87e-7	Alzheimer's disease;
KIRP	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	5.02e-11	Blood metabolite levels;
KIRP	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg11895451	chr1:16533891	ARHGEF19	0.46	6.29	0.37	1.46e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.92	-9.8	-0.53	2.38e-19	Systolic blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23426792	chr5:162946055	MAT2B	-0.39	-6.11	-0.36	3.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg02475777	chr4:1388615	CRIPAK	0.38	4.88	0.3	1.95e-6	Obesity-related traits;
KIRP	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.55	7.09	0.41	1.4e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.92	11.17	0.58	1.08e-23	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.52	6.83	0.4	6.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.57	-7.8	-0.45	1.81e-13	Obesity-related traits;
KIRP	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03934478	chr11:495069	RNH1	-0.75	-6.26	-0.37	1.72e-9	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04993682	chr5:36242273	C5orf33	0.49	6.23	0.37	2e-9	Parkinson's disease;
KIRP	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.91	-14.42	-0.68	1.4e-34	Stearic acid (18:0) levels;
KIRP	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.58	-0.34	6.19e-8	Aortic root size;
KIRP	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg15103426	chr22:29168792	CCDC117	0.53	5.37	0.32	1.83e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg12131826	chr15:77904385	NA	-0.48	-6.33	-0.37	1.15e-9	Type 2 diabetes;
KIRP	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.06	-0.5	4.21e-17	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08445409	chr5:57878919	RAB3C	-0.45	-6.16	-0.37	3.02e-9	Migraine with aura;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19853194	chr18:9913725	VAPA	0.51	6.93	0.4	3.75e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-0.7	-7.55	-0.43	8.41e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.93	16.27	0.72	6.71e-41	Mortality in heart failure;
KIRP	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	5.98	0.36	7.76e-9	Height;
KIRP	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1440410	0.835	rs7670624	chr4:144050245	T/C	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs6585424	1.000	rs11201966	chr10:81931780	T/C	cg27417294	chr10:81904244	PLAC9	0.55	5.41	0.33	1.5e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.79	7.23	0.42	6.16e-12	Mean platelet volume;
KIRP	cis	rs1832871	0.672	rs62437399	chr6:158784251	C/A	cg07215822	chr6:158701037	NA	-0.63	-7.27	-0.42	4.86e-12	Height;
KIRP	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg18350739	chr11:68623251	NA	-0.48	-7.47	-0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27280296	chr14:90422339	TDP1;C14orf143	0.45	6.08	0.36	4.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg01689657	chr7:91764605	CYP51A1	0.42	6.19	0.37	2.46e-9	Breast cancer;
KIRP	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.54	-5.37	-0.32	1.79e-7	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.83	13.38	0.65	4.83e-31	Metabolic syndrome;
KIRP	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs4356932	0.935	rs115828298	chr4:76967941	G/T	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.94	-0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10875746	0.903	rs17122666	chr12:48502574	C/T	cg26205652	chr12:48591994	NA	0.78	10.49	0.56	1.58e-21	Longevity (90 years and older);
KIRP	cis	rs1978968	1.000	rs2099943	chr22:18438559	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.62	-7.95	-0.45	6.62e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.1	-0.36	4.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg00262122	chr8:11665843	FDFT1	-0.41	-5.2	-0.31	4.13e-7	Morning vs. evening chronotype;
KIRP	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00677455	chr12:58241039	CTDSP2	-0.97	-12.36	-0.62	1.26e-27	Multiple sclerosis;
KIRP	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	9.0	0.5	6.27e-17	Cognitive test performance;
KIRP	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-10.19	-0.54	1.4e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg05022688	chr3:170137633	CLDN11	-0.41	-5.03	-0.31	9.58e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs4845875	0.563	rs10864540	chr1:11838099	A/G	cg24844545	chr1:11908347	NPPA	0.37	4.92	0.3	1.55e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs981946	0.544	rs10498660	chr6:3343544	C/T	cg18842474	chr6:3356384	SLC22A23	0.39	5.17	0.31	4.94e-7	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
KIRP	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.83	-12.26	-0.62	2.82e-27	Dental caries;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06995966	chr5:137204467	MYOT	0.4	6.48	0.38	5.09e-10	C-reactive protein;
KIRP	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.61	11.38	0.59	2.22e-24	Bone mineral density;
KIRP	cis	rs9815354	0.680	rs73073285	chr3:42027566	T/G	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.55	-5.8	-0.35	2e-8	Smoking behavior;
KIRP	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.46	-5.99	-0.36	7.38e-9	Body mass index;
KIRP	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-15.75	-0.71	3.95e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9928842	0.823	rs6564243	chr16:75296001	A/C	cg09066997	chr16:75300724	BCAR1	0.55	4.88	0.3	1.88e-6	Alcoholic chronic pancreatitis;
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg12486944	chr17:80159399	CCDC57	0.4	5.45	0.33	1.19e-7	Life satisfaction;
KIRP	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.68	-9.04	-0.5	4.95e-17	Longevity;
KIRP	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg02487422	chr3:49467188	NICN1	0.39	5.35	0.32	2.03e-7	Parkinson's disease;
KIRP	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.75	0.81	3.16e-59	Prudent dietary pattern;
KIRP	cis	rs1978968	1.000	rs28434757	chr22:18451554	G/A	cg02610425	chr22:18483192	MICAL3	0.37	5.08	0.31	7.3e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.27	17.42	0.74	8.12e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg03808351	chr9:123631620	PHF19	0.36	5.01	0.3	1.02e-6	Rheumatoid arthritis;
KIRP	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.83	12.52	0.62	3.78e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.47	7.16	0.42	9.35e-12	Lymphocyte counts;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03811519	chr9:134001305	NUP214	0.85	7.57	0.43	7.46e-13	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.72	-6.91	-0.4	4.08e-11	Menarche (age at onset);
KIRP	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.47	5.92	0.35	1.1e-8	Initial pursuit acceleration;
KIRP	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.83	8.9	0.49	1.22e-16	Alzheimer's disease;
KIRP	cis	rs931127	0.658	rs4930305	chr11:65464000	A/G	cg11569703	chr11:65557185	OVOL1	-0.41	-6.96	-0.41	3.05e-11	Systemic lupus erythematosus;
KIRP	cis	rs7224685	0.569	rs8067427	chr17:3997517	C/T	cg09597638	chr17:3907349	NA	0.52	5.21	0.32	3.99e-7	Type 2 diabetes;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02561205	chr11:65479380	KAT5	-0.46	-6.1	-0.36	4.04e-9	Myopia;
KIRP	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.07	0.36	4.88e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.76	11.34	0.59	3.06e-24	Blood metabolite ratios;
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.75	7.75	0.44	2.43e-13	Lung function (FEV1/FVC);
KIRP	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.24	0.55	1.01e-20	Cognitive test performance;
KIRP	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	0.84	11.02	0.57	3.25e-23	Primary sclerosing cholangitis;
KIRP	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg04132472	chr17:19861366	AKAP10	-0.4	-5.16	-0.31	4.99e-7	Schizophrenia;
KIRP	cis	rs4789452	1.000	rs35825162	chr17:75373188	G/A	cg02320862	chr17:75370284	SEPT9	-0.37	-5.09	-0.31	6.99e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg06217071	chr17:408420	NA	-0.73	-11.48	-0.59	1.06e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg11031976	chr2:198649780	BOLL	-0.54	-5.2	-0.31	4.14e-7	Ulcerative colitis;
KIRP	cis	rs236907	0.859	rs6656852	chr1:171752373	A/G	cg01410279	chr1:171621941	MYOC	-0.48	-5.37	-0.32	1.81e-7	Mean platelet volume;
KIRP	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg02367723	chr1:46378857	MAST2	0.44	5.08	0.31	7.46e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.55	6.57	0.39	2.99e-10	Metabolite levels;
KIRP	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg10547527	chr2:198650123	BOLL	-0.57	-5.21	-0.32	3.93e-7	Ulcerative colitis;
KIRP	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg24315340	chr6:146058215	EPM2A	0.43	5.45	0.33	1.21e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg02524346	chr8:600233	NA	0.8	5.82	0.35	1.78e-8	IgG glycosylation;
KIRP	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.1e-11	Obesity-related traits;
KIRP	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.86	0.4	5.6e-11	Bipolar disorder;
KIRP	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg26373071	chr5:1325741	CLPTM1L	0.55	7.42	0.43	1.85e-12	Lung cancer;
KIRP	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg16434002	chr17:42200994	HDAC5	-0.54	-6.93	-0.4	3.73e-11	Total body bone mineral density;
KIRP	cis	rs1823913	0.637	rs12624271	chr2:192153312	A/G	cg12404831	chr2:192114017	MYO1B	-0.45	-6.16	-0.37	2.88e-9	Obesity-related traits;
KIRP	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg08773314	chr2:239334832	ASB1	-0.55	-5.47	-0.33	1.08e-7	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06560300	chr5:1278791	TERT	0.41	6.09	0.36	4.31e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg04733989	chr22:42467013	NAGA	0.45	5.21	0.32	4.02e-7	Cognitive function;
KIRP	trans	rs13132184	0.507	rs67733859	chr4:38042347	G/A	cg26279261	chr19:17346089	NR2F6	-0.59	-6.04	-0.36	5.6e-9	Verbal declarative memory;
KIRP	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg12091567	chr17:66097778	LOC651250	0.79	9.61	0.52	8.97e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.93	15.32	0.7	1.22e-37	Bone mineral density;
KIRP	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.79	-9.74	-0.53	3.51e-19	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2380220	0.720	rs9400397	chr6:95980623	C/A	cg15832292	chr6:96025679	MANEA	0.65	6.24	0.37	1.85e-9	Behavioural disinhibition (generation interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20951949	chr17:34898162	NA	0.47	6.23	0.37	1.98e-9	Interleukin-4 levels;
KIRP	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.7	-8.06	-0.46	3.35e-14	Menarche (age at onset);
KIRP	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	8.54	0.48	1.42e-15	Renal function-related traits (BUN);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03787326	chr3:48130820	MAP4	0.49	6.93	0.4	3.65e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg08209163	chr13:28024472	MTIF3	-0.89	-6.28	-0.37	1.56e-9	P wave terminal force;
KIRP	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.45	-0.43	1.55e-12	Menopause (age at onset);
KIRP	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg24315340	chr6:146058215	EPM2A	-0.38	-4.89	-0.3	1.86e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.31e-9	Schizophrenia;
KIRP	cis	rs10858047	0.883	rs761755	chr1:115222434	G/A	cg12756093	chr1:115239321	AMPD1	-0.68	-6.46	-0.38	5.7e-10	Autism;
KIRP	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.93	-0.3	1.51e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs12220238	0.915	rs7073139	chr10:76071189	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.65	0.39	1.92e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1011018	0.955	rs66985026	chr7:139457829	G/A	cg03224163	chr7:139420300	HIPK2	-0.47	-5.04	-0.31	8.97e-7	Systolic blood pressure;
KIRP	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg05669848	chr5:237993	SDHA	-0.49	-5.13	-0.31	5.79e-7	Breast cancer;
KIRP	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.6	-8.4	-0.47	3.56e-15	Diastolic blood pressure;
KIRP	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg24579218	chr15:68104479	NA	-0.6	-9.93	-0.54	9e-20	Restless legs syndrome;
KIRP	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	10.71	0.56	3.23e-22	Coronary artery disease;
KIRP	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.02	0.3	1.02e-6	Retinal vascular caliber;
KIRP	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.18	-0.37	2.64e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.64	-5.96	-0.36	8.57e-9	Narcolepsy;
KIRP	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.3	0.47	6.97e-15	Neutrophil percentage of white cells;
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00448482	chr18:13726497	C18orf19;RNMT	0.39	5.16	0.31	5.03e-7	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.18	-0.61	5.18e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg15655495	chr12:38532458	NA	-0.28	-5.05	-0.31	8.72e-7	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.69	9.81	0.53	2.26e-19	Retinal vascular caliber;
KIRP	cis	rs17023223	0.537	rs12086549	chr1:119614337	A/T	cg18261050	chr1:119551319	NA	-0.57	-7.61	-0.44	5.68e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg04013166	chr16:89971882	TCF25	0.71	7.62	0.44	5.62e-13	Skin colour saturation;
KIRP	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.97	-0.36	8.05e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg04733989	chr22:42467013	NAGA	0.52	6.22	0.37	2.16e-9	Cognitive function;
KIRP	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg02275930	chr1:2372054	NA	-0.59	-8.34	-0.47	5.45e-15	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03228602	chr6:7888995	TXNDC5	0.45	6.33	0.37	1.16e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.15	-0.36	3.16e-9	Obesity-related traits;
KIRP	cis	rs11025523	0.904	rs10833311	chr11:20379638	C/T	cg19653624	chr11:20408972	PRMT3	-0.52	-5.57	-0.33	6.83e-8	Obesity-related traits;
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.61	8.94	0.5	9.34e-17	Lung cancer;
KIRP	cis	rs8067287	0.595	rs62065423	chr17:16828571	C/T	cg26910001	chr17:16838321	NA	-0.61	-5.98	-0.36	7.62e-9	Diabetic kidney disease;
KIRP	cis	rs2278796	0.558	rs35288741	chr1:204928155	A/G	cg17947172	chr1:204966197	NFASC	0.43	5.62	0.34	5.24e-8	Mean platelet volume;
KIRP	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.57	-7.87	-0.45	1.1e-13	Social autistic-like traits;
KIRP	cis	rs4006360	0.524	rs7219230	chr17:39286180	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.44	-6.44	-0.38	6.31e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.18	0.51	1.78e-17	Bladder cancer;
KIRP	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg21479132	chr6:26055353	NA	0.76	5.06	0.31	8.17e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.55	-6.61	-0.39	2.33e-10	Mosquito bite size;
KIRP	cis	rs735860	0.726	rs209517	chr6:53206989	A/T	cg10236188	chr6:53219634	NA	0.4	5.45	0.33	1.2e-7	Glaucoma;
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg25347419	chr2:177043501	NA	0.43	5.87	0.35	1.4e-8	IgG glycosylation;
KIRP	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-6.97	-0.41	2.82e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs1215050	0.682	rs6839343	chr4:98839732	G/A	cg17366294	chr4:99064904	C4orf37	0.42	5.33	0.32	2.24e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9649213	0.593	rs34534766	chr7:97920871	G/C	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg02297831	chr4:17616191	MED28	0.55	6.9	0.4	4.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg17366294	chr4:99064904	C4orf37	0.42	6.1	0.36	4.17e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg01879757	chr17:41196368	BRCA1	-0.77	-10.54	-0.56	1.12e-21	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6594499	0.872	rs10051830	chr5:110452845	G/A	cg04022379	chr5:110408740	TSLP	0.47	7.14	0.41	1.05e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-6.28	-0.37	1.49e-9	Total body bone mineral density;
KIRP	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg03060546	chr3:49711283	APEH	-0.66	-6.19	-0.37	2.5e-9	Cognitive function;
KIRP	cis	rs909341	0.818	rs2750483	chr20:62345470	A/G	cg11503966	chr20:62272292	STMN3	-0.43	-6.1	-0.36	4.03e-9	Atopic dermatitis;
KIRP	cis	rs698833	0.926	rs698835	chr2:44737089	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.87	0.3	1.97e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs9400467	0.508	rs11153294	chr6:111730246	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.71	-0.34	3.22e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg02896835	chr1:92012615	NA	0.43	5.7	0.34	3.39e-8	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16605745	chr12:48099745	RPAP3	0.46	6.6	0.39	2.49e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs732716	0.740	rs78869060	chr19:4444742	A/G	cg03719555	chr19:4455413	UBXN6	0.49	7.47	0.43	1.37e-12	Mean corpuscular volume;
KIRP	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.39	0.43	2.34e-12	Retinal vascular caliber;
KIRP	cis	rs7209700	0.894	rs7212751	chr17:45355499	A/G	cg08085267	chr17:45401833	C17orf57	0.44	5.49	0.33	9.97e-8	IgG glycosylation;
KIRP	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.74	-9.3	-0.51	7.85e-18	Aortic root size;
KIRP	cis	rs4776059	1.000	rs12914502	chr15:52911335	A/G	cg25063058	chr15:52860530	ARPP19	0.59	6.45	0.38	5.96e-10	Schizophrenia;
KIRP	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg03627880	chr6:151815985	C6orf97	-0.43	-5.01	-0.3	1.03e-6	Menarche (age at onset);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01805784	chr5:176873808	PRR7	0.47	6.94	0.4	3.47e-11	Myopia (pathological);
KIRP	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs876084	0.722	rs1401813	chr8:121042513	A/G	cg22335954	chr8:121166405	COL14A1	0.4	4.95	0.3	1.36e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.09	0.46	2.65e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg10207240	chr12:122356781	WDR66	0.48	6.52	0.38	3.97e-10	Mean corpuscular volume;
KIRP	trans	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg18187862	chr3:45730750	SACM1L	0.54	6.15	0.37	3.15e-9	Primary sclerosing cholangitis;
KIRP	cis	rs883565	0.569	rs1274971	chr3:39161464	G/A	cg01426195	chr3:39028469	NA	-0.52	-8.32	-0.47	5.98e-15	Handedness;
KIRP	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg01689657	chr7:91764605	CYP51A1	0.39	5.32	0.32	2.3e-7	Breast cancer;
KIRP	cis	rs5753618	0.583	rs5753628	chr22:31860322	A/G	cg02404636	chr22:31891804	SFI1	0.53	6.02	0.36	6.28e-9	Colorectal cancer;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg14221460	chr8:27183342	PTK2B	0.52	6.72	0.39	1.25e-10	Neuroticism;
KIRP	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg21186296	chr8:27182909	PTK2B	0.45	5.64	0.34	4.76e-8	Neuroticism;
KIRP	cis	rs2929278	0.617	rs694461	chr15:44096063	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.5	-6.14	-0.36	3.36e-9	Schizophrenia;
KIRP	cis	rs3779635	0.713	rs4733063	chr8:27302885	A/G	cg18234130	chr8:27182889	PTK2B	0.41	5.23	0.32	3.61e-7	Neuroticism;
KIRP	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg07382826	chr16:28625726	SULT1A1	0.48	5.6	0.34	5.6e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-6.92	-0.4	3.97e-11	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.71	-9.18	-0.5	1.87e-17	Coronary artery disease;
KIRP	cis	rs2790457	0.795	rs7903703	chr10:28935149	T/C	cg04045419	chr10:28823091	WAC	-0.46	-5.21	-0.32	3.9e-7	Multiple myeloma;
KIRP	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.81	-11.75	-0.6	1.36e-25	Systemic lupus erythematosus;
KIRP	cis	rs9640161	0.658	rs57888387	chr7:150004244	G/A	cg17279839	chr7:150038598	RARRES2	0.5	6.18	0.37	2.58e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2916247	1.000	rs2920470	chr8:92977484	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.53	-6.95	-0.41	3.2e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-7.75	-0.44	2.47e-13	Parkinson's disease;
KIRP	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.5	-6.47	-0.38	5.19e-10	Corneal astigmatism;
KIRP	cis	rs8523	0.901	rs1570069	chr6:11017825	A/G	cg13562911	chr6:11044106	ELOVL2	0.38	4.92	0.3	1.55e-6	Red blood cell fatty acid levels;
KIRP	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.9	13.54	0.65	1.37e-31	Monocyte count;
KIRP	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15441656	chr8:8560934	CLDN23	0.47	6.43	0.38	6.7e-10	Survival in pancreatic cancer;
KIRP	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg09455208	chr3:40491958	NA	0.29	4.89	0.3	1.81e-6	Renal cell carcinoma;
KIRP	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.67	-0.48	5.76e-16	Joint mobility (Beighton score);
KIRP	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.61	-0.44	5.73e-13	Response to antipsychotic treatment;
KIRP	cis	rs4908768	0.657	rs1353130	chr1:8822364	T/C	cg25722041	chr1:8623473	RERE	0.53	6.9	0.4	4.43e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	9.81	0.53	2.22e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg07621104	chr11:117668040	DSCAML1	0.42	6.2	0.37	2.34e-9	Myopia;
KIRP	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.67	-7.96	-0.45	6.27e-14	Menarche (age at onset);
KIRP	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs509477	1.000	rs11660848	chr18:32574010	T/C	cg23791764	chr18:32556832	MAPRE2	-0.54	-6.55	-0.39	3.31e-10	Cerebrospinal fluid AB1-42 levels;
KIRP	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-6.61	-0.39	2.39e-10	Fear of minor pain;
KIRP	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg11901034	chr3:128598214	ACAD9	-0.44	-5.54	-0.33	7.66e-8	IgG glycosylation;
KIRP	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24549020	chr5:56110836	MAP3K1	0.5	5.13	0.31	5.95e-7	Initial pursuit acceleration;
KIRP	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-6.76	-0.4	9.74e-11	Aortic root size;
KIRP	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.71	8.67	0.48	5.76e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.78	12.0	0.61	1.94e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg26681399	chr22:41777847	TEF	-0.49	-5.3	-0.32	2.58e-7	Vitiligo;
KIRP	trans	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg01620082	chr3:125678407	NA	-0.88	-6.13	-0.36	3.54e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.28	17.22	0.74	3.74e-44	Corneal structure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25892041	chr4:115544155	UGT8	-0.41	-6.48	-0.38	5e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.5	6.57	0.39	3.02e-10	Height;
KIRP	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.3	-0.37	1.37e-9	Monocyte count;
KIRP	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.51	-6.2	-0.37	2.37e-9	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.13.1455853R	chr13:96602186	UGGT2	0.48	6.47	0.38	5.14e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.71	8.29	0.47	7.38e-15	Corneal astigmatism;
KIRP	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.78	10.29	0.55	7.13e-21	Platelet count;
KIRP	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.47	-6.52	-0.38	3.92e-10	Coronary artery disease;
KIRP	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.5	-6.13	-0.36	3.54e-9	Type 2 diabetes;
KIRP	cis	rs4356932	1.000	rs4859600	chr4:76959967	C/G	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.74	-11.23	-0.58	6.92e-24	Oral cavity cancer;
KIRP	cis	rs7818345	0.967	rs7004435	chr8:19282732	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.43	6.26	0.37	1.68e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.59	7.29	0.42	4.22e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs787274	0.850	rs10759604	chr9:115639748	G/A	cg13803584	chr9:115635662	SNX30	-0.75	-7.96	-0.45	6.36e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs61990749	0.597	rs59848135	chr14:78129000	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.77	-6.89	-0.4	4.56e-11	Fibroblast growth factor basic levels;
KIRP	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.69	-5.08	-0.31	7.37e-7	Cognitive function;
KIRP	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.69	-9.73	-0.53	3.8e-19	Obesity-related traits;
KIRP	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.13	-0.46	2.12e-14	Migraine;Coronary artery disease;
KIRP	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.94	-0.5	9.56e-17	Extrinsic epigenetic age acceleration;
KIRP	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.55	-0.56	1.08e-21	Neuroticism;
KIRP	cis	rs698813	0.851	rs786413	chr2:44702758	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.65	0.34	4.33e-8	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg23985595	chr17:80112537	CCDC57	0.38	5.7	0.34	3.47e-8	Life satisfaction;
KIRP	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg12927641	chr6:109611667	NA	-0.38	-4.86	-0.3	2.11e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.84	13.87	0.66	1.01e-32	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg10756647	chr7:56101905	PSPH	0.92	6.5	0.38	4.32e-10	Diabetic kidney disease;
KIRP	cis	rs7681423	1.000	rs12644950	chr4:155537321	G/A	cg20735720	chr4:155535218	FGG	-0.66	-8.61	-0.48	9.11e-16	Fibrinogen;
KIRP	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg07157834	chr1:205819609	PM20D1	0.5	5.33	0.32	2.17e-7	Basophil percentage of granulocytes;
KIRP	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg06647332	chr5:131281008	NA	0.46	4.98	0.3	1.18e-6	Life satisfaction;
KIRP	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.76	9.48	0.52	2.28e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.21	-0.32	4.05e-7	Schizophrenia;
KIRP	cis	rs55882075	0.634	rs12518476	chr5:179110850	A/G	cg14593053	chr5:179126677	CANX	0.59	7.27	0.42	4.82e-12	Monocyte percentage of white cells;
KIRP	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.62	8.28	0.47	8.01e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25637520	chr19:5043247	KDM4B	0.44	6.08	0.36	4.62e-9	Survival in pancreatic cancer;
KIRP	cis	rs911119	0.913	rs6048922	chr20:23578116	G/C	cg16589663	chr20:23618590	CST3	0.49	4.95	0.3	1.4e-6	Chronic kidney disease;
KIRP	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-1.04	-19.28	-0.78	4.36e-51	Height;
KIRP	cis	rs6834538	0.577	rs10034556	chr4:113449650	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	5.27	0.32	3e-7	Free thyroxine concentration;
KIRP	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg24631222	chr15:78858424	CHRNA5	0.76	8.88	0.49	1.46e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg04369109	chr6:150039330	LATS1	-0.52	-6.59	-0.39	2.63e-10	Lung cancer;
KIRP	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.59	10.85	0.57	1.14e-22	Bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06291112	chr10:75757817	VCL	0.5	6.2	0.37	2.35e-9	Parkinson's disease;
KIRP	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg05692746	chr2:100937584	LONRF2	-0.41	-5.3	-0.32	2.56e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7404928	0.526	rs11645239	chr16:23847062	C/G	cg21745164	chr16:23765304	CHP2	-0.62	-7.6	-0.44	6.24e-13	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.77	11.39	0.59	1.96e-24	Obesity-related traits;
KIRP	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.98	-0.45	5.55e-14	Coffee consumption (cups per day);
KIRP	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.43	-5.99	-0.36	7.3e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-8.7	-0.48	4.94e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.4	-7.83	-0.45	1.43e-13	Educational attainment (years of education);
KIRP	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.29	-0.32	2.66e-7	Tonsillectomy;
KIRP	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.8	-0.35	2.01e-8	Morning vs. evening chronotype;
KIRP	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.46	-0.33	1.14e-7	Pulmonary function;
KIRP	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.7	-7.88	-0.45	1.06e-13	Adiposity;
KIRP	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.63	7.82	0.45	1.5700000000000001e-13	Multiple sclerosis;
KIRP	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg11945507	chr8:142233382	SLC45A4	-0.66	-9.3	-0.51	7.92e-18	Immature fraction of reticulocytes;
KIRP	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg18190219	chr22:46762943	CELSR1	-0.93	-7.35	-0.42	2.88e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg06740227	chr12:86229804	RASSF9	0.52	6.6	0.39	2.48e-10	Major depressive disorder;
KIRP	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg01097406	chr16:89675127	NA	0.31	5.22	0.32	3.83e-7	Hemoglobin concentration;
KIRP	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs10463554	1.000	rs3776864	chr5:102327868	A/C	cg23492399	chr5:102201601	PAM	-0.43	-4.9	-0.3	1.73e-6	Parkinson's disease;
KIRP	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.0	-0.36	6.97e-9	Diastolic blood pressure;
KIRP	cis	rs965513	1.000	rs1588635	chr9:100537802	A/C	cg13688889	chr9:100608707	NA	-0.58	-7.09	-0.41	1.38e-11	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs9443189	0.950	rs6938349	chr6:76484280	A/T	cg01950844	chr6:76311363	SENP6	0.51	5.11	0.31	6.55e-7	Prostate cancer;
KIRP	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.73	-0.39	1.19e-10	Obesity-related traits;
KIRP	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.9	-0.6	4.45e-26	Eye color traits;
KIRP	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.77	0.4	9.53e-11	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.82	0.66	1.54e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2133450	0.508	rs9825942	chr3:7350426	C/G	cg19930620	chr3:7340148	GRM7	-0.4	-5.6	-0.34	5.82e-8	Early response to risperidone in schizophrenia;
KIRP	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.75	9.04	0.5	4.72e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-6.54	-0.38	3.51e-10	Blood metabolite levels;
KIRP	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg23102388	chr7:1867652	MAD1L1	-0.43	-5.89	-0.35	1.29e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	1.11	7.59	0.44	6.82e-13	Skin colour saturation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27430053	chr16:686402	C16orf13	0.48	6.21	0.37	2.23e-9	Parkinson's disease;
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg21186296	chr8:27182909	PTK2B	0.51	6.41	0.38	7.26e-10	Neuroticism;
KIRP	cis	rs2242116	0.900	rs1001284	chr3:46933960	C/G	cg23352942	chr3:46931381	PTH1R	-0.51	-6.92	-0.4	3.93e-11	Birth weight;
KIRP	cis	rs3748682	0.821	rs12030690	chr1:38258007	G/C	cg12658694	chr1:38397304	INPP5B	0.54	5.88	0.35	1.35e-8	Hypothyroidism;
KIRP	cis	rs9815354	0.857	rs9816772	chr3:41872877	C/T	cg03022575	chr3:42003672	ULK4	0.59	6.73	0.39	1.21e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.44	5.64	0.34	4.65e-8	Crohn's disease;
KIRP	cis	rs600806	0.778	rs11101961	chr1:110008813	T/C	cg02175308	chr1:109941060	SORT1	-0.26	-4.88	-0.3	1.87e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6102059	0.642	rs55963293	chr20:39204277	T/C	cg06665391	chr20:39312290	NA	0.41	5.15	0.31	5.31e-7	LDL cholesterol;
KIRP	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.5	12.99	0.64	1e-29	Cutaneous nevi;
KIRP	cis	rs1635	0.655	rs2281041	chr6:28303845	G/C	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20535931	chr7:97615658	OCM2	0.42	6.04	0.36	5.59e-9	Survival in pancreatic cancer;
KIRP	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.45	-0.33	1.2e-7	Testicular germ cell tumor;
KIRP	cis	rs35883536	0.967	rs2783689	chr1:101092411	C/G	cg06223162	chr1:101003688	GPR88	-0.33	-6.85	-0.4	5.88e-11	Monocyte count;
KIRP	cis	rs7560272	0.538	rs13000788	chr2:73918312	C/T	cg20560298	chr2:73613845	ALMS1	0.48	5.77	0.35	2.39e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13579957	chr2:62132778	COMMD1	0.46	6.06	0.36	5.09e-9	Parkinson's disease;
KIRP	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg03342759	chr3:160939853	NMD3	-0.56	-6.33	-0.37	1.17e-9	Parkinson's disease;
KIRP	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.76	8.92	0.49	1.11e-16	Adiposity;
KIRP	cis	rs71636778	0.543	rs17162333	chr1:27236757	C/G	cg12203394	chr1:27248618	NUDC	0.62	5.31	0.32	2.48e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.44	-5.66	-0.34	4.18e-8	QT interval;
KIRP	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.25	6.75	0.4	1.07e-10	Crohn's disease;
KIRP	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.02	-0.3	1.01e-6	Fear of minor pain;
KIRP	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg11945507	chr8:142233382	SLC45A4	0.49	6.46	0.38	5.71e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.46	0.38	5.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.08	-0.36	4.67e-9	Type 2 diabetes;
KIRP	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.02	0.67	3.31e-33	Platelet count;
KIRP	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.93	-0.45	7.63e-14	Tonsillectomy;
KIRP	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.56	-7.51	-0.43	1.1e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs960902	0.648	rs11124585	chr2:37711892	G/A	cg25341268	chr2:37734390	NA	0.6	7.78	0.44	1.99e-13	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg07701084	chr6:150067640	NUP43	0.61	7.95	0.45	6.88e-14	Lung cancer;
KIRP	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.52	6.71	0.39	1.3e-10	Crohn's disease;
KIRP	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	11.12	0.58	1.53e-23	Total body bone mineral density;
KIRP	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	1.0	13.24	0.65	1.42e-30	Homoarginine levels;
KIRP	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.66	-9.29	-0.51	8.3e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.75	-8.12	-0.46	2.31e-14	Gut microbiome composition (summer);
KIRP	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.2	13.58	0.65	9.88e-32	Uric acid levels;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg11641102	chr8:27183873	PTK2B	0.45	5.77	0.35	2.4e-8	Neuroticism;
KIRP	cis	rs7224685	0.689	rs4508454	chr17:4198650	C/T	cg05562828	chr17:3906858	NA	-0.42	-5.07	-0.31	8.01e-7	Type 2 diabetes;
KIRP	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg00129232	chr17:37814104	STARD3	-0.54	-6.76	-0.4	9.86e-11	Self-reported allergy;
KIRP	trans	rs643955	0.637	rs4841271	chr8:9870137	T/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.77	-0.44	2.15e-13	Systemic lupus erythematosus;
KIRP	cis	rs12476592	0.602	rs262525	chr2:63893158	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.98	-0.3	1.2e-6	Childhood ear infection;
KIRP	cis	rs4950322	0.570	rs1999820	chr1:146741989	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23521916	chr3:48754752	IP6K2	0.47	6.48	0.38	5.05e-10	Survival in pancreatic cancer;
KIRP	cis	rs71520386	0.530	rs10256628	chr7:22883259	G/C	cg15401507	chr7:22894281	NA	0.42	5.3	0.32	2.63e-7	Fibrinogen levels;
KIRP	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.79	-0.35	2.18e-8	Height;
KIRP	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg08126542	chr6:37504118	NA	-0.83	-13.22	-0.64	1.7e-30	Cognitive performance;
KIRP	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.44	0.33	1.3e-7	Menopause (age at onset);
KIRP	cis	rs2151522	0.762	rs9401914	chr6:127160264	G/T	cg21431617	chr6:127135037	NA	0.29	5.16	0.31	4.99e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	6.42	0.38	6.88e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg07212818	chr11:638076	DRD4	-0.39	-4.89	-0.3	1.8e-6	Systemic lupus erythematosus;
KIRP	trans	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.34e-9	Bladder cancer;
KIRP	cis	rs259842	0.759	rs7557122	chr2:180683326	A/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.42	-0.33	1.45e-7	Blood protein levels;
KIRP	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg18477163	chr1:228402036	OBSCN	-0.29	-5.56	-0.33	6.87e-8	Parkinson's disease;
KIRP	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg09184832	chr6:79620586	NA	-0.4	-5.19	-0.31	4.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg00074818	chr8:8560427	CLDN23	0.42	6.42	0.38	7.04e-10	Obesity-related traits;
KIRP	cis	rs6732160	0.588	rs1430344	chr2:73373344	G/A	cg01422370	chr2:73384389	NA	0.51	6.92	0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-6.91	-0.4	4.13e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs35883536	0.565	rs2647322	chr1:101031962	G/T	cg09408571	chr1:101003634	GPR88	0.24	5.53	0.33	8.18e-8	Monocyte count;
KIRP	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg19875535	chr5:140030758	IK	0.64	8.75	0.49	3.4e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7688540	0.771	rs61795001	chr4:242057	C/T	cg17891759	chr4:299121	NA	-0.51	-5.27	-0.32	2.93e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07294234	chr8:42911341	FNTA	0.47	6.36	0.38	9.59e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.51e-15	Mortality in heart failure;
KIRP	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05025164	chr4:1340916	KIAA1530	-0.51	-6.61	-0.39	2.38e-10	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.37	0.65	5.08e-31	Personality dimensions;
KIRP	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.74	6.71	0.39	1.35e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06620762	chr15:76136437	UBE2Q2	0.51	6.88	0.4	4.87e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.98	11.0	0.57	3.64e-23	Eosinophil percentage of granulocytes;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16905586	chr3:49761211	GMPPB	0.47	6.2	0.37	2.32e-9	Myopia (pathological);
KIRP	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.99	16.13	0.72	2.02e-40	Uric acid clearance;
KIRP	cis	rs10046574	0.519	rs34274894	chr7:135214725	G/C	cg27474649	chr7:135195673	CNOT4	0.55	5.01	0.3	1.02e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.9	14.09	0.67	1.86e-33	Height;
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07648498	chr16:89883185	FANCA	0.44	5.82	0.35	1.86e-8	Vitiligo;
KIRP	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg22875332	chr1:76189707	ACADM	-0.34	-4.95	-0.3	1.37e-6	Daytime sleep phenotypes;
KIRP	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg00919237	chr7:87102261	ABCB4	-0.73	-9.1	-0.5	3.24e-17	Gallbladder cancer;
KIRP	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg22681709	chr2:178499509	PDE11A	-0.62	-8.79	-0.49	2.65e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9381040	0.692	rs3088370	chr6:41157670	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-5.54	-0.33	7.64e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	11.78	0.6	1.05e-25	Platelet count;
KIRP	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg03959625	chr15:84868606	LOC388152	0.46	5.39	0.32	1.68e-7	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.08	0.61	1.06e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.89	0.4	4.62e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg07451762	chr16:28383216	NA	0.43	5.6	0.34	5.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4654899	0.865	rs72973154	chr1:21459125	G/T	cg05370193	chr1:21551575	ECE1	0.45	5.61	0.34	5.53e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.83	0.4	6.56e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.63	6.56	0.39	3.18e-10	Gastritis;
KIRP	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg04702396	chr17:15466718	FAM18B2	0.5	6.47	0.38	5.14e-10	Educational attainment (years of education);
KIRP	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	5.37	0.32	1.81e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs76662990	1.000	rs7732552	chr5:73851137	G/A	cg01264639	chr5:73839484	NA	0.58	5.27	0.32	2.97e-7	Residual cognition;
KIRP	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.09	0.41	1.41e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg04226714	chr8:49833948	SNAI2	-0.48	-6.49	-0.38	4.75e-10	Life satisfaction;
KIRP	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.2	0.61	4.23e-27	Bipolar disorder;
KIRP	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg12046867	chr14:103022105	NA	-0.54	-6.99	-0.41	2.6e-11	Platelet count;
KIRP	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg24315340	chr6:146058215	EPM2A	0.42	5.24	0.32	3.53e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs876084	0.505	rs9969405	chr8:121107146	A/G	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.6	6.97	0.41	2.92e-11	Pancreatic cancer;
KIRP	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.66	-5.73	-0.34	2.92e-8	Schizophrenia;
KIRP	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.57	8.25	0.47	9.52e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06481639	chr22:41940642	POLR3H	-0.47	-5.52	-0.33	8.5e-8	Vitiligo;
KIRP	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-7.57	-0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	0.55	6.54	0.38	3.54e-10	Prudent dietary pattern;
KIRP	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg00405596	chr8:11794950	NA	-0.39	-4.99	-0.3	1.17e-6	Retinal vascular caliber;
KIRP	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg02367723	chr1:46378857	MAST2	0.43	4.97	0.3	1.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs56804039	0.524	rs11783173	chr8:8362710	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.03	-0.31	9.54e-7	Cervical cancer;
KIRP	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.59	-7.73	-0.44	2.81e-13	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg05220968	chr6:146057943	EPM2A	-0.42	-5.44	-0.33	1.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg11693508	chr17:37793320	STARD3	0.8	8.38	0.47	4.13e-15	Bipolar disorder;
KIRP	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.81	-11.11	-0.58	1.69e-23	Total body bone mineral density;
KIRP	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.63	-7.71	-0.44	3.18e-13	Lung cancer;
KIRP	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	0.92	12.02	0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	cis	rs335206	0.641	rs335210	chr5:122501864	A/G	cg16368670	chr5:122501738	PRDM6	-0.33	-5.06	-0.31	8.05e-7	QRS duration;
KIRP	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg21643547	chr1:205240462	TMCC2	-0.54	-7.86	-0.45	1.23e-13	Red blood cell count;
KIRP	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs1440410	0.835	rs4690771	chr4:144051097	G/A	cg01719995	chr4:144104893	USP38	0.48	6.56	0.39	3.1e-10	Ischemic stroke;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.76	6.75	0.4	1.08e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16976116	0.901	rs9920220	chr15:55503982	T/C	cg11288833	chr15:55489084	RSL24D1	0.65	7.17	0.42	8.78e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.2	-0.31	4.17e-7	Cervical cancer;
KIRP	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.56	7.31	0.42	3.84e-12	Breast cancer;
KIRP	cis	rs11627756	0.915	rs12100848	chr14:103127449	T/C	cg01864069	chr14:103024347	NA	0.4	4.84	0.3	2.26e-6	Mean platelet volume;
KIRP	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.4e-12	Prudent dietary pattern;
KIRP	cis	rs3087591	0.639	rs757379	chr17:29724557	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	8.44	0.47	2.85e-15	Hip circumference;
KIRP	cis	rs96067	0.805	rs11263860	chr1:36601368	C/G	cg24686825	chr1:36642396	MAP7D1	-0.41	-4.88	-0.3	1.9e-6	Corneal structure;
KIRP	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg05585630	chr7:157510462	PTPRN2	-0.41	-5.56	-0.33	6.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.17	-0.31	4.85e-7	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06782920	chr4:52904570	SGCB	0.54	7.11	0.41	1.28e-11	Parkinson's disease;
KIRP	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.71	-9.18	-0.5	1.87e-17	Coronary artery disease;
KIRP	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg23387468	chr7:139079360	LUC7L2	0.3	5.11	0.31	6.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.57	7.46	0.43	1.49e-12	Colorectal cancer;
KIRP	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.85	14.41	0.68	1.58e-34	Vitiligo;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05210886	chr1:245133216	EFCAB2	-0.49	-6.43	-0.38	6.43e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.44	7.75	0.44	2.42e-13	Renal cell carcinoma;
KIRP	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.74	0.44	2.52e-13	Personality dimensions;
KIRP	cis	rs787274	1.000	rs10739370	chr9:115556941	A/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.55	-0.39	3.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs2457480	0.543	rs1905150	chr10:44713311	G/A	cg09554077	chr10:44749378	NA	0.53	7.3	0.42	3.99e-12	Coronary artery disease;
KIRP	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.82	12.55	0.62	2.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg06634786	chr22:41940651	POLR3H	-0.51	-6.18	-0.37	2.67e-9	Vitiligo;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15491540	chr20:13145549	SPTLC3	0.55	6.32	0.37	1.19e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.74	-9.68	-0.53	5.51e-19	Mean platelet volume;
KIRP	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.5	6.16	0.37	2.96e-9	Menopause (age at onset);
KIRP	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.63	8.69	0.48	5.17e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg26875233	chr11:93583750	C11orf90	-0.4	-7.55	-0.43	8.25e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.15	0.31	5.4e-7	Educational attainment;
KIRP	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.39	5.35	0.32	2.01e-7	Endometrial cancer;
KIRP	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.61	8.55	0.48	1.33e-15	Endometrial cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14653418	chr10:32217953	ARHGAP12	-0.57	-6.64	-0.39	1.94e-10	Interleukin-4 levels;
KIRP	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg09890400	chr1:26503858	CNKSR1	0.41	5.51	0.33	9e-8	Height;
KIRP	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg25319279	chr11:5960081	NA	-0.62	-6.46	-0.38	5.65e-10	DNA methylation (variation);
KIRP	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	7.59	0.44	6.76e-13	Height;
KIRP	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg03684893	chr10:554711	DIP2C	-0.47	-6.84	-0.4	6.33e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8179	0.645	rs7804293	chr7:92287849	T/G	cg15732164	chr7:92237376	CDK6	-0.45	-5.64	-0.34	4.59e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.47	5.35	0.32	2.01e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08484665	chr2:70314817	PCBP1	0.5	7.03	0.41	2.02e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.03e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	8.56	0.48	1.2e-15	Schizophrenia;
KIRP	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg15655495	chr12:38532458	NA	-0.26	-4.96	-0.3	1.3e-6	Bladder cancer;
KIRP	cis	rs12643440	0.922	rs965766	chr4:17209501	T/C	cg22650099	chr4:17144496	NA	-0.5	-6.1	-0.36	4.05e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-5.98	-0.36	7.76e-9	Urate levels in overweight individuals;
KIRP	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.34	0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.78	6.81	0.4	7.57e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-5.98	-0.36	7.92e-9	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg06637938	chr14:75390232	RPS6KL1	0.48	6.83	0.4	6.44e-11	Height;
KIRP	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg25706552	chr1:244017396	NA	0.62	6.59	0.39	2.65e-10	RR interval (heart rate);
KIRP	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.91	14.41	0.68	1.57e-34	Dental caries;
KIRP	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.01	16.84	0.73	7.87e-43	Schizophrenia;
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg08657492	chr7:27170832	HOXA4	0.31	4.94	0.3	1.42e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-5.04	-0.31	9.21e-7	Neuroticism;
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg04369109	chr6:150039330	LATS1	-0.63	-8.15	-0.46	1.8e-14	Lung cancer;
KIRP	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg08603382	chr10:743973	NA	0.46	6.75	0.4	1.05e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs4664293	0.801	rs7607143	chr2:160584761	T/C	cg08347373	chr2:160653686	CD302	-0.36	-5.54	-0.33	7.65e-8	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.23	0.42	6.26e-12	Aortic root size;
KIRP	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.32	0.51	7.02e-18	Bladder cancer;
KIRP	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg24060327	chr5:131705240	SLC22A5	0.63	6.82	0.4	6.85e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	1.0	13.03	0.64	7.14e-30	Neutrophil percentage of white cells;
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.72	11.03	0.58	2.97e-23	Menarche (age at onset);
KIRP	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg13180566	chr4:1052158	NA	-0.5	-5.11	-0.31	6.37e-7	Recombination rate (females);
KIRP	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.54	7.25	0.42	5.28e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00852783	chr1:26633632	UBXN11	0.57	7.52	0.43	9.98e-13	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04036272	chr10:61665557	CCDC6	0.5	6.44	0.38	6.11e-10	Parkinson's disease;
KIRP	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.17	0.31	4.95e-7	Smoking behavior;
KIRP	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Hypertriglyceridemia;
KIRP	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.65	8.08	0.46	2.97e-14	Breast cancer;
KIRP	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg04310649	chr10:35416472	CREM	-0.59	-6.96	-0.41	3.15e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	8.12	0.46	2.19e-14	Electroencephalogram traits;
KIRP	cis	rs9914988	0.613	rs1806982	chr17:27266143	C/T	cg10538030	chr17:27276405	PHF12	-0.63	-6.0	-0.36	6.96e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.6	7.65	0.44	4.55e-13	Resting heart rate;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10020600	chr19:39397911	NFKBIB	-0.52	-6.26	-0.37	1.69e-9	Inflammatory biomarkers;
KIRP	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.4	9.59	0.52	1.03e-18	Corneal astigmatism;
KIRP	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg01378222	chr16:28622494	SULT1A1	0.69	6.53	0.38	3.81e-10	Platelet distribution width;
KIRP	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.69	8.89	0.49	1.31e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.92	-12.33	-0.62	1.66e-27	Platelet distribution width;
KIRP	cis	rs1322639	0.614	rs6900964	chr6:169566763	A/G	cg04662567	chr6:169592167	NA	-0.69	-5.65	-0.34	4.33e-8	Pulse pressure;
KIRP	cis	rs9400467	0.506	rs12192617	chr6:111490275	A/G	cg15721981	chr6:111408429	SLC16A10	0.78	7.27	0.42	4.84e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg02733842	chr7:1102375	C7orf50	0.54	5.54	0.33	7.63e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2594989	0.943	rs2252601	chr3:11481234	A/G	cg01796438	chr3:11312864	ATG7	-0.64	-7.78	-0.44	1.97e-13	Circulating chemerin levels;
KIRP	cis	rs7084402	0.967	rs7098606	chr10:60277089	C/T	cg05938607	chr10:60274200	BICC1	0.45	10.84	0.57	1.22e-22	Refractive error;
KIRP	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.42	-0.33	1.4e-7	Educational attainment (years of education);
KIRP	cis	rs113084984	0.538	rs12994384	chr2:11683965	C/T	cg07314298	chr2:11723111	GREB1	0.37	5.09	0.31	7.11e-7	Breast cancer;
KIRP	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg15655495	chr12:38532458	NA	-0.28	-5.01	-0.3	1.06e-6	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.8	10.88	0.57	9.29e-23	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.2	-0.46	1.3e-14	Personality dimensions;
KIRP	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.03e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.59	-0.44	6.57e-13	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25878872	chr4:159593506	ETFDH;C4orf46	0.45	6.44	0.38	6.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09047884	chr22:43484984	TTLL1	0.9	6.1	0.36	4.09e-9	P wave terminal force;
KIRP	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.2	21.72	0.81	3.97e-59	Cognitive function;
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.7	-8.89	-0.49	1.35e-16	Ileal carcinoids;
KIRP	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.73	9.65	0.52	6.87e-19	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21016266	chr12:122356598	WDR66	0.68	9.69	0.53	5e-19	Mean platelet volume;
KIRP	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg05304507	chr6:116381966	FRK	0.21	5.82	0.35	1.85e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg02398342	chr17:80708632	TBCD;FN3K	-0.59	-8.13	-0.46	2.06e-14	Glycated hemoglobin levels;
KIRP	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg07511934	chr16:89386912	ANKRD11	0.42	5.36	0.32	1.87e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.32	-6.83	-0.4	6.44e-11	Cutaneous nevi;
KIRP	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg07827796	chr19:33622959	WDR88	0.41	4.94	0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg06521331	chr12:34319734	NA	-0.49	-6.09	-0.36	4.43e-9	Bladder cancer;
KIRP	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-4.91	-0.3	1.65e-6	Lung cancer;
KIRP	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg02073558	chr3:44770973	ZNF501	0.63	8.91	0.49	1.14e-16	Depressive symptoms;
KIRP	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg03808351	chr9:123631620	PHF19	0.43	5.97	0.36	8.45e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.72	-0.34	3.04e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg11886554	chr3:170076028	SKIL	0.5	5.57	0.33	6.67e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.55	6.51	0.38	4.1e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00830626	chr22:42229212	SREBF2	-0.58	-6.27	-0.37	1.64e-9	Menopause (age at onset);
KIRP	cis	rs238295	0.805	rs6038214	chr20:5569822	C/G	cg24001556	chr20:5591874	RP5-1022P6.2	0.51	5.1	0.31	6.72e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs7640424	0.691	rs170534	chr3:107840830	T/C	cg09227934	chr3:107805635	CD47	0.3	5.37	0.32	1.78e-7	Body mass index;
KIRP	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12560992	chr17:57184187	TRIM37	0.61	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg00405596	chr8:11794950	NA	-0.51	-6.65	-0.39	1.83e-10	Retinal vascular caliber;
KIRP	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.56	-6.44	-0.38	6.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	1.0	9.22	0.51	1.42e-17	Systolic blood pressure;
KIRP	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.15	22.1	0.82	2.39e-60	Exhaled nitric oxide output;
KIRP	cis	rs13385	0.769	rs10045510	chr5:139613188	T/C	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.71	11.07	0.58	2.17e-23	Resting heart rate;
KIRP	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg00405596	chr8:11794950	NA	0.53	7.14	0.41	1.06e-11	Mood instability;
KIRP	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.0	-0.3	1.1e-6	Pulmonary function;
KIRP	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.63	6.61	0.39	2.3e-10	Gut microbiome composition (summer);
KIRP	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg03894339	chr8:19674705	INTS10	0.66	7.65	0.44	4.51e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.76	10.66	0.56	4.65e-22	Body mass index;
KIRP	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.68	7.91	0.45	8.49e-14	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27026673	chr2:39664343	MAP4K3	0.46	6.07	0.36	4.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20135002	chr11:47629003	NA	-0.48	-5.88	-0.35	1.36e-8	Subjective well-being;
KIRP	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.46	6.28	0.37	1.55e-9	Systolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24377657	chr11:27723245	BDNF	-0.39	-6.1	-0.36	4.06e-9	Interleukin-4 levels;
KIRP	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg16586182	chr3:47516702	SCAP	0.74	9.94	0.54	8.55e-20	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07751222	chr4:102268245	PPP3CA	0.47	6.47	0.38	5.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	trans	rs1859156	0.812	rs7698986	chr4:95825114	T/G	cg24204951	chr2:239172084	PER2	0.28	6.58	0.39	2.74e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs12476592	0.516	rs1922421	chr2:63592792	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.14	-0.31	5.5e-7	Childhood ear infection;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg04527057	chr20:5107457	CDS2;PCNA	0.54	6.14	0.36	3.37e-9	Electroencephalogram traits;
KIRP	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.7	-0.39	1.4e-10	Coronary artery calcification;
KIRP	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg23625390	chr15:77176239	SCAPER	0.54	7.01	0.41	2.26e-11	Blood metabolite levels;
KIRP	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg27411982	chr8:10470053	RP1L1	0.46	5.58	0.34	6.44e-8	Morning vs. evening chronotype;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08247611	chr16:71928811	KIAA0174	0.45	6.04	0.36	5.78e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg10047753	chr17:41438598	NA	1.16	17.91	0.75	1.72e-46	Menopause (age at onset);
KIRP	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.26	11.87	0.6	5.43e-26	Diabetic retinopathy;
KIRP	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg17376030	chr22:41985996	PMM1	0.59	6.22	0.37	2.08e-9	Vitiligo;
KIRP	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	11.27	0.58	5.18e-24	Smoking behavior;
KIRP	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.55	6.98	0.41	2.71e-11	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs6669919	0.901	rs7527396	chr1:211667857	C/T	cg10512769	chr1:211675356	NA	-0.65	-10.23	-0.55	1.1e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.51	-7.24	-0.42	5.85e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.02e-8	Motion sickness;
KIRP	cis	rs17331151	0.573	rs11626	chr3:52873984	C/T	cg06204229	chr3:52865917	ITIH4	0.5	7.39	0.43	2.31e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg24101359	chr6:42928495	GNMT	0.56	7.92	0.45	8.27e-14	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs981844	1.000	rs72731669	chr4:154662464	G/A	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.79	8.03	0.46	4.02e-14	Hip geometry;
KIRP	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg00310523	chr12:86230176	RASSF9	0.55	8.4	0.47	3.52e-15	Major depressive disorder;
KIRP	trans	rs7999699	0.841	rs1924807	chr13:48303281	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.56	5.94	0.35	9.81e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg27624424	chr6:160112604	SOD2	0.55	6.52	0.38	3.94e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs58785573	0.513	rs12510215	chr4:38591188	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.46	5.64	0.34	4.65e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg03609598	chr5:56110824	MAP3K1	-0.46	-5.2	-0.31	4.22e-7	Coronary artery disease;
KIRP	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.67	-5.65	-0.34	4.5e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg16898833	chr6:26189333	HIST1H4D	0.73	5.08	0.31	7.59e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.63	-9.45	-0.52	2.77e-18	Hip circumference;
KIRP	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg21475434	chr5:93447410	FAM172A	0.73	5.91	0.35	1.11e-8	Diabetic retinopathy;
KIRP	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.15	0.54	1.8899999999999998e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	1.11	8.83	0.49	2e-16	Alzheimer's disease;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg23978390	chr7:1156363	C7orf50	0.6	7.54	0.43	9.2e-13	Longevity;Endometriosis;
KIRP	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg27490568	chr2:178487706	NA	0.51	6.84	0.4	6.09e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6088813	0.961	rs3795159	chr20:33896262	C/G	cg14752227	chr20:34000481	UQCC	0.46	5.89	0.35	1.25e-8	Height;
KIRP	cis	rs234043	1.000	rs234051	chr3:172311712	C/T	cg22572614	chr3:172241975	TNFSF10	0.3	5.47	0.33	1.12e-7	Renal cell carcinoma;
KIRP	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg07777115	chr5:623756	CEP72	-0.59	-6.03	-0.36	6.1e-9	Obesity-related traits;
KIRP	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.33	0.37	1.16e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.75	-7.05	-0.41	1.81e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08439880	chr3:133502540	NA	-0.41	-4.98	-0.3	1.2e-6	Iron status biomarkers;
KIRP	cis	rs11138902	0.649	rs7871891	chr9:72142202	A/G	cg14397918	chr9:72078829	APBA1	0.33	5.1	0.31	6.8e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.69	10.31	0.55	6.01e-21	Prostate cancer;
KIRP	cis	rs6959887	0.962	rs6976783	chr7:35285642	A/G	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs9653442	0.564	rs11687586	chr2:100789346	A/G	cg17356467	chr2:100759845	AFF3	0.38	5.35	0.32	2.01e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7818345	1.000	rs7823194	chr8:19292528	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.76	0.34	2.44e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.5	7.07	0.41	1.58e-11	Mean corpuscular volume;
KIRP	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.5	6.72	0.39	1.26e-10	Obesity-related traits;
KIRP	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.63	7.49	0.43	1.23e-12	Type 2 diabetes;
KIRP	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg21851534	chr17:3907994	ZZEF1	0.43	5.04	0.31	8.85e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs78487399	0.710	rs79629200	chr2:43602932	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.04	-0.31	9.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.75	7.7	0.44	3.33e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.51	6.29	0.37	1.43e-9	Radiation response;
KIRP	cis	rs1816752	0.819	rs7316961	chr13:24985177	C/T	cg22771759	chr13:24902376	NA	0.39	5.08	0.31	7.36e-7	Obesity-related traits;
KIRP	cis	rs7919006	0.793	rs58552023	chr10:76783198	G/A	cg01390419	chr10:76803856	DUPD1	0.52	6.31	0.37	1.27e-9	Weight;
KIRP	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg07271561	chr3:50359363	HYAL2	-0.49	-5.98	-0.36	7.65e-9	Schizophrenia;
KIRP	cis	rs7826238	0.526	rs876955	chr8:8310884	C/G	cg15556689	chr8:8085844	FLJ10661	0.63	7.61	0.44	5.74e-13	Systolic blood pressure;
KIRP	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.34e-7	Breast cancer;
KIRP	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.57	8.17	0.46	1.66e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.53e-22	Coronary artery disease;
KIRP	cis	rs10904908	1.000	rs10904908	chr10:17260290	A/G	cg01003015	chr10:17271136	VIM	-0.42	-4.92	-0.3	1.59e-6	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg24874828	chr4:187887005	NA	-0.55	-8.85	-0.49	1.78e-16	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.3	25.75	0.85	8.84e-72	IgG glycosylation;
KIRP	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	9.54	0.52	1.48e-18	Coffee consumption (cups per day);
KIRP	cis	rs1318772	1.000	rs446272	chr5:112801861	A/G	cg12552261	chr5:112820674	MCC	-0.8	-5.11	-0.31	6.49e-7	F-cell distribution;
KIRP	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg08847533	chr14:75593920	NEK9	0.53	6.2	0.37	2.43e-9	IgG glycosylation;
KIRP	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg13147721	chr7:65941812	NA	1.02	7.05	0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.6	-6.26	-0.37	1.72e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7923609	0.967	rs10740134	chr10:65315433	T/C	cg08743896	chr10:65200160	JMJD1C	-0.34	-5.03	-0.31	9.66e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1468333	1.000	rs217274	chr5:137490974	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.47	5.23	0.32	3.67e-7	Resting heart rate;
KIRP	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11987759	chr7:65425863	GUSB	-0.68	-9.46	-0.52	2.56e-18	Aortic root size;
KIRP	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.73	8.57	0.48	1.13e-15	Type 2 diabetes;
KIRP	cis	rs17030434	1.000	rs12646758	chr4:154731625	A/G	cg14289246	chr4:154710475	SFRP2	-0.82	-9.67	-0.52	5.9e-19	Electrocardiographic conduction measures;
KIRP	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.67	-7.21	-0.42	6.77e-12	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13754255	chr15:65426202	PDCD7	0.47	6.18	0.37	2.66e-9	Parkinson's disease;
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg05562828	chr17:3906858	NA	0.62	10.74	0.56	2.63e-22	Type 2 diabetes;
KIRP	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	13.2	0.64	1.95e-30	Platelet count;
KIRP	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.81	-11.12	-0.58	1.48e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.7	-0.44	3.23e-13	Diisocyanate-induced asthma;
KIRP	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.6	-9.41	-0.51	3.77e-18	Prostate cancer;
KIRP	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.54e-16	Motion sickness;
KIRP	cis	rs4704187	0.687	rs7709707	chr5:74363575	T/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg02153584	chr22:29168773	CCDC117	0.58	5.91	0.35	1.15e-8	Hematocrit;Hemoglobin concentration;
KIRP	trans	rs7618501	0.521	rs11712056	chr3:49914397	T/C	cg21659725	chr3:3221576	CRBN	0.52	6.43	0.38	6.45e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg19770292	chr5:1868693	NA	0.42	5.51	0.33	8.94e-8	Cardiovascular disease risk factors;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.17	-0.31	4.82e-7	Life satisfaction;
KIRP	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs60843830	1.000	rs9213	chr2:218386	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.53	0.48	1.5e-15	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg20140201	chr2:241835670	C2orf54	-0.35	-5.34	-0.32	2.16e-7	Urinary metabolites;
KIRP	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10174797	chr19:8464628	RAB11B	0.51	6.41	0.38	7.33e-10	HDL cholesterol;
KIRP	cis	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg00405596	chr8:11794950	NA	-0.43	-5.4	-0.33	1.54e-7	Triglycerides;
KIRP	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg23587288	chr2:27483067	SLC30A3	-0.72	-7.66	-0.44	4.15e-13	Blood metabolite levels;
KIRP	cis	rs1620921	0.505	rs11756055	chr6:161210622	C/T	cg01280913	chr6:161186852	NA	-0.58	-7.69	-0.44	3.56e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.52	-11.48	-0.59	9.99e-25	Diabetic kidney disease;
KIRP	cis	rs8179	0.645	rs11765954	chr7:92280695	A/G	cg15732164	chr7:92237376	CDK6	-0.38	-5.03	-0.31	9.61e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.17	0.61	5.34e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg11271282	chr2:238384023	NA	0.47	5.37	0.32	1.86e-7	Prostate cancer;
KIRP	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg06027949	chr8:82754900	SNX16	-0.56	-7.09	-0.41	1.41e-11	Diastolic blood pressure;
KIRP	cis	rs2012796	1.000	rs8008024	chr14:81818492	A/G	cg02996355	chr14:81879375	NA	0.46	6.16	0.37	2.97e-9	Night sleep phenotypes;
KIRP	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg16434002	chr17:42200994	HDAC5	-0.58	-7.15	-0.41	9.76e-12	Total body bone mineral density;
KIRP	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg26875233	chr11:93583750	C11orf90	0.35	6.77	0.4	9.63e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs35995292	0.500	rs28369620	chr7:38921872	C/T	cg19327137	chr7:38886074	VPS41	0.79	12.13	0.61	7.34e-27	Subjective well-being (multi-trait analysis);
KIRP	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.84	10.42	0.55	2.72e-21	Obesity-related traits;
KIRP	cis	rs7033996	1.000	rs62541929	chr9:35922113	A/C	cg00918944	chr9:35908117	LOC158376	0.36	5.0	0.3	1.08e-6	Urate levels (BMI interaction);
KIRP	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.47	6.15	0.36	3.14e-9	Alzheimer's disease (late onset);
KIRP	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg09904177	chr6:26538194	HMGN4	0.43	5.82	0.35	1.8e-8	Schizophrenia;
KIRP	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg23188684	chr11:67383651	NA	-0.41	-5.15	-0.31	5.34e-7	Mean corpuscular volume;
KIRP	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.52	7.53	0.43	9.34e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg16558253	chr16:72132732	DHX38	-0.5	-7.27	-0.42	4.74e-12	Fibrinogen levels;
KIRP	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.84	-13.52	-0.65	1.59e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg05805236	chr11:65401703	PCNXL3	-0.57	-7.42	-0.43	1.92e-12	Acne (severe);
KIRP	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg10503236	chr1:231470652	EXOC8	-0.49	-7.07	-0.41	1.57e-11	Hemoglobin concentration;
KIRP	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg00579200	chr11:133705235	NA	-0.38	-4.89	-0.3	1.83e-6	Childhood ear infection;
KIRP	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.48	5.22	0.32	3.76e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg11764359	chr7:65958608	NA	0.78	5.06	0.31	8.19e-7	Diabetic kidney disease;
KIRP	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.15	-0.36	3.17e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg23188430	chr6:125850052	NA	-0.34	-5.44	-0.33	1.28e-7	Brugada syndrome;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06745235	chr1:180471494	ACBD6	0.57	6.65	0.39	1.86e-10	Smoking initiation;
KIRP	cis	rs4073054	0.564	rs10797094	chr1:161182672	G/A	cg04436964	chr1:161167745	NDUFS2;ADAMTS4	-0.32	-5.18	-0.31	4.56e-7	Blood metabolite levels;
KIRP	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.58	-7.2	-0.42	7.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg07274523	chr3:49395745	GPX1	0.71	8.51	0.48	1.73e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.85	0.49	1.7e-16	Bipolar disorder;
KIRP	cis	rs12999616	0.571	rs35263587	chr2:98506906	C/T	cg26665480	chr2:98280029	ACTR1B	0.48	5.19	0.31	4.48e-7	Colorectal cancer;
KIRP	cis	rs1010254	0.559	rs72808328	chr5:151746310	G/A	cg12297329	chr5:152029980	NA	-0.62	-6.36	-0.38	9.89e-10	Optic nerve measurement (cup area);
KIRP	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.59	-6.53	-0.38	3.73e-10	Height;
KIRP	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg05187965	chr10:45406764	TMEM72	-0.32	-7.61	-0.44	5.98e-13	Mean corpuscular volume;
KIRP	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	5.6	0.34	5.76e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg07402062	chr16:89894098	SPIRE2	0.32	6.59	0.39	2.6e-10	Vitiligo;
KIRP	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg05729581	chr11:3078854	CARS	-0.51	-6.38	-0.38	8.79e-10	Longevity;
KIRP	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	0.81	13.61	0.66	8.18e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.79	-7.32	-0.42	3.58e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg07310318	chr6:150185595	LRP11	-0.61	-6.69	-0.39	1.52e-10	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13482925	chr10:64028750	RTKN2	0.55	6.5	0.38	4.33e-10	Smoking initiation;
KIRP	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.24	0.55	1.02e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg08619932	chr19:49200058	FUT2	0.37	5.72	0.34	3.16e-8	Dietary macronutrient intake;
KIRP	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg18190219	chr22:46762943	CELSR1	-0.61	-6.36	-0.38	1e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs17221829	0.703	rs10765229	chr11:89392575	T/G	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-9.41	-0.51	3.73e-18	Morning vs. evening chronotype;
KIRP	cis	rs2916247	0.773	rs1471763	chr8:93100864	A/T	cg10183463	chr8:93005414	RUNX1T1	0.5	5.92	0.35	1.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg10117171	chr1:25599238	RHD	0.43	5.88	0.35	1.32e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.36	-5.12	-0.31	6.18e-7	Motion sickness;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27664390	chr15:59171928	SLTM	0.55	6.52	0.38	3.97e-10	Interleukin-4 levels;
KIRP	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg20936604	chr3:58311152	NA	-0.6	-5.07	-0.31	7.92e-7	Cholesterol, total;
KIRP	cis	rs1165472	0.755	rs1849680	chr1:56161430	G/A	cg11523071	chr1:56160889	NA	-0.59	-7.61	-0.44	5.8e-13	Paclitaxel-induced neuropathy;
KIRP	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03934478	chr11:495069	RNH1	0.87	6.74	0.39	1.1e-10	Body mass index;
KIRP	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg17507749	chr15:85114479	UBE2QP1	0.77	8.87	0.49	1.52e-16	Schizophrenia;
KIRP	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04902049	chr1:36622448	MAP7D1	-0.48	-6.08	-0.36	4.62e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.04	-11.54	-0.59	6.39e-25	Colorectal cancer;
KIRP	cis	rs4908768	0.686	rs79644886	chr1:8803216	A/C	cg25722041	chr1:8623473	RERE	0.61	7.88	0.45	1.03e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg21775007	chr8:11205619	TDH	-0.51	-6.47	-0.38	5.34e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg12826209	chr6:26865740	GUSBL1	0.77	5.4	0.33	1.56e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.01	15.65	0.71	8.82e-39	Chronic sinus infection;
KIRP	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-9.39	-0.51	4.13e-18	Response to antipsychotic treatment;
KIRP	cis	rs151997	0.538	rs62367392	chr5:50270298	T/C	cg06027927	chr5:50259733	NA	0.58	6.92	0.4	3.86e-11	Callous-unemotional behaviour;
KIRP	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-6.16	-0.37	2.96e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17712092	chr4:129076599	LARP1B	-0.58	-7.18	-0.42	8.45e-12	Eosinophil percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09844983	chr1:28240714	RPA2	0.57	6.6	0.39	2.5e-10	Smoking initiation;
KIRP	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.53	-0.38	3.75e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	7.95	0.45	6.97e-14	Multiple sclerosis;
KIRP	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg02462569	chr6:150064036	NUP43	-0.43	-6.64	-0.39	2.04e-10	Lung cancer;
KIRP	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.21	0.32	3.97e-7	Educational attainment;
KIRP	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.41	-5.03	-0.31	9.58e-7	Blood metabolite levels;
KIRP	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg25182066	chr10:30743637	MAP3K8	-0.71	-8.84	-0.49	1.84e-16	Inflammatory bowel disease;
KIRP	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.61	-7.35	-0.42	2.97e-12	Glomerular filtration rate;
KIRP	cis	rs1472147	0.696	rs1532222	chr7:128516945	A/C	cg17511168	chr7:128516960	KCP	-0.53	-7.21	-0.42	6.7e-12	Calcium levels;
KIRP	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.64	-9.87	-0.53	1.44e-19	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.55	-8.23	-0.46	1.13e-14	Inflammatory skin disease;
KIRP	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.43	0.33	1.35e-7	Breast cancer;
KIRP	cis	rs35883536	1.000	rs12239531	chr1:101085661	A/G	cg06223162	chr1:101003688	GPR88	0.31	6.29	0.37	1.47e-9	Monocyte count;
KIRP	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1950626	0.833	rs12892225	chr14:101415413	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.85	0.4	5.99e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.4	5.02	0.3	9.83e-7	Rheumatoid arthritis;
KIRP	cis	rs11264213	0.901	rs584873	chr1:36431806	C/A	cg27506609	chr1:36549197	TEKT2	1.17	7.3	0.42	3.88e-12	Schizophrenia;
KIRP	cis	rs1983891	0.908	rs2148342	chr6:41519522	G/A	cg20194872	chr6:41519635	FOXP4	0.55	7.11	0.41	1.28e-11	Prostate cancer;
KIRP	cis	rs926938	0.584	rs1286558	chr1:115357587	C/T	cg12756093	chr1:115239321	AMPD1	0.61	8.7	0.49	4.71e-16	Autism;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg01765077	chr12:122356316	WDR66	0.63	8.67	0.48	5.87e-16	Mean corpuscular volume;
KIRP	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-0.84	-9.22	-0.51	1.42e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4460629	0.742	rs7548955	chr1:155082298	T/C	cg02153340	chr1:155202674	NA	-0.35	-5.01	-0.3	1.04e-6	Serum magnesium levels;
KIRP	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	1.09	11.39	0.59	2.02e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg26134248	chr17:3907702	NA	0.59	8.95	0.5	8.93e-17	Type 2 diabetes;
KIRP	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.64	9.27	0.51	1e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13185784	0.667	rs4309929	chr5:179650988	A/C	cg23248424	chr5:179741104	GFPT2	-0.51	-5.33	-0.32	2.18e-7	TRAIL levels;
KIRP	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg14580859	chr9:123691850	NA	0.37	5.18	0.31	4.52e-7	Rheumatoid arthritis;
KIRP	trans	rs61931739	0.577	rs7313428	chr12:33672325	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.16	-0.37	2.88e-9	Morning vs. evening chronotype;
KIRP	cis	rs714031	0.785	rs11704439	chr22:40069493	T/G	cg21377881	chr22:40064566	CACNA1I	-0.68	-10.66	-0.56	4.81e-22	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs10518128	1.000	rs4076318	chr4:75701081	C/T	cg20122727	chr4:75719957	BTC	0.58	5.88	0.35	1.33e-8	Electroencephalogram traits;
KIRP	cis	rs17286411	0.836	rs9937626	chr16:71903750	G/A	cg04254540	chr16:71951199	KIAA0174	-0.4	-5.26	-0.32	3.13e-7	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs71636778	0.543	rs11810321	chr1:27220521	T/G	cg12203394	chr1:27248618	NUDC	0.67	5.73	0.34	2.9e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg16989719	chr2:238392110	NA	-0.54	-7.38	-0.43	2.4e-12	Prostate cancer;
KIRP	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-4.86	-0.3	2.1e-6	Neuroticism;
KIRP	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	0.44	6.01	0.36	6.66e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.42	6.24	0.37	1.9e-9	Schizophrenia;
KIRP	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg21475434	chr5:93447410	FAM172A	-0.43	-4.86	-0.3	2.11e-6	Diabetic retinopathy;
KIRP	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg00319359	chr11:70116639	PPFIA1	0.66	6.46	0.38	5.58e-10	Coronary artery disease;
KIRP	cis	rs1448094	0.872	rs12322940	chr12:86406708	G/C	cg00310523	chr12:86230176	RASSF9	0.4	6.1	0.36	4.14e-9	Major depressive disorder;
KIRP	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.34	0.37	1.1e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.26	0.55	8.5e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg13482628	chr17:19912719	NA	0.69	10.64	0.56	5.33e-22	Schizophrenia;
KIRP	cis	rs911119	0.955	rs6048933	chr20:23595637	T/G	cg16589663	chr20:23618590	CST3	0.68	6.28	0.37	1.49e-9	Chronic kidney disease;
KIRP	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7998202	0.667	rs99126	chr13:113359336	C/G	cg02820901	chr13:113351484	ATP11A	-0.59	-5.56	-0.33	7.02e-8	Glycated hemoglobin levels;
KIRP	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.55	-0.39	3.36e-10	Response to antipsychotic treatment;
KIRP	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.19	-0.31	4.39e-7	Neuroticism;
KIRP	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg13010199	chr12:38710504	ALG10B	0.52	6.93	0.4	3.63e-11	Bladder cancer;
KIRP	cis	rs9323205	0.953	rs61144314	chr14:51620556	G/A	cg23942311	chr14:51606299	NA	-0.58	-6.34	-0.37	1.09e-9	Cancer;
KIRP	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.73	8.88	0.49	1.48e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.1	-0.36	4.04e-9	Multiple myeloma (IgH translocation);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18057185	chr3:48342999	NME6	-0.56	-6.39	-0.38	8.2e-10	Menopause (age at onset);
KIRP	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	15.24	0.7	2.26e-37	Alzheimer's disease;
KIRP	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-9.93	-0.53	9.27e-20	Blood trace element (Zn levels);
KIRP	cis	rs684232	0.644	rs870183	chr17:599811	A/G	cg15660573	chr17:549704	VPS53	-0.76	-11.29	-0.58	4.25e-24	Prostate cancer;
KIRP	cis	rs2904967	1.000	rs630055	chr11:65087533	G/T	cg12562828	chr11:65076843	NA	-0.47	-7.14	-0.41	1.05e-11	Mean corpuscular volume;
KIRP	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg21775007	chr8:11205619	TDH	0.46	6.2	0.37	2.35e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6545883	0.929	rs2593635	chr2:61634706	A/C	cg15711740	chr2:61764176	XPO1	0.62	8.05	0.46	3.48e-14	Tuberculosis;
KIRP	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg09201719	chr10:104596890	CYP17A1	0.36	5.02	0.3	9.87e-7	Arsenic metabolism;
KIRP	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.04	14.87	0.69	4.14e-36	Cognitive ability;
KIRP	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	cg21523751	chr1:182988639	NA	0.45	7.22	0.42	6.3e-12	Hypertriglyceridemia;
KIRP	cis	rs5769707	0.605	rs2071900	chr22:50052175	A/G	cg20744362	chr22:50050164	C22orf34	0.34	5.22	0.32	3.72e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.52	-0.43	1e-12	Blood pressure;
KIRP	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.87	0.57	9.93e-23	Cognitive test performance;
KIRP	cis	rs1147199	0.585	rs72737612	chr9:87239850	A/G	cg22402007	chr9:87282823	NTRK2	0.4	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg10755058	chr3:40428713	ENTPD3	-0.42	-6.07	-0.36	4.75e-9	Renal cell carcinoma;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg23151374	chr4:164415611	C4orf43	0.55	6.42	0.38	6.89e-10	Sleep duration;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.55	-7.78	-0.44	2.05e-13	Obesity-related traits;
KIRP	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.73	9.41	0.51	3.71e-18	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.64	-6.04	-0.36	5.63e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg24803719	chr17:45855879	NA	-0.41	-5.37	-0.32	1.78e-7	IgG glycosylation;
KIRP	cis	rs6540556	0.608	rs4844891	chr1:209914409	A/C	cg23920097	chr1:209922102	NA	-0.4	-5.37	-0.32	1.78e-7	Red blood cell count;
KIRP	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-8.27	-0.47	8.36e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs7188697	0.922	rs173475	chr16:58580530	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.08	0.31	7.6e-7	QT interval;
KIRP	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.5	6.92	0.4	3.85e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	17.44	0.74	6.65e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg26876637	chr1:152193138	HRNR	0.72	9.22	0.51	1.4e-17	Atopic dermatitis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03339057	chr1:218745126	NA	0.38	6.1	0.36	4e-9	C-reactive protein;
KIRP	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg21775007	chr8:11205619	TDH	-0.41	-5.2	-0.31	4.26e-7	Neuroticism;
KIRP	cis	rs1712517	1.000	rs3123794	chr10:105033742	A/G	cg05636881	chr10:105038444	INA	0.45	6.52	0.38	3.91e-10	Migraine;
KIRP	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg15676125	chr6:33679581	C6orf125	0.42	5.37	0.32	1.83e-7	Plateletcrit;
KIRP	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-9.22	-0.51	1.36e-17	Bone mineral density;
KIRP	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg16497661	chr14:103986332	CKB	0.39	5.17	0.31	4.85e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.23e-7	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.49	5.19	0.31	4.43e-7	Breast cancer;
KIRP	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.43	8.61	0.48	8.98e-16	Coronary artery disease;
KIRP	cis	rs13315871	1.000	rs13317400	chr3:58408792	T/G	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs554111	0.891	rs659046	chr1:21047725	C/T	cg08890418	chr1:21044141	KIF17	-0.64	-10.24	-0.55	1.02e-20	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	11.27	0.58	5.12e-24	Personality dimensions;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg01765077	chr12:122356316	WDR66	0.6	8.49	0.48	1.97e-15	Mean corpuscular volume;
KIRP	cis	rs6701037	1.000	rs6681020	chr1:175125264	G/A	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.21	-0.32	3.99e-7	Alcohol dependence;
KIRP	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg16584676	chr17:46985605	UBE2Z	0.47	5.91	0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.66	-7.17	-0.42	8.49e-12	Vitiligo;
KIRP	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.71	-0.53	4.34e-19	Morning vs. evening chronotype;
KIRP	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.68	10.1	0.54	2.78e-20	Dupuytren's disease;
KIRP	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.86	13.04	0.64	6.53e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs9409565	0.826	rs9409778	chr9:97242839	G/A	cg05679027	chr9:99775184	HIATL2	-0.54	-6.58	-0.39	2.89e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07080220	chr10:102295463	HIF1AN	0.73	7.0	0.41	2.44e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	cis	rs829883	0.659	rs11109517	chr12:98921574	A/C	cg25150519	chr12:98850993	NA	0.76	9.17	0.5	2.01e-17	Colorectal adenoma (advanced);
KIRP	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.7	8.43	0.47	2.95e-15	Breast cancer;
KIRP	cis	rs72730918	0.564	rs12441057	chr15:51896769	A/G	cg14296394	chr15:51910925	DMXL2	-0.76	-10.68	-0.56	4.03e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs988913	0.706	rs10948884	chr6:54941841	C/T	cg03513858	chr6:54763001	FAM83B	-0.37	-5.12	-0.31	6.16e-7	Menarche (age at onset);
KIRP	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.5	-5.48	-0.33	1.07e-7	Vitiligo;
KIRP	cis	rs2267137	0.903	rs2283850	chr22:29772391	G/C	cg07256473	chr22:29710276	RASL10A	0.46	7.38	0.43	2.44e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.56	7.41	0.43	2e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg22705602	chr4:152727874	NA	-0.54	-9.4	-0.51	4.04e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14154487	chr9:125133314	PTGS1	0.46	6.29	0.37	1.43e-9	Myopia (pathological);
KIRP	cis	rs960902	0.666	rs4503967	chr2:37718457	C/T	cg25341268	chr2:37734390	NA	-0.56	-7.26	-0.42	5.21e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs7709377	0.597	rs11241375	chr5:115519813	T/C	cg23108291	chr5:115420582	COMMD10	0.4	4.85	0.3	2.15e-6	Metabolite levels  (X-11787);
KIRP	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.7	-10.97	-0.57	4.58e-23	Hepatocellular carcinoma;
KIRP	cis	rs10849893	0.557	rs61955091	chr12:121833975	A/G	cg01154721	chr12:121881891	KDM2B	-0.41	-5.5	-0.33	9.34e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg17644776	chr2:200775616	C2orf69	0.64	6.65	0.39	1.93e-10	Schizophrenia;
KIRP	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.58	7.42	0.43	1.92e-12	Aortic root size;
KIRP	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.09	-0.5	3.46e-17	Mean corpuscular volume;
KIRP	cis	rs1555895	0.656	rs1536338	chr10:838378	C/T	cg10017260	chr10:834428	NA	0.43	6.42	0.38	6.82e-10	Survival in rectal cancer;
KIRP	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.85	-13.46	-0.65	2.52e-31	Breast cancer;
KIRP	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.91	11.79	0.6	1.01e-25	Homoarginine levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02197005	chr4:187840611	NA	-0.37	-6.23	-0.37	2.05e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6977660	0.607	rs7357321	chr7:19817636	C/T	cg07541023	chr7:19748670	TWISTNB	0.52	5.28	0.32	2.88e-7	Thyroid stimulating hormone;
KIRP	cis	rs2742417	0.967	rs1969625	chr3:45734975	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.43e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6832769	1.000	rs12643926	chr4:56310621	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	5.9	0.35	1.2e-8	Renal cell carcinoma;
KIRP	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg08738300	chr3:44038990	NA	-0.69	-9.78	-0.53	2.76e-19	Coronary artery disease;
KIRP	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg26513180	chr16:89883248	FANCA	0.59	5.51	0.33	9e-8	Skin colour saturation;
KIRP	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.55	6.8	0.4	8.1e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.19	-0.37	2.44e-9	IgG glycosylation;
KIRP	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.31	0.58	3.64e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg19025524	chr12:109796872	NA	-0.38	-4.93	-0.3	1.49e-6	Neuroticism;
KIRP	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg08807101	chr21:30365312	RNF160	-0.59	-7.25	-0.42	5.28e-12	Cognitive test performance;
KIRP	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6457821	1.000	rs73411755	chr6:35319290	G/C	cg06087101	chr6:35551932	FKBP5	0.58	5.19	0.31	4.48e-7	Height;
KIRP	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.63	-9.22	-0.51	1.41e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1559088	0.512	rs36085438	chr19:33562145	G/A	cg17764715	chr19:33622953	WDR88	0.52	4.96	0.3	1.3e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.52	-6.63	-0.39	2.11e-10	Birth weight;
KIRP	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.78	-12.21	-0.61	3.9e-27	Rheumatoid arthritis;
KIRP	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg19773385	chr1:10388646	KIF1B	0.36	4.99	0.3	1.16e-6	Prostate cancer;
KIRP	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.55	-7.18	-0.42	8.2e-12	Corneal structure;
KIRP	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg25753631	chr6:25732923	NA	-0.27	-4.99	-0.3	1.12e-6	Iron status biomarkers;
KIRP	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.4	5.12	0.31	6.19e-7	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	7.75	0.44	2.45e-13	Colorectal cancer;
KIRP	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg18478394	chr8:109455254	TTC35	0.52	6.55	0.39	3.32e-10	Dupuytren's disease;
KIRP	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.32	0.59	3.41e-24	Exhaled nitric oxide levels;
KIRP	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.83	-10.22	-0.55	1.15e-20	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.76e-15	Aortic root size;
KIRP	cis	rs77688320	0.535	rs3815515	chr2:202257930	C/A	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.46	-6.99	-0.41	2.58e-11	Coronary artery disease;
KIRP	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.72	10.58	0.56	8.66e-22	Schizophrenia;
KIRP	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg23479056	chr15:41276147	INO80	-0.41	-5.14	-0.31	5.56e-7	Menopause (age at onset);
KIRP	cis	rs12134040	0.646	rs61835532	chr1:236511729	T/G	cg21399712	chr1:236511386	NA	-0.53	-7.36	-0.42	2.71e-12	Urate levels (BMI interaction);
KIRP	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg04865290	chr3:52927548	TMEM110	-0.62	-6.92	-0.4	3.85e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs12762955	0.608	rs7922760	chr10:1156815	G/C	cg18964960	chr10:1102726	WDR37	-0.47	-4.89	-0.3	1.86e-6	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg17376030	chr22:41985996	PMM1	0.73	7.71	0.44	3.17e-13	Vitiligo;
KIRP	cis	rs1376877	0.519	rs10197623	chr2:204243759	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.51	5.28	0.32	2.84e-7	Subclinical atherosclerosis traits (other);
KIRP	cis	rs2120243	0.935	rs9681270	chr3:157143996	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.51	7.03	0.41	2e-11	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9826463	0.582	rs73238173	chr3:142110644	C/G	cg20824294	chr3:142316082	PLS1	0.39	5.86	0.35	1.47e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4789452	1.000	rs35971812	chr17:75373362	C/A	cg12985929	chr17:75370611	SEPT9	-0.43	-5.86	-0.35	1.51e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	0.96	14.8	0.69	7.24e-36	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs17221829	0.733	rs12797439	chr11:89376199	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg19847130	chr8:10466454	RP1L1	0.4	5.78	0.35	2.31e-8	Neuroticism;
KIRP	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-4.87	-0.3	1.99e-6	IgG glycosylation;
KIRP	cis	rs6832769	1.000	rs3805154	chr4:56363927	C/T	cg05960024	chr4:56376020	CLOCK	0.73	9.43	0.52	3.31e-18	Personality dimensions;
KIRP	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg09455208	chr3:40491958	NA	0.41	7.05	0.41	1.77e-11	Renal cell carcinoma;
KIRP	cis	rs7635838	0.892	rs9310384	chr3:11491980	A/G	cg00170343	chr3:11313890	ATG7	0.47	6.12	0.36	3.63e-9	HDL cholesterol;
KIRP	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.88	-10.61	-0.56	6.5600000000000005e-22	Gut microbiome composition (summer);
KIRP	cis	rs698833	0.819	rs1372078	chr2:44543389	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-5.14	-0.31	5.52e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1163251	0.623	rs493427	chr1:120207482	A/T	cg19096424	chr1:120255104	PHGDH	-0.47	-5.92	-0.35	1.1e-8	Blood metabolite levels;
KIRP	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.45	-0.38	5.78e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.48	-7.3	-0.42	3.91e-12	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.06	0.31	8.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	4.93e-23	Prudent dietary pattern;
KIRP	cis	rs5743618	0.537	rs10470854	chr4:38768533	A/G	cg06935464	chr4:38784597	TLR10	0.39	4.89	0.3	1.82e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11613427	chr3:52932208	TMEM110	-0.31	-5.15	-0.31	5.26e-7	Schizophrenia;
KIRP	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg15432903	chr11:17409602	KCNJ11	0.44	6.27	0.37	1.64e-9	Body mass index;Social communication problems;
KIRP	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg00310523	chr12:86230176	RASSF9	0.38	5.78	0.35	2.27e-8	Major depressive disorder;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-8.94	-0.5	9.47e-17	Longevity;Endometriosis;
KIRP	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg10636054	chr15:40330586	SRP14	0.68	6.34	0.37	1.09e-9	Response to haloperidol in psychosis;
KIRP	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.22e-13	Coronary artery calcification;
KIRP	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.72	5.79	0.35	2.12e-8	Diabetic retinopathy;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13846960	chr9:2718456	KCNV2	0.5	6.16	0.37	2.93e-9	Pancreatic cancer;
KIRP	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg18709589	chr6:96969512	KIAA0776	0.33	5.02	0.3	9.82e-7	Headache;
KIRP	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	1.17	7.66	0.44	4.38e-13	Type 2 diabetes nephropathy;
KIRP	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.7	-9.86	-0.53	1.53e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg12210378	chr14:105685021	BRF1	-0.39	-6.07	-0.36	4.75e-9	Coronary artery disease;
KIRP	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-6.57	-0.39	2.91e-10	Vitiligo;
KIRP	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.8	9.72	0.53	4.21e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs17030434	1.000	rs1456391	chr4:154720485	A/G	cg14289246	chr4:154710475	SFRP2	-0.8	-9.68	-0.53	5.45e-19	Electrocardiographic conduction measures;
KIRP	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs7624766	0.555	rs718757	chr3:160534225	A/G	cg22637730	chr3:160473554	PPM1L	-0.44	-5.48	-0.33	1.06e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs4845459	0.933	rs11205044	chr1:152593437	T/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.0	-0.36	7.01e-9	Psoriasis;
KIRP	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg14092571	chr14:90743983	NA	0.45	5.66	0.34	4.16e-8	Mortality in heart failure;
KIRP	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.63	-0.39	2.06e-10	Total body bone mineral density;
KIRP	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg17372223	chr3:52568218	NT5DC2	0.32	5.34	0.32	2.09e-7	Cognitive function;
KIRP	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg25319279	chr11:5960081	NA	-0.57	-5.77	-0.35	2.33e-8	DNA methylation (variation);
KIRP	cis	rs6009527	0.752	rs7286232	chr22:49568490	A/G	cg12746016	chr22:49560550	NA	0.44	6.23	0.37	2.01e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
KIRP	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg15507776	chr3:136538369	TMEM22	0.49	7.01	0.41	2.31e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg02838143	chr10:126606107	NA	0.53	6.78	0.4	8.7e-11	Myopia (pathological);
KIRP	cis	rs13065560	0.594	rs4575820	chr3:38886179	A/G	cg01426195	chr3:39028469	NA	0.45	6.91	0.4	4.07e-11	Interleukin-18 levels;
KIRP	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.46	5.97	0.36	8.17e-9	Gout;
KIRP	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.25	0.42	5.44e-12	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg13607699	chr17:42295918	UBTF	-0.47	-5.8	-0.35	2.05e-8	Total body bone mineral density;
KIRP	cis	rs6545883	1.000	rs6545883	chr2:61772257	A/G	cg15711740	chr2:61764176	XPO1	-0.56	-7.61	-0.44	5.78e-13	Tuberculosis;
KIRP	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg07777115	chr5:623756	CEP72	0.56	5.54	0.33	7.77e-8	Lung disease severity in cystic fibrosis;
KIRP	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.96e-18	Morning vs. evening chronotype;
KIRP	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.43	-6.45	-0.38	5.72e-10	Platelet distribution width;
KIRP	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.51	-7.21	-0.42	6.7e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg08662619	chr6:150070041	PCMT1	0.39	6.41	0.38	7.52e-10	Lung cancer;
KIRP	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg00864860	chr1:7907996	UTS2	-0.5	-5.96	-0.36	8.54e-9	Crohn's disease;
KIRP	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.58	9.41	0.51	3.62e-18	Coronary artery disease;
KIRP	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg17470449	chr10:769945	NA	0.57	6.04	0.36	5.56e-9	Uric acid levels;
KIRP	cis	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg02972257	chr16:68554789	NA	-0.58	-5.71	-0.34	3.25e-8	Ulcerative colitis;
KIRP	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg00852783	chr1:26633632	UBXN11	0.53	7.64	0.44	4.7e-13	Obesity-related traits;
KIRP	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.03	-0.31	9.35e-7	Morning vs. evening chronotype;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg15980914	chr19:28297092	NA	0.43	6.98	0.41	2.76e-11	Serum protein levels (sST2);
KIRP	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg16127683	chr15:40268777	EIF2AK4	0.32	5.08	0.31	7.31e-7	Response to haloperidol in psychosis;
KIRP	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.89	0.81	1.13e-59	Prudent dietary pattern;
KIRP	trans	rs12517041	1.000	rs10064195	chr5:23278179	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.86	-7.94	-0.45	7.27e-14	Calcium levels;
KIRP	cis	rs1018697	1.000	rs10786710	chr10:104548739	C/T	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.5	-6.11	-0.36	3.92e-9	Menarche (age at onset);
KIRP	cis	rs6982240	0.569	rs6992278	chr8:142279383	C/G	cg24134292	chr8:142315841	NA	-0.34	-4.95	-0.3	1.35e-6	Tonsillectomy;
KIRP	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs2862064	0.932	rs1393208	chr5:156477725	G/A	cg12943317	chr5:156479607	HAVCR1	-0.89	-8.0	-0.45	4.8e-14	Platelet count;
KIRP	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	11.76	0.6	1.23e-25	Electrocardiographic conduction measures;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg21523564	chr15:75251491	NA	0.41	6.66	0.39	1.79e-10	Breast cancer;
KIRP	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.81	-10.87	-0.57	9.75e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs7129556	0.911	rs10899394	chr11:77324261	A/G	cg12586386	chr11:77299805	AQP11	0.43	5.67	0.34	4.09e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs2635047	0.615	rs938134	chr18:44751374	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	6.87	0.4	5.13e-11	Educational attainment;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11648981	chr1:108331378	VAV3	0.46	6.51	0.38	4.13e-10	Survival in pancreatic cancer;
KIRP	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg23307798	chr14:103986281	CKB	-0.51	-6.82	-0.4	7.21e-11	Coronary artery disease;
KIRP	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.5	7.16	0.42	9.39e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.59	-9.22	-0.51	1.39e-17	Longevity;
KIRP	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	1.04	14.41	0.68	1.47e-34	Menopause (age at onset);
KIRP	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.58	-0.34	6.31e-8	Headache;
KIRP	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg12573674	chr2:1569213	NA	-0.58	-5.49	-0.33	9.84e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9783347	0.961	rs4150588	chr11:18360131	G/A	cg15585147	chr11:18324498	HPS5	0.37	4.97	0.3	1.27e-6	Pancreatic cancer;
KIRP	cis	rs2051773	0.539	rs6486345	chr11:17038777	A/G	cg15432903	chr11:17409602	KCNJ11	-0.49	-5.91	-0.35	1.14e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-4.96	-0.3	1.29e-6	Electroencephalogram traits;
KIRP	cis	rs250677	0.687	rs250679	chr5:148434952	A/T	cg12140854	chr5:148520817	ABLIM3	0.5	5.28	0.32	2.82e-7	Breast cancer;
KIRP	cis	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg21546286	chr11:48923668	NA	0.51	6.67	0.39	1.65e-10	HDL cholesterol;
KIRP	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.4	4.97	0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg21698718	chr17:80085957	CCDC57	0.37	5.4	0.33	1.58e-7	Life satisfaction;
KIRP	cis	rs6102059	0.667	rs6124254	chr20:39218023	C/G	cg22477343	chr20:39312069	NA	0.48	6.37	0.38	9.48e-10	LDL cholesterol;
KIRP	trans	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg06521331	chr12:34319734	NA	-0.58	-7.05	-0.41	1.83e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.53	6.24	0.37	1.94e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.17	25.54	0.85	3.95e-71	Schizophrenia;
KIRP	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg23202291	chr11:1979235	NA	0.42	5.41	0.33	1.51e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs10518128	0.850	rs72867583	chr4:75699724	T/A	cg20122727	chr4:75719957	BTC	0.59	5.95	0.35	9.21e-9	Electroencephalogram traits;
KIRP	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.61	-0.34	5.4e-8	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs4700695	0.841	rs152933	chr5:65359530	A/G	cg21114390	chr5:65439923	SFRS12	-0.57	-6.03	-0.36	6.01e-9	Facial morphology (factor 19);
KIRP	cis	rs6690583	0.538	rs963488	chr1:85542687	C/T	cg22153463	chr1:85462885	MCOLN2	-0.48	-4.86	-0.3	2.11e-6	Serum sulfate level;
KIRP	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg15128208	chr22:42549153	NA	0.72	8.22	0.46	1.16e-14	Birth weight;
KIRP	cis	rs2904967	0.929	rs1783486	chr11:65008917	A/G	cg09225861	chr11:65069680	NA	-0.41	-5.02	-0.3	1.01e-6	Mean corpuscular volume;
KIRP	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg17182837	chr8:41585554	ANK1	-0.5	-5.31	-0.32	2.47e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	6.14	0.36	3.24e-9	Personality dimensions;
KIRP	cis	rs7215564	0.818	rs35459747	chr17:78661475	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.2e-7	Myopia (pathological);
KIRP	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.69	-7.92	-0.45	8.39e-14	Lung cancer;
KIRP	cis	rs2483058	0.767	rs10779631	chr1:206622288	C/T	cg19452316	chr1:206680966	RASSF5	0.41	5.53	0.33	7.98e-8	Cholesterol and Triglycerides;
KIRP	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.7	-0.34	3.4e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4700695	0.841	rs706680	chr5:65317338	T/C	cg21114390	chr5:65439923	SFRS12	0.62	6.66	0.39	1.82e-10	Facial morphology (factor 19);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13981034	chr14:21860709	SNORD9;CHD8	0.61	7.51	0.43	1.08e-12	Interleukin-4 levels;
KIRP	cis	rs4594175	0.707	rs4901096	chr14:51722826	G/C	cg23942311	chr14:51606299	NA	0.42	5.46	0.33	1.18e-7	Cancer;
KIRP	trans	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg06521331	chr12:34319734	NA	-0.6	-7.13	-0.41	1.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.66	-8.54	-0.48	1.4e-15	Calcium levels;
KIRP	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.5	6.15	0.37	3.09e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.77	8.65	0.48	6.67e-16	Coronary artery disease;
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg19536664	chr17:6899085	ALOX12	0.45	6.77	0.4	9.56e-11	Tonsillectomy;
KIRP	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg21926883	chr2:100939477	LONRF2	-0.53	-6.98	-0.41	2.73e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.29	-0.47	7.54e-15	Monocyte percentage of white cells;
KIRP	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg00800038	chr16:89945340	TCF25	-0.78	-5.27	-0.32	3.04e-7	Skin colour saturation;
KIRP	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.77	-11.46	-0.59	1.18e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.46	6.66	0.39	1.79e-10	Sitting height ratio;
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg01798813	chr17:3906674	NA	-0.51	-7.08	-0.41	1.47e-11	Type 2 diabetes;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.48	5.98	0.36	7.92e-9	Initial pursuit acceleration;
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg21698718	chr17:80085957	CCDC57	-0.36	-5.11	-0.31	6.56e-7	Life satisfaction;
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg09597638	chr17:3907349	NA	-0.74	-13.8	-0.66	1.77e-32	Type 2 diabetes;
KIRP	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg13010199	chr12:38710504	ALG10B	0.62	7.71	0.44	3.18e-13	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Bipolar disorder;
KIRP	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.66	-8.23	-0.46	1.13e-14	Blood metabolite levels;
KIRP	cis	rs12986413	1.000	rs12982593	chr19:2175891	C/A	cg09261902	chr19:2140048	AP3D1	0.64	10.0	0.54	5.7e-20	Height;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09172817	chr18:9915098	VAPA	0.97	6.55	0.39	3.26e-10	P wave terminal force;
KIRP	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.54	-6.69	-0.39	1.48e-10	Coronary artery disease;
KIRP	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.42	5.16	0.31	5.05e-7	Diabetic retinopathy;
KIRP	trans	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg24644049	chr4:85504048	CDS1	1.09	6.99	0.41	2.59e-11	Skin colour saturation;
KIRP	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg08975724	chr8:8085496	FLJ10661	0.65	8.73	0.49	3.95e-16	Systemic lupus erythematosus;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg08132940	chr7:1081526	C7orf50	-0.62	-6.29	-0.37	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs193541	0.632	rs430069	chr5:122263351	G/A	cg19412675	chr5:122181750	SNX24	0.61	6.35	0.38	1.03e-9	Glucose homeostasis traits;
KIRP	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg07596299	chr11:71824057	C11orf51	-0.86	-5.73	-0.34	2.95e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg23231163	chr10:75533350	FUT11	-0.34	-5.11	-0.31	6.6e-7	Inflammatory bowel disease;
KIRP	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg10117171	chr1:25599238	RHD	-0.37	-5.1	-0.31	6.93e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg11846333	chr4:119757529	SEC24D	-1.13	-6.37	-0.38	9.03e-10	Cannabis dependence symptom count;
KIRP	cis	rs1440410	0.835	rs11725565	chr4:144137359	C/T	cg01719995	chr4:144104893	USP38	-0.45	-6.14	-0.36	3.28e-9	Ischemic stroke;
KIRP	cis	rs4076764	0.522	rs10799914	chr1:163353205	A/G	cg24596788	chr1:163392923	NA	-0.37	-5.24	-0.32	3.4e-7	Motion sickness;
KIRP	cis	rs4594175	0.926	rs4901083	chr14:51604998	C/A	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs7903847	0.642	rs7092350	chr10:99140218	A/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.9	-0.35	1.17e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.76	-8.87	-0.49	1.57e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs600806	1.000	rs600806	chr1:109840629	A/G	cg02175308	chr1:109941060	SORT1	0.3	5.52	0.33	8.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg20302533	chr7:39170763	POU6F2	0.26	5.18	0.31	4.7e-7	IgG glycosylation;
KIRP	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs3120667	0.720	rs72698963	chr1:152416482	G/C	cg26876637	chr1:152193138	HRNR	-0.64	-5.96	-0.36	8.74e-9	Eating disorders;
KIRP	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.2	-0.31	4.25e-7	Ulcerative colitis;
KIRP	cis	rs3087591	0.553	rs2854334	chr17:29715500	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	9.6	0.52	9.37e-19	Hip circumference;
KIRP	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg10326726	chr10:51549505	MSMB	0.56	7.96	0.45	6.4e-14	Prostate-specific antigen levels;
KIRP	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg26384229	chr12:38710491	ALG10B	0.71	9.79	0.53	2.49e-19	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.56	-7.24	-0.42	5.74e-12	Aortic root size;
KIRP	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.0	11.16	0.58	1.12e-23	Body mass index;
KIRP	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.69	9.12	0.5	2.8e-17	Bladder cancer;
KIRP	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11620689	chr3:105244696	ALCAM	-0.45	-6.65	-0.39	1.93e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg13293535	chr8:11597251	GATA4	0.38	4.88	0.3	1.87e-6	Retinal vascular caliber;
KIRP	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg03929089	chr4:120376271	NA	0.75	6.66	0.39	1.74e-10	Intraocular pressure;
KIRP	cis	rs4704187	0.687	rs11957125	chr5:74527639	G/A	cg03227963	chr5:74354835	NA	0.4	5.82	0.35	1.84e-8	Response to amphetamines;
KIRP	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.9	-11.62	-0.6	3.47e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg21734707	chr17:3908241	ZZEF1	0.63	9.55	0.52	1.35e-18	Type 2 diabetes;
KIRP	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg08603382	chr10:743973	NA	0.48	6.9	0.4	4.39e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg12315302	chr6:26189340	HIST1H4D	0.73	5.27	0.32	3.01e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.62	-7.72	-0.44	2.98e-13	Body mass index;
KIRP	cis	rs1497828	0.871	rs2646842	chr1:217555946	G/A	cg04411442	chr1:217543379	NA	0.41	6.19	0.37	2.53e-9	Dialysis-related mortality;
KIRP	cis	rs2224391	0.628	rs2753231	chr6:5248915	C/A	cg13962347	chr6:5174647	LYRM4	-0.72	-9.91	-0.53	1.1e-19	Height;
KIRP	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg14456004	chr13:21872349	NA	-1.14	-14.21	-0.67	7.06e-34	White matter hyperintensity burden;
KIRP	cis	rs1359582	0.661	rs814633	chr10:90416756	A/T	cg15661332	chr10:90342814	RNLS	-0.57	-5.82	-0.35	1.82e-8	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg00405596	chr8:11794950	NA	-0.48	-6.29	-0.37	1.48e-9	Monocyte count;
KIRP	cis	rs17106184	1.000	rs11205773	chr1:51284905	C/T	cg07174182	chr1:51127561	FAF1	0.58	4.89	0.3	1.8e-6	Type 2 diabetes;
KIRP	cis	rs7615316	0.763	rs10935465	chr3:142271797	A/C	cg20824294	chr3:142316082	PLS1	0.23	5.02	0.3	9.86e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg13206674	chr6:150067644	NUP43	0.52	7.41	0.43	1.96e-12	Testicular germ cell tumor;
KIRP	cis	rs9886651	0.905	rs10110243	chr8:128805020	A/G	cg24514600	chr8:128805414	PVT1	-0.73	-12.54	-0.62	3.17e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs7561273	0.609	rs2080727	chr2:24350907	A/G	cg20701182	chr2:24300061	SF3B14	0.49	6.03	0.36	5.88e-9	Quantitative traits;
KIRP	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.83	-0.49	2.01e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.9	14.09	0.67	1.86e-33	Height;
KIRP	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs4845459	0.967	rs6701307	chr1:152590444	G/A	cg07796016	chr1:152779584	LCE1C	-0.49	-6.04	-0.36	5.63e-9	Psoriasis;
KIRP	cis	rs12615966	0.651	rs72830472	chr2:105407426	C/T	cg16465502	chr2:105461796	NA	0.95	7.88	0.45	1.05e-13	Pancreatic cancer;
KIRP	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.79	10.69	0.56	3.81e-22	Aortic root size;
KIRP	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg00981070	chr1:2046702	PRKCZ	-0.42	-6.93	-0.4	3.64e-11	Height;
KIRP	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs933360	0.585	rs10281065	chr7:50829973	G/T	cg14240098	chr7:50518052	FIGNL1	-0.45	-5.03	-0.31	9.45e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs4716602	0.586	rs13224457	chr7:156161005	G/T	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs2071426	0.959	rs35427080	chr10:96803649	A/G	cg09036531	chr10:96991505	NA	-0.63	-6.96	-0.41	3e-11	Blood metabolite levels;
KIRP	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.62	-7.76	-0.44	2.23e-13	Dental caries;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06048524	chr10:44880542	CXCL12	0.44	6.16	0.37	3.02e-9	Parkinson's disease;
KIRP	cis	rs10982256	0.774	rs10759711	chr9:117253308	T/G	cg13636371	chr9:117264095	DFNB31	0.58	8.29	0.47	7.39e-15	Bipolar disorder;
KIRP	trans	rs2488389	0.513	rs2821108	chr1:197342686	T/C	cg08466517	chr4:122138632	TNIP3	-0.48	-6.16	-0.37	2.97e-9	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs9308731	1.000	rs6746608	chr2:111892984	C/T	cg23466623	chr2:111982296	NA	0.43	5.47	0.33	1.13e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.12	-0.36	3.73e-9	Red cell distribution width;
KIRP	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.79	-10.29	-0.55	7e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs494562	0.892	rs9353310	chr6:86126199	C/T	cg27039625	chr6:86159096	NT5E	0.49	6.07	0.36	4.82e-9	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg19847130	chr8:10466454	RP1L1	0.46	6.74	0.39	1.1e-10	Joint mobility (Beighton score);
KIRP	cis	rs2274273	1.000	rs66871576	chr14:55629050	C/T	cg04306507	chr14:55594613	LGALS3	0.44	6.78	0.4	8.74e-11	Protein biomarker;
KIRP	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.81	9.62	0.52	8.69e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.86	-0.3	2.13e-6	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg05754148	chr16:3507555	NAT15	0.49	4.89	0.3	1.79e-6	Tuberculosis;
KIRP	cis	rs9469913	0.799	rs3800457	chr6:34663598	C/T	cg17674042	chr6:34482479	PACSIN1	0.47	6.28	0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.75	-0.34	2.68e-8	IgG glycosylation;
KIRP	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.64	9.25	0.51	1.14e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.45	5.23	0.32	3.58e-7	Body mass index;
KIRP	cis	rs236907	0.812	rs35249022	chr1:171760767	A/G	cg01410279	chr1:171621941	MYOC	-0.49	-5.57	-0.33	6.83e-8	Mean platelet volume;
KIRP	trans	rs9371601	0.859	rs214951	chr6:152721029	T/C	cg05529123	chr2:66910386	NA	-0.46	-6.43	-0.38	6.51e-10	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-6.58	-0.39	2.89e-10	Body mass index;
KIRP	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.9	14.14	0.67	1.24e-33	Height;
KIRP	cis	rs258892	0.895	rs155429	chr5:72108080	G/A	cg21869765	chr5:72125136	TNPO1	-0.56	-6.18	-0.37	2.57e-9	Small cell lung carcinoma;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.85	0.63	2.85e-29	Platelet count;
KIRP	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.34	-4.85	-0.3	2.19e-6	IgG glycosylation;
KIRP	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg24565620	chr2:194026	NA	0.75	8.09	0.46	2.73e-14	Blood protein levels;
KIRP	cis	rs4764487	0.735	rs2159521	chr12:6349328	A/G	cg08284733	chr12:6341482	CD9	0.62	11.18	0.58	9.69e-24	Mean platelet volume;
KIRP	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg00310523	chr12:86230176	RASSF9	-0.39	-6.03	-0.36	6.11e-9	Major depressive disorder;
KIRP	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.86	-11.2	-0.58	8.51e-24	Cognitive function;
KIRP	cis	rs554111	0.660	rs541464	chr1:21067095	C/T	cg21184320	chr1:21044207	KIF17	0.4	5.9	0.35	1.2e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.32	-0.42	3.57e-12	Initial pursuit acceleration;
KIRP	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg18833306	chr6:118973337	C6orf204	0.39	5.12	0.31	6.12e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	4.87	0.3	2.02e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.17	-0.37	2.83e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.27	-0.32	2.95e-7	Fibrinogen levels;
KIRP	cis	rs526231	0.543	rs246916	chr5:102557515	T/C	cg23492399	chr5:102201601	PAM	-0.49	-5.29	-0.32	2.64e-7	Primary biliary cholangitis;
KIRP	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.42	5.6	0.34	5.57e-8	Immature fraction of reticulocytes;
KIRP	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg10047753	chr17:41438598	NA	0.83	11.36	0.59	2.55e-24	Menopause (age at onset);
KIRP	cis	rs12615966	1.000	rs55805894	chr2:105380420	A/T	cg16465502	chr2:105461796	NA	0.55	5.22	0.32	3.73e-7	Pancreatic cancer;
KIRP	cis	rs2708977	0.643	rs35071802	chr2:97402064	T/C	cg01950434	chr2:97203154	ARID5A	0.48	5.8	0.35	1.98e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs16828019	0.777	rs35080169	chr1:41454959	G/A	cg03387723	chr1:41708464	SCMH1	-0.75	-6.05	-0.36	5.48e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg23985595	chr17:80112537	CCDC57	0.34	5.11	0.31	6.35e-7	Life satisfaction;
KIRP	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg00745463	chr17:30367425	LRRC37B	-0.67	-6.67	-0.39	1.63e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.67	8.67	0.48	5.79e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.77	-11.54	-0.59	6.39e-25	Obesity-related traits;
KIRP	cis	rs600806	0.850	rs4120621	chr1:109949008	A/G	cg02175308	chr1:109941060	SORT1	-0.26	-4.92	-0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs1941687	0.702	rs9956636	chr18:31304974	C/T	cg27147174	chr7:100797783	AP1S1	-0.59	-7.46	-0.43	1.51e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg21479132	chr6:26055353	NA	0.73	4.89	0.3	1.83e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.67	10.4	0.55	3.04e-21	Pulse pressure;
KIRP	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg04725166	chr1:7887271	PER3	-0.36	-5.8	-0.35	2.06e-8	Crohn's disease;
KIRP	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.42	-0.33	1.41e-7	Platelet count;
KIRP	cis	rs2151522	0.526	rs12234117	chr6:127203296	T/C	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs4143844	0.867	rs11555596	chr15:62145955	C/T	cg04814990	chr13:111957387	ARHGEF7	0.98	6.47	0.38	5.18e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13783244	chr4:140005441	ELF2	0.43	6.05	0.36	5.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.73	10.36	0.55	4.17e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.46	-0.38	5.45e-10	Mood instability;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg22776125	chr6:167041314	RPS6KA2	0.69	6.5	0.38	4.38e-10	Lung function (FEV1);
KIRP	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg09253696	chr17:73873529	TRIM47	-0.34	-4.99	-0.3	1.12e-6	Psoriasis;
KIRP	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg27432699	chr2:27873401	GPN1	-0.47	-5.88	-0.35	1.32e-8	Total body bone mineral density;
KIRP	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.38	0.32	1.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg23985595	chr17:80112537	CCDC57	0.36	5.59	0.34	6.16e-8	Life satisfaction;
KIRP	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16644764	chr1:117210276	IGSF3	-0.58	-7.49	-0.43	1.25e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg13628971	chr7:2884303	GNA12	0.4	4.96	0.3	1.32e-6	Height;
KIRP	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06544989	chr22:39130855	UNC84B	0.43	7.04	0.41	1.92e-11	Menopause (age at onset);
KIRP	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg11965913	chr1:205819406	PM20D1	0.54	6.06	0.36	4.95e-9	Prostate-specific antigen levels;
KIRP	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg06223162	chr1:101003688	GPR88	-0.43	-8.8	-0.49	2.41e-16	Monocyte count;
KIRP	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg18350739	chr11:68623251	NA	-0.48	-7.45	-0.43	1.6e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00321850	chr1:175162397	KIAA0040	0.36	6.47	0.38	5.28e-10	Alcohol dependence;
KIRP	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.95	0.4	3.32e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4716602	0.596	rs10275400	chr7:156161550	A/G	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.82	-11.89	-0.6	4.7e-26	Blood metabolite levels;
KIRP	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.57	0.33	6.76e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-7.54	-0.43	9.03e-13	Mean corpuscular volume;
KIRP	trans	rs9944715	0.954	rs9960378	chr18:43811262	G/A	cg01718231	chr17:29326311	RNF135	-0.5	-6.03	-0.36	6.11e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs78487399	0.808	rs76282560	chr2:43682635	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.89	-0.3	1.85e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.15	0.69	4.56e-37	Metabolic syndrome;
KIRP	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.24	-0.62	3.27e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.55	0.43	8.46e-13	IgG glycosylation;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26748024	chr6:42420298	TRERF1	-0.57	-6.43	-0.38	6.51e-10	Menopause (age at onset);
KIRP	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	1.08	22.49	0.82	1.31e-61	Parkinson's disease;
KIRP	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	7.97	0.45	6.08e-14	Systolic blood pressure;
KIRP	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17376030	chr22:41985996	PMM1	0.69	7.53	0.43	9.54e-13	Vitiligo;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23437337	chr4:54239663	NA	0.45	6.52	0.38	4.01e-10	Interleukin-4 levels;
KIRP	cis	rs2820315	1.000	rs2678204	chr1:201800511	T/G	cg11586189	chr1:201857591	SHISA4	-0.42	-6.03	-0.36	5.96e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs4236601	0.720	rs17588172	chr7:116154015	G/T	cg05166801	chr7:116143459	CAV2	-0.49	-6.2	-0.37	2.41e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs12580194	0.593	rs11171432	chr12:55757696	G/C	cg19537932	chr12:55886519	OR6C68	-0.47	-6.22	-0.37	2.12e-9	Cancer;
KIRP	cis	rs1485395	0.588	rs7969195	chr12:53942789	G/A	cg16917193	chr12:54089295	NA	0.63	5.72	0.34	3.04e-8	Migraine without aura;
KIRP	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.46	-0.38	5.54e-10	Response to antipsychotic treatment;
KIRP	cis	rs240764	0.817	rs240110	chr6:101059629	T/C	cg09795085	chr6:101329169	ASCC3	0.43	5.16	0.31	5.2e-7	Neuroticism;
KIRP	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.69e-15	Aortic root size;
KIRP	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.68	-0.44	3.66e-13	Total cholesterol levels;
KIRP	cis	rs988913	1.000	rs9367600	chr6:54837977	T/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.5	-0.33	9.29e-8	Menarche (age at onset);
KIRP	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs2997447	0.723	rs61776623	chr1:26474490	A/G	cg19633962	chr1:26362018	EXTL1	-0.55	-4.88	-0.3	1.92e-6	QRS complex (12-leadsum);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02570171	chr17:39822195	NA	0.45	6.06	0.36	5.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg23903597	chr17:61704154	MAP3K3	-0.42	-5.24	-0.32	3.52e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg14675211	chr2:100938903	LONRF2	0.56	7.12	0.41	1.18e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg16961080	chr7:75115640	POM121C	-0.47	-6.2	-0.37	2.32e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs73200209	0.744	rs73198012	chr12:116463855	G/A	cg01776926	chr12:116560359	MED13L	-0.55	-5.47	-0.33	1.1e-7	Total body bone mineral density;
KIRP	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg02002194	chr4:3960332	NA	0.45	6.36	0.38	9.55e-10	Neuroticism;
KIRP	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26207909	chr14:103986467	CKB	0.54	7.13	0.41	1.09e-11	Body mass index;
KIRP	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.56	-7.17	-0.42	8.62e-12	Prudent dietary pattern;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.63	8.63	0.48	7.62e-16	Mean corpuscular volume;
KIRP	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.78	-0.35	2.27e-8	Chronic sinus infection;
KIRP	cis	rs72829446	0.932	rs62059822	chr17:7470560	G/A	cg02795151	chr17:7402630	POLR2A	0.71	4.93	0.3	1.52e-6	Androgen levels;
KIRP	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.51	0.33	9.06e-8	Schizophrenia;
KIRP	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.36	0.51	5.16e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.72	-12.94	-0.64	1.49e-29	Body mass index;
KIRP	cis	rs4704187	0.687	rs10942732	chr5:74538259	A/G	cg03227963	chr5:74354835	NA	0.43	6.23	0.37	2.03e-9	Response to amphetamines;
KIRP	cis	rs7172677	0.793	rs8029712	chr15:75418170	T/A	cg14082893	chr15:75400931	NA	0.34	5.17	0.31	4.73e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2274273	0.901	rs17674563	chr14:55831125	G/A	cg04306507	chr14:55594613	LGALS3	0.4	5.85	0.35	1.54e-8	Protein biomarker;
KIRP	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.44	-0.33	1.26e-7	Blood metabolite levels;
KIRP	cis	rs2742417	1.000	rs2742437	chr3:45743277	G/A	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	2.95e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7546094	0.530	rs2999158	chr1:113239478	T/C	cg22162597	chr1:113214053	CAPZA1	-0.49	-5.59	-0.34	6.06e-8	Platelet distribution width;
KIRP	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg23307798	chr14:103986281	CKB	-0.82	-14.64	-0.68	2.49e-35	Body mass index;
KIRP	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Bipolar disorder;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02331583	chr17:40021711	KLHL11	-0.59	-6.92	-0.4	3.89e-11	Brain structure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12977696	chr17:1303516	YWHAE	0.56	6.98	0.41	2.79e-11	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10309340	chr10:102747329	C10orf2;MRPL43	0.47	6.29	0.37	1.46e-9	Parkinson's disease;
KIRP	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg21573476	chr21:45109991	RRP1B	0.61	8.2	0.46	1.29e-14	Mean corpuscular volume;
KIRP	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.67	6.81	0.4	7.55e-11	Vitiligo;
KIRP	trans	rs9989735	0.572	rs933957	chr2:231177904	T/C	cg11004284	chr3:15470105	METTL6;EAF1	0.45	6.04	0.36	5.6e-9	Crohn's disease;
KIRP	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg11621586	chr10:70884670	VPS26A	1.09	13.49	0.65	2.04e-31	Left atrial antero-posterior diameter;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20142390	chr21:40564147	BRWD1	-0.41	-6.17	-0.37	2.81e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.62	-9.02	-0.5	5.55e-17	Urate levels in overweight individuals;
KIRP	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17554472	chr22:41940697	POLR3H	0.73	7.47	0.43	1.42e-12	Vitiligo;
KIRP	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.5	-0.59	8.96e-25	Blood metabolite levels;
KIRP	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.65	8.91	0.49	1.2e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9584850	0.794	rs72655609	chr13:99128622	C/G	cg20750642	chr13:99100586	FARP1	-0.55	-6.44	-0.38	6.26e-10	Neuroticism;
KIRP	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	6.56	0.39	3.09e-10	Height;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg15181151	chr6:150070149	PCMT1	0.29	4.89	0.3	1.8e-6	Lung cancer;
KIRP	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.18	-21.84	-0.81	1.65e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4132509	0.947	rs10927041	chr1:243731890	T/C	cg21452805	chr1:244014465	NA	0.56	5.73	0.34	2.91e-8	RR interval (heart rate);
KIRP	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg16898833	chr6:26189333	HIST1H4D	0.64	4.91	0.3	1.68e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23422044	chr7:1970798	MAD1L1	-0.69	-7.18	-0.42	8.39e-12	Bipolar disorder;
KIRP	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.03	11.68	0.6	2.37e-25	Gut microbiome composition (summer);
KIRP	trans	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg10756647	chr7:56101905	PSPH	1.01	7.5	0.43	1.16e-12	Diabetic kidney disease;
KIRP	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.3	-0.37	1.36e-9	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12126796	chr10:123687380	ATE1	0.47	6.19	0.37	2.46e-9	Parkinson's disease;
KIRP	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg21132104	chr15:45694354	SPATA5L1	0.51	6.08	0.36	4.52e-9	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg07051648	chr19:49177693	NTN5;SEC1	-0.47	-5.98	-0.36	7.76e-9	Dietary macronutrient intake;
KIRP	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.46	5.34	0.32	2.09e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg03351412	chr1:154909251	PMVK	0.6	7.55	0.43	8.6e-13	Prostate cancer;
KIRP	cis	rs6541297	0.887	rs6541295	chr1:230281698	A/G	cg05784532	chr1:230284198	GALNT2	0.5	6.24	0.37	1.91e-9	Coronary artery disease;
KIRP	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg16989719	chr2:238392110	NA	0.54	7.15	0.41	9.72e-12	Prostate cancer;
KIRP	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.62	-0.34	5.17e-8	Aortic root size;
KIRP	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.15	0.31	5.36e-7	Menopause (age at onset);
KIRP	cis	rs4566357	1.000	rs2177598	chr2:227922900	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.07	-0.31	7.96e-7	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.42	7.23	0.42	6.05e-12	Renal cell carcinoma;
KIRP	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.43	5.73	0.34	2.9e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg12131826	chr15:77904385	NA	-0.49	-6.46	-0.38	5.65e-10	Type 2 diabetes;
KIRP	cis	rs4414128	0.778	rs2386655	chr10:5673528	G/A	cg12223502	chr10:5658492	NA	0.52	5.7	0.34	3.36e-8	Breast cancer;
KIRP	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.48	-4.87	-0.3	2.03e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.86e-15	Neutrophil percentage of white cells;
KIRP	cis	rs2625529	0.689	rs12898868	chr15:72112918	A/G	cg16672083	chr15:72433130	SENP8	0.44	6.26	0.37	1.72e-9	Red blood cell count;
KIRP	cis	rs7039377	0.554	rs7873962	chr9:38673606	T/G	cg14625731	chr9:38672608	NA	-0.36	-4.98	-0.3	1.2e-6	Obesity-related traits;
KIRP	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	1.09	8.89	0.49	1.35e-16	Plasma clusterin levels;
KIRP	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg27205649	chr11:78285834	NARS2	0.68	9.0	0.5	6.16e-17	Alzheimer's disease (survival time);
KIRP	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18854735	chr1:1822972	GNB1	-0.56	-7.13	-0.41	1.09e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.58	0.63	2.45e-28	Morning vs. evening chronotype;
KIRP	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	4.86	0.3	2.07e-6	Rheumatoid arthritis;
KIRP	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg02073558	chr3:44770973	ZNF501	0.59	8.21	0.46	1.29e-14	Depressive symptoms;
KIRP	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg15488143	chr7:128924101	AHCYL2	0.62	6.79	0.4	8.54e-11	White matter hyperintensity burden;
KIRP	trans	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg10756647	chr7:56101905	PSPH	1.01	7.5	0.43	1.16e-12	Diabetic kidney disease;
KIRP	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg10381502	chr11:71823885	C11orf51	-1.17	-8.23	-0.46	1.08e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg21625330	chr8:9911636	MSRA	-0.38	-5.01	-0.3	1.04e-6	Neuroticism;
KIRP	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.97	16.13	0.72	2.03e-40	Bone mineral density;
KIRP	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg14580859	chr9:123691850	NA	0.35	4.94	0.3	1.43e-6	Rheumatoid arthritis;
KIRP	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.37	-5.17	-0.31	4.92e-7	Educational attainment;
KIRP	cis	rs9443189	0.950	rs276698	chr6:76473071	T/C	cg01950844	chr6:76311363	SENP6	0.52	5.27	0.32	2.95e-7	Prostate cancer;
KIRP	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.45	-6.04	-0.36	5.64e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg14675211	chr2:100938903	LONRF2	0.55	6.94	0.4	3.38e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.83	-0.4	6.67e-11	Lung cancer;
KIRP	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg19847130	chr8:10466454	RP1L1	0.34	5.26	0.32	3.2e-7	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg13939156	chr17:80058883	NA	-0.49	-7.4	-0.43	2.2e-12	Life satisfaction;
KIRP	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.99	13.28	0.65	1.02e-30	Cognitive function;
KIRP	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg05973401	chr12:123451056	ABCB9	-0.58	-5.29	-0.32	2.74e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs2213920	0.679	rs7862261	chr9:118187677	A/G	cg13918206	chr9:118159781	DEC1	1.0	10.45	0.55	2.2e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg07274523	chr3:49395745	GPX1	0.69	8.58	0.48	1.08e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.84	11.37	0.59	2.3e-24	Morning vs. evening chronotype;
KIRP	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg24972876	chr7:65420302	NA	0.44	6.37	0.38	8.99e-10	Calcium levels;
KIRP	cis	rs7078012	0.504	rs17878361	chr10:81688477	C/T	cg24613050	chr10:81743128	NA	-0.53	-4.96	-0.3	1.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06998765	chr14:75389618	RPS6KL1	0.25	4.97	0.3	1.27e-6	Caffeine consumption;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs7666738	0.546	rs13105521	chr4:98734419	C/T	cg05340658	chr4:99064831	C4orf37	0.65	7.79	0.44	1.84e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	10.13	0.54	2.17e-20	Prudent dietary pattern;
KIRP	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07570687	chr10:102243282	WNT8B	0.51	6.26	0.37	1.74e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs8018808	0.935	rs4899655	chr14:77898077	G/A	cg20045696	chr14:77926864	AHSA1	0.45	5.46	0.33	1.17e-7	Myeloid white cell count;
KIRP	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.44	-5.83	-0.35	1.7e-8	Blood metabolite levels;
KIRP	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg19875535	chr5:140030758	IK	0.66	9.27	0.51	9.77e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	12.08	0.61	1.07e-26	Smoking behavior;
KIRP	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12292205	chr6:26970375	C6orf41	-0.65	-7.34	-0.42	3.09e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.54	-6.4	-0.38	7.95e-10	Corneal astigmatism;
KIRP	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg16680214	chr1:154839983	KCNN3	-0.41	-6.34	-0.37	1.11e-9	Prostate cancer;
KIRP	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.72	-12.98	-0.64	1.09e-29	Body mass index;
KIRP	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg16141378	chr3:129829833	LOC729375	0.54	7.07	0.41	1.61e-11	Retinal vascular caliber;
KIRP	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.82	13.0	0.64	9.12e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2997105	1.000	rs9597262	chr13:56349749	G/A	cg08528735	chr3:184428879	MAGEF1	0.57	6.19	0.37	2.54e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23903597	chr17:61704154	MAP3K3	-0.56	-6.98	-0.41	2.67e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.03	-0.36	5.82e-9	Depression;
KIRP	cis	rs2223471	0.967	rs2281158	chr6:50730735	C/G	cg03432817	chr6:50765336	NA	-0.51	-8.19	-0.46	1.41e-14	Subcutaneous adipose tissue;
KIRP	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.96	14.78	0.69	8.24e-36	Multiple system atrophy;
KIRP	cis	rs4742903	0.967	rs10820610	chr9:106907819	G/A	cg14250997	chr9:106856677	SMC2	0.4	5.22	0.32	3.76e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.7	-7.56	-0.43	8.01e-13	Breast cancer;
KIRP	cis	rs988913	0.957	rs9475068	chr6:54791581	A/G	cg03513858	chr6:54763001	FAM83B	-0.39	-5.48	-0.33	1.05e-7	Menarche (age at onset);
KIRP	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.74	11.62	0.6	3.52e-25	Resting heart rate;
KIRP	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.06	-0.31	8.37e-7	Psoriasis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16140139	chr2:44126665	LRPPRC	-0.43	-6.75	-0.4	1.03e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11671005	0.568	rs73068325	chr19:59079096	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.55	-6.35	-0.38	1.06e-9	Mean platelet volume;
KIRP	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.43	-0.33	1.37e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-0.57	-8.19	-0.46	1.4e-14	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	1.11	17.89	0.75	2.12e-46	Homoarginine levels;
KIRP	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.74	12.15	0.61	6.32e-27	Metabolite levels;
KIRP	cis	rs2839627	0.598	rs56098337	chr21:44271365	G/T	cg03543861	chr21:44258195	NA	0.54	6.03	0.36	5.98e-9	Information processing speed;
KIRP	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.62	8.84	0.49	1.87e-16	Morning vs. evening chronotype;
KIRP	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.54	-7.02	-0.41	2.17e-11	Blood metabolite levels;
KIRP	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg07884673	chr3:53033167	SFMBT1	0.92	6.93	0.4	3.64e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg07796016	chr1:152779584	LCE1C	-0.45	-5.73	-0.34	2.87e-8	Inflammatory skin disease;
KIRP	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg08975724	chr8:8085496	FLJ10661	0.65	9.05	0.5	4.59e-17	Retinal vascular caliber;
KIRP	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg17644776	chr2:200775616	C2orf69	0.56	5.89	0.35	1.25e-8	Schizophrenia;
KIRP	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg00129232	chr17:37814104	STARD3	0.41	4.95	0.3	1.35e-6	Asthma;
KIRP	cis	rs3849570	0.643	rs1851928	chr3:81975395	C/T	cg07356753	chr3:81810745	GBE1	-0.54	-7.13	-0.41	1.15e-11	Waist circumference;Body mass index;
KIRP	cis	rs4742903	0.904	rs10124553	chr9:106993898	G/A	cg14250997	chr9:106856677	SMC2	0.38	5.07	0.31	7.93e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg21014159	chr11:117668035	DSCAML1	0.41	6.12	0.36	3.66e-9	Myopia;
KIRP	cis	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4805272	0.925	rs9304627	chr19:29325456	T/A	cg15000279	chr19:29285009	NA	-0.37	-5.27	-0.32	2.96e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg18190219	chr22:46762943	CELSR1	-0.61	-5.78	-0.35	2.3e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4900069	0.764	rs7146008	chr14:91593301	C/T	cg12167284	chr14:91592793	SNORA11B;C14orf159	0.45	5.57	0.33	6.74e-8	Resting heart rate;
KIRP	cis	rs752010	0.967	rs6681441	chr1:42098321	G/A	cg06885757	chr1:42089581	HIVEP3	0.57	8.76	0.49	3.16e-16	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg24631222	chr15:78858424	CHRNA5	0.76	9.08	0.5	3.53e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.96	0.36	8.55e-9	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15015913	chr1:17282008	CROCC	0.5	6.31	0.37	1.27e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg12560992	chr17:57184187	TRIM37	0.6	6.42	0.38	6.94e-10	Testicular germ cell tumor;
KIRP	cis	rs3784262	0.669	rs12148281	chr15:58311061	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.02	-0.3	9.92e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg22771759	chr13:24902376	NA	0.37	4.86	0.3	2.11e-6	Obesity-related traits;
KIRP	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg12573674	chr2:1569213	NA	-0.55	-4.87	-0.3	2.01e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	trans	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg26043149	chr18:55253948	FECH	-0.76	-8.38	-0.47	3.97e-15	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7084402	0.967	rs1658480	chr10:60289374	C/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.96	-0.57	5.09e-23	Refractive error;
KIRP	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg23188430	chr6:125850052	NA	-0.32	-4.94	-0.3	1.46e-6	Brugada syndrome;
KIRP	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.28	-0.37	1.54e-9	Neuroticism;
KIRP	cis	rs28719689	0.730	rs62483953	chr8:1260558	A/C	cg22761795	chr8:1265118	NA	0.97	7.22	0.42	6.41e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6728302	0.557	rs2741321	chr2:233280239	A/G	cg14418609	chr2:233286870	NA	0.73	5.64	0.34	4.6e-8	Height;
KIRP	cis	rs6807915	0.541	rs310757	chr3:12281063	C/T	cg15873301	chr3:12045459	SYN2	0.36	4.98	0.3	1.18e-6	Leprosy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05849176	chr6:100754688	NA	0.45	6.46	0.38	5.66e-10	Interleukin-4 levels;
KIRP	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	1.14	8.89	0.49	1.31e-16	Lymphocyte counts;
KIRP	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg17595323	chr11:93583763	C11orf90	-0.39	-6.12	-0.36	3.75e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10861342	1.000	rs1076	chr12:105562788	C/T	cg23923672	chr12:105501055	KIAA1033	-0.89	-7.32	-0.42	3.51e-12	IgG glycosylation;
KIRP	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg03171003	chr2:111875934	NA	0.41	5.84	0.35	1.61e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.65	10.11	0.54	2.61e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24547755	chr1:150980980	FAM63A;PRUNE	0.52	6.69	0.39	1.51e-10	Parkinson's disease;
KIRP	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.65	10.47	0.56	1.88e-21	Morning vs. evening chronotype;
KIRP	cis	rs4494114	0.967	rs9438980	chr1:39355371	A/G	cg25970120	chr1:39325951	RRAGC	-0.39	-4.96	-0.3	1.33e-6	Blood protein levels;
KIRP	cis	rs4950322	0.570	rs72692920	chr1:146780214	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.41	-0.33	1.52e-7	Protein quantitative trait loci;
KIRP	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08280861	chr8:58055591	NA	0.69	5.05	0.31	8.69e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2820315	0.928	rs2678210	chr1:201787940	T/C	cg11586189	chr1:201857591	SHISA4	-0.37	-4.89	-0.3	1.83e-6	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.41	5.77	0.35	2.33e-8	Endometrial cancer;
KIRP	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg00981070	chr1:2046702	PRKCZ	0.42	5.89	0.35	1.25e-8	Height;
KIRP	trans	rs7999699	0.871	rs12429525	chr13:48309416	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs33912345	0.669	rs1269982	chr14:60874253	T/G	cg27398547	chr14:60952738	C14orf39	-0.39	-5.18	-0.31	4.67e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.28	0.62	2.4e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7737355	1.000	rs27663	chr5:130741438	T/G	cg25547332	chr5:131281432	NA	-0.47	-5.26	-0.32	3.14e-7	Life satisfaction;
KIRP	cis	rs2278796	0.639	rs4950977	chr1:204970777	T/A	cg17947172	chr1:204966197	NFASC	0.66	8.8	0.49	2.45e-16	Mean platelet volume;
KIRP	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg00074818	chr8:8560427	CLDN23	0.4	6.27	0.37	1.65e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg17376030	chr22:41985996	PMM1	-0.52	-6.46	-0.38	5.42e-10	Vitiligo;
KIRP	cis	rs13226913	0.967	rs2881756	chr7:7256440	C/T	cg04827551	chr7:7268805	C1GALT1	-0.36	-5.17	-0.31	4.82e-7	Serum galactose-deficient IgA1 levels;
KIRP	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg08975724	chr8:8085496	FLJ10661	0.55	7.42	0.43	1.92e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg04398451	chr17:18023971	MYO15A	-0.68	-9.44	-0.52	3.02e-18	Total body bone mineral density;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00920043	chr1:11333412	UBIAD1	0.51	6.68	0.39	1.6e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg00074818	chr8:8560427	CLDN23	0.4	6.49	0.38	4.67e-10	Obesity-related traits;
KIRP	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.73	9.42	0.51	3.55e-18	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg09507567	chr10:124027408	NA	0.31	5.88	0.35	1.36e-8	Total body bone mineral density;
KIRP	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.29	-13.16	-0.64	2.58e-30	Diabetic retinopathy;
KIRP	cis	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg00262122	chr8:11665843	FDFT1	0.44	5.08	0.31	7.32e-7	Neuroticism;
KIRP	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg06307176	chr5:131281290	NA	0.56	6.08	0.36	4.58e-9	Life satisfaction;
KIRP	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg07148914	chr20:33460835	GGT7	0.49	6.14	0.36	3.29e-9	Height;
KIRP	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs2562456	0.833	rs55920089	chr19:21520693	A/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.93	-0.3	1.49e-6	Pain;
KIRP	cis	rs7769051	0.614	rs76404165	chr6:133235936	T/G	cg22852734	chr6:133119734	C6orf192	0.82	5.42	0.33	1.39e-7	Type 2 diabetes nephropathy;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg21226059	chr5:178986404	RUFY1	0.59	10.25	0.55	9.08e-21	Lung cancer;
KIRP	cis	rs11955398	0.606	rs56137970	chr5:59873462	C/T	cg02684056	chr5:59996105	DEPDC1B	0.44	5.11	0.31	6.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.93	13.5	0.65	1.86e-31	Bladder cancer;
KIRP	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.64	8.17	0.46	1.68e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg02073558	chr3:44770973	ZNF501	0.6	8.44	0.47	2.67e-15	Depressive symptoms;
KIRP	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg23307798	chr14:103986281	CKB	-0.64	-7.6	-0.44	6.36e-13	Bone mineral density;
KIRP	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg20673091	chr1:2541236	MMEL1	0.66	10.03	0.54	4.47e-20	Ulcerative colitis;
KIRP	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg13319975	chr6:146136371	FBXO30	-0.41	-5.7	-0.34	3.42e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	5.11	0.31	6.32e-7	Neuroticism;
KIRP	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg09555818	chr19:45449301	APOC2	0.5	7.26	0.42	4.94e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.48	5.83	0.35	1.73e-8	Diabetic kidney disease;
KIRP	cis	rs2219968	0.961	rs1121551	chr8:78958512	A/G	cg00738934	chr8:78996279	NA	0.43	5.37	0.32	1.78e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg15432903	chr11:17409602	KCNJ11	0.44	6.27	0.37	1.62e-9	Body mass index;Social communication problems;
KIRP	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.18	-0.42	8.45e-12	Aortic root size;
KIRP	cis	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg06521331	chr12:34319734	NA	-0.45	-5.2	-0.31	4.21e-7	Resting heart rate;
KIRP	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-6.48	-0.38	5.01e-10	Coronary artery disease;
KIRP	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.28	-0.37	1.55e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.4	-0.51	4.04e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4780401	0.933	rs7203803	chr16:11812291	A/G	cg01061890	chr16:11836724	TXNDC11	0.41	5.27	0.32	3.02e-7	Rheumatoid arthritis;
KIRP	cis	rs514024	0.700	rs505268	chr9:130493724	C/T	cg13643465	chr9:130375613	STXBP1	0.42	5.61	0.34	5.53e-8	Eating disorders (purging via substances);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg05549419	chr7:75513140	RHBDD2	0.4	6.04	0.36	5.71e-9	Serum protein levels (sST2);
KIRP	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.72	10.16	0.54	1.75e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.79	11.89	0.6	4.6e-26	Prostate cancer;
KIRP	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg11584989	chr19:19387371	SF4	0.4	5.18	0.31	4.57e-7	Tonsillectomy;
KIRP	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg27462398	chr1:86174642	ZNHIT6	-0.53	-7.12	-0.41	1.19e-11	Urate levels in overweight individuals;
KIRP	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.63	-8.54	-0.48	1.37e-15	Platelet count;
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg07777115	chr5:623756	CEP72	-0.56	-5.71	-0.34	3.33e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs71277158	0.688	rs73879178	chr3:169872834	C/T	cg04067573	chr3:169899625	PHC3	0.64	6.13	0.36	3.57e-9	Prostate cancer;
KIRP	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg10755058	chr3:40428713	ENTPD3	0.37	5.11	0.31	6.55e-7	Renal cell carcinoma;
KIRP	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.59	7.78	0.44	2e-13	Schizophrenia;
KIRP	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.65	-0.34	4.44e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs897080	0.515	rs1067404	chr2:44675823	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.58	-5.87	-0.35	1.43e-8	Height;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.18	-0.31	4.67e-7	Breast cancer;
KIRP	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18932078	chr1:2524107	MMEL1	0.4	5.44	0.33	1.28e-7	Ulcerative colitis;
KIRP	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg07451762	chr16:28383216	NA	0.39	5.02	0.3	9.79e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.35e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg04132472	chr17:19861366	AKAP10	0.68	10.3	0.55	6.65e-21	Schizophrenia;
KIRP	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.58	-6.22	-0.37	2.11e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg21926883	chr2:100939477	LONRF2	-0.55	-7.43	-0.43	1.77e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.35	-0.32	2.05e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-7.51	-0.43	1.08e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg02038168	chr22:39784481	NA	-0.4	-5.0	-0.3	1.07e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-0.99	-14.33	-0.67	2.92e-34	Blood trace element (Zn levels);
KIRP	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.95	11.13	0.58	1.39e-23	Corneal astigmatism;
KIRP	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17554472	chr22:41940697	POLR3H	-0.68	-7.12	-0.41	1.19e-11	Vitiligo;
KIRP	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.52	-0.33	8.43e-8	Aortic root size;
KIRP	cis	rs7084402	0.875	rs1593671	chr10:60295969	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.13	-0.31	5.81e-7	Post bronchodilator FEV1;
KIRP	cis	rs12976411	0.867	rs12985626	chr19:32828993	A/G	cg18253629	chr19:32836317	ZNF507	-0.65	-5.06	-0.31	8.23e-7	Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.38	0.51	4.46e-18	Morning vs. evening chronotype;
KIRP	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.67	-8.1	-0.46	2.48e-14	Height;
KIRP	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.07	-0.64	5.21e-30	Chronic sinus infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04085542	chr5:93414338	FAM172A	-0.42	-6.45	-0.38	6.03e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg05347473	chr6:146136440	FBXO30	0.48	6.72	0.39	1.24e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4356932	0.935	rs4345214	chr4:76954169	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.81	-11.05	-0.58	2.66e-23	Total body bone mineral density;
KIRP	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.89	14.27	0.67	4.57e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg25902810	chr10:99078978	FRAT1	-0.59	-7.11	-0.41	1.28e-11	Monocyte count;
KIRP	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.5	-0.38	4.46e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-5.75	-0.34	2.59e-8	Bipolar disorder;
KIRP	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg13010199	chr12:38710504	ALG10B	0.46	5.92	0.35	1.1e-8	Morning vs. evening chronotype;
KIRP	cis	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.49	-0.33	1.02e-7	HDL cholesterol;
KIRP	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.51	6.26	0.37	1.67e-9	Asthma (sex interaction);
KIRP	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03934478	chr11:495069	RNH1	0.78	6.45	0.38	5.86e-10	Body mass index;
KIRP	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.12	-0.36	3.71e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-0.93	-8.32	-0.47	6.1e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg10223061	chr2:219282414	VIL1	-0.38	-6.22	-0.37	2.1e-9	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07817967	chr1:184721222	EDEM3	0.4	6.15	0.37	3.16e-9	Myopia (pathological);
KIRP	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.95	0.5	8.58e-17	Resting heart rate;
KIRP	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg00800038	chr16:89945340	TCF25	-0.89	-7.28	-0.42	4.62e-12	Skin colour saturation;
KIRP	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	13.1	0.64	4.12e-30	Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03065641	chr8:145133200	EXOSC4	0.51	6.11	0.36	3.81e-9	Smoking initiation;
KIRP	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.99	-0.3	1.15e-6	Neutrophil percentage of white cells;
KIRP	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg03735888	chr19:58951602	ZNF132	0.45	5.35	0.32	2.02e-7	Uric acid clearance;
KIRP	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.64	-8.04	-0.46	3.78e-14	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	5.98	0.36	7.63e-9	Schizophrenia;
KIRP	cis	rs7116495	1.000	rs656640	chr11:71781710	T/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.62	10.16	0.54	1.8e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.73	-7.19	-0.42	7.61e-12	Menarche (age at onset);
KIRP	cis	rs6466055	0.932	rs6466056	chr7:104929267	T/C	cg04380332	chr7:105027541	SRPK2	0.51	7.78	0.44	2.05e-13	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.74	9.46	0.52	2.63e-18	Coronary artery disease;
KIRP	trans	rs7246760	1.000	rs7246760	chr19:9918229	G/A	cg02900749	chr2:68251473	NA	-0.96	-8.75	-0.49	3.55e-16	Pursuit maintenance gain;
KIRP	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	13.89	0.66	8.89e-33	Cognitive ability;
KIRP	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	7.38	0.43	2.39e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.61	5.78	0.35	2.21e-8	Plateletcrit;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg23848541	chr22:30722865	TBC1D10A	-0.59	-6.64	-0.39	1.94e-10	Menopause (age at onset);
KIRP	cis	rs7188697	0.922	rs1981961	chr16:58597291	A/T	cg21335942	chr16:58549945	SETD6	-0.47	-5.09	-0.31	7.14e-7	QT interval;
KIRP	cis	rs662064	0.962	rs585870	chr1:10549628	G/T	cg19773385	chr1:10388646	KIF1B	0.39	5.14	0.31	5.61e-7	Asthma;
KIRP	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.93	13.05	0.64	6.13e-30	Cognitive function;
KIRP	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.81	7.74	0.44	2.53e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg06223162	chr1:101003688	GPR88	0.34	7.02	0.41	2.16e-11	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26687499	chr3:135914775	MSL2	0.49	6.14	0.36	3.35e-9	Parkinson's disease;
KIRP	cis	rs758324	0.947	rs253943	chr5:131320730	C/T	cg06647332	chr5:131281008	NA	0.47	5.17	0.31	4.79e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10875746	0.903	rs4760681	chr12:48505230	C/T	cg26205652	chr12:48591994	NA	0.76	10.29	0.55	6.86e-21	Longevity (90 years and older);
KIRP	cis	rs6484504	0.625	rs7112412	chr11:31370271	T/C	cg26647111	chr11:31128758	NA	0.44	5.1	0.31	6.66e-7	Red blood cell count;
KIRP	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-1.03	-13.74	-0.66	2.89e-32	Orofacial clefts;
KIRP	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg13978929	chr19:21580086	ZNF493	0.51	5.1	0.31	6.8e-7	Pain;
KIRP	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2069036	0.743	rs9988752	chr10:16075416	C/A	cg15121417	chr7:730641	PRKAR1B	0.48	6.14	0.36	3.26e-9	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
KIRP	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.4	6.61	0.39	2.37e-10	Testicular germ cell tumor;
KIRP	cis	rs77688320	0.535	rs13001194	chr2:202261175	C/T	cg06431681	chr2:202330990	STRADB	0.52	6.97	0.41	2.94e-11	Breast cancer;
KIRP	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.59	6.51	0.38	4.25e-10	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg23958373	chr8:599963	NA	0.88	6.96	0.41	3.06e-11	IgG glycosylation;
KIRP	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.06	-22.02	-0.81	4.34e-60	Myeloid white cell count;
KIRP	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg17376030	chr22:41985996	PMM1	-0.82	-8.81	-0.49	2.3e-16	Vitiligo;
KIRP	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.29	0.42	4.12e-12	Prudent dietary pattern;
KIRP	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.51	-0.33	9.22e-8	Pulmonary function;
KIRP	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.59	7.91	0.45	8.76e-14	Breast cancer;
KIRP	cis	rs7221595	0.756	rs35102999	chr17:3892700	G/A	cg05562828	chr17:3906858	NA	0.61	6.86	0.4	5.61e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs714027	0.605	rs4820830	chr22:30531091	C/T	cg27665648	chr22:30112403	NA	-0.44	-6.24	-0.37	1.9e-9	Lymphocyte counts;
KIRP	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.7	9.62	0.52	8.22e-19	Post bronchodilator FEV1;
KIRP	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.44	-5.15	-0.31	5.45e-7	Metabolite levels;
KIRP	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg07843065	chr1:150265600	MRPS21	0.44	5.99	0.36	7.26e-9	Migraine;
KIRP	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg23601095	chr6:26197514	HIST1H3D	0.91	7.47	0.43	1.36e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg12826209	chr6:26865740	GUSBL1	0.69	6.78	0.4	8.94e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7394190	0.748	rs3740293	chr10:75406141	A/C	cg04833713	chr10:74871078	NUDT13	0.51	6.56	0.39	3.08e-10	Incident atrial fibrillation;
KIRP	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.63	-8.02	-0.46	4.23e-14	Diastolic blood pressure;
KIRP	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg11494091	chr17:61959527	GH2	-0.8	-12.3	-0.62	2e-27	Prudent dietary pattern;
KIRP	cis	rs796364	0.539	rs6738494	chr2:200697058	A/C	cg23649088	chr2:200775458	C2orf69	0.57	5.56	0.33	6.86e-8	Schizophrenia;
KIRP	cis	rs1982963	0.613	rs2749885	chr14:52516567	T/C	cg05884192	chr14:52515736	NID2	0.53	5.46	0.33	1.15e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-13.09	-0.64	4.71e-30	Vitiligo;
KIRP	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.67	8.55	0.48	1.36e-15	Extraversion;
KIRP	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.89	0.4	4.52e-11	Tonsillectomy;
KIRP	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.46	-5.92	-0.35	1.06e-8	Breast cancer;
KIRP	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg12560992	chr17:57184187	TRIM37	0.6	5.6	0.34	5.72e-8	Cognitive test performance;
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg19893067	chr17:80732956	TBCD	0.35	4.86	0.3	2.1e-6	Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg01320579	chr17:75405842	SEPT9	0.45	7.16	0.42	9.33e-12	Airflow obstruction;
KIRP	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	9.53	0.52	1.63e-18	Cognitive test performance;
KIRP	trans	rs656319	0.591	rs17734690	chr8:9713196	T/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.98	-0.45	5.51e-14	Myopia (pathological);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11978873	chr1:226251224	H3F3A;LOC440926	0.93	6.06	0.36	5.14e-9	P wave terminal force;
KIRP	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg10381502	chr11:71823885	C11orf51	-1.08	-7.75	-0.44	2.46e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs2745572	0.538	rs4587210	chr6:1543191	C/T	cg01806741	chr6:1527072	NA	-0.33	-5.08	-0.31	7.49e-7	Glaucoma (high intraocular pressure);Glaucoma (primary open-angle);Intraocular pressure;
KIRP	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg00977110	chr5:151150581	G3BP1	-0.6	-6.01	-0.36	6.81e-9	Preschool internalizing problems;
KIRP	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	1.16	8.55	0.48	1.31e-15	Gut microbiota (bacterial taxa);
KIRP	cis	rs10089	0.552	rs11955148	chr5:127557814	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	8.5	0.48	1.82e-15	Ileal carcinoids;
KIRP	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg26338869	chr17:61819248	STRADA	0.52	6.25	0.37	1.78e-9	Prudent dietary pattern;
KIRP	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.39	17.43	0.74	7.18e-45	Uric acid levels;
KIRP	cis	rs3109167	0.524	rs2713192	chr7:83125010	C/T	cg14519356	chr7:83097669	SEMA3E	0.54	7.14	0.41	1.07e-11	Blood protein levels;
KIRP	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.75	-0.4	1.03e-10	Type 2 diabetes;
KIRP	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.49	-7.09	-0.41	1.4e-11	Endometriosis;
KIRP	trans	rs7404843	0.777	rs6498552	chr16:15539901	T/G	cg02716450	chr16:28638775	NA	-0.8	-8.25	-0.47	9.48e-15	Testicular germ cell tumor;
KIRP	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg04037228	chr3:45636386	LIMD1	0.35	5.22	0.32	3.82e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7805747	1.000	rs10480299	chr7:151405818	A/G	cg17611936	chr7:151411526	PRKAG2	0.47	6.03	0.36	6.07e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
KIRP	cis	rs287982	1.000	rs287976	chr2:9969688	G/T	cg10881225	chr2:9984929	TAF1B	-0.41	-5.02	-0.3	1.01e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.63	6.52	0.38	3.88e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.77	-9.61	-0.52	9.14e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs240764	0.817	rs6905221	chr6:101151537	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-5.23	-0.32	3.65e-7	Neuroticism;
KIRP	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.49	-5.55	-0.33	7.46e-8	Prion diseases;
KIRP	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg21926883	chr2:100939477	LONRF2	-0.55	-7.58	-0.44	7.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9638182	0.778	rs35332062	chr7:73012042	G/A	cg14087351	chr7:73037990	MLXIPL	-0.53	-4.91	-0.3	1.62e-6	Triglycerides;
KIRP	cis	rs732716	0.785	rs11085073	chr19:4375162	A/G	cg21720385	chr19:4455239	UBXN6	-0.66	-7.77	-0.44	2.17e-13	Mean corpuscular volume;
KIRP	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg22776125	chr6:167041314	RPS6KA2	0.5	6.09	0.36	4.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-4.97	-0.3	1.28e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4704187	0.687	rs1477933	chr5:74437153	G/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.76	-0.73	1.41e-42	Height;
KIRP	trans	rs13170463	0.579	rs34929832	chr5:8040958	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.82	-14.56	-0.68	4.55e-35	Post bronchodilator FEV1;
KIRP	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg19507638	chr5:93509721	C5orf36	0.58	5.12	0.31	6.18e-7	Diabetic retinopathy;
KIRP	cis	rs2219968	0.669	rs10099742	chr8:78871804	C/G	cg00738934	chr8:78996279	NA	-0.37	-5.08	-0.31	7.57e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.31	0.37	1.26e-9	Morning vs. evening chronotype;
KIRP	trans	rs7939886	0.920	rs7113835	chr11:55947007	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg21064579	chr19:49206444	FUT2	-0.53	-7.59	-0.44	6.76e-13	Dietary macronutrient intake;
KIRP	cis	rs6832769	0.961	rs3736545	chr4:56310343	C/G	cg09317128	chr4:56265301	TMEM165	0.55	7.35	0.42	2.96e-12	Personality dimensions;
KIRP	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.09	-0.36	4.39e-9	Total body bone mineral density;
KIRP	cis	rs151997	0.830	rs27282	chr5:50198970	G/A	cg06027927	chr5:50259733	NA	0.53	7.3	0.42	3.96e-12	Callous-unemotional behaviour;
KIRP	cis	rs6466055	0.589	rs2097942	chr7:104725105	A/G	cg04380332	chr7:105027541	SRPK2	0.38	5.26	0.32	3.19e-7	Schizophrenia;
KIRP	cis	rs7582720	1.000	rs78128841	chr2:203663975	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.19	10.48	0.56	1.76e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07395648	chr5:131743802	NA	-0.59	-8.27	-0.47	8.5e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg27165867	chr14:105738592	BRF1	-0.41	-4.9	-0.3	1.72e-6	Platelet count;
KIRP	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	0.48	6.15	0.36	3.19e-9	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg21427119	chr20:30132790	HM13	-0.43	-5.17	-0.31	4.88e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.94	-0.3	1.48e-6	Metabolite levels;
KIRP	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.54	-8.73	-0.49	4.01e-16	Prostate cancer;
KIRP	cis	rs17384381	1.000	rs12758768	chr1:85835206	C/T	cg16011679	chr1:85725395	C1orf52	0.8	7.91	0.45	8.87e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.46	0.68	1.07e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2073300	1.000	rs6106669	chr20:23460328	C/T	cg12480562	chr20:23434244	CST11	0.57	5.8	0.35	2.02e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7715811	1.000	rs67731984	chr5:13774014	G/A	cg07548982	chr5:13769939	DNAH5	-0.55	-6.69	-0.39	1.5e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg23307798	chr14:103986281	CKB	0.76	13.08	0.64	4.77e-30	Body mass index;
KIRP	cis	rs7737355	0.947	rs6596009	chr5:130608093	C/A	cg06307176	chr5:131281290	NA	0.65	5.95	0.35	9.26e-9	Life satisfaction;
KIRP	cis	rs16828019	0.852	rs12048187	chr1:41616183	A/G	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4414128	0.778	rs11256474	chr10:5681783	C/T	cg12223502	chr10:5658492	NA	0.5	5.48	0.33	1.05e-7	Breast cancer;
KIRP	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	7.37	0.43	2.57e-12	Neuroticism;
KIRP	trans	rs9329221	0.509	rs3088186	chr8:10226355	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	6.24	0.37	1.88e-9	Neuroticism;
KIRP	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg16584676	chr17:46985605	UBE2Z	0.49	6.03	0.36	5.82e-9	Type 2 diabetes;
KIRP	cis	rs3736485	0.966	rs1031664	chr15:51754897	C/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.17	-0.31	4.78e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg18806716	chr10:30721971	MAP3K8	0.32	5.06	0.31	8.25e-7	Inflammatory bowel disease;
KIRP	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-7.65	-0.44	4.68e-13	Morning vs. evening chronotype;
KIRP	cis	rs714027	0.566	rs4820827	chr22:30477589	T/C	cg01021169	chr22:30184971	ASCC2	0.44	5.56	0.33	7.13e-8	Lymphocyte counts;
KIRP	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.73	10.31	0.55	6.2e-21	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.3	5.75	0.34	2.7e-8	Lung cancer;
KIRP	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg27170947	chr2:26402098	FAM59B	0.64	7.1	0.41	1.34e-11	Gut microbiome composition (summer);
KIRP	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg00931491	chr16:28608288	SULT1A2	-0.25	-5.04	-0.31	9.19e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg25486957	chr4:152246857	NA	0.44	4.9	0.3	1.73e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4262150	0.883	rs72799157	chr5:152119416	C/A	cg12297329	chr5:152029980	NA	-0.66	-8.35	-0.47	4.9e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.44	-0.47	2.75e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.56	8.23	0.46	1.09e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg13010199	chr12:38710504	ALG10B	0.63	7.81	0.45	1.63e-13	Morning vs. evening chronotype;
KIRP	cis	rs6882716	1.000	rs6882716	chr5:10797886	G/A	cg14521931	chr5:10832172	NA	-0.79	-8.71	-0.49	4.62e-16	Alcohol consumption (maxi-drinks);
KIRP	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.29	28.11	0.87	9.15e-79	IgG glycosylation;
KIRP	cis	rs9321453	1.000	rs6937846	chr6:134775632	A/G	cg08754004	chr6:134775465	NA	-0.43	-5.12	-0.31	6.31e-7	Urate levels;
KIRP	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg00800038	chr16:89945340	TCF25	-0.89	-7.26	-0.42	5.02e-12	Skin colour saturation;
KIRP	cis	rs78487399	0.908	rs17031092	chr2:43809248	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.79	-0.35	2.11e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.08	0.36	4.62e-9	Mean corpuscular volume;
KIRP	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs7923609	0.934	rs10822153	chr10:65056813	C/A	cg01631684	chr10:65280961	REEP3	-0.48	-5.7	-0.34	3.44e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg04990556	chr1:26633338	UBXN11	0.65	6.6	0.39	2.54e-10	Obesity-related traits;
KIRP	cis	rs6991838	0.584	rs4275254	chr8:66501364	A/G	cg13398993	chr8:66546079	ARMC1	-0.47	-5.43	-0.33	1.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.43	0.38	6.59e-10	Electroencephalogram traits;
KIRP	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg03808351	chr9:123631620	PHF19	0.44	6.13	0.36	3.41e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.55	8.22	0.46	1.2e-14	Itch intensity from mosquito bite;
KIRP	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	1.0	14.74	0.68	1.15e-35	Cognitive function;
KIRP	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg17470723	chr8:74884337	TCEB1	0.63	8.01	0.45	4.52e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12210905	1.000	rs12201774	chr6:27058312	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.68	-0.39	1.6e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	cis	rs397969	0.596	rs7209653	chr17:19882084	A/G	cg04132472	chr17:19861366	AKAP10	0.55	7.12	0.41	1.18e-11	Platelet count;
KIRP	trans	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg13565492	chr6:43139072	SRF	-0.94	-8.68	-0.48	5.62e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.84	13.77	0.66	2.27e-32	Multiple myeloma;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10769649	chr1:2111330	PRKCZ	0.45	6.19	0.37	2.53e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	1.0	8.13	0.46	2.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.14	-0.36	3.21e-9	Neuroticism;
KIRP	cis	rs1712517	0.838	rs1891293	chr10:105001797	C/T	cg05636881	chr10:105038444	INA	-0.38	-5.6	-0.34	5.85e-8	Migraine;
KIRP	cis	rs2077654	0.822	rs12279699	chr11:17443348	G/A	cg25308976	chr11:17434268	ABCC8	0.88	6.15	0.36	3.18e-9	Gout;
KIRP	cis	rs960902	1.000	rs960902	chr2:37731665	G/A	cg25341268	chr2:37734390	NA	0.5	6.63	0.39	2.09e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs6732160	0.588	rs7578991	chr2:73376171	A/G	cg01422370	chr2:73384389	NA	0.51	6.92	0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs78487399	0.908	rs76765584	chr2:43808034	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-5.37	-0.32	1.86e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	0.78	6.39	0.38	8.44e-10	IgG glycosylation;
KIRP	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.42	-0.33	1.39e-7	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27420264	chr11:122933026	HSPA8	0.53	6.64	0.39	1.98e-10	Parkinson's disease;
KIRP	cis	rs13102973	0.965	rs4437307	chr4:135861598	C/T	cg14419869	chr4:135874104	NA	-0.6	-10.47	-0.56	1.8e-21	Subjective well-being;
KIRP	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg12160578	chr15:63334699	TPM1	0.63	6.68	0.39	1.58e-10	Orofacial clefts;
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg01097406	chr16:89675127	NA	-0.3	-4.98	-0.3	1.18e-6	Vitiligo;
KIRP	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.56	-5.14	-0.31	5.67e-7	Major depressive disorder;
KIRP	cis	rs7688540	0.665	rs11731933	chr4:239159	G/A	cg17891759	chr4:299121	NA	-0.45	-5.1	-0.31	6.63e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6466055	0.612	rs67421818	chr7:104860671	T/G	cg04380332	chr7:105027541	SRPK2	0.39	5.38	0.32	1.76e-7	Schizophrenia;
KIRP	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg10434728	chr15:90938212	IQGAP1	-0.36	-6.68	-0.39	1.57e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg16479474	chr6:28041457	NA	0.47	5.08	0.31	7.33e-7	Depression;
KIRP	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg26248373	chr2:1572462	NA	-0.62	-6.01	-0.36	6.48e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.8	0.45	1.78e-13	Coffee consumption (cups per day);
KIRP	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-10.86	-0.57	1.09e-22	Menopause (age at onset);
KIRP	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg25019033	chr10:957182	NA	-0.55	-6.73	-0.39	1.22e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs7010267	0.902	rs10505348	chr8:119972696	A/G	cg01975934	chr8:119970761	NA	-0.42	-5.34	-0.32	2.13e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.63	0.34	5.02e-8	Lung cancer;
KIRP	cis	rs2671245	0.865	rs2767516	chr1:56164063	A/G	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9398803	0.671	rs1155939	chr6:126866133	C/A	cg19875578	chr6:126661172	C6orf173	0.41	5.18	0.31	4.69e-7	Male-pattern baldness;
KIRP	cis	rs6516091	0.850	rs1884651	chr20:6047012	A/C	cg25325723	chr20:6104886	FERMT1	-0.51	-5.14	-0.31	5.63e-7	Abdominal aortic aneurysm;
KIRP	cis	rs2273669	0.667	rs77936298	chr6:109350616	A/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs7507204	1.000	rs7507204	chr19:3428834	G/C	cg08380311	chr19:3435252	NFIC	0.66	7.2	0.42	7.51e-12	Height;
KIRP	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.66	8.4	0.47	3.63e-15	Prudent dietary pattern;
KIRP	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg18944383	chr4:111397179	ENPEP	0.54	9.3	0.51	7.75e-18	Height;
KIRP	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg24585782	chr17:78113791	EIF4A3	-0.53	-6.27	-0.37	1.59e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4722404	0.620	rs6978200	chr7:3118835	A/G	cg19214707	chr7:3157722	NA	-0.42	-5.0	-0.3	1.09e-6	Atopic dermatitis;
KIRP	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg23594656	chr7:65796392	TPST1	-0.43	-5.94	-0.35	9.75e-9	Aortic root size;
KIRP	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.37	-5.86	-0.35	1.5e-8	Testicular germ cell tumor;
KIRP	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-8.13	-0.46	2.09e-14	Pancreatic cancer;
KIRP	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.18	-0.51	1.86e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23873398	chr14:36278529	RALGAPA1	0.49	6.49	0.38	4.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.73	-0.49	3.87e-16	Mood instability;
KIRP	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg00784671	chr22:46762841	CELSR1	-0.85	-8.28	-0.47	7.7e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2016266	0.855	rs4759086	chr12:53666713	A/G	cg16917193	chr12:54089295	NA	0.46	5.81	0.35	1.97e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.68	10.07	0.54	3.5e-20	Brugada syndrome;
KIRP	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg26597838	chr10:835615	NA	-0.54	-6.72	-0.39	1.25e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	1.03	7.09	0.41	1.39e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9381107	0.860	rs9369385	chr6:9477277	A/G	cg14735645	chr6:9486422	NA	-0.58	-7.16	-0.42	9.39e-12	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.53	7.24	0.42	5.58e-12	Schizophrenia;
KIRP	cis	rs11016883	0.905	rs11597322	chr10:131492126	C/T	cg14312783	chr10:131504572	MGMT	0.44	5.36	0.32	1.95e-7	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.69	8.53	0.48	1.53e-15	Multiple sclerosis;
KIRP	cis	rs2790457	0.795	rs7903703	chr10:28935149	T/C	cg05705492	chr10:28955341	NA	-0.57	-8.49	-0.48	1.98e-15	Multiple myeloma;
KIRP	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	5.34	0.32	2.16e-7	Leprosy;
KIRP	cis	rs12210905	0.920	rs9366690	chr6:27291079	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.71	-0.39	1.35e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg17376030	chr22:41985996	PMM1	-0.53	-6.05	-0.36	5.3e-9	Vitiligo;
KIRP	cis	rs35740288	0.753	rs4843095	chr15:86275131	T/G	cg17133734	chr15:86042851	AKAP13	-0.49	-5.31	-0.32	2.47e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg08901578	chr4:187885870	NA	-0.53	-8.72	-0.49	4.12e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.25	-0.37	1.76e-9	Parkinson's disease;
KIRP	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg12598211	chr12:123634384	NA	0.43	4.95	0.3	1.39e-6	Neutrophil percentage of white cells;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08002795	chr4:83351453	HNRPDL;ENOPH1	-0.57	-6.15	-0.37	3.13e-9	Menopause (age at onset);
KIRP	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.13	-0.36	3.46e-9	Daytime sleep phenotypes;
KIRP	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg14972814	chr11:95582409	MTMR2	0.34	5.58	0.34	6.3e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.52	6.73	0.39	1.16e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.78	-11.8	-0.6	8.87e-26	Hip circumference;
KIRP	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.75	10.26	0.55	8.79e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-6.92	-0.4	3.85e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.4	5.11	0.31	6.49e-7	Leprosy;
KIRP	cis	rs921943	1.000	rs933684	chr5:78324075	A/C	cg26802063	chr5:78281964	ARSB	0.49	6.08	0.36	4.56e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg05973401	chr12:123451056	ABCB9	-0.62	-7.31	-0.42	3.84e-12	Platelet count;
KIRP	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg16558253	chr16:72132732	DHX38	-0.44	-4.86	-0.3	2.07e-6	Coronary artery disease;
KIRP	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.76	9.17	0.5	2.01e-17	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg13198984	chr17:80129470	CCDC57	0.55	8.33	0.47	5.61e-15	Life satisfaction;
KIRP	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.77	-11.23	-0.58	6.58e-24	Caffeine consumption;
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg18234130	chr8:27182889	PTK2B	0.51	6.6	0.39	2.51e-10	Neuroticism;
KIRP	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02725872	chr8:58115012	NA	-0.64	-6.18	-0.37	2.66e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg07192821	chr15:45003560	B2M	0.44	6.16	0.37	2.97e-9	Ischemic stroke;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15312298	chr8:127570908	FAM84B	0.59	7.04	0.41	1.86e-11	Smoking initiation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22218588	chr6:155548093	TIAM2	-0.44	-6.25	-0.37	1.83e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-5.39	-0.33	1.61e-7	HDL cholesterol;
KIRP	cis	rs7172677	1.000	rs4886422	chr15:75426723	C/T	cg14664628	chr15:75095509	CSK	-0.5	-5.58	-0.33	6.49e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4481887	0.830	rs1538703	chr1:248519821	T/G	cg00666640	chr1:248458726	OR2T12	0.38	5.41	0.33	1.53e-7	Common traits (Other);
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.74	7.8	0.45	1.72e-13	Platelet count;
KIRP	cis	rs13095912	1.000	rs13100034	chr3:185318804	G/A	cg11274856	chr3:185301563	NA	0.53	6.9	0.4	4.29e-11	Systolic blood pressure;
KIRP	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	5.61	0.34	5.52e-8	Schizophrenia;
KIRP	cis	rs9815354	0.812	rs17218103	chr3:41943724	A/G	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg08662619	chr6:150070041	PCMT1	0.34	5.31	0.32	2.45e-7	Lung cancer;
KIRP	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.63	7.86	0.45	1.21e-13	Colorectal cancer;
KIRP	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.43	5.73	0.34	3e-8	Age-related hearing impairment;
KIRP	cis	rs1800469	1.000	rs2317130	chr19:41861674	C/T	cg08477640	chr19:41863820	B9D2	0.54	6.45	0.38	5.78e-10	Colorectal cancer;
KIRP	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.76	-7.33	-0.42	3.22e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.49	6.52	0.38	3.95e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg18016565	chr1:150552671	MCL1	-0.36	-5.45	-0.33	1.25e-7	Tonsillectomy;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg01185801	chr11:65265397	MALAT1	0.47	6.28	0.37	1.52e-9	Ischemic stroke;
KIRP	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.32	0.37	1.22e-9	Total body bone mineral density;
KIRP	trans	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg10756647	chr7:56101905	PSPH	1.07	8.27	0.47	8.36e-15	Diabetic kidney disease;
KIRP	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg23625390	chr15:77176239	SCAPER	0.54	7.49	0.43	1.24e-12	Blood metabolite levels;
KIRP	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg13731523	chr4:3047190	NA	-0.38	-6.18	-0.37	2.58e-9	Serum sulfate level;
KIRP	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	13.76	0.66	2.38e-32	Colorectal cancer;
KIRP	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg13180566	chr4:1052158	NA	-0.55	-5.52	-0.33	8.47e-8	Recombination rate (females);
KIRP	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.43e-11	Response to antipsychotic treatment;
KIRP	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06634786	chr22:41940651	POLR3H	-0.42	-5.02	-0.3	1.01e-6	Vitiligo;
KIRP	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.21	-0.46	1.21e-14	Rheumatoid arthritis;
KIRP	trans	rs12043259	1.000	rs6674877	chr1:204826114	C/T	cg11485465	chr5:54518469	NA	-0.39	-6.12	-0.36	3.7e-9	Addiction;
KIRP	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg16586182	chr3:47516702	SCAP	-0.75	-10.38	-0.55	3.62e-21	Colorectal cancer;
KIRP	cis	rs7845219	0.544	rs9643352	chr8:95918288	C/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.41	-0.38	7.53e-10	Type 2 diabetes;
KIRP	cis	rs2274273	0.840	rs11626751	chr14:55835227	T/C	cg04306507	chr14:55594613	LGALS3	0.44	6.92	0.4	3.98e-11	Protein biomarker;
KIRP	cis	rs29784	0.838	rs251230	chr5:172526570	A/G	cg01251646	chr5:172719820	NA	0.35	5.25	0.32	3.28e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.36	3.92e-9	Heart rate;
KIRP	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg07384080	chr1:156148190	NA	0.29	4.88	0.3	1.93e-6	Testicular germ cell tumor;
KIRP	cis	rs7017914	0.967	rs59992214	chr8:71599545	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.07	0.31	7.79e-7	Tonsillectomy;
KIRP	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg18306943	chr3:40428807	ENTPD3	-0.45	-6.23	-0.37	2.05e-9	Renal cell carcinoma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13858054	chr9:86595264	HNRNPK;RMI1	0.46	6.36	0.38	9.54e-10	Survival in pancreatic cancer;
KIRP	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	cg12689670	chr1:183009347	LAMC1	-0.42	-6.16	-0.37	3e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg22906224	chr7:99728672	NA	-0.64	-7.85	-0.45	1.31e-13	Coronary artery disease;
KIRP	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.95	-14.94	-0.69	2.35e-36	Height;
KIRP	cis	rs6788895	1.000	rs41372346	chr3:150489116	C/G	cg09723797	chr3:150481914	SIAH2	0.8	5.22	0.32	3.73e-7	Breast cancer;
KIRP	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg05938607	chr10:60274200	BICC1	-0.46	-11.34	-0.59	3.05e-24	Refractive error;
KIRP	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.69	9.0	0.5	6.35e-17	Bladder cancer;
KIRP	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg26554054	chr8:600488	NA	0.69	5.21	0.32	3.91e-7	IgG glycosylation;
KIRP	cis	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg26585981	chr11:48327164	OR4S1	-0.47	-5.64	-0.34	4.65e-8	HDL cholesterol;
KIRP	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	1.0	14.57	0.68	4.19e-35	Monocyte count;
KIRP	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	10.57	0.56	8.84e-22	Electrocardiographic conduction measures;
KIRP	trans	rs2055729	0.645	rs62489489	chr8:9753073	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	6.27	0.37	1.57e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12049351	0.774	rs34232465	chr1:229631112	C/T	cg11742688	chr1:229674241	ABCB10	-0.39	-6.03	-0.36	6.13e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg01559446	chr3:44596178	ZNF167	-0.35	-5.09	-0.31	7.06e-7	Depressive symptoms;
KIRP	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.71	-6.49	-0.38	4.61e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6681460	0.649	rs967322	chr1:67003446	C/T	cg02459107	chr1:67143332	SGIP1	0.39	5.44	0.33	1.29e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.45	5.22	0.32	3.84e-7	Colorectal cancer;
KIRP	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs7923609	0.812	rs10822155	chr10:65071215	C/A	cg01631684	chr10:65280961	REEP3	-0.47	-5.25	-0.32	3.22e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.21	0.32	3.98e-7	Renal cell carcinoma;
KIRP	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg18882449	chr10:104885122	NT5C2	-0.43	-4.87	-0.3	1.99e-6	Arsenic metabolism;
KIRP	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.45	5.74	0.34	2.75e-8	Longevity;
KIRP	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-6.02	-0.36	6.16e-9	Aortic root size;
KIRP	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg07645718	chr20:61493192	TCFL5	0.78	6.1	0.36	4.11e-9	Obesity-related traits;
KIRP	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.52	9.22	0.51	1.42e-17	Vitiligo;
KIRP	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.73	-9.17	-0.5	1.95e-17	Blood pressure (smoking interaction);
KIRP	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg05083358	chr7:2394359	EIF3B	-0.73	-7.13	-0.41	1.09e-11	Multiple sclerosis;
KIRP	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg14593290	chr7:50529359	DDC	0.43	5.38	0.32	1.78e-7	Malaria;
KIRP	cis	rs9815354	0.627	rs73073268	chr3:42021403	C/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg17509989	chr5:176798049	RGS14	0.76	8.51	0.48	1.71e-15	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs75064307	0.734	rs2124736	chr3:108095365	G/A	cg14703454	chr3:108065259	HHLA2	0.58	6.63	0.39	2.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.54	-0.38	3.53e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg10756647	chr7:56101905	PSPH	0.95	6.85	0.4	6.05e-11	Diabetic kidney disease;
KIRP	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Body mass index;
KIRP	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-6.53	-0.38	3.77e-10	Menarche (age at onset);
KIRP	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.51	6.53	0.38	3.7e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs77688320	0.517	rs12991600	chr2:202337236	A/G	cg06431681	chr2:202330990	STRADB	0.54	6.9	0.4	4.35e-11	Breast cancer;
KIRP	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.45	6.4e-14	Aortic root size;
KIRP	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg10223061	chr2:219282414	VIL1	-0.33	-5.46	-0.33	1.14e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs9463078	0.505	rs2038556	chr6:44740568	A/G	cg25276700	chr6:44698697	NA	0.34	4.94	0.3	1.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.2	0.46	1.35e-14	Morning vs. evening chronotype;
KIRP	cis	rs5742915	0.513	rs752004	chr15:74329021	T/C	cg17221444	chr15:74284820	STOML1	-0.43	-5.05	-0.31	8.45e-7	Height;Paget's disease;
KIRP	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg10189774	chr4:17578691	LAP3	0.51	6.26	0.37	1.71e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg05835009	chr4:710272	PCGF3	0.57	7.02	0.41	2.17e-11	White blood cell count;
KIRP	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg16141378	chr3:129829833	LOC729375	-0.56	-6.81	-0.4	7.27e-11	Mood instability;
KIRP	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.66	5.22	0.32	3.88e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6540559	0.546	rs57315825	chr1:210030197	C/T	cg22029157	chr1:209979665	IRF6	0.51	5.4	0.33	1.59e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.71	-0.34	3.19e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.64	-8.95	-0.5	8.74e-17	Brugada syndrome;
KIRP	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg01280390	chr8:19363452	CSGALNACT1	-0.39	-5.13	-0.31	6e-7	Oropharynx cancer;
KIRP	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.42	5.38	0.32	1.74e-7	Aortic root size;
KIRP	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05776053	chr2:74358815	NA	0.5	5.17	0.31	4.9e-7	Gestational age at birth (maternal effect);
KIRP	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg01280390	chr8:19363452	CSGALNACT1	-0.44	-5.94	-0.35	9.5e-9	Oropharynx cancer;
KIRP	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07234876	chr8:600039	NA	0.82	6.32	0.37	1.21e-9	IgG glycosylation;
KIRP	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg11833968	chr6:79620685	NA	-0.45	-6.87	-0.4	5.3e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.75	10.31	0.55	5.83e-21	Parkinson's disease;
KIRP	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.95	0.41	3.29e-11	Vitiligo;
KIRP	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg04398451	chr17:18023971	MYO15A	0.67	8.93	0.49	1.02e-16	Total body bone mineral density;
KIRP	cis	rs6723108	0.738	rs7599054	chr2:135540546	A/G	cg25422880	chr2:135218333	TMEM163	-0.49	-7.05	-0.41	1.82e-11	Type 2 diabetes;
KIRP	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.47	7.18	0.42	8.37e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.83	11.6	0.59	4.15e-25	Systemic sclerosis;
KIRP	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.53	6.26	0.37	1.69e-9	Mean corpuscular volume;
KIRP	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg16141378	chr3:129829833	LOC729375	0.55	7.59	0.44	6.72e-13	Neuroticism;
KIRP	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg09795085	chr6:101329169	ASCC3	-0.49	-5.86	-0.35	1.45e-8	Neuroticism;
KIRP	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.96	-11.9	-0.6	4.32e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.76	0.44	2.29e-13	Mood instability;
KIRP	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg01422370	chr2:73384389	NA	0.49	6.63	0.39	2.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg00629941	chr15:75287862	SCAMP5	-0.5	-5.25	-0.32	3.27e-7	Blood trace element (Zn levels);
KIRP	cis	rs963731	0.649	rs10201980	chr2:39204820	C/T	cg04010122	chr2:39346883	SOS1	0.76	5.23	0.32	3.65e-7	Corticobasal degeneration;
KIRP	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg10932868	chr11:921992	NA	0.59	7.51	0.43	1.1e-12	Alzheimer's disease (late onset);
KIRP	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.99	-0.5	6.53e-17	Mean corpuscular volume;
KIRP	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg10503236	chr1:231470652	EXOC8	-0.53	-7.36	-0.42	2.83e-12	Hemoglobin concentration;
KIRP	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	12.97	0.64	1.18e-29	Smoking behavior;
KIRP	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.44	-0.38	6.35e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.8	9.05	0.5	4.37e-17	Corneal astigmatism;
KIRP	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg22800045	chr5:56110881	MAP3K1	0.45	5.0	0.3	1.1e-6	Coronary artery disease;
KIRP	cis	rs6504622	0.905	rs3851787	chr17:45046982	A/G	cg24703533	chr17:45055318	NA	0.39	5.45	0.33	1.23e-7	Orofacial clefts;
KIRP	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.33	0.37	1.14e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-6.76	-0.4	9.92e-11	Mean corpuscular volume;
KIRP	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.34	-0.42	3.15e-12	Morning vs. evening chronotype;
KIRP	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.93	15.97	0.71	7.16e-40	Breast cancer;
KIRP	cis	rs10875746	0.669	rs10467101	chr12:48607737	T/C	cg26205652	chr12:48591994	NA	0.67	8.72	0.49	4.14e-16	Longevity (90 years and older);
KIRP	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.43	-0.47	2.86e-15	Body mass index;
KIRP	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg13271783	chr10:134563150	INPP5A	-0.62	-7.89	-0.45	1.01e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs911119	0.908	rs8121147	chr20:23601708	T/C	cg09631192	chr20:23583594	CST9	-0.49	-5.08	-0.31	7.52e-7	Chronic kidney disease;
KIRP	cis	rs71597109	0.681	rs13146194	chr4:102723640	T/C	cg14855874	chr4:102712397	BANK1	0.4	5.06	0.31	8.4e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs4692589	0.897	rs35585674	chr4:170975963	A/C	cg19918862	chr4:170955249	NA	0.41	4.91	0.3	1.67e-6	Anxiety disorder;
KIRP	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.46	6.82	0.4	6.97e-11	Major depressive disorder;
KIRP	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.66	8.08	0.46	2.97e-14	Vitiligo;
KIRP	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.44	5.98	0.36	7.81e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.68	9.56	0.52	1.26e-18	Obesity-related traits;
KIRP	cis	rs4262150	0.508	rs72795366	chr5:151920076	T/A	cg12297329	chr5:152029980	NA	-0.71	-8.7	-0.49	4.89e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7084402	0.935	rs4141671	chr10:60338753	T/C	cg05938607	chr10:60274200	BICC1	0.41	9.76	0.53	3.22e-19	Refractive error;
KIRP	cis	rs4722166	0.598	rs4722179	chr7:22803861	C/A	cg05472934	chr7:22766657	IL6	0.49	6.66	0.39	1.78e-10	Lung cancer;
KIRP	trans	rs7084921	0.608	rs12775433	chr10:101834092	C/T	cg13808641	chr9:96006533	WNK2	-0.4	-6.06	-0.36	5.06e-9	Bone mineral density;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg22907277	chr7:1156413	C7orf50	0.64	6.33	0.37	1.14e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg03235661	chr20:60525775	NA	-0.3	-4.97	-0.3	1.25e-6	Body mass index;
KIRP	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg14689365	chr7:158441557	NCAPG2	0.39	4.93	0.3	1.52e-6	Height;
KIRP	cis	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg21775007	chr8:11205619	TDH	-0.45	-5.85	-0.35	1.53e-8	Triglycerides;
KIRP	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.85	12.22	0.61	3.7e-27	Neuroticism;
KIRP	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.66	-9.31	-0.51	7.28e-18	Blood protein levels;
KIRP	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg15790184	chr11:494944	RNH1	0.42	5.08	0.31	7.49e-7	Systemic lupus erythematosus;
KIRP	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.27	-5.6	-0.34	5.73e-8	Menarche (age at onset);
KIRP	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg00677455	chr12:58241039	CTDSP2	-0.58	-6.9	-0.4	4.36e-11	Multiple sclerosis;
KIRP	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg23791538	chr6:167370224	RNASET2	-0.47	-5.71	-0.34	3.2e-8	Rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08213337	chr2:178937673	PDE11A	-0.48	-6.16	-0.37	2.94e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6700559	0.740	rs11582610	chr1:200645101	C/T	cg07804481	chr1:200639085	DDX59	0.5	6.6	0.39	2.52e-10	Coronary artery disease;
KIRP	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg21775007	chr8:11205619	TDH	-0.43	-5.64	-0.34	4.59e-8	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19556438	chr19:33793146	CEBPA;LOC80054	0.55	6.84	0.4	6.12e-11	Parkinson's disease;
KIRP	trans	rs1106684	1.000	rs2333893	chr7:131453982	T/G	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg23151374	chr4:164415611	C4orf43	0.75	6.37	0.38	9.35e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg18882449	chr10:104885122	NT5C2	0.51	6.65	0.39	1.89e-10	Arsenic metabolism;
KIRP	cis	rs4478037	0.558	rs57225144	chr3:33078354	G/C	cg19404215	chr3:33155277	CRTAP	0.88	5.61	0.34	5.54e-8	Major depressive disorder;
KIRP	cis	rs6707387	0.662	rs7557848	chr2:214347653	C/T	cg08319019	chr2:214017104	IKZF2	0.43	4.93	0.3	1.5e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.87	11.37	0.59	2.29e-24	Cognitive function;
KIRP	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg08392591	chr16:89556376	ANKRD11	0.4	5.14	0.31	5.63e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6429082	0.509	rs2803845	chr1:235520228	C/G	cg26050004	chr1:235667680	B3GALNT2	0.39	4.88	0.3	1.93e-6	Adiposity;
KIRP	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs9596863	1.000	rs9568941	chr13:54419426	A/G	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2299587	0.689	rs2285303	chr8:17797409	A/G	cg01800426	chr8:17659068	MTUS1	-0.53	-6.17	-0.37	2.76e-9	Economic and political preferences;
KIRP	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg25319279	chr11:5960081	NA	-0.54	-5.34	-0.32	2.11e-7	DNA methylation (variation);
KIRP	cis	rs9398803	0.687	rs9401897	chr6:126940641	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	5.03	0.31	9.33e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg03511173	chr18:77590860	NA	0.52	4.96	0.3	1.33e-6	Opioid sensitivity;
KIRP	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.84	10.15	0.54	1.97e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.64	-9.18	-0.51	1.78e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1190552	0.706	rs2146426	chr14:102995068	A/G	cg18135206	chr14:102964638	TECPR2	0.47	5.54	0.33	7.93e-8	Blood protein levels;
KIRP	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.38	-0.47	4.18e-15	Retinal vascular caliber;
KIRP	cis	rs3731896	0.948	rs3770224	chr2:220147166	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.52	5.74	0.34	2.82e-8	Educational attainment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05410609	chr14:100070556	CCDC85C	0.46	6.41	0.38	7.43e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.62	7.58	0.44	6.82e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.59	-5.89	-0.35	1.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.55	-7.69	-0.44	3.58e-13	Coronary artery disease;
KIRP	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg21890820	chr11:65308645	LTBP3	0.39	4.95	0.3	1.36e-6	Bone mineral density;
KIRP	cis	rs9462846	0.688	rs116255295	chr6:42906241	G/A	cg02353165	chr6:42928485	GNMT	0.64	7.21	0.42	6.91e-12	Blood protein levels;
KIRP	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.57	-0.39	2.95e-10	Monocyte percentage of white cells;
KIRP	cis	rs1559088	0.948	rs7257858	chr19:33591231	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-5.64	-0.34	4.69e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs490234	0.812	rs4838284	chr9:128446365	G/T	cg14078157	chr9:128172775	NA	-0.57	-6.69	-0.39	1.46e-10	Mean arterial pressure;
KIRP	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg05072774	chr3:49840536	C3orf54	0.44	5.56	0.33	7.18e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21954346	chr16:68271489	ESRP2	0.52	6.03	0.36	6.08e-9	Smoking initiation;
KIRP	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	0.95	13.99	0.67	4.14e-33	Dupuytren's disease;
KIRP	cis	rs1215050	0.791	rs1669745	chr4:98842047	G/A	cg05340658	chr4:99064831	C4orf37	-0.58	-7.06	-0.41	1.65e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs6032067	1.000	rs6032052	chr20:43829883	C/A	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.7	0.39	1.44e-10	Height;
KIRP	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg00262122	chr8:11665843	FDFT1	-0.39	-4.87	-0.3	1.98e-6	Triglycerides;
KIRP	trans	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-9.8	-0.53	2.39e-19	Systemic lupus erythematosus;
KIRP	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.59	-6.6	-0.39	2.46e-10	Aortic root size;
KIRP	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.83	12.5	0.62	4.25e-28	Body mass index;
KIRP	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.15	-0.41	9.63e-12	Neuroticism;
KIRP	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg24675658	chr1:53192096	ZYG11B	0.65	7.1	0.41	1.31e-11	Monocyte count;
KIRP	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg19847130	chr8:10466454	RP1L1	0.33	4.86	0.3	2.1e-6	Retinal vascular caliber;
KIRP	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.46	-5.59	-0.34	5.93e-8	Testicular germ cell tumor;
KIRP	cis	rs12519773	0.597	rs10514370	chr5:92435481	G/T	cg18783429	chr5:92414398	NA	0.34	5.74	0.34	2.74e-8	Migraine;
KIRP	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg06060754	chr5:176797920	RGS14	-0.51	-5.93	-0.35	1.04e-8	Urate levels in lean individuals;
KIRP	trans	rs4296809	0.505	rs10434608	chr5:44053616	G/A	cg04689058	chr16:66953825	CDH16	0.6	6.06	0.36	5.01e-9	Brain structure;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg01334186	chr1:151372572	PSMB4	0.52	6.35	0.38	1.06e-9	Sleep duration;
KIRP	cis	rs76693355	0.512	rs7129944	chr11:120299707	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.43	-5.6	-0.34	5.73e-8	Intraocular pressure;
KIRP	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-11.67	-0.6	2.53e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg11738485	chr19:12877000	HOOK2	0.42	5.17	0.31	4.84e-7	Bipolar disorder;
KIRP	cis	rs494562	0.892	rs1744121	chr6:86115189	T/C	cg27039625	chr6:86159096	NT5E	0.42	5.1	0.31	6.65e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs45535039	1.000	rs36109901	chr11:119083318	A/C	cg16724696	chr11:118992527	HINFP	0.4	4.93	0.3	1.49e-6	Plateletcrit;
KIRP	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg10047753	chr17:41438598	NA	1.13	18.09	0.76	4.3e-47	Menopause (age at onset);
KIRP	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16386425	chr10:429943	DIP2C	-0.49	-6.72	-0.39	1.25e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	cis	rs7100689	1.000	rs7100689	chr10:82222178	C/A	cg00277334	chr10:82204260	NA	-0.55	-5.0	-0.3	1.11e-6	Post bronchodilator FEV1;
KIRP	cis	rs4748857	0.782	rs4748848	chr10:23531244	C/T	cg12804278	chr10:23633326	C10orf67	0.43	5.47	0.33	1.09e-7	Systemic lupus erythematosus;
KIRP	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg14675211	chr2:100938903	LONRF2	0.49	6.38	0.38	8.59e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-12.96	-0.64	1.26e-29	Blood metabolite levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20295353	chr14:64989846	ZBTB1	0.53	7.18	0.42	8.44e-12	Interleukin-4 levels;
KIRP	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg16105309	chr15:79090380	ADAMTS7	0.6	7.8	0.45	1.72e-13	Schizophrenia;
KIRP	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-8.45	-0.47	2.58e-15	Response to antipsychotic treatment;
KIRP	cis	rs9393813	0.901	rs12529756	chr6:27471448	C/T	cg03332623	chr6:27441972	ZNF184	-0.35	-5.28	-0.32	2.79e-7	Bipolar disorder;
KIRP	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg08392591	chr16:89556376	ANKRD11	0.41	5.23	0.32	3.59e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-5.4	-0.33	1.57e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg00405596	chr8:11794950	NA	0.46	6.01	0.36	6.78e-9	Triglycerides;
KIRP	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg05082376	chr22:42548792	NA	0.45	5.75	0.34	2.61e-8	Schizophrenia;
KIRP	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.95	-16.64	-0.73	3.52e-42	Height;
KIRP	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.69	8.77	0.49	3e-16	Schizophrenia;
KIRP	trans	rs8073060	0.586	rs72829933	chr17:34056406	C/T	cg19694781	chr19:47549865	TMEM160	1.18	14.49	0.68	7.85e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.94	13.31	0.65	8.27e-31	Menopause (age at onset);
KIRP	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg13611997	chr5:233750	SDHA	0.4	5.02	0.3	9.9e-7	Breast cancer;
KIRP	cis	rs9815354	0.812	rs73069240	chr3:41950973	A/T	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8067545	0.667	rs7222403	chr17:19879164	T/C	cg04132472	chr17:19861366	AKAP10	0.64	9.48	0.52	2.31e-18	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08761248	chr12:56615735	RNF41	0.56	7.97	0.45	5.97e-14	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.77	10.08	0.54	3.23e-20	Menopause (age at onset);
KIRP	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.41	5.29	0.32	2.7e-7	Birth weight;
KIRP	trans	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	6.99	0.41	2.54e-11	Mean corpuscular volume;
KIRP	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg18016565	chr1:150552671	MCL1	0.4	6.05	0.36	5.49e-9	Melanoma;
KIRP	cis	rs1298062	0.771	rs4801833	chr19:50995932	T/G	cg11430371	chr19:50961752	MYBPC2	0.36	4.96	0.3	1.33e-6	Age of smoking initiation;
KIRP	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21214613	chr1:16344536	HSPB7	0.35	5.17	0.31	4.89e-7	Systolic blood pressure;
KIRP	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg27205649	chr11:78285834	NARS2	-0.67	-7.37	-0.43	2.6e-12	Alzheimer's disease (survival time);
KIRP	cis	rs7301016	0.707	rs7302602	chr12:63052199	C/T	cg01804193	chr12:63026212	NA	-0.53	-5.79	-0.35	2.18e-8	IgG glycosylation;
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg21186296	chr8:27182909	PTK2B	0.5	6.35	0.38	1e-9	Neuroticism;
KIRP	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-6.88	-0.4	4.97e-11	Axial length;
KIRP	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.82	-10.35	-0.55	4.45e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.74	9.46	0.52	2.63e-18	Coronary artery disease;
KIRP	cis	rs12220238	0.659	rs10824208	chr10:76357634	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.8	7.13	0.41	1.1e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	0.85	7.63	0.44	5.13e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg04731861	chr2:219085781	ARPC2	0.28	7.25	0.42	5.45e-12	Colorectal cancer;
KIRP	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg25418670	chr11:30344373	C11orf46	-0.59	-4.98	-0.3	1.21e-6	Morning vs. evening chronotype;
KIRP	cis	rs7751419	0.651	rs10947779	chr6:39093617	A/G	cg25014318	chr6:39016776	GLP1R	0.35	4.98	0.3	1.18e-6	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg14091149	chr1:16273971	ZBTB17	0.35	5.02	0.31	9.78e-7	Dilated cardiomyopathy;
KIRP	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg03342759	chr3:160939853	NMD3	-0.69	-8.93	-0.49	1.02e-16	Morning vs. evening chronotype;
KIRP	cis	rs6782228	0.675	rs4857918	chr3:128383960	T/C	cg18648031	chr3:128330563	NA	0.26	5.26	0.32	3.1e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.84	-10.39	-0.55	3.26e-21	Menarche (age at onset);
KIRP	trans	rs74233809	0.901	rs4409766	chr10:104616663	A/G	cg06319475	chr8:145105829	NA	-0.4	-6.23	-0.37	1.97e-9	Birth weight;
KIRP	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.62	6.35	0.38	1.06e-9	Gut microbiome composition (summer);
KIRP	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.86	-0.4	5.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.49	-5.9	-0.35	1.21e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7394190	0.748	rs11541237	chr10:75530962	C/T	cg04833713	chr10:74871078	NUDT13	0.43	4.86	0.3	2.1e-6	Incident atrial fibrillation;
KIRP	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.65	9.25	0.51	1.11e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg21573476	chr21:45109991	RRP1B	-0.62	-8.29	-0.47	7.54e-15	Mean corpuscular volume;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg11501364	chr13:99851660	UBAC2	-0.42	-6.07	-0.36	4.82e-9	Select biomarker traits;
KIRP	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.67	7.04	0.41	1.94e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.89	9.13	0.5	2.65e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.84e-7	Total body bone mineral density;
KIRP	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	0.76	4.94	0.3	1.47e-6	Plateletcrit;
KIRP	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.24	-0.47	1.02e-14	Retinal vascular caliber;
KIRP	cis	rs3857747	0.931	rs11772072	chr7:40386344	G/A	cg00420559	chr7:40367873	C7orf10	-0.59	-8.1	-0.46	2.63e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg16814680	chr8:91681699	NA	0.45	6.03	0.36	5.92e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.73	8.57	0.48	1.13e-15	Type 2 diabetes;
KIRP	cis	rs6832769	0.885	rs6815516	chr4:56399184	A/T	cg09317128	chr4:56265301	TMEM165	-0.55	-7.35	-0.42	2.89e-12	Personality dimensions;
KIRP	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.58	-6.12	-0.36	3.68e-9	Obesity-related traits;
KIRP	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg16511985	chr3:153974050	SGEF	0.37	5.09	0.31	7.08e-7	Coronary artery disease;
KIRP	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.53	-7.11	-0.41	1.29e-11	Height;
KIRP	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg23594656	chr7:65796392	TPST1	0.51	7.97	0.45	5.76e-14	Aortic root size;
KIRP	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg22244940	chr12:132335942	MMP17	0.52	6.35	0.38	1.06e-9	Migraine;
KIRP	cis	rs76917914	0.780	rs1059273	chr9:100849500	G/T	cg03040243	chr9:100819229	NANS	0.6	6.71	0.39	1.3100000000000001e-10	Immature fraction of reticulocytes;
KIRP	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7737355	0.947	rs11744232	chr5:130911732	A/G	cg25547332	chr5:131281432	NA	0.4	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg12384639	chr17:618140	VPS53	0.48	5.88	0.35	1.33e-8	Prostate cancer;
KIRP	cis	rs4761097	0.537	rs6539857	chr12:85177419	C/G	cg00765312	chr12:85674694	ALX1	0.49	5.77	0.35	2.42e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg00204512	chr16:28754710	NA	0.46	6.06	0.36	5.06e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4635969	0.718	rs27071	chr5:1346081	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.61	-6.84	-0.4	6.19e-11	Testicular germ cell tumor;Testicular germ cell cancer;
KIRP	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	1.16	13.72	0.66	3.44e-32	Red blood cell traits;
KIRP	trans	rs7246760	1.000	rs2287839	chr19:9940814	C/G	cg02900749	chr2:68251473	NA	-1.02	-9.18	-0.51	1.87e-17	Pursuit maintenance gain;
KIRP	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	6.93	0.4	3.61e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11814422	chr18:47018265	SNORD58A;RPL17;SNORD58B	0.53	6.2	0.37	2.4e-9	Smoking initiation;
KIRP	cis	rs13065560	0.560	rs11716777	chr3:38957755	G/T	cg01426195	chr3:39028469	NA	0.41	5.98	0.36	7.82e-9	Interleukin-18 levels;
KIRP	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.58	0.34	6.2e-8	Parkinson's disease;
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.44	5.21	0.32	3.93e-7	Longevity;Endometriosis;
KIRP	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg00409905	chr10:38381863	ZNF37A	0.63	6.97	0.41	2.88e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg21775007	chr8:11205619	TDH	0.49	6.41	0.38	7.29e-10	Retinal vascular caliber;
KIRP	cis	rs7584330	0.628	rs73098849	chr2:238389739	G/A	cg14458575	chr2:238380390	NA	0.63	6.66	0.39	1.76e-10	Prostate cancer;
KIRP	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.22	13.95	0.66	5.51e-33	Corneal structure;
KIRP	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs6668534	1.000	rs6668534	chr1:161671995	C/T	cg26561570	chr1:161602002	FCGR3B	-0.41	-5.24	-0.32	3.48e-7	Blood protein levels;
KIRP	trans	rs2281597	0.664	rs1543464	chr1:34304477	A/G	cg19991458	chr15:67417651	SMAD3	-0.48	-6.14	-0.36	3.23e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg21699342	chr2:239360505	ASB1	0.48	5.66	0.34	4.16e-8	Multiple system atrophy;
KIRP	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg00405596	chr8:11794950	NA	0.59	8.41	0.47	3.31e-15	Myopia (pathological);
KIRP	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.3	-0.32	2.57e-7	Bipolar disorder;
KIRP	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.76	-8.98	-0.5	7.47e-17	Pancreatic cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12595439	chr6:64290026	PTP4A1	-0.44	-6.77	-0.4	9.28e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4144743	0.528	rs16941802	chr17:45355353	C/G	cg18085866	chr17:45331354	ITGB3	0.68	5.48	0.33	1.06e-7	Body mass index;
KIRP	cis	rs4908768	0.817	rs11587482	chr1:8743195	T/G	cg25722041	chr1:8623473	RERE	0.77	8.64	0.48	7.26e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.98	-0.41	2.8e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg11234688	chr2:1609660	NA	0.6	5.29	0.32	2.65e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.43	-5.74	-0.34	2.82e-8	Refractive error;
KIRP	cis	rs2929278	0.561	rs2927071	chr15:43919081	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.46	5.68	0.34	3.82e-8	Schizophrenia;
KIRP	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.63	-7.67	-0.44	4.12e-13	Metabolic traits;LDL cholesterol;
KIRP	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.48	5.16	0.31	5.12e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg06740227	chr12:86229804	RASSF9	-0.48	-5.88	-0.35	1.34e-8	Major depressive disorder;
KIRP	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.35	-0.38	1.04e-9	Blood pressure;
KIRP	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs1215050	0.791	rs165250	chr4:98696259	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.55	0.39	3.26e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg19743168	chr1:23544995	NA	0.52	7.29	0.42	4.27e-12	Height;
KIRP	cis	rs10795061	0.576	rs6601744	chr10:3711563	C/A	cg22632523	chr10:3711048	NA	0.35	5.37	0.32	1.85e-7	Subjective well-being;
KIRP	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.66	9.68	0.53	5.43e-19	Dupuytren's disease;
KIRP	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.86	9.39	0.51	4.35e-18	Osteoarthritis;
KIRP	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg26338869	chr17:61819248	STRADA	-0.43	-5.25	-0.32	3.27e-7	Prudent dietary pattern;
KIRP	cis	rs4006360	0.629	rs72625995	chr17:39253835	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-8.9	-0.49	1.24e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00689492	chr4:1303491	MAEA	0.31	5.3	0.32	2.52e-7	Obesity-related traits;
KIRP	cis	rs6499755	0.768	rs31096	chr16:55367403	T/C	cg05099576	chr16:55362342	IRX6	0.33	6.7	0.39	1.4e-10	Hypospadias;
KIRP	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.51e-19	Prudent dietary pattern;
KIRP	cis	rs78487399	0.808	rs6708735	chr2:43731354	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.06	-0.31	8.28e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg09597638	chr17:3907349	NA	0.75	14.16	0.67	1.07e-33	Type 2 diabetes;
KIRP	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.15	0.5	2.3e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	7.63	0.44	5.23e-13	Lung cancer in ever smokers;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.8e-7	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.47	-0.38	5.2e-10	Lung cancer;
KIRP	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03934478	chr11:495069	RNH1	0.87	6.74	0.39	1.1e-10	Body mass index;
KIRP	cis	rs11710088	0.895	rs4482615	chr3:149198681	T/C	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.43	-0.33	1.36e-7	QRS duration;
KIRP	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.2	0.51	1.59e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs60311166	1.000	rs58725214	chr3:52593214	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.9	5.55	0.33	7.28e-8	CTACK levels;
KIRP	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.33	0.37	1.12e-9	Aortic root size;
KIRP	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.88	12.39	0.62	1.01e-27	Primary sclerosing cholangitis;
KIRP	cis	rs7084402	1.000	rs717452	chr10:60268270	A/G	cg05938607	chr10:60274200	BICC1	-0.4	-9.62	-0.52	8.64e-19	Refractive error;
KIRP	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.46	6.67	0.39	1.68e-10	Urate levels in lean individuals;
KIRP	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.59	-9.42	-0.51	3.55e-18	C-reactive protein levels;
KIRP	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15850155	chr6:160426268	IGF2R	0.54	6.13	0.36	3.44e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27019801	chr14:31926776	C14orf126	0.48	6.26	0.37	1.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2658782	0.724	rs1563445	chr11:93246042	A/G	cg15737290	chr11:93063684	CCDC67	0.64	7.08	0.41	1.54e-11	Pulmonary function decline;
KIRP	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	9.48	0.52	2.23e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.67	-5.04	-0.31	9.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09127853	chr11:19263291	E2F8	-0.43	-6.17	-0.37	2.76e-9	Myopia;
KIRP	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-7.26	-0.42	5.03e-12	Coronary artery disease;
KIRP	cis	rs501120	0.657	rs115299170	chr10:44742925	T/C	cg09554077	chr10:44749378	NA	0.77	11.99	0.61	2.1e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs72730918	0.590	rs2606136	chr15:51971533	A/G	cg14296394	chr15:51910925	DMXL2	0.76	10.61	0.56	6.92e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs612683	0.694	rs6688166	chr1:101000717	G/C	cg09408571	chr1:101003634	GPR88	0.35	7.9	0.45	9.45e-14	Breast cancer;
KIRP	cis	rs580438	0.529	rs7653172	chr3:13435550	T/C	cg10657019	chr3:13328039	NA	-0.49	-6.36	-0.38	9.94e-10	Myringotomy;
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg23736307	chr8:27182930	PTK2B	0.55	7.04	0.41	1.9e-11	Neuroticism;
KIRP	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg01065977	chr19:18549689	ISYNA1	-0.43	-6.59	-0.39	2.73e-10	Breast cancer;
KIRP	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.24e-6	Menopause (age at onset);
KIRP	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.3	-0.42	3.91e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg25281562	chr12:121454272	C12orf43	0.55	6.07	0.36	4.81e-9	N-glycan levels;
KIRP	trans	rs4143844	0.867	rs62009074	chr15:62152058	A/G	cg04814990	chr13:111957387	ARHGEF7	0.99	6.51	0.38	4.3e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.42	-6.14	-0.36	3.25e-9	Coronary artery disease;
KIRP	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg26695010	chr11:65641043	EFEMP2	0.47	5.68	0.34	3.76e-8	Eosinophil percentage of white cells;
KIRP	cis	rs986417	1.000	rs12587609	chr14:60928850	C/G	cg27398547	chr14:60952738	C14orf39	0.74	7.43	0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg01236616	chr12:121019343	POP5	-1.27	-15.31	-0.7	1.24e-37	Type 1 diabetes nephropathy;
KIRP	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.79	9.02	0.5	5.33e-17	Corneal astigmatism;
KIRP	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.71	7.23	0.42	6.2e-12	Vitiligo;
KIRP	cis	rs11723261	0.621	rs7692530	chr4:123445	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.5	5.33	0.32	2.23e-7	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.57	-9.23	-0.51	1.29e-17	Prostate cancer;
KIRP	trans	rs7999699	0.902	rs1924805	chr13:48308368	G/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.78	-11.91	-0.6	4.07e-26	Height;
KIRP	cis	rs11874712	0.965	rs12954944	chr18:43664115	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg06521331	chr12:34319734	NA	-0.48	-5.56	-0.33	6.85e-8	Resting heart rate;
KIRP	cis	rs2904967	0.866	rs8638	chr11:65064918	C/G	cg09225861	chr11:65069680	NA	0.45	5.84	0.35	1.66e-8	Mean corpuscular volume;
KIRP	cis	rs2307121	0.700	rs10471661	chr5:64746627	A/G	cg11190754	chr5:64858552	CENPK;PPWD1	0.44	5.66	0.34	4.18e-8	Corneal structure;
KIRP	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.54	7.19	0.42	7.66e-12	Blood metabolite levels;
KIRP	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg11465639	chr17:19241549	NA	0.38	4.85	0.3	2.18e-6	Schizophrenia;
KIRP	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg26441486	chr22:50317300	CRELD2	0.48	7.99	0.45	5.21e-14	Schizophrenia;
KIRP	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg14675211	chr2:100938903	LONRF2	0.48	6.22	0.37	2.14e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs4356932	1.000	rs6532114	chr4:76957974	T/C	cg00809888	chr4:76862425	NAAA	0.42	5.93	0.35	1.05e-8	Blood protein levels;
KIRP	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.61	-9.0	-0.5	6.12e-17	Brugada syndrome;
KIRP	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.44	6.97	0.41	2.88e-11	Inflammatory bowel disease;
KIRP	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg21919602	chr1:242011447	EXO1	-0.46	-5.85	-0.35	1.59e-8	Menopause (age at onset);
KIRP	cis	rs7190997	0.525	rs11150612	chr16:31357760	G/A	cg02846316	chr16:31340340	ITGAM	0.39	4.95	0.3	1.39e-6	IgA nephropathy;
KIRP	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg16141378	chr3:129829833	LOC729375	0.48	6.05	0.36	5.3300000000000004e-09	Neuroticism;
KIRP	cis	rs12311304	1.000	rs6488766	chr12:15374630	A/G	cg08258403	chr12:15378311	NA	0.34	4.91	0.3	1.66e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.24	-0.64	1.46e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.61	8.75	0.49	3.53e-16	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.04	8.02	0.46	4.31e-14	Skin colour saturation;
KIRP	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24549020	chr5:56110836	MAP3K1	0.52	5.02	0.31	9.76e-7	Initial pursuit acceleration;
KIRP	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.4	6.87	0.4	5.13e-11	Renal cell carcinoma;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg17441377	chr17:3906640	NA	0.38	4.9	0.3	1.76e-6	Type 2 diabetes;
KIRP	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs7520050	0.807	rs4468203	chr1:46113272	T/C	cg03146154	chr1:46216737	IPP	0.43	5.4	0.33	1.6e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.91	11.67	0.6	2.4e-25	Homoarginine levels;
KIRP	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.63	-6.25	-0.37	1.81e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03502236	chr11:1074682	MUC2	0.44	7.1	0.41	1.36e-11	Interleukin-4 levels;
KIRP	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.69	-0.34	3.67e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg16586182	chr3:47516702	SCAP	0.83	11.93	0.61	3.38e-26	Colorectal cancer;
KIRP	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg27462398	chr1:86174642	ZNHIT6	-0.45	-5.19	-0.31	4.32e-7	Urate levels in overweight individuals;
KIRP	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg08994789	chr17:28903642	LRRC37B2	0.72	8.32	0.47	6.05e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7246865	0.954	rs55957788	chr19:17207851	G/A	cg18440316	chr19:18077727	KCNN1	-0.41	-5.81	-0.35	1.95e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2880765	0.525	rs35899940	chr15:86053697	A/G	cg15340431	chr15:86040528	AKAP13	-0.46	-5.85	-0.35	1.53e-8	Coronary artery disease;
KIRP	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.06	0.31	8.06e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	1.1	17.57	0.75	2.4e-45	Migraine;
KIRP	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.95	15.64	0.71	9.51e-39	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg23172400	chr8:95962367	TP53INP1	-0.33	-6.83	-0.4	6.6e-11	Type 2 diabetes;
KIRP	cis	rs4716602	0.542	rs13224561	chr7:156161063	G/A	cg16983916	chr7:156159713	NA	-0.45	-5.63	-0.34	4.94e-8	Anti-saccade response;
KIRP	cis	rs1562975	0.609	rs11932691	chr4:109431283	C/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.41	5.03	0.31	9.66e-7	Height;
KIRP	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.56	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21214613	chr1:16344536	HSPB7	0.35	5.34	0.32	2.17e-7	Dilated cardiomyopathy;
KIRP	trans	rs11834041	1.000	rs61939325	chr12:128235408	C/G	cg08266923	chr10:70166773	RUFY2	-0.67	-6.3	-0.37	1.37e-9	Response to cognitive-behavioural therapy in anxiety disorder;
KIRP	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.08e-6	Aortic root size;
KIRP	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.2	-0.51	1.59e-17	Neuroticism;
KIRP	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.95	16.37	0.72	3.08e-41	Breast cancer;
KIRP	cis	rs9928842	0.823	rs2870472	chr16:75278841	C/G	cg09066997	chr16:75300724	BCAR1	0.64	5.43	0.33	1.38e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.59	-8.4	-0.47	3.7e-15	Urate levels in overweight individuals;
KIRP	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.64	-9.18	-0.51	1.77e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.49	7.87	0.45	1.09e-13	Sudden cardiac arrest;
KIRP	cis	rs8093481	1.000	rs9957990	chr18:10690811	T/C	cg21165219	chr18:10698044	FAM38B	-0.46	-5.69	-0.34	3.53e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs3026101	0.671	rs3026125	chr17:5293627	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg10578777	chr12:7781093	NA	0.57	5.75	0.34	2.62e-8	HDL cholesterol levels;
KIRP	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.67	8.65	0.48	6.64e-16	Age at first birth;
KIRP	cis	rs55788414	0.932	rs8048115	chr16:81182554	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.29	-0.47	7.58e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	1.02	17.32	0.74	1.72e-44	Bone mineral density;
KIRP	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.32	0.42	3.5e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.09	0.46	2.7e-14	Body mass index;
KIRP	cis	rs7534824	0.625	rs61782081	chr1:101507074	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	7.24	0.42	5.66e-12	Refractive astigmatism;
KIRP	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.05	-0.41	1.82e-11	Joint mobility (Beighton score);
KIRP	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg04374321	chr14:90722782	PSMC1	0.82	12.37	0.62	1.22e-27	Mortality in heart failure;
KIRP	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg14914422	chr1:46958856	NA	-0.41	-5.17	-0.31	4.85e-7	Monobrow;
KIRP	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg12131826	chr15:77904385	NA	0.49	5.7	0.34	3.41e-8	Type 2 diabetes;
KIRP	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.54	5.19	0.31	4.33e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
KIRP	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.65	-12.43	-0.62	7.44e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg06565975	chr8:143823917	SLURP1	-0.5	-7.23	-0.42	6.02e-12	Urinary tract infection frequency;
KIRP	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	trans	rs7656342	0.535	rs4575993	chr4:9858744	A/G	cg26043149	chr18:55253948	FECH	0.52	6.32	0.37	1.21e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg18154014	chr19:37997991	ZNF793	0.69	6.13	0.36	3.56e-9	Coronary artery calcification;
KIRP	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.76	9.31	0.51	7.31e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-5.17	-0.31	4.76e-7	Vitiligo;
KIRP	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.64	5.53	0.33	8.18e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg17441377	chr17:3906640	NA	0.48	6.99	0.41	2.62e-11	Type 2 diabetes;
KIRP	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.82	9.84	0.53	1.75e-19	Corneal astigmatism;
KIRP	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.07	0.41	1.56e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9859260	1.000	rs2239641	chr3:195789414	T/C	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.38	-8.12	-0.46	2.23e-14	Body mass index;
KIRP	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.16	-0.37	2.93e-9	Bipolar disorder;
KIRP	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg04691961	chr3:161091175	C3orf57	0.45	6.66	0.39	1.78e-10	Morning vs. evening chronotype;
KIRP	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.72	-8.51	-0.48	1.76e-15	Resting heart rate;
KIRP	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Alcohol dependence;
KIRP	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.8	10.27	0.55	7.81e-21	Mean platelet volume;
KIRP	cis	rs2230307	0.572	rs11166408	chr1:100641350	A/T	cg24955406	chr1:100503596	HIAT1	-0.58	-5.88	-0.35	1.34e-8	Carotid intima media thickness;
KIRP	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.37	-4.86	-0.3	2.06e-6	Hypertriglyceridemia;
KIRP	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg24375607	chr4:120327624	NA	0.55	5.6	0.34	5.71e-8	Corneal astigmatism;
KIRP	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.67	-9.9	-0.53	1.17e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	0.8	9.67	0.52	5.89e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.84	12.1	0.61	9.63e-27	Longevity;
KIRP	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.83	0.49	2.03e-16	Electroencephalogram traits;
KIRP	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg01620082	chr3:125678407	NA	-1.09	-6.86	-0.4	5.53e-11	Depression;
KIRP	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg17145862	chr1:211918768	LPGAT1	0.61	6.63	0.39	2.07e-10	Crohn's disease;
KIRP	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs883115	0.846	rs1566386	chr1:224803800	T/C	cg01808320	chr1:224927238	CNIH3	-0.37	-5.26	-0.32	3.08e-7	Cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04333463	chr8:62626687	ASPH	0.54	6.53	0.38	3.67e-10	C-reactive protein;
KIRP	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05347473	chr6:146136440	FBXO30	0.63	9.16	0.5	2.14e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.93	0.53	9.23e-20	Coffee consumption (cups per day);
KIRP	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.7	-10.26	-0.55	8.35e-21	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-6.81	-0.4	7.27e-11	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23172579	chr4:141677235	TBC1D9	0.51	6.85	0.4	5.86e-11	Parkinson's disease;
KIRP	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.64	9.37	0.51	4.96e-18	Vitiligo;
KIRP	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.38	5.23	0.32	3.63e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs933360	0.585	rs6951356	chr7:50829767	C/G	cg20003124	chr12:4557277	NA	0.53	6.47	0.38	5.22e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg18306943	chr3:40428807	ENTPD3	0.46	5.86	0.35	1.45e-8	Renal cell carcinoma;
KIRP	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.69	9.08	0.5	3.62e-17	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.94	-0.4	3.51e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07638904	chr22:19166425	SLC25A1	0.55	7.34	0.42	3.18e-12	Myopia (pathological);
KIRP	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg09571762	chr12:39539558	NA	0.34	5.04	0.31	9.09e-7	Morning vs. evening chronotype;
KIRP	cis	rs2929278	0.617	rs4617832	chr15:44030579	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-6.89	-0.4	4.55e-11	Schizophrenia;
KIRP	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.58	-7.99	-0.45	5.14e-14	Height;
KIRP	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.02	-11.08	-0.58	2.02e-23	Alzheimer's disease;
KIRP	cis	rs2274273	0.588	rs7155054	chr14:55750662	A/G	cg04306507	chr14:55594613	LGALS3	0.41	5.94	0.35	9.42e-9	Protein biomarker;
KIRP	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg27124370	chr19:33622961	WDR88	0.73	10.56	0.56	9.77e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg24972876	chr7:65420302	NA	-0.4	-5.48	-0.33	1.05e-7	Aortic root size;
KIRP	cis	rs539514	0.556	rs1108412	chr13:76321497	G/A	cg04757411	chr13:76259545	LMO7	-0.36	-5.02	-0.3	1.01e-6	Type 1 diabetes;
KIRP	trans	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg19894588	chr14:64061835	NA	-0.46	-6.2	-0.37	2.37e-9	Fat distribution (HIV);
KIRP	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17554472	chr22:41940697	POLR3H	-0.7	-7.17	-0.42	9.01e-12	Vitiligo;
KIRP	cis	rs6256	1.000	rs12421404	chr11:13561788	C/T	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg00405596	chr8:11794950	NA	-0.46	-5.67	-0.34	4.06e-8	Monocyte count;
KIRP	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg06042504	chr8:55087323	NA	-0.54	-6.69	-0.39	1.5e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg06521331	chr12:34319734	NA	-0.48	-6.07	-0.36	4.89e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.41	5.33	0.32	2.19e-7	Birth weight;
KIRP	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg23565292	chr14:50234668	KLHDC2	-0.41	-4.88	-0.3	1.87e-6	Carotid intima media thickness;
KIRP	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.84	0.63	3.22e-29	Morning vs. evening chronotype;
KIRP	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg24848339	chr3:12840334	CAND2	0.32	4.88	0.3	1.94e-6	QRS complex (12-leadsum);
KIRP	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.53e-7	Tonsillectomy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10835423	chr1:112162393	RAP1A	0.45	6.22	0.37	2.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.46	6.3	0.37	1.34e-9	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20783806	chr2:419684	NA	0.56	7.66	0.44	4.36e-13	Interleukin-4 levels;
KIRP	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.82	-0.53	2.07e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-8.88	-0.49	1.46e-16	Platelet count;
KIRP	cis	rs12362504	0.504	rs1546541	chr11:9900438	T/C	cg07197493	chr11:9884649	SBF2	-0.43	-6.04	-0.36	5.59e-9	Survival in pancreatic cancer;
KIRP	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.33	6.34	0.37	1.11e-9	Alcohol dependence;
KIRP	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.48	-6.56	-0.39	3.07e-10	Asthma;
KIRP	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg14558114	chr2:88469736	THNSL2	0.66	5.37	0.32	1.81e-7	Plasma clusterin levels;
KIRP	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.68	8.98	0.5	7.32e-17	Longevity;
KIRP	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.76	7.66	0.44	4.37e-13	Lung function (FEV1/FVC);
KIRP	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.04	0.36	5.64e-9	Lung cancer;
KIRP	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02711726	chr17:80685570	FN3KRP	-0.71	-10.29	-0.55	6.77e-21	Glycated hemoglobin levels;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg09264619	chr17:80180166	NA	0.34	4.89	0.3	1.83e-6	Life satisfaction;
KIRP	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg16584676	chr17:46985605	UBE2Z	0.49	5.94	0.35	9.42e-9	Type 2 diabetes;
KIRP	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs220519	0.745	rs220527	chr20:37277153	G/T	cg24308336	chr20:37270989	C20orf95	0.24	5.22	0.32	3.73e-7	Schizophrenia;
KIRP	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.45	-0.55	2.24e-21	Chronic sinus infection;
KIRP	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg16524733	chr11:117070046	TAGLN	0.38	4.93	0.3	1.54e-6	Blood protein levels;
KIRP	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg05220968	chr6:146057943	EPM2A	-0.38	-4.85	-0.3	2.24e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg23682824	chr7:23144976	KLHL7	0.51	5.95	0.35	9.14e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.45	6.33	0.37	1.13e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.62	7.92	0.45	8.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.96	16.35	0.72	3.45e-41	Breast cancer;
KIRP	cis	rs3755132	0.929	rs6743630	chr2:15768256	G/A	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg26247618	chr15:44119245	WDR76	0.53	6.75	0.4	1.04e-10	Bladder cancer;
KIRP	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21545522	chr1:205238299	TMCC2	0.47	6.25	0.37	1.83e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.73	-7.83	-0.45	1.41e-13	Blood pressure (smoking interaction);
KIRP	cis	rs11731606	0.508	rs7696494	chr4:95285174	G/A	cg00507259	chr4:95128692	SMARCAD1	0.6	5.96	0.36	8.75e-9	Mean platelet volume;
KIRP	cis	rs6466055	0.777	rs10487150	chr7:104797450	A/C	cg04380332	chr7:105027541	SRPK2	-0.64	-9.63	-0.52	7.81e-19	Schizophrenia;
KIRP	cis	rs3756766	0.500	rs7715815	chr5:137660982	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.41	4.97	0.3	1.27e-6	Schizophrenia;
KIRP	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg03959625	chr15:84868606	LOC388152	0.46	5.43	0.33	1.34e-7	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg00656387	chr3:40428638	ENTPD3	0.38	4.87	0.3	1.96e-6	Renal cell carcinoma;
KIRP	cis	rs2224391	0.590	rs72813697	chr6:5274266	T/A	cg13962347	chr6:5174647	LYRM4	-0.81	-8.16	-0.46	1.75e-14	Height;
KIRP	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.91	-0.49	1.17e-16	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg01677386	chr11:118938358	VPS11	0.5	5.53	0.33	8.27e-8	Coronary artery disease;
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.62	9.54	0.52	1.51e-18	Lung cancer;
KIRP	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.67	-9.89	-0.53	1.24e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.45	-0.47	2.6e-15	Common traits (Other);
KIRP	trans	rs7999699	0.871	rs12429531	chr13:48309349	G/A	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg26412358	chr1:26503933	CNKSR1	0.39	5.53	0.33	8.14e-8	Height;
KIRP	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg02023728	chr11:77925099	USP35	-0.31	-5.05	-0.31	8.57e-7	Alzheimer's disease (survival time);
KIRP	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.85	-9.85	-0.53	1.61e-19	Osteoarthritis;
KIRP	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg16497661	chr14:103986332	CKB	-0.5	-6.38	-0.38	8.51e-10	Coronary artery disease;
KIRP	cis	rs963731	0.522	rs1454222	chr2:39215895	C/A	cg04010122	chr2:39346883	SOS1	-0.87	-5.78	-0.35	2.31e-8	Corticobasal degeneration;
KIRP	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.53	-8.83	-0.49	2.01e-16	Eye color traits;
KIRP	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.28	-0.37	1.56e-9	Morning vs. evening chronotype;
KIRP	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.25	0.47	9.89e-15	Colorectal cancer;
KIRP	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.89	0.35	1.26e-8	Life satisfaction;
KIRP	cis	rs75920871	0.688	rs61905678	chr11:116834785	C/T	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg14696996	chr19:15285081	NOTCH3	0.73	6.74	0.39	1.11e-10	Pulse pressure;
KIRP	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-19.64	-0.78	2.77e-52	Height;
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.63	9.82	0.53	2.03e-19	Lung cancer;
KIRP	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg06453172	chr10:134556979	INPP5A	-0.52	-5.67	-0.34	4.04e-8	Migraine;
KIRP	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg15083037	chr5:83017644	HAPLN1	-0.58	-7.41	-0.43	2e-12	Prostate cancer;
KIRP	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.93	-0.3	1.51e-6	Schizophrenia;
KIRP	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08822215	chr16:89438651	ANKRD11	-0.42	-5.66	-0.34	4.22e-8	Multiple myeloma (IgH translocation);
KIRP	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg12856521	chr11:46389249	DGKZ	0.54	6.9	0.4	4.3e-11	Crohn's disease;
KIRP	cis	rs4728302	0.934	rs10258052	chr7:133635874	T/C	cg10665199	chr7:133106180	EXOC4	-0.41	-5.03	-0.31	9.39e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg15488143	chr7:128924101	AHCYL2	0.61	6.54	0.39	3.46e-10	White matter hyperintensity burden;
KIRP	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26617929	chr16:1858877	NA	-0.8	-7.57	-0.43	7.36e-13	Ankle injury;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14576291	chr9:134526136	RAPGEF1	-0.45	-6.07	-0.36	4.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03934478	chr11:495069	RNH1	0.86	7.0	0.41	2.46e-11	Body mass index;
KIRP	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.92	15.65	0.71	8.71e-39	Metabolic syndrome;
KIRP	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	16.81	0.73	9.61e-43	Platelet count;
KIRP	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg08885076	chr2:99613938	TSGA10	-0.64	-11.05	-0.58	2.58e-23	Chronic sinus infection;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21016266	chr12:122356598	WDR66	0.65	8.71	0.49	4.51e-16	Mean corpuscular volume;
KIRP	cis	rs597583	0.664	rs4936384	chr11:117398591	C/T	cg27161313	chr11:117392002	DSCAML1	-0.54	-5.91	-0.35	1.16e-8	Putamen volume;
KIRP	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg13072238	chr3:49761600	GMPPB	-0.57	-5.34	-0.32	2.1e-7	Menarche (age at onset);
KIRP	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	0.79	11.09	0.58	1.91e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.07	0.31	7.94e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg27411982	chr8:10470053	RP1L1	0.39	5.08	0.31	7.57e-7	Neuroticism;
KIRP	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.62	-0.52	8.4e-19	Hemoglobin concentration;
KIRP	cis	rs73198271	1.000	rs4840356	chr8:8607527	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.14	-0.31	5.53e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg00277334	chr10:82204260	NA	-0.46	-5.26	-0.32	3.11e-7	Post bronchodilator FEV1;
KIRP	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.94	14.54	0.68	5.52e-35	Alcohol dependence;
KIRP	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12311346	chr5:56204834	C5orf35	-0.35	-4.86	-0.3	2.11e-6	Coronary artery disease;
KIRP	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-0.42	-5.46	-0.33	1.17e-7	Acne (severe);
KIRP	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.6	7.23	0.42	6.12e-12	Dialysis-related mortality;
KIRP	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.4	6.13	0.36	3.51e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg13786083	chr1:19110734	NA	-0.44	-5.23	-0.32	3.61e-7	Drug-induced liver injury (nitrofurantoin);
KIRP	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.44	-0.38	6.35e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-9.3	-0.51	7.72e-18	Colorectal cancer;
KIRP	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg07382826	chr16:28625726	SULT1A1	0.51	6.16	0.37	2.96e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9473924	0.542	rs9463665	chr6:50928520	G/T	cg14470998	chr6:50812995	TFAP2B	0.8	7.51	0.43	1.12e-12	Body mass index;
KIRP	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23281280	chr6:28129359	ZNF389	0.45	4.93	0.3	1.53e-6	Depression;
KIRP	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	7.63	0.44	5e-13	Type 2 diabetes;
KIRP	cis	rs11955175	1.000	rs11953977	chr5:40674690	G/C	cg17351974	chr5:40835760	RPL37	0.54	4.9	0.3	1.73e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2976388	0.625	rs2257840	chr8:143809193	C/T	cg06565975	chr8:143823917	SLURP1	0.46	7.15	0.41	1.01e-11	Urinary tract infection frequency;
KIRP	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg10189774	chr4:17578691	LAP3	-0.49	-5.29	-0.32	2.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16447950	chr5:562315	NA	-0.47	-6.12	-0.36	3.66e-9	Obesity-related traits;
KIRP	cis	rs300890	0.689	rs7697838	chr4:144247348	T/C	cg01601573	chr4:144256835	GAB1	0.34	4.92	0.3	1.6e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs4713675	0.584	rs6916949	chr6:33678290	C/G	cg15676125	chr6:33679581	C6orf125	0.42	5.49	0.33	1.02e-7	Plateletcrit;
KIRP	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.78	11.61	0.59	3.85e-25	Heart rate;
KIRP	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.0	7.25	0.42	5.32e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.11	-0.41	1.28e-11	Menopause (age at onset);
KIRP	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.54	-0.48	1.43e-15	Retinal vascular caliber;
KIRP	cis	rs35740288	0.787	rs727379	chr15:86229890	A/G	cg10818794	chr15:86012489	AKAP13	-0.42	-5.0	-0.3	1.1e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-5.14	-0.31	5.71e-7	Putamen volume;
KIRP	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg00343986	chr7:65444356	GUSB	0.49	5.92	0.35	1.07e-8	Calcium levels;
KIRP	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.71	-9.62	-0.52	8.48e-19	Colorectal cancer;
KIRP	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg16898833	chr6:26189333	HIST1H4D	0.96	5.55	0.33	7.26e-8	Breast cancer;
KIRP	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg16558253	chr16:72132732	DHX38	-0.55	-8.08	-0.46	2.84e-14	Fibrinogen levels;
KIRP	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg03929089	chr4:120376271	NA	-0.53	-6.54	-0.38	3.44e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	trans	rs10242455	0.557	rs59672032	chr7:99058697	T/C	cg09045935	chr12:6379348	NA	0.84	6.83	0.4	6.75e-11	Blood metabolite levels;
KIRP	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.08	-0.46	2.89e-14	Aortic root size;
KIRP	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg23594656	chr7:65796392	TPST1	0.37	4.94	0.3	1.44e-6	Aortic root size;
KIRP	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg08134877	chr2:44394819	PPM1B	0.5	5.04	0.31	8.88e-7	Height;
KIRP	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg18753928	chr3:113234510	CCDC52	-0.63	-5.65	-0.34	4.4e-8	Dental caries;
KIRP	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg21643547	chr1:205240462	TMCC2	-0.7	-10.63	-0.56	5.86e-22	Red blood cell count;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg12903374	chr3:15643321	BTD;HACL1	-0.44	-6.03	-0.36	6.13e-9	Serum protein levels (sST2);
KIRP	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.14	0.31	5.69e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.69	-8.32	-0.47	5.92e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg12384639	chr17:618140	VPS53	0.47	5.92	0.35	1.05e-8	Prostate cancer;
KIRP	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg10189774	chr4:17578691	LAP3	0.54	6.81	0.4	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg12131826	chr15:77904385	NA	-0.37	-4.85	-0.3	2.19e-6	Type 2 diabetes;
KIRP	cis	rs494562	0.892	rs7771860	chr6:86130729	C/T	cg27039625	chr6:86159096	NT5E	0.44	5.75	0.34	2.67e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs2302729	0.929	rs10744567	chr12:2780816	A/G	cg19945202	chr12:2788847	CACNA1C	-0.82	-10.06	-0.54	3.68e-20	Sleep quality;
KIRP	cis	rs1215050	0.904	rs890469	chr4:98923293	T/C	cg17366294	chr4:99064904	C4orf37	-0.38	-4.97	-0.3	1.23e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg13332499	chr17:408570	NA	0.38	5.01	0.3	1.05e-6	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.03	-0.41	2e-11	Initial pursuit acceleration;
KIRP	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	0.79	8.26	0.47	8.74e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.14	0.46	1.99e-14	Response to antipsychotic treatment;
KIRP	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.54	-6.47	-0.38	5.12e-10	Longevity;Endometriosis;
KIRP	cis	rs10510653	0.522	rs58075697	chr3:32023275	G/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.78	7.37	0.43	2.51e-12	Schizophrenia;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs516946	1.000	rs35273426	chr8:41524688	C/T	cg19441908	chr8:41529140	ANK1	0.5	7.04	0.41	1.94e-11	Type 2 diabetes;
KIRP	cis	rs12681963	0.688	rs4733396	chr8:30003405	C/T	cg04374813	chr8:30012889	DCTN6	0.51	5.73	0.34	2.93e-8	Migraine;
KIRP	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.78	0.44	2.01e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4722404	0.801	rs6945344	chr7:3133163	A/G	cg19214707	chr7:3157722	NA	-0.44	-5.34	-0.32	2.14e-7	Atopic dermatitis;
KIRP	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06634786	chr22:41940651	POLR3H	-0.43	-4.92	-0.3	1.58e-6	Vitiligo;
KIRP	cis	rs10128264	0.934	rs1250589	chr10:80980304	C/G	cg18737081	chr10:80999807	ZMIZ1	-0.32	-5.92	-0.35	1.06e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.89	-0.35	1.25e-8	Breast cancer;
KIRP	cis	rs4740619	0.590	rs1359955	chr9:16040879	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-15.09	-0.69	7.14e-37	Chronic sinus infection;
KIRP	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg04691961	chr3:161091175	C3orf57	-0.39	-5.36	-0.32	1.87e-7	Educational attainment (years of education);
KIRP	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	6.81	0.4	7.53e-11	Parkinson's disease;
KIRP	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	26.17	0.86	4.67e-73	Chronic sinus infection;
KIRP	cis	rs3818717	0.538	rs4925108	chr17:17649423	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.41	-5.0	-0.3	1.08e-6	Lymphocyte counts;
KIRP	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.47	-4.97	-0.3	1.23e-6	Platelet distribution width;
KIRP	cis	rs7572644	0.699	rs2016616	chr2:28134037	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.39	-0.32	1.67e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg07274523	chr3:49395745	GPX1	0.65	7.85	0.45	1.28e-13	Educational attainment;
KIRP	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.9	13.36	0.65	5.67e-31	Neuroticism;
KIRP	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg23484912	chr5:273055	PDCD6	0.56	6.91	0.4	4.01e-11	Pancreatic cancer;
KIRP	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.5	7.08	0.41	1.46e-11	Red blood cell count;
KIRP	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.55	-0.33	7.4e-8	Neuroticism;
KIRP	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.42	-0.51	3.36e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2718058	0.501	rs2717938	chr7:37702545	C/T	cg15028436	chr7:37888078	TXNDC3	-0.42	-5.09	-0.31	7.22e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.5	7.87	0.45	1.1e-13	Testicular germ cell tumor;
KIRP	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.74	-9.71	-0.53	4.58e-19	Body mass index;
KIRP	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Bladder cancer;
KIRP	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.94	-15.78	-0.71	3.19e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg03834567	chr2:218808745	TNS1	-0.43	-5.2	-0.31	4.25e-7	Ulcerative colitis;
KIRP	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	0.94	8.47	0.48	2.21e-15	Plateletcrit;
KIRP	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg14580859	chr9:123691850	NA	0.35	5.09	0.31	7.25e-7	Rheumatoid arthritis;
KIRP	cis	rs7011049	0.841	rs7819865	chr8:53870344	C/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14310890	chr6:108881016	FOXO3	0.53	6.09	0.36	4.43e-9	Smoking initiation;
KIRP	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg16141378	chr3:129829833	LOC729375	-0.51	-6.88	-0.4	5.08e-11	Mood instability;
KIRP	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.77	10.14	0.54	2.06e-20	Huntington's disease progression;
KIRP	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.22	0.32	3.88e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.51	-6.78	-0.4	8.72e-11	Blood protein levels;
KIRP	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.33	-0.32	2.23e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19280121	chr17:21117780	TMEM11	0.55	6.67	0.39	1.69e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07570687	chr10:102243282	WNT8B	0.49	6.09	0.36	4.33e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.68	9.21	0.51	1.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg17145862	chr1:211918768	LPGAT1	-0.9	-13.12	-0.64	3.65e-30	Leprosy;
KIRP	trans	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg00938859	chr5:1591904	SDHAP3	0.53	6.26	0.37	1.69e-9	Breast cancer;
KIRP	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg00204512	chr16:28754710	NA	-0.43	-5.33	-0.32	2.22e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26311118	chr5:171615462	STK10	0.49	6.54	0.38	3.59e-10	Parkinson's disease;
KIRP	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg05340658	chr4:99064831	C4orf37	0.67	8.12	0.46	2.18e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.39	-0.43	2.26e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg00621247	chr5:1949277	NA	-0.49	-5.33	-0.32	2.26e-7	Gut microbiome composition (winter);
KIRP	trans	rs7939886	0.920	rs17150048	chr11:56063711	A/G	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg06598544	chr20:61472147	COL9A3	-0.83	-6.66	-0.39	1.81e-10	Obesity-related traits;
KIRP	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg27124370	chr19:33622961	WDR88	0.72	10.3	0.55	6.39e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg25753631	chr6:25732923	NA	-0.29	-5.37	-0.32	1.86e-7	Iron status biomarkers;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.61	8.99	0.5	6.78e-17	Lung cancer;
KIRP	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg19773385	chr1:10388646	KIF1B	-0.7	-10.82	-0.57	1.39e-22	Hepatocellular carcinoma;
KIRP	cis	rs5167	0.506	rs35193317	chr19:45470344	C/T	cg13119609	chr19:45449297	APOC2	-0.56	-8.12	-0.46	2.23e-14	Blood protein levels;
KIRP	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.63	5.12	0.31	6.23e-7	Bipolar disorder;
KIRP	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.99	0.3	1.17e-6	Childhood ear infection;
KIRP	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.62	11.64	0.6	3.02e-25	Bone mineral density;
KIRP	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg02002194	chr4:3960332	NA	-0.42	-6.09	-0.36	4.21e-9	Mood instability;
KIRP	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg26043149	chr18:55253948	FECH	-0.62	-6.84	-0.4	6.06e-11	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.22	-0.51	1.39e-17	Platelet count;
KIRP	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg11987759	chr7:65425863	GUSB	-0.43	-5.59	-0.34	5.89e-8	Aortic root size;
KIRP	cis	rs4523957	0.890	rs432200	chr17:2191960	A/G	cg16513277	chr17:2031491	SMG6	0.6	8.29	0.47	7.6e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00025877	chr6:34164284	NA	-0.5	-7.64	-0.44	4.85e-13	Metabolic traits;
KIRP	cis	rs9398803	0.830	rs1490387	chr6:126834083	C/A	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.15e-10	Male-pattern baldness;
KIRP	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg23100626	chr2:96804247	ASTL	0.45	6.4	0.38	7.89e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs754423	0.515	rs768022	chr14:52553180	G/C	cg10149976	chr14:52535953	NID2	-0.35	-4.93	-0.3	1.5e-6	Craniofacial microsomia;
KIRP	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg21523564	chr15:75251491	NA	0.35	5.93	0.35	1.02e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4332428	1.000	rs4332428	chr10:4965434	A/G	cg19648686	chr10:5044992	AKR1C2	-0.79	-6.63	-0.39	2.1e-10	Height;
KIRP	cis	rs12949688	0.575	rs10083864	chr17:55837910	C/T	cg12582317	chr17:55822272	NA	-0.43	-6.14	-0.36	3.35e-9	Schizophrenia;
KIRP	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00300879	chr1:26503847	CNKSR1	0.48	6.78	0.4	9.12e-11	Height;
KIRP	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg03465714	chr1:152285911	FLG	-0.41	-4.93	-0.3	1.55e-6	Atopic dermatitis;
KIRP	cis	rs2901656	0.934	rs2285176	chr1:172421744	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.43	5.43	0.33	1.38e-7	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs9863706	0.785	rs4677156	chr3:72417857	A/T	cg05607079	chr3:72387937	NA	-0.53	-6.72	-0.39	1.23e-10	Height;
KIRP	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.35e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6752107	0.935	rs10929326	chr2:234151045	T/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.49	6.43	0.38	6.72e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.69	7.35	0.42	2.91e-12	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg13206674	chr6:150067644	NUP43	0.62	8.47	0.48	2.18e-15	Lung cancer;
KIRP	cis	rs9948	1.000	rs72811623	chr2:97496473	C/T	cg01990225	chr2:97406019	LMAN2L	-1.05	-7.43	-0.43	1.78e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7709377	0.546	rs712561	chr5:115552945	G/T	cg23108291	chr5:115420582	COMMD10	-0.44	-5.29	-0.32	2.74e-7	Metabolite levels  (X-11787);
KIRP	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.68	9.02	0.5	5.5e-17	Response to fenofibrate (adiponectin levels);
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg11219407	chr1:154531432	UBE2Q1	-0.56	-6.54	-0.38	3.45e-10	Brain structure;
KIRP	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg17366294	chr4:99064904	C4orf37	0.46	5.49	0.33	1e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg14952266	chr13:112191215	NA	0.46	6.67	0.39	1.68e-10	Hepatitis;
KIRP	cis	rs7534824	0.625	rs61780331	chr1:101480610	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.01	0.41	2.29e-11	Refractive astigmatism;
KIRP	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.7	6.83	0.4	6.69e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.99	13.27	0.65	1.16e-30	Breast cancer;
KIRP	cis	rs8084125	0.765	rs62105165	chr18:74944464	A/G	cg05528293	chr18:74961138	GALR1	0.5	5.35	0.32	2.03e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.85	11.79	0.6	9.83e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg14541582	chr5:601475	NA	-0.55	-6.14	-0.36	3.3e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11166927	1.000	rs11778622	chr8:140805582	A/G	cg16909799	chr8:140841666	TRAPPC9	0.73	10.66	0.56	4.53e-22	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.69	-8.12	-0.46	2.31e-14	Menarche (age at onset);
KIRP	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg04132472	chr17:19861366	AKAP10	0.67	10.47	0.56	1.86e-21	Schizophrenia;
KIRP	cis	rs4936891	0.645	rs896891	chr11:123910740	C/T	cg22125253	chr11:123886957	OR10G4	0.56	8.25	0.47	9.66e-15	Male fertility;
KIRP	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-7.33	-0.42	3.35e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg06204229	chr3:52865917	ITIH4	0.56	7.83	0.45	1.42e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.38	-0.47	4e-15	Joint mobility (Beighton score);
KIRP	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19318889	chr4:1322082	MAEA	0.44	5.53	0.33	8.23e-8	Longevity;
KIRP	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs10518128	1.000	rs6532432	chr4:75696811	C/A	cg20122727	chr4:75719957	BTC	0.52	4.92	0.3	1.59e-6	Electroencephalogram traits;
KIRP	cis	rs16828019	0.777	rs67450703	chr1:41460129	A/G	cg03387723	chr1:41708464	SCMH1	-0.75	-6.08	-0.36	4.5e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs282587	0.569	rs166865	chr13:113384879	A/G	cg04656015	chr13:113407548	ATP11A	0.6	7.15	0.41	1e-11	Glycated hemoglobin levels;
KIRP	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-1.17	-15.67	-0.71	7.37e-39	Platelet distribution width;
KIRP	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.83	0.53	1.86e-19	Pulse pressure;
KIRP	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg05938607	chr10:60274200	BICC1	-0.46	-11.23	-0.58	6.59e-24	Refractive error;
KIRP	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.11	0.41	1.27e-11	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs7033996	0.915	rs62541932	chr9:35939747	C/T	cg00918944	chr9:35908117	LOC158376	0.38	5.29	0.32	2.69e-7	Urate levels (BMI interaction);
KIRP	cis	rs67385638	0.962	rs2187608	chr11:5269931	G/C	cg12559170	chr11:5275217	HBG2	0.52	7.71	0.44	3.03e-13	Hemoglobin levels;
KIRP	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.72	-0.39	1.25e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	7.21	0.42	7.01e-12	Height;
KIRP	cis	rs17681684	0.565	rs12150182	chr17:9764757	C/T	cg26853458	chr17:9805074	RCVRN	0.54	5.08	0.31	7.64e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.65	0.52	7.02e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7903847	0.642	rs10882923	chr10:99159018	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-5.97	-0.36	8.36e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg19445457	chr11:5799446	OR52N5	0.4	4.97	0.3	1.24e-6	DNA methylation (variation);
KIRP	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	21.14	0.8	3.07e-57	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg17376030	chr22:41985996	PMM1	0.52	5.78	0.35	2.21e-8	Vitiligo;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01566544	chr8:144399214	TOP1MT	0.45	6.23	0.37	2.02e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	1.07	21.56	0.81	1.32e-58	Parkinson's disease;
KIRP	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg25019033	chr10:957182	NA	-0.55	-6.75	-0.4	1.04e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg11204139	chr17:3907470	NA	0.85	16.14	0.72	1.92e-40	Type 2 diabetes;
KIRP	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg15436174	chr10:43711423	RASGEF1A	0.79	8.53	0.48	1.48e-15	Hirschsprung disease;
KIRP	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	8.71	0.49	4.58e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-10.59	-0.56	7.76e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	trans	rs12043259	1.000	rs6685987	chr1:204825967	G/A	cg11485465	chr5:54518469	NA	0.41	6.51	0.38	4.24e-10	Addiction;
KIRP	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg10790698	chr19:18539756	SSBP4	-0.34	-7.34	-0.42	3.14e-12	Breast cancer;
KIRP	cis	rs7851660	0.874	rs7868534	chr9:100632606	G/A	cg13688889	chr9:100608707	NA	-0.67	-8.78	-0.49	2.74e-16	Strep throat;
KIRP	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	1.2	11.16	0.58	1.11e-23	Lymphocyte counts;
KIRP	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.61	0.48	9.06e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6881634	0.768	rs4704495	chr5:77624910	C/T	cg11446398	chr5:77624930	NA	0.67	10.09	0.54	3e-20	Hippocampal atrophy;
KIRP	cis	rs12140703	0.510	rs1572993	chr1:205045087	G/A	cg00857998	chr1:205179979	DSTYK	-0.51	-6.88	-0.4	4.88e-11	Reticulocyte count;
KIRP	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.62	-6.8	-0.4	7.76e-11	DNA methylation (variation);
KIRP	cis	rs6546324	0.625	rs2902024	chr2:67836718	T/C	cg15745817	chr2:67799979	NA	-0.52	-6.1	-0.36	4.14e-9	Endometriosis;
KIRP	cis	rs10940138	0.501	rs2101598	chr5:67248995	C/T	ch.5.1281357F	chr5:67228439	NA	-0.5	-7.4	-0.43	2.19e-12	Menarche (age at onset);
KIRP	cis	rs9596863	0.898	rs9568902	chr13:54324954	G/A	ch.13.53330881F	chr13:54432880	NA	0.58	5.57	0.33	6.79e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs6466055	0.661	rs6466050	chr7:104897059	T/C	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs61884328	0.777	rs61897784	chr11:47154514	A/G	cg23433285	chr11:47201945	PACSIN3	0.76	5.56	0.33	7.13e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg02811702	chr13:24901961	NA	0.41	5.28	0.32	2.88e-7	Obesity-related traits;
KIRP	cis	rs7870753	0.838	rs10820634	chr9:99215104	T/C	cg25260653	chr9:99212216	HABP4	0.57	6.1	0.36	4.02e-9	Height;
KIRP	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs258892	0.895	rs4254882	chr5:72031649	T/C	cg21869765	chr5:72125136	TNPO1	-0.52	-5.83	-0.35	1.71e-8	Small cell lung carcinoma;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00933542	chr6:150070202	PCMT1	0.28	5.62	0.34	5.11e-8	Lung cancer;
KIRP	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.52	7.44	0.43	1.72e-12	Type 2 diabetes;
KIRP	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.27	0.37	1.59e-9	Subjective well-being;
KIRP	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.85	13.41	0.65	3.9e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	6.04	0.36	5.71e-9	Menarche (age at onset);
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg19893067	chr17:80732956	TBCD	-0.36	-4.94	-0.3	1.42e-6	Glycated hemoglobin levels;
KIRP	cis	rs2692947	0.637	rs72492201	chr2:96630201	G/A	cg23100626	chr2:96804247	ASTL	0.43	5.83	0.35	1.77e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7084402	0.967	rs1658443	chr10:60316926	G/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.89	-0.57	8.19e-23	Refractive error;
KIRP	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg24498760	chr8:49746867	NA	-0.39	-4.86	-0.3	2.09e-6	Blood metabolite ratios;
KIRP	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-12.12	-0.61	7.81e-27	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-5.78	-0.35	2.31e-8	Aortic root size;
KIRP	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.69	-7.08	-0.41	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg02297831	chr4:17616191	MED28	0.53	6.64	0.39	1.99e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.17	0.37	2.86e-9	Menopause (age at onset);
KIRP	cis	rs2882667	0.964	rs11958050	chr5:138301828	A/G	cg04439458	chr5:138467593	SIL1	-0.39	-6.17	-0.37	2.73e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.91	14.14	0.67	1.28e-33	Testicular germ cell tumor;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07977202	chr11:66311348	ZDHHC24	-0.22	-6.05	-0.36	5.3300000000000004e-09	Bladder cancer;
KIRP	cis	rs9308433	0.529	rs55760458	chr1:214491536	G/C	cg06198575	chr1:214491504	SMYD2	0.54	6.95	0.4	3.33e-11	IgG glycosylation;
KIRP	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.94	-0.79	2.66e-53	Schizophrenia;
KIRP	cis	rs2671245	0.767	rs1514133	chr1:56119340	T/C	cg11523071	chr1:56160889	NA	-0.36	-5.3	-0.32	2.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00678005	chr8:9597722	TNKS;MIR597	-0.41	-6.3	-0.37	1.34e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg03315344	chr16:75512273	CHST6	0.56	5.44	0.33	1.27e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7005380	0.538	rs7461170	chr8:120916254	A/G	cg21645572	chr8:120931649	DEPDC6	0.48	6.75	0.4	1.08e-10	Interstitial lung disease;
KIRP	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg23594656	chr7:65796392	TPST1	-0.34	-5.03	-0.31	9.27e-7	Aortic root size;
KIRP	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.74	-9.09	-0.5	3.3e-17	Cognitive function;
KIRP	cis	rs4281086	0.930	rs12674796	chr8:10337909	G/T	cg01072821	chr8:10382165	T-SP1	0.36	4.86	0.3	2.06e-6	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg18306943	chr3:40428807	ENTPD3	0.38	5.1	0.31	6.8e-7	Renal cell carcinoma;
KIRP	cis	rs6466055	0.615	rs1204061	chr7:104964249	A/G	cg04380332	chr7:105027541	SRPK2	-0.37	-5.06	-0.31	8.19e-7	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg13047869	chr3:10149882	C3orf24	0.55	5.46	0.33	1.15e-7	Alzheimer's disease;
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg00933542	chr6:150070202	PCMT1	0.28	4.94	0.3	1.43e-6	Lung cancer;
KIRP	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.83	12.9	0.64	2.07e-29	Testicular germ cell tumor;
KIRP	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg05802129	chr4:122689817	NA	-0.47	-6.84	-0.4	6.24e-11	Type 2 diabetes;
KIRP	cis	rs1983891	0.874	rs1326322	chr6:41512462	G/T	cg20194872	chr6:41519635	FOXP4	0.48	6.03	0.36	5.91e-9	Prostate cancer;
KIRP	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	6.35	0.38	1.03e-9	Mean platelet volume;
KIRP	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.57	-6.86	-0.4	5.43e-11	Metabolic traits;
KIRP	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.92	14.42	0.68	1.39e-34	Coronary artery disease;
KIRP	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.53	6.16	0.37	3.01e-9	Mean platelet volume;
KIRP	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg19610905	chr11:61596333	FADS2	-0.53	-6.6	-0.39	2.49e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs5756931	0.503	rs2012725	chr22:38536861	C/G	cg25457927	chr22:38595422	NA	-0.34	-6.6	-0.39	2.52e-10	Triglycerides;
KIRP	trans	rs7523050	0.642	rs12044219	chr1:109481236	T/C	cg07834955	chr10:99531879	SFRP5	0.65	6.13	0.36	3.38e-9	Fat distribution (HIV);
KIRP	cis	rs2456568	0.557	rs2456567	chr11:93698409	G/A	cg26875233	chr11:93583750	C11orf90	-0.28	-5.04	-0.31	9.24e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg02023728	chr11:77925099	USP35	-0.3	-5.08	-0.31	7.6e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.88	-0.49	1.42e-16	Response to antipsychotic treatment;
KIRP	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg14003231	chr6:33640908	ITPR3	0.29	5.17	0.31	4.92e-7	Plateletcrit;
KIRP	cis	rs4908768	0.579	rs55840223	chr1:8862787	G/C	cg25722041	chr1:8623473	RERE	0.66	8.27	0.47	8.56e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	15.05	0.69	1e-36	Chronic sinus infection;
KIRP	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.48	-0.38	4.89e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.04e-7	Putamen volume;
KIRP	cis	rs986417	0.748	rs9989223	chr14:60942525	C/A	cg27398547	chr14:60952738	C14orf39	0.69	7.08	0.41	1.49e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg23594656	chr7:65796392	TPST1	0.39	5.69	0.34	3.6e-8	Aortic root size;
KIRP	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2016266	0.502	rs34745537	chr12:53635435	G/A	cg04065151	chr12:53682969	ESPL1	-0.4	-5.0	-0.3	1.1e-6	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24739679	chr1:193304834	NA	0.38	6.08	0.36	4.64e-9	Survival in pancreatic cancer;
KIRP	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.81	-11.98	-0.61	2.31e-26	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15048078	chr4:38665599	KLF3;FLJ13197	-0.62	-6.72	-0.39	1.29e-10	Menopause (age at onset);
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg01798813	chr17:3906674	NA	0.61	8.62	0.48	8.44e-16	Type 2 diabetes;
KIRP	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg10047753	chr17:41438598	NA	0.88	11.95	0.61	2.97e-26	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs28719689	0.655	rs17063833	chr8:1275384	A/G	cg22761795	chr8:1265118	NA	0.63	6.15	0.37	3.09e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.58	-5.43	-0.33	1.35e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.6	6.57	0.39	3.02e-10	Vitiligo;
KIRP	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.87	-0.3	1.97e-6	Breast cancer;
KIRP	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg14159672	chr1:205819179	PM20D1	-0.56	-5.18	-0.31	4.54e-7	Menarche (age at onset);
KIRP	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg17376030	chr22:41985996	PMM1	-0.53	-6.05	-0.36	5.3e-9	Vitiligo;
KIRP	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.45	-0.62	6.35e-28	Exhaled nitric oxide output;
KIRP	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.85	-0.4	5.97e-11	Monocyte percentage of white cells;
KIRP	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg04362960	chr10:104952993	NT5C2	-0.43	-4.9	-0.3	1.71e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	cis	rs311392	0.554	rs311423	chr8:55104694	G/A	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.41e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.66	-8.84	-0.49	1.86e-16	Motion sickness;
KIRP	cis	rs6708331	0.752	rs7558246	chr2:70202613	C/T	cg05298696	chr2:70188691	ASPRV1	-0.39	-4.95	-0.3	1.37e-6	Obesity-related traits;
KIRP	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00526316	chr1:151043472	GABPB2	0.63	7.41	0.43	1.99e-12	Smoking initiation;
KIRP	cis	rs6669919	0.553	rs7527603	chr1:211668090	G/A	cg10512769	chr1:211675356	NA	-0.77	-11.0	-0.57	3.79e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg12623918	chr2:306882	NA	0.43	5.31	0.32	2.48e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg22437258	chr11:111473054	SIK2	-0.57	-6.61	-0.39	2.3e-10	Primary sclerosing cholangitis;
KIRP	trans	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg18187862	chr3:45730750	SACM1L	0.54	6.18	0.37	2.71e-9	Primary sclerosing cholangitis;
KIRP	cis	rs6738627	0.895	rs6754919	chr2:165507843	C/T	cg03182029	chr2:165697222	COBLL1	0.38	4.96	0.3	1.31e-6	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg02158880	chr13:53174818	NA	0.38	5.13	0.31	5.87e-7	Lewy body disease;
KIRP	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	1.0	8.16	0.46	1.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7707921	0.801	rs862243	chr5:81586829	C/G	cg07807695	chr5:81608485	ATP6AP1L	-0.45	-5.85	-0.35	1.53e-8	Breast cancer;
KIRP	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.62	-0.48	8.09e-16	Osteoarthritis;
KIRP	cis	rs921943	1.000	rs3797537	chr5:78322650	A/G	cg26802063	chr5:78281964	ARSB	0.49	6.1	0.36	4.13e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02886878	chr17:53499011	MMD	0.49	6.08	0.36	4.54e-9	Parkinson's disease;
KIRP	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.18	-0.31	4.68e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg06307176	chr5:131281290	NA	-0.52	-5.73	-0.34	2.93e-8	Life satisfaction;
KIRP	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg03522245	chr20:25566470	NINL	0.45	5.52	0.33	8.76e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.43	0.52	3.16e-18	IgG glycosylation;
KIRP	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg04132472	chr17:19861366	AKAP10	0.64	9.48	0.52	2.3e-18	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.57	5.28	0.32	2.84e-7	Major depressive disorder;
KIRP	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg17376030	chr22:41985996	PMM1	0.59	6.58	0.39	2.79e-10	Vitiligo;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00934066	chr14:68882780	RAD51L1	-0.41	-6.17	-0.37	2.82e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7539542	0.556	rs4950888	chr1:202872625	C/T	cg08940984	chr1:202857613	RABIF	0.46	5.79	0.35	2.15e-8	Mean platelet volume;
KIRP	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.9	-0.35	1.17e-8	Breast cancer;
KIRP	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg18350739	chr11:68623251	NA	-0.52	-8.02	-0.46	4.4e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg17143192	chr8:8559678	CLDN23	0.7	7.99	0.45	5.14e-14	Obesity-related traits;
KIRP	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.58	-6.88	-0.4	4.93e-11	Mosquito bite size;
KIRP	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.62	9.0	0.5	6.23e-17	Colorectal cancer;
KIRP	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	0.97	11.32	0.59	3.33e-24	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg13628971	chr7:2884303	GNA12	0.6	6.83	0.4	6.49e-11	Height;
KIRP	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg20526800	chr20:33880825	FAM83C	-0.4	-4.95	-0.3	1.37e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.82	12.1	0.61	9.39e-27	Menarche (age at onset);
KIRP	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.33	0.51	6.23e-18	Coffee consumption (cups per day);
KIRP	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg03959625	chr15:84868606	LOC388152	0.49	5.67	0.34	4.02e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15680989	chr5:1112221	SLC12A7	0.47	6.07	0.36	4.86e-9	Parkinson's disease;
KIRP	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg18944383	chr4:111397179	ENPEP	0.55	9.67	0.52	6e-19	Height;
KIRP	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.27e-16	Gut microbiome composition (summer);
KIRP	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.72	-10.97	-0.57	4.72e-23	Hepatocellular carcinoma;
KIRP	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.79	10.54	0.56	1.12e-21	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs933360	0.503	rs10231012	chr7:50876790	G/T	cg20003124	chr12:4557277	NA	0.51	6.04	0.36	5.73e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.6	7.69	0.44	3.49e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11997175	0.583	rs17781020	chr8:33850858	C/G	cg04338863	chr8:33670619	NA	0.44	5.1	0.31	6.65e-7	Body mass index;
KIRP	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.22	-0.46	1.18e-14	Retinal vascular caliber;
KIRP	cis	rs930036	0.602	rs3770440	chr2:171803962	T/G	cg12801329	chr2:171670795	NA	0.42	4.89	0.3	1.81e-6	Menopause (age at onset);
KIRP	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.67	-7.82	-0.45	1.51e-13	IgG glycosylation;
KIRP	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-0.64	-6.23	-0.37	2.05e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.63	0.52	8.08e-19	Lung cancer;
KIRP	cis	rs787274	0.557	rs2182048	chr9:115668970	C/T	cg13803584	chr9:115635662	SNX30	0.68	5.94	0.35	9.9e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01141445	chr4:186944988	NA	0.46	6.16	0.37	2.89e-9	Survival in pancreatic cancer;
KIRP	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.61	7.56	0.43	8.17e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	6.76	0.4	9.95e-11	Lung function (FEV1/FVC);
KIRP	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg13165212	chr22:42675999	NA	-0.28	-4.94	-0.3	1.44e-6	Cognitive function;
KIRP	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.36	-5.21	-0.32	4.08e-7	Body mass index;
KIRP	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.75	-0.57	2.4e-22	Height;
KIRP	cis	rs8079658	0.586	rs9894277	chr17:63856501	T/G	cg18091269	chr17:63822838	CCDC46	0.36	4.85	0.3	2.21e-6	Post bronchodilator FEV1;
KIRP	cis	rs1018697	1.000	rs6584525	chr10:104551981	G/A	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg15190599	chr6:26156487	HIST1H1E	-0.46	-6.23	-0.37	2.04e-9	Morning vs. evening chronotype;
KIRP	cis	rs6466055	0.612	rs1135958	chr7:104920741	C/A	cg04380332	chr7:105027541	SRPK2	0.37	5.03	0.31	9.68e-7	Schizophrenia;
KIRP	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.53	-0.33	8.22e-8	Hip geometry;
KIRP	cis	rs4683702	0.686	rs34516933	chr3:142603861	T/A	cg22826874	chr3:142608218	PCOLCE2	-0.37	-5.47	-0.33	1.13e-7	Blood protein levels;
KIRP	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.78	9.67	0.52	5.72e-19	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs853308	1.000	rs2687818	chr8:133928876	C/T	cg06478102	chr15:73992274	CD276	-0.48	-6.05	-0.36	5.49e-9	Vitiligo;
KIRP	cis	rs33912345	0.695	rs1254264	chr14:60839173	A/T	cg27398547	chr14:60952738	C14orf39	-0.42	-5.63	-0.34	4.9e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg10402321	chr1:26617780	UBXN11	-0.41	-5.31	-0.32	2.5e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.31	-6.41	-0.38	7.2e-10	Cutaneous nevi;
KIRP	cis	rs2084898	0.550	rs550164	chr11:120002727	C/T	cg24611264	chr11:120008944	TRIM29	-0.28	-5.24	-0.32	3.49e-7	Stroke (pediatric);
KIRP	cis	rs7939886	0.920	rs7946368	chr11:55804219	C/A	cg07850316	chr11:56344833	OR5M10;OR8U8	0.69	5.4	0.33	1.55e-7	Myopia (pathological);
KIRP	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.63	-0.56	5.96e-22	Height;
KIRP	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg08662619	chr6:150070041	PCMT1	0.34	5.46	0.33	1.15e-7	Lung cancer;
KIRP	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg02487422	chr3:49467188	NICN1	0.38	5.29	0.32	2.68e-7	Parkinson's disease;
KIRP	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-1.0	-16.56	-0.73	6.89e-42	Height;
KIRP	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg23845249	chr11:68861649	NA	0.58	8.01	0.45	4.58e-14	Blond vs. brown hair color;
KIRP	cis	rs2505998	0.843	rs2435344	chr10:43585874	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.79	-0.35	2.18e-8	Hirschsprung disease;
KIRP	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.66	6.39	0.38	8.04e-10	Eotaxin levels;
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-5.41	-0.33	1.51e-7	Lung cancer;
KIRP	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs55675132	0.548	rs12144576	chr1:115361733	C/A	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs4692589	1.000	rs1871683	chr4:170937348	T/C	cg19918862	chr4:170955249	NA	0.42	5.13	0.31	5.78e-7	Anxiety disorder;
KIRP	cis	rs2456568	0.695	rs908748	chr11:93690148	G/A	cg26875233	chr11:93583750	C11orf90	0.33	6.24	0.37	1.92e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg26585981	chr11:48327164	OR4S1	-0.41	-5.28	-0.32	2.77e-7	Height;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg13906792	chr15:75199810	C15orf17	-0.38	-5.4	-0.33	1.57e-7	Breast cancer;
KIRP	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.41	0.38	7.53e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2220004	0.642	rs78895935	chr11:56044213	T/C	cg01505312	chr11:56258856	OR5M8;OR8U8	0.52	5.41	0.33	1.51e-7	Odorant perception (&beta-damascenone);
KIRP	cis	rs12144044	0.701	rs2999159	chr1:113230758	A/G	cg22162597	chr1:113214053	CAPZA1	-0.86	-8.68	-0.48	5.58e-16	Glomerular filtration rate (creatinine);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg05320259	chr20:25370897	ABHD12	0.72	6.16	0.37	3.02e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg00241281	chr14:105779794	PACS2	-0.36	-4.99	-0.3	1.12e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.55	7.23	0.42	6.04e-12	Height;
KIRP	cis	rs6909279	0.933	rs7753676	chr6:151876815	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.47	-6.19	-0.37	2.43e-9	Bone mineral density;
KIRP	trans	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.7	0.39	1.39e-10	Retinal vascular caliber;
KIRP	cis	rs10924309	0.737	rs4378245	chr1:245852727	G/A	cg00036263	chr1:245852353	KIF26B	-0.54	-7.67	-0.44	3.94e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.2	0.64	1.95e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2275906	0.748	rs11969868	chr6:25878506	A/G	cg21844956	chr6:25963442	TRIM38	0.52	5.02	0.3	1.01e-6	Urate levels in lean individuals;
KIRP	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	1.03	14.03	0.67	2.95e-33	Menopause (age at onset);
KIRP	cis	rs7542091	0.506	rs992976	chr1:210066658	A/T	cg22029157	chr1:209979665	IRF6	-0.41	-6.3	-0.37	1.34e-9	Monobrow;
KIRP	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-8.46	-0.47	2.49e-15	Cognitive function;
KIRP	cis	rs62151617	1.000	rs34579452	chr2:70794980	T/C	cg24334149	chr2:71175539	ATP6V1B1	0.5	5.06	0.31	8.18e-7	Hair shape;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.4.1169037R	chr4:57221592	AASDH	0.46	6.37	0.38	9.18e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg07777115	chr5:623756	CEP72	-0.53	-5.73	-0.34	2.91e-8	Obesity-related traits;
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.47	5.75	0.34	2.67e-8	Longevity;
KIRP	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg10818794	chr15:86012489	AKAP13	-0.5	-7.11	-0.41	1.28e-11	Coronary artery disease;
KIRP	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg09408571	chr1:101003634	GPR88	0.23	5.18	0.31	4.72e-7	Breast cancer;
KIRP	cis	rs4938330	0.608	rs3882897	chr11:117091227	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg20913747	chr6:44695427	NA	-0.38	-4.87	-0.3	2.04e-6	Total body bone mineral density;
KIRP	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.52	-11.48	-0.59	9.99e-25	Diabetic kidney disease;
KIRP	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.46	-5.86	-0.35	1.5e-8	Recombination rate (males);
KIRP	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.65	-6.75	-0.4	1.06e-10	Body mass index;
KIRP	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-5.53	-0.33	8.09e-8	Total body bone mineral density;
KIRP	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.74	8.26	0.47	9.07e-15	Menarche (age at onset);
KIRP	cis	rs17121403	0.661	rs12135824	chr1:100500762	T/C	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.55	-8.49	-0.48	1.96e-15	Schizophrenia;
KIRP	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-4.9	-0.3	1.7e-6	Crohn's disease;
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.75	6.95	0.41	3.21e-11	Lung disease severity in cystic fibrosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19169976	chr17:48071254	DLX3	0.49	7.3	0.42	3.86e-12	Parkinson's disease;
KIRP	cis	rs11718455	0.629	rs4082418	chr3:43908243	C/T	cg21419209	chr3:44054225	NA	0.48	5.89	0.35	1.26e-8	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11418813	chr15:70203031	NA	0.51	6.13	0.36	3.47e-9	Interleukin-4 levels;
KIRP	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs10773046	0.740	rs10846567	chr12:124360117	A/C	cg18594669	chr12:124364423	DNAH10	-0.36	-4.93	-0.3	1.53e-6	Osteoarthritis (hip);
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.61	9.06	0.5	4.05e-17	Immature fraction of reticulocytes;
KIRP	cis	rs6978712	0.591	rs60267009	chr7:127077576	T/A	cg24655706	chr7:127078268	NA	0.68	5.36	0.32	1.88e-7	Medication adherence in chronic diseases;
KIRP	cis	rs7539409	0.915	rs6576945	chr1:84252882	A/G	cg10977910	chr1:84465055	TTLL7	0.63	4.91	0.3	1.68e-6	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21186775	chr2:173941045	ZAK	0.55	6.72	0.39	1.28e-10	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.75	11.18	0.58	9.9e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4950322	0.570	rs17356233	chr1:146740502	C/G	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.31	6.15	0.37	3.13e-9	Schizophrenia;
KIRP	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.48	7.32	0.42	3.61e-12	Resting heart rate;
KIRP	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg18944383	chr4:111397179	ENPEP	-0.44	-7.04	-0.41	1.95e-11	Coronary artery disease;
KIRP	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg19650706	chr5:140594406	PCDHB13	0.44	4.85	0.3	2.18e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.8	12.55	0.62	2.88e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.67	8.94	0.5	9.46e-17	Eye color traits;
KIRP	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg16339924	chr4:17578868	LAP3	-0.66	-7.75	-0.44	2.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-9.23	-0.51	1.33e-17	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.65	-7.58	-0.43	7.23e-13	Lung cancer;Squamous cell lung carcinoma;
KIRP	trans	rs7830939	1.000	rs7830939	chr8:9380132	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.29	-0.37	1.42e-9	Neuroticism;
KIRP	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg08662619	chr6:150070041	PCMT1	0.33	5.21	0.32	3.99e-7	Testicular germ cell tumor;
KIRP	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.49	6.76	0.4	9.81e-11	Red blood cell count;
KIRP	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-8.5	-0.48	1.89e-15	Extraversion;
KIRP	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg06740227	chr12:86229804	RASSF9	0.44	5.59	0.34	5.9e-8	Major depressive disorder;
KIRP	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.94	-0.79	2.66e-53	Schizophrenia;
KIRP	cis	rs883565	0.606	rs7650682	chr3:39079418	C/A	cg01426195	chr3:39028469	NA	-0.65	-10.59	-0.56	7.94e-22	Handedness;
KIRP	cis	rs501120	0.584	rs11238906	chr10:44685925	T/C	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.54	-0.43	8.99e-13	Platelet count;
KIRP	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.42	6.46	0.38	5.64e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.41	-6.45	-0.38	5.84e-10	Body mass index;
KIRP	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.07	-0.31	7.97e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4474465	0.920	rs12222907	chr11:78219726	C/T	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.48e-7	Alzheimer's disease (survival time);
KIRP	cis	rs78545713	0.649	rs113407109	chr6:26224403	T/G	cg23601095	chr6:26197514	HIST1H3D	0.88	5.22	0.32	3.83e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.47	6.01	0.36	6.7e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1434579	0.966	rs1062093	chr19:44931995	C/G	cg15540054	chr19:45004280	ZNF180	0.55	5.99	0.36	7.4e-9	Tuberculosis;
KIRP	cis	rs1971762	0.730	rs7963016	chr12:54072819	T/A	cg16917193	chr12:54089295	NA	0.7	9.62	0.52	8.38e-19	Height;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.42	-5.25	-0.32	3.22e-7	Longevity;Endometriosis;
KIRP	cis	rs7246657	0.712	rs4803263	chr19:38066782	G/A	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.43	-5.16	-0.31	5.11e-7	Glycated hemoglobin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26076884	chr2:118943736	NA	0.42	6.35	0.38	1.02e-9	Survival in pancreatic cancer;
KIRP	cis	rs11605924	0.967	rs7121611	chr11:45864142	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.54	-6.79	-0.4	8.12e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-1.05	-14.59	-0.68	3.65e-35	Alopecia areata;
KIRP	trans	rs4942242	0.574	rs9533557	chr13:44197487	C/G	cg19169023	chr15:41853346	TYRO3	0.54	6.26	0.37	1.67e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg14580859	chr9:123691850	NA	0.35	5.0	0.3	1.08e-6	Rheumatoid arthritis;
KIRP	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00585698	chr12:123750864	CDK2AP1	0.45	5.68	0.34	3.87e-8	Neutrophil percentage of white cells;
KIRP	cis	rs5743890	0.545	rs34410363	chr11:1375606	C/T	cg06066251	chr11:1309984	TOLLIP	0.59	5.27	0.32	2.93e-7	Idiopathic pulmonary fibrosis;
KIRP	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg08975724	chr8:8085496	FLJ10661	-0.67	-9.03	-0.5	5.2e-17	Neuroticism;
KIRP	cis	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg21775007	chr8:11205619	TDH	0.39	5.33	0.32	2.24e-7	Monocyte count;
KIRP	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg10950524	chr7:2139216	MAD1L1	0.29	5.24	0.32	3.54e-7	Schizophrenia;
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg19893067	chr17:80732956	TBCD	-0.35	-4.85	-0.3	2.16e-6	Glycated hemoglobin levels;
KIRP	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.82	10.35	0.55	4.36e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.68	-11.21	-0.58	7.85e-24	Urate levels in overweight individuals;
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg21361702	chr7:150065534	REPIN1	0.58	6.3	0.37	1.38e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs575018	0.836	rs4321731	chr5:100585247	G/A	cg03848127	chr5:100126093	NA	-0.41	-4.9	-0.3	1.73e-6	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg22974920	chr21:40686053	BRWD1	0.47	5.29	0.32	2.71e-7	Cognitive function;
KIRP	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.59	-7.07	-0.41	1.64e-11	Monocyte count;
KIRP	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg03351412	chr1:154909251	PMVK	0.59	7.05	0.41	1.83e-11	Prostate cancer;
KIRP	cis	rs9913156	0.670	rs4416072	chr17:4570036	C/T	cg19197139	chr17:4613644	ARRB2	0.58	6.25	0.37	1.76e-9	Lymphocyte counts;
KIRP	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.59	-7.23	-0.42	5.92e-12	Myeloid white cell count;
KIRP	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg12140854	chr5:148520817	ABLIM3	0.53	5.98	0.36	7.76e-9	Breast cancer;
KIRP	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26617929	chr16:1858877	NA	0.68	6.45	0.38	5.99e-10	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs2554380	0.628	rs7179507	chr15:84473531	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.32	-5.0	-0.3	1.09e-6	Height;
KIRP	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.86	0.4	5.46e-11	Blood metabolite levels;
KIRP	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg10578777	chr12:7781093	NA	0.57	5.83	0.35	1.71e-8	HDL cholesterol levels;
KIRP	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg19752551	chr11:57585705	CTNND1	-0.68	-11.45	-0.59	1.26e-24	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13443103	chr9:139743284	PHPT1	0.44	6.17	0.37	2.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4764487	0.687	rs3181300	chr12:6345199	C/T	cg08284733	chr12:6341482	CD9	0.56	9.16	0.5	2.13e-17	Mean platelet volume;
KIRP	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	0.84	7.9	0.45	9.43e-14	Methadone dose in opioid dependence;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg16266895	chr12:101674004	UTP20	0.67	6.42	0.38	6.85e-10	Lung function (FEV1);
KIRP	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.63	0.52	7.7e-19	Prudent dietary pattern;
KIRP	cis	rs7590368	0.715	rs72779474	chr2:10965980	G/A	cg15705551	chr2:10952987	PDIA6	0.64	5.51	0.33	8.87e-8	Educational attainment (years of education);
KIRP	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-0.96	-10.98	-0.57	4.42e-23	Blood protein levels;
KIRP	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.38	-0.47	4.06e-15	Platelet count;
KIRP	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	6.45	0.38	5.78e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2790457	0.958	rs2790455	chr10:28847077	A/G	cg05705492	chr10:28955341	NA	-0.54	-8.16	-0.46	1.77e-14	Multiple myeloma;
KIRP	cis	rs7225151	0.710	rs59587437	chr17:5230117	A/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.71	-0.34	3.23e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.47	-0.38	5.37e-10	Coronary artery disease;
KIRP	cis	rs1978968	0.751	rs5992139	chr22:18458636	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.72	-9.16	-0.5	2.03e-17	Presence of antiphospholipid antibodies;
KIRP	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	0.83	13.77	0.66	2.33e-32	Breast cancer;
KIRP	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.68	9.58	0.52	1.12e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg00814883	chr7:100076585	TSC22D4	-0.54	-5.12	-0.31	6.15e-7	Lung function (FEV1/FVC);
KIRP	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.55	-6.59	-0.39	2.59e-10	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.84	11.65	0.6	2.86e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.71	-7.04	-0.41	1.9e-11	Ulcerative colitis;
KIRP	cis	rs6708331	0.517	rs6546572	chr2:70373642	C/T	cg05298696	chr2:70188691	ASPRV1	-0.45	-6.05	-0.36	5.31e-9	Obesity-related traits;
KIRP	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg17294928	chr15:75287854	SCAMP5	0.5	6.2	0.37	2.31e-9	Caffeine consumption;
KIRP	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg01879757	chr17:41196368	BRCA1	-0.66	-9.79	-0.53	2.57e-19	Menopause (age at onset);
KIRP	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.36	4.9	0.3	1.73e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs644148	0.836	rs2571110	chr19:45000712	T/C	cg15540054	chr19:45004280	ZNF180	-0.75	-9.15	-0.5	2.2e-17	Personality dimensions;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19504496	chr19:36119917	RBM42	0.5	6.23	0.37	2.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05601917	chr6:125855416	NA	-0.36	-5.44	-0.33	1.27e-7	Brugada syndrome;
KIRP	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg08975724	chr8:8085496	FLJ10661	0.62	8.5	0.48	1.89e-15	Mood instability;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.86	11.49	0.59	9.51e-25	Longevity;Endometriosis;
KIRP	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg12598211	chr12:123634384	NA	-0.43	-5.25	-0.32	3.35e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10174797	chr19:8464628	RAB11B	0.51	6.39	0.38	8.13e-10	HDL cholesterol;
KIRP	cis	rs1062746	0.545	rs3815947	chr16:87359648	C/T	cg02258303	chr16:87377426	FBXO31	-0.46	-5.58	-0.34	6.27e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.9	-0.45	9.06e-14	Homocysteine levels;
KIRP	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.34	5.22	0.32	3.73e-7	Myeloid white cell count;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.64e-16	Life satisfaction;
KIRP	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26207909	chr14:103986467	CKB	0.74	10.62	0.56	6.17e-22	Body mass index;
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg09597638	chr17:3907349	NA	0.57	8.22	0.46	1.14e-14	Type 2 diabetes;
KIRP	cis	rs7737355	0.755	rs1151481	chr5:130926374	A/C	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg18306943	chr3:40428807	ENTPD3	0.37	4.92	0.3	1.61e-6	Renal cell carcinoma;
KIRP	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.7	10.63	0.56	5.67e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.46	6.75	0.4	1.04e-10	Carotid intima media thickness;
KIRP	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.49	7.97	0.45	5.9e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	0.95	11.72	0.6	1.74e-25	Corneal structure;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.45	7.71	0.44	3.11e-13	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1971256	0.500	rs6925359	chr6:151798783	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-6.25	-0.37	1.79e-9	Endometriosis;
KIRP	cis	rs7011049	1.000	rs72643577	chr8:53846358	A/T	cg26025543	chr8:53854495	NA	0.75	7.86	0.45	1.16e-13	Systolic blood pressure;
KIRP	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.93	12.46	0.62	6.15e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs7129556	0.775	rs623907	chr11:77501448	T/A	cg12586386	chr11:77299805	AQP11	0.41	5.48	0.33	1.07e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00334798	chr11:72929553	P2RY2	0.48	7.17	0.42	8.88e-12	Parkinson's disease;
KIRP	cis	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.37	-0.43	2.63e-12	Morning vs. evening chronotype;
KIRP	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg09455208	chr3:40491958	NA	0.39	6.68	0.39	1.6e-10	Renal cell carcinoma;
KIRP	cis	rs4332037	0.530	rs62434669	chr7:1866946	G/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-5.65	-0.34	4.32e-8	Bipolar disorder;
KIRP	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg21858823	chr1:15850916	CASP9	0.54	5.77	0.35	2.42e-8	Systolic blood pressure;
KIRP	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg03959625	chr15:84868606	LOC388152	0.69	8.44	0.47	2.77e-15	Schizophrenia;
KIRP	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg11833968	chr6:79620685	NA	-0.47	-7.15	-0.41	9.78e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4566357	1.000	rs4566357	chr2:227922015	C/T	cg11843606	chr2:227700838	RHBDD1	0.4	4.91	0.3	1.68e-6	Coronary artery disease;
KIRP	cis	rs2733201	1.000	rs11070419	chr15:44327179	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-5.9	-0.35	1.17e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.62	7.01	0.41	2.31e-11	Initial pursuit acceleration;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02992881	chr13:50699806	DLEU2	-0.54	-6.47	-0.38	5.27e-10	Interleukin-4 levels;
KIRP	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg17554472	chr22:41940697	POLR3H	-0.58	-6.35	-0.38	1.05e-9	Vitiligo;
KIRP	trans	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg24644049	chr4:85504048	CDS1	1.09	6.99	0.41	2.59e-11	Skin colour saturation;
KIRP	cis	rs8060686	0.858	rs7196789	chr16:67927124	C/T	cg04539111	chr16:67997858	SLC12A4	-0.43	-5.02	-0.31	9.76e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg16650896	chr7:64838774	ZNF92	0.73	6.19	0.37	2.46e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg00310523	chr12:86230176	RASSF9	0.39	6.03	0.36	6.06e-9	Major depressive disorder;
KIRP	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg18404041	chr3:52824283	ITIH1	-0.48	-5.48	-0.33	1.08e-7	Schizophrenia;
KIRP	cis	rs4835473	0.932	rs1842484	chr4:144714982	G/C	cg08833778	chr4:144622313	FREM3	0.34	5.01	0.3	1.04e-6	Immature fraction of reticulocytes;
KIRP	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg02175503	chr12:58329896	NA	0.66	8.02	0.46	4.22e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03759077	chr2:153575599	ARL6IP6	0.6	7.2	0.42	7.27e-12	Smoking initiation;
KIRP	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg09699651	chr6:150184138	LRP11	0.54	7.28	0.42	4.47e-12	Testicular germ cell tumor;
KIRP	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg02378861	chr5:212933	CCDC127	-0.79	-5.9	-0.35	1.17e-8	Fat distribution (HIV);
KIRP	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	14.58	0.68	3.99e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9309473	1.000	rs2421555	chr2:73816955	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.07	-0.31	7.7300000000000005e-07	Metabolite levels;
KIRP	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	11.08	0.58	2.06e-23	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22855876	chr2:27256034	TMEM214	0.49	6.1	0.36	4.14e-9	Parkinson's disease;
KIRP	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg13636640	chr20:31349939	DNMT3B	0.96	15.77	0.71	3.42e-39	Ulcerative colitis;
KIRP	cis	rs73206853	0.686	rs56339227	chr12:111164963	T/C	cg12870014	chr12:110450643	ANKRD13A	0.49	4.85	0.3	2.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs2625529	0.938	rs4776579	chr15:72132608	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-7.33	-0.42	3.23e-12	Red blood cell count;
KIRP	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.39	-4.86	-0.3	2.07e-6	Rheumatoid arthritis;
KIRP	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.56	6.09	0.36	4.43e-9	Bipolar disorder;
KIRP	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	5.37	0.32	1.84e-7	Menarche (age at onset);
KIRP	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.63	-6.36	-0.38	9.9e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.51	5.82	0.35	1.8e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs4363506	0.625	rs10765122	chr10:129285634	G/A	cg07804728	chr10:129284050	NA	0.42	5.78	0.35	2.25e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13692869	chr1:169336982	NME7;BLZF1	0.53	6.06	0.36	5.15e-9	Smoking initiation;
KIRP	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg05347473	chr6:146136440	FBXO30	0.54	7.59	0.44	6.48e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5753037	0.838	rs28749829	chr22:30219326	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.0	-0.3	1.08e-6	Type 1 diabetes;
KIRP	cis	rs1190545	0.588	rs4906213	chr14:102991021	C/T	cg10241871	chr14:102965420	TECPR2	-0.43	-5.11	-0.31	6.59e-7	Platelet count;
KIRP	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.64	4.57e-30	Bladder cancer;
KIRP	cis	rs193541	0.632	rs4835896	chr5:122121240	C/T	cg19412675	chr5:122181750	SNX24	-0.55	-5.86	-0.35	1.52e-8	Glucose homeostasis traits;
KIRP	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg21475434	chr5:93447410	FAM172A	0.77	6.9	0.4	4.46e-11	Diabetic retinopathy;
KIRP	cis	rs259282	0.524	rs11878322	chr19:33122886	C/T	cg02997394	chr19:33096574	ANKRD27	-0.43	-4.91	-0.3	1.69e-6	Schizophrenia;
KIRP	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.49	0.33	9.78e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg27490568	chr2:178487706	NA	0.49	6.56	0.39	3.22e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2658782	0.654	rs2605617	chr11:93243333	T/C	cg15737290	chr11:93063684	CCDC67	0.68	7.69	0.44	3.47e-13	Pulmonary function decline;
KIRP	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.41	-5.13	-0.31	5.99e-7	Ulcerative colitis;
KIRP	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg23649088	chr2:200775458	C2orf69	0.53	5.08	0.31	7.37e-7	Schizophrenia;
KIRP	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.7	9.24	0.51	1.21e-17	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs72772090	1.000	rs72772090	chr5:96036311	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-4.86	-0.3	2.13e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.74	-10.8	-0.57	1.6e-22	Height;
KIRP	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.38	-0.32	1.76e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg26384229	chr12:38710491	ALG10B	0.71	9.83	0.53	1.93e-19	Morning vs. evening chronotype;
KIRP	cis	rs7681423	0.906	rs56010410	chr4:155502869	T/C	cg20735720	chr4:155535218	FGG	-0.52	-6.25	-0.37	1.82e-9	Fibrinogen;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg10463451	chr21:37432625	SETD4	-0.43	-6.34	-0.37	1.12e-9	Erectile dysfunction in type 1 diabetes;
KIRP	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg00405596	chr8:11794950	NA	0.52	7.15	0.41	9.82e-12	Mood instability;
KIRP	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	1.1	20.16	0.79	5.03e-54	Bone mineral density;
KIRP	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg13482628	chr17:19912719	NA	0.53	6.82	0.4	6.89e-11	Schizophrenia;
KIRP	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg05347473	chr6:146136440	FBXO30	0.46	6.59	0.39	2.63e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177876	0.822	rs8177950	chr16:81116895	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-6.83	-0.4	6.56e-11	Tonsillectomy;
KIRP	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-5.95	-0.35	9.25e-9	Diastolic blood pressure;
KIRP	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.74	9.58	0.52	1.09e-18	Huntington's disease progression;
KIRP	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg02297831	chr4:17616191	MED28	0.6	7.5	0.43	1.17e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.39	0.33	1.63e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.68	-9.5	-0.52	1.98e-18	Retinal vascular caliber;
KIRP	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-5.67	-0.34	4.04e-8	Height;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.72	-10.42	-0.55	2.77e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.76	11.64	0.6	3.19e-25	Longevity;Endometriosis;
KIRP	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	7.85	0.45	1.27e-13	IgG glycosylation;
KIRP	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.83	10.75	0.57	2.34e-22	Mean platelet volume;
KIRP	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.1	-0.36	4.04e-9	Type 2 diabetes;
KIRP	cis	rs72960926	0.744	rs67076726	chr6:74992577	A/G	cg03266952	chr6:74778945	NA	-0.64	-5.71	-0.34	3.23e-8	Metabolite levels (MHPG);
KIRP	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.36	0.62	1.28e-27	Smoking behavior;
KIRP	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.93	-0.49	1.02e-16	Neuroticism;
KIRP	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	1.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02701443	chr2:190648932	PMS1;ORMDL1	0.44	6.42	0.38	6.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.35	0.32	2e-7	Lung cancer;
KIRP	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	0.44	6.01	0.36	6.72e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00864171	chr11:67383662	NA	-0.4	-5.05	-0.31	8.44e-7	Mean corpuscular volume;
KIRP	cis	rs7267005	0.661	rs79010119	chr20:34370071	A/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.46	5.7	0.34	3.42e-8	Common traits (Other);
KIRP	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.58	-9.26	-0.51	1.01e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.96	-8.04	-0.46	3.76e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.7	11.26	0.58	5.5e-24	Lung cancer;
KIRP	cis	rs2790457	0.958	rs2532744	chr10:28902618	T/G	cg05705492	chr10:28955341	NA	-0.55	-8.31	-0.47	6.46e-15	Multiple myeloma;
KIRP	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	7.41	0.43	2.05e-12	Neuroticism;
KIRP	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg06027949	chr8:82754900	SNX16	-0.53	-5.74	-0.34	2.76e-8	Diastolic blood pressure;
KIRP	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.57	6.96	0.41	3.08e-11	Alzheimer's disease (late onset);
KIRP	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.22	-0.37	2.13e-9	Retinal vascular caliber;
KIRP	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.94	14.27	0.67	4.46e-34	Personality dimensions;
KIRP	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-5.81	-0.35	1.97e-8	Renal function-related traits (BUN);
KIRP	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-6.71	-0.39	1.35e-10	Colorectal cancer;
KIRP	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.53	0.48	1.49e-15	Morning vs. evening chronotype;
KIRP	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.7	-0.34	3.4e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.89	-12.86	-0.63	2.8e-29	Tonsillectomy;
KIRP	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.71	8.06	0.46	3.24e-14	Corneal astigmatism;
KIRP	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg27426351	chr10:43362370	NA	0.45	6.2	0.37	2.37e-9	Blood protein levels;
KIRP	cis	rs4889855	0.556	rs9897453	chr17:78634300	C/T	cg09596252	chr17:78655493	RPTOR	0.5	5.75	0.34	2.6e-8	Fractional excretion of uric acid;
KIRP	cis	rs6662572	0.737	rs7552810	chr1:46452823	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.64	0.34	4.58e-8	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12983728	0.505	rs12460050	chr19:58666109	G/A	cg07378217	chr19:58662286	ZNF329	-0.45	-4.96	-0.3	1.34e-6	Cholesterol, total;
KIRP	cis	rs654950	0.841	rs676383	chr1:41993753	C/T	cg06885757	chr1:42089581	HIVEP3	-0.51	-7.47	-0.43	1.37e-12	Airway imaging phenotypes;
KIRP	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.69	-12.51	-0.62	4.11e-28	White blood cell count (basophil);
KIRP	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	1.31	9.58	0.52	1.11e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg05802129	chr4:122689817	NA	-0.58	-7.33	-0.42	3.27e-12	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10958369	0.613	rs7812717	chr8:54433922	A/C	cg12485204	chr8:54507357	NA	0.42	5.41	0.33	1.51e-7	Response to antineoplastic agents;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.51	5.52	0.33	8.56e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg05315796	chr3:52349193	DNAH1	0.46	7.02	0.41	2.19e-11	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05508315	chr3:122605312	LOC100129550	0.47	6.45	0.38	5.91e-10	Interleukin-4 levels;
KIRP	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg27490568	chr2:178487706	NA	0.48	6.31	0.37	1.29e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.24	-0.42	5.56e-12	Bladder cancer;
KIRP	cis	rs1524927	1.000	rs13310130	chr7:96346088	T/G	cg03808172	chr7:96339361	SHFM1	0.37	4.91	0.3	1.69e-6	Total body bone mineral density;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.23	-24.64	-0.84	2.17e-68	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.7	6.84	0.4	6.3e-11	Axial length;
KIRP	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.47	0.38	5.32e-10	Personality dimensions;
KIRP	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg16414030	chr3:133502952	NA	0.51	5.9	0.35	1.18e-8	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.07	-0.31	7.72e-7	Carotid intima media thickness;
KIRP	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg00405596	chr8:11794950	NA	0.57	7.9	0.45	9.26e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg16141378	chr3:129829833	LOC729375	0.6	8.31	0.47	6.65e-15	Neuroticism;
KIRP	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg19126910	chr11:111249659	POU2AF1	0.49	6.02	0.36	6.46e-9	Primary biliary cholangitis;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg13922124	chr7:105221991	EFCAB10	0.49	6.67	0.39	1.68e-10	Asthma;
KIRP	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.33	-4.95	-0.3	1.36e-6	Body mass index;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg19713609	chr11:819941	PNPLA2	-0.46	-6.13	-0.36	3.55e-9	Hippocampal sclerosis of aging;
KIRP	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.94	16.56	0.73	7.01e-42	Metabolic syndrome;
KIRP	cis	rs745080	0.596	rs2145956	chr14:53044103	T/A	cg23333723	chr14:53022898	GPR137C	-0.35	-4.9	-0.3	1.71e-6	Orofacial clefts;
KIRP	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.41	5.19	0.31	4.35e-7	Birth weight;
KIRP	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg21775007	chr8:11205619	TDH	0.43	5.67	0.34	3.91e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs859767	0.501	rs6745983	chr2:135430709	C/T	cg12500956	chr2:135428796	TMEM163	-0.42	-5.79	-0.35	2.17e-8	Neuroticism;
KIRP	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg21253087	chr9:139290292	SNAPC4	0.47	6.73	0.39	1.19e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg05304507	chr6:116381966	FRK	0.22	5.8	0.35	2.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg03647239	chr10:116582469	FAM160B1	0.48	5.52	0.33	8.45e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg12131826	chr15:77904385	NA	0.41	5.38	0.32	1.75e-7	Type 2 diabetes;
KIRP	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.14	-0.31	5.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1832871	0.711	rs9459769	chr6:158666493	T/C	cg07215822	chr6:158701037	NA	-0.64	-7.41	-0.43	2.03e-12	Height;
KIRP	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg17507749	chr15:85114479	UBE2QP1	0.86	9.88	0.53	1.33e-19	Schizophrenia;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05676635	chr4:142142438	ZNF330	-0.47	-6.92	-0.4	3.95e-11	Warfarin maintenance dose;
KIRP	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg18944383	chr4:111397179	ENPEP	0.49	8.14	0.46	1.98e-14	Coronary artery disease;
KIRP	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.78	0.53	2.64e-19	Multiple sclerosis;
KIRP	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-6.26	-0.37	1.74e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg10503236	chr1:231470652	EXOC8	0.46	6.55	0.39	3.31e-10	Hemoglobin concentration;
KIRP	cis	rs6088813	0.883	rs1406948	chr20:33905619	G/A	cg14752227	chr20:34000481	UQCC	0.46	5.49	0.33	9.75e-8	Height;
KIRP	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg00647317	chr7:50633725	DDC	0.39	5.63	0.34	4.9e-8	Systemic sclerosis;
KIRP	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.6	7.85	0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.77	6.77	0.4	9.27e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.18	-0.37	2.63e-9	Hemoglobin concentration;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg16048942	chr17:1953617	MIR132;MIR212	-0.47	-6.08	-0.36	4.47e-9	Myopia;
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-4.91	-0.3	1.68e-6	Electroencephalogram traits;
KIRP	cis	rs2278796	0.608	rs11240332	chr1:204969317	C/T	cg17947172	chr1:204966197	NFASC	0.63	8.36	0.47	4.66e-15	Mean platelet volume;
KIRP	cis	rs11955398	0.563	rs4700385	chr5:60032599	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.01	-0.3	1.06e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7221595	0.825	rs12601931	chr17:3986097	T/C	cg05562828	chr17:3906858	NA	0.57	6.08	0.36	4.59e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.22	-0.46	1.16e-14	Monocyte percentage of white cells;
KIRP	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.72	-0.56	3e-22	Menopause (age at onset);
KIRP	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg21573476	chr21:45109991	RRP1B	-0.65	-9.2	-0.51	1.64e-17	Mean corpuscular volume;
KIRP	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg23188430	chr6:125850052	NA	-0.33	-5.27	-0.32	2.92e-7	Brugada syndrome;
KIRP	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg13685349	chr14:81879247	NA	0.29	4.85	0.3	2.24e-6	Prudent dietary pattern;
KIRP	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2663905	0.560	rs1879454	chr15:81377717	C/A	cg09888468	chr15:81410853	NA	-0.58	-6.6	-0.39	2.45e-10	QT interval (drug interaction);
KIRP	cis	rs1014246	1.000	rs2240705	chr10:118467334	C/T	cg14919929	chr10:118506882	NA	0.57	7.09	0.41	1.43e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg15655495	chr12:38532458	NA	0.27	5.36	0.32	1.91e-7	Bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24327389	chr8:11882982	NA	-0.43	-6.3	-0.37	1.35e-9	Survival in pancreatic cancer;
KIRP	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.69	-7.16	-0.42	9.32e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.62	-0.34	5.06e-8	Ulcerative colitis;
KIRP	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg03060546	chr3:49711283	APEH	-0.63	-6.6	-0.39	2.51e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg04317338	chr11:64019027	PLCB3	-0.43	-5.13	-0.31	5.75e-7	Platelet count;
KIRP	cis	rs151997	0.571	rs13340385	chr5:50318847	T/G	cg06027927	chr5:50259733	NA	0.51	6.09	0.36	4.39e-9	Callous-unemotional behaviour;
KIRP	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.01	-0.36	6.63e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg03938580	chr17:65373390	PITPNC1	0.58	6.08	0.36	4.47e-9	QT interval;
KIRP	cis	rs9473924	0.580	rs66462826	chr6:50814877	C/A	cg14470998	chr6:50812995	TFAP2B	0.99	8.81	0.49	2.24e-16	Body mass index;
KIRP	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.89	0.35	1.25e-8	Motion sickness;
KIRP	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.66	9.74	0.53	3.55e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.51	0.59	8.43e-25	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07145255	chr5:59995354	DEPDC1B	0.52	7.03	0.41	1.98e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg11707556	chr5:10655725	ANKRD33B	0.67	8.44	0.47	2.7e-15	Coronary artery disease;
KIRP	cis	rs1816752	0.712	rs2862898	chr13:24988461	A/G	cg02811702	chr13:24901961	NA	0.41	5.38	0.32	1.77e-7	Obesity-related traits;
KIRP	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.91	11.25	0.58	5.62e-24	Response to bleomycin (chromatid breaks);
KIRP	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.08	0.5	3.57e-17	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24633967	chr5:134195255	C5orf24	-0.4	-6.11	-0.36	3.93e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9398803	0.713	rs9375447	chr6:126874091	A/G	cg19875578	chr6:126661172	C6orf173	0.41	5.2	0.31	4.1e-7	Male-pattern baldness;
KIRP	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	10.64	0.56	5.42e-22	Menopause (age at onset);
KIRP	cis	rs73206853	0.688	rs7314248	chr12:110559173	G/A	cg12870014	chr12:110450643	ANKRD13A	0.57	5.75	0.34	2.62e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.61	-0.34	5.34e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	1.21	8.59	0.48	9.83e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs8077577	1.000	rs8077577	chr17:18064730	C/T	cg18869244	chr17:18121946	NA	0.49	5.4	0.33	1.59e-7	Obesity-related traits;
KIRP	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	ch.6.197209F	chr6:7297596	SSR1	-0.5	-6.27	-0.37	1.58e-9	Parkinson's disease;
KIRP	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.48	0.59	1.04e-24	Alzheimer's disease;
KIRP	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg18016565	chr1:150552671	MCL1	0.35	5.51	0.33	8.88e-8	Melanoma;
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.7	9.65	0.52	6.84e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-5.93	-0.35	1.03e-8	Morning vs. evening chronotype;
KIRP	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15557168	chr22:42548783	NA	-0.46	-5.98	-0.36	7.87e-9	Cognitive function;
KIRP	cis	rs7635838	0.596	rs13353463	chr3:11260221	T/C	cg00170343	chr3:11313890	ATG7	0.5	6.66	0.39	1.78e-10	HDL cholesterol;
KIRP	cis	rs7215564	0.818	rs1032130	chr17:78610636	A/G	cg06153925	chr17:78755379	RPTOR	-0.45	-5.96	-0.36	8.75e-9	Myopia (pathological);
KIRP	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.61	9.95	0.54	7.98e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2625529	0.689	rs2957742	chr15:72302894	C/G	cg16672083	chr15:72433130	SENP8	0.43	6.13	0.36	3.55e-9	Red blood cell count;
KIRP	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg13736514	chr6:26305472	NA	-0.49	-5.2	-0.31	4.26e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg22892276	chr19:37744593	NA	0.41	6.52	0.38	3.94e-10	C-reactive protein;
KIRP	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg01689657	chr7:91764605	CYP51A1	0.45	6.82	0.4	6.87e-11	Breast cancer;
KIRP	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg21775007	chr8:11205619	TDH	0.49	6.6	0.39	2.48e-10	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18591441	chr10:74452317	CCDC109A	0.5	6.35	0.38	1.05e-9	Parkinson's disease;
KIRP	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.24	-6.43	-0.38	6.69e-10	Mean corpuscular volume;
KIRP	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.45	0.33	1.2e-7	Thyroid stimulating hormone;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg14743352	chr8:145734503	MFSD3	-1.07	-6.04	-0.36	5.55e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs6142102	0.961	rs6057957	chr20:32549858	T/G	cg08999081	chr20:33150536	PIGU	0.5	5.95	0.35	9.16e-9	Skin pigmentation;
KIRP	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.42	0.33	1.41e-7	Putamen volume;
KIRP	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg15816464	chr17:2026533	SMG6	0.35	5.24	0.32	3.39e-7	Total body bone mineral density;
KIRP	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-9.31	-0.51	7.3e-18	Educational attainment;
KIRP	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg08975724	chr8:8085496	FLJ10661	-0.74	-10.38	-0.55	3.7e-21	Triglycerides;
KIRP	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.88	9.38	0.51	4.52e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18166862	chr1:166136262	FAM78B	0.45	6.16	0.37	2.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7621025	0.505	rs61789642	chr3:136109696	C/T	cg15507776	chr3:136538369	TMEM22	-0.69	-5.92	-0.35	1.07e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg14829360	chr17:73884958	NA	0.46	6.08	0.36	4.54e-9	White matter hyperintensity burden;
KIRP	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.22	-0.61	3.75e-27	Ulcerative colitis;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00008839	chr19:2269146	OAZ1	-0.5	-6.06	-0.36	5.09e-9	Pancreatic cancer;
KIRP	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	0.6	8.11	0.46	2.45e-14	Prostate cancer;
KIRP	cis	rs4926611	0.762	rs2950250	chr1:54042714	T/G	cg08927728	chr1:54059983	GLIS1	-0.25	-5.48	-0.33	1.07e-7	Hand grip strength;
KIRP	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.2	0.37	2.42e-9	Ovarian reserve;
KIRP	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg08668510	chr10:1095578	IDI1	0.82	5.62	0.34	5.03e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg12658694	chr1:38397304	INPP5B	-0.66	-7.86	-0.45	1.21e-13	Coronary artery disease;
KIRP	cis	rs13132184	0.507	rs4832748	chr4:38056045	C/T	cg14409701	chr4:38048871	TBC1D1	0.75	7.36	0.42	2.82e-12	Verbal declarative memory;
KIRP	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg12315302	chr6:26189340	HIST1H4D	0.78	5.12	0.31	6.24e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6433857	0.536	rs12464424	chr2:181349137	A/G	cg23363182	chr2:181467187	NA	-0.38	-5.27	-0.32	3e-7	Body mass index;
KIRP	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.7	-8.47	-0.48	2.21e-15	Platelet distribution width;
KIRP	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.84	14.41	0.68	1.56e-34	Prostate-specific antigen levels;
KIRP	cis	rs6867032	1.000	rs4074914	chr5:2020274	C/T	cg26526719	chr5:1949144	NA	0.45	5.2	0.31	4.14e-7	Gut microbiome composition (winter);
KIRP	cis	rs12580194	1.000	rs73118926	chr12:55703335	A/G	cg11794356	chr12:55725991	OR6C3	-0.42	-5.09	-0.31	7.01e-7	Cancer;
KIRP	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.39	-0.33	1.64e-7	Personality dimensions;
KIRP	cis	rs9488822	0.636	rs1544155	chr6:116346394	C/A	cg18764771	chr6:116381957	FRK	0.2	5.39	0.33	1.65e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.17	-0.31	4.9e-7	Dupuytren's disease;
KIRP	cis	rs3736485	0.934	rs882385	chr15:51882369	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9309711	0.922	rs7561600	chr2:3486093	G/C	cg10845886	chr2:3471009	TTC15	-0.72	-10.92	-0.57	6.69e-23	Neurofibrillary tangles;
KIRP	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-6.9	-0.4	4.49e-11	Gut microbiome composition (summer);
KIRP	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.23	17.83	0.75	3.24e-46	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02602480	chr2:62422689	B3GNT2	0.46	6.91	0.4	4.14e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.63	-0.34	4.89e-8	Cognitive function;
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg13092806	chr2:177043255	NA	0.54	7.16	0.42	9.07e-12	IgG glycosylation;
KIRP	cis	rs4908768	0.639	rs4908512	chr1:8830366	A/T	cg25722041	chr1:8623473	RERE	0.64	7.93	0.45	7.54e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.69	9.82	0.53	2.01e-19	Prostate cancer;
KIRP	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.48	0.38	4.89e-10	Personality dimensions;
KIRP	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	11.37	0.59	2.43e-24	Smoking behavior;
KIRP	cis	rs76917914	0.735	rs4742716	chr9:100851420	C/T	cg03040243	chr9:100819229	NANS	0.64	7.21	0.42	6.99e-12	Immature fraction of reticulocytes;
KIRP	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-8.16	-0.46	1.74e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg03714773	chr7:91764589	CYP51A1	0.37	5.41	0.33	1.52e-7	Breast cancer;
KIRP	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.82	-8.44	-0.47	2.68e-15	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg05340658	chr4:99064831	C4orf37	0.66	7.68	0.44	3.69e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg07148914	chr20:33460835	GGT7	-0.55	-7.19	-0.42	7.62e-12	Height;
KIRP	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg00647317	chr7:50633725	DDC	0.56	8.21	0.46	1.24e-14	Systemic sclerosis;
KIRP	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg15737290	chr11:93063684	CCDC67	0.59	7.09	0.41	1.44e-11	Pulmonary function decline;
KIRP	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg11650704	chr1:154556575	ADAR	-0.44	-5.39	-0.33	1.64e-7	Blood protein levels;
KIRP	cis	rs6693567	0.565	rs1776276	chr1:150293078	A/C	cg09579323	chr1:150459698	TARS2	0.41	5.19	0.31	4.39e-7	Migraine;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13106472	chr14:30612659	NA	-0.42	-6.34	-0.37	1.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg13165212	chr22:42675999	NA	0.34	5.7	0.34	3.43e-8	Cognitive function;
KIRP	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.48	-5.3	-0.32	2.52e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.07e-10	Height;
KIRP	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2514805	0.803	rs2446823	chr8:95127612	G/T	cg25377915	chr8:95127949	NA	0.57	5.22	0.32	3.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg05805236	chr11:65401703	PCNXL3	-0.39	-5.17	-0.31	4.79e-7	Acne (severe);
KIRP	cis	rs7635838	0.892	rs6442252	chr3:11451416	T/C	cg00170343	chr3:11313890	ATG7	0.44	5.76	0.34	2.5e-8	HDL cholesterol;
KIRP	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.49	5.12	0.31	6.03e-7	Recombination rate (females);
KIRP	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg00629941	chr15:75287862	SCAMP5	-0.49	-5.22	-0.32	3.79e-7	Blood trace element (Zn levels);
KIRP	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.53	6.66	0.39	1.74e-10	Tuberculosis;
KIRP	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.33	7.33e-8	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.16	7.71	0.44	3.1e-13	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg11688874	chr10:28822482	WAC	-0.48	-6.22	-0.37	2.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg05370193	chr1:21551575	ECE1	0.38	5.13	0.31	5.87e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs882732	0.947	rs3762123	chr14:95029163	A/G	cg08495878	chr14:95027859	SERPINA4	-0.4	-4.93	-0.3	1.51e-6	Blood protein levels;
KIRP	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.24	-6.39	-0.38	8.18e-10	Crohn's disease;
KIRP	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.4	-0.55	3.19e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs67257959	0.586	rs8105085	chr19:17159962	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.5	5.99	0.36	7.3e-9	Selective IgA deficiency;
KIRP	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg06212747	chr3:49208901	KLHDC8B	0.7	8.25	0.47	9.68e-15	Menarche (age at onset);
KIRP	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.71	9.1	0.5	3.08e-17	Heart rate;
KIRP	cis	rs10267417	0.603	rs2214320	chr7:19946700	T/C	cg05791153	chr7:19748676	TWISTNB	0.5	4.94	0.3	1.47e-6	Night sleep phenotypes;
KIRP	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg18357526	chr6:26021779	HIST1H4A	0.49	6.61	0.39	2.4e-10	Height;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg01324507	chr7:1177794	C7orf50	0.41	5.05	0.31	8.79e-7	Longevity;Endometriosis;
KIRP	trans	rs11634944	0.869	rs4906936	chr15:25188189	G/T	cg10471437	chr16:28074462	GSG1L	0.49	6.12	0.36	3.6e-9	Interleukin-8 levels;
KIRP	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg25338242	chr13:114786047	RASA3	0.42	5.14	0.31	5.48e-7	Schizophrenia;
KIRP	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06481639	chr22:41940642	POLR3H	0.75	7.51	0.43	1.06e-12	Vitiligo;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24558718	chr10:853215	NA	0.44	6.12	0.36	3.75e-9	Survival in pancreatic cancer;
KIRP	cis	rs9815354	0.812	rs17217746	chr3:41926021	A/G	cg03022575	chr3:42003672	ULK4	0.79	8.16	0.46	1.69e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.79	14.73	0.68	1.22e-35	Lymphocyte counts;
KIRP	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.27	25.74	0.85	9.46e-72	IgG glycosylation;
KIRP	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg11833968	chr6:79620685	NA	-0.42	-5.05	-0.31	8.66e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs16828019	0.852	rs12759050	chr1:41664204	T/A	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.62	-0.44	5.44e-13	Triglycerides;
KIRP	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9522267	0.643	rs9522279	chr13:112221296	C/T	cg14952266	chr13:112191215	NA	0.39	5.19	0.31	4.42e-7	Hepatitis;
KIRP	cis	rs1165472	0.526	rs769977	chr1:56115798	A/G	cg11523071	chr1:56160889	NA	-0.42	-6.3	-0.37	1.37e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs58785573	0.513	rs6531648	chr4:38592137	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.39	4.88	0.3	1.91e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.48	-7.89	-0.45	1.02e-13	Platelet distribution width;
KIRP	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg05370193	chr1:21551575	ECE1	-0.36	-4.93	-0.3	1.54e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg24110177	chr3:50126178	RBM5	-0.61	-7.86	-0.45	1.21e-13	Menarche (age at onset);
KIRP	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.58	-0.33	6.48e-8	Menopause (age at onset);
KIRP	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.39	-0.32	1.68e-7	Bipolar disorder;
KIRP	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.6	-6.96	-0.41	3.04e-11	Bipolar disorder;
KIRP	cis	rs2131877	0.573	rs4300953	chr3:194846903	A/G	cg19775763	chr3:194786989	NA	-0.44	-5.33	-0.32	2.25e-7	Non-small cell lung cancer;
KIRP	cis	rs12049351	0.774	rs4925456	chr1:229623896	A/T	cg11742688	chr1:229674241	ABCB10	-0.39	-5.8	-0.35	2.01e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg13175981	chr1:150552382	MCL1	0.49	6.01	0.36	6.81e-9	Monocyte chemoattractant protein-1 levels;
KIRP	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.53	-0.43	9.9e-13	Resting heart rate;
KIRP	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	5.81	0.35	1.93e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.44	6.0	0.36	6.84e-9	Sitting height ratio;
KIRP	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.41e-8	Schizophrenia;
KIRP	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg02175503	chr12:58329896	NA	0.48	5.39	0.33	1.61e-7	Multiple sclerosis;
KIRP	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-8.53	-0.48	1.51e-15	Bladder cancer;
KIRP	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg06223162	chr1:101003688	GPR88	0.5	10.5	0.56	1.5e-21	Breast cancer;
KIRP	trans	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg06521331	chr12:34319734	NA	-0.51	-6.35	-0.38	1.04e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.64	8.99	0.5	6.77e-17	Schizophrenia;
KIRP	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.8	-0.45	1.75e-13	Sudden cardiac arrest;
KIRP	cis	rs7646881	0.812	rs7624408	chr3:158460058	G/A	cg19483011	chr3:158453295	NA	-0.56	-5.89	-0.35	1.23e-8	Tetralogy of Fallot;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02481015	chr6:163148718	PACRG;PARK2	0.55	6.58	0.39	2.75e-10	Smoking initiation;
KIRP	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg12756093	chr1:115239321	AMPD1	0.58	8.18	0.46	1.57e-14	Autism;
KIRP	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13693582	chr14:69441902	ACTN1	-0.43	-6.14	-0.36	3.23e-9	Inflammatory biomarkers;
KIRP	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg01677386	chr11:118938358	VPS11	-0.45	-4.96	-0.3	1.34e-6	Coronary artery disease;
KIRP	cis	rs12986413	0.651	rs2238609	chr19:2146629	C/T	cg09261902	chr19:2140048	AP3D1	0.72	11.51	0.59	8.2e-25	Height;
KIRP	cis	rs7312774	0.618	rs10861680	chr12:107323730	T/C	cg16260113	chr12:107380972	MTERFD3	0.77	6.81	0.4	7.58e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg00343986	chr7:65444356	GUSB	0.5	6.06	0.36	5.02e-9	Aortic root size;
KIRP	cis	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg08501292	chr6:25962987	TRIM38	0.88	6.16	0.37	2.91e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.55	-0.39	3.36e-10	Mean platelet volume;
KIRP	cis	rs4356932	1.000	rs6532105	chr4:76953895	C/A	cg19388996	chr4:76862389	NAAA	0.38	4.91	0.3	1.64e-6	Blood protein levels;
KIRP	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg24375607	chr4:120327624	NA	0.55	6.34	0.37	1.11e-9	Corneal astigmatism;
KIRP	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg05973401	chr12:123451056	ABCB9	-0.6	-5.51	-0.33	9.22e-8	Neutrophil percentage of white cells;
KIRP	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg03808351	chr9:123631620	PHF19	0.41	5.54	0.33	7.78e-8	Rheumatoid arthritis;
KIRP	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.66	9.29	0.51	8.52e-18	Morning vs. evening chronotype;
KIRP	cis	rs71277158	0.688	rs2287482	chr3:169765795	A/C	cg04067573	chr3:169899625	PHC3	0.54	5.04	0.31	9e-7	Prostate cancer;
KIRP	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.61	7.9	0.45	9.24e-14	HDL cholesterol;
KIRP	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg06212747	chr3:49208901	KLHDC8B	0.65	5.61	0.34	5.4e-8	Menarche (age at onset);
KIRP	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.5	6.58	0.39	2.77e-10	Schizophrenia;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg18342900	chr16:46865048	C16orf87	0.52	6.24	0.37	1.93e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg26566898	chr11:117069891	TAGLN	0.38	4.96	0.3	1.29e-6	Blood protein levels;
KIRP	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.85	0.69	4.8e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg17457637	chr7:27170717	HOXA4	0.35	5.24	0.32	3.4e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg11952622	chr19:58962976	ZNF324B	0.43	4.96	0.3	1.32e-6	Uric acid clearance;
KIRP	cis	rs1021993	0.545	rs17014395	chr1:209548807	T/G	cg24446417	chr1:209558027	NA	-0.51	-4.89	-0.3	1.78e-6	Gut microbiome composition (winter);
KIRP	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.65	10.25	0.55	9.36e-21	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.73	0.44	2.79e-13	Coffee consumption (cups per day);
KIRP	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg20991723	chr1:152506922	NA	-0.46	-5.5	-0.33	9.59e-8	Hair morphology;
KIRP	cis	rs12900413	0.523	rs11636525	chr15:90300478	A/G	cg24650279	chr15:90327240	NA	-0.41	-5.08	-0.31	7.51e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.89	14.02	0.67	3.23e-33	Longevity;Endometriosis;
KIRP	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg12560992	chr17:57184187	TRIM37	0.61	5.47	0.33	1.13e-7	Cognitive test performance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15631343	chr1:8090712	NA	0.49	6.28	0.37	1.49e-9	Interleukin-4 levels;
KIRP	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.85	-10.54	-0.56	1.15e-21	Vitamin D levels;
KIRP	cis	rs754423	0.703	rs2029974	chr14:52522095	C/T	cg05884192	chr14:52515736	NID2	-0.67	-7.92	-0.45	8.05e-14	Craniofacial microsomia;
KIRP	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06156847	chr2:113672199	IL1F7	-0.44	-6.25	-0.37	1.8e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.93	-12.34	-0.62	1.47e-27	Platelet distribution width;
KIRP	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg13877915	chr19:58951672	ZNF132	0.61	5.91	0.35	1.15e-8	Mean platelet volume;
KIRP	cis	rs28493229	0.786	rs73546894	chr19:41189203	C/T	cg21869046	chr19:41225005	ITPKC	0.43	5.67	0.34	3.96e-8	Kawasaki disease;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.44	-0.33	1.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.48	-6.73	-0.39	1.18e-10	Height;
KIRP	cis	rs7582720	1.000	rs72932770	chr2:203680954	T/C	cg08076091	chr2:203926405	NBEAL1	0.83	8.63	0.48	7.67e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.61	8.02	0.46	4.33e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.6	0.44	6.11e-13	Personality dimensions;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg05562828	chr17:3906858	NA	0.72	14.1	0.67	1.68e-33	Type 2 diabetes;
KIRP	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg01620082	chr3:125678407	NA	-1.13	-7.19	-0.42	7.84e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.8	8.54	0.48	1.37e-15	Alzheimer's disease;
KIRP	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.81	9.62	0.52	8.67e-19	Corneal astigmatism;
KIRP	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-7.21	-0.42	6.93e-12	Schizophrenia;
KIRP	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.11	0.41	1.26e-11	Lung cancer;
KIRP	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.75	12.38	0.62	1.06e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-0.53	-7.43	-0.43	1.79e-12	Coronary artery disease;
KIRP	cis	rs7621025	0.630	rs1681816	chr3:136474762	C/G	cg15507776	chr3:136538369	TMEM22	-0.43	-5.51	-0.33	8.97e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs1823913	0.637	rs4853574	chr2:192160839	A/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.18	-0.37	2.6e-9	Obesity-related traits;
KIRP	cis	rs2151522	0.603	rs1930942	chr6:127197001	A/G	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2692947	0.760	rs2438924	chr2:96645069	A/G	cg23100626	chr2:96804247	ASTL	0.46	6.8	0.4	7.86e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs732765	0.734	rs3784021	chr14:75200653	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.86	-0.3	2.08e-6	Non-small cell lung cancer;
KIRP	cis	rs7681423	0.951	rs11099961	chr4:155503212	C/T	cg20735720	chr4:155535218	FGG	-0.54	-7.06	-0.41	1.65e-11	Fibrinogen;
KIRP	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg22732515	chr19:44031385	ETHE1	0.58	8.17	0.46	1.58e-14	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.55	-7.78	-0.44	2.06e-13	Longevity;Endometriosis;
KIRP	cis	rs76917914	0.589	rs55972150	chr9:100863941	G/T	cg03040243	chr9:100819229	NANS	0.48	5.1	0.31	6.95e-7	Immature fraction of reticulocytes;
KIRP	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs4478858	0.647	rs12752761	chr1:31710888	T/C	cg00250761	chr1:31883323	NA	-0.32	-5.56	-0.33	6.93e-8	Alcohol dependence;
KIRP	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg03929089	chr4:120376271	NA	0.7	6.21	0.37	2.21e-9	Axial length;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.65	9.16	0.5	2.04e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2278729	0.514	rs1057591	chr2:101623745	T/A	cg15506514	chr2:101638852	TBC1D8	0.44	4.9	0.3	1.75e-6	Osteoporosis-related phenotypes;
KIRP	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11987759	chr7:65425863	GUSB	0.49	6.43	0.38	6.58e-10	Aortic root size;
KIRP	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.68	7.81	0.45	1.64e-13	Primary sclerosing cholangitis;
KIRP	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg16606324	chr3:10149918	C3orf24	0.69	5.82	0.35	1.82e-8	Alzheimer's disease;
KIRP	cis	rs752092	0.894	rs8043243	chr15:101771453	C/T	cg19997662	chr15:101784653	CHSY1	-0.68	-10.1	-0.54	2.71e-20	Corneal structure;
KIRP	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.42	-0.38	6.99e-10	Total body bone mineral density;
KIRP	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg07212818	chr11:638076	DRD4	-0.39	-4.92	-0.3	1.57e-6	Systemic lupus erythematosus;
KIRP	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	trans	rs800082	0.668	rs6805395	chr3:144292116	T/C	cg24215973	chr2:240111563	HDAC4	-0.57	-7.76	-0.44	2.29e-13	Smoking behavior;
KIRP	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg17554472	chr22:41940697	POLR3H	-0.43	-5.36	-0.32	1.89e-7	Neuroticism;
KIRP	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.72	-9.7	-0.53	4.86e-19	Personality dimensions;
KIRP	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.6	-6.61	-0.39	2.32e-10	Pancreatic cancer;
KIRP	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.66	-0.48	6.39e-16	Coronary artery disease;
KIRP	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	5.89	0.35	1.25e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.01	-0.3	1.05e-6	Pulmonary function;
KIRP	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.8	-0.53	2.34e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	9.15	0.5	2.26e-17	Aortic root size;
KIRP	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg20302533	chr7:39170763	POU6F2	0.26	5.14	0.31	5.72e-7	IgG glycosylation;
KIRP	cis	rs10504073	0.584	rs12546490	chr8:49932841	C/T	cg00325661	chr8:49890786	NA	0.76	11.05	0.58	2.6e-23	Blood metabolite ratios;
KIRP	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.23	0.32	3.59e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.511	rs2035659	chr12:33826241	T/C	cg26384229	chr12:38710491	ALG10B	0.51	6.72	0.39	1.27e-10	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.55	0.39	3.25e-10	Bipolar disorder;
KIRP	cis	rs1417569	0.546	rs2994623	chr10:31192193	G/C	cg00428179	chr10:31322131	ZNF438	-0.37	-5.54	-0.33	7.83e-8	Tuberculosis;
KIRP	cis	rs2033732	0.706	rs1370420	chr8:85068234	G/T	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.53	7.24	0.42	5.83e-12	Mean corpuscular volume;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.21	11.11	0.58	1.67e-23	Alzheimer's disease (late onset);
KIRP	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.54	6.29	0.37	1.48e-9	Macular telangiectasia type 2;
KIRP	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg16255804	chr6:135334527	HBS1L	-0.34	-5.38	-0.32	1.7e-7	Red blood cell count;
KIRP	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.96	-0.36	8.59e-9	Height;
KIRP	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg09754948	chr16:28834200	ATXN2L	0.46	5.09	0.31	7.03e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg00631329	chr6:26305371	NA	-0.73	-9.5	-0.52	1.99e-18	Educational attainment;
KIRP	cis	rs9549328	0.642	rs2993343	chr13:113616844	C/G	cg17524180	chr13:113633600	MCF2L	0.25	4.93	0.3	1.48e-6	Systolic blood pressure;
KIRP	trans	rs2043599	0.748	rs74446689	chr19:56463697	A/G	cg25841159	chr17:74137454	FOXJ1	-0.96	-6.06	-0.36	5.2e-9	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs17065868	0.536	rs9533861	chr13:45033166	T/A	cg10246903	chr13:45222710	NA	0.58	4.92	0.3	1.59e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18076651	chr12:53625605	RARG	0.61	7.07	0.41	1.6e-11	Lung function (FEV1);
KIRP	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg07930552	chr6:133119739	C6orf192	0.82	5.79	0.35	2.13e-8	Type 2 diabetes nephropathy;
KIRP	cis	rs2224391	1.000	rs9504370	chr6:5261601	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.94	-0.4	3.55e-11	Height;
KIRP	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg09890400	chr1:26503858	CNKSR1	0.42	5.81	0.35	1.94e-8	Height;
KIRP	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg16524733	chr11:117070046	TAGLN	0.44	5.81	0.35	1.97e-8	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00767560	chr19:19887256	LOC284440	0.53	6.31	0.37	1.32e-9	Smoking initiation;
KIRP	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.71	9.51	0.52	1.89e-18	Bladder cancer;
KIRP	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.61	-7.01	-0.41	2.26e-11	Prudent dietary pattern;
KIRP	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.39	-0.33	1.61e-7	Bipolar disorder;
KIRP	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17467752	chr17:38218738	THRA	-0.56	-7.16	-0.42	9.31e-12	Myeloid white cell count;
KIRP	cis	rs7712401	0.601	rs246306	chr5:122279218	G/C	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg02524346	chr8:600233	NA	-0.87	-5.7	-0.34	3.39e-8	IgG glycosylation;
KIRP	cis	rs10186029	0.509	rs6733869	chr2:213949073	T/C	cg08319019	chr2:214017104	IKZF2	-0.48	-5.2	-0.31	4.2e-7	Systemic sclerosis;
KIRP	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg06307176	chr5:131281290	NA	-0.51	-5.62	-0.34	5.26e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.81	10.41	0.55	2.8e-21	Breast cancer;
KIRP	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg25007680	chr1:8021821	PARK7	0.65	9.04	0.5	4.86e-17	Response to antidepressants and depression;
KIRP	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg18478394	chr8:109455254	TTC35	0.48	5.95	0.35	9.1e-9	Dupuytren's disease;
KIRP	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg23565292	chr14:50234668	KLHDC2	-0.43	-5.26	-0.32	3.14e-7	Carotid intima media thickness;
KIRP	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.45	-0.78	1.14e-51	Height;
KIRP	cis	rs2219968	1.000	rs7818353	chr8:78972826	C/A	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg02038168	chr22:39784481	NA	-0.45	-5.58	-0.34	6.36e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg11941060	chr3:133502564	NA	-0.45	-5.59	-0.34	5.9e-8	Iron status biomarkers;
KIRP	cis	rs2273669	0.915	rs6908714	chr6:109294336	T/C	cg05315195	chr6:109294784	ARMC2	-0.49	-5.59	-0.34	6.1e-8	Prostate cancer;
KIRP	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg14024328	chr4:719362	PCGF3	-0.56	-8.69	-0.48	5.03e-16	White blood cell count;
KIRP	cis	rs2562456	0.833	rs2968076	chr19:21637101	C/T	cg25650185	chr19:21324782	ZNF431	0.47	4.99	0.3	1.13e-6	Pain;
KIRP	cis	rs12282928	0.959	rs11039637	chr11:48306980	C/T	cg26585981	chr11:48327164	OR4S1	0.5	6.08	0.36	4.6e-9	Migraine - clinic-based;
KIRP	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg07636037	chr3:49044803	WDR6	0.54	5.12	0.31	6.26e-7	Menarche (age at onset);
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.61	8.88	0.49	1.41e-16	Lung cancer;
KIRP	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.58	-6.27	-0.37	1.6e-9	Serum sulfate level;
KIRP	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg26384229	chr12:38710491	ALG10B	0.56	6.21	0.37	2.2e-9	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.44	0.47	2.82e-15	Motion sickness;
KIRP	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.41	5.37	0.32	1.81e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg18016565	chr1:150552671	MCL1	0.35	5.51	0.33	8.88e-8	Melanoma;
KIRP	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg09631939	chr20:60582478	TAF4	-0.39	-4.9	-0.3	1.76e-6	Body mass index;
KIRP	cis	rs2299587	0.554	rs2073565	chr8:17743649	T/C	cg01800426	chr8:17659068	MTUS1	-0.45	-5.4	-0.33	1.54e-7	Economic and political preferences;
KIRP	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-9.24	-0.51	1.23e-17	Resting heart rate;
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg05562828	chr17:3906858	NA	0.73	14.49	0.68	8.16e-35	Type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13198984	chr17:80129470	CCDC57	0.56	8.56	0.48	1.22e-15	Life satisfaction;
KIRP	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.18	0.42	8.11e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs16828019	0.789	rs36084778	chr1:41479538	A/G	cg03387723	chr1:41708464	SCMH1	-0.73	-6.28	-0.37	1.55e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.63	-7.99	-0.45	5.15e-14	Breast cancer;
KIRP	cis	rs6539288	0.677	rs11113144	chr12:107323422	T/C	cg15890332	chr12:107067104	RFX4	0.35	5.61	0.34	5.34e-8	Total body bone mineral density;
KIRP	cis	rs2281603	0.570	rs11625265	chr14:64977321	A/G	cg01860774	chr14:64969374	ZBTB25	0.35	5.64	0.34	4.69e-8	Lymphocyte counts;
KIRP	cis	rs2302729	0.578	rs7315556	chr12:2773855	G/A	cg19945202	chr12:2788847	CACNA1C	-0.78	-11.36	-0.59	2.51e-24	Sleep quality;
KIRP	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg18904891	chr8:8559673	CLDN23	0.71	7.91	0.45	8.57e-14	Obesity-related traits;
KIRP	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs9359856	0.518	rs10485242	chr6:90183389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.58	-6.08	-0.36	4.61e-9	Bipolar disorder;
KIRP	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.68	-7.56	-0.43	7.82e-13	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.17	0.31	4.75e-7	Life satisfaction;
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg09695851	chr17:3907499	NA	-0.82	-14.78	-0.69	8.57e-36	Type 2 diabetes;
KIRP	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.63	8.7	0.49	4.74e-16	Autism;
KIRP	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.26	-0.32	3.06e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.53	-0.65	1.54e-31	Exhaled nitric oxide output;
KIRP	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14169450	chr9:139327907	INPP5E	-0.33	-4.89	-0.3	1.79e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.73	-8.0	-0.45	4.9e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg06740227	chr12:86229804	RASSF9	0.46	5.64	0.34	4.77e-8	Major depressive disorder;
KIRP	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg06627628	chr2:24431161	ITSN2	-0.56	-4.88	-0.3	1.93e-6	Lymphocyte counts;
KIRP	cis	rs2219968	0.962	rs13263076	chr8:78970258	T/C	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.65	-7.12	-0.41	1.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs17301259	0.564	rs4727185	chr7:88428840	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-5.35	-0.32	2.06e-7	Heschl's gyrus morphology;
KIRP	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg11234688	chr2:1609660	NA	0.62	5.56	0.33	6.91e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9826463	0.757	rs73240310	chr3:142240459	T/C	cg20824294	chr3:142316082	PLS1	0.41	6.45	0.38	5.9e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-1.17	-21.78	-0.81	2.55e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.79	-14.84	-0.69	5.07e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg05721485	chr17:44071124	MAPT	0.6	7.8	0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7640424	0.750	rs13074183	chr3:107851467	G/A	cg09227934	chr3:107805635	CD47	-0.41	-6.78	-0.4	8.94e-11	Body mass index;
KIRP	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg00852783	chr1:26633632	UBXN11	0.54	7.51	0.43	1.07e-12	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.44	5.64	0.34	4.65e-8	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg07701084	chr6:150067640	NUP43	0.72	10.29	0.55	6.99e-21	Lung cancer;
KIRP	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg12181417	chr19:49337499	HSD17B14	-0.47	-5.01	-0.3	1.02e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10073892	0.664	rs1910290	chr5:101891951	A/G	cg19774478	chr5:101632501	SLCO4C1	0.52	5.25	0.32	3.33e-7	Cognitive decline (age-related);
KIRP	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg03289416	chr15:75166202	SCAMP2	0.42	5.46	0.33	1.18e-7	Systemic lupus erythematosus;
KIRP	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg09699651	chr6:150184138	LRP11	0.59	8.17	0.46	1.6e-14	Testicular germ cell tumor;
KIRP	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.78	-10.78	-0.57	1.86e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.67	-0.34	3.95e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.41e-8	Schizophrenia;
KIRP	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.84	10.58	0.56	8.22e-22	Platelet distribution width;
KIRP	cis	rs9596863	1.000	rs7318666	chr13:54418960	C/G	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.66	-0.34	4.22e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg04310649	chr10:35416472	CREM	-0.55	-6.24	-0.37	1.93e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs242364	0.530	rs66921363	chr21:28866669	A/G	cg01278232	chr17:17606846	RAI1	-0.59	-6.44	-0.38	6.19e-10	Daytime sleep phenotypes;
KIRP	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg08313168	chr12:7315531	NA	0.7	6.28	0.37	1.56e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs7246760	0.867	rs57943754	chr19:9841283	G/A	cg02900749	chr2:68251473	NA	-1.08	-8.92	-0.49	1.09e-16	Pursuit maintenance gain;
KIRP	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.75	-0.44	2.47e-13	Total cholesterol levels;
KIRP	cis	rs745080	0.674	rs11624388	chr14:52995786	T/G	cg23333723	chr14:53022898	GPR137C	-0.41	-5.64	-0.34	4.67e-8	Orofacial clefts;
KIRP	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg06223162	chr1:101003688	GPR88	0.45	9.36	0.51	5.06e-18	Monocyte count;
KIRP	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.49	7.46	0.43	1.44e-12	Major depressive disorder;
KIRP	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg16898833	chr6:26189333	HIST1H4D	0.66	5.04	0.31	9.09e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11077161	chr14:71996050	SIPA1L1	-0.41	-6.2	-0.37	2.4e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.21	0.37	2.18e-9	Hemoglobin concentration;
KIRP	cis	rs9488822	0.636	rs6937104	chr6:116375302	A/G	cg18764771	chr6:116381957	FRK	0.19	5.04	0.31	9.21e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg00405596	chr8:11794950	NA	0.55	7.63	0.44	5.2e-13	Myopia (pathological);
KIRP	cis	rs4262150	0.544	rs2961745	chr5:151916826	C/T	cg12297329	chr5:152029980	NA	-0.56	-7.18	-0.42	8.26e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs858239	0.539	rs2141305	chr7:23191899	T/C	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6968419	0.649	rs58624059	chr7:115868798	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg11503966	chr20:62272292	STMN3	-0.42	-5.78	-0.35	2.29e-8	Atopic dermatitis;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg07859478	chr19:808116	PTBP1	0.45	6.04	0.36	5.67e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs34435647	1	rs34435647	chr2:160518289	CT/C	cg08347373	chr2:160653686	CD302	-0.39	-5.89	-0.35	1.27e-8	Granulocyte percentage of myeloid white cells;Neutrophil percentage of white cells;
KIRP	cis	rs9372498	0.831	rs62421535	chr6:118724565	C/A	cg18833306	chr6:118973337	C6orf204	-0.57	-5.21	-0.32	4.03e-7	Diastolic blood pressure;
KIRP	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.64	-7.96	-0.45	6.5e-14	Longevity;
KIRP	cis	rs13095912	0.778	rs7651346	chr3:185300395	G/A	cg11274856	chr3:185301563	NA	0.62	7.62	0.44	5.51e-13	Systolic blood pressure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21127189	chr4:39368001	RFC1	-0.49	-6.46	-0.38	5.6e-10	Metabolic traits;
KIRP	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg18132916	chr6:79620363	NA	-0.45	-5.06	-0.31	8.09e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs4132509	1.000	rs10927050	chr1:243805907	A/G	cg25706552	chr1:244017396	NA	0.58	7.67	0.44	4.07e-13	RR interval (heart rate);
KIRP	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.72	8.44	0.47	2.83e-15	High light scatter reticulocyte count;
KIRP	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-5.1	-0.31	6.8e-7	Schizophrenia;
KIRP	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.18	-0.46	1.53e-14	Response to antipsychotic treatment;
KIRP	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg13373371	chr19:49828787	SLC6A16	0.4	4.87	0.3	2e-6	Multiple sclerosis;
KIRP	cis	rs1030268	0.608	rs12707106	chr7:133311350	A/T	cg10665199	chr7:133106180	EXOC4	0.6	5.84	0.35	1.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs198389	0.568	rs12406667	chr1:11873851	C/T	cg24844545	chr1:11908347	NPPA	0.35	4.87	0.3	2.03e-6	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
KIRP	cis	rs2033732	0.789	rs7821259	chr8:85081619	T/G	cg05716166	chr8:85095498	RALYL	0.51	5.77	0.35	2.38e-8	Body mass index;
KIRP	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.32	-0.32	2.29e-7	Pulmonary function;
KIRP	cis	rs4688759	0.764	rs2023953	chr3:50103917	G/A	cg03060546	chr3:49711283	APEH	-0.76	-6.19	-0.37	2.52e-9	Blood protein levels;
KIRP	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.52	-7.16	-0.42	9.26e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs979961	0.568	rs78858846	chr4:117919195	C/T	cg02574033	chr7:141398961	KIAA1147	0.88	6.14	0.36	3.22e-9	Ulcerative colitis;
KIRP	cis	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg08773314	chr2:239334832	ASB1	-0.55	-5.73	-0.34	2.89e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg20887711	chr4:1340912	KIAA1530	0.42	4.87	0.3	1.97e-6	Obesity-related traits;
KIRP	cis	rs17321999	0.516	rs72787748	chr2:30506642	G/A	cg05247661	chr2:30472410	LBH	0.62	5.08	0.31	7.38e-7	Systemic lupus erythematosus;
KIRP	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	trans	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg06521331	chr12:34319734	NA	-0.51	-6.24	-0.37	1.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.63	6.31	0.37	1.28e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3105593	0.965	rs8029073	chr15:50913148	T/A	cg08437265	chr15:50716283	USP8	0.41	5.1	0.31	6.69e-7	QT interval;
KIRP	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg13397359	chr6:42928475	GNMT	0.44	4.94	0.3	1.44e-6	Blood protein levels;
KIRP	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg25019033	chr10:957182	NA	-0.55	-6.75	-0.4	1.04e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	10.9	0.57	7.63e-23	Mean platelet volume;
KIRP	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-9.16	-0.5	2.07e-17	Hypospadias;
KIRP	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-9.59	-0.52	1.01e-18	Body mass index;
KIRP	cis	rs7572644	0.640	rs4564736	chr2:28069543	A/T	cg27432699	chr2:27873401	GPN1	0.48	5.78	0.35	2.26e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.73	10.73	0.56	2.71e-22	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg23533926	chr12:111358616	MYL2	-0.47	-6.21	-0.37	2.19e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6959887	0.962	rs10264435	chr7:35296663	C/T	cg06685737	chr7:35301730	NA	0.45	6.61	0.39	2.39e-10	Birth weight;
KIRP	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg12560992	chr17:57184187	TRIM37	0.46	5.41	0.33	1.49e-7	Cognitive test performance;
KIRP	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-10.68	-0.56	4e-22	Chronic sinus infection;
KIRP	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg27211696	chr2:191398769	TMEM194B	-0.73	-8.31	-0.47	6.46e-15	Diastolic blood pressure;
KIRP	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.81	-10.97	-0.57	4.74e-23	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00096806	chr17:61086969	TANC2	-0.42	-6.45	-0.38	6e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.83	14.1	0.67	1.76e-33	Vitiligo;
KIRP	cis	rs8177876	0.822	rs8177939	chr16:81119196	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg11650704	chr1:154556575	ADAR	-0.38	-4.97	-0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13198984	chr17:80129470	CCDC57	-0.57	-8.7	-0.48	4.9e-16	Life satisfaction;
KIRP	cis	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg16898833	chr6:26189333	HIST1H4D	0.98	5.91	0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs7520050	0.966	rs6662641	chr1:46571509	T/A	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg05527609	chr1:210001259	C1orf107	-0.47	-5.14	-0.31	5.48e-7	Red blood cell count;
KIRP	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.74	-9.05	-0.5	4.42e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg24826892	chr11:71159390	DHCR7	0.44	4.89	0.3	1.81e-6	Vitamin D levels;
KIRP	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg23032965	chr3:12705835	RAF1	0.71	7.85	0.45	1.28e-13	Cholesterol, total;
KIRP	cis	rs7665939	1.000	rs72709206	chr4:190109171	T/C	cg09826759	chr4:190284978	NA	-0.75	-5.09	-0.31	7.17e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.85	0.35	1.56e-8	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21291383	chr1:42800883	FOXJ3	0.51	6.38	0.38	8.95e-10	Parkinson's disease;
KIRP	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg05973401	chr12:123451056	ABCB9	0.56	6.49	0.38	4.58e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-1.06	-21.35	-0.81	6.16e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6496667	1.000	rs62019272	chr15:90858974	C/A	cg10434728	chr15:90938212	IQGAP1	0.42	5.53	0.33	8.25e-8	Rheumatoid arthritis;
KIRP	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg04310649	chr10:35416472	CREM	-0.57	-6.51	-0.38	4.29e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.71	-10.93	-0.57	6.26e-23	Height;
KIRP	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.5	7.1	0.41	1.37e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.79	-0.4	8.37e-11	Monocyte percentage of white cells;
KIRP	cis	rs4764487	0.760	rs733700	chr12:6337974	A/G	cg08284733	chr12:6341482	CD9	0.6	10.27	0.55	7.81e-21	Mean platelet volume;
KIRP	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg02487422	chr3:49467188	NICN1	0.35	4.93	0.3	1.5e-6	Parkinson's disease;
KIRP	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.59	8.01	0.45	4.53e-14	Morning vs. evening chronotype;
KIRP	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.1	-0.31	6.95e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg25706552	chr1:244017396	NA	0.61	6.37	0.38	9.42e-10	RR interval (heart rate);
KIRP	cis	rs7116495	1.000	rs3793938	chr11:71823133	G/A	cg18441811	chr11:71824068	C11orf51	0.64	5.1	0.31	6.78e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.91	10.04	0.54	4.23e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-7.1	-0.41	1.33e-11	Coronary artery disease;
KIRP	trans	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	6.04	0.36	5.74e-9	Neuroticism;
KIRP	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.98	-0.36	7.64e-9	Neuroticism;
KIRP	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	cis	rs9362426	1.000	rs406900	chr6:88085447	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	5.54	0.33	7.61e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg07148914	chr20:33460835	GGT7	-0.41	-5.07	-0.31	7.84e-7	Height;
KIRP	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03605463	chr16:89740564	NA	-0.43	-5.07	-0.31	7.83e-7	Vitiligo;
KIRP	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg03395511	chr6:291903	DUSP22	-0.54	-6.18	-0.37	2.62e-9	Menopause (age at onset);
KIRP	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-9.29	-0.51	8.36e-18	Triglycerides;
KIRP	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.65	7.81	0.45	1.65e-13	Vitamin D levels;
KIRP	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.65	-10.45	-0.55	2.09e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg04519387	chr11:65556438	OVOL1	0.35	5.41	0.33	1.52e-7	Acne (severe);
KIRP	cis	rs62413470	0.935	rs17817730	chr6:55935255	G/C	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	1.09	17.61	0.75	1.78e-45	Cognitive function;
KIRP	cis	rs1125355	0.589	rs62183013	chr2:159607874	G/A	cg02251393	chr2:159651559	DAPL1	0.42	4.93	0.3	1.53e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.53	7.03	0.41	2.01e-11	Prostate cancer;
KIRP	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.29	5.8	0.35	2.02e-8	Coronary artery disease;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.93	16.26	0.72	7.45e-41	Menarche (age at onset);
KIRP	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.61	0.34	5.44e-8	Bipolar disorder;
KIRP	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.34	-0.37	1.1e-9	Alcohol dependence;
KIRP	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg06360820	chr2:242988706	NA	-0.8	-7.41	-0.43	2.03e-12	Obesity-related traits;
KIRP	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg02023728	chr11:77925099	USP35	0.32	5.49	0.33	9.97e-8	Alzheimer's disease (survival time);
KIRP	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.87	-0.57	9.59e-23	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23010693	chr14:103911341	MARK3	-0.43	-6.64	-0.39	2.02e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13385	0.728	rs28477538	chr5:139565634	C/T	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg23594656	chr7:65796392	TPST1	0.4	6.07	0.36	4.92e-9	Aortic root size;
KIRP	cis	rs4926611	0.698	rs35227000	chr1:54060016	G/C	cg08927728	chr1:54059983	GLIS1	0.3	6.29	0.37	1.48e-9	Hand grip strength;
KIRP	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg21419209	chr3:44054225	NA	-0.73	-9.15	-0.5	2.19e-17	Coronary artery disease;
KIRP	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg04289385	chr6:36355825	ETV7	0.39	5.17	0.31	4.86e-7	Platelet distribution width;
KIRP	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-6.81	-0.4	7.5e-11	Chronic sinus infection;
KIRP	cis	rs6466055	0.661	rs1010340	chr7:104830695	T/C	cg04380332	chr7:105027541	SRPK2	0.36	5.06	0.31	8.06e-7	Schizophrenia;
KIRP	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13512333	chr11:14796080	PDE3B	0.34	6.16	0.37	2.89e-9	C-reactive protein;
KIRP	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4561483	0.603	rs7202065	chr16:11951045	C/T	cg08843971	chr16:11963173	GSPT1	0.55	7.66	0.44	4.31e-13	Testicular germ cell tumor;
KIRP	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.02	12.59	0.63	2.11e-28	Testicular germ cell tumor;
KIRP	cis	rs7582720	0.945	rs72932759	chr2:203674288	G/A	cg08076091	chr2:203926405	NBEAL1	0.83	8.63	0.48	7.67e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.8	-10.88	-0.57	9.33e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg05342945	chr12:48394962	COL2A1	-0.45	-4.9	-0.3	1.72e-6	Lung cancer;
KIRP	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg10434728	chr15:90938212	IQGAP1	0.44	8.46	0.47	2.34e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg17366294	chr4:99064904	C4orf37	-0.37	-5.13	-0.31	5.85e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs13170463	0.579	rs11743105	chr5:8038936	T/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg09695851	chr17:3907499	NA	0.7	11.13	0.58	1.44e-23	Type 2 diabetes;
KIRP	cis	rs12615966	0.932	rs60065121	chr2:105368305	T/C	cg16465502	chr2:105461796	NA	0.68	6.06	0.36	4.95e-9	Pancreatic cancer;
KIRP	cis	rs12900413	0.687	rs12902786	chr15:90304376	G/A	cg24650279	chr15:90327240	NA	-0.41	-5.17	-0.31	4.79e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg24315340	chr6:146058215	EPM2A	0.42	5.28	0.32	2.84e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-8.85	-0.49	1.76e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.95	-0.3	1.4e-6	Breast cancer;
KIRP	cis	rs4851254	0.660	rs114552491	chr2:100709533	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-5.09	-0.31	7.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs55863869	0.748	rs7604033	chr2:179626017	A/G	cg02880032	chr2:179629472	TTN	-0.68	-5.44	-0.33	1.3e-7	QT interval;
KIRP	cis	rs11264213	0.892	rs12037102	chr1:36261733	T/G	cg27506609	chr1:36549197	TEKT2	0.75	7.22	0.42	6.45e-12	Schizophrenia;
KIRP	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg15704280	chr7:45808275	SEPT13	0.69	6.28	0.37	1.53e-9	Axial length;
KIRP	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg16506815	chr2:162101123	NA	0.52	6.15	0.37	3.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg25547332	chr5:131281432	NA	-0.46	-5.33	-0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg24253500	chr15:84953950	NA	0.53	5.89	0.35	1.26e-8	Schizophrenia;
KIRP	cis	rs9603616	0.747	rs6563740	chr13:40241873	G/T	cg26701198	chr13:40229707	COG6	0.43	5.13	0.31	5.97e-7	Rheumatoid arthritis;
KIRP	cis	rs2273669	0.667	rs12374597	chr6:109346184	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs6495367	1.000	rs13380109	chr15:79378775	G/A	cg17916960	chr15:79447300	NA	0.3	5.19	0.31	4.37e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7149242	0.922	rs9671394	chr14:101159674	C/T	cg18089426	chr14:101175970	NA	-0.54	-7.12	-0.41	1.19e-11	Platelet count;
KIRP	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.32	-0.32	2.36e-7	Subjective well-being;
KIRP	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.22	13.59	0.65	9.37e-32	Eosinophil percentage of granulocytes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25355723	chr17:37910446	NA	-0.47	-6.41	-0.38	7.49e-10	Metabolic traits;
KIRP	cis	rs6738627	1.000	rs10187501	chr2:165532454	A/G	cg03182029	chr2:165697222	COBLL1	0.41	5.32	0.32	2.38e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs3736594	0.546	rs965813	chr2:27789861	T/A	cg27432699	chr2:27873401	GPN1	0.55	6.12	0.36	3.7e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg19773385	chr1:10388646	KIF1B	-0.67	-8.78	-0.49	2.92e-16	Hepatocellular carcinoma;
KIRP	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.67	5.56	0.33	7.04e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg06521331	chr12:34319734	NA	-0.58	-7.07	-0.41	1.59e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9900062	0.519	rs2676293	chr17:62710461	T/C	cg02097616	chr17:62675921	NA	0.51	6.13	0.36	3.43e-9	QT interval;
KIRP	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.6	-7.21	-0.42	6.94e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg15436174	chr10:43711423	RASGEF1A	0.76	8.44	0.47	2.68e-15	Hirschsprung disease;
KIRP	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs7851660	0.809	rs7044799	chr9:100665393	A/T	cg13688889	chr9:100608707	NA	-0.68	-8.66	-0.48	6.18e-16	Strep throat;
KIRP	cis	rs4790312	0.765	rs3760230	chr17:1994071	C/G	cg24156229	chr17:1948635	NA	-0.45	-6.08	-0.36	4.66e-9	Left atrial antero-posterior diameter;
KIRP	cis	rs42648	0.837	rs13239439	chr7:89924400	C/A	cg25739043	chr7:89950458	NA	-0.45	-6.99	-0.41	2.62e-11	Homocysteine levels;
KIRP	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.53e-7	Plateletcrit;
KIRP	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg03128060	chr6:142623767	GPR126	0.35	5.13	0.31	5.87e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.43	-0.33	1.34e-7	Longevity;Endometriosis;
KIRP	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	1.11	7.84	0.45	1.34e-13	Skin colour saturation;
KIRP	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.6	7.91	0.45	8.48e-14	Alcohol dependence;
KIRP	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg19773385	chr1:10388646	KIF1B	-0.4	-5.83	-0.35	1.76e-8	Hepatocellular carcinoma;
KIRP	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4762326	0.565	rs1964592	chr12:95644008	T/C	cg07737802	chr12:95537812	FGD6	0.37	4.89	0.3	1.78e-6	Endometriosis;
KIRP	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.56	0.65	1.2e-31	Chronic sinus infection;
KIRP	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg22549504	chr19:17448937	GTPBP3	-0.45	-4.97	-0.3	1.27e-6	Systemic lupus erythematosus;
KIRP	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.44	5.73	0.34	2.87e-8	Motion sickness;
KIRP	cis	rs2274273	0.870	rs7160523	chr14:55594560	G/T	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	4.07e-15	Protein biomarker;
KIRP	cis	rs2278796	0.639	rs4951152	chr1:204970495	G/T	cg17449235	chr1:204966235	NFASC	0.58	8.01	0.45	4.51e-14	Mean platelet volume;
KIRP	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg11204139	chr17:3907470	NA	0.51	6.17	0.37	2.72e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22133949	chr7:102327236	NA	-0.42	-6.13	-0.36	3.53e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg03605463	chr16:89740564	NA	-0.46	-5.25	-0.32	3.25e-7	Vitiligo;
KIRP	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.34	-7.06	-0.41	1.72e-11	Urinary metabolites;
KIRP	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg14768367	chr16:72042858	DHODH	-0.91	-9.98	-0.54	6.65e-20	Blood protein levels;
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.88	-13.14	-0.64	2.99e-30	Longevity;
KIRP	cis	rs7084402	0.967	rs1649065	chr10:60306386	T/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg09408571	chr1:101003634	GPR88	0.34	7.9	0.45	9.12e-14	Breast cancer;
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.93	15.72	0.71	5.02e-39	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg10756647	chr7:56101905	PSPH	1.08	8.58	0.48	1.08e-15	Diabetic kidney disease;
KIRP	cis	rs6684428	0.536	rs6695436	chr1:56390156	G/T	cg11651538	chr1:56320950	NA	-0.53	-7.27	-0.42	4.74e-12	Airflow obstruction;
KIRP	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.91	11.63	0.6	3.43e-25	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10322724	chr4:20253556	NA	0.51	6.88	0.4	5.05e-11	Parkinson's disease;
KIRP	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg15880211	chr22:50250494	ZBED4	0.57	5.05	0.31	8.57e-7	Schizophrenia;
KIRP	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.68	9.17	0.5	1.94e-17	Crohn's disease;
KIRP	cis	rs737008	1.000	rs737008	chr16:11374866	G/T	cg00044050	chr16:11439710	C16orf75	-0.62	-7.3	-0.42	3.91e-12	Obesity-related traits;
KIRP	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg04370829	chr17:406249	NA	0.4	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	5.62	0.34	5.23e-8	Diastolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26284901	chr15:73925319	NPTN	0.58	8.08	0.46	2.89e-14	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg00405596	chr8:11794950	NA	0.6	8.68	0.48	5.44e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2236918	0.901	rs1776135	chr1:242025530	A/G	cg17736920	chr1:242011382	EXO1	0.72	9.22	0.51	1.43e-17	Menopause (age at onset);
KIRP	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg17376030	chr22:41985996	PMM1	0.54	6.21	0.37	2.21e-9	Vitiligo;
KIRP	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2273156	1.000	rs8017191	chr14:35469991	G/A	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.37	-0.32	1.87e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.78	-11.37	-0.59	2.33e-24	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs56116382	0.668	rs4688759	chr3:50008118	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.78	-6.14	-0.36	3.34e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02923393	chr16:1543003	TELO2	0.68	6.29	0.37	1.41e-9	Lung function (FEV1);
KIRP	trans	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7011049	0.915	rs66905540	chr8:53862641	A/G	cg26025543	chr8:53854495	NA	0.6	6.44	0.38	6.32e-10	Systolic blood pressure;
KIRP	cis	rs367943	0.712	rs255861	chr5:112745327	G/A	cg12552261	chr5:112820674	MCC	0.57	6.69	0.39	1.49e-10	Type 2 diabetes;
KIRP	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg15880211	chr22:50250494	ZBED4	0.47	5.63	0.34	4.9e-8	Schizophrenia;
KIRP	cis	rs62413470	1.000	rs62404866	chr6:55956146	G/A	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18970250	chr4:169142962	DDX60	0.39	6.06	0.36	5.04e-9	C-reactive protein;
KIRP	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg03060546	chr3:49711283	APEH	0.43	5.55	0.33	7.37e-8	Parkinson's disease;
KIRP	cis	rs7523050	0.642	rs12044219	chr1:109481236	T/C	cg08274380	chr1:109419600	GPSM2	0.99	9.1	0.5	3.27e-17	Fat distribution (HIV);
KIRP	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.58	7.63	0.44	5.17e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7089973	0.844	rs10510007	chr10:116636721	A/G	cg03647239	chr10:116582469	FAM160B1	0.45	5.23	0.32	3.7e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.87	14.3	0.67	3.52e-34	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg08773314	chr2:239334832	ASB1	-0.34	-4.96	-0.3	1.32e-6	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.72	-10.47	-0.56	1.88e-21	Hip circumference;
KIRP	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.62	-8.59	-0.48	1e-15	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg09264619	chr17:80180166	NA	-0.41	-5.92	-0.35	1.05e-8	Life satisfaction;
KIRP	cis	rs3737883	1.000	rs10753933	chr1:203026214	T/G	cg03900565	chr1:203031815	PPFIA4	0.42	6.06	0.36	5.09e-9	Early onset atrial fibrillation;
KIRP	cis	rs3112255	0.967	rs2015067	chr2:101305478	T/C	cg01042948	chr2:101319752	NA	0.43	6.15	0.36	3.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8053891	0.507	rs34150651	chr16:72028112	G/A	cg01557791	chr16:72042693	DHODH	-0.47	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.69	8.74	0.49	3.65e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08439880	chr3:133502540	NA	-0.49	-6.17	-0.37	2.77e-9	Iron status biomarkers;
KIRP	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.91	-14.47	-0.68	9.76e-35	Ulcerative colitis;
KIRP	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg02725872	chr8:58115012	NA	-0.56	-6.14	-0.36	3.27e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg07803811	chr1:43423981	SLC2A1	0.43	4.89	0.3	1.79e-6	Red cell distribution width;
KIRP	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.23	-0.32	3.69e-7	Pulmonary function;
KIRP	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg04519387	chr11:65556438	OVOL1	0.34	5.24	0.32	3.53e-7	Acne (severe);
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.69	11.23	0.58	6.93e-24	Mean corpuscular volume;
KIRP	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.44	-5.27	-0.32	3.05e-7	Longevity;
KIRP	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	11.34	0.59	2.89e-24	Menopause (age at onset);
KIRP	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.83	12.04	0.61	1.52e-26	Bladder cancer;
KIRP	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg03788504	chr6:150331562	NA	-0.33	-6.17	-0.37	2.74e-9	Alopecia areata;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg05800758	chr8:101225800	SPAG1	0.7	6.58	0.39	2.85e-10	Lung function (FEV1);
KIRP	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg22852734	chr6:133119734	C6orf192	1.14	13.89	0.66	8.62e-33	Type 2 diabetes nephropathy;
KIRP	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.93	-13.73	-0.66	3.2e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	9.63	0.52	8.07e-19	Alzheimer's disease;
KIRP	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-5.74	-0.34	2.79e-8	Parkinson's disease;
KIRP	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.49	-7.34	-0.42	3.12e-12	Electroencephalogram traits;
KIRP	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-5.01	-0.3	1.02e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	0.82	10.58	0.56	8.52e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg04310649	chr10:35416472	CREM	0.6	7.07	0.41	1.59e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18050194	chr3:42623358	SEC22C	0.56	7.82	0.45	1.52e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.62	6.58	0.39	2.77e-10	Corneal structure;
KIRP	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-5.28	-0.32	2.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12210905	1.000	rs1102557	chr6:27149794	C/A	cg11502198	chr6:26597334	ABT1	0.78	5.1	0.31	6.83e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg13147721	chr7:65941812	NA	-0.96	-6.78	-0.4	8.76e-11	Diabetic kidney disease;
KIRP	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg18586891	chr4:952366	TMEM175	0.59	5.42	0.33	1.42e-7	Parkinson's disease;
KIRP	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg22138327	chr13:27999177	GTF3A	0.89	6.77	0.4	9.38e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg06212747	chr3:49208901	KLHDC8B	0.65	9.06	0.5	4.12e-17	Resting heart rate;
KIRP	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.86	-13.48	-0.65	2.24e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.82	0.35	1.8e-8	Schizophrenia;
KIRP	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14126091	chr2:105946410	TGFBRAP1	-0.57	-6.38	-0.38	8.56e-10	Menopause (age at onset);
KIRP	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.91	-0.45	8.48e-14	Neuroticism;
KIRP	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg21191810	chr6:118973309	C6orf204	-0.4	-5.64	-0.34	4.55e-8	Electrocardiographic conduction measures;
KIRP	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.69	10.24	0.55	9.91e-21	Dupuytren's disease;
KIRP	cis	rs17221829	0.616	rs75627051	chr11:89360903	C/T	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.3	-0.32	2.53e-7	Anxiety in major depressive disorder;
KIRP	cis	rs2151522	0.603	rs11154377	chr6:127200701	A/G	cg21431617	chr6:127135037	NA	0.31	5.3	0.32	2.53e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.86	12.62	0.63	1.69e-28	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs911119	0.913	rs13038990	chr20:23589053	C/T	cg09631192	chr20:23583594	CST9	-0.52	-5.43	-0.33	1.37e-7	Chronic kidney disease;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-1.03	-12.12	-0.61	7.75e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg05802129	chr4:122689817	NA	-0.48	-6.15	-0.37	3.08e-9	Type 2 diabetes;
KIRP	cis	rs2446066	0.605	rs7298336	chr12:53957330	G/T	cg16917193	chr12:54089295	NA	0.7	5.65	0.34	4.5e-8	Red blood cell count;
KIRP	cis	rs394563	0.591	rs6570963	chr6:149691355	T/G	cg16235748	chr6:149772707	ZC3H12D	0.31	5.15	0.31	5.33e-7	Dupuytren's disease;
KIRP	cis	rs1420338	0.933	rs62451689	chr7:34178719	C/T	cg01275685	chr7:34179230	BMPER	-0.61	-9.4	-0.51	3.83e-18	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.83	-13.32	-0.65	7.72e-31	Blood metabolite levels;
KIRP	cis	rs6968419	0.781	rs66652906	chr7:115881159	G/A	cg02561103	chr7:115862891	TES	-0.43	-6.15	-0.36	3.16e-9	Intraocular pressure;
KIRP	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg16077055	chr2:106428750	NCK2	0.28	5.58	0.34	6.25e-8	Addiction;
KIRP	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg23950597	chr19:37808831	NA	-0.67	-5.99	-0.36	7.32e-9	Coronary artery calcification;
KIRP	cis	rs7534824	0.625	rs7414132	chr1:101526413	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	6.87	0.4	5.31e-11	Refractive astigmatism;
KIRP	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	9.1	0.5	3.1e-17	Smoking behavior;
KIRP	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg17279839	chr7:150038598	RARRES2	0.43	5.22	0.32	3.77e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4494114	0.967	rs9438986	chr1:39369652	T/G	cg25970120	chr1:39325951	RRAGC	-0.41	-5.1	-0.31	6.86e-7	Blood protein levels;
KIRP	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	1.03	16.57	0.73	6.58e-42	Menopause (age at onset);
KIRP	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.71	9.59	0.52	1.02e-18	Height;
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.52	-6.44	-0.38	6.23e-10	Longevity;Endometriosis;
KIRP	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.65	-8.58	-0.48	1.09e-15	Lymphocyte percentage of white cells;
KIRP	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.55	-7.6	-0.44	6.29e-13	Motion sickness;
KIRP	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg18478394	chr8:109455254	TTC35	0.58	7.27	0.42	4.78e-12	Dupuytren's disease;
KIRP	cis	rs6708331	0.517	rs11890741	chr2:70360506	T/C	cg01613454	chr2:70366299	NA	0.4	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg05709478	chr1:6581295	PLEKHG5	0.66	5.81	0.35	1.95e-8	Body mass index;
KIRP	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs3126085	0.935	rs2184953	chr1:152280782	A/G	cg26876637	chr1:152193138	HRNR	-0.67	-8.9	-0.49	1.21e-16	Atopic dermatitis;
KIRP	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-6.29	-0.37	1.43e-9	Obesity (extreme);
KIRP	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.27	-5.65	-0.34	4.52e-8	Menarche (age at onset);
KIRP	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg15841412	chr13:111365552	ING1	0.49	5.54	0.33	7.92e-8	Coronary artery disease;
KIRP	cis	rs939574	0.790	rs2385397	chr2:220087796	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.85	-6.58	-0.39	2.8e-10	Platelet distribution width;
KIRP	cis	rs4845875	0.600	rs4846041	chr1:11837051	C/T	cg24844545	chr1:11908347	NPPA	0.37	4.9	0.3	1.73e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.79	10.8	0.57	1.61e-22	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs208520	0.909	rs55813840	chr6:67012508	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.35	0.42	2.88e-12	Exhaled nitric oxide output;
KIRP	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	13.93	0.66	6.55e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.55	7.65	0.44	4.41e-13	Schizophrenia;
KIRP	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.49	6.52	0.38	3.95e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9790314	0.613	rs1447620	chr3:160616211	T/C	cg19274270	chr17:78178856	CARD14	0.34	6.18	0.37	2.69e-9	Morning vs. evening chronotype;
KIRP	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-5.22	-0.32	3.77e-7	Chronic sinus infection;
KIRP	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg06012730	chr15:75315579	PPCDC	-0.4	-4.99	-0.3	1.13e-6	Blood trace element (Zn levels);
KIRP	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg00852783	chr1:26633632	UBXN11	-0.53	-5.68	-0.34	3.73e-8	Obesity-related traits;
KIRP	cis	rs73198271	0.595	rs56152067	chr8:8592992	G/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.7	0.71	5.85e-39	Chronic sinus infection;
KIRP	cis	rs8084125	0.832	rs62105175	chr18:74948498	T/C	cg26065057	chr18:74961000	GALR1	0.6	6.2	0.37	2.42e-9	Obesity-related traits;
KIRP	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.72	9.84	0.53	1.74e-19	Prostate cancer;
KIRP	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg21775007	chr8:11205619	TDH	-0.52	-6.99	-0.41	2.62e-11	Retinal vascular caliber;
KIRP	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.65	-6.21	-0.37	2.24e-9	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
KIRP	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26526719	chr5:1949144	NA	0.42	5.08	0.31	7.32e-7	Gut microbiome composition (winter);
KIRP	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.53	6.67	0.39	1.68e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22762745	chr3:195602360	TNK2	-0.44	-6.14	-0.36	3.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg24503407	chr1:205819492	PM20D1	0.46	5.28	0.32	2.82e-7	White blood cell types;
KIRP	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07570687	chr10:102243282	WNT8B	0.51	6.64	0.39	1.98e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.63	7.61	0.44	5.67e-13	Coronary artery disease;
KIRP	cis	rs7224685	0.569	rs34377654	chr17:3990201	G/A	cg11204139	chr17:3907470	NA	0.58	5.46	0.33	1.15e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.57	-7.48	-0.43	1.31e-12	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04769705	chr14:69262517	C14orf181	0.49	6.87	0.4	5.37e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.58	-5.16	-0.31	5.18e-7	Smoking behavior;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11479258	chr12:2999997	TULP3	0.57	7.13	0.41	1.14e-11	Parkinson's disease;
KIRP	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg00491522	chr10:135256596	NA	0.56	5.98	0.36	7.67e-9	Systemic lupus erythematosus;
KIRP	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.46	0.33	1.17e-7	Putamen volume;
KIRP	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.78	10.92	0.57	6.71e-23	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg25039879	chr17:56429692	SUPT4H1	0.58	5.18	0.31	4.51e-7	Cognitive test performance;
KIRP	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.47	0.38	5.31e-10	Birth weight;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13938909	chr1:89873226	LOC400759	0.51	6.23	0.37	2e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.4	0.51	3.89e-18	Morning vs. evening chronotype;
KIRP	cis	rs4700695	0.920	rs251303	chr5:65248753	A/C	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.81	-0.35	1.96e-8	Endometrial cancer;
KIRP	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg23950597	chr19:37808831	NA	-0.76	-6.7	-0.39	1.37e-10	Coronary artery calcification;
KIRP	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg26384229	chr12:38710491	ALG10B	0.69	8.76	0.49	3.29e-16	Resting heart rate;
KIRP	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.85	11.68	0.6	2.21e-25	Obesity-related traits;
KIRP	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.22	-0.37	2.11e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7565981	1.000	rs11893548	chr2:101428774	A/G	cg02232089	chr2:101440696	NPAS2	0.54	4.93	0.3	1.53e-6	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg21479132	chr6:26055353	NA	0.81	5.67	0.34	4.09e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.44e-11	Schizophrenia;
KIRP	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.76	11.74	0.6	1.44e-25	Oral cavity cancer;
KIRP	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.77	10.87	0.57	1.02e-22	Systolic blood pressure;
KIRP	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-6.81	-0.4	7.33e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg13978929	chr19:21580086	ZNF493	0.51	4.95	0.3	1.36e-6	Pain;
KIRP	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.64	8.85	0.49	1.75e-16	Mood instability;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20285609	chr1:41622030	SCMH1	0.57	6.36	0.38	9.76e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg00405596	chr8:11794950	NA	0.62	8.71	0.49	4.42e-16	Neuroticism;
KIRP	cis	rs4073221	0.654	rs35320569	chr3:18289750	T/C	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg20237496	chr19:47104468	CALM3	0.5	6.42	0.38	6.86e-10	DNA methylation (variation);
KIRP	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg00792783	chr2:198669748	PLCL1	-0.47	-5.31	-0.32	2.43e-7	Dermatomyositis;
KIRP	cis	rs78761021	0.502	rs12150273	chr17:9765514	G/C	cg26853458	chr17:9805074	RCVRN	0.53	5.03	0.31	9.38e-7	Type 2 diabetes;
KIRP	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs3820928	0.839	rs12470666	chr2:227876525	G/A	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.71	-0.34	3.24e-8	Pulmonary function;
KIRP	trans	rs13170463	0.579	rs78222079	chr5:8042042	C/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.19	-0.31	4.35e-7	Alcohol dependence;
KIRP	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.78	-0.35	2.3e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4356932	0.875	rs10034055	chr4:76970539	C/T	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.74	0.4	1.09e-10	Cognitive function;
KIRP	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg05315796	chr3:52349193	DNAH1	0.38	5.82	0.35	1.78e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09119654	chr2:61293073	KIAA1841	0.47	6.35	0.38	1.01e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.66	0.34	4.19e-8	Breast cancer;
KIRP	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg00806126	chr19:22604979	ZNF98	0.65	7.07	0.41	1.57e-11	Pain;
KIRP	cis	rs4663866	0.908	rs2304670	chr2:239165636	C/T	cg17283117	chr2:239148619	HES6	0.7	5.06	0.31	8.32e-7	Irritable bowel syndrome;
KIRP	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.97	-13.25	-0.65	1.33e-30	Ulcerative colitis;
KIRP	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Parkinson's disease;
KIRP	cis	rs15676	1.000	rs15676	chr9:131572027	A/G	cg00228799	chr9:131580591	ENDOG	-0.57	-6.45	-0.38	5.83e-10	Blood metabolite levels;
KIRP	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07570687	chr10:102243282	WNT8B	0.52	6.64	0.39	1.94e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.02	0.36	6.36e-9	Menopause (age at onset);
KIRP	cis	rs1823913	0.637	rs4853581	chr2:192166259	C/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.75	-9.27	-0.51	9.85e-18	Personality dimensions;
KIRP	cis	rs7814319	0.700	rs11995989	chr8:97264456	C/G	cg20787634	chr8:97240163	UQCRB	-0.58	-7.81	-0.45	1.66e-13	Lung function (FVC);
KIRP	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg02490460	chr8:1365502	NA	-0.48	-5.03	-0.31	9.56e-7	Triglycerides;
KIRP	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.67	-5.04	-0.31	9.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.08	-0.36	4.65e-9	Aortic root size;
KIRP	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg06640241	chr16:89574553	SPG7	0.64	8.5	0.48	1.8e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.6	-7.54	-0.43	9.07e-13	Fibrinogen levels;
KIRP	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg10017260	chr10:834428	NA	-0.55	-5.42	-0.33	1.44e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16701124	chr4:115406970	NA	-0.42	-6.61	-0.39	2.42e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg22325292	chr17:80708367	FN3K	0.37	5.04	0.31	9e-7	Glycated hemoglobin levels;
KIRP	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-6.54	-0.38	3.52e-10	Schizophrenia;
KIRP	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.39	6.32	0.37	1.24e-9	Body mass index;
KIRP	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.37	-5.47	-0.33	1.11e-7	Headache;
KIRP	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg18964960	chr10:1102726	WDR37	-0.55	-6.0	-0.36	6.93e-9	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14305383	chr9:132400216	ASB6	0.48	6.63	0.39	2.14e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.32e-12	Uric acid levels;
KIRP	cis	rs911119	0.866	rs6048920	chr20:23576844	A/G	cg09631192	chr20:23583594	CST9	-0.49	-5.22	-0.32	3.88e-7	Chronic kidney disease;
KIRP	cis	rs3736485	0.932	rs2899477	chr15:51937701	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.14	-0.31	5.56e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	0.8	7.92	0.45	8.37e-14	Mitochondrial DNA levels;
KIRP	trans	rs7157940	0.692	rs4905163	chr14:94570770	A/G	cg11750133	chr10:93647217	NA	0.49	6.24	0.37	1.95e-9	Anthropometric traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14987222	chr20:18123352	CSRP2BP;PET117	0.44	6.2	0.37	2.38e-9	Survival in pancreatic cancer;
KIRP	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg01411142	chr8:19674711	INTS10	-0.45	-4.94	-0.3	1.43e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11987759	chr7:65425863	GUSB	-0.41	-4.92	-0.3	1.55e-6	Aortic root size;
KIRP	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg24565620	chr2:194026	NA	-0.71	-8.47	-0.48	2.31e-15	Blood protein levels;
KIRP	cis	rs6832769	0.961	rs11939815	chr4:56358283	T/G	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs3737883	1.000	rs871298	chr1:203039602	C/G	cg03900565	chr1:203031815	PPFIA4	0.42	5.95	0.35	9e-9	Early onset atrial fibrillation;
KIRP	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	5.85	0.35	1.53e-8	Depressive symptoms;
KIRP	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg07309820	chr7:148901717	ZNF282	-0.4	-5.2	-0.31	4.18e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.57	8.03	0.46	4.14e-14	Tuberculosis;
KIRP	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.82	-13.27	-0.65	1.11e-30	Prostate cancer;
KIRP	cis	rs8177876	0.915	rs12444974	chr16:81128230	G/A	cg08591886	chr16:81111003	C16orf46	-0.64	-5.0	-0.3	1.07e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4654899	0.802	rs61781104	chr1:21257235	T/A	cg05370193	chr1:21551575	ECE1	0.44	5.37	0.32	1.83e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.62	-0.34	5.11e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg01721255	chr8:58191610	C8orf71	0.6	5.42	0.33	1.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.7	9.35	0.51	5.55e-18	Eye color traits;
KIRP	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.79	-0.4	8.5e-11	HDL cholesterol;
KIRP	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	10.42	0.55	2.79e-21	Electrocardiographic conduction measures;
KIRP	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg25272121	chr1:152190972	HRNR	-0.42	-5.83	-0.35	1.77e-8	Inflammatory skin disease;
KIRP	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.46	-7.51	-0.43	1.07e-12	Height;
KIRP	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg16313264	chr11:57103491	SSRP1	0.69	7.05	0.41	1.83e-11	Lung function (FEV1);
KIRP	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-7.1	-0.41	1.36e-11	Coronary artery disease;
KIRP	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.3	-0.37	1.4e-9	IgG glycosylation;
KIRP	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg19847130	chr8:10466454	RP1L1	-0.4	-5.75	-0.34	2.59e-8	Retinal vascular caliber;
KIRP	cis	rs1010254	0.510	rs1035401	chr5:151709678	T/C	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	11.21	0.58	7.73e-24	Smoking behavior;
KIRP	cis	rs10073892	0.701	rs28786103	chr5:101722151	T/C	cg19774478	chr5:101632501	SLCO4C1	0.68	6.63	0.39	2.12e-10	Cognitive decline (age-related);
KIRP	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg01559446	chr3:44596178	ZNF167	-0.37	-5.22	-0.32	3.81e-7	Depressive symptoms;
KIRP	cis	rs448720	0.840	rs35640546	chr15:68185981	T/C	cg24579218	chr15:68104479	NA	0.35	4.98	0.3	1.22e-6	Cognitive performance;
KIRP	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg14250997	chr9:106856677	SMC2	0.44	6.14	0.36	3.37e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Colorectal cancer;
KIRP	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg24296786	chr1:45957014	TESK2	0.43	5.49	0.33	9.91e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2663905	0.560	rs1879454	chr15:81377717	C/A	cg18837035	chr15:81426597	C15orf26	-0.48	-5.18	-0.31	4.51e-7	QT interval (drug interaction);
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg24826892	chr11:71159390	DHCR7	0.44	5.04	0.31	9.01e-7	Vitamin D levels;
KIRP	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-7.51	-0.43	1.1e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.89e-10	Bipolar disorder;
KIRP	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.64	-0.52	7.55e-19	Retinal vascular caliber;
KIRP	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.91	11.14	0.58	1.3e-23	Platelet distribution width;
KIRP	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.63	9.52	0.52	1.71e-18	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs10214930	0.697	rs5009225	chr7:27616785	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.89	0.3	1.84e-6	Hypospadias;
KIRP	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.37	-6.79	-0.4	8.41e-11	Graves' disease;
KIRP	cis	rs7546668	1.000	rs4646090	chr1:15822073	A/G	cg21858823	chr1:15850916	CASP9	0.46	5.1	0.31	6.64e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-6.99	-0.41	2.54e-11	Monocyte count;
KIRP	cis	rs9398803	0.624	rs9372837	chr6:126638124	G/A	cg19875578	chr6:126661172	C6orf173	0.4	5.05	0.31	8.49e-7	Male-pattern baldness;
KIRP	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	14.56	0.68	4.8e-35	Alzheimer's disease;
KIRP	cis	rs4774899	0.966	rs12903115	chr15:57495151	T/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.03	-0.31	9.42e-7	Urinary tract infection frequency;
KIRP	cis	rs17221829	0.645	rs12288897	chr11:89388816	C/T	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.35	-0.32	2.03e-7	Anxiety in major depressive disorder;
KIRP	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg01872077	chr2:219646372	CYP27A1	0.39	4.91	0.3	1.7e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.25	-5.33	-0.32	2.24e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg21523564	chr15:75251491	NA	-0.35	-5.94	-0.35	9.57e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg26139080	chr11:47293733	MADD	-0.42	-5.27	-0.32	3e-7	HDL cholesterol;
KIRP	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.57	-6.27	-0.37	1.62e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg21360079	chr12:107162445	NA	0.67	9.76	0.53	3.15e-19	Heart rate;
KIRP	cis	rs909341	0.909	rs1151624	chr20:62369895	A/G	cg03999872	chr20:62272968	STMN3	0.59	6.83	0.4	6.8e-11	Atopic dermatitis;
KIRP	cis	rs2976388	0.935	rs2920285	chr8:143756218	G/C	cg17252645	chr8:143867129	LY6D	-0.3	-4.86	-0.3	2.08e-6	Urinary tract infection frequency;
KIRP	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs4742903	0.791	rs6479226	chr9:106972872	T/G	cg14250997	chr9:106856677	SMC2	0.37	5.02	0.3	9.96e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs981844	0.961	rs17299034	chr4:154671396	A/G	cg14289246	chr4:154710475	SFRP2	0.67	7.54	0.43	9.09e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg03146154	chr1:46216737	IPP	0.54	5.51	0.33	8.89e-8	Platelet count;
KIRP	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg05370193	chr1:21551575	ECE1	-0.38	-5.17	-0.31	4.87e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7539409	0.651	rs910182	chr1:84297117	A/G	cg10977910	chr1:84465055	TTLL7	0.54	5.12	0.31	6.29e-7	Alzheimer's disease;
KIRP	cis	rs2290402	0.536	rs4690336	chr4:867242	A/G	cg00846425	chr4:957561	DGKQ	0.45	4.88	0.3	1.89e-6	Type 2 diabetes;
KIRP	cis	rs5167	0.506	rs7257916	chr19:45482884	T/C	cg09555818	chr19:45449301	APOC2	-0.56	-8.08	-0.46	3.01e-14	Blood protein levels;
KIRP	cis	rs1318772	1.000	rs11738587	chr5:112693781	C/G	cg12552261	chr5:112820674	MCC	0.73	6.3	0.37	1.36e-9	F-cell distribution;
KIRP	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.53	-0.52	1.59e-18	Response to antipsychotic treatment;
KIRP	cis	rs16828019	0.777	rs115916606	chr1:41642700	C/G	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10864907	0.553	rs7580877	chr2:113718310	C/A	cg06156847	chr2:113672199	IL1F7	-0.42	-5.86	-0.35	1.45e-8	Pulmonary function;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg09993021	chr2:155101781	GALNT13	0.42	6.33	0.37	1.13e-9	Migraine with aura;
KIRP	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.77	11.4	0.59	1.89e-24	Menarche (age at onset);
KIRP	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg01849466	chr14:104193079	ZFYVE21	-0.58	-7.53	-0.43	9.47e-13	Schizophrenia;
KIRP	cis	rs258892	0.947	rs266435	chr5:72174432	C/G	cg21869765	chr5:72125136	TNPO1	0.58	6.44	0.38	6.16e-10	Small cell lung carcinoma;
KIRP	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	7.97	0.45	5.84e-14	Type 2 diabetes;
KIRP	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.29	-9.3	-0.51	7.85e-18	Height;
KIRP	cis	rs6438504	0.885	rs41271389	chr3:118917641	T/C	cg25372693	chr3:118959985	B4GALT4	0.32	5.48	0.33	1.06e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg04315214	chr1:2043799	PRKCZ	-0.33	-5.38	-0.32	1.73e-7	Height;
KIRP	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	6.64	0.39	1.99e-10	Glomerular filtration rate;
KIRP	cis	rs7011049	0.841	rs117219249	chr8:53871963	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg08198773	chr8:1697536	NA	0.52	6.33	0.37	1.12e-9	Systolic blood pressure;
KIRP	cis	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg24375607	chr4:120327624	NA	0.57	5.85	0.35	1.54e-8	Corneal astigmatism;
KIRP	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00585698	chr12:123750864	CDK2AP1	0.49	4.99	0.3	1.17e-6	Neutrophil percentage of white cells;
KIRP	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg22974920	chr21:40686053	BRWD1	0.51	6.07	0.36	4.86e-9	Cognitive function;
KIRP	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.84	10.5	0.56	1.54e-21	Coronary artery disease;
KIRP	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg20701182	chr2:24300061	SF3B14	-0.41	-5.23	-0.32	3.69e-7	Asthma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.7	8.54	0.48	1.4e-15	Smoking initiation;
KIRP	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.8	0.4	7.94e-11	Schizophrenia;
KIRP	cis	rs2522056	1.000	rs2706393	chr5:131796067	G/A	cg07395648	chr5:131743802	NA	0.55	6.56	0.39	3.2e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.69	-12.76	-0.63	5.73e-29	White blood cell count (basophil);
KIRP	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg02487422	chr3:49467188	NICN1	0.36	5.02	0.3	1e-6	Parkinson's disease;
KIRP	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg02725872	chr8:58115012	NA	-0.51	-5.74	-0.34	2.81e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9843304	0.529	rs4681510	chr3:149201573	A/T	cg08667024	chr3:149219783	TM4SF4	-0.42	-6.44	-0.38	6.21e-10	Gallstone disease;
KIRP	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23422044	chr7:1970798	MAD1L1	-0.65	-6.52	-0.38	4.05e-10	Bipolar disorder;
KIRP	cis	rs4789452	1.000	rs4789452	chr17:75372850	G/A	cg12985929	chr17:75370611	SEPT9	-0.4	-5.61	-0.34	5.52e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.75	9.47	0.52	2.45e-18	Huntington's disease progression;
KIRP	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg19554555	chr3:13937349	NA	-0.47	-6.39	-0.38	8.22e-10	Ovarian reserve;
KIRP	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.52	0.59	7.61e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.06	0.36	5.13e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.72	-9.79	-0.53	2.48e-19	Inflammatory bowel disease;
KIRP	cis	rs3755132	0.866	rs6755261	chr2:15761783	T/G	cg12888861	chr2:15731646	DDX1	0.42	5.46	0.33	1.17e-7	Wilms tumor;
KIRP	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg23601095	chr6:26197514	HIST1H3D	0.91	7.46	0.43	1.45e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.57	0.52	1.2e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg04865290	chr3:52927548	TMEM110	-0.66	-7.15	-0.41	9.96e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.44	-5.43	-0.33	1.32e-7	Iron status biomarkers;
KIRP	cis	rs9914578	1.000	rs10459917	chr17:2009752	G/T	cg16513277	chr17:2031491	SMG6	0.7	8.35	0.47	5.09e-15	Body mass index;
KIRP	cis	rs2574975	0.679	rs2255720	chr10:52132986	T/C	cg10034176	chr10:52120283	SGMS1	-0.53	-7.19	-0.42	7.55e-12	Response to amphetamines;
KIRP	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.61	12.42	0.62	7.9e-28	Diabetic kidney disease;
KIRP	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.75	9.1	0.5	3.09e-17	Response to antipsychotic treatment;
KIRP	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27286337	chr10:134555280	INPP5A	0.91	10.94	0.57	5.7e-23	Migraine;
KIRP	cis	rs2147904	0.934	rs812487	chr1:42366198	G/A	cg16685388	chr1:42384056	HIVEP3	0.28	4.96	0.3	1.31e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg13628971	chr7:2884303	GNA12	0.58	6.95	0.41	3.3e-11	Height;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-8.73	-0.49	3.83e-16	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	13.92	0.66	7.22e-33	Platelet count;
KIRP	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.36	-5.17	-0.31	4.85e-7	Monocyte count;
KIRP	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.45	5.05	0.31	8.74e-7	Schizophrenia;
KIRP	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs74181299	0.571	rs12990465	chr2:65281401	C/T	cg05010058	chr2:65284262	CEP68	0.44	5.54	0.33	7.78e-8	Pulse pressure;
KIRP	cis	rs6910061	1.000	rs5027679	chr6:11118871	A/G	cg27233058	chr6:11094804	LOC221710	-0.57	-5.83	-0.35	1.76e-8	Diabetic kidney disease;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg01238044	chr22:24384105	GSTT1	-0.58	-7.56	-0.43	8.21e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg18135555	chr8:22132992	PIWIL2	0.41	6.17	0.37	2.74e-9	Hypertriglyceridemia;
KIRP	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.53	-8.36	-0.47	4.61e-15	Prostate cancer;
KIRP	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.56	0.39	3.18e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg12560992	chr17:57184187	TRIM37	0.57	6.12	0.36	3.57e-9	Cognitive test performance;
KIRP	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs28595532	0.720	rs72670228	chr4:119309516	T/C	cg21605333	chr4:119757512	SEC24D	1.01	6.86	0.4	5.61e-11	Cannabis dependence symptom count;
KIRP	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.3	-8.08	-0.46	2.91e-14	Rheumatoid arthritis;
KIRP	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg07395648	chr5:131743802	NA	-0.59	-8.58	-0.48	1.08e-15	Blood metabolite levels;
KIRP	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.71	11.03	0.58	3.08e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18544826	chr20:51588785	TSHZ2	0.48	6.25	0.37	1.81e-9	Parkinson's disease;
KIRP	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg05360138	chr12:110035743	NA	0.5	5.58	0.34	6.41e-8	Neuroticism;
KIRP	cis	rs13082711	0.911	rs7644466	chr3:27515271	C/G	cg02860705	chr3:27208620	NA	0.47	6.59	0.39	2.61e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.68	0.48	5.55e-16	Motion sickness;
KIRP	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	ch.8.33884649F	chr8:33765107	NA	0.51	6.14	0.36	3.23e-9	Body mass index;
KIRP	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.73	8.57	0.48	1.13e-15	Type 2 diabetes;
KIRP	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.8	-11.02	-0.57	3.18e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg16989719	chr2:238392110	NA	-0.6	-5.94	-0.35	9.92e-9	Prostate cancer;
KIRP	cis	rs981844	0.696	rs17030349	chr4:154636039	C/T	cg14289246	chr4:154710475	SFRP2	0.57	6.45	0.38	5.92e-10	Response to statins (LDL cholesterol change);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07160589	chr1:63988470	ITGB3BP;EFCAB7	0.47	6.71	0.39	1.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1659258	0.568	rs1659262	chr2:88600380	T/A	cg00685853	chr2:88648947	NA	-0.54	-6.21	-0.37	2.25e-9	Visceral fat;
KIRP	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.91	-0.35	1.16e-8	Alzheimer's disease (late onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18610616	chr10:68039681	CTNNA3	-0.38	-6.07	-0.36	4.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg15112475	chr7:1198522	ZFAND2A	-0.48	-4.99	-0.3	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.31	12.4	0.62	9.26e-28	Diabetic retinopathy;
KIRP	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg09549813	chr16:4587862	C16orf5	-0.33	-4.98	-0.3	1.22e-6	Schizophrenia;
KIRP	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	10.48	0.56	1.79e-21	Cognitive test performance;
KIRP	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg22138327	chr13:27999177	GTF3A	0.89	6.55	0.39	3.28e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35740288	0.770	rs11632750	chr15:86215614	A/C	cg17133734	chr15:86042851	AKAP13	-0.49	-5.41	-0.33	1.5e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.62	0.39	2.26e-10	Mean platelet volume;
KIRP	cis	rs4594175	0.926	rs113095693	chr14:51600511	G/C	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	0.83	12.39	0.62	9.95e-28	Dupuytren's disease;
KIRP	cis	rs35995292	0.534	rs7793692	chr7:38940580	G/C	cg19327137	chr7:38886074	VPS41	0.82	12.85	0.63	2.88e-29	Subjective well-being (multi-trait analysis);
KIRP	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg20243544	chr17:37824526	PNMT	0.55	7.91	0.45	8.66e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs9815354	0.812	rs73069390	chr3:41785513	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.3	0.47	6.91e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6484504	0.532	rs2774403	chr11:31320530	A/T	cg26647111	chr11:31128758	NA	0.43	5.12	0.31	6.12e-7	Red blood cell count;
KIRP	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg23594656	chr7:65796392	TPST1	0.39	5.66	0.34	4.29e-8	Cotinine glucuronidation;
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.38	6.18	0.37	2.59e-9	Electroencephalogram traits;
KIRP	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12315302	chr6:26189340	HIST1H4D	0.65	5.3	0.32	2.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09976282	chr15:31357238	TRPM1;MIR211	0.59	6.67	0.39	1.63e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs11718455	0.618	rs35351588	chr3:43926386	C/G	cg21419209	chr3:44054225	NA	-0.69	-7.43	-0.43	1.75e-12	Coronary artery disease;
KIRP	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg10189774	chr4:17578691	LAP3	0.44	4.96	0.3	1.33e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7546094	0.935	rs7554345	chr1:113122956	T/G	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg08501292	chr6:25962987	TRIM38	1.05	7.83	0.45	1.41e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.61	-0.39	2.39e-10	Obesity-related traits;
KIRP	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.59	7.9	0.45	9.1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.51	6.59	0.39	2.73e-10	Alcohol dependence;
KIRP	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg04865290	chr3:52927548	TMEM110	-0.62	-6.22	-0.37	2.17e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4389656	0.778	rs2279654	chr5:6742886	C/T	cg10857441	chr5:6722123	POLS	0.46	5.64	0.34	4.71e-8	Coronary artery disease;
KIRP	cis	rs1434579	0.865	rs35813988	chr19:44940420	G/A	cg15540054	chr19:45004280	ZNF180	0.54	5.81	0.35	1.92e-8	Tuberculosis;
KIRP	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg10932868	chr11:921992	NA	0.64	8.51	0.48	1.72e-15	Alzheimer's disease (late onset);
KIRP	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg03152288	chr2:177042942	NA	-0.51	-6.14	-0.36	3.24e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs838147	0.537	rs485073	chr19:49207255	A/G	cg16867584	chr19:49200180	FUT2	0.33	5.27	0.32	2.97e-7	Dietary macronutrient intake;
KIRP	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.82	-8.25	-0.47	9.95e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24466479	chr2:17935221	SMC6;GEN1	0.46	6.38	0.38	8.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg26513180	chr16:89883248	FANCA	0.81	5.49	0.33	1e-7	Skin colour saturation;
KIRP	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg22916017	chr11:64110731	CCDC88B	0.51	5.63	0.34	4.99e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7560272	0.695	rs780394	chr2:73700930	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.76	0.34	2.48e-8	Schizophrenia;
KIRP	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg25281562	chr12:121454272	C12orf43	0.51	5.5	0.33	9.64e-8	N-glycan levels;
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.91e-8	Life satisfaction;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg05665937	chr4:1216051	CTBP1	0.44	5.61	0.34	5.33e-8	Obesity-related traits;
KIRP	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.64	-9.4	-0.51	3.87e-18	Body mass index;
KIRP	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.83	10.01	0.54	5.26e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.88	12.81	0.63	4.08e-29	Body mass index (adult);
KIRP	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs4148660	1.000	rs4148660	chr12:22059617	C/G	cg14669847	chr12:22099120	NA	0.34	5.8	0.35	2e-8	Gout;
KIRP	cis	rs259282	0.583	rs12981373	chr19:33108189	C/T	cg02997394	chr19:33096574	ANKRD27	-0.48	-5.5	-0.33	9.6e-8	Schizophrenia;
KIRP	cis	rs79387448	0.614	rs6719130	chr2:102958236	C/T	cg20060108	chr2:102954350	IL1RL1	-0.69	-6.12	-0.36	3.58e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.73	-9.84	-0.53	1.73e-19	Pancreatic cancer;
KIRP	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg10932868	chr11:921992	NA	0.66	8.92	0.49	1.12e-16	Alzheimer's disease (late onset);
KIRP	cis	rs300890	0.536	rs300924	chr4:144182185	C/T	cg01719995	chr4:144104893	USP38	0.39	5.11	0.31	6.38e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	5.31	0.32	2.49e-7	Homoarginine levels;
KIRP	cis	rs7712401	0.601	rs152039	chr5:122220665	C/T	cg19412675	chr5:122181750	SNX24	0.5	5.49	0.33	1.01e-7	Mean platelet volume;
KIRP	cis	rs6838801	0.521	rs17322529	chr4:77560811	A/G	cg17476223	chr4:77663285	SHROOM3	-0.44	-6.6	-0.39	2.52e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg25664220	chr3:72788482	NA	-0.35	-5.14	-0.31	5.58e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09602541	chr3:174792068	NAALADL2	0.39	6.06	0.36	5.07e-9	C-reactive protein;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg07454192	chr8:74888262	TMEM70	0.74	6.38	0.38	8.86e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg12405258	chr13:114927641	NA	0.47	6.54	0.38	3.5e-10	Schizophrenia;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg22764044	chr5:178986830	RUFY1	0.54	8.24	0.47	1.02e-14	Lung cancer;
KIRP	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs9826463	0.582	rs73238176	chr3:142114256	G/A	cg20824294	chr3:142316082	PLS1	0.44	6.35	0.38	1.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg20578329	chr17:80767326	TBCD	0.58	7.1	0.41	1.31e-11	Breast cancer;
KIRP	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	10.88	0.57	9.37e-23	Total body bone mineral density;
KIRP	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.53	5.21	0.32	3.99e-7	Alzheimer's disease;
KIRP	cis	rs2108225	0.967	rs6979054	chr7:107447488	A/C	cg18560240	chr7:107437656	SLC26A3	-0.42	-5.29	-0.32	2.67e-7	Ulcerative colitis;
KIRP	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.19	-0.37	2.54e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
KIRP	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.4	4.89	0.3	1.83e-6	Educational attainment;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05886006	chr1:161359784	NA	0.57	6.93	0.4	3.57e-11	Smoking initiation;
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20456258	chr4:962124	DGKQ	0.43	8.27	0.47	8.7e-15	Sjögren's syndrome;
KIRP	cis	rs2274273	0.837	rs59871474	chr14:55779363	T/C	cg04306507	chr14:55594613	LGALS3	0.43	6.62	0.39	2.24e-10	Protein biomarker;
KIRP	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.49	-0.38	4.76e-10	Mood instability;
KIRP	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-5.43	-0.33	1.36e-7	Aortic root size;
KIRP	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg08668510	chr10:1095578	IDI1	0.94	7.02	0.41	2.15e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg10755058	chr3:40428713	ENTPD3	0.36	4.88	0.3	1.94e-6	Renal cell carcinoma;
KIRP	cis	rs12210905	0.925	rs12214640	chr6:26762080	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-5.74	-0.34	2.79e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs2625529	0.824	rs10518979	chr15:72268986	A/G	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs10858047	0.883	rs12039811	chr1:115107550	T/C	cg12756093	chr1:115239321	AMPD1	0.64	6.15	0.37	3.05e-9	Autism;
KIRP	cis	rs10861342	1.000	rs115224406	chr12:105578060	C/T	cg23923672	chr12:105501055	KIAA1033	0.81	6.24	0.37	1.9e-9	IgG glycosylation;
KIRP	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.44	5.77	0.35	2.42e-8	Initial pursuit acceleration;
KIRP	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg10189774	chr4:17578691	LAP3	0.54	6.81	0.4	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg05775895	chr3:12838266	CAND2	0.37	5.92	0.35	1.06e-8	P wave duration;
KIRP	cis	rs11997175	0.902	rs7462140	chr8:33717880	A/G	cg04338863	chr8:33670619	NA	0.39	5.08	0.31	7.41e-7	Body mass index;
KIRP	cis	rs13315871	1.000	rs28626602	chr3:58409786	G/C	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg10434728	chr15:90938212	IQGAP1	0.42	7.85	0.45	1.27e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.81	0.66	1.72e-32	Electrocardiographic conduction measures;
KIRP	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg13147721	chr7:65941812	NA	-0.87	-6.35	-0.38	1.05e-9	Diabetic kidney disease;
KIRP	cis	rs4851254	1.000	rs4851254	chr2:100762937	C/G	cg17356467	chr2:100759845	AFF3	0.62	8.0	0.45	4.88e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs6593803	0.601	rs1086602	chr1:147288818	T/C	cg27546670	chr1:147246839	GJA5	-0.5	-6.1	-0.36	4e-9	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs8062405	0.573	rs7187575	chr16:28990101	C/T	cg07382826	chr16:28625726	SULT1A1	-0.49	-5.19	-0.31	4.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.18	-4.95	-0.3	1.39e-6	Coronary artery disease;
KIRP	cis	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg06521331	chr12:34319734	NA	-0.62	-7.36	-0.42	2.72e-12	Morning vs. evening chronotype;
KIRP	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg00343986	chr7:65444356	GUSB	-0.42	-5.15	-0.31	5.37e-7	Aortic root size;
KIRP	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.45	-6.19	-0.37	2.56e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-5.57	-0.33	6.83e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.9e-8	Glomerular filtration rate;
KIRP	cis	rs2594989	0.943	rs2454499	chr3:11500531	T/C	cg01796438	chr3:11312864	ATG7	-0.67	-8.19	-0.46	1.45e-14	Circulating chemerin levels;
KIRP	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.54	5.17	0.31	4.81e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg08134877	chr2:44394819	PPM1B	0.49	5.03	0.31	9.26e-7	Height;
KIRP	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	1.0	14.45	0.68	1.13e-34	Cognitive function;
KIRP	cis	rs1832871	0.672	rs56115227	chr6:158773884	G/A	cg07215822	chr6:158701037	NA	-0.63	-7.27	-0.42	4.72e-12	Height;
KIRP	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg23594656	chr7:65796392	TPST1	0.43	6.02	0.36	6.47e-9	Aortic root size;
KIRP	cis	rs735539	0.645	rs3825444	chr13:21173926	A/G	cg04906043	chr13:21280425	IL17D	-0.49	-5.69	-0.34	3.65e-8	Dental caries;
KIRP	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.62	-7.99	-0.45	5.39e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg24253500	chr15:84953950	NA	0.62	6.53	0.38	3.73e-10	Schizophrenia;
KIRP	cis	rs1873147	1.000	rs12443295	chr15:63313666	C/T	cg12160578	chr15:63334699	TPM1	-0.48	-5.88	-0.35	1.36e-8	Orofacial clefts;
KIRP	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg01631408	chr1:248437212	OR2T33	-0.61	-7.78	-0.44	1.99e-13	Common traits (Other);
KIRP	cis	rs13102973	0.614	rs7693794	chr4:135886753	C/G	cg14419869	chr4:135874104	NA	-0.48	-7.18	-0.42	8.08e-12	Subjective well-being;
KIRP	cis	rs7395581	0.918	rs7124955	chr11:47315274	A/T	cg26139080	chr11:47293733	MADD	-0.42	-5.28	-0.32	2.81e-7	HDL cholesterol;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15059389	chr1:12079390	MIIP	0.51	7.15	0.41	9.67e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.7	13.88	0.66	9.9e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs984222	0.527	rs2794315	chr1:119577666	G/T	cg18261050	chr1:119551319	NA	0.34	4.87	0.3	1.97e-6	Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;
KIRP	cis	rs4790312	0.513	rs12451211	chr17:1965542	A/G	cg24156229	chr17:1948635	NA	0.42	5.02	0.3	9.83e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg00647317	chr7:50633725	DDC	-0.42	-5.53	-0.33	8.07e-8	Malaria;
KIRP	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg00262122	chr8:11665843	FDFT1	0.43	5.41	0.33	1.52e-7	Morning vs. evening chronotype;
KIRP	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.61	8.28	0.47	7.91e-15	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg10756647	chr7:56101905	PSPH	0.97	7.01	0.41	2.23e-11	Diabetic kidney disease;
KIRP	cis	rs1975974	1.000	rs1985718	chr17:21731656	C/T	cg18423549	chr17:21743878	NA	-0.46	-4.85	-0.3	2.23e-6	Psoriasis;
KIRP	cis	rs311392	0.554	rs377045	chr8:55098409	A/C	cg20636351	chr8:55087400	NA	-0.53	-6.43	-0.38	6.74e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19753526	chr2:106015546	FHL2	0.44	6.46	0.38	5.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.9	11.04	0.58	2.78e-23	White matter hyperintensity burden;
KIRP	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg13319975	chr6:146136371	FBXO30	0.49	6.66	0.39	1.79e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	7.05	0.41	1.82e-11	Height;
KIRP	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.68	0.71	7.03e-39	Metabolic syndrome;
KIRP	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.4	7.87	0.45	1.12e-13	Red cell distribution width;
KIRP	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.67	0.39	1.71e-10	Educational attainment;
KIRP	cis	rs12137294	0.761	rs1172150	chr1:205221861	A/G	cg21643547	chr1:205240462	TMCC2	-0.48	-6.83	-0.4	6.8e-11	Red cell distribution width;
KIRP	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.83	10.74	0.57	2.55e-22	Primary sclerosing cholangitis;
KIRP	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05601917	chr6:125855416	NA	-0.33	-4.88	-0.3	1.94e-6	Brugada syndrome;
KIRP	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.93	15.34	0.7	1e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.99	10.52	0.56	1.32e-21	Exhaled nitric oxide output;
KIRP	cis	rs112591243	0.685	rs2839282	chr21:47902822	C/G	cg26904215	chr21:47823096	PCNT	0.86	6.89	0.4	4.57e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg07862535	chr7:139043722	LUC7L2	-0.44	-4.99	-0.3	1.13e-6	Diisocyanate-induced asthma;
KIRP	cis	rs7463659	0.512	rs6992045	chr8:135448749	T/C	cg13434034	chr8:135477110	NA	0.45	5.86	0.35	1.5e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.57	6.69	0.39	1.49e-10	Mean corpuscular volume;
KIRP	cis	rs7814319	0.646	rs938828	chr8:97316821	A/C	cg20787634	chr8:97240163	UQCRB	-0.56	-8.49	-0.48	1.94e-15	Lung function (FVC);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15815767	chr2:46769831	RHOQ	0.5	6.36	0.38	9.75e-10	Parkinson's disease;
KIRP	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg00106254	chr7:1943704	MAD1L1	0.59	6.41	0.38	7.51e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg02527881	chr3:46936655	PTH1R	0.43	6.16	0.37	2.91e-9	Colorectal cancer;
KIRP	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	12.82	0.63	3.72e-29	Smoking behavior;
KIRP	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg09324608	chr17:30823087	MYO1D	0.5	6.35	0.38	1e-9	Schizophrenia;
KIRP	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg23422044	chr7:1970798	MAD1L1	0.59	6.22	0.37	2.12e-9	Bipolar disorder;
KIRP	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.7	-8.49	-0.48	1.94e-15	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	-0.44	-5.01	-0.3	1.04e-6	Menopause (age at onset);
KIRP	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs4363385	0.574	rs4041402	chr1:152947397	T/C	cg07796016	chr1:152779584	LCE1C	-0.47	-5.92	-0.35	1.07e-8	Inflammatory skin disease;
KIRP	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.84	10.11	0.54	2.52e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg20637307	chr2:213403960	ERBB4	0.95	16.83	0.73	7.97e-43	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.53	7.08	0.41	1.52e-11	Prudent dietary pattern;
KIRP	cis	rs2072732	0.861	rs12036378	chr1:2955158	G/A	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg16917193	chr12:54089295	NA	0.38	4.98	0.3	1.2e-6	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4073416	0.542	rs8010726	chr14:65932597	C/T	cg03016385	chr14:66212404	NA	-0.52	-6.45	-0.38	5.93e-10	N-glycan levels;
KIRP	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg26681399	chr22:41777847	TEF	-0.46	-5.19	-0.31	4.37e-7	Vitiligo;
KIRP	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg14459158	chr9:96720562	NA	0.3	5.31	0.32	2.43e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.67	0.34	3.97e-8	Lung cancer;
KIRP	cis	rs3735025	0.854	rs11771579	chr7:137062785	C/A	cg13839563	chr7:136910420	NA	-0.43	-5.03	-0.31	9.37e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg09699651	chr6:150184138	LRP11	0.49	6.47	0.38	5.2e-10	Lung cancer;
KIRP	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12786942	0.502	rs12798689	chr11:101301836	G/T	cg03942599	chr11:101341554	TRPC6	0.39	4.85	0.3	2.2e-6	Facial depth;
KIRP	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg16497661	chr14:103986332	CKB	-0.48	-4.99	-0.3	1.13e-6	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12347084	chr2:74757155	HTRA2;AUP1	0.55	6.77	0.4	9.2e-11	Parkinson's disease;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00802000	chr16:706648	WDR90	-0.39	-4.93	-0.3	1.52e-6	Height;
KIRP	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.47	6.01	0.36	6.63e-9	Response to temozolomide;
KIRP	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.48	-5.81	-0.35	1.93e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs1497828	0.869	rs2646838	chr1:217552687	C/G	cg04411442	chr1:217543379	NA	0.31	4.97	0.3	1.27e-6	Dialysis-related mortality;
KIRP	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.58	6.73	0.39	1.15e-10	HDL cholesterol;
KIRP	cis	rs600806	0.850	rs3768494	chr1:109935427	A/G	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs629535	0.520	rs644952	chr8:70009087	C/T	cg21567404	chr3:27674614	NA	-0.66	-8.82	-0.49	2.2e-16	Dupuytren's disease;
KIRP	cis	rs9535307	0.719	rs1009333	chr13:50383341	T/C	cg04663916	chr13:50265991	EBPL	-0.57	-6.04	-0.36	5.6e-9	Obesity-related traits;
KIRP	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg12483005	chr1:23474871	LUZP1	0.38	4.91	0.3	1.67e-6	Height;
KIRP	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26207909	chr14:103986467	CKB	0.74	10.52	0.56	1.27e-21	Body mass index;
KIRP	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.19	-0.31	4.46e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13401104	0.796	rs10929165	chr2:237111187	C/G	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs6690583	0.943	rs1837329	chr1:85469614	G/A	cg22153463	chr1:85462885	MCOLN2	-0.68	-7.23	-0.42	6.12e-12	Serum sulfate level;
KIRP	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.46	-0.43	1.52e-12	Type 2 diabetes;
KIRP	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.54	6.87	0.4	5.35e-11	Phospholipid levels (plasma);
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg16606324	chr3:10149918	C3orf24	0.56	5.14	0.31	5.57e-7	Alzheimer's disease;
KIRP	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.97	0.36	8.12e-9	Birth weight;
KIRP	cis	rs2051211	0.895	rs17037798	chr3:38555474	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.77	-9.1	-0.5	3.13e-17	QRS duration;
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg21186296	chr8:27182909	PTK2B	0.5	6.24	0.37	1.91e-9	Neuroticism;
KIRP	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg25039879	chr17:56429692	SUPT4H1	0.72	6.39	0.38	8.23e-10	Cognitive test performance;
KIRP	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.61	6.14	0.36	3.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg26384229	chr12:38710491	ALG10B	0.6	8.34	0.47	5.28e-15	Morning vs. evening chronotype;
KIRP	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	0.77	7.56	0.43	8.01e-13	Prostate cancer;
KIRP	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.78	10.86	0.57	1.02e-22	Mean corpuscular hemoglobin;
KIRP	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.64	0.44	4.73e-13	Colorectal cancer;
KIRP	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg11569703	chr11:65557185	OVOL1	0.78	14.68	0.68	1.87e-35	Acne (severe);
KIRP	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.53	0.52	1.59e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg04634417	chr5:140220803	PCDHA6;PCDHA2;PCDHA1;PCDHA8;PCDHA7;PCDHA5;PCDHA3;PCDHA4	-0.42	-4.94	-0.3	1.46e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7980799	0.905	rs4244865	chr12:33511917	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-6.56	-0.39	3.19e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	15.82	0.71	2.37e-39	Platelet count;
KIRP	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.44	5.33	0.32	2.19e-7	Diastolic blood pressure;
KIRP	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.62	7.6	0.44	6.12e-13	Corneal astigmatism;
KIRP	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.56	0.33	6.86e-8	Lung cancer;
KIRP	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.6	-7.1	-0.41	1.36e-11	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.72	9.66	0.52	6.26e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.92	-0.53	9.84e-20	Hemoglobin concentration;
KIRP	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.55	0.43	8.67e-13	Mood instability;
KIRP	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.65	0.44	4.49e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7.01e-8	Schizophrenia;
KIRP	cis	rs7202877	0.610	rs11149814	chr16:75332981	T/C	cg03315344	chr16:75512273	CHST6	0.58	5.58	0.34	6.43e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs2625529	0.652	rs1481862	chr15:72245648	G/A	cg16672083	chr15:72433130	SENP8	0.43	6.07	0.36	4.69e-9	Red blood cell count;
KIRP	trans	rs13170463	0.850	rs11742385	chr5:8038928	A/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7551222	0.646	rs4951382	chr1:204451495	T/C	cg20240347	chr1:204465584	NA	-0.41	-7.33	-0.42	3.3e-12	Schizophrenia;
KIRP	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.63	-8.5	-0.48	1.87e-15	Colorectal cancer;
KIRP	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.76	-9.83	-0.53	1.96e-19	Aortic root size;
KIRP	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.62	8.08	0.46	3.01e-14	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9663711	1	rs9663711	chr10:104547628	C/A	cg04362960	chr10:104952993	NT5C2	0.52	6.26	0.37	1.72e-9	Carotid plaque burden;
KIRP	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.41	-7.22	-0.42	6.59e-12	Refractive error;
KIRP	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9596863	0.756	rs9316652	chr13:54279802	T/C	ch.13.53330881F	chr13:54432880	NA	0.56	5.19	0.31	4.48e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25517755	chr10:38738941	LOC399744	-0.52	-7.24	-0.42	5.75e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg08885076	chr2:99613938	TSGA10	-0.36	-5.09	-0.31	7.26e-7	Chronic sinus infection;
KIRP	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.92	14.48	0.68	8.69e-35	Mean corpuscular volume;
KIRP	cis	rs72934535	0.667	rs76829926	chr2:204384361	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.65	5.23	0.32	3.63e-7	Coronary artery disease;
KIRP	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.37	7.25	0.42	5.37e-12	IgG glycosylation;
KIRP	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg10932868	chr11:921992	NA	0.53	6.73	0.39	1.19e-10	Alzheimer's disease (late onset);
KIRP	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.53	-0.48	1.5e-15	Blood metabolite levels;
KIRP	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg03060546	chr3:49711283	APEH	0.49	6.34	0.37	1.08e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05347473	chr6:146136440	FBXO30	0.63	8.94	0.5	9.41e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg08132940	chr7:1081526	C7orf50	-0.7	-6.88	-0.4	5.03e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28735056	0.508	rs67651675	chr18:77673562	A/G	cg20368463	chr18:77673604	PQLC1	-0.89	-14.79	-0.69	7.81e-36	Schizophrenia;
KIRP	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.65	8.11	0.46	2.45e-14	Body mass index;
KIRP	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11987759	chr7:65425863	GUSB	-0.68	-9.46	-0.52	2.65e-18	Aortic root size;
KIRP	cis	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg19847130	chr8:10466454	RP1L1	0.35	5.22	0.32	3.73e-7	Neuroticism;
KIRP	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg06026331	chr20:60912101	LAMA5	-0.47	-5.8	-0.35	2.06e-8	Colorectal cancer;
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg11204139	chr17:3907470	NA	0.82	15.06	0.69	9.54e-37	Type 2 diabetes;
KIRP	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg08648136	chr8:956695	NA	0.39	5.38	0.32	1.76e-7	Schizophrenia;
KIRP	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	9.47	0.52	2.48e-18	Hip circumference;
KIRP	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.4	-0.43	2.1e-12	Triglycerides;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.78	12.27	0.62	2.5e-27	Menarche (age at onset);
KIRP	cis	rs77688320	0.535	rs10186894	chr2:202305632	C/T	cg06431681	chr2:202330990	STRADB	0.47	5.46	0.33	1.18e-7	Breast cancer;
KIRP	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg13880726	chr7:1868755	MAD1L1	0.53	6.25	0.37	1.83e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg06533319	chr4:3265114	C4orf44	0.55	6.81	0.4	7.31e-11	Parental longevity (mother's age at death);
KIRP	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.56	6.12	0.36	3.65e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.35	-7.95	-0.45	6.83e-14	Cutaneous nevi;
KIRP	cis	rs698833	0.852	rs698774	chr2:44584314	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.22	0.37	2.07e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.71	0.34	3.23e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.75	11.06	0.58	2.46e-23	Prudent dietary pattern;
KIRP	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.67	8.33	0.47	5.65e-15	Dilated cardiomyopathy;
KIRP	cis	rs4700695	0.764	rs10066817	chr5:65319853	A/G	cg21114390	chr5:65439923	SFRS12	0.57	6.03	0.36	6.01e-9	Facial morphology (factor 19);
KIRP	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs7809950	0.862	rs58391518	chr7:107030787	T/C	cg23024343	chr7:107201750	COG5	-0.46	-6.87	-0.4	5.21e-11	Coronary artery disease;
KIRP	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.54	8.31	0.47	6.71e-15	Lung cancer;
KIRP	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Educational attainment;
KIRP	trans	rs5760842	0.517	rs2076123	chr22:25501884	T/C	cg16733866	chr21:42792609	MX1	0.69	8.91	0.49	1.15e-16	Recurrent major depressive disorder;
KIRP	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg17133734	chr15:86042851	AKAP13	-0.42	-5.24	-0.32	3.38e-7	Interstitial lung disease;
KIRP	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg18306943	chr3:40428807	ENTPD3	0.43	5.63	0.34	4.96e-8	Renal cell carcinoma;
KIRP	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg08533674	chr1:46993347	NA	-0.46	-5.81	-0.35	1.91e-8	Monobrow;
KIRP	cis	rs7258465	0.965	rs8100767	chr19:18589088	T/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.44	-0.43	1.73e-12	Breast cancer;
KIRP	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.95	-7.47	-0.43	1.4e-12	Body mass index;
KIRP	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg18225595	chr11:63971243	STIP1	0.45	5.47	0.33	1.1e-7	Platelet count;
KIRP	cis	rs2479724	0.870	rs7766817	chr6:41918104	T/A	cg17623882	chr6:41773611	USP49	-0.47	-5.78	-0.35	2.31e-8	Menarche (age at onset);
KIRP	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-9.27	-0.51	9.69e-18	Colorectal cancer;
KIRP	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg04865290	chr3:52927548	TMEM110	-0.56	-6.3	-0.37	1.33e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.82	-8.88	-0.49	1.42e-16	Chronic sinus infection;
KIRP	cis	rs73200209	0.744	rs17498543	chr12:116581796	T/C	cg01776926	chr12:116560359	MED13L	-0.52	-5.84	-0.35	1.62e-8	Total body bone mineral density;
KIRP	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg18657303	chr4:1051139	NA	0.55	4.99	0.3	1.16e-6	Recombination rate (females);
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.36	-0.38	9.7e-10	Lung cancer;
KIRP	cis	rs2479106	0.591	rs4836935	chr9:126345893	T/G	cg16191174	chr9:126692580	DENND1A	0.39	5.21	0.32	4.07e-7	Polycystic ovary syndrome;
KIRP	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg15660573	chr17:549704	VPS53	-0.95	-15.04	-0.69	1.04e-36	Prostate cancer;
KIRP	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06481639	chr22:41940642	POLR3H	-0.73	-7.46	-0.43	1.53e-12	Vitiligo;
KIRP	cis	rs4776059	0.550	rs73396766	chr15:52911516	C/T	cg25063058	chr15:52860530	ARPP19	-0.58	-4.97	-0.3	1.27e-6	Schizophrenia;
KIRP	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.13	21.8	0.81	2.13e-59	Exhaled nitric oxide output;
KIRP	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.63	7.63	0.44	5.12e-13	Age at first birth;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.58	-6.91	-0.4	4.06e-11	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg03714773	chr7:91764589	CYP51A1	0.39	5.64	0.34	4.58e-8	Breast cancer;
KIRP	cis	rs75920871	0.623	rs7946729	chr11:116963180	C/T	cg04087571	chr11:116723030	SIK3	-0.28	-5.55	-0.33	7.25e-8	Subjective well-being;
KIRP	trans	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg04702396	chr17:15466718	FAM18B2	-0.5	-6.28	-0.37	1.5e-9	Educational attainment (years of education);
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.67	10.21	0.55	1.27e-20	Lung cancer;
KIRP	cis	rs6963495	0.556	rs818474	chr7:105155243	A/T	cg19920283	chr7:105172520	RINT1	0.54	6.13	0.36	3.5e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs494562	0.773	rs6919207	chr6:86129271	C/T	cg17644557	chr6:86159103	NT5E	0.55	5.16	0.31	5.06e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.28	-0.32	2.86e-7	Coronary artery disease;
KIRP	cis	rs72772090	0.710	rs11750399	chr5:96077940	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-5.77	-0.35	2.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7017914	0.934	rs6987313	chr8:71570989	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.52	6.25	0.37	1.84e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg27494647	chr7:150038898	RARRES2	0.39	5.9	0.35	1.19e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.59	-7.55	-0.43	8.34e-13	Personality dimensions;
KIRP	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.9	-14.09	-0.67	1.83e-33	Height;
KIRP	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.64	7.97	0.45	5.84e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.44	5.31	0.32	2.5e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.65	9.21	0.51	1.5e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg25407064	chr15:40226267	EIF2AK4	0.58	5.64	0.34	4.74e-8	Response to haloperidol in psychosis;
KIRP	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg03808351	chr9:123631620	PHF19	0.4	5.44	0.33	1.29e-7	Rheumatoid arthritis;
KIRP	cis	rs240764	0.680	rs239234	chr6:101101234	G/A	cg09795085	chr6:101329169	ASCC3	0.44	5.35	0.32	2.04e-7	Neuroticism;
KIRP	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.46	-0.38	5.42e-10	Myopia (pathological);
KIRP	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg22000725	chr19:8478147	MARCH2	-0.45	-6.05	-0.36	5.41e-9	Type 1 diabetes;
KIRP	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg02461776	chr11:598696	PHRF1	0.69	7.55	0.43	8.52e-13	Systemic lupus erythematosus;
KIRP	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.57	8.53	0.48	1.53e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.47	-5.74	-0.34	2.72e-8	Coronary artery disease;
KIRP	cis	rs7818345	1.000	rs6984145	chr8:19294111	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.75	0.34	2.65e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg20744362	chr22:50050164	C22orf34	0.32	5.38	0.32	1.76e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg06060754	chr5:176797920	RGS14	0.47	7.15	0.41	9.65e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.68	10.51	0.56	1.39e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.77	-0.35	2.41e-8	Morning vs. evening chronotype;
KIRP	cis	rs8014252	0.803	rs8012025	chr14:71012205	T/C	cg19730268	chr14:71022823	NA	-0.6	-5.71	-0.34	3.27e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.12e-6	Atopic dermatitis;
KIRP	cis	rs960902	0.747	rs17020823	chr2:37717068	T/C	cg25341268	chr2:37734390	NA	0.65	8.7	0.49	4.89e-16	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24473846	chr20:47538502	ARFGEF2	0.47	6.05	0.36	5.32e-9	Parkinson's disease;
KIRP	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.71	-9.15	-0.5	2.22e-17	Eosinophil percentage of white cells;
KIRP	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6987853	0.931	rs2923444	chr8:42397004	C/T	cg09913449	chr8:42400586	C8orf40	0.4	5.05	0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.78	-11.92	-0.61	3.66e-26	Hip circumference;
KIRP	cis	rs7078219	0.743	rs7095953	chr10:101274425	C/T	cg07044859	chr10:101282883	NA	0.42	6.32	0.37	1.23e-9	Dental caries;
KIRP	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.41	0.33	1.5e-7	Menopause (age at onset);
KIRP	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.95	14.86	0.69	4.59e-36	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.52	0.52	1.72e-18	Lung cancer;
KIRP	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.9	-13.19	-0.64	2.18e-30	Height;
KIRP	cis	rs4776059	0.959	rs12898644	chr15:52905233	A/G	cg25063058	chr15:52860530	ARPP19	0.58	6.38	0.38	8.75e-10	Schizophrenia;
KIRP	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.74	-0.34	2.71e-8	Personality dimensions;
KIRP	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg05156742	chr15:59063176	FAM63B	0.53	6.3	0.37	1.4e-9	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06801811	chr1:92650644	NA	-0.41	-6.44	-0.38	6.31e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg24972876	chr7:65420302	NA	0.41	5.61	0.34	5.36e-8	Calcium levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15813266	chr4:188045689	NA	0.55	7.97	0.45	5.77e-14	Interleukin-4 levels;
KIRP	cis	rs11690462	0.528	rs1344734	chr2:26637068	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.46	5.17	0.31	4.77e-7	Coronary artery disease;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg13699009	chr12:122356056	WDR66	0.73	11.92	0.61	3.59e-26	Mean corpuscular volume;
KIRP	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.48	7.23	0.42	5.98e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg01268866	chr2:3683757	COLEC11	-0.44	-5.4	-0.33	1.57e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.5	-8.54	-0.48	1.41e-15	Refractive error;
KIRP	cis	rs78487399	0.908	rs77994584	chr2:43817076	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.87	-0.3	2.03e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-1.21	-11.25	-0.58	5.94e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.78	11.1	0.58	1.79e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs10782582	1.000	rs10782582	chr1:76383297	A/G	cg10523679	chr1:76189770	ACADM	0.43	6.4	0.38	8.02e-10	Daytime sleep phenotypes;
KIRP	cis	rs75229567	0.618	rs1882194	chr12:70215086	C/G	cg10114359	chr12:70132523	RAB3IP	-0.58	-5.13	-0.31	5.9e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.5	-0.48	1.91e-15	Coronary artery disease;
KIRP	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg03188948	chr7:1209495	NA	0.78	5.39	0.33	1.64e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1788820	0.917	rs1788760	chr18:21137442	A/G	cg14672496	chr18:21087552	C18orf8	0.4	5.53	0.33	8.22e-8	Body mass index;
KIRP	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.14	-16.25	-0.72	7.84e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs7011507	1.000	rs74757189	chr8:49180013	T/C	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.42	-5.49	-0.33	9.91e-8	Childhood ear infection;
KIRP	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg16989719	chr2:238392110	NA	-0.67	-6.24	-0.37	1.95e-9	Prostate cancer;
KIRP	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.47	6.98	0.41	2.66e-11	Tuberculosis;
KIRP	cis	rs1448094	0.802	rs7397730	chr12:86416212	T/C	cg06740227	chr12:86229804	RASSF9	0.4	4.99	0.3	1.13e-6	Major depressive disorder;
KIRP	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg14092571	chr14:90743983	NA	-0.4	-5.37	-0.32	1.81e-7	Mortality in heart failure;
KIRP	cis	rs966423	0.527	rs6723847	chr2:218256489	C/T	cg15335768	chr2:218268053	DIRC3	-0.45	-6.52	-0.38	3.95e-10	Thyroid cancer;
KIRP	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.69	9.59	0.52	1.04e-18	Mean platelet volume;
KIRP	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	1.24	8.7	0.48	4.98e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg13206674	chr6:150067644	NUP43	0.63	9.22	0.51	1.42e-17	Lung cancer;
KIRP	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2150410	0.833	rs8128118	chr21:40592229	A/G	cg11890956	chr21:40555474	PSMG1	0.65	5.07	0.31	7.93e-7	Temperament (bipolar disorder);
KIRP	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg19077165	chr18:44547161	KATNAL2	0.43	5.51	0.33	8.9e-8	Educational attainment;
KIRP	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg27124370	chr19:33622961	WDR88	0.71	10.37	0.55	3.74e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.29	-5.62	-0.34	5.04e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg05347473	chr6:146136440	FBXO30	-0.48	-6.55	-0.39	3.24e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.98	-0.36	7.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.52	7.51	0.43	1.06e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg19567339	chr10:100142640	NA	0.44	4.95	0.3	1.36e-6	Metabolite levels;
KIRP	cis	rs501120	1.000	rs493874	chr10:44764077	C/T	cg09554077	chr10:44749378	NA	0.7	10.73	0.56	2.84e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-6.43	-0.38	6.61e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg00933542	chr6:150070202	PCMT1	0.26	4.9	0.3	1.76e-6	Lung cancer;
KIRP	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.62e-8	Endometrial cancer;
KIRP	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.3	-0.55	6.24e-21	Hemoglobin concentration;
KIRP	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.56	-0.33	6.86e-8	Recombination measurement;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19273467	chr1:32110819	PEF1	0.54	6.32	0.37	1.2e-9	Smoking initiation;
KIRP	cis	rs61863818	0.533	rs954148	chr10:99123006	T/C	cg08345082	chr10:99160200	RRP12	-0.36	-5.09	-0.31	7.25e-7	Monocyte percentage of white cells;
KIRP	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.91	13.46	0.65	2.63e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg05552183	chr6:42928497	GNMT	0.8	13.0	0.64	8.94e-30	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1978968	0.827	rs5992134	chr22:18433994	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.56	-6.95	-0.4	3.32e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg08999081	chr20:33150536	PIGU	0.45	5.77	0.35	2.4e-8	Height;
KIRP	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg05991184	chr2:219186017	PNKD	0.34	4.99	0.3	1.14e-6	Colorectal cancer;
KIRP	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg23752985	chr2:85803571	VAMP8	0.45	5.29	0.32	2.65e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.25e-10	Colorectal cancer;
KIRP	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg07621104	chr11:117668040	DSCAML1	0.47	7.1	0.41	1.31e-11	Myopia;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22168489	chr12:122356033	WDR66	-0.65	-10.01	-0.54	5.07e-20	Mean corpuscular volume;
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg12486944	chr17:80159399	CCDC57	-0.41	-5.54	-0.33	7.74e-8	Life satisfaction;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg01238044	chr22:24384105	GSTT1	0.43	4.95	0.3	1.39e-6	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15738916	chr2:102314495	MAP4K4	-0.48	-6.19	-0.37	2.49e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg17294928	chr15:75287854	SCAMP5	0.37	5.02	0.3	1.01e-6	Breast cancer;
KIRP	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.46	-6.07	-0.36	4.91e-9	Menarche (age at onset);
KIRP	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg01391022	chr12:122360665	WDR66	0.37	5.05	0.31	8.73e-7	Mean corpuscular volume;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07308232	chr7:1071921	C7orf50	-0.66	-8.45	-0.47	2.63e-15	Longevity;Endometriosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01585784	chr2:120517537	PTPN4	0.46	6.35	0.38	1.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6032067	0.852	rs2868240	chr20:43874039	A/G	cg10761708	chr20:43804764	PI3	-0.49	-5.25	-0.32	3.23e-7	Blood protein levels;
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.43	5.72	0.34	3.11e-8	Testicular germ cell tumor;
KIRP	cis	rs1823913	0.637	rs35200176	chr2:192168260	C/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs9834373	0.887	rs71324630	chr3:78486657	G/A	cg06138941	chr3:78371609	NA	-0.38	-5.04	-0.31	9.08e-7	Protein quantitative trait loci;
KIRP	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-10.17	-0.54	1.65e-20	Body mass index;
KIRP	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.4	-5.37	-0.32	1.84e-7	Homoarginine levels;
KIRP	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.48	6.04	0.36	5.76e-9	Primary tooth development (time to first tooth eruption);
KIRP	cis	rs1476670	0.710	rs2477616	chr1:44504809	G/A	cg09470012	chr1:44509516	NA	0.36	5.64	0.34	4.63e-8	Eotaxin levels;
KIRP	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.47	0.33	1.13e-7	Menopause (age at onset);
KIRP	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.89	14.55	0.68	4.91e-35	Headache;
KIRP	cis	rs7264396	0.563	rs6058296	chr20:34269225	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.41	-0.38	7.23e-10	Total cholesterol levels;
KIRP	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.85	11.66	0.6	2.71e-25	Coronary artery disease;
KIRP	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.71	9.53	0.52	1.64e-18	Height;
KIRP	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg00507259	chr4:95128692	SMARCAD1	0.39	5.0	0.3	1.09e-6	QT interval;
KIRP	cis	rs2033732	0.706	rs966286	chr8:85068865	C/T	cg05716166	chr8:85095498	RALYL	-0.53	-5.9	-0.35	1.17e-8	Body mass index;
KIRP	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg05315796	chr3:52349193	DNAH1	0.43	6.38	0.38	8.67e-10	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.41	6.09	0.36	4.43e-9	Carotid intima media thickness;
KIRP	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07570687	chr10:102243282	WNT8B	0.46	5.38	0.32	1.71e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg23307798	chr14:103986281	CKB	0.36	4.91	0.3	1.63e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg03146154	chr1:46216737	IPP	0.54	5.5	0.33	9.29e-8	Platelet count;
KIRP	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-6.79	-0.4	8.21e-11	Daytime sleep phenotypes;
KIRP	cis	rs9420	0.528	rs11229077	chr11:57399072	A/G	cg19752551	chr11:57585705	CTNND1	0.6	8.49	0.48	2.02e-15	Schizophrenia;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-12.64	-0.63	1.54e-28	Alzheimer's disease;
KIRP	cis	rs6032067	0.777	rs34916007	chr20:43782952	T/G	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.55	-0.33	7.54e-8	Neutrophil percentage of white cells;
KIRP	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6968419	0.714	rs3807980	chr7:115893647	A/G	cg02561103	chr7:115862891	TES	-0.41	-5.87	-0.35	1.39e-8	Intraocular pressure;
KIRP	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs7771547	0.607	rs614028	chr6:36484252	G/A	cg04289385	chr6:36355825	ETV7	0.44	6.83	0.4	6.54e-11	Platelet distribution width;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03647317	chr4:187891568	NA	-0.78	-13.0	-0.64	8.99e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2151522	0.724	rs62426305	chr6:127117529	C/A	cg21431617	chr6:127135037	NA	0.3	5.62	0.34	5.17e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg01631408	chr1:248437212	OR2T33	0.68	8.56	0.48	1.24e-15	Common traits (Other);
KIRP	cis	rs6748734	0.600	rs10202620	chr2:241820912	G/C	cg04034577	chr2:241836375	C2orf54	-0.27	-4.99	-0.3	1.14e-6	Urinary metabolites;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg02462569	chr6:150064036	NUP43	-0.34	-5.15	-0.31	5.46e-7	Lung cancer;
KIRP	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.85	0.49	1.7e-16	Bipolar disorder;
KIRP	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg22709100	chr7:91322751	NA	0.42	5.34	0.32	2.12e-7	Breast cancer;
KIRP	cis	rs9547996	0.808	rs9547976	chr13:38185728	A/G	cg13634560	chr13:38173852	POSTN	-0.4	-5.55	-0.33	7.2e-8	Diastolic blood pressure;
KIRP	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg27129171	chr3:47204927	SETD2	0.45	5.83	0.35	1.77e-8	Birth weight;
KIRP	cis	rs3026101	0.624	rs12601818	chr17:5320438	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.85	0.35	1.57e-8	Body mass index;
KIRP	cis	rs9372498	0.536	rs28605789	chr6:118889952	G/A	cg18833306	chr6:118973337	C6orf204	-0.47	-5.04	-0.31	9.1e-7	Diastolic blood pressure;
KIRP	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.67	-10.17	-0.54	1.67e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg04780086	chr2:111875790	ACOXL	0.47	6.53	0.38	3.81e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.56e-25	Diabetic kidney disease;
KIRP	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.57	-6.08	-0.36	4.66e-9	Obesity-related traits;
KIRP	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg13271783	chr10:134563150	INPP5A	0.61	7.7	0.44	3.27e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.71e-25	Vitiligo;
KIRP	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	11.55	0.59	5.94e-25	Schizophrenia;
KIRP	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.26	-5.31	-0.32	2.45e-7	Menarche (age at onset);
KIRP	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.9	16.24	0.72	8.56e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4132509	0.793	rs10803161	chr1:243990770	T/C	cg25706552	chr1:244017396	NA	0.62	7.6	0.44	6.07e-13	RR interval (heart rate);
KIRP	cis	rs12220238	0.841	rs10824161	chr10:76133762	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.68	-6.67	-0.39	1.67e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4363385	0.510	rs61811902	chr1:153053464	A/G	cg07796016	chr1:152779584	LCE1C	-0.49	-5.95	-0.35	9.41e-9	Inflammatory skin disease;
KIRP	trans	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.8200000000000003e-11	Bladder cancer;
KIRP	cis	rs27434	0.583	rs151954	chr5:96157689	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.06e-8	Ankylosing spondylitis;
KIRP	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.77	-0.35	2.42e-8	Electroencephalogram traits;
KIRP	trans	rs10772939	0.595	rs993694	chr12:16600984	G/A	cg20863947	chr2:120124202	DBI;C2orf76	-0.52	-6.4	-0.38	7.83e-10	Economic and political preferences;
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.57	-7.48	-0.43	1.31e-12	Aortic root size;
KIRP	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.48	6.46	0.38	5.54e-10	Dupuytren's disease;
KIRP	cis	rs728616	0.681	rs34816332	chr10:81907967	G/A	cg27417294	chr10:81904244	PLAC9	0.56	5.05	0.31	8.68e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg02725872	chr8:58115012	NA	-0.47	-5.68	-0.34	3.77e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg08992911	chr2:238395768	MLPH	0.56	5.43	0.33	1.38e-7	Prostate cancer;
KIRP	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg26138937	chr11:71823887	C11orf51	-1.01	-6.95	-0.41	3.25e-11	Severe influenza A (H1N1) infection;
KIRP	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg11707556	chr5:10655725	ANKRD33B	0.58	7.23	0.42	6.14e-12	Coronary artery disease;
KIRP	cis	rs7075426	0.669	rs4934220	chr10:88288206	A/G	cg07322936	chr10:88137208	NA	-0.48	-5.2	-0.31	4.27e-7	Migraine without aura;
KIRP	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.52	-0.43	1.03e-12	Systolic blood pressure;
KIRP	cis	rs7224685	0.569	rs34356467	chr17:3978531	G/T	cg11204139	chr17:3907470	NA	0.58	5.67	0.34	4.05e-8	Type 2 diabetes;
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg13906792	chr15:75199810	C15orf17	-0.36	-5.3	-0.32	2.51e-7	Breast cancer;
KIRP	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg19913688	chr11:428466	ANO9	-0.74	-5.43	-0.33	1.36e-7	Body mass index;
KIRP	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg23594656	chr7:65796392	TPST1	-0.51	-8.06	-0.46	3.3e-14	Aortic root size;
KIRP	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-6.98	-0.41	2.69e-11	Systemic lupus erythematosus;
KIRP	cis	rs4242434	0.892	rs1809452	chr8:22491397	G/A	cg03733263	chr8:22462867	KIAA1967	1.16	16.63	0.73	3.84e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg06637938	chr14:75390232	RPS6KL1	0.53	7.52	0.43	1.03e-12	Height;
KIRP	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.43	5.94	0.35	9.76e-9	Plateletcrit;
KIRP	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg22974920	chr21:40686053	BRWD1	0.5	5.95	0.35	9.33e-9	Cognitive function;
KIRP	cis	rs8014252	0.803	rs10483830	chr14:71054478	T/C	cg11204974	chr14:71022665	NA	-0.69	-7.17	-0.42	8.58e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg24315340	chr6:146058215	EPM2A	0.41	5.11	0.31	6.55e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.68	-8.03	-0.46	4.16e-14	Pancreatic cancer;
KIRP	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg14835575	chr10:16859367	RSU1	0.53	7.11	0.41	1.24e-11	Platelet distribution width;
KIRP	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.68	9.13	0.5	2.64e-17	Personality dimensions;
KIRP	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.64	-0.39	1.99e-10	Joint mobility (Beighton score);
KIRP	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg19000871	chr14:103996768	TRMT61A	-0.46	-5.2	-0.31	4.2e-7	Reticulocyte count;
KIRP	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	Neuroticism;
KIRP	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.33	-5.13	-0.31	6.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.45	-5.44	-0.33	1.29e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7033996	1.000	rs16932799	chr9:35949949	G/A	cg00918944	chr9:35908117	LOC158376	0.38	5.34	0.32	2.12e-7	Urate levels (BMI interaction);
KIRP	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.72	0.34	3.1e-8	Total cholesterol levels;
KIRP	cis	rs9815354	0.597	rs79626430	chr3:42023786	A/G	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1538970	1.000	rs4660853	chr1:45849090	C/T	cg05343316	chr1:45956843	TESK2	0.64	7.29	0.42	4.16e-12	Platelet count;
KIRP	cis	rs8018808	1.000	rs4903580	chr14:77850978	C/T	cg20045696	chr14:77926864	AHSA1	-0.44	-5.47	-0.33	1.13e-7	Myeloid white cell count;
KIRP	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.85e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6466055	0.777	rs2299319	chr7:104877916	C/T	cg04380332	chr7:105027541	SRPK2	-0.57	-8.66	-0.48	6.37e-16	Schizophrenia;
KIRP	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg07827796	chr19:33622959	WDR88	0.41	4.94	0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.48	6.53	0.38	3.68e-10	Gout;
KIRP	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13047869	chr3:10149882	C3orf24	0.55	5.1	0.31	6.8e-7	Alzheimer's disease;
KIRP	cis	rs1335587	0.518	rs9513904	chr13:102107582	G/A	cg13538571	chr13:102108074	ITGBL1	0.42	5.42	0.33	1.43e-7	Obesity-related traits;
KIRP	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.96	-0.3	1.29e-6	Pulmonary function;
KIRP	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.65	-6.87	-0.4	5.17e-11	Vitiligo;
KIRP	cis	rs10208940	0.920	rs13422657	chr2:68706989	T/C	cg12452813	chr2:68675892	NA	0.47	5.07	0.31	7.97e-7	Urate levels in lean individuals;
KIRP	cis	rs6132905	0.590	rs75298178	chr20:2603683	G/A	cg24848351	chr20:2622020	TMC2	-0.57	-5.19	-0.31	4.32e-7	Mumps;
KIRP	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.71	8.48	0.48	2.11e-15	Mammographic density (dense area);
KIRP	cis	rs56161922	0.908	rs55952744	chr1:207860158	C/G	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.6	7.28	0.42	4.52e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	cis	rs74181299	0.750	rs12472718	chr2:65327620	G/A	cg05010058	chr2:65284262	CEP68	-0.5	-6.95	-0.41	3.25e-11	Pulse pressure;
KIRP	cis	rs10463316	0.855	rs352701	chr5:150736474	A/G	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.25	-0.37	1.78e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4302748	0.862	rs11974209	chr7:36184479	A/G	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.93	16.12	0.72	2.14e-40	Breast cancer;
KIRP	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg17644776	chr2:200775616	C2orf69	-0.61	-6.26	-0.37	1.71e-9	Schizophrenia;
KIRP	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.53	-6.98	-0.41	2.7e-11	Immature fraction of reticulocytes;
KIRP	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.77	6.94	0.4	3.5e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs10465746	0.747	rs34155960	chr1:84447539	T/G	cg10977910	chr1:84465055	TTLL7	0.58	7.3	0.42	4.04e-12	Obesity-related traits;
KIRP	trans	rs193541	0.530	rs6595405	chr5:122084745	C/T	cg05232207	chr8:969542	NA	-0.55	-6.16	-0.37	2.98e-9	Glucose homeostasis traits;
KIRP	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.72	10.19	0.54	1.45e-20	Schizophrenia;
KIRP	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.13	0.31	5.87e-7	Rheumatoid arthritis;
KIRP	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg25019722	chr6:37503610	NA	-0.95	-15.32	-0.7	1.18e-37	Cognitive performance;
KIRP	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg08992911	chr2:238395768	MLPH	0.47	5.44	0.33	1.28e-7	Prostate cancer;
KIRP	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg00495681	chr13:53174319	NA	0.44	5.94	0.35	9.45e-9	Lewy body disease;
KIRP	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.15	-0.31	5.27e-7	Triglycerides;
KIRP	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	cis	rs12580194	1.000	rs4262806	chr12:55711562	T/A	cg11794356	chr12:55725991	OR6C3	-0.4	-5.45	-0.33	1.24e-7	Cancer;
KIRP	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg21419209	chr3:44054225	NA	-0.73	-9.05	-0.5	4.45e-17	Coronary artery disease;
KIRP	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg11766577	chr21:47581405	C21orf56	-0.43	-5.13	-0.31	5.92e-7	Testicular germ cell tumor;
KIRP	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-7.27	-0.42	4.79e-12	Glomerular filtration rate (creatinine);
KIRP	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.22	-0.42	6.51e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13102973	0.640	rs6535053	chr4:135882242	T/C	cg14419869	chr4:135874104	NA	0.36	5.15	0.31	5.25e-7	Subjective well-being;
KIRP	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.71	0.34	3.25e-8	Morning vs. evening chronotype;
KIRP	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg24747557	chr10:131355152	MGMT	0.5	6.28	0.37	1.55e-9	Response to temozolomide;
KIRP	cis	rs3752645	0.764	rs2041526	chr7:106692629	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-5.19	-0.31	4.35e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.2	0.37	2.37e-9	Lung cancer;
KIRP	cis	rs77688320	0.535	rs2540441	chr2:202346669	C/T	cg06431681	chr2:202330990	STRADB	-0.53	-6.55	-0.39	3.34e-10	Breast cancer;
KIRP	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-7.62	-0.44	5.42e-13	Migraine;Coronary artery disease;
KIRP	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.57	-0.48	1.14e-15	Blood trace element (Zn levels);
KIRP	cis	rs7010876	0.568	rs939280	chr8:89223569	G/A	cg08624180	chr8:89339080	MMP16	0.52	4.94	0.3	1.46e-6	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg26354017	chr1:205819088	PM20D1	0.49	5.69	0.34	3.68e-8	Parkinson's disease;
KIRP	cis	rs12976411	0.850	rs3760932	chr19:32835191	T/C	cg02282382	chr19:32836354	ZNF507	0.69	5.2	0.31	4.17e-7	Coronary artery disease;
KIRP	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg02297831	chr4:17616191	MED28	0.6	7.42	0.43	1.85e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.56	-0.33	7.12e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg03150409	chr4:1892317	WHSC1	0.44	6.21	0.37	2.22e-9	Blood metabolite levels;
KIRP	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.95	-0.3	1.37e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2559856	1.000	rs2559856	chr12:102089561	A/G	cg12924262	chr12:102091054	CHPT1	0.45	5.69	0.34	3.57e-8	Blood protein levels;
KIRP	cis	rs4132509	1.000	rs9287269	chr1:243954551	G/A	cg25706552	chr1:244017396	NA	0.56	7.47	0.43	1.38e-12	RR interval (heart rate);
KIRP	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.1	-0.31	6.69e-7	Metabolite levels;
KIRP	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.67	9.74	0.53	3.68e-19	Lymphocyte counts;
KIRP	cis	rs9596863	0.898	rs34617186	chr13:54370594	A/G	ch.13.53330881F	chr13:54432880	NA	0.61	6.01	0.36	6.69e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.46	-6.27	-0.37	1.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg09788416	chr12:39539408	NA	0.43	5.25	0.32	3.22e-7	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg08975724	chr8:8085496	FLJ10661	0.61	7.54	0.43	8.87e-13	Retinal vascular caliber;
KIRP	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08439880	chr3:133502540	NA	-0.5	-6.21	-0.37	2.25e-9	Iron status biomarkers;
KIRP	cis	rs8060686	0.844	rs73597581	chr16:67682234	G/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-4.99	-0.3	1.14e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7175404	1.000	rs7168138	chr15:94042788	C/G	cg23502883	chr15:93959149	NA	0.56	5.91	0.35	1.13e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.92	-0.45	8.44e-14	Triglycerides;
KIRP	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg02023728	chr11:77925099	USP35	-0.29	-4.98	-0.3	1.18e-6	Alzheimer's disease (survival time);
KIRP	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-10.11	-0.54	2.56e-20	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.01	0.45	4.74e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9311676	0.656	rs68021431	chr3:58403136	A/G	cg06643156	chr3:58380774	PXK	0.35	4.96	0.3	1.31e-6	Systemic lupus erythematosus;
KIRP	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg15664640	chr17:80829946	TBCD	0.66	5.62	0.34	5.26e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.67	-0.34	4.07e-8	Depression;
KIRP	cis	rs4148660	0.804	rs10770870	chr12:22075226	A/G	cg14669847	chr12:22099120	NA	0.33	5.61	0.34	5.45e-8	Gout;
KIRP	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.84	13.07	0.64	5.51e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.64	-0.34	4.7e-8	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.1	-0.31	6.91e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.07	-20.03	-0.79	1.4e-53	Height;
KIRP	cis	rs77633900	0.881	rs1875883	chr15:76638231	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-5.34	-0.32	2.09e-7	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-6.86	-0.4	5.68e-11	Mean platelet volume;
KIRP	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.01	0.41	2.28e-11	Retinal vascular caliber;
KIRP	cis	rs6681460	0.649	rs1947083	chr1:67004801	G/A	cg02459107	chr1:67143332	SGIP1	0.38	5.43	0.33	1.36e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.42	-0.33	1.39e-7	Aortic root size;
KIRP	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg05370193	chr1:21551575	ECE1	-0.48	-6.42	-0.38	6.99e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.94	0.4	3.44e-11	Schizophrenia;
KIRP	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg23594656	chr7:65796392	TPST1	-0.51	-8.06	-0.46	3.3e-14	Aortic root size;
KIRP	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg24009623	chr19:33667908	NA	-0.49	-6.41	-0.38	7.47e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-5.41	-0.33	1.49e-7	Triglycerides;
KIRP	trans	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg13165212	chr22:42675999	NA	0.28	5.05	0.31	8.78e-7	Cognitive function;
KIRP	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-0.98	-8.37	-0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg13334819	chr7:99746414	C7orf59	0.52	5.99	0.36	7.47e-9	Coronary artery disease;
KIRP	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg19292749	chr17:79650816	ARL16;HGS	0.52	4.95	0.3	1.38e-6	Dental caries;
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg17441377	chr17:3906640	NA	-0.5	-7.39	-0.43	2.29e-12	Type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.47	-5.04	-0.31	9.05e-7	Alzheimer's disease;
KIRP	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg01631408	chr1:248437212	OR2T33	-0.6	-7.9	-0.45	9.47e-14	Common traits (Other);
KIRP	cis	rs8135828	0.955	rs2530656	chr22:29992758	G/A	cg23204276	chr22:29729285	AP1B1;SNORD125	0.45	5.12	0.31	6.24e-7	Lipid traits;
KIRP	cis	rs9475752	0.644	rs35336675	chr6:56851757	T/C	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs4748857	0.947	rs7089898	chr10:23591365	C/T	cg12804278	chr10:23633326	C10orf67	0.45	5.53	0.33	8.34e-8	Systemic lupus erythematosus;
KIRP	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.47	-0.33	1.12e-7	Height;
KIRP	cis	rs10489525	0.530	rs11102884	chr1:115612947	A/G	cg12756093	chr1:115239321	AMPD1	0.41	5.13	0.31	5.94e-7	Autism;
KIRP	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.59	-8.45	-0.47	2.51e-15	Gut microbiome composition (summer);
KIRP	cis	rs7560272	0.501	rs10191988	chr2:73947787	A/G	cg20560298	chr2:73613845	ALMS1	0.45	5.21	0.31	4.09e-7	Schizophrenia;
KIRP	cis	rs1866706	0.896	rs7940022	chr11:12873906	G/T	cg25843174	chr11:12811716	TEAD1	-0.34	-5.88	-0.35	1.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg19468946	chr17:37922297	IKZF3	-0.45	-6.3	-0.37	1.34e-9	Asthma;
KIRP	cis	rs6545883	0.791	rs4672445	chr2:61655008	T/C	cg15711740	chr2:61764176	XPO1	0.62	8.14	0.46	1.96e-14	Tuberculosis;
KIRP	cis	rs17023223	0.537	rs2645301	chr1:119590420	C/T	cg05756136	chr1:119680316	WARS2	-0.57	-7.72	-0.44	2.99e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg15655495	chr12:38532458	NA	-0.28	-5.34	-0.32	2.1e-7	Bladder cancer;
KIRP	cis	rs9921338	0.961	rs7187870	chr16:11431919	T/C	cg00044050	chr16:11439710	C16orf75	-0.55	-5.84	-0.35	1.68e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs62380364	0.602	rs591228	chr5:88064809	G/A	cg24804195	chr5:87968844	LOC645323	-0.43	-5.53	-0.33	8.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	0.75	11.17	0.58	1.08e-23	Prudent dietary pattern;
KIRP	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.54	6.8	0.4	7.97e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9393813	0.529	rs4711155	chr6:27446446	C/A	cg03332623	chr6:27441972	ZNF184	-0.39	-5.37	-0.32	1.81e-7	Bipolar disorder;
KIRP	trans	rs972578	0.668	rs9607961	chr22:43232818	C/T	cg15321293	chr3:36422198	STAC	-0.48	-6.28	-0.37	1.49e-9	Mean platelet volume;
KIRP	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.61	8.6	0.48	9.65e-16	Lymphocyte counts;
KIRP	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.69	8.16	0.46	1.68e-14	Schizophrenia;
KIRP	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.74	7.61	0.44	5.7e-13	Schizophrenia;
KIRP	cis	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs10209697	1	rs10209697	chr2:222549197	G/A	cg27403388	chr2:222639321	NA	-0.6	-5.03	-0.31	9.67e-7	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
KIRP	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg26875137	chr12:53738046	NA	0.43	6.37	0.38	9.03e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.6	7.1	0.41	1.3e-11	DNA methylation (variation);
KIRP	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.27	-17.28	-0.74	2.34e-44	Breast cancer;
KIRP	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg07382826	chr16:28625726	SULT1A1	0.44	5.17	0.31	4.76e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.47	-0.43	1.42e-12	Retinal vascular caliber;
KIRP	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.31	5.38	0.32	1.76e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg11635098	chr7:100497156	NA	-0.64	-6.95	-0.41	3.17e-11	Resting heart rate;
KIRP	cis	rs62380364	0.565	rs617944	chr5:88057915	T/C	cg22951263	chr5:87985283	NA	-0.45	-6.26	-0.37	1.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg21858823	chr1:15850916	CASP9	0.55	5.91	0.35	1.15e-8	Systolic blood pressure;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07308232	chr7:1071921	C7orf50	-0.51	-6.49	-0.38	4.79e-10	Longevity;Endometriosis;
KIRP	cis	rs965513	0.530	rs1912995	chr9:100530899	A/G	cg13688889	chr9:100608707	NA	-0.49	-6.37	-0.38	9.35e-10	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg11584989	chr19:19387371	SF4	0.42	5.37	0.32	1.85e-7	Tonsillectomy;
KIRP	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.43	-5.07	-0.31	7.74e-7	Resting heart rate;
KIRP	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.56	7.72	0.44	2.89e-13	Blood metabolite levels;
KIRP	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	0.95	18.21	0.76	1.76e-47	Dental caries;
KIRP	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.58	10.59	0.56	7.48e-22	Bone mineral density;
KIRP	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.62	0.44	5.41e-13	White blood cell count;
KIRP	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	1.02	14.2	0.67	7.86e-34	Blood protein levels;
KIRP	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.6	7.24	0.42	5.8e-12	Schizophrenia;
KIRP	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.18	0.42	8.16e-12	Rheumatoid arthritis;
KIRP	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.33	-0.32	2.27e-7	Bipolar disorder;
KIRP	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-4.89	-0.3	1.83e-6	Schizophrenia;
KIRP	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg06521331	chr12:34319734	NA	-0.52	-6.4	-0.38	7.64e-10	Bladder cancer;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22168489	chr12:122356033	WDR66	0.57	8.61	0.48	8.6e-16	Mean corpuscular volume;
KIRP	cis	rs6841333	0.716	rs2276886	chr4:76928428	C/T	cg24176760	chr4:76958061	ART3;CXCL11	-0.46	-5.08	-0.31	7.31e-7	Monokine induced by gamma interferon levels;
KIRP	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1318772	1.000	rs11241202	chr5:112692298	G/A	cg12552261	chr5:112820674	MCC	0.74	6.35	0.38	1.02e-9	F-cell distribution;
KIRP	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg12315302	chr6:26189340	HIST1H4D	1.08	6.49	0.38	4.71e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3087591	0.592	rs2342054	chr17:29724708	G/A	cg24425628	chr17:29625626	OMG;NF1	0.63	9.15	0.5	2.31e-17	Hip circumference;
KIRP	cis	rs394563	0.591	rs237026	chr6:149720681	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.39	-6.11	-0.36	3.79e-9	Dupuytren's disease;
KIRP	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg01028140	chr2:1542097	TPO	-0.76	-6.78	-0.4	8.63e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.84	-12.5	-0.62	4.35e-28	Height;
KIRP	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.8	7.24	0.42	5.71e-12	Mean platelet volume;
KIRP	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg23422044	chr7:1970798	MAD1L1	-0.69	-7.09	-0.41	1.43e-11	Bipolar disorder;
KIRP	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.65	-10.46	-0.55	1.95e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg00982548	chr2:198649783	BOLL	-0.54	-5.25	-0.32	3.23e-7	Ulcerative colitis;
KIRP	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.59	7.98	0.45	5.7e-14	Morning vs. evening chronotype;
KIRP	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg19402173	chr7:128379420	CALU	-0.62	-8.05	-0.46	3.59e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg18190219	chr22:46762943	CELSR1	-0.73	-5.46	-0.33	1.15e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg11632617	chr15:75315747	PPCDC	-0.61	-5.26	-0.32	3.14e-7	Lung cancer;
KIRP	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.47	6.06	0.36	4.94e-9	Colorectal cancer;
KIRP	cis	rs9469913	0.799	rs2744972	chr6:34659054	C/T	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.41	-0.38	7.3e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	4.93	0.3	1.54e-6	Schizophrenia;
KIRP	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14169450	chr9:139327907	INPP5E	0.4	5.82	0.35	1.85e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26629960	chr19:1479218	C19orf25	0.46	6.1	0.36	4.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.65	8.02	0.46	4.41e-14	Blood metabolite levels;
KIRP	cis	rs2267137	0.836	rs2283855	chr22:29796775	T/C	cg07256473	chr22:29710276	RASL10A	0.44	6.82	0.4	7e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7011507	1.000	rs4552931	chr8:49171227	A/G	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	cis	rs3735025	0.927	rs34997884	chr7:137066364	G/A	cg13839563	chr7:136910420	NA	-0.43	-4.88	-0.3	1.94e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg27398637	chr11:122830231	C11orf63	-0.77	-10.3	-0.55	6.37e-21	Menarche (age at onset);
KIRP	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.55	-6.88	-0.4	4.88e-11	Prudent dietary pattern;
KIRP	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.26	-0.78	4.82e-51	Height;
KIRP	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs11264213	0.643	rs10908407	chr1:36162328	C/T	cg27506609	chr1:36549197	TEKT2	0.61	5.68	0.34	3.76e-8	Schizophrenia;
KIRP	trans	rs7012814	1	rs7012814	chr8:9173358	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.62	0.39	2.19e-10	Fibrinogen levels;
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg09699651	chr6:150184138	LRP11	-0.48	-6.2	-0.37	2.32e-9	Lung cancer;
KIRP	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6662572	0.737	rs72692632	chr1:46437192	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.52	0.33	8.53e-8	Blood protein levels;
KIRP	cis	rs9914544	0.564	rs11868520	chr17:18770367	A/G	cg26378065	chr17:18585709	ZNF286B	0.38	4.98	0.3	1.19e-6	Educational attainment (years of education);
KIRP	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.43	5.11	0.31	6.44e-7	Aortic root size;
KIRP	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg24250549	chr1:154909240	PMVK	0.76	9.82	0.53	2.1e-19	Prostate cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27572529	chr10:21823470	MLLT10	-0.52	-6.18	-0.37	2.69e-9	Migraine with aura;
KIRP	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg19899395	chr1:46959349	NA	0.45	5.53	0.33	8.2e-8	Monobrow;
KIRP	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.11	-0.31	6.57e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1620921	0.563	rs1806449	chr6:161280932	G/T	cg01280913	chr6:161186852	NA	-0.39	-5.17	-0.31	4.85e-7	Lipoprotein (a) - cholesterol levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg26283532	chr4:119757274	SEC24D	0.47	6.19	0.37	2.43e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.5	-6.68	-0.39	1.56e-10	Smooth-surface caries;
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg11814155	chr7:99998594	ZCWPW1	0.54	5.38	0.32	1.76e-7	Platelet count;
KIRP	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg02389323	chr16:88786976	FAM38A	0.79	6.59	0.39	2.61e-10	Plateletcrit;
KIRP	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-7.49	-0.43	1.23e-12	Alzheimer's disease;
KIRP	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg10224037	chr5:178157518	ZNF354A	0.87	10.34	0.55	4.85e-21	Neutrophil percentage of white cells;
KIRP	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.81	11.0	0.57	3.62e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg21108841	chr4:24914750	CCDC149	-0.47	-5.67	-0.34	4.04e-8	Heschl's gyrus morphology;
KIRP	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.95	-0.41	3.19e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg06060754	chr5:176797920	RGS14	0.44	6.56	0.39	3.1e-10	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg09201719	chr10:104596890	CYP17A1	0.36	5.12	0.31	6.3e-7	Arsenic metabolism;
KIRP	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg21573476	chr21:45109991	RRP1B	-0.65	-8.79	-0.49	2.71e-16	Mean corpuscular volume;
KIRP	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.04	0.41	1.88e-11	Aortic root size;
KIRP	cis	rs2820315	1.000	rs2172935	chr1:201826340	A/G	cg11586189	chr1:201857591	SHISA4	0.39	5.46	0.33	1.14e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.44	6.05	0.36	5.37e-9	Optic nerve measurement (cup area);
KIRP	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.86	-0.4	5.68e-11	Monocyte count;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.81	-10.99	-0.57	4.1000000000000003e-23	Longevity;Endometriosis;
KIRP	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg01522456	chr1:115632236	TSPAN2	-0.43	-5.93	-0.35	1.04e-8	Autism;
KIRP	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-8.56	-0.48	1.24e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs2223471	0.754	rs2744490	chr6:50765876	T/A	cg03432817	chr6:50765336	NA	-0.55	-9.42	-0.52	3.36e-18	Subcutaneous adipose tissue;
KIRP	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg26597838	chr10:835615	NA	0.5	6.22	0.37	2.07e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs17655565	0.581	rs2298794	chr12:52760732	G/A	cg07925835	chr12:52762777	KRT85	0.49	5.11	0.31	6.45e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14751398	chr6:20402153	E2F3	0.69	6.62	0.39	2.22e-10	Lung function (FEV1);
KIRP	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg05785598	chr3:49045655	WDR6	0.32	5.87	0.35	1.4e-8	Parkinson's disease;
KIRP	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg21132104	chr15:45694354	SPATA5L1	0.52	6.17	0.37	2.73e-9	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.46	5.74	0.34	2.73e-8	Asthma;
KIRP	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14169450	chr9:139327907	INPP5E	0.54	6.26	0.37	1.68e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs1843834	0.721	rs6436507	chr2:225598242	T/A	cg22509189	chr2:225307070	NA	-0.44	-5.38	-0.32	1.7e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg06521331	chr12:34319734	NA	-0.47	-6.02	-0.36	6.34e-9	Morning vs. evening chronotype;
KIRP	cis	rs1009181	0.585	rs2183947	chr6:26159356	G/A	cg00631329	chr6:26305371	NA	-0.54	-5.69	-0.34	3.6e-8	Childhood ear infection;
KIRP	cis	rs2057178	1.000	rs61889186	chr11:32367570	C/G	cg05837727	chr11:32355149	NA	0.43	4.86	0.3	2.06e-6	Tuberculosis;
KIRP	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.46	6.97	0.41	2.83e-11	Coronary artery disease;
KIRP	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.7	10.62	0.56	6.26e-22	Height;
KIRP	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.56	-6.68	-0.39	1.56e-10	Diabetic retinopathy;
KIRP	cis	rs675026	0.853	rs548339	chr6:154460799	T/C	cg07813322	chr6:154414604	OPRM1	-0.41	-5.34	-0.32	2.07e-7	Hypertension;
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg13092806	chr2:177043255	NA	0.63	8.8	0.49	2.41e-16	IgG glycosylation;
KIRP	cis	rs500492	0.542	rs421245	chr16:1074458	G/C	cg03495660	chr16:1074500	NA	0.5	5.62	0.34	5.24e-8	Polycystic ovary syndrome;
KIRP	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.45	-5.54	-0.33	7.82e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg07234876	chr8:600039	NA	-0.98	-6.35	-0.38	1.02e-9	IgG glycosylation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05741611	chr18:51884982	C18orf54	0.51	6.73	0.39	1.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72772090	1.000	rs56116814	chr5:96048714	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.53	-4.96	-0.3	1.34e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.65	0.34	4.41e-8	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03965885	chr4:78079304	CCNG2	0.49	6.17	0.37	2.74e-9	Parkinson's disease;
KIRP	cis	rs752010	0.662	rs10890154	chr1:42106740	C/T	cg06885757	chr1:42089581	HIVEP3	0.54	8.09	0.46	2.66e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs1883415	0.534	rs2817205	chr6:24477134	G/A	cg20631270	chr6:24437470	GPLD1	0.39	4.92	0.3	1.55e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg07395648	chr5:131743802	NA	-0.35	-4.88	-0.3	1.95e-6	Blood metabolite levels;
KIRP	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.41	8.23	0.46	1.1e-14	Multiple system atrophy;
KIRP	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg22117172	chr7:91764530	CYP51A1	-0.4	-5.79	-0.35	2.18e-8	Breast cancer;
KIRP	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.78	-12.8	-0.63	4.44e-29	Brugada syndrome;
KIRP	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2151522	0.762	rs9375474	chr6:127177019	T/C	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4356975	0.563	rs4694171	chr4:69954297	T/A	cg27372994	chr4:70080453	UGT2B11	0.37	4.92	0.3	1.56e-6	Obesity-related traits;
KIRP	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg00646381	chr17:77835854	NA	0.54	7.19	0.42	7.76e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
KIRP	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	11.27	0.58	4.92e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19171272	chr22:38449367	NA	-0.56	-8.35	-0.47	5.15e-15	Glioblastoma;Glioma;
KIRP	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs57338032	0.891	rs11634990	chr15:78771186	T/C	cg06917634	chr15:78832804	PSMA4	0.55	4.86	0.3	2.1e-6	CTACK levels;
KIRP	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.22	0.46	1.16e-14	Lung cancer;
KIRP	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg23894439	chr1:183413866	NA	0.38	5.07	0.31	7.88e-7	Systemic lupus erythematosus;
KIRP	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.97	13.64	0.66	6.26e-32	Cognitive function;
KIRP	cis	rs2120243	0.539	rs2124497	chr3:157120259	T/G	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs397969	0.646	rs1638528	chr17:19837929	A/G	cg13482628	chr17:19912719	NA	0.51	6.21	0.37	2.23e-9	Platelet count;
KIRP	cis	rs12220238	1.000	rs7073432	chr10:75953350	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.56	0.43	8.03e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg10284592	chr11:57434942	ZDHHC5	-0.48	-6.3	-0.37	1.34e-9	Platelet-derived growth factor BB levels;
KIRP	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg16111737	chr12:117408163	FBXW8	-0.5	-4.92	-0.3	1.56e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.72	-8.98	-0.5	7.33e-17	Gestational age at birth (maternal effect);
KIRP	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg09890400	chr1:26503858	CNKSR1	0.45	6.22	0.37	2.14e-9	Height;
KIRP	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg05082376	chr22:42548792	NA	-0.37	-4.95	-0.3	1.38e-6	Schizophrenia;
KIRP	trans	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg02002194	chr4:3960332	NA	-0.46	-6.16	-0.37	3.02e-9	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10829342	chr17:72744524	SLC9A3R1	0.49	6.66	0.39	1.73e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.54	9.02	0.5	5.56e-17	Eye color traits;
KIRP	cis	rs6546324	0.514	rs2861639	chr2:67779919	G/C	cg15745817	chr2:67799979	NA	-0.61	-6.2	-0.37	2.4e-9	Endometriosis;
KIRP	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg22437258	chr11:111473054	SIK2	0.59	7.15	0.42	9.62e-12	Primary sclerosing cholangitis;
KIRP	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	5.35	0.32	1.98e-7	Menarche (age at onset);
KIRP	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg01420254	chr6:26195488	NA	1.24	11.27	0.58	4.85e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg23307798	chr14:103986281	CKB	-0.52	-6.99	-0.41	2.62e-11	Coronary artery disease;
KIRP	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg07080220	chr10:102295463	HIF1AN	-0.76	-8.01	-0.45	4.63e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.51	0.62	4.18e-28	Platelet count;
KIRP	cis	rs2904967	0.703	rs2904979	chr11:65000719	C/T	cg12562828	chr11:65076843	NA	-0.74	-8.68	-0.48	5.61e-16	Mean corpuscular volume;
KIRP	cis	rs13185784	0.703	rs35394934	chr5:179677555	T/C	cg02891314	chr5:179741120	GFPT2	0.54	5.24	0.32	3.45e-7	TRAIL levels;
KIRP	trans	rs6741892	1.000	rs6741892	chr2:38916970	A/T	cg07212940	chr3:62304165	C3orf14	0.8	6.17	0.37	2.84e-9	5-HTT brain serotonin transporter levels;
KIRP	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg00409905	chr10:38381863	ZNF37A	0.55	6.11	0.36	3.98e-9	Obesity (extreme);
KIRP	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.43	7.35	0.42	2.86e-12	Renal cell carcinoma;
KIRP	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg15327641	chr2:3715039	ALLC	-0.41	-5.18	-0.31	4.6e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg03647239	chr10:116582469	FAM160B1	0.52	5.95	0.35	9.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs42648	0.869	rs42611	chr7:89950060	C/A	cg25739043	chr7:89950458	NA	-0.46	-7.16	-0.42	9.4e-12	Homocysteine levels;
KIRP	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg26681399	chr22:41777847	TEF	-0.46	-4.97	-0.3	1.25e-6	Vitiligo;
KIRP	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.42	5.28	0.32	2.89e-7	Melanoma;
KIRP	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.33	-7.38	-0.43	2.37e-12	Cutaneous nevi;
KIRP	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg16989719	chr2:238392110	NA	-0.41	-5.48	-0.33	1.08e-7	Prostate cancer;
KIRP	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.62	9.14	0.5	2.4e-17	Systemic lupus erythematosus;
KIRP	cis	rs72627123	0.656	rs4646864	chr14:74526703	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	5.26	0.32	3.09e-7	Morning vs. evening chronotype;
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.52	0.65	1.65e-31	Platelet count;
KIRP	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.64	0.44	4.93e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1519814	1.000	rs10087151	chr8:121172261	C/T	cg22335954	chr8:121166405	COL14A1	-0.65	-6.55	-0.39	3.36e-10	Breast cancer;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.4	-5.58	-0.34	6.35e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	4.06e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.44	-5.59	-0.34	6.01e-8	Cognitive test performance;
KIRP	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.52	-5.74	-0.34	2.73e-8	Platelet distribution width;
KIRP	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01855760	chr4:68567075	LOC550112;UBA6	0.52	6.19	0.37	2.53e-9	Smoking initiation;
KIRP	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg24315340	chr6:146058215	EPM2A	0.41	5.12	0.31	6.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.26	-0.37	1.69e-9	Cardiac Troponin-T levels;
KIRP	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.58	7.83	0.45	1.45e-13	Height;
KIRP	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18826267	chr19:5978573	RANBP3	0.55	6.89	0.4	4.56e-11	Parkinson's disease;
KIRP	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.4	-0.51	3.98e-18	Response to antipsychotic treatment;
KIRP	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.91e-9	Response to antipsychotic treatment;
KIRP	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-6.87	-0.4	5.16e-11	Lung cancer;
KIRP	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg00405596	chr8:11794950	NA	-0.49	-6.45	-0.38	5.73e-10	Retinal vascular caliber;
KIRP	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.44	-0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.36	-0.38	9.93e-10	Alcohol dependence;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03311339	chr17:64299562	PRKCA	0.45	6.13	0.36	3.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01056903	chr20:44601024	ZNF335	0.54	6.17	0.37	2.73e-9	Smoking initiation;
KIRP	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	cg04338863	chr8:33670619	NA	0.47	6.15	0.36	3.19e-9	Body mass index;
KIRP	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.05	-0.31	8.7e-7	Coronary artery disease;
KIRP	cis	rs6684514	1.000	rs12121805	chr1:156257876	A/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg18882449	chr10:104885122	NT5C2	-0.5	-6.47	-0.38	5.22e-10	Arsenic metabolism;
KIRP	cis	rs5750854	0.726	rs3788557	chr22:39977211	C/T	cg10455938	chr22:40058150	CACNA1I	0.39	5.31	0.32	2.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs13102973	0.965	rs4469136	chr4:135850051	C/T	cg14419869	chr4:135874104	NA	0.52	8.63	0.48	7.65e-16	Subjective well-being;
KIRP	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.48	-0.33	1.07e-7	Pulmonary function;
KIRP	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	5.73	0.34	2.89e-8	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20504025	chr11:74659950	XRRA1;SPCS2	0.43	6.11	0.36	3.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4742903	0.509	rs10991115	chr9:106896111	C/T	cg14250997	chr9:106856677	SMC2	0.43	5.93	0.35	1.02e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.53	5.14	0.31	5.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.67	9.42	0.51	3.38e-18	Colorectal cancer;
KIRP	cis	rs1697139	0.710	rs6888412	chr5:66526800	G/C	cg11553311	chr5:66541588	NA	0.39	5.27	0.32	2.99e-7	Breast cancer;
KIRP	cis	rs1933737	0.501	rs195502	chr6:116192026	A/G	cg26893134	chr6:116381904	FRK	0.18	4.92	0.3	1.59e-6	Urate levels;
KIRP	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.4	-5.04	-0.31	9.08e-7	Pubertal anthropometrics;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06434972	chr7:44122219	POLM	0.6	7.05	0.41	1.79e-11	Smoking initiation;
KIRP	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs12043259	0.730	rs7539437	chr1:204795888	G/T	cg11485465	chr5:54518469	NA	0.37	6.13	0.36	3.41e-9	Addiction;
KIRP	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs3818717	0.541	rs55767800	chr17:17674967	T/C	cg04398451	chr17:18023971	MYO15A	0.45	5.56	0.33	7.05e-8	Lymphocyte counts;
KIRP	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg14541582	chr5:601475	NA	-0.58	-6.59	-0.39	2.73e-10	Obesity-related traits;
KIRP	trans	rs13170463	0.579	rs35048331	chr5:8048625	A/G	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs7666738	0.539	rs13150465	chr4:99094892	C/T	cg17366294	chr4:99064904	C4orf37	-0.45	-4.93	-0.3	1.5e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg04920474	chr2:44395004	PPM1B	0.37	4.95	0.3	1.41e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.71	10.63	0.56	5.71e-22	Eosinophilic esophagitis;
KIRP	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.15	0.31	5.21e-7	Cognitive test performance;
KIRP	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg21064579	chr19:49206444	FUT2	0.56	8.28	0.47	8.01e-15	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs10046574	0.561	rs10214966	chr7:135196642	A/G	cg27474649	chr7:135195673	CNOT4	0.55	4.97	0.3	1.24e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	trans	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg06521331	chr12:34319734	NA	-0.57	-6.99	-0.41	2.52e-11	Heart rate;
KIRP	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.55	6.03	0.36	5.83e-9	Exhaled nitric oxide output;
KIRP	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.63	0.48	7.63e-16	Prudent dietary pattern;
KIRP	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.15	-21.31	-0.81	8.57e-58	Exhaled nitric oxide output;
KIRP	cis	rs3925075	0.525	rs2011491	chr16:31280255	G/A	cg02846316	chr16:31340340	ITGAM	0.43	5.17	0.31	4.77e-7	IgA nephropathy;
KIRP	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.16	10.25	0.55	9.23e-21	Lymphocyte counts;
KIRP	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.64	-9.26	-0.51	1.06e-17	Educational attainment;
KIRP	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg16141378	chr3:129829833	LOC729375	-0.48	-6.59	-0.39	2.63e-10	Neuroticism;
KIRP	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg16482183	chr6:26056742	HIST1H1C	0.57	6.51	0.38	4.16e-10	Iron status biomarkers;
KIRP	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.46	0.38	5.45e-10	Personality dimensions;
KIRP	cis	rs13401104	0.686	rs1530954	chr2:237110960	C/G	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.5	-0.38	4.38e-10	Neuroticism;
KIRP	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg26554054	chr8:600488	NA	0.54	4.91	0.3	1.64e-6	IgG glycosylation;
KIRP	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.26	0.37	1.72e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.39	0.33	1.62e-7	Coronary artery disease;
KIRP	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.59	7.72	0.44	2.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.8	-13.36	-0.65	5.59e-31	Itch intensity from mosquito bite;
KIRP	cis	rs500492	0.542	rs2573148	chr16:1073372	C/T	cg03495660	chr16:1074500	NA	0.48	5.44	0.33	1.29e-7	Polycystic ovary syndrome;
KIRP	cis	rs4638749	0.501	rs9917180	chr2:108747645	A/C	cg06795125	chr2:108905320	SULT1C2	0.3	5.5	0.33	9.74e-8	Blood pressure;
KIRP	cis	rs6577655	0.561	rs6577654	chr8:135593610	G/A	cg17885191	chr8:135476712	NA	0.7	6.57	0.39	3.03e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg00579200	chr11:133705235	NA	-0.42	-5.58	-0.34	6.27e-8	Childhood ear infection;
KIRP	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17376030	chr22:41985996	PMM1	0.83	8.95	0.5	8.83e-17	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23327483	chr22:24110105	CHCHD10	0.47	6.2	0.37	2.33e-9	Parkinson's disease;
KIRP	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.83	0.35	1.69e-8	Menopause (age at onset);
KIRP	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.84	0.45	1.4e-13	Rheumatoid arthritis;
KIRP	cis	rs9672608	1.000	rs9672608	chr15:78797463	T/A	cg06917634	chr15:78832804	PSMA4	-0.52	-5.19	-0.31	4.45e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs9296736	0.890	rs9637973	chr6:53903152	C/T	cg04374786	chr6:53939321	C6orf142	0.37	4.93	0.3	1.53e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg24874828	chr4:187887005	NA	-0.48	-7.14	-0.41	1.05e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8079658	0.953	rs969981	chr17:63818989	A/G	cg18091269	chr17:63822838	CCDC46	0.48	6.87	0.4	5.27e-11	Post bronchodilator FEV1;
KIRP	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg18944383	chr4:111397179	ENPEP	-0.71	-13.29	-0.65	9.53e-31	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08845439	chr1:151512945	TUFT1	0.48	6.39	0.38	8.44e-10	Parkinson's disease;
KIRP	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	1.14	14.76	0.69	9.46e-36	Response to hepatitis C treatment;
KIRP	cis	rs6772849	0.930	rs4857912	chr3:128329224	G/A	cg08795948	chr3:128337044	NA	0.47	5.83	0.35	1.73e-8	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs2301888	1.000	rs2240335	chr1:17674537	G/T	cg01790353	chr1:17674483	PADI4	0.41	5.51	0.33	9.15e-8	Rheumatoid arthritis;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg20887711	chr4:1340912	KIAA1530	0.49	6.15	0.37	3.06e-9	Longevity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02988255	chr11:60621110	GPR44	-0.41	-6.02	-0.36	6.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg01280390	chr8:19363452	CSGALNACT1	0.39	5.2	0.31	4.26e-7	Oropharynx cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26319343	chr19:5623198	SAFB2;SAFB	-0.49	-6.66	-0.39	1.77e-10	Metabolic traits;
KIRP	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.48	6.78	0.4	8.7e-11	Coronary artery disease;
KIRP	cis	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	5.04	0.31	9.05e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9815354	0.767	rs17281182	chr3:41817263	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.43	-0.33	1.38e-7	Schizophrenia;
KIRP	cis	rs11603020	0.950	rs3824988	chr11:57377968	C/T	cg19752551	chr11:57585705	CTNND1	0.7	9.75	0.53	3.27e-19	Blood protein levels;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.75	-8.09	-0.46	2.7e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.92	10.62	0.56	6.18e-22	Neuroticism;
KIRP	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.21	0.61	4.06e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7246657	0.722	rs2909098	chr19:38204248	G/A	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg15655495	chr12:38532458	NA	0.27	5.36	0.32	1.89e-7	Morning vs. evening chronotype;
KIRP	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.72	-7.66	-0.44	4.21e-13	Gut microbiome composition (summer);
KIRP	cis	rs4748857	0.891	rs4747458	chr10:23586914	T/G	cg12804278	chr10:23633326	C10orf67	0.43	5.35	0.32	2.03e-7	Systemic lupus erythematosus;
KIRP	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.59	-9.29	-0.51	8.5e-18	Coronary artery disease;
KIRP	cis	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg16898833	chr6:26189333	HIST1H4D	0.81	5.92	0.35	1.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.68	6.9	0.4	4.38e-11	Corneal astigmatism;
KIRP	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.58	-6.94	-0.4	3.48e-11	Monocyte count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27572510	chr17:35474613	ACACA	0.49	6.23	0.37	1.98e-9	Interleukin-4 levels;
KIRP	cis	rs12913538	0.862	rs4774441	chr15:62887791	C/T	cg09983546	chr15:62884068	NA	0.6	8.8	0.49	2.47e-16	Sleep depth;
KIRP	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.58	-0.34	6.18e-8	Platelet count;
KIRP	trans	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.26	0.37	1.68e-9	Mean corpuscular volume;
KIRP	cis	rs9400271	0.504	rs9784763	chr6:109624937	A/G	cg01475377	chr6:109611718	NA	0.38	5.56	0.33	6.84e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg00080972	chr5:178986291	RUFY1	0.39	5.81	0.35	1.89e-8	Lung cancer;
KIRP	cis	rs10267417	0.535	rs10271196	chr7:19938329	A/C	cg05791153	chr7:19748676	TWISTNB	0.49	4.91	0.3	1.64e-6	Night sleep phenotypes;
KIRP	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg03734594	chr13:111297400	CARS2	0.36	5.69	0.34	3.56e-8	Coronary artery disease;
KIRP	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.98	13.8	0.66	1.79e-32	Platelet distribution width;
KIRP	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21214613	chr1:16344536	HSPB7	0.35	4.98	0.3	1.2e-6	Dilated cardiomyopathy;
KIRP	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg03605463	chr16:89740564	NA	-0.4	-4.85	-0.3	2.16e-6	Vitiligo;
KIRP	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.82	-8.61	-0.48	9e-16	Body mass index;
KIRP	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.8	-13.36	-0.65	5.59e-31	Itch intensity from mosquito bite;
KIRP	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.62	0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs12449568	0.874	rs12452882	chr17:54405494	C/G	cg04456437	chr3:119217424	C3orf1	0.48	6.13	0.36	3.38e-9	Height;
KIRP	cis	rs7326068	0.610	rs8000601	chr13:21339384	G/A	cg04906043	chr13:21280425	IL17D	-0.43	-4.97	-0.3	1.26e-6	Schizophrenia, bipolar disorder and depression (combined);
KIRP	cis	rs72627509	0.638	rs78272732	chr4:57870537	T/A	cg26694713	chr4:57773883	REST	0.62	5.02	0.31	9.78e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg05802129	chr4:122689817	NA	-0.58	-7.14	-0.41	1.08e-11	Type 2 diabetes;
KIRP	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	11.51	0.59	8.51e-25	Systolic blood pressure;
KIRP	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.96	-14.43	-0.68	1.29e-34	Coronary artery disease;
KIRP	cis	rs2151522	0.762	rs9375472	chr6:127168375	A/G	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1134634	0.520	rs872678	chr4:15655698	T/C	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.8	-0.35	2.06e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21643547	chr1:205240462	TMCC2	-0.69	-10.53	-0.56	1.19e-21	Red blood cell count;
KIRP	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.48	-5.98	-0.36	7.68e-9	Longevity;
KIRP	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.09	-0.41	1.45e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg08888203	chr3:10149979	C3orf24	0.5	5.36	0.32	1.92e-7	Alzheimer's disease;
KIRP	cis	rs62413470	1.000	rs12208823	chr6:55966902	G/A	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs4936894	0.500	rs12795997	chr11:124171574	G/C	cg27160556	chr11:124181099	OR8D1	-0.45	-6.49	-0.38	4.57e-10	Aging (time to death);
KIRP	trans	rs4349753	0.870	rs248566	chr5:144184330	T/C	cg16033277	chr17:80885358	TBCD	0.4	6.24	0.37	1.89e-9	Photic sneeze reflex;
KIRP	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg04306507	chr14:55594613	LGALS3	0.53	8.15	0.46	1.85e-14	Protein biomarker;
KIRP	cis	rs11671005	0.735	rs3764529	chr19:58945089	A/G	cg13877915	chr19:58951672	ZNF132	0.61	5.91	0.35	1.15e-8	Mean platelet volume;
KIRP	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs9603616	0.712	rs9548871	chr13:40238481	T/C	cg26701198	chr13:40229707	COG6	0.45	5.35	0.32	1.98e-7	Rheumatoid arthritis;
KIRP	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.9	-0.35	1.19e-8	Glomerular filtration rate;
KIRP	cis	rs78487399	0.710	rs76215753	chr2:43597142	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.03	-0.31	9.56e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg05775895	chr3:12838266	CAND2	0.5	8.73	0.49	3.92e-16	QRS complex (12-leadsum);
KIRP	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-1.05	-14.86	-0.69	4.33e-36	Orofacial clefts;
KIRP	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.91	-0.64	1.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.99	7.8	0.45	1.71e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6921919	0.583	rs2027361	chr6:28388308	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.52	6.44	0.38	6.23e-10	Subjective well-being;
KIRP	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.9	-0.3	1.71e-6	Schizophrenia;
KIRP	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.4	-5.07	-0.31	7.96e-7	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26748024	chr6:42420298	TRERF1	0.51	7.08	0.41	1.54e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-4.88	-0.3	1.87e-6	Neuroticism;
KIRP	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg09873164	chr1:152488093	CRCT1	0.56	7.18	0.42	8.04e-12	Hair morphology;
KIRP	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-10.12	-0.54	2.32e-20	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13930105	chr1:158083475	NA	0.45	6.04	0.36	5.52e-9	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.1.69949640R	chr1:70177052	NA	0.46	6.25	0.37	1.83e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg23920097	chr1:209922102	NA	-0.47	-5.62	-0.34	5.07e-8	Red blood cell count;
KIRP	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.44	5.79	0.35	2.11e-8	Obesity-related traits;
KIRP	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.89	-11.39	-0.59	2.02e-24	Breast cancer;
KIRP	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg05347473	chr6:146136440	FBXO30	-0.56	-7.76	-0.44	2.25e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	8.02e-8	Blood protein levels;
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.55	-0.48	1.36e-15	Lymphocyte counts;
KIRP	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg15038512	chr6:170123185	PHF10	-0.56	-8.58	-0.48	1.08e-15	Obesity-related traits;
KIRP	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg15282417	chr9:129245246	FAM125B	0.44	7.4	0.43	2.19e-12	Intraocular pressure;
KIRP	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.39	0.43	2.34e-12	Retinal vascular caliber;
KIRP	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-0.96	-9.46	-0.52	2.63e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg22563815	chr15:78856949	CHRNA5	0.41	5.92	0.35	1.1e-8	Sudden cardiac arrest;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg12692727	chr7:1102344	C7orf50	0.47	5.01	0.3	1.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.51	4.98	0.3	1.19e-6	Skin colour saturation;
KIRP	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.47	-5.55	-0.33	7.46e-8	Carotid intima media thickness;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	5.45	0.33	1.25e-7	Obesity-related traits;
KIRP	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.51	-5.59	-0.34	6.06e-8	Resting heart rate;
KIRP	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg06740227	chr12:86229804	RASSF9	-0.51	-6.66	-0.39	1.76e-10	Major depressive disorder;
KIRP	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.12e-8	Life satisfaction;
KIRP	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.03	11.68	0.6	2.22e-25	Gut microbiome composition (summer);
KIRP	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.48	6.78	0.4	8.94e-11	Red blood cell count;
KIRP	cis	rs9398803	0.661	rs853985	chr6:127020173	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.44	-0.33	1.26e-7	Male-pattern baldness;
KIRP	cis	rs4954585	0.659	rs4072435	chr2:137013901	C/T	cg05194412	chr2:137003533	NA	0.56	7.66	0.44	4.14e-13	Colorectal cancer;
KIRP	cis	rs4835473	0.897	rs11100812	chr4:144711553	T/C	cg08833778	chr4:144622313	FREM3	0.34	4.91	0.3	1.67e-6	Immature fraction of reticulocytes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22975147	chr17:8021903	ALOXE3	0.65	7.81	0.45	1.69e-13	Smoking initiation;
KIRP	cis	rs755109	1.000	rs111696803	chr9:100696636	G/A	cg13688889	chr9:100608707	NA	-0.42	-4.92	-0.3	1.62e-6	Quantitative traits;
KIRP	cis	rs735860	0.572	rs186003	chr6:53185124	A/C	cg10236188	chr6:53219634	NA	0.41	5.46	0.33	1.19e-7	Glaucoma;
KIRP	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.92	-10.65	-0.56	4.91e-22	White matter hyperintensity burden;
KIRP	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg10326726	chr10:51549505	MSMB	-0.54	-7.92	-0.45	8.42e-14	Prostate-specific antigen levels;
KIRP	cis	rs26949	0.547	rs248909	chr5:59850194	A/C	cg02684056	chr5:59996105	DEPDC1B	0.47	5.37	0.32	1.84e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.5	8.74	0.49	3.76e-16	QRS complex (12-leadsum);
KIRP	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.57	-8.18	-0.46	1.54e-14	Testicular germ cell tumor;
KIRP	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.34	0.32	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05477027	chr19:46295590	DMWD	0.51	6.09	0.36	4.41e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg02709834	chr1:75198841	CRYZ;TYW3	0.42	5.33	0.32	2.18e-7	Resistin levels;
KIRP	cis	rs12643440	0.538	rs2041444	chr4:17138005	A/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3789045	0.774	rs4252733	chr1:204516918	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.21	-0.37	2.22e-9	Educational attainment (college completion);
KIRP	cis	rs981844	0.857	rs62325142	chr4:154717790	A/G	cg14289246	chr4:154710475	SFRP2	0.69	8.03	0.46	4.06e-14	Response to statins (LDL cholesterol change);
KIRP	cis	rs9473924	0.542	rs9473922	chr6:50831792	C/T	cg14470998	chr6:50812995	TFAP2B	0.83	7.68	0.44	3.65e-13	Body mass index;
KIRP	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08280861	chr8:58055591	NA	0.62	5.17	0.31	4.83e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg25281562	chr12:121454272	C12orf43	0.45	4.88	0.3	1.91e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14350958	chr8:2752736	NA	-0.38	-6.2	-0.37	2.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.63	8.39	0.47	3.88e-15	Colorectal cancer;
KIRP	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.23	0.42	6.24e-12	Bipolar disorder;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02967595	chr19:16653665	CHERP	-0.48	-6.17	-0.37	2.72e-9	Myopia;
KIRP	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg15660573	chr17:549704	VPS53	-0.84	-12.8	-0.63	4.16e-29	Prostate cancer;
KIRP	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg04865290	chr3:52927548	TMEM110	0.46	5.88	0.35	1.31e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9381107	0.505	rs9369420	chr6:9486467	A/G	cg14735645	chr6:9486422	NA	0.6	8.6	0.48	9.33e-16	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11151314	chr10:134548998	INPP5A	0.48	6.35	0.38	1.01e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg10840412	chr1:235813424	GNG4	0.68	6.11	0.36	3.96e-9	Bipolar disorder;
KIRP	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-1.07	-16.34	-0.72	3.82e-41	Cognitive function;
KIRP	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Hypertriglyceridemia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05222840	chr12:15942164	EPS8	0.49	6.1	0.36	4.18e-9	Parkinson's disease;
KIRP	cis	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg27411982	chr8:10470053	RP1L1	0.4	4.86	0.3	2.05e-6	Neuroticism;
KIRP	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg14458575	chr2:238380390	NA	0.55	5.81	0.35	1.97e-8	Prostate cancer;
KIRP	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.19	-15.3	-0.7	1.38e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg02631906	chr1:45987864	PRDX1	0.53	6.34	0.37	1.11e-9	Sleep duration;
KIRP	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.73	9.47	0.52	2.41e-18	Platelet count;
KIRP	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs42648	0.507	rs4397318	chr7:89728269	G/A	cg25739043	chr7:89950458	NA	0.35	5.27	0.32	3.01e-7	Homocysteine levels;
KIRP	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	5.34	0.32	2.06e-7	Renal cell carcinoma;
KIRP	cis	rs12049351	0.774	rs754022	chr1:229637645	C/A	cg11742688	chr1:229674241	ABCB10	-0.37	-5.7	-0.34	3.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs9831754	0.906	rs2314196	chr3:78411050	C/T	cg06138941	chr3:78371609	NA	-0.74	-10.83	-0.57	1.28e-22	Calcium levels;
KIRP	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs10924970	0.904	rs10924500	chr1:235351436	T/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.08	0.31	7.56e-7	Asthma;
KIRP	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg10760299	chr15:45669010	GATM	0.35	5.13	0.31	5.79e-7	Homoarginine levels;
KIRP	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.81	-10.32	-0.55	5.77e-21	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.03	0.41	2.05e-11	Prudent dietary pattern;
KIRP	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05903289	chr2:130345205	NA	-0.37	-4.84	-0.3	2.25e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs62413470	1.000	rs12206920	chr6:55966027	C/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	trans	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg06521331	chr12:34319734	NA	-0.5	-6.24	-0.37	1.92e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16424326	chr11:92931250	SLC36A4	-0.52	-6.34	-0.37	1.08e-9	Interleukin-4 levels;
KIRP	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg05623727	chr3:50126028	RBM5	0.35	5.3	0.32	2.61e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7715811	0.913	rs4368727	chr5:13770248	C/T	cg07548982	chr5:13769939	DNAH5	-0.55	-6.89	-0.4	4.75e-11	Subclinical atherosclerosis traits (other);
KIRP	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg06871246	chr4:1363661	KIAA1530	-0.55	-6.86	-0.4	5.46e-11	Longevity;
KIRP	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg04609801	chr16:28609176	SULT1A2	-0.56	-5.35	-0.32	2.03e-7	Platelet distribution width;
KIRP	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.39	-5.82	-0.35	1.82e-8	Ulcerative colitis;
KIRP	trans	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	5.04	0.31	8.84e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg09597638	chr17:3907349	NA	-0.74	-13.77	-0.66	2.22e-32	Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.92e-15	Aortic root size;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08280861	chr8:58055591	NA	0.6	5.11	0.31	6.37e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg13010199	chr12:38710504	ALG10B	0.65	8.56	0.48	1.27e-15	Morning vs. evening chronotype;
KIRP	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25517755	chr10:38738941	LOC399744	-0.39	-5.52	-0.33	8.6e-8	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg25233709	chr10:116636983	FAM160B1	0.34	5.16	0.31	5.07e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7771547	0.855	rs4713987	chr6:36599010	T/C	cg04289385	chr6:36355825	ETV7	0.4	5.56	0.33	7.03e-8	Platelet distribution width;
KIRP	cis	rs2191566	0.761	rs446016	chr19:44501518	A/G	cg20607764	chr19:44506953	ZNF230	-0.45	-5.16	-0.31	5.05e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3755132	0.929	rs7594193	chr2:15750640	C/T	cg12888861	chr2:15731646	DDX1	-0.42	-5.48	-0.33	1.05e-7	Wilms tumor;
KIRP	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg18477163	chr1:228402036	OBSCN	0.37	7.35	0.42	2.86e-12	Diastolic blood pressure;
KIRP	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.03	17.47	0.74	5.27e-45	Testicular germ cell tumor;
KIRP	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg16586182	chr3:47516702	SCAP	-0.74	-10.26	-0.55	8.58e-21	Colorectal cancer;
KIRP	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-7.69	-0.44	3.44e-13	Bipolar disorder;
KIRP	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.43	-5.96	-0.36	8.63e-9	Monocyte count;
KIRP	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.56	6.46	0.38	5.52e-10	Alzheimer's disease (late onset);
KIRP	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.81	-10.75	-0.57	2.34e-22	Body mass index;
KIRP	cis	rs7113874	0.802	rs7941510	chr11:8677063	C/A	cg08015107	chr11:8618950	NA	-0.43	-5.68	-0.34	3.86e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg13206674	chr6:150067644	NUP43	0.51	7.27	0.42	4.76e-12	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg21698718	chr17:80085957	CCDC57	-0.36	-5.11	-0.31	6.56e-7	Life satisfaction;
KIRP	cis	rs79478560	0.552	rs10773041	chr12:124342181	G/A	cg18594669	chr12:124364423	DNAH10	0.36	4.85	0.3	2.15e-6	Lymphocyte counts;
KIRP	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.62	8.58	0.48	1.08e-15	Bladder cancer;
KIRP	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg25547332	chr5:131281432	NA	0.47	5.15	0.31	5.31e-7	Life satisfaction;
KIRP	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.21	0.32	4.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs55692468	0.539	rs4664110	chr2:153318414	C/T	cg04681845	chr2:153283485	FMNL2	-0.53	-6.82	-0.4	7.19e-11	Intraocular pressure;
KIRP	trans	rs10819937	0.945	rs952279	chr9:104207547	T/A	cg24374857	chr1:41158439	NFYC;LOC100130557	-0.46	-6.15	-0.37	3.16e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs72772090	0.522	rs17398914	chr5:96005180	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.75	-5.2	-0.31	4.11e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.79	7.72	0.44	2.94e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2290402	0.536	rs2061846	chr4:852484	A/G	cg00846425	chr4:957561	DGKQ	-0.47	-5.24	-0.32	3.49e-7	Type 2 diabetes;
KIRP	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg06747863	chr12:118810789	TAOK3	0.53	6.67	0.39	1.7e-10	Asthma;
KIRP	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.27	-0.32	3.04e-7	Bladder cancer;
KIRP	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.64	0.73	3.72e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg18132916	chr6:79620363	NA	-0.37	-5.03	-0.31	9.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg09165964	chr15:75287851	SCAMP5	0.46	5.79	0.35	2.11e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.36	0.38	9.54e-10	Breast cancer;
KIRP	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.59	-7.01	-0.41	2.29e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.68	9.17	0.5	2e-17	Eye color traits;
KIRP	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg27462398	chr1:86174642	ZNHIT6	-0.46	-5.34	-0.32	2.1e-7	Urate levels in overweight individuals;
KIRP	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.75	-0.44	2.38e-13	Type 2 diabetes;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13671198	chr9:128524817	PBX3	0.4	6.47	0.38	5.3e-10	C-reactive protein;
KIRP	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	5.99	0.36	7.52e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.88	9.85	0.53	1.64e-19	Gut microbiome composition (summer);
KIRP	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg18964960	chr10:1102726	WDR37	-0.54	-5.72	-0.34	3.03e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg21775007	chr8:11205619	TDH	-0.48	-6.4	-0.38	7.69e-10	Triglycerides;
KIRP	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs77688320	0.553	rs12473387	chr2:202280501	A/G	cg06431681	chr2:202330990	STRADB	0.51	6.25	0.37	1.79e-9	Breast cancer;
KIRP	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg12311346	chr5:56204834	C5orf35	-0.36	-5.02	-0.31	9.74e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.39	8.29	0.47	7.54e-15	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00218146	chr15:31619396	KLF13	0.56	7.21	0.42	6.87e-12	Parkinson's disease;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.76	10.58	0.56	8.27e-22	Eye color traits;
KIRP	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.88	13.55	0.65	1.28e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	11.93	0.61	3.48e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	11.48	0.59	1.06e-24	Smoking behavior;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs72848980	0.582	rs4917391	chr10:105282664	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.46	5.31	0.32	2.43e-7	White matter hyperintensity burden;
KIRP	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg26965718	chr17:79658957	HGS	-0.61	-5.7	-0.34	3.47e-8	Dental caries;
KIRP	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.43	7.68	0.44	3.86e-13	Superior crus of antihelix expression;
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	0.93	8.51	0.48	1.73e-15	Severe influenza A (H1N1) infection;
KIRP	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.63	5.07	0.31	7.9e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9635324	0.516	rs7165012	chr15:40654038	C/T	cg08996748	chr15:40651036	DISP2	0.35	5.1	0.31	6.69e-7	Blood metabolite ratios;Blood metabolite levels;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs860295	0.702	rs12047756	chr1:155624944	G/A	cg02153340	chr1:155202674	NA	-0.51	-6.91	-0.4	4.08e-11	Body mass index;
KIRP	cis	rs6496667	0.908	rs11856966	chr15:90857411	G/A	cg10434728	chr15:90938212	IQGAP1	0.4	5.46	0.33	1.13e-7	Rheumatoid arthritis;
KIRP	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg05347473	chr6:146136440	FBXO30	0.63	8.97	0.5	7.54e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg14092571	chr14:90743983	NA	0.41	4.98	0.3	1.19e-6	Mortality in heart failure;
KIRP	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg21858823	chr1:15850916	CASP9	0.53	5.66	0.34	4.11e-8	Systolic blood pressure;
KIRP	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-7.1	-0.41	1.36e-11	Coronary artery disease;
KIRP	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg08461772	chr7:95026248	PON3	0.42	6.09	0.36	4.38e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27094166	chr5:148931083	CSNK1A1	0.47	6.04	0.36	5.7e-9	Parkinson's disease;
KIRP	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12292205	chr6:26970375	C6orf41	0.59	6.55	0.39	3.35e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	1.16	14.94	0.69	2.34e-36	Response to hepatitis C treatment;
KIRP	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.38	7.65	0.44	4.55e-13	Diastolic blood pressure;
KIRP	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-0.79	-12.62	-0.63	1.68e-28	Prudent dietary pattern;
KIRP	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg08975724	chr8:8085496	FLJ10661	0.56	6.99	0.41	2.64e-11	Mood instability;
KIRP	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.94	-16.19	-0.72	1.29e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs918629	0.530	rs10070197	chr5:95241868	T/C	cg16656078	chr5:95278638	ELL2	-0.35	-5.35	-0.32	1.98e-7	IgG glycosylation;
KIRP	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.43	5.02	0.3	9.97e-7	Aortic root size;
KIRP	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.51	-5.33	-0.32	2.2e-7	Lymphocyte counts;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15323937	chr11:64599019	CDC42BPG	0.48	6.31	0.37	1.31e-9	Pancreatic cancer;
KIRP	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg22508957	chr16:3507546	NAT15	0.58	7.19	0.42	7.67e-12	Tuberculosis;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.91	0.53	1.06e-19	Longevity;
KIRP	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.84	9.95	0.54	8.16e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4073416	0.542	rs11158603	chr14:66072040	C/T	cg03016385	chr14:66212404	NA	-0.56	-6.8	-0.4	7.99e-11	N-glycan levels;
KIRP	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.42	-7.28	-0.42	4.48e-12	Heart rate;
KIRP	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.41	5.85	0.35	1.52e-8	Endometrial cancer;
KIRP	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.39	0.38	8.33e-10	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	10.32	0.55	5.58e-21	Cognitive test performance;
KIRP	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.51	-5.84	-0.35	1.63e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg04202892	chr2:111875749	ACOXL	0.5	6.91	0.4	4.13e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs3815308	0.530	rs12983546	chr19:2195065	G/T	cg09261902	chr19:2140048	AP3D1	0.58	8.36	0.47	4.7e-15	Breast cancer;
KIRP	cis	rs6005807	0.582	rs8136767	chr22:29008626	G/A	cg12565055	chr22:29076175	TTC28	0.61	5.24	0.32	3.5e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.43	-5.65	-0.34	4.51e-8	Menarche (age at onset);
KIRP	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg25566285	chr7:158114605	PTPRN2	0.78	12.64	0.63	1.45e-28	Calcium levels;
KIRP	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg24315340	chr6:146058215	EPM2A	0.41	5.15	0.31	5.45e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.68	0.34	3.73e-8	Coronary artery disease;
KIRP	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.93	12.1	0.61	9.14e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	4.99	0.3	1.15e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2908197	0.713	rs2961038	chr7:75952070	G/C	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.3	-5.0	-0.3	1.09e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs2281603	0.570	rs9323451	chr14:64971749	G/A	cg01860774	chr14:64969374	ZBTB25	0.35	5.65	0.34	4.35e-8	Lymphocyte counts;
KIRP	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg15488143	chr7:128924101	AHCYL2	0.61	6.74	0.39	1.11e-10	White matter hyperintensity burden;
KIRP	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg02503808	chr4:7069936	GRPEL1	-0.83	-10.55	-0.56	1.06e-21	Monocyte percentage of white cells;
KIRP	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg01403660	chr11:68851641	TPCN2	0.67	7.58	0.44	6.92e-13	Blond vs. brown hair color;
KIRP	cis	rs5771242	0.845	rs2295225	chr22:50618797	C/G	cg16473166	chr22:50639996	SELO	0.7	7.17	0.42	8.57e-12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	cis	rs11191205	0.685	rs1374471	chr10:103659601	C/A	cg15320455	chr10:103880129	LDB1	0.67	5.29	0.32	2.66e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.85	-11.85	-0.6	6.43e-26	Coronary artery disease;
KIRP	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26306683	chr17:18585705	ZNF286B	-0.53	-6.58	-0.39	2.88e-10	Educational attainment (years of education);
KIRP	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg27205649	chr11:78285834	NARS2	0.81	11.58	0.59	4.88e-25	Alzheimer's disease (survival time);
KIRP	cis	rs2976388	0.935	rs2920285	chr8:143756218	G/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.53	-0.38	3.83e-10	Urinary tract infection frequency;
KIRP	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg23985595	chr17:80112537	CCDC57	0.39	5.93	0.35	1.03e-8	Life satisfaction;
KIRP	cis	rs1816854	0.938	rs7966902	chr12:44200485	A/C	cg20956634	chr12:44200518	TWF1	0.52	5.56	0.33	6.99e-8	Inflammatory bowel disease;
KIRP	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.56	-6.88	-0.4	4.94e-11	Corneal curvature;
KIRP	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.53	-5.89	-0.35	1.27e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.07	0.46	3.17e-14	Retinal vascular caliber;
KIRP	trans	rs972578	0.765	rs7073	chr22:43266363	C/T	cg15321293	chr3:36422198	STAC	-0.48	-6.24	-0.37	1.94e-9	Mean platelet volume;
KIRP	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg27398547	chr14:60952738	C14orf39	-0.66	-5.78	-0.35	2.25e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg26513180	chr16:89883248	FANCA	0.88	14.66	0.68	2.18e-35	Vitiligo;
KIRP	cis	rs202011557	1	rs202011557	chr2:102913642	A/AAAAC	cg22835712	chr2:102737379	NA	0.43	4.91	0.3	1.67e-6	Asthma;
KIRP	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.37	0.59	2.42e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10053473	chr17:62856997	LRRC37A3	0.69	7.21	0.42	6.95e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs13132184	0.507	rs4832748	chr4:38056045	C/T	cg19090437	chr4:38080799	TBC1D1	0.5	4.95	0.3	1.38e-6	Verbal declarative memory;
KIRP	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-8.4	-0.47	3.66e-15	Coronary artery disease;
KIRP	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg09165964	chr15:75287851	SCAMP5	-0.36	-4.84	-0.3	2.25e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-1.03	-13.12	-0.64	3.6e-30	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.23	-0.46	1.12e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.98	13.38	0.65	4.78e-31	Vitamin D levels;
KIRP	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg19610905	chr11:61596333	FADS2	-0.56	-8.5	-0.48	1.84e-15	Trans fatty acid levels;
KIRP	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg25650185	chr19:21324782	ZNF431	0.47	4.87	0.3	1.99e-6	Pain;
KIRP	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg14456004	chr13:21872349	NA	-1.11	-13.81	-0.66	1.62e-32	White matter hyperintensity burden;
KIRP	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.46	0.38	5.56e-10	Bipolar disorder;
KIRP	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	1.01	16.06	0.72	3.4e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.5	5.35	0.32	2.04e-7	Alzheimer's disease;
KIRP	cis	rs2073300	1.000	rs6048810	chr20:23446429	G/A	cg12062639	chr20:23401060	NAPB	0.8	6.97	0.41	2.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2554380	0.628	rs919069	chr15:84444528	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.34	-5.05	-0.31	8.69e-7	Height;
KIRP	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg06115741	chr20:33292138	TP53INP2	-0.38	-5.14	-0.31	5.66e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9810890	1.000	rs73198856	chr3:128513001	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs523522	0.602	rs7970933	chr12:120862474	G/A	cg12219531	chr12:120966889	COQ5	0.57	5.49	0.33	1.02e-7	High light scatter reticulocyte count;
KIRP	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.62	8.2	0.46	1.32e-14	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19398112	chr19:14529923	DDX39	0.47	6.73	0.39	1.18e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs732716	0.785	rs9973266	chr19:4392715	G/A	cg21720385	chr19:4455239	UBXN6	0.71	8.6	0.48	9.56e-16	Mean corpuscular volume;
KIRP	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.35	19.06	0.77	2.43e-50	Corneal structure;
KIRP	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	7.98	0.45	5.5e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18357526	chr6:26021779	HIST1H4A	0.53	6.78	0.4	9.03e-11	Height;
KIRP	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.53	-0.38	3.67e-10	Educational attainment;
KIRP	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.85e-6	Parkinson's disease;
KIRP	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg05973401	chr12:123451056	ABCB9	0.63	6.75	0.4	1.08e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg18501202	chr6:125855421	NA	-0.32	-4.92	-0.3	1.56e-6	Brugada syndrome;
KIRP	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.85	16.3	0.72	5.4e-41	Anterior chamber depth;
KIRP	cis	rs8067545	0.532	rs4925074	chr17:19962554	C/T	cg13482628	chr17:19912719	NA	0.46	5.16	0.31	5.01e-7	Schizophrenia;
KIRP	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.79	12.72	0.63	7.88e-29	Blood metabolite levels;
KIRP	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.05	-13.37	-0.65	5.12e-31	Exhaled nitric oxide output;
KIRP	cis	rs1978968	1.000	rs5992922	chr22:18445287	A/G	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.37	0.65	5.08e-31	Personality dimensions;
KIRP	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	9.03	0.5	5.17e-17	Bone mineral density;
KIRP	trans	rs553086	0.941	rs7117365	chr11:56738678	A/G	cg25055403	chr14:24701388	NEDD8;GMPR2	0.55	6.55	0.39	3.3e-10	Fear of severe pain;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg11204139	chr17:3907470	NA	-0.81	-15.0	-0.69	1.48e-36	Type 2 diabetes;
KIRP	cis	rs4664293	0.902	rs13391919	chr2:160560160	T/C	cg08347373	chr2:160653686	CD302	-0.39	-5.95	-0.35	9.19e-9	Monocyte percentage of white cells;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.4	-0.33	1.55e-7	Obesity-related traits;
KIRP	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.79	7.31	0.42	3.65e-12	Mean platelet volume;
KIRP	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12631819	chr5:38953624	RICTOR	-0.39	-6.09	-0.36	4.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7845219	0.544	rs10956932	chr8:95948202	C/T	cg13393036	chr8:95962371	TP53INP1	0.3	5.83	0.35	1.78e-8	Type 2 diabetes;
KIRP	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg25811766	chr13:21894605	NA	-0.6	-5.93	-0.35	1.01e-8	White matter hyperintensity burden;
KIRP	cis	rs2278796	0.608	rs6700188	chr1:204969066	A/G	cg04862289	chr1:204966208	NFASC	0.67	9.47	0.52	2.48e-18	Mean platelet volume;
KIRP	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs3105593	1.000	rs11636964	chr15:50899616	A/G	cg05456662	chr15:50716270	USP8	0.41	5.04	0.31	8.84e-7	QT interval;
KIRP	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.52	-5.79	-0.35	2.15e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4356932	1.000	rs6820370	chr4:76952278	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.62e-9	Blood protein levels;
KIRP	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	1.35	10.84	0.57	1.19e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg02336718	chr17:17403227	NA	0.36	5.46	0.33	1.13e-7	Total body bone mineral density;
KIRP	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg14972814	chr11:95582409	MTMR2	0.33	4.98	0.3	1.21e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.03	14.28	0.67	4.37e-34	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg02725872	chr8:58115012	NA	-0.55	-6.35	-0.38	1.05e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.78	-11.76	-0.6	1.21e-25	Systemic lupus erythematosus;
KIRP	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-6.8	-0.4	7.85e-11	Response to antipsychotic treatment;
KIRP	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.59	9.79	0.53	2.56e-19	Schizophrenia;
KIRP	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-8.4	-0.47	3.52e-15	Response to antipsychotic treatment;
KIRP	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg00277334	chr10:82204260	NA	-0.44	-4.87	-0.3	1.99e-6	Post bronchodilator FEV1;
KIRP	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.25	6.79	0.4	8.5e-11	Crohn's disease;
KIRP	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	9.42	0.51	3.44e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg01677386	chr11:118938358	VPS11	-0.47	-5.11	-0.31	6.54e-7	Coronary artery disease;
KIRP	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg07972983	chr1:205091412	RBBP5	0.43	5.1	0.31	6.71e-7	Red blood cell count;
KIRP	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.72	-8.86	-0.49	1.59e-16	Cognitive function;
KIRP	cis	rs9318086	0.534	rs7996675	chr13:24373930	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.41	-4.95	-0.3	1.4e-6	Myopia (pathological);
KIRP	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.64	9.72	0.53	4.29e-19	Dupuytren's disease;
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg16590910	chr6:42928470	GNMT	0.38	5.21	0.32	3.9e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.95	14.17	0.67	9.68e-34	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	8.91	0.49	1.14e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.96	13.06	0.64	5.63e-30	Menopause (age at onset);
KIRP	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg19847130	chr8:10466454	RP1L1	0.36	5.27	0.32	3.05e-7	Systolic blood pressure;
KIRP	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg03563238	chr19:33554763	RHPN2	0.33	6.12	0.36	3.6e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg03834567	chr2:218808745	TNS1	0.39	4.95	0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.6	-7.75	-0.44	2.47e-13	Retinal vascular caliber;
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg03115019	chr17:80708279	FN3K	-0.43	-5.11	-0.31	6.34e-7	Glycated hemoglobin levels;
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.55	7.14	0.41	1.02e-11	Menarche (age at onset);
KIRP	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg16586182	chr3:47516702	SCAP	0.83	11.63	0.6	3.39e-25	Colorectal cancer;
KIRP	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg18190219	chr22:46762943	CELSR1	-0.93	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.92	-8.56	-0.48	1.21e-15	Rheumatoid arthritis;
KIRP	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg00601450	chr5:74908170	NA	-0.41	-4.92	-0.3	1.55e-6	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
KIRP	cis	rs7833787	1.000	rs7002237	chr8:18704514	A/G	cg17701159	chr8:18705777	PSD3	0.38	7.37	0.43	2.64e-12	Obesity-related traits;
KIRP	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.48	6.09	0.36	4.32e-9	Motion sickness;
KIRP	trans	rs9650657	0.648	rs6601512	chr8:10585596	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.48	-0.38	4.96e-10	Neuroticism;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09373786	chr8:93156639	NA	0.42	6.69	0.39	1.46e-10	Cancer;
KIRP	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.71	-9.99	-0.54	6.06e-20	Blood metabolite levels;
KIRP	cis	rs258892	0.895	rs10065972	chr5:72044091	A/G	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg06121193	chr1:90282411	NA	-0.47	-6.79	-0.4	8.27e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2051773	0.567	rs12794156	chr11:17063005	G/C	cg15432903	chr11:17409602	KCNJ11	-0.53	-6.13	-0.36	3.41e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.61	6.65	0.39	1.83e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg05721485	chr17:44071124	MAPT	-0.55	-7.64	-0.44	4.82e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11072804	1	rs11072804	chr15:79078486	T/G	cg04896959	chr15:78267971	NA	0.52	6.81	0.4	7.57e-11	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6882046	0.513	rs194225	chr5:88001186	A/G	cg22951263	chr5:87985283	NA	-0.48	-6.83	-0.4	6.58e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs735539	0.598	rs2149769	chr13:21266227	C/T	cg02792322	chr13:21280448	IL17D	0.31	4.89	0.3	1.8e-6	Dental caries;
KIRP	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg17145862	chr1:211918768	LPGAT1	-0.91	-13.07	-0.64	5.55e-30	Leprosy;
KIRP	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.59	9.7	0.53	4.81e-19	Schizophrenia;
KIRP	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg22535103	chr8:58192502	C8orf71	-0.86	-8.21	-0.46	1.25e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.8	-9.0	-0.5	6.27e-17	Bipolar disorder;
KIRP	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg13647721	chr17:30228624	UTP6	0.53	5.07	0.31	7.96e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.49	0.38	4.82e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.75	-11.08	-0.58	2.06e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00321850	chr1:175162397	KIAA0040	-0.35	-6.2	-0.37	2.35e-9	Alcohol dependence;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.66	-0.44	4.26e-13	Life satisfaction;
KIRP	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg07701084	chr6:150067640	NUP43	0.61	7.95	0.45	6.88e-14	Lung cancer;
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.6	-8.16	-0.46	1.71e-14	Glycated hemoglobin levels;
KIRP	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.94	15.07	0.69	8.18e-37	Coronary artery disease;
KIRP	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg08280861	chr8:58055591	NA	0.68	6.25	0.37	1.76e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	trans	rs17079247	0.841	rs9602701	chr13:85810155	A/T	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs6120849	0.707	rs3746448	chr20:33572979	C/T	cg24642439	chr20:33292090	TP53INP2	0.6	5.61	0.34	5.47e-8	Protein C levels;
KIRP	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg01334186	chr1:151372572	PSMB4	-0.46	-6.12	-0.36	3.64e-9	Neuroticism;
KIRP	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.87	-0.35	1.39e-8	Breast cancer;
KIRP	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.6	-0.44	6.35e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs7538876	1.000	rs4920603	chr1:17727379	C/G	cg07965774	chr1:17746286	RCC2	-0.28	-4.99	-0.3	1.12e-6	Basal cell carcinoma;
KIRP	cis	rs9814567	0.555	rs1498726	chr3:134167300	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	9.27	0.51	9.72e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2120243	0.539	rs9878474	chr3:157123147	A/G	cg24825693	chr3:157122686	VEPH1	0.56	9.69	0.53	5.1e-19	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.16	-0.5	2.17e-17	Triglycerides;
KIRP	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg19847130	chr8:10466454	RP1L1	-0.43	-6.22	-0.37	2.16e-9	Retinal vascular caliber;
KIRP	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.43	0.43	1.75e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg00405596	chr8:11794950	NA	0.56	7.85	0.45	1.25e-13	Monocyte count;
KIRP	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg18306943	chr3:40428807	ENTPD3	0.45	5.91	0.35	1.12e-8	Renal cell carcinoma;
KIRP	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.95	-0.3	1.4e-6	Blood metabolite levels;
KIRP	trans	rs12517041	0.671	rs13160333	chr5:23272168	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.52	-6.62	-0.39	2.21e-10	Calcium levels;
KIRP	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.64	0.66	6.25e-32	Electrocardiographic conduction measures;
KIRP	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.33	-0.37	1.16e-9	Arsenic metabolism;
KIRP	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00889227	chr1:205173544	DSTYK	-0.38	-5.45	-0.33	1.25e-7	Red blood cell count;
KIRP	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.96	8.05	0.46	3.49e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7939886	0.920	rs4612826	chr11:55948005	C/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.37	5.78	0.35	2.21e-8	Multiple sclerosis;
KIRP	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.74	-8.89	-0.49	1.37e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.69	8.34	0.47	5.17e-15	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22042996	chr8:15400485	TUSC3	-0.41	-6.21	-0.37	2.24e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.57	-6.41	-0.38	7.18e-10	Blood metabolite levels;
KIRP	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.7	-10.24	-0.55	9.72e-21	Bladder cancer;
KIRP	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg06740227	chr12:86229804	RASSF9	-0.41	-5.25	-0.32	3.34e-7	Major depressive disorder;
KIRP	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.7	10.97	0.57	4.65e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg18833306	chr6:118973337	C6orf204	-0.48	-4.86	-0.3	2.13e-6	Diastolic blood pressure;
KIRP	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.68	0.85	1.49e-71	Chronic sinus infection;
KIRP	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.59e-15	Mortality in heart failure;
KIRP	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	1.06	18.8	0.77	1.68e-49	Gut microbiome composition (winter);
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.51	-6.57	-0.39	3.06e-10	Testicular germ cell tumor;
KIRP	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.75	12.0	0.61	1.96e-26	Vitiligo;
KIRP	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.49	-5.12	-0.31	6.07e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs494562	0.667	rs693077	chr6:86102437	C/T	cg21730993	chr6:86159210	NT5E	0.6	5.84	0.35	1.67e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.69	-0.48	5.26e-16	Alzheimer's disease;
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg12486944	chr17:80159399	CCDC57	0.38	5.11	0.31	6.4e-7	Life satisfaction;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg16034541	chr3:195490309	MUC4	-0.59	-5.51	-0.33	9.25e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.11e-32	Monocyte count;
KIRP	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg18836844	chr8:998428	NA	0.38	4.84	0.3	2.25e-6	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19917639	chr1:175128381	KIAA0040	0.48	6.31	0.37	1.28e-9	Interleukin-4 levels;
KIRP	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.98	14.09	0.67	1.9e-33	Platelet distribution width;
KIRP	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.74	-9.73	-0.53	3.97e-19	Type 2 diabetes;
KIRP	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	1.04	20.25	0.79	2.6e-54	Breast cancer;
KIRP	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	10.55	0.56	1.06e-21	Exhaled nitric oxide levels;
KIRP	trans	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg06521331	chr12:34319734	NA	-0.51	-6.27	-0.37	1.57e-9	Bladder cancer;
KIRP	trans	rs1941687	0.831	rs1353168	chr18:31359762	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-7.06	-0.41	1.71e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg06636001	chr8:8085503	FLJ10661	0.72	9.99	0.54	5.88e-20	Mood instability;
KIRP	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18357526	chr6:26021779	HIST1H4A	0.5	6.58	0.39	2.8e-10	Iron status biomarkers;
KIRP	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.48	-0.52	2.27e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs12476592	0.602	rs1356390	chr2:63669625	C/T	cg17519650	chr2:63277830	OTX1	0.45	4.99	0.3	1.12e-6	Childhood ear infection;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg17933722	chr1:116711077	NA	0.45	6.54	0.38	3.49e-10	Educational attainment;
KIRP	cis	rs9393813	0.529	rs12526864	chr6:27456242	C/T	cg03332623	chr6:27441972	ZNF184	0.37	5.2	0.31	4.2e-7	Bipolar disorder;
KIRP	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg03808351	chr9:123631620	PHF19	-0.4	-4.96	-0.3	1.31e-6	Birth weight;
KIRP	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg15128208	chr22:42549153	NA	0.72	8.02	0.46	4.17e-14	Birth weight;
KIRP	cis	rs60311166	1.000	rs60823713	chr3:52573101	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.9	5.55	0.33	7.28e-8	CTACK levels;
KIRP	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	16.01	0.71	5.02e-40	Platelet count;
KIRP	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	5.28	0.32	2.81e-7	Myopia (pathological);
KIRP	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.88	0.4	4.84e-11	Electroencephalogram traits;
KIRP	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.73	-7.98	-0.45	5.56e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg23307798	chr14:103986281	CKB	0.48	6.74	0.39	1.15e-10	Body mass index;
KIRP	cis	rs6942756	0.876	rs57263220	chr7:129010858	C/A	cg15488143	chr7:128924101	AHCYL2	0.44	5.01	0.3	1.06e-6	White matter hyperintensity burden;
KIRP	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg10223061	chr2:219282414	VIL1	0.43	7.0	0.41	2.43e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs16857609	1.000	rs12990503	chr2:218294217	C/G	cg15335768	chr2:218268053	DIRC3	0.34	5.02	0.3	1e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	1.1	9.97	0.54	6.83e-20	Lymphocyte counts;
KIRP	cis	rs76533333	1.000	rs76533333	chr13:113352916	A/G	cg21786786	chr13:113365464	ATP11A	-0.59	-5.0	-0.3	1.09e-6	Red cell distribution width;
KIRP	cis	rs9596863	0.851	rs4632022	chr13:54379457	C/T	ch.13.53330881F	chr13:54432880	NA	0.62	6.09	0.36	4.22e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9326248	0.861	rs4938343	chr11:117003528	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.51	4.93	0.3	1.5e-6	Blood protein levels;
KIRP	trans	rs9944715	1.000	rs9951624	chr18:43840829	A/G	cg01718231	chr17:29326311	RNF135	-0.52	-6.21	-0.37	2.25e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg21724239	chr8:58056113	NA	0.51	4.9	0.3	1.76e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.81	-0.66	1.62e-32	Tonsillectomy;
KIRP	cis	rs9290877	0.667	rs17615154	chr3:188450757	A/G	cg17392043	chr3:188495102	LPP	-0.51	-6.22	-0.37	2.1e-9	IgE levels;
KIRP	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg12963866	chr19:57752005	ZNF805	-0.49	-6.15	-0.36	3.19e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg07167872	chr1:205819463	PM20D1	0.46	5.17	0.31	4.82e-7	Prostate-specific antigen levels;
KIRP	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.48	-5.86	-0.35	1.46e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23903597	chr17:61704154	MAP3K3	0.66	8.67	0.48	5.98e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg12705353	chr12:122356852	WDR66	0.53	7.12	0.41	1.18e-11	Mean corpuscular volume;
KIRP	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.73	10.42	0.55	2.66e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.06	20.06	0.79	1.06e-53	Testicular germ cell tumor;
KIRP	cis	rs2554380	0.800	rs2562768	chr15:84382953	C/T	cg14598478	chr15:84363061	ADAMTSL3	0.5	7.2	0.42	7.09e-12	Height;
KIRP	cis	rs960902	0.648	rs11124584	chr2:37711857	C/T	cg25341268	chr2:37734390	NA	0.53	6.84	0.4	6.09e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs35883536	1.000	rs4908087	chr1:101088594	C/T	cg06223162	chr1:101003688	GPR88	0.32	6.48	0.38	4.87e-10	Monocyte count;
KIRP	cis	rs3743266	0.507	rs10162677	chr15:60748568	C/T	cg22293140	chr15:60689852	ANXA2	-0.63	-5.74	-0.34	2.81e-8	Menarche (age at onset);
KIRP	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.68	-8.55	-0.48	1.32e-15	Body mass index;
KIRP	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.52	-0.48	1.62e-15	Blood trace element (Zn levels);
KIRP	cis	rs7923609	0.934	rs2893919	chr10:65134778	G/A	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.55	-0.33	7.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17776563	0.959	rs28687418	chr15:89115862	G/A	cg05013243	chr15:89149849	MIR1179	0.41	4.92	0.3	1.59e-6	Thyroid hormone levels;
KIRP	cis	rs13132184	0.507	rs13118113	chr4:38035396	A/G	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.19	-0.31	4.41e-7	Verbal declarative memory;
KIRP	cis	rs80207740	0.941	rs2076940	chr8:21836020	A/G	cg17168535	chr8:21777572	XPO7	0.76	6.9	0.4	4.46e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs2055729	0.591	rs6987670	chr8:9883177	C/T	cg21625330	chr8:9911636	MSRA	-0.46	-5.76	-0.34	2.52e-8	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	1.09	7.88	0.45	1.04e-13	Skin colour saturation;
KIRP	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-5.98	-0.36	7.88e-9	Lung cancer;
KIRP	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.18	-0.42	8.45e-12	Aortic root size;
KIRP	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.61	-0.39	2.31e-10	Glomerular filtration rate;
KIRP	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.36	-8.22	-0.46	1.21e-14	Cutaneous nevi;
KIRP	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	0.96	18.34	0.76	6.33e-48	Dental caries;
KIRP	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg03060546	chr3:49711283	APEH	-0.58	-5.08	-0.31	7.36e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.73	-0.44	2.67e-13	Height;
KIRP	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	6.38	0.38	8.93e-10	Personality dimensions;
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg16060761	chr17:80687452	NA	-0.51	-6.6	-0.39	2.45e-10	Glycated hemoglobin levels;
KIRP	cis	rs7130144	0.541	rs7941653	chr11:130460365	C/A	cg26307797	chr11:130446613	NA	-0.63	-5.2	-0.31	4.19e-7	Urate levels in lean individuals;
KIRP	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.51	-7.42	-0.43	1.86e-12	Daytime sleep phenotypes;
KIRP	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg11168104	chr5:1857477	NA	-0.4	-5.05	-0.31	8.46e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg00383909	chr3:49044727	WDR6	0.66	6.0	0.36	6.97e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7252505	0.892	rs12463087	chr19:33606692	C/T	cg17764715	chr19:33622953	WDR88	0.7	5.93	0.35	1.03e-8	Colorectal cancer;
KIRP	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.25	-0.42	5.38e-12	Response to antipsychotic treatment;
KIRP	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1978968	0.871	rs5746498	chr22:18435794	C/T	cg03078520	chr22:18463400	MICAL3	0.5	6.05	0.36	5.44e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg00792783	chr2:198669748	PLCL1	0.45	5.05	0.31	8.78e-7	Intracranial aneurysm;
KIRP	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.3	-0.37	1.38e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.7	10.62	0.56	6.1e-22	Chronic obstructive pulmonary disease;
KIRP	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg19468946	chr17:37922297	IKZF3	0.44	6.38	0.38	8.49e-10	Self-reported allergy;
KIRP	cis	rs2591576	0.681	rs7724232	chr5:165421642	T/A	cg13976338	chr5:165423657	NA	-0.88	-13.95	-0.66	5.79e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg18016565	chr1:150552671	MCL1	0.38	5.82	0.35	1.85e-8	Melanoma;
KIRP	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg10326726	chr10:51549505	MSMB	0.61	8.74	0.49	3.73e-16	Prostate-specific antigen levels;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg12950624	chr19:46000154	RTN2	0.51	6.25	0.37	1.76e-9	Electroencephalogram traits;
KIRP	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	1.06	9.99	0.54	6.12e-20	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.75	-9.69	-0.53	5.15e-19	Coronary artery disease;
KIRP	cis	rs2120243	0.539	rs1545596	chr3:157118526	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg07701084	chr6:150067640	NUP43	0.68	9.4	0.51	3.96e-18	Lung cancer;
KIRP	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.66	5.61	0.34	5.49e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7808935	0.768	rs739704	chr7:27989768	G/A	cg05786569	chr7:27702416	HIBADH	0.52	5.46	0.33	1.16e-7	Prostate cancer;
KIRP	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4713118	0.662	rs469228	chr6:27970704	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.45	-4.99	-0.3	1.12e-6	Parkinson's disease;
KIRP	cis	rs7656342	0.636	rs10012880	chr4:9835480	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.43	-0.33	1.33e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg18404041	chr3:52824283	ITIH1	0.45	5.83	0.35	1.73e-8	Schizophrenia;
KIRP	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg08999081	chr20:33150536	PIGU	-0.41	-5.34	-0.32	2.11e-7	Height;
KIRP	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg13180566	chr4:1052158	NA	-0.54	-5.46	-0.33	1.19e-7	Recombination rate (females);
KIRP	cis	rs6563943	0.963	rs78221356	chr16:83631303	G/A	cg01935413	chr16:83636749	CDH13	0.41	5.69	0.34	3.61e-8	Height;
KIRP	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs8014252	0.803	rs12588723	chr14:70984951	C/T	cg11204974	chr14:71022665	NA	0.76	7.22	0.42	6.38e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg03388025	chr16:89894329	SPIRE2	0.31	5.35	0.32	1.98e-7	Vitiligo;
KIRP	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg23950597	chr19:37808831	NA	-0.64	-6.6	-0.39	2.55e-10	Coronary artery calcification;
KIRP	cis	rs745080	0.674	rs10129727	chr14:52938757	G/A	cg23333723	chr14:53022898	GPR137C	-0.4	-5.51	-0.33	9.02e-8	Orofacial clefts;
KIRP	cis	rs12580194	0.593	rs61956269	chr12:55768023	C/T	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg07423050	chr13:99094983	FARP1	0.31	5.19	0.31	4.42e-7	Longevity;
KIRP	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg26441486	chr22:50317300	CRELD2	0.44	5.05	0.31	8.76e-7	Mean platelet volume;
KIRP	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.74	6.94	0.4	3.44e-11	Pulse pressure;
KIRP	cis	rs10875746	0.855	rs2269936	chr12:48425235	G/A	cg26205652	chr12:48591994	NA	0.77	10.38	0.55	3.71e-21	Longevity (90 years and older);
KIRP	cis	rs7614311	1.000	rs2637983	chr3:63821632	G/A	cg22134162	chr3:63841271	THOC7	-0.33	-5.24	-0.32	3.45e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg07157834	chr1:205819609	PM20D1	0.5	5.33	0.32	2.21e-7	Parkinson's disease;
KIRP	cis	rs6504340	0.739	rs66459980	chr17:46672716	C/T	cg05487507	chr17:46671861	LOC404266;HOXB5	0.61	7.14	0.41	1.02e-11	Primary tooth development (number of teeth);
KIRP	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.4	-5.14	-0.31	5.56e-7	Parkinson's disease;
KIRP	cis	rs741702	0.890	rs2967897	chr19:13031210	T/C	cg11738485	chr19:12877000	HOOK2	0.44	5.39	0.32	1.69e-7	Red blood cell traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22721468	chr1:249120642	SH3BP5L	0.49	6.43	0.38	6.53e-10	Parkinson's disease;
KIRP	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.17	0.42	9e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7760949	0.963	rs9349840	chr6:13903809	G/A	cg27413430	chr6:13925136	RNF182	0.41	5.34	0.32	2.09e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg25019033	chr10:957182	NA	-0.71	-9.32	-0.51	6.92e-18	Eosinophil percentage of granulocytes;
KIRP	cis	rs7534824	0.583	rs6577225	chr1:101506126	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	7.34	0.42	3.15e-12	Refractive astigmatism;
KIRP	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg25664220	chr3:72788482	NA	-0.33	-4.95	-0.3	1.4e-6	Motion sickness;
KIRP	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg14580859	chr9:123691850	NA	0.35	5.06	0.31	8.21e-7	Rheumatoid arthritis;
KIRP	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg13293535	chr8:11597251	GATA4	-0.41	-5.31	-0.32	2.51e-7	Retinal vascular caliber;
KIRP	cis	rs4671400	0.571	rs28480287	chr2:61489289	G/C	cg15711740	chr2:61764176	XPO1	0.63	6.84	0.4	6.31e-11	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.89	-12.93	-0.64	1.63e-29	Tonsillectomy;
KIRP	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.88	12.39	0.62	1.01e-27	Primary sclerosing cholangitis;
KIRP	cis	rs10858047	0.883	rs975446	chr1:115187361	C/A	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.88	-12.85	-0.63	3.03e-29	Height;
KIRP	cis	rs7539409	0.651	rs6576953	chr1:84316946	A/G	cg10977910	chr1:84465055	TTLL7	0.6	5.53	0.33	8.04e-8	Alzheimer's disease;
KIRP	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.31	-0.32	2.39e-7	Breast cancer;
KIRP	cis	rs9815354	1.000	rs6789260	chr3:41776350	G/C	cg03022575	chr3:42003672	ULK4	0.65	6.77	0.4	9.28e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg02733842	chr7:1102375	C7orf50	0.57	5.87	0.35	1.42e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs362296	0.671	rs3135173	chr4:3257373	T/C	cg06533319	chr4:3265114	C4orf44	0.59	7.41	0.43	2.04e-12	Parental longevity (mother's age at death);
KIRP	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-8.3	-0.47	6.84e-15	Educational attainment;
KIRP	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	12.2	0.61	4.53e-27	Monocyte percentage of white cells;
KIRP	cis	rs12496230	0.514	rs6801039	chr3:66838986	C/T	cg17646820	chr3:66848679	NA	-0.29	-4.89	-0.3	1.8e-6	Type 2 diabetes;
KIRP	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26617929	chr16:1858877	NA	-0.64	-5.51	-0.33	9.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-10.28	-0.55	7.45e-21	Morning vs. evening chronotype;
KIRP	cis	rs9326248	0.590	rs2542063	chr11:116684767	C/T	cg16524733	chr11:117070046	TAGLN	0.38	4.88	0.3	1.95e-6	Blood protein levels;
KIRP	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.21	5.63	0.34	4.91e-8	Mean corpuscular volume;
KIRP	cis	rs8093481	1.000	rs9944796	chr18:10693839	T/C	cg21165219	chr18:10698044	FAM38B	-0.44	-5.43	-0.33	1.38e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.5	-6.31	-0.37	1.29e-9	Prudent dietary pattern;
KIRP	cis	rs1620921	0.934	rs1740432	chr6:161210470	A/G	cg01280913	chr6:161186852	NA	-0.39	-5.31	-0.32	2.47e-7	Lipoprotein (a) - cholesterol levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09254361	chr3:52008107	ABHD14B;ABHD14A	0.46	6.36	0.38	9.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg05156742	chr15:59063176	FAM63B	0.58	7.16	0.42	9.06e-12	Schizophrenia;
KIRP	cis	rs3935685	0.874	rs4334265	chr15:78007432	T/C	cg25212270	chr15:78015279	NA	0.59	7.92	0.45	7.99e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg06671706	chr8:8559999	CLDN23	0.47	5.65	0.34	4.48e-8	Obesity-related traits;
KIRP	cis	rs988913	0.957	rs7746965	chr6:54844432	G/T	cg03513858	chr6:54763001	FAM83B	-0.37	-5.36	-0.32	1.93e-7	Menarche (age at onset);
KIRP	cis	rs13067260	0.655	rs6788166	chr3:123718686	G/T	cg19918027	chr3:123987645	KALRN	-0.61	-5.52	-0.33	8.6e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4638749	0.501	rs6733637	chr2:108804564	A/G	cg06795125	chr2:108905320	SULT1C2	-0.32	-5.97	-0.36	8.09e-9	Blood pressure;
KIRP	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	cg04338863	chr8:33670619	NA	0.48	6.3	0.37	1.36e-9	Body mass index;
KIRP	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.51	-6.66	-0.39	1.78e-10	Pancreatic cancer;
KIRP	cis	rs17023223	0.537	rs17023174	chr1:119593301	T/C	cg18261050	chr1:119551319	NA	0.52	6.98	0.41	2.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.47	5.93	0.35	1e-8	IgG glycosylation;
KIRP	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg01631408	chr1:248437212	OR2T33	-0.45	-5.84	-0.35	1.68e-8	Common traits (Other);
KIRP	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.86	-0.35	1.49e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9534288	0.659	rs9534314	chr13:46654844	A/G	cg15192986	chr13:46630673	CPB2	-0.79	-9.58	-0.52	1.09e-18	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05280555	chr3:32727089	CNOT10	0.45	6.15	0.37	3.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.56	7.95	0.45	6.71e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.28	-0.32	2.78e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg27147174	chr7:100797783	AP1S1	-0.69	-8.89	-0.49	1.36e-16	Life satisfaction;
KIRP	trans	rs1864585	0.520	rs17718772	chr8:10648056	G/C	cg26278703	chr11:58910052	FAM111A	0.64	6.6	0.39	2.55e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs113123495	0.623	rs2485256	chr19:5694349	G/A	cg26242866	chr19:5711310	LONP1	0.75	4.95	0.3	1.41e-6	Obsessive-compulsive symptoms;
KIRP	cis	rs7751419	0.651	rs59030947	chr6:39094731	C/T	cg08089693	chr6:39098871	NA	-0.68	-9.76	-0.53	3.22e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.43	-0.47	2.87e-15	Common traits (Other);
KIRP	cis	rs12580194	0.554	rs12579852	chr12:55716569	T/A	cg19537932	chr12:55886519	OR6C68	-0.5	-6.27	-0.37	1.57e-9	Cancer;
KIRP	cis	rs8028182	0.666	rs4886708	chr15:75762608	C/T	cg20655648	chr15:75932815	IMP3	0.55	7.01	0.41	2.28e-11	Sudden cardiac arrest;
KIRP	cis	rs4523957	0.890	rs12941621	chr17:2194852	C/T	cg16513277	chr17:2031491	SMG6	0.57	7.63	0.44	5.15e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-1.07	-14.85	-0.69	4.91e-36	Orofacial clefts;
KIRP	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.62	-6.77	-0.4	9.46e-11	Schizophrenia;
KIRP	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.87	-12.61	-0.63	1.81e-28	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs10267417	0.556	rs10233274	chr7:19966248	C/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.96	0.3	1.31e-6	Night sleep phenotypes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12279877	chr17:35294230	LHX1	-0.46	-6.61	-0.39	2.35e-10	Metabolic traits;
KIRP	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg05335186	chr13:53173507	NA	0.44	6.48	0.38	4.91e-10	Lewy body disease;
KIRP	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg10645314	chr2:3704589	ALLC	-0.64	-7.1	-0.41	1.32e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12791968	0.649	rs3802785	chr11:44995441	C/T	cg11846598	chr11:44996168	LOC221122	-0.52	-5.75	-0.34	2.65e-8	Inhibitory control;
KIRP	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg02696742	chr7:106810147	HBP1	-0.76	-8.52	-0.48	1.58e-15	Coronary artery disease;
KIRP	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg08133631	chr1:26527909	CATSPER4	-0.44	-4.88	-0.3	1.93e-6	Obesity-related traits;
KIRP	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg03834567	chr2:218808745	TNS1	0.43	5.43	0.33	1.38e-7	Ulcerative colitis;
KIRP	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg13047869	chr3:10149882	C3orf24	0.53	5.11	0.31	6.32e-7	Alzheimer's disease;
KIRP	cis	rs13191362	0.688	rs73025321	chr6:162974896	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	5.47	0.33	1.08e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs714027	0.605	rs2899147	chr22:30533065	A/G	cg01021169	chr22:30184971	ASCC2	0.44	5.59	0.34	6.05e-8	Lymphocyte counts;
KIRP	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg05692746	chr2:100937584	LONRF2	-0.46	-5.87	-0.35	1.44e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-0.86	-8.46	-0.47	2.33e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.74	9.13	0.5	2.64e-17	Total body bone mineral density;
KIRP	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg21186296	chr8:27182909	PTK2B	0.5	6.34	0.37	1.1e-9	Neuroticism;
KIRP	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg05347473	chr6:146136440	FBXO30	-0.5	-6.9	-0.4	4.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.82	-13.06	-0.64	5.95e-30	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg04374321	chr14:90722782	PSMC1	0.53	5.8	0.35	2.06e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs2860975	0.620	rs1934953	chr10:96797470	A/G	cg09036531	chr10:96991505	NA	0.49	5.87	0.35	1.41e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs3134353	0.932	rs3100052	chr8:101967139	A/G	cg07585502	chr8:101912084	NA	-0.4	-4.89	-0.3	1.84e-6	Body mass index;
KIRP	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg18129178	chr5:148520854	ABLIM3	0.49	5.15	0.31	5.24e-7	Breast cancer;
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.53	6.79	0.4	8.27e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	cg21523751	chr1:182988639	NA	-0.44	-6.84	-0.4	6.37e-11	Colorectal cancer;
KIRP	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg10326726	chr10:51549505	MSMB	-0.6	-9.1	-0.5	3.13e-17	Prostate-specific antigen levels;
KIRP	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06499271	chr3:47324530	KIF9;KLHL18	0.51	6.41	0.38	7.34e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19346786	chr7:2764209	NA	-0.38	-6.34	-0.37	1.1e-9	Height;
KIRP	cis	rs13185784	0.667	rs4700924	chr5:179645870	A/C	cg13944838	chr5:179740914	GFPT2	-0.47	-4.86	-0.3	2.14e-6	TRAIL levels;
KIRP	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.82	-11.92	-0.61	3.6e-26	Headache;
KIRP	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05901451	chr6:126070800	HEY2	0.4	5.59	0.34	5.87e-8	Endometrial cancer;
KIRP	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-8.02	-0.46	4.42e-14	Vitiligo;
KIRP	trans	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg25042112	chr7:64838748	ZNF92	-0.57	-6.12	-0.36	3.69e-9	Pain;
KIRP	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg10935138	chr17:73851978	WBP2	0.58	7.51	0.43	1.11e-12	Psoriasis;
KIRP	cis	rs6832769	0.922	rs9993675	chr4:56243522	C/T	cg09317128	chr4:56265301	TMEM165	0.46	5.83	0.35	1.7e-8	Personality dimensions;
KIRP	cis	rs4356932	0.656	rs13126007	chr4:76862255	G/A	cg19388996	chr4:76862389	NAAA	-0.42	-5.25	-0.32	3.35e-7	Blood protein levels;
KIRP	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19346786	chr7:2764209	NA	-0.35	-5.86	-0.35	1.46e-8	Height;
KIRP	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-9.47	-0.52	2.47e-18	Response to antipsychotic treatment;
KIRP	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg02297831	chr4:17616191	MED28	0.51	6.44	0.38	6.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6191	0.935	rs4634384	chr5:142780697	C/T	cg08845721	chr5:142780693	NR3C1	-0.39	-5.38	-0.32	1.74e-7	Night sleep phenotypes;
KIRP	cis	rs930036	0.602	rs34532258	chr2:171784262	C/G	cg12801329	chr2:171670795	NA	0.46	5.14	0.31	5.5e-7	Menopause (age at onset);
KIRP	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.59	10.31	0.55	6e-21	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.82	8.92	0.49	1.12e-16	Prostate cancer;
KIRP	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.67	-11.19	-0.58	9.31e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg10018233	chr7:150070692	REPIN1	0.79	9.93	0.54	9.14e-20	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs76288851	0.668	rs73203606	chr3:126543124	G/A	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs4664293	0.836	rs10190704	chr2:160594962	G/A	cg08347373	chr2:160653686	CD302	-0.42	-6.4	-0.38	7.73e-10	Monocyte percentage of white cells;
KIRP	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-9.43	-0.52	3.26e-18	Response to antipsychotic treatment;
KIRP	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg26827852	chr1:89887630	LOC400759	0.41	5.3	0.32	2.63e-7	Carotid intima media thickness;
KIRP	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg23505145	chr19:12996616	KLF1	0.57	8.41	0.47	3.42e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20135002	chr11:47629003	NA	-0.48	-5.7	-0.34	3.42e-8	Subjective well-being;
KIRP	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.98	-0.5	7.4e-17	Retinal vascular caliber;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg14022721	chr22:25507536	KIAA1671	0.52	6.41	0.38	7.43e-10	Sleep duration;
KIRP	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.73	0.44	2.79e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.26	5.05	0.31	8.79e-7	Coronary artery disease;
KIRP	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.52	-6.19	-0.37	2.51e-9	Diastolic blood pressure;
KIRP	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.03e-9	Morning vs. evening chronotype;
KIRP	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.91	15.5	0.7	2.9e-38	Metabolic syndrome;
KIRP	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg08975724	chr8:8085496	FLJ10661	0.59	7.82	0.45	1.58e-13	Mood instability;
KIRP	cis	rs6723108	0.738	rs6751833	chr2:135537898	G/T	cg25422880	chr2:135218333	TMEM163	-0.47	-6.85	-0.4	5.87e-11	Type 2 diabetes;
KIRP	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg13978929	chr19:21580086	ZNF493	-0.52	-5.05	-0.31	8.57e-7	Pain;
KIRP	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.94	0.4	3.51e-11	Platelet count;
KIRP	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.3	-6.16	-0.37	2.93e-9	Reticulocyte count;
KIRP	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.76	11.4	0.59	1.87e-24	Oral cavity cancer;
KIRP	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg02725872	chr8:58115012	NA	-0.61	-6.33	-0.37	1.15e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	8.11	0.46	2.39e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.91e-8	Lung cancer;
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg14375499	chr17:6899207	ALOX12	-0.38	-5.85	-0.35	1.55e-8	Tonsillectomy;
KIRP	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7084402	0.967	rs1649069	chr10:60303695	A/G	cg05938607	chr10:60274200	BICC1	0.43	10.17	0.54	1.66e-20	Refractive error;
KIRP	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.83	0.49	1.99e-16	Motion sickness;
KIRP	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg00576331	chr11:65640516	EFEMP2	0.51	5.65	0.34	4.46e-8	Crohn's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26229092	chr10:31816809	ZEB1	-0.44	-7.1	-0.41	1.3e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.69	10.4	0.55	3.01e-21	Menarche (age at onset);
KIRP	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg08999081	chr20:33150536	PIGU	0.46	4.93	0.3	1.54e-6	Protein C levels;
KIRP	cis	rs6662572	0.585	rs12042481	chr1:45964766	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.57	5.52	0.33	8.81e-8	Blood protein levels;
KIRP	cis	rs35740288	0.770	rs35348278	chr15:86200340	G/A	cg17133734	chr15:86042851	AKAP13	-0.5	-5.63	-0.34	4.92e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg10950524	chr7:2139216	MAD1L1	0.31	4.85	0.3	2.15e-6	Bipolar disorder and schizophrenia;
KIRP	trans	rs12690897	0.609	rs4466324	chr7:85275522	C/T	cg03355690	chr6:35265616	DEF6	-0.3	-6.1	-0.36	4.07e-9	Macrophage inflammatory protein 1a levels;
KIRP	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.82	12.21	0.61	4.2e-27	IgG glycosylation;
KIRP	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.45	-5.25	-0.32	3.28e-7	Reticulocyte count;
KIRP	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg10547527	chr2:198650123	BOLL	-0.56	-5.06	-0.31	8.05e-7	Ulcerative colitis;
KIRP	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg07148914	chr20:33460835	GGT7	-0.55	-7.22	-0.42	6.51e-12	Height;
KIRP	cis	rs4889855	0.530	rs7220588	chr17:78598231	G/A	cg09596252	chr17:78655493	RPTOR	0.51	5.86	0.35	1.51e-8	Fractional excretion of uric acid;
KIRP	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs10207060	0.500	rs7600350	chr2:240716225	T/C	cg20333904	chr2:240724165	NA	-0.41	-4.86	-0.3	2.14e-6	Obesity-related traits;
KIRP	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.51	-0.65	1.76e-31	Ulcerative colitis;
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03647317	chr4:187891568	NA	0.8	13.56	0.65	1.18e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.49e-20	Coffee consumption (cups per day);
KIRP	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.97	15.29	0.7	1.55e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6450176	1.000	rs7707547	chr5:53295737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.09	-0.58	1.94e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2075064	0.900	rs10760309	chr9:126792005	A/G	cg14112217	chr9:126806003	NA	0.34	4.87	0.3	1.97e-6	Waist circumference;
KIRP	cis	rs1866706	0.855	rs12289262	chr11:12894758	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-5.1	-0.31	6.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg15893493	chr8:124194847	FAM83A	0.87	6.8	0.4	8.01e-11	Urinary uromodulin levels;
KIRP	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.29	-0.42	4.1e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg09455208	chr3:40491958	NA	0.34	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg15192750	chr16:69999425	NA	0.45	4.84	0.3	2.26e-6	IgE levels;
KIRP	cis	rs12681366	0.663	rs4735294	chr8:95490541	T/C	cg13257157	chr8:95487014	RAD54B	0.44	5.55	0.33	7.26e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.18	-0.51	1.78e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09022952	chr11:65820066	SF3B2	0.51	6.38	0.38	8.95e-10	Parkinson's disease;
KIRP	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg17863274	chr19:49399704	TULP2	-0.41	-5.84	-0.35	1.61e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.24e-7	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs17321999	1.000	rs10171296	chr2:30481309	A/G	cg05247661	chr2:30472410	LBH	0.67	6.96	0.41	3.14e-11	Systemic lupus erythematosus;
KIRP	cis	rs6662572	0.806	rs56067046	chr1:46044314	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.18	0.31	4.73e-7	Blood protein levels;
KIRP	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg14675211	chr2:100938903	LONRF2	0.47	6.05	0.36	5.46e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.9	-0.71	1.23e-39	Chronic sinus infection;
KIRP	cis	rs3764563	1.000	rs586608	chr19:15694168	C/T	cg20725493	chr19:15740067	CYP4F8	0.83	5.91	0.35	1.11e-8	Inflammatory biomarkers;
KIRP	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.45	0.33	1.25e-7	Blood protein levels;
KIRP	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.76	10.9	0.57	7.89e-23	Schizophrenia;
KIRP	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.56	0.65	1.2e-31	Chronic sinus infection;
KIRP	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.78	0.53	2.72e-19	Coffee consumption (cups per day);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg15629884	chr8:144446189	NA	1.02	6.54	0.38	3.59e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.67	-9.85	-0.53	1.66e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4971059	0.654	rs4276913	chr1:155131673	A/G	cg02153340	chr1:155202674	NA	-0.42	-5.81	-0.35	1.88e-8	Breast cancer;
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.69	6.0	0.36	7.08e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10073892	0.511	rs6596506	chr5:101881380	A/T	cg19774478	chr5:101632501	SLCO4C1	0.51	5.58	0.34	6.27e-8	Cognitive decline (age-related);
KIRP	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs2279817	0.780	rs79136279	chr1:18008121	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.54	-0.48	1.38e-15	Neuroticism;
KIRP	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.12	-0.36	3.6e-9	Breast cancer;
KIRP	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg13160058	chr8:26243215	BNIP3L	-0.47	-6.99	-0.41	2.58e-11	Red cell distribution width;
KIRP	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg05973401	chr12:123451056	ABCB9	0.56	6.49	0.38	4.58e-10	Neutrophil percentage of white cells;
KIRP	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-8.57	-0.48	1.19e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.59	0.73	5.57e-42	Chronic sinus infection;
KIRP	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.95	0.35	9.15e-9	Personality dimensions;
KIRP	cis	rs4523957	0.690	rs4790884	chr17:2105299	G/C	cg16513277	chr17:2031491	SMG6	-0.69	-9.76	-0.53	3.2e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2997447	0.846	rs61775428	chr1:26409126	G/C	cg19633962	chr1:26362018	EXTL1	-0.69	-5.8	-0.35	2.04e-8	QRS complex (12-leadsum);
KIRP	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	11.08	0.58	2.09e-23	Response to antipsychotic treatment;
KIRP	cis	rs10488172	0.761	rs4731986	chr7:133619974	G/A	cg10665199	chr7:133106180	EXOC4	-0.58	-5.73	-0.34	2.98e-8	Tonometry;
KIRP	cis	rs775227	0.574	rs35765657	chr3:113078384	C/T	cg18753928	chr3:113234510	CCDC52	-0.55	-5.48	-0.33	1.04e-7	Dental caries;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.95	16.17	0.72	1.43e-40	Menarche (age at onset);
KIRP	cis	rs4523957	0.614	rs7208638	chr17:2061334	G/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs5743618	0.537	rs11734337	chr4:38773067	A/G	cg06935464	chr4:38784597	TLR10	0.39	4.88	0.3	1.94e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs986417	1.000	rs1072328	chr14:60876439	C/G	cg27398547	chr14:60952738	C14orf39	-0.64	-5.79	-0.35	2.14e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg26043149	chr18:55253948	FECH	0.5	6.13	0.36	3.47e-9	Bone mineral density;
KIRP	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.54	6.89	0.4	4.78e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs1420338	0.967	rs10224203	chr7:34149593	C/T	cg01275685	chr7:34179230	BMPER	-0.51	-7.62	-0.44	5.61e-13	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-5.3	-0.32	2.61e-7	Neuroticism;
KIRP	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7809615	0.901	rs6947974	chr7:99156506	G/A	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite ratios;
KIRP	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	10.04	0.54	4.1e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg04455712	chr21:45112962	RRP1B	0.45	5.26	0.32	3.18e-7	Mean corpuscular volume;
KIRP	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg21573476	chr21:45109991	RRP1B	-0.59	-7.87	-0.45	1.11e-13	Mean corpuscular volume;
KIRP	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg18850127	chr7:39170497	POU6F2	0.28	5.15	0.31	5.23e-7	IgG glycosylation;
KIRP	cis	rs16976116	0.851	rs13380400	chr15:55490518	A/G	cg11288833	chr15:55489084	RSL24D1	0.66	7.46	0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.32	0.32	2.32e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg08890418	chr1:21044141	KIF17	-0.41	-6.3	-0.37	1.37e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.45	-0.33	1.24e-7	Colorectal cancer;
KIRP	cis	rs5013026	1	rs5013026	chr22:18171650	C/T	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.04	-0.31	9.11e-7	Neutrophil count;
KIRP	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.43	-4.85	-0.3	2.17e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs35740288	0.770	rs1382534	chr15:86142170	A/T	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg00684032	chr4:1343700	KIAA1530	0.51	6.67	0.39	1.66e-10	Obesity-related traits;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg19839035	chr2:20424326	SDC1	0.55	6.72	0.39	1.28e-10	Inflammatory biomarkers;
KIRP	cis	rs6959887	0.926	rs17606554	chr7:35276336	G/A	cg06685737	chr7:35301730	NA	0.44	6.3	0.37	1.34e-9	Birth weight;
KIRP	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg09596252	chr17:78655493	RPTOR	0.61	8.13	0.46	2.12e-14	Obesity;
KIRP	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg26874229	chr2:105853672	NA	-0.4	-5.43	-0.33	1.34e-7	Type 2 diabetes;
KIRP	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.69	8.89	0.49	1.35e-16	Total body bone mineral density;
KIRP	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.68	-12.44	-0.62	6.84e-28	White blood cell count (basophil);
KIRP	cis	rs7113874	1.000	rs7126235	chr11:8689336	C/T	cg08015107	chr11:8618950	NA	-0.35	-4.88	-0.3	1.89e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs829661	0.793	rs6740440	chr2:30794590	A/T	cg10949345	chr2:30726833	LCLAT1	1.01	12.62	0.63	1.8e-28	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg20731937	chr12:48336164	NA	0.41	5.34	0.32	2.14e-7	Longevity (90 years and older);
KIRP	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.14	-0.36	3.32e-9	IgG glycosylation;
KIRP	cis	rs4638749	0.501	rs1385957	chr2:108755104	T/G	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.14	-0.31	5.57e-7	Blood pressure;
KIRP	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg26681399	chr22:41777847	TEF	-0.54	-5.39	-0.33	1.65e-7	Vitiligo;
KIRP	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg03735888	chr19:58951602	ZNF132	0.46	5.51	0.33	9e-8	Uric acid clearance;
KIRP	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.59	7.09	0.41	1.45e-11	Pulse pressure;
KIRP	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.77	0.35	2.38e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.45	0.52	2.75e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.67	9.85	0.53	1.65e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6832769	1.000	rs7673908	chr4:56394819	A/G	cg09317128	chr4:56265301	TMEM165	-0.55	-7.34	-0.42	3.09e-12	Personality dimensions;
KIRP	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.73	9.27	0.51	9.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4740619	0.619	rs10810523	chr9:16034642	T/G	cg14451791	chr9:16040625	NA	-0.42	-5.46	-0.33	1.16e-7	Body mass index;
KIRP	cis	rs6545883	0.895	rs2442029	chr2:61679552	G/T	cg15711740	chr2:61764176	XPO1	-0.61	-7.78	-0.44	1.97e-13	Tuberculosis;
KIRP	cis	rs7937840	0.559	rs2000957	chr11:61877744	A/G	cg01969543	chr11:61895209	INCENP	-0.48	-6.23	-0.37	1.98e-9	Breast cancer;
KIRP	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg24807547	chr6:37504484	NA	-0.53	-7.61	-0.44	5.9e-13	Cognitive performance;
KIRP	cis	rs6142102	0.580	rs9753679	chr20:32540860	G/A	cg08999081	chr20:33150536	PIGU	0.39	4.92	0.3	1.56e-6	Skin pigmentation;
KIRP	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg25664220	chr3:72788482	NA	-0.35	-5.09	-0.31	7.08e-7	Motion sickness;
KIRP	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.73	-0.53	3.76e-19	Response to antipsychotic treatment;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11831058	chr3:128902720	CNBP	0.52	7.03	0.41	2.07e-11	Survival in pancreatic cancer;
KIRP	cis	rs282587	0.502	rs416018	chr13:113396488	G/A	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.82e-12	Glycated hemoglobin levels;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg02733842	chr7:1102375	C7orf50	0.43	5.15	0.31	5.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.85	12.87	0.63	2.61e-29	Height;
KIRP	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08023458	chr14:101438461	SNORD114-14;SNORD114-15;SNORD114-16	-0.42	-6.48	-0.38	4.96e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2120243	0.539	rs6441126	chr3:157095016	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-9.03	-0.5	5.16e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg14024328	chr4:719362	PCGF3	-0.57	-8.82	-0.49	2.1e-16	White blood cell count;
KIRP	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-8.13	-0.46	2.13e-14	Personality dimensions;
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.62	8.15	0.46	1.9e-14	Longevity;Endometriosis;
KIRP	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	4.93e-23	Prudent dietary pattern;
KIRP	cis	rs6545883	0.507	rs10169662	chr2:61507936	T/C	cg15711740	chr2:61764176	XPO1	0.47	5.77	0.35	2.4e-8	Tuberculosis;
KIRP	cis	rs12999616	0.602	rs17489259	chr2:98392302	G/A	cg26665480	chr2:98280029	ACTR1B	0.47	5.01	0.3	1.06e-6	Colorectal cancer;
KIRP	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg25828445	chr12:7781288	NA	0.52	5.19	0.31	4.41e-7	HDL cholesterol levels;
KIRP	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.43	-0.52	3.1e-18	Brugada syndrome;
KIRP	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08957018	chr22:42487540	NDUFA6	-0.52	-6.89	-0.4	4.56e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg11859384	chr17:80120422	CCDC57	0.45	5.74	0.34	2.82e-8	Life satisfaction;
KIRP	cis	rs3126085	1.000	rs12405278	chr1:152282267	G/A	cg26876637	chr1:152193138	HRNR	-0.83	-8.46	-0.47	2.47e-15	Atopic dermatitis;
KIRP	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg13047869	chr3:10149882	C3orf24	0.58	4.88	0.3	1.93e-6	Alzheimer's disease;
KIRP	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg16141378	chr3:129829833	LOC729375	0.56	7.63	0.44	5.07e-13	Neuroticism;
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03647317	chr4:187891568	NA	-0.77	-12.96	-0.64	1.23e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg12573674	chr2:1569213	NA	-0.56	-6.41	-0.38	7.37e-10	IgG glycosylation;
KIRP	cis	rs34339938	1	rs34339938	chr12:123678364	GAC/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.11e-6	Plateletcrit;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10385411	chr19:48897143	GRIN2D	0.45	6.43	0.38	6.63e-10	Parkinson's disease;
KIRP	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.57	7.77	0.44	2.18e-13	Prostate cancer;
KIRP	cis	rs58649573	0.552	rs3780681	chr9:126784287	T/A	cg14112217	chr9:126806003	NA	0.37	5.54	0.33	7.59e-8	Post-traumatic stress disorder;
KIRP	trans	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg23594656	chr7:65796392	TPST1	0.39	5.74	0.34	2.72e-8	Aortic root size;
KIRP	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	5.86	0.35	1.46e-8	Schizophrenia;
KIRP	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	5.85	0.35	1.56e-8	Total body bone mineral density;
KIRP	cis	rs3745672	0.590	rs75275742	chr19:12168397	G/A	cg20127191	chr19:12306497	NA	-0.7	-5.82	-0.35	1.84e-8	Multiple sclerosis;
KIRP	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.53	7.14	0.41	1.06e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.67	9.21	0.51	1.51e-17	Lymphocyte counts;
KIRP	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.61	8.76	0.49	3.17e-16	Neurofibrillary tangles;
KIRP	cis	rs3736485	0.934	rs1077361	chr15:51880919	T/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg20701182	chr2:24300061	SF3B14	0.6	5.3	0.32	2.59e-7	Lymphocyte counts;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg24272514	chr6:16760725	ATXN1	-0.6	-6.61	-0.39	2.37e-10	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07194495	chr7:148958859	ZNF783	0.57	7.02	0.41	2.09e-11	Smoking initiation;
KIRP	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg04087571	chr11:116723030	SIK3	-0.26	-5.56	-0.33	6.84e-8	Subjective well-being;
KIRP	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.64	7.83	0.45	1.5e-13	Corneal astigmatism;
KIRP	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.78	-11.35	-0.59	2.73e-24	Response to temozolomide;
KIRP	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.74	6.79	0.4	8.5e-11	Mean platelet volume;
KIRP	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.71	8.23	0.46	1.12e-14	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15543167	chr8:117886618	RAD21	0.53	7.22	0.42	6.49e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg02975922	chr3:195473998	MUC4	-0.55	-6.43	-0.38	6.49e-10	Pancreatic cancer;
KIRP	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	-0.65	-7.72	-0.44	2.93e-13	Itch intensity from mosquito bite;
KIRP	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg18093559	chr17:18951025	GRAP	0.5	6.18	0.37	2.64e-9	Schizophrenia;
KIRP	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg16558253	chr16:72132732	DHX38	-0.6	-9.04	-0.5	4.93e-17	Fibrinogen levels;
KIRP	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.77	8.83	0.49	2.06e-16	Adiposity;
KIRP	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg00129232	chr17:37814104	STARD3	-0.67	-7.25	-0.42	5.53e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs6921919	0.583	rs11751693	chr6:28345083	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.81	11.87	0.6	5.31e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.36	0.51	5.19e-18	IgG glycosylation;
KIRP	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg25486957	chr4:152246857	NA	-0.5	-5.48	-0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs62158211	0.908	rs62158169	chr2:114081827	C/T	cg17784749	chr2:114082611	LOC440839	0.79	8.71	0.49	4.43e-16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-7.75	-0.44	2.38e-13	Mean corpuscular volume;
KIRP	cis	rs7833787	1.000	rs34270955	chr8:18705250	G/C	cg17701159	chr8:18705777	PSD3	-0.38	-7.36	-0.42	2.75e-12	Obesity-related traits;
KIRP	trans	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.18	0.42	8.05e-12	Mean corpuscular volume;
KIRP	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg05639522	chr1:247681581	NA	0.59	5.46	0.33	1.17e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.45	0.59	1.26e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.77	10.26	0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg26695010	chr11:65641043	EFEMP2	0.47	5.82	0.35	1.83e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7005380	0.581	rs9987165	chr8:120933873	T/C	cg21645572	chr8:120931649	DEPDC6	-0.52	-7.2	-0.42	7.45e-12	Interstitial lung disease;
KIRP	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.32	5.29	0.32	2.65e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.42	5.01	0.3	1.03e-6	Aortic root size;
KIRP	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg06917634	chr15:78832804	PSMA4	0.5	5.74	0.34	2.82e-8	Sudden cardiac arrest;
KIRP	trans	rs7939886	0.841	rs11227582	chr11:55995736	C/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.31	0.42	3.78e-12	Height;
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg09553402	chr5:180229753	MGAT1	-0.89	-6.24	-0.37	1.91e-9	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	cis	rs1009170	0.794	rs2402112	chr14:92582172	G/A	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.45	0.33	1.23e-7	Dialysis-related mortality;
KIRP	cis	rs7729447	0.804	rs116090595	chr5:32698148	T/G	cg16267343	chr5:32710456	NPR3	0.55	6.39	0.38	8.44e-10	Blood pressure;
KIRP	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00361562	chr2:198649771	BOLL	-0.5	-5.3	-0.32	2.51e-7	Ulcerative colitis;
KIRP	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.48	-0.33	1.08e-7	Metabolite levels;
KIRP	cis	rs7712401	0.601	rs30035	chr5:122278545	A/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.98	9.94	0.54	8.43e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.6	8.32	0.47	6.08e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10875746	0.903	rs61918806	chr12:48484433	G/A	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg03651054	chr13:50194643	NA	0.59	8.18	0.46	1.51e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs11673344	0.830	rs3745770	chr19:37488565	C/G	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.2	-0.31	4.16e-7	Obesity-related traits;
KIRP	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.86	-0.49	1.6e-16	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg09795085	chr6:101329169	ASCC3	-0.49	-5.87	-0.35	1.4e-8	Neuroticism;
KIRP	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.95	14.82	0.69	5.89e-36	Breast cancer;
KIRP	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg13334819	chr7:99746414	C7orf59	-0.55	-5.73	-0.34	2.95e-8	Coronary artery disease;
KIRP	trans	rs6687758	0.687	rs12123928	chr1:222121875	C/T	cg11122944	chr17:9924800	GAS7	0.47	6.09	0.36	4.37e-9	Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);Colorectal cancer;
KIRP	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.94	-0.4	3.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.75	10.65	0.56	4.98e-22	Prudent dietary pattern;
KIRP	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg12131826	chr15:77904385	NA	0.49	5.7	0.34	3.41e-8	Type 2 diabetes;
KIRP	cis	rs7011049	1.000	rs72643579	chr8:53846705	C/A	cg26025543	chr8:53854495	NA	0.75	7.86	0.45	1.16e-13	Systolic blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07776166	chr4:175254137	KIAA1712	-0.43	-6.92	-0.4	3.94e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg07862535	chr7:139043722	LUC7L2	0.51	5.68	0.34	3.73e-8	Diisocyanate-induced asthma;
KIRP	cis	rs10929159	0.928	rs7557693	chr2:236920713	G/A	cg20128773	chr2:236923534	AGAP1	0.32	5.45	0.33	1.22e-7	Parkinson's disease;
KIRP	cis	rs28830936	0.966	rs17733613	chr15:41917585	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.5	-0.33	9.72e-8	Diastolic blood pressure;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg08901578	chr4:187885870	NA	-0.51	-7.92	-0.45	7.97e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7084402	0.902	rs1582826	chr10:60297175	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg00745463	chr17:30367425	LRRC37B	-0.92	-6.22	-0.37	2.18e-9	Height;
KIRP	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.47	6.84	0.4	6.16e-11	Sitting height ratio;
KIRP	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17554472	chr22:41940697	POLR3H	0.54	5.81	0.35	1.89e-8	Vitiligo;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg07216194	chr8:27182965	PTK2B	0.43	5.37	0.32	1.83e-7	Neuroticism;
KIRP	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.46	-5.81	-0.35	1.94e-8	Coronary artery disease;
KIRP	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.11	-0.61	9.02e-27	Alzheimer's disease;
KIRP	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.41	-0.38	7.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.91	0.4	4.03e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.6	0.44	6.1e-13	White blood cell count;
KIRP	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.67	8.55	0.48	1.32e-15	Prudent dietary pattern;
KIRP	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-7.17	-0.42	8.65e-12	Hip circumference adjusted for BMI;
KIRP	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.57	-0.48	1.13e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg26965718	chr17:79658957	HGS	-0.64	-5.23	-0.32	3.6e-7	Dental caries;
KIRP	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.63	4.86	0.3	2.12e-6	Schizophrenia;
KIRP	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg21360079	chr12:107162445	NA	-0.71	-10.14	-0.54	1.99e-20	Heart rate;
KIRP	cis	rs71277158	0.688	rs879161	chr3:169812115	A/G	cg04067573	chr3:169899625	PHC3	0.59	5.7	0.34	3.36e-8	Prostate cancer;
KIRP	cis	rs8084125	1.000	rs1944560	chr18:74939705	G/T	cg26065057	chr18:74961000	GALR1	0.57	5.93	0.35	1.03e-8	Obesity-related traits;
KIRP	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.88	9.99	0.54	6.25e-20	Gut microbiome composition (summer);
KIRP	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.29	-0.47	7.36e-15	Triglycerides;
KIRP	cis	rs601339	1.000	rs645491	chr12:123181661	T/C	cg18578876	chr12:123200353	GPR109B	0.49	4.87	0.3	2.03e-6	Adiponectin levels;
KIRP	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.46	-5.69	-0.34	3.51e-8	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24542667	chr1:43209606	NA	-0.44	-6.23	-0.37	1.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.53	-7.69	-0.44	3.51e-13	Daytime sleep phenotypes;
KIRP	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01633841	chr1:54872108	SSBP3	0.5	6.18	0.37	2.71e-9	Parkinson's disease;
KIRP	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg09201719	chr10:104596890	CYP17A1	0.38	5.55	0.33	7.31e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04691540	chr1:179198414	ABL2	0.79	6.87	0.4	5.34e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.66	-7.25	-0.42	5.45e-12	Corneal structure;
KIRP	trans	rs6734238	0.966	rs6750559	chr2:113841532	C/T	cg11332951	chr1:2396472	NA	-0.42	-6.19	-0.37	2.48e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.44	6.19	0.37	2.47e-9	Childhood ear infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03699633	chr11:74098949	PGM2L1	-0.41	-6.23	-0.37	1.96e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-0.89	-6.17	-0.37	2.81e-9	Inflammatory biomarkers;
KIRP	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.79	0.35	2.16e-8	Motion sickness;
KIRP	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.53	-6.77	-0.4	9.29e-11	Blood metabolite levels;
KIRP	cis	rs61935443	0.778	rs78522691	chr12:95267340	G/T	cg21533806	chr12:95267307	NA	0.67	6.61	0.39	2.3e-10	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg08662619	chr6:150070041	PCMT1	0.39	6.49	0.38	4.58e-10	Lung cancer;
KIRP	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg25838818	chr2:108905173	SULT1C2	-0.52	-7.94	-0.45	7.14e-14	Blood pressure;
KIRP	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg13880726	chr7:1868755	MAD1L1	0.5	5.56	0.33	7.06e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs13401104	0.716	rs11682806	chr2:237138825	A/T	cg19324714	chr2:237145437	ASB18	0.54	5.5	0.33	9.37e-8	Educational attainment;
KIRP	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17467752	chr17:38218738	THRA	-0.53	-7.02	-0.41	2.1e-11	Myeloid white cell count;
KIRP	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.76	10.18	0.54	1.53e-20	Resting heart rate;
KIRP	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg11846333	chr4:119757529	SEC24D	1.09	6.26	0.37	1.7e-9	Cannabis dependence symptom count;
KIRP	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg04733989	chr22:42467013	NAGA	0.57	7.53	0.43	9.84e-13	Cognitive function;
KIRP	cis	rs2380205	0.935	rs2380201	chr10:5894650	C/T	cg27141509	chr10:5886111	NA	-0.39	-5.73	-0.34	2.93e-8	Breast cancer;
KIRP	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.82	11.88	0.6	4.97e-26	Bladder cancer;
KIRP	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.79	13.49	0.65	2e-31	Anterior chamber depth;
KIRP	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.47	-6.68	-0.39	1.61e-10	Blood metabolite levels;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3105593	1.000	rs3131590	chr15:50840955	G/T	cg05456662	chr15:50716270	USP8	0.4	5.03	0.31	9.55e-7	QT interval;
KIRP	cis	rs68170813	0.652	rs12533694	chr7:107102817	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-6.89	-0.4	4.7e-11	Coronary artery disease;
KIRP	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.18	-0.54	1.54e-20	Response to antipsychotic treatment;
KIRP	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg15848620	chr12:58087721	OS9	-0.49	-5.76	-0.34	2.51e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg03188948	chr7:1209495	NA	0.44	4.91	0.3	1.66e-6	Longevity;Endometriosis;
KIRP	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.49	-5.09	-0.31	7.07e-7	Fat distribution (HIV);
KIRP	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg10189774	chr4:17578691	LAP3	0.47	5.6	0.34	5.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg21366198	chr4:185655624	MLF1IP	-0.39	-5.3	-0.32	2.53e-7	Kawasaki disease;
KIRP	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.38	-0.51	4.52e-18	Hemoglobin concentration;
KIRP	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.49	-5.8	-0.35	2.01e-8	Body mass index;
KIRP	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.63	8.58	0.48	1.09e-15	Total body bone mineral density;
KIRP	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.71	9.84	0.53	1.83e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.61	-8.9	-0.49	1.27e-16	Urate levels in overweight individuals;
KIRP	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.07	0.31	7.91e-7	Lymphocyte counts;
KIRP	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg17108064	chr15:78857060	CHRNA5	0.37	5.28	0.32	2.81e-7	Sudden cardiac arrest;
KIRP	cis	rs732716	0.889	rs55637375	chr19:4386845	A/G	cg03719555	chr19:4455413	UBXN6	0.51	7.71	0.44	3.06e-13	Mean corpuscular volume;
KIRP	cis	rs9831754	0.756	rs9817660	chr3:78426373	T/C	cg06138941	chr3:78371609	NA	-0.76	-10.8	-0.57	1.65e-22	Calcium levels;
KIRP	cis	rs7945705	1.000	rs7937298	chr11:8867509	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.12	0.36	3.71e-9	Hemoglobin concentration;
KIRP	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-0.56	-7.2	-0.42	7.18e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1829883	0.835	rs10068675	chr5:98890617	C/G	cg08333243	chr5:99726346	NA	-0.39	-5.26	-0.32	3.15e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.95	14.01	0.67	3.42e-33	Response to bleomycin (chromatid breaks);
KIRP	trans	rs7246760	0.867	rs66943818	chr19:9746367	G/A	cg02900749	chr2:68251473	NA	-1.13	-8.96	-0.5	8.55e-17	Pursuit maintenance gain;
KIRP	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-9.54	-0.52	1.48e-18	Response to antipsychotic treatment;
KIRP	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.41	-0.38	7.43e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	17.02	0.74	1.92e-43	Platelet count;
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.73	10.26	0.55	8.38e-21	Lung cancer;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.69	-9.99	-0.54	5.98e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1182180	0.538	rs4722006	chr7:2765723	A/G	cg03961401	chr7:2768911	GNA12	-0.43	-5.13	-0.31	5.92e-7	Platelet count;
KIRP	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg01097406	chr16:89675127	NA	0.45	7.88	0.45	1.03e-13	Vitiligo;
KIRP	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg19847130	chr8:10466454	RP1L1	-0.35	-4.93	-0.3	1.52e-6	Retinal vascular caliber;
KIRP	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	12.52	0.62	3.89e-28	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg08662619	chr6:150070041	PCMT1	0.38	6.19	0.37	2.5e-9	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15828828	chr19:36980699	ZNF566	0.53	6.84	0.4	6.35e-11	Parkinson's disease;
KIRP	cis	rs7818345	0.935	rs12542575	chr8:19286558	A/T	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.42	0.38	7.02e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.97	0.54	7.01e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12096656	chr8:55047838	MRPL15	0.49	6.36	0.38	9.85e-10	Parkinson's disease;
KIRP	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.76	6.66	0.39	1.78e-10	Body mass index;
KIRP	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg11569703	chr11:65557185	OVOL1	0.42	7.12	0.41	1.21e-11	Systemic lupus erythematosus;
KIRP	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05665937	chr4:1216051	CTBP1	-0.44	-5.45	-0.33	1.24e-7	Obesity-related traits;
KIRP	trans	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg02002194	chr4:3960332	NA	0.42	6.04	0.36	5.54e-9	Mood instability;
KIRP	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-6.88	-0.4	5.06e-11	Gut microbiome composition (summer);
KIRP	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.95	12.7	0.63	9.12e-29	Vitamin D levels;
KIRP	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg00666640	chr1:248458726	OR2T12	0.46	5.49	0.33	1.01e-7	Common traits (Other);
KIRP	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.75	-10.9	-0.57	7.78e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.24	-6.16	-0.37	2.95e-9	Mean corpuscular volume;
KIRP	cis	rs2279817	0.698	rs12742948	chr1:18006550	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-9.63	-0.52	7.74e-19	Neuroticism;
KIRP	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.39	-5.64	-0.34	4.56e-8	Pubertal anthropometrics;
KIRP	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.08	-12.82	-0.63	3.6e-29	Alzheimer's disease;
KIRP	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	9.75	0.53	3.26e-19	Cognitive test performance;
KIRP	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.94	0.4	3.36e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs10267417	0.522	rs34867920	chr7:19936646	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.86	0.3	2.07e-6	Night sleep phenotypes;
KIRP	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.88	12.59	0.63	2.27e-28	Mean platelet volume;
KIRP	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg01097406	chr16:89675127	NA	0.54	9.74	0.53	3.59e-19	Vitiligo;
KIRP	cis	rs78487399	0.731	rs6722104	chr2:43752346	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.12	-0.31	6.19e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6580083	1.000	rs7720917	chr5:153864932	C/G	cg21964928	chr5:153872958	NA	-0.43	-6.04	-0.36	5.73e-9	QRS duration;
KIRP	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg17376030	chr22:41985996	PMM1	-0.53	-6.06	-0.36	5.14e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7804356	0.813	rs76438067	chr7:26911904	C/T	cg03456212	chr7:26904342	SKAP2	-0.59	-5.27	-0.32	2.98e-7	Type 1 diabetes;
KIRP	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg10223061	chr2:219282414	VIL1	0.42	6.46	0.38	5.47e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.03	-0.41	2.01e-11	Joint mobility (Beighton score);
KIRP	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.33	-0.37	1.14e-9	Type 2 diabetes;
KIRP	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg17279839	chr7:150038598	RARRES2	0.46	6.11	0.36	3.81e-9	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg19663137	chr11:117049536	SIDT2	0.49	6.01	0.36	6.49e-9	Educational attainment;
KIRP	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	trans	rs9790314	0.663	rs12639128	chr3:160639645	A/G	cg19274270	chr17:78178856	CARD14	0.35	6.21	0.37	2.22e-9	Morning vs. evening chronotype;
KIRP	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg08773314	chr2:239334832	ASB1	0.42	7.36	0.42	2.73e-12	Multiple system atrophy;
KIRP	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-8.38	-0.47	4.12e-15	Cognitive function;
KIRP	cis	rs3736485	0.934	rs28410165	chr15:51875019	C/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.56	7.54	0.43	9.28e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	0.76	5.69	0.34	3.54e-8	IgG glycosylation;
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg11641102	chr8:27183873	PTK2B	0.46	6.03	0.36	6.02e-9	Neuroticism;
KIRP	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	1.03	14.95	0.69	2.1e-36	Cognitive function;
KIRP	cis	rs2970992	0.764	rs2175792	chr2:101323275	T/C	cg01042948	chr2:101319752	NA	0.44	6.91	0.4	4.02e-11	Educational attainment;
KIRP	cis	rs787274	0.764	rs1891402	chr9:115567184	T/C	cg13803584	chr9:115635662	SNX30	-0.72	-6.55	-0.39	3.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.67	8.88	0.49	1.48e-16	Renal function-related traits (BUN);
KIRP	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-5.11	-0.31	6.55e-7	Prostate cancer;
KIRP	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7614311	0.636	rs3821902	chr3:63941697	T/G	cg22134162	chr3:63841271	THOC7	-0.49	-5.91	-0.35	1.13e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.13	-0.41	1.09e-11	Menopause (age at onset);
KIRP	cis	rs6681460	0.932	rs492109	chr1:67187133	C/A	cg13052034	chr1:66999238	SGIP1	-0.37	-5.32	-0.32	2.34e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg03808351	chr9:123631620	PHF19	0.35	4.9	0.3	1.74e-6	Rheumatoid arthritis;
KIRP	cis	rs12210905	0.925	rs12193820	chr6:27113811	A/G	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	5.82	0.35	1.84e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg21184320	chr1:21044207	KIF17	-0.38	-5.75	-0.34	2.6e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.2	0.31	4.29e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11809207	0.859	rs61776644	chr1:26505548	T/C	cg19633962	chr1:26362018	EXTL1	-0.58	-5.41	-0.33	1.51e-7	Height;
KIRP	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	5.66	0.34	4.18e-8	Renal cell carcinoma;
KIRP	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg14689365	chr7:158441557	NCAPG2	0.46	5.73	0.34	2.88e-8	Height;
KIRP	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg16482183	chr6:26056742	HIST1H1C	-0.63	-7.18	-0.42	8.3e-12	Iron status biomarkers;
KIRP	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg18833306	chr6:118973337	C6orf204	0.39	5.17	0.31	4.82e-7	Electrocardiographic conduction measures;
KIRP	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg24169773	chr3:122142474	KPNA1	-0.56	-5.83	-0.35	1.77e-8	LDL cholesterol levels;
KIRP	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.85	12.14	0.61	6.87e-27	Multiple sclerosis;
KIRP	cis	rs2400749	0.830	rs2144805	chr14:100028788	A/G	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.47	-0.33	1.1e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg21775007	chr8:11205619	TDH	-0.48	-6.22	-0.37	2.15e-9	Systolic blood pressure;
KIRP	cis	rs6921919	0.583	rs6899389	chr6:28381140	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.56	-6.89	-0.4	4.65e-11	Iron status biomarkers;
KIRP	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.66	-9.01	-0.5	6e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.69	-8.42	-0.47	3.05e-15	Cognitive function;
KIRP	cis	rs4523957	0.651	rs8082485	chr17:2060407	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14576291	chr9:134526136	RAPGEF1	0.53	6.18	0.37	2.67e-9	Interleukin-4 levels;
KIRP	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	trans	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg06521331	chr12:34319734	NA	-0.51	-6.21	-0.37	2.3e-9	Bladder cancer;
KIRP	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.76	11.23	0.58	6.92e-24	Bladder cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23645931	chr10:135233032	MTG1	0.47	6.51	0.38	4.2e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02358165	chr17:78388892	FLJ35220;LOC100294362	0.49	6.05	0.36	5.36e-9	Parkinson's disease;
KIRP	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg09990169	chr2:241835740	C2orf54	-0.37	-5.69	-0.34	3.54e-8	Urinary metabolites;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.27	-5.84	-0.35	1.63e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.77	-0.35	2.34e-8	Multiple sclerosis;
KIRP	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	1.0	16.17	0.72	1.49e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg24804195	chr5:87968844	LOC645323	-0.47	-6.17	-0.37	2.73e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs977987	0.864	rs37593	chr16:75496907	T/C	cg03315344	chr16:75512273	CHST6	-0.7	-10.54	-0.56	1.1e-21	Dupuytren's disease;
KIRP	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs17121403	0.661	rs11166405	chr1:100598299	A/G	cg24955406	chr1:100503596	HIAT1	0.78	5.11	0.31	6.5e-7	Pulmonary function decline;
KIRP	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.4	-4.94	-0.3	1.43e-6	Longevity;
KIRP	cis	rs7258465	1.000	rs10425982	chr19:18586519	T/A	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.9	-0.35	1.17e-8	Breast cancer;
KIRP	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg22437258	chr11:111473054	SIK2	-0.54	-6.11	-0.36	3.92e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	6.05	0.36	5.38e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10886503	0.777	rs7101354	chr10:121267016	C/T	cg17804342	chr10:121271663	RGS10	0.57	6.11	0.36	3.88e-9	Obstetric antiphospholipid syndrome;
KIRP	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.67	-10.34	-0.55	4.86e-21	Heart rate;
KIRP	cis	rs9308731	0.583	rs7596789	chr2:111932616	G/A	cg04202892	chr2:111875749	ACOXL	0.48	6.48	0.38	4.85e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg04111992	chr7:158790115	NA	-0.4	-4.86	-0.3	2.06e-6	Facial morphology (factor 20);
KIRP	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.54	5.39	0.33	1.62e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg00792783	chr2:198669748	PLCL1	0.46	5.24	0.32	3.39e-7	Dermatomyositis;
KIRP	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.51	0.65	1.76e-31	Bladder cancer;
KIRP	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	cg12689670	chr1:183009347	LAMC1	0.56	7.79	0.44	1.88e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs6494488	0.500	rs16948170	chr15:64967654	C/T	cg03791955	chr15:65024147	NA	-0.56	-4.87	-0.3	2.01e-6	Coronary artery disease;
KIRP	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg03894339	chr8:19674705	INTS10	0.61	7.34	0.42	3.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg00262122	chr8:11665843	FDFT1	0.42	5.23	0.32	3.63e-7	Myopia (pathological);
KIRP	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.81	0.49	2.36e-16	Motion sickness;
KIRP	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.06	-0.31	8.16e-7	Neutrophil percentage of white cells;
KIRP	cis	rs490234	0.966	rs638168	chr9:128435256	G/A	cg14078157	chr9:128172775	NA	0.39	4.87	0.3	2.04e-6	Mean arterial pressure;
KIRP	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.39	0.38	8.44e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9815354	0.767	rs75651509	chr3:41953564	A/G	cg03022575	chr3:42003672	ULK4	0.83	8.65	0.48	6.79e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-6.81	-0.4	7.49e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs28489187	0.706	rs233066	chr1:85804930	T/C	cg16011679	chr1:85725395	C1orf52	0.55	6.64	0.39	1.98e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg15128208	chr22:42549153	NA	0.7	7.86	0.45	1.17e-13	Birth weight;
KIRP	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	10.08	0.54	3.25e-20	Homoarginine levels;
KIRP	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg23231163	chr10:75533350	FUT11	-0.34	-5.11	-0.31	6.6e-7	Inflammatory bowel disease;
KIRP	cis	rs61884328	0.777	rs17790420	chr11:47169555	G/A	cg23433285	chr11:47201945	PACSIN3	0.65	5.39	0.32	1.66e-7	Total body bone mineral density (age over 60);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13754661	chr9:137533360	COL5A1	-0.45	-6.22	-0.37	2.17e-9	Metabolic traits;
KIRP	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg02931644	chr1:25747376	RHCE	0.37	6.63	0.39	2.13e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.3	-4.93	-0.3	1.5e-6	Height;
KIRP	cis	rs2274459	0.841	rs12203688	chr6:33693624	G/T	cg06253072	chr6:33679850	C6orf125	-0.55	-5.67	-0.34	3.89e-8	Obesity (extreme);
KIRP	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.95	-14.31	-0.67	3.34e-34	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17264240	chr4:186456976	PDLIM3	-0.46	-6.53	-0.38	3.68e-10	Survival in pancreatic cancer;
KIRP	cis	rs77861329	0.748	rs731684	chr3:52109841	T/C	cg08692210	chr3:52188851	WDR51A	0.57	5.51	0.33	9.19e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2346160	0.932	rs2026993	chr6:167661034	T/C	cg27333441	chr6:167680455	NA	0.44	5.89	0.35	1.23e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg23978390	chr7:1156363	C7orf50	0.42	5.08	0.31	7.3e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.32	1.9e-7	Menopause (age at onset);
KIRP	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.57	-0.33	6.74e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	0.75	10.94	0.57	5.86e-23	Prudent dietary pattern;
KIRP	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.33	0.37	1.12e-9	Rheumatoid arthritis;
KIRP	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	0.95	11.72	0.6	1.74e-25	Corneal structure;
KIRP	cis	rs240764	0.658	rs9404054	chr6:101256597	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-5.1	-0.31	6.71e-7	Neuroticism;
KIRP	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.88	10.11	0.54	2.49e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6568686	0.577	rs174398	chr6:111919462	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.51	5.14	0.31	5.64e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg10818794	chr15:86012489	AKAP13	-0.5	-7.17	-0.42	8.83e-12	Coronary artery disease;
KIRP	cis	rs1010254	0.559	rs72808307	chr5:151728607	G/A	cg12297329	chr5:152029980	NA	-0.66	-6.71	-0.39	1.29e-10	Optic nerve measurement (cup area);
KIRP	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.92	11.45	0.59	1.34e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg15488143	chr7:128924101	AHCYL2	0.43	5.0	0.3	1.08e-6	White matter hyperintensity burden;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.96	-0.3	1.34e-6	Life satisfaction;
KIRP	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.71	10.49	0.56	1.56e-21	HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg05370193	chr1:21551575	ECE1	0.43	5.5	0.33	9.62e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.42	-5.16	-0.31	5.04e-7	Neurofibrillary tangles;
KIRP	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.66	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.52	0.65	1.65e-31	Platelet count;
KIRP	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.57	7.47	0.43	1.38e-12	Vitiligo;
KIRP	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg08125733	chr17:73851984	WBP2	0.43	5.36	0.32	1.87e-7	White matter hyperintensity burden;
KIRP	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.53	6.72	0.39	1.24e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.17	-0.31	4.79e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.19	-0.61	4.63e-27	Ulcerative colitis;
KIRP	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg10223061	chr2:219282414	VIL1	-0.39	-6.39	-0.38	8.32e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.6	-12.28	-0.62	2.45e-27	Diabetic kidney disease;
KIRP	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg08999081	chr20:33150536	PIGU	0.47	6.29	0.37	1.48e-9	Height;
KIRP	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21545522	chr1:205238299	TMCC2	0.49	6.47	0.38	5.39e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05025164	chr4:1340916	KIAA1530	0.75	10.07	0.54	3.41e-20	Longevity;
KIRP	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg04034577	chr2:241836375	C2orf54	-0.46	-9.05	-0.5	4.57e-17	Urinary metabolites;
KIRP	cis	rs4950322	0.570	rs72691012	chr1:146711400	G/C	cg22381352	chr1:146742008	CHD1L	-0.41	-4.96	-0.3	1.34e-6	Protein quantitative trait loci;
KIRP	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-5.78	-0.35	2.26e-8	Total body bone mineral density;
KIRP	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18252515	chr7:66147081	NA	0.46	5.67	0.34	3.9e-8	Aortic root size;
KIRP	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg04310649	chr10:35416472	CREM	-0.54	-6.09	-0.36	4.35e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6987853	0.966	rs2923439	chr8:42429122	A/G	cg09913449	chr8:42400586	C8orf40	0.41	5.37	0.32	1.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2554380	0.943	rs979543	chr15:84352564	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.53	-7.63	-0.44	5.07e-13	Height;
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14169450	chr9:139327907	INPP5E	0.42	6.0	0.36	7.05e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13606994	chr1:44402422	ARTN	-0.28	-5.39	-0.33	1.64e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.66	-8.93	-0.49	1.01e-16	Huntington's disease progression;
KIRP	cis	rs12643440	0.538	rs6834807	chr4:17138244	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg24296786	chr1:45957014	TESK2	0.5	5.51	0.33	8.93e-8	Homocysteine levels;
KIRP	cis	rs357618	0.965	rs187180	chr5:150847995	G/A	cg22672639	chr5:150884813	FAT2	0.35	5.34	0.32	2.15e-7	Basophil percentage of white cells;
KIRP	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.47	0.48	2.29e-15	Prudent dietary pattern;
KIRP	trans	rs3730682	0.694	rs648383	chr18:51778993	G/C	cg02273398	chr6:50817400	NA	0.5	6.12	0.36	3.74e-9	Psoriasis;
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.16	-0.37	2.96e-9	Lung cancer;
KIRP	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.35	1.28e-8	Mean platelet volume;
KIRP	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg10523679	chr1:76189770	ACADM	-0.48	-6.58	-0.39	2.88e-10	Daytime sleep phenotypes;
KIRP	cis	rs7656342	0.621	rs13152172	chr4:9855141	C/G	cg11266682	chr4:10021025	SLC2A9	0.32	5.05	0.31	8.56e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs10214930	0.602	rs2098315	chr7:27580645	T/A	cg22168087	chr7:27702803	HIBADH	0.47	5.0	0.3	1.08e-6	Hypospadias;
KIRP	trans	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.03	-0.41	2.01e-11	Diabetic kidney disease;
KIRP	cis	rs9400467	0.537	rs354533	chr6:111487104	T/G	cg15721981	chr6:111408429	SLC16A10	0.77	7.12	0.41	1.16e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs687432	0.774	rs12796166	chr11:57881420	T/G	cg19752551	chr11:57585705	CTNND1	-0.64	-8.23	-0.46	1.09e-14	Parkinson's disease;
KIRP	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg05669848	chr5:237993	SDHA	-0.49	-5.18	-0.31	4.67e-7	Breast cancer;
KIRP	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.45	-0.47	2.65e-15	Mood instability;
KIRP	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg05669848	chr5:237993	SDHA	-0.48	-5.0	-0.3	1.09e-6	Breast cancer;
KIRP	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.8	10.27	0.55	7.81e-21	Mean platelet volume;
KIRP	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.45	-5.73	-0.34	2.99e-8	Schizophrenia;
KIRP	cis	rs2281603	1.000	rs2281603	chr14:64926097	T/C	cg25009451	chr14:65006716	HSPA2	0.51	5.53	0.33	8.25e-8	Lymphocyte counts;
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg15181151	chr6:150070149	PCMT1	0.29	4.96	0.3	1.32e-6	Lung cancer;
KIRP	trans	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg10756647	chr7:56101905	PSPH	0.91	7.13	0.41	1.08e-11	Diabetic kidney disease;
KIRP	cis	rs12806663	1	rs12806663	chr11:62001414	C/A	cg01969543	chr11:61895209	INCENP	0.64	6.39	0.38	8.25e-10	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
KIRP	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.37	-4.99	-0.3	1.14e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.38	-0.43	2.45e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9513627	1.000	rs7338761	chr13:100119731	A/G	cg25919922	chr13:100150906	NA	-0.66	-5.32	-0.32	2.35e-7	Obesity-related traits;
KIRP	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg17294928	chr15:75287854	SCAMP5	-0.71	-6.34	-0.37	1.11e-9	Lung cancer;
KIRP	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	0.99	18.45	0.76	2.6e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.43	9.25	0.51	1.13e-17	Vitiligo;
KIRP	cis	rs35771425	0.600	rs1020336	chr1:211661016	C/T	cg10512769	chr1:211675356	NA	-0.68	-8.21	-0.46	1.23e-14	Educational attainment (years of education);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03281393	chr13:99479732	DOCK9	0.56	7.12	0.41	1.18e-11	Interleukin-4 levels;
KIRP	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg24315340	chr6:146058215	EPM2A	-0.38	-4.86	-0.3	2.07e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.91	-10.43	-0.55	2.42e-21	Diastolic blood pressure;
KIRP	cis	rs17092148	1.000	rs62211612	chr20:33386156	C/T	cg16810054	chr20:33298113	TP53INP2	0.45	5.6	0.34	5.78e-8	Neuroticism;
KIRP	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.26	0.55	8.41e-21	Coffee consumption (cups per day);
KIRP	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.7	-7.06	-0.41	1.65e-11	Vitiligo;
KIRP	cis	rs9914544	0.564	rs7223173	chr17:18805887	A/G	cg26378065	chr17:18585709	ZNF286B	0.39	4.86	0.3	2.12e-6	Educational attainment (years of education);
KIRP	cis	rs1832871	0.672	rs9456285	chr6:158732819	T/G	cg07215822	chr6:158701037	NA	-0.65	-7.44	-0.43	1.7e-12	Height;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20407834	chr10:129797019	PTPRE	-0.41	-6.16	-0.37	2.92e-9	Inflammatory biomarkers;
KIRP	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.59	-0.48	9.95e-16	Mood instability;
KIRP	cis	rs7814319	0.700	rs871798	chr8:97257982	T/C	cg20787634	chr8:97240163	UQCRB	-0.59	-7.79	-0.44	1.91e-13	Lung function (FVC);
KIRP	cis	rs3857067	1.000	rs2219755	chr4:95015684	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.42	-6.21	-0.37	2.28e-9	Height;
KIRP	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg16141378	chr3:129829833	LOC729375	0.55	7.02	0.41	2.11e-11	Triglycerides;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg09355771	chr2:177043147	NA	0.51	6.8	0.4	7.88e-11	IgG glycosylation;
KIRP	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.14	-0.41	1.03e-11	Morning vs. evening chronotype;
KIRP	cis	rs4006360	0.632	rs4986668	chr17:39250408	T/G	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg13628971	chr7:2884303	GNA12	0.62	7.25	0.42	5.33e-12	Height;
KIRP	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.4	-6.16	-0.37	2.91e-9	Body mass index;
KIRP	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.58	7.58	0.44	6.83e-13	Retinal vascular caliber;
KIRP	cis	rs6568686	0.730	rs4947120	chr6:111819044	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.58	-5.29	-0.32	2.66e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02196731	chr4:87855982	AFF1	0.5	6.18	0.37	2.63e-9	Parkinson's disease;
KIRP	trans	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.21	-0.42	6.77e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg15181151	chr6:150070149	PCMT1	0.32	5.39	0.33	1.64e-7	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01688141	chr8:23539808	NKX3-1	0.5	6.04	0.36	5.54e-9	Smoking initiation;
KIRP	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg02023728	chr11:77925099	USP35	0.35	5.75	0.34	2.64e-8	Alzheimer's disease (survival time);
KIRP	cis	rs6681460	0.934	rs4655635	chr1:67068240	T/G	cg02459107	chr1:67143332	SGIP1	0.43	6.29	0.37	1.43e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.08	0.31	7.51e-7	Smoking behavior;
KIRP	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.65	8.08	0.46	2.97e-14	Breast cancer;
KIRP	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg03959625	chr15:84868606	LOC388152	0.61	7.16	0.42	9.3e-12	Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10718078	chr1:201951076	RNPEP	-0.44	-6.17	-0.37	2.78e-9	Inflammatory biomarkers;
KIRP	cis	rs35740288	0.770	rs11631386	chr15:86191995	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-5.29	-0.32	2.73e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg23533926	chr12:111358616	MYL2	-0.48	-6.35	-0.38	1.01e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	0.7	5.27	0.32	2.96e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.68	-9.16	-0.5	2.17e-17	Eye color traits;
KIRP	cis	rs2908197	0.762	rs2908192	chr7:75949617	C/T	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.27	-4.91	-0.3	1.68e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-1.0	-10.5	-0.56	1.52e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs9815354	1.000	rs1716685	chr3:41925301	C/T	cg03022575	chr3:42003672	ULK4	0.48	5.42	0.33	1.43e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs7116495	0.609	rs1892920	chr11:71702431	A/G	cg18441811	chr11:71824068	C11orf51	-0.83	-5.58	-0.34	6.41e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2391754	0.596	rs6948683	chr7:29337609	G/A	cg00901138	chr7:29329370	CHN2	-0.43	-5.25	-0.32	3.24e-7	CSF tryptophan concentration in tuberculous meningitis;
KIRP	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg13147721	chr7:65941812	NA	-0.99	-6.64	-0.39	1.98e-10	Diabetic kidney disease;
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05025164	chr4:1340916	KIAA1530	0.54	7.12	0.41	1.18e-11	Longevity;
KIRP	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.63	8.03	0.46	4.1e-14	Iron status biomarkers;
KIRP	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg25753631	chr6:25732923	NA	-0.28	-5.3	-0.32	2.53e-7	Iron status biomarkers;
KIRP	cis	rs6693567	0.565	rs1260404	chr1:150304150	T/A	cg09579323	chr1:150459698	TARS2	0.4	5.07	0.31	7.86e-7	Migraine;
KIRP	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg16141378	chr3:129829833	LOC729375	0.61	8.2	0.46	1.33e-14	Triglycerides;
KIRP	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.99	-0.45	5.16e-14	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg11693508	chr17:37793320	STARD3	-0.71	-7.74	-0.44	2.65e-13	Bipolar disorder;
KIRP	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg05347473	chr6:146136440	FBXO30	0.61	8.62	0.48	8.4e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13198984	chr17:80129470	CCDC57	-0.54	-8.15	-0.46	1.81e-14	Life satisfaction;
KIRP	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.51	-6.34	-0.37	1.1e-9	Neurofibrillary tangles;
KIRP	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.37	8.48	0.48	2.18e-15	Asthma (sex interaction);
KIRP	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg16558253	chr16:72132732	DHX38	-0.5	-7.22	-0.42	6.58e-12	Fibrinogen levels;
KIRP	cis	rs752010	0.967	rs6703597	chr1:42097904	C/T	cg06885757	chr1:42089581	HIVEP3	0.62	9.51	0.52	1.83e-18	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-10.1	-0.54	2.82e-20	Total body bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11926764	chr11:92930916	SLC36A4	-0.52	-6.36	-0.38	1e-9	Interleukin-4 levels;
KIRP	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	8.57	0.48	1.13e-15	Neuroticism;
KIRP	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg20140201	chr2:241835670	C2orf54	-0.31	-4.92	-0.3	1.59e-6	Urinary metabolites;
KIRP	cis	rs741951	1.000	rs741951	chr21:46269526	G/A	cg08823554	chr21:46269191	NA	-0.69	-6.39	-0.38	8.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.43	-6.28	-0.37	1.5e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs11671005	0.693	rs11084542	chr19:58932099	T/A	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs13132184	0.507	rs67733859	chr4:38042347	G/A	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.19	-0.31	4.45e-7	Verbal declarative memory;
KIRP	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.55	0.52	1.36e-18	Prudent dietary pattern;
KIRP	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg19847130	chr8:10466454	RP1L1	0.37	5.54	0.33	7.69e-8	Retinal vascular caliber;
KIRP	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.59	0.34	6e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.79	-10.18	-0.54	1.56e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioma;Non-glioblastoma glioma;Glioblastoma;
KIRP	trans	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.71	-0.44	3.05e-13	Colorectal cancer;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.62	9.31	0.51	7.24e-18	Lung cancer;
KIRP	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.36	-5.27	-0.32	2.91e-7	Body mass index;
KIRP	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.84	12.16	0.61	5.94e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-10.4	-0.55	3.12e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.72	9.25	0.51	1.12e-17	Age at first birth;
KIRP	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.9	-0.45	9.06e-14	Homocysteine levels;
KIRP	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg03609598	chr5:56110824	MAP3K1	0.46	5.35	0.32	2.03e-7	Initial pursuit acceleration;
KIRP	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.82	9.38	0.51	4.45e-18	Response to diuretic therapy;
KIRP	cis	rs6681460	0.932	rs523188	chr1:67174422	A/G	cg13052034	chr1:66999238	SGIP1	0.38	5.21	0.32	3.94e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs11078597	0.708	rs7503952	chr17:1649259	G/C	cg17514665	chr17:1657533	SERPINF2	0.45	5.66	0.34	4.22e-8	Serum albumin level;
KIRP	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	0.74	10.26	0.55	8.63e-21	Red blood cell count;
KIRP	cis	rs6669119	0.668	rs17352385	chr1:19087695	A/G	cg26220594	chr1:19110978	NA	0.67	6.16	0.37	3.02e-9	Percentage gas trapping;
KIRP	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.52	7.67	0.44	4.03e-13	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.7	-9.01	-0.5	5.87e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg00074818	chr8:8560427	CLDN23	-0.28	-5.01	-0.3	1.06e-6	Neuroticism;
KIRP	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.51	-0.43	1.06e-12	Neuroticism;
KIRP	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.27	26.0	0.86	1.6e-72	IgG glycosylation;
KIRP	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.85e-7	Diabetic retinopathy;
KIRP	cis	rs9372253	0.564	rs2057151	chr6:110716608	G/C	cg19196401	chr6:110721138	DDO	-0.41	-5.96	-0.36	8.54e-9	Platelet distribution width;
KIRP	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-9.27	-0.51	9.82e-18	Total body bone mineral density;
KIRP	cis	rs829661	0.793	rs2593442	chr2:30846262	G/A	cg10949345	chr2:30726833	LCLAT1	1.1	13.49	0.65	2.06e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.81	-0.35	1.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs13102973	0.645	rs11734870	chr4:135885118	T/A	cg14419869	chr4:135874104	NA	0.38	6.02	0.36	6.18e-9	Subjective well-being;
KIRP	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.72	-8.5	-0.48	1.82e-15	Blood pressure (smoking interaction);
KIRP	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.56e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.47	-0.33	1.09e-7	Aortic root size;
KIRP	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs12282928	0.918	rs1503174	chr11:48246336	A/G	cg26585981	chr11:48327164	OR4S1	-0.5	-5.66	-0.34	4.15e-8	Migraine - clinic-based;
KIRP	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.92	-10.58	-0.56	8.28e-22	Diastolic blood pressure;
KIRP	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg23067535	chr8:124195133	FAM83A	-0.72	-7.1	-0.41	1.31e-11	Urinary uromodulin levels;
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs4936891	0.542	rs10790620	chr11:123863989	C/T	cg22125253	chr11:123886957	OR10G4	-0.4	-5.67	-0.34	4.02e-8	Male fertility;
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg01765077	chr12:122356316	WDR66	0.49	6.48	0.38	4.97e-10	Mean corpuscular volume;
KIRP	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg20368463	chr18:77673604	PQLC1	0.66	5.48	0.33	1.05e-7	Opioid sensitivity;
KIRP	cis	rs4236601	0.778	rs4730751	chr7:116180850	C/A	cg05166801	chr7:116143459	CAV2	0.42	4.9	0.3	1.71e-6	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs259282	0.584	rs10416758	chr19:33107716	C/T	cg02997394	chr19:33096574	ANKRD27	-0.52	-6.13	-0.36	3.41e-9	Schizophrenia;
KIRP	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg22138327	chr13:27999177	GTF3A	-1.02	-7.62	-0.44	5.38e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7202877	0.656	rs977986	chr16:75506696	T/G	cg03315344	chr16:75512273	CHST6	0.58	5.55	0.33	7.2e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.21	0.46	1.25e-14	IgG glycosylation;
KIRP	cis	rs9616064	0.670	rs9616045	chr22:46949292	C/T	cg05621596	chr22:47072043	GRAMD4	-0.49	-5.09	-0.31	7.04e-7	Urate levels in obese individuals;
KIRP	trans	rs225245	0.782	rs321599	chr17:33905745	C/T	cg19694781	chr19:47549865	TMEM160	-0.53	-6.49	-0.38	4.73e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs5770872	0.511	rs56168974	chr22:50831338	A/G	cg09860653	chr1:19970708	NBL1	-0.56	-6.87	-0.4	5.38e-11	Tonsillectomy;
KIRP	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg11941060	chr3:133502564	NA	-0.51	-6.1	-0.36	4.04e-9	Iron status biomarkers;
KIRP	cis	rs17030434	0.654	rs10021447	chr4:154646459	A/C	cg14289246	chr4:154710475	SFRP2	-0.66	-7.6	-0.44	6.22e-13	Electrocardiographic conduction measures;
KIRP	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.3	-0.37	1.33e-9	Total cholesterol levels;
KIRP	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg02725872	chr8:58115012	NA	-0.51	-6.5	-0.38	4.36e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6466055	0.777	rs2299308	chr7:104825819	A/C	cg04380332	chr7:105027541	SRPK2	-0.62	-9.18	-0.5	1.89e-17	Schizophrenia;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg01013754	chr1:224622131	WDR26	-0.5	-6.35	-0.38	1.06e-9	Migraine with aura;
KIRP	cis	rs34779708	0.733	rs7086715	chr10:35541840	A/G	cg03585969	chr10:35415529	CREM	0.61	7.05	0.41	1.78e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1569175	0.655	rs10166751	chr2:200882982	T/A	cg17644776	chr2:200775616	C2orf69	-0.69	-4.92	-0.3	1.61e-6	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Body mass index;
KIRP	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg22705602	chr4:152727874	NA	-0.51	-8.61	-0.48	8.89e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4356932	1.000	rs4859415	chr4:76956528	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg00405596	chr8:11794950	NA	-0.4	-5.06	-0.31	8.03e-7	Retinal vascular caliber;
KIRP	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg08738300	chr3:44038990	NA	0.66	9.16	0.5	2.08e-17	Coronary artery disease;
KIRP	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.39	7.61	0.44	5.69e-13	Height;
KIRP	cis	rs17539620	0.624	rs56737784	chr6:154848694	C/T	cg20019720	chr6:154832845	CNKSR3	0.44	5.83	0.35	1.73e-8	Lipoprotein (a) levels;
KIRP	cis	rs7017914	0.902	rs11991273	chr8:71645860	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg26022315	chr17:47021804	SNF8	0.42	5.44	0.33	1.31e-7	Type 2 diabetes;
KIRP	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg05362011	chr13:21860987	NA	-0.48	-5.35	-0.32	2.05e-7	White matter hyperintensity burden;
KIRP	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.43	6.21	0.37	2.25e-9	Sitting height ratio;
KIRP	cis	rs9603616	0.719	rs4277227	chr13:40239003	A/T	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg18154014	chr19:37997991	ZNF793	-0.7	-7.63	-0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg13736514	chr6:26305472	NA	-0.5	-6.34	-0.37	1.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.85	0.35	1.56e-8	Morning vs. evening chronotype;
KIRP	cis	rs2019216	0.500	rs6565385	chr17:21897646	C/A	cg22648282	chr17:21454238	C17orf51	-0.52	-6.56	-0.39	3.16e-10	Pelvic organ prolapse;
KIRP	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg20636351	chr8:55087400	NA	-0.62	-7.67	-0.44	4.06e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	0.9	10.49	0.56	1.66e-21	Testicular germ cell tumor;
KIRP	cis	rs9928842	0.770	rs8048371	chr16:75275547	C/T	cg09066997	chr16:75300724	BCAR1	0.64	5.47	0.33	1.13e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.51	6.07	0.36	4.79e-9	Corneal astigmatism;
KIRP	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.64	-7.29	-0.42	4.19e-12	Menarche (age at onset);
KIRP	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg01879757	chr17:41196368	BRCA1	-0.79	-10.85	-0.57	1.15e-22	Menopause (age at onset);
KIRP	cis	rs3733418	0.929	rs12507869	chr4:165895674	T/C	cg10852876	chr4:165953100	TRIM60	-0.48	-5.32	-0.32	2.29e-7	Obesity-related traits;
KIRP	trans	rs2504916	0.955	rs2504930	chr6:160845219	T/C	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.59	-6.04	-0.36	5.73e-9	Response to hepatitis C treatment;
KIRP	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg04306507	chr14:55594613	LGALS3	0.49	7.66	0.44	4.31e-13	Protein biomarker;
KIRP	cis	rs3789045	0.707	rs61421373	chr1:204560440	C/T	cg08641003	chr1:204589008	LRRN2	-0.51	-5.62	-0.34	5.25e-8	Educational attainment (college completion);
KIRP	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg20140201	chr2:241835670	C2orf54	0.35	5.02	0.3	9.86e-7	Urinary metabolites;
KIRP	cis	rs7084402	0.967	rs7897298	chr10:60274606	T/C	cg05938607	chr10:60274200	BICC1	0.42	10.22	0.55	1.15e-20	Refractive error;
KIRP	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg21401794	chr1:90099060	LRRC8C	-0.67	-9.2	-0.51	1.59e-17	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	6.52	0.38	4.03e-10	Height;
KIRP	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	7.57	0.43	7.56e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17515702	chr17:76210520	BIRC5;EPR1	0.46	6.02	0.36	6.47e-9	Parkinson's disease;
KIRP	cis	rs9290877	0.580	rs1568668	chr3:188467286	G/A	cg17392043	chr3:188495102	LPP	-0.5	-6.35	-0.38	1.01e-9	IgE levels;
KIRP	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg18412871	chr13:95254051	GPR180	-0.61	-7.4	-0.43	2.09e-12	Triglyceride levels;
KIRP	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg03060546	chr3:49711283	APEH	-0.6	-6.02	-0.36	6.31e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.51	6.33	0.37	1.15e-9	Menarche (age at onset);
KIRP	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-1.03	-18.72	-0.77	3.19e-49	Height;
KIRP	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg26818010	chr10:134567672	INPP5A	-0.71	-7.93	-0.45	7.65e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.42	5.41	0.33	1.47e-7	Aortic root size;
KIRP	cis	rs2108622	1.000	rs62107762	chr19:15982538	C/G	cg19546583	chr19:16022523	NA	-0.43	-4.98	-0.3	1.21e-6	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg15459742	chr9:111775564	CTNNAL1	0.53	6.05	0.36	5.25e-9	Sleep duration;
KIRP	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg24633833	chr3:10029261	TMEM111	0.53	5.18	0.31	4.72e-7	Alzheimer's disease;
KIRP	cis	rs1971762	0.527	rs784568	chr12:53927554	C/A	cg16917193	chr12:54089295	NA	-0.81	-13.67	-0.66	5.17e-32	Height;
KIRP	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg12315302	chr6:26189340	HIST1H4D	0.82	5.77	0.35	2.32e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2274273	0.837	rs10141552	chr14:55746091	C/T	cg04306507	chr14:55594613	LGALS3	-0.43	-6.57	-0.39	2.95e-10	Protein biomarker;
KIRP	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.66	-8.49	-0.48	1.91e-15	Personality dimensions;
KIRP	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg04780086	chr2:111875790	ACOXL	0.44	6.1	0.36	4.1e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg02570527	chr1:10970165	NA	-0.43	-5.26	-0.32	3.14e-7	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11645754	chr17:21188174	MAP2K3	-0.43	-6.08	-0.36	4.65e-9	Metabolic traits;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.74	6.55	0.39	3.41e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13067260	0.655	rs13315848	chr3:123721267	A/G	cg19918027	chr3:123987645	KALRN	-0.59	-5.43	-0.33	1.37e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.65	-10.3	-0.55	6.66e-21	Calcium levels;
KIRP	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg03959625	chr15:84868606	LOC388152	0.45	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2224391	0.590	rs2753235	chr6:5252182	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.53	6.34	0.37	1.07e-9	Height;
KIRP	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs4728302	0.869	rs7792905	chr7:133595602	G/T	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg02640540	chr1:67518911	SLC35D1	0.4	4.98	0.3	1.21e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg00074818	chr8:8560427	CLDN23	0.4	6.33	0.37	1.16e-9	Obesity-related traits;
KIRP	cis	rs7577696	0.597	rs13006495	chr2:32355490	C/T	cg02381751	chr2:32503542	YIPF4	-0.52	-5.33	-0.32	2.27e-7	Inflammatory biomarkers;
KIRP	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg08501292	chr6:25962987	TRIM38	-1.1	-8.13	-0.46	2.13e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.75	0.49	3.51e-16	Bipolar disorder;
KIRP	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg14829360	chr17:73884958	NA	-0.47	-6.27	-0.37	1.63e-9	White matter hyperintensity burden;
KIRP	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg07382826	chr16:28625726	SULT1A1	0.47	5.19	0.31	4.33e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9826463	0.640	rs11714087	chr3:142405348	T/C	cg20824294	chr3:142316082	PLS1	0.4	5.25	0.32	3.27e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs281408	0.559	rs204248	chr19:49216224	G/C	cg13540341	chr19:49222985	MAMSTR	0.37	6.25	0.37	1.78e-9	Urinary metabolites (H-NMR features);
KIRP	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.05	0.36	5.3300000000000004e-09	Ovarian reserve;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.47	-5.9	-0.35	1.22e-8	Longevity;Endometriosis;
KIRP	cis	rs9381040	0.692	rs4714430	chr6:41157054	T/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.44	-5.54	-0.33	7.64e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4594175	0.926	rs9323206	chr14:51621800	C/T	cg23942311	chr14:51606299	NA	0.53	6.9	0.4	4.27e-11	Cancer;
KIRP	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.8	10.14	0.54	2.02e-20	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.32	0.42	3.57e-12	Mean corpuscular volume;
KIRP	cis	rs785830	0.717	rs617453	chr9:223339	A/G	cg14500300	chr9:211689	NA	0.52	6.96	0.41	3.01e-11	Platelet distribution width;
KIRP	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg13147721	chr7:65941812	NA	1.03	7.17	0.42	8.85e-12	Diabetic kidney disease;
KIRP	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg22800045	chr5:56110881	MAP3K1	0.7	7.56	0.43	8.14e-13	Initial pursuit acceleration;
KIRP	cis	rs9912468	0.901	rs67828405	chr17:64324384	C/T	cg19474267	chr17:64306194	PRKCA	0.59	8.41	0.47	3.32e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs1519814	0.956	rs4871036	chr8:121101758	T/C	cg22335954	chr8:121166405	COL14A1	-0.49	-5.07	-0.31	7.83e-7	Breast cancer;
KIRP	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg13628971	chr7:2884303	GNA12	0.6	6.8	0.4	8.06e-11	Height;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01391022	chr12:122360665	WDR66	-0.42	-6.56	-0.39	3.24e-10	Mean corpuscular volume;
KIRP	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg19847130	chr8:10466454	RP1L1	0.33	5.21	0.32	4.02e-7	Triglycerides;
KIRP	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.3	-0.32	2.59e-7	Joint mobility (Beighton score);
KIRP	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg00319359	chr11:70116639	PPFIA1	0.64	6.27	0.37	1.58e-9	Coronary artery disease;
KIRP	cis	rs1978968	0.763	rs9605475	chr22:18463306	T/C	cg02610425	chr22:18483192	MICAL3	0.37	5.6	0.34	5.79e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg12559939	chr2:27858050	GPN1	0.41	5.19	0.31	4.33e-7	Oral cavity cancer;
KIRP	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg20003494	chr4:90757398	SNCA	-0.42	-5.47	-0.33	1.08e-7	Neuroticism;
KIRP	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.56	6.81	0.4	7.31e-11	Eosinophil percentage of white cells;
KIRP	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg08280861	chr8:58055591	NA	-0.53	-4.93	-0.3	1.51e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg00024416	chr22:24240387	NA	-0.35	-5.03	-0.31	9.32e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg11650704	chr1:154556575	ADAR	-0.43	-5.27	-0.32	2.96e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg15117754	chr3:10150083	C3orf24	0.54	5.15	0.31	5.25e-7	Alzheimer's disease;
KIRP	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg08779649	chr13:50194554	NA	0.48	6.38	0.38	8.76e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-1.18	-15.69	-0.71	6.37e-39	Obesity-related traits;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25022560	chr1:205782239	SLC41A1	-0.58	-6.33	-0.37	1.14e-9	Menopause (age at onset);
KIRP	cis	rs1440410	0.571	rs4410482	chr4:144037651	A/T	cg01719995	chr4:144104893	USP38	0.45	6.02	0.36	6.29e-9	Ischemic stroke;
KIRP	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg27426351	chr10:43362370	NA	0.44	6.28	0.37	1.54e-9	Blood protein levels;
KIRP	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-7.29	-0.42	4.11e-12	Vitiligo;
KIRP	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg13319975	chr6:146136371	FBXO30	0.45	6.03	0.36	5.95e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg04607699	chr11:48328132	OR4S1	-0.37	-5.18	-0.31	4.56e-7	HDL cholesterol;
KIRP	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.65	8.26	0.47	9.32e-15	Breast cancer;
KIRP	cis	rs3857067	1.000	rs7685048	chr4:95027784	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.85e-7	QT interval;
KIRP	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.49	-7.4	-0.43	2.11e-12	Resting heart rate;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg23131131	chr22:24373011	LOC391322	-0.55	-6.95	-0.4	3.32e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.44	-5.72	-0.34	3.06e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg24203234	chr3:128598194	ACAD9	0.44	5.03	0.31	9.39e-7	IgG glycosylation;
KIRP	cis	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg04607699	chr11:48328132	OR4S1	-0.39	-5.57	-0.33	6.55e-8	Migraine - clinic-based;
KIRP	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.86	11.36	0.59	2.61e-24	Cognitive function;
KIRP	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	1.05	21.91	0.81	9.7e-60	Parkinson's disease;
KIRP	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.44	-5.58	-0.34	6.25e-8	Initial pursuit acceleration;
KIRP	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	ch.8.33884649F	chr8:33765107	NA	0.54	6.75	0.4	1.05e-10	Body mass index;
KIRP	cis	rs1925690	1.000	rs1925690	chr6:87867063	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.65	-5.03	-0.31	9.29e-7	Entorhinal cortical volume (Alzheimer's disease interaction);
KIRP	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg17554472	chr22:41940697	POLR3H	0.43	5.16	0.31	4.99e-7	Vitiligo;
KIRP	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	12.06	0.61	1.27e-26	Smoking behavior;
KIRP	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.49	6.03	0.36	6.09e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.67	-8.0	-0.45	4.76e-14	Blood protein levels;
KIRP	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	0.71	6.22	0.37	2.08e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6681460	0.966	rs4655646	chr1:67094336	G/A	cg02459107	chr1:67143332	SGIP1	0.49	6.95	0.41	3.21e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.86	12.76	0.63	6.03e-29	Menarche (age at onset);
KIRP	cis	rs977987	0.528	rs9926933	chr16:75501567	A/G	cg07303275	chr16:75499416	TMEM170A	-0.5	-6.07	-0.36	4.73e-9	Dupuytren's disease;
KIRP	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.73	-0.39	1.16e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg01420254	chr6:26195488	NA	0.62	6.21	0.37	2.25e-9	Gout;Renal underexcretion gout;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08065241	chr3:56502265	ERC2	-0.6	-6.54	-0.38	3.63e-10	Menopause (age at onset);
KIRP	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.74	9.18	0.51	1.77e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg18944383	chr4:111397179	ENPEP	0.61	11.1	0.58	1.78e-23	Height;
KIRP	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg25281562	chr12:121454272	C12orf43	0.56	6.52	0.38	4.06e-10	N-glycan levels;
KIRP	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg08717414	chr16:71523259	ZNF19	-0.49	-5.33	-0.32	2.19e-7	Post bronchodilator FEV1;
KIRP	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg21360079	chr12:107162445	NA	-0.67	-9.47	-0.52	2.47e-18	Heart rate;
KIRP	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg12311346	chr5:56204834	C5orf35	-0.37	-4.95	-0.3	1.4e-6	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg26084005	chr2:241760190	KIF1A	-0.49	-6.99	-0.41	2.57e-11	Urinary metabolites;
KIRP	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.23	-0.42	6.1e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.89	0.45	9.98e-14	Lung cancer in ever smokers;
KIRP	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.72	10.72	0.56	2.93e-22	Height;
KIRP	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg03433033	chr1:76189801	ACADM	-0.46	-6.52	-0.38	4e-10	Daytime sleep phenotypes;
KIRP	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.46	5.39	0.33	1.63e-7	Diastolic blood pressure;
KIRP	cis	rs2733310	0.895	rs1657934	chr15:57113810	A/G	cg13626582	chr15:57592083	LOC283663	-0.23	-5.03	-0.31	9.57e-7	Mean platelet volume;
KIRP	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.58	7.0	0.41	2.42e-11	Blood metabolite levels;
KIRP	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg04731861	chr2:219085781	ARPC2	0.26	6.66	0.39	1.82e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg11382394	chr1:2564504	MMEL1	-0.38	-4.87	-0.3	2.02e-6	Ulcerative colitis;
KIRP	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.97	10.29	0.55	6.83e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06583605	chr4:56818360	CEP135	-0.41	-6.47	-0.38	5.2e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	15.05	0.69	1.03e-36	Platelet count;
KIRP	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	7.14	0.41	1.07e-11	Iron status biomarkers;
KIRP	cis	rs2790457	0.792	rs1265845	chr10:28927223	C/T	cg04045419	chr10:28823091	WAC	-0.43	-4.91	-0.3	1.66e-6	Multiple myeloma;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg05562828	chr17:3906858	NA	0.49	7.33	0.42	3.25e-12	Type 2 diabetes;
KIRP	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg05768032	chr16:30646687	NA	-0.42	-5.46	-0.33	1.17e-7	Dementia with Lewy bodies;
KIRP	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg04101203	chr11:20408940	PRMT3	-0.5	-5.06	-0.31	8.24e-7	Pursuit maintenance gain;
KIRP	trans	rs7158300	1.000	rs11849778	chr14:92484227	C/T	cg22777467	chr5:125826160	GRAMD3	0.5	6.04	0.36	5.68e-9	Height;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03216853	chr11:18034662	SERGEF	0.55	6.73	0.39	1.19e-10	Myopia (pathological);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06824382	chr7:47621332	NA	0.44	6.25	0.37	1.78e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs741951	0.508	rs77301499	chr21:46283276	T/C	cg08823554	chr21:46269191	NA	-0.51	-5.24	-0.32	3.5e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.55	-0.43	8.23e-13	Mean corpuscular volume;
KIRP	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-0.88	-9.38	-0.51	4.67e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.14	16.36	0.72	3.37e-41	Breast cancer;
KIRP	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg06558623	chr16:89946397	TCF25	1.09	7.35	0.42	3.01e-12	Skin colour saturation;
KIRP	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	3.92e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg09163369	chr1:210001066	C1orf107	0.58	6.31	0.37	1.31e-9	Orofacial clefts;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10013645	chr10:35501529	CREM	0.6	8.11	0.46	2.33e-14	Interleukin-4 levels;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	trans	rs4650994	0.816	rs2811304	chr1:178596794	A/T	cg05059571	chr16:84539110	KIAA1609	0.56	7.25	0.42	5.49e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18323984	chr6:45386802	RUNX2	-0.41	-6.14	-0.36	3.24e-9	Inflammatory biomarkers;
KIRP	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	6.56	0.39	3.13e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.93	-12.24	-0.62	3.17e-27	Platelet distribution width;
KIRP	cis	rs2976388	0.935	rs2978980	chr8:143757708	T/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.53	-0.38	3.84e-10	Urinary tract infection frequency;
KIRP	cis	rs4742903	0.868	rs4743684	chr9:106852385	A/C	cg14250997	chr9:106856677	SMC2	0.43	5.84	0.35	1.63e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.46	6.37	0.38	9.4e-10	Red blood cell count;
KIRP	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.75	0.71	4.13e-39	Chronic sinus infection;
KIRP	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.83	-0.35	1.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.48	-6.01	-0.36	6.7e-9	Refractive error;
KIRP	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.45	-5.25	-0.32	3.37e-7	Cognitive function;
KIRP	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg23422044	chr7:1970798	MAD1L1	0.71	7.22	0.42	6.51e-12	Bipolar disorder;
KIRP	cis	rs365132	0.875	rs187114	chr5:176364039	A/G	cg16309518	chr5:176445507	NA	-0.79	-11.99	-0.61	2.25e-26	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs17641971	0.662	rs2385229	chr8:50003869	T/C	cg00325661	chr8:49890786	NA	0.44	5.69	0.34	3.54e-8	Blood metabolite levels;
KIRP	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg05370193	chr1:21551575	ECE1	0.41	5.84	0.35	1.69e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.73	-10.13	-0.54	2.18e-20	Plateletcrit;Platelet count;
KIRP	trans	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg17822266	chr1:2720087	NA	-0.46	-6.32	-0.37	1.19e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.44	-8.99	-0.5	6.6e-17	Multiple system atrophy;
KIRP	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.59e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg14228332	chr4:119757509	SEC24D	-0.77	-4.9	-0.3	1.77e-6	Cannabis dependence symptom count;
KIRP	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.86	12.51	0.62	4.09e-28	Personality dimensions;
KIRP	cis	rs2274471	0.678	rs7867965	chr9:5104574	G/T	cg03390472	chr9:5043263	JAK2	-0.43	-4.85	-0.3	2.23e-6	Crohn's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00128877	chr1:47070178	MKNK1	0.54	6.34	0.37	1.07e-9	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17182946	chr8:143406192	TSNARE1	-0.47	-6.12	-0.36	3.68e-9	Parkinson's disease;
KIRP	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg22117172	chr7:91764530	CYP51A1	0.41	5.76	0.34	2.55e-8	Breast cancer;
KIRP	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.96	14.28	0.67	4.14e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg07342512	chr1:65886002	LEPROT;LEPR	-0.9	-6.24	-0.37	1.88e-9	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.5	-7.05	-0.41	1.79e-11	Schizophrenia;
KIRP	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.79	0.57	1.84e-22	Exhaled nitric oxide levels;
KIRP	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg06440553	chr19:41222923	ADCK4;ITPKC	0.45	6.13	0.36	3.48e-9	Coronary artery disease;
KIRP	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg06060754	chr5:176797920	RGS14	0.47	7.2	0.42	7.28e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.02	-0.3	9.85e-7	Obesity-related traits;
KIRP	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.56	6.97	0.41	2.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4789452	0.655	rs2001613	chr17:75383679	C/T	cg02320862	chr17:75370284	SEPT9	-0.36	-4.92	-0.3	1.6e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11446345	chr19:17445677	ANO8	0.53	6.34	0.37	1.09e-9	Smoking initiation;
KIRP	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	4.96	0.3	1.29e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg11941060	chr3:133502564	NA	-0.47	-5.83	-0.35	1.74e-8	Iron status biomarkers;
KIRP	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg05785598	chr3:49045655	WDR6	0.28	5.16	0.31	5.14e-7	Parkinson's disease;
KIRP	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.82	8.19	0.46	1.44e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg26585981	chr11:48327164	OR4S1	-0.4	-4.86	-0.3	2.1e-6	HDL cholesterol;
KIRP	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg25730555	chr22:47059586	GRAMD4	0.52	6.16	0.37	2.93e-9	Urate levels in obese individuals;
KIRP	cis	rs73058052	0.597	rs11083979	chr19:50096144	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	6.03	0.36	6.06e-9	Fibrinogen levels;
KIRP	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.96	14.86	0.69	4.54e-36	Menopause (age at onset);
KIRP	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.36	-5.29	-0.32	2.69e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs479844	0.617	rs12146493	chr11:65547333	G/A	cg04293602	chr11:65553660	OVOL1	0.25	5.33	0.32	2.21e-7	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
KIRP	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg07689907	chr11:61582574	FADS1	0.42	5.16	0.31	5.01e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg12091567	chr17:66097778	LOC651250	-0.83	-10.32	-0.55	5.65e-21	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-0.93	-11.55	-0.59	6.24e-25	Vitiligo;
KIRP	cis	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg00262122	chr8:11665843	FDFT1	-0.44	-5.11	-0.31	6.56e-7	Triglycerides;
KIRP	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg11271282	chr2:238384023	NA	0.46	5.22	0.32	3.81e-7	Prostate cancer;
KIRP	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.32	-6.5	-0.38	4.39e-10	Arsenic metabolism;
KIRP	trans	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.62	0.39	2.26e-10	Coronary artery disease;
KIRP	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	7.55	0.43	8.54e-13	Menarche (age at onset);
KIRP	cis	rs4774830	0.744	rs73420376	chr15:56283648	T/C	cg24530489	chr15:56299380	NA	-0.8	-5.27	-0.32	2.93e-7	Delta-5 desaturase activity;
KIRP	cis	rs7737355	1.000	rs12517604	chr5:130748500	T/C	cg06307176	chr5:131281290	NA	-0.54	-5.88	-0.35	1.34e-8	Life satisfaction;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg06610204	chr17:21030148	DHRS7B	-0.49	-6.53	-0.38	3.68e-10	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs427941	0.562	rs6970800	chr7:101780471	T/C	cg06246474	chr7:101738831	CUX1	0.52	6.34	0.37	1.08e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs11690462	0.963	rs13014464	chr2:26581018	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.41	4.88	0.3	1.89e-6	Coronary artery disease;
KIRP	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.54	6.94	0.4	3.37e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg01529538	chr14:23388837	RBM23	0.41	5.22	0.32	3.8e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs2916247	0.954	rs7011377	chr8:93020588	A/C	cg10183463	chr8:93005414	RUNX1T1	0.56	7.44	0.43	1.65e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs8018808	0.935	rs17824316	chr14:77930407	G/A	cg20045696	chr14:77926864	AHSA1	0.46	5.61	0.34	5.39e-8	Myeloid white cell count;
KIRP	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg00825309	chr19:58991885	ZNF446	-0.58	-7.17	-0.42	8.58e-12	Uric acid clearance;
KIRP	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.91	15.76	0.71	3.8e-39	Metabolic syndrome;
KIRP	cis	rs2236918	0.710	rs851781	chr1:242034868	C/T	cg17736920	chr1:242011382	EXO1	0.47	5.79	0.35	2.1e-8	Menopause (age at onset);
KIRP	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.69	-9.05	-0.5	4.52e-17	Huntington's disease progression;
KIRP	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.57	7.2	0.42	7.15e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.61	-8.88	-0.49	1.46e-16	Urate levels in overweight individuals;
KIRP	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	7.95	0.45	6.88e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg08975724	chr8:8085496	FLJ10661	0.54	7.18	0.42	8.03e-12	Retinal vascular caliber;
KIRP	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg01200585	chr1:228362443	C1orf69	0.47	5.65	0.34	4.46e-8	Diastolic blood pressure;
KIRP	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs877282	0.898	rs11253356	chr10:768604	G/A	cg17470449	chr10:769945	NA	0.67	7.24	0.42	5.86e-12	Uric acid levels;
KIRP	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.11	0.61	8.95e-27	Blood protein levels;
KIRP	cis	rs6832769	1.000	rs473005	chr4:56288125	A/C	cg05960024	chr4:56376020	CLOCK	0.62	8.0	0.45	5.01e-14	Personality dimensions;
KIRP	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg06935464	chr4:38784597	TLR10	0.52	5.23	0.32	3.67e-7	Breast cancer;
KIRP	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg05552183	chr6:42928497	GNMT	-0.68	-7.68	-0.44	3.71e-13	Blood protein levels;
KIRP	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.65	-0.52	6.92e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs1023500	0.956	rs1894713	chr22:42335621	G/A	cg04733989	chr22:42467013	NAGA	-0.52	-5.66	-0.34	4.3e-8	Schizophrenia;
KIRP	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26314531	chr2:26401878	FAM59B	-0.51	-5.7	-0.34	3.47e-8	Gut microbiome composition (summer);
KIRP	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs2151522	0.762	rs34897829	chr6:127163136	A/G	cg21431617	chr6:127135037	NA	0.29	5.2	0.31	4.25e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg11783602	chr8:55087084	NA	-0.58	-7.22	-0.42	6.48e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6987853	0.623	rs10109400	chr8:42455353	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.22	0.32	3.72e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg13775310	chr9:114937099	SUSD1	-0.58	-6.48	-0.38	4.96e-10	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.79	10.71	0.56	3.14e-22	Coronary artery disease;
KIRP	trans	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg06521331	chr12:34319734	NA	-0.5	-6.2	-0.37	2.38e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	18.89	0.77	8.89e-50	Height;
KIRP	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg10047753	chr17:41438598	NA	1.17	19.34	0.78	2.71e-51	Menopause (age at onset);
KIRP	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg04780086	chr2:111875790	ACOXL	0.45	6.27	0.37	1.64e-9	Chronic lymphocytic leukemia;
KIRP	trans	rs1422110	0.819	rs1422114	chr5:85483880	A/G	cg01787110	chr1:109008453	NBPF6	0.7	8.39	0.47	3.95e-15	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.87	-11.4	-0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg10167378	chr1:228756711	NA	0.87	7.13	0.41	1.14e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.77	-10.39	-0.55	3.35e-21	Aortic root size;
KIRP	cis	rs2239815	0.515	rs9625600	chr22:29244395	T/C	cg02153584	chr22:29168773	CCDC117	0.58	5.5	0.33	9.4e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.29	-6.16	-0.37	3.02e-9	Cutaneous nevi;
KIRP	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.33	-0.32	2.22e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6500395	0.735	rs16946340	chr16:48667717	G/A	cg04672837	chr16:48644449	N4BP1	0.44	6.01	0.36	6.77e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2294693	0.634	rs9471470	chr6:41012991	A/T	cg14769373	chr6:40998127	UNC5CL	-0.46	-5.09	-0.31	7.16e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs714515	0.502	rs4916254	chr1:172364012	G/A	cg01573306	chr1:172330400	DNM3	0.42	5.4	0.33	1.59e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	cg21523751	chr1:182988639	NA	0.42	6.6	0.39	2.46e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs259842	0.669	rs16867045	chr2:180720513	C/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.39	-5.13	-0.31	5.91e-7	Blood protein levels;
KIRP	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.7	10.72	0.56	2.93e-22	Retinal vascular caliber;
KIRP	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg08799069	chr10:126477246	METTL10	-0.49	-6.53	-0.38	3.7e-10	Asthma;
KIRP	cis	rs76793172	0.623	rs2014377	chr19:46269313	G/C	cg11657440	chr19:46296263	DMWD	0.74	5.22	0.32	3.75e-7	Eosinophil counts;
KIRP	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg26039829	chr8:22132926	PIWIL2	0.43	5.46	0.33	1.18e-7	Hypertriglyceridemia;
KIRP	cis	rs6504950	0.830	rs12938118	chr17:53037359	T/C	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.75	9.11	0.5	2.87e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg02997394	chr19:33096574	ANKRD27	-0.5	-5.89	-0.35	1.25e-8	Mean platelet volume;
KIRP	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.56	8.49	0.48	2.02e-15	Total body bone mineral density;
KIRP	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg20673841	chr7:107026890	COG5	0.41	5.03	0.31	9.3e-7	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2377585	0.524	rs10505736	chr12:8841834	T/C	cg03761649	chr12:8850719	RIMKLB	0.49	4.93	0.3	1.53e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	ch.8.33884649F	chr8:33765107	NA	0.51	5.96	0.36	8.84e-9	Body mass index;
KIRP	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.77	-7.45	-0.43	1.56e-12	Psoriasis vulgaris;
KIRP	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.28	7.49	0.43	1.26e-12	Primary biliary cholangitis;
KIRP	cis	rs7989336	0.528	rs1927787	chr13:96928111	T/C	cg02571835	chr13:96230311	CLDN10	0.39	5.29	0.32	2.72e-7	Obesity;
KIRP	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.6	8.17	0.46	1.65e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.64	-5.93	-0.35	1.01e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.32	0.42	3.55e-12	Neuroticism;
KIRP	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg00745463	chr17:30367425	LRRC37B	-0.57	-5.71	-0.34	3.2e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg07148914	chr20:33460835	GGT7	0.42	5.16	0.31	5.11e-7	Height;
KIRP	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.61	-6.61	-0.39	2.43e-10	Crohn's disease;
KIRP	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg13962347	chr6:5174647	LYRM4	-0.62	-8.5	-0.48	1.85e-15	Height;
KIRP	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg00012203	chr2:219082015	ARPC2	-0.41	-5.1	-0.31	6.83e-7	Ulcerative colitis;
KIRP	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg22117172	chr7:91764530	CYP51A1	0.36	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.08	0.41	1.49e-11	Testicular germ cell tumor;
KIRP	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg06219351	chr7:158114137	PTPRN2	-0.59	-8.24	-0.47	1e-14	Calcium levels;
KIRP	cis	rs860295	0.557	rs11264372	chr1:155412930	A/G	cg02153340	chr1:155202674	NA	-0.56	-7.35	-0.42	3e-12	Body mass index;
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs2299587	0.554	rs11778309	chr8:17747433	T/C	cg01800426	chr8:17659068	MTUS1	-0.44	-5.27	-0.32	2.92e-7	Economic and political preferences;
KIRP	cis	rs11758351	0.660	rs6918339	chr6:26211780	G/C	cg23601095	chr6:26197514	HIST1H3D	0.56	5.46	0.33	1.17e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.35	0.32	2.03e-7	Diisocyanate-induced asthma;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04141141	chr5:54777774	PPAP2A	0.39	6.23	0.37	2.04e-9	C-reactive protein;
KIRP	cis	rs9644630	0.864	rs4339658	chr8:19347059	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.4	-5.33	-0.32	2.21e-7	Oropharynx cancer;
KIRP	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.56	-0.33	6.85e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs2901460	0.509	rs12465313	chr2:62078301	G/A	cg02183531	chr2:62113199	CCT4	-0.51	-5.22	-0.32	3.88e-7	Mean corpuscular volume;
KIRP	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg10223061	chr2:219282414	VIL1	-0.33	-5.37	-0.32	1.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	1.06	15.34	0.7	1.02e-37	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17505193	chr1:896310	KLHL17	0.5	6.27	0.37	1.6e-9	Parkinson's disease;
KIRP	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.69	10.1	0.54	2.74e-20	Glycated hemoglobin levels;
KIRP	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg15026998	chr2:160761622	LY75	-0.36	-5.2	-0.31	4.12e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.52	6.76	0.4	1e-10	Menopause (age at onset);
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg02733842	chr7:1102375	C7orf50	-0.49	-5.12	-0.31	6.13e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7116495	0.609	rs595062	chr11:71809635	C/T	cg07596299	chr11:71824057	C11orf51	0.93	5.89	0.35	1.29e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.62	7.85	0.45	1.27e-13	Body mass index (adult);
KIRP	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.74	9.28	0.51	9.01e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.46	5.34	0.32	2.09e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg00310523	chr12:86230176	RASSF9	-0.57	-8.93	-0.49	9.94e-17	Major depressive disorder;
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg05255149	chr17:80675120	FN3KRP	-0.45	-4.86	-0.3	2.08e-6	Glycated hemoglobin levels;
KIRP	cis	rs11038871	1.000	rs7949371	chr11:46522304	C/T	cg16389345	chr11:46697382	NA	-0.49	-6.62	-0.39	2.22e-10	Immunoglobulin A;
KIRP	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.75	10.5	0.56	1.48e-21	Parkinson's disease;
KIRP	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.14	14.07	0.67	2.17e-33	IgG glycosylation;
KIRP	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg25664220	chr3:72788482	NA	-0.37	-5.31	-0.32	2.49e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.92	12.65	0.63	1.39e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	1.09	20.03	0.79	1.36e-53	Gut microbiome composition (winter);
KIRP	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg15557168	chr22:42548783	NA	0.37	5.17	0.31	4.83e-7	Cognitive function;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05662582	chr11:93517353	MED17	0.44	6.11	0.36	3.8e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4356932	1.000	rs12233806	chr4:76984263	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg18944383	chr4:111397179	ENPEP	0.62	11.31	0.58	3.64e-24	Height;
KIRP	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.73	7.26	0.42	5.12e-12	Menarche (age at onset);
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03388025	chr16:89894329	SPIRE2	0.42	8.69	0.48	5.32e-16	Vitiligo;
KIRP	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.78	8.78	0.49	2.85e-16	Corneal astigmatism;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19613905	chr15:56757180	MNS1	-0.47	-6.01	-0.36	6.48e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.71	0.49	4.6e-16	IgG glycosylation;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.81	-10.91	-0.57	7.22e-23	Longevity;Endometriosis;
KIRP	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg26205652	chr12:48591994	NA	-0.48	-5.17	-0.31	4.75e-7	Lung cancer;
KIRP	trans	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg06521331	chr12:34319734	NA	-0.53	-6.46	-0.38	5.62e-10	Bladder cancer;
KIRP	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.46	-6.2	-0.37	2.38e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg24253500	chr15:84953950	NA	0.52	5.8	0.35	2.06e-8	Schizophrenia;
KIRP	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg00343986	chr7:65444356	GUSB	-0.4	-4.88	-0.3	1.87e-6	Aortic root size;
KIRP	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.77	12.26	0.62	2.78e-27	Idiopathic membranous nephropathy;
KIRP	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg20578329	chr17:80767326	TBCD	-0.69	-8.0	-0.45	4.79e-14	Breast cancer;
KIRP	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	5.12	0.31	6.1e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	17.44	0.74	6.65e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	12.33	0.62	1.58e-27	Smoking behavior;
KIRP	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg23533926	chr12:111358616	MYL2	-0.48	-6.33	-0.37	1.18e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg00343986	chr7:65444356	GUSB	-0.41	-4.89	-0.3	1.79e-6	Aortic root size;
KIRP	cis	rs73200209	0.912	rs2288134	chr12:116441395	G/T	cg01776926	chr12:116560359	MED13L	-0.45	-5.18	-0.31	4.69e-7	Total body bone mineral density;
KIRP	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20135002	chr11:47629003	NA	-0.48	-5.21	-0.32	4.01e-7	Subjective well-being;
KIRP	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	1.02	10.21	0.55	1.22e-20	Psoriasis;
KIRP	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg17264618	chr3:40429014	ENTPD3	-0.33	-5.02	-0.3	1.01e-6	Renal cell carcinoma;
KIRP	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.48	6.18	0.37	2.62e-9	QT interval;
KIRP	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.57	7.15	0.41	9.86e-12	QRS duration;
KIRP	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg05304507	chr6:116381966	FRK	0.21	5.42	0.33	1.44e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.58	-6.57	-0.39	2.96e-10	Hypospadias;
KIRP	cis	rs8027181	0.839	rs8033073	chr15:73051093	G/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.3	0.42	3.98e-12	Triglyceride levels;
KIRP	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.91	-11.7	-0.6	1.96e-25	Breast cancer;
KIRP	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg00405596	chr8:11794950	NA	0.46	5.7	0.34	3.39e-8	Retinal vascular caliber;
KIRP	cis	rs14403	1.000	rs111667565	chr1:243669012	T/C	cg21452805	chr1:244014465	NA	0.56	5.56	0.33	7.14e-8	Schizophrenia;
KIRP	cis	rs7845219	0.525	rs10956931	chr8:95930301	A/G	cg23172400	chr8:95962367	TP53INP1	-0.28	-5.39	-0.33	1.63e-7	Type 2 diabetes;
KIRP	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg21775007	chr8:11205619	TDH	-0.39	-5.0	-0.3	1.07e-6	Morning vs. evening chronotype;
KIRP	trans	rs7999699	0.902	rs3862745	chr13:48329771	C/T	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg05991184	chr2:219186017	PNKD	0.39	5.38	0.32	1.71e-7	Colorectal cancer;
KIRP	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg07395648	chr5:131743802	NA	-0.35	-5.11	-0.31	6.52e-7	Blood metabolite levels;
KIRP	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.68	8.0	0.45	4.81e-14	DNA methylation (variation);
KIRP	cis	rs7221595	0.825	rs71366590	chr17:4006685	T/A	cg09695851	chr17:3907499	NA	0.54	5.13	0.31	5.8e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.75	-8.18	-0.46	1.5e-14	Diastolic blood pressure;
KIRP	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.02	0.3	1.01e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.67	8.26	0.47	8.94e-15	Dilated cardiomyopathy;
KIRP	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg26827852	chr1:89887630	LOC400759	0.37	5.12	0.31	6.15e-7	Carotid intima media thickness;
KIRP	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18252515	chr7:66147081	NA	0.46	5.66	0.34	4.2e-8	Aortic root size;
KIRP	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.61	-8.03	-0.46	4.16e-14	Inhibitory control;
KIRP	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.81	-8.26	-0.47	8.89e-15	Diisocyanate-induced asthma;
KIRP	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	trans	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg18335740	chr13:41363409	SLC25A15	0.48	7.1	0.41	1.29e-11	Lewy body disease;
KIRP	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.79	12.52	0.62	3.89e-28	Monocyte percentage of white cells;
KIRP	cis	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg27411982	chr8:10470053	RP1L1	-0.54	-7.03	-0.41	2e-11	Neuroticism;
KIRP	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.56	-0.33	6.92e-8	Blood metabolite levels;
KIRP	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg09904177	chr6:26538194	HMGN4	0.53	5.68	0.34	3.7e-8	Small cell lung carcinoma;
KIRP	trans	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.75	-0.4	1.03e-10	Heart rate;
KIRP	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.56	7.43	0.43	1.81e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg24331049	chr13:111365604	ING1	0.96	12.93	0.64	1.64e-29	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg01689657	chr7:91764605	CYP51A1	0.42	6.03	0.36	5.91e-9	Breast cancer;
KIRP	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.46	-6.23	-0.37	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13294100	0.929	rs7030014	chr9:17581661	C/T	cg11213383	chr9:17579734	SH3GL2	-0.52	-6.71	-0.39	1.33e-10	Parkinson's disease;
KIRP	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.67	7.32	0.42	3.58e-12	Corneal astigmatism;
KIRP	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	1.0	17.65	0.75	1.31e-45	Breast cancer;
KIRP	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.01	13.13	0.64	3.3e-30	Corneal structure;
KIRP	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.56	7.48	0.43	1.3e-12	Hemoglobin concentration;
KIRP	cis	rs77633900	0.772	rs2957560	chr15:76700310	A/T	cg21673338	chr15:77095150	SCAPER	-0.63	-5.56	-0.33	6.91e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.62	8.07	0.46	3.18e-14	Systemic lupus erythematosus;
KIRP	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg05665937	chr4:1216051	CTBP1	0.53	7.01	0.41	2.28e-11	Obesity-related traits;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg22023784	chr20:54933826	C20orf108	0.5	6.18	0.37	2.63e-9	Myopia (pathological);
KIRP	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.74	-10.34	-0.55	4.77e-21	Hip circumference adjusted for BMI;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13236315	chr12:53645720	MFSD5	0.53	7.2	0.42	7.24e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs228437	0.529	rs111902295	chr6:135004748	G/A	cg24504307	chr6:134963096	NA	0.45	5.15	0.31	5.36e-7	Melanoma;
KIRP	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg02870584	chr11:65547924	DKFZp761E198	0.42	5.05	0.31	8.63e-7	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
KIRP	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.17	0.37	2.84e-9	Hemoglobin concentration;
KIRP	cis	rs2219968	0.728	rs1988920	chr8:78841080	G/T	cg00738934	chr8:78996279	NA	-0.38	-5.14	-0.31	5.71e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg21573476	chr21:45109991	RRP1B	0.78	10.95	0.57	5.58e-23	Mean corpuscular volume;
KIRP	cis	rs28571765	1	rs28571765	chr8:55449281	T/C	cg19005830	chr8:55467175	NA	-0.56	-4.99	-0.3	1.12e-6	Multiple myeloma;
KIRP	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg06953865	chr19:18549723	ISYNA1	0.42	6.15	0.37	3.06e-9	Breast cancer;
KIRP	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.82	-10.41	-0.55	2.81e-21	Coronary artery disease;
KIRP	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.42	-6.31	-0.37	1.3e-9	Schizophrenia;
KIRP	cis	rs997295	1.000	rs11630417	chr15:68012609	T/C	cg24579218	chr15:68104479	NA	0.37	5.61	0.34	5.54e-8	Motion sickness;
KIRP	cis	rs7903847	0.642	rs7896100	chr10:99156994	C/T	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17467752	chr17:38218738	THRA	-0.57	-7.79	-0.44	1.91e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.79	-0.44	1.89e-13	Retinal vascular caliber;
KIRP	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.65	-7.88	-0.45	1.05e-13	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.44	-0.33	1.26e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg01236616	chr12:121019343	POP5	-1.27	-15.31	-0.7	1.24e-37	Type 1 diabetes nephropathy;
KIRP	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.64	8.96	0.5	8.16e-17	Lymphocyte counts;
KIRP	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.81	-0.4	7.26e-11	Systolic blood pressure;
KIRP	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.41	-5.36	-0.32	1.94e-7	Renal cell carcinoma;
KIRP	cis	rs28834970	0.925	rs2322599	chr8:27211910	G/A	cg23736307	chr8:27182930	PTK2B	-0.48	-6.13	-0.36	3.49e-9	Alzheimer's disease (late onset);
KIRP	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	2.97e-7	Tonsillectomy;
KIRP	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.79	12.03	0.61	1.61e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.17	18.47	0.76	2.24e-48	Cognitive function;
KIRP	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg21858823	chr1:15850916	CASP9	0.54	5.81	0.35	1.92e-8	Systolic blood pressure;
KIRP	cis	rs35123781	1.000	rs601324	chr5:139057179	C/G	cg10513866	chr5:139070639	NA	0.35	4.87	0.3	2e-6	Schizophrenia;
KIRP	cis	rs13326165	0.585	rs11708581	chr3:52428988	C/A	cg01348873	chr3:52349823	DNAH1	0.69	5.15	0.31	5.33e-7	HDL cholesterol;HDL cholesterol levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22962425	chr14:58891595	TIMM9	0.48	7.49	0.43	1.22e-12	Survival in pancreatic cancer;
KIRP	cis	rs7084402	0.967	rs1649032	chr10:60279701	T/C	cg05938607	chr10:60274200	BICC1	0.46	11.06	0.58	2.41e-23	Refractive error;
KIRP	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs6442310	1.000	rs4135247	chr3:12396588	G/A	cg02700894	chr3:12045449	SYN2	-0.38	-5.06	-0.31	8.35e-7	Hematocrit;
KIRP	cis	rs113084984	0.718	rs7568223	chr2:11683423	G/T	cg07314298	chr2:11723111	GREB1	0.39	5.12	0.31	6.04e-7	Breast cancer;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.87	10.07	0.54	3.37e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.79	-0.4	8.23e-11	Longevity;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.24	-0.37	1.9e-9	Lung cancer;
KIRP	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.76e-11	Aortic root size;
KIRP	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg23625390	chr15:77176239	SCAPER	-0.45	-5.9	-0.35	1.2e-8	Blood metabolite levels;
KIRP	cis	rs7665939	0.860	rs61745583	chr4:190125993	A/G	cg09826759	chr4:190284978	NA	-0.81	-5.66	-0.34	4.27e-8	Amyotrophic lateral sclerosis;
KIRP	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg23950597	chr19:37808831	NA	-0.58	-6.2	-0.37	2.37e-9	Coronary artery calcification;
KIRP	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg20198684	chr19:45742032	NA	0.4	5.17	0.31	4.95e-7	Monocyte percentage of white cells;
KIRP	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs41005	1.000	rs193931	chr2:8107435	A/G	cg03155496	chr2:8117019	LOC339788	-0.6	-10.05	-0.54	3.95e-20	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-8.43	-0.47	3.04e-15	Gut microbiome composition (summer);
KIRP	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg13010199	chr12:38710504	ALG10B	0.54	6.68	0.39	1.6e-10	Resting heart rate;
KIRP	cis	rs787274	1.000	rs787272	chr9:115549547	C/T	cg13803584	chr9:115635662	SNX30	0.67	7.22	0.42	6.43e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg12718519	chr1:2058417	PRKCZ	0.22	4.86	0.3	2.11e-6	Height;
KIRP	cis	rs4713118	0.662	rs175954	chr6:28011585	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.18	-0.31	4.6e-7	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg11031976	chr2:198649780	BOLL	-0.51	-4.95	-0.3	1.35e-6	Ulcerative colitis;
KIRP	cis	rs4646404	0.526	rs12939945	chr17:17476914	T/C	cg01246520	chr17:17644344	RAI1	-0.32	-5.6	-0.34	5.86e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.67	-7.99	-0.45	5.16e-14	Menarche (age at onset);
KIRP	cis	rs714515	0.586	rs4916263	chr1:172450689	A/C	cg01573306	chr1:172330400	DNM3	0.4	5.08	0.31	7.54e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg06808227	chr14:105710500	BRF1	-0.79	-10.92	-0.57	6.89e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs5753037	0.869	rs2301402	chr22:30234045	G/A	cg01021169	chr22:30184971	ASCC2	-0.46	-5.32	-0.32	2.34e-7	Type 1 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09567644	chr16:11350363	SOCS1	0.47	6.23	0.37	1.96e-9	Parkinson's disease;
KIRP	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.77	9.02	0.5	5.45e-17	HIV-1 control;
KIRP	cis	rs9434723	0.920	rs2239560	chr1:9304731	C/T	cg04199779	chr1:9294473	H6PD	0.53	6.53	0.38	3.66e-10	Height;
KIRP	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.44	-0.47	2.78e-15	Retinal vascular caliber;
KIRP	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.19	-0.51	1.66e-17	Platelet count;
KIRP	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.43	-0.7	4.83e-38	Alzheimer's disease;
KIRP	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22509189	chr2:225307070	NA	-0.48	-5.49	-0.33	1.01e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-7.38	-0.43	2.37e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.43	0.33	1.35e-7	Resting heart rate;
KIRP	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-11.4	-0.59	1.85e-24	Obesity-related traits;
KIRP	cis	rs939574	0.586	rs3731892	chr2:220136351	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.66	-7.22	-0.42	6.45e-12	Platelet distribution width;
KIRP	cis	rs35123781	0.502	rs355160	chr5:138953589	C/T	cg11459648	chr5:138714337	SLC23A1	-0.35	-4.87	-0.3	2.02e-6	Schizophrenia;
KIRP	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.74	9.81	0.53	2.13e-19	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg23594656	chr7:65796392	TPST1	-0.38	-5.4	-0.33	1.58e-7	Aortic root size;
KIRP	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg19507638	chr5:93509721	C5orf36	-0.58	-5.05	-0.31	8.67e-7	Diabetic retinopathy;
KIRP	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.78	8.87	0.49	1.56e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.21	-0.42	6.97e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7224685	0.817	rs9901620	chr17:4165741	G/C	cg05562828	chr17:3906858	NA	0.54	6.42	0.38	6.85e-10	Type 2 diabetes;
KIRP	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.47	-5.63	-0.34	4.91e-8	Monobrow;
KIRP	cis	rs911119	0.913	rs6106685	chr20:23581612	A/C	cg16589663	chr20:23618590	CST3	0.5	5.13	0.31	5.97e-7	Chronic kidney disease;
KIRP	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	cg21523751	chr1:182988639	NA	0.42	6.45	0.38	5.91e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08392591	chr16:89556376	ANKRD11	-0.43	-5.74	-0.34	2.77e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	8.38	0.47	4.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.6	-6.69	-0.39	1.47e-10	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	1.07	21.28	0.8	1.07e-57	Height;
KIRP	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg00852783	chr1:26633632	UBXN11	0.52	5.62	0.34	5.25e-8	Obesity-related traits;
KIRP	cis	rs11583043	0.575	rs12727971	chr1:101589175	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	5.57	0.33	6.71e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7760949	0.852	rs9464423	chr6:13931851	A/G	cg27413430	chr6:13925136	RNF182	0.52	6.09	0.36	4.23e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs4950322	0.517	rs114823926	chr1:146753478	A/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.49	-0.33	9.88e-8	Protein quantitative trait loci;
KIRP	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.7	-10.28	-0.55	7.61e-21	Hip circumference;
KIRP	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.64	8.16	0.46	1.72e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs812925	0.859	rs778138	chr2:61687214	A/C	cg15711740	chr2:61764176	XPO1	-0.44	-4.98	-0.3	1.21e-6	Immature fraction of reticulocytes;
KIRP	cis	rs6893300	1.000	rs62406177	chr5:179164209	C/G	cg14593053	chr5:179126677	CANX	-0.57	-6.28	-0.37	1.52e-9	Resting heart rate;
KIRP	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.17	-0.61	5.51e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4356932	1.000	rs4401475	chr4:76975924	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs13108043	0.573	rs35245331	chr4:87924755	G/T	cg11209507	chr4:87813803	C4orf36	0.46	4.95	0.3	1.4e-6	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26634707	chr19:59030662	ZBTB45	0.51	6.21	0.37	2.24e-9	Parkinson's disease;
KIRP	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.45	-0.52	2.81e-18	Neuroticism;
KIRP	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.97	12.78	0.63	5.17e-29	Cognitive function;
KIRP	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20041257	chr19:10828819	DNM2;MIR638	0.51	6.38	0.38	8.55e-10	Parkinson's disease;
KIRP	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg18478394	chr8:109455254	TTC35	0.58	7.27	0.42	4.78e-12	Dupuytren's disease;
KIRP	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg00405596	chr8:11794950	NA	0.44	5.51	0.33	9.08e-8	Retinal vascular caliber;
KIRP	cis	rs7719624	0.680	rs1442	chr5:135382989	G/C	cg16684184	chr5:135415129	NA	-0.38	-5.54	-0.33	7.85e-8	Response to cytidine analogues (gemcitabine);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20488697	chr17:79885644	LOC92659;MAFG	0.54	6.26	0.37	1.66e-9	Smoking initiation;
KIRP	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.21	0.37	2.19e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg21851534	chr17:3907994	ZZEF1	0.72	12.14	0.61	6.85e-27	Type 2 diabetes;
KIRP	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.68	-8.37	-0.47	4.39e-15	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg07701084	chr6:150067640	NUP43	0.71	10.0	0.54	5.56e-20	Lung cancer;
KIRP	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.44	5.81	0.35	1.96e-8	Blood metabolite levels;
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg02782426	chr3:40428986	ENTPD3	-0.34	-5.23	-0.32	3.69e-7	Renal cell carcinoma;
KIRP	cis	rs868036	0.560	rs12443086	chr15:68080454	C/A	cg24579218	chr15:68104479	NA	-0.41	-6.34	-0.37	1.1e-9	Restless legs syndrome;
KIRP	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.8	12.14	0.61	7.15e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.8e-8	Body mass index;
KIRP	cis	rs4805272	0.849	rs17591205	chr19:29321469	T/C	cg15000279	chr19:29285009	NA	-0.41	-6.11	-0.36	3.77e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg15226275	chr6:116381976	FRK	0.22	6.01	0.36	6.55e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.25	7.26	0.42	5.18e-12	Type 2 diabetes;
KIRP	cis	rs838147	0.733	rs8106205	chr19:49250197	T/C	cg08619932	chr19:49200058	FUT2	-0.34	-5.01	-0.3	1.02e-6	Dietary macronutrient intake;
KIRP	trans	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19894588	chr14:64061835	NA	0.51	6.97	0.41	2.98e-11	Glioblastoma;Glioma;
KIRP	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.9	-15.75	-0.71	3.99e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.68	8.02	0.46	4.32e-14	Height;
KIRP	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2997447	0.846	rs17257086	chr1:26392535	C/T	cg19633962	chr1:26362018	EXTL1	-0.75	-6.33	-0.37	1.13e-9	QRS complex (12-leadsum);
KIRP	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg23533419	chr12:54090519	NA	-0.32	-5.13	-0.31	5.78e-7	Height;
KIRP	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	1.0	17.27	0.74	2.54e-44	Breast cancer;
KIRP	cis	rs2092850	1	rs2092850	chr6:88100419	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-5.05	-0.31	8.45e-7	Itch intensity from mosquito bite;
KIRP	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg19257562	chr1:2043853	PRKCZ	0.37	5.4	0.33	1.58e-7	Height;
KIRP	cis	rs754423	0.515	rs1950733	chr14:52563772	G/A	cg10149976	chr14:52535953	NID2	-0.39	-5.5	-0.33	9.59e-8	Craniofacial microsomia;
KIRP	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-6.07	-0.36	4.76e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	1.05	19.27	0.78	4.64e-51	Heart rate;
KIRP	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.84	-13.35	-0.65	6.28e-31	Blood metabolite levels;
KIRP	trans	rs7710178	0.938	rs17639646	chr5:155962974	C/T	cg23165310	chr3:181422217	SOX2OT	0.74	6.18	0.37	2.71e-9	Airway responsiveness in chronic obstructive pulmonary disease;
KIRP	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.69	-7.95	-0.45	6.93e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	7.76	0.44	2.3e-13	Bipolar disorder;
KIRP	cis	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg02972257	chr16:68554789	NA	0.73	7.07	0.41	1.61e-11	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02924347	chr16:2390352	ABCA17P;ABCA3	0.51	6.59	0.39	2.65e-10	Parkinson's disease;
KIRP	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg13699009	chr12:122356056	WDR66	-0.51	-6.76	-0.4	9.79e-11	Mean corpuscular volume;
KIRP	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg16342193	chr10:102329863	NA	-0.37	-4.96	-0.3	1.32e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg00383909	chr3:49044727	WDR6	0.55	5.48	0.33	1.07e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg02462569	chr6:150064036	NUP43	-0.37	-5.6	-0.34	5.73e-8	Lung cancer;
KIRP	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.58	8.33	0.47	5.69e-15	Metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03512643	chr14:74486160	C14orf45;ENTPD5	0.5	6.7	0.39	1.39e-10	Parkinson's disease;
KIRP	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg26207909	chr14:103986467	CKB	-0.39	-4.95	-0.3	1.38e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	15.86	0.71	1.69e-39	Height;
KIRP	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	1.04	12.2	0.61	4.38e-27	Response to antineoplastic agents;
KIRP	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.27	-0.42	4.68e-12	Daytime sleep phenotypes;
KIRP	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.71	9.18	0.51	1.86e-17	Educational attainment;
KIRP	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg26875233	chr11:93583750	C11orf90	-0.41	-7.76	-0.44	2.29e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.52	-6.41	-0.38	7.27e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	1.19	15.05	0.69	9.97e-37	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.86	-0.3	2.05e-6	Crohn's disease;
KIRP	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg14092571	chr14:90743983	NA	0.41	4.98	0.3	1.2e-6	Mortality in heart failure;
KIRP	cis	rs6693567	0.565	rs1776275	chr1:150269437	G/T	cg07843065	chr1:150265600	MRPS21	-0.47	-6.71	-0.39	1.36e-10	Migraine;
KIRP	cis	rs13132184	0.507	rs17607518	chr4:38092697	A/G	cg19090437	chr4:38080799	TBC1D1	-0.53	-5.11	-0.31	6.56e-7	Verbal declarative memory;
KIRP	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.36	-5.3	-0.32	2.61e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.71	7.14	0.41	1.04e-11	Chronic kidney disease;
KIRP	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg18944383	chr4:111397179	ENPEP	-0.59	-10.35	-0.55	4.33e-21	Coronary artery disease;
KIRP	cis	rs2738058	0.798	rs2472562	chr8:6812249	A/C	cg02787689	chr8:6828103	DEFA10P	0.27	5.18	0.31	4.69e-7	Periodontitis (PAL4Q3);IgA nephropathy;
KIRP	cis	rs17221829	0.669	rs7128681	chr11:89383644	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-4.9	-0.3	1.71e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg19401529	chr3:49056140	DALRD3	0.92	6.88	0.4	4.91e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs1829883	1.000	rs1523381	chr5:98773754	T/C	cg08333243	chr5:99726346	NA	-0.38	-5.04	-0.31	8.97e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg14458575	chr2:238380390	NA	0.43	4.91	0.3	1.69e-6	Prostate cancer;
KIRP	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.79	-10.96	-0.57	4.98e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4363385	0.510	rs61815707	chr1:152909018	T/C	cg25856811	chr1:152973957	SPRR3	-0.37	-5.12	-0.31	6.07e-7	Inflammatory skin disease;
KIRP	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-8.69	-0.48	5.15e-16	Chronic sinus infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12484756	chr19:10764617	ILF3;LOC147727	0.45	6.25	0.37	1.8e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.8	7.4	0.43	2.18e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.7	7.74	0.44	2.53e-13	Neutrophil percentage of white cells;
KIRP	cis	rs6102059	0.642	rs55965801	chr20:39204273	T/C	cg22477343	chr20:39312069	NA	0.5	6.56	0.39	3.14e-10	LDL cholesterol;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg09699651	chr6:150184138	LRP11	0.47	6.18	0.37	2.59e-9	Lung cancer;
KIRP	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg06565975	chr8:143823917	SLURP1	0.47	7.42	0.43	1.88e-12	Urinary tract infection frequency;
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg11859384	chr17:80120422	CCDC57	-0.44	-5.63	-0.34	4.84e-8	Life satisfaction;
KIRP	cis	rs1497828	0.956	rs5002693	chr1:217530191	T/A	cg04411442	chr1:217543379	NA	-0.43	-6.58	-0.39	2.73e-10	Dialysis-related mortality;
KIRP	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.16	-0.42	9.13e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.53	0.38	3.76e-10	Endometrial cancer;
KIRP	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg17595323	chr11:93583763	C11orf90	-0.39	-6.44	-0.38	6.39e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.4	-5.03	-0.31	9.37e-7	Pubertal anthropometrics;
KIRP	cis	rs9608946	1.000	rs8137718	chr22:30888959	T/C	cg23383138	chr22:30885012	SEC14L4	0.4	4.94	0.3	1.44e-6	Red cell distribution width;
KIRP	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-14.43	-0.68	1.29e-34	Coronary artery disease;
KIRP	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg14593290	chr7:50529359	DDC	-0.67	-8.28	-0.47	7.84e-15	Malaria;
KIRP	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg21132104	chr15:45694354	SPATA5L1	0.72	8.61	0.48	8.92e-16	Homoarginine levels;
KIRP	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.51	-0.38	4.24e-10	Urinary tract infection frequency;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05744073	chr17:1953268	MIR132	0.46	6.09	0.36	4.3e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.26	0.55	8.66e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4073416	0.504	rs2064695	chr14:66067088	A/C	cg03016385	chr14:66212404	NA	-0.38	-5.1	-0.31	6.75e-7	N-glycan levels;
KIRP	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs11203032	0.710	rs10887923	chr10:90930404	C/T	cg16672925	chr10:90967113	CH25H	0.73	7.26	0.42	5.11e-12	Heart failure;
KIRP	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.44	4.96	0.3	1.31e-6	HDL cholesterol;
KIRP	cis	rs16857609	0.628	rs2568159	chr2:218334503	C/T	cg15335768	chr2:218268053	DIRC3	-0.37	-5.52	-0.33	8.54e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg00857998	chr1:205179979	DSTYK	0.62	7.38	0.43	2.41e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4664304	0.629	rs56122507	chr2:160847353	T/C	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.3	-0.32	2.59e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.63	-9.2	-0.51	1.6e-17	Heart rate;
KIRP	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.47	5.97	0.36	8.33e-9	Initial pursuit acceleration;
KIRP	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg27205649	chr11:78285834	NARS2	-0.53	-5.49	-0.33	9.99e-8	Testicular germ cell tumor;
KIRP	cis	rs17301259	0.548	rs2519953	chr7:88402008	T/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.3	-4.92	-0.3	1.57e-6	Heschl's gyrus morphology;
KIRP	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00889227	chr1:205173544	DSTYK	-0.41	-5.8	-0.35	2.06e-8	Red blood cell count;
KIRP	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.5	-0.33	9.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7180079	0.563	rs537130	chr15:64872545	A/G	cg15337035	chr15:64978493	NA	-0.47	-5.12	-0.31	6.12e-7	Monocyte count;
KIRP	cis	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.22e-12	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	7.87	0.45	1.15e-13	Retinal vascular caliber;
KIRP	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg24881330	chr22:46731750	TRMU	0.79	5.46	0.33	1.19e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg17724175	chr1:150552817	MCL1	0.32	5.53	0.33	8.27e-8	Melanoma;
KIRP	cis	rs3784262	0.528	rs17820966	chr15:58336662	A/G	cg12031962	chr15:58353849	ALDH1A2	0.35	4.85	0.3	2.21e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	6.76	0.4	1e-10	Coronary artery disease;
KIRP	cis	rs3026101	0.697	rs1806267	chr17:5322106	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.83	0.35	1.71e-8	Body mass index;
KIRP	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg05347473	chr6:146136440	FBXO30	0.59	8.35	0.47	5.04e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs7688540	0.771	rs4129956	chr4:302008	A/C	cg17891759	chr4:299121	NA	-0.49	-5.0	-0.3	1.11e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.55	-0.39	3.3e-10	Neuroticism;
KIRP	cis	rs4664293	0.967	rs13032135	chr2:160532099	T/C	cg08347373	chr2:160653686	CD302	-0.37	-5.72	-0.34	3.11e-8	Monocyte percentage of white cells;
KIRP	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs12476592	0.516	rs6717060	chr2:63568608	G/A	cg17519650	chr2:63277830	OTX1	-0.42	-4.89	-0.3	1.83e-6	Childhood ear infection;
KIRP	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.63	-6.59	-0.39	2.61e-10	DNA methylation (variation);
KIRP	cis	rs4926298	1.000	rs11085829	chr19:13174312	G/A	cg06417478	chr19:12876846	HOOK2	-0.4	-4.87	-0.3	2.01e-6	Bipolar disorder;
KIRP	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg02297831	chr4:17616191	MED28	0.55	6.89	0.4	4.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.52	6.57	0.39	3.05e-10	Tonsillectomy;
KIRP	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg24848339	chr3:12840334	CAND2	0.36	5.55	0.33	7.33e-8	P wave duration;
KIRP	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	1.18	10.36	0.55	4.28e-21	Gout;Renal underexcretion gout;
KIRP	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.57	7.41	0.43	2.04e-12	Breast cancer;
KIRP	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-7.5	-0.43	1.16e-12	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.98	-0.41	2.73e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs8077577	0.895	rs11658477	chr17:18044893	G/A	cg09161412	chr17:18057145	MYO15A	-0.41	-5.31	-0.32	2.49e-7	Obesity-related traits;
KIRP	cis	rs11225247	0.881	rs77227803	chr11:102255684	T/C	cg06323957	chr11:102217781	BIRC2	0.9	5.33	0.32	2.23e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.41	-0.38	7.22e-10	Uric acid levels;
KIRP	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.26	-5.42	-0.33	1.45e-7	Menarche (age at onset);
KIRP	trans	rs55728055	0.661	rs41302569	chr22:32046953	C/A	cg02791973	chr19:1132256	SBNO2	-0.61	-6.64	-0.39	1.96e-10	Age-related hearing impairment;
KIRP	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12893428	chr3:195717962	SDHAP1	-0.36	-4.9	-0.3	1.71e-6	Mean corpuscular volume;
KIRP	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.59	-7.14	-0.41	1.07e-11	Blood metabolite levels;
KIRP	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg17764715	chr19:33622953	WDR88	0.66	8.26	0.47	9.11e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg14346243	chr4:90757452	SNCA	-0.38	-4.85	-0.3	2.14e-6	Neuroticism;
KIRP	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg15442037	chr11:69286293	NA	-0.55	-6.61	-0.39	2.32e-10	Breast cancer (early onset);
KIRP	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-7.27	-0.42	4.87e-12	Tonsillectomy;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg02445972	chr17:7166593	CLDN7	0.64	6.03	0.36	5.92e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9815354	0.767	rs73830585	chr3:42003698	T/A	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4262150	0.544	rs4391147	chr5:151898364	G/C	cg12297329	chr5:152029980	NA	-0.72	-8.9	-0.49	1.21e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7010876	0.523	rs10104620	chr8:89216061	C/T	cg08624180	chr8:89339080	MMP16	-0.53	-4.97	-0.3	1.25e-6	Schizophrenia;
KIRP	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-0.9	-6.84	-0.4	6.2e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	1.24	10.77	0.57	2.05e-22	Gut microbiota (bacterial taxa);
KIRP	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.44	-0.65	3.06e-31	Height;
KIRP	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg06307176	chr5:131281290	NA	0.54	5.88	0.35	1.35e-8	Life satisfaction;
KIRP	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	cg04338863	chr8:33670619	NA	0.42	5.57	0.33	6.81e-8	Body mass index;
KIRP	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg09455208	chr3:40491958	NA	-0.37	-6.57	-0.39	2.9e-10	Renal cell carcinoma;
KIRP	cis	rs7715811	1.000	rs1502050	chr5:13779743	A/G	cg07548982	chr5:13769939	DNAH5	-0.54	-6.83	-0.4	6.8e-11	Subclinical atherosclerosis traits (other);
KIRP	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-6.97	-0.41	2.9e-11	Fear of minor pain;
KIRP	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.33	-0.37	1.17e-9	Mood instability;
KIRP	cis	rs743757	1.000	rs2073496	chr3:50431142	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.3	0.32	2.56e-7	Diastolic blood pressure;
KIRP	cis	rs9815354	0.812	rs17215883	chr3:41841873	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4740619	0.588	rs1328278	chr9:16030535	G/A	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg14254433	chr6:34482411	PACSIN1	-0.46	-5.5	-0.33	9.61e-8	Pubertal anthropometrics;Coronary artery disease;
KIRP	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-6.42	-0.38	7.09e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7188697	0.882	rs9921370	chr16:58611935	C/A	cg21335942	chr16:58549945	SETD6	-0.46	-5.12	-0.31	6.31e-7	QT interval;
KIRP	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.66	-0.34	4.21e-8	Height;
KIRP	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.71	-10.06	-0.54	3.66e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15179113	chr7:156433342	C7orf13;RNF32	-0.46	-6.24	-0.37	1.9e-9	Metabolic traits;
KIRP	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg07930552	chr6:133119739	C6orf192	0.83	5.4	0.33	1.56e-7	Type 2 diabetes nephropathy;
KIRP	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.78	0.4	8.91e-11	Coffee consumption (cups per day);
KIRP	cis	rs1359582	1.000	rs2576163	chr10:90327666	A/T	cg15661332	chr10:90342814	RNLS	0.55	5.22	0.32	3.84e-7	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.64	8.53	0.48	1.56e-15	Prostate cancer;
KIRP	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.47	7.62	0.44	5.64e-13	Testicular germ cell tumor;
KIRP	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.92	13.31	0.65	8.57e-31	Tonsillectomy;
KIRP	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.29	0.47	7.23e-15	Personality dimensions;
KIRP	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg07451762	chr16:28383216	NA	0.38	4.93	0.3	1.51e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg17434043	chr11:2907123	CDKN1C	0.47	6.43	0.38	6.6e-10	Asthma;
KIRP	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7527798	0.592	rs12144801	chr1:207857773	A/G	cg09232269	chr1:207846808	CR1L	-0.36	-5.27	-0.32	2.93e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs3026101	0.671	rs886361	chr17:5292762	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.91	9.92	0.53	9.89e-20	Corneal astigmatism;
KIRP	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.88	-12.61	-0.63	1.9e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg05315796	chr3:52349193	DNAH1	0.44	6.71	0.39	1.3100000000000001e-10	Bipolar disorder;
KIRP	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg05721485	chr17:44071124	MAPT	0.6	7.74	0.44	2.57e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.48	1.43e-15	Motion sickness;
KIRP	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.64	6.98	0.41	2.73e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg02023728	chr11:77925099	USP35	-0.31	-5.35	-0.32	2.04e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7181230	1.000	rs28620926	chr15:40357171	A/G	cg00868766	chr15:40364524	NA	0.35	5.39	0.32	1.65e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg26205652	chr12:48591994	NA	0.48	5.05	0.31	8.42e-7	Lung cancer;
KIRP	cis	rs16975963	0.644	rs73037036	chr19:38161070	A/T	cg18030218	chr19:38865513	PSMD8	0.56	5.05	0.31	8.61e-7	Longevity;
KIRP	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg04455712	chr21:45112962	RRP1B	-0.39	-5.07	-0.31	7.7300000000000005e-07	Mean corpuscular hemoglobin;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09517757	chr8:58174422	NA	0.47	7.17	0.42	8.57e-12	Survival in pancreatic cancer;
KIRP	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	5.76	0.34	2.48e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs79881201	0.640	rs77192209	chr5:110472216	C/G	cg04022379	chr5:110408740	TSLP	-0.51	-5.69	-0.34	3.66e-8	Sum eosinophil basophil counts;
KIRP	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10073892	0.743	rs10063002	chr5:101655572	C/T	cg19774478	chr5:101632501	SLCO4C1	0.63	6.52	0.38	3.92e-10	Cognitive decline (age-related);
KIRP	cis	rs1298062	0.790	rs1274604	chr19:50969325	A/G	cg11430371	chr19:50961752	MYBPC2	0.37	4.94	0.3	1.43e-6	Age of smoking initiation;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg07701084	chr6:150067640	NUP43	0.73	10.01	0.54	5.25e-20	Lung cancer;
KIRP	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.16	-10.75	-0.57	2.31e-22	Body mass index;
KIRP	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg02495767	chr7:1030999	NA	-0.42	-5.81	-0.35	1.93e-8	Longevity;Endometriosis;
KIRP	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg00495681	chr13:53174319	NA	0.38	5.18	0.31	4.58e-7	Lewy body disease;
KIRP	cis	rs76793172	1.000	rs7257342	chr19:46356418	C/T	cg00442267	chr19:46317840	RSPH6A	-0.7	-5.98	-0.36	7.61e-9	Eosinophil counts;
KIRP	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg14683738	chr19:37701593	ZNF585B	0.48	4.95	0.3	1.35e-6	Coronary artery calcification;
KIRP	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.07	0.41	1.6e-11	Mean platelet volume;
KIRP	cis	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg24222995	chr7:28995786	TRIL	-0.26	-4.88	-0.3	1.94e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	14.2	0.67	8.17e-34	Lymphocyte counts;
KIRP	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg00343986	chr7:65444356	GUSB	-0.4	-4.9	-0.3	1.72e-6	Aortic root size;
KIRP	cis	rs629922	0.642	rs531831	chr11:114071814	A/G	cg25009965	chr11:114031120	ZBTB16	-0.44	-5.25	-0.32	3.22e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs4073221	0.860	rs13060052	chr3:18257585	C/A	cg07694806	chr3:18168406	NA	-0.78	-6.76	-0.4	1.02e-10	Parkinson's disease;
KIRP	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg03929089	chr4:120376271	NA	0.97	6.95	0.41	3.17e-11	Myopia (pathological);
KIRP	cis	rs6977660	0.619	rs4721823	chr7:19785888	G/C	cg05791153	chr7:19748676	TWISTNB	0.55	5.34	0.32	2.11e-7	Thyroid stimulating hormone;
KIRP	cis	rs1867631	0.958	rs7520226	chr1:67080995	T/G	cg13052034	chr1:66999238	SGIP1	0.47	6.57	0.39	3.01e-10	Menopause (age at onset);
KIRP	cis	rs6142102	0.961	rs6088355	chr20:32545887	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	6.3	0.37	1.39e-9	Skin pigmentation;
KIRP	cis	rs2281603	0.951	rs12589947	chr14:64982171	G/T	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	trans	rs78049276	0.736	rs6841473	chr4:148407652	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.68	-7.41	-0.43	1.99e-12	Pulse pressure;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10012599	chr11:46744754	F2	0.61	6.65	0.39	1.87e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10463316	0.894	rs7718085	chr5:150742957	G/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.59	-0.39	2.61e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs12476592	0.602	rs6546009	chr2:63745742	G/C	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.83	11.23	0.58	6.93e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.72	7.88	0.45	1.04e-13	Corneal astigmatism;
KIRP	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg14768367	chr16:72042858	DHODH	0.45	5.5	0.33	9.51e-8	Fibrinogen levels;
KIRP	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg01559446	chr3:44596178	ZNF167	0.37	5.27	0.32	2.97e-7	Depressive symptoms;
KIRP	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.64	-8.37	-0.47	4.27e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg04374321	chr14:90722782	PSMC1	-0.84	-11.78	-0.6	1.08e-25	Mortality in heart failure;
KIRP	cis	rs1816752	0.652	rs2902356	chr13:24988471	C/T	cg22771759	chr13:24902376	NA	0.39	5.06	0.31	8.15e-7	Obesity-related traits;
KIRP	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg26248373	chr2:1572462	NA	-0.69	-7.6	-0.44	6.21e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg12486944	chr17:80159399	CCDC57	-0.37	-4.99	-0.3	1.14e-6	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17742459	chr8:38710358	TACC1	-0.41	-6.15	-0.37	3.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.65	-0.52	6.66e-19	Response to antipsychotic treatment;
KIRP	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.82	-11.97	-0.61	2.48e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs9311676	0.609	rs55797456	chr3:58378206	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.57	7.38	0.43	2.38e-12	Retinal vascular caliber;
KIRP	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.34	-6.46	-0.38	5.42e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg23301140	chr18:77439876	CTDP1	0.44	5.0	0.3	1.07e-6	Monocyte count;
KIRP	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.94	-0.45	7.19e-14	Eye color traits;
KIRP	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg18350739	chr11:68623251	NA	-0.48	-7.65	-0.44	4.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg09990169	chr2:241835740	C2orf54	-0.45	-6.57	-0.39	2.91e-10	Urinary metabolites;
KIRP	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.47	-6.04	-0.36	5.72e-9	Schizophrenia;
KIRP	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.64	9.51	0.52	1.85e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	trans	rs933360	0.535	rs11974751	chr7:50845090	A/G	cg20003124	chr12:4557277	NA	0.52	6.19	0.37	2.51e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg07701084	chr6:150067640	NUP43	0.74	9.99	0.54	5.95e-20	Lung cancer;
KIRP	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg14768367	chr16:72042858	DHODH	0.48	5.9	0.35	1.21e-8	Fibrinogen levels;
KIRP	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	cg07049167	chr1:166818506	POGK	0.64	6.89	0.4	4.77e-11	Refractive astigmatism;
KIRP	cis	rs3733418	0.860	rs12647419	chr4:165929153	G/A	cg10852876	chr4:165953100	TRIM60	-0.53	-5.97	-0.36	8.04e-9	Obesity-related traits;
KIRP	cis	rs11997175	0.583	rs7009719	chr8:33834824	C/G	ch.8.33884649F	chr8:33765107	NA	0.52	6.56	0.39	3.08e-10	Body mass index;
KIRP	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.65	-9.42	-0.51	3.4e-18	Colorectal cancer;
KIRP	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21545522	chr1:205238299	TMCC2	0.55	7.33	0.42	3.34e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.23	-0.37	1.97e-9	Dilated cardiomyopathy;
KIRP	cis	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.13	0.31	5.86e-7	Triglycerides;
KIRP	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-6.7	-0.39	1.45e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs4517514	0.509	rs10830417	chr11:89871940	A/G	cg06174606	chr11:89959870	NA	-0.54	-5.37	-0.32	1.79e-7	Trans fatty acid levels;
KIRP	cis	rs2970992	0.764	rs2137669	chr2:101330992	G/T	cg01042948	chr2:101319752	NA	0.42	6.03	0.36	5.83e-9	Educational attainment;
KIRP	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.82	11.68	0.6	2.26e-25	Colorectal cancer;
KIRP	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.51	-7.07	-0.41	1.64e-11	Motion sickness;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.03	0.36	6.08e-9	Lung cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg19768950	chr2:182521921	CERKL	0.43	6.09	0.36	4.24e-9	Educational attainment;
KIRP	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg23307798	chr14:103986281	CKB	-0.51	-6.82	-0.4	7.21e-11	Coronary artery disease;
KIRP	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	0.82	6.33	0.37	1.17e-9	Mitochondrial DNA levels;
KIRP	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.57	-7.75	-0.44	2.41e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg17724175	chr1:150552817	MCL1	0.38	6.41	0.38	7.33e-10	Tonsillectomy;
KIRP	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.67	9.47	0.52	2.48e-18	Rheumatoid arthritis;
KIRP	cis	rs11638352	1.000	rs4924728	chr15:44289953	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.73	-5.62	-0.34	5.11e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg08501292	chr6:25962987	TRIM38	0.99	7.58	0.44	6.93e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.72	10.14	0.54	2.01e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.82	13.25	0.65	1.36e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg04348816	chr7:5461417	TNRC18	0.49	6.28	0.37	1.52e-9	Inflammatory biomarkers;
KIRP	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg13147721	chr7:65941812	NA	-1.0	-7.02	-0.41	2.17e-11	Diabetic kidney disease;
KIRP	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.36	7.52e-9	Morning vs. evening chronotype;
KIRP	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.37	-6.44	-0.38	6.31e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	cis	rs755109	1.000	rs3758254	chr9:100701001	A/G	cg13688889	chr9:100608707	NA	-0.43	-5.0	-0.3	1.1e-6	Quantitative traits;
KIRP	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.57	7.45	0.43	1.57e-12	Tuberculosis;
KIRP	cis	rs10140922	0.567	rs8016860	chr14:35635320	T/C	cg07166546	chr14:35805898	NA	-0.23	-5.49	-0.33	1.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.27	5.46	0.33	1.16e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	4.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.79	0.6	1.03e-25	Heart rate;
KIRP	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	4.99	0.3	1.15e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.67	9.69	0.53	5.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15480897	chr4:151505467	LRBA;MAB21L2	0.49	5.45	0.33	1.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.97	11.5	0.59	9.04e-25	Exhaled nitric oxide levels;
KIRP	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg02725872	chr8:58115012	NA	-0.59	-7.21	-0.42	6.83e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.26	0.32	3.16e-7	Asthma;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg09695851	chr17:3907499	NA	0.84	15.64	0.71	9.75e-39	Type 2 diabetes;
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg26516362	chr5:178986906	RUFY1	-0.41	-7.24	-0.42	5.89e-12	Lung cancer;
KIRP	cis	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg21775007	chr8:11205619	TDH	-0.41	-5.07	-0.31	7.7300000000000005e-07	Triglycerides;
KIRP	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.44	-5.76	-0.34	2.56e-8	Menopause (age at onset);
KIRP	cis	rs7252981	0.632	rs11878202	chr19:19744079	T/C	cg03709012	chr19:19516395	GATAD2A	-0.46	-4.93	-0.3	1.5e-6	Perceived unattractiveness to mosquitoes;
KIRP	trans	rs1973993	0.561	rs6593609	chr1:96991652	C/T	cg10631902	chr5:14652156	NA	-0.56	-6.81	-0.4	7.34e-11	Weight;
KIRP	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.92	10.97	0.57	4.58e-23	Post bronchodilator FEV1;
KIRP	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg09163369	chr1:210001066	C1orf107	0.49	6.16	0.37	2.89e-9	Orofacial clefts;
KIRP	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.36	-8.12	-0.46	2.29e-14	Cutaneous nevi;
KIRP	trans	rs12043259	0.615	rs4951128	chr1:204796511	G/A	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg27205649	chr11:78285834	NARS2	-0.53	-5.19	-0.31	4.38e-7	Testicular germ cell tumor;
KIRP	cis	rs11673344	0.566	rs1545755	chr19:37981509	A/T	cg14683738	chr19:37701593	ZNF585B	-0.44	-5.14	-0.31	5.52e-7	Obesity-related traits;
KIRP	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg10547527	chr2:198650123	BOLL	-0.52	-4.89	-0.3	1.82e-6	Ulcerative colitis;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg12651014	chr10:32735292	CCDC7	-0.48	-7.06	-0.41	1.71e-11	Serum protein levels (sST2);
KIRP	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.74	-10.63	-0.56	5.82e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	1.06	20.74	0.8	6.1e-56	Parkinson's disease;
KIRP	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg24375607	chr4:120327624	NA	0.39	4.95	0.3	1.39e-6	Diastolic blood pressure;
KIRP	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	1.09	20.45	0.79	5.78e-55	Monocyte count;
KIRP	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg10223061	chr2:219282414	VIL1	-0.32	-5.26	-0.32	3.08e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1847505	0.609	rs1504418	chr13:61459644	A/G	cg25164009	chr13:61490935	NA	0.54	5.48	0.33	1.08e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs77972916	0.561	rs10167415	chr2:43552460	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-7.38	-0.43	2.5e-12	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08120951	chr16:88734359	MGC23284	-0.43	-6.13	-0.36	3.53e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg02972257	chr16:68554789	NA	-0.5	-4.86	-0.3	2.08e-6	Ulcerative colitis;
KIRP	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg04691961	chr3:161091175	C3orf57	0.5	7.67	0.44	4.08e-13	Morning vs. evening chronotype;
KIRP	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.04	8.02	0.46	4.31e-14	Skin colour saturation;
KIRP	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.38	7.55	0.43	8.23e-13	Mean corpuscular volume;
KIRP	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.43	0.59	1.55e-24	Alzheimer's disease;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg05370861	chr8:38034167	BAG4;LSM1	0.49	6.02	0.36	6.22e-9	Educational attainment;
KIRP	cis	rs1891498	0.516	rs1495955	chr1:147249285	T/C	cg27546670	chr1:147246839	GJA5	-0.75	-10.17	-0.54	1.64e-20	Cognitive performance;
KIRP	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.59	7.89	0.45	1e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs2274273	0.870	rs7158768	chr14:55763612	A/C	cg04306507	chr14:55594613	LGALS3	0.52	8.13	0.46	2.09e-14	Protein biomarker;
KIRP	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg00405596	chr8:11794950	NA	0.53	7.14	0.41	1.06e-11	Mood instability;
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00802000	chr16:706648	WDR90	-0.39	-4.93	-0.3	1.52e-6	Height;
KIRP	cis	rs2944755	0.919	rs2944753	chr8:141576363	G/C	cg26074100	chr8:141568712	EIF2C2	-0.49	-7.29	-0.42	4.12e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg12908607	chr1:44402522	ARTN	-0.35	-5.12	-0.31	6.18e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7870753	0.730	rs7853063	chr9:99154371	A/G	cg25260653	chr9:99212216	HABP4	0.5	5.32	0.32	2.36e-7	Height;
KIRP	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg22705602	chr4:152727874	NA	-0.54	-9.64	-0.52	7.09e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19379625	chr4:71859087	DCK	0.57	6.67	0.39	1.7e-10	Smoking initiation;
KIRP	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.81	9.86	0.53	1.54e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15320075	chr8:145703422	NA	-0.59	-7.79	-0.44	1.91e-13	Age at first birth;
KIRP	cis	rs7766436	0.885	rs765782	chr6:22592216	A/G	cg13666174	chr6:22585274	NA	-0.46	-6.67	-0.39	1.71e-10	Coronary artery disease;
KIRP	cis	rs7301016	0.707	rs11174583	chr12:63051064	T/C	cg01804193	chr12:63026212	NA	0.54	5.86	0.35	1.46e-8	IgG glycosylation;
KIRP	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-5.65	-0.34	4.5e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.81	10.95	0.57	5.46e-23	Platelet count;
KIRP	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg09699651	chr6:150184138	LRP11	0.55	7.62	0.44	5.41e-13	Testicular germ cell tumor;
KIRP	cis	rs1443512	0.812	rs2078098	chr12:54337527	C/A	cg17410650	chr12:54324560	NA	-0.45	-5.68	-0.34	3.76e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.18	0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.83	10.23	0.55	1.03e-20	Corneal astigmatism;
KIRP	trans	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg26043149	chr18:55253948	FECH	0.51	6.19	0.37	2.5e-9	Bone mineral density;
KIRP	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg17366294	chr4:99064904	C4orf37	0.37	5.13	0.31	5.78e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6142102	0.517	rs6142050	chr20:32527128	G/A	cg24642439	chr20:33292090	TP53INP2	0.47	5.6	0.34	5.6e-8	Skin pigmentation;
KIRP	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.65	-7.19	-0.42	7.68e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-7.05	-0.41	1.77e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	4.9	0.3	1.73e-6	Personality dimensions;
KIRP	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.45	-6.17	-0.37	2.83e-9	Coronary artery disease;
KIRP	cis	rs4478858	0.647	rs10798835	chr1:31709055	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.35	-0.32	2.02e-7	Alcohol dependence;
KIRP	cis	rs6882046	0.513	rs254780	chr5:88019747	G/C	cg24804195	chr5:87968844	LOC645323	-0.48	-6.27	-0.37	1.63e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	13.13	0.64	3.43e-30	Personality dimensions;
KIRP	cis	rs4566357	1.000	rs4536647	chr2:227921977	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.04	-0.31	9.03e-7	Coronary artery disease;
KIRP	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.13	0.5	2.55e-17	Menopause (age at onset);
KIRP	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs6968419	0.755	rs4710	chr7:115897392	G/C	cg02561103	chr7:115862891	TES	-0.41	-5.87	-0.35	1.43e-8	Intraocular pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18105667	chr2:211480881	CPS1;LOC29034	-0.38	-6.16	-0.37	2.87e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.43	0.38	6.53e-10	Breast cancer;
KIRP	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.5	7.04	0.41	1.87e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg06640241	chr16:89574553	SPG7	0.83	13.03	0.64	7.07e-30	Multiple myeloma (IgH translocation);
KIRP	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.13	0.46	2.14e-14	Bipolar disorder;
KIRP	cis	rs3784262	0.692	rs3784256	chr15:58263046	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.96	-0.3	1.34e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs75920871	1.000	rs17120233	chr11:116871223	A/G	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs3120667	0.720	rs12029431	chr1:152391547	C/G	cg26876637	chr1:152193138	HRNR	-0.65	-6.17	-0.37	2.85e-9	Eating disorders;
KIRP	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.75	6.75	0.4	1.08e-10	Diabetic retinopathy;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16311803	chr12:88178298	NA	0.41	6.47	0.38	5.31e-10	Cancer;
KIRP	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	0.95	8.76	0.49	3.29e-16	Blood protein levels;
KIRP	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13409248	chr3:40428643	ENTPD3	0.38	4.99	0.3	1.13e-6	Renal cell carcinoma;
KIRP	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg23188684	chr11:67383651	NA	-0.41	-5.15	-0.31	5.34e-7	Mean corpuscular volume;
KIRP	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg10755058	chr3:40428713	ENTPD3	0.47	6.58	0.39	2.78e-10	Renal cell carcinoma;
KIRP	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.55	-0.39	3.33e-10	Uric acid levels;
KIRP	cis	rs78487399	0.808	rs112387154	chr2:43763231	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.86	-0.3	2.1e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs812925	0.892	rs1186699	chr2:61662555	C/A	cg15711740	chr2:61764176	XPO1	-0.47	-5.5	-0.33	9.47e-8	Immature fraction of reticulocytes;
KIRP	cis	rs11195062	0.521	rs4562740	chr10:111951930	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.34	-5.36	-0.32	1.87e-7	Multiple myeloma;
KIRP	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg20573242	chr4:122745356	CCNA2	0.41	5.06	0.31	8.17e-7	Type 2 diabetes;
KIRP	cis	rs2273669	0.588	rs12201102	chr6:109317388	A/G	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg20750642	chr13:99100586	FARP1	0.42	5.12	0.31	6.12e-7	Neuroticism;
KIRP	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.37	6.46	0.38	5.46e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.64	-8.6	-0.48	9.78e-16	Body mass index;
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.52	-7.19	-0.42	7.86e-12	Renal function-related traits (BUN);
KIRP	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.17	0.37	2.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs35740288	0.685	rs72748184	chr15:86244665	G/T	cg17133734	chr15:86042851	AKAP13	-0.46	-4.87	-0.3	2e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg25418670	chr11:30344373	C11orf46	0.6	5.07	0.31	7.92e-7	Morning vs. evening chronotype;
KIRP	cis	rs6956675	0.915	rs10232119	chr7:62638227	C/T	cg08930214	chr7:62859557	LOC100287834	0.53	6.2	0.37	2.38e-9	Obesity-related traits;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg11641102	chr8:27183873	PTK2B	0.46	6.05	0.36	5.5e-9	Neuroticism;
KIRP	cis	rs2953174	0.786	rs2975749	chr2:241519093	A/G	cg07929629	chr2:241523174	NA	0.67	5.63	0.34	4.87e-8	Bipolar disorder;
KIRP	cis	rs526231	0.575	rs62362523	chr5:102313683	C/T	cg23492399	chr5:102201601	PAM	-0.49	-5.56	-0.33	7.01e-8	Primary biliary cholangitis;
KIRP	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.55	-0.33	7.51e-8	Pulmonary function;
KIRP	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22695372	chr1:94354654	GCLM	-0.43	-6.05	-0.36	5.38e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7127900	1.000	rs7123312	chr11:2232359	A/G	cg25635251	chr11:2234043	NA	0.52	7.81	0.45	1.63e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06666157	chr19:4791552	FEM1A	0.78	6.63	0.39	2.06e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.38	-4.96	-0.3	1.29e-6	Triglycerides;
KIRP	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.55	-7.79	-0.45	1.82e-13	Huntington's disease progression;
KIRP	trans	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg24644049	chr4:85504048	CDS1	-0.99	-6.98	-0.41	2.81e-11	Skin colour saturation;
KIRP	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg01879757	chr17:41196368	BRCA1	-0.58	-7.77	-0.44	2.11e-13	Menopause (age at onset);
KIRP	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.76	-0.34	2.52e-8	Reticulocyte count;
KIRP	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.11	-0.41	1.25e-11	Mood instability;
KIRP	cis	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg19847130	chr8:10466454	RP1L1	-0.32	-5.03	-0.31	9.6e-7	Neuroticism;
KIRP	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.02	0.31	9.7e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg23649088	chr2:200775458	C2orf69	-0.52	-5.46	-0.33	1.17e-7	Schizophrenia;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.54	-7.17	-0.42	8.54e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.35	-7.07	-0.41	1.58e-11	Type 2 diabetes;
KIRP	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg01214346	chr17:406501	NA	0.4	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.66	6.18	0.37	2.64e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg18279126	chr7:2041391	MAD1L1	0.5	5.26	0.32	3.18e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.38	0.43	2.45e-12	Prudent dietary pattern;
KIRP	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg14541582	chr5:601475	NA	-0.56	-6.3	-0.37	1.34e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg07713946	chr22:31675144	LIMK2	0.3	4.89	0.3	1.86e-6	Colorectal cancer;
KIRP	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs73206853	0.686	rs7139314	chr12:110923871	G/A	cg12870014	chr12:110450643	ANKRD13A	0.51	4.87	0.3	2.02e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg05342945	chr12:48394962	COL2A1	-0.48	-5.18	-0.31	4.6e-7	Lung cancer;
KIRP	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg05973401	chr12:123451056	ABCB9	0.55	6.03	0.36	5.86e-9	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.72	0.39	1.24e-10	Bipolar disorder;
KIRP	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.36	3.85e-9	Heart rate;
KIRP	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg16414030	chr3:133502952	NA	-0.43	-4.97	-0.3	1.28e-6	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg01065977	chr19:18549689	ISYNA1	-0.37	-5.53	-0.33	8.14e-8	Breast cancer;
KIRP	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.32	1.9e-7	Menopause (age at onset);
KIRP	cis	rs6601327	0.635	rs34782826	chr8:9663630	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.07	-0.31	7.98e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.61	-7.89	-0.45	9.63e-14	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.88	13.39	0.65	4.55e-31	Ulcerative colitis;
KIRP	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	1.09	19.02	0.77	3.26e-50	Schizophrenia;
KIRP	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06544989	chr22:39130855	UNC84B	0.49	8.1	0.46	2.55e-14	Menopause (age at onset);
KIRP	cis	rs14057	0.864	rs34559878	chr1:6759095	G/A	cg16431369	chr1:6694556	THAP3;DNAJC11	-0.42	-5.01	-0.3	1.06e-6	Systolic blood pressure;
KIRP	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1011018	0.955	rs12703395	chr7:139427361	A/G	cg03224163	chr7:139420300	HIPK2	-0.46	-4.91	-0.3	1.68e-6	Systolic blood pressure;
KIRP	cis	rs6191	0.904	rs4582314	chr5:142780695	C/A	cg08845721	chr5:142780693	NR3C1	-0.39	-5.38	-0.32	1.74e-7	Night sleep phenotypes;
KIRP	cis	rs2274273	0.967	rs17832359	chr14:55615941	T/C	cg04306507	chr14:55594613	LGALS3	0.45	6.93	0.4	3.61e-11	Protein biomarker;
KIRP	cis	rs4654899	0.643	rs1408409	chr1:21089781	T/C	cg08890418	chr1:21044141	KIF17	0.34	5.13	0.31	5.74e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs1864585	0.520	rs1549793	chr8:10655764	A/G	cg26278703	chr11:58910052	FAM111A	0.63	6.48	0.38	4.92e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg09571762	chr12:39539558	NA	0.36	4.98	0.3	1.22e-6	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg27124370	chr19:33622961	WDR88	0.72	10.11	0.54	2.55e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg17885191	chr8:135476712	NA	0.53	6.17	0.37	2.83e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg23477460	chr3:66848765	NA	0.62	7.16	0.42	9.41e-12	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg09699651	chr6:150184138	LRP11	0.41	5.24	0.32	3.38e-7	Lung cancer;
KIRP	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.44	5.46	0.33	1.17e-7	Aortic root size;
KIRP	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.71	-8.11	-0.46	2.34e-14	Adiposity;
KIRP	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.43	0.38	6.54e-10	Breast cancer;
KIRP	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.11	-0.41	1.27e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.59	9.5	0.52	1.9e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg04607699	chr11:48328132	OR4S1	-0.33	-4.99	-0.3	1.15e-6	Height;
KIRP	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	8.1	0.46	2.5e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.73	-9.96	-0.54	7.6e-20	Ear protrusion;
KIRP	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12963246	chr6:28129442	ZNF389	0.41	4.87	0.3	2.04e-6	Parkinson's disease;
KIRP	cis	rs4748857	0.947	rs4748855	chr10:23599075	G/A	cg12804278	chr10:23633326	C10orf67	0.43	5.23	0.32	3.61e-7	Systemic lupus erythematosus;
KIRP	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-5.97	-0.36	8.28e-9	Breast cancer;
KIRP	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg15764593	chr10:829463	NA	-0.83	-8.94	-0.5	9.39e-17	Uric acid levels;
KIRP	cis	rs17125944	0.615	rs1886785	chr14:53312106	A/C	cg00686598	chr14:53173677	PSMC6	-0.7	-6.63	-0.39	2.1e-10	Alzheimer's disease (late onset);
KIRP	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.56e-13	Coffee consumption (cups per day);
KIRP	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg12140854	chr5:148520817	ABLIM3	0.53	6.11	0.36	3.82e-9	Breast cancer;
KIRP	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.25	-6.63	-0.39	2.17e-10	Mean corpuscular volume;
KIRP	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg05340658	chr4:99064831	C4orf37	0.64	6.64	0.39	2.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.47	5.04	0.31	9.2e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.69	-8.42	-0.47	3.22e-15	Cognitive function;
KIRP	cis	rs2625529	0.775	rs12913042	chr15:72202309	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.1	-0.36	4.07e-9	Red blood cell count;
KIRP	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg19338460	chr6:170058176	WDR27	-0.71	-8.26	-0.47	9.1e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs3124314	1.000	rs2069258	chr1:152045626	A/G	cg13071333	chr1:152595882	LCE3A	0.36	5.18	0.31	4.66e-7	Hair morphology;
KIRP	cis	rs62413470	1.000	rs62406152	chr6:55932036	C/T	cg13327911	chr6:55965977	COL21A1	0.57	5.14	0.31	5.68e-7	Joint mobility (Beighton score);
KIRP	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg01616529	chr11:638424	DRD4	-0.44	-5.72	-0.34	3.04e-8	Systemic lupus erythematosus;
KIRP	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	0.92	12.22	0.61	3.71e-27	Primary sclerosing cholangitis;
KIRP	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.66	0.34	4.1e-8	Total cholesterol levels;
KIRP	trans	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg19274270	chr17:78178856	CARD14	0.36	6.48	0.38	5.05e-10	Morning vs. evening chronotype;
KIRP	cis	rs4132509	1.000	rs2290754	chr1:243806268	A/C	cg21452805	chr1:244014465	NA	0.53	5.38	0.32	1.7e-7	RR interval (heart rate);
KIRP	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20135002	chr11:47629003	NA	-0.48	-5.5	-0.33	9.73e-8	Subjective well-being;
KIRP	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.69	-6.88	-0.4	4.96e-11	Chronic sinus infection;
KIRP	cis	rs7011049	0.778	rs73601293	chr8:53870103	G/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08822215	chr16:89438651	ANKRD11	0.46	6.36	0.38	1e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	7.9	0.45	9.41e-14	Lymphocyte counts;
KIRP	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.48	-0.43	1.27e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1018697	0.897	rs2150929	chr10:104550937	T/A	cg04362960	chr10:104952993	NT5C2	0.49	5.85	0.35	1.55e-8	Colorectal adenoma (advanced);
KIRP	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-8.36	-0.47	4.62e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25584787	chr5:93693854	C5orf36	-0.4	-6.05	-0.36	5.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg03735888	chr19:58951602	ZNF132	0.46	5.51	0.33	9e-8	Uric acid clearance;
KIRP	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.53	6.83	0.4	6.75e-11	Height;
KIRP	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg03351412	chr1:154909251	PMVK	0.59	7.68	0.44	3.66e-13	Prostate cancer;
KIRP	cis	rs6700559	0.679	rs7520407	chr1:200655728	C/T	cg07804481	chr1:200639085	DDX59	0.48	6.1	0.36	3.99e-9	Coronary artery disease;
KIRP	cis	rs9581857	0.579	rs76614377	chr13:27974251	A/T	cg22138327	chr13:27999177	GTF3A	1.0	7.3	0.42	3.95e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.58	-6.54	-0.38	3.62e-10	Aortic root size;
KIRP	cis	rs42648	0.623	rs194505	chr7:89841307	G/A	cg25739043	chr7:89950458	NA	-0.43	-6.87	-0.4	5.35e-11	Homocysteine levels;
KIRP	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg23950597	chr19:37808831	NA	-0.7	-6.08	-0.36	4.56e-9	Coronary artery calcification;
KIRP	cis	rs17095355	1.000	rs12570820	chr10:111732507	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.37	-5.17	-0.31	4.92e-7	Biliary atresia;
KIRP	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg08975724	chr8:8085496	FLJ10661	0.49	5.79	0.35	2.17e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.63	7.82	0.45	1.5700000000000001e-13	Multiple sclerosis;
KIRP	cis	rs4233802	1.000	rs4425095	chr2:151139757	C/T	cg25300694	chr2:151184358	NA	0.86	6.7	0.39	1.42e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs1215050	0.791	rs6532702	chr4:98766641	C/T	cg05340658	chr4:99064831	C4orf37	0.5	5.71	0.34	3.17e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.89	-0.35	1.23e-8	Response to antipsychotic treatment;
KIRP	cis	rs300890	0.513	rs4566607	chr4:144062242	G/C	cg01719995	chr4:144104893	USP38	-0.43	-5.51	-0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21643547	chr1:205240462	TMCC2	-0.73	-11.64	-0.6	3e-25	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4953911	1.000	rs7573104	chr2:135065943	G/A	cg18482303	chr2:135041380	MGAT5	-0.26	-5.16	-0.31	5.2e-7	Multiple sclerosis (severity);
KIRP	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg01943577	chr7:158741284	NA	-0.37	-5.07	-0.31	7.68e-7	Height;
KIRP	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg06533319	chr4:3265114	C4orf44	0.59	7.72	0.44	3.01e-13	Parental longevity (mother's age at death);
KIRP	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.68	-13.17	-0.64	2.46e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.58e-7	Body mass index;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.83	9.63	0.52	8.03e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg05714579	chr10:131428358	MGMT	0.43	5.26	0.32	3.06e-7	Response to temozolomide;
KIRP	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.9	14.09	0.67	1.86e-33	Height;
KIRP	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg05315796	chr3:52349193	DNAH1	0.38	5.86	0.35	1.49e-8	Bipolar disorder;
KIRP	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg18944383	chr4:111397179	ENPEP	0.44	7.21	0.42	6.72e-12	Height;
KIRP	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg00310523	chr12:86230176	RASSF9	0.48	7.23	0.42	5.95e-12	Major depressive disorder;
KIRP	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.56	-6.39	-0.38	8.3e-10	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.19	-0.61	4.63e-27	Ulcerative colitis;
KIRP	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	7.79	0.44	1.87e-13	Cognitive test performance;
KIRP	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg02367723	chr1:46378857	MAST2	-0.43	-4.93	-0.3	1.5e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg17507749	chr15:85114479	UBE2QP1	-0.76	-7.19	-0.42	7.89e-12	Schizophrenia;
KIRP	cis	rs8062405	0.558	rs151228	chr16:28563026	A/G	cg00931491	chr16:28608288	SULT1A2	-0.24	-5.21	-0.32	3.9e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12210905	1.000	rs12214930	chr6:27093715	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs7523273	0.526	rs12132176	chr1:207884287	A/T	cg22525895	chr1:207977042	MIR29B2	0.49	5.94	0.35	9.69e-9	Schizophrenia;
KIRP	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.52	-7.29	-0.42	4.11e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs1880828	0.516	rs78684188	chr3:55056216	A/G	cg21790587	chr12:132699738	GALNT9	-0.75	-7.37	-0.43	2.65e-12	Lung cancer in ever smokers;
KIRP	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.63	-7.97	-0.45	5.99e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs228437	0.913	rs73554512	chr6:134941513	G/A	cg24504307	chr6:134963096	NA	0.56	7.91	0.45	8.54e-14	Melanoma;
KIRP	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.57	8.18	0.46	1.56e-14	Huntington's disease progression;
KIRP	cis	rs9810890	1.000	rs73196983	chr3:128452500	G/T	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.57	0.52	1.2e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.92	14.65	0.68	2.36e-35	Testicular germ cell tumor;
KIRP	cis	rs7116495	1.000	rs4338555	chr11:71755696	T/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.65	9.37	0.51	4.71e-18	Schizophrenia;
KIRP	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg05527609	chr1:210001259	C1orf107	0.55	7.74	0.44	2.55e-13	Monobrow;
KIRP	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.7	0.48	4.9e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs367943	0.712	rs1850407	chr5:112721569	C/A	cg12552261	chr5:112820674	MCC	0.56	6.61	0.39	2.32e-10	Type 2 diabetes;
KIRP	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.97	0.41	2.93e-11	Coffee consumption (cups per day);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg16716883	chr10:74079772	NA	0.7	6.33	0.37	1.15e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg12751644	chr20:60527061	NA	-0.41	-5.0	-0.3	1.09e-6	Body mass index;
KIRP	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs6973256	0.605	rs7808879	chr7:133345471	A/T	cg10665199	chr7:133106180	EXOC4	0.5	6.3	0.37	1.35e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	0.97	16.83	0.73	8.14e-43	Menarche (age at onset);
KIRP	cis	rs11209002	0.614	rs4655515	chr1:67566898	T/C	cg02640540	chr1:67518911	SLC35D1	0.6	6.78	0.4	8.92e-11	Crohn's disease;
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	0.86	14.26	0.67	4.99e-34	Vitiligo;
KIRP	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.59	0.73	5.3e-42	Electrocardiographic conduction measures;
KIRP	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs2790457	0.760	rs1265834	chr10:28941861	A/G	cg05705492	chr10:28955341	NA	0.53	7.59	0.44	6.56e-13	Multiple myeloma;
KIRP	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	0.97	16.62	0.73	4.37e-42	Ulcerative colitis;
KIRP	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.54	0.43	9.21e-13	White blood cell count;
KIRP	cis	rs11583043	0.575	rs12727971	chr1:101589175	A/G	cg17443007	chr1:101659419	NA	0.41	5.79	0.35	2.14e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-0.53	-7.24	-0.42	5.56e-12	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg18357526	chr6:26021779	HIST1H4A	0.51	6.82	0.4	7.14e-11	Height;
KIRP	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.89	9.73	0.53	3.8e-19	Gut microbiome composition (summer);
KIRP	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-11.27	-0.58	5e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg00852783	chr1:26633632	UBXN11	0.52	7.57	0.43	7.46e-13	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg08662619	chr6:150070041	PCMT1	0.38	6.33	0.37	1.15e-9	Lung cancer;
KIRP	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg26531700	chr6:26746687	NA	-0.46	-6.69	-0.39	1.52e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.25	0.32	3.3e-7	Leprosy;
KIRP	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg07166546	chr14:35805898	NA	-0.28	-6.66	-0.39	1.8e-10	Psoriasis;
KIRP	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.56	-5.35	-0.32	2.03e-7	Narcolepsy;
KIRP	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.6	11.94	0.61	3.11e-26	Diabetic kidney disease;
KIRP	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.43	0.74	7.26e-45	Height;
KIRP	cis	rs7084402	0.935	rs1649068	chr10:60304864	A/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.3	-0.55	6.36e-21	Refractive error;
KIRP	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.76	10.64	0.56	5.57e-22	Type 2 diabetes;
KIRP	cis	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.73	-0.34	2.91e-8	Monocyte count;
KIRP	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.8	10.16	0.54	1.82e-20	Breast cancer;
KIRP	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.78	0.53	2.72e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24420205	chr19:9546157	ZNF266	-0.51	-6.5	-0.38	4.36e-10	Interleukin-4 levels;
KIRP	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.44	5.78	0.35	2.29e-8	Schizophrenia;
KIRP	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.57	5.51	0.33	9.16e-8	Glioblastoma;
KIRP	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg09788416	chr12:39539408	NA	0.39	4.84	0.3	2.26e-6	Morning vs. evening chronotype;
KIRP	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.49	-0.43	1.21e-12	Body mass index;
KIRP	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg13010199	chr12:38710504	ALG10B	-0.38	-4.89	-0.3	1.86e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg09695851	chr17:3907499	NA	0.53	6.2	0.37	2.3e-9	Type 2 diabetes;
KIRP	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.82	-15.11	-0.69	6.01e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13939156	chr17:80058883	NA	-0.48	-7.07	-0.41	1.63e-11	Life satisfaction;
KIRP	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.69	-6.14	-0.36	3.22e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.77	-0.35	2.42e-8	Height;
KIRP	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.62	-7.99	-0.45	5.16e-14	Uric acid levels;
KIRP	cis	rs4148660	0.534	rs2277404	chr12:22078556	T/C	cg14669847	chr12:22099120	NA	0.43	7.46	0.43	1.46e-12	Gout;
KIRP	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg16497661	chr14:103986332	CKB	0.81	13.59	0.65	9.51e-32	Body mass index;
KIRP	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.83	8.76	0.49	3.16e-16	Prostate cancer;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.26	-4.87	-0.3	2.01e-6	Lymphocyte counts;
KIRP	cis	rs6662572	0.737	rs10749859	chr1:46314170	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.72	0.34	3.02e-8	Blood protein levels;
KIRP	cis	rs1040	0.873	rs10280	chr6:169617430	T/C	cg04662567	chr6:169592167	NA	-0.45	-5.27	-0.32	2.93e-7	Joint mobility (Beighton score);
KIRP	cis	rs806215	1.000	rs327511	chr7:127257261	G/T	cg25922125	chr7:127225783	GCC1	0.44	4.98	0.3	1.2e-6	Type 2 diabetes;
KIRP	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06634786	chr22:41940651	POLR3H	0.44	5.14	0.31	5.5e-7	Vitiligo;
KIRP	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg18154014	chr19:37997991	ZNF793	0.73	7.81	0.45	1.69e-13	Coronary artery calcification;
KIRP	trans	rs1105228	0.819	rs561112	chr6:165715891	T/C	cg13676706	chr12:127944448	NA	-0.4	-6.02	-0.36	6.2e-9	Number of pregnancies;Number of children;
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg26134248	chr17:3907702	NA	0.55	8.2	0.46	1.34e-14	Type 2 diabetes;
KIRP	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg22732515	chr19:44031385	ETHE1	0.65	9.25	0.51	1.16e-17	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs2599510	0.811	rs2243844	chr2:32775984	G/T	cg02381751	chr2:32503542	YIPF4	0.5	5.72	0.34	3.09e-8	Interleukin-18 levels;
KIRP	cis	rs2791713	0.626	rs34766740	chr1:207172611	T/A	cg24040043	chr1:207224982	YOD1	0.29	4.95	0.3	1.37e-6	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-13.81	-0.66	1.68e-32	Body mass index;
KIRP	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg23067535	chr8:124195133	FAM83A	-0.73	-6.94	-0.4	3.38e-11	Urinary uromodulin levels;
KIRP	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.49	-5.32	-0.32	2.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg24289452	chr6:170231220	NA	-0.75	-5.08	-0.31	7.31e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.93	-15.79	-0.71	3.04e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.01	0.3	1.03e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4700695	0.614	rs371246	chr5:65209126	G/A	cg21114390	chr5:65439923	SFRS12	0.52	4.94	0.3	1.47e-6	Facial morphology (factor 19);
KIRP	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1832871	0.655	rs6920121	chr6:158678504	C/T	cg07215822	chr6:158701037	NA	0.6	6.85	0.4	6.05e-11	Height;
KIRP	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg02002194	chr4:3960332	NA	0.42	6.04	0.36	5.74e-9	Retinal vascular caliber;
KIRP	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.51	-0.56	1.4e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-8.23	-0.46	1.07e-14	Colorectal cancer;
KIRP	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.87	8.86	0.49	1.61e-16	Prostate cancer;
KIRP	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg18367735	chr17:79674897	NA	0.76	7.46	0.43	1.51e-12	Dental caries;
KIRP	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-9.35	-0.51	5.74e-18	Morning vs. evening chronotype;
KIRP	cis	rs2290402	0.536	rs60492656	chr4:875008	C/T	cg14517359	chr4:903473	GAK	-0.54	-5.83	-0.35	1.71e-8	Type 2 diabetes;
KIRP	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.65	6.29	0.37	1.42e-9	White matter integrity;
KIRP	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.77	-8.92	-0.49	1.07e-16	Schizophrenia;
KIRP	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.65	6.51	0.38	4.25e-10	Axial length;
KIRP	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.24	6.3	0.37	1.36e-9	Crohn's disease;
KIRP	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.86	-11.24	-0.58	6.5e-24	Cognitive function;
KIRP	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.5	-6.13	-0.36	3.47e-9	Eosinophil percentage of white cells;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21016266	chr12:122356598	WDR66	-0.61	-8.5	-0.48	1.84e-15	Mean corpuscular volume;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.57	-0.33	6.8e-8	Life satisfaction;
KIRP	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.87	9.05	0.5	4.54e-17	Exhaled nitric oxide output;
KIRP	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.28	-0.37	1.49e-9	Total body bone mineral density;
KIRP	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg04370829	chr17:406249	NA	0.39	4.86	0.3	2.11e-6	Prostate cancer;
KIRP	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.4	-0.47	3.69e-15	Triglycerides;
KIRP	cis	rs7084402	0.967	rs12259990	chr10:60297574	A/G	cg05938607	chr10:60274200	BICC1	0.38	9.0	0.5	6.31e-17	Refractive error;
KIRP	cis	rs7766436	0.885	rs13198355	chr6:22577119	C/G	cg13666174	chr6:22585274	NA	-0.46	-6.14	-0.36	3.31e-9	Coronary artery disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27254348	chr10:112443773	RBM20	0.38	6.15	0.37	3.17e-9	Migraine with aura;
KIRP	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.73	-9.07	-0.5	3.81e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4851254	0.920	rs4850920	chr2:100757308	C/A	cg17356467	chr2:100759845	AFF3	0.62	8.04	0.46	3.81e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg13819577	chr1:248512075	OR14C36	-0.39	-5.12	-0.31	6.07e-7	Common traits (Other);
KIRP	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-6.51	-0.38	4.16e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2290402	0.536	rs73207791	chr4:865941	A/G	cg14517359	chr4:903473	GAK	-0.53	-5.57	-0.33	6.83e-8	Type 2 diabetes;
KIRP	cis	rs7246657	0.639	rs12459015	chr19:38083189	T/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.57	6.9	0.4	4.36e-11	Type 2 diabetes;
KIRP	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg17401720	chr7:158221031	PTPRN2	0.35	5.32	0.32	2.31e-7	Obesity-related traits;
KIRP	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.42	0.38	7.08e-10	Educational attainment;
KIRP	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.84	12.14	0.61	6.92e-27	Eye color traits;
KIRP	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg26875233	chr11:93583750	C11orf90	-0.42	-7.84	-0.45	1.38e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg13385521	chr17:29058706	SUZ12P	0.84	6.53	0.38	3.67e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg22366001	chr1:2066006	PRKCZ	-0.38	-5.19	-0.31	4.5e-7	Height;
KIRP	cis	rs3126085	0.560	rs11204982	chr1:152322042	A/G	cg26876637	chr1:152193138	HRNR	-0.48	-5.67	-0.34	4.07e-8	Atopic dermatitis;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg11859384	chr17:80120422	CCDC57	-0.47	-5.9	-0.35	1.22e-8	Life satisfaction;
KIRP	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg18190219	chr22:46762943	CELSR1	-0.74	-7.54	-0.43	9.04e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7027203	0.576	rs7848045	chr9:96551824	G/A	cg14598338	chr9:96623480	NA	0.46	7.15	0.41	9.67e-12	DNA methylation (variation);
KIRP	cis	rs12208915	0.848	rs9343834	chr6:79517671	G/A	cg18132916	chr6:79620363	NA	0.54	5.1	0.31	6.69e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs687432	0.887	rs11601202	chr11:57773160	A/T	cg19752551	chr11:57585705	CTNND1	-0.68	-8.88	-0.49	1.44e-16	Parkinson's disease;
KIRP	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg05315796	chr3:52349193	DNAH1	0.5	7.81	0.45	1.68e-13	Electroencephalogram traits;
KIRP	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	5.11	0.31	6.34e-7	Childhood ear infection;
KIRP	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg12741994	chr3:170137321	CLDN11	-0.44	-5.0	-0.3	1.07e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.82	-12.36	-0.62	1.31e-27	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1710354	0.843	rs1710355	chr19:51801861	T/G	cg04944904	chr19:51845941	VSIG10L	0.38	5.5	0.33	9.32e-8	Blood protein levels;
KIRP	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.41	-8.27	-0.47	8.22e-15	Longevity;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg26513180	chr16:89883248	FANCA	0.84	13.74	0.66	2.98e-32	Vitiligo;
KIRP	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg07827796	chr19:33622959	WDR88	0.53	7.17	0.42	8.85e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg03959625	chr15:84868606	LOC388152	0.51	5.8	0.35	1.98e-8	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19929006	chr7:12376625	VWDE	-0.4	-6.21	-0.37	2.27e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9393777	0.623	rs13211166	chr6:27265940	T/A	cg22548220	chr6:27277996	POM121L2	0.47	5.92	0.35	1.06e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg05370193	chr1:21551575	ECE1	-0.36	-4.96	-0.3	1.32e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.48	-4.89	-0.3	1.86e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg17108064	chr15:78857060	CHRNA5	0.36	5.26	0.32	3.12e-7	Sudden cardiac arrest;
KIRP	cis	rs4845875	0.600	rs4846040	chr1:11837048	C/G	cg24844545	chr1:11908347	NPPA	0.37	4.9	0.3	1.73e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06850241	chr22:41845214	NA	-0.53	-5.95	-0.35	9.02e-9	Vitiligo;
KIRP	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.32	0.47	6.15e-15	Neuroticism;
KIRP	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.79	9.22	0.51	1.43e-17	Sudden cardiac arrest;
KIRP	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.57	13.83	0.66	1.41e-32	Airflow obstruction;
KIRP	cis	rs12476592	0.602	rs989527	chr2:63726791	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.35	-0.47	5.06e-15	Common traits (Other);
KIRP	cis	rs2275565	0.810	rs4659730	chr1:237012520	G/C	cg17297354	chr1:237056641	MTR	-0.47	-5.42	-0.33	1.39e-7	Homocysteine levels;
KIRP	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-1.01	-12.19	-0.61	4.57e-27	Breast cancer;
KIRP	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.57	8.29	0.47	7.26e-15	Huntington's disease progression;
KIRP	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg25039879	chr17:56429692	SUPT4H1	0.6	5.13	0.31	5.77e-7	Cognitive test performance;
KIRP	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.69	-9.59	-0.52	1.06e-18	Bone properties (heel);
KIRP	cis	rs2644899	0.859	rs2545755	chr19:41293162	T/G	cg24958765	chr19:41283667	RAB4B	-0.59	-6.39	-0.38	8.14e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg00094735	chr5:1949198	NA	-0.54	-5.72	-0.34	3.09e-8	Gut microbiome composition (winter);
KIRP	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-9.32	-0.51	6.79e-18	Developmental language disorder (linguistic errors);
KIRP	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.46	4.85	0.3	2.16e-6	Obesity (extreme);
KIRP	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg16141378	chr3:129829833	LOC729375	0.5	6.15	0.37	3.1e-9	Retinal vascular caliber;
KIRP	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	1.13	14.23	0.67	6.18e-34	Pulmonary function decline;
KIRP	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg17145862	chr1:211918768	LPGAT1	-0.65	-7.77	-0.44	2.07e-13	Crohn's disease;
KIRP	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.86	-11.79	-0.6	1.01e-25	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7951870	1.000	rs11038897	chr11:46470827	C/T	cg16389345	chr11:46697382	NA	-0.46	-5.13	-0.31	5.98e-7	Schizophrenia;
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg09355771	chr2:177043147	NA	0.47	6.11	0.36	3.92e-9	IgG glycosylation;
KIRP	cis	rs7923452	0.938	rs34560372	chr10:30773831	G/A	cg25182066	chr10:30743637	MAP3K8	0.6	5.42	0.33	1.45e-7	Itch intensity from mosquito bite;
KIRP	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg06627628	chr2:24431161	ITSN2	-0.6	-5.39	-0.33	1.61e-7	Lymphocyte counts;
KIRP	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-8.12	-0.46	2.26e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16524936	chr4:1340807	KIAA1530	-0.47	-5.99	-0.36	7.52e-9	Longevity;
KIRP	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg17328964	chr8:145687451	CYHR1	-0.7	-9.12	-0.5	2.8e-17	Age at first birth;
KIRP	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg13607699	chr17:42295918	UBTF	0.46	5.7	0.34	3.39e-8	Total body bone mineral density;
KIRP	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg16362232	chr11:430036	ANO9	0.6	4.89	0.3	1.78e-6	Body mass index;
KIRP	cis	rs1440410	0.835	rs10029243	chr4:144060744	T/C	cg01719995	chr4:144104893	USP38	0.44	5.99	0.36	7.24e-9	Ischemic stroke;
KIRP	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg06102403	chr20:30458708	TTLL9;DUSP15	0.56	5.95	0.35	9.35e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.25	-0.37	1.83e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.99	11.89	0.6	4.52e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4332428	1.000	rs7908994	chr10:5008383	C/T	cg19648686	chr10:5044992	AKR1C2	-0.77	-7.07	-0.41	1.58e-11	Height;
KIRP	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg16434002	chr17:42200994	HDAC5	0.45	5.6	0.34	5.61e-8	Total body bone mineral density;
KIRP	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.35	0.47	4.86e-15	Motion sickness;
KIRP	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.79	-0.35	2.09e-8	Aortic root size;
KIRP	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	6.03	0.36	6.08e-9	Schizophrenia;
KIRP	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.36	0.38	9.91e-10	Total body bone mineral density;
KIRP	cis	rs9886651	0.776	rs4733560	chr8:128779001	G/A	cg24514600	chr8:128805414	PVT1	-0.71	-11.97	-0.61	2.44e-26	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.31	5.59	0.34	6.07e-8	Calcium levels;
KIRP	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.64	-0.34	4.75e-8	Testicular germ cell tumor;
KIRP	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.21	-0.32	4.04e-7	Neuroticism;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg02733842	chr7:1102375	C7orf50	0.43	5.06	0.31	8.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.39	0.55	3.29e-21	Dupuytren's disease;
KIRP	cis	rs11227306	0.934	rs2234458	chr11:65639374	C/T	cg26695010	chr11:65641043	EFEMP2	0.47	5.63	0.34	5e-8	DNA methylation (variation);
KIRP	cis	rs9653442	0.564	rs11902705	chr2:100795207	A/G	cg22139774	chr2:100720529	AFF3	0.3	5.01	0.3	1.05e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg11569703	chr11:65557185	OVOL1	0.73	14.09	0.67	1.89e-33	Acne (severe);
KIRP	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.46	-5.82	-0.35	1.82e-8	Mean corpuscular volume;
KIRP	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg16077055	chr2:106428750	NCK2	0.29	5.85	0.35	1.57e-8	Addiction;
KIRP	cis	rs6956675	1.000	rs7801458	chr7:62597651	A/G	cg08930214	chr7:62859557	LOC100287834	0.51	5.84	0.35	1.67e-8	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-4.87	-0.3	1.96e-6	Personality dimensions;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg13198984	chr17:80129470	CCDC57	0.57	8.66	0.48	6.46e-16	Life satisfaction;
KIRP	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.65	-0.44	4.53e-13	Height;
KIRP	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg19507638	chr5:93509721	C5orf36	-0.59	-5.31	-0.32	2.47e-7	Diabetic retinopathy;
KIRP	cis	rs2151522	0.603	rs11154378	chr6:127200733	A/T	cg21431617	chr6:127135037	NA	0.31	5.3	0.32	2.53e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs8523	0.901	rs9295752	chr6:11010800	T/G	cg13562911	chr6:11044106	ELOVL2	0.39	5.08	0.31	7.36e-7	Red blood cell fatty acid levels;
KIRP	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Life satisfaction;
KIRP	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg16049864	chr8:95962084	TP53INP1	-0.36	-5.68	-0.34	3.83e-8	Type 2 diabetes;
KIRP	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg23594656	chr7:65796392	TPST1	-0.41	-5.82	-0.35	1.84e-8	Aortic root size;
KIRP	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.42	-0.33	1.39e-7	Ovarian reserve;
KIRP	cis	rs2274273	0.662	rs67092614	chr14:55672055	G/A	cg04306507	chr14:55594613	LGALS3	0.41	5.41	0.33	1.51e-7	Protein biomarker;
KIRP	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.22	-0.32	3.8e-7	Autism;
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg19923238	chr8:142232952	SLC45A4	0.45	5.27	0.32	2.93e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7221595	0.756	rs35852805	chr17:3892563	C/T	cg11204139	chr17:3907470	NA	0.57	5.66	0.34	4.13e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg03060546	chr3:49711283	APEH	-0.65	-6.64	-0.39	1.98e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1581057	0.898	rs7628479	chr3:161819948	A/G	cg09318158	chr19:54191610	MIR1283-1	-0.41	-6.13	-0.36	3.39e-9	Social communication problems;
KIRP	cis	rs2411233	0.839	rs1380939	chr15:39309815	T/C	cg05886626	chr15:39873553	THBS1	0.32	4.86	0.3	2.05e-6	Platelet count;
KIRP	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg15234197	chr11:68924956	NA	0.35	4.99	0.3	1.12e-6	Blond vs. brown hair color;
KIRP	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.65	6.21	0.37	2.28e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	1.0	16.96	0.73	3.01e-43	Menopause (age at onset);
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg23736307	chr8:27182930	PTK2B	0.55	7.03	0.41	1.97e-11	Neuroticism;
KIRP	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg16083429	chr3:49237500	CCDC36	-0.39	-5.12	-0.31	6.26e-7	Menarche (age at onset);
KIRP	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.49	-6.53	-0.38	3.82e-10	Multiple sclerosis;
KIRP	cis	rs7572644	0.640	rs4666014	chr2:28019175	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-5.66	-0.34	4.13e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.5	5.17	0.31	4.77e-7	Smoking behavior;
KIRP	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16066237	chr21:36261033	RUNX1	0.49	7.07	0.41	1.62e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg10223061	chr2:219282414	VIL1	-0.33	-5.4	-0.33	1.54e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.73	-8.88	-0.49	1.43e-16	Cognitive function;
KIRP	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg19761014	chr17:28927070	LRRC37B2	0.68	5.04	0.31	9.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg24315340	chr6:146058215	EPM2A	-0.43	-5.54	-0.33	7.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-5.05	-0.31	8.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.65	8.34	0.47	5.41e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg18657303	chr4:1051139	NA	0.55	4.99	0.3	1.16e-6	Recombination rate (females);
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.67	-9.38	-0.51	4.42e-18	Paraoxonase activity;
KIRP	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg07451762	chr16:28383216	NA	0.42	5.51	0.33	8.94e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7072216	0.881	rs2147896	chr10:100148176	A/G	cg26618903	chr10:100175079	PYROXD2	-0.33	-4.95	-0.3	1.38e-6	Metabolite levels;
KIRP	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg17294928	chr15:75287854	SCAMP5	-0.78	-5.02	-0.3	1.02e-6	Blood trace element (Zn levels);
KIRP	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg20295408	chr7:1910781	MAD1L1	0.47	5.56	0.33	7.17e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9393777	0.668	rs3800318	chr6:27263641	A/T	cg22548220	chr6:27277996	POM121L2	0.47	5.92	0.35	1.06e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.44	5.31	0.32	2.47e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.65	-9.72	-0.53	4.29e-19	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg25922125	chr7:127225783	GCC1	-0.54	-5.43	-0.33	1.33e-7	Type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25321988	chr19:49946433	NA	-0.44	-6.16	-0.37	2.93e-9	Metabolic traits;
KIRP	cis	rs9290877	0.667	rs9820669	chr3:188462854	T/C	cg17392043	chr3:188495102	LPP	-0.48	-6.2	-0.37	2.38e-9	IgE levels;
KIRP	cis	rs240764	0.621	rs4840154	chr6:101225723	A/C	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	trans	rs73017046	0.557	rs74972852	chr6:148894828	G/A	cg08280468	chr16:12997534	SHISA9	-0.72	-6.04	-0.36	5.68e-9	Major depression and alcohol dependence;
KIRP	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.87	12.73	0.63	7.63e-29	Coronary artery disease;
KIRP	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.52	-11.26	-0.58	5.57e-24	Refractive error;
KIRP	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg04906043	chr13:21280425	IL17D	-0.67	-9.38	-0.51	4.58e-18	Dental caries;
KIRP	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg13180566	chr4:1052158	NA	-0.52	-5.32	-0.32	2.29e-7	Recombination rate (females);
KIRP	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.7	9.25	0.51	1.13e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg22852734	chr6:133119734	C6orf192	1.21	11.18	0.58	9.66e-24	Type 2 diabetes nephropathy;
KIRP	cis	rs17065868	0.764	rs6561177	chr13:45015539	C/T	cg10246903	chr13:45222710	NA	0.51	4.87	0.3	1.97e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2742417	1.000	rs2742438	chr3:45743390	G/T	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7072216	0.922	rs10786415	chr10:100151266	A/G	cg26618903	chr10:100175079	PYROXD2	-0.34	-4.96	-0.3	1.34e-6	Metabolite levels;
KIRP	cis	rs4704187	0.640	rs7721018	chr5:74492978	C/T	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.56	5.13	0.31	5.97e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13664195	chr17:3539527	SHPK;CTNS	0.51	6.24	0.37	1.95e-9	Parkinson's disease;
KIRP	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.46	5.6	0.34	5.68e-8	Proinsulin levels;
KIRP	cis	rs2289681	0.525	rs34637106	chr17:42985772	C/T	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.6	-6.57	-0.39	2.99e-10	Cognitive function;
KIRP	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.87	-0.57	9.67e-23	Height;
KIRP	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	cis	rs28830936	0.966	rs3743024	chr15:42118971	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.64	-0.39	1.96e-10	Diastolic blood pressure;
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.53	6.56	0.39	3.2e-10	Menopause (age at onset);
KIRP	cis	rs668210	0.793	rs1204011	chr11:65741086	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-7.03	-0.41	1.98e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7940866	0.817	rs961491	chr11:130866090	G/T	cg12179176	chr11:130786555	SNX19	0.55	6.33	0.37	1.15e-9	Schizophrenia;
KIRP	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg06042504	chr8:55087323	NA	-0.53	-6.42	-0.38	6.94e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.05e-8	Skin colour saturation;
KIRP	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.57	4.97	0.3	1.25e-6	Diabetic retinopathy;
KIRP	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg15691649	chr6:25882328	NA	-0.46	-5.53	-0.33	7.98e-8	Blood metabolite levels;
KIRP	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.67	-7.61	-0.44	5.78e-13	Type 2 diabetes;
KIRP	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg24459738	chr19:57751996	ZNF805	-0.56	-7.03	-0.41	2.08e-11	Hyperactive-impulsive symptoms;
KIRP	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.66	8.82	0.49	2.18e-16	Bladder cancer;
KIRP	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg10755058	chr3:40428713	ENTPD3	0.47	6.55	0.39	3.25e-10	Renal cell carcinoma;
KIRP	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.73e-7	Reticulocyte count;
KIRP	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg05527609	chr1:210001259	C1orf107	-0.45	-5.46	-0.33	1.15e-7	Red blood cell count;
KIRP	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.32	5.77	0.35	2.43e-8	Renal cell carcinoma;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01962510	chr22:18957837	DGCR5	-0.48	-6.05	-0.36	5.29e-9	Myopia;
KIRP	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	6.48	0.38	4.91e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4664293	0.867	rs13428679	chr2:160593198	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.7	8.74	0.49	3.77e-16	Longevity;
KIRP	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-1.18	-13.26	-0.65	1.19e-30	Monocyte percentage of white cells;
KIRP	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg08499158	chr17:42289980	UBTF	0.52	6.49	0.38	4.62e-10	Total body bone mineral density;
KIRP	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg10950524	chr7:2139216	MAD1L1	0.31	4.85	0.3	2.2e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-1.03	-19.83	-0.78	6.08e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs8067545	0.720	rs9916675	chr17:19900168	A/G	cg04132472	chr17:19861366	AKAP10	0.61	8.85	0.49	1.79e-16	Schizophrenia;
KIRP	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.68	10.06	0.54	3.75e-20	Dupuytren's disease;
KIRP	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Parkinson's disease;
KIRP	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.53	0.75	3.39e-45	Cognitive function;
KIRP	cis	rs12282928	1.000	rs1503169	chr11:48271287	C/T	cg26585981	chr11:48327164	OR4S1	-0.5	-6.03	-0.36	6.1e-9	Migraine - clinic-based;
KIRP	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg14851346	chr12:38532713	NA	-0.39	-4.93	-0.3	1.54e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg27532560	chr4:187881888	NA	-0.73	-12.12	-0.61	7.87e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.73	8.54	0.48	1.4e-15	Obesity-related traits;
KIRP	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg18904891	chr8:8559673	CLDN23	0.64	7.22	0.42	6.64e-12	Obesity-related traits;
KIRP	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg02297831	chr4:17616191	MED28	0.6	7.63	0.44	5.21e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4849845	0.889	rs4241156	chr2:121031695	C/T	cg24070213	chr2:121070622	NA	0.39	5.38	0.32	1.7e-7	Mean platelet volume;
KIRP	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.2	0.58	8.63e-24	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg03929089	chr4:120376271	NA	-0.93	-6.82	-0.4	7.22e-11	Myopia (pathological);
KIRP	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.48	6.18	0.37	2.66e-9	Height;
KIRP	cis	rs4835473	0.545	rs10022856	chr4:144714310	A/T	cg08833778	chr4:144622313	FREM3	0.34	4.91	0.3	1.67e-6	Immature fraction of reticulocytes;
KIRP	cis	rs2617583	0.967	rs2652510	chr5:1447860	C/T	cg07151155	chr5:1473589	LPCAT1	-0.42	-5.48	-0.33	1.04e-7	Breast cancer;
KIRP	cis	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg01181863	chr3:195395398	SDHAP2	-0.44	-4.95	-0.3	1.35e-6	Mean corpuscular volume;
KIRP	cis	rs4262150	0.810	rs72797241	chr5:151999410	G/A	cg12297329	chr5:152029980	NA	-0.65	-8.09	-0.46	2.82e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-6.14	-0.36	3.35e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-5.64	-0.34	4.65e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg21926883	chr2:100939477	LONRF2	0.63	8.67	0.48	6.01e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	cg04338863	chr8:33670619	NA	0.47	6.1	0.36	4e-9	Body mass index;
KIRP	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg19507638	chr5:93509721	C5orf36	-0.52	-4.92	-0.3	1.61e-6	Diabetic retinopathy;
KIRP	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.6	-0.44	6.2800000000000005e-13	Bladder cancer;
KIRP	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs7751419	0.651	rs67034191	chr6:39094811	G/A	cg08089693	chr6:39098871	NA	-0.69	-9.81	-0.53	2.15e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.61	8.24	0.47	1.01e-14	Prostate cancer;
KIRP	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.46	6.94	0.4	3.4e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.82	-8.76	-0.49	3.16e-16	Hair shape;
KIRP	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.34	-0.32	2.12e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg13409248	chr3:40428643	ENTPD3	0.38	5.17	0.31	4.94e-7	Renal cell carcinoma;
KIRP	cis	rs9311676	0.656	rs11130638	chr3:58405947	A/G	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-5.12	-0.31	6.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.6	8.58	0.48	1.08e-15	Neurofibrillary tangles;
KIRP	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04004882	chr2:215674386	BARD1	0.66	6.71	0.39	1.3e-10	Neuroblastoma;
KIRP	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.75	-10.92	-0.57	6.9e-23	Waist circumference;Body mass index;
KIRP	cis	rs2120243	0.591	rs9871290	chr3:157099591	A/G	cg24825693	chr3:157122686	VEPH1	-0.57	-8.8	-0.49	2.5e-16	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg00262122	chr8:11665843	FDFT1	0.44	5.37	0.32	1.85e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg07636037	chr3:49044803	WDR6	-0.73	-5.61	-0.34	5.3e-8	Cognitive function;
KIRP	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6499100	0.695	rs4784258	chr16:52837310	C/T	cg03441257	chr1:150039089	VPS45	0.49	6.6	0.39	2.44e-10	Tetralogy of Fallot;
KIRP	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.37e-8	Motion sickness;
KIRP	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg00405596	chr8:11794950	NA	0.36	4.94	0.3	1.47e-6	Neuroticism;
KIRP	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs997295	1.000	rs4363822	chr15:67992583	A/G	cg24579218	chr15:68104479	NA	0.37	5.62	0.34	5.06e-8	Motion sickness;
KIRP	cis	rs28834970	0.925	rs6987305	chr8:27208126	G/A	cg06815112	chr8:27182871	PTK2B	-0.43	-5.47	-0.33	1.1e-7	Alzheimer's disease (late onset);
KIRP	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.46	-5.45	-0.33	1.21e-7	Schizophrenia;
KIRP	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg01620082	chr3:125678407	NA	-1.29	-8.05	-0.46	3.5e-14	Depression;
KIRP	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10174797	chr19:8464628	RAB11B	0.51	6.41	0.38	7.33e-10	HDL cholesterol;
KIRP	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.68	9.21	0.51	1.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.74	11.5	0.59	8.98e-25	Neuroticism;
KIRP	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg06360820	chr2:242988706	NA	-1.15	-9.45	-0.52	2.84e-18	Obesity-related traits;
KIRP	trans	rs12517041	0.872	rs6887084	chr5:23307439	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs7714584	1.000	rs76872831	chr5:150171559	A/G	cg22134413	chr5:150180641	NA	1.06	7.54	0.43	8.79e-13	Crohn's disease;
KIRP	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg25019033	chr10:957182	NA	-0.65	-7.9	-0.45	9.17e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.66	-11.03	-0.58	3.05e-23	Menopause (age at onset);
KIRP	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg21926883	chr2:100939477	LONRF2	-0.64	-8.78	-0.49	2.76e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg10017260	chr10:834428	NA	-0.55	-5.41	-0.33	1.53e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13430298	chr2:228336928	AGFG1	0.5	6.28	0.37	1.5e-9	Parkinson's disease;
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg13906792	chr15:75199810	C15orf17	-0.35	-4.91	-0.3	1.68e-6	Breast cancer;
KIRP	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	1.29	10.41	0.55	2.91e-21	Prostate cancer;
KIRP	cis	rs490234	0.966	rs1250737	chr9:128428813	G/A	cg14078157	chr9:128172775	NA	0.39	4.91	0.3	1.67e-6	Mean arterial pressure;
KIRP	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-7.18	-0.42	8.32e-12	Coffee consumption (cups per day);
KIRP	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	6.04	0.36	5.74e-9	Menopause (age at onset);
KIRP	cis	rs865483	0.895	rs4795203	chr17:35828972	T/C	cg06716730	chr17:35851459	DUSP14	0.26	6.24	0.37	1.85e-9	Monocyte count;
KIRP	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.97	-14.28	-0.67	4.16e-34	Ulcerative colitis;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg05255149	chr17:80675120	FN3KRP	0.45	4.87	0.3	2.03e-6	Glycated hemoglobin levels;
KIRP	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.77	-0.35	2.34e-8	Personality dimensions;
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08280861	chr8:58055591	NA	0.71	5.49	0.33	9.82e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04924415	chr12:100661456	SCYL2;DEPDC4	0.48	6.09	0.36	4.24e-9	Parkinson's disease;
KIRP	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.39	-6.63	-0.39	2.08e-10	Colorectal or endometrial cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07695826	chr18:51884330	C18orf54	0.42	6.04	0.36	5.8e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg22800045	chr5:56110881	MAP3K1	0.59	6.83	0.4	6.48e-11	Initial pursuit acceleration;
KIRP	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg23894439	chr1:183413866	NA	-0.4	-5.21	-0.32	4.08e-7	Systemic lupus erythematosus;
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg11945507	chr8:142233382	SLC45A4	-0.92	-16.03	-0.71	4.55e-40	Immature fraction of reticulocytes;
KIRP	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg25547332	chr5:131281432	NA	-0.48	-5.38	-0.32	1.69e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.34	-0.51	5.94e-18	Platelet count;
KIRP	cis	rs11955398	0.625	rs10939857	chr5:59956801	C/T	cg02684056	chr5:59996105	DEPDC1B	0.44	4.98	0.3	1.18e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00684032	chr4:1343700	KIAA1530	-0.5	-6.45	-0.38	5.88e-10	Obesity-related traits;
KIRP	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg08712631	chr7:1960676	MAD1L1	-0.4	-5.11	-0.31	6.32e-7	Neuroticism;
KIRP	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.83	7.87	0.45	1.14e-13	Menopause (age at onset);
KIRP	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.69	0.44	3.47e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.75	11.5	0.59	9.18e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg11987759	chr7:65425863	GUSB	-0.6	-8.22	-0.46	1.21e-14	Calcium levels;
KIRP	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg15841412	chr13:111365552	ING1	0.52	5.96	0.36	8.59e-9	Coronary artery disease;
KIRP	cis	rs12900413	0.687	rs34284515	chr15:90308061	T/G	cg24650279	chr15:90327240	NA	-0.41	-5.27	-0.32	2.93e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg20578329	chr17:80767326	TBCD	-0.66	-7.74	-0.44	2.56e-13	Breast cancer;
KIRP	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.81	11.69	0.6	2.18e-25	Itch intensity from mosquito bite;
KIRP	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg08992911	chr2:238395768	MLPH	0.45	5.62	0.34	5.19e-8	Prostate cancer;
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg06654118	chr4:1303317	MAEA	0.29	5.18	0.31	4.7e-7	Obesity-related traits;
KIRP	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg06740227	chr12:86229804	RASSF9	-0.4	-4.98	-0.3	1.18e-6	Major depressive disorder;
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg07701084	chr6:150067640	NUP43	0.67	8.06	0.46	3.27e-14	Lung cancer;
KIRP	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.57	-6.72	-0.39	1.24e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.27	-0.32	3.02e-7	Educational attainment (years of education);
KIRP	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg24304309	chr1:154577895	ADAR	0.35	5.38	0.32	1.76e-7	Blood protein levels;
KIRP	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg24565620	chr2:194026	NA	0.67	6.1	0.36	4.06e-9	Blood protein levels;
KIRP	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	cis	rs77633900	0.772	rs2460161	chr15:76640430	C/T	cg21673338	chr15:77095150	SCAPER	-0.67	-5.7	-0.34	3.48e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs2411233	0.811	rs3850776	chr15:39262872	T/A	cg02291532	chr15:39874776	THBS1	0.41	5.42	0.33	1.4e-7	Platelet count;
KIRP	cis	rs7289126	0.966	rs2267378	chr22:38630956	G/A	cg25457927	chr22:38595422	NA	-0.3	-6.53	-0.38	3.78e-10	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg17376030	chr22:41985996	PMM1	0.63	7.01	0.41	2.33e-11	Vitiligo;
KIRP	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-9.04	-0.5	4.9e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg08738300	chr3:44038990	NA	0.68	9.56	0.52	1.28e-18	Coronary artery disease;
KIRP	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.8	-9.99	-0.54	6.02e-20	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.95	10.93	0.57	6.13e-23	Corneal astigmatism;
KIRP	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	1.1	17.93	0.75	1.54e-46	Cognitive function;
KIRP	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.02	-0.36	6.39e-9	Breast cancer;
KIRP	cis	rs4955124	0.730	rs12639105	chr3:32047336	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.78	6.48	0.38	4.86e-10	Schizophrenia;
KIRP	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg03714773	chr7:91764589	CYP51A1	0.36	5.45	0.33	1.22e-7	Breast cancer;
KIRP	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.74	11.07	0.58	2.26e-23	Resting heart rate;
KIRP	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-5.84	-0.35	1.63e-8	Fear of minor pain;
KIRP	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19524238	chr7:2802976	GNA12	-0.38	-5.22	-0.32	3.82e-7	Height;
KIRP	cis	rs654950	0.875	rs632166	chr1:41995681	T/C	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.41	-0.38	7.29e-10	Airway imaging phenotypes;
KIRP	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.0	19.17	0.77	1e-50	Prudent dietary pattern;
KIRP	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg10818794	chr15:86012489	AKAP13	-0.49	-7.04	-0.41	1.89e-11	Coronary artery disease;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-5.74	-0.34	2.8e-8	Response to antipsychotic treatment;
KIRP	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.93	11.56	0.59	5.47e-25	Menopause (age at onset);
KIRP	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.64	7.43	0.43	1.82e-12	Height;
KIRP	cis	rs806215	1.000	rs806196	chr7:127248414	A/G	cg25922125	chr7:127225783	GCC1	0.47	5.05	0.31	8.61e-7	Type 2 diabetes;
KIRP	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.19e-15	Retinal vascular caliber;
KIRP	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	5.62	0.34	5.13e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01008834	chr1:150207620	ANP32E	-0.47	-6.03	-0.36	5.87e-9	Myopia;
KIRP	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg19468946	chr17:37922297	IKZF3	-0.46	-6.54	-0.38	3.6e-10	Asthma;
KIRP	trans	rs6572548	0.885	rs7156741	chr14:49622979	G/A	cg27110129	chr4:15683224	LOC285550	0.47	6.02	0.36	6.21e-9	Subjective well-being;
KIRP	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg02297831	chr4:17616191	MED28	0.62	7.75	0.44	2.47e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.84	-0.35	1.65e-8	Educational attainment;
KIRP	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg08501292	chr6:25962987	TRIM38	0.88	7.0	0.41	2.43e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.46	5.81	0.35	1.91e-8	Multiple sclerosis;
KIRP	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.39	4.85	0.3	2.15e-6	Common traits (Other);
KIRP	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.92	-13.35	-0.65	5.84e-31	Tonsillectomy;
KIRP	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg00409905	chr10:38381863	ZNF37A	0.55	6.2	0.37	2.43e-9	Obesity (extreme);
KIRP	cis	rs2154427	0.872	rs78882615	chr21:34100648	G/T	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.67	-5.67	-0.34	3.93e-8	Bilirubin levels;
KIRP	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg20243544	chr17:37824526	PNMT	0.43	4.88	0.3	1.94e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg06042504	chr8:55087323	NA	-0.58	-6.86	-0.4	5.54e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4908768	0.906	rs12402539	chr1:8538303	C/A	cg25722041	chr1:8623473	RERE	0.77	9.81	0.53	2.16e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg17133734	chr15:86042851	AKAP13	-0.47	-5.93	-0.35	1e-8	Coronary artery disease;
KIRP	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg00784671	chr22:46762841	CELSR1	-0.91	-8.29	-0.47	7.47e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23903597	chr17:61704154	MAP3K3	-0.59	-6.49	-0.38	4.61e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg16988262	chr1:15930761	NA	0.39	5.16	0.31	5.16e-7	Systolic blood pressure;
KIRP	cis	rs12210905	0.688	rs12215386	chr6:27406877	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.74	-0.34	2.75e-8	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11370532	chr19:12912578	PRDX2	0.51	6.04	0.36	5.54e-9	Parkinson's disease;
KIRP	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg12856521	chr11:46389249	DGKZ	-0.58	-7.23	-0.42	6.11e-12	Crohn's disease;
KIRP	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.69	-11.7	-0.6	1.97e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	1.0	12.99	0.64	9.6e-30	Neutrophil percentage of white cells;
KIRP	cis	rs9896052	0.559	rs7220850	chr17:73436994	T/C	cg25649188	chr17:73499917	CASKIN2	0.6	5.82	0.35	1.87e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.49	4.99	0.3	1.12e-6	Alzheimer's disease;
KIRP	cis	rs7267005	0.661	rs75471627	chr20:34433982	C/T	cg17201900	chr20:34330562	RBM39	0.99	5.53	0.33	8.2e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg00650088	chr1:227169808	CABC1	0.42	6.02	0.36	6.3e-9	Warfarin maintenance dose;
KIRP	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg01879757	chr17:41196368	BRCA1	-0.76	-10.42	-0.55	2.73e-21	Menopause (age at onset);
KIRP	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg15848620	chr12:58087721	OS9	-0.47	-5.44	-0.33	1.27e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.77	-8.36	-0.47	4.69e-15	Corneal astigmatism;
KIRP	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg16141378	chr3:129829833	LOC729375	-0.53	-6.86	-0.4	5.69e-11	Retinal vascular caliber;
KIRP	cis	rs4560672	1.000	rs7741311	chr6:158581594	T/G	cg14029994	chr6:158589857	SERAC1;GTF2H5	-0.56	-4.96	-0.3	1.33e-6	Smoking quantity;
KIRP	cis	rs490234	0.552	rs2841327	chr9:128156503	G/A	cg14078157	chr9:128172775	NA	-0.39	-4.86	-0.3	2.08e-6	Mean arterial pressure;
KIRP	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.72	10.08	0.54	3.18e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg05156742	chr15:59063176	FAM63B	0.59	7.7	0.44	3.27e-13	Schizophrenia;
KIRP	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.61	8.35	0.47	5.12e-15	Lymphocyte counts;
KIRP	cis	rs6750047	0.566	rs1157184	chr2:38285774	C/G	cg07380506	chr2:38303506	CYP1B1	0.43	5.66	0.34	4.25e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs1829883	0.701	rs6890382	chr5:98972664	A/G	cg08333243	chr5:99726346	NA	0.41	5.08	0.31	7.57e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg21546286	chr11:48923668	NA	0.4	4.88	0.3	1.93e-6	HDL cholesterol;
KIRP	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.27	5.45	0.33	1.2e-7	Height;
KIRP	cis	rs7011049	1.000	rs79169015	chr8:53843908	C/T	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg20003494	chr4:90757398	SNCA	-0.37	-4.87	-0.3	2.01e-6	Neuroticism;
KIRP	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg07395648	chr5:131743802	NA	-0.36	-4.95	-0.3	1.38e-6	Blood metabolite levels;
KIRP	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	10.24	0.55	1.02e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg21360079	chr12:107162445	NA	-0.63	-8.82	-0.49	2.16e-16	Heart rate;
KIRP	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.53	6.78	0.4	8.89e-11	Mean platelet volume;
KIRP	cis	rs7551222	0.691	rs4951077	chr1:204482262	G/A	cg20240347	chr1:204465584	NA	-0.45	-8.53	-0.48	1.54e-15	Schizophrenia;
KIRP	cis	rs4926298	1.000	rs1077151	chr19:13151108	A/G	cg06417478	chr19:12876846	HOOK2	-0.4	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs4971059	0.629	rs9297	chr1:155106550	A/G	cg02153340	chr1:155202674	NA	-0.41	-5.95	-0.35	9.27e-9	Breast cancer;
KIRP	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.59	-5.84	-0.35	1.65e-8	DNA methylation (variation);
KIRP	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg09165964	chr15:75287851	SCAMP5	0.43	5.47	0.33	1.09e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg19338460	chr6:170058176	WDR27	-0.59	-6.97	-0.41	2.86e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg07870213	chr5:140052090	DND1	0.63	7.67	0.44	4.03e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg09256448	chr16:638327	NA	0.35	4.9	0.3	1.73e-6	Height;
KIRP	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10267417	0.603	rs10081315	chr7:19934007	T/A	cg05791153	chr7:19748676	TWISTNB	0.5	5.04	0.31	9.22e-7	Night sleep phenotypes;
KIRP	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.53	6.23	0.37	2.05e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg09579323	chr1:150459698	TARS2	-0.4	-5.03	-0.31	9.47e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.56	-6.74	-0.39	1.12e-10	Uric acid levels;
KIRP	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg14851346	chr12:38532713	NA	-0.39	-4.93	-0.3	1.54e-6	Morning vs. evening chronotype;
KIRP	cis	rs7113874	0.959	rs4929928	chr11:8675086	T/C	cg08015107	chr11:8618950	NA	0.35	4.95	0.3	1.37e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.38	8.05	0.46	3.45e-14	IgG glycosylation;
KIRP	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg25039879	chr17:56429692	SUPT4H1	0.61	5.35	0.32	1.98e-7	Cognitive test performance;
KIRP	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg23920097	chr1:209922102	NA	-0.44	-6.09	-0.36	4.34e-9	Red blood cell count;
KIRP	cis	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg00852783	chr1:26633632	UBXN11	-0.53	-5.37	-0.32	1.83e-7	Obesity-related traits;
KIRP	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.71	-7.95	-0.45	6.89e-14	Pursuit maintenance gain;
KIRP	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg15704280	chr7:45808275	SEPT13	0.71	6.34	0.37	1.08e-9	Intraocular pressure;
KIRP	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	8.02	0.46	4.32e-14	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg15226275	chr6:116381976	FRK	0.22	5.96	0.36	8.64e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	8.09	0.46	2.71e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.43e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10465746	0.901	rs17475760	chr1:84398435	A/T	cg10977910	chr1:84465055	TTLL7	0.47	5.77	0.35	2.37e-8	Obesity-related traits;
KIRP	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg06740227	chr12:86229804	RASSF9	0.4	5.09	0.31	6.95e-7	Major depressive disorder;
KIRP	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.44	6.02	0.36	6.4e-9	Total body bone mineral density;
KIRP	cis	rs35160687	0.814	rs1863063	chr2:86518249	A/C	cg10973622	chr2:86423274	IMMT	0.47	5.93	0.35	1e-8	Night sleep phenotypes;
KIRP	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.94	14.44	0.68	1.22e-34	Intelligence (multi-trait analysis);
KIRP	cis	rs1134634	0.520	rs28522268	chr4:15603467	G/C	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.86	-0.35	1.45e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7188697	0.885	rs1646010	chr16:58549204	G/C	cg21335942	chr16:58549945	SETD6	0.47	5.14	0.31	5.6e-7	QT interval;
KIRP	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg05082376	chr22:42548792	NA	-0.45	-5.36	-0.32	1.91e-7	Schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19844325	chr19:18314808	RAB3A	0.5	6.2	0.37	2.35e-9	Myopia (pathological);
KIRP	cis	rs742071	0.586	rs2153193	chr1:18943063	G/A	cg22389438	chr1:18926496	NA	-0.4	-5.65	-0.34	4.41e-8	Nonsyndromic cleft lip with cleft palate;Orofacial clefts;
KIRP	cis	rs2219968	0.743	rs34849429	chr8:78909689	G/T	cg00738934	chr8:78996279	NA	-0.39	-5.28	-0.32	2.79e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.61	-8.29	-0.47	7.4e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	0.94	8.24	0.47	1.03e-14	Skin colour saturation;
KIRP	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.42	-5.08	-0.31	7.3e-7	Schizophrenia;
KIRP	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	12.13	0.61	7.58e-27	Menopause (age at onset);
KIRP	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.8	-0.35	2.06e-8	Educational attainment;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg16627807	chr19:40596541	ZNF780A	0.66	6.18	0.37	2.66e-9	Lung function (FEV1);
KIRP	cis	rs8067287	0.749	rs62065427	chr17:16831560	C/T	cg26910001	chr17:16838321	NA	-0.61	-5.83	-0.35	1.75e-8	Diabetic kidney disease;
KIRP	cis	rs548987	0.529	rs9467618	chr6:25824809	C/T	cg12310025	chr6:25882481	NA	-0.43	-5.04	-0.31	8.84e-7	Homocysteine levels;
KIRP	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.39	17.28	0.74	2.34e-44	Uric acid levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15731816	chr14:75230414	YLPM1	0.53	7.0	0.41	2.39e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg09597638	chr17:3907349	NA	0.75	14.28	0.67	4.32e-34	Type 2 diabetes;
KIRP	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg20243544	chr17:37824526	PNMT	0.55	8.09	0.46	2.72e-14	Asthma;
KIRP	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.73	-8.88	-0.49	1.43e-16	Cognitive function;
KIRP	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.95	10.65	0.56	5.11e-22	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9810890	1.000	rs73210614	chr3:128641354	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg15893493	chr8:124194847	FAM83A	0.86	6.48	0.38	4.99e-10	Urinary uromodulin levels;
KIRP	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.86	10.83	0.57	1.32e-22	Coronary artery disease;
KIRP	cis	rs12913538	0.575	rs35909407	chr15:62890035	A/G	cg09983546	chr15:62884068	NA	0.49	6.08	0.36	4.53e-9	Sleep depth;
KIRP	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.64	0.48	7.34e-16	Bipolar disorder;
KIRP	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.45	-6.02	-0.36	6.36e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.27	-0.32	2.98e-7	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg06871246	chr4:1363661	KIAA1530	0.44	5.47	0.33	1.09e-7	Obesity-related traits;
KIRP	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.61	6.22	0.37	2.15e-9	Gastritis;
KIRP	cis	rs9549367	0.659	rs9549703	chr13:113885094	T/TTAG	cg18105134	chr13:113819100	PROZ	-1.0	-12.2	-0.61	4.45e-27	Platelet distribution width;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg09699651	chr6:150184138	LRP11	0.48	6.49	0.38	4.69e-10	Lung cancer;
KIRP	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg20243544	chr17:37824526	PNMT	0.47	5.36	0.32	1.9e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.72	9.58	0.52	1.16e-18	Menarche (age at onset);
KIRP	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.4	-0.38	7.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg24375607	chr4:120327624	NA	0.57	6.5	0.38	4.5e-10	Corneal astigmatism;
KIRP	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg03929089	chr4:120376271	NA	0.69	6.06	0.36	5.12e-9	Axial length;
KIRP	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg16497661	chr14:103986332	CKB	0.77	11.98	0.61	2.31e-26	Body mass index;
KIRP	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10136773	chr11:94906134	SESN3	0.46	6.88	0.4	4.95e-11	Interleukin-4 levels;
KIRP	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.47	-5.91	-0.35	1.13e-8	Blood metabolite levels;
KIRP	cis	rs7119167	0.851	rs11823979	chr11:73254598	G/A	cg17517138	chr11:73019481	ARHGEF17	0.49	5.12	0.31	6.19e-7	Blood protein levels;
KIRP	cis	rs11997175	0.583	rs4739562	chr8:33844064	C/T	cg04338863	chr8:33670619	NA	-0.45	-5.13	-0.31	5.83e-7	Body mass index;
KIRP	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg22138327	chr13:27999177	GTF3A	1.01	7.56	0.43	8.2e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.73	10.23	0.55	1.1e-20	Mean corpuscular volume;
KIRP	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16414030	chr3:133502952	NA	-0.48	-5.48	-0.33	1.04e-7	Iron status biomarkers;
KIRP	cis	rs1035491	0.893	rs1459192	chr5:63944519	C/T	cg01791865	chr5:63954708	NA	0.33	5.0	0.3	1.12e-6	Body mass index;
KIRP	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.18	19.53	0.78	6.2e-52	Cognitive function;
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.28	-0.37	1.51e-9	Lung cancer;
KIRP	cis	rs10421328	0.821	rs10423311	chr19:19757262	C/G	cg03709012	chr19:19516395	GATAD2A	0.45	5.17	0.31	4.93e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs11945232	0.624	rs35607673	chr4:88363217	C/T	cg23841344	chr4:88312519	HSD17B11	-0.58	-6.44	-0.38	6.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg18806716	chr10:30721971	MAP3K8	-0.32	-4.99	-0.3	1.14e-6	Inflammatory bowel disease;
KIRP	cis	rs699	0.556	rs2478525	chr1:230865350	C/G	cg07502417	chr1:230849801	AGT	0.24	4.89	0.3	1.83e-6	Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.66	9.44	0.52	3.01e-18	Morning vs. evening chronotype;
KIRP	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.77	-0.35	2.33e-8	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	5.9	0.35	1.2e-8	Renal cell carcinoma;
KIRP	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	1.08	7.65	0.44	4.45e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-6.47	-0.38	5.17e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.56	-0.33	7.02e-8	Life satisfaction;
KIRP	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg05347473	chr6:146136440	FBXO30	0.57	8.14	0.46	1.94e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg22834172	chr17:37774349	NA	0.51	6.31	0.37	1.26e-9	Body mass index in non-asthmatics;
KIRP	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.15e-9	Coronary artery disease;
KIRP	cis	rs367943	0.712	rs10053654	chr5:112724314	G/C	cg12552261	chr5:112820674	MCC	0.57	6.76	0.4	1.02e-10	Type 2 diabetes;
KIRP	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.98	-0.3	1.21e-6	Schizophrenia;
KIRP	cis	rs2150410	0.915	rs2142117	chr21:40669305	C/T	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg21186296	chr8:27182909	PTK2B	-0.48	-5.9	-0.35	1.23e-8	Alzheimer's disease (late onset);
KIRP	trans	rs7999699	0.869	rs2181959	chr13:48294190	T/A	cg23237801	chr1:16476620	EPHA2	0.51	6.37	0.38	9.43e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.69	-0.34	3.65e-8	Fear of minor pain;
KIRP	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.63	-0.39	2.1e-10	Aortic root size;
KIRP	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg19906672	chr4:6918868	TBC1D14	0.48	5.09	0.31	7.07e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs68092024	0.704	rs704576	chr3:99487154	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-4.94	-0.3	1.42e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.44	-0.38	6.1e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	5.79	0.35	2.16e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg15488143	chr7:128924101	AHCYL2	-0.47	-6.03	-0.36	5.92e-9	White matter hyperintensity burden;
KIRP	cis	rs2235573	0.662	rs2076369	chr22:38463652	T/G	cg19171272	chr22:38449367	NA	-0.67	-9.42	-0.51	3.52e-18	Glioblastoma;Glioma;
KIRP	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.29	0.32	2.65e-7	Diabetic retinopathy;
KIRP	cis	rs1519814	1.000	rs1519814	chr8:121115024	T/G	cg22335954	chr8:121166405	COL14A1	-0.59	-5.99	-0.36	7.34e-9	Breast cancer;
KIRP	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.45	-0.33	1.2e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1962073	0.667	rs11250004	chr8:10270958	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.04	-0.41	1.94e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08280861	chr8:58055591	NA	0.71	6.4	0.38	7.68e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-10.07	-0.54	3.37e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.59	0.48	1e-15	Morning vs. evening chronotype;
KIRP	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg08076091	chr2:203926405	NBEAL1	0.83	8.72	0.49	4.33e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg01304814	chr3:48885189	PRKAR2A	0.56	5.2	0.31	4.29e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.81	13.98	0.67	4.49e-33	Heart rate;
KIRP	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg03235661	chr20:60525775	NA	-0.32	-5.34	-0.32	2.14e-7	Body mass index;
KIRP	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.52	5.32	0.32	2.35e-7	Smoking behavior;
KIRP	trans	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.09	-0.41	1.41e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg18404041	chr3:52824283	ITIH1	-0.36	-5.21	-0.32	4.01e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg01798813	chr17:3906674	NA	0.52	7.21	0.42	6.88e-12	Type 2 diabetes;
KIRP	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg15660573	chr17:549704	VPS53	-0.84	-12.79	-0.63	4.74e-29	Prostate cancer;
KIRP	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.91	10.41	0.55	2.94e-21	Corneal astigmatism;
KIRP	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-5.96	-0.36	8.62e-9	Axial length;
KIRP	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.78	8.94	0.5	9.25e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg11247378	chr22:39784982	NA	0.42	5.27	0.32	3.02e-7	IgG glycosylation;
KIRP	cis	rs10488172	0.857	rs4731953	chr7:133103048	A/G	cg10665199	chr7:133106180	EXOC4	0.49	5.17	0.31	4.79e-7	Tonometry;
KIRP	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	9.17	0.5	1.96e-17	Chronic sinus infection;
KIRP	cis	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg02795151	chr17:7402630	POLR2A	0.78	8.03	0.46	4.11e-14	Androgen levels;
KIRP	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.61	6.28	0.37	1.52e-9	Gut microbiome composition (summer);
KIRP	trans	rs4742903	0.509	rs10820619	chr9:106964344	G/C	cg06629767	chr10:72238406	KIAA1274	-0.45	-6.22	-0.37	2.14e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs1106684	1.000	rs17792713	chr7:131463279	C/T	cg13607082	chr12:122652224	LRRC43	-0.65	-6.6	-0.39	2.58e-10	Body mass index;
KIRP	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg00405596	chr8:11794950	NA	0.6	8.44	0.47	2.74e-15	Neuroticism;
KIRP	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg03188948	chr7:1209495	NA	0.76	5.25	0.32	3.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs56399783	0.901	rs73033408	chr7:2879755	C/T	cg19731401	chr7:2775893	GNA12	0.74	6.13	0.36	3.55e-9	Childhood ear infection;
KIRP	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	0.92	5.3	0.32	2.58e-7	Height;
KIRP	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-6.83	-0.4	6.46e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03079559	chr16:68057026	DUS2L;DDX28	0.49	6.3	0.37	1.39e-9	Parkinson's disease;
KIRP	cis	rs6732160	0.588	rs2043101	chr2:73374050	A/G	cg01422370	chr2:73384389	NA	0.5	6.73	0.39	1.22e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs73195822	0.614	rs73194057	chr12:111216913	T/C	cg12870014	chr12:110450643	ANKRD13A	0.49	5.92	0.35	1.05e-8	Itch intensity from mosquito bite;
KIRP	cis	rs11955175	1.000	rs11956741	chr5:40677576	G/C	cg04002187	chr5:40835754	RPL37	0.68	5.28	0.32	2.84e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02575159	chr20:25176220	ENTPD6	0.49	6.17	0.37	2.83e-9	Parkinson's disease;
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg03160526	chr17:80928410	B3GNTL1	0.4	5.05	0.31	8.47e-7	Glycated hemoglobin levels;
KIRP	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.51	-6.67	-0.39	1.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6495367	1.000	rs6495367	chr15:79375347	C/T	cg17916960	chr15:79447300	NA	0.32	5.44	0.33	1.27e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.64	-7.73	-0.44	2.81e-13	Obesity-related traits;
KIRP	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-8.62	-0.48	8.21e-16	Platelet count;
KIRP	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg00977110	chr5:151150581	G3BP1	0.6	6.02	0.36	6.19e-9	Preschool internalizing problems;
KIRP	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.43	-6.15	-0.37	3.03e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg21643547	chr1:205240462	TMCC2	-0.7	-10.64	-0.56	5.51e-22	Red blood cell count;
KIRP	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg12591125	chr7:1885375	MAD1L1	0.64	6.16	0.37	2.99e-9	Bipolar disorder;
KIRP	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg02980000	chr4:1222292	CTBP1	0.88	7.98	0.45	5.71e-14	Systolic blood pressure;
KIRP	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg00262122	chr8:11665843	FDFT1	-0.45	-5.48	-0.33	1.05e-7	Retinal vascular caliber;
KIRP	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24549020	chr5:56110836	MAP3K1	0.5	4.86	0.3	2.13e-6	Initial pursuit acceleration;
KIRP	cis	rs9473924	0.632	rs7741703	chr6:50876941	T/C	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg23752985	chr2:85803571	VAMP8	0.59	8.41	0.47	3.42e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21643547	chr1:205240462	TMCC2	-0.7	-10.64	-0.56	5.51e-22	Red blood cell count;
KIRP	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg25866889	chr13:114914595	NA	-0.4	-5.58	-0.34	6.35e-8	Schizophrenia;
KIRP	cis	rs8067354	0.645	rs2132715	chr17:57858374	A/T	cg02344993	chr17:57696989	CLTC	0.55	5.03	0.31	9.67e-7	Hemoglobin concentration;
KIRP	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.55	6.33	0.37	1.16e-9	Aortic root size;
KIRP	cis	rs687432	0.885	rs61903967	chr11:57802389	T/A	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg12560992	chr17:57184187	TRIM37	0.58	5.3	0.32	2.61e-7	Cognitive test performance;
KIRP	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg15655495	chr12:38532458	NA	0.25	4.85	0.3	2.16e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9296736	0.922	rs614956	chr6:53950865	G/A	cg04374786	chr6:53939321	C6orf142	0.38	5.03	0.31	9.56e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.44	7.24	0.42	5.81e-12	Testicular germ cell tumor;
KIRP	cis	rs732765	0.734	rs9323602	chr14:75182008	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.46	-4.95	-0.3	1.4e-6	Non-small cell lung cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15358743	chr18:56807035	SEC11C	0.54	6.58	0.39	2.82e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9398803	0.678	rs9375448	chr6:126896782	A/T	cg19875578	chr6:126661172	C6orf173	0.42	5.41	0.33	1.47e-7	Male-pattern baldness;
KIRP	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.24	0.72	8.42e-41	Electrocardiographic conduction measures;
KIRP	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.52	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.83	11.63	0.6	3.37e-25	Monocyte count;
KIRP	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.65	9.27	0.51	1.01e-17	Alcohol dependence;
KIRP	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg04731861	chr2:219085781	ARPC2	-0.27	-6.44	-0.38	6.06e-10	Colorectal cancer;
KIRP	cis	rs4654899	0.772	rs951805	chr1:21060356	A/G	cg05370193	chr1:21551575	ECE1	-0.43	-5.57	-0.33	6.54e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10114408	0.959	rs1890379	chr9:96665767	A/G	cg14598338	chr9:96623480	NA	-0.32	-4.92	-0.3	1.57e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs3736485	0.966	rs8041514	chr15:51866054	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23617067	chr1:220292508	IARS2;MIR194-1;MIR215	-0.42	-6.18	-0.37	2.6e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19723775	chr5:179050963	HNRNPH1	-0.55	-6.41	-0.38	7.48e-10	Lung cancer;
KIRP	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.67	-0.34	4.01e-8	IgG glycosylation;
KIRP	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg11833968	chr6:79620685	NA	-0.37	-5.12	-0.31	6.06e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg19875535	chr5:140030758	IK	-0.72	-10.41	-0.55	2.81e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	1.02	14.3	0.67	3.57e-34	Menarche (age at onset);
KIRP	trans	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg12623145	chr2:97778927	ANKRD36	0.6	6.04	0.36	5.77e-9	Hip geometry;
KIRP	cis	rs6256	1.000	rs10500783	chr11:13573614	C/T	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg07424592	chr7:64974309	NA	0.75	4.97	0.3	1.28e-6	Diabetic kidney disease;
KIRP	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg21401794	chr1:90099060	LRRC8C	-0.7	-9.8	-0.53	2.38e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg16905586	chr3:49761211	GMPPB	-0.48	-6.73	-0.39	1.15e-10	Thyroid cancer;
KIRP	cis	rs698813	0.614	rs811494	chr2:44725047	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.01	0.3	1.03e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.72	10.29	0.55	6.95e-21	High light scatter reticulocyte count;
KIRP	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.73	-7.8	-0.45	1.71e-13	Blood pressure (smoking interaction);
KIRP	cis	rs6832769	1.000	rs28572116	chr4:56424344	A/T	cg05960024	chr4:56376020	CLOCK	-0.72	-9.37	-0.51	4.83e-18	Personality dimensions;
KIRP	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.91	-0.53	1.07e-19	Neuroticism;
KIRP	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg00129232	chr17:37814104	STARD3	-0.69	-7.48	-0.43	1.28e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.69	-7.41	-0.43	1.99e-12	Response to diuretic therapy;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.33	0.47	5.63e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg00106254	chr7:1943704	MAD1L1	-0.53	-5.69	-0.34	3.67e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg16141378	chr3:129829833	LOC729375	0.52	6.77	0.4	9.48e-11	Retinal vascular caliber;
KIRP	trans	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg05926928	chr17:57297772	GDPD1	0.55	6.69	0.39	1.49e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.41	6.3	0.37	1.36e-9	Lipoprotein (a) levels;
KIRP	cis	rs7712401	0.601	rs144597	chr5:122223232	A/C	cg19412675	chr5:122181750	SNX24	0.51	5.58	0.34	6.28e-8	Mean platelet volume;
KIRP	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2573652	1.000	rs2573652	chr15:100514614	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.63	-8.74	-0.49	3.66e-16	Height;
KIRP	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.63	-8.26	-0.47	8.9e-15	Multiple myeloma (IgH translocation);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10463451	chr21:37432625	SETD4	0.49	7.43	0.43	1.74e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg19636519	chr7:99541626	NA	0.28	4.86	0.3	2.07e-6	Coronary artery disease;
KIRP	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg16105309	chr15:79090380	ADAMTS7	0.6	7.8	0.45	1.72e-13	Schizophrenia;
KIRP	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.41	0.33	1.47e-7	Lung cancer;
KIRP	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg13798780	chr7:105162888	PUS7	0.4	4.93	0.3	1.52e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.45	-5.8	-0.35	2.04e-8	Aortic root size;
KIRP	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg00800038	chr16:89945340	TCF25	-0.69	-4.98	-0.3	1.17e-6	Skin colour saturation;
KIRP	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.88	-10.41	-0.55	2.81e-21	Gut microbiome composition (summer);
KIRP	cis	rs1985732	1	rs1985732	chr6:26376161	A/G	cg14345882	chr6:26364793	BTN3A2	0.35	5.38	0.32	1.7e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7635838	0.892	rs9310379	chr3:11434143	C/T	cg00170343	chr3:11313890	ATG7	-0.42	-5.39	-0.33	1.62e-7	HDL cholesterol;
KIRP	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.29	0.37	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7116495	1.000	rs7949480	chr11:71697588	T/C	cg26138937	chr11:71823887	C11orf51	-0.72	-5.83	-0.35	1.7e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Hypertriglyceridemia;
KIRP	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs193541	0.632	rs415417	chr5:122322884	G/A	cg19412675	chr5:122181750	SNX24	-0.6	-6.45	-0.38	6.03e-10	Glucose homeostasis traits;
KIRP	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.81	-11.9	-0.6	4.4e-26	Asthma;
KIRP	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.87	8.5	0.48	1.87e-15	Alzheimer's disease;
KIRP	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg12131826	chr15:77904385	NA	-0.38	-4.94	-0.3	1.47e-6	Type 2 diabetes;
KIRP	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.73	-10.9	-0.57	7.68e-23	Hip circumference;
KIRP	cis	rs7116495	1.000	rs2508858	chr11:71805405	C/G	cg26138937	chr11:71823887	C11orf51	0.67	5.32	0.32	2.37e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.72	-7.8	-0.45	1.82e-13	DNA methylation (variation);
KIRP	cis	rs2274459	1.000	rs34339105	chr6:33723457	G/T	cg06253072	chr6:33679850	C6orf125	0.48	4.86	0.3	2.07e-6	Obesity (extreme);
KIRP	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.96	11.28	0.58	4.81e-24	Corneal astigmatism;
KIRP	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.73	-10.46	-0.55	1.99e-21	Height;
KIRP	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2970992	0.764	rs2090012	chr2:101330582	T/C	cg01042948	chr2:101319752	NA	0.42	6.03	0.36	5.83e-9	Educational attainment;
KIRP	cis	rs918629	0.530	rs3815768	chr5:95236459	C/T	cg16656078	chr5:95278638	ELL2	-0.38	-5.85	-0.35	1.56e-8	IgG glycosylation;
KIRP	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg00981070	chr1:2046702	PRKCZ	0.41	5.86	0.35	1.5e-8	Height;
KIRP	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.81	0.66	1.7e-32	Cognitive function;
KIRP	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg05926928	chr17:57297772	GDPD1	0.97	10.39	0.55	3.36e-21	Opioid sensitivity;
KIRP	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.84	0.35	1.61e-8	Personality dimensions;
KIRP	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	1.03	19.64	0.78	2.8e-52	Ulcerative colitis;
KIRP	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.73	9.96	0.54	7.49e-20	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12441221	chr1:156542351	IQGAP3	0.52	6.6	0.39	2.45e-10	Parkinson's disease;
KIRP	cis	rs735860	0.737	rs2397139	chr6:53150804	C/G	cg10236188	chr6:53219634	NA	-0.36	-4.85	-0.3	2.23e-6	Glaucoma;
KIRP	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg14343924	chr8:8086146	FLJ10661	0.49	5.59	0.34	5.9e-8	Systolic blood pressure;
KIRP	cis	rs7130144	0.541	rs73572230	chr11:130460843	G/A	cg26307797	chr11:130446613	NA	-0.63	-5.2	-0.31	4.19e-7	Urate levels in lean individuals;
KIRP	cis	rs9783347	1.000	rs10734259	chr11:18314865	A/G	cg15585147	chr11:18324498	HPS5	0.47	6.36	0.38	9.83e-10	Pancreatic cancer;
KIRP	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.84	10.13	0.54	2.17e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	cg21523751	chr1:182988639	NA	0.35	4.95	0.3	1.36e-6	Fuchs's corneal dystrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12678006	chr1:155164622	MIR92B	0.49	7.04	0.41	1.93e-11	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.6	-0.39	2.47e-10	Glomerular filtration rate;
KIRP	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.16	-0.79	5.05e-54	Height;
KIRP	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.9	16.36	0.72	3.37e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg14458575	chr2:238380390	NA	0.48	5.4	0.33	1.59e-7	Prostate cancer;
KIRP	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.65	8.37	0.47	4.31e-15	Height;
KIRP	cis	rs2692947	0.550	rs12623771	chr2:96633504	A/G	cg23100626	chr2:96804247	ASTL	0.46	6.8	0.4	7.86e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.62	5.24	0.32	3.44e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs12900413	0.687	rs13343248	chr15:90311226	A/T	cg24650279	chr15:90327240	NA	-0.41	-5.23	-0.32	3.7e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg06636001	chr8:8085503	FLJ10661	0.73	9.87	0.53	1.41e-19	Systolic blood pressure;
KIRP	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg17757837	chr7:157058334	UBE3C	-0.82	-11.3	-0.58	4.04e-24	Body mass index;
KIRP	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06544989	chr22:39130855	UNC84B	-0.46	-7.39	-0.43	2.32e-12	Menopause (age at onset);
KIRP	cis	rs1018697	1.000	rs7896903	chr10:104566417	A/G	cg04362960	chr10:104952993	NT5C2	0.47	5.66	0.34	4.14e-8	Colorectal adenoma (advanced);
KIRP	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00938859	chr5:1591904	SDHAP3	0.59	7.95	0.45	6.54e-14	Breast cancer;
KIRP	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.56	7.7	0.44	3.27e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg20993868	chr7:22813445	NA	0.62	9.05	0.5	4.52e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6500395	1.000	rs924476	chr16:48556847	C/T	cg04672837	chr16:48644449	N4BP1	0.54	7.48	0.43	1.35e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.73	10.08	0.54	3.18e-20	Plateletcrit;Platelet count;
KIRP	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg06671706	chr8:8559999	CLDN23	0.54	6.41	0.38	7.57e-10	Obesity-related traits;
KIRP	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.26	-0.37	1.73e-9	Response to antipsychotic treatment;
KIRP	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.43	0.33	1.37e-7	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg10760299	chr15:45669010	GATM	0.33	5.19	0.31	4.4e-7	Homoarginine levels;
KIRP	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.65	-7.31	-0.42	3.67e-12	Menarche (age at onset);
KIRP	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg01522456	chr1:115632236	TSPAN2	-0.35	-4.85	-0.3	2.23e-6	Autism;
KIRP	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27286337	chr10:134555280	INPP5A	0.87	10.09	0.54	2.99e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg11235152	chr1:67600687	NA	0.68	9.93	0.53	9.41e-20	Psoriasis;
KIRP	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg10117171	chr1:25599238	RHD	-0.41	-5.54	-0.33	7.83e-8	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg00204512	chr16:28754710	NA	0.46	5.9	0.35	1.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-4.9	-0.3	1.72e-6	Aortic root size;
KIRP	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.72	-10.67	-0.56	4.2e-22	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs7714584	1.000	rs4958842	chr5:150224877	G/A	cg22134413	chr5:150180641	NA	0.82	6.92	0.4	3.87e-11	Crohn's disease;
KIRP	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.3e-21	Educational attainment;
KIRP	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.58	7.85	0.45	1.31e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.19	-0.37	2.44e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6466055	0.777	rs2237613	chr7:104845253	G/C	cg04380332	chr7:105027541	SRPK2	-0.63	-9.69	-0.53	4.96e-19	Schizophrenia;
KIRP	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.53	6.01	0.36	6.6e-9	Platelet distribution width;
KIRP	cis	rs2671245	0.933	rs2819490	chr1:56164478	T/C	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg00031303	chr3:195681400	NA	0.59	6.94	0.4	3.42e-11	Pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.93	12.01	0.61	1.84e-26	Menopause (age at onset);
KIRP	cis	rs55863869	0.748	rs2291310	chr2:179623758	C/T	cg02880032	chr2:179629472	TTN	-0.68	-6.12	-0.36	3.66e-9	QT interval;
KIRP	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-1.04	-19.26	-0.78	4.97e-51	Height;
KIRP	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.71	-10.32	-0.55	5.4e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg11970804	chr8:8084126	NA	-0.39	-5.09	-0.31	7.02e-7	Neuroticism;
KIRP	cis	rs33912345	0.695	rs1254300	chr14:60884751	C/G	cg27398547	chr14:60952738	C14orf39	-0.39	-5.26	-0.32	3.2e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg04362960	chr10:104952993	NT5C2	0.55	6.21	0.37	2.24e-9	Waist circumference;Hip circumference;
KIRP	cis	rs2387326	0.717	rs12252256	chr10:129944616	C/T	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.84	12.02	0.61	1.73e-26	Schizophrenia;
KIRP	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.83	-7.12	-0.41	1.17e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.96	0.36	8.48e-9	Lung cancer;
KIRP	cis	rs365132	0.517	rs7706790	chr5:176359136	C/T	cg16309518	chr5:176445507	NA	-0.66	-7.85	-0.45	1.31e-13	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs7621025	0.691	rs9845762	chr3:136356464	C/T	cg15507776	chr3:136538369	TMEM22	0.39	5.13	0.31	5.86e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs12476592	0.602	rs10168545	chr2:63734284	C/A	cg17519650	chr2:63277830	OTX1	-0.42	-4.88	-0.3	1.93e-6	Childhood ear infection;
KIRP	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24110177	chr3:50126178	RBM5	0.44	5.6	0.34	5.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12900413	0.645	rs28507224	chr15:90305393	T/C	cg24650279	chr15:90327240	NA	-0.43	-5.43	-0.33	1.34e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-8.48	-0.48	2.15e-15	Colorectal cancer;
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg05627522	chr15:75251581	NA	0.38	5.88	0.35	1.32e-8	Breast cancer;
KIRP	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg13607699	chr17:42295918	UBTF	-0.56	-6.93	-0.4	3.63e-11	Total body bone mineral density;
KIRP	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14893161	chr1:205819251	PM20D1	0.45	4.99	0.3	1.12e-6	Parkinson's disease;
KIRP	cis	rs7766436	0.885	rs12111204	chr6:22578227	C/T	cg13666174	chr6:22585274	NA	-0.44	-6.17	-0.37	2.84e-9	Coronary artery disease;
KIRP	cis	rs6669119	0.668	rs75088145	chr1:19092368	G/A	cg26220594	chr1:19110978	NA	0.65	5.9	0.35	1.18e-8	Percentage gas trapping;
KIRP	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.51	-0.33	9.19e-8	Coronary artery disease;
KIRP	cis	rs17023223	0.537	rs2765532	chr1:119591546	T/C	cg18261050	chr1:119551319	NA	0.52	6.98	0.41	2.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs282587	0.569	rs282562	chr13:113375249	T/G	cg04656015	chr13:113407548	ATP11A	-0.56	-5.9	-0.35	1.2e-8	Glycated hemoglobin levels;
KIRP	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg00784671	chr22:46762841	CELSR1	0.61	8.55	0.48	1.37e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.66	-9.83	-0.53	1.88e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs1422110	0.519	rs12055343	chr5:85437684	T/C	cg01787110	chr1:109008453	NBPF6	0.69	8.51	0.48	1.67e-15	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.57	-6.38	-0.38	8.82e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg23719950	chr11:63933701	MACROD1	-0.65	-6.42	-0.38	7.03e-10	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07079407	chr3:122233852	KPNA1	0.55	6.94	0.4	3.45e-11	Parkinson's disease;
KIRP	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.59	6.4	0.38	7.88e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.87	-11.98	-0.61	2.29e-26	Obesity-related traits;
KIRP	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg12373951	chr3:133503437	NA	0.37	5.16	0.31	5.08e-7	Ankle injury;
KIRP	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.64	7.88	0.45	1.09e-13	Lymphocyte counts;
KIRP	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg07234876	chr8:600039	NA	-1.03	-6.39	-0.38	8.43e-10	IgG glycosylation;
KIRP	cis	rs10929159	0.928	rs2123511	chr2:236923187	C/T	cg20128773	chr2:236923534	AGAP1	0.3	5.12	0.31	6.3e-7	Parkinson's disease;
KIRP	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg00360474	chr6:37504404	NA	-0.47	-6.5	-0.38	4.47e-10	Cognitive performance;
KIRP	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04037228	chr3:45636386	LIMD1	0.38	5.71	0.34	3.18e-8	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg11569703	chr11:65557185	OVOL1	0.49	7.23	0.42	6.11e-12	Breast cancer;
KIRP	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	7.48	0.43	1.31e-12	Total body bone mineral density;
KIRP	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg08501292	chr6:25962987	TRIM38	1.01	5.78	0.35	2.24e-8	Breast cancer;
KIRP	cis	rs4356975	0.563	rs6600879	chr4:69960387	C/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.56	-7.34	-0.42	3.06e-12	Alzheimer's disease;
KIRP	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg13615516	chr5:77269221	NA	0.5	7.69	0.44	3.47e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-5.28	-0.32	2.88e-7	Height;
KIRP	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg00079375	chr15:79125835	NA	0.37	5.33	0.32	2.27e-7	Coronary artery disease;
KIRP	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg07701084	chr6:150067640	NUP43	0.56	7.26	0.42	4.92e-12	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26959303	chr3:133375668	TOPBP1	-0.46	-6.81	-0.4	7.38e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg06636001	chr8:8085503	FLJ10661	0.87	12.06	0.61	1.32e-26	Mood instability;
KIRP	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg20936604	chr3:58311152	NA	-0.76	-5.57	-0.33	6.79e-8	Cholesterol, total;
KIRP	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg08280861	chr8:58055591	NA	0.64	5.86	0.35	1.45e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02018176	chr4:1364513	KIAA1530	-0.38	-4.92	-0.3	1.58e-6	Obesity-related traits;
KIRP	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg23565292	chr14:50234668	KLHDC2	-0.41	-4.87	-0.3	2.04e-6	Carotid intima media thickness;
KIRP	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.33	0.59	3.17e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg10755058	chr3:40428713	ENTPD3	-0.46	-6.11	-0.36	3.9e-9	Renal cell carcinoma;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg03034864	chr1:234509241	C1orf31	0.51	6.08	0.36	4.5e-9	Educational attainment;
KIRP	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg11833968	chr6:79620685	NA	-0.46	-6.94	-0.4	3.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg16606324	chr3:10149918	C3orf24	0.65	5.63	0.34	4.88e-8	Alzheimer's disease;
KIRP	cis	rs72730918	0.590	rs2061425	chr15:51748146	T/C	cg14296394	chr15:51910925	DMXL2	0.76	10.32	0.55	5.42e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg11211951	chr8:145729740	GPT	-0.35	-5.76	-0.34	2.47e-8	Age at first birth;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02101719	chr7:148787553	ZNF786	0.51	6.02	0.36	6.24e-9	Smoking initiation;
KIRP	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs6910061	1.000	rs6938870	chr6:11095317	A/G	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg01620082	chr3:125678407	NA	-1.18	-7.63	-0.44	5.19e-13	Depression;
KIRP	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-9.61	-0.52	9.32e-19	Asthma;
KIRP	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18252515	chr7:66147081	NA	-0.44	-5.4	-0.33	1.57e-7	Aortic root size;
KIRP	cis	rs10189230	0.935	rs3770145	chr2:222345147	T/C	cg14652038	chr2:222343519	EPHA4	0.52	7.43	0.43	1.74e-12	Urate levels in lean individuals;
KIRP	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.76	9.82	0.53	1.99e-19	Aortic root size;
KIRP	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg14221460	chr8:27183342	PTK2B	0.54	7.06	0.41	1.69e-11	Neuroticism;
KIRP	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.62	-0.39	2.2e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23161317	chr6:28129485	ZNF389	0.46	5.35	0.32	2.05e-7	Depression;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.23	-0.55	1.09e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7009516	0.846	rs13257546	chr8:24218697	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.29	5.9	0.35	1.17e-8	Hair greying;
KIRP	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg17595323	chr11:93583763	C11orf90	-0.37	-6.3	-0.37	1.35e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg09137382	chr11:130731461	NA	0.59	8.58	0.48	1.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs17221829	0.673	rs10765226	chr11:89385013	A/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.25e-6	Anxiety in major depressive disorder;
KIRP	cis	rs4789693	0.518	rs6502117	chr17:80452592	G/C	cg04308225	chr17:80449738	NA	0.55	6.4	0.38	7.69e-10	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.88	-10.09	-0.54	3.02e-20	Corneal astigmatism;
KIRP	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg14541582	chr5:601475	NA	-0.55	-6.14	-0.36	3.3e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10875746	0.951	rs2269935	chr12:48516464	G/T	cg26205652	chr12:48591994	NA	0.78	10.33	0.55	5.24e-21	Longevity (90 years and older);
KIRP	cis	rs259282	0.628	rs2287669	chr19:33110204	T/C	cg02997394	chr19:33096574	ANKRD27	-0.53	-6.3	-0.37	1.4e-9	Schizophrenia;
KIRP	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg11693508	chr17:37793320	STARD3	0.75	8.36	0.47	4.69e-15	Neuroticism;
KIRP	cis	rs74181299	0.571	rs71424153	chr2:65280894	G/C	cg05010058	chr2:65284262	CEP68	0.42	5.3	0.32	2.58e-7	Pulse pressure;
KIRP	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	0.96	16.11	0.72	2.42e-40	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08780837	chr5:132362247	ZCCHC10	0.48	6.17	0.37	2.86e-9	Parkinson's disease;
KIRP	cis	rs9715521	0.718	rs7441564	chr4:59845405	A/T	cg11281224	chr4:60001000	NA	-0.4	-4.96	-0.3	1.33e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1440410	0.795	rs6822299	chr4:144182363	T/C	cg01719995	chr4:144104893	USP38	0.39	5.13	0.31	5.84e-7	Ischemic stroke;
KIRP	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg06521331	chr12:34319734	NA	-0.5	-6.14	-0.36	3.36e-9	Morning vs. evening chronotype;
KIRP	cis	rs3026101	0.671	rs1806242	chr17:5304763	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg02248941	chr16:2239361	CASKIN1	0.38	5.31	0.32	2.44e-7	Height;
KIRP	cis	rs11264213	0.901	rs630364	chr1:36449304	C/T	cg27506609	chr1:36549197	TEKT2	0.92	9.64	0.52	7.51e-19	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	14.81	0.69	6.35e-36	Platelet count;
KIRP	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg01689657	chr7:91764605	CYP51A1	0.41	5.91	0.35	1.15e-8	Breast cancer;
KIRP	cis	rs4762326	0.584	rs7954978	chr12:95647235	A/G	cg07737802	chr12:95537812	FGD6	0.37	4.89	0.3	1.78e-6	Endometriosis;
KIRP	cis	rs16858210	0.874	rs55666767	chr3:183573235	C/T	cg25686905	chr3:183603175	PARL	-0.43	-5.03	-0.31	9.37e-7	Menopause (age at onset);
KIRP	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.28	-0.37	1.53e-9	QT interval;
KIRP	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.48	6.61	0.39	2.3e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12524338	chr4:183729343	NA	0.62	5.5	0.33	9.45e-8	Pediatric autoimmune diseases;
KIRP	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg01843034	chr6:37503916	NA	-0.86	-12.28	-0.62	2.38e-27	Cognitive performance;
KIRP	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg15358701	chr1:161410459	NA	0.68	6.26	0.37	1.74e-9	Rheumatoid arthritis;
KIRP	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg02389323	chr16:88786976	FAM38A	1.04	8.69	0.48	5.02e-16	Plateletcrit;
KIRP	cis	rs7919006	0.623	rs75595613	chr10:76679000	A/T	cg01390419	chr10:76803856	DUPD1	0.45	5.03	0.31	9.62e-7	Weight;
KIRP	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.01	-0.3	1.04e-6	Pulmonary function;
KIRP	cis	rs10992471	0.528	rs7860786	chr9:95245473	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.48	-0.33	1.07e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18252515	chr7:66147081	NA	0.44	5.15	0.31	5.36e-7	Aortic root size;
KIRP	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05220968	chr6:146057943	EPM2A	-0.43	-5.37	-0.32	1.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073416	0.535	rs7150448	chr14:65871502	C/T	cg03016385	chr14:66212404	NA	-0.54	-6.65	-0.39	1.89e-10	N-glycan levels;
KIRP	cis	rs7998202	0.667	rs408220	chr13:113370267	T/C	cg04656015	chr13:113407548	ATP11A	-0.52	-5.34	-0.32	2.13e-7	Glycated hemoglobin levels;
KIRP	cis	rs9535307	0.858	rs6561553	chr13:50261089	A/G	cg04663916	chr13:50265991	EBPL	0.72	7.54	0.43	9.1e-13	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg11859384	chr17:80120422	CCDC57	-0.41	-5.13	-0.31	5.75e-7	Life satisfaction;
KIRP	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg22437258	chr11:111473054	SIK2	0.61	7.13	0.41	1.11e-11	Primary sclerosing cholangitis;
KIRP	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.5	5.72	0.34	3.12e-8	Mosquito bite size;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-5.43	-0.33	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06481639	chr22:41940642	POLR3H	0.73	7.57	0.43	7.65e-13	Vitiligo;
KIRP	cis	rs2290402	0.536	rs73207790	chr4:865430	G/A	cg14517359	chr4:903473	GAK	-0.55	-5.78	-0.35	2.27e-8	Type 2 diabetes;
KIRP	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.83	8.66	0.48	6.35e-16	Cerebrospinal P-tau181p levels;
KIRP	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	7.3	0.42	4.02e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.35	-0.32	1.97e-7	Aortic root size;
KIRP	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg16989719	chr2:238392110	NA	-0.54	-6.1	-0.36	4.11e-9	Prostate cancer;
KIRP	cis	rs259842	0.612	rs10183495	chr2:180669177	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	0.41	5.45	0.33	1.22e-7	Blood protein levels;
KIRP	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg13660082	chr14:53194042	PSMC6	-0.67	-7.31	-0.42	3.8e-12	Alzheimer's disease (late onset);
KIRP	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.44	-7.6	-0.44	6.14e-13	Systemic lupus erythematosus;
KIRP	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.3	0.37	1.37e-9	Red blood cell count;
KIRP	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.64	7.78	0.44	2.02e-13	Height;
KIRP	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.18e-11	Blood metabolite levels;
KIRP	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.29	7.75	0.44	2.39e-13	Crohn's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05414026	chr15:72410489	MYO9A;SENP8	0.51	6.13	0.36	3.4e-9	Myopia (pathological);
KIRP	trans	rs12517041	0.938	rs4701357	chr5:23263746	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.64	-6.84	-0.4	6.13e-11	Calcium levels;
KIRP	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-1.02	-13.31	-0.65	8.28e-31	Body mass index;
KIRP	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg14403583	chr14:105418241	AHNAK2	-0.69	-9.51	-0.52	1.77e-18	Rheumatoid arthritis;
KIRP	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-8.57	-0.48	1.17e-15	Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15452973	chr8:101114661	RGS22	-0.39	-6.1	-0.36	4.01e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.02	-0.36	6.28e-9	Height;
KIRP	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-1.19	-12.19	-0.61	4.6e-27	Monocyte percentage of white cells;
KIRP	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.56e-17	Retinal vascular caliber;
KIRP	cis	rs4474465	1.000	rs7929712	chr11:78158542	T/C	cg02023728	chr11:77925099	USP35	0.35	5.53	0.33	8.22e-8	Alzheimer's disease (survival time);
KIRP	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg00310523	chr12:86230176	RASSF9	0.4	6.11	0.36	3.91e-9	Major depressive disorder;
KIRP	cis	rs4663866	0.901	rs35713061	chr2:239183774	C/T	cg17283117	chr2:239148619	HES6	0.7	5.07	0.31	7.88e-7	Irritable bowel syndrome;
KIRP	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg01629716	chr15:45996671	NA	0.37	6.59	0.39	2.68e-10	Waist circumference;Weight;
KIRP	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.47	5.66	0.34	4.15e-8	Educational attainment (years of education);
KIRP	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg18882449	chr10:104885122	NT5C2	-0.49	-6.32	-0.37	1.23e-9	Arsenic metabolism;
KIRP	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg10523679	chr1:76189770	ACADM	-0.46	-6.3	-0.37	1.35e-9	Daytime sleep phenotypes;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg09699651	chr6:150184138	LRP11	0.5	6.74	0.39	1.13e-10	Lung cancer;
KIRP	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	1.0	14.4	0.68	1.62e-34	Menarche (age at onset);
KIRP	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.9	-13.67	-0.66	5.12e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs7646881	0.812	rs7624161	chr3:158459914	C/G	cg19483011	chr3:158453295	NA	-0.49	-5.47	-0.33	1.1e-7	Tetralogy of Fallot;
KIRP	cis	rs867371	1.000	rs7173339	chr15:82467594	A/G	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.39e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.12	10.6	0.56	7.38e-22	Alzheimer's disease (late onset);
KIRP	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.63	-8.19	-0.46	1.39e-14	Colorectal cancer;
KIRP	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	trans	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg11693508	chr17:37793320	STARD3	0.49	6.67	0.39	1.68e-10	Neuroticism;
KIRP	cis	rs9596863	1.000	rs1545659	chr13:54433788	G/A	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.64	-0.34	4.68e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2882667	0.964	rs2288824	chr5:138298396	C/T	cg04439458	chr5:138467593	SIL1	-0.46	-7.23	-0.42	6.08e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	1.08	15.83	0.71	2.07e-39	Menopause (age at onset);
KIRP	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.84	-0.35	1.65e-8	Schizophrenia;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg23034840	chr1:205782522	SLC41A1	0.62	8.29	0.47	7.31e-15	Menarche (age at onset);
KIRP	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	1.11	14.49	0.68	7.93e-35	Pulmonary function decline;
KIRP	cis	rs4849845	0.853	rs13386533	chr2:121029586	G/A	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs258892	0.895	rs6871969	chr5:72085036	C/T	cg21869765	chr5:72125136	TNPO1	-0.54	-5.91	-0.35	1.13e-8	Small cell lung carcinoma;
KIRP	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg10017260	chr10:834428	NA	-0.52	-5.3	-0.32	2.63e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.78	-0.35	2.3e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs17092148	0.887	rs2889849	chr20:33164277	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	4.85	0.3	2.17e-6	Neuroticism;
KIRP	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg17279839	chr7:150038598	RARRES2	0.43	5.24	0.32	3.46e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg16576597	chr16:28551801	NUPR1	0.36	5.25	0.32	3.24e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	5.48	0.33	1.03e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg04374321	chr14:90722782	PSMC1	0.51	5.57	0.33	6.52e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs735539	0.645	rs9552252	chr13:21192905	C/T	cg27499820	chr13:21296301	IL17D	0.35	5.06	0.31	8.11e-7	Dental caries;
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg12486944	chr17:80159399	CCDC57	0.38	5.2	0.31	4.13e-7	Life satisfaction;
KIRP	cis	rs12936587	0.811	rs12945496	chr17:17537197	G/C	cg01246520	chr17:17644344	RAI1	-0.37	-5.94	-0.35	9.81e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.96	15.43	0.7	4.97e-38	Breast cancer;
KIRP	trans	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.8	-0.4	7.8e-11	Heart rate;
KIRP	cis	rs4356932	1.000	rs10010920	chr4:76982733	C/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs7215564	0.908	rs34143200	chr17:78673008	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.14	0.31	5.6e-7	Myopia (pathological);
KIRP	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.75	8.4	0.47	3.58e-15	Response to diuretic therapy;
KIRP	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.86	15.96	0.71	7.99e-40	Anterior chamber depth;
KIRP	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.73	-11.52	-0.59	7.57e-25	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	7.92e-7	Electrocardiographic conduction measures;
KIRP	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.41	-6.67	-0.39	1.71e-10	Type 2 diabetes;
KIRP	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06544989	chr22:39130855	UNC84B	-0.47	-7.71	-0.44	3.11e-13	Menopause (age at onset);
KIRP	trans	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg16141378	chr3:129829833	LOC729375	0.51	6.62	0.39	2.23e-10	Neuroticism;
KIRP	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.49	-0.43	1.26e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9399401	0.961	rs7774095	chr6:142670862	C/A	cg03128060	chr6:142623767	GPR126	0.31	5.18	0.31	4.7e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg14132834	chr19:41945861	ATP5SL	-0.54	-7.19	-0.42	7.69e-12	Height;
KIRP	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17507749	chr15:85114479	UBE2QP1	0.7	7.67	0.44	4.08e-13	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg11641102	chr8:27183873	PTK2B	-0.44	-5.69	-0.34	3.64e-8	Neuroticism;
KIRP	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-5.12	-0.31	6.31e-7	Vitiligo;
KIRP	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	11.16	0.58	1.18e-23	Personality dimensions;
KIRP	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-1.2	-9.45	-0.52	2.71e-18	Gout;Renal underexcretion gout;
KIRP	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.21	0.42	6.7e-12	Height;
KIRP	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg11846333	chr4:119757529	SEC24D	1.06	6.9	0.4	4.38e-11	Cannabis dependence symptom count;
KIRP	cis	rs600806	0.672	rs1144594	chr1:110029475	A/G	cg23032129	chr1:109941072	SORT1	-0.31	-5.29	-0.32	2.72e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Smoking initiation;
KIRP	cis	rs60154123	0.667	rs650854	chr1:210465315	G/C	cg09074223	chr1:210466472	NA	0.5	5.71	0.34	3.22e-8	Coronary artery disease;
KIRP	trans	rs7939886	0.920	rs11227463	chr11:55955447	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.26	0.32	3.08e-7	Life satisfaction;
KIRP	cis	rs10203711	1.000	rs12692239	chr2:239553947	T/C	cg14580085	chr2:239553406	NA	0.39	5.22	0.32	3.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77688320	0.553	rs2714488	chr2:202269773	T/C	cg06431681	chr2:202330990	STRADB	-0.47	-5.48	-0.33	1.05e-7	Breast cancer;
KIRP	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg05340658	chr4:99064831	C4orf37	-0.56	-6.95	-0.4	3.32e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.8	10.79	0.57	1.84e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg07701084	chr6:150067640	NUP43	0.72	9.49	0.52	2.1e-18	Lung cancer;
KIRP	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg04310649	chr10:35416472	CREM	-0.59	-7.16	-0.42	9.33e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.02	0.46	4.34e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	13.21	0.64	1.75e-30	Platelet count;
KIRP	cis	rs4704187	0.687	rs4621540	chr5:74371203	T/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg00319359	chr11:70116639	PPFIA1	0.81	7.0	0.41	2.39e-11	Coronary artery disease;
KIRP	cis	rs9549367	0.529	rs55946737	chr13:113810014	A/G	cg00898013	chr13:113819073	PROZ	-0.59	-5.69	-0.34	3.59e-8	Platelet distribution width;
KIRP	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-6.45	-0.38	5.75e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17101923	0.627	rs71450835	chr12:66321671	G/A	cg06712651	chr12:66351869	HMGA2	-0.55	-5.71	-0.34	3.26e-8	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs2505998	0.833	rs2505536	chr10:43592204	A/T	cg15436174	chr10:43711423	RASGEF1A	0.53	5.81	0.35	1.93e-8	Hirschsprung disease;
KIRP	cis	rs2219968	0.828	rs62508223	chr8:78941534	G/C	cg00738934	chr8:78996279	NA	-0.36	-4.94	-0.3	1.42e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg01843034	chr6:37503916	NA	-0.68	-7.98	-0.45	5.4e-14	Cognitive performance;
KIRP	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg18944383	chr4:111397179	ENPEP	0.48	8.16	0.46	1.72e-14	Height;
KIRP	cis	rs13102973	0.666	rs11727313	chr4:135884490	A/C	cg14419869	chr4:135874104	NA	0.35	5.02	0.3	9.85e-7	Subjective well-being;
KIRP	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.56	7.93	0.45	7.53e-14	Huntington's disease progression;
KIRP	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.59	8.0	0.45	4.88e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.04	-0.41	1.94e-11	Myopia (pathological);
KIRP	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.77	-9.64	-0.52	7.38e-19	Obesity-related traits;
KIRP	cis	rs61990749	0.511	rs7146020	chr14:78358319	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.61	4.86	0.3	2.11e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	trans	rs225245	0.817	rs225290	chr17:33927904	C/G	cg19694781	chr19:47549865	TMEM160	-0.53	-6.45	-0.38	5.86e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	14.92	0.69	2.72e-36	Body mass index (adult);
KIRP	cis	rs7919006	0.793	rs7901279	chr10:76804588	G/A	cg01390419	chr10:76803856	DUPD1	0.52	6.05	0.36	5.36e-9	Weight;
KIRP	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs2033732	0.826	rs12546578	chr8:85085268	A/T	cg05716166	chr8:85095498	RALYL	-0.49	-5.61	-0.34	5.43e-8	Body mass index;
KIRP	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.67	8.87	0.49	1.56e-16	Corneal astigmatism;
KIRP	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.13	0.31	5.84e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1209950	1.000	rs1013841	chr21:40173345	A/G	cg02119577	chr21:40195074	ETS2	-0.31	-4.85	-0.3	2.18e-6	Non-small cell lung cancer (survival);
KIRP	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	8.05	0.46	3.54e-14	Mean platelet volume;
KIRP	cis	rs80282103	0.618	rs17155886	chr10:1145182	A/G	cg08668510	chr10:1095578	IDI1	0.95	6.43	0.38	6.76e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs12210905	1.000	rs7756481	chr6:27115069	G/C	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg05347473	chr6:146136440	FBXO30	0.62	8.8	0.49	2.54e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.86	-12.22	-0.61	3.88e-27	Schizophrenia;
KIRP	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg25157839	chr3:43626312	ANO10	0.58	6.6	0.39	2.44e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs61884328	0.852	rs61896122	chr11:47084871	A/T	cg23433285	chr11:47201945	PACSIN3	0.79	6.35	0.38	1.04e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-9.18	-0.51	1.84e-17	Morning vs. evening chronotype;
KIRP	cis	rs28374715	0.629	rs2118740	chr15:41577232	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.14	-16.68	-0.73	2.71e-42	Ulcerative colitis;
KIRP	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.6	9.49	0.52	2.1e-18	Vitamin D levels;
KIRP	cis	rs4363385	0.553	rs61813181	chr1:152942177	T/C	cg13444842	chr1:152974279	SPRR3	-0.48	-6.91	-0.4	4.25e-11	Inflammatory skin disease;
KIRP	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	0.86	10.9	0.57	7.68e-23	Prostate cancer;
KIRP	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg22117172	chr7:91764530	CYP51A1	0.43	6.17	0.37	2.82e-9	Breast cancer;
KIRP	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.54	6.94	0.4	3.41e-11	Longevity;
KIRP	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg00792783	chr2:198669748	PLCL1	0.46	5.04	0.31	9.03e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Bipolar disorder;
KIRP	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.83	-7.12	-0.41	1.16e-11	Major depressive disorder;
KIRP	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg26681399	chr22:41777847	TEF	-0.45	-5.04	-0.31	9.21e-7	Vitiligo;
KIRP	cis	rs2377585	0.653	rs7299203	chr12:8849161	G/A	cg03761649	chr12:8850719	RIMKLB	0.54	5.38	0.32	1.76e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg05861140	chr6:150128134	PCMT1	-0.54	-7.75	-0.44	2.48e-13	Lung cancer;
KIRP	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg05082376	chr22:42548792	NA	-0.47	-6.1	-0.36	4.11e-9	Schizophrenia;
KIRP	cis	rs72627123	0.867	rs73301500	chr14:74473413	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.97	0.3	1.24e-6	Morning vs. evening chronotype;
KIRP	cis	rs9826463	1.000	rs4582093	chr3:142342945	A/G	cg20824294	chr3:142316082	PLS1	0.34	5.82	0.35	1.84e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.45	0.33	1.21e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg16141378	chr3:129829833	LOC729375	0.54	7.14	0.41	1.06e-11	Morning vs. evening chronotype;
KIRP	cis	rs13294100	0.861	rs2754341	chr9:17572069	A/G	cg11213383	chr9:17579734	SH3GL2	-0.48	-6.08	-0.36	4.47e-9	Parkinson's disease;
KIRP	cis	rs7017914	0.967	rs17760497	chr8:71617045	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.44	5.9	0.35	1.23e-8	Homoarginine levels;
KIRP	trans	rs1973993	0.561	rs56983671	chr1:96988608	C/T	cg10631902	chr5:14652156	NA	-0.56	-6.82	-0.4	6.96e-11	Weight;
KIRP	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.64	8.99	0.5	6.7e-17	Prostate cancer;
KIRP	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg11645453	chr3:52864694	ITIH4	-0.35	-5.38	-0.32	1.77e-7	Body mass index;
KIRP	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.5	6.89	0.4	4.75e-11	Schizophrenia;
KIRP	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.24	13.66	0.66	5.48e-32	Uric acid levels;
KIRP	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg09408571	chr1:101003634	GPR88	-0.22	-4.96	-0.3	1.34e-6	Breast cancer;
KIRP	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg13736514	chr6:26305472	NA	-0.43	-4.86	-0.3	2.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2573652	1.000	rs2581343	chr15:100514418	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.72	-11.48	-0.59	1.02e-24	Height;
KIRP	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg24826892	chr11:71159390	DHCR7	0.43	5.15	0.31	5.26e-7	Vitamin D levels;
KIRP	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.57	7.02	0.41	2.21e-11	Arsenic metabolism;
KIRP	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg23625390	chr15:77176239	SCAPER	0.49	6.25	0.37	1.81e-9	Blood metabolite levels;
KIRP	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg00360474	chr6:37504404	NA	-0.47	-6.69	-0.39	1.48e-10	Cognitive performance;
KIRP	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg19592336	chr6:28129416	ZNF389	0.48	5.56	0.33	6.98e-8	Depression;
KIRP	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs9346649	0.583	rs4708642	chr6:168491500	G/A	cg09211372	chr6:168490623	NA	-0.37	-6.49	-0.38	4.58e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.8	-0.35	2.05e-8	Height;
KIRP	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.79	-10.55	-0.56	1.07e-21	Platelet count;
KIRP	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg11131117	chr7:1891496	MAD1L1	0.4	4.85	0.3	2.19e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.64	-6.59	-0.39	2.6200000000000003e-10	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg05861140	chr6:150128134	PCMT1	-0.48	-6.73	-0.39	1.18e-10	Lung cancer;
KIRP	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.37	-0.43	2.63e-12	Response to antipsychotic treatment;
KIRP	cis	rs7656342	0.570	rs7683831	chr4:9845079	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.95	-0.35	9.11e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.33	-0.42	3.21e-12	Type 2 diabetes;
KIRP	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-0.83	-12.27	-0.62	2.62e-27	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg04154034	chr17:28927549	LRRC37B2	0.49	4.94	0.3	1.46e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg10047753	chr17:41438598	NA	0.93	12.88	0.63	2.31e-29	Menopause (age at onset);
KIRP	cis	rs9896052	0.614	rs4789201	chr17:73440579	A/G	cg25649188	chr17:73499917	CASKIN2	0.47	6.18	0.37	2.69e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg17207736	chr8:142237307	SLC45A4	-0.4	-4.91	-0.3	1.65e-6	Immature fraction of reticulocytes;
KIRP	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg22168489	chr12:122356033	WDR66	-0.57	-7.74	-0.44	2.59e-13	Mean corpuscular volume;
KIRP	cis	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg21775007	chr8:11205619	TDH	-0.43	-5.44	-0.33	1.26e-7	Monocyte count;
KIRP	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.77	5.77	0.35	2.33e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07569020	chr1:193156434	B3GALT2;CDC73	-0.4	-6.06	-0.36	5.13e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg18944383	chr4:111397179	ENPEP	0.71	13.3	0.65	9.3e-31	Coronary artery disease;
KIRP	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.44	6.16	0.37	2.96e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-7.47	-0.43	1.36e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9400467	0.506	rs12203093	chr6:111585382	T/C	cg15721981	chr6:111408429	SLC16A10	0.75	6.92	0.4	3.85e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg18825076	chr15:78729989	IREB2	-0.43	-5.13	-0.31	5.75e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-1.05	-13.04	-0.64	6.73e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs939574	0.512	rs10194278	chr2:220138408	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.56	6.09	0.36	4.28e-9	Platelet distribution width;
KIRP	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.48	-0.48	2.1e-15	Coronary artery disease;
KIRP	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg26531700	chr6:26746687	NA	0.46	6.16	0.37	2.92e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00089353	chr3:160473693	PPM1L	-0.45	-6.24	-0.37	1.89e-9	Metabolic traits;
KIRP	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.05e-8	Motion sickness;
KIRP	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg24315340	chr6:146058215	EPM2A	-0.38	-4.86	-0.3	2.07e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.25	-0.37	1.81e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg21775007	chr8:11205619	TDH	0.42	5.35	0.32	1.98e-7	Neuroticism;
KIRP	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg26876637	chr1:152193138	HRNR	-0.88	-8.79	-0.49	2.58e-16	Atopic dermatitis;
KIRP	cis	rs72772090	0.539	rs72775818	chr5:96193215	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg13119609	chr19:45449297	APOC2	0.39	5.03	0.31	9.52e-7	Blood protein levels;
KIRP	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg05709478	chr1:6581295	PLEKHG5	0.68	7.58	0.44	7.1e-13	Body mass index;
KIRP	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	10.89	0.57	8.61e-23	Hip circumference adjusted for BMI;
KIRP	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.67	6.3	0.37	1.38e-9	Eotaxin levels;
KIRP	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-12.94	-0.64	1.51e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.68	0.39	1.63e-10	Mean platelet volume;
KIRP	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	5.88	0.35	1.34e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23528488	chr4:85818121	WDFY3	0.42	6.93	0.4	3.64e-11	C-reactive protein;
KIRP	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
KIRP	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	7.9	0.45	9.46e-14	Total cholesterol levels;
KIRP	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.76	-6.96	-0.41	3e-11	Alzheimer's disease (late onset);
KIRP	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.67	-8.49	-0.48	2.01e-15	Morning vs. evening chronotype;
KIRP	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.91	-0.64	1.86e-29	Exhaled nitric oxide output;
KIRP	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg06533319	chr4:3265114	C4orf44	-0.43	-4.99	-0.3	1.13e-6	Serum sulfate level;
KIRP	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Body mass index;
KIRP	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.59	-5.2	-0.31	4.16e-7	Other erythrocyte phenotypes;
KIRP	cis	rs9488822	0.651	rs3798228	chr6:116321156	T/C	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg04609801	chr16:28609176	SULT1A2	0.58	5.7	0.34	3.44e-8	Platelet distribution width;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg12560992	chr17:57184187	TRIM37	0.6	6.36	0.38	1e-9	Testicular germ cell tumor;
KIRP	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.63	7.33	0.42	3.29e-12	Obesity-related traits;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.64	8.4	0.47	3.69e-15	Longevity;Endometriosis;
KIRP	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7429990	0.965	rs7651237	chr3:48105528	A/G	cg11946769	chr3:48343235	NME6	-0.5	-5.48	-0.33	1.06e-7	Educational attainment (years of education);
KIRP	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.42	5.08	0.31	7.59e-7	Body mass index;
KIRP	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.56	-7.77	-0.44	2.15e-13	Motion sickness;
KIRP	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.17	-0.37	2.83e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.92	10.19	0.54	1.4e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	9.33	0.51	6.67e-18	Homoarginine levels;
KIRP	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.89	0.45	9.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-10.1	-0.54	2.75e-20	Total body bone mineral density;
KIRP	cis	rs963731	0.649	rs6752850	chr2:39220655	C/T	cg04010122	chr2:39346883	SOS1	-0.79	-5.42	-0.33	1.43e-7	Corticobasal degeneration;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18402987	chr7:1209562	NA	0.44	5.11	0.31	6.41e-7	Longevity;Endometriosis;
KIRP	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	1.23	8.9	0.49	1.25e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs78487399	0.710	rs75330033	chr2:43697723	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.14	-0.31	5.69e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg13319975	chr6:146136371	FBXO30	0.43	5.83	0.35	1.74e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7106204	0.514	rs2083753	chr11:24255896	A/G	ch.11.24196551F	chr11:24239977	NA	0.87	10.55	0.56	1.04e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg23205692	chr1:25664452	TMEM50A	0.34	4.84	0.3	2.26e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs9921338	0.961	rs57579443	chr16:11442997	G/C	cg00044050	chr16:11439710	C16orf75	-0.52	-5.5	-0.33	9.62e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg26373071	chr5:1325741	CLPTM1L	0.54	7.03	0.41	2.05e-11	Lung cancer;
KIRP	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs12210905	0.920	rs12191414	chr6:27278634	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.86	-6.58	-0.39	2.85e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.72	9.96	0.54	7.46e-20	Mood instability;
KIRP	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.73	-8.59	-0.48	1.04e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.77	-0.35	2.41e-8	Reticulocyte count;
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg08662619	chr6:150070041	PCMT1	0.35	5.47	0.33	1.11e-7	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09419486	chr15:60690242	ANXA2	0.59	7.7	0.44	3.33e-13	Parkinson's disease;
KIRP	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg21775007	chr8:11205619	TDH	0.52	6.41	0.38	7.57e-10	Mood instability;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg06941879	chr19:45971137	FOSB	0.48	6.07	0.36	4.83e-9	Asthma;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.51	6.9	0.4	4.48e-11	Coronary artery disease;
KIRP	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg06289844	chr6:126071538	HEY2	-0.35	-4.85	-0.3	2.24e-6	Endometrial cancer;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.67	0.34	3.96e-8	Lung cancer;
KIRP	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.78	11.92	0.61	3.74e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg00106254	chr7:1943704	MAD1L1	-0.62	-6.73	-0.39	1.21e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.08	-0.41	1.46e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs6749447	1.000	rs35851104	chr2:169026086	G/T	cg10223061	chr2:219282414	VIL1	-0.37	-6.07	-0.36	4.88e-9	Blood pressure;
KIRP	cis	rs56161922	0.908	rs55952744	chr1:207860158	C/G	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg27194152	chr7:157982427	PTPRN2	0.57	7.7	0.44	3.28e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	1.03	15.26	0.7	1.9e-37	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg22604316	chr1:46958801	NA	0.45	6.44	0.38	6.06e-10	Monobrow;
KIRP	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.6	-0.44	6.37e-13	Type 2 diabetes;
KIRP	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg04944784	chr2:26401820	FAM59B	-0.43	-5.09	-0.31	6.99e-7	Gut microbiome composition (summer);
KIRP	trans	rs9329221	0.502	rs11777364	chr8:10288546	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.72	0.39	1.26e-10	Neuroticism;
KIRP	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05347473	chr6:146136440	FBXO30	0.41	5.61	0.34	5.45e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27009633	chr5:126366552	MARCH3	0.45	6.06	0.36	5.16e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05220968	chr6:146057943	EPM2A	-0.39	-4.97	-0.3	1.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.13	0.31	5.94e-7	Asthma;
KIRP	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27189623	chr16:705930	WDR90	0.42	5.84	0.35	1.63e-8	Height;
KIRP	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.01	0.41	2.35e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7404928	0.718	rs2106376	chr16:23863402	C/A	cg05497750	chr16:23765381	CHP2	-0.41	-4.88	-0.3	1.88e-6	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.43	5.66	0.34	4.14e-8	Melanoma;
KIRP	cis	rs7130144	0.541	rs7110730	chr11:130457867	C/T	cg26307797	chr11:130446613	NA	-0.62	-5.13	-0.31	5.94e-7	Urate levels in lean individuals;
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07308232	chr7:1071921	C7orf50	-0.69	-9.03	-0.5	5.19e-17	Longevity;Endometriosis;
KIRP	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg19592336	chr6:28129416	ZNF389	0.49	5.61	0.34	5.46e-8	Depression;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15044954	chr7:89874365	C7orf63	0.7	6.58	0.39	2.85e-10	Lung function (FEV1);
KIRP	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.89	-15.47	-0.7	3.75e-38	Breast cancer;
KIRP	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg24315340	chr6:146058215	EPM2A	0.39	4.94	0.3	1.45e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg07810366	chr2:100720526	AFF3	-0.32	-5.88	-0.35	1.3e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6456042	0.756	rs2197450	chr6:166585112	C/T	cg11088901	chr6:166572345	T	-0.34	-4.97	-0.3	1.23e-6	Asthma;
KIRP	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg00012203	chr2:219082015	ARPC2	-0.49	-5.82	-0.35	1.86e-8	Ulcerative colitis;
KIRP	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg12369402	chr1:90227771	NA	-0.36	-5.12	-0.31	6.02e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.49	-6.41	-0.38	7.36e-10	Schizophrenia;
KIRP	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg15782153	chr7:917662	C7orf20	0.47	4.85	0.3	2.15e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-7.71	-0.44	3.17e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.77	-11.69	-0.6	2.05e-25	Hip circumference;
KIRP	cis	rs367943	0.649	rs255866	chr5:112748532	A/T	cg12552261	chr5:112820674	MCC	0.57	6.69	0.39	1.49e-10	Type 2 diabetes;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06592026	chr13:114091254	ADPRHL1	0.42	6.15	0.37	3.05e-9	Cancer;
KIRP	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.01	17.09	0.74	1.06e-43	Testicular germ cell tumor;
KIRP	cis	rs1440410	0.835	rs13133090	chr4:144077069	T/C	cg01719995	chr4:144104893	USP38	0.4	5.23	0.32	3.65e-7	Ischemic stroke;
KIRP	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg01879757	chr17:41196368	BRCA1	-0.53	-7.12	-0.41	1.2e-11	Menopause (age at onset);
KIRP	cis	rs4356932	0.691	rs7436021	chr4:76905472	A/G	cg00809888	chr4:76862425	NAAA	0.5	7.03	0.41	2.03e-11	Blood protein levels;
KIRP	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.04	0.36	5.72e-9	Height;
KIRP	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg06742321	chr12:123595122	PITPNM2	0.48	5.59	0.34	6.11e-8	Neutrophil percentage of white cells;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg04025307	chr7:1156635	C7orf50	0.53	7.36	0.42	2.7e-12	Longevity;Endometriosis;
KIRP	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.63	9.08	0.5	3.67e-17	Vitiligo;
KIRP	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2904967	0.929	rs10750761	chr11:65002091	A/C	cg09225861	chr11:65069680	NA	-0.44	-5.49	-0.33	1.01e-7	Mean corpuscular volume;
KIRP	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg22508957	chr16:3507546	NAT15	0.65	7.67	0.44	4.02e-13	Tuberculosis;
KIRP	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg26084005	chr2:241760190	KIF1A	-0.51	-6.87	-0.4	5.36e-11	Urinary metabolites;
KIRP	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.41	-0.51	3.71e-18	Mean corpuscular volume;
KIRP	cis	rs6973256	0.897	rs2345941	chr7:133337635	C/T	cg10665199	chr7:133106180	EXOC4	0.39	4.86	0.3	2.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.58	6.89	0.4	4.76e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.82	10.95	0.57	5.46e-23	Menarche (age at onset);
KIRP	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.06e-11	Bipolar disorder;
KIRP	cis	rs2797685	0.617	rs172933	chr1:7844680	T/C	cg00864860	chr1:7907996	UTS2	0.47	5.67	0.34	4.02e-8	Crohn's disease;
KIRP	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.67	-7.74	-0.44	2.53e-13	Diabetic retinopathy;
KIRP	cis	rs6001982	0.748	rs73167063	chr22:40866656	G/A	cg07138101	chr22:40742427	ADSL	0.71	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg06740227	chr12:86229804	RASSF9	-0.49	-6.36	-0.38	9.83e-10	Major depressive disorder;
KIRP	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.94	13.14	0.64	3.06e-30	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg06713675	chr4:122721982	EXOSC9	-0.62	-6.79	-0.4	8.34e-11	Type 2 diabetes;
KIRP	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-7.72	-0.44	2.93e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs17030434	0.954	rs17030570	chr4:154755186	A/G	cg14289246	chr4:154710475	SFRP2	0.76	9.47	0.52	2.5e-18	Electrocardiographic conduction measures;
KIRP	trans	rs7939886	0.920	rs1481926	chr11:55973281	C/T	cg03929089	chr4:120376271	NA	0.94	6.41	0.38	7.38e-10	Myopia (pathological);
KIRP	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	11.78	0.6	1.07e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01008726	chr5:36986137	NIPBL	-0.44	-7.0	-0.41	2.49e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg12963246	chr6:28129442	ZNF389	0.53	6.43	0.38	6.49e-10	Depression;
KIRP	cis	rs357618	1.000	rs441652	chr5:150847505	T/C	cg22672639	chr5:150884813	FAT2	0.32	4.86	0.3	2.1e-6	Basophil percentage of white cells;
KIRP	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-8.75	-0.49	3.49e-16	Response to antipsychotic treatment;
KIRP	cis	rs300890	0.513	rs10000911	chr4:144136193	T/G	cg01719995	chr4:144104893	USP38	0.39	5.03	0.31	9.65e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	17.22	0.74	3.76e-44	Platelet count;
KIRP	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg21186296	chr8:27182909	PTK2B	0.45	5.64	0.34	4.76e-8	Neuroticism;
KIRP	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg08283408	chr3:49949060	MON1A	0.43	5.69	0.34	3.6e-8	Body mass index;
KIRP	cis	rs745821	0.541	rs11082832	chr18:48115431	T/A	cg18923635	chr18:48083994	NA	0.42	4.89	0.3	1.86e-6	Diastolic blood pressure;
KIRP	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.98	-0.57	4.23e-23	Exhaled nitric oxide output;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs10782582	0.609	rs78556436	chr1:76352875	G/A	cg10523679	chr1:76189770	ACADM	-0.46	-6.09	-0.36	4.3e-9	Daytime sleep phenotypes;
KIRP	cis	rs9653442	0.545	rs4490209	chr2:100766711	C/G	cg17356467	chr2:100759845	AFF3	0.46	6.16	0.37	2.88e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1355223	0.902	rs836467	chr11:34737432	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-4.94	-0.3	1.44e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg24315340	chr6:146058215	EPM2A	0.39	4.97	0.3	1.28e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4849845	0.849	rs6739106	chr2:121053244	G/C	cg24070213	chr2:121070622	NA	0.39	5.35	0.32	1.99e-7	Mean platelet volume;
KIRP	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs77861329	1.000	rs28452586	chr3:52176007	A/G	cg08692210	chr3:52188851	WDR51A	0.94	7.86	0.45	1.19e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.82e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.53	6.97	0.41	2.81e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg15252951	chr6:33757062	LEMD2	0.47	5.39	0.33	1.63e-7	Crohn's disease;
KIRP	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs13361707	0.726	rs1122655	chr5:40807927	C/T	cg01087697	chr5:40835557	RPL37	-0.43	-4.96	-0.3	1.34e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2929278	0.589	rs7174732	chr15:44038463	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.48	-5.81	-0.35	1.95e-8	Schizophrenia;
KIRP	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg23923672	chr12:105501055	KIAA1033	0.87	9.04	0.5	4.76e-17	IgG glycosylation;
KIRP	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	10.24	0.55	1.02e-20	Bone mineral density;
KIRP	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg07274523	chr3:49395745	GPX1	0.7	8.66	0.48	6.53e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.96	10.72	0.56	3.05e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.22e-12	Morning vs. evening chronotype;
KIRP	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.83	-12.18	-0.61	4.94e-27	Metabolic syndrome;
KIRP	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg14673194	chr17:80132900	CCDC57	-0.74	-8.02	-0.46	4.22e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs9379774	0.935	rs212927	chr6:25534677	C/T	cg11734164	chr3:87101920	NA	0.55	6.02	0.36	6.38e-9	Coronary artery disease;
KIRP	cis	rs2278796	0.639	rs12145998	chr1:204969419	C/T	cg17947172	chr1:204966197	NFASC	0.64	8.63	0.48	7.89e-16	Mean platelet volume;
KIRP	cis	rs9815354	1.000	rs9842261	chr3:41822708	A/G	cg03022575	chr3:42003672	ULK4	-0.59	-6.33	-0.37	1.15e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg23594656	chr7:65796392	TPST1	-0.41	-5.82	-0.35	1.84e-8	Aortic root size;
KIRP	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.53	7.29	0.42	4.14e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06747863	chr12:118810789	TAOK3	0.73	6.16	0.37	2.93e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.44	5.74	0.34	2.78e-8	Childhood ear infection;
KIRP	cis	rs2733310	0.843	rs8037956	chr15:57564149	C/T	cg13626582	chr15:57592083	LOC283663	0.27	6.11	0.36	3.84e-9	Mean platelet volume;
KIRP	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.9e-11	Schizophrenia;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.87	-12.68	-0.63	1.13e-28	Longevity;
KIRP	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg24579218	chr15:68104479	NA	0.47	7.63	0.44	5.06e-13	Restless legs syndrome;
KIRP	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.29	0.42	4.25e-12	Aortic root size;
KIRP	cis	rs17065868	1.000	rs9533919	chr13:45156951	C/T	cg10246903	chr13:45222710	NA	0.6	5.92	0.35	1.08e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.6	7.68	0.44	3.64e-13	Alcohol dependence;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.06e-7	Life satisfaction;
KIRP	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-5.09	-0.31	7.05e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.06	0.36	4.95e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs259282	0.605	rs3760937	chr19:33106893	A/G	cg02997394	chr19:33096574	ANKRD27	-0.55	-6.75	-0.4	1.08e-10	Schizophrenia;
KIRP	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.6	-7.84	-0.45	1.38e-13	Pulse pressure;
KIRP	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.49	5.96	0.35	8.92e-9	Lymphocyte counts;
KIRP	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10203711	0.966	rs9287635	chr2:239582267	C/T	cg14580085	chr2:239553406	NA	0.4	5.19	0.31	4.36e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg11503966	chr20:62272292	STMN3	-0.41	-5.91	-0.35	1.16e-8	Atopic dermatitis;
KIRP	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg12549451	chr6:135224345	NA	0.44	5.56	0.33	6.9e-8	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.67	-7.26	-0.42	4.99e-12	Corneal structure;
KIRP	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.89	13.25	0.65	1.28e-30	Coronary artery disease;
KIRP	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.96	13.03	0.64	7.38e-30	Menopause (age at onset);
KIRP	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg13482628	chr17:19912719	NA	0.61	8.7	0.48	4.9e-16	Schizophrenia;
KIRP	cis	rs4776059	1.000	rs10851521	chr15:52942111	G/A	cg22715398	chr15:52968154	KIAA1370	-0.58	-6.95	-0.41	3.18e-11	Schizophrenia;
KIRP	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.75	-12.06	-0.61	1.24e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg01763666	chr17:80159506	CCDC57	0.37	5.06	0.31	8.31e-7	Life satisfaction;
KIRP	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.71	10.27	0.55	7.74e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.51	6.1	0.36	4.03e-9	Urinary tract infection frequency;
KIRP	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.46	-5.91	-0.35	1.12e-8	Motion sickness;
KIRP	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.8	-9.93	-0.53	9.56e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg06521331	chr12:34319734	NA	-0.48	-5.99	-0.36	7.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs2901656	0.546	rs9425598	chr1:172371922	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.4	5.16	0.31	5.03e-7	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.62	0.73	4.34e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg02279127	chr19:55574702	RDH13	0.51	6.26	0.37	1.68e-9	Inflammatory biomarkers;
KIRP	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.75	8.52	0.48	1.67e-15	Systolic blood pressure;
KIRP	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06481639	chr22:41940642	POLR3H	-0.7	-6.83	-0.4	6.74e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.3	0.51	8.02e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs3751972	0.748	rs1034895	chr17:26225558	C/G	cg06301529	chr17:26127522	NOS2	0.37	5.18	0.31	4.57e-7	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	1.23	11.99	0.61	2.19e-26	Diabetic retinopathy;
KIRP	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.66	8.13	0.46	2.07e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg05805236	chr11:65401703	PCNXL3	-0.51	-6.96	-0.41	3.12e-11	Acne (severe);
KIRP	cis	rs7833787	1.000	rs7844375	chr8:18703258	A/G	cg17701159	chr8:18705777	PSD3	-0.37	-6.99	-0.41	2.6e-11	Obesity-related traits;
KIRP	cis	rs4601821	0.895	rs7130431	chr11:113238223	A/C	cg14159747	chr11:113255604	NA	0.34	5.0	0.3	1.1e-6	Alcoholic chronic pancreatitis;
KIRP	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	1.03	13.36	0.65	5.62e-31	Neutrophil percentage of white cells;
KIRP	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg11498726	chr8:26250323	BNIP3L	-0.45	-7.02	-0.41	2.2e-11	Red cell distribution width;
KIRP	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.56	5.88	0.35	1.3e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg08648136	chr8:956695	NA	0.49	7.68	0.44	3.77e-13	Schizophrenia;
KIRP	cis	rs12049351	0.774	rs12042841	chr1:229640617	A/G	cg11742688	chr1:229674241	ABCB10	0.39	5.9	0.35	1.22e-8	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs9987353	0.784	rs330014	chr8:9128844	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.21	-0.37	2.27e-9	Recombination measurement;
KIRP	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21014159	chr11:117668035	DSCAML1	0.41	5.07	0.31	7.66e-7	Myopia;
KIRP	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	cg04338863	chr8:33670619	NA	0.41	5.33	0.32	2.18e-7	Body mass index;
KIRP	cis	rs6466055	0.589	rs111595825	chr7:104649037	A/G	cg04380332	chr7:105027541	SRPK2	0.4	5.35	0.32	2.04e-7	Schizophrenia;
KIRP	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.63e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.42	5.88	0.35	1.37e-8	Endometrial cancer;
KIRP	cis	rs13102973	0.600	rs7662887	chr4:135883864	G/A	cg14419869	chr4:135874104	NA	0.35	5.02	0.3	9.85e-7	Subjective well-being;
KIRP	cis	rs6959887	0.926	rs6959445	chr7:35285821	T/C	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs7714584	1.000	rs74955473	chr5:150174558	T/A	cg22134413	chr5:150180641	NA	1.06	7.46	0.43	1.48e-12	Crohn's disease;
KIRP	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.43	-6.4	-0.38	7.71e-10	Height;
KIRP	cis	rs28489187	0.683	rs1554597	chr1:85877098	C/T	cg16011679	chr1:85725395	C1orf52	-0.48	-5.93	-0.35	1.02e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-1.14	-16.15	-0.72	1.78e-40	Monocyte percentage of white cells;
KIRP	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.7	7.63	0.44	5.08e-13	Corneal astigmatism;
KIRP	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg11833968	chr6:79620685	NA	-0.36	-4.86	-0.3	2.1e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg02980000	chr4:1222292	CTBP1	0.78	8.98	0.5	7.02e-17	Systolic blood pressure;
KIRP	cis	rs2882667	0.690	rs10078079	chr5:138256139	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-4.9	-0.3	1.76e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.61	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs12643440	0.538	rs62296685	chr4:17137580	T/C	cg22650099	chr4:17144496	NA	-0.71	-8.89	-0.49	1.32e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	1.0	17.56	0.75	2.63e-45	Breast cancer;
KIRP	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg03289416	chr15:75166202	SCAMP2	0.44	5.81	0.35	1.95e-8	Breast cancer;
KIRP	cis	rs9603616	0.684	rs4485233	chr13:40251422	A/G	cg26701198	chr13:40229707	COG6	0.44	5.14	0.31	5.59e-7	Rheumatoid arthritis;
KIRP	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.82	0.35	1.83e-8	Melanoma;
KIRP	cis	rs11078597	0.614	rs62090057	chr17:1645526	C/T	cg17514665	chr17:1657533	SERPINF2	0.46	5.69	0.34	3.64e-8	Serum albumin level;
KIRP	cis	rs7301016	0.948	rs11174537	chr12:62929827	G/C	cg01804193	chr12:63026212	NA	0.54	5.64	0.34	4.68e-8	IgG glycosylation;
KIRP	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.02	0.31	9.74e-7	Schizophrenia;
KIRP	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg02297831	chr4:17616191	MED28	-0.52	-6.01	-0.36	6.63e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.76	10.23	0.55	1.06e-20	Eye color traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07647798	chr19:16296063	FAM32A	0.47	6.09	0.36	4.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg27205649	chr11:78285834	NARS2	-0.51	-4.88	-0.3	1.9e-6	Testicular germ cell tumor;
KIRP	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg12861170	chr19:19639553	YJEFN3	-0.47	-5.3	-0.32	2.6e-7	Bipolar disorder;
KIRP	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg00405596	chr8:11794950	NA	0.48	6.43	0.38	6.64e-10	Retinal vascular caliber;
KIRP	cis	rs1511802	0.666	rs13106826	chr4:187125168	T/A	cg24794857	chr4:187113578	CYP4V2	0.38	5.41	0.33	1.49e-7	Blood protein levels;
KIRP	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg13319975	chr6:146136371	FBXO30	0.47	6.46	0.38	5.45e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg02023728	chr11:77925099	USP35	0.44	7.45	0.43	1.56e-12	Testicular germ cell tumor;
KIRP	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.1	-0.41	1.31e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.49	10.81	0.57	1.5e-22	Diabetic kidney disease;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg12559939	chr2:27858050	GPN1	-0.42	-5.28	-0.32	2.89e-7	Oral cavity cancer;
KIRP	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.65	7.3	0.42	3.87e-12	Testicular germ cell tumor;
KIRP	cis	rs17253792	0.545	rs3742570	chr14:56016434	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26126750	chr3:195809198	TFRC	0.49	6.77	0.4	9.49e-11	Survival in pancreatic cancer;
KIRP	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg27426351	chr10:43362370	NA	0.43	6.23	0.37	2.05e-9	Blood protein levels;
KIRP	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.39	-6.16	-0.37	2.98e-9	Type 2 diabetes;
KIRP	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Colorectal cancer;
KIRP	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg20965017	chr5:231967	SDHA	-0.55	-6.34	-0.38	1.06e-9	Breast cancer;
KIRP	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11987759	chr7:65425863	GUSB	-0.61	-8.13	-0.46	2.07e-14	Aortic root size;
KIRP	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.39	-0.38	8.22e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6088813	1.000	rs6142369	chr20:33973315	T/G	cg14752227	chr20:34000481	UQCC	-0.53	-6.9	-0.4	4.27e-11	Height;
KIRP	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.51	-7.15	-0.42	9.59e-12	Motion sickness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09897656	chr8:92342833	SLC26A7	-0.38	-6.4	-0.38	7.78e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg23736307	chr8:27182930	PTK2B	0.53	6.75	0.4	1.05e-10	Neuroticism;
KIRP	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.27	-0.37	1.59e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12311346	chr5:56204834	C5orf35	-0.42	-5.34	-0.32	2.11e-7	Coronary artery disease;
KIRP	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.49	-5.73	-0.34	2.93e-8	Mean corpuscular hemoglobin;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18232832	chr5:138940696	UBE2D2	0.52	6.47	0.38	5.37e-10	Parkinson's disease;
KIRP	cis	rs2976388	0.967	rs2585183	chr8:143766059	C/G	cg06565975	chr8:143823917	SLURP1	-0.45	-6.63	-0.39	2.07e-10	Urinary tract infection frequency;
KIRP	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.5	6.7	0.39	1.44e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg08501292	chr6:25962987	TRIM38	1.09	8.16	0.46	1.79e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.88	-15.62	-0.71	1.08e-38	Body mass index;
KIRP	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs2273669	0.667	rs6916819	chr6:109371129	A/G	cg05315195	chr6:109294784	ARMC2	-0.6	-6.16	-0.37	2.88e-9	Prostate cancer;
KIRP	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.09	12.24	0.62	3.11e-27	Cannabis dependence symptom count;
KIRP	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.68	-0.44	3.68e-13	Pulmonary function;
KIRP	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg10189774	chr4:17578691	LAP3	0.5	6.07	0.36	4.85e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs16857609	0.628	rs1478587	chr2:218334982	C/T	cg15335768	chr2:218268053	DIRC3	-0.37	-5.52	-0.33	8.72e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.64	7.67	0.44	3.95e-13	Aortic root size;
KIRP	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg03970086	chr16:88974840	CBFA2T3	0.43	5.66	0.34	4.1e-8	Social autistic-like traits;
KIRP	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.08	0.58	2.02e-23	Exhaled nitric oxide levels;
KIRP	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-6.47	-0.38	5.31e-10	Axial length;
KIRP	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg18016565	chr1:150552671	MCL1	0.39	5.99	0.36	7.22e-9	Melanoma;
KIRP	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg09754948	chr16:28834200	ATXN2L	0.42	4.85	0.3	2.15e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.52	-5.32	-0.32	2.32e-7	Menarche (age at onset);
KIRP	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg21918786	chr6:109611834	NA	0.34	5.19	0.31	4.45e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg21452805	chr1:244014465	NA	0.59	6.02	0.36	6.18e-9	RR interval (heart rate);
KIRP	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.64	-4.87	-0.3	1.99e-6	Toenail selenium levels;
KIRP	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	6.72	0.39	1.23e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6881634	0.501	rs10942852	chr5:77698582	G/T	cg02919814	chr21:37666008	DOPEY2	-0.4	-6.02	-0.36	6.31e-9	Hippocampal atrophy;
KIRP	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19524238	chr7:2802976	GNA12	-0.36	-4.88	-0.3	1.9e-6	Height;
KIRP	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg23803603	chr1:2058230	PRKCZ	0.4	5.68	0.34	3.83e-8	Height;
KIRP	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.57	-6.61	-0.39	2.36e-10	Diabetic retinopathy;
KIRP	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs9653442	0.545	rs12712067	chr2:100763900	A/C	cg17356467	chr2:100759845	AFF3	-0.38	-4.85	-0.3	2.2e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg04455712	chr21:45112962	RRP1B	0.55	6.54	0.38	3.58e-10	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17679864	chr3:40498818	RPL14	0.5	6.18	0.37	2.58e-9	Parkinson's disease;
KIRP	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.64	-9.58	-0.52	1.15e-18	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg20261243	chr20:44718728	NCOA5	0.6	7.85	0.45	1.24e-13	Asthma;
KIRP	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg02811702	chr13:24901961	NA	0.4	5.35	0.32	2e-7	Obesity-related traits;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04006554	chr6:46138530	ENPP5	-0.57	-6.41	-0.38	7.33e-10	Menopause (age at onset);
KIRP	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg09911534	chr15:67153556	NA	0.43	5.39	0.32	1.67e-7	Lung cancer (smoking interaction);
KIRP	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.46	-5.83	-0.35	1.72e-8	Total body bone mineral density;
KIRP	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg21827317	chr3:136751795	NA	0.35	4.99	0.3	1.13e-6	Neuroticism;
KIRP	cis	rs7602568	1.000	rs4637065	chr2:28588184	T/C	cg27432699	chr2:27873401	GPN1	-0.47	-5.17	-0.31	4.93e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs76693355	0.512	rs11824032	chr11:120224789	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.42	-5.34	-0.32	2.13e-7	Intraocular pressure;
KIRP	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.1	0.31	6.71e-7	Childhood ear infection;
KIRP	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg00677455	chr12:58241039	CTDSP2	0.98	12.84	0.63	3.12e-29	Multiple sclerosis;
KIRP	cis	rs2997447	0.846	rs61775419	chr1:26395539	C/T	cg19633962	chr1:26362018	EXTL1	-0.74	-6.24	-0.37	1.95e-9	QRS complex (12-leadsum);
KIRP	cis	rs7903847	0.642	rs11189175	chr10:99139609	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-5.8	-0.35	1.99e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg15038512	chr6:170123185	PHF10	-0.55	-8.46	-0.47	2.42e-15	Obesity-related traits;
KIRP	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.43	-0.38	6.71e-10	Mood instability;
KIRP	cis	rs11702148	0.552	rs6517178	chr21:34888621	C/T	cg14850771	chr21:34775459	IFNGR2	-0.37	-5.05	-0.31	8.53e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.17	-0.46	1.58e-14	Joint mobility (Beighton score);
KIRP	cis	rs7017914	0.934	rs17760050	chr8:71574251	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.59	7.93	0.45	7.72e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.53	-6.33	-0.37	1.16e-9	Bone mineral density;
KIRP	cis	rs2790457	0.958	rs2807754	chr10:28887192	C/T	cg05705492	chr10:28955341	NA	-0.54	-8.27	-0.47	8.66e-15	Multiple myeloma;
KIRP	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg00666640	chr1:248458726	OR2T12	0.47	5.76	0.34	2.48e-8	Common traits (Other);
KIRP	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg24807547	chr6:37504484	NA	-0.53	-7.92	-0.45	7.93e-14	Cognitive performance;
KIRP	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg02023728	chr11:77925099	USP35	0.35	5.51	0.33	8.96e-8	Alzheimer's disease (survival time);
KIRP	cis	rs7129556	0.737	rs537811	chr11:77468088	C/A	cg12586386	chr11:77299805	AQP11	0.4	5.38	0.32	1.73e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs2411233	0.905	rs12899025	chr15:39297872	G/A	cg19287857	chr15:39890699	NA	0.38	5.32	0.32	2.31e-7	Platelet count;
KIRP	trans	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.19	-0.42	7.91e-12	Neuroticism;
KIRP	cis	rs8018808	0.935	rs1061629	chr14:77926011	A/G	cg18872420	chr14:78023429	SPTLC2	-0.4	-5.7	-0.34	3.36e-8	Myeloid white cell count;
KIRP	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.53	7.32	0.42	3.51e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg11833968	chr6:79620685	NA	-0.45	-6.74	-0.4	1.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.78	13.72	0.66	3.44e-32	Height;
KIRP	trans	rs933360	0.585	rs6945597	chr7:50838927	T/A	cg20003124	chr12:4557277	NA	0.55	6.73	0.39	1.19e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.45	-0.38	5.89e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13185784	0.703	rs35394934	chr5:179677555	T/C	cg13944838	chr5:179740914	GFPT2	0.53	5.16	0.31	5.17e-7	TRAIL levels;
KIRP	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.75	10.79	0.57	1.76e-22	Parkinson's disease;
KIRP	cis	rs10073892	0.620	rs10440756	chr5:101929429	A/G	cg19774478	chr5:101632501	SLCO4C1	0.53	5.32	0.32	2.28e-7	Cognitive decline (age-related);
KIRP	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg18461458	chr19:21324796	ZNF431	0.48	4.99	0.3	1.15e-6	Pain;
KIRP	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.32	-0.32	2.3e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.0	-0.3	1.11e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg22604316	chr1:46958801	NA	0.46	6.59	0.39	2.66e-10	Monobrow;
KIRP	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.69	-9.11	-0.5	2.94e-17	Huntington's disease progression;
KIRP	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.19	-0.31	4.44e-7	Obesity-related traits;
KIRP	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.88	-10.07	-0.54	3.33e-20	Gut microbiome composition (summer);
KIRP	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-6.87	-0.4	5.2e-11	Vitiligo;
KIRP	cis	rs2230307	0.505	rs641458	chr1:100578672	G/C	cg24955406	chr1:100503596	HIAT1	-0.67	-7.5	-0.43	1.15e-12	Carotid intima media thickness;
KIRP	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg07395648	chr5:131743802	NA	-0.51	-7.4	-0.43	2.09e-12	Breast cancer;
KIRP	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.55	5.81	0.35	1.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.88	-11.05	-0.58	2.54e-23	Prostate cancer;
KIRP	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	0.82	7.06	0.41	1.68e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg06386533	chr2:46925753	SOCS5	0.55	5.35	0.32	1.98e-7	Height;
KIRP	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg20673091	chr1:2541236	MMEL1	0.78	12.61	0.63	1.94e-28	Ulcerative colitis;
KIRP	cis	rs7523050	0.643	rs17563938	chr1:109401654	C/T	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.4e-8	Schizophrenia;
KIRP	cis	rs9815354	0.812	rs766286	chr3:41838329	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs35883536	1.000	rs2297712	chr1:101092813	C/T	cg06223162	chr1:101003688	GPR88	0.32	6.54	0.38	3.6e-10	Monocyte count;
KIRP	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg24253500	chr15:84953950	NA	0.65	7.22	0.42	6.53e-12	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02725872	chr8:58115012	NA	-0.75	-7.05	-0.41	1.83e-11	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10508217	chr1:68629102	GPR177	0.51	6.41	0.38	7.17e-10	Interleukin-4 levels;
KIRP	cis	rs9420	0.528	rs34052104	chr11:57384519	A/C	cg19752551	chr11:57585705	CTNND1	-0.71	-9.84	-0.53	1.71e-19	Schizophrenia;
KIRP	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.32	5.72	0.34	3.07e-8	Renal cell carcinoma;
KIRP	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg26690034	chr1:75198963	CRYZ;TYW3	0.46	5.48	0.33	1.03e-7	Resistin levels;
KIRP	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs734999	0.545	rs10797436	chr1:2538349	G/A	cg18932078	chr1:2524107	MMEL1	0.44	6.0	0.36	7.03e-9	Ulcerative colitis;
KIRP	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	9.12	0.5	2.84e-17	Resting heart rate;
KIRP	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.58	7.79	0.44	1.91e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg11836154	chr14:105451476	C14orf79	0.48	6.54	0.38	3.49e-10	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs4748857	0.947	rs6482263	chr10:23604518	T/C	cg12804278	chr10:23633326	C10orf67	0.43	5.24	0.32	3.49e-7	Systemic lupus erythematosus;
KIRP	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-5.0	-0.3	1.1e-6	Pulmonary function;
KIRP	cis	rs2574975	0.531	rs927046	chr10:52211068	A/G	cg10034176	chr10:52120283	SGMS1	0.39	5.55	0.33	7.2e-8	Response to amphetamines;
KIRP	cis	rs9393813	0.791	rs35690855	chr6:27341471	A/C	cg18711553	chr6:27366782	ZNF391	-0.37	-5.39	-0.32	1.67e-7	Bipolar disorder;
KIRP	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg08514558	chr10:81106712	PPIF	0.45	6.16	0.37	2.9e-9	Height;
KIRP	cis	rs427941	1.000	rs10808119	chr7:101840716	G/A	cg06246474	chr7:101738831	CUX1	0.52	6.25	0.37	1.79e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.85	13.33	0.65	6.89e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7267005	1.000	rs17093175	chr20:34447796	A/T	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.47	-5.78	-0.35	2.22e-8	Diastolic blood pressure;
KIRP	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.61	-6.48	-0.38	4.96e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08113998	chr19:17830452	MAP1S	0.51	6.29	0.37	1.43e-9	Parkinson's disease;
KIRP	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg03474202	chr17:45855739	NA	0.49	7.71	0.44	3.12e-13	IgG glycosylation;
KIRP	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg03684893	chr10:554711	DIP2C	0.39	5.44	0.33	1.29e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs1497828	0.956	rs1007736	chr1:217547852	C/T	cg04411442	chr1:217543379	NA	0.42	6.4	0.38	7.84e-10	Dialysis-related mortality;
KIRP	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	10.37	0.55	3.98e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03191889	chr4:75858262	PARM1	0.51	6.8	0.4	7.77e-11	Parkinson's disease;
KIRP	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21659725	chr3:3221576	CRBN	0.7	9.69	0.53	4.98e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg19442545	chr10:75533431	FUT11	0.38	5.21	0.32	3.98e-7	Inflammatory bowel disease;
KIRP	cis	rs6088813	0.961	rs981819	chr20:33924112	C/T	cg14752227	chr20:34000481	UQCC	0.47	6.02	0.36	6.19e-9	Height;
KIRP	cis	rs1847202	1.000	rs6807627	chr3:72939767	C/T	cg06781948	chr3:72941472	GXYLT2	0.4	5.32	0.32	2.33e-7	Motion sickness;
KIRP	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.96	-13.81	-0.66	1.68e-32	Schizophrenia;
KIRP	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.74	-8.68	-0.48	5.41e-16	Gut microbiome composition (summer);
KIRP	cis	rs10214930	0.813	rs12700829	chr7:27687102	C/T	cg22168087	chr7:27702803	HIBADH	0.51	5.13	0.31	5.91e-7	Hypospadias;
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	15.33	0.7	1.1e-37	Platelet count;
KIRP	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.24	0.64	1.45e-30	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7589728	0.748	rs35051888	chr2:88482258	G/A	cg07952391	chr2:88470173	THNSL2	0.76	5.82	0.35	1.83e-8	Plasma clusterin levels;
KIRP	cis	rs963731	0.649	rs78421201	chr2:39339424	C/A	cg04010122	chr2:39346883	SOS1	0.93	6.39	0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs4953911	1.000	rs12618392	chr2:135067102	A/G	cg18482303	chr2:135041380	MGAT5	-0.28	-5.37	-0.32	1.79e-7	Multiple sclerosis (severity);
KIRP	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.12	12.23	0.61	3.47e-27	Nonalcoholic fatty liver disease;
KIRP	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs6788895	1.000	rs79709238	chr3:150488477	A/C	cg09723797	chr3:150481914	SIAH2	0.81	5.21	0.32	3.94e-7	Breast cancer;
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.47	0.33	1.13e-7	Lung cancer;
KIRP	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.12e-8	Life satisfaction;
KIRP	cis	rs6091737	1.000	rs2870276	chr20:52350534	C/T	cg20178976	chr20:52357117	NA	-0.44	-5.39	-0.33	1.64e-7	Calcium levels;
KIRP	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.33	-5.65	-0.34	4.33e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg03563238	chr19:33554763	RHPN2	-0.3	-5.33	-0.32	2.19e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.91	14.89	0.69	3.59e-36	Breast cancer;
KIRP	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.64	-8.18	-0.46	1.55e-14	Iron status biomarkers;
KIRP	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-6.88	-0.4	5.06e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg20936604	chr3:58311152	NA	-0.69	-5.89	-0.35	1.27e-8	Cholesterol, total;
KIRP	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.67e-19	Prudent dietary pattern;
KIRP	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06634786	chr22:41940651	POLR3H	-0.47	-5.21	-0.32	4.03e-7	Vitiligo;
KIRP	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.38	8.0	0.45	4.74e-14	Mean corpuscular volume;
KIRP	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg17757837	chr7:157058334	UBE3C	-0.81	-11.27	-0.58	5.08e-24	Body mass index;
KIRP	trans	rs1412115	0.530	rs10763956	chr10:34091783	A/G	cg14502980	chr11:125133439	PKNOX2	-0.5	-6.16	-0.37	2.98e-9	Schizophrenia;
KIRP	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12016809	chr21:47604291	C21orf56	-0.36	-4.87	-0.3	1.97e-6	Testicular germ cell tumor;
KIRP	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.42	-5.52	-0.33	8.59e-8	IgG glycosylation;
KIRP	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.55	-0.43	8.75e-13	Height;
KIRP	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.98	-0.3	1.21e-6	Schizophrenia;
KIRP	cis	rs7666738	0.546	rs17546687	chr4:98769266	T/A	cg05340658	chr4:99064831	C4orf37	0.64	7.35	0.42	2.94e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg18209359	chr17:80159595	CCDC57	0.39	5.22	0.32	3.86e-7	Life satisfaction;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.54	5.39	0.33	1.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.44	6.21	0.37	2.2e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs509477	0.962	rs562412	chr18:32576305	T/C	cg23791764	chr18:32556832	MAPRE2	-0.54	-6.83	-0.4	6.69e-11	Cerebrospinal fluid AB1-42 levels;
KIRP	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.95	16.49	0.72	1.15e-41	Coronary artery disease;
KIRP	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg14593290	chr7:50529359	DDC	0.79	9.86	0.53	1.5700000000000001e-19	Malaria;
KIRP	cis	rs10073892	0.703	rs10038081	chr5:101638266	T/C	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	7.0	0.41	2.44e-11	Mean corpuscular volume;
KIRP	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg24881330	chr22:46731750	TRMU	0.64	5.44	0.33	1.28e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg12560992	chr17:57184187	TRIM37	-0.62	-6.48	-0.38	4.94e-10	Testicular germ cell tumor;
KIRP	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.96	6.74	0.39	1.11e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg06115741	chr20:33292138	TP53INP2	0.38	5.1	0.31	6.68e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs55962025	0.883	rs363099	chr4:3162056	C/T	cg13731523	chr4:3047190	NA	0.32	4.98	0.3	1.21e-6	Parental longevity (mother's age at death);
KIRP	cis	rs7805747	1.000	rs10480300	chr7:151406005	C/T	cg17611936	chr7:151411526	PRKAG2	0.48	6.05	0.36	5.29e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
KIRP	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Intracranial aneurysm;
KIRP	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.64	-0.39	1.95e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.64	8.12	0.46	2.23e-14	Tonsillectomy;
KIRP	cis	rs1371867	0.775	rs3020183	chr8:101233297	A/T	cg11906718	chr8:101322791	RNF19A	-0.67	-8.38	-0.47	4.05e-15	Atrioventricular conduction;
KIRP	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.7	-0.39	1.43e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs1978968	1.000	rs1110660	chr22:18444693	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg08885076	chr2:99613938	TSGA10	-0.42	-6.37	-0.38	9.13e-10	Fear of minor pain;
KIRP	cis	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19171272	chr22:38449367	NA	-0.58	-8.89	-0.49	1.34e-16	Glioblastoma;Glioma;
KIRP	cis	rs10782582	0.609	rs5745553	chr1:76379135	A/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.11	-0.41	1.24e-11	Daytime sleep phenotypes;
KIRP	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	14.54	0.68	5.3e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs800082	0.690	rs800081	chr3:144339980	C/T	cg24215973	chr2:240111563	HDAC4	0.53	7.08	0.41	1.53e-11	Smoking behavior;
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg23693289	chr8:27183097	PTK2B	0.55	7.12	0.41	1.15e-11	Neuroticism;
KIRP	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05025164	chr4:1340916	KIAA1530	0.38	4.92	0.3	1.6e-6	Obesity-related traits;
KIRP	cis	rs364477	0.818	rs279890	chr9:978108	T/C	cg13952963	chr9:998547	NA	0.58	4.94	0.3	1.42e-6	Major depressive disorder;
KIRP	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.51	6.2	0.37	2.39e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22906224	chr7:99728672	NA	-0.54	-6.58	-0.39	2.76e-10	Coronary artery disease;
KIRP	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg07596299	chr11:71824057	C11orf51	0.93	5.89	0.35	1.29e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.6	10.61	0.56	6.47e-22	Erythrocyte sedimentation rate;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg03398387	chr6:160114178	SOD2	0.51	6.13	0.36	3.48e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.38	-0.68	1.98e-34	Alzheimer's disease;
KIRP	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.71e-31	Diabetic retinopathy;
KIRP	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.83	-14.23	-0.67	6.41e-34	Post bronchodilator FEV1;
KIRP	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg13010199	chr12:38710504	ALG10B	0.45	5.85	0.35	1.56e-8	Morning vs. evening chronotype;
KIRP	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs9653442	0.545	rs12987209	chr2:100761148	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg04691961	chr3:161091175	C3orf57	-0.54	-8.22	-0.46	1.14e-14	Morning vs. evening chronotype;
KIRP	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.47	7.56	0.43	7.76e-13	Eye color traits;
KIRP	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg05973401	chr12:123451056	ABCB9	0.61	7.16	0.42	9.5e-12	Platelet count;
KIRP	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg27490568	chr2:178487706	NA	0.46	6.02	0.36	6.16e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23281280	chr6:28129359	ZNF389	0.49	5.47	0.33	1.08e-7	Depression;
KIRP	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.77	11.48	0.59	1.04e-24	Heart rate;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01626477	chr2:30454344	LBH	-0.52	-6.41	-0.38	7.26e-10	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.43	5.22	0.32	3.87e-7	HDL cholesterol;
KIRP	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.42	-0.51	3.36e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01025762	chr7:107531363	DLD	0.56	6.6	0.39	2.48e-10	Smoking initiation;
KIRP	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.14	0.74	7.35e-44	Cognitive function;
KIRP	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26314531	chr2:26401878	FAM59B	-0.48	-5.01	-0.3	1.03e-6	Gut microbiome composition (summer);
KIRP	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.41	-0.47	3.35e-15	Mood instability;
KIRP	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg08890418	chr1:21044141	KIF17	0.35	5.24	0.32	3.43e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.96	12.97	0.64	1.14e-29	Multiple sclerosis;
KIRP	cis	rs9400467	0.506	rs17539875	chr6:111674350	C/T	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.18	-0.31	4.68e-7	Life satisfaction;
KIRP	cis	rs7113874	0.578	rs1026021	chr11:8564778	C/T	cg08015107	chr11:8618950	NA	0.76	9.1	0.5	3.28e-17	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4765905	0.675	rs2283287	chr12:2298724	T/C	cg10668781	chr12:2307325	CACNA1C	-0.35	-6.99	-0.41	2.62e-11	Schizophrenia;
KIRP	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01493522	chr13:37497338	NA	-0.39	-5.09	-0.31	7.16e-7	Coronary artery disease;
KIRP	cis	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.58	-8.36	-0.47	4.69e-15	Huntington's disease progression;
KIRP	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg00977110	chr5:151150581	G3BP1	0.53	5.46	0.33	1.18e-7	Preschool internalizing problems;
KIRP	cis	rs8028182	0.636	rs12708520	chr15:75830539	C/T	cg20655648	chr15:75932815	IMP3	0.55	7.06	0.41	1.7e-11	Sudden cardiac arrest;
KIRP	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	9.42	0.52	3.34e-18	Mood instability;
KIRP	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg13010199	chr12:38710504	ALG10B	-0.52	-6.92	-0.4	3.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.19	-0.37	2.53e-9	QT interval;
KIRP	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg26531700	chr6:26746687	NA	0.47	6.83	0.4	6.62e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	1.07	15.77	0.71	3.56e-39	Menopause (age at onset);
KIRP	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.81e-19	Height;
KIRP	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg11815991	chr20:30193098	ID1	0.45	4.87	0.3	2.02e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs11225247	0.772	rs11501343	chr11:102227214	A/C	cg06323957	chr11:102217781	BIRC2	0.77	5.0	0.3	1.11e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg00800038	chr16:89945340	TCF25	-0.73	-5.09	-0.31	7.11e-7	Skin colour saturation;
KIRP	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.35	-7.12	-0.41	1.19e-11	Arsenic metabolism;
KIRP	cis	rs10463316	0.894	rs4246024	chr5:150740987	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.57	-0.39	2.95e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18018530	chr2:31558544	XDH	-0.42	-5.68	-0.34	3.81e-8	Inflammatory biomarkers;
KIRP	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg02495767	chr7:1030999	NA	-0.42	-5.85	-0.35	1.55e-8	Longevity;Endometriosis;
KIRP	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	12.86	0.63	2.62e-29	Personality dimensions;
KIRP	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.74	-0.57	2.54e-22	Chronic sinus infection;
KIRP	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.75	11.36	0.59	2.5300000000000002e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	7.37	0.43	2.56e-12	Response to antipsychotic treatment;
KIRP	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg01631408	chr1:248437212	OR2T33	-0.72	-9.56	-0.52	1.25e-18	Common traits (Other);
KIRP	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg18944383	chr4:111397179	ENPEP	0.51	8.47	0.48	2.27e-15	Coronary artery disease;
KIRP	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg24642439	chr20:33292090	TP53INP2	0.46	5.25	0.32	3.33e-7	Height;
KIRP	cis	rs1215050	0.791	rs1215054	chr4:98863009	T/G	cg17366294	chr4:99064904	C4orf37	-0.39	-5.28	-0.32	2.8e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1448094	0.967	rs7301496	chr12:86321212	A/C	cg00310523	chr12:86230176	RASSF9	0.38	5.8	0.35	2.07e-8	Major depressive disorder;
KIRP	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs6578185	0.684	rs9987318	chr8:142437352	A/G	cg15142913	chr8:142440250	PTP4A3	-0.41	-5.51	-0.33	9.23e-8	Endometriosis;
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	5.01	0.3	1.03e-6	Electroencephalogram traits;
KIRP	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg07936489	chr17:37558343	FBXL20	-0.5	-6.44	-0.38	6.2e-10	Asthma;
KIRP	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.7	6.84	0.4	6.3e-11	Axial length;
KIRP	cis	rs4460629	0.742	rs11581730	chr1:155082158	A/T	cg02153340	chr1:155202674	NA	-0.35	-5.01	-0.3	1.04e-6	Serum magnesium levels;
KIRP	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs72772090	0.539	rs72773986	chr5:96159717	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.93	-0.4	3.57e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg12140854	chr5:148520817	ABLIM3	-0.57	-6.39	-0.38	8.46e-10	Breast cancer;
KIRP	cis	rs829661	0.532	rs7602714	chr2:30789607	C/G	cg10949345	chr2:30726833	LCLAT1	0.42	5.91	0.35	1.11e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg23594656	chr7:65796392	TPST1	0.51	7.93	0.45	7.68e-14	Aortic root size;
KIRP	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.06	0.54	3.67e-20	Lung cancer in ever smokers;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23366861	chr22:42739856	NA	-0.46	-6.22	-0.37	2.17e-9	Metabolic traits;
KIRP	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg02811702	chr13:24901961	NA	0.42	5.54	0.33	7.77e-8	Obesity-related traits;
KIRP	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg07856975	chr6:36356162	ETV7	-0.38	-5.57	-0.33	6.69e-8	Platelet distribution width;
KIRP	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.55	-0.39	3.42e-10	Response to antipsychotic treatment;
KIRP	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03576123	chr11:487126	PTDSS2	-1.02	-8.36	-0.47	4.55e-15	Body mass index;
KIRP	cis	rs1440410	0.835	rs4337690	chr4:144069561	G/T	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.64	8.62	0.48	8.18e-16	Motion sickness;
KIRP	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.64	8.46	0.47	2.49e-15	Eosinophil percentage of white cells;
KIRP	cis	rs142472947	1	rs142472947	chr1:8520487	AAAG/A	cg25722041	chr1:8623473	RERE	0.78	9.96	0.54	7.4e-20	White blood cell count;
KIRP	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.78	8.5	0.48	1.83e-15	Cholesterol, total;
KIRP	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.58	-6.67	-0.39	1.66e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.41	6.72	0.39	1.27e-10	Testicular germ cell tumor;
KIRP	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.78	11.2	0.58	8.19e-24	Bladder cancer;
KIRP	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.44	-5.41	-0.33	1.49e-7	Aortic root size;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg07145255	chr5:59995354	DEPDC1B	0.52	6.37	0.38	9.32e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.46	7.13	0.41	1.12e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg10253484	chr15:75165896	SCAMP2	0.64	6.04	0.36	5.76e-9	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs8077577	0.895	rs16960986	chr17:18108562	A/G	cg18869244	chr17:18121946	NA	-0.44	-5.3	-0.32	2.61e-7	Obesity-related traits;
KIRP	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.16	-0.31	5.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg17644776	chr2:200775616	C2orf69	0.5	5.62	0.34	5.06e-8	Osteoporosis;
KIRP	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.63	9.57	0.52	1.23e-18	Immature fraction of reticulocytes;
KIRP	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg13271783	chr10:134563150	INPP5A	-0.53	-6.59	-0.39	2.59e-10	Migraine;
KIRP	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.57	-8.25	-0.47	9.94e-15	Type 2 diabetes;
KIRP	cis	rs7582720	0.836	rs72938315	chr2:204121063	C/G	cg08076091	chr2:203926405	NBEAL1	0.79	8.21	0.46	1.24e-14	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7116495	0.609	rs73531955	chr11:71687794	A/C	cg07596299	chr11:71824057	C11orf51	0.76	5.0	0.3	1.09e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11987759	chr7:65425863	GUSB	-0.49	-6.37	-0.38	9.01e-10	Aortic root size;
KIRP	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.32	5.1	0.31	6.65e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.45	-5.22	-0.32	3.77e-7	Reticulocyte count;
KIRP	cis	rs2223471	0.523	rs657271	chr6:50582557	C/A	cg03432817	chr6:50765336	NA	-0.34	-4.96	-0.3	1.31e-6	Subcutaneous adipose tissue;
KIRP	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.93	-0.4	3.7e-11	Daytime sleep phenotypes;
KIRP	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.62	8.99	0.5	6.55e-17	Colorectal cancer;
KIRP	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.48	-0.79	4.47e-55	Height;
KIRP	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.95	11.17	0.58	1.08e-23	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.42	5.84	0.35	1.61e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1620921	0.756	rs783163	chr6:161182401	A/T	cg01280913	chr6:161186852	NA	-0.71	-10.34	-0.55	4.96e-21	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2851682	1.000	rs2524296	chr11:61601378	C/T	cg07689907	chr11:61582574	FADS1	0.65	5.0	0.3	1.07e-6	Gestational age at birth (child effect);Trans fatty acid levels;
KIRP	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg17145862	chr1:211918768	LPGAT1	-0.91	-13.27	-0.65	1.14e-30	Leprosy;
KIRP	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg13628971	chr7:2884303	GNA12	0.41	5.2	0.31	4.23e-7	Height;
KIRP	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg00241281	chr14:105779794	PACS2	-0.36	-4.97	-0.3	1.27e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.45	-5.45	-0.33	1.21e-7	Response to antipsychotic treatment;
KIRP	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.22	-0.46	1.2e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg22974920	chr21:40686053	BRWD1	0.44	5.28	0.32	2.79e-7	Cognitive function;
KIRP	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg13409248	chr3:40428643	ENTPD3	0.41	5.4	0.33	1.54e-7	Renal cell carcinoma;
KIRP	cis	rs56161922	1.000	rs74401244	chr1:207844799	T/C	cg11752769	chr1:207818423	CR1L	-0.77	-5.03	-0.31	9.67e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg01290665	chr5:178018968	COL23A1	1.03	6.6	0.39	2.56e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.89	-11.65	-0.6	2.84e-25	Type 2 diabetes;
KIRP	cis	rs11121246	0.518	rs6684644	chr1:8910578	G/C	cg06972019	chr1:8937448	ENO1	0.41	5.1	0.31	6.8e-7	Plateletcrit;
KIRP	cis	rs4780401	0.588	rs1050068	chr16:11769948	C/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-4.9	-0.3	1.71e-6	Rheumatoid arthritis;
KIRP	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg18350739	chr11:68623251	NA	-0.48	-7.47	-0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2075064	0.546	rs1887341	chr9:126769291	A/G	cg14112217	chr9:126806003	NA	0.34	4.85	0.3	2.18e-6	Waist circumference;
KIRP	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg21747090	chr2:27597821	SNX17	-0.39	-5.27	-0.32	2.96e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs459482	0.508	rs461093	chr21:42800190	C/G	cg14166395	chr21:42792516	MX1	-0.45	-5.46	-0.33	1.18e-7	IgG glycosylation;
KIRP	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.82	10.08	0.54	3.27e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg23067535	chr8:124195133	FAM83A	-0.72	-7.1	-0.41	1.31e-11	Urinary uromodulin levels;
KIRP	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20135002	chr11:47629003	NA	-0.48	-5.78	-0.35	2.23e-8	Subjective well-being;
KIRP	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg15556689	chr8:8085844	FLJ10661	0.54	7.41	0.43	2.06e-12	Neuroticism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10267162	chr2:97001818	NCAPH	0.52	6.5	0.38	4.32e-10	Myopia (pathological);
KIRP	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.5	0.38	4.48e-10	Lung cancer;
KIRP	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08524871	chr22:21996365	SDF2L1	-0.51	-6.27	-0.37	1.57e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1635	0.678	rs73400575	chr6:28184308	G/C	cg24848467	chr6:28134517	ZNF389	-0.78	-5.0	-0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.67	-9.16	-0.5	2.08e-17	Huntington's disease progression;
KIRP	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.77	-10.48	-0.56	1.72e-21	Aortic root size;
KIRP	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	4.93	0.3	1.54e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9815354	1.000	rs73081364	chr3:41913616	G/C	cg03022575	chr3:42003672	ULK4	0.64	6.79	0.4	8.29e-11	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg17554472	chr22:41940697	POLR3H	0.68	7.2	0.42	7.14e-12	Vitiligo;
KIRP	cis	rs8113308	0.515	rs73066981	chr19:52462399	C/T	cg25782003	chr19:52490127	ZNF350	0.81	6.08	0.36	4.56e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs71403859	0.541	rs73588051	chr16:71388627	A/G	cg08717414	chr16:71523259	ZNF19	-1.05	-7.96	-0.45	6.21e-14	Post bronchodilator FEV1;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13757859	chr2:182757706	SSFA2	0.46	6.49	0.38	4.58e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg08975724	chr8:8085496	FLJ10661	0.58	7.16	0.42	9.32e-12	Retinal vascular caliber;
KIRP	cis	rs2274459	0.841	rs3818526	chr6:33660973	T/C	cg06253072	chr6:33679850	C6orf125	0.48	5.19	0.31	4.48e-7	Obesity (extreme);
KIRP	cis	rs10140922	0.567	rs8015470	chr14:35635209	C/T	cg07166546	chr14:35805898	NA	-0.23	-5.49	-0.33	9.94e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.69	5.73	0.34	3e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.95	-0.3	1.41e-6	Pulmonary function;
KIRP	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg02353165	chr6:42928485	GNMT	0.75	11.53	0.59	7.35e-25	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05152354	chr12:48152931	RAPGEF3	0.52	6.41	0.38	7.27e-10	Parkinson's disease;
KIRP	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg13206674	chr6:150067644	NUP43	0.52	7.41	0.43	1.96e-12	Testicular germ cell tumor;
KIRP	cis	rs12360000	0.770	rs12251959	chr10:1902277	C/T	cg26364871	chr10:1889757	NA	-0.57	-7.0	-0.41	2.43e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs10128264	0.902	rs1250587	chr10:80978021	A/G	cg20744163	chr10:80999841	ZMIZ1	-0.33	-5.52	-0.33	8.77e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg03342759	chr3:160939853	NMD3	0.41	5.01	0.3	1.04e-6	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14938029	chr20:23421747	CSTL1	0.4	6.27	0.37	1.62e-9	Survival in pancreatic cancer;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg06074448	chr4:187884817	NA	-0.76	-12.66	-0.63	1.26e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.37	5.28	0.32	2.8e-7	Coronary artery disease;
KIRP	cis	rs9815354	1.000	rs73069396	chr3:41787236	A/T	cg03022575	chr3:42003672	ULK4	0.51	5.72	0.34	3.16e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg00405596	chr8:11794950	NA	0.41	5.38	0.32	1.75e-7	Retinal vascular caliber;
KIRP	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.19	-0.46	1.4e-14	Joint mobility (Beighton score);
KIRP	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.75	-0.34	2.59e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.77	9.42	0.51	3.4e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17065868	0.655	rs9533870	chr13:45051780	T/C	cg10246903	chr13:45222710	NA	0.6	5.84	0.35	1.66e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg21361702	chr7:150065534	REPIN1	0.68	7.11	0.41	1.24e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.05	0.46	3.6e-14	Lung cancer;
KIRP	cis	rs6832769	0.890	rs1980273	chr4:56367401	C/G	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15113064	chr3:124774855	HEG1	0.49	6.48	0.38	4.99e-10	Myopia (pathological);
KIRP	cis	rs10465746	0.714	rs12141272	chr1:84434517	C/T	cg10977910	chr1:84465055	TTLL7	0.57	7.19	0.42	7.66e-12	Obesity-related traits;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.56	-7.54	-0.43	8.81e-13	Longevity;Endometriosis;
KIRP	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01594514	chr11:67374213	NDUFV1	0.47	6.18	0.37	2.58e-9	Parkinson's disease;
KIRP	cis	rs738321	0.756	rs12169611	chr22:38513735	T/C	cg25457927	chr22:38595422	NA	-0.28	-5.43	-0.33	1.34e-7	Breast cancer;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09755102	chr1:33283495	S100PBP;YARS	-0.48	-6.12	-0.36	3.69e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.54	-8.24	-0.47	1.04e-14	Huntington's disease progression;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16970804	chr5:43042108	LOC153684	0.98	6.74	0.39	1.13e-10	P wave terminal force;
KIRP	cis	rs6473252	0.522	rs11779701	chr8:81825326	A/G	cg08595989	chr8:81827712	NA	-0.27	-5.11	-0.31	6.5e-7	Breast cancer;
KIRP	cis	rs13102973	0.965	rs13108037	chr4:135885643	A/G	cg14419869	chr4:135874104	NA	-0.48	-7.71	-0.44	3.19e-13	Subjective well-being;
KIRP	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.39	-0.43	2.24e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.66e-7	Diabetic retinopathy;
KIRP	cis	rs12476592	0.571	rs185499	chr2:63867523	G/T	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs12519773	0.641	rs4489042	chr5:92428154	G/C	cg18783429	chr5:92414398	NA	0.35	5.81	0.35	1.88e-8	Migraine;
KIRP	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg25457927	chr22:38595422	NA	-0.3	-6.17	-0.37	2.73e-9	Breast cancer;
KIRP	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg19507638	chr5:93509721	C5orf36	-0.55	-5.1	-0.31	6.64e-7	Diabetic retinopathy;
KIRP	cis	rs812925	0.893	rs778160	chr2:61557164	A/G	cg15711740	chr2:61764176	XPO1	-0.46	-4.95	-0.3	1.35e-6	Immature fraction of reticulocytes;
KIRP	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg19773385	chr1:10388646	KIF1B	-0.72	-11.58	-0.59	4.95e-25	Hepatocellular carcinoma;
KIRP	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.29	-0.32	2.74e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg13512537	chr8:22265999	SLC39A14	-0.41	-5.46	-0.33	1.16e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.05	-0.36	5.27e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.49	-7.35	-0.42	3e-12	Electroencephalogram traits;
KIRP	cis	rs988913	0.874	rs9382398	chr6:54783266	C/T	cg03513858	chr6:54763001	FAM83B	-0.39	-5.39	-0.32	1.68e-7	Menarche (age at onset);
KIRP	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.18	-0.46	1.56e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2457480	0.657	rs2624683	chr10:44679140	A/G	cg09554077	chr10:44749378	NA	0.51	6.78	0.4	8.66e-11	Coronary artery disease;
KIRP	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg27572855	chr1:25598939	RHD	-0.47	-7.87	-0.45	1.13e-13	Erythrocyte sedimentation rate;
KIRP	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06544989	chr22:39130855	UNC84B	-0.44	-7.68	-0.44	3.67e-13	Menopause (age at onset);
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg16586182	chr3:47516702	SCAP	-0.74	-10.45	-0.55	2.17e-21	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13704678	chr3:10362667	SEC13	0.54	6.91	0.4	4.22e-11	Parkinson's disease;
KIRP	cis	rs282587	0.569	rs408826	chr13:113415268	G/A	cg04656015	chr13:113407548	ATP11A	0.59	6.32	0.37	1.23e-9	Glycated hemoglobin levels;
KIRP	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-5.1	-0.31	6.83e-7	Blood metabolite levels;
KIRP	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs112591243	0.685	rs74671132	chr21:47963485	T/C	cg26904215	chr21:47823096	PCNT	-0.78	-5.68	-0.34	3.79e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg05973401	chr12:123451056	ABCB9	0.49	5.27	0.32	3.05e-7	Neutrophil percentage of white cells;
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg07051648	chr19:49177693	NTN5;SEC1	-0.43	-5.6	-0.34	5.59e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.06	-23.05	-0.83	2.19e-63	Myeloid white cell count;
KIRP	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.57	7.17	0.42	8.81e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.2	14.2	0.67	8.22e-34	Uric acid levels;
KIRP	cis	rs236907	0.859	rs2232819	chr1:171755182	G/A	cg01410279	chr1:171621941	MYOC	-0.52	-5.13	-0.31	5.96e-7	Mean platelet volume;
KIRP	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	1.04	14.46	0.68	1.05e-34	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3784262	0.669	rs12915508	chr15:58302036	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.89	-0.3	1.79e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg01864069	chr14:103024347	NA	-0.85	-10.1	-0.54	2.75e-20	Platelet count;
KIRP	cis	rs11638352	1.000	rs4924728	chr15:44289953	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.78	-6.13	-0.36	3.5e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg01338084	chr22:32026380	PISD	1.03	7.65	0.44	4.68e-13	Age-related hearing impairment;
KIRP	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-7.86	-0.45	1.23e-13	Blood protein levels;
KIRP	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg21858823	chr1:15850916	CASP9	0.51	5.5	0.33	9.5e-8	Systolic blood pressure;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.66	9.73	0.53	3.86e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.46	-6.46	-0.38	5.64e-10	Coronary artery disease;
KIRP	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg20060108	chr2:102954350	IL1RL1	-0.59	-4.97	-0.3	1.24e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6684514	1.000	rs12563631	chr1:156258953	T/C	cg16558208	chr1:156270281	VHLL	-0.42	-5.64	-0.34	4.56e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg25650185	chr19:21324782	ZNF431	0.48	5.1	0.31	6.75e-7	Pain;
KIRP	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg20307385	chr11:47447363	PSMC3	-0.62	-7.13	-0.41	1.1e-11	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.9	12.83	0.63	3.49e-29	Bladder cancer;
KIRP	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.01	17.43	0.74	7.68e-45	Multiple system atrophy;
KIRP	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg20887711	chr4:1340912	KIAA1530	-0.45	-5.84	-0.35	1.65e-8	Obesity-related traits;
KIRP	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23161317	chr6:28129485	ZNF389	-0.48	-5.77	-0.35	2.33e-8	Depression;
KIRP	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-6.94	-0.4	3.53e-11	Vitiligo;
KIRP	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9815354	0.812	rs73081392	chr3:41923009	G/A	cg03022575	chr3:42003672	ULK4	0.8	8.18	0.46	1.54e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.98	-11.76	-0.6	1.29e-25	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg05562828	chr17:3906858	NA	-0.51	-6.82	-0.4	7.17e-11	Type 2 diabetes;
KIRP	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg08807101	chr21:30365312	RNF160	0.71	8.49	0.48	1.99e-15	Selective IgA deficiency;
KIRP	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.01	-0.45	4.7e-14	Mean corpuscular volume;
KIRP	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.51	5.46	0.33	1.14e-7	Subjective well-being;
KIRP	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg03315344	chr16:75512273	CHST6	-0.57	-5.18	-0.31	4.65e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.65	-9.19	-0.51	1.73e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.27	-0.32	2.92e-7	Menarche (age at onset);
KIRP	cis	rs2151522	0.563	rs2022477	chr6:127109885	T/C	cg21431617	chr6:127135037	NA	0.33	5.98	0.36	7.81e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9467773	0.595	rs3799379	chr6:26404694	C/T	cg09904177	chr6:26538194	HMGN4	-0.41	-5.17	-0.31	4.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.96	12.78	0.63	4.97e-29	Menopause (age at onset);
KIRP	cis	rs14057	0.930	rs3789573	chr1:6730905	T/C	cg27299712	chr1:6550532	PLEKHG5	0.39	4.89	0.3	1.82e-6	Systolic blood pressure;
KIRP	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.45	-0.38	5.96e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-5.34	-0.32	2.14e-7	Joint mobility (Beighton score);
KIRP	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.21	-0.42	6.82e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg15704280	chr7:45808275	SEPT13	0.68	6.17	0.37	2.74e-9	Intraocular pressure;
KIRP	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs9962915	1.000	rs1785415	chr18:5598976	G/A	cg12967001	chr18:5544089	EPB41L3	-0.41	-5.1	-0.31	6.9e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg16917193	chr12:54089295	NA	-0.86	-16.56	-0.73	6.88e-42	Height;
KIRP	cis	rs7719624	0.811	rs17689879	chr5:135393138	C/T	cg16684184	chr5:135415129	NA	-0.34	-4.98	-0.3	1.21e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg24009623	chr19:33667908	NA	0.47	5.71	0.34	3.18e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs4363385	0.667	rs78426057	chr1:152964528	T/C	cg13444842	chr1:152974279	SPRR3	-0.35	-4.92	-0.3	1.55e-6	Inflammatory skin disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07347276	chr11:34949324	PDHX	-0.43	-6.96	-0.41	3.1e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg13393036	chr8:95962371	TP53INP1	-0.31	-6.08	-0.36	4.63e-9	Type 2 diabetes;
KIRP	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	13.8	0.66	1.84e-32	Primary sclerosing cholangitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16113692	chr11:22851502	SVIP	-0.48	-6.1	-0.36	4.16e-9	Interleukin-4 levels;
KIRP	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-6.11	-0.36	3.77e-9	Bipolar disorder;
KIRP	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs3126085	0.515	rs12760712	chr1:152355550	G/A	cg26876637	chr1:152193138	HRNR	-0.48	-6.01	-0.36	6.73e-9	Atopic dermatitis;
KIRP	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.52	-6.34	-0.37	1.07e-9	Longevity;Endometriosis;
KIRP	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg00677455	chr12:58241039	CTDSP2	0.76	9.74	0.53	3.51e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg01559446	chr3:44596178	ZNF167	-0.36	-5.29	-0.32	2.76e-7	Depressive symptoms;
KIRP	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.89	10.57	0.56	9.14e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4774899	1.000	rs1462156	chr15:57503423	A/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.26	-0.32	3.15e-7	Urinary tract infection frequency;
KIRP	cis	rs9534288	0.699	rs2296642	chr13:46656669	A/G	cg15192986	chr13:46630673	CPB2	-0.78	-9.29	-0.51	8.71e-18	Blood protein levels;
KIRP	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.61	-6.73	-0.39	1.21e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg23748340	chr12:48592721	NA	-0.44	-5.0	-0.3	1.09e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.39	-5.65	-0.34	4.43e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.77	-10.29	-0.55	7.1e-21	Adiposity;
KIRP	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg09408571	chr1:101003634	GPR88	-0.24	-5.42	-0.33	1.45e-7	Monocyte count;
KIRP	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.33	0.55	5.23e-21	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg18045831	chr1:19577885	MRTO4;KIAA0090	0.43	6.1	0.36	4.12e-9	Ischemic stroke;
KIRP	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.73	-8.9	-0.49	1.26e-16	Vitiligo;
KIRP	cis	rs4740619	0.619	rs10738428	chr9:16046489	T/C	cg14451791	chr9:16040625	NA	-0.42	-5.51	-0.33	8.94e-8	Body mass index;
KIRP	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg22089800	chr15:90895588	ZNF774	0.43	5.13	0.31	5.79e-7	Rheumatoid arthritis;
KIRP	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.16	0.54	1.78e-20	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01100763	chr16:3174416	NA	0.49	6.07	0.36	4.93e-9	Parkinson's disease;
KIRP	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg16989719	chr2:238392110	NA	-0.57	-5.66	-0.34	4.16e-8	Prostate cancer;
KIRP	cis	rs11583043	0.708	rs10493942	chr1:101545482	G/A	cg17443007	chr1:101659419	NA	0.41	5.54	0.33	7.61e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.68	-0.39	1.58e-10	Myopia (pathological);
KIRP	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-0.41	-5.11	-0.31	6.43e-7	Type 2 diabetes;
KIRP	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.75	-9.53	-0.52	1.59e-18	Facial morphology (factor 19);
KIRP	cis	rs12986413	0.680	rs4807213	chr19:2194769	A/G	cg09261902	chr19:2140048	AP3D1	0.6	9.15	0.5	2.28e-17	Height;
KIRP	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg06636001	chr8:8085503	FLJ10661	0.88	12.18	0.61	4.95e-27	Systolic blood pressure;
KIRP	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.38	5.66	0.34	4.23e-8	Platelet distribution width;
KIRP	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg11150807	chr10:43354902	NA	0.69	7.6	0.44	6.22e-13	Blood protein levels;
KIRP	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg00800038	chr16:89945340	TCF25	-0.68	-5.0	-0.3	1.1e-6	Skin colour saturation;
KIRP	trans	rs4349753	0.904	rs990701	chr5:144197278	T/A	cg16033277	chr17:80885358	TBCD	0.4	6.15	0.37	3.17e-9	Photic sneeze reflex;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.91e-8	Life satisfaction;
KIRP	cis	rs3736485	0.966	rs12101730	chr15:51800733	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.1	-0.31	6.83e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10500715	0.533	rs7115754	chr11:9877047	A/G	cg25247837	chr11:9897069	SBF2	0.41	5.96	0.36	8.47e-9	Pancreatic cancer;
KIRP	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	5.24	0.32	3.39e-7	Height;
KIRP	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg05347473	chr6:146136440	FBXO30	0.63	9.13	0.5	2.62e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.63	-6.75	-0.4	1.07e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg09658497	chr7:2847517	GNA12	-0.35	-4.99	-0.3	1.13e-6	Height;
KIRP	cis	rs17023223	0.537	rs2645302	chr1:119590398	A/C	cg18261050	chr1:119551319	NA	0.53	7.04	0.41	1.94e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.75	-7.6	-0.44	6.22e-13	Gut microbiome composition (summer);
KIRP	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.93	-0.3	1.53e-6	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.09	-0.31	7.16e-7	Lung cancer;
KIRP	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.2	16.09	0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16418258	chr15:42840397	LRRC57;HAUS2	0.66	7.67	0.44	3.98e-13	Lung cancer in ever smokers;
KIRP	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg16141378	chr3:129829833	LOC729375	0.62	8.4	0.47	3.51e-15	Triglycerides;
KIRP	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg25356066	chr3:128598488	ACAD9	0.5	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23279887	chr19:19249481	TMEM161A	0.49	6.09	0.36	4.26e-9	Inflammatory biomarkers;
KIRP	cis	rs7224685	0.569	rs8082425	chr17:3991706	C/G	cg05562828	chr17:3906858	NA	0.56	5.81	0.35	1.91e-8	Type 2 diabetes;
KIRP	cis	rs1256061	0.624	rs1152582	chr14:64692630	G/C	cg21174375	chr14:64681225	SYNE2	0.51	5.67	0.34	4.07e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg06204229	chr3:52865917	ITIH4	0.48	5.45	0.33	1.23e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg10760299	chr15:45669010	GATM	-0.34	-5.25	-0.32	3.3e-7	Homoarginine levels;
KIRP	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-0.76	-8.11	-0.46	2.41e-14	Mean corpuscular hemoglobin;
KIRP	trans	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg05973401	chr12:123451056	ABCB9	0.55	6.2	0.37	2.35e-9	Neutrophil percentage of white cells;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg23693289	chr8:27183097	PTK2B	0.57	7.34	0.42	3.05e-12	Neuroticism;
KIRP	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg10018233	chr7:150070692	REPIN1	0.7	9.22	0.51	1.41e-17	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.63	-8.15	-0.46	1.82e-14	Colorectal cancer;
KIRP	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg25753631	chr6:25732923	NA	-0.29	-5.35	-0.32	2.01e-7	Iron status biomarkers;
KIRP	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.74	9.67	0.52	6.12e-19	Childhood ear infection;
KIRP	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.52	-6.82	-0.4	7.11e-11	Hip circumference;Waist circumference;
KIRP	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg12483005	chr1:23474871	LUZP1	0.43	4.88	0.3	1.94e-6	Height;
KIRP	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg10755058	chr3:40428713	ENTPD3	0.44	6.24	0.37	1.85e-9	Renal cell carcinoma;
KIRP	cis	rs16828019	0.852	rs12408956	chr1:41651952	G/A	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.49	5.8	0.35	1.99e-8	Glycated hemoglobin levels;
KIRP	cis	rs914615	0.552	rs4276914	chr1:155142229	G/A	cg02153340	chr1:155202674	NA	-0.48	-7.21	-0.42	6.92e-12	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.64	-7.36	-0.42	2.68e-12	Height;
KIRP	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.74	0.4	1.09e-10	Breast cancer;
KIRP	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-1.11	-9.13	-0.5	2.5e-17	Body mass index;
KIRP	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.61	0.39	2.43e-10	Colorectal cancer;
KIRP	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.69	-0.48	5.12e-16	Neuroticism;
KIRP	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.62	8.92	0.49	1.07e-16	Vitiligo;
KIRP	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.74	-0.39	1.14e-10	Morning vs. evening chronotype;
KIRP	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg26681399	chr22:41777847	TEF	0.51	5.18	0.31	4.65e-7	Vitiligo;
KIRP	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.41	-0.47	3.34e-15	Colorectal cancer;
KIRP	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.54	-7.3	-0.42	3.87e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6142102	0.961	rs6087557	chr20:32698275	T/C	cg08999081	chr20:33150536	PIGU	0.54	7.14	0.41	1.08e-11	Skin pigmentation;
KIRP	trans	rs76288851	0.733	rs77537105	chr3:126454763	G/A	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.38	-0.43	2.41e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11987759	chr7:65425863	GUSB	0.44	5.7	0.34	3.44e-8	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04874113	chr1:226271304	NA	0.46	6.46	0.38	5.46e-10	Parkinson's disease;
KIRP	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg06204229	chr3:52865917	ITIH4	0.61	6.74	0.39	1.12e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg17125719	chr8:71185581	NCOA2	0.41	6.11	0.36	3.91e-9	Migraine with aura;
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg06815112	chr8:27182871	PTK2B	0.51	6.62	0.39	2.27e-10	Neuroticism;
KIRP	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00791764	chr4:53727839	RASL11B	0.46	6.32	0.37	1.25e-9	Optic nerve measurement (cup area);
KIRP	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-4.85	-0.3	2.21e-6	Schizophrenia;
KIRP	cis	rs3821902	0.547	rs56237630	chr3:64049375	C/A	cg09006292	chr3:64049408	NA	-0.54	-6.37	-0.38	9.47e-10	Breast cancer;
KIRP	cis	rs11834862	0.653	rs11246997	chr12:132690684	G/A	cg19601865	chr12:132687172	GALNT9	-0.45	-4.88	-0.3	1.89e-6	Anti-saccade response;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20163532	chr17:56064356	VEZF1	0.58	6.66	0.39	1.76e-10	Lung cancer in ever smokers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26859901	chr19:35759185	USF2	0.5	6.3	0.37	1.35e-9	Parkinson's disease;
KIRP	cis	rs13315871	0.929	rs17354606	chr3:58237289	T/C	cg20936604	chr3:58311152	NA	-0.73	-5.28	-0.32	2.8e-7	Cholesterol, total;
KIRP	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.85	-0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.39	8.38	0.47	4.03e-15	Mean corpuscular volume;
KIRP	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg07541023	chr7:19748670	TWISTNB	0.63	5.69	0.34	3.55e-8	Thyroid stimulating hormone;
KIRP	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.99	14.63	0.68	2.7900000000000003e-35	Multiple sclerosis;
KIRP	cis	rs687432	0.774	rs7120102	chr11:57868130	T/C	cg19752551	chr11:57585705	CTNND1	-0.66	-8.52	-0.48	1.59e-15	Parkinson's disease;
KIRP	cis	rs520865	0.786	rs486683	chr5:80345197	C/T	cg17330048	chr5:80257322	RASGRF2	-0.45	-6.62	-0.39	2.2e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.56	6.51	0.38	4.18e-10	Aortic root size;
KIRP	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg10223061	chr2:219282414	VIL1	0.31	5.01	0.3	1.06e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.47e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg03714773	chr7:91764589	CYP51A1	-0.35	-5.1	-0.31	6.93e-7	Breast cancer;
KIRP	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg17252645	chr8:143867129	LY6D	-0.31	-5.02	-0.3	9.87e-7	Urinary tract infection frequency;
KIRP	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg23479056	chr15:41276147	INO80	-0.38	-5.16	-0.31	5.17e-7	Menopause (age at onset);
KIRP	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.63	6.91	0.4	4.24e-11	Prostate cancer;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.5	6.5	0.38	4.37e-10	Testicular germ cell tumor;
KIRP	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.88	14.18	0.67	9.43e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg08017634	chr8:144659831	NAPRT1	0.81	5.14	0.31	5.54e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-1.01	-19.53	-0.78	6.3e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg00310523	chr12:86230176	RASSF9	0.39	6.08	0.36	4.5e-9	Major depressive disorder;
KIRP	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.67	-8.5	-0.48	1.84e-15	Orofacial clefts;
KIRP	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.46	0.47	2.38e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.88	-0.4	5.04e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg03161606	chr19:29218774	NA	0.74	6.63	0.39	2.08e-10	Methadone dose in opioid dependence;
KIRP	cis	rs10518128	1.000	rs10009741	chr4:75711506	C/T	cg20122727	chr4:75719957	BTC	0.59	5.97	0.36	8.15e-9	Electroencephalogram traits;
KIRP	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.57	8.72	0.49	4.36e-16	Personality dimensions;
KIRP	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.66	6.09	0.36	4.33e-9	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03652890	chr22:30685706	GATSL3	0.49	6.52	0.38	3.85e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg10223061	chr2:219282414	VIL1	-0.32	-5.2	-0.31	4.19e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	1.08	19.48	0.78	9.24e-52	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03642425	chr3:122746419	SEMA5B	0.5	6.22	0.37	2.11e-9	Parkinson's disease;
KIRP	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.56	-6.92	-0.4	3.97e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg22117172	chr7:91764530	CYP51A1	-0.36	-5.06	-0.31	8.39e-7	Breast cancer;
KIRP	cis	rs17453880	0.750	rs4262091	chr5:151925416	A/G	cg12297329	chr5:152029980	NA	0.53	7.84	0.45	1.35e-13	Subjective well-being;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13626774	chr8:68256266	ARFGEF1	-0.5	-6.68	-0.39	1.59e-10	Myopia;
KIRP	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.1	-0.31	6.72e-7	Type 2 diabetes;
KIRP	cis	rs6700896	0.931	rs11208715	chr1:66154414	G/T	cg04111102	chr1:66153794	NA	0.34	5.05	0.31	8.53e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.86	-8.54	-0.48	1.42e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs6001982	0.584	rs56150793	chr22:40824087	G/C	cg07138101	chr22:40742427	ADSL	0.68	5.32	0.32	2.3e-7	Breast cancer;
KIRP	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.51	-7.11	-0.41	1.26e-11	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg14082893	chr15:75400931	NA	-0.36	-5.26	-0.32	3.16e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22496380	chr5:211416	CCDC127	-1.14	-7.75	-0.44	2.38e-13	Breast cancer;
KIRP	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.42	-8.14	-0.46	1.99e-14	Urinary metabolites;
KIRP	cis	rs3764563	0.935	rs17708232	chr19:15686744	A/G	cg20725493	chr19:15740067	CYP4F8	-0.83	-6.03	-0.36	5.92e-9	Inflammatory biomarkers;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08827079	chr19:35225142	ZNF181	0.44	6.08	0.36	4.44e-9	Survival in pancreatic cancer;
KIRP	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	6.87	0.4	5.13e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs9447004	0.557	rs2173854	chr6:74426775	T/A	cg03006477	chr6:74432658	CD109	0.24	5.06	0.31	8.06e-7	Blood protein levels;Calcium levels;
KIRP	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.26	0.37	1.68e-9	Endometrial cancer;
KIRP	cis	rs1408799	0.830	rs10960748	chr9:12668805	A/C	cg05274944	chr9:12693694	TYRP1	0.37	5.23	0.32	3.56e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg04519387	chr11:65556438	OVOL1	0.35	5.01	0.3	1.03e-6	Acne (severe);
KIRP	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	cg04338863	chr8:33670619	NA	0.48	6.2	0.37	2.32e-9	Body mass index;
KIRP	cis	rs997295	0.520	rs4776971	chr15:68081097	C/A	cg24579218	chr15:68104479	NA	-0.42	-6.41	-0.38	7.37e-10	Motion sickness;
KIRP	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg19752551	chr11:57585705	CTNND1	-0.81	-13.51	-0.65	1.77e-31	Schizophrenia;
KIRP	cis	rs6882046	0.513	rs618298	chr5:88038390	A/G	cg24804195	chr5:87968844	LOC645323	-0.46	-6.13	-0.36	3.52e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs829661	0.793	rs2593466	chr2:30873367	C/T	cg10949345	chr2:30726833	LCLAT1	1.15	14.13	0.67	1.34e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs4742903	0.509	rs7873500	chr9:106965334	T/C	cg06629767	chr10:72238406	KIAA1274	-0.45	-6.22	-0.37	2.14e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.34	-0.51	5.91e-18	Neuroticism;
KIRP	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.56	-7.64	-0.44	4.98e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	1.13	15.51	0.7	2.66e-38	Post bronchodilator FEV1;
KIRP	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.41	4.88	0.3	1.88e-6	Colorectal cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07954054	chr1:225590862	LBR	0.44	6.41	0.38	7.19e-10	C-reactive protein;
KIRP	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.12e-8	Life satisfaction;
KIRP	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg19847130	chr8:10466454	RP1L1	0.32	4.87	0.3	1.99e-6	Neuroticism;
KIRP	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.56	7.19	0.42	7.55e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs4742903	0.527	rs55909255	chr9:106871788	T/C	cg14250997	chr9:106856677	SMC2	0.42	5.75	0.34	2.69e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02723850	chr17:6918181	C17orf49	0.49	6.14	0.36	3.23e-9	Parkinson's disease;
KIRP	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	7.29	0.42	4.2e-12	Coffee consumption (cups per day);
KIRP	trans	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.83	-0.4	6.5500000000000006e-11	Heart rate;
KIRP	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.74	-8.06	-0.46	3.24e-14	Type 2 diabetes;
KIRP	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	5.65	0.34	4.51e-8	Renal cell carcinoma;
KIRP	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg23166289	chr1:210001082	C1orf107	0.4	4.9	0.3	1.7e-6	Orofacial clefts;
KIRP	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg26531700	chr6:26746687	NA	0.39	5.0	0.3	1.11e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10518128	1.000	rs6834806	chr4:75715826	T/C	cg20122727	chr4:75719957	BTC	0.56	5.69	0.34	3.55e-8	Electroencephalogram traits;
KIRP	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	14.24	0.67	5.77e-34	Electrocardiographic conduction measures;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20308189	chr12:122261415	SETD1B	-0.49	-6.58	-0.39	2.76e-10	Parkinson's disease;
KIRP	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg18753928	chr3:113234510	CCDC52	-0.52	-6.48	-0.38	4.98e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.52	-6.39	-0.38	8.32e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg01689657	chr7:91764605	CYP51A1	0.4	5.62	0.34	5.14e-8	Breast cancer;
KIRP	cis	rs2219968	1.000	rs13281300	chr8:78966585	A/G	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg15896084	chr13:114927664	NA	0.47	6.29	0.37	1.43e-9	Schizophrenia;
KIRP	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	5.81	0.35	1.93e-8	Mean platelet volume;
KIRP	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg17507749	chr15:85114479	UBE2QP1	0.74	6.86	0.4	5.45e-11	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-9.33	-0.51	6.24e-18	Coffee consumption (cups per day);
KIRP	cis	rs7523273	0.568	rs61821293	chr1:208007277	T/G	cg22525895	chr1:207977042	MIR29B2	-0.61	-5.82	-0.35	1.83e-8	Schizophrenia;
KIRP	cis	rs714027	0.585	rs9614077	chr22:30244949	C/T	cg27665648	chr22:30112403	NA	0.47	6.05	0.36	5.49e-9	Lymphocyte counts;
KIRP	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.35	-0.42	2.91e-12	Fear of minor pain;
KIRP	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg10818794	chr15:86012489	AKAP13	0.52	7.33	0.42	3.38e-12	Coronary artery disease;
KIRP	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs17742757	0.521	rs2736324	chr8:11328182	C/G	cg21775007	chr8:11205619	TDH	0.46	5.88	0.35	1.31e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.3	-7.15	-0.41	9.77e-12	Mean corpuscular volume;
KIRP	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.61	-0.34	5.34e-8	Morning vs. evening chronotype;
KIRP	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	9.71	0.53	4.51e-19	Schizophrenia;
KIRP	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.22	-0.37	2.07e-9	Height;
KIRP	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.79	0.44	1.89e-13	Morning vs. evening chronotype;
KIRP	cis	rs4285214	0.715	rs10079692	chr5:124025450	A/G	cg15082166	chr5:124005151	ZNF608	-0.47	-5.47	-0.33	1.08e-7	Survival in pancreatic cancer;
KIRP	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg01270228	chr10:1369114	ADARB2	0.44	5.59	0.34	6.12e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.6	6.24	0.37	1.93e-9	Gut microbiome composition (summer);
KIRP	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06212747	chr3:49208901	KLHDC8B	0.87	13.7	0.66	4.1e-32	Menarche (age at onset);
KIRP	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg07274523	chr3:49395745	GPX1	0.71	8.38	0.47	4.23e-15	Educational attainment;
KIRP	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.72	-0.44	2.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg19116668	chr7:99932089	PMS2L1	0.42	5.16	0.31	5.09e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01869136	chr14:56755262	PELI2	-0.46	-6.53	-0.38	3.67e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs910873	0.505	rs6058089	chr20:33194257	C/T	cg16810054	chr20:33298113	TP53INP2	0.45	5.09	0.31	7.26e-7	Melanoma;
KIRP	cis	rs6496667	0.779	rs16944509	chr15:91032003	G/A	cg10434728	chr15:90938212	IQGAP1	0.39	5.02	0.3	9.99e-7	Rheumatoid arthritis;
KIRP	cis	rs6430538	0.582	rs1942053	chr2:135579205	G/C	cg25422880	chr2:135218333	TMEM163	-0.43	-6.03	-0.36	5.91e-9	Parkinson's disease;
KIRP	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-14.55	-0.68	4.93e-35	Height;
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.92	14.65	0.68	2.36e-35	Testicular germ cell tumor;
KIRP	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.51e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.71	10.61	0.56	6.67e-22	Lewy body disease;
KIRP	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.7	-0.39	1.39e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg05627522	chr15:75251581	NA	0.36	5.46	0.33	1.18e-7	Breast cancer;
KIRP	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-5.15	-0.31	5.22e-7	Eosinophil percentage of white cells;
KIRP	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.31	13.46	0.65	2.48e-31	Diabetic retinopathy;
KIRP	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.25	-0.62	2.92e-27	Alzheimer's disease;
KIRP	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg12131826	chr15:77904385	NA	-0.49	-6.14	-0.36	3.37e-9	Type 2 diabetes;
KIRP	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.64	-0.44	4.86e-13	Body mass index;
KIRP	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg16497661	chr14:103986332	CKB	-0.52	-6.94	-0.4	3.48e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	0.85	7.7	0.44	3.29e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10518128	0.510	rs10005089	chr4:75694606	C/T	cg20122727	chr4:75719957	BTC	0.61	7.54	0.43	8.92e-13	Electroencephalogram traits;
KIRP	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.85	-11.89	-0.6	4.79e-26	Total body bone mineral density;
KIRP	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-9.01	-0.5	5.97e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs240764	0.621	rs9404052	chr6:101249718	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-5.09	-0.31	7.14e-7	Neuroticism;
KIRP	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.45	6.76	0.4	1.02e-10	Coronary artery disease;
KIRP	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.41	5.05	0.31	8.8e-7	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg02733842	chr7:1102375	C7orf50	-0.47	-4.97	-0.3	1.25e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs7078219	0.897	rs10883360	chr10:101281158	C/G	cg07044859	chr10:101282883	NA	-0.31	-5.25	-0.32	3.26e-7	Dental caries;
KIRP	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	5.89	0.35	1.25e-8	Breast cancer;
KIRP	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg02073558	chr3:44770973	ZNF501	0.61	8.65	0.48	6.57e-16	Depressive symptoms;
KIRP	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.11e-7	Breast cancer;
KIRP	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg05991184	chr2:219186017	PNKD	0.36	5.06	0.31	8.33e-7	Colorectal cancer;
KIRP	cis	rs1023500	1.000	rs1023500	chr22:42340844	C/T	cg04733989	chr22:42467013	NAGA	0.53	5.92	0.35	1.1e-8	Schizophrenia;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.81	-8.58	-0.48	1.11e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.42	-0.33	1.45e-7	Menarche (age at onset);
KIRP	cis	rs2223471	0.561	rs2281159	chr6:50726262	G/A	cg03432817	chr6:50765336	NA	-0.35	-5.14	-0.31	5.53e-7	Subcutaneous adipose tissue;
KIRP	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg14092571	chr14:90743983	NA	-0.42	-5.5	-0.33	9.47e-8	Mortality in heart failure;
KIRP	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.82	7.08	0.41	1.54e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg14675211	chr2:100938903	LONRF2	0.5	6.54	0.38	3.56e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	1.000	rs7929712	chr11:78158542	T/C	cg27205649	chr11:78285834	NARS2	-0.65	-7.33	-0.42	3.32e-12	Alzheimer's disease (survival time);
KIRP	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.28	7.47	0.43	1.42e-12	Primary biliary cholangitis;
KIRP	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27297192	chr10:134578999	INPP5A	0.56	7.18	0.42	8.26e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16189024	chr3:101568236	NFKBIZ	0.53	6.74	0.39	1.1e-10	Parkinson's disease;
KIRP	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.46	5.72	0.34	3.13e-8	Lymphocyte counts;
KIRP	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg24692254	chr21:30365293	RNF160	-0.5	-5.16	-0.31	5.1e-7	Cognitive test performance;
KIRP	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.95	0.3	1.4e-6	Bipolar disorder;
KIRP	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg15068132	chr12:102092402	CHPT1	-0.4	-5.25	-0.32	3.27e-7	Blood protein levels;
KIRP	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.92	-0.4	3.89e-11	Type 2 diabetes;
KIRP	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.68	-8.07	-0.46	3.17e-14	Blood protein levels;
KIRP	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	0.48	5.03	0.31	9.31e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs1712517	0.771	rs61871160	chr10:105144288	C/T	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.31e-9	Migraine;
KIRP	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg02951883	chr7:2050386	MAD1L1	0.68	8.11	0.46	2.36e-14	Schizophrenia;
KIRP	cis	rs2661868	0.788	rs2708631	chr1:8463510	C/T	cg03610117	chr1:8450231	RERE	-0.71	-8.86	-0.49	1.65e-16	Life satisfaction;
KIRP	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.64	9.03	0.5	5.3e-17	Bladder cancer;
KIRP	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	13.11	0.64	3.91e-30	Personality dimensions;
KIRP	cis	rs78487399	0.908	rs7602701	chr2:43841119	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.9	-0.3	1.75e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.79	0.63	4.52e-29	Platelet count;
KIRP	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.21	0.37	2.19e-9	Breast cancer;
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg21851534	chr17:3907994	ZZEF1	0.7	11.54	0.59	6.79e-25	Type 2 diabetes;
KIRP	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.97	15.67	0.71	7.77e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.55	-0.52	1.37e-18	Mean corpuscular volume;
KIRP	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg04731861	chr2:219085781	ARPC2	-0.21	-5.1	-0.31	6.78e-7	Colorectal cancer;
KIRP	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.69	-8.92	-0.49	1.12e-16	Blood metabolite levels;
KIRP	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	6.96	0.41	3.06e-11	Platelet count;
KIRP	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.7	-13.15	-0.64	2.79e-30	White blood cell count (basophil);
KIRP	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg12559939	chr2:27858050	GPN1	-0.42	-5.25	-0.32	3.25e-7	Oral cavity cancer;
KIRP	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg08888203	chr3:10149979	C3orf24	0.46	4.86	0.3	2.09e-6	Alzheimer's disease;
KIRP	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg25019033	chr10:957182	NA	-0.57	-6.96	-0.41	3.02e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.54	-9.44	-0.52	3.09e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.48	7.53	0.43	9.79e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4332428	1.000	rs4341440	chr10:4965293	G/A	cg19648686	chr10:5044992	AKR1C2	-0.81	-6.78	-0.4	8.71e-11	Height;
KIRP	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg08645402	chr16:4508243	NA	0.47	5.96	0.36	8.53e-9	Schizophrenia;
KIRP	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg04287289	chr16:89883240	FANCA	0.7	4.93	0.3	1.48e-6	Skin colour saturation;
KIRP	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.97	-0.3	1.27e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2625529	0.586	rs2306489	chr15:72227471	G/A	cg16672083	chr15:72433130	SENP8	0.45	6.34	0.37	1.08e-9	Red blood cell count;
KIRP	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	1.03	8.28	0.47	7.77e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg14820908	chr5:178986412	RUFY1	0.38	5.35	0.32	2.01e-7	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11374425	chr3:62359677	FEZF2	-0.48	-6.34	-0.37	1.11e-9	Interleukin-4 levels;
KIRP	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.62	-8.27	-0.47	8.39e-15	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.75	-0.4	1.05e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4523957	0.928	rs11869805	chr17:2176532	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.31	-0.47	6.46e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10982256	0.805	rs10759714	chr9:117267591	C/T	cg13636371	chr9:117264095	DFNB31	-0.39	-5.01	-0.3	1.06e-6	Bipolar disorder;
KIRP	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg07395648	chr5:131743802	NA	-0.54	-7.42	-0.43	1.86e-12	Breast cancer;
KIRP	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg09029085	chr17:47094198	IGF2BP1	0.25	5.64	0.34	4.75e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2371030	0.900	rs10932350	chr2:211565772	G/A	cg18417063	chr2:211583084	NA	-0.51	-7.23	-0.42	6.2e-12	Non-small cell lung cancer;
KIRP	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg02187348	chr16:89574699	SPG7	0.42	5.13	0.31	5.98e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.13	0.31	5.85e-7	Educational attainment;
KIRP	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.76	-10.44	-0.55	2.33e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg06742321	chr12:123595122	PITPNM2	0.42	5.13	0.31	5.86e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.59	-8.37	-0.47	4.26e-15	Calcium levels;
KIRP	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.07	7.95	0.45	6.84e-14	Cognitive function;
KIRP	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg07599136	chr5:415885	AHRR	0.7	6.3	0.37	1.39e-9	Fat distribution (HIV);
KIRP	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.78	10.24	0.55	1e-20	Aortic root size;
KIRP	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-8.7	-0.49	4.81e-16	Response to antipsychotic treatment;
KIRP	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-4.9	-0.3	1.75e-6	Initial pursuit acceleration;
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-5.98	-0.36	7.69e-9	Lung cancer;
KIRP	cis	rs17057718	0.898	rs1077034	chr3:57138228	T/A	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-5.0	-0.3	1.09e-6	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14470479	chr9:34339403	NUDT2	0.52	6.25	0.37	1.8e-9	Interleukin-4 levels;
KIRP	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	cg12689670	chr1:183009347	LAMC1	0.46	6.6	0.39	2.45e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.16	-0.37	3.01e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.86	-9.04	-0.5	4.73e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.62	-10.22	-0.55	1.11e-20	Sense of smell;
KIRP	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg03060546	chr3:49711283	APEH	-0.65	-5.97	-0.36	8.07e-9	Cognitive function;
KIRP	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17507749	chr15:85114479	UBE2QP1	0.71	8.0	0.45	5.05e-14	Schizophrenia;
KIRP	cis	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.4	-0.33	1.61e-7	HDL cholesterol;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10909192	chr14:45579847	PRPF39;SNORD127	-0.46	-7.15	-0.41	9.8e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg02725872	chr8:58115012	NA	-0.6	-7.42	-0.43	1.86e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg08132940	chr7:1081526	C7orf50	-0.7	-7.03	-0.41	1.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.88e-8	Motion sickness;
KIRP	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.7	11.21	0.58	7.71e-24	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	0.9	8.28	0.47	7.85e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.53	-0.38	3.64e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11997175	0.626	rs12155927	chr8:33789851	A/G	ch.8.33884649F	chr8:33765107	NA	0.46	5.58	0.34	6.42e-8	Body mass index;
KIRP	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19671926	chr4:122722719	EXOSC9	0.51	6.15	0.37	3.05e-9	Type 2 diabetes;
KIRP	cis	rs4658101	0.667	rs4658235	chr1:92049788	G/A	cg09075522	chr1:92031145	NA	0.46	5.64	0.34	4.72e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.84	13.91	0.66	7.65e-33	Multiple myeloma;
KIRP	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	1.22	9.15	0.5	2.21e-17	Economic and political preferences (immigration/crime);
KIRP	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.76	11.35	0.59	2.66e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg16497661	chr14:103986332	CKB	-0.47	-6.21	-0.37	2.23e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	11.89	0.6	4.77e-26	Lung cancer in ever smokers;
KIRP	cis	rs7688540	0.771	rs11723261	chr4:282499	A/G	cg17891759	chr4:299121	NA	-0.49	-5.13	-0.31	5.79e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6689305	1.000	rs11166344	chr1:100272171	C/G	cg06223162	chr1:101003688	GPR88	-0.36	-4.87	-0.3	1.96e-6	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs2290159	0.615	rs7610956	chr3:12677158	A/G	cg23032965	chr3:12705835	RAF1	0.78	8.45	0.47	2.57e-15	Cholesterol, total;
KIRP	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg13206674	chr6:150067644	NUP43	0.55	7.86	0.45	1.22e-13	Testicular germ cell tumor;
KIRP	cis	rs1318772	1.000	rs11746828	chr5:112718008	C/A	cg12552261	chr5:112820674	MCC	0.72	5.15	0.31	5.37e-7	F-cell distribution;
KIRP	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg14541582	chr5:601475	NA	-0.57	-6.34	-0.37	1.09e-9	Obesity-related traits;
KIRP	cis	rs3105593	1.000	rs11634746	chr15:50941496	T/A	cg05456662	chr15:50716270	USP8	0.41	4.9	0.3	1.75e-6	QT interval;
KIRP	cis	rs12823128	0.766	rs12581140	chr12:26930054	T/C	cg14081884	chr12:26986758	ITPR2	0.4	5.01	0.3	1.02e-6	Birth weight;
KIRP	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg03289416	chr15:75166202	SCAMP2	-0.43	-6.07	-0.36	4.93e-9	Caffeine consumption;
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.72	9.69	0.53	5.06e-19	Longevity;
KIRP	cis	rs4742903	0.545	rs7039927	chr9:106986804	A/G	cg14250997	chr9:106856677	SMC2	0.38	5.2	0.31	4.1e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-5.4	-0.33	1.54e-7	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16528272	chr4:3502518	NA	-0.45	-6.21	-0.37	2.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg13010199	chr12:38710504	ALG10B	-0.56	-7.1	-0.41	1.33e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg01631408	chr1:248437212	OR2T33	-0.65	-8.28	-0.47	7.96e-15	Common traits (Other);
KIRP	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	0.82	9.05	0.5	4.52e-17	Gut microbiome composition (summer);
KIRP	cis	rs6540556	0.521	rs1337531	chr1:209911988	T/G	cg23920097	chr1:209922102	NA	-0.4	-5.5	-0.33	9.44e-8	Red blood cell count;
KIRP	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.72	-10.93	-0.57	6.15e-23	Hepatocellular carcinoma;
KIRP	cis	rs6142102	0.961	rs4911401	chr20:32654562	C/A	cg24642439	chr20:33292090	TP53INP2	0.61	6.85	0.4	5.76e-11	Skin pigmentation;
KIRP	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.13	-20.79	-0.8	4.2e-56	Triglycerides;
KIRP	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.24	0.32	3.53e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs35934224	0.783	rs16984299	chr22:19863593	C/T	cg11182965	chr22:19864308	TXNRD2	0.4	6.25	0.37	1.77e-9	Glaucoma (primary open-angle);
KIRP	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg19500275	chr17:80737654	TBCD	0.46	5.47	0.33	1.11e-7	Glycated hemoglobin levels;
KIRP	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.47	-6.99	-0.41	2.59e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6684428	0.536	rs11804906	chr1:56394231	A/G	cg11651538	chr1:56320950	NA	-0.56	-7.91	-0.45	8.46e-14	Airflow obstruction;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01821754	chr1:1822399	GNB1	-0.6	-6.46	-0.38	5.59e-10	Menopause (age at onset);
KIRP	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg03609598	chr5:56110824	MAP3K1	0.47	5.69	0.34	3.54e-8	Coronary artery disease;
KIRP	trans	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg25214090	chr10:38739885	LOC399744	0.52	6.78	0.4	8.88e-11	Diastolic blood pressure;
KIRP	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg07741184	chr6:167504864	NA	0.2	5.1	0.31	6.63e-7	Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15477097	chr7:44161483	POLD2	-0.46	-6.55	-0.39	3.26e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg18350739	chr11:68623251	NA	-0.49	-7.66	-0.44	4.18e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.83	-0.53	1.96e-19	Aortic root size;
KIRP	cis	rs504918	0.561	rs11712039	chr3:123973586	C/T	cg05766129	chr3:123988013	KALRN	-0.44	-5.45	-0.33	1.25e-7	Schizophrenia;
KIRP	cis	rs4955124	0.558	rs4502621	chr3:32019900	C/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	7.44	0.43	1.66e-12	Schizophrenia;
KIRP	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.66	8.66	0.48	6.3e-16	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.21	-0.51	1.52e-17	Personality dimensions;
KIRP	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg12855166	chr17:30846586	MYO1D	-0.38	-5.94	-0.35	9.43e-9	Schizophrenia;
KIRP	cis	rs12049351	0.524	rs4925495	chr1:229624424	C/T	cg11742688	chr1:229674241	ABCB10	-0.39	-6.08	-0.36	4.51e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg05347473	chr6:146136440	FBXO30	0.57	8.12	0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.95	16.34	0.72	3.97e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg05484376	chr2:27715224	FNDC4	0.41	6.81	0.4	7.41e-11	Total body bone mineral density;
KIRP	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.71	-7.2	-0.42	7.37e-12	Vitiligo;
KIRP	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.02	0.54	4.99e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-0.82	-11.65	-0.6	2.91e-25	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6545883	0.929	rs6545873	chr2:61733012	T/C	cg15711740	chr2:61764176	XPO1	-0.59	-7.99	-0.45	5.24e-14	Tuberculosis;
KIRP	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg19875535	chr5:140030758	IK	-0.66	-9.48	-0.52	2.28e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.65	8.29	0.47	7.54e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	1.09	22.03	0.81	3.82e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg10932868	chr11:921992	NA	0.49	5.88	0.35	1.35e-8	Alzheimer's disease (late onset);
KIRP	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1014246	0.848	rs10787718	chr10:118467648	A/G	cg14919929	chr10:118506882	NA	-0.65	-7.89	-0.45	9.68e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19759251	chr3:44803167	KIF15;KIAA1143	0.47	6.15	0.37	3.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7539542	0.529	rs6699298	chr1:202853593	C/T	cg19681188	chr1:202830198	LOC148709	-0.48	-5.27	-0.32	3.05e-7	Mean platelet volume;
KIRP	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.52	6.29	0.37	1.47e-9	Bone mineral density;
KIRP	cis	rs6909279	0.678	rs6557143	chr6:151848611	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	0.42	5.1	0.31	6.81e-7	Bone mineral density;
KIRP	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg00405596	chr8:11794950	NA	-0.43	-5.57	-0.33	6.62e-8	Triglycerides;
KIRP	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	0.65	5.86	0.35	1.49e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs10861661	0.963	rs10861662	chr12:107178653	A/C	cg21360079	chr12:107162445	NA	-0.6	-6.49	-0.38	4.65e-10	Triglyceride levels;
KIRP	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	7.27	0.42	4.75e-12	Exhaled nitric oxide output;
KIRP	cis	rs9815354	0.951	rs1717028	chr3:41902964	C/T	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.6	-9.4	-0.51	3.83e-18	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.64	0.34	4.68e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	8.05	0.46	3.59e-14	Tonsillectomy;
KIRP	cis	rs9547996	0.879	rs11619443	chr13:38169715	C/G	cg13634560	chr13:38173852	POSTN	-0.4	-5.54	-0.33	7.8e-8	Diastolic blood pressure;
KIRP	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg00631329	chr6:26305371	NA	-0.73	-9.5	-0.52	1.99e-18	Educational attainment;
KIRP	cis	rs1891498	0.602	rs10900396	chr1:147242596	C/T	cg27546670	chr1:147246839	GJA5	-0.76	-10.67	-0.56	4.23e-22	Cognitive performance;
KIRP	cis	rs7662987	0.793	rs78790289	chr4:99987887	G/T	cg13256891	chr4:100009986	ADH5	-0.65	-5.29	-0.32	2.67e-7	Smoking initiation;
KIRP	cis	rs1978968	0.956	rs7290762	chr22:18449130	C/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.78	-0.4	8.68e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.92	-0.4	3.89e-11	Type 2 diabetes;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22168489	chr12:122356033	WDR66	0.64	9.76	0.53	3.2e-19	Mean corpuscular volume;
KIRP	cis	rs72627123	0.867	rs73301493	chr14:74472197	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.97	0.3	1.24e-6	Morning vs. evening chronotype;
KIRP	trans	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg00938859	chr5:1591904	SDHAP3	0.59	7.9	0.45	9.32e-14	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17959962	chr12:29865352	TMTC1	-0.43	-6.32	-0.37	1.19e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg06795125	chr2:108905320	SULT1C2	-0.48	-8.37	-0.47	4.43e-15	Blood pressure;
KIRP	cis	rs8014252	0.803	rs59233924	chr14:71050660	A/G	cg11204974	chr14:71022665	NA	-0.64	-6.78	-0.4	9.06e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.61	0.44	6e-13	Aortic root size;
KIRP	cis	rs4809219	1	rs4809219	chr20:62303115	C/A	cg03999872	chr20:62272968	STMN3	0.61	7.0	0.41	2.42e-11	Atopic dermatitis;
KIRP	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.56	-7.16	-0.42	9.39e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg20169779	chr10:135381914	SYCE1	0.69	7.27	0.42	4.81e-12	Gout;
KIRP	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg03060546	chr3:49711283	APEH	-0.57	-5.02	-0.3	1.01e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11997175	0.510	rs10503953	chr8:33797783	C/T	cg04338863	chr8:33670619	NA	0.48	6.49	0.38	4.75e-10	Body mass index;
KIRP	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.62	7.97	0.45	5.94e-14	Recalcitrant atopic dermatitis;
KIRP	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg17328964	chr8:145687451	CYHR1	-0.54	-6.83	-0.4	6.48e-11	Age at first birth;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg07897831	chr17:73512512	CASKIN2;TSEN54	0.56	6.96	0.41	3.07e-11	Plasma plasminogen activator levels;
KIRP	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.87	0.35	1.39e-8	Renal cell carcinoma;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.46	-0.33	1.15e-7	Life satisfaction;
KIRP	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg06212747	chr3:49208901	KLHDC8B	0.64	9.04	0.5	4.85e-17	Resting heart rate;
KIRP	cis	rs10421328	0.784	rs11667828	chr19:19768474	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.46	-5.39	-0.32	1.66e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.5	-6.98	-0.41	2.78e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs2963155	0.518	rs9324918	chr5:142767160	T/C	cg17617527	chr5:142782415	NR3C1	0.76	7.6	0.44	6.29e-13	Breast cancer;
KIRP	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs1978968	1.000	rs1076543	chr22:18446490	T/C	cg03078520	chr22:18463400	MICAL3	-0.64	-7.63	-0.44	5.29e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.68	9.63	0.52	8.06e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.65	-7.08	-0.41	1.49e-11	DNA methylation (variation);
KIRP	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.77	8.69	0.48	5.16e-16	Corneal astigmatism;
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.66	-0.44	4.27e-13	Platelet count;
KIRP	cis	rs698833	0.926	rs786626	chr2:44604066	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	5.01	0.3	1.02e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22336107	chr19:14606894	GIPC1	0.5	6.36	0.38	9.86e-10	Parkinson's disease;
KIRP	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg02336718	chr17:17403227	NA	0.35	5.27	0.32	3.04e-7	Total body bone mineral density;
KIRP	cis	rs7976059	0.824	rs12230839	chr12:52249405	A/G	cg27042523	chr12:52245356	NA	0.76	11.52	0.59	7.55e-25	Urate levels;
KIRP	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	1.11	16.31	0.72	4.73e-41	Breast cancer;
KIRP	trans	rs7939886	0.920	rs11227917	chr11:56095322	T/C	cg03929089	chr4:120376271	NA	0.89	6.13	0.36	3.53e-9	Myopia (pathological);
KIRP	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg08875078	chr22:50639485	SELO	-0.4	-5.19	-0.31	4.41e-7	Obesity-related traits;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg22074858	chr1:89488430	GBP3	-0.41	-6.13	-0.36	3.5e-9	Cancer;
KIRP	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg23307798	chr14:103986281	CKB	0.77	13.23	0.64	1.51e-30	Body mass index;
KIRP	cis	rs4805272	1.000	rs7258298	chr19:29323530	A/C	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.29	-0.32	2.67e-7	Breast cancer;
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.55	-0.33	7.47e-8	Electroencephalogram traits;
KIRP	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.55	-7.37	-0.43	2.58e-12	Schizophrenia;
KIRP	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.76	10.05	0.54	4e-20	Systolic blood pressure;
KIRP	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.63	-9.64	-0.52	7.54e-19	Colorectal cancer;
KIRP	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg05785598	chr3:49045655	WDR6	-0.31	-5.29	-0.32	2.76e-7	Parkinson's disease;
KIRP	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg24848339	chr3:12840334	CAND2	-0.34	-5.05	-0.31	8.72e-7	QRS complex (12-leadsum);
KIRP	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.63	5.93	0.35	1.04e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.56	-0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.83	8.81	0.49	2.35e-16	Exhaled nitric oxide output;
KIRP	cis	rs580438	0.529	rs4684934	chr3:13422271	C/T	cg10657019	chr3:13328039	NA	-0.52	-6.82	-0.4	6.94e-11	Myringotomy;
KIRP	trans	rs1620921	0.967	rs11902	chr6:161174871	C/G	cg01090089	chr7:6570974	GRID2IP	0.38	6.02	0.36	6.34e-9	Lipoprotein (a) - cholesterol levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg12660383	chr4:124171623	SPATA5	0.38	6.33	0.37	1.18e-9	C-reactive protein;
KIRP	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.32	8.57	0.48	1.15e-15	Crohn's disease;
KIRP	cis	rs960902	0.764	rs7574012	chr2:37727230	A/G	cg25341268	chr2:37734390	NA	0.54	7.34	0.42	3.2e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.48e-11	Diabetic kidney disease;
KIRP	cis	rs72772090	0.539	rs11740375	chr5:96112897	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.75	-6.69	-0.39	1.52e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.13	-0.31	5.79e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg14343924	chr8:8086146	FLJ10661	0.44	5.28	0.32	2.82e-7	Mood instability;
KIRP	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg16497661	chr14:103986332	CKB	0.75	11.15	0.58	1.21e-23	Body mass index;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01114163	chr5:1856713	NA	-0.44	-5.42	-0.33	1.44e-7	Cardiovascular disease risk factors;
KIRP	cis	rs920590	0.679	rs58556504	chr8:19653674	A/G	cg03894339	chr8:19674705	INTS10	0.41	4.99	0.3	1.13e-6	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg04369109	chr6:150039330	LATS1	-0.65	-8.55	-0.48	1.35e-15	Lung cancer;
KIRP	cis	rs4908768	0.535	rs2748456	chr1:8466750	C/T	cg03610117	chr1:8450231	RERE	-0.72	-8.99	-0.5	6.8e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs4886920	0.638	rs4886919	chr15:78107164	A/G	cg10461261	chr15:78109450	NA	-0.32	-5.15	-0.31	5.22e-7	Neuroticism;
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg01763666	chr17:80159506	CCDC57	-0.38	-5.17	-0.31	4.82e-7	Life satisfaction;
KIRP	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs4302748	0.647	rs12540878	chr7:36192694	C/G	cg24442661	chr7:36192818	EEPD1	0.67	7.46	0.43	1.47e-12	Platelet count;
KIRP	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg05335186	chr13:53173507	NA	0.36	5.42	0.33	1.4e-7	Lewy body disease;
KIRP	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg00919237	chr7:87102261	ABCB4	0.76	9.61	0.52	8.91e-19	Gallbladder cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15806313	chr20:48330624	B4GALT5	-0.5	-6.22	-0.37	2.18e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.35	-4.92	-0.3	1.55e-6	Motion sickness;
KIRP	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg03877680	chr5:178157825	ZNF354A	1.02	13.44	0.65	3.13e-31	Neutrophil percentage of white cells;
KIRP	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg00806126	chr19:22604979	ZNF98	0.68	7.16	0.42	9.34e-12	Pain;
KIRP	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.3	-0.47	6.97e-15	Retinal vascular caliber;
KIRP	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg08923054	chr8:41654455	ANK1	0.74	7.96	0.45	6.16e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4356975	0.563	rs4478248	chr4:69947216	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.1	-0.36	4e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.66	-9.01	-0.5	5.91e-17	Non-obstructive azoospermia;
KIRP	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg17691542	chr6:26056736	HIST1H1C	-0.4	-5.08	-0.31	7.58e-7	Schizophrenia;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs258892	0.894	rs155435	chr5:72200093	G/A	cg21869765	chr5:72125136	TNPO1	0.58	6.39	0.38	8.43e-10	Small cell lung carcinoma;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg14664628	chr15:75095509	CSK	-0.65	-7.93	-0.45	7.9e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs12693043	0.727	rs2163236	chr2:175431707	C/G	cg11778734	chr2:175439522	WIPF1	-0.58	-8.25	-0.47	9.84e-15	Urate levels (BMI interaction);
KIRP	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg24375607	chr4:120327624	NA	-0.57	-6.63	-0.39	2.15e-10	Corneal astigmatism;
KIRP	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.65	-7.22	-0.42	6.45e-12	Multiple sclerosis;
KIRP	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19171272	chr22:38449367	NA	-0.55	-7.95	-0.45	6.91e-14	Glioblastoma;Glioma;
KIRP	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	0.38	4.87	0.3	2.02e-6	Type 2 diabetes;
KIRP	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg23992470	chr4:843637	GAK	-0.62	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2279817	0.863	rs871088	chr1:18017558	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.68	9.03	0.5	5.04e-17	Neuroticism;
KIRP	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.66	-4.89	-0.3	1.84e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08048268	chr3:133502702	NA	-0.4	-4.97	-0.3	1.25e-6	Iron status biomarkers;
KIRP	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg01320579	chr17:75405842	SEPT9	0.48	7.81	0.45	1.66e-13	Airflow obstruction;
KIRP	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.77	11.0	0.57	3.76e-23	Menarche (age at onset);
KIRP	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.78	6.54	0.38	3.58e-10	Fat distribution (HIV);
KIRP	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.69	10.02	0.54	4.98e-20	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.81	-0.57	1.57e-22	Height;
KIRP	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.44	-7.21	-0.42	6.93e-12	Superior crus of antihelix expression;
KIRP	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg12160578	chr15:63334699	TPM1	0.65	6.78	0.4	8.67e-11	Orofacial clefts;
KIRP	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg18200150	chr17:30822561	MYO1D	0.49	6.1	0.36	4.08e-9	Schizophrenia;
KIRP	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg04166393	chr7:2884313	GNA12	0.4	5.34	0.32	2.12e-7	Height;
KIRP	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg01879757	chr17:41196368	BRCA1	-0.78	-10.81	-0.57	1.57e-22	Menopause (age at onset);
KIRP	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	0.75	11.04	0.58	2.82e-23	Prudent dietary pattern;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07648498	chr16:89883185	FANCA	0.38	4.85	0.3	2.17e-6	Vitiligo;
KIRP	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg12311346	chr5:56204834	C5orf35	-0.35	-4.92	-0.3	1.56e-6	Coronary artery disease;
KIRP	cis	rs7615316	0.779	rs7652687	chr3:142123276	G/A	cg20824294	chr3:142316082	PLS1	0.24	5.82	0.35	1.81e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.96	16.18	0.72	1.4e-40	Breast cancer;
KIRP	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg04374321	chr14:90722782	PSMC1	-0.61	-8.13	-0.46	2.13e-14	Mortality in heart failure;
KIRP	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg21226059	chr5:178986404	RUFY1	0.45	6.91	0.4	4.22e-11	Lung cancer;
KIRP	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.75	10.88	0.57	9.17e-23	Body mass index;
KIRP	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.91	-11.91	-0.6	3.98e-26	Cognitive function;
KIRP	cis	rs12541635	0.639	rs10095827	chr8:106984403	A/G	cg10147462	chr8:107024639	NA	0.35	5.19	0.31	4.34e-7	Age of smoking initiation;
KIRP	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-1.01	-11.46	-0.59	1.24e-24	Educational attainment;
KIRP	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg17507749	chr15:85114479	UBE2QP1	0.89	9.87	0.53	1.44e-19	Schizophrenia;
KIRP	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	1.12	10.26	0.55	8.5e-21	Lymphocyte counts;
KIRP	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.11	-0.41	1.25e-11	Mood instability;
KIRP	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.58	-6.06	-0.36	5.02e-9	Ulcerative colitis;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg21851534	chr17:3907994	ZZEF1	0.66	10.59	0.56	7.61e-22	Type 2 diabetes;
KIRP	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg18806716	chr10:30721971	MAP3K8	-0.3	-4.95	-0.3	1.41e-6	Inflammatory bowel disease;
KIRP	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.66	7.76	0.44	2.25e-13	Platelet distribution width;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14045486	chr9:78505662	PCSK5	-0.57	-6.26	-0.37	1.68e-9	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14084888	chr8:117777782	UTP23	0.48	6.2	0.37	2.32e-9	Interleukin-4 levels;
KIRP	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.73e-8	Tonsillectomy;
KIRP	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6684514	1.000	rs12117903	chr1:156311165	G/T	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.67e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg26531700	chr6:26746687	NA	-0.46	-6.46	-0.38	5.44e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24549020	chr5:56110836	MAP3K1	0.51	4.9	0.3	1.73e-6	Initial pursuit acceleration;
KIRP	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg18306943	chr3:40428807	ENTPD3	0.45	6.15	0.37	3.11e-9	Renal cell carcinoma;
KIRP	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-10.31	-0.55	5.92e-21	Vitiligo;
KIRP	cis	rs3789045	1.000	rs3789044	chr1:204589101	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.5	-5.0	-0.3	1.07e-6	Educational attainment (college completion);
KIRP	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg10144569	chr3:42726640	KBTBD5	0.5	5.56	0.33	6.86e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-5.39	-0.32	1.67e-7	Aortic root size;
KIRP	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.73	7.47	0.43	1.43e-12	Prostate cancer;
KIRP	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.92	-0.4	3.8e-11	Total body bone mineral density;
KIRP	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.11	-17.89	-0.75	2.04e-46	Homoarginine levels;
KIRP	cis	rs2033732	0.643	rs10101396	chr8:85060125	A/G	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg23307798	chr14:103986281	CKB	0.49	6.6	0.39	2.44e-10	Coronary artery disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14598413	chr17:41561277	DHX8	0.56	6.25	0.37	1.84e-9	Lung cancer in ever smokers;
KIRP	cis	rs10208940	0.920	rs10205573	chr2:68829419	A/T	cg12452813	chr2:68675892	NA	0.45	4.91	0.3	1.64e-6	Urate levels in lean individuals;
KIRP	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg02403541	chr12:121454288	C12orf43	0.5	6.26	0.37	1.67e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg14338887	chr6:42928500	GNMT	0.59	8.91	0.49	1.18e-16	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.41	0.33	1.47e-7	Body mass index;
KIRP	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.56	5.96	0.35	8.92e-9	Neutrophil percentage of white cells;
KIRP	cis	rs57024841	0.819	rs11145948	chr9:139857912	C/T	cg00693599	chr9:139836323	FBXW5	-0.46	-6.07	-0.36	4.91e-9	Beta-trace protein levels;
KIRP	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg22800045	chr5:56110881	MAP3K1	0.8	8.4	0.47	3.53e-15	Initial pursuit acceleration;
KIRP	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg00806126	chr19:22604979	ZNF98	0.63	6.66	0.39	1.79e-10	Pain;
KIRP	cis	rs4692589	0.606	rs11943813	chr4:170938243	T/C	cg19918862	chr4:170955249	NA	0.52	5.67	0.34	4.01e-8	Anxiety disorder;
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg02996583	chr8:142237188	SLC45A4	-0.49	-5.98	-0.36	7.78e-9	Immature fraction of reticulocytes;
KIRP	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg23479056	chr15:41276147	INO80	-0.42	-6.26	-0.37	1.74e-9	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.64	0.44	4.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.47	6.6	0.39	2.55e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg02336718	chr17:17403227	NA	0.35	5.52	0.33	8.71e-8	Total body bone mineral density;
KIRP	cis	rs4851254	0.618	rs7596359	chr2:100665274	T/G	cg17356467	chr2:100759845	AFF3	0.55	5.79	0.35	2.16e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg23682824	chr7:23144976	KLHL7	0.47	5.69	0.34	3.52e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg11846333	chr4:119757529	SEC24D	0.94	5.89	0.35	1.25e-8	Cannabis dependence symptom count;
KIRP	cis	rs7246657	0.551	rs10419174	chr19:37605341	A/G	cg23950597	chr19:37808831	NA	-0.7	-6.08	-0.36	4.56e-9	Coronary artery calcification;
KIRP	cis	rs11264213	1.000	rs11264213	chr1:36283954	A/G	cg27506609	chr1:36549197	TEKT2	0.73	7.14	0.41	1.04e-11	Schizophrenia;
KIRP	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.41	-7.3	-0.42	3.92e-12	Refractive error;
KIRP	trans	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg04702396	chr17:15466718	FAM18B2	0.51	6.58	0.39	2.84e-10	Educational attainment (years of education);
KIRP	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg18944383	chr4:111397179	ENPEP	0.53	9.27	0.51	1.01e-17	Height;
KIRP	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.62	-9.02	-0.5	5.55e-17	Urate levels in overweight individuals;
KIRP	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05601917	chr6:125855416	NA	-0.34	-5.08	-0.31	7.59e-7	Brugada syndrome;
KIRP	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs3789045	1.000	rs12046747	chr1:204593696	G/A	cg18185008	chr1:204589407	LRRN2	-0.67	-7.58	-0.44	7.05e-13	Educational attainment (college completion);
KIRP	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	trans	rs2997105	0.938	rs73203342	chr13:56350466	G/A	cg08528735	chr3:184428879	MAGEF1	0.57	6.19	0.37	2.54e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10433594	chr6:139696771	CITED2	0.53	6.79	0.4	8.2e-11	Parkinson's disease;
KIRP	cis	rs3105593	1.000	rs3848130	chr15:50892111	A/G	cg08437265	chr15:50716283	USP8	0.39	4.94	0.3	1.48e-6	QT interval;
KIRP	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.45	-5.28	-0.32	2.8e-7	Total body bone mineral density;
KIRP	cis	rs7615316	1.000	rs9862919	chr3:142341146	G/A	cg20824294	chr3:142316082	PLS1	0.22	4.93	0.3	1.55e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7809615	0.901	rs6947974	chr7:99156506	G/A	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite ratios;
KIRP	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.41	0.59	1.69e-24	Height;
KIRP	cis	rs911119	1.000	rs2016161	chr20:23621174	G/T	cg16589663	chr20:23618590	CST3	-0.56	-5.98	-0.36	7.72e-9	Chronic kidney disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03009524	chr14:56645829	PELI2	0.39	6.1	0.36	4.2e-9	C-reactive protein;
KIRP	cis	rs7221595	0.825	rs8069643	chr17:3971237	C/T	cg09695851	chr17:3907499	NA	0.59	6.2	0.37	2.37e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg00647317	chr7:50633725	DDC	0.39	5.62	0.34	5.19e-8	Systemic sclerosis;
KIRP	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.41	11.11	0.58	1.7e-23	Prostate cancer;
KIRP	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-6.95	-0.41	3.22e-11	Response to antipsychotic treatment;
KIRP	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.64	-7.61	-0.44	5.86e-13	Menarche (age at onset);
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg11204139	chr17:3907470	NA	0.85	16.24	0.72	8.71e-41	Type 2 diabetes;
KIRP	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.84e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.25e-14	Aortic root size;
KIRP	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-6.2	-0.37	2.38e-9	Bone mineral density;
KIRP	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-6.4	-0.38	7.98e-10	LDL cholesterol levels;
KIRP	cis	rs7617773	0.851	rs13068288	chr3:48331751	A/T	cg11946769	chr3:48343235	NME6	0.72	8.57	0.48	1.18e-15	Coronary artery disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12571005	chr2:202316370	STRADB;TRAK2	-0.57	-6.25	-0.37	1.8e-9	Menopause (age at onset);
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg17441377	chr17:3906640	NA	0.52	7.66	0.44	4.33e-13	Type 2 diabetes;
KIRP	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-5.96	-0.36	8.65e-9	QT interval;
KIRP	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg03474202	chr17:45855739	NA	-0.45	-6.21	-0.37	2.23e-9	IgG glycosylation;
KIRP	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg25173405	chr17:45401733	C17orf57	0.49	6.3	0.37	1.39e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.11	-0.36	3.79e-9	Depression;
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-5.02	-0.31	9.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.66	11.44	0.59	1.4e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg27398637	chr11:122830231	C11orf63	-0.76	-10.01	-0.54	5.11e-20	Menarche (age at onset);
KIRP	cis	rs4400599	0.642	rs4364874	chr1:154167788	C/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-6.07	-0.36	4.72e-9	Platelet distribution width;
KIRP	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg11247378	chr22:39784982	NA	-0.47	-6.05	-0.36	5.41e-9	IgG glycosylation;
KIRP	cis	rs10267417	0.603	rs10260797	chr7:19890181	A/G	cg05791153	chr7:19748676	TWISTNB	0.55	5.07	0.31	7.72e-7	Night sleep phenotypes;
KIRP	cis	rs8084125	1.000	rs7229560	chr18:74955538	C/T	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs7243821	0.672	rs11665320	chr18:52581893	C/T	cg26630735	chr18:52626848	CCDC68	0.49	5.14	0.31	5.68e-7	Chin dimples;
KIRP	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg08499158	chr17:42289980	UBTF	0.52	6.49	0.38	4.64e-10	Total body bone mineral density;
KIRP	cis	rs3762637	1.000	rs7644540	chr3:122210052	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.95	-0.35	9.24e-9	LDL cholesterol levels;
KIRP	cis	rs6960043	0.818	rs4719433	chr7:15065003	A/G	cg19272540	chr7:15055459	NA	-0.21	-6.02	-0.36	6.39e-9	Type 2 diabetes;
KIRP	cis	rs11169552	0.510	rs10876063	chr12:50972085	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-4.91	-0.3	1.68e-6	Colorectal cancer;
KIRP	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg13660082	chr14:53194042	PSMC6	-0.69	-7.19	-0.42	7.91e-12	Alzheimer's disease (late onset);
KIRP	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.12	-0.31	6.23e-7	Vitamin D levels;
KIRP	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-5.06	-0.31	8.4e-7	Obesity-related traits;
KIRP	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg12131826	chr15:77904385	NA	0.42	5.67	0.34	4.07e-8	Type 2 diabetes;
KIRP	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	5.9	0.35	1.17e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.35	-0.32	2.05e-7	Schizophrenia;
KIRP	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg17764715	chr19:33622953	WDR88	-0.58	-4.92	-0.3	1.62e-6	Bone properties (heel);
KIRP	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.62	8.46	0.47	2.49e-15	Obesity-related traits;
KIRP	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg02153340	chr1:155202674	NA	-0.36	-4.93	-0.3	1.52e-6	Serum magnesium levels;
KIRP	cis	rs11170631	0.504	rs12817180	chr12:54035448	A/G	cg23533419	chr12:54090519	NA	-0.34	-5.08	-0.31	7.43e-7	Height;
KIRP	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg23587288	chr2:27483067	SLC30A3	0.59	6.84	0.4	6.18e-11	Blood metabolite levels;
KIRP	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07167872	chr1:205819463	PM20D1	-0.42	-5.07	-0.31	7.88e-7	Menarche (age at onset);
KIRP	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.8	-9.07	-0.5	4e-17	Diastolic blood pressure;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01995811	chr19:44079904	XRCC1	0.59	6.52	0.38	3.94e-10	Lung cancer in ever smokers;
KIRP	cis	rs2239815	0.515	rs5762839	chr22:29231447	C/T	cg02153584	chr22:29168773	CCDC117	0.58	5.88	0.35	1.35e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	trans	rs7084921	0.579	rs2862947	chr10:101863817	C/G	cg13808641	chr9:96006533	WNK2	-0.44	-6.58	-0.39	2.84e-10	Bone mineral density;
KIRP	cis	rs2562456	0.793	rs2219839	chr19:21516322	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg10189774	chr4:17578691	LAP3	0.48	5.75	0.34	2.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg24253500	chr15:84953950	NA	-0.38	-4.85	-0.3	2.19e-6	P wave terminal force;
KIRP	cis	rs559928	0.502	rs11601686	chr11:64189110	C/T	cg05555928	chr11:63887634	MACROD1	-0.42	-5.02	-0.3	9.79e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg20592017	chr15:40364740	NA	0.34	5.01	0.3	1.04e-6	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs2562456	0.876	rs4638726	chr19:21592512	A/G	cg18461458	chr19:21324796	ZNF431	-0.54	-5.15	-0.31	5.22e-7	Pain;
KIRP	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg13736514	chr6:26305472	NA	-0.45	-4.84	-0.3	2.26e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	1.06	20.02	0.79	1.53e-53	Heart rate;
KIRP	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.33	5.39	0.33	1.64e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg11005552	chr10:105648138	OBFC1	0.4	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19078520	chr2:135676222	CCNT2	0.47	6.04	0.36	5.56e-9	Parkinson's disease;
KIRP	cis	rs2625529	0.617	rs2929509	chr15:72239272	T/C	cg16672083	chr15:72433130	SENP8	0.43	6.18	0.37	2.67e-9	Red blood cell count;
KIRP	cis	rs11077998	0.967	rs4614761	chr17:80505809	C/T	cg10255544	chr17:80519551	FOXK2	0.49	7.7	0.44	3.4e-13	Reticulocyte fraction of red cells;
KIRP	trans	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg24644049	chr4:85504048	CDS1	1.0	6.89	0.4	4.58e-11	Skin colour saturation;
KIRP	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.24	6.3	0.37	1.33e-9	Crohn's disease;
KIRP	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg10755058	chr3:40428713	ENTPD3	-0.37	-5.29	-0.32	2.7e-7	Renal cell carcinoma;
KIRP	cis	rs2279817	0.820	rs924686	chr1:18027726	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.6	9.68	0.53	5.58e-19	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20563447	chr15:67359289	SMAD3	0.48	6.46	0.38	5.41e-10	Parkinson's disease;
KIRP	cis	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg02972257	chr16:68554789	NA	-0.72	-6.98	-0.41	2.72e-11	Ulcerative colitis;
KIRP	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg00361562	chr2:198649771	BOLL	-0.53	-5.19	-0.31	4.41e-7	Ulcerative colitis;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs7246657	0.722	rs13744	chr19:38077912	C/T	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg00376283	chr12:123451042	ABCB9	0.62	7.21	0.42	6.83e-12	Neutrophil percentage of white cells;
KIRP	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.52	0.38	3.94e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs55962025	0.842	rs363088	chr4:3210330	A/T	cg13731523	chr4:3047190	NA	0.32	4.89	0.3	1.86e-6	Parental longevity (mother's age at death);
KIRP	cis	rs6450176	0.909	rs66872223	chr5:53292730	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.0	-0.57	3.88e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7180079	0.620	rs567065	chr15:64877707	T/G	cg15337035	chr15:64978493	NA	-0.47	-5.18	-0.31	4.65e-7	Monocyte count;
KIRP	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg10223061	chr2:219282414	VIL1	0.28	4.86	0.3	2.14e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.44	-0.33	1.3e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg01529538	chr14:23388837	RBM23	0.41	5.22	0.32	3.8e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.72	8.86	0.49	1.67e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.71	9.45	0.52	2.84e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05347473	chr6:146136440	FBXO30	-0.63	-9.2	-0.51	1.61e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg11814155	chr7:99998594	ZCWPW1	0.55	5.19	0.31	4.32e-7	Platelet count;
KIRP	cis	rs240764	0.817	rs239230	chr6:101105862	C/A	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg09264619	chr17:80180166	NA	-0.51	-5.92	-0.35	1.07e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs4601821	0.823	rs10891546	chr11:113265292	C/T	cg14159747	chr11:113255604	NA	-0.36	-5.28	-0.32	2.85e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg22947322	chr17:47091978	IGF2BP1	-0.4	-5.22	-0.32	3.83e-7	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs1847202	1.000	rs1847202	chr3:72934371	T/C	cg06781948	chr3:72941472	GXYLT2	0.4	5.18	0.31	4.6e-7	Motion sickness;
KIRP	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.61	0.44	5.68e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07897831	chr17:73512512	CASKIN2;TSEN54	0.51	7.53	0.43	9.81e-13	Survival in pancreatic cancer;
KIRP	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg15605315	chr1:45957053	TESK2	-0.53	-6.88	-0.4	4.85e-11	High light scatter reticulocyte count;
KIRP	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.9	10.58	0.56	8.39e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs3857747	0.578	rs10951634	chr7:40386835	A/C	cg00420559	chr7:40367873	C7orf10	-0.43	-6.23	-0.37	1.96e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26036199	chr1:153940256	SLC39A1;CREB3L4	0.5	6.2	0.37	2.43e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12648482	chr13:52768676	THSD1P	0.47	6.1	0.36	4.12e-9	Parkinson's disease;
KIRP	cis	rs6669919	0.553	rs12568639	chr1:211675300	G/A	cg10512769	chr1:211675356	NA	-0.78	-11.34	-0.59	2.87e-24	Intelligence (multi-trait analysis);
KIRP	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	13.09	0.64	4.43e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.79	12.73	0.63	7.66e-29	Prostate cancer;
KIRP	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg00405596	chr8:11794950	NA	-0.49	-6.31	-0.37	1.26e-9	Neuroticism;
KIRP	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg21395723	chr22:39101663	GTPBP1	0.47	6.37	0.38	9e-10	Menopause (age at onset);
KIRP	cis	rs3821902	0.646	rs17344653	chr3:64015989	C/T	cg09006292	chr3:64049408	NA	-0.52	-5.41	-0.33	1.49e-7	Breast cancer;
KIRP	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	5.34	0.32	2.1e-7	Leprosy;
KIRP	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg01320579	chr17:75405842	SEPT9	0.53	8.48	0.48	2.12e-15	Airflow obstruction;
KIRP	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18364779	chr6:26104403	HIST1H4C	0.39	5.17	0.31	4.92e-7	Schizophrenia;
KIRP	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.63	-6.75	-0.4	1.04e-10	Gut microbiome composition (summer);
KIRP	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.6	0.39	2.45e-10	Educational attainment;
KIRP	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg23920097	chr1:209922102	NA	-0.39	-5.22	-0.32	3.87e-7	Red blood cell count;
KIRP	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.06	-0.46	3.42e-14	Systemic lupus erythematosus;
KIRP	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.59	-6.29	-0.37	1.48e-9	Ulcerative colitis;
KIRP	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg20913747	chr6:44695427	NA	-0.4	-5.09	-0.31	7.26e-7	Total body bone mineral density;
KIRP	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg21401794	chr1:90099060	LRRC8C	0.55	7.2	0.42	7.38e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.55	0.52	1.42e-18	Morning vs. evening chronotype;
KIRP	cis	rs4144743	1.000	rs61312893	chr17:45325023	C/G	cg18085866	chr17:45331354	ITGB3	-0.78	-8.71	-0.49	4.66e-16	Body mass index;
KIRP	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg24579218	chr15:68104479	NA	-0.43	-6.36	-0.38	9.49e-10	Obesity;
KIRP	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.97	13.45	0.65	2.79e-31	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg11641102	chr8:27183873	PTK2B	0.45	5.86	0.35	1.51e-8	Neuroticism;
KIRP	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	6.01	0.36	6.72e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2790457	0.874	rs2790446	chr10:28801030	A/G	cg05705492	chr10:28955341	NA	-0.53	-7.81	-0.45	1.63e-13	Multiple myeloma;
KIRP	cis	rs911119	0.913	rs4815222	chr20:23576964	A/G	cg16589663	chr20:23618590	CST3	-0.49	-4.96	-0.3	1.3e-6	Chronic kidney disease;
KIRP	cis	rs7737355	0.738	rs7734666	chr5:130861456	A/G	cg06307176	chr5:131281290	NA	0.42	5.0	0.3	1.09e-6	Life satisfaction;
KIRP	cis	rs6988636	0.710	rs73339626	chr8:124142757	A/G	cg23067535	chr8:124195133	FAM83A	-0.66	-5.55	-0.33	7.38e-8	Urinary uromodulin levels;
KIRP	cis	rs9653442	0.527	rs10185059	chr2:100790172	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.1	-0.31	6.76e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.24	-0.51	1.24e-17	Aortic root size;
KIRP	trans	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-6.07	-0.36	4.83e-9	Endometrial cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12690929	chr4:115287672	NA	-0.37	-6.03	-0.36	5.92e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg12615879	chr12:58013172	SLC26A10	0.36	5.41	0.33	1.47e-7	Multiple sclerosis;
KIRP	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.9	6.8	0.4	8.03e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg23307798	chr14:103986281	CKB	0.52	7.46	0.43	1.51e-12	Body mass index;
KIRP	cis	rs7520050	0.902	rs9429088	chr1:46497500	T/A	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.76e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg06637938	chr14:75390232	RPS6KL1	0.49	6.91	0.4	4.13e-11	Caffeine consumption;
KIRP	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg26331595	chr3:39149181	GORASP1;TTC21A	0.44	4.99	0.3	1.15e-6	Handedness;
KIRP	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	0.86	7.15	0.41	9.71e-12	Mean corpuscular volume;
KIRP	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg24253500	chr15:84953950	NA	0.51	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	0.87	9.21	0.51	1.46e-17	Methadone dose in opioid dependence;
KIRP	cis	rs28834970	0.928	rs17057043	chr8:27220310	C/T	cg23693289	chr8:27183097	PTK2B	-0.44	-5.54	-0.33	7.89e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.79	-7.39	-0.43	2.29e-12	Coronary artery calcification;
KIRP	cis	rs7180079	0.620	rs588379	chr15:64892133	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs920590	1.000	rs920590	chr8:19651161	A/G	cg03894339	chr8:19674705	INTS10	0.46	5.79	0.35	2.17e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg05973401	chr12:123451056	ABCB9	0.54	5.89	0.35	1.26e-8	Neutrophil percentage of white cells;
KIRP	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.4	-0.33	1.56e-7	Autism;
KIRP	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18503615	chr14:75760948	NA	0.49	6.05	0.36	5.29e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.89e-16	Life satisfaction;
KIRP	cis	rs8014252	0.803	rs74062733	chr14:70995394	A/G	cg11204974	chr14:71022665	NA	-0.75	-7.43	-0.43	1.83e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.81	11.27	0.58	5.0600000000000004e-24	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.06	-0.36	5.11e-9	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg11608241	chr8:8085544	FLJ10661	0.5	6.33	0.37	1.18e-9	Systolic blood pressure;
KIRP	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg15445000	chr17:37608096	MED1	0.47	5.52	0.33	8.69e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs9547996	0.885	rs9547991	chr13:38217415	A/G	cg13634560	chr13:38173852	POSTN	-0.35	-5.04	-0.31	8.86e-7	Diastolic blood pressure;
KIRP	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.78	9.64	0.52	7.28e-19	Blood trace element (Cu levels);
KIRP	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.46	5.97	0.36	8.46e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.12	-0.64	3.53e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07169764	chr2:136633963	MCM6	-0.55	-6.39	-0.38	8.13e-10	Mosquito bite size;
KIRP	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg01620082	chr3:125678407	NA	-0.95	-6.3	-0.37	1.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.55	7.86	0.45	1.23e-13	Bipolar disorder;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg16259859	chr1:33005001	ZBTB8A	-0.46	-6.11	-0.36	3.87e-9	Colorectal cancer;
KIRP	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg26876637	chr1:152193138	HRNR	0.72	9.72	0.53	4.25e-19	Atopic dermatitis;
KIRP	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.74	-9.07	-0.5	4.02e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17065868	0.881	rs61948000	chr13:45166545	C/T	cg10246903	chr13:45222710	NA	0.71	6.6	0.39	2.56e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9473924	0.632	rs9357678	chr6:50863811	A/G	cg03432817	chr6:50765336	NA	0.35	5.41	0.33	1.52e-7	Body mass index;
KIRP	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.04	-0.31	8.92e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.79	13.14	0.64	3.14e-30	Calcium levels;
KIRP	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.34	-0.32	2.06e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg26513180	chr16:89883248	FANCA	0.72	5.57	0.33	6.59e-8	Skin colour saturation;
KIRP	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.79	0.35	2.1e-8	Monocyte percentage of white cells;
KIRP	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg06634786	chr22:41940651	POLR3H	-0.47	-5.08	-0.31	7.45e-7	Neuroticism;
KIRP	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.69	-7.3	-0.42	3.97e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.07	-0.46	3.04e-14	Joint mobility (Beighton score);
KIRP	cis	rs365132	0.875	rs353479	chr5:176372593	C/T	cg16309518	chr5:176445507	NA	-0.6	-8.73	-0.49	3.96e-16	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg00800038	chr16:89945340	TCF25	-0.73	-5.09	-0.31	7.11e-7	Skin colour saturation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19844325	chr19:18314808	RAB3A	0.52	7.18	0.42	8.35e-12	Survival in pancreatic cancer;
KIRP	cis	rs6725041	0.819	rs10048673	chr2:213083282	A/G	cg20637307	chr2:213403960	ERBB4	-0.41	-5.35	-0.32	1.99e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.24	-0.32	3.51e-7	Height;
KIRP	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.56	7.2	0.42	7.27e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.75	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg16268157	chr7:99778414	STAG3	-0.52	-5.57	-0.33	6.76e-8	Lung function (FEV1/FVC);
KIRP	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.96	11.6	0.59	4.08e-25	Corneal astigmatism;
KIRP	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.56	-6.82	-0.4	6.81e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7084402	0.967	rs1649034	chr10:60279324	G/A	cg05938607	chr10:60274200	BICC1	0.44	10.67	0.56	4.29e-22	Refractive error;
KIRP	cis	rs829883	0.867	rs1641640	chr12:98896017	A/G	cg25150519	chr12:98850993	NA	0.86	12.97	0.64	1.12e-29	Colorectal adenoma (advanced);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21939482	chr7:6388130	C7orf70	0.59	7.25	0.42	5.3e-12	Smoking initiation;
KIRP	cis	rs7301016	1.000	rs10877859	chr12:62873873	G/A	cg01804193	chr12:63026212	NA	0.53	5.36	0.32	1.91e-7	IgG glycosylation;
KIRP	cis	rs7172677	0.508	rs12917120	chr15:75329091	T/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-7.02	-0.41	2.2e-11	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.7	-8.46	-0.47	2.35e-15	Cognitive function;
KIRP	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg17108064	chr15:78857060	CHRNA5	-0.37	-5.43	-0.33	1.37e-7	Sudden cardiac arrest;
KIRP	cis	rs12949688	0.682	rs7503947	chr17:55838518	C/A	cg12582317	chr17:55822272	NA	0.45	6.09	0.36	4.38e-9	Schizophrenia;
KIRP	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs7809615	0.748	rs11973173	chr7:99032399	A/G	cg12290671	chr7:99195819	NA	-0.47	-5.31	-0.32	2.5e-7	Blood metabolite ratios;
KIRP	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg18833306	chr6:118973337	C6orf204	0.42	5.39	0.33	1.63e-7	Electrocardiographic conduction measures;
KIRP	cis	rs6681460	1.000	rs1325263	chr1:67129791	C/A	cg13052034	chr1:66999238	SGIP1	0.43	5.93	0.35	1.04e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg09699651	chr6:150184138	LRP11	0.47	6.35	0.38	1.03e-9	Lung cancer;
KIRP	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.38	3.82e-10	Vitiligo;
KIRP	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21643547	chr1:205240462	TMCC2	-0.83	-12.75	-0.63	6.29e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7572644	0.699	rs7593127	chr2:28258027	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10053473	chr17:62856997	LRRC37A3	0.69	7.48	0.43	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.4e-12	Bipolar disorder;
KIRP	trans	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg25288420	chr1:78511713	GIPC2	-0.51	-6.71	-0.39	1.35e-10	Obesity-related traits;
KIRP	cis	rs963731	0.649	rs6544183	chr2:39186339	C/T	cg04010122	chr2:39346883	SOS1	-0.78	-5.29	-0.32	2.71e-7	Corticobasal degeneration;
KIRP	cis	rs897080	0.552	rs1067318	chr2:44634509	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.95	0.35	8.95e-9	Height;
KIRP	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	10.22	0.55	1.13e-20	Blood protein levels;
KIRP	trans	rs800082	0.668	rs7643301	chr3:144293612	G/A	cg24215973	chr2:240111563	HDAC4	-0.57	-7.76	-0.44	2.29e-13	Smoking behavior;
KIRP	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.06	19.08	0.77	2.08e-50	Triglycerides;
KIRP	cis	rs7075426	0.669	rs10887608	chr10:88191938	A/G	cg07322936	chr10:88137208	NA	-0.52	-5.74	-0.34	2.77e-8	Migraine without aura;
KIRP	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.46	5.96	0.36	8.6e-9	Blood protein levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05539622	chr2:73298971	SFXN5	-0.54	-6.16	-0.37	3.02e-9	Menopause (age at onset);
KIRP	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	8.94	0.5	9.37e-17	Eosinophil percentage of white cells;
KIRP	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg09873164	chr1:152488093	CRCT1	-0.57	-7.28	-0.42	4.42e-12	Hair morphology;
KIRP	cis	rs580438	0.510	rs4684927	chr3:13371636	A/G	cg10657019	chr3:13328039	NA	-0.57	-7.66	-0.44	4.23e-13	Myringotomy;
KIRP	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.59	9.8	0.53	2.31e-19	Total body bone mineral density;
KIRP	cis	rs13223928	0.572	rs12538887	chr7:3134821	G/A	cg19214707	chr7:3157722	NA	-0.69	-8.92	-0.49	1.05e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	trans	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.44e-12	Bladder cancer;
KIRP	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.58	-0.8	2.03e-55	Height;
KIRP	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-1.06	-11.04	-0.58	2.85e-23	Blood protein levels;
KIRP	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg00405596	chr8:11794950	NA	-0.56	-7.89	-0.45	1.01e-13	Monocyte count;
KIRP	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg05085585	chr16:30420623	ZNF771	0.35	4.93	0.3	1.54e-6	Tonsillectomy;
KIRP	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg09597638	chr17:3907349	NA	0.51	5.13	0.31	5.77e-7	Type 2 diabetes;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22618164	chr12:122356400	WDR66	-0.61	-8.59	-0.48	1e-15	Mean corpuscular volume;
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg13206674	chr6:150067644	NUP43	0.62	8.97	0.5	7.63e-17	Lung cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14572436	chr9:6328010	TPD52L3	-0.46	-6.84	-0.4	6.17e-11	Inflammatory biomarkers;
KIRP	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.63	0.48	7.63e-16	Morning vs. evening chronotype;
KIRP	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg11262906	chr1:85462892	MCOLN2	-0.59	-6.74	-0.39	1.14e-10	Serum sulfate level;
KIRP	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg00806126	chr19:22604979	ZNF98	0.68	7.14	0.41	1.07e-11	Pain;
KIRP	cis	rs4748857	0.891	rs4747456	chr10:23571136	A/T	cg12804278	chr10:23633326	C10orf67	0.43	5.34	0.32	2.1e-7	Systemic lupus erythematosus;
KIRP	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg18944383	chr4:111397179	ENPEP	0.68	12.19	0.61	4.55e-27	Coronary artery disease;
KIRP	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg11235152	chr1:67600687	NA	-0.45	-6.3	-0.37	1.4e-9	Psoriasis;
KIRP	cis	rs1629083	0.875	rs1626649	chr11:118071097	T/C	cg18857871	chr11:118064634	AMICA1	0.69	9.82	0.53	2.01e-19	Lung cancer;
KIRP	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg00982548	chr2:198649783	BOLL	-0.53	-4.95	-0.3	1.41e-6	Ulcerative colitis;
KIRP	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	trans	rs10772939	0.574	rs10734896	chr12:16600256	C/T	cg20863947	chr2:120124202	DBI;C2orf76	-0.51	-6.23	-0.37	2.02e-9	Economic and political preferences;
KIRP	cis	rs11264213	0.786	rs72659696	chr1:36313665	G/A	cg27506609	chr1:36549197	TEKT2	0.98	5.49	0.33	1e-7	Schizophrenia;
KIRP	cis	rs9815354	0.680	rs73073274	chr3:42022810	T/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.58	7.21	0.42	6.86e-12	Renal function-related traits (BUN);
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.74	0.44	2.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-0.95	-12.12	-0.61	8.2e-27	Blood protein levels;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg00024416	chr22:24240387	NA	0.41	6.02	0.36	6.17e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	1.1	14.81	0.69	6.35e-36	IgG glycosylation;
KIRP	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.46	5.5	0.33	9.65e-8	Airway imaging phenotypes;
KIRP	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg11382394	chr1:2564504	MMEL1	0.38	4.88	0.3	1.89e-6	Ulcerative colitis;
KIRP	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25517755	chr10:38738941	LOC399744	-0.52	-7.1	-0.41	1.36e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3112255	0.935	rs4851365	chr2:101291137	C/T	cg01042948	chr2:101319752	NA	-0.43	-6.23	-0.37	2.02e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6142102	1.000	rs2143230	chr20:32724345	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	6.4	0.38	7.99e-10	Skin pigmentation;
KIRP	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.67e-19	Prudent dietary pattern;
KIRP	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.52	-0.33	8.73e-8	Neutrophil percentage of white cells;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.75	11.77	0.6	1.16e-25	Longevity;Endometriosis;
KIRP	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.05	-0.31	8.52e-7	Educational attainment (years of education);
KIRP	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg02811702	chr13:24901961	NA	0.43	5.72	0.34	3.09e-8	Obesity-related traits;
KIRP	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg07395648	chr5:131743802	NA	-0.6	-8.35	-0.47	5.15e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.42	-0.33	1.44e-7	Schizophrenia;
KIRP	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg00982548	chr2:198649783	BOLL	-0.55	-5.04	-0.31	9.05e-7	Ulcerative colitis;
KIRP	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1440410	0.835	rs13121583	chr4:144070585	T/C	cg19876092	chr4:144208277	NA	0.29	4.85	0.3	2.15e-6	Ischemic stroke;
KIRP	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg13736514	chr6:26305472	NA	-0.46	-5.08	-0.31	7.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg23594656	chr7:65796392	TPST1	-0.34	-4.95	-0.3	1.39e-6	Aortic root size;
KIRP	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.56	-6.62	-0.39	2.24e-10	Axial length;
KIRP	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg03060546	chr3:49711283	APEH	-0.75	-5.6	-0.34	5.8e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-1.06	-14.82	-0.69	5.92e-36	Alopecia areata;
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.42	5.46	0.33	1.16e-7	Cardiovascular disease risk factors;
KIRP	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.84	9.96	0.54	7.36e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10267417	0.535	rs6960731	chr7:19869379	C/G	cg05791153	chr7:19748676	TWISTNB	-0.53	-4.97	-0.3	1.28e-6	Night sleep phenotypes;
KIRP	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.81	-12.93	-0.64	1.58e-29	Monocyte percentage of white cells;
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg19723775	chr5:179050963	HNRNPH1	0.44	5.01	0.3	1.06e-6	Lung cancer;
KIRP	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.84	11.05	0.58	2.68e-23	Monocyte count;
KIRP	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg13160058	chr8:26243215	BNIP3L	-0.51	-6.93	-0.4	3.63e-11	Red cell distribution width;
KIRP	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.44	-11.05	-0.58	2.66e-23	Diabetic kidney disease;
KIRP	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.41e-9	Aortic root size;
KIRP	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.91	8.67	0.48	6.05e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs72772090	0.539	rs72775817	chr5:96190709	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.44	2.78e-13	Neuroticism;
KIRP	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.23	-0.32	3.64e-7	Schizophrenia;
KIRP	cis	rs2929278	0.588	rs1975364	chr15:44150189	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	5.71	0.34	3.21e-8	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg13147721	chr7:65941812	NA	-1.01	-7.0	-0.41	2.46e-11	Diabetic kidney disease;
KIRP	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.47	-5.79	-0.35	2.15e-8	Resistin levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00993799	chr7:104653126	LOC100216545	0.91	6.4	0.38	7.9e-10	P wave terminal force;
KIRP	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg27205649	chr11:78285834	NARS2	-0.55	-5.09	-0.31	7.06e-7	Testicular germ cell tumor;
KIRP	cis	rs300890	0.513	rs4269133	chr4:144046845	C/G	cg01719995	chr4:144104893	USP38	0.44	5.66	0.34	4.31e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg11833968	chr6:79620685	NA	0.51	7.66	0.44	4.26e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.61	8.75	0.49	3.57e-16	Resting heart rate;
KIRP	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs3748682	0.861	rs72661832	chr1:38260733	C/T	cg12658694	chr1:38397304	INPP5B	0.52	5.68	0.34	3.74e-8	Hypothyroidism;
KIRP	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.71	-8.45	-0.47	2.64e-15	Blood metabolite levels;
KIRP	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	0.58	6.06	0.36	4.99e-9	Interleukin-17 levels;
KIRP	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg19913688	chr11:428466	ANO9	-0.73	-5.68	-0.34	3.78e-8	Body mass index;
KIRP	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg07424592	chr7:64974309	NA	0.75	4.93	0.3	1.51e-6	Diabetic kidney disease;
KIRP	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg13906792	chr15:75199810	C15orf17	-0.37	-5.61	-0.34	5.35e-8	Breast cancer;
KIRP	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg25319279	chr11:5960081	NA	-0.53	-5.86	-0.35	1.46e-8	DNA methylation (variation);
KIRP	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Schizophrenia;
KIRP	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.64	8.66	0.48	6.3e-16	Prostate cancer;
KIRP	cis	rs6499255	1.000	rs4580150	chr16:69814953	G/A	cg15192750	chr16:69999425	NA	0.46	4.86	0.3	2.1e-6	IgE levels;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.82	8.43	0.47	2.89e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14751398	chr6:20402153	E2F3	0.52	6.18	0.37	2.59e-9	Smoking initiation;
KIRP	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.71	0.39	1.29e-10	Height;
KIRP	cis	rs6684514	1.000	rs12118238	chr1:156235221	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-5.86	-0.35	1.51e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01132139	chr11:76091836	PRKRIR	-0.47	-7.01	-0.41	2.29e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4692589	1.000	rs12643956	chr4:170932819	A/C	cg19918862	chr4:170955249	NA	0.48	5.84	0.35	1.64e-8	Anxiety disorder;
KIRP	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.57	7.28	0.42	4.42e-12	Schizophrenia;
KIRP	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.86	10.6	0.56	6.96e-22	Homoarginine levels;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg20958497	chr19:18058885	NA	0.54	6.14	0.36	3.22e-9	Electroencephalogram traits;
KIRP	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg06417478	chr19:12876846	HOOK2	0.4	4.93	0.3	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
KIRP	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.96	12.53	0.62	3.49e-28	Platelet distribution width;
KIRP	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.16	-0.37	2.94e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg04369109	chr6:150039330	LATS1	-0.5	-6.44	-0.38	6.26e-10	Lung cancer;
KIRP	cis	rs4414128	0.725	rs45451594	chr10:5658757	G/A	cg12223502	chr10:5658492	NA	0.51	5.45	0.33	1.24e-7	Breast cancer;
KIRP	trans	rs76288851	0.799	rs56031528	chr3:126676545	C/T	cg13821433	chr2:26726535	OTOF	0.58	6.45	0.38	6.03e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg04037228	chr3:45636386	LIMD1	0.35	5.22	0.32	3.83e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg12560992	chr17:57184187	TRIM37	0.55	5.13	0.31	5.81e-7	Cognitive test performance;
KIRP	cis	rs631288	0.557	rs6697092	chr1:146659277	C/G	cg25205988	chr1:146714368	CHD1L	1.02	6.08	0.36	4.57e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg07701084	chr6:150067640	NUP43	0.59	7.61	0.44	5.96e-13	Lung cancer;
KIRP	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.8	10.73	0.56	2.76e-22	Height;
KIRP	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg17986701	chr20:44574422	PCIF1	0.47	7.33	0.42	3.36e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg26221568	chr5:50259444	NA	0.51	6.72	0.39	1.24e-10	Inflammatory biomarkers;
KIRP	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-6.53	-0.38	3.77e-10	Type 2 diabetes;
KIRP	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg09579323	chr1:150459698	TARS2	0.4	5.07	0.31	7.86e-7	Migraine;
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg21523564	chr15:75251491	NA	0.4	6.51	0.38	4.26e-10	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14393609	chr7:65229607	NA	0.47	6.37	0.38	9.11e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.49	-0.43	1.2e-12	Body mass index;
KIRP	cis	rs7903847	0.642	rs11189177	chr10:99141663	C/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.4	-5.12	-0.31	6.14e-7	IgG glycosylation;
KIRP	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg05072774	chr3:49840536	C3orf54	0.43	5.57	0.33	6.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg10117171	chr1:25599238	RHD	0.38	5.21	0.32	4.01e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs2119480	0.963	rs9515267	chr13:111332848	C/T	cg24331049	chr13:111365604	ING1	0.45	5.4	0.33	1.54e-7	Diastolic blood pressure;
KIRP	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.65	8.92	0.49	1.09e-16	Longevity;
KIRP	cis	rs10267417	0.603	rs10242620	chr7:19897885	G/T	cg05791153	chr7:19748676	TWISTNB	0.55	5.07	0.31	7.72e-7	Night sleep phenotypes;
KIRP	cis	rs1838105	0.674	rs1634260	chr17:45174285	G/A	cg16759221	chr17:45003025	GOSR2	-0.36	-5.3	-0.32	2.55e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg19847130	chr8:10466454	RP1L1	0.38	5.66	0.34	4.18e-8	Retinal vascular caliber;
KIRP	cis	rs2562456	0.833	rs7260065	chr19:21516977	A/G	cg18461458	chr19:21324796	ZNF431	-0.51	-4.93	-0.3	1.49e-6	Pain;
KIRP	cis	rs1829883	0.668	rs10035117	chr5:98989782	G/T	cg08333243	chr5:99726346	NA	0.4	5.24	0.32	3.48e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.44	-5.15	-0.31	5.36e-7	Iron status biomarkers;
KIRP	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.85	15.77	0.71	3.42e-39	Anterior chamber depth;
KIRP	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.57	-6.42	-0.38	6.89e-10	Vitiligo;
KIRP	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.73	10.02	0.54	4.82e-20	Red blood cell count;
KIRP	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg08992911	chr2:238395768	MLPH	0.42	5.2	0.31	4.15e-7	Prostate cancer;
KIRP	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.36	6.58	0.39	2.85e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg10755058	chr3:40428713	ENTPD3	0.45	6.34	0.38	1.06e-9	Renal cell carcinoma;
KIRP	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.66	-8.3	-0.47	6.82e-15	Facial morphology (factor 23);
KIRP	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21014159	chr11:117668035	DSCAML1	0.43	5.44	0.33	1.26e-7	Myopia;
KIRP	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.81	10.96	0.57	5.23e-23	Morning vs. evening chronotype;
KIRP	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg04865290	chr3:52927548	TMEM110	-0.57	-7.36	-0.42	2.7e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg25338242	chr13:114786047	RASA3	0.41	4.94	0.3	1.42e-6	Schizophrenia;
KIRP	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.73	0.34	2.93e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12995491	0.933	rs34366691	chr2:88537451	G/A	cg04511125	chr2:88470314	THNSL2	-0.44	-5.5	-0.33	9.64e-8	Response to metformin (IC50);
KIRP	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	9.99	0.54	5.85e-20	Lung cancer in ever smokers;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg24846343	chr22:24311635	DDTL	-0.46	-4.97	-0.3	1.24e-6	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.71	0.39	1.3e-10	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24879426	chr3:49449864	RHOA;TCTA	0.52	6.52	0.38	4.02e-10	Parkinson's disease;
KIRP	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg16434002	chr17:42200994	HDAC5	0.46	5.83	0.35	1.77e-8	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.86	11.35	0.59	2.73e-24	Selective IgA deficiency;
KIRP	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-1.08	-19.28	-0.78	4.16e-51	Migraine;
KIRP	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.64	9.3	0.51	8.11e-18	Lewy body disease;
KIRP	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.52	7.44	0.43	1.7e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.58	9.48	0.52	2.2e-18	Schizophrenia;
KIRP	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.89	15.6	0.71	1.3e-38	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.43	-6.04	-0.36	5.78e-9	Ovarian reserve;
KIRP	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg05156742	chr15:59063176	FAM63B	0.58	7.32	0.42	3.58e-12	Schizophrenia;
KIRP	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg00310523	chr12:86230176	RASSF9	-0.4	-6.06	-0.36	5.19e-9	Major depressive disorder;
KIRP	cis	rs17428704	0.571	rs10866506	chr5:14377919	A/G	cg26595256	chr5:14380529	TRIO	0.88	6.98	0.41	2.75e-11	Electroencephalogram traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19238531	chr2:136875144	CXCR4	0.49	6.55	0.39	3.34e-10	Parkinson's disease;
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.71	9.64	0.52	7.14e-19	Longevity;
KIRP	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg16141378	chr3:129829833	LOC729375	-0.59	-7.8	-0.45	1.72e-13	Mood instability;
KIRP	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.77	7.93	0.45	7.57e-14	White matter hyperintensity burden;
KIRP	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.63	-8.72	-0.49	4.13e-16	Autism;
KIRP	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg08514558	chr10:81106712	PPIF	0.38	5.15	0.31	5.23e-7	Height;
KIRP	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg03388025	chr16:89894329	SPIRE2	0.31	5.63	0.34	4.95e-8	Vitiligo;
KIRP	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.52	-7.63	-0.44	5.27e-13	Aortic root size;
KIRP	cis	rs6708331	0.540	rs28623550	chr2:70366392	T/C	cg05298696	chr2:70188691	ASPRV1	-0.41	-5.52	-0.33	8.39e-8	Obesity-related traits;
KIRP	cis	rs4073054	0.512	rs4656993	chr1:161176137	A/G	cg04436964	chr1:161167745	NDUFS2;ADAMTS4	-0.32	-5.18	-0.31	4.61e-7	Blood metabolite levels;
KIRP	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg13628971	chr7:2884303	GNA12	0.39	5.14	0.31	5.55e-7	Height;
KIRP	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.46	-5.88	-0.35	1.34e-8	Schizophrenia;
KIRP	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg15655495	chr12:38532458	NA	0.27	5.04	0.31	8.89e-7	Bladder cancer;
KIRP	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.58	-6.71	-0.39	1.33e-10	Red cell distribution width;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.61	0.34	5.52e-8	Lung cancer;
KIRP	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.44	-5.64	-0.34	4.77e-8	Personality dimensions;
KIRP	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg07148914	chr20:33460835	GGT7	-0.53	-7.0	-0.41	2.46e-11	Height;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22168489	chr12:122356033	WDR66	0.68	10.23	0.55	1.05e-20	Mean corpuscular volume;
KIRP	cis	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg08997352	chr12:9597637	DDX12	-0.7	-8.73	-0.49	4.06e-16	Breast size;
KIRP	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg26065057	chr18:74961000	GALR1	0.54	5.86	0.35	1.46e-8	Obesity-related traits;
KIRP	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs2882667	0.858	rs11242448	chr5:138443154	C/A	cg04439458	chr5:138467593	SIL1	-0.54	-7.95	-0.45	6.9e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7709377	0.570	rs10065554	chr5:115426746	T/C	cg23108291	chr5:115420582	COMMD10	0.41	4.98	0.3	1.22e-6	Metabolite levels  (X-11787);
KIRP	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.62	8.38	0.47	4.15e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.55	0.33	7.25e-8	Coronary artery disease;
KIRP	cis	rs1538970	0.924	rs1007858	chr1:45912005	C/T	cg03146154	chr1:46216737	IPP	0.47	4.85	0.3	2.18e-6	Platelet count;
KIRP	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.6	6.77	0.4	9.32e-11	Monocyte percentage of white cells;
KIRP	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.27	-5.6	-0.34	5.73e-8	Menarche (age at onset);
KIRP	cis	rs3857067	0.806	rs7676797	chr4:95099194	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.04	-0.36	5.52e-9	QT interval;
KIRP	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.74	0.39	1.13e-10	Height;
KIRP	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-6.43	-0.38	6.76e-10	Obesity-related traits;
KIRP	cis	rs6681460	0.901	rs1373911	chr1:67041065	T/C	cg02459107	chr1:67143332	SGIP1	0.42	5.94	0.35	9.78e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.15	-16.0	-0.71	5.48e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg18261050	chr1:119551319	NA	0.5	6.48	0.38	4.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11987759	chr7:65425863	GUSB	0.48	6.11	0.36	3.9e-9	Aortic root size;
KIRP	trans	rs2997105	0.941	rs2997098	chr13:56413673	A/T	cg08528735	chr3:184428879	MAGEF1	-0.59	-6.03	-0.36	6.02e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg25547332	chr5:131281432	NA	0.51	5.63	0.34	4.88e-8	Life satisfaction;
KIRP	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg03929089	chr4:120376271	NA	-0.69	-8.56	-0.48	1.21e-15	Height;
KIRP	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.69	-0.34	3.53e-8	Parkinson's disease;
KIRP	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.83	11.67	0.6	2.46e-25	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.57	0.39	2.96e-10	Renal cell carcinoma;
KIRP	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg01304814	chr3:48885189	PRKAR2A	0.72	4.93	0.3	1.49e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg25233709	chr10:116636983	FAM160B1	0.35	5.36	0.32	1.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2033908	0.620	rs10765996	chr11:12853043	A/G	cg25843174	chr11:12811716	TEAD1	-0.29	-5.43	-0.33	1.35e-7	Sitting height ratio;
KIRP	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.48	-5.2	-0.31	4.26e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg02023728	chr11:77925099	USP35	-0.3	-5.28	-0.32	2.85e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.2e-24	Cognitive test performance;
KIRP	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.66	9.07	0.5	3.99e-17	Systemic lupus erythematosus;
KIRP	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg23161317	chr6:28129485	ZNF389	0.39	4.87	0.3	1.98e-6	Cardiac Troponin-T levels;
KIRP	cis	rs12210905	0.688	rs114157955	chr6:27329878	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg26134248	chr17:3907702	NA	0.58	8.79	0.49	2.59e-16	Type 2 diabetes;
KIRP	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg01631408	chr1:248437212	OR2T33	-0.48	-6.52	-0.38	3.99e-10	Common traits (Other);
KIRP	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.78	7.2	0.42	7.12e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.77	-10.29	-0.55	7.1e-21	Adiposity;
KIRP	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg03834567	chr2:218808745	TNS1	0.47	5.73	0.34	2.96e-8	Ulcerative colitis;
KIRP	cis	rs882732	1.000	rs8019677	chr14:95040431	C/T	cg05186455	chr14:95027692	SERPINA4	-0.4	-5.37	-0.32	1.83e-7	Blood protein levels;
KIRP	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg05973401	chr12:123451056	ABCB9	0.62	7.23	0.42	5.98e-12	Platelet count;
KIRP	cis	rs4728302	0.838	rs13231095	chr7:133604436	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.61	0.34	5.51e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.28	11.96	0.61	2.77e-26	Alzheimer's disease (late onset);
KIRP	trans	rs909341	0.716	rs71325463	chr20:62362834	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.95	-0.41	3.34e-11	Atopic dermatitis;
KIRP	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.21	-0.42	7.07e-12	Chronic sinus infection;
KIRP	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-0.84	-7.87	-0.45	1.11e-13	Opioid sensitivity;
KIRP	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg00405596	chr8:11794950	NA	-0.52	-6.91	-0.4	4.14e-11	Retinal vascular caliber;
KIRP	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg24009623	chr19:33667908	NA	0.45	5.41	0.33	1.48e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.39	-0.32	1.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08413565	chr3:129035733	H1FX;C3orf47	0.63	6.14	0.36	3.24e-9	Lung function (FEV1);
KIRP	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg18306943	chr3:40428807	ENTPD3	0.42	5.9	0.35	1.2e-8	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05698098	chr11:61595494	FADS2	0.44	6.24	0.37	1.87e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg05347473	chr6:146136440	FBXO30	0.56	8.03	0.46	4.11e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7539542	0.556	rs10753928	chr1:202891045	A/C	cg08940984	chr1:202857613	RABIF	-0.44	-5.25	-0.32	3.3e-7	Mean platelet volume;
KIRP	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg16898833	chr6:26189333	HIST1H4D	0.74	5.34	0.32	2.11e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.49	-5.16	-0.31	4.97e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs71386933	0.543	rs36114735	chr16:72017683	C/T	cg08717414	chr16:71523259	ZNF19	-0.75	-4.97	-0.3	1.25e-6	Post bronchodilator FEV1;
KIRP	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.84	-10.54	-0.56	1.12e-21	Vitamin D levels;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg10254082	chr7:997346	NA	0.46	4.88	0.3	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	13.42	0.65	3.43e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7546668	1.000	rs9298	chr1:15897020	C/T	cg21858823	chr1:15850916	CASP9	0.48	5.22	0.32	3.79e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg15839431	chr19:19639596	YJEFN3	0.48	5.21	0.32	3.93e-7	Bipolar disorder;
KIRP	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg15488143	chr7:128924101	AHCYL2	0.63	6.99	0.41	2.56e-11	White matter hyperintensity burden;
KIRP	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg06565975	chr8:143823917	SLURP1	-0.43	-6.54	-0.38	3.57e-10	Urinary tract infection frequency;
KIRP	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.59	-7.22	-0.42	6.31e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg24375607	chr4:120327624	NA	0.48	5.61	0.34	5.47e-8	Corneal astigmatism;
KIRP	cis	rs9394841	0.692	rs2395795	chr6:41802354	G/A	cg08135965	chr6:41755394	TOMM6	0.52	5.55	0.33	7.51e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs1050631	1.000	rs3110564	chr18:33701589	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.52	-6.45	-0.38	5.99e-10	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg12463550	chr7:65579703	CRCP	-0.44	-4.95	-0.3	1.41e-6	Aortic root size;
KIRP	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	1.13	16.67	0.73	2.82e-42	Monocyte percentage of white cells;
KIRP	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg19116668	chr7:99932089	PMS2L1	-0.51	-5.82	-0.35	1.86e-8	Coronary artery disease;
KIRP	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.49	6.36	0.38	1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28489187	0.577	rs6697083	chr1:85887775	A/T	cg16011679	chr1:85725395	C1orf52	-0.45	-5.57	-0.33	6.5e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1034435	0.962	rs1894542	chr22:48890335	G/C	cg05992904	chr22:48892994	FAM19A5	-0.69	-9.19	-0.51	1.66e-17	Late-onset Alzheimer's disease;
KIRP	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.82	11.54	0.59	6.63e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.22e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg08738300	chr3:44038990	NA	0.67	9.15	0.5	2.19e-17	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00645628	chr1:101213654	NA	-0.37	-6.06	-0.36	5.21e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.66	6.56	0.39	3.14e-10	Menarche (age at onset);
KIRP	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	8.89	0.49	1.37e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Body mass index;
KIRP	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.35	0.62	1.34e-27	Ileal carcinoids;
KIRP	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg08975724	chr8:8085496	FLJ10661	0.61	8.73	0.49	3.86e-16	Neuroticism;
KIRP	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg05315796	chr3:52349193	DNAH1	0.5	7.71	0.44	3.06e-13	Electroencephalogram traits;
KIRP	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.8	5.29	0.32	2.7e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10214930	0.697	rs4140899	chr7:27625027	G/A	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg22800045	chr5:56110881	MAP3K1	0.74	7.24	0.42	5.56e-12	Initial pursuit acceleration;
KIRP	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.59	-6.46	-0.38	5.56e-10	Menarche (age at onset);
KIRP	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-6.73	-0.39	1.15e-10	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg23985595	chr17:80112537	CCDC57	0.34	5.1	0.31	6.8e-7	Life satisfaction;
KIRP	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-9.92	-0.53	1.01e-19	Coronary artery disease;
KIRP	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.07	-0.36	4.85e-9	Ulcerative colitis;
KIRP	trans	rs7157940	0.692	rs4905163	chr14:94570770	A/G	cg05520288	chr5:34929958	DNAJC21	0.63	7.07	0.41	1.59e-11	Anthropometric traits;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg06452064	chr7:23571393	TRA2A	0.49	6.1	0.36	3.99e-9	Beard thickness;
KIRP	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.77	-0.44	2.18e-13	Type 2 diabetes;
KIRP	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg15893493	chr8:124194847	FAM83A	0.88	6.61	0.39	2.36e-10	Urinary uromodulin levels;
KIRP	cis	rs9308433	0.529	rs904321	chr1:214506550	G/C	cg06198575	chr1:214491504	SMYD2	0.46	5.81	0.35	1.94e-8	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.17	-0.37	2.86e-9	Lung cancer;
KIRP	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.49	-5.99	-0.36	7.33e-9	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.82	0.35	1.78e-8	Lung cancer;
KIRP	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.2	-12.92	-0.64	1.67e-29	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg06937882	chr20:24974362	C20orf3	-0.43	-4.89	-0.3	1.86e-6	Blood protein levels;
KIRP	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs4671400	0.571	rs62152270	chr2:61494260	C/A	cg15711740	chr2:61764176	XPO1	0.62	6.73	0.39	1.2e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs1559777	0.702	rs12440259	chr15:58087011	T/C	cg08140891	chr1:154955627	FLAD1	-0.57	-6.15	-0.37	3.11e-9	Myopia (pathological);
KIRP	cis	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg06521331	chr12:34319734	NA	-0.42	-5.26	-0.32	3.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs7849270	1.000	rs7036236	chr9:131899299	G/A	cg13538475	chr9:131942899	NA	-0.32	-5.14	-0.31	5.72e-7	Blood metabolite ratios;
KIRP	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.35	5.65	0.34	4.34e-8	Menarche (age at onset);
KIRP	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-0.67	-7.81	-0.45	1.65e-13	Bone mineral density;
KIRP	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.83	0.53	1.9e-19	Hip circumference adjusted for BMI;
KIRP	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg23533926	chr12:111358616	MYL2	-0.48	-6.33	-0.37	1.18e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.75	7.63	0.44	5.15e-13	Resting heart rate;
KIRP	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg01304814	chr3:48885189	PRKAR2A	-0.7	-5.69	-0.34	3.68e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg16497661	chr14:103986332	CKB	-0.51	-6.49	-0.38	4.77e-10	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.02	-0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs6832769	1.000	rs473005	chr4:56288125	A/C	cg09317128	chr4:56265301	TMEM165	0.52	6.82	0.4	6.84e-11	Personality dimensions;
KIRP	cis	rs2591576	0.627	rs10077591	chr5:165362010	C/T	cg13976338	chr5:165423657	NA	-0.62	-8.19	-0.46	1.39e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg11859384	chr17:80120422	CCDC57	0.47	5.91	0.35	1.11e-8	Life satisfaction;
KIRP	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.91	14.82	0.69	5.91e-36	Dental caries;
KIRP	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-7.54	-0.43	8.86e-13	Bladder cancer;
KIRP	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.11	0.58	1.6e-23	Smoking behavior;
KIRP	cis	rs6832769	0.961	rs2140077	chr4:56338953	A/G	cg05960024	chr4:56376020	CLOCK	0.7	8.76	0.49	3.26e-16	Personality dimensions;
KIRP	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg22009923	chr11:832065	CD151	-0.34	-4.93	-0.3	1.5e-6	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.05	-0.36	5.32e-9	Lung cancer;
KIRP	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.9	-0.49	1.21e-16	Urate levels in overweight individuals;
KIRP	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.07	-0.5	3.79e-17	Retinal vascular caliber;
KIRP	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.92	-13.48	-0.65	2.22e-31	Coronary artery disease;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg02475777	chr4:1388615	CRIPAK	0.48	6.8	0.4	7.98e-11	Longevity;
KIRP	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-5.79	-0.35	2.11e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-0.64	-8.73	-0.49	3.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg04289385	chr6:36355825	ETV7	0.42	6.62	0.39	2.23e-10	Platelet distribution width;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.42	6.31	0.37	1.32e-9	Lymphocyte counts;
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg00684032	chr4:1343700	KIAA1530	0.52	6.91	0.4	4.01e-11	Longevity;
KIRP	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg03684893	chr10:554711	DIP2C	-0.35	-4.94	-0.3	1.43e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.74	8.99	0.5	6.68e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg08923054	chr8:41654455	ANK1	0.57	5.93	0.35	1.02e-8	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9547996	0.842	rs1028728	chr13:38173816	A/T	cg13634560	chr13:38173852	POSTN	-0.41	-5.6	-0.34	5.73e-8	Diastolic blood pressure;
KIRP	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg06027949	chr8:82754900	SNX16	-0.61	-6.6	-0.39	2.53e-10	Diastolic blood pressure;
KIRP	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg08975724	chr8:8085496	FLJ10661	0.67	8.57	0.48	1.19e-15	Neuroticism;
KIRP	cis	rs58649573	0.509	rs3780683	chr9:126789208	C/T	cg14112217	chr9:126806003	NA	0.36	5.17	0.31	4.79e-7	Post-traumatic stress disorder;
KIRP	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17376030	chr22:41985996	PMM1	0.69	7.13	0.41	1.09e-11	Vitiligo;
KIRP	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.58	-0.43	7.26e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.62	-8.27	-0.47	8.6e-15	Mean corpuscular volume;
KIRP	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.67	-11.0	-0.57	3.73e-23	Lung function (FVC);
KIRP	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg24579218	chr15:68104479	NA	-0.54	-8.52	-0.48	1.66e-15	Restless legs syndrome;
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg13395646	chr4:1353034	KIAA1530	-0.54	-7.25	-0.42	5.49e-12	Obesity-related traits;
KIRP	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg20636351	chr8:55087400	NA	-0.65	-8.0	-0.45	5.03e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.47	5.28	0.32	2.83e-7	Osteoporosis;
KIRP	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.4	4.97	0.3	1.28e-6	Aortic root size;
KIRP	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06544989	chr22:39130855	UNC84B	0.52	9.09	0.5	3.42e-17	Menopause (age at onset);
KIRP	cis	rs112374894	1.000	rs74077915	chr14:89025583	G/A	cg01020840	chr14:89016979	PTPN21	0.81	5.71	0.34	3.26e-8	Prudent dietary pattern;
KIRP	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.85	-0.35	1.56e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg09015484	chr9:96929106	NA	0.85	7.3	0.42	3.92e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1971762	0.527	rs2365343	chr12:54038149	C/T	cg16917193	chr12:54089295	NA	-0.83	-14.82	-0.69	6.3e-36	Height;
KIRP	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg04374321	chr14:90722782	PSMC1	-0.61	-8.22	-0.46	1.2e-14	Mortality in heart failure;
KIRP	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.86	-9.75	-0.53	3.45e-19	Body mass index;
KIRP	cis	rs7301016	1.000	rs10877857	chr12:62872211	C/T	cg01804193	chr12:63026212	NA	0.53	5.36	0.32	1.91e-7	IgG glycosylation;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg05025164	chr4:1340916	KIAA1530	0.46	5.56	0.33	7.18e-8	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13939156	chr17:80058883	NA	-0.47	-7.16	-0.42	9.44e-12	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16681246	chr2:65541310	SPRED2	0.43	6.09	0.36	4.33e-9	Interleukin-4 levels;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg23693289	chr8:27183097	PTK2B	0.58	7.5	0.43	1.18e-12	Neuroticism;
KIRP	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg19197139	chr17:4613644	ARRB2	0.72	7.52	0.43	1.02e-12	Lymphocyte counts;
KIRP	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.26	-0.7	1.84e-37	Gut microbiome composition (summer);
KIRP	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.58	-6.96	-0.41	3.16e-11	Mosquito bite size;
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg09546172	chr21:43933663	SLC37A1	0.5	6.39	0.38	8.15e-10	QT interval;
KIRP	cis	rs2458413	0.542	rs2458412	chr8:105363901	C/G	cg08657449	chr8:105351661	TM7SF4	-0.36	-5.83	-0.35	1.7e-8	Paget's disease;
KIRP	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.48	-0.33	1.04e-7	Aortic root size;
KIRP	cis	rs7178572	0.789	rs4886869	chr15:77799657	A/G	cg12131826	chr15:77904385	NA	0.43	6.21	0.37	2.24e-9	Type 2 diabetes;
KIRP	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg19507638	chr5:93509721	C5orf36	-0.56	-4.91	-0.3	1.68e-6	Diabetic retinopathy;
KIRP	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.21	0.32	3.94e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1440410	0.571	rs10471103	chr4:144033656	T/G	cg01719995	chr4:144104893	USP38	0.46	6.07	0.36	4.92e-9	Ischemic stroke;
KIRP	cis	rs7870753	0.838	rs1057687	chr9:99252464	A/G	cg25260653	chr9:99212216	HABP4	0.55	6.16	0.37	2.9e-9	Height;
KIRP	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.75	-11.0	-0.57	3.62e-23	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06451949	chr17:48942959	NA	0.47	6.19	0.37	2.48e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg01391022	chr12:122360665	WDR66	-0.36	-5.32	-0.32	2.37e-7	Mean corpuscular volume;
KIRP	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg05333889	chr7:157238977	NA	-0.4	-5.56	-0.33	7.09e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs1961637	0.514	rs6436369	chr2:223897917	A/G	cg02552189	chr2:223891284	NA	-0.59	-8.33	-0.47	5.65e-15	Oropharynx cancer;
KIRP	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.5	5.22	0.32	3.88e-7	Subjective well-being;
KIRP	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.42e-9	Menopause (age at onset);
KIRP	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.5	6.5	0.38	4.51e-10	HDL cholesterol levels;
KIRP	cis	rs6723226	0.732	rs6747560	chr2:32784766	T/G	cg02381751	chr2:32503542	YIPF4	0.86	11.03	0.58	2.9e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	7.54	0.43	9.18e-13	Bipolar disorder;
KIRP	cis	rs4704187	0.687	rs6864324	chr5:74497885	C/T	cg03227963	chr5:74354835	NA	-0.4	-5.88	-0.35	1.35e-8	Response to amphetamines;
KIRP	cis	rs10129255	0.518	rs8009594	chr14:107185733	G/T	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.2e-12	Prudent dietary pattern;
KIRP	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.58	-0.48	1.07e-15	Personality dimensions;
KIRP	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.66	-8.23	-0.46	1.11e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1562975	0.681	rs55770064	chr4:109470762	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.43	5.07	0.31	7.93e-7	Height;
KIRP	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg04998671	chr14:104000505	TRMT61A	0.55	6.48	0.38	4.93e-10	Coronary artery disease;
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.8e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01213445	chr15:91537450	PRC1	0.55	7.26	0.42	5.2e-12	Parkinson's disease;
KIRP	cis	rs4702718	0.674	rs6881964	chr5:10687002	A/T	cg14521931	chr5:10832172	NA	0.41	5.42	0.33	1.41e-7	Obesity-related traits;
KIRP	cis	rs12460243	1.000	rs12460243	chr19:8131240	C/T	cg06488775	chr19:8115360	NA	0.51	5.04	0.31	9.14e-7	Neurocognitive impairment in HIV-1 infection (continuous);
KIRP	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg06809458	chr5:150460512	TNIP1	0.48	6.23	0.37	2.01e-9	DNA methylation (variation);
KIRP	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg02336718	chr17:17403227	NA	0.37	5.53	0.33	8.23e-8	Total body bone mineral density;
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg10729496	chr3:10149963	C3orf24	0.55	5.01	0.3	1.04e-6	Alzheimer's disease;
KIRP	cis	rs7017914	0.967	rs34677078	chr8:71617715	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs13361707	0.920	rs2329353	chr5:40748268	A/G	cg01087697	chr5:40835557	RPL37	0.5	5.71	0.34	3.21e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.52	7.1	0.41	1.37e-11	IgG glycosylation;
KIRP	cis	rs3105593	0.933	rs3131597	chr15:50828995	G/A	cg08437265	chr15:50716283	USP8	0.38	5.16	0.31	5e-7	QT interval;
KIRP	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg22077389	chr15:40226273	EIF2AK4	-0.6	-6.14	-0.36	3.22e-9	Response to haloperidol in psychosis;
KIRP	cis	rs55788414	0.932	rs28514797	chr16:81185070	G/A	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.32	-0.47	5.89e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg17706604	chr8:67624734	SGK3	0.51	6.07	0.36	4.78e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg10253484	chr15:75165896	SCAMP2	-0.52	-6.16	-0.37	3e-9	Breast cancer;
KIRP	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg13798912	chr7:905769	UNC84A	0.56	5.64	0.34	4.73e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.66	9.32	0.51	6.79e-18	Mood instability;
KIRP	cis	rs7584330	0.554	rs56881028	chr2:238446678	C/G	cg14458575	chr2:238380390	NA	0.48	5.48	0.33	1.03e-7	Prostate cancer;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg09360458	chr1:14075560	PRDM2	-0.61	-6.71	-0.39	1.36e-10	Response to statin therapy;
KIRP	trans	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg03735916	chr2:200715285	NA	-0.45	-6.04	-0.36	5.63e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6888304	0.589	rs13158282	chr5:31052350	A/G	cg10919204	chr5:31193340	CDH6	-0.38	-5.06	-0.31	8.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7523273	0.565	rs2796239	chr1:207902206	G/A	cg22525895	chr1:207977042	MIR29B2	-0.45	-5.82	-0.35	1.81e-8	Schizophrenia;
KIRP	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-13.22	-0.64	1.73e-30	Blood metabolite levels;
KIRP	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.63	0.34	4.96e-8	Total cholesterol levels;
KIRP	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg10259518	chr2:233765616	NGEF	0.34	4.93	0.3	1.51e-6	Coronary artery disease;
KIRP	cis	rs1298062	0.861	rs2431827	chr19:50994214	C/G	cg11430371	chr19:50961752	MYBPC2	0.36	4.96	0.3	1.33e-6	Age of smoking initiation;
KIRP	cis	rs1152591	0.669	rs2978381	chr14:64766652	T/C	cg21174375	chr14:64681225	SYNE2	0.38	5.06	0.31	8.39e-7	Atrial fibrillation;
KIRP	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg27205649	chr11:78285834	NARS2	0.64	8.42	0.47	3.18e-15	Alzheimer's disease (survival time);
KIRP	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg00405596	chr8:11794950	NA	-0.43	-5.29	-0.32	2.74e-7	Neuroticism;
KIRP	cis	rs253959	0.607	rs712574	chr5:115645582	G/A	cg23108291	chr5:115420582	COMMD10	-0.46	-5.12	-0.31	6.13e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.69	-7.06	-0.41	1.65e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg16898833	chr6:26189333	HIST1H4D	0.84	5.59	0.34	5.9e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7849270	0.851	rs1819381	chr9:131908007	G/A	cg13538475	chr9:131942899	NA	-0.33	-5.34	-0.32	2.11e-7	Blood metabolite ratios;
KIRP	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.81e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-0.83	-9.68	-0.53	5.64e-19	Pulmonary function decline;
KIRP	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg12042659	chr19:58951599	ZNF132	0.51	6.19	0.37	2.46e-9	Uric acid clearance;
KIRP	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-7.89	-0.45	9.74e-14	Bipolar disorder;
KIRP	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.71	-8.11	-0.46	2.34e-14	Adiposity;
KIRP	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.62	9.61	0.52	8.78e-19	Bone mineral density;
KIRP	cis	rs250677	0.522	rs12523526	chr5:148349107	A/C	cg12140854	chr5:148520817	ABLIM3	0.47	5.25	0.32	3.29e-7	Breast cancer;
KIRP	cis	rs8179	0.645	rs6960181	chr7:92277477	C/T	cg15732164	chr7:92237376	CDK6	-0.5	-6.46	-0.38	5.68e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13544758	chr6:35889047	SRPK1	-0.49	-6.96	-0.41	3.08e-11	Metabolic traits;
KIRP	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg17425144	chr1:10567563	PEX14	0.45	7.6	0.44	6.08e-13	Hand grip strength;
KIRP	trans	rs1424233	1.000	rs11646606	chr16:79677233	A/G	cg11120865	chr14:21853037	SUPT16H	0.36	6.03	0.36	6.13e-9	Obesity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25624927	chr3:48936479	SLC25A20	0.49	6.37	0.38	8.97e-10	Parkinson's disease;
KIRP	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.39	-5.17	-0.31	4.96e-7	Body mass index;
KIRP	cis	rs10208940	0.843	rs7608248	chr2:68851403	C/T	cg12452813	chr2:68675892	NA	0.46	5.1	0.31	6.92e-7	Urate levels in lean individuals;
KIRP	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg16898833	chr6:26189333	HIST1H4D	0.77	5.23	0.32	3.67e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18255839	chr2:239335447	ASB1	0.42	5.09	0.31	7.16e-7	Multiple system atrophy;
KIRP	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-1.05	-10.83	-0.57	1.29e-22	Blood protein levels;
KIRP	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.52	-6.35	-0.38	1e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	7.14	0.41	1.03e-11	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg06740227	chr12:86229804	RASSF9	0.4	4.98	0.3	1.21e-6	Major depressive disorder;
KIRP	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs7851660	0.594	rs28703314	chr9:100660145	A/T	cg13688889	chr9:100608707	NA	-0.68	-8.56	-0.48	1.22e-15	Strep throat;
KIRP	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg04398451	chr17:18023971	MYO15A	-0.88	-12.94	-0.64	1.41e-29	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23339899	chr8:145137239	GPAA1	0.54	6.69	0.39	1.49e-10	Parkinson's disease;
KIRP	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06544989	chr22:39130855	UNC84B	0.47	6.99	0.41	2.64e-11	Menopause (age at onset);
KIRP	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.41	-0.47	3.25e-15	Response to antipsychotic treatment;
KIRP	cis	rs6102059	0.572	rs6129631	chr20:39190359	C/T	cg06665391	chr20:39312290	NA	0.4	4.99	0.3	1.17e-6	LDL cholesterol;
KIRP	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.65	9.54	0.52	1.49e-18	Dupuytren's disease;
KIRP	cis	rs6430538	0.621	rs11900331	chr2:135571903	A/T	cg12500956	chr2:135428796	TMEM163	0.39	5.11	0.31	6.45e-7	Parkinson's disease;
KIRP	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg18350739	chr11:68623251	NA	-0.48	-7.65	-0.44	4.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg14973383	chr2:242577159	THAP4;ATG4B	-0.46	-6.03	-0.36	5.88e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs4713118	0.784	rs9468219	chr6:27731755	C/A	cg20933634	chr6:27740509	NA	0.39	5.15	0.31	5.24e-7	Parkinson's disease;
KIRP	cis	rs580438	0.510	rs6804464	chr3:13398963	C/T	cg10657019	chr3:13328039	NA	0.49	6.38	0.38	8.83e-10	Myringotomy;
KIRP	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg12131826	chr15:77904385	NA	0.48	5.75	0.34	2.67e-8	Type 2 diabetes;
KIRP	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg26531700	chr6:26746687	NA	0.46	6.45	0.38	5.73e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.83	6.96	0.41	3.1e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.2	-0.31	4.29e-7	Bipolar disorder;
KIRP	cis	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg24110177	chr3:50126178	RBM5	-0.66	-9.15	-0.5	2.22e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg01631408	chr1:248437212	OR2T33	-0.45	-5.89	-0.35	1.24e-8	Common traits (Other);
KIRP	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg19468946	chr17:37922297	IKZF3	-0.48	-6.55	-0.39	3.34e-10	Self-reported allergy;
KIRP	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.38	-4.85	-0.3	2.21e-6	Multiple myeloma;
KIRP	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg12598211	chr12:123634384	NA	-0.41	-5.0	-0.3	1.1e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7178909	0.797	rs1910586	chr15:90440489	T/G	cg19708238	chr15:90437601	AP3S2	0.6	8.3	0.47	7.1e-15	Common traits (Other);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09584691	chr10:44285881	HNRNPA3P1	0.44	6.77	0.4	9.47e-11	Cancer;
KIRP	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg07689907	chr11:61582574	FADS1	0.48	6.04	0.36	5.69e-9	Trans fatty acid levels;
KIRP	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Schizophrenia;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.61	-8.81	-0.49	2.36e-16	Renal function-related traits (BUN);
KIRP	cis	rs11169552	0.510	rs4768912	chr12:51135940	G/A	cg12884762	chr12:50931848	DIP2B	-0.44	-4.97	-0.3	1.25e-6	Colorectal cancer;
KIRP	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.38	-0.32	1.7e-7	Pulmonary function;
KIRP	cis	rs9912468	0.754	rs4791069	chr17:64316508	A/T	cg19474267	chr17:64306194	PRKCA	0.57	8.02	0.46	4.24e-14	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg19847130	chr8:10466454	RP1L1	0.38	5.75	0.34	2.63e-8	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs9581857	0.579	rs77509251	chr13:27959981	G/A	cg22138327	chr13:27999177	GTF3A	1.06	7.53	0.43	9.38e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-1.06	-21.4	-0.81	4.34e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs526231	0.511	rs1826673	chr5:102345916	G/A	cg23492399	chr5:102201601	PAM	-0.45	-5.04	-0.31	9.02e-7	Primary biliary cholangitis;
KIRP	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.87e-32	Mean platelet volume;
KIRP	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.68	-0.66	4.79e-32	Primary sclerosing cholangitis;
KIRP	cis	rs72820985	1.000	rs34502201	chr16:80844202	C/T	cg04448709	chr16:81349954	GAN	-0.52	-5.26	-0.32	3.12e-7	Breast cancer;
KIRP	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs9463078	0.547	rs720576	chr6:44729974	A/T	cg25276700	chr6:44698697	NA	0.35	5.06	0.31	8.28e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.32	-0.32	2.33e-7	Skin colour saturation;
KIRP	cis	rs427941	0.632	rs201527	chr7:101774451	T/C	cg06246474	chr7:101738831	CUX1	0.53	6.42	0.38	7.05e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06475006	chr16:89985975	MC1R	-0.69	-4.97	-0.3	1.27e-6	Skin colour saturation;
KIRP	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	8.04	0.46	3.78e-14	Lung cancer in ever smokers;
KIRP	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.97	-0.36	8.33e-9	Breast cancer;
KIRP	cis	rs62229266	0.557	rs4817761	chr21:37395556	C/T	cg12218747	chr21:37451666	NA	-0.5	-6.07	-0.36	4.93e-9	Mitral valve prolapse;
KIRP	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.76	11.24	0.58	6.31e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2279817	1.000	rs4920619	chr1:18023112	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.65	9.87	0.53	1.4e-19	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24054508	chr1:38273761	C1orf122;YRDC	0.46	6.26	0.37	1.68e-9	Survival in pancreatic cancer;
KIRP	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg01065977	chr19:18549689	ISYNA1	0.4	5.94	0.35	9.92e-9	Breast cancer;
KIRP	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.71	7.12	0.41	1.17e-11	Menarche (age at onset);
KIRP	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-5.71	-0.34	3.16e-8	Response to antipsychotic treatment;
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.67	8.35	0.47	4.96e-15	Aortic root size;
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-5.98	-0.36	7.69e-9	Lung cancer;
KIRP	cis	rs7213347	0.611	rs1231207	chr17:2125450	A/C	cg15816464	chr17:2026533	SMG6	0.35	5.23	0.32	3.7e-7	Total body bone mineral density;
KIRP	cis	rs6577655	0.517	rs9693237	chr8:135578218	G/A	cg17885191	chr8:135476712	NA	0.69	6.8	0.4	8.05e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg12591125	chr7:1885375	MAD1L1	0.61	6.04	0.36	5.6e-9	Bipolar disorder;
KIRP	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg17845761	chr1:175162550	KIAA0040	-0.34	-6.23	-0.37	2.03e-9	Alcohol dependence;
KIRP	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs2299587	0.560	rs3913556	chr8:17781401	A/G	cg01800426	chr8:17659068	MTUS1	-0.64	-7.67	-0.44	4.03e-13	Economic and political preferences;
KIRP	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.39	-7.28	-0.42	4.54e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.53	6.25	0.37	1.76e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg02158880	chr13:53174818	NA	0.37	4.86	0.3	2.12e-6	Lewy body disease;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg21016266	chr12:122356598	WDR66	0.51	6.9	0.4	4.51e-11	Mean corpuscular volume;
KIRP	trans	rs12545912	0.710	rs10903317	chr8:9555907	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.21	-0.37	2.29e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.9	-0.3	1.76e-6	Pulmonary function;
KIRP	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs8014252	0.803	rs74062733	chr14:70995394	A/G	cg19730268	chr14:71022823	NA	-0.73	-6.54	-0.38	3.56e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4936894	0.500	rs4556547	chr11:124124775	C/T	cg27160556	chr11:124181099	OR8D1	0.47	6.76	0.4	1.01e-10	Aging (time to death);
KIRP	cis	rs925228	0.504	rs7568176	chr2:24313758	T/A	cg01493198	chr2:24299560	SF3B14	0.78	6.35	0.38	1.05e-9	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg00631329	chr6:26305371	NA	-0.67	-9.09	-0.5	3.44e-17	Educational attainment;
KIRP	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.91	-0.35	1.13e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-8.28	-0.47	7.76e-15	Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.53	7.33	0.42	3.3e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs735539	0.521	rs1810717	chr13:21412235	A/G	cg04906043	chr13:21280425	IL17D	-0.45	-5.42	-0.33	1.42e-7	Dental caries;
KIRP	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.68	-0.34	3.72e-8	Bipolar disorder;
KIRP	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.75	12.1	0.61	9.41e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.76	-0.63	5.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg00717180	chr2:96193071	NA	-0.49	-6.1	-0.36	4.09e-9	HDL cholesterol;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg08901578	chr4:187885870	NA	0.51	7.81	0.45	1.61e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.18	14.16	0.67	1.09e-33	Corneal structure;
KIRP	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg27411982	chr8:10470053	RP1L1	-0.4	-4.96	-0.3	1.32e-6	Triglycerides;
KIRP	cis	rs6589219	0.721	rs7944895	chr11:111167776	C/G	cg25129781	chr11:111156908	C11orf53	-0.43	-5.75	-0.34	2.66e-8	Colorectal cancer;
KIRP	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.84	-12.69	-0.63	1.04e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.5	6.35	0.38	1.06e-9	Total body bone mineral density;
KIRP	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.48	9.08	0.5	3.6e-17	Erythrocyte sedimentation rate;
KIRP	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.75	-7.68	-0.44	3.78e-13	Hair shape;
KIRP	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg24642439	chr20:33292090	TP53INP2	0.53	6.29	0.37	1.43e-9	Height;
KIRP	cis	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg07460842	chr6:66804631	NA	0.55	6.43	0.38	6.63e-10	Metabolite levels;
KIRP	cis	rs6005807	0.719	rs9625524	chr22:29052951	C/T	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg19743168	chr1:23544995	NA	0.5	6.94	0.4	3.46e-11	Height;
KIRP	cis	rs1635	0.655	rs73742536	chr6:28303243	G/A	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.58	6.96	0.41	3.02e-11	Aortic root size;
KIRP	cis	rs7849270	0.760	rs1075650	chr9:131938913	T/C	cg13538475	chr9:131942899	NA	0.36	5.15	0.31	5.42e-7	Blood metabolite ratios;
KIRP	cis	rs7539542	0.556	rs10753926	chr1:202876085	C/T	cg08940984	chr1:202857613	RABIF	0.46	5.79	0.35	2.15e-8	Mean platelet volume;
KIRP	cis	rs4664293	0.967	rs13000070	chr2:160525774	C/G	cg08347373	chr2:160653686	CD302	-0.43	-6.35	-0.38	1.04e-9	Monocyte percentage of white cells;
KIRP	cis	rs7180079	0.620	rs1008917	chr15:65059651	A/G	cg15337035	chr15:64978493	NA	-0.47	-5.13	-0.31	5.88e-7	Monocyte count;
KIRP	cis	rs6832769	1.000	rs4864998	chr4:56332606	A/G	cg09317128	chr4:56265301	TMEM165	0.52	6.56	0.39	3.13e-10	Personality dimensions;
KIRP	trans	rs913655	0.739	rs2480337	chr10:19126895	A/T	cg27106950	chr16:11367916	PRM3	-0.55	-6.1	-0.36	4.16e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
KIRP	cis	rs4805272	0.889	rs6509071	chr19:29329651	A/G	cg15000279	chr19:29285009	NA	-0.36	-5.2	-0.31	4.17e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg05315796	chr3:52349193	DNAH1	0.4	6.43	0.38	6.59e-10	Bipolar disorder;
KIRP	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.04	0.31	8.84e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg08885076	chr2:99613938	TSGA10	-0.45	-6.55	-0.39	3.38e-10	Fear of minor pain;
KIRP	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07167872	chr1:205819463	PM20D1	0.45	5.06	0.31	8.28e-7	Parkinson's disease;
KIRP	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.35	0.38	1.04e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4791746	1.000	rs2055232	chr17:8614880	C/T	cg03115937	chr17:8649504	CCDC42	0.52	6.43	0.38	6.64e-10	Heroin dependence;
KIRP	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.61	-6.48	-0.38	4.87e-10	Bipolar disorder;
KIRP	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.58	-6.96	-0.41	3.16e-11	Mosquito bite size;
KIRP	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	1.03	11.57	0.59	5.15e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.73e-8	Aortic root size;
KIRP	cis	rs2223471	0.602	rs2235496	chr6:50727570	G/A	cg03432817	chr6:50765336	NA	-0.35	-5.06	-0.31	8.07e-7	Subcutaneous adipose tissue;
KIRP	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.66	6.89	0.4	4.6e-11	Gout;
KIRP	trans	rs6987004	0.822	rs72634682	chr8:34325317	G/A	cg21198219	chr11:128558454	NA	0.46	6.11	0.36	3.97e-9	Pulmonary function decline;
KIRP	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg09904177	chr6:26538194	HMGN4	-0.43	-5.61	-0.34	5.5e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.38	-7.85	-0.45	1.31e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg17376030	chr22:41985996	PMM1	-0.71	-7.54	-0.43	8.8e-13	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10083996	chr14:51298088	NIN	0.51	6.26	0.37	1.74e-9	Parkinson's disease;
KIRP	cis	rs787274	1.000	rs10739373	chr9:115593239	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-6.66	-0.39	1.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7252505	1.000	rs8111272	chr19:33606105	C/T	cg17764715	chr19:33622953	WDR88	0.7	5.93	0.35	1.03e-8	Colorectal cancer;
KIRP	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.47	0.33	1.12e-7	Tonsillectomy;
KIRP	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg22732515	chr19:44031385	ETHE1	0.62	8.84	0.49	1.88e-16	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg18154014	chr19:37997991	ZNF793	0.7	6.0	0.36	7.06e-9	Coronary artery calcification;
KIRP	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.17e-37	Height;
KIRP	cis	rs7493	0.901	rs11764079	chr7:95026229	A/G	cg17330251	chr7:94953956	PON1	0.49	5.71	0.34	3.29e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg13798912	chr7:905769	UNC84A	0.54	5.47	0.33	1.09e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.45	-6.62	-0.39	2.25e-10	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02725872	chr8:58115012	NA	-0.59	-7.08	-0.41	1.5e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs10426930	0.621	rs6510833	chr19:5008399	G/A	cg18473234	chr19:5097819	KDM4B	0.51	5.16	0.31	5.1e-7	Monocyte percentage of white cells;
KIRP	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg12384639	chr17:618140	VPS53	0.49	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg02931644	chr1:25747376	RHCE	0.36	6.54	0.38	3.62e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg00250761	chr1:31883323	NA	-0.32	-5.53	-0.33	8.13e-8	Alcohol dependence;
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs8028182	0.577	rs28693593	chr15:75849776	A/C	cg20655648	chr15:75932815	IMP3	0.55	7.06	0.41	1.7e-11	Sudden cardiac arrest;
KIRP	cis	rs7078219	0.505	rs10883373	chr10:101292484	G/A	cg07044859	chr10:101282883	NA	-0.3	-5.35	-0.32	2.05e-7	Dental caries;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14431789	chr10:97081759	SORBS1	0.47	6.77	0.4	9.16e-11	Interleukin-4 levels;
KIRP	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.7	0.48	4.9e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg24476569	chr13:95954382	ABCC4	-0.6	-9.32	-0.51	6.92e-18	Blood metabolite levels;
KIRP	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08048268	chr3:133502702	NA	-0.41	-5.01	-0.3	1.06e-6	Iron status biomarkers;
KIRP	cis	rs1712517	0.740	rs11191643	chr10:105057561	C/G	cg05636881	chr10:105038444	INA	0.45	6.7	0.39	1.38e-10	Migraine;
KIRP	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg07884673	chr3:53033167	SFMBT1	1.0	7.75	0.44	2.48e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11688874	chr10:28822482	WAC	0.65	6.03	0.36	5.91e-9	Lung function (FEV1);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24217936	chr4:15006634	CPEB2	0.47	6.1	0.36	4.02e-9	Parkinson's disease;
KIRP	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.55	6.22	0.37	2.11e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.63	8.69	0.48	5.07e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.91	14.47	0.68	9.51e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Hypertriglyceridemia;
KIRP	cis	rs7523050	0.730	rs67312582	chr1:109423976	A/G	cg08274380	chr1:109419600	GPSM2	1.16	10.22	0.55	1.14e-20	Fat distribution (HIV);
KIRP	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.38	-0.38	8.87e-10	Daytime sleep phenotypes;
KIRP	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.89	14.05	0.67	2.5e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs526231	0.578	rs10515337	chr5:102301368	C/T	cg23492399	chr5:102201601	PAM	0.46	5.21	0.32	4e-7	Primary biliary cholangitis;
KIRP	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg04362960	chr10:104952993	NT5C2	0.63	7.2	0.42	7.29e-12	Arsenic metabolism;
KIRP	cis	rs7694379	0.534	rs10028441	chr4:88290265	A/G	cg23841344	chr4:88312519	HSD17B11	-0.43	-5.14	-0.31	5.56e-7	Platelet count;
KIRP	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.07e-11	Blood metabolite levels;
KIRP	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.92	13.43	0.65	3.31e-31	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs5753618	0.607	rs5753621	chr22:31847647	T/C	cg02404636	chr22:31891804	SFI1	0.53	6.15	0.36	3.18e-9	Colorectal cancer;
KIRP	cis	rs629922	0.507	rs583331	chr11:114057007	G/C	cg01914181	chr11:114070210	ZBTB16	-0.53	-5.38	-0.32	1.78e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.53	0.38	3.68e-10	Mood instability;
KIRP	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg09184832	chr6:79620586	NA	-0.53	-7.49	-0.43	1.25e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6693295	0.729	rs2787995	chr1:246232189	C/G	cg11798871	chr1:246315928	SMYD3	-0.4	-5.09	-0.31	7.28e-7	Migraine - clinic-based;Migraine with aura;
KIRP	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg16141378	chr3:129829833	LOC729375	-0.47	-6.1	-0.36	4.08e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.35	-0.42	2.95e-12	Type 2 diabetes;
KIRP	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg24747557	chr10:131355152	MGMT	-0.41	-5.49	-0.33	9.89e-8	Response to temozolomide;
KIRP	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.49	-0.38	4.8e-10	Response to antipsychotic treatment;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10187365	chr21:34860956	DNAJC28	0.52	6.54	0.38	3.44e-10	Interleukin-4 levels;
KIRP	cis	rs301043	0.559	rs7133095	chr12:95835336	C/T	cg06159896	chr12:95840443	NA	-0.23	-5.1	-0.31	6.87e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.67	8.39	0.47	3.92e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2268667	0.597	rs1403955	chr1:85940105	G/T	cg16011679	chr1:85725395	C1orf52	-0.4	-5.08	-0.31	7.44e-7	Asymmetrical dimethylarginine levels;
KIRP	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.88	-0.3	1.9e-6	Bipolar disorder;
KIRP	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg26751094	chr13:95954534	ABCC4	-0.7	-9.67	-0.52	5.81e-19	Blood metabolite levels;
KIRP	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg13770153	chr20:60521292	NA	-0.45	-5.46	-0.33	1.19e-7	Body mass index;
KIRP	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.67e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs909341	0.909	rs1741708	chr20:62372041	G/T	cg11503966	chr20:62272292	STMN3	-0.4	-5.5	-0.33	9.68e-8	Atopic dermatitis;
KIRP	cis	rs7737355	1.000	rs30736	chr5:130724240	A/G	cg06647332	chr5:131281008	NA	-0.47	-5.18	-0.31	4.53e-7	Life satisfaction;
KIRP	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.43	5.56	0.33	6.85e-8	Blood metabolite levels;
KIRP	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.7	-0.34	3.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	0.78	8.55	0.48	1.3e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg13385521	chr17:29058706	SUZ12P	0.64	6.55	0.39	3.29e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18424968	chr16:54963240	NA	0.56	6.3	0.37	1.37e-9	Lung cancer in ever smokers;
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.12	12.96	0.64	1.29e-29	Platelet count;
KIRP	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg02319466	chr17:76381040	PGS1	0.49	6.77	0.4	9.4e-11	HDL cholesterol levels;
KIRP	cis	rs4664293	0.805	rs6432559	chr2:160607160	A/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.74	-6.75	-0.4	1.08e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.65	-8.17	-0.46	1.6e-14	Facial morphology (factor 19);
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg01765077	chr12:122356316	WDR66	0.64	8.78	0.49	2.79e-16	Mean corpuscular volume;
KIRP	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.9	-12.67	-0.63	1.21e-28	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06217312	chr1:150552348	MCL1	0.52	6.83	0.4	6.5500000000000006e-11	Parkinson's disease;
KIRP	cis	rs6684428	0.610	rs10493189	chr1:56315657	A/G	cg11651538	chr1:56320950	NA	-0.74	-7.3	-0.42	4.02e-12	Airflow obstruction;
KIRP	cis	rs7017914	0.967	rs7001162	chr8:71587470	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.85	-0.45	1.24e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.22	-0.37	2.14e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2270927	1.000	rs2270927	chr5:75591710	C/G	cg13563193	chr19:33072644	PDCD5	0.72	6.4	0.38	7.75e-10	Mean corpuscular volume;
KIRP	trans	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg17822266	chr1:2720087	NA	0.44	6.12	0.36	3.6e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.5	-7.14	-0.41	1.04e-11	Height;
KIRP	cis	rs11628318	0.515	rs12433517	chr14:103126912	T/G	cg01864069	chr14:103024347	NA	0.4	4.84	0.3	2.26e-6	Platelet count;
KIRP	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.95e-8	Endometrial cancer;
KIRP	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.54	-0.52	1.48e-18	Triglycerides;
KIRP	cis	rs11871801	0.517	rs10454087	chr17:40735641	C/T	cg14558262	chr17:40713999	COASY	0.47	5.06	0.31	8.02e-7	Crohn's disease;
KIRP	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-10.75	-0.57	2.37e-22	Morning vs. evening chronotype;
KIRP	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg08283408	chr3:49949060	MON1A	0.36	4.85	0.3	2.22e-6	Body mass index;
KIRP	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.11	-18.97	-0.77	4.8e-50	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	5.95e-24	Aortic root size;
KIRP	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	1.1	8.58	0.48	1.05e-15	Skin colour saturation;
KIRP	cis	rs6738485	1.000	rs6738485	chr2:106809960	C/T	cg16099169	chr2:106886729	NA	-0.42	-6.07	-0.36	4.8e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.48	-11.34	-0.59	2.93e-24	Diabetic kidney disease;
KIRP	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg03788504	chr6:150331562	NA	-0.33	-6.17	-0.37	2.74e-9	Alopecia areata;
KIRP	cis	rs4638749	0.680	rs12612935	chr2:108818409	A/G	cg06795125	chr2:108905320	SULT1C2	-0.53	-7.47	-0.43	1.41e-12	Blood pressure;
KIRP	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.62	4.91	0.3	1.65e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.71	-7.14	-0.41	1.04e-11	Vitiligo;
KIRP	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	9.99	0.54	6.18e-20	Lung cancer in ever smokers;
KIRP	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.48	-5.81	-0.35	1.93e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg13206674	chr6:150067644	NUP43	0.56	8.08	0.46	2.91e-14	Lung cancer;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-1.1	-21.29	-0.81	9.68e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.55	-9.27	-0.51	9.74e-18	Height;
KIRP	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg05315796	chr3:52349193	DNAH1	0.41	6.56	0.39	3.07e-10	Bipolar disorder;
KIRP	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.47	-7.05	-0.41	1.8e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.55	-8.12	-0.46	2.32e-14	Coronary artery disease;
KIRP	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg03060546	chr3:49711283	APEH	-0.71	-5.48	-0.33	1.05e-7	Cognitive function;
KIRP	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.44	0.33	1.31e-7	Homoarginine levels;
KIRP	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.61	0.48	9.09e-16	Prudent dietary pattern;
KIRP	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg27087555	chr16:88793112	FAM38A	-0.55	-5.82	-0.35	1.85e-8	Autism spectrum disorder-related traits;
KIRP	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg03563238	chr19:33554763	RHPN2	0.29	5.16	0.31	4.97e-7	Bone properties (heel);
KIRP	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg00129232	chr17:37814104	STARD3	0.72	8.04	0.46	3.86e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg09163369	chr1:210001066	C1orf107	0.52	6.31	0.37	1.3e-9	Orofacial clefts;
KIRP	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.71	-9.84	-0.53	1.76e-19	Ear protrusion;
KIRP	cis	rs1983891	0.673	rs912883	chr6:41552040	T/C	cg20194872	chr6:41519635	FOXP4	0.48	6.29	0.37	1.44e-9	Prostate cancer;
KIRP	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg07701084	chr6:150067640	NUP43	0.69	9.38	0.51	4.63e-18	Lung cancer;
KIRP	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.43	0.52	3.23e-18	Colorectal cancer;
KIRP	cis	rs1635	0.826	rs115041649	chr6:28274653	G/C	cg15743358	chr6:28303923	ZNF323	-0.76	-5.47	-0.33	1.13e-7	Schizophrenia;
KIRP	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg22903471	chr2:27725779	GCKR	0.4	5.58	0.34	6.43e-8	Oral cavity cancer;
KIRP	cis	rs12210905	0.841	rs72839470	chr6:27309304	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.29	-0.37	1.41e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	6.6	0.39	2.58e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs6693295	0.729	rs10802325	chr1:246213454	C/A	cg11798871	chr1:246315928	SMYD3	-0.42	-5.26	-0.32	3.12e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.81e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9513593	1.000	rs9513593	chr13:99950260	G/A	cg21788972	chr13:99853209	UBAC2	-0.45	-4.89	-0.3	1.79e-6	Psoriasis;
KIRP	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.76	-10.95	-0.57	5.51e-23	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.9	-0.57	7.61e-23	Height;
KIRP	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg24503407	chr1:205819492	PM20D1	-0.47	-5.3	-0.32	2.56e-7	Parkinson's disease;
KIRP	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.48	6.9	0.4	4.31e-11	Sitting height ratio;
KIRP	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg02175503	chr12:58329896	NA	0.66	7.92	0.45	8.03e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs7951870	1.000	rs61882709	chr11:46472414	G/A	cg01183821	chr12:46123850	ARID2	-0.62	-6.14	-0.36	3.26e-9	Schizophrenia;
KIRP	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.53	7.56	0.43	7.84e-13	Obesity-related traits;
KIRP	cis	rs8523	0.901	rs9380025	chr6:11011074	T/G	cg13562911	chr6:11044106	ELOVL2	0.39	5.02	0.31	9.76e-7	Red blood cell fatty acid levels;
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg12486944	chr17:80159399	CCDC57	0.39	5.17	0.31	4.75e-7	Life satisfaction;
KIRP	cis	rs3962382	1	rs3962382	chr1:68165693	A/C	cg10178795	chr1:68298432	GNG12	-0.46	-5.16	-0.31	5.2e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9815354	1.000	rs56121764	chr3:41883975	T/C	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg08807101	chr21:30365312	RNF160	-0.55	-5.34	-0.32	2.16e-7	Cognitive test performance;
KIRP	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.7	-11.45	-0.59	1.28e-24	Menopause (age at onset);
KIRP	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg11833968	chr6:79620685	NA	-0.36	-4.96	-0.3	1.34e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.733	rs7070778	chr10:35541688	T/C	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.94	0.57	6.02e-23	Personality dimensions;
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg22764044	chr5:178986830	RUFY1	-0.46	-6.73	-0.39	1.21e-10	Lung cancer;
KIRP	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg02733842	chr7:1102375	C7orf50	-0.52	-4.91	-0.3	1.7e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg22105103	chr4:187893119	NA	0.7	10.03	0.54	4.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.74	6.5	0.38	4.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg19731401	chr7:2775893	GNA12	0.82	7.59	0.44	6.43e-13	Childhood ear infection;
KIRP	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg23958373	chr8:599963	NA	-0.96	-6.18	-0.37	2.61e-9	IgG glycosylation;
KIRP	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.39	-5.76	-0.34	2.56e-8	Pubertal anthropometrics;
KIRP	cis	rs2414059	0.548	rs3098177	chr15:50783777	A/G	cg08437265	chr15:50716283	USP8	-0.36	-5.09	-0.31	7.01e-7	QT interval;
KIRP	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg26022315	chr17:47021804	SNF8	0.42	5.4	0.33	1.54e-7	Type 2 diabetes;
KIRP	cis	rs2637030	0.559	rs2637027	chr5:52980471	G/A	cg06476337	chr5:52856530	NDUFS4	0.56	6.3	0.37	1.34e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	trans	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg25288420	chr1:78511713	GIPC2	0.56	7.61	0.44	5.67e-13	Obesity-related traits;
KIRP	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07685180	chr8:600429	NA	0.73	5.29	0.32	2.65e-7	IgG glycosylation;
KIRP	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs1843834	0.721	rs6715655	chr2:225582284	C/T	cg22455342	chr2:225449267	CUL3	-0.44	-5.11	-0.31	6.47e-7	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs708547	0.647	rs781668	chr4:57825140	C/T	cg12819144	chr4:165953018	TRIM60	-0.39	-6.02	-0.36	6.33e-9	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.36	5.04	0.31	9.05e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7116495	0.609	rs2276384	chr11:71701523	A/G	cg18441811	chr11:71824068	C11orf51	0.83	5.58	0.34	6.41e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs3750082	0.855	rs12536402	chr7:32936419	C/G	cg08946731	chr7:32981826	RP9P	-0.33	-4.89	-0.3	1.85e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg23693289	chr8:27183097	PTK2B	0.48	6.01	0.36	6.61e-9	Neuroticism;
KIRP	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg20673091	chr1:2541236	MMEL1	0.78	12.65	0.63	1.36e-28	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg21546286	chr11:48923668	NA	-0.48	-6.11	-0.36	3.97e-9	HDL cholesterol;
KIRP	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.79	-9.09	-0.5	3.37e-17	Coronary artery disease;
KIRP	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-8.29	-0.47	7.63e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg23594656	chr7:65796392	TPST1	-0.45	-6.32	-0.37	1.23e-9	Aortic root size;
KIRP	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06544989	chr22:39130855	UNC84B	0.44	6.66	0.39	1.75e-10	Menopause (age at onset);
KIRP	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg06050784	chr16:88016603	BANP	0.41	5.12	0.31	6.3e-7	Menopause (age at onset);
KIRP	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg09163369	chr1:210001066	C1orf107	0.46	5.04	0.31	9.07e-7	Orofacial clefts;
KIRP	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.41	-5.81	-0.35	1.94e-8	Height;
KIRP	cis	rs2223471	0.502	rs614142	chr6:50622951	C/T	cg03432817	chr6:50765336	NA	-0.37	-5.43	-0.33	1.36e-7	Subcutaneous adipose tissue;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21016266	chr12:122356598	WDR66	0.66	9.0	0.5	6.35e-17	Mean corpuscular volume;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08085208	chr14:75348779	DLST	-0.5	-6.1	-0.36	4.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.96	-0.5	8.41e-17	Platelet count;
KIRP	cis	rs9398803	0.687	rs12208811	chr6:126926898	T/G	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg19847130	chr8:10466454	RP1L1	0.37	5.47	0.33	1.13e-7	Retinal vascular caliber;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg07693037	chr3:128216748	NA	0.43	6.03	0.36	5.83e-9	Asthma;
KIRP	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.82	-13.13	-0.64	3.35e-30	Longevity;
KIRP	cis	rs8044868	0.561	rs3909542	chr16:72183505	C/T	cg16558253	chr16:72132732	DHX38	-0.36	-4.95	-0.3	1.38e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.93	-0.4	3.7e-11	Initial pursuit acceleration;
KIRP	cis	rs4523957	0.583	rs923863	chr17:2031387	A/G	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.87	-13.49	-0.65	2.06e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.59	0.52	1.03e-18	Dupuytren's disease;
KIRP	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg05347473	chr6:146136440	FBXO30	0.49	6.77	0.4	9.26e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12366960	chr10:23122421	NA	0.47	7.12	0.41	1.21e-11	Survival in pancreatic cancer;
KIRP	cis	rs754423	0.558	rs10498441	chr14:52544224	C/T	cg10149976	chr14:52535953	NID2	-0.41	-6.39	-0.38	8.31e-10	Craniofacial microsomia;
KIRP	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.66	-0.63	1.29e-28	Exhaled nitric oxide output;
KIRP	cis	rs7520050	0.933	rs12565042	chr1:46299110	C/A	cg03146154	chr1:46216737	IPP	-0.4	-5.05	-0.31	8.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg06115741	chr20:33292138	TP53INP2	0.4	4.86	0.3	2.13e-6	Height;
KIRP	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.42	5.29	0.32	2.74e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.58	-7.1	-0.41	1.34e-11	Obesity-related traits;
KIRP	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.85	12.78	0.63	5.02e-29	Height;
KIRP	cis	rs12692119	0.667	rs10179856	chr2:127616758	G/A	cg25501666	chr2:127640322	NA	-0.43	-4.98	-0.3	1.22e-6	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg13319975	chr6:146136371	FBXO30	-0.55	-7.49	-0.43	1.24e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.35	-0.42	2.93e-12	Morning vs. evening chronotype;
KIRP	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg05756136	chr1:119680316	WARS2	-0.62	-8.41	-0.47	3.43e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.83	-0.35	1.7e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18357526	chr6:26021779	HIST1H4A	0.52	6.74	0.39	1.12e-10	Height;
KIRP	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	1.03	18.37	0.76	4.72e-48	Leprosy;
KIRP	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	4.92	0.3	1.55e-6	Total cholesterol levels;
KIRP	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg02175308	chr1:109941060	SORT1	0.29	5.45	0.33	1.21e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.61	-9.08	-0.5	3.7e-17	Monocyte percentage of white cells;
KIRP	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg09324608	chr17:30823087	MYO1D	0.55	7.25	0.42	5.43e-12	Schizophrenia;
KIRP	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.36	-0.32	1.87e-7	Pulmonary function;
KIRP	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs889512	0.642	rs3826110	chr16:75277780	G/A	cg03315344	chr16:75512273	CHST6	-0.61	-5.0	-0.3	1.11e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.54	-7.04	-0.41	1.94e-11	Alzheimer's disease;
KIRP	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.54	7.92	0.45	8.2e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7656342	0.636	rs1914874	chr4:9839490	C/A	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.45	-0.33	1.24e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.31	-0.32	2.39e-7	Breast cancer;
KIRP	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.38	-5.18	-0.31	4.63e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.77	6.45	0.38	5.79e-10	Body mass index;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02900441	chr1:15911134	AGMAT	-0.49	-6.11	-0.36	3.82e-9	Menopause (age at onset);
KIRP	cis	rs2882667	0.931	rs7706391	chr5:138349164	G/A	cg04439458	chr5:138467593	SIL1	-0.45	-7.53	-0.43	9.67e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7712401	0.601	rs418229	chr5:122341664	T/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.41	-0.33	1.48e-7	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.61	-0.34	5.49e-8	Lung cancer;
KIRP	cis	rs16976116	0.901	rs73409853	chr15:55502681	A/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.38	-0.32	1.75e-7	Height;
KIRP	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg17724175	chr1:150552817	MCL1	0.35	5.81	0.35	1.92e-8	Melanoma;
KIRP	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.9	16.45	0.72	1.62e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg13010199	chr12:38710504	ALG10B	0.53	6.48	0.38	4.92e-10	Resting heart rate;
KIRP	cis	rs7688540	0.771	rs79366248	chr4:266659	T/C	cg17891759	chr4:299121	NA	-0.49	-5.13	-0.31	5.79e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs4713675	0.565	rs9469566	chr6:33667605	G/T	cg15676125	chr6:33679581	C6orf125	0.42	5.57	0.33	6.81e-8	Plateletcrit;
KIRP	cis	rs77861329	1.000	rs28659792	chr3:52107966	G/C	cg08692210	chr3:52188851	WDR51A	0.84	5.87	0.35	1.39e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Bladder cancer;
KIRP	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	1.03	14.03	0.67	2.95e-33	Menopause (age at onset);
KIRP	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.07	0.41	1.6e-11	Mean platelet volume;
KIRP	cis	rs4664304	0.708	rs7564243	chr2:160726868	G/A	cg23995753	chr2:160760732	LY75	-0.4	-5.46	-0.33	1.17e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg00800569	chr2:239229395	TRAF3IP1	-0.41	-4.86	-0.3	2.12e-6	Multiple system atrophy;
KIRP	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.34	5.28	0.32	2.85e-7	Asthma;
KIRP	cis	rs1712517	0.771	rs2008530	chr10:105058839	G/A	cg05636881	chr10:105038444	INA	0.43	6.21	0.37	2.23e-9	Migraine;
KIRP	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.67	-9.28	-0.51	9.15e-18	Prostate cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03229959	chr8:38089560	DDHD2	0.65	7.86	0.45	1.16e-13	Smoking initiation;
KIRP	cis	rs2562456	0.754	rs62109227	chr19:21536930	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.61	8.11	0.46	2.38e-14	Multiple myeloma (IgH translocation);
KIRP	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	8.3	0.47	7.03e-15	Lung function (FEV1/FVC);
KIRP	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.74	-8.47	-0.48	2.27e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.76	0.44	2.23e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.51	7.93	0.45	7.81e-14	Platelet distribution width;
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg16606324	chr3:10149918	C3orf24	0.6	5.39	0.33	1.63e-7	Alzheimer's disease;
KIRP	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-0.57	-8.09	-0.46	2.8e-14	Coronary artery disease;
KIRP	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.38	4.99	0.3	1.12e-6	Dupuytren's disease;
KIRP	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg00631329	chr6:26305371	NA	-0.66	-8.93	-0.49	1.04e-16	Educational attainment;
KIRP	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	7.62	0.44	5.35e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.17	0.31	4.87e-7	Schizophrenia;
KIRP	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.72	-8.53	-0.48	1.56e-15	Resting heart rate;
KIRP	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.41	-0.51	3.62e-18	Body mass index;
KIRP	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg08975724	chr8:8085496	FLJ10661	0.7	9.62	0.52	8.26e-19	Mood instability;
KIRP	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg27426351	chr10:43362370	NA	0.35	4.9	0.3	1.72e-6	Blood protein levels;
KIRP	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg27129171	chr3:47204927	SETD2	0.43	5.39	0.32	1.65e-7	Birth weight;
KIRP	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg19761014	chr17:28927070	LRRC37B2	0.68	5.04	0.31	9.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.63	-8.71	-0.49	4.64e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs17079247	0.841	rs1038734	chr13:85806119	A/G	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs7590368	0.620	rs55675740	chr2:10920088	C/T	cg15705551	chr2:10952987	PDIA6	0.66	5.59	0.34	6.02e-8	Educational attainment (years of education);
KIRP	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.84	10.15	0.54	1.97e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg16558253	chr16:72132732	DHX38	-0.59	-6.35	-0.38	1.05e-9	Coronary artery disease;
KIRP	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05025164	chr4:1340916	KIAA1530	0.41	5.09	0.31	7.1e-7	Obesity-related traits;
KIRP	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg13289132	chr10:30722225	MAP3K8	-0.41	-5.08	-0.31	7.41e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg01616529	chr11:638424	DRD4	-0.5	-6.41	-0.38	7.2e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs17209837	1.000	rs45502492	chr7:87089898	C/T	cg00919237	chr7:87102261	ABCB4	-0.74	-7.48	-0.43	1.35e-12	Gallbladder cancer;
KIRP	cis	rs4356932	1.000	rs10017484	chr4:76984936	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs2718058	0.704	rs2722295	chr7:37834426	C/T	cg15028436	chr7:37888078	TXNDC3	0.43	5.13	0.31	5.95e-7	Alzheimer's disease (late onset);
KIRP	cis	rs6516091	1.000	rs62199229	chr20:6047896	C/T	cg25325723	chr20:6104886	FERMT1	-0.49	-5.56	-0.33	7.04e-8	Abdominal aortic aneurysm;
KIRP	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.54	-0.33	7.7e-8	Parkinson's disease;
KIRP	cis	rs7560272	0.538	rs6732812	chr2:73922475	T/C	cg20560298	chr2:73613845	ALMS1	0.5	6.08	0.36	4.64e-9	Schizophrenia;
KIRP	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.9	-15.5	-0.7	2.93e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.02	-0.46	4.35e-14	Morning vs. evening chronotype;
KIRP	cis	rs41563	0.519	rs11980772	chr7:104913675	A/G	cg04380332	chr7:105027541	SRPK2	-0.68	-6.69	-0.39	1.45e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-5.56	-0.33	7.04e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2573652	0.722	rs11852383	chr15:100542765	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.51	-7.36	-0.42	2.82e-12	Height;
KIRP	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15128208	chr22:42549153	NA	-0.43	-5.45	-0.33	1.23e-7	Cognitive function;
KIRP	cis	rs77861329	1.000	rs171294	chr3:52203599	C/G	cg08692210	chr3:52188851	WDR51A	0.94	7.35	0.42	2.96e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.62e-8	Aortic root size;
KIRP	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg27124370	chr19:33622961	WDR88	0.72	10.11	0.54	2.55e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg13482628	chr17:19912719	NA	0.57	8.08	0.46	2.93e-14	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.73	-0.44	2.69e-13	Platelet count;
KIRP	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.5	-0.59	8.96e-25	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03385696	chr7:75988425	YWHAG	0.51	6.22	0.37	2.1e-9	Parkinson's disease;
KIRP	cis	rs2671245	0.933	rs1514142	chr1:56161484	T/C	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6988636	0.534	rs62521778	chr8:124122794	T/G	cg23067535	chr8:124195133	FAM83A	-0.55	-4.93	-0.3	1.53e-6	Urinary uromodulin levels;
KIRP	cis	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.44	5.91	0.35	1.15e-8	Leprosy;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg09914675	chr16:1993179	SEPX1	-0.47	-6.24	-0.37	1.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.48	-9.44	-0.52	2.94e-18	Longevity;
KIRP	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg23479056	chr15:41276147	INO80	-0.39	-5.25	-0.32	3.26e-7	Menopause (age at onset);
KIRP	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg22437258	chr11:111473054	SIK2	0.48	5.99	0.36	7.38e-9	Primary sclerosing cholangitis;
KIRP	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg20302533	chr7:39170763	POU6F2	0.26	5.46	0.33	1.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg13147721	chr7:65941812	NA	-0.91	-6.56	-0.39	3.19e-10	Diabetic kidney disease;
KIRP	cis	rs883565	0.568	rs6599004	chr3:39095678	C/T	cg01426195	chr3:39028469	NA	-0.74	-12.99	-0.64	1.01e-29	Handedness;
KIRP	cis	rs10865541	1.000	rs10165099	chr2:3402591	T/C	cg11642891	chr2:3452563	TTC15	-0.49	-6.36	-0.38	9.68e-10	Obesity-related traits;
KIRP	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.81	-6.49	-0.38	4.76e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9398803	0.932	rs9401876	chr6:126669479	C/A	cg19875578	chr6:126661172	C6orf173	0.49	6.49	0.38	4.73e-10	Male-pattern baldness;
KIRP	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg01631408	chr1:248437212	OR2T33	-0.68	-8.74	-0.49	3.75e-16	Common traits (Other);
KIRP	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.71	-7.72	-0.44	2.94e-13	Vitiligo;
KIRP	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.94	-9.37	-0.51	4.96e-18	Multiple sclerosis;
KIRP	trans	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg10756647	chr7:56101905	PSPH	-0.96	-6.94	-0.4	3.56e-11	Diabetic kidney disease;
KIRP	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.61	-9.64	-0.52	7.24e-19	Sense of smell;
KIRP	cis	rs6578185	0.782	rs6578184	chr8:142453003	A/G	cg07762003	chr8:142452454	FLJ43860	-0.66	-10.07	-0.54	3.47e-20	Endometriosis;
KIRP	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.66	8.53	0.48	1.48e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-5.14	-0.31	5.67e-7	Neuroticism;
KIRP	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.93	12.17	0.61	5.32e-27	Menopause (age at onset);
KIRP	cis	rs789859	0.611	rs1077729	chr3:194418126	A/G	cg03198678	chr3:194381165	LSG1	0.35	5.09	0.31	7.21e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg02138098	chr1:2040968	PRKCZ	-0.44	-6.0	-0.36	7.17e-9	Height;
KIRP	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg08885076	chr2:99613938	TSGA10	-0.54	-9.27	-0.51	1.01e-17	Chronic sinus infection;
KIRP	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.72	-7.1	-0.41	1.32e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16603176	chr17:73726241	ITGB4	0.49	6.25	0.37	1.77e-9	Interleukin-4 levels;
KIRP	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.95	0.57	5.61e-23	Bladder cancer;
KIRP	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.48	6.26	0.37	1.66e-9	Resistin levels;
KIRP	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.82	0.4	6.83e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3762637	1.000	rs10934602	chr3:122223182	A/C	cg24169773	chr3:122142474	KPNA1	0.52	5.93	0.35	1.03e-8	LDL cholesterol levels;
KIRP	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.76	-0.4	1.01e-10	Response to antipsychotic treatment;
KIRP	cis	rs62070183	0.595	rs4490045	chr17:31251099	G/A	cg05781649	chr17:31146240	MYO1D	-0.49	-4.86	-0.3	2.11e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.59	6.55	0.39	3.42e-10	Aortic root size;
KIRP	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.49e-13	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg03289416	chr15:75166202	SCAMP2	0.44	6.21	0.37	2.25e-9	Breast cancer;
KIRP	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg05973401	chr12:123451056	ABCB9	0.56	6.49	0.38	4.58e-10	Neutrophil percentage of white cells;
KIRP	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg13615516	chr5:77269221	NA	0.52	8.12	0.46	2.28e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	trans	rs1429107	0.618	rs17023251	chr4:148354371	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-6.02	-0.36	6.38e-9	Obesity-related traits;
KIRP	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.95	15.24	0.7	2.31e-37	Bone mineral density;
KIRP	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg09699651	chr6:150184138	LRP11	0.45	5.71	0.34	3.23e-8	Lung cancer;
KIRP	cis	rs17095355	1.000	rs17126902	chr10:111710381	A/G	cg00817464	chr10:111662876	XPNPEP1	0.38	5.19	0.31	4.46e-7	Biliary atresia;
KIRP	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.83	-0.49	2.05e-16	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15678380	chr5:126430183	NA	-0.47	-6.72	-0.39	1.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg17470723	chr8:74884337	TCEB1	0.64	8.22	0.46	1.19e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.9	-14.05	-0.67	2.53e-33	Height;
KIRP	cis	rs9311676	0.656	rs7620012	chr3:58373716	G/A	cg06643156	chr3:58380774	PXK	0.35	4.97	0.3	1.27e-6	Systemic lupus erythematosus;
KIRP	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.45	-6.35	-0.38	1.05e-9	Sitting height ratio;
KIRP	trans	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg19894588	chr14:64061835	NA	-0.46	-6.24	-0.37	1.92e-9	Fat distribution (HIV);
KIRP	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.48	-5.56	-0.33	6.93e-8	Obesity-related traits;
KIRP	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.4	-0.43	2.13e-12	Morning vs. evening chronotype;
KIRP	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.5	-5.46	-0.33	1.14e-7	Total body bone mineral density;
KIRP	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg07451762	chr16:28383216	NA	0.38	5.07	0.31	8.01e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg06212747	chr3:49208901	KLHDC8B	0.59	6.39	0.38	8.06e-10	Menarche (age at onset);
KIRP	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.71	0.44	3.1e-13	Coffee consumption (cups per day);
KIRP	cis	rs10129255	0.500	rs8022547	chr14:107190222	A/T	cg23076370	chr14:107095027	NA	-0.4	-5.04	-0.31	9.16e-7	Kawasaki disease;
KIRP	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg15691649	chr6:25882328	NA	0.42	5.11	0.31	6.6e-7	Blood metabolite levels;
KIRP	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg03653399	chr8:142233436	SLC45A4	-0.47	-5.85	-0.35	1.52e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg26681399	chr22:41777847	TEF	-0.53	-5.01	-0.3	1.04e-6	Vitiligo;
KIRP	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.56	-0.52	1.26e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg19773385	chr1:10388646	KIF1B	0.45	6.37	0.38	9.27e-10	Hepatocellular carcinoma;
KIRP	cis	rs7809799	0.571	rs67909852	chr7:98944926	T/C	cg12290671	chr7:99195819	NA	-0.71	-5.37	-0.32	1.84e-7	Ulcerative colitis;
KIRP	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.69	-0.34	3.6e-8	Recombination measurement;
KIRP	cis	rs3779635	1.000	rs725788	chr8:27265371	T/C	cg23693289	chr8:27183097	PTK2B	0.49	6.35	0.38	1.04e-9	Neuroticism;
KIRP	cis	rs12530134	0.590	rs760492	chr6:170743989	A/G	cg16453901	chr6:170730693	NA	-0.87	-6.24	-0.37	1.91e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.6	8.18	0.46	1.57e-14	Response to temozolomide;
KIRP	cis	rs9826463	0.941	rs73238201	chr3:142204728	C/T	cg20824294	chr3:142316082	PLS1	0.31	4.99	0.3	1.12e-6	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.41	5.28	0.32	2.89e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs752010	0.644	rs7413657	chr1:42103382	T/C	cg06885757	chr1:42089581	HIVEP3	0.67	10.1	0.54	2.73e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.8	-11.66	-0.6	2.7e-25	Mortality in heart failure;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12560154	chr19:11925149	ZNF440	0.46	6.2	0.37	2.43e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-4.86	-0.3	2.11e-6	Neuroticism;
KIRP	cis	rs698813	0.774	rs1085492	chr2:44609371	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.3	0.37	1.38e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.03	-0.31	9.64e-7	IgG glycosylation;
KIRP	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg20295408	chr7:1910781	MAD1L1	-0.54	-5.6	-0.34	5.83e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	9.7	0.53	4.85e-19	Post bronchodilator FEV1;
KIRP	cis	rs13315871	1.000	rs9860970	chr3:58353781	C/T	cg12435725	chr3:58293450	RPP14	-0.5	-5.39	-0.33	1.62e-7	Cholesterol, total;
KIRP	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.28	22.49	0.82	1.3e-61	Breast cancer;
KIRP	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	1.11	16.42	0.72	2.13e-41	Breast cancer;
KIRP	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg12288994	chr5:1860383	NA	0.5	6.65	0.39	1.85e-10	Cardiovascular disease risk factors;
KIRP	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg21231944	chr12:82153410	PPFIA2	-0.41	-4.91	-0.3	1.7e-6	Resting heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03800012	chr7:35734842	HERPUD2	0.49	6.16	0.37	3.02e-9	Parkinson's disease;
KIRP	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.89	-8.45	-0.47	2.64e-15	Rheumatoid arthritis;
KIRP	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg20813462	chr7:2646259	IQCE	0.66	6.53	0.38	3.75e-10	Urate levels in lean individuals;
KIRP	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.26	26.19	0.86	4.3e-73	IgG glycosylation;
KIRP	cis	rs287982	1.000	rs287980	chr2:9971366	G/A	cg10881225	chr2:9984929	TAF1B	-0.41	-4.95	-0.3	1.4e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs6684514	1.000	rs7522948	chr1:156275308	C/T	cg16558208	chr1:156270281	VHLL	-0.5	-6.31	-0.37	1.26e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.6	-8.15	-0.46	1.88e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.1	-0.41	1.31e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4774899	1.000	rs12900986	chr15:57258736	C/G	cg13626582	chr15:57592083	LOC283663	0.2	4.94	0.3	1.47e-6	Urinary tract infection frequency;
KIRP	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.42	6.14	0.36	3.33e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg04865290	chr3:52927548	TMEM110	-0.64	-6.76	-0.4	1.01e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	4.95	0.3	1.37e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg10434728	chr15:90938212	IQGAP1	-0.39	-7.13	-0.41	1.09e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs554111	0.593	rs4654906	chr1:21509642	A/T	cg21184320	chr1:21044207	KIF17	0.37	5.57	0.33	6.51e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2273669	0.504	rs77608624	chr6:109442854	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-5.14	-0.31	5.53e-7	Prostate cancer;
KIRP	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.71	-10.06	-0.54	3.66e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg04398451	chr17:18023971	MYO15A	-0.68	-9.44	-0.52	3.02e-18	Total body bone mineral density;
KIRP	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg15128208	chr22:42549153	NA	0.71	7.97	0.45	5.84e-14	Birth weight;
KIRP	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.78	-10.94	-0.57	5.83e-23	Asthma;
KIRP	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.63	0.39	2.15e-10	Renal cell carcinoma;
KIRP	cis	rs9816226	0.645	rs16860471	chr3:185847441	G/T	cg00760338	chr3:185826511	ETV5	-0.65	-6.03	-0.36	5.94e-9	Obesity;Body mass index;
KIRP	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.6	0.48	9.5e-16	Motion sickness;
KIRP	cis	rs282587	0.569	rs419334	chr13:113415346	G/A	cg04656015	chr13:113407548	ATP11A	0.58	6.33	0.37	1.12e-9	Glycated hemoglobin levels;
KIRP	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.61	6.73	0.39	1.22e-10	Aortic root size;
KIRP	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16414030	chr3:133502952	NA	-0.53	-6.06	-0.36	4.96e-9	Iron status biomarkers;
KIRP	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.77	-0.44	2.19e-13	Total cholesterol levels;
KIRP	cis	rs7246657	0.722	rs2927746	chr19:38156570	G/A	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.33	-0.47	5.84e-15	Retinal vascular caliber;
KIRP	cis	rs427941	0.632	rs201475	chr7:101745883	G/T	cg06246474	chr7:101738831	CUX1	0.53	6.49	0.38	4.6e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.78	9.69	0.53	5.02e-19	Monocyte percentage of white cells;
KIRP	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.1e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.92	13.52	0.65	1.64e-31	Chronic sinus infection;
KIRP	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.73	10.1	0.54	2.68e-20	Multiple sclerosis;
KIRP	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg10189774	chr4:17578691	LAP3	0.41	5.02	0.3	9.83e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3736485	0.932	rs2124879	chr15:51916833	T/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.16	-0.31	5.12e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.57	-4.86	-0.3	2.05e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.59	-0.44	6.82e-13	Life satisfaction;
KIRP	cis	rs897080	0.515	rs1067357	chr2:44663064	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.61	6.1	0.36	4.18e-9	Height;
KIRP	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg21605333	chr4:119757512	SEC24D	1.59	11.88	0.6	5.19e-26	Cannabis dependence symptom count;
KIRP	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.58e-6	Total body bone mineral density;
KIRP	cis	rs2302729	0.625	rs12228313	chr12:2831297	C/T	cg19945202	chr12:2788847	CACNA1C	0.59	5.47	0.33	1.11e-7	Sleep quality;
KIRP	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.19	13.43	0.65	3.25e-31	Eosinophil percentage of granulocytes;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg09978321	chr19:33864421	CEBPG	0.52	6.53	0.38	3.77e-10	Colorectal cancer;
KIRP	cis	rs501120	0.810	rs474281	chr10:44749120	T/C	cg09554077	chr10:44749378	NA	0.71	11.01	0.57	3.39e-23	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26856871	chr21:45363775	AGPAT3	-0.5	-6.04	-0.36	5.78e-9	Parkinson's disease;
KIRP	cis	rs2742417	1.000	rs2249357	chr3:45758381	C/A	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	2.96e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg24848339	chr3:12840334	CAND2	0.31	4.9	0.3	1.71e-6	P wave duration;
KIRP	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/G	cg20655648	chr15:75932815	IMP3	0.6	7.56	0.43	8.09e-13	Sudden cardiac arrest;
KIRP	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.72	11.48	0.59	1.05e-24	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs2708977	0.698	rs772159	chr2:97036439	G/A	cg22654517	chr2:96458247	NA	0.31	5.01	0.3	1.03e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.39	-5.06	-0.31	8.25e-7	Height;
KIRP	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.18	21.46	0.81	2.71e-58	Cognitive function;
KIRP	cis	rs7187994	0.848	rs62050862	chr16:84781949	G/A	cg11201751	chr16:85158047	NA	0.48	4.98	0.3	1.19e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg21366198	chr4:185655624	MLF1IP	-0.41	-5.43	-0.33	1.37e-7	Kawasaki disease;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg14564558	chr6:111303128	RPF2	0.46	6.23	0.37	2.05e-9	Bladder cancer;
KIRP	cis	rs6450176	1.000	rs4588541	chr5:53300640	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.46	-0.59	1.19e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.71	7.77	0.44	2.09e-13	Gut microbiome composition (summer);
KIRP	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-5.36	-0.32	1.94e-7	Aortic root size;
KIRP	cis	rs61542988	0.535	rs10807813	chr7:22829961	C/T	cg11367502	chr7:22862612	TOMM7	0.47	4.85	0.3	2.22e-6	Fibrinogen levels;
KIRP	cis	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg21546286	chr11:48923668	NA	-0.48	-6.12	-0.36	3.74e-9	HDL cholesterol;
KIRP	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.4	-0.72	2.45e-41	Height;
KIRP	trans	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg03735916	chr2:200715285	NA	-0.46	-6.19	-0.37	2.53e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg07393940	chr7:158741817	NA	0.44	6.05	0.36	5.37e-9	Life satisfaction;
KIRP	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg11783602	chr8:55087084	NA	-0.47	-5.81	-0.35	1.94e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.5	8.41	0.47	3.39e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs75920871	0.841	rs112151056	chr11:116919368	G/A	cg23684410	chr11:116897558	SIK3	0.54	5.83	0.35	1.73e-8	Subjective well-being;
KIRP	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.02	-0.3	9.86e-7	Fear of minor pain;
KIRP	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg01620082	chr3:125678407	NA	-1.18	-7.43	-0.43	1.79e-12	Depression;
KIRP	trans	rs7729273	0.830	rs13175341	chr5:7193456	G/C	cg13850847	chr9:136131739	ABO	0.52	6.57	0.39	2.91e-10	Cognitive performance;
KIRP	cis	rs4955124	0.558	rs78465094	chr3:32019016	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	7.44	0.43	1.66e-12	Schizophrenia;
KIRP	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.35	-0.47	4.91e-15	Mean corpuscular volume;
KIRP	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.41	0.33	1.46e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9303542	0.625	rs7207109	chr17:46607817	C/T	cg04904318	chr17:46607828	HOXB1	-0.63	-7.2	-0.42	7.46e-12	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.69	-8.87	-0.49	1.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.74	-0.53	3.57e-19	Body mass index;
KIRP	cis	rs73198271	0.628	rs11783707	chr8:8589609	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.63	6.85	0.4	5.91e-11	Smoking initiation;
KIRP	cis	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.13e-6	Androgen levels;
KIRP	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08280861	chr8:58055591	NA	0.7	5.29	0.32	2.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.76	0.71	3.8e-39	Chronic sinus infection;
KIRP	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.07	0.46	3.05e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.75	0.81	3.16e-59	Prudent dietary pattern;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13460439	chr1:200522459	KIF14	-0.42	-6.49	-0.38	4.65e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06798480	chr3:9439221	SETD5;LOC440944	0.5	6.07	0.36	4.83e-9	Parkinson's disease;
KIRP	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.4	0.47	3.5e-15	Mood instability;
KIRP	cis	rs6831280	0.925	rs4647940	chr4:1020391	C/G	cg03414932	chr4:1008425	FGFRL1	-0.58	-5.68	-0.34	3.78e-8	Total body bone mineral density;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg03270376	chr2:219536588	RNF25;STK36	0.52	6.06	0.36	5.11e-9	Sleep duration;
KIRP	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg16586182	chr3:47516702	SCAP	0.64	8.83	0.49	2.02e-16	Colorectal cancer;
KIRP	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	0.84	7.54	0.43	8.76e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.46	-6.99	-0.41	2.58e-11	Coronary artery disease;
KIRP	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26526719	chr5:1949144	NA	-0.47	-5.42	-0.33	1.39e-7	Gut microbiome composition (winter);
KIRP	cis	rs10267417	0.603	rs10249779	chr7:19939812	C/G	cg05791153	chr7:19748676	TWISTNB	-0.56	-5.77	-0.34	2.44e-8	Night sleep phenotypes;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08894960	chr1:237061516	MTR	0.6	6.62	0.39	2.21e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	7.38	0.43	2.4e-12	Iron status biomarkers;
KIRP	cis	rs6977660	0.714	rs28605851	chr7:19815219	G/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.83	0.35	1.75e-8	Thyroid stimulating hormone;
KIRP	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg26531700	chr6:26746687	NA	0.46	6.48	0.38	5.11e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	0.87	12.46	0.62	5.92e-28	Homoarginine levels;
KIRP	cis	rs111294930	1	rs111294930	chr5:152177121	A/G	cg12297329	chr5:152029980	NA	-0.64	-7.99	-0.45	5.1e-14	Schizophrenia;
KIRP	cis	rs8018808	0.902	rs147316	chr14:77888664	C/T	cg18872420	chr14:78023429	SPTLC2	0.35	5.08	0.31	7.3e-7	Myeloid white cell count;
KIRP	cis	rs2738048	1.000	rs2702910	chr8:6823891	G/A	cg02787689	chr8:6828103	DEFA10P	-0.32	-6.17	-0.37	2.74e-9	IgA nephropathy;
KIRP	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.39	4.86	0.3	2.08e-6	Renal function-related traits (BUN);
KIRP	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.08	0.58	2.02e-23	Exhaled nitric oxide levels;
KIRP	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg04896959	chr15:78267971	NA	0.76	10.4	0.55	3.22e-21	Coronary artery disease or large artery stroke;
KIRP	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	11.51	0.59	8.19e-25	Smoking behavior;
KIRP	cis	rs17125944	0.686	rs4901305	chr14:53364271	C/T	cg00686598	chr14:53173677	PSMC6	-0.67	-6.39	-0.38	8.06e-10	Alzheimer's disease (late onset);
KIRP	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.54	-0.7	2.13e-38	Gut microbiome composition (summer);
KIRP	cis	rs12249377	0.528	rs2901127	chr10:92595066	C/T	cg20430496	chr10:92484088	NA	0.69	5.31	0.32	2.4e-7	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs35740288	0.770	rs11634707	chr15:86151867	A/G	cg17133734	chr15:86042851	AKAP13	-0.5	-5.42	-0.33	1.4e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	9.29	0.51	8.31e-18	Total body bone mineral density;
KIRP	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg21747090	chr2:27597821	SNX17	-0.38	-5.25	-0.32	3.32e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	1.01	11.42	0.59	1.65e-24	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg13736514	chr6:26305472	NA	-0.72	-9.04	-0.5	4.86e-17	Educational attainment;
KIRP	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-1.05	-13.01	-0.64	8.4000000000000007e-30	Breast cancer;
KIRP	cis	rs17023223	0.537	rs10923756	chr1:119674648	A/T	cg18261050	chr1:119551319	NA	0.52	6.78	0.4	8.93e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-6.43	-0.38	6.61e-10	Lung cancer;
KIRP	cis	rs9309473	0.950	rs10206899	chr2:73900900	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.26	-0.32	3.07e-7	Metabolite levels;
KIRP	cis	rs1018836	0.739	rs6993715	chr8:91531188	G/C	cg16814680	chr8:91681699	NA	-0.7	-8.1	-0.46	2.51e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs34375054	0.573	rs12811438	chr12:125653490	C/T	cg25124228	chr12:125621409	AACS	-0.57	-5.76	-0.34	2.54e-8	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24564603	chr7:158456404	NCAPG2	0.41	4.96	0.3	1.33e-6	Height;
KIRP	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22117172	chr7:91764530	CYP51A1	0.45	6.16	0.37	2.94e-9	Breast cancer;
KIRP	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.52	7.31	0.42	3.71e-12	Coronary artery disease;
KIRP	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg10189774	chr4:17578691	LAP3	0.42	5.04	0.31	9.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.75	0.49	3.51e-16	Bipolar disorder;
KIRP	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.55	-0.7	1.9e-38	Gut microbiome composition (summer);
KIRP	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.58	0.52	1.1e-18	Alzheimer's disease;
KIRP	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05665937	chr4:1216051	CTBP1	0.55	7.66	0.44	4.2e-13	Obesity-related traits;
KIRP	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18932078	chr1:2524107	MMEL1	0.39	5.35	0.32	2.03e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.91	14.35	0.68	2.35e-34	Mean corpuscular volume;
KIRP	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-12.9	-0.64	1.97e-29	Dental caries;
KIRP	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg03808351	chr9:123631620	PHF19	0.43	5.88	0.35	1.3e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.8	-11.75	-0.6	1.4e-25	Dental caries;
KIRP	cis	rs12496230	0.794	rs725161	chr3:66860401	G/A	cg17646820	chr3:66848679	NA	0.39	6.34	0.37	1.06e-9	Type 2 diabetes;
KIRP	cis	rs9290877	0.667	rs6444324	chr3:188457961	C/G	cg17392043	chr3:188495102	LPP	-0.51	-6.63	-0.39	2.1e-10	IgE levels;
KIRP	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	8.33	0.47	5.58e-15	Response to antipsychotic treatment;
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.58	-7.04	-0.41	1.92e-11	Menopause (age at onset);
KIRP	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.49	-6.22	-0.37	2.14e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs2273669	0.915	rs6941125	chr6:109287209	T/A	cg05315195	chr6:109294784	ARMC2	-0.46	-5.17	-0.31	4.82e-7	Prostate cancer;
KIRP	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.19	-0.46	1.43e-14	Common traits (Other);
KIRP	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.43	5.02	0.3	9.97e-7	Aortic root size;
KIRP	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg16898833	chr6:26189333	HIST1H4D	0.65	4.92	0.3	1.61e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11997175	0.766	rs60855034	chr8:33684732	G/A	cg04338863	chr8:33670619	NA	0.4	5.3	0.32	2.55e-7	Body mass index;
KIRP	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg06271696	chr7:157225062	NA	-0.39	-4.89	-0.3	1.82e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg07423050	chr13:99094983	FARP1	-0.59	-9.14	-0.5	2.48e-17	Neuroticism;
KIRP	cis	rs1185460	0.547	rs666741	chr11:118911350	A/C	cg23280166	chr11:118938394	VPS11	-0.44	-5.14	-0.31	5.65e-7	Coronary artery disease;
KIRP	cis	rs2274273	0.870	rs11851169	chr14:55815932	G/A	cg04306507	chr14:55594613	LGALS3	0.43	6.6	0.39	2.47e-10	Protein biomarker;
KIRP	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.77	0.44	2.17e-13	Height;
KIRP	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg10645314	chr2:3704589	ALLC	-0.64	-7.1	-0.41	1.32e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg01988459	chr11:68622903	NA	-0.45	-6.18	-0.37	2.71e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	9.32	0.51	6.91e-18	Exhaled nitric oxide levels;
KIRP	cis	rs7404928	1.000	rs7404928	chr16:23888840	T/C	cg21745164	chr16:23765304	CHP2	-0.49	-6.4	-0.38	7.98e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg00074818	chr8:8560427	CLDN23	0.37	5.82	0.35	1.79e-8	Obesity-related traits;
KIRP	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.35	5.42	0.33	1.43e-7	Calcium levels;
KIRP	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	0.93	14.58	0.68	3.99e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22420249	chr8:108298379	ANGPT1	-0.38	-6.17	-0.37	2.73e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg10503236	chr1:231470652	EXOC8	-0.48	-6.78	-0.4	8.82e-11	Hemoglobin concentration;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05959111	chr1:211999985	LPGAT1	-0.45	-6.88	-0.4	4.85e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.43	-5.3	-0.32	2.56e-7	Acne (severe);
KIRP	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.45	-5.48	-0.33	1.07e-7	Iron status biomarkers;
KIRP	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg25664220	chr3:72788482	NA	-0.35	-5.18	-0.31	4.69e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg17443007	chr1:101659419	NA	0.4	5.64	0.34	4.74e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.94	0.35	9.62e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7267005	1.000	rs112146116	chr20:34465485	T/C	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg04034577	chr2:241836375	C2orf54	-0.29	-5.46	-0.33	1.14e-7	Urinary metabolites;
KIRP	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.76	9.7	0.53	4.74e-19	Menopause (age at onset);
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.78	-11.75	-0.6	1.37e-25	Paraoxonase activity;
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg15664640	chr17:80829946	TBCD	0.38	4.94	0.3	1.42e-6	Glycated hemoglobin levels;
KIRP	cis	rs12900413	0.687	rs28475471	chr15:90311749	C/T	cg24650279	chr15:90327240	NA	-0.4	-5.13	-0.31	5.93e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg22676075	chr6:135203613	NA	0.5	7.18	0.42	8.21e-12	Red blood cell count;
KIRP	cis	rs7538876	0.903	rs1324368	chr1:17752000	A/G	cg07965774	chr1:17746286	RCC2	0.28	4.85	0.3	2.18e-6	Basal cell carcinoma;
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.19	15.25	0.7	2.09e-37	Platelet count;
KIRP	cis	rs4789452	0.934	rs3987888	chr17:75370274	T/C	cg02320862	chr17:75370284	SEPT9	-0.38	-5.32	-0.32	2.29e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.76	9.37	0.51	4.73e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg25922239	chr6:33757077	LEMD2	0.52	6.41	0.38	7.56e-10	Crohn's disease;
KIRP	cis	rs6142102	0.961	rs4911392	chr20:32570518	G/C	cg24642439	chr20:33292090	TP53INP2	0.56	6.79	0.4	8.12e-11	Skin pigmentation;
KIRP	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.53	-0.52	1.59e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19564017	chr6:135721680	AHI1	0.39	6.15	0.37	3.12e-9	C-reactive protein;
KIRP	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05665937	chr4:1216051	CTBP1	0.55	7.64	0.44	4.86e-13	Obesity-related traits;
KIRP	cis	rs6540559	0.808	rs11119358	chr1:210042456	T/C	cg22029157	chr1:209979665	IRF6	0.57	5.97	0.36	8.09e-9	Cleft lip with or without cleft palate;
KIRP	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg17133734	chr15:86042851	AKAP13	-0.41	-5.13	-0.31	5.97e-7	Interstitial lung disease;
KIRP	cis	rs7973719	0.899	rs12424618	chr12:7344802	A/G	cg07052231	chr12:7363540	PEX5	0.39	5.08	0.31	7.6e-7	IgG glycosylation;
KIRP	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg23594656	chr7:65796392	TPST1	0.42	5.84	0.35	1.62e-8	Aortic root size;
KIRP	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg23587288	chr2:27483067	SLC30A3	-0.65	-7.31	-0.42	3.74e-12	Blood metabolite levels;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.73	11.49	0.59	9.44e-25	Menarche (age at onset);
KIRP	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.51	8.49	0.48	2.02e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6142102	0.625	rs9753690	chr20:32540801	C/G	cg08999081	chr20:33150536	PIGU	0.4	4.98	0.3	1.21e-6	Skin pigmentation;
KIRP	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs1511802	0.501	rs7684025	chr4:187116227	C/T	cg24794857	chr4:187113578	CYP4V2	0.37	5.22	0.32	3.77e-7	Blood protein levels;
KIRP	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.97	-0.3	1.23e-6	Coronary artery disease;
KIRP	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.24	0.32	3.54e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6544713	1.000	rs4245791	chr2:44074431	A/G	cg21783355	chr2:44066198	ABCG5;ABCG8	-0.39	-5.4	-0.33	1.53e-7	Coronary artery disease;LDL cholesterol;
KIRP	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.57	8.02	0.46	4.33e-14	Immature fraction of reticulocytes;
KIRP	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs926938	0.783	rs2144428	chr1:115269211	G/A	cg01522456	chr1:115632236	TSPAN2	0.4	5.36	0.32	1.87e-7	Autism;
KIRP	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg24154853	chr7:158122151	PTPRN2	0.38	5.41	0.33	1.47e-7	Calcium levels;
KIRP	cis	rs12693043	0.701	rs3815969	chr2:175432098	G/A	cg11778734	chr2:175439522	WIPF1	-0.6	-8.47	-0.48	2.31e-15	Urate levels (BMI interaction);
KIRP	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.47	-5.97	-0.36	8.23e-9	Blood metabolite levels;
KIRP	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.19	-24.18	-0.84	5.93e-67	Exhaled nitric oxide output;
KIRP	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg24503407	chr1:205819492	PM20D1	0.47	5.29	0.32	2.66e-7	Prostate-specific antigen levels;
KIRP	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.49	-5.79	-0.35	2.17e-8	Body mass index;
KIRP	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg02569458	chr12:86230093	RASSF9	0.36	5.28	0.32	2.78e-7	Major depressive disorder;
KIRP	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.46	-0.43	1.45e-12	Response to antipsychotic treatment;
KIRP	trans	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.83	-13.44	-0.65	3.12e-31	Dental caries;
KIRP	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg13147721	chr7:65941812	NA	-1.0	-6.82	-0.4	6.95e-11	Diabetic kidney disease;
KIRP	cis	rs7175404	0.793	rs8031668	chr15:94033461	G/A	cg23502883	chr15:93959149	NA	0.46	5.41	0.33	1.52e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.49	6.61	0.39	2.41e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs4502545	0.546	rs9310865	chr3:28450399	G/C	cg09974965	chr14:106361640	NA	-0.55	-6.24	-0.37	1.95e-9	Lymphocyte counts;Lymphocyte percentage of white cells;
KIRP	cis	rs56079296	0.850	rs10477627	chr5:121383974	G/C	cg05256605	chr5:121412184	LOX	-0.48	-5.32	-0.32	2.29e-7	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	1.03	18.62	0.76	7.28e-49	Breast cancer;
KIRP	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	13.81	0.66	1.69e-32	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07926482	chr16:84651521	COTL1	0.49	6.41	0.38	7.34e-10	Parkinson's disease;
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.68	6.19	0.37	2.57e-9	Lung function (FEV1/FVC);
KIRP	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02034447	chr16:89574710	SPG7	0.4	5.15	0.31	5.33e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.52	-7.29	-0.42	4.11e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.74	9.48	0.52	2.28e-18	Coronary artery disease;
KIRP	cis	rs12282928	0.700	rs10838817	chr11:48200265	G/A	cg26585981	chr11:48327164	OR4S1	-0.49	-5.9	-0.35	1.22e-8	Migraine - clinic-based;
KIRP	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.64	-8.23	-0.46	1.07e-14	Colorectal cancer;
KIRP	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg02795151	chr17:7402630	POLR2A	0.78	8.03	0.46	4.11e-14	IgM levels;
KIRP	cis	rs7712401	0.540	rs416763	chr5:122317241	G/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg25706552	chr1:244017396	NA	0.61	6.48	0.38	4.96e-10	RR interval (heart rate);
KIRP	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.33	6.36	0.38	9.79e-10	Alcohol dependence;
KIRP	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	11.32	0.59	3.38e-24	Bone mineral density;
KIRP	cis	rs9905704	0.681	rs7225128	chr17:56636854	T/C	cg12560992	chr17:57184187	TRIM37	-0.54	-4.97	-0.3	1.27e-6	Testicular germ cell tumor;
KIRP	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.86	11.53	0.59	7.25e-25	Coronary artery disease;
KIRP	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	9.62	0.52	8.5e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg14689365	chr7:158441557	NCAPG2	-0.4	-4.95	-0.3	1.39e-6	Height;
KIRP	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-16.08	-0.72	3.07e-40	Electrocardiographic conduction measures;
KIRP	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg15841412	chr13:111365552	ING1	0.57	6.44	0.38	6.38e-10	Coronary artery disease;
KIRP	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23161317	chr6:28129485	ZNF389	0.46	5.33	0.32	2.2e-7	Depression;
KIRP	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg05370193	chr1:21551575	ECE1	-0.38	-5.15	-0.31	5.35e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02807482	chr3:125708958	NA	-0.53	-5.18	-0.31	4.62e-7	Blood pressure (smoking interaction);
KIRP	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.32e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20118822	chr4:119831531	SYNPO2	-0.38	-6.17	-0.37	2.72e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.11	-0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs330071	0.549	rs11785593	chr8:9256324	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	6.49	0.38	4.77e-10	Acne (severe);
KIRP	trans	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg10756647	chr7:56101905	PSPH	-0.98	-7.08	-0.41	1.55e-11	Diabetic kidney disease;
KIRP	cis	rs2294693	0.891	rs9367093	chr6:41012117	A/C	cg14769373	chr6:40998127	UNC5CL	-0.52	-5.51	-0.33	8.96e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg05562828	chr17:3906858	NA	0.77	16.33	0.72	4.28e-41	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27343303	chr11:34380546	NA	-0.45	-6.38	-0.38	8.63e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.67e-6	Depression;
KIRP	cis	rs12580194	0.593	rs11832308	chr12:55755506	C/A	cg19537932	chr12:55886519	OR6C68	-0.47	-6.22	-0.37	2.12e-9	Cancer;
KIRP	cis	rs494562	1.000	rs495469	chr6:86117025	C/T	cg21730993	chr6:86159210	NT5E	0.49	4.95	0.3	1.36e-6	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6910061	1.000	rs28542236	chr6:11106966	T/C	cg27233058	chr6:11094804	LOC221710	0.57	5.76	0.34	2.46e-8	Diabetic kidney disease;
KIRP	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg16141378	chr3:129829833	LOC729375	0.53	7.12	0.41	1.21e-11	Retinal vascular caliber;
KIRP	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.62	-8.83	-0.49	2.07e-16	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs7560272	0.538	rs13006448	chr2:73924424	G/T	cg20560298	chr2:73613845	ALMS1	0.55	6.66	0.39	1.77e-10	Schizophrenia;
KIRP	cis	rs6593803	0.846	rs6669493	chr1:147202308	C/T	cg27546670	chr1:147246839	GJA5	0.63	7.09	0.41	1.45e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs708547	0.541	rs6554392	chr4:57739948	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.66	-8.02	-0.46	4.37e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.81	9.24	0.51	1.25e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs4654899	0.865	rs61779075	chr1:21417027	T/C	cg05370193	chr1:21551575	ECE1	0.45	5.61	0.34	5.3e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs1413885	0.549	rs9436725	chr1:65852870	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.75	0.34	2.59e-8	Anticoagulant levels;
KIRP	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg14664628	chr15:75095509	CSK	-1.14	-18.91	-0.77	7.5e-50	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg13798780	chr7:105162888	PUS7	0.56	4.92	0.3	1.58e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7481584	1.000	rs3814964	chr11:2999507	G/T	cg25174290	chr11:3078921	CARS	-0.55	-6.08	-0.36	4.67e-9	Calcium levels;
KIRP	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.98	10.12	0.54	2.42e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17507749	chr15:85114479	UBE2QP1	0.72	7.93	0.45	7.76e-14	Schizophrenia;
KIRP	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg00319359	chr11:70116639	PPFIA1	0.77	6.27	0.37	1.59e-9	Coronary artery disease;
KIRP	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.6	9.28	0.51	9.07e-18	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.26	0.32	3.1e-7	Tonsillectomy;
KIRP	cis	rs6088813	1.000	rs6141549	chr20:33974051	T/C	cg14752227	chr20:34000481	UQCC	-0.52	-6.86	-0.4	5.42e-11	Height;
KIRP	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg03258749	chr1:151040405	MLLT11	-0.89	-11.01	-0.57	3.45e-23	Blood trace element (Cu levels);
KIRP	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs7975161	0.638	rs10861170	chr12:104615957	A/G	cg25273343	chr12:104657179	TXNRD1	-0.46	-5.28	-0.32	2.8e-7	Toenail selenium levels;
KIRP	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg00343986	chr7:65444356	GUSB	0.49	5.91	0.35	1.13e-8	Aortic root size;
KIRP	cis	rs7187994	0.848	rs34923260	chr16:84773460	A/G	cg07647771	chr16:84786436	USP10	-0.5	-6.08	-0.36	4.59e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.55	-6.44	-0.38	6.17e-10	Aortic root size;
KIRP	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17376030	chr22:41985996	PMM1	0.82	8.83	0.49	2.05e-16	Vitiligo;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13939156	chr17:80058883	NA	0.5	7.51	0.43	1.11e-12	Life satisfaction;
KIRP	trans	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.61	-7.68	-0.44	3.68e-13	Mean corpuscular volume;
KIRP	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.66	-8.4	-0.47	3.61e-15	Iron status biomarkers;
KIRP	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.8	14.93	0.69	2.56e-36	Lymphocyte counts;
KIRP	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg04657146	chr19:12876947	HOOK2	-0.46	-5.56	-0.33	6.9e-8	Mean corpuscular volume;
KIRP	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.51	6.94	0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg25390656	chr10:92980550	PCGF5	0.59	6.28	0.37	1.54e-9	Response to statin therapy;
KIRP	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg10223061	chr2:219282414	VIL1	0.29	4.91	0.3	1.65e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6466055	0.661	rs17640711	chr7:104936920	A/T	cg04380332	chr7:105027541	SRPK2	0.35	4.91	0.3	1.65e-6	Schizophrenia;
KIRP	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg19847130	chr8:10466454	RP1L1	-0.42	-6.15	-0.37	3.13e-9	Retinal vascular caliber;
KIRP	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00938859	chr5:1591904	SDHAP3	0.59	8.0	0.45	5.05e-14	Breast cancer;
KIRP	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.77	-0.35	2.38e-8	Educational attainment;
KIRP	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg21360079	chr12:107162445	NA	-0.68	-9.47	-0.52	2.37e-18	Heart rate;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11317019	chr17:42219250	C17orf53	0.74	6.25	0.37	1.76e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.26	-0.32	3.08e-7	Skin colour saturation;
KIRP	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.67	-7.96	-0.45	6.27e-14	Menarche (age at onset);
KIRP	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.6	6.49	0.38	4.76e-10	Gut microbiome composition (summer);
KIRP	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg10755058	chr3:40428713	ENTPD3	0.49	6.67	0.39	1.64e-10	Renal cell carcinoma;
KIRP	trans	rs6598541	0.615	rs8027767	chr15:99297503	C/A	cg14806252	chr4:2244001	HAUS3	0.45	6.04	0.36	5.51e-9	Urate levels;
KIRP	cis	rs13315871	1.000	rs28417694	chr3:58373939	A/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.12	-0.31	6.19e-7	Cholesterol, total;
KIRP	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.54	6.91	0.4	4.02e-11	Coronary heart disease;
KIRP	cis	rs73200209	0.744	rs61939683	chr12:116508474	T/G	cg01776926	chr12:116560359	MED13L	-0.57	-6.27	-0.37	1.62e-9	Total body bone mineral density;
KIRP	cis	rs6001982	0.667	rs73167092	chr22:40892127	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs7219021	0.705	rs67174000	chr17:46982380	G/A	cg16584676	chr17:46985605	UBE2Z	-0.42	-4.86	-0.3	2.07e-6	Schizophrenia or bipolar disorder;
KIRP	cis	rs7923609	0.967	rs7095571	chr10:65150959	T/G	cg01631684	chr10:65280961	REEP3	-0.51	-5.94	-0.35	9.88e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.48	5.7	0.34	3.41e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg18129178	chr5:148520854	ABLIM3	0.48	5.15	0.31	5.44e-7	Breast cancer;
KIRP	cis	rs4561483	0.603	rs11075033	chr16:12006338	C/T	cg08843971	chr16:11963173	GSPT1	0.53	7.52	0.43	1.04e-12	Testicular germ cell tumor;
KIRP	cis	rs61935443	0.614	rs11107792	chr12:95317126	G/C	cg21533806	chr12:95267307	NA	0.59	5.38	0.32	1.74e-7	Schizophrenia;
KIRP	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	12.97	0.64	1.18e-29	Smoking behavior;
KIRP	trans	rs11165623	0.792	rs1125358	chr1:96971800	T/C	cg10631902	chr5:14652156	NA	-0.57	-8.44	-0.47	2.69e-15	Hip circumference;Waist circumference;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.35e-7	Life satisfaction;
KIRP	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg22906224	chr7:99728672	NA	0.46	5.55	0.33	7.53e-8	Coronary artery disease;
KIRP	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs8141529	0.551	rs34578331	chr22:29347215	G/T	cg02153584	chr22:29168773	CCDC117	0.59	5.5	0.33	9.44e-8	Lymphocyte counts;
KIRP	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.55	-7.37	-0.43	2.56e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.96	11.41	0.59	1.81e-24	Corneal astigmatism;
KIRP	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg19402173	chr7:128379420	CALU	-0.61	-7.86	-0.45	1.18e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs3007168	0.951	rs3007074	chr14:51604731	T/A	cg23942311	chr14:51606299	NA	0.51	5.47	0.33	1.08e-7	Cancer;
KIRP	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.63	-6.69	-0.39	1.54e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.91	11.02	0.57	3.2e-23	Gestational age at birth (maternal effect);
KIRP	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.92	-11.72	-0.6	1.68e-25	Platelet distribution width;
KIRP	cis	rs7083	1.000	rs664011	chr11:117108318	T/A	cg11523350	chr11:117171073	BACE1	-0.25	-4.88	-0.3	1.93e-6	Blood protein levels;
KIRP	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg12435725	chr3:58293450	RPP14	-0.52	-5.14	-0.31	5.56e-7	Cholesterol, total;
KIRP	cis	rs7916697	0.626	rs61854803	chr10:70014638	T/C	cg06988349	chr10:69991859	ATOH7	0.39	5.05	0.31	8.58e-7	Optic disc area;
KIRP	cis	rs946836	0.562	rs11211631	chr1:48383741	A/C	cg08121652	chr1:48381824	NA	0.22	5.04	0.31	8.9e-7	White matter integrity;
KIRP	cis	rs3750965	0.920	rs10896421	chr11:68863048	T/C	cg06818126	chr11:68850279	TPCN2	-0.53	-6.31	-0.37	1.28e-9	Hair color;
KIRP	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg06027949	chr8:82754900	SNX16	0.46	5.64	0.34	4.61e-8	Diastolic blood pressure;
KIRP	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg06108461	chr20:60628389	TAF4	-0.55	-6.86	-0.4	5.4e-11	Body mass index;
KIRP	cis	rs76917914	0.820	rs2281732	chr9:100845007	A/G	cg03040243	chr9:100819229	NANS	0.62	6.85	0.4	5.83e-11	Immature fraction of reticulocytes;
KIRP	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.7	-0.73	2.25e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	1.04	14.57	0.68	4.28e-35	Menopause (age at onset);
KIRP	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.58	-6.09	-0.36	4.26e-9	Obesity-related traits;
KIRP	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.26	0.51	1.02e-17	Height;
KIRP	cis	rs59868192	0.925	rs2724934	chr15:42252156	C/T	cg20935245	chr15:42234343	EHD4	-0.48	-5.26	-0.32	3.1e-7	White blood cell count;
KIRP	cis	rs55692468	0.606	rs1878632	chr2:153323158	A/C	cg04681845	chr2:153283485	FMNL2	-0.52	-6.61	-0.39	2.37e-10	Intraocular pressure;
KIRP	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg02773041	chr1:40204384	PPIE	0.59	7.85	0.45	1.25e-13	Blood protein levels;
KIRP	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.67	-9.46	-0.52	2.58e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs10486003	1.000	rs75595736	chr7:97199074	T/G	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.66	-5.22	-0.32	3.77e-7	Response to platinum-based agents;
KIRP	cis	rs960902	0.747	rs6724538	chr2:37728018	A/C	cg25341268	chr2:37734390	NA	-0.57	-7.91	-0.45	8.76e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg19731401	chr7:2775893	GNA12	0.76	7.36	0.42	2.77e-12	Childhood ear infection;
KIRP	cis	rs1440410	0.835	rs4690777	chr4:144109535	T/C	cg01719995	chr4:144104893	USP38	0.39	5.25	0.32	3.32e-7	Ischemic stroke;
KIRP	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg24699146	chr1:24152579	HMGCL	-0.41	-5.13	-0.31	5.8e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-5.52	-0.33	8.55e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.65	0.34	4.35e-8	Educational attainment;
KIRP	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.54	-7.12	-0.41	1.2e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs17095355	0.901	rs10884919	chr10:111757791	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.09	-0.36	4.33e-9	Biliary atresia;
KIRP	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.44	15.11	0.69	6.13e-37	Schizophrenia;
KIRP	cis	rs2274273	0.624	rs8014540	chr14:55841688	C/A	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.44e-7	Protein biomarker;
KIRP	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg07511934	chr16:89386912	ANKRD11	-0.4	-5.2	-0.31	4.27e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg03959625	chr15:84868606	LOC388152	0.45	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg21466736	chr12:48725269	NA	-0.45	-5.87	-0.35	1.39e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25517755	chr10:38738941	LOC399744	0.53	7.25	0.42	5.53e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg04935436	chr20:30431758	NA	0.51	5.94	0.35	9.62e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.76	-7.57	-0.43	7.48e-13	Bipolar disorder;
KIRP	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.6	-6.88	-0.4	4.96e-11	Menarche (age at onset);
KIRP	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-5.1	-0.31	6.76e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7312774	0.618	rs726943	chr12:107331647	A/G	cg16260113	chr12:107380972	MTERFD3	0.84	7.63	0.44	5.23e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs6977660	0.714	rs6970798	chr7:19816741	G/C	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.53	6.7	0.39	1.44e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs9409565	0.855	rs9409720	chr9:97074179	A/G	cg05679027	chr9:99775184	HIATL2	0.51	6.3	0.37	1.4e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg07576016	chr5:1523261	LPCAT1	-0.45	-6.15	-0.37	3.19e-9	Cancer;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16524936	chr4:1340807	KIAA1530	-0.43	-5.21	-0.32	3.93e-7	Longevity;
KIRP	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	12.29	0.62	2.19e-27	Ileal carcinoids;
KIRP	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2130392	0.562	rs876838	chr4:185655487	G/T	cg21366198	chr4:185655624	MLF1IP	0.49	6.89	0.4	4.53e-11	Kawasaki disease;
KIRP	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg06637938	chr14:75390232	RPS6KL1	0.49	6.91	0.4	4.13e-11	Caffeine consumption;
KIRP	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.92	14.69	0.68	1.7000000000000001e-35	Dental caries;
KIRP	cis	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg20368463	chr18:77673604	PQLC1	-0.57	-6.13	-0.36	3.55e-9	Opioid sensitivity;
KIRP	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-9.59	-0.52	1.06e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg00647317	chr7:50633725	DDC	-0.46	-5.07	-0.31	8.01e-7	Malaria;
KIRP	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	6.27	0.37	1.58e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg23422044	chr7:1970798	MAD1L1	-0.67	-6.34	-0.37	1.1e-9	Neuroticism;
KIRP	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.44	6.54	0.38	3.57e-10	Major depressive disorder;
KIRP	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-8.04	-0.46	3.82e-14	Bipolar disorder;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17808901	chr3:39093368	WDR48	0.63	6.03	0.36	6.12e-9	Lung function (FEV1);
KIRP	trans	rs78438709	1.000	rs76432564	chr10:124150727	A/G	cg08224212	chr11:34196093	ABTB2	-0.93	-6.03	-0.36	6e-9	Headache;
KIRP	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg26338869	chr17:61819248	STRADA	0.51	6.14	0.36	3.31e-9	Prudent dietary pattern;
KIRP	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.53	6.84	0.4	6.23e-11	IgG glycosylation;
KIRP	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg03808351	chr9:123631620	PHF19	0.43	5.83	0.35	1.71e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg10818794	chr15:86012489	AKAP13	0.51	7.24	0.42	5.88e-12	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11987759	chr7:65425863	GUSB	0.61	7.99	0.45	5.33e-14	Aortic root size;
KIRP	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg26248373	chr2:1572462	NA	-0.62	-7.61	-0.44	5.82e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.79	13.32	0.65	7.55e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs933360	0.553	rs6979369	chr7:50831871	A/C	cg20003124	chr12:4557277	NA	0.53	6.46	0.38	5.69e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.76	10.3	0.55	6.4e-21	Pancreatic cancer;
KIRP	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-5.19	-0.31	4.49e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg25288420	chr1:78511713	GIPC2	-0.51	-6.78	-0.4	8.92e-11	Obesity-related traits;
KIRP	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18364779	chr6:26104403	HIST1H4C	0.38	5.18	0.31	4.58e-7	Schizophrenia;
KIRP	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg26531700	chr6:26746687	NA	0.41	5.63	0.34	4.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03934478	chr11:495069	RNH1	0.75	5.98	0.36	7.81e-9	Body mass index;
KIRP	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.41	-0.47	3.36e-15	Inflammatory bowel disease;
KIRP	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg20673091	chr1:2541236	MMEL1	0.42	6.02	0.36	6.3e-9	Ulcerative colitis;
KIRP	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21016266	chr12:122356598	WDR66	0.67	9.12	0.5	2.71e-17	Mean corpuscular volume;
KIRP	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.74	-9.64	-0.52	7.18e-19	Asthma;
KIRP	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs28489187	0.558	rs6576763	chr1:85859376	T/C	cg16011679	chr1:85725395	C1orf52	-0.46	-5.75	-0.34	2.64e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6967385	0.560	rs7790370	chr7:12353523	G/C	cg20607287	chr7:12443886	VWDE	0.39	5.03	0.31	9.65e-7	Response to taxane treatment (placlitaxel);
KIRP	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.41	-5.1	-0.31	6.71e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs1440410	0.798	rs4690775	chr4:144085860	A/G	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg14289246	chr4:154710475	SFRP2	0.55	6.7	0.39	1.44e-10	Response to statins (LDL cholesterol change);
KIRP	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs10129255	0.536	rs6576201	chr14:107139713	A/G	cg23076370	chr14:107095027	NA	0.38	4.92	0.3	1.58e-6	Kawasaki disease;
KIRP	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.77	-0.57	2.13e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.18	0.7	3.63e-37	Platelet count;
KIRP	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.79	10.22	0.55	1.19e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs877282	0.583	rs10904566	chr10:821662	C/G	cg22713356	chr15:30763199	NA	0.88	8.69	0.48	5.04e-16	Uric acid levels;
KIRP	cis	rs2901656	0.691	rs10798005	chr1:172382965	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	-0.42	-5.43	-0.33	1.35e-7	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs7630877	0.962	rs17748864	chr3:179649511	C/T	cg18765712	chr3:179670323	PEX5L	0.5	6.1	0.36	3.98e-9	Type 2 diabetes;
KIRP	cis	rs7712401	0.601	rs257813	chr5:122217168	G/A	cg19412675	chr5:122181750	SNX24	0.51	5.55	0.33	7.52e-8	Mean platelet volume;
KIRP	trans	rs8054556	0.787	rs35105141	chr16:30057148	C/T	cg13500354	chr6:168617491	NA	0.33	6.11	0.36	3.81e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.84	0.4	6.24e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg05729581	chr11:3078854	CARS	-0.48	-5.79	-0.35	2.11e-8	Longevity;
KIRP	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.47	6.08	0.36	4.68e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.19	-0.61	4.82e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6901004	0.803	rs354531	chr6:111548933	C/T	cg15721981	chr6:111408429	SLC16A10	-0.57	-7.76	-0.44	2.33e-13	Blood metabolite levels;
KIRP	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg23387468	chr7:139079360	LUC7L2	0.3	5.11	0.31	6.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs35300120	0.719	rs58437968	chr1:233662301	A/G	cg23054119	chr1:233659267	NA	-0.41	-5.71	-0.34	3.17e-8	Cognitive function;
KIRP	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.52	5.93	0.35	1.05e-8	HDL cholesterol;
KIRP	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.82	11.75	0.6	1.36e-25	Body mass index;
KIRP	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.12	12.38	0.62	1.1e-27	Corneal structure;
KIRP	cis	rs1413885	0.549	rs10889546	chr1:65851759	G/A	cg13202122	chr1:65886182	LEPROT;LEPR	0.41	4.87	0.3	2.04e-6	Anticoagulant levels;
KIRP	cis	rs9880211	0.528	rs75685279	chr3:136434833	A/C	cg15507776	chr3:136538369	TMEM22	0.44	5.24	0.32	3.42e-7	Body mass index;Height;
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg03128060	chr6:142623767	GPR126	0.36	5.2	0.31	4.21e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg11271282	chr2:238384023	NA	0.56	6.5	0.38	4.33e-10	Prostate cancer;
KIRP	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.26	0.42	4.92e-12	Prudent dietary pattern;
KIRP	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg05665937	chr4:1216051	CTBP1	0.59	8.46	0.47	2.37e-15	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.83	11.85	0.6	6.37e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.18	-0.37	2.63e-9	Colorectal cancer;
KIRP	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.58	7.45	0.43	1.6e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9815354	0.812	rs55916855	chr3:42002761	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11834862	0.598	rs11246996	chr12:132690579	C/A	cg05229598	chr12:132699923	GALNT9	-0.57	-6.03	-0.36	6.13e-9	Anti-saccade response;
KIRP	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21972741	chr5:435613	AHRR	0.53	7.04	0.41	1.88e-11	Cystic fibrosis severity;
KIRP	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.84	-0.35	1.66e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs78487399	0.808	rs72865297	chr2:43743248	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.4	-0.33	1.53e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.63	-6.32	-0.37	1.23e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9398803	0.865	rs9385399	chr6:126759033	A/C	cg19875578	chr6:126661172	C6orf173	-0.43	-5.43	-0.33	1.36e-7	Male-pattern baldness;
KIRP	cis	rs12210905	1.000	rs3800310	chr6:27206843	C/G	cg11502198	chr6:26597334	ABT1	-0.83	-5.27	-0.32	3.03e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs17101923	0.853	rs12424086	chr12:66364509	T/C	cg06712651	chr12:66351869	HMGA2	-0.56	-5.87	-0.35	1.37e-8	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19700328	chr14:106028568	NA	-0.59	-6.57	-0.39	2.96e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.43	-0.38	6.64e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.83	12.9	0.64	2.05e-29	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-1.07	-12.38	-0.62	1.09e-27	Vitiligo;
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg15117754	chr3:10150083	C3orf24	-0.53	-5.28	-0.32	2.9e-7	Alzheimer's disease;
KIRP	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg04248312	chr19:17393744	ANKLE1	-0.81	-9.02	-0.5	5.64e-17	Systemic lupus erythematosus;
KIRP	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.49	7.06	0.41	1.69e-11	Lewy body disease;
KIRP	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.19	-0.37	2.45e-9	Neuroticism;
KIRP	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.76	10.97	0.57	4.87e-23	Schizophrenia;
KIRP	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.4	5.95	0.35	9.03e-9	Hypertriglyceridemia;
KIRP	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	ch.8.33884649F	chr8:33765107	NA	0.57	6.29	0.37	1.48e-9	Body mass index;
KIRP	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.45	5.08	0.31	7.35e-7	Interleukin-17 levels;
KIRP	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.39	-0.51	4.37e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg04310649	chr10:35416472	CREM	-0.59	-6.98	-0.41	2.7e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg03609598	chr5:56110824	MAP3K1	0.48	5.51	0.33	9.24e-8	Initial pursuit acceleration;
KIRP	cis	rs9653442	0.564	rs56054309	chr2:100794940	T/C	cg17356467	chr2:100759845	AFF3	0.4	5.62	0.34	5.25e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27591053	chr5:180671165	GNB2L1;SNORD95	0.45	6.55	0.39	3.4e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg01338084	chr22:32026380	PISD	0.95	7.22	0.42	6.55e-12	Age-related hearing impairment;
KIRP	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.53	6.68	0.39	1.56e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-5.41	-0.33	1.49e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.29	-0.55	6.9299999999999992e-21	Chronic sinus infection;
KIRP	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.75	10.84	0.57	1.24e-22	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs56161922	1.000	rs12567945	chr1:207841934	T/C	cg09557387	chr1:207818395	CR1L	1.08	6.5	0.38	4.51e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.67	-6.81	-0.4	7.45e-11	Ulcerative colitis;
KIRP	cis	rs526231	0.575	rs12652973	chr5:102306322	G/A	cg23492399	chr5:102201601	PAM	-0.49	-5.39	-0.32	1.68e-7	Primary biliary cholangitis;
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg04369109	chr6:150039330	LATS1	-0.59	-7.61	-0.44	5.84e-13	Lung cancer;
KIRP	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg22778903	chr21:42741698	MX2	0.6	7.94	0.45	7.12e-14	Melanoma;
KIRP	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg13319975	chr6:146136371	FBXO30	0.41	5.76	0.34	2.46e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01200585	chr1:228362443	C1orf69	0.41	5.14	0.31	5.58e-7	Diastolic blood pressure;
KIRP	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.59	-7.33	-0.42	3.3e-12	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.29e-9	Obesity-related traits;
KIRP	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg23698023	chr8:27181813	PTK2B	0.34	5.1	0.31	6.68e-7	Neuroticism;
KIRP	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg14927855	chr7:155151427	NA	0.7	8.15	0.46	1.83e-14	Stem cell growth factor beta levels;
KIRP	cis	rs4356932	1.000	rs4859598	chr4:76959828	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16318349	chr1:154917307	PBXIP1	-0.31	-5.4	-0.33	1.55e-7	Prostate cancer;
KIRP	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg07741184	chr6:167504864	NA	-0.21	-5.44	-0.33	1.29e-7	Crohn's disease;
KIRP	cis	rs7404095	0.775	rs886114	chr16:23865986	C/T	cg21745164	chr16:23765304	CHP2	0.35	4.92	0.3	1.61e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.59	-9.74	-0.53	3.56e-19	Schizophrenia;
KIRP	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.77	-10.81	-0.57	1.49e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg20607798	chr8:58055168	NA	0.77	5.98	0.36	7.94e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs336284	0.564	rs336285	chr7:35298564	A/G	cg06685737	chr7:35301730	NA	0.52	6.04	0.36	5.53e-9	Suicide;Suicide behavior;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg03115019	chr17:80708279	FN3K	0.42	4.99	0.3	1.15e-6	Glycated hemoglobin levels;
KIRP	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	8.15	0.46	1.89e-14	Schizophrenia;
KIRP	cis	rs2979489	0.891	rs2979508	chr8:30388444	C/T	cg26383811	chr8:30366931	RBPMS	-0.45	-6.28	-0.37	1.54e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg06108461	chr20:60628389	TAF4	-0.54	-6.3	-0.37	1.37e-9	Body mass index;
KIRP	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg25706552	chr1:244017396	NA	0.52	6.05	0.36	5.3300000000000004e-09	RR interval (heart rate);
KIRP	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.67	7.75	0.44	2.43e-13	HIV-1 control;
KIRP	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.11	-0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg21419209	chr3:44054225	NA	0.73	9.25	0.51	1.12e-17	Coronary artery disease;
KIRP	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	6.09	0.36	4.31e-9	Response to antipsychotic treatment;
KIRP	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg18164611	chr1:46958628	NA	0.45	5.65	0.34	4.46e-8	Monobrow;
KIRP	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.61	-6.48	-0.38	4.96e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.56	-9.03	-0.5	5.21e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs554111	0.660	rs667687	chr1:21072577	A/G	cg08890418	chr1:21044141	KIF17	0.55	8.76	0.49	3.22e-16	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg03512499	chr6:134216920	NA	-0.48	-6.26	-0.37	1.73e-9	Coronary artery disease;
KIRP	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.47	6.02	0.36	6.31e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.5	0.72	1.14e-41	Chronic sinus infection;
KIRP	cis	rs11169552	0.510	rs4768893	chr12:50960480	C/T	cg12884762	chr12:50931848	DIP2B	-0.45	-5.1	-0.31	6.91e-7	Colorectal cancer;
KIRP	cis	rs2434422	0.708	rs16983728	chr19:52839110	T/C	cg17271561	chr19:52839334	ZNF610	-0.84	-6.19	-0.37	2.45e-9	Cannabis use (initiation);
KIRP	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03934478	chr11:495069	RNH1	0.88	6.84	0.4	6.4e-11	Body mass index;
KIRP	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg19338460	chr6:170058176	WDR27	-1.22	-9.65	-0.52	6.62e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs3105593	1.000	rs3131584	chr15:50847401	G/A	cg05456662	chr15:50716270	USP8	0.39	4.99	0.3	1.15e-6	QT interval;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03620623	chr19:50303257	AP2A1	-0.46	-6.05	-0.36	5.23e-9	Parkinson's disease;
KIRP	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.45	-6.83	-0.4	6.52e-11	Coronary artery disease;
KIRP	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg07001201	chr5:642380	CEP72	0.68	6.21	0.37	2.29e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.59	-6.64	-0.39	2.01e-10	Coronary artery disease;
KIRP	cis	rs918629	0.567	rs10069748	chr5:95241222	C/T	cg16656078	chr5:95278638	ELL2	0.34	5.29	0.32	2.68e-7	IgG glycosylation;
KIRP	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.8	0.4	8.09e-11	Breast cancer;
KIRP	cis	rs55871839	0.643	rs10105665	chr8:59799367	A/G	cg07426533	chr8:59803705	TOX	-0.52	-8.78	-0.49	2.74e-16	Pneumonia;
KIRP	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg00800569	chr2:239229395	TRAF3IP1	0.47	5.01	0.3	1.04e-6	Multiple system atrophy;
KIRP	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg07382826	chr16:28625726	SULT1A1	0.46	5.09	0.31	7.23e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg23067535	chr8:124195133	FAM83A	-0.72	-7.1	-0.41	1.31e-11	Urinary uromodulin levels;
KIRP	cis	rs13102973	0.797	rs4453983	chr4:135905424	A/C	cg14419869	chr4:135874104	NA	0.48	7.5	0.43	1.13e-12	Subjective well-being;
KIRP	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg05973401	chr12:123451056	ABCB9	0.49	5.5	0.33	9.49e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.7	-7.54	-0.43	9.06e-13	Gut microbiome composition (summer);
KIRP	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.47	-7.16	-0.42	9.28e-12	Coronary artery disease;
KIRP	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg15880211	chr22:50250494	ZBED4	0.48	5.69	0.34	3.58e-8	Schizophrenia;
KIRP	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.21	-0.37	2.29e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg06204229	chr3:52865917	ITIH4	0.46	5.32	0.32	2.28e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8077577	0.895	rs16960980	chr17:18100858	C/T	cg18869244	chr17:18121946	NA	0.5	5.7	0.34	3.37e-8	Obesity-related traits;
KIRP	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.83	0.53	1.86e-19	Heart rate;
KIRP	cis	rs9654415	0.560	rs28659820	chr5:72549518	G/A	cg14879418	chr5:72571312	NA	-0.45	-5.43	-0.33	1.38e-7	Eyebrow thickness;
KIRP	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg01689657	chr7:91764605	CYP51A1	0.46	6.66	0.39	1.77e-10	Breast cancer;
KIRP	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06634786	chr22:41940651	POLR3H	-0.58	-6.22	-0.37	2.17e-9	Vitiligo;
KIRP	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg04317338	chr11:64019027	PLCB3	0.8	6.16	0.37	2.9e-9	Mean platelet volume;
KIRP	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.57	-6.54	-0.38	3.53e-10	Menarche (age at onset);
KIRP	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.13	0.5	2.55e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg03150409	chr4:1892317	WHSC1	0.48	6.92	0.4	3.86e-11	Morning vs. evening chronotype;
KIRP	cis	rs4073416	0.568	rs1121885	chr14:66156914	A/G	cg03016385	chr14:66212404	NA	-0.54	-6.72	-0.39	1.22e-10	N-glycan levels;
KIRP	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg27446573	chr6:127587934	RNF146	0.95	11.91	0.6	4.13e-26	Breast cancer;
KIRP	cis	rs7630877	0.962	rs17748709	chr3:179642526	A/T	cg18765712	chr3:179670323	PEX5L	0.5	6.17	0.37	2.85e-9	Type 2 diabetes;
KIRP	cis	rs8192282	0.646	rs4288587	chr1:154492357	A/T	cg07911225	chr1:154474108	TDRD10;SHE	-0.34	-4.97	-0.3	1.24e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03352830	chr11:487213	PTDSS2	0.77	6.22	0.37	2.15e-9	Body mass index;
KIRP	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.28	0.37	1.49e-9	Retinal vascular caliber;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg03724423	chr7:27170755	HOXA4	-0.41	-5.87	-0.35	1.43e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg05370193	chr1:21551575	ECE1	0.45	6.28	0.37	1.5e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-8.63	-0.48	7.74e-16	Resting heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10500218	chr1:181058063	IER5	0.48	7.01	0.41	2.22e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12643440	0.538	rs2041440	chr4:17136032	T/C	cg22650099	chr4:17144496	NA	-0.71	-8.79	-0.49	2.66e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs11225247	0.881	rs12279056	chr11:102257584	T/A	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9308433	0.529	rs867444	chr1:214502160	T/C	cg06198575	chr1:214491504	SMYD2	0.47	5.93	0.35	1e-8	IgG glycosylation;
KIRP	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.39	-4.9	-0.3	1.77e-6	Carotid intima media thickness;
KIRP	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg07827796	chr19:33622959	WDR88	0.44	5.24	0.32	3.47e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.04e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.86	-8.58	-0.48	1.08e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.77	-0.71	3.49e-39	Immature fraction of reticulocytes;
KIRP	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg15655495	chr12:38532458	NA	-0.28	-4.98	-0.3	1.2e-6	Morning vs. evening chronotype;
KIRP	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-12.79	-0.63	4.74e-29	Dental caries;
KIRP	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.83	-10.05	-0.54	3.95e-20	Vitamin D levels;
KIRP	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.5	-0.78	7.83e-52	Height;
KIRP	cis	rs3892630	0.500	rs35170371	chr19:33355081	G/A	cg22980127	chr19:33182716	NUDT19	0.97	10.07	0.54	3.34e-20	Red blood cell traits;
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg03115019	chr17:80708279	FN3K	0.42	4.96	0.3	1.3e-6	Glycated hemoglobin levels;
KIRP	cis	rs7760949	0.963	rs1467729	chr6:13911167	C/T	cg27413430	chr6:13925136	RNF182	-0.44	-5.71	-0.34	3.25e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2033732	0.706	rs7830484	chr8:85068154	C/G	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg23307798	chr14:103986281	CKB	-0.5	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.63	10.41	0.55	2.93e-21	Lung cancer;
KIRP	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg11166453	chr1:247681781	NA	0.64	5.64	0.34	4.69e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg04202892	chr2:111875749	ACOXL	0.46	6.48	0.38	5.02e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.63	8.62	0.48	8.24e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.38	-5.83	-0.35	1.75e-8	Height;
KIRP	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.61	-9.47	-0.52	2.45e-18	Sense of smell;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg24874828	chr4:187887005	NA	-0.47	-7.06	-0.41	1.68e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg00409905	chr10:38381863	ZNF37A	-0.57	-6.08	-0.36	4.64e-9	Obesity (extreme);
KIRP	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.5	5.81	0.35	1.93e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.43	7.55	0.43	8.43e-13	Renal cell carcinoma;
KIRP	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg07451762	chr16:28383216	NA	0.42	5.48	0.33	1.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg06565975	chr8:143823917	SLURP1	0.47	7.39	0.43	2.31e-12	Urinary tract infection frequency;
KIRP	cis	rs739496	0.542	rs10849937	chr12:111792427	A/G	cg10833066	chr12:111807467	FAM109A	0.4	4.85	0.3	2.14e-6	Platelet count;
KIRP	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg11161011	chr14:65562177	MAX	-0.63	-7.97	-0.45	6.06e-14	Obesity-related traits;
KIRP	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg24296786	chr1:45957014	TESK2	0.51	5.71	0.34	3.29e-8	Homocysteine levels;
KIRP	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg25356066	chr3:128598488	ACAD9	0.52	6.02	0.36	6.18e-9	IgG glycosylation;
KIRP	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.65	7.33	0.42	3.32e-12	Height;
KIRP	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs7923609	0.967	rs7082470	chr10:65277026	G/A	cg01631684	chr10:65280961	REEP3	-0.51	-6.06	-0.36	4.95e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9469913	0.808	rs2744971	chr6:34581636	T/G	cg14254433	chr6:34482411	PACSIN1	-0.43	-5.32	-0.32	2.33e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs12519773	0.555	rs1845840	chr5:92388210	G/A	cg18783429	chr5:92414398	NA	-0.34	-5.78	-0.35	2.27e-8	Migraine;
KIRP	cis	rs7106204	0.534	rs74650605	chr11:24253414	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	6.94	0.4	3.5e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.88	-10.42	-0.55	2.66e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg04691961	chr3:161091175	C3orf57	-0.62	-10.0	-0.54	5.68e-20	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.84	12.18	0.61	4.95e-27	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-0.74	-10.41	-0.55	2.86e-21	White blood cell count;
KIRP	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg06148736	chr22:18985691	NA	0.31	5.1	0.31	6.87e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2916247	1.000	rs2976502	chr8:92980734	A/G	cg10183463	chr8:93005414	RUNX1T1	0.57	7.39	0.43	2.33e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-11.72	-0.6	1.73e-25	Dental caries;
KIRP	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg04369109	chr6:150039330	LATS1	-0.46	-5.62	-0.34	5.17e-8	Lung cancer;
KIRP	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs10214930	0.671	rs1009252	chr7:27621673	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.92	0.3	1.61e-6	Hypospadias;
KIRP	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.78	-10.42	-0.55	2.77e-21	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs12517041	1.000	rs7736335	chr5:23288232	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.79	-0.49	2.56e-16	Calcium levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05602854	chr6:34217152	C6orf1	0.51	6.54	0.38	3.45e-10	Parkinson's disease;
KIRP	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg14851346	chr12:38532713	NA	-0.4	-4.96	-0.3	1.3e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg18306943	chr3:40428807	ENTPD3	0.42	5.84	0.35	1.67e-8	Renal cell carcinoma;
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.5	6.88	0.4	4.99e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg10818794	chr15:86012489	AKAP13	-0.53	-7.53	-0.43	9.9e-13	Coronary artery disease;
KIRP	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	1.13	16.94	0.73	3.44e-43	Monocyte percentage of white cells;
KIRP	cis	rs220519	0.745	rs220530	chr20:37271866	C/T	cg24308336	chr20:37270989	C20orf95	-0.25	-5.66	-0.34	4.18e-8	Schizophrenia;
KIRP	cis	rs7224685	0.569	rs8082425	chr17:3991706	C/G	cg09695851	chr17:3907499	NA	0.57	5.29	0.32	2.64e-7	Type 2 diabetes;
KIRP	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.03	12.55	0.62	2.95e-28	Testicular germ cell tumor;
KIRP	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg15848620	chr12:58087721	OS9	-0.51	-5.96	-0.36	8.53e-9	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.99	-16.4	-0.72	2.4e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.64	-5.95	-0.35	9.24e-9	Inflammatory bowel disease;
KIRP	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg05775895	chr3:12838266	CAND2	0.46	7.59	0.44	6.73e-13	QRS complex (12-leadsum);
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg07216194	chr8:27182965	PTK2B	0.45	5.6	0.34	5.82e-8	Neuroticism;
KIRP	trans	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg25042112	chr7:64838748	ZNF92	-0.6	-6.19	-0.37	2.54e-9	Pain;
KIRP	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg05973401	chr12:123451056	ABCB9	0.63	7.53	0.43	9.88e-13	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.07	0.5	3.81e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.35	-5.01	-0.3	1.06e-6	Motion sickness;
KIRP	cis	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg15128208	chr22:42549153	NA	0.55	6.01	0.36	6.83e-9	Birth weight;
KIRP	cis	rs2273669	0.667	rs3734649	chr6:109294752	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.61	-0.39	2.35e-10	Prostate cancer;
KIRP	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.46	-6.83	-0.4	6.46e-11	Electroencephalogram traits;
KIRP	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.8	-7.97	-0.45	6.06e-14	Systemic lupus erythematosus;
KIRP	cis	rs526231	0.584	rs246914	chr5:102559407	T/C	cg23492399	chr5:102201601	PAM	-0.59	-5.81	-0.35	1.88e-8	Primary biliary cholangitis;
KIRP	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.85	-8.49	-0.48	2.03e-15	Coronary artery calcification;
KIRP	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.28	-0.32	2.87e-7	Neuroticism;
KIRP	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg01294253	chr9:136912663	BRD3	-0.39	-5.37	-0.32	1.82e-7	Platelet distribution width;
KIRP	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.49	0.48	1.92e-15	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00155593	chr15:60690279	ANXA2	0.47	6.2	0.37	2.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8062405	0.728	rs9931989	chr16:28906084	G/C	cg07382826	chr16:28625726	SULT1A1	-0.45	-5.0	-0.3	1.09e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17655565	0.581	rs73093302	chr12:52763203	A/G	cg07925835	chr12:52762777	KRT85	0.48	5.23	0.32	3.55e-7	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.43	0.59	1.46e-24	Heart rate;
KIRP	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.6	-7.57	-0.43	7.49e-13	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11804381	chr22:36662414	APOL1	0.44	6.29	0.37	1.47e-9	Survival in pancreatic cancer;
KIRP	cis	rs1783925	1.000	rs640364	chr11:125300766	G/A	cg03464685	chr11:125439445	EI24	-0.44	-4.92	-0.3	1.56e-6	Formal thought disorder in schizophrenia;
KIRP	cis	rs4965006	0.915	rs7969545	chr12:132419157	C/T	cg00588090	chr12:132412438	PUS1	-0.57	-6.23	-0.37	2.01e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.11e-7	Breast cancer;
KIRP	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.57	-7.06	-0.41	1.66e-11	Arsenic metabolism;
KIRP	cis	rs2836950	0.959	rs4818008	chr21:40611442	T/A	cg11644478	chr21:40555479	PSMG1	-0.53	-5.23	-0.32	3.66e-7	Menarche (age at onset);
KIRP	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.31e-9	Schizophrenia;
KIRP	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.5	-6.79	-0.4	8.59e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.74	-7.06	-0.41	1.72e-11	Platelet count;
KIRP	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16318349	chr1:154917307	PBXIP1	-0.29	-5.17	-0.31	4.75e-7	Prostate cancer;
KIRP	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.62	8.63	0.48	7.73e-16	Height;
KIRP	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg21452805	chr1:244014465	NA	0.69	5.95	0.35	9.02e-9	RR interval (heart rate);
KIRP	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg16917193	chr12:54089295	NA	-0.53	-6.59	-0.39	2.72e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.73	-9.84	-0.53	1.82e-19	Blood metabolite levels;
KIRP	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07600858	chr19:15529452	AKAP8L	0.54	6.94	0.4	3.48e-11	Parkinson's disease;
KIRP	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg11707556	chr5:10655725	ANKRD33B	0.67	8.44	0.47	2.8e-15	Coronary artery disease;
KIRP	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.61	0.34	5.46e-8	Lung cancer;
KIRP	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.81	-11.45	-0.59	1.33e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg01557791	chr16:72042693	DHODH	-0.43	-5.27	-0.32	2.95e-7	Fibrinogen levels;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg02733842	chr7:1102375	C7orf50	0.59	6.02	0.36	6.17e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg13939156	chr17:80058883	NA	-0.47	-5.5	-0.33	9.3e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12181797	chr4:4292013	ZNF509;LYAR	0.5	6.82	0.4	7.03e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8014252	0.708	rs74062730	chr14:70991650	A/C	cg19730268	chr14:71022823	NA	-0.73	-6.55	-0.39	3.35e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.61	6.64	0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.67	-8.13	-0.46	2.1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.88	-16.3	-0.72	5.26e-41	Body mass index;
KIRP	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.63	-8.37	-0.47	4.31e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2790457	0.792	rs1265830	chr10:28912223	A/G	cg05705492	chr10:28955341	NA	0.54	8.44	0.47	2.84e-15	Multiple myeloma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20613370	chr20:45318380	TP53RK	0.46	6.29	0.37	1.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.64	8.88	0.49	1.42e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs959260	1.000	rs2891713	chr17:73386622	G/C	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.09	-0.36	4.32e-9	Systemic lupus erythematosus;
KIRP	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	9.01	0.5	5.92e-17	Exhaled nitric oxide output;
KIRP	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.56	-6.92	-0.4	3.97e-11	Cognitive test performance;
KIRP	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.9	13.19	0.64	2.16e-30	Selective IgA deficiency;
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg12486944	chr17:80159399	CCDC57	-0.39	-5.17	-0.31	4.89e-7	Life satisfaction;
KIRP	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg25486957	chr4:152246857	NA	-0.5	-5.47	-0.33	1.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9831754	0.756	rs6548554	chr3:78423185	C/T	cg06138941	chr3:78371609	NA	-0.77	-10.86	-0.57	1.1e-22	Calcium levels;
KIRP	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg01557791	chr16:72042693	DHODH	-0.51	-6.35	-0.38	1.05e-9	Fibrinogen levels;
KIRP	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.94	15.7	0.71	5.89e-39	Blood protein levels;
KIRP	cis	rs6882046	0.513	rs254780	chr5:88019747	G/C	cg22951263	chr5:87985283	NA	-0.47	-6.53	-0.38	3.74e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.38	0.51	4.53e-18	Lung cancer in ever smokers;
KIRP	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.18	13.91	0.66	7.62e-33	Uric acid levels;
KIRP	cis	rs6545883	0.562	rs777588	chr2:61426820	G/A	cg15711740	chr2:61764176	XPO1	-0.58	-7.68	-0.44	3.82e-13	Tuberculosis;
KIRP	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.43	5.43	0.33	1.33e-7	Aortic root size;
KIRP	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.74	9.25	0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs45430	0.928	rs398206	chr21:42742036	C/A	cg06102954	chr21:42741788	MX2	0.54	7.45	0.43	1.62e-12	Melanoma;
KIRP	trans	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg25214090	chr10:38739885	LOC399744	0.68	8.41	0.47	3.35e-15	Corneal astigmatism;
KIRP	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg00405596	chr8:11794950	NA	-0.48	-6.38	-0.38	8.89e-10	Retinal vascular caliber;
KIRP	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.24e-6	Recombination rate (females);
KIRP	cis	rs40363	1.000	rs40363	chr16:3509056	G/A	cg22508957	chr16:3507546	NAT15	0.54	7.18	0.42	8.06e-12	Tuberculosis;
KIRP	cis	rs6832769	1.000	rs6832769	chr4:56298194	C/T	cg09317128	chr4:56265301	TMEM165	0.52	6.77	0.4	9.15e-11	Personality dimensions;
KIRP	cis	rs8063160	0.533	rs58656226	chr16:89745091	T/G	cg07984980	chr16:89898383	SPIRE2	0.86	5.17	0.31	4.8e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.69	9.18	0.51	1.83e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.63	6.31	0.37	1.33e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10106407	chr11:66234251	PELI3	-0.49	-6.44	-0.38	6.09e-10	Morning vs. evening chronotype;
KIRP	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.71	-7.02	-0.41	2.13e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.6	-7.85	-0.45	1.24e-13	Prudent dietary pattern;
KIRP	cis	rs7116495	0.609	rs73543640	chr11:71834374	G/T	cg26138937	chr11:71823887	C11orf51	1.16	8.02	0.46	4.37e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.54	6.64	0.39	2e-10	Arsenic metabolism;
KIRP	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.87	13.11	0.64	4.01e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.4	-5.39	-0.33	1.64e-7	Blood metabolite levels;
KIRP	cis	rs9308731	0.583	rs6726007	chr2:111932122	A/T	cg03171003	chr2:111875934	NA	0.42	5.74	0.34	2.78e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.23	0.37	1.97e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-6.36	-0.38	9.92e-10	Aortic root size;
KIRP	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-0.53	-7.22	-0.42	6.45e-12	Coronary artery disease;
KIRP	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.54	-0.33	7.57e-8	Blood metabolite levels;
KIRP	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.58	-6.96	-0.41	3.15e-11	Aortic root size;
KIRP	cis	rs10802346	0.636	rs10924640	chr1:246420554	G/C	cg15962031	chr1:246363574	SMYD3	0.79	5.92	0.35	1.07e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18364779	chr6:26104403	HIST1H4C	0.42	5.5	0.33	9.36e-8	Schizophrenia;
KIRP	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg19292749	chr17:79650816	ARL16;HGS	0.52	4.95	0.3	1.38e-6	Dental caries;
KIRP	cis	rs300890	1.000	rs624189	chr4:144245363	G/T	cg19876092	chr4:144208277	NA	0.44	7.22	0.42	6.59e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11645453	chr3:52864694	ITIH4	-0.36	-5.49	-0.33	9.95e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.65	-0.34	4.47e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1983891	0.643	rs3800284	chr6:41558365	G/C	cg20194872	chr6:41519635	FOXP4	0.46	6.06	0.36	5.16e-9	Prostate cancer;
KIRP	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.89	-11.86	-0.6	5.86e-26	Exhaled nitric oxide output;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-0.87	-14.74	-0.68	1.11e-35	Vitiligo;
KIRP	cis	rs9815354	0.812	rs55682201	chr3:41848497	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.6	8.18	0.46	1.55e-14	Vitiligo;
KIRP	cis	rs2278796	0.918	rs2290138	chr1:204956325	C/G	cg04862289	chr1:204966208	NFASC	-0.57	-7.87	-0.45	1.12e-13	Mean platelet volume;
KIRP	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg23505145	chr19:12996616	KLF1	0.58	8.38	0.47	3.99e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6142102	0.812	rs6120440	chr20:32517585	A/G	cg24642439	chr20:33292090	TP53INP2	-0.65	-6.27	-0.37	1.61e-9	Skin pigmentation;
KIRP	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	1.06	23.28	0.83	3.94e-64	Breast cancer;
KIRP	cis	rs953387	0.824	rs6716987	chr2:136963494	G/T	cg05194412	chr2:137003533	NA	-0.39	-5.04	-0.31	9.18e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg06212747	chr3:49208901	KLHDC8B	0.87	13.57	0.65	1.1e-31	Menarche (age at onset);
KIRP	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg03465714	chr1:152285911	FLG	-0.41	-4.91	-0.3	1.65e-6	Atopic dermatitis;
KIRP	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg21475434	chr5:93447410	FAM172A	0.74	5.82	0.35	1.83e-8	Diabetic retinopathy;
KIRP	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg02487422	chr3:49467188	NICN1	0.43	6.01	0.36	6.5e-9	Menarche (age at onset);
KIRP	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.95e-22	Gout;Renal underexcretion gout;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg04183933	chr2:198363868	HSPD1;HSPE1	0.98	6.5	0.38	4.55e-10	P wave terminal force;
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.32e-15	Life satisfaction;
KIRP	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	1.0	16.17	0.72	1.49e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs714515	0.900	rs991790	chr1:172340917	C/G	cg01573306	chr1:172330400	DNM3	0.46	5.91	0.35	1.13e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-8.46	-0.47	2.45e-15	Morning vs. evening chronotype;
KIRP	cis	rs2143950	0.765	rs75359261	chr14:35705057	G/A	cg09327582	chr14:35236912	BAZ1A	-0.61	-5.78	-0.35	2.21e-8	Atopic dermatitis;
KIRP	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.06	-0.5	4.22e-17	Rheumatoid arthritis;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg13648088	chr10:124768538	ACADSB;IKZF5	-0.46	-6.15	-0.37	3.19e-9	Blood metabolite levels;
KIRP	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.55	7.3	0.42	4.04e-12	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
KIRP	trans	rs78944489	0.764	rs12464589	chr2:73470615	G/A	cg18655438	chr5:1077845	SLC12A7	-0.83	-6.06	-0.36	5.19e-9	Schizophrenia;
KIRP	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg03060546	chr3:49711283	APEH	-0.68	-5.21	-0.32	3.9e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg12940439	chr1:67600707	NA	0.35	5.33	0.32	2.21e-7	Psoriasis;
KIRP	cis	rs501120	0.810	rs498810	chr10:44740776	A/C	cg09554077	chr10:44749378	NA	0.74	12.35	0.62	1.37e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04876069	chr12:132293656	NA	-0.42	-4.87	-0.3	2.04e-6	Migraine;
KIRP	cis	rs1635	0.655	rs723475	chr6:28304841	G/T	cg15743358	chr6:28303923	ZNF323	0.9	6.67	0.39	1.65e-10	Schizophrenia;
KIRP	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg12076274	chr19:5536788	NA	0.39	6.14	0.36	3.23e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.62	-6.66	-0.39	1.82e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg24110177	chr3:50126178	RBM5	0.45	5.8	0.35	2.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.08e-11	Morning vs. evening chronotype;
KIRP	cis	rs9436747	0.626	rs7524834	chr1:65950230	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-4.88	-0.3	1.87e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg09788416	chr12:39539408	NA	0.41	5.21	0.32	3.91e-7	Morning vs. evening chronotype;
KIRP	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	6.09	0.36	4.32e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	8.01	0.45	4.65e-14	Eosinophil percentage of white cells;
KIRP	cis	rs1805008	0.703	rs76839250	chr16:90051269	A/G	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.14	-7.65	-0.44	4.4e-13	Skin colour saturation;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg06815112	chr8:27182871	PTK2B	-0.53	-6.7	-0.39	1.41e-10	Neuroticism;
KIRP	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg26571870	chr16:85723150	GINS2	0.51	5.58	0.34	6.39e-8	Platelet distribution width;
KIRP	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.87	-0.3	2.02e-6	Breast cancer;
KIRP	cis	rs78487399	0.710	rs74616425	chr2:43613582	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-5.23	-0.32	3.54e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg05220968	chr6:146057943	EPM2A	0.4	5.22	0.32	3.77e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.82	-11.06	-0.58	2.32e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.96	7.8	0.45	1.79e-13	Alzheimer's disease (late onset);
KIRP	cis	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg21775007	chr8:11205619	TDH	-0.46	-5.91	-0.35	1.11e-8	Triglycerides;
KIRP	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.43	0.47	3.04e-15	Electroencephalogram traits;
KIRP	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg06937882	chr20:24974362	C20orf3	-0.43	-4.89	-0.3	1.86e-6	Blood protein levels;
KIRP	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.31	5.68	0.34	3.7e-8	Renal cell carcinoma;
KIRP	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.6	7.44	0.43	1.69e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.71	-9.76	-0.53	3.19e-19	Plateletcrit;Platelet count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23207280	chr3:152147674	MBNL1	0.44	6.17	0.37	2.76e-9	Interleukin-4 levels;
KIRP	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg02503808	chr4:7069936	GRPEL1	0.94	12.75	0.63	6.19e-29	Monocyte percentage of white cells;
KIRP	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.51	-6.04	-0.36	5.55e-9	Total body bone mineral density;
KIRP	cis	rs7656342	0.569	rs28591077	chr4:9863678	A/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.16	-0.37	2.89e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg18190219	chr22:46762943	CELSR1	-0.62	-6.3	-0.37	1.33e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1620921	0.603	rs1084659	chr6:161163777	A/G	cg01280913	chr6:161186852	NA	-0.63	-8.66	-0.48	6.52e-16	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.85	0.45	1.25e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27189623	chr16:705930	WDR90	0.45	6.26	0.37	1.68e-9	Height;
KIRP	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.02	-0.3	9.86e-7	Fear of minor pain;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14592024	chr15:48624386	DUT	0.5	7.24	0.42	5.83e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.84	9.1	0.5	3.24e-17	Prostate cancer;
KIRP	trans	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00643111	chr16:31483443	TGFB1I1	0.44	6.25	0.37	1.78e-9	Parkinson's disease;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.45	5.35	0.32	2e-7	Longevity;Endometriosis;
KIRP	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg27121462	chr16:89883253	FANCA	-0.48	-6.12	-0.36	3.72e-9	Vitiligo;
KIRP	cis	rs4722166	0.532	rs1546763	chr7:22757843	G/A	cg05472934	chr7:22766657	IL6	0.5	6.4	0.38	7.62e-10	Lung cancer;
KIRP	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs6882046	0.513	rs42850	chr5:88019474	G/A	cg24804195	chr5:87968844	LOC645323	-0.47	-6.22	-0.37	2.17e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg10254082	chr7:997346	NA	0.47	4.9	0.3	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg00684032	chr4:1343700	KIAA1530	0.75	10.31	0.55	6.09e-21	Obesity-related traits;
KIRP	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg01879757	chr17:41196368	BRCA1	-0.73	-10.2	-0.55	1.34e-20	Menopause (age at onset);
KIRP	trans	rs1106684	1.000	rs11767669	chr7:131462696	A/C	cg13607082	chr12:122652224	LRRC43	-0.66	-6.72	-0.39	1.28e-10	Body mass index;
KIRP	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg26875233	chr11:93583750	C11orf90	-0.36	-6.66	-0.39	1.75e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.56	9.38	0.51	4.41e-18	Prostate cancer;
KIRP	trans	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00950418	chr7:105029125	SRPK2	-0.53	-6.55	-0.39	3.43e-10	Height;
KIRP	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg23587288	chr2:27483067	SLC30A3	-0.7	-7.39	-0.43	2.33e-12	Blood metabolite levels;
KIRP	cis	rs2594989	1.000	rs2594986	chr3:11330964	G/A	cg01796438	chr3:11312864	ATG7	-0.7	-8.14	-0.46	2.02e-14	Circulating chemerin levels;
KIRP	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.54	-6.6	-0.39	2.52e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs882732	1.000	rs10139629	chr14:95035277	C/T	cg08495878	chr14:95027859	SERPINA4	-0.43	-5.17	-0.31	4.82e-7	Blood protein levels;
KIRP	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg03060546	chr3:49711283	APEH	0.44	5.53	0.33	8.36e-8	Parkinson's disease;
KIRP	cis	rs4704187	0.625	rs11947996	chr5:74545548	A/T	cg03227963	chr5:74354835	NA	0.41	5.96	0.36	8.61e-9	Response to amphetamines;
KIRP	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.62	7.49	0.43	1.24e-12	Airflow obstruction;
KIRP	cis	rs13401104	0.796	rs60159414	chr2:237119178	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.89	14.78	0.69	8.58e-36	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs698833	0.892	rs1067371	chr2:44651982	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.99	0.3	1.16e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs12517041	1.000	rs4547895	chr5:23323269	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.86	-7.69	-0.44	3.49e-13	Calcium levels;
KIRP	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7520050	0.902	rs4626927	chr1:46248645	C/T	cg24296786	chr1:45957014	TESK2	0.39	4.98	0.3	1.19e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.55	-7.99	-0.45	5.18e-14	Vitiligo;
KIRP	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg04725166	chr1:7887271	PER3	-0.35	-5.54	-0.33	7.73e-8	Crohn's disease;
KIRP	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.73	8.94	0.5	9.79e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.62	8.09	0.46	2.72e-14	Coronary artery disease;
KIRP	cis	rs867371	1.000	rs7181655	chr15:82455616	T/C	cg06066596	chr15:83166174	LOC80154	-0.47	-5.61	-0.34	5.39e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg17747265	chr1:1875780	NA	0.45	6.17	0.37	2.78e-9	Body mass index;
KIRP	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.29	0.47	7.62e-15	Menopause (age at onset);
KIRP	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.93	11.51	0.59	8.56e-25	Response to antineoplastic agents;
KIRP	cis	rs6499255	1.000	rs12925371	chr16:69773885	G/A	cg15192750	chr16:69999425	NA	0.49	4.87	0.3	2e-6	IgE levels;
KIRP	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.97	-13.35	-0.65	5.89e-31	Ulcerative colitis;
KIRP	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg16586182	chr3:47516702	SCAP	0.83	11.47	0.59	1.12e-24	Colorectal cancer;
KIRP	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg03060546	chr3:49711283	APEH	-0.6	-5.26	-0.32	3.13e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs748404	0.560	rs529611	chr15:43805988	T/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.35	0.32	2e-7	Lung cancer;
KIRP	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.51	-6.2	-0.37	2.36e-9	Ulcerative colitis;
KIRP	cis	rs787274	0.867	rs6477959	chr9:115554296	G/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.54	-0.39	3.45e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg17757837	chr7:157058334	UBE3C	0.77	11.03	0.58	2.9e-23	Body mass index;
KIRP	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg05756136	chr1:119680316	WARS2	-0.62	-8.44	-0.47	2.81e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg01721255	chr8:58191610	C8orf71	0.65	5.46	0.33	1.17e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.23	17.49	0.74	4.56e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7096127	1.000	rs12244616	chr10:24500406	C/T	cg04122385	chr10:24535410	KIAA1217;PRINS	0.51	6.38	0.38	8.95e-10	Lobe attachment (rater scored);
KIRP	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg03006477	chr6:74432658	CD109	0.25	5.3	0.32	2.62e-7	Blood protein levels;Calcium levels;
KIRP	cis	rs13401104	0.796	rs35819191	chr2:237119051	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.57	6.73	0.39	1.19e-10	Mosquito bite size;
KIRP	cis	rs4523957	0.583	rs2641437	chr17:2019158	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-11.28	-0.58	4.78e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.47	-0.43	1.36e-12	Body mass index;
KIRP	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.92	-10.64	-0.56	5.25e-22	Breast cancer;
KIRP	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.7	7.11	0.41	1.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.31	-5.71	-0.34	3.19e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.27e-11	Diabetic kidney disease;
KIRP	cis	rs988913	0.662	rs11754240	chr6:54921499	T/G	cg03513858	chr6:54763001	FAM83B	-0.35	-4.87	-0.3	2.03e-6	Menarche (age at onset);
KIRP	cis	rs986417	0.681	rs1254329	chr14:60912870	G/A	cg27398547	chr14:60952738	C14orf39	-0.74	-7.43	-0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs16828019	0.852	rs12742803	chr1:41648131	G/A	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13837097	chr14:55034666	SAMD4A	0.51	6.44	0.38	6.36e-10	Parkinson's disease;
KIRP	cis	rs1559088	0.573	rs1270591	chr19:33622942	C/T	cg27124370	chr19:33622961	WDR88	-0.76	-10.8	-0.57	1.71e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg02353165	chr6:42928485	GNMT	0.7	10.73	0.56	2.75e-22	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.73	-8.21	-0.46	1.24e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.9	-10.1	-0.54	2.7e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9815354	0.812	rs73071328	chr3:41810055	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.32	0.47	6.13e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2888674	0.933	rs10267707	chr7:150510973	C/G	cg05726600	chr7:150498594	TMEM176B;TMEM176A	0.32	5.02	0.3	9.93e-7	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
KIRP	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg06307176	chr5:131281290	NA	0.56	6.37	0.38	9.09e-10	Life satisfaction;
KIRP	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg01475377	chr6:109611718	NA	-0.42	-5.89	-0.35	1.26e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs3105593	0.521	rs3098205	chr15:50742977	G/T	cg05456662	chr15:50716270	USP8	0.36	4.89	0.3	1.79e-6	QT interval;
KIRP	cis	rs244731	0.920	rs72813185	chr5:176739110	C/A	cg06060754	chr5:176797920	RGS14	0.57	6.29	0.37	1.43e-9	Urate levels in lean individuals;
KIRP	cis	rs1978968	1.000	rs5992921	chr22:18445263	C/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15057359	chr2:77750866	LRRTM4	0.35	6.06	0.36	5.11e-9	C-reactive protein;
KIRP	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.81	10.95	0.57	5.46e-23	Platelet count;
KIRP	cis	rs4074493	1.000	rs4460622	chr1:231173033	C/T	cg22172038	chr1:231176991	FAM89A	0.28	4.87	0.3	2e-6	Carotid plaque burden (smoking interaction);
KIRP	cis	rs7546094	1.000	rs10745330	chr1:113083439	C/T	cg22162597	chr1:113214053	CAPZA1	0.47	6.56	0.39	3.13e-10	Platelet distribution width;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg12891197	chr22:38902464	DDX17	-0.61	-6.51	-0.38	4.23e-10	Response to statin therapy;
KIRP	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.55	7.3	0.42	4.04e-12	Red blood cell count;
KIRP	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg23791538	chr6:167370224	RNASET2	-0.47	-5.59	-0.34	6.02e-8	Crohn's disease;
KIRP	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg07862535	chr7:139043722	LUC7L2	0.48	5.3	0.32	2.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs859767	0.501	rs71348712	chr2:135391590	T/A	cg12500956	chr2:135428796	TMEM163	-0.41	-5.55	-0.33	7.43e-8	Neuroticism;
KIRP	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.38	6.44	0.38	6.3e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg08392591	chr16:89556376	ANKRD11	0.47	6.33	0.37	1.17e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.78	9.47	0.52	2.44e-18	Response to antipsychotic treatment;
KIRP	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.94	-14.49	-0.68	8.29e-35	Height;
KIRP	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg19645103	chr12:69753606	YEATS4	-0.47	-5.41	-0.33	1.53e-7	Response to diuretic therapy;
KIRP	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg18461458	chr19:21324796	ZNF431	0.46	4.97	0.3	1.23e-6	Pain;
KIRP	cis	rs1448094	0.817	rs7972773	chr12:86340774	A/C	cg02569458	chr12:86230093	RASSF9	0.37	5.36	0.32	1.95e-7	Major depressive disorder;
KIRP	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.75e-13	Bipolar disorder;
KIRP	cis	rs6142102	0.602	rs10485503	chr20:32557842	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	6.01	0.36	6.64e-9	Skin pigmentation;
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg15117754	chr3:10150083	C3orf24	0.54	5.23	0.32	3.7e-7	Alzheimer's disease;
KIRP	cis	rs7180079	0.620	rs7403350	chr15:65045291	C/G	cg15337035	chr15:64978493	NA	0.47	5.2	0.31	4.15e-7	Monocyte count;
KIRP	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.65	7.89	0.45	1e-13	Calcium levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25124064	chr12:111051096	TCTN1	0.46	6.2	0.37	2.37e-9	Survival in pancreatic cancer;
KIRP	cis	rs253959	0.921	rs254174	chr5:115621603	A/C	cg23108291	chr5:115420582	COMMD10	0.4	4.87	0.3	1.98e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.38	13.83	0.66	1.49e-32	Schizophrenia;
KIRP	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg18016565	chr1:150552671	MCL1	0.36	5.4	0.33	1.55e-7	Melanoma;
KIRP	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg26354017	chr1:205819088	PM20D1	0.45	5.23	0.32	3.63e-7	Parkinson's disease;
KIRP	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg05527609	chr1:210001259	C1orf107	-0.42	-5.3	-0.32	2.63e-7	Red blood cell count;
KIRP	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.49e-20	Coffee consumption (cups per day);
KIRP	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg16141378	chr3:129829833	LOC729375	0.53	6.99	0.41	2.64e-11	Retinal vascular caliber;
KIRP	cis	rs35740288	0.770	rs11630968	chr15:86118001	C/T	cg17133734	chr15:86042851	AKAP13	-0.5	-5.57	-0.33	6.54e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.79	-0.35	2.09e-8	Height;
KIRP	cis	rs3736485	0.966	rs8031903	chr15:51838161	C/T	cg14296394	chr15:51910925	DMXL2	-0.36	-5.32	-0.32	2.3e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg10207240	chr12:122356781	WDR66	0.59	7.94	0.45	7.27e-14	Mean corpuscular volume;
KIRP	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.78	12.44	0.62	6.76e-28	Coronary artery disease;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg24633833	chr3:10029261	TMEM111	0.54	5.28	0.32	2.78e-7	Alzheimer's disease;
KIRP	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.5	5.17	0.31	4.77e-7	Smoking behavior;
KIRP	cis	rs4805272	0.962	rs2042192	chr19:29321076	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg09610735	chr10:22609918	BMI1	0.5	6.16	0.37	2.96e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg18306943	chr3:40428807	ENTPD3	0.46	6.03	0.36	5.87e-9	Renal cell carcinoma;
KIRP	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.19	0.37	2.47e-9	Educational attainment;
KIRP	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.09	-20.08	-0.79	9.21e-54	Height;
KIRP	cis	rs9790314	0.638	rs6764019	chr3:160638851	A/C	cg04691961	chr3:161091175	C3orf57	0.45	6.37	0.38	9.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02725872	chr8:58115012	NA	-0.74	-7.76	-0.44	2.24e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg24253500	chr15:84953950	NA	0.51	5.83	0.35	1.72e-8	Schizophrenia;
KIRP	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs1050631	0.592	rs1789508	chr18:33736845	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.93	0.35	1.02e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg05692746	chr2:100937584	LONRF2	-0.43	-5.16	-0.31	5.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs77861329	0.925	rs72964042	chr3:52088485	A/C	cg08692210	chr3:52188851	WDR51A	0.87	6.03	0.36	5.87e-9	Macrophage inflammatory protein 1b levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15312298	chr8:127570908	FAM84B	0.51	6.11	0.36	3.92e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7224685	0.817	rs9901620	chr17:4165741	G/C	cg21851534	chr17:3907994	ZZEF1	0.47	4.98	0.3	1.22e-6	Type 2 diabetes;
KIRP	cis	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg08501292	chr6:25962987	TRIM38	0.88	6.16	0.37	2.91e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg08461772	chr7:95026248	PON3	0.42	5.71	0.34	3.23e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.49	-5.86	-0.35	1.49e-8	Facial morphology (factor 20);
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4742903	0.509	rs1889285	chr9:106926693	A/G	cg14250997	chr9:106856677	SMC2	0.38	5.07	0.31	7.8e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.77	0.35	2.38e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.99	0.5	6.95e-17	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.38	-0.43	2.5e-12	Aortic root size;
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.89	-0.3	1.84e-6	Renal cell carcinoma;
KIRP	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg05315796	chr3:52349193	DNAH1	0.39	6.15	0.37	3.04e-9	Electroencephalogram traits;
KIRP	cis	rs78487399	0.808	rs17030925	chr2:43713808	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.03	-0.31	9.62e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2274273	0.870	rs17741831	chr14:55816715	T/A	cg04306507	chr14:55594613	LGALS3	0.43	6.56	0.39	3.14e-10	Protein biomarker;
KIRP	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg02367723	chr1:46378857	MAST2	-0.43	-4.95	-0.3	1.37e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	9.69	0.53	5.25e-19	Lung cancer in ever smokers;
KIRP	cis	rs12210905	1.000	rs12153912	chr6:27179829	A/G	cg23155468	chr6:27110703	HIST1H2BK	0.62	5.73	0.34	2.88e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg02297831	chr4:17616191	MED28	0.52	6.59	0.39	2.67e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7923609	0.967	rs10761766	chr10:65190327	G/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg24874828	chr4:187887005	NA	0.49	7.18	0.42	8.27e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.57	6.92	0.4	3.94e-11	DNA methylation (variation);
KIRP	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs732716	0.785	rs62130978	chr19:4429007	C/T	cg19820705	chr19:4455316	UBXN6	0.67	8.26	0.47	9.24e-15	Mean corpuscular volume;
KIRP	cis	rs12360000	0.864	rs12767731	chr10:1907712	T/C	cg26364871	chr10:1889757	NA	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.58	-0.48	1.11e-15	Triglycerides;
KIRP	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.64	0.39	2e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg02678768	chr17:74002944	EVPL	0.37	4.9	0.3	1.72e-6	White matter hyperintensity burden;
KIRP	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg12173498	chr6:36355764	ETV7	0.3	4.96	0.3	1.33e-6	Platelet distribution width;
KIRP	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.21e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.8	11.04	0.58	2.81e-23	Aortic root size;
KIRP	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg17218026	chr1:154582156	ADAR	0.35	5.85	0.35	1.55e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs75920871	0.764	rs61903394	chr11:116931898	G/A	cg23684410	chr11:116897558	SIK3	0.56	6.09	0.36	4.27e-9	Subjective well-being;
KIRP	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg00074818	chr8:8560427	CLDN23	0.43	6.46	0.38	5.64e-10	Obesity-related traits;
KIRP	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg26513180	chr16:89883248	FANCA	0.84	5.5	0.33	9.72e-8	Skin colour saturation;
KIRP	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.68	10.02	0.54	4.85e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6681460	0.576	rs1338194	chr1:66986476	T/A	cg13052034	chr1:66999238	SGIP1	0.41	5.43	0.33	1.33e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.6	-5.19	-0.31	4.45e-7	Narcolepsy;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14222140	chr1:24711941	C1orf201	0.48	6.51	0.38	4.17e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12549025	0.536	rs9644075	chr8:23359961	C/G	cg00472375	chr8:23315376	ENTPD4	0.56	5.1	0.31	6.85e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg10326726	chr10:51549505	MSMB	-0.56	-8.36	-0.47	4.81e-15	Prostate-specific antigen levels;
KIRP	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-5.42	-0.33	1.42e-7	Bipolar disorder;
KIRP	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg07645718	chr20:61493192	TCFL5	0.73	6.28	0.37	1.49e-9	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.43	5.62	0.34	5.19e-8	Homoarginine levels;
KIRP	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs78487399	0.808	rs7587268	chr2:43673892	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.45	-0.33	1.25e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7737355	1.000	rs2549018	chr5:130698949	C/T	cg06307176	chr5:131281290	NA	-0.53	-5.71	-0.34	3.2e-8	Life satisfaction;
KIRP	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg12501888	chr15:85177176	SCAND2	-0.39	-4.99	-0.3	1.15e-6	P wave terminal force;
KIRP	cis	rs612683	0.524	rs11166456	chr1:100925633	C/T	cg06223162	chr1:101003688	GPR88	0.43	8.55	0.48	1.28e-15	Breast cancer;
KIRP	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	5.03	0.31	9.55e-7	Rheumatoid arthritis;
KIRP	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-13.03	-0.64	7.18e-30	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17289202	chr18:56530789	ZNF532	0.51	6.25	0.37	1.75e-9	Parkinson's disease;
KIRP	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg00074818	chr8:8560427	CLDN23	0.38	6.26	0.37	1.72e-9	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg15181151	chr6:150070149	PCMT1	0.31	5.22	0.32	3.88e-7	Lung cancer;
KIRP	cis	rs12580194	0.593	rs7311751	chr12:55748847	A/G	cg19537932	chr12:55886519	OR6C68	-0.46	-6.13	-0.36	3.42e-9	Cancer;
KIRP	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.83	-10.2	-0.55	1.35e-20	Vitiligo;
KIRP	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.01	-16.77	-0.73	1.34e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1577917	0.545	rs9294338	chr6:86474368	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	6.86	0.4	5.6e-11	Response to antipsychotic treatment;
KIRP	cis	rs897080	0.515	rs698800	chr2:44690787	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.85	0.35	1.56e-8	Height;
KIRP	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg18305652	chr10:134549665	INPP5A	0.47	7.09	0.41	1.46e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	9.01	0.5	5.79e-17	Motion sickness;
KIRP	cis	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg21546286	chr11:48923668	NA	-0.48	-6.03	-0.36	5.96e-9	HDL cholesterol;
KIRP	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.22	0.46	1.19e-14	Personality dimensions;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17892601	chr1:66723177	PDE4B	0.43	6.99	0.41	2.52e-11	C-reactive protein;
KIRP	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs72730918	0.590	rs1378895	chr15:51937295	G/A	cg14296394	chr15:51910925	DMXL2	-0.78	-10.94	-0.57	6.04e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs17095355	0.688	rs1349348	chr10:111794554	T/C	cg00817464	chr10:111662876	XPNPEP1	0.41	5.68	0.34	3.77e-8	Biliary atresia;
KIRP	cis	rs7923609	0.846	rs7098181	chr10:65027143	G/T	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.1	-0.31	6.68e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10073892	0.828	rs1393624	chr5:101876951	A/G	cg19774478	chr5:101632501	SLCO4C1	0.58	6.05	0.36	5.38e-9	Cognitive decline (age-related);
KIRP	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg01877450	chr7:97915802	BRI3	-0.57	-7.46	-0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11209185	0.509	rs1926279	chr1:68450681	A/G	cg22082780	chr1:68452167	NA	0.33	5.02	0.3	9.94e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10400419	1.000	rs10400419	chr12:66389968	C/T	cg06712651	chr12:66351869	HMGA2	0.62	9.5	0.52	2.01e-18	Axial length;
KIRP	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg21466736	chr12:48725269	NA	-0.5	-6.21	-0.37	2.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-0.82	-9.03	-0.5	5.16e-17	Gut microbiome composition (summer);
KIRP	cis	rs4006360	0.574	rs35944108	chr17:39238561	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.66	-0.48	6.38e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.85	7.98	0.45	5.48e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.71	6.93	0.4	3.58e-11	Type 2 diabetes;
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21016266	chr12:122356598	WDR66	0.65	8.82	0.49	2.21e-16	Mean corpuscular volume;
KIRP	cis	rs8077577	0.945	rs62073649	chr17:18080522	T/C	cg09161412	chr17:18057145	MYO15A	-0.4	-5.27	-0.32	3.03e-7	Obesity-related traits;
KIRP	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.55	-6.53	-0.38	3.83e-10	Coronary artery disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23690785	chr4:130030465	C4orf33	0.41	6.28	0.37	1.52e-9	Migraine with aura;
KIRP	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.63	-9.09	-0.5	3.35e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg02640540	chr1:67518911	SLC35D1	0.43	5.24	0.32	3.47e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs75920871	0.858	rs17120197	chr11:116845104	C/T	cg23684410	chr11:116897558	SIK3	-0.48	-5.6	-0.34	5.73e-8	Subjective well-being;
KIRP	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.39	6.69	0.39	1.46e-10	Heart rate;
KIRP	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg12963246	chr6:28129442	ZNF389	0.5	6.25	0.37	1.78e-9	Depression;
KIRP	cis	rs13315871	0.929	rs35557787	chr3:58234536	T/C	cg20936604	chr3:58311152	NA	-0.67	-5.82	-0.35	1.78e-8	Cholesterol, total;
KIRP	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.96	15.77	0.71	3.41e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.54	-6.17	-0.37	2.75e-9	Body mass index;
KIRP	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.53	-7.02	-0.41	2.16e-11	Ulcerative colitis;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg07343612	chr16:622815	PIGQ	-0.88	-13.45	-0.65	2.88e-31	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04406444	chr1:214454777	SMYD2	0.51	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.77	-0.44	2.15e-13	Total cholesterol levels;
KIRP	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.7	-6.08	-0.36	4.66e-9	Bronchopulmonary dysplasia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05571164	chr3:23958917	NKIRAS1;RPL15	0.48	6.29	0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.99	7.84	0.45	1.38e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6723108	0.591	rs13399952	chr2:135394404	A/G	cg25422880	chr2:135218333	TMEM163	0.38	5.65	0.34	4.35e-8	Type 2 diabetes;
KIRP	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.72	9.45	0.52	2.73e-18	Sudden cardiac arrest;
KIRP	cis	rs6466055	0.661	rs6954830	chr7:104915462	A/G	cg04380332	chr7:105027541	SRPK2	0.38	5.22	0.32	3.88e-7	Schizophrenia;
KIRP	cis	rs7546094	1.000	rs7513716	chr1:113089320	A/T	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs60311166	0.661	rs57298447	chr3:52659384	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.93	5.79	0.35	2.11e-8	CTACK levels;
KIRP	cis	rs4765905	1.000	rs1006737	chr12:2345295	A/G	cg10668781	chr12:2307325	CACNA1C	0.28	5.21	0.32	4e-7	Schizophrenia;
KIRP	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.38	-4.89	-0.3	1.84e-6	Mean platelet volume;
KIRP	cis	rs4654899	0.802	rs17449966	chr1:21203996	A/G	cg05370193	chr1:21551575	ECE1	0.42	5.11	0.31	6.41e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg09455208	chr3:40491958	NA	0.31	5.25	0.32	3.3e-7	Renal cell carcinoma;
KIRP	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.67	8.84	0.49	1.94e-16	Total cholesterol levels;
KIRP	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.15	-0.37	3.08e-9	Response to antipsychotic treatment;
KIRP	trans	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg10756647	chr7:56101905	PSPH	1.04	7.95	0.45	6.92e-14	Diabetic kidney disease;
KIRP	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg00898013	chr13:113819073	PROZ	-0.59	-5.63	-0.34	4.9e-8	Blood protein levels;
KIRP	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.86	11.72	0.6	1.74e-25	Mood instability;
KIRP	cis	rs859767	0.501	rs1123184	chr2:135431057	C/G	cg12500956	chr2:135428796	TMEM163	-0.41	-5.56	-0.33	6.94e-8	Neuroticism;
KIRP	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.44	5.32	0.32	2.31e-7	Metabolite levels (MHPG);
KIRP	cis	rs6901250	0.569	rs621486	chr6:117089143	T/C	cg05399210	chr6:117082661	FAM162B	-0.48	-6.88	-0.4	4.88e-11	C-reactive protein levels;
KIRP	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26500144	chr6:36646390	CDKN1A	0.49	6.3	0.37	1.33e-9	Parkinson's disease;
KIRP	cis	rs7113850	0.541	rs78048500	chr11:24217764	T/G	ch.11.24196551F	chr11:24239977	NA	0.94	7.7	0.44	3.28e-13	Bone fracture in osteoporosis;
KIRP	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg05072774	chr3:49840536	C3orf54	0.44	5.52	0.33	8.55e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6504340	0.793	rs12946855	chr17:46608030	G/A	cg04904318	chr17:46607828	HOXB1	-0.64	-7.46	-0.43	1.47e-12	Primary tooth development (number of teeth);
KIRP	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.75	8.54	0.48	1.44e-15	Sudden cardiac arrest;
KIRP	cis	rs9900972	0.877	rs8082025	chr17:76876464	C/T	cg20937029	chr17:76870563	TIMP2	0.43	4.91	0.3	1.67e-6	Obesity-related traits;
KIRP	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.74e-7	Schizophrenia;
KIRP	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.94	15.51	0.7	2.56e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-8.89	-0.49	1.31e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.05	-0.36	5.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg26876637	chr1:152193138	HRNR	-0.67	-8.93	-0.49	1.02e-16	Atopic dermatitis;
KIRP	cis	rs4523957	0.820	rs216193	chr17:2203453	A/G	cg16513277	chr17:2031491	SMG6	0.52	6.95	0.41	3.26e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-0.78	-10.98	-0.57	4.27e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs2625529	0.824	rs12916951	chr15:72252498	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.19	-0.37	2.55e-9	Red blood cell count;
KIRP	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.67	8.58	0.48	1.09e-15	Alcohol dependence;
KIRP	cis	rs4363385	0.510	rs11576797	chr1:153049417	T/C	cg07796016	chr1:152779584	LCE1C	-0.5	-6.27	-0.37	1.57e-9	Inflammatory skin disease;
KIRP	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.11	0.36	3.97e-9	Rheumatoid arthritis;
KIRP	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg22676075	chr6:135203613	NA	-0.57	-7.42	-0.43	1.95e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.79	11.59	0.59	4.64e-25	Heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12727513	chr3:42632622	SS18L2	0.52	6.31	0.37	1.26e-9	Parkinson's disease;
KIRP	cis	rs8523	0.933	rs1225717	chr6:10978240	C/T	cg13562911	chr6:11044106	ELOVL2	-0.44	-5.39	-0.33	1.62e-7	Red blood cell fatty acid levels;
KIRP	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.98	-14.7	-0.68	1.51e-35	Coronary artery disease;
KIRP	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.73	-11.67	-0.6	2.53e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.83	8.55	0.48	1.36e-15	Prostate cancer;
KIRP	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg08885076	chr2:99613938	TSGA10	0.53	9.27	0.51	9.88e-18	Chronic sinus infection;
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg02462569	chr6:150064036	NUP43	-0.42	-6.41	-0.38	7.36e-10	Lung cancer;
KIRP	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.46	-5.77	-0.35	2.37e-8	Educational attainment (years of education);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg08871016	chr21:45079232	HSF2BP;RRP1B	0.91	6.46	0.38	5.51e-10	P wave terminal force;
KIRP	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.58	7.76	0.44	2.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.51	6.27	0.37	1.65e-9	Menopause (age at onset);
KIRP	cis	rs1210638	1.000	rs2518806	chr22:18976603	A/G	cg12798833	chr22:18958832	DGCR5	-0.41	-4.97	-0.3	1.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg17986701	chr20:44574422	PCIF1	0.47	7.27	0.42	4.85e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.74	-0.53	3.7e-19	Menopause (age at onset);
KIRP	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11987759	chr7:65425863	GUSB	-0.67	-9.06	-0.5	4.19e-17	Aortic root size;
KIRP	cis	rs6893300	0.785	rs6895902	chr5:179201847	C/T	cg14593053	chr5:179126677	CANX	-0.56	-7.1	-0.41	1.3e-11	Resting heart rate;
KIRP	cis	rs7923609	1.000	rs7073746	chr10:64904071	A/G	cg01631684	chr10:65280961	REEP3	-0.49	-5.71	-0.34	3.25e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg03342759	chr3:160939853	NMD3	-0.49	-5.87	-0.35	1.39e-8	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	5.67	0.34	3.94e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.62	7.77	0.44	2.09e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13343954	0.825	rs12461135	chr19:33534185	A/G	cg17764715	chr19:33622953	WDR88	0.72	8.11	0.46	2.47e-14	Colorectal cancer;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg11301795	chr4:187892539	NA	-1.05	-20.92	-0.8	1.63e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.81	-11.9	-0.6	4.23e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	1.11	10.15	0.54	1.85e-20	Lymphocyte counts;
KIRP	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg10950524	chr7:2139216	MAD1L1	0.28	4.84	0.3	2.26e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.65	-9.65	-0.52	6.81e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.39	4.86	0.3	2.07e-6	Rheumatoid arthritis;
KIRP	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg08662619	chr6:150070041	PCMT1	0.39	6.41	0.38	7.41e-10	Lung cancer;
KIRP	cis	rs16828019	0.852	rs12759050	chr1:41664204	T/A	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	1.000	rs40396	chr5:130708044	C/G	cg25547332	chr5:131281432	NA	-0.47	-5.24	-0.32	3.5e-7	Life satisfaction;
KIRP	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-9.33	-0.51	6.29e-18	Morning vs. evening chronotype;
KIRP	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg00277334	chr10:82204260	NA	-0.47	-5.31	-0.32	2.44e-7	Post bronchodilator FEV1;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21971972	chr4:160078666	NA	-0.44	-6.69	-0.39	1.53e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6684428	0.536	rs4468206	chr1:56397362	A/T	cg11651538	chr1:56320950	NA	-0.55	-8.15	-0.46	1.89e-14	Airflow obstruction;
KIRP	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.97	-10.81	-0.57	1.56e-22	Lung cancer in ever smokers;
KIRP	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.71	-9.58	-0.52	1.11e-18	Personality dimensions;
KIRP	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.52	5.75	0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs7011507	0.947	rs77746636	chr8:49184421	G/T	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9309473	1.000	rs11901272	chr2:73720444	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.6	-0.34	5.63e-8	Metabolite levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09667589	chr1:151400745	POGZ	0.53	7.29	0.42	4.25e-12	Interleukin-4 levels;
KIRP	cis	rs10761482	0.813	rs7083624	chr10:62121239	G/C	cg01186212	chr10:62110162	ANK3	-0.29	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs5747327	0.804	rs2401165	chr22:18147071	C/T	cg19898043	chr22:18121309	BCL2L13	-0.42	-5.07	-0.31	7.89e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.11	-0.36	3.77e-9	Bladder cancer;
KIRP	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.49	5.5	0.33	9.42e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.53	-0.48	1.49e-15	Osteoarthritis;
KIRP	cis	rs3136516	0.504	rs7925678	chr11:46570859	C/T	cg16389345	chr11:46697382	NA	0.52	6.83	0.4	6.52e-11	Venous thromboembolism;
KIRP	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs7903847	0.620	rs10882903	chr10:99115584	A/T	cg20016023	chr10:99160130	RRP12	-0.41	-5.59	-0.34	6.06e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10858047	0.883	rs6701427	chr1:115216886	C/T	cg12756093	chr1:115239321	AMPD1	-0.68	-6.46	-0.38	5.7e-10	Autism;
KIRP	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg03465714	chr1:152285911	FLG	0.5	5.54	0.33	7.7e-8	Atopic dermatitis;
KIRP	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg10503236	chr1:231470652	EXOC8	-0.51	-7.22	-0.42	6.4e-12	Hemoglobin concentration;
KIRP	cis	rs2403221	0.547	rs4910508	chr11:9847690	T/G	cg07197493	chr11:9884649	SBF2	-0.35	-4.9	-0.3	1.72e-6	Smoking initiation;
KIRP	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg02811702	chr13:24901961	NA	-0.43	-5.32	-0.32	2.33e-7	Obesity-related traits;
KIRP	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	1.2	14.66	0.68	2.14e-35	Type 2 diabetes nephropathy;
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg05457628	chr5:178986728	RUFY1	0.63	10.33	0.55	5.02e-21	Lung cancer;
KIRP	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.75	9.49	0.52	2.09e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	1.07	19.38	0.78	1.97e-51	Caffeine consumption;
KIRP	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg05315796	chr3:52349193	DNAH1	0.39	6.35	0.38	1.02e-9	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.46	6.52	0.38	3.98e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.29	0.47	7.48e-15	Schizophrenia;
KIRP	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg11906718	chr8:101322791	RNF19A	-0.47	-6.26	-0.37	1.66e-9	Atrioventricular conduction;
KIRP	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.57	7.57	0.43	7.54e-13	Bladder cancer;
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.34	-0.51	5.94e-18	Platelet count;
KIRP	cis	rs4478858	0.684	rs12121165	chr1:31725542	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs6438504	0.922	rs55651430	chr3:118922403	G/A	cg25372693	chr3:118959985	B4GALT4	0.32	5.39	0.33	1.65e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.65	9.2	0.51	1.56e-17	Alcohol dependence;
KIRP	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg12365907	chr3:28373304	AZI2	0.39	6.09	0.36	4.42e-9	Schizophrenia;
KIRP	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.51	6.36	0.38	9.71e-10	Total body bone mineral density;
KIRP	cis	rs9828933	1.000	rs9828933	chr3:64002897	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.7	-7.33	-0.42	3.34e-12	Type 2 diabetes;
KIRP	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	9.71	0.53	4.45e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.24e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	0.66	6.27	0.37	1.64e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.74	8.99	0.5	6.66e-17	Mammographic density (dense area);
KIRP	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.88	-12.26	-0.62	2.68e-27	Coronary artery disease;
KIRP	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg00990874	chr7:1149470	C7orf50	-0.41	-4.85	-0.3	2.22e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.89	-13.87	-0.66	1.05e-32	Height;
KIRP	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.73	0.53	3.99e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg07395648	chr5:131743802	NA	0.37	5.21	0.32	4.07e-7	Blood metabolite levels;
KIRP	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.74	-10.29	-0.55	7.16e-21	Fibrinogen levels;
KIRP	cis	rs6988636	0.710	rs59229243	chr8:124155673	G/A	cg15893493	chr8:124194847	FAM83A	0.89	7.24	0.42	5.67e-12	Urinary uromodulin levels;
KIRP	cis	rs8054556	0.669	rs12931955	chr16:30013066	A/G	cg06326092	chr16:30034487	C16orf92	0.42	6.13	0.36	3.45e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.83	0.49	1.98e-16	Motion sickness;
KIRP	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-8.5	-0.48	1.79e-15	Morning vs. evening chronotype;
KIRP	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg23100626	chr2:96804247	ASTL	-0.46	-6.23	-0.37	1.96e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg11650704	chr1:154556575	ADAR	-0.43	-5.27	-0.32	3.06e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.91	0.4	4.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829661	0.793	rs2609924	chr2:30836241	T/G	cg10949345	chr2:30726833	LCLAT1	1.19	14.43	0.68	1.33e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.93	-15.66	-0.71	8.08e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.78	9.94	0.54	8.86e-20	Corneal astigmatism;
KIRP	cis	rs4765905	1.000	rs769087	chr12:2344644	G/A	cg10668781	chr12:2307325	CACNA1C	-0.29	-5.24	-0.32	3.37e-7	Schizophrenia;
KIRP	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.91	0.53	1.08e-19	Schizophrenia;
KIRP	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.52	-6.21	-0.37	2.19e-9	Body mass index;
KIRP	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.29	0.32	2.77e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg14835575	chr10:16859367	RSU1	0.58	7.65	0.44	4.64e-13	Platelet distribution width;
KIRP	cis	rs10782582	0.632	rs11810154	chr1:76239973	C/G	cg10523679	chr1:76189770	ACADM	-0.47	-6.48	-0.38	4.96e-10	Daytime sleep phenotypes;
KIRP	cis	rs77861329	0.660	rs6778442	chr3:52148483	T/C	cg08692210	chr3:52188851	WDR51A	0.59	6.01	0.36	6.56e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs6142102	0.961	rs8123521	chr20:32668885	A/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.71	0.39	1.3e-10	Skin pigmentation;
KIRP	cis	rs427941	0.703	rs201450	chr7:101739441	A/T	cg06246474	chr7:101738831	CUX1	-0.54	-6.71	-0.39	1.36e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4566357	1.000	rs2141829	chr2:227922454	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.24	-0.32	3.46e-7	Coronary artery disease;
KIRP	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.65	-6.87	-0.4	5.31e-11	Vitiligo;
KIRP	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	7.45	0.43	1.55e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg24069376	chr3:38537580	EXOG	0.3	4.98	0.3	1.18e-6	Electrocardiographic conduction measures;
KIRP	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg23307798	chr14:103986281	CKB	0.78	13.73	0.66	3.23e-32	Body mass index;
KIRP	cis	rs6076065	0.683	rs2424556	chr20:23419556	C/T	cg26790198	chr20:23419120	CSTL1	-0.36	-5.25	-0.32	3.22e-7	Facial morphology (factor 15, philtrum width);
KIRP	cis	rs10129255	0.500	rs1974468	chr14:107142166	A/G	cg23076370	chr14:107095027	NA	-0.44	-5.38	-0.32	1.72e-7	Kawasaki disease;
KIRP	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.42	-6.2	-0.37	2.39e-9	Coronary artery disease;
KIRP	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg01631408	chr1:248437212	OR2T33	-0.7	-9.36	-0.51	5.3e-18	Common traits (Other);
KIRP	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.68	0.53	5.54e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs1941687	0.673	rs4427879	chr18:31404751	A/G	cg27147174	chr7:100797783	AP1S1	-0.5	-6.05	-0.36	5.26e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg12560992	chr17:57184187	TRIM37	0.61	6.71	0.39	1.35e-10	Testicular germ cell tumor;
KIRP	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.78	11.41	0.59	1.75e-24	Hip circumference;
KIRP	cis	rs7851660	0.839	rs10818213	chr9:100648631	T/C	cg13688889	chr9:100608707	NA	-0.67	-8.52	-0.48	1.66e-15	Strep throat;
KIRP	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.64	8.65	0.48	6.93e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs7224314	1.000	rs62084078	chr17:65386886	T/C	cg01507342	chr17:65387096	PITPNC1	-0.53	-7.77	-0.44	2.18e-13	Diisocyanate-induced asthma;
KIRP	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.34	5.28	0.32	2.85e-7	Asthma;
KIRP	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg23127183	chr11:57508653	C11orf31	-0.54	-6.9	-0.4	4.39e-11	Schizophrenia;
KIRP	cis	rs6016377	0.798	rs6029182	chr20:39179402	A/C	cg22477343	chr20:39312069	NA	0.46	6.02	0.36	6.31e-9	Birth weight;
KIRP	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	1.11	8.26	0.47	9.1e-15	Skin colour saturation;
KIRP	cis	rs11605924	0.901	rs6485644	chr11:45855998	C/T	cg23097878	chr11:45879730	CRY2	0.33	6.69	0.39	1.51e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	6.71	0.39	1.35e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs4073221	0.929	rs67878364	chr3:18281446	T/C	cg07694806	chr3:18168406	NA	-0.83	-7.08	-0.41	1.52e-11	Parkinson's disease;
KIRP	cis	rs6593803	0.693	rs2352868	chr1:147210965	A/G	cg27546670	chr1:147246839	GJA5	0.63	7.13	0.41	1.13e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.56	-0.56	9.73e-22	Height;
KIRP	cis	rs2733310	0.744	rs8023343	chr15:57219774	C/A	cg13626582	chr15:57592083	LOC283663	0.28	6.25	0.37	1.82e-9	Mean platelet volume;
KIRP	trans	rs587242	1.000	rs552032	chr1:96895482	G/C	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11698762	chr2:74648964	WDR54	0.59	6.24	0.37	1.88e-9	Lung function (FEV1);
KIRP	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg23625390	chr15:77176239	SCAPER	0.54	7.13	0.41	1.12e-11	Blood metabolite levels;
KIRP	cis	rs4764487	0.685	rs2268010	chr12:6339856	T/C	cg08284733	chr12:6341482	CD9	0.58	9.35	0.51	5.67e-18	Mean platelet volume;
KIRP	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.6	-0.39	2.46e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.09	0.36	4.21e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg17554472	chr22:41940697	POLR3H	-0.68	-7.06	-0.41	1.67e-11	Vitiligo;
KIRP	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.7	9.34	0.51	6.16e-18	Crohn's disease;
KIRP	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs4776059	0.798	rs4774634	chr15:52872488	G/C	cg25063058	chr15:52860530	ARPP19	0.57	6.29	0.37	1.41e-9	Schizophrenia;
KIRP	cis	rs8014252	0.803	rs57598551	chr14:71068401	G/A	cg11204974	chr14:71022665	NA	-0.74	-7.32	-0.42	3.53e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.42	7.24	0.42	5.87e-12	Renal cell carcinoma;
KIRP	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	trans	rs12043259	0.892	rs4951140	chr1:204823161	A/G	cg11485465	chr5:54518469	NA	0.4	6.4	0.38	7.68e-10	Addiction;
KIRP	cis	rs2274273	0.870	rs17741542	chr14:55805861	A/G	cg04306507	chr14:55594613	LGALS3	-0.43	-6.34	-0.37	1.07e-9	Protein biomarker;
KIRP	cis	rs11955175	1.000	rs11956743	chr5:40677593	G/A	cg05478818	chr5:40835740	RPL37	0.68	5.09	0.31	7.26e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs5758511	0.731	rs12158579	chr22:42351289	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.37	4.9	0.3	1.7e-6	Birth weight;
KIRP	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg00981070	chr1:2046702	PRKCZ	-0.35	-6.24	-0.37	1.93e-9	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09028132	chr20:37078135	SNORA60;SNHG11	0.5	6.48	0.38	5.1e-10	Survival in pancreatic cancer;
KIRP	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.46	5.84	0.35	1.66e-8	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg10047753	chr17:41438598	NA	1.13	17.99	0.75	9.13e-47	Menopause (age at onset);
KIRP	cis	rs2742234	1.000	rs2742234	chr10:43612609	A/G	cg02780029	chr10:43622663	RET	0.38	5.63	0.34	4.98e-8	Hirschsprung disease;
KIRP	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg25811766	chr13:21894605	NA	-0.58	-5.64	-0.34	4.61e-8	White matter hyperintensity burden;
KIRP	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg02725872	chr8:58115012	NA	-0.53	-6.02	-0.36	6.19e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.49	6.73	0.39	1.2e-10	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01493318	chr18:8705700	NA	0.46	6.05	0.36	5.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg07212818	chr11:638076	DRD4	-0.39	-4.91	-0.3	1.68e-6	Systemic lupus erythematosus;
KIRP	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.84	13.07	0.64	5.41e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7221595	0.825	rs9896963	chr17:3966591	T/C	cg09695851	chr17:3907499	NA	0.62	6.45	0.38	6.01e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg24955955	chr5:415729	AHRR	0.75	5.97	0.36	8.03e-9	Fat distribution (HIV);
KIRP	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg17279839	chr7:150038598	RARRES2	0.49	6.58	0.39	2.8e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6866344	0.569	rs56027952	chr5:178150181	C/A	cg10224037	chr5:178157518	ZNF354A	0.9	10.47	0.56	1.9e-21	Neutrophil percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07820310	chr20:44035078	DBNDD2;SYS1-DBNDD2	0.52	7.44	0.43	1.63e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg02807482	chr3:125708958	NA	-0.55	-5.2	-0.31	4.29e-7	Blood pressure (smoking interaction);
KIRP	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.37	-0.43	2.56e-12	Body mass index;
KIRP	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.53	-0.38	3.66e-10	Aortic root size;
KIRP	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	trans	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg25042112	chr7:64838748	ZNF92	-0.59	-6.19	-0.37	2.46e-9	Pain;
KIRP	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.73	9.97	0.54	6.73e-20	Red blood cell count;
KIRP	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.71	8.95	0.5	8.77e-17	Renal function-related traits (BUN);
KIRP	cis	rs6840360	1.000	rs10007167	chr4:152603655	C/T	cg22705602	chr4:152727874	NA	-0.44	-7.0	-0.41	2.49e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9308731	0.842	rs56173510	chr2:111928436	G/T	cg23466623	chr2:111982296	NA	-0.45	-5.7	-0.34	3.5e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.94	-0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1656402	1.000	rs3108614	chr2:233425485	T/G	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	0.87	10.32	0.55	5.59e-21	Corneal structure;
KIRP	cis	rs72627123	0.656	rs17096949	chr14:74602360	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.91	0.3	1.7e-6	Morning vs. evening chronotype;
KIRP	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-8.35	-0.47	4.96e-15	Morning vs. evening chronotype;
KIRP	cis	rs6681460	0.608	rs10889624	chr1:67005807	A/G	cg13052034	chr1:66999238	SGIP1	0.43	6.14	0.36	3.36e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs62056376	0.736	rs1233651	chr17:32639361	C/T	cg04960603	chr2:119604313	EN1	0.54	6.11	0.36	3.91e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7929679	0.521	rs1509667	chr11:34791303	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg20673841	chr7:107026890	COG5	0.4	4.97	0.3	1.28e-6	Coronary artery disease;
KIRP	cis	rs16976116	0.901	rs8027098	chr15:55492269	C/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11638352	0.661	rs2114415	chr15:44432894	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.06	-0.36	5.1e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.78	-11.91	-0.6	3.9e-26	Height;
KIRP	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg23422044	chr7:1970798	MAD1L1	-0.53	-6.32	-0.37	1.23e-9	Bipolar disorder;
KIRP	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.72	-0.39	1.22e-10	Educational attainment;
KIRP	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs2494938	0.730	rs1771307	chr6:40515132	T/C	cg14084896	chr6:40530702	LRFN2	-0.46	-6.0	-0.36	6.87e-9	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.51	6.4	0.38	7.8e-10	Monocyte count;
KIRP	cis	rs13361707	0.920	rs3805497	chr5:40746885	A/T	cg01087697	chr5:40835557	RPL37	-0.48	-5.46	-0.33	1.16e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg25042112	chr7:64838748	ZNF92	-0.6	-6.34	-0.37	1.1e-9	Pain;
KIRP	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg00080972	chr5:178986291	RUFY1	0.37	5.49	0.33	1.01e-7	Lung cancer;
KIRP	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg09264619	chr17:80180166	NA	0.37	5.42	0.33	1.42e-7	Life satisfaction;
KIRP	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg04398451	chr17:18023971	MYO15A	-0.62	-8.35	-0.47	5.05e-15	Total body bone mineral density;
KIRP	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.08e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.42	-0.33	1.39e-7	Body mass index;
KIRP	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs911119	0.913	rs13043266	chr20:23588127	C/T	cg16589663	chr20:23618590	CST3	0.67	6.25	0.37	1.77e-9	Chronic kidney disease;
KIRP	cis	rs11997175	0.603	rs7016580	chr8:33824135	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.4	0.33	1.55e-7	Body mass index;
KIRP	cis	rs698833	0.859	rs786612	chr2:44600819	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.26	0.32	3.14e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg19847130	chr8:10466454	RP1L1	-0.36	-5.22	-0.32	3.72e-7	Retinal vascular caliber;
KIRP	cis	rs1971762	0.545	rs10783585	chr12:53977317	T/G	cg23533419	chr12:54090519	NA	-0.33	-5.09	-0.31	7.13e-7	Height;
KIRP	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.42	-0.33	1.44e-7	Schizophrenia;
KIRP	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg08619932	chr19:49200058	FUT2	0.38	5.99	0.36	7.32e-9	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg03188948	chr7:1209495	NA	0.49	5.47	0.33	1.09e-7	Longevity;Endometriosis;
KIRP	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg10760299	chr15:45669010	GATM	0.37	5.38	0.32	1.69e-7	Homoarginine levels;
KIRP	cis	rs4118325	0.603	rs4915017	chr1:107701368	C/T	cg01939741	chr1:107680714	NA	-0.54	-5.07	-0.31	7.97e-7	AIDS;
KIRP	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.65	-9.71	-0.53	4.33e-19	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26251401	chr19:36236539	PSENEN;U2AF1L4	0.43	6.05	0.36	5.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg19913688	chr11:428466	ANO9	-0.84	-6.47	-0.38	5.33e-10	Body mass index;
KIRP	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.58	6.33	0.37	1.15e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.76	-8.15	-0.46	1.87e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg07384165	chr1:10488281	NA	-0.43	-5.38	-0.32	1.77e-7	Breast size;
KIRP	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.5	0.38	4.44e-10	Myopia (pathological);
KIRP	cis	rs35892873	0.959	rs756182	chr3:126093885	C/T	cg15490784	chr3:126061950	KLF15	0.51	6.24	0.37	1.89e-9	Male-pattern baldness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11388258	chr1:151484008	CGN	0.54	6.98	0.41	2.77e-11	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg12692727	chr7:1102344	C7orf50	0.48	5.16	0.31	5.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.83	9.58	0.52	1.1e-18	Neutrophil percentage of white cells;
KIRP	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg26752003	chr8:145688521	CYHR1	-0.53	-6.31	-0.37	1.27e-9	Age at first birth;
KIRP	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.09	-0.31	7.21e-7	Schizophrenia;
KIRP	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg03834567	chr2:218808745	TNS1	0.47	5.73	0.34	2.93e-8	Ulcerative colitis;
KIRP	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-0.78	-9.22	-0.51	1.37e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4713675	0.584	rs9380375	chr6:33682391	G/A	cg15676125	chr6:33679581	C6orf125	0.42	5.53	0.33	8.28e-8	Plateletcrit;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg26129310	chr6:37664451	MDGA1	-0.43	-6.05	-0.36	5.48e-9	Morning vs. evening chronotype;
KIRP	cis	rs17123764	0.818	rs52824916	chr12:49993678	C/T	cg02054252	chr12:50078554	FMNL3	0.49	5.17	0.31	4.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs5417	0.610	rs222843	chr17:7145981	T/C	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.67	-9.97	-0.54	7.06e-20	Diastolic blood pressure;
KIRP	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg13514129	chr1:39547527	MACF1	0.54	8.06	0.46	3.25e-14	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.31	-0.72	4.76e-41	Height;
KIRP	cis	rs12148477	0.583	rs930921	chr15:51658631	A/G	cg25905881	chr15:51634250	GLDN	0.39	4.91	0.3	1.68e-6	Follicule stimulating hormone;
KIRP	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.85	10.63	0.56	5.83e-22	Multiple sclerosis;
KIRP	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-6.12	-0.36	3.63e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9400467	0.506	rs12191195	chr6:111712718	C/G	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.83	-13.22	-0.64	1.73e-30	Blood metabolite levels;
KIRP	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.75	0.34	2.58e-8	Platelet count;
KIRP	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	9.21	0.51	1.53e-17	Cognitive test performance;
KIRP	cis	rs904251	1.000	rs12212090	chr6:37431808	A/G	cg01843034	chr6:37503916	NA	-0.68	-8.85	-0.49	1.78e-16	Cognitive performance;
KIRP	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	7.87	0.45	1.15e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg02390115	chr1:21767211	NBPF3	0.63	8.94	0.5	9.32e-17	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.81	7.81	0.45	1.7e-13	Lung function (FEV1/FVC);
KIRP	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07215822	chr6:158701037	NA	-0.62	-7.12	-0.41	1.19e-11	Height;
KIRP	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg05714579	chr10:131428358	MGMT	0.52	6.79	0.4	8.33e-11	Response to temozolomide;
KIRP	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.43	1.36e-12	Body mass index;
KIRP	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	5.79	0.35	2.14e-8	Height;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg16590910	chr6:42928470	GNMT	0.4	5.61	0.34	5.44e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs918629	0.530	rs3777197	chr5:95237916	T/C	cg16656078	chr5:95278638	ELL2	-0.35	-5.48	-0.33	1.06e-7	IgG glycosylation;
KIRP	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs77633900	0.772	rs2957607	chr15:76686527	A/G	cg21673338	chr15:77095150	SCAPER	0.64	5.61	0.34	5.42e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.68	9.25	0.51	1.16e-17	Height;
KIRP	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.33	-0.47	5.71e-15	Systemic lupus erythematosus;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11594683	chr17:80886910	TBCD	0.55	6.92	0.4	3.83e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3736594	0.643	rs2384655	chr2:27952235	A/T	cg27432699	chr2:27873401	GPN1	-0.64	-8.29	-0.47	7.57e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1440410	0.835	rs10034769	chr4:144052893	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.13e-10	Ischemic stroke;
KIRP	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25517755	chr10:38738941	LOC399744	-0.52	-7.14	-0.41	1.05e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.34	5.46	0.33	1.14e-7	Testicular germ cell tumor;
KIRP	trans	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.93	-0.4	3.66e-11	Bladder cancer;
KIRP	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg08975724	chr8:8085496	FLJ10661	0.58	7.19	0.42	7.78e-12	Retinal vascular caliber;
KIRP	cis	rs4713675	0.565	rs60704560	chr6:33713300	C/T	cg14003231	chr6:33640908	ITPR3	0.3	5.11	0.31	6.35e-7	Plateletcrit;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03157633	chr12:13154475	HTR7P;HEBP1	0.47	7.1	0.41	1.31e-11	Survival in pancreatic cancer;
KIRP	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.63	-7.21	-0.42	6.74e-12	Menarche (age at onset);
KIRP	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.59	7.85	0.45	1.27e-13	Response to temozolomide;
KIRP	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.64	-9.79	-0.53	2.61e-19	Total body bone mineral density;
KIRP	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-16.76	-0.73	1.48e-42	Height;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg21523564	chr15:75251491	NA	0.48	8.15	0.46	1.91e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.56	-7.83	-0.45	1.48e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.69	-8.62	-0.48	8.25e-16	Neutrophil percentage of white cells;
KIRP	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.27	-0.55	8.13e-21	Alzheimer's disease (late onset);
KIRP	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg00079375	chr15:79125835	NA	0.36	5.27	0.32	3.02e-7	Coronary artery disease;
KIRP	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg25922239	chr6:33757077	LEMD2	0.65	7.97	0.45	6.05e-14	Crohn's disease;
KIRP	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg06108461	chr20:60628389	TAF4	-0.55	-6.86	-0.4	5.4e-11	Body mass index;
KIRP	cis	rs253959	0.607	rs785369	chr5:115646154	T/C	cg23108291	chr5:115420582	COMMD10	-0.45	-5.09	-0.31	6.97e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg20628663	chr10:43360327	NA	-0.62	-5.72	-0.34	3.12e-8	Blood protein levels;
KIRP	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg11608241	chr8:8085544	FLJ10661	0.44	5.12	0.31	6.27e-7	Mood instability;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.32	-0.47	6.17e-15	Triglycerides;
KIRP	cis	rs2908197	0.737	rs6465097	chr7:75972914	T/C	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.3	-5.03	-0.31	9.31e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg22875332	chr1:76189707	ACADM	0.49	5.91	0.35	1.14e-8	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.82	12.19	0.61	4.57e-27	Multiple myeloma;
KIRP	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.75	8.07	0.46	3.12e-14	Bipolar disorder;
KIRP	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.97	14.61	0.68	3.07e-35	Sudden cardiac arrest;
KIRP	cis	rs75920871	0.764	rs80259223	chr11:116924318	G/A	cg23684410	chr11:116897558	SIK3	0.57	4.94	0.3	1.44e-6	Subjective well-being;
KIRP	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	cis	rs73200209	0.833	rs2161859	chr12:116455513	A/T	cg01776926	chr12:116560359	MED13L	-0.41	-4.99	-0.3	1.12e-6	Total body bone mineral density;
KIRP	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.81e-8	Body mass index;
KIRP	cis	rs7542091	1.000	rs7542091	chr1:210031948	G/C	cg23166289	chr1:210001082	C1orf107	-0.41	-5.41	-0.33	1.53e-7	Monobrow;
KIRP	cis	rs79387448	0.614	rs6719130	chr2:102958236	C/T	cg09003973	chr2:102972529	NA	1.28	10.6	0.56	7.11e-22	Gut microbiota (bacterial taxa);
KIRP	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.46	-5.28	-0.32	2.87e-7	Type 2 diabetes;
KIRP	cis	rs1003719	0.667	rs2298684	chr21:38445095	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	10.73	0.56	2.83e-22	Eye color traits;
KIRP	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.77	10.38	0.55	3.59e-21	Menopause (age at onset);
KIRP	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.67	0.44	3.94e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs11673344	0.536	rs62108291	chr19:38150358	A/G	cg14683738	chr19:37701593	ZNF585B	-0.41	-5.13	-0.31	5.8e-7	Obesity-related traits;
KIRP	cis	rs56079296	0.563	rs28501242	chr5:121351698	T/G	cg05256605	chr5:121412184	LOX	-0.55	-4.95	-0.3	1.39e-6	Coronary artery disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg22051586	chr4:881820	GAK	0.57	6.41	0.38	7.18e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg14789911	chr21:47582049	C21orf56	-0.44	-5.47	-0.33	1.1e-7	Testicular germ cell tumor;
KIRP	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg05335186	chr13:53173507	NA	-0.34	-5.38	-0.32	1.72e-7	Lewy body disease;
KIRP	cis	rs61542988	0.570	rs62448268	chr7:22829464	G/A	cg11367502	chr7:22862612	TOMM7	0.53	5.62	0.34	5.12e-8	Fibrinogen levels;
KIRP	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg22974920	chr21:40686053	BRWD1	0.49	5.54	0.33	7.67e-8	Cognitive function;
KIRP	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.79	10.79	0.57	1.72e-22	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.98	13.58	0.65	1.03e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.45	-6.0	-0.36	6.91e-9	Response to temozolomide;
KIRP	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.6	7.92	0.45	8.23e-14	Retinal vascular caliber;
KIRP	cis	rs2398893	0.883	rs11999153	chr9:96835847	G/A	cg14459158	chr9:96720562	NA	0.31	5.65	0.34	4.38e-8	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg02153584	chr22:29168773	CCDC117	0.59	6.01	0.36	6.58e-9	Pancreatic cancer;
KIRP	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	IgG glycosylation;
KIRP	trans	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg10756647	chr7:56101905	PSPH	0.92	6.69	0.39	1.47e-10	Diabetic kidney disease;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	1.1	21.37	0.81	5.3e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2299587	0.897	rs3850745	chr8:17784277	G/A	cg01800426	chr8:17659068	MTUS1	-0.41	-5.07	-0.31	7.99e-7	Economic and political preferences;
KIRP	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg26138937	chr11:71823887	C11orf51	-1.15	-7.98	-0.45	5.63e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg26516362	chr5:178986906	RUFY1	0.42	7.09	0.41	1.38e-11	Lung cancer;
KIRP	trans	rs4349753	0.904	rs446327	chr5:144191930	T/G	cg16033277	chr17:80885358	TBCD	0.4	6.24	0.37	1.9e-9	Photic sneeze reflex;
KIRP	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg20607798	chr8:58055168	NA	0.6	5.42	0.33	1.39e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg10253484	chr15:75165896	SCAMP2	0.49	5.4	0.33	1.6e-7	Systemic lupus erythematosus;
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05165339	chr4:1420672	NA	-0.34	-5.12	-0.31	6.32e-7	Longevity;
KIRP	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg04691961	chr3:161091175	C3orf57	-0.66	-11.15	-0.58	1.2e-23	Morning vs. evening chronotype;
KIRP	cis	rs13088645	0.532	rs7623580	chr3:134164345	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.54	0.38	3.52e-10	Coronary artery disease;
KIRP	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.58	-6.6	-0.39	2.54e-10	Hypospadias;
KIRP	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	9.36	0.51	5.36e-18	Response to bleomycin (chromatid breaks);
KIRP	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.93	14.95	0.69	2.15e-36	Menopause (age at onset);
KIRP	cis	rs3126085	0.515	rs7514696	chr1:152363874	G/A	cg26876637	chr1:152193138	HRNR	-0.52	-6.66	-0.39	1.83e-10	Atopic dermatitis;
KIRP	cis	rs929596	0.563	rs1105880	chr2:234601965	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-7.88	-0.45	1.03e-13	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg01025720	chr13:113346439	ATP11A	0.52	4.86	0.3	2.12e-6	Glycated hemoglobin levels;
KIRP	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.56	6.93	0.4	3.75e-11	Subjective well-being;
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.68	-9.87	-0.53	1.39e-19	Paraoxonase activity;
KIRP	cis	rs7116495	0.541	rs579320	chr11:71794954	G/T	cg26138937	chr11:71823887	C11orf51	-0.65	-5.06	-0.31	8.15e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg27229962	chr1:161099900	DEDD	-0.57	-6.3	-0.37	1.4e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs3136516	0.935	rs4506602	chr11:46815633	C/T	cg16389345	chr11:46697382	NA	0.57	7.89	0.45	9.85e-14	Venous thromboembolism;
KIRP	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg13731523	chr4:3047190	NA	-0.39	-6.26	-0.37	1.71e-9	Serum sulfate level;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg18209359	chr17:80159595	CCDC57	0.4	5.22	0.32	3.79e-7	Life satisfaction;
KIRP	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg23803603	chr1:2058230	PRKCZ	0.4	5.68	0.34	3.83e-8	Height;
KIRP	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg11189052	chr15:85197271	WDR73	0.5	5.19	0.31	4.34e-7	Schizophrenia;
KIRP	trans	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg09022993	chr4:52917875	SPATA18	0.36	6.07	0.36	4.83e-9	Schizophrenia;
KIRP	cis	rs7998202	0.667	rs282587	chr13:113351662	G/A	cg02820901	chr13:113351484	ATP11A	0.68	6.29	0.37	1.46e-9	Glycated hemoglobin levels;
KIRP	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-7.64	-0.44	4.91e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.49	0.62	4.56e-28	Ileal carcinoids;
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg21285383	chr16:89894308	SPIRE2	0.33	6.14	0.36	3.2e-9	Vitiligo;
KIRP	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.83	-0.49	2.01e-16	Mean corpuscular volume;
KIRP	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.45e-8	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09067715	chr16:702600	WDR90	0.52	6.61	0.39	2.35e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg10845886	chr2:3471009	TTC15	-0.52	-7.38	-0.43	2.37e-12	Neurofibrillary tangles;
KIRP	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg24807547	chr6:37504484	NA	-0.51	-7.75	-0.44	2.48e-13	Cognitive performance;
KIRP	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg19752551	chr11:57585705	CTNND1	0.67	11.21	0.58	7.59e-24	Schizophrenia;
KIRP	cis	rs2072732	0.861	rs12046233	chr1:2960608	A/G	cg11731671	chr1:2995604	PRDM16	-0.52	-5.98	-0.36	7.84e-9	Plateletcrit;
KIRP	cis	rs10998624	1	rs10998624	chr10:70939801	G/A	cg11621586	chr10:70884670	VPS26A	-1.06	-7.08	-0.41	1.49e-11	Immune reponse to smallpox (secreted IL-1beta);
KIRP	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg10189774	chr4:17578691	LAP3	0.44	5.21	0.32	3.9e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.17	0.42	8.94e-12	Arsenic metabolism;
KIRP	cis	rs2898681	0.614	rs11947787	chr4:53705225	C/A	cg00338735	chr4:53728038	RASL11B	0.44	5.63	0.34	4.95e-8	Optic nerve measurement (cup area);
KIRP	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.83	-10.4	-0.55	3.22e-21	Vitamin D levels;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.1	0.5	3.07e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.92	-0.35	1.1e-8	Height;
KIRP	cis	rs12249377	0.519	rs12259401	chr10:92594121	T/G	cg14313238	chr10:92632228	RPP30	0.43	5.21	0.32	4.02e-7	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg02569458	chr12:86230093	RASSF9	-0.52	-7.56	-0.43	8.08e-13	Major depressive disorder;
KIRP	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.69	-0.39	1.52e-10	Menopause (age at onset);
KIRP	cis	rs8084125	1.000	rs72978668	chr18:74953748	A/C	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06850241	chr22:41845214	NA	0.39	5.15	0.31	5.22e-7	Vitiligo;
KIRP	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.59	-0.59	4.58e-25	Eye color traits;
KIRP	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg18461458	chr19:21324796	ZNF431	0.47	4.94	0.3	1.45e-6	Pain;
KIRP	cis	rs212524	0.544	rs7551107	chr1:21559702	C/A	cg08890418	chr1:21044141	KIF17	0.4	5.94	0.35	9.92e-9	Height;
KIRP	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg07384165	chr1:10488281	NA	-0.42	-5.38	-0.32	1.75e-7	Breast size;
KIRP	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	cg12689670	chr1:183009347	LAMC1	0.47	6.64	0.39	1.96e-10	Colorectal cancer;
KIRP	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.7	10.68	0.56	4.05e-22	Noise-induced hearing loss;
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.62	-0.34	5.22e-8	Lung cancer;
KIRP	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg09555818	chr19:45449301	APOC2	0.41	5.33	0.32	2.25e-7	Blood protein levels;
KIRP	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg15147215	chr3:52552868	STAB1	-0.28	-5.05	-0.31	8.72e-7	Bipolar disorder;
KIRP	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	0.63	6.86	0.4	5.47e-11	Crohn's disease;
KIRP	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg05709478	chr1:6581295	PLEKHG5	0.63	6.15	0.37	3.11e-9	Body mass index;
KIRP	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg23682824	chr7:23144976	KLHL7	0.46	5.57	0.33	6.76e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.81	8.8	0.49	2.5e-16	HIV-1 control;
KIRP	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg06204229	chr3:52865917	ITIH4	0.54	5.93	0.35	1.04e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.47	6.48	0.38	4.98e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs736801	0.891	rs11242115	chr5:131826413	G/C	cg07395648	chr5:131743802	NA	-0.47	-6.1	-0.36	4.04e-9	Breast cancer;Mosquito bite size;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03931078	chr17:66453919	WIPI1	0.49	6.79	0.4	8.46e-11	Survival in pancreatic cancer;
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.3	0.65	8.9e-31	Platelet count;
KIRP	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.85	-0.53	1.66e-19	Response to antipsychotic treatment;
KIRP	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.98	0.36	7.96e-9	Breast cancer;
KIRP	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.79	-0.35	2.17e-8	Colorectal cancer;
KIRP	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17376030	chr22:41985996	PMM1	0.76	8.08	0.46	2.89e-14	Vitiligo;
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.62	9.36	0.51	5.23e-18	Immature fraction of reticulocytes;
KIRP	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.29	7.78	0.44	1.95e-13	Crohn's disease;
KIRP	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg18586891	chr4:952366	TMEM175	0.59	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9400467	0.506	rs12190135	chr6:111698204	T/C	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.35	12.29	0.62	2.19e-27	Diabetic retinopathy;
KIRP	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg07382826	chr16:28625726	SULT1A1	0.48	5.47	0.33	1.09e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg04727924	chr7:799746	HEATR2	0.6	5.57	0.33	6.65e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.96	10.56	0.56	9.76e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4356932	1.000	rs6532111	chr4:76955914	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	6.89	0.4	4.7e-11	Tonsillectomy;
KIRP	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg09631192	chr20:23583594	CST9	-0.57	-5.52	-0.33	8.67e-8	Chronic kidney disease;
KIRP	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg02725872	chr8:58115012	NA	-0.45	-5.14	-0.31	5.6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg14851346	chr12:38532713	NA	-0.4	-4.98	-0.3	1.18e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4774830	0.744	rs62046383	chr15:56303623	C/T	cg24530489	chr15:56299380	NA	-0.81	-5.48	-0.33	1.03e-7	Delta-5 desaturase activity;
KIRP	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.78	0.44	1.96e-13	Obesity-related traits;
KIRP	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.85	11.34	0.59	3.03e-24	Morning vs. evening chronotype;
KIRP	cis	rs2172802	0.659	rs28713421	chr4:62497085	C/T	cg04118610	chr4:62707027	LPHN3	0.58	7.15	0.41	1e-11	Partial epilepsies;
KIRP	cis	rs7666738	0.515	rs28615369	chr4:98896858	C/T	cg05340658	chr4:99064831	C4orf37	0.66	7.89	0.45	9.64e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg26248373	chr2:1572462	NA	-0.82	-10.99	-0.57	4.15e-23	IgG glycosylation;
KIRP	cis	rs8133932	0.608	rs382195	chr21:47339222	G/A	cg11214348	chr21:47283868	PCBP3	-0.44	-5.12	-0.31	6.18e-7	Schizophrenia;
KIRP	cis	rs11955175	1.000	rs11960585	chr5:40662007	C/A	cg05478818	chr5:40835740	RPL37	0.69	5.36	0.32	1.94e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	9.26	0.51	1.08e-17	IgG glycosylation;
KIRP	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.1	-12.91	-0.64	1.89e-29	Vitiligo;
KIRP	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg12218747	chr21:37451666	NA	-0.42	-5.28	-0.32	2.81e-7	Mitral valve prolapse;
KIRP	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.69	-8.35	-0.47	4.97e-15	Aortic root size;
KIRP	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg26207909	chr14:103986467	CKB	-0.43	-5.33	-0.32	2.26e-7	Coronary artery disease;
KIRP	cis	rs2150410	0.915	rs4816623	chr21:40693843	C/A	cg11890956	chr21:40555474	PSMG1	0.8	5.56	0.33	7.12e-8	Temperament (bipolar disorder);
KIRP	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	trans	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg10756647	chr7:56101905	PSPH	0.99	7.04	0.41	1.9e-11	Diabetic kidney disease;
KIRP	cis	rs7178572	0.625	rs12904553	chr15:77845959	G/A	cg12131826	chr15:77904385	NA	0.38	5.18	0.31	4.62e-7	Type 2 diabetes;
KIRP	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg08992911	chr2:238395768	MLPH	0.49	5.02	0.3	1e-6	Prostate cancer;
KIRP	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-0.39	-4.99	-0.3	1.12e-6	Type 2 diabetes;
KIRP	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg26850624	chr5:429559	AHRR	0.37	7.27	0.42	4.84e-12	Cystic fibrosis severity;
KIRP	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg11189052	chr15:85197271	WDR73	0.55	5.71	0.34	3.24e-8	Schizophrenia;
KIRP	cis	rs76662990	0.908	rs17645885	chr5:73850292	A/G	cg01264639	chr5:73839484	NA	0.57	5.38	0.32	1.72e-7	Residual cognition;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03647317	chr4:187891568	NA	-0.79	-13.24	-0.65	1.43e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10214930	0.781	rs759271	chr7:27647113	C/G	cg22168087	chr7:27702803	HIBADH	0.51	5.09	0.31	7.04e-7	Hypospadias;
KIRP	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg24315340	chr6:146058215	EPM2A	0.43	5.39	0.32	1.66e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-7.97	-0.45	5.87e-14	Personality dimensions;
KIRP	cis	rs4523957	0.855	rs7217226	chr17:2136065	A/C	cg16513277	chr17:2031491	SMG6	-0.69	-9.61	-0.52	8.94e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs72960926	0.744	rs7776273	chr6:74967693	T/C	cg03266952	chr6:74778945	NA	-0.59	-4.9	-0.3	1.76e-6	Metabolite levels (MHPG);
KIRP	trans	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg14715136	chr2:108537789	NA	0.38	6.12	0.36	3.77e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs4919044	0.808	rs7895700	chr10:94791099	A/G	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg08076091	chr2:203926405	NBEAL1	0.85	8.63	0.48	7.88e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg16926213	chr1:1841314	NA	-0.31	-5.34	-0.32	2.08e-7	Body mass index;
KIRP	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.42	-5.91	-0.35	1.15e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.82	11.22	0.58	7.13e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.58	-0.34	6.4e-8	Life satisfaction;
KIRP	cis	rs12786942	0.660	rs11224764	chr11:101309570	A/C	cg03942599	chr11:101341554	TRPC6	0.47	5.97	0.36	8.34e-9	Facial depth;
KIRP	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.52	6.66	0.39	1.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg23531873	chr3:25705861	TOP2B	-1.1	-6.06	-0.36	4.98e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.68	-0.34	3.75e-8	IgG glycosylation;
KIRP	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.69	-7.65	-0.44	4.5e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	5.47	0.33	1.1e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.08	0.31	7.6e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7590368	0.715	rs72779452	chr2:10959461	G/T	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.63	6.85	0.4	5.94e-11	Corneal structure;
KIRP	cis	rs4356932	1.000	rs11097224	chr4:76989670	C/A	cg00809888	chr4:76862425	NAAA	0.45	6.34	0.37	1.08e-9	Blood protein levels;
KIRP	trans	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.06	-0.41	1.65e-11	Bladder cancer;
KIRP	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg05872129	chr22:39784769	NA	-0.41	-5.51	-0.33	8.87e-8	IgG glycosylation;
KIRP	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.79	12.27	0.62	2.61e-27	Colorectal cancer;
KIRP	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	8.56	0.48	1.21e-15	Alzheimer's disease;
KIRP	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg09491104	chr22:46646882	C22orf40	-0.55	-6.01	-0.36	6.82e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg15068132	chr12:102092402	CHPT1	-0.4	-5.15	-0.31	5.26e-7	Blood protein levels;
KIRP	cis	rs714515	0.934	rs9425298	chr1:172358834	T/C	cg01573306	chr1:172330400	DNM3	0.44	5.79	0.35	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs11039798	0.920	rs7478904	chr11:48630323	C/T	cg03929089	chr4:120376271	NA	0.88	6.43	0.38	6.43e-10	Axial length;
KIRP	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg04374321	chr14:90722782	PSMC1	0.6	6.97	0.41	2.95e-11	Mortality in heart failure;
KIRP	cis	rs16976116	0.951	rs9300	chr15:55489065	G/A	cg11288833	chr15:55489084	RSL24D1	0.68	7.94	0.45	7.05e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7903847	0.642	rs10882914	chr10:99142057	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.36	0.38	9.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.61	-5.42	-0.33	1.39e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12580194	0.593	rs12099665	chr12:55731191	G/T	cg11794356	chr12:55725991	OR6C3	-0.54	-7.21	-0.42	7.07e-12	Cancer;
KIRP	cis	rs830233	0.525	rs1992708	chr5:165366109	A/T	cg13976338	chr5:165423657	NA	-0.47	-5.01	-0.3	1.02e-6	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.62	0.34	5.23e-8	Lung cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15956162	chr14:39605657	SIP1	0.39	6.2	0.37	2.36e-9	Survival in pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.91	-9.99	-0.54	6.13e-20	Pulmonary function decline;
KIRP	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg17385448	chr1:15911702	AGMAT	0.26	5.0	0.3	1.11e-6	Systolic blood pressure;
KIRP	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg00409905	chr10:38381863	ZNF37A	0.56	5.61	0.34	5.31e-8	Obesity (extreme);
KIRP	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.04	-16.07	-0.72	3.13e-40	Homoarginine levels;
KIRP	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.02	0.36	6.47e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg06585982	chr3:143692056	C3orf58	0.59	7.6	0.44	6.39e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7924005	0.891	rs11593335	chr10:6160702	A/T	cg17191567	chr10:6178319	NA	-0.49	-5.23	-0.32	3.58e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.46	6.37	0.38	9.08e-10	Dupuytren's disease;
KIRP	cis	rs28719689	0.655	rs58892423	chr8:1276014	A/C	cg22761795	chr8:1265118	NA	0.55	4.94	0.3	1.41e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg13699009	chr12:122356056	WDR66	0.73	11.36	0.59	2.49e-24	Mean corpuscular volume;
KIRP	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg25173405	chr17:45401733	C17orf57	0.44	5.72	0.34	3.09e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.2	0.46	1.37e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.79	12.7	0.63	9.3e-29	Schizophrenia;
KIRP	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-1.08	-21.06	-0.8	5.72e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.69	7.05	0.41	1.77e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	10.45	0.55	2.1e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs897080	0.515	rs1067359	chr2:44661997	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	5.68	0.34	3.85e-8	Height;
KIRP	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg07395648	chr5:131743802	NA	-0.54	-7.71	-0.44	3.1e-13	Breast cancer;
KIRP	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg26513180	chr16:89883248	FANCA	0.82	5.64	0.34	4.71e-8	Skin colour saturation;
KIRP	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.74	7.64	0.44	4.87e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-5.43	-0.33	1.32e-7	Neuroticism;
KIRP	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.49e-11	Type 2 diabetes;
KIRP	cis	rs6959887	0.926	rs17674881	chr7:35276262	C/G	cg06685737	chr7:35301730	NA	0.44	6.3	0.37	1.34e-9	Birth weight;
KIRP	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg10434728	chr15:90938212	IQGAP1	0.38	7.12	0.41	1.15e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg10253484	chr15:75165896	SCAMP2	-0.44	-5.14	-0.31	5.59e-7	Breast cancer;
KIRP	cis	rs7919006	0.793	rs2395126	chr10:76768023	G/A	cg01390419	chr10:76803856	DUPD1	0.5	5.83	0.35	1.75e-8	Weight;
KIRP	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.12	-0.41	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg12450255	chr15:34659304	LPCAT4	0.72	6.19	0.37	2.56e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.32	6.51	0.38	4.19e-10	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.33	-0.37	1.13e-9	Lung cancer;
KIRP	cis	rs7580658	0.521	rs7605733	chr2:127931787	T/G	cg16751203	chr2:127950803	CYP27C1	0.37	4.94	0.3	1.44e-6	Protein C levels;
KIRP	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.43	-5.04	-0.31	8.98e-7	Aortic root size;
KIRP	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.55	-0.33	7.55e-8	Fear of minor pain;
KIRP	cis	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg26378065	chr17:18585709	ZNF286B	0.4	5.08	0.31	7.55e-7	Educational attainment (years of education);
KIRP	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.42	-5.08	-0.31	7.59e-7	Blood metabolite levels;
KIRP	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg05973401	chr12:123451056	ABCB9	0.61	7.16	0.42	9.38e-12	Platelet count;
KIRP	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.84	-13.42	-0.65	3.38e-31	Breast cancer;
KIRP	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.24e-11	Iron status biomarkers;
KIRP	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	cis	rs2964802	0.505	rs13179252	chr5:10805662	A/G	cg14521931	chr5:10832172	NA	-0.71	-10.52	-0.56	1.31e-21	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.71	-9.63	-0.52	7.94e-19	Waist circumference;Body mass index;
KIRP	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.53	-6.54	-0.38	3.54e-10	Longevity;
KIRP	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg25547332	chr5:131281432	NA	-0.46	-5.14	-0.31	5.58e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg06533319	chr4:3265114	C4orf44	0.44	4.92	0.3	1.56e-6	Serum sulfate level;
KIRP	cis	rs35740288	0.822	rs11638720	chr15:86229273	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-5.0	-0.3	1.1e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.68	7.42	0.43	1.9e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg12615879	chr12:58013172	SLC26A10	0.35	5.07	0.31	7.86e-7	Multiple sclerosis;
KIRP	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.82	-14.41	-0.68	1.47e-34	Post bronchodilator FEV1;
KIRP	cis	rs68170813	0.652	rs17403088	chr7:107111373	C/A	cg02696742	chr7:106810147	HBP1	-0.71	-6.59	-0.39	2.59e-10	Coronary artery disease;
KIRP	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.64	-6.11	-0.36	3.86e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8028182	0.636	rs11637068	chr15:75743002	G/A	cg20655648	chr15:75932815	IMP3	0.51	6.58	0.39	2.84e-10	Sudden cardiac arrest;
KIRP	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.66	-8.1	-0.46	2.54e-14	Aortic root size;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04106862	chr16:22309278	POLR3E	-0.49	-6.15	-0.37	3.1e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6539288	0.677	rs7315989	chr12:107339788	A/G	cg15890332	chr12:107067104	RFX4	0.36	5.81	0.35	1.9e-8	Total body bone mineral density;
KIRP	cis	rs4356975	0.563	rs4522933	chr4:69949498	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs36715	1.000	rs36693	chr5:127548700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	8.7	0.49	4.84e-16	Breast cancer;
KIRP	cis	rs3774830	0.743	rs195127	chr4:5429650	C/T	cg26943120	chr4:5472116	STK32B	-0.21	-5.27	-0.32	2.94e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg27189623	chr16:705930	WDR90	0.44	6.04	0.36	5.78e-9	Height;
KIRP	cis	rs10788972	0.873	rs4926619	chr1:54558101	A/G	cg25741118	chr1:54482237	LDLRAD1	-0.29	-5.02	-0.3	1.01e-6	Parkinson disease and lewy body pathology;
KIRP	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-8.2	-0.46	1.3e-14	Bipolar disorder;
KIRP	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.46	5.11	0.31	6.35e-7	Schizophrenia;
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	7.5	0.43	1.13e-12	Lung function (FEV1/FVC);
KIRP	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg13660082	chr14:53194042	PSMC6	-0.71	-7.3	-0.42	3.88e-12	Alzheimer's disease (late onset);
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03647317	chr4:187891568	NA	-0.77	-13.04	-0.64	7.01e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.51	6.87	0.4	5.15e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.66	8.79	0.49	2.68e-16	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7119038	0.629	rs73001429	chr11:118603165	T/G	cg19308663	chr11:118741387	NA	0.49	8.04	0.46	3.9e-14	Sjögren's syndrome;
KIRP	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	8.1	0.46	2.57e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.56	7.74	0.44	2.56e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg03060546	chr3:49711283	APEH	0.65	6.67	0.39	1.63e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	5.8	0.35	2.01e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg02297831	chr4:17616191	MED28	0.58	7.37	0.43	2.65e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3026101	0.671	rs28437236	chr17:5319214	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs6977660	0.714	rs10224920	chr7:19816173	A/T	cg05791153	chr7:19748676	TWISTNB	0.6	5.98	0.36	8e-9	Thyroid stimulating hormone;
KIRP	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6058796	1.000	rs9636547	chr20:31262033	T/A	cg13636640	chr20:31349939	DNMT3B	0.57	5.06	0.31	8.04e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs2151522	0.603	rs35870379	chr6:127198875	C/A	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01446731	chr15:80770633	ARNT2	-0.33	-6.01	-0.36	6.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs12517041	1.000	rs10068478	chr5:23297003	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs1355223	0.902	rs1597962	chr11:34727172	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.75e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg07148914	chr20:33460835	GGT7	0.55	7.26	0.42	5.08e-12	Height;
KIRP	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-6.15	-0.37	3.06e-9	Chronic sinus infection;
KIRP	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg24315340	chr6:146058215	EPM2A	0.44	5.45	0.33	1.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg21285383	chr16:89894308	SPIRE2	-0.31	-6.02	-0.36	6.38e-9	Vitiligo;
KIRP	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg06115741	chr20:33292138	TP53INP2	0.39	5.22	0.32	3.74e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.65	12.14	0.61	6.98e-27	Blood protein levels;
KIRP	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.84	-9.44	-0.52	3.07e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1864729	1.000	rs2583504	chr8:98283404	G/C	cg08679828	chr8:102218111	ZNF706	-0.68	-6.2	-0.37	2.4e-9	Estradiol plasma levels (breast cancer);
KIRP	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.1	0.36	4.12e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.45	-11.3	-0.58	4.1e-24	Diabetic kidney disease;
KIRP	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.04	0.41	1.88e-11	Mean corpuscular volume;
KIRP	cis	rs6580649	0.941	rs4141065	chr12:48523499	G/A	cg26205652	chr12:48591994	NA	-0.51	-5.96	-0.36	8.81e-9	Lung cancer;
KIRP	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg22875332	chr1:76189707	ACADM	-0.34	-5.0	-0.3	1.11e-6	Daytime sleep phenotypes;
KIRP	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.1	-0.31	6.73e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	10.23	0.55	1.09e-20	Lymphocyte counts;
KIRP	cis	rs1867631	0.959	rs11208914	chr1:67049728	C/T	cg13052034	chr1:66999238	SGIP1	0.5	7.02	0.41	2.11e-11	Menopause (age at onset);
KIRP	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg15133208	chr4:90757351	SNCA	0.38	4.92	0.3	1.6e-6	Neuroticism;
KIRP	cis	rs282587	0.569	rs413110	chr13:113413755	A/G	cg04656015	chr13:113407548	ATP11A	-0.57	-6.37	-0.38	9.46e-10	Glycated hemoglobin levels;
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.78	-12.06	-0.61	1.3e-26	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.62	-7.39	-0.43	2.32e-12	Menarche (age at onset);
KIRP	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.82	12.13	0.61	7.75e-27	Blood metabolite ratios;
KIRP	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg12463550	chr7:65579703	CRCP	-0.57	-6.94	-0.4	3.48e-11	Aortic root size;
KIRP	cis	rs6058796	1.000	rs6087972	chr20:31268102	A/G	cg13636640	chr20:31349939	DNMT3B	0.61	5.31	0.32	2.49e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.2	-0.31	4.28e-7	Metabolite levels;
KIRP	cis	rs2463822	0.514	rs10750972	chr11:62053687	A/G	cg06239285	chr11:62104954	ASRGL1	0.56	6.14	0.36	3.29e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg23594656	chr7:65796392	TPST1	0.35	5.09	0.31	7.2e-7	Aortic root size;
KIRP	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg01304814	chr3:48885189	PRKAR2A	0.63	5.59	0.34	5.87e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.55	6.0	0.36	6.83e-9	Type 2 diabetes;
KIRP	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00677455	chr12:58241039	CTDSP2	0.55	6.79	0.4	8.46e-11	Multiple sclerosis;
KIRP	cis	rs1978968	1.000	rs11704733	chr22:18446212	T/G	cg02610425	chr22:18483192	MICAL3	0.36	5.03	0.31	9.49e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg21452805	chr1:244014465	NA	0.73	6.49	0.38	4.59e-10	RR interval (heart rate);
KIRP	cis	rs279910	0.862	rs279899	chr9:965006	A/T	cg13952963	chr9:998547	NA	-0.51	-5.8	-0.35	1.99e-8	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs2151522	0.762	rs115190460	chr6:127170744	A/G	cg21431617	chr6:127135037	NA	0.29	5.16	0.31	5.14e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg23484912	chr5:273055	PDCD6	0.68	8.22	0.46	1.18e-14	Pancreatic cancer;
KIRP	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-6.73	-0.39	1.19e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg00666640	chr1:248458726	OR2T12	0.37	5.19	0.31	4.46e-7	Common traits (Other);
KIRP	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.73	-8.86	-0.49	1.64e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs4131099	0.793	rs16949691	chr16:51363260	C/A	cg02207200	chr8:17353980	SLC7A2	0.56	6.29	0.37	1.43e-9	Personality dimensions;
KIRP	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg17554472	chr22:41940697	POLR3H	0.47	5.29	0.32	2.73e-7	Vitiligo;
KIRP	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	5.46	0.33	1.19e-7	Renal cell carcinoma;
KIRP	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.7	-10.58	-0.56	8.31e-22	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10663220	chr12:13249129	GSG1	0.51	6.19	0.37	2.54e-9	Interleukin-4 levels;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.44	6.09	0.36	4.27e-9	Lymphocyte counts;
KIRP	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs116979167	0.545	rs1706914	chr7:105196445	A/T	cg19920283	chr7:105172520	RINT1	0.49	5.53	0.33	8.17e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2929278	0.617	rs575082	chr15:44110142	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.5	-6.03	-0.36	5.9e-9	Schizophrenia;
KIRP	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26526719	chr5:1949144	NA	-0.42	-5.08	-0.31	7.54e-7	Gut microbiome composition (winter);
KIRP	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg06636001	chr8:8085503	FLJ10661	0.56	7.67	0.44	3.92e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.78	-10.95	-0.57	5.35e-23	Dental caries;
KIRP	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg00405596	chr8:11794950	NA	-0.51	-6.74	-0.39	1.1e-10	Retinal vascular caliber;
KIRP	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.64	9.47	0.52	2.35e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.2	21.52	0.81	1.77e-58	Cognitive function;
KIRP	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.07	8.85	0.49	1.74e-16	Mitochondrial DNA levels;
KIRP	cis	rs8014252	0.803	rs17108201	chr14:70988931	A/G	cg11204974	chr14:71022665	NA	-0.74	-7.39	-0.43	2.35e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.86	11.77	0.6	1.17e-25	Tonsillectomy;
KIRP	cis	rs6681460	0.634	rs4142763	chr1:66998036	A/G	cg13052034	chr1:66999238	SGIP1	0.41	5.68	0.34	3.83e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg08662619	chr6:150070041	PCMT1	0.33	5.18	0.31	4.66e-7	Lung cancer;
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg23985595	chr17:80112537	CCDC57	-0.34	-5.14	-0.31	5.53e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg05044414	chr3:183734942	ABCC5	0.38	5.83	0.35	1.72e-8	Anterior chamber depth;
KIRP	cis	rs7937840	0.581	rs4963461	chr11:61884044	G/A	cg01969543	chr11:61895209	INCENP	-0.47	-6.16	-0.37	2.87e-9	Breast cancer;
KIRP	cis	rs3746446	0.678	rs6120777	chr20:33560172	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	5.73	0.34	2.95e-8	Congenital left-sided heart lesions;
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13939156	chr17:80058883	NA	-0.49	-7.36	-0.42	2.8e-12	Life satisfaction;
KIRP	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.59	7.79	0.44	1.89e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-16.98	-0.73	2.52e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.58	-7.31	-0.42	3.7e-12	Uric acid levels;
KIRP	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.76	10.19	0.54	1.39e-20	Squamous cell carcinoma;
KIRP	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg23601095	chr6:26197514	HIST1H3D	0.97	8.23	0.46	1.08e-14	Gout;Renal underexcretion gout;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19640789	chr19:8650112	ADAMTS10	0.52	6.61	0.39	2.31e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3736594	0.527	rs62141279	chr2:27771415	C/T	cg27432699	chr2:27873401	GPN1	0.57	6.26	0.37	1.73e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs10858047	0.883	rs6695699	chr1:115209951	C/A	cg12756093	chr1:115239321	AMPD1	-0.67	-6.45	-0.38	5.97e-10	Autism;
KIRP	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.47	-5.65	-0.34	4.32e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.41	5.7	0.34	3.39e-8	Aortic root size;
KIRP	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.48	-6.47	-0.38	5.28e-10	Multiple sclerosis;
KIRP	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg16268157	chr7:99778414	STAG3	-0.56	-6.06	-0.36	5.13e-9	Lung function (FEV1/FVC);
KIRP	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.61	4.87	0.3	1.99e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg24747557	chr10:131355152	MGMT	-0.39	-5.22	-0.32	3.76e-7	Response to temozolomide;
KIRP	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.65	7.9	0.45	9.17e-14	Vitiligo;
KIRP	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg27165867	chr14:105738592	BRF1	-0.41	-4.89	-0.3	1.85e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg17279839	chr7:150038598	RARRES2	0.44	5.96	0.35	8.9e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs867371	0.929	rs1045508	chr15:82449906	A/C	cg00614314	chr15:82944287	LOC80154	-0.52	-6.12	-0.36	3.63e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.45	-5.3	-0.32	2.63e-7	Reticulocyte count;
KIRP	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg25019722	chr6:37503610	NA	-0.93	-14.03	-0.67	2.92e-33	Cognitive performance;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02073427	chr10:15252052	NA	0.46	6.5	0.38	4.41e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	0.85	9.86	0.53	1.53e-19	Testicular germ cell tumor;
KIRP	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-12.4	-0.62	9.59e-28	Cognitive function;
KIRP	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.66	-0.44	4.37e-13	Neuroticism;
KIRP	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.63	10.03	0.54	4.47e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.43	-0.52	3.3e-18	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22832808	chr15:48726513	FBN1	-0.38	-6.3	-0.37	1.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg12969734	chr22:50962224	SCO2	0.57	5.63	0.34	4.89e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9398235	0.929	rs2073211	chr6:110729270	A/G	cg19196401	chr6:110721138	DDO	0.44	4.94	0.3	1.42e-6	Systemic lupus erythematosus;
KIRP	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.41	-5.26	-0.32	3.08e-7	Renal cell carcinoma;
KIRP	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg10144569	chr3:42726640	KBTBD5	-0.48	-5.0	-0.3	1.11e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Bladder cancer;
KIRP	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.43	-5.41	-0.33	1.47e-7	Ulcerative colitis;
KIRP	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.59	-8.31	-0.47	6.47e-15	Calcium levels;
KIRP	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg04132472	chr17:19861366	AKAP10	-0.4	-5.2	-0.31	4.17e-7	Schizophrenia;
KIRP	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg23601095	chr6:26197514	HIST1H3D	0.83	5.81	0.35	1.95e-8	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19690901	chr21:40817844	SH3BGR	0.51	7.01	0.41	2.28e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs815815	0.583	rs11125126	chr2:47395379	C/T	cg27223769	chr2:47403360	CALM2	-0.68	-8.44	-0.47	2.69e-15	Dialysis-related mortality;
KIRP	cis	rs3751972	0.911	rs9630740	chr17:26242756	C/G	cg26853415	chr17:26127438	NOS2	-0.46	-5.07	-0.31	7.65e-7	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	7.09	0.41	1.42e-11	Total body bone mineral density;
KIRP	cis	rs56161922	1.000	rs72468035	chr1:207812405	C/T	cg11752769	chr1:207818423	CR1L	-0.77	-5.0	-0.3	1.09e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.92	-13.95	-0.66	5.47e-33	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg13010199	chr12:38710504	ALG10B	-0.39	-5.06	-0.31	8.09e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.55	0.39	3.31e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.99	-0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg23587288	chr2:27483067	SLC30A3	-0.56	-6.97	-0.41	2.95e-11	Blood metabolite levels;
KIRP	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg15841412	chr13:111365552	ING1	0.52	5.38	0.32	1.75e-7	Coronary artery disease;
KIRP	cis	rs975752	0.867	rs11190444	chr10:102024352	C/T	cg13817732	chr10:102046368	BLOC1S2	0.72	6.01	0.36	6.83e-9	Schizophrenia;
KIRP	cis	rs2795502	0.515	rs116848302	chr10:43367783	G/A	cg11150807	chr10:43354902	NA	0.74	5.48	0.33	1.03e-7	Blood protein levels;
KIRP	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg03834567	chr2:218808745	TNS1	0.48	5.99	0.36	7.47e-9	Ulcerative colitis;
KIRP	cis	rs42648	0.535	rs6978118	chr7:89800241	T/A	cg25739043	chr7:89950458	NA	-0.34	-5.29	-0.32	2.7e-7	Homocysteine levels;
KIRP	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-0.39	-5.12	-0.31	6.3e-7	Acne (severe);
KIRP	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.8	0.4	7.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07128233	chr10:65217182	JMJD1C	0.43	6.01	0.36	6.51e-9	Migraine with aura;
KIRP	cis	rs12208915	0.848	rs12209635	chr6:79532215	C/T	cg18132916	chr6:79620363	NA	0.56	5.33	0.32	2.18e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs1165472	0.806	rs12568471	chr1:56144766	C/T	cg11523071	chr1:56160889	NA	-0.64	-8.22	-0.46	1.14e-14	Paclitaxel-induced neuropathy;
KIRP	cis	rs9399401	0.845	rs263184	chr6:142862022	A/G	cg09547025	chr6:142721804	GPR126	0.34	5.2	0.31	4.16e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg03735888	chr19:58951602	ZNF132	0.48	5.76	0.34	2.49e-8	Uric acid clearance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14155388	chr9:92087586	SEMA4D	0.46	6.02	0.36	6.2e-9	Interleukin-4 levels;
KIRP	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg05156742	chr15:59063176	FAM63B	0.58	7.32	0.42	3.58e-12	Schizophrenia;
KIRP	trans	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg10756647	chr7:56101905	PSPH	1.07	8.32	0.47	6.01e-15	Diabetic kidney disease;
KIRP	cis	rs9596863	1.000	rs4471558	chr13:54413349	A/T	ch.13.53330881F	chr13:54432880	NA	0.51	5.48	0.33	1.03e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg03808351	chr9:123631620	PHF19	0.4	5.34	0.32	2.1e-7	Rheumatoid arthritis;
KIRP	cis	rs34746873	0.778	rs2459523	chr8:62876448	T/C	cg01509237	chr8:63160509	NKAIN3	0.44	5.49	0.33	1e-7	Neurofibrillary tangles;
KIRP	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg23100626	chr2:96804247	ASTL	0.48	6.99	0.41	2.57e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg21419209	chr3:44054225	NA	-0.76	-9.41	-0.51	3.75e-18	Coronary artery disease;
KIRP	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.01	11.42	0.59	1.65e-24	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-6.14	-0.36	3.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg25486957	chr4:152246857	NA	-0.55	-5.96	-0.36	8.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.59	-8.14	-0.46	1.93e-14	Breast cancer;
KIRP	cis	rs6684514	1.000	rs67034206	chr1:156270260	C/T	cg16558208	chr1:156270281	VHLL	-0.45	-5.97	-0.36	8.03e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg05639522	chr1:247681581	NA	0.59	6.62	0.39	2.26e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.34	5.82	0.35	1.83e-8	Mean platelet volume;
KIRP	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg08822215	chr16:89438651	ANKRD11	-0.51	-6.72	-0.39	1.28e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg21775007	chr8:11205619	TDH	0.39	5.33	0.32	2.18e-7	Monocyte count;
KIRP	cis	rs7860634	0.872	rs7847312	chr9:139089718	A/C	cg04455058	chr9:139085579	NA	0.66	9.69	0.53	5.25e-19	Thyroid hormone levels;
KIRP	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.26	0.32	3.07e-7	Depression;
KIRP	cis	rs4006360	0.635	rs1848811	chr17:39235963	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.9	-0.53	1.14e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.0	-0.36	7.18e-9	Parkinson's disease;
KIRP	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.69	10.07	0.54	3.36e-20	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.47	0.38	5.33e-10	Neuroticism;
KIRP	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.71	-0.44	3.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.47	6.35	0.38	1.03e-9	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.45	6.32	0.37	1.24e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.62	8.65	0.48	6.89e-16	Blood protein levels;
KIRP	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.59	8.59	0.48	1.03e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.15e-20	Dupuytren's disease;
KIRP	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.62	-7.19	-0.42	7.64e-12	Prudent dietary pattern;
KIRP	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.49	6.39	0.38	8.08e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.62	-0.48	8.07e-16	Triglycerides;
KIRP	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2150410	0.915	rs6517539	chr21:40657383	C/T	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10919176	chr8:110346552	NUDCD1;ENY2	0.45	6.14	0.36	3.36e-9	Inflammatory biomarkers;
KIRP	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.47	-6.01	-0.36	6.76e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2274273	0.805	rs11628437	chr14:55775468	G/A	cg04306507	chr14:55594613	LGALS3	0.43	6.62	0.39	2.24e-10	Protein biomarker;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg07747251	chr5:1868357	NA	0.43	5.56	0.33	7.09e-8	Cardiovascular disease risk factors;
KIRP	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg07541023	chr7:19748670	TWISTNB	0.63	5.77	0.35	2.43e-8	Thyroid stimulating hormone;
KIRP	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs4671400	0.543	rs10178135	chr2:61485267	T/C	cg15711740	chr2:61764176	XPO1	0.61	7.0	0.41	2.43e-11	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg05802129	chr4:122689817	NA	-0.46	-6.77	-0.4	9.43e-11	Type 2 diabetes;
KIRP	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.77	0.35	2.43e-8	Aortic root size;
KIRP	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.87	-11.4	-0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-5.22	-0.32	3.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg02336718	chr17:17403227	NA	0.33	5.26	0.32	3.1e-7	Lymphocyte counts;
KIRP	cis	rs1957429	0.520	rs17102258	chr14:65332369	G/A	cg23373153	chr14:65346875	NA	-0.65	-5.34	-0.32	2.1e-7	Pediatric areal bone mineral density (radius);
KIRP	trans	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg10756647	chr7:56101905	PSPH	0.97	6.65	0.39	1.92e-10	Diabetic kidney disease;
KIRP	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg06636001	chr8:8085503	FLJ10661	0.7	9.07	0.5	3.79e-17	Retinal vascular caliber;
KIRP	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg22117172	chr7:91764530	CYP51A1	-0.44	-6.2	-0.37	2.32e-9	Breast cancer;
KIRP	cis	rs2625529	0.529	rs1552133	chr15:72232897	T/A	cg16672083	chr15:72433130	SENP8	0.45	6.25	0.37	1.82e-9	Red blood cell count;
KIRP	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.02	-0.3	1.01e-6	Pulmonary function;
KIRP	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.62	-8.86	-0.49	1.59e-16	Body mass index;
KIRP	cis	rs6142102	0.961	rs2056990	chr20:32623464	C/T	cg08999081	chr20:33150536	PIGU	0.51	6.07	0.36	4.78e-9	Skin pigmentation;
KIRP	cis	rs3925075	0.531	rs4075052	chr16:31348233	G/T	cg02846316	chr16:31340340	ITGAM	-0.46	-5.62	-0.34	5.18e-8	IgA nephropathy;
KIRP	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.75	9.99	0.54	5.86e-20	Coronary artery disease;
KIRP	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg20936604	chr3:58311152	NA	-0.66	-5.42	-0.33	1.4e-7	Cholesterol, total;
KIRP	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	1.02	12.93	0.64	1.53e-29	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg13607699	chr17:42295918	UBTF	-0.48	-6.03	-0.36	5.95e-9	Total body bone mineral density;
KIRP	trans	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg06521331	chr12:34319734	NA	-0.58	-7.03	-0.41	2e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6832769	1.000	rs17085889	chr4:56402115	G/A	cg05960024	chr4:56376020	CLOCK	-0.62	-8.0	-0.45	4.94e-14	Personality dimensions;
KIRP	cis	rs6733011	0.628	rs4851163	chr2:99466664	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.37	-0.32	1.81e-7	Bipolar disorder;
KIRP	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg04733989	chr22:42467013	NAGA	0.85	11.93	0.61	3.44e-26	Schizophrenia;
KIRP	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26314531	chr2:26401878	FAM59B	0.46	4.86	0.3	2.09e-6	Gut microbiome composition (summer);
KIRP	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.74	10.37	0.55	3.91e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9905704	0.918	rs654743	chr17:56736490	T/C	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21808881	chr11:561538	RASSF7;C11orf35	0.48	6.79	0.4	8.4e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.3	-5.76	-0.34	2.53e-8	Educational attainment (years of education);
KIRP	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.2	0.46	1.33e-14	Motion sickness;
KIRP	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-1.06	-13.18	-0.64	2.33e-30	Exhaled nitric oxide output;
KIRP	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7116495	0.609	rs7111379	chr11:71826319	C/T	cg10381502	chr11:71823885	C11orf51	1.15	7.55	0.43	8.26e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs1010254	0.510	rs1363418	chr5:151699834	G/T	cg12297329	chr5:152029980	NA	0.66	6.81	0.4	7.54e-11	Optic nerve measurement (cup area);
KIRP	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.41	-5.6	-0.34	5.65e-8	Endometrial cancer;
KIRP	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg24315340	chr6:146058215	EPM2A	0.45	5.64	0.34	4.75e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs427941	0.632	rs201469	chr7:101743932	C/G	cg06246474	chr7:101738831	CUX1	0.53	6.49	0.38	4.6e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg19847130	chr8:10466454	RP1L1	-0.37	-5.56	-0.33	6.92e-8	Retinal vascular caliber;
KIRP	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg08888203	chr3:10149979	C3orf24	0.49	5.13	0.31	5.78e-7	Alzheimer's disease;
KIRP	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.6	0.34	5.62e-8	Putamen volume;
KIRP	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.88	11.79	0.6	1.01e-25	Coronary artery disease;
KIRP	cis	rs2371030	0.802	rs1319591	chr2:211572501	T/C	cg18417063	chr2:211583084	NA	-0.45	-6.13	-0.36	3.5e-9	Non-small cell lung cancer;
KIRP	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.07	0.41	1.58e-11	Height;
KIRP	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.76	9.35	0.51	5.61e-18	Response to antipsychotic treatment;
KIRP	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.23	0.46	1.11e-14	IgG glycosylation;
KIRP	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.84	-12.83	-0.63	3.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.17	0.31	4.96e-7	Asthma;
KIRP	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.28	0.42	4.41e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9535307	0.651	rs1198327	chr13:50387759	G/A	cg04663916	chr13:50265991	EBPL	-0.56	-5.45	-0.33	1.2e-7	Obesity-related traits;
KIRP	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.64	8.34	0.47	5.39e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.92	-14.68	-0.68	1.78e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs12541635	0.677	rs1496180	chr8:106973877	T/G	cg10147462	chr8:107024639	NA	0.34	5.07	0.31	7.77e-7	Age of smoking initiation;
KIRP	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.66	-8.51	-0.48	1.73e-15	Extraversion;
KIRP	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg00684032	chr4:1343700	KIAA1530	0.52	6.47	0.38	5.16e-10	Obesity-related traits;
KIRP	cis	rs8033133	0.881	rs8031260	chr15:25316831	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.57	-6.59	-0.39	2.72e-10	Blood osmolality (transformed sodium);
KIRP	cis	rs4704187	0.601	rs77819698	chr5:74530658	G/T	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.71e-8	Response to amphetamines;
KIRP	cis	rs5753618	0.509	rs1034589	chr22:31579233	C/T	cg02404636	chr22:31891804	SFI1	-0.48	-5.32	-0.32	2.3e-7	Colorectal cancer;
KIRP	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.23	-0.37	2.05e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg14517863	chr17:44321492	NA	0.49	5.63	0.34	5.02e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	5.0	0.3	1.07e-6	Rheumatoid arthritis;
KIRP	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg12756093	chr1:115239321	AMPD1	0.54	6.61	0.39	2.32e-10	Autism;
KIRP	cis	rs1559088	0.948	rs3760893	chr19:33597930	C/A	cg03563238	chr19:33554763	RHPN2	-0.32	-5.67	-0.34	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.56	0.43	7.84e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-11.4	-0.59	1.85e-24	Obesity-related traits;
KIRP	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.03	0.41	2.06e-11	Caffeine consumption;
KIRP	cis	rs2387326	0.671	rs10829346	chr10:129946104	C/T	cg16087940	chr10:129947807	NA	-0.43	-5.86	-0.35	1.5e-8	Select biomarker traits;
KIRP	cis	rs447921	0.861	rs4789297	chr17:74447351	G/T	cg16776035	chr17:74542680	NA	-0.54	-5.07	-0.31	7.74e-7	Mitochondrial DNA levels;
KIRP	cis	rs8018808	0.935	rs11623826	chr14:77912862	A/C	cg20045696	chr14:77926864	AHSA1	0.49	6.02	0.36	6.34e-9	Myeloid white cell count;
KIRP	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg19196401	chr6:110721138	DDO	-0.48	-7.61	-0.44	5.81e-13	Platelet distribution width;
KIRP	cis	rs4765905	0.610	rs10848633	chr12:2316019	A/G	cg10668781	chr12:2307325	CACNA1C	-0.33	-6.63	-0.39	2.15e-10	Schizophrenia;
KIRP	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.85	9.76	0.53	3.1e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.93	-14.3	-0.67	3.47e-34	Lung cancer;
KIRP	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-11.39	-0.59	2.04e-24	Menarche (age at onset);
KIRP	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg08499158	chr17:42289980	UBTF	-0.64	-7.35	-0.42	2.9e-12	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	13.2	0.64	1.95e-30	Platelet count;
KIRP	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.82	-12.34	-0.62	1.53e-27	Blood metabolite levels;
KIRP	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11987759	chr7:65425863	GUSB	0.58	7.77	0.44	2.11e-13	Aortic root size;
KIRP	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9398803	0.723	rs1262545	chr6:127074587	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.5	-0.33	9.37e-8	Male-pattern baldness;
KIRP	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.59	-0.44	6.69e-13	Total cholesterol levels;
KIRP	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.17	-0.42	8.85e-12	Glomerular filtration rate;
KIRP	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-5.67	-0.34	3.91e-8	Cutaneous nevi;
KIRP	cis	rs9810890	1.000	rs73196999	chr3:128460581	G/A	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.05	-0.41	1.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.56	-6.27	-0.37	1.65e-9	Blood metabolite levels;
KIRP	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.67	-8.25	-0.47	9.53e-15	Schizophrenia;
KIRP	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.81	-12.01	-0.61	1.84e-26	Ulcerative colitis;
KIRP	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg01529538	chr14:23388837	RBM23	0.4	5.15	0.31	5.24e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs6973256	0.834	rs11768150	chr7:133335011	T/G	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.56e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg21864845	chr1:1208426	UBE2J2	0.52	6.25	0.37	1.78e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs501120	0.584	rs1704221	chr10:44710930	G/A	cg09554077	chr10:44749378	NA	0.65	7.28	0.42	4.59e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10851779	chr21:38640028	DSCR3	0.53	6.66	0.39	1.76e-10	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.22e-15	Motion sickness;
KIRP	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg24585782	chr17:78113791	EIF4A3	-0.52	-6.02	-0.36	6.18e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg08885076	chr2:99613938	TSGA10	-0.55	-9.47	-0.52	2.38e-18	Chronic sinus infection;
KIRP	cis	rs4663866	1.000	rs71426509	chr2:239175334	A/C	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.81	-0.45	1.62e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs62413470	0.935	rs12214662	chr6:55970247	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.38	-0.38	8.8e-10	Bladder cancer;
KIRP	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg04455712	chr21:45112962	RRP1B	-0.48	-6.51	-0.38	4.28e-10	Mean corpuscular volume;
KIRP	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.63	8.71	0.49	4.5e-16	Longevity;
KIRP	trans	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg19274270	chr17:78178856	CARD14	-0.36	-6.4	-0.38	7.87e-10	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg13939156	chr17:80058883	NA	-0.5	-7.48	-0.43	1.3e-12	Life satisfaction;
KIRP	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.05	-0.31	8.74e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg21427119	chr20:30132790	HM13	-0.64	-6.31	-0.37	1.31e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.34	5.05	0.31	8.66e-7	Colorectal cancer;
KIRP	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg08662619	chr6:150070041	PCMT1	0.34	5.22	0.32	3.73e-7	Lung cancer;
KIRP	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg10189774	chr4:17578691	LAP3	0.46	5.32	0.32	2.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	5.63	0.34	4.93e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.26	-17.25	-0.74	2.96e-44	Breast cancer;
KIRP	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.32	0.37	1.22e-9	Joint mobility (Beighton score);
KIRP	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.92	-0.53	9.84e-20	Hemoglobin concentration;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg11310629	chr13:45991975	SLC25A30	0.5	6.1	0.36	4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11864453	0.616	rs9938025	chr16:72022041	A/G	cg16558253	chr16:72132732	DHX38	0.38	4.91	0.3	1.67e-6	Fibrinogen levels;
KIRP	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.9	-0.57	7.72e-23	Chronic sinus infection;
KIRP	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg21919602	chr1:242011447	EXO1	-0.46	-5.85	-0.35	1.54e-8	Menopause (age at onset);
KIRP	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.45	-0.52	2.78e-18	Mood instability;
KIRP	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg06647332	chr5:131281008	NA	0.44	5.0	0.3	1.09e-6	Life satisfaction;
KIRP	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4006360	0.575	rs447608	chr17:39308497	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.44	-6.01	-0.36	6.73e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs8014252	0.803	rs61388426	chr14:71045002	G/A	cg19730268	chr14:71022823	NA	-0.7	-6.25	-0.37	1.77e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg14825094	chr17:61818420	STRADA	-0.42	-4.86	-0.3	2.05e-6	Height;
KIRP	cis	rs6585424	0.850	rs61860036	chr10:81934859	C/T	cg27417294	chr10:81904244	PLAC9	0.53	5.1	0.31	6.66e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.29	0.37	1.45e-9	Uric acid levels;
KIRP	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg27284194	chr4:1044797	NA	0.51	4.89	0.3	1.83e-6	Recombination rate (females);
KIRP	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.62	-7.23	-0.42	6.18e-12	Dental caries;
KIRP	cis	rs6546324	0.580	rs4362541	chr2:67842866	A/T	cg15745817	chr2:67799979	NA	-0.66	-7.29	-0.42	4.12e-12	Endometriosis;
KIRP	cis	rs66561647	1.000	rs66561647	chr8:128971861	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.52	7.26	0.42	4.96e-12	Hemoglobin concentration;
KIRP	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.82	-12.23	-0.62	3.4e-27	Asthma;
KIRP	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg18806716	chr10:30721971	MAP3K8	0.32	5.25	0.32	3.25e-7	Inflammatory bowel disease;
KIRP	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg11502198	chr6:26597334	ABT1	0.51	6.61	0.39	2.34e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg06050784	chr16:88016603	BANP	0.42	5.32	0.32	2.38e-7	Menopause (age at onset);
KIRP	cis	rs983545	0.508	rs2347655	chr3:16894193	T/C	cg23220897	chr3:16924709	NA	-0.29	-5.01	-0.3	1.04e-6	Blood protein levels;
KIRP	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg17863274	chr19:49399704	TULP2	-0.41	-5.84	-0.35	1.61e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7538876	0.903	rs6681150	chr1:17750685	G/A	cg01904812	chr1:17746340	RCC2	0.29	5.06	0.31	8.34e-7	Basal cell carcinoma;
KIRP	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.67	-7.96	-0.45	6.27e-14	Menarche (age at onset);
KIRP	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.59	-0.44	6.48e-13	Bladder cancer;
KIRP	cis	rs6859018	0.950	rs3213093	chr5:158750979	C/T	cg26646896	chr5:158686746	NA	-0.34	-4.95	-0.3	1.36e-6	Serum sulfate level;
KIRP	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg03959625	chr15:84868606	LOC388152	0.56	6.29	0.37	1.4e-9	Schizophrenia;
KIRP	cis	rs11634397	0.536	rs2140155	chr15:80429209	C/A	cg08257866	chr15:80351198	ZFAND6	0.51	5.25	0.32	3.28e-7	Type 2 diabetes;
KIRP	cis	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.44	-5.4	-0.33	1.54e-7	Leprosy;
KIRP	cis	rs6477493	0.526	rs10820447	chr9:99132044	C/T	cg25260653	chr9:99212216	HABP4	0.51	4.91	0.3	1.67e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7941030	0.902	rs10750217	chr11:122531574	A/G	cg20555462	chr11:122535518	UBASH3B	-0.43	-5.34	-0.32	2.09e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs12716641	0.684	rs4840668	chr8:6897352	G/C	cg26123975	chr8:6873754	DEFA1;DEFA3;DEFA1B	-0.35	-4.9	-0.3	1.71e-6	IgA nephropathy;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.56	8.1	0.46	2.58e-14	Carotid intima media thickness;
KIRP	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg07384165	chr1:10488281	NA	-0.39	-5.18	-0.31	4.55e-7	Breast size;
KIRP	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.69	8.78	0.49	2.73e-16	Eosinophil percentage of white cells;
KIRP	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08595102	chr7:6414623	RAC1	0.49	6.37	0.38	9.36e-10	Parkinson's disease;
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	13.65	0.66	5.67e-32	Platelet count;
KIRP	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.48	-6.25	-0.37	1.76e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.58	7.1	0.41	1.35e-11	Osteoporosis;
KIRP	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	10.35	0.55	4.62e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg15557168	chr22:42548783	NA	-0.37	-5.1	-0.31	6.72e-7	Cognitive function;
KIRP	cis	rs6782228	0.585	rs9841161	chr3:128331870	A/G	cg18648031	chr3:128330563	NA	0.27	5.64	0.34	4.66e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	11.02	0.57	3.28e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3767633	0.858	rs4300199	chr1:161852057	A/G	cg09175582	chr1:161736000	ATF6	0.74	6.03	0.36	5.88e-9	IgG glycosylation;
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.7e-13	Life satisfaction;
KIRP	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.52	6.48	0.38	5.06e-10	Coronary heart disease;
KIRP	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg19025524	chr12:109796872	NA	-0.39	-5.36	-0.32	1.95e-7	Neuroticism;
KIRP	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg22800045	chr5:56110881	MAP3K1	0.82	8.72	0.49	4.14e-16	Initial pursuit acceleration;
KIRP	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg01420254	chr6:26195488	NA	1.2	10.59	0.56	7.88e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg05347473	chr6:146136440	FBXO30	-0.62	-9.06	-0.5	4.24e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg05484376	chr2:27715224	FNDC4	0.3	4.88	0.3	1.91e-6	Oral cavity cancer;
KIRP	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg20573242	chr4:122745356	CCNA2	0.4	5.0	0.3	1.08e-6	Type 2 diabetes;
KIRP	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg09699651	chr6:150184138	LRP11	0.45	5.83	0.35	1.75e-8	Lung cancer;
KIRP	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.3	-0.32	2.59e-7	Bipolar disorder;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg25175986	chr10:30722773	MAP3K8	-0.46	-6.09	-0.36	4.34e-9	Hippocampal sclerosis of aging;
KIRP	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.84	11.42	0.59	1.65e-24	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.56	0.43	8.02e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.92	13.13	0.64	3.29e-30	Cognitive function;
KIRP	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.82	0.35	1.79e-8	Coronary artery disease;
KIRP	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.05	11.96	0.61	2.67e-26	Vitiligo;
KIRP	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg09873164	chr1:152488093	CRCT1	0.52	6.54	0.38	3.5e-10	Hair morphology;
KIRP	cis	rs1816752	0.783	rs9507333	chr13:24978310	G/A	cg02811702	chr13:24901961	NA	0.41	5.41	0.33	1.52e-7	Obesity-related traits;
KIRP	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg24579218	chr15:68104479	NA	-0.55	-7.79	-0.44	1.89e-13	Restless legs syndrome;
KIRP	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg25930673	chr12:123319894	HIP1R	-0.69	-5.88	-0.35	1.34e-8	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg10047753	chr17:41438598	NA	1.15	18.7	0.77	3.85e-49	Menopause (age at onset);
KIRP	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.21	15.16	0.69	4.26e-37	Alzheimer's disease;
KIRP	cis	rs9815354	1.000	rs73079321	chr3:41863910	C/T	cg03022575	chr3:42003672	ULK4	0.6	7.01	0.41	2.28e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.51	-8.51	-0.48	1.68e-15	Height;
KIRP	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-1.02	-17.26	-0.74	2.74e-44	Height;
KIRP	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.37	-0.32	1.78e-7	Neutrophil percentage of white cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08638632	chr2:192446259	NA	-0.41	-6.29	-0.37	1.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs909341	0.808	rs2263805	chr20:62351150	T/C	cg03999872	chr20:62272968	STMN3	-0.59	-6.8	-0.4	7.85e-11	Atopic dermatitis;
KIRP	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-0.7	-5.44	-0.33	1.31e-7	Major depressive disorder;
KIRP	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg13147721	chr7:65941812	NA	0.99	6.72	0.39	1.27e-10	Diabetic kidney disease;
KIRP	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg18478394	chr8:109455254	TTC35	0.6	7.56	0.43	8.17e-13	Dupuytren's disease;
KIRP	cis	rs7757419	0.877	rs7755620	chr6:34435189	T/C	cg25473981	chr6:34433676	PACSIN1	0.42	5.14	0.31	5.54e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
KIRP	cis	rs28489187	0.505	rs7525786	chr1:85884076	C/T	cg16011679	chr1:85725395	C1orf52	-0.39	-4.94	-0.3	1.43e-6	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11987759	chr7:65425863	GUSB	-0.63	-8.43	-0.47	2.9e-15	Aortic root size;
KIRP	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.51	4.95	0.3	1.38e-6	Recombination rate (females);
KIRP	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.62	-6.27	-0.37	1.65e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg07884673	chr3:53033167	SFMBT1	1.03	7.6	0.44	6.23e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg21132104	chr15:45694354	SPATA5L1	-0.56	-6.61	-0.39	2.31e-10	Glomerular filtration rate;
KIRP	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg00343986	chr7:65444356	GUSB	-0.4	-4.95	-0.3	1.4e-6	Aortic root size;
KIRP	trans	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg18187862	chr3:45730750	SACM1L	0.54	6.09	0.36	4.37e-9	Primary sclerosing cholangitis;
KIRP	cis	rs6546324	0.625	rs1023693	chr2:67868732	T/C	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.59	-6.55	-0.39	3.43e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs72829446	0.530	rs3853820	chr17:7396781	A/T	cg17788227	chr17:7347145	FGF11;CHRNB1	0.47	5.03	0.31	9.42e-7	Androgen levels;
KIRP	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	1.05	14.72	0.68	1.29e-35	Menopause (age at onset);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg06012509	chr6:43027269	KLC4;MRPL2	0.93	6.31	0.37	1.29e-9	P wave terminal force;
KIRP	cis	rs300890	0.642	rs3792653	chr4:144308661	T/A	cg01719995	chr4:144104893	USP38	-0.4	-4.92	-0.3	1.61e-6	Nasopharyngeal carcinoma;
KIRP	trans	rs9324380	0.696	rs4246516	chr1:98420453	G/C	cg00449390	chr7:158379223	PTPRN2	-0.59	-6.09	-0.36	4.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg21775007	chr8:11205619	TDH	-0.49	-6.37	-0.38	9.28e-10	Triglycerides;
KIRP	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg11189052	chr15:85197271	WDR73	-0.54	-5.1	-0.31	6.76e-7	Schizophrenia;
KIRP	trans	rs62056376	0.736	rs758293	chr17:32640523	A/T	cg17487170	chr5:133451259	TCF7	0.51	6.04	0.36	5.74e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.75	9.85	0.53	1.69e-19	Huntington's disease progression;
KIRP	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg16342193	chr10:102329863	NA	-0.37	-4.84	-0.3	2.26e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-12.15	-0.61	6.26e-27	Morning vs. evening chronotype;
KIRP	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.52	-6.21	-0.37	2.19e-9	Body mass index;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01283332	chr5:1856932	NA	-0.51	-6.66	-0.39	1.75e-10	Cardiovascular disease risk factors;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.49e-13	Life satisfaction;
KIRP	cis	rs4073416	0.542	rs1889731	chr14:65942711	C/G	cg03016385	chr14:66212404	NA	-0.56	-6.99	-0.41	2.52e-11	N-glycan levels;
KIRP	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs6601327	0.635	rs34782826	chr8:9663630	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.1	-0.41	1.33e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-6.26	-0.37	1.67e-9	Longevity;Endometriosis;
KIRP	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg10591111	chr5:226296	SDHA	0.48	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg20673091	chr1:2541236	MMEL1	0.41	5.65	0.34	4.5e-8	Ulcerative colitis;
KIRP	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	23.98	0.84	2.56e-66	Chronic sinus infection;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg25533220	chr19:2328480	SPPL2B;LSM7	0.45	6.04	0.36	5.53e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-0.99	-11.85	-0.6	6.3e-26	Breast cancer;
KIRP	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg14003231	chr6:33640908	ITPR3	0.3	5.15	0.31	5.22e-7	Plateletcrit;
KIRP	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.52	-6.76	-0.4	9.78e-11	Bipolar disorder;
KIRP	cis	rs950776	0.612	rs8038920	chr15:78974545	A/G	cg06917634	chr15:78832804	PSMA4	-0.46	-5.19	-0.31	4.42e-7	Sudden cardiac arrest;
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg17383207	chr2:97426488	CNNM4	-0.45	-6.02	-0.36	6.26e-9	Type 1 diabetes;
KIRP	cis	rs6959887	1.000	rs10249005	chr7:35294854	A/G	cg06685737	chr7:35301730	NA	0.45	6.66	0.39	1.78e-10	Birth weight;
KIRP	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.02	16.99	0.73	2.4e-43	Multiple system atrophy;
KIRP	cis	rs231513	0.911	rs231525	chr17:41951283	C/T	cg26893861	chr17:41843967	DUSP3	-0.48	-4.95	-0.3	1.4e-6	Cognitive function;
KIRP	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.52	6.09	0.36	4.35e-9	Coronary artery disease;
KIRP	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg22903471	chr2:27725779	GCKR	0.43	6.12	0.36	3.74e-9	Oral cavity cancer;
KIRP	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-6.96	-0.41	3.11e-11	Self-reported allergy;
KIRP	cis	rs7534824	0.507	rs7518380	chr1:101451262	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.55	5.16	0.31	5.1e-7	Refractive astigmatism;
KIRP	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg13010199	chr12:38710504	ALG10B	0.6	7.44	0.43	1.73e-12	Morning vs. evening chronotype;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05482956	chr11:16635016	NA	0.45	6.26	0.37	1.66e-9	Smoking initiation;
KIRP	cis	rs4073221	0.860	rs67054573	chr3:18209808	T/A	cg07694806	chr3:18168406	NA	-0.72	-6.23	-0.37	2.03e-9	Parkinson's disease;
KIRP	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.78	6.55	0.39	3.3e-10	Fat distribution (HIV);
KIRP	cis	rs12900413	0.603	rs12911871	chr15:90301429	T/C	cg24650279	chr15:90327240	NA	-0.42	-5.2	-0.31	4.27e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.28e-7	Schizophrenia;
KIRP	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.03	0.31	9.61e-7	Schizophrenia;
KIRP	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg08313168	chr12:7315531	NA	0.69	6.35	0.38	1.04e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.06e-6	Aortic root size;
KIRP	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.31	-0.42	3.63e-12	Ulcerative colitis;
KIRP	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg00507259	chr4:95128692	SMARCAD1	0.41	5.24	0.32	3.37e-7	QT interval;
KIRP	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-7.36	-0.42	2.8e-12	Total cholesterol levels;
KIRP	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg14128973	chr19:11649462	CNN1	0.51	5.91	0.35	1.13e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.72	9.71	0.53	4.46e-19	Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25723933	chr1:155099956	EFNA1	0.48	6.41	0.38	7.18e-10	Parkinson's disease;
KIRP	cis	rs4692589	1.000	rs11727880	chr4:170937467	C/T	cg19918862	chr4:170955249	NA	0.42	5.07	0.31	7.77e-7	Anxiety disorder;
KIRP	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.37e-10	Aortic root size;
KIRP	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Retinal vascular caliber;
KIRP	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.94	-16.26	-0.72	7.37e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.09	0.31	7e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.94	0.4	3.49e-11	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.75	-9.64	-0.52	7.28e-19	Aortic root size;
KIRP	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg01529538	chr14:23388837	RBM23	0.39	4.96	0.3	1.33e-6	Cognitive ability (multi-trait analysis);
KIRP	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02725872	chr8:58115012	NA	-0.73	-7.23	-0.42	6.13e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.84	-10.7	-0.56	3.45e-22	Cognitive function;
KIRP	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg05347473	chr6:146136440	FBXO30	-0.51	-7.29	-0.42	4.24e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4132509	0.895	rs12045787	chr1:244011843	T/A	cg25706552	chr1:244017396	NA	0.6	7.24	0.42	5.6e-12	RR interval (heart rate);
KIRP	trans	rs7867456	0.546	rs10757178	chr9:21046674	A/G	cg01245129	chr14:64320049	SYNE2	0.49	6.09	0.36	4.37e-9	Axial length;
KIRP	cis	rs6977660	0.714	rs7357319	chr7:19817525	A/G	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg04226714	chr8:49833948	SNAI2	-0.53	-7.14	-0.41	1.04e-11	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg15181151	chr6:150070149	PCMT1	0.28	4.87	0.3	2.01e-6	Lung cancer;
KIRP	cis	rs2274273	0.554	rs3742564	chr14:55530120	C/T	cg04306507	chr14:55594613	LGALS3	-0.38	-5.72	-0.34	3.01e-8	Protein biomarker;
KIRP	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	10.26	0.55	8.5e-21	Lymphocyte counts;
KIRP	cis	rs6968419	0.650	rs1881287	chr7:115866354	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.75	10.14	0.54	2.01e-20	Red blood cell count;
KIRP	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.04	-0.31	8.97e-7	Inflammatory skin disease;
KIRP	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg17724175	chr1:150552817	MCL1	-0.44	-7.35	-0.42	2.9e-12	Urate levels;
KIRP	cis	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg20701182	chr2:24300061	SF3B14	-0.99	-10.48	-0.56	1.7e-21	Lymphocyte counts;
KIRP	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.56	-0.56	9.73e-22	Height;
KIRP	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg00360474	chr6:37504404	NA	-0.5	-7.42	-0.43	1.87e-12	Cognitive performance;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00968640	chr1:185834094	HMCN1	-0.43	-6.31	-0.37	1.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg07689907	chr11:61582574	FADS1	-0.47	-5.86	-0.35	1.51e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg24747557	chr10:131355152	MGMT	-0.46	-6.41	-0.38	7.41e-10	Response to temozolomide;
KIRP	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.36	-0.38	1e-9	Hemoglobin concentration;
KIRP	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg19554555	chr3:13937349	NA	0.54	7.98	0.45	5.72e-14	Ovarian reserve;
KIRP	cis	rs7180079	0.620	rs4777571	chr15:65055182	C/G	cg15337035	chr15:64978493	NA	-0.5	-5.5	-0.33	9.37e-8	Monocyte count;
KIRP	cis	rs12949688	0.967	rs1990231	chr17:55821002	G/C	cg12582317	chr17:55822272	NA	0.63	10.62	0.56	6.06e-22	Schizophrenia;
KIRP	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.22	-0.32	3.72e-7	Breast cancer;
KIRP	cis	rs8177876	0.749	rs11537	chr16:81080499	C/G	cg08591886	chr16:81111003	C16orf46	-0.58	-5.2	-0.31	4.24e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg18198730	chr1:247681584	NA	0.63	5.66	0.34	4.27e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9513627	0.831	rs7319727	chr13:100125541	A/T	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs9398803	0.698	rs853970	chr6:127063983	A/G	cg19875578	chr6:126661172	C6orf173	-0.37	-4.86	-0.3	2.05e-6	Male-pattern baldness;
KIRP	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.59	0.39	2.6200000000000003e-10	Educational attainment;
KIRP	cis	rs9535307	0.584	rs9596197	chr13:50406988	G/T	cg04663916	chr13:50265991	EBPL	0.59	5.75	0.34	2.6e-8	Obesity-related traits;
KIRP	cis	rs6988636	0.710	rs62521799	chr8:124134987	G/A	cg15893493	chr8:124194847	FAM83A	0.92	6.76	0.4	9.85e-11	Urinary uromodulin levels;
KIRP	cis	rs4523957	0.614	rs7212964	chr17:2059319	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs4959799	0.655	rs1127473	chr6:3270578	C/T	cg10513992	chr6:3293720	SLC22A23	-0.75	-5.54	-0.33	7.82e-8	Survival in rectal cancer;
KIRP	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.6e-34	Breast cancer;
KIRP	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg24579218	chr15:68104479	NA	0.38	5.41	0.33	1.47e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07091593	chr3:187455718	BCL6	0.46	6.06	0.36	5.04e-9	Parkinson's disease;
KIRP	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2979489	0.891	rs16877096	chr8:30364388	T/C	cg26383811	chr8:30366931	RBPMS	-0.49	-7.65	-0.44	4.65e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.46	5.82	0.35	1.87e-8	Height;
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg17294928	chr15:75287854	SCAMP5	0.57	7.67	0.44	3.91e-13	Breast cancer;
KIRP	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	trans	rs7939886	0.920	rs60073283	chr11:56094356	A/C	cg03929089	chr4:120376271	NA	0.89	6.13	0.36	3.53e-9	Myopia (pathological);
KIRP	trans	rs1859156	0.767	rs17501058	chr4:95815162	C/T	cg24204951	chr2:239172084	PER2	0.29	6.7	0.39	1.42e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg01557791	chr16:72042693	DHODH	-0.7	-7.82	-0.45	1.5700000000000001e-13	Blood protein levels;
KIRP	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-1.05	-8.92	-0.49	1.07e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.22	-0.37	2.1e-9	Lung cancer;
KIRP	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg13256891	chr4:100009986	ADH5	0.62	7.56	0.43	8.19e-13	Alcohol dependence;
KIRP	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg03468072	chr12:39539422	NA	0.42	6.05	0.36	5.39e-9	Morning vs. evening chronotype;
KIRP	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs3736485	0.966	rs12372948	chr15:51894311	A/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.32	-0.32	2.28e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	cg04338863	chr8:33670619	NA	0.49	6.68	0.39	1.6e-10	Body mass index;
KIRP	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.82	10.09	0.54	2.92e-20	Corneal astigmatism;
KIRP	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-7.42	-0.43	1.87e-12	Gut microbiome composition (summer);
KIRP	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg19913688	chr11:428466	ANO9	-0.76	-6.04	-0.36	5.71e-9	Body mass index;
KIRP	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg04226714	chr8:49833948	SNAI2	-0.45	-6.18	-0.37	2.66e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg09873164	chr1:152488093	CRCT1	0.4	4.89	0.3	1.8e-6	Hair morphology;
KIRP	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg00204512	chr16:28754710	NA	0.45	5.62	0.34	5.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.53	-6.04	-0.36	5.51e-9	Schizophrenia;
KIRP	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg06781948	chr3:72941472	GXYLT2	-0.49	-6.48	-0.38	5e-10	Motion sickness;
KIRP	cis	rs9436747	0.626	rs11590603	chr1:65951897	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.46	-4.86	-0.3	2.08e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.49	-0.43	1.23e-12	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18794426	chr1:3563325	WDR8	0.57	7.01	0.41	2.28e-11	Interleukin-4 levels;
KIRP	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.46	-5.25	-0.32	3.34e-7	Squamous cell lung carcinoma;
KIRP	cis	rs1408799	0.695	rs1137134	chr9:12712157	G/A	cg05274944	chr9:12693694	TYRP1	0.4	5.73	0.34	2.94e-8	Eye color;Blue vs. green eyes;
KIRP	cis	rs6504950	1.000	rs7222197	chr17:53047499	A/G	cg26251398	chr17:52985966	TOM1L1	-0.38	-4.99	-0.3	1.16e-6	Breast cancer;
KIRP	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.58	-0.34	6.36e-8	IgG glycosylation;
KIRP	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.43	-6.15	-0.37	3.03e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg06042504	chr8:55087323	NA	-0.51	-6.08	-0.36	4.67e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg17644776	chr2:200775616	C2orf69	0.58	6.16	0.37	2.93e-9	Schizophrenia;
KIRP	cis	rs7374004	0.840	rs62242767	chr3:38636842	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.4	4.92	0.3	1.6e-6	PR interval;
KIRP	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.09	19.17	0.77	1.03e-50	Schizophrenia;
KIRP	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.76	-7.95	-0.45	6.57e-14	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg18306943	chr3:40428807	ENTPD3	0.39	5.48	0.33	1.05e-7	Renal cell carcinoma;
KIRP	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.77	8.74	0.49	3.72e-16	Cognitive ability;
KIRP	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.42	-5.33	-0.32	2.23e-7	QT interval;
KIRP	trans	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg05926928	chr17:57297772	GDPD1	0.54	6.56	0.39	3.17e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg20991723	chr1:152506922	NA	-0.45	-5.43	-0.33	1.34e-7	Hair morphology;
KIRP	cis	rs6545883	0.558	rs7587389	chr2:61649791	A/G	cg15711740	chr2:61764176	XPO1	0.44	5.52	0.33	8.63e-8	Tuberculosis;
KIRP	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.57	-8.18	-0.46	1.54e-14	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-5.17	-0.31	4.88e-7	Life satisfaction;
KIRP	cis	rs829661	0.689	rs829696	chr2:30651080	C/T	cg10949345	chr2:30726833	LCLAT1	-1.13	-14.57	-0.68	4.43e-35	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25461793	chr19:17212553	MYO9B	-0.47	-6.08	-0.36	4.61e-9	Parkinson's disease;
KIRP	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.48	-6.65	-0.39	1.88e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg00262122	chr8:11665843	FDFT1	-0.47	-5.8	-0.35	2.04e-8	Triglycerides;
KIRP	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg19650706	chr5:140594406	PCDHB13	-0.44	-4.97	-0.3	1.26e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00376283	chr12:123451042	ABCB9	-0.63	-7.4	-0.43	2.1e-12	Neutrophil percentage of white cells;
KIRP	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.48	-5.84	-0.35	1.66e-8	Menarche (age at onset);
KIRP	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg10047753	chr17:41438598	NA	0.81	11.23	0.58	6.73e-24	Menopause (age at onset);
KIRP	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.7	-9.08	-0.5	3.69e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.45	-5.02	-0.3	1.01e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg18357526	chr6:26021779	HIST1H4A	0.43	5.03	0.31	9.42e-7	Height;
KIRP	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.74	10.43	0.55	2.46e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.35	5.72	0.34	3.03e-8	Monocyte count;
KIRP	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.46	-5.83	-0.35	1.74e-8	Blood metabolite levels;
KIRP	cis	rs3736485	0.966	rs11070855	chr15:51850283	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.49e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.7	-7.75	-0.44	2.35e-13	Body mass index;
KIRP	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg04013166	chr16:89971882	TCF25	0.72	8.07	0.46	3.13e-14	Skin colour saturation;
KIRP	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.59	6.97	0.41	2.83e-11	Corneal astigmatism;
KIRP	cis	rs10465746	0.967	rs12748268	chr1:84374438	T/C	cg10977910	chr1:84465055	TTLL7	0.43	5.16	0.31	4.99e-7	Obesity-related traits;
KIRP	cis	rs253959	0.921	rs785377	chr5:115663974	G/A	cg23108291	chr5:115420582	COMMD10	-0.42	-4.93	-0.3	1.49e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.56	-8.38	-0.47	4.08e-15	Blood metabolite levels;
KIRP	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.08	0.58	2.11e-23	Primary sclerosing cholangitis;
KIRP	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.36	-4.92	-0.3	1.58e-6	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18032386	chr10:45953678	MARCH8	0.49	6.26	0.37	1.71e-9	Interleukin-4 levels;
KIRP	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.03	0.31	9.57e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg25319279	chr11:5960081	NA	-0.57	-5.77	-0.35	2.42e-8	DNA methylation (variation);
KIRP	cis	rs13132184	0.507	rs35308860	chr4:38035526	T/G	cg14409701	chr4:38048871	TBC1D1	-0.79	-7.61	-0.44	5.78e-13	Verbal declarative memory;
KIRP	cis	rs1823913	1.000	rs1840377	chr2:192122718	T/C	cg12404831	chr2:192114017	MYO1B	-0.5	-6.77	-0.4	9.57e-11	Obesity-related traits;
KIRP	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg17366294	chr4:99064904	C4orf37	0.49	6.75	0.4	1.08e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.39	-0.33	1.63e-7	Diastolic blood pressure;
KIRP	cis	rs2573652	1.000	rs12440866	chr15:100517010	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.74	-11.49	-0.59	9.5e-25	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20263444	chr12:57482590	NAB2	0.56	7.02	0.41	2.17e-11	Parkinson's disease;
KIRP	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg20003494	chr4:90757398	SNCA	-0.41	-4.88	-0.3	1.88e-6	Neuroticism;
KIRP	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.51	6.93	0.4	3.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.46	-0.43	1.51e-12	Bipolar disorder;
KIRP	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg11941060	chr3:133502564	NA	-0.5	-6.05	-0.36	5.25e-9	Iron status biomarkers;
KIRP	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs6142102	0.961	rs4911144	chr20:32614371	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	6.52	0.38	4.03e-10	Skin pigmentation;
KIRP	cis	rs6430538	0.671	rs4954176	chr2:135543649	C/T	cg12500956	chr2:135428796	TMEM163	0.43	5.38	0.32	1.77e-7	Parkinson's disease;
KIRP	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21545522	chr1:205238299	TMCC2	0.44	5.88	0.35	1.31e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg01689657	chr7:91764605	CYP51A1	0.45	6.5	0.38	4.45e-10	Breast cancer;
KIRP	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.5	7.78	0.44	2.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.73	0.39	1.15e-10	Lung cancer;
KIRP	cis	rs526231	0.543	rs4386712	chr5:102369234	T/C	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg23594656	chr7:65796392	TPST1	-0.37	-5.19	-0.31	4.5e-7	Aortic root size;
KIRP	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg22633769	chr20:60982531	CABLES2	-0.46	-5.91	-0.35	1.13e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs62413470	1.000	rs4295484	chr6:55965646	C/A	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2380220	0.574	rs7766765	chr6:95997362	G/A	cg15832292	chr6:96025679	MANEA	0.71	6.8	0.4	7.88e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.75	7.91	0.45	8.51e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.89	-11.97	-0.61	2.56e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg17279839	chr7:150038598	RARRES2	0.43	5.56	0.33	6.95e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.46	-6.01	-0.36	6.67e-9	Crohn's disease;
KIRP	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.66	-0.52	6.47e-19	Exhaled nitric oxide output;
KIRP	cis	rs1355223	0.573	rs286865	chr11:34719916	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.59	6.79	0.4	8.27e-11	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13065560	0.560	rs4491835	chr3:39005889	T/C	cg01426195	chr3:39028469	NA	-0.43	-6.16	-0.37	2.99e-9	Interleukin-18 levels;
KIRP	cis	rs12900413	0.687	rs28493563	chr15:90309505	C/T	cg24650279	chr15:90327240	NA	-0.4	-4.96	-0.3	1.31e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs13385	0.769	rs10038443	chr5:139565028	A/G	cg01860693	chr5:139557145	C5orf32	0.49	5.33	0.32	2.22e-7	Atrial fibrillation;
KIRP	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.52	-6.68	-0.39	1.55e-10	Schizophrenia;
KIRP	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.52	-0.52	1.66e-18	Myopia (pathological);
KIRP	cis	rs6589219	0.721	rs6589218	chr11:111167557	A/C	cg25129781	chr11:111156908	C11orf53	-0.45	-5.91	-0.35	1.12e-8	Colorectal cancer;
KIRP	cis	rs13033859	0.526	rs12477065	chr2:292753	C/T	cg10118717	chr2:203439	NA	-0.38	-5.13	-0.31	5.9e-7	Mitochondrial DNA levels;
KIRP	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19524238	chr7:2802976	GNA12	-0.37	-4.98	-0.3	1.21e-6	Height;
KIRP	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.62	-7.87	-0.45	1.15e-13	Colorectal cancer;
KIRP	cis	rs8028182	0.636	rs4545784	chr15:75755651	A/G	cg20655648	chr15:75932815	IMP3	0.52	6.65	0.39	1.91e-10	Sudden cardiac arrest;
KIRP	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.81	9.6	0.52	9.71e-19	Pulmonary function decline;
KIRP	cis	rs57590327	0.679	rs62265397	chr3:81543883	A/T	cg07356753	chr3:81810745	GBE1	-0.59	-6.46	-0.38	5.53e-10	Extraversion;
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.58	8.98	0.5	7.41e-17	Lung cancer;
KIRP	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-6.41	-0.38	7.43e-10	Endometrial cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17515702	chr17:76210520	BIRC5;EPR1	-0.45	-6.36	-0.38	9.89e-10	Metabolic traits;
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg22325292	chr17:80708367	FN3K	0.38	5.1	0.31	6.83e-7	Glycated hemoglobin levels;
KIRP	cis	rs9905704	0.627	rs1267544	chr17:56643398	T/G	cg12560992	chr17:57184187	TRIM37	-0.52	-5.33	-0.32	2.27e-7	Testicular germ cell tumor;
KIRP	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07234876	chr8:600039	NA	0.8	6.16	0.37	2.98e-9	IgG glycosylation;
KIRP	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg08761264	chr16:28874980	SH2B1	-0.51	-5.89	-0.35	1.29e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.58	-0.34	6.28e-8	Lung cancer;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26782824	chr11:82867961	PCF11	0.52	6.08	0.36	4.59e-9	Lung cancer in ever smokers;
KIRP	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg15848620	chr12:58087721	OS9	-0.45	-5.17	-0.31	4.9e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg05370193	chr1:21551575	ECE1	0.44	6.12	0.36	3.6e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg11707556	chr5:10655725	ANKRD33B	0.52	6.6	0.39	2.47e-10	Height;
KIRP	cis	rs2652822	0.901	rs4775622	chr15:63408179	A/C	cg02713581	chr15:63449717	RPS27L	0.64	7.48	0.43	1.32e-12	Metabolic traits;
KIRP	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.66	8.5	0.48	1.86e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.8	10.94	0.57	6.03e-23	Systemic lupus erythematosus;
KIRP	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg03060546	chr3:49711283	APEH	0.49	6.53	0.38	3.66e-10	Parkinson's disease;
KIRP	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg00409905	chr10:38381863	ZNF37A	0.61	6.58	0.39	2.87e-10	Obesity (extreme);
KIRP	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg10755058	chr3:40428713	ENTPD3	0.48	6.57	0.39	2.96e-10	Renal cell carcinoma;
KIRP	cis	rs35934224	0.783	rs7290770	chr22:19861161	C/T	cg11182965	chr22:19864308	TXNRD2	-0.51	-5.92	-0.35	1.1e-8	Glaucoma (primary open-angle);
KIRP	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.99	14.27	0.67	4.73e-34	Cognitive function;
KIRP	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2294693	1.000	rs2294693	chr6:41005502	T/C	cg14769373	chr6:40998127	UNC5CL	-0.52	-5.74	-0.34	2.73e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.79	-10.58	-0.56	8.28e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs914615	0.552	rs11264339	chr1:155140648	A/G	cg02153340	chr1:155202674	NA	0.39	6.03	0.36	6.06e-9	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.72	-12.64	-0.63	1.51e-28	Body mass index;
KIRP	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.67	7.89	0.45	9.88e-14	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03155301	chr11:12776288	TEAD1	0.43	6.71	0.39	1.33e-10	C-reactive protein;
KIRP	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.99	9.15	0.5	2.23e-17	Systolic blood pressure;
KIRP	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.57	-0.43	7.47e-13	Bladder cancer;
KIRP	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.7	7.84	0.45	1.37e-13	Response to diuretic therapy;
KIRP	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg05998816	chr21:47859926	PCNT	0.53	5.81	0.35	1.9e-8	Lymphocyte counts;
KIRP	cis	rs6942756	0.876	rs57263220	chr7:129010858	C/A	cg02491457	chr7:128862824	NA	-0.57	-6.41	-0.38	7.19e-10	White matter hyperintensity burden;
KIRP	cis	rs654384	0.545	rs4723419	chr7:4174716	C/T	cg04612959	chr7:4183976	SDK1	0.31	5.06	0.31	8.06e-7	Positive affect;
KIRP	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.52	-6.76	-0.4	9.94e-11	Body mass index;
KIRP	cis	rs4789693	0.518	rs6502117	chr17:80452592	G/C	cg18538270	chr17:80415818	NARF	-0.44	-5.29	-0.32	2.69e-7	Glucocorticoid-induced osteonecrosis;
KIRP	trans	rs1493916	0.606	rs10432168	chr18:31312106	T/C	cg04226714	chr8:49833948	SNAI2	-0.48	-6.06	-0.36	5.17e-9	Life satisfaction;
KIRP	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg17207736	chr8:142237307	SLC45A4	-0.43	-5.26	-0.32	3.11e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.69	10.21	0.55	1.25e-20	Prostate cancer;
KIRP	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.8	-10.93	-0.57	6.46e-23	Aortic root size;
KIRP	cis	rs13315871	1.000	rs35542947	chr3:58323244	C/T	cg12435725	chr3:58293450	RPP14	-0.48	-5.14	-0.31	5.49e-7	Cholesterol, total;
KIRP	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	0.8	8.77	0.49	3.04e-16	Gut microbiome composition (summer);
KIRP	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg02725872	chr8:58115012	NA	-0.53	-6.04	-0.36	5.78e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	7.92	0.45	8.3e-14	Menarche (age at onset);
KIRP	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg18586891	chr4:952366	TMEM175	0.57	5.15	0.31	5.44e-7	Parkinson's disease;
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.73	10.96	0.57	4.97e-23	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.54	8.62	0.48	8.36e-16	Lymphocyte counts;
KIRP	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.09	0.36	4.3e-9	Alzheimer's disease (late onset);
KIRP	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-14.02	-0.67	3.17e-33	Alzheimer's disease;
KIRP	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.59	-6.64	-0.39	1.95e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg24209194	chr3:40518798	ZNF619	0.4	5.18	0.31	4.73e-7	Renal cell carcinoma;
KIRP	cis	rs10782582	0.609	rs946163	chr1:76383049	A/G	cg03433033	chr1:76189801	ACADM	0.46	6.38	0.38	8.77e-10	Daytime sleep phenotypes;
KIRP	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.59	5.39	0.32	1.68e-7	Alzheimer's disease;
KIRP	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.42	0.59	1.68e-24	Height;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.54	-7.01	-0.41	2.32e-11	Longevity;Endometriosis;
KIRP	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg09571762	chr12:39539558	NA	0.37	5.17	0.31	4.95e-7	Morning vs. evening chronotype;
KIRP	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	1.15	10.68	0.56	3.99e-22	Red blood cell traits;
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg19500275	chr17:80737654	TBCD	-0.49	-5.86	-0.35	1.46e-8	Glycated hemoglobin levels;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg21186296	chr8:27182909	PTK2B	0.51	6.54	0.38	3.49e-10	Neuroticism;
KIRP	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg18154014	chr19:37997991	ZNF793	0.91	9.33	0.51	6.56e-18	Coronary artery calcification;
KIRP	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg04725166	chr1:7887271	PER3	-0.36	-5.41	-0.33	1.5e-7	Crohn's disease;
KIRP	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.47	6.86	0.4	5.69e-11	Coronary artery disease;
KIRP	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg17376030	chr22:41985996	PMM1	-0.58	-6.66	-0.39	1.79e-10	Vitiligo;
KIRP	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-9.63	-0.52	7.95e-19	Morning vs. evening chronotype;
KIRP	cis	rs1891498	0.571	rs1495957	chr1:147238351	C/T	cg27546670	chr1:147246839	GJA5	-0.74	-10.11	-0.54	2.54e-20	Cognitive performance;
KIRP	cis	rs11225247	0.649	rs11607214	chr11:102225224	A/G	cg06323957	chr11:102217781	BIRC2	0.77	4.97	0.3	1.27e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17376030	chr22:41985996	PMM1	-0.81	-8.45	-0.47	2.55e-15	Vitiligo;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15871127	chr13:110960198	COL4A1;COL4A2	0.42	6.07	0.36	4.69e-9	Smoking initiation;
KIRP	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg03146154	chr1:46216737	IPP	0.55	5.85	0.35	1.56e-8	Platelet count;
KIRP	cis	rs7828089	1.000	rs7837964	chr8:22264417	G/C	cg13512537	chr8:22265999	SLC39A14	-0.45	-6.09	-0.36	4.34e-9	Verbal declarative memory;
KIRP	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg11494091	chr17:61959527	GH2	0.47	5.82	0.35	1.8e-8	Height;
KIRP	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.54	-6.41	-0.38	7.34e-10	Macular telangiectasia type 2;
KIRP	trans	rs7980799	0.935	rs1905427	chr12:33534368	T/C	cg26384229	chr12:38710491	ALG10B	-0.53	-6.46	-0.38	5.67e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs61542988	0.570	rs7781074	chr7:22826360	A/G	cg11367502	chr7:22862612	TOMM7	-0.53	-5.68	-0.34	3.81e-8	Fibrinogen levels;
KIRP	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.21	0.51	1.51e-17	Bladder cancer;
KIRP	cis	rs6708331	0.517	rs12992553	chr2:70360262	A/G	cg01613454	chr2:70366299	NA	0.4	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs12145833	0.596	rs61833913	chr1:243440028	C/G	cg02356786	chr1:243265016	LOC731275	0.86	6.02	0.36	6.25e-9	Obesity (early onset extreme);
KIRP	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.64	-0.44	4.94e-13	Neuroticism;
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg22718636	chr4:961658	DGKQ	0.35	6.29	0.37	1.42e-9	Sjögren's syndrome;
KIRP	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.11e-7	Breast cancer;
KIRP	cis	rs57786342	0.624	rs4899262	chr14:69283545	G/A	cg03189333	chr14:69283534	NA	-0.41	-4.9	-0.3	1.73e-6	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.7	0.34	3.49e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04689371	chr19:56166368	U2AF2	0.47	6.1	0.36	4.11e-9	Parkinson's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24572153	chr13:21047387	CRYL1	0.45	6.17	0.37	2.76e-9	Survival in pancreatic cancer;
KIRP	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.78	0.4	8.94e-11	Colorectal cancer;
KIRP	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.57	-9.31	-0.51	7.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.43	-6.04	-0.36	5.79e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs10267417	0.603	rs2214319	chr7:19946286	T/C	cg05791153	chr7:19748676	TWISTNB	0.51	5.12	0.31	6.3e-7	Night sleep phenotypes;
KIRP	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg21775007	chr8:11205619	TDH	0.68	9.38	0.51	4.45e-18	Retinal vascular caliber;
KIRP	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.02	-0.3	9.9e-7	Neutrophil percentage of white cells;
KIRP	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg19636519	chr7:99541626	NA	0.32	5.55	0.33	7.52e-8	Coronary artery disease;
KIRP	cis	rs1440410	0.560	rs4299537	chr4:144048308	T/C	cg01719995	chr4:144104893	USP38	0.42	5.44	0.33	1.31e-7	Ischemic stroke;
KIRP	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg03468072	chr12:39539422	NA	0.44	5.73	0.34	2.86e-8	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-1.15	-19.73	-0.78	1.35e-52	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg07636037	chr3:49044803	WDR6	0.64	9.17	0.5	1.98e-17	Resting heart rate;
KIRP	cis	rs193541	0.632	rs10037044	chr5:122123299	A/G	cg19412675	chr5:122181750	SNX24	-0.56	-5.97	-0.36	8.44e-9	Glucose homeostasis traits;
KIRP	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg09699651	chr6:150184138	LRP11	0.47	6.22	0.37	2.15e-9	Lung cancer;
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.68	8.15	0.46	1.86e-14	Longevity;Endometriosis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09564133	chr5:176738847	MXD3	0.68	6.29	0.37	1.46e-9	Lung function (FEV1);
KIRP	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg00579200	chr11:133705235	NA	-0.38	-5.07	-0.31	7.7e-7	Childhood ear infection;
KIRP	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.99	14.25	0.67	5.48e-34	Platelet distribution width;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03777405	chr17:46125833	NFE2L1	-0.46	-6.31	-0.37	1.31e-9	Metabolic traits;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	5.37	0.32	1.84e-7	Obesity-related traits;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg16931447	chr4:875861	GAK	-0.47	-6.01	-0.36	6.54e-9	Sjögren's syndrome;
KIRP	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11987759	chr7:65425863	GUSB	0.58	7.63	0.44	5.1e-13	Aortic root size;
KIRP	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.81	-0.35	1.93e-8	Parkinson's disease;
KIRP	cis	rs2458413	0.542	rs2669451	chr8:105371096	C/A	cg08657449	chr8:105351661	TM7SF4	-0.33	-5.39	-0.32	1.66e-7	Paget's disease;
KIRP	cis	rs4356932	0.967	rs6532103	chr4:76953885	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.19	0.37	2.53e-9	Blood protein levels;
KIRP	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.76	8.8	0.49	2.46e-16	High light scatter reticulocyte count;
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.76	12.09	0.61	1.02e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1816752	0.819	rs4770664	chr13:24988833	C/T	cg22771759	chr13:24902376	NA	0.39	5.08	0.31	7.43e-7	Obesity-related traits;
KIRP	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.37	0.59	2.28e-24	Morning vs. evening chronotype;
KIRP	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.05	-0.36	5.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg18478394	chr8:109455254	TTC35	0.6	7.47	0.43	1.4e-12	Dupuytren's disease;
KIRP	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg00343986	chr7:65444356	GUSB	0.46	5.63	0.34	5e-8	Calcium levels;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs6832769	1.000	rs3805152	chr4:56359658	C/T	cg09317128	chr4:56265301	TMEM165	0.53	6.58	0.39	2.84e-10	Personality dimensions;
KIRP	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-10.18	-0.54	1.49e-20	Colorectal cancer;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.56	7.26	0.42	5.09e-12	Longevity;Endometriosis;
KIRP	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.08	-0.5	3.71e-17	Rheumatoid arthritis;
KIRP	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg20387954	chr3:183756860	HTR3D	0.61	8.96	0.5	8.18e-17	Anterior chamber depth;
KIRP	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.95	-14.57	-0.68	4.29e-35	Height;
KIRP	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	5.1	0.31	6.71e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs7980799	0.935	rs10732554	chr12:33533374	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-6.53	-0.38	3.75e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.77	-0.63	5.32e-29	Headache;
KIRP	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	9.8	0.53	2.3e-19	Coffee consumption (cups per day);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05724965	chr11:122753715	C11orf63	0.43	6.33	0.37	1.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg11815991	chr20:30193098	ID1	-0.45	-4.87	-0.3	2.02e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9653442	0.545	rs11681227	chr2:100754997	A/G	cg17356467	chr2:100759845	AFF3	0.42	5.65	0.34	4.34e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.66	7.8	0.45	1.75e-13	Breast cancer;
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.64	0.52	7.52e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7656342	0.622	rs13105954	chr4:9868417	C/G	cg11266682	chr4:10021025	SLC2A9	0.32	5.1	0.31	6.71e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24207248	chr17:78965708	CHMP6	0.51	6.18	0.37	2.66e-9	Parkinson's disease;
KIRP	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.77	0.4	9.27e-11	Axial length;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg23884241	chr7:27169957	HOXA4	-0.34	-5.38	-0.32	1.71e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2658782	0.704	rs2605614	chr11:93232745	A/G	cg15737290	chr11:93063684	CCDC67	0.7	7.72	0.44	2.86e-13	Pulmonary function decline;
KIRP	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg15448220	chr1:150897856	SETDB1	-0.4	-5.19	-0.31	4.32e-7	Tonsillectomy;
KIRP	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.08	19.15	0.77	1.13e-50	Triglycerides;
KIRP	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.59	7.66	0.44	4.29e-13	Prudent dietary pattern;
KIRP	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg00405596	chr8:11794950	NA	0.62	8.71	0.49	4.42e-16	Neuroticism;
KIRP	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22496380	chr5:211416	CCDC127	-1.16	-7.57	-0.43	7.37e-13	Asthma (childhood onset);
KIRP	cis	rs1134634	0.520	rs1473166	chr4:15557491	A/T	cg16509355	chr4:15471240	CC2D2A	-0.3	-5.11	-0.31	6.35e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.46	-0.33	1.14e-7	Pulmonary function;
KIRP	cis	rs11671005	0.652	rs11670864	chr19:59030580	G/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.6	-6.77	-0.4	9.63e-11	Mean platelet volume;
KIRP	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-6.87	-0.4	5.2e-11	Blood metabolite levels;
KIRP	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg15660573	chr17:549704	VPS53	-0.94	-15.05	-0.69	9.79e-37	Prostate cancer;
KIRP	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.03	12.23	0.61	3.6e-27	Platelet count;
KIRP	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.54	-6.22	-0.37	2.13e-9	Menarche (age at onset);
KIRP	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg09165964	chr15:75287851	SCAMP5	-1.1	-7.47	-0.43	1.43e-12	Lung cancer;
KIRP	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg07596299	chr11:71824057	C11orf51	0.9	5.21	0.31	4.09e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs1816752	0.712	rs2862898	chr13:24988461	A/G	cg22771759	chr13:24902376	NA	0.39	5.06	0.31	8.15e-7	Obesity-related traits;
KIRP	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.51	6.89	0.4	4.58e-11	Schizophrenia;
KIRP	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.64	-7.25	-0.42	5.39e-12	Gut microbiome composition (summer);
KIRP	cis	rs12900413	0.687	rs12908343	chr15:90319095	C/T	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.5e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs6142102	0.651	rs6059692	chr20:32746203	T/C	cg08999081	chr20:33150536	PIGU	-0.44	-4.86	-0.3	2.12e-6	Skin pigmentation;
KIRP	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg05802129	chr4:122689817	NA	-0.57	-6.88	-0.4	5.05e-11	Type 2 diabetes;
KIRP	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.54	7.2	0.42	7.12e-12	Menopause (age at onset);
KIRP	trans	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.75	-0.4	1.03e-10	Heart rate;
KIRP	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.49	-6.05	-0.36	5.22e-9	Mean platelet volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19749445	chr14:92493378	TRIP11	0.47	6.78	0.4	8.99e-11	Survival in pancreatic cancer;
KIRP	trans	rs4143844	0.867	rs17238096	chr15:62146598	C/T	cg04814990	chr13:111957387	ARHGEF7	0.98	6.26	0.37	1.75e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg10756647	chr7:56101905	PSPH	1.02	7.7	0.44	3.32e-13	Diabetic kidney disease;
KIRP	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.62	-9.15	-0.5	2.21e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4887140	1.000	rs4887140	chr15:74046663	G/T	cg11789681	chr15:74046708	NA	0.62	6.1	0.36	4.09e-9	Glucose homeostasis traits;
KIRP	cis	rs4523957	0.579	rs4790883	chr17:2087605	T/C	cg16513277	chr17:2031491	SMG6	-0.71	-10.24	-0.55	9.87e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.52	-5.74	-0.34	2.79e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg07636037	chr3:49044803	WDR6	0.54	5.12	0.31	6.26e-7	Menarche (age at onset);
KIRP	cis	rs7212590	0.655	rs34687426	chr17:57997857	A/G	cg10252138	chr17:58120427	NA	-0.6	-5.43	-0.33	1.37e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs10207060	0.500	rs72992164	chr2:240711780	G/A	cg20333904	chr2:240724165	NA	-0.51	-6.01	-0.36	6.5e-9	Obesity-related traits;
KIRP	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg27462398	chr1:86174642	ZNHIT6	-0.6	-8.75	-0.49	3.46e-16	Urate levels in overweight individuals;
KIRP	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg21640587	chr11:117668038	DSCAML1	0.45	6.59	0.39	2.72e-10	Myopia;
KIRP	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-11.06	-0.58	2.4e-23	Personality dimensions;
KIRP	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.53	7.13	0.41	1.14e-11	Depressive symptoms;
KIRP	trans	rs6499100	0.695	rs4784258	chr16:52837310	C/T	cg20968010	chr1:40505947	CAP1	0.49	6.07	0.36	4.85e-9	Tetralogy of Fallot;
KIRP	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.58	6.64	0.39	2e-10	Vitiligo;
KIRP	cis	rs4700695	0.841	rs251308	chr5:65284279	C/T	cg21114390	chr5:65439923	SFRS12	-0.54	-5.03	-0.31	9.29e-7	Facial morphology (factor 19);
KIRP	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.18	0.37	2.59e-9	Menopause (age at onset);
KIRP	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg06521331	chr12:34319734	NA	0.6	7.43	0.43	1.8e-12	Morning vs. evening chronotype;
KIRP	cis	rs5753037	0.809	rs5763512	chr22:30212366	C/T	cg01021169	chr22:30184971	ASCC2	-0.39	-4.87	-0.3	1.96e-6	Type 1 diabetes;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.7	10.31	0.55	6e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17065868	0.881	rs7325282	chr13:45070519	T/A	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11987759	chr7:65425863	GUSB	-0.45	-5.48	-0.33	1.05e-7	Aortic root size;
KIRP	cis	rs6575793	0.513	rs1190867	chr14:101069135	G/T	cg18516195	chr14:101012996	BEGAIN	-0.43	-5.51	-0.33	8.97e-8	Menarche (age at onset);
KIRP	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-5.04	-0.31	8.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78487399	0.808	rs6761129	chr2:43735713	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.39	-0.33	1.65e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.67	-10.1	-0.54	2.67e-20	Hepatocellular carcinoma;
KIRP	cis	rs73787773	0.668	rs59043064	chr5:111491066	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.52	-4.98	-0.3	1.18e-6	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	10.49	0.56	1.61e-21	Cognitive test performance;
KIRP	cis	rs7851660	0.839	rs2417575	chr9:100628642	G/A	cg13688889	chr9:100608707	NA	-0.67	-8.83	-0.49	1.97e-16	Strep throat;
KIRP	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg27432699	chr2:27873401	GPN1	-0.43	-5.47	-0.33	1.12e-7	Menopause (age at onset);
KIRP	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.51	6.53	0.38	3.7e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg03342759	chr3:160939853	NMD3	0.41	5.01	0.3	1.04e-6	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.87	9.69	0.53	4.96e-19	Corneal astigmatism;
KIRP	cis	rs9972944	0.729	rs12939140	chr17:63777249	T/A	cg07283582	chr17:63770753	CCDC46	0.52	8.57	0.48	1.2e-15	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14789568	chr1:29508095	SFRS4	0.45	6.56	0.39	3.23e-10	Survival in pancreatic cancer;
KIRP	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.82	-11.45	-0.59	1.32e-24	Coronary artery disease;
KIRP	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg22974920	chr21:40686053	BRWD1	0.42	4.92	0.3	1.57e-6	Cognitive function;
KIRP	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.83	11.69	0.6	2.1e-25	Gestational age at birth (maternal effect);
KIRP	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-8.66	-0.48	6.15e-16	Gut microbiome composition (summer);
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg08805041	chr16:621841	PIGQ	-0.39	-5.36	-0.32	1.88e-7	Height;
KIRP	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg20542592	chr8:11973495	FAM66D	0.4	5.08	0.31	7.42e-7	Triglycerides;
KIRP	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.0	7.27	0.42	4.89e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4805272	1.000	rs888831	chr19:29324588	A/G	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.61	6.24	0.37	1.93e-9	Body mass index;
KIRP	cis	rs4852324	0.536	rs17009553	chr2:74220035	A/G	cg19729930	chr2:74357872	NA	-0.68	-5.44	-0.33	1.28e-7	Systemic lupus erythematosus;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17366332	chr4:2758278	TNIP2	0.46	6.06	0.36	5.21e-9	Parkinson's disease;
KIRP	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg24112000	chr20:60950667	NA	-0.6	-9.09	-0.5	3.28e-17	Colorectal cancer;
KIRP	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg01304814	chr3:48885189	PRKAR2A	0.59	5.29	0.32	2.71e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.73e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs965604	1.000	rs12903295	chr15:78778972	A/G	cg24631222	chr15:78858424	CHRNA5	-0.39	-4.88	-0.3	1.94e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg04889106	chr6:3751618	C6orf145	-0.56	-6.44	-0.38	6.35e-10	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	trans	rs1864585	0.520	rs6984391	chr8:10646111	A/G	cg26278703	chr11:58910052	FAM111A	0.64	6.62	0.39	2.18e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.44	-5.64	-0.34	4.59e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.84	-0.53	1.76e-19	Height;
KIRP	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.52	-8.06	-0.46	3.39e-14	Huntington's disease progression;
KIRP	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg16141378	chr3:129829833	LOC729375	-0.51	-6.92	-0.4	3.85e-11	Neuroticism;
KIRP	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg11189052	chr15:85197271	WDR73	0.54	5.57	0.33	6.77e-8	Schizophrenia;
KIRP	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.46	6.47	0.38	5.37e-10	Sitting height ratio;
KIRP	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg18200150	chr17:30822561	MYO1D	0.48	5.94	0.35	9.86e-9	Schizophrenia;
KIRP	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-7.12	-0.41	1.21e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.65	-7.58	-0.44	7.15e-13	Systemic lupus erythematosus;
KIRP	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.6	-0.44	6.26e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.36	-0.32	1.93e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs75920871	0.800	rs17120251	chr11:116923488	A/G	cg23684410	chr11:116897558	SIK3	0.45	4.97	0.3	1.24e-6	Subjective well-being;
KIRP	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg13010199	chr12:38710504	ALG10B	0.52	6.68	0.39	1.59e-10	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg03959625	chr15:84868606	LOC388152	0.63	6.73	0.39	1.2e-10	Schizophrenia;
KIRP	cis	rs2273156	0.500	rs17103120	chr14:35703839	C/T	cg09327582	chr14:35236912	BAZ1A	0.65	6.07	0.36	4.82e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs17023223	0.537	rs2645305	chr1:119561365	A/G	cg05756136	chr1:119680316	WARS2	-0.57	-7.62	-0.44	5.32e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs9650657	0.683	rs7005905	chr8:10585144	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.08	0.36	4.66e-9	Neuroticism;
KIRP	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.81	11.14	0.58	1.37e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg08999081	chr20:33150536	PIGU	0.46	6.24	0.37	1.87e-9	Height;
KIRP	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg21643547	chr1:205240462	TMCC2	-0.66	-9.75	-0.53	3.29e-19	Red blood cell count;
KIRP	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg18700516	chr19:44507157	ZNF230	0.48	5.52	0.33	8.44e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-1.12	-8.97	-0.5	7.48e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg17691542	chr6:26056736	HIST1H1C	0.49	6.4	0.38	7.64e-10	Height;
KIRP	cis	rs4638749	0.501	rs1486193	chr2:108756025	G/A	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.94	-0.3	1.43e-6	Blood pressure;
KIRP	cis	rs17023223	0.581	rs10923750	chr1:119650795	T/G	cg18261050	chr1:119551319	NA	0.53	6.89	0.4	4.64e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-6.09	-0.36	4.34e-9	Total body bone mineral density;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.73	11.42	0.59	1.6e-24	Menarche (age at onset);
KIRP	cis	rs9372498	0.536	rs62421539	chr6:118730559	C/A	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg07395648	chr5:131743802	NA	-0.51	-7.4	-0.43	2.09e-12	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17317165	chr5:108280702	FER	-0.43	-6.49	-0.38	4.65e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.44	5.25	0.32	3.32e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9972944	0.651	rs9906040	chr17:63840825	A/G	cg07283582	chr17:63770753	CCDC46	-0.5	-8.01	-0.45	4.59e-14	Total body bone mineral density;
KIRP	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.03	0.41	2.09e-11	Bipolar disorder;
KIRP	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg21775007	chr8:11205619	TDH	-0.41	-5.13	-0.31	5.99e-7	Triglycerides;
KIRP	cis	rs830233	0.689	rs62383292	chr5:165423954	C/T	cg13976338	chr5:165423657	NA	-0.72	-7.64	-0.44	4.76e-13	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs8067545	0.640	rs10083840	chr17:19965972	A/G	cg13482628	chr17:19912719	NA	0.6	7.67	0.44	3.99e-13	Schizophrenia;
KIRP	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.92	-13.95	-0.66	5.39e-33	Ulcerative colitis;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg27532560	chr4:187881888	NA	-0.75	-12.83	-0.63	3.53e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.68	10.27	0.55	8.12e-21	Pulse pressure;
KIRP	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.5	7.8	0.45	1.8e-13	Testicular germ cell tumor;
KIRP	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg05507819	chr15:63340323	TPM1	0.5	6.23	0.37	2e-9	Platelet count;
KIRP	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg10434728	chr15:90938212	IQGAP1	0.31	5.21	0.32	3.96e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg13266496	chr6:110720918	DDO	0.37	5.82	0.35	1.85e-8	Platelet distribution width;
KIRP	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	1.04	9.25	0.51	1.13e-17	Left atrial antero-posterior diameter;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.56	-7.29	-0.42	4.31e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg23803603	chr1:2058230	PRKCZ	-0.42	-6.16	-0.37	2.97e-9	Height;
KIRP	cis	rs6681460	1.000	rs7532173	chr1:67086111	A/G	cg02459107	chr1:67143332	SGIP1	0.45	6.27	0.37	1.6e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16100063	chr1:10690011	PEX14	0.5	6.56	0.39	3.18e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-5.07	-0.31	7.83e-7	Systolic blood pressure;
KIRP	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg19610905	chr11:61596333	FADS2	-0.35	-5.2	-0.31	4.14e-7	Trans fatty acid levels;
KIRP	cis	rs7766436	0.648	rs6908475	chr6:22572798	A/G	cg13666174	chr6:22585274	NA	-0.34	-4.9	-0.3	1.76e-6	Coronary artery disease;
KIRP	cis	rs10802346	0.636	rs12047380	chr1:246394817	C/T	cg15962031	chr1:246363574	SMYD3	-0.71	-5.03	-0.31	9.3e-7	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-6.64	-0.39	1.94e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.13	-0.31	5.81e-7	Post bronchodilator FEV1;
KIRP	cis	rs2404618	0.624	rs4457358	chr8:1477213	C/A	cg02903104	chr8:1507517	DLGAP2	0.38	5.88	0.35	1.35e-8	Lung cancer;
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05665937	chr4:1216051	CTBP1	0.46	6.26	0.37	1.66e-9	Obesity-related traits;
KIRP	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg07068956	chr7:100330872	ZAN	0.4	5.39	0.32	1.67e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg10223061	chr2:219282414	VIL1	0.34	5.6	0.34	5.84e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.49	-0.33	1.02e-7	Neuroticism;
KIRP	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs6963495	0.615	rs1728645	chr7:105205115	A/G	cg19920283	chr7:105172520	RINT1	0.55	5.67	0.34	3.9e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs77688320	0.553	rs2244438	chr2:202252539	G/A	cg06431681	chr2:202330990	STRADB	-0.48	-5.65	-0.34	4.4e-8	Breast cancer;
KIRP	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11987759	chr7:65425863	GUSB	0.51	6.86	0.4	5.64e-11	Aortic root size;
KIRP	cis	rs11169225	0.901	rs12372344	chr12:50348359	T/C	cg04450003	chr12:50355995	AQP5	0.57	9.09	0.5	3.43e-17	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.29	-0.55	6.81e-21	Height;
KIRP	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.54	-0.38	3.5e-10	Glomerular filtration rate;
KIRP	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.34	-0.37	1.09e-9	Obesity-related traits;
KIRP	cis	rs7937612	0.965	rs4938806	chr11:120274353	C/A	cg24566217	chr11:120254723	ARHGEF12	-0.49	-7.44	-0.43	1.64e-12	Intraocular pressure;
KIRP	cis	rs4702718	0.748	rs3822411	chr5:10684942	T/C	cg14521931	chr5:10832172	NA	0.43	5.51	0.33	8.98e-8	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg16479474	chr6:28041457	NA	-0.44	-4.91	-0.3	1.64e-6	Depression;
KIRP	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg11262906	chr1:85462892	MCOLN2	-0.56	-6.69	-0.39	1.53e-10	Serum sulfate level;
KIRP	cis	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.63	-7.97	-0.45	5.99e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg09264619	chr17:80180166	NA	-0.36	-5.3	-0.32	2.57e-7	Life satisfaction;
KIRP	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.5	6.9	0.4	4.32e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.59	-9.5	-0.52	1.95e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.55	-0.33	7.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs929596	0.603	rs2602363	chr2:234520525	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.69	-0.34	3.62e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs3109167	0.666	rs10270844	chr7:83109037	C/T	cg14519356	chr7:83097669	SEMA3E	0.45	6.36	0.38	9.89e-10	Blood protein levels;
KIRP	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.56	0.48	1.23e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.7	-10.96	-0.57	4.95e-23	Hepatocellular carcinoma;
KIRP	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.35	0.38	1.02e-9	Subjective well-being;
KIRP	trans	rs12517041	1.000	rs1593966	chr5:23313785	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg19731401	chr7:2775893	GNA12	0.77	7.26	0.42	5.04e-12	Childhood ear infection;
KIRP	trans	rs7404843	0.704	rs112251447	chr16:15521872	G/A	cg02716450	chr16:28638775	NA	1.01	10.12	0.54	2.45e-20	Testicular germ cell tumor;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19171120	chr6:47682172	GPR115	0.57	6.74	0.39	1.13e-10	Interleukin-4 levels;
KIRP	cis	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg14972814	chr11:95582409	MTMR2	0.34	5.88	0.35	1.33e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs77688320	0.535	rs11680694	chr2:202258221	C/T	cg06431681	chr2:202330990	STRADB	0.51	6.96	0.41	3.16e-11	Breast cancer;
KIRP	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.94	12.34	0.62	1.47e-27	Menopause (age at onset);
KIRP	cis	rs580438	0.529	rs7641084	chr3:13435392	C/G	cg10657019	chr3:13328039	NA	-0.49	-6.36	-0.38	9.94e-10	Myringotomy;
KIRP	trans	rs55728055	0.661	rs62237773	chr22:31965054	A/G	cg02791973	chr19:1132256	SBNO2	-0.57	-6.12	-0.36	3.76e-9	Age-related hearing impairment;
KIRP	cis	rs3857747	0.931	rs10227645	chr7:40364609	G/C	cg00420559	chr7:40367873	C7orf10	-0.6	-8.46	-0.47	2.37e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg20573242	chr4:122745356	CCNA2	0.41	5.07	0.31	7.84e-7	Type 2 diabetes;
KIRP	cis	rs78487399	0.908	rs6731636	chr2:43843046	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.52	-0.33	8.49e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	5.82	0.35	1.85e-8	Cognitive test performance;
KIRP	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.69	0.44	3.47e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg16558253	chr16:72132732	DHX38	-0.45	-5.6	-0.34	5.85e-8	Blood protein levels;
KIRP	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg25173405	chr17:45401733	C17orf57	0.48	6.41	0.38	7.56e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.53	0.81	1.65e-58	Prudent dietary pattern;
KIRP	cis	rs3857747	0.861	rs10263494	chr7:40428906	G/A	cg00420559	chr7:40367873	C7orf10	0.62	7.94	0.45	7.19e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg00646381	chr17:77835854	NA	0.57	7.6	0.44	6.35e-13	Glucocorticoid-induced osteonecrosis (age 10 years and older);
KIRP	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.55	-7.63	-0.44	5.31e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.47	-7.01	-0.41	2.3e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.9	-0.4	4.37e-11	Height;
KIRP	cis	rs6725041	0.547	rs6753945	chr2:213204574	T/C	cg20637307	chr2:213403960	ERBB4	-0.48	-6.13	-0.36	3.45e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg10017260	chr10:834428	NA	-0.54	-5.42	-0.33	1.46e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg09754948	chr16:28834200	ATXN2L	0.5	5.81	0.35	1.96e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4268898	0.552	rs11125444	chr2:24367205	G/T	cg06627628	chr2:24431161	ITSN2	0.48	5.77	0.35	2.42e-8	Asthma;
KIRP	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg07777115	chr5:623756	CEP72	-0.55	-5.51	-0.33	8.85e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	1.15	14.48	0.68	9.06e-35	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.53	-11.05	-0.58	2.64e-23	Monocyte percentage of white cells;
KIRP	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.38	-9.34	-0.51	5.99e-18	Asthma (sex interaction);
KIRP	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	9.63	0.52	7.81e-19	Post bronchodilator FEV1;
KIRP	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.45	6.29	0.37	1.42e-9	Dupuytren's disease;
KIRP	cis	rs10214930	0.671	rs6963585	chr7:27583823	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.22e-6	Hypospadias;
KIRP	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22433210	chr17:43662623	NA	0.88	9.38	0.51	4.49e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7221595	0.825	rs2290437	chr17:3923115	G/A	cg11204139	chr17:3907470	NA	0.61	6.52	0.38	3.9e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-0.74	-8.81	-0.49	2.23e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg11693508	chr17:37793320	STARD3	0.75	8.1	0.46	2.56e-14	Neuroticism;
KIRP	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06634786	chr22:41940651	POLR3H	-0.47	-5.35	-0.32	2.06e-7	Vitiligo;
KIRP	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.29	-7.8	-0.45	1.73e-13	Rheumatoid arthritis;
KIRP	cis	rs2425143	1.000	rs11696947	chr20:34312658	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg00800038	chr16:89945340	TCF25	-0.72	-4.87	-0.3	1.96e-6	Skin colour saturation;
KIRP	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg18477163	chr1:228402036	OBSCN	0.29	5.57	0.33	6.61e-8	Diastolic blood pressure;
KIRP	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.53	7.15	0.42	9.61e-12	Schizophrenia;
KIRP	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.37	-0.38	9.07e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg10755058	chr3:40428713	ENTPD3	0.47	6.68	0.39	1.58e-10	Renal cell carcinoma;
KIRP	cis	rs8060686	0.920	rs12448923	chr16:67839128	C/T	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.2	-0.31	4.16e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.49	-6.58	-0.39	2.79e-10	Multiple sclerosis;
KIRP	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	8.41	0.47	3.42e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs1978968	0.957	rs2053601	chr22:18448605	G/C	cg02610425	chr22:18483192	MICAL3	0.36	5.04	0.31	8.99e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4748857	0.891	rs4748858	chr10:23599920	G/A	cg12804278	chr10:23633326	C10orf67	0.44	5.22	0.32	3.75e-7	Systemic lupus erythematosus;
KIRP	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg19875535	chr5:140030758	IK	-0.55	-6.78	-0.4	8.65e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg20965017	chr5:231967	SDHA	-0.58	-6.79	-0.4	8.17e-11	Breast cancer;
KIRP	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg27129171	chr3:47204927	SETD2	0.43	5.56	0.33	6.87e-8	Birth weight;
KIRP	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.63	0.44	5.18e-13	Tonsillectomy;
KIRP	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg07511934	chr16:89386912	ANKRD11	0.39	4.97	0.3	1.26e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs3751972	0.911	rs2191058	chr17:26232917	T/C	cg26853415	chr17:26127438	NOS2	-0.45	-4.97	-0.3	1.26e-6	Fractional exhaled nitric oxide (childhood);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg22782929	chr10:21784432	C10orf114	1.03	7.2	0.42	7.11e-12	P wave terminal force;
KIRP	cis	rs476633	0.573	rs2099652	chr15:41528745	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.8	-10.37	-0.55	3.76e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.83	6.82	0.4	6.86e-11	Initial pursuit acceleration;
KIRP	cis	rs2505998	0.833	rs1864404	chr10:43604390	A/T	cg15436174	chr10:43711423	RASGEF1A	-0.53	-5.69	-0.34	3.63e-8	Hirschsprung disease;
KIRP	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.68	8.1	0.46	2.57e-14	Diabetic retinopathy;
KIRP	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg00977110	chr5:151150581	G3BP1	0.63	6.29	0.37	1.42e-9	Preschool internalizing problems;
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg26134248	chr17:3907702	NA	0.52	6.9	0.4	4.35e-11	Type 2 diabetes;
KIRP	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg07817648	chr10:79422355	NA	-0.54	-6.49	-0.38	4.61e-10	Bone mineral density;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg06634961	chr4:53582034	NA	-0.43	-6.15	-0.37	3.16e-9	Inflammatory biomarkers;
KIRP	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg13271783	chr10:134563150	INPP5A	-0.54	-6.88	-0.4	4.81e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.77	-9.95	-0.54	7.92e-20	Ulcerative colitis;
KIRP	cis	rs7975161	0.882	rs4964270	chr12:104652398	A/G	cg25273343	chr12:104657179	TXNRD1	-0.61	-5.41	-0.33	1.47e-7	Toenail selenium levels;
KIRP	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-9.93	-0.53	9.4e-20	Alzheimer's disease;
KIRP	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.76	12.66	0.63	1.25e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg18016565	chr1:150552671	MCL1	0.39	5.98	0.36	7.65e-9	Melanoma;
KIRP	cis	rs231513	0.954	rs231514	chr17:41964516	C/T	cg26893861	chr17:41843967	DUSP3	-0.58	-5.06	-0.31	8.04e-7	Cognitive function;
KIRP	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.58	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg06026331	chr20:60912101	LAMA5	0.77	9.54	0.52	1.47e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07570687	chr10:102243282	WNT8B	0.42	4.85	0.3	2.21e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg00800038	chr16:89945340	TCF25	-0.89	-7.16	-0.42	9.48e-12	Skin colour saturation;
KIRP	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg08499158	chr17:42289980	UBTF	0.46	5.96	0.36	8.78e-9	Total body bone mineral density;
KIRP	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg07395648	chr5:131743802	NA	0.59	6.78	0.4	8.72e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs2797160	0.547	rs10872298	chr6:125956348	A/C	cg05901451	chr6:126070800	HEY2	-0.37	-5.11	-0.31	6.5e-7	Endometrial cancer;
KIRP	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg13319975	chr6:146136371	FBXO30	0.45	5.97	0.36	8.34e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77633900	0.772	rs16968196	chr15:76682238	C/T	cg21673338	chr15:77095150	SCAPER	-0.58	-4.87	-0.3	2.04e-6	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7546094	1.000	rs2999155	chr1:113221658	G/A	cg22162597	chr1:113214053	CAPZA1	-0.51	-7.29	-0.42	4.24e-12	Platelet distribution width;
KIRP	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg09491104	chr22:46646882	C22orf40	0.62	8.11	0.46	2.33e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg26061582	chr7:22766209	IL6	0.5	5.56	0.33	7.06e-8	Lung cancer;
KIRP	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg14541582	chr5:601475	NA	-0.57	-6.5	-0.38	4.44e-10	Obesity-related traits;
KIRP	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.64	7.83	0.45	1.5e-13	Corneal astigmatism;
KIRP	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.36	4.88	0.3	1.94e-6	Mean platelet volume;
KIRP	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.82	-0.35	1.78e-8	Bipolar disorder;
KIRP	cis	rs7129556	0.775	rs72945598	chr11:77367738	C/T	cg12586386	chr11:77299805	AQP11	0.46	5.25	0.32	3.24e-7	Weight loss (gastric bypass surgery);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18729886	chr14:61788339	PRKCH	0.43	6.22	0.37	2.14e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.91e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16917537	chr7:73098262	DNAJC30;WBSCR22	0.55	6.32	0.37	1.22e-9	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19783536	chr22:18111421	ATP6V1E1	0.48	6.11	0.36	3.9e-9	Parkinson's disease;
KIRP	cis	rs2411233	0.837	rs12911780	chr15:39250617	A/G	cg05886626	chr15:39873553	THBS1	0.35	5.16	0.31	5.14e-7	Platelet count;
KIRP	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.41	-7.35	-0.42	2.96e-12	Refractive error;
KIRP	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.72	-8.57	-0.48	1.14e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg07395648	chr5:131743802	NA	0.55	7.71	0.44	3.05e-13	Breast cancer;
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg15893493	chr8:124194847	FAM83A	0.93	8.13	0.46	2.14e-14	Urinary uromodulin levels;
KIRP	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	6.33	0.37	1.18e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10556349	chr10:835070	NA	0.58	4.91	0.3	1.67e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.59	6.4	0.38	7.74e-10	Corneal astigmatism;
KIRP	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11987759	chr7:65425863	GUSB	-0.61	-8.17	-0.46	1.66e-14	Aortic root size;
KIRP	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-4.95	-0.3	1.4e-6	Parkinson's disease;
KIRP	trans	rs6499766	1.000	rs9940227	chr16:55614794	T/C	cg12196692	chr5:41071405	HEATR7B2	-0.41	-6.11	-0.36	3.81e-9	Thyroid hormone levels;
KIRP	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12315302	chr6:26189340	HIST1H4D	0.87	6.11	0.36	3.93e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17507749	chr15:85114479	UBE2QP1	0.73	8.18	0.46	1.51e-14	Schizophrenia;
KIRP	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg24253500	chr15:84953950	NA	0.52	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg05220968	chr6:146057943	EPM2A	-0.39	-5.06	-0.31	8.37e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1894292	0.715	rs1957659	chr4:74472081	C/T	cg12566645	chr4:74483141	RASSF6	0.37	5.11	0.31	6.62e-7	Prostate cancer;
KIRP	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.69	7.14	0.41	1.02e-11	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10661629	chr19:2900748	ZNF57	0.62	8.05	0.46	3.46e-14	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.68	8.96	0.5	8.21e-17	Motion sickness;
KIRP	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg19468946	chr17:37922297	IKZF3	-0.45	-6.32	-0.37	1.21e-9	Self-reported allergy;
KIRP	cis	rs6987853	0.933	rs2923430	chr8:42391195	T/C	cg09913449	chr8:42400586	C8orf40	0.38	4.91	0.3	1.66e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.54	6.7	0.39	1.38e-10	Body mass index;
KIRP	cis	rs926938	0.841	rs11588144	chr1:115239355	G/A	cg12756093	chr1:115239321	AMPD1	-0.98	-18.77	-0.77	2.21e-49	Autism;
KIRP	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.66	10.11	0.54	2.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.39	-5.35	-0.32	2.02e-7	Aortic root size;
KIRP	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.87	13.36	0.65	5.74e-31	Longevity;Endometriosis;
KIRP	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.95	12.47	0.62	5.34e-28	Homoarginine levels;
KIRP	cis	rs2522056	1.000	rs886286	chr5:131795597	A/G	cg07395648	chr5:131743802	NA	0.55	6.56	0.39	3.2e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg05072774	chr3:49840536	C3orf54	-0.38	-4.86	-0.3	2.11e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2522056	1.000	rs2706379	chr5:131805735	C/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.11	0.36	3.77e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.51	-7.26	-0.42	5.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg09873164	chr1:152488093	CRCT1	0.5	6.37	0.38	9.19e-10	Hair morphology;
KIRP	cis	rs4919044	0.756	rs2478239	chr10:94806370	A/T	cg05127821	chr10:94822908	CYP26C1	-1.04	-10.84	-0.57	1.23e-22	Coronary artery disease;
KIRP	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	1.1	12.0	0.61	1.94e-26	Corneal structure;
KIRP	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.63	-8.48	-0.48	2.06e-15	Aortic root size;
KIRP	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.48	-6.9	-0.4	4.3e-11	Schizophrenia;
KIRP	cis	rs2172802	0.560	rs12499359	chr4:62563415	A/G	cg04118610	chr4:62707027	LPHN3	0.47	5.77	0.35	2.42e-8	Partial epilepsies;
KIRP	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.53	0.75	3.39e-45	Cognitive function;
KIRP	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.97	-16.51	-0.73	1e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-5.23	-0.32	3.55e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg05926928	chr17:57297772	GDPD1	0.99	10.6	0.56	7.05e-22	Opioid sensitivity;
KIRP	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.51	7.15	0.41	9.99e-12	Metabolite levels (small molecules and protein measures);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06385459	chr4:82393184	RASGEF1B	0.54	7.1	0.41	1.37e-11	Parkinson's disease;
KIRP	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg22903471	chr2:27725779	GCKR	-0.46	-4.92	-0.3	1.57e-6	Blood metabolite levels;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg01391022	chr12:122360665	WDR66	-0.38	-5.65	-0.34	4.41e-8	Mean corpuscular volume;
KIRP	cis	rs4908768	0.906	rs55858268	chr1:8554696	C/T	cg25722041	chr1:8623473	RERE	0.78	9.88	0.53	1.37e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.5	-5.71	-0.34	3.3e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Colorectal cancer;
KIRP	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg05998816	chr21:47859926	PCNT	0.52	6.17	0.37	2.73e-9	Lymphocyte counts;
KIRP	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.86	-0.35	1.46e-8	Bipolar disorder;
KIRP	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg08313168	chr12:7315531	NA	0.69	6.26	0.37	1.74e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07098314	chr17:39823360	NA	0.55	6.95	0.41	3.25e-11	Smoking initiation;
KIRP	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg07645718	chr20:61493192	TCFL5	0.73	6.14	0.36	3.21e-9	Obesity-related traits;
KIRP	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	trans	rs12517041	1.000	rs1366452	chr5:23279222	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.86	-7.94	-0.45	7.27e-14	Calcium levels;
KIRP	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-1.07	-14.56	-0.68	4.77e-35	Alopecia areata;
KIRP	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg24203234	chr3:128598194	ACAD9	0.44	5.06	0.31	8.3e-7	IgG glycosylation;
KIRP	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05025164	chr4:1340916	KIAA1530	0.46	6.06	0.36	5.11e-9	Obesity-related traits;
KIRP	cis	rs7903847	0.642	rs10882922	chr10:99158537	C/T	cg20016023	chr10:99160130	RRP12	-0.43	-5.83	-0.35	1.73e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1440410	0.798	rs1440416	chr4:144155035	T/C	cg01719995	chr4:144104893	USP38	0.44	6.02	0.36	6.35e-9	Ischemic stroke;
KIRP	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-8.84	-0.49	1.87e-16	Platelet count;
KIRP	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg01620082	chr3:125678407	NA	-1.19	-7.59	-0.44	6.51e-13	Depression;
KIRP	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg16486109	chr11:613632	IRF7	0.41	4.99	0.3	1.12e-6	Systemic lupus erythematosus;
KIRP	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg18441811	chr11:71824068	C11orf51	-0.78	-4.99	-0.3	1.13e-6	Severe influenza A (H1N1) infection;
KIRP	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg21775007	chr8:11205619	TDH	0.48	6.41	0.38	7.37e-10	Systolic blood pressure;
KIRP	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.64	-0.48	7.16e-16	Response to antipsychotic treatment;
KIRP	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.53	6.09	0.36	4.35e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg19680485	chr15:31195859	MTMR15	-0.55	-5.19	-0.31	4.42e-7	Hypertriglyceridemia;
KIRP	cis	rs708547	0.511	rs1713998	chr4:57844902	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	8.56	0.48	1.26e-15	Response to bleomycin (chromatid breaks);
KIRP	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.12	-0.41	1.19e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg08885076	chr2:99613938	TSGA10	-0.64	-11.35	-0.59	2.68e-24	Chronic sinus infection;
KIRP	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	cg12689670	chr1:183009347	LAMC1	0.56	7.85	0.45	1.32e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs2213920	0.522	rs7847118	chr9:118199763	T/C	cg13918206	chr9:118159781	DEC1	1.0	10.34	0.55	4.68e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs787274	1.000	rs787295	chr9:115541606	C/G	cg13803584	chr9:115635662	SNX30	0.72	8.16	0.46	1.74e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.45	0.38	5.9e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.53	5.54	0.33	7.8e-8	Recombination rate (females);
KIRP	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-6.96	-0.41	3.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg12705353	chr12:122356852	WDR66	0.43	5.76	0.34	2.44e-8	Mean corpuscular volume;
KIRP	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg11645453	chr3:52864694	ITIH4	-0.42	-6.28	-0.37	1.48e-9	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg06204229	chr3:52865917	ITIH4	0.47	5.42	0.33	1.39e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs73242632	1.000	rs73242625	chr4:57856339	A/G	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	4.89	0.3	1.8e-6	Congenital heart disease (maternal effect);
KIRP	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg27205649	chr11:78285834	NARS2	-0.57	-6.46	-0.38	5.67e-10	Testicular germ cell tumor;
KIRP	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.89	-9.34	-0.51	5.92e-18	Neuroticism;
KIRP	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.33	-0.32	2.26e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.46	5.96	0.36	8.86e-9	Initial pursuit acceleration;
KIRP	cis	rs1832871	0.644	rs56180963	chr6:158773990	G/A	cg07215822	chr6:158701037	NA	-0.63	-7.27	-0.42	4.72e-12	Height;
KIRP	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg11608241	chr8:8085544	FLJ10661	-0.49	-6.31	-0.37	1.28e-9	Retinal vascular caliber;
KIRP	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg07274523	chr3:49395745	GPX1	0.69	8.58	0.48	1.08e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.95	-14.56	-0.68	4.52e-35	Schizophrenia;
KIRP	cis	rs12579753	0.667	rs11610904	chr12:82300416	A/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.65	-0.34	4.51e-8	Resting heart rate;
KIRP	cis	rs7084402	0.967	rs7097576	chr10:60277055	G/A	cg05938607	chr10:60274200	BICC1	0.45	10.84	0.57	1.22e-22	Refractive error;
KIRP	cis	rs8067545	0.717	rs9907788	chr17:20008903	T/C	cg04132472	chr17:19861366	AKAP10	0.46	6.39	0.38	8.13e-10	Schizophrenia;
KIRP	cis	rs4663866	0.901	rs3739066	chr2:239184124	G/T	cg17283117	chr2:239148619	HES6	0.7	5.07	0.31	7.88e-7	Irritable bowel syndrome;
KIRP	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.75	-0.63	6.4e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.66	-6.42	-0.38	7.09e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg08807892	chr2:162101083	NA	0.64	8.82	0.49	2.11e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs9467160	1.000	rs9461011	chr6:24440351	C/T	cg20631270	chr6:24437470	GPLD1	-0.46	-4.9	-0.3	1.77e-6	Liver enzyme levels;
KIRP	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	11.31	0.59	3.57e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26002218	chr14:103986227	CKB	0.26	5.02	0.31	9.69e-7	Body mass index;
KIRP	cis	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg21775007	chr8:11205619	TDH	-0.45	-5.83	-0.35	1.76e-8	Triglycerides;
KIRP	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.1	-0.41	1.37e-11	Fear of minor pain;
KIRP	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg00806126	chr19:22604979	ZNF98	-0.67	-7.04	-0.41	1.86e-11	Pain;
KIRP	cis	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13939156	chr17:80058883	NA	0.53	8.54	0.48	1.39e-15	Life satisfaction;
KIRP	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.41	4.98	0.3	1.22e-6	Diabetic retinopathy;
KIRP	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.73	9.31	0.51	7.61e-18	Mood instability;
KIRP	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg18944383	chr4:111397179	ENPEP	0.52	9.14	0.5	2.35e-17	Height;
KIRP	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.68	-7.56	-0.43	7.95e-13	Multiple sclerosis;
KIRP	cis	rs737008	0.959	rs11865598	chr16:11403432	T/C	cg00044050	chr16:11439710	C16orf75	0.6	7.08	0.41	1.49e-11	Obesity-related traits;
KIRP	cis	rs769267	0.501	rs2074295	chr19:19369435	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	6.28	0.37	1.51e-9	Tonsillectomy;
KIRP	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.73	-7.98	-0.45	5.56e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.71	8.58	0.48	1.12e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8177876	0.822	rs28672349	chr16:81114373	T/C	cg08591886	chr16:81111003	C16orf46	-0.59	-5.76	-0.34	2.45e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg15282417	chr9:129245246	FAM125B	0.46	8.01	0.45	4.55e-14	Intraocular pressure;
KIRP	cis	rs909341	0.818	rs6122154	chr20:62359345	C/T	cg11503966	chr20:62272292	STMN3	-0.42	-5.77	-0.35	2.32e-8	Atopic dermatitis;
KIRP	cis	rs2916247	0.954	rs4623481	chr8:93079345	T/G	cg10183463	chr8:93005414	RUNX1T1	-0.49	-6.28	-0.37	1.55e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9328573	0.935	rs12900347	chr15:100509459	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.38	-5.01	-0.3	1.02e-6	Urate levels in lean individuals;
KIRP	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-11.17	-0.58	1.02e-23	Colorectal cancer;
KIRP	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg10169327	chr19:45448959	APOC2	0.33	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.68	9.89	0.53	1.21e-19	Dupuytren's disease;
KIRP	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-9.01	-0.5	6e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.92	9.62	0.52	8.39e-19	Neuroticism;
KIRP	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg02297831	chr4:17616191	MED28	0.59	7.07	0.41	1.55e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg18490616	chr2:88469792	THNSL2	0.66	5.33	0.32	2.23e-7	Plasma clusterin levels;
KIRP	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19346786	chr7:2764209	NA	-0.37	-6.1	-0.36	4.18e-9	Height;
KIRP	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26314531	chr2:26401878	FAM59B	0.48	5.2	0.31	4.17e-7	Gut microbiome composition (summer);
KIRP	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.06	0.54	3.54e-20	Total body bone mineral density;
KIRP	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg24503407	chr1:205819492	PM20D1	0.43	4.96	0.3	1.32e-6	Prostate-specific antigen levels;
KIRP	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg10503236	chr1:231470652	EXOC8	-0.55	-7.51	-0.43	1.11e-12	Hemoglobin concentration;
KIRP	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg07701084	chr6:150067640	NUP43	0.5	5.48	0.33	1.04e-7	Lung cancer;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.78	11.98	0.61	2.39e-26	Menarche (age at onset);
KIRP	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.56	-0.39	3.16e-10	Uric acid levels;
KIRP	trans	rs112627313	1	rs112627313	chr3:45330051	T/A	cg00416945	chr16:88165722	NA	0.59	6.04	0.36	5.7e-9	Schizophrenia;
KIRP	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg13514129	chr1:39547527	MACF1	0.53	7.97	0.45	5.93e-14	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg23682824	chr7:23144976	KLHL7	0.56	6.81	0.4	7.54e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2071426	0.622	rs7919295	chr10:96772808	T/C	cg09036531	chr10:96991505	NA	-0.46	-5.34	-0.32	2.1e-7	Blood metabolite levels;
KIRP	cis	rs7771547	0.642	rs628213	chr6:36508646	T/C	cg04289385	chr6:36355825	ETV7	0.45	6.86	0.4	5.61e-11	Platelet distribution width;
KIRP	cis	rs10982256	0.817	rs10817631	chr9:117267942	G/T	cg13636371	chr9:117264095	DFNB31	-0.39	-5.01	-0.3	1.06e-6	Bipolar disorder;
KIRP	cis	rs8077577	0.945	rs62073611	chr17:18071961	C/G	cg18869244	chr17:18121946	NA	0.45	4.91	0.3	1.62e-6	Obesity-related traits;
KIRP	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg05255149	chr17:80675120	FN3KRP	0.49	5.44	0.33	1.25e-7	Glycated hemoglobin levels;
KIRP	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg11503966	chr20:62272292	STMN3	-0.41	-5.87	-0.35	1.41e-8	Atopic dermatitis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01953317	chr2:55642894	CCDC88A	0.38	6.06	0.36	5.06e-9	C-reactive protein;
KIRP	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.85	-10.37	-0.55	3.92e-21	Vitiligo;
KIRP	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.74	-10.95	-0.57	5.41e-23	Hip circumference;
KIRP	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.55	6.46	0.38	5.48e-10	Mean corpuscular volume;
KIRP	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg07382826	chr16:28625726	SULT1A1	0.51	5.83	0.35	1.72e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.71	9.08	0.5	3.61e-17	Bladder cancer;
KIRP	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg09695851	chr17:3907499	NA	0.44	5.15	0.31	5.34e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg26681399	chr22:41777847	TEF	-0.6	-4.95	-0.3	1.4e-6	Vitiligo;
KIRP	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.53	-6.47	-0.38	5.31e-10	Type 2 diabetes;
KIRP	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg00360474	chr6:37504404	NA	-0.45	-6.33	-0.37	1.13e-9	Cognitive performance;
KIRP	trans	rs7246760	0.867	rs56377135	chr19:9820116	C/T	cg02900749	chr2:68251473	NA	-1.19	-10.02	-0.54	4.82e-20	Pursuit maintenance gain;
KIRP	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg03808351	chr9:123631620	PHF19	0.4	5.41	0.33	1.52e-7	Rheumatoid arthritis;
KIRP	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	1.02	9.12	0.5	2.72e-17	Nonalcoholic fatty liver disease;
KIRP	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20135002	chr11:47629003	NA	-0.46	-5.07	-0.31	7.97e-7	Subjective well-being;
KIRP	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.88	-0.49	1.46e-16	Mood instability;
KIRP	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.5	7.35	0.42	2.91e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	1.23	10.82	0.57	1.43e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07648498	chr16:89883185	FANCA	0.4	5.15	0.31	5.22e-7	Vitiligo;
KIRP	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06850241	chr22:41845214	NA	-0.49	-5.51	-0.33	9.05e-8	Vitiligo;
KIRP	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.77	0.49	2.92e-16	Bipolar disorder;
KIRP	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.42	-6.27	-0.37	1.63e-9	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14576128	chr12:1100379	ERC1	0.49	6.05	0.36	5.3e-9	Parkinson's disease;
KIRP	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	7.1	0.41	1.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg13660082	chr14:53194042	PSMC6	-0.67	-6.51	-0.38	4.25e-10	Alzheimer's disease (late onset);
KIRP	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg17207736	chr8:142237307	SLC45A4	-0.43	-5.49	-0.33	9.81e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7538876	0.935	rs1408420	chr1:17754815	A/G	cg10329579	chr1:17754830	RCC2	0.38	4.96	0.3	1.33e-6	Basal cell carcinoma;
KIRP	cis	rs2688419	0.565	rs2688414	chr3:23078904	T/C	cg00327796	chr3:23032191	NA	-0.42	-5.93	-0.35	1.05e-8	Type 2 diabetes;
KIRP	cis	rs10518128	1.000	rs28624565	chr4:75713287	C/T	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08822215	chr16:89438651	ANKRD11	-0.47	-6.36	-0.38	9.9e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00585698	chr12:123750864	CDK2AP1	-0.49	-4.87	-0.3	2e-6	Platelet count;
KIRP	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg09658497	chr7:2847517	GNA12	-0.33	-4.99	-0.3	1.12e-6	Height;
KIRP	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.41	5.19	0.31	4.45e-7	Multiple sclerosis;
KIRP	cis	rs79149102	0.737	rs12593975	chr15:75189591	G/A	cg09165964	chr15:75287851	SCAMP5	-0.88	-5.49	-0.33	9.8e-8	Lung cancer;
KIRP	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2457480	0.778	rs1704217	chr10:44729307	T/C	cg09554077	chr10:44749378	NA	0.7	7.7	0.44	3.41e-13	Coronary artery disease;
KIRP	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	1.01	16.62	0.73	4.45e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg23649088	chr2:200775458	C2orf69	0.67	5.84	0.35	1.68e-8	Schizophrenia;
KIRP	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-0.94	-13.58	-0.65	9.95e-32	Tonsillectomy;
KIRP	cis	rs714515	0.569	rs9425628	chr1:172451442	A/T	cg01573306	chr1:172330400	DNM3	0.39	4.87	0.3	2e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	13.71	0.66	3.61e-32	Platelet count;
KIRP	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg18338521	chr10:69995036	NA	-0.4	-5.13	-0.31	5.96e-7	Optic disc area;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7523273	0.568	rs11118668	chr1:208017915	A/G	cg22525895	chr1:207977042	MIR29B2	0.54	5.32	0.32	2.31e-7	Schizophrenia;
KIRP	cis	rs2191566	1.000	rs390369	chr19:44506984	C/T	cg18700516	chr19:44507157	ZNF230	0.47	5.47	0.33	1.12e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg08975724	chr8:8085496	FLJ10661	0.51	5.95	0.35	9.32e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.13	0.54	2.22e-20	Cognitive test performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00369061	chr11:129765581	NFRKB	0.51	6.58	0.39	2.85e-10	Parkinson's disease;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.85	14.15	0.67	1.16e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.18	-0.31	4.67e-7	Bipolar disorder;
KIRP	cis	rs258892	0.947	rs4443401	chr5:72213483	G/A	cg21869765	chr5:72125136	TNPO1	0.58	6.51	0.38	4.28e-10	Small cell lung carcinoma;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.11e-7	Life satisfaction;
KIRP	cis	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg08773314	chr2:239334832	ASB1	-0.53	-5.36	-0.32	1.95e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.02e-8	Motion sickness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11757651	chr6:141807188	NA	-0.43	-6.48	-0.38	4.95e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7221595	0.825	rs8076743	chr17:3916537	A/T	cg09597638	chr17:3907349	NA	0.61	6.41	0.38	7.38e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2591576	0.718	rs10063607	chr5:165436083	A/G	cg13976338	chr5:165423657	NA	-0.71	-10.42	-0.55	2.73e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2274273	0.615	rs17672058	chr14:55673394	C/T	cg04306507	chr14:55594613	LGALS3	0.41	5.41	0.33	1.51e-7	Protein biomarker;
KIRP	cis	rs13102973	0.899	rs13119071	chr4:135909862	G/T	cg14419869	chr4:135874104	NA	0.47	7.26	0.42	5.14e-12	Subjective well-being;
KIRP	cis	rs4805272	1.000	rs61697193	chr19:29321595	C/T	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg18836844	chr8:998428	NA	0.38	4.91	0.3	1.7e-6	Schizophrenia;
KIRP	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg08975724	chr8:8085496	FLJ10661	0.62	8.7	0.49	4.72e-16	Neuroticism;
KIRP	cis	rs7827545	1.000	rs6578229	chr8:135562453	T/G	cg17885191	chr8:135476712	NA	0.52	6.26	0.37	1.66e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs12022452	0.591	rs12049435	chr1:40990560	C/T	cg25568243	chr1:40974465	DEM1	0.53	5.71	0.34	3.16e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs2072732	0.821	rs12033401	chr1:2944086	C/T	cg11731671	chr1:2995604	PRDM16	-0.55	-6.17	-0.37	2.76e-9	Plateletcrit;
KIRP	cis	rs7760535	0.826	rs3777905	chr6:111870588	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.45	-5.71	-0.34	3.22e-8	Metabolic traits;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04395431	chr14:45619710	FANCM	0.39	6.18	0.37	2.71e-9	C-reactive protein;
KIRP	cis	rs4783244	0.862	rs1541928	chr16:82656804	A/C	cg09415485	chr16:82663111	CDH13	0.29	5.62	0.34	5.25e-8	Adiponectin levels;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.2	-0.55	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18252515	chr7:66147081	NA	-0.42	-4.91	-0.3	1.69e-6	Aortic root size;
KIRP	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg04362960	chr10:104952993	NT5C2	0.51	5.58	0.34	6.43e-8	Colorectal cancer;
KIRP	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.6	-0.34	5.74e-8	Height;
KIRP	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg00262122	chr8:11665843	FDFT1	0.44	5.48	0.33	1.04e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.38	5.1	0.31	6.67e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6832769	0.961	rs11947623	chr4:56349190	C/A	cg09317128	chr4:56265301	TMEM165	0.55	7.44	0.43	1.63e-12	Personality dimensions;
KIRP	cis	rs11955398	0.716	rs1379117	chr5:59942309	T/C	cg02684056	chr5:59996105	DEPDC1B	0.42	4.93	0.3	1.48e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg04989706	chr14:50066350	PPIL5	-0.49	-6.04	-0.36	5.66e-9	Carotid intima media thickness;
KIRP	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	22.53	0.82	9.97e-62	Chronic sinus infection;
KIRP	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.76	-10.64	-0.56	5.3e-22	Blood metabolite levels;
KIRP	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.3	0.47	6.97e-15	Neutrophil percentage of white cells;
KIRP	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.52	-6.28	-0.37	1.56e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg22974920	chr21:40686053	BRWD1	0.49	5.59	0.34	6e-8	Cognitive function;
KIRP	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.37	-0.47	4.47e-15	Morning vs. evening chronotype;
KIRP	cis	rs7923609	0.875	rs10740118	chr10:65101207	C/G	cg01631684	chr10:65280961	REEP3	0.48	5.49	0.33	1.01e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.4	9.87	0.53	1.42e-19	Corneal astigmatism;
KIRP	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-5.37	-0.32	1.86e-7	Asthma;
KIRP	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.91	10.47	0.56	1.82e-21	Neuroticism;
KIRP	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg25272121	chr1:152190972	HRNR	0.42	4.9	0.3	1.78e-6	Inflammatory skin disease;
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.6	8.94	0.5	9.48e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.11	-0.31	6.32e-7	Pulmonary function;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg02742455	chr11:66489646	SPTBN2	0.52	6.03	0.36	5.98e-9	Response to statin therapy;
KIRP	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.93	-16.07	-0.72	3.34e-40	Metabolic syndrome;
KIRP	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.44	7.03	0.41	2.07e-11	Testicular germ cell tumor;
KIRP	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.58	-6.85	-0.4	5.95e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7005380	0.581	rs28461628	chr8:120940867	G/A	cg21645572	chr8:120931649	DEPDC6	-0.49	-6.61	-0.39	2.39e-10	Interstitial lung disease;
KIRP	cis	rs8027181	0.839	rs8025333	chr15:73025121	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.5	7.4	0.43	2.09e-12	Triglyceride levels;
KIRP	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-5.79	-0.35	2.14e-8	Lung cancer;
KIRP	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg04166393	chr7:2884313	GNA12	0.7	8.45	0.47	2.62e-15	Height;
KIRP	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.39	6.63	0.39	2.07e-10	Heart rate;
KIRP	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg17507749	chr15:85114479	UBE2QP1	0.87	9.92	0.53	1e-19	Schizophrenia;
KIRP	trans	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	6.63	0.39	2.09e-10	Schizophrenia;
KIRP	cis	rs4363385	0.667	rs11803197	chr1:152934420	G/A	cg07796016	chr1:152779584	LCE1C	-0.43	-5.16	-0.31	5.12e-7	Inflammatory skin disease;
KIRP	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.58	-0.34	6.36e-8	Colorectal cancer;
KIRP	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs1891275	0.515	rs4244930	chr10:93466849	T/C	cg07889827	chr10:93443413	NA	-0.43	-7.33	-0.42	3.29e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg00981070	chr1:2046702	PRKCZ	-0.33	-5.8	-0.35	2.03e-8	Height;
KIRP	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.43	-5.04	-0.31	9.16e-7	Aortic root size;
KIRP	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.87	-0.35	1.37e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg20578329	chr17:80767326	TBCD	-0.78	-8.31	-0.47	6.44e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.86	0.35	1.45e-8	Monocyte percentage of white cells;
KIRP	cis	rs11671005	0.651	rs55716128	chr19:59048754	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.58	-6.69	-0.39	1.47e-10	Mean platelet volume;
KIRP	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.15	0.31	5.34e-7	Educational attainment;
KIRP	cis	rs9788682	0.747	rs2869045	chr15:78718899	T/C	cg06917634	chr15:78832804	PSMA4	0.56	5.43	0.33	1.38e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs8093481	1.000	rs3748422	chr18:10691216	G/A	cg21165219	chr18:10698044	FAM38B	-0.44	-5.49	-0.33	9.81e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08805041	chr16:621841	PIGQ	-0.37	-5.09	-0.31	7.12e-7	Height;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.74	11.5	0.59	8.8e-25	Menarche (age at onset);
KIRP	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg24747557	chr10:131355152	MGMT	-0.45	-6.15	-0.36	3.15e-9	Response to temozolomide;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24114822	chr1:84542225	NA	-0.5	-7.51	-0.43	1.12e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs62413470	1.000	rs12189567	chr6:55933942	A/G	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	trans	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.76	-0.4	1.02e-10	Neuroticism;
KIRP	cis	rs5753618	0.583	rs2273251	chr22:31843567	G/C	cg02404636	chr22:31891804	SFI1	0.53	6.08	0.36	4.63e-9	Colorectal cancer;
KIRP	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	6.91	0.4	4.12e-11	Monocyte count;
KIRP	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg13072238	chr3:49761600	GMPPB	0.64	5.57	0.33	6.76e-8	Menarche (age at onset);
KIRP	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg17885191	chr8:135476712	NA	0.53	6.14	0.36	3.31e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs28834970	0.925	rs2322599	chr8:27211910	G/A	cg23693289	chr8:27183097	PTK2B	-0.47	-5.89	-0.35	1.26e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg26384229	chr12:38710491	ALG10B	0.61	7.97	0.45	5.89e-14	Bladder cancer;
KIRP	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg05220968	chr6:146057943	EPM2A	0.39	5.01	0.3	1.06e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg00405596	chr8:11794950	NA	0.48	6.09	0.36	4.25e-9	Retinal vascular caliber;
KIRP	cis	rs6743226	0.811	rs10933537	chr2:242154930	C/G	cg10021735	chr2:242295487	FARP2	-0.45	-5.78	-0.35	2.29e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	trans	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg17422427	chr2:241507521	RNPEPL1	-0.56	-6.23	-0.37	2.03e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1941687	0.797	rs12967889	chr18:31399371	G/A	cg27147174	chr7:100797783	AP1S1	-0.54	-6.57	-0.39	3.05e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2904967	0.929	rs611910	chr11:65049278	A/G	cg12562828	chr11:65076843	NA	0.58	8.61	0.48	9.09e-16	Mean corpuscular volume;
KIRP	cis	rs10207060	0.500	rs6731870	chr2:240708096	C/A	cg20333904	chr2:240724165	NA	-0.41	-4.92	-0.3	1.58e-6	Obesity-related traits;
KIRP	cis	rs13226913	0.967	rs2881755	chr7:7256439	C/T	cg04827551	chr7:7268805	C1GALT1	-0.36	-5.17	-0.31	4.82e-7	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	1.05	22.23	0.82	8.86e-61	Parkinson's disease;
KIRP	cis	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.22e-12	Morning vs. evening chronotype;
KIRP	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-6.03	-0.36	5.81e-9	Joint mobility (Beighton score);
KIRP	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg23216685	chr1:86174607	ZNHIT6	0.53	6.75	0.4	1.07e-10	Urate levels in overweight individuals;
KIRP	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.17	0.31	4.76e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.84	9.38	0.51	4.63e-18	High light scatter reticulocyte count;
KIRP	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.21	-0.32	4.01e-7	Bipolar disorder;
KIRP	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.33	-5.02	-0.31	9.77e-7	Mean corpuscular volume;
KIRP	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg14541582	chr5:601475	NA	-0.58	-6.59	-0.39	2.73e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7236492	0.872	rs74949301	chr18:77229409	C/G	cg15644404	chr18:77186268	NFATC1	-0.92	-7.25	-0.42	5.48e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1829883	0.898	rs2460684	chr5:98776329	C/T	cg08333243	chr5:99726346	NA	-0.39	-5.18	-0.31	4.69e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg09264619	chr17:80180166	NA	-0.37	-5.36	-0.32	1.94e-7	Life satisfaction;
KIRP	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.23	-0.32	3.61e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.73	7.5	0.43	1.17e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.71e-31	Diabetic retinopathy;
KIRP	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg03647239	chr10:116582469	FAM160B1	0.42	5.08	0.31	7.44e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.37	0.43	2.6e-12	Major depressive disorder;
KIRP	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg13072238	chr3:49761600	GMPPB	0.57	5.65	0.34	4.34e-8	Menarche (age at onset);
KIRP	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg11645453	chr3:52864694	ITIH4	-0.35	-5.43	-0.33	1.33e-7	Body mass index;
KIRP	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.75	-9.89	-0.53	1.21e-19	Blood metabolite levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04100724	chr12:92539208	BTG1	0.6	7.4	0.43	2.16e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7546094	0.875	rs1110043	chr1:113236421	G/A	cg22162597	chr1:113214053	CAPZA1	-0.43	-5.63	-0.34	4.91e-8	Platelet distribution width;
KIRP	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.06	-0.41	1.71e-11	Joint mobility (Beighton score);
KIRP	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.93	12.86	0.63	2.65e-29	Cognitive function;
KIRP	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.67	9.4	0.51	3.87e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6992848	0.759	rs4736141	chr8:141139963	C/T	cg13911501	chr8:141220320	TRAPPC9	0.41	4.99	0.3	1.15e-6	Response to amphetamines;
KIRP	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.43	-0.38	6.75e-10	Height;
KIRP	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.53	7.3	0.42	3.87e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs6832769	0.925	rs1965467	chr4:56322740	G/A	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs73058052	0.542	rs10414643	chr19:50097784	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.49	5.9	0.35	1.19e-8	Fibrinogen levels;
KIRP	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	5.79	0.35	2.15e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11877825	0.813	rs34276557	chr18:10571005	A/G	cg07277756	chr18:10589357	NA	0.5	6.08	0.36	4.68e-9	Gut microbiota (bacterial taxa);
KIRP	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg16141378	chr3:129829833	LOC729375	0.62	8.54	0.48	1.44e-15	Retinal vascular caliber;
KIRP	cis	rs1659258	0.568	rs1258409	chr2:88619238	G/A	cg00685853	chr2:88648947	NA	-0.5	-5.92	-0.35	1.05e-8	Visceral fat;
KIRP	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg10189774	chr4:17578691	LAP3	0.44	5.28	0.32	2.9e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.24	-0.32	3.53e-7	Pulmonary function;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.55	-7.23	-0.42	6.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-6.03	-0.36	5.92e-9	Lung cancer;
KIRP	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg23736307	chr8:27182930	PTK2B	0.55	7.04	0.41	1.9e-11	Neuroticism;
KIRP	cis	rs13102973	0.674	rs11730572	chr4:135885397	C/T	cg14419869	chr4:135874104	NA	0.38	6.02	0.36	6.18e-9	Subjective well-being;
KIRP	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.78	-10.61	-0.56	6.76e-22	Aortic root size;
KIRP	cis	rs2594989	1.000	rs2594967	chr3:11349748	T/G	cg01796438	chr3:11312864	ATG7	-0.61	-7.31	-0.42	3.66e-12	Circulating chemerin levels;
KIRP	cis	rs3136516	0.935	rs11038993	chr11:46810916	A/C	cg16389345	chr11:46697382	NA	-0.56	-7.64	-0.44	4.78e-13	Venous thromboembolism;
KIRP	cis	rs6496667	0.779	rs8034045	chr15:90947899	T/C	cg10434728	chr15:90938212	IQGAP1	0.38	4.96	0.3	1.29e-6	Rheumatoid arthritis;
KIRP	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09699651	chr6:150184138	LRP11	0.56	7.52	0.43	1.04e-12	Testicular germ cell tumor;
KIRP	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg02367723	chr1:46378857	MAST2	-0.43	-4.93	-0.3	1.5e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg18225595	chr11:63971243	STIP1	-0.65	-5.89	-0.35	1.29e-8	Mean platelet volume;
KIRP	cis	rs504918	0.556	rs11719623	chr3:123978818	A/C	cg05766129	chr3:123988013	KALRN	-0.49	-6.03	-0.36	6e-9	Schizophrenia;
KIRP	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.04	0.36	5.72e-9	Alzheimer's disease (late onset);
KIRP	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.93	-0.3	1.49e-6	Prostate cancer;
KIRP	cis	rs10465746	0.570	rs11163884	chr1:84472760	A/G	cg10977910	chr1:84465055	TTLL7	0.47	5.73	0.34	2.94e-8	Obesity-related traits;
KIRP	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.44	5.97	0.36	8.4e-9	Blood metabolite levels;
KIRP	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.4	-6.35	-0.38	1.06e-9	Body mass index;
KIRP	cis	rs2929282	1	rs2929282	chr15:44245931	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	5.14	0.31	5.62e-7	Triglycerides;Triglyceride levels;
KIRP	cis	rs12134040	0.646	rs12734378	chr1:236511354	A/G	cg21399712	chr1:236511386	NA	0.53	7.37	0.43	2.66e-12	Urate levels (BMI interaction);
KIRP	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg03857632	chr5:75013392	C5orf37	-0.47	-6.24	-0.37	1.86e-9	Thyroid cancer;
KIRP	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg06223162	chr1:101003688	GPR88	-0.42	-8.35	-0.47	4.86e-15	Monocyte count;
KIRP	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.08	-15.4	-0.7	6.16e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12476592	0.571	rs2592386	chr2:63894064	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.94	-0.3	1.41e-6	Childhood ear infection;
KIRP	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg22974920	chr21:40686053	BRWD1	0.48	5.55	0.33	7.48e-8	Cognitive function;
KIRP	cis	rs67366981	0.925	rs66846709	chr14:77692812	G/A	cg22824376	chr14:77648248	TMEM63C	0.81	6.36	0.38	1e-9	Obsessive-compulsive symptoms;
KIRP	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg00122941	chr17:4613640	ARRB2	-0.68	-7.56	-0.43	7.76e-13	Lymphocyte counts;
KIRP	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg13385521	chr17:29058706	SUZ12P	0.52	5.06	0.31	8.24e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg16077055	chr2:106428750	NCK2	0.3	6.16	0.37	2.98e-9	Addiction;
KIRP	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg00800038	chr16:89945340	TCF25	-0.68	-5.0	-0.3	1.1e-6	Skin colour saturation;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.66	-9.36	-0.51	5.06e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.92	-0.49	1.09e-16	Mean corpuscular volume;
KIRP	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.76e-9	Breast cancer;
KIRP	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg16141378	chr3:129829833	LOC729375	0.62	8.55	0.48	1.32e-15	Triglycerides;
KIRP	cis	rs6834538	0.597	rs6822451	chr4:113463265	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.44	5.4	0.33	1.56e-7	Free thyroxine concentration;
KIRP	cis	rs7221595	0.825	rs4790552	chr17:3923366	G/A	cg21734707	chr17:3908241	ZZEF1	0.58	6.01	0.36	6.83e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg05347473	chr6:146136440	FBXO30	0.49	7.05	0.41	1.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	6.2	0.37	2.35e-9	Multiple sclerosis;
KIRP	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg06481639	chr22:41940642	POLR3H	-0.45	-4.99	-0.3	1.15e-6	Neuroticism;
KIRP	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg08992911	chr2:238395768	MLPH	0.45	5.55	0.33	7.24e-8	Prostate cancer;
KIRP	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.51	7.97	0.45	5.89e-14	Itch intensity from mosquito bite;
KIRP	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg05692746	chr2:100937584	LONRF2	-0.38	-4.98	-0.3	1.22e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg20302533	chr7:39170763	POU6F2	0.26	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg07395648	chr5:131743802	NA	0.53	6.28	0.37	1.5e-9	Lymphocyte counts;Fibrinogen;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg24854085	chr5:95158523	GLRX	0.55	6.63	0.39	2.07e-10	Educational attainment;
KIRP	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg00405596	chr8:11794950	NA	0.59	8.37	0.47	4.5e-15	Neuroticism;
KIRP	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.01	-0.36	6.63e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.25	-0.67	5.48e-34	Alzheimer's disease;
KIRP	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg07828340	chr4:882639	GAK	0.74	7.13	0.41	1.1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.41	-6.03	-0.36	5.84e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.23	0.42	6.21e-12	Prudent dietary pattern;
KIRP	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.48	4.96	0.3	1.3e-6	Total cholesterol levels;
KIRP	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-6.88	-0.4	4.83e-11	Aortic root size;
KIRP	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg12623918	chr2:306882	NA	0.41	5.09	0.31	7.2e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7851660	0.809	rs7032114	chr9:100656459	T/G	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-6.02	-0.36	6.36e-9	Vitiligo;
KIRP	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.64	-7.71	-0.44	3.09e-13	Non-response to antidepressants and depression;
KIRP	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg23719950	chr11:63933701	MACROD1	-0.63	-5.33	-0.32	2.21e-7	Mean platelet volume;
KIRP	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.05	0.69	9.78e-37	Platelet count;
KIRP	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.39	5.36	0.32	1.93e-7	Lewy body disease;
KIRP	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	6.12	0.36	3.76e-9	Menopause (age at onset);
KIRP	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.32	5.87	0.35	1.44e-8	Calcium levels;
KIRP	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.31	8.0	0.45	4.74e-14	Primary biliary cholangitis;
KIRP	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.53	5.24	0.32	3.46e-7	Diastolic blood pressure;
KIRP	cis	rs9420	0.528	rs11229075	chr11:57391023	A/C	cg23127183	chr11:57508653	C11orf31	-0.46	-5.35	-0.32	1.99e-7	Schizophrenia;
KIRP	trans	rs12517041	1.000	rs35670742	chr5:23281811	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.87	-8.13	-0.46	2.12e-14	Calcium levels;
KIRP	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.74	-10.54	-0.56	1.09e-21	Height;
KIRP	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.13	0.31	5.79e-7	Height;
KIRP	cis	rs8079658	0.951	rs114298253	chr17:63833653	C/G	cg18091269	chr17:63822838	CCDC46	-0.56	-7.66	-0.44	4.32e-13	Post bronchodilator FEV1;
KIRP	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.26	0.47	8.87e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	17.57	0.75	2.51e-45	Homoarginine levels;
KIRP	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.86	-11.53	-0.59	7.32e-25	Cognitive function;
KIRP	cis	rs2882877	0.560	rs11568351	chr2:190445194	C/G	cg10752008	chr2:190445175	SLC40A1	-0.55	-6.03	-0.36	6.01e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg02175503	chr12:58329896	NA	0.87	10.28	0.55	7.24e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.93	0.57	6.37e-23	Cognitive test performance;
KIRP	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	0.96	15.35	0.7	9.6e-38	Breast cancer;
KIRP	trans	rs9371601	0.859	rs488673	chr6:152719602	G/A	cg05529123	chr2:66910386	NA	-0.47	-6.49	-0.38	4.8e-10	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg11845111	chr2:191398756	TMEM194B	-0.93	-9.63	-0.52	7.68e-19	Diastolic blood pressure;
KIRP	cis	rs6484504	0.625	rs10835766	chr11:31374329	C/A	cg26647111	chr11:31128758	NA	0.43	4.99	0.3	1.12e-6	Red blood cell count;
KIRP	cis	rs2554380	0.943	rs2585040	chr15:84340468	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.17	-0.46	1.63e-14	Height;
KIRP	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.87	14.05	0.67	2.58e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.65	8.19	0.46	1.47e-14	Morning vs. evening chronotype;
KIRP	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.5	-0.38	4.38e-10	Axial length;
KIRP	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.62	7.56	0.43	8.11e-13	Type 2 diabetes;
KIRP	cis	rs7129556	0.737	rs2154972	chr11:77488825	G/A	cg12586386	chr11:77299805	AQP11	0.41	5.4	0.33	1.6e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.05	0.46	3.59e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.59e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg24315340	chr6:146058215	EPM2A	-0.37	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.26	0.42	4.99e-12	Prudent dietary pattern;
KIRP	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.23	0.32	3.55e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.66	-9.18	-0.51	1.83e-17	Colorectal cancer;
KIRP	cis	rs151997	0.925	rs27570	chr5:50191974	G/A	cg06027927	chr5:50259733	NA	0.59	7.37	0.43	2.57e-12	Callous-unemotional behaviour;
KIRP	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.48	6.02	0.36	6.39e-9	Initial pursuit acceleration;
KIRP	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.59	7.61	0.44	6.01e-13	Monocyte count;
KIRP	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-5.1	-0.31	6.84e-7	IgG glycosylation;
KIRP	cis	rs9547996	0.879	rs9547986	chr13:38203982	C/T	cg13634560	chr13:38173852	POSTN	-0.4	-5.59	-0.34	6.11e-8	Diastolic blood pressure;
KIRP	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.42	-0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.48	0.43	1.28e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.32	-0.55	5.54e-21	Hemoglobin concentration;
KIRP	trans	rs12529514	1.000	rs12529514	chr6:14096658	A/G	cg02955631	chr11:119293601	THY1	-0.61	-6.03	-0.36	5.82e-9	Rheumatoid arthritis;
KIRP	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg00338735	chr4:53728038	RASL11B	0.48	5.6	0.34	5.77e-8	Optic nerve measurement (cup area);
KIRP	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg11707556	chr5:10655725	ANKRD33B	0.55	6.84	0.4	6.1e-11	Height;
KIRP	cis	rs7923609	1.000	rs10761742	chr10:65085048	A/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.44	-0.33	1.32e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.79	-0.35	2.15e-8	Endometrial cancer;
KIRP	cis	rs897080	0.515	rs1067368	chr2:44654889	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.83	0.35	1.77e-8	Height;
KIRP	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.61	-7.14	-0.41	1.03e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.7	9.85	0.53	1.68e-19	Hip circumference;
KIRP	cis	rs6921919	0.583	rs2071965	chr6:28403225	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.31	-0.37	1.29e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4654899	0.680	rs10916900	chr1:21239059	C/G	cg08890418	chr1:21044141	KIF17	0.35	5.3	0.32	2.56e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.73	6.44	0.38	6.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00677455	chr12:58241039	CTDSP2	-0.52	-6.36	-0.38	9.94e-10	Multiple sclerosis;
KIRP	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.76	8.65	0.48	6.96e-16	Breast cancer;
KIRP	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg27205649	chr11:78285834	NARS2	-0.52	-4.85	-0.3	2.22e-6	Testicular germ cell tumor;
KIRP	cis	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg19171272	chr22:38449367	NA	-0.6	-9.0	-0.5	6.23e-17	Glioblastoma;Glioma;
KIRP	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.64	-0.39	1.98e-10	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.74	-9.84	-0.53	1.75e-19	Childhood ear infection;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg01763666	chr17:80159506	CCDC57	-0.36	-5.03	-0.31	9.64e-7	Life satisfaction;
KIRP	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg07936489	chr17:37558343	FBXL20	-0.57	-7.61	-0.44	5.83e-13	Asthma;
KIRP	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.35	-4.9	-0.3	1.76e-6	Hepatitis;
KIRP	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.41	-5.69	-0.34	3.59e-8	Plateletcrit;
KIRP	cis	rs1021993	0.597	rs17014323	chr1:209513852	G/A	cg24446417	chr1:209558027	NA	-0.49	-4.94	-0.3	1.42e-6	Gut microbiome composition (winter);
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.87	-0.6	5.24e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2072732	0.898	rs2981856	chr1:2972524	T/C	cg11731671	chr1:2995604	PRDM16	-0.42	-5.56	-0.33	6.87e-8	Plateletcrit;
KIRP	cis	rs77505915	0.512	rs12921808	chr16:75383984	T/C	cg07303275	chr16:75499416	TMEM170A	-0.5	-6.4	-0.38	7.63e-10	Migraine;
KIRP	cis	rs4664293	0.667	rs3815876	chr2:160640151	A/G	cg08347373	chr2:160653686	CD302	-0.38	-5.99	-0.36	7.45e-9	Monocyte percentage of white cells;
KIRP	cis	rs1971762	1.000	rs3892761	chr12:54070445	A/T	cg16917193	chr12:54089295	NA	0.68	9.08	0.5	3.77e-17	Height;
KIRP	cis	rs6681460	1.000	rs964574	chr1:67062885	T/C	cg02459107	chr1:67143332	SGIP1	0.48	6.9	0.4	4.42e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.51	-7.28	-0.42	4.5e-12	Red blood cell count;
KIRP	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg15068132	chr12:102092402	CHPT1	-0.39	-5.12	-0.31	6.31e-7	Blood protein levels;
KIRP	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg03999872	chr20:62272968	STMN3	0.44	5.18	0.31	4.71e-7	Prostate cancer;
KIRP	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.71e-36	Prostate cancer;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg09264619	chr17:80180166	NA	0.34	4.89	0.3	1.82e-6	Life satisfaction;
KIRP	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.74	7.45	0.43	1.53e-12	Uric acid levels;
KIRP	trans	rs13170463	0.579	rs74634376	chr5:8048232	C/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs4671400	0.571	rs12615222	chr2:61494895	C/T	cg15711740	chr2:61764176	XPO1	0.62	6.7	0.39	1.38e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs11577318	0.538	rs10902745	chr1:26687070	G/C	cg00852783	chr1:26633632	UBXN11	-0.46	-5.24	-0.32	3.46e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg05370193	chr1:21551575	ECE1	0.43	6.02	0.36	6.27e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg10189774	chr4:17578691	LAP3	0.49	5.79	0.35	2.15e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.52	5.08	0.31	7.33e-7	Recombination rate (females);
KIRP	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.37	0.32	1.86e-7	Menopause (age at onset);
KIRP	cis	rs4950322	0.570	rs72692907	chr1:146773610	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.4	-0.33	1.54e-7	Protein quantitative trait loci;
KIRP	cis	rs1538970	0.847	rs1771550	chr1:45883565	C/T	cg05343316	chr1:45956843	TESK2	-0.67	-7.77	-0.44	2.18e-13	Platelet count;
KIRP	cis	rs1559088	0.895	rs7259582	chr19:33593979	A/G	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.64	-0.39	1.95e-10	Monocyte percentage of white cells;
KIRP	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.63	9.41	0.51	3.71e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4073416	0.518	rs10150412	chr14:65916791	C/T	cg03016385	chr14:66212404	NA	-0.54	-6.71	-0.39	1.35e-10	N-glycan levels;
KIRP	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg16141378	chr3:129829833	LOC729375	-0.49	-6.12	-0.36	3.57e-9	Mood instability;
KIRP	cis	rs258892	0.895	rs3846645	chr5:72023160	T/A	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs1440410	0.798	rs34168479	chr4:144140592	G/A	cg01719995	chr4:144104893	USP38	0.44	6.02	0.36	6.35e-9	Ischemic stroke;
KIRP	cis	rs6504340	0.739	rs872760	chr17:46668951	A/G	cg04904318	chr17:46607828	HOXB1	-0.55	-5.68	-0.34	3.77e-8	Primary tooth development (number of teeth);
KIRP	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.48	5.03	0.31	9.31e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.51	6.68	0.39	1.55e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.76	-9.39	-0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg07585502	chr8:101912084	NA	-0.61	-8.58	-0.48	1.1e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	6.88	0.4	4.84e-11	Bipolar disorder;
KIRP	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	10.81	0.57	1.55e-22	Personality dimensions;
KIRP	cis	rs4356932	1.000	rs9884374	chr4:76946718	A/T	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.05e-8	Skin colour saturation;
KIRP	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg21890820	chr11:65308645	LTBP3	0.58	5.57	0.33	6.67e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-1.3	-13.13	-0.64	3.27e-30	Post bronchodilator FEV1;
KIRP	cis	rs2275565	0.872	rs72762130	chr1:237056710	A/G	cg17297354	chr1:237056641	MTR	-0.47	-5.09	-0.31	7.23e-7	Homocysteine levels;
KIRP	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg09699651	chr6:150184138	LRP11	0.39	5.11	0.31	6.52e-7	Lung cancer;
KIRP	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.85	-11.26	-0.58	5.56e-24	Type 2 diabetes;
KIRP	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	7.08	0.41	1.49e-11	Response to antipsychotic treatment;
KIRP	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg06102954	chr21:42741788	MX2	0.55	7.7	0.44	3.41e-13	Melanoma;
KIRP	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg11235152	chr1:67600687	NA	0.75	11.12	0.58	1.49e-23	Psoriasis;
KIRP	cis	rs4742903	0.527	rs7042705	chr9:106863047	C/T	cg14250997	chr9:106856677	SMC2	0.44	6.05	0.36	5.22e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03226245	chr19:36486125	SDHAF1	0.68	6.4	0.38	7.81e-10	Lung function (FEV1);
KIRP	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.38	-0.38	8.58e-10	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24626003	chr11:6502573	ARFIP2;FXC1	0.48	6.13	0.36	3.44e-9	Parkinson's disease;
KIRP	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg14458575	chr2:238380390	NA	0.56	7.64	0.44	4.9e-13	Prostate cancer;
KIRP	cis	rs2625529	0.668	rs12591338	chr15:72556847	T/A	cg16672083	chr15:72433130	SENP8	-0.44	-5.26	-0.32	3.14e-7	Red blood cell count;
KIRP	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.36	-0.32	1.91e-7	Cholesterol, total;
KIRP	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02807482	chr3:125708958	NA	-0.53	-5.35	-0.32	2.04e-7	Blood pressure (smoking interaction);
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.45	5.42	0.33	1.39e-7	Longevity;Endometriosis;
KIRP	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26207909	chr14:103986467	CKB	0.74	10.59	0.56	7.51e-22	Body mass index;
KIRP	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.46	-5.02	-0.3	1.01e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg26513180	chr16:89883248	FANCA	0.82	5.61	0.34	5.48e-8	Skin colour saturation;
KIRP	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.6	7.19	0.42	7.88e-12	QRS duration;
KIRP	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16257484	chr1:155239421	CLK2	0.56	7.09	0.41	1.43e-11	Interleukin-4 levels;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	10.85	0.57	1.15e-22	Lymphocyte counts;
KIRP	cis	rs7538876	1.000	rs12134662	chr1:17724767	A/G	cg07394400	chr1:17752023	RCC2	-0.34	-4.85	-0.3	2.24e-6	Basal cell carcinoma;
KIRP	cis	rs494562	0.892	rs515980	chr6:86119917	C/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6016377	0.689	rs6102039	chr20:39195039	T/G	cg06665391	chr20:39312290	NA	0.45	5.66	0.34	4.26e-8	Birth weight;
KIRP	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.69	6.69	0.39	1.51e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.48	-0.52	2.18e-18	Coronary artery disease;
KIRP	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03605463	chr16:89740564	NA	-0.43	-5.06	-0.31	8.39e-7	Vitiligo;
KIRP	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg21466736	chr12:48725269	NA	-0.46	-5.88	-0.35	1.32e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg05025164	chr4:1340916	KIAA1530	0.52	6.79	0.4	8.17e-11	Longevity;
KIRP	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.63	-8.37	-0.47	4.31e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs71277158	0.688	rs888507	chr3:169811039	G/C	cg04067573	chr3:169899625	PHC3	0.63	5.93	0.35	1.01e-8	Prostate cancer;
KIRP	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.15	-0.46	1.83e-14	Neuroticism;
KIRP	cis	rs6882076	1.000	rs6878680	chr5:156387137	G/C	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.03	-0.41	2.04e-11	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs3924048	0.574	rs11121930	chr1:12616956	C/A	cg00291366	chr1:12616550	NA	0.45	6.37	0.38	9.43e-10	Optic cup area;
KIRP	cis	rs7590368	1.000	rs55771723	chr2:10961902	T/C	cg15705551	chr2:10952987	PDIA6	0.46	4.94	0.3	1.44e-6	Educational attainment (years of education);
KIRP	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07930192	chr7:1003750	NA	0.4	4.93	0.3	1.5e-6	Longevity;Endometriosis;
KIRP	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.04	-0.36	5.77e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.28	0.37	1.52e-9	Lung cancer;
KIRP	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.11	-0.41	1.26e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10782582	0.609	rs1796810	chr1:76403305	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.42	-0.38	6.98e-10	Daytime sleep phenotypes;
KIRP	cis	rs11997175	0.511	rs4613957	chr8:33673130	C/T	cg04338863	chr8:33670619	NA	-0.46	-6.21	-0.37	2.2e-9	Body mass index;
KIRP	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg26681399	chr22:41777847	TEF	0.54	5.32	0.32	2.32e-7	Vitiligo;
KIRP	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg16926213	chr1:1841314	NA	0.33	5.6	0.34	5.86e-8	Body mass index;
KIRP	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg23752985	chr2:85803571	VAMP8	-0.54	-7.79	-0.44	1.87e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs12230513	0.732	rs60683621	chr12:55863224	C/G	cg11794356	chr12:55725991	OR6C3	-0.53	-6.46	-0.38	5.66e-10	Contrast sensitivity;
KIRP	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	5.81	0.35	1.94e-8	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg08890418	chr1:21044141	KIF17	-0.43	-6.37	-0.38	9.35e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs13359291	0.596	rs74661587	chr5:122457125	A/G	cg16368670	chr5:122501738	PRDM6	-0.48	-5.47	-0.33	1.13e-7	Systolic blood pressure;
KIRP	cis	rs3736594	0.546	rs6734059	chr2:27808154	C/T	cg27432699	chr2:27873401	GPN1	-0.55	-6.07	-0.36	4.87e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-6.09	-0.36	4.41e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg22437258	chr11:111473054	SIK2	0.54	6.18	0.37	2.59e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg02375832	chr11:62437615	C11orf48	-0.42	-5.21	-0.32	3.95e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16405210	chr4:1374714	KIAA1530	-0.58	-8.25	-0.47	9.5e-15	Longevity;
KIRP	trans	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg16141378	chr3:129829833	LOC729375	0.6	8.0	0.45	4.97e-14	Triglycerides;
KIRP	cis	rs9826463	0.757	rs113288103	chr3:142175321	C/T	cg20824294	chr3:142316082	PLS1	0.46	6.71	0.39	1.36e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.13	0.31	5.87e-7	Tonsillectomy;
KIRP	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg16141378	chr3:129829833	LOC729375	0.57	7.64	0.44	4.8e-13	Triglycerides;
KIRP	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.47	5.66	0.34	4.11e-8	Resistin levels;
KIRP	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.86	-0.35	1.52e-8	IgG glycosylation;
KIRP	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg21644426	chr2:191273491	MFSD6	-0.51	-4.85	-0.3	2.15e-6	Diastolic blood pressure;
KIRP	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg21775007	chr8:11205619	TDH	-0.47	-5.82	-0.35	1.8e-8	Triglycerides;
KIRP	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg05527609	chr1:210001259	C1orf107	0.42	5.1	0.31	6.91e-7	Red blood cell count;
KIRP	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg21827317	chr3:136751795	NA	0.39	5.33	0.32	2.23e-7	Neuroticism;
KIRP	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.05	-0.31	8.75e-7	Red blood cell count;
KIRP	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg16141378	chr3:129829833	LOC729375	0.49	6.7	0.39	1.41e-10	Triglycerides;
KIRP	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.85	-10.39	-0.55	3.46e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg24642439	chr20:33292090	TP53INP2	0.55	7.32	0.42	3.6e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg11833968	chr6:79620685	NA	-0.46	-6.88	-0.4	4.83e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg06740227	chr12:86229804	RASSF9	0.5	6.22	0.37	2.16e-9	Major depressive disorder;
KIRP	cis	rs1635	0.655	rs58019071	chr6:28304016	T/C	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs11583043	0.575	rs12727971	chr1:101589175	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.05	0.31	8.44e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.73	-0.34	2.97e-8	Body mass index;
KIRP	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg06742321	chr12:123595122	PITPNM2	0.46	5.7	0.34	3.35e-8	Platelet count;
KIRP	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.63	-10.2	-0.55	1.38e-20	Prostate cancer;
KIRP	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.47	6.5	0.38	4.37e-10	Testicular germ cell tumor;
KIRP	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg26517889	chr13:25497356	CENPJ	0.94	6.27	0.37	1.62e-9	P wave terminal force;
KIRP	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.26	-0.37	1.72e-9	QT interval;
KIRP	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.76	0.57	2.19e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs3105593	1.000	rs3131573	chr15:50869601	G/A	cg05456662	chr15:50716270	USP8	0.42	5.18	0.31	4.7e-7	QT interval;
KIRP	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg06102403	chr20:30458708	TTLL9;DUSP15	0.54	6.04	0.36	5.53e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs997295	1.000	rs938878	chr15:67993366	C/T	cg24579218	chr15:68104479	NA	0.37	5.62	0.34	5.06e-8	Motion sickness;
KIRP	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.52	-6.59	-0.39	2.63e-10	Systemic lupus erythematosus;
KIRP	cis	rs7712401	0.601	rs246269	chr5:122256741	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.28	0.32	2.78e-7	Mean platelet volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25456317	chr4:123160876	KIAA1109	0.4	6.05	0.36	5.42e-9	Survival in pancreatic cancer;
KIRP	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.86	-11.24	-0.58	6.5e-24	Cognitive function;
KIRP	trans	rs1462872	0.736	rs383632	chr8:31806048	T/C	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs4728302	0.869	rs2059298	chr7:133603245	C/G	cg10665199	chr7:133106180	EXOC4	0.46	5.61	0.34	5.51e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.63	7.69	0.44	3.44e-13	Coronary artery disease;
KIRP	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.2	0.42	7.25e-12	Morning vs. evening chronotype;
KIRP	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12292205	chr6:26970375	C6orf41	-0.58	-6.2	-0.37	2.37e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8018808	0.935	rs4903584	chr14:77934758	A/G	cg20045696	chr14:77926864	AHSA1	0.45	5.46	0.33	1.18e-7	Myeloid white cell count;
KIRP	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1424233	0.935	rs751043	chr16:79686458	A/G	cg11120865	chr14:21853037	SUPT16H	0.38	6.28	0.37	1.54e-9	Obesity;
KIRP	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg21605333	chr4:119757512	SEC24D	1.54	10.69	0.56	3.77e-22	Cannabis dependence symptom count;
KIRP	cis	rs2274273	0.624	rs10146637	chr14:55744810	G/A	cg04306507	chr14:55594613	LGALS3	0.41	5.67	0.34	3.95e-8	Protein biomarker;
KIRP	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg19442545	chr10:75533431	FUT11	-0.37	-5.0	-0.3	1.09e-6	Inflammatory bowel disease;
KIRP	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.09	24.91	0.85	3.36e-69	Multiple myeloma;
KIRP	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.65	0.34	4.5e-8	Coronary artery disease;
KIRP	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	1.23	10.48	0.56	1.74e-21	Gut microbiota (bacterial taxa);
KIRP	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.56	7.66	0.44	4.23e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs7688540	0.623	rs11735968	chr4:238820	A/G	cg17891759	chr4:299121	NA	-0.51	-5.27	-0.32	2.93e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs981844	1.000	rs17299041	chr4:154673127	T/C	cg14289246	chr4:154710475	SFRP2	0.67	7.53	0.43	9.88e-13	Response to statins (LDL cholesterol change);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19681357	chr19:14261858	LPHN1	-0.52	-6.36	-0.38	9.99e-10	Parkinson's disease;
KIRP	cis	rs17095355	1.000	rs11194940	chr10:111742223	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.1	-0.36	4.03e-9	Biliary atresia;
KIRP	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	6.04	0.36	5.81e-9	Type 2 diabetes;
KIRP	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg05370193	chr1:21551575	ECE1	0.42	5.89	0.35	1.28e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.89	9.7	0.53	4.76e-19	Gut microbiome composition (summer);
KIRP	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.53	7.22	0.42	6.38e-12	Kawasaki disease;
KIRP	cis	rs859767	0.501	rs1568120	chr2:135406890	A/G	cg12500956	chr2:135428796	TMEM163	-0.41	-5.59	-0.34	6.07e-8	Neuroticism;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.37	-4.95	-0.3	1.39e-6	Blood metabolite levels;
KIRP	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg12573674	chr2:1569213	NA	0.58	5.15	0.31	5.29e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.99	17.56	0.75	2.75e-45	Breast cancer;
KIRP	cis	rs1318772	0.932	rs2914152	chr5:112895674	A/G	cg12552261	chr5:112820674	MCC	0.78	5.38	0.32	1.74e-7	F-cell distribution;
KIRP	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg24848339	chr3:12840334	CAND2	0.33	5.36	0.32	1.89e-7	P wave duration;
KIRP	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04417954	chr15:91073943	CRTC3	0.58	6.54	0.38	3.61e-10	Lung cancer in ever smokers;
KIRP	cis	rs7941030	0.934	rs11601869	chr11:122528023	G/A	cg20555462	chr11:122535518	UBASH3B	-0.45	-5.47	-0.33	1.1e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs11874712	0.563	rs2850646	chr18:43674646	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.38	-5.66	-0.34	4.18e-8	Migraine - clinic-based;
KIRP	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg17646820	chr3:66848679	NA	0.74	9.82	0.53	2e-19	Type 2 diabetes;
KIRP	trans	rs7980799	0.933	rs11052705	chr12:33588388	T/C	cg26384229	chr12:38710491	ALG10B	-0.56	-6.91	-0.4	4.07e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg15557168	chr22:42548783	NA	-0.37	-5.3	-0.32	2.61e-7	Cognitive function;
KIRP	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Body mass index;
KIRP	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-6.87	-0.4	5.11e-11	Response to antipsychotic treatment;
KIRP	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	8.45	0.47	2.61e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg04989706	chr14:50066350	PPIL5	-0.46	-5.5	-0.33	9.64e-8	Carotid intima media thickness;
KIRP	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.63	8.71	0.49	4.53e-16	Bladder cancer;
KIRP	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-8.27	-0.47	8.5e-15	Longevity;Endometriosis;
KIRP	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-9.43	-0.52	3.26e-18	Response to antipsychotic treatment;
KIRP	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg20140201	chr2:241835670	C2orf54	-0.35	-5.34	-0.32	2.08e-7	Urinary metabolites;
KIRP	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-7.15	-0.41	1e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.64	-0.52	7.48e-19	Mean corpuscular volume;
KIRP	cis	rs72634258	0.554	rs68024107	chr1:7914066	G/C	cg00042356	chr1:8021962	PARK7	0.57	5.03	0.31	9.57e-7	Inflammatory bowel disease;
KIRP	cis	rs745080	0.674	rs11626983	chr14:52966413	C/T	cg23333723	chr14:53022898	GPR137C	-0.4	-5.56	-0.33	6.97e-8	Orofacial clefts;
KIRP	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg05347473	chr6:146136440	FBXO30	-0.47	-6.65	-0.39	1.84e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-5.18	-0.31	4.51e-7	Total body bone mineral density;
KIRP	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.61	6.88	0.4	4.95e-11	Aortic root size;
KIRP	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg13010199	chr12:38710504	ALG10B	0.58	7.25	0.42	5.48e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.71	0.34	3.31e-8	Bipolar disorder;
KIRP	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg25356066	chr3:128598488	ACAD9	0.56	6.43	0.38	6.48e-10	IgG glycosylation;
KIRP	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	1.02	8.92	0.49	1.11e-16	Pulse pressure;
KIRP	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.77	-9.79	-0.53	2.44e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs1863824	0.625	rs11202023	chr10:88165453	C/T	cg07322936	chr10:88137208	NA	-0.54	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.23	0.37	1.96e-9	Subjective well-being;
KIRP	cis	rs11650494	0.710	rs8066722	chr17:47475007	A/G	cg08112188	chr17:47440006	ZNF652	-1.01	-6.95	-0.41	3.24e-11	Prostate cancer;
KIRP	cis	rs12188164	0.554	rs72711364	chr5:415323	A/G	cg26850624	chr5:429559	AHRR	-0.44	-7.37	-0.43	2.62e-12	Cystic fibrosis severity;
KIRP	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg20701182	chr2:24300061	SF3B14	0.58	5.16	0.31	5.13e-7	Lymphocyte counts;
KIRP	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16524936	chr4:1340807	KIAA1530	-0.43	-5.37	-0.32	1.86e-7	Longevity;
KIRP	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12480562	chr20:23434244	CST11	0.65	5.28	0.32	2.82e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.04	0.36	5.73e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs1422110	0.681	rs35625401	chr5:85465408	G/A	cg01787110	chr1:109008453	NBPF6	0.76	9.19	0.51	1.74e-17	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs367943	0.712	rs13157609	chr5:112683583	G/A	cg12552261	chr5:112820674	MCC	0.5	5.71	0.34	3.24e-8	Type 2 diabetes;
KIRP	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27297192	chr10:134578999	INPP5A	0.62	7.79	0.45	1.82e-13	Migraine;
KIRP	cis	rs4742903	0.967	rs10991119	chr9:106905277	C/T	cg14250997	chr9:106856677	SMC2	-0.36	-4.85	-0.3	2.19e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs716804	0.592	rs10770106	chr11:10312077	A/C	cg01453529	chr11:10209919	SBF2	-0.86	-6.55	-0.39	3.34e-10	Neuroticism;
KIRP	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs193541	0.530	rs2045626	chr5:122081253	A/C	cg19412675	chr5:122181750	SNX24	0.51	5.6	0.34	5.73e-8	Glucose homeostasis traits;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14139633	chr9:131103210	SLC27A4	0.52	6.6	0.39	2.45e-10	Myopia (pathological);
KIRP	cis	rs9815354	1.000	rs1716999	chr3:41930041	C/G	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.11e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs17095355	1.000	rs13377169	chr10:111729414	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.0	-0.36	6.86e-9	Biliary atresia;
KIRP	cis	rs2929278	0.561	rs3099045	chr15:43923955	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	6.11	0.36	3.92e-9	Schizophrenia;
KIRP	cis	rs6988636	0.818	rs73339658	chr8:124173007	A/G	cg23067535	chr8:124195133	FAM83A	-0.8	-6.6	-0.39	2.57e-10	Urinary uromodulin levels;
KIRP	cis	rs7937612	0.965	rs12420378	chr11:120250699	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.79	-0.4	8.54e-11	Intraocular pressure;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.76	10.25	0.55	9.53e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.53	6.54	0.38	3.57e-10	Monocyte count;
KIRP	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.72	-8.19	-0.46	1.47e-14	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17157630	chr2:74648928	WDR54	-0.42	-6.17	-0.37	2.79e-9	Metabolic traits;
KIRP	cis	rs236907	0.859	rs56365362	chr1:171752193	G/A	cg01410279	chr1:171621941	MYOC	-0.48	-5.37	-0.32	1.81e-7	Mean platelet volume;
KIRP	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.61	-0.39	2.37e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs73200209	0.744	rs74349961	chr12:116467560	T/C	cg01776926	chr12:116560359	MED13L	-0.56	-6.1	-0.36	4.18e-9	Total body bone mineral density;
KIRP	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11877825	0.826	rs8082984	chr18:10571904	C/T	cg07277756	chr18:10589357	NA	0.56	6.81	0.4	7.23e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs656319	0.729	rs471480	chr8:9812462	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.19	-0.37	2.5e-9	Myopia (pathological);
KIRP	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.91	-0.3	1.65e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.8	11.51	0.59	8.11e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.75	-9.43	-0.52	3.15e-18	Urate levels in obese individuals;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07837717	chr19:2841006	ZNF555	0.54	7.16	0.42	9.38e-12	Parkinson's disease;
KIRP	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.53e-7	Tonsillectomy;
KIRP	cis	rs2150410	0.915	rs2026266	chr21:40599720	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.55	7.29	0.42	4.25e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1448094	0.967	rs10863115	chr12:86332586	T/C	cg06740227	chr12:86229804	RASSF9	0.4	5.04	0.31	9.04e-7	Major depressive disorder;
KIRP	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.5	11.54	0.59	6.64e-25	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7737355	1.000	rs248652	chr5:130654837	A/T	cg25547332	chr5:131281432	NA	-0.49	-5.43	-0.33	1.36e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18280463	chr1:145473698	ANKRD34A	0.44	6.26	0.37	1.66e-9	Parkinson's disease;
KIRP	cis	rs7849270	1.000	rs10819466	chr9:131881492	G/C	cg13538475	chr9:131942899	NA	-0.31	-4.98	-0.3	1.21e-6	Blood metabolite ratios;
KIRP	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg21361702	chr7:150065534	REPIN1	0.59	5.78	0.35	2.22e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs812925	0.502	rs6545868	chr2:61655365	T/C	cg15711740	chr2:61764176	XPO1	0.45	5.81	0.35	1.91e-8	Immature fraction of reticulocytes;
KIRP	cis	rs13185784	0.703	rs35394934	chr5:179677555	T/C	cg23248424	chr5:179741104	GFPT2	0.57	5.55	0.33	7.22e-8	TRAIL levels;
KIRP	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	cg12689670	chr1:183009347	LAMC1	-0.45	-6.45	-0.38	5.8e-10	Colorectal cancer;
KIRP	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg00889227	chr1:205173544	DSTYK	-0.35	-5.05	-0.31	8.74e-7	Red blood cell count;
KIRP	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.56	-7.79	-0.44	1.85e-13	Dilated cardiomyopathy;
KIRP	cis	rs11880706	0.667	rs10425506	chr19:6110911	G/T	cg18109231	chr19:6110877	RFX2	0.76	5.13	0.31	5.89e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg00629928	chr5:358741	AHRR	0.51	5.14	0.31	5.6e-7	Breast cancer;
KIRP	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18252515	chr7:66147081	NA	-0.44	-5.4	-0.33	1.55e-7	Aortic root size;
KIRP	cis	rs6558530	0.666	rs6558518	chr8:1697309	G/T	cg08198773	chr8:1697536	NA	0.52	6.49	0.38	4.81e-10	Systolic blood pressure;
KIRP	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg16482183	chr6:26056742	HIST1H1C	0.63	7.38	0.43	2.4e-12	Iron status biomarkers;
KIRP	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.67	7.76	0.44	2.31e-13	Corneal astigmatism;
KIRP	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg04398451	chr17:18023971	MYO15A	-0.65	-8.69	-0.48	5.33e-16	Total body bone mineral density;
KIRP	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.62	6.66	0.39	1.77e-10	Gut microbiome composition (summer);
KIRP	trans	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg19274270	chr17:78178856	CARD14	-0.33	-6.16	-0.37	3e-9	Morning vs. evening chronotype;
KIRP	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg26084005	chr2:241760190	KIF1A	-0.47	-5.82	-0.35	1.83e-8	Urinary metabolites;
KIRP	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg15421430	chr19:7599081	PNPLA6	-0.49	-6.57	-0.39	2.98e-10	Morning vs. evening chronotype;
KIRP	trans	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg19274270	chr17:78178856	CARD14	0.36	6.68	0.39	1.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.84	-13.35	-0.65	5.91e-31	Breast cancer;
KIRP	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.47	-7.78	-0.44	1.99e-13	White blood cell count (basophil);
KIRP	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.32	0.37	1.22e-9	Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg08283408	chr3:49949060	MON1A	0.4	5.26	0.32	3.11e-7	Body mass index;
KIRP	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.49	7.99	0.45	5.35e-14	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg07827796	chr19:33622959	WDR88	0.42	5.03	0.31	9.26e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19553056	chr4:142142166	ZNF330	0.47	6.22	0.37	2.1e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg27205649	chr11:78285834	NARS2	0.65	8.65	0.48	6.88e-16	Alzheimer's disease (survival time);
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.55	5.43	0.33	1.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.9	-0.53	1.11e-19	Response to antipsychotic treatment;
KIRP	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.97	15.43	0.7	5.14e-38	Gait variability;
KIRP	cis	rs9653442	0.545	rs11681227	chr2:100754997	A/G	cg22139774	chr2:100720529	AFF3	-0.33	-5.36	-0.32	1.95e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.39	0.38	8.3e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17666538	1.000	rs57896286	chr8:571479	T/C	cg02524346	chr8:600233	NA	-0.87	-5.64	-0.34	4.74e-8	IgG glycosylation;
KIRP	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.7	-10.25	-0.55	9.3e-21	Ulcerative colitis;
KIRP	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg21523564	chr15:75251491	NA	0.36	6.01	0.36	6.68e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs758324	0.947	rs422291	chr5:131320942	A/T	cg06647332	chr5:131281008	NA	-0.45	-4.99	-0.3	1.13e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg20295408	chr7:1910781	MAD1L1	0.49	5.77	0.35	2.37e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs16958440	1.000	rs62096466	chr18:44636171	T/G	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.75	11.36	0.59	2.5e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05665937	chr4:1216051	CTBP1	-0.47	-6.41	-0.38	7.36e-10	Obesity-related traits;
KIRP	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.54	-0.33	7.91e-8	Bipolar disorder;
KIRP	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg17691542	chr6:26056736	HIST1H1C	0.43	5.69	0.34	3.6e-8	Height;
KIRP	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.19	-0.46	1.39e-14	Monocyte percentage of white cells;
KIRP	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.66	8.53	0.48	1.51e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg07636037	chr3:49044803	WDR6	0.58	5.6	0.34	5.69e-8	Menarche (age at onset);
KIRP	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.43	0.43	1.82e-12	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14096962	chr3:58419817	PDHB	0.45	6.39	0.38	8.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg19507638	chr5:93509721	C5orf36	-0.59	-5.32	-0.32	2.36e-7	Diabetic retinopathy;
KIRP	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.79	8.97	0.5	7.59e-17	Gut microbiome composition (summer);
KIRP	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg06671706	chr8:8559999	CLDN23	0.58	6.66	0.39	1.8e-10	Obesity-related traits;
KIRP	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.27	0.32	2.99e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6725041	0.547	rs61696052	chr2:213201295	G/C	cg16329650	chr2:213403929	ERBB4	-0.38	-4.94	-0.3	1.41e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.55	-0.39	3.27e-10	Hemoglobin concentration;
KIRP	trans	rs10507577	0.630	rs75887637	chr13:53917360	T/A	cg13487983	chr9:137296319	RXRA	-0.53	-6.02	-0.36	6.32e-9	Select biomarker traits;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg09659697	chr5:54529994	CCNO	-0.61	-6.14	-0.36	3.32e-9	Response to statin therapy;
KIRP	cis	rs35740288	0.770	rs745191	chr15:86123170	G/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.49	-0.33	1.01e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.62	-6.85	-0.4	5.77e-11	Response to antineoplastic agents;
KIRP	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg27572855	chr1:25598939	RHD	0.57	10.04	0.54	4.34e-20	Erythrocyte sedimentation rate;
KIRP	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-7.33	-0.42	3.32e-12	Vitiligo;
KIRP	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.73	10.13	0.54	2.27e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	6.11	0.36	3.93e-9	Total cholesterol levels;
KIRP	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg16586182	chr3:47516702	SCAP	0.69	9.3	0.51	7.72e-18	Colorectal cancer;
KIRP	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg00629941	chr15:75287862	SCAMP5	-0.51	-5.41	-0.33	1.5e-7	Blood trace element (Zn levels);
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.93	10.95	0.57	5.28e-23	Corneal astigmatism;
KIRP	cis	rs2071403	0.966	rs9677074	chr2:1409353	G/C	cg06500727	chr2:1417164	TPO	0.5	7.85	0.45	1.26e-13	Thyroid peroxidase antibody positivity;
KIRP	cis	rs2573652	1.000	rs2573651	chr15:100514109	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.68	-10.23	-0.55	1.11e-20	Height;
KIRP	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg14416269	chr4:6271139	WFS1	0.33	4.95	0.3	1.36e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.38	-0.32	1.76e-7	Corneal structure;
KIRP	cis	rs71277158	0.688	rs12497114	chr3:169799521	T/A	cg04067573	chr3:169899625	PHC3	0.57	5.46	0.33	1.15e-7	Prostate cancer;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	-0.37	-5.53	-0.33	8.17e-8	Lymphocyte counts;
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.26	-5.47	-0.33	1.12e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs35123781	0.696	rs4912755	chr5:139070651	A/G	cg10513866	chr5:139070639	NA	0.54	7.39	0.43	2.35e-12	Schizophrenia;
KIRP	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.58	8.38	0.47	4.15e-15	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg07701084	chr6:150067640	NUP43	-0.63	-8.02	-0.46	4.33e-14	Lung cancer;
KIRP	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg03959625	chr15:84868606	LOC388152	-0.66	-7.35	-0.42	2.89e-12	Schizophrenia;
KIRP	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.66	9.05	0.5	4.34e-17	Mood instability;
KIRP	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg20991723	chr1:152506922	NA	-0.45	-5.36	-0.32	1.93e-7	Hair morphology;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08931102	chr16:67261071	TMEM208;LRRC29	0.43	6.04	0.36	5.68e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg25173405	chr17:45401733	C17orf57	0.46	6.11	0.36	3.82e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7116495	1.000	rs671681	chr11:71782812	T/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs490234	0.805	rs562004	chr9:128321771	T/C	cg14078157	chr9:128172775	NA	0.41	5.21	0.32	3.93e-7	Mean arterial pressure;
KIRP	cis	rs787274	0.867	rs787279	chr9:115539514	T/C	cg13803584	chr9:115635662	SNX30	-0.75	-8.49	-0.48	2.02e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg06204229	chr3:52865917	ITIH4	0.52	7.53	0.43	9.85e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.66	8.13	0.46	2.16e-14	Schizophrenia;
KIRP	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.47	-7.94	-0.45	7.3e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs7534824	0.543	rs10493940	chr1:101377845	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.97	0.36	8.28e-9	Refractive astigmatism;
KIRP	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.51	-0.38	4.3e-10	Blood pressure;
KIRP	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.73	-7.94	-0.45	7.22e-14	Hair shape;
KIRP	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg11843606	chr2:227700838	RHBDD1	0.39	4.96	0.3	1.29e-6	Pulmonary function;
KIRP	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.28	-0.37	1.52e-9	Response to antipsychotic treatment;
KIRP	cis	rs6546324	0.580	rs2861684	chr2:67837380	T/C	cg15745817	chr2:67799979	NA	-0.52	-6.1	-0.36	4.14e-9	Endometriosis;
KIRP	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.63	8.52	0.48	1.6e-15	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.1	10.42	0.55	2.68e-21	Atopic dermatitis;
KIRP	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	5.17	0.31	4.93e-7	Schizophrenia;
KIRP	trans	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.48	-0.43	1.34e-12	Atopic dermatitis;
KIRP	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.68	-9.25	-0.51	1.1e-17	Rheumatoid arthritis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15682797	chr8:1049394	NA	0.43	6.5	0.38	4.37e-10	Survival in pancreatic cancer;
KIRP	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg17788227	chr17:7347145	FGF11;CHRNB1	0.5	5.15	0.31	5.24e-7	Androgen levels;
KIRP	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1961637	0.642	rs895774	chr2:223886563	A/G	cg02552189	chr2:223891284	NA	-0.45	-6.7	-0.39	1.41e-10	Oropharynx cancer;
KIRP	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.45	-5.67	-0.34	3.94e-8	Menarche (age at onset);
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.58	-7.51	-0.43	1.11e-12	Breast cancer;
KIRP	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg04025307	chr7:1156635	C7orf50	0.57	6.19	0.37	2.46e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.49	0.48	1.92e-15	Motion sickness;
KIRP	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.51	-5.97	-0.36	8.24e-9	Systolic blood pressure;
KIRP	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg00982548	chr2:198649783	BOLL	-0.52	-5.1	-0.31	6.64e-7	Ulcerative colitis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22075328	chr22:23412381	RTDR1;GNAZ	-0.47	-6.36	-0.38	9.55e-10	Myopia;
KIRP	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.81	-10.81	-0.57	1.59e-22	Prostate cancer;
KIRP	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.75	-8.79	-0.49	2.69e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.83	12.79	0.63	4.61e-29	Testicular germ cell tumor;
KIRP	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.61	-0.6	3.77e-25	Eye color traits;
KIRP	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.51e-25	Morning vs. evening chronotype;
KIRP	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.76	10.87	0.57	9.72e-23	Schizophrenia;
KIRP	cis	rs7615316	1.000	rs2030613	chr3:142343391	G/A	cg20824294	chr3:142316082	PLS1	0.22	4.94	0.3	1.42e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.67	6.43	0.38	6.64e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg17376030	chr22:41985996	PMM1	0.47	5.22	0.32	3.77e-7	Vitiligo;
KIRP	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg02527881	chr3:46936655	PTH1R	-0.37	-5.15	-0.31	5.29e-7	Colorectal cancer;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00150989	chr17:74303935	QRICH2	0.55	7.12	0.41	1.22e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1408799	0.830	rs10960751	chr9:12675264	T/C	cg05274944	chr9:12693694	TYRP1	0.36	5.24	0.32	3.37e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs12210905	0.925	rs12214640	chr6:26762080	G/A	cg11502198	chr6:26597334	ABT1	-0.83	-5.77	-0.35	2.36e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17376030	chr22:41985996	PMM1	0.68	7.27	0.42	4.81e-12	Vitiligo;
KIRP	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg04727924	chr7:799746	HEATR2	-0.66	-6.61	-0.39	2.39e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.39	-0.32	1.69e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg01304814	chr3:48885189	PRKAR2A	0.55	5.06	0.31	8.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg03060546	chr3:49711283	APEH	-0.63	-6.08	-0.36	4.48e-9	Cognitive function;
KIRP	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg24315340	chr6:146058215	EPM2A	0.41	5.37	0.32	1.8e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs986417	0.748	rs4901986	chr14:60969333	T/C	cg27398547	chr14:60952738	C14orf39	0.64	6.31	0.37	1.31e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.54	-0.56	1.16e-21	Response to antipsychotic treatment;
KIRP	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg19554555	chr3:13937349	NA	-0.46	-6.2	-0.37	2.42e-9	Ovarian reserve;
KIRP	cis	rs8038465	0.615	rs8024862	chr15:73958290	C/T	cg15420318	chr15:73925796	NPTN	0.65	9.38	0.51	4.41e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.55	-0.33	7.21e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20261243	chr20:44718728	NCOA5	0.54	7.32	0.42	3.56e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6456042	0.756	rs3099265	chr6:166581751	C/G	cg11088901	chr6:166572345	T	-0.36	-5.23	-0.32	3.56e-7	Asthma;
KIRP	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	9.8	0.53	2.27e-19	Mean platelet volume;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03813033	chr19:50380022	AKT1S1;TBC1D17	0.59	6.56	0.39	3.2e-10	Lung cancer in ever smokers;
KIRP	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.9	8.3	0.47	6.8e-15	Systolic blood pressure;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16101703	chr5:65440440	SFRS12	0.47	6.76	0.4	9.93e-11	Survival in pancreatic cancer;
KIRP	cis	rs7766436	0.885	rs13210010	chr6:22585075	C/T	cg13666174	chr6:22585274	NA	-0.46	-6.47	-0.38	5.22e-10	Coronary artery disease;
KIRP	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Body mass index;
KIRP	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.4	5.14	0.31	5.48e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7246657	0.663	rs9304568	chr19:38054508	C/A	cg18154014	chr19:37997991	ZNF793	0.64	7.06	0.41	1.69e-11	Coronary artery calcification;
KIRP	cis	rs9488822	0.623	rs195518	chr6:116241693	A/G	cg15226275	chr6:116381976	FRK	0.21	5.44	0.33	1.3e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8113308	0.810	rs8100521	chr19:52449643	A/G	cg24732339	chr19:52471368	ZNF350	-0.45	-5.02	-0.3	9.83e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.05	0.31	8.68e-7	Tonsillectomy;
KIRP	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg04935436	chr20:30431758	NA	0.38	5.24	0.32	3.45e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.44	-5.6	-0.34	5.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.83	-0.35	1.73e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs300890	0.841	rs6840603	chr4:144227576	T/C	cg19876092	chr4:144208277	NA	0.38	5.99	0.36	7.59e-9	Nasopharyngeal carcinoma;
KIRP	trans	rs1961649	0.607	rs11109920	chr12:99957542	A/G	cg00491523	chr16:6913336	A2BP1	-0.33	-6.09	-0.36	4.32e-9	Metabolite levels (HVA/5-HIAA ratio);
KIRP	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.87	-9.94	-0.54	8.36e-20	Alcohol dependence;Nicotine use;
KIRP	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.97	11.53	0.59	7.35e-25	Exhaled nitric oxide levels;
KIRP	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.66	6.5	0.38	4.46e-10	Eotaxin levels;
KIRP	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg13165212	chr22:42675999	NA	0.28	5.05	0.31	8.78e-7	Cognitive function;
KIRP	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06481639	chr22:41940642	POLR3H	-0.72	-7.5	-0.43	1.12e-12	Vitiligo;
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.55	0.33	7.35e-8	Lung cancer;
KIRP	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg13611997	chr5:233750	SDHA	-0.43	-5.27	-0.32	2.91e-7	Breast cancer;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg23307798	chr14:103986281	CKB	-0.43	-5.9	-0.35	1.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.54	-7.72	-0.44	2.99e-13	Type 2 diabetes;
KIRP	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16414030	chr3:133502952	NA	-0.51	-5.99	-0.36	7.22e-9	Iron status biomarkers;
KIRP	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg20169779	chr10:135381914	SYCE1	0.45	5.23	0.32	3.56e-7	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.4	-0.43	2.13e-12	Platelet count;
KIRP	cis	rs7615316	0.603	rs9839186	chr3:141960278	G/C	cg20824294	chr3:142316082	PLS1	0.23	5.25	0.32	3.23e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.52	-6.68	-0.39	1.61e-10	Type 2 diabetes;
KIRP	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg13206674	chr6:150067644	NUP43	0.66	9.79	0.53	2.5e-19	Lung cancer;
KIRP	cis	rs4561483	0.831	rs8052900	chr16:11940390	T/C	cg08843971	chr16:11963173	GSPT1	0.53	6.84	0.4	6.06e-11	Testicular germ cell tumor;
KIRP	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg04166393	chr7:2884313	GNA12	0.64	7.36	0.42	2.69e-12	Height;
KIRP	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs10214930	0.752	rs12531518	chr7:27661139	A/G	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.63	-7.39	-0.43	2.25e-12	Type 2 diabetes;
KIRP	cis	rs981844	1.000	rs981844	chr4:154652028	A/G	cg14289246	chr4:154710475	SFRP2	0.64	6.37	0.38	9.31e-10	Response to statins (LDL cholesterol change);
KIRP	trans	rs13170463	0.579	rs13159876	chr5:8039236	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs10045504	0.502	rs57589709	chr5:38733853	C/T	cg15396434	chr5:38725168	NA	-0.97	-9.71	-0.53	4.53e-19	Night sleep phenotypes;
KIRP	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	trans	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg16141378	chr3:129829833	LOC729375	0.54	6.18	0.37	2.64e-9	Neuroticism;
KIRP	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg24747557	chr10:131355152	MGMT	0.4	5.42	0.33	1.45e-7	Response to temozolomide;
KIRP	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06307176	chr5:131281290	NA	-0.54	-5.89	-0.35	1.26e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg04607699	chr11:48328132	OR4S1	-0.35	-4.95	-0.3	1.39e-6	HDL cholesterol;
KIRP	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg08126542	chr6:37504118	NA	0.66	9.67	0.52	5.91e-19	Cognitive performance;
KIRP	cis	rs2644899	0.593	rs3733828	chr19:41310609	A/G	cg24958765	chr19:41283667	RAB4B	-0.48	-5.78	-0.35	2.24e-8	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg04804543	chr8:142233427	SLC45A4	-0.59	-7.54	-0.43	9.2e-13	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.57	-7.59	-0.44	6.7e-13	Retinal vascular caliber;
KIRP	cis	rs13132184	0.507	rs35308860	chr4:38035526	T/G	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.19	-0.31	4.41e-7	Verbal declarative memory;
KIRP	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg02725872	chr8:58115012	NA	-0.62	-5.6	-0.34	5.61e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6691722	0.503	rs3765428	chr1:24706113	G/A	cg18323236	chr1:24743029	NIPAL3	0.44	6.29	0.37	1.45e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg12501888	chr15:85177176	SCAND2	-0.42	-5.45	-0.33	1.24e-7	P wave terminal force;
KIRP	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg03959625	chr15:84868606	LOC388152	0.49	5.67	0.34	3.99e-8	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs896623	0.672	rs17051320	chr4:122119281	C/T	cg19463078	chr4:122099598	TNIP3	-0.32	-4.95	-0.3	1.38e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.872	rs7975457	chr12:86410404	C/T	cg06740227	chr12:86229804	RASSF9	0.4	5.02	0.31	9.76e-7	Major depressive disorder;
KIRP	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.79	-0.35	2.14e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.11	-0.54	2.58e-20	Colorectal cancer;
KIRP	cis	rs4889855	0.556	rs9911795	chr17:78626115	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.15	0.37	3.1e-9	Fractional excretion of uric acid;
KIRP	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-6.16	-0.37	2.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1800795	0.599	rs1546762	chr7:22757503	C/T	cg05472934	chr7:22766657	IL6	0.5	6.4	0.38	7.62e-10	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
KIRP	trans	rs1422110	0.718	rs10079231	chr5:85439369	A/G	cg01787110	chr1:109008453	NBPF6	0.74	9.1	0.5	3.22e-17	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.21	0.51	1.49e-17	Prudent dietary pattern;
KIRP	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg02951883	chr7:2050386	MAD1L1	-0.45	-4.98	-0.3	1.19e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9625935	0.957	rs41162	chr22:30408710	C/T	cg01021169	chr22:30184971	ASCC2	0.42	4.85	0.3	2.2e-6	Tonsillectomy;
KIRP	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg21064579	chr19:49206444	FUT2	0.46	5.91	0.35	1.11e-8	Dietary macronutrient intake;
KIRP	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.45	5.33	0.32	2.21e-7	Airway imaging phenotypes;
KIRP	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg21294424	chr19:58662284	ZNF329	0.6	5.58	0.34	6.39e-8	Cholesterol, total;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg08713116	chr13:41885295	NAA16	-0.47	-6.38	-0.38	8.76e-10	Morning vs. evening chronotype;
KIRP	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg05791153	chr7:19748676	TWISTNB	-0.58	-5.82	-0.35	1.83e-8	Thyroid stimulating hormone;
KIRP	cis	rs7180079	0.620	rs637748	chr15:64858492	A/G	cg15337035	chr15:64978493	NA	-0.46	-5.02	-0.3	9.79e-7	Monocyte count;
KIRP	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07685180	chr8:600429	NA	0.66	4.86	0.3	2.06e-6	IgG glycosylation;
KIRP	cis	rs140569062	1	rs140569062	chr19:39345909	G/T	cg07859880	chr19:39323060	ECH1	0.51	6.72	0.39	1.28e-10	Anti-saccade response;
KIRP	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	0.91	13.69	0.66	4.25e-32	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9972944	0.534	rs7208926	chr17:63863210	G/A	cg07283582	chr17:63770753	CCDC46	-0.44	-6.7	-0.39	1.45e-10	Total body bone mineral density;
KIRP	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg11663144	chr21:46675770	NA	-0.53	-6.72	-0.39	1.23e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg18904891	chr8:8559673	CLDN23	0.56	6.45	0.38	5.74e-10	Obesity-related traits;
KIRP	cis	rs698833	0.620	rs1067354	chr2:44663675	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.7	0.34	3.38e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.52	-7.93	-0.45	7.87e-14	Huntington's disease progression;
KIRP	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.42e-13	Morning vs. evening chronotype;
KIRP	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg12501888	chr15:85177176	SCAND2	-0.42	-5.21	-0.32	3.98e-7	P wave terminal force;
KIRP	cis	rs6689125	1	rs6689125	chr1:171736037	G/A	cg01410279	chr1:171621941	MYOC	-0.55	-5.57	-0.33	6.75e-8	Platelet distribution width;
KIRP	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-10.8	-0.57	1.67e-22	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg08085267	chr17:45401833	C17orf57	-0.56	-7.08	-0.41	1.49e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.42	0.38	6.91e-10	Retinal vascular caliber;
KIRP	cis	rs9309473	0.898	rs7587577	chr2:73832786	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.43	-0.33	1.34e-7	Metabolite levels;
KIRP	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg23587288	chr2:27483067	SLC30A3	0.55	6.91	0.4	4.03e-11	Blood metabolite levels;
KIRP	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.59	6.57	0.39	2.97e-10	Platelet count;
KIRP	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.37	6.74	0.39	1.15e-10	Monocyte percentage of white cells;
KIRP	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.61	7.5	0.43	1.16e-12	Total body bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18827066	chr8:117709777	EIF3H	0.47	6.36	0.38	9.49e-10	Interleukin-4 levels;
KIRP	trans	rs6601327	0.635	rs34782826	chr8:9663630	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.72	-0.39	1.25e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.64	8.53	0.48	1.54e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.57	8.45	0.47	2.51e-15	Fat distribution (HIV);
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg24879335	chr3:133465180	TF	0.4	5.72	0.34	3.11e-8	Iron status biomarkers;
KIRP	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.56	0.43	8e-13	Colorectal cancer;
KIRP	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs17401966	0.597	rs3903151	chr1:10260592	A/G	cg19773385	chr1:10388646	KIF1B	-0.52	-7.31	-0.42	3.72e-12	Hepatocellular carcinoma;
KIRP	cis	rs2274273	0.686	rs68083077	chr14:55574428	G/A	cg04306507	chr14:55594613	LGALS3	0.42	5.65	0.34	4.32e-8	Protein biomarker;
KIRP	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-8.34	-0.47	5.21e-15	Colorectal cancer;
KIRP	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg24009623	chr19:33667908	NA	0.5	6.35	0.38	1.03e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.4	5.0	0.3	1.07e-6	Menarche (age at onset);
KIRP	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs2625529	0.824	rs4131630	chr15:72355398	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.81	11.47	0.59	1.13e-24	Obesity-related traits;
KIRP	cis	rs5498	0.869	rs2569702	chr19:10403947	A/G	cg10604476	chr19:10403908	ICAM5	0.32	4.94	0.3	1.41e-6	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg05941025	chr16:89927596	SPIRE2	0.34	5.33	0.32	2.21e-7	Vitiligo;
KIRP	cis	rs877282	0.853	rs4579862	chr10:753298	A/C	cg17470449	chr10:769945	NA	0.64	6.25	0.37	1.76e-9	Uric acid levels;
KIRP	cis	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg10524888	chr4:39529563	UGDH	-0.4	-5.28	-0.32	2.81e-7	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	8.54	0.48	1.44e-15	Platelet distribution width;
KIRP	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-6.63	-0.39	2.17e-10	Blood trace element (Cu levels);
KIRP	cis	rs4006360	0.657	rs12939793	chr17:39233537	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.65	-9.16	-0.5	2.04e-17	Bipolar disorder and schizophrenia;
KIRP	cis	rs10814247	0.648	rs7025623	chr9:35262761	C/T	cg15271616	chr9:35490515	RUSC2	-0.36	-5.14	-0.31	5.61e-7	Psoriasis;
KIRP	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs2224391	0.822	rs2773321	chr6:5262220	C/G	cg13962347	chr6:5174647	LYRM4	-0.62	-8.42	-0.47	3.16e-15	Height;
KIRP	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.97	-14.01	-0.67	3.62e-33	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.54	6.62	0.39	2.28e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.59	7.29	0.42	4.21e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.77	-0.4	9.25e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg07701084	chr6:150067640	NUP43	0.5	5.48	0.33	1.04e-7	Lung cancer;
KIRP	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13409248	chr3:40428643	ENTPD3	0.39	5.05	0.31	8.81e-7	Renal cell carcinoma;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg17269277	chr4:1796142	FGFR3	-0.54	-6.2	-0.37	2.4e-9	Menopause (age at onset);
KIRP	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	7.97	0.45	5.92e-14	Personality dimensions;
KIRP	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.6	8.88	0.49	1.43e-16	Coronary artery disease;
KIRP	cis	rs75920871	1.000	rs61905705	chr11:116883776	A/T	cg23684410	chr11:116897558	SIK3	0.57	6.15	0.37	3.05e-9	Subjective well-being;
KIRP	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg04998671	chr14:104000505	TRMT61A	-0.7	-6.86	-0.4	5.68e-11	Coronary artery disease;
KIRP	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg02319466	chr17:76381040	PGS1	0.53	7.15	0.41	1e-11	HDL cholesterol;
KIRP	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.46	-7.32	-0.42	3.42e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.59	0.34	6.11e-8	Melanoma;
KIRP	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg03806693	chr22:41940476	POLR3H	-0.52	-6.05	-0.36	5.37e-9	Neuroticism;
KIRP	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg05768032	chr16:30646687	NA	0.47	5.34	0.32	2.08e-7	Dementia with Lewy bodies;
KIRP	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.52	2.77e-18	Prostate cancer;
KIRP	cis	rs7719624	0.540	rs7728953	chr5:135544695	C/A	cg12897067	chr5:135418308	NA	0.42	4.94	0.3	1.45e-6	Response to cytidine analogues (gemcitabine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02677352	chr4:48833292	OCIAD1	0.46	6.16	0.37	3.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.53	7.14	0.41	1.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.67	7.75	0.44	2.36e-13	Corneal astigmatism;
KIRP	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg15047889	chr8:124780837	FAM91A1	-0.48	-4.86	-0.3	2.12e-6	Pancreatic cancer;
KIRP	cis	rs75920871	1.000	rs7950213	chr11:116868654	C/A	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.65	-9.98	-0.54	6.38e-20	Hepatocellular carcinoma;
KIRP	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.64	-8.32	-0.47	5.99e-15	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.82e-10	Protein C levels;
KIRP	cis	rs7582720	1.000	rs72932731	chr2:203650410	A/G	cg08076091	chr2:203926405	NBEAL1	0.85	8.37	0.47	4.49e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7221595	0.825	rs8076743	chr17:3916537	A/T	cg09695851	chr17:3907499	NA	0.66	6.53	0.38	3.64e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.78	0.35	2.26e-8	Breast cancer;
KIRP	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs78487399	0.908	rs7568901	chr2:43814984	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-4.85	-0.3	2.17e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.3	-0.37	1.37e-9	Diastolic blood pressure;
KIRP	cis	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg27487796	chr7:28973253	NA	-0.22	-4.93	-0.3	1.52e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg12191964	chr2:43823338	THADA	-0.47	-6.51	-0.38	4.08e-10	Morning vs. evening chronotype;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg07970400	chr15:40650285	DISP2	0.6	6.36	0.38	9.99e-10	Response to statin therapy;
KIRP	trans	rs12043259	0.730	rs6593914	chr1:204800117	C/T	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.7	-9.29	-0.51	8.47e-18	Morning vs. evening chronotype;
KIRP	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.44	-0.47	2.78e-15	Colorectal cancer;
KIRP	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg12962167	chr3:53033115	SFMBT1	0.71	5.17	0.31	4.85e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6545883	0.929	rs6705235	chr2:61713580	G/C	cg15711740	chr2:61764176	XPO1	-0.6	-7.97	-0.45	5.95e-14	Tuberculosis;
KIRP	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.37	-0.43	2.59e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.68	8.99	0.5	6.54e-17	Multiple sclerosis;
KIRP	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.54	-0.52	1.43e-18	Gut microbiome composition (summer);
KIRP	cis	rs2278796	0.724	rs2794860	chr1:204968392	A/G	cg17449235	chr1:204966235	NFASC	0.51	7.38	0.43	2.37e-12	Mean platelet volume;
KIRP	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.39	-9.78	-0.53	2.73e-19	Corneal astigmatism;
KIRP	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg17243659	chr21:48055224	PRMT2	1.05	6.22	0.37	2.1e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs9682041	0.740	rs2111826	chr3:170140846	A/G	cg11886554	chr3:170076028	SKIL	0.89	7.41	0.43	1.97e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg01765077	chr12:122356316	WDR66	0.62	8.64	0.48	7.46e-16	Mean corpuscular volume;
KIRP	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.36	0.51	5.19e-18	IgG glycosylation;
KIRP	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg00792783	chr2:198669748	PLCL1	0.47	5.25	0.32	3.3e-7	Dermatomyositis;
KIRP	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg06815112	chr8:27182871	PTK2B	0.54	6.98	0.41	2.65e-11	Neuroticism;
KIRP	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg01214346	chr17:406501	NA	0.4	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs62355272	0.793	rs7718034	chr5:35825602	A/G	cg13894535	chr5:35919491	CAPSL	-0.48	-5.38	-0.32	1.76e-7	Lymphocyte counts;
KIRP	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg12560992	chr17:57184187	TRIM37	0.54	5.83	0.35	1.74e-8	Cognitive test performance;
KIRP	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.67	9.32	0.51	6.68e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.43	7.35	0.42	2.86e-12	Renal cell carcinoma;
KIRP	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg18850127	chr7:39170497	POU6F2	0.28	5.51	0.33	8.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-8.45	-0.47	2.62e-15	Response to antipsychotic treatment;
KIRP	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs501120	0.584	rs11238890	chr10:44669226	A/T	cg09554077	chr10:44749378	NA	0.58	6.16	0.37	2.95e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.53	-0.43	9.32e-13	Initial pursuit acceleration;
KIRP	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg23307798	chr14:103986281	CKB	-0.39	-5.27	-0.32	2.98e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.77	-11.9	-0.6	4.41e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs17641971	0.645	rs186891	chr8:50038758	T/C	cg00325661	chr8:49890786	NA	0.47	5.87	0.35	1.39e-8	Blood metabolite levels;
KIRP	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	1.01	16.03	0.71	4.37e-40	Bipolar disorder;
KIRP	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg05527609	chr1:210001259	C1orf107	0.43	5.28	0.32	2.79e-7	Red blood cell count;
KIRP	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.66	-9.48	-0.52	2.32e-18	Prudent dietary pattern;
KIRP	cis	rs9517302	0.512	rs9517305	chr13:99097910	G/C	cg22223119	chr13:99095684	FARP1	-0.43	-5.15	-0.31	5.26e-7	Obesity-related traits;
KIRP	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-0.9	-12.37	-0.62	1.16e-27	Gut microbiota (bacterial taxa);
KIRP	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-5.55	-0.33	7.57e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.8	9.16	0.5	2.13e-17	HDL cholesterol;
KIRP	cis	rs6991838	0.584	rs7814841	chr8:66541563	A/G	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.32	-5.35	-0.32	2.01e-7	Height;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01110552	chr10:103578627	MGEA5	-0.52	-6.87	-0.4	5.25e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.86	-0.35	1.44e-8	IgG glycosylation;
KIRP	cis	rs4704846	0.556	rs2862719	chr5:156500629	A/G	cg12943317	chr5:156479607	HAVCR1	-0.52	-5.03	-0.31	9.34e-7	Blood protein levels;
KIRP	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.73	-0.6	1.61e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9921338	0.887	rs6498183	chr16:11430908	C/T	cg00044050	chr16:11439710	C16orf75	-0.55	-5.88	-0.35	1.36e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg07636037	chr3:49044803	WDR6	-0.75	-5.59	-0.34	6.12e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs13170463	0.579	rs13156419	chr5:8041464	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs1018697	1.000	rs7086400	chr10:104562097	G/A	cg04362960	chr10:104952993	NT5C2	0.49	5.92	0.35	1.06e-8	Colorectal adenoma (advanced);
KIRP	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg05315796	chr3:52349193	DNAH1	-0.41	-6.51	-0.38	4.23e-10	Electroencephalogram traits;
KIRP	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-13.23	-0.64	1.52e-30	Tonsillectomy;
KIRP	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg19507638	chr5:93509721	C5orf36	-0.57	-5.0	-0.3	1.08e-6	Diabetic retinopathy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04707787	chr10:89622160	PTEN;KILLIN	0.45	6.58	0.39	2.77e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4852324	0.536	rs13387174	chr2:74206685	G/A	cg19729930	chr2:74357872	NA	0.69	5.35	0.32	2.06e-7	Systemic lupus erythematosus;
KIRP	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg12573674	chr2:1569213	NA	-0.66	-7.44	-0.43	1.69e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.66	0.34	4.17e-8	Lung cancer;
KIRP	trans	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg15371732	chr17:78194151	SLC26A11;SGSH	0.56	6.44	0.38	6.07e-10	Cystic fibrosis severity;
KIRP	cis	rs4791746	1.000	rs904170	chr17:8613830	G/A	cg03115937	chr17:8649504	CCDC42	-0.54	-5.73	-0.34	2.91e-8	Heroin dependence;
KIRP	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.8	0.49	2.43e-16	Menopause (age at onset);
KIRP	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.75	10.09	0.54	2.85e-20	Schizophrenia;
KIRP	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-6.49	-0.38	4.71e-10	Vitamin D levels;
KIRP	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg01689657	chr7:91764605	CYP51A1	0.43	6.41	0.38	7.44e-10	Breast cancer;
KIRP	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.98	-12.63	-0.63	1.56e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.57	7.33	0.42	3.32e-12	Blood metabolite ratios;
KIRP	cis	rs7976059	0.895	rs73109505	chr12:52244921	G/A	cg27042523	chr12:52245356	NA	0.76	11.59	0.59	4.56e-25	Urate levels;
KIRP	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-12.19	-0.61	4.9e-27	Lymphocyte percentage of white cells;
KIRP	cis	rs8177876	0.822	rs74437879	chr16:81112592	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg21419209	chr3:44054225	NA	-0.74	-9.22	-0.51	1.43e-17	Coronary artery disease;
KIRP	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg07001201	chr5:642380	CEP72	0.68	6.38	0.38	8.52e-10	Obesity-related traits;
KIRP	cis	rs2483058	0.767	rs4127124	chr1:206624362	A/C	cg19452316	chr1:206680966	RASSF5	0.41	5.55	0.33	7.45e-8	Cholesterol and Triglycerides;
KIRP	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg10790698	chr19:18539756	SSBP4	-0.35	-7.48	-0.43	1.31e-12	Breast cancer;
KIRP	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg16141378	chr3:129829833	LOC729375	0.49	6.33	0.37	1.17e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.86	-9.04	-0.5	4.69e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-11.46	-0.59	1.23e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.79	11.28	0.58	4.57e-24	Bladder cancer;
KIRP	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg02569458	chr12:86230093	RASSF9	0.35	5.1	0.31	6.71e-7	Major depressive disorder;
KIRP	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg11608241	chr8:8085544	FLJ10661	-0.44	-5.41	-0.33	1.49e-7	Myopia (pathological);
KIRP	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg24169773	chr3:122142474	KPNA1	-0.54	-5.55	-0.33	7.51e-8	LDL cholesterol levels;
KIRP	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	0.99	18.45	0.76	2.6e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.62	-10.15	-0.54	1.92e-20	Anterior chamber depth;
KIRP	cis	rs7828089	0.624	rs7001171	chr8:22270040	T/G	cg13512537	chr8:22265999	SLC39A14	-0.5	-6.68	-0.39	1.57e-10	Verbal declarative memory;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs2073300	1.000	rs6132629	chr20:23451251	G/A	cg12480562	chr20:23434244	CST11	0.62	6.25	0.37	1.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06481639	chr22:41940642	POLR3H	0.73	7.67	0.44	4.03e-13	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg03171003	chr2:111875934	NA	0.44	6.24	0.37	1.94e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg00958927	chr1:175162553	KIAA0040	-0.29	-4.93	-0.3	1.53e-6	Alcohol dependence;
KIRP	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg16584676	chr17:46985605	UBE2Z	0.47	5.76	0.34	2.51e-8	Type 2 diabetes;
KIRP	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg27205649	chr11:78285834	NARS2	-0.67	-8.6	-0.48	9.47e-16	Alzheimer's disease (survival time);
KIRP	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.34	0.37	1.07e-9	Morning vs. evening chronotype;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00826921	chr3:143692146	C3orf58	0.91	6.12	0.36	3.63e-9	P wave terminal force;
KIRP	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.28	0.42	4.61e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.48	0.43	1.28e-12	Neuroticism;
KIRP	cis	rs7771547	0.642	rs668499	chr6:36496379	A/G	cg07856975	chr6:36356162	ETV7	0.36	5.17	0.31	4.91e-7	Platelet distribution width;
KIRP	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg27398547	chr14:60952738	C14orf39	0.67	5.72	0.34	3.02e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	8.08	0.46	2.83e-14	Colorectal cancer;
KIRP	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.38	0.47	4.01e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-0.67	-5.11	-0.31	6.58e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.67	-0.48	5.93e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.7	6.95	0.41	3.18e-11	Bipolar disorder;
KIRP	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.73	-9.32	-0.51	6.87e-18	Coronary artery disease;
KIRP	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.44	5.31	0.32	2.43e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6973256	0.897	rs2909224	chr7:133331041	C/G	cg10665199	chr7:133106180	EXOC4	-0.51	-6.37	-0.38	9.2e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.07	-0.41	1.56e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.3	1e-6	Initial pursuit acceleration;
KIRP	cis	rs6693567	0.565	rs471738	chr1:150276429	G/A	cg09579323	chr1:150459698	TARS2	-0.4	-5.04	-0.31	9.22e-7	Migraine;
KIRP	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.36	8.55	0.48	1.34e-15	Asthma (sex interaction);
KIRP	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.63	8.12	0.46	2.31e-14	Crohn's disease;
KIRP	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.19	16.27	0.72	6.65e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs597583	1.000	rs597583	chr11:117421799	C/G	cg27161313	chr11:117392002	DSCAML1	-0.48	-5.21	-0.32	4.05e-7	Putamen volume;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	5.71	0.34	3.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7710178	0.877	rs4516838	chr5:155948651	A/G	cg23165310	chr3:181422217	SOX2OT	0.75	6.15	0.37	3.07e-9	Airway responsiveness in chronic obstructive pulmonary disease;
KIRP	cis	rs259282	0.514	rs10420153	chr19:33112957	C/T	cg02997394	chr19:33096574	ANKRD27	-0.48	-4.93	-0.3	1.53e-6	Schizophrenia;
KIRP	cis	rs9843304	0.528	rs1317213	chr3:149191150	C/T	cg08667024	chr3:149219783	TM4SF4	0.57	8.74	0.49	3.74e-16	Gallstone disease;
KIRP	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg13319975	chr6:146136371	FBXO30	0.43	5.84	0.35	1.65e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4074493	1.000	rs4074493	chr1:231172281	C/T	cg22172038	chr1:231176991	FAM89A	0.28	4.85	0.3	2.19e-6	Carotid plaque burden (smoking interaction);
KIRP	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.79	-7.32	-0.42	3.58e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg02725872	chr8:58115012	NA	-0.55	-6.08	-0.36	4.52e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg16586182	chr3:47516702	SCAP	0.64	8.6	0.48	9.74e-16	Colorectal cancer;
KIRP	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.89	-12.59	-0.63	2.2e-28	Primary sclerosing cholangitis;
KIRP	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.71	-7.96	-0.45	6.18e-14	Menarche (age at onset);
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg00814883	chr7:100076585	TSC22D4	-0.52	-4.9	-0.3	1.74e-6	Lung function (FEV1/FVC);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03682872	chr6:158402912	SYNJ2	-0.58	-6.57	-0.39	2.99e-10	Interleukin-4 levels;
KIRP	cis	rs918629	0.530	rs967546	chr5:95232551	G/A	cg16656078	chr5:95278638	ELL2	-0.38	-5.69	-0.34	3.58e-8	IgG glycosylation;
KIRP	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	5.91	0.35	1.15e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg16586182	chr3:47516702	SCAP	0.42	5.0	0.3	1.1e-6	Birth weight;
KIRP	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg09699651	chr6:150184138	LRP11	0.48	6.12	0.36	3.71e-9	Lung cancer;
KIRP	cis	rs73058052	0.569	rs10417980	chr19:50101713	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.52	6.3	0.37	1.38e-9	Fibrinogen levels;
KIRP	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.73	10.84	0.57	1.23e-22	Orofacial clefts;
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.88	15.97	0.71	6.87e-40	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg04990556	chr1:26633338	UBXN11	0.62	5.74	0.34	2.75e-8	Obesity-related traits;
KIRP	cis	rs8060686	0.516	rs8062085	chr16:68289313	C/A	cg26727032	chr16:67993705	SLC12A4	-0.71	-7.78	-0.44	2.05e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.71	0.44	3.15e-13	Height;
KIRP	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-14.23	-0.67	6.32e-34	Gut microbiome composition (summer);
KIRP	cis	rs10875746	0.951	rs10875747	chr12:48525861	A/G	cg26205652	chr12:48591994	NA	0.77	10.39	0.55	3.28e-21	Longevity (90 years and older);
KIRP	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-14.8	-0.69	6.98e-36	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg02100629	chr10:71892760	AIFM2	-0.39	-5.05	-0.31	8.58e-7	Blood protein levels;
KIRP	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg00745463	chr17:30367425	LRRC37B	-0.82	-6.94	-0.4	3.52e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.88	12.07	0.61	1.16e-26	Breast cancer;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-1.09	-17.5	-0.74	4.21e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-5.32	-0.32	2.38e-7	Chronic sinus infection;
KIRP	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.68	9.44	0.52	3.08e-18	Blood protein levels;
KIRP	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg02297831	chr4:17616191	MED28	0.61	7.66	0.44	4.33e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.72	-0.44	2.95e-13	Retinal vascular caliber;
KIRP	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg05555928	chr11:63887634	MACROD1	-0.61	-5.33	-0.32	2.24e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg06766960	chr11:133703094	NA	-0.6	-7.77	-0.44	2.13e-13	Childhood ear infection;
KIRP	trans	rs225245	0.782	rs225293	chr17:33925906	A/G	cg19694781	chr19:47549865	TMEM160	-0.51	-6.2	-0.37	2.34e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg25356066	chr3:128598488	ACAD9	0.47	5.43	0.33	1.38e-7	IgG glycosylation;
KIRP	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.81	12.88	0.63	2.37e-29	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.78	11.23	0.58	6.77e-24	Bladder cancer;
KIRP	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.7	9.54	0.52	1.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.71	6.42	0.38	6.85e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.33	8.4	0.47	3.65e-15	Primary biliary cholangitis;
KIRP	cis	rs7188697	0.922	rs37057	chr16:58561954	T/C	cg21335942	chr16:58549945	SETD6	0.47	5.16	0.31	5e-7	QT interval;
KIRP	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg06223162	chr1:101003688	GPR88	-0.42	-8.66	-0.48	6.25e-16	Monocyte count;
KIRP	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	5.95	0.35	9.23e-9	Platelet count;
KIRP	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg23682824	chr7:23144976	KLHL7	0.55	6.73	0.39	1.16e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.73	7.13	0.41	1.09e-11	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14178294	chr17:43109690	DCAKD	0.55	6.65	0.39	1.89e-10	Interleukin-4 levels;
KIRP	cis	rs1978968	0.763	rs5992943	chr22:18465756	A/C	cg03078520	chr22:18463400	MICAL3	-0.75	-9.18	-0.51	1.76e-17	Presence of antiphospholipid antibodies;
KIRP	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	cis	rs3736594	0.513	rs62141278	chr2:27768381	C/T	cg27432699	chr2:27873401	GPN1	0.57	6.28	0.37	1.56e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.56	-0.56	9.77e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs787274	1.000	rs787301	chr9:115542737	G/T	cg13803584	chr9:115635662	SNX30	0.75	8.25	0.47	9.33e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg25182066	chr10:30743637	MAP3K8	-0.67	-9.22	-0.51	1.35e-17	Inflammatory bowel disease;
KIRP	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.3e-20	Coffee consumption (cups per day);
KIRP	cis	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg00405596	chr8:11794950	NA	-0.51	-6.87	-0.4	5.37e-11	Monocyte count;
KIRP	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg21905437	chr5:178450457	ZNF879	0.58	6.78	0.4	9.04e-11	Pubertal anthropometrics;
KIRP	trans	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-10.08	-0.54	3.21e-20	Triglycerides;
KIRP	cis	rs7116495	1.000	rs482013	chr11:71803962	G/A	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg03188948	chr7:1209495	NA	0.63	6.32	0.37	1.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.46	-5.93	-0.35	1.04e-8	Bladder cancer;
KIRP	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.46	6.29	0.37	1.43e-9	Coronary artery disease;
KIRP	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.65	-9.16	-0.5	2.06e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7577696	0.554	rs3769605	chr2:32322456	A/G	cg02381751	chr2:32503542	YIPF4	-0.52	-5.25	-0.32	3.25e-7	Inflammatory biomarkers;
KIRP	cis	rs80282103	0.618	rs76068439	chr10:1121018	T/A	cg08668510	chr10:1095578	IDI1	0.95	5.63	0.34	4.79e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01740020	chr11:12132460	MICAL2	0.45	6.15	0.37	3.06e-9	Parkinson's disease;
KIRP	cis	rs16858210	0.837	rs11716104	chr3:183581999	G/C	cg25686905	chr3:183603175	PARL	-0.41	-4.87	-0.3	2.03e-6	Menopause (age at onset);
KIRP	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.32	0.37	1.24e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg16751203	chr2:127950803	CYP27C1	0.38	4.95	0.3	1.37e-6	Protein C levels;
KIRP	cis	rs72843166	0.589	rs72841385	chr17:61426880	C/T	cg19683800	chr17:61518354	CYB561	-0.42	-5.22	-0.32	3.77e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22022973	chr19:21933745	LOC641367;ZNF100	0.48	6.24	0.37	1.92e-9	Pancreatic cancer;
KIRP	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg27205649	chr11:78285834	NARS2	0.63	7.38	0.43	2.47e-12	Alzheimer's disease (survival time);
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg08662619	chr6:150070041	PCMT1	0.35	5.85	0.35	1.59e-8	Lung cancer;
KIRP	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg00405596	chr8:11794950	NA	-0.37	-4.93	-0.3	1.53e-6	Morning vs. evening chronotype;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg20821899	chr2:196642630	DNAH7	-0.8	-6.14	-0.36	3.21e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.28	0.62	2.28e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg06636001	chr8:8085503	FLJ10661	0.71	9.06	0.5	4.22e-17	Retinal vascular caliber;
KIRP	cis	rs12282928	0.694	rs1872023	chr11:48343659	C/A	cg26585981	chr11:48327164	OR4S1	0.5	6.07	0.36	4.7e-9	Migraine - clinic-based;
KIRP	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.97	0.36	8.28e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg17252645	chr8:143867129	LY6D	-0.52	-9.71	-0.53	4.61e-19	Urinary tract infection frequency;
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21016266	chr12:122356598	WDR66	0.48	6.27	0.37	1.64e-9	Mean corpuscular volume;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.79	7.09	0.41	1.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4253772	0.872	rs79700435	chr22:46638211	G/A	cg24881330	chr22:46731750	TRMU	0.64	5.39	0.33	1.65e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs35740288	0.731	rs11638407	chr15:86094655	A/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.26	-0.32	3.13e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7792596	0.565	rs58784836	chr7:93985600	G/C	cg20814616	chr7:94014465	NA	-0.4	-6.37	-0.38	9.47e-10	Intelligence;
KIRP	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs1215050	0.791	rs165247	chr4:98692399	A/G	cg05340658	chr4:99064831	C4orf37	0.54	6.48	0.38	4.96e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg06521331	chr12:34319734	NA	-0.56	-6.92	-0.4	3.88e-11	Bladder cancer;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.42	5.5	0.33	9.37e-8	Longevity;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.46	6.79	0.4	8.2e-11	Urate levels in lean individuals;
KIRP	cis	rs12995491	0.902	rs6737641	chr2:88529471	A/T	cg04511125	chr2:88470314	THNSL2	-0.43	-5.38	-0.32	1.74e-7	Response to metformin (IC50);
KIRP	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.62	0.39	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.63	8.12	0.46	2.32e-14	Prudent dietary pattern;
KIRP	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.64	-9.43	-0.52	3.21e-18	Body mass index;
KIRP	cis	rs6001982	0.584	rs73167045	chr22:40842923	T/C	cg07138101	chr22:40742427	ADSL	0.69	5.75	0.34	2.64e-8	Breast cancer;
KIRP	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg14458575	chr2:238380390	NA	0.73	7.5	0.43	1.17e-12	Prostate cancer;
KIRP	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7508	0.573	rs11203932	chr8:17900371	A/G	cg01800426	chr8:17659068	MTUS1	-0.42	-5.35	-0.32	2e-7	Atrial fibrillation;
KIRP	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg15655495	chr12:38532458	NA	-0.26	-5.0	-0.3	1.07e-6	Heart rate;
KIRP	cis	rs3099143	0.901	rs3764244	chr15:77223740	T/C	cg21673338	chr15:77095150	SCAPER	-0.52	-5.42	-0.33	1.4e-7	Recalcitrant atopic dermatitis;
KIRP	cis	rs669446	0.533	rs7543520	chr1:44243866	T/C	cg12599982	chr1:44399894	ARTN	0.42	5.21	0.32	4.01e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs12532214	0.690	rs6971710	chr7:3140173	G/A	cg19214707	chr7:3157722	NA	-0.68	-6.33	-0.37	1.15e-9	Itch intensity from mosquito bite;
KIRP	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg00310523	chr12:86230176	RASSF9	0.39	5.99	0.36	7.29e-9	Major depressive disorder;
KIRP	cis	rs55962025	0.711	rs363063	chr4:3141488	G/A	cg06533319	chr4:3265114	C4orf44	0.39	5.05	0.31	8.55e-7	Parental longevity (mother's age at death);
KIRP	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.17	0.37	2.77e-9	Personality dimensions;
KIRP	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg15890332	chr12:107067104	RFX4	-0.39	-6.6	-0.39	2.49e-10	Heart rate;
KIRP	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg02175308	chr1:109941060	SORT1	-0.26	-5.0	-0.3	1.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg22676075	chr6:135203613	NA	0.48	6.87	0.4	5.22e-11	Red blood cell count;
KIRP	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.56	8.98	0.5	7e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.99	13.24	0.64	1.46e-30	Menopause (age at onset);
KIRP	trans	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg18187862	chr3:45730750	SACM1L	0.53	6.1	0.36	4.05e-9	Primary sclerosing cholangitis;
KIRP	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.53	6.2	0.37	2.34e-9	Aortic root size;
KIRP	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.58	-7.1	-0.41	1.35e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	0.99	13.73	0.66	3.12e-32	Total cholesterol levels;
KIRP	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07169764	chr2:136633963	MCM6	0.58	6.86	0.4	5.51e-11	Mosquito bite size;
KIRP	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg00106254	chr7:1943704	MAD1L1	-0.62	-6.73	-0.39	1.21e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.58	-6.87	-0.4	5.23e-11	Mosquito bite size;
KIRP	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11987759	chr7:65425863	GUSB	0.48	6.25	0.37	1.81e-9	Aortic root size;
KIRP	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.88	-0.35	1.3e-8	Height;
KIRP	trans	rs9443189	0.950	rs276698	chr6:76473071	T/C	cg06311355	chr22:24577269	SUSD2	0.31	6.05	0.36	5.42e-9	Prostate cancer;
KIRP	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.23	-0.46	1.1e-14	Monocyte percentage of white cells;
KIRP	cis	rs7951870	0.504	rs7484125	chr11:46588267	C/T	cg16389345	chr11:46697382	NA	-0.52	-7.03	-0.41	1.97e-11	Schizophrenia;
KIRP	cis	rs6968419	0.755	rs3823977	chr7:115893407	A/T	cg02561103	chr7:115862891	TES	-0.41	-5.93	-0.35	1.04e-8	Intraocular pressure;
KIRP	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg05347473	chr6:146136440	FBXO30	0.56	7.77	0.44	2.07e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.9	-0.4	4.26e-11	Vitiligo;
KIRP	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg23172400	chr8:95962367	TP53INP1	-0.27	-5.36	-0.32	1.91e-7	Type 2 diabetes;
KIRP	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.73	7.35	0.42	2.85e-12	Bipolar disorder;
KIRP	cis	rs12580194	0.593	rs12581959	chr12:55787311	G/A	cg19537932	chr12:55886519	OR6C68	-0.52	-6.41	-0.38	7.21e-10	Cancer;
KIRP	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg12573674	chr2:1569213	NA	-0.59	-5.29	-0.32	2.64e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2224391	0.737	rs36117780	chr6:5262233	A/G	cg13962347	chr6:5174647	LYRM4	-0.62	-8.42	-0.47	3.16e-15	Height;
KIRP	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.48	-7.7	-0.44	3.23e-13	Height;
KIRP	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06850241	chr22:41845214	NA	0.42	4.86	0.3	2.13e-6	Vitiligo;
KIRP	cis	rs1978968	0.833	rs5992941	chr22:18463747	T/C	cg02610425	chr22:18483192	MICAL3	0.37	5.5	0.33	9.37e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22590775	chr19:49891494	CCDC155	0.66	9.08	0.5	3.56e-17	Multiple sclerosis;
KIRP	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg22617819	chr1:44378782	ST3GAL3	-0.36	-5.75	-0.34	2.66e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.94	11.72	0.6	1.69e-25	Alzheimer's disease;
KIRP	cis	rs662064	0.925	rs597438	chr1:10554505	A/G	cg19773385	chr1:10388646	KIF1B	0.41	5.46	0.33	1.16e-7	Asthma;
KIRP	trans	rs11840092	0.623	rs79476007	chr13:58095999	A/G	cg10539861	chr10:101418593	ENTPD7	0.62	6.05	0.36	5.44e-9	Alcohol dependence (age at onset);
KIRP	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.34	-0.32	2.06e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20749790	chr20:4982291	SLC23A2	0.45	6.19	0.37	2.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg03468072	chr12:39539422	NA	0.43	5.92	0.35	1.07e-8	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg01559446	chr3:44596178	ZNF167	-0.38	-5.57	-0.33	6.8e-8	Depressive symptoms;
KIRP	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg25272121	chr1:152190972	HRNR	-0.43	-5.95	-0.35	9.09e-9	Inflammatory skin disease;
KIRP	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.41	7.49	0.43	1.25e-12	Vitiligo;
KIRP	cis	rs34779708	0.931	rs34087268	chr10:35346724	T/G	cg04310649	chr10:35416472	CREM	-0.54	-6.02	-0.36	6.43e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11605275	1.000	rs11604681	chr11:20031042	G/A	cg14835545	chr11:20032148	NAV2	-0.81	-6.2	-0.37	2.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.46	-6.48	-0.38	4.87e-10	Coronary artery disease;
KIRP	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1891275	0.515	rs11186666	chr10:93477919	T/C	cg07889827	chr10:93443413	NA	-0.43	-7.33	-0.42	3.29e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	14.28	0.67	4.27e-34	Platelet count;
KIRP	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg23024343	chr7:107201750	COG5	0.4	4.93	0.3	1.48e-6	Coronary artery disease;
KIRP	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2120243	0.647	rs9289983	chr3:157146005	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.37	5.06	0.31	8.25e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs8060686	0.858	rs7198357	chr16:67884619	A/G	cg26727032	chr16:67993705	SLC12A4	0.78	9.47	0.52	2.5e-18	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg06740227	chr12:86229804	RASSF9	-0.48	-5.88	-0.35	1.34e-8	Major depressive disorder;
KIRP	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg23127183	chr11:57508653	C11orf31	-0.53	-6.71	-0.39	1.32e-10	Schizophrenia;
KIRP	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.56	8.03	0.46	3.99e-14	Carotid intima media thickness;
KIRP	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.25	-0.32	3.3e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8014252	0.614	rs60251828	chr14:71061451	C/G	cg19730268	chr14:71022823	NA	-0.72	-6.4	-0.38	7.9e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4561483	0.564	rs12444127	chr16:12018010	T/A	cg08843971	chr16:11963173	GSPT1	0.56	7.81	0.45	1.7e-13	Testicular germ cell tumor;
KIRP	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg03714773	chr7:91764589	CYP51A1	0.39	5.63	0.34	4.96e-8	Breast cancer;
KIRP	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg01721255	chr8:58191610	C8orf71	0.7	5.68	0.34	3.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2910162	1.000	rs888656	chr5:159903870	C/G	cg03306240	chr5:159912455	MIR146A	-0.42	-6.32	-0.37	1.21e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9308731	1.000	rs7567444	chr2:111863438	T/C	cg23466623	chr2:111982296	NA	-0.46	-5.66	-0.34	4.2e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.56	5.14	0.31	5.57e-7	Bipolar disorder;
KIRP	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	6.48	0.38	5.03e-10	Initial pursuit acceleration;
KIRP	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	7.28	0.42	4.49e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-5.32	-0.32	2.31e-7	Crohn's disease;
KIRP	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg10018233	chr7:150070692	REPIN1	0.58	7.48	0.43	1.29e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg19847130	chr8:10466454	RP1L1	0.38	5.95	0.35	9.26e-9	Neuroticism;
KIRP	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	trans	rs2047076	1.000	rs62365097	chr5:76059490	C/T	cg26241462	chr11:6677965	DCHS1	-0.51	-6.14	-0.36	3.24e-9	Monocyte count;
KIRP	cis	rs12900413	0.603	rs2882677	chr15:90299514	C/T	cg24650279	chr15:90327240	NA	-0.41	-5.16	-0.31	5.09e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs6142102	0.602	rs11696338	chr20:32687611	T/C	cg08999081	chr20:33150536	PIGU	0.38	4.9	0.3	1.72e-6	Skin pigmentation;
KIRP	cis	rs7646881	0.812	rs73017540	chr3:158460788	T/A	cg19483011	chr3:158453295	NA	-0.56	-5.89	-0.35	1.23e-8	Tetralogy of Fallot;
KIRP	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-9.44	-0.52	3e-18	Morning vs. evening chronotype;
KIRP	cis	rs6547631	0.844	rs13012309	chr2:85907924	G/A	cg24620635	chr2:85921963	GNLY	0.32	4.86	0.3	2.07e-6	Blood protein levels;
KIRP	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.59	-7.37	-0.43	2.57e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6681460	0.576	rs2859914	chr1:66989840	A/G	cg13052034	chr1:66999238	SGIP1	0.42	5.65	0.34	4.5e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs16912285	0.591	rs12794505	chr11:24364195	A/G	ch.11.24196551F	chr11:24239977	NA	-0.62	-5.92	-0.35	1.07e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs17023223	0.537	rs10923741	chr1:119604473	A/T	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	2.94e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg04691961	chr3:161091175	C3orf57	-0.39	-5.7	-0.34	3.33e-8	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg02462569	chr6:150064036	NUP43	-0.47	-6.82	-0.4	6.93e-11	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18874425	chr19:2754747	SGTA	-0.44	-6.33	-0.37	1.15e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9469913	0.668	rs76967117	chr6:34603691	G/A	cg17674042	chr6:34482479	PACSIN1	-0.58	-6.04	-0.36	5.79e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23479892	chr3:15469033	METTL6;EAF1	0.49	6.32	0.37	1.2e-9	Parkinson's disease;
KIRP	cis	rs12780845	0.540	rs3780962	chr10:17193346	A/G	cg01003015	chr10:17271136	VIM	-0.48	-6.34	-0.37	1.11e-9	Homocysteine levels;
KIRP	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.93	6.32	0.37	1.23e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs35110281	0.755	rs8127297	chr21:45063847	G/A	cg21573476	chr21:45109991	RRP1B	-0.6	-8.01	-0.45	4.48e-14	Mean corpuscular volume;
KIRP	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.08	-0.31	7.29e-7	Parkinson's disease;
KIRP	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg17554472	chr22:41940697	POLR3H	-0.6	-6.41	-0.38	7.35e-10	Vitiligo;
KIRP	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.8	-0.4	7.95e-11	Mood instability;
KIRP	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.71	9.92	0.53	1.03e-19	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg05347473	chr6:146136440	FBXO30	0.61	8.63	0.48	7.62e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg11410718	chr7:27170412	HOXA4	-0.38	-5.42	-0.33	1.39e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.41	0.55	3e-21	Dupuytren's disease;
KIRP	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.88	-12.34	-0.62	1.47e-27	Personality dimensions;
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg10207240	chr12:122356781	WDR66	-0.56	-7.49	-0.43	1.21e-12	Mean corpuscular volume;
KIRP	cis	rs1816752	0.875	rs8001187	chr13:24976414	G/A	cg02811702	chr13:24901961	NA	0.41	5.28	0.32	2.79e-7	Obesity-related traits;
KIRP	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.79	0.4	8.57e-11	Tonsillectomy;
KIRP	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	4.88	0.3	1.89e-6	Schizophrenia;
KIRP	cis	rs9310709	0.518	rs506284	chr3:23048922	A/T	cg00327796	chr3:23032191	NA	-0.4	-5.09	-0.31	7.12e-7	Chronic kidney disease and serum creatinine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24581572	chr1:205197876	TMCC2	0.48	6.58	0.39	2.83e-10	Smoking initiation;
KIRP	cis	rs17453880	0.929	rs4391148	chr5:152026986	T/C	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.02	0.3	1.01e-6	Renal cell carcinoma;
KIRP	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.5	0.48	1.81e-15	IgG glycosylation;
KIRP	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg07395648	chr5:131743802	NA	-0.53	-7.62	-0.44	5.51e-13	Breast cancer;
KIRP	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.87	0.4	5.13e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26465101	chr13:111367253	ING1	0.44	6.5	0.38	4.45e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg00938859	chr5:1591904	SDHAP3	0.6	8.0	0.45	5.04e-14	Breast cancer;
KIRP	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.39	-0.32	1.66e-7	Height;
KIRP	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	1.07	22.86	0.82	8.78e-63	Parkinson's disease;
KIRP	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg25547332	chr5:131281432	NA	0.48	5.45	0.33	1.2e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9469913	0.604	rs2814948	chr6:34653413	G/A	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.13	-0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs17453880	0.929	rs7707955	chr5:152042028	G/T	cg12297329	chr5:152029980	NA	0.7	10.47	0.56	1.93e-21	Subjective well-being;
KIRP	cis	rs394563	0.559	rs7752555	chr6:149671116	A/G	cg16235748	chr6:149772707	ZC3H12D	0.3	5.0	0.3	1.11e-6	Dupuytren's disease;
KIRP	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg02887458	chr19:19495540	GATAD2A	0.47	5.69	0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.52	6.4	0.38	7.72e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs35740288	0.770	rs35348278	chr15:86200340	G/A	cg10818794	chr15:86012489	AKAP13	-0.43	-5.29	-0.32	2.76e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.66	8.44	0.47	2.68e-15	Multiple sclerosis;
KIRP	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.7	-11.45	-0.59	1.28e-24	Menopause (age at onset);
KIRP	cis	rs55788414	0.932	rs28583467	chr16:81186428	G/C	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.21	-0.46	1.23e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	1.23	10.34	0.55	4.97e-21	Gut microbiota (bacterial taxa);
KIRP	cis	rs4523957	0.928	rs216183	chr17:2173923	A/G	cg16513277	chr17:2031491	SMG6	0.61	8.41	0.47	3.28e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12549025	0.782	rs3736030	chr8:23392733	C/T	cg00472375	chr8:23315376	ENTPD4	0.66	5.75	0.34	2.65e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11764359	chr7:65958608	NA	0.62	6.71	0.39	1.3100000000000001e-10	Aortic root size;
KIRP	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.56	6.02	0.36	6.45e-9	Gut microbiome composition (summer);
KIRP	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.51	0.38	4.13e-10	Menarche (age at onset);
KIRP	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg13072238	chr3:49761600	GMPPB	-0.64	-5.97	-0.36	8.05e-9	Menarche (age at onset);
KIRP	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg04455712	chr21:45112962	RRP1B	0.5	6.89	0.4	4.75e-11	Mean corpuscular volume;
KIRP	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg22676075	chr6:135203613	NA	0.51	7.41	0.43	1.97e-12	Red blood cell count;
KIRP	cis	rs40363	1.000	rs40363	chr16:3509056	G/A	cg21433313	chr16:3507492	NAT15	0.64	7.67	0.44	4.12e-13	Tuberculosis;
KIRP	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.06	0.41	1.68e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg14221460	chr8:27183342	PTK2B	0.5	6.61	0.39	2.42e-10	Neuroticism;
KIRP	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg06121193	chr1:90282411	NA	-0.49	-6.9	-0.4	4.29e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg02733842	chr7:1102375	C7orf50	0.57	5.85	0.35	1.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9398803	0.865	rs1538172	chr6:126748493	A/G	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.35e-10	Male-pattern baldness;
KIRP	trans	rs7246760	0.609	rs12459250	chr19:9909543	C/T	cg02900749	chr2:68251473	NA	-0.89	-8.03	-0.46	4.03e-14	Pursuit maintenance gain;
KIRP	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.49	-6.48	-0.38	5.05e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2299587	0.582	rs17515033	chr8:17898518	A/T	cg01800426	chr8:17659068	MTUS1	-0.44	-5.45	-0.33	1.22e-7	Economic and political preferences;
KIRP	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.7	9.58	0.52	1.16e-18	Mean corpuscular volume;
KIRP	cis	rs894344	0.776	rs16905189	chr8:135598132	C/G	cg09855544	chr8:135498122	ZFAT	0.43	5.5	0.33	9.44e-8	Systolic blood pressure;
KIRP	trans	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg16905586	chr3:49761211	GMPPB	-0.47	-6.24	-0.37	1.87e-9	Atopic dermatitis;
KIRP	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg19468946	chr17:37922297	IKZF3	-0.39	-5.0	-0.3	1.08e-6	Primary biliary cholangitis;
KIRP	cis	rs7712401	0.562	rs383638	chr5:122324678	A/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.84	-12.49	-0.62	4.66e-28	Strep throat;
KIRP	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-9.11	-0.5	3.03e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.45	5.15	0.31	5.46e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.7	9.93	0.53	9.57e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.6	8.12	0.46	2.25e-14	Prostate cancer;
KIRP	cis	rs55962025	0.883	rs362273	chr4:3227419	A/G	cg06533319	chr4:3265114	C4orf44	0.45	4.97	0.3	1.25e-6	Parental longevity (mother's age at death);
KIRP	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.98	0.3	1.21e-6	Menopause (age at onset);
KIRP	cis	rs7737355	0.812	rs244735	chr5:130818061	C/T	cg06307176	chr5:131281290	NA	0.41	4.96	0.3	1.3e-6	Life satisfaction;
KIRP	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.67	7.86	0.45	1.19e-13	Testicular germ cell tumor;
KIRP	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9653442	0.545	rs2009095	chr2:100765081	C/T	cg17356467	chr2:100759845	AFF3	0.45	6.11	0.36	3.78e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.45	5.41	0.33	1.52e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs208520	0.821	rs9363572	chr6:67012231	C/T	cg07460842	chr6:66804631	NA	0.89	7.62	0.44	5.55e-13	Exhaled nitric oxide output;
KIRP	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg05484376	chr2:27715224	FNDC4	0.37	6.08	0.36	4.45e-9	Total body bone mineral density;
KIRP	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.92	12.49	0.62	4.59e-28	Cognitive function;
KIRP	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg18944383	chr4:111397179	ENPEP	0.53	8.38	0.47	4.2e-15	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.87	-12.75	-0.63	6.3e-29	Bone mineral density;
KIRP	trans	rs909341	0.909	rs1151624	chr20:62369895	A/G	cg01311341	chr22:25575246	KIAA1671	0.6	6.91	0.4	4.04e-11	Atopic dermatitis;
KIRP	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg00310523	chr12:86230176	RASSF9	0.43	6.64	0.39	1.95e-10	Major depressive disorder;
KIRP	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg11189052	chr15:85197271	WDR73	-0.53	-4.99	-0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg24881330	chr22:46731750	TRMU	0.68	5.26	0.32	3.19e-7	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs12517041	1.000	rs6870220	chr5:23304587	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.81	6.77	0.4	9.61e-11	Calcium levels;
KIRP	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.4	-6.17	-0.37	2.81e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5.05e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg27147174	chr7:100797783	AP1S1	0.58	7.49	0.43	1.25e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs812925	0.533	rs60997156	chr2:61396539	T/A	cg15711740	chr2:61764176	XPO1	-0.44	-5.35	-0.32	2.02e-7	Immature fraction of reticulocytes;
KIRP	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.43	0.74	7.58e-45	Height;
KIRP	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.46	-6.72	-0.39	1.24e-10	Daytime sleep phenotypes;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	-0.43	-6.02	-0.36	6.17e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.9	-0.45	9.23e-14	Type 2 diabetes;
KIRP	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.25	-0.55	9.2e-21	Schizophrenia;
KIRP	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.78	12.77	0.63	5.66e-29	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.93	-11.13	-0.58	1.44e-23	White matter hyperintensity burden;
KIRP	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.66	9.2	0.51	1.55e-17	Multiple sclerosis;
KIRP	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg09201719	chr10:104596890	CYP17A1	0.4	5.88	0.35	1.33e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs4728302	0.607	rs2042452	chr7:133581093	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.02	0.3	1.01e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	7.07	0.41	1.58e-11	Educational attainment;
KIRP	cis	rs2591576	0.870	rs153283	chr5:165411846	A/G	cg13976338	chr5:165423657	NA	-0.69	-9.86	-0.53	1.58e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg00852783	chr1:26633632	UBXN11	0.54	7.6	0.44	6.18e-13	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19879471	chr8:82394653	FABP4	-0.38	-6.06	-0.36	5.09e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20785715	chr8:144718023	ZNF623	0.52	6.12	0.36	3.67e-9	Inflammatory biomarkers;
KIRP	cis	rs17453880	0.632	rs2964243	chr5:151921873	C/T	cg12297329	chr5:152029980	NA	-0.49	-7.03	-0.41	2e-11	Subjective well-being;
KIRP	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg00405596	chr8:11794950	NA	-0.51	-6.73	-0.39	1.2e-10	Triglycerides;
KIRP	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.26e-9	Schizophrenia;
KIRP	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.63	6.37	0.38	9.19e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09219196	chr12:53901441	NPFF	0.48	6.05	0.36	5.4e-9	Interleukin-4 levels;
KIRP	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs11018874	0.709	rs10830428	chr11:89894294	C/G	cg06174606	chr11:89959870	NA	0.52	5.68	0.34	3.76e-8	White blood cell types;
KIRP	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg03585969	chr10:35415529	CREM	0.76	9.39	0.51	4.29e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2573652	0.723	rs2573655	chr15:100515709	A/C	cg09918751	chr15:100517450	ADAMTS17	-0.8	-12.62	-0.63	1.7e-28	Height;
KIRP	cis	rs2742417	1.000	rs2742435	chr3:45740863	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-5.0	-0.3	1.08e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.71	-10.61	-0.56	6.48e-22	Dupuytren's disease;
KIRP	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-0.84	-9.99	-0.54	6.12e-20	Gut microbiome composition (summer);
KIRP	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-1.17	-14.98	-0.69	1.74e-36	Platelet distribution width;
KIRP	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg04731861	chr2:219085781	ARPC2	0.3	7.61	0.44	5.73e-13	Colorectal cancer;
KIRP	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.94	13.64	0.66	6.36e-32	Coronary artery disease;
KIRP	cis	rs2594989	0.887	rs2442799	chr3:11488640	A/G	cg01796438	chr3:11312864	ATG7	-0.56	-6.54	-0.38	3.56e-10	Circulating chemerin levels;
KIRP	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.42	-5.84	-0.35	1.6e-8	Monocyte count;
KIRP	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.6	8.11	0.46	2.34e-14	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg10495392	chr1:46806563	NSUN4	0.47	5.33	0.32	2.2e-7	Menopause (age at onset);
KIRP	cis	rs2862064	1.000	rs11747316	chr5:156422948	A/G	cg12943317	chr5:156479607	HAVCR1	-0.89	-7.26	-0.42	4.92e-12	Platelet count;
KIRP	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.23	0.32	3.62e-7	Lung cancer;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg05335186	chr13:53173507	NA	0.33	5.24	0.32	3.52e-7	Lewy body disease;
KIRP	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.97	0.36	8.3e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.46	-6.7	-0.39	1.4e-10	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg20673091	chr1:2541236	MMEL1	0.66	9.84	0.53	1.81e-19	Ulcerative colitis;
KIRP	cis	rs9815354	1.000	rs2625667	chr3:41900951	C/A	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4851251	1.000	rs4851251	chr2:100753490	C/T	cg07810366	chr2:100720526	AFF3	0.36	4.93	0.3	1.52e-6	Educational attainment (years of education);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06757784	chr15:66994613	SMAD6	0.49	6.4	0.38	7.7e-10	Parkinson's disease;
KIRP	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.39	1.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02843535	chr17:18759628	NA	0.51	6.05	0.36	5.46e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.66	-10.26	-0.55	8.8e-21	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.65	0.34	4.39e-8	Aortic root size;
KIRP	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-6.21	-0.37	2.3e-9	Aortic root size;
KIRP	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.24	0.47	1.02e-14	Motion sickness;
KIRP	cis	rs911119	1.000	rs34374560	chr20:23609462	C/T	cg09631192	chr20:23583594	CST9	-0.5	-4.9	-0.3	1.71e-6	Chronic kidney disease;
KIRP	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.97e-44	Breast cancer;
KIRP	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg24803719	chr17:45855879	NA	-0.39	-5.16	-0.31	5.16e-7	IgG glycosylation;
KIRP	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.16	16.26	0.72	7.26e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs897080	0.515	rs696595	chr2:44682692	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	5.81	0.35	1.97e-8	Height;
KIRP	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg08126542	chr6:37504118	NA	-0.55	-7.34	-0.42	3.02e-12	Cognitive performance;
KIRP	cis	rs910873	0.505	rs67260051	chr20:33448417	C/T	cg16810054	chr20:33298113	TP53INP2	0.41	4.93	0.3	1.53e-6	Melanoma;
KIRP	cis	rs7017914	0.967	rs1348535	chr8:71662741	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.1	-0.31	6.94e-7	Bone mineral density;
KIRP	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-6.93	-0.4	3.68e-11	Self-reported allergy;
KIRP	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-1.02	-12.51	-0.62	4.13e-28	Breast cancer;
KIRP	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg08125733	chr17:73851984	WBP2	-0.51	-6.35	-0.38	1.06e-9	White matter hyperintensity burden;
KIRP	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.08	-0.31	7.53e-7	Inflammatory skin disease;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.72e-7	Life satisfaction;
KIRP	cis	rs372883	0.519	rs2832274	chr21:30600189	A/T	cg08807101	chr21:30365312	RNF160	0.77	9.7	0.53	4.92e-19	Pancreatic cancer;
KIRP	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.28	0.58	4.68e-24	Alzheimer's disease;
KIRP	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs151997	0.671	rs493507	chr5:50219675	G/T	cg06027927	chr5:50259733	NA	-0.53	-7.33	-0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25565998	chr19:56166418	U2AF2	0.51	6.41	0.38	7.3e-10	Parkinson's disease;
KIRP	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.47	-0.38	5.37e-10	Coronary artery disease;
KIRP	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.57	7.66	0.44	4.38e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg06740227	chr12:86229804	RASSF9	-0.47	-5.96	-0.36	8.57e-9	Major depressive disorder;
KIRP	cis	rs7010876	0.568	rs7357573	chr8:89229980	A/G	cg08624180	chr8:89339080	MMP16	-0.53	-5.14	-0.31	5.63e-7	Schizophrenia;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg05491852	chr1:3663832	KIAA0495	0.64	6.34	0.37	1.12e-9	Lung function (FEV1);
KIRP	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.45	5.84	0.35	1.63e-8	Blood protein levels;
KIRP	cis	rs7536201	1.000	rs7536201	chr1:25293084	T/C	cg23273869	chr1:25296894	NA	-0.37	-5.05	-0.31	8.54e-7	Psoriasis vulgaris;
KIRP	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg24324837	chr19:49891574	CCDC155	0.66	8.52	0.48	1.6e-15	Multiple sclerosis;
KIRP	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.86	-13.48	-0.65	2.26e-31	Breast cancer;
KIRP	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	6.13	0.36	3.39e-9	Recombination measurement;
KIRP	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08822215	chr16:89438651	ANKRD11	-0.46	-6.35	-0.38	1.01e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.63	6.76	0.4	9.69e-11	Gut microbiome composition (summer);
KIRP	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg27147174	chr7:100797783	AP1S1	-0.67	-8.61	-0.48	9.03e-16	Life satisfaction;
KIRP	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12893428	chr3:195717962	SDHAP1	0.43	5.28	0.32	2.81e-7	Pancreatic cancer;
KIRP	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg21132104	chr15:45694354	SPATA5L1	0.75	9.61	0.52	8.79e-19	Homoarginine levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18854735	chr1:1822972	GNB1	0.91	6.45	0.38	5.74e-10	P wave terminal force;
KIRP	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.83	-7.43	-0.43	1.82e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.85	12.23	0.61	3.45e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.74	-7.37	-0.43	2.65e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1318772	1.000	rs11748646	chr5:112662479	A/G	cg12552261	chr5:112820674	MCC	0.82	5.09	0.31	6.97e-7	F-cell distribution;
KIRP	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.78	-0.44	1.94e-13	Coffee consumption (cups per day);
KIRP	cis	rs13385	0.769	rs56997077	chr5:139558412	C/T	cg01860693	chr5:139557145	C5orf32	0.49	5.1	0.31	6.86e-7	Atrial fibrillation;
KIRP	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	7.1	0.41	1.34e-11	Coffee consumption (cups per day);
KIRP	cis	rs7017914	0.967	rs13254908	chr8:71626098	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.54	-5.15	-0.31	5.46e-7	Narcolepsy;
KIRP	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Hypertriglyceridemia;
KIRP	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.57	7.64	0.44	4.93e-13	Schizophrenia;
KIRP	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00585698	chr12:123750864	CDK2AP1	0.49	5.62	0.34	5.29e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.55	-6.83	-0.4	6.61e-11	Hirschsprung disease;
KIRP	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12826209	chr6:26865740	GUSBL1	0.68	6.44	0.38	6.12e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg05347473	chr6:146136440	FBXO30	-0.46	-6.64	-0.39	2.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	9.34	0.51	6e-18	Cognitive test performance;
KIRP	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.68	-8.42	-0.47	3.24e-15	Iron status biomarkers;
KIRP	cis	rs4356932	1.000	rs6848603	chr4:76973521	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.42	7.24	0.42	5.87e-12	Renal cell carcinoma;
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.17	-14.35	-0.67	2.52e-34	Platelet count;
KIRP	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg08461772	chr7:95026248	PON3	0.42	5.92	0.35	1.1e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs5753618	0.519	rs5997939	chr22:31677130	C/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.37	-0.32	1.8e-7	Colorectal cancer;
KIRP	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.34	-7.38	-0.43	2.48e-12	Cutaneous nevi;
KIRP	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg26876637	chr1:152193138	HRNR	0.8	10.39	0.55	3.39e-21	Atopic dermatitis;
KIRP	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.59	7.65	0.44	4.41e-13	Height;
KIRP	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.6	0.34	5.83e-8	Educational attainment;
KIRP	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.5	-6.99	-0.41	2.64e-11	Height;
KIRP	cis	rs3857747	0.931	rs4588741	chr7:40365508	G/T	cg00420559	chr7:40367873	C7orf10	-0.61	-8.26	-0.47	8.98e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg21252483	chr19:49399788	TULP2	-0.48	-6.31	-0.37	1.31e-9	Red cell distribution width;
KIRP	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.53	0.56	1.2e-21	Cognitive test performance;
KIRP	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg09184832	chr6:79620586	NA	-0.53	-7.38	-0.43	2.36e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs17095355	1.000	rs11194924	chr10:111695773	G/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.0	-0.36	7.17e-9	Biliary atresia;
KIRP	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.43	-5.5	-0.33	9.41e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs228437	0.565	rs7749820	chr6:134961923	C/T	cg24504307	chr6:134963096	NA	0.32	5.56	0.33	7.19e-8	Melanoma;
KIRP	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.45	6.24	0.37	1.89e-9	Sitting height ratio;
KIRP	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs11603020	0.950	rs28362948	chr11:57369013	A/C	cg23127183	chr11:57508653	C11orf31	-0.46	-5.42	-0.33	1.41e-7	Blood protein levels;
KIRP	cis	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg08773314	chr2:239334832	ASB1	-0.51	-4.92	-0.3	1.59e-6	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.71	9.88	0.53	1.29e-19	Mood instability;
KIRP	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.85	-8.02	-0.46	4.2e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg16473166	chr22:50639996	SELO	0.64	8.14	0.46	1.92e-14	Obesity-related traits;
KIRP	cis	rs1538970	0.924	rs11211108	chr1:45891152	C/T	cg05343316	chr1:45956843	TESK2	0.71	8.03	0.46	4.02e-14	Platelet count;
KIRP	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg00083206	chr6:110721305	DDO	-0.44	-6.72	-0.39	1.26e-10	Platelet distribution width;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15148028	chr1:245755268	KIF26B	-0.48	-6.34	-0.37	1.07e-9	Survival in pancreatic cancer;
KIRP	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg11189052	chr15:85197271	WDR73	0.48	5.03	0.31	9.69e-7	Schizophrenia;
KIRP	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.9	9.12	0.5	2.85e-17	Methadone dose in opioid dependence;
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.62	9.04	0.5	4.67e-17	Lung cancer;
KIRP	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.65	-9.37	-0.51	4.88e-18	Retinal vascular caliber;
KIRP	cis	rs4812048	0.503	rs41314904	chr20:57564489	G/A	cg23907860	chr20:57583709	CTSZ	0.49	5.0	0.3	1.09e-6	Mean platelet volume;
KIRP	cis	rs78761021	0.755	rs17744048	chr17:9794996	A/G	cg26853458	chr17:9805074	RCVRN	0.51	4.9	0.3	1.74e-6	Type 2 diabetes;
KIRP	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg06558623	chr16:89946397	TCF25	1.1	8.02	0.46	4.38e-14	Skin colour saturation;
KIRP	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	0.85	12.2	0.61	4.23e-27	Homoarginine levels;
KIRP	cis	rs9790314	0.613	rs55956394	chr3:160590693	C/T	cg04691961	chr3:161091175	C3orf57	0.45	6.33	0.37	1.16e-9	Morning vs. evening chronotype;
KIRP	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	6.56	0.39	3.15e-10	Schizophrenia;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.71	6.7	0.39	1.42e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-6.04	-0.36	5.66e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18252515	chr7:66147081	NA	-0.43	-4.96	-0.3	1.34e-6	Aortic root size;
KIRP	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg00409905	chr10:38381863	ZNF37A	-0.54	-6.05	-0.36	5.28e-9	Obesity (extreme);
KIRP	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg07274523	chr3:49395745	GPX1	0.69	8.61	0.48	9.02e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9400467	0.537	rs12210707	chr6:111538387	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.57	5.36	0.32	1.93e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs300890	0.513	rs4605600	chr4:144045705	A/T	cg01719995	chr4:144104893	USP38	0.43	5.58	0.34	6.29e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.65	-0.66	5.95e-32	Monocyte count;
KIRP	cis	rs6991838	0.584	rs61083799	chr8:66487103	C/T	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	1.000	rs10014049	chr4:76953532	C/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.62e-9	Blood protein levels;
KIRP	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.67	-9.45	-0.52	2.73e-18	QRS duration;
KIRP	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg25356066	chr3:128598488	ACAD9	0.5	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.45	-0.33	1.25e-7	Colorectal cancer;
KIRP	cis	rs887797	0.507	rs16959643	chr17:64554417	C/T	cg27019712	chr17:64599478	PRKCA	0.4	5.42	0.33	1.39e-7	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
KIRP	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.82	-8.98	-0.5	7.08e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg05973401	chr12:123451056	ABCB9	-0.48	-5.36	-0.32	1.94e-7	Neutrophil percentage of white cells;
KIRP	cis	rs838147	0.844	rs11083948	chr19:49248120	A/G	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.3e-7	Dietary macronutrient intake;
KIRP	cis	rs76917914	0.820	rs7846880	chr9:100822940	G/A	cg03040243	chr9:100819229	NANS	0.62	6.61	0.39	2.3e-10	Immature fraction of reticulocytes;
KIRP	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg10755058	chr3:40428713	ENTPD3	0.49	6.65	0.39	1.9e-10	Renal cell carcinoma;
KIRP	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.81	10.84	0.57	1.2e-22	Pancreatic cancer;
KIRP	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.33	5.06	0.31	8.1e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.6	8.58	0.48	1.09e-15	Resting heart rate;
KIRP	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg26850624	chr5:429559	AHRR	0.32	5.82	0.35	1.8e-8	Cystic fibrosis severity;
KIRP	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg15117754	chr3:10150083	C3orf24	0.48	4.92	0.3	1.62e-6	Alzheimer's disease;
KIRP	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.63	0.56	5.86e-22	Hip circumference adjusted for BMI;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02537014	chr2:168974265	STK39	-0.38	-6.16	-0.37	2.87e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs10875746	0.623	rs10875793	chr12:48697430	T/A	cg20731937	chr12:48336164	NA	0.48	5.87	0.35	1.39e-8	Longevity (90 years and older);
KIRP	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.09	-0.31	6.96e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs2441986	0.894	rs2443443	chr11:57948952	G/A	cg19752551	chr11:57585705	CTNND1	0.41	5.05	0.31	8.57e-7	Systolic blood pressure;
KIRP	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs75920871	1.000	rs75858236	chr11:116872263	A/G	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs13401104	0.796	rs10929171	chr2:237115622	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7508	0.511	rs438818	chr8:17899561	A/G	cg01800426	chr8:17659068	MTUS1	-0.46	-4.93	-0.3	1.49e-6	Atrial fibrillation;
KIRP	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.8	-0.45	1.71e-13	Gut microbiome composition (summer);
KIRP	cis	rs6969780	0.778	rs61384251	chr7:27146202	A/G	cg26364809	chr7:27145159	NA	-0.62	-5.55	-0.33	7.31e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2456568	0.606	rs11020616	chr11:93691594	C/T	cg26875233	chr11:93583750	C11orf90	0.31	5.58	0.34	6.41e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-0.65	-7.0	-0.41	2.41e-11	YKL-40 levels;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09747230	chr5:43613142	NNT	0.61	6.79	0.4	8.25e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg02160872	chr5:212506	CCDC127	-0.46	-5.01	-0.3	1.04e-6	Breast cancer;
KIRP	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.39	-0.38	8.06e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg24879335	chr3:133465180	TF	-0.45	-7.54	-0.43	9.04e-13	Iron status biomarkers;
KIRP	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.89	0.49	1.33e-16	Motion sickness;
KIRP	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	14.36	0.68	2.18e-34	Tonsillectomy;
KIRP	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	8.52	0.48	1.67e-15	Mood instability;
KIRP	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.68	4.95	0.3	1.38e-6	Childhood ear infection;
KIRP	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06481639	chr22:41940642	POLR3H	0.46	5.64	0.34	4.77e-8	Vitiligo;
KIRP	cis	rs16948098	1	rs16948098	chr15:44219607	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	7.1	0.41	1.35e-11	Serum albumin level;
KIRP	cis	rs877282	1.000	rs11253363	chr10:771891	A/G	cg17470449	chr10:769945	NA	0.62	6.27	0.37	1.59e-9	Uric acid levels;
KIRP	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.52	-8.16	-0.46	1.74e-14	Monocyte count;
KIRP	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16414030	chr3:133502952	NA	-0.51	-5.99	-0.36	7.37e-9	Iron status biomarkers;
KIRP	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	1.04	19.59	0.78	3.86e-52	Heart rate;
KIRP	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.84	-0.45	1.37e-13	Type 2 diabetes;
KIRP	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg02336718	chr17:17403227	NA	-0.32	-4.91	-0.3	1.69e-6	Total body bone mineral density;
KIRP	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08822215	chr16:89438651	ANKRD11	-0.46	-6.3	-0.37	1.36e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.55	-7.09	-0.41	1.39e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg18240062	chr17:79603768	NPLOC4	0.69	8.32	0.47	6.16e-15	Myopia;
KIRP	cis	rs9290877	0.667	rs9858643	chr3:188464910	C/T	cg17392043	chr3:188495102	LPP	-0.55	-7.07	-0.41	1.62e-11	IgE levels;
KIRP	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.44	5.73	0.34	3e-8	Motion sickness;
KIRP	cis	rs17123764	0.818	rs11169081	chr12:49985210	G/A	cg20471783	chr12:50157085	TMBIM6	0.33	5.05	0.31	8.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10465746	0.658	rs980418	chr1:84365653	T/G	cg10977910	chr1:84465055	TTLL7	0.55	7.0	0.41	2.39e-11	Obesity-related traits;
KIRP	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg00982548	chr2:198649783	BOLL	-0.53	-4.93	-0.3	1.48e-6	Ulcerative colitis;
KIRP	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.59	-5.09	-0.31	7.25e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg25486957	chr4:152246857	NA	-0.51	-5.68	-0.34	3.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3105593	0.965	rs3109891	chr15:50874964	T/C	cg05456662	chr15:50716270	USP8	0.41	5.1	0.31	6.78e-7	QT interval;
KIRP	trans	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg17822266	chr1:2720087	NA	-0.46	-6.28	-0.37	1.51e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg02811702	chr13:24901961	NA	0.4	5.37	0.32	1.84e-7	Obesity-related traits;
KIRP	cis	rs12615966	1.000	rs9941641	chr2:105384179	A/G	cg16465502	chr2:105461796	NA	0.55	5.38	0.32	1.77e-7	Pancreatic cancer;
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg01721255	chr8:58191610	C8orf71	-0.53	-4.93	-0.3	1.48e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1829883	0.898	rs13184400	chr5:98784722	G/A	cg08333243	chr5:99726346	NA	-0.39	-5.2	-0.31	4.27e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.89	0.35	1.29e-8	Breast cancer;
KIRP	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	5.09	0.31	7.15e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06500355	chr6:111804104	REV3L	0.56	7.42	0.43	1.87e-12	Gut microbiome composition (summer);
KIRP	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg00405596	chr8:11794950	NA	-0.42	-5.41	-0.33	1.51e-7	Triglycerides;
KIRP	cis	rs6960043	0.905	rs7786873	chr7:15060410	A/G	cg19272540	chr7:15055459	NA	-0.21	-5.54	-0.33	7.74e-8	Type 2 diabetes;
KIRP	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg22903471	chr2:27725779	GCKR	-0.39	-5.37	-0.32	1.82e-7	Oral cavity cancer;
KIRP	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs4349753	0.904	rs456670	chr5:144156836	C/G	cg16033277	chr17:80885358	TBCD	-0.4	-6.13	-0.36	3.57e-9	Photic sneeze reflex;
KIRP	cis	rs7224685	0.530	rs36019144	chr17:3987499	T/C	cg09695851	chr17:3907499	NA	0.6	5.66	0.34	4.26e-8	Type 2 diabetes;
KIRP	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7719624	0.545	rs12521108	chr5:135409124	G/A	cg16684184	chr5:135415129	NA	-0.34	-5.2	-0.31	4.28e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg26134248	chr17:3907702	NA	-0.54	-7.83	-0.45	1.42e-13	Type 2 diabetes;
KIRP	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg06212747	chr3:49208901	KLHDC8B	0.51	5.2	0.31	4.25e-7	Menarche (age at onset);
KIRP	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg21937377	chr3:194868750	C3orf21	0.24	5.06	0.31	8.04e-7	Non-small cell lung cancer;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg23352942	chr3:46931381	PTH1R	-0.51	-6.84	-0.4	6.27e-11	Birth weight;
KIRP	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg08662619	chr6:150070041	PCMT1	0.36	5.78	0.35	2.24e-8	Lung cancer;
KIRP	cis	rs7527798	1.000	rs12748243	chr1:207872657	C/T	cg09232269	chr1:207846808	CR1L	-0.41	-5.03	-0.31	9.63e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.36	0.47	4.69e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17321999	0.516	rs10495774	chr2:30506676	C/T	cg05247661	chr2:30472410	LBH	-0.62	-5.1	-0.31	6.8e-7	Systemic lupus erythematosus;
KIRP	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg18944383	chr4:111397179	ENPEP	-0.53	-6.24	-0.37	1.94e-9	Intraocular pressure;
KIRP	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.63	8.97	0.5	7.87e-17	Schizophrenia;
KIRP	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg24375607	chr4:120327624	NA	-0.48	-5.72	-0.34	3.12e-8	Corneal astigmatism;
KIRP	cis	rs2151522	0.525	rs7748362	chr6:127156364	A/G	cg21431617	chr6:127135037	NA	0.31	5.48	0.33	1.03e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.65	5.49	0.33	1.01e-7	Bipolar disorder;
KIRP	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg20312557	chr2:97357134	FER1L5	-0.79	-5.39	-0.32	1.66e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg08873628	chr1:175162347	KIAA0040	-0.4	-5.83	-0.35	1.7e-8	Alcohol dependence;
KIRP	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg07946961	chr19:1955956	C19orf34;CSNK1G2	-0.39	-4.92	-0.3	1.56e-6	Coronary artery disease;
KIRP	cis	rs4654899	1.000	rs6700718	chr1:21299363	A/C	cg05370193	chr1:21551575	ECE1	-0.4	-5.51	-0.33	9.06e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.77	0.35	2.37e-8	Blood protein levels;
KIRP	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11987759	chr7:65425863	GUSB	-0.62	-8.25	-0.47	9.49e-15	Aortic root size;
KIRP	cis	rs3109167	0.524	rs73174586	chr7:83133021	T/C	cg14519356	chr7:83097669	SEMA3E	0.5	6.58	0.39	2.75e-10	Blood protein levels;
KIRP	cis	rs2230307	0.536	rs834277	chr1:100510855	T/G	cg24955406	chr1:100503596	HIAT1	0.69	7.93	0.45	7.78e-14	Carotid intima media thickness;
KIRP	cis	rs4356932	1.000	rs10025102	chr4:76955358	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg13165212	chr22:42675999	NA	0.4	6.85	0.4	5.84e-11	Cognitive function;
KIRP	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-6.42	-0.38	7.16e-10	IgG glycosylation;
KIRP	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg01849789	chr22:41697279	ZC3H7B	-0.42	-5.22	-0.32	3.9e-7	Neuroticism;
KIRP	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg05669848	chr5:237993	SDHA	-0.48	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs5753618	0.561	rs5753521	chr22:31638027	T/C	cg02404636	chr22:31891804	SFI1	-0.47	-5.2	-0.31	4.22e-7	Colorectal cancer;
KIRP	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg20169779	chr10:135381914	SYCE1	-0.63	-5.84	-0.35	1.64e-8	Gout;
KIRP	cis	rs4664293	1.000	rs6432542	chr2:160480536	T/C	cg08347373	chr2:160653686	CD302	-0.39	-5.95	-0.35	9e-9	Monocyte percentage of white cells;
KIRP	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.77	-9.3	-0.51	8.15e-18	Type 2 diabetes;
KIRP	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg20744362	chr22:50050164	C22orf34	0.35	5.31	0.32	2.4e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.35	-5.13	-0.31	5.76e-7	Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20540327	chr15:72668275	HEXA;C15orf34	0.55	6.57	0.39	3.02e-10	Smoking initiation;
KIRP	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.54	-5.78	-0.35	2.28e-8	Aortic root size;
KIRP	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg26338869	chr17:61819248	STRADA	0.54	6.48	0.38	4.95e-10	Prudent dietary pattern;
KIRP	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs7945718	0.870	rs10765988	chr11:12731218	C/T	cg25843174	chr11:12811716	TEAD1	0.44	8.27	0.47	8.46e-15	Educational attainment (years of education);
KIRP	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11814370	chr10:105110944	PCGF6	0.48	6.08	0.36	4.52e-9	Parkinson's disease;
KIRP	cis	rs72634258	0.786	rs7514098	chr1:8177632	G/A	cg00042356	chr1:8021962	PARK7	0.5	4.95	0.3	1.37e-6	Inflammatory bowel disease;
KIRP	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg06521331	chr12:34319734	NA	-0.61	-7.38	-0.43	2.45e-12	Morning vs. evening chronotype;
KIRP	cis	rs7870753	0.685	rs10820632	chr9:99212233	G/T	cg25260653	chr9:99212216	HABP4	0.56	5.93	0.35	9.96e-9	Height;
KIRP	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-11.78	-0.6	1.06e-25	Systemic lupus erythematosus;
KIRP	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg09904177	chr6:26538194	HMGN4	0.54	7.44	0.43	1.63e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg07384165	chr1:10488281	NA	-0.41	-5.39	-0.33	1.61e-7	Breast size;
KIRP	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.5	6.15	0.37	3.07e-9	Alzheimer's disease (late onset);
KIRP	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.52	0.56	1.27e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.27	-0.32	3.04e-7	Bladder cancer;
KIRP	cis	rs920590	0.837	rs4398935	chr8:19649487	T/C	cg03894339	chr8:19674705	INTS10	0.45	5.58	0.34	6.35e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2979489	0.699	rs17554116	chr8:30419334	C/T	cg26383811	chr8:30366931	RBPMS	-0.44	-5.98	-0.36	7.81e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.0	-13.91	-0.66	7.46e-33	Ulcerative colitis;
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg09699651	chr6:150184138	LRP11	0.4	5.22	0.32	3.87e-7	Lung cancer;
KIRP	cis	rs7656342	0.665	rs10939600	chr4:9886931	A/T	cg11266682	chr4:10021025	SLC2A9	-0.35	-5.53	-0.33	8.35e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg01843034	chr6:37503916	NA	-0.92	-13.27	-0.65	1.12e-30	Cognitive performance;
KIRP	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg16077055	chr2:106428750	NCK2	0.29	5.91	0.35	1.15e-8	Addiction;
KIRP	cis	rs10899021	1.000	rs11236211	chr11:74393211	G/A	cg25880958	chr11:74394337	NA	-0.66	-5.04	-0.31	8.95e-7	Response to metformin (IC50);
KIRP	cis	rs16975963	0.594	rs73039018	chr19:38217894	C/A	cg18030218	chr19:38865513	PSMD8	0.56	4.97	0.3	1.24e-6	Longevity;
KIRP	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg16329650	chr2:213403929	ERBB4	0.48	6.47	0.38	5.26e-10	Symmetrical dimethylarginine levels;
KIRP	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	13.1	0.64	4.12e-30	Alzheimer's disease;
KIRP	cis	rs72829446	0.530	rs12325773	chr17:7393871	G/A	cg02795151	chr17:7402630	POLR2A	0.77	7.9	0.45	9.54e-14	Androgen levels;
KIRP	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.99	0.71	6.11e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg03653399	chr8:142233436	SLC45A4	0.91	14.42	0.68	1.45e-34	Immature fraction of reticulocytes;
KIRP	cis	rs6746896	0.708	rs968470	chr2:97423626	T/C	cg01990225	chr2:97406019	LMAN2L	-0.55	-7.1	-0.41	1.35e-11	Bipolar disorder;
KIRP	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg17279839	chr7:150038598	RARRES2	0.42	5.82	0.35	1.85e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2387326	1.000	rs34558168	chr10:129932106	T/C	cg16087940	chr10:129947807	NA	-0.46	-6.05	-0.36	5.48e-9	Select biomarker traits;
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.59	5.33	0.32	2.22e-7	Alzheimer's disease;
KIRP	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg09455208	chr3:40491958	NA	0.36	6.32	0.37	1.21e-9	Renal cell carcinoma;
KIRP	cis	rs16958440	1.000	rs62096470	chr18:44641466	G/C	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg19468946	chr17:37922297	IKZF3	-0.47	-6.57	-0.39	3.04e-10	Asthma;
KIRP	trans	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg13565492	chr6:43139072	SRF	-0.81	-7.2	-0.42	7.25e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.24e-6	Menopause (age at onset);
KIRP	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.49	6.27	0.37	1.58e-9	Age-related hearing impairment;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.43	-5.17	-0.31	4.77e-7	Longevity;Endometriosis;
KIRP	trans	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg15469184	chr8:337539	NA	0.62	7.12	0.41	1.16e-11	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27591053	chr5:180671165	GNB2L1;SNORD95	0.5	6.67	0.39	1.7e-10	Parkinson's disease;
KIRP	cis	rs17407555	0.560	rs73229842	chr4:10044524	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.02	-0.3	9.87e-7	Schizophrenia (age at onset);
KIRP	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.78	10.1	0.54	2.82e-20	Aortic root size;
KIRP	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg05729581	chr11:3078854	CARS	-0.55	-7.05	-0.41	1.8e-11	Longevity;
KIRP	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.65	-9.27	-0.51	9.66e-18	Retinal vascular caliber;
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.59	-8.32	-0.47	6.13e-15	Mean corpuscular volume;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg25984524	chr10:104871849	NT5C2	0.43	6.92	0.4	3.9e-11	C-reactive protein;
KIRP	cis	rs4523957	0.928	rs6502155	chr17:2176964	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.33	-0.47	5.86e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2191566	0.960	rs12232810	chr19:44525122	A/G	cg18700516	chr19:44507157	ZNF230	-0.44	-5.17	-0.31	4.8e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.04	0.61	1.54e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs73198271	0.628	rs11783944	chr8:8597801	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.2	-0.31	4.12e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.59	-7.89	-0.45	1.02e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7828089	0.967	rs7828414	chr8:22264585	T/C	cg13512537	chr8:22265999	SLC39A14	-0.45	-6.09	-0.36	4.3e-9	Verbal declarative memory;
KIRP	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.52	-6.66	-0.39	1.74e-10	Longevity;
KIRP	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg17810781	chr1:201082982	CACNA1S	0.44	7.07	0.41	1.55e-11	Permanent tooth development;
KIRP	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.59	-0.34	6.13e-8	Aortic root size;
KIRP	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg06289844	chr6:126071538	HEY2	0.44	6.49	0.38	4.67e-10	Brugada syndrome;
KIRP	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2729354	0.768	rs2581922	chr11:57265400	C/T	cg24343310	chr11:57249947	NA	0.27	5.22	0.32	3.88e-7	Blood protein levels;
KIRP	cis	rs7688540	0.771	rs61794996	chr4:209328	C/G	cg17891759	chr4:299121	NA	-0.52	-5.35	-0.32	1.98e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.4	-0.51	4.05e-18	Neuroticism;
KIRP	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.19	-0.61	4.63e-27	Ulcerative colitis;
KIRP	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	cg21523751	chr1:182988639	NA	0.35	4.95	0.3	1.38e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs62413470	0.748	rs12198686	chr6:55951231	G/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs7520050	0.966	rs12410071	chr1:46358886	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.55e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	11.08	0.58	2.1e-23	Cognitive test performance;
KIRP	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.47	6.83	0.4	6.51e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12282928	0.959	rs7928042	chr11:48257996	C/T	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs12220238	0.841	rs11000942	chr10:76025256	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.32	0.37	1.23e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg07701084	chr6:150067640	NUP43	0.69	8.95	0.5	9.16e-17	Lung cancer;
KIRP	cis	rs7849270	0.879	rs10988197	chr9:131841259	G/A	cg13538475	chr9:131942899	NA	-0.37	-5.8	-0.35	1.98e-8	Blood metabolite ratios;
KIRP	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.18e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.94	-16.04	-0.71	4.17e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg06634786	chr22:41940651	POLR3H	-0.49	-5.34	-0.32	2.08e-7	Neuroticism;
KIRP	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg16141378	chr3:129829833	LOC729375	-0.51	-6.22	-0.37	2.13e-9	Retinal vascular caliber;
KIRP	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20782743	chr18:24445262	AQP4;C18orf16	0.4	6.04	0.36	5.62e-9	Survival in pancreatic cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19775071	chr5:59893187	DEPDC1B	-0.4	-6.26	-0.37	1.69e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.65	7.83	0.45	1.47e-13	Height;
KIRP	cis	rs7017914	0.934	rs13255886	chr8:71565954	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.11	-0.31	6.58e-7	Bone mineral density;
KIRP	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.56	7.63	0.44	5.07e-13	Colorectal cancer;
KIRP	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg09173681	chr1:183549694	NCF2	-0.82	-11.01	-0.57	3.48e-23	Systemic lupus erythematosus;
KIRP	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11987759	chr7:65425863	GUSB	-0.54	-7.14	-0.41	1.04e-11	Aortic root size;
KIRP	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg26681399	chr22:41777847	TEF	0.46	4.84	0.3	2.26e-6	Vitiligo;
KIRP	trans	rs7702057	0.530	rs58510083	chr5:115444798	C/T	cg04256898	chr15:93129916	NA	-0.66	-6.49	-0.38	4.6e-10	Amyotrophic lateral sclerosis;
KIRP	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.4	5.09	0.31	7.17e-7	Sitting height ratio;
KIRP	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.77	8.69	0.48	5.16e-16	Corneal astigmatism;
KIRP	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs2230307	0.536	rs575971	chr1:100546591	T/C	cg24955406	chr1:100503596	HIAT1	0.68	7.68	0.44	3.78e-13	Carotid intima media thickness;
KIRP	cis	rs1200821	0.552	rs12253170	chr10:37601063	A/G	cg00409905	chr10:38381863	ZNF37A	-0.41	-5.53	-0.33	8.14e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.72	5.79	0.35	2.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4774899	1.000	rs12050758	chr15:57495303	A/G	cg13626582	chr15:57592083	LOC283663	-0.2	-5.04	-0.31	9.02e-7	Urinary tract infection frequency;
KIRP	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.64	0.73	3.72e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.64	5.71	0.34	3.22e-8	Alzheimer's disease;
KIRP	cis	rs2554380	1.000	rs2730076	chr15:84315985	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.63	-8.63	-0.48	8e-16	Height;
KIRP	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.88	0.4	4.84e-11	Electroencephalogram traits;
KIRP	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.36	-0.38	9.79e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7252505	0.892	rs13345828	chr19:33599323	G/T	cg17764715	chr19:33622953	WDR88	0.62	5.57	0.33	6.54e-8	Colorectal cancer;
KIRP	cis	rs6589219	0.866	rs4477469	chr11:111160753	C/T	cg25129781	chr11:111156908	C11orf53	-0.5	-6.55	-0.39	3.27e-10	Colorectal cancer;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg18209359	chr17:80159595	CCDC57	-0.41	-5.39	-0.33	1.62e-7	Life satisfaction;
KIRP	cis	rs7202877	0.561	rs4888369	chr16:75307277	T/C	cg03315344	chr16:75512273	CHST6	0.59	5.25	0.32	3.27e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs526231	0.511	rs28062	chr5:102540201	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.54	-0.33	7.62e-8	Primary biliary cholangitis;
KIRP	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.47	5.53	0.33	8.3e-8	Response to antidepressants in depression;
KIRP	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg25547332	chr5:131281432	NA	0.44	4.88	0.3	1.94e-6	Life satisfaction;
KIRP	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.51	-6.38	-0.38	8.87e-10	Coronary artery disease;
KIRP	cis	rs4262150	0.920	rs13187261	chr5:152286739	G/A	cg12297329	chr5:152029980	NA	0.45	6.21	0.37	2.25e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg25486957	chr4:152246857	NA	-0.52	-5.69	-0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4234798	0.500	rs34694340	chr4:7221424	A/C	cg18431297	chr4:7219810	SORCS2	0.65	8.57	0.48	1.16e-15	Insulin-like growth factors;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-6.28	-0.37	1.5e-9	Lung cancer;
KIRP	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.26	-0.37	1.71e-9	Monocyte percentage of white cells;
KIRP	cis	rs7712401	0.584	rs4836382	chr5:122376641	G/A	cg19412675	chr5:122181750	SNX24	0.47	5.33	0.32	2.22e-7	Mean platelet volume;
KIRP	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg06740227	chr12:86229804	RASSF9	0.51	6.61	0.39	2.33e-10	Major depressive disorder;
KIRP	cis	rs6001982	0.667	rs17001907	chr22:40834346	T/C	cg07138101	chr22:40742427	ADSL	0.68	5.27	0.32	2.98e-7	Breast cancer;
KIRP	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	5.09e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.63	8.41	0.47	3.26e-15	Mood instability;
KIRP	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.24	11.89	0.6	4.51e-26	Diabetic retinopathy;
KIRP	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg04865290	chr3:52927548	TMEM110	-0.42	-5.24	-0.32	3.43e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.02	-0.54	4.94e-20	Response to antipsychotic treatment;
KIRP	cis	rs2279817	0.735	rs11580813	chr1:17981913	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.59	7.44	0.43	1.64e-12	Neuroticism;
KIRP	cis	rs1403694	1.000	rs1403694	chr3:186439998	T/C	cg12454167	chr3:186435060	KNG1	0.49	8.64	0.48	7.01e-16	Blood protein levels;
KIRP	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-1.11	-8.09	-0.46	2.7e-14	Mitochondrial DNA levels;
KIRP	cis	rs17321999	0.904	rs906865	chr2:30478173	C/T	cg05247661	chr2:30472410	LBH	0.68	8.01	0.45	4.51e-14	Systemic lupus erythematosus;
KIRP	cis	rs13226913	0.967	rs4318980	chr7:7256490	G/A	cg04827551	chr7:7268805	C1GALT1	-0.36	-5.17	-0.31	4.82e-7	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.58	-6.04	-0.36	5.7e-9	Total cholesterol levels;
KIRP	cis	rs2034088	1.000	rs3744731	chr17:420467	T/C	cg01214346	chr17:406501	NA	-0.45	-5.62	-0.34	5.19e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg02023728	chr11:77925099	USP35	-0.33	-4.95	-0.3	1.37e-6	Alzheimer's disease (survival time);
KIRP	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.55	6.46	0.38	5.62e-10	Mean corpuscular volume;
KIRP	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg08501292	chr6:25962987	TRIM38	1.07	7.09	0.41	1.44e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6539288	0.674	rs4964494	chr12:107284460	A/G	cg21360079	chr12:107162445	NA	-0.52	-7.42	-0.43	1.91e-12	Total body bone mineral density;
KIRP	cis	rs472402	0.580	rs11134173	chr5:6659696	C/A	cg08700190	chr5:6636046	SRD5A1	-0.44	-5.38	-0.32	1.73e-7	Response to amphetamines;
KIRP	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.52	-0.43	9.94e-13	Triglycerides;
KIRP	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg12935359	chr14:103987150	CKB	-0.36	-4.86	-0.3	2.1e-6	Monocyte count;
KIRP	cis	rs1009181	0.585	rs2066295	chr6:26168903	A/G	cg13736514	chr6:26305472	NA	-0.57	-6.38	-0.38	8.94e-10	Childhood ear infection;
KIRP	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.57	-6.04	-0.36	5.57e-9	DNA methylation (variation);
KIRP	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.6	-7.33	-0.42	3.27e-12	Red blood cell count;
KIRP	cis	rs9653442	0.527	rs4850923	chr2:100782256	A/C	cg07810366	chr2:100720526	AFF3	-0.31	-4.96	-0.3	1.34e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg16141378	chr3:129829833	LOC729375	0.47	6.07	0.36	4.77e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg10189774	chr4:17578691	LAP3	-0.46	-5.58	-0.34	6.36e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.59	7.37	0.43	2.51e-12	Arsenic metabolism;
KIRP	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	9.32	0.51	6.98e-18	Cognitive test performance;
KIRP	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.41	7.03	0.41	2e-11	Heart rate;
KIRP	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg18595228	chr15:67193261	NA	0.56	5.07	0.31	7.79e-7	Lung cancer (smoking interaction);
KIRP	cis	rs7172677	0.737	rs6495154	chr15:75437262	G/C	cg14664628	chr15:75095509	CSK	-0.55	-6.08	-0.36	4.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1847202	1.000	rs7651022	chr3:72924564	T/C	cg06781948	chr3:72941472	GXYLT2	0.38	4.94	0.3	1.45e-6	Motion sickness;
KIRP	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03934478	chr11:495069	RNH1	0.83	6.78	0.4	8.78e-11	Body mass index;
KIRP	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg26335602	chr6:28129616	ZNF389	-0.44	-4.87	-0.3	1.96e-6	Depression;
KIRP	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.7	-8.97	-0.5	7.6e-17	Sudden cardiac arrest;
KIRP	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.34	-18.87	-0.77	9.97e-50	Corneal structure;
KIRP	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-6.0	-0.36	6.86e-9	Bipolar disorder;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg23359706	chr19:11491839	EPOR	0.65	6.11	0.36	3.85e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg11161011	chr14:65562177	MAX	-0.61	-8.04	-0.46	3.79e-14	Obesity-related traits;
KIRP	cis	rs6450176	0.909	rs6866586	chr5:53295568	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.09	-0.58	1.94e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9426935	0.902	rs4596938	chr1:153794697	T/C	cg09895920	chr1:153941186	CREB3L4;SLC39A1	0.28	4.85	0.3	2.17e-6	Lentiform nucleus volume;
KIRP	cis	rs3931020	0.657	rs277369	chr1:75234661	T/C	cg10128416	chr1:75198403	TYW3;CRYZ	-0.46	-5.59	-0.34	6.01e-8	Resistin levels;
KIRP	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.56	7.12	0.41	1.16e-11	Colorectal cancer;
KIRP	cis	rs501120	1.000	rs522293	chr10:44756703	G/A	cg09554077	chr10:44749378	NA	0.72	11.38	0.59	2.26e-24	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.41	-5.15	-0.31	5.25e-7	Crohn's disease;
KIRP	cis	rs71277158	0.688	rs11925129	chr3:169775228	C/A	cg04067573	chr3:169899625	PHC3	0.51	4.87	0.3	1.96e-6	Prostate cancer;
KIRP	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.14	-0.31	5.67e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3829109	0.534	rs563	chr9:139296485	C/T	cg21253087	chr9:139290292	SNAPC4	-0.48	-5.45	-0.33	1.22e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs2172802	0.560	rs1497913	chr4:62559086	C/T	cg04118610	chr4:62707027	LPHN3	-0.48	-5.9	-0.35	1.21e-8	Partial epilepsies;
KIRP	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	trans	rs972578	0.765	rs2092664	chr22:43270440	A/C	cg15321293	chr3:36422198	STAC	-0.48	-6.24	-0.37	1.94e-9	Mean platelet volume;
KIRP	cis	rs7945071	0.507	rs10789763	chr11:110304997	C/T	cg04157658	chr11:110243994	NA	0.32	5.17	0.31	4.78e-7	Cognitive function;
KIRP	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	4.9	0.3	1.74e-6	Cognitive test performance;
KIRP	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.8	-11.81	-0.6	8.38e-26	Height;
KIRP	trans	rs7819412	0.502	rs34440473	chr8:10906841	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.14	0.41	1.04e-11	Triglycerides;
KIRP	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.91	12.61	0.63	1.83e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.59	-7.1	-0.41	1.3e-11	Corneal structure;
KIRP	cis	rs9467603	0.925	rs35436081	chr6:25700342	G/A	cg08501292	chr6:25962987	TRIM38	0.7	4.87	0.3	2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.63	7.45	0.43	1.58e-12	Height;
KIRP	cis	rs9302065	0.595	rs1547746	chr13:95964267	G/A	cg26751094	chr13:95954534	ABCC4	-0.49	-6.4	-0.38	7.64e-10	Blood metabolite levels;
KIRP	cis	rs1461503	0.838	rs7107012	chr11:122829813	G/A	cg27398637	chr11:122830231	C11orf63	-0.81	-11.77	-0.6	1.18e-25	Menarche (age at onset);
KIRP	cis	rs4664304	0.620	rs2556086	chr2:160708446	G/T	cg03641300	chr2:160917029	PLA2R1	-0.35	-5.31	-0.32	2.5e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg23131131	chr22:24373011	LOC391322	-0.68	-7.2	-0.42	7.35e-12	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05220968	chr6:146057943	EPM2A	-0.42	-5.58	-0.34	6.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3736594	0.546	rs7571558	chr2:27839832	C/G	cg27432699	chr2:27873401	GPN1	0.57	6.71	0.39	1.32e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19717773	chr7:2847554	GNA12	-0.37	-5.68	-0.34	3.71e-8	Height;
KIRP	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.14	14.99	0.69	1.64e-36	Gut microbiome composition (summer);
KIRP	cis	rs9905704	0.718	rs62083527	chr17:56667853	T/C	cg12560992	chr17:57184187	TRIM37	0.53	4.92	0.3	1.61e-6	Testicular germ cell tumor;
KIRP	cis	rs6001982	0.748	rs17001974	chr22:40877384	C/T	cg07138101	chr22:40742427	ADSL	0.7	5.67	0.34	3.92e-8	Breast cancer;
KIRP	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26314531	chr2:26401878	FAM59B	-0.48	-4.95	-0.3	1.39e-6	Gut microbiome composition (summer);
KIRP	cis	rs75804782	0.625	rs1039887	chr2:239434892	A/G	cg18131467	chr2:239335373	ASB1	-0.56	-5.15	-0.31	5.33e-7	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs10073892	0.662	rs10067051	chr5:101642275	T/G	cg19774478	chr5:101632501	SLCO4C1	0.62	6.38	0.38	8.78e-10	Cognitive decline (age-related);
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.61	-0.34	5.47e-8	Life satisfaction;
KIRP	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.83	0.63	3.5e-29	Smoking behavior;
KIRP	cis	rs4776059	0.959	rs4548810	chr15:52943814	C/T	cg22715398	chr15:52968154	KIAA1370	-0.51	-6.08	-0.36	4.53e-9	Schizophrenia;
KIRP	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.07	11.94	0.61	3.29e-26	Vitiligo;
KIRP	cis	rs2798269	0.646	rs4770182	chr13:22179186	G/T	cg17543804	chr13:22179073	EFHA1	-0.37	-5.54	-0.33	7.58e-8	PR segment;
KIRP	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.81	-10.31	-0.55	5.83e-21	Lymphocyte percentage of white cells;
KIRP	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg23594656	chr7:65796392	TPST1	-0.45	-7.11	-0.41	1.28e-11	Aortic root size;
KIRP	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.16	-0.42	9.31e-12	Menopause (age at onset);
KIRP	cis	rs2299587	0.689	rs12546237	chr8:17797055	A/G	cg01800426	chr8:17659068	MTUS1	-0.53	-6.17	-0.37	2.76e-9	Economic and political preferences;
KIRP	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.42	-5.3	-0.32	2.56e-7	Platelet count;
KIRP	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.16	0.31	4.99e-7	Depression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21135948	chr21:34915592	GART;SON	0.43	6.48	0.38	4.95e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-7.42	-0.43	1.9e-12	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs3007168	1.000	rs3007169	chr14:51607897	A/G	cg23942311	chr14:51606299	NA	0.54	5.71	0.34	3.22e-8	Cancer;
KIRP	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.74	6.66	0.39	1.78e-10	Diabetic retinopathy;
KIRP	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	5.36	0.32	1.92e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg11845111	chr2:191398756	TMEM194B	-0.95	-10.02	-0.54	4.89e-20	Diastolic blood pressure;
KIRP	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.77	11.82	0.6	7.66e-26	Colorectal cancer;
KIRP	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.43	5.26	0.32	3.07e-7	Testicular germ cell tumor;
KIRP	cis	rs7212590	0.655	rs56198517	chr17:57976582	G/T	cg10252138	chr17:58120427	NA	-0.69	-5.72	-0.34	3.09e-8	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.95	0.5	8.72e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.52	7.07	0.41	1.58e-11	Height;
KIRP	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.45	-6.02	-0.36	6.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.8	10.78	0.57	1.87e-22	Adiposity;
KIRP	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.38	-5.0	-0.3	1.12e-6	Schizophrenia;
KIRP	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.2	0.37	2.34e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs860295	0.729	rs4971072	chr1:155273869	G/A	cg02153340	chr1:155202674	NA	0.42	5.25	0.32	3.32e-7	Body mass index;
KIRP	cis	rs829661	0.739	rs829563	chr2:30695497	T/A	cg10949345	chr2:30726833	LCLAT1	0.83	11.4	0.59	1.92e-24	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.51	-0.33	9.16e-8	IgG glycosylation;
KIRP	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.96	-14.72	-0.68	1.28e-35	Personality dimensions;
KIRP	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.31	0.37	1.32e-9	Height;
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg04772025	chr11:68637568	NA	0.71	8.35	0.47	4.89e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs33912345	0.722	rs1018532	chr14:60970975	T/G	cg27398547	chr14:60952738	C14orf39	0.39	5.04	0.31	9.12e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg17133734	chr15:86042851	AKAP13	-0.44	-5.49	-0.33	1.01e-7	Coronary artery disease;
KIRP	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.67	-9.48	-0.52	2.32e-18	Height;
KIRP	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg17788362	chr6:86352627	SYNCRIP	0.48	6.3	0.37	1.38e-9	Smooth-surface caries;
KIRP	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.48	-7.24	-0.42	5.85e-12	Electroencephalogram traits;
KIRP	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.05	0.41	1.81e-11	Lymphocyte counts;
KIRP	cis	rs71403859	0.730	rs71386933	chr16:71821800	A/T	cg08717414	chr16:71523259	ZNF19	-0.93	-7.93	-0.45	7.89e-14	Post bronchodilator FEV1;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.78	-9.83	-0.53	1.96e-19	Longevity;Endometriosis;
KIRP	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.81	-0.4	7.32e-11	Type 2 diabetes;
KIRP	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg25174290	chr11:3078921	CARS	-0.56	-6.04	-0.36	5.52e-9	Calcium levels;
KIRP	cis	rs131805	1.000	rs131805	chr22:50964153	T/C	cg12969734	chr22:50962224	SCO2	0.57	5.59	0.34	6.06e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg15026998	chr2:160761622	LY75	-0.35	-5.03	-0.31	9.42e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.44	-7.0	-0.41	2.39e-11	Superior crus of antihelix expression;
KIRP	cis	rs7520050	0.966	rs785503	chr1:46595868	T/C	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg01200585	chr1:228362443	C1orf69	0.55	7.05	0.41	1.83e-11	Diastolic blood pressure;
KIRP	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.95	14.99	0.69	1.55e-36	Metabolite levels;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.19e-7	Life satisfaction;
KIRP	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.66	9.24	0.51	1.25e-17	Dental caries;
KIRP	cis	rs11997175	1.000	rs7838577	chr8:33760802	A/G	cg04338863	chr8:33670619	NA	0.41	5.36	0.32	1.87e-7	Body mass index;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13969321	chr5:6713231	POLS	0.5	6.33	0.37	1.18e-9	Myopia (pathological);
KIRP	cis	rs4302748	0.862	rs11768269	chr7:36172741	A/G	cg24442661	chr7:36192818	EEPD1	0.57	6.26	0.37	1.71e-9	Platelet count;
KIRP	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.79	-7.6	-0.44	6.24e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg23352942	chr3:46931381	PTH1R	-0.52	-7.16	-0.42	9.16e-12	Birth weight;
KIRP	cis	rs735539	1.000	rs3000676	chr13:21286442	A/T	cg02792322	chr13:21280448	IL17D	-0.3	-4.85	-0.3	2.23e-6	Dental caries;
KIRP	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.77	-10.29	-0.55	7.1e-21	Adiposity;
KIRP	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.82	12.58	0.63	2.32e-28	Height;
KIRP	cis	rs12760731	0.720	rs722321	chr1:178420220	C/T	cg00404053	chr1:178313656	RASAL2	0.65	5.0	0.3	1.09e-6	Obesity-related traits;
KIRP	cis	rs7005380	0.581	rs12679478	chr8:120916234	T/C	cg21645572	chr8:120931649	DEPDC6	0.48	6.75	0.4	1.08e-10	Interstitial lung disease;
KIRP	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs2882667	0.858	rs17207870	chr5:138387737	T/C	cg04439458	chr5:138467593	SIL1	-0.51	-7.71	-0.44	3.04e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs73198271	0.531	rs112930476	chr8:8671551	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.16	-0.31	5.18e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.65	-6.19	-0.37	2.52e-9	Lung function (FEV1/FVC);
KIRP	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.4	-5.19	-0.31	4.38e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.5	7.94	0.45	7.38e-14	Testicular germ cell tumor;
KIRP	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg13263691	chr18:77568018	NA	-0.51	-6.88	-0.4	4.89e-11	Schizophrenia;
KIRP	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg24130564	chr14:104152367	KLC1	-0.51	-6.83	-0.4	6.78e-11	Body mass index;
KIRP	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11987759	chr7:65425863	GUSB	0.57	7.67	0.44	4.09e-13	Aortic root size;
KIRP	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-11.47	-0.59	1.15e-24	Dental caries;
KIRP	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.86	10.44	0.55	2.4e-21	Response to antineoplastic agents;
KIRP	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg23188430	chr6:125850052	NA	-0.34	-5.33	-0.32	2.27e-7	Brugada syndrome;
KIRP	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14159672	chr1:205819179	PM20D1	0.46	5.09	0.31	7e-7	Parkinson's disease;
KIRP	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.55	7.0	0.41	2.5e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.48	-0.43	1.34e-12	Atopic dermatitis;
KIRP	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.65	8.99	0.5	6.75e-17	Blood protein levels;
KIRP	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.28	-0.37	1.51e-9	Morning vs. evening chronotype;
KIRP	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.45	-0.43	1.58e-12	Neuroticism;
KIRP	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.16	-0.42	9.09e-12	Type 2 diabetes;
KIRP	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg23815491	chr16:72088622	HP	0.47	6.89	0.4	4.57e-11	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18876405	chr7:65276391	NA	0.43	5.31	0.32	2.4e-7	Aortic root size;
KIRP	cis	rs13185784	0.703	rs1127580	chr5:179661528	C/T	cg23248424	chr5:179741104	GFPT2	0.45	5.0	0.3	1.07e-6	TRAIL levels;
KIRP	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.15	0.37	3.09e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15884510	chr21:47401911	COL6A1	0.53	6.73	0.39	1.19e-10	Smoking initiation;
KIRP	cis	rs4765905	0.500	rs1016388	chr12:2321868	A/T	cg10668781	chr12:2307325	CACNA1C	-0.27	-5.2	-0.31	4.26e-7	Schizophrenia;
KIRP	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.36	-4.91	-0.3	1.64e-6	Metabolite levels;
KIRP	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.88	0.35	1.3e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.62	-7.02	-0.41	2.19e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-10.43	-0.55	2.48e-21	Urinary metabolites;
KIRP	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.62	-7.38	-0.43	2.36e-12	Mean platelet volume;
KIRP	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.68	-0.34	3.74e-8	Response to antipsychotic treatment;
KIRP	cis	rs4908768	0.556	rs11121230	chr1:8834706	C/T	cg25722041	chr1:8623473	RERE	0.65	8.17	0.46	1.6e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27315239	chr1:53593711	SLC1A7	0.43	6.15	0.37	3.04e-9	Survival in pancreatic cancer;
KIRP	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg21747090	chr2:27597821	SNX17	-0.36	-4.91	-0.3	1.66e-6	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05485520	chr3:45883628	LZTFL1	0.68	8.26	0.47	9.1e-15	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04354879	chr17:42634955	FZD2	0.48	6.56	0.39	3.18e-10	Parkinson's disease;
KIRP	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg03060546	chr3:49711283	APEH	-0.76	-5.73	-0.34	2.89e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.69	-8.42	-0.47	3.22e-15	Cognitive function;
KIRP	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg06042504	chr8:55087323	NA	-0.59	-7.23	-0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	1.0	14.36	0.68	2.19e-34	Alcohol dependence;
KIRP	cis	rs732716	0.785	rs56272533	chr19:4420042	T/C	cg03719555	chr19:4455413	UBXN6	0.48	7.36	0.42	2.69e-12	Mean corpuscular volume;
KIRP	cis	rs1403694	1.000	rs1624230	chr3:186438935	A/C	cg12454167	chr3:186435060	KNG1	-0.48	-8.53	-0.48	1.52e-15	Blood protein levels;
KIRP	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg06565975	chr8:143823917	SLURP1	0.35	5.1	0.31	6.85e-7	Urinary tract infection frequency;
KIRP	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.77	-0.4	9.25e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg08712631	chr7:1960676	MAD1L1	-0.43	-5.61	-0.34	5.42e-8	Neuroticism;
KIRP	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg09682330	chr6:28411287	ZSCAN23	-0.4	-5.15	-0.31	5.35e-7	Pubertal anthropometrics;
KIRP	cis	rs9880211	0.898	rs28877020	chr3:136395716	T/G	cg21827317	chr3:136751795	NA	-0.45	-4.85	-0.3	2.21e-6	Body mass index;Height;
KIRP	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.86	-0.49	1.69e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.57	7.76	0.44	2.33e-13	Total body bone mineral density;
KIRP	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.73	-8.76	-0.49	3.13e-16	Breast size;
KIRP	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	1.16	10.25	0.55	9.23e-21	Lymphocyte counts;
KIRP	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg04218760	chr10:45406644	TMEM72	-0.23	-6.2	-0.37	2.43e-9	Mean corpuscular volume;
KIRP	cis	rs12997796	0.556	rs34933869	chr2:86922397	T/C	cg25203885	chr2:87302643	LOC285074	-0.7	-5.58	-0.34	6.36e-8	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-6.35	-0.38	1.02e-9	Renal cell carcinoma;
KIRP	cis	rs12230513	0.632	rs59213907	chr12:55728911	A/T	cg11794356	chr12:55725991	OR6C3	-0.54	-7.13	-0.41	1.11e-11	Contrast sensitivity;
KIRP	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg19257562	chr1:2043853	PRKCZ	-0.38	-5.48	-0.33	1.04e-7	Height;
KIRP	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.77	9.59	0.52	1.02e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.57	6.6	0.39	2.52e-10	Osteoporosis;
KIRP	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg00684032	chr4:1343700	KIAA1530	0.52	6.82	0.4	7.1e-11	Longevity;
KIRP	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg06060754	chr5:176797920	RGS14	0.45	6.9	0.4	4.45e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-6.16	-0.37	2.87e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.43	7.3	0.42	3.99e-12	Heart rate;
KIRP	cis	rs3925075	0.531	rs4594268	chr16:31343243	T/C	cg02846316	chr16:31340340	ITGAM	0.46	5.53	0.33	8.22e-8	IgA nephropathy;
KIRP	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.66	9.79	0.53	2.46e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.49	-6.34	-0.37	1.11e-9	Blood metabolite levels;
KIRP	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	cis	rs7221595	0.825	rs61442612	chr17:3961019	C/T	cg09695851	chr17:3907499	NA	0.54	5.2	0.31	4.27e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7523273	0.564	rs1977268	chr1:207881036	A/C	cg22525895	chr1:207977042	MIR29B2	0.5	5.93	0.35	1e-8	Schizophrenia;
KIRP	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.59	5.8	0.35	2.04e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.12	-10.05	-0.54	3.88e-20	Plateletcrit;
KIRP	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	0.97	15.95	0.71	8.22e-40	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs2944591	0.505	rs2592118	chr2:233792425	C/T	cg11972305	chr2:233791962	NGEF	-0.51	-7.7	-0.44	3.34e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.76	5.89	0.35	1.29e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	0.84	7.54	0.43	8.76e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.62	-8.49	-0.48	2.01e-15	Total body bone mineral density;
KIRP	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10170310	1.000	rs10803568	chr2:139290914	T/C	cg10095539	chr2:139258744	SPOPL	0.37	5.88	0.35	1.35e-8	Response to antipsychotic treatment;
KIRP	cis	rs7274811	0.711	rs291698	chr20:31982250	A/T	cg03904042	chr20:32255491	NECAB3;C20orf134	0.41	4.9	0.3	1.74e-6	Height;
KIRP	cis	rs9469913	0.733	rs11756392	chr6:34807894	G/T	cg17674042	chr6:34482479	PACSIN1	-0.38	-5.23	-0.32	3.56e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-6.67	-0.39	1.64e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.81	12.03	0.61	1.63e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs775227	0.574	rs36108475	chr3:113038406	C/T	cg18753928	chr3:113234510	CCDC52	-0.6	-5.76	-0.34	2.49e-8	Dental caries;
KIRP	cis	rs3218477	1.000	rs3218477	chr7:152357059	C/T	cg06618968	chr7:152373420	XRCC2	-0.84	-5.47	-0.33	1.09e-7	Mean platelet volume;
KIRP	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg16524733	chr11:117070046	TAGLN	0.41	5.45	0.33	1.2e-7	Blood protein levels;
KIRP	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg25457927	chr22:38595422	NA	-0.25	-5.01	-0.3	1.06e-6	Melanoma;
KIRP	cis	rs1891275	0.515	rs7475294	chr10:93508199	T/C	cg07889827	chr10:93443413	NA	-0.43	-7.25	-0.42	5.53e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-5.78	-0.35	2.23e-8	Body mass index;
KIRP	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.53	-0.33	8.22e-8	Hip geometry;
KIRP	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.76	9.48	0.52	2.28e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg04306507	chr14:55594613	LGALS3	0.46	7.2	0.42	7.1e-12	Protein biomarker;
KIRP	cis	rs15676	0.783	rs4489410	chr9:131591649	A/C	cg00228799	chr9:131580591	ENDOG	-0.49	-5.44	-0.33	1.3e-7	Blood metabolite levels;
KIRP	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg04990556	chr1:26633338	UBXN11	0.64	6.07	0.36	4.77e-9	Obesity-related traits;
KIRP	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg14703610	chr5:56206110	C5orf35	0.51	7.07	0.41	1.57e-11	Coronary artery disease;
KIRP	cis	rs4692589	1.000	rs4692785	chr4:170938593	C/T	cg19918862	chr4:170955249	NA	0.42	5.07	0.31	7.77e-7	Anxiety disorder;
KIRP	cis	rs2299587	0.804	rs34086303	chr8:17790437	T/C	cg01800426	chr8:17659068	MTUS1	-0.41	-4.89	-0.3	1.82e-6	Economic and political preferences;
KIRP	cis	rs4236601	1.000	rs6950798	chr7:116161585	T/C	cg05166801	chr7:116143459	CAV2	0.48	5.95	0.35	9.23e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.43	-0.38	6.59e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4664293	0.932	rs4665104	chr2:160532358	C/T	cg08347373	chr2:160653686	CD302	-0.38	-5.86	-0.35	1.45e-8	Monocyte percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14924826	chr10:112679428	NCRNA00081;SHOC2	0.45	6.53	0.38	3.83e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.47	8.47	0.48	2.2e-15	Superior crus of antihelix expression;
KIRP	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	7.82	0.45	1.5700000000000001e-13	Personality dimensions;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg24892139	chr5:35618383	SPEF2	0.51	6.14	0.36	3.35e-9	Beard thickness;
KIRP	cis	rs6504950	0.720	rs12602751	chr17:52994174	C/A	cg26251398	chr17:52985966	TOM1L1	0.43	5.99	0.36	7.35e-9	Breast cancer;
KIRP	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg05527609	chr1:210001259	C1orf107	-0.6	-6.94	-0.4	3.48e-11	Red blood cell count;
KIRP	cis	rs7116495	1.000	rs2845857	chr11:71715215	C/G	cg26138937	chr11:71823887	C11orf51	-0.72	-5.83	-0.35	1.74e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg08499158	chr17:42289980	UBTF	-0.66	-8.94	-0.49	9.82e-17	Total body bone mineral density;
KIRP	cis	rs77372450	0.636	rs6556105	chr5:157022864	C/T	cg05585991	chr5:157099197	C5orf52	0.43	5.22	0.32	3.86e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs17209837	1.000	rs45554032	chr7:87078547	G/T	cg00919237	chr7:87102261	ABCB4	-0.62	-6.6	-0.39	2.57e-10	Gallbladder cancer;
KIRP	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.71	8.67	0.48	5.83e-16	Mammographic density (dense area);
KIRP	cis	rs13401104	0.587	rs7569760	chr2:237145713	A/C	cg26422059	chr2:237146110	ASB18	0.46	5.27	0.32	3.03e-7	Educational attainment;
KIRP	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.7	-7.53	-0.43	9.87e-13	DNA methylation (variation);
KIRP	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.82	-12.01	-0.61	1.83e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.94	15.18	0.7	3.6e-37	Metabolite levels;
KIRP	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.8	11.79	0.6	9.92e-26	Heart rate;
KIRP	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.79	-13.01	-0.64	8.37e-30	Prostate cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27627854	chr11:108158382	ATM	-0.42	-6.68	-0.39	1.62e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.73	-0.49	3.86e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg18357526	chr6:26021779	HIST1H4A	0.47	5.5	0.33	9.28e-8	Blood metabolite levels;
KIRP	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg03388025	chr16:89894329	SPIRE2	-0.31	-5.78	-0.35	2.29e-8	Vitiligo;
KIRP	cis	rs12643440	0.521	rs16868330	chr4:17168826	A/G	cg22650099	chr4:17144496	NA	-0.73	-6.5	-0.38	4.42e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.94	-14.61	-0.68	3.24e-35	Height;
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.75	11.04	0.58	2.75e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg07384165	chr1:10488281	NA	-0.46	-5.82	-0.35	1.83e-8	Prostate cancer;
KIRP	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.81	-0.35	1.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.93	13.63	0.66	6.67e-32	Bladder cancer;
KIRP	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.89	11.5	0.59	8.66e-25	Gestational age at birth (maternal effect);
KIRP	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg23307798	chr14:103986281	CKB	0.76	13.07	0.64	5.41e-30	Body mass index;
KIRP	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg14458575	chr2:238380390	NA	0.51	7.08	0.41	1.53e-11	Prostate cancer;
KIRP	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-7.14	-0.41	1.06e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11355319	chr5:89825117	LYSMD3	0.53	6.28	0.37	1.55e-9	Smoking initiation;
KIRP	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.74	9.13	0.5	2.67e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6991838	0.584	rs34494846	chr8:66514632	T/C	cg13398993	chr8:66546079	ARMC1	-0.44	-5.08	-0.31	7.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.49	-5.12	-0.31	6.07e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg23283320	chr21:48055893	PRMT2	1.37	8.56	0.48	1.25e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22618164	chr12:122356400	WDR66	0.65	8.8	0.49	2.47e-16	Mean corpuscular volume;
KIRP	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	cis	rs6496667	0.779	rs8033512	chr15:90945307	A/T	cg10434728	chr15:90938212	IQGAP1	0.39	5.19	0.31	4.5e-7	Rheumatoid arthritis;
KIRP	cis	rs2797160	0.515	rs4897149	chr6:125980018	G/T	cg05901451	chr6:126070800	HEY2	0.35	4.87	0.3	1.97e-6	Endometrial cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14077144	chr6:24665159	TTRAP	0.56	7.13	0.41	1.12e-11	Interleukin-4 levels;
KIRP	cis	rs2230307	0.536	rs631977	chr1:100544564	C/G	cg24955406	chr1:100503596	HIAT1	0.58	6.27	0.37	1.58e-9	Carotid intima media thickness;
KIRP	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg18154014	chr19:37997991	ZNF793	-0.91	-9.38	-0.51	4.49e-18	Coronary artery calcification;
KIRP	cis	rs6032067	1.000	rs6017509	chr20:43830362	A/G	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.89	-0.3	1.86e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg02367723	chr1:46378857	MAST2	0.41	4.89	0.3	1.86e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg20965017	chr5:231967	SDHA	-0.53	-6.11	-0.36	3.91e-9	Breast cancer;
KIRP	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg19773385	chr1:10388646	KIF1B	0.68	9.74	0.53	3.55e-19	Hepatocellular carcinoma;
KIRP	cis	rs17023223	0.537	rs17023171	chr1:119593268	A/C	cg05756136	chr1:119680316	WARS2	-0.58	-7.76	-0.44	2.23e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.69	-10.11	-0.54	2.64e-20	Lung cancer;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16696536	chr3:59035729	C3orf67	0.43	6.11	0.36	3.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg11153868	chr12:69751374	NA	0.38	4.86	0.3	2.1e-6	Response to diuretic therapy;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg01287788	chr2:86362935	SNORD94;PTCD3	0.43	6.33	0.37	1.13e-9	Morning vs. evening chronotype;
KIRP	cis	rs17067123	0.614	rs2383271	chr4:180071469	G/A	cg26610307	chr4:180072759	NA	-0.47	-5.15	-0.31	5.26e-7	Response to hepatitis C treatment;
KIRP	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.56	-6.43	-0.38	6.65e-10	Breast cancer;
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13939156	chr17:80058883	NA	0.48	7.21	0.42	6.99e-12	Life satisfaction;
KIRP	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.36	0.32	1.89e-7	Educational attainment;
KIRP	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg22563815	chr15:78856949	CHRNA5	0.5	7.71	0.44	3.07e-13	Sudden cardiac arrest;
KIRP	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs4908768	0.906	rs751790	chr1:8529141	C/T	cg25722041	chr1:8623473	RERE	-0.69	-7.57	-0.43	7.42e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs12517041	1.000	rs6452110	chr5:23299802	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg03929089	chr4:120376271	NA	-0.56	-6.53	-0.38	3.69e-10	HDL cholesterol;
KIRP	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16386425	chr10:429943	DIP2C	0.38	4.95	0.3	1.41e-6	Psychosis in Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07664667	chr16:778351	HAGHL	0.48	6.09	0.36	4.3e-9	Parkinson's disease;
KIRP	trans	rs2997105	1.000	rs9597258	chr13:56336439	A/G	cg08528735	chr3:184428879	MAGEF1	0.57	6.3	0.37	1.35e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg12405258	chr13:114927641	NA	0.49	6.99	0.41	2.58e-11	Schizophrenia;
KIRP	cis	rs9649213	0.593	rs6465662	chr7:97917801	A/T	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.52	0.43	1.03e-12	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.24	-0.37	1.89e-9	Lung cancer;
KIRP	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs2997447	0.681	rs11247854	chr1:26399230	C/T	cg20415053	chr1:26527928	CATSPER4	-0.34	-5.07	-0.31	7.78e-7	QRS complex (12-leadsum);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15450734	chr14:103541957	NA	0.49	6.34	0.37	1.1e-9	Smoking initiation;
KIRP	cis	rs2048656	0.637	rs10107396	chr8:9673152	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-5.24	-0.32	3.54e-7	Schizophrenia;
KIRP	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg08999081	chr20:33150536	PIGU	-0.39	-5.03	-0.31	9.59e-7	Height;
KIRP	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.59	8.25	0.47	9.87e-15	Lung cancer;
KIRP	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg19468946	chr17:37922297	IKZF3	-0.47	-6.49	-0.38	4.66e-10	Self-reported allergy;
KIRP	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.9	-0.3	1.76e-6	Neutrophil percentage of white cells;
KIRP	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.31	0.37	1.3e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg06742321	chr12:123595122	PITPNM2	0.44	5.42	0.33	1.39e-7	Platelet count;
KIRP	cis	rs12022452	0.591	rs61781641	chr1:40983084	G/T	cg25568243	chr1:40974465	DEM1	0.53	5.71	0.34	3.16e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg08132940	chr7:1081526	C7orf50	-0.67	-6.85	-0.4	6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.57	-7.01	-0.41	2.23e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05472934	chr7:22766657	IL6	0.81	10.34	0.55	4.95e-21	Lung cancer;
KIRP	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-5.25	-0.32	3.29e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg04733989	chr22:42467013	NAGA	0.59	7.72	0.44	3e-13	Cognitive function;
KIRP	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg19774624	chr17:42201019	HDAC5	-0.66	-7.5	-0.43	1.13e-12	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs934734	0.563	rs11673956	chr2:65597657	A/G	cg08085232	chr2:65598271	SPRED2	-0.56	-7.23	-0.42	5.98e-12	Rheumatoid arthritis;
KIRP	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.52	6.45	0.38	6.04e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs4782151	1.000	rs5025199	chr16:9328518	C/T	ch.16.364290R	chr16:9436357	NA	0.32	4.93	0.3	1.48e-6	Cervical cancer;
KIRP	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.65	10.06	0.54	3.65e-20	Platelet distribution width;
KIRP	cis	rs12976411	1.000	rs16967013	chr19:32859514	C/G	cg02282382	chr19:32836354	ZNF507	0.69	5.16	0.31	5.08e-7	Coronary artery disease;
KIRP	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.02	-0.3	1.01e-6	Pulmonary function;
KIRP	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.92	10.56	0.56	9.34e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg10207240	chr12:122356781	WDR66	0.5	6.35	0.38	1.01e-9	Mean corpuscular volume;
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.49	7.17	0.42	8.98e-12	Testicular germ cell tumor;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg01238044	chr22:24384105	GSTT1	0.54	6.89	0.4	4.55e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg01391022	chr12:122360665	WDR66	-0.37	-5.26	-0.32	3.19e-7	Mean corpuscular volume;
KIRP	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs7572644	0.629	rs28662360	chr2:28208920	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.3	-0.32	2.57e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs6142102	0.923	rs6057961	chr20:32573811	A/G	cg08999081	chr20:33150536	PIGU	0.48	5.6	0.34	5.76e-8	Skin pigmentation;
KIRP	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg25457927	chr22:38595422	NA	-0.32	-6.53	-0.38	3.78e-10	Breast cancer;
KIRP	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg20302533	chr7:39170763	POU6F2	0.26	5.18	0.31	4.7e-7	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13072241	chr6:142622808	GPR126	0.47	6.45	0.38	5.97e-10	Parkinson's disease;
KIRP	cis	rs4740619	0.682	rs10810514	chr9:16011896	C/G	cg14451791	chr9:16040625	NA	-0.39	-4.89	-0.3	1.85e-6	Body mass index;
KIRP	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11987759	chr7:65425863	GUSB	-0.63	-8.39	-0.47	3.86e-15	Aortic root size;
KIRP	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.77	9.53	0.52	1.57e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.02	0.46	4.21e-14	Coffee consumption (cups per day);
KIRP	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg20503657	chr10:835505	NA	-0.56	-6.8	-0.4	7.96e-11	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg22437258	chr11:111473054	SIK2	-0.58	-6.38	-0.38	8.54e-10	Primary sclerosing cholangitis;
KIRP	cis	rs2034088	1.000	rs3744731	chr17:420467	T/C	cg13332499	chr17:408570	NA	0.63	8.5	0.48	1.91e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.41	-5.65	-0.34	4.36e-8	Abdominal aortic aneurysm;
KIRP	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.36	6.07	0.36	4.84e-9	Heart rate;
KIRP	cis	rs8044868	0.530	rs7189115	chr16:72098952	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-5.4	-0.33	1.54e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.49	-5.19	-0.31	4.33e-7	Corneal structure;
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-4.97	-0.3	1.23e-6	Longevity;Endometriosis;
KIRP	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg26373071	chr5:1325741	CLPTM1L	0.55	7.32	0.42	3.48e-12	Lung cancer;
KIRP	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg07274523	chr3:49395745	GPX1	0.72	8.92	0.49	1.07e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6450176	0.633	rs617777	chr5:53330440	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-9.15	-0.5	2.21e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg00310523	chr12:86230176	RASSF9	0.41	6.38	0.38	8.49e-10	Major depressive disorder;
KIRP	cis	rs12973672	1.000	rs10421599	chr19:35767933	G/A	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.78	0.35	2.3e-8	Motion sickness;
KIRP	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-0.96	-14.87	-0.69	4.01e-36	Gut microbiome composition (winter);
KIRP	trans	rs4650943	0.586	rs352302	chr1:176255930	C/T	cg06097592	chr20:35580241	SAMHD1	0.49	6.08	0.36	4.62e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in inactive individuals;
KIRP	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2278796	0.639	rs11240330	chr1:204968258	C/A	cg17947172	chr1:204966197	NFASC	0.67	8.87	0.49	1.56e-16	Mean platelet volume;
KIRP	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg26681399	chr22:41777847	TEF	-0.5	-5.16	-0.31	5.07e-7	Vitiligo;
KIRP	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-9.18	-0.51	1.84e-17	Coronary artery disease;
KIRP	cis	rs7084402	0.967	rs1658451	chr10:60311527	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.53	-0.56	1.22e-21	Refractive error;
KIRP	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.0	-16.43	-0.72	1.89e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.71	9.01	0.5	5.88e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg25358565	chr5:93447407	FAM172A	0.58	6.88	0.4	4.86e-11	Diabetic retinopathy;
KIRP	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.65	7.97	0.45	5.98e-14	Type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.58	5.21	0.31	4.09e-7	Alzheimer's disease;
KIRP	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg17517138	chr11:73019481	ARHGEF17	0.72	6.04	0.36	5.67e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.51	-0.33	9.17e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg08198773	chr8:1697536	NA	0.44	5.68	0.34	3.75e-8	Systolic blood pressure;
KIRP	cis	rs3733418	0.860	rs13142064	chr4:165943549	G/A	cg10852876	chr4:165953100	TRIM60	-0.47	-5.18	-0.31	4.63e-7	Obesity-related traits;
KIRP	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.45	-0.33	1.23e-7	Neuroticism;
KIRP	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.84	-12.27	-0.62	2.61e-27	Systemic lupus erythematosus;
KIRP	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg23752985	chr2:85803571	VAMP8	0.59	8.82	0.49	2.11e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.55	6.08	0.36	4.48e-9	Monocyte percentage of white cells;
KIRP	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg07382826	chr16:28625726	SULT1A1	0.51	5.83	0.35	1.72e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-8.45	-0.47	2.63e-15	Morning vs. evening chronotype;
KIRP	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-8.59	-0.48	1.02e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg11952622	chr19:58962976	ZNF324B	0.46	5.64	0.34	4.64e-8	Uric acid clearance;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.5	6.88	0.4	4.99e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2926702	0.810	rs35229942	chr8:71318230	C/A	cg21651000	chr8:71129472	NCOA2	-0.5	-4.87	-0.3	1.97e-6	Non-small cell lung cancer;
KIRP	cis	rs2191566	0.540	rs436739	chr19:44495553	A/G	cg18700516	chr19:44507157	ZNF230	0.46	5.31	0.32	2.45e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs918629	0.530	rs3777193	chr5:95246760	G/A	cg16656078	chr5:95278638	ELL2	-0.35	-5.39	-0.32	1.67e-7	IgG glycosylation;
KIRP	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.26	0.37	1.67e-9	Coronary artery disease;
KIRP	cis	rs7937612	1.000	rs7951250	chr11:120309036	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.89	-0.4	4.57e-11	Intraocular pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00291981	chr3:49591748	BSN	0.52	6.51	0.38	4.24e-10	Parkinson's disease;
KIRP	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg17554472	chr22:41940697	POLR3H	-0.55	-6.26	-0.37	1.67e-9	Vitiligo;
KIRP	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00585698	chr12:123750864	CDK2AP1	-0.48	-6.0	-0.36	7.08e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.45	-5.83	-0.35	1.77e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.37	-15.0	-0.69	1.5e-36	Schizophrenia;
KIRP	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg24315340	chr6:146058215	EPM2A	0.43	5.36	0.32	1.88e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.3	0.37	1.39e-9	Intraocular pressure;
KIRP	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.23	0.67	6.32e-34	Electrocardiographic conduction measures;
KIRP	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-6.08	-0.36	4.51e-9	Educational attainment;
KIRP	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.87	12.43	0.62	7.62e-28	Monocyte count;
KIRP	cis	rs13424612	0.801	rs4076744	chr2:240902988	G/C	cg19172429	chr2:240878313	NA	0.29	4.94	0.3	1.48e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.91	11.17	0.58	1.04e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg21926883	chr2:100939477	LONRF2	-0.57	-7.99	-0.45	5.34e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg00125455	chr20:44574271	PCIF1	0.45	8.79	0.49	2.7e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg06740227	chr12:86229804	RASSF9	-0.44	-5.27	-0.32	2.95e-7	Major depressive disorder;
KIRP	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.69	-7.73	-0.44	2.83e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1800795	0.530	rs62449494	chr7:22758035	A/G	cg05472934	chr7:22766657	IL6	0.37	4.88	0.3	1.88e-6	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
KIRP	cis	rs6910061	1.000	rs73445479	chr6:11114770	T/C	cg27233058	chr6:11094804	LOC221710	0.57	5.83	0.35	1.7e-8	Diabetic kidney disease;
KIRP	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg10434728	chr15:90938212	IQGAP1	0.43	7.32	0.42	3.5e-12	Rheumatoid arthritis;
KIRP	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg23387468	chr7:139079360	LUC7L2	-0.3	-5.24	-0.32	3.4e-7	Diisocyanate-induced asthma;
KIRP	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.54	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs903263	0.965	rs10874428	chr1:84560010	G/A	cg09414863	chr1:85049548	NA	0.34	4.86	0.3	2.13e-6	Breast cancer (male);
KIRP	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.27	-21.97	-0.81	5.93e-60	Breast cancer;
KIRP	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg07274523	chr3:49395745	GPX1	0.56	5.14	0.31	5.69e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg01270228	chr10:1369114	ADARB2	0.44	5.59	0.34	6.12e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg25039879	chr17:56429692	SUPT4H1	0.59	5.28	0.32	2.8e-7	Cognitive test performance;
KIRP	cis	rs1062746	0.520	rs17770996	chr16:87330207	G/A	cg02258303	chr16:87377426	FBXO31	-0.43	-5.15	-0.31	5.37e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.2e-15	Atrioventricular conduction;
KIRP	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.62	0.39	2.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8032158	1.000	rs28773028	chr15:56262339	C/G	cg02198044	chr15:56286336	NEDD4	-0.43	-4.94	-0.3	1.46e-6	Keloid;
KIRP	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.29	-0.62	2.2e-27	Blood trace element (Zn levels);
KIRP	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg07395648	chr5:131743802	NA	-0.52	-7.44	-0.43	1.7e-12	Breast cancer;
KIRP	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg13798912	chr7:905769	UNC84A	0.54	5.47	0.33	1.09e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg09597638	chr17:3907349	NA	0.57	8.35	0.47	5.02e-15	Type 2 diabetes;
KIRP	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.26	6.73	0.39	1.2e-10	Crohn's disease;
KIRP	cis	rs427941	0.740	rs67531258	chr7:101829087	G/A	cg06246474	chr7:101738831	CUX1	0.46	5.31	0.32	2.46e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-1.03	-19.02	-0.77	3.26e-50	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs368123	0.686	rs2774226	chr6:160700386	G/A	cg19643109	chr6:160697625	NA	-0.3	-6.69	-0.39	1.5e-10	Waist circumference;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg27532560	chr4:187881888	NA	-0.74	-12.72	-0.63	7.95e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.47	5.93	0.35	1.03e-8	Resistin levels;
KIRP	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.74	0.44	2.56e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg10547527	chr2:198650123	BOLL	-0.5	-4.93	-0.3	1.54e-6	Ulcerative colitis;
KIRP	cis	rs494562	1.000	rs7763191	chr6:86118317	A/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs1858037	0.867	rs2118305	chr2:65605220	A/C	cg08085232	chr2:65598271	SPRED2	-0.54	-6.49	-0.38	4.78e-10	Rheumatoid arthritis;
KIRP	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.31	0.51	7.33e-18	Lymphocyte counts;
KIRP	cis	rs897080	0.515	rs1067337	chr2:44624859	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.95	0.35	8.95e-9	Height;
KIRP	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.88	10.36	0.55	4.1e-21	Gut microbiome composition (summer);
KIRP	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.46	-6.46	-0.38	5.48e-10	Sitting height ratio;
KIRP	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.81	11.61	0.59	3.95e-25	Heart rate;
KIRP	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg15507776	chr3:136538369	TMEM22	0.55	7.83	0.45	1.44e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	0.956	rs7291304	chr22:18421821	C/A	cg02610425	chr22:18483192	MICAL3	0.37	5.02	0.3	1e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg22907277	chr7:1156413	C7orf50	0.87	8.2	0.46	1.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.02	-0.46	4.43e-14	Mean corpuscular volume;
KIRP	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-7.58	-0.44	6.89e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg19847130	chr8:10466454	RP1L1	-0.42	-6.15	-0.37	3.13e-9	Retinal vascular caliber;
KIRP	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg04455712	chr21:45112962	RRP1B	0.48	6.66	0.39	1.81e-10	Mean corpuscular volume;
KIRP	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.66	11.53	0.59	6.86e-25	Obesity (extreme);
KIRP	cis	rs35771425	1.000	rs11580728	chr1:211614280	C/T	cg10512769	chr1:211675356	NA	-0.59	-6.23	-0.37	2.01e-9	Educational attainment (years of education);
KIRP	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.46	-6.83	-0.4	6.46e-11	Electroencephalogram traits;
KIRP	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.7	5.8	0.35	2.03e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg24699146	chr1:24152579	HMGCL	-0.42	-5.53	-0.33	8.3e-8	Immature fraction of reticulocytes;
KIRP	cis	rs986417	1.000	rs1950904	chr14:60964954	G/C	cg27398547	chr14:60952738	C14orf39	0.63	5.86	0.35	1.5e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.8	11.43	0.59	1.51e-24	Mood instability;
KIRP	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.88	-0.57	8.98e-23	Exhaled nitric oxide output;
KIRP	cis	rs28489187	0.660	rs3949301	chr1:85863383	G/A	cg16011679	chr1:85725395	C1orf52	-0.49	-5.99	-0.36	7.33e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg24846343	chr22:24311635	DDTL	-0.46	-5.61	-0.34	5.33e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg05347473	chr6:146136440	FBXO30	-0.58	-8.35	-0.47	5.07e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2274273	0.934	rs10144418	chr14:55817708	T/C	cg04306507	chr14:55594613	LGALS3	0.41	5.98	0.36	7.61e-9	Protein biomarker;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21347644	chr2:149401942	EPC2	0.49	6.67	0.39	1.7e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08887356	chr15:65578962	PARP16	0.55	7.28	0.42	4.46e-12	Parkinson's disease;
KIRP	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.82	12.27	0.62	2.59e-27	Ulcerative colitis;
KIRP	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3789045	0.866	rs61817482	chr1:204570347	G/A	cg18185008	chr1:204589407	LRRN2	-0.62	-6.45	-0.38	5.83e-10	Educational attainment (college completion);
KIRP	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.45e-21	Diabetic kidney disease;
KIRP	cis	rs6577655	0.517	rs4909294	chr8:135588020	C/T	cg17885191	chr8:135476712	NA	0.66	6.59	0.39	2.65e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.26	24.2	0.84	5.33e-67	IgG glycosylation;
KIRP	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.45	6.72	0.39	1.24e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg11846333	chr4:119757529	SEC24D	1.14	7.06	0.41	1.73e-11	Cannabis dependence symptom count;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13198984	chr17:80129470	CCDC57	0.57	8.57	0.48	1.18e-15	Life satisfaction;
KIRP	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs10214930	0.752	rs7808275	chr7:27661504	C/T	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs96067	0.805	rs4653162	chr1:36613704	G/T	cg27506609	chr1:36549197	TEKT2	0.5	5.88	0.35	1.34e-8	Corneal structure;
KIRP	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg20965017	chr5:231967	SDHA	-0.59	-6.86	-0.4	5.69e-11	Breast cancer;
KIRP	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg21605333	chr4:119757512	SEC24D	1.41	9.98	0.54	6.38e-20	Cannabis dependence symptom count;
KIRP	cis	rs2916247	1.000	rs2979854	chr8:92978039	G/A	cg10183463	chr8:93005414	RUNX1T1	0.57	7.57	0.43	7.27e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg07382826	chr16:28625726	SULT1A1	0.5	5.77	0.35	2.43e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.16	0.67	1.06e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg09137382	chr11:130731461	NA	0.52	7.32	0.42	3.54e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.52	7.37	0.43	2.54e-12	Systemic lupus erythematosus;
KIRP	cis	rs6504249	0.893	rs2521827	chr17:62692728	T/G	cg02097616	chr17:62675921	NA	0.52	6.22	0.37	2.06e-9	Joint mobility (Beighton score);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06865629	chr18:19409164	MIR1-2;MIB1	-0.44	-6.19	-0.37	2.5e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg19539972	chr4:7069911	GRPEL1	-0.91	-9.05	-0.5	4.41e-17	Monocyte percentage of white cells;
KIRP	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7007076	0.710	rs6995232	chr8:124710610	G/A	cg00283535	chr8:124749564	ANXA13	0.48	5.65	0.34	4.41e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.71	-9.74	-0.53	3.51e-19	Menarche (age at onset);
KIRP	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg19623624	chr10:135278901	LOC619207	-0.5	-5.66	-0.34	4.26e-8	Systemic lupus erythematosus;
KIRP	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg18888403	chr1:24152774	HMGCL	-0.35	-5.17	-0.31	4.97e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg00310523	chr12:86230176	RASSF9	0.56	8.87	0.49	1.56e-16	Major depressive disorder;
KIRP	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	5.57	0.33	6.59e-8	Thyroid stimulating hormone;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-4.97	-0.3	1.28e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.56	0.43	7.99e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs4765905	0.610	rs2239024	chr12:2311313	C/T	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg13147721	chr7:65941812	NA	-0.97	-7.44	-0.43	1.63e-12	Diabetic kidney disease;
KIRP	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg07451762	chr16:28383216	NA	0.39	5.05	0.31	8.8e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg18105134	chr13:113819100	PROZ	-1.05	-14.44	-0.68	1.2e-34	Platelet distribution width;
KIRP	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.83	-0.35	1.73e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.59e-11	Tonsillectomy;
KIRP	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.77	11.05	0.58	2.6e-23	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07678449	chr4:171011395	AADAT	-0.42	-6.08	-0.36	4.55e-9	Myopia;
KIRP	trans	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg06521331	chr12:34319734	NA	0.51	6.52	0.38	4.02e-10	Bladder cancer;
KIRP	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg24315340	chr6:146058215	EPM2A	0.42	5.07	0.31	8e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.6	7.66	0.44	4.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs12044355	0.927	rs17748239	chr1:231834901	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.48	-5.65	-0.34	4.5e-8	Alzheimer's disease;
KIRP	cis	rs56116382	0.668	rs4688759	chr3:50008118	T/C	cg03060546	chr3:49711283	APEH	-0.76	-6.19	-0.37	2.52e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs10073892	0.633	rs72777964	chr5:101613526	G/A	cg19774478	chr5:101632501	SLCO4C1	0.57	6.08	0.36	4.45e-9	Cognitive decline (age-related);
KIRP	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.82	11.05	0.58	2.67e-23	Height;
KIRP	cis	rs6142102	0.961	rs6059587	chr20:32542926	C/G	cg24642439	chr20:33292090	TP53INP2	0.58	6.3	0.37	1.39e-9	Skin pigmentation;
KIRP	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg26769984	chr7:1090371	C7orf50	0.87	6.83	0.4	6.56e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.15	-20.28	-0.79	2.02e-54	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2425143	1.000	rs2425142	chr20:34350346	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-5.96	-0.35	8.92e-9	Blood protein levels;
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.25	-5.21	-0.32	3.93e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	9.83	0.53	1.94e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg08712631	chr7:1960676	MAD1L1	-0.43	-5.49	-0.33	9.91e-8	Neuroticism;
KIRP	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg03714773	chr7:91764589	CYP51A1	0.4	5.82	0.35	1.86e-8	Breast cancer;
KIRP	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.67	10.25	0.55	9.34e-21	Blood metabolite ratios;
KIRP	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg24009623	chr19:33667908	NA	0.47	5.73	0.34	2.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.83	10.86	0.57	1.03e-22	Menarche (age at onset);
KIRP	cis	rs6977660	0.660	rs12531296	chr7:19816450	A/C	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2839627	0.638	rs60342559	chr21:44310051	T/C	cg03543861	chr21:44258195	NA	0.57	6.06	0.36	5.21e-9	Information processing speed;
KIRP	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	1.03	20.39	0.79	8.53e-55	Parkinson's disease;
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg23698023	chr8:27181813	PTK2B	0.36	5.39	0.32	1.65e-7	Neuroticism;
KIRP	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-8.36	-0.47	4.72e-15	Parkinson's disease;
KIRP	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.35	-0.42	2.89e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg23985595	chr17:80112537	CCDC57	-0.37	-5.43	-0.33	1.38e-7	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg01721255	chr8:58191610	C8orf71	0.5	4.89	0.3	1.85e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg20607798	chr8:58055168	NA	0.67	5.25	0.32	3.29e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2274273	0.870	rs3783650	chr14:55848972	A/C	cg04306507	chr14:55594613	LGALS3	0.52	8.24	0.47	1.01e-14	Protein biomarker;
KIRP	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg12483005	chr1:23474871	LUZP1	0.39	4.98	0.3	1.22e-6	Height;
KIRP	cis	rs6445967	0.832	rs1055973	chr3:58308960	T/C	cg16569813	chr3:58235849	ABHD6	-0.34	-5.08	-0.31	7.37e-7	Platelet count;
KIRP	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.81	-0.49	2.28e-16	Height;
KIRP	cis	rs830124	0.673	rs529736	chr12:122384457	A/C	cg21171335	chr12:122356390	WDR66	0.52	5.36	0.32	1.93e-7	Urinary metabolites;
KIRP	cis	rs3764563	0.932	rs617436	chr19:15693151	T/C	cg20725493	chr19:15740067	CYP4F8	0.86	6.21	0.37	2.29e-9	Inflammatory biomarkers;
KIRP	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11987759	chr7:65425863	GUSB	0.51	6.8	0.4	7.76e-11	Aortic root size;
KIRP	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23903597	chr17:61704154	MAP3K3	-0.62	-8.22	-0.46	1.14e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.42	-4.91	-0.3	1.66e-6	Monocyte count;
KIRP	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.37	-0.38	9.35e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.5	0.33	9.4e-8	Lung cancer;
KIRP	cis	rs514024	0.519	rs6478788	chr9:130376248	G/A	cg13643465	chr9:130375613	STXBP1	0.36	4.98	0.3	1.18e-6	Eating disorders (purging via substances);
KIRP	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg17376030	chr22:41985996	PMM1	0.48	5.11	0.31	6.46e-7	Vitiligo;
KIRP	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.54	-6.63	-0.39	2.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10073892	0.743	rs13359604	chr5:101653600	C/T	cg19774478	chr5:101632501	SLCO4C1	0.62	6.44	0.38	6.32e-10	Cognitive decline (age-related);
KIRP	cis	rs3790645	1.000	rs396997	chr1:26893067	T/C	cg23229016	chr1:26872525	RPS6KA1	0.23	6.15	0.37	3.1e-9	Glucose homeostasis traits;
KIRP	cis	rs1538970	0.924	rs1494812	chr1:45876999	C/T	cg05343316	chr1:45956843	TESK2	0.67	7.73	0.44	2.69e-13	Platelet count;
KIRP	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg23682824	chr7:23144976	KLHL7	0.47	5.65	0.34	4.36e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg12317470	chr15:67143691	NA	0.56	5.81	0.35	1.94e-8	Lung cancer (smoking interaction);
KIRP	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05585630	chr7:157510462	PTPRN2	-0.55	-8.18	-0.46	1.57e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07089783	chr10:31607955	ZEB1;LOC220930	0.48	6.25	0.37	1.84e-9	Parkinson's disease;
KIRP	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg23067535	chr8:124195133	FAM83A	0.63	5.86	0.35	1.44e-8	Urinary uromodulin levels;
KIRP	cis	rs830383	0.584	rs9790983	chr5:165503408	G/T	cg13976338	chr5:165423657	NA	-0.43	-4.99	-0.3	1.15e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.28	-0.32	2.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.73	-7.27	-0.42	4.81e-12	Menarche (age at onset);
KIRP	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg13010199	chr12:38710504	ALG10B	0.68	8.82	0.49	2.21e-16	Morning vs. evening chronotype;
KIRP	cis	rs6001982	0.584	rs73167044	chr22:40842405	T/C	cg07138101	chr22:40742427	ADSL	0.67	5.58	0.34	6.33e-8	Breast cancer;
KIRP	cis	rs7246657	0.663	rs10408619	chr19:38070474	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.4	-6.27	-0.37	1.57e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs13102973	0.863	rs11099307	chr4:135908104	T/C	cg14419869	chr4:135874104	NA	0.48	7.44	0.43	1.67e-12	Subjective well-being;
KIRP	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg26248373	chr2:1572462	NA	-0.65	-7.88	-0.45	1.08e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7792596	0.565	rs10464587	chr7:93982039	G/A	cg20814616	chr7:94014465	NA	-0.38	-6.18	-0.37	2.62e-9	Intelligence;
KIRP	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.19	21.88	0.81	1.2e-59	Cognitive function;
KIRP	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	1.03	12.66	0.63	1.31e-28	Breast cancer;
KIRP	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg14250997	chr9:106856677	SMC2	0.43	5.9	0.35	1.19e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.65	-12.46	-0.62	5.94e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg09417038	chr21:47716443	C21orf57	-0.38	-5.28	-0.32	2.82e-7	Testicular germ cell tumor;
KIRP	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg25182066	chr10:30743637	MAP3K8	0.59	7.13	0.41	1.1e-11	Inflammatory bowel disease;
KIRP	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg11657440	chr19:46296263	DMWD	-0.73	-9.37	-0.51	4.97e-18	Coronary artery disease;
KIRP	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg10117171	chr1:25599238	RHD	-0.38	-5.31	-0.32	2.5e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg08662619	chr6:150070041	PCMT1	0.36	5.74	0.34	2.78e-8	Lung cancer;
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg23985595	chr17:80112537	CCDC57	0.38	5.7	0.34	3.47e-8	Life satisfaction;
KIRP	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.82	0.4	6.89e-11	Bipolar disorder;
KIRP	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg16917193	chr12:54089295	NA	0.87	16.53	0.73	8.65e-42	Height;
KIRP	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-5.1	-0.31	6.87e-7	Height;
KIRP	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg16268157	chr7:99778414	STAG3	-0.54	-5.93	-0.35	1.03e-8	Lung function (FEV1/FVC);
KIRP	cis	rs8177876	0.731	rs74882687	chr16:81118920	C/A	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	9.04	0.5	4.64e-17	Coffee consumption (cups per day);
KIRP	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg19554555	chr3:13937349	NA	0.53	7.08	0.41	1.46e-11	Ovarian reserve;
KIRP	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01200585	chr1:228362443	C1orf69	0.46	5.81	0.35	1.97e-8	Diastolic blood pressure;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.42	8.89	0.49	1.32e-16	Vitiligo;
KIRP	cis	rs6684514	0.778	rs11264477	chr1:156321154	C/T	cg16558208	chr1:156270281	VHLL	-0.45	-5.46	-0.33	1.18e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.6	-8.58	-0.48	1.07e-15	Urate levels in overweight individuals;
KIRP	cis	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg21625330	chr8:9911636	MSRA	0.37	4.85	0.3	2.22e-6	Neuroticism;
KIRP	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg02297831	chr4:17616191	MED28	0.6	7.69	0.44	3.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.05	0.31	8.43e-7	Height;
KIRP	cis	rs4901847	0.643	rs36051876	chr14:58596241	C/T	cg15908186	chr14:58618357	C14orf37	0.61	7.97	0.45	6e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.44	5.66	0.34	4.16e-8	Renal cell carcinoma;
KIRP	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.28	7.45	0.43	1.54e-12	Primary biliary cholangitis;
KIRP	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs4006360	0.646	rs8080447	chr17:39301276	T/A	cg25341923	chr17:39239918	KRTAP4-7	-0.53	-8.05	-0.46	3.65e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.43	5.15	0.31	5.43e-7	Neuroticism;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg01334186	chr1:151372572	PSMB4	0.51	6.41	0.38	7.57e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12580194	1.000	rs12580194	chr12:55696558	A/G	cg11794356	chr12:55725991	OR6C3	0.37	5.17	0.31	4.81e-7	Cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15798530	chr4:122855216	TRPC3	0.38	6.09	0.36	4.35e-9	C-reactive protein;
KIRP	cis	rs5995756	0.761	rs5995759	chr22:40006626	T/C	cg10455938	chr22:40058150	CACNA1I	-0.54	-8.04	-0.46	3.86e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg00800038	chr16:89945340	TCF25	-0.67	-6.64	-0.39	2.03e-10	Skin colour saturation;
KIRP	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	8.18	0.46	1.52e-14	Red cell distribution width;
KIRP	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg18888403	chr1:24152774	HMGCL	0.36	5.0	0.3	1.09e-6	Immature fraction of reticulocytes;
KIRP	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.42	6.97	0.41	2.83e-11	Hemoglobin concentration;
KIRP	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.52	6.96	0.41	3.11e-11	Subjective well-being;Cardiovascular disease risk factors;
KIRP	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-6.35	-0.38	1.05e-9	Aortic root size;
KIRP	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	0.91	13.69	0.66	4.37e-32	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg12623918	chr2:306882	NA	0.42	5.29	0.32	2.65e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.52	5.02	0.3	1.02e-6	Recombination rate (females);
KIRP	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.02	-0.3	9.8e-7	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22332577	chr8:30925694	WRN	0.39	6.07	0.36	4.69e-9	Interleukin-4 levels;
KIRP	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg26174226	chr8:58114915	NA	-0.61	-7.15	-0.41	1e-11	Developmental language disorder (linguistic errors);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg15421701	chr8:142030550	NA	0.47	6.3	0.37	1.36e-9	Educational attainment;
KIRP	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs1011018	0.955	rs7807797	chr7:139462493	A/G	cg03224163	chr7:139420300	HIPK2	-0.47	-5.06	-0.31	8.18e-7	Systolic blood pressure;
KIRP	cis	rs6662572	0.671	rs12047120	chr1:46478496	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.35e-8	Blood protein levels;
KIRP	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg03351412	chr1:154909251	PMVK	0.58	7.02	0.41	2.2e-11	Prostate cancer;
KIRP	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.53	-5.46	-0.33	1.19e-7	Testicular germ cell tumor;Testicular germ cell cancer;
KIRP	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.5	-7.4	-0.43	2.21e-12	Coronary artery disease;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg08132940	chr7:1081526	C7orf50	-0.46	-5.3	-0.32	2.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2150410	0.764	rs2776310	chr21:40715831	A/G	cg11890956	chr21:40555474	PSMG1	0.69	5.04	0.31	8.85e-7	Temperament (bipolar disorder);
KIRP	cis	rs714027	0.526	rs73164755	chr22:30590015	A/G	cg01021169	chr22:30184971	ASCC2	-0.42	-5.33	-0.32	2.2e-7	Lymphocyte counts;
KIRP	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.04	0.36	5.67e-9	Menopause (age at onset);
KIRP	cis	rs255758	0.600	rs255754	chr5:53320109	T/C	cg22592108	chr5:53304441	ARL15	0.4	5.58	0.34	6.25e-8	Rheumatoid arthritis;
KIRP	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08695707	chr1:197871847	C1orf53	0.67	6.22	0.37	2.1e-9	Lung function (FEV1);
KIRP	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg08461772	chr7:95026248	PON3	0.4	5.86	0.35	1.47e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7951870	1.000	rs57744667	chr11:46697142	C/T	cg19486271	chr11:47235900	DDB2	0.53	5.01	0.3	1.05e-6	Schizophrenia;
KIRP	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.87	13.8	0.66	1.76e-32	Blood protein levels;
KIRP	cis	rs490234	0.783	rs7852065	chr9:128462023	T/C	cg14078157	chr9:128172775	NA	-0.41	-4.96	-0.3	1.31e-6	Mean arterial pressure;
KIRP	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg26138937	chr11:71823887	C11orf51	-1.15	-7.98	-0.45	5.56e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.89	-0.35	1.29e-8	IgG glycosylation;
KIRP	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg02795151	chr17:7402630	POLR2A	0.78	8.04	0.46	3.8e-14	Androgen levels;
KIRP	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg10223061	chr2:219282414	VIL1	-0.38	-5.96	-0.36	8.8e-9	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	trans	rs1995809	0.793	rs12501290	chr4:147967605	G/A	cg23682866	chr10:43858278	NA	0.6	6.23	0.37	1.99e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-7.71	-0.44	3.05e-13	Vitamin D levels;
KIRP	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg07424592	chr7:64974309	NA	0.78	5.07	0.31	7.94e-7	Diabetic kidney disease;
KIRP	cis	rs7312774	0.748	rs12308071	chr12:107314539	T/A	cg16260113	chr12:107380972	MTERFD3	0.72	6.48	0.38	5.04e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs6142102	0.923	rs2284377	chr20:32586682	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.69	0.39	1.46e-10	Skin pigmentation;
KIRP	cis	rs6545883	0.894	rs10496092	chr2:61524679	C/T	cg15711740	chr2:61764176	XPO1	0.6	7.75	0.44	2.43e-13	Tuberculosis;
KIRP	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.74	-0.39	1.1e-10	Myopia (pathological);
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg11641102	chr8:27183873	PTK2B	0.43	5.59	0.34	5.98e-8	Neuroticism;
KIRP	trans	rs61931739	0.629	rs17637821	chr12:33701108	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.09	-0.36	4.24e-9	Morning vs. evening chronotype;
KIRP	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13626774	chr8:68256266	ARFGEF1	0.58	7.65	0.44	4.67e-13	Parkinson's disease;
KIRP	cis	rs11731606	0.667	rs2639793	chr4:95414563	A/G	cg20625393	chr4:95128694	SMARCAD1	-0.5	-5.06	-0.31	8.34e-7	Mean platelet volume;
KIRP	cis	rs7127900	0.950	rs6579003	chr11:2232310	A/C	cg25635251	chr11:2234043	NA	0.52	7.86	0.45	1.22e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg18944383	chr4:111397179	ENPEP	0.79	16.9	0.73	4.84e-43	Height;
KIRP	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg16586182	chr3:47516702	SCAP	-0.55	-6.52	-0.38	4.05e-10	Birth weight;
KIRP	cis	rs41563	0.547	rs11761429	chr7:104943125	T/A	cg04380332	chr7:105027541	SRPK2	-0.67	-6.65	-0.39	1.84e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.16	0.37	2.9e-9	Platelet count;
KIRP	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.44	0.52	2.94e-18	Colorectal cancer;
KIRP	cis	rs6504340	0.793	rs56128659	chr17:46621828	T/A	cg04904318	chr17:46607828	HOXB1	-0.64	-6.73	-0.39	1.21e-10	Primary tooth development (number of teeth);
KIRP	cis	rs9400467	0.528	rs6568680	chr6:111776164	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.45	-5.83	-0.35	1.71e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.78	6.75	0.4	1.03e-10	Mean platelet volume;
KIRP	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg02527881	chr3:46936655	PTH1R	-0.42	-6.06	-0.36	5.21e-9	Colorectal cancer;
KIRP	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs15676	0.783	rs4837316	chr9:131577450	A/G	cg00228799	chr9:131580591	ENDOG	0.59	6.65	0.39	1.9e-10	Blood metabolite levels;
KIRP	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs55962025	0.883	rs363099	chr4:3162056	C/T	cg06533319	chr4:3265114	C4orf44	0.48	5.11	0.31	6.34e-7	Parental longevity (mother's age at death);
KIRP	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.34	-0.62	1.55e-27	Alzheimer's disease;
KIRP	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.99	0.3	1.12e-6	Cognitive test performance;
KIRP	cis	rs7429990	0.932	rs11130155	chr3:48140428	A/C	cg11946769	chr3:48343235	NME6	-0.44	-5.35	-0.32	2.01e-7	Educational attainment (years of education);
KIRP	cis	rs1957429	0.520	rs72625647	chr14:65344106	T/C	cg23373153	chr14:65346875	NA	-0.72	-4.96	-0.3	1.35e-6	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg18451016	chr1:38461880	NA	0.42	5.63	0.34	4.9e-8	Coronary artery disease;
KIRP	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.29	25.71	0.85	1.16e-71	IgG glycosylation;
KIRP	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-5.85	-0.35	1.55e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7923609	0.778	rs7075195	chr10:65050659	A/G	cg01631684	chr10:65280961	REEP3	-0.47	-5.43	-0.33	1.38e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8080784	0.660	rs8079951	chr17:59242764	T/A	cg19021197	chr17:59476212	TBX2	-0.5	-5.33	-0.32	2.17e-7	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.99e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg07501729	chr16:846077	CHTF18	0.43	5.42	0.33	1.42e-7	Mean corpuscular volume;
KIRP	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.71	7.79	0.44	1.85e-13	Gestational age at birth (maternal effect);
KIRP	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg02725872	chr8:58115012	NA	-0.63	-5.65	-0.34	4.43e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg18944383	chr4:111397179	ENPEP	-0.53	-6.24	-0.37	1.94e-9	Axial length;
KIRP	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	ch.1.3259774R	chr1:166827647	TADA1	-0.42	-5.13	-0.31	5.91e-7	Refractive astigmatism;
KIRP	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg25036284	chr2:26402008	FAM59B	-0.67	-6.93	-0.4	3.65e-11	Gut microbiome composition (summer);
KIRP	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg04226714	chr8:49833948	SNAI2	-0.51	-6.83	-0.4	6.56e-11	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15384640	chr17:6557720	NA	0.47	6.12	0.36	3.67e-9	Interleukin-4 levels;
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg13906792	chr15:75199810	C15orf17	-0.37	-5.41	-0.33	1.52e-7	Breast cancer;
KIRP	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.55	-4.96	-0.3	1.34e-6	Other erythrocyte phenotypes;
KIRP	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg25019033	chr10:957182	NA	0.37	4.97	0.3	1.28e-6	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg06521331	chr12:34319734	NA	-0.61	-7.28	-0.42	4.44e-12	Morning vs. evening chronotype;
KIRP	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg15247329	chr7:2764246	NA	-0.37	-5.22	-0.32	3.81e-7	Height;
KIRP	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.84	11.16	0.58	1.17e-23	Menarche (age at onset);
KIRP	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg13409248	chr3:40428643	ENTPD3	0.41	5.35	0.32	2.01e-7	Renal cell carcinoma;
KIRP	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18252515	chr7:66147081	NA	0.46	5.13	0.31	5.81e-7	Aortic root size;
KIRP	cis	rs74181299	0.964	rs1009358	chr2:65276452	C/T	cg05010058	chr2:65284262	CEP68	-0.46	-6.7	-0.39	1.45e-10	Pulse pressure;
KIRP	cis	rs9398803	0.830	rs9401885	chr6:126825837	C/G	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.15e-10	Male-pattern baldness;
KIRP	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg00981070	chr1:2046702	PRKCZ	0.36	5.2	0.31	4.14e-7	Height;
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg05665937	chr4:1216051	CTBP1	0.45	5.86	0.35	1.46e-8	Obesity-related traits;
KIRP	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.75	11.25	0.58	6.04e-24	Oral cavity cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10699967	chr12:50898744	DIP2B	0.5	6.16	0.37	2.89e-9	Parkinson's disease;
KIRP	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.08	-0.46	2.87e-14	Neuroticism;
KIRP	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.54	5.64	0.34	4.63e-8	Urate levels in lean individuals;
KIRP	trans	rs11923600	0.652	rs6788105	chr3:175972344	T/A	cg00728300	chr16:87903283	SLC7A5	0.48	6.06	0.36	5.21e-9	Height;
KIRP	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg25767906	chr1:53392781	SCP2	-0.35	-4.87	-0.3	1.96e-6	Monocyte count;
KIRP	cis	rs4356975	0.583	rs6819757	chr4:69958664	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-8.13	-0.46	2.1e-14	Mortality in heart failure;
KIRP	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.62	-0.63	1.68e-28	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12943539	chr2:27851867	GPN1;CCDC121	0.56	6.94	0.4	3.36e-11	Parkinson's disease;
KIRP	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23007540	chr8:142179688	DENND3	0.48	6.55	0.39	3.27e-10	Survival in pancreatic cancer;
KIRP	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	9.93	0.53	9.17e-20	Lung cancer in ever smokers;
KIRP	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Educational attainment;
KIRP	cis	rs7116495	1.000	rs493065	chr11:71796929	T/C	cg26138937	chr11:71823887	C11orf51	-0.65	-5.06	-0.31	8.15e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.55	-0.39	3.38e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2384207	0.584	rs6489898	chr12:113765246	G/A	cg13296563	chr12:112847257	RPL6	-0.6	-4.92	-0.3	1.61e-6	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.59	6.15	0.37	3.11e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs12210905	1.000	rs6902012	chr6:27243767	C/T	cg23155468	chr6:27110703	HIST1H2BK	0.8	6.74	0.39	1.11e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.61	-0.44	5.87e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg07451762	chr16:28383216	NA	0.42	5.5	0.33	9.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg23682824	chr7:23144976	KLHL7	0.54	6.5	0.38	4.48e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs13095912	0.819	rs11918734	chr3:185296602	T/C	cg11274856	chr3:185301563	NA	0.6	7.55	0.43	8.29e-13	Systolic blood pressure;
KIRP	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg21573476	chr21:45109991	RRP1B	-0.76	-9.73	-0.53	3.75e-19	Mean corpuscular volume;
KIRP	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-1.08	-15.28	-0.7	1.62e-37	Multiple sclerosis;
KIRP	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg25174290	chr11:3078921	CARS	-0.68	-8.83	-0.49	2.07e-16	Calcium levels;
KIRP	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg21161173	chr5:140098174	VTRNA1-2	0.4	5.19	0.31	4.38e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.63	8.19	0.46	1.41e-14	Blood protein levels;
KIRP	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.8	-10.0	-0.54	5.59e-20	Platelet distribution width;
KIRP	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg26585981	chr11:48327164	OR4S1	-0.5	-6.29	-0.37	1.41e-9	Migraine - clinic-based;
KIRP	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.65	7.88	0.45	1.05e-13	Calcium levels;
KIRP	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg19847130	chr8:10466454	RP1L1	0.35	5.27	0.32	3.06e-7	Retinal vascular caliber;
KIRP	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.77	0.35	2.41e-8	Aortic root size;
KIRP	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.91	-13.06	-0.64	5.81e-30	Tonsillectomy;
KIRP	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg17376030	chr22:41985996	PMM1	0.47	5.42	0.33	1.44e-7	Vitiligo;
KIRP	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs4332428	1.000	rs7893456	chr10:5007862	T/C	cg19648686	chr10:5044992	AKR1C2	-0.91	-8.14	-0.46	2.01e-14	Height;
KIRP	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.61	8.74	0.49	3.63e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10489202	1.000	rs3767474	chr1:168062398	C/T	cg24449463	chr1:168025552	DCAF6	-0.52	-5.82	-0.35	1.8e-8	Schizophrenia;
KIRP	cis	rs13401104	0.587	rs62190972	chr2:237145164	T/C	cg02367144	chr2:237146137	ASB18	0.4	5.25	0.32	3.26e-7	Educational attainment;
KIRP	cis	rs11673344	0.864	rs55921822	chr19:37496812	C/T	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.18	-0.31	4.64e-7	Obesity-related traits;
KIRP	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-6.19	-0.37	2.55e-9	Lung function (FEV1/FVC);
KIRP	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg27211696	chr2:191398769	TMEM194B	-0.77	-8.92	-0.49	1.06e-16	Diastolic blood pressure;
KIRP	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	1.01	9.26	0.51	1.07e-17	Left atrial antero-posterior diameter;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07760720	chr5:140080012	ZMAT2	0.96	6.31	0.37	1.27e-9	P wave terminal force;
KIRP	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.5	6.4	0.38	7.87e-10	Blood metabolite levels;
KIRP	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.32	-0.65	7.71e-31	Primary sclerosing cholangitis;
KIRP	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg18171855	chr10:2543474	NA	0.56	7.2	0.42	7.42e-12	Age-related hearing impairment;
KIRP	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg09137382	chr11:130731461	NA	0.51	7.36	0.42	2.71e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	6.09	0.36	4.27e-9	Personality dimensions;
KIRP	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.41	5.5	0.33	9.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4950322	0.570	rs111370771	chr1:146733077	A/G	cg22381352	chr1:146742008	CHD1L	-0.46	-5.52	-0.33	8.64e-8	Protein quantitative trait loci;
KIRP	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.8	9.11	0.5	2.92e-17	Corneal astigmatism;
KIRP	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg24296786	chr1:45957014	TESK2	0.53	6.33	0.37	1.14e-9	Homocysteine levels;
KIRP	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg11783602	chr8:55087084	NA	-0.59	-7.22	-0.42	6.3e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg03877680	chr5:178157825	ZNF354A	1.02	13.42	0.65	3.43e-31	Neutrophil percentage of white cells;
KIRP	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18364779	chr6:26104403	HIST1H4C	0.62	8.17	0.46	1.61e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg06066596	chr15:83166174	LOC80154	-0.44	-6.02	-0.36	6.21e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.47	5.43	0.33	1.35e-7	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg07884673	chr3:53033167	SFMBT1	0.92	6.93	0.4	3.64e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg05527609	chr1:210001259	C1orf107	-0.37	-4.94	-0.3	1.47e-6	Monobrow;
KIRP	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg27121462	chr16:89883253	FANCA	0.52	6.66	0.39	1.81e-10	Vitiligo;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15459742	chr9:111775564	CTNNAL1	0.49	6.4	0.38	7.6e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21016266	chr12:122356598	WDR66	0.61	8.37	0.47	4.38e-15	Mean corpuscular volume;
KIRP	cis	rs12311304	0.965	rs11056399	chr12:15365510	C/T	cg08258403	chr12:15378311	NA	0.34	5.13	0.31	6e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	1.09	17.02	0.74	1.85e-43	Homoarginine levels;
KIRP	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg10578777	chr12:7781093	NA	0.56	5.64	0.34	4.76e-8	HDL cholesterol levels;
KIRP	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.27	-0.32	2.99e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg24642439	chr20:33292090	TP53INP2	0.45	5.36	0.32	1.89e-7	Height;
KIRP	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg08648136	chr8:956695	NA	0.45	7.0	0.41	2.38e-11	Schizophrenia;
KIRP	trans	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg11608241	chr8:8085544	FLJ10661	-0.54	-6.83	-0.4	6.46e-11	Triglycerides;
KIRP	cis	rs4132509	0.625	rs1417121	chr1:243669350	G/C	cg25706552	chr1:244017396	NA	0.37	5.39	0.33	1.61e-7	RR interval (heart rate);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08502240	chr19:984437	WDR18	0.46	6.22	0.37	2.17e-9	Survival in pancreatic cancer;
KIRP	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg18154014	chr19:37997991	ZNF793	0.62	6.68	0.39	1.6e-10	Coronary artery calcification;
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg24874828	chr4:187887005	NA	-0.48	-7.01	-0.41	2.22e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg26876637	chr1:152193138	HRNR	0.73	9.36	0.51	5.39e-18	Atopic dermatitis;
KIRP	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg05347473	chr6:146136440	FBXO30	0.47	6.82	0.4	6.88e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	11.04	0.58	2.71e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.55	-6.94	-0.4	3.42e-11	Longevity;Endometriosis;
KIRP	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.5	-7.43	-0.43	1.8e-12	Itch intensity from mosquito bite;
KIRP	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.92	-0.35	1.05e-8	Breast cancer;
KIRP	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.75	-0.34	2.63e-8	Fear of minor pain;
KIRP	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg17294928	chr15:75287854	SCAMP5	-0.7	-6.21	-0.37	2.18e-9	Lung cancer;
KIRP	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.69	-8.21	-0.46	1.26e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.7	0.34	3.36e-8	Blood protein levels;
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg07414643	chr4:187882934	NA	0.4	5.3	0.32	2.63e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11955175	1.000	rs11955175	chr5:40626753	C/T	cg04002187	chr5:40835754	RPL37	-0.68	-5.7	-0.34	3.43e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs911555	0.755	rs2756122	chr14:103983033	C/G	cg16497661	chr14:103986332	CKB	0.41	5.27	0.32	3.03e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.53	6.23	0.37	2.05e-9	Uric acid levels;
KIRP	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg03152288	chr2:177042942	NA	-0.5	-5.99	-0.36	7.38e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg15660573	chr17:549704	VPS53	-0.83	-12.52	-0.62	3.7e-28	Prostate cancer;
KIRP	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.85	0.4	5.8200000000000003e-11	Mean platelet volume;
KIRP	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.28e-8	Retinal vascular caliber;
KIRP	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-6.82	-0.4	6.98e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.4e-11	Response to antipsychotic treatment;
KIRP	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.02	12.27	0.62	2.49e-27	Testicular germ cell tumor;
KIRP	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	0.97	7.56	0.43	7.84e-13	Type 2 diabetes nephropathy;
KIRP	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg02160872	chr5:212506	CCDC127	-0.46	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02711726	chr17:80685570	FN3KRP	-0.54	-7.22	-0.42	6.4e-12	Glycated hemoglobin levels;
KIRP	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Bladder cancer;
KIRP	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg26207909	chr14:103986467	CKB	-0.38	-4.93	-0.3	1.54e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs6956675	0.831	rs4718878	chr7:62656497	T/C	cg08930214	chr7:62859557	LOC100287834	0.41	4.93	0.3	1.52e-6	Obesity-related traits;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.58	-5.99	-0.36	7.28e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.74	-10.91	-0.57	7.38e-23	Hip circumference;
KIRP	cis	rs7666738	0.546	rs10007424	chr4:98885450	C/T	cg05340658	chr4:99064831	C4orf37	0.66	7.89	0.45	9.64e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg24110177	chr3:50126178	RBM5	-0.45	-5.37	-0.32	1.81e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.47	-4.85	-0.3	2.24e-6	Schizophrenia;
KIRP	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg25039879	chr17:56429692	SUPT4H1	0.57	5.05	0.31	8.47e-7	Cognitive test performance;
KIRP	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg10381502	chr11:71823885	C11orf51	-1.11	-7.75	-0.44	2.41e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg13877915	chr19:58951672	ZNF132	0.63	7.21	0.42	6.68e-12	Mean platelet volume;
KIRP	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg19500275	chr17:80737654	TBCD	0.48	5.75	0.34	2.66e-8	Glycated hemoglobin levels;
KIRP	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.61	-6.86	-0.4	5.6e-11	Response to antineoplastic agents;
KIRP	cis	rs11169552	0.510	rs10876072	chr12:51013559	G/C	cg12884762	chr12:50931848	DIP2B	-0.43	-5.04	-0.31	8.96e-7	Colorectal cancer;
KIRP	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg08975724	chr8:8085496	FLJ10661	0.61	8.24	0.47	9.96e-15	Retinal vascular caliber;
KIRP	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.67	7.21	0.42	6.68e-12	Diastolic blood pressure;
KIRP	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg13147721	chr7:65941812	NA	-1.03	-6.94	-0.4	3.39e-11	Gout;
KIRP	cis	rs870825	0.518	rs56034065	chr4:185655402	A/G	cg04058563	chr4:185651563	MLF1IP	1.01	10.36	0.55	4.28e-21	Blood protein levels;
KIRP	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg17145862	chr1:211918768	LPGAT1	0.76	10.56	0.56	9.43e-22	Leprosy;
KIRP	cis	rs60311166	1.000	rs7643568	chr3:52578474	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.95	6.9	0.4	4.5e-11	CTACK levels;
KIRP	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.09	0.72	2.71e-40	Lymphocyte percentage of white cells;
KIRP	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg15556689	chr8:8085844	FLJ10661	0.7	8.77	0.49	3.11e-16	Retinal vascular caliber;
KIRP	cis	rs6568686	0.786	rs4145457	chr6:111821182	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.58	-5.29	-0.32	2.66e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs7937612	1.000	rs10790383	chr11:120344526	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.85	-0.4	5.76e-11	Intraocular pressure;
KIRP	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg08280861	chr8:58055591	NA	0.52	4.85	0.3	2.21e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs669484	0.541	rs1407931	chr9:10406556	A/G	cg25509871	chr19:40871557	PLD3	-0.66	-6.42	-0.38	6.8e-10	Gestational age at birth (child effect);
KIRP	cis	rs1867631	0.585	rs11208922	chr1:67080226	T/C	cg13052034	chr1:66999238	SGIP1	0.42	6.13	0.36	3.45e-9	Menopause (age at onset);
KIRP	trans	rs12043259	0.730	rs6593913	chr1:204800005	A/G	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg07862535	chr7:139043722	LUC7L2	0.45	5.08	0.31	7.43e-7	Diisocyanate-induced asthma;
KIRP	cis	rs17428704	0.571	rs62344981	chr5:14348593	C/T	cg26595256	chr5:14380529	TRIO	-0.82	-6.14	-0.36	3.34e-9	Electroencephalogram traits;
KIRP	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	5.49	0.33	9.91e-8	Birth weight;
KIRP	trans	rs587242	1.000	rs12030271	chr1:96892099	A/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg19468946	chr17:37922297	IKZF3	-0.41	-5.36	-0.32	1.87e-7	Asthma;
KIRP	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.5	-7.09	-0.41	1.41e-11	Schizophrenia;
KIRP	cis	rs2219968	1.000	rs2128017	chr8:78964682	T/G	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg20526800	chr20:33880825	FAM83C	0.4	4.91	0.3	1.7e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05220968	chr6:146057943	EPM2A	0.4	5.05	0.31	8.41e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1359582	0.757	rs1214468	chr10:90413865	A/T	cg15661332	chr10:90342814	RNLS	0.57	5.92	0.35	1.07e-8	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.78	-8.79	-0.49	2.59e-16	Pancreatic cancer;
KIRP	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4716602	0.596	rs12698432	chr7:156158719	C/G	cg16983916	chr7:156159713	NA	0.44	5.8	0.35	2.02e-8	Anti-saccade response;
KIRP	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg20578329	chr17:80767326	TBCD	0.54	7.46	0.43	1.47e-12	Breast cancer;
KIRP	cis	rs10186029	0.509	rs10194726	chr2:213936876	G/A	cg08319019	chr2:214017104	IKZF2	-0.44	-5.2	-0.31	4.12e-7	Systemic sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08355568	chr6:7108248	RREB1	0.49	6.35	0.38	1.06e-9	Parkinson's disease;
KIRP	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.9e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7923609	1.000	rs4399232	chr10:64999490	C/T	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.53	-0.33	8e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11711311	0.712	rs4682139	chr3:113331859	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.36	-0.32	1.9e-7	IgG glycosylation;
KIRP	cis	rs1891275	0.509	rs34190234	chr10:93443074	A/C	cg07889827	chr10:93443413	NA	-0.41	-6.84	-0.4	6.36e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9993810	1	rs9993810	chr4:77614640	G/A	cg17476223	chr4:77663285	SHROOM3	0.49	6.7	0.39	1.4e-10	Magnesium levels;
KIRP	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.72	9.5	0.52	2.01e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.25	17.35	0.74	1.36e-44	Type 1 diabetes nephropathy;
KIRP	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.83	7.75	0.44	2.35e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg18882449	chr10:104885122	NT5C2	-0.41	-5.3	-0.32	2.54e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.76	11.17	0.58	1.1e-23	Red cell distribution width;
KIRP	cis	rs10510057	0.637	rs10886513	chr10:121323173	T/C	cg06765389	chr10:121379685	NA	-0.47	-7.43	-0.43	1.8e-12	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg01238044	chr22:24384105	GSTT1	-0.49	-6.17	-0.37	2.76e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg17294928	chr15:75287854	SCAMP5	-0.67	-5.53	-0.33	8.1e-8	Lung cancer;
KIRP	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.53	-6.53	-0.38	3.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10904849	1	rs10904849	chr10:16997266	G/T	cg24571822	chr10:17009592	CUBN	0.62	8.4	0.47	3.5e-15	Colorectal cancer;
KIRP	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-1.07	-12.69	-0.63	9.8e-29	Exhaled nitric oxide output;
KIRP	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg10755058	chr3:40428713	ENTPD3	-0.41	-5.9	-0.35	1.21e-8	Renal cell carcinoma;
KIRP	cis	rs7611694	0.609	rs13091945	chr3:113172110	T/C	cg12596171	chr3:113251061	SIDT1	0.42	5.12	0.31	6.02e-7	Prostate cancer;
KIRP	cis	rs7224685	0.569	rs34859684	chr17:3982628	G/C	cg09597638	chr17:3907349	NA	0.53	5.59	0.34	5.96e-8	Type 2 diabetes;
KIRP	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg05347473	chr6:146136440	FBXO30	0.54	7.78	0.44	2e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1859156	0.767	rs34628453	chr4:95791203	A/C	cg24204951	chr2:239172084	PER2	0.29	6.3	0.37	1.35e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.94	-0.35	9.76e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg00277334	chr10:82204260	NA	-0.49	-5.65	-0.34	4.31e-8	Post bronchodilator FEV1;
KIRP	trans	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.15	-0.46	1.85e-14	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4356932	1.000	rs10856875	chr4:76987167	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg03396347	chr1:1875803	NA	-0.6	-9.01	-0.5	6.05e-17	Body mass index;
KIRP	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.54	-7.37	-0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05665937	chr4:1216051	CTBP1	0.44	6.02	0.36	6.2e-9	Obesity-related traits;
KIRP	cis	rs2412208	1.000	rs2412208	chr1:7092782	T/G	cg20434152	chr1:7120926	CAMTA1	-0.37	-4.9	-0.3	1.73e-6	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs12200782	0.929	rs72836467	chr6:26353927	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-5.32	-0.32	2.28e-7	Small cell lung carcinoma;
KIRP	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg17376030	chr22:41985996	PMM1	0.55	6.45	0.38	5.98e-10	Vitiligo;
KIRP	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg03098644	chr7:100410630	EPHB4	0.49	5.05	0.31	8.68e-7	Other erythrocyte phenotypes;
KIRP	cis	rs7714584	1.000	rs3900064	chr5:150264414	C/G	cg22134413	chr5:150180641	NA	-0.56	-5.03	-0.31	9.65e-7	Crohn's disease;
KIRP	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg09264619	chr17:80180166	NA	0.51	6.09	0.36	4.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7011507	1.000	rs7832085	chr8:49161509	A/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg02996583	chr8:142237188	SLC45A4	-0.5	-6.06	-0.36	5e-9	Immature fraction of reticulocytes;
KIRP	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.32	8.46	0.47	2.46e-15	Crohn's disease;
KIRP	cis	rs9612	1.000	rs58896392	chr19:44269142	G/A	cg08581076	chr19:44259116	C19orf61	0.58	5.88	0.35	1.32e-8	Exhaled nitric oxide output;
KIRP	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.51	7.72	0.44	2.88e-13	IgG glycosylation;
KIRP	cis	rs17123764	1.000	rs11833411	chr12:50000387	T/C	cg20471783	chr12:50157085	TMBIM6	0.32	4.99	0.3	1.15e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg20302533	chr7:39170763	POU6F2	0.31	6.6	0.39	2.49e-10	IgG glycosylation;
KIRP	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.03e-9	Depression;
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg09264619	chr17:80180166	NA	-0.4	-5.74	-0.34	2.79e-8	Life satisfaction;
KIRP	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs654384	0.966	rs612476	chr7:4165790	G/A	cg21882563	chr7:4172065	SDK1	-0.41	-5.37	-0.32	1.8e-7	Positive affect;
KIRP	cis	rs1656402	0.953	rs1190441	chr2:233422237	C/T	cg03852847	chr2:233439513	NA	-0.65	-9.93	-0.54	9e-20	Non-small cell lung cancer (survival);
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg00738919	chr7:1100172	C7orf50	0.42	4.96	0.3	1.33e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg18646521	chr2:111875858	NA	0.4	5.77	0.35	2.37e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.42	6.41	0.38	7.25e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs1805008	0.640	rs17226232	chr16:89851574	A/G	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.17	-7.96	-0.45	6.45e-14	Skin colour saturation;
KIRP	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.75	-8.26	-0.47	8.89e-15	Hair shape;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15313226	chr2:191045668	C2orf88	0.43	6.06	0.36	5.08e-9	Parkinson's disease;
KIRP	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	6.72	0.39	1.25e-10	Coronary artery disease;
KIRP	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.92e-14	Coffee consumption (cups per day);
KIRP	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.84	0.3	2.25e-6	Menarche (age at onset);
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg02725872	chr8:58115012	NA	-0.81	-8.15	-0.46	1.87e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs4073416	0.508	rs7140341	chr14:66070417	C/G	cg03016385	chr14:66212404	NA	-0.55	-6.76	-0.4	9.94e-11	N-glycan levels;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg18234130	chr8:27182889	PTK2B	0.57	7.36	0.42	2.77e-12	Neuroticism;
KIRP	cis	rs2658782	0.901	rs11601056	chr11:93229161	C/T	cg15737290	chr11:93063684	CCDC67	-0.81	-7.79	-0.44	1.9e-13	Pulmonary function decline;
KIRP	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17554472	chr22:41940697	POLR3H	-0.61	-6.56	-0.39	3.13e-10	Vitiligo;
KIRP	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.55	8.47	0.48	2.22e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.28	24.69	0.84	1.6e-68	IgG glycosylation;
KIRP	trans	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg22153745	chr1:153894579	GATAD2B	-0.62	-6.64	-0.39	1.98e-10	Total cholesterol levels;
KIRP	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.09e-15	Menarche (age at onset);
KIRP	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.3	4.99	0.3	1.17e-6	Electrocardiographic conduction measures;
KIRP	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg04369109	chr6:150039330	LATS1	-0.47	-5.7	-0.34	3.42e-8	Lung cancer;
KIRP	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.4	-0.43	2.13e-12	Bipolar disorder;
KIRP	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg12253828	chr6:101329408	ASCC3	1.01	8.49	0.48	2.04e-15	Economic and political preferences (immigration/crime);
KIRP	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg24642439	chr20:33292090	TP53INP2	0.46	5.36	0.32	1.9e-7	Height;
KIRP	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg04132472	chr17:19861366	AKAP10	0.65	10.01	0.54	5.18e-20	Schizophrenia;
KIRP	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.6	6.47	0.38	5.19e-10	Diisocyanate-induced asthma;
KIRP	cis	rs490234	0.871	rs13288032	chr9:128255582	T/A	cg14078157	chr9:128172775	NA	-0.61	-7.28	-0.42	4.53e-12	Mean arterial pressure;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.69	10.89	0.57	8.54e-23	Longevity;Endometriosis;
KIRP	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.52	5.45	0.33	1.22e-7	Birth weight;
KIRP	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg00241281	chr14:105779794	PACS2	-0.38	-5.29	-0.32	2.64e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2191566	0.576	rs395803	chr19:44494694	A/G	cg18700516	chr19:44507157	ZNF230	0.42	4.85	0.3	2.2e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg02775129	chr4:119771670	NA	-0.87	-4.93	-0.3	1.54e-6	Cannabis dependence symptom count;
KIRP	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.43	-8.52	-0.48	1.62e-15	Urinary metabolites;
KIRP	cis	rs72730918	0.590	rs2606141	chr15:51946246	T/G	cg14296394	chr15:51910925	DMXL2	-0.78	-11.08	-0.58	2.04e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs2412819	0.599	rs2470120	chr15:43929070	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.77	0.4	9.63e-11	Lung cancer;
KIRP	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	6.13e-8	Lung cancer;
KIRP	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.63	8.59	0.48	9.81e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.62	7.84	0.45	1.37e-13	Neuroticism;
KIRP	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.32	-6.9	-0.4	4.26e-11	Cutaneous nevi;
KIRP	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg01620082	chr3:125678407	NA	-1.32	-8.31	-0.47	6.61e-15	Lung cancer;
KIRP	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18932078	chr1:2524107	MMEL1	0.43	5.75	0.34	2.61e-8	Ulcerative colitis;
KIRP	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.63	8.15	0.46	1.91e-14	Response to diuretic therapy;
KIRP	cis	rs829661	0.793	rs829653	chr2:30714906	G/A	cg10949345	chr2:30726833	LCLAT1	1.12	15.57	0.7	1.69e-38	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.25	17.47	0.74	5.64e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg09408571	chr1:101003634	GPR88	-0.24	-5.39	-0.32	1.67e-7	Monocyte count;
KIRP	cis	rs7715811	1.000	rs10050673	chr5:13761643	G/A	cg07548982	chr5:13769939	DNAH5	-0.52	-6.45	-0.38	5.83e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg11965913	chr1:205819406	PM20D1	0.5	5.51	0.33	8.99e-8	Parkinson's disease;
KIRP	cis	rs861020	0.560	rs649275	chr1:209950681	T/C	cg05527609	chr1:210001259	C1orf107	0.54	7.7	0.44	3.42e-13	Orofacial clefts;
KIRP	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-7.08	-0.41	1.47e-11	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08677398	chr8:58056175	NA	0.59	4.95	0.3	1.37e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2150410	0.915	rs11702268	chr21:40600313	T/C	cg11890956	chr21:40555474	PSMG1	0.74	5.33	0.32	2.25e-7	Temperament (bipolar disorder);
KIRP	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg18190219	chr22:46762943	CELSR1	-0.86	-7.09	-0.41	1.4e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2407308	0.565	rs7821609	chr8:4014579	C/G	cg01921437	chr8:3974145	CSMD1	-0.45	-5.29	-0.32	2.72e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg04293602	chr11:65553660	OVOL1	-0.26	-5.57	-0.33	6.63e-8	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
KIRP	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06544989	chr22:39130855	UNC84B	0.49	8.64	0.48	7.35e-16	Menopause (age at onset);
KIRP	cis	rs1678542	1.000	rs11172254	chr12:57968738	C/T	cg00677455	chr12:58241039	CTDSP2	-0.5	-5.56	-0.33	6.88e-8	Rheumatoid arthritis;
KIRP	cis	rs889398	0.835	rs12925429	chr16:69801539	G/A	cg09409435	chr16:70099608	PDXDC2	-0.44	-5.31	-0.32	2.47e-7	Body mass index;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.19	0.42	7.86e-12	Testicular germ cell tumor;
KIRP	cis	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg17261830	chr14:75593525	NEK9	0.35	5.0	0.3	1.1e-6	Caffeine consumption;
KIRP	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.41	-8.23	-0.46	1.12e-14	Longevity;
KIRP	cis	rs7116495	1.000	rs1573502	chr11:71747428	C/T	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-7.49	-0.43	1.23e-12	Vitiligo;
KIRP	cis	rs6545883	0.894	rs2463102	chr2:61571295	G/C	cg15711740	chr2:61764176	XPO1	0.59	7.73	0.44	2.71e-13	Tuberculosis;
KIRP	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.49	5.68	0.34	3.73e-8	Aortic root size;
KIRP	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	12.68	0.63	1.13e-28	Personality dimensions;
KIRP	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	0.8	7.96	0.45	6.24e-14	Mitochondrial DNA levels;
KIRP	cis	rs3120667	0.790	rs11590822	chr1:152392959	A/G	cg26876637	chr1:152193138	HRNR	-0.53	-5.56	-0.33	6.85e-8	Eating disorders;
KIRP	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.39	6.32	0.37	1.24e-9	Body mass index;
KIRP	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9547692	1.000	rs11619849	chr13:37468238	A/G	cg01493522	chr13:37497338	NA	-0.41	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg25019033	chr10:957182	NA	-0.65	-7.9	-0.45	9.17e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs9826463	0.757	rs75100831	chr3:142244647	T/C	cg20824294	chr3:142316082	PLS1	0.39	6.25	0.37	1.84e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.63	-7.8	-0.45	1.77e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg03312124	chr17:33416003	RFFL	-0.47	-6.42	-0.38	6.77e-10	Serum protein levels (sST2);
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.79	-0.4	8.12e-11	Immature fraction of reticulocytes;
KIRP	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.58	-0.39	2.79e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.09e-16	Life satisfaction;
KIRP	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.43e-12	Obesity-related traits;
KIRP	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21747090	chr2:27597821	SNX17	-0.49	-6.73	-0.39	1.19e-10	Total body bone mineral density;
KIRP	cis	rs1256061	0.603	rs3020445	chr14:64788644	A/G	cg21174375	chr14:64681225	SYNE2	0.48	5.41	0.33	1.5e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.34	-0.37	1.12e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2820315	0.867	rs2644135	chr1:201856256	C/G	cg11586189	chr1:201857591	SHISA4	0.38	5.28	0.32	2.83e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs2904967	0.866	rs526502	chr11:65026590	T/C	cg12562828	chr11:65076843	NA	-0.47	-7.14	-0.41	1.04e-11	Mean corpuscular volume;
KIRP	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.43	0.38	6.65e-10	Morning vs. evening chronotype;
KIRP	cis	rs2150410	0.915	rs8130099	chr21:40682571	C/G	cg11890956	chr21:40555474	PSMG1	0.83	5.8	0.35	2.02e-8	Temperament (bipolar disorder);
KIRP	cis	rs7903847	0.642	rs1048442	chr10:99160152	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.82	-0.35	1.78e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg19773385	chr1:10388646	KIF1B	-0.68	-9.51	-0.52	1.88e-18	Hepatocellular carcinoma;
KIRP	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.33	-0.32	2.22e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9815354	0.761	rs73083329	chr3:41927151	C/T	cg03022575	chr3:42003672	ULK4	0.77	7.99	0.45	5.18e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4936894	0.519	rs10893203	chr11:124167628	C/A	cg27160556	chr11:124181099	OR8D1	-0.44	-6.3	-0.37	1.39e-9	Aging (time to death);
KIRP	cis	rs4908768	0.512	rs4908784	chr1:8900568	C/T	cg25722041	chr1:8623473	RERE	0.44	4.89	0.3	1.84e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.67	8.53	0.48	1.55e-15	Longevity;Endometriosis;
KIRP	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.16	0.46	1.77e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	1.04	18.94	0.77	5.69e-50	Heart rate;
KIRP	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg13962347	chr6:5174647	LYRM4	-0.63	-8.66	-0.48	6.49e-16	Height;
KIRP	cis	rs77861329	1.000	rs9815010	chr3:52196548	C/T	cg08692210	chr3:52188851	WDR51A	0.95	7.42	0.43	1.95e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.25	0.55	9.39e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg23594656	chr7:65796392	TPST1	0.51	7.82	0.45	1.53e-13	Aortic root size;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17517854	chr1:32645323	TXLNA	-0.46	-6.03	-0.36	6.01e-9	Metabolic traits;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs12930096	0.938	rs12444653	chr16:11677955	A/C	cg07439791	chr16:11680400	LITAF	0.7	6.1	0.36	4.02e-9	QT interval;
KIRP	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	trans	rs6052563	1.000	rs6107465	chr20:4436757	G/A	cg03627468	chr16:79331759	NA	0.66	6.06	0.36	5.08e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	8.79	0.49	2.65e-16	LDL cholesterol;
KIRP	cis	rs479844	0.617	rs12146493	chr11:65547333	G/A	cg11569703	chr11:65557185	OVOL1	-0.51	-8.48	-0.48	2.06e-15	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
KIRP	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.52	-0.43	1e-12	Blood pressure;
KIRP	cis	rs6466055	0.739	rs6943183	chr7:104819479	T/C	cg04380332	chr7:105027541	SRPK2	-0.62	-9.16	-0.5	2.06e-17	Schizophrenia;
KIRP	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.78	-11.76	-0.6	1.29e-25	Hip circumference;
KIRP	cis	rs10073892	0.830	rs28602449	chr5:101610006	G/A	cg19774478	chr5:101632501	SLCO4C1	0.65	6.3	0.37	1.33e-9	Cognitive decline (age-related);
KIRP	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg25008857	chr14:105974488	NA	0.43	4.84	0.3	2.25e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg23594656	chr7:65796392	TPST1	0.44	6.17	0.37	2.81e-9	Aortic root size;
KIRP	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18937934	chr13:32634615	FRY	0.47	6.65	0.39	1.93e-10	Interleukin-4 levels;
KIRP	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs10875746	0.669	rs61940962	chr12:48595477	A/C	cg20731937	chr12:48336164	NA	0.48	6.38	0.38	8.73e-10	Longevity (90 years and older);
KIRP	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg06795125	chr2:108905320	SULT1C2	-0.39	-6.88	-0.4	4.83e-11	Blood pressure;
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg12591125	chr7:1885375	MAD1L1	0.58	5.81	0.35	1.9e-8	Bipolar disorder;
KIRP	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	cg04338863	chr8:33670619	NA	0.41	5.18	0.31	4.59e-7	Body mass index;
KIRP	cis	rs77861329	0.920	rs808787	chr3:52203249	G/A	cg08692210	chr3:52188851	WDR51A	0.94	7.35	0.42	2.96e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs6467136	0.765	rs1592365	chr7:127151323	C/A	cg08586737	chr7:127225949	GCC1	-0.37	-4.9	-0.3	1.71e-6	Type 2 diabetes;
KIRP	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.48	7.01	0.41	2.33e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs712039	0.652	rs853196	chr17:35848659	A/T	cg16670864	chr17:35848621	DUSP14	0.47	5.79	0.35	2.12e-8	Tuberculosis;
KIRP	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17344932	chr17:38183730	MED24;SNORD124	0.44	6.73	0.39	1.18e-10	Myeloid white cell count;
KIRP	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	0.73	8.54	0.48	1.39e-15	Pediatric areal bone mineral density (radius);
KIRP	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	cg12689670	chr1:183009347	LAMC1	0.56	7.77	0.44	2.13e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.5	6.36	0.38	1e-9	Breast cancer;
KIRP	cis	rs2281603	0.951	rs12588886	chr14:64996944	T/A	cg25009451	chr14:65006716	HSPA2	0.48	5.25	0.32	3.26e-7	Lymphocyte counts;
KIRP	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.81	-11.41	-0.59	1.74e-24	Dental caries;
KIRP	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg00553149	chr7:99775558	STAG3;GPC2	0.47	5.88	0.35	1.31e-8	Coronary artery disease;
KIRP	trans	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.26	-0.37	1.72e-9	Obesity-related traits;
KIRP	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11031527	chr4:1005061	FGFRL1	0.44	6.19	0.37	2.45e-9	Parkinson's disease;
KIRP	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-7.59	-0.44	6.71e-13	Morning vs. evening chronotype;
KIRP	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg20991723	chr1:152506922	NA	-0.46	-5.52	-0.33	8.46e-8	Hair morphology;
KIRP	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.76	9.62	0.52	8.58e-19	Aortic root size;
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg01798813	chr17:3906674	NA	0.61	8.58	0.48	1.08e-15	Type 2 diabetes;
KIRP	cis	rs7852872	0.965	rs6478240	chr9:119249198	A/G	cg13792444	chr9:119245443	ASTN2	0.39	5.75	0.34	2.7e-8	Hippocampal volume;
KIRP	cis	rs6681460	1.000	rs6681460	chr1:67123057	C/T	cg13052034	chr1:66999238	SGIP1	-0.44	-6.22	-0.37	2.15e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05665937	chr4:1216051	CTBP1	0.49	7.07	0.41	1.6e-11	Obesity-related traits;
KIRP	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.15	-0.37	3.17e-9	Retinal vascular caliber;
KIRP	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.36	5.66	0.34	4.21e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.64	6.99	0.41	2.51e-11	Gut microbiome composition (summer);
KIRP	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs17123764	1.000	rs74089566	chr12:49956575	T/C	cg20471783	chr12:50157085	TMBIM6	0.43	5.66	0.34	4.19e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.77	10.82	0.57	1.47e-22	Diastolic blood pressure;
KIRP	trans	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg02820040	chr2:241836501	C2orf54	-0.25	-5.53	-0.33	8.04e-8	Urinary metabolites;
KIRP	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-5.72	-0.34	3.09e-8	Coronary artery disease;
KIRP	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.97	-0.5	7.67e-17	Mood instability;
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.73	10.86	0.57	1.04e-22	Longevity;Endometriosis;
KIRP	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.59	8.12	0.46	2.23e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.46	6.85	0.4	5.83e-11	Bipolar disorder;
KIRP	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06481639	chr22:41940642	POLR3H	-0.48	-5.83	-0.35	1.69e-8	Vitiligo;
KIRP	cis	rs12230513	0.732	rs61956358	chr12:55852286	G/T	cg11794356	chr12:55725991	OR6C3	-0.52	-6.34	-0.37	1.12e-9	Contrast sensitivity;
KIRP	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg18944383	chr4:111397179	ENPEP	0.46	7.39	0.43	2.31e-12	Coronary artery disease;
KIRP	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22903657	chr4:1355424	KIAA1530	-0.54	-7.73	-0.44	2.8e-13	Obesity-related traits;
KIRP	cis	rs7737355	0.812	rs798414	chr5:130696450	C/T	cg06307176	chr5:131281290	NA	-0.44	-5.39	-0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs9547996	0.879	rs9547958	chr13:38140879	A/T	cg13634560	chr13:38173852	POSTN	0.4	5.53	0.33	8.14e-8	Diastolic blood pressure;
KIRP	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg17554472	chr22:41940697	POLR3H	-0.4	-4.9	-0.3	1.77e-6	Vitiligo;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06072644	chr17:31780500	ACCN1	0.39	6.02	0.36	6.47e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.42	8.67	0.48	5.94e-16	Vitiligo;
KIRP	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-14.39	-0.68	1.83e-34	Chronic sinus infection;
KIRP	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.41	-0.38	7.33e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg19636519	chr7:99541626	NA	0.32	5.92	0.35	1.08e-8	Coronary artery disease;
KIRP	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.54	6.37	0.38	9.41e-10	Aortic root size;
KIRP	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg26507422	chr16:88990409	CBFA2T3	-0.35	-4.9	-0.3	1.72e-6	Social autistic-like traits;
KIRP	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg09873164	chr1:152488093	CRCT1	0.6	7.73	0.44	2.76e-13	Hair morphology;
KIRP	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11613427	chr3:52932208	TMEM110	-0.33	-5.44	-0.33	1.3e-7	Schizophrenia;
KIRP	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg14458575	chr2:238380390	NA	0.6	8.15	0.46	1.84e-14	Prostate cancer;
KIRP	cis	rs370915	0.963	rs59452206	chr4:187816484	G/T	cg19519643	chr4:187840862	NA	-0.45	-5.8	-0.35	2.05e-8	Gout;
KIRP	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.79	-0.66	2.02e-32	Tonsillectomy;
KIRP	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.97e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs2224391	0.518	rs72815610	chr6:5283881	T/G	cg13962347	chr6:5174647	LYRM4	-0.68	-6.45	-0.38	5.94e-10	Height;
KIRP	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.65	0.56	4.92e-22	Cognitive test performance;
KIRP	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.63	7.9	0.45	9.27e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs57561814	0.655	rs8180726	chr7:22749306	A/C	cg01770232	chr7:22766155	IL6	0.65	5.35	0.32	2.06e-7	Tonsillectomy;
KIRP	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	0.63	5.55	0.33	7.49e-8	Blood pressure (smoking interaction);
KIRP	cis	rs56079296	0.642	rs12657394	chr5:121308199	C/T	cg05256605	chr5:121412184	LOX	-0.51	-5.65	-0.34	4.43e-8	Coronary artery disease;
KIRP	cis	rs2864527	0.826	rs57292829	chr18:9324321	A/G	cg16053677	chr18:9261071	ANKRD12	-0.94	-4.91	-0.3	1.65e-6	Dental caries;
KIRP	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg13180566	chr4:1052158	NA	-0.52	-5.32	-0.32	2.29e-7	Recombination rate (females);
KIRP	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.69	10.21	0.55	1.22e-20	Dupuytren's disease;
KIRP	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg04289385	chr6:36355825	ETV7	0.38	5.0	0.3	1.11e-6	Platelet distribution width;
KIRP	cis	rs3126085	0.825	rs116321073	chr1:152240413	A/T	cg26876637	chr1:152193138	HRNR	0.73	8.91	0.49	1.14e-16	Atopic dermatitis;
KIRP	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.76	-9.8	-0.53	2.28e-19	Aortic root size;
KIRP	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg00846425	chr4:957561	DGKQ	-0.52	-5.35	-0.32	1.98e-7	Type 2 diabetes;
KIRP	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.39	0.51	4.38e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.46	6.72	0.39	1.24e-10	Urate levels in lean individuals;
KIRP	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.47	6.42	0.38	7.11e-10	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.5	-0.48	1.79e-15	Life satisfaction;
KIRP	cis	rs2562456	0.833	rs2650801	chr19:21635355	C/T	cg25650185	chr19:21324782	ZNF431	-0.49	-5.27	-0.32	3.03e-7	Pain;
KIRP	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.96	-0.3	1.29e-6	Type 2 diabetes;
KIRP	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg14851346	chr12:38532713	NA	-0.4	-5.06	-0.31	8.33e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg17443007	chr1:101659419	NA	0.4	5.64	0.34	4.74e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs1712517	0.904	rs4918007	chr10:105107470	G/A	cg05636881	chr10:105038444	INA	-0.43	-6.13	-0.36	3.4e-9	Migraine;
KIRP	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg04989706	chr14:50066350	PPIL5	-0.5	-5.79	-0.35	2.09e-8	Carotid intima media thickness;
KIRP	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg27121462	chr16:89883253	FANCA	-0.48	-6.16	-0.37	3.01e-9	Vitiligo;
KIRP	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06505273	chr16:24850292	NA	-0.37	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg10189774	chr4:17578691	LAP3	0.5	5.94	0.35	9.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.22	-0.46	1.2e-14	Monocyte percentage of white cells;
KIRP	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg12311346	chr5:56204834	C5orf35	-0.39	-5.37	-0.32	1.87e-7	Breast cancer;Breast cancer (early onset);
KIRP	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg04740939	chr16:88559868	ZFPM1	0.58	6.42	0.38	6.99e-10	Hepatitis;
KIRP	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg05802129	chr4:122689817	NA	-0.59	-7.21	-0.42	6.67e-12	Type 2 diabetes;
KIRP	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg10189774	chr4:17578691	LAP3	0.51	6.18	0.37	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs300774	0.841	rs410690	chr2:203346	G/A	cg21211680	chr2:198530	NA	0.59	6.45	0.38	5.91e-10	Suicide attempts in bipolar disorder;
KIRP	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.55	7.74	0.44	2.55e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg08992911	chr2:238395768	MLPH	0.42	5.19	0.31	4.3e-7	Prostate cancer;
KIRP	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.85	13.03	0.64	7.52e-30	Colorectal cancer;
KIRP	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.33	4.93	0.3	1.51e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7621025	0.542	rs71336078	chr3:136489602	G/A	cg15507776	chr3:136538369	TMEM22	-0.7	-6.4	-0.38	7.8e-10	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.31	0.37	1.3e-9	Menarche (age at onset);
KIRP	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.96	11.18	0.58	1.01e-23	Corneal astigmatism;
KIRP	cis	rs6456042	0.964	rs3127418	chr6:166538176	G/T	cg11088901	chr6:166572345	T	-0.32	-4.87	-0.3	2.04e-6	Asthma;
KIRP	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg11645453	chr3:52864694	ITIH4	-0.34	-5.07	-0.31	7.67e-7	Body mass index;
KIRP	cis	rs1546924	0.669	rs197439	chr1:112280990	A/G	cg23955903	chr1:112298873	DDX20;C1orf183	0.44	5.54	0.33	7.67e-8	Body mass index;
KIRP	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.23	-21.13	-0.8	3.28e-57	Breast cancer;
KIRP	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.66	8.68	0.48	5.48e-16	Menarche (age at onset);
KIRP	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.77	13.08	0.64	5.07e-30	Cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08935602	chr16:2509817	C16orf59	0.65	6.28	0.37	1.49e-9	Lung function (FEV1);
KIRP	cis	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.81	-0.35	1.88e-8	HDL cholesterol;
KIRP	trans	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg24644049	chr4:85504048	CDS1	1.03	6.86	0.4	5.6e-11	Skin colour saturation;
KIRP	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg17757837	chr7:157058334	UBE3C	-0.81	-11.11	-0.58	1.7e-23	Body mass index;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.38	-0.43	2.39e-12	Type 2 diabetes;
KIRP	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.01	-0.41	2.32e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg16680214	chr1:154839983	KCNN3	0.37	5.62	0.34	5.17e-8	Prostate cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12232835	chr3:183979215	ECE2;CAMK2N2	-0.52	-6.72	-0.39	1.27e-10	Myopia;
KIRP	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg10840412	chr1:235813424	GNG4	0.75	6.67	0.39	1.69e-10	Bipolar disorder;
KIRP	cis	rs9815354	0.556	rs56201224	chr3:42004427	A/C	cg03022575	chr3:42003672	ULK4	0.79	8.37	0.47	4.39e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.36e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.5	-0.38	4.38e-10	Response to antipsychotic treatment;
KIRP	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.8	-0.4	7.92e-11	Coronary artery disease;
KIRP	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	1.08	11.7	0.6	1.99e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg05484376	chr2:27715224	FNDC4	-0.3	-5.05	-0.31	8.55e-7	Oral cavity cancer;
KIRP	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	0.93	7.93	0.45	7.48e-14	Activated partial thromboplastin time;
KIRP	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	7.4	0.43	2.1e-12	Neuroticism;
KIRP	cis	rs12580194	0.556	rs12099811	chr12:55731200	T/A	cg19537932	chr12:55886519	OR6C68	-0.48	-6.38	-0.38	8.78e-10	Cancer;
KIRP	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg02725872	chr8:58115012	NA	-0.52	-6.29	-0.37	1.44e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg18350739	chr11:68623251	NA	-0.46	-7.24	-0.42	5.63e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg23978390	chr7:1156363	C7orf50	0.57	5.58	0.34	6.42e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg21466736	chr12:48725269	NA	-0.45	-5.79	-0.35	2.09e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.97	11.63	0.6	3.41e-25	Exhaled nitric oxide levels;
KIRP	cis	rs239198	0.521	rs9377241	chr6:101334265	C/T	cg09795085	chr6:101329169	ASCC3	0.48	5.54	0.33	7.89e-8	Menarche (age at onset);
KIRP	cis	rs4664293	0.613	rs9784044	chr2:160622365	C/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg07167872	chr1:205819463	PM20D1	0.54	5.92	0.35	1.1e-8	Parkinson's disease;
KIRP	cis	rs8027181	1.000	rs8027181	chr15:73088869	A/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.36	4.85	0.3	2.15e-6	Triglyceride levels;
KIRP	cis	rs7766436	0.885	rs13209127	chr6:22597625	A/G	cg13666174	chr6:22585274	NA	0.47	6.45	0.38	5.85e-10	Coronary artery disease;
KIRP	cis	rs9325144	1.000	rs9325144	chr12:39018673	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-6.35	-0.38	1.03e-9	Morning vs. evening chronotype;
KIRP	cis	rs12230513	0.732	rs61547125	chr12:55814082	C/G	cg11794356	chr12:55725991	OR6C3	-0.48	-5.9	-0.35	1.2e-8	Contrast sensitivity;
KIRP	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.47	-5.41	-0.33	1.48e-7	Schizophrenia;
KIRP	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg02887458	chr19:19495540	GATAD2A	0.43	4.86	0.3	2.09e-6	Bipolar disorder;
KIRP	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg16586182	chr3:47516702	SCAP	-0.69	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs867371	1.000	rs6495643	chr15:82479254	C/G	cg00614314	chr15:82944287	LOC80154	0.54	6.46	0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg10517650	chr3:113235015	CCDC52	-0.41	-5.08	-0.31	7.45e-7	Dental caries;
KIRP	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.78	0.35	2.2e-8	Menopause (age at onset);
KIRP	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.17	0.31	4.96e-7	Asthma;
KIRP	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.83	11.26	0.58	5.52e-24	Systemic lupus erythematosus;
KIRP	cis	rs7582720	0.945	rs72932720	chr2:203646934	C/G	cg08076091	chr2:203926405	NBEAL1	0.83	8.27	0.47	8.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg00778059	chr13:24734742	SPATA13	-0.62	-6.33	-0.37	1.17e-9	Response to statin therapy;
KIRP	cis	rs35995292	0.926	rs10259755	chr7:38897012	A/C	cg19327137	chr7:38886074	VPS41	0.52	6.29	0.37	1.42e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs7258465	1.000	rs7252848	chr19:18612351	C/G	cg10790698	chr19:18539756	SSBP4	-0.33	-7.0	-0.41	2.48e-11	Breast cancer;
KIRP	cis	rs78487399	0.808	rs12104615	chr2:43676938	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs151997	0.649	rs152688	chr5:50211776	C/T	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg02175503	chr12:58329896	NA	0.64	7.75	0.44	2.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04016957	chr4:1044486	NA	-0.45	-5.81	-0.35	1.93e-8	Recombination rate (males);
KIRP	cis	rs6504622	0.818	rs3851784	chr17:45040117	C/T	cg24703533	chr17:45055318	NA	0.4	5.75	0.34	2.67e-8	Orofacial clefts;
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.25	-5.27	-0.32	3e-7	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.79	10.78	0.57	1.86e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg07166546	chr14:35805898	NA	-0.27	-6.54	-0.38	3.55e-10	Psoriasis;
KIRP	cis	rs258892	0.793	rs34657	chr5:72148196	G/A	cg21869765	chr5:72125136	TNPO1	0.57	6.26	0.37	1.7e-9	Small cell lung carcinoma;
KIRP	cis	rs75920871	0.623	rs57582454	chr11:116961892	G/A	cg04087571	chr11:116723030	SIK3	-0.28	-5.55	-0.33	7.25e-8	Subjective well-being;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27243121	chr11:70281584	CTTN	0.45	6.05	0.36	5.36e-9	Interleukin-4 levels;
KIRP	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg04833713	chr10:74871078	NUDT13	0.43	4.91	0.3	1.69e-6	Incident atrial fibrillation;
KIRP	cis	rs6662572	0.737	rs7530480	chr1:46399655	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.55e-8	Blood protein levels;
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.2	-0.42	7.22e-12	Response to antipsychotic treatment;
KIRP	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21214613	chr1:16344536	HSPB7	0.36	5.11	0.31	6.33e-7	Dilated cardiomyopathy;
KIRP	trans	rs270421	0.617	rs384216	chr16:79245465	T/C	cg26284735	chr3:5065165	NA	0.24	6.02	0.36	6.31e-9	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs72820985	1.000	rs74030462	chr16:80841294	G/A	cg04448709	chr16:81349954	GAN	-0.49	-5.01	-0.3	1.04e-6	Breast cancer;
KIRP	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.74	10.22	0.55	1.12e-20	Plateletcrit;Platelet count;
KIRP	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.84	-0.53	1.8e-19	Response to antipsychotic treatment;
KIRP	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	21.71	0.81	4.34e-59	Chronic sinus infection;
KIRP	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	1.16	7.57	0.43	7.51e-13	Type 2 diabetes nephropathy;
KIRP	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.49	-0.33	1.02e-7	Colorectal cancer;
KIRP	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg14972814	chr11:95582409	MTMR2	0.3	5.15	0.31	5.35e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.32	0.37	1.24e-9	Educational attainment;
KIRP	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg21918786	chr6:109611834	NA	0.34	5.17	0.31	4.96e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.66	-8.93	-0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.89	11.78	0.6	1.06e-25	Orofacial clefts;
KIRP	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-0.85	-6.5	-0.38	4.52e-10	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg12692727	chr7:1102344	C7orf50	0.47	5.04	0.31	9.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg03060546	chr3:49711283	APEH	0.43	5.65	0.34	4.38e-8	Parkinson's disease;
KIRP	cis	rs9826463	0.582	rs73238136	chr3:142038959	T/C	cg20824294	chr3:142316082	PLS1	0.42	6.01	0.36	6.82e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12213875	0.502	rs13195864	chr6:14604236	G/A	cg01527307	chr6:14500441	NA	-0.4	-5.27	-0.32	2.95e-7	Ovarian reserve;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02921003	chr12:75728281	GLIPR1L1	0.44	6.13	0.36	3.45e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg10360139	chr7:1886902	MAD1L1	-0.44	-4.94	-0.3	1.44e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.7	7.67	0.44	4.05e-13	Neutrophil percentage of white cells;
KIRP	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.76	-0.44	2.34e-13	Mood instability;
KIRP	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.18e-19	Prudent dietary pattern;
KIRP	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	5.76	0.34	2.53e-8	Blood metabolite levels;
KIRP	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.71	-7.79	-0.44	1.83e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs787274	0.867	rs786981	chr9:115457856	T/G	cg13803584	chr9:115635662	SNX30	0.61	6.97	0.41	2.93e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10924309	0.546	rs7535506	chr1:245867743	G/A	cg00036263	chr1:245852353	KIF26B	0.38	4.92	0.3	1.59e-6	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs2131877	0.573	rs4266129	chr3:194846933	T/C	cg16306870	chr3:194868790	C3orf21	0.2	4.92	0.3	1.56e-6	Non-small cell lung cancer;
KIRP	trans	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.08	0.36	4.63e-9	Retinal vascular caliber;
KIRP	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	cg12689670	chr1:183009347	LAMC1	-0.46	-6.59	-0.39	2.66e-10	Hypertriglyceridemia;
KIRP	cis	rs7757419	1.000	rs7773610	chr6:34435180	C/A	cg25473981	chr6:34433676	PACSIN1	0.42	5.14	0.31	5.54e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;
KIRP	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.74	11.03	0.58	3.03e-23	Neutrophil percentage of white cells;
KIRP	cis	rs8060686	0.516	rs7187202	chr16:68273895	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-7.64	-0.44	4.92e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.61	-0.34	5.55e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6993770	0.661	rs16873235	chr8:106518323	A/G	cg12797828	chr8:106520928	ZFPM2	-0.33	-4.92	-0.3	1.58e-6	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
KIRP	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.18	0.31	4.69e-7	Height;
KIRP	cis	rs7084402	0.967	rs1649062	chr10:60309326	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.94	0.5	9.47e-17	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22994018	chr11:105448797	NA	-0.45	-7.23	-0.42	5.94e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	10.18	0.54	1.54e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.98	-9.76	-0.53	3.18e-19	Cerebrospinal P-tau181p levels;
KIRP	cis	rs909341	0.909	rs2427532	chr20:62363817	G/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.77	-0.35	2.32e-8	Atopic dermatitis;
KIRP	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg25036284	chr2:26402008	FAM59B	-0.54	-5.58	-0.34	6.3e-8	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15403654	chr17:7747012	KDM6B	0.51	6.43	0.38	6.71e-10	Parkinson's disease;
KIRP	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.62	-8.2	-0.46	1.38e-14	Aortic root size;
KIRP	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-6.7	-0.39	1.45e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg18367735	chr17:79674897	NA	0.74	7.45	0.43	1.54e-12	Dental caries;
KIRP	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.86	-0.63	2.83e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs4950322	0.542	rs1932977	chr1:146688941	A/G	cg22381352	chr1:146742008	CHD1L	-0.38	-5.16	-0.31	4.99e-7	Protein quantitative trait loci;
KIRP	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg02336718	chr17:17403227	NA	-0.31	-4.96	-0.3	1.3e-6	Total body bone mineral density;
KIRP	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-5.95	-0.35	9.27e-9	Blood metabolite levels;
KIRP	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.84	-12.9	-0.64	2e-29	Blood metabolite levels;
KIRP	cis	rs26949	0.504	rs10054744	chr5:60040047	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.35	-0.32	2.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg23307798	chr14:103986281	CKB	-0.51	-6.93	-0.4	3.73e-11	Coronary artery disease;
KIRP	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg05220968	chr6:146057943	EPM2A	0.41	5.37	0.32	1.83e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7612445	0.536	rs116226990	chr3:179077765	G/T	cg01750654	chr3:179170617	GNB4	-0.49	-5.46	-0.33	1.18e-7	Resting heart rate;Heart rate;
KIRP	cis	rs253959	0.545	rs712593	chr5:115657397	G/T	cg23108291	chr5:115420582	COMMD10	-0.51	-5.69	-0.34	3.66e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.44	-0.52	2.91e-18	Gut microbiome composition (summer);
KIRP	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg09455208	chr3:40491958	NA	0.31	5.66	0.34	4.26e-8	Renal cell carcinoma;
KIRP	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg23594656	chr7:65796392	TPST1	0.39	5.9	0.35	1.2e-8	Aortic root size;
KIRP	trans	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg03345454	chr2:202901428	FZD7	-0.41	-6.02	-0.36	6.43e-9	Migraine;
KIRP	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.71	9.92	0.53	9.73e-20	Body mass index;
KIRP	cis	rs501120	0.925	rs535949	chr10:44752330	A/C	cg09554077	chr10:44749378	NA	-0.77	-12.71	-0.63	8.8e-29	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-6.22	-0.37	2.17e-9	Body mass index;
KIRP	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.54	-0.43	9.27e-13	Bipolar disorder;
KIRP	cis	rs10760158	0.587	rs10985212	chr9:124100828	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.42	5.12	0.31	6.29e-7	Pulse pressure;
KIRP	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.3	0.32	2.61e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.34	-0.51	6.14e-18	Gut microbiome composition (summer);
KIRP	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.66	-7.46	-0.43	1.52e-12	Blood pressure (smoking interaction);
KIRP	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg11972305	chr2:233791962	NGEF	0.38	5.2	0.31	4.17e-7	Schizophrenia;
KIRP	cis	rs13095912	1.000	rs13100229	chr3:185343200	C/T	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.1e-11	Systolic blood pressure;
KIRP	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg05044414	chr3:183734942	ABCC5	0.38	5.79	0.35	2.17e-8	Anterior chamber depth;
KIRP	cis	rs7624766	0.555	rs1378657	chr3:160526759	G/A	cg22637730	chr3:160473554	PPM1L	0.4	4.95	0.3	1.38e-6	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.71	10.92	0.57	6.82e-23	Coronary artery disease;
KIRP	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.66	9.09	0.5	3.47e-17	Obesity-related traits;
KIRP	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg23995753	chr2:160760732	LY75	-0.4	-5.42	-0.33	1.44e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.75	-8.74	-0.49	3.73e-16	Platelet distribution width;
KIRP	cis	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg19847130	chr8:10466454	RP1L1	-0.34	-5.31	-0.32	2.5e-7	Neuroticism;
KIRP	trans	rs5417	0.775	rs222852	chr17:7140606	A/G	cg15655154	chr3:113604241	GRAMD1C	0.52	7.36	0.42	2.82e-12	Diastolic blood pressure;
KIRP	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg00012203	chr2:219082015	ARPC2	-0.66	-8.48	-0.48	2.11e-15	Colorectal cancer;
KIRP	cis	rs4262150	0.883	rs72799151	chr5:152110837	C/A	cg12297329	chr5:152029980	NA	-0.66	-8.35	-0.47	4.9e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2271400	0.852	rs1450741	chr8:56792159	T/C	cg08894788	chr8:56792171	LYN	-0.37	-5.67	-0.34	4.06e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
KIRP	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-8.96	-0.5	8.54e-17	Brugada syndrome;
KIRP	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg08662619	chr6:150070041	PCMT1	0.35	5.64	0.34	4.64e-8	Lung cancer;
KIRP	cis	rs71403859	0.502	rs17345863	chr16:71523261	C/T	cg08717414	chr16:71523259	ZNF19	-1.31	-13.31	-0.65	8.28e-31	Post bronchodilator FEV1;
KIRP	cis	rs7635838	0.827	rs9848170	chr3:11495983	G/C	cg00170343	chr3:11313890	ATG7	0.46	5.94	0.35	9.74e-9	HDL cholesterol;
KIRP	cis	rs1978968	1.000	rs2099943	chr22:18438559	A/G	cg03078520	chr22:18463400	MICAL3	-0.68	-8.7	-0.49	4.84e-16	Presence of antiphospholipid antibodies;
KIRP	cis	rs3007168	1.000	rs3007079	chr14:51613517	A/G	cg23942311	chr14:51606299	NA	0.54	5.71	0.34	3.22e-8	Cancer;
KIRP	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.04	0.31	9.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	IgG glycosylation;
KIRP	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	0.41	5.11	0.31	6.43e-7	Type 2 diabetes;
KIRP	cis	rs490234	0.841	rs477813	chr9:128416874	C/T	cg14078157	chr9:128172775	NA	0.45	5.72	0.34	3.14e-8	Mean arterial pressure;
KIRP	cis	rs7818345	1.000	rs12675717	chr8:19293177	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.76	0.34	2.44e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg16989719	chr2:238392110	NA	-0.56	-6.04	-0.36	5.79e-9	Prostate cancer;
KIRP	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg00684032	chr4:1343700	KIAA1530	0.5	6.67	0.39	1.65e-10	Obesity-related traits;
KIRP	cis	rs75920871	1.000	rs61905677	chr11:116833655	T/G	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs3744061	0.505	rs9915915	chr17:74652274	A/G	cg27546012	chr17:74684504	MXRA7	-0.45	-5.95	-0.35	9.33e-9	Retinal arteriolar caliber;
KIRP	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03651054	chr13:50194643	NA	0.74	11.43	0.59	1.46e-24	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg06521331	chr12:34319734	NA	0.61	7.38	0.43	2.39e-12	Morning vs. evening chronotype;
KIRP	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.56	8.2	0.46	1.34e-14	Reticulocyte fraction of red cells;
KIRP	trans	rs9409565	0.826	rs4744345	chr9:97207669	G/A	cg05679027	chr9:99775184	HIATL2	-0.56	-6.71	-0.39	1.33e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg22437258	chr11:111473054	SIK2	0.55	6.06	0.36	5.08e-9	Primary sclerosing cholangitis;
KIRP	cis	rs4664293	0.867	rs12998291	chr2:160595903	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.39	9.56	0.52	1.29e-18	Corneal astigmatism;
KIRP	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.43	0.55	2.42e-21	Cognitive test performance;
KIRP	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg01304814	chr3:48885189	PRKAR2A	0.7	5.18	0.31	4.54e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4666002	0.636	rs13023194	chr2:27967260	G/C	cg27432699	chr2:27873401	GPN1	0.56	5.18	0.31	4.54e-7	Phospholipid levels (plasma);
KIRP	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg15556689	chr8:8085844	FLJ10661	0.45	5.48	0.33	1.04e-7	Recombination measurement;
KIRP	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	1.09	17.39	0.74	9.94e-45	Cognitive function;
KIRP	trans	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-7.69	-0.44	3.59e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs504918	0.616	rs4289301	chr3:123982611	C/T	cg05766129	chr3:123988013	KALRN	0.46	6.48	0.38	5.08e-10	Schizophrenia;
KIRP	trans	rs6601327	0.665	rs12546411	chr8:9655916	T/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.76	-0.4	9.86e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.55	-6.87	-0.4	5.36e-11	Coronary artery disease;
KIRP	trans	rs10895140	0.756	rs4312036	chr11:101519352	C/T	cg18590709	chr17:49122713	SPAG9	0.48	6.1	0.36	4.17e-9	Menarche (age at onset);
KIRP	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg18190219	chr22:46762943	CELSR1	-0.89	-7.13	-0.41	1.11e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.48	6.86	0.4	5.6e-11	Lewy body disease;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg07389463	chr12:132296394	NA	0.35	5.18	0.31	4.65e-7	Migraine;
KIRP	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg12963246	chr6:28129442	ZNF389	0.54	6.16	0.37	2.97e-9	Depression;
KIRP	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	14.98	0.69	1.75e-36	Menopause (age at onset);
KIRP	cis	rs10463316	0.862	rs11747047	chr5:150777953	C/T	cg03212797	chr5:150827313	SLC36A1	-0.55	-7.24	-0.42	5.74e-12	Metabolite levels (Pyroglutamine);
KIRP	cis	rs447921	0.861	rs66686654	chr17:74430310	A/T	cg17201438	chr17:74438067	UBE2O	0.44	4.93	0.3	1.52e-6	Mitochondrial DNA levels;
KIRP	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg24826892	chr11:71159390	DHCR7	0.43	5.11	0.31	6.38e-7	Vitamin D levels;
KIRP	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg21545522	chr1:205238299	TMCC2	0.43	5.81	0.35	1.91e-8	Red blood cell count;
KIRP	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.92	-0.4	3.86e-11	Joint mobility (Beighton score);
KIRP	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.99	8.13	0.46	2.1e-14	Body mass index;
KIRP	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs838721	0.574	rs13003198	chr2:234257105	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.45	5.07	0.31	7.97e-7	Total body bone mineral density;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.54	5.39	0.33	1.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg05361325	chr10:32636312	EPC1	-0.65	-6.14	-0.36	3.26e-9	Sexual dysfunction (female);
KIRP	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.9	-15.54	-0.7	2.08e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00889227	chr1:205173544	DSTYK	0.41	5.82	0.35	1.79e-8	Red blood cell count;
KIRP	cis	rs2273669	0.504	rs75555274	chr6:109478385	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.14	-0.31	5.53e-7	Prostate cancer;
KIRP	cis	rs2223471	0.719	rs2744489	chr6:50766781	G/A	cg14470998	chr6:50812995	TFAP2B	-0.38	-5.02	-0.3	1.01e-6	Subcutaneous adipose tissue;
KIRP	cis	rs4819052	0.851	rs2256000	chr21:46685909	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.35	0.38	1.04e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.03	-0.67	3.08e-33	Primary sclerosing cholangitis;
KIRP	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg14689365	chr7:158441557	NCAPG2	0.4	5.08	0.31	7.46e-7	Height;
KIRP	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-6.91	-0.4	4.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	0.72	6.84	0.4	6.42e-11	Methadone dose in opioid dependence;
KIRP	cis	rs10875746	0.551	rs2054903	chr12:48724493	C/T	cg26205652	chr12:48591994	NA	0.77	9.92	0.53	9.92e-20	Longevity (90 years and older);
KIRP	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg09549813	chr16:4587862	C16orf5	0.35	5.1	0.31	6.9e-7	Schizophrenia;
KIRP	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg21385522	chr1:16154831	NA	0.45	5.56	0.33	7.18e-8	Systolic blood pressure;
KIRP	cis	rs7501812	0.561	rs62064119	chr17:17741808	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.53	5.05	0.31	8.41e-7	TB-LM or TBLH-BMD (pleiotropy);
KIRP	cis	rs897080	0.552	rs1067384	chr2:44644554	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.77	0.35	2.4e-8	Height;
KIRP	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-6.16	-0.37	2.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	8.63	0.48	7.7e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg04398451	chr17:18023971	MYO15A	0.72	9.72	0.53	4.1e-19	Total body bone mineral density;
KIRP	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	cis	rs9494145	0.680	rs9402686	chr6:135427817	G/A	cg22676075	chr6:135203613	NA	0.41	4.86	0.3	2.07e-6	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
KIRP	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.49	5.26	0.32	3.12e-7	Multiple sclerosis;
KIRP	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.59	7.63	0.44	5.25e-13	Breast cancer;
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg09699651	chr6:150184138	LRP11	-0.47	-6.2	-0.37	2.36e-9	Lung cancer;
KIRP	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06850241	chr22:41845214	NA	-0.47	-5.27	-0.32	3e-7	Vitiligo;
KIRP	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.66	8.86	0.49	1.69e-16	Bladder cancer;
KIRP	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.87	-0.4	5.26e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-8.69	-0.48	5.31e-16	Height;
KIRP	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg21918786	chr6:109611834	NA	-0.39	-5.53	-0.33	8.07e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.12	16.42	0.72	2.07e-41	Breast cancer;
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg08662619	chr6:150070041	PCMT1	0.37	5.97	0.36	8.16e-9	Lung cancer;
KIRP	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-8.72	-0.49	4.13e-16	Alzheimer's disease (survival time);
KIRP	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.75	8.24	0.47	1.02e-14	Corneal astigmatism;
KIRP	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs12534701	1.000	rs3807297	chr7:154682304	G/A	cg24255201	chr7:154684926	DPP6	0.63	8.78	0.49	2.86e-16	Colorectal cancer (diet interaction);
KIRP	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-0.74	-7.4	-0.43	2.16e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11987759	chr7:65425863	GUSB	-0.42	-4.87	-0.3	1.98e-6	Aortic root size;
KIRP	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.19	-21.55	-0.81	1.38e-58	Cognitive function;
KIRP	cis	rs2688608	0.905	rs2633300	chr10:75656647	A/C	cg19442545	chr10:75533431	FUT11	-0.36	-4.9	-0.3	1.72e-6	Inflammatory bowel disease;
KIRP	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg14820908	chr5:178986412	RUFY1	0.39	5.42	0.33	1.42e-7	Lung cancer;
KIRP	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.08	0.31	7.51e-7	Smoking behavior;
KIRP	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.42	5.56	0.33	6.98e-8	Hypertriglyceridemia;
KIRP	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.66	-8.67	-0.48	5.9e-16	Colorectal cancer;
KIRP	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg00631329	chr6:26305371	NA	-0.67	-9.19	-0.51	1.68e-17	Educational attainment;
KIRP	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg04935436	chr20:30431758	NA	0.53	6.49	0.38	4.72e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg25811766	chr13:21894605	NA	-0.6	-5.82	-0.35	1.79e-8	White matter hyperintensity burden;
KIRP	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.54	-7.29	-0.42	4.31e-12	Schizophrenia;
KIRP	cis	rs4742903	0.967	rs4743690	chr9:106909577	T/C	cg14250997	chr9:106856677	SMC2	0.4	5.2	0.31	4.18e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs1106684	1.000	rs12535142	chr7:131465533	C/A	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.24	-6.43	-0.38	6.55e-10	Mean corpuscular volume;
KIRP	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg23024343	chr7:107201750	COG5	0.4	4.93	0.3	1.48e-6	Coronary artery disease;
KIRP	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-8.72	-0.49	4.19e-16	Personality dimensions;
KIRP	cis	rs894344	0.748	rs16905190	chr8:135598265	C/T	cg09855544	chr8:135498122	ZFAT	-0.4	-5.31	-0.32	2.43e-7	Systolic blood pressure;
KIRP	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.21	20.32	0.79	1.46e-54	Cognitive function;
KIRP	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.12	-0.5	2.82e-17	Mood instability;
KIRP	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg01849789	chr22:41697279	ZC3H7B	-0.52	-5.59	-0.34	6.16e-8	Neuroticism;
KIRP	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.26	-0.32	3.18e-7	Breast cancer;
KIRP	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.02	0.36	6.19e-9	Mean platelet volume;
KIRP	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.74	8.58	0.48	1.11e-15	Platelet distribution width;
KIRP	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.49	-5.97	-0.36	8.19e-9	Systemic lupus erythematosus;
KIRP	cis	rs580438	0.792	rs357113	chr3:13327947	G/T	cg10657019	chr3:13328039	NA	-0.89	-13.02	-0.64	7.68e-30	Myringotomy;
KIRP	cis	rs4722166	0.704	rs4321884	chr7:22741459	A/T	cg05472934	chr7:22766657	IL6	0.45	5.91	0.35	1.16e-8	Lung cancer;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg08662619	chr6:150070041	PCMT1	0.33	5.22	0.32	3.83e-7	Lung cancer;
KIRP	cis	rs4664293	0.967	rs7597488	chr2:160547096	T/G	cg08347373	chr2:160653686	CD302	-0.39	-5.94	-0.35	9.93e-9	Monocyte percentage of white cells;
KIRP	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	3.99e-15	Protein biomarker;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24141233	chr1:212781895	ATF3	0.5	6.62	0.39	2.26e-10	Parkinson's disease;
KIRP	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.78	10.07	0.54	3.52e-20	Coronary artery disease;
KIRP	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg08999081	chr20:33150536	PIGU	0.43	5.36	0.32	1.87e-7	Coronary artery disease;
KIRP	trans	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg19274270	chr17:78178856	CARD14	-0.37	-6.65	-0.39	1.85e-10	Morning vs. evening chronotype;
KIRP	cis	rs7534824	0.625	rs12563134	chr1:101468558	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.68	-5.49	-0.33	9.83e-8	Refractive astigmatism;
KIRP	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.93	-0.57	6.32e-23	Colorectal cancer;
KIRP	cis	rs1816752	0.875	rs17384871	chr13:25059097	T/C	cg02811702	chr13:24901961	NA	0.39	5.07	0.31	7.74e-7	Obesity-related traits;
KIRP	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.61	9.03	0.5	5.02e-17	Menarche (age at onset);
KIRP	cis	rs7923609	0.967	rs7896783	chr10:65162153	G/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs240764	0.817	rs240147	chr6:101078300	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.64	-7.82	-0.45	1.56e-13	Aortic root size;
KIRP	cis	rs2282032	0.527	rs8009799	chr14:90766365	A/G	cg04374321	chr14:90722782	PSMC1	0.56	6.82	0.4	6.84e-11	Longevity;
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg16329197	chr12:53359506	NA	-0.54	-4.97	-0.3	1.24e-6	Prostate cancer;
KIRP	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg01988459	chr11:68622903	NA	-0.44	-6.15	-0.37	3.06e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4851254	0.961	rs13028981	chr2:100795783	C/T	cg17356467	chr2:100759845	AFF3	0.58	7.18	0.42	8.13e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-1.07	-21.4	-0.81	4.45e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9608946	1.000	rs8138759	chr22:30884427	C/T	cg23383138	chr22:30885012	SEC14L4	0.4	4.93	0.3	1.52e-6	Red cell distribution width;
KIRP	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg00405596	chr8:11794950	NA	0.48	6.39	0.38	8.16e-10	Retinal vascular caliber;
KIRP	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.88	10.11	0.54	2.49e-20	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg11474317	chr22:50968852	TYMP;ODF3B	-0.59	-6.82	-0.4	6.97e-11	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09361219	chr2:61293079	KIAA1841	0.49	6.37	0.38	9.21e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.92	0.3	1.61e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.82	0.35	1.87e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2223471	0.967	rs9381894	chr6:50733085	T/C	cg03432817	chr6:50765336	NA	-0.43	-6.32	-0.37	1.24e-9	Subcutaneous adipose tissue;
KIRP	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.65	-8.43	-0.47	2.88e-15	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg17441377	chr17:3906640	NA	0.52	7.84	0.45	1.4e-13	Type 2 diabetes;
KIRP	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs6921919	0.583	rs12697938	chr6:28341099	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.42	-6.03	-0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg23803603	chr1:2058230	PRKCZ	0.37	5.72	0.34	3.11e-8	Height;
KIRP	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.27	-0.37	1.59e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	0.97	10.58	0.56	8.13e-22	Blood protein levels;
KIRP	cis	rs6952809	1.000	rs6952809	chr7:2448493	T/C	cg23289794	chr7:2394357	EIF3B	-0.41	-5.0	-0.3	1.12e-6	Multiple sclerosis;
KIRP	trans	rs7404843	0.789	rs222907	chr16:15498807	A/G	cg02716450	chr16:28638775	NA	0.94	10.49	0.56	1.56e-21	Testicular germ cell tumor;
KIRP	cis	rs6783573	1.000	rs6783573	chr3:46600520	A/G	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.5	-6.07	-0.36	4.7e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.59	-0.34	5.96e-8	Body mass index;
KIRP	cis	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg04691961	chr3:161091175	C3orf57	0.46	6.71	0.39	1.35e-10	Morning vs. evening chronotype;
KIRP	cis	rs2223471	0.754	rs2817361	chr6:50771563	C/T	cg03432817	chr6:50765336	NA	-0.55	-9.42	-0.52	3.36e-18	Subcutaneous adipose tissue;
KIRP	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	14.94	0.69	2.38e-36	Height;
KIRP	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg20701182	chr2:24300061	SF3B14	0.5	5.03	0.31	9.64e-7	Lymphocyte counts;
KIRP	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.83	12.45	0.62	6.57e-28	Colorectal cancer;
KIRP	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	6.9	0.4	4.36e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	13.23	0.64	1.54e-30	Post bronchodilator FEV1;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg12705353	chr12:122356852	WDR66	0.52	6.73	0.39	1.2e-10	Mean corpuscular volume;
KIRP	cis	rs6445967	1.000	rs11713627	chr3:58306946	T/G	cg16569813	chr3:58235849	ABHD6	-0.33	-4.89	-0.3	1.82e-6	Platelet count;
KIRP	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg21573476	chr21:45109991	RRP1B	-0.54	-7.5	-0.43	1.18e-12	Mean corpuscular volume;
KIRP	cis	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg06521331	chr12:34319734	NA	-0.45	-5.2	-0.31	4.21e-7	Resting heart rate;
KIRP	cis	rs6568686	0.786	rs9387014	chr6:111850541	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.54	-5.07	-0.31	7.66e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.57	6.84	0.4	6.09e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7187994	0.848	rs16974527	chr16:84782822	C/T	cg07647771	chr16:84786436	USP10	-0.37	-5.22	-0.32	3.74e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg25902810	chr10:99078978	FRAT1	-0.5	-5.96	-0.36	8.69e-9	Monocyte count;
KIRP	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.81	-10.68	-0.56	3.91e-22	Coronary artery disease;
KIRP	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.3	-0.32	2.54e-7	Parkinson's disease;
KIRP	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg24826892	chr11:71159390	DHCR7	0.42	5.08	0.31	7.52e-7	Vitamin D levels;
KIRP	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.48	5.97	0.36	8.46e-9	Height;
KIRP	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg05991184	chr2:219186017	PNKD	0.36	5.09	0.31	7.25e-7	Colorectal cancer;
KIRP	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.51	6.93	0.4	3.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.41	5.52	0.33	8.45e-8	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	5.02	0.3	9.88e-7	Breast cancer;
KIRP	cis	rs6032067	0.777	rs13037087	chr20:43834313	T/C	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs1829883	0.717	rs3107827	chr5:98798591	A/G	cg08333243	chr5:99726346	NA	-0.39	-5.17	-0.31	4.79e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.37	1.34e-9	Bladder cancer;
KIRP	cis	rs10782582	0.609	rs1628063	chr1:76391646	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.43	-0.38	6.58e-10	Daytime sleep phenotypes;
KIRP	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg26695010	chr11:65641043	EFEMP2	-0.5	-4.99	-0.3	1.12e-6	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg07701084	chr6:150067640	NUP43	0.7	9.64	0.52	7.12e-19	Lung cancer;
KIRP	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg19875535	chr5:140030758	IK	-0.71	-10.07	-0.54	3.41e-20	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs28395178	1	rs28395178	chr15:78850558	G/A	cg24631222	chr15:78858424	CHRNA5	1.08	13.6	0.66	8.62e-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.2	-0.31	4.17e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17712092	chr4:129076599	LARP1B	-0.55	-6.16	-0.37	3e-9	Breast cancer;
KIRP	cis	rs13082711	0.520	rs2643825	chr3:27562613	A/G	cg02860705	chr3:27208620	NA	0.4	5.36	0.32	1.89e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs3784262	0.669	rs4646595	chr15:58302341	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.89	-0.3	1.8e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg07936489	chr17:37558343	FBXL20	-0.5	-6.44	-0.38	6.2e-10	Asthma;
KIRP	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	9.11	0.5	2.98e-17	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.65	-5.0	-0.3	1.1e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.64	-0.66	6.24e-32	Response to antipsychotic treatment;
KIRP	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14598338	chr9:96623480	NA	0.62	9.74	0.53	3.52e-19	DNA methylation (variation);
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg19500275	chr17:80737654	TBCD	-0.54	-7.08	-0.41	1.53e-11	Glycated hemoglobin levels;
KIRP	cis	rs7536201	1.000	rs7555518	chr1:25299404	T/A	cg23273869	chr1:25296894	NA	-0.39	-5.64	-0.34	4.6e-8	Psoriasis vulgaris;
KIRP	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg05874882	chr4:1763078	NA	-0.39	-4.92	-0.3	1.56e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg10326726	chr10:51549505	MSMB	-0.63	-9.3	-0.51	7.69e-18	Prostate-specific antigen levels;
KIRP	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.33	0.32	2.22e-7	Personality dimensions;
KIRP	cis	rs7246657	0.722	rs2972447	chr19:38129736	C/T	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.69	7.2	0.42	7.29e-12	Migraine;Coronary artery disease;
KIRP	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14159672	chr1:205819179	PM20D1	-0.61	-5.93	-0.35	1.01e-8	Menarche (age at onset);
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg13373371	chr19:49828787	SLC6A16	0.4	4.87	0.3	2e-6	Multiple sclerosis;
KIRP	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg24807547	chr6:37504484	NA	-0.61	-9.46	-0.52	2.53e-18	Cognitive performance;
KIRP	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.68	10.01	0.54	5.41e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.36	-4.93	-0.3	1.49e-6	Neuroticism;
KIRP	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg17425144	chr1:10567563	PEX14	-0.32	-5.67	-0.34	4.09e-8	Hepatocellular carcinoma;
KIRP	cis	rs9488822	0.549	rs195527	chr6:116250858	T/C	cg15226275	chr6:116381976	FRK	0.21	5.4	0.33	1.56e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg10017260	chr10:834428	NA	-0.39	-5.64	-0.34	4.62e-8	Survival in rectal cancer;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg05941025	chr16:89927596	SPIRE2	0.36	5.7	0.34	3.34e-8	Vitiligo;
KIRP	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg18306943	chr3:40428807	ENTPD3	0.41	5.38	0.32	1.76e-7	Renal cell carcinoma;
KIRP	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.1	-0.41	1.37e-11	Menopause (age at onset);
KIRP	cis	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg21775007	chr8:11205619	TDH	0.4	4.94	0.3	1.42e-6	Triglycerides;
KIRP	trans	rs7980799	0.933	rs11052705	chr12:33588388	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.08	-0.36	4.68e-9	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.85	13.33	0.65	6.89e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs74181299	0.648	rs1050676	chr2:65310831	A/T	cg05010058	chr2:65284262	CEP68	-0.42	-5.74	-0.34	2.79e-8	Pulse pressure;
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg21285383	chr16:89894308	SPIRE2	0.32	6.0	0.36	6.95e-9	Vitiligo;
KIRP	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.54	-0.33	7.7e-8	Parkinson's disease;
KIRP	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.19	-0.31	4.38e-7	Headache;
KIRP	cis	rs4646404	0.509	rs4646368	chr17:17465458	G/A	cg01246520	chr17:17644344	RAI1	-0.33	-5.59	-0.34	5.92e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05347473	chr6:146136440	FBXO30	0.58	8.3	0.47	6.96e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg26597838	chr10:835615	NA	-0.51	-6.22	-0.37	2.12e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs12973672	0.812	rs2280744	chr19:35755386	G/A	cg12095397	chr19:35769544	USF2	0.69	6.36	0.38	9.6e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.82	8.81	0.49	2.37e-16	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07705912	chr1:154155363	TPM3	0.5	6.73	0.39	1.22e-10	Parkinson's disease;
KIRP	cis	rs28595532	0.748	rs72670258	chr4:119391660	A/T	cg21605333	chr4:119757512	SEC24D	1.1	8.25	0.47	9.55e-15	Cannabis dependence symptom count;
KIRP	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.23	-0.37	2.05e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs242364	0.576	rs6516768	chr21:28870697	C/G	cg01278232	chr17:17606846	RAI1	0.57	6.03	0.36	5.97e-9	Daytime sleep phenotypes;
KIRP	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.19	0.37	2.53e-9	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.72e-7	Life satisfaction;
KIRP	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg15556689	chr8:8085844	FLJ10661	0.65	8.43	0.47	3.01e-15	Retinal vascular caliber;
KIRP	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg02023728	chr11:77925099	USP35	-0.29	-4.97	-0.3	1.28e-6	Alzheimer's disease (survival time);
KIRP	cis	rs7681423	1.000	rs7681423	chr4:155542248	C/T	cg20735720	chr4:155535218	FGG	-0.65	-8.53	-0.48	1.54e-15	Fibrinogen;
KIRP	cis	rs5167	0.539	rs4803783	chr19:45470458	G/C	cg13119609	chr19:45449297	APOC2	-0.38	-5.18	-0.31	4.53e-7	Blood protein levels;
KIRP	cis	rs918629	0.567	rs17085266	chr5:95247634	A/C	cg16656078	chr5:95278638	ELL2	-0.35	-5.37	-0.32	1.85e-7	IgG glycosylation;
KIRP	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.97	-12.93	-0.64	1.59e-29	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26370409	chr1:10002828	NMNAT1;LZIC	0.52	6.09	0.36	4.26e-9	Smoking initiation;
KIRP	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.24	0.55	1.01e-20	Cognitive test performance;
KIRP	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.94	14.51	0.68	6.99e-35	Menopause (age at onset);
KIRP	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	9.45	0.52	2.87e-18	Smoking behavior;
KIRP	cis	rs2562456	0.833	rs1626404	chr19:21483788	C/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.98	-0.3	1.18e-6	Pain;
KIRP	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg12219531	chr12:120966889	COQ5	0.59	5.91	0.35	1.15e-8	High light scatter reticulocyte count;
KIRP	cis	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.46	-0.38	5.7e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg25036284	chr2:26402008	FAM59B	-0.51	-5.37	-0.32	1.86e-7	Gut microbiome composition (summer);
KIRP	cis	rs6882076	1.000	rs1501908	chr5:156398169	C/G	cg12943317	chr5:156479607	HAVCR1	0.59	7.38	0.43	2.43e-12	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-7.01	-0.41	2.31e-11	Skin colour saturation;
KIRP	cis	rs6686842	0.689	rs2885697	chr1:41544279	G/T	cg24596898	chr1:41849189	NA	-0.45	-6.05	-0.36	5.32e-9	Height;
KIRP	cis	rs7520050	0.966	rs785520	chr1:46568836	T/C	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.9	-0.3	1.7e-6	Life satisfaction;
KIRP	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.38	-8.31	-0.47	6.65e-15	Breast cancer;
KIRP	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg16482183	chr6:26056742	HIST1H1C	0.63	7.33	0.42	3.36e-12	Iron status biomarkers;
KIRP	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.44	-4.9	-0.3	1.71e-6	Platelet distribution width;
KIRP	cis	rs6991838	0.584	rs4637885	chr8:66497084	T/C	cg13398993	chr8:66546079	ARMC1	-0.47	-5.37	-0.32	1.85e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg00262122	chr8:11665843	FDFT1	0.42	5.14	0.31	5.47e-7	Retinal vascular caliber;
KIRP	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg11153868	chr12:69751374	NA	0.38	4.86	0.3	2.1e-6	Response to diuretic therapy;
KIRP	cis	rs6546886	0.957	rs28450901	chr2:74252382	C/G	cg14702570	chr2:74259524	NA	-0.29	-5.89	-0.35	1.29e-8	Dialysis-related mortality;
KIRP	cis	rs3087591	0.960	rs4795575	chr17:29452625	A/G	cg24425628	chr17:29625626	OMG;NF1	0.76	10.83	0.57	1.31e-22	Hip circumference;
KIRP	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg20387954	chr3:183756860	HTR3D	0.51	7.09	0.41	1.42e-11	Anterior chamber depth;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01744160	chr15:83680526	C15orf40	0.48	6.45	0.38	5.96e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	8.31	0.47	6.71e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-5.64	-0.34	4.64e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs9436747	0.605	rs61779815	chr1:65943197	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-4.87	-0.3	2.01e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs1829883	0.798	rs2049313	chr5:98802976	T/G	cg08333243	chr5:99726346	NA	-0.4	-5.31	-0.32	2.49e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11574514	0.661	rs9925393	chr16:67780829	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.34	-0.32	2.08e-7	Crohn's disease;
KIRP	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.8	11.79	0.6	9.92e-26	Heart rate;
KIRP	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23422044	chr7:1970798	MAD1L1	-0.61	-6.32	-0.37	1.23e-9	Bipolar disorder;
KIRP	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg12559939	chr2:27858050	GPN1	0.42	5.21	0.32	3.99e-7	Oral cavity cancer;
KIRP	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.49	5.16	0.31	5.04e-7	Breast cancer;
KIRP	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg25547332	chr5:131281432	NA	0.48	5.37	0.32	1.84e-7	Life satisfaction;
KIRP	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg25547332	chr5:131281432	NA	0.47	5.31	0.32	2.5e-7	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10106016	chr10:105345203	NEURL	0.5	6.27	0.37	1.63e-9	Interleukin-4 levels;
KIRP	trans	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.34	-0.37	1.12e-9	Bladder cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09433780	chr3:57262354	APPL1	0.54	6.56	0.39	3.1e-10	Smoking initiation;
KIRP	cis	rs3112255	1.000	rs3112255	chr2:101317260	C/A	cg01042948	chr2:101319752	NA	0.45	6.49	0.38	4.64e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.83	14.22	0.67	6.63e-34	Brugada syndrome;
KIRP	cis	rs33912345	0.669	rs1254299	chr14:60884440	G/A	cg27398547	chr14:60952738	C14orf39	-0.39	-5.26	-0.32	3.2e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.44	-5.73	-0.34	2.97e-8	Testicular germ cell tumor;
KIRP	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg21775007	chr8:11205619	TDH	-0.46	-6.26	-0.37	1.74e-9	Neuroticism;
KIRP	trans	rs55728055	0.661	rs62237843	chr22:32026946	C/G	cg02791973	chr19:1132256	SBNO2	-0.61	-6.64	-0.39	1.96e-10	Age-related hearing impairment;
KIRP	cis	rs55871839	0.708	rs1562612	chr8:59817068	A/G	cg07426533	chr8:59803705	TOX	-0.48	-7.94	-0.45	7.38e-14	Pneumonia;
KIRP	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	0.81	8.86	0.49	1.62e-16	Mean corpuscular hemoglobin;
KIRP	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.56	-6.11	-0.36	3.79e-9	Menarche (age at onset);
KIRP	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.78	-10.53	-0.56	1.23e-21	Iron status biomarkers;
KIRP	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.94	-0.45	6.97e-14	Coffee consumption (cups per day);
KIRP	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17554472	chr22:41940697	POLR3H	0.63	6.86	0.4	5.41e-11	Vitiligo;
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg09699651	chr6:150184138	LRP11	0.47	6.29	0.37	1.41e-9	Lung cancer;
KIRP	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.7	-0.53	4.73e-19	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12489322	chr5:60628376	ZSWIM6	0.45	6.25	0.37	1.77e-9	Survival in pancreatic cancer;
KIRP	cis	rs6457821	1.000	rs112754776	chr6:35354831	A/T	cg06087101	chr6:35551932	FKBP5	0.58	5.19	0.31	4.48e-7	Height;
KIRP	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg03115019	chr17:80708279	FN3K	0.42	5.09	0.31	7.27e-7	Glycated hemoglobin levels;
KIRP	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg09408571	chr1:101003634	GPR88	0.32	7.47	0.43	1.43e-12	Breast cancer;
KIRP	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.87	0.3	2.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg02655711	chr22:19163373	SLC25A1	0.46	6.37	0.38	9.2e-10	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	7.13	0.41	1.12e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.39	-0.33	1.62e-7	Menarche (age at onset);
KIRP	cis	rs9612	0.718	rs346531	chr19:44239927	T/C	cg08581076	chr19:44259116	C19orf61	0.43	4.89	0.3	1.83e-6	Exhaled nitric oxide output;
KIRP	trans	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.47	-6.14	-0.36	3.29e-9	Mean corpuscular volume;
KIRP	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg07395648	chr5:131743802	NA	-0.54	-7.64	-0.44	4.94e-13	Blood metabolite levels;
KIRP	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg24253500	chr15:84953950	NA	0.51	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.77	0.53	2.85e-19	Prudent dietary pattern;
KIRP	cis	rs9547996	0.879	rs9547985	chr13:38203181	G/A	cg13634560	chr13:38173852	POSTN	-0.39	-5.5	-0.33	9.54e-8	Diastolic blood pressure;
KIRP	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.61	-8.31	-0.47	6.62e-15	Diastolic blood pressure;
KIRP	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.99	-0.45	5.32e-14	Monocyte percentage of white cells;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.63	-9.01	-0.5	5.91e-17	Longevity;Endometriosis;
KIRP	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17376030	chr22:41985996	PMM1	-0.81	-8.16	-0.46	1.71e-14	Vitiligo;
KIRP	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.56	-6.23	-0.37	2.04e-9	Aortic root size;
KIRP	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg08076091	chr2:203926405	NBEAL1	0.85	8.63	0.48	7.88e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.53	7.36	0.42	2.83e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs867371	0.896	rs6495647	chr15:82537049	C/G	cg06066596	chr15:83166174	LOC80154	-0.46	-5.39	-0.33	1.63e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7127900	1.000	rs7127162	chr11:2229360	C/T	cg25635251	chr11:2234043	NA	0.53	8.0	0.45	4.9e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg19752551	chr11:57585705	CTNND1	-0.8	-13.27	-0.65	1.13e-30	Schizophrenia;
KIRP	cis	rs7258465	1.000	rs10427083	chr19:18550276	C/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.59	-0.44	6.79e-13	Breast cancer;
KIRP	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-4.97	-0.3	1.24e-6	Alzheimer's disease;
KIRP	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.28	-0.47	7.76e-15	Neuroticism;
KIRP	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.9	10.65	0.56	5.17e-22	Exhaled nitric oxide levels;
KIRP	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16414030	chr3:133502952	NA	-0.57	-6.55	-0.39	3.25e-10	Iron status biomarkers;
KIRP	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.26	-0.37	1.68e-9	Response to antipsychotic treatment;
KIRP	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg07138768	chr7:917805	C7orf20	0.32	5.29	0.32	2.72e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.77	10.42	0.55	2.65e-21	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg10017260	chr10:834428	NA	-0.56	-5.3	-0.32	2.55e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.56	-0.39	3.08e-10	Blood pressure;
KIRP	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg26441486	chr22:50317300	CRELD2	0.49	6.58	0.39	2.82e-10	Schizophrenia;
KIRP	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg07689907	chr11:61582574	FADS1	-0.58	-7.13	-0.41	1.13e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.48	7.14	0.41	1.04e-11	Inattentive symptoms;
KIRP	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg05775895	chr3:12838266	CAND2	0.37	5.21	0.32	4.08e-7	QRS complex (12-leadsum);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05628496	chr17:17991167	DRG2	0.62	7.66	0.44	4.37e-13	Smoking initiation;
KIRP	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg23533926	chr12:111358616	MYL2	-0.52	-6.96	-0.41	3.06e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Colorectal cancer;
KIRP	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg09165964	chr15:75287851	SCAMP5	-0.37	-4.99	-0.3	1.13e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs11955175	1.000	rs45480797	chr5:40680964	C/G	cg04002187	chr5:40835754	RPL37	0.71	5.54	0.33	7.82e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7714584	1.000	rs10463307	chr5:150254620	C/T	cg22134413	chr5:150180641	NA	0.7	5.9	0.35	1.2e-8	Crohn's disease;
KIRP	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-9.98	-0.54	6.61e-20	Body mass index;
KIRP	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.42	-5.26	-0.32	3.2e-7	Aortic root size;
KIRP	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.95	-0.61	2.84e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg00405596	chr8:11794950	NA	0.47	5.89	0.35	1.24e-8	Monocyte count;
KIRP	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg06521331	chr12:34319734	NA	0.63	7.45	0.43	1.58e-12	Morning vs. evening chronotype;
KIRP	cis	rs9653442	0.527	rs13003982	chr2:100759078	T/C	cg07810366	chr2:100720526	AFF3	-0.31	-4.99	-0.3	1.16e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg26965718	chr17:79658957	HGS	-0.63	-5.75	-0.34	2.61e-8	Dental caries;
KIRP	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg26566898	chr11:117069891	TAGLN	0.4	4.97	0.3	1.28e-6	Blood protein levels;
KIRP	cis	rs2387326	0.868	rs769005	chr10:129920241	C/T	cg16087940	chr10:129947807	NA	-0.4	-5.18	-0.31	4.53e-7	Select biomarker traits;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg15059389	chr1:12079390	MIIP	0.5	6.55	0.39	3.34e-10	Colorectal cancer;
KIRP	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-7.17	-0.42	8.59e-12	Coronary artery disease;
KIRP	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.44	5.43	0.33	1.34e-7	Testicular germ cell tumor;
KIRP	cis	rs7119	0.637	rs12913005	chr15:77856571	T/A	cg12131826	chr15:77904385	NA	0.41	4.97	0.3	1.24e-6	Type 2 diabetes;
KIRP	cis	rs6969780	1.000	rs1548497	chr7:27174316	A/G	cg26364809	chr7:27145159	NA	0.53	5.0	0.3	1.08e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs10463316	0.817	rs1318783	chr5:150814807	T/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.47	-0.38	5.38e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.18e-7	Breast cancer;
KIRP	cis	rs9659323	0.623	rs12091291	chr1:119478828	A/G	cg18261050	chr1:119551319	NA	-0.4	-5.17	-0.31	4.83e-7	Body mass index;
KIRP	cis	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	trans	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.13	-0.41	1.08e-11	Bladder cancer;
KIRP	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg24488311	chr11:68621650	NA	-0.49	-5.97	-0.36	8.33e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs860295	0.702	rs11264387	chr1:155563152	G/T	cg02153340	chr1:155202674	NA	-0.54	-7.34	-0.42	3.17e-12	Body mass index;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.76	11.92	0.61	3.68e-26	Menarche (age at onset);
KIRP	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg23067535	chr8:124195133	FAM83A	-0.78	-7.63	-0.44	5.05e-13	Urinary uromodulin levels;
KIRP	trans	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg26043149	chr18:55253948	FECH	0.55	6.7	0.39	1.4e-10	Bone mineral density;
KIRP	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-7.31	-0.42	3.84e-12	Vitiligo;
KIRP	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs16976116	0.901	rs28591259	chr15:55498940	T/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15970375	chr11:130184946	ZBTB44	0.4	6.11	0.36	3.98e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.35	4.9	0.3	1.7e-6	Coronary artery disease;
KIRP	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.46	5.6	0.34	5.71e-8	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.76	11.02	0.57	3.36e-23	Prostate cancer;
KIRP	cis	rs9840812	0.861	rs1153871	chr3:135954599	T/C	cg15507776	chr3:136538369	TMEM22	0.42	5.4	0.33	1.54e-7	Fibrinogen levels;
KIRP	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg04935436	chr20:30431758	NA	0.5	6.62	0.39	2.27e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs1497828	0.956	rs2815222	chr1:217522229	T/A	cg04411442	chr1:217543379	NA	-0.3	-4.9	-0.3	1.75e-6	Dialysis-related mortality;
KIRP	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.85	-0.4	6.05e-11	Aortic root size;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg13145120	chr7:130145329	MEST	-0.46	-6.3	-0.37	1.36e-9	Select biomarker traits;
KIRP	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	6.52	0.38	3.97e-10	Tonsillectomy;
KIRP	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.74	-8.89	-0.49	1.33e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.54	6.83	0.4	6.74e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg06647332	chr5:131281008	NA	0.43	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs255758	0.727	rs255748	chr5:53318376	T/C	cg22592108	chr5:53304441	ARL15	0.45	5.84	0.35	1.61e-8	Rheumatoid arthritis;
KIRP	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.67	0.34	4.02e-8	Schizophrenia;
KIRP	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.24	-0.32	3.41e-7	Triglycerides;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.75	-10.87	-0.57	9.58e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg13736514	chr6:26305472	NA	-0.68	-8.62	-0.48	8.04e-16	Mosquito bite size;
KIRP	cis	rs4073416	0.542	rs1959145	chr14:65954740	A/G	cg03016385	chr14:66212404	NA	-0.54	-6.74	-0.39	1.11e-10	N-glycan levels;
KIRP	cis	rs2446066	0.659	rs11170566	chr12:53907067	C/T	cg16917193	chr12:54089295	NA	0.61	4.9	0.3	1.75e-6	Red blood cell count;
KIRP	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs687432	0.717	rs12799639	chr11:57757561	C/T	cg19752551	chr11:57585705	CTNND1	-0.44	-5.82	-0.35	1.81e-8	Parkinson's disease;
KIRP	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg14673194	chr17:80132900	CCDC57	0.76	8.48	0.48	2.05e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22879515	chr11:111383515	MIR34B;BTG4;MIR34C	-0.45	-6.1	-0.36	4.02e-9	Interleukin-4 levels;
KIRP	cis	rs58688157	0.921	rs35600572	chr11:617214	A/G	cg02461776	chr11:598696	PHRF1	0.52	5.48	0.33	1.05e-7	Systemic lupus erythematosus;
KIRP	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-12.07	-0.61	1.15e-26	Headache;
KIRP	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.7	0.63	9.47e-29	Morning vs. evening chronotype;
KIRP	cis	rs7116495	0.881	rs676721	chr11:71770638	G/A	cg07596299	chr11:71824057	C11orf51	-0.62	-4.93	-0.3	1.49e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.48	-5.11	-0.31	6.5e-7	Platelet distribution width;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg04562522	chr1:22469714	WNT4	0.5	6.14	0.36	3.27e-9	Obesity-related traits;
KIRP	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg16586182	chr3:47516702	SCAP	-0.55	-6.62	-0.39	2.29e-10	Birth weight;
KIRP	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg27068330	chr11:65405492	SIPA1	-0.43	-5.78	-0.35	2.26e-8	Acne (severe);
KIRP	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.83	11.22	0.58	7.06e-24	Morning vs. evening chronotype;
KIRP	cis	rs4356932	1.000	rs4359937	chr4:76972155	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.0	0.36	7.16e-9	Blood protein levels;
KIRP	cis	rs10861342	1.000	rs1345095	chr12:105471577	C/T	cg23923672	chr12:105501055	KIAA1033	0.78	5.83	0.35	1.7e-8	IgG glycosylation;
KIRP	cis	rs7221595	0.825	rs12601931	chr17:3986097	T/C	cg11204139	chr17:3907470	NA	0.59	5.66	0.34	4.12e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	1.13	13.87	0.66	1.01e-32	IgG glycosylation;
KIRP	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.28	-0.42	4.56e-12	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg00531865	chr16:30841666	NA	0.38	5.27	0.32	3.03e-7	Dementia with Lewy bodies;
KIRP	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.54	17.6	0.75	1.98e-45	Opioid sensitivity;
KIRP	cis	rs2415984	0.622	rs61993303	chr14:46949716	G/C	cg14871534	chr14:47121158	RPL10L	-0.43	-5.24	-0.32	3.43e-7	Number of children ever born;
KIRP	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	15.15	0.69	4.63e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs10079346	chr5:74536655	G/A	cg03227963	chr5:74354835	NA	0.4	5.84	0.35	1.67e-8	Response to amphetamines;
KIRP	trans	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg25042112	chr7:64838748	ZNF92	-0.61	-6.48	-0.38	4.95e-10	Pain;
KIRP	cis	rs907612	0.638	rs907613	chr11:1874292	G/A	cg05305434	chr11:1874049	LSP1	0.39	8.26	0.47	8.99e-15	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12311304	0.871	rs9787983	chr12:15412898	A/G	cg08258403	chr12:15378311	NA	0.38	5.48	0.33	1.03e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.1	-0.36	4.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	5.15	0.31	5.35e-7	Schizophrenia;
KIRP	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.27	-0.42	4.63e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6545883	0.965	rs1562308	chr2:61768421	A/C	cg15711740	chr2:61764176	XPO1	-0.63	-8.58	-0.48	1.06e-15	Tuberculosis;
KIRP	cis	rs742115	0.563	rs12663475	chr6:11297296	T/C	cg25250968	chr6:11318770	NEDD9	-0.42	-5.97	-0.36	8.05e-9	Coronary artery disease;
KIRP	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.72	-6.09	-0.36	4.32e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.61	7.13	0.41	1.1e-11	Height;
KIRP	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.83	-11.19	-0.58	9.01e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.69	-10.21	-0.55	1.23e-20	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.8	-0.4	7.92e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.48	6.31	0.37	1.3e-9	Menopause (age at onset);
KIRP	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg05555928	chr11:63887634	MACROD1	0.49	7.05	0.41	1.78e-11	Platelet count;
KIRP	cis	rs10872587	0.555	rs2265470	chr6:146219232	T/C	cg05347473	chr6:146136440	FBXO30	0.59	6.48	0.38	5.02e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.57	-5.22	-0.32	3.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7172677	1.000	rs62027286	chr15:75429720	T/C	cg14664628	chr15:75095509	CSK	-0.49	-5.27	-0.32	3e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.66	6.92	0.4	4e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.44	0.33	1.27e-7	Menopause (age at onset);
KIRP	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg07167872	chr1:205819463	PM20D1	0.46	5.09	0.31	7.22e-7	Prostate-specific antigen levels;
KIRP	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.94e-20	Alzheimer's disease (late onset);
KIRP	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg03724423	chr7:27170755	HOXA4	-0.32	-4.99	-0.3	1.14e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07701084	chr6:150067640	NUP43	0.69	9.17	0.5	1.96e-17	Lung cancer;
KIRP	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg09491104	chr22:46646882	C22orf40	-0.63	-8.76	-0.49	3.34e-16	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-5.0	-0.3	1.08e-6	Cognitive function;
KIRP	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.67	8.58	0.48	1.08e-15	Coronary artery disease;
KIRP	cis	rs10197940	0.686	rs11675385	chr2:152262042	G/A	cg06191203	chr2:152266755	RIF1	-0.71	-8.35	-0.47	5.04e-15	Lung cancer;
KIRP	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.55	0.33	7.36e-8	Educational attainment;
KIRP	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg06640241	chr16:89574553	SPG7	0.62	7.86	0.45	1.21e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs6546886	0.912	rs4331526	chr2:74294449	A/C	cg14702570	chr2:74259524	NA	-0.27	-5.4	-0.33	1.6e-7	Dialysis-related mortality;
KIRP	cis	rs17321999	0.516	rs7606266	chr2:30501997	C/T	cg05247661	chr2:30472410	LBH	0.63	5.5	0.33	9.46e-8	Systemic lupus erythematosus;
KIRP	cis	rs4363506	0.635	rs10765123	chr10:129286134	C/T	cg07804728	chr10:129284050	NA	-0.47	-6.17	-0.37	2.86e-9	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.71	8.48	0.48	2.11e-15	Mammographic density (dense area);
KIRP	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.84	-8.15	-0.46	1.88e-14	Systolic blood pressure;
KIRP	cis	rs240764	0.817	rs239238	chr6:101094880	G/T	cg09795085	chr6:101329169	ASCC3	0.47	5.58	0.34	6.38e-8	Neuroticism;
KIRP	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.59	8.07	0.46	3.18e-14	Depressive symptoms;
KIRP	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg00504896	chr12:9437009	LOC642846	-0.51	-6.39	-0.38	8.45e-10	Breast size;
KIRP	trans	rs1106684	0.929	rs73163156	chr7:131461494	A/G	cg13607082	chr12:122652224	LRRC43	-0.65	-6.6	-0.39	2.58e-10	Body mass index;
KIRP	cis	rs6921919	0.525	rs9468361	chr6:28346318	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72772090	0.710	rs11750400	chr5:96077968	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-5.77	-0.35	2.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	0.96	10.41	0.55	2.96e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8133932	0.654	rs7410101	chr21:47328383	G/A	cg11214348	chr21:47283868	PCBP3	0.44	5.1	0.31	6.71e-7	Schizophrenia;
KIRP	cis	rs74181299	0.684	rs6756585	chr2:65340070	G/A	cg05010058	chr2:65284262	CEP68	-0.43	-5.75	-0.34	2.67e-8	Pulse pressure;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09667589	chr1:151400745	POGZ	0.45	6.72	0.39	1.28e-10	Survival in pancreatic cancer;
KIRP	cis	rs6545883	0.524	rs7561697	chr2:61519165	G/C	cg15711740	chr2:61764176	XPO1	0.46	5.67	0.34	4.02e-8	Tuberculosis;
KIRP	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	Neuroticism;
KIRP	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.82	-11.78	-0.6	1.09e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-9.9	-0.53	1.14e-19	Body mass index;
KIRP	cis	rs4356932	1.000	rs4456983	chr4:76958688	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-0.83	-9.09	-0.5	3.44e-17	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.82	9.34	0.51	6.06e-18	High light scatter reticulocyte count;
KIRP	cis	rs7224685	0.569	rs8066707	chr17:3996550	T/C	cg09597638	chr17:3907349	NA	0.52	5.26	0.32	3.12e-7	Type 2 diabetes;
KIRP	cis	rs8067545	0.553	rs4577147	chr17:19944023	T/C	cg13482628	chr17:19912719	NA	0.45	5.17	0.31	4.75e-7	Schizophrenia;
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.53	7.07	0.41	1.62e-11	Menarche (age at onset);
KIRP	cis	rs1642645	0.872	rs642112	chr1:42453317	C/T	cg26038582	chr1:42384390	HIVEP3	0.29	4.86	0.3	2.05e-6	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs3857067	1.000	rs6532462	chr4:95026833	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.86e-7	QT interval;
KIRP	cis	rs9326248	0.515	rs2727793	chr11:116683374	C/T	cg16524733	chr11:117070046	TAGLN	0.39	4.92	0.3	1.62e-6	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg22117172	chr7:91764530	CYP51A1	-0.37	-5.07	-0.31	7.7e-7	Breast cancer;
KIRP	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg16606324	chr3:10149918	C3orf24	0.54	5.07	0.31	7.84e-7	Alzheimer's disease;
KIRP	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.74	-9.92	-0.53	9.82e-20	Obesity-related traits;
KIRP	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg03714773	chr7:91764589	CYP51A1	0.39	5.64	0.34	4.58e-8	Breast cancer;
KIRP	cis	rs8523	0.804	rs3798720	chr6:11040002	C/T	cg13562911	chr6:11044106	ELOVL2	0.44	5.67	0.34	3.99e-8	Red blood cell fatty acid levels;
KIRP	cis	rs959260	1.000	rs4789188	chr17:73397871	A/C	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.09	-0.36	4.32e-9	Systemic lupus erythematosus;
KIRP	trans	rs6601327	0.635	rs10099122	chr8:9568003	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.07	-0.41	1.6e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.8	12.12	0.61	8.05e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7225151	1.000	rs4456560	chr17:5140399	G/T	cg24500398	chr17:5266808	RABEP1	-0.54	-6.08	-0.36	4.64e-9	Alzheimer's disease (late onset);
KIRP	cis	rs1318772	1.000	rs164252	chr5:112791801	T/A	cg12552261	chr5:112820674	MCC	-0.8	-6.38	-0.38	8.77e-10	F-cell distribution;
KIRP	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg02462569	chr6:150064036	NUP43	-0.37	-5.62	-0.34	5.03e-8	Lung cancer;
KIRP	cis	rs10875746	0.729	rs11168357	chr12:48412138	G/A	cg20731937	chr12:48336164	NA	0.5	6.38	0.38	8.68e-10	Longevity (90 years and older);
KIRP	cis	rs2274273	1.000	rs3742566	chr14:55595839	T/A	cg04306507	chr14:55594613	LGALS3	0.49	7.62	0.44	5.63e-13	Protein biomarker;
KIRP	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.46	-0.52	2.66e-18	Colorectal cancer;
KIRP	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.56	6.21	0.37	2.19e-9	Coronary artery disease;
KIRP	cis	rs13102973	0.720	rs7672296	chr4:135890056	C/G	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.66	8.7	0.49	4.74e-16	Educational attainment;
KIRP	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg21643547	chr1:205240462	TMCC2	-0.72	-10.96	-0.57	5.23e-23	Red blood cell count;
KIRP	cis	rs42648	0.837	rs42615	chr7:89950501	G/T	cg25739043	chr7:89950458	NA	-0.46	-7.16	-0.42	9.55e-12	Homocysteine levels;
KIRP	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg22676075	chr6:135203613	NA	0.51	7.28	0.42	4.47e-12	Red blood cell count;
KIRP	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg05785598	chr3:49045655	WDR6	0.31	5.52	0.33	8.43e-8	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.49	-7.73	-0.44	2.78e-13	Waist circumference adjusted for body mass index;
KIRP	trans	rs7863100	0.711	rs34430407	chr9:18657011	G/A	cg13196806	chr10:133996309	JAKMIP3	0.58	6.09	0.36	4.23e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs397969	0.646	rs203478	chr17:19829842	G/C	cg13482628	chr17:19912719	NA	0.47	5.3	0.32	2.62e-7	Platelet count;
KIRP	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg18016565	chr1:150552671	MCL1	-0.4	-5.95	-0.35	9.29e-9	Melanoma;
KIRP	cis	rs12200782	0.929	rs72843734	chr6:26448344	C/G	cg11502198	chr6:26597334	ABT1	-0.73	-4.9	-0.3	1.74e-6	Small cell lung carcinoma;
KIRP	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-10.86	-0.57	1.06e-22	Menopause (age at onset);
KIRP	cis	rs2494938	0.807	rs205514	chr6:40513372	T/C	cg14084896	chr6:40530702	LRFN2	-0.39	-4.93	-0.3	1.5e-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs7119167	0.722	rs7131383	chr11:73071263	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.51	-5.44	-0.33	1.31e-7	Blood protein levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05201865	chr16:25026718	ARHGAP17	-0.5	-6.57	-0.39	2.95e-10	Myopia;
KIRP	cis	rs6988636	0.710	rs73339623	chr8:124140288	A/G	cg23067535	chr8:124195133	FAM83A	-0.66	-5.55	-0.33	7.38e-8	Urinary uromodulin levels;
KIRP	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg04287289	chr16:89883240	FANCA	0.59	7.5	0.43	1.18e-12	Vitiligo;
KIRP	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg16553119	chr1:165599451	MGST3	-0.43	-4.99	-0.3	1.15e-6	Total ventricular volume;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.05	-0.36	5.49e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.38	-0.38	8.94e-10	Menopause (age at onset);
KIRP	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	9.25	0.51	1.11e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs963731	0.649	rs10186762	chr2:39219361	A/G	cg04010122	chr2:39346883	SOS1	-0.85	-5.85	-0.35	1.57e-8	Corticobasal degeneration;
KIRP	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg02336718	chr17:17403227	NA	-0.33	-5.31	-0.32	2.45e-7	Total body bone mineral density;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21016266	chr12:122356598	WDR66	0.62	8.21	0.46	1.22e-14	Mean corpuscular volume;
KIRP	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg09003973	chr2:102972529	NA	1.1	8.32	0.47	5.98e-15	Gut microbiota (bacterial taxa);
KIRP	cis	rs17123764	0.892	rs11169126	chr12:50115614	C/T	cg20471783	chr12:50157085	TMBIM6	0.42	5.99	0.36	7.49e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08866780	chr21:27543523	APP	0.46	6.24	0.37	1.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35079168	0.923	rs10858276	chr9:137287913	C/T	cg13941235	chr9:137270186	RXRA	-0.25	-5.23	-0.32	3.63e-7	Intelligence;
KIRP	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg07507129	chr1:2371847	NA	-0.45	-5.82	-0.35	1.86e-8	Schizophrenia;
KIRP	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.45	-0.38	5.82e-10	LDL cholesterol levels;
KIRP	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg00631329	chr6:26305371	NA	-0.7	-8.94	-0.5	9.37e-17	Educational attainment;
KIRP	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs9303542	0.559	rs8079617	chr17:46610028	T/G	cg04904318	chr17:46607828	HOXB1	-0.62	-6.69	-0.39	1.46e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.45	6.77	0.4	9.28e-11	Coronary artery disease;
KIRP	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.45	6.29	0.37	1.42e-9	Dupuytren's disease;
KIRP	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg19899395	chr1:46959349	NA	0.39	4.88	0.3	1.95e-6	Monobrow;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg00684032	chr4:1343700	KIAA1530	0.43	4.96	0.3	1.33e-6	Longevity;
KIRP	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg03188948	chr7:1209495	NA	0.76	5.09	0.31	7.14e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs494562	0.773	rs6919207	chr6:86129271	C/T	cg27039625	chr6:86159096	NT5E	0.5	6.29	0.37	1.44e-9	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-7.09	-0.41	1.43e-11	Bipolar disorder;
KIRP	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg00343986	chr7:65444356	GUSB	0.41	5.01	0.3	1.02e-6	Aortic root size;
KIRP	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-21.62	-0.81	8.1e-59	Ulcerative colitis;
KIRP	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg01765077	chr12:122356316	WDR66	0.46	6.18	0.37	2.65e-9	Mean corpuscular volume;
KIRP	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-9.63	-0.52	7.6e-19	Morning vs. evening chronotype;
KIRP	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg23352942	chr3:46931381	PTH1R	-0.51	-7.04	-0.41	1.87e-11	Birth weight;
KIRP	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg00977110	chr5:151150581	G3BP1	0.6	6.08	0.36	4.62e-9	Preschool internalizing problems;
KIRP	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg19847130	chr8:10466454	RP1L1	0.38	5.75	0.34	2.63e-8	Retinal vascular caliber;
KIRP	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg21095983	chr6:86352623	SYNCRIP	0.5	6.93	0.4	3.57e-11	Smooth-surface caries;
KIRP	cis	rs6995541	0.647	rs7833128	chr8:10684422	T/C	cg12568669	chr8:11666485	FDFT1	0.22	5.0	0.3	1.11e-6	Triglyceride levels;
KIRP	cis	rs4523957	0.583	rs2760743	chr17:2017079	A/C	cg16513277	chr17:2031491	SMG6	0.81	11.71	0.6	1.78e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.65	-6.43	-0.38	6.66e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	1.18	11.52	0.59	7.86e-25	Red blood cell traits;
KIRP	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg19000871	chr14:103996768	TRMT61A	-0.56	-6.02	-0.36	6.18e-9	Reticulocyte count;
KIRP	cis	rs10924970	0.967	rs3765793	chr1:235368277	T/A	cg26050004	chr1:235667680	B3GALNT2	0.42	5.22	0.32	3.78e-7	Asthma;
KIRP	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg23985595	chr17:80112537	CCDC57	0.31	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs6707387	0.641	rs10192180	chr2:214413283	C/A	cg08319019	chr2:214017104	IKZF2	0.47	5.3	0.32	2.64e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs7818345	0.740	rs10097813	chr8:19271968	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.36	4.94	0.3	1.45e-6	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7665939	1.000	rs72709223	chr4:190119797	G/T	cg14840187	chr4:190284988	NA	-0.8	-6.12	-0.36	3.57e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.11	-0.46	2.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24364564	chr17:38519136	GJD3	-0.48	-6.78	-0.4	9.02e-11	Myopia;
KIRP	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg08133631	chr1:26527909	CATSPER4	-0.44	-5.05	-0.31	8.71e-7	Obesity-related traits;
KIRP	trans	rs263156	0.967	rs263119	chr6:142892729	A/G	cg01789478	chr2:182545485	NEUROD1	-0.35	-6.14	-0.36	3.37e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	trans	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg13565492	chr6:43139072	SRF	-0.94	-8.64	-0.48	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9478217	1	rs9478217	chr6:151874122	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.52	-6.67	-0.39	1.71e-10	Total body bone mineral density (age 30-45);
KIRP	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-9.08	-0.5	3.6e-17	Migraine;Coronary artery disease;
KIRP	cis	rs2411233	1.000	rs10851374	chr15:39270049	C/A	cg02291532	chr15:39874776	THBS1	0.4	5.44	0.33	1.31e-7	Platelet count;
KIRP	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg18154014	chr19:37997991	ZNF793	0.74	7.84	0.45	1.34e-13	Coronary artery calcification;
KIRP	cis	rs1050631	0.564	rs681757	chr18:33744766	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.02	-0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.74	-0.53	3.57e-19	Body mass index;
KIRP	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	5.05e-11	Aortic root size;
KIRP	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg23188430	chr6:125850052	NA	-0.32	-5.03	-0.31	9.37e-7	Brugada syndrome;
KIRP	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.42	5.45	0.33	1.25e-7	Crohn's disease;
KIRP	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg09184832	chr6:79620586	NA	-0.5	-7.06	-0.41	1.7e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-16.12	-0.72	2.15e-40	Electrocardiographic conduction measures;
KIRP	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05025164	chr4:1340916	KIAA1530	0.4	5.24	0.32	3.45e-7	Obesity-related traits;
KIRP	cis	rs6091737	0.954	rs6097549	chr20:52342899	A/C	cg20178976	chr20:52357117	NA	-0.45	-5.44	-0.33	1.28e-7	Calcium levels;
KIRP	cis	rs597583	0.671	rs679223	chr11:117412621	G/A	cg27161313	chr11:117392002	DSCAML1	-0.56	-5.12	-0.31	6.05e-7	Putamen volume;
KIRP	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	6.05	0.36	5.48e-9	Depressive symptoms;
KIRP	cis	rs755109	1.000	rs12377604	chr9:100697287	A/G	cg13688889	chr9:100608707	NA	-0.42	-4.92	-0.3	1.62e-6	Quantitative traits;
KIRP	cis	rs960902	0.620	rs4384766	chr2:37733001	G/T	cg25341268	chr2:37734390	NA	-0.52	-6.86	-0.4	5.69e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs7033996	1.000	rs7847862	chr9:35933210	A/G	cg00918944	chr9:35908117	LOC158376	0.39	5.48	0.33	1.04e-7	Urate levels (BMI interaction);
KIRP	trans	rs2270927	0.790	rs6874435	chr5:75574855	A/G	cg13563193	chr19:33072644	PDCD5	0.82	7.55	0.43	8.48e-13	Mean corpuscular volume;
KIRP	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.25e-14	Aortic root size;
KIRP	cis	rs1978968	0.956	rs4992882	chr22:18445021	T/G	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.24	-0.37	1.89e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.93	12.16	0.61	5.78e-27	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18156543	chr17:48172978	PDK2	0.49	6.22	0.37	2.11e-9	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4523957	0.820	rs57307236	chr17:2159502	A/G	cg16513277	chr17:2031491	SMG6	-0.5	-6.74	-0.39	1.1e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8033133	0.602	rs3803326	chr15:25328715	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.56	-7.23	-0.42	6.19e-12	Blood osmolality (transformed sodium);
KIRP	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.09	0.54	3.04e-20	Dupuytren's disease;
KIRP	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg09355771	chr2:177043147	NA	-0.43	-5.06	-0.31	8.4e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg01200585	chr1:228362443	C1orf69	0.47	5.69	0.34	3.51e-8	Diastolic blood pressure;
KIRP	cis	rs7923609	0.934	rs10761771	chr10:65230164	T/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.86	-0.35	1.46e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-10.46	-0.55	2.02e-21	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6102059	0.692	rs2206689	chr20:39209518	A/G	cg22477343	chr20:39312069	NA	0.48	6.24	0.37	1.88e-9	LDL cholesterol;
KIRP	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg27529037	chr20:44575021	PCIF1	0.47	5.72	0.34	3.16e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg23163573	chr2:108905468	SULT1C2	-0.28	-5.18	-0.31	4.61e-7	Lobe size;
KIRP	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.51	7.13	0.41	1.1e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg01721255	chr8:58191610	C8orf71	0.52	5.15	0.31	5.44e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1832871	0.672	rs7745596	chr6:158732991	T/A	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.59	10.4	0.55	3.16e-21	Erythrocyte sedimentation rate;
KIRP	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.99	-12.32	-0.62	1.8e-27	Response to antineoplastic agents;
KIRP	cis	rs1050631	0.564	rs1785910	chr18:33729871	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.67	0.34	3.91e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.75	10.19	0.54	1.43e-20	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg16989719	chr2:238392110	NA	-0.59	-6.06	-0.36	5.08e-9	Prostate cancer;
KIRP	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.68	9.61	0.52	9.22e-19	Lymphocyte counts;
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg27532560	chr4:187881888	NA	-0.76	-12.87	-0.63	2.59e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.62	0.39	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14655249	chr9:86595816	HNRNPK;RMI1	0.53	6.1	0.36	4.06e-9	Smoking initiation;
KIRP	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg03808351	chr9:123631620	PHF19	0.41	5.54	0.33	7.67e-8	Rheumatoid arthritis;
KIRP	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.42	5.96	0.36	8.62e-9	Body mass index;
KIRP	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.71	7.11	0.41	1.22e-11	Chronic kidney disease;
KIRP	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.55	7.56	0.43	7.94e-13	Colorectal cancer;
KIRP	cis	rs2019216	0.542	rs7217513	chr17:21933536	C/A	cg22648282	chr17:21454238	C17orf51	-0.56	-6.89	-0.4	4.61e-11	Pelvic organ prolapse;
KIRP	cis	rs2929278	0.546	rs686666	chr15:44161550	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	5.71	0.34	3.21e-8	Schizophrenia;
KIRP	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.51e-25	Morning vs. evening chronotype;
KIRP	cis	rs787274	1.000	rs4246892	chr9:115588649	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-6.66	-0.39	1.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg19400545	chr4:124319236	SPRY1	-0.46	-6.43	-0.38	6.69e-10	Blood metabolite levels;
KIRP	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg21775007	chr8:11205619	TDH	-0.53	-6.87	-0.4	5.09e-11	Neuroticism;
KIRP	cis	rs6669119	0.668	rs17352385	chr1:19087695	A/G	cg19637330	chr1:19110922	NA	0.63	5.55	0.33	7.3e-8	Percentage gas trapping;
KIRP	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-11.69	-0.6	2.11e-25	Vitiligo;
KIRP	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg05484376	chr2:27715224	FNDC4	0.41	6.81	0.4	7.41e-11	Total body bone mineral density;
KIRP	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.77	-10.82	-0.57	1.44e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.57	7.69	0.44	3.46e-13	Mean corpuscular volume;
KIRP	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.91	11.31	0.58	3.74e-24	Homoarginine levels;
KIRP	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.54	0.33	7.73e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.56	0.33	7.03e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4664304	0.789	rs2063439	chr2:160800101	C/A	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.15	-0.31	5.26e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs17394429	0.524	rs270086	chr8:3276242	A/G	cg08428819	chr10:123924042	TACC2	0.48	6.66	0.39	1.82e-10	Obesity-related traits;
KIRP	cis	rs9393813	0.516	rs4713098	chr6:27403605	C/T	cg18711553	chr6:27366782	ZNF391	-0.37	-4.88	-0.3	1.93e-6	Bipolar disorder;
KIRP	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs12145833	0.596	rs61833906	chr1:243419706	T/C	cg02356786	chr1:243265016	LOC731275	0.89	6.01	0.36	6.66e-9	Obesity (early onset extreme);
KIRP	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.94	12.18	0.61	5e-27	Breast cancer;
KIRP	cis	rs12200782	1.000	rs12199239	chr6:26432570	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.72	-6.27	-0.37	1.63e-9	Small cell lung carcinoma;
KIRP	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg13119609	chr19:45449297	APOC2	0.52	7.36	0.42	2.69e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	0.43	5.96	0.36	8.65e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg18154014	chr19:37997991	ZNF793	0.68	6.1	0.36	4.08e-9	Coronary artery calcification;
KIRP	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.47	-6.08	-0.36	4.49e-9	Dietary macronutrient intake;
KIRP	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	6.47	0.38	5.37e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg11886554	chr3:170076028	SKIL	-0.5	-5.57	-0.33	6.67e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg04691961	chr3:161091175	C3orf57	-0.67	-10.94	-0.57	6.01e-23	Morning vs. evening chronotype;
KIRP	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.74e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg00278547	chr2:177037212	HOXD3	-0.39	-5.17	-0.31	4.91e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs2820315	0.928	rs2644111	chr1:201802052	G/A	cg11586189	chr1:201857591	SHISA4	-0.39	-5.45	-0.33	1.21e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg00409905	chr10:38381863	ZNF37A	-0.66	-6.29	-0.37	1.43e-9	Obesity (extreme);
KIRP	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.74	-8.59	-0.48	1.03e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.69	8.41	0.47	3.34e-15	Lung cancer;
KIRP	cis	rs16912285	0.688	rs12801367	chr11:24321827	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	8.71	0.49	4.42e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg17425144	chr1:10567563	PEX14	0.44	8.48	0.48	2.04e-15	Breast cancer;
KIRP	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg27411982	chr8:10470053	RP1L1	0.42	5.06	0.31	8.07e-7	Retinal vascular caliber;
KIRP	cis	rs10073892	0.633	rs9327815	chr5:101618286	A/G	cg19774478	chr5:101632501	SLCO4C1	0.56	6.07	0.36	4.79e-9	Cognitive decline (age-related);
KIRP	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-6.59	-0.39	2.67e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.94	0.4	3.44e-11	Schizophrenia;
KIRP	cis	rs193541	0.632	rs246276	chr5:122239957	G/A	cg19412675	chr5:122181750	SNX24	0.59	6.23	0.37	2.01e-9	Glucose homeostasis traits;
KIRP	cis	rs829661	0.901	rs829620	chr2:30750660	C/A	cg10949345	chr2:30726833	LCLAT1	0.72	10.48	0.56	1.77e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg12620499	chr2:216877984	MREG	0.99	14.66	0.68	2.17e-35	Alcohol dependence;
KIRP	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg13819577	chr1:248512075	OR14C36	-0.35	-4.91	-0.3	1.63e-6	Common traits (Other);
KIRP	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.32	-0.32	2.39e-7	Height;
KIRP	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.61	8.52	0.48	1.66e-15	Lewy body disease;
KIRP	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg11498726	chr8:26250323	BNIP3L	-0.56	-7.64	-0.44	4.72e-13	Red cell distribution width;
KIRP	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg21360079	chr12:107162445	NA	-0.67	-9.59	-0.52	1.06e-18	Heart rate;
KIRP	cis	rs17401966	0.522	rs946504	chr1:10308597	T/C	cg17425144	chr1:10567563	PEX14	-0.3	-5.31	-0.32	2.49e-7	Hepatocellular carcinoma;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.72	6.08	0.36	4.51e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg20965017	chr5:231967	SDHA	-0.58	-6.78	-0.4	8.71e-11	Breast cancer;
KIRP	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg06212747	chr3:49208901	KLHDC8B	0.51	5.03	0.31	9.33e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20135002	chr11:47629003	NA	-0.47	-5.27	-0.32	2.97e-7	Subjective well-being;
KIRP	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg16268157	chr7:99778414	STAG3	-0.52	-5.65	-0.34	4.52e-8	Lung function (FEV1/FVC);
KIRP	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg04132472	chr17:19861366	AKAP10	0.38	4.86	0.3	2.05e-6	Schizophrenia;
KIRP	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg01721255	chr8:58191610	C8orf71	0.54	5.73	0.34	2.94e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.85	0.49	1.79e-16	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03037437	chr2:232263444	B3GNT7	-0.49	-6.36	-0.38	9.67e-10	Parkinson's disease;
KIRP	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.5	6.89	0.4	4.75e-11	Schizophrenia;
KIRP	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-6.09	-0.36	4.37e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs151349	0.714	rs6026647	chr20:57606791	C/T	cg23907860	chr20:57583709	CTSZ	-0.38	-4.88	-0.3	1.87e-6	Platelet distribution width;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg21086891	chr3:192635035	C3orf59	0.51	6.08	0.36	4.64e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7106204	0.764	rs11821644	chr11:24212686	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	8.4	0.47	3.64e-15	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	cis	rs11634397	0.513	rs1916048	chr15:80412579	C/T	cg08257866	chr15:80351198	ZFAND6	0.54	5.57	0.33	6.73e-8	Type 2 diabetes;
KIRP	cis	rs1448094	0.765	rs4919773	chr12:86337559	C/T	cg00310523	chr12:86230176	RASSF9	0.41	6.28	0.37	1.55e-9	Major depressive disorder;
KIRP	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.61	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs16828019	0.632	rs12749196	chr1:41460783	G/A	cg18742814	chr1:41828276	NA	0.68	5.73	0.34	2.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs16937956	0.597	rs16937958	chr11:8404535	C/A	cg08015107	chr11:8618950	NA	-0.55	-7.03	-0.41	2.05e-11	Body mass index;
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-9.41	-0.51	3.57e-18	Platelet count;
KIRP	trans	rs9371601	0.742	rs214947	chr6:152713847	A/G	cg05529123	chr2:66910386	NA	-0.45	-6.17	-0.37	2.81e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24187352	chr11:356313	NA	0.51	6.45	0.38	5.77e-10	Parkinson's disease;
KIRP	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg23587288	chr2:27483067	SLC30A3	-0.65	-6.84	-0.4	6.11e-11	Blood metabolite levels;
KIRP	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.4	5.44	0.33	1.31e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs12586317	0.531	rs72666607	chr14:35770806	G/C	cg07166546	chr14:35805898	NA	-0.3	-7.17	-0.42	8.92e-12	Psoriasis;
KIRP	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4950322	0.570	rs72692905	chr1:146773253	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.38	-0.32	1.77e-7	Protein quantitative trait loci;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg18538332	chr22:24372958	LOC391322	-0.64	-8.35	-0.47	5e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.6	0.39	2.56e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg16141378	chr3:129829833	LOC729375	0.58	7.31	0.42	3.68e-12	Triglycerides;
KIRP	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg08501292	chr6:25962987	TRIM38	1.0	7.48	0.43	1.32e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6977660	0.505	rs9639338	chr7:19869778	T/A	cg05791153	chr7:19748676	TWISTNB	0.55	5.32	0.32	2.33e-7	Thyroid stimulating hormone;
KIRP	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.34	11.93	0.61	3.52e-26	Diabetic retinopathy;
KIRP	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.69	-10.59	-0.56	7.58e-22	Educational attainment;
KIRP	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-10.87	-0.57	9.82e-23	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.21	19.6	0.78	3.6e-52	Breast cancer;
KIRP	cis	rs78487399	0.710	rs78681698	chr2:43598160	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.09	-0.31	7.03e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.37	1.6e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.61	7.22	0.42	6.65e-12	White matter hyperintensity burden;
KIRP	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.74	10.3	0.55	6.59e-21	Red blood cell count;
KIRP	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg05805236	chr11:65401703	PCNXL3	-0.56	-7.11	-0.41	1.28e-11	Acne (severe);
KIRP	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7116495	0.609	rs674319	chr11:71775391	T/C	cg10381502	chr11:71823885	C11orf51	-1.17	-8.23	-0.46	1.08e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.52	-7.64	-0.44	4.82e-13	Monocyte percentage of white cells;
KIRP	cis	rs244293	0.760	rs12945393	chr17:53045243	G/A	cg07707039	chr17:53042137	COX11	-0.4	-5.06	-0.31	8.25e-7	Menarche (age at onset);
KIRP	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.54	5.84	0.35	1.64e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg18404041	chr3:52824283	ITIH1	0.36	5.14	0.31	5.64e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.04	-0.5	4.65e-17	Retinal vascular caliber;
KIRP	cis	rs501120	0.636	rs920172	chr10:44782724	T/C	cg09554077	chr10:44749378	NA	0.6	6.03	0.36	6.09e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	6.93	0.4	3.74e-11	Menarche (age at onset);
KIRP	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg10547527	chr2:198650123	BOLL	-0.53	-5.16	-0.31	5.1e-7	Ulcerative colitis;
KIRP	cis	rs925228	0.504	rs7568272	chr2:24313785	T/C	cg01493198	chr2:24299560	SF3B14	0.78	6.4	0.38	7.66e-10	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs9359856	0.518	rs10944451	chr6:90262341	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.5	-5.32	-0.32	2.36e-7	Bipolar disorder;
KIRP	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg14972814	chr11:95582409	MTMR2	0.32	5.52	0.33	8.5e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg21984481	chr17:79567631	NPLOC4	-0.44	-7.03	-0.41	2.03e-11	Eye color traits;
KIRP	cis	rs33912345	0.750	rs1018533	chr14:60971137	T/C	cg27398547	chr14:60952738	C14orf39	0.39	5.04	0.31	9.12e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs7523273	0.597	rs6657476	chr1:207960104	G/T	cg22525895	chr1:207977042	MIR29B2	-0.6	-5.86	-0.35	1.52e-8	Schizophrenia;
KIRP	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg08501292	chr6:25962987	TRIM38	1.1	6.16	0.37	2.98e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2224391	0.628	rs2773316	chr6:5254448	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.53	-0.38	3.69e-10	Height;
KIRP	cis	rs4654899	1.000	rs7543126	chr1:21406088	T/G	cg05370193	chr1:21551575	ECE1	0.38	5.22	0.32	3.79e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.25	14.39	0.68	1.76e-34	Uric acid levels;
KIRP	cis	rs2587695	0.901	rs2587683	chr2:120292249	C/T	cg07176264	chr2:120281999	SCTR	-0.32	-5.1	-0.31	6.93e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.17	-0.5	1.98e-17	Mean corpuscular volume;
KIRP	cis	rs259282	0.605	rs34727912	chr19:33110058	A/C	cg02997394	chr19:33096574	ANKRD27	-0.53	-6.3	-0.37	1.36e-9	Schizophrenia;
KIRP	cis	rs7635838	0.819	rs12714866	chr3:11539058	C/T	cg00170343	chr3:11313890	ATG7	0.46	5.78	0.35	2.25e-8	HDL cholesterol;
KIRP	cis	rs1035491	0.715	rs876355	chr5:63919625	G/T	cg01791865	chr5:63954708	NA	-0.33	-5.14	-0.31	5.62e-7	Body mass index;
KIRP	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-35.15	-0.91	6.94e-98	Myeloid white cell count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00540891	chr10:43572244	RET	-0.46	-6.65	-0.39	1.85e-10	Metabolic traits;
KIRP	cis	rs2562456	0.833	rs2968076	chr19:21637101	C/T	cg00806126	chr19:22604979	ZNF98	0.61	6.43	0.38	6.55e-10	Pain;
KIRP	cis	rs4356932	0.691	rs6827617	chr4:76916146	G/A	cg19388996	chr4:76862389	NAAA	0.43	5.48	0.33	1.06e-7	Blood protein levels;
KIRP	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs10423674	0.526	rs12462498	chr19:18832950	A/G	cg14292368	chr19:18793705	CRTC1	0.52	6.53	0.38	3.67e-10	Menarche (age at onset);
KIRP	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg00576331	chr11:65640516	EFEMP2	-0.53	-5.77	-0.35	2.33e-8	Crohn's disease;
KIRP	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg26384229	chr12:38710491	ALG10B	0.72	9.74	0.53	3.54e-19	Morning vs. evening chronotype;
KIRP	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg01629716	chr15:45996671	NA	-0.37	-6.69	-0.39	1.5e-10	Waist circumference;Weight;
KIRP	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-0.64	-8.73	-0.49	3.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.07	-0.31	7.68e-7	Obesity-related traits;
KIRP	cis	rs4789452	0.934	rs3987888	chr17:75370274	T/C	cg05184938	chr17:75369939	SEPT9	-0.38	-5.32	-0.32	2.36e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.4	-5.0	-0.3	1.11e-6	Blood protein levels;
KIRP	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg24631222	chr15:78858424	CHRNA5	0.8	9.7	0.53	4.8e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2797160	0.522	rs6925158	chr6:125940188	T/G	cg05901451	chr6:126070800	HEY2	-0.36	-4.98	-0.3	1.18e-6	Endometrial cancer;
KIRP	cis	rs10465746	0.967	rs7531537	chr1:84414924	C/T	cg10977910	chr1:84465055	TTLL7	0.47	5.76	0.34	2.53e-8	Obesity-related traits;
KIRP	cis	rs12208915	0.731	rs9361473	chr6:79657042	C/T	cg09184832	chr6:79620586	NA	0.47	5.19	0.31	4.38e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs3105593	1.000	rs1986074	chr15:50857452	T/C	cg05456662	chr15:50716270	USP8	0.39	4.9	0.3	1.76e-6	QT interval;
KIRP	cis	rs10849689	1	rs10849689	chr12:110493222	A/G	cg12870014	chr12:110450643	ANKRD13A	0.53	6.97	0.41	2.83e-11	Schizophrenia;
KIRP	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.37	5.35	0.32	1.98e-7	Mean corpuscular volume;
KIRP	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg15147215	chr3:52552868	STAB1	0.31	5.63	0.34	4.82e-8	Electroencephalogram traits;
KIRP	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27297192	chr10:134578999	INPP5A	0.6	7.34	0.42	3.08e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9972944	0.756	rs6504344	chr17:63756668	C/T	cg07283582	chr17:63770753	CCDC46	-0.44	-7.23	-0.42	5.91e-12	Total body bone mineral density;
KIRP	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg07972983	chr1:205091412	RBBP5	0.43	5.1	0.31	6.71e-7	Red blood cell count;
KIRP	cis	rs829661	0.793	rs895662	chr2:30874229	A/G	cg10949345	chr2:30726833	LCLAT1	1.2	14.38	0.68	1.98e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.99	-0.5	6.76e-17	Retinal vascular caliber;
KIRP	cis	rs2230307	0.505	rs482873	chr1:100589757	C/T	cg24955406	chr1:100503596	HIAT1	-0.67	-7.49	-0.43	1.27e-12	Carotid intima media thickness;
KIRP	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.4	-0.38	7.85e-10	Axial length;
KIRP	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg02073558	chr3:44770973	ZNF501	0.48	5.56	0.33	7e-8	IgG glycosylation;
KIRP	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg23102388	chr7:1867652	MAD1L1	-0.49	-6.57	-0.39	3.04e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs3736485	0.903	rs4545756	chr15:51877790	A/G	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg15117754	chr3:10150083	C3orf24	0.51	5.09	0.31	7.1e-7	Alzheimer's disease;
KIRP	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.05	0.36	5.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7119038	0.774	rs11217038	chr11:118677355	G/A	cg19308663	chr11:118741387	NA	0.59	9.86	0.53	1.53e-19	Sjögren's syndrome;
KIRP	cis	rs8018808	0.935	rs11623826	chr14:77912862	A/C	cg18872420	chr14:78023429	SPTLC2	0.34	5.09	0.31	7.19e-7	Myeloid white cell count;
KIRP	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.06	-0.31	8.09e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2652822	0.525	rs35594365	chr15:63520154	T/C	cg02713581	chr15:63449717	RPS27L	0.48	5.35	0.32	1.97e-7	Metabolic traits;
KIRP	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg17264618	chr3:40429014	ENTPD3	-0.37	-5.95	-0.35	9.04e-9	Renal cell carcinoma;
KIRP	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.28	0.62	2.44e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg22134162	chr3:63841271	THOC7	-0.43	-5.18	-0.31	4.65e-7	Lung function (FVC);Lung function (FEV1);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15190738	chr8:20161380	NA	0.46	6.39	0.38	8.42e-10	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-7.3	-0.42	3.98e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9400467	0.506	rs78051065	chr6:111600406	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.1	-0.41	1.3e-11	Migraine;Coronary artery disease;
KIRP	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23161317	chr6:28129485	ZNF389	-0.46	-5.43	-0.33	1.34e-7	Depression;
KIRP	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18252515	chr7:66147081	NA	-0.46	-5.35	-0.32	1.98e-7	Aortic root size;
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg02696790	chr15:75250997	RPP25	0.33	5.44	0.33	1.29e-7	Caffeine consumption;
KIRP	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg21523564	chr15:75251491	NA	-0.36	-6.05	-0.36	5.42e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs6832769	1.000	rs11733864	chr4:56321530	C/T	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg11814155	chr7:99998594	ZCWPW1	0.55	5.38	0.32	1.71e-7	Platelet count;
KIRP	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs7221595	0.825	rs12942967	chr17:3921834	C/T	cg09695851	chr17:3907499	NA	0.6	6.08	0.36	4.59e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg17376030	chr22:41985996	PMM1	0.8	8.21	0.46	1.24e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22857025	chr5:266934	NA	-0.96	-6.28	-0.37	1.52e-9	Breast cancer;
KIRP	cis	rs11718455	0.767	rs9861276	chr3:43989595	C/T	cg08738300	chr3:44038990	NA	0.64	8.69	0.48	5.11e-16	Coronary artery disease;
KIRP	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.86	-0.4	5.42e-11	Type 2 diabetes;
KIRP	trans	rs7729273	0.956	rs13162883	chr5:7185942	C/T	cg13850847	chr9:136131739	ABO	0.5	6.44	0.38	6.32e-10	Cognitive performance;
KIRP	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08045932	chr20:61659980	NA	0.54	6.74	0.39	1.14e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg25281562	chr12:121454272	C12orf43	0.51	5.5	0.33	9.64e-8	N-glycan levels;
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg21016266	chr12:122356598	WDR66	0.55	7.24	0.42	5.81e-12	Mean corpuscular volume;
KIRP	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg07274523	chr3:49395745	GPX1	0.69	8.62	0.48	8.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs714027	0.626	rs4336042	chr22:30552511	G/A	cg01021169	chr22:30184971	ASCC2	0.44	5.59	0.34	6.05e-8	Lymphocyte counts;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13686307	chr2:232651122	COPS7B	-0.48	-6.11	-0.36	3.9e-9	Myopia;
KIRP	cis	rs7951870	0.945	rs12574259	chr11:46704439	A/G	cg19486271	chr11:47235900	DDB2	0.53	5.01	0.3	1.05e-6	Schizophrenia;
KIRP	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg04691961	chr3:161091175	C3orf57	-0.36	-5.26	-0.32	3.08e-7	Kawasaki disease;
KIRP	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.37	6.58	0.39	2.82e-10	Left ventricle wall thickness;
KIRP	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs7845219	0.544	rs34293080	chr8:95908078	G/T	cg16049864	chr8:95962084	TP53INP1	-0.39	-6.24	-0.37	1.89e-9	Type 2 diabetes;
KIRP	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.4	-0.33	1.58e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	23.0	0.83	3.19e-63	Chronic sinus infection;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07913137	chr13:60587694	DIAPH3	0.4	6.05	0.36	5.42e-9	Migraine with aura;
KIRP	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-9.81	-0.53	2.14e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg19767477	chr5:127420684	SLC12A2	-0.35	-4.89	-0.3	1.78e-6	Ileal carcinoids;
KIRP	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.67	-7.76	-0.44	2.3e-13	Primary sclerosing cholangitis;
KIRP	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg12756093	chr1:115239321	AMPD1	-0.51	-6.77	-0.4	9.29e-11	Autism;
KIRP	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg22117172	chr7:91764530	CYP51A1	-0.37	-5.16	-0.31	5.07e-7	Breast cancer;
KIRP	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.5	6.79	0.4	8.45e-11	Mean corpuscular volume;
KIRP	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg13615516	chr5:77269221	NA	0.5	7.84	0.45	1.39e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	7.47	0.43	1.41e-12	Migraine;Coronary artery disease;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg03801030	chr11:6440781	APBB1	0.51	6.29	0.37	1.45e-9	Beard thickness;
KIRP	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg09201719	chr10:104596890	CYP17A1	0.37	5.32	0.32	2.28e-7	Arsenic metabolism;
KIRP	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.43	-5.99	-0.36	7.5e-9	Monocyte count;
KIRP	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.34	-5.59	-0.34	6.02e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	1.01	14.2	0.67	7.89e-34	Cognitive function;
KIRP	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.74	8.61	0.48	8.82e-16	Obesity-related traits;
KIRP	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg23307798	chr14:103986281	CKB	-0.47	-6.36	-0.38	9.7e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12904129	0.602	rs56266237	chr15:92243390	T/G	cg04509607	chr15:91538344	PRC1	0.41	4.94	0.3	1.45e-6	Gait speed in old age;
KIRP	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.43	6.57	0.39	2.94e-10	Schizophrenia;
KIRP	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24549020	chr5:56110836	MAP3K1	0.55	5.37	0.32	1.86e-7	Type 2 diabetes;
KIRP	cis	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg06521331	chr12:34319734	NA	-0.47	-5.75	-0.34	2.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.83	8.5	0.48	1.81e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs11731606	0.508	rs12108275	chr4:95298847	T/G	cg00507259	chr4:95128692	SMARCAD1	0.53	5.15	0.31	5.24e-7	Mean platelet volume;
KIRP	cis	rs3735025	0.963	rs320706	chr7:137052670	G/A	cg13839563	chr7:136910420	NA	0.39	4.93	0.3	1.52e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06481639	chr22:41940642	POLR3H	0.68	6.99	0.41	2.53e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg14003231	chr6:33640908	ITPR3	0.28	5.07	0.31	7.67e-7	Plateletcrit;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12833451	chr3:33729800	CLASP2	-0.41	-6.23	-0.37	1.98e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.69	-0.34	3.52e-8	Bipolar disorder;
KIRP	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.83	9.96	0.54	7.25e-20	Corneal astigmatism;
KIRP	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg10351095	chr21:47802916	PCNT	-0.44	-5.56	-0.33	7.18e-8	Testicular germ cell tumor;
KIRP	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.42	4.94	0.3	1.43e-6	Height;
KIRP	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.43	5.02	0.3	9.97e-7	Aortic root size;
KIRP	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.7	0.34	3.5e-8	Homoarginine levels;
KIRP	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg27147174	chr7:100797783	AP1S1	0.6	7.8	0.45	1.73e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.65	-6.32	-0.37	1.23e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs56146971	0.763	rs55950330	chr14:91872978	C/T	cg16433844	chr14:91963127	SMEK1	-0.57	-5.38	-0.32	1.75e-7	Alzheimer disease and age of onset;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg23985595	chr17:80112537	CCDC57	0.4	6.1	0.36	4.03e-9	Life satisfaction;
KIRP	cis	rs3931020	0.566	rs1327086	chr1:75271032	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.49	6.16	0.37	2.95e-9	Resistin levels;
KIRP	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.1	-0.31	6.93e-7	Crohn's disease;
KIRP	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.46	6.82	0.4	7.14e-11	Coronary artery disease;
KIRP	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg17644776	chr2:200775616	C2orf69	-0.53	-4.86	-0.3	2.08e-6	Schizophrenia;
KIRP	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14240646	chr10:27532245	ACBD5	-0.73	-7.28	-0.42	4.54e-12	Breast cancer;
KIRP	cis	rs6542838	0.641	rs6760065	chr2:99486318	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-5.15	-0.31	5.31e-7	Fear of minor pain;
KIRP	cis	rs859767	0.519	rs11688414	chr2:135420237	G/A	cg12500956	chr2:135428796	TMEM163	-0.48	-6.33	-0.37	1.16e-9	Neuroticism;
KIRP	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg03929089	chr4:120376271	NA	0.67	6.28	0.37	1.53e-9	Intraocular pressure;
KIRP	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.71	10.24	0.55	1.02e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg00784671	chr22:46762841	CELSR1	-0.61	-6.11	-0.36	3.96e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs698833	0.926	rs1067342	chr2:44622256	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.81	0.4	7.55e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11987759	chr7:65425863	GUSB	-0.52	-7.0	-0.41	2.38e-11	Aortic root size;
KIRP	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.69	8.34	0.47	5.17e-15	Aortic root size;
KIRP	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.05	-0.58	2.5e-23	Height;
KIRP	cis	rs12096438	1.000	rs6687605	chr1:25889632	T/C	cg21452808	chr1:25900135	NA	-0.39	-6.34	-0.37	1.11e-9	Platelet count;Mean platelet volume;
KIRP	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.62	0.52	8.17e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00540353	chr1:171454829	BAT2L2	0.45	6.6	0.39	2.47e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.73	9.7	0.53	4.66e-19	Breast cancer;
KIRP	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.53	-0.38	3.81e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27379520	chr16:89615117	SPG7	-0.42	-6.09	-0.36	4.32e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	trans	rs225245	0.782	rs225272	chr17:33969911	T/C	cg19694781	chr19:47549865	TMEM160	-0.53	-6.49	-0.38	4.68e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg20060108	chr2:102954350	IL1RL1	-0.62	-5.0	-0.3	1.11e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	3.99e-15	Protein biomarker;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg08080985	chr9:77703079	C9orf95;OSTF1	0.56	7.41	0.43	2e-12	Educational attainment;
KIRP	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24110177	chr3:50126178	RBM5	0.55	7.15	0.41	9.75e-12	Body mass index;
KIRP	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.59	0.52	1.08e-18	Dupuytren's disease;
KIRP	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.7	-8.87	-0.49	1.57e-16	Systemic lupus erythematosus;
KIRP	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.63	-7.4	-0.43	2.13e-12	Uric acid levels;
KIRP	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.69	-0.39	1.51e-10	Axial length;
KIRP	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg00409905	chr10:38381863	ZNF37A	0.57	7.64	0.44	4.78e-13	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.54	6.44	0.38	6.37e-10	Obesity-related traits;
KIRP	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.68	-8.23	-0.46	1.12e-14	Blood protein levels;
KIRP	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.62	-7.42	-0.43	1.9e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs55962025	0.711	rs2071662	chr4:3223891	T/C	cg06533319	chr4:3265114	C4orf44	0.42	5.35	0.32	1.97e-7	Parental longevity (mother's age at death);
KIRP	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.5	-4.97	-0.3	1.25e-6	Type 2 diabetes;
KIRP	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg16255804	chr6:135334527	HBS1L	-0.34	-5.47	-0.33	1.09e-7	Red blood cell count;
KIRP	cis	rs41005	0.967	rs6753101	chr2:8104849	G/T	cg03155496	chr2:8117019	LOC339788	-0.55	-8.99	-0.5	6.8e-17	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs7760535	0.826	rs10872068	chr6:111849860	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.42	5.45	0.33	1.22e-7	Metabolic traits;
KIRP	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.38	6.48	0.38	5.01e-10	Heart rate;
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg03653399	chr8:142233436	SLC45A4	0.94	14.75	0.68	1.08e-35	Immature fraction of reticulocytes;
KIRP	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.24	-0.37	1.85e-9	Triglycerides;
KIRP	cis	rs59197085	0.636	rs57573379	chr7:128465646	A/G	cg00734629	chr7:128471146	FLNC	0.45	5.19	0.31	4.34e-7	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.29	-0.32	2.76e-7	Metabolite levels;
KIRP	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.78	10.11	0.54	2.59e-20	Aortic root size;
KIRP	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	1.1	17.86	0.75	2.61e-46	Cognitive function;
KIRP	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs1595825	0.678	rs57265854	chr2:198917263	C/A	cg11031976	chr2:198649780	BOLL	-0.53	-5.08	-0.31	7.56e-7	Ulcerative colitis;
KIRP	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg15128208	chr22:42549153	NA	0.72	8.19	0.46	1.46e-14	Birth weight;
KIRP	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.41	7.03	0.41	2e-11	Renal cell carcinoma;
KIRP	cis	rs4591494	0.520	rs7431176	chr3:7934523	T/A	cg06740372	chr3:7957779	NA	-0.36	-4.88	-0.3	1.89e-6	Factor VII;
KIRP	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	cg04338863	chr8:33670619	NA	0.48	6.31	0.37	1.31e-9	Body mass index;
KIRP	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg18709589	chr6:96969512	KIAA0776	-0.38	-5.5	-0.33	9.29e-8	Headache;
KIRP	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg19773385	chr1:10388646	KIF1B	-0.68	-9.0	-0.5	6.27e-17	Hepatocellular carcinoma;
KIRP	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.36	0.59	2.52e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg14275779	chr17:40830236	PLEKHH3	0.81	7.1	0.41	1.3e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	1.13	14.52	0.68	6.59e-35	IgG glycosylation;
KIRP	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.3	-0.42	3.92e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg09184832	chr6:79620586	NA	0.55	7.43	0.43	1.83e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-6.35	-0.38	1.06e-9	Bipolar disorder;
KIRP	cis	rs1134634	0.520	rs2160044	chr4:15558343	C/T	cg16509355	chr4:15471240	CC2D2A	-0.3	-5.11	-0.31	6.35e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03407747	chr17:6899364	ALOX12	0.29	5.19	0.31	4.39e-7	Tonsillectomy;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg06606381	chr12:133084897	FBRSL1	-1.09	-6.41	-0.38	7.21e-10	Depression;
KIRP	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg01579765	chr21:45077557	HSF2BP	0.37	6.91	0.4	4.11e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg16898833	chr6:26189333	HIST1H4D	0.81	6.4	0.38	7.88e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs11203032	0.831	rs7074977	chr10:90948409	C/T	cg16672925	chr10:90967113	CH25H	0.46	5.68	0.34	3.82e-8	Heart failure;
KIRP	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.88	-12.75	-0.63	6.46e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg27326032	chr3:127006922	NA	0.43	6.12	0.36	3.76e-9	Morning vs. evening chronotype;
KIRP	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.75	-7.57	-0.43	7.59e-13	Body mass index;
KIRP	cis	rs3105593	0.575	rs4318151	chr15:50729274	A/G	cg05456662	chr15:50716270	USP8	0.46	5.97	0.36	8.08e-9	QT interval;
KIRP	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg17376030	chr22:41985996	PMM1	0.63	5.35	0.32	2.02e-7	Vitiligo;
KIRP	cis	rs4791746	0.901	rs4445935	chr17:8618603	G/C	cg03115937	chr17:8649504	CCDC42	-0.52	-6.29	-0.37	1.43e-9	Heroin dependence;
KIRP	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.32	8.15	0.46	1.79e-14	Primary biliary cholangitis;
KIRP	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg21926883	chr2:100939477	LONRF2	-0.54	-7.09	-0.41	1.38e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.49	-6.36	-0.38	9.89e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3857747	0.827	rs4236367	chr7:40457271	G/A	cg00420559	chr7:40367873	C7orf10	-0.58	-7.92	-0.45	8.2e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg20542592	chr8:11973495	FAM66D	0.42	5.19	0.31	4.41e-7	Triglycerides;
KIRP	cis	rs2179367	0.959	rs9377212	chr6:149704901	G/C	cg16235748	chr6:149772707	ZC3H12D	-0.29	-4.85	-0.3	2.2e-6	Dupuytren's disease;
KIRP	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg14675211	chr2:100938903	LONRF2	-0.44	-5.31	-0.32	2.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg18586891	chr4:952366	TMEM175	0.64	5.76	0.34	2.51e-8	Parkinson's disease;
KIRP	cis	rs72634258	0.891	rs404381	chr1:8080745	C/T	cg25007680	chr1:8021821	PARK7	0.42	4.88	0.3	1.95e-6	Inflammatory bowel disease;
KIRP	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg12315302	chr6:26189340	HIST1H4D	0.99	6.87	0.4	5.11e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-5.96	-0.36	8.62e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.45	-6.73	-0.39	1.19e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg00677455	chr12:58241039	CTDSP2	-0.58	-6.98	-0.41	2.77e-11	Multiple sclerosis;
KIRP	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.29	-0.37	1.43e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.28	0.47	7.89e-15	Morning vs. evening chronotype;
KIRP	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg04374321	chr14:90722782	PSMC1	0.99	17.84	0.75	3.05e-46	Mortality in heart failure;
KIRP	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.68	-6.69	-0.39	1.52e-10	Bipolar disorder;
KIRP	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-7.12	-0.41	1.19e-11	Personality dimensions;
KIRP	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-6.76	-0.4	9.76e-11	Aortic root size;
KIRP	cis	rs7017914	0.902	rs35580034	chr8:71572073	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs2718058	0.630	rs2709120	chr7:37809412	T/C	cg15028436	chr7:37888078	TXNDC3	0.5	5.28	0.32	2.87e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7534824	0.625	rs17409422	chr1:101502386	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.28	0.32	2.81e-7	Refractive astigmatism;
KIRP	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.53	-7.43	-0.43	1.74e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7011049	1.000	rs72640865	chr8:53842471	C/T	cg26025543	chr8:53854495	NA	0.74	7.56	0.43	7.99e-13	Systolic blood pressure;
KIRP	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg07423050	chr13:99094983	FARP1	0.34	5.48	0.33	1.06e-7	Longevity;
KIRP	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.69	10.55	0.56	1.03e-21	Blood metabolite ratios;
KIRP	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs829661	0.947	rs829669	chr2:30720752	A/G	cg10949345	chr2:30726833	LCLAT1	0.69	9.75	0.53	3.29e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01704976	chr3:52273381	TWF2	0.45	6.23	0.37	2.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg11522683	chr6:37501428	NA	-0.38	-5.15	-0.31	5.35e-7	Cognitive performance;
KIRP	cis	rs6540556	0.517	rs11119328	chr1:209885318	C/A	cg23920097	chr1:209922102	NA	-0.45	-5.2	-0.31	4.13e-7	Red blood cell count;
KIRP	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.46	-7.63	-0.44	5.16e-13	Height;
KIRP	cis	rs12579753	0.667	rs7486325	chr12:82302291	G/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.67	-0.34	3.93e-8	Resting heart rate;
KIRP	cis	rs28834970	0.675	rs7013346	chr8:27228666	C/A	cg18234130	chr8:27182889	PTK2B	-0.43	-5.12	-0.31	6.2e-7	Alzheimer's disease (late onset);
KIRP	cis	rs9296736	0.890	rs1325831	chr6:53904347	C/T	cg04374786	chr6:53939321	C6orf142	-0.38	-5.12	-0.31	6.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17712092	chr4:129076599	LARP1B	-0.56	-6.95	-0.41	3.19e-11	Eosinophil percentage of white cells;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12975709	chr7:47317262	TNS3	0.57	6.86	0.4	5.71e-11	Interleukin-4 levels;
KIRP	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11987759	chr7:65425863	GUSB	0.62	8.72	0.49	4.37e-16	Aortic root size;
KIRP	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg19767477	chr5:127420684	SLC12A2	-0.37	-5.29	-0.32	2.71e-7	Ileal carcinoids;
KIRP	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22857025	chr5:266934	NA	-0.84	-7.24	-0.42	5.8e-12	Asthma (childhood onset);
KIRP	cis	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg08133631	chr1:26527909	CATSPER4	0.47	5.28	0.32	2.81e-7	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs4690686	0.500	rs4690431	chr4:177264251	G/A	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs7737355	0.699	rs7711311	chr5:130781339	G/A	cg06307176	chr5:131281290	NA	-0.42	-5.02	-0.3	9.8e-7	Life satisfaction;
KIRP	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	9.03	0.5	4.99e-17	Motion sickness;
KIRP	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26526719	chr5:1949144	NA	0.44	5.32	0.32	2.37e-7	Gut microbiome composition (winter);
KIRP	cis	rs4262150	0.774	rs72799105	chr5:152048633	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.19	-0.46	1.46e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg23985595	chr17:80112537	CCDC57	-0.37	-5.55	-0.33	7.31e-8	Life satisfaction;
KIRP	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.72	-0.49	4.36e-16	Neuroticism;
KIRP	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.5	-8.43	-0.47	2.9e-15	Refractive error;
KIRP	cis	rs9309473	0.519	rs35421685	chr2:73910138	T/C	cg20560298	chr2:73613845	ALMS1	0.49	6.05	0.36	5.22e-9	Metabolite levels;
KIRP	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg12140854	chr5:148520817	ABLIM3	-0.51	-5.81	-0.35	1.9e-8	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18899058	chr7:98581413	TRRAP	-0.43	-6.29	-0.37	1.45e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg05347473	chr6:146136440	FBXO30	0.57	8.03	0.46	3.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.55	-9.09	-0.5	3.31e-17	Prostate cancer;
KIRP	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.58	-7.37	-0.43	2.55e-12	Personality dimensions;
KIRP	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg10169327	chr19:45448959	APOC2	0.33	4.97	0.3	1.26e-6	Blood protein levels;
KIRP	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.43	-5.26	-0.32	3.14e-7	Neuroticism;
KIRP	cis	rs9535307	0.929	rs9535316	chr13:50312397	G/A	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs858239	0.600	rs59073109	chr7:23133226	C/A	cg23682824	chr7:23144976	KLHL7	0.45	5.34	0.32	2.15e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4908768	0.725	rs11121214	chr1:8728665	C/T	cg25722041	chr1:8623473	RERE	0.82	9.66	0.52	6.45e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	0.99	10.68	0.56	3.95e-22	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03670164	chr3:178789707	ZMAT3	0.5	6.16	0.37	2.91e-9	Parkinson's disease;
KIRP	cis	rs6466055	0.661	rs2299327	chr7:104905252	C/T	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	6.96e-7	Schizophrenia;
KIRP	cis	rs9534288	0.659	rs1581846	chr13:46650686	G/A	cg15192986	chr13:46630673	CPB2	-0.72	-9.17	-0.5	1.92e-17	Blood protein levels;
KIRP	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.37	0.32	1.82e-7	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg22117172	chr7:91764530	CYP51A1	0.4	5.52	0.33	8.7e-8	Breast cancer;
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19723775	chr5:179050963	HNRNPH1	-0.46	-5.36	-0.32	1.94e-7	Lung cancer;
KIRP	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg03653399	chr8:142233436	SLC45A4	0.45	4.87	0.3	2.04e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.33	-0.32	2.27e-7	Bipolar disorder;
KIRP	cis	rs6991838	0.557	rs67685675	chr8:66486606	T/C	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-5.77	-0.35	2.36e-8	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs4356932	1.000	rs4583787	chr4:76955069	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.05	-0.5	4.33e-17	Personality dimensions;
KIRP	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.46	-0.43	1.53e-12	Morning vs. evening chronotype;
KIRP	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg22563815	chr15:78856949	CHRNA5	-0.41	-6.48	-0.38	5.05e-10	Sudden cardiac arrest;
KIRP	cis	rs9479482	0.648	rs912558	chr6:150385730	G/T	cg03788504	chr6:150331562	NA	0.33	6.02	0.36	6.14e-9	Alopecia areata;
KIRP	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.77	11.61	0.6	3.77e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.5	6.5	0.38	4.51e-10	HDL cholesterol levels;
KIRP	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.41	-5.16	-0.31	5.2e-7	Aortic root size;
KIRP	trans	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg25214090	chr10:38739885	LOC399744	0.7	8.08	0.46	2.86e-14	Corneal astigmatism;
KIRP	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.82e-7	Cognitive function;
KIRP	cis	rs1950626	0.743	rs12884454	chr14:101465627	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.62	6.33	0.37	1.15e-9	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22885407	chr2:132440298	NA	0.48	6.21	0.37	2.28e-9	Parkinson's disease;
KIRP	cis	rs8177876	0.822	rs77475047	chr16:81106960	T/C	cg08591886	chr16:81111003	C16orf46	-0.76	-5.89	-0.35	1.27e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg08648136	chr8:956695	NA	0.49	7.68	0.44	3.86e-13	Schizophrenia;
KIRP	cis	rs9815354	0.638	rs73071259	chr3:42001847	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	cis	rs17023223	0.537	rs2765533	chr1:119597395	T/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.21	-0.42	6.83e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17040068	chr7:102715209	ARMC10;FBXL13	-0.5	-6.41	-0.38	7.38e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg01422370	chr2:73384389	NA	0.41	5.39	0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12476592	0.602	rs10176522	chr2:63722433	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-4.91	-0.3	1.66e-6	Childhood ear infection;
KIRP	cis	rs7221595	0.778	rs57625058	chr17:3914513	T/G	cg09597638	chr17:3907349	NA	0.59	6.04	0.36	5.6e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.74	-7.78	-0.44	1.95e-13	Vitiligo;
KIRP	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.48	6.2	0.37	2.42e-9	Platelet count;
KIRP	cis	rs9549260	0.564	rs12184871	chr13:41291928	C/A	cg21288729	chr13:41239152	FOXO1	0.55	7.24	0.42	5.6e-12	Red blood cell count;
KIRP	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.81	-10.54	-0.56	1.11e-21	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg17376030	chr22:41985996	PMM1	-0.6	-6.93	-0.4	3.67e-11	Vitiligo;
KIRP	cis	rs11997175	0.646	rs28785323	chr8:33736104	C/G	ch.8.33884649F	chr8:33765107	NA	0.62	7.79	0.45	1.82e-13	Body mass index;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15485817	chr17:79791312	FAM195B	0.5	6.48	0.38	4.88e-10	DNA methylation (variation);
KIRP	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg18404041	chr3:52824283	ITIH1	-0.45	-5.59	-0.34	5.99e-8	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.76	11.2	0.58	8.75e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.9	8.67	0.48	5.74e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-7.12	-0.41	1.18e-11	Morning vs. evening chronotype;
KIRP	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs9815354	0.812	rs73069208	chr3:41939198	C/T	cg03022575	chr3:42003672	ULK4	0.77	7.9	0.45	9.42e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18528640	chr1:155579964	MSTO1	0.45	6.09	0.36	4.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.78	11.23	0.58	6.77e-24	Bladder cancer;
KIRP	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.77	8.03	0.46	4e-14	Corneal astigmatism;
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.78	0.66	2.07e-32	Platelet count;
KIRP	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg07936489	chr17:37558343	FBXL20	-0.42	-5.22	-0.32	3.89e-7	Asthma;
KIRP	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	4.94	0.3	1.42e-6	Menarche (age at onset);
KIRP	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.41	0.51	3.58e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs6977660	0.619	rs10223937	chr7:19787697	C/T	cg07541023	chr7:19748670	TWISTNB	0.55	5.67	0.34	3.96e-8	Thyroid stimulating hormone;
KIRP	cis	rs1823913	0.599	rs56328712	chr2:192138533	C/G	cg12404831	chr2:192114017	MYO1B	0.53	7.39	0.43	2.22e-12	Obesity-related traits;
KIRP	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	ch.8.33884649F	chr8:33765107	NA	0.6	7.55	0.43	8.37e-13	Body mass index;
KIRP	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.43	-8.71	-0.49	4.6e-16	Longevity;
KIRP	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg20701182	chr2:24300061	SF3B14	0.91	10.13	0.54	2.24e-20	Lymphocyte counts;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13876163	chr1:45140495	C1orf228;TMEM53	0.58	7.09	0.41	1.42e-11	Smoking initiation;
KIRP	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg06521331	chr12:34319734	NA	-0.64	-7.58	-0.44	6.9e-13	Morning vs. evening chronotype;
KIRP	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-12.07	-0.61	1.22e-26	Exhaled nitric oxide output;
KIRP	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.26	13.43	0.65	3.21e-31	Eosinophil percentage of granulocytes;
KIRP	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24110177	chr3:50126178	RBM5	0.45	5.81	0.35	1.89e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.69	9.3	0.51	7.87e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg22437258	chr11:111473054	SIK2	0.57	6.55	0.39	3.33e-10	Primary sclerosing cholangitis;
KIRP	cis	rs3733418	0.860	rs35449092	chr4:165949676	C/G	cg10852876	chr4:165953100	TRIM60	-0.5	-5.39	-0.32	1.68e-7	Obesity-related traits;
KIRP	cis	rs12496230	0.794	rs6549425	chr3:66866811	T/A	cg04995300	chr3:66848608	NA	0.43	6.44	0.38	6.3e-10	Type 2 diabetes;
KIRP	cis	rs4764487	1.000	rs4764487	chr12:6332838	A/G	cg08284733	chr12:6341482	CD9	0.41	6.3	0.37	1.35e-9	Mean platelet volume;
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.13	11.75	0.6	1.35e-25	Platelet count;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.57	8.94	0.5	9.39e-17	Mean corpuscular volume;
KIRP	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.8	-11.16	-0.58	1.12e-23	Longevity;Endometriosis;
KIRP	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.97	0.45	6.06e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	1.0	9.91	0.53	1.08e-19	Psoriasis;
KIRP	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	9.09	0.5	3.37e-17	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.47	-0.33	1.08e-7	Lung cancer;
KIRP	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.97	16.88	0.73	5.57e-43	Menarche (age at onset);
KIRP	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg12855166	chr17:30846586	MYO1D	0.39	5.21	0.32	3.98e-7	Schizophrenia;
KIRP	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.85	10.27	0.55	7.91e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	0.38	4.87	0.3	2.02e-6	Type 2 diabetes;
KIRP	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	9.99	0.54	5.85e-20	Lung cancer in ever smokers;
KIRP	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.92e-18	Morning vs. evening chronotype;
KIRP	cis	rs13034020	0.641	rs12996153	chr2:61222736	A/G	cg18625361	chr2:61244694	PEX13;PUS10	-0.55	-4.98	-0.3	1.17e-6	Hodgkin's lymphoma;
KIRP	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7017914	0.967	rs34409123	chr8:71662116	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.42	8.7	0.49	4.79e-16	Vitiligo;
KIRP	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.08	0.46	2.87e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg01872077	chr2:219646372	CYP27A1	0.43	5.96	0.36	8.56e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.11	-0.46	2.44e-14	Idiopathic membranous nephropathy;
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg27532560	chr4:187881888	NA	-0.73	-12.39	-0.62	9.92e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4356975	0.563	rs4446391	chr4:69952082	A/T	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs17030434	1.000	rs75418383	chr4:154719084	A/G	cg14289246	chr4:154710475	SFRP2	-0.8	-9.61	-0.52	8.78e-19	Electrocardiographic conduction measures;
KIRP	cis	rs72848980	0.582	rs72848951	chr10:105277167	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.46	4.96	0.3	1.3e-6	White matter hyperintensity burden;
KIRP	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7319311	0.589	rs9588150	chr13:111025042	T/C	cg06243866	chr13:111019493	COL4A2	0.59	6.25	0.37	1.82e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.21	0.51	1.51e-17	Corneal astigmatism;
KIRP	cis	rs7674212	0.541	rs2623064	chr4:104030792	C/A	cg16532752	chr4:104119610	CENPE	-0.43	-5.31	-0.32	2.5e-7	Type 2 diabetes;
KIRP	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00791764	chr4:53727839	RASL11B	0.44	5.98	0.36	7.82e-9	Optic nerve measurement (cup area);
KIRP	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	6.58	0.39	2.88e-10	Neuroticism;
KIRP	cis	rs6466055	0.637	rs1144	chr7:104756355	T/C	cg04380332	chr7:105027541	SRPK2	-0.64	-9.75	-0.53	3.27e-19	Schizophrenia;
KIRP	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg17595323	chr11:93583763	C11orf90	-0.39	-6.6	-0.39	2.5e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.45	5.31	0.32	2.51e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg12598211	chr12:123634384	NA	-0.43	-5.22	-0.32	3.8e-7	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.6	7.9	0.45	9.02e-14	Mean corpuscular volume;
KIRP	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg04132472	chr17:19861366	AKAP10	0.42	5.84	0.35	1.62e-8	Schizophrenia;
KIRP	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03352830	chr11:487213	PTDSS2	0.75	6.23	0.37	2e-9	Body mass index;
KIRP	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9815354	0.812	rs73073352	chr3:41842184	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-6.73	-0.39	1.21e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.37	-5.84	-0.35	1.66e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.67	-5.65	-0.34	4.33e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg01798813	chr17:3906674	NA	0.62	8.81	0.49	2.23e-16	Type 2 diabetes;
KIRP	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.53	7.24	0.42	5.58e-12	Schizophrenia;
KIRP	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.77	-7.61	-0.44	5.92e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.3	0.58	4.05e-24	Cognitive test performance;
KIRP	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	0.93	10.34	0.55	4.76e-21	Triglycerides;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09529537	chr5:78531947	JMY	0.49	6.36	0.38	9.93e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-6.87	-0.4	5.14e-11	Total body bone mineral density;
KIRP	cis	rs4803468	0.934	rs8103531	chr19:41891974	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-18.5	-0.76	1.73e-48	Height;
KIRP	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11987759	chr7:65425863	GUSB	-0.56	-7.64	-0.44	4.94e-13	Aortic root size;
KIRP	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.49	7.05	0.41	1.77e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.68	9.39	0.51	4.23e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.74	-0.34	2.83e-8	Type 2 diabetes;
KIRP	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21545522	chr1:205238299	TMCC2	0.45	5.88	0.35	1.3e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.63	-7.2	-0.42	7.37e-12	Type 2 diabetes;
KIRP	cis	rs2908197	0.737	rs6978009	chr7:75992234	A/C	cg22830091	chr7:75961684	YWHAG	0.39	5.13	0.31	5.96e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs78438709	1.000	rs2281674	chr10:124130308	G/C	cg08224212	chr11:34196093	ABTB2	-0.96	-6.26	-0.37	1.74e-9	Headache;
KIRP	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.76	12.66	0.63	1.3e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12605564	chr3:129035140	H1FX;C3orf47	0.53	7.07	0.41	1.64e-11	Myopia (pathological);
KIRP	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg21419209	chr3:44054225	NA	-0.75	-9.36	-0.51	5.28e-18	Coronary artery disease;
KIRP	trans	rs34421088	0.560	rs11780851	chr8:11401116	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-7.61	-0.44	5.83e-13	Neuroticism;
KIRP	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.45	-6.44	-0.38	6.37e-10	Testicular germ cell tumor;
KIRP	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-5.6	-0.34	5.73e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.79	-0.4	8.5e-11	Aortic root size;
KIRP	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.61	9.95	0.54	7.82e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs4560672	0.938	rs977794	chr6:158538222	G/C	cg14029994	chr6:158589857	SERAC1;GTF2H5	0.57	5.02	0.31	9.69e-7	Smoking quantity;
KIRP	cis	rs9420	0.528	rs11229080	chr11:57399511	T/C	cg19752551	chr11:57585705	CTNND1	-0.6	-8.49	-0.48	2.02e-15	Schizophrenia;
KIRP	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.53	-0.38	3.75e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs876084	0.505	rs12541796	chr8:121112830	G/A	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.28	-0.32	2.9e-7	Obesity-related traits;
KIRP	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-5.05	-0.31	8.74e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs59868192	0.925	rs60772450	chr15:42247472	G/C	cg20935245	chr15:42234343	EHD4	-0.55	-5.4	-0.33	1.58e-7	White blood cell count;
KIRP	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.34	-0.42	3.04e-12	Type 2 diabetes;
KIRP	cis	rs6142102	0.961	rs2268080	chr20:32597716	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.69	0.39	1.46e-10	Skin pigmentation;
KIRP	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.37	0.38	9.25e-10	Bipolar disorder;
KIRP	cis	rs4262150	0.810	rs55648940	chr5:151951656	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.83	11.41	0.59	1.73e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg17340268	chr14:105411764	AHNAK2	0.4	5.19	0.31	4.36e-7	Rheumatoid arthritis;
KIRP	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.47	0.48	2.19e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.42	4.89e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.59	-6.86	-0.4	5.69e-11	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04437751	chr3:10206628	IRAK2	0.47	6.14	0.36	3.26e-9	Smoking initiation;
KIRP	cis	rs7084402	0.967	rs1658421	chr10:60331928	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg24110177	chr3:50126178	RBM5	0.55	7.06	0.41	1.66e-11	Body mass index;
KIRP	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.56	-15.48	-0.7	3.24e-38	Hip circumference adjusted for BMI;
KIRP	trans	rs7863100	0.711	rs71506891	chr9:18650613	G/C	cg13196806	chr10:133996309	JAKMIP3	0.6	6.11	0.36	3.93e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.02	-0.46	4.23e-14	Migraine;Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs10214930	0.647	rs6966587	chr7:27690363	C/T	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.51	6.97	0.41	2.85e-11	Mean corpuscular volume;
KIRP	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	12.09	0.61	1.03e-26	Lymphocyte percentage of white cells;
KIRP	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.7	10.43	0.55	2.5e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg11972305	chr2:233791962	NGEF	-0.38	-5.27	-0.32	2.98e-7	Schizophrenia;
KIRP	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.86	-10.9	-0.57	8.01e-23	Dupuytren's disease;
KIRP	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.71	9.99	0.54	5.98e-20	Aortic root size;
KIRP	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.43	5.41	0.33	1.5e-7	Aortic root size;
KIRP	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg06640241	chr16:89574553	SPG7	-0.43	-5.0	-0.3	1.1e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg07384165	chr1:10488281	NA	0.44	5.7	0.34	3.39e-8	Asthma;
KIRP	cis	rs7246657	0.550	rs9941475	chr19:38064517	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18252515	chr7:66147081	NA	-0.47	-5.57	-0.33	6.77e-8	Aortic root size;
KIRP	cis	rs4713675	0.565	rs4711343	chr6:33714548	G/A	cg15676125	chr6:33679581	C6orf125	0.42	5.34	0.32	2.08e-7	Plateletcrit;
KIRP	cis	rs10940138	0.501	rs6872437	chr5:67239886	C/T	ch.5.1281357F	chr5:67228439	NA	0.49	7.53	0.43	9.64e-13	Menarche (age at onset);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg16636182	chr19:5112710	KDM4B	0.48	6.92	0.4	3.93e-11	Serum protein levels (sST2);
KIRP	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg24110177	chr3:50126178	RBM5	0.55	7.07	0.41	1.6e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.96	14.67	0.68	1.99e-35	Coronary artery disease;
KIRP	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg05729581	chr11:3078854	CARS	0.4	5.16	0.31	5.16e-7	Longevity;
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg02996583	chr8:142237188	SLC45A4	-0.5	-6.06	-0.36	5e-9	Immature fraction of reticulocytes;
KIRP	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.88	12.81	0.63	4.08e-29	Mean platelet volume;
KIRP	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg23231163	chr10:75533350	FUT11	-0.34	-5.11	-0.31	6.6e-7	Inflammatory bowel disease;
KIRP	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.44	5.53	0.33	8e-8	Height;
KIRP	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.36	6.17e-9	Morning vs. evening chronotype;
KIRP	cis	rs13359291	0.841	rs11241673	chr5:122475348	G/T	cg16368670	chr5:122501738	PRDM6	-0.51	-6.25	-0.37	1.82e-9	Systolic blood pressure;
KIRP	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.95	16.34	0.72	3.97e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.23	0.32	3.66e-7	Asthma;
KIRP	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg19116668	chr7:99932089	PMS2L1	-0.54	-6.21	-0.37	2.28e-9	Coronary artery disease;
KIRP	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.77	0.44	2.18e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs57994353	0.568	rs10747044	chr9:139319129	G/T	cg21253087	chr9:139290292	SNAPC4	0.41	4.86	0.3	2.09e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.23	-0.64	1.57e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	cis	rs745080	0.658	rs10150835	chr14:53038016	C/G	cg23333723	chr14:53022898	GPR137C	-0.37	-5.16	-0.31	5.17e-7	Orofacial clefts;
KIRP	cis	rs12431939	0.948	rs12436158	chr14:51669891	G/A	cg23942311	chr14:51606299	NA	-0.61	-5.34	-0.32	2.1e-7	Cancer;
KIRP	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.65	8.85	0.49	1.81e-16	Alcohol dependence;
KIRP	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.6	-8.65	-0.48	6.62e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.53	5.78	0.35	2.3e-8	Lung cancer;
KIRP	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.89	14.0	0.67	3.85e-33	Mean corpuscular volume;
KIRP	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.72	-0.34	3.07e-8	Aortic root size;
KIRP	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.12	-21.33	-0.81	7.38e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21545522	chr1:205238299	TMCC2	0.5	6.57	0.39	3.02e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs698833	0.886	rs2927433	chr2:44580737	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.9	0.3	1.73e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg22974920	chr21:40686053	BRWD1	0.5	6.0	0.36	6.96e-9	Cognitive function;
KIRP	cis	rs73086581	1.000	rs11906274	chr20:3945536	G/A	cg02187196	chr20:3869020	PANK2	0.47	4.9	0.3	1.72e-6	Response to antidepressants in depression;
KIRP	trans	rs6841333	0.694	rs35882473	chr4:76988082	G/A	cg26475094	chr16:56891111	MIR138-2	-0.49	-6.08	-0.36	4.56e-9	Monokine induced by gamma interferon levels;
KIRP	cis	rs7916697	0.578	rs1900002	chr10:70004552	G/C	cg06988349	chr10:69991859	ATOH7	0.39	5.12	0.31	6.18e-7	Optic disc area;
KIRP	cis	rs34375054	0.573	rs12579211	chr12:125647752	C/T	cg25124228	chr12:125621409	AACS	-0.56	-5.63	-0.34	4.8e-8	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.98	14.09	0.67	1.86e-33	Cognitive function;
KIRP	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-0.83	-9.37	-0.51	4.92e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg22535103	chr8:58192502	C8orf71	-0.8	-5.37	-0.32	1.84e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09504829	chr8:126442440	TRIB1	0.47	6.56	0.39	3.15e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1546924	0.669	rs6687953	chr1:112293512	A/G	cg23955903	chr1:112298873	DDX20;C1orf183	0.46	5.87	0.35	1.43e-8	Body mass index;
KIRP	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg26513180	chr16:89883248	FANCA	0.7	5.72	0.34	3.06e-8	Skin colour saturation;
KIRP	cis	rs11166927	1.000	rs13256946	chr8:140805101	G/A	cg16909799	chr8:140841666	TRAPPC9	0.73	10.71	0.56	3.19e-22	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs75200691	0.818	rs58863591	chr8:13051717	C/T	cg26244164	chr8:12987449	DLC1	-0.35	-5.0	-0.3	1.08e-6	Emphysema imaging phenotypes;
KIRP	cis	rs679087	0.606	rs167318	chr12:29943124	T/C	cg14258853	chr12:29935411	TMTC1	-0.48	-4.94	-0.3	1.41e-6	Schizophrenia;
KIRP	cis	rs6882046	0.513	rs187270	chr5:88026870	C/T	cg24804195	chr5:87968844	LOC645323	-0.44	-5.83	-0.35	1.77e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.7	-0.34	3.4e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.18	-0.31	4.61e-7	Metabolite levels;
KIRP	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.7	9.6	0.52	9.53e-19	Longevity;
KIRP	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.5	-7.22	-0.42	6.43e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg14703610	chr5:56206110	C5orf35	0.49	6.79	0.4	8.3e-11	Coronary artery disease;
KIRP	cis	rs4073221	0.615	rs34827863	chr3:18207634	T/G	cg07694806	chr3:18168406	NA	-0.64	-5.95	-0.35	9.38e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg26681399	chr22:41777847	TEF	-0.5	-5.24	-0.32	3.5e-7	Vitiligo;
KIRP	cis	rs7224685	0.569	rs8082227	chr17:3991563	C/T	cg09695851	chr17:3907499	NA	0.58	5.28	0.32	2.78e-7	Type 2 diabetes;
KIRP	cis	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	5.92	0.35	1.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg17133734	chr15:86042851	AKAP13	-0.45	-5.66	-0.34	4.16e-8	Coronary artery disease;
KIRP	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg18404041	chr3:52824283	ITIH1	0.45	5.67	0.34	4.01e-8	Schizophrenia;
KIRP	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg09201719	chr10:104596890	CYP17A1	0.36	5.1	0.31	6.73e-7	Arsenic metabolism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05907398	chr15:56643419	NA	0.45	6.99	0.41	2.59e-11	C-reactive protein;
KIRP	trans	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.8200000000000003e-11	Bladder cancer;
KIRP	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg05340658	chr4:99064831	C4orf37	0.57	6.84	0.4	6.26e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs920590	0.573	rs12547934	chr8:19680736	T/C	cg03894339	chr8:19674705	INTS10	-0.52	-6.08	-0.36	4.54e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.53	-4.9	-0.3	1.77e-6	Other erythrocyte phenotypes;
KIRP	cis	rs8027181	1.000	rs8030477	chr15:73085815	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.37	4.91	0.3	1.67e-6	Triglyceride levels;
KIRP	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.65	7.12	0.41	1.16e-11	Large artery stroke;
KIRP	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.59	-7.01	-0.41	2.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16576597	chr16:28551801	NUPR1	0.37	5.26	0.32	3.09e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13053817	1.000	rs73405097	chr22:29855836	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.43	-5.28	-0.32	2.84e-7	Carotid atherosclerosis in HIV infection;
KIRP	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.47	-7.2	-0.42	7.45e-12	Coronary artery disease;
KIRP	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.86	10.73	0.56	2.78e-22	Coronary artery disease;
KIRP	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	1.1	21.84	0.81	1.6e-59	Height;
KIRP	cis	rs2274273	0.773	rs10147765	chr14:55827826	G/A	cg04306507	chr14:55594613	LGALS3	0.44	6.65	0.39	1.85e-10	Protein biomarker;
KIRP	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-1.11	-9.82	-0.53	2.1e-19	Coronary artery disease;
KIRP	cis	rs7180079	0.620	rs633275	chr15:64895319	T/G	cg15337035	chr15:64978493	NA	-0.46	-5.01	-0.3	1.04e-6	Monocyte count;
KIRP	cis	rs4664293	0.967	rs3940435	chr2:160494783	G/A	cg08347373	chr2:160653686	CD302	-0.4	-6.18	-0.37	2.62e-9	Monocyte percentage of white cells;
KIRP	cis	rs2905347	0.656	rs2051723	chr7:22665843	C/G	cg23521230	chr7:22704884	NA	0.44	4.99	0.3	1.15e-6	Major depression and alcohol dependence;
KIRP	cis	rs16912285	0.748	rs58504811	chr11:24252020	T/G	ch.11.24196551F	chr11:24239977	NA	0.82	9.28	0.51	9.07e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs72960926	0.744	rs67280742	chr6:75004753	T/C	cg03266952	chr6:74778945	NA	-0.65	-5.36	-0.32	1.91e-7	Metabolite levels (MHPG);
KIRP	cis	rs1440410	0.835	rs6829621	chr4:144052971	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.13e-10	Ischemic stroke;
KIRP	cis	rs6496044	0.507	rs2467096	chr15:86210678	G/A	cg10818794	chr15:86012489	AKAP13	0.42	5.77	0.35	2.33e-8	Interstitial lung disease;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.83	-14.43	-0.68	1.28e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.56	10.36	0.55	4.1e-21	Iron status biomarkers (transferrin levels);
KIRP	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.94	12.86	0.63	2.65e-29	Vitamin D levels;
KIRP	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.76	-7.54	-0.43	8.91e-13	Gut microbiome composition (summer);
KIRP	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg14784868	chr12:69753453	YEATS4	0.59	4.98	0.3	1.19e-6	Response to diuretic therapy;
KIRP	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	1.06	20.85	0.8	2.63e-56	Parkinson's disease;
KIRP	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.75	-9.13	-0.5	2.57e-17	Iron status biomarkers;
KIRP	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg21775007	chr8:11205619	TDH	-0.42	-5.3	-0.32	2.52e-7	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14160804	chr18:12703040	PSMG2;CEP76	0.49	6.07	0.36	4.7e-9	Parkinson's disease;
KIRP	cis	rs918629	0.530	rs11744881	chr5:95240865	A/T	cg16656078	chr5:95278638	ELL2	0.37	5.61	0.34	5.53e-8	IgG glycosylation;
KIRP	cis	rs62229266	0.804	rs56279140	chr21:37424361	C/T	cg08632701	chr21:37451849	NA	-0.43	-5.38	-0.32	1.72e-7	Mitral valve prolapse;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08330117	chr8:90770456	RIPK2	0.69	6.69	0.39	1.49e-10	Lung function (FEV1);
KIRP	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg06102403	chr20:30458708	TTLL9;DUSP15	0.56	5.99	0.36	7.4e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs6504622	0.818	rs11079742	chr17:45020128	A/G	cg24703533	chr17:45055318	NA	-0.37	-5.06	-0.31	8.2e-7	Orofacial clefts;
KIRP	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg24315340	chr6:146058215	EPM2A	0.4	4.95	0.3	1.41e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11195062	0.729	rs10787226	chr10:111981917	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.32	-5.17	-0.31	4.89e-7	Multiple myeloma;
KIRP	cis	rs12580194	0.593	rs4590978	chr12:55725086	G/T	cg19537932	chr12:55886519	OR6C68	-0.51	-6.55	-0.39	3.35e-10	Cancer;
KIRP	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg11833968	chr6:79620685	NA	-0.47	-7.05	-0.41	1.83e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg01879757	chr17:41196368	BRCA1	-0.73	-10.2	-0.55	1.34e-20	Menopause (age at onset);
KIRP	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg00094735	chr5:1949198	NA	0.45	5.47	0.33	1.13e-7	Gut microbiome composition (winter);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.31	0.42	3.73e-12	Lymphocyte counts;
KIRP	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.77	8.58	0.48	1.07e-15	Corneal astigmatism;
KIRP	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg16989719	chr2:238392110	NA	0.52	6.78	0.4	8.78e-11	Prostate cancer;
KIRP	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.85	-0.4	6.05e-11	Height;
KIRP	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.12	-0.41	1.16e-11	Response to antipsychotic treatment;
KIRP	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4073416	0.569	rs7147636	chr14:66011184	T/C	cg03016385	chr14:66212404	NA	-0.46	-5.82	-0.35	1.83e-8	N-glycan levels;
KIRP	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg18764771	chr6:116381957	FRK	0.18	4.92	0.3	1.61e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7560272	0.538	rs4852976	chr2:73936322	T/C	cg20560298	chr2:73613845	ALMS1	0.46	5.5	0.33	9.51e-8	Schizophrenia;
KIRP	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.59	-6.93	-0.4	3.76e-11	Bipolar disorder;
KIRP	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.55	7.23	0.42	5.97e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs853679	0.546	rs200953	chr6:27837267	T/C	cg26587870	chr6:27730563	NA	-0.64	-4.98	-0.3	1.17e-6	Depression;
KIRP	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg15556689	chr8:8085844	FLJ10661	0.64	8.07	0.46	3.17e-14	Retinal vascular caliber;
KIRP	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.7	-7.51	-0.43	1.12e-12	Body mass index;
KIRP	cis	rs4780401	0.728	rs8191290	chr16:11765954	C/A	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.09	-0.31	7.08e-7	Rheumatoid arthritis;
KIRP	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs4478137	0.931	rs7687423	chr4:164250797	C/T	cg06758707	chr4:164254230	NPY1R	-0.67	-8.75	-0.49	3.51e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.95	-11.48	-0.59	1.03e-24	Alzheimer's disease;
KIRP	cis	rs4262150	0.883	rs113790150	chr5:152272524	T/C	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.93e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.78	-10.31	-0.55	6.08e-21	Aortic root size;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05468351	chr5:21459598	LOC728411	0.6	6.89	0.4	4.52e-11	Lung cancer in ever smokers;
KIRP	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs56161922	0.908	rs55689175	chr1:207859699	G/C	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg01620082	chr3:125678407	NA	-0.85	-6.24	-0.37	1.88e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1983891	1.000	rs4714486	chr6:41542417	C/T	cg20194872	chr6:41519635	FOXP4	0.57	7.32	0.42	3.43e-12	Prostate cancer;
KIRP	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg20636351	chr8:55087400	NA	-0.62	-7.63	-0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg09264619	chr17:80180166	NA	-0.41	-5.93	-0.35	1.02e-8	Life satisfaction;
KIRP	cis	rs2019216	0.500	rs71371082	chr17:21889647	T/C	cg22648282	chr17:21454238	C17orf51	-0.52	-6.16	-0.37	3.01e-9	Pelvic organ prolapse;
KIRP	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg11839771	chr15:80205821	ST20	-0.43	-6.48	-0.38	5.11e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.08	0.41	1.49e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.57	-0.43	7.4e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs10760158	0.620	rs10739596	chr9:124090123	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.41	4.92	0.3	1.61e-6	Pulse pressure;
KIRP	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-10.59	-0.56	7.74e-22	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.92	15.43	0.7	5.12e-38	Chronic sinus infection;
KIRP	cis	rs959260	0.688	rs4789176	chr17:73352868	A/T	cg20590849	chr17:73267439	MIF4GD	-0.52	-5.33	-0.32	2.22e-7	Systemic lupus erythematosus;
KIRP	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg16736954	chr20:23401023	NAPB	0.65	5.11	0.31	6.49e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs55675132	0.510	rs10489526	chr1:115293527	C/A	cg12756093	chr1:115239321	AMPD1	0.65	6.41	0.38	7.5e-10	Schizophrenia;
KIRP	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.6	-7.69	-0.44	3.64e-13	Plateletcrit;Platelet count;
KIRP	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.74	0.71	4.2e-39	Bipolar disorder;
KIRP	cis	rs300774	0.925	rs6735974	chr2:179581	A/G	cg21211680	chr2:198530	NA	-0.59	-6.13	-0.36	3.48e-9	Suicide attempts in bipolar disorder;
KIRP	cis	rs882732	0.947	rs3762123	chr14:95029163	A/G	cg05186455	chr14:95027692	SERPINA4	-0.34	-5.17	-0.31	4.93e-7	Blood protein levels;
KIRP	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.85	-0.35	1.59e-8	Electroencephalogram traits;
KIRP	cis	rs4006360	0.524	rs4986678	chr17:39225182	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.59	-8.25	-0.47	9.85e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg19731401	chr7:2775893	GNA12	0.67	6.38	0.38	8.74e-10	Childhood ear infection;
KIRP	cis	rs4006360	0.575	rs7503162	chr17:39233899	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.91	-0.53	1.05e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs6838801	0.521	rs12501918	chr4:77560294	T/C	cg17476223	chr4:77663285	SHROOM3	-0.44	-6.6	-0.39	2.56e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.61	-0.39	2.42e-10	Aortic root size;
KIRP	cis	rs9653442	0.545	rs12987212	chr2:100761156	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.48	6.79	0.4	8.29e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.98	-0.36	7.94e-9	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg01721255	chr8:58191610	C8orf71	0.63	5.73	0.34	2.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg12826209	chr6:26865740	GUSBL1	0.8	5.4	0.33	1.55e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg04374321	chr14:90722782	PSMC1	0.94	16.17	0.72	1.45e-40	Mortality in heart failure;
KIRP	cis	rs7814319	0.700	rs35290014	chr8:97263930	T/C	cg20787634	chr8:97240163	UQCRB	-0.58	-7.8	-0.45	1.75e-13	Lung function (FVC);
KIRP	cis	rs2150410	0.833	rs6517529	chr21:40584598	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Colorectal cancer;
KIRP	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg14675211	chr2:100938903	LONRF2	0.48	6.33	0.37	1.16e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs694419	0.617	rs28654257	chr18:60159026	T/C	cg11881472	chr11:36442485	PRR5L	-0.34	-6.16	-0.37	3e-9	Serum albumin level;
KIRP	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg08134877	chr2:44394819	PPM1B	0.5	4.88	0.3	1.92e-6	Height;
KIRP	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.48	-6.2	-0.37	2.33e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.43	5.38	0.32	1.69e-7	Melanoma;
KIRP	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7756236	0.521	rs11969445	chr6:36625382	C/T	cg08179530	chr6:36648295	CDKN1A	-0.45	-5.82	-0.35	1.86e-8	QRS duration;
KIRP	cis	rs4700695	0.841	rs402100	chr5:65266125	A/G	cg21114390	chr5:65439923	SFRS12	0.57	5.84	0.35	1.62e-8	Facial morphology (factor 19);
KIRP	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg13444842	chr1:152974279	SPRR3	-0.35	-4.93	-0.3	1.53e-6	Inflammatory skin disease;
KIRP	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.78	-10.98	-0.57	4.32e-23	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg17764715	chr19:33622953	WDR88	0.67	8.38	0.47	4.1e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13135284	0.509	rs13137572	chr4:154852641	T/C	cg05574313	chr4:155338166	DCHS2	-0.37	-4.89	-0.3	1.8e-6	DNA methylation (parent-of-origin);
KIRP	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg11062466	chr8:58055876	NA	0.57	5.39	0.32	1.66e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9398803	0.624	rs1455737	chr6:126647204	T/G	cg19875578	chr6:126661172	C6orf173	0.4	5.05	0.31	8.53e-7	Male-pattern baldness;
KIRP	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-0.92	-7.11	-0.41	1.28e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.12	-0.41	1.21e-11	Triglycerides;
KIRP	cis	rs860295	0.812	rs11264363	chr1:155318308	C/G	cg02153340	chr1:155202674	NA	-0.39	-5.03	-0.31	9.33e-7	Body mass index;
KIRP	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg08132940	chr7:1081526	C7orf50	-0.44	-5.09	-0.31	7.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.55	7.43	0.43	1.78e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg07167872	chr1:205819463	PM20D1	0.55	6.04	0.36	5.81e-9	Parkinson's disease;
KIRP	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.34	-0.32	2.08e-7	Schizophrenia;
KIRP	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7998202	0.667	rs282576	chr13:113358864	A/G	cg02820901	chr13:113351484	ATP11A	0.65	6.12	0.36	3.7e-9	Glycated hemoglobin levels;
KIRP	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg00310523	chr12:86230176	RASSF9	0.4	6.13	0.36	3.55e-9	Major depressive disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06027112	chr8:49890360	NA	0.5	6.39	0.38	8.25e-10	Interleukin-4 levels;
KIRP	cis	rs2574975	0.679	rs2060560	chr10:52127483	C/T	cg10034176	chr10:52120283	SGMS1	-0.52	-6.95	-0.41	3.3e-11	Response to amphetamines;
KIRP	cis	rs16828019	0.777	rs16911	chr1:41498021	C/T	cg03387723	chr1:41708464	SCMH1	-0.77	-6.23	-0.37	2.01e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs155346	0.625	rs2560713	chr5:139358308	G/C	cg24724630	chr5:139362307	NRG2	-0.38	-4.99	-0.3	1.15e-6	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.24	-0.42	5.82e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7809615	0.901	rs11761528	chr7:99118801	C/T	cg24024660	chr7:99195788	NA	-0.57	-5.07	-0.31	7.78e-7	Blood metabolite ratios;
KIRP	cis	rs6545883	0.524	rs12713435	chr2:61499789	C/T	cg15711740	chr2:61764176	XPO1	0.43	5.4	0.33	1.55e-7	Tuberculosis;
KIRP	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs372883	0.509	rs1999322	chr21:30533959	A/T	cg24692254	chr21:30365293	RNF160	0.45	5.43	0.33	1.37e-7	Pancreatic cancer;
KIRP	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg16586182	chr3:47516702	SCAP	0.82	11.12	0.58	1.55e-23	Colorectal cancer;
KIRP	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15320075	chr8:145703422	NA	-0.61	-8.15	-0.46	1.88e-14	Age at first birth;
KIRP	cis	rs10128264	0.902	rs1250582	chr10:80973447	G/T	cg20744163	chr10:80999841	ZMIZ1	-0.29	-4.89	-0.3	1.79e-6	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs6466055	0.666	rs4730081	chr7:105006850	C/T	cg04380332	chr7:105027541	SRPK2	-0.63	-9.33	-0.51	6.6e-18	Schizophrenia;
KIRP	cis	rs1816752	0.905	rs4769348	chr13:24975113	G/A	cg02811702	chr13:24901961	NA	0.4	5.19	0.31	4.37e-7	Obesity-related traits;
KIRP	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs7572644	0.640	rs7593136	chr2:28017792	A/G	cg27432699	chr2:27873401	GPN1	0.49	5.83	0.35	1.7e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg05562828	chr17:3906858	NA	0.62	10.98	0.57	4.29e-23	Type 2 diabetes;
KIRP	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.62	-6.91	-0.4	4.23e-11	Neuroticism;
KIRP	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.12	-17.94	-0.75	1.35e-46	Primary sclerosing cholangitis;
KIRP	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.06	18.25	0.76	1.27e-47	Multiple system atrophy;
KIRP	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.36	-0.47	4.69e-15	Mean corpuscular volume;
KIRP	cis	rs8032158	0.963	rs16976600	chr15:56154635	C/T	cg02198044	chr15:56286336	NEDD4	-0.43	-5.05	-0.31	8.55e-7	Keloid;
KIRP	cis	rs2150410	0.915	rs1541101	chr21:40603930	C/T	cg11890956	chr21:40555474	PSMG1	0.75	5.38	0.32	1.77e-7	Temperament (bipolar disorder);
KIRP	cis	rs10782582	0.609	rs1796815	chr1:76396793	T/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.93	-0.35	1.03e-8	Daytime sleep phenotypes;
KIRP	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-11.1	-0.58	1.77e-23	Morning vs. evening chronotype;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg12427896	chr2:111880694	BCL2L11	0.56	6.75	0.4	1.04e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07640645	chr4:175204879	FBXO8;KIAA1712	-0.53	-6.97	-0.41	2.94e-11	Interleukin-4 levels;
KIRP	cis	rs597583	0.806	rs1940039	chr11:117393102	C/T	cg27161313	chr11:117392002	DSCAML1	-0.54	-6.12	-0.36	3.72e-9	Putamen volume;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-1.03	-12.17	-0.61	5.31e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs113084984	0.718	rs7609384	chr2:11683631	A/G	cg07314298	chr2:11723111	GREB1	0.39	5.12	0.31	6.04e-7	Breast cancer;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11987759	chr7:65425863	GUSB	-0.61	-8.17	-0.46	1.66e-14	Aortic root size;
KIRP	cis	rs375066	0.592	rs349050	chr19:44301425	G/A	cg11993925	chr19:44307056	LYPD5	-0.36	-5.01	-0.3	1.06e-6	Breast cancer;
KIRP	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg17425144	chr1:10567563	PEX14	0.4	7.06	0.41	1.73e-11	Hand grip strength;
KIRP	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	6.89	0.4	4.54e-11	Height;
KIRP	cis	rs17453880	0.929	rs6886482	chr5:152031320	G/C	cg12297329	chr5:152029980	NA	-0.72	-11.2	-0.58	8.35e-24	Subjective well-being;
KIRP	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg14132834	chr19:41945861	ATP5SL	-0.59	-8.05	-0.46	3.64e-14	Height;
KIRP	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.77	9.69	0.53	4.97e-19	Menarche (age at onset);
KIRP	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg09491104	chr22:46646882	C22orf40	-0.52	-5.99	-0.36	7.41e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2018683	0.932	rs4386882	chr7:28989270	C/T	cg27487796	chr7:28973253	NA	-0.21	-4.93	-0.3	1.53e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20135002	chr11:47629003	NA	-0.44	-4.95	-0.3	1.37e-6	Subjective well-being;
KIRP	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	12.0	0.61	2.04e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	11.27	0.58	5.18e-24	Smoking behavior;
KIRP	cis	rs8179	0.700	rs42043	chr7:92247333	A/G	cg15732164	chr7:92237376	CDK6	-0.52	-6.8	-0.4	7.95e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	11.53	0.59	7e-25	Bone mineral density;
KIRP	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg06026331	chr20:60912101	LAMA5	0.79	9.39	0.51	4.39e-18	Colorectal cancer;
KIRP	cis	rs12313068	0.709	rs11829777	chr12:110503770	T/C	cg12870014	chr12:110450643	ANKRD13A	0.56	7.38	0.43	2.48e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg18209359	chr17:80159595	CCDC57	-0.42	-5.56	-0.33	7.18e-8	Life satisfaction;
KIRP	cis	rs9409565	0.826	rs9409767	chr9:97228524	T/C	cg04523069	chr9:97136363	HIATL1	0.49	6.46	0.38	5.63e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs892085	0.559	rs11670097	chr19:10877127	T/C	cg17710535	chr19:10819994	QTRT1	-0.47	-5.75	-0.34	2.7e-8	Psoriasis vulgaris;Psoriasis;
KIRP	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg11970804	chr8:8084126	NA	-0.4	-5.22	-0.32	3.72e-7	Neuroticism;
KIRP	cis	rs2599510	0.783	rs2710630	chr2:32765997	A/C	cg02381751	chr2:32503542	YIPF4	-0.45	-5.06	-0.31	8.32e-7	Interleukin-18 levels;
KIRP	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg08222618	chr4:941054	TMEM175	-0.57	-4.88	-0.3	1.92e-6	Parkinson's disease;
KIRP	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.01	15.28	0.7	1.66e-37	Orofacial clefts;
KIRP	cis	rs7646501	0.510	rs6801153	chr3:24113697	A/G	cg21910673	chr3:24143257	LOC152024	-0.36	-4.87	-0.3	1.95e-6	Cognitive ability;Intelligence;
KIRP	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.06	-0.36	5.14e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-9.1	-0.5	3.27e-17	Neuroticism;
KIRP	cis	rs858239	0.600	rs6967475	chr7:23128982	C/T	cg23682824	chr7:23144976	KLHL7	0.44	5.25	0.32	3.34e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01008834	chr1:150207620	ANP32E	0.49	6.08	0.36	4.55e-9	Parkinson's disease;
KIRP	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.85	8.07	0.46	3.15e-14	Systolic blood pressure;
KIRP	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg23127183	chr11:57508653	C11orf31	-0.45	-6.17	-0.37	2.78e-9	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-1.19	-13.12	-0.64	3.72e-30	Breast cancer;
KIRP	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg24375607	chr4:120327624	NA	0.39	4.85	0.3	2.17e-6	Diastolic blood pressure;
KIRP	cis	rs6921919	0.583	rs6922429	chr6:28381345	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.28e-7	Bipolar disorder;
KIRP	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.38	-0.55	3.49e-21	Colorectal cancer;
KIRP	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg27068330	chr11:65405492	SIPA1	0.39	5.34	0.32	2.08e-7	Acne (severe);
KIRP	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg16917193	chr12:54089295	NA	0.85	16.18	0.72	1.32e-40	Height;
KIRP	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg23335576	chr14:104009727	NA	0.39	5.59	0.34	6.17e-8	Body mass index;
KIRP	cis	rs4666002	0.789	rs6727388	chr2:27932587	A/G	cg27432699	chr2:27873401	GPN1	0.55	5.27	0.32	2.96e-7	Phospholipid levels (plasma);
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.9	-0.35	1.21e-8	Life satisfaction;
KIRP	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg06156847	chr2:113672199	IL1F7	-0.43	-6.07	-0.36	4.92e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.54	7.29	0.42	4.17e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.66	6.56	0.39	3.21e-10	Eotaxin levels;
KIRP	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg13880726	chr7:1868755	MAD1L1	-0.51	-5.71	-0.34	3.22e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg25019033	chr10:957182	NA	-0.59	-7.24	-0.42	5.86e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg01214346	chr17:406501	NA	0.4	4.84	0.3	2.25e-6	Prostate cancer;
KIRP	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg01721255	chr8:58191610	C8orf71	0.55	5.8	0.35	2.05e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6456156	1.000	rs6911766	chr6:167523170	T/G	cg07741184	chr6:167504864	NA	-0.21	-5.02	-0.3	9.88e-7	Primary biliary cholangitis;
KIRP	cis	rs7508	0.618	rs13266287	chr8:17871598	T/A	cg01800426	chr8:17659068	MTUS1	-0.51	-6.52	-0.38	3.94e-10	Atrial fibrillation;
KIRP	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.69	-6.02	-0.36	6.38e-9	Body mass index;
KIRP	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-5.03	-0.31	9.42e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.49	6.12	0.36	3.67e-9	Subjective well-being;
KIRP	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.15	-0.37	3.07e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg04733989	chr22:42467013	NAGA	-0.4	-5.09	-0.31	7.24e-7	Intelligence;
KIRP	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg25039879	chr17:56429692	SUPT4H1	0.57	5.09	0.31	7.23e-7	Cognitive test performance;
KIRP	cis	rs8079658	1.000	rs17695630	chr17:63801593	G/C	cg18091269	chr17:63822838	CCDC46	-0.56	-7.77	-0.44	2.06e-13	Post bronchodilator FEV1;
KIRP	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg09201719	chr10:104596890	CYP17A1	0.39	5.67	0.34	3.91e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7666738	0.546	rs6827131	chr4:98744810	C/G	cg05340658	chr4:99064831	C4orf37	0.66	7.67	0.44	4.04e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg00792783	chr2:198669748	PLCL1	0.47	5.4	0.33	1.6e-7	Dermatomyositis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09379601	chr19:12992224	DNASE2	0.48	6.61	0.39	2.39e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14039299	chr9:135251409	TTF1	0.58	6.49	0.38	4.64e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.88	10.1	0.54	2.66e-20	Eosinophil percentage of granulocytes;
KIRP	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	trans	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg07577569	chr20:40245965	CHD6	-0.44	-6.02	-0.36	6.15e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4908768	0.906	rs12401496	chr1:8600401	C/T	cg03610117	chr1:8450231	RERE	-0.5	-5.22	-0.32	3.72e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3026101	0.671	rs1806265	chr17:5320044	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.5	6.49	0.38	4.58e-10	Body mass index;
KIRP	cis	rs7671900	0.965	rs9996312	chr4:88285222	T/A	cg23841344	chr4:88312519	HSD17B11	-0.53	-7.08	-0.41	1.47e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2270927	0.510	rs246814	chr5:75599208	C/T	cg13563193	chr19:33072644	PDCD5	0.94	6.66	0.39	1.73e-10	Mean corpuscular volume;
KIRP	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg21252483	chr19:49399788	TULP2	-0.47	-6.3	-0.37	1.35e-9	Red cell distribution width;
KIRP	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg08999081	chr20:33150536	PIGU	-0.39	-5.04	-0.31	8.85e-7	Height;
KIRP	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg17376030	chr22:41985996	PMM1	-0.78	-8.4	-0.47	3.55e-15	Vitiligo;
KIRP	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12311346	chr5:56204834	C5orf35	-0.46	-5.85	-0.35	1.56e-8	Coronary artery disease;
KIRP	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg26876637	chr1:152193138	HRNR	0.75	10.04	0.54	4.2e-20	Atopic dermatitis;
KIRP	cis	rs812925	0.519	rs2922089	chr2:61625129	T/G	cg15711740	chr2:61764176	XPO1	0.47	5.92	0.35	1.05e-8	Immature fraction of reticulocytes;
KIRP	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.93	-9.93	-0.54	9.05e-20	Body mass index;
KIRP	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.5	6.19	0.37	2.53e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.72	-0.34	3.14e-8	Colorectal cancer;
KIRP	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg10047753	chr17:41438598	NA	1.12	17.9	0.75	1.83e-46	Menopause (age at onset);
KIRP	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg07395648	chr5:131743802	NA	-0.57	-8.35	-0.47	5.01e-15	Blood metabolite levels;
KIRP	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.54	-5.55	-0.33	7.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs925255	0.682	rs7590263	chr2:28645802	C/T	cg01273330	chr2:28605224	NA	-0.32	-5.61	-0.34	5.39e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.29	0.51	8.32e-18	Cognitive test performance;
KIRP	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9596863	0.948	rs9568907	chr13:54335565	C/G	ch.13.53330881F	chr13:54432880	NA	0.6	5.79	0.35	2.16e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.76	-0.44	2.22e-13	Retinal vascular caliber;
KIRP	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.45	5.87	0.35	1.41e-8	Crohn's disease;
KIRP	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg26681399	chr22:41777847	TEF	-0.5	-5.48	-0.33	1.03e-7	Vitiligo;
KIRP	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.48	6.67	0.39	1.66e-10	Lewy body disease;
KIRP	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg15507776	chr3:136538369	TMEM22	0.4	5.41	0.33	1.47e-7	Neuroticism;
KIRP	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg04362960	chr10:104952993	NT5C2	0.64	7.52	0.43	1.01e-12	Arsenic metabolism;
KIRP	cis	rs9533799	1.000	rs11620543	chr13:44798371	G/A	cg19190762	chr13:44806055	NA	0.59	7.99	0.45	5.33e-14	Amyotrophic lateral sclerosis;
KIRP	cis	rs939574	0.722	rs55951006	chr2:220132151	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.9	6.7	0.39	1.41e-10	Platelet distribution width;
KIRP	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.42	-8.4	-0.47	3.47e-15	Longevity;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg09597638	chr17:3907349	NA	0.75	14.34	0.67	2.62e-34	Type 2 diabetes;
KIRP	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg05457628	chr5:178986728	RUFY1	0.55	8.35	0.47	4.93e-15	Lung cancer;
KIRP	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.41	-0.33	1.46e-7	Neuroticism;
KIRP	cis	rs3617	0.521	rs11713763	chr3:53160360	G/A	cg05315796	chr3:52349193	DNAH1	0.37	5.1	0.31	6.78e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg18209359	chr17:80159595	CCDC57	-0.39	-5.14	-0.31	5.69e-7	Life satisfaction;
KIRP	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	1.06	20.1	0.79	8.22e-54	Height;
KIRP	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.9	12.65	0.63	1.41e-28	Coronary artery disease;
KIRP	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg05800321	chr8:143867799	LY6D	-0.3	-4.89	-0.3	1.86e-6	Urinary tract infection frequency;
KIRP	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg13319975	chr6:146136371	FBXO30	0.41	5.63	0.34	4.89e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg23845249	chr11:68861649	NA	0.56	7.93	0.45	7.79e-14	Blond vs. brown hair color;
KIRP	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.96	12.84	0.63	3.29e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg09333952	chr1:22778738	ZBTB40	0.55	6.77	0.4	9.37e-11	DNA methylation (variation);
KIRP	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.74	-8.83	-0.49	2.04e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18252515	chr7:66147081	NA	0.42	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg09936142	chr19:10668400	KRI1	-0.44	-5.14	-0.31	5.52e-7	Inflammatory skin disease;
KIRP	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg19650706	chr5:140594406	PCDHB13	-0.46	-5.05	-0.31	8.78e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.34	5.33	0.32	2.2e-7	QRS complex (12-leadsum);
KIRP	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.57	7.41	0.43	2.03e-12	Schizophrenia;
KIRP	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-0.76	-7.74	-0.44	2.54e-13	Gout;
KIRP	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.77	0.44	2.16e-13	Coffee consumption (cups per day);
KIRP	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-8.94	-0.5	9.46e-17	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20701145	chr12:12714809	DUSP16	0.49	6.49	0.38	4.63e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19524238	chr7:2802976	GNA12	-0.33	-4.84	-0.3	2.26e-6	Height;
KIRP	cis	rs8453	0.639	rs12128420	chr1:115335925	C/T	cg12756093	chr1:115239321	AMPD1	-0.54	-5.88	-0.35	1.34e-8	Autism;
KIRP	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg01631408	chr1:248437212	OR2T33	-0.69	-9.25	-0.51	1.11e-17	Common traits (Other);
KIRP	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.46	-5.78	-0.35	2.29e-8	Blood metabolite levels;
KIRP	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg06647332	chr5:131281008	NA	0.45	5.07	0.31	7.86e-7	Life satisfaction;
KIRP	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg05861140	chr6:150128134	PCMT1	-0.5	-7.13	-0.41	1.09e-11	Lung cancer;
KIRP	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.02	0.5	5.61e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg24375607	chr4:120327624	NA	-0.47	-5.11	-0.31	6.36e-7	Corneal astigmatism;
KIRP	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-5.17	-0.31	4.83e-7	Common traits (Other);
KIRP	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.37	4.99	0.3	1.16e-6	Dupuytren's disease;
KIRP	cis	rs1050631	1.000	rs1789514	chr18:33692654	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.46	5.78	0.35	2.29e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.9	0.53	1.13e-19	Ileal carcinoids;
KIRP	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	0.6	5.13	0.31	6.01e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg24101359	chr6:42928495	GNMT	0.51	7.38	0.43	2.39e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg24881330	chr22:46731750	TRMU	0.65	4.93	0.3	1.48e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg01879757	chr17:41196368	BRCA1	-0.77	-10.53	-0.56	1.23e-21	Menopause (age at onset);
KIRP	cis	rs4594175	0.892	rs10135768	chr14:51671017	G/T	cg23942311	chr14:51606299	NA	0.45	6.01	0.36	6.64e-9	Cancer;
KIRP	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.44	6.04	0.36	5.72e-9	Testicular germ cell tumor;
KIRP	cis	rs7608910	0.556	rs10181042	chr2:61224259	A/G	cg10580144	chr2:61372316	C2orf74	-0.38	-5.04	-0.31	8.84e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs965513	1.000	rs7847663	chr9:100544868	C/T	cg13688889	chr9:100608707	NA	-0.59	-7.48	-0.43	1.32e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.95	-15.29	-0.7	1.53e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.38	4.91	0.3	1.68e-6	Melanoma;
KIRP	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.9	0.3	1.7e-6	Renal cell carcinoma;
KIRP	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22509189	chr2:225307070	NA	-0.52	-5.99	-0.36	7.55e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs12780845	0.540	rs3824632	chr10:17230999	A/G	cg01003015	chr10:17271136	VIM	0.42	4.96	0.3	1.33e-6	Homocysteine levels;
KIRP	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	1.07	19.6	0.78	3.78e-52	Caffeine consumption;
KIRP	cis	rs11252926	0.732	rs10904541	chr10:744008	A/G	cg08603382	chr10:743973	NA	-0.7	-10.72	-0.56	3.06e-22	Psychosis in Alzheimer's disease;
KIRP	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.57	6.57	0.39	2.97e-10	Coronary artery disease;
KIRP	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg07382826	chr16:28625726	SULT1A1	0.46	5.1	0.31	6.82e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.45	-0.38	5.77e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6973256	0.901	rs2991231	chr7:133321915	T/C	cg10665199	chr7:133106180	EXOC4	-0.49	-6.24	-0.37	1.87e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6838801	1.000	rs1986966	chr4:77558777	C/T	cg17476223	chr4:77663285	SHROOM3	-0.48	-6.54	-0.38	3.48e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.4	-0.43	2.14e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs8103278	0.860	rs11669073	chr19:46324880	C/T	cg14061069	chr19:46274453	DMPK	-0.59	-8.87	-0.49	1.58e-16	Coronary artery disease;
KIRP	cis	rs7714584	1.000	rs12652003	chr5:150231945	T/C	cg22134413	chr5:150180641	NA	0.81	6.9	0.4	4.32e-11	Crohn's disease;
KIRP	cis	rs6545883	0.894	rs2600672	chr2:61536740	A/G	cg15711740	chr2:61764176	XPO1	-0.61	-8.12	-0.46	2.2e-14	Tuberculosis;
KIRP	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg12560992	chr17:57184187	TRIM37	-0.97	-13.22	-0.64	1.65e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs8067545	0.512	rs34726000	chr17:19887821	G/T	cg04132472	chr17:19861366	AKAP10	0.48	5.66	0.34	4.3e-8	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.89	0.35	1.25e-8	Lung cancer;
KIRP	cis	rs7624766	0.555	rs2049214	chr3:160512501	C/T	cg22637730	chr3:160473554	PPM1L	0.44	5.53	0.33	8.07e-8	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs9905704	0.718	rs1271647	chr17:56655872	G/C	cg12560992	chr17:57184187	TRIM37	-0.53	-4.92	-0.3	1.61e-6	Testicular germ cell tumor;
KIRP	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg12311346	chr5:56204834	C5orf35	-0.41	-5.62	-0.34	5.13e-8	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs11195062	0.693	rs11195033	chr10:111980235	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.32	-5.17	-0.31	4.89e-7	Multiple myeloma;
KIRP	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg09788416	chr12:39539408	NA	0.4	5.21	0.32	4.02e-7	Morning vs. evening chronotype;
KIRP	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	0.97	10.96	0.57	4.88e-23	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg16102102	chr5:83017553	HAPLN1	-0.81	-10.56	-0.56	9.38e-22	Prostate cancer;
KIRP	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg02336718	chr17:17403227	NA	0.33	5.19	0.31	4.42e-7	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14522873	chr20:21283801	XRN2	0.49	6.76	0.4	1.02e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg25486957	chr4:152246857	NA	-0.43	-5.16	-0.31	5.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.72	-10.61	-0.56	6.48e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	9.25	0.51	1.11e-17	Bone mineral density;
KIRP	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.48	7.27	0.42	4.87e-12	Resting heart rate;
KIRP	cis	rs9308731	1.000	rs1980045	chr2:111904541	A/G	cg23466623	chr2:111982296	NA	-0.39	-4.95	-0.3	1.36e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.33	-0.32	2.22e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg19507638	chr5:93509721	C5orf36	-0.55	-5.11	-0.31	6.36e-7	Diabetic retinopathy;
KIRP	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.44	5.84	0.35	1.66e-8	Mean corpuscular volume;
KIRP	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	10.22	0.55	1.14e-20	Bone mineral density;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21010435	chr7:157208882	DNAJB6	0.47	6.13	0.36	3.52e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.41	-0.33	1.51e-7	Neuroticism;
KIRP	trans	rs208520	0.909	rs62414639	chr6:67023706	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.35	0.42	2.88e-12	Exhaled nitric oxide output;
KIRP	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.5	-4.89	-0.3	1.84e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs7870753	0.735	rs34476861	chr9:99247166	T/G	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg23100626	chr2:96804247	ASTL	0.44	5.64	0.34	4.65e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg17304646	chr3:125932534	NA	0.3	5.2	0.31	4.28e-7	Metabolite levels;
KIRP	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.43	-6.15	-0.37	3.03e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg00319359	chr11:70116639	PPFIA1	0.57	5.95	0.35	8.96e-9	Coronary artery disease;
KIRP	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-5.89	-0.35	1.28e-8	Vitamin D levels;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.79	6.85	0.4	5.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3822411	0.541	rs1080438	chr5:10740747	C/T	cg14521931	chr5:10832172	NA	0.51	6.24	0.37	1.89e-9	Sum eosinophil basophil counts;
KIRP	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.68	-7.2	-0.42	7.29e-12	Alcohol dependence;
KIRP	cis	rs6832769	0.961	rs11947476	chr4:56339751	T/C	cg09317128	chr4:56265301	TMEM165	0.55	7.44	0.43	1.63e-12	Personality dimensions;
KIRP	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	8.64	0.48	7.44e-16	Schizophrenia;
KIRP	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.72	8.31	0.47	6.6e-15	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07925619	chr17:39913753	JUP	0.45	6.04	0.36	5.73e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg06121193	chr1:90282411	NA	-0.48	-6.73	-0.39	1.2e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.69	-8.71	-0.49	4.41e-16	Body mass index;
KIRP	cis	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.72	-0.39	1.28e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.49	5.19	0.31	4.43e-7	Breast cancer;
KIRP	cis	rs8014252	0.711	rs59044667	chr14:71043704	A/G	cg19730268	chr14:71022823	NA	-0.71	-6.29	-0.37	1.44e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-4.89	-0.3	1.81e-6	Educational attainment;
KIRP	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg23845249	chr11:68861649	NA	0.56	8.0	0.45	4.83e-14	Blond vs. brown hair color;
KIRP	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05347473	chr6:146136440	FBXO30	0.59	8.52	0.48	1.59e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09331632	chr6:111303308	RPF2	-0.43	-5.77	-0.35	2.36e-8	Metabolic traits;
KIRP	cis	rs617219	0.710	rs10054122	chr5:78581371	A/T	cg22188827	chr5:78429774	NA	0.39	4.92	0.3	1.56e-6	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-7.03	-0.41	2.01e-11	Vitiligo;
KIRP	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-5.22	-0.32	3.84e-7	Skin colour saturation;
KIRP	cis	rs12595433	1.000	rs4775593	chr15:63295172	C/A	cg03196360	chr15:63270641	NA	-0.28	-5.06	-0.31	8.26e-7	Obesity-related traits;
KIRP	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg09455208	chr3:40491958	NA	0.34	5.75	0.34	2.69e-8	Renal cell carcinoma;
KIRP	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Corneal astigmatism;
KIRP	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.49	-0.43	1.27e-12	Mood instability;
KIRP	trans	rs12709013	0.591	rs2406234	chr16:58835744	G/A	cg12115882	chr11:133449267	NA	-0.44	-6.04	-0.36	5.59e-9	Blood metabolite ratios;
KIRP	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg23752985	chr2:85803571	VAMP8	0.6	8.85	0.49	1.77e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6840360	0.573	rs7692939	chr4:152258455	C/T	cg25486957	chr4:152246857	NA	-0.44	-5.6	-0.34	5.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.15	0.41	9.81e-12	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10322360	chr1:10535135	PEX14	0.49	6.09	0.36	4.25e-9	Parkinson's disease;
KIRP	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-8.39	-0.47	3.87e-15	Coronary artery disease;
KIRP	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.96	11.18	0.58	1.01e-23	Corneal astigmatism;
KIRP	cis	rs526231	0.543	rs34807	chr5:102428522	T/C	cg23492399	chr5:102201601	PAM	-0.52	-5.74	-0.34	2.76e-8	Primary biliary cholangitis;
KIRP	cis	rs13343954	0.778	rs10426551	chr19:33541514	A/G	cg27124370	chr19:33622961	WDR88	0.6	6.73	0.39	1.21e-10	Colorectal cancer;
KIRP	cis	rs6840360	0.582	rs4696259	chr4:152310788	A/G	cg25486957	chr4:152246857	NA	-0.42	-5.11	-0.31	6.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10463316	0.780	rs6894899	chr5:150775913	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.61	-0.39	2.41e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.96	8.08	0.46	2.93e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg11569703	chr11:65557185	OVOL1	0.78	15.18	0.7	3.57e-37	Acne (severe);
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg11410718	chr7:27170412	HOXA4	-0.42	-5.9	-0.35	1.18e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.53	-8.14	-0.46	1.98e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4776059	1.000	rs12914047	chr15:52970993	G/A	cg25063058	chr15:52860530	ARPP19	0.55	5.9	0.35	1.17e-8	Schizophrenia;
KIRP	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg12573674	chr2:1569213	NA	-0.57	-5.92	-0.35	1.1e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg25019033	chr10:957182	NA	-0.71	-9.32	-0.51	6.92e-18	Eosinophil percentage of granulocytes;
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.63	9.52	0.52	1.68e-18	Lung cancer;
KIRP	cis	rs9905704	0.918	rs302857	chr17:56692387	C/G	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	cis	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg06637938	chr14:75390232	RPS6KL1	0.43	6.02	0.36	6.3e-9	Height;
KIRP	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg11503966	chr20:62272292	STMN3	0.47	6.51	0.38	4.1e-10	Atopic dermatitis;
KIRP	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.61	-6.48	-0.38	4.96e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.59	-7.17	-0.42	8.79e-12	Arsenic metabolism;
KIRP	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg26384229	chr12:38710491	ALG10B	0.51	6.6	0.39	2.52e-10	Resting heart rate;
KIRP	cis	rs13401104	0.796	rs72620808	chr2:237114372	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg00409905	chr10:38381863	ZNF37A	0.58	5.85	0.35	1.55e-8	Obesity (extreme);
KIRP	cis	rs2046867	0.568	rs1553376	chr3:72828151	T/C	cg25664220	chr3:72788482	NA	-0.48	-7.29	-0.42	4.26e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.64	7.47	0.43	1.38e-12	Eosinophil percentage of white cells;
KIRP	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg02980000	chr4:1222292	CTBP1	0.82	9.29	0.51	8.64e-18	Systolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03207439	chr20:9495199	C20orf103	-0.42	-6.17	-0.37	2.79e-9	Interleukin-4 levels;
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg05562828	chr17:3906858	NA	0.72	14.35	0.68	2.41e-34	Type 2 diabetes;
KIRP	cis	rs2594989	0.832	rs13325556	chr3:11566961	T/G	cg01796438	chr3:11312864	ATG7	0.66	7.79	0.44	1.88e-13	Circulating chemerin levels;
KIRP	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.61	-6.58	-0.39	2.8e-10	DNA methylation (variation);
KIRP	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg19338460	chr6:170058176	WDR27	-0.55	-6.53	-0.38	3.76e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9815354	0.951	rs9817510	chr3:41813108	C/T	cg03022575	chr3:42003672	ULK4	0.58	6.82	0.4	7.12e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs830233	0.689	rs62383297	chr5:165434238	C/A	cg13976338	chr5:165423657	NA	-0.73	-7.75	-0.44	2.41e-13	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs12220238	0.841	rs11000952	chr10:76037336	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.27	0.37	1.64e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.93	0.3	1.49e-6	Menarche (age at onset);
KIRP	cis	rs35661897	0.920	rs12476220	chr2:227312391	A/C	cg03426602	chr2:227312417	NA	0.56	6.91	0.4	4.09e-11	Urinary tract infection frequency;
KIRP	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20135002	chr11:47629003	NA	-0.48	-5.76	-0.34	2.51e-8	Subjective well-being;
KIRP	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg05472934	chr7:22766657	IL6	0.57	6.52	0.38	4.07e-10	Lung cancer;
KIRP	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.86	-10.93	-0.57	6.31e-23	Parkinson's disease;
KIRP	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.23	-0.32	3.67e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.55	8.04	0.46	3.76e-14	Huntington's disease progression;
KIRP	cis	rs929596	0.564	rs2741038	chr2:234563998	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-5.58	-0.34	6.31e-8	Total bilirubin levels in HIV-1 infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23316886	chr14:37186181	SLC25A21	0.45	6.21	0.37	2.18e-9	Interleukin-4 levels;
KIRP	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg18132916	chr6:79620363	NA	-0.41	-5.72	-0.34	3.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-7.03	-0.41	2.05e-11	Neutrophil percentage of white cells;
KIRP	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13401104	0.796	rs1377448	chr2:237119886	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7923609	0.841	rs7920036	chr10:65293860	T/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.66	-0.34	4.17e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg27144592	chr16:783916	NARFL	0.37	5.11	0.31	6.5e-7	Height;
KIRP	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg14558114	chr2:88469736	THNSL2	0.65	5.3	0.32	2.51e-7	Plasma clusterin levels;
KIRP	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.68	-8.85	-0.49	1.8e-16	Personality dimensions;
KIRP	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Hypertriglyceridemia;
KIRP	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.82	0.81	1.91e-59	Prudent dietary pattern;
KIRP	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.57	8.17	0.46	1.66e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg21734707	chr17:3908241	ZZEF1	-0.59	-8.63	-0.48	7.67e-16	Type 2 diabetes;
KIRP	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg15448220	chr1:150897856	SETDB1	-0.39	-5.09	-0.31	7.18e-7	Tonsillectomy;
KIRP	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.51e-19	Prudent dietary pattern;
KIRP	cis	rs11997175	0.766	rs6995220	chr8:33708919	C/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.84	0.35	1.65e-8	Body mass index;
KIRP	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg04989706	chr14:50066350	PPIL5	-0.47	-5.62	-0.34	5.12e-8	Carotid intima media thickness;
KIRP	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs918629	0.530	rs13361837	chr5:95250478	T/G	cg16656078	chr5:95278638	ELL2	-0.36	-5.45	-0.33	1.24e-7	IgG glycosylation;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22887498	chr19:39401301	NA	0.51	6.74	0.39	1.12e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.04	-0.36	5.66e-9	Lung cancer;
KIRP	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.38	-0.51	4.47e-18	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07694848	chr2:20424984	SDC1	0.5	6.22	0.37	2.12e-9	Parkinson's disease;
KIRP	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg14541582	chr5:601475	NA	-0.54	-5.94	-0.35	9.55e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.68	9.79	0.53	2.52e-19	Dupuytren's disease;
KIRP	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	9.97	0.54	7.15e-20	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.46	-5.07	-0.31	7.91e-7	Schizophrenia;
KIRP	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg24253500	chr15:84953950	NA	0.51	5.7	0.34	3.37e-8	Schizophrenia;
KIRP	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.6	6.94	0.4	3.41e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.94	15.61	0.71	1.21e-38	Blood protein levels;
KIRP	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.47	-0.33	1.12e-7	Height;
KIRP	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.8	7.34	0.42	3.08e-12	Obesity-related traits;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09378441	chr7:36429182	ANLN;KIAA0895	1.05	6.92	0.4	3.91e-11	P wave terminal force;
KIRP	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.68	-11.46	-0.59	1.2e-24	Urate levels in overweight individuals;
KIRP	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.89	15.12	0.69	5.55e-37	Mortality in heart failure;
KIRP	trans	rs10772939	0.574	rs4483647	chr12:16598935	G/T	cg20863947	chr2:120124202	DBI;C2orf76	0.5	6.2	0.37	2.34e-9	Economic and political preferences;
KIRP	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	11.27	0.58	5.18e-24	Smoking behavior;
KIRP	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.21	0.61	4.07e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7999699	0.967	rs7326753	chr13:48333280	C/A	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	6.82e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.87	-13.41	-0.65	3.68e-31	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04260258	chr11:65386128	PCNXL3	0.48	6.06	0.36	5.13e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611198	0.846	rs5757730	chr22:39967430	A/G	cg10455938	chr22:40058150	CACNA1I	0.49	6.91	0.4	4.25e-11	Schizophrenia;
KIRP	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.79	-11.42	-0.59	1.6e-24	Bladder cancer;
KIRP	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg09699651	chr6:150184138	LRP11	0.53	7.16	0.42	9.24e-12	Testicular germ cell tumor;
KIRP	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26314531	chr2:26401878	FAM59B	-0.48	-5.11	-0.31	6.41e-7	Gut microbiome composition (summer);
KIRP	cis	rs7503807	0.664	rs8068637	chr17:78614470	C/T	cg09596252	chr17:78655493	RPTOR	0.52	5.94	0.35	9.61e-9	Obesity;
KIRP	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.51	-7.82	-0.45	1.52e-13	Huntington's disease progression;
KIRP	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.67	-9.54	-0.52	1.46e-18	Retinal vascular caliber;
KIRP	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg11584989	chr19:19387371	SF4	0.8	7.37	0.43	2.51e-12	Bipolar disorder;
KIRP	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.95	15.56	0.7	1.77e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg08975724	chr8:8085496	FLJ10661	0.54	6.47	0.38	5.33e-10	Retinal vascular caliber;
KIRP	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.41	8.5	0.48	1.82e-15	Coronary artery disease;
KIRP	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.69	9.65	0.52	6.74e-19	Blood protein levels;
KIRP	cis	rs6725041	0.819	rs4375810	chr2:213094412	T/C	cg20637307	chr2:213403960	ERBB4	-0.39	-5.12	-0.31	6.15e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs3007168	0.951	rs8022611	chr14:51658932	G/C	cg23942311	chr14:51606299	NA	0.57	5.99	0.36	7.39e-9	Cancer;
KIRP	cis	rs4074493	1.000	rs4378192	chr1:231173379	C/T	cg22172038	chr1:231176991	FAM89A	0.28	4.87	0.3	1.96e-6	Carotid plaque burden (smoking interaction);
KIRP	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg22437258	chr11:111473054	SIK2	0.59	7.35	0.42	3.01e-12	Primary sclerosing cholangitis;
KIRP	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.58	-7.3	-0.42	3.93e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-8.8	-0.49	2.53e-16	Schizophrenia;
KIRP	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg12826209	chr6:26865740	GUSBL1	0.76	5.99	0.36	7.4e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72634258	0.945	rs34157438	chr1:8023586	C/T	cg00042356	chr1:8021962	PARK7	0.92	7.4	0.43	2.09e-12	Inflammatory bowel disease;
KIRP	cis	rs526231	0.543	rs257302	chr5:102416130	G/T	cg23492399	chr5:102201601	PAM	-0.49	-5.41	-0.33	1.48e-7	Primary biliary cholangitis;
KIRP	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg09455208	chr3:40491958	NA	0.36	6.29	0.37	1.46e-9	Renal cell carcinoma;
KIRP	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.71	10.04	0.54	4.11e-20	Caffeine consumption;
KIRP	cis	rs4776059	1.000	rs11853917	chr15:52922054	T/C	cg22715398	chr15:52968154	KIAA1370	-0.59	-7.17	-0.42	8.63e-12	Schizophrenia;
KIRP	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg10932868	chr11:921992	NA	0.65	8.7	0.48	4.95e-16	Alzheimer's disease (late onset);
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg04804543	chr8:142233427	SLC45A4	-1.03	-17.96	-0.75	1.18e-46	Immature fraction of reticulocytes;
KIRP	cis	rs5753037	0.585	rs36572	chr22:30200936	T/C	cg01021169	chr22:30184971	ASCC2	-0.51	-7.2	-0.42	7.49e-12	Type 1 diabetes;
KIRP	cis	rs526231	0.543	rs8488	chr5:102538752	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.61	-0.34	5.34e-8	Primary biliary cholangitis;
KIRP	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.39	-5.91	-0.35	1.13e-8	Height;
KIRP	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.87	0.35	1.42e-8	Tonsillectomy;
KIRP	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	1.03	19.73	0.78	1.31e-52	Height;
KIRP	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.83	8.51	0.48	1.68e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11317019	chr17:42219250	C17orf53	0.55	6.32	0.37	1.25e-9	Smoking initiation;
KIRP	cis	rs9810259	0.966	rs13066322	chr3:12269266	C/T	cg22839075	chr3:12045461	SYN2	-0.34	-5.04	-0.31	9e-7	Platelet count;
KIRP	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg00361562	chr2:198649771	BOLL	-0.51	-4.92	-0.3	1.55e-6	Ulcerative colitis;
KIRP	cis	rs9503598	0.644	rs9503593	chr6:3430787	T/C	cg00476032	chr6:3446245	SLC22A23	0.37	4.99	0.3	1.13e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	1.42	11.45	0.59	1.26e-24	Prostate cancer;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	6.72	0.39	1.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7106204	0.541	rs75552854	chr11:24231824	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	8.34	0.47	5.17e-15	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.77	8.91	0.49	1.15e-16	Corneal astigmatism;
KIRP	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg27347728	chr4:17578864	LAP3	0.41	4.88	0.3	1.92e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg19257562	chr1:2043853	PRKCZ	-0.33	-4.96	-0.3	1.33e-6	Height;
KIRP	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg14664628	chr15:75095509	CSK	0.44	5.51	0.33	8.93e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Life satisfaction;
KIRP	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg12435725	chr3:58293450	RPP14	-0.52	-5.37	-0.32	1.81e-7	Cholesterol, total;
KIRP	cis	rs6988636	0.710	rs73339621	chr8:124138936	C/T	cg22384356	chr8:124195192	FAM83A	-0.54	-4.89	-0.3	1.82e-6	Urinary uromodulin levels;
KIRP	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg07843065	chr1:150265600	MRPS21	0.42	5.71	0.34	3.21e-8	Migraine;
KIRP	cis	rs4073416	0.542	rs10144979	chr14:65997638	G/A	cg03016385	chr14:66212404	NA	-0.53	-6.41	-0.38	7.43e-10	N-glycan levels;
KIRP	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg02524346	chr8:600233	NA	0.86	6.13	0.36	3.55e-9	IgG glycosylation;
KIRP	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.56	-6.97	-0.41	2.85e-11	Uric acid clearance;
KIRP	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg02187348	chr16:89574699	SPG7	0.48	5.96	0.36	8.57e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.08	-0.41	1.47e-11	Mood instability;
KIRP	cis	rs4262150	0.667	rs4130910	chr5:152251643	T/C	cg12297329	chr5:152029980	NA	0.47	6.6	0.39	2.48e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-4.99	-0.3	1.12e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4774899	0.934	rs11071309	chr15:57482877	G/T	cg13626582	chr15:57592083	LOC283663	-0.21	-4.9	-0.3	1.73e-6	Urinary tract infection frequency;
KIRP	trans	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg01620082	chr3:125678407	NA	-1.24	-7.61	-0.44	5.83e-13	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13006227	chr2:62132614	COMMD1	0.49	6.79	0.4	8.28e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6142102	0.625	rs6141431	chr20:32540314	G/A	cg08999081	chr20:33150536	PIGU	0.4	4.98	0.3	1.21e-6	Skin pigmentation;
KIRP	cis	rs8077577	0.945	rs11655731	chr17:18107525	G/T	cg09161412	chr17:18057145	MYO15A	-0.42	-5.25	-0.32	3.22e-7	Obesity-related traits;
KIRP	cis	rs2637030	0.502	rs1844698	chr5:52970339	G/A	cg06476337	chr5:52856530	NDUFS4	0.54	5.86	0.35	1.46e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08180261	chr2:86668980	KDM3A	-0.5	-6.28	-0.37	1.54e-9	Migraine with aura;
KIRP	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.52	6.21	0.37	2.27e-9	Adiposity;
KIRP	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-7.6	-0.44	6.11e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg16309518	chr5:176445507	NA	-0.88	-13.54	-0.65	1.33e-31	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18805032	chr6:3853096	NA	0.47	6.18	0.37	2.71e-9	Interleukin-4 levels;
KIRP	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs10489525	0.583	rs12034918	chr1:115626285	C/T	cg01522456	chr1:115632236	TSPAN2	0.79	10.56	0.56	9.78e-22	Autism;
KIRP	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg10189774	chr4:17578691	LAP3	0.47	5.66	0.34	4.14e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.84	12.88	0.63	2.41e-29	Longevity;
KIRP	cis	rs834811	0.831	rs1097147	chr7:135880446	C/T	cg01726295	chr7:135938950	NA	0.35	4.85	0.3	2.19e-6	Post-traumatic stress disorder;
KIRP	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.67	9.1	0.5	3.22e-17	Morning vs. evening chronotype;
KIRP	cis	rs11955175	1.000	rs78426328	chr5:40673176	G/T	cg04002187	chr5:40835754	RPL37	0.67	5.41	0.33	1.5e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4812048	0.649	rs3761257	chr20:57618787	C/T	cg14073986	chr20:57617431	SLMO2	0.65	6.16	0.37	2.93e-9	Mean platelet volume;
KIRP	cis	rs8032158	1.000	rs8029247	chr15:56273446	C/T	cg02198044	chr15:56286336	NEDD4	0.46	5.44	0.33	1.31e-7	Keloid;
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.79	-14.73	-0.68	1.28e-35	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10437825	chr8:68334606	CPA6	-0.46	-7.07	-0.41	1.57e-11	Inflammatory biomarkers;
KIRP	cis	rs34779708	0.733	rs12777960	chr10:35541026	C/A	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1823913	0.599	rs13427761	chr2:192133982	C/G	cg12404831	chr2:192114017	MYO1B	-0.48	-6.57	-0.39	2.94e-10	Obesity-related traits;
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.46	6.0	0.36	7.19e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	5.27	0.32	2.95e-7	Renal cell carcinoma;
KIRP	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.18	-0.37	2.68e-9	Bipolar disorder;
KIRP	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	5.82	0.35	1.79e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13827970	chr14:55369959	GCH1	0.51	6.04	0.36	5.67e-9	Lung cancer in ever smokers;
KIRP	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg26681399	chr22:41777847	TEF	-0.5	-4.99	-0.3	1.12e-6	Vitiligo;
KIRP	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.57	5.28	0.32	2.9e-7	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.2	-0.46	1.31e-14	Retinal vascular caliber;
KIRP	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26526719	chr5:1949144	NA	0.43	5.18	0.31	4.58e-7	Gut microbiome composition (winter);
KIRP	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	9.33	0.51	6.59e-18	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6991838	0.584	rs3765205	chr8:66517486	C/T	cg13398993	chr8:66546079	ARMC1	-0.45	-5.23	-0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg06521331	chr12:34319734	NA	-0.56	-6.87	-0.4	5.14e-11	Morning vs. evening chronotype;
KIRP	cis	rs17739167	0.550	rs1426890	chr15:42226125	G/A	cg20935245	chr15:42234343	EHD4	0.51	8.14	0.46	2e-14	Monocyte count;
KIRP	cis	rs7712401	0.765	rs4349713	chr5:122391626	A/G	cg19412675	chr5:122181750	SNX24	0.42	4.89	0.3	1.82e-6	Mean platelet volume;
KIRP	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.24	0.32	3.46e-7	Schizophrenia;
KIRP	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg23933602	chr10:16859644	RSU1	0.53	5.7	0.34	3.39e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.7	-9.98	-0.54	6.49e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg01629716	chr15:45996671	NA	0.37	6.6	0.39	2.48e-10	Waist circumference;Weight;
KIRP	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.89	14.75	0.68	1.08e-35	Prostate cancer;
KIRP	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg18350739	chr11:68623251	NA	-0.48	-7.47	-0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg06307176	chr5:131281290	NA	-0.51	-5.55	-0.33	7.46e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg08885076	chr2:99613938	TSGA10	-0.47	-7.09	-0.41	1.44e-11	Fear of minor pain;
KIRP	cis	rs12580194	0.593	rs73118998	chr12:55736659	T/C	cg19537932	chr12:55886519	OR6C68	-0.48	-6.34	-0.37	1.12e-9	Cancer;
KIRP	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg09355771	chr2:177043147	NA	-0.44	-5.2	-0.31	4.23e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg04490037	chr7:50633773	DDC	-0.42	-5.2	-0.31	4.26e-7	Malaria;
KIRP	trans	rs9409565	0.826	rs2769813	chr9:97151194	C/T	cg05679027	chr9:99775184	HIATL2	0.55	6.78	0.4	8.68e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs2282300	0.637	rs10742240	chr11:30429438	A/G	cg05756220	chr11:30038685	KCNA4	-0.33	-4.88	-0.3	1.9e-6	Morning vs. evening chronotype;
KIRP	cis	rs7709377	0.521	rs7723358	chr5:115548365	A/G	cg23108291	chr5:115420582	COMMD10	0.44	5.29	0.32	2.66e-7	Metabolite levels  (X-11787);
KIRP	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.84	-0.53	1.76e-19	Height;
KIRP	cis	rs662064	0.962	rs648399	chr1:10556485	T/C	cg17425144	chr1:10567563	PEX14	0.33	5.61	0.34	5.32e-8	Asthma;
KIRP	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.55	7.61	0.44	5.79e-13	Temperament;
KIRP	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Smoking initiation;
KIRP	cis	rs1440410	0.560	rs4413361	chr4:144111955	C/T	cg01719995	chr4:144104893	USP38	0.41	5.25	0.32	3.21e-7	Ischemic stroke;
KIRP	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.68	-9.33	-0.51	6.38e-18	Lymphocyte counts;
KIRP	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg22139774	chr2:100720529	AFF3	-0.39	-4.87	-0.3	2.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3790645	1.000	rs444482	chr1:26890648	C/G	cg23229016	chr1:26872525	RPS6KA1	0.23	6.16	0.37	2.88e-9	Glucose homeostasis traits;
KIRP	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-6.17	-0.37	2.82e-9	Schizophrenia;
KIRP	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.66	10.52	0.56	1.27e-21	Pulse pressure;
KIRP	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.38	-15.16	-0.7	4.02e-37	Schizophrenia;
KIRP	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05665937	chr4:1216051	CTBP1	0.53	7.34	0.42	3.1e-12	Obesity-related traits;
KIRP	cis	rs8070740	0.898	rs9896735	chr17:5325808	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.58	-7.38	-0.43	2.36e-12	Menopause (age at onset);
KIRP	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg13939156	chr17:80058883	NA	-0.48	-5.45	-0.33	1.25e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.57	6.61	0.39	2.42e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg05347473	chr6:146136440	FBXO30	0.49	6.79	0.4	8.28e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg24804195	chr5:87968844	LOC645323	-0.47	-6.17	-0.37	2.73e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs13034020	0.594	rs10496090	chr2:61254033	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.55	5.1	0.31	6.71e-7	Hodgkin's lymphoma;
KIRP	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.62	-0.34	5.06e-8	Ulcerative colitis;
KIRP	cis	rs7766436	0.885	rs1418311	chr6:22594964	T/G	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs62413470	0.810	rs12214559	chr6:55960936	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.58	-12.09	-0.61	9.99e-27	Diabetic kidney disease;
KIRP	cis	rs865483	0.861	rs56186148	chr17:35768827	T/A	cg06716730	chr17:35851459	DUSP14	-0.25	-5.77	-0.35	2.42e-8	Monocyte count;
KIRP	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.54	-6.94	-0.4	3.43e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.32	0.59	3.41e-24	Exhaled nitric oxide levels;
KIRP	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.69	-6.01	-0.36	6.74e-9	Coronary artery calcification;
KIRP	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.73	10.45	0.55	2.12e-21	Retinal vascular caliber;
KIRP	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.53	6.97	0.41	2.88e-11	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.64	-7.75	-0.44	2.36e-13	Cognitive test performance;
KIRP	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.51	-6.58	-0.39	2.86e-10	Breast cancer;
KIRP	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-6.68	-0.39	1.54e-10	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs935971	chr4:1045265	G/A	cg13180566	chr4:1052158	NA	-0.51	-5.11	-0.31	6.48e-7	Recombination rate (females);
KIRP	cis	rs4750440	0.706	rs12358733	chr10:14016290	A/G	cg27542038	chr10:14027202	FRMD4A	0.5	6.72	0.39	1.26e-10	Adiponectin levels;
KIRP	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg20673091	chr1:2541236	MMEL1	0.79	12.8	0.63	4.42e-29	Ulcerative colitis;
KIRP	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg12935359	chr14:103987150	CKB	0.37	5.69	0.34	3.61e-8	Body mass index;
KIRP	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg08761264	chr16:28874980	SH2B1	-0.51	-5.88	-0.35	1.3e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg13877915	chr19:58951672	ZNF132	0.57	7.14	0.41	1.04e-11	Uric acid clearance;
KIRP	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.99	-14.16	-0.67	1.08e-33	Cognitive ability;
KIRP	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.79	-0.49	2.6e-16	Osteoarthritis;
KIRP	cis	rs9488822	0.662	rs195531	chr6:116252551	A/T	cg26893134	chr6:116381904	FRK	0.19	5.3	0.32	2.6e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-6.17	-0.37	2.84e-9	Aortic root size;
KIRP	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.84	0.45	1.4e-13	Height;
KIRP	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4356932	1.000	rs4535358	chr4:76974409	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.42	0.47	3.18e-15	Electroencephalogram traits;
KIRP	trans	rs1941687	0.702	rs1493924	chr18:31314721	T/C	cg27147174	chr7:100797783	AP1S1	-0.56	-7.18	-0.42	8.46e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.97	16.02	0.71	4.62e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs9608946	1.000	rs9608942	chr22:30887446	T/C	cg23383138	chr22:30885012	SEC14L4	0.4	4.94	0.3	1.44e-6	Red cell distribution width;
KIRP	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.82	-0.71	2.31e-39	Chronic sinus infection;
KIRP	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.71	-8.36	-0.47	4.61e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.51	0.59	8.52e-25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.6	-0.39	2.51e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.62	-9.09	-0.5	3.32e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-0.82	-9.23	-0.51	1.26e-17	Gut microbiome composition (summer);
KIRP	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.41	5.85	0.35	1.53e-8	Bipolar disorder;
KIRP	cis	rs7834588	0.544	rs13277301	chr8:63816442	C/T	cg12194929	chr8:63776755	NKAIN3	-0.26	-4.85	-0.3	2.19e-6	Response to Vitamin E supplementation;
KIRP	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.77	-0.44	2.1e-13	Neuroticism;
KIRP	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg11584989	chr19:19387371	SF4	0.57	5.68	0.34	3.72e-8	Bipolar disorder;
KIRP	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg11833968	chr6:79620685	NA	-0.38	-5.74	-0.34	2.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs754423	0.703	rs1540700	chr14:52521773	G/A	cg10149976	chr14:52535953	NID2	-0.42	-5.55	-0.33	7.56e-8	Craniofacial microsomia;
KIRP	cis	rs710987	0.787	rs828544	chr5:3520064	G/T	cg14530963	chr5:3489551	NA	-0.41	-4.99	-0.3	1.15e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs698813	0.756	rs2592196	chr2:44605522	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.42	0.38	7.12e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.65	-9.77	-0.53	3e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1823913	0.599	rs13002286	chr2:192150352	A/G	cg12404831	chr2:192114017	MYO1B	-0.54	-7.52	-0.43	9.93e-13	Obesity-related traits;
KIRP	cis	rs28489187	0.617	rs233109	chr1:85783101	T/C	cg16011679	chr1:85725395	C1orf52	0.44	5.42	0.33	1.44e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.54	-7.18	-0.42	8.4e-12	White matter hyperintensity burden;
KIRP	cis	rs1863824	0.625	rs2018507	chr10:88163251	A/G	cg07322936	chr10:88137208	NA	0.54	5.53	0.33	8.36e-8	Schizophrenia;
KIRP	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.57	-7.11	-0.41	1.23e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08577743	chr9:38621011	C9orf122;ANKRD18A	0.48	6.58	0.39	2.75e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.67	-0.56	4.25e-22	Gut microbiome composition (summer);
KIRP	cis	rs7572644	0.713	rs4666025	chr2:28073894	C/T	cg27432699	chr2:27873401	GPN1	0.45	5.01	0.3	1.06e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.39	-0.38	8.23e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg04731861	chr2:219085781	ARPC2	-0.24	-6.24	-0.37	1.89e-9	Colorectal cancer;
KIRP	cis	rs9535307	0.929	rs1407441	chr13:50290990	T/C	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.04	0.36	5.72e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19775406	chr17:5390252	MIS12;DERL2	0.45	6.09	0.36	4.41e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.7	-9.28	-0.51	9.4e-18	Response to bleomycin (chromatid breaks);
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.46	5.97	0.36	8.17e-9	Gout;
KIRP	cis	rs17123764	0.892	rs74952881	chr12:50108943	A/G	cg20471783	chr12:50157085	TMBIM6	0.4	5.31	0.32	2.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.58	7.16	0.42	9.42e-12	Coronary artery disease;
KIRP	cis	rs897080	0.515	rs698795	chr2:44689326	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.79	0.35	2.09e-8	Height;
KIRP	cis	rs6142102	0.961	rs973409	chr20:32536364	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	6.32	0.37	1.22e-9	Skin pigmentation;
KIRP	cis	rs17065868	0.764	rs9595130	chr13:45043439	G/A	cg10246903	chr13:45222710	NA	0.52	4.91	0.3	1.69e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6977660	0.660	rs13225400	chr7:19817016	A/G	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.84	9.62	0.52	8.54e-19	High light scatter reticulocyte count;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07738938	chr7:5372608	TNRC18	0.51	6.4	0.38	7.66e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg19906672	chr4:6918868	TBC1D14	0.51	5.18	0.31	4.56e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.53	8.74	0.49	3.73e-16	Rheumatoid arthritis;
KIRP	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg22705602	chr4:152727874	NA	-0.55	-9.78	-0.53	2.67e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00149659	chr3:10157352	C3orf10	0.92	9.86	0.53	1.53e-19	Alzheimer's disease;
KIRP	cis	rs2290159	0.898	rs2290160	chr3:12633083	A/G	cg23032965	chr3:12705835	RAF1	0.7	7.79	0.44	1.91e-13	Cholesterol, total;
KIRP	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	8.17	0.46	1.64e-14	Neuroticism;
KIRP	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg13615516	chr5:77269221	NA	0.51	7.87	0.45	1.1e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72634258	0.945	rs225120	chr1:8046378	C/T	cg00042356	chr1:8021962	PARK7	0.53	4.98	0.3	1.18e-6	Inflammatory bowel disease;
KIRP	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg21747090	chr2:27597821	SNX17	-0.47	-6.47	-0.38	5.4e-10	Total body bone mineral density;
KIRP	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.48	-5.82	-0.35	1.84e-8	Body mass index;
KIRP	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg03959625	chr15:84868606	LOC388152	0.62	6.87	0.4	5.21e-11	Schizophrenia;
KIRP	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg05347473	chr6:146136440	FBXO30	-0.62	-9.13	-0.5	2.61e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg06115741	chr20:33292138	TP53INP2	0.41	5.33	0.32	2.22e-7	Coronary artery disease;
KIRP	cis	rs7590368	0.774	rs3932106	chr2:10916408	C/T	cg15705551	chr2:10952987	PDIA6	0.5	5.36	0.32	1.88e-7	Educational attainment (years of education);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06492699	chr3:39149242	GORASP1;TTC21A	0.53	6.85	0.4	6.05e-11	Parkinson's disease;
KIRP	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg00495681	chr13:53174319	NA	0.4	5.45	0.33	1.23e-7	Lewy body disease;
KIRP	cis	rs500492	0.542	rs416055	chr16:1074931	G/A	cg09791621	chr16:1078722	NA	0.45	5.05	0.31	8.79e-7	Polycystic ovary syndrome;
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.59	-0.39	2.69e-10	Lymphocyte counts;
KIRP	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	15.1	0.69	6.59e-37	Gut microbiome composition (summer);
KIRP	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs9467160	0.581	rs2817244	chr6:24464511	G/T	cg20631270	chr6:24437470	GPLD1	0.43	5.0	0.3	1.09e-6	Liver enzyme levels;
KIRP	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg15212455	chr7:39170539	POU6F2	0.26	6.05	0.36	5.42e-9	IgG glycosylation;
KIRP	cis	rs12143943	0.802	rs12117054	chr1:204454741	G/A	cg20240347	chr1:204465584	NA	-0.37	-6.58	-0.39	2.79e-10	Cognitive performance;
KIRP	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg00933542	chr6:150070202	PCMT1	0.27	5.14	0.31	5.7e-7	Lung cancer;
KIRP	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.24	-0.32	3.38e-7	Mean platelet volume;
KIRP	cis	rs4750440	0.702	rs11258775	chr10:14029742	T/C	cg27542038	chr10:14027202	FRMD4A	-0.48	-6.7	-0.39	1.41e-10	Adiponectin levels;
KIRP	cis	rs7709377	0.595	rs1677406	chr5:115612389	T/G	cg23108291	chr5:115420582	COMMD10	-0.45	-5.53	-0.33	8.08e-8	Metabolite levels  (X-11787);
KIRP	cis	rs853679	0.527	rs9461443	chr6:28194629	A/T	cg12963246	chr6:28129442	ZNF389	0.44	5.19	0.31	4.38e-7	Depression;
KIRP	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.34	5.37	0.32	1.85e-7	Asthma;
KIRP	cis	rs9905704	0.633	rs2632523	chr17:56506634	G/A	cg12560992	chr17:57184187	TRIM37	0.55	5.22	0.32	3.75e-7	Testicular germ cell tumor;
KIRP	cis	rs10761482	0.601	rs7074460	chr10:62184843	A/G	cg01186212	chr10:62110162	ANK3	-0.32	-5.29	-0.32	2.77e-7	Schizophrenia;
KIRP	cis	rs490234	0.841	rs521119	chr9:128314394	T/C	cg14078157	chr9:128172775	NA	0.4	5.04	0.31	8.88e-7	Mean arterial pressure;
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs7766436	0.553	rs55936918	chr6:22610269	A/T	cg13666174	chr6:22585274	NA	-0.45	-5.1	-0.31	6.94e-7	Coronary artery disease;
KIRP	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.44	5.96	0.36	8.5e-9	Dupuytren's disease;
KIRP	cis	rs6669919	0.530	rs11587621	chr1:211668400	C/T	cg10512769	chr1:211675356	NA	0.78	11.29	0.58	4.16e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg07952391	chr2:88470173	THNSL2	0.92	7.57	0.43	7.56e-13	Plasma clusterin levels;
KIRP	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.58	-9.1	-0.5	3.11e-17	Neuroticism;
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.51	6.18	0.37	2.64e-9	Longevity;Endometriosis;
KIRP	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.07	0.41	1.56e-11	Testicular germ cell tumor;
KIRP	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg04691961	chr3:161091175	C3orf57	-0.4	-6.01	-0.36	6.74e-9	Morning vs. evening chronotype;
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.91	16.23	0.72	9.39e-41	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	6.15	0.37	3.1e-9	Mean platelet volume;
KIRP	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.17e-6	Pulmonary function;
KIRP	cis	rs62413470	0.935	rs4482975	chr6:55948580	C/T	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg25782563	chr17:17380313	MED9	0.5	6.17	0.37	2.74e-9	C-reactive protein;
KIRP	cis	rs7258465	1.000	rs10405636	chr19:18538742	A/C	cg01065977	chr19:18549689	ISYNA1	-0.38	-5.86	-0.35	1.48e-8	Breast cancer;
KIRP	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	9.37	0.51	5.04e-18	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9596863	0.898	rs35359752	chr13:54364643	T/C	ch.13.53330881F	chr13:54432880	NA	0.61	5.98	0.36	7.99e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg12131826	chr15:77904385	NA	-0.43	-5.2	-0.31	4.28e-7	Type 2 diabetes;
KIRP	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.4	4.84	0.3	2.25e-6	Refractive astigmatism;
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.24	-24.52	-0.84	5.43e-68	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.89	0.49	1.34e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs155346	1.000	rs155346	chr5:139390377	C/T	cg01090482	chr5:139365336	NRG2	0.42	5.21	0.32	3.9e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs9372498	0.505	rs9481811	chr6:118801174	T/C	cg18833306	chr6:118973337	C6orf204	-0.46	-4.91	-0.3	1.68e-6	Diastolic blood pressure;
KIRP	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg05973401	chr12:123451056	ABCB9	-0.59	-5.37	-0.32	1.84e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg20243544	chr17:37824526	PNMT	-0.4	-4.9	-0.3	1.72e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg07653901	chr22:50250238	ZBED4	-0.63	-6.91	-0.4	4.15e-11	Schizophrenia;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.73	-0.34	2.91e-8	Life satisfaction;
KIRP	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.84	13.92	0.66	7.17e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg21906852	chr1:75198582	TYW3;CRYZ	0.47	5.56	0.33	7.18e-8	Resistin levels;
KIRP	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg07884673	chr3:53033167	SFMBT1	0.81	6.38	0.38	8.86e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs55882075	0.808	rs6867806	chr5:179179585	C/G	cg14593053	chr5:179126677	CANX	0.65	8.76	0.49	3.29e-16	Monocyte percentage of white cells;
KIRP	cis	rs10940138	0.830	rs10447112	chr5:67219761	G/A	ch.5.1281357F	chr5:67228439	NA	0.79	12.46	0.62	5.85e-28	Menarche (age at onset);
KIRP	cis	rs9596863	0.898	rs7328420	chr13:54320465	G/A	ch.13.53330881F	chr13:54432880	NA	0.59	5.57	0.33	6.77e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.38	-7.14	-0.41	1.06e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg26513180	chr16:89883248	FANCA	0.83	5.57	0.33	6.68e-8	Skin colour saturation;
KIRP	cis	rs12210905	1.000	rs12205921	chr6:27113540	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7903847	0.620	rs10882907	chr10:99125788	C/G	cg20016023	chr10:99160130	RRP12	0.41	5.64	0.34	4.73e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.36	0.62	1.28e-27	Smoking behavior;
KIRP	cis	rs2790457	0.958	rs2790454	chr10:28842032	A/G	cg04045419	chr10:28823091	WAC	-0.42	-4.85	-0.3	2.14e-6	Multiple myeloma;
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16524936	chr4:1340807	KIAA1530	-0.51	-6.48	-0.38	5.01e-10	Longevity;
KIRP	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg08822215	chr16:89438651	ANKRD11	0.46	5.98	0.36	7.76e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg26373071	chr5:1325741	CLPTM1L	0.54	7.14	0.41	1.03e-11	Lung cancer;
KIRP	cis	rs10861342	0.786	rs11112393	chr12:105548053	C/T	cg23923672	chr12:105501055	KIAA1033	0.86	8.91	0.49	1.2e-16	IgG glycosylation;
KIRP	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg06307176	chr5:131281290	NA	0.53	5.92	0.35	1.06e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.92	0.4	3.99e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.49	-6.49	-0.38	4.71e-10	Asthma;
KIRP	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg08313168	chr12:7315531	NA	0.69	6.29	0.37	1.48e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10073892	0.913	rs10078757	chr5:101699907	A/G	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.96e-11	Cognitive decline (age-related);
KIRP	trans	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg07211511	chr3:129823064	LOC729375	-0.88	-9.97	-0.54	6.75e-20	Blood pressure (smoking interaction);
KIRP	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.06	-0.36	5.14e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.69	6.55	0.39	3.3e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg19025524	chr12:109796872	NA	-0.57	-8.07	-0.46	3.05e-14	Neuroticism;
KIRP	cis	rs7523050	0.643	rs35520362	chr1:109419841	C/T	cg08274380	chr1:109419600	GPSM2	1.18	10.33	0.55	5.16e-21	Fat distribution (HIV);
KIRP	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg09667013	chr22:42394590	WBP2NL	0.37	4.92	0.3	1.55e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg07636037	chr3:49044803	WDR6	0.55	5.25	0.32	3.28e-7	Menarche (age at onset);
KIRP	cis	rs7833787	0.965	rs6991832	chr8:18710941	A/C	cg17701159	chr8:18705777	PSD3	0.37	6.89	0.4	4.57e-11	Obesity-related traits;
KIRP	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.61	-0.39	2.41e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg04691961	chr3:161091175	C3orf57	0.39	5.03	0.31	9.52e-7	Parkinson's disease;
KIRP	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.45	-6.01	-0.36	6.6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6442310	0.534	rs796313	chr3:12449528	G/T	cg22839075	chr3:12045461	SYN2	-0.35	-5.05	-0.31	8.68e-7	Hematocrit;
KIRP	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-0.76	-8.69	-0.48	5.15e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg21775007	chr8:11205619	TDH	-0.45	-5.89	-0.35	1.26e-8	Neuroticism;
KIRP	cis	rs8133932	0.654	rs2776402	chr21:47360761	T/C	cg11214348	chr21:47283868	PCBP3	-0.39	-5.02	-0.3	9.95e-7	Schizophrenia;
KIRP	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.51e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs12022452	0.591	rs11208315	chr1:40985402	G/C	cg25568243	chr1:40974465	DEM1	0.53	5.71	0.34	3.16e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg04578738	chr17:34136331	TAF15	0.47	6.29	0.37	1.44e-9	Ischemic stroke;
KIRP	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg26681399	chr22:41777847	TEF	0.45	4.9	0.3	1.72e-6	Vitiligo;
KIRP	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.69	9.0	0.5	6.12e-17	Cognitive function;
KIRP	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg19700328	chr14:106028568	NA	-0.62	-6.77	-0.4	9.66e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	0.94	14.54	0.68	5.3e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9653442	0.510	rs11891046	chr2:100794402	C/G	cg22139774	chr2:100720529	AFF3	-0.29	-4.92	-0.3	1.57e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.8	10.97	0.57	4.72e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg01557791	chr16:72042693	DHODH	-0.41	-4.99	-0.3	1.13e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs6142618	0.555	rs3746602	chr20:30662837	A/G	cg09796376	chr20:30640595	HCK	-0.41	-5.71	-0.34	3.25e-8	Inflammatory bowel disease;
KIRP	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.6	-0.48	9.23e-16	Retinal vascular caliber;
KIRP	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg19913688	chr11:428466	ANO9	-0.77	-6.03	-0.36	6.05e-9	Body mass index;
KIRP	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg19847130	chr8:10466454	RP1L1	-0.33	-5.11	-0.31	6.38e-7	Retinal vascular caliber;
KIRP	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.7	-5.17	-0.31	4.78e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.54	0.38	3.53e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1440410	0.798	rs7663553	chr4:144049036	T/C	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs2282032	1.000	rs56015111	chr14:90768946	G/A	cg04374321	chr14:90722782	PSMC1	0.57	5.32	0.32	2.33e-7	Longevity;
KIRP	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg00792783	chr2:198669748	PLCL1	0.45	5.05	0.31	8.78e-7	Dermatomyositis;
KIRP	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10802521	chr3:52805072	NEK4	0.41	5.23	0.32	3.71e-7	Bipolar disorder;
KIRP	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-4.97	-0.3	1.26e-6	Educational attainment (years of education);
KIRP	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	8.26	0.47	8.85e-15	Personality dimensions;
KIRP	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.35	-4.9	-0.3	1.72e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg08662619	chr6:150070041	PCMT1	0.33	4.9	0.3	1.7e-6	Lung cancer;
KIRP	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.56	7.59	0.44	6.77e-13	Total body bone mineral density;
KIRP	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg00919237	chr7:87102261	ABCB4	-0.73	-9.14	-0.5	2.44e-17	Gallbladder cancer;
KIRP	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg19875535	chr5:140030758	IK	0.53	6.59	0.39	2.59e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7523273	0.597	rs4844619	chr1:207960708	C/T	cg22525895	chr1:207977042	MIR29B2	-0.6	-5.86	-0.35	1.52e-8	Schizophrenia;
KIRP	cis	rs4148660	1.000	rs870134	chr12:22079318	G/A	cg14669847	chr12:22099120	NA	0.34	5.73	0.34	2.91e-8	Gout;
KIRP	cis	rs17023223	0.553	rs55696509	chr1:119686656	A/G	cg05756136	chr1:119680316	WARS2	-0.55	-6.29	-0.37	1.42e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.67	-8.16	-0.46	1.71e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26617929	chr16:1858877	NA	-0.65	-5.28	-0.32	2.77e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg06598631	chr6:88300029	RARS2;ORC3L	-0.41	-5.0	-0.3	1.11e-6	Monocyte percentage of white cells;
KIRP	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.75	-11.76	-0.6	1.21e-25	Prostate cancer;
KIRP	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.59	5.06	0.31	8.35e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.13	-0.31	5.92e-7	Pulmonary function;
KIRP	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg15655495	chr12:38532458	NA	-0.26	-4.93	-0.3	1.5e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	4.9	0.3	1.72e-6	Diisocyanate-induced asthma;
KIRP	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.24	8.68	0.48	5.55e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25508633	chr19:10218184	SNORD105;PPAN-P2RY11;PPAN	0.42	6.66	0.39	1.75e-10	Survival in pancreatic cancer;
KIRP	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg01721255	chr8:58191610	C8orf71	0.66	5.64	0.34	4.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.77	-6.56	-0.39	3.23e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.3	-0.32	2.57e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.73	9.52	0.52	1.75e-18	Coronary artery disease;
KIRP	cis	rs2569991	0.588	rs14191	chr3:12940346	G/A	cg22481960	chr3:13008800	IQSEC1	-0.54	-5.39	-0.33	1.64e-7	Periodontitis (DPAL);
KIRP	cis	rs12143943	0.966	rs3747632	chr1:204587240	G/A	cg20240347	chr1:204465584	NA	-0.35	-6.34	-0.37	1.07e-9	Cognitive performance;
KIRP	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.88	0.35	1.3e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.05	0.41	1.75e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.44	5.58	0.34	6.29e-8	Educational attainment (years of education);
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.49	0.33	9.95e-8	Lung cancer;
KIRP	cis	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.42	-0.47	3.06e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg24296786	chr1:45957014	TESK2	0.51	5.65	0.34	4.39e-8	Homocysteine levels;
KIRP	cis	rs11997175	1.000	rs6468201	chr8:33746854	G/C	ch.8.33884649F	chr8:33765107	NA	0.53	6.5	0.38	4.46e-10	Body mass index;
KIRP	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	6.81	0.4	7.26e-11	Initial pursuit acceleration;
KIRP	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.83e-16	Immature fraction of reticulocytes;
KIRP	cis	rs8066384	1	rs8066384	chr17:78625756	T/C	cg09596252	chr17:78655493	RPTOR	0.55	6.15	0.37	3.1e-9	Schizophrenia;
KIRP	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg06766960	chr11:133703094	NA	-0.75	-9.92	-0.53	9.81e-20	Childhood ear infection;
KIRP	cis	rs6882076	1.000	rs6882076	chr5:156390297	T/C	cg12943317	chr5:156479607	HAVCR1	-0.62	-7.67	-0.44	3.95e-13	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.66	7.72	0.44	2.9e-13	Gestational age at birth (maternal effect);
KIRP	cis	rs13209747	0.682	rs114624515	chr6:127137608	C/T	cg21431617	chr6:127135037	NA	0.33	5.96	0.35	8.92e-9	Diastolic blood pressure;Systolic blood pressure;Blood pressure;
KIRP	cis	rs2288884	0.559	rs8111873	chr19:52517520	T/C	cg05974498	chr19:52599256	ZNF841	0.36	5.1	0.31	6.7e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
KIRP	cis	rs17092148	0.731	rs35507767	chr20:33361364	A/T	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.45	-0.33	1.2e-7	Neuroticism;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg21670451	chr5:139781334	ANKHD1;ANKHD1-EIF4EBP3	0.5	6.03	0.36	6.08e-9	Asthma;
KIRP	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.75	9.99	0.54	6.14e-20	Mean platelet volume;
KIRP	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg16141378	chr3:129829833	LOC729375	0.56	7.63	0.44	5.16e-13	Neuroticism;
KIRP	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg05526886	chr2:227700861	RHBDD1	0.45	5.42	0.33	1.4e-7	Pulmonary function;
KIRP	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg11608241	chr8:8085544	FLJ10661	-0.42	-4.85	-0.3	2.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.89	-14.08	-0.67	2.11e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	cis	rs7737355	0.947	rs6596009	chr5:130608093	C/A	cg06647332	chr5:131281008	NA	0.61	5.81	0.35	1.92e-8	Life satisfaction;
KIRP	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.46	-5.87	-0.35	1.42e-8	Motion sickness;
KIRP	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.54	6.37	0.38	9.41e-10	Aortic root size;
KIRP	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13748552	chr7:150929513	CHPF2	0.5	7.12	0.41	1.16e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.33	0.37	1.12e-9	Aortic root size;
KIRP	cis	rs1440410	0.795	rs11728962	chr4:144079871	T/G	cg19876092	chr4:144208277	NA	0.29	4.85	0.3	2.15e-6	Ischemic stroke;
KIRP	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-10.59	-0.56	7.68e-22	Exhaled nitric oxide output;
KIRP	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg01843034	chr6:37503916	NA	-0.82	-11.5	-0.59	9.23e-25	Cognitive performance;
KIRP	cis	rs2230307	0.656	rs7531066	chr1:100463804	A/G	cg24955406	chr1:100503596	HIAT1	0.56	5.57	0.33	6.57e-8	Carotid intima media thickness;
KIRP	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg19610905	chr11:61596333	FADS2	0.45	5.4	0.33	1.53e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg05861140	chr6:150128134	PCMT1	-0.55	-7.91	-0.45	8.7e-14	Lung cancer;
KIRP	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg16434002	chr17:42200994	HDAC5	-0.46	-5.69	-0.34	3.66e-8	Total body bone mineral density;
KIRP	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-6.98	-0.41	2.75e-11	Daytime sleep phenotypes;
KIRP	cis	rs4363506	0.625	rs10765118	chr10:129285183	G/A	cg07804728	chr10:129284050	NA	0.42	5.78	0.35	2.25e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Intracranial aneurysm;
KIRP	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19671926	chr4:122722719	EXOSC9	0.49	5.91	0.35	1.11e-8	Type 2 diabetes;
KIRP	cis	rs1981331	1.000	rs118078026	chr21:48012129	T/C	cg23283320	chr21:48055893	PRMT2	1.36	8.52	0.48	1.58e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.58	0.48	1.09e-15	Motion sickness;
KIRP	cis	rs1978968	1.000	rs5992135	chr22:18447114	C/T	cg02610425	chr22:18483192	MICAL3	0.36	5.07	0.31	7.93e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs10214930	0.697	rs7789788	chr7:27622611	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.89	0.3	1.84e-6	Hypospadias;
KIRP	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg25019033	chr10:957182	NA	-0.61	-7.44	-0.43	1.7e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs4523957	0.893	rs9909895	chr17:2161633	G/A	cg16513277	chr17:2031491	SMG6	-0.58	-8.01	-0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs295140	0.565	rs295139	chr2:201159988	T/A	cg23649088	chr2:200775458	C2orf69	0.41	5.16	0.31	5e-7	QT interval;
KIRP	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.23	0.42	5.94e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg02297831	chr4:17616191	MED28	0.51	5.99	0.36	7.58e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06134974	chr12:51477539	CSRNP2	-0.43	-6.07	-0.36	4.79e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	9.64	0.52	7.44e-19	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.79	9.05	0.5	4.43e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1816752	0.633	rs8002387	chr13:24990444	A/G	cg02811702	chr13:24901961	NA	0.4	5.29	0.32	2.68e-7	Obesity-related traits;
KIRP	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg17425144	chr1:10567563	PEX14	0.5	9.75	0.53	3.38e-19	Breast size;
KIRP	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg00677455	chr12:58241039	CTDSP2	-0.59	-7.09	-0.41	1.45e-11	Multiple sclerosis;
KIRP	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	1.04	13.7	0.66	3.91e-32	Neutrophil percentage of white cells;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.95	-0.54	7.99e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.79	-6.16	-0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.19	-15.97	-0.71	7.06e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg02792322	chr13:21280448	IL17D	-0.31	-5.13	-0.31	5.76e-7	Dental caries;
KIRP	cis	rs580438	0.510	rs6442380	chr3:13427998	G/T	cg10657019	chr3:13328039	NA	-0.48	-6.24	-0.37	1.86e-9	Myringotomy;
KIRP	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17507749	chr15:85114479	UBE2QP1	0.72	7.86	0.45	1.16e-13	Schizophrenia;
KIRP	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg12311346	chr5:56204834	C5orf35	-0.36	-4.93	-0.3	1.52e-6	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg16434002	chr17:42200994	HDAC5	-0.49	-5.8	-0.35	2.07e-8	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13982590	chr19:39078193	RYR1	-0.42	-6.5	-0.38	4.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg08514558	chr10:81106712	PPIF	0.42	5.81	0.35	1.96e-8	Height;
KIRP	cis	rs13132184	0.507	rs12645411	chr4:38044516	T/C	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.2	-0.31	4.13e-7	Verbal declarative memory;
KIRP	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.64	-0.34	4.7e-8	Testicular germ cell tumor;
KIRP	cis	rs12210905	1.000	rs72843633	chr6:27182949	C/T	cg11502198	chr6:26597334	ABT1	-0.82	-5.1	-0.31	6.95e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12311346	chr5:56204834	C5orf35	-0.37	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09538573	chr8:9952636	MSRA	0.45	6.92	0.4	3.99e-11	Interleukin-4 levels;
KIRP	cis	rs35883536	0.967	rs3904673	chr1:101137162	A/C	cg06223162	chr1:101003688	GPR88	0.33	6.69	0.39	1.45e-10	Monocyte count;
KIRP	cis	rs17286411	0.836	rs13332180	chr16:71929859	C/T	cg04254540	chr16:71951199	KIAA0174	-0.37	-4.93	-0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg00800038	chr16:89945340	TCF25	-0.67	-6.6	-0.39	2.45e-10	Skin colour saturation;
KIRP	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.7	-10.03	-0.54	4.63e-20	Extrinsic epigenetic age acceleration;
KIRP	trans	rs62056376	0.646	rs4795895	chr17:32611446	A/G	cg17635953	chr13:28535085	NA	0.6	6.1	0.36	3.99e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.0	13.79	0.66	1.95e-32	Response to antipsychotic treatment;
KIRP	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg26531700	chr6:26746687	NA	0.4	5.47	0.33	1.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg06740227	chr12:86229804	RASSF9	0.47	5.66	0.34	4.17e-8	Major depressive disorder;
KIRP	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg26207909	chr14:103986467	CKB	-0.49	-6.19	-0.37	2.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.5	-0.33	9.74e-8	Educational attainment;
KIRP	cis	rs7113850	0.541	rs78737372	chr11:24233984	G/A	ch.11.24196551F	chr11:24239977	NA	0.93	7.72	0.44	2.99e-13	Bone fracture in osteoporosis;
KIRP	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.16	0.54	1.8e-20	Exhaled nitric oxide output;
KIRP	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.84	8.06	0.46	3.32e-14	Weight;
KIRP	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.71	-8.41	-0.47	3.45e-15	Pancreatic cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26070281	chr14:21560028	ZNF219	0.52	6.77	0.4	9.25e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.33	-0.37	1.16e-9	Arsenic metabolism;
KIRP	cis	rs780094	0.500	rs4665987	chr2:27755825	G/A	cg05484376	chr2:27715224	FNDC4	-0.35	-5.29	-0.32	2.66e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg22633769	chr20:60982531	CABLES2	-0.51	-6.58	-0.39	2.82e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs909341	0.537	rs6089971	chr20:62385846	G/A	cg03999872	chr20:62272968	STMN3	-0.47	-4.9	-0.3	1.72e-6	Atopic dermatitis;
KIRP	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg07952391	chr2:88470173	THNSL2	0.92	7.57	0.43	7.56e-13	Plasma clusterin levels;
KIRP	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-5.09	-0.31	6.98e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.91	10.53	0.56	1.2e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg08461772	chr7:95026248	PON3	0.41	6.0	0.36	7.12e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.35	-0.32	1.99e-7	Lung cancer;
KIRP	cis	rs10929159	0.928	rs2317305	chr2:236922151	G/A	cg20128773	chr2:236923534	AGAP1	0.3	5.15	0.31	5.25e-7	Parkinson's disease;
KIRP	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	1.0	12.92	0.64	1.71e-29	Vitamin D levels;
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.44	-6.12	-0.36	3.6e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs4731207	0.594	rs6968500	chr7:124431722	G/C	cg05630886	chr7:124431682	NA	-0.34	-5.69	-0.34	3.68e-8	Cutaneous malignant melanoma;
KIRP	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06505273	chr16:24850292	NA	0.38	5.25	0.32	3.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.87	-9.67	-0.52	5.72e-19	Exhaled nitric oxide output;
KIRP	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.24	-0.32	3.37e-7	Coronary artery disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg08862778	chr1:11322643	MTOR	0.53	6.52	0.38	4.06e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg14541582	chr5:601475	NA	-0.55	-6.22	-0.37	2.15e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	1.22	9.15	0.5	2.21e-17	Economic and political preferences (immigration/crime);
KIRP	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.55	-6.56	-0.39	3.12e-10	Glomerular filtration rate;
KIRP	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg02725872	chr8:58115012	NA	-0.53	-5.87	-0.35	1.42e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg16926213	chr1:1841314	NA	0.33	5.59	0.34	5.94e-8	Body mass index;
KIRP	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.65	0.44	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.76	7.76	0.44	2.21e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.56	6.83	0.4	6.5e-11	Aortic root size;
KIRP	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.46	6.36	0.38	9.75e-10	Coronary artery disease;
KIRP	cis	rs501120	0.640	rs10900001	chr10:44695585	C/G	cg09554077	chr10:44749378	NA	0.56	6.04	0.36	5.61e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg21475434	chr5:93447410	FAM172A	-0.45	-5.31	-0.32	2.5e-7	Diabetic retinopathy;
KIRP	cis	rs8060686	0.516	rs9939821	chr16:68167787	T/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-7.07	-0.41	1.56e-11	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg06815112	chr8:27182871	PTK2B	0.5	6.51	0.38	4.16e-10	Neuroticism;
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07402062	chr16:89894098	SPIRE2	0.34	6.99	0.41	2.53e-11	Vitiligo;
KIRP	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.81	12.03	0.61	1.63e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.27	0.32	2.97e-7	Asthma;
KIRP	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21385522	chr1:16154831	NA	0.45	5.58	0.33	6.49e-8	Systolic blood pressure;
KIRP	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.16	-0.31	5.02e-7	Bipolar disorder;
KIRP	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-0.79	-7.7	-0.44	3.32e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg16141378	chr3:129829833	LOC729375	-0.53	-6.63	-0.39	2.16e-10	Retinal vascular caliber;
KIRP	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs42648	0.564	rs39267	chr7:89771509	A/G	cg25739043	chr7:89950458	NA	-0.39	-6.08	-0.36	4.54e-9	Homocysteine levels;
KIRP	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.56	5.88	0.35	1.3e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.5	6.5	0.38	4.33e-10	High light scatter reticulocyte count;
KIRP	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.75	10.47	0.56	1.9e-21	Response to antipsychotic treatment;
KIRP	cis	rs2929278	0.589	rs11638972	chr15:44074691	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.26	-0.37	1.68e-9	Schizophrenia;
KIRP	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg06795125	chr2:108905320	SULT1C2	-0.48	-8.38	-0.47	4.17e-15	Blood pressure;
KIRP	cis	rs754423	0.511	rs1497084	chr14:52521322	A/T	cg10149976	chr14:52535953	NID2	-0.34	-4.85	-0.3	2.18e-6	Craniofacial microsomia;
KIRP	cis	rs8033133	0.602	rs3803326	chr15:25328715	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.47	-5.85	-0.35	1.54e-8	Blood osmolality (transformed sodium);
KIRP	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg20703242	chr1:230279135	GALNT2	0.41	6.8	0.4	7.74e-11	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg06289844	chr6:126071538	HEY2	0.43	6.3	0.37	1.37e-9	Brugada syndrome;
KIRP	cis	rs4478858	0.735	rs7556340	chr1:31788453	A/T	cg00250761	chr1:31883323	NA	-0.31	-5.55	-0.33	7.24e-8	Alcohol dependence;
KIRP	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.83	11.46	0.59	1.18e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17818399	0.675	rs35949012	chr2:46860401	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.65	0.34	4.43e-8	Height;
KIRP	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg13753209	chr17:57696993	CLTC	0.51	4.93	0.3	1.5e-6	Hemoglobin concentration;
KIRP	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg13615516	chr5:77269221	NA	0.52	8.12	0.46	2.28e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg02569458	chr12:86230093	RASSF9	-0.52	-7.64	-0.44	4.79e-13	Major depressive disorder;
KIRP	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg03468072	chr12:39539422	NA	0.39	5.78	0.35	2.24e-8	Morning vs. evening chronotype;
KIRP	cis	rs7929679	0.521	rs10768097	chr11:34792902	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs9308731	0.591	rs10439381	chr2:111936459	A/G	cg04202892	chr2:111875749	ACOXL	0.42	5.72	0.34	3.05e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs1519814	0.956	rs4369033	chr8:121138921	C/A	cg22335954	chr8:121166405	COL14A1	-0.62	-6.35	-0.38	1.03e-9	Breast cancer;
KIRP	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg05315796	chr3:52349193	DNAH1	0.45	6.78	0.4	8.86e-11	Bipolar disorder;
KIRP	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Bipolar disorder;
KIRP	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	5.73	0.34	2.99e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3736485	0.966	rs2414109	chr15:51901015	C/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.22	-0.32	3.83e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg00262122	chr8:11665843	FDFT1	-0.45	-5.35	-0.32	1.99e-7	Triglycerides;
KIRP	cis	rs3120667	0.790	rs3753443	chr1:152387807	C/T	cg26876637	chr1:152193138	HRNR	-0.59	-5.53	-0.33	7.99e-8	Eating disorders;
KIRP	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg00745463	chr17:30367425	LRRC37B	-0.92	-7.37	-0.43	2.53e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.63	7.98	0.45	5.55e-14	Schizophrenia;
KIRP	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	11.8	0.6	9.08e-26	Monocyte count;
KIRP	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg02487422	chr3:49467188	NICN1	0.41	5.7	0.34	3.4e-8	Parkinson's disease;
KIRP	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg02725872	chr8:58115012	NA	-0.75	-7.74	-0.44	2.65e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg00631329	chr6:26305371	NA	-0.65	-9.1	-0.5	3.13e-17	Educational attainment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10230308	chr17:61678218	TACO1	0.49	6.67	0.39	1.71e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16519495	chr1:225782482	ENAH	-0.49	-7.46	-0.43	1.48e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.81	9.62	0.52	8.67e-19	Corneal astigmatism;
KIRP	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.8	-10.63	-0.56	5.61e-22	Breast cancer;
KIRP	cis	rs9920506	0.536	rs1316971	chr15:78930510	A/G	cg24631222	chr15:78858424	CHRNA5	-0.47	-5.25	-0.32	3.21e-7	Post bronchodilator FEV1;
KIRP	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg00677455	chr12:58241039	CTDSP2	-0.46	-5.26	-0.32	3.18e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4950322	0.570	rs72691033	chr1:146732921	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-5.52	-0.33	8.64e-8	Protein quantitative trait loci;
KIRP	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg07001201	chr5:642380	CEP72	0.69	6.55	0.39	3.4e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.58	-7.69	-0.44	3.59e-13	Response to temozolomide;
KIRP	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.35e-7	Bladder cancer;
KIRP	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg05621596	chr22:47072043	GRAMD4	-0.74	-9.15	-0.5	2.17e-17	Urate levels in obese individuals;
KIRP	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.58	-6.38	-0.38	8.56e-10	DNA methylation (variation);
KIRP	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.5	6.55	0.39	3.39e-10	IgG glycosylation;
KIRP	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.93	0.45	7.79e-14	Morning vs. evening chronotype;
KIRP	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.55	-5.8	-0.35	2e-8	Smoking behavior;
KIRP	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg13482628	chr17:19912719	NA	0.62	8.84	0.49	1.84e-16	Schizophrenia;
KIRP	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg27205649	chr11:78285834	NARS2	0.67	8.93	0.49	1.04e-16	Alzheimer's disease (survival time);
KIRP	cis	rs2172802	0.570	rs13142656	chr4:62527386	C/T	cg04118610	chr4:62707027	LPHN3	0.43	5.33	0.32	2.25e-7	Partial epilepsies;
KIRP	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg13319975	chr6:146136371	FBXO30	0.46	6.18	0.37	2.71e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4908768	0.906	rs11584261	chr1:8560366	C/A	cg25722041	chr1:8623473	RERE	0.79	10.01	0.54	5.12e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.85	-0.4	5.76e-11	Bladder cancer;
KIRP	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.69	-9.73	-0.53	3.97e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10861342	1.000	rs11112397	chr12:105568381	T/C	cg23923672	chr12:105501055	KIAA1033	0.87	8.89	0.49	1.29e-16	IgG glycosylation;
KIRP	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.63	-7.66	-0.44	4.34e-13	Gut microbiome composition (summer);
KIRP	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.57	-9.41	-0.51	3.71e-18	Prostate cancer;
KIRP	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23161317	chr6:28129485	ZNF389	0.42	4.92	0.3	1.57e-6	Depression;
KIRP	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.3	5.96	0.36	8.67e-9	Schizophrenia;
KIRP	cis	rs9653442	0.564	rs12712071	chr2:100793876	G/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.33	-0.32	2.21e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.76	10.03	0.54	4.49e-20	Breast cancer;
KIRP	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.34	-0.81	6.97e-58	Ulcerative colitis;
KIRP	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg09788416	chr12:39539408	NA	0.42	5.35	0.32	2.02e-7	Morning vs. evening chronotype;
KIRP	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19524238	chr7:2802976	GNA12	-0.37	-4.95	-0.3	1.4e-6	Height;
KIRP	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.68	-0.34	3.72e-8	Pulmonary function;
KIRP	cis	rs4237845	0.591	rs11172388	chr12:58337132	A/T	cg02175503	chr12:58329896	NA	0.87	10.32	0.55	5.56e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2072732	0.716	rs72856433	chr1:2954061	G/A	cg11731671	chr1:2995604	PRDM16	-0.44	-5.83	-0.35	1.7e-8	Plateletcrit;
KIRP	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg16255804	chr6:135334527	HBS1L	0.31	4.96	0.3	1.33e-6	Red blood cell count;
KIRP	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.41	-5.38	-0.32	1.74e-7	Blood protein levels;
KIRP	cis	rs9596863	1.000	rs1379831	chr13:54418506	C/G	ch.13.53330881F	chr13:54432880	NA	0.49	5.24	0.32	3.37e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26629188	chr21:47878281	DIP2A	0.52	6.1	0.36	4.18e-9	Smoking initiation;
KIRP	cis	rs2694528	0.544	rs6449481	chr5:59911179	G/C	cg11474532	chr5:59995715	DEPDC1B	0.84	6.43	0.38	6.4e-10	Parkinson's disease;
KIRP	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.57	7.05	0.41	1.75e-11	Total body bone mineral density;
KIRP	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.85	-12.28	-0.62	2.33e-27	Alzheimer's disease (survival time);
KIRP	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg11584989	chr19:19387371	SF4	0.42	5.3	0.32	2.53e-7	Tonsillectomy;
KIRP	trans	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg18335740	chr13:41363409	SLC25A15	0.48	7.12	0.41	1.18e-11	Lewy body disease;
KIRP	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	6.33	0.37	1.15e-9	Platelet count;
KIRP	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.43	-7.85	-0.45	1.26e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.84	12.99	0.64	1e-29	Total body bone mineral density;
KIRP	cis	rs35955747	0.870	rs4820969	chr22:31773573	C/G	cg02404636	chr22:31891804	SFI1	-0.37	-4.91	-0.3	1.63e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	trans	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg01620082	chr3:125678407	NA	-1.14	-6.68	-0.39	1.55e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.52	-6.98	-0.41	2.66e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.65	-7.62	-0.44	5.48e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.4	5.24	0.32	3.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs494562	0.892	rs7771860	chr6:86130729	C/T	cg21730993	chr6:86159210	NT5E	0.51	5.19	0.31	4.35e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13316171	chr2:187351035	ZC3H15	0.53	6.51	0.38	4.13e-10	Inflammatory biomarkers;
KIRP	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07080220	chr10:102295463	HIF1AN	0.77	7.09	0.41	1.46e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg06609049	chr19:2785107	THOP1	0.9	11.17	0.58	1.09e-23	Total cholesterol levels;
KIRP	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.58	0.48	1.07e-15	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13939156	chr17:80058883	NA	-0.48	-7.21	-0.42	7.02e-12	Life satisfaction;
KIRP	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21659725	chr3:3221576	CRBN	-0.58	-7.15	-0.41	9.79e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9296736	1.000	rs9296736	chr6:53924697	A/G	cg04374786	chr6:53939321	C6orf142	0.39	5.19	0.31	4.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.12e-22	Coronary artery disease;
KIRP	cis	rs6968419	0.714	rs7811984	chr7:115886079	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.04	-0.36	5.73e-9	Intraocular pressure;
KIRP	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6496667	1.000	rs4261510	chr15:90890606	G/A	cg10434728	chr15:90938212	IQGAP1	0.38	5.05	0.31	8.48e-7	Rheumatoid arthritis;
KIRP	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.67	-0.34	3.91e-8	Huntington's disease progression;
KIRP	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.67	6.07	0.36	4.91e-9	Schizophrenia;
KIRP	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.07	-0.54	3.41e-20	Hemoglobin concentration;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09497020	chr5:893046	TRIP13;BRD9	-0.44	-6.03	-0.36	6.09e-9	Metabolic traits;
KIRP	cis	rs17065868	1.000	rs9533923	chr13:45169096	A/G	cg10246903	chr13:45222710	NA	0.71	6.6	0.39	2.56e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg02038168	chr22:39784481	NA	-0.42	-4.93	-0.3	1.53e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs929596	0.531	rs2741019	chr2:234510688	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-5.41	-0.33	1.46e-7	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs405956	1.000	rs9322831	chr6:105558337	G/A	cg22580625	chr6:105627791	POPDC3	-0.61	-6.58	-0.39	2.77e-10	QT interval;
KIRP	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg12131826	chr15:77904385	NA	0.47	6.41	0.38	7.51e-10	Type 2 diabetes;
KIRP	cis	rs1656402	0.906	rs1190435	chr2:233424106	A/G	cg03852847	chr2:233439513	NA	0.7	11.53	0.59	6.86e-25	Non-small cell lung cancer (survival);
KIRP	cis	rs57994353	0.598	rs72775768	chr9:139324574	C/T	cg14169450	chr9:139327907	INPP5E	0.6	7.91	0.45	8.72e-14	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs2997447	0.669	rs61776624	chr1:26474580	A/C	cg19633962	chr1:26362018	EXTL1	-0.55	-4.88	-0.3	1.92e-6	QRS complex (12-leadsum);
KIRP	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.33e-20	Hemoglobin concentration;
KIRP	cis	rs78545713	0.649	rs114015443	chr6:26221979	A/G	cg01420254	chr6:26195488	NA	1.21	7.59	0.44	6.71e-13	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.72	0.34	3.1e-8	Homoarginine levels;
KIRP	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.76	10.2	0.55	1.3e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4400599	0.642	rs4072431	chr1:154167116	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.42	-6.1	-0.36	4.17e-9	Platelet distribution width;
KIRP	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg19847130	chr8:10466454	RP1L1	0.37	5.46	0.33	1.16e-7	Triglycerides;
KIRP	cis	rs7615316	0.779	rs4608715	chr3:142051147	T/C	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.3e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.42	5.39	0.33	1.63e-7	Aortic root size;
KIRP	cis	rs6815814	0.768	rs6851685	chr4:38893843	G/T	cg06935464	chr4:38784597	TLR10	0.55	6.27	0.37	1.58e-9	Breast cancer;
KIRP	cis	rs228437	1.000	rs985121	chr6:134930893	C/T	cg24504307	chr6:134963096	NA	-0.53	-7.75	-0.44	2.49e-13	Melanoma;
KIRP	cis	rs7116495	1.000	rs2511116	chr11:71802160	G/A	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg10818794	chr15:86012489	AKAP13	-0.52	-7.33	-0.42	3.38e-12	Coronary artery disease;
KIRP	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.56	6.78	0.4	9.05e-11	Breast cancer;
KIRP	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg00857998	chr1:205179979	DSTYK	0.48	6.11	0.36	3.87e-9	Red blood cell count;
KIRP	cis	rs6142102	0.602	rs2268086	chr20:32648738	C/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-5.55	-0.33	7.43e-8	Skin pigmentation;
KIRP	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08508325	chr11:3079039	CARS	0.31	5.73	0.34	2.97e-8	Calcium levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04703844	chr8:74207197	RPL7;RDH10	0.67	8.01	0.45	4.5e-14	Smoking initiation;
KIRP	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg23340505	chr13:114927933	NA	0.33	5.13	0.31	5.75e-7	Schizophrenia;
KIRP	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.73	8.96	0.5	8.52e-17	Mammographic density (dense area);
KIRP	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg07382826	chr16:28625726	SULT1A1	0.51	6.06	0.36	4.95e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg10434728	chr15:90938212	IQGAP1	0.42	7.98	0.45	5.64e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.68	9.09	0.5	3.5e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs17067123	0.614	rs6857116	chr4:180062542	G/A	cg26610307	chr4:180072759	NA	-0.45	-4.88	-0.3	1.88e-6	Response to hepatitis C treatment;
KIRP	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg24579218	chr15:68104479	NA	-0.36	-5.22	-0.32	3.83e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs6832769	1.000	rs10005989	chr4:56405206	C/T	cg09317128	chr4:56265301	TMEM165	-0.55	-7.35	-0.42	2.89e-12	Personality dimensions;
KIRP	cis	rs73200209	0.744	rs58471589	chr12:116573035	A/C	cg01776926	chr12:116560359	MED13L	-0.54	-6.01	-0.36	6.62e-9	Total body bone mineral density;
KIRP	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21545522	chr1:205238299	TMCC2	0.5	6.56	0.39	3.21e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21859337	chr1:117210332	IGSF3	0.49	6.02	0.36	6.38e-9	Parkinson's disease;
KIRP	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.37	8.5	0.48	1.88e-15	Asthma (sex interaction);
KIRP	cis	rs13326165	0.585	rs724801	chr3:52488517	C/T	cg01348873	chr3:52349823	DNAH1	0.71	5.37	0.32	1.81e-7	HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs4984778	0.717	rs2738892	chr16:1268758	A/G	cg09075268	chr16:1270372	CACNA1H	0.54	6.72	0.39	1.26e-10	Blood protein levels;
KIRP	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	6.43	0.38	6.46e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.52	0.43	1.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.45	-5.6	-0.34	5.76e-8	Aortic root size;
KIRP	cis	rs33912345	0.750	rs1271527	chr14:60859698	G/A	cg27398547	chr14:60952738	C14orf39	-0.39	-5.12	-0.31	6.21e-7	Glaucoma (high intraocular pressure);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07479961	chr18:658340	TYMS;C18orf56	0.54	6.61	0.39	2.3e-10	Parkinson's disease;
KIRP	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg20387954	chr3:183756860	HTR3D	0.55	8.18	0.46	1.54e-14	Anterior chamber depth;
KIRP	cis	rs930036	0.576	rs6724493	chr2:171779109	C/T	cg12801329	chr2:171670795	NA	0.46	5.24	0.32	3.44e-7	Menopause (age at onset);
KIRP	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg18694418	chr7:2742484	AMZ1	0.46	5.18	0.31	4.73e-7	Height;
KIRP	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg11632617	chr15:75315747	PPCDC	-0.65	-5.71	-0.34	3.22e-8	Lung cancer;
KIRP	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.48	5.8	0.35	2.01e-8	Asthma (sex interaction);
KIRP	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.2	-0.31	4.16e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg07393940	chr7:158741817	NA	0.46	6.29	0.37	1.48e-9	Life satisfaction;
KIRP	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	4.89	0.3	1.8e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs11203032	0.831	rs11203019	chr10:90952774	A/T	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg23682824	chr7:23144976	KLHL7	0.44	5.27	0.32	3.02e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg09695851	chr17:3907499	NA	0.54	7.32	0.42	3.55e-12	Type 2 diabetes;
KIRP	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	1.2	11.38	0.59	2.16e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7394190	0.748	rs1057410	chr10:75574079	G/A	cg04833713	chr10:74871078	NUDT13	0.46	5.06	0.31	8.29e-7	Incident atrial fibrillation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06943149	chr12:77157476	ZDHHC17	0.59	7.29	0.42	4.18e-12	Smoking initiation;
KIRP	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.71	-0.49	4.6e-16	Neuroticism;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08743896	chr10:65200160	JMJD1C	0.43	6.27	0.37	1.64e-9	Migraine with aura;
KIRP	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	4.96	0.3	1.3e-6	Resting heart rate;
KIRP	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	cis	rs4762326	0.966	rs3596	chr12:95696420	A/G	cg07737802	chr12:95537812	FGD6	0.46	6.49	0.38	4.59e-10	Endometriosis;
KIRP	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.2	0.42	7.39e-12	Bipolar disorder;
KIRP	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23281280	chr6:28129359	ZNF389	0.44	4.87	0.3	2.01e-6	Depression;
KIRP	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.67	-7.59	-0.44	6.61e-13	Lung cancer;
KIRP	cis	rs2275565	0.872	rs3768136	chr1:237027453	T/A	cg17297354	chr1:237056641	MTR	-0.4	-5.11	-0.31	6.33e-7	Homocysteine levels;
KIRP	cis	rs7809950	0.559	rs2248465	chr7:107303628	C/T	cg23024343	chr7:107201750	COG5	0.46	6.97	0.41	2.95e-11	Coronary artery disease;
KIRP	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.55	7.05	0.41	1.83e-11	Crohn's disease;
KIRP	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	0.95	17.16	0.74	6.35e-44	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.38	-0.78	2.03e-51	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg19592336	chr6:28129416	ZNF389	0.52	5.87	0.35	1.42e-8	Depression;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18863203	chr18:6898679	ARHGAP28	-0.4	-6.02	-0.36	6.32e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs17772222	0.606	rs1955598	chr14:88823655	C/T	cg01893041	chr5:67583972	PIK3R1	-0.51	-6.5	-0.38	4.46e-10	Coronary artery calcification;
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg01765077	chr12:122356316	WDR66	-0.48	-6.4	-0.38	7.63e-10	Mean corpuscular volume;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg16645202	chr15:92397488	SLCO3A1	0.46	6.13	0.36	3.55e-9	Colorectal cancer;
KIRP	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.52	-6.82	-0.4	6.87e-11	Pancreatic cancer;
KIRP	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg02462569	chr6:150064036	NUP43	-0.33	-4.85	-0.3	2.18e-6	Lung cancer;
KIRP	cis	rs16976116	0.901	rs1061873	chr15:55496756	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg13132307	chr17:10533415	MYH3	0.41	6.2	0.37	2.33e-9	Educational attainment;
KIRP	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.65	7.77	0.44	2.11e-13	Corneal astigmatism;
KIRP	trans	rs1422110	0.543	rs888804	chr5:85411181	G/A	cg01787110	chr1:109008453	NBPF6	0.63	7.95	0.45	6.9e-14	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs11209002	0.614	rs4655673	chr1:67555018	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	6.59	0.39	2.63e-10	Crohn's disease;
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.38	-4.89	-0.3	1.78e-6	Testicular germ cell tumor;
KIRP	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg21926883	chr2:100939477	LONRF2	-0.52	-7.03	-0.41	2e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.530	rs36019144	chr17:3987499	T/C	cg09597638	chr17:3907349	NA	0.55	5.57	0.33	6.58e-8	Type 2 diabetes;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02359409	chr6:42947317	PEX6	-0.47	-6.18	-0.37	2.68e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	1.25	9.23	0.51	1.27e-17	LDL cholesterol;
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg05342682	chr7:94953680	PON1	-0.61	-8.4	-0.47	3.5e-15	Paraoxonase activity;
KIRP	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-10.38	-0.55	3.52e-21	Neuroticism;
KIRP	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.24	-12.39	-0.62	9.95e-28	Atopic dermatitis;
KIRP	cis	rs12822507	0.732	rs4555	chr12:12796872	T/C	cg11838227	chr12:12764436	CREBL2	0.43	5.05	0.31	8.52e-7	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01839850	chr22:38240395	ANKRD54;MIR658	0.61	7.27	0.42	4.67e-12	Smoking initiation;
KIRP	cis	rs6558530	0.615	rs12674711	chr8:1699608	A/G	cg08198773	chr8:1697536	NA	0.5	6.23	0.37	1.98e-9	Systolic blood pressure;
KIRP	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg04289385	chr6:36355825	ETV7	0.43	6.83	0.4	6.48e-11	Platelet distribution width;
KIRP	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.61	6.82	0.4	7.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg13808641	chr9:96006533	WNK2	-0.4	-6.11	-0.36	3.87e-9	Liver enzyme levels;
KIRP	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.81	-8.73	-0.49	3.85e-16	Prostate cancer;
KIRP	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22542300	chr6:7585749	DSP	-0.54	-6.91	-0.4	4.25e-11	Parkinson's disease;
KIRP	cis	rs698833	0.828	rs3738984	chr2:44531484	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.5	-6.02	-0.36	6.18e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs9650657	0.836	rs4841438	chr8:10606756	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.19	-0.37	2.44e-9	Neuroticism;
KIRP	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-4.98	-0.3	1.19e-6	Joint mobility (Beighton score);
KIRP	cis	rs2594989	1.000	rs2595002	chr3:11373700	G/A	cg01796438	chr3:11312864	ATG7	-0.56	-6.95	-0.4	3.32e-11	Circulating chemerin levels;
KIRP	cis	rs507506	0.712	rs1875673	chr17:7108506	T/G	cg25256661	chr17:7137939	DVL2	-0.81	-11.11	-0.58	1.66e-23	Adiponectin levels;
KIRP	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.48	-6.35	-0.38	1.02e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	6.29	0.37	1.43e-9	Height;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00509281	chr10:62554092	CDC2;CDK1	0.41	6.39	0.38	8.46e-10	C-reactive protein;
KIRP	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg19761014	chr17:28927070	LRRC37B2	0.68	6.52	0.38	3.88e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs62056376	0.736	rs1233651	chr17:32639361	C/T	cg06688323	chr4:4858340	NA	0.59	6.25	0.37	1.77e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.26	0.62	2.85e-27	Ileal carcinoids;
KIRP	cis	rs26949	0.503	rs1867702	chr5:59897983	T/C	cg02684056	chr5:59996105	DEPDC1B	0.45	5.25	0.32	3.31e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs662064	0.962	rs648324	chr1:10556447	G/T	cg19773385	chr1:10388646	KIF1B	0.4	5.11	0.31	6.39e-7	Asthma;
KIRP	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.64	7.69	0.44	3.46e-13	Obesity-related traits;
KIRP	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.33	5.04	0.31	8.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.46	6.39	0.38	8.41e-10	Dupuytren's disease;
KIRP	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg16141378	chr3:129829833	LOC729375	0.52	6.8	0.4	7.89e-11	Retinal vascular caliber;
KIRP	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.41	5.36	0.32	1.93e-7	Childhood ear infection;
KIRP	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-5.6	-0.34	5.83e-8	Height;
KIRP	cis	rs12681288	0.782	rs2600499	chr8:1026619	C/T	cg08648136	chr8:956695	NA	0.45	5.86	0.35	1.44e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01623984	chr12:120632437	GCN1L1	0.56	7.11	0.41	1.29e-11	Parkinson's disease;
KIRP	cis	rs7187994	0.848	rs7185949	chr16:84779248	T/G	cg07647771	chr16:84786436	USP10	-0.43	-5.54	-0.33	7.74e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2273669	0.588	rs78276890	chr6:109305299	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.43	-4.98	-0.3	1.2e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs12406019	0.510	rs12126464	chr1:78608215	T/C	cg20826526	chr3:156266748	SSR3	-0.46	-6.11	-0.36	3.94e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.47	-0.38	5.12e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.78	12.44	0.62	6.84e-28	Coronary artery disease;
KIRP	cis	rs28489187	0.683	rs1498373	chr1:85790633	G/A	cg16011679	chr1:85725395	C1orf52	0.54	6.55	0.39	3.39e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs13401104	0.796	rs1530956	chr2:237111086	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.78	-10.9	-0.57	7.8e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg00310523	chr12:86230176	RASSF9	0.55	8.6	0.48	9.5e-16	Major depressive disorder;
KIRP	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.51	6.22	0.37	2.07e-9	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs367943	0.799	rs10057321	chr5:112974729	A/G	cg12552261	chr5:112820674	MCC	0.6	6.4	0.38	7.68e-10	Type 2 diabetes;
KIRP	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg27608139	chr16:2294856	DCI	0.46	5.87	0.35	1.42e-8	Height;
KIRP	cis	rs6968419	0.788	rs72603592	chr7:115831195	C/T	cg02561103	chr7:115862891	TES	-0.35	-4.86	-0.3	2.08e-6	Intraocular pressure;
KIRP	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg00262122	chr8:11665843	FDFT1	0.41	5.12	0.31	6.15e-7	Neuroticism;
KIRP	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg02175503	chr12:58329896	NA	0.74	9.2	0.51	1.59e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg01304814	chr3:48885189	PRKAR2A	0.69	5.32	0.32	2.37e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.66	-12.44	-0.62	6.87e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.55	7.14	0.41	1.04e-11	Breast cancer;
KIRP	cis	rs684232	0.583	rs2543776	chr17:557149	G/A	cg15660573	chr17:549704	VPS53	-0.88	-13.52	-0.65	1.57e-31	Prostate cancer;
KIRP	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00321850	chr1:175162397	KIAA0040	-0.34	-6.17	-0.37	2.77e-9	Alcohol dependence;
KIRP	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18252515	chr7:66147081	NA	0.42	4.87	0.3	1.96e-6	Calcium levels;
KIRP	cis	rs2151522	0.762	rs9372846	chr6:127154752	C/G	cg21431617	chr6:127135037	NA	0.3	5.29	0.32	2.69e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg17207736	chr8:142237307	SLC45A4	-0.52	-6.68	-0.39	1.62e-10	Immature fraction of reticulocytes;
KIRP	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.39	5.58	0.34	6.24e-8	Sitting height ratio;
KIRP	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-6.04	-0.36	5.51e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.79	-15.03	-0.69	1.2e-36	Obesity-related traits;
KIRP	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.14	9.53	0.52	1.59e-18	Cognitive function;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg08560604	chr13:90014813	NA	-0.4	-6.09	-0.36	4.26e-9	Inflammatory biomarkers;
KIRP	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.73	11.07	0.58	2.23e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg15488143	chr7:128924101	AHCYL2	0.57	6.23	0.37	2.05e-9	White matter hyperintensity burden;
KIRP	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg20636351	chr8:55087400	NA	0.62	7.63	0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.55	-5.38	-0.32	1.74e-7	Pubertal anthropometrics;
KIRP	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.27	0.42	4.71e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg09873164	chr1:152488093	CRCT1	0.58	7.25	0.42	5.54e-12	Hair morphology;
KIRP	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-5.84	-0.35	1.66e-8	Metabolite levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22818913	chr6:37467785	C6orf129	-0.47	-6.18	-0.37	2.61e-9	Metabolic traits;
KIRP	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg16482183	chr6:26056742	HIST1H1C	0.45	5.65	0.34	4.42e-8	Height;
KIRP	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.53	-6.39	-0.38	8.45e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8028182	0.636	rs12909863	chr15:75825822	G/C	cg20655648	chr15:75932815	IMP3	0.55	7.06	0.41	1.7e-11	Sudden cardiac arrest;
KIRP	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.49	-6.21	-0.37	2.24e-9	Coronary heart disease;
KIRP	cis	rs2737618	0.722	rs2821330	chr1:200082464	C/T	cg21825944	chr1:200113062	NR5A2	0.56	7.54	0.43	8.86e-13	Uric acid levels;
KIRP	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.4	-5.33	-0.32	2.28e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg13293535	chr8:11597251	GATA4	-0.38	-4.94	-0.3	1.44e-6	Retinal vascular caliber;
KIRP	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.56	-7.15	-0.41	9.88e-12	Iron status biomarkers;
KIRP	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg21361702	chr7:150065534	REPIN1	0.67	6.73	0.39	1.17e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.76	-7.29	-0.42	4.26e-12	Psoriasis vulgaris;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg07374928	chr11:126099286	FAM118B	-0.41	-6.17	-0.37	2.82e-9	Inflammatory biomarkers;
KIRP	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13198984	chr17:80129470	CCDC57	-0.58	-8.78	-0.49	2.83e-16	Life satisfaction;
KIRP	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg17524265	chr8:144659883	NAPRT1	0.79	5.05	0.31	8.58e-7	Attention deficit hyperactivity disorder;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11848740	chr1:185113945	C1orf25	0.38	6.03	0.36	5.97e-9	C-reactive protein;
KIRP	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg24633833	chr3:10029261	TMEM111	0.48	4.93	0.3	1.53e-6	Alzheimer's disease;
KIRP	cis	rs6466055	0.661	rs6950104	chr7:104877373	G/A	cg04380332	chr7:105027541	SRPK2	0.38	5.21	0.32	4e-7	Schizophrenia;
KIRP	cis	rs6793245	0.810	rs9843500	chr3:38588095	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.55	-6.7	-0.39	1.39e-10	QT interval;
KIRP	cis	rs12618769	0.597	rs4851131	chr2:99036802	A/C	cg10123293	chr2:99228465	UNC50	0.44	4.88	0.3	1.92e-6	Bipolar disorder;
KIRP	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.73	9.5	0.52	1.91e-18	Body mass index;
KIRP	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19929409	chr14:56755226	PELI2	-0.42	-6.07	-0.36	4.84e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.5	6.87	0.4	5.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.25	0.32	3.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.81	-0.57	1.53e-22	Menopause (age at onset);
KIRP	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg20488157	chr14:104394430	TDRD9	0.74	10.71	0.56	3.2e-22	Bipolar disorder;
KIRP	cis	rs258892	0.895	rs2338790	chr5:72055184	A/T	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg24112000	chr20:60950667	NA	0.56	8.59	0.48	1.02e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg05973401	chr12:123451056	ABCB9	0.55	6.26	0.37	1.69e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7737355	0.853	rs26004	chr5:130988955	G/T	cg25547332	chr5:131281432	NA	0.39	4.92	0.3	1.59e-6	Life satisfaction;
KIRP	cis	rs6568686	0.730	rs4947120	chr6:111819044	G/A	cg15721981	chr6:111408429	SLC16A10	-0.69	-5.96	-0.36	8.63e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg21775007	chr8:11205619	TDH	-0.52	-6.66	-0.39	1.81e-10	Neuroticism;
KIRP	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg26752003	chr8:145688521	CYHR1	0.7	9.22	0.51	1.36e-17	Age at first birth;
KIRP	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	-0.86	-8.14	-0.46	2.04e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	1.01	10.46	0.55	1.98e-21	Eosinophilic esophagitis;
KIRP	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.49	-5.39	-0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.69	7.75	0.44	2.48e-13	Vitiligo;
KIRP	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07256732	chr16:621771	PIGQ	-0.43	-5.98	-0.36	7.85e-9	Height;
KIRP	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg03152288	chr2:177042942	NA	-0.5	-5.98	-0.36	7.7e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs13033859	0.894	rs1996398	chr2:181196	G/T	cg10118717	chr2:203439	NA	-0.47	-7.72	-0.44	2.98e-13	Mitochondrial DNA levels;
KIRP	cis	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg06521331	chr12:34319734	NA	-0.62	-7.53	-0.43	9.9e-13	Morning vs. evening chronotype;
KIRP	cis	rs2970992	0.764	rs7558261	chr2:101324632	A/T	cg01042948	chr2:101319752	NA	0.46	6.92	0.4	3.95e-11	Educational attainment;
KIRP	cis	rs15676	0.947	rs2805103	chr9:131598897	T/A	cg00228799	chr9:131580591	ENDOG	0.58	6.61	0.39	2.39e-10	Blood metabolite levels;
KIRP	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg02711726	chr17:80685570	FN3KRP	-0.52	-7.19	-0.42	7.59e-12	Glycated hemoglobin levels;
KIRP	cis	rs7523273	0.564	rs7543097	chr1:207882592	T/G	cg22525895	chr1:207977042	MIR29B2	0.49	5.97	0.36	8.43e-9	Schizophrenia;
KIRP	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg11657440	chr19:46296263	DMWD	-0.74	-9.63	-0.52	7.83e-19	Coronary artery disease;
KIRP	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.69	9.39	0.51	4.3e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs447921	0.813	rs4419085	chr17:74443683	C/T	cg16776035	chr17:74542680	NA	0.56	5.14	0.31	5.65e-7	Mitochondrial DNA levels;
KIRP	cis	rs2282032	1.000	rs114316342	chr14:90736477	C/T	cg04374321	chr14:90722782	PSMC1	0.59	5.58	0.34	6.23e-8	Longevity;
KIRP	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg15839431	chr19:19639596	YJEFN3	-0.5	-5.25	-0.32	3.22e-7	Bipolar disorder;
KIRP	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.43	-5.38	-0.32	1.7e-7	IgG glycosylation;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg21982660	chr20:17922310	SNX5	-0.49	-6.71	-0.39	1.34e-10	Bladder cancer;
KIRP	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.73	7.7	0.44	3.3e-13	Obesity-related traits;
KIRP	trans	rs12517041	0.935	rs10077662	chr5:23294524	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.96	-0.5	8.24e-17	Calcium levels;
KIRP	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.54	-6.95	-0.4	3.35e-11	Longevity;
KIRP	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.62	-5.51	-0.33	9.26e-8	Putamen volume;
KIRP	cis	rs4472734	0.813	rs6698007	chr1:214624286	A/C	cg00063699	chr1:214624242	PTPN14	-0.45	-6.43	-0.38	6.42e-10	Height;
KIRP	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg11502198	chr6:26597334	ABT1	0.54	6.84	0.4	6.35e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg14403583	chr14:105418241	AHNAK2	0.64	8.72	0.49	4.28e-16	Rheumatoid arthritis;
KIRP	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.81	10.15	0.54	1.8899999999999998e-20	Total cholesterol levels;
KIRP	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.72	-8.74	-0.49	3.63e-16	Blood protein levels;
KIRP	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg27205649	chr11:78285834	NARS2	-0.6	-7.04	-0.41	1.89e-11	Testicular germ cell tumor;
KIRP	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg23307798	chr14:103986281	CKB	-0.5	-5.43	-0.33	1.35e-7	Coronary artery disease;
KIRP	cis	rs1190596	0.525	rs6575901	chr14:102691854	A/G	cg18135206	chr14:102964638	TECPR2	0.46	5.1	0.31	6.75e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg08975724	chr8:8085496	FLJ10661	0.7	9.41	0.51	3.58e-18	Mood instability;
KIRP	cis	rs7665939	1.000	rs72709215	chr4:190112465	C/A	cg14840187	chr4:190284988	NA	-0.95	-6.88	-0.4	4.8e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	11.56	0.59	5.63e-25	Total body bone mineral density;
KIRP	cis	rs2151522	0.724	rs9385405	chr6:127106997	G/C	cg21431617	chr6:127135037	NA	0.28	5.36	0.32	1.93e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6142102	0.961	rs2268080	chr20:32597716	G/A	cg08999081	chr20:33150536	PIGU	0.49	5.83	0.35	1.7e-8	Skin pigmentation;
KIRP	cis	rs362272	0.525	rs1313768	chr4:3054017	T/C	cg14003022	chr4:3043019	NA	-0.38	-4.97	-0.3	1.24e-6	Serum sulfate level;
KIRP	cis	rs1619661	0.530	rs1623851	chr10:44691241	C/T	cg09554077	chr10:44749378	NA	-0.43	-6.39	-0.38	8.39e-10	QT interval (ambient particulate matter interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14926149	chr2:148602819	ACVR2A	0.45	6.13	0.36	3.51e-9	Survival in pancreatic cancer;
KIRP	cis	rs684232	0.835	rs12450003	chr17:519015	T/C	cg15660573	chr17:549704	VPS53	-0.52	-6.56	-0.39	3.19e-10	Prostate cancer;
KIRP	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg24315340	chr6:146058215	EPM2A	-0.39	-5.03	-0.31	9.58e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9783347	1.000	rs10741741	chr11:18342081	C/T	cg15585147	chr11:18324498	HPS5	-0.37	-5.05	-0.31	8.5e-7	Pancreatic cancer;
KIRP	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg23594656	chr7:65796392	TPST1	0.38	5.63	0.34	4.97e-8	Aortic root size;
KIRP	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.89	12.18	0.61	5e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs4740619	0.619	rs1328280	chr9:16030903	C/T	cg14451791	chr9:16040625	NA	0.4	5.23	0.32	3.55e-7	Body mass index;
KIRP	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg12826209	chr6:26865740	GUSBL1	0.8	5.39	0.32	1.67e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	trans	rs16971802	0.881	rs7217473	chr17:34319064	C/T	cg21918548	chr8:145956024	ZNF251	-0.54	-6.16	-0.37	2.99e-9	Blood protein levels;
KIRP	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.62	-0.44	5.58e-13	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.0	0.61	2.01e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.37	-5.79	-0.35	2.1e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08704250	chr15:31115839	NA	-0.59	-8.46	-0.47	2.43e-15	Huntington's disease progression;
KIRP	trans	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs78487399	0.710	rs76857293	chr2:43591676	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-4.96	-0.3	1.31e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	7.61	0.44	5.88e-13	Lymphocyte counts;
KIRP	cis	rs17123764	0.818	rs7977389	chr12:49981722	T/C	cg02054252	chr12:50078554	FMNL3	0.47	5.46	0.33	1.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.73	-10.84	-0.57	1.22e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.78	6.81	0.4	7.57e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.59	-8.08	-0.46	2.93e-14	Vitiligo;
KIRP	cis	rs2387326	0.717	rs12254442	chr10:129945793	C/T	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.47	0.38	5.34e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6988636	0.818	rs62521808	chr8:124169568	C/T	cg23067535	chr8:124195133	FAM83A	-0.81	-6.63	-0.39	2.14e-10	Urinary uromodulin levels;
KIRP	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	6.98	0.41	2.79e-11	Height;
KIRP	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg02725872	chr8:58115012	NA	-0.36	-4.93	-0.3	1.51e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg00745463	chr17:30367425	LRRC37B	0.75	6.51	0.38	4.18e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.87	-7.76	-0.44	2.33e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7565981	1.000	rs7593399	chr2:101424409	C/T	cg02232089	chr2:101440696	NPAS2	-0.58	-5.42	-0.33	1.45e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs11997175	0.646	rs6468196	chr8:33734183	T/C	ch.8.33884649F	chr8:33765107	NA	0.58	6.47	0.38	5.38e-10	Body mass index;
KIRP	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	cg12689670	chr1:183009347	LAMC1	0.45	6.38	0.38	8.57e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.29	7.81	0.45	1.64e-13	Crohn's disease;
KIRP	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.51	6.0	0.36	7.15e-9	Multiple sclerosis;
KIRP	cis	rs9815354	0.812	rs73828254	chr3:41810180	T/A	cg03022575	chr3:42003672	ULK4	0.81	8.32	0.47	6.13e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs16828019	0.777	rs12748235	chr1:41466221	G/A	cg24596898	chr1:41849189	NA	0.64	4.93	0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7106204	0.614	rs117122818	chr11:24245880	C/T	ch.11.24196551F	chr11:24239977	NA	0.94	7.89	0.45	9.72e-14	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg06636001	chr8:8085503	FLJ10661	-0.82	-12.03	-0.61	1.62e-26	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21160824	chr9:131710451	NUP188;DOLK	0.5	6.91	0.4	4.22e-11	Parkinson's disease;
KIRP	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	1.05	17.44	0.74	6.65e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7635838	0.892	rs3942925	chr3:11442921	T/C	cg00170343	chr3:11313890	ATG7	0.45	5.8	0.35	2.06e-8	HDL cholesterol;
KIRP	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg21775007	chr8:11205619	TDH	-0.5	-6.48	-0.38	4.99e-10	Systolic blood pressure;
KIRP	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg21475434	chr5:93447410	FAM172A	-0.45	-5.08	-0.31	7.3e-7	Diabetic retinopathy;
KIRP	cis	rs62355272	0.965	rs987107	chr5:35875227	C/T	cg13894535	chr5:35919491	CAPSL	-0.52	-6.32	-0.37	1.22e-9	Lymphocyte counts;
KIRP	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.67	-9.21	-0.51	1.46e-17	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs7172677	1.000	rs55662404	chr15:75432341	G/A	cg14664628	chr15:75095509	CSK	0.56	5.9	0.35	1.22e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	0.79	8.24	0.46	1.05e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs6669919	0.565	rs10863911	chr1:211686860	C/T	cg10512769	chr1:211675356	NA	-0.41	-5.24	-0.32	3.41e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	7.36	0.42	2.77e-12	Morning vs. evening chronotype;
KIRP	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.2	22.58	0.82	6.74e-62	Schizophrenia;
KIRP	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	13.02	0.64	7.78e-30	Menopause (age at onset);
KIRP	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg03653399	chr8:142233436	SLC45A4	-0.72	-9.53	-0.52	1.62e-18	Immature fraction of reticulocytes;
KIRP	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.39	-5.06	-0.31	8.25e-7	Blood protein levels;
KIRP	cis	rs4936894	0.500	rs10893165	chr11:124077170	G/A	cg27160556	chr11:124181099	OR8D1	-0.4	-5.94	-0.35	9.6e-9	Aging (time to death);
KIRP	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06544989	chr22:39130855	UNC84B	0.52	8.31	0.47	6.32e-15	Menopause (age at onset);
KIRP	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-6.5	-0.38	4.47e-10	Retinal vascular caliber;
KIRP	cis	rs367943	0.672	rs1517207	chr5:112717245	G/A	cg12552261	chr5:112820674	MCC	0.56	6.61	0.39	2.32e-10	Type 2 diabetes;
KIRP	trans	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg16141378	chr3:129829833	LOC729375	0.46	6.04	0.36	5.71e-9	Mood instability;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.09	-0.41	1.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg15893493	chr8:124194847	FAM83A	0.88	7.32	0.42	3.62e-12	Urinary uromodulin levels;
KIRP	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg03808351	chr9:123631620	PHF19	0.41	5.58	0.34	6.33e-8	Rheumatoid arthritis;
KIRP	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg22467129	chr15:76604101	ETFA	-0.39	-5.45	-0.33	1.24e-7	Blood metabolite levels;
KIRP	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.39	0.32	1.66e-7	Alzheimer's disease;
KIRP	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.23	-0.42	5.97e-12	Type 2 diabetes;
KIRP	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg23625390	chr15:77176239	SCAPER	-0.78	-10.77	-0.57	2.07e-22	Blood metabolite levels;
KIRP	cis	rs9912468	0.934	rs8071250	chr17:64321567	C/T	cg19474267	chr17:64306194	PRKCA	-0.65	-9.46	-0.52	2.69e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.46	-6.88	-0.4	4.81e-11	Vitamin D levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12885476	chr2:191514216	NAB1	0.46	6.02	0.36	6.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10464059	0.511	rs3805705	chr5:179738237	T/C	cg23248424	chr5:179741104	GFPT2	0.71	6.87	0.4	5.31e-11	Parkinson's disease;
KIRP	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg18305652	chr10:134549665	INPP5A	0.47	7.32	0.42	3.57e-12	Migraine;
KIRP	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.89	13.86	0.66	1.16e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.56	7.13	0.41	1.12e-11	Systemic lupus erythematosus;
KIRP	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.81	9.21	0.51	1.53e-17	High light scatter reticulocyte count;
KIRP	cis	rs2014572	0.967	rs8112572	chr19:57759612	T/C	cg24459738	chr19:57751996	ZNF805	-0.58	-7.17	-0.42	8.82e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-36.13	-0.92	2.34e-100	Myeloid white cell count;
KIRP	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.76	-10.35	-0.55	4.37e-21	Sudden cardiac arrest;
KIRP	cis	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg26585981	chr11:48327164	OR4S1	-0.43	-5.41	-0.33	1.47e-7	HDL cholesterol;
KIRP	cis	rs7818345	1.000	rs4409408	chr8:19311538	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	5.65	0.34	4.4e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs4740619	0.619	rs1887668	chr9:16033321	G/C	cg14451791	chr9:16040625	NA	-0.42	-5.39	-0.33	1.63e-7	Body mass index;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg21698718	chr17:80085957	CCDC57	0.38	5.55	0.33	7.31e-8	Life satisfaction;
KIRP	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05025164	chr4:1340916	KIAA1530	-0.49	-6.3	-0.37	1.35e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg26681399	chr22:41777847	TEF	-0.49	-4.91	-0.3	1.63e-6	Vitiligo;
KIRP	cis	rs6708331	0.517	rs11890741	chr2:70360506	T/C	cg05298696	chr2:70188691	ASPRV1	-0.4	-5.33	-0.32	2.21e-7	Obesity-related traits;
KIRP	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	8.91	0.49	1.17e-16	Mood instability;
KIRP	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg00981070	chr1:2046702	PRKCZ	0.32	5.53	0.33	8.3e-8	Height;
KIRP	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.39	-5.15	-0.31	5.4e-7	Monocyte percentage of white cells;
KIRP	cis	rs9323205	0.954	rs9672122	chr14:51582391	A/G	cg23942311	chr14:51606299	NA	-0.47	-4.96	-0.3	1.3e-6	Cancer;
KIRP	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg09571762	chr12:39539558	NA	0.37	5.07	0.31	7.9e-7	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.44	0.38	6.21e-10	Breast cancer;
KIRP	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg03714773	chr7:91764589	CYP51A1	0.38	5.56	0.33	6.93e-8	Breast cancer;
KIRP	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.57	8.89	0.49	1.3e-16	Personality dimensions;
KIRP	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.78e-7	Aortic root size;
KIRP	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg24375607	chr4:120327624	NA	0.52	5.32	0.32	2.32e-7	Corneal astigmatism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24273718	chr3:129158802	IFT122;MBD4	0.49	6.67	0.39	1.63e-10	Survival in pancreatic cancer;
KIRP	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.67	-8.79	-0.49	2.7e-16	Selective IgA deficiency;
KIRP	cis	rs34421088	0.532	rs2409754	chr8:11155613	A/G	cg00405596	chr8:11794950	NA	0.41	4.91	0.3	1.68e-6	Neuroticism;
KIRP	cis	rs12049351	0.774	rs12138176	chr1:229657902	G/A	cg11742688	chr1:229674241	ABCB10	-0.4	-5.49	-0.33	1e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs804292	0.803	rs8191598	chr8:11635616	A/G	cg26752888	chr8:11627280	NEIL2	1.14	11.78	0.6	1.04e-25	Alcohol dependence;Nicotine use;
KIRP	cis	rs10465746	0.570	rs6658559	chr1:84467412	A/G	cg10977910	chr1:84465055	TTLL7	0.48	5.9	0.35	1.2e-8	Obesity-related traits;
KIRP	cis	rs74181299	0.964	rs2540949	chr2:65284231	A/T	cg05010058	chr2:65284262	CEP68	0.46	6.39	0.38	8.43e-10	Pulse pressure;
KIRP	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg18461458	chr19:21324796	ZNF431	0.48	5.1	0.31	6.94e-7	Pain;
KIRP	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.92	12.5	0.62	4.25e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7084402	0.967	rs1649022	chr10:60285867	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg20701182	chr2:24300061	SF3B14	-0.41	-5.2	-0.31	4.2e-7	Asthma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09682251	chr3:50654786	MAPKAPK3	0.52	6.36	0.38	9.7e-10	Parkinson's disease;
KIRP	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.13	0.46	2.05e-14	Neutrophil percentage of white cells;
KIRP	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05220968	chr6:146057943	EPM2A	-0.38	-4.85	-0.3	2.19e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg13736514	chr6:26305472	NA	-0.47	-4.9	-0.3	1.75e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-7.82	-0.45	1.59e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg20673091	chr1:2541236	MMEL1	0.66	9.71	0.53	4.45e-19	Ulcerative colitis;
KIRP	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	8.1	0.46	2.57e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.48	-5.6	-0.34	5.72e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs11038871	1.000	rs3802890	chr11:46534546	A/G	cg16389345	chr11:46697382	NA	-0.5	-6.83	-0.4	6.43e-11	Immunoglobulin A;
KIRP	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.67	8.58	0.48	1.09e-15	Eosinophil percentage of white cells;
KIRP	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg12046867	chr14:103022105	NA	-0.5	-6.09	-0.36	4.36e-9	Platelet count;
KIRP	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.5	0.43	1.16e-12	Morning vs. evening chronotype;
KIRP	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg14593290	chr7:50529359	DDC	-0.78	-9.87	-0.53	1.45e-19	Malaria;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg27411982	chr8:10470053	RP1L1	-0.39	-4.86	-0.3	2.11e-6	Neuroticism;
KIRP	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-8.76	-0.49	3.2e-16	Personality dimensions;
KIRP	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.8	11.85	0.6	6.13e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs57549656	0.659	rs72980733	chr19:2711316	G/C	cg06609049	chr19:2785107	THOP1	0.53	4.9	0.3	1.7e-6	Schizophrenia;
KIRP	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11987759	chr7:65425863	GUSB	-0.62	-8.44	-0.47	2.69e-15	Calcium levels;
KIRP	cis	rs12681963	0.764	rs7838088	chr8:29996824	C/T	cg04374813	chr8:30012889	DCTN6	0.48	4.85	0.3	2.21e-6	Migraine;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg07701084	chr6:150067640	NUP43	0.7	9.33	0.51	6.38e-18	Lung cancer;
KIRP	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.63	-8.09	-0.46	2.74e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.76	-9.52	-0.52	1.69e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg00981070	chr1:2046702	PRKCZ	0.42	6.9	0.4	4.46e-11	Height;
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg13206674	chr6:150067644	NUP43	0.62	9.58	0.52	1.15e-18	Lung cancer;
KIRP	cis	rs8084125	1.000	rs72978665	chr18:74953641	A/G	cg15443732	chr18:74961078	GALR1	0.57	5.58	0.33	6.47e-8	Obesity-related traits;
KIRP	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.87	10.58	0.56	8.2e-22	Pulmonary function decline;
KIRP	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg16586182	chr3:47516702	SCAP	0.83	11.16	0.58	1.12e-23	Colorectal cancer;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg21803754	chr20:60718392	PSMA7;SS18L1	0.49	6.07	0.36	4.82e-9	DNA methylation (variation);
KIRP	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.76e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.77	-10.29	-0.55	7.1e-21	Adiposity;
KIRP	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg17105886	chr17:28927953	LRRC37B2	0.54	5.64	0.34	4.72e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.51	-0.33	9.16e-8	IgG glycosylation;
KIRP	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.14	0.58	1.34e-23	Alzheimer's disease;
KIRP	cis	rs7213347	0.707	rs216182	chr17:2173063	A/G	cg15816464	chr17:2026533	SMG6	-0.36	-5.32	-0.32	2.3e-7	Total body bone mineral density;
KIRP	cis	rs7572644	0.699	rs1458396	chr2:28136351	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.33	-0.32	2.23e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1062177	0.694	rs2915816	chr5:151115857	G/A	cg00977110	chr5:151150581	G3BP1	-0.57	-6.16	-0.37	2.94e-9	Preschool internalizing problems;
KIRP	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg07777115	chr5:623756	CEP72	-0.56	-5.54	-0.33	7.77e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19171272	chr22:38449367	NA	-0.56	-8.27	-0.47	8.26e-15	Glioblastoma;Glioma;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-1.07	-16.97	-0.73	2.74e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.49	6.41	0.38	7.42e-10	Menopause (age at onset);
KIRP	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg22681709	chr2:178499509	PDE11A	-0.62	-8.14	-0.46	2.02e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.73	8.94	0.5	9.79e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2970992	0.764	rs6542984	chr2:101324884	C/T	cg01042948	chr2:101319752	NA	0.45	6.78	0.4	8.87e-11	Educational attainment;
KIRP	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.39	-8.14	-0.46	2e-14	Body mass index;
KIRP	cis	rs67478160	0.634	rs2144079	chr14:104258884	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-8.0	-0.45	4.9e-14	Schizophrenia;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.76e-7	Life satisfaction;
KIRP	cis	rs28489187	0.643	rs997251	chr1:85845367	T/C	cg16011679	chr1:85725395	C1orf52	0.55	6.66	0.39	1.82e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg19694781	chr19:47549865	TMEM160	0.58	7.7	0.44	3.3e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07847428	chr19:8478158	MARCH2	0.52	6.64	0.39	2.04e-10	Myopia (pathological);
KIRP	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg26681399	chr22:41777847	TEF	0.55	5.35	0.32	1.97e-7	Vitiligo;
KIRP	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.59	-7.33	-0.42	3.27e-12	Extraversion;
KIRP	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	0.6	5.13	0.31	6.01e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.54	-7.22	-0.42	6.57e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-8.84	-0.49	1.93e-16	Retinal vascular caliber;
KIRP	cis	rs9309473	0.898	rs10209517	chr2:73845392	C/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.44	-0.33	1.26e-7	Metabolite levels;
KIRP	cis	rs4654899	0.802	rs6685306	chr1:21219050	C/T	cg05370193	chr1:21551575	ECE1	0.42	5.09	0.31	7.22e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs1497406	0.590	rs6676143	chr1:16528218	G/T	cg11895451	chr1:16533891	ARHGEF19	0.34	4.89	0.3	1.8e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg08477640	chr19:41863820	B9D2	0.43	5.31	0.32	2.47e-7	Migraine;Coronary artery disease;
KIRP	cis	rs12519773	1.000	rs7711868	chr5:92461247	T/A	cg18783429	chr5:92414398	NA	0.3	5.2	0.31	4.11e-7	Migraine;
KIRP	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg23815491	chr16:72088622	HP	-0.34	-5.07	-0.31	7.99e-7	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21883802	chr14:92413706	FBLN5	0.45	6.2	0.37	2.33e-9	Parkinson's disease;
KIRP	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.64	-8.4	-0.47	3.52e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6987853	0.966	rs1901282	chr8:42392942	C/G	cg09913449	chr8:42400586	C8orf40	0.4	5.05	0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.45e-39	Headache;
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs7666738	0.546	rs34159897	chr4:98787367	T/C	cg05340658	chr4:99064831	C4orf37	0.66	7.9	0.45	9.2e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	11.64	0.6	3.2e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4660306	0.744	rs11211114	chr1:45926243	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.51	6.15	0.37	3.12e-9	Homocysteine levels;
KIRP	trans	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg25065723	chr10:132892405	TCERG1L	-0.5	-6.15	-0.37	3.13e-9	Coronary artery disease;
KIRP	cis	rs4765905	0.675	rs11614764	chr12:2300607	G/C	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.76	-0.4	1.02e-10	Schizophrenia;
KIRP	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.13	0.31	5.94e-7	Asthma;
KIRP	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.53	-6.96	-0.41	3.13e-11	Tuberculosis;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.76	11.45	0.59	1.3e-24	Menarche (age at onset);
KIRP	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg05861140	chr6:150128134	PCMT1	0.53	7.56	0.43	8.09e-13	Lung cancer;
KIRP	trans	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs911119	1.000	rs6036478	chr20:23611359	C/A	cg16589663	chr20:23618590	CST3	0.62	5.97	0.36	8.17e-9	Chronic kidney disease;
KIRP	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.9	15.39	0.7	6.91e-38	Metabolic syndrome;
KIRP	cis	rs4654899	0.865	rs7541923	chr1:21403582	G/C	cg05370193	chr1:21551575	ECE1	0.47	6.34	0.37	1.07e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-1.1	-24.58	-0.84	3.51e-68	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12249377	0.519	rs35987367	chr10:92591992	C/T	cg14313238	chr10:92632228	RPP30	0.44	5.3	0.32	2.6e-7	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg18016565	chr1:150552671	MCL1	0.39	5.98	0.36	7.65e-9	Melanoma;
KIRP	cis	rs6091737	1.000	rs2870276	chr20:52350534	C/T	cg11837293	chr20:52356911	NA	-0.39	-4.94	-0.3	1.48e-6	Calcium levels;
KIRP	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.38	-0.47	3.98e-15	Total cholesterol levels;
KIRP	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	5.98	0.36	7.9e-9	Platelet count;
KIRP	trans	rs1424233	1.000	rs9921354	chr16:79683450	C/T	cg11120865	chr14:21853037	SUPT16H	-0.37	-6.45	-0.38	5.77e-10	Obesity;
KIRP	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.46	-6.39	-0.38	8.17e-10	Blood metabolite levels;
KIRP	cis	rs7027203	0.557	rs2487023	chr9:96509943	C/G	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.87e-10	DNA methylation (variation);
KIRP	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.04	8.02	0.46	4.31e-14	Skin colour saturation;
KIRP	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg18132916	chr6:79620363	NA	-0.41	-5.63	-0.34	4.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08392591	chr16:89556376	ANKRD11	0.4	5.4	0.33	1.58e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.28e-7	Childhood ear infection;
KIRP	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.51	-5.9	-0.35	1.21e-8	Aortic root size;
KIRP	cis	rs447921	0.861	rs12951513	chr17:74455069	C/T	cg17201438	chr17:74438067	UBE2O	0.47	5.07	0.31	7.75e-7	Mitochondrial DNA levels;
KIRP	cis	rs3925075	1.000	rs11859274	chr16:31361059	C/T	cg02846316	chr16:31340340	ITGAM	0.61	9.47	0.52	2.39e-18	IgA nephropathy;
KIRP	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.7	-11.7	-0.6	1.98e-25	Gout;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25224222	chr19:45971050	FOSB	0.51	6.54	0.38	3.51e-10	Parkinson's disease;
KIRP	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.5	5.31	0.32	2.42e-7	Alzheimer's disease;
KIRP	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg00343986	chr7:65444356	GUSB	0.39	4.86	0.3	2.12e-6	Aortic root size;
KIRP	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg17652424	chr22:38574118	PLA2G6	0.26	5.29	0.32	2.65e-7	Cutaneous nevi;
KIRP	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.38	6.72	0.39	1.27e-10	Left ventricle wall thickness;
KIRP	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.44	6.71	0.39	1.33e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.59	-7.31	-0.42	3.71e-12	Iron status biomarkers;
KIRP	cis	rs35000415	0.938	rs71581958	chr7:128665542	C/T	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg20636351	chr8:55087400	NA	-0.62	-7.63	-0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.12	14.65	0.68	2.34e-35	Gout;Urate levels;Serum uric acid levels;
KIRP	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.73	-0.78	1.35e-52	Height;
KIRP	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.84	-0.35	1.66e-8	Crohn's disease;
KIRP	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.76	-9.81	-0.53	2.19e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.46	6.92	0.4	3.97e-11	Neuroticism;
KIRP	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.86	-0.35	1.47e-8	Systolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11388258	chr1:151484008	CGN	0.5	6.94	0.4	3.43e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs580438	0.529	rs7635926	chr3:13428413	A/G	cg10657019	chr3:13328039	NA	0.49	6.4	0.38	7.75e-10	Myringotomy;
KIRP	cis	rs7582720	0.806	rs10932008	chr2:204048840	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.54	-5.83	-0.35	1.71e-8	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01792182	chr7:856023	UNC84A	0.49	7.06	0.41	1.67e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13881405	chr9:92220388	GADD45G	0.62	7.64	0.44	4.97e-13	Smoking initiation;
KIRP	cis	rs9638182	0.666	rs2286276	chr7:72987354	C/T	cg07452164	chr7:72993570	TBL2	0.52	6.08	0.36	4.45e-9	Triglycerides;
KIRP	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	1.06	22.67	0.82	3.39e-62	Breast cancer;
KIRP	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06544989	chr22:39130855	UNC84B	0.51	9.02	0.5	5.56e-17	Menopause (age at onset);
KIRP	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg18882449	chr10:104885122	NT5C2	0.51	6.61	0.39	2.33e-10	Arsenic metabolism;
KIRP	cis	rs10982256	0.774	rs7034891	chr9:117245252	C/G	cg13636371	chr9:117264095	DFNB31	-0.5	-6.69	-0.39	1.52e-10	Bipolar disorder;
KIRP	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg05156742	chr15:59063176	FAM63B	0.52	6.58	0.39	2.83e-10	Asperger disorder;
KIRP	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	10.12	0.54	2.39e-20	Post bronchodilator FEV1;
KIRP	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6991838	0.584	rs60023200	chr8:66486782	C/T	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11055008	0.620	rs10845608	chr12:12836088	C/T	cg04607235	chr12:12878440	APOLD1	0.49	5.68	0.34	3.77e-8	Pulse pressure;
KIRP	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg06740227	chr12:86229804	RASSF9	-0.44	-5.27	-0.32	2.95e-7	Major depressive disorder;
KIRP	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	0.9	13.86	0.66	1.17e-32	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg22974920	chr21:40686053	BRWD1	0.5	5.92	0.35	1.1e-8	Cognitive function;
KIRP	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11997175	0.655	rs7833512	chr8:33662884	C/T	cg04338863	chr8:33670619	NA	0.4	5.45	0.33	1.25e-7	Body mass index;
KIRP	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.62	7.32	0.42	3.49e-12	Schizophrenia;
KIRP	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.78	-0.44	2.05e-13	Total cholesterol levels;
KIRP	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg00405596	chr8:11794950	NA	0.59	8.42	0.47	3.22e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.42	-6.1	-0.36	3.99e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs963731	0.649	rs10153761	chr2:39262068	C/T	cg04010122	chr2:39346883	SOS1	-1.06	-7.14	-0.41	1.02e-11	Corticobasal degeneration;
KIRP	cis	rs4253772	0.530	rs9615980	chr22:46791143	A/T	cg18190219	chr22:46762943	CELSR1	-0.78	-6.99	-0.41	2.6e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg13385521	chr17:29058706	SUZ12P	0.7	6.91	0.4	4.14e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.15	15.72	0.71	5.01e-39	Lymphocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05226707	chr1:31846699	FABP3	0.44	6.18	0.37	2.62e-9	Parkinson's disease;
KIRP	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg01843034	chr6:37503916	NA	0.76	10.99	0.57	4.02e-23	Cognitive performance;
KIRP	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.03	-0.46	3.99e-14	Morning vs. evening chronotype;
KIRP	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.58	-8.98	-0.5	7.34e-17	Coronary artery disease;
KIRP	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.33	-0.42	3.24e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11638511	0.522	rs10152977	chr15:78560927	A/C	cg08594606	chr15:78556512	DNAJA4	-0.37	-4.91	-0.3	1.67e-6	Red blood cell count;
KIRP	cis	rs58688157	0.960	rs34449380	chr11:617221	T/G	cg01616529	chr11:638424	DRD4	-0.37	-5.0	-0.3	1.08e-6	Systemic lupus erythematosus;
KIRP	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-15.28	-0.7	1.61e-37	Electrocardiographic conduction measures;
KIRP	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	1.05	11.48	0.59	1e-24	Height;
KIRP	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.26e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.57	-4.95	-0.3	1.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1497828	0.871	rs2815248	chr1:217572871	C/T	cg04411442	chr1:217543379	NA	0.44	6.5	0.38	4.39e-10	Dialysis-related mortality;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08722104	chr11:47448306	PSMC3	0.48	6.33	0.37	1.16e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7715806	0.500	rs72633986	chr5:75006449	T/A	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1832871	0.643	rs7750656	chr6:158725907	C/T	cg07215822	chr6:158701037	NA	-0.65	-7.43	-0.43	1.76e-12	Height;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg26917132	chr16:87425759	FBXO31;MAP1LC3B	0.52	6.36	0.38	9.64e-10	Educational attainment;
KIRP	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.8	6.42	0.38	6.85e-10	Initial pursuit acceleration;
KIRP	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs643506	0.967	rs2850248	chr11:111644824	C/A	cg09085632	chr11:111637200	PPP2R1B	0.53	5.96	0.36	8.62e-9	Breast cancer;
KIRP	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.01	0.45	4.74e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg07148914	chr20:33460835	GGT7	-0.54	-7.12	-0.41	1.21e-11	Height;
KIRP	cis	rs7520050	0.931	rs11211224	chr1:46384388	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.77e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.19	20.82	0.8	3.43e-56	Cognitive function;
KIRP	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.61	7.47	0.43	1.43e-12	Iron status biomarkers;
KIRP	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg00094735	chr5:1949198	NA	0.47	5.64	0.34	4.58e-8	Gut microbiome composition (winter);
KIRP	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.7	-9.81	-0.53	2.2e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	trans	rs78438709	1.000	rs12571218	chr10:124147588	A/G	cg08224212	chr11:34196093	ABTB2	-1.01	-6.49	-0.38	4.57e-10	Headache;
KIRP	cis	rs9308731	0.605	rs6754738	chr2:111948543	T/C	cg04780086	chr2:111875790	ACOXL	0.36	4.84	0.3	2.26e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg08125733	chr17:73851984	WBP2	0.53	6.59	0.39	2.63e-10	White matter hyperintensity burden;
KIRP	cis	rs471756	0.594	rs785843	chr9:262617	C/A	cg14500300	chr9:211689	NA	0.44	5.98	0.36	7.63e-9	Mean platelet volume;
KIRP	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Smoking initiation;
KIRP	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.89	16.27	0.72	6.84e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg20965017	chr5:231967	SDHA	-0.53	-6.11	-0.36	3.91e-9	Breast cancer;
KIRP	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	8.57	0.48	1.12e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	10.11	0.54	2.57e-20	Lung cancer in ever smokers;
KIRP	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05025164	chr4:1340916	KIAA1530	-0.53	-6.94	-0.4	3.37e-11	Obesity-related traits;
KIRP	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.84	10.18	0.54	1.54e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs55962025	0.737	rs2237006	chr4:3228492	A/G	cg06533319	chr4:3265114	C4orf44	0.41	5.19	0.31	4.31e-7	Parental longevity (mother's age at death);
KIRP	cis	rs10266483	0.843	rs667644	chr7:63750558	C/A	cg04636841	chr7:63768139	NA	-0.39	-5.05	-0.31	8.52e-7	Response to statin therapy;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg01363902	chr12:121022439	NA	-0.44	-6.13	-0.36	3.54e-9	Neuroticism;
KIRP	cis	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs897080	0.552	rs1067320	chr2:44633122	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.95	0.35	8.95e-9	Height;
KIRP	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.63	-10.45	-0.55	2.17e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.44	-5.98	-0.36	7.71e-9	Refractive error;
KIRP	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg12560992	chr17:57184187	TRIM37	0.61	5.4	0.33	1.6e-7	Cognitive test performance;
KIRP	cis	rs3774830	0.534	rs7687596	chr4:5472092	C/T	cg26943120	chr4:5472116	STK32B	-0.29	-7.53	-0.43	9.72e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7903847	0.642	rs6584128	chr10:99171926	G/T	cg20016023	chr10:99160130	RRP12	0.41	5.6	0.34	5.63e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.64	6.7	0.39	1.42e-10	Graves' disease;
KIRP	cis	rs10513788	0.578	rs72622586	chr3:181994804	A/G	cg01449425	chr3:181957089	NA	-0.43	-5.56	-0.33	7.07e-8	Cognitive function;
KIRP	cis	rs12580194	0.593	rs7485979	chr12:55789043	A/T	cg11794356	chr12:55725991	OR6C3	0.54	7.09	0.41	1.41e-11	Cancer;
KIRP	cis	rs61160187	0.503	rs377321	chr5:59851740	G/C	cg02684056	chr5:59996105	DEPDC1B	0.43	5.09	0.31	7.28e-7	Educational attainment (years of education);Educational attainment (college completion);
KIRP	cis	rs2006771	0.846	rs6518754	chr22:32097775	C/T	cg02404636	chr22:31891804	SFI1	0.47	6.04	0.36	5.64e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg23262073	chr20:60523788	NA	0.57	5.6	0.34	5.58e-8	Body mass index;
KIRP	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.14	-0.31	5.56e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs17095355	1.000	rs55897175	chr10:111699190	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.52	-0.38	3.89e-10	Biliary atresia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02252918	chr12:124458442	ZNF664;CCDC92	0.63	7.39	0.43	2.23e-12	Smoking initiation;
KIRP	cis	rs981844	1.000	rs2579916	chr4:154659972	G/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs77688320	0.553	rs2080322	chr2:202379040	T/C	cg06431681	chr2:202330990	STRADB	-0.44	-5.23	-0.32	3.65e-7	Breast cancer;
KIRP	trans	rs12043259	0.730	rs6593912	chr1:204797180	T/G	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.57	-7.05	-0.41	1.83e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg07645718	chr20:61493192	TCFL5	0.78	6.14	0.36	3.36e-9	Obesity-related traits;
KIRP	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg09408571	chr1:101003634	GPR88	-0.24	-5.72	-0.34	3.04e-8	Breast cancer;
KIRP	cis	rs4664304	0.629	rs57751799	chr2:160854180	A/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.46	-0.33	1.17e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg21775007	chr8:11205619	TDH	-0.44	-5.74	-0.34	2.77e-8	Triglycerides;
KIRP	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.76	9.62	0.52	8.58e-19	Aortic root size;
KIRP	cis	rs662064	1.000	rs662064	chr1:10557251	T/C	cg17425144	chr1:10567563	PEX14	0.34	5.8	0.35	2.03e-8	Asthma;
KIRP	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.9	0.35	1.21e-8	Menopause (age at onset);
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.39	0.32	1.67e-7	Life satisfaction;
KIRP	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg09408571	chr1:101003634	GPR88	-0.24	-5.54	-0.33	7.85e-8	Monocyte count;
KIRP	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.58	-7.14	-0.41	1.04e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	13.06	0.64	5.62e-30	Platelet count;
KIRP	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.48	6.33	0.37	1.13e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.64	5.55	0.33	7.3e-8	Schizophrenia;
KIRP	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.7	9.82	0.53	2.06e-19	Mood instability;
KIRP	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg06623918	chr6:96969491	KIAA0776	0.79	7.6	0.44	6.33e-13	Migraine;Coronary artery disease;
KIRP	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	6.67	0.39	1.69e-10	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg15556689	chr8:8085844	FLJ10661	0.61	7.47	0.43	1.4e-12	Neuroticism;
KIRP	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs13095912	1.000	rs36066570	chr3:185314454	C/A	cg11274856	chr3:185301563	NA	0.51	6.6	0.39	2.55e-10	Systolic blood pressure;
KIRP	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg13206674	chr6:150067644	NUP43	0.52	7.36	0.42	2.75e-12	Lung cancer;
KIRP	cis	rs17221829	0.733	rs11600976	chr11:89360842	A/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.81	10.46	0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg22029157	chr1:209979665	IRF6	0.59	7.07	0.41	1.6e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.9e-6	Common traits (Other);
KIRP	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.76	-0.4	1e-10	Type 2 diabetes;
KIRP	cis	rs3764563	0.935	rs667386	chr19:15695617	T/C	cg20725493	chr19:15740067	CYP4F8	0.86	6.07	0.36	4.73e-9	Inflammatory biomarkers;
KIRP	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg15128208	chr22:42549153	NA	0.53	5.3	0.32	2.54e-7	Birth weight;
KIRP	cis	rs904251	0.523	rs2776920	chr6:37480605	G/A	cg01843034	chr6:37503916	NA	-0.96	-15.55	-0.7	1.97e-38	Cognitive performance;
KIRP	cis	rs2348418	0.715	rs11049720	chr12:28720410	A/G	cg13890972	chr12:28721907	NA	-0.33	-5.16	-0.31	5.04e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg14650228	chr8:144573510	ZC3H3	-0.75	-5.36	-0.32	1.88e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs240764	0.817	rs239237	chr6:101094940	A/G	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg27654529	chr19:35418345	ZNF30	-0.5	-6.45	-0.38	5.95e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg09699651	chr6:150184138	LRP11	0.59	8.17	0.46	1.6e-14	Testicular germ cell tumor;
KIRP	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.25	13.41	0.65	3.93e-31	Uric acid levels;
KIRP	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg24881330	chr22:46731750	TRMU	0.81	5.9	0.35	1.22e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg16576597	chr16:28551801	NUPR1	0.36	5.48	0.33	1.06e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.59	-8.46	-0.47	2.38e-15	Testicular germ cell tumor;
KIRP	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs2278796	0.639	rs6702469	chr1:204968787	A/G	cg17947172	chr1:204966197	NFASC	0.68	8.98	0.5	7.06e-17	Mean platelet volume;
KIRP	trans	rs2048656	0.605	rs11989726	chr8:9648687	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.58	0.39	2.89e-10	Schizophrenia;
KIRP	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.71	9.99	0.54	5.98e-20	Calcium levels;
KIRP	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.7	-13.15	-0.64	2.79e-30	White blood cell count (basophil);
KIRP	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg05692746	chr2:100937584	LONRF2	-0.39	-5.06	-0.31	8.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg04662567	chr6:169592167	NA	-0.73	-6.26	-0.37	1.69e-9	Pulse pressure;
KIRP	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.91	14.47	0.68	9.51e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.7	-0.39	1.45e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg26513180	chr16:89883248	FANCA	0.56	6.79	0.4	8.28e-11	Vitiligo;
KIRP	cis	rs4959799	0.557	rs61246041	chr6:3274406	G/T	cg03657281	chr6:3270030	SLC22A23	0.79	6.06	0.36	5.14e-9	Survival in rectal cancer;
KIRP	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20135002	chr11:47629003	NA	-0.44	-4.95	-0.3	1.37e-6	Subjective well-being;
KIRP	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.66	0.34	4.25e-8	Breast cancer;
KIRP	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg16586182	chr3:47516702	SCAP	0.66	8.16	0.46	1.77e-14	Colorectal cancer;
KIRP	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg09201719	chr10:104596890	CYP17A1	-0.38	-5.6	-0.34	5.73e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg06671706	chr8:8559999	CLDN23	0.47	5.38	0.32	1.72e-7	Obesity-related traits;
KIRP	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.92	-0.45	8.3e-14	Colorectal cancer;
KIRP	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.33	-4.88	-0.3	1.88e-6	Monocyte count;
KIRP	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12379764	chr21:47803548	PCNT	0.43	5.19	0.31	4.33e-7	Testicular germ cell tumor;
KIRP	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.67	9.64	0.52	7.35e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.33	5.08	0.31	7.42e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg01320579	chr17:75405842	SEPT9	0.46	7.55	0.43	8.54e-13	Airflow obstruction;
KIRP	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg13010199	chr12:38710504	ALG10B	-0.39	-5.06	-0.31	8.28e-7	Heart rate;
KIRP	cis	rs73198271	0.710	rs11779565	chr8:8680020	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.62	-0.39	2.29e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.53	-6.04	-0.36	5.51e-9	Schizophrenia;
KIRP	cis	rs6921919	0.583	rs9468354	chr6:28337801	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.42	-6.03	-0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg23422044	chr7:1970798	MAD1L1	-0.59	-6.22	-0.37	2.12e-9	Neuroticism;
KIRP	cis	rs7688540	0.771	rs61795006	chr4:253601	C/G	cg17891759	chr4:299121	NA	-0.44	-5.12	-0.31	6.03e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.76	-10.61	-0.56	6.95e-22	Blood metabolite levels;
KIRP	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.31	7.83	0.45	1.46e-13	Primary biliary cholangitis;
KIRP	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg11150807	chr10:43354902	NA	0.58	6.48	0.38	5.03e-10	Blood protein levels;
KIRP	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-9.54	-0.52	1.53e-18	Hemoglobin concentration;
KIRP	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.85	8.89	0.49	1.38e-16	Pulmonary function decline;
KIRP	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg19752551	chr11:57585705	CTNND1	-0.8	-13.18	-0.64	2.24e-30	Schizophrenia;
KIRP	cis	rs10465746	0.570	rs11163885	chr1:84472956	A/G	cg10977910	chr1:84465055	TTLL7	0.47	5.73	0.34	2.94e-8	Obesity-related traits;
KIRP	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs12210905	1.000	rs12214930	chr6:27093715	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg08648136	chr8:956695	NA	0.46	6.32	0.37	1.21e-9	Schizophrenia;
KIRP	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg07653901	chr22:50250238	ZBED4	-0.61	-6.63	-0.39	2.15e-10	Schizophrenia;
KIRP	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.67	-9.32	-0.51	7.04e-18	Schizophrenia;
KIRP	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg27205649	chr11:78285834	NARS2	-0.66	-7.67	-0.44	3.96e-13	Alzheimer's disease (survival time);
KIRP	cis	rs7129556	0.737	rs7951033	chr11:77534444	G/A	cg12586386	chr11:77299805	AQP11	-0.41	-5.5	-0.33	9.68e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.87e-10	Fibrinogen levels;
KIRP	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-4.9	-0.3	1.76e-6	Longevity;Endometriosis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27343663	chr17:79082811	BAIAP2	0.46	6.23	0.37	2.05e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.15	0.37	3.09e-9	Ovarian reserve;
KIRP	trans	rs61884327	0.527	rs756343	chr11:46550276	C/A	cg10758369	chr1:48459236	NA	0.5	6.11	0.36	3.9e-9	Total body bone mineral density;
KIRP	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.62e-9	Lung cancer;
KIRP	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.88	-8.51	-0.48	1.71e-15	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs7870753	0.636	rs10761006	chr9:99178784	A/G	cg25260653	chr9:99212216	HABP4	0.56	5.72	0.34	3.04e-8	Height;
KIRP	trans	rs6601327	0.504	rs2048655	chr8:9645562	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	6.43	0.38	6.66e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.54	5.96	0.36	8.57e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7945718	0.650	rs10831889	chr11:12665834	A/T	cg25843174	chr11:12811716	TEAD1	0.36	6.37	0.38	9.09e-10	Educational attainment (years of education);
KIRP	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg13010199	chr12:38710504	ALG10B	0.49	6.3	0.37	1.34e-9	Bladder cancer;
KIRP	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.42	5.99	0.36	7.53e-9	Sitting height ratio;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08578395	chr10:52502681	ASAH2B	-0.39	-6.14	-0.36	3.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.86	6.42	0.38	6.91e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6450176	1.000	rs9687611	chr5:53300288	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.35	-0.59	2.82e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg23649088	chr2:200775458	C2orf69	-0.39	-5.09	-0.31	7.14e-7	QT interval;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg09659803	chr11:495198	RNH1	-0.43	-6.18	-0.37	2.58e-9	Bladder cancer;
KIRP	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-0.67	-7.47	-0.43	1.39e-12	Gut microbiome composition (summer);
KIRP	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-10.12	-0.54	2.35e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1971762	0.527	rs1683151	chr12:53946219	C/G	cg16917193	chr12:54089295	NA	-0.83	-14.09	-0.67	1.86e-33	Height;
KIRP	cis	rs4704187	0.687	rs10214239	chr5:74357475	G/A	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.09e-8	Response to amphetamines;
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg21734707	chr17:3908241	ZZEF1	0.69	10.42	0.55	2.71e-21	Type 2 diabetes;
KIRP	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.41	5.69	0.34	3.64e-8	Electroencephalogram traits;
KIRP	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.15	9.34	0.51	5.98e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7122257	0.542	rs7120813	chr11:11151077	G/A	cg16931664	chr11:11169707	NA	-0.45	-6.32	-0.37	1.23e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6546886	0.912	rs6745576	chr2:74304378	C/G	cg14702570	chr2:74259524	NA	0.26	5.05	0.31	8.66e-7	Dialysis-related mortality;
KIRP	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	5.68	0.34	3.75e-8	Type 2 diabetes;
KIRP	cis	rs963731	0.649	rs297143	chr2:39320067	T/C	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg19500275	chr17:80737654	TBCD	0.44	5.33	0.32	2.18e-7	Glycated hemoglobin levels;
KIRP	cis	rs11967485	0.609	rs62435818	chr6:157160073	G/A	cg23222435	chr6:157204239	ARID1B	-0.75	-5.2	-0.31	4.28e-7	Calcium levels;
KIRP	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg26207909	chr14:103986467	CKB	-0.44	-5.3	-0.32	2.52e-7	Coronary artery disease;
KIRP	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg00255919	chr5:131827918	IRF1	0.28	5.82	0.35	1.84e-8	Asthma (sex interaction);
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg25347419	chr2:177043501	NA	0.47	6.58	0.39	2.79e-10	IgG glycosylation;
KIRP	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.65	-6.09	-0.36	4.27e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg20243544	chr17:37824526	PNMT	0.5	7.37	0.43	2.57e-12	Asthma;
KIRP	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.09	-0.46	2.8e-14	Mood instability;
KIRP	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.62	8.92	0.49	1.07e-16	Resting heart rate;
KIRP	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.02	-0.36	6.17e-9	Personality dimensions;
KIRP	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg18882449	chr10:104885122	NT5C2	0.49	6.33	0.37	1.13e-9	Arsenic metabolism;
KIRP	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg25174290	chr11:3078921	CARS	-0.55	-6.08	-0.36	4.64e-9	Calcium levels;
KIRP	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg23601095	chr6:26197514	HIST1H3D	0.92	7.44	0.43	1.69e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.52	6.34	0.37	1.07e-9	Monocyte count;
KIRP	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	1.04	19.18	0.77	9.06e-51	Heart rate;
KIRP	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.46	-6.37	-0.38	9.32e-10	Blood metabolite levels;
KIRP	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.7	7.06	0.41	1.67e-11	Menarche (age at onset);
KIRP	cis	rs1867631	0.585	rs9787219	chr1:67080159	G/C	cg02459107	chr1:67143332	SGIP1	0.39	5.81	0.35	1.93e-8	Menopause (age at onset);
KIRP	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.48	-6.41	-0.38	7.29e-10	IgG glycosylation;
KIRP	cis	rs7221595	0.778	rs8077986	chr17:3902951	A/G	cg05562828	chr17:3906858	NA	0.63	7.02	0.41	2.21e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.9	-0.35	1.23e-8	Bipolar disorder;
KIRP	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg13444842	chr1:152974279	SPRR3	-0.37	-5.21	-0.32	4.07e-7	Inflammatory skin disease;
KIRP	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2299587	0.897	rs3850744	chr8:17784203	A/G	cg01800426	chr8:17659068	MTUS1	-0.4	-5.03	-0.31	9.64e-7	Economic and political preferences;
KIRP	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg00325661	chr8:49890786	NA	0.44	5.6	0.34	5.77e-8	Sudden cardiac arrest;
KIRP	cis	rs9400467	0.506	rs12192147	chr6:111648057	G/C	cg15721981	chr6:111408429	SLC16A10	0.7	6.16	0.37	2.93e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg07004394	chr14:106090750	NA	-0.43	-5.02	-0.3	1e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.4	9.87	0.53	1.42e-19	Corneal astigmatism;
KIRP	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.23	-0.42	5.97e-12	Type 2 diabetes;
KIRP	cis	rs17023223	0.509	rs10923740	chr1:119600287	C/T	cg05756136	chr1:119680316	WARS2	-0.56	-7.53	-0.43	9.66e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.46	5.88	0.35	1.33e-8	Blood protein levels;
KIRP	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg06204229	chr3:52865917	ITIH4	0.46	5.32	0.32	2.28e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.79	7.79	0.44	1.89e-13	Bipolar disorder;
KIRP	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	0.84	12.62	0.63	1.72e-28	Body mass index;
KIRP	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg02378861	chr5:212933	CCDC127	-0.71	-5.61	-0.34	5.43e-8	Fat distribution (HIV);
KIRP	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.59	7.75	0.44	2.46e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.76	13.44	0.65	3.08e-31	Height;
KIRP	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.92	10.64	0.56	5.52e-22	Corneal astigmatism;
KIRP	cis	rs3105593	1.000	rs56118429	chr15:50923849	T/A	cg05456662	chr15:50716270	USP8	0.42	5.14	0.31	5.54e-7	QT interval;
KIRP	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg19683494	chr5:74908142	NA	-0.46	-5.29	-0.32	2.67e-7	Age-related disease endophenotypes;
KIRP	cis	rs8179	0.761	rs42034	chr7:92239144	A/G	cg15732164	chr7:92237376	CDK6	-0.54	-6.73	-0.39	1.15e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg08773314	chr2:239334832	ASB1	-0.56	-5.71	-0.34	3.16e-8	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs16867225	1.000	rs7560282	chr2:181039814	C/T	cg18179931	chr3:194119058	GP5	-0.41	-6.47	-0.38	5.23e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.66	-7.58	-0.44	6.84e-13	Testicular germ cell tumor;
KIRP	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.83	13.29	0.65	1e-30	Longevity;Endometriosis;
KIRP	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.63	-7.92	-0.45	8.23e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.08	-18.81	-0.77	1.61e-49	Triglycerides;
KIRP	trans	rs972578	0.791	rs5751380	chr22:43227867	G/C	cg15321293	chr3:36422198	STAC	-0.46	-6.02	-0.36	6.37e-9	Mean platelet volume;
KIRP	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg25507518	chr7:2405875	EIF3B	0.42	5.03	0.31	9.25e-7	Multiple sclerosis;
KIRP	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg15068132	chr12:102092402	CHPT1	-0.39	-5.12	-0.31	6.31e-7	Blood protein levels;
KIRP	cis	rs7951870	0.945	rs61884301	chr11:46729115	G/T	cg19486271	chr11:47235900	DDB2	0.53	5.0	0.3	1.09e-6	Schizophrenia;
KIRP	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg22777020	chr22:31556080	RNF185	-0.48	-5.11	-0.31	6.62e-7	Colorectal cancer;
KIRP	cis	rs9547692	0.878	rs9531990	chr13:37449605	T/C	cg01493522	chr13:37497338	NA	-0.46	-5.52	-0.33	8.79e-8	Coronary artery disease;
KIRP	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18252515	chr7:66147081	NA	-0.47	-5.53	-0.33	8.12e-8	Aortic root size;
KIRP	cis	rs2594989	0.943	rs2442785	chr3:11521828	C/T	cg01796438	chr3:11312864	ATG7	-0.63	-7.68	-0.44	3.83e-13	Circulating chemerin levels;
KIRP	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.72	-12.98	-0.64	1.08e-29	Body mass index;
KIRP	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg02175503	chr12:58329896	NA	-0.58	-6.3	-0.37	1.35e-9	Multiple sclerosis;
KIRP	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.86	10.59	0.56	7.59e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6840360	0.935	rs3919716	chr4:152456387	A/G	cg25486957	chr4:152246857	NA	-0.44	-5.14	-0.31	5.71e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00889227	chr1:205173544	DSTYK	-0.38	-5.48	-0.33	1.06e-7	Red blood cell count;
KIRP	cis	rs55675132	0.548	rs17274725	chr1:115377469	C/T	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs17065868	1.000	rs61947999	chr13:45166125	G/T	cg10246903	chr13:45222710	NA	0.71	6.53	0.38	3.66e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.48	-7.08	-0.41	1.51e-11	Bipolar disorder;
KIRP	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.56	7.23	0.42	6.02e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.51e-40	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs7581030	0.958	rs6761251	chr2:71521191	T/G	cg07678644	chr2:71558969	ZNF638	0.46	4.96	0.3	1.33e-6	Testicular germ cell tumor;
KIRP	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.79	9.45	0.52	2.81e-18	Corneal astigmatism;
KIRP	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.27	0.42	4.78e-12	Height;
KIRP	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.81	12.63	0.63	1.67e-28	Multiple myeloma (IgH translocation);
KIRP	cis	rs6593803	0.547	rs7528262	chr1:147248817	C/T	cg27546670	chr1:147246839	GJA5	-0.73	-10.38	-0.55	3.5e-21	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.51	-5.93	-0.35	1.04e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6840360	0.904	rs73862064	chr4:152503100	T/A	cg25486957	chr4:152246857	NA	-0.46	-5.3	-0.32	2.6e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg09779392	chr19:11094753	SMARCA4	-0.54	-6.51	-0.38	4.12e-10	Protein C levels;
KIRP	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.77	-9.7	-0.53	4.72e-19	Ileal carcinoids;
KIRP	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.59	-6.23	-0.37	2.05e-9	Vitiligo;
KIRP	cis	rs737693	1.000	rs114176245	chr11:102719534	C/T	cg19620758	chr11:102826565	MMP13	0.69	5.33	0.32	2.21e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.86	-8.82	-0.49	2.19e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.81	-11.34	-0.59	3.07e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.69	5.73	0.34	3e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs55728055	0.661	rs55648708	chr22:32032062	G/A	cg01338084	chr22:32026380	PISD	0.97	6.07	0.36	4.78e-9	Age-related hearing impairment;
KIRP	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.66	8.06	0.46	3.41e-14	Calcium levels;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg19294448	chr17:6900799	ALOX12	-0.37	-4.86	-0.3	2.13e-6	Tonsillectomy;
KIRP	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.68	-7.49	-0.43	1.22e-12	Vitiligo;
KIRP	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.75	8.04	0.46	3.66e-14	Bipolar disorder;
KIRP	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs34311866	0.808	rs17783233	chr4:976598	T/C	cg02070118	chr4:952128	TMEM175	0.57	4.94	0.3	1.47e-6	Parkinson's disease;
KIRP	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.71	-10.07	-0.54	3.33e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg06027949	chr8:82754900	SNX16	-0.56	-7.09	-0.41	1.41e-11	Diastolic blood pressure;
KIRP	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.96	-8.0	-0.45	4.86e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.09	-0.64	4.71e-30	Alzheimer's disease;
KIRP	cis	rs9549260	0.564	rs4941990	chr13:41299857	A/C	cg21288729	chr13:41239152	FOXO1	0.56	7.35	0.42	2.85e-12	Red blood cell count;
KIRP	cis	rs59868192	0.925	rs16972296	chr15:42229041	C/T	cg20935245	chr15:42234343	EHD4	-0.52	-5.21	-0.32	4.08e-7	White blood cell count;
KIRP	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-7.07	-0.41	1.59e-11	Chronic sinus infection;
KIRP	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16958440	1.000	rs60422392	chr18:44621473	T/C	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.7	8.29	0.47	7.56e-15	Schizophrenia;
KIRP	cis	rs9815354	0.812	rs56728371	chr3:41999381	T/A	cg03022575	chr3:42003672	ULK4	0.79	8.1	0.46	2.62e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11169552	0.510	rs4768853	chr12:50981785	A/C	cg12884762	chr12:50931848	DIP2B	-0.41	-4.87	-0.3	2.01e-6	Colorectal cancer;
KIRP	cis	rs9790314	0.582	rs6796201	chr3:160634313	A/G	cg04691961	chr3:161091175	C3orf57	0.44	6.34	0.37	1.11e-9	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.1	-0.41	1.37e-11	Retinal vascular caliber;
KIRP	cis	rs66696671	0.545	rs7099126	chr10:121387549	C/T	cg06765389	chr10:121379685	NA	0.45	6.85	0.4	5.77e-11	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg07216194	chr8:27182965	PTK2B	0.44	5.47	0.33	1.09e-7	Neuroticism;
KIRP	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg05370193	chr1:21551575	ECE1	0.43	6.06	0.36	5.17e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.96e-9	Breast cancer;
KIRP	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14169450	chr9:139327907	INPP5E	0.6	6.92	0.4	3.98e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg16898833	chr6:26189333	HIST1H4D	0.87	5.38	0.32	1.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.32e-7	Lymphocyte counts;
KIRP	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg04013166	chr16:89971882	TCF25	0.67	5.63	0.34	4.83e-8	Skin colour saturation;
KIRP	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg11569703	chr11:65557185	OVOL1	0.73	14.09	0.67	1.89e-33	Acne (severe);
KIRP	cis	rs10814247	0.702	rs7036061	chr9:35213538	T/C	cg15271616	chr9:35490515	RUSC2	-0.37	-5.2	-0.31	4.29e-7	Psoriasis;
KIRP	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-0.85	-9.15	-0.5	2.21e-17	Gut microbiome composition (summer);
KIRP	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg05072774	chr3:49840536	C3orf54	0.41	5.14	0.31	5.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg25547332	chr5:131281432	NA	-0.49	-5.52	-0.33	8.62e-8	Life satisfaction;
KIRP	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.7	10.98	0.57	4.41e-23	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs57561814	0.655	rs6461660	chr7:22742134	T/C	cg01770232	chr7:22766155	IL6	0.57	5.18	0.31	4.67e-7	Tonsillectomy;
KIRP	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs5995756	0.554	rs4522708	chr22:39985283	G/A	cg10455938	chr22:40058150	CACNA1I	0.38	5.34	0.32	2.14e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6546324	0.625	rs2861686	chr2:67838051	A/T	cg15745817	chr2:67799979	NA	-0.69	-7.44	-0.43	1.72e-12	Endometriosis;
KIRP	trans	rs1979541	0.614	rs75131490	chr6:159119927	T/C	cg13300630	chr3:78756422	ROBO1	-0.83	-6.07	-0.36	4.7e-9	Lipoprotein (a) levels;
KIRP	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12963246	chr6:28129442	ZNF389	0.51	6.3	0.37	1.38e-9	Depression;
KIRP	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-0.98	-10.44	-0.55	2.38e-21	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs1823913	0.614	rs6434459	chr2:192165612	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.7	8.55	0.48	1.31e-15	Obesity-related traits;
KIRP	cis	rs12995491	0.763	rs1914735	chr2:88511953	A/T	cg04511125	chr2:88470314	THNSL2	-0.45	-5.56	-0.33	7e-8	Response to metformin (IC50);
KIRP	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Parkinson's disease;
KIRP	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg08975724	chr8:8085496	FLJ10661	0.63	8.2	0.46	1.32e-14	Mood instability;
KIRP	cis	rs5167	0.677	rs12709889	chr19:45453239	A/G	cg13119609	chr19:45449297	APOC2	-0.43	-5.18	-0.31	4.67e-7	Blood protein levels;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7740797	0.967	rs3757291	chr6:155124583	G/T	cg10120070	chr7:159023682	NA	-0.4	-6.02	-0.36	6.31e-9	Colorectal or endometrial cancer;
KIRP	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26207909	chr14:103986467	CKB	0.74	11.0	0.57	3.85e-23	Body mass index;
KIRP	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.6	7.41	0.43	2.05e-12	Cognitive test performance;
KIRP	cis	rs8054556	0.647	rs4077410	chr16:29998200	A/G	cg06326092	chr16:30034487	C16orf92	0.42	6.21	0.37	2.25e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7127900	0.539	rs7114418	chr11:2228709	G/A	cg25635251	chr11:2234043	NA	0.45	7.08	0.41	1.54e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs897080	0.515	rs1067321	chr2:44631312	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.85	0.35	1.55e-8	Height;
KIRP	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg03468072	chr12:39539422	NA	0.41	5.89	0.35	1.26e-8	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Bladder cancer;
KIRP	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg02569458	chr12:86230093	RASSF9	0.36	5.32	0.32	2.34e-7	Major depressive disorder;
KIRP	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg23024343	chr7:107201750	COG5	-0.39	-4.86	-0.3	2.12e-6	Coronary artery disease;
KIRP	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-1.05	-13.0	-0.64	8.88e-30	Breast cancer;
KIRP	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.65	7.62	0.44	5.53e-13	Diabetic retinopathy;
KIRP	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.6	-0.44	6.21e-13	Neuroticism;
KIRP	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg12963246	chr6:28129442	ZNF389	0.4	5.06	0.31	8.07e-7	Cardiac Troponin-T levels;
KIRP	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.75	7.93	0.45	7.64e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-5.66	-0.34	4.21e-8	Renal function-related traits (BUN);
KIRP	cis	rs33912345	0.695	rs1956874	chr14:60846211	C/A	cg27398547	chr14:60952738	C14orf39	-0.41	-5.55	-0.33	7.33e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.26e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg16584676	chr17:46985605	UBE2Z	0.43	5.23	0.32	3.6e-7	Type 2 diabetes;
KIRP	cis	rs1010254	0.510	rs72806384	chr5:151703958	A/G	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.71	10.97	0.57	4.6e-23	Height;
KIRP	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.88	-0.35	1.3e-8	Response to antipsychotic treatment;
KIRP	cis	rs10214930	0.560	rs1015750	chr7:27593219	G/A	cg22168087	chr7:27702803	HIBADH	0.46	4.91	0.3	1.68e-6	Hypospadias;
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg07511668	chr11:68622177	NA	0.44	5.81	0.35	1.93e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4302748	0.862	rs57007022	chr7:36187369	C/T	cg24442661	chr7:36192818	EEPD1	0.61	6.87	0.4	5.16e-11	Platelet count;
KIRP	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.75	10.61	0.56	6.48e-22	Menopause (age at onset);
KIRP	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg02631126	chr6:28058918	ZSCAN12L1	-0.45	-4.99	-0.3	1.13e-6	Parkinson's disease;
KIRP	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg07930552	chr6:133119739	C6orf192	0.98	6.31	0.37	1.27e-9	Type 2 diabetes nephropathy;
KIRP	cis	rs78487399	0.764	rs12473987	chr2:43812180	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.85	-0.35	1.55e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.11	-0.41	1.26e-11	Neuroticism;
KIRP	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg23161317	chr6:28129485	ZNF389	0.48	5.52	0.33	8.75e-8	Depression;
KIRP	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.54	0.59	6.69e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg10547527	chr2:198650123	BOLL	-0.55	-5.05	-0.31	8.41e-7	Ulcerative colitis;
KIRP	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-5.1	-0.31	6.84e-7	Eosinophil percentage of white cells;
KIRP	cis	rs4787491	0.765	rs4788216	chr16:30048077	C/G	cg06326092	chr16:30034487	C16orf92	0.5	7.82	0.45	1.54e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs7944735	0.567	rs76477746	chr11:48103368	G/C	cg03929089	chr4:120376271	NA	0.93	7.09	0.41	1.45e-11	Intraocular pressure;
KIRP	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg04935436	chr20:30431758	NA	0.54	6.63	0.39	2.17e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg27417294	chr10:81904244	PLAC9	0.37	5.22	0.32	3.85e-7	Sarcoidosis;
KIRP	cis	rs17023223	0.537	rs61808892	chr1:119599207	C/T	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	3e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg06521331	chr12:34319734	NA	-0.6	-6.99	-0.41	2.59e-11	Bladder cancer;
KIRP	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg24796726	chr7:884288	UNC84A	-0.59	-5.39	-0.32	1.67e-7	Initial pursuit acceleration;
KIRP	trans	rs13170463	0.579	rs6883198	chr5:8036657	G/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg12560992	chr17:57184187	TRIM37	0.68	6.43	0.38	6.45e-10	Cognitive test performance;
KIRP	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.33	5.36	0.32	1.87e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.77	9.67	0.52	6.09e-19	White matter hyperintensity burden;
KIRP	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg01689657	chr7:91764605	CYP51A1	0.45	6.71	0.39	1.3e-10	Breast cancer;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.63	9.58	0.52	1.14e-18	Lung cancer;
KIRP	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.83	11.24	0.58	6.42e-24	Menarche (age at onset);
KIRP	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05220968	chr6:146057943	EPM2A	0.39	4.93	0.3	1.52e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.69	10.24	0.55	9.91e-21	Dupuytren's disease;
KIRP	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.35	5.01	0.3	1.06e-6	Menarche (age at onset);
KIRP	cis	rs3109167	0.666	rs6467949	chr7:83106868	G/A	cg14519356	chr7:83097669	SEMA3E	-0.46	-6.34	-0.37	1.11e-9	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs981844	0.775	rs56101345	chr4:154764261	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.66	0.44	4.13e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.92	-0.9	4.05e-92	Myeloid white cell count;
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.92	0.53	1.01e-19	Lung cancer;
KIRP	cis	rs2920503	0.959	rs2920502	chr3:12329195	G/C	cg23514324	chr3:12329213	PPARG	0.64	7.42	0.43	1.89e-12	LDL cholesterol;
KIRP	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-15.86	-0.71	1.68e-39	Colorectal cancer;
KIRP	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.71	10.33	0.55	5.04e-21	High light scatter reticulocyte count;
KIRP	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs1461503	0.934	rs7113330	chr11:122843358	C/T	cg27398637	chr11:122830231	C11orf63	-0.68	-8.99	-0.5	6.86e-17	Menarche (age at onset);
KIRP	cis	rs9400271	0.632	rs949881	chr6:109586240	A/G	cg21918786	chr6:109611834	NA	-0.37	-5.45	-0.33	1.2e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.76	11.24	0.58	6.31e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.53	7.71	0.44	3.15e-13	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.1	-0.41	1.37e-11	Menopause (age at onset);
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.67	8.72	0.49	4.19e-16	Longevity;
KIRP	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg12315302	chr6:26189340	HIST1H4D	1.08	6.48	0.38	4.86e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21182616	chr4:1363182	KIAA1530	0.41	6.16	0.37	2.94e-9	Survival in pancreatic cancer;
KIRP	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg02696742	chr7:106810147	HBP1	-0.8	-7.99	-0.45	5.19e-14	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg21573476	chr21:45109991	RRP1B	-0.59	-8.29	-0.47	7.49e-15	Mean corpuscular volume;
KIRP	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.37	-5.1	-0.31	6.79e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.44	-5.44	-0.33	1.25e-7	Longevity;Endometriosis;
KIRP	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.74	0.53	3.63e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7582720	1.000	rs3845800	chr2:203734365	A/T	cg08076091	chr2:203926405	NBEAL1	-0.75	-8.45	-0.47	2.62e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg13010199	chr12:38710504	ALG10B	0.68	8.65	0.48	6.95e-16	Morning vs. evening chronotype;
KIRP	cis	rs75920871	0.623	rs17120244	chr11:116919511	C/T	cg04087571	chr11:116723030	SIK3	-0.27	-5.54	-0.33	7.71e-8	Subjective well-being;
KIRP	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08704250	chr15:31115839	NA	-0.59	-7.75	-0.44	2.4e-13	Huntington's disease progression;
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg23736307	chr8:27182930	PTK2B	0.53	6.66	0.39	1.79e-10	Neuroticism;
KIRP	cis	rs2371030	1.000	rs4517917	chr2:211568913	C/T	cg18417063	chr2:211583084	NA	-0.52	-7.52	-0.43	1.03e-12	Non-small cell lung cancer;
KIRP	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.57	0.48	1.13e-15	Prudent dietary pattern;
KIRP	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11987759	chr7:65425863	GUSB	-0.46	-6.32	-0.37	1.23e-9	Aortic root size;
KIRP	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg05804037	chr4:1090086	RNF212	-0.35	-5.01	-0.3	1.03e-6	Recombination rate (males);
KIRP	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg09579323	chr1:150459698	TARS2	-0.38	-4.87	-0.3	2.02e-6	Migraine;
KIRP	cis	rs6696846	0.936	rs12134724	chr1:205039288	T/C	cg00889227	chr1:205173544	DSTYK	-0.36	-4.98	-0.3	1.18e-6	Red blood cell count;
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	0.84	15.44	0.7	4.46e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg18350739	chr11:68623251	NA	-0.47	-7.31	-0.42	3.7e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.57	-6.08	-0.36	4.66e-9	Obesity-related traits;
KIRP	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.91	10.94	0.57	5.96e-23	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg07541023	chr7:19748670	TWISTNB	0.66	6.22	0.37	2.18e-9	Thyroid stimulating hormone;
KIRP	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg22437258	chr11:111473054	SIK2	-0.54	-6.11	-0.36	3.92e-9	Primary sclerosing cholangitis;
KIRP	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.67e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15825264	chr17:655740	ELP2P;GEMIN4	0.46	6.44	0.38	6.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.39	-0.32	1.66e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9400271	0.632	rs949882	chr6:109586062	A/G	cg01475377	chr6:109611718	NA	0.37	5.29	0.32	2.74e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg17306686	chr7:157230923	NA	0.53	7.99	0.45	5.23e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	1.06	20.4	0.79	8.23e-55	Height;
KIRP	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.79	8.28	0.47	7.94e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.79	7.67	0.44	4.01e-13	Diisocyanate-induced asthma;
KIRP	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs698813	0.572	rs12613771	chr2:44490660	C/A	cg04920474	chr2:44395004	PPM1B	0.37	4.96	0.3	1.33e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs12496230	0.909	rs13075691	chr3:66857626	T/A	cg17646820	chr3:66848679	NA	0.46	6.6	0.39	2.57e-10	Type 2 diabetes;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-0.64	-5.55	-0.33	7.22e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.42	5.38	0.32	1.76e-7	Aortic root size;
KIRP	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.82	10.19	0.54	1.4e-20	Corneal astigmatism;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg14092571	chr14:90743983	NA	-0.41	-5.38	-0.32	1.75e-7	Mortality in heart failure;
KIRP	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg14972814	chr11:95582409	MTMR2	0.3	5.15	0.31	5.35e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs16854884	0.657	rs1025984	chr3:143756187	C/G	cg06585982	chr3:143692056	C3orf58	-0.54	-7.41	-0.43	2.07e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs9912468	0.534	rs4791076	chr17:64237889	C/A	cg19474267	chr17:64306194	PRKCA	-0.4	-5.13	-0.31	5.81e-7	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03210589	chr16:57519987	DOK4	0.46	6.47	0.38	5.21e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2055729	0.645	rs62489486	chr8:9741925	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	6.25	0.37	1.79e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg08283408	chr3:49949060	MON1A	-0.43	-5.65	-0.34	4.49e-8	Body mass index;
KIRP	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	10.64	0.56	5.34e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg04132472	chr17:19861366	AKAP10	0.4	5.24	0.32	3.44e-7	Schizophrenia;
KIRP	trans	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg22903471	chr2:27725779	GCKR	0.4	5.58	0.34	6.43e-8	Oral cavity cancer;
KIRP	cis	rs1829883	0.898	rs1464639	chr5:98786821	A/G	cg08333243	chr5:99726346	NA	-0.41	-5.44	-0.33	1.29e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.68	7.29	0.42	4.34e-12	Lymphocyte counts;
KIRP	cis	rs1816854	0.938	rs3764004	chr12:44201451	T/C	cg20956634	chr12:44200518	TWF1	0.46	5.0	0.3	1.08e-6	Inflammatory bowel disease;
KIRP	cis	rs10214930	0.697	rs9639552	chr7:27575523	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.93	0.3	1.53e-6	Hypospadias;
KIRP	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg00405596	chr8:11794950	NA	0.45	6.04	0.36	5.79e-9	Neuroticism;
KIRP	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4765905	0.640	rs11062159	chr12:2326224	G/A	cg10668781	chr12:2307325	CACNA1C	-0.37	-7.04	-0.41	1.96e-11	Schizophrenia;
KIRP	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.4	0.72	2.43e-41	Lymphocyte percentage of white cells;
KIRP	trans	rs10782582	0.758	rs5745557	chr1:76379337	G/A	cg10283277	chr11:111472630	SIK2	-0.31	-6.21	-0.37	2.23e-9	Daytime sleep phenotypes;
KIRP	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg06223162	chr1:101003688	GPR88	-0.43	-8.75	-0.49	3.38e-16	Monocyte count;
KIRP	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.36	-4.97	-0.3	1.25e-6	Neuroticism;
KIRP	cis	rs7119038	0.818	rs2155433	chr11:118612921	G/A	cg19308663	chr11:118741387	NA	0.42	6.95	0.41	3.26e-11	Sjögren's syndrome;
KIRP	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	0.82	8.97	0.5	7.88e-17	Gut microbiome composition (summer);
KIRP	cis	rs12580194	0.593	rs59676560	chr12:55745425	T/C	cg11794356	chr12:55725991	OR6C3	-0.6	-8.62	-0.48	8.4e-16	Cancer;
KIRP	cis	rs5752773	0.610	rs695318	chr22:28882973	G/A	cg16849201	chr22:29715310	NA	-0.3	-5.07	-0.31	7.84e-7	Vertical cup-disc ratio;
KIRP	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.92	0.35	1.08e-8	Renal cell carcinoma;
KIRP	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.3	0.37	1.4e-9	Red blood cell count;
KIRP	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.52	6.19	0.37	2.55e-9	Parkinson's disease;
KIRP	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg27426351	chr10:43362370	NA	0.44	6.28	0.37	1.54e-9	Blood protein levels;
KIRP	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.55	-7.6	-0.44	6.17e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02711726	chr17:80685570	FN3KRP	-0.6	-8.11	-0.46	2.33e-14	Glycated hemoglobin levels;
KIRP	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs1595825	1.000	rs1440090	chr2:198879297	T/G	cg00982548	chr2:198649783	BOLL	-0.5	-4.98	-0.3	1.18e-6	Ulcerative colitis;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg03115019	chr17:80708279	FN3K	-0.43	-5.11	-0.31	6.34e-7	Glycated hemoglobin levels;
KIRP	cis	rs708547	0.957	rs1718875	chr4:57837438	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.78	8.53	0.48	1.54e-15	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg05998816	chr21:47859926	PCNT	0.53	6.06	0.36	5.11e-9	Lymphocyte counts;
KIRP	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs225245	0.755	rs226432	chr17:34043825	G/A	cg19694781	chr19:47549865	TMEM160	0.52	6.26	0.37	1.73e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6929812	0.613	rs13215560	chr6:27481939	A/G	cg03332623	chr6:27441972	ZNF184	-0.34	-5.04	-0.31	8.82e-7	Neuroticism (multi-trait analysis);
KIRP	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg25174290	chr11:3078921	CARS	-0.68	-8.99	-0.5	6.95e-17	Calcium levels;
KIRP	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	6.24	0.37	1.94e-9	Response to antipsychotic treatment;
KIRP	cis	rs6102059	0.667	rs6129649	chr20:39234223	C/T	cg22477343	chr20:39312069	NA	-0.51	-6.44	-0.38	6.18e-10	LDL cholesterol;
KIRP	cis	rs6466055	0.501	rs7776707	chr7:104605530	C/A	cg04380332	chr7:105027541	SRPK2	-0.62	-9.14	-0.5	2.47e-17	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23959187	chr17:46102881	NA	0.56	6.59	0.39	2.59e-10	Smoking initiation;
KIRP	cis	rs9828933	0.808	rs3733125	chr3:63981635	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.89	-6.13	-0.36	3.41e-9	Type 2 diabetes;
KIRP	cis	rs9816226	0.591	rs1516725	chr3:185824004	T/C	cg00760338	chr3:185826511	ETV5	0.78	6.73	0.39	1.17e-10	Obesity;Body mass index;
KIRP	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.5	7.3	0.42	4e-12	Coronary artery disease;
KIRP	cis	rs7998202	0.667	rs282575	chr13:113359524	G/C	cg04656015	chr13:113407548	ATP11A	-0.51	-5.68	-0.34	3.78e-8	Glycated hemoglobin levels;
KIRP	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs2019216	0.500	rs12939173	chr17:21900749	T/C	cg22648282	chr17:21454238	C17orf51	-0.5	-5.39	-0.32	1.68e-7	Pelvic organ prolapse;
KIRP	cis	rs2790457	0.833	rs1265846	chr10:28929097	A/G	cg05705492	chr10:28955341	NA	-0.53	-7.9	-0.45	9.49e-14	Multiple myeloma;
KIRP	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg22903471	chr2:27725779	GCKR	-0.46	-4.85	-0.3	2.2e-6	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03582537	chr8:64081405	YTHDF3	0.54	7.19	0.42	7.67e-12	Parkinson's disease;
KIRP	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.5	7.16	0.42	9.02e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg25251562	chr2:3704773	ALLC	-0.51	-6.0	-0.36	7.07e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg20673091	chr1:2541236	MMEL1	-0.66	-9.89	-0.53	1.25e-19	Ulcerative colitis;
KIRP	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.88	13.38	0.65	4.75e-31	Mean corpuscular hemoglobin;
KIRP	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg08975724	chr8:8085496	FLJ10661	0.53	6.4	0.38	7.72e-10	Systolic blood pressure;
KIRP	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.61	7.84	0.45	1.33e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg07636037	chr3:49044803	WDR6	-0.75	-5.29	-0.32	2.75e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.22	-0.37	2.11e-9	Lung cancer;
KIRP	cis	rs9810890	1.000	rs73198827	chr3:128489521	G/T	cg15033153	chr3:128514015	RAB7A	0.76	6.21	0.37	2.28e-9	Dental caries;
KIRP	cis	rs13418717	1.000	rs13411741	chr2:127666335	G/A	cg25501666	chr2:127640322	NA	0.88	5.84	0.35	1.6e-8	Heart failure;
KIRP	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg16141378	chr3:129829833	LOC729375	0.54	7.29	0.42	4.14e-12	Morning vs. evening chronotype;
KIRP	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.4	4.98	0.3	1.2e-6	Multiple sclerosis;
KIRP	cis	rs11650494	0.710	rs76651802	chr17:47473785	A/G	cg08112188	chr17:47440006	ZNF652	1.11	7.26	0.42	5.04e-12	Prostate cancer;
KIRP	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg05991184	chr2:219186017	PNKD	0.36	5.02	0.3	9.84e-7	Colorectal cancer;
KIRP	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.4	6.11	0.36	3.83e-9	Lung cancer;
KIRP	cis	rs16975963	0.644	rs78644049	chr19:38113042	T/A	cg18030218	chr19:38865513	PSMD8	0.54	4.85	0.3	2.15e-6	Longevity;
KIRP	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg17133734	chr15:86042851	AKAP13	-0.44	-5.38	-0.32	1.75e-7	Coronary artery disease;
KIRP	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.21	-5.19	-0.31	4.36e-7	Coronary artery disease;
KIRP	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.52	-7.33	-0.42	3.22e-12	Coronary artery disease;
KIRP	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.79	-8.08	-0.46	2.95e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg11569703	chr11:65557185	OVOL1	0.41	6.88	0.4	5.02e-11	Systemic lupus erythematosus;
KIRP	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	8.85	0.49	1.71e-16	Cognitive test performance;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16051027	chr20:32320358	ZNF341	0.58	6.8	0.4	8.01e-11	Smoking initiation;
KIRP	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg18132916	chr6:79620363	NA	-0.41	-5.74	-0.34	2.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg23100626	chr2:96804247	ASTL	0.52	7.55	0.43	8.3e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-8.41	-0.47	3.27e-15	Triglycerides;
KIRP	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.73	-9.46	-0.52	2.56e-18	Childhood ear infection;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01454612	chr17:57693600	NA	0.37	6.16	0.37	2.94e-9	C-reactive protein;
KIRP	cis	rs11885103	0.634	rs13001871	chr2:593701	G/A	cg21195176	chr2:593345	NA	0.37	4.97	0.3	1.27e-6	Heschl's gyrus morphology;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14360444	chr9:129643082	ZBTB34	-0.53	-6.75	-0.4	1.07e-10	Inflammatory biomarkers;
KIRP	cis	rs829883	0.659	rs12366950	chr12:98947900	T/C	cg25150519	chr12:98850993	NA	-0.77	-9.25	-0.51	1.16e-17	Colorectal adenoma (advanced);
KIRP	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.91	-0.35	1.16e-8	IgG glycosylation;
KIRP	cis	rs11790388	0.505	rs2417046	chr9:129754730	C/T	cg13970942	chr9:129673409	NA	-0.37	-4.99	-0.3	1.15e-6	Schizophrenia;
KIRP	cis	rs6681460	0.649	rs1415984	chr1:67002117	A/G	cg13052034	chr1:66999238	SGIP1	0.41	5.52	0.33	8.59e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6466055	0.661	rs6466048	chr7:104896865	C/T	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	7.01e-7	Schizophrenia;
KIRP	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.93	14.13	0.67	1.36e-33	Personality dimensions;
KIRP	cis	rs3767633	0.858	rs6698065	chr1:161891528	G/A	cg09175582	chr1:161736000	ATF6	0.61	4.96	0.3	1.34e-6	IgG glycosylation;
KIRP	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.38	-5.46	-0.33	1.18e-7	Coronary artery disease;
KIRP	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	7.15	0.41	1.01e-11	Height;
KIRP	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.53	7.11	0.41	1.24e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.44	-6.2	-0.37	2.37e-9	Coronary artery disease;
KIRP	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.69	8.72	0.49	4.3e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.25	26.58	0.86	2.91e-74	IgG glycosylation;
KIRP	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.58	-0.52	1.09e-18	Aortic root size;
KIRP	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.05	0.41	1.83e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14234805	chr20:37101345	RALGAPB	0.45	6.2	0.37	2.32e-9	Survival in pancreatic cancer;
KIRP	cis	rs4073221	0.929	rs35274326	chr3:18282459	C/G	cg07694806	chr3:18168406	NA	-0.83	-7.08	-0.41	1.52e-11	Parkinson's disease;
KIRP	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg07511934	chr16:89386912	ANKRD11	0.47	6.05	0.36	5.31e-9	Multiple myeloma (IgH translocation);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10002088	chr19:9271911	ZNF317	-0.51	-6.13	-0.36	3.52e-9	Inflammatory biomarkers;
KIRP	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-0.8	-8.77	-0.49	3.05e-16	Gut microbiome composition (summer);
KIRP	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg22914934	chr11:76156056	C11orf30	0.53	6.41	0.38	7.56e-10	Educational attainment;
KIRP	cis	rs6993770	0.661	rs1868650	chr8:106517912	T/C	cg12797828	chr8:106520928	ZFPM2	-0.34	-5.0	-0.3	1.07e-6	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
KIRP	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg04935436	chr20:30431758	NA	0.51	5.94	0.35	9.62e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14473030	chr9:119336987	ASTN2	0.41	5.55	0.33	7.21e-8	Survival in pancreatic cancer;
KIRP	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.49	6.73	0.39	1.21e-10	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg15028436	chr7:37888078	TXNDC3	0.71	9.42	0.51	3.44e-18	Alzheimer's disease (late onset);
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.61	8.94	0.5	9.34e-17	Lung cancer;
KIRP	cis	rs7274811	0.744	rs6141411	chr20:32157934	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.39	-4.91	-0.3	1.65e-6	Height;
KIRP	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.39	-5.1	-0.31	6.93e-7	Body mass index;
KIRP	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.45	-5.66	-0.34	4.2e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.38	-5.93	-0.35	1.05e-8	Attention deficit hyperactivity disorder;
KIRP	trans	rs12529514	1.000	rs2235369	chr6:14118505	G/A	cg02955631	chr11:119293601	THY1	-0.59	-6.06	-0.36	5.01e-9	Rheumatoid arthritis;
KIRP	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.78	-11.94	-0.61	3.18e-26	Longevity;
KIRP	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.68	-8.07	-0.46	3.15e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11581903	0.929	rs34275176	chr1:53056063	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.55	5.39	0.32	1.67e-7	Joint mobility (Beighton score);
KIRP	cis	rs7589342	0.501	rs7602971	chr2:106440675	G/A	cg16077055	chr2:106428750	NCK2	0.23	5.1	0.31	6.71e-7	Addiction;
KIRP	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg04455712	chr21:45112962	RRP1B	-0.45	-5.94	-0.35	9.7e-9	Mean corpuscular volume;
KIRP	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg09165964	chr15:75287851	SCAMP5	0.6	8.05	0.46	3.58e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.13	13.11	0.64	4.02e-30	Platelet count;
KIRP	cis	rs2916247	1.000	rs28728418	chr8:93061878	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7688540	0.609	rs77700883	chr4:232532	G/A	cg17891759	chr4:299121	NA	-0.47	-4.85	-0.3	2.24e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	8.08	0.46	2.95e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg04132472	chr17:19861366	AKAP10	0.38	4.86	0.3	2.1e-6	Schizophrenia;
KIRP	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.6	-0.34	5.75e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.96	-15.61	-0.71	1.23e-38	Monocyte count;
KIRP	cis	rs6921919	0.583	rs1416918	chr6:28358335	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.55	0.73	7.42e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.72	6.1	0.36	4.11e-9	Inflammatory bowel disease;
KIRP	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg20302533	chr7:39170763	POU6F2	0.3	6.28	0.37	1.51e-9	IgG glycosylation;
KIRP	cis	rs3789045	0.729	rs61817460	chr1:204543579	G/A	cg18185008	chr1:204589407	LRRN2	-0.62	-6.7	-0.39	1.4e-10	Educational attainment (college completion);
KIRP	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg10130564	chr11:117069849	TAGLN	0.41	5.08	0.31	7.51e-7	Blood protein levels;
KIRP	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.74	9.43	0.52	3.26e-18	Menopause (age at onset);
KIRP	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.78	11.59	0.59	4.35e-25	Obesity-related traits;
KIRP	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.66	7.33	0.42	3.33e-12	Initial pursuit acceleration;
KIRP	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18252515	chr7:66147081	NA	0.46	5.63	0.34	4.85e-8	Aortic root size;
KIRP	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.8	-0.57	1.61e-22	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02577989	chr13:44716179	NA	0.48	6.54	0.38	3.49e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.94	-0.35	9.76e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.21	13.08	0.64	5.04e-30	Corneal structure;
KIRP	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11987759	chr7:65425863	GUSB	-0.55	-7.47	-0.43	1.37e-12	Aortic root size;
KIRP	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.44	-7.04	-0.41	1.92e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9398803	0.651	rs4339479	chr6:126936953	G/A	cg19875578	chr6:126661172	C6orf173	0.38	4.97	0.3	1.27e-6	Male-pattern baldness;
KIRP	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.74	-8.98	-0.5	6.99e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6959887	0.962	rs10255047	chr7:35283910	G/A	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg22396632	chr1:3079212	PRDM16	-0.37	-4.95	-0.3	1.37e-6	Migraine;
KIRP	cis	rs4908768	0.906	rs6678982	chr1:8577185	C/A	cg03610117	chr1:8450231	RERE	-0.45	-5.11	-0.31	6.55e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.83	8.3	0.47	6.85e-15	Fibroblast growth factor basic levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13181052	chr1:40420675	MFSD2A	0.45	6.34	0.37	1.12e-9	Parkinson's disease;
KIRP	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	7.35	0.42	2.96e-12	Neuroticism;
KIRP	trans	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.52	6.03	0.36	5.91e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs911119	0.913	rs4815222	chr20:23576964	A/G	cg09631192	chr20:23583594	CST9	0.49	5.2	0.31	4.26e-7	Chronic kidney disease;
KIRP	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg14851346	chr12:38532713	NA	-0.4	-4.98	-0.3	1.19e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.63	9.0	0.5	6.44e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.54	-5.6	-0.34	5.72e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg15664640	chr17:80829946	TBCD	-0.66	-5.91	-0.35	1.16e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs1408799	0.671	rs2733832	chr9:12704725	C/T	cg05274944	chr9:12693694	TYRP1	0.4	5.69	0.34	3.65e-8	Eye color;Blue vs. green eyes;
KIRP	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg06307176	chr5:131281290	NA	0.55	6.48	0.38	5.1e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6540556	1.000	rs6540556	chr1:209936631	G/A	cg23920097	chr1:209922102	NA	-0.41	-5.42	-0.33	1.42e-7	Red blood cell count;
KIRP	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg01631408	chr1:248437212	OR2T33	-0.64	-8.54	-0.48	1.4e-15	Common traits (Other);
KIRP	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg26248373	chr2:1572462	NA	-0.65	-7.01	-0.41	2.22e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.56e-17	Retinal vascular caliber;
KIRP	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg18882449	chr10:104885122	NT5C2	-0.5	-6.47	-0.38	5.22e-10	Arsenic metabolism;
KIRP	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-12.11	-0.61	8.47e-27	Systemic lupus erythematosus;
KIRP	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.82	12.65	0.63	1.42e-28	Prostate cancer;
KIRP	cis	rs1978968	0.731	rs9605462	chr22:18459859	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.8	-11.35	-0.59	2.7e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg18402987	chr7:1209562	NA	0.66	6.28	0.37	1.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs9547996	0.879	rs2209230	chr13:38187158	A/G	cg13634560	chr13:38173852	POSTN	-0.4	-5.55	-0.33	7.2e-8	Diastolic blood pressure;
KIRP	cis	rs28489187	0.660	rs4949900	chr1:85861034	T/G	cg16011679	chr1:85725395	C1orf52	-0.51	-6.24	-0.37	1.85e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.68	-9.05	-0.5	4.33e-17	Sudden cardiac arrest;
KIRP	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.99	-0.45	5.23e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	9.08	0.5	3.75e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1511802	0.614	rs12507156	chr4:187116832	C/T	cg23442198	chr4:187126114	CYP4V2	0.4	5.43	0.33	1.34e-7	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01443390	chr4:1017903	FGFRL1	-0.49	-6.74	-0.39	1.14e-10	Parkinson's disease;
KIRP	cis	rs7714584	1.000	rs80075680	chr5:150223737	C/T	cg22134413	chr5:150180641	NA	0.57	5.08	0.31	7.4e-7	Crohn's disease;
KIRP	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg20243544	chr17:37824526	PNMT	0.52	7.35	0.42	2.88e-12	Asthma;
KIRP	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.65	-7.66	-0.44	4.35e-13	Mean platelet volume;
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg02733842	chr7:1102375	C7orf50	-0.48	-5.04	-0.31	9.13e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg25547332	chr5:131281432	NA	0.48	5.38	0.32	1.72e-7	Life satisfaction;
KIRP	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg19847130	chr8:10466454	RP1L1	0.36	5.3	0.32	2.52e-7	Triglycerides;
KIRP	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.38	5.09	0.31	7.07e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg01362455	chr6:29855490	HLA-H	0.5	5.65	0.34	4.32e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-6.81	-0.4	7.38e-11	Heart rate;
KIRP	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg27124370	chr19:33622961	WDR88	0.73	10.38	0.55	3.58e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.58	-7.18	-0.42	8.13e-12	Iron status biomarkers;
KIRP	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	10.18	0.54	1.48e-20	Cognitive test performance;
KIRP	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.36e-11	Arsenic metabolism;
KIRP	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7594645	1.000	rs115889150	chr2:207597807	A/G	cg26343667	chr3:156391915	TIPARP;LOC100287227	0.91	6.03	0.36	6.07e-9	Episodic memory;
KIRP	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg01028140	chr2:1542097	TPO	-0.55	-6.06	-0.36	5.13e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg12042659	chr19:58951599	ZNF132	0.49	5.93	0.35	1.01e-8	Uric acid clearance;
KIRP	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.42	-6.82	-0.4	7e-11	Body mass index;
KIRP	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.16	-0.31	5.2e-7	Fear of minor pain;
KIRP	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26248373	chr2:1572462	NA	-0.78	-10.28	-0.55	7.7e-21	IgG glycosylation;
KIRP	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.46	6.49	0.38	4.57e-10	Dupuytren's disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24022402	chr3:9834453	ARPC4;TADA3	0.67	6.17	0.37	2.84e-9	Lung function (FEV1);
KIRP	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.91	-14.91	-0.69	2.98e-36	Urate levels in lean individuals;
KIRP	cis	rs7116495	0.867	rs529567	chr11:71580537	G/A	cg11196788	chr11:71737549	NUMA1	-0.5	-4.95	-0.3	1.36e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg14768367	chr16:72042858	DHODH	0.5	6.24	0.37	1.94e-9	Fibrinogen levels;
KIRP	cis	rs11955175	1.000	rs75728011	chr5:40797505	A/C	cg04002187	chr5:40835754	RPL37	0.82	5.67	0.34	4.04e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg00656387	chr3:40428638	ENTPD3	-0.38	-5.18	-0.31	4.7e-7	Renal cell carcinoma;
KIRP	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg07827796	chr19:33622959	WDR88	-0.41	-4.95	-0.3	1.4e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg24110177	chr3:50126178	RBM5	-0.42	-5.45	-0.33	1.2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9547996	1.000	rs9547999	chr13:38223366	T/C	cg13634560	chr13:38173852	POSTN	-0.36	-5.09	-0.31	7.12e-7	Diastolic blood pressure;
KIRP	cis	rs742134	1.000	rs872842	chr22:43530631	T/A	cg26453588	chr22:43506021	BIK	0.36	5.2	0.31	4.26e-7	Prostate cancer;
KIRP	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg06212747	chr3:49208901	KLHDC8B	0.63	8.85	0.49	1.78e-16	Resting heart rate;
KIRP	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg07541023	chr7:19748670	TWISTNB	0.84	7.32	0.42	3.51e-12	Thyroid stimulating hormone;
KIRP	cis	rs34779708	0.733	rs11010146	chr10:35541561	T/A	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs11568563	0.504	rs4762698	chr12:21332843	A/G	cg10614021	chr12:14134486	GRIN2B	-0.69	-6.04	-0.36	5.61e-9	Progressive supranuclear palsy;
KIRP	cis	rs8077577	0.689	rs2273029	chr17:18236339	G/A	cg18869244	chr17:18121946	NA	0.45	5.06	0.31	8.21e-7	Obesity-related traits;
KIRP	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.13	0.41	1.08e-11	Height;
KIRP	cis	rs6466055	0.661	rs17640644	chr7:104918169	A/G	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.03e-6	Schizophrenia;
KIRP	cis	rs9381107	0.527	rs2294730	chr6:9517476	C/A	cg14735645	chr6:9486422	NA	-0.61	-5.98	-0.36	7.64e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.92	10.71	0.56	3.26e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg11783602	chr8:55087084	NA	-0.57	-7.07	-0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.01	13.86	0.66	1.13e-32	Response to antipsychotic treatment;
KIRP	trans	rs7246760	0.867	rs2287843	chr19:9769913	G/A	cg02900749	chr2:68251473	NA	-1.14	-9.29	-0.51	8.61e-18	Pursuit maintenance gain;
KIRP	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.84	12.19	0.61	4.65e-27	Colorectal cancer;
KIRP	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs698833	0.692	rs786410	chr2:44731156	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.95	0.3	1.37e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs8084125	1.000	rs7230071	chr18:74955482	A/G	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg25110126	chr1:46999211	NA	0.51	6.46	0.38	5.64e-10	Monobrow;
KIRP	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.51	-0.65	1.75e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.16	0.54	1.78e-20	Total body bone mineral density;
KIRP	cis	rs865483	0.826	rs853198	chr17:35849342	A/C	cg06716730	chr17:35851459	DUSP14	0.26	6.22	0.37	2.17e-9	Monocyte count;
KIRP	cis	rs9826463	0.582	rs73238130	chr3:142004004	G/A	cg20824294	chr3:142316082	PLS1	0.46	6.62	0.39	2.29e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	7.44	0.43	1.67e-12	Height;
KIRP	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg23815491	chr16:72088622	HP	0.51	7.52	0.43	1.02e-12	Blood protein levels;
KIRP	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20135002	chr11:47629003	NA	-0.48	-5.83	-0.35	1.73e-8	Subjective well-being;
KIRP	cis	rs860295	0.729	rs11264369	chr1:155359830	T/C	cg02153340	chr1:155202674	NA	0.42	5.55	0.33	7.34e-8	Body mass index;
KIRP	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg21643547	chr1:205240462	TMCC2	-0.64	-9.45	-0.52	2.73e-18	Red blood cell count;
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.04	0.36	5.51e-9	Lung cancer;
KIRP	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg16898833	chr6:26189333	HIST1H4D	0.66	5.04	0.31	9.09e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09685351	chr22:45148319	ARHGAP8;PRR5-ARHGAP8	0.47	6.47	0.38	5.4e-10	Smoking initiation;
KIRP	cis	rs10865541	1.000	rs11684337	chr2:3395287	A/G	cg11642891	chr2:3452563	TTC15	0.51	6.57	0.39	2.97e-10	Obesity-related traits;
KIRP	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	0.58	4.95	0.3	1.38e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.77	-9.68	-0.53	5.58e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2273669	0.667	rs7767882	chr6:109334971	C/A	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs4356932	1.000	rs13130018	chr4:76955519	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs501120	1.000	rs634963	chr10:44760033	T/C	cg09554077	chr10:44749378	NA	0.7	10.73	0.56	2.84e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	9.89	0.53	1.21e-19	Blood protein levels;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	6.96	0.41	2.99e-11	Breast cancer;
KIRP	cis	rs698833	0.926	rs1067394	chr2:44638123	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.54	0.38	3.63e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.34	5.34	0.32	2.1e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3789045	0.685	rs12036042	chr1:204469314	T/C	cg18185008	chr1:204589407	LRRN2	-0.6	-6.41	-0.38	7.36e-10	Educational attainment (college completion);
KIRP	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.9	-14.96	-0.69	1.99e-36	Breast cancer;
KIRP	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg16898833	chr6:26189333	HIST1H4D	0.95	5.79	0.35	2.15e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17401966	0.522	rs4845930	chr1:10319049	G/A	cg17425144	chr1:10567563	PEX14	-0.3	-5.35	-0.32	2.05e-7	Hepatocellular carcinoma;
KIRP	trans	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg19274270	chr17:78178856	CARD14	0.36	6.5	0.38	4.4e-10	Morning vs. evening chronotype;
KIRP	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg21253087	chr9:139290292	SNAPC4	0.45	6.39	0.38	8.23e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs282587	0.569	rs914012	chr13:113386715	C/T	cg04656015	chr13:113407548	ATP11A	0.6	6.41	0.38	7.36e-10	Glycated hemoglobin levels;
KIRP	cis	rs4901847	0.967	rs8015039	chr14:58547391	A/C	cg15908186	chr14:58618357	C14orf37	-0.44	-5.67	-0.34	3.95e-8	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg13397359	chr6:42928475	GNMT	0.43	4.96	0.3	1.29e-6	Blood protein levels;
KIRP	trans	rs12517041	1.000	rs16892312	chr5:23279764	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.36	-0.47	4.82e-15	Calcium levels;
KIRP	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg21427119	chr20:30132790	HM13	-0.52	-5.83	-0.35	1.78e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg10755058	chr3:40428713	ENTPD3	0.48	6.59	0.39	2.72e-10	Renal cell carcinoma;
KIRP	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.9	-12.31	-0.62	1.94e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.89	0.45	1.02e-13	Coffee consumption (cups per day);
KIRP	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.34e-8	Platelet count;
KIRP	cis	rs72634030	0.826	rs72634017	chr17:5188652	C/T	cg20802942	chr17:5185005	RABEP1	0.52	5.06	0.31	8.32e-7	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.96e-8	Life satisfaction;
KIRP	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.24	-0.47	9.98e-15	Blood protein levels;
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg19723775	chr5:179050963	HNRNPH1	0.44	4.99	0.3	1.17e-6	Lung cancer;
KIRP	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.86	-0.3	2.05e-6	Crohn's disease;
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.03e-9	Depression;
KIRP	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg07148914	chr20:33460835	GGT7	0.42	5.16	0.31	5.11e-7	Height;
KIRP	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.78	10.11	0.54	2.59e-20	Aortic root size;
KIRP	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs6142102	0.812	rs4911375	chr20:32516022	C/A	cg08999081	chr20:33150536	PIGU	0.47	5.72	0.34	3.12e-8	Skin pigmentation;
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.52	0.65	1.65e-31	Platelet count;
KIRP	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg23995753	chr2:160760732	LY75	-0.44	-5.83	-0.35	1.75e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.23	-0.55	1.05e-20	Hypospadias;
KIRP	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.67	-7.98	-0.45	5.71e-14	Menarche (age at onset);
KIRP	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.45	-0.33	1.2e-7	Recombination measurement;
KIRP	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	1.09	20.03	0.79	1.36e-53	Gut microbiome composition (winter);
KIRP	cis	rs7011049	1.000	rs11997538	chr8:53832663	A/C	cg26025543	chr8:53854495	NA	0.72	7.76	0.44	2.31e-13	Systolic blood pressure;
KIRP	cis	rs4711350	0.765	rs943476	chr6:33750086	A/G	cg25922239	chr6:33757077	LEMD2	0.49	5.17	0.31	4.96e-7	Schizophrenia;
KIRP	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-6.86	-0.4	5.68e-11	Morning vs. evening chronotype;
KIRP	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.81	11.33	0.59	3.17e-24	Breast cancer;
KIRP	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg13319975	chr6:146136371	FBXO30	-0.45	-6.53	-0.38	3.82e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2494938	0.730	rs205515	chr6:40514185	A/G	cg14084896	chr6:40530702	LRFN2	-0.44	-5.85	-0.35	1.59e-8	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs2862064	0.685	rs2862066	chr5:156447395	T/G	cg12943317	chr5:156479607	HAVCR1	-0.74	-6.94	-0.4	3.37e-11	Platelet count;
KIRP	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg01620082	chr3:125678407	NA	-1.14	-7.3	-0.42	4.03e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.47	7.24	0.42	5.65e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg16141378	chr3:129829833	LOC729375	0.51	6.49	0.38	4.78e-10	Myopia (pathological);
KIRP	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.98	0.45	5.51e-14	Height;
KIRP	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.53	-0.33	8.22e-8	Hip geometry;
KIRP	cis	rs4356932	0.967	rs6856681	chr4:76975113	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg17435250	chr19:41386441	CYP2A7	-0.36	-4.85	-0.3	2.18e-6	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs2286379	1.000	rs1044825	chr12:1901485	G/T	cg05227549	chr12:1770782	NA	-0.31	-5.07	-0.31	7.7300000000000005e-07	Blood pressure (smoking interaction);
KIRP	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg01950434	chr2:97203154	ARID5A	-0.57	-7.12	-0.41	1.21e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.9	-0.4	4.27e-11	Lymphocyte counts;
KIRP	cis	rs6496044	0.507	rs7175731	chr15:86154346	C/T	cg10818794	chr15:86012489	AKAP13	0.42	5.71	0.34	3.3e-8	Interstitial lung disease;
KIRP	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg17376030	chr22:41985996	PMM1	-0.76	-8.35	-0.47	5.06e-15	Vitiligo;
KIRP	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg13444842	chr1:152974279	SPRR3	-0.43	-5.9	-0.35	1.17e-8	Inflammatory skin disease;
KIRP	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	1.12	8.66	0.48	6.47e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg18778933	chr5:52760204	NA	0.58	6.41	0.38	7.39e-10	Response to statin therapy;
KIRP	cis	rs75920871	0.589	rs56081989	chr11:117085305	G/A	cg23684410	chr11:116897558	SIK3	0.5	5.1	0.31	6.94e-7	Subjective well-being;
KIRP	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg05044414	chr3:183734942	ABCC5	0.37	5.78	0.35	2.21e-8	Anterior chamber depth;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17736116	chr15:56923479	ZNF280D	0.42	6.83	0.4	6.49e-11	C-reactive protein;
KIRP	cis	rs77688320	0.553	rs3795966	chr2:202245244	A/G	cg06431681	chr2:202330990	STRADB	0.51	6.78	0.4	9.02e-11	Breast cancer;
KIRP	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg23100626	chr2:96804247	ASTL	0.43	5.39	0.32	1.68e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg26338869	chr17:61819248	STRADA	-0.45	-5.5	-0.33	9.59e-8	Prudent dietary pattern;
KIRP	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.85	-9.16	-0.5	2.17e-17	HIV-1 control;
KIRP	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg22681709	chr2:178499509	PDE11A	-0.61	-8.59	-0.48	1.05e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	8.6	0.48	9.71e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9434723	0.841	rs12083129	chr1:9311323	G/A	cg04199779	chr1:9294473	H6PD	0.52	5.68	0.34	3.79e-8	Height;
KIRP	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.94	-16.26	-0.72	7.37e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.34e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.72	-0.49	4.3e-16	Mood instability;
KIRP	cis	rs2882667	0.964	rs11739351	chr5:138311742	A/G	cg04439458	chr5:138467593	SIL1	-0.45	-6.76	-0.4	9.73e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01991305	chr12:95611539	VEZT;FGD6	0.45	6.25	0.37	1.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7937612	1.000	rs10790380	chr11:120233158	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.06	-0.41	1.67e-11	Intraocular pressure;
KIRP	cis	rs2273669	0.504	rs58411385	chr6:109498294	G/T	cg05315195	chr6:109294784	ARMC2	-0.53	-5.01	-0.3	1.02e-6	Prostate cancer;
KIRP	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg26441486	chr22:50317300	CRELD2	0.48	7.8	0.45	1.76e-13	Schizophrenia;
KIRP	cis	rs9473924	0.505	rs7746581	chr6:50853479	T/C	cg14470998	chr6:50812995	TFAP2B	0.84	7.72	0.44	2.96e-13	Body mass index;
KIRP	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg05315796	chr3:52349193	DNAH1	0.41	6.56	0.39	3.07e-10	Bipolar disorder;
KIRP	cis	rs7760535	0.826	rs7753887	chr6:111855107	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.42	-5.3	-0.32	2.63e-7	Metabolic traits;
KIRP	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	6.13	0.36	3.4e-9	Aortic root size;
KIRP	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.72	9.83	0.53	1.86e-19	Heart rate;
KIRP	cis	rs787274	1.000	rs4304397	chr9:115598154	C/T	cg13803584	chr9:115635662	SNX30	0.69	6.29	0.37	1.44e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.73	-8.3	-0.47	7.03e-15	Menarche (age at onset);
KIRP	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.54	7.03	0.41	1.98e-11	Tuberculosis;
KIRP	cis	rs6991838	0.550	rs4737750	chr8:66550959	G/C	cg13398993	chr8:66546079	ARMC1	0.47	5.34	0.32	2.07e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg00086871	chr4:6988644	TBC1D14	-0.43	-5.1	-0.31	6.78e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg24315340	chr6:146058215	EPM2A	0.4	5.1	0.31	6.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.79	0.44	1.89e-13	Morning vs. evening chronotype;
KIRP	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg13736514	chr6:26305472	NA	-0.73	-9.4	-0.51	4e-18	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20434586	chr6:43237511	TTBK1	0.43	6.1	0.36	4.05e-9	Parkinson's disease;
KIRP	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.47	7.11	0.41	1.27e-11	Tumor biomarkers;
KIRP	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg10189774	chr4:17578691	LAP3	0.43	5.17	0.31	4.95e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg03563238	chr19:33554763	RHPN2	-0.3	-5.38	-0.32	1.71e-7	Colorectal cancer;
KIRP	cis	rs2411233	0.839	rs1380939	chr15:39309815	T/C	cg02291532	chr15:39874776	THBS1	0.44	5.83	0.35	1.69e-8	Platelet count;
KIRP	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg15841412	chr13:111365552	ING1	-0.48	-5.21	-0.32	3.95e-7	Coronary artery disease;
KIRP	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.68	7.63	0.44	5.25e-13	High light scatter reticulocyte count;
KIRP	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg17279839	chr7:150038598	RARRES2	0.45	6.17	0.37	2.77e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.27	-4.92	-0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg02415014	chr8:143852576	LYNX1	-0.31	-4.93	-0.3	1.53e-6	Urinary tract infection frequency;
KIRP	cis	rs13361707	0.920	rs7716285	chr5:40711361	A/G	cg01087697	chr5:40835557	RPL37	-0.48	-5.44	-0.33	1.3e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.59	6.15	0.37	3.11e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.68	6.98	0.41	2.71e-11	D-dimer levels;
KIRP	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19717773	chr7:2847554	GNA12	-0.33	-5.33	-0.32	2.25e-7	Height;
KIRP	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg25251562	chr2:3704773	ALLC	-0.53	-6.06	-0.36	5.13e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.79	12.03	0.61	1.61e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7677751	1.000	rs73252946	chr4:55125992	G/A	cg17187183	chr4:55093834	PDGFRA	0.72	6.74	0.39	1.1e-10	Corneal astigmatism;
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.74	0.34	2.78e-8	Lung cancer;
KIRP	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.74	9.48	0.52	2.28e-18	Coronary artery disease;
KIRP	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg23649088	chr2:200775458	C2orf69	-0.57	-4.96	-0.3	1.31e-6	Schizophrenia;
KIRP	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.46	-5.73	-0.34	2.96e-8	Common traits (Other);
KIRP	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.39	-0.51	4.37e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg17294928	chr15:75287854	SCAMP5	0.57	7.61	0.44	5.9e-13	Breast cancer;
KIRP	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg19847130	chr8:10466454	RP1L1	0.38	5.75	0.34	2.66e-8	Neuroticism;
KIRP	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg11814155	chr7:99998594	ZCWPW1	0.56	5.18	0.31	4.67e-7	Lung function (FEV1/FVC);
KIRP	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.16	0.37	2.9e-9	Neuroticism;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.52	5.13	0.31	5.75e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.88	0.35	1.32e-8	Total cholesterol levels;
KIRP	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg21252483	chr19:49399788	TULP2	-0.47	-6.18	-0.37	2.69e-9	Red cell distribution width;
KIRP	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg21918786	chr6:109611834	NA	-0.4	-5.62	-0.34	5.11e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.57	7.46	0.43	1.45e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.62	-5.74	-0.34	2.79e-8	Narcolepsy;
KIRP	cis	rs1134634	0.520	rs10025837	chr4:15549985	C/T	cg16509355	chr4:15471240	CC2D2A	-0.3	-5.08	-0.31	7.33e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.2e-24	Cognitive test performance;
KIRP	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.51	-0.38	4.28e-10	Parkinson's disease;
KIRP	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.53	-6.1	-0.36	4.04e-9	Inhibitory control;
KIRP	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.53	0.38	3.71e-10	Neuroticism;
KIRP	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg06937882	chr20:24974362	C20orf3	-0.43	-4.89	-0.3	1.86e-6	Blood protein levels;
KIRP	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.42	5.28	0.32	2.85e-7	Cardiac Troponin-T levels;
KIRP	cis	rs16937956	0.597	rs2311434	chr11:8406049	T/C	cg08015107	chr11:8618950	NA	-0.55	-7.08	-0.41	1.55e-11	Body mass index;
KIRP	cis	rs8012	0.517	rs2009218	chr19:13034584	A/G	cg11738485	chr19:12877000	HOOK2	0.41	4.94	0.3	1.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
KIRP	cis	rs4664304	0.772	rs12692572	chr2:160743793	G/A	cg03641300	chr2:160917029	PLA2R1	0.4	6.29	0.37	1.42e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg00206168	chr11:65308501	LTBP3	0.75	5.55	0.33	7.5e-8	Height;
KIRP	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18252515	chr7:66147081	NA	0.44	5.29	0.32	2.67e-7	Aortic root size;
KIRP	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.44	5.57	0.33	6.75e-8	HDL cholesterol;
KIRP	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg00631329	chr6:26305371	NA	-0.6	-7.75	-0.44	2.35e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.02	-0.46	4.19e-14	Mean corpuscular volume;
KIRP	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	12.49	0.62	4.8e-28	Smoking behavior;
KIRP	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.75	-9.23	-0.51	1.26e-17	Response to antipsychotic treatment;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg01534423	chr17:18965556	NA	0.86	6.38	0.38	8.51e-10	P wave terminal force;
KIRP	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg03647239	chr10:116582469	FAM160B1	0.47	5.35	0.32	1.96e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs6707387	0.737	rs6751454	chr2:214574807	C/A	cg08319019	chr2:214017104	IKZF2	0.43	4.87	0.3	1.96e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg24397884	chr7:158709396	WDR60	0.58	7.43	0.43	1.79e-12	Height;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.77	-14.25	-0.67	5.21e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.64	-8.34	-0.47	5.49e-15	Inflammatory bowel disease;
KIRP	cis	rs7113874	1.000	rs36092927	chr11:8692339	G/A	cg08015107	chr11:8618950	NA	-0.35	-4.87	-0.3	1.96e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17872895	chr10:75007153	DNAJC9	0.52	6.69	0.39	1.5e-10	Parkinson's disease;
KIRP	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg17724175	chr1:150552817	MCL1	0.35	5.92	0.35	1.05e-8	Melanoma;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.83	10.84	0.57	1.22e-22	Vitamin D levels;
KIRP	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.74	0.53	3.55e-19	Hip circumference adjusted for BMI;
KIRP	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	8.56	0.48	1.26e-15	Neuroticism;
KIRP	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.5	-0.38	4.51e-10	Recombination measurement;
KIRP	trans	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg19274270	chr17:78178856	CARD14	0.36	6.48	0.38	4.9e-10	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.78	12.01	0.61	1.88e-26	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.84	11.41	0.59	1.81e-24	Morning vs. evening chronotype;
KIRP	cis	rs2150410	0.764	rs914157	chr21:40615853	A/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.46	-6.35	-0.38	1.06e-9	Endometrial cancer;
KIRP	cis	rs7119038	0.818	rs715412	chr11:118684610	G/A	cg19308663	chr11:118741387	NA	0.6	10.08	0.54	3.06e-20	Sjögren's syndrome;
KIRP	cis	rs7084402	0.935	rs11006192	chr10:60343638	T/C	cg05938607	chr10:60274200	BICC1	-0.4	-9.53	-0.52	1.54e-18	Refractive error;
KIRP	cis	rs7520050	0.966	rs1707304	chr1:46598269	C/A	cg03146154	chr1:46216737	IPP	-0.41	-5.34	-0.32	2.1e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg17872895	chr10:75007153	DNAJC9	-0.55	-6.17	-0.37	2.74e-9	Menopause (age at onset);
KIRP	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	cis	rs7084402	0.967	rs1593678	chr10:60291548	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs4356932	1.000	rs4535358	chr4:76974409	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16725305	chr2:18780617	NA	0.47	7.36	0.42	2.81e-12	Survival in pancreatic cancer;
KIRP	cis	rs3750082	0.785	rs4720085	chr7:32968136	C/T	cg08946731	chr7:32981826	RP9P	-0.34	-5.37	-0.32	1.79e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.56	-8.68	-0.48	5.53e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.7	9.13	0.5	2.62e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12311304	1.000	rs1479407	chr12:15391524	G/T	cg08258403	chr12:15378311	NA	0.36	5.04	0.31	8.84e-7	Behavioural disinhibition (generation interaction);
KIRP	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.29	-0.47	7.48e-15	Neuroticism;
KIRP	cis	rs6453429	0.720	rs486580	chr5:78367424	A/G	cg06501366	chr5:78365687	BHMT2;DMGDH	-0.34	-5.92	-0.35	1.08e-8	Urinary metabolites;
KIRP	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.84	10.15	0.54	1.97e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	0.74	7.77	0.44	2.15e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.82	0.45	1.58e-13	Height;
KIRP	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg07810366	chr2:100720526	AFF3	0.36	6.54	0.38	3.63e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs8014252	0.803	rs2877672	chr14:71036259	T/C	cg19730268	chr14:71022823	NA	-0.5	-4.87	-0.3	2.04e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.58	-0.39	2.8e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.56	-5.94	-0.35	9.47e-9	Ulcerative colitis;
KIRP	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	0.83	7.42	0.43	1.93e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.62	-0.52	8.4e-19	Hemoglobin concentration;
KIRP	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg14458575	chr2:238380390	NA	0.56	7.7	0.44	3.38e-13	Prostate cancer;
KIRP	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	1.0	10.6	0.56	7.27e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg00012203	chr2:219082015	ARPC2	-0.67	-8.3	-0.47	7.13e-15	Colorectal cancer;
KIRP	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.53	7.57	0.43	7.53e-13	Obesity-related traits;
KIRP	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.05e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12973672	1.000	rs34832786	chr19:35769518	T/C	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg14703610	chr5:56206110	C5orf35	0.5	6.56	0.39	3.15e-10	Coronary artery disease;
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.43	-4.94	-0.3	1.44e-6	Longevity;Endometriosis;
KIRP	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg04414720	chr1:150670196	GOLPH3L	0.4	5.08	0.31	7.61e-7	Urate levels;
KIRP	cis	rs239198	0.534	rs1813223	chr6:101331909	C/T	cg09795085	chr6:101329169	ASCC3	0.48	5.52	0.33	8.4e-8	Menarche (age at onset);
KIRP	cis	rs7105934	1.000	rs10796817	chr11:69241032	A/G	cg24478926	chr11:69237550	NA	0.59	5.68	0.34	3.88e-8	Renal cell carcinoma;
KIRP	cis	rs35955747	0.902	rs131202	chr22:31709309	A/C	cg02404636	chr22:31891804	SFI1	0.38	4.96	0.3	1.31e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.73	9.44	0.52	3.04e-18	Bladder cancer;
KIRP	cis	rs56313388	0.629	rs12598649	chr16:56320824	G/A	cg02433656	chr16:56322654	GNAO1	0.44	5.03	0.31	9.62e-7	Pulse pressure;
KIRP	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.11	0.36	3.95e-9	Personality dimensions;
KIRP	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.23	0.62	3.39e-27	Platelet count;
KIRP	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.1	0.41	1.31e-11	Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05573287	chr3:12983221	IQSEC1	-0.49	-6.25	-0.37	1.81e-9	Parkinson's disease;
KIRP	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg04727924	chr7:799746	HEATR2	-0.76	-8.66	-0.48	6.52e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4356975	0.509	rs6600884	chr4:69968066	A/C	cg21945989	chr4:70826695	CSN2	-0.34	-5.18	-0.31	4.73e-7	Obesity-related traits;
KIRP	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg19913688	chr11:428466	ANO9	-0.83	-6.53	-0.38	3.76e-10	Body mass index;
KIRP	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-6.05	-0.36	5.49e-9	Morning vs. evening chronotype;
KIRP	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs3026101	0.671	rs56018748	chr17:5316939	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.56	-6.19	-0.37	2.45e-9	Iron status biomarkers;
KIRP	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg02023728	chr11:77925099	USP35	0.33	5.33	0.32	2.24e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9434723	0.536	rs10489436	chr1:9285721	C/T	cg04199779	chr1:9294473	H6PD	-0.47	-5.44	-0.33	1.31e-7	Height;
KIRP	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.27	-0.42	4.91e-12	Mood instability;
KIRP	cis	rs1014246	0.848	rs11197799	chr10:118457650	C/T	cg14919929	chr10:118506882	NA	0.69	9.13	0.5	2.57e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.64	8.17	0.46	1.59e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg07148914	chr20:33460835	GGT7	-0.52	-6.97	-0.41	2.81e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg06066596	chr15:83166174	LOC80154	-0.51	-5.82	-0.35	1.84e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.6	-7.12	-0.41	1.21e-11	Migraine;Coronary artery disease;
KIRP	cis	rs57786342	0.569	rs4899260	chr14:69278204	C/T	cg03189333	chr14:69283534	NA	-0.41	-5.07	-0.31	7.65e-7	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg01721255	chr8:58191610	C8orf71	0.7	5.68	0.34	3.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.76	7.84	0.45	1.41e-13	Resting heart rate;
KIRP	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.61	5.68	0.34	3.83e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11628318	1.000	rs11628318	chr14:103040087	T/A	cg12046867	chr14:103022105	NA	-0.46	-6.19	-0.37	2.54e-9	Platelet count;
KIRP	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.44	-7.05	-0.41	1.8e-11	Superior crus of antihelix expression;
KIRP	cis	rs28834970	0.925	rs6987305	chr8:27208126	G/A	cg21186296	chr8:27182909	PTK2B	-0.42	-5.29	-0.32	2.71e-7	Alzheimer's disease (late onset);
KIRP	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg12560992	chr17:57184187	TRIM37	0.62	6.63	0.39	2.06e-10	Testicular germ cell tumor;
KIRP	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-7.0	-0.41	2.42e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7084402	0.967	rs1658489	chr10:60285924	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs77140172	0.677	rs28435799	chr4:89617931	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.79	5.01	0.3	1.04e-6	Post bronchodilator FEV1;
KIRP	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.14.1056569F	chr14:73577815	RBM25	0.47	6.5	0.38	4.37e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg01877450	chr7:97915802	BRI3	-0.57	-7.33	-0.42	3.3e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35123781	1.000	rs601728	chr5:139057076	T/C	cg10513866	chr5:139070639	NA	0.35	4.9	0.3	1.71e-6	Schizophrenia;
KIRP	cis	rs1200921	0.642	rs1200822	chr10:37559954	T/G	cg00409905	chr10:38381863	ZNF37A	0.38	4.88	0.3	1.94e-6	Breast cancer;
KIRP	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg14972814	chr11:95582409	MTMR2	0.34	5.69	0.34	3.62e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.49	6.37	0.38	9.1e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.58	-6.06	-0.36	5.02e-9	Ulcerative colitis;
KIRP	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.6	8.27	0.47	8.26e-15	Morning vs. evening chronotype;
KIRP	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.29	-0.32	2.77e-7	Menarche (age at onset);
KIRP	trans	rs7999699	0.902	rs9534766	chr13:48295111	C/T	cg23237801	chr1:16476620	EPHA2	0.52	6.49	0.38	4.68e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs7116495	1.000	rs2511075	chr11:71780257	T/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7665939	0.860	rs61745583	chr4:190125993	A/G	cg14840187	chr4:190284988	NA	-0.95	-7.13	-0.41	1.09e-11	Amyotrophic lateral sclerosis;
KIRP	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg16141378	chr3:129829833	LOC729375	0.48	6.37	0.38	9.15e-10	Triglycerides;
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg04025307	chr7:1156635	C7orf50	-0.53	-7.32	-0.42	3.48e-12	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03322749	chr9:125026979	RBM18;MRRF	0.57	6.83	0.4	6.66e-11	Smoking initiation;
KIRP	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg14159672	chr1:205819179	PM20D1	0.5	5.11	0.31	6.38e-7	Parkinson's disease;
KIRP	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.4	-5.73	-0.34	2.89e-8	Pubertal anthropometrics;
KIRP	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2279817	0.780	rs35588575	chr1:18007045	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.54	-0.48	1.38e-15	Neuroticism;
KIRP	cis	rs79149102	0.649	rs1531162	chr15:75111984	C/T	cg09165964	chr15:75287851	SCAMP5	-0.69	-5.23	-0.32	3.66e-7	Lung cancer;
KIRP	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg01028140	chr2:1542097	TPO	-0.75	-7.36	-0.42	2.76e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.47	6.0	0.36	6.84e-9	Initial pursuit acceleration;
KIRP	cis	rs4262150	0.842	rs17113771	chr5:152278020	C/T	cg12297329	chr5:152029980	NA	-0.5	-6.83	-0.4	6.64e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.98	0.3	1.19e-6	Menopause (age at onset);
KIRP	cis	rs11074306	0.561	rs4778120	chr15:28065035	T/G	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.62e-6	Uveal melanoma;
KIRP	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.52	7.51	0.43	1.11e-12	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22733051	chr1:204380802	PPP1R15B	0.5	6.04	0.36	5.81e-9	Parkinson's disease;
KIRP	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg17252645	chr8:143867129	LY6D	-0.32	-5.04	-0.31	9.19e-7	Urinary tract infection frequency;
KIRP	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.75	10.77	0.57	2.1e-22	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.66	-8.72	-0.49	4.14e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6751744	0.514	rs12386214	chr2:160531523	C/T	cg08347373	chr2:160653686	CD302	-0.38	-5.86	-0.35	1.45e-8	Dysphagia;
KIRP	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg00074818	chr8:8560427	CLDN23	0.4	6.29	0.37	1.47e-9	Obesity-related traits;
KIRP	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.62	-8.84	-0.49	1.91e-16	Endometrial cancer;
KIRP	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.87	-12.57	-0.63	2.5e-28	Total body bone mineral density;
KIRP	cis	rs2625529	0.824	rs7172309	chr15:72384483	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.07	-0.36	4.86e-9	Red blood cell count;
KIRP	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg23166289	chr1:210001082	C1orf107	0.53	5.94	0.35	9.8e-9	Orofacial clefts;
KIRP	cis	rs7714584	1.000	rs11749391	chr5:150229066	T/C	cg22134413	chr5:150180641	NA	0.55	4.91	0.3	1.7e-6	Crohn's disease;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.98	0.3	1.21e-6	Life satisfaction;
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg14275779	chr17:40830236	PLEKHH3	-0.5	-6.18	-0.37	2.62e-9	Type 1 diabetes nephropathy;
KIRP	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg01872077	chr2:219646372	CYP27A1	-0.37	-5.1	-0.31	6.78e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11987759	chr7:65425863	GUSB	-0.69	-9.72	-0.53	4.23e-19	Calcium levels;
KIRP	cis	rs4073221	0.789	rs9824915	chr3:18263272	G/T	cg07694806	chr3:18168406	NA	-0.72	-6.28	-0.37	1.56e-9	Parkinson's disease;
KIRP	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg21419209	chr3:44054225	NA	-0.73	-9.0	-0.5	6.18e-17	Coronary artery disease;
KIRP	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg07378217	chr19:58662286	ZNF329	-0.59	-5.39	-0.33	1.65e-7	Cholesterol, total;
KIRP	cis	rs6594713	0.717	rs9326891	chr5:112873928	C/T	cg12552261	chr5:112820674	MCC	0.56	5.55	0.33	7.51e-8	Brain cytoarchitecture;
KIRP	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg08885800	chr1:201084119	NA	0.39	5.43	0.33	1.35e-7	Permanent tooth development;
KIRP	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.55	0.33	7.33e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9912468	1.000	rs9890911	chr17:64315569	T/C	cg19474267	chr17:64306194	PRKCA	-0.65	-9.32	-0.51	7.11e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg20813462	chr7:2646259	IQCE	0.65	6.22	0.37	2.08e-9	Urate levels in lean individuals;
KIRP	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.78	-8.77	-0.49	2.95e-16	Parkinson's disease;
KIRP	cis	rs17209837	1.000	rs4148814	chr7:87091543	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-7.48	-0.43	1.35e-12	Gallbladder cancer;
KIRP	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.23	12.24	0.62	3.3e-27	Diabetic retinopathy;
KIRP	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs58688157	0.960	rs112006329	chr11:617228	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.64	-7.73	-0.44	2.71e-13	Systemic lupus erythematosus;
KIRP	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.94	15.14	0.69	4.99e-37	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.63	10.45	0.55	2.22e-21	Lung cancer;
KIRP	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.77	-11.89	-0.6	4.74e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs2551802	0.615	rs17395735	chr2:177067780	C/T	cg13092806	chr2:177043255	NA	0.44	5.39	0.33	1.63e-7	Motion sickness;
KIRP	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg24747557	chr10:131355152	MGMT	0.5	6.87	0.4	5.24e-11	Response to temozolomide;
KIRP	cis	rs860295	0.812	rs3820594	chr1:155829511	C/T	cg02153340	chr1:155202674	NA	-0.41	-5.57	-0.33	6.55e-8	Body mass index;
KIRP	cis	rs76533333	0.831	rs12876143	chr13:113366291	T/C	cg21786786	chr13:113365464	ATP11A	-0.58	-4.93	-0.3	1.54e-6	Red cell distribution width;
KIRP	cis	rs2901656	0.652	rs3213563	chr1:172412995	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	6.19	0.37	2.51e-9	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg20936604	chr3:58311152	NA	-0.66	-4.9	-0.3	1.77e-6	Cholesterol, total;
KIRP	cis	rs13082711	0.954	rs34348584	chr3:27532704	T/C	cg02860705	chr3:27208620	NA	0.55	7.07	0.41	1.62e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg24881330	chr22:46731750	TRMU	0.65	4.89	0.3	1.8e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.24	-6.94	-0.4	3.4e-11	Type 2 diabetes;
KIRP	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg25124228	chr12:125621409	AACS	-0.59	-6.68	-0.39	1.61e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.83	11.46	0.59	1.17e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	5.69	0.34	3.64e-8	Height;
KIRP	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.63	6.61	0.39	2.3e-10	Gut microbiome composition (summer);
KIRP	trans	rs1941687	0.764	rs1493918	chr18:31381845	C/G	cg27147174	chr7:100797783	AP1S1	-0.69	-8.94	-0.5	9.73e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg14541582	chr5:601475	NA	-0.55	-6.19	-0.37	2.46e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	0.65	6.45	0.38	5.9e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs2790457	1.000	rs2790457	chr10:28856819	G/A	cg05705492	chr10:28955341	NA	-0.54	-8.16	-0.46	1.77e-14	Multiple myeloma;
KIRP	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.55	-6.78	-0.4	8.88e-11	Coronary artery disease;
KIRP	cis	rs7577293	1.000	rs12151742	chr2:85933003	C/T	cg19805943	chr2:85933069	NA	-0.41	-5.1	-0.31	6.69e-7	Blood protein levels;
KIRP	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg04727924	chr7:799746	HEATR2	0.61	5.64	0.34	4.56e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.19	-0.42	7.97e-12	Glomerular filtration rate;
KIRP	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg17554472	chr22:41940697	POLR3H	-0.67	-7.22	-0.42	6.46e-12	Vitiligo;
KIRP	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg16077055	chr2:106428750	NCK2	-0.28	-5.7	-0.34	3.35e-8	Addiction;
KIRP	cis	rs13361707	0.881	rs7705504	chr5:40739261	C/T	cg01087697	chr5:40835557	RPL37	-0.49	-5.51	-0.33	9.03e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2224391	0.628	rs11752747	chr6:5272671	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-5.59	-0.34	5.97e-8	Height;
KIRP	cis	rs7178909	0.872	rs61345389	chr15:90435885	T/C	cg19708238	chr15:90437601	AP3S2	0.58	8.07	0.46	3.18e-14	Common traits (Other);
KIRP	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.05	-0.36	5.24e-9	Rheumatoid arthritis;
KIRP	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.65	8.02	0.46	4.41e-14	Blood metabolite levels;
KIRP	cis	rs1958560	0.830	rs12895401	chr14:66064827	G/A	cg03016385	chr14:66212404	NA	-0.39	-5.06	-0.31	8.28e-7	Menarche (age at onset);
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-9.53	-0.52	1.59e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.59	-8.2	-0.46	1.36e-14	Response to temozolomide;
KIRP	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.13	0.46	2.07e-14	Electroencephalogram traits;
KIRP	cis	rs2411233	0.817	rs1841439	chr15:39285085	A/C	cg02291532	chr15:39874776	THBS1	-0.5	-6.58	-0.39	2.89e-10	Platelet count;
KIRP	cis	rs7903847	0.642	rs4635018	chr10:99137839	C/G	cg20016023	chr10:99160130	RRP12	0.42	5.71	0.34	3.23e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2219968	0.743	rs7833315	chr8:78931987	T/C	cg00738934	chr8:78996279	NA	-0.36	-4.88	-0.3	1.93e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2224391	0.628	rs2773311	chr6:5250866	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-6.9	-0.4	4.3e-11	Height;
KIRP	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg06640241	chr16:89574553	SPG7	-0.53	-6.31	-0.37	1.32e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs2235573	0.805	rs132934	chr22:38489558	G/T	cg19171272	chr22:38449367	NA	0.54	7.35	0.42	2.91e-12	Glioblastoma;Glioma;
KIRP	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs9549328	0.670	rs3011475	chr13:113616866	T/C	cg17524180	chr13:113633600	MCF2L	0.27	5.1	0.31	6.9e-7	Systolic blood pressure;
KIRP	cis	rs2150410	0.915	rs68114370	chr21:40550728	C/T	cg11890956	chr21:40555474	PSMG1	-0.76	-5.58	-0.33	6.49e-8	Temperament (bipolar disorder);
KIRP	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg26681399	chr22:41777847	TEF	0.54	5.33	0.32	2.17e-7	Vitiligo;
KIRP	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.59	-8.27	-0.47	8.51e-15	Neuroticism;
KIRP	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-6.87	-0.4	5.2e-11	Vitiligo;
KIRP	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg07541023	chr7:19748670	TWISTNB	-0.72	-6.43	-0.38	6.75e-10	Thyroid stimulating hormone;
KIRP	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg05639522	chr1:247681581	NA	0.55	5.25	0.32	3.34e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2742417	1.000	rs938363	chr3:45746364	T/G	cg04037228	chr3:45636386	LIMD1	0.35	5.03	0.31	9.66e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.25e-10	Hepatitis;
KIRP	cis	rs14168	1.000	rs7082597	chr10:53462136	T/G	cg18823846	chr10:53459691	PRKG1;CSTF2T	0.6	5.39	0.32	1.68e-7	Mammographic density (non-dense area);
KIRP	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg13409248	chr3:40428643	ENTPD3	-0.39	-5.56	-0.33	7.19e-8	Renal cell carcinoma;
KIRP	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.32	-6.37	-0.38	9.33e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg00250761	chr1:31883323	NA	0.31	5.48	0.33	1.08e-7	Alcohol dependence;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg10351095	chr21:47802916	PCNT	-0.41	-5.18	-0.31	4.55e-7	Testicular germ cell tumor;
KIRP	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.5	-7.78	-0.44	1.98e-13	IgG glycosylation;
KIRP	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg09455208	chr3:40491958	NA	0.32	5.88	0.35	1.3e-8	Renal cell carcinoma;
KIRP	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.06e-10	Obesity-related traits;
KIRP	cis	rs17030434	0.627	rs17371643	chr4:154769372	C/T	cg14289246	chr4:154710475	SFRP2	-0.55	-7.47	-0.43	1.38e-12	Electrocardiographic conduction measures;
KIRP	cis	rs3126085	0.560	rs3120665	chr1:152316590	A/G	cg26876637	chr1:152193138	HRNR	-0.51	-6.12	-0.36	3.76e-9	Atopic dermatitis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02257712	chr5:150080478	RBM22	0.58	7.09	0.41	1.44e-11	Smoking initiation;
KIRP	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg20387954	chr3:183756860	HTR3D	0.64	9.43	0.52	3.29e-18	Anterior chamber depth;
KIRP	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.51	-7.05	-0.41	1.85e-11	Asthma;
KIRP	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08280861	chr8:58055591	NA	0.71	5.23	0.32	3.69e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg17133734	chr15:86042851	AKAP13	-0.46	-5.8	-0.35	2.03e-8	Coronary artery disease;
KIRP	cis	rs6466055	0.777	rs3801281	chr7:104889573	T/C	cg04380332	chr7:105027541	SRPK2	0.64	9.73	0.53	3.76e-19	Schizophrenia;
KIRP	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.78	11.96	0.61	2.69e-26	Blood metabolite levels;
KIRP	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.76	-0.34	2.44e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.76	-11.62	-0.6	3.64e-25	Prostate cancer;
KIRP	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.7	6.4	0.38	7.74e-10	Mean platelet volume;
KIRP	cis	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg06521331	chr12:34319734	NA	-0.6	-7.03	-0.41	1.97e-11	Morning vs. evening chronotype;
KIRP	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.45	6.4	0.38	7.72e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.62	8.95	0.5	9.03e-17	Resting heart rate;
KIRP	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg07001201	chr5:642380	CEP72	0.69	6.47	0.38	5.38e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg20368463	chr18:77673604	PQLC1	-0.6	-7.96	-0.45	6.23e-14	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.47	-10.9	-0.57	8.04e-23	Diabetic kidney disease;
KIRP	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg12963246	chr6:28129442	ZNF389	0.48	5.89	0.35	1.26e-8	Depression;
KIRP	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg23736307	chr8:27182930	PTK2B	0.55	7.07	0.41	1.6e-11	Neuroticism;
KIRP	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg18404041	chr3:52824283	ITIH1	0.36	5.06	0.31	8.07e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.39	5.44	0.33	1.27e-7	Night sleep phenotypes;
KIRP	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg08501292	chr6:25962987	TRIM38	0.7	4.92	0.3	1.58e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	1.000	rs13053667	chr22:18443404	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.51	0.43	1.1e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.85	11.51	0.59	8.19e-25	Selective IgA deficiency;
KIRP	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg03465714	chr1:152285911	FLG	-0.44	-5.35	-0.32	2.03e-7	Atopic dermatitis;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg04025307	chr7:1156635	C7orf50	0.76	7.77	0.44	2.08e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.44	0.38	6.31e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	8.36	0.47	4.81e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg03342759	chr3:160939853	NMD3	0.44	5.35	0.32	1.99e-7	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.43	0.55	2.57e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.31e-9	Schizophrenia;
KIRP	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12667521	chr19:29218732	NA	0.93	9.2	0.51	1.59e-17	Methadone dose in opioid dependence;
KIRP	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg11130432	chr3:121712080	ILDR1	-0.45	-5.37	-0.32	1.86e-7	Multiple sclerosis;
KIRP	trans	rs1620921	0.967	rs1652482	chr6:161197885	G/A	cg01090089	chr7:6570974	GRID2IP	0.39	6.18	0.37	2.66e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg15117754	chr3:10150083	C3orf24	0.54	5.03	0.31	9.68e-7	Alzheimer's disease;
KIRP	cis	rs867371	0.502	rs7176926	chr15:82538094	A/G	cg00614314	chr15:82944287	LOC80154	0.42	5.4	0.33	1.53e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26098624	chr6:41511564	NA	-0.46	-6.1	-0.36	4.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.84	13.97	0.67	4.61e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.17	-0.31	4.86e-7	Bipolar disorder;
KIRP	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg25457927	chr22:38595422	NA	-0.27	-5.52	-0.33	8.74e-8	Cutaneous nevi;
KIRP	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg13271783	chr10:134563150	INPP5A	0.35	4.91	0.3	1.69e-6	Migraine;
KIRP	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.73	10.36	0.55	4.27e-21	Mood instability;
KIRP	cis	rs3540	0.804	rs3743418	chr15:90934331	A/G	cg10434728	chr15:90938212	IQGAP1	0.37	5.28	0.32	2.84e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg01689657	chr7:91764605	CYP51A1	0.36	5.26	0.32	3.09e-7	Breast cancer;
KIRP	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg20673091	chr1:2541236	MMEL1	0.79	12.91	0.64	1.81e-29	Ulcerative colitis;
KIRP	cis	rs918629	0.567	rs2548594	chr5:95244414	C/T	cg16656078	chr5:95278638	ELL2	-0.35	-5.39	-0.33	1.62e-7	IgG glycosylation;
KIRP	cis	rs34779708	0.733	rs16935945	chr10:35540320	A/C	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg10305451	chr2:177043427	NA	0.55	7.69	0.44	3.45e-13	IgG glycosylation;
KIRP	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg08847533	chr14:75593920	NEK9	-0.54	-6.42	-0.38	7.11e-10	IgG glycosylation;
KIRP	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.53	-0.48	1.5e-15	Calcium levels;
KIRP	cis	rs963731	0.649	rs1454223	chr2:39224351	G/T	cg04010122	chr2:39346883	SOS1	-0.85	-5.85	-0.35	1.57e-8	Corticobasal degeneration;
KIRP	cis	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-7.38	-0.43	2.48e-12	Morning vs. evening chronotype;
KIRP	cis	rs12200782	0.674	rs12207224	chr6:26519280	A/T	cg11502198	chr6:26597334	ABT1	-0.76	-5.19	-0.31	4.44e-7	Small cell lung carcinoma;
KIRP	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	1.18	9.68	0.53	5.45e-19	Lymphocyte counts;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09256448	chr16:638327	NA	0.35	4.98	0.3	1.2e-6	Height;
KIRP	cis	rs4908768	0.906	rs12568293	chr1:8540912	C/T	cg25722041	chr1:8623473	RERE	-0.77	-9.8	-0.53	2.34e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.88	-14.02	-0.67	3.3e-33	Urate levels in lean individuals;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg12486944	chr17:80159399	CCDC57	0.4	5.37	0.32	1.78e-7	Life satisfaction;
KIRP	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.13	22.32	0.82	4.65e-61	Testicular germ cell tumor;
KIRP	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	6.95	0.41	3.24e-11	Retinal vascular caliber;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg27532560	chr4:187881888	NA	-0.69	-11.05	-0.58	2.59e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.569	rs28481302	chr17:4011527	T/G	cg05562828	chr17:3906858	NA	0.5	5.11	0.31	6.45e-7	Type 2 diabetes;
KIRP	cis	rs17123764	0.818	rs876889	chr12:49983378	C/T	cg20471783	chr12:50157085	TMBIM6	0.31	4.89	0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg09571762	chr12:39539558	NA	0.35	4.86	0.3	2.05e-6	Morning vs. evening chronotype;
KIRP	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.71	8.66	0.48	6.23e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02470625	chr7:39453784	POU6F2	0.82	6.13	0.36	3.51e-9	P wave terminal force;
KIRP	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg01689657	chr7:91764605	CYP51A1	-0.38	-5.43	-0.33	1.36e-7	Breast cancer;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.12	-0.31	6.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.08	-0.31	7.58e-7	Cervical cancer;
KIRP	trans	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg24644049	chr4:85504048	CDS1	0.95	6.42	0.38	6.88e-10	Skin colour saturation;
KIRP	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs848512	0.533	rs3770841	chr2:36715689	C/T	cg09467607	chr2:36825704	FEZ2	0.37	5.2	0.31	4.24e-7	IgE levels in asthmatics;
KIRP	cis	rs317865	0.609	rs73234660	chr4:16221047	G/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.72	5.27	0.32	2.96e-7	Kidney disease (early stage) in type 1 diabetes;
KIRP	cis	rs9475752	0.793	rs34979183	chr6:56842763	G/C	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg07216194	chr8:27182965	PTK2B	0.46	5.54	0.33	7.71e-8	Neuroticism;
KIRP	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06850241	chr22:41845214	NA	-0.46	-5.62	-0.34	5.12e-8	Vitiligo;
KIRP	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg07382826	chr16:28625726	SULT1A1	-0.49	-5.71	-0.34	3.25e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.78	11.18	0.58	9.85e-24	Recombination rate (males);
KIRP	cis	rs7106204	0.534	rs78539127	chr11:24256698	T/A	ch.11.24196551F	chr11:24239977	NA	0.84	6.91	0.4	4.09e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.24	-0.37	1.95e-9	Arsenic metabolism;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.55	6.33	0.37	1.16e-9	Aortic root size;
KIRP	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.66	5.61	0.34	5.49e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg14664628	chr15:75095509	CSK	-0.64	-7.72	-0.44	2.85e-13	Caffeine consumption;
KIRP	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.13	-0.36	3.48e-9	Depression;
KIRP	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.46	6.19	0.37	2.45e-9	Monocyte count;
KIRP	cis	rs1023500	1.000	rs1023497	chr22:42340508	C/G	cg04733989	chr22:42467013	NAGA	-0.51	-5.63	-0.34	4.91e-8	Schizophrenia;
KIRP	cis	rs1559088	0.739	rs9304845	chr19:33592794	A/G	cg07827796	chr19:33622959	WDR88	0.41	4.91	0.3	1.65e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs380904	0.519	rs10102146	chr8:144649156	G/A	cg21643262	chr8:144646939	NA	0.58	5.7	0.34	3.38e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs904092	0.678	rs1230026	chr4:100185619	T/G	cg12011299	chr4:100065546	ADH4	0.49	4.94	0.3	1.42e-6	Alcohol dependence;
KIRP	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	7.0	0.41	2.45e-11	Chronic sinus infection;
KIRP	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.45	-6.33	-0.37	1.15e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg21427119	chr20:30132790	HM13	-0.42	-5.0	-0.3	1.08e-6	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.49	6.23	0.37	2.06e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg10790698	chr19:18539756	SSBP4	-0.33	-7.22	-0.42	6.41e-12	Breast cancer;
KIRP	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.54	-7.13	-0.41	1.13e-11	Breast cancer;
KIRP	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg03060546	chr3:49711283	APEH	0.44	5.56	0.33	7.12e-8	Parkinson's disease;
KIRP	cis	rs7119038	0.818	rs56043232	chr11:118648373	C/T	cg19308663	chr11:118741387	NA	0.57	8.73	0.49	4.02e-16	Sjögren's syndrome;
KIRP	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.96	11.6	0.59	4.21e-25	Corneal astigmatism;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11310629	chr13:45991975	SLC25A30	0.46	6.16	0.37	2.95e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	1.0	10.98	0.57	4.31e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.5	-6.27	-0.37	1.64e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9427116	0.840	rs9427113	chr1:154626477	A/G	cg24304309	chr1:154577895	ADAR	0.33	4.96	0.3	1.3e-6	Blood protein levels;
KIRP	cis	rs9400467	0.506	rs12199656	chr6:111675143	A/C	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-0.58	-7.14	-0.41	1.06e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg25566285	chr7:158114605	PTPRN2	0.74	11.64	0.6	3e-25	Calcium levels;
KIRP	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg01251548	chr11:17372745	DKFZp686O24166	-0.39	-5.1	-0.31	6.76e-7	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.14	-0.31	5.71e-7	Life satisfaction;
KIRP	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.81	10.72	0.56	3.07e-22	Breast cancer;
KIRP	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.54	5.42	0.33	1.42e-7	Body mass index;
KIRP	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg06637938	chr14:75390232	RPS6KL1	0.48	6.83	0.4	6.44e-11	Height;
KIRP	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.7	-9.98	-0.54	6.51e-20	Colorectal cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09755102	chr1:33283495	S100PBP;YARS	0.51	6.77	0.4	9.4e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.02	14.13	0.67	1.33e-33	Response to antipsychotic treatment;
KIRP	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.23	0.7	2.45e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.59	-12.45	-0.62	6.65e-28	Diabetic kidney disease;
KIRP	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg17796960	chr10:135278976	LOC619207	-0.48	-5.51	-0.33	8.83e-8	Systemic lupus erythematosus;
KIRP	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	1.0	16.26	0.72	7.09e-41	Menopause (age at onset);
KIRP	cis	rs8067354	0.645	rs2645492	chr17:57875554	A/G	cg02344993	chr17:57696989	CLTC	-0.56	-5.08	-0.31	7.34e-7	Hemoglobin concentration;
KIRP	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.81	10.72	0.56	3.07e-22	Breast cancer;
KIRP	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg21858823	chr1:15850916	CASP9	0.53	5.66	0.34	4.11e-8	Systolic blood pressure;
KIRP	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg25547332	chr5:131281432	NA	0.46	5.33	0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs208520	0.909	rs9354411	chr6:67019930	A/G	cg07460842	chr6:66804631	NA	0.9	7.6	0.44	6.23e-13	Exhaled nitric oxide output;
KIRP	cis	rs13401104	0.796	rs12472312	chr2:237113030	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-0.52	-7.17	-0.42	8.89e-12	Coronary artery disease;
KIRP	cis	rs2274471	0.680	rs10974907	chr9:5002188	C/A	cg03390472	chr9:5043263	JAK2	-0.44	-5.02	-0.3	1e-6	Crohn's disease;
KIRP	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.93	13.5	0.65	1.86e-31	Bladder cancer;
KIRP	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.47	-6.11	-0.36	3.81e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8067545	1.000	rs8065337	chr17:19941879	C/A	cg04132472	chr17:19861366	AKAP10	0.47	6.78	0.4	8.85e-11	Schizophrenia;
KIRP	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs2299587	0.585	rs2073569	chr8:17782158	T/G	cg01800426	chr8:17659068	MTUS1	-0.62	-7.4	-0.43	2.18e-12	Economic and political preferences;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg26138937	chr11:71823887	C11orf51	-1.01	-6.88	-0.4	5.04e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs4654899	0.680	rs6692553	chr1:21221497	C/T	cg08890418	chr1:21044141	KIF17	-0.35	-5.3	-0.32	2.52e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs365132	0.875	rs353494	chr5:176431759	C/G	cg16309518	chr5:176445507	NA	-0.8	-12.17	-0.61	5.62e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg11130432	chr3:121712080	ILDR1	-0.43	-5.03	-0.31	9.37e-7	Multiple sclerosis;
KIRP	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.93	-14.61	-0.68	3.07e-35	Mean corpuscular volume;
KIRP	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg18461021	chr18:74961002	GALR1	0.51	5.27	0.32	2.95e-7	Obesity-related traits;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.95	0.35	9.31e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.07	-0.41	1.57e-11	Neuroticism;
KIRP	cis	rs34779708	0.733	rs7914468	chr10:35548071	G/A	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.86	-11.0	-0.57	3.77e-23	Parkinson's disease;
KIRP	cis	rs10788309	0.525	rs11200783	chr10:85767961	C/T	cg03623264	chr10:85672087	NA	-0.38	-4.91	-0.3	1.7e-6	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
KIRP	cis	rs71636778	0.543	rs17162330	chr1:27236212	A/G	cg12203394	chr1:27248618	NUDC	0.62	5.31	0.32	2.48e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg04310649	chr10:35416472	CREM	-0.54	-6.11	-0.36	3.77e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg21573476	chr21:45109991	RRP1B	0.57	7.86	0.45	1.2e-13	Mean corpuscular volume;
KIRP	cis	rs60154123	0.730	rs689248	chr1:210463122	A/G	cg09074223	chr1:210466472	NA	-0.42	-4.85	-0.3	2.21e-6	Coronary artery disease;
KIRP	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.39	-0.43	2.24e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	6.06	0.36	5.17e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg04310649	chr10:35416472	CREM	-0.52	-5.93	-0.35	1.03e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.36	-5.0	-0.3	1.1e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg15655495	chr12:38532458	NA	-0.28	-5.3	-0.32	2.57e-7	Bladder cancer;
KIRP	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	11.74	0.6	1.47e-25	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.65	6.5	0.38	4.44e-10	Gastritis;
KIRP	cis	rs2151522	0.603	rs13204751	chr6:127201802	A/G	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs11610422	0.953	rs12824490	chr12:31414490	C/T	cg14306366	chr12:31406441	NA	-0.57	-5.88	-0.35	1.36e-8	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.44	4.89	0.3	1.81e-6	Tuberculosis;
KIRP	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs57590327	0.679	rs35942842	chr3:81588362	G/A	cg07356753	chr3:81810745	GBE1	-0.59	-6.27	-0.37	1.62e-9	Extraversion;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.53	7.13	0.41	1.1e-11	Testicular germ cell tumor;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15606180	chr19:3557658	C19orf28	-0.56	-6.02	-0.36	6.35e-9	Menopause (age at onset);
KIRP	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg08600765	chr20:34638493	LOC647979	-0.73	-6.5	-0.38	4.44e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg07988820	chr12:82153109	PPFIA2	-0.58	-7.24	-0.42	5.74e-12	Resting heart rate;
KIRP	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg08885076	chr2:99613938	TSGA10	-0.49	-6.04	-0.36	5.72e-9	Chronic sinus infection;
KIRP	cis	rs2625529	0.761	rs8028532	chr15:72348054	G/A	cg16672083	chr15:72433130	SENP8	-0.48	-5.9	-0.35	1.2e-8	Red blood cell count;
KIRP	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.08	-0.46	2.94e-14	Coffee consumption (cups per day);
KIRP	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.55	-6.56	-0.39	3.18e-10	Mosquito bite size;
KIRP	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg05368731	chr17:41323189	NBR1	0.92	10.43	0.55	2.49e-21	Menopause (age at onset);
KIRP	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg09508736	chr19:41385865	CYP2A7	-0.49	-5.97	-0.36	8.24e-9	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg07541023	chr7:19748670	TWISTNB	0.61	5.27	0.32	3.05e-7	Thyroid stimulating hormone;
KIRP	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg13119609	chr19:45449297	APOC2	0.39	5.03	0.31	9.52e-7	Blood protein levels;
KIRP	cis	rs6504340	0.739	rs4793589	chr17:46667863	G/C	cg04904318	chr17:46607828	HOXB1	-0.55	-5.68	-0.34	3.77e-8	Primary tooth development (number of teeth);
KIRP	cis	rs1040	1.000	rs10945405	chr6:169621136	C/T	cg04662567	chr6:169592167	NA	0.43	5.12	0.31	6.06e-7	Joint mobility (Beighton score);
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.46	-5.39	-0.33	1.64e-7	Longevity;Endometriosis;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs12496230	0.794	rs6795104	chr3:66861887	A/G	cg04995300	chr3:66848608	NA	0.44	6.56	0.39	3.09e-10	Type 2 diabetes;
KIRP	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-6.63	-0.39	2.08e-10	Total cholesterol levels;
KIRP	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.01	0.67	3.42e-33	Chronic sinus infection;
KIRP	cis	rs865483	0.929	rs8064314	chr17:35858392	A/G	cg06716730	chr17:35851459	DUSP14	0.23	5.62	0.34	5.16e-8	Monocyte count;
KIRP	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg25182066	chr10:30743637	MAP3K8	0.55	6.96	0.41	3.15e-11	Inflammatory bowel disease;
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg16415121	chr6:88299659	ORC3L;RARS2	-0.49	-6.77	-0.4	9.15e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs9790314	0.589	rs4679662	chr3:160603024	T/C	cg04691961	chr3:161091175	C3orf57	0.43	6.2	0.37	2.34e-9	Morning vs. evening chronotype;
KIRP	cis	rs12220238	0.822	rs11000979	chr10:76067865	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.16	0.37	2.87e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg19773385	chr1:10388646	KIF1B	-0.69	-9.31	-0.51	7.18e-18	Hepatocellular carcinoma;
KIRP	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.8	6.68	0.39	1.56e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.52	7.66	0.44	4.29e-13	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.44	7.68	0.44	3.83e-13	Systemic lupus erythematosus;
KIRP	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	cg12689670	chr1:183009347	LAMC1	0.56	7.79	0.44	1.89e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs12311304	0.965	rs12307666	chr12:15388204	A/G	cg08258403	chr12:15378311	NA	0.4	5.9	0.35	1.21e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2494663	0.560	rs55696120	chr1:154049599	T/C	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.98	-0.3	1.21e-6	Mean platelet volume;
KIRP	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.43	-4.91	-0.3	1.68e-6	HDL cholesterol;
KIRP	cis	rs4356932	0.935	rs4129781	chr4:76959388	C/G	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.99	17.35	0.74	1.38e-44	Breast cancer;
KIRP	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg22906224	chr7:99728672	NA	-0.66	-7.95	-0.45	6.55e-14	Coronary artery disease;
KIRP	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	7.74	0.44	2.51e-13	Height;
KIRP	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.95e-8	Type 2 diabetes;
KIRP	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.42	5.46	0.33	1.16e-7	Height;
KIRP	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.59	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs259842	0.794	rs165373	chr2:180681096	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.45	-0.33	1.22e-7	Blood protein levels;
KIRP	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.14	-0.31	5.68e-7	Primary biliary cholangitis;
KIRP	trans	rs2163503	1.000	rs2163501	chr1:71749563	G/A	cg27386431	chr1:200990482	KIF21B	-0.67	-6.47	-0.38	5.38e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs17095355	1.000	rs12570607	chr10:111696704	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.09	-0.36	4.42e-9	Biliary atresia;
KIRP	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg10761708	chr20:43804764	PI3	0.5	5.19	0.31	4.45e-7	Blood protein levels;
KIRP	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg00405596	chr8:11794950	NA	0.59	8.41	0.47	3.31e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.39	0.38	8.3e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.14	-24.38	-0.84	1.43e-67	Testicular germ cell tumor;
KIRP	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.36e-14	Aortic root size;
KIRP	cis	rs12220238	0.915	rs11001003	chr10:76099944	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.62	0.39	2.23e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg26326168	chr12:133405726	GOLGA3	-0.47	-6.29	-0.37	1.44e-9	Myopia;
KIRP	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.63	7.66	0.44	4.33e-13	Platelet count;
KIRP	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg11569703	chr11:65557185	OVOL1	0.33	4.96	0.3	1.3e-6	Eosinophil percentage of white cells;
KIRP	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.77	-7.12	-0.41	1.18e-11	Opioid sensitivity;
KIRP	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.13	-0.36	3.54e-9	Systolic blood pressure;
KIRP	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.38	-5.43	-0.33	1.34e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	0.97	11.38	0.59	2.23e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1620921	0.505	rs4708888	chr6:161206490	A/C	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg05082376	chr22:42548792	NA	-0.46	-5.8	-0.35	2.01e-8	Schizophrenia;
KIRP	cis	rs7187994	0.848	rs12443928	chr16:84780202	G/T	cg11201751	chr16:85158047	NA	0.52	5.14	0.31	5.48e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7709377	0.595	rs173813	chr5:115632671	A/C	cg23108291	chr5:115420582	COMMD10	-0.43	-5.19	-0.31	4.48e-7	Metabolite levels  (X-11787);
KIRP	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00585698	chr12:123750864	CDK2AP1	0.5	6.51	0.38	4.17e-10	Neutrophil percentage of white cells;
KIRP	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg04990556	chr1:26633338	UBXN11	-0.56	-6.81	-0.4	7.58e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.34	-4.93	-0.3	1.49e-6	Monocyte count;
KIRP	cis	rs5753037	0.653	rs140131	chr22:30151716	A/G	cg01021169	chr22:30184971	ASCC2	-0.44	-6.16	-0.37	2.95e-9	Type 1 diabetes;
KIRP	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.76	6.34	0.37	1.08e-9	Body mass index;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11074362	chr9:19297575	DENND4C	0.38	6.12	0.36	3.67e-9	C-reactive protein;
KIRP	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19524238	chr7:2802976	GNA12	-0.33	-4.87	-0.3	1.98e-6	Height;
KIRP	cis	rs10073892	0.789	rs62372234	chr5:101664960	G/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.37	0.38	9.42e-10	Cognitive decline (age-related);
KIRP	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg06268327	chr11:63885740	FLRT1;MACROD1	-0.43	-5.01	-0.3	1.02e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2594989	0.733	rs9811482	chr3:11578591	C/T	cg01796438	chr3:11312864	ATG7	0.46	5.96	0.36	8.68e-9	Circulating chemerin levels;
KIRP	cis	rs12982744	0.613	rs34615083	chr19:2138041	T/C	cg09261902	chr19:2140048	AP3D1	0.43	5.59	0.34	5.93e-8	Osteoarthritis;Height;
KIRP	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	7.92e-7	Electrocardiographic conduction measures;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01829450	chr3:135914745	MSL2	0.51	6.58	0.39	2.86e-10	Myopia (pathological);
KIRP	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg11062466	chr8:58055876	NA	0.56	5.09	0.31	7.02e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08363605	chr15:50474388	SLC27A2	0.51	6.26	0.37	1.66e-9	Parkinson's disease;
KIRP	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.65	9.2	0.51	1.64e-17	Brugada syndrome;
KIRP	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg11833968	chr6:79620685	NA	-0.38	-5.23	-0.32	3.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.86	-0.3	2.06e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.72	9.87	0.53	1.45e-19	Red blood cell count;
KIRP	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.55	6.97	0.41	2.93e-11	Breast cancer;
KIRP	cis	rs35740288	0.731	rs35085180	chr15:86102612	T/C	cg17133734	chr15:86042851	AKAP13	-0.53	-5.82	-0.35	1.81e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26055420	chr1:118148456	FAM46C	0.53	6.62	0.39	2.18e-10	Parkinson's disease;
KIRP	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg12549451	chr6:135224345	NA	-0.43	-5.28	-0.32	2.78e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.06	19.02	0.77	3.25e-50	Triglycerides;
KIRP	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-9.41	-0.51	3.76e-18	Coronary artery disease;
KIRP	cis	rs7106204	0.534	rs4923167	chr11:24274441	G/T	ch.11.24196551F	chr11:24239977	NA	0.67	5.24	0.32	3.43e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.47	5.7	0.34	3.35e-8	Glycated hemoglobin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05272556	chr6:34360624	NUDT3	0.5	6.06	0.36	5.17e-9	Parkinson's disease;
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg21851534	chr17:3907994	ZZEF1	0.5	6.53	0.38	3.64e-10	Type 2 diabetes;
KIRP	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.25	-0.32	3.35e-7	Inflammatory bowel disease;
KIRP	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.85	-0.35	1.58e-8	Schizophrenia;
KIRP	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.35	5.37	0.32	1.79e-7	Renal function-related traits (BUN);
KIRP	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.44	-5.48	-0.33	1.03e-7	Aortic root size;
KIRP	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg23307798	chr14:103986281	CKB	0.47	5.2	0.31	4.25e-7	Coronary artery disease;
KIRP	cis	rs74181299	0.892	rs2249105	chr2:65287896	C/T	cg05010058	chr2:65284262	CEP68	-0.51	-7.44	-0.43	1.69e-12	Pulse pressure;
KIRP	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.71	-6.83	-0.4	6.56e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2820315	1.000	rs2644112	chr1:201806106	T/C	cg11586189	chr1:201857591	SHISA4	-0.39	-5.45	-0.33	1.21e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.5	-0.43	1.18e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08452062	chr19:40854347	C19orf47;PLD3	0.5	6.05	0.36	5.39e-9	Parkinson's disease;
KIRP	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg26207909	chr14:103986467	CKB	-0.44	-5.29	-0.32	2.71e-7	Coronary artery disease;
KIRP	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg13628971	chr7:2884303	GNA12	-0.37	-4.86	-0.3	2.06e-6	Height;
KIRP	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09006498	chr2:131850875	FAM168B	0.5	6.42	0.38	7.15e-10	Parkinson's disease;
KIRP	cis	rs12913538	0.641	rs12591920	chr15:62902495	A/C	cg09983546	chr15:62884068	NA	-0.45	-6.04	-0.36	5.58e-9	Sleep depth;
KIRP	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.57	0.48	1.13e-15	Motion sickness;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg08901578	chr4:187885870	NA	-0.45	-6.85	-0.4	5.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-6.69	-0.39	1.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24758426	chr20:62185430	C20orf195	-0.43	-6.04	-0.36	5.54e-9	Myopia;
KIRP	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.29	10.43	0.55	2.48e-21	Prostate cancer;
KIRP	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.1	-0.36	4.03e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.64	-8.09	-0.46	2.7e-14	Iron status biomarkers;
KIRP	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.51	-6.96	-0.41	3.01e-11	Obesity-related traits;
KIRP	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.29	0.47	7.59e-15	Motion sickness;
KIRP	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg02297831	chr4:17616191	MED28	0.62	7.75	0.44	2.47e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg13660082	chr14:53194042	PSMC6	-0.78	-7.56	-0.43	8.04e-13	Alzheimer's disease (late onset);
KIRP	cis	rs7246657	0.551	rs10419174	chr19:37605341	A/G	cg18154014	chr19:37997991	ZNF793	0.6	5.11	0.31	6.52e-7	Coronary artery calcification;
KIRP	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg07382826	chr16:28625726	SULT1A1	0.51	6.06	0.36	4.95e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg06060754	chr5:176797920	RGS14	0.65	7.93	0.45	7.86e-14	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.65	9.55	0.52	1.35e-18	Dupuytren's disease;
KIRP	cis	rs4979906	1.000	rs11002241	chr10:79445327	C/T	cg07817648	chr10:79422355	NA	-0.45	-4.98	-0.3	1.2e-6	Mortality in heart failure;
KIRP	cis	rs11264213	0.901	rs2765013	chr1:36374101	C/T	cg27506609	chr1:36549197	TEKT2	0.97	9.91	0.53	1.08e-19	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3741151	0.773	rs28400367	chr11:73112421	C/A	cg17517138	chr11:73019481	ARHGEF17	1.17	8.57	0.48	1.13e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs258892	0.895	rs11948547	chr5:72041022	C/T	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4638749	0.501	rs1872594	chr2:108746813	T/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.91	-0.3	1.64e-6	Blood pressure;
KIRP	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg00677455	chr12:58241039	CTDSP2	-0.59	-7.2	-0.42	7.34e-12	Multiple sclerosis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08748207	chr12:46777589	NA	0.47	6.47	0.38	5.38e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs9400467	0.506	rs12207774	chr6:111657576	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.08	-0.41	1.48e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1062746	0.520	rs17698303	chr16:87329543	C/G	cg02258303	chr16:87377426	FBXO31	-0.42	-5.15	-0.31	5.3e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.37	-7.87	-0.45	1.15e-13	Breast cancer;
KIRP	cis	rs7129556	0.954	rs11512896	chr11:77275718	A/G	cg12586386	chr11:77299805	AQP11	0.41	5.47	0.33	1.11e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.72	7.3	0.42	3.94e-12	Resting heart rate;
KIRP	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg06611532	chr13:114900021	NA	0.22	5.1	0.31	6.65e-7	Schizophrenia;
KIRP	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg13010199	chr12:38710504	ALG10B	0.63	8.31	0.47	6.29e-15	Heart rate;
KIRP	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg21926883	chr2:100939477	LONRF2	-0.43	-5.6	-0.34	5.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg21775007	chr8:11205619	TDH	-0.52	-6.97	-0.41	2.95e-11	Triglycerides;
KIRP	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.64	-9.26	-0.51	1.06e-17	Educational attainment;
KIRP	cis	rs494562	0.892	rs7753711	chr6:86130699	G/T	cg21730993	chr6:86159210	NT5E	-0.49	-4.95	-0.3	1.4e-6	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	9.92	0.53	1e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.61	-8.46	-0.47	2.39e-15	Diastolic blood pressure;
KIRP	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg21573476	chr21:45109991	RRP1B	0.57	7.64	0.44	4.76e-13	Mean corpuscular volume;
KIRP	cis	rs2278796	0.789	rs12136572	chr1:204962660	G/A	cg04862289	chr1:204966208	NFASC	0.74	10.36	0.55	4.17e-21	Mean platelet volume;
KIRP	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg16497661	chr14:103986332	CKB	0.81	13.7	0.66	3.82e-32	Body mass index;
KIRP	cis	rs72820985	1.000	rs11643914	chr16:80846208	C/T	cg04448709	chr16:81349954	GAN	-0.52	-5.32	-0.32	2.28e-7	Breast cancer;
KIRP	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.35	-0.38	1.03e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs35264875	1.000	rs72919428	chr11:68828949	C/T	cg01403660	chr11:68851641	TPCN2	0.66	6.36	0.38	9.63e-10	Blond vs. brown hair color;
KIRP	cis	rs62025270	0.547	rs386346	chr15:86194559	A/T	cg10818794	chr15:86012489	AKAP13	0.39	4.86	0.3	2.13e-6	Idiopathic pulmonary fibrosis;
KIRP	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.48	-5.11	-0.31	6.5e-7	Platelet distribution width;
KIRP	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.3	0.58	4.05e-24	Cognitive test performance;
KIRP	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg20701182	chr2:24300061	SF3B14	0.42	5.36	0.32	1.92e-7	Asthma;
KIRP	cis	rs33912345	0.695	rs1313684	chr14:60877740	C/A	cg27398547	chr14:60952738	C14orf39	-0.4	-5.44	-0.33	1.3e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg10761708	chr20:43804764	PI3	0.52	5.47	0.33	1.09e-7	Blood protein levels;
KIRP	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-7.66	-0.44	4.25e-13	Bipolar disorder;
KIRP	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.38	4.46e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.53	-0.33	8.16e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10193935	0.786	rs13416119	chr2:42462930	A/G	cg27598129	chr2:42591480	NA	-0.79	-5.74	-0.34	2.83e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.95	-15.59	-0.7	1.43e-38	Breast cancer;
KIRP	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.98	15.56	0.7	1.85e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg07435449	chr11:120005650	TRIM29	0.46	6.12	0.36	3.69e-9	Stroke (pediatric);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg24581572	chr1:205197876	TMCC2	0.48	6.68	0.39	1.57e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.44	-0.43	1.71e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs3789045	0.688	rs6668637	chr1:204452295	A/G	cg18185008	chr1:204589407	LRRN2	-0.54	-5.83	-0.35	1.74e-8	Educational attainment (college completion);
KIRP	cis	rs7919006	0.793	rs72803467	chr10:76801386	A/T	cg01390419	chr10:76803856	DUPD1	0.51	5.99	0.36	7.36e-9	Weight;
KIRP	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg05784532	chr1:230284198	GALNT2	0.41	6.2	0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	9.06	0.5	4.24e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg16989719	chr2:238392110	NA	-0.56	-7.73	-0.44	2.7e-13	Prostate cancer;
KIRP	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.82	-12.93	-0.64	1.54e-29	Dental caries;
KIRP	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg19197139	chr17:4613644	ARRB2	-0.64	-6.83	-0.4	6.78e-11	Lymphocyte counts;
KIRP	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg08603382	chr10:743973	NA	0.45	6.59	0.39	2.69e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	6.54	0.38	3.51e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs9535307	0.929	rs9535340	chr13:50357873	A/C	cg04663916	chr13:50265991	EBPL	0.65	6.89	0.4	4.66e-11	Obesity-related traits;
KIRP	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.65	-7.95	-0.45	6.77e-14	Body mass index;
KIRP	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.29	8.05	0.46	3.44e-14	Rheumatoid arthritis;
KIRP	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.89	-0.3	1.78e-6	Prostate cancer;
KIRP	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.2	-0.31	4.29e-7	Tonsillectomy;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg15181151	chr6:150070149	PCMT1	0.31	5.3	0.32	2.62e-7	Lung cancer;
KIRP	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg23594656	chr7:65796392	TPST1	-0.45	-7.06	-0.41	1.74e-11	Aortic root size;
KIRP	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7998202	0.614	rs282571	chr13:113366234	C/G	cg02820901	chr13:113351484	ATP11A	0.62	5.76	0.34	2.46e-8	Glycated hemoglobin levels;
KIRP	cis	rs31771	0.690	rs31764	chr5:165501885	G/A	cg13976338	chr5:165423657	NA	0.55	4.98	0.3	1.18e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7551222	0.752	rs6681905	chr1:204535789	T/G	cg20240347	chr1:204465584	NA	-0.44	-8.34	-0.47	5.25e-15	Schizophrenia;
KIRP	cis	rs60154123	0.730	rs10779528	chr1:210457378	C/T	cg09074223	chr1:210466472	NA	0.57	5.96	0.36	8.64e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg02462569	chr6:150064036	NUP43	-0.37	-5.6	-0.34	5.69e-8	Lung cancer;
KIRP	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.36	5.39	0.33	1.62e-7	Type 2 diabetes;
KIRP	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	8.89	0.49	1.32e-16	Bipolar disorder;
KIRP	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.37	-5.56	-0.33	7.18e-8	Eotaxin levels;
KIRP	cis	rs8077059	0.513	rs9892194	chr17:55825825	C/T	cg12582317	chr17:55822272	NA	-0.49	-7.65	-0.44	4.64e-13	Sex hormone-binding globulin levels;
KIRP	cis	rs6681460	0.899	rs499263	chr1:67179937	T/C	cg02459107	chr1:67143332	SGIP1	0.41	5.91	0.35	1.13e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs4702718	0.632	rs1866386	chr5:10682728	G/A	cg14521931	chr5:10832172	NA	0.51	5.52	0.33	8.73e-8	Obesity-related traits;
KIRP	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.7	9.49	0.52	2.11e-18	Systemic lupus erythematosus;
KIRP	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-6.89	-0.4	4.72e-11	Menarche (age at onset);
KIRP	cis	rs244293	0.730	rs2332314	chr17:53033007	T/G	cg07707039	chr17:53042137	COX11	-0.41	-5.11	-0.31	6.33e-7	Menarche (age at onset);
KIRP	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg23920097	chr1:209922102	NA	0.44	5.9	0.35	1.18e-8	Red blood cell count;
KIRP	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg13798780	chr7:105162888	PUS7	-0.46	-5.01	-0.3	1.06e-6	Bipolar disorder (body mass index interaction);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03599658	chr7:4803508	FOXK1	0.46	6.17	0.37	2.77e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.82	11.71	0.6	1.87e-25	Glomerular filtration rate (creatinine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14019158	chr19:45754992	MARK4	0.51	6.38	0.38	8.76e-10	Parkinson's disease;
KIRP	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.43	-5.46	-0.33	1.15e-7	Mean platelet volume;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg04899180	chr1:45266286	PLK3	0.51	6.3	0.37	1.39e-9	DNA methylation (variation);
KIRP	cis	rs1629083	0.967	rs4938492	chr11:118126675	T/C	cg18857871	chr11:118064634	AMICA1	0.62	8.29	0.47	7.34e-15	Lung cancer;
KIRP	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg17133734	chr15:86042851	AKAP13	-0.45	-5.63	-0.34	5.02e-8	Interstitial lung disease;
KIRP	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg00129232	chr17:37814104	STARD3	-0.5	-6.38	-0.38	8.85e-10	Self-reported allergy;
KIRP	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg16083429	chr3:49237500	CCDC36	-0.39	-5.17	-0.31	4.78e-7	Menarche (age at onset);
KIRP	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.42	-5.29	-0.32	2.65e-7	Birth weight;
KIRP	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-1.01	-17.13	-0.74	8.12e-44	Height;
KIRP	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.5	0.38	4.47e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.85	12.66	0.63	1.25e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg16141378	chr3:129829833	LOC729375	0.49	6.4	0.38	7.84e-10	Mood instability;
KIRP	trans	rs4650994	0.623	rs2248666	chr1:178620601	G/T	cg05059571	chr16:84539110	KIAA1609	0.51	6.8	0.4	8.07e-11	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.82	-13.27	-0.65	1.1e-30	Vitiligo;
KIRP	cis	rs13395090	1.000	rs11687349	chr2:3717496	A/C	cg15327641	chr2:3715039	ALLC	0.69	9.62	0.52	8.45e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12949688	0.967	rs12949028	chr17:55825470	A/C	cg12582317	chr17:55822272	NA	0.58	9.32	0.51	6.73e-18	Schizophrenia;
KIRP	cis	rs13424612	1.000	rs34849118	chr2:240919912	T/C	cg01812947	chr2:240904978	NDUFA10	0.4	5.25	0.32	3.27e-7	Odorant perception (isobutyraldehyde);
KIRP	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.55	7.19	0.42	7.66e-12	Response to temozolomide;
KIRP	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg16141378	chr3:129829833	LOC729375	0.61	7.76	0.44	2.23e-13	Neuroticism;
KIRP	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-11.96	-0.61	2.77e-26	Vitiligo;
KIRP	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.73	10.8	0.57	1.61e-22	Orofacial clefts;
KIRP	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06505273	chr16:24850292	NA	0.41	5.65	0.34	4.45e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.7	8.69	0.48	5.25e-16	Menopause (age at onset);
KIRP	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.55	7.59	0.44	6.62e-13	Blood metabolite levels;
KIRP	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg15556689	chr8:8085844	FLJ10661	0.64	8.07	0.46	3.17e-14	Retinal vascular caliber;
KIRP	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg17691542	chr6:26056736	HIST1H1C	0.65	7.7	0.44	3.39e-13	Iron status biomarkers;
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19500275	chr17:80737654	TBCD	0.48	5.68	0.34	3.72e-8	Glycated hemoglobin levels;
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg05562828	chr17:3906858	NA	0.71	13.92	0.66	6.98e-33	Type 2 diabetes;
KIRP	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg04202892	chr2:111875749	ACOXL	0.5	6.89	0.4	4.6e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg04731861	chr2:219085781	ARPC2	0.3	7.56	0.43	7.99e-13	Colorectal cancer;
KIRP	cis	rs6137287	0.883	rs6047319	chr20:21218345	A/G	cg04219410	chr20:21106687	PLK1S1	-0.38	-4.9	-0.3	1.75e-6	Height;
KIRP	cis	rs72949976	0.734	rs62189579	chr2:214016984	T/A	cg08319019	chr2:214017104	IKZF2	-0.71	-7.96	-0.45	6.27e-14	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.65	-7.19	-0.42	7.68e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27144592	chr16:783916	NARFL	0.37	5.11	0.31	6.42e-7	Height;
KIRP	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.14	0.58	1.34e-23	Alzheimer's disease;
KIRP	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.61	7.74	0.44	2.63e-13	Coronary artery disease;
KIRP	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.66	6.97	0.41	2.85e-11	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.86	8.19	0.46	1.44e-14	Systolic blood pressure;
KIRP	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.83	-9.91	-0.53	1.1e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4006360	0.514	rs1588393	chr17:39247900	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.58	-8.91	-0.49	1.19e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs9815354	0.951	rs9850310	chr3:41891098	T/C	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7103648	0.966	rs11500477	chr11:47409051	T/A	cg03711944	chr11:47377212	SPI1	-0.3	-4.98	-0.3	1.22e-6	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.05	-0.41	1.76e-11	Morning vs. evening chronotype;
KIRP	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg12623918	chr2:306882	NA	0.39	4.9	0.3	1.71e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs6681460	0.576	rs7355221	chr1:66986301	G/C	cg13052034	chr1:66999238	SGIP1	0.41	5.34	0.32	2.11e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg17105886	chr17:28927953	LRRC37B2	-0.52	-5.27	-0.32	2.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg08076091	chr2:203926405	NBEAL1	0.91	9.46	0.52	2.52e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.66	0.39	1.79e-10	Skin colour saturation;
KIRP	cis	rs6545883	0.894	rs778143	chr2:61581890	A/C	cg15711740	chr2:61764176	XPO1	-0.57	-7.28	-0.42	4.51e-12	Tuberculosis;
KIRP	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg17401720	chr7:158221031	PTPRN2	-0.31	-4.86	-0.3	2.13e-6	Obesity-related traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08267002	chr2:74741573	TLX2	0.47	6.24	0.37	1.85e-9	Smoking initiation;
KIRP	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg16511985	chr3:153974050	SGEF	0.39	5.49	0.33	1.02e-7	Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-20.07	-0.79	1e-53	Height;
KIRP	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg07843065	chr1:150265600	MRPS21	0.44	5.99	0.36	7.26e-9	Migraine;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12510286	chr2:27309317	KHK	0.52	6.58	0.39	2.85e-10	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg01238044	chr22:24384105	GSTT1	-0.58	-7.68	-0.44	3.87e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg26207909	chr14:103986467	CKB	-0.49	-6.25	-0.37	1.77e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.43e-13	Corneal astigmatism;
KIRP	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.94	12.28	0.62	2.32e-27	Menopause (age at onset);
KIRP	cis	rs6832769	1.000	rs3805154	chr4:56363927	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.04	0.41	1.92e-11	Personality dimensions;
KIRP	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.46	-0.38	5.54e-10	Response to antipsychotic treatment;
KIRP	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg27124370	chr19:33622961	WDR88	0.71	10.37	0.55	3.74e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.74	-7.78	-0.44	2e-13	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14248188	chr9:98273349	PTCH1	0.49	6.07	0.36	4.76e-9	Parkinson's disease;
KIRP	cis	rs9311676	0.632	rs6445978	chr3:58379586	T/A	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.77	6.98	0.41	2.69e-11	Alzheimer's disease;
KIRP	cis	rs6546886	0.912	rs7601526	chr2:74278481	A/G	cg14702570	chr2:74259524	NA	-0.31	-6.1	-0.36	4.02e-9	Dialysis-related mortality;
KIRP	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.55	-5.5	-0.33	9.39e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.13	0.46	2.11e-14	Longevity;Endometriosis;
KIRP	cis	rs7577696	0.539	rs13010405	chr2:32338204	A/T	cg02381751	chr2:32503542	YIPF4	-0.53	-5.27	-0.32	3.02e-7	Inflammatory biomarkers;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.89	-0.53	1.28e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-1.01	-19.86	-0.78	4.94e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg24304309	chr1:154577895	ADAR	0.37	5.57	0.33	6.65e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.21	0.37	2.19e-9	Retinal vascular caliber;
KIRP	cis	rs1062753	0.527	rs2187959	chr22:42347844	T/G	cg15128208	chr22:42549153	NA	0.44	5.8	0.35	2.05e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg25356066	chr3:128598488	ACAD9	0.47	5.39	0.32	1.67e-7	IgG glycosylation;
KIRP	cis	rs12210905	1.000	rs9393796	chr6:27226965	T/G	cg11502198	chr6:26597334	ABT1	-0.71	-4.94	-0.3	1.42e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.46	6.61	0.39	2.32e-10	Sitting height ratio;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg07414643	chr4:187882934	NA	0.4	5.22	0.32	3.73e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg13906792	chr15:75199810	C15orf17	-0.37	-5.35	-0.32	2.05e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs12230513	0.793	rs6581066	chr12:55926695	G/A	cg03330747	chr12:56361238	CDK2;SILV	-0.38	-4.89	-0.3	1.85e-6	Contrast sensitivity;
KIRP	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.81	10.13	0.54	2.27e-20	Systolic blood pressure;
KIRP	cis	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg08773314	chr2:239334832	ASB1	-0.45	-4.87	-0.3	2e-6	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg02367723	chr1:46378857	MAST2	-0.43	-4.95	-0.3	1.37e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg24375607	chr4:120327624	NA	0.4	5.01	0.3	1.05e-6	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21330094	chr4:8418132	ACOX3	-0.47	-6.07	-0.36	4.84e-9	Parkinson's disease;
KIRP	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.54	-6.93	-0.4	3.62e-11	Prudent dietary pattern;
KIRP	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg09184832	chr6:79620586	NA	-0.39	-4.98	-0.3	1.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.669	rs10875792	chr12:48697423	T/A	cg20731937	chr12:48336164	NA	0.48	5.87	0.35	1.39e-8	Longevity (90 years and older);
KIRP	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg26441486	chr22:50317300	CRELD2	0.49	5.63	0.34	4.81e-8	Schizophrenia;
KIRP	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg27432699	chr2:27873401	GPN1	0.5	6.78	0.4	8.96e-11	Total body bone mineral density;
KIRP	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs4700695	0.764	rs36300	chr5:65348153	C/T	cg21114390	chr5:65439923	SFRS12	0.58	5.34	0.32	2.13e-7	Facial morphology (factor 19);
KIRP	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.9	-13.64	-0.66	6.48e-32	Coronary artery disease;
KIRP	cis	rs7809615	0.901	rs10808111	chr7:99070884	T/A	cg24024660	chr7:99195788	NA	-0.57	-5.07	-0.31	7.78e-7	Blood metabolite ratios;
KIRP	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg19418458	chr7:158789849	NA	-0.49	-5.95	-0.35	9.1e-9	Facial morphology (factor 20);
KIRP	cis	rs4273100	0.564	rs10445411	chr17:19265797	C/T	cg25447019	chr17:19030144	GRAPL	0.58	7.85	0.45	1.26e-13	Schizophrenia;
KIRP	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg25019033	chr10:957182	NA	0.38	5.1	0.31	6.7e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.38	-0.43	2.48e-12	Joint mobility (Beighton score);
KIRP	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg01879757	chr17:41196368	BRCA1	-0.78	-10.91	-0.57	7.13e-23	Menopause (age at onset);
KIRP	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-1.05	-12.8	-0.63	4.33e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.44	-5.28	-0.32	2.88e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.7	-9.21	-0.51	1.45e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6546886	0.957	rs4371381	chr2:74246613	T/C	cg14702570	chr2:74259524	NA	-0.33	-6.63	-0.39	2.1e-10	Dialysis-related mortality;
KIRP	cis	rs904251	0.686	rs1224128	chr6:37415676	C/A	cg25019722	chr6:37503610	NA	-0.62	-6.4	-0.38	7.99e-10	Cognitive performance;
KIRP	cis	rs78487399	0.710	rs6759383	chr2:43805228	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.78	-0.35	2.28e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.79	9.74	0.53	3.6e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.31	-0.47	6.31e-15	Response to antipsychotic treatment;
KIRP	cis	rs3857067	1.000	rs1397027	chr4:95013562	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.85	-0.3	2.16e-6	QT interval;
KIRP	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.69	-0.56	3.73e-22	Triglycerides;
KIRP	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg04691961	chr3:161091175	C3orf57	-0.49	-7.22	-0.42	6.47e-12	Morning vs. evening chronotype;
KIRP	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.44	5.66	0.34	4.27e-8	Body mass index;
KIRP	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.82	13.41	0.65	3.93e-31	Intelligence (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21795699	chr17:15903687	ZSWIM7;TTC19	1.08	7.43	0.43	1.83e-12	P wave terminal force;
KIRP	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg08085267	chr17:45401833	C17orf57	0.57	7.43	0.43	1.81e-12	Multiple sclerosis or amyotrophic lateral sclerosis;
KIRP	cis	rs9843304	0.568	rs13062027	chr3:149212679	G/C	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.79	-0.35	2.13e-8	Gallstone disease;
KIRP	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.66	-9.6	-0.52	9.93e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2006771	0.810	rs2006648	chr22:32081929	T/C	cg02404636	chr22:31891804	SFI1	-0.45	-5.76	-0.34	2.51e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg07395648	chr5:131743802	NA	0.37	5.15	0.31	5.23e-7	Blood metabolite levels;
KIRP	cis	rs7614311	0.636	rs56165216	chr3:63916620	C/T	cg22134162	chr3:63841271	THOC7	-0.36	-4.87	-0.3	2.02e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	10.15	0.54	1.98e-20	Neuroticism;
KIRP	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg16586182	chr3:47516702	SCAP	-0.81	-11.47	-0.59	1.15e-24	Colorectal cancer;
KIRP	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg19554555	chr3:13937349	NA	-0.47	-6.32	-0.37	1.2e-9	Ovarian reserve;
KIRP	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	1.26	9.11	0.5	2.91e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2057178	1.000	rs11031731	chr11:32365430	G/A	cg06489367	chr11:32355509	NA	0.45	5.09	0.31	7.03e-7	Tuberculosis;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.83	12.23	0.61	3.52e-27	Menarche (age at onset);
KIRP	cis	rs1440410	0.795	rs3967098	chr4:144195781	T/C	cg01719995	chr4:144104893	USP38	0.39	5.0	0.3	1.07e-6	Ischemic stroke;
KIRP	cis	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg06521331	chr12:34319734	NA	-0.43	-5.51	-0.33	9.26e-8	Morning vs. evening chronotype;
KIRP	cis	rs10267417	0.584	rs10247789	chr7:19863570	G/C	cg05791153	chr7:19748676	TWISTNB	0.49	4.89	0.3	1.83e-6	Night sleep phenotypes;
KIRP	cis	rs2802372	0.718	rs2104419	chr10:81039475	T/C	cg18688392	chr10:81059414	ZMIZ1	-0.44	-5.93	-0.35	1.02e-8	Granulocyte count;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	7.54	0.43	9.06e-13	Lymphocyte counts;
KIRP	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.06	0.36	5.09e-9	Bipolar disorder;
KIRP	trans	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.6	-6.11	-0.36	3.92e-9	Obesity-related traits;
KIRP	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg14024328	chr4:719362	PCGF3	-0.56	-8.63	-0.48	7.61e-16	White blood cell count;
KIRP	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.61	-6.94	-0.4	3.56e-11	DNA methylation (variation);
KIRP	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	7.33	0.42	3.23e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03044510	chr21:27107978	ATP5J;GABPA	0.49	6.71	0.39	1.33e-10	Parkinson's disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg09861631	chr1:236767555	HEATR1	-0.41	-6.23	-0.37	1.98e-9	Migraine with aura;
KIRP	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.72	11.58	0.59	4.69e-25	Weight;
KIRP	cis	rs1009181	0.560	rs9379829	chr6:26172219	C/T	cg00631329	chr6:26305371	NA	-0.61	-6.15	-0.37	3.03e-9	Childhood ear infection;
KIRP	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg21360079	chr12:107162445	NA	-0.66	-9.48	-0.52	2.19e-18	Heart rate;
KIRP	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg15432903	chr11:17409602	KCNJ11	0.52	6.02	0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.64	-8.65	-0.48	6.95e-16	Cognitive test performance;
KIRP	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.09	0.36	4.25e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.86	-0.35	1.46e-8	Bipolar disorder;
KIRP	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03352830	chr11:487213	PTDSS2	0.76	6.11	0.36	3.81e-9	Body mass index;
KIRP	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg09455208	chr3:40491958	NA	0.32	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	0.89	12.06	0.61	1.24e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg00857998	chr1:205179979	DSTYK	0.48	6.11	0.36	3.87e-9	Red blood cell count;
KIRP	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg21573476	chr21:45109991	RRP1B	-0.54	-7.35	-0.42	2.97e-12	Mean corpuscular volume;
KIRP	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.78	-9.95	-0.54	8.12e-20	Blood trace element (Zn levels);
KIRP	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.39	-0.33	1.63e-7	Life satisfaction;
KIRP	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg15744005	chr10:104629667	AS3MT	0.33	5.66	0.34	4.26e-8	Arsenic metabolism;
KIRP	cis	rs2481665	1.000	rs2481665	chr1:62594677	T/C	cg18591186	chr1:62594603	INADL	-0.69	-10.7	-0.56	3.55e-22	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg10189774	chr4:17578691	LAP3	0.5	6.09	0.36	4.29e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg01631408	chr1:248437212	OR2T33	0.57	7.58	0.44	7.08e-13	Common traits (Other);
KIRP	cis	rs273218	1.000	rs273217	chr5:53380938	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.71	7.63	0.44	5.21e-13	Migraine;
KIRP	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.48	-6.99	-0.41	2.65e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15700487	chr1:150669759	GOLPH3L	0.47	6.36	0.38	9.82e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6540556	0.723	rs11119327	chr1:209883804	T/C	cg05527609	chr1:210001259	C1orf107	-0.5	-5.27	-0.32	2.94e-7	Red blood cell count;
KIRP	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg16898833	chr6:26189333	HIST1H4D	0.81	5.92	0.35	1.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.55	7.37	0.43	2.63e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg20991723	chr1:152506922	NA	-0.45	-5.43	-0.33	1.34e-7	Hair morphology;
KIRP	cis	rs10979	0.679	rs9321918	chr6:143883460	T/C	cg25407410	chr6:143891975	LOC285740	-0.66	-7.98	-0.45	5.67e-14	Hypospadias;
KIRP	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg08890418	chr1:21044141	KIF17	-0.41	-6.3	-0.37	1.37e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg02175308	chr1:109941060	SORT1	-0.29	-5.56	-0.33	6.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg06637938	chr14:75390232	RPS6KL1	0.5	7.03	0.41	2.09e-11	Caffeine consumption;
KIRP	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	6.09	0.36	4.25e-9	Schizophrenia;
KIRP	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg01657329	chr11:68192670	LRP5	0.52	5.61	0.34	5.38e-8	Total body bone mineral density;
KIRP	trans	rs7939886	0.920	rs1031978	chr11:55965641	G/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg26441486	chr22:50317300	CRELD2	0.54	7.79	0.44	1.94e-13	Schizophrenia;
KIRP	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.93	12.56	0.63	2.78e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.608	rs12129718	chr1:209912540	C/T	cg23920097	chr1:209922102	NA	-0.4	-5.01	-0.3	1.04e-6	Red blood cell count;
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13198984	chr17:80129470	CCDC57	-0.54	-8.16	-0.46	1.76e-14	Life satisfaction;
KIRP	cis	rs6832769	1.000	rs4865010	chr4:56414962	A/C	cg09317128	chr4:56265301	TMEM165	-0.52	-6.75	-0.4	1.06e-10	Personality dimensions;
KIRP	cis	rs4302748	0.909	rs1882062	chr7:36188719	C/T	cg24442661	chr7:36192818	EEPD1	0.58	6.25	0.37	1.77e-9	Platelet count;
KIRP	cis	rs12230513	0.732	rs7971742	chr12:55848486	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-7.55	-0.43	8.49e-13	Contrast sensitivity;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.57	-7.48	-0.43	1.3e-12	Vitiligo;
KIRP	cis	rs6733011	0.628	rs6542838	chr2:99452458	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.33	-0.32	2.2e-7	Bipolar disorder;
KIRP	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.54	-7.57	-0.43	7.46e-13	IgG glycosylation;
KIRP	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg18764771	chr6:116381957	FRK	0.18	5.12	0.31	6.2e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg26769984	chr7:1090371	C7orf50	0.54	5.6	0.34	5.68e-8	Bronchopulmonary dysplasia;
KIRP	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.83	11.24	0.58	6.25e-24	Morning vs. evening chronotype;
KIRP	cis	rs4765905	0.671	rs3922316	chr12:2331144	C/A	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.62	-0.34	5.07e-8	Schizophrenia;
KIRP	cis	rs11874712	0.966	rs8093880	chr18:43666786	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.42	-5.94	-0.35	9.42e-9	Migraine - clinic-based;
KIRP	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.54	-0.43	9.27e-13	Bipolar disorder;
KIRP	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.36	-0.47	4.74e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs1978968	0.525	rs4819649	chr22:18396329	A/C	cg03078520	chr22:18463400	MICAL3	0.51	6.68	0.39	1.55e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg07645718	chr20:61493192	TCFL5	-0.74	-6.58	-0.39	2.81e-10	Obesity-related traits;
KIRP	cis	rs7224685	0.569	rs8082483	chr17:4000849	G/A	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.72e-7	Type 2 diabetes;
KIRP	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.13e-6	Bladder cancer;
KIRP	cis	rs2862064	0.932	rs6870977	chr5:156446249	T/C	cg12943317	chr5:156479607	HAVCR1	-0.89	-7.96	-0.45	6.21e-14	Platelet count;
KIRP	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs889398	0.741	rs2362642	chr16:69931458	G/A	cg09409435	chr16:70099608	PDXDC2	0.45	5.25	0.32	3.31e-7	Body mass index;
KIRP	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.93	14.08	0.67	2.01e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6893300	0.524	rs12374446	chr5:179131143	A/G	cg14593053	chr5:179126677	CANX	0.78	11.35	0.59	2.65e-24	Resting heart rate;
KIRP	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.53	6.21	0.37	2.22e-9	Height;
KIRP	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.51	-6.51	-0.38	4.17e-10	Schizophrenia;
KIRP	cis	rs10203711	0.966	rs4663939	chr2:239569867	C/A	cg14580085	chr2:239553406	NA	0.39	5.22	0.32	3.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.05	0.31	8.45e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg19882132	chr14:106167949	NA	-0.44	-5.33	-0.32	2.21e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs7601312	1.000	rs12618767	chr2:229321200	G/C	cg02542817	chr2:229291442	NA	-0.39	-5.8	-0.35	2.08e-8	Schizophrenia;
KIRP	cis	rs10208940	0.920	rs7580719	chr2:68833572	A/G	cg12452813	chr2:68675892	NA	-0.45	-4.91	-0.3	1.64e-6	Urate levels in lean individuals;
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs259842	0.670	rs4894128	chr2:180707310	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.39	-5.26	-0.32	3.09e-7	Blood protein levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14368592	chr20:61981657	CHRNA4	0.42	6.22	0.37	2.16e-9	Metabolic traits;
KIRP	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	9.76	0.53	3.16e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9649213	0.593	rs3801264	chr7:97950620	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9522267	0.737	rs9522276	chr13:112220208	C/T	cg14952266	chr13:112191215	NA	0.38	5.02	0.3	1.01e-6	Hepatitis;
KIRP	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-9.45	-0.52	2.87e-18	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7808935	1.000	rs7808935	chr7:27977363	T/C	cg22168087	chr7:27702803	HIBADH	0.63	6.88	0.4	4.84e-11	Prostate cancer;
KIRP	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-4.99	-0.3	1.14e-6	Educational attainment;
KIRP	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.18	-0.31	4.55e-7	Bladder cancer;
KIRP	cis	rs4774830	0.744	rs62046386	chr15:56305252	G/A	cg24530489	chr15:56299380	NA	-0.88	-5.36	-0.32	1.93e-7	Delta-5 desaturase activity;
KIRP	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.54	-6.78	-0.4	9.07e-11	Urate levels in overweight individuals;
KIRP	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg08761264	chr16:28874980	SH2B1	-0.52	-6.0	-0.36	6.93e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2658782	0.654	rs2605622	chr11:93248242	A/G	cg15737290	chr11:93063684	CCDC67	0.67	7.92	0.45	8.19e-14	Pulmonary function decline;
KIRP	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-0.9	-9.94	-0.54	8.47e-20	Gut microbiome composition (summer);
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg02811702	chr13:24901961	NA	0.4	5.14	0.31	5.62e-7	Obesity-related traits;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg13453750	chr1:205783389	SLC41A1	-0.51	-7.48	-0.43	1.35e-12	Menarche (age at onset);
KIRP	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg09754948	chr16:28834200	ATXN2L	0.49	5.75	0.34	2.59e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08402873	chr20:10653164	JAG1	0.45	5.82	0.35	1.84e-8	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.01	0.41	2.28e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2281603	0.951	rs11158544	chr14:64996487	G/T	cg25009451	chr14:65006716	HSPA2	0.48	5.25	0.32	3.26e-7	Lymphocyte counts;
KIRP	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.98	-10.4	-0.55	3.16e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs10129255	0.536	rs3944157	chr14:107138303	C/T	cg23076370	chr14:107095027	NA	-0.4	-5.09	-0.31	7.1e-7	Kawasaki disease;
KIRP	cis	rs10267417	0.603	rs28819981	chr7:19933631	A/G	cg05791153	chr7:19748676	TWISTNB	0.51	4.85	0.3	2.22e-6	Night sleep phenotypes;
KIRP	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.53	-7.21	-0.42	6.85e-12	Response to temozolomide;
KIRP	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.8	9.17	0.5	2.02e-17	Corneal astigmatism;
KIRP	trans	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.53	7.11	0.41	1.22e-11	Blood trace element (Cu levels);
KIRP	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.67	8.51	0.48	1.68e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs1448094	0.813	rs6539942	chr12:86452969	T/C	cg06740227	chr12:86229804	RASSF9	-0.43	-5.46	-0.33	1.14e-7	Major depressive disorder;
KIRP	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.43	-5.73	-0.34	2.87e-8	Schizophrenia;
KIRP	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.85	-8.98	-0.5	7.16e-17	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg06212747	chr3:49208901	KLHDC8B	0.65	9.08	0.5	3.56e-17	Resting heart rate;
KIRP	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.74	9.39	0.51	4.31e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	cis	rs6939532	0.522	rs2073528	chr6:26375143	G/C	cg12826209	chr6:26865740	GUSBL1	0.47	5.5	0.33	9.29e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23667707	chr7:152569949	NA	-0.43	-6.5	-0.38	4.51e-10	Pancreatic cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21647170	chr7:56119546	CCT6A;PSPH	0.58	6.77	0.4	9.29e-11	Smoking initiation;
KIRP	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.95	-0.45	6.69e-14	Retinal vascular caliber;
KIRP	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.53	-0.33	8.05e-8	Schizophrenia;
KIRP	cis	rs885389	1.000	rs885389	chr12:131621762	C/T	cg06374807	chr12:131606857	GPR133	0.47	6.21	0.37	2.28e-9	RR interval (heart rate);
KIRP	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.51	0.33	9.24e-8	Major depressive disorder;
KIRP	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.6	-8.67	-0.48	5.81e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg02792322	chr13:21280448	IL17D	0.3	4.93	0.3	1.55e-6	Dental caries;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.63	8.59	0.48	1.03e-15	Longevity;Endometriosis;
KIRP	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.26	0.55	8.5e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg23649088	chr2:200775458	C2orf69	-0.68	-5.87	-0.35	1.4e-8	Schizophrenia;
KIRP	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.44	6.31	0.37	1.28e-9	Testicular germ cell tumor;
KIRP	cis	rs7937612	1.000	rs723937	chr11:120312746	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.89	-0.4	4.57e-11	Intraocular pressure;
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.13	12.63	0.63	1.55e-28	Platelet count;
KIRP	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.93	12.3	0.62	2.01e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.41	6.37	0.38	9.4e-10	Prostate cancer;
KIRP	cis	rs9400467	0.537	rs12202411	chr6:111488518	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg21385522	chr1:16154831	NA	0.5	6.35	0.38	1.05e-9	Dilated cardiomyopathy;
KIRP	cis	rs62413470	1.000	rs12209509	chr6:55962183	G/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs2299587	0.637	rs6586677	chr8:17890687	A/G	cg01800426	chr8:17659068	MTUS1	-0.42	-5.05	-0.31	8.62e-7	Economic and political preferences;
KIRP	cis	rs1829883	0.775	rs2548103	chr5:98899755	T/C	cg08333243	chr5:99726346	NA	-0.42	-5.33	-0.32	2.19e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.47	7.18	0.42	8.37e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.12	0.36	3.59e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg20243544	chr17:37824526	PNMT	0.51	7.38	0.43	2.4e-12	Asthma;
KIRP	cis	rs2077654	0.822	rs7939973	chr11:17433291	G/T	cg25308976	chr11:17434268	ABCC8	1.07	10.92	0.57	6.92e-23	Gout;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09093137	chr7:105028539	SRPK2	-0.52	-6.71	-0.39	1.35e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4150161	0.656	rs2288026	chr16:84220344	C/G	cg10106505	chr16:84220380	TAF1C	0.73	4.98	0.3	1.19e-6	Systolic blood pressure response to hydrochlorothiazide in hypertension;
KIRP	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg13256891	chr4:100009986	ADH5	0.52	6.43	0.38	6.53e-10	Alcohol dependence;
KIRP	cis	rs1975991	0.503	rs9844744	chr3:187980503	G/C	cg17585528	chr3:187988060	LPP	-0.49	-5.69	-0.34	3.68e-8	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg20818283	chr2:191399100	TMEM194B	0.54	6.78	0.4	8.66e-11	Pulse pressure;
KIRP	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg24060327	chr5:131705240	SLC22A5	0.65	6.82	0.4	7.2e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.63	-6.57	-0.39	3.02e-10	Gut microbiome composition (summer);
KIRP	cis	rs12210905	0.688	rs78285097	chr6:27374644	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.62	-0.39	2.26e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.69	6.69	0.39	1.51e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.9	14.35	0.67	2.53e-34	Dental caries;
KIRP	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.97	0.36	8.1e-9	Breast cancer;
KIRP	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.26	-16.92	-0.73	4.11e-43	Breast cancer;
KIRP	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02972257	chr16:68554789	NA	-0.57	-6.09	-0.36	4.43e-9	Ulcerative colitis;
KIRP	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg22974920	chr21:40686053	BRWD1	0.5	5.88	0.35	1.34e-8	Cognitive function;
KIRP	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg07451762	chr16:28383216	NA	0.42	5.5	0.33	9.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg02002194	chr4:3960332	NA	0.45	6.51	0.38	4.29e-10	Neuroticism;
KIRP	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.7	-10.12	-0.54	2.33e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-5.93	-0.35	1.03e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg19636519	chr7:99541626	NA	0.28	4.92	0.3	1.56e-6	Coronary artery disease;
KIRP	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.75e-15	Aortic root size;
KIRP	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg07596299	chr11:71824057	C11orf51	-0.86	-5.73	-0.34	2.95e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.69	9.91	0.53	1.08e-19	Dupuytren's disease;
KIRP	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12976411	1.000	rs35677812	chr19:32842896	A/G	cg02282382	chr19:32836354	ZNF507	0.7	5.18	0.31	4.68e-7	Coronary artery disease;
KIRP	cis	rs526231	0.543	rs34770	chr5:102447646	A/C	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.35	1.27e-8	Primary biliary cholangitis;
KIRP	trans	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.66	8.29	0.47	7.3e-15	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg13798575	chr9:95087839	CENPP;NOL8	0.5	6.4	0.38	7.69e-10	Height;
KIRP	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg25319279	chr11:5960081	NA	-0.49	-5.04	-0.31	9.07e-7	DNA methylation (variation);
KIRP	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg17133734	chr15:86042851	AKAP13	-0.47	-5.97	-0.36	8.04e-9	Coronary artery disease;
KIRP	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg00666640	chr1:248458726	OR2T12	-0.46	-5.77	-0.35	2.4e-8	Common traits (Other);
KIRP	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg27129171	chr3:47204927	SETD2	0.77	11.57	0.59	5.06e-25	Colorectal cancer;
KIRP	cis	rs5753037	0.702	rs249398	chr22:30214704	G/C	cg01021169	chr22:30184971	ASCC2	-0.39	-5.3	-0.32	2.64e-7	Type 1 diabetes;
KIRP	cis	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg06521331	chr12:34319734	NA	-0.63	-7.59	-0.44	6.56e-13	Morning vs. evening chronotype;
KIRP	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.97	12.42	0.62	8.02e-28	Homoarginine levels;
KIRP	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg00405596	chr8:11794950	NA	-0.45	-5.7	-0.34	3.48e-8	Retinal vascular caliber;
KIRP	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg21605333	chr4:119757512	SEC24D	1.54	11.78	0.6	1.07e-25	Cannabis dependence symptom count;
KIRP	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.43	-0.33	1.36e-7	Aortic root size;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.74	6.29	0.37	1.45e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.77	10.82	0.57	1.47e-22	Diastolic blood pressure;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.51	-6.96	-0.41	3.12e-11	Testicular germ cell tumor;
KIRP	cis	rs189798	0.738	rs330911	chr8:8996273	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	4.89	0.3	1.81e-6	Myopia (pathological);
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.53	7.04	0.41	1.88e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg06212747	chr3:49208901	KLHDC8B	0.61	6.44	0.38	6.29e-10	Menarche (age at onset);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg21708767	chr2:25565514	DNMT3A	-0.46	-6.34	-0.37	1.09e-9	Myopia;
KIRP	cis	rs11955398	0.585	rs1117674	chr5:60035007	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.63	9.15	0.5	2.2e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.49	-6.11	-0.36	3.81e-9	Facial morphology (factor 20);
KIRP	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.62	6.43	0.38	6.56e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg24315340	chr6:146058215	EPM2A	-0.45	-5.55	-0.33	7.19e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22288577	chr15:91498497	RCCD1	-0.5	-6.34	-0.37	1.08e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.21	-0.51	1.49e-17	Platelet count;
KIRP	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.59	-7.92	-0.45	8.41e-14	Vitiligo;
KIRP	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg22875332	chr1:76189707	ACADM	-0.33	-4.87	-0.3	1.98e-6	Daytime sleep phenotypes;
KIRP	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg11995313	chr8:8860691	ERI1	0.4	5.52	0.33	8.5e-8	Myopia;Myopia (pathological);
KIRP	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.24	0.37	1.89e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27540799	chr1:2335599	RER1	-0.5	-7.03	-0.41	2.04e-11	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg14703610	chr5:56206110	C5orf35	0.51	6.78	0.4	8.83e-11	Coronary artery disease;
KIRP	cis	rs2273669	0.667	rs12195728	chr6:109278873	A/G	cg05315195	chr6:109294784	ARMC2	-0.55	-5.78	-0.35	2.24e-8	Prostate cancer;
KIRP	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg02012338	chr4:187126139	CYP4V2	0.89	7.39	0.43	2.35e-12	Blood protein levels;
KIRP	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg05315796	chr3:52349193	DNAH1	0.45	6.78	0.4	8.86e-11	Bipolar disorder;
KIRP	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.47	0.38	5.33e-10	Mean platelet volume;
KIRP	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg12292205	chr6:26970375	C6orf41	0.34	5.01	0.3	1.05e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1497406	0.898	rs36086195	chr1:16510894	C/T	cg03887218	chr1:16534349	ARHGEF19	0.46	6.03	0.36	5.88e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.84	17.08	0.74	1.2e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.7	10.19	0.54	1.45e-20	Lymphocyte counts;
KIRP	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.85	13.25	0.65	1.34e-30	Psoriasis;
KIRP	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg00656387	chr3:40428638	ENTPD3	0.4	5.1	0.31	6.79e-7	Renal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg23985595	chr17:80112537	CCDC57	-0.34	-5.19	-0.31	4.45e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.7	-0.34	3.39e-8	Life satisfaction;
KIRP	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg02996583	chr8:142237188	SLC45A4	0.49	6.05	0.36	5.22e-9	Immature fraction of reticulocytes;
KIRP	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg04317338	chr11:64019027	PLCB3	0.83	6.33	0.37	1.14e-9	Mean platelet volume;
KIRP	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.63	-5.85	-0.35	1.55e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg02782426	chr3:40428986	ENTPD3	-0.32	-4.86	-0.3	2.07e-6	Renal cell carcinoma;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg07701084	chr6:150067640	NUP43	0.75	10.23	0.55	1.11e-20	Lung cancer;
KIRP	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-5.12	-0.31	6.31e-7	Vitiligo;
KIRP	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs6466055	0.589	rs11978288	chr7:104643470	C/T	cg04380332	chr7:105027541	SRPK2	-0.4	-5.36	-0.32	1.94e-7	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.75	10.4	0.55	3e-21	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg11189052	chr15:85197271	WDR73	-0.49	-5.93	-0.35	1.04e-8	P wave terminal force;
KIRP	trans	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg10756647	chr7:56101905	PSPH	1.07	8.27	0.47	8.7e-15	Diabetic kidney disease;
KIRP	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.97	-12.77	-0.63	5.3e-29	Homoarginine levels;
KIRP	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg06417478	chr19:12876846	HOOK2	0.4	4.92	0.3	1.57e-6	Bipolar disorder;
KIRP	trans	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg13482628	chr17:19912719	NA	0.62	8.84	0.49	1.84e-16	Schizophrenia;
KIRP	cis	rs17065868	1.000	rs9533901	chr13:45116611	A/T	cg10246903	chr13:45222710	NA	0.72	6.4	0.38	7.86e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6681460	0.932	rs524114	chr1:67188335	C/T	cg13052034	chr1:66999238	SGIP1	-0.35	-5.05	-0.31	8.56e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7766436	0.922	rs13217043	chr6:22612831	T/A	cg13666174	chr6:22585274	NA	-0.46	-6.12	-0.36	3.65e-9	Coronary artery disease;
KIRP	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg17595323	chr11:93583763	C11orf90	-0.38	-6.47	-0.38	5.37e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4955124	0.558	rs17028710	chr3:32037880	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	6.69	0.39	1.52e-10	Schizophrenia;
KIRP	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.61	6.7	0.39	1.4e-10	Vitiligo;
KIRP	cis	rs7709377	0.546	rs1090077	chr5:115582050	A/G	cg23108291	chr5:115420582	COMMD10	0.41	4.93	0.3	1.54e-6	Metabolite levels  (X-11787);
KIRP	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.84	-10.82	-0.57	1.44e-22	Cognitive function;
KIRP	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg16179182	chr5:140090404	VTRNA1-1	0.5	6.81	0.4	7.38e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3931020	0.657	rs7522428	chr1:75178360	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.42	0.33	1.45e-7	Resistin levels;
KIRP	cis	rs62413470	1.000	rs17683846	chr6:55945010	C/T	cg13327911	chr6:55965977	COL21A1	0.58	4.88	0.3	1.88e-6	Joint mobility (Beighton score);
KIRP	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.93	-0.35	1.05e-8	Obesity-related traits;
KIRP	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg21045802	chr8:109455806	TTC35	0.35	4.9	0.3	1.76e-6	Dupuytren's disease;
KIRP	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18364779	chr6:26104403	HIST1H4C	0.59	7.77	0.44	2.16e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	0.66	6.39	0.38	8.22e-10	Skin colour saturation;
KIRP	cis	rs17033621	0.967	rs12613828	chr2:107609216	C/T	cg17818308	chr2:107502146	ST6GAL2	0.37	4.88	0.3	1.88e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.61	7.29	0.42	4.23e-12	Mosquito bite size;
KIRP	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-11.96	-0.61	2.77e-26	Vitiligo;
KIRP	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg25457927	chr22:38595422	NA	-0.28	-6.19	-0.37	2.45e-9	Cutaneous nevi;
KIRP	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs7771547	0.607	rs614028	chr6:36484252	G/A	cg07856975	chr6:36356162	ETV7	0.36	5.19	0.31	4.36e-7	Platelet distribution width;
KIRP	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.92	-9.54	-0.52	1.46e-18	HIV-1 control;
KIRP	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.98	0.36	7.67e-9	Bipolar disorder;
KIRP	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-10.34	-0.55	4.92e-21	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs2400749	0.798	rs2400746	chr14:100034727	A/G	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.33	-0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.82	-0.45	1.54e-13	Breast cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15495717	chr6:34231501	NA	0.46	6.58	0.39	2.76e-10	Survival in pancreatic cancer;
KIRP	cis	rs8033133	0.560	rs1549478	chr15:25332200	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.42	-5.24	-0.32	3.45e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.71	-9.64	-0.52	7.55e-19	Personality dimensions;
KIRP	cis	rs1978968	0.763	rs5992136	chr22:18453103	G/C	cg02610425	chr22:18483192	MICAL3	0.36	5.41	0.33	1.5e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.58	0.44	6.97e-13	Tonsillectomy;
KIRP	cis	rs1519814	1.000	rs7000103	chr8:121166200	A/C	cg22335954	chr8:121166405	COL14A1	-0.66	-6.41	-0.38	7.38e-10	Breast cancer;
KIRP	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.28	-0.7	1.67e-37	Alzheimer's disease;
KIRP	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg23920097	chr1:209922102	NA	-0.42	-5.52	-0.33	8.62e-8	Red blood cell count;
KIRP	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.29	14.33	0.67	2.76e-34	Uric acid levels;
KIRP	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg24807547	chr6:37504484	NA	-0.62	-10.0	-0.54	5.65e-20	Cognitive performance;
KIRP	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg06289844	chr6:126071538	HEY2	0.45	6.71	0.39	1.33e-10	Brugada syndrome;
KIRP	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg00857998	chr1:205179979	DSTYK	0.6	7.57	0.43	7.71e-13	Red blood cell count;
KIRP	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg14983838	chr19:29218262	NA	0.73	7.06	0.41	1.66e-11	Methadone dose in opioid dependence;
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg02462569	chr6:150064036	NUP43	-0.33	-4.92	-0.3	1.56e-6	Lung cancer;
KIRP	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg10047753	chr17:41438598	NA	1.12	17.65	0.75	1.31e-45	Menopause (age at onset);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05466223	chr11:17158572	PIK3C2A	0.47	7.89	0.45	1.01e-13	C-reactive protein;
KIRP	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06481639	chr22:41940642	POLR3H	0.66	6.93	0.4	3.66e-11	Vitiligo;
KIRP	cis	rs4363385	0.510	rs7541328	chr1:152894142	C/G	cg25856811	chr1:152973957	SPRR3	-0.4	-5.54	-0.33	7.78e-8	Inflammatory skin disease;
KIRP	cis	rs918629	0.798	rs2548595	chr5:95284341	C/T	cg16656078	chr5:95278638	ELL2	-0.44	-6.38	-0.38	8.81e-10	IgG glycosylation;
KIRP	cis	rs7188697	0.922	rs28307	chr16:58577138	A/C	cg21335942	chr16:58549945	SETD6	0.45	4.95	0.3	1.4e-6	QT interval;
KIRP	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.73	8.96	0.5	8.52e-17	Mammographic density (dense area);
KIRP	trans	rs909341	0.810	rs2427529	chr20:62359564	T/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.91	-0.4	4.06e-11	Atopic dermatitis;
KIRP	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-6.89	-0.4	4.6e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11264213	0.786	rs72659702	chr1:36317471	G/C	cg27506609	chr1:36549197	TEKT2	1.01	5.59	0.34	5.87e-8	Schizophrenia;
KIRP	cis	rs7845219	0.555	rs1129152	chr8:95888307	C/T	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.26	-0.37	1.71e-9	Type 2 diabetes;
KIRP	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg18944383	chr4:111397179	ENPEP	0.41	6.36	0.38	1e-9	Coronary artery disease;
KIRP	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs829661	0.793	rs1470536	chr2:30868277	C/A	cg10949345	chr2:30726833	LCLAT1	1.02	12.77	0.63	5.49e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs4589502	1.000	rs2414925	chr15:67129986	A/G	cg12317470	chr15:67143691	NA	0.64	5.32	0.32	2.34e-7	Lung cancer (smoking interaction);
KIRP	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg10047753	chr17:41438598	NA	1.16	19.33	0.78	2.89e-51	Menopause (age at onset);
KIRP	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.18	-0.31	4.58e-7	Testicular germ cell tumor;
KIRP	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.15	0.37	3.09e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs8141529	0.529	rs35017742	chr22:29216585	C/T	cg02153584	chr22:29168773	CCDC117	0.55	4.87	0.3	2.01e-6	Lymphocyte counts;
KIRP	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-8.92	-0.49	1.06e-16	Platelet count;
KIRP	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg26513180	chr16:89883248	FANCA	0.58	7.58	0.43	7.17e-13	Vitiligo;
KIRP	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.94	-16.16	-0.72	1.6e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11605924	0.792	rs10838524	chr11:45870177	A/G	cg23097878	chr11:45879730	CRY2	0.3	6.12	0.36	3.68e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs10411936	0.608	rs7259642	chr19:16601926	C/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.5	0.33	9.52e-8	White blood cell count;Multiple sclerosis;
KIRP	cis	rs10518128	1.000	rs114810099	chr4:75708771	T/A	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg10433463	chr1:1889099	KIAA1751	0.39	5.8	0.35	2.01e-8	Body mass index;
KIRP	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.45	5.28	0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg04025307	chr7:1156635	C7orf50	0.56	6.71	0.39	1.3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.6	7.19	0.42	7.79e-12	Colorectal cancer;
KIRP	cis	rs35264875	1.000	rs72919428	chr11:68828949	C/T	cg23845249	chr11:68861649	NA	0.56	8.01	0.45	4.71e-14	Blond vs. brown hair color;
KIRP	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg23166289	chr1:210001082	C1orf107	0.41	5.03	0.31	9.56e-7	Orofacial clefts;
KIRP	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.36	4.94	0.3	1.48e-6	Coronary artery disease;
KIRP	cis	rs73206853	0.764	rs55887805	chr12:110597246	T/C	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs920590	0.796	rs7820505	chr8:19634829	A/G	cg03894339	chr8:19674705	INTS10	-0.48	-5.66	-0.34	4.28e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs11825064	0.725	rs77025955	chr11:134489259	C/A	cg06603561	chr11:134479413	NA	-0.66	-5.05	-0.31	8.62e-7	Seasonality;
KIRP	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg02297831	chr4:17616191	MED28	0.49	5.68	0.34	3.69e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg23594656	chr7:65796392	TPST1	0.5	7.69	0.44	3.45e-13	Aortic root size;
KIRP	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg13615516	chr5:77269221	NA	0.48	7.58	0.44	7.24e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.87	-16.14	-0.72	1.91e-40	Body mass index;
KIRP	cis	rs6738627	0.861	rs6713419	chr2:165508300	A/G	cg03182029	chr2:165697222	COBLL1	0.38	4.93	0.3	1.55e-6	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.75	-10.17	-0.54	1.65e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.44	5.44	0.33	1.27e-7	Aortic root size;
KIRP	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg06637938	chr14:75390232	RPS6KL1	0.44	5.94	0.35	9.51e-9	Height;
KIRP	cis	rs11673344	0.518	rs73033134	chr19:38086947	G/T	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.43	-0.33	1.34e-7	Obesity-related traits;
KIRP	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.67	-0.44	4.02e-13	Height;
KIRP	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.71	6.67	0.39	1.7e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg10254082	chr7:997346	NA	0.47	4.96	0.3	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs300890	0.513	rs7435424	chr4:144124278	T/C	cg01719995	chr4:144104893	USP38	0.4	5.19	0.31	4.35e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg23335576	chr14:104009727	NA	0.36	5.08	0.31	7.41e-7	Body mass index;
KIRP	cis	rs9815354	0.812	rs12108049	chr3:41958161	A/G	cg03022575	chr3:42003672	ULK4	0.8	8.68	0.48	5.58e-16	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.59	8.2	0.46	1.34e-14	Mean corpuscular volume;
KIRP	cis	rs12049351	0.719	rs10916499	chr1:229641078	T/G	cg11742688	chr1:229674241	ABCB10	-0.38	-5.9	-0.35	1.19e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg12486944	chr17:80159399	CCDC57	0.38	5.2	0.31	4.13e-7	Life satisfaction;
KIRP	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.65	-9.0	-0.5	6.47e-17	Colorectal cancer;
KIRP	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg20637307	chr2:213403960	ERBB4	0.55	7.53	0.43	9.9e-13	Symmetrical dimethylarginine levels;
KIRP	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.69	-9.26	-0.51	1.07e-17	Dental caries;
KIRP	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs7640424	0.649	rs17233248	chr3:107899513	T/C	cg09227934	chr3:107805635	CD47	-0.36	-6.11	-0.36	3.85e-9	Body mass index;
KIRP	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg00147788	chr6:125855365	NA	-0.32	-5.02	-0.3	9.97e-7	Brugada syndrome;
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg12486944	chr17:80159399	CCDC57	0.39	5.28	0.32	2.9e-7	Life satisfaction;
KIRP	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg24130564	chr14:104152367	KLC1	-0.52	-7.0	-0.41	2.38e-11	Body mass index;
KIRP	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg25019722	chr6:37503610	NA	-0.95	-15.32	-0.7	1.18e-37	Cognitive performance;
KIRP	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.84	-11.02	-0.58	3.15e-23	Obesity-related traits;
KIRP	cis	rs12101261	0.580	rs3783949	chr14:81448382	A/C	cg06600135	chr14:81408086	NA	0.38	4.99	0.3	1.13e-6	Graves' disease;
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs6593803	0.805	rs11576092	chr1:147198761	C/T	cg27546670	chr1:147246839	GJA5	-0.54	-5.78	-0.35	2.29e-8	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.21	0.37	2.19e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-7.46	-0.43	1.46e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg23625390	chr15:77176239	SCAPER	-0.49	-6.56	-0.39	3.1e-10	Blood metabolite levels;
KIRP	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26306683	chr17:18585705	ZNF286B	0.6	7.53	0.43	9.6e-13	Educational attainment (years of education);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17447240	chr7:557606	PDGFA	0.44	6.36	0.38	9.75e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.57	8.04	0.46	3.75e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg21077578	chr7:1022970	CYP2W1	0.36	4.96	0.3	1.32e-6	Longevity;Endometriosis;
KIRP	cis	rs4742903	0.875	rs7041529	chr9:106991539	G/A	cg14250997	chr9:106856677	SMC2	0.38	5.07	0.31	7.93e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg16141378	chr3:129829833	LOC729375	-0.56	-7.35	-0.42	2.87e-12	Myopia (pathological);
KIRP	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.69	7.91	0.45	8.48e-14	Monocyte count;
KIRP	cis	rs60871478	0.635	rs4725122	chr7:785318	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.53	4.89	0.3	1.78e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.04	0.54	4.36e-20	Total body bone mineral density;
KIRP	cis	rs9834373	0.853	rs13322529	chr3:78495795	A/G	cg06138941	chr3:78371609	NA	-0.37	-4.86	-0.3	2.06e-6	Protein quantitative trait loci;
KIRP	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	10.45	0.55	2.19e-21	Hip circumference;
KIRP	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg20991723	chr1:152506922	NA	-0.45	-5.42	-0.33	1.39e-7	Hair morphology;
KIRP	trans	rs28595532	0.641	rs72670220	chr4:119300053	A/G	cg26518628	chr1:97050305	NA	-0.81	-6.13	-0.36	3.42e-9	Cannabis dependence symptom count;
KIRP	cis	rs9937943	0.616	rs12923487	chr16:74644112	G/T	cg01733217	chr16:74700730	RFWD3	0.61	5.49	0.33	9.81e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs1712517	0.873	rs7913461	chr10:105001325	A/G	cg05636881	chr10:105038444	INA	0.44	6.36	0.38	9.69e-10	Migraine;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg15128208	chr22:42549153	NA	0.37	4.89	0.3	1.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs12517041	0.873	rs6886748	chr5:23307271	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.75	-0.44	2.49e-13	Calcium levels;
KIRP	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.46	-0.38	5.54e-10	Bipolar disorder;
KIRP	cis	rs6714788	0.503	rs2309748	chr2:100681449	A/T	cg22139774	chr2:100720529	AFF3	-0.3	-4.84	-0.3	2.26e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.46	6.61	0.39	2.32e-10	Sitting height ratio;
KIRP	cis	rs748404	0.518	rs2927085	chr15:43989530	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.51	6.2	0.37	2.34e-9	Lung cancer;
KIRP	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.17e-16	Motion sickness;
KIRP	cis	rs2415984	0.622	rs61993302	chr14:46949684	C/T	cg14871534	chr14:47121158	RPL10L	-0.41	-5.07	-0.31	7.83e-7	Number of children ever born;
KIRP	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.77	-0.4	9.53e-11	Morning vs. evening chronotype;
KIRP	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg17724175	chr1:150552817	MCL1	0.38	6.55	0.39	3.35e-10	Tonsillectomy;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.64	8.02	0.46	4.35e-14	Menarche (age at onset);
KIRP	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg09455208	chr3:40491958	NA	0.36	6.43	0.38	6.63e-10	Renal cell carcinoma;
KIRP	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg00074818	chr8:8560427	CLDN23	-0.42	-6.3	-0.37	1.38e-9	Obesity-related traits;
KIRP	cis	rs4975616	0.843	rs6866783	chr5:1312020	T/C	cg06550200	chr5:1325588	CLPTM1L	0.79	10.29	0.55	6.8e-21	Lung cancer;
KIRP	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg19743168	chr1:23544995	NA	0.65	9.34	0.51	5.97e-18	Height;
KIRP	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg07001201	chr5:642380	CEP72	0.68	6.1	0.36	4.08e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg04865290	chr3:52927548	TMEM110	-0.66	-7.01	-0.41	2.22e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg02023728	chr11:77925099	USP35	0.41	6.72	0.39	1.23e-10	Testicular germ cell tumor;
KIRP	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	6.5	0.38	4.47e-10	Height;
KIRP	cis	rs9614461	0.609	rs9614653	chr22:45767391	A/G	cg13318129	chr22:45737514	FAM118A	-0.59	-7.24	-0.42	5.57e-12	Tonsillectomy;
KIRP	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg05756136	chr1:119680316	WARS2	-0.62	-8.36	-0.47	4.76e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg21014159	chr11:117668035	DSCAML1	0.36	5.36	0.32	1.88e-7	Myopia;
KIRP	cis	rs501120	0.584	rs674746	chr10:44733522	A/T	cg09554077	chr10:44749378	NA	0.7	7.78	0.44	2.03e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-4.89	-0.3	1.8e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.57	7.3	0.42	3.86e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.45	-5.54	-0.33	7.67e-8	P wave terminal force;
KIRP	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.69	10.36	0.55	4.13e-21	Pulse pressure;
KIRP	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg26811252	chr16:29126840	RRN3P2	0.47	6.31	0.37	1.31e-9	Menopause (age at onset);
KIRP	cis	rs10814247	0.592	rs10972499	chr9:35514700	A/T	cg15271616	chr9:35490515	RUSC2	0.42	5.05	0.31	8.62e-7	Psoriasis;
KIRP	trans	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.18	-0.42	8.42e-12	Bladder cancer;
KIRP	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.47	6.15	0.36	3.16e-9	Platelet count;
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.68	-9.49	-0.52	2.17e-18	Longevity;
KIRP	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.42	-6.27	-0.37	1.62e-9	Coronary artery disease;
KIRP	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.64	-5.99	-0.36	7.58e-9	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.48	-6.13	-0.36	3.52e-9	Motion sickness;
KIRP	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg21395723	chr22:39101663	GTPBP1	-0.45	-5.95	-0.35	9.06e-9	Menopause (age at onset);
KIRP	cis	rs11881751	0.568	rs10404611	chr19:5035136	C/T	cg04571196	chr19:4910051	UHRF1	0.47	5.26	0.32	3.07e-7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	8.1	0.46	2.48e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1434579	0.897	rs2037903	chr19:44945136	G/A	cg15540054	chr19:45004280	ZNF180	0.52	5.64	0.34	4.61e-8	Tuberculosis;
KIRP	cis	rs698833	0.508	rs698765	chr2:44573671	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.26	0.37	1.7e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg22307029	chr19:49891270	CCDC155	0.72	9.2	0.51	1.56e-17	Multiple sclerosis;
KIRP	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg01304814	chr3:48885189	PRKAR2A	0.61	5.25	0.32	3.24e-7	Cognitive function;
KIRP	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg00999904	chr2:3704751	ALLC	-0.42	-4.87	-0.3	2.01e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.88	-13.74	-0.66	2.98e-32	Height;
KIRP	cis	rs8177876	0.749	rs75923695	chr16:81093894	T/C	cg08591886	chr16:81111003	C16orf46	-0.7	-5.65	-0.34	4.46e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.41	0.38	7.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg01238044	chr22:24384105	GSTT1	-0.63	-8.1	-0.46	2.59e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.71	9.78	0.53	2.71e-19	Height;
KIRP	cis	rs2230307	0.536	rs564938	chr1:100592901	T/C	cg24955406	chr1:100503596	HIAT1	-0.67	-7.5	-0.43	1.15e-12	Carotid intima media thickness;
KIRP	cis	rs1950626	0.833	rs12891189	chr14:101415523	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.83	0.4	6.72e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg23682824	chr7:23144976	KLHL7	0.48	5.74	0.34	2.71e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03553434	chr21:38790111	DYRK1A	-0.4	-6.21	-0.37	2.27e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.93	5.08	0.31	7.54e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg26876637	chr1:152193138	HRNR	-0.77	-8.77	-0.49	3.09e-16	Atopic dermatitis;
KIRP	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.82	11.88	0.6	4.97e-26	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24710309	chr1:235423736	ARID4B	-0.41	-6.41	-0.38	7.24e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg10523679	chr1:76189770	ACADM	-0.48	-6.65	-0.39	1.93e-10	Daytime sleep phenotypes;
KIRP	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	6.56	0.39	3.2e-10	Schizophrenia;
KIRP	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23281280	chr6:28129359	ZNF389	0.47	5.01	0.3	1.03e-6	Parkinson's disease;
KIRP	cis	rs6142102	0.649	rs4911382	chr20:32553095	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.75	0.34	2.67e-8	Skin pigmentation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27543672	chr1:84541035	NA	-0.4	-6.12	-0.36	3.7e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.6	6.97	0.41	2.88e-11	Schizophrenia;
KIRP	cis	rs12143943	0.934	rs4951406	chr1:204554603	A/G	cg20240347	chr1:204465584	NA	-0.36	-6.66	-0.39	1.82e-10	Cognitive performance;
KIRP	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.97	9.84	0.53	1.73e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3755132	1.000	rs16862788	chr2:15725850	G/C	cg12888861	chr2:15731646	DDX1	0.39	4.95	0.3	1.38e-6	Wilms tumor;
KIRP	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.44	5.64	0.34	4.75e-8	Response to temozolomide;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.62	-7.86	-0.45	1.23e-13	Longevity;
KIRP	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	trans	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg11693508	chr17:37793320	STARD3	0.83	8.23	0.46	1.12e-14	Neuroticism;
KIRP	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg22437258	chr11:111473054	SIK2	-0.56	-6.15	-0.36	3.13e-9	Primary sclerosing cholangitis;
KIRP	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-6.68	-0.39	1.54e-10	Gut microbiome composition (summer);
KIRP	cis	rs6832769	1.000	rs6812042	chr4:56396079	A/C	cg09317128	chr4:56265301	TMEM165	0.53	6.8	0.4	8.04e-11	Personality dimensions;
KIRP	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.57	0.33	6.68e-8	Skin colour saturation;
KIRP	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.29	0.37	1.44e-9	Homocysteine levels;
KIRP	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.4	-5.97	-0.36	8.37e-9	Height;
KIRP	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21643547	chr1:205240462	TMCC2	-0.87	-14.77	-0.69	9.12e-36	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg22676075	chr6:135203613	NA	0.48	6.98	0.41	2.76e-11	Red blood cell count;
KIRP	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.49	-6.44	-0.38	6.21e-10	Hemoglobin concentration;
KIRP	cis	rs9653442	0.545	rs1821827	chr2:100764717	T/C	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs17789174	0.953	rs11149708	chr16:85104919	T/G	cg01715842	chr16:85045600	ZDHHC7	-0.44	-5.5	-0.33	9.62e-8	Dysphagia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27120934	chr6:129480619	LAMA2	-0.5	-7.2	-0.42	7.39e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs687432	0.774	rs17152376	chr11:57884929	A/T	cg19752551	chr11:57585705	CTNND1	-0.64	-8.23	-0.46	1.09e-14	Parkinson's disease;
KIRP	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6256	1.000	rs11022872	chr11:13564845	C/T	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs9400467	0.506	rs12207199	chr6:111525906	G/A	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs926938	0.520	rs6660624	chr1:115272163	G/A	cg12756093	chr1:115239321	AMPD1	-0.83	-11.55	-0.59	6e-25	Autism;
KIRP	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.35	5.47	0.33	1.09e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs17123764	1.000	rs17123764	chr12:49947952	C/T	cg02054252	chr12:50078554	FMNL3	0.5	5.01	0.3	1.05e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03352830	chr11:487213	PTDSS2	0.76	6.11	0.36	3.81e-9	Body mass index;
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg23736307	chr8:27182930	PTK2B	0.52	6.69	0.39	1.52e-10	Neuroticism;
KIRP	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.68	8.73	0.49	3.88e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06481639	chr22:41940642	POLR3H	-0.49	-5.4	-0.33	1.55e-7	Vitiligo;
KIRP	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	1.06	20.38	0.79	9.63e-55	Height;
KIRP	cis	rs2415984	0.622	rs12435397	chr14:46940867	G/A	cg14871534	chr14:47121158	RPL10L	-0.41	-5.08	-0.31	7.44e-7	Number of children ever born;
KIRP	cis	rs992157	0.932	rs4672884	chr2:219182481	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.22	-0.37	2.08e-9	Colorectal cancer;
KIRP	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.84	-10.71	-0.56	3.25e-22	Parkinson's disease;
KIRP	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg22153407	chr1:230290089	GALNT2	0.35	4.92	0.3	1.58e-6	Coronary artery disease;
KIRP	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.98	13.38	0.65	4.78e-31	Vitamin D levels;
KIRP	cis	rs909341	0.868	rs2738758	chr20:62349625	C/G	cg11503966	chr20:62272292	STMN3	0.42	6.05	0.36	5.32e-9	Atopic dermatitis;
KIRP	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg01304814	chr3:48885189	PRKAR2A	0.62	5.29	0.32	2.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg19847130	chr8:10466454	RP1L1	0.36	5.29	0.32	2.69e-7	Triglycerides;
KIRP	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg05362011	chr13:21860987	NA	-0.47	-5.19	-0.31	4.45e-7	White matter hyperintensity burden;
KIRP	cis	rs909341	0.859	rs3208008	chr20:62326110	A/C	cg03999872	chr20:62272968	STMN3	0.56	6.58	0.39	2.79e-10	Atopic dermatitis;
KIRP	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.99	12.11	0.61	8.77e-27	Post bronchodilator FEV1;
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.54	-6.24	-0.37	1.95e-9	Menopause (age at onset);
KIRP	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.98	-0.36	7.96e-9	Type 2 diabetes;
KIRP	cis	rs732765	0.734	rs2270425	chr14:75179734	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.41	-5.04	-0.31	9.16e-7	Non-small cell lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15852879	chr9:132404411	ASB6	0.57	7.48	0.43	1.28e-12	Parkinson's disease;
KIRP	cis	rs212524	0.544	rs6665399	chr1:21553933	T/C	cg08890418	chr1:21044141	KIF17	0.39	5.77	0.35	2.4e-8	Height;
KIRP	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.9e-26	Heart rate;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12489547	chr11:15959637	NA	0.52	7.63	0.44	5.02e-13	Survival in pancreatic cancer;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg16978263	chr3:160118452	SMC4;IFT80	0.44	6.09	0.36	4.32e-9	Ischemic stroke;
KIRP	trans	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.36	0.47	4.69e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.64	7.41	0.43	2.03e-12	Bone mineral density;
KIRP	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg07952391	chr2:88470173	THNSL2	0.92	7.57	0.43	7.56e-13	Plasma clusterin levels;
KIRP	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg24315340	chr6:146058215	EPM2A	-0.43	-5.48	-0.33	1.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.51	-11.48	-0.59	1.04e-24	Diabetic kidney disease;
KIRP	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.67	-10.34	-0.55	4.86e-21	Heart rate;
KIRP	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.04	0.41	1.96e-11	Height;
KIRP	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg18944383	chr4:111397179	ENPEP	-0.53	-9.11	-0.5	3.05e-17	Coronary artery disease;
KIRP	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	1.04	16.87	0.73	6.04e-43	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Parkinson's disease;
KIRP	cis	rs10214930	0.813	rs2391445	chr7:27648871	C/G	cg22168087	chr7:27702803	HIBADH	0.51	5.09	0.31	7.04e-7	Hypospadias;
KIRP	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg11503966	chr20:62272292	STMN3	0.44	6.13	0.36	3.54e-9	Atopic dermatitis;
KIRP	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.73	7.31	0.42	3.78e-12	Bipolar disorder;
KIRP	cis	rs1978968	0.700	rs10854521	chr22:18482600	C/T	cg03078520	chr22:18463400	MICAL3	-0.64	-7.45	-0.43	1.58e-12	Presence of antiphospholipid antibodies;
KIRP	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg02002194	chr4:3960332	NA	0.42	6.04	0.36	5.53e-9	Retinal vascular caliber;
KIRP	cis	rs3824344	0.507	rs10814501	chr9:37019304	C/T	cg14294708	chr9:37120828	ZCCHC7	0.39	4.9	0.3	1.72e-6	Intelligence;
KIRP	cis	rs9443189	0.901	rs2038624	chr6:76560707	T/C	cg01950844	chr6:76311363	SENP6	-0.6	-5.72	-0.34	3.03e-8	Prostate cancer;
KIRP	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg08885076	chr2:99613938	TSGA10	-0.42	-6.4	-0.38	7.63e-10	Fear of minor pain;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14509437	chr2:37543814	PRKD3	0.39	6.18	0.37	2.66e-9	C-reactive protein;
KIRP	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.17	0.42	8.68e-12	Mean corpuscular volume;
KIRP	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	6.86	0.4	5.65e-11	Systemic lupus erythematosus;
KIRP	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg13798780	chr7:105162888	PUS7	0.66	6.1	0.36	4.09e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.14	-0.36	3.32e-9	Diastolic blood pressure;
KIRP	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.24	0.37	1.89e-9	Monocyte percentage of white cells;
KIRP	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.13	-0.41	1.14e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07570687	chr10:102243282	WNT8B	0.49	6.07	0.36	4.7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10802346	0.636	rs12133862	chr1:246389442	G/A	cg15962031	chr1:246363574	SMYD3	0.79	5.92	0.35	1.07e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.61	-9.04	-0.5	4.88e-17	Body mass index;
KIRP	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg13010199	chr12:38710504	ALG10B	-0.48	-6.09	-0.36	4.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg05315796	chr3:52349193	DNAH1	0.44	6.79	0.4	8.35e-11	Bipolar disorder;
KIRP	cis	rs62413470	1.000	rs12193911	chr6:55966889	A/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.9	10.36	0.55	4.15e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9810890	1.000	rs73198868	chr3:128529111	T/C	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs4936894	0.500	rs12280723	chr11:124075804	A/G	cg27160556	chr11:124181099	OR8D1	-0.4	-5.92	-0.35	1.09e-8	Aging (time to death);
KIRP	cis	rs1950626	0.743	rs12889283	chr14:101466001	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.55	5.94	0.35	9.63e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs17533156	0.954	rs73376341	chr17:75116150	C/T	cg11416367	chr17:75137675	SEC14L1	0.53	5.44	0.33	1.28e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12230513	0.632	rs59213907	chr12:55728911	A/T	cg19537932	chr12:55886519	OR6C68	-0.51	-6.55	-0.39	3.35e-10	Contrast sensitivity;
KIRP	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg26138937	chr11:71823887	C11orf51	-1.15	-8.03	-0.46	3.95e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.74	9.47	0.52	2.49e-18	Platelet count;
KIRP	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.62	-0.66	7.52e-32	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg09165964	chr15:75287851	SCAMP5	-0.94	-8.38	-0.47	4.2e-15	Lung cancer;
KIRP	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.91e-9	Response to antipsychotic treatment;
KIRP	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.43	0.33	1.37e-7	Morning vs. evening chronotype;
KIRP	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.94	-12.26	-0.62	2.82e-27	Platelet distribution width;
KIRP	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.9	-12.39	-0.62	1.04e-27	Intelligence (multi-trait analysis);
KIRP	trans	rs587242	1.000	rs12757248	chr1:96898294	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.65	7.83	0.45	1.45e-13	Multiple sclerosis;
KIRP	cis	rs7116495	1.000	rs116781589	chr11:71825006	G/T	cg26138937	chr11:71823887	C11orf51	0.7	5.55	0.33	7.4e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.48	5.61	0.34	5.32e-8	Multiple sclerosis;
KIRP	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.28	-5.52	-0.33	8.45e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14182682	chr14:57857589	NAA30	-0.51	-6.77	-0.4	9.4e-11	Survival in pancreatic cancer;
KIRP	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21643547	chr1:205240462	TMCC2	-0.82	-12.71	-0.63	8.37e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10500570	chr8:100549776	MIR599;VPS13B;MIR875	-0.93	-6.82	-0.4	6.88e-11	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg22963979	chr7:1858916	MAD1L1	0.63	9.2	0.51	1.62e-17	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg01721255	chr8:58191610	C8orf71	0.52	5.28	0.32	2.83e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.58	9.41	0.51	3.62e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.42	-4.97	-0.3	1.27e-6	P wave terminal force;
KIRP	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg05555928	chr11:63887634	MACROD1	-0.56	-5.12	-0.31	6.27e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.5e-21	Bone mineral density;
KIRP	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg27211696	chr2:191398769	TMEM194B	-0.6	-7.24	-0.42	5.8e-12	Diastolic blood pressure;
KIRP	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.66e-9	Colorectal cancer;
KIRP	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg24296786	chr1:45957014	TESK2	0.63	8.38	0.47	4.08e-15	High light scatter reticulocyte count;
KIRP	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.6	-6.95	-0.41	3.27e-11	Iron status biomarkers;
KIRP	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg18882449	chr10:104885122	NT5C2	-0.5	-6.41	-0.38	7.57e-10	Arsenic metabolism;
KIRP	cis	rs12823128	1.000	rs12823128	chr12:26872730	C/T	cg14081884	chr12:26986758	ITPR2	-0.43	-5.56	-0.33	6.93e-8	Birth weight;
KIRP	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg01616529	chr11:638424	DRD4	-0.37	-5.03	-0.31	9.43e-7	Systemic lupus erythematosus;
KIRP	cis	rs9488822	0.662	rs496311	chr6:116274730	A/G	cg15226275	chr6:116381976	FRK	0.22	5.94	0.35	9.83e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.82	0.53	1.98e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs2150410	0.833	rs9979547	chr21:40664438	T/C	cg11890956	chr21:40555474	PSMG1	0.81	5.66	0.34	4.28e-8	Temperament (bipolar disorder);
KIRP	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg15117754	chr3:10150083	C3orf24	0.51	5.09	0.31	7.1e-7	Alzheimer's disease;
KIRP	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.6	-6.61	-0.39	2.41e-10	Pancreatic cancer;
KIRP	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.05	-0.36	5.28e-9	Parkinson's disease;
KIRP	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.89	-13.79	-0.66	2.01e-32	Systemic lupus erythematosus;
KIRP	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.64	8.68	0.48	5.5e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15664640	chr17:80829946	TBCD	-0.9	-11.25	-0.58	5.98e-24	Breast cancer;
KIRP	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg09408571	chr1:101003634	GPR88	0.23	5.25	0.32	3.26e-7	Monocyte count;
KIRP	cis	rs259282	0.538	rs12151311	chr19:33112707	T/C	cg02997394	chr19:33096574	ANKRD27	-0.5	-5.01	-0.3	1.04e-6	Schizophrenia;
KIRP	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg21775007	chr8:11205619	TDH	-0.48	-6.2	-0.37	2.32e-9	Joint mobility (Beighton score);
KIRP	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.36	-5.14	-0.31	5.73e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg08738300	chr3:44038990	NA	0.69	9.74	0.53	3.69e-19	Coronary artery disease;
KIRP	cis	rs7215564	0.908	rs2873060	chr17:78663497	A/C	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs13095912	1.000	rs34965813	chr3:185333012	T/C	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.1e-11	Systolic blood pressure;
KIRP	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.22e-21	Alzheimer's disease (late onset);
KIRP	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.13e-12	Uric acid levels;
KIRP	trans	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg02002194	chr4:3960332	NA	-0.45	-6.56	-0.39	3.23e-10	Mood instability;
KIRP	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.44	5.66	0.34	4.27e-8	Body mass index;
KIRP	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.87	13.66	0.66	5.5e-32	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.63	8.71	0.49	4.47e-16	Lymphocyte counts;
KIRP	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21643547	chr1:205240462	TMCC2	-0.76	-11.64	-0.6	3.04e-25	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-0.84	-9.19	-0.51	1.74e-17	Gut microbiome composition (summer);
KIRP	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-9.9	-0.53	1.17e-19	Total body bone mineral density;
KIRP	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10207060	0.500	rs28540721	chr2:240714045	C/T	cg20333904	chr2:240724165	NA	-0.41	-4.85	-0.3	2.21e-6	Obesity-related traits;
KIRP	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.78	9.69	0.53	5.02e-19	Monocyte percentage of white cells;
KIRP	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.58	6.66	0.39	1.8e-10	HDL cholesterol;
KIRP	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg13607699	chr17:42295918	UBTF	0.49	6.06	0.36	5.16e-9	Total body bone mineral density;
KIRP	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.15	0.37	3.09e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg02591564	chr12:125578355	AACS	-0.5	-5.15	-0.31	5.47e-7	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.55	0.56	1.05e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.22	23.45	0.83	1.2e-64	Ulcerative colitis;
KIRP	cis	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg19680485	chr15:31195859	MTMR15	-0.55	-5.05	-0.31	8.44e-7	Hypertriglyceridemia;
KIRP	cis	rs12220238	0.722	rs10509350	chr10:76383071	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.53	-6.06	-0.36	5.15e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9296095	1.000	rs5745568	chr6:33548394	G/T	cg14003231	chr6:33640908	ITPR3	0.36	4.91	0.3	1.68e-6	Platelet count;
KIRP	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.51	-6.6	-0.39	2.53e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg23594656	chr7:65796392	TPST1	0.5	7.69	0.44	3.45e-13	Aortic root size;
KIRP	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg05785598	chr3:49045655	WDR6	0.27	4.9	0.3	1.77e-6	Parkinson's disease;
KIRP	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.83	-12.69	-0.63	1.01e-28	Blood metabolite levels;
KIRP	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.51	6.21	0.37	2.2e-9	Glycated hemoglobin levels;
KIRP	cis	rs3087591	0.537	rs75847291	chr17:29717854	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.68	-6.01	-0.36	6.68e-9	Hip circumference;
KIRP	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg10755058	chr3:40428713	ENTPD3	0.44	6.38	0.38	8.81e-10	Renal cell carcinoma;
KIRP	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.78e-7	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12997166	chr7:6048663	PMS2;AIMP2	0.52	6.46	0.38	5.48e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02322203	chr16:67464610	HSD11B2	0.43	6.14	0.36	3.27e-9	Parkinson's disease;
KIRP	cis	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg07797693	chr8:10454129	NA	0.34	4.92	0.3	1.6e-6	Neuroticism;
KIRP	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg15117754	chr3:10150083	C3orf24	0.64	5.2	0.31	4.13e-7	Alzheimer's disease;
KIRP	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.21	-0.46	1.23e-14	Personality dimensions;
KIRP	cis	rs4950322	0.570	rs72691041	chr1:146738743	G/A	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg11906718	chr8:101322791	RNF19A	0.65	8.29	0.47	7.25e-15	Atrioventricular conduction;
KIRP	cis	rs41005	1.000	rs41007	chr2:8109043	A/G	cg03155496	chr2:8117019	LOC339788	-0.6	-10.08	-0.54	3.25e-20	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.92	15.79	0.71	2.95e-39	Menarche (age at onset);
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg04804543	chr8:142233427	SLC45A4	-1.03	-17.9	-0.75	1.86e-46	Immature fraction of reticulocytes;
KIRP	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-1.08	-21.37	-0.81	5.39e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.58	6.94	0.4	3.54e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6496667	0.779	rs8035817	chr15:90974327	G/A	cg10434728	chr15:90938212	IQGAP1	0.38	5.0	0.3	1.07e-6	Rheumatoid arthritis;
KIRP	trans	rs2548003	0.518	rs2548015	chr5:28726109	A/C	cg12623145	chr2:97778927	ANKRD36	0.61	6.12	0.36	3.72e-9	Hip geometry;
KIRP	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-9.98	-0.54	6.44e-20	Blood trace element (Zn levels);
KIRP	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg04202892	chr2:111875749	ACOXL	0.46	6.5	0.38	4.4e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg18016565	chr1:150552671	MCL1	-0.36	-5.11	-0.31	6.5e-7	Melanoma;
KIRP	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.35	-0.38	1.03e-9	Coronary artery disease;
KIRP	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.02	-0.31	9.72e-7	Obesity-related traits;
KIRP	cis	rs1832871	0.965	rs1832872	chr6:158721813	G/A	cg07215822	chr6:158701037	NA	0.49	6.34	0.37	1.09e-9	Height;
KIRP	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.9	10.65	0.56	5.17e-22	Exhaled nitric oxide levels;
KIRP	cis	rs7215564	0.908	rs56078934	chr17:78658849	A/C	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	trans	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg06521331	chr12:34319734	NA	0.57	7.02	0.41	2.11e-11	Bladder cancer;
KIRP	cis	rs612683	0.536	rs1335753	chr1:101027157	G/T	cg09408571	chr1:101003634	GPR88	0.33	7.57	0.43	7.61e-13	Breast cancer;
KIRP	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.17	-0.31	4.85e-7	Pulmonary function;
KIRP	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.64	0.34	4.63e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.77	-14.31	-0.67	3.22e-34	Lymphocyte counts;
KIRP	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs6466055	0.777	rs11765899	chr7:104923002	T/C	cg04380332	chr7:105027541	SRPK2	0.63	9.49	0.52	2.13e-18	Schizophrenia;
KIRP	cis	rs57338032	0.891	rs2869048	chr15:78747568	A/G	cg06917634	chr15:78832804	PSMA4	0.56	4.98	0.3	1.17e-6	CTACK levels;
KIRP	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-5.77	-0.35	2.43e-8	Parkinson's disease;
KIRP	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	0.82	10.08	0.54	3.14e-20	Prostate cancer;
KIRP	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.22	0.61	3.68e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.69	-6.71	-0.39	1.37e-10	White matter integrity;
KIRP	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.66e-9	Colorectal cancer;
KIRP	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg19906672	chr4:6918868	TBC1D14	0.56	5.52	0.33	8.54e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs4764487	0.622	rs2268014	chr12:6325582	C/G	cg08284733	chr12:6341482	CD9	0.45	7.27	0.42	4.83e-12	Mean platelet volume;
KIRP	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs17381785	0.903	rs12640148	chr4:14919872	C/T	cg12377275	chr4:15005593	CPEB2	-0.55	-6.28	-0.37	1.54e-9	Urate levels in overweight individuals;
KIRP	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg01689657	chr7:91764605	CYP51A1	-0.43	-6.48	-0.38	4.93e-10	Breast cancer;
KIRP	cis	rs8103278	0.507	rs8112282	chr19:46265029	C/T	cg14061069	chr19:46274453	DMPK	0.67	11.63	0.6	3.3e-25	Coronary artery disease;
KIRP	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.69	8.75	0.49	3.44e-16	Monocyte count;
KIRP	cis	rs12906542	0.580	rs4509986	chr15:78267385	A/T	cg13940834	chr15:78236707	NA	-0.51	-6.41	-0.38	7.4e-10	Breast cancer;
KIRP	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.58	-0.48	1.07e-15	Retinal vascular caliber;
KIRP	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg15488143	chr7:128924101	AHCYL2	0.59	6.38	0.38	8.87e-10	White matter hyperintensity burden;
KIRP	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.76	6.16	0.37	2.88e-9	Diabetic retinopathy;
KIRP	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.92	0.3	1.56e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1335587	0.582	rs3916910	chr13:102108308	A/G	cg13538571	chr13:102108074	ITGBL1	-0.43	-5.38	-0.32	1.71e-7	Obesity-related traits;
KIRP	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10865541	0.967	rs6751808	chr2:3397377	A/G	cg11642891	chr2:3452563	TTC15	-0.5	-6.39	-0.38	8.18e-10	Obesity-related traits;
KIRP	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg24375607	chr4:120327624	NA	0.49	5.8	0.35	2.07e-8	Educational attainment;
KIRP	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	-0.82	-8.27	-0.47	8.26e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg15655495	chr12:38532458	NA	-0.29	-5.03	-0.31	9.42e-7	Bladder cancer;
KIRP	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg06386533	chr2:46925753	SOCS5	0.47	5.08	0.31	7.59e-7	Height;
KIRP	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.37	5.49	0.33	1e-7	Survival in rectal cancer;
KIRP	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg00981070	chr1:2046702	PRKCZ	-0.32	-5.52	-0.33	8.48e-8	Height;
KIRP	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.93	-0.4	3.7e-11	Initial pursuit acceleration;
KIRP	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.95	-10.19	-0.54	1.43e-20	Schizophrenia;
KIRP	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg22437258	chr11:111473054	SIK2	0.59	7.16	0.42	9.2e-12	Primary sclerosing cholangitis;
KIRP	cis	rs2665103	0.655	rs1501367	chr15:82522816	A/G	cg00614314	chr15:82944287	LOC80154	0.43	5.44	0.33	1.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	5.03	0.31	9.62e-7	Schizophrenia;
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.5	5.78	0.35	2.28e-8	Glycated hemoglobin levels;
KIRP	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg23594656	chr7:65796392	TPST1	-0.5	-7.81	-0.45	1.67e-13	Aortic root size;
KIRP	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.54	0.38	3.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg09764611	chr12:132620959	NA	-0.53	-5.16	-0.31	5.21e-7	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs9488822	0.585	rs195525	chr6:116248273	C/T	cg18764771	chr6:116381957	FRK	0.19	4.86	0.3	2.12e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27297192	chr10:134578999	INPP5A	0.57	7.17	0.42	8.88e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs75920871	0.623	rs11823889	chr11:116960403	G/A	cg04087571	chr11:116723030	SIK3	-0.27	-5.51	-0.33	9.09e-8	Subjective well-being;
KIRP	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg04607699	chr11:48328132	OR4S1	0.39	5.74	0.34	2.71e-8	Migraine - clinic-based;
KIRP	trans	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.65	7.12	0.41	1.2e-11	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.74	-0.34	2.71e-8	Life satisfaction;
KIRP	cis	rs1497828	0.912	rs1497832	chr1:217527626	A/G	cg04411442	chr1:217543379	NA	-0.3	-4.92	-0.3	1.57e-6	Dialysis-related mortality;
KIRP	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg03235661	chr20:60525775	NA	-0.31	-5.25	-0.32	3.37e-7	Body mass index;
KIRP	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.45	-0.38	6.05e-10	Coronary artery disease;
KIRP	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.68	9.3	0.51	8.18e-18	Morning vs. evening chronotype;
KIRP	cis	rs687432	0.774	rs61902763	chr11:57880437	C/T	cg19752551	chr11:57585705	CTNND1	-0.64	-8.2	-0.46	1.32e-14	Parkinson's disease;
KIRP	cis	rs7590368	0.748	rs72779478	chr2:10967124	C/T	cg15705551	chr2:10952987	PDIA6	0.64	5.51	0.33	8.87e-8	Educational attainment (years of education);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg25631650	chr19:633157	POLRMT	0.51	6.23	0.37	2.01e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.81	-10.28	-0.55	7.43e-21	Longevity;Endometriosis;
KIRP	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg21605333	chr4:119757512	SEC24D	1.56	10.56	0.56	9.77e-22	Cannabis dependence symptom count;
KIRP	cis	rs2548003	0.518	rs2548015	chr5:28726109	A/C	cg22863700	chr5:28928346	NA	0.61	6.29	0.37	1.43e-9	Hip geometry;
KIRP	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.54	-7.19	-0.42	7.78e-12	Red blood cell count;
KIRP	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.63	10.45	0.55	2.11e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.6	0.34	5.86e-8	Breast cancer;
KIRP	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.49	-5.8	-0.35	2.01e-8	Body mass index;
KIRP	cis	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg04990556	chr1:26633338	UBXN11	-0.68	-6.51	-0.38	4.08e-10	Obesity-related traits;
KIRP	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.56	8.21	0.46	1.23e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs11225247	0.772	rs10219215	chr11:102238237	C/T	cg06323957	chr11:102217781	BIRC2	0.79	5.61	0.34	5.47e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg20636351	chr8:55087400	NA	-0.53	-6.43	-0.38	6.74e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.6	7.29	0.42	4.25e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.56	7.62	0.44	5.65e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.62	7.9	0.45	9.04e-14	Longevity;Endometriosis;
KIRP	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg14972814	chr11:95582409	MTMR2	0.35	5.92	0.35	1.1e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.49	6.39	0.38	8.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	1.02	14.23	0.67	6.2e-34	Menopause (age at onset);
KIRP	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.73	9.52	0.52	1.7e-18	N-glycan levels;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	4.83e-8	Lung cancer;
KIRP	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-12.4	-0.62	9.5e-28	Electrocardiographic conduction measures;
KIRP	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.78	8.84	0.49	1.86e-16	Corneal astigmatism;
KIRP	trans	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg26384229	chr12:38710491	ALG10B	0.74	9.77	0.53	2.93e-19	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.22	-0.32	3.78e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.71	-8.69	-0.48	5.21e-16	Resting heart rate;
KIRP	cis	rs7119167	0.802	rs11235743	chr11:73124826	A/G	cg17517138	chr11:73019481	ARHGEF17	0.47	4.94	0.3	1.42e-6	Blood protein levels;
KIRP	cis	rs10267417	0.535	rs6956976	chr7:19869168	G/A	cg05791153	chr7:19748676	TWISTNB	0.56	5.36	0.32	1.93e-7	Night sleep phenotypes;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg11641102	chr8:27183873	PTK2B	0.45	5.94	0.35	9.86e-9	Neuroticism;
KIRP	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Bladder cancer;
KIRP	cis	rs963731	0.737	rs6544197	chr2:39315388	T/C	cg04010122	chr2:39346883	SOS1	-0.91	-6.45	-0.38	5.74e-10	Corticobasal degeneration;
KIRP	cis	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-5.5	-0.33	9.68e-8	Myopia (pathological);
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.61	5.7	0.34	3.41e-8	Alzheimer's disease;
KIRP	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.54	7.23	0.42	5.95e-12	Colorectal cancer;
KIRP	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.49	-0.38	4.8e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05464172	chr8:97247954	UQCRB	0.51	6.18	0.37	2.69e-9	Smoking initiation;
KIRP	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.76	-0.34	2.52e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02250992	chr12:125348168	SCARB1	0.4	6.07	0.36	4.94e-9	Cancer;
KIRP	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.64	7.64	0.44	4.8e-13	Testicular germ cell tumor;
KIRP	cis	rs2635047	0.699	rs2247578	chr18:44745056	A/G	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.01	-0.3	1.02e-6	Educational attainment;
KIRP	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.61	9.09	0.5	3.37e-17	Itch intensity from mosquito bite;
KIRP	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg21905437	chr5:178450457	ZNF879	0.57	6.67	0.39	1.64e-10	Pubertal anthropometrics;
KIRP	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-0.78	-8.81	-0.49	2.25e-16	Diastolic blood pressure;
KIRP	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.35	0.51	5.79e-18	Bladder cancer;
KIRP	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.65	-6.8	-0.4	7.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs830383	0.512	rs830386	chr5:165479749	A/C	cg13976338	chr5:165423657	NA	0.59	5.83	0.35	1.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg08999081	chr20:33150536	PIGU	0.47	6.21	0.37	2.29e-9	Height;
KIRP	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg18016565	chr1:150552671	MCL1	0.38	5.79	0.35	2.14e-8	Tonsillectomy;
KIRP	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.75	-9.7	-0.53	4.8e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg08807101	chr21:30365312	RNF160	-0.59	-5.77	-0.35	2.31e-8	Cognitive test performance;
KIRP	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg11502198	chr6:26597334	ABT1	-0.48	-6.07	-0.36	4.87e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.64	7.99	0.45	5.14e-14	Breast cancer;
KIRP	cis	rs6977660	0.619	rs12534026	chr7:19788687	T/C	cg05791153	chr7:19748676	TWISTNB	0.49	5.1	0.31	6.77e-7	Thyroid stimulating hormone;
KIRP	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg08603382	chr10:743973	NA	0.53	7.84	0.45	1.4e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.44	5.32	0.32	2.34e-7	Body mass index;
KIRP	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-6.98	-0.41	2.79e-11	Vitamin D levels;
KIRP	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg02151108	chr14:50098012	C14orf104	-0.54	-7.24	-0.42	5.88e-12	Carotid intima media thickness;
KIRP	cis	rs526231	0.543	rs62362521	chr5:102306061	G/A	cg23492399	chr5:102201601	PAM	-0.49	-5.39	-0.32	1.68e-7	Primary biliary cholangitis;
KIRP	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.84	-14.25	-0.67	5.37e-34	Heart rate;
KIRP	cis	rs16936870	0.543	rs7008415	chr8:71195191	C/T	cg14232793	chr8:71155543	NCOA2	0.54	6.3	0.37	1.35e-9	QT interval;
KIRP	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg11189052	chr15:85197271	WDR73	0.51	5.23	0.32	3.71e-7	Schizophrenia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20136959	chr13:49821950	CDADC1	-0.47	-6.03	-0.36	5.92e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22768531	chr19:49403500	NUCB1	0.47	6.54	0.38	3.48e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.45	5.89	0.35	1.28e-8	Height;
KIRP	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-6.44	-0.38	6.2e-10	Ulcerative colitis;
KIRP	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg09408571	chr1:101003634	GPR88	0.24	5.38	0.32	1.69e-7	Monocyte count;
KIRP	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.73	10.22	0.55	1.17e-20	Plateletcrit;Platelet count;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg14838017	chr1:160232450	DCAF8	0.95	6.15	0.37	3.11e-9	P wave terminal force;
KIRP	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg01879757	chr17:41196368	BRCA1	-0.73	-10.26	-0.55	8.77e-21	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04998420	chr1:153508511	S100A6	0.45	6.15	0.37	3.09e-9	Parkinson's disease;
KIRP	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.65	-9.98	-0.54	6.38e-20	Hepatocellular carcinoma;
KIRP	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2048656	0.523	rs6990300	chr8:9547861	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.48	-0.38	5.02e-10	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg05861140	chr6:150128134	PCMT1	-0.52	-7.23	-0.42	6.24e-12	Lung cancer;
KIRP	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg10792982	chr14:105748885	BRF1	0.96	15.25	0.7	2.12e-37	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg03289416	chr15:75166202	SCAMP2	0.53	7.25	0.42	5.35e-12	Breast cancer;
KIRP	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg24399712	chr22:39784796	NA	-0.64	-7.88	-0.45	1.07e-13	IgG glycosylation;
KIRP	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg12549451	chr6:135224345	NA	-0.47	-6.09	-0.36	4.42e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.57	8.12	0.46	2.22e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.75	0.44	2.41e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.4	-5.1	-0.31	6.9e-7	Renal function-related traits (BUN);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg20940459	chr1:173793922	CENPL;DARS2	1.12	7.64	0.44	4.69e-13	P wave terminal force;
KIRP	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.52	-6.19	-0.37	2.51e-9	Diastolic blood pressure;
KIRP	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg00405596	chr8:11794950	NA	-0.4	-4.94	-0.3	1.47e-6	Systolic blood pressure;
KIRP	cis	rs4253311	0.520	rs7687818	chr4:187122060	A/G	cg24794857	chr4:187113578	CYP4V2	0.38	5.39	0.33	1.64e-7	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
KIRP	cis	rs5753618	0.504	rs5753669	chr22:31905819	T/G	cg02404636	chr22:31891804	SFI1	0.56	6.55	0.39	3.35e-10	Colorectal cancer;
KIRP	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg17507749	chr15:85114479	UBE2QP1	0.84	9.71	0.53	4.36e-19	Schizophrenia;
KIRP	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-1.2	-12.93	-0.64	1.52e-29	Monocyte percentage of white cells;
KIRP	cis	rs7394190	0.748	rs11000728	chr10:75404300	C/G	cg04833713	chr10:74871078	NUDT13	0.49	5.63	0.34	4.83e-8	Incident atrial fibrillation;
KIRP	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg11189052	chr15:85197271	WDR73	0.52	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.38	-4.92	-0.3	1.59e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6466055	0.574	rs3087867	chr7:105028238	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.05	0.31	8.61e-7	Schizophrenia;
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg02696790	chr15:75250997	RPP25	0.32	5.57	0.33	6.74e-8	Breast cancer;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08808811	chr3:184079573	CLCN2	0.47	6.22	0.37	2.08e-9	Myopia (pathological);
KIRP	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.92	10.32	0.55	5.55e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs3739821	1.000	rs3739821	chr9:130702477	A/G	cg21181453	chr9:130700954	DPM2	0.47	6.97	0.41	2.83e-11	Glaucoma (primary angle closure);
KIRP	cis	rs11710088	0.740	rs73152645	chr3:149206096	A/G	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.11	-0.31	6.35e-7	QRS duration;
KIRP	cis	rs9547996	0.842	rs11147662	chr13:38213816	T/C	cg13634560	chr13:38173852	POSTN	-0.39	-5.51	-0.33	9.08e-8	Diastolic blood pressure;
KIRP	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.4	-0.33	1.57e-7	Bipolar disorder;
KIRP	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.31	6.32	0.37	1.24e-9	Schizophrenia;
KIRP	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.58	7.69	0.44	3.44e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.92	-0.35	1.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6032067	0.759	rs1007138	chr20:43816835	A/C	cg10761708	chr20:43804764	PI3	0.43	4.94	0.3	1.44e-6	Blood protein levels;
KIRP	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	9.25	0.51	1.11e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.56e-13	Coffee consumption (cups per day);
KIRP	cis	rs9653442	0.527	rs12712064	chr2:100756548	C/T	cg07810366	chr2:100720526	AFF3	-0.31	-5.1	-0.31	6.82e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg18225595	chr11:63971243	STIP1	0.65	5.98	0.36	7.85e-9	Mean platelet volume;
KIRP	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg21573476	chr21:45109991	RRP1B	-0.71	-10.71	-0.56	3.27e-22	Mean corpuscular volume;
KIRP	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17467752	chr17:38218738	THRA	-0.54	-6.87	-0.4	5.13e-11	White blood cell count;
KIRP	cis	rs970821	0.667	rs1030590	chr8:124754410	A/G	cg00283535	chr8:124749564	ANXA13	0.37	6.46	0.38	5.44e-10	Breast cancer;
KIRP	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.81	-11.18	-0.58	1.01e-23	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg07701084	chr6:150067640	NUP43	0.64	8.27	0.47	8.45e-15	Lung cancer;
KIRP	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg10845886	chr2:3471009	TTC15	-0.54	-7.87	-0.45	1.13e-13	Neurofibrillary tangles;
KIRP	cis	rs12493885	0.818	rs1713817	chr3:153872345	A/G	cg10247383	chr3:153839028	SGEF	-0.6	-5.07	-0.31	7.88e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs12496230	0.794	rs9813067	chr3:66862644	T/C	cg04995300	chr3:66848608	NA	0.45	6.8	0.4	8e-11	Type 2 diabetes;
KIRP	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg23594656	chr7:65796392	TPST1	-0.42	-5.81	-0.35	1.95e-8	Aortic root size;
KIRP	cis	rs7246657	0.663	rs4803287	chr19:38079435	A/G	cg18154014	chr19:37997991	ZNF793	0.55	5.87	0.35	1.37e-8	Coronary artery calcification;
KIRP	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.5	-6.86	-0.4	5.64e-11	Obesity-related traits;
KIRP	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.76	-0.34	2.52e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg09658497	chr7:2847517	GNA12	-0.37	-5.17	-0.31	4.75e-7	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10996014	chr3:49449848	RHOA;TCTA	0.5	6.69	0.39	1.51e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03951121	chr21:33673209	MRAP	-0.39	-6.03	-0.36	6.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12986413	0.874	rs4806832	chr19:2184652	C/T	cg09261902	chr19:2140048	AP3D1	0.63	9.54	0.52	1.49e-18	Height;
KIRP	cis	rs2172802	0.693	rs4860097	chr4:62482723	A/G	cg04118610	chr4:62707027	LPHN3	-0.52	-6.02	-0.36	6.26e-9	Partial epilepsies;
KIRP	cis	rs934734	0.563	rs11673987	chr2:65597671	A/G	cg08085232	chr2:65598271	SPRED2	-0.56	-7.23	-0.42	5.98e-12	Rheumatoid arthritis;
KIRP	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg03684893	chr10:554711	DIP2C	-0.49	-7.55	-0.43	8.38e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg03808351	chr9:123631620	PHF19	0.48	6.72	0.39	1.26e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg23594656	chr7:65796392	TPST1	0.44	6.04	0.36	5.76e-9	Aortic root size;
KIRP	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg16574807	chr4:6945745	TBC1D14	0.66	5.87	0.35	1.41e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.78	-8.75	-0.49	3.56e-16	Cholesterol, total;
KIRP	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.81	9.81	0.53	2.22e-19	Corneal astigmatism;
KIRP	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.58	6.6	0.39	2.51e-10	Vitiligo;
KIRP	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg19847130	chr8:10466454	RP1L1	0.42	6.13	0.36	3.47e-9	Joint mobility (Beighton score);
KIRP	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.37	-0.32	1.8e-7	Metabolite levels;
KIRP	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4523957	0.533	rs9899330	chr17:2185827	A/T	cg16513277	chr17:2031491	SMG6	-0.51	-5.79	-0.35	2.09e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.87	0.3	2.03e-6	Rheumatoid arthritis;
KIRP	cis	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg21775007	chr8:11205619	TDH	0.39	5.33	0.32	2.24e-7	Monocyte count;
KIRP	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.99	8.67	0.48	5.79e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg21479132	chr6:26055353	NA	-0.76	-4.88	-0.3	1.95e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6807915	0.603	rs7632481	chr3:12293966	A/G	cg02700894	chr3:12045449	SYN2	-0.43	-5.89	-0.35	1.27e-8	Leprosy;
KIRP	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs494562	1.000	rs495472	chr6:86117021	C/T	cg27039625	chr6:86159096	NT5E	0.45	5.78	0.35	2.28e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17554472	chr22:41940697	POLR3H	-0.58	-6.35	-0.38	1.01e-9	Vitiligo;
KIRP	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.49	-10.18	-0.54	1.52e-20	Rheumatoid arthritis;
KIRP	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.66	7.53	0.43	9.33e-13	Height;
KIRP	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.96	-0.45	6.48e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7116495	1.000	rs949325	chr11:71729656	A/G	cg18441811	chr11:71824068	C11orf51	-0.61	-4.91	-0.3	1.63e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg03060546	chr3:49711283	APEH	-0.58	-5.16	-0.31	5.17e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-1.08	-15.99	-0.71	6.3e-40	Menopause (age at onset);
KIRP	cis	rs255758	0.768	rs255750	chr5:53319475	C/T	cg22592108	chr5:53304441	ARL15	0.46	6.02	0.36	6.47e-9	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.48	-0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs3857747	0.578	rs4143205	chr7:40368296	A/G	cg00420559	chr7:40367873	C7orf10	-0.45	-6.55	-0.39	3.27e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.81	11.15	0.58	1.24e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12210905	0.688	rs72845027	chr6:27528199	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-5.83	-0.35	1.72e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.83	-11.64	-0.6	3.1e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg10223061	chr2:219282414	VIL1	-0.35	-5.83	-0.35	1.71e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg05941025	chr16:89927596	SPIRE2	0.32	5.12	0.31	6.29e-7	Vitiligo;
KIRP	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg04691961	chr3:161091175	C3orf57	-0.38	-5.28	-0.32	2.8e-7	Kawasaki disease;
KIRP	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.42	-5.23	-0.32	3.6e-7	Schizophrenia;
KIRP	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.38	-4.97	-0.3	1.23e-6	Mean platelet volume;
KIRP	cis	rs918959	0.793	rs16867353	chr2:181552816	A/T	cg04166432	chr2:181843717	UBE2E3	-0.7	-5.06	-0.31	8.28e-7	Systemic lupus erythematosus;
KIRP	cis	rs6547631	0.635	rs934774	chr2:85898143	G/T	cg07313956	chr2:85895360	SFTPB	0.42	6.15	0.37	3.09e-9	Blood protein levels;
KIRP	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.74	10.47	0.56	1.86e-21	Parkinson's disease;
KIRP	cis	rs1971762	1.000	rs916134	chr12:54069803	A/G	cg09709951	chr12:54017699	ATF7	0.42	5.33	0.32	2.18e-7	Height;
KIRP	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg23594656	chr7:65796392	TPST1	0.37	5.29	0.32	2.71e-7	Aortic root size;
KIRP	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg10818794	chr15:86012489	AKAP13	-0.48	-6.71	-0.39	1.35e-10	Interstitial lung disease;
KIRP	cis	rs7651039	0.641	rs6773682	chr3:15676426	G/A	cg16303742	chr3:15540471	COLQ	0.52	6.78	0.4	8.69e-11	Coronary heart disease;
KIRP	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.9	7.45	0.43	1.56e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg07274523	chr3:49395745	GPX1	0.72	8.48	0.48	2.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg10047753	chr17:41438598	NA	1.15	18.22	0.76	1.51e-47	Menopause (age at onset);
KIRP	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.52	-5.66	-0.34	4.1e-8	Neuroticism;
KIRP	cis	rs7572644	0.541	rs2839791	chr2:28232279	A/C	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-6.68	-0.39	1.55e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4356975	0.527	rs12643840	chr4:69947963	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.19	0.42	7.97e-12	Lung cancer;
KIRP	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg17133734	chr15:86042851	AKAP13	-0.46	-5.88	-0.35	1.36e-8	Coronary artery disease;
KIRP	cis	rs7760535	0.811	rs1002475	chr6:111709589	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.8	-0.35	1.98e-8	Metabolic traits;
KIRP	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	6.1	0.36	4.06e-9	Iron status biomarkers;
KIRP	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.9	-9.65	-0.52	6.95e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs62355272	0.965	rs11960511	chr5:35883241	A/G	cg13894535	chr5:35919491	CAPSL	-0.48	-5.7	-0.34	3.39e-8	Lymphocyte counts;
KIRP	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.37	5.09	0.31	6.97e-7	Neuroticism;
KIRP	cis	rs477692	0.549	rs7079744	chr10:131454790	G/A	cg24747557	chr10:131355152	MGMT	0.41	5.37	0.32	1.79e-7	Response to temozolomide;
KIRP	cis	rs35343117	1	rs35343117	chr15:86079115	C/G	cg15340431	chr15:86040528	AKAP13	-0.48	-6.05	-0.36	5.46e-9	Psoriasis;
KIRP	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg13482628	chr17:19912719	NA	-0.54	-7.0	-0.41	2.46e-11	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg03585969	chr10:35415529	CREM	0.79	9.51	0.52	1.78e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02773889	chr13:42615649	NA	0.48	6.18	0.37	2.69e-9	C-reactive protein;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03160445	chr3:100120349	LNP1;TOMM70A	0.49	6.03	0.36	5.98e-9	Asthma;
KIRP	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.29	0.51	8.51e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg17646820	chr3:66848679	NA	0.67	8.85	0.49	1.76e-16	Type 2 diabetes;
KIRP	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.83	-12.05	-0.61	1.35e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.46	5.81	0.35	1.89e-8	Blood metabolite levels;
KIRP	cis	rs2573652	0.755	rs6598286	chr15:100515985	G/T	cg09918751	chr15:100517450	ADAMTS17	-0.79	-13.32	-0.65	7.56e-31	Height;
KIRP	cis	rs9341835	0.740	rs4710255	chr6:64156268	A/C	cg03326410	chr6:64151739	NA	-0.39	-4.87	-0.3	1.96e-6	Schizophrenia;
KIRP	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.24	-24.47	-0.84	7.36e-68	Exhaled nitric oxide output;
KIRP	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg23100626	chr2:96804247	ASTL	0.51	7.82	0.45	1.52e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs73200209	0.703	rs73200247	chr12:116723069	T/A	cg01776926	chr12:116560359	MED13L	-0.55	-5.93	-0.35	1.04e-8	Total body bone mineral density;
KIRP	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.69	-8.74	-0.49	3.79e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs2296342	0.522	rs1536036	chr6:33632014	A/G	cg14003231	chr6:33640908	ITPR3	0.28	5.12	0.31	6.31e-7	Schizophrenia;
KIRP	cis	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg19847130	chr8:10466454	RP1L1	-0.34	-5.31	-0.32	2.5e-7	Neuroticism;
KIRP	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	9.21	0.51	1.51e-17	Cognitive test performance;
KIRP	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg26412358	chr1:26503933	CNKSR1	0.39	5.53	0.33	8.14e-8	Height;
KIRP	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.54	7.6	0.44	6.04e-13	Schizophrenia;
KIRP	cis	rs7246657	0.722	rs2927746	chr19:38156570	G/A	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg18357526	chr6:26021779	HIST1H4A	0.52	6.88	0.4	5.08e-11	Height;
KIRP	cis	rs9815354	1.000	rs9847975	chr3:41786904	A/G	cg03022575	chr3:42003672	ULK4	0.64	6.58	0.39	2.81e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs829661	0.688	rs10175399	chr2:30798133	T/G	cg10949345	chr2:30726833	LCLAT1	0.7	9.21	0.51	1.47e-17	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.64	-5.0	-0.3	1.1e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.23	0.32	3.56e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4478858	0.735	rs12404861	chr1:31861271	G/A	cg00250761	chr1:31883323	NA	-0.29	-4.85	-0.3	2.2e-6	Alcohol dependence;
KIRP	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18252515	chr7:66147081	NA	0.41	4.87	0.3	1.96e-6	Aortic root size;
KIRP	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.97	12.94	0.64	1.42e-29	Menopause (age at onset);
KIRP	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg18196295	chr10:418757	DIP2C	0.4	4.95	0.3	1.39e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs4671458	1.000	rs72813418	chr2:63385242	C/G	cg17519650	chr2:63277830	OTX1	-0.56	-5.58	-0.34	6.2e-8	Subjective well-being;
KIRP	cis	rs6690583	0.623	rs2083283	chr1:85439996	C/A	cg22153463	chr1:85462885	MCOLN2	0.62	5.16	0.31	5.1e-7	Serum sulfate level;
KIRP	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg19500275	chr17:80737654	TBCD	0.46	5.47	0.33	1.13e-7	Glycated hemoglobin levels;
KIRP	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	-0.47	-5.56	-0.33	7.01e-8	Glycated hemoglobin levels;
KIRP	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	8.53	0.48	1.52e-15	Acne (severe);
KIRP	trans	rs10486722	0.565	rs11766394	chr7:41758188	T/C	cg07952040	chr12:110562126	IFT81	-0.59	-6.2	-0.37	2.34e-9	Pit-and-Fissure caries;
KIRP	cis	rs9399401	0.961	rs2039986	chr6:142655238	G/A	cg03128060	chr6:142623767	GPR126	0.3	4.91	0.3	1.62e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs72934535	0.689	rs10176600	chr2:204402793	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.62	5.0	0.3	1.1e-6	Coronary artery disease;
KIRP	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg10935138	chr17:73851978	WBP2	0.59	7.72	0.44	2.98e-13	Psoriasis;
KIRP	cis	rs9890032	0.618	rs1979507	chr17:29138020	A/T	cg13385521	chr17:29058706	SUZ12P	0.45	5.23	0.32	3.57e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.54	-6.75	-0.4	1.07e-10	Urate levels in overweight individuals;
KIRP	cis	rs28489187	0.660	rs2207368	chr1:85847683	A/G	cg16011679	chr1:85725395	C1orf52	0.53	6.52	0.38	3.88e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16104446	chr8:48873951	MCM4;PRKDC	0.6	7.13	0.41	1.09e-11	Smoking initiation;
KIRP	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg27205649	chr11:78285834	NARS2	-0.62	-7.36	-0.42	2.72e-12	Alzheimer's disease (survival time);
KIRP	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.88	8.66	0.48	6.43e-16	Fibroblast growth factor basic levels;
KIRP	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00889227	chr1:205173544	DSTYK	-0.37	-5.23	-0.32	3.66e-7	Red blood cell count;
KIRP	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.81	0.4	7.47e-11	Acne (severe);
KIRP	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg26513180	chr16:89883248	FANCA	0.84	14.04	0.67	2.78e-33	Vitiligo;
KIRP	cis	rs73200209	0.744	rs11615877	chr12:116709800	C/T	cg01776926	chr12:116560359	MED13L	-0.57	-6.3	-0.37	1.33e-9	Total body bone mineral density;
KIRP	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11987759	chr7:65425863	GUSB	-0.67	-9.32	-0.51	7.04e-18	Aortic root size;
KIRP	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.53	-6.2	-0.37	2.38e-9	HDL cholesterol;
KIRP	cis	rs876084	0.505	rs11985173	chr8:121107511	G/A	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12482755	chr19:12902295	JUNB	-0.6	-6.56	-0.39	3.18e-10	Menopause (age at onset);
KIRP	cis	rs11638352	0.661	rs2706492	chr15:44423846	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-4.92	-0.3	1.59e-6	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg17691542	chr6:26056736	HIST1H1C	0.49	6.43	0.38	6.49e-10	Height;
KIRP	cis	rs10988449	1.000	rs41276768	chr9:132371226	A/T	cg18327994	chr9:132372705	NA	-0.58	-5.36	-0.32	1.94e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs228437	0.657	rs9402619	chr6:134910055	A/C	cg24504307	chr6:134963096	NA	-0.33	-5.29	-0.32	2.73e-7	Melanoma;
KIRP	trans	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.27e-12	Bladder cancer;
KIRP	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.18	0.54	1.5e-20	Coffee consumption (cups per day);
KIRP	cis	rs11169552	0.510	rs4768852	chr12:50960289	A/C	cg12884762	chr12:50931848	DIP2B	-0.42	-4.98	-0.3	1.21e-6	Colorectal cancer;
KIRP	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg21573476	chr21:45109991	RRP1B	-0.59	-8.31	-0.47	6.41e-15	Mean corpuscular volume;
KIRP	cis	rs9443645	0.527	rs9718121	chr6:79729887	T/A	cg11833968	chr6:79620685	NA	-0.34	-4.94	-0.3	1.45e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.42	7.11	0.41	1.29e-11	Renal cell carcinoma;
KIRP	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	9.41	0.51	3.63e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg09904177	chr6:26538194	HMGN4	-0.44	-5.82	-0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs8063160	0.935	rs73283859	chr16:90062520	G/C	cg07984980	chr16:89898383	SPIRE2	1.07	5.86	0.35	1.48e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.85	8.3	0.47	7.08e-15	Large artery stroke;
KIRP	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg08392591	chr16:89556376	ANKRD11	0.5	6.93	0.4	3.67e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.59	-6.08	-0.36	4.65e-9	Body mass index;
KIRP	cis	rs2235573	0.789	rs4821733	chr22:38449394	A/G	cg19171272	chr22:38449367	NA	0.7	11.81	0.6	8.22e-26	Glioblastoma;Glioma;
KIRP	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.12	0.41	1.15e-11	Aortic root size;
KIRP	cis	rs6690583	0.623	rs2028304	chr1:85488030	G/A	cg22153463	chr1:85462885	MCOLN2	-0.61	-5.29	-0.32	2.7e-7	Serum sulfate level;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.78	6.52	0.38	4.06e-10	Body mass index;
KIRP	cis	rs10214930	0.697	rs2391443	chr7:27625929	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.71	7.1	0.41	1.31e-11	Lymphocyte counts;
KIRP	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-1.05	-14.44	-0.68	1.2e-34	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27140938	chr4:25235459	PI4K2B	0.52	6.62	0.39	2.19e-10	Parkinson's disease;
KIRP	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.97	-9.66	-0.52	6.2800000000000005e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.3	-7.07	-0.41	1.58e-11	Mean corpuscular volume;
KIRP	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.67	8.9	0.49	1.29e-16	Morning vs. evening chronotype;
KIRP	cis	rs490234	0.702	rs2416964	chr9:128360413	C/T	cg14078157	chr9:128172775	NA	-0.58	-6.79	-0.4	8.47e-11	Mean arterial pressure;
KIRP	cis	rs11203032	0.831	rs11203018	chr10:90948783	T/C	cg16672925	chr10:90967113	CH25H	0.78	8.07	0.46	3.2e-14	Heart failure;
KIRP	cis	rs10129255	0.500	rs12101190	chr14:107192386	C/T	cg23076370	chr14:107095027	NA	-0.4	-4.87	-0.3	2e-6	Kawasaki disease;
KIRP	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg20701182	chr2:24300061	SF3B14	0.63	5.35	0.32	1.98e-7	Birth weight;
KIRP	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.75	10.04	0.54	4.33e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs35000415	0.938	rs10488631	chr7:128594183	T/C	cg19972273	chr7:128594194	NA	0.85	6.25	0.37	1.81e-9	Systemic lupus erythematosus;
KIRP	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg03806693	chr22:41940476	POLR3H	-0.54	-5.67	-0.34	4.01e-8	Neuroticism;
KIRP	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.88	-14.97	-0.69	1.89e-36	Breast cancer;
KIRP	cis	rs427941	0.872	rs56077916	chr7:101842569	C/T	cg06246474	chr7:101738831	CUX1	0.43	5.03	0.31	9.51e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.62	5.52	0.33	8.47e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg05714579	chr10:131428358	MGMT	-0.49	-6.32	-0.37	1.21e-9	Response to temozolomide;
KIRP	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.0	-20.63	-0.8	1.45e-55	Myeloid white cell count;
KIRP	cis	rs7084402	0.565	rs1982173	chr10:60334002	G/T	cg05938607	chr10:60274200	BICC1	-0.37	-8.05	-0.46	3.44e-14	Refractive error;
KIRP	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-8.3	-0.47	7.03e-15	Morning vs. evening chronotype;
KIRP	cis	rs6973256	0.897	rs4731970	chr7:133326602	C/T	cg10665199	chr7:133106180	EXOC4	-0.52	-6.6	-0.39	2.57e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.94	-7.59	-0.44	6.61e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18252515	chr7:66147081	NA	-0.47	-5.76	-0.34	2.48e-8	Aortic root size;
KIRP	cis	rs6838801	0.823	rs7677054	chr4:77594463	A/C	cg17476223	chr4:77663285	SHROOM3	0.56	8.08	0.46	2.86e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs11264213	0.901	rs688833	chr1:36455600	C/T	cg27506609	chr1:36549197	TEKT2	0.96	10.29	0.55	7.02e-21	Schizophrenia;
KIRP	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs17065868	1.000	rs9595144	chr13:45107333	C/G	cg10246903	chr13:45222710	NA	0.64	7.02	0.41	2.17e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.56	-0.43	8.17e-13	Type 2 diabetes;
KIRP	cis	rs71277158	0.624	rs61493476	chr3:169887831	C/A	cg04067573	chr3:169899625	PHC3	0.64	5.93	0.35	1e-8	Prostate cancer;
KIRP	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg01689657	chr7:91764605	CYP51A1	0.48	7.15	0.41	1.02e-11	Breast cancer;
KIRP	cis	rs793571	0.590	rs673813	chr15:59077171	A/T	cg05156742	chr15:59063176	FAM63B	0.61	7.79	0.44	1.84e-13	Schizophrenia;
KIRP	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg16141378	chr3:129829833	LOC729375	-0.53	-6.75	-0.4	1.07e-10	Neuroticism;
KIRP	trans	rs13170463	0.579	rs71606010	chr5:8042776	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg12046867	chr14:103022105	NA	0.6	7.76	0.44	2.29e-13	Platelet count;
KIRP	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg00376283	chr12:123451042	ABCB9	-0.6	-5.31	-0.32	2.51e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22168489	chr12:122356033	WDR66	-0.63	-9.44	-0.52	3.07e-18	Mean corpuscular volume;
KIRP	cis	rs7084402	0.967	rs1649037	chr10:60331135	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.55	-0.56	1.03e-21	Refractive error;
KIRP	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	4.97	0.3	1.26e-6	Diabetic retinopathy;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg02733842	chr7:1102375	C7orf50	-0.48	-4.97	-0.3	1.28e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs2048656	0.524	rs13270518	chr8:9536713	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.3	-0.37	1.37e-9	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs9469913	0.740	rs2744937	chr6:34557246	C/T	cg14254433	chr6:34482411	PACSIN1	-0.45	-5.55	-0.33	7.5e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.41	5.69	0.34	3.55e-8	Endometrial cancer;
KIRP	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-7.25	-0.42	5.28e-12	Cognitive test performance;
KIRP	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26002218	chr14:103986227	CKB	0.29	5.73	0.34	2.94e-8	Body mass index;
KIRP	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	7.92	0.45	8.32e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs16857609	0.628	rs1478592	chr2:218346107	T/C	cg15335768	chr2:218268053	DIRC3	-0.39	-5.69	-0.34	3.54e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.96	14.49	0.68	8.28e-35	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg04691961	chr3:161091175	C3orf57	0.46	6.76	0.4	9.74e-11	Morning vs. evening chronotype;
KIRP	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	0.84	9.64	0.52	7.31e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg19847130	chr8:10466454	RP1L1	0.38	5.61	0.34	5.49e-8	Retinal vascular caliber;
KIRP	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.48	6.25	0.37	1.79e-9	Blood protein levels;
KIRP	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.17	18.84	0.77	1.29e-49	Ulcerative colitis;
KIRP	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg23307798	chr14:103986281	CKB	-0.76	-12.67	-0.63	1.22e-28	Bone mineral density;
KIRP	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.24	0.37	1.86e-9	Rheumatoid arthritis;
KIRP	cis	rs2733310	0.842	rs1657937	chr15:57112054	G/C	cg13626582	chr15:57592083	LOC283663	-0.23	-5.09	-0.31	7.07e-7	Mean platelet volume;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs2072732	0.861	rs55873718	chr1:2940012	A/G	cg11731671	chr1:2995604	PRDM16	-0.44	-5.26	-0.32	3.1e-7	Plateletcrit;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14128259	chr12:27848523	REP15	0.44	6.29	0.37	1.41e-9	Survival in pancreatic cancer;
KIRP	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg11584989	chr19:19387371	SF4	0.41	5.26	0.32	3.11e-7	Tonsillectomy;
KIRP	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg24879335	chr3:133465180	TF	0.43	6.73	0.39	1.16e-10	Iron status biomarkers (transferrin levels);
KIRP	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg02390115	chr1:21767211	NBPF3	0.65	9.35	0.51	5.59e-18	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-0.96	-15.32	-0.7	1.22e-37	Height;
KIRP	cis	rs539514	0.690	rs1924214	chr13:76317632	A/G	cg04757411	chr13:76259545	LMO7	-0.35	-4.87	-0.3	1.98e-6	Type 1 diabetes;
KIRP	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg06115741	chr20:33292138	TP53INP2	-0.36	-4.91	-0.3	1.63e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs698833	0.886	rs2304770	chr2:44569328	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.01	0.36	6.68e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs6684428	0.536	rs6588591	chr1:56402956	A/G	cg11651538	chr1:56320950	NA	-0.54	-7.45	-0.43	1.59e-12	Airflow obstruction;
KIRP	cis	rs12714314	0.560	rs7355555	chr2:1946646	A/C	cg20846728	chr2:1843184	MYT1L	-0.36	-5.8	-0.35	2e-8	Type 2 diabetes (age of onset);
KIRP	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.7	-7.27	-0.42	4.9e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22092082	chr2:191184568	HIBCH	0.48	6.29	0.37	1.41e-9	Parkinson's disease;
KIRP	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.58	5.7	0.34	3.36e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1570884	0.684	rs7326825	chr13:50113450	G/A	cg11801959	chr13:50123613	RCBTB1	-0.35	-4.85	-0.3	2.22e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6504622	0.875	rs28553405	chr17:45045895	A/G	cg24703533	chr17:45055318	NA	0.39	5.56	0.33	7.03e-8	Orofacial clefts;
KIRP	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.24	0.42	5.56e-12	Bipolar disorder;
KIRP	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08711118	chr3:126327472	TXNRD3IT1	0.56	6.86	0.4	5.6e-11	Interleukin-4 levels;
KIRP	cis	rs259842	0.759	rs165379	chr2:180692742	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.56	-0.33	6.87e-8	Blood protein levels;
KIRP	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.18	-0.54	1.51e-20	Response to antipsychotic treatment;
KIRP	cis	rs258892	1.000	rs26577	chr5:72299039	C/T	cg21869765	chr5:72125136	TNPO1	-0.51	-6.23	-0.37	2.04e-9	Small cell lung carcinoma;
KIRP	cis	rs714027	0.585	rs73162764	chr22:30358745	G/A	cg01021169	chr22:30184971	ASCC2	-0.4	-4.9	-0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.71	-0.39	1.36e-10	Renal cell carcinoma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19741408	chr1:90460434	ZNF326;LOC492303	0.53	6.22	0.37	2.17e-9	Smoking initiation;
KIRP	trans	rs263063	1.000	rs263063	chr19:5022604	T/C	cg21100077	chr13:100627366	NA	-0.91	-6.21	-0.37	2.18e-9	Periodontitis (CDC/AAP);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13880412	chr4:186041022	NA	-0.39	-6.2	-0.37	2.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.59	8.69	0.48	5.34e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.66	-7.09	-0.41	1.42e-11	Corneal structure;
KIRP	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg02570527	chr1:10970165	NA	0.42	5.09	0.31	7.16e-7	Body mass index;
KIRP	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.79	-0.35	2.17e-8	Colorectal cancer;
KIRP	cis	rs2742417	0.935	rs2742442	chr3:45748599	T/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg03060546	chr3:49711283	APEH	-0.64	-6.65	-0.39	1.83e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	1.29	8.99	0.5	6.76e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.61	7.77	0.44	2.09e-13	Homocysteine levels;
KIRP	cis	rs2658782	0.547	rs4344448	chr11:93047047	T/C	cg15737290	chr11:93063684	CCDC67	1.1	14.96	0.69	2.02e-36	Pulmonary function decline;
KIRP	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg08975724	chr8:8085496	FLJ10661	0.7	9.44	0.52	2.99e-18	Mood instability;
KIRP	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.44	6.47	0.38	5.22e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs7712401	0.601	rs40818	chr5:122295073	T/C	cg19412675	chr5:122181750	SNX24	0.45	4.95	0.3	1.35e-6	Mean platelet volume;
KIRP	cis	rs3736485	0.966	rs11634039	chr15:51895575	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.15	-0.31	5.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	0.76	6.39	0.38	8.29e-10	Fat distribution (HIV);
KIRP	cis	rs35995292	0.534	rs2392607	chr7:38930380	G/A	cg19327137	chr7:38886074	VPS41	0.82	12.86	0.63	2.73e-29	Subjective well-being (multi-trait analysis);
KIRP	cis	rs7091068	0.532	rs1018634	chr10:95401292	G/A	cg20715218	chr10:95462985	C10orf4	-0.58	-6.69	-0.39	1.51e-10	Urinary tract infection frequency;
KIRP	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg15839431	chr19:19639596	YJEFN3	0.54	5.46	0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg03887218	chr1:16534349	ARHGEF19	0.58	7.76	0.44	2.27e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg22437258	chr11:111473054	SIK2	0.58	6.79	0.4	8.51e-11	Primary sclerosing cholangitis;
KIRP	cis	rs78487399	0.808	rs6728106	chr2:43683885	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.77	-0.35	2.42e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4664304	0.789	rs2063439	chr2:160800101	C/A	cg23995753	chr2:160760732	LY75	-0.38	-4.85	-0.3	2.22e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg10223061	chr2:219282414	VIL1	0.31	5.01	0.3	1.06e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08436643	chr17:73257657	MRPS7;GGA3	0.51	6.24	0.37	1.93e-9	Parkinson's disease;
KIRP	cis	rs918629	0.724	rs10515232	chr5:95310985	A/G	cg16656078	chr5:95278638	ELL2	0.5	7.32	0.42	3.6e-12	IgG glycosylation;
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.86	14.15	0.67	1.17e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.51	-7.27	-0.42	4.91e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.62	-0.34	5.13e-8	Crohn's disease;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.59	8.12	0.46	2.3e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg05072774	chr3:49840536	C3orf54	0.43	5.47	0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4704187	0.687	rs4295370	chr5:74528858	G/T	cg03227963	chr5:74354835	NA	0.4	5.85	0.35	1.6e-8	Response to amphetamines;
KIRP	cis	rs6545883	0.929	rs778154	chr2:61646631	T/C	cg15711740	chr2:61764176	XPO1	0.62	8.02	0.46	4.26e-14	Tuberculosis;
KIRP	cis	rs12431939	0.626	rs7350715	chr14:51717060	C/A	cg23942311	chr14:51606299	NA	0.46	5.16	0.31	5.06e-7	Cancer;
KIRP	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg09904177	chr6:26538194	HMGN4	0.53	6.89	0.4	4.7e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-9.16	-0.5	2.11e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg05425664	chr17:57184151	TRIM37	0.45	5.04	0.31	9.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg21253087	chr9:139290292	SNAPC4	0.39	4.88	0.3	1.9e-6	Monocyte percentage of white cells;
KIRP	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.52	6.54	0.39	3.44e-10	Coronary heart disease;
KIRP	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.88	-0.6	5.1e-26	Eye color traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09254361	chr3:52008107	ABHD14B;ABHD14A	-0.45	-6.08	-0.36	4.64e-9	Metabolic traits;
KIRP	cis	rs11235843	0.602	rs1830069	chr11:73433229	C/G	cg18195628	chr11:73498948	MRPL48	-0.49	-5.06	-0.31	8.29e-7	Hand grip strength;
KIRP	cis	rs1886644	0.700	rs10493758	chr1:85349184	C/T	cg08479277	chr1:85350632	LPAR3	0.42	5.14	0.31	5.57e-7	Glucose homeostasis traits;
KIRP	cis	rs7851660	0.844	rs907581	chr9:100622189	A/G	cg13688889	chr9:100608707	NA	-0.69	-8.99	-0.5	6.83e-17	Strep throat;
KIRP	cis	rs10073892	0.660	rs13172780	chr5:101985792	A/G	cg19774478	chr5:101632501	SLCO4C1	0.54	5.53	0.33	8.24e-8	Cognitive decline (age-related);
KIRP	trans	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg17145862	chr1:211918768	LPGAT1	-0.55	-6.92	-0.4	3.89e-11	Leprosy;
KIRP	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	6.13	0.36	3.53e-9	Height;
KIRP	cis	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs4566357	0.930	rs13398295	chr2:227926873	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg00738919	chr7:1100172	C7orf50	0.42	4.97	0.3	1.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12681366	0.663	rs2919662	chr8:95470272	C/A	cg13257157	chr8:95487014	RAD54B	0.41	5.05	0.31	8.78e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.37	5.27	0.32	2.98e-7	Calcium levels;
KIRP	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg00898013	chr13:113819073	PROZ	-0.54	-5.96	-0.36	8.61e-9	Platelet distribution width;
KIRP	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.45	6.04	0.36	5.55e-9	Dupuytren's disease;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg09699651	chr6:150184138	LRP11	0.45	6.15	0.37	3.06e-9	Lung cancer;
KIRP	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.54	-6.09	-0.36	4.22e-9	Menarche (age at onset);
KIRP	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.78	-10.5	-0.56	1.5e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4762326	1.000	rs4471514	chr12:95667337	C/T	cg07737802	chr12:95537812	FGD6	0.46	6.43	0.38	6.51e-10	Endometriosis;
KIRP	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg26022315	chr17:47021804	SNF8	0.44	5.69	0.34	3.57e-8	Type 2 diabetes;
KIRP	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg06042504	chr8:55087323	NA	-0.54	-6.69	-0.39	1.5e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.73	7.19	0.42	7.61e-12	Menarche (age at onset);
KIRP	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.57	-6.15	-0.36	3.15e-9	Gut microbiome composition (summer);
KIRP	trans	rs2048656	0.540	rs55868514	chr8:9680400	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.07	-0.46	3.12e-14	Schizophrenia;
KIRP	trans	rs12517041	1.000	rs10052994	chr5:23292784	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.49	-0.33	9.99e-8	Blood metabolite levels;
KIRP	cis	rs7666738	0.546	rs2098935	chr4:98914376	A/G	cg05340658	chr4:99064831	C4orf37	0.67	7.99	0.45	5.36e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs1062177	0.855	rs919263	chr5:151265853	A/G	cg00977110	chr5:151150581	G3BP1	0.56	5.86	0.35	1.47e-8	Preschool internalizing problems;
KIRP	cis	rs2742234	0.955	rs2075913	chr10:43622368	T/A	cg02780029	chr10:43622663	RET	-0.37	-5.45	-0.33	1.22e-7	Hirschsprung disease;
KIRP	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg12384639	chr17:618140	VPS53	0.46	5.88	0.35	1.34e-8	Prostate cancer;
KIRP	cis	rs3741798	0.901	rs61922024	chr12:12485881	C/A	cg08615371	chr12:12503544	MANSC1	0.94	8.28	0.47	7.84e-15	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00557709	chr1:82268801	LPHN2	-0.48	-6.04	-0.36	5.56e-9	Interleukin-4 levels;
KIRP	cis	rs4356975	0.522	rs7434332	chr4:69964859	G/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs12210905	1.000	rs9368493	chr6:27228300	T/G	cg11502198	chr6:26597334	ABT1	-0.73	-4.99	-0.3	1.14e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.48	-0.56	1.68e-21	Triglycerides;
KIRP	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.79	7.49	0.43	1.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.02	-0.5	5.56e-17	Retinal vascular caliber;
KIRP	cis	rs8018808	0.935	rs6574372	chr14:77906295	T/G	cg18872420	chr14:78023429	SPTLC2	0.37	5.39	0.33	1.61e-7	Myeloid white cell count;
KIRP	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg12595281	chr15:93633172	RGMA	0.46	5.35	0.32	1.98e-7	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
KIRP	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.66	9.6	0.52	1e-18	Dupuytren's disease;
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg01324507	chr7:1177794	C7orf50	0.55	4.96	0.3	1.32e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12826209	chr6:26865740	GUSBL1	0.73	8.69	0.48	5.32e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg12549451	chr6:135224345	NA	-0.47	-5.88	-0.35	1.33e-8	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1005224	1.000	rs1981898	chr14:76175565	C/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-4.86	-0.3	2.05e-6	Large artery stroke;
KIRP	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	trans	rs11634944	0.676	rs220028	chr15:25201037	C/T	cg10471437	chr16:28074462	GSG1L	0.49	6.18	0.37	2.61e-9	Interleukin-8 levels;
KIRP	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.54	7.96	0.45	6.29e-14	Monocyte percentage of white cells;
KIRP	cis	rs9400467	0.508	rs1676863	chr6:111641590	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-5.21	-0.32	3.92e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.46	5.4	0.33	1.58e-7	Glycated hemoglobin levels;
KIRP	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-6.85	-0.4	5.96e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg26207909	chr14:103986467	CKB	0.39	5.01	0.3	1.06e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00268518	chr11:71164106	NADSYN1	-0.46	-6.23	-0.37	2.02e-9	Metabolic traits;
KIRP	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg10189774	chr4:17578691	LAP3	0.52	6.39	0.38	8.35e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg24315340	chr6:146058215	EPM2A	0.39	4.93	0.3	1.5e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.6	6.2	0.37	2.34e-9	DNA methylation (variation);
KIRP	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.47	-0.38	5.39e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-1.04	-11.47	-0.59	1.09e-24	Type 2 diabetes nephropathy;
KIRP	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	5.23	0.32	3.6e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1570884	0.684	rs7326825	chr13:50113450	G/A	cg03651054	chr13:50194643	NA	0.63	8.93	0.49	9.96e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg08807892	chr2:162101083	NA	0.43	5.24	0.32	3.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.74	9.57	0.52	1.21e-18	Psoriasis;
KIRP	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg00031303	chr3:195681400	NA	0.7	7.92	0.45	8.35e-14	Pancreatic cancer;
KIRP	cis	rs2067663	0.786	rs661311	chr5:88034867	T/C	cg18498987	chr5:88179539	MEF2C	-0.39	-5.07	-0.31	7.98e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7551222	0.752	rs4951393	chr1:204489557	A/C	cg20240347	chr1:204465584	NA	0.43	8.19	0.46	1.45e-14	Schizophrenia;
KIRP	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6993770	0.661	rs1868649	chr8:106517865	G/A	cg12797828	chr8:106520928	ZFPM2	-0.34	-5.0	-0.3	1.07e-6	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
KIRP	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.49	6.72	0.39	1.24e-10	Height;
KIRP	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.63	8.8	0.49	2.45e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.29	-0.51	8.48e-18	Mean corpuscular volume;
KIRP	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg22705602	chr4:152727874	NA	0.54	9.22	0.51	1.36e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.78	10.98	0.57	4.24e-23	Adiponectin levels;
KIRP	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg22138327	chr13:27999177	GTF3A	0.91	6.95	0.4	3.31e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.08	0.46	2.96e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs3026101	0.671	rs8081481	chr17:5282763	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.88	0.35	1.3e-8	Body mass index;
KIRP	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg02378861	chr5:212933	CCDC127	-0.68	-5.63	-0.34	4.9e-8	Fat distribution (HIV);
KIRP	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg13147721	chr7:65941812	NA	1.03	7.48	0.43	1.28e-12	Diabetic kidney disease;
KIRP	cis	rs4414128	0.832	rs2386648	chr10:5680914	T/A	cg12223502	chr10:5658492	NA	0.48	5.44	0.33	1.26e-7	Breast cancer;
KIRP	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.46	10.01	0.54	5.15e-20	Mean corpuscular volume;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg16721845	chr11:68518800	MTL5	-0.42	-6.02	-0.36	6.17e-9	Myopia;
KIRP	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.44	6.58	0.39	2.79e-10	Major depressive disorder;
KIRP	cis	rs687432	0.851	rs6591444	chr11:57724059	G/A	cg19752551	chr11:57585705	CTNND1	-0.54	-7.64	-0.44	4.78e-13	Parkinson's disease;
KIRP	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.56	-8.7	-0.48	4.99e-16	Obesity-related traits;
KIRP	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg00106254	chr7:1943704	MAD1L1	-0.6	-6.57	-0.39	2.98e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9409565	1.000	rs9409565	chr9:97251034	C/T	cg04523069	chr9:97136363	HIATL1	0.43	5.75	0.34	2.7e-8	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg18016565	chr1:150552671	MCL1	0.36	5.58	0.34	6.34e-8	Urate levels;
KIRP	cis	rs2219968	0.962	rs13254874	chr8:78944681	T/C	cg00738934	chr8:78996279	NA	0.39	5.04	0.31	9.24e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.43	0.38	6.54e-10	Breast cancer;
KIRP	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.26	-0.78	5.05e-51	Schizophrenia;
KIRP	cis	rs9972944	0.756	rs7222229	chr17:63765025	T/G	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.66	7.54	0.43	9.16e-13	Corneal astigmatism;
KIRP	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.34	-5.77	-0.35	2.36e-8	Height;
KIRP	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.79	-11.99	-0.61	2.2e-26	Lymphocyte counts;
KIRP	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19524238	chr7:2802976	GNA12	-0.39	-5.33	-0.32	2.24e-7	Height;
KIRP	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.62	9.13	0.5	2.52e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	12.24	0.62	3.19e-27	Platelet count;
KIRP	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg03714773	chr7:91764589	CYP51A1	0.38	5.44	0.33	1.27e-7	Breast cancer;
KIRP	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.52	-6.49	-0.38	4.57e-10	Menopause (age at onset);
KIRP	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg22676075	chr6:135203613	NA	0.49	6.95	0.41	3.3e-11	Red blood cell count;
KIRP	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.76	7.71	0.44	3.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-13.02	-0.64	8.07e-30	Headache;
KIRP	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg03342759	chr3:160939853	NMD3	0.45	5.45	0.33	1.21e-7	Morning vs. evening chronotype;
KIRP	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	6.84	0.4	6.19e-11	Platelet count;
KIRP	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg22604316	chr1:46958801	NA	0.42	6.25	0.37	1.77e-9	Monobrow;
KIRP	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-11.45	-0.59	1.33e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.69	-9.96	-0.54	7.7e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1448094	0.791	rs61929394	chr12:86331541	C/A	cg00310523	chr12:86230176	RASSF9	0.41	6.43	0.38	6.75e-10	Major depressive disorder;
KIRP	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.32	5.08	0.31	7.61e-7	Testicular germ cell tumor;
KIRP	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11800013	chr3:100119718	LNP1;TOMM70A	-0.49	-6.4	-0.38	7.9e-10	Myopia;
KIRP	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg15674680	chr20:60982522	CABLES2	0.42	5.1	0.31	6.89e-7	Colorectal cancer;
KIRP	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg17376030	chr22:41985996	PMM1	0.59	6.22	0.37	2.08e-9	Vitiligo;
KIRP	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg16497661	chr14:103986332	CKB	0.78	11.88	0.6	4.93e-26	Body mass index;
KIRP	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg04998671	chr14:104000505	TRMT61A	-0.54	-6.38	-0.38	8.83e-10	Coronary artery disease;
KIRP	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	0.92	7.22	0.42	6.47e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg08454507	chr17:78755406	RPTOR	-0.31	-4.99	-0.3	1.15e-6	Myopia (pathological);
KIRP	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.76	-11.38	-0.59	2.12e-24	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.6	9.27	0.51	9.91e-18	Personality dimensions;
KIRP	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs830383	0.554	rs11960198	chr5:165510433	C/T	cg13976338	chr5:165423657	NA	-0.51	-5.69	-0.34	3.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6088813	1.000	rs735531	chr20:33947730	T/C	cg14752227	chr20:34000481	UQCC	-0.52	-6.91	-0.4	4.24e-11	Height;
KIRP	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	1.1	14.15	0.67	1.17e-33	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg26554054	chr8:600488	NA	0.77	5.77	0.35	2.43e-8	IgG glycosylation;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.63	-8.9	-0.49	1.23e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7178909	0.872	rs3867167	chr15:90433790	T/C	cg19708238	chr15:90437601	AP3S2	0.55	7.54	0.43	8.95e-13	Common traits (Other);
KIRP	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg00982548	chr2:198649783	BOLL	-0.6	-5.5	-0.33	9.46e-8	Ulcerative colitis;
KIRP	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.8	-0.49	2.44e-16	Blood metabolite levels;
KIRP	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	5.29	0.32	2.7e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs13034020	0.690	rs13014803	chr2:61167216	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.6	4.92	0.3	1.6e-6	Hodgkin's lymphoma;
KIRP	cis	rs1978968	0.912	rs12157484	chr22:18455122	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-7.01	-0.41	2.26e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs2274273	0.588	rs2297816	chr14:55833038	A/G	cg04306507	chr14:55594613	LGALS3	0.39	5.35	0.32	2.02e-7	Protein biomarker;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-11.82	-0.6	7.98e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01003382	chr2:60777624	BCL11A	-0.47	-6.17	-0.37	2.86e-9	Myopia;
KIRP	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg10189774	chr4:17578691	LAP3	0.44	5.39	0.32	1.67e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22117172	chr7:91764530	CYP51A1	0.48	6.67	0.39	1.66e-10	Breast cancer;
KIRP	cis	rs9810890	1.000	rs114431655	chr3:128459173	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg01689657	chr7:91764605	CYP51A1	-0.41	-6.04	-0.36	5.79e-9	Breast cancer;
KIRP	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg25019722	chr6:37503610	NA	-0.74	-8.81	-0.49	2.24e-16	Cognitive performance;
KIRP	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg02367723	chr1:46378857	MAST2	0.44	5.08	0.31	7.63e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.9	-0.49	1.25e-16	Personality dimensions;
KIRP	trans	rs2391285	0.503	rs1557988	chr7:26601316	C/T	cg18745279	chr15:93580022	NA	-0.46	-6.15	-0.37	3.11e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.12	-0.41	1.16e-11	Neuroticism;
KIRP	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg26681399	chr22:41777847	TEF	-0.5	-4.95	-0.3	1.37e-6	Vitiligo;
KIRP	cis	rs911119	0.908	rs8121147	chr20:23601708	T/C	cg16589663	chr20:23618590	CST3	0.56	5.6	0.34	5.7e-8	Chronic kidney disease;
KIRP	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.46	-6.06	-0.36	5.11e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.74	0.34	2.71e-8	Blood protein levels;
KIRP	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.33	-7.28	-0.42	4.51e-12	Cutaneous nevi;
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg14221460	chr8:27183342	PTK2B	0.52	6.74	0.39	1.11e-10	Neuroticism;
KIRP	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg10053473	chr17:62856997	LRRC37A3	0.65	8.06	0.46	3.31e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg08885076	chr2:99613938	TSGA10	0.59	10.21	0.55	1.25e-20	Chronic sinus infection;
KIRP	cis	rs13361707	1.000	rs10074991	chr5:40790551	C/T	cg01087697	chr5:40835557	RPL37	-0.44	-5.11	-0.31	6.52e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg23335576	chr14:104009727	NA	-0.35	-4.93	-0.3	1.49e-6	Bone mineral density;
KIRP	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01737828	chr15:75230659	COX5A	0.48	6.24	0.37	1.89e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Colorectal cancer;
KIRP	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg15147215	chr3:52552868	STAB1	-0.35	-6.08	-0.36	4.57e-9	Electroencephalogram traits;
KIRP	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2019216	1.000	rs3751916	chr17:21909270	T/C	cg22648282	chr17:21454238	C17orf51	-0.39	-5.17	-0.31	4.76e-7	Pelvic organ prolapse;
KIRP	cis	rs6539288	0.589	rs1037013	chr12:107219308	A/G	cg15890332	chr12:107067104	RFX4	0.34	5.91	0.35	1.13e-8	Total body bone mineral density;
KIRP	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.9	13.19	0.64	2.16e-30	Bladder cancer;
KIRP	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.51	-5.88	-0.35	1.31e-8	Metabolite levels;
KIRP	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.53	6.2	0.37	2.34e-9	Aortic root size;
KIRP	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg11845111	chr2:191398756	TMEM194B	0.93	10.01	0.54	5.07e-20	Diastolic blood pressure;
KIRP	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg17507749	chr15:85114479	UBE2QP1	-0.81	-8.44	-0.47	2.75e-15	Schizophrenia;
KIRP	cis	rs7870753	0.628	rs10820598	chr9:99189255	A/G	cg25260653	chr9:99212216	HABP4	0.56	5.69	0.34	3.57e-8	Height;
KIRP	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg03060546	chr3:49711283	APEH	0.45	5.72	0.34	3.1e-8	Parkinson's disease;
KIRP	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg16736954	chr20:23401023	NAPB	0.65	5.11	0.31	6.49e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.8	-10.51	-0.56	1.37e-21	Coronary artery disease;
KIRP	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.66	11.52	0.59	7.91e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.49	5.5	0.33	9.72e-8	Diisocyanate-induced asthma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15113916	chr3:161082567	C3orf57	0.42	6.22	0.37	2.1e-9	Interleukin-4 levels;
KIRP	cis	rs7524258	0.900	rs6689574	chr1:7288534	C/G	cg07173049	chr1:7289937	CAMTA1	0.66	10.53	0.56	1.24e-21	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg09872104	chr7:134855509	C7orf49	-0.88	-6.41	-0.38	7.38e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6466055	0.589	rs67780803	chr7:104977168	C/T	cg04380332	chr7:105027541	SRPK2	0.36	4.98	0.3	1.2e-6	Schizophrenia;
KIRP	cis	rs775227	0.574	rs2018912	chr3:113060140	A/G	cg18753928	chr3:113234510	CCDC52	-0.55	-5.48	-0.33	1.04e-7	Dental caries;
KIRP	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg27624424	chr6:160112604	SOD2	0.55	6.52	0.38	3.94e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4716602	0.573	rs34810003	chr7:156160883	T/C	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	0.89	10.79	0.57	1.84e-22	Corneal structure;
KIRP	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.9e-7	Aortic root size;
KIRP	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg18016565	chr1:150552671	MCL1	0.37	5.74	0.34	2.83e-8	Tonsillectomy;
KIRP	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.5	6.27	0.37	1.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.64	5.53	0.33	8.18e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg09231725	chr11:64357281	SLC22A12	0.6	7.86	0.45	1.22e-13	Urate levels in obese individuals;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.32e-15	Life satisfaction;
KIRP	cis	rs2882667	0.652	rs6596463	chr5:138444926	A/G	cg04439458	chr5:138467593	SIL1	-0.4	-6.35	-0.38	1.04e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.45	-5.67	-0.34	3.91e-8	Retinal vascular caliber;
KIRP	cis	rs2172802	0.570	rs1497899	chr4:62545911	T/C	cg04118610	chr4:62707027	LPHN3	-0.43	-5.25	-0.32	3.26e-7	Partial epilepsies;
KIRP	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg25182066	chr10:30743637	MAP3K8	-0.67	-9.3	-0.51	8.06e-18	Inflammatory bowel disease;
KIRP	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.46	5.6	0.34	5.63e-8	Blood metabolite levels;
KIRP	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	1.07	22.7	0.82	2.85e-62	Parkinson's disease;
KIRP	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg00684032	chr4:1343700	KIAA1530	0.52	6.47	0.38	5.28e-10	Obesity-related traits;
KIRP	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.69	8.15	0.46	1.83e-14	Diabetic retinopathy;
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08109568	chr15:31115862	NA	-0.76	-9.49	-0.52	2.12e-18	Huntington's disease progression;
KIRP	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.97	0.36	8.1e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg20542592	chr8:11973495	FAM66D	0.37	4.88	0.3	1.93e-6	Neuroticism;
KIRP	cis	rs2292096	0.929	rs6667419	chr1:200756197	G/C	cg07580975	chr1:200843333	NA	0.37	4.85	0.3	2.17e-6	Epilepsy;
KIRP	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg17646820	chr3:66848679	NA	0.75	8.96	0.5	8.14e-17	Type 2 diabetes;
KIRP	cis	rs5758511	0.573	rs1883205	chr22:42243020	A/G	cg15128208	chr22:42549153	NA	-0.44	-5.06	-0.31	8.28e-7	Birth weight;
KIRP	cis	rs593531	0.592	rs3168173	chr11:74042787	A/G	cg18195628	chr11:73498948	MRPL48	-0.42	-4.9	-0.3	1.73e-6	Neuroticism;
KIRP	cis	rs7106204	0.609	rs12801799	chr11:24300630	A/T	ch.11.24196551F	chr11:24239977	NA	0.72	5.64	0.34	4.73e-8	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg23594656	chr7:65796392	TPST1	0.46	7.14	0.41	1.05e-11	Aortic root size;
KIRP	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-1.15	-8.12	-0.46	2.22e-14	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.54	-5.49	-0.33	1.02e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00495681	chr13:53174319	NA	-0.38	-5.07	-0.31	7.82e-7	Lewy body disease;
KIRP	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.4	0.33	1.59e-7	Lung cancer;
KIRP	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-1.01	-13.16	-0.64	2.56e-30	Dilated cardiomyopathy;
KIRP	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.75	-9.88	-0.53	1.37e-19	Age at first birth;
KIRP	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15331902	chr7:107302261	SLC26A4;LOC286002	0.46	6.07	0.36	4.93e-9	DNA methylation (variation);
KIRP	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg15485101	chr11:133734466	NA	0.42	5.73	0.34	2.98e-8	Childhood ear infection;
KIRP	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg00982548	chr2:198649783	BOLL	-0.6	-5.5	-0.33	9.46e-8	Ulcerative colitis;
KIRP	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg18837035	chr15:81426597	C15orf26	-0.39	-4.87	-0.3	2.02e-6	QT interval (drug interaction);
KIRP	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.75	0.4	1.04e-10	Tonsillectomy;
KIRP	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.18	10.55	0.56	1.01e-21	Atopic dermatitis;
KIRP	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg01843034	chr6:37503916	NA	-0.81	-11.51	-0.59	7.99e-25	Cognitive performance;
KIRP	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg09455208	chr3:40491958	NA	0.36	6.24	0.37	1.86e-9	Renal cell carcinoma;
KIRP	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs533123	0.877	rs482692	chr1:29154255	T/C	cg08366446	chr1:29138936	OPRD1	0.9	7.16	0.42	9.15e-12	Schizophrenia;
KIRP	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	5.83	0.35	1.74e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs829661	0.739	rs2602784	chr2:30872493	G/C	cg10949345	chr2:30726833	LCLAT1	1.09	13.36	0.65	5.56e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs4638749	0.501	rs2220261	chr2:108758885	G/A	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.14	-0.31	5.57e-7	Blood pressure;
KIRP	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg17264618	chr3:40429014	ENTPD3	-0.36	-5.52	-0.33	8.58e-8	Renal cell carcinoma;
KIRP	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	cg21523751	chr1:182988639	NA	0.4	6.19	0.37	2.45e-9	Colorectal cancer;
KIRP	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg03060546	chr3:49711283	APEH	0.45	5.78	0.35	2.29e-8	Parkinson's disease;
KIRP	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.48	6.24	0.37	1.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1524927	1.000	rs11765843	chr7:96341168	T/A	cg00227355	chr7:96336147	SHFM1	-0.32	-4.86	-0.3	2.12e-6	Total body bone mineral density;
KIRP	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.83e-16	Immature fraction of reticulocytes;
KIRP	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.44	0.38	6.18e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9308731	0.563	rs6760053	chr2:111932997	C/G	cg04780086	chr2:111875790	ACOXL	0.43	5.91	0.35	1.14e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.7	-8.32	-0.47	6.15e-15	Gut microbiome composition (summer);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04296903	chr1:1203256	UBE2J2	0.52	6.74	0.39	1.11e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.05	-0.31	8.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13434631	chr9:37422914	GRHPR	0.51	6.46	0.38	5.66e-10	Parkinson's disease;
KIRP	cis	rs745821	0.701	rs73959979	chr18:48122758	G/A	cg18923635	chr18:48083994	NA	0.45	4.88	0.3	1.93e-6	Diastolic blood pressure;
KIRP	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	1.0	10.19	0.54	1.48e-20	Psoriasis;
KIRP	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg10253484	chr15:75165896	SCAMP2	-0.53	-6.43	-0.38	6.64e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.7.143447326F	chr7:143816393	NA	-0.47	-6.63	-0.39	2.12e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg19847130	chr8:10466454	RP1L1	-0.42	-5.95	-0.35	9.26e-9	Retinal vascular caliber;
KIRP	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg24826892	chr11:71159390	DHCR7	0.44	4.89	0.3	1.81e-6	Vitamin D levels;
KIRP	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs2197308	0.585	rs10878014	chr12:38114496	A/G	cg26384229	chr12:38710491	ALG10B	0.58	7.54	0.43	9.32e-13	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.65	0.34	4.51e-8	Neutrophil percentage of white cells;
KIRP	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg06121193	chr1:90282411	NA	-0.48	-6.98	-0.41	2.73e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05665937	chr4:1216051	CTBP1	-0.46	-6.17	-0.37	2.75e-9	Obesity-related traits;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg15288179	chr5:32585739	SUB1	0.56	6.6	0.39	2.56e-10	Plasma plasminogen activator levels;
KIRP	cis	rs2798269	0.668	rs1199938	chr13:22068225	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.42	-5.21	-0.32	3.92e-7	PR segment;
KIRP	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.73	-9.72	-0.53	4.06e-19	Hemoglobin concentration;
KIRP	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg24642439	chr20:33292090	TP53INP2	0.5	5.66	0.34	4.26e-8	Height;
KIRP	cis	rs714031	1.000	rs4821909	chr22:40066418	T/C	cg21377881	chr22:40064566	CACNA1I	-0.66	-10.05	-0.54	3.95e-20	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7534824	0.543	rs17408457	chr1:101385693	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	7.35	0.42	2.97e-12	Refractive astigmatism;
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg06145435	chr7:1022769	CYP2W1	0.34	5.25	0.32	3.33e-7	Longevity;Endometriosis;
KIRP	cis	rs9443189	0.865	rs2748940	chr6:76434027	C/T	cg01950844	chr6:76311363	SENP6	-0.57	-6.05	-0.36	5.34e-9	Prostate cancer;
KIRP	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg04369109	chr6:150039330	LATS1	-0.61	-7.89	-0.45	9.73e-14	Lung cancer;
KIRP	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs42648	0.596	rs194513	chr7:89850170	G/T	cg25739043	chr7:89950458	NA	-0.42	-6.75	-0.4	1.06e-10	Homocysteine levels;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg07181902	chr2:85829892	TMEM150A	-0.46	-6.54	-0.38	3.44e-10	Serum protein levels (sST2);
KIRP	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.67	-7.91	-0.45	8.64e-14	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12180372	chr14:94547582	DDX24;IFI27L1	0.5	6.31	0.37	1.32e-9	Parkinson's disease;
KIRP	cis	rs4006360	0.588	rs2001523	chr17:39262814	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.6	-8.73	-0.49	3.84e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.6	7.92	0.45	8.44e-14	Multiple sclerosis;
KIRP	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.21	-0.42	6.9e-12	Neuroticism;
KIRP	cis	rs7792596	1.000	rs2027983	chr7:94004513	A/T	cg20814616	chr7:94014465	NA	-0.33	-5.48	-0.33	1.04e-7	Intelligence;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.66	9.37	0.51	4.72e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	trans	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.32	-0.37	1.25e-9	Neuroticism;
KIRP	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg24579218	chr15:68104479	NA	-0.4	-6.23	-0.37	2.06e-9	Restless legs syndrome;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20033557	chr15:63414489	LACTB	-0.54	-6.12	-0.36	3.71e-9	Interleukin-4 levels;
KIRP	cis	rs9488822	0.585	rs195517	chr6:116241584	G/A	cg15226275	chr6:116381976	FRK	0.22	5.76	0.34	2.46e-8	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.6	-6.11	-0.36	3.92e-9	Obesity-related traits;
KIRP	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg25233709	chr10:116636983	FAM160B1	0.35	5.29	0.32	2.68e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs737693	1.000	rs72981683	chr11:102722614	G/A	cg19620758	chr11:102826565	MMP13	0.74	5.86	0.35	1.47e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02551244	chr2:23608357	KLHL29	0.53	6.17	0.37	2.86e-9	Smoking initiation;
KIRP	cis	rs960902	0.747	rs62135565	chr2:37717507	T/C	cg25341268	chr2:37734390	NA	0.67	8.96	0.5	8.31e-17	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.39	5.09	0.31	7.27e-7	Blood protein levels;
KIRP	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.79	-7.81	-0.45	1.62e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs10073892	0.581	rs1376902	chr5:101643112	A/G	cg19774478	chr5:101632501	SLCO4C1	0.62	6.27	0.37	1.58e-9	Cognitive decline (age-related);
KIRP	cis	rs1978968	1.000	rs1076543	chr22:18446490	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.78	-0.4	8.73e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	8.1	0.46	2.62e-14	Iron status biomarkers;
KIRP	cis	rs2151522	0.603	rs12664316	chr6:127201834	C/T	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.51	-5.32	-0.32	2.34e-7	Corneal structure;
KIRP	cis	rs6708331	0.517	rs11692018	chr2:70369154	A/C	cg05298696	chr2:70188691	ASPRV1	-0.41	-5.53	-0.33	7.99e-8	Obesity-related traits;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09947615	chr4:42659549	ATP8A1	0.93	6.15	0.37	3.04e-9	P wave terminal force;
KIRP	cis	rs10875746	0.669	rs9634261	chr12:48686871	A/G	cg20731937	chr12:48336164	NA	0.43	5.77	0.35	2.41e-8	Longevity (90 years and older);
KIRP	cis	rs785830	0.558	rs549624	chr9:259554	G/A	cg14500300	chr9:211689	NA	0.41	5.54	0.33	7.89e-8	Platelet distribution width;
KIRP	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01200585	chr1:228362443	C1orf69	0.41	5.1	0.31	6.72e-7	Diastolic blood pressure;
KIRP	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.73	8.26	0.47	9.03e-15	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg17724175	chr1:150552817	MCL1	0.35	5.98	0.36	8e-9	Tonsillectomy;
KIRP	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23598886	chr18:12777645	NA	0.74	6.09	0.36	4.28e-9	Inflammatory skin disease;
KIRP	cis	rs6959887	0.962	rs10280486	chr7:35283278	A/C	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg12560992	chr17:57184187	TRIM37	0.61	6.45	0.38	5.75e-10	Testicular germ cell tumor;
KIRP	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.45	-6.3	-0.37	1.34e-9	Childhood ear infection;
KIRP	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-5.76	-0.34	2.47e-8	HDL cholesterol;
KIRP	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg15534755	chr11:117069859	TAGLN	-0.41	-5.2	-0.31	4.13e-7	Blood protein levels;
KIRP	trans	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg11693508	chr17:37793320	STARD3	0.81	8.72	0.49	4.33e-16	Bipolar disorder;
KIRP	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg24699146	chr1:24152579	HMGCL	-0.48	-6.59	-0.39	2.68e-10	Immature fraction of reticulocytes;
KIRP	cis	rs9815354	0.951	rs73830511	chr3:41864643	G/T	cg03022575	chr3:42003672	ULK4	0.6	7.01	0.41	2.28e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.66	8.1	0.46	2.51e-14	Blood metabolite levels;
KIRP	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.73	-0.39	1.17e-10	Alcohol dependence;
KIRP	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	6.88	0.4	5.06e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg14673194	chr17:80132900	CCDC57	-0.72	-7.93	-0.45	7.55e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.16	0.54	1.76e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9400467	0.506	rs12207199	chr6:111525906	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg12598211	chr12:123634384	NA	-0.43	-5.02	-0.31	9.72e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs240764	0.578	rs9399688	chr6:101215786	C/T	cg09795085	chr6:101329169	ASCC3	0.46	5.34	0.32	2.14e-7	Neuroticism;
KIRP	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.52	-7.35	-0.42	2.86e-12	Kawasaki disease;
KIRP	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.98	-9.06	-0.5	4.11e-17	Type 2 diabetes;
KIRP	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.82	9.87	0.53	1.47e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
KIRP	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.97	-16.44	-0.72	1.71e-41	Breast cancer;
KIRP	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.95	0.41	3.31e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs2625529	0.652	rs11072350	chr15:72464609	T/G	cg16672083	chr15:72433130	SENP8	0.39	5.45	0.33	1.25e-7	Red blood cell count;
KIRP	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg25427524	chr10:38739819	LOC399744	0.6	6.59	0.39	2.59e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.77	9.74	0.53	3.6e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.79	-8.92	-0.49	1.07e-16	Diastolic blood pressure;
KIRP	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-5.63	-0.34	4.98e-8	Blood metabolite levels;
KIRP	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg04166393	chr7:2884313	GNA12	0.45	5.93	0.35	1.01e-8	Height;
KIRP	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg24296786	chr1:45957014	TESK2	0.62	8.33	0.47	5.84e-15	High light scatter reticulocyte count;
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg01283332	chr5:1856932	NA	-0.5	-6.46	-0.38	5.63e-10	Cardiovascular disease risk factors;
KIRP	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.56	5.9	0.35	1.22e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.92	-0.49	1.08e-16	Total cholesterol levels;
KIRP	cis	rs829661	0.739	rs2602807	chr2:30843651	G/A	cg10949345	chr2:30726833	LCLAT1	1.11	13.54	0.65	1.35e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-6.07	-0.36	4.79e-9	Coronary artery disease;
KIRP	cis	rs10984466	1	rs10984466	chr9:100707992	A/G	cg13688889	chr9:100608707	NA	-0.46	-5.47	-0.33	1.08e-7	Platelet count;
KIRP	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg06027949	chr8:82754900	SNX16	0.54	5.77	0.35	2.37e-8	Diastolic blood pressure;
KIRP	cis	rs714027	0.511	rs131274	chr22:30153864	G/A	cg27665648	chr22:30112403	NA	0.45	6.38	0.38	8.61e-10	Lymphocyte counts;
KIRP	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg11952622	chr19:58962976	ZNF324B	0.43	4.98	0.3	1.22e-6	Uric acid clearance;
KIRP	trans	rs3128341	0.877	rs17526561	chr1:72818226	C/A	cg16299813	chr17:79632380	C17orf90;CCDC137	-0.34	-6.1	-0.36	4.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.72	9.5	0.52	2.01e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9815354	1.000	rs9842305	chr3:41998412	G/A	cg03022575	chr3:42003672	ULK4	-0.5	-5.65	-0.34	4.46e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg05340658	chr4:99064831	C4orf37	0.65	7.83	0.45	1.46e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.58	5.32	0.32	2.28e-7	Pre-treatment pain in head and neck squamous cell carcinoma;
KIRP	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg21573476	chr21:45109991	RRP1B	-0.56	-7.62	-0.44	5.41e-13	Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.5	0.33	9.73e-8	Lung cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10083996	chr14:51298088	NIN	-0.47	-6.2	-0.37	2.43e-9	Metabolic traits;
KIRP	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18971241	chr14:76045025	FLVCR2	0.51	6.59	0.39	2.65e-10	Parkinson's disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18045575	chr2:27341901	CGREF1	-0.5	-6.07	-0.36	4.76e-9	Menopause (age at onset);
KIRP	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.7	8.8	0.49	2.44e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.35	-0.38	1.05e-9	Schizophrenia;
KIRP	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.53	-7.49	-0.43	1.2e-12	Alcohol dependence;
KIRP	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.11	-0.31	6.41e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.25	-0.42	5.5e-12	Vitiligo;
KIRP	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.94	11.0	0.57	3.73e-23	Neuroticism;
KIRP	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.6	6.83	0.4	6.49e-11	Aortic root size;
KIRP	cis	rs3760982	0.935	rs10422990	chr19:44295273	C/T	cg11993925	chr19:44307056	LYPD5	0.36	5.0	0.3	1.07e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg17376030	chr22:41985996	PMM1	-0.59	-7.16	-0.42	9.08e-12	Vitiligo;
KIRP	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg19847866	chr10:1019161	NA	0.48	5.65	0.34	4.37e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.73	5.87	0.35	1.41e-8	Diabetic retinopathy;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25622597	chr3:49449489	RHOA;TCTA	0.53	6.18	0.37	2.58e-9	Myopia (pathological);
KIRP	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.73	7.68	0.44	3.67e-13	Lymphocyte counts;
KIRP	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.61	6.64	0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs1784203	1.000	rs4753098	chr11:93417437	C/T	cg10353388	chr11:93474820	C11orf54;TAF1D	-1.4	-8.41	-0.47	3.45e-15	Waist circumference adjusted for body mass index;
KIRP	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11645453	chr3:52864694	ITIH4	0.33	4.87	0.3	2.02e-6	Bipolar disorder;
KIRP	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg03929089	chr4:120376271	NA	0.76	6.7	0.39	1.43e-10	Intraocular pressure;
KIRP	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06544989	chr22:39130855	UNC84B	0.42	6.47	0.38	5.34e-10	Menopause (age at onset);
KIRP	cis	rs9427116	0.702	rs884618	chr1:154601157	A/G	cg11650704	chr1:154556575	ADAR	-0.4	-4.91	-0.3	1.69e-6	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.63	9.55	0.52	1.41e-18	Lung cancer;
KIRP	cis	rs6459788	0.630	rs11977865	chr7:157234112	G/A	cg07338119	chr7:157211683	NA	-0.47	-5.71	-0.34	3.22e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg21605333	chr4:119757512	SEC24D	1.56	10.58	0.56	8.15e-22	Cannabis dependence symptom count;
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg12486944	chr17:80159399	CCDC57	0.4	5.5	0.33	9.49e-8	Life satisfaction;
KIRP	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.2	0.37	2.36e-9	Monocyte count;
KIRP	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.86	9.98	0.54	6.66e-20	Cisplatin-induced ototoxicity;
KIRP	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs77633900	0.614	rs12442966	chr15:76918290	G/T	cg21673338	chr15:77095150	SCAPER	0.5	6.14	0.36	3.28e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg10189774	chr4:17578691	LAP3	0.42	5.03	0.31	9.38e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg05926928	chr17:57297772	GDPD1	0.67	6.56	0.39	3.12e-10	Opioid sensitivity;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00907211	chr7:128828520	SMO	-0.46	-6.33	-0.37	1.14e-9	Myopia;
KIRP	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.5	-6.75	-0.4	1.03e-10	Total body bone mineral density;
KIRP	trans	rs1325163	0.568	rs17156733	chr10:45145453	G/C	cg08650676	chr5:172045026	NA	-0.46	-6.08	-0.36	4.46e-9	Chickenpox;
KIRP	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.9	-0.4	4.51e-11	Response to antipsychotic treatment;
KIRP	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg16141378	chr3:129829833	LOC729375	0.49	6.38	0.38	8.81e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg26697477	chr16:1836234	NUBP2	-0.64	-7.65	-0.44	4.61e-13	Insulin-like growth factors;
KIRP	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.62	-8.97	-0.5	7.89e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs7127900	0.948	rs62650858	chr11:2226905	C/T	cg25635251	chr11:2234043	NA	0.52	7.89	0.45	1.01e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.92	-0.4	3.85e-11	Acne (severe);
KIRP	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.5	0.81	2.06e-58	Prudent dietary pattern;
KIRP	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.37	6.6	0.39	2.44e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs548987	0.507	rs1408268	chr6:25826986	T/A	cg03264133	chr6:25882463	NA	-0.42	-5.0	-0.3	1.09e-6	Homocysteine levels;
KIRP	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg20703242	chr1:230279135	GALNT2	0.42	8.23	0.46	1.13e-14	Coronary artery disease;
KIRP	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.88	11.2	0.58	8.43e-24	Response to diuretic therapy;
KIRP	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg07930552	chr6:133119739	C6orf192	0.83	5.83	0.35	1.71e-8	Type 2 diabetes nephropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10279124	chr16:69419953	TERF2	0.51	6.3	0.37	1.35e-9	Parkinson's disease;
KIRP	cis	rs7258015	0.909	rs2304237	chr19:10446568	T/C	cg25279553	chr19:10444815	RAVER1;ICAM3	0.49	6.33	0.37	1.15e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.95	15.24	0.7	2.25e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs2437772	0.521	rs2439518	chr8:97517389	G/A	cg10292139	chr8:97507561	SDC2	-0.42	-5.52	-0.33	8.61e-8	Post-traumatic stress disorder;
KIRP	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.49	5.25	0.32	3.36e-7	Schizophrenia;
KIRP	cis	rs62027291	0.654	rs62028181	chr15:77006293	A/G	cg23625390	chr15:77176239	SCAPER	-0.69	-4.94	-0.3	1.44e-6	Plateletcrit;
KIRP	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.46	5.98	0.36	8.01e-9	Age at first birth;
KIRP	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00338735	chr4:53728038	RASL11B	0.5	5.91	0.35	1.11e-8	Optic nerve measurement (cup area);
KIRP	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.47	5.96	0.36	8.5e-9	Testicular germ cell tumor;
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg07721244	chr1:72749275	NEGR1	0.39	6.31	0.37	1.27e-9	Suicide attempts in major depressive disorder;
KIRP	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg04289385	chr6:36355825	ETV7	0.47	7.43	0.43	1.76e-12	Platelet distribution width;
KIRP	cis	rs934734	0.563	rs11126035	chr2:65597066	T/C	cg08085232	chr2:65598271	SPRED2	-0.56	-7.22	-0.42	6.64e-12	Rheumatoid arthritis;
KIRP	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.77	7.94	0.45	7.42e-14	Uric acid levels;
KIRP	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	0.77	8.42	0.47	3.06e-15	Initial pursuit acceleration;
KIRP	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.34	-7.05	-0.41	1.79e-11	Urinary metabolites;
KIRP	cis	rs1829883	0.804	rs2963537	chr5:98800110	C/T	cg08333243	chr5:99726346	NA	-0.4	-5.17	-0.31	4.76e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs66716358	0.562	rs10838258	chr11:44326859	G/C	cg02785814	chr11:44338707	NA	-0.4	-5.34	-0.32	2.11e-7	Monobrow;
KIRP	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.21e-6	Blood protein levels;
KIRP	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.59	8.35	0.47	4.87e-15	Autism;
KIRP	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.24e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2832270	0.525	rs73192156	chr21:30457526	C/G	cg24692254	chr21:30365293	RNF160	-0.58	-5.51	-0.33	9.05e-8	Response to mTOR inhibitor (everolimus);
KIRP	cis	rs4722166	0.598	rs7804146	chr7:22800929	C/G	cg05472934	chr7:22766657	IL6	0.5	6.89	0.4	4.63e-11	Lung cancer;
KIRP	cis	rs4936894	0.500	rs11219535	chr11:124119565	G/A	cg27160556	chr11:124181099	OR8D1	-0.39	-5.81	-0.35	1.89e-8	Aging (time to death);
KIRP	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-0.84	-7.39	-0.43	2.33e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7851660	0.772	rs6478471	chr9:100664382	A/G	cg13688889	chr9:100608707	NA	-0.68	-8.54	-0.48	1.43e-15	Strep throat;
KIRP	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.54	-5.07	-0.31	7.82e-7	Narcolepsy;
KIRP	cis	rs9659323	0.623	rs12091291	chr1:119478828	A/G	cg05756136	chr1:119680316	WARS2	0.39	5.03	0.31	9.66e-7	Body mass index;
KIRP	cis	rs4722166	0.567	rs62449490	chr7:22748491	T/G	cg05472934	chr7:22766657	IL6	0.38	5.09	0.31	7.02e-7	Lung cancer;
KIRP	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.15	-0.46	1.81e-14	Response to antipsychotic treatment;
KIRP	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-1.14	-13.63	-0.66	6.98e-32	Breast cancer;
KIRP	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.65	-0.8	1.2e-55	Height;
KIRP	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg11235152	chr1:67600687	NA	0.72	10.84	0.57	1.26e-22	Psoriasis;
KIRP	cis	rs17101923	0.806	rs35083527	chr12:66336692	C/T	cg06712651	chr12:66351869	HMGA2	-0.58	-5.96	-0.36	8.78e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.38	-4.87	-0.3	1.96e-6	Height;
KIRP	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.54	7.16	0.42	9.31e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.46	5.91	0.35	1.16e-8	Brain structure;
KIRP	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.18	0.31	4.55e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs997295	0.966	rs3784692	chr15:67988133	C/T	cg24579218	chr15:68104479	NA	0.37	5.64	0.34	4.54e-8	Motion sickness;
KIRP	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg14829155	chr15:31115871	NA	-0.76	-9.5	-0.52	1.99e-18	Huntington's disease progression;
KIRP	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.82	-9.98	-0.54	6.4e-20	Blood protein levels;
KIRP	cis	rs829661	0.793	rs7572318	chr2:30808845	T/C	cg10949345	chr2:30726833	LCLAT1	1.01	13.05	0.64	6.23e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg00938859	chr5:1591904	SDHAP3	0.55	6.02	0.36	6.29e-9	Breast cancer;
KIRP	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg23422044	chr7:1970798	MAD1L1	-0.52	-6.86	-0.4	5.53e-11	Neuroticism;
KIRP	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	5.76	0.34	2.44e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.74	-0.39	1.11e-10	Lung cancer;
KIRP	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.03	12.73	0.63	7.15e-29	Exhaled nitric oxide output;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-5.33	-0.32	2.23e-7	Longevity;Endometriosis;
KIRP	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.66	6.54	0.38	3.57e-10	Axial length;
KIRP	cis	rs6442310	0.534	rs2028759	chr3:12418612	C/T	cg22839075	chr3:12045461	SYN2	0.4	5.79	0.35	2.14e-8	Hematocrit;
KIRP	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg00405596	chr8:11794950	NA	0.55	6.83	0.4	6.54e-11	Systolic blood pressure;
KIRP	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg03714773	chr7:91764589	CYP51A1	-0.35	-5.03	-0.31	9.53e-7	Breast cancer;
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs3752645	0.764	rs78715818	chr7:106684638	C/G	cg02696742	chr7:106810147	HBP1	-0.75	-5.13	-0.31	6e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.54	-0.43	9.31e-13	Type 2 diabetes;
KIRP	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.55	-7.03	-0.41	2.03e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg04935436	chr20:30431758	NA	-0.53	-6.54	-0.38	3.6e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.11	0.46	2.43e-14	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg02569458	chr12:86230093	RASSF9	0.36	5.27	0.32	3.03e-7	Major depressive disorder;
KIRP	cis	rs2729354	0.729	rs2581923	chr11:57249991	C/T	cg24343310	chr11:57249947	NA	0.28	5.2	0.31	4.25e-7	Blood protein levels;
KIRP	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.48	-5.83	-0.35	1.72e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg22717608	chr11:34937665	PDHX;APIP	-0.41	-5.14	-0.31	5.57e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4523957	0.553	rs9909515	chr17:2039733	T/C	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2688419	0.545	rs6550719	chr3:23072185	C/G	cg00327796	chr3:23032191	NA	-0.42	-6.0	-0.36	6.91e-9	Type 2 diabetes;
KIRP	cis	rs830233	0.647	rs26443	chr5:165374321	A/G	cg13976338	chr5:165423657	NA	-0.5	-5.83	-0.35	1.7e-8	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg11569703	chr11:65557185	OVOL1	-0.31	-4.97	-0.3	1.24e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7551222	0.681	rs2045623	chr1:204497413	A/G	cg20240347	chr1:204465584	NA	-0.46	-8.8	-0.49	2.5e-16	Schizophrenia;
KIRP	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.14	-0.36	3.36e-9	Neuroticism;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg18132916	chr6:79620363	NA	0.4	5.64	0.34	4.62e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg25486957	chr4:152246857	NA	-0.54	-5.83	-0.35	1.72e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12580194	0.593	rs61957938	chr12:55747266	C/G	cg19537932	chr12:55886519	OR6C68	-0.5	-6.47	-0.38	5.14e-10	Cancer;
KIRP	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.66	8.53	0.48	1.5e-15	Prudent dietary pattern;
KIRP	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	1.01	14.37	0.68	2.09e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9815354	0.812	rs73069357	chr3:41753319	T/G	cg03022575	chr3:42003672	ULK4	0.75	7.2	0.42	7.38e-12	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22251048	chr13:111314707	CARS2	0.48	6.09	0.36	4.21e-9	Interleukin-4 levels;
KIRP	cis	rs55962025	0.804	rs3775061	chr4:3238754	A/G	cg06533319	chr4:3265114	C4orf44	0.49	5.27	0.32	3e-7	Parental longevity (mother's age at death);
KIRP	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg27205649	chr11:78285834	NARS2	-0.65	-7.32	-0.42	3.59e-12	Alzheimer's disease (survival time);
KIRP	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg06647332	chr5:131281008	NA	0.45	5.07	0.31	7.86e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs34091987	0.582	rs2193054	chr17:70025809	C/G	cg09344028	chr17:70110421	NA	0.27	5.38	0.32	1.78e-7	Nose size;
KIRP	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg24631222	chr15:78858424	CHRNA5	0.8	9.71	0.53	4.5e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg26022315	chr17:47021804	SNF8	0.43	5.5	0.33	9.59e-8	Type 2 diabetes;
KIRP	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.91	0.53	1.06e-19	Monocyte percentage of white cells;
KIRP	cis	rs2191566	0.576	rs419839	chr19:44495598	C/T	cg18700516	chr19:44507157	ZNF230	0.42	4.85	0.3	2.23e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6429082	0.509	rs6699315	chr1:235525253	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.41	-5.12	-0.31	6.23e-7	Adiposity;
KIRP	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.29	25.71	0.85	1.16e-71	IgG glycosylation;
KIRP	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg26022315	chr17:47021804	SNF8	-0.4	-5.13	-0.31	5.76e-7	Type 2 diabetes;
KIRP	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg00933542	chr6:150070202	PCMT1	0.27	5.34	0.32	2.13e-7	Lung cancer;
KIRP	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.54	-6.43	-0.38	6.61e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7084921	0.608	rs2862948	chr10:101864173	A/G	cg13808641	chr9:96006533	WNK2	-0.41	-6.25	-0.37	1.79e-9	Bone mineral density;
KIRP	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg10760299	chr15:45669010	GATM	0.35	5.09	0.31	7.03e-7	Homoarginine levels;
KIRP	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg10223061	chr2:219282414	VIL1	-0.4	-6.37	-0.38	9.28e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7572644	0.640	rs4665392	chr2:28029649	A/G	cg27432699	chr2:27873401	GPN1	0.5	6.05	0.36	5.48e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.58	0.8	2.03e-55	Prudent dietary pattern;
KIRP	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.54	-0.33	7.63e-8	Life satisfaction;
KIRP	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.78	-0.53	2.8e-19	Response to antipsychotic treatment;
KIRP	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.02	10.88	0.57	9.33e-23	HIV-1 control;
KIRP	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.55	6.05	0.36	5.26e-9	Bone mineral density (spine);
KIRP	cis	rs4786125	0.636	rs7192853	chr16:6918241	G/C	cg03623568	chr16:6915990	A2BP1	-0.43	-5.34	-0.32	2.11e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.28	-5.08	-0.31	7.51e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.5	6.64	0.39	1.96e-10	Longevity;Endometriosis;
KIRP	cis	rs4561483	0.798	rs456325	chr16:12012562	C/G	cg08843971	chr16:11963173	GSPT1	-0.59	-7.82	-0.45	1.58e-13	Testicular germ cell tumor;
KIRP	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.61	7.71	0.44	3.04e-13	Coronary artery disease;
KIRP	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.58	-6.17	-0.37	2.81e-9	Obesity-related traits;
KIRP	cis	rs73086581	0.741	rs17212649	chr20:3853093	A/G	cg02187196	chr20:3869020	PANK2	0.58	5.21	0.32	4.05e-7	Response to antidepressants in depression;
KIRP	cis	rs17123764	0.818	rs13066	chr12:49960551	C/A	cg20471783	chr12:50157085	TMBIM6	0.33	5.11	0.31	6.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-5.51	-0.33	9.24e-8	Metabolite levels;
KIRP	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	1.05	17.44	0.74	6.69e-45	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs7011049	1.000	rs72648409	chr8:53857307	T/C	cg26025543	chr8:53854495	NA	0.75	7.78	0.44	2.06e-13	Systolic blood pressure;
KIRP	cis	rs6921919	0.583	rs7775132	chr6:28347013	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2625529	0.526	rs11637611	chr15:72551712	C/T	cg16672083	chr15:72433130	SENP8	0.39	5.44	0.33	1.3e-7	Red blood cell count;
KIRP	cis	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.58	9.36	0.51	5.2e-18	C-reactive protein levels;
KIRP	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.8	-9.81	-0.53	2.2e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg00262122	chr8:11665843	FDFT1	0.4	4.95	0.3	1.37e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs865483	0.895	rs1016678	chr17:35874192	A/G	cg06716730	chr17:35851459	DUSP14	0.23	5.35	0.32	2.06e-7	Monocyte count;
KIRP	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	0.84	8.07	0.46	3.02e-14	Methadone dose in opioid dependence;
KIRP	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.42	-5.4	-0.33	1.54e-7	Coronary artery disease;
KIRP	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.42	-5.96	-0.36	8.62e-9	Mean corpuscular volume;
KIRP	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.85	-0.53	1.62e-19	Total body bone mineral density;
KIRP	cis	rs4790312	0.729	rs9906546	chr17:1995614	C/G	cg24156229	chr17:1948635	NA	-0.41	-5.19	-0.31	4.37e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.78	0.6	1.1e-25	Longevity;
KIRP	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg19636519	chr7:99541626	NA	0.38	7.02	0.41	2.17e-11	Coronary artery disease;
KIRP	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.83	9.56	0.52	1.29e-18	Platelet count;
KIRP	cis	rs4902647	0.678	rs194747	chr14:69281878	T/C	cg03189333	chr14:69283534	NA	-0.44	-5.53	-0.33	8.27e-8	Multiple sclerosis;
KIRP	cis	rs2737618	0.722	rs2737680	chr1:200088559	C/A	cg21825944	chr1:200113062	NR5A2	-0.58	-8.2	-0.46	1.34e-14	Uric acid levels;
KIRP	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.51	7.17	0.42	8.65e-12	Schizophrenia;
KIRP	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg05315796	chr3:52349193	DNAH1	0.39	6.15	0.37	3.04e-9	Electroencephalogram traits;
KIRP	trans	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg24644049	chr4:85504048	CDS1	0.93	6.88	0.4	4.86e-11	Skin colour saturation;
KIRP	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.26	-0.32	3.07e-7	Obesity-related traits;
KIRP	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-11.65	-0.6	2.81e-25	Exhaled nitric oxide output;
KIRP	cis	rs860295	0.580	rs2282301	chr1:155868625	A/G	cg02153340	chr1:155202674	NA	0.41	5.24	0.32	3.47e-7	Body mass index;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg03929089	chr4:120376271	NA	0.72	6.59	0.39	2.6200000000000003e-10	Intraocular pressure;
KIRP	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg26811252	chr16:29126840	RRN3P2	0.67	9.04	0.5	4.94e-17	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.26	0.47	8.93e-15	Obesity-related traits;
KIRP	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.66	8.23	0.46	1.1e-14	Body mass index;
KIRP	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.6	-8.54	-0.48	1.44e-15	Urate levels in overweight individuals;
KIRP	cis	rs9311676	0.632	rs11130630	chr3:58360800	A/G	cg06643156	chr3:58380774	PXK	0.36	5.14	0.31	5.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg06042504	chr8:55087323	NA	-0.61	-7.48	-0.43	1.34e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs400736	0.562	rs12711516	chr1:8181227	G/C	cg25007680	chr1:8021821	PARK7	-0.46	-6.02	-0.36	6.21e-9	Response to antidepressants and depression;
KIRP	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.74	10.68	0.56	4.02e-22	Sleep quality;
KIRP	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg23324259	chr8:82754387	SNX16	0.44	4.88	0.3	1.9e-6	Diastolic blood pressure;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.15	-0.36	3.14e-9	Lymphocyte counts;
KIRP	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	11.27	0.58	5.18e-24	Smoking behavior;
KIRP	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.47	-7.21	-0.42	7e-12	Daytime sleep phenotypes;
KIRP	cis	rs2594989	0.887	rs2616535	chr3:11595167	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-7.02	-0.41	2.17e-11	Circulating chemerin levels;
KIRP	cis	rs9400467	0.506	rs17539875	chr6:111674350	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.75	10.94	0.57	5.96e-23	Schizophrenia;
KIRP	cis	rs11825064	0.510	rs74765580	chr11:134517903	A/G	cg06603561	chr11:134479413	NA	-0.98	-7.06	-0.41	1.69e-11	Seasonality;
KIRP	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg11569703	chr11:65557185	OVOL1	-0.48	-8.57	-0.48	1.18e-15	Acne (severe);
KIRP	cis	rs2591576	0.935	rs830230	chr5:165402097	T/C	cg13976338	chr5:165423657	NA	-0.63	-8.92	-0.49	1.08e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg27490568	chr2:178487706	NA	0.48	6.45	0.38	6.04e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2000999	0.514	rs17604662	chr16:72221464	A/G	cg04254540	chr16:71951199	KIAA0174	-0.74	-5.26	-0.32	3.2e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.57	-15.08	-0.69	7.68e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.17	0.61	5.41e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.6	7.79	0.44	1.91e-13	Coffee consumption (cups per day);
KIRP	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-9.86	-0.53	1.52e-19	Alzheimer's disease;
KIRP	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.97	-0.45	6.11e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg01879757	chr17:41196368	BRCA1	-0.54	-7.36	-0.42	2.83e-12	Menopause (age at onset);
KIRP	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.67	-8.73	-0.49	3.85e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs4908768	0.582	rs12410893	chr1:8878885	A/G	cg25722041	chr1:8623473	RERE	0.67	8.39	0.47	3.78e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-15.38	-0.7	7.22e-38	Ulcerative colitis;
KIRP	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg07148914	chr20:33460835	GGT7	-0.54	-7.15	-0.41	9.81e-12	Height;
KIRP	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.05	-0.36	5.32e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25642048	chr8:74207199	RPL7;RDH10	0.52	6.86	0.4	5.4e-11	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.17	-0.37	2.76e-9	Lung cancer;
KIRP	cis	rs35740288	0.822	rs4843092	chr15:86233180	G/A	cg17133734	chr15:86042851	AKAP13	-0.49	-5.32	-0.32	2.29e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg23166289	chr1:210001082	C1orf107	-0.42	-5.53	-0.33	8.09e-8	Monobrow;
KIRP	cis	rs13006833	0.668	rs2664253	chr2:191148558	G/A	cg21644426	chr2:191273491	MFSD6	0.41	4.92	0.3	1.56e-6	Urinary metabolites;
KIRP	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.52	6.24	0.37	1.85e-9	Multiple sclerosis;
KIRP	trans	rs9650657	0.525	rs7819602	chr8:10726842	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.58	-0.39	2.87e-10	Neuroticism;
KIRP	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-11.22	-0.58	7.11e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.93	14.58	0.68	4.03e-35	Coronary artery disease;
KIRP	trans	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-5.43	-0.33	1.32e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg09699651	chr6:150184138	LRP11	-0.47	-6.1	-0.36	4.14e-9	Lung cancer;
KIRP	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.83	6.87	0.4	5.14e-11	Major depressive disorder;
KIRP	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.55	-6.38	-0.38	8.71e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg16141378	chr3:129829833	LOC729375	0.46	6.05	0.36	5.49e-9	Triglycerides;
KIRP	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg23894439	chr1:183413866	NA	0.39	5.17	0.31	4.9e-7	Systemic lupus erythematosus;
KIRP	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg23307798	chr14:103986281	CKB	0.47	6.8	0.4	7.66e-11	Body mass index;
KIRP	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg15556689	chr8:8085844	FLJ10661	0.69	9.56	0.52	1.33e-18	Triglycerides;
KIRP	cis	rs6456042	0.829	rs3127419	chr6:166538527	A/G	cg11088901	chr6:166572345	T	-0.32	-4.87	-0.3	2.04e-6	Asthma;
KIRP	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg10818794	chr15:86012489	AKAP13	-0.47	-6.52	-0.38	3.93e-10	Interstitial lung disease;
KIRP	trans	rs1620921	0.840	rs783178	chr6:161169739	C/T	cg01090089	chr7:6570974	GRID2IP	0.38	6.04	0.36	5.77e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.49	-8.03	-0.46	4.03e-14	Height;
KIRP	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.48	-0.48	2.11e-15	Coronary artery disease;
KIRP	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.58	-7.31	-0.42	3.64e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7635838	0.892	rs754015	chr3:11493945	T/C	cg00170343	chr3:11313890	ATG7	0.47	6.02	0.36	6.42e-9	HDL cholesterol;
KIRP	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.67	9.65	0.52	6.63e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg26811252	chr16:29126840	RRN3P2	0.77	10.29	0.55	7.12e-21	Menopause (age at onset);
KIRP	cis	rs12220238	0.722	rs7894466	chr10:76401365	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	6.01	0.36	6.82e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08722104	chr11:47448306	PSMC3	0.57	6.69	0.39	1.49e-10	Smoking initiation;
KIRP	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.62	-0.34	5.22e-8	Cholesterol, total;
KIRP	cis	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg00405596	chr8:11794950	NA	-0.53	-6.64	-0.39	2.05e-10	Triglycerides;
KIRP	cis	rs8077577	0.943	rs62073603	chr17:18064316	C/T	cg09161412	chr17:18057145	MYO15A	-0.39	-5.07	-0.31	7.9e-7	Obesity-related traits;
KIRP	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	0.43	5.86	0.35	1.5e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.72	0.39	1.24e-10	Morning vs. evening chronotype;
KIRP	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.46	-5.75	-0.34	2.58e-8	Monocyte count;
KIRP	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg14593290	chr7:50529359	DDC	-0.76	-9.46	-0.52	2.67e-18	Malaria;
KIRP	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg26751094	chr13:95954534	ABCC4	-0.57	-8.03	-0.46	3.98e-14	Blood metabolite levels;
KIRP	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg06173513	chr14:71954034	LOC145474	0.42	6.19	0.37	2.56e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09412850	chr12:132835834	GALNT9	0.4	6.27	0.37	1.65e-9	Survival in pancreatic cancer;
KIRP	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.25	0.32	3.28e-7	Educational attainment;
KIRP	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06481639	chr22:41940642	POLR3H	0.68	6.9	0.4	4.29e-11	Vitiligo;
KIRP	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg04287289	chr16:89883240	FANCA	0.57	7.68	0.44	3.86e-13	Vitiligo;
KIRP	cis	rs7172677	0.737	rs12442392	chr15:75437478	G/T	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7225151	0.808	rs77493189	chr17:5118951	T/G	cg24500398	chr17:5266808	RABEP1	-0.5	-4.92	-0.3	1.6e-6	Alzheimer's disease (late onset);
KIRP	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg02782426	chr3:40428986	ENTPD3	-0.32	-4.86	-0.3	2.07e-6	Renal cell carcinoma;
KIRP	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg12560992	chr17:57184187	TRIM37	0.63	6.73	0.39	1.2e-10	Testicular germ cell tumor;
KIRP	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg08975724	chr8:8085496	FLJ10661	0.54	7.28	0.42	4.6e-12	Triglycerides;
KIRP	cis	rs12282928	0.876	rs7942250	chr11:48243481	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-5.76	-0.34	2.54e-8	Migraine - clinic-based;
KIRP	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg10189774	chr4:17578691	LAP3	0.55	6.9	0.4	4.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-0.83	-14.92	-0.69	2.79e-36	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23098811	chr1:215450695	NA	0.46	6.26	0.37	1.72e-9	Interleukin-4 levels;
KIRP	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg16497661	chr14:103986332	CKB	-0.52	-6.85	-0.4	5.9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg12257156	chr7:158823799	VIPR2	0.3	4.98	0.3	1.19e-6	Facial morphology (factor 20);
KIRP	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.89	8.19	0.46	1.45e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	7.17	0.42	8.75e-12	Height;
KIRP	cis	rs2598107	0.601	rs3807612	chr7:37957771	A/G	cg25225232	chr7:37962694	EPDR1	-0.44	-5.18	-0.31	4.63e-7	Dupuytren's disease;
KIRP	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg04944784	chr2:26401820	FAM59B	-0.69	-7.41	-0.43	1.97e-12	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-1.02	-17.35	-0.74	1.44e-44	Height;
KIRP	cis	rs7221595	0.825	rs62072392	chr17:3910125	A/G	cg09695851	chr17:3907499	NA	0.63	6.11	0.36	3.87e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00149659	chr3:10157352	C3orf10	0.52	6.22	0.37	2.15e-9	Alzheimer's disease;
KIRP	cis	rs9761603	0.602	rs9759431	chr4:138412229	T/A	cg12033966	chr4:138453416	PCDH18	0.41	5.46	0.33	1.18e-7	Diastolic blood pressure;
KIRP	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.5	0.68	7.43e-35	Chronic sinus infection;
KIRP	trans	rs1859156	0.767	rs1444932	chr4:95839222	T/G	cg24204951	chr2:239172084	PER2	0.31	6.66	0.39	1.8e-10	Attention deficit hyperactivity disorder;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg26742440	chr11:73472391	RAB6A	0.48	6.34	0.37	1.1e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	1.14	14.62	0.68	2.95e-35	Response to hepatitis C treatment;
KIRP	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.55	8.7	0.48	4.97e-16	C-reactive protein levels;
KIRP	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	13.93	0.66	6.34e-33	Body mass index (adult);
KIRP	cis	rs10754283	0.967	rs1320563	chr1:90121032	G/A	cg06121193	chr1:90282411	NA	-0.52	-7.41	-0.43	1.96e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg03351412	chr1:154909251	PMVK	0.59	7.61	0.44	5.91e-13	Prostate cancer;
KIRP	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs3764563	1.000	rs681417	chr19:15694802	G/T	cg20725493	chr19:15740067	CYP4F8	0.86	6.07	0.36	4.73e-9	Inflammatory biomarkers;
KIRP	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.65	-0.34	4.33e-8	Coronary artery disease;
KIRP	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.01	-10.32	-0.55	5.68e-21	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.57	6.58	0.39	2.8e-10	Aortic root size;
KIRP	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg21452805	chr1:244014465	NA	0.59	5.72	0.34	3.13e-8	RR interval (heart rate);
KIRP	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.61	-9.3	-0.51	7.95e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.38	5.93	0.35	1.05e-8	Body mass index;
KIRP	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-8.75	-0.49	3.36e-16	Migraine;Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23223339	chr3:58419543	PDHB	0.56	7.12	0.41	1.19e-11	Parkinson's disease;
KIRP	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.79	-0.53	2.55e-19	Mood instability;
KIRP	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.91	10.4	0.55	3.1e-21	Corneal astigmatism;
KIRP	cis	rs3857747	0.694	rs4534056	chr7:40450567	A/C	cg00420559	chr7:40367873	C7orf10	-0.58	-7.98	-0.45	5.7e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.5	7.72	0.44	2.88e-13	Testicular germ cell tumor;
KIRP	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg03351412	chr1:154909251	PMVK	-0.39	-5.05	-0.31	8.63e-7	Prostate cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18272543	chr7:27779524	TAX1BP1	0.9	6.21	0.37	2.3e-9	P wave terminal force;
KIRP	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.38	5.19	0.31	4.33e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs11997175	0.583	rs67830367	chr8:33833788	G/C	ch.8.33884649F	chr8:33765107	NA	0.52	6.56	0.39	3.08e-10	Body mass index;
KIRP	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.9	14.98	0.69	1.68e-36	Metabolite levels;
KIRP	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.67	-9.61	-0.52	9.35e-19	Brugada syndrome;
KIRP	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.44	-5.97	-0.36	8.16e-9	Lung cancer;
KIRP	trans	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg05059571	chr16:84539110	KIAA1609	0.63	8.48	0.48	2.12e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.67	9.14	0.5	2.37e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg09558224	chr1:33430421	RNF19B	0.52	6.03	0.36	6.07e-9	Plasma plasminogen activator levels;
KIRP	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.82	-12.9	-0.64	1.97e-29	Dental caries;
KIRP	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.8	10.98	0.57	4.52e-23	Aortic root size;
KIRP	trans	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg16141378	chr3:129829833	LOC729375	0.58	7.68	0.44	3.79e-13	Joint mobility (Beighton score);
KIRP	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	4.99	0.3	1.17e-6	Bipolar disorder;
KIRP	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg14829360	chr17:73884958	NA	0.47	6.26	0.37	1.71e-9	White matter hyperintensity burden;
KIRP	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg27490568	chr2:178487706	NA	0.47	6.2	0.37	2.39e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	8.17	0.46	1.67e-14	Nonalcoholic fatty liver disease;
KIRP	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg27490568	chr2:178487706	NA	1.01	11.87	0.6	5.62e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.73	0.49	3.83e-16	IgG glycosylation;
KIRP	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg07856975	chr6:36356162	ETV7	0.4	5.87	0.35	1.4e-8	Platelet distribution width;
KIRP	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg05805236	chr11:65401703	PCNXL3	0.42	4.97	0.3	1.27e-6	Urate levels;
KIRP	cis	rs7646881	0.953	rs73015657	chr3:158451932	G/A	cg19483011	chr3:158453295	NA	-0.58	-6.35	-0.38	1.03e-9	Tetralogy of Fallot;
KIRP	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg17788227	chr17:7347145	FGF11;CHRNB1	0.49	5.08	0.31	7.45e-7	Androgen levels;
KIRP	cis	rs7572263	0.724	rs12986551	chr2:209052303	T/C	cg23998903	chr2:209048830	C2orf80	-0.36	-5.25	-0.32	3.22e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg10144569	chr3:42726640	KBTBD5	0.5	5.55	0.33	7.3e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg22705602	chr4:152727874	NA	-0.5	-8.7	-0.49	4.8e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs7605235	0.794	rs2384234	chr2:25658808	C/T	cg19212948	chr16:24551685	RBBP6	0.54	6.28	0.37	1.48e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.34	0.37	1.11e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9761603	0.737	rs13120802	chr4:138416821	A/T	cg12033966	chr4:138453416	PCDH18	0.44	5.89	0.35	1.28e-8	Diastolic blood pressure;
KIRP	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.45	1.59e-13	Morning vs. evening chronotype;
KIRP	cis	rs2299587	0.554	rs17634704	chr8:17753306	A/G	cg01800426	chr8:17659068	MTUS1	-0.44	-5.2	-0.31	4.24e-7	Economic and political preferences;
KIRP	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.58	-7.92	-0.45	8.23e-14	Diastolic blood pressure;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg05562828	chr17:3906858	NA	0.74	14.78	0.69	8.59e-36	Type 2 diabetes;
KIRP	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg10664184	chr19:17420304	DDA1	0.79	9.05	0.5	4.46e-17	Systemic lupus erythematosus;
KIRP	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	cg21523751	chr1:182988639	NA	0.43	6.65	0.39	1.86e-10	Hypertriglyceridemia;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg02150674	chr10:13342205	PHYH	-0.48	-6.39	-0.38	8.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	trans	rs4938303	0.681	rs118074548	chr11:116546503	T/C	cg13754915	chr9:140174272	C9orf167	-0.73	-6.17	-0.37	2.79e-9	Triglycerides;
KIRP	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg26876637	chr1:152193138	HRNR	0.73	9.6	0.52	9.91e-19	Atopic dermatitis;
KIRP	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.7	-12.88	-0.63	2.42e-29	Body mass index;
KIRP	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10754283	0.871	rs72712569	chr1:90125657	G/C	cg06121193	chr1:90282411	NA	0.51	6.73	0.39	1.19e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.41	6.21	0.37	2.28e-9	Neuroticism;
KIRP	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg08499158	chr17:42289980	UBTF	-0.46	-5.94	-0.35	9.77e-9	Total body bone mineral density;
KIRP	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg20312557	chr2:97357134	FER1L5	-0.72	-5.26	-0.32	3.18e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6032067	0.929	rs56131549	chr20:43842014	A/T	cg10761708	chr20:43804764	PI3	0.52	5.34	0.32	2.08e-7	Blood protein levels;
KIRP	cis	rs17592366	0.838	rs17102754	chr14:35271273	G/T	cg09327582	chr14:35236912	BAZ1A	-0.66	-4.99	-0.3	1.15e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.53	-6.15	-0.36	3.16e-9	Aortic root size;
KIRP	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09524192	chr20:39657308	TOP1	0.49	6.13	0.36	3.51e-9	Parkinson's disease;
KIRP	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.53	6.77	0.4	9.43e-11	Crohn's disease;
KIRP	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.02	0.69	1.24e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11847929	chr5:134210233	TXNDC15	-0.48	-6.06	-0.36	5.08e-9	Myopia;
KIRP	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg11972305	chr2:233791962	NGEF	0.39	5.49	0.33	1.02e-7	Schizophrenia;
KIRP	cis	rs17453880	0.929	rs4487479	chr5:152008600	C/G	cg12297329	chr5:152029980	NA	-0.7	-10.75	-0.57	2.4e-22	Subjective well-being;
KIRP	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.87	-14.62	-0.68	2.89e-35	Prostate cancer;
KIRP	cis	rs876084	0.505	rs10216978	chr8:121105620	C/A	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12431939	0.779	rs2999381	chr14:51645368	T/C	cg23942311	chr14:51606299	NA	0.46	5.34	0.32	2.12e-7	Cancer;
KIRP	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11878675	chr2:74211845	NA	0.54	7.75	0.44	2.37e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7770628	0.682	rs7772437	chr6:161115245	A/T	cg08531365	chr6:161123263	PLG	0.27	4.91	0.3	1.64e-6	Protein quantitative trait loci;Lipoprotein (a) levels;
KIRP	cis	rs4713675	0.584	rs749847	chr6:33665001	G/C	cg15676125	chr6:33679581	C6orf125	0.42	5.61	0.34	5.56e-8	Plateletcrit;
KIRP	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	8.82	0.49	2.2e-16	Bipolar disorder;
KIRP	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg12011299	chr4:100065546	ADH4	-0.5	-6.9	-0.4	4.4e-11	Alcohol dependence;
KIRP	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg03563238	chr19:33554763	RHPN2	-0.3	-5.23	-0.32	3.64e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.74	11.29	0.58	4.46e-24	Oral cavity cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06870609	chr15:89787223	FANCI	0.45	6.1	0.36	4.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.72	7.98	0.45	5.55e-14	Menarche (age at onset);
KIRP	cis	rs914615	0.552	rs7556304	chr1:155139509	T/C	cg02153340	chr1:155202674	NA	-0.47	-7.19	-0.42	7.56e-12	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.6	0.34	5.85e-8	Putamen volume;
KIRP	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg23682824	chr7:23144976	KLHL7	0.58	7.13	0.41	1.12e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg13819577	chr1:248512075	OR14C36	-0.39	-5.22	-0.32	3.79e-7	Common traits (Other);
KIRP	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	13.94	0.66	6.19e-33	Platelet count;
KIRP	cis	rs12458130	1.000	rs598417	chr18:8666881	C/T	cg25899954	chr18:8660164	NA	-0.61	-5.8	-0.35	2.08e-8	Inflammatory skin disease;
KIRP	cis	rs732716	0.853	rs72990643	chr19:4454736	C/T	cg19820705	chr19:4455316	UBXN6	0.67	8.31	0.47	6.48e-15	Mean corpuscular volume;
KIRP	cis	rs10140922	0.607	rs2415274	chr14:35651467	A/G	cg07166546	chr14:35805898	NA	-0.26	-6.16	-0.37	2.89e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg02975922	chr3:195473998	MUC4	-0.52	-5.85	-0.35	1.55e-8	Pancreatic cancer;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.63	9.36	0.51	5.27e-18	Vitiligo;
KIRP	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg16434002	chr17:42200994	HDAC5	-0.57	-7.06	-0.41	1.73e-11	Total body bone mineral density;
KIRP	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg21395723	chr22:39101663	GTPBP1	0.45	5.47	0.33	1.08e-7	Menopause (age at onset);
KIRP	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.57	8.83	0.49	1.98e-16	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
KIRP	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg00576331	chr11:65640516	EFEMP2	-0.43	-5.36	-0.32	1.96e-7	DNA methylation (variation);
KIRP	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg14768367	chr16:72042858	DHODH	0.45	5.41	0.33	1.51e-7	Fibrinogen levels;
KIRP	cis	rs2278796	0.639	rs6702469	chr1:204968787	A/G	cg17449235	chr1:204966235	NFASC	0.59	8.02	0.46	4.44e-14	Mean platelet volume;
KIRP	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg05370193	chr1:21551575	ECE1	-0.38	-5.11	-0.31	6.36e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2742417	0.967	rs2742441	chr3:45748429	G/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.48	-9.73	-0.53	3.73e-19	Monocyte percentage of white cells;
KIRP	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.64	-0.34	4.64e-8	Breast cancer;
KIRP	cis	rs829661	0.790	rs1252651	chr2:30703758	C/A	cg10949345	chr2:30726833	LCLAT1	1.13	15.93	0.71	9.72e-40	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04910470	chr15:41709534	RTF1	0.54	6.98	0.41	2.76e-11	Parkinson's disease;
KIRP	cis	rs882732	0.576	rs10139508	chr14:95035399	A/G	cg08495878	chr14:95027859	SERPINA4	-0.47	-6.23	-0.37	1.95e-9	Blood protein levels;
KIRP	cis	rs7078219	0.505	rs4129133	chr10:101284570	T/C	cg07044859	chr10:101282883	NA	-0.3	-5.2	-0.31	4.14e-7	Dental caries;
KIRP	trans	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg02030672	chr11:45687055	CHST1	0.51	6.6	0.39	2.53e-10	Obesity-related traits;
KIRP	cis	rs35740288	0.688	rs12904047	chr15:86212866	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.48	-0.33	1.04e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1476679	0.830	rs6971558	chr7:100079857	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.5	-5.34	-0.32	2.11e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2617583	0.935	rs2975223	chr5:1443603	T/C	cg07151155	chr5:1473589	LPCAT1	-0.42	-5.86	-0.35	1.49e-8	Breast cancer;
KIRP	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.78	0.35	2.2e-8	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8014252	0.803	rs7158201	chr14:71010546	A/G	cg11204974	chr14:71022665	NA	0.59	6.39	0.38	8.09e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.66	9.95	0.54	7.8e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.87	-13.77	-0.66	2.36e-32	Menarche (age at onset);
KIRP	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg05692746	chr2:100937584	LONRF2	-0.39	-5.18	-0.31	4.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6589219	0.721	rs12296076	chr11:111166504	C/T	cg25129781	chr11:111156908	C11orf53	-0.46	-6.17	-0.37	2.86e-9	Colorectal cancer;
KIRP	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.78	9.61	0.52	8.97e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7737355	0.741	rs6875363	chr5:130581195	A/G	cg06647332	chr5:131281008	NA	-0.54	-5.22	-0.32	3.9e-7	Life satisfaction;
KIRP	cis	rs12220238	0.915	rs61045754	chr10:76153125	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.29	0.37	1.48e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6499755	0.712	rs31091	chr16:55363818	T/C	cg05099576	chr16:55362342	IRX6	0.3	6.26	0.37	1.72e-9	Hypospadias;
KIRP	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg17145862	chr1:211918768	LPGAT1	-0.94	-13.26	-0.65	1.23e-30	Leprosy;
KIRP	cis	rs1322639	0.614	rs6900200	chr6:169566173	T/C	cg04662567	chr6:169592167	NA	-0.64	-5.42	-0.33	1.4e-7	Pulse pressure;
KIRP	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11987759	chr7:65425863	GUSB	0.62	7.97	0.45	5.85e-14	Aortic root size;
KIRP	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.69	7.4	0.43	2.09e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7236492	0.748	rs80321964	chr18:77210152	G/C	cg15644404	chr18:77186268	NFATC1	-0.93	-7.62	-0.44	5.49e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11877825	0.826	rs4121955	chr18:10569879	C/A	cg25239095	chr18:10589360	NA	0.39	4.85	0.3	2.17e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.65	-7.89	-0.45	9.83e-14	Exhaled nitric oxide output;
KIRP	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.69	-9.47	-0.52	2.4e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.44	0.47	2.69e-15	Bipolar disorder;
KIRP	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.67	9.32	0.51	6.68e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-1.1	-18.54	-0.76	1.29e-48	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg19847130	chr8:10466454	RP1L1	-0.37	-5.51	-0.33	8.95e-8	Retinal vascular caliber;
KIRP	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14169450	chr9:139327907	INPP5E	0.33	4.88	0.3	1.91e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03647317	chr4:187891568	NA	-0.75	-11.82	-0.6	7.79e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7404928	0.718	rs2106376	chr16:23863402	C/A	cg21745164	chr16:23765304	CHP2	-0.6	-7.44	-0.43	1.7e-12	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg19445457	chr11:5799446	OR52N5	-0.44	-5.15	-0.31	5.39e-7	DNA methylation (variation);
KIRP	cis	rs2120243	0.539	rs988587	chr3:157054271	A/C	cg24825693	chr3:157122686	VEPH1	-0.54	-8.46	-0.47	2.42e-15	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg04025307	chr7:1156635	C7orf50	0.74	7.77	0.44	2.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.42	-6.27	-0.37	1.57e-9	Coronary artery disease;
KIRP	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg03160526	chr17:80928410	B3GNTL1	0.41	5.08	0.31	7.56e-7	Glycated hemoglobin levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00778544	chr1:151584659	SNX27	-0.45	-6.24	-0.37	1.87e-9	Metabolic traits;
KIRP	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	14.12	0.67	1.52e-33	Cognitive ability;
KIRP	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg09238746	chr17:78121135	EIF4A3	-0.43	-5.49	-0.33	1.02e-7	Yeast infection;
KIRP	cis	rs687432	0.748	rs6591450	chr11:57790430	C/G	cg19752551	chr11:57585705	CTNND1	-0.46	-6.03	-0.36	5.82e-9	Parkinson's disease;
KIRP	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg21475434	chr5:93447410	FAM172A	0.44	5.11	0.31	6.56e-7	Diabetic retinopathy;
KIRP	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.77	0.35	2.4e-8	Aortic root size;
KIRP	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.66	-10.19	-0.54	1.43e-20	Total body bone mineral density;
KIRP	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg12718519	chr1:2058417	PRKCZ	-0.21	-5.95	-0.35	9.32e-9	Height;
KIRP	cis	rs7923609	0.902	rs10733793	chr10:65323809	T/G	cg01631684	chr10:65280961	REEP3	-0.46	-5.45	-0.33	1.23e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1355223	0.902	rs286861	chr11:34718424	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.65	-0.34	4.36e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-14.39	-0.68	1.83e-34	Chronic sinus infection;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03157738	chr19:11308118	KANK2	0.49	6.1	0.36	3.99e-9	Asthma;
KIRP	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg24488311	chr11:68621650	NA	0.48	5.85	0.35	1.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.22	0.72	1.01e-40	Electrocardiographic conduction measures;
KIRP	cis	rs876084	0.505	rs9297614	chr8:121105444	C/T	cg06265175	chr8:121136014	COL14A1	0.51	6.42	0.38	7.01e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-5.6	-0.34	5.65e-8	Personality dimensions;
KIRP	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3755132	0.929	rs6724800	chr2:15786243	A/G	cg12888861	chr2:15731646	DDX1	0.41	5.29	0.32	2.65e-7	Wilms tumor;
KIRP	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	11.02	0.58	3.12e-23	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg07827796	chr19:33622959	WDR88	0.49	6.25	0.37	1.78e-9	Bone properties (heel);
KIRP	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-11.72	-0.6	1.74e-25	Dental caries;
KIRP	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.92	12.57	0.63	2.49e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7635838	0.822	rs9861633	chr3:11473437	C/G	cg00170343	chr3:11313890	ATG7	0.46	5.91	0.35	1.15e-8	HDL cholesterol;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.73e-8	Life satisfaction;
KIRP	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg16141378	chr3:129829833	LOC729375	0.5	6.18	0.37	2.69e-9	Neuroticism;
KIRP	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.45	-0.52	2.82e-18	Aortic root size;
KIRP	cis	rs311392	0.554	rs311387	chr8:55101623	A/G	cg11783602	chr8:55087084	NA	0.48	6.02	0.36	6.14e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg01304814	chr3:48885189	PRKAR2A	0.56	5.16	0.31	4.98e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs883565	0.502	rs4374473	chr3:38942618	C/T	cg01426195	chr3:39028469	NA	0.48	7.32	0.42	3.42e-12	Handedness;
KIRP	trans	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg06521331	chr12:34319734	NA	-0.5	-6.2	-0.37	2.38e-9	Bladder cancer;
KIRP	cis	rs11161851	1.000	rs11161851	chr1:75298782	A/G	cg11196437	chr1:75593865	LHX8	-0.41	-6.01	-0.36	6.61e-9	Visceral fat;
KIRP	trans	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03602288	chr17:46641863	HOXB3	0.44	6.12	0.36	3.76e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.4	5.04	0.31	9.08e-7	Total body bone mineral density;
KIRP	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.62	-0.39	2.21e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9400467	0.537	rs354533	chr6:111487104	T/G	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.05	0.31	8.59e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12049351	0.719	rs10916492	chr1:229634396	G/T	cg11742688	chr1:229674241	ABCB10	-0.37	-5.52	-0.33	8.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg02487422	chr3:49467188	NICN1	0.39	5.56	0.33	7.02e-8	Menarche (age at onset);
KIRP	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2908197	0.662	rs917423	chr7:75984717	A/G	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.29	-4.88	-0.3	1.94e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-7.83	-0.45	1.42e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg06647332	chr5:131281008	NA	0.46	5.33	0.32	2.19e-7	Life satisfaction;
KIRP	cis	rs75920871	0.623	rs7932655	chr11:116962563	T/A	cg04087571	chr11:116723030	SIK3	-0.28	-5.53	-0.33	8.31e-8	Subjective well-being;
KIRP	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg04607699	chr11:48328132	OR4S1	-0.39	-5.54	-0.33	7.88e-8	Migraine - clinic-based;
KIRP	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.54	9.61	0.52	8.91e-19	Bone mineral density;
KIRP	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24372043	chr1:109102573	FAM102B	0.52	6.21	0.37	2.22e-9	Myopia (pathological);
KIRP	cis	rs654384	0.966	rs612476	chr7:4165790	G/A	cg04612959	chr7:4183976	SDK1	-0.33	-5.16	-0.31	5.02e-7	Positive affect;
KIRP	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg26681399	chr22:41777847	TEF	-0.5	-5.35	-0.32	2.03e-7	Vitiligo;
KIRP	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	0.43	5.15	0.31	5.41e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14829155	chr15:31115871	NA	-0.73	-9.7	-0.53	4.8e-19	Huntington's disease progression;
KIRP	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg02160872	chr5:212506	CCDC127	-0.46	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.56	6.98	0.41	2.8e-11	Longevity;Endometriosis;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-5.89	-0.35	1.28e-8	Longevity;Endometriosis;
KIRP	cis	rs7215564	0.730	rs7212125	chr17:78628863	C/T	cg06153925	chr17:78755379	RPTOR	-0.33	-5.18	-0.31	4.57e-7	Myopia (pathological);
KIRP	cis	rs7572644	0.699	rs7602328	chr2:28235184	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs745080	1.000	rs7159631	chr14:52934531	G/A	cg23333723	chr14:53022898	GPR137C	-0.41	-5.65	-0.34	4.37e-8	Orofacial clefts;
KIRP	cis	rs1891498	0.571	rs1495956	chr1:147238486	C/T	cg27546670	chr1:147246839	GJA5	-0.74	-10.32	-0.55	5.75e-21	Cognitive performance;
KIRP	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg05791153	chr7:19748676	TWISTNB	0.69	6.16	0.37	2.87e-9	Thyroid stimulating hormone;
KIRP	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.83	-14.59	-0.68	3.59e-35	Post bronchodilator FEV1;
KIRP	cis	rs72772090	1.000	rs72772092	chr5:96046912	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.52	-4.87	-0.3	2.02e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10140922	0.966	rs8003074	chr14:35821692	A/C	cg07166546	chr14:35805898	NA	-0.24	-5.94	-0.35	9.76e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg12559939	chr2:27858050	GPN1	0.4	5.01	0.3	1.05e-6	Oral cavity cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16262623	chr17:42297029	UBTF	-0.47	-6.16	-0.37	2.99e-9	Metabolic traits;
KIRP	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg10495392	chr1:46806563	NSUN4	-0.47	-5.33	-0.32	2.2e-7	Menopause (age at onset);
KIRP	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.58	-6.39	-0.38	8.33e-10	DNA methylation (variation);
KIRP	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.78	-11.08	-0.58	2.09e-23	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12279877	chr17:35294230	LHX1	-0.45	-6.12	-0.36	3.7e-9	Myopia;
KIRP	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.53	-5.03	-0.31	9.54e-7	Other erythrocyte phenotypes;
KIRP	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.03	0.64	7.35e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.64	-0.44	4.73e-13	Neuroticism;
KIRP	cis	rs5753618	0.583	rs8141150	chr22:31800336	C/T	cg02404636	chr22:31891804	SFI1	0.52	5.81	0.35	1.97e-8	Colorectal cancer;
KIRP	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-6.73	-0.39	1.15e-10	Axial length;
KIRP	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg00405596	chr8:11794950	NA	-0.41	-5.22	-0.32	3.8e-7	Retinal vascular caliber;
KIRP	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.49	-6.11	-0.36	3.97e-9	Coronary artery disease;
KIRP	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg08975724	chr8:8085496	FLJ10661	0.65	7.91	0.45	8.95e-14	Neuroticism;
KIRP	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg02887458	chr19:19495540	GATAD2A	0.45	5.39	0.33	1.64e-7	Bipolar disorder;
KIRP	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	cis	rs7224685	0.569	rs12950730	chr17:3994225	G/T	cg05562828	chr17:3906858	NA	0.53	5.81	0.35	1.9e-8	Type 2 diabetes;
KIRP	cis	rs17125944	0.686	rs912861	chr14:53333290	C/G	cg00686598	chr14:53173677	PSMC6	-0.75	-7.41	-0.43	1.99e-12	Alzheimer's disease (late onset);
KIRP	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.81	-11.78	-0.6	1.09e-25	Autism;
KIRP	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.22	-0.37	2.11e-9	Dilated cardiomyopathy;
KIRP	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg02487422	chr3:49467188	NICN1	0.35	5.0	0.3	1.08e-6	Parkinson's disease;
KIRP	cis	rs7923452	0.641	rs928055	chr10:30731146	G/A	cg25182066	chr10:30743637	MAP3K8	0.51	5.97	0.36	8.06e-9	Itch intensity from mosquito bite;
KIRP	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.89e-44	Breast cancer;
KIRP	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg05785598	chr3:49045655	WDR6	-0.33	-5.97	-0.36	8.36e-9	Parkinson's disease;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg02737830	chr12:64616354	C12orf66	0.55	6.37	0.38	9e-10	Sleep duration;
KIRP	cis	rs2294693	0.687	rs4714424	chr6:41012506	T/C	cg14769373	chr6:40998127	UNC5CL	-0.43	-5.27	-0.32	3.02e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6570726	0.533	rs1832374	chr6:145717752	A/G	cg23711669	chr6:146136114	FBXO30	0.43	5.52	0.33	8.62e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6738028	0.524	rs7565457	chr2:111935478	C/T	cg04780086	chr2:111875790	ACOXL	0.39	5.18	0.31	4.7e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs7084402	0.967	rs1365740	chr10:60277549	A/C	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.13	12.0	0.61	2.03e-26	Nonalcoholic fatty liver disease;
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg08662619	chr6:150070041	PCMT1	0.36	5.98	0.36	7.89e-9	Lung cancer;
KIRP	cis	rs7011049	0.778	rs72648433	chr8:53879562	C/T	cg26025543	chr8:53854495	NA	0.65	6.84	0.4	6.38e-11	Systolic blood pressure;
KIRP	cis	rs35740288	0.685	rs12899481	chr15:86308970	C/T	cg17133734	chr15:86042851	AKAP13	-0.5	-5.53	-0.33	8.24e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-6.88	-0.4	5.01e-11	D-dimer levels;
KIRP	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.94	15.28	0.7	1.59e-37	Menopause (age at onset);
KIRP	trans	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.89	-0.4	4.63e-11	Bladder cancer;
KIRP	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.46	6.35	0.38	1.02e-9	Sitting height ratio;
KIRP	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-5.94	-0.35	9.67e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.76	6.24	0.37	1.86e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2738048	1.000	rs2738048	chr8:6822785	A/G	cg02787689	chr8:6828103	DEFA10P	-0.3	-5.93	-0.35	1.01e-8	IgA nephropathy;
KIRP	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg03959625	chr15:84868606	LOC388152	0.49	5.98	0.36	7.76e-9	Schizophrenia;
KIRP	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg10547527	chr2:198650123	BOLL	-0.55	-5.04	-0.31	8.83e-7	Ulcerative colitis;
KIRP	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg22705602	chr4:152727874	NA	-0.55	-9.5	-0.52	2.03e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg04025307	chr7:1156635	C7orf50	0.69	7.38	0.43	2.44e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg22705602	chr4:152727874	NA	-0.54	-9.51	-0.52	1.84e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg21360079	chr12:107162445	NA	-0.66	-9.67	-0.52	5.83e-19	Heart rate;
KIRP	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs623323	1.000	rs623323	chr17:700020	A/G	cg02666820	chr17:700054	NA	1.14	16.09	0.72	2.66e-40	Type 2 diabetes;
KIRP	cis	rs6977660	0.714	rs6977079	chr7:19818207	G/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg23052386	chr13:111553101	ANKRD10	0.54	6.33	0.37	1.13e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10822145	1	rs10822145	chr10:64934548	C/T	cg01631684	chr10:65280961	REEP3	-0.48	-5.74	-0.34	2.71e-8	Triglycerides;
KIRP	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg08501292	chr6:25962987	TRIM38	1.01	7.69	0.44	3.46e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.7	0.56	3.43e-22	Lung cancer in ever smokers;
KIRP	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.57	-0.33	6.79e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.87	-11.63	-0.6	3.29e-25	Cognitive function;
KIRP	cis	rs6973256	0.569	rs13246174	chr7:133395004	C/T	cg10665199	chr7:133106180	EXOC4	0.5	6.32	0.37	1.24e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8106542	0.906	rs2288904	chr19:10742170	A/G	cg19742686	chr19:10823913	QTRT1	0.46	4.92	0.3	1.61e-6	Platelet distribution width;
KIRP	cis	rs7818345	0.967	rs7015440	chr8:19276991	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.29	0.37	1.41e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg26134248	chr17:3907702	NA	-0.4	-5.3	-0.32	2.53e-7	Type 2 diabetes;
KIRP	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.73e-10	Diabetic kidney disease;
KIRP	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	9.9	0.53	1.18e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg26876637	chr1:152193138	HRNR	-0.66	-8.67	-0.48	6.03e-16	Atopic dermatitis;
KIRP	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.53	-8.07	-0.46	3.06e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs580438	1.000	rs552525	chr3:13347755	A/G	cg10657019	chr3:13328039	NA	-0.71	-9.16	-0.5	2.1e-17	Myringotomy;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	4.91	0.3	1.69e-6	Electroencephalogram traits;
KIRP	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.24	12.65	0.63	1.34e-28	Diabetic retinopathy;
KIRP	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.71	8.43	0.47	2.97e-15	Corneal astigmatism;
KIRP	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.89	-11.47	-0.59	1.12e-24	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.56	-0.33	6.85e-8	Life satisfaction;
KIRP	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19671926	chr4:122722719	EXOSC9	0.5	6.04	0.36	5.54e-9	Type 2 diabetes;
KIRP	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	15.76	0.71	3.68e-39	Body mass index (adult);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03510158	chr14:74318586	PTGR2	0.54	7.7	0.44	3.23e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03934478	chr11:495069	RNH1	0.86	6.85	0.4	5.83e-11	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21229170	chr8:129331407	NA	0.51	6.83	0.4	6.69e-11	Interleukin-4 levels;
KIRP	cis	rs9653442	0.545	rs11123810	chr2:100759285	T/C	cg17356467	chr2:100759845	AFF3	0.42	5.65	0.34	4.32e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs8063160	0.666	rs12918773	chr16:89741403	G/A	cg07984980	chr16:89898383	SPIRE2	0.84	4.9	0.3	1.75e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg01721255	chr8:58191610	C8orf71	0.61	5.48	0.33	1.07e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.89	0.35	1.29e-8	Total cholesterol levels;
KIRP	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs34853779	1	rs34853779	chr4:144240024	CT/C	cg19876092	chr4:144208277	NA	0.37	5.85	0.35	1.52e-8	Breast cancer;
KIRP	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-1.04	-10.41	-0.55	2.85e-21	Type 2 diabetes;
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	17.56	0.75	2.73e-45	Platelet count;
KIRP	cis	rs16975963	0.644	rs73035158	chr19:38141880	C/A	cg18030218	chr19:38865513	PSMD8	0.53	4.86	0.3	2.06e-6	Longevity;
KIRP	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Bladder cancer;
KIRP	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.57	7.74	0.44	2.63e-13	Prostate cancer;
KIRP	cis	rs9807841	0.538	rs714307	chr19:10835405	C/T	cg17710535	chr19:10819994	QTRT1	0.43	5.06	0.31	8.09e-7	Inflammatory skin disease;
KIRP	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.44	0.33	1.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg04935436	chr20:30431758	NA	0.49	5.85	0.35	1.54e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs11658311	1.000	rs73978990	chr17:17504559	G/T	cg01246520	chr17:17644344	RAI1	0.53	4.89	0.3	1.83e-6	Obsessive-compulsive symptoms;
KIRP	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg23649088	chr2:200775458	C2orf69	0.39	5.08	0.31	7.38e-7	QT interval;
KIRP	cis	rs7252981	0.632	rs11878202	chr19:19744079	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.47	-4.96	-0.3	1.35e-6	Perceived unattractiveness to mosquitoes;
KIRP	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.98	-0.45	5.59e-14	Triglycerides;
KIRP	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	10.02	0.54	4.71e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.39	3.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-1.0	-16.93	-0.73	3.77e-43	Height;
KIRP	cis	rs3218477	1.000	rs3218467	chr7:152359552	C/G	cg06618968	chr7:152373420	XRCC2	-0.84	-5.47	-0.33	1.09e-7	Mean platelet volume;
KIRP	cis	rs7007076	0.901	rs1529618	chr8:124723689	G/A	cg00283535	chr8:124749564	ANXA13	0.59	6.73	0.39	1.21e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.06	11.81	0.6	8.54e-26	Lung cancer in ever smokers;
KIRP	cis	rs7572644	0.713	rs11127129	chr2:28076708	C/G	cg27432699	chr2:27873401	GPN1	-0.44	-4.9	-0.3	1.73e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs4845875	0.600	rs10779765	chr1:11838011	T/C	cg24844545	chr1:11908347	NPPA	0.37	4.92	0.3	1.55e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	trans	rs1106684	1.000	rs55975923	chr7:131463363	T/C	cg13607082	chr12:122652224	LRRC43	-0.66	-6.62	-0.39	2.29e-10	Body mass index;
KIRP	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.44	5.38	0.32	1.76e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg18154014	chr19:37997991	ZNF793	0.63	5.35	0.32	2.02e-7	Coronary artery calcification;
KIRP	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.41	0.74	8.87e-45	Height;
KIRP	cis	rs67385638	0.802	rs7119142	chr11:5309078	A/G	cg12559170	chr11:5275217	HBG2	0.45	6.3	0.37	1.35e-9	Hemoglobin levels;
KIRP	cis	rs7635838	0.819	rs2454481	chr3:11535178	C/T	cg00170343	chr3:11313890	ATG7	0.46	5.78	0.35	2.25e-8	HDL cholesterol;
KIRP	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.93	9.57	0.52	1.19e-18	Platelet distribution width;
KIRP	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.61	-0.39	2.38e-10	Response to antipsychotic treatment;
KIRP	cis	rs5753037	0.630	rs140111	chr22:30131570	A/G	cg01021169	chr22:30184971	ASCC2	-0.45	-6.27	-0.37	1.65e-9	Type 1 diabetes;
KIRP	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg01238044	chr22:24384105	GSTT1	-0.56	-7.25	-0.42	5.43e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7633770	0.931	rs12637421	chr3:46695074	T/C	cg11219411	chr3:46661640	NA	0.5	6.43	0.38	6.46e-10	Coronary artery disease;
KIRP	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.45	-6.05	-0.36	5.38e-9	Height;
KIRP	cis	rs9400467	0.506	rs12209435	chr6:111643037	G/A	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg15841412	chr13:111365552	ING1	0.49	5.59	0.34	6.09e-8	Coronary artery disease;
KIRP	cis	rs7814319	0.674	rs7836698	chr8:97242849	C/T	cg20787634	chr8:97240163	UQCRB	-0.58	-7.79	-0.44	1.89e-13	Lung function (FVC);
KIRP	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	14.07	0.67	2.12e-33	Tonsillectomy;
KIRP	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg08807101	chr21:30365312	RNF160	0.58	7.01	0.41	2.33e-11	Pancreatic cancer;
KIRP	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11987759	chr7:65425863	GUSB	-0.64	-8.46	-0.47	2.39e-15	Aortic root size;
KIRP	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg23842812	chr7:76127459	DTX2	-0.52	-5.14	-0.31	5.66e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	12.61	0.63	1.91e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	0.93	12.76	0.63	5.71e-29	Homoarginine levels;
KIRP	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.45	-6.9	-0.4	4.44e-11	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15204945	chr19:39694177	SYCN	0.5	6.24	0.37	1.91e-9	Interleukin-4 levels;
KIRP	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs6901004	0.803	rs402014	chr6:111527696	C/T	cg15721981	chr6:111408429	SLC16A10	-0.45	-6.07	-0.36	4.71e-9	Blood metabolite levels;
KIRP	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-0.66	-7.79	-0.44	1.87e-13	Initial pursuit acceleration;
KIRP	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.6	-0.39	2.47e-10	Mood instability;
KIRP	cis	rs2223471	0.905	rs9349557	chr6:50733176	G/A	cg03432817	chr6:50765336	NA	-0.43	-6.58	-0.39	2.83e-10	Subcutaneous adipose tissue;
KIRP	cis	rs8038465	0.615	rs6495074	chr15:73959013	A/G	cg15420318	chr15:73925796	NPTN	0.62	8.77	0.49	2.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-5.3	-0.32	2.52e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.65	-10.07	-0.54	3.35e-20	Hip circumference;Waist circumference;
KIRP	cis	rs1881396	0.945	rs1881395	chr2:27838549	G/A	cg27432699	chr2:27873401	GPN1	0.53	6.16	0.37	2.88e-9	Nonalcoholic fatty liver disease;
KIRP	cis	rs7523273	0.925	rs12749612	chr1:208006749	A/G	cg22525895	chr1:207977042	MIR29B2	-0.67	-8.29	-0.47	7.26e-15	Schizophrenia;
KIRP	cis	rs6750795	0.518	rs1434519	chr2:232433761	A/G	cg19187155	chr2:232395269	NMUR1	0.68	7.48	0.43	1.34e-12	Height;
KIRP	cis	rs6690583	0.623	rs893620	chr1:85425821	T/C	cg22153463	chr1:85462885	MCOLN2	0.59	4.86	0.3	2.1e-6	Serum sulfate level;
KIRP	cis	rs77688320	0.535	rs11691118	chr2:202269844	G/A	cg06431681	chr2:202330990	STRADB	0.51	6.87	0.4	5.16e-11	Breast cancer;
KIRP	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg21184320	chr1:21044207	KIF17	-0.36	-5.49	-0.33	9.91e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg26043149	chr18:55253948	FECH	0.51	6.19	0.37	2.5e-9	Bone mineral density;
KIRP	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.85	-0.53	1.6e-19	Coronary artery disease;
KIRP	cis	rs1978968	1.000	rs7286219	chr22:18445709	G/C	cg02610425	chr22:18483192	MICAL3	0.37	5.16	0.31	4.98e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.14e-11	Blood metabolite levels;
KIRP	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg23067535	chr8:124195133	FAM83A	-0.72	-7.1	-0.41	1.31e-11	Urinary uromodulin levels;
KIRP	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.41	-5.94	-0.35	9.65e-9	Height;
KIRP	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.38	0.32	1.72e-7	Coronary artery disease;
KIRP	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.26	26.64	0.86	1.85e-74	IgG glycosylation;
KIRP	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg08742575	chr21:47604166	C21orf56	-0.38	-5.08	-0.31	7.31e-7	Testicular germ cell tumor;
KIRP	cis	rs4478037	0.731	rs9835090	chr3:33107671	G/T	cg19404215	chr3:33155277	CRTAP	0.63	5.78	0.35	2.28e-8	Major depressive disorder;
KIRP	cis	rs2380205	0.967	rs4256891	chr10:5888058	T/C	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg00012203	chr2:219082015	ARPC2	0.84	11.94	0.61	3.19e-26	Colorectal cancer;
KIRP	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.35	-0.32	2.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg23477460	chr3:66848765	NA	0.62	7.16	0.42	9.41e-12	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg18209359	chr17:80159595	CCDC57	-0.41	-5.46	-0.33	1.16e-7	Life satisfaction;
KIRP	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.5	6.89	0.4	4.75e-11	Mean corpuscular volume;
KIRP	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg12257156	chr7:158823799	VIPR2	0.3	4.95	0.3	1.36e-6	Facial morphology (factor 20);
KIRP	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg25486957	chr4:152246857	NA	-0.5	-5.48	-0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg07936489	chr17:37558343	FBXL20	-0.41	-5.01	-0.3	1.05e-6	Asthma;
KIRP	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.63	-0.34	4.98e-8	Recombination measurement;
KIRP	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg03834567	chr2:218808745	TNS1	0.47	5.7	0.34	3.46e-8	Ulcerative colitis;
KIRP	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg07395648	chr5:131743802	NA	-0.56	-7.81	-0.45	1.65e-13	Breast cancer;Mosquito bite size;
KIRP	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.6	-0.44	6.39e-13	Initial pursuit acceleration;
KIRP	cis	rs4849845	0.653	rs34874174	chr2:121011980	A/C	cg24070213	chr2:121070622	NA	0.38	5.67	0.34	3.97e-8	Mean platelet volume;
KIRP	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg23682824	chr7:23144976	KLHL7	0.51	5.97	0.36	8.4e-9	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10191600	chr6:89391994	RNGTT	-0.43	-6.83	-0.4	6.73e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg11650704	chr1:154556575	ADAR	-0.41	-4.97	-0.3	1.23e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7116495	1.000	rs675185	chr11:71775572	T/G	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg17252645	chr8:143867129	LY6D	-0.31	-4.98	-0.3	1.21e-6	Urinary tract infection frequency;
KIRP	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	1.26	18.3	0.76	8.61e-48	Night sleep phenotypes;
KIRP	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg25547332	chr5:131281432	NA	0.49	5.27	0.32	2.95e-7	Life satisfaction;
KIRP	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	6.45	0.38	6e-10	Neuroticism;
KIRP	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	0.84	7.54	0.43	8.76e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.32	-0.42	3.45e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.48	-6.56	-0.39	3.07e-10	Asthma;
KIRP	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg23335576	chr14:104009727	NA	0.4	5.7	0.34	3.42e-8	Body mass index;
KIRP	cis	rs13424612	0.930	rs12478169	chr2:240951603	C/T	cg01812947	chr2:240904978	NDUFA10	0.5	6.51	0.38	4.1e-10	Odorant perception (isobutyraldehyde);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg12843872	chr7:90894352	FZD1	-0.55	-6.88	-0.4	5.04e-11	Neuroticism;
KIRP	cis	rs9290877	0.667	rs9833465	chr3:188454859	C/A	cg17392043	chr3:188495102	LPP	-0.5	-6.51	-0.38	4.13e-10	IgE levels;
KIRP	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.9	13.99	0.67	4.02e-33	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24534173	chr17:3375043	SPATA22	0.47	6.24	0.37	1.87e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.73	-0.39	1.19e-10	Capecitabine sensitivity;
KIRP	cis	rs2901656	0.934	rs2285170	chr1:172425529	C/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.44	5.47	0.33	1.09e-7	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg09238746	chr17:78121135	EIF4A3	-0.4	-4.99	-0.3	1.16e-6	Yeast infection;
KIRP	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg27147174	chr7:100797783	AP1S1	-0.7	-8.95	-0.5	8.96e-17	Life satisfaction;
KIRP	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.17	-0.37	2.79e-9	Obesity-related traits;
KIRP	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg24881330	chr22:46731750	TRMU	0.72	6.07	0.36	4.78e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg23587288	chr2:27483067	SLC30A3	-0.64	-7.23	-0.42	6.19e-12	Blood metabolite levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01694628	chr15:25478725	SNORD115-35	-0.47	-6.87	-0.4	5.37e-11	Survival in pancreatic cancer;
KIRP	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.69	-9.51	-0.52	1.83e-18	Breast cancer;
KIRP	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg22654517	chr2:96458247	NA	0.34	5.07	0.31	7.78e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.41	6.23	0.37	1.99e-9	Hypertriglyceridemia;
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.56	-6.69	-0.39	1.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg03289416	chr15:75166202	SCAMP2	0.5	6.73	0.39	1.17e-10	Breast cancer;
KIRP	cis	rs3736485	0.966	rs11634180	chr15:51895757	G/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.15	-0.31	5.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg16590910	chr6:42928470	GNMT	0.38	5.3	0.32	2.53e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1147199	0.585	rs72737614	chr9:87244571	A/G	cg22402007	chr9:87282823	NTRK2	0.4	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs490234	0.769	rs519812	chr9:128348790	T/G	cg14078157	chr9:128172775	NA	0.39	4.88	0.3	1.92e-6	Mean arterial pressure;
KIRP	cis	rs7766436	0.885	rs6935379	chr6:22581462	A/G	cg13666174	chr6:22585274	NA	-0.44	-6.1	-0.36	4.02e-9	Coronary artery disease;
KIRP	cis	rs4740619	0.619	rs10810521	chr9:16031471	C/G	cg14451791	chr9:16040625	NA	-0.42	-5.44	-0.33	1.3e-7	Body mass index;
KIRP	cis	rs853679	0.546	rs175597	chr6:27810626	T/C	cg21204522	chr6:27730016	NA	-0.74	-5.45	-0.33	1.19e-7	Depression;
KIRP	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.85	-13.03	-0.64	7.31e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg19636519	chr7:99541626	NA	0.27	4.85	0.3	2.23e-6	Coronary artery disease;
KIRP	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg15488143	chr7:128924101	AHCYL2	0.6	6.51	0.38	4.28e-10	White matter hyperintensity burden;
KIRP	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.74	-7.85	-0.45	1.32e-13	Blood pressure (smoking interaction);
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg17441377	chr17:3906640	NA	0.52	7.77	0.44	2.07e-13	Type 2 diabetes;
KIRP	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg21033440	chr11:65409861	SIPA1	-0.46	-5.07	-0.31	7.67e-7	Blood pressure (age interaction);
KIRP	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg27494647	chr7:150038898	RARRES2	0.38	5.67	0.34	3.95e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.93	0.3	1.49e-6	Leprosy;
KIRP	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.6	7.83	0.45	1.46e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-15.88	-0.71	1.5e-39	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11671005	0.504	rs2305119	chr19:59067623	C/T	cg22037779	chr5:139682734	PFDN1	-0.53	-6.31	-0.37	1.26e-9	Mean platelet volume;
KIRP	cis	rs5762813	0.510	rs35814864	chr22:29285148	T/C	cg02153584	chr22:29168773	CCDC117	0.58	4.95	0.3	1.37e-6	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg01872077	chr2:219646372	CYP27A1	0.41	5.31	0.32	2.45e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.34	-0.32	2.11e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.19	15.25	0.7	2.09e-37	Platelet count;
KIRP	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg12131826	chr15:77904385	NA	0.43	5.67	0.34	4.07e-8	Type 2 diabetes;
KIRP	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.96	13.1	0.64	4.29e-30	Breast cancer;
KIRP	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14895029	chr7:2775587	GNA12	-0.43	-5.08	-0.31	7.52e-7	Height;
KIRP	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.59	6.43	0.38	6.62e-10	Aortic root size;
KIRP	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-21.89	-0.81	1.15e-59	Height;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15331837	chr8:142232772	SLC45A4	0.46	6.22	0.37	2.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Educational attainment;
KIRP	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg10189774	chr4:17578691	LAP3	0.55	6.87	0.4	5.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03510158	chr14:74318586	PTGR2	0.48	6.15	0.37	3.14e-9	Parkinson's disease;
KIRP	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.1	-0.46	2.56e-14	Body mass index;
KIRP	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg18646521	chr2:111875858	NA	0.4	5.77	0.35	2.34e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.81	-8.92	-0.49	1.08e-16	Response to diuretic therapy;
KIRP	cis	rs10211205	0.945	rs10186625	chr2:236617112	G/A	cg13770573	chr2:236586376	AGAP1	-0.55	-5.97	-0.36	8.04e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.62	-6.59	-0.39	2.6200000000000003e-10	DNA methylation (variation);
KIRP	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.68	8.91	0.49	1.18e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.59	-0.34	6.17e-8	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-8.96	-0.5	8.54e-17	Brugada syndrome;
KIRP	cis	rs13226913	0.967	rs10251505	chr7:7254489	A/G	cg04827551	chr7:7268805	C1GALT1	0.35	5.21	0.32	3.9e-7	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg18016565	chr1:150552671	MCL1	0.38	5.82	0.35	1.85e-8	Melanoma;
KIRP	cis	rs1147199	0.585	rs72737616	chr9:87244935	C/T	cg22402007	chr9:87282823	NTRK2	0.4	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.69	8.72	0.49	4.3e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.53	7.26	0.42	5.22e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg20542592	chr8:11973495	FAM66D	0.4	5.08	0.31	7.42e-7	Neuroticism;
KIRP	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.79	-8.08	-0.46	2.95e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	4.88	0.3	1.9e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-6.74	-0.39	1.14e-10	Sjögren's syndrome;Systemic lupus erythematosus;
KIRP	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg00576331	chr11:65640516	EFEMP2	0.51	5.65	0.34	4.46e-8	Crohn's disease;
KIRP	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg09998033	chr7:158218633	PTPRN2	0.37	4.87	0.3	2.02e-6	Obesity-related traits;
KIRP	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.62	-8.49	-0.48	2.02e-15	Autism;
KIRP	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.99	15.83	0.71	2.17e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.37	5.11	0.31	6.6e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26337566	chr1:243391613	CEP170	-0.41	-6.47	-0.38	5.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.62	-8.72	-0.49	4.27e-16	Mean corpuscular volume;
KIRP	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.67	-7.42	-0.43	1.96e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9400467	0.506	rs10456872	chr6:111586667	C/T	cg15721981	chr6:111408429	SLC16A10	0.75	6.87	0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.67	8.71	0.49	4.67e-16	Lymphocyte counts;
KIRP	cis	rs6445967	1.000	rs7622074	chr3:58312297	A/G	cg16569813	chr3:58235849	ABHD6	-0.33	-5.01	-0.3	1.04e-6	Platelet count;
KIRP	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.64	8.18	0.46	1.49e-14	Response to antipsychotic treatment;
KIRP	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.36	0.47	4.75e-15	Motion sickness;
KIRP	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.9	0.3	1.71e-6	Educational attainment;
KIRP	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.32	-0.42	3.47e-12	Bipolar disorder;
KIRP	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.49	-0.33	9.78e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg12598211	chr12:123634384	NA	-0.41	-4.98	-0.3	1.2e-6	Neutrophil percentage of white cells;
KIRP	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg00343986	chr7:65444356	GUSB	-0.41	-5.03	-0.31	9.53e-7	Aortic root size;
KIRP	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.27	0.42	4.63e-12	Coffee consumption (cups per day);
KIRP	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg10818794	chr15:86012489	AKAP13	-0.51	-7.25	-0.42	5.46e-12	Coronary artery disease;
KIRP	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg03468072	chr12:39539422	NA	0.43	5.77	0.35	2.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs6558174	0.802	rs3758040	chr8:22487087	T/C	cg03733263	chr8:22462867	KIAA1967	0.53	6.32	0.37	1.25e-9	Breast cancer;
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.71	-10.59	-0.56	7.71e-22	Monocyte percentage of white cells;
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg19923238	chr8:142232952	SLC45A4	0.45	5.33	0.32	2.19e-7	Immature fraction of reticulocytes;
KIRP	cis	rs16828019	0.852	rs3820090	chr1:41573652	A/G	cg08144172	chr1:41849203	NA	0.62	4.89	0.3	1.78e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.41	-0.43	2.08e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7113874	1.000	rs10840099	chr11:8667680	T/C	cg08015107	chr11:8618950	NA	0.34	4.86	0.3	2.11e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.35	0.47	5.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg02336718	chr17:17403227	NA	0.4	6.2	0.37	2.35e-9	Total body bone mineral density;
KIRP	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.49	6.0	0.36	6.87e-9	Initial pursuit acceleration;
KIRP	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.22	0.46	1.2e-14	Total body bone mineral density;
KIRP	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg22563815	chr15:78856949	CHRNA5	0.5	7.94	0.45	7.4e-14	Sudden cardiac arrest;
KIRP	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg00204512	chr16:28754710	NA	0.49	6.36	0.38	9.92e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14834257	chr1:153586504	S100A16	0.44	6.04	0.36	5.7e-9	Survival in pancreatic cancer;
KIRP	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.73	9.71	0.53	4.53e-19	Breast cancer;
KIRP	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg02359409	chr6:42947317	PEX6	-0.38	-5.15	-0.31	5.4e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6504950	0.830	rs17817901	chr17:53038745	A/G	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.85	12.89	0.63	2.22e-29	Height;
KIRP	cis	rs10782582	0.609	rs11161848	chr1:76367722	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-7.01	-0.41	2.35e-11	Daytime sleep phenotypes;
KIRP	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-5.1	-0.31	6.76e-7	Ulcerative colitis;
KIRP	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs60154123	0.730	rs4844987	chr1:210458190	G/T	cg09074223	chr1:210466472	NA	0.54	5.55	0.33	7.25e-8	Coronary artery disease;
KIRP	trans	rs1864585	0.520	rs17774398	chr8:10632496	A/G	cg26278703	chr11:58910052	FAM111A	-0.62	-6.28	-0.37	1.49e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4731207	0.698	rs886704	chr7:124422266	C/T	cg05630886	chr7:124431682	NA	-0.29	-4.89	-0.3	1.78e-6	Cutaneous malignant melanoma;
KIRP	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.62	6.71	0.39	1.3100000000000001e-10	Gut microbiome composition (summer);
KIRP	cis	rs6968419	0.674	rs6466571	chr7:115910045	A/G	cg02561103	chr7:115862891	TES	0.41	5.85	0.35	1.55e-8	Intraocular pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03442064	chr6:41515050	FOXP4	0.58	6.96	0.41	3.14e-11	Smoking initiation;
KIRP	cis	rs12210905	1.000	rs72842200	chr6:27068036	C/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6960043	0.818	rs1558318	chr7:15065612	A/T	cg19272540	chr7:15055459	NA	-0.23	-6.49	-0.38	4.74e-10	Type 2 diabetes;
KIRP	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14706720	chr19:44259176	C19orf61	0.52	7.16	0.42	9.42e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs687432	0.924	rs1397273	chr11:57705324	C/T	cg19752551	chr11:57585705	CTNND1	0.4	5.41	0.33	1.52e-7	Parkinson's disease;
KIRP	cis	rs7106204	1.000	rs7931691	chr11:24221123	C/A	ch.11.24196551F	chr11:24239977	NA	0.82	8.76	0.49	3.27e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	13.13	0.64	3.33e-30	Intelligence (multi-trait analysis);
KIRP	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.68	-8.35	-0.47	4.95e-15	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1318772	1.000	rs36611	chr5:112755990	A/C	cg12552261	chr5:112820674	MCC	0.77	4.97	0.3	1.24e-6	F-cell distribution;
KIRP	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.97	14.9	0.69	3.21e-36	Diastolic blood pressure;
KIRP	cis	rs7582720	0.667	rs114863726	chr2:204158375	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.05	8.25	0.47	9.35e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7939886	0.920	rs59895837	chr11:56096099	T/A	cg03929089	chr4:120376271	NA	0.89	6.13	0.36	3.53e-9	Myopia (pathological);
KIRP	cis	rs7870753	0.838	rs3802441	chr9:99220395	A/G	cg25260653	chr9:99212216	HABP4	0.56	6.2	0.37	2.38e-9	Height;
KIRP	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.61	9.31	0.51	7.28e-18	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06966887	chr5:443603	EXOC3;C5orf55	0.56	7.61	0.44	5.97e-13	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs17253792	0.545	rs71412688	chr14:56021539	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs988913	0.723	rs9464197	chr6:54998738	A/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.42	-0.33	1.39e-7	Menarche (age at onset);
KIRP	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs4237845	0.591	rs11172389	chr12:58337671	G/A	cg02175503	chr12:58329896	NA	0.88	10.44	0.55	2.32e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg13010199	chr12:38710504	ALG10B	0.64	7.84	0.45	1.34e-13	Morning vs. evening chronotype;
KIRP	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg25801113	chr15:45476975	SHF	-0.44	-8.11	-0.46	2.41e-14	Uric acid levels;
KIRP	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.72	0.49	4.13e-16	IgG glycosylation;
KIRP	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.9	-15.29	-0.7	1.51e-37	Oral cavity cancer;
KIRP	cis	rs4704187	0.712	rs7701262	chr5:74365986	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-1.07	-20.49	-0.79	4.04e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg26134248	chr17:3907702	NA	0.56	8.31	0.47	6.62e-15	Type 2 diabetes;
KIRP	cis	rs59698941	0.943	rs12520928	chr5:132305891	C/A	cg14825688	chr5:132208181	LEAP2	-0.51	-4.9	-0.3	1.74e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.32	-7.27	-0.42	4.87e-12	Mean corpuscular volume;
KIRP	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs11874712	1.000	rs9783888	chr18:43651370	G/T	cg26436583	chr18:43649176	PSTPIP2	-0.43	-5.86	-0.35	1.49e-8	Migraine - clinic-based;
KIRP	cis	rs554111	0.891	rs671905	chr1:21047092	A/T	cg21184320	chr1:21044207	KIF17	0.48	6.88	0.4	5.03e-11	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6681460	0.604	rs7546825	chr1:67101802	A/G	cg13052034	chr1:66999238	SGIP1	0.35	4.97	0.3	1.23e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.5	-0.52	1.97e-18	Mood instability;
KIRP	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.53	-7.15	-0.41	9.86e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9457247	0.811	rs239936	chr6:167411616	C/T	cg07741184	chr6:167504864	NA	0.22	5.64	0.34	4.6e-8	Crohn's disease;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg21698718	chr17:80085957	CCDC57	-0.34	-4.89	-0.3	1.86e-6	Life satisfaction;
KIRP	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg23587288	chr2:27483067	SLC30A3	-0.67	-7.63	-0.44	5.13e-13	Blood metabolite levels;
KIRP	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg23100626	chr2:96804247	ASTL	0.45	6.21	0.37	2.29e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg12131826	chr15:77904385	NA	0.44	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.67	-8.41	-0.47	3.32e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.96	11.38	0.59	2.27e-24	Corneal astigmatism;
KIRP	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.13	9.3	0.51	8.1e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs80282103	0.618	rs74117849	chr10:1165425	A/G	cg08668510	chr10:1095578	IDI1	0.93	6.16	0.37	2.96e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-10.58	-0.56	8.28e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.81	-0.35	1.93e-8	Recombination measurement;
KIRP	cis	rs2904967	0.703	rs2957111	chr11:65003447	A/C	cg12562828	chr11:65076843	NA	-0.86	-11.64	-0.6	3.17e-25	Mean corpuscular volume;
KIRP	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.59	7.2	0.42	7.23e-12	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.72	9.31	0.51	7.41e-18	Bladder cancer;
KIRP	cis	rs42648	0.564	rs1541428	chr7:89836279	A/G	cg25739043	chr7:89950458	NA	-0.39	-6.05	-0.36	5.39e-9	Homocysteine levels;
KIRP	cis	rs6547631	0.635	rs4616480	chr2:85897768	C/T	cg24620635	chr2:85921963	GNLY	0.37	5.56	0.33	7.08e-8	Blood protein levels;
KIRP	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.9	11.12	0.58	1.55e-23	Eosinophil percentage of granulocytes;
KIRP	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.77	9.52	0.52	1.7e-18	Coronary artery disease;
KIRP	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg08514558	chr10:81106712	PPIF	0.41	5.75	0.34	2.64e-8	Height;
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-4.97	-0.3	1.24e-6	Life satisfaction;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.93	-14.11	-0.67	1.59e-33	Longevity;Endometriosis;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04787407	chr4:99916511	METAP1	0.57	6.33	0.37	1.14e-9	Lung cancer in ever smokers;
KIRP	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.53	4.89	0.3	1.78e-6	Height;
KIRP	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.55	7.4	0.43	2.14e-12	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.45	-0.38	5.89e-10	Retinal vascular caliber;
KIRP	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	7.52	0.43	1.01e-12	Systemic lupus erythematosus;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00027037	chr18:21977708	OSBPL1A	-0.45	-6.22	-0.37	2.18e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg19539972	chr4:7069911	GRPEL1	0.44	5.15	0.31	5.24e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg24009623	chr19:33667908	NA	0.45	5.41	0.33	1.48e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	13.63	0.66	6.71e-32	Tonsillectomy;
KIRP	cis	rs9815354	1.000	rs9839399	chr3:41928044	G/A	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.11e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg21361702	chr7:150065534	REPIN1	0.51	5.01	0.3	1.06e-6	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14893161	chr1:205819251	PM20D1	0.5	5.54	0.33	7.83e-8	Parkinson's disease;
KIRP	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26526719	chr5:1949144	NA	0.44	5.25	0.32	3.29e-7	Gut microbiome composition (winter);
KIRP	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg05370193	chr1:21551575	ECE1	0.38	5.19	0.31	4.41e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs13343954	0.825	rs12461135	chr19:33534185	A/G	cg27124370	chr19:33622961	WDR88	0.62	6.85	0.4	5.77e-11	Colorectal cancer;
KIRP	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg13393036	chr8:95962371	TP53INP1	0.38	7.51	0.43	1.09e-12	Type 2 diabetes;
KIRP	cis	rs17321999	0.951	rs73925103	chr2:30474515	A/C	cg05247661	chr2:30472410	LBH	0.75	8.11	0.46	2.36e-14	Systemic lupus erythematosus;
KIRP	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs4332428	1.000	rs35464459	chr10:4964640	T/C	cg19648686	chr10:5044992	AKR1C2	-0.93	-7.65	-0.44	4.62e-13	Height;
KIRP	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg17376030	chr22:41985996	PMM1	-0.54	-5.73	-0.34	2.93e-8	Vitiligo;
KIRP	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg23387468	chr7:139079360	LUC7L2	0.3	5.23	0.32	3.68e-7	Diisocyanate-induced asthma;
KIRP	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.69	7.22	0.42	6.28e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.77	8.87	0.49	1.49e-16	Corneal astigmatism;
KIRP	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.31e-14	Obesity-related traits;
KIRP	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.47	5.91	0.35	1.16e-8	Facial morphology (factor 20);
KIRP	trans	rs12043259	0.730	rs750089	chr1:204810199	C/T	cg11485465	chr5:54518469	NA	0.36	6.35	0.38	1.03e-9	Addiction;
KIRP	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08564027	chr20:61660810	NA	0.92	13.93	0.66	6.5e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.38	-5.1	-0.31	6.8e-7	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
KIRP	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.65	-8.18	-0.46	1.54e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4654899	0.680	rs10916885	chr1:21188703	A/T	cg08890418	chr1:21044141	KIF17	-0.34	-5.06	-0.31	8.18e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.55	7.57	0.43	7.28e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.29	12.33	0.62	1.61e-27	Diabetic retinopathy;
KIRP	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.6	-7.43	-0.43	1.8e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.83	12.58	0.63	2.36e-28	Ulcerative colitis;
KIRP	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg19507638	chr5:93509721	C5orf36	-0.57	-5.18	-0.31	4.69e-7	Diabetic retinopathy;
KIRP	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg27490568	chr2:178487706	NA	0.41	5.53	0.33	8.04e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.13e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.43	5.14	0.31	5.5e-7	Aortic root size;
KIRP	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg00405596	chr8:11794950	NA	-0.47	-6.52	-0.38	3.94e-10	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22085335	chr2:11052081	KCNF1	0.48	6.57	0.39	3.05e-10	Parkinson's disease;
KIRP	cis	rs427941	0.694	rs2529094	chr7:101739617	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.71	0.39	1.36e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-1.07	-8.19	-0.46	1.38e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.75	-10.9	-0.57	7.78e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.3	1e-6	Initial pursuit acceleration;
KIRP	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-9.04	-0.5	4.65e-17	Total cholesterol levels;
KIRP	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.7	-8.66	-0.48	6.38e-16	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.57	7.81	0.45	1.66e-13	Vitiligo;
KIRP	trans	rs2055729	0.710	rs114038384	chr8:9737519	T/A	cg06636001	chr8:8085503	FLJ10661	0.56	6.2	0.37	2.31e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs968451	0.552	rs715505	chr22:39751251	G/C	cg24399712	chr22:39784796	NA	-0.44	-5.61	-0.34	5.45e-8	Primary biliary cholangitis;
KIRP	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg22676075	chr6:135203613	NA	0.46	6.64	0.39	1.94e-10	Red blood cell count;
KIRP	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.6	-6.49	-0.38	4.68e-10	Gut microbiome composition (summer);
KIRP	cis	rs6684514	0.961	rs72710222	chr1:156285995	T/C	cg16558208	chr1:156270281	VHLL	-0.43	-5.73	-0.34	2.9e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6496667	0.642	rs58218975	chr15:91056798	C/G	cg10434728	chr15:90938212	IQGAP1	0.38	4.87	0.3	1.96e-6	Rheumatoid arthritis;
KIRP	cis	rs9443645	0.527	rs9718121	chr6:79729887	T/A	cg09184832	chr6:79620586	NA	-0.38	-5.09	-0.31	6.97e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg10223061	chr2:219282414	VIL1	0.35	5.64	0.34	4.76e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.72e-6	Systolic blood pressure;
KIRP	cis	rs78487399	0.908	rs74854268	chr2:43844079	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.13	-0.31	5.87e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg02187348	chr16:89574699	SPG7	0.41	4.96	0.3	1.31e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.12	-0.61	8.02e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg21640587	chr11:117668038	DSCAML1	0.45	6.66	0.39	1.76e-10	Myopia;
KIRP	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg08992911	chr2:238395768	MLPH	0.4	5.08	0.31	7.52e-7	Prostate cancer;
KIRP	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.52	-5.89	-0.35	1.29e-8	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.91	14.93	0.69	2.49e-36	Metabolic syndrome;
KIRP	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.79	-8.71	-0.49	4.41e-16	Hirschsprung disease;
KIRP	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.68	-9.25	-0.51	1.15e-17	Response to temozolomide;
KIRP	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg11833968	chr6:79620685	NA	-0.44	-6.44	-0.38	6.31e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.67	-8.1	-0.46	2.62e-14	Aortic root size;
KIRP	cis	rs2019216	0.835	rs402052	chr17:21908388	G/C	cg22648282	chr17:21454238	C17orf51	-0.38	-5.09	-0.31	7.2e-7	Pelvic organ prolapse;
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.83	14.27	0.67	4.58e-34	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.63	8.49	0.48	1.97e-15	Lung cancer;
KIRP	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg03959625	chr15:84868606	LOC388152	0.53	6.16	0.37	2.98e-9	Schizophrenia;
KIRP	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.91	-14.7	-0.68	1.61e-35	Height;
KIRP	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg13010199	chr12:38710504	ALG10B	0.49	6.54	0.38	3.58e-10	Bladder cancer;
KIRP	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.55	-0.48	1.3e-15	Mood instability;
KIRP	cis	rs10875746	0.951	rs8804	chr12:48541757	A/G	cg26205652	chr12:48591994	NA	0.75	10.29	0.55	6.88e-21	Longevity (90 years and older);
KIRP	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.3	-6.36	-0.38	9.55e-10	Cutaneous nevi;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11532578	chr1:10387937	KIF1B	0.42	6.22	0.37	2.12e-9	Migraine with aura;
KIRP	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg03585969	chr10:35415529	CREM	0.8	9.69	0.53	5.17e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.24	-0.37	1.88e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-12.98	-0.64	1.04e-29	Vitiligo;
KIRP	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs2367563	0.964	rs7980442	chr12:96056774	T/C	cg19013339	chr12:96052514	NTN4	0.36	5.49	0.33	1.02e-7	Allergic dermatitis (nickel);
KIRP	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg06565975	chr8:143823917	SLURP1	0.58	8.23	0.46	1.08e-14	Urinary tract infection frequency;
KIRP	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.35	0.62	1.34e-27	Ileal carcinoids;
KIRP	cis	rs10858047	0.883	rs3789624	chr1:115116434	A/G	cg12756093	chr1:115239321	AMPD1	0.69	6.52	0.38	4.07e-10	Autism;
KIRP	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.67	-11.79	-0.6	1.03e-25	White blood cell count (basophil);
KIRP	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs11679564	0.714	rs4670638	chr2:37164911	C/G	cg14987922	chr2:37194071	STRN	0.49	5.79	0.35	2.19e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.55	-9.47	-0.52	2.39e-18	Obesity-related traits;
KIRP	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg18132916	chr6:79620363	NA	-0.44	-6.12	-0.36	3.68e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg26681399	chr22:41777847	TEF	0.43	4.9	0.3	1.73e-6	Vitiligo;
KIRP	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg09163369	chr1:210001066	C1orf107	-0.46	-6.02	-0.36	6.37e-9	Monobrow;
KIRP	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.69	-8.67	-0.48	5.98e-16	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1971762	0.762	rs4759282	chr12:54072435	C/A	cg16917193	chr12:54089295	NA	0.72	9.77	0.53	2.81e-19	Height;
KIRP	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg01559446	chr3:44596178	ZNF167	-0.35	-5.1	-0.31	6.85e-7	Depressive symptoms;
KIRP	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10185552	chr2:61404578	AHSA2	0.52	6.37	0.38	9.08e-10	Parkinson's disease;
KIRP	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg06268327	chr11:63885740	FLRT1;MACROD1	0.44	5.07	0.31	7.79e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.83	8.65	0.48	6.75e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs62355272	0.900	rs6872264	chr5:35831790	A/G	cg13894535	chr5:35919491	CAPSL	-0.4	-5.06	-0.31	8.31e-7	Lymphocyte counts;
KIRP	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.43	-6.45	-0.38	5.94e-10	Tuberculosis;
KIRP	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg13939156	chr17:80058883	NA	-0.48	-5.5	-0.33	9.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	1.1	20.31	0.79	1.64e-54	Gut microbiome composition (winter);
KIRP	cis	rs35883536	1.000	rs17403905	chr1:101107358	T/C	cg06223162	chr1:101003688	GPR88	0.32	6.58	0.39	2.73e-10	Monocyte count;
KIRP	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.58	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs12043259	0.730	rs7524795	chr1:204793408	T/C	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg17724175	chr1:150552817	MCL1	-0.44	-7.28	-0.42	4.41e-12	Urate levels;
KIRP	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-8.44	-0.47	2.73e-15	Mean corpuscular volume;
KIRP	cis	rs12049351	0.774	rs10916495	chr1:229635521	A/G	cg11742688	chr1:229674241	ABCB10	-0.37	-5.52	-0.33	8.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.72	-0.34	3.09e-8	Neuroticism;
KIRP	cis	rs11955398	0.585	rs4700384	chr5:60032471	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.33	-0.32	2.23e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13147522	chr11:68228078	SAPS3	0.52	6.52	0.38	3.95e-10	Parkinson's disease;
KIRP	cis	rs367943	0.712	rs26967	chr5:112741467	C/G	cg12552261	chr5:112820674	MCC	0.56	6.69	0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg14784868	chr12:69753453	YEATS4	0.5	5.17	0.31	4.89e-7	Response to diuretic therapy;
KIRP	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg23587288	chr2:27483067	SLC30A3	0.59	7.6	0.44	6.36e-13	Blood metabolite levels;
KIRP	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.43	-0.52	3.23e-18	Coronary artery disease;
KIRP	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.6	6.83	0.4	6.5500000000000006e-11	Vitiligo;
KIRP	trans	rs11809524	0.759	rs7513552	chr1:103520958	T/C	cg15143788	chr5:92909434	FLJ42709	-0.51	-6.12	-0.36	3.57e-9	Bone mineral density;
KIRP	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-0.96	-8.59	-0.48	1.01e-15	Blood protein levels;
KIRP	cis	rs6594713	0.756	rs6872490	chr5:112784592	T/C	cg12552261	chr5:112820674	MCC	0.65	6.91	0.4	4.04e-11	Brain cytoarchitecture;
KIRP	cis	rs684232	0.901	rs450289	chr17:629896	G/T	cg12384639	chr17:618140	VPS53	0.38	4.87	0.3	1.96e-6	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs2904967	0.929	rs1195733	chr11:65016838	C/A	cg09225861	chr11:65069680	NA	-0.43	-5.65	-0.34	4.38e-8	Mean corpuscular volume;
KIRP	cis	rs6076065	0.651	rs6114085	chr20:23419276	T/A	cg26790198	chr20:23419120	CSTL1	-0.36	-5.25	-0.32	3.22e-7	Facial morphology (factor 15, philtrum width);
KIRP	trans	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg16141378	chr3:129829833	LOC729375	0.57	7.66	0.44	4.39e-13	Mood instability;
KIRP	cis	rs16857609	0.628	rs1382438	chr2:218338829	A/C	cg15335768	chr2:218268053	DIRC3	-0.36	-5.33	-0.32	2.18e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs6005807	0.719	rs9625522	chr22:29045212	C/A	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs28489187	0.706	rs233091	chr1:85823044	G/C	cg16011679	chr1:85725395	C1orf52	0.49	6.13	0.36	3.44e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg11641102	chr8:27183873	PTK2B	0.43	5.65	0.34	4.32e-8	Neuroticism;
KIRP	cis	rs2219968	1.000	rs34130020	chr8:78962583	T/C	cg00738934	chr8:78996279	NA	0.41	5.14	0.31	5.49e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.04	0.31	8.95e-7	Parkinson's disease;
KIRP	cis	rs17410015	0.764	rs17610195	chr1:101428464	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	5.06	0.31	8.1e-7	Response to antipsychotic treatment;
KIRP	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.86	13.3	0.65	8.91e-31	Multiple myeloma;
KIRP	cis	rs78487399	0.908	rs35478206	chr2:43831032	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.18	-0.31	4.73e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs35883536	0.528	rs1577512	chr1:101030832	G/A	cg06223162	chr1:101003688	GPR88	0.47	9.71	0.53	4.36e-19	Monocyte count;
KIRP	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg11518657	chr1:67396239	MIER1	-0.6	-5.91	-0.35	1.17e-8	Lymphocyte percentage of white cells;
KIRP	trans	rs2302464	1.000	rs6811179	chr4:15685351	A/T	cg05318361	chr4:1166839	LOC100130872-SPON2;SPON2	0.5	6.07	0.36	4.9e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	ch.11.340609R	chr11:12831013	TEAD1	0.45	5.61	0.34	5.57e-8	Educational attainment (years of education);
KIRP	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg12559939	chr2:27858050	GPN1	0.41	5.09	0.31	6.97e-7	Oral cavity cancer;
KIRP	cis	rs6684514	1.000	rs12041164	chr1:156279811	G/A	cg16558208	chr1:156270281	VHLL	-0.43	-5.79	-0.35	2.13e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg03235661	chr20:60525775	NA	-0.34	-5.24	-0.32	3.53e-7	Body mass index;
KIRP	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.62	7.8	0.45	1.76e-13	Coronary artery disease;
KIRP	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.52	6.36	0.38	9.52e-10	Bone mineral density;
KIRP	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.03	0.41	2.09e-11	Bipolar disorder;
KIRP	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg20701182	chr2:24300061	SF3B14	0.64	5.46	0.33	1.19e-7	Lymphocyte counts;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.6	-0.34	5.66e-8	Life satisfaction;
KIRP	cis	rs7246657	0.638	rs7246461	chr19:38196581	C/G	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.02	-0.3	9.93e-7	Coronary artery calcification;
KIRP	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.72	10.52	0.56	1.32e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.65	0.34	4.43e-8	Skin colour saturation;
KIRP	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg24998770	chr7:37888106	TXNDC3	0.45	5.96	0.36	8.68e-9	Alzheimer's disease (late onset);
KIRP	cis	rs714515	0.934	rs2301453	chr1:172358167	A/G	cg01573306	chr1:172330400	DNM3	-0.43	-5.67	-0.34	3.89e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.88	11.64	0.6	3e-25	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs17030434	0.953	rs11099905	chr4:154686183	A/G	cg14289246	chr4:154710475	SFRP2	0.76	9.02	0.5	5.48e-17	Electrocardiographic conduction measures;
KIRP	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg08662619	chr6:150070041	PCMT1	0.39	6.41	0.38	7.41e-10	Lung cancer;
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg01798813	chr17:3906674	NA	0.51	7.16	0.42	9.18e-12	Type 2 diabetes;
KIRP	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg04310649	chr10:35416472	CREM	-0.59	-6.96	-0.41	3.15e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.94	12.28	0.62	2.32e-27	Menopause (age at onset);
KIRP	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.2	8.42	0.47	3.13e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.68	-6.91	-0.4	4.18e-11	Migraine;Coronary artery disease;
KIRP	cis	rs6690583	0.623	rs12042910	chr1:85452580	G/A	cg22153463	chr1:85462885	MCOLN2	0.59	5.37	0.32	1.84e-7	Serum sulfate level;
KIRP	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17376030	chr22:41985996	PMM1	-0.62	-6.57	-0.39	2.95e-10	Vitiligo;
KIRP	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.46	5.96	0.36	8.85e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.32	-0.37	1.21e-9	Diastolic blood pressure;
KIRP	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.37	-5.18	-0.31	4.62e-7	Plateletcrit;
KIRP	cis	rs14403	1.000	rs74777638	chr1:243661742	T/C	cg21452805	chr1:244014465	NA	0.54	5.31	0.32	2.48e-7	Schizophrenia;
KIRP	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg23587288	chr2:27483067	SLC30A3	-0.71	-8.08	-0.46	2.84e-14	Blood metabolite levels;
KIRP	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-8.85	-0.49	1.73e-16	Chronic sinus infection;
KIRP	cis	rs7106204	0.925	rs3924745	chr11:24223001	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	10.87	0.57	1.01e-22	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg02920148	chr11:66056751	YIF1A	0.49	6.06	0.36	5.01e-9	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11458533	chr7:127307809	SND1	-0.43	-6.49	-0.38	4.75e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg09231725	chr11:64357281	SLC22A12	0.61	8.24	0.47	9.97e-15	Urate levels in obese individuals;
KIRP	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	8.17	0.46	1.58e-14	Schizophrenia;
KIRP	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.71	-8.14	-0.46	2.01e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg08662619	chr6:150070041	PCMT1	0.39	6.4	0.38	7.93e-10	Lung cancer;
KIRP	cis	rs4740619	0.684	rs1887669	chr9:16035428	G/A	cg14451791	chr9:16040625	NA	-0.39	-5.15	-0.31	5.42e-7	Body mass index;
KIRP	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.37	-0.47	4.41e-15	Neuroticism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01975338	chr14:97326473	VRK1	0.39	6.06	0.36	4.98e-9	C-reactive protein;
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.23	-0.32	3.62e-7	Lung cancer;
KIRP	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.59	-6.45	-0.38	5.81e-10	Aortic root size;
KIRP	cis	rs9843304	0.528	rs12488846	chr3:149186061	C/T	cg08667024	chr3:149219783	TM4SF4	-0.42	-6.49	-0.38	4.62e-10	Gallstone disease;
KIRP	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.58	0.39	2.87e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.22	0.42	6.37e-12	Height;
KIRP	cis	rs8077577	1.000	rs7207276	chr17:18065737	G/C	cg18869244	chr17:18121946	NA	0.48	5.38	0.32	1.78e-7	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg07701084	chr6:150067640	NUP43	0.72	10.17	0.54	1.71e-20	Lung cancer;
KIRP	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg12384639	chr17:618140	VPS53	0.49	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.09	0.41	1.46e-11	Lung cancer;
KIRP	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.44	-6.58	-0.39	2.79e-10	Schizophrenia;
KIRP	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg07274523	chr3:49395745	GPX1	0.58	5.52	0.33	8.75e-8	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg03465714	chr1:152285911	FLG	0.52	5.59	0.34	5.89e-8	Atopic dermatitis;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg05861140	chr6:150128134	PCMT1	-0.48	-6.76	-0.4	1.01e-10	Lung cancer;
KIRP	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.46	5.27	0.32	2.96e-7	Schizophrenia;
KIRP	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg09137382	chr11:130731461	NA	0.56	8.2	0.46	1.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-9.03	-0.5	5.1e-17	Morning vs. evening chronotype;
KIRP	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11050527	chr8:54755511	ATP6V1H	0.67	6.19	0.37	2.56e-9	Lung function (FEV1);
KIRP	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.67	7.12	0.41	1.2e-11	Gout;
KIRP	cis	rs34779708	0.931	rs4934720	chr10:35376800	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg05991184	chr2:219186017	PNKD	-0.36	-5.07	-0.31	7.79e-7	Colorectal cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27124293	chr6:170124346	PHF10	-0.58	-6.31	-0.37	1.26e-9	Menopause (age at onset);
KIRP	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg01566213	chr4:1579287	NA	0.37	5.14	0.31	5.68e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.49	6.13	0.36	3.53e-9	Height;
KIRP	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.67	-8.52	-0.48	1.59e-15	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	1.08	20.24	0.79	2.69e-54	Height;
KIRP	cis	rs503341	0.756	rs11231596	chr11:63594222	G/A	cg04362095	chr11:63592001	C11orf84	-0.79	-12.14	-0.61	6.91e-27	Pulse pressure;
KIRP	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg20999797	chr1:1681921	NA	0.53	8.22	0.46	1.15e-14	Body mass index;
KIRP	cis	rs8105265	1	rs8105265	chr19:2920705	A/G	cg07504200	chr19:2889208	NA	-0.61	-5.05	-0.31	8.8e-7	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-1.05	-11.82	-0.6	7.77e-26	Corneal structure;
KIRP	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg11972305	chr2:233791962	NGEF	0.4	4.97	0.3	1.28e-6	Schizophrenia;
KIRP	cis	rs7520050	0.966	rs61783220	chr1:46335312	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg19116668	chr7:99932089	PMS2L1	-0.54	-6.21	-0.37	2.28e-9	Coronary artery disease;
KIRP	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg01971667	chr8:817044	NA	-0.52	-6.59	-0.39	2.61e-10	Clozapine-induced cytotoxicity;
KIRP	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.85	-0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.76	12.09	0.61	9.78e-27	Menarche (age at onset);
KIRP	cis	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12736577	chr2:52480467	NA	-0.39	-6.47	-0.38	5.31e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Educational attainment;
KIRP	cis	rs7520050	0.966	rs785491	chr1:46583418	G/A	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7551222	0.680	rs2125855	chr1:204546947	T/C	cg20240347	chr1:204465584	NA	-0.38	-6.19	-0.37	2.48e-9	Schizophrenia;
KIRP	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg16649577	chr8:11646810	NA	0.38	5.22	0.32	3.76e-7	Retinal vascular caliber;
KIRP	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs2299587	0.650	rs12548412	chr8:17796970	G/T	cg01800426	chr8:17659068	MTUS1	-0.59	-6.89	-0.4	4.76e-11	Economic and political preferences;
KIRP	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.73	0.34	2.88e-8	Bipolar disorder;
KIRP	cis	rs11249608	0.750	rs6891216	chr5:178447026	G/C	cg21905437	chr5:178450457	ZNF879	0.51	5.88	0.35	1.33e-8	Pubertal anthropometrics;
KIRP	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	1.05	21.47	0.81	2.61e-58	Breast cancer;
KIRP	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.74	-9.85	-0.53	1.68e-19	Childhood ear infection;
KIRP	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.09	-0.31	7.03e-7	Heart rate;
KIRP	cis	rs5753618	0.561	rs9609254	chr22:31705942	G/A	cg02404636	chr22:31891804	SFI1	0.47	5.33	0.32	2.2e-7	Colorectal cancer;
KIRP	trans	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg00405596	chr8:11794950	NA	-0.45	-6.04	-0.36	5.53e-9	Myopia;Myopia (pathological);
KIRP	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg03653399	chr8:142233436	SLC45A4	-0.74	-10.01	-0.54	5.36e-20	Immature fraction of reticulocytes;
KIRP	cis	rs1699337	0.538	rs66615477	chr3:12298314	G/T	cg02700894	chr3:12045449	SYN2	-0.37	-5.08	-0.31	7.31e-7	Cholesterol, total;
KIRP	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.68	10.44	0.55	2.34e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg13147721	chr7:65941812	NA	0.78	6.38	0.38	8.52e-10	Diabetic kidney disease;
KIRP	cis	rs7011507	1.000	rs76600923	chr8:49120467	C/T	cg15325961	chr8:49183143	NA	0.64	5.17	0.31	4.94e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg15252951	chr6:33757062	LEMD2	0.48	5.53	0.33	8.29e-8	Crohn's disease;
KIRP	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg05082376	chr22:42548792	NA	-0.44	-5.84	-0.35	1.63e-8	Schizophrenia;
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg16931447	chr4:875861	GAK	-0.46	-5.88	-0.35	1.32e-8	Sjögren's syndrome;
KIRP	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.64	9.51	0.52	1.85e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.49	6.46	0.38	5.63e-10	Body mass index;
KIRP	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.41	5.27	0.32	2.97e-7	Aortic root size;
KIRP	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.61	-6.71	-0.39	1.3100000000000001e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.98	-0.36	7.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.97	14.18	0.67	9e-34	Morning vs. evening chronotype;
KIRP	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07570687	chr10:102243282	WNT8B	0.54	7.11	0.41	1.25e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg19680485	chr15:31195859	MTMR15	-0.54	-5.02	-0.3	1e-6	Hypertriglyceridemia;
KIRP	cis	rs16970672	0.824	rs9904097	chr17:75984984	A/G	cg08969274	chr17:75848810	NA	0.34	5.08	0.31	7.46e-7	Psychosis and Alzheimer's disease;
KIRP	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.96	10.72	0.56	3.05e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg22437258	chr11:111473054	SIK2	0.55	6.46	0.38	5.71e-10	Primary sclerosing cholangitis;
KIRP	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg21427119	chr20:30132790	HM13	-0.55	-6.08	-0.36	4.54e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.72	-9.04	-0.5	4.71e-17	Aortic root size;
KIRP	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.68	9.04	0.5	4.87e-17	Mood instability;
KIRP	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.83	0.49	2.05e-16	Bladder cancer;
KIRP	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.72	8.94	0.5	9.41e-17	Gut microbiome composition (summer);
KIRP	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.83	11.55	0.59	5.94e-25	Schizophrenia;
KIRP	cis	rs1030877	1.000	rs2576737	chr2:105891510	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.67	10.68	0.56	4.01e-22	Obesity-related traits;
KIRP	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg05340658	chr4:99064831	C4orf37	0.46	5.14	0.31	5.63e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.63	0.44	5.21e-13	Neuroticism;
KIRP	cis	rs1215050	0.791	rs6838628	chr4:98809574	A/G	cg05340658	chr4:99064831	C4orf37	0.58	7.0	0.41	2.41e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg24060327	chr5:131705240	SLC22A5	-0.43	-4.88	-0.3	1.9e-6	Breast cancer;Mosquito bite size;
KIRP	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-5.14	-0.31	5.48e-7	Neuroticism;
KIRP	cis	rs2733310	0.895	rs2278613	chr15:57179300	A/G	cg13626582	chr15:57592083	LOC283663	0.24	5.63	0.34	4.95e-8	Mean platelet volume;
KIRP	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4073416	0.595	rs1956010	chr14:66151090	G/A	cg03016385	chr14:66212404	NA	-0.39	-5.0	-0.3	1.12e-6	N-glycan levels;
KIRP	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg00147788	chr6:125855365	NA	-0.31	-4.93	-0.3	1.51e-6	Brugada syndrome;
KIRP	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.94	-14.46	-0.68	1.01e-34	Lung cancer;
KIRP	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.45	5.22	0.32	3.77e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4971059	0.654	rs4971076	chr1:155124772	C/A	cg02153340	chr1:155202674	NA	-0.43	-6.14	-0.36	3.21e-9	Breast cancer;
KIRP	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg24315340	chr6:146058215	EPM2A	0.4	4.98	0.3	1.21e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg12262378	chr17:6899522	ALOX12	0.33	6.04	0.36	5.69e-9	Tonsillectomy;
KIRP	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.37	-0.32	1.78e-7	Lung cancer;
KIRP	cis	rs9653442	0.545	rs1821826	chr2:100764711	C/T	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	IgG glycosylation;
KIRP	cis	rs4650994	0.571	rs6425486	chr1:178528822	G/A	cg12486710	chr1:178512616	C1orf220	-0.23	-4.93	-0.3	1.49e-6	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg27490568	chr2:178487706	NA	0.53	7.31	0.42	3.76e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs74181299	0.653	rs2723091	chr2:65302017	C/T	cg05010058	chr2:65284262	CEP68	0.39	4.87	0.3	2e-6	Pulse pressure;
KIRP	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg19468946	chr17:37922297	IKZF3	-0.38	-5.2	-0.31	4.15e-7	Asthma;
KIRP	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.75	-0.57	2.4e-22	Height;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26471467	chr22:38669073	TMEM184B	-0.5	-5.18	-0.31	4.53e-7	Menopause (age at onset);
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg03188948	chr7:1209495	NA	0.86	7.6	0.44	6.11e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.68	10.02	0.54	4.93e-20	Dupuytren's disease;
KIRP	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.6	8.84	0.49	1.84e-16	Menarche (age at onset);
KIRP	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.15	0.31	5.47e-7	Menopause (age at onset);
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.63	8.63	0.48	7.62e-16	Mean corpuscular volume;
KIRP	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.65	-0.52	6.93e-19	Response to antipsychotic treatment;
KIRP	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.51	5.93	0.35	1.01e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs7005380	0.531	rs7018038	chr8:120934904	T/C	cg21645572	chr8:120931649	DEPDC6	-0.5	-6.76	-0.4	9.94e-11	Interstitial lung disease;
KIRP	trans	rs7939886	0.920	rs10792448	chr11:55804542	C/G	cg03929089	chr4:120376271	NA	0.95	7.05	0.41	1.75e-11	Myopia (pathological);
KIRP	cis	rs7709377	0.574	rs1508875	chr5:115496470	C/T	cg23108291	chr5:115420582	COMMD10	-0.41	-4.85	-0.3	2.19e-6	Metabolite levels  (X-11787);
KIRP	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg19773385	chr1:10388646	KIF1B	-0.7	-9.9	-0.53	1.18e-19	Hepatocellular carcinoma;
KIRP	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg18882449	chr10:104885122	NT5C2	-0.47	-5.99	-0.36	7.3e-9	Arsenic metabolism;
KIRP	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg12315302	chr6:26189340	HIST1H4D	0.95	6.52	0.38	4.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg13334819	chr7:99746414	C7orf59	0.53	6.01	0.36	6.53e-9	Coronary artery disease;
KIRP	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.11e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg10755058	chr3:40428713	ENTPD3	0.39	5.51	0.33	8.95e-8	Renal cell carcinoma;
KIRP	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2013441	0.670	rs35317166	chr17:19959820	T/A	cg04132472	chr17:19861366	AKAP10	0.43	4.98	0.3	1.2e-6	Obesity-related traits;
KIRP	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.12	0.46	2.23e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg01304814	chr3:48885189	PRKAR2A	0.58	5.1	0.31	6.93e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02801073	chr3:50388115	TUSC4;CYB561D2	0.63	8.28	0.47	7.86e-15	Parkinson's disease;
KIRP	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.77	10.26	0.55	8.31e-21	Alzheimer's disease (late onset);
KIRP	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.49	0.33	1.01e-7	Menopause (age at onset);
KIRP	cis	rs6669919	0.967	rs6678844	chr1:211674774	G/T	cg10512769	chr1:211675356	NA	-0.64	-10.23	-0.55	1.03e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg24203234	chr3:128598194	ACAD9	0.44	5.09	0.31	7.28e-7	IgG glycosylation;
KIRP	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.52	6.89	0.4	4.62e-11	Height;
KIRP	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	4.98e-9	Depression;
KIRP	cis	rs12786942	0.569	rs11224766	chr11:101312430	T/A	cg03942599	chr11:101341554	TRPC6	0.54	7.5	0.43	1.12e-12	Facial depth;
KIRP	cis	rs7082209	1.000	rs61856381	chr10:44811172	T/C	cg13191911	chr10:44806660	NA	-0.5	-4.88	-0.3	1.9e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs5756391	0.546	rs9607390	chr22:37314533	C/T	cg16356956	chr22:37317934	CSF2RB	0.37	5.05	0.31	8.53e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.15	12.98	0.64	1.11e-29	Uric acid levels;
KIRP	cis	rs6901004	0.803	rs1040903	chr6:111470153	A/C	cg15721981	chr6:111408429	SLC16A10	-0.57	-7.74	-0.44	2.65e-13	Blood metabolite levels;
KIRP	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg11833968	chr6:79620685	NA	-0.37	-5.57	-0.33	6.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04731861	chr2:219085781	ARPC2	-0.28	-7.24	-0.42	5.86e-12	Colorectal cancer;
KIRP	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg17372223	chr3:52568218	NT5DC2	0.32	5.34	0.32	2.12e-7	Bipolar disorder;
KIRP	cis	rs4356932	1.000	rs4859598	chr4:76959828	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs7756236	0.521	rs6930671	chr6:36625272	T/C	cg08179530	chr6:36648295	CDKN1A	0.44	5.73	0.34	2.99e-8	QRS duration;
KIRP	cis	rs918629	0.567	rs6877329	chr5:95261538	C/G	cg16656078	chr5:95278638	ELL2	-0.35	-5.3	-0.32	2.61e-7	IgG glycosylation;
KIRP	cis	rs10214930	0.813	rs6462033	chr7:27618685	A/G	cg22168087	chr7:27702803	HIBADH	0.52	5.03	0.31	9.5e-7	Hypospadias;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.04	-0.31	9.2e-7	Life satisfaction;
KIRP	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg05941025	chr16:89927596	SPIRE2	0.35	5.5	0.33	9.46e-8	Vitiligo;
KIRP	cis	rs793571	0.714	rs972801	chr15:58921198	C/T	cg05156742	chr15:59063176	FAM63B	-0.51	-6.14	-0.36	3.38e-9	Schizophrenia;
KIRP	cis	rs8010715	0.816	rs6573572	chr14:24599230	C/A	cg23112188	chr14:24563095	PCK2	-0.34	-5.04	-0.31	9.06e-7	IgG glycosylation;
KIRP	cis	rs17095355	1.000	rs17095350	chr10:111701708	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.04	-0.36	5.62e-9	Biliary atresia;
KIRP	cis	rs741677	0.964	rs8077122	chr17:495522	G/A	cg06217071	chr17:408420	NA	-0.5	-7.16	-0.42	9.13e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8028182	0.636	rs11636031	chr15:75815758	T/C	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.56	6.54	0.38	3.51e-10	Corneal astigmatism;
KIRP	cis	rs2671245	0.966	rs2819487	chr1:56163856	C/T	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16936870	0.543	rs61606320	chr8:71259488	A/G	cg14232793	chr8:71155543	NCOA2	0.54	6.24	0.37	1.95e-9	QT interval;
KIRP	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.23	-0.42	5.94e-12	Type 2 diabetes;
KIRP	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg14541582	chr5:601475	NA	-0.58	-6.64	-0.39	2.04e-10	Obesity-related traits;
KIRP	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17376030	chr22:41985996	PMM1	0.71	7.58	0.43	7.18e-13	Vitiligo;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.23	-0.55	1.09e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs986417	0.818	rs10144990	chr14:60927816	T/C	cg27398547	chr14:60952738	C14orf39	0.67	5.77	0.35	2.42e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.72	-10.67	-0.56	4.25e-22	Hip circumference;
KIRP	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg23752985	chr2:85803571	VAMP8	0.45	5.41	0.33	1.49e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg24253500	chr15:84953950	NA	0.63	6.81	0.4	7.62e-11	Schizophrenia;
KIRP	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg17366294	chr4:99064904	C4orf37	0.44	6.4	0.38	7.84e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.79	5.06	0.31	8.15e-7	LDL cholesterol levels;Total cholesterol levels;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg11431257	chr3:143692087	C3orf58	-0.49	-6.85	-0.4	5.79e-11	Morning vs. evening chronotype;
KIRP	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-6.16	-0.37	3.02e-9	Breast cancer;
KIRP	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg11204139	chr17:3907470	NA	-0.81	-14.66	-0.68	2.21e-35	Type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg16926213	chr1:1841314	NA	0.31	5.23	0.32	3.64e-7	Body mass index;
KIRP	cis	rs1355223	0.902	rs34610590	chr11:34725440	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.75e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.59	7.79	0.44	1.89e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.93	-0.35	1.04e-8	Crohn's disease;
KIRP	cis	rs6743068	0.541	rs12052257	chr2:202241594	C/T	cg06431681	chr2:202330990	STRADB	-0.38	-5.3	-0.32	2.58e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs6691722	0.503	rs3765432	chr1:24706461	A/G	cg18323236	chr1:24743029	NIPAL3	0.46	6.57	0.39	3e-10	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02725872	chr8:58115012	NA	-0.65	-6.29	-0.37	1.47e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.5	-7.09	-0.41	1.42e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.23	-0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.74	-10.83	-0.57	1.34e-22	Dupuytren's disease;
KIRP	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.73	-5.97	-0.36	8.24e-9	Diabetic retinopathy;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg25703541	chr22:24373054	LOC391322	-0.93	-15.25	-0.7	2.03e-37	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.75	8.09	0.46	2.74e-14	Uric acid levels;
KIRP	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.66	9.31	0.51	7.31e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg22764044	chr5:178986830	RUFY1	0.52	7.72	0.44	2.84e-13	Lung cancer;
KIRP	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.59	-6.34	-0.37	1.08e-9	DNA methylation (variation);
KIRP	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg08975724	chr8:8085496	FLJ10661	0.51	6.69	0.39	1.49e-10	Joint mobility (Beighton score);
KIRP	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	6.02	0.36	6.37e-9	Type 2 diabetes;
KIRP	cis	rs11577318	0.579	rs35456934	chr1:26686864	G/A	cg00852783	chr1:26633632	UBXN11	-0.46	-5.24	-0.32	3.46e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9962915	1.000	rs1785409	chr18:5594739	C/T	cg12967001	chr18:5544089	EPB41L3	0.4	4.99	0.3	1.13e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.08	-0.41	1.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg02487422	chr3:49467188	NICN1	0.45	4.93	0.3	1.51e-6	Menarche (age at onset);
KIRP	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.2e-8	Aortic root size;
KIRP	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg25173405	chr17:45401733	C17orf57	-0.45	-6.2	-0.37	2.33e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.26e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11756659	0.653	rs185635	chr6:25957109	G/A	cg21844956	chr6:25963442	TRIM38	0.47	5.14	0.31	5.69e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg17724175	chr1:150552817	MCL1	0.3	5.01	0.3	1.03e-6	Melanoma;
KIRP	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-6.0	-0.36	7.04e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6723108	0.651	rs35215000	chr2:135367656	C/A	cg12500956	chr2:135428796	TMEM163	-0.41	-5.67	-0.34	3.92e-8	Type 2 diabetes;
KIRP	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg11814155	chr7:99998594	ZCWPW1	0.56	5.45	0.33	1.2e-7	Platelet count;
KIRP	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.47	3.67e-15	Motion sickness;
KIRP	cis	rs8044868	0.530	rs4788464	chr16:72223899	T/C	cg16558253	chr16:72132732	DHX38	-0.38	-5.11	-0.31	6.51e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.23	-0.37	2.05e-9	Breast cancer;
KIRP	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg23791538	chr6:167370224	RNASET2	-0.46	-5.71	-0.34	3.24e-8	Crohn's disease;
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.88	-0.45	1.07e-13	Platelet count;
KIRP	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg15893493	chr8:124194847	FAM83A	0.98	7.08	0.41	1.53e-11	Urinary uromodulin levels;
KIRP	cis	rs10203711	0.705	rs4286234	chr2:239616695	G/C	cg14580085	chr2:239553406	NA	0.38	4.88	0.3	1.93e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg02175503	chr12:58329896	NA	0.55	5.95	0.35	9.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg21775007	chr8:11205619	TDH	-0.6	-7.69	-0.44	3.57e-13	Retinal vascular caliber;
KIRP	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.72	10.62	0.56	6.08e-22	Coronary artery disease;
KIRP	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.54	6.41	0.38	7.3e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.76	9.49	0.52	2.07e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg11569703	chr11:65557185	OVOL1	0.73	14.09	0.67	1.89e-33	Acne (severe);
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg26174226	chr8:58114915	NA	-0.53	-5.22	-0.32	3.76e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.08	0.31	7.43e-7	Height;
KIRP	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.44	-9.9	-0.53	1.18e-19	Alzheimer's disease (late onset);
KIRP	cis	rs10982256	0.774	rs13286452	chr9:117246574	C/T	cg13636371	chr9:117264095	DFNB31	0.58	8.05	0.46	3.48e-14	Bipolar disorder;
KIRP	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg16141378	chr3:129829833	LOC729375	0.61	8.21	0.46	1.25e-14	Neuroticism;
KIRP	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg23594656	chr7:65796392	TPST1	-0.45	-6.34	-0.37	1.12e-9	Aortic root size;
KIRP	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg20312557	chr2:97357134	FER1L5	-0.73	-5.29	-0.32	2.64e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.56	0.33	6.86e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08100565	chr3:140660748	SLC25A36	0.51	6.14	0.36	3.25e-9	Parkinson's disease;
KIRP	cis	rs6700559	0.740	rs4437908	chr1:200648439	A/G	cg07804481	chr1:200639085	DDX59	0.5	6.55	0.39	3.37e-10	Coronary artery disease;
KIRP	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg08975724	chr8:8085496	FLJ10661	0.59	8.17	0.46	1.58e-14	Neuroticism;
KIRP	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.18	0.51	1.85e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.8	10.76	0.57	2.17e-22	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs12543645	0.609	rs35112858	chr8:10277269	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.07	0.36	4.86e-9	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07562458	chr1:224622430	WDR26	0.49	7.06	0.41	1.67e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.52	0.48	1.57e-15	Motion sickness;
KIRP	cis	rs8192282	0.739	rs12124333	chr1:154478292	T/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.33	-4.87	-0.3	1.98e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg11584989	chr19:19387371	SF4	0.41	5.27	0.32	3.05e-7	Tonsillectomy;
KIRP	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.49	6.76	0.4	9.81e-11	Red blood cell count;
KIRP	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.46	6.32	0.37	1.19e-9	Gout;
KIRP	cis	rs2481665	0.740	rs2457831	chr1:62633581	C/T	cg18591186	chr1:62594603	INADL	0.56	8.32	0.47	6.2e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg18944383	chr4:111397179	ENPEP	-0.42	-6.93	-0.4	3.59e-11	Coronary artery disease;
KIRP	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.74	-8.21	-0.46	1.29e-14	Corneal astigmatism;
KIRP	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.59	0.44	6.6e-13	Major depressive disorder;
KIRP	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.44	6.08	0.36	4.57e-9	Total body bone mineral density;
KIRP	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg17376030	chr22:41985996	PMM1	-0.83	-8.91	-0.49	1.18e-16	Cannabis dependence symptom count;
KIRP	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	0.85	7.43	0.43	1.74e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.76	10.7	0.56	3.42e-22	Red blood cell count;
KIRP	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.19	-0.51	1.69e-17	Platelet count;
KIRP	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.54	7.08	0.41	1.47e-11	HDL cholesterol;
KIRP	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.79	-8.17	-0.46	1.65e-14	Multiple sclerosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22746109	chr2:20494247	PUM2	-0.38	-6.25	-0.37	1.83e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg16989719	chr2:238392110	NA	-0.59	-8.33	-0.47	5.88e-15	Prostate cancer;
KIRP	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.02	-0.5	5.42e-17	Retinal vascular caliber;
KIRP	cis	rs2048656	0.540	rs55868514	chr8:9680400	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-5.49	-0.33	1e-7	Schizophrenia;
KIRP	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg02297831	chr4:17616191	MED28	-0.51	-6.29	-0.37	1.47e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg10223061	chr2:219282414	VIL1	0.31	5.0	0.3	1.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10861661	0.963	rs10444533	chr12:107229705	A/G	cg15890332	chr12:107067104	RFX4	-0.36	-4.99	-0.3	1.12e-6	Triglyceride levels;
KIRP	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg22117172	chr7:91764530	CYP51A1	-0.41	-5.61	-0.34	5.35e-8	Breast cancer;
KIRP	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.7	-7.75	-0.44	2.47e-13	Body mass index;
KIRP	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.6	-8.2	-0.46	1.3e-14	Total body bone mineral density;
KIRP	cis	rs7084402	0.967	rs1658467	chr10:60295316	A/G	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs17221829	0.733	rs12363392	chr11:89370598	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg00898013	chr13:113819073	PROZ	0.55	5.96	0.36	8.57e-9	Platelet distribution width;
KIRP	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg01872077	chr2:219646372	CYP27A1	0.38	4.92	0.3	1.58e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.62	8.24	0.47	1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.57	8.38	0.47	3.97e-15	Blood metabolite levels;
KIRP	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12560992	chr17:57184187	TRIM37	0.62	7.15	0.41	9.94e-12	Testicular germ cell tumor;
KIRP	cis	rs6142102	0.961	rs6119447	chr20:32668576	A/G	cg08999081	chr20:33150536	PIGU	0.52	6.84	0.4	6.06e-11	Skin pigmentation;
KIRP	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.72	-9.72	-0.53	4.17e-19	Morning vs. evening chronotype;
KIRP	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.51	0.48	1.73e-15	Bipolar disorder;
KIRP	cis	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg05311720	chr10:102757887	LZTS2	0.43	5.16	0.31	5.06e-7	Educational attainment;
KIRP	cis	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg19847130	chr8:10466454	RP1L1	0.36	5.03	0.31	9.56e-7	Triglycerides;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08768569	chr10:106400565	SORCS3	0.46	6.45	0.38	5.82e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11225247	1.000	rs11225243	chr11:102275302	C/A	cg06323957	chr11:102217781	BIRC2	0.93	5.95	0.35	9.21e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07080220	chr10:102295463	HIF1AN	0.78	7.63	0.44	5.3e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.64	-7.25	-0.42	5.38e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs13185784	0.703	rs55756747	chr5:179675052	C/A	cg23248424	chr5:179741104	GFPT2	0.57	5.55	0.33	7.22e-8	TRAIL levels;
KIRP	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.46	0.68	1.07e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9314323	0.558	rs7828560	chr8:26188998	G/A	cg13160058	chr8:26243215	BNIP3L	-0.45	-6.5	-0.38	4.46e-10	Red cell distribution width;
KIRP	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.29	0.37	1.41e-9	Breast cancer;
KIRP	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.44	-5.49	-0.33	9.79e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs6484504	0.553	rs7113880	chr11:31279557	A/G	cg26647111	chr11:31128758	NA	-0.43	-5.1	-0.31	6.69e-7	Red blood cell count;
KIRP	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.93	7.81	0.45	1.64e-13	Body mass index;
KIRP	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg24687543	chr11:63912206	MACROD1	0.52	4.94	0.3	1.45e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg02475777	chr4:1388615	CRIPAK	0.52	4.96	0.3	1.34e-6	Recombination rate (females);
KIRP	cis	rs4959799	0.557	rs1127466	chr6:3270937	G/C	cg10513992	chr6:3293720	SLC22A23	-0.75	-5.54	-0.33	7.82e-8	Survival in rectal cancer;
KIRP	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.84	0.49	1.83e-16	Bipolar disorder;
KIRP	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18252515	chr7:66147081	NA	0.47	5.5	0.33	9.54e-8	Aortic root size;
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.96	10.36	0.55	4.28e-21	Alzheimer's disease;
KIRP	cis	rs8070740	0.898	rs9303192	chr17:5324836	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.36	0.43	2.68e-12	Menopause (age at onset);
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg16590910	chr6:42928470	GNMT	0.44	6.1	0.36	4.05e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg06212747	chr3:49208901	KLHDC8B	0.69	8.14	0.46	1.95e-14	Menarche (age at onset);
KIRP	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg13798780	chr7:105162888	PUS7	0.48	5.12	0.31	6.16e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg18016565	chr1:150552671	MCL1	0.37	5.65	0.34	4.41e-8	Melanoma;
KIRP	trans	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	6.18	0.37	2.61e-9	Ulcerative colitis;
KIRP	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1524927	0.966	rs12704871	chr7:96334274	C/T	cg03808172	chr7:96339361	SHFM1	-0.4	-5.24	-0.32	3.5e-7	Total body bone mineral density;
KIRP	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg19767477	chr5:127420684	SLC12A2	0.36	5.09	0.31	7.25e-7	Ileal carcinoids;
KIRP	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.54	7.41	0.43	1.96e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg25288420	chr1:78511713	GIPC2	-0.49	-6.72	-0.39	1.25e-10	Obesity-related traits;
KIRP	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	0.95	11.58	0.59	4.92e-25	Testicular germ cell tumor;
KIRP	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg18093559	chr17:18951025	GRAP	0.55	6.76	0.4	9.75e-11	Schizophrenia;
KIRP	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.83	12.39	0.62	9.8e-28	Longevity;
KIRP	cis	rs7106204	0.513	rs7131112	chr11:24249402	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	9.17	0.5	1.95e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.39	-6.01	-0.36	6.6e-9	Neuroticism;
KIRP	cis	rs7404095	0.695	rs11647116	chr16:23865875	A/G	cg21745164	chr16:23765304	CHP2	0.36	5.38	0.32	1.75e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.18	10.57	0.56	8.72e-22	Atopic dermatitis;
KIRP	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg01028140	chr2:1542097	TPO	-0.6	-6.03	-0.36	6.11e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg00684032	chr4:1343700	KIAA1530	0.43	4.95	0.3	1.4e-6	Longevity;
KIRP	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg12940439	chr1:67600707	NA	0.38	5.47	0.33	1.09e-7	Psoriasis;
KIRP	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-7.59	-0.44	6.5e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.06	-0.36	5.02e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6684514	0.885	rs12036837	chr1:156283895	A/C	cg16558208	chr1:156270281	VHLL	-0.43	-5.61	-0.34	5.44e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg05861140	chr6:150128134	PCMT1	-0.5	-7.09	-0.41	1.41e-11	Lung cancer;
KIRP	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg02569458	chr12:86230093	RASSF9	-0.51	-7.34	-0.42	3.11e-12	Major depressive disorder;
KIRP	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-7.2	-0.42	7.48e-12	Colorectal cancer;
KIRP	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg19773385	chr1:10388646	KIF1B	0.66	9.92	0.53	9.85e-20	Hepatocellular carcinoma;
KIRP	cis	rs13385	0.769	rs7705999	chr5:139576049	T/A	cg01860693	chr5:139557145	C5orf32	0.49	5.38	0.32	1.75e-7	Atrial fibrillation;
KIRP	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg12046867	chr14:103022105	NA	-0.53	-6.05	-0.36	5.24e-9	Platelet count;
KIRP	cis	rs2882667	0.858	rs13174479	chr5:138444170	G/A	cg04439458	chr5:138467593	SIL1	-0.51	-7.51	-0.43	1.12e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.27	-0.51	1e-17	Hemoglobin concentration;
KIRP	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.62	-9.31	-0.51	7.61e-18	Body mass index;
KIRP	cis	rs6540556	0.736	rs2076152	chr1:209936060	A/G	cg23920097	chr1:209922102	NA	-0.4	-5.5	-0.33	9.6e-8	Red blood cell count;
KIRP	cis	rs9816226	0.591	rs10513801	chr3:185822353	T/G	cg00760338	chr3:185826511	ETV5	-0.84	-6.54	-0.38	3.56e-10	Obesity;Body mass index;
KIRP	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.5	6.57	0.39	3.02e-10	Height;
KIRP	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.55	7.54	0.43	9.01e-13	Colorectal cancer;
KIRP	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.64	7.77	0.44	2.14e-13	Coronary artery disease;
KIRP	cis	rs9905704	0.633	rs2680707	chr17:56455641	T/C	cg12560992	chr17:57184187	TRIM37	-0.56	-5.31	-0.32	2.41e-7	Testicular germ cell tumor;
KIRP	cis	rs1413885	0.516	rs10789183	chr1:65856779	G/C	cg13202122	chr1:65886182	LEPROT;LEPR	0.41	4.85	0.3	2.19e-6	Anticoagulant levels;
KIRP	cis	rs1594829	0.535	rs11784209	chr8:26170246	T/C	cg11498726	chr8:26250323	BNIP3L	-0.32	-4.9	-0.3	1.7e-6	Height;
KIRP	trans	rs9409565	0.787	rs11789704	chr9:97233408	C/T	cg05679027	chr9:99775184	HIATL2	-0.55	-6.7	-0.39	1.42e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg23736307	chr8:27182930	PTK2B	-0.55	-6.73	-0.39	1.18e-10	Alzheimer's disease (late onset);
KIRP	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg04731861	chr2:219085781	ARPC2	-0.23	-6.01	-0.36	6.49e-9	Colorectal cancer;
KIRP	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.65	-7.91	-0.45	8.75e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10489525	0.502	rs12026930	chr1:115597836	G/A	cg12756093	chr1:115239321	AMPD1	-0.44	-5.33	-0.32	2.23e-7	Autism;
KIRP	cis	rs1448094	0.967	rs10863118	chr12:86339232	C/G	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.32	0.47	6.17e-15	Lung cancer;
KIRP	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg12940923	chr8:10282607	MSRA	0.39	5.08	0.31	7.34e-7	Triglycerides;
KIRP	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.73	-8.82	-0.49	2.18e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.55	7.57	0.43	7.64e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg07930552	chr6:133119739	C6orf192	1.12	9.63	0.52	7.7e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.62	-8.17	-0.46	1.61e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.36	-7.93	-0.45	7.66e-14	Cutaneous nevi;
KIRP	cis	rs10203711	0.966	rs10167210	chr2:239601726	A/C	cg14580085	chr2:239553406	NA	-0.38	-5.0	-0.3	1.12e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.83	9.64	0.52	7.45e-19	Systolic blood pressure;
KIRP	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	1.02e-7	Type 2 diabetes;
KIRP	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.81	-11.76	-0.6	1.24e-25	Autism;
KIRP	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-11.59	-0.59	4.47e-25	Monocyte percentage of white cells;
KIRP	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.02	0.5	5.61e-17	Bladder cancer;
KIRP	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg27247782	chr7:158767135	NA	-0.43	-5.21	-0.32	3.92e-7	Facial morphology (factor 20);
KIRP	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg08847533	chr14:75593920	NEK9	-0.53	-6.35	-0.38	1.04e-9	IgG glycosylation;
KIRP	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4886920	0.894	rs12910504	chr15:78132347	G/A	cg10461261	chr15:78109450	NA	-0.3	-4.9	-0.3	1.74e-6	Neuroticism;
KIRP	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.68	-7.85	-0.45	1.26e-13	Alcohol dependence;
KIRP	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg04166393	chr7:2884313	GNA12	0.44	5.7	0.34	3.36e-8	Height;
KIRP	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.82	11.33	0.59	3.13e-24	Morning vs. evening chronotype;
KIRP	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.42	4.84	0.3	2.24e-6	Height;
KIRP	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg21775007	chr8:11205619	TDH	0.37	4.85	0.3	2.22e-6	Neuroticism;
KIRP	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.65	7.44	0.43	1.71e-12	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg12573674	chr2:1569213	NA	-0.57	-5.15	-0.31	5.23e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs253959	0.545	rs712600	chr5:115658895	T/C	cg23108291	chr5:115420582	COMMD10	-0.53	-6.03	-0.36	5.91e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg27202017	chr16:2318549	RNPS1	-0.48	-6.3	-0.37	1.37e-9	Myopia;
KIRP	cis	rs1971762	0.527	rs6580958	chr12:54073483	A/G	cg16917193	chr12:54089295	NA	0.99	19.91	0.79	3.3e-53	Height;
KIRP	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg24375607	chr4:120327624	NA	0.54	5.54	0.33	7.63e-8	Corneal astigmatism;
KIRP	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg01420254	chr6:26195488	NA	-1.09	-9.33	-0.51	6.37e-18	Gout;Renal underexcretion gout;
KIRP	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.59	-7.28	-0.42	4.61e-12	Coronary artery disease;
KIRP	cis	rs4638749	0.677	rs17035849	chr2:108842593	G/T	cg25838818	chr2:108905173	SULT1C2	-0.4	-6.2	-0.37	2.36e-9	Blood pressure;
KIRP	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg18305652	chr10:134549665	INPP5A	0.47	7.32	0.42	3.57e-12	Migraine;
KIRP	cis	rs9654415	0.560	rs6891189	chr5:72549745	A/G	cg14879418	chr5:72571312	NA	-0.48	-6.13	-0.36	3.41e-9	Eyebrow thickness;
KIRP	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	9.26	0.51	1.08e-17	IgG glycosylation;
KIRP	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.91	-0.4	4.14e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.97e-8	Endometrial cancer;
KIRP	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-1.0	-11.32	-0.59	3.37e-24	Exhaled nitric oxide output;
KIRP	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4262150	0.883	rs72799148	chr5:152107108	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.35	-0.47	4.88e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.5	-5.95	-0.35	9.05e-9	Response to antidepressants in depression;
KIRP	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.2	13.21	0.64	1.84e-30	Nonalcoholic fatty liver disease;
KIRP	cis	rs35740288	0.731	rs2344440	chr15:86161565	T/C	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.41	-0.47	3.44e-15	Mean corpuscular volume;
KIRP	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.42	0.47	3.25e-15	Morning vs. evening chronotype;
KIRP	cis	rs7570971	1.000	rs1375131	chr2:135954797	T/C	cg07169764	chr2:136633963	MCM6	0.48	5.52	0.33	8.54e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg20731937	chr12:48336164	NA	0.41	5.26	0.32	3.11e-7	Longevity (90 years and older);
KIRP	cis	rs6959887	0.926	rs714958	chr7:35290225	C/A	cg06685737	chr7:35301730	NA	0.43	6.31	0.37	1.26e-9	Birth weight;
KIRP	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg05673287	chr15:77411982	SGK269	0.38	4.89	0.3	1.78e-6	Type 2 diabetes;
KIRP	trans	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg06521331	chr12:34319734	NA	-0.57	-6.88	-0.4	4.96e-11	Bladder cancer;
KIRP	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.48	-5.11	-0.31	6.59e-7	Platelet distribution width;
KIRP	cis	rs10463316	0.817	rs1508772	chr5:150816561	A/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.37	-0.38	9.16e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg03468072	chr12:39539422	NA	0.45	5.94	0.35	9.85e-9	Heart rate;
KIRP	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg01721255	chr8:58191610	C8orf71	0.62	5.5	0.33	9.61e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11637445	0.677	rs3784713	chr15:68073013	C/T	cg24579218	chr15:68104479	NA	-0.44	-6.58	-0.39	2.74e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.8	-7.4	-0.43	2.12e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs10131728	1.000	rs12894001	chr14:81695072	A/G	cg01989461	chr14:81687754	GTF2A1	-0.72	-5.6	-0.34	5.82e-8	IgG glycosylation;
KIRP	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	0.92	7.86	0.45	1.2e-13	Skin colour saturation;
KIRP	cis	rs2979489	0.891	rs4285443	chr8:30327317	A/G	cg26383811	chr8:30366931	RBPMS	-0.38	-5.19	-0.31	4.45e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	5.77	0.35	2.37e-8	HIV-1 control;
KIRP	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.58	0.39	2.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4237845	0.613	rs3751327	chr12:58335274	C/A	cg02175503	chr12:58329896	NA	0.88	10.79	0.57	1.72e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	0.91	11.93	0.61	3.35e-26	Blood trace element (Zn levels);
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg01097406	chr16:89675127	NA	-0.32	-5.32	-0.32	2.38e-7	Vitiligo;
KIRP	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs6088813	0.677	rs941664	chr20:33939973	G/C	cg14752227	chr20:34000481	UQCC	-0.46	-5.19	-0.31	4.5e-7	Height;
KIRP	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11987759	chr7:65425863	GUSB	0.5	6.72	0.39	1.23e-10	Aortic root size;
KIRP	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.87	-12.48	-0.62	5.26e-28	Height;
KIRP	cis	rs11825064	0.720	rs7128710	chr11:134497143	G/A	cg06603561	chr11:134479413	NA	-0.74	-6.02	-0.36	6.27e-9	Seasonality;
KIRP	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg27124370	chr19:33622961	WDR88	0.55	6.83	0.4	6.61e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7188697	0.922	rs7186997	chr16:58603348	A/G	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14156121	chr10:33948478	NA	-0.51	-6.78	-0.4	8.61e-11	Inflammatory biomarkers;
KIRP	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg21605333	chr4:119757512	SEC24D	1.6	11.71	0.6	1.76e-25	Cannabis dependence symptom count;
KIRP	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.8	8.77	0.49	2.99e-16	Corneal astigmatism;
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.73	-7.68	-0.44	3.78e-13	Platelet count;
KIRP	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-0.54	-7.67	-0.44	3.98e-13	Coronary artery disease;
KIRP	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.56	-7.98	-0.45	5.53e-14	Gut microbiome composition (summer);
KIRP	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-7.38	-0.43	2.4e-12	Alzheimer's disease (survival time);
KIRP	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg14186256	chr22:23484241	RTDR1	-0.52	-5.15	-0.31	5.28e-7	Serum parathyroid hormone levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18887228	chr6:64356606	PHF3	-0.47	-7.33	-0.42	3.23e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg00122941	chr17:4613640	ARRB2	0.82	8.71	0.49	4.49e-16	Lymphocyte counts;
KIRP	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg21433313	chr16:3507492	NAT15	0.65	7.18	0.42	8.35e-12	Tuberculosis;
KIRP	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-9.58	-0.52	1.1e-18	Bladder cancer;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00689492	chr4:1303491	MAEA	0.32	5.49	0.33	1.01e-7	Obesity-related traits;
KIRP	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg22852734	chr6:133119734	C6orf192	0.97	7.02	0.41	2.22e-11	Type 2 diabetes nephropathy;
KIRP	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg15247329	chr7:2764246	NA	-0.41	-5.91	-0.35	1.13e-8	Height;
KIRP	cis	rs2290159	0.948	rs9852128	chr3:12635623	A/G	cg23032965	chr3:12705835	RAF1	0.65	7.33	0.42	3.3e-12	Cholesterol, total;
KIRP	cis	rs311392	0.902	rs2666874	chr8:55091561	A/T	cg11783602	chr8:55087084	NA	0.57	7.07	0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6732160	0.845	rs9989755	chr2:73361948	T/C	cg01422370	chr2:73384389	NA	0.4	5.24	0.32	3.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4851250	0.580	rs56909870	chr2:100620017	C/T	cg17356467	chr2:100759845	AFF3	0.54	4.99	0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.56	-7.66	-0.44	4.4e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.55	-7.69	-0.44	3.42e-13	Migraine;
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg08662619	chr6:150070041	PCMT1	0.38	6.39	0.38	8.4e-10	Lung cancer;
KIRP	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.56	-0.33	6.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.88	-12.51	-0.62	4e-28	Longevity;Endometriosis;
KIRP	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.87	13.44	0.65	2.98e-31	Ulcerative colitis;
KIRP	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg01620082	chr3:125678407	NA	-1.18	-7.63	-0.44	5.19e-13	Depression;
KIRP	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg01559446	chr3:44596178	ZNF167	-0.38	-5.36	-0.32	1.93e-7	Depressive symptoms;
KIRP	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.86	-13.17	-0.64	2.41e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.57	7.95	0.45	6.58e-14	Longevity;Endometriosis;
KIRP	cis	rs6594713	0.642	rs13169748	chr5:112848999	C/T	cg12552261	chr5:112820674	MCC	0.55	4.94	0.3	1.48e-6	Brain cytoarchitecture;
KIRP	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg10547527	chr2:198650123	BOLL	-0.55	-5.04	-0.31	8.83e-7	Ulcerative colitis;
KIRP	cis	rs11877825	0.865	rs8098008	chr18:10569443	C/T	cg07277756	chr18:10589357	NA	0.48	6.11	0.36	3.89e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.18	0.31	4.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg16482183	chr6:26056742	HIST1H1C	0.42	4.92	0.3	1.59e-6	Iron status biomarkers;
KIRP	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.69	0.44	3.64e-13	Retinal vascular caliber;
KIRP	cis	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.5	-0.33	9.61e-8	Joint mobility (Beighton score);
KIRP	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-5.0	-0.3	1.09e-6	Renal cell carcinoma;
KIRP	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg03511173	chr18:77590860	NA	-0.46	-5.04	-0.31	9.21e-7	Opioid sensitivity;
KIRP	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.42	5.48	0.33	1.06e-7	Melanoma;
KIRP	cis	rs16854884	1.000	rs58251824	chr3:143786258	T/C	cg06585982	chr3:143692056	C3orf58	0.5	5.71	0.34	3.24e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.59	6.72	0.39	1.24e-10	Cannabis dependence symptom count;
KIRP	cis	rs1497828	0.956	rs2492872	chr1:217556242	C/A	cg04411442	chr1:217543379	NA	0.41	6.17	0.37	2.8e-9	Dialysis-related mortality;
KIRP	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg08761264	chr16:28874980	SH2B1	-0.46	-5.26	-0.32	3.14e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-5.82	-0.35	1.8e-8	Morning vs. evening chronotype;
KIRP	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg23202291	chr11:1979235	NA	-0.46	-5.95	-0.35	9.01e-9	DNA methylation (variation);
KIRP	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg04414720	chr1:150670196	GOLPH3L	-0.41	-5.27	-0.32	2.97e-7	Urate levels;
KIRP	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg13010199	chr12:38710504	ALG10B	0.65	8.13	0.46	2.05e-14	Morning vs. evening chronotype;
KIRP	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg13319975	chr6:146136371	FBXO30	0.41	5.7	0.34	3.39e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.76	0.44	2.32e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg15620404	chr13:113666762	MCF2L	-0.48	-4.88	-0.3	1.92e-6	Systolic blood pressure;
KIRP	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.55	0.33	7.34e-8	Educational attainment;
KIRP	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.69	-7.16	-0.42	9.32e-12	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs402219	0.921	rs394352	chr6:160808395	C/T	cg26861457	chr19:6712380	C3	-0.46	-6.1	-0.36	4.09e-9	Monocyte early outgrowth colony forming units;
KIRP	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg24488311	chr11:68621650	NA	0.41	5.03	0.31	9.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.39	7.73	0.44	2.77e-13	Multiple system atrophy;
KIRP	cis	rs754423	0.703	rs2101919	chr14:52520368	C/T	cg05884192	chr14:52515736	NID2	-0.67	-8.03	-0.46	3.95e-14	Craniofacial microsomia;
KIRP	cis	rs6832769	0.922	rs60797008	chr4:56388672	A/T	cg05960024	chr4:56376020	CLOCK	-0.67	-8.44	-0.47	2.69e-15	Personality dimensions;
KIRP	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg00074818	chr8:8560427	CLDN23	0.45	6.84	0.4	6.13e-11	Obesity-related traits;
KIRP	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	1.15	9.48	0.52	2.24e-18	Skin colour saturation;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg05861140	chr6:150128134	PCMT1	-0.48	-6.92	-0.4	3.81e-11	Lung cancer;
KIRP	trans	rs2048656	0.637	rs10107396	chr8:9673152	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.68	-0.44	3.77e-13	Schizophrenia;
KIRP	cis	rs4474465	1.000	rs7933612	chr11:78209366	G/T	cg27205649	chr11:78285834	NARS2	0.61	7.24	0.42	5.65e-12	Alzheimer's disease (survival time);
KIRP	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.98	13.0	0.64	9.55e-30	Vitamin D levels;
KIRP	cis	rs7712401	0.601	rs34233716	chr5:122316365	C/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.49	-0.33	1e-7	Mean platelet volume;
KIRP	cis	rs7766436	0.885	rs11759879	chr6:22587130	C/T	cg13666174	chr6:22585274	NA	-0.49	-6.66	-0.39	1.82e-10	Coronary artery disease;
KIRP	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg22585957	chr12:8234808	NECAP1	-0.46	-6.21	-0.37	2.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs960902	0.764	rs11124586	chr2:37728467	G/A	cg25341268	chr2:37734390	NA	-0.54	-7.29	-0.42	4.11e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg26207909	chr14:103986467	CKB	0.41	5.24	0.32	3.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg02073558	chr3:44770973	ZNF501	0.68	10.68	0.56	4.1e-22	Depressive symptoms;
KIRP	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg11833968	chr6:79620685	NA	-0.39	-5.34	-0.32	2.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.76	-6.76	-0.4	9.88e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg00405596	chr8:11794950	NA	-0.46	-5.99	-0.36	7.28e-9	Triglycerides;
KIRP	cis	rs57590327	0.503	rs9874184	chr3:81505439	C/T	cg07356753	chr3:81810745	GBE1	0.49	6.19	0.37	2.46e-9	Extraversion;
KIRP	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg11584989	chr19:19387371	SF4	-0.55	-5.81	-0.35	1.94e-8	Attention deficit hyperactivity disorder symptom score;
KIRP	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.45	5.3	0.32	2.53e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.57	-0.56	8.87e-22	Chronic sinus infection;
KIRP	cis	rs4851254	0.550	rs13402289	chr2:100659389	C/T	cg22139774	chr2:100720529	AFF3	-0.4	-5.12	-0.31	6.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg19847130	chr8:10466454	RP1L1	0.36	5.7	0.34	3.34e-8	Neuroticism;
KIRP	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg10503236	chr1:231470652	EXOC8	-0.49	-6.62	-0.39	2.22e-10	Hemoglobin concentration;
KIRP	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg02811702	chr13:24901961	NA	0.41	5.41	0.33	1.49e-7	Obesity-related traits;
KIRP	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.57	-5.44	-0.33	1.3e-7	Narcolepsy;
KIRP	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.06	-0.36	4.97e-9	Metabolite levels;
KIRP	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg17764715	chr19:33622953	WDR88	0.68	8.24	0.47	1.02e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.92	14.72	0.68	1.32e-35	Blood protein levels;
KIRP	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg07653901	chr22:50250238	ZBED4	0.47	5.6	0.34	5.69e-8	Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13981034	chr14:21860709	SNORD9;CHD8	-0.5	-6.18	-0.37	2.71e-9	Inflammatory biomarkers;
KIRP	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.91	15.17	0.7	3.85e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.14	16.52	0.73	9.43e-42	Breast cancer;
KIRP	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.61	7.92	0.45	7.93e-14	Prudent dietary pattern;
KIRP	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	4.06e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs2668423	0.922	rs2668417	chr19:1365827	C/G	cg02639931	chr19:1387894	NDUFS7	-0.73	-9.31	-0.51	7.66e-18	Nonalcoholic fatty liver disease;
KIRP	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	1.09	17.85	0.75	2.83e-46	Cognitive function;
KIRP	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	8.23	0.46	1.11e-14	Type 2 diabetes;
KIRP	cis	rs698833	0.892	rs786408	chr2:44733156	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.16	0.31	5.21e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07944736	chr1:28908226	SNHG12;SNORA44;SNORA16A	0.51	7.1	0.41	1.37e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.75	-9.99	-0.54	5.93e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg22563815	chr15:78856949	CHRNA5	0.43	6.0	0.36	6.89e-9	Sudden cardiac arrest;
KIRP	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg20991723	chr1:152506922	NA	-0.46	-5.5	-0.33	9.59e-8	Hair morphology;
KIRP	cis	rs67756423	0.521	rs7846298	chr8:143318417	G/A	cg24996280	chr8:143481281	TSNARE1	0.42	5.92	0.35	1.06e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.68	-8.22	-0.46	1.2e-14	Height;
KIRP	trans	rs67180937	0.583	rs2936052	chr1:222802376	A/G	cg09730170	chr20:23586680	CST9	0.43	6.09	0.36	4.25e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg24459738	chr19:57751996	ZNF805	-0.58	-7.17	-0.42	8.82e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs10932679	0.532	rs2712162	chr2:217661788	C/T	cg05032264	chr2:217675019	NA	-0.42	-5.84	-0.35	1.62e-8	Pulse pressure;
KIRP	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg00784671	chr22:46762841	CELSR1	-0.6	-8.06	-0.46	3.39e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.91	8.87	0.49	1.5e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg07636037	chr3:49044803	WDR6	-0.71	-5.63	-0.34	5.01e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.38	-5.03	-0.31	9.35e-7	Renal function-related traits (BUN);
KIRP	cis	rs2274273	0.870	rs7153645	chr14:55771518	C/G	cg04306507	chr14:55594613	LGALS3	0.44	6.56	0.39	3.08e-10	Protein biomarker;
KIRP	cis	rs6132905	0.590	rs80219859	chr20:2606491	G/T	cg24848351	chr20:2622020	TMC2	-0.53	-5.07	-0.31	7.95e-7	Mumps;
KIRP	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.74	7.27	0.42	4.85e-12	Vitiligo;
KIRP	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-5.22	-0.32	3.79e-7	Ulcerative colitis;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg13699009	chr12:122356056	WDR66	0.7	11.05	0.58	2.56e-23	Mean corpuscular volume;
KIRP	cis	rs7083	1.000	rs524085	chr11:117137647	G/A	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.6	11.32	0.59	3.38e-24	Bone mineral density;
KIRP	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs35000415	0.688	rs59110799	chr7:128716007	G/T	cg19972273	chr7:128594194	NA	0.62	5.18	0.31	4.65e-7	Systemic lupus erythematosus;
KIRP	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.14	0.54	1.99e-20	Cognitive test performance;
KIRP	cis	rs62380364	0.602	rs640177	chr5:88002084	T/A	cg24804195	chr5:87968844	LOC645323	-0.47	-6.23	-0.37	2.05e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3105593	0.605	rs3131562	chr15:50772479	C/T	cg05456662	chr15:50716270	USP8	0.45	5.89	0.35	1.28e-8	QT interval;
KIRP	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.71e-31	Diabetic retinopathy;
KIRP	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.74	6.81	0.4	7.37e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg07138768	chr7:917805	C7orf20	0.33	5.43	0.33	1.35e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06115741	chr20:33292138	TP53INP2	-0.42	-5.51	-0.33	8.96e-8	Coronary artery disease;
KIRP	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg19743168	chr1:23544995	NA	0.46	6.3	0.37	1.4e-9	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19701416	chr10:28592092	NA	0.46	6.23	0.37	1.98e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs503734	0.502	rs1994201	chr3:100970062	C/T	cg27318481	chr3:100970896	IMPG2	0.55	7.58	0.44	7.03e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.59	-7.91	-0.45	8.45e-14	Vitiligo;
KIRP	cis	rs7674212	0.510	rs2720468	chr4:104085153	A/G	cg16532752	chr4:104119610	CENPE	-0.42	-5.01	-0.3	1.05e-6	Type 2 diabetes;
KIRP	cis	rs6688363	0.943	rs1016732	chr1:160086968	A/G	cg01023271	chr1:160068607	IGSF8	0.55	5.0	0.3	1.09e-6	Response to antipsychotic treatment;
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg01765077	chr12:122356316	WDR66	0.63	8.44	0.47	2.66e-15	Mean corpuscular volume;
KIRP	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-8.43	-0.47	3.04e-15	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21311850	chr2:210867278	RPE	0.5	6.27	0.37	1.58e-9	Parkinson's disease;
KIRP	cis	rs4750440	0.614	rs898718	chr10:14027235	C/T	cg27542038	chr10:14027202	FRMD4A	-0.62	-8.15	-0.46	1.85e-14	Adiponectin levels;
KIRP	cis	rs6987853	0.787	rs2974300	chr8:42440532	C/T	cg09913449	chr8:42400586	C8orf40	0.4	5.36	0.32	1.9e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	8.51	0.48	1.68e-15	Post bronchodilator FEV1;
KIRP	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.76	-0.4	9.72e-11	Menopause (age at onset);
KIRP	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg13206674	chr6:150067644	NUP43	0.56	8.08	0.46	2.85e-14	Lung cancer;
KIRP	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg07138768	chr7:917805	C7orf20	-0.3	-4.99	-0.3	1.14e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs1010254	0.543	rs113559777	chr5:151816645	T/C	cg12297329	chr5:152029980	NA	-0.64	-6.66	-0.39	1.82e-10	Optic nerve measurement (cup area);
KIRP	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.85	-12.83	-0.63	3.3e-29	Height;
KIRP	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs1950626	0.623	rs2295657	chr14:101430620	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.51	5.83	0.35	1.73e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.61	7.09	0.41	1.43e-11	Osteoporosis;
KIRP	cis	rs4711336	0.967	rs4711338	chr6:33660188	T/C	cg15676125	chr6:33679581	C6orf125	0.41	5.52	0.33	8.65e-8	Height;
KIRP	cis	rs2635047	0.615	rs2571005	chr18:44714365	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-5.6	-0.34	5.59e-8	Educational attainment;
KIRP	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg05973401	chr12:123451056	ABCB9	-0.51	-5.55	-0.33	7.36e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg12940923	chr8:10282607	MSRA	-0.41	-5.23	-0.32	3.67e-7	Neuroticism;
KIRP	cis	rs2410601	0.562	rs13275125	chr8:18898352	T/A	cg19414122	chr8:18896631	NA	0.48	6.4	0.38	7.91e-10	Urinary albumin excretion rate in type 1 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20974424	chr5:640382	CEP72	0.45	6.16	0.37	2.93e-9	Survival in pancreatic cancer;
KIRP	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.75	0.4	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-7.68	-0.44	3.66e-13	Total body bone mineral density;
KIRP	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-5.96	-0.36	8.72e-9	Gut microbiome composition (summer);
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg15112475	chr7:1198522	ZFAND2A	-0.41	-5.07	-0.31	7.7300000000000005e-07	Longevity;Endometriosis;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-4.86	-0.3	2.1e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.69	6.77	0.4	9.35e-11	Breast cancer;
KIRP	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.22	-0.37	2.13e-9	Retinal vascular caliber;
KIRP	cis	rs10131728	1.000	rs12883359	chr14:81665187	T/C	cg01989461	chr14:81687754	GTF2A1	-0.75	-5.92	-0.35	1.1e-8	IgG glycosylation;
KIRP	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg15704280	chr7:45808275	SEPT13	-0.67	-8.41	-0.47	3.39e-15	Height;
KIRP	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.65	9.12	0.5	2.75e-17	Lymphocyte counts;
KIRP	cis	rs6733011	0.600	rs1356424	chr2:99425838	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-5.12	-0.31	6.06e-7	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21809007	chr19:6739524	TRIP10	0.49	6.72	0.39	1.23e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg24857795	chr5:149363940	SLC26A2	-0.46	-6.38	-0.38	8.61e-10	Select biomarker traits;
KIRP	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg05861140	chr6:150128134	PCMT1	-0.49	-6.96	-0.41	3.1e-11	Lung cancer;
KIRP	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg20302533	chr7:39170763	POU6F2	0.3	6.19	0.37	2.45e-9	IgG glycosylation;
KIRP	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-0.63	-5.43	-0.33	1.35e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2019216	0.521	rs6565386	chr17:21901755	A/G	cg22648282	chr17:21454238	C17orf51	0.47	6.01	0.36	6.54e-9	Pelvic organ prolapse;
KIRP	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg17845761	chr1:175162550	KIAA0040	0.34	6.45	0.38	6.03e-10	Alcohol dependence;
KIRP	cis	rs73200209	0.744	rs61939697	chr12:116555491	T/C	cg01776926	chr12:116560359	MED13L	-0.54	-6.03	-0.36	5.82e-9	Total body bone mineral density;
KIRP	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg16576083	chr14:105354267	KIAA0284	-0.56	-7.64	-0.44	4.73e-13	IgG glycosylation;
KIRP	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.32	-7.48	-0.43	1.32e-12	Mean corpuscular volume;
KIRP	cis	rs7078219	0.505	rs7077040	chr10:101281014	C/G	cg07044859	chr10:101282883	NA	-0.33	-6.04	-0.36	5.52e-9	Dental caries;
KIRP	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg11569703	chr11:65557185	OVOL1	0.73	14.06	0.67	2.46e-33	Acne (severe);
KIRP	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg07621104	chr11:117668040	DSCAML1	0.49	7.61	0.44	5.85e-13	Myopia;
KIRP	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg11150807	chr10:43354902	NA	0.62	7.02	0.41	2.19e-11	Blood protein levels;
KIRP	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg16497661	chr14:103986332	CKB	0.55	7.66	0.44	4.23e-13	Body mass index;
KIRP	cis	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg06521331	chr12:34319734	NA	-0.61	-7.2	-0.42	7.35e-12	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-15.63	-0.71	1.02e-38	Height;
KIRP	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.54	-6.71	-0.39	1.36e-10	Coronary artery disease;
KIRP	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.26	-0.42	5.12e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg17644776	chr2:200775616	C2orf69	0.56	6.04	0.36	5.81e-9	Schizophrenia;
KIRP	cis	rs10211205	1.000	rs13389509	chr2:236614630	T/C	cg13770573	chr2:236586376	AGAP1	-0.55	-5.97	-0.36	8.04e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs712039	0.617	rs60118041	chr17:35803252	G/A	cg16670864	chr17:35848621	DUSP14	0.43	5.38	0.32	1.71e-7	Tuberculosis;
KIRP	cis	rs12534701	1.000	rs12534701	chr7:154680910	A/C	cg24255201	chr7:154684926	DPP6	-0.62	-8.79	-0.49	2.63e-16	Colorectal cancer (diet interaction);
KIRP	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	9.16	0.5	2.1e-17	Cognitive test performance;
KIRP	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.85	11.46	0.59	1.2e-24	Coronary artery disease;
KIRP	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12667521	chr19:29218732	NA	0.93	9.2	0.51	1.59e-17	Methadone dose in opioid dependence;
KIRP	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg24060327	chr5:131705240	SLC22A5	-0.54	-7.21	-0.42	6.66e-12	Acylcarnitine levels;
KIRP	cis	rs1355223	0.902	rs1588353	chr11:34730814	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.75e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.9	0.4	4.36e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs7712401	0.601	rs30067	chr5:122293668	A/T	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg13147721	chr7:65941812	NA	-1.03	-7.08	-0.41	1.51e-11	Gout;
KIRP	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	1.01	11.03	0.58	3.07e-23	Blood protein levels;
KIRP	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02725872	chr8:58115012	NA	-0.76	-7.71	-0.44	3.1e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs7851660	0.844	rs10759975	chr9:100625193	C/T	cg13688889	chr9:100608707	NA	0.68	8.75	0.49	3.53e-16	Strep throat;
KIRP	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg11833968	chr6:79620685	NA	-0.45	-6.78	-0.4	9.1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.45	7.22	0.42	6.4e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg12705353	chr12:122356852	WDR66	0.58	8.08	0.46	2.99e-14	Mean platelet volume;
KIRP	cis	rs7078219	0.505	rs7908704	chr10:101293318	G/A	cg07044859	chr10:101282883	NA	-0.31	-5.57	-0.33	6.57e-8	Dental caries;
KIRP	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.7	-0.34	3.36e-8	Parkinson's disease;
KIRP	cis	rs6969780	0.778	rs2465276	chr7:27145717	G/A	cg26364809	chr7:27145159	NA	-0.6	-5.36	-0.32	1.88e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg08126542	chr6:37504118	NA	-0.73	-10.38	-0.55	3.48e-21	Cognitive performance;
KIRP	cis	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10258271	chr2:31361593	GALNT14	0.42	4.89	0.3	1.82e-6	Inflammatory biomarkers;
KIRP	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.63	-9.86	-0.53	1.49e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2119480	0.731	rs378399	chr13:111308040	G/C	cg24331049	chr13:111365604	ING1	-0.45	-5.35	-0.32	1.98e-7	Diastolic blood pressure;
KIRP	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.2	0.42	7.27e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs71403859	0.502	rs35981926	chr16:71500755	A/T	cg08717414	chr16:71523259	ZNF19	-1.2	-10.55	-0.56	1.04e-21	Post bronchodilator FEV1;
KIRP	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.61	-0.34	5.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1021993	0.597	rs4844807	chr1:209511114	T/A	cg24446417	chr1:209558027	NA	-0.49	-4.96	-0.3	1.32e-6	Gut microbiome composition (winter);
KIRP	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg26441486	chr22:50317300	CRELD2	0.4	6.49	0.38	4.73e-10	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.74	10.39	0.55	3.42e-21	Parkinson's disease;
KIRP	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg24296786	chr1:45957014	TESK2	-0.65	-8.63	-0.48	7.6e-16	High light scatter reticulocyte count;
KIRP	cis	rs2230307	0.656	rs521348	chr1:100481162	C/A	cg24955406	chr1:100503596	HIAT1	0.56	5.6	0.34	5.65e-8	Carotid intima media thickness;
KIRP	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.2	-0.37	2.33e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg25753631	chr6:25732923	NA	-0.28	-5.17	-0.31	4.96e-7	Iron status biomarkers;
KIRP	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg26513180	chr16:89883248	FANCA	-0.4	-5.07	-0.31	7.66e-7	Vitiligo;
KIRP	cis	rs2411233	0.811	rs2033544	chr15:39262972	G/T	cg19287857	chr15:39890699	NA	-0.46	-6.69	-0.39	1.5e-10	Platelet count;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg01162549	chr5:141367464	RNF14	0.39	6.04	0.36	5.6e-9	Serum protein levels (sST2);
KIRP	cis	rs7688540	0.771	rs61792116	chr4:301077	T/C	cg17891759	chr4:299121	NA	-0.5	-5.12	-0.31	6.28e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6956675	0.915	rs7787116	chr7:62654060	G/A	cg08930214	chr7:62859557	LOC100287834	0.43	5.23	0.32	3.57e-7	Obesity-related traits;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg02297831	chr4:17616191	MED28	-0.5	-6.21	-0.37	2.2e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.93	15.52	0.7	2.38e-38	Breast cancer;
KIRP	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.93	0.49	1.02e-16	Bladder cancer;
KIRP	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.01	11.64	0.6	3.21e-25	Body mass index;
KIRP	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg06585982	chr3:143692056	C3orf58	0.62	7.72	0.44	2.94e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.77	-5.6	-0.34	5.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	-0.48	-6.08	-0.36	4.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.92	-13.94	-0.66	6.29e-33	Monocyte count;
KIRP	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.62	-8.94	-0.5	9.75e-17	Brugada syndrome;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.88	8.45	0.47	2.54e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62355272	0.580	rs1025039	chr5:35901857	A/C	cg13894535	chr5:35919491	CAPSL	0.36	4.9	0.3	1.71e-6	Lymphocyte counts;
KIRP	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	cg21523751	chr1:182988639	NA	0.45	7.18	0.42	8.15e-12	Colorectal cancer;
KIRP	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06634786	chr22:41940651	POLR3H	0.42	4.94	0.3	1.45e-6	Vitiligo;
KIRP	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.6	8.76	0.49	3.27e-16	Height;
KIRP	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	1.22	11.24	0.58	6.49e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg04080417	chr5:1859792	NA	-0.64	-8.15	-0.46	1.86e-14	Cardiovascular disease risk factors;
KIRP	cis	rs2916247	1.000	rs11785362	chr8:93045784	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.56	-7.0	-0.41	2.42e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.98	10.18	0.54	1.53e-20	Alzheimer's disease;
KIRP	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.85	0.35	1.56e-8	Total cholesterol levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00907211	chr7:128828520	SMO	0.52	7.0	0.41	2.4e-11	Parkinson's disease;
KIRP	cis	rs11955398	0.625	rs10805370	chr5:59984244	A/T	cg02684056	chr5:59996105	DEPDC1B	0.49	5.53	0.33	8.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6539288	0.630	rs1055332	chr12:107348625	T/A	cg21360079	chr12:107162445	NA	-0.46	-5.67	-0.34	4.01e-8	Total body bone mineral density;
KIRP	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg02297831	chr4:17616191	MED28	0.52	6.5	0.38	4.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg07936489	chr17:37558343	FBXL20	-0.53	-6.16	-0.37	2.97e-9	Primary biliary cholangitis;
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.91	0.35	1.11e-8	Life satisfaction;
KIRP	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs1519814	1.000	rs4271006	chr8:121146640	T/G	cg22335954	chr8:121166405	COL14A1	-0.62	-6.35	-0.38	1.03e-9	Breast cancer;
KIRP	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg16898833	chr6:26189333	HIST1H4D	0.83	5.36	0.32	1.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg00599163	chr2:162100495	NA	0.44	5.07	0.31	7.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg06212747	chr3:49208901	KLHDC8B	0.57	6.86	0.4	5.57e-11	Menarche (age at onset);
KIRP	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg15488143	chr7:128924101	AHCYL2	0.62	6.58	0.39	2.84e-10	White matter hyperintensity burden;
KIRP	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.98	14.12	0.67	1.47e-33	Cognitive function;
KIRP	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.65	-9.14	-0.5	2.36e-17	Retinal vascular caliber;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.33	-5.44	-0.33	1.31e-7	Renal function-related traits (BUN);
KIRP	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.44	6.01	0.36	6.5e-9	Total body bone mineral density;
KIRP	cis	rs8060686	0.623	rs6499163	chr16:68243486	G/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-8.73	-0.49	4.08e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg09699651	chr6:150184138	LRP11	0.46	5.92	0.35	1.05e-8	Lung cancer;
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.83	0.63	3.31e-29	Platelet count;
KIRP	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.66	-8.57	-0.48	1.19e-15	Aortic root size;
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.65	-9.79	-0.53	2.5e-19	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg26875233	chr11:93583750	C11orf90	0.35	6.98	0.41	2.7e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg05961215	chr15:35280640	ZNF770	0.8	6.97	0.41	2.93e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-7.04	-0.41	1.88e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.87	11.4	0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.66	-7.91	-0.45	8.62e-14	Blood protein levels;
KIRP	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.9	-13.19	-0.64	2.18e-30	Height;
KIRP	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs860295	0.580	rs6672284	chr1:155277963	C/T	cg02153340	chr1:155202674	NA	-0.55	-7.62	-0.44	5.49e-13	Body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08391848	chr19:5661611	SAFB	0.51	6.43	0.38	6.72e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg23594656	chr7:65796392	TPST1	0.51	7.96	0.45	6.37e-14	Aortic root size;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.74	6.51	0.38	4.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13190036	0.551	rs1052432	chr5:176564189	G/A	cg04708888	chr5:176739561	MXD3	0.6	5.01	0.3	1.03e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg08499158	chr17:42289980	UBTF	-0.57	-7.61	-0.44	5.73e-13	Total body bone mineral density;
KIRP	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-10.21	-0.55	1.22e-20	Dental caries;
KIRP	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.65	7.75	0.44	2.43e-13	Testicular germ cell tumor;
KIRP	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.79	8.76	0.49	3.17e-16	Diastolic blood pressure;
KIRP	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.83	13.68	0.66	4.54e-32	Monocyte percentage of white cells;
KIRP	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Dermatomyositis;
KIRP	cis	rs72848980	0.512	rs11191749	chr10:105378840	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.77	9.67	0.52	6.09e-19	White matter hyperintensity burden;
KIRP	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.71	-8.75	-0.49	3.54e-16	Corneal structure;
KIRP	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg13147721	chr7:65941812	NA	-1.01	-7.08	-0.41	1.48e-11	Diabetic kidney disease;
KIRP	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.24	0.47	1.01e-14	Eosinophil percentage of white cells;
KIRP	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.13	-0.31	5.96e-7	Blood metabolite levels;
KIRP	cis	rs2733310	0.947	rs1652748	chr15:57170911	C/T	cg13626582	chr15:57592083	LOC283663	0.23	5.31	0.32	2.42e-7	Mean platelet volume;
KIRP	cis	rs6599192	1	rs6599192	chr3:41992408	G/A	cg03022575	chr3:42003672	ULK4	-0.5	-5.66	-0.34	4.2e-8	Multiple myeloma;
KIRP	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg05941025	chr16:89927596	SPIRE2	0.38	5.88	0.35	1.34e-8	Vitiligo;
KIRP	cis	rs17221829	0.599	rs7112871	chr11:89404829	G/A	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.23	-0.32	3.55e-7	Anxiety in major depressive disorder;
KIRP	cis	rs4262150	0.544	rs4958550	chr5:151889813	G/A	cg12297329	chr5:152029980	NA	-0.74	-9.14	-0.5	2.48e-17	Bipolar disorder and schizophrenia;
KIRP	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg01988459	chr11:68622903	NA	-0.43	-5.82	-0.35	1.81e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.42	4.9	0.3	1.74e-6	Aortic root size;
KIRP	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg19731401	chr7:2775893	GNA12	0.68	6.6	0.39	2.45e-10	Childhood ear infection;
KIRP	cis	rs8060686	0.516	rs8059575	chr16:68272635	C/G	cg26727032	chr16:67993705	SLC12A4	-0.69	-7.64	-0.44	4.92e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg18016565	chr1:150552671	MCL1	-0.37	-5.82	-0.35	1.86e-8	Melanoma;
KIRP	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg04310649	chr10:35416472	CREM	-0.55	-6.16	-0.37	2.89e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.47	-6.15	-0.37	3.12e-9	Blood metabolite levels;
KIRP	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.64	-10.28	-0.55	7.69e-21	Gout;
KIRP	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg12315302	chr6:26189340	HIST1H4D	0.74	4.99	0.3	1.13e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.64	-8.02	-0.46	4.29e-14	Body mass index;
KIRP	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg17470723	chr8:74884337	TCEB1	0.62	8.0	0.45	4.96e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.87	-12.02	-0.61	1.71e-26	Longevity;Endometriosis;
KIRP	cis	rs10203711	0.933	rs7591829	chr2:239586185	A/T	cg14580085	chr2:239553406	NA	0.4	5.13	0.31	5.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19313758	chr11:64889193	FAU;MRPL49	0.52	6.02	0.36	6.38e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs506338	0.517	rs471618	chr11:64465403	T/C	cg09231725	chr11:64357281	SLC22A12	-0.51	-5.78	-0.35	2.31e-8	Body mass index;Urate levels;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.64	9.1	0.5	3.17e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg15664640	chr17:80829946	TBCD	-0.52	-5.17	-0.31	4.76e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14576291	chr9:134526136	RAPGEF1	0.49	6.33	0.37	1.15e-9	Survival in pancreatic cancer;
KIRP	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg01181863	chr3:195395398	SDHAP2	0.55	7.42	0.43	1.91e-12	Pancreatic cancer;
KIRP	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg26207909	chr14:103986467	CKB	0.5	5.14	0.31	5.47e-7	Monocyte count;
KIRP	cis	rs830383	0.695	rs7712594	chr5:165465607	A/G	cg13976338	chr5:165423657	NA	-0.39	-4.9	-0.3	1.74e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs587242	1.000	rs2968487	chr1:96887370	C/T	cg10631902	chr5:14652156	NA	0.53	6.08	0.36	4.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18252515	chr7:66147081	NA	0.46	5.53	0.33	8.18e-8	Aortic root size;
KIRP	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	0.99	11.77	0.6	1.14e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg26384229	chr12:38710491	ALG10B	0.51	6.42	0.38	6.79e-10	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-10.07	-0.54	3.35e-20	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08822215	chr16:89438651	ANKRD11	-0.47	-6.48	-0.38	4.95e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03466779	chr4:7666141	SORCS2	-0.46	-7.04	-0.41	1.93e-11	Parkinson's disease;
KIRP	cis	rs911119	0.657	rs6114214	chr20:23627924	A/T	cg16589663	chr20:23618590	CST3	0.6	5.24	0.32	3.54e-7	Chronic kidney disease;
KIRP	trans	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.02	0.36	6.19e-9	Retinal vascular caliber;
KIRP	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg10818794	chr15:86012489	AKAP13	-0.49	-6.97	-0.41	2.85e-11	Interstitial lung disease;
KIRP	cis	rs10875746	0.556	rs4760619	chr12:48499931	A/T	cg26205652	chr12:48591994	NA	0.73	7.74	0.44	2.53e-13	Longevity (90 years and older);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23861930	chr19:42746965	GSK3A	0.51	6.26	0.37	1.66e-9	Parkinson's disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg26531923	chr6:24646364	KIAA0319	0.46	6.16	0.37	2.87e-9	Neuroticism;
KIRP	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg15327641	chr2:3715039	ALLC	0.47	5.95	0.35	9.22e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.43	-5.53	-0.33	8.1e-8	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.3	-6.45	-0.38	5.84e-10	Asthma (sex interaction);
KIRP	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg05791153	chr7:19748676	TWISTNB	0.69	6.16	0.37	2.87e-9	Thyroid stimulating hormone;
KIRP	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg00806126	chr19:22604979	ZNF98	0.67	6.95	0.4	3.34e-11	Pain;
KIRP	cis	rs8113308	1.000	rs8105440	chr19:52451900	T/C	cg25782003	chr19:52490127	ZNF350	0.53	5.25	0.32	3.23e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs925946	0.518	rs7107410	chr11:27551388	T/C	cg18117895	chr11:27722066	BDNF	0.46	4.96	0.3	1.31e-6	Body mass index;Weight;
KIRP	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.61	7.8	0.45	1.72e-13	Coronary artery disease;
KIRP	cis	rs6466055	0.661	rs55949446	chr7:104911827	C/T	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11987759	chr7:65425863	GUSB	-0.58	-7.76	-0.44	2.26e-13	Aortic root size;
KIRP	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg11555438	chr13:111297484	CARS2	0.32	4.92	0.3	1.61e-6	Coronary artery disease;
KIRP	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	0.94	8.17	0.46	1.61e-14	Interleukin-17 levels;
KIRP	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs2882667	0.858	rs4643949	chr5:138372345	C/T	cg04439458	chr5:138467593	SIL1	-0.44	-7.51	-0.43	1.07e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01114163	chr5:1856713	NA	-0.44	-5.39	-0.32	1.68e-7	Cardiovascular disease risk factors;
KIRP	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg07216194	chr8:27182965	PTK2B	0.47	5.88	0.35	1.32e-8	Neuroticism;
KIRP	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	11.12	0.58	1.52e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-8.89	-0.49	1.31e-16	Eye color traits;
KIRP	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-22.17	-0.82	1.38e-60	Height;
KIRP	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg13206674	chr6:150067644	NUP43	0.59	8.35	0.47	4.85e-15	Lung cancer;
KIRP	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg10503236	chr1:231470652	EXOC8	-0.52	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg03188948	chr7:1209495	NA	0.47	5.19	0.31	4.44e-7	Longevity;Endometriosis;
KIRP	cis	rs17023223	0.537	rs2794313	chr1:119587440	T/C	cg05756136	chr1:119680316	WARS2	-0.56	-7.64	-0.44	4.86e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs933688	0.689	rs12697808	chr5:90605389	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.51	-5.14	-0.31	5.54e-7	Smoking behavior;
KIRP	cis	rs1190552	1.000	rs1190552	chr14:102911907	A/G	cg10241871	chr14:102965420	TECPR2	0.46	4.94	0.3	1.46e-6	Blood protein levels;
KIRP	trans	rs7863100	0.711	rs13291906	chr9:18649713	C/A	cg13196806	chr10:133996309	JAKMIP3	0.6	6.03	0.36	5.92e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg09904177	chr6:26538194	HMGN4	0.54	5.8	0.35	2.01e-8	Small cell lung carcinoma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22237707	chr2:236812587	AGAP1	0.47	6.4	0.38	7.76e-10	Interleukin-4 levels;
KIRP	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg19507638	chr5:93509721	C5orf36	-0.59	-5.31	-0.32	2.47e-7	Diabetic retinopathy;
KIRP	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.62	-0.44	5.52e-13	Neuroticism;
KIRP	cis	rs1142	0.504	rs2470945	chr7:104585760	C/A	cg04380332	chr7:105027541	SRPK2	-0.55	-8.06	-0.46	3.28e-14	Advanced age-related macular degeneration;
KIRP	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs16828019	0.789	rs34216154	chr1:41670907	G/A	cg03387723	chr1:41708464	SCMH1	-0.8	-6.72	-0.39	1.26e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg24644049	chr4:85504048	CDS1	1.09	6.99	0.41	2.61e-11	Skin colour saturation;
KIRP	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.77	9.05	0.5	4.6e-17	Corneal astigmatism;
KIRP	cis	rs56146971	0.714	rs17804071	chr14:91852876	C/T	cg10511902	chr14:91842949	CCDC88C	0.53	5.73	0.34	2.97e-8	Alzheimer disease and age of onset;
KIRP	cis	rs10114408	0.918	rs4475560	chr9:96662067	T/C	cg14598338	chr9:96623480	NA	-0.32	-4.88	-0.3	1.95e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.37	1.98e-9	Aortic root size;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg07007312	chr4:961505	DGKQ	0.34	4.99	0.3	1.17e-6	Sjögren's syndrome;
KIRP	cis	rs3818717	0.541	rs55767800	chr17:17674967	T/C	cg02336718	chr17:17403227	NA	-0.33	-5.07	-0.31	7.94e-7	Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14851460	chr1:20235923	OTUD3	-0.48	-6.14	-0.36	3.34e-9	Inflammatory biomarkers;
KIRP	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg21926883	chr2:100939477	LONRF2	0.55	7.4	0.43	2.16e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg17691542	chr6:26056736	HIST1H1C	0.45	5.98	0.36	7.95e-9	Schizophrenia;
KIRP	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.79	12.69	0.63	1.05e-28	Idiopathic membranous nephropathy;
KIRP	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.77	-7.35	-0.42	2.95e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.96	13.81	0.66	1.7e-32	Cognitive function;
KIRP	cis	rs933360	0.585	rs2074722	chr7:50834782	G/T	cg14240098	chr7:50518052	FIGNL1	0.43	4.92	0.3	1.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.18	-0.31	4.69e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg13902645	chr11:5959945	NA	-0.61	-6.39	-0.38	8.28e-10	DNA methylation (variation);
KIRP	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.96	15.76	0.71	3.75e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.78	-0.4	8.82e-11	Capecitabine sensitivity;
KIRP	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.76	-6.97	-0.41	2.9100000000000002e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.8	10.94	0.57	5.9e-23	Aortic root size;
KIRP	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg27422857	chr2:105853526	NA	-0.43	-5.66	-0.34	4.14e-8	Type 2 diabetes;
KIRP	cis	rs1050631	0.564	rs559289	chr18:33752890	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.67	0.34	4.02e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg00277334	chr10:82204260	NA	-0.62	-6.29	-0.37	1.45e-9	Post bronchodilator FEV1;
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	0.97	16.78	0.73	1.26e-42	Menarche (age at onset);
KIRP	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg06781948	chr3:72941472	GXYLT2	0.47	6.16	0.37	3.01e-9	Motion sickness;
KIRP	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg08280861	chr8:58055591	NA	0.54	5.15	0.31	5.36e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12501888	chr15:85177176	SCAND2	-0.42	-5.11	-0.31	6.38e-7	P wave terminal force;
KIRP	cis	rs62070183	0.882	rs62070187	chr17:31190724	A/G	cg05781649	chr17:31146240	MYO1D	-0.5	-5.02	-0.31	9.74e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg09904177	chr6:26538194	HMGN4	0.4	5.05	0.31	8.7e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg21360079	chr12:107162445	NA	-0.67	-9.39	-0.51	4.23e-18	Heart rate;
KIRP	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-5.58	-0.34	6.41e-8	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10774018	chr14:68067098	PIGH	-0.53	-6.07	-0.36	4.9e-9	Interleukin-4 levels;
KIRP	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.79	12.86	0.63	2.62e-29	Dupuytren's disease;
KIRP	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.15	0.41	9.92e-12	Nose size;
KIRP	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-8.95	-0.5	8.65e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6969780	1.000	rs6973182	chr7:27172321	C/T	cg26364809	chr7:27145159	NA	-0.59	-5.13	-0.31	5.81e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg04034577	chr2:241836375	C2orf54	-0.46	-9.05	-0.5	4.57e-17	Urinary metabolites;
KIRP	cis	rs4132509	1.000	rs2290754	chr1:243806268	A/C	cg25706552	chr1:244017396	NA	0.57	7.44	0.43	1.66e-12	RR interval (heart rate);
KIRP	trans	rs1106684	0.929	rs2878054	chr7:131454160	A/C	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.52	5.59	0.34	6.07e-8	Bipolar disorder;
KIRP	cis	rs240764	0.621	rs12175456	chr6:101219511	A/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.02	-0.36	6.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.02	-0.36	6.34e-9	Recombination measurement;
KIRP	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.64	-7.93	-0.45	7.46e-14	Iron status biomarkers;
KIRP	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg13010199	chr12:38710504	ALG10B	0.44	5.46	0.33	1.17e-7	Morning vs. evening chronotype;
KIRP	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.92	0.45	8.04e-14	Iron status biomarkers;
KIRP	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg07777115	chr5:623756	CEP72	-0.59	-6.04	-0.36	5.56e-9	Obesity-related traits;
KIRP	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg06742321	chr12:123595122	PITPNM2	0.43	5.39	0.33	1.63e-7	Platelet count;
KIRP	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg24409356	chr1:165738333	TMCO1	-0.72	-6.06	-0.36	5.09e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-16.83	-0.73	8.37e-43	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg15556689	chr8:8085844	FLJ10661	0.64	8.26	0.47	9.05e-15	Neuroticism;
KIRP	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15128208	chr22:42549153	NA	0.45	5.68	0.34	3.69e-8	Cognitive function;
KIRP	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.5	0.38	4.47e-10	Platelet count;
KIRP	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.75	-10.39	-0.55	3.28e-21	Hypospadias;
KIRP	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.76	-9.25	-0.51	1.14e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg04865290	chr3:52927548	TMEM110	-0.39	-5.11	-0.31	6.38e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs35110281	0.755	rs8127297	chr21:45063847	G/A	cg04455712	chr21:45112962	RRP1B	0.52	6.9	0.4	4.27e-11	Mean corpuscular volume;
KIRP	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg06212747	chr3:49208901	KLHDC8B	0.63	8.64	0.48	7.03e-16	Resting heart rate;
KIRP	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.89	0.3	1.85e-6	Tonsillectomy;
KIRP	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	15.22	0.7	2.51e-37	Homoarginine levels;
KIRP	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.55	-5.81	-0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs929596	0.564	rs2741027	chr2:234518011	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.69	-0.34	3.62e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.81	0.4	7.52e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.42	5.28	0.32	2.82e-7	Aortic root size;
KIRP	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.94	11.04	0.58	2.79e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.61	-0.52	8.92e-19	Lung cancer;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.99	0.36	7.41e-9	Lung cancer;
KIRP	cis	rs1697139	0.710	rs6866416	chr5:66517476	A/G	cg11553311	chr5:66541588	NA	0.42	5.68	0.34	3.7e-8	Breast cancer;
KIRP	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-10.77	-0.57	2.09e-22	Colorectal cancer;
KIRP	cis	rs4302748	0.862	rs79729347	chr7:36184584	G/A	cg24442661	chr7:36192818	EEPD1	0.63	6.69	0.39	1.46e-10	Platelet count;
KIRP	cis	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg02972257	chr16:68554789	NA	0.83	7.55	0.43	8.65e-13	Ulcerative colitis;
KIRP	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-4.88	-0.3	1.95e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs2862064	1.000	rs2902128	chr5:156421347	C/T	cg12943317	chr5:156479607	HAVCR1	-0.89	-7.26	-0.42	4.92e-12	Platelet count;
KIRP	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg27494647	chr7:150038898	RARRES2	0.39	6.01	0.36	6.75e-9	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08535374	chr1:110679730	NA	0.53	6.63	0.39	2.14e-10	Smoking initiation;
KIRP	cis	rs12049351	0.774	rs6657735	chr1:229626832	A/G	cg11742688	chr1:229674241	ABCB10	-0.39	-5.79	-0.35	2.11e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	13.58	0.65	1.01e-31	Platelet count;
KIRP	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.85	12.97	0.64	1.19e-29	Colorectal cancer;
KIRP	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs7809615	0.748	rs34257469	chr7:99150185	T/C	cg12290671	chr7:99195819	NA	-0.47	-5.09	-0.31	7.1e-7	Blood metabolite ratios;
KIRP	cis	rs28655083	0.957	rs7185514	chr16:77070129	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.55	-6.26	-0.37	1.75e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.34	0.51	6.08e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4742903	0.935	rs726203	chr9:106906437	A/G	cg14250997	chr9:106856677	SMC2	0.43	5.97	0.36	8.38e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg10950524	chr7:2139216	MAD1L1	-0.28	-4.9	-0.3	1.71e-6	Schizophrenia;
KIRP	cis	rs9815354	1.000	rs9820192	chr3:41889281	G/A	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs71636778	0.722	rs12746395	chr1:27168188	G/C	cg12203394	chr1:27248618	NUDC	0.7	5.66	0.34	4.14e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs2400749	0.660	rs12897741	chr14:100017729	C/A	cg19965031	chr14:100038389	CCDC85C	-0.42	-5.07	-0.31	7.93e-7	Alzheimer's disease (survival time);
KIRP	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.28	13.08	0.64	4.85e-30	Diabetic retinopathy;
KIRP	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-11.96	-0.61	2.72e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7809950	0.768	rs62482493	chr7:106951579	T/C	cg23024343	chr7:107201750	COG5	-0.53	-7.42	-0.43	1.9e-12	Coronary artery disease;
KIRP	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg12501888	chr15:85177176	SCAND2	-0.42	-5.22	-0.32	3.76e-7	P wave terminal force;
KIRP	cis	rs6738028	0.504	rs11123406	chr2:111950541	C/T	cg23466623	chr2:111982296	NA	0.54	7.19	0.42	7.94e-12	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.37	10.51	0.56	1.35e-21	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18554811	chr13:48877691	RB1	0.47	6.2	0.37	2.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.61	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg21858823	chr1:15850916	CASP9	0.54	5.75	0.34	2.63e-8	Systolic blood pressure;
KIRP	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.77	8.51	0.48	1.77e-15	Cholesterol, total;
KIRP	cis	rs5753037	0.834	rs713656	chr22:30212194	C/G	cg01021169	chr22:30184971	ASCC2	-0.41	-5.0	-0.3	1.11e-6	Type 1 diabetes;
KIRP	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.59	7.88	0.45	1.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg12042659	chr19:58951599	ZNF132	0.5	6.09	0.36	4.35e-9	Uric acid clearance;
KIRP	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.86	12.49	0.62	4.91e-28	Total body bone mineral density;
KIRP	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg16141378	chr3:129829833	LOC729375	-0.47	-6.08	-0.36	4.56e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg10761708	chr20:43804764	PI3	0.5	5.2	0.31	4.22e-7	Blood protein levels;
KIRP	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	0.91	10.43	0.55	2.45e-21	Triglycerides;
KIRP	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg27494647	chr7:150038898	RARRES2	0.43	6.26	0.37	1.69e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs35995292	1.000	rs3779119	chr7:38942248	C/G	cg19327137	chr7:38886074	VPS41	0.52	6.09	0.36	4.41e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg17207736	chr8:142237307	SLC45A4	-0.43	-5.35	-0.32	2.05e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2562456	0.833	rs4334427	chr19:21520892	A/G	cg18461458	chr19:21324796	ZNF431	-0.51	-4.93	-0.3	1.49e-6	Pain;
KIRP	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg02175503	chr12:58329896	NA	0.53	5.77	0.35	2.34e-8	Multiple sclerosis;
KIRP	cis	rs698833	0.852	rs2241870	chr2:44549204	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.92	0.35	1.08e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg01620082	chr3:125678407	NA	-1.24	-7.96	-0.45	6.31e-14	Depression;
KIRP	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.13	0.41	1.11e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.6e-19	Prudent dietary pattern;
KIRP	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.56	8.2	0.46	1.35e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-8.37	-0.47	4.39e-15	Morning vs. evening chronotype;
KIRP	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg20194872	chr6:41519635	FOXP4	0.57	7.34	0.42	3.16e-12	Prostate cancer;
KIRP	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.08	-0.5	3.58e-17	Response to antipsychotic treatment;
KIRP	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17350441	chr10:88389642	NA	0.51	6.51	0.38	4.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8113308	1.000	rs8113308	chr19:52445386	T/C	cg24732339	chr19:52471368	ZNF350	-0.5	-5.93	-0.35	9.97e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.77	11.53	0.59	7.34e-25	Hip circumference;
KIRP	trans	rs1530530	1.000	rs3803221	chr13:25241724	A/G	cg10418263	chr6:35265544	DEF6	0.53	6.1	0.36	4.06e-9	Obesity-related traits;
KIRP	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.39	5.9	0.35	1.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.98e-34	Menopause (age at onset);
KIRP	cis	rs6988636	0.534	rs62520599	chr8:124095147	G/C	cg15893493	chr8:124194847	FAM83A	0.78	6.14	0.36	3.37e-9	Urinary uromodulin levels;
KIRP	cis	rs16857609	0.545	rs6754399	chr2:218356952	A/G	cg15335768	chr2:218268053	DIRC3	-0.34	-4.97	-0.3	1.24e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.84	-0.35	1.66e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11673344	0.526	rs73033122	chr19:38076907	T/C	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.52	-0.33	8.41e-8	Obesity-related traits;
KIRP	cis	rs9972944	0.729	rs10083870	chr17:63773272	C/T	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.79	9.53	0.52	1.63e-18	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.51	-0.38	4.14e-10	Aortic root size;
KIRP	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.29	-0.47	7.35e-15	Mean corpuscular volume;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg01506766	chr13:46626746	ZC3H13	-0.43	-6.06	-0.36	5.11e-9	Hippocampal sclerosis of aging;
KIRP	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.69	0.48	5.24e-16	Prudent dietary pattern;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14360444	chr9:129643082	ZBTB34	0.59	6.27	0.37	1.63e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2548003	0.541	rs2014310	chr5:28723589	T/C	cg22863700	chr5:28928346	NA	0.61	6.34	0.37	1.1e-9	Hip geometry;
KIRP	cis	rs12210905	1.000	rs72843641	chr6:27203335	C/G	cg11502198	chr6:26597334	ABT1	-0.83	-5.28	-0.32	2.87e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.87	12.71	0.63	8.56e-29	Monocyte count;
KIRP	cis	rs7809615	0.551	rs952319	chr7:99171449	C/T	cg12290671	chr7:99195819	NA	-0.5	-5.93	-0.35	1.01e-8	Blood metabolite ratios;
KIRP	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.64	6.4	0.38	7.78e-10	Height;
KIRP	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.64	11.8	0.6	9.15e-26	Blood protein levels;
KIRP	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg18944383	chr4:111397179	ENPEP	0.52	9.11	0.5	2.88e-17	Height;
KIRP	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	1.04	11.52	0.59	7.66e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9900972	0.959	rs4789941	chr17:76877500	G/C	cg20937029	chr17:76870563	TIMP2	0.44	5.15	0.31	5.24e-7	Obesity-related traits;
KIRP	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.83	9.7	0.53	4.82e-19	Platelet count;
KIRP	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23544223	chr18:12777786	NA	0.68	5.77	0.35	2.42e-8	Inflammatory skin disease;
KIRP	cis	rs9826463	0.702	rs55994893	chr3:142304694	G/C	cg20824294	chr3:142316082	PLS1	0.42	6.55	0.39	3.3e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg17644776	chr2:200775616	C2orf69	-0.62	-5.67	-0.34	4.01e-8	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.69	-7.24	-0.42	5.67e-12	Urate levels in lean individuals;
KIRP	trans	rs13170463	0.579	rs71606008	chr5:8041706	G/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.41	-4.85	-0.3	2.2e-6	Monocyte count;
KIRP	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.79	6.4	0.38	7.75e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14233716	chr9:90497253	C9orf79	-0.4	-6.44	-0.38	6.06e-10	Inflammatory biomarkers;
KIRP	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.64	-9.66	-0.52	6.39e-19	Fibrinogen levels;
KIRP	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.88	9.75	0.53	3.36e-19	Corneal astigmatism;
KIRP	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg04725166	chr1:7887271	PER3	0.41	5.09	0.31	7.29e-7	Crohn's disease;
KIRP	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.61	-6.63	-0.39	2.11e-10	Corneal structure;
KIRP	cis	rs16936870	0.543	rs4546698	chr8:71029632	A/G	cg14232793	chr8:71155543	NCOA2	0.53	6.14	0.36	3.21e-9	QT interval;
KIRP	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg24009623	chr19:33667908	NA	0.5	6.32	0.37	1.24e-9	Colorectal cancer;
KIRP	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.47	5.41	0.33	1.51e-7	Metabolite levels;
KIRP	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg09473613	chr1:24152604	HMGCL	0.45	6.14	0.36	3.24e-9	Immature fraction of reticulocytes;
KIRP	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg02175503	chr12:58329896	NA	0.67	7.82	0.45	1.59e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.52	6.58	0.39	2.84e-10	Primary sclerosing cholangitis;
KIRP	cis	rs2708977	0.699	rs631746	chr2:97065499	A/G	cg01950434	chr2:97203154	ARID5A	-0.42	-5.47	-0.33	1.1e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10128251	0.674	rs4750473	chr10:5722561	C/T	cg11519256	chr10:5708881	ASB13	0.5	6.58	0.39	2.77e-10	Childhood ear infection;
KIRP	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.69	8.97	0.5	7.7e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg11494091	chr17:61959527	GH2	-0.67	-9.41	-0.51	3.67e-18	Prudent dietary pattern;
KIRP	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.26	-5.45	-0.33	1.23e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-1.13	-13.33	-0.65	7.34e-31	Platelet count;
KIRP	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg03808351	chr9:123631620	PHF19	0.47	6.5	0.38	4.54e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs8079658	1.000	rs8079658	chr17:63791483	C/T	cg18091269	chr17:63822838	CCDC46	-0.56	-7.5	-0.43	1.16e-12	Post bronchodilator FEV1;
KIRP	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg17757837	chr7:157058334	UBE3C	0.71	9.48	0.52	2.2e-18	Body mass index;
KIRP	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	7.98	0.45	5.54e-14	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs11673344	0.864	rs79927931	chr19:37503143	G/A	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.2	-0.31	4.28e-7	Obesity-related traits;
KIRP	cis	rs6142102	0.923	rs6059635	chr20:32613493	A/T	cg24642439	chr20:33292090	TP53INP2	0.56	6.46	0.38	5.7e-10	Skin pigmentation;
KIRP	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.44	-0.33	1.31e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg07395648	chr5:131743802	NA	0.58	8.6	0.48	9.6e-16	Blood metabolite levels;
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg13699009	chr12:122356056	WDR66	0.68	10.85	0.57	1.16e-22	Mean corpuscular volume;
KIRP	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-7.6	-0.44	6.07e-13	Gut microbiome composition (summer);
KIRP	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg22284058	chr8:142237359	SLC45A4	0.47	5.82	0.35	1.82e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg07843065	chr1:150265600	MRPS21	0.41	5.61	0.34	5.45e-8	Migraine;
KIRP	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg24803719	chr17:45855879	NA	-0.44	-5.73	-0.34	2.87e-8	IgG glycosylation;
KIRP	cis	rs4721295	0.540	rs59134428	chr7:2195445	G/A	cg10950524	chr7:2139216	MAD1L1	0.31	5.08	0.31	7.58e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.23	0.37	2.01e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.86	10.37	0.55	3.75e-21	Eosinophil percentage of granulocytes;
KIRP	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg23533926	chr12:111358616	MYL2	-0.49	-6.47	-0.38	5.4e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1413885	0.516	rs7537733	chr1:65838229	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.54	5.96	0.36	8.89e-9	Anticoagulant levels;
KIRP	cis	rs11169225	1.000	rs7299924	chr12:50348961	A/G	cg04450003	chr12:50355995	AQP5	0.57	9.09	0.5	3.43e-17	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4778581	0.500	rs2114714	chr15:80426720	T/C	cg08257866	chr15:80351198	ZFAND6	0.49	5.14	0.31	5.66e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15369608	chr2:239975220	HDAC4	0.54	7.08	0.41	1.54e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4690686	1.000	rs4690686	chr4:177242959	C/T	cg17059388	chr4:177262070	NA	0.5	6.53	0.38	3.72e-10	Essential tremor;
KIRP	cis	rs8077577	0.747	rs57490980	chr17:18160753	T/A	cg18869244	chr17:18121946	NA	0.42	4.87	0.3	1.97e-6	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs78487399	0.808	rs12105626	chr2:43678759	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.89	-0.3	1.85e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6815814	1.000	rs6815814	chr4:38816338	A/C	cg06935464	chr4:38784597	TLR10	0.51	6.12	0.36	3.72e-9	Breast cancer;
KIRP	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18252515	chr7:66147081	NA	0.42	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Hypertriglyceridemia;
KIRP	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.66	7.75	0.44	2.43e-13	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg11693508	chr17:37793320	STARD3	0.8	8.44	0.47	2.78e-15	Bipolar disorder;
KIRP	cis	rs7709377	0.546	rs10079176	chr5:115454408	A/G	cg23108291	chr5:115420582	COMMD10	0.41	4.94	0.3	1.43e-6	Metabolite levels  (X-11787);
KIRP	trans	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg24644049	chr4:85504048	CDS1	1.05	7.45	0.43	1.56e-12	Skin colour saturation;
KIRP	cis	rs11783469	0.524	rs17089283	chr8:23335762	A/T	cg00472375	chr8:23315376	ENTPD4	0.53	5.37	0.32	1.82e-7	Reticulocyte count;
KIRP	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	10.44	0.55	2.35e-21	Bone mineral density;
KIRP	trans	rs12545912	0.770	rs12114182	chr8:9537635	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.41	-0.38	7.34e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.64	7.29	0.42	4.18e-12	Coronary artery disease;
KIRP	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg13034073	chr7:2769681	GNA12	0.28	5.01	0.3	1.04e-6	Height;
KIRP	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg01475377	chr6:109611718	NA	-0.36	-5.24	-0.32	3.44e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.96	0.3	1.29e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10203711	0.600	rs1810138	chr2:239561888	T/C	cg14580085	chr2:239553406	NA	0.39	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.57	7.0	0.41	2.48e-11	Aortic root size;
KIRP	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.87	-0.4	5.37e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg06219351	chr7:158114137	PTPRN2	-0.56	-6.42	-0.38	6.88e-10	Response to amphetamines;
KIRP	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.83	11.22	0.58	7.06e-24	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.84	-10.99	-0.57	3.91e-23	Longevity;Endometriosis;
KIRP	cis	rs9888739	0.800	rs1143678	chr16:31343005	C/T	cg15817542	chr16:31343056	ITGAM	-0.49	-5.11	-0.31	6.36e-7	Systemic lupus erythematosus;
KIRP	cis	rs6545883	0.859	rs13004855	chr2:61505072	C/T	cg15711740	chr2:61764176	XPO1	0.59	7.67	0.44	4.12e-13	Tuberculosis;
KIRP	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.53	7.17	0.42	8.64e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.97	-12.64	-0.63	1.53e-28	Platelet distribution width;
KIRP	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.05	0.31	8.8e-7	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12615966	0.932	rs4013898	chr2:105369671	C/T	cg16465502	chr2:105461796	NA	0.68	6.06	0.36	5.11e-9	Pancreatic cancer;
KIRP	cis	rs4750440	0.706	rs10906555	chr10:14016879	G/A	cg27542038	chr10:14027202	FRMD4A	-0.49	-6.52	-0.38	4.06e-10	Adiponectin levels;
KIRP	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	9.01	0.5	6.06e-17	Personality dimensions;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg13922124	chr7:105221991	EFCAB10	0.47	6.05	0.36	5.37e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6732160	0.588	rs2043100	chr2:73374096	T/C	cg01422370	chr2:73384389	NA	0.51	6.92	0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.66	0.48	6.33e-16	Exhaled nitric oxide output;
KIRP	cis	rs8084125	1.000	rs62105185	chr18:74954808	G/A	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11987759	chr7:65425863	GUSB	-0.7	-9.76	-0.53	3.05e-19	Calcium levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15681038	chr19:37064156	ZNF529	0.46	6.27	0.37	1.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11644362	0.966	rs4781348	chr16:12986742	A/C	cg06890432	chr16:12997467	SHISA9	-0.41	-6.61	-0.39	2.35e-10	Positive affect;Subjective well-being;
KIRP	cis	rs405956	0.685	rs9404605	chr6:105585511	G/A	cg22580625	chr6:105627791	POPDC3	-0.54	-5.69	-0.34	3.64e-8	QT interval;
KIRP	cis	rs4561483	0.624	rs2215928	chr16:11927918	A/T	cg08843971	chr16:11963173	GSPT1	-0.5	-6.85	-0.4	5.73e-11	Testicular germ cell tumor;
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.83	11.28	0.58	4.49e-24	Height;
KIRP	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg04727924	chr7:799746	HEATR2	0.64	5.86	0.35	1.49e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.1	-8.56	-0.48	1.24e-15	Mitochondrial DNA levels;
KIRP	trans	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.8	-0.4	7.8e-11	Heart rate;
KIRP	cis	rs12956009	0.583	rs7240132	chr18:44858634	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.06	-0.31	8.1e-7	Educational attainment (years of education);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg20566420	chr12:122327043	PSMD9	-0.48	-6.08	-0.36	4.65e-9	Neuroticism;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs667920	0.512	rs13069695	chr3:136291562	T/C	cg15507776	chr3:136538369	TMEM22	-0.67	-5.87	-0.35	1.37e-8	Coronary artery disease;
KIRP	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.5	-6.61	-0.39	2.39e-10	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17376030	chr22:41985996	PMM1	0.7	7.29	0.42	4.28e-12	Vitiligo;
KIRP	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg05220968	chr6:146057943	EPM2A	-0.43	-5.52	-0.33	8.48e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.64	6.66	0.39	1.73e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06369833	chr19:40909697	PRX	-0.5	-6.11	-0.36	3.96e-9	Menopause (age at onset);
KIRP	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.35	7.29	0.42	4.27e-12	Body mass index;
KIRP	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.54	7.47	0.43	1.44e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg20003494	chr4:90757398	SNCA	-0.4	-5.35	-0.32	2.03e-7	Neuroticism;
KIRP	cis	rs7187994	0.895	rs7184644	chr16:84786460	C/A	cg07647771	chr16:84786436	USP10	-0.42	-5.42	-0.33	1.44e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg03146154	chr1:46216737	IPP	-0.42	-5.36	-0.32	1.95e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.85	7.09	0.41	1.45e-11	Plateletcrit;
KIRP	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg15534755	chr11:117069859	TAGLN	0.41	4.87	0.3	1.97e-6	Blood protein levels;
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg01391022	chr12:122360665	WDR66	-0.37	-5.35	-0.32	2.02e-7	Mean corpuscular volume;
KIRP	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.76	0.53	3.09e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg25036284	chr2:26402008	FAM59B	-0.51	-5.37	-0.32	1.85e-7	Gut microbiome composition (summer);
KIRP	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.72	0.39	1.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.46	6.86	0.4	5.55e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.64	6.29	0.37	1.41e-9	Eotaxin levels;
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg07511668	chr11:68622177	NA	-0.39	-5.26	-0.32	3.09e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg21545522	chr1:205238299	TMCC2	0.39	5.26	0.32	3.11e-7	Red blood cell count;
KIRP	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-4.9	-0.3	1.76e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.61	7.25	0.42	5.4e-12	Orofacial clefts;
KIRP	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg03735888	chr19:58951602	ZNF132	0.45	5.33	0.32	2.22e-7	Uric acid clearance;
KIRP	cis	rs11825064	0.725	rs78690751	chr11:134479441	C/T	cg06603561	chr11:134479413	NA	-1.1	-7.55	-0.43	8.24e-13	Seasonality;
KIRP	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.9	12.19	0.61	4.64e-27	Menopause (age at onset);
KIRP	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.11e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5756391	0.546	rs2899276	chr22:37312173	A/G	cg16356956	chr22:37317934	CSF2RB	0.43	5.62	0.34	5.18e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs7849270	0.879	rs7859344	chr9:131848382	T/A	cg13538475	chr9:131942899	NA	-0.37	-5.71	-0.34	3.23e-8	Blood metabolite ratios;
KIRP	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg00405596	chr8:11794950	NA	0.56	7.63	0.44	5.11e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg23565292	chr14:50234668	KLHDC2	-0.43	-5.02	-0.31	9.78e-7	Carotid intima media thickness;
KIRP	cis	rs1440410	0.835	rs13139558	chr4:144070563	G/A	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	cis	rs7729447	0.813	rs7715779	chr5:32690199	T/G	cg16267343	chr5:32710456	NPR3	0.52	6.02	0.36	6.16e-9	Blood pressure;
KIRP	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.82	11.98	0.61	2.37e-26	Bladder cancer;
KIRP	cis	rs72772090	0.539	rs11750671	chr5:96188482	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20085812	chr3:39149038	GORASP1;TTC21A	0.51	6.5	0.38	4.49e-10	Myopia (pathological);
KIRP	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.65	7.75	0.44	2.38e-13	Testicular germ cell tumor;
KIRP	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.91	14.64	0.68	2.44e-35	Mean corpuscular volume;
KIRP	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.14	-0.41	1.03e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg17376030	chr22:41985996	PMM1	0.5	6.1	0.36	4.18e-9	Vitiligo;
KIRP	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.48e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg14972814	chr11:95582409	MTMR2	0.39	6.52	0.38	3.96e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg09579323	chr1:150459698	TARS2	0.4	5.01	0.3	1.04e-6	Migraine;
KIRP	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg13165212	chr22:42675999	NA	0.35	5.98	0.36	7.78e-9	Cognitive function;
KIRP	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.96	13.58	0.65	1.01e-31	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.74	10.28	0.55	7.28e-21	Schizophrenia;
KIRP	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10788972	0.844	rs7555099	chr1:54561916	C/T	cg25741118	chr1:54482237	LDLRAD1	-0.29	-4.88	-0.3	1.94e-6	Parkinson disease and lewy body pathology;
KIRP	cis	rs3931020	0.508	rs2345436	chr1:75198740	A/C	cg26855724	chr1:75198818	TYW3;CRYZ	0.43	5.24	0.32	3.48e-7	Resistin levels;
KIRP	cis	rs4262150	0.693	rs3924314	chr5:152302912	C/A	cg12297329	chr5:152029980	NA	0.47	6.66	0.39	1.82e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.82	0.4	7.2e-11	Electroencephalogram traits;
KIRP	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	7.11	0.41	1.24e-11	Educational attainment;
KIRP	cis	rs7927592	0.645	rs7950900	chr11:68293545	G/A	cg16797656	chr11:68205561	LRP5	0.32	4.85	0.3	2.22e-6	Total body bone mineral density;
KIRP	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.66	8.64	0.48	7.29e-16	Multiple sclerosis;
KIRP	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg15282417	chr9:129245246	FAM125B	0.45	7.73	0.44	2.7e-13	Intraocular pressure;
KIRP	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.43	5.25	0.32	3.33e-7	Iron status biomarkers;
KIRP	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.89	13.44	0.65	2.96e-31	Testicular germ cell tumor;
KIRP	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg07541023	chr7:19748670	TWISTNB	0.77	6.38	0.38	8.94e-10	Thyroid stimulating hormone;
KIRP	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.76	-0.53	3.2e-19	Idiopathic membranous nephropathy;
KIRP	cis	rs6568686	0.730	rs4526232	chr6:111857045	A/G	cg15721981	chr6:111408429	SLC16A10	-0.57	-5.24	-0.32	3.47e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg16329197	chr12:53359506	NA	-0.54	-4.99	-0.3	1.12e-6	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01765249	chr17:59476334	TBX2	0.45	6.06	0.36	4.96e-9	Parkinson's disease;
KIRP	cis	rs6988636	0.584	rs75096144	chr8:124131225	C/T	cg15893493	chr8:124194847	FAM83A	0.86	6.17	0.37	2.79e-9	Urinary uromodulin levels;
KIRP	cis	rs17381785	0.715	rs7686227	chr4:14911253	A/G	cg12377275	chr4:15005593	CPEB2	0.47	5.7	0.34	3.41e-8	Urate levels in overweight individuals;
KIRP	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.69	-7.43	-0.43	1.79e-12	Corneal structure;
KIRP	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.55	6.07	0.36	4.72e-9	Bone mineral density (spine);
KIRP	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs501120	0.535	rs10900002	chr10:44697564	A/T	cg09554077	chr10:44749378	NA	0.51	5.5	0.33	9.68e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg02725872	chr8:58115012	NA	0.72	7.85	0.45	1.27e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05220968	chr6:146057943	EPM2A	-0.41	-5.28	-0.32	2.82e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.7	-0.68	1.58e-35	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01166685	chr10:94608070	EXOC6	0.47	6.42	0.38	6.83e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09447457	chr6:24721528	NA	0.48	6.07	0.36	4.86e-9	Parkinson's disease;
KIRP	cis	rs7523273	0.517	rs2985106	chr1:207892033	T/G	cg22525895	chr1:207977042	MIR29B2	-0.43	-5.3	-0.32	2.57e-7	Schizophrenia;
KIRP	cis	rs11702148	0.552	rs2154583	chr21:34888940	T/G	cg14850771	chr21:34775459	IFNGR2	0.38	5.29	0.32	2.72e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg11833968	chr6:79620685	NA	-0.45	-6.79	-0.4	8.2e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	7.03	0.41	2.08e-11	Total body bone mineral density;
KIRP	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.5	-7.11	-0.41	1.23e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg27124370	chr19:33622961	WDR88	0.6	7.48	0.43	1.29e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.77	-0.35	2.32e-8	IgG glycosylation;
KIRP	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-1.0	-9.43	-0.52	3.2e-18	Diabetic kidney disease;
KIRP	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	1.06	13.66	0.66	5.49e-32	Post bronchodilator FEV1;
KIRP	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.8	12.61	0.63	1.84e-28	Hepatocellular carcinoma;
KIRP	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg16797656	chr11:68205561	LRP5	-0.41	-5.85	-0.35	1.54e-8	Bone mineral density (spine);
KIRP	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.69	8.22	0.46	1.18e-14	Blood protein levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15210612	chr3:98312534	CPOX	-0.56	-6.25	-0.37	1.83e-9	Menopause (age at onset);
KIRP	cis	rs12210905	1.000	rs72843609	chr6:27125877	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	2.02e-7	Life satisfaction;
KIRP	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.45	-0.33	1.2e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.56	-7.4	-0.43	2.21e-12	White matter hyperintensity burden;
KIRP	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.08	-0.58	2e-23	Chronic sinus infection;
KIRP	cis	rs7084402	0.967	rs1621811	chr10:60320664	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.77	-0.57	2.01e-22	Refractive error;
KIRP	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg03929089	chr4:120376271	NA	-0.56	-6.64	-0.39	2.03e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.71	6.05	0.36	5.32e-9	Cognitive function;
KIRP	trans	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.07	-0.41	1.64e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg02187348	chr16:89574699	SPG7	0.47	5.56	0.33	6.92e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs4908768	0.871	rs4908775	chr1:8794410	G/A	cg03610117	chr1:8450231	RERE	-0.46	-4.95	-0.3	1.39e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7714584	1.000	rs12656538	chr5:150251380	A/G	cg22134413	chr5:150180641	NA	0.95	7.46	0.43	1.52e-12	Crohn's disease;
KIRP	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.07	12.77	0.63	5.3e-29	Vitiligo;
KIRP	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.76	10.0	0.54	5.44e-20	Orofacial clefts;
KIRP	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.6	5.75	0.34	2.69e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg12463550	chr7:65579703	CRCP	0.44	4.89	0.3	1.8e-6	Aortic root size;
KIRP	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg10047753	chr17:41438598	NA	1.12	18.06	0.76	5.49e-47	Menopause (age at onset);
KIRP	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.58	7.16	0.42	9.42e-12	Coronary artery disease;
KIRP	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.22	0.37	2.18e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.77	-0.44	2.16e-13	Type 2 diabetes;
KIRP	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg07395648	chr5:131743802	NA	-0.54	-7.85	-0.45	1.25e-13	Acylcarnitine levels;
KIRP	cis	rs2236918	1.000	rs2797605	chr1:242025245	A/T	cg17736920	chr1:242011382	EXO1	0.76	10.03	0.54	4.43e-20	Menopause (age at onset);
KIRP	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg18932078	chr1:2524107	MMEL1	0.48	6.55	0.39	3.31e-10	Ulcerative colitis;
KIRP	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.31	-0.7	1.29e-37	Alzheimer's disease;
KIRP	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg23335576	chr14:104009727	NA	0.39	5.69	0.34	3.58e-8	Body mass index;
KIRP	cis	rs2916247	1.000	rs2916247	chr8:93013666	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.94	-0.45	7.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg10117171	chr1:25599238	RHD	0.38	5.14	0.31	5.49e-7	Erythrocyte sedimentation rate;
KIRP	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg17145862	chr1:211918768	LPGAT1	0.74	10.07	0.54	3.51e-20	Leprosy;
KIRP	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg21360079	chr12:107162445	NA	0.68	9.73	0.53	3.79e-19	Heart rate;
KIRP	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg20651018	chr11:3035856	CARS	-0.36	-4.89	-0.3	1.8e-6	Longevity;
KIRP	cis	rs72843166	0.898	rs72843193	chr17:61205015	A/G	cg19683800	chr17:61518354	CYB561	-0.41	-4.95	-0.3	1.35e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09024023	chr11:46105316	PHF21A	0.39	6.4	0.38	7.61e-10	C-reactive protein;
KIRP	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.45	-5.24	-0.32	3.53e-7	Reticulocyte count;
KIRP	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg21798802	chr22:38057573	PDXP	0.35	5.02	0.3	9.8e-7	Fat distribution (HIV);
KIRP	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.81	-12.28	-0.62	2.37e-27	Coronary artery disease;
KIRP	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.13	-0.61	7.19e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg18612461	chr15:75251733	NA	0.34	5.21	0.32	4.07e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.61	7.73	0.44	2.73e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.48	5.17	0.31	4.78e-7	Subjective well-being;
KIRP	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.62	8.41	0.47	3.26e-15	Height;
KIRP	trans	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg14791747	chr16:20752902	THUMPD1	0.64	6.94	0.4	3.5e-11	Cognitive test performance;
KIRP	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.65	7.52	0.43	1.05e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.89	0.49	1.3e-16	Morning vs. evening chronotype;
KIRP	cis	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg07585502	chr8:101912084	NA	0.64	8.24	0.47	1.03e-14	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6977660	0.714	rs6945753	chr7:19814255	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	5.79	0.35	2.09e-8	Thyroid stimulating hormone;
KIRP	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.29	0.37	1.41e-9	Breast cancer;
KIRP	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg26513180	chr16:89883248	FANCA	-0.6	-7.87	-0.45	1.13e-13	Vitiligo;
KIRP	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.53	-5.4	-0.33	1.58e-7	Subjective well-being;
KIRP	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.34	-0.32	2.08e-7	Electroencephalogram traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22636316	chr11:6624756	ILK;RRP8	0.51	6.28	0.37	1.53e-9	Parkinson's disease;
KIRP	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg13047869	chr3:10149882	C3orf24	0.61	5.18	0.31	4.61e-7	Alzheimer's disease;
KIRP	cis	rs644148	0.730	rs2686766	chr19:44991595	T/G	cg15540054	chr19:45004280	ZNF180	-0.63	-6.93	-0.4	3.67e-11	Personality dimensions;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03188526	chr2:55556201	CCDC88A	0.39	6.61	0.39	2.4e-10	C-reactive protein;
KIRP	cis	rs7561273	0.609	rs1056122	chr2:24342505	C/T	cg20701182	chr2:24300061	SF3B14	-0.48	-6.04	-0.36	5.76e-9	Quantitative traits;
KIRP	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg00800038	chr16:89945340	TCF25	-0.61	-5.86	-0.35	1.51e-8	Skin colour saturation;
KIRP	cis	rs10792830	0.741	rs519778	chr11:85764693	T/C	cg07180834	chr11:85838833	NA	-0.33	-4.87	-0.3	1.98e-6	Psychosis and Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.42e-6	Life satisfaction;
KIRP	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg24315340	chr6:146058215	EPM2A	0.42	5.28	0.32	2.84e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg03465714	chr1:152285911	FLG	-0.43	-5.15	-0.31	5.4e-7	Atopic dermatitis;
KIRP	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.53	6.62	0.39	2.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg25019033	chr10:957182	NA	-0.69	-8.68	-0.48	5.63e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.39	-9.66	-0.52	6.3e-19	Asthma (sex interaction);
KIRP	cis	rs231513	0.906	rs1642611	chr17:41997712	T/C	cg26893861	chr17:41843967	DUSP3	-0.6	-5.04	-0.31	8.9e-7	Cognitive function;
KIRP	cis	rs6929812	0.934	rs6908553	chr6:27379372	A/G	cg03332623	chr6:27441972	ZNF184	-0.35	-5.05	-0.31	8.51e-7	Neuroticism (multi-trait analysis);
KIRP	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.44	-5.22	-0.32	3.79e-7	Crohn's disease;
KIRP	cis	rs7119167	0.636	rs56397594	chr11:73038579	T/C	cg17517138	chr11:73019481	ARHGEF17	0.46	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs238295	0.805	rs6053527	chr20:5582457	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.48	-4.85	-0.3	2.2e-6	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs28489187	0.730	rs233130	chr1:85795112	T/C	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.75e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05347473	chr6:146136440	FBXO30	-0.6	-8.82	-0.49	2.16e-16	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	1.01	15.83	0.71	2.07e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2067615	1.000	rs2067615	chr12:107149422	A/T	cg15890332	chr12:107067104	RFX4	-0.3	-4.95	-0.3	1.4e-6	Heart rate;
KIRP	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg26516362	chr5:178986906	RUFY1	0.39	6.55	0.39	3.25e-10	Lung cancer;
KIRP	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.86	16.39	0.72	2.64e-41	Anterior chamber depth;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.59	0.52	1.07e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.69	9.89	0.53	1.2e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04238871	chr10:126431886	FAM53B	0.48	7.08	0.41	1.51e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05220968	chr6:146057943	EPM2A	0.38	4.89	0.3	1.8e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.27	-0.42	4.75e-12	Retinal vascular caliber;
KIRP	trans	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg15469184	chr8:337539	NA	-0.53	-6.43	-0.38	6.64e-10	Obesity-related traits;
KIRP	cis	rs3784262	0.528	rs4144005	chr15:58330094	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.36	-4.97	-0.3	1.25e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03165700	chr11:108093220	ATM;NPAT	-0.47	-6.22	-0.37	2.13e-9	Interleukin-4 levels;
KIRP	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.52	-6.84	-0.4	6.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.47	-5.63	-0.34	4.96e-8	Carotid intima media thickness;
KIRP	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.34e-8	Aortic root size;
KIRP	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17376030	chr22:41985996	PMM1	0.69	7.2	0.42	7.16e-12	Vitiligo;
KIRP	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.39	6.77	0.4	9.63e-11	Heart rate;
KIRP	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.88	11.46	0.59	1.17e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	1.07	19.17	0.77	1.04e-50	Bone mineral density;
KIRP	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg04132472	chr17:19861366	AKAP10	-0.38	-4.91	-0.3	1.68e-6	Schizophrenia;
KIRP	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg21427119	chr20:30132790	HM13	-0.55	-6.27	-0.37	1.62e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20623943	chr1:47799834	CMPK1	0.47	6.38	0.38	8.64e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs3736485	0.609	rs11638154	chr15:51969416	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-4.98	-0.3	1.19e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1345301	1.000	rs1420093	chr2:102870458	T/C	cg12451869	chr2:102867685	NA	0.38	5.71	0.34	3.32e-8	Waist circumference;
KIRP	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.7	8.09	0.46	2.73e-14	High light scatter reticulocyte count;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	6.73	0.39	1.18e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg11833968	chr6:79620685	NA	-0.45	-6.93	-0.4	3.78e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7011049	0.908	rs72640866	chr8:53843014	C/T	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17554472	chr22:41940697	POLR3H	0.67	7.16	0.42	9.31e-12	Vitiligo;
KIRP	cis	rs9473924	0.505	rs2817332	chr6:50848522	T/A	cg14470998	chr6:50812995	TFAP2B	-0.78	-7.4	-0.43	2.1e-12	Body mass index;
KIRP	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.69	-9.63	-0.52	8.06e-19	Primary sclerosing cholangitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14363242	chr7:81601173	CACNA2D1	-0.45	-6.62	-0.39	2.25e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs78487399	0.908	rs17031095	chr2:43819139	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.93	-0.3	1.53e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.71	6.22	0.37	2.11e-9	Inflammatory bowel disease;
KIRP	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg15038512	chr6:170123185	PHF10	0.47	5.36	0.32	1.89e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg25866889	chr13:114914595	NA	-0.41	-5.69	-0.34	3.59e-8	Schizophrenia;
KIRP	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg24796726	chr7:884288	UNC84A	-0.59	-5.41	-0.33	1.52e-7	Initial pursuit acceleration;
KIRP	cis	rs965513	1.000	rs925489	chr9:100546600	C/T	cg13688889	chr9:100608707	NA	-0.59	-7.56	-0.43	7.89e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg17595323	chr11:93583763	C11orf90	-0.42	-7.08	-0.41	1.55e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg23391107	chr17:45924227	SP6	0.5	6.53	0.38	3.64e-10	Ease of getting up in the morning;
KIRP	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.62	7.55	0.43	8.36e-13	Dialysis-related mortality;
KIRP	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.91	0.45	8.6e-14	Obesity-related traits;
KIRP	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	10.87	0.57	9.82e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05322217	chr17:36575655	NA	0.43	6.24	0.37	1.91e-9	Parkinson's disease;
KIRP	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.63e-16	Motion sickness;
KIRP	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.36	5.28	0.32	2.78e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.62	0.44	5.41e-13	Joint mobility (Beighton score);
KIRP	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-9.69	-0.53	5.06e-19	Waist circumference;Body mass index;
KIRP	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg25650185	chr19:21324782	ZNF431	-0.49	-5.08	-0.31	7.39e-7	Pain;
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.29	-5.73	-0.34	2.99e-8	Lymphocyte counts;
KIRP	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04975846	chr16:88923880	TRAPPC2L;GALNS	0.6	7.58	0.44	7.13e-13	Parkinson's disease;
KIRP	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs8033133	0.957	rs3742952	chr15:25351026	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.44	-5.26	-0.32	3.11e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.81	0.81	1.94e-59	Prudent dietary pattern;
KIRP	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg02725872	chr8:58115012	NA	-0.47	-5.69	-0.34	3.54e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg13679303	chr9:96623674	NA	-0.48	-6.65	-0.39	1.89e-10	DNA methylation (variation);
KIRP	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg26513180	chr16:89883248	FANCA	0.42	5.21	0.32	4.08e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.88	12.7	0.63	9.56e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.67	-8.32	-0.47	6.08e-15	Recalcitrant atopic dermatitis;
KIRP	trans	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.56	0.39	3.1e-10	Retinal vascular caliber;
KIRP	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg23752985	chr2:85803571	VAMP8	0.62	9.27	0.51	9.48e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg27532560	chr4:187881888	NA	-0.74	-12.5	-0.62	4.49e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-12.34	-0.62	1.44e-27	Chronic sinus infection;
KIRP	cis	rs28489187	0.683	rs6657817	chr1:85874614	C/T	cg16011679	chr1:85725395	C1orf52	-0.48	-5.9	-0.35	1.2e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs6191	0.935	rs7716360	chr5:142764741	T/C	cg08845721	chr5:142780693	NR3C1	-0.39	-5.32	-0.32	2.36e-7	Night sleep phenotypes;
KIRP	cis	rs2278796	0.639	rs6661381	chr1:204971553	A/G	cg04862289	chr1:204966208	NFASC	0.66	9.16	0.5	2.11e-17	Mean platelet volume;
KIRP	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg21573476	chr21:45109991	RRP1B	-0.64	-8.62	-0.48	8.54e-16	Mean corpuscular volume;
KIRP	cis	rs12900413	0.687	rs6496602	chr15:90317797	A/G	cg24650279	chr15:90327240	NA	-0.39	-4.98	-0.3	1.2e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg16497661	chr14:103986332	CKB	0.39	5.13	0.31	5.77e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.71	-8.92	-0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg05768032	chr16:30646687	NA	0.52	6.36	0.38	9.84e-10	Multiple myeloma;
KIRP	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.53	-0.33	8.13e-8	Mood instability;
KIRP	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.8	-10.21	-0.55	1.2e-20	Breast cancer;
KIRP	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg17788362	chr6:86352627	SYNCRIP	0.5	6.47	0.38	5.25e-10	Smooth-surface caries;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17335440	chr11:48161380	PTPRJ	-0.47	-6.64	-0.39	2.01e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27297192	chr10:134578999	INPP5A	0.62	7.65	0.44	4.66e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg02030672	chr11:45687055	CHST1	0.52	6.57	0.39	2.98e-10	Obesity-related traits;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.76	7.22	0.42	6.66e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.8	12.76	0.63	5.74e-29	Schizophrenia;
KIRP	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg22951263	chr5:87985283	NA	0.48	6.78	0.4	8.73e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.83	13.27	0.65	1.16e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.64	9.21	0.51	1.53e-17	Resting heart rate;
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg11204139	chr17:3907470	NA	0.82	15.47	0.7	3.64e-38	Type 2 diabetes;
KIRP	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.32	5.9	0.35	1.17e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg03060546	chr3:49711283	APEH	0.47	6.21	0.37	2.28e-9	Parkinson's disease;
KIRP	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.09	-0.41	1.45e-11	Mean corpuscular volume;
KIRP	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.6	7.73	0.44	2.81e-13	Eosinophil percentage of white cells;
KIRP	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.8	-11.02	-0.57	3.18e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.15	-0.36	3.14e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.83	-12.25	-0.62	3.05e-27	Systemic lupus erythematosus;
KIRP	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg20701182	chr2:24300061	SF3B14	0.6	5.27	0.32	2.95e-7	Lymphocyte counts;
KIRP	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg08975724	chr8:8085496	FLJ10661	-0.72	-9.41	-0.51	3.65e-18	Triglycerides;
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.27	-0.32	3.02e-7	Breast cancer;
KIRP	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg17372223	chr3:52568218	NT5DC2	0.32	4.91	0.3	1.67e-6	Electroencephalogram traits;
KIRP	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-15.16	-0.7	4.13e-37	Alzheimer's disease;
KIRP	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.3	0.55	6.31e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13385	0.813	rs13185866	chr5:139681897	G/A	cg01860693	chr5:139557145	C5orf32	0.48	4.99	0.3	1.13e-6	Atrial fibrillation;
KIRP	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.42	-4.85	-0.3	2.16e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.29	12.33	0.62	1.61e-27	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21587412	chr3:107244153	BBX	0.54	6.64	0.39	2.03e-10	Parkinson's disease;
KIRP	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg27121462	chr16:89883253	FANCA	0.51	6.2	0.37	2.35e-9	Vitiligo;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.56	6.78	0.4	9.08e-11	Longevity;Endometriosis;
KIRP	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.55	-7.68	-0.44	3.71e-13	Pulmonary function;
KIRP	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg05973401	chr12:123451056	ABCB9	0.49	5.0	0.3	1.09e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7017914	0.967	rs62508819	chr8:71718106	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11987759	chr7:65425863	GUSB	0.51	6.94	0.4	3.52e-11	Aortic root size;
KIRP	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-6.68	-0.39	1.61e-10	Menarche (age at onset);
KIRP	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg25182066	chr10:30743637	MAP3K8	-0.66	-8.66	-0.48	6.39e-16	Inflammatory bowel disease;
KIRP	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	cis	rs9309473	1.000	rs6546838	chr2:73679280	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.72	-0.34	3.04e-8	Metabolite levels;
KIRP	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.81	10.0	0.54	5.57e-20	Menarche (age at onset);
KIRP	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg08761264	chr16:28874980	SH2B1	-0.51	-5.9	-0.35	1.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg25019033	chr10:957182	NA	-0.52	-6.68	-0.39	1.55e-10	Eosinophil percentage of granulocytes;
KIRP	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.35	0.42	2.99e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09800235	chr12:133250183	POLE	0.59	6.44	0.38	6.34e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg13160058	chr8:26243215	BNIP3L	-0.5	-7.48	-0.43	1.29e-12	Red cell distribution width;
KIRP	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.24	0.32	3.47e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.69	8.48	0.48	2.07e-15	Neutrophil percentage of white cells;
KIRP	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.73	0.34	2.86e-8	Motion sickness;
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg06815112	chr8:27182871	PTK2B	0.52	6.7	0.39	1.43e-10	Neuroticism;
KIRP	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.19e-8	Pubertal anthropometrics;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16709874	chr1:211433282	RCOR3	0.44	6.33	0.37	1.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.49	-5.19	-0.31	4.32e-7	Obesity (extreme);
KIRP	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	9.69	0.53	5.25e-19	Lung cancer in ever smokers;
KIRP	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg27124370	chr19:33622961	WDR88	0.6	7.43	0.43	1.84e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg18709589	chr6:96969512	KIAA0776	0.34	5.16	0.31	5.18e-7	Headache;
KIRP	cis	rs8133932	0.621	rs1124309	chr21:47328767	C/A	cg11214348	chr21:47283868	PCBP3	0.47	5.36	0.32	1.95e-7	Schizophrenia;
KIRP	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg22508957	chr16:3507546	NAT15	0.58	7.1	0.41	1.3e-11	Tuberculosis;
KIRP	cis	rs42648	0.792	rs4236517	chr7:89963465	A/T	cg25739043	chr7:89950458	NA	-0.43	-6.8	-0.4	7.67e-11	Homocysteine levels;
KIRP	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg20415053	chr1:26527928	CATSPER4	-0.43	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs7712401	0.601	rs30026	chr5:122284568	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs10924970	0.805	rs2789363	chr1:235519034	A/T	cg26050004	chr1:235667680	B3GALNT2	0.41	4.9	0.3	1.74e-6	Asthma;
KIRP	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg19445457	chr11:5799446	OR52N5	-0.44	-5.23	-0.32	3.62e-7	DNA methylation (variation);
KIRP	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.66	0.34	4.24e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.74	11.3	0.58	4.02e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2071426	0.876	rs79039719	chr10:96768414	G/A	cg09036531	chr10:96991505	NA	-0.63	-6.44	-0.38	6.21e-10	Blood metabolite levels;
KIRP	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.89	13.52	0.65	1.64e-31	Coronary artery disease;
KIRP	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.5	7.4	0.43	2.21e-12	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg17757837	chr7:157058334	UBE3C	-0.82	-11.3	-0.58	4.15e-24	Body mass index;
KIRP	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.7	-0.6	2e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06028808	chr11:68637592	NA	0.69	7.68	0.44	3.77e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	1.01	18.94	0.77	5.88e-50	Parkinson's disease;
KIRP	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.61	8.18	0.46	1.54e-14	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg26681399	chr22:41777847	TEF	-0.5	-5.15	-0.31	5.25e-7	Vitiligo;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20566420	chr12:122327043	PSMD9	0.55	6.51	0.38	4.16e-10	Smoking initiation;
KIRP	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.09	0.61	9.76e-27	Bipolar disorder;
KIRP	cis	rs6681460	0.966	rs10889643	chr1:67143368	G/C	cg02459107	chr1:67143332	SGIP1	0.53	7.52	0.43	1.05e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs9612	1.000	rs12611034	chr19:44268678	C/T	cg08581076	chr19:44259116	C19orf61	0.5	5.43	0.33	1.37e-7	Exhaled nitric oxide output;
KIRP	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs9469913	0.799	rs2814996	chr6:34621314	T/C	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.28	-0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg25319279	chr11:5960081	NA	-0.57	-5.78	-0.35	2.25e-8	DNA methylation (variation);
KIRP	cis	rs4262150	0.883	rs4437425	chr5:152238341	G/A	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.79	10.11	0.54	2.47e-20	Neutrophil percentage of white cells;
KIRP	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.42	-0.33	1.42e-7	IgG glycosylation;
KIRP	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.89	0.49	1.38e-16	Prudent dietary pattern;
KIRP	cis	rs3026101	0.624	rs62072673	chr17:5317669	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.85	0.35	1.54e-8	Body mass index;
KIRP	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.05	20.21	0.79	3.38e-54	Schizophrenia;
KIRP	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-7.15	-0.41	9.83e-12	Metabolite levels;
KIRP	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.51	7.25	0.42	5.43e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg03929089	chr4:120376271	NA	0.7	6.2	0.37	2.34e-9	Axial length;
KIRP	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg21684588	chr1:67600265	NA	-0.41	-4.89	-0.3	1.85e-6	Psoriasis;
KIRP	cis	rs4742903	0.509	rs1889286	chr9:106962928	A/G	cg14250997	chr9:106856677	SMC2	0.37	4.88	0.3	1.87e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.5	0.33	9.72e-8	Diisocyanate-induced asthma;
KIRP	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.15	0.37	3.04e-9	Rheumatoid arthritis;
KIRP	cis	rs1116547	0.714	rs7730801	chr5:112768340	T/A	cg12552261	chr5:112820674	MCC	-0.47	-5.09	-0.31	7.21e-7	Cerebral amyloid angiopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24337881	chr12:102091387	CHPT1	0.54	6.73	0.39	1.21e-10	Parkinson's disease;
KIRP	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.77	-0.53	2.82e-19	Response to antipsychotic treatment;
KIRP	cis	rs3825932	0.778	rs1036938	chr15:79237247	C/G	cg25744700	chr15:79237217	CTSH	0.42	5.13	0.31	5.8e-7	Type 1 diabetes;
KIRP	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	6.07	0.36	4.88e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-6.59	-0.39	2.73e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg06740227	chr12:86229804	RASSF9	-0.44	-5.28	-0.32	2.85e-7	Major depressive disorder;
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg18234130	chr8:27182889	PTK2B	0.56	7.21	0.42	6.94e-12	Neuroticism;
KIRP	cis	rs1448094	0.817	rs10863112	chr12:86330844	C/T	cg00310523	chr12:86230176	RASSF9	0.42	6.43	0.38	6.51e-10	Major depressive disorder;
KIRP	cis	rs74181299	0.819	rs2723087	chr2:65298282	T/A	cg05010058	chr2:65284262	CEP68	0.44	6.24	0.37	1.89e-9	Pulse pressure;
KIRP	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.8	0.6	8.89e-26	Cannabis dependence symptom count;
KIRP	cis	rs73086581	1.000	rs6052209	chr20:3961747	G/A	cg02187196	chr20:3869020	PANK2	0.47	4.9	0.3	1.72e-6	Response to antidepressants in depression;
KIRP	cis	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.3	-0.37	1.39e-9	Migraine - clinic-based;
KIRP	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.03	-0.31	9.54e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2120243	0.621	rs7634847	chr3:157159145	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.48	6.05	0.36	5.31e-9	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg26384229	chr12:38710491	ALG10B	0.52	6.92	0.4	3.88e-11	Morning vs. evening chronotype;
KIRP	cis	rs6960043	0.683	rs10278686	chr7:15031450	C/T	cg19272540	chr7:15055459	NA	0.2	5.43	0.33	1.36e-7	Type 2 diabetes;
KIRP	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.58	6.86	0.4	5.5e-11	HDL cholesterol;
KIRP	cis	rs2191566	0.821	rs59756444	chr19:44513656	C/G	cg18700516	chr19:44507157	ZNF230	-0.51	-5.9	-0.35	1.22e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03934478	chr11:495069	RNH1	0.78	6.45	0.38	5.86e-10	Body mass index;
KIRP	cis	rs7558233	0.614	rs7601850	chr2:23678118	T/A	cg00747342	chr2:23700632	KLHL29	0.62	5.73	0.34	2.95e-8	Cannabis use (initiation);
KIRP	cis	rs13315871	1.000	rs4367085	chr3:58389235	A/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.12	-0.31	6.19e-7	Cholesterol, total;
KIRP	trans	rs6810798	0.536	rs72953535	chr4:148319263	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.6	-6.94	-0.4	3.52e-11	Coronary artery disease;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.11	-20.48	-0.79	4.36e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.17	-0.61	5.51e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg11641102	chr8:27183873	PTK2B	0.45	5.84	0.35	1.66e-8	Neuroticism;
KIRP	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.73	-10.01	-0.54	5.06e-20	Age at first birth;
KIRP	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg21427119	chr20:30132790	HM13	-0.62	-6.67	-0.39	1.7e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg05805236	chr11:65401703	PCNXL3	-0.38	-4.94	-0.3	1.42e-6	Acne (severe);
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.34	-0.32	2.08e-7	Life satisfaction;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.17	0.31	4.75e-7	Life satisfaction;
KIRP	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.69	-7.46	-0.43	1.47e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6738627	1.000	rs7609045	chr2:165555207	G/A	cg03182029	chr2:165697222	COBLL1	0.43	5.47	0.33	1.12e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg16306078	chr6:126000798	NA	-0.26	-4.87	-0.3	1.97e-6	Endometrial cancer;
KIRP	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg06307176	chr5:131281290	NA	0.55	5.87	0.35	1.44e-8	Life satisfaction;
KIRP	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg04362960	chr10:104952993	NT5C2	0.43	4.9	0.3	1.71e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.44	-5.35	-0.32	2.02e-7	Coronary artery disease;
KIRP	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg16141378	chr3:129829833	LOC729375	-0.48	-6.27	-0.37	1.59e-9	Systolic blood pressure;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg15105011	chr4:940614	TMEM175	0.45	4.86	0.3	2.09e-6	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	cg12689670	chr1:183009347	LAMC1	0.45	6.39	0.38	8.41e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.42	5.32	0.32	2.33e-7	Cystic fibrosis severity;
KIRP	cis	rs258892	0.843	rs10053857	chr5:72042019	C/T	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg18234130	chr8:27182889	PTK2B	-0.52	-6.43	-0.38	6.64e-10	Alzheimer's disease (late onset);
KIRP	cis	rs9398803	0.661	rs9375449	chr6:126963807	T/C	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs7246657	0.722	rs2075284	chr19:38189616	T/C	cg23950597	chr19:37808831	NA	0.61	6.63	0.39	2.11e-10	Coronary artery calcification;
KIRP	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg06637938	chr14:75390232	RPS6KL1	0.48	6.8	0.4	8.1e-11	Caffeine consumption;
KIRP	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26818010	chr10:134567672	INPP5A	-0.6	-6.86	-0.4	5.7e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.13	-0.31	5.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs282587	0.569	rs385656	chr13:113413234	C/T	cg04656015	chr13:113407548	ATP11A	0.63	6.99	0.41	2.6e-11	Glycated hemoglobin levels;
KIRP	cis	rs9815354	1.000	rs1717021	chr3:41983860	A/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.1e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2746347	0.722	rs2796520	chr1:57130577	A/G	cg09935045	chr1:57111199	PRKAA2	0.52	5.35	0.32	1.99e-7	Lymphocyte counts;
KIRP	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg00076555	chr3:49705435	BSN	0.29	4.98	0.3	1.21e-6	Body mass index;
KIRP	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg05025164	chr4:1340916	KIAA1530	0.51	6.54	0.39	3.46e-10	Longevity;
KIRP	cis	rs6542838	0.641	rs883773	chr2:99491635	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-4.94	-0.3	1.46e-6	Fear of minor pain;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01964720	chr5:126366472	MARCH3	-0.46	-6.03	-0.36	6.13e-9	Myopia;
KIRP	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	5.02e-11	Blood metabolite levels;
KIRP	cis	rs7737355	1.000	rs248652	chr5:130654837	A/T	cg06307176	chr5:131281290	NA	-0.53	-5.75	-0.34	2.69e-8	Life satisfaction;
KIRP	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg23505145	chr19:12996616	KLF1	0.55	8.02	0.46	4.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.73e-10	Diabetic kidney disease;
KIRP	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg16141378	chr3:129829833	LOC729375	-0.48	-6.38	-0.38	8.56e-10	Retinal vascular caliber;
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.27	0.32	2.96e-7	Lung cancer;
KIRP	cis	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19171272	chr22:38449367	NA	-0.57	-8.22	-0.46	1.2e-14	Glioblastoma;Glioma;
KIRP	cis	rs3790645	1.000	rs3790645	chr1:26884864	G/A	cg23229016	chr1:26872525	RPS6KA1	0.22	5.96	0.36	8.58e-9	Glucose homeostasis traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06251832	chr8:144952627	NA	-0.43	-6.38	-0.38	8.73e-10	Metabolic traits;
KIRP	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg24250549	chr1:154909240	PMVK	0.49	6.67	0.39	1.64e-10	Prostate cancer;
KIRP	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-5.67	-0.34	3.91e-8	HDL cholesterol;
KIRP	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.79e-7	Bladder cancer;
KIRP	trans	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.95	-0.41	3.34e-11	Atopic dermatitis;
KIRP	cis	rs7116495	0.609	rs3750907	chr11:71822560	T/C	cg26138937	chr11:71823887	C11orf51	1.12	6.64	0.39	1.94e-10	Severe influenza A (H1N1) infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15769409	chr9:138372274	KIAA0649	0.58	6.61	0.39	2.35e-10	Smoking initiation;
KIRP	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg20701182	chr2:24300061	SF3B14	0.49	5.08	0.31	7.48e-7	Asthma;
KIRP	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.92	-0.45	8.37e-14	Retinal vascular caliber;
KIRP	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.67	-10.03	-0.54	4.55e-20	Pulse pressure;
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.86	-0.4	5.68e-11	Lung cancer;
KIRP	cis	rs889398	0.741	rs7190013	chr16:69908248	G/A	cg09409435	chr16:70099608	PDXDC2	0.4	4.96	0.3	1.34e-6	Body mass index;
KIRP	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-5.11	-0.31	6.44e-7	Putamen volume;
KIRP	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg15733309	chr7:157513707	PTPRN2	0.58	8.74	0.49	3.66e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs236907	0.812	rs2232807	chr1:171750095	T/C	cg01410279	chr1:171621941	MYOC	-0.47	-5.18	-0.31	4.7e-7	Mean platelet volume;
KIRP	cis	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	5.0	0.3	1.07e-6	Leprosy;
KIRP	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.46	-5.03	-0.31	9.26e-7	Obesity (extreme);
KIRP	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.87	-12.43	-0.62	7.25e-28	Total body bone mineral density;
KIRP	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Colorectal cancer;
KIRP	cis	rs7998202	0.667	rs282577	chr13:113358838	G/A	cg04656015	chr13:113407548	ATP11A	-0.5	-5.37	-0.32	1.8e-7	Glycated hemoglobin levels;
KIRP	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	6.51	0.38	4.2e-10	Menarche (age at onset);
KIRP	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs4851254	0.961	rs11691486	chr2:100796182	T/C	cg17356467	chr2:100759845	AFF3	0.58	7.18	0.42	8.13e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg16486109	chr11:613632	IRF7	0.45	5.06	0.31	8.35e-7	Systemic lupus erythematosus;
KIRP	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.51	-7.87	-0.45	1.1e-13	IgG glycosylation;
KIRP	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.07	-0.5	3.89e-17	Schizophrenia;
KIRP	cis	rs4953318	0.704	rs10495927	chr2:46352499	A/G	cg12428440	chr2:46370979	PRKCE	0.42	6.31	0.37	1.28e-9	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg09455208	chr3:40491958	NA	0.31	5.26	0.32	3.17e-7	Renal cell carcinoma;
KIRP	cis	rs35740288	0.770	rs11635711	chr15:86126486	C/G	cg17133734	chr15:86042851	AKAP13	-0.5	-5.25	-0.32	3.37e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs13102973	0.640	rs6833827	chr4:135839731	T/C	cg14419869	chr4:135874104	NA	0.5	8.26	0.47	9.05e-15	Subjective well-being;
KIRP	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.71	8.26	0.47	8.93e-15	Obesity-related traits;
KIRP	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-7.37	-0.43	2.56e-12	Body mass index;
KIRP	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg02527881	chr3:46936655	PTH1R	-0.44	-6.26	-0.37	1.69e-9	Colorectal cancer;
KIRP	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg09029085	chr17:47094198	IGF2BP1	0.25	5.74	0.34	2.72e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	12.88	0.63	2.41e-29	Tonsillectomy;
KIRP	cis	rs9326248	0.574	rs1263173	chr11:116681008	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.43	5.01	0.3	1.03e-6	Blood protein levels;
KIRP	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4638749	0.501	rs13421955	chr2:108748076	A/T	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.07	-0.31	7.95e-7	Blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14935078	chr19:17414399	ABHD8	0.48	6.11	0.36	3.86e-9	Parkinson's disease;
KIRP	cis	rs62413470	1.000	rs12210228	chr6:55973083	G/A	cg13327911	chr6:55965977	COL21A1	0.55	4.97	0.3	1.25e-6	Joint mobility (Beighton score);
KIRP	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg10381502	chr11:71823885	C11orf51	-1.17	-8.23	-0.46	1.08e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs6669119	0.668	rs79187116	chr1:19091297	G/A	cg19637330	chr1:19110922	NA	0.63	5.58	0.34	6.37e-8	Percentage gas trapping;
KIRP	cis	rs7172677	1.000	rs2029519	chr15:75415962	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-6.02	-0.36	6.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg12384639	chr17:618140	VPS53	0.46	5.8	0.35	2.08e-8	Prostate cancer;
KIRP	cis	rs7402982	0.647	rs4966007	chr15:99200056	G/A	cg03437748	chr15:99193247	IGF1R	0.78	9.49	0.52	2.13e-18	Birth weight;
KIRP	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg05775895	chr3:12838266	CAND2	0.36	6.13	0.36	3.45e-9	QRS complex (12-leadsum);
KIRP	cis	rs2224391	0.590	rs2773298	chr6:5242067	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-5.88	-0.35	1.34e-8	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01789728	chr20:57607451	ATP5E	0.49	6.4	0.38	7.75e-10	Parkinson's disease;
KIRP	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.39	0.55	3.29e-21	Dupuytren's disease;
KIRP	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg13409248	chr3:40428643	ENTPD3	-0.39	-5.48	-0.33	1.06e-7	Renal cell carcinoma;
KIRP	cis	rs3736485	0.934	rs17609812	chr15:51879260	G/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.74	-0.34	2.73e-8	Bone mineral density;
KIRP	cis	rs9815354	1.000	rs6599175	chr3:41786009	C/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.09e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.44	-0.72	1.73e-41	Height;
KIRP	cis	rs10214930	0.706	rs10081338	chr7:27698588	G/T	cg22168087	chr7:27702803	HIBADH	-0.52	-5.26	-0.32	3.18e-7	Hypospadias;
KIRP	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg06634786	chr22:41940651	POLR3H	-0.46	-5.06	-0.31	8.08e-7	Neuroticism;
KIRP	cis	rs5753037	0.615	rs131279	chr22:30155251	G/C	cg01021169	chr22:30184971	ASCC2	-0.43	-5.93	-0.35	1.01e-8	Type 1 diabetes;
KIRP	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07640336	chr12:132677496	NA	0.45	6.3	0.37	1.34e-9	Anti-saccade response;
KIRP	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	12.18	0.61	5.05e-27	Bipolar disorder;
KIRP	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.17	0.37	2.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg06565975	chr8:143823917	SLURP1	0.45	7.01	0.41	2.26e-11	Urinary tract infection frequency;
KIRP	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg06307176	chr5:131281290	NA	-0.55	-6.48	-0.38	5.1e-10	Life satisfaction;
KIRP	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	9.01	0.5	5.96e-17	Lymphocyte percentage of white cells;
KIRP	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg16141378	chr3:129829833	LOC729375	0.57	7.7	0.44	3.4e-13	Triglycerides;
KIRP	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg01294253	chr9:136912663	BRD3	0.39	5.21	0.32	4.08e-7	Platelet distribution width;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-1.0	-17.6	-0.75	1.97e-45	Longevity;Endometriosis;
KIRP	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.84	-0.45	1.39e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg13175981	chr1:150552382	MCL1	0.61	7.61	0.44	5.97e-13	Tonsillectomy;
KIRP	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.92	0.4	3.87e-11	Aortic root size;
KIRP	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.91	11.86	0.6	5.98e-26	Homoarginine levels;
KIRP	cis	rs7874142	0.546	rs10776906	chr9:137692089	A/T	cg13803559	chr9:137684506	COL5A1	0.37	4.98	0.3	1.19e-6	Longevity;
KIRP	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg03959625	chr15:84868606	LOC388152	0.6	6.77	0.4	9.49e-11	Schizophrenia;
KIRP	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg14703610	chr5:56206110	C5orf35	0.48	6.54	0.38	3.6e-10	Breast cancer;Breast cancer (early onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18762620	chr15:75940301	SNX33	0.57	7.16	0.42	9.45e-12	Parkinson's disease;
KIRP	trans	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg06521331	chr12:34319734	NA	-0.53	-6.73	-0.39	1.18e-10	Heart rate;
KIRP	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.5	6.35	0.38	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22564026	chr6:163608419	PACRG	-0.39	-6.03	-0.36	5.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg11135003	chr1:225998164	EPHX1	0.56	6.59	0.39	2.64e-10	Plasma plasminogen activator levels;
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.62	-6.33	-0.37	1.15e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6732160	0.838	rs13411380	chr2:73382846	G/C	cg01422370	chr2:73384389	NA	0.41	5.46	0.33	1.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.47	-7.15	-0.41	9.7e-12	Daytime sleep phenotypes;
KIRP	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17252645	chr8:143867129	LY6D	0.52	9.39	0.51	4.23e-18	Urinary tract infection frequency;
KIRP	cis	rs4262150	0.883	rs11167589	chr5:152098705	C/G	cg12297329	chr5:152029980	NA	-0.55	-7.17	-0.42	8.99e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.81	10.06	0.54	3.63e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg10254082	chr7:997346	NA	0.46	4.98	0.3	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.76	0.4	1.02e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11166927	0.548	rs4736099	chr8:140828745	T/C	cg16909799	chr8:140841666	TRAPPC9	-0.79	-11.91	-0.6	4.13e-26	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs1978968	1.000	rs1978968	chr22:18448113	A/G	cg03078520	chr22:18463400	MICAL3	0.74	8.48	0.48	2.05e-15	Presence of antiphospholipid antibodies;
KIRP	trans	rs7999699	0.967	rs4119501	chr13:48332425	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	6.84e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.76	-9.83	-0.53	1.96e-19	Aortic root size;
KIRP	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.51	0.38	4.3e-10	Height;
KIRP	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.75	9.06	0.5	4.18e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg26205652	chr12:48591994	NA	0.48	5.32	0.32	2.39e-7	Lung cancer;
KIRP	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7572644	0.640	rs4583413	chr2:28074824	C/T	cg27432699	chr2:27873401	GPN1	0.48	5.78	0.35	2.26e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.59	7.79	0.45	1.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.63	-8.42	-0.47	3.05e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg13165212	chr22:42675999	NA	0.28	5.05	0.31	8.78e-7	Cognitive function;
KIRP	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg09555818	chr19:45449301	APOC2	0.51	7.46	0.43	1.44e-12	Blood protein levels;
KIRP	cis	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.52	-0.33	8.61e-8	HDL cholesterol;
KIRP	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.92	-0.4	3.83e-11	Bipolar disorder;
KIRP	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.72	-0.53	4.08e-19	Height;
KIRP	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.64	6.32	0.37	1.22e-9	Axial length;
KIRP	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.57	-0.33	6.77e-8	Fear of minor pain;
KIRP	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg24304309	chr1:154577895	ADAR	0.35	5.32	0.32	2.37e-7	Blood protein levels;
KIRP	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	1.1	15.58	0.7	1.59e-38	Breast cancer;
KIRP	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg17554472	chr22:41940697	POLR3H	-0.48	-5.37	-0.32	1.85e-7	Neuroticism;
KIRP	cis	rs2708977	0.637	rs687950	chr2:97069612	C/G	cg01950434	chr2:97203154	ARID5A	0.4	4.93	0.3	1.53e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9826463	0.582	rs73238148	chr3:142061446	G/A	cg20824294	chr3:142316082	PLS1	0.43	6.31	0.37	1.32e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg10818794	chr15:86012489	AKAP13	-0.48	-6.71	-0.39	1.35e-10	Interstitial lung disease;
KIRP	cis	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.85e-9	Leprosy;
KIRP	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.95	-0.3	1.38e-6	Schizophrenia;
KIRP	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.7	-0.39	1.38e-10	Obesity-related traits;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg11318576	chr5:130599431	CDC42SE2	-0.46	-6.29	-0.37	1.41e-9	Blood metabolite levels;
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02475777	chr4:1388615	CRIPAK	0.37	4.96	0.3	1.34e-6	Obesity-related traits;
KIRP	cis	rs9400467	0.506	rs118071464	chr6:111626672	C/T	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.69	0.34	3.53e-8	Educational attainment;
KIRP	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-5.97	-0.36	8.38e-9	Response to antipsychotic treatment;
KIRP	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs62413470	0.935	rs62406154	chr6:55935856	A/G	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.53	-6.26	-0.37	1.68e-9	Multiple sclerosis;
KIRP	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.82	8.66	0.48	6.2e-16	Prostate cancer;
KIRP	cis	rs526231	0.511	rs3756582	chr5:102339552	G/C	cg23492399	chr5:102201601	PAM	-0.45	-5.04	-0.31	9.02e-7	Primary biliary cholangitis;
KIRP	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg05484376	chr2:27715224	FNDC4	0.35	5.65	0.34	4.46e-8	Total body bone mineral density;
KIRP	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg09165964	chr15:75287851	SCAMP5	-0.9	-8.36	-0.47	4.7e-15	Lung cancer;
KIRP	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg22906224	chr7:99728672	NA	0.67	8.64	0.48	7.08e-16	Coronary artery disease;
KIRP	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg08885076	chr2:99613938	TSGA10	-0.41	-6.16	-0.37	3.02e-9	Bipolar disorder;
KIRP	cis	rs236907	0.859	rs1045456	chr1:171766564	A/G	cg01410279	chr1:171621941	MYOC	0.45	5.27	0.32	2.92e-7	Mean platelet volume;
KIRP	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.76	-0.63	5.78e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00675838	chr6:97285024	GPR63	0.46	6.33	0.37	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.63	-8.15	-0.46	1.9e-14	Colorectal cancer;
KIRP	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.45	-6.01	-0.36	6.53e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg14196790	chr5:131705035	SLC22A5	0.32	4.86	0.3	2.13e-6	Blood metabolite levels;
KIRP	cis	rs6723108	0.738	rs6751833	chr2:135537898	G/T	cg12500956	chr2:135428796	TMEM163	0.46	5.98	0.36	7.75e-9	Type 2 diabetes;
KIRP	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg25547332	chr5:131281432	NA	0.47	5.27	0.32	3e-7	Life satisfaction;
KIRP	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.65	7.97	0.45	5.76e-14	Alcohol dependence;
KIRP	cis	rs11997175	0.603	rs4739381	chr8:33806892	C/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.42	0.33	1.42e-7	Body mass index;
KIRP	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg23307798	chr14:103986281	CKB	0.47	6.58	0.39	2.8e-10	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24739679	chr1:193304834	NA	0.43	6.17	0.37	2.79e-9	Interleukin-4 levels;
KIRP	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.56	7.52	0.43	1.04e-12	Blood metabolite levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09845883	chr1:154197610	UBAP2L	-0.48	-6.18	-0.37	2.59e-9	Inflammatory biomarkers;
KIRP	cis	rs2997447	0.706	rs61776573	chr1:26429356	A/C	cg19633962	chr1:26362018	EXTL1	-0.62	-5.85	-0.35	1.6e-8	QRS complex (12-leadsum);
KIRP	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg08975724	chr8:8085496	FLJ10661	0.62	7.25	0.42	5.52e-12	Systemic lupus erythematosus;
KIRP	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	trans	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17183009	chr3:120277827	NA	0.54	6.44	0.38	6.37e-10	Corneal astigmatism;
KIRP	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.13	0.72	1.96e-40	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg16141378	chr3:129829833	LOC729375	0.55	7.09	0.41	1.43e-11	Triglycerides;
KIRP	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.48	-5.31	-0.32	2.44e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs10411936	0.682	rs8103805	chr19:16598433	T/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.36	0.32	1.9e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs4886920	0.541	rs11853098	chr15:78129033	C/T	cg10461261	chr15:78109450	NA	0.36	5.76	0.34	2.52e-8	Neuroticism;
KIRP	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.28e-7	Red blood cell count;
KIRP	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-9.32	-0.51	6.84e-18	Hypospadias;
KIRP	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.52	5.84	0.35	1.64e-8	Iron status biomarkers;
KIRP	cis	rs6545883	0.507	rs62149712	chr2:61601272	T/C	cg15711740	chr2:61764176	XPO1	0.45	5.4	0.33	1.56e-7	Tuberculosis;
KIRP	cis	rs11625487	0.609	rs17824567	chr14:77976450	G/T	cg20045696	chr14:77926864	AHSA1	0.66	5.74	0.34	2.83e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs8523	0.804	rs4711171	chr6:11074347	C/T	cg13562911	chr6:11044106	ELOVL2	0.43	5.85	0.35	1.6e-8	Red blood cell fatty acid levels;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	10.31	0.55	6.1e-21	Lymphocyte counts;
KIRP	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.64e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.66	7.67	0.44	4.02e-13	Alcohol dependence;
KIRP	cis	rs7096127	1.000	rs3936155	chr10:24503255	A/G	cg04122385	chr10:24535410	KIAA1217;PRINS	-0.4	-4.94	-0.3	1.42e-6	Lobe attachment (rater scored);
KIRP	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.58	-9.46	-0.52	2.56e-18	Prostate cancer;
KIRP	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-9.22	-0.51	1.35e-17	Morning vs. evening chronotype;
KIRP	cis	rs9394841	0.667	rs3747750	chr6:41760372	C/G	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15679981	chr2:45616428	SRBD1	0.47	6.14	0.36	3.29e-9	Interleukin-4 levels;
KIRP	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg22168087	chr7:27702803	HIBADH	-0.6	-7.71	-0.44	3.13e-13	Hypospadias;
KIRP	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg16497661	chr14:103986332	CKB	-0.9	-15.94	-0.71	8.78e-40	Body mass index;
KIRP	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15026099	chr1:67220432	TCTEX1D1	-0.43	-6.35	-0.38	1.01e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg04995300	chr3:66848608	NA	0.76	8.16	0.46	1.68e-14	Type 2 diabetes;
KIRP	cis	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg11502198	chr6:26597334	ABT1	-0.8	-5.42	-0.33	1.39e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.72	8.59	0.48	1.01e-15	Neutrophil percentage of white cells;
KIRP	cis	rs12200782	0.929	rs72843734	chr6:26448344	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.72	-6.27	-0.37	1.63e-9	Small cell lung carcinoma;
KIRP	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg20701182	chr2:24300061	SF3B14	-0.41	-5.26	-0.32	3.15e-7	Asthma;
KIRP	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg01028140	chr2:1542097	TPO	-0.57	-6.2	-0.37	2.38e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg05729581	chr11:3078854	CARS	-0.5	-5.95	-0.35	9.14e-9	Longevity;
KIRP	cis	rs10979	0.603	rs9321920	chr6:143883588	C/G	cg25407410	chr6:143891975	LOC285740	-0.65	-8.03	-0.46	4.09e-14	Hypospadias;
KIRP	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg24807547	chr6:37504484	NA	-0.55	-8.14	-0.46	1.93e-14	Cognitive performance;
KIRP	trans	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg24009623	chr19:33667908	NA	0.47	5.71	0.34	3.18e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5995756	0.688	rs11705236	chr22:40010682	G/A	cg10455938	chr22:40058150	CACNA1I	-0.56	-8.37	-0.47	4.5e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs7635838	0.892	rs9836167	chr3:11493392	C/T	cg00170343	chr3:11313890	ATG7	0.46	5.95	0.35	9.03e-9	HDL cholesterol;
KIRP	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg27494647	chr7:150038898	RARRES2	0.39	5.31	0.32	2.41e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.33	-0.32	2.26e-7	Aortic root size;
KIRP	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg00599163	chr2:162100495	NA	-0.43	-5.48	-0.33	1.04e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.58	0.34	6.36e-8	Menopause (age at onset);
KIRP	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.39	5.48	0.33	1.04e-7	Endometrial cancer;
KIRP	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs432925	0.529	rs2885415	chr16:395396	A/G	cg26913058	chr16:419975	MRPL28	0.48	5.41	0.33	1.53e-7	Morning vs. evening chronotype;
KIRP	cis	rs8077577	0.747	rs57697650	chr17:18224695	G/A	cg18869244	chr17:18121946	NA	0.44	4.99	0.3	1.15e-6	Obesity-related traits;
KIRP	cis	rs11874712	0.899	rs11872954	chr18:43686450	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.28	-0.32	2.89e-7	Migraine - clinic-based;
KIRP	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.24	0.32	3.46e-7	Smoking behavior;
KIRP	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg10223061	chr2:219282414	VIL1	0.43	7.0	0.41	2.42e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.73	10.38	0.55	3.72e-21	Body mass index;
KIRP	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg12140854	chr5:148520817	ABLIM3	-0.43	-4.95	-0.3	1.37e-6	Breast cancer;
KIRP	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.38	0.55	3.66e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7646881	0.812	rs59957986	chr3:158458913	G/A	cg19483011	chr3:158453295	NA	-0.56	-5.97	-0.36	8.22e-9	Tetralogy of Fallot;
KIRP	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.7	10.2	0.55	1.37e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg04369109	chr6:150039330	LATS1	-0.46	-5.68	-0.34	3.88e-8	Lung cancer;
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.25	6.54	0.38	3.55e-10	Crohn's disease;
KIRP	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	0.88	10.15	0.54	1.94e-20	Corneal structure;
KIRP	cis	rs6088813	1.000	rs224329	chr20:34019579	C/T	cg14752227	chr20:34000481	UQCC	0.48	6.03	0.36	5.96e-9	Height;
KIRP	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg06365898	chr1:16533907	ARHGEF19	0.48	6.41	0.38	7.53e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg09699651	chr6:150184138	LRP11	0.51	6.66	0.39	1.82e-10	Lung cancer;
KIRP	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg08999081	chr20:33150536	PIGU	0.47	6.28	0.37	1.52e-9	Height;
KIRP	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.91	-10.18	-0.54	1.49e-20	Blood protein levels;
KIRP	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg24112000	chr20:60950667	NA	0.58	8.99	0.5	6.65e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.65	7.89	0.45	1.01e-13	Aortic root size;
KIRP	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg26681399	chr22:41777847	TEF	-0.49	-5.0	-0.3	1.09e-6	Vitiligo;
KIRP	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg05340658	chr4:99064831	C4orf37	0.69	9.26	0.51	1.07e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10924970	0.967	rs12030186	chr1:235397477	G/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs9584850	0.794	rs17470961	chr13:99135314	A/G	cg20750642	chr13:99100586	FARP1	-0.5	-5.99	-0.36	7.46e-9	Neuroticism;
KIRP	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.85	-12.78	-0.63	4.97e-29	Strep throat;
KIRP	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.03	-0.31	9.66e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.7	-0.34	3.45e-8	Fear of minor pain;
KIRP	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg07936489	chr17:37558343	FBXL20	-0.5	-6.44	-0.38	6.2e-10	Asthma;
KIRP	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg21640587	chr11:117668038	DSCAML1	0.38	5.43	0.33	1.32e-7	Myopia;
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.83	11.03	0.58	3.03e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.8	-10.53	-0.56	1.23e-21	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18711899	chr14:99947545	SETD3;CCNK	0.52	6.51	0.38	4.16e-10	Parkinson's disease;
KIRP	cis	rs3849570	0.673	rs13068700	chr3:81975817	G/C	cg07356753	chr3:81810745	GBE1	-0.62	-7.96	-0.45	6.28e-14	Waist circumference;Body mass index;
KIRP	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9473924	0.542	rs35546156	chr6:50829785	C/T	cg14470998	chr6:50812995	TFAP2B	0.98	8.66	0.48	6.16e-16	Body mass index;
KIRP	cis	rs12780845	0.540	rs12770238	chr10:17209570	C/G	cg01003015	chr10:17271136	VIM	0.42	5.35	0.32	2.05e-7	Homocysteine levels;
KIRP	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg02002194	chr4:3960332	NA	-0.42	-6.14	-0.36	3.35e-9	Mood instability;
KIRP	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.68	9.57	0.52	1.18e-18	Prostate cancer;
KIRP	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-0.8	-10.58	-0.56	8.28e-22	Urate levels;
KIRP	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.84	-0.35	1.62e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.63	-8.29	-0.47	7.21e-15	Systolic blood pressure;
KIRP	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs4363385	0.693	rs56347903	chr1:152932175	T/G	cg07796016	chr1:152779584	LCE1C	-0.41	-4.91	-0.3	1.7e-6	Inflammatory skin disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg05854894	chr18:9475337	RALBP1	0.49	6.02	0.36	6.22e-9	Inflammatory biomarkers;
KIRP	cis	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg08773314	chr2:239334832	ASB1	-0.54	-5.48	-0.33	1.07e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs4765905	0.610	rs2239018	chr12:2304357	C/T	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.82	-0.35	1.83e-8	Schizophrenia;
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06028808	chr11:68637592	NA	0.7	8.25	0.47	9.48e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05472934	chr7:22766657	IL6	0.8	10.19	0.54	1.41e-20	Lung cancer;
KIRP	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg20146580	chr19:50432106	NUP62;ATF5;IL4I1	-0.43	-6.02	-0.36	6.45e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13443385	chr2:192245185	MYO1B	0.45	6.44	0.38	6.13e-10	Interleukin-4 levels;
KIRP	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	7.08	0.41	1.48e-11	Height;
KIRP	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	0.88	12.09	0.61	9.94e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9815354	0.627	rs80120812	chr3:42021760	C/T	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs16936870	0.571	rs7003804	chr8:71089631	T/C	cg14232793	chr8:71155543	NCOA2	-0.53	-6.05	-0.36	5.4e-9	QT interval;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4742903	0.527	rs7350223	chr9:106885332	A/G	cg14250997	chr9:106856677	SMC2	0.43	5.87	0.35	1.41e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg26134248	chr17:3907702	NA	0.41	5.2	0.31	4.25e-7	Type 2 diabetes;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-4.92	-0.3	1.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg24699146	chr1:24152579	HMGCL	0.42	5.49	0.33	1e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.32	-0.42	3.41e-12	Mood instability;
KIRP	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg06565975	chr8:143823917	SLURP1	-0.36	-5.18	-0.31	4.52e-7	Urinary tract infection frequency;
KIRP	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg15320075	chr8:145703422	NA	0.72	9.68	0.53	5.44e-19	Age at first birth;
KIRP	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6504950	0.695	rs9904377	chr17:52985982	C/T	cg26251398	chr17:52985966	TOM1L1	0.45	6.33	0.37	1.15e-9	Breast cancer;
KIRP	cis	rs62384625	0.927	rs1835967	chr5:141482700	C/T	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.09	-0.31	7.09e-7	White blood cell count (basophil);
KIRP	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-5.64	-0.34	4.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.55	-5.38	-0.32	1.76e-7	Height;
KIRP	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg19468946	chr17:37922297	IKZF3	-0.49	-6.73	-0.39	1.18e-10	Self-reported allergy;
KIRP	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg07541023	chr7:19748670	TWISTNB	0.65	5.81	0.35	1.94e-8	Thyroid stimulating hormone;
KIRP	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.02	0.36	6.18e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.67	6.87	0.4	5.15e-11	Corneal astigmatism;
KIRP	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.79	-0.35	2.16e-8	Pulmonary function;
KIRP	cis	rs4776059	1.000	rs12914502	chr15:52911335	A/G	cg22715398	chr15:52968154	KIAA1370	-0.66	-7.86	-0.45	1.17e-13	Schizophrenia;
KIRP	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg05484376	chr2:27715224	FNDC4	0.37	6.12	0.36	3.64e-9	Total body bone mineral density;
KIRP	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg06740227	chr12:86229804	RASSF9	0.48	6.28	0.37	1.51e-9	Major depressive disorder;
KIRP	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg01689657	chr7:91764605	CYP51A1	0.45	6.71	0.39	1.3e-10	Breast cancer;
KIRP	cis	rs1023500	1.000	rs1047997	chr22:42334953	C/G	cg04733989	chr22:42467013	NAGA	-0.54	-5.91	-0.35	1.16e-8	Schizophrenia;
KIRP	cis	rs4236601	0.679	rs12668473	chr7:116145639	C/T	cg12739419	chr7:116140593	CAV2	0.45	5.6	0.34	5.71e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg18944383	chr4:111397179	ENPEP	0.5	7.84	0.45	1.37e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.82	11.68	0.6	2.23e-25	Glomerular filtration rate (creatinine);
KIRP	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.26	-0.72	7.06e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	6.7	0.39	1.41e-10	Aortic root size;
KIRP	cis	rs4118325	0.522	rs12746268	chr1:107707248	G/T	cg01939741	chr1:107680714	NA	-0.51	-5.09	-0.31	7.24e-7	AIDS;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg04025307	chr7:1156635	C7orf50	0.72	7.18	0.42	8.39e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.59	-6.79	-0.4	8.41e-11	Menarche (age at onset);
KIRP	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.47	5.7	0.34	3.47e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.8	10.47	0.56	1.92e-21	Platelet count;
KIRP	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg26811252	chr16:29126840	RRN3P2	0.66	8.78	0.49	2.77e-16	Menopause (age at onset);
KIRP	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg12598211	chr12:123634384	NA	-0.4	-4.94	-0.3	1.42e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.5	-0.33	9.56e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7665939	1.000	rs72709219	chr4:190115517	A/G	cg14840187	chr4:190284988	NA	-0.94	-6.85	-0.4	5.94e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.77	8.08	0.46	2.94e-14	Corneal astigmatism;
KIRP	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.97	-12.62	-0.63	1.69e-28	Bipolar disorder and schizophrenia;
KIRP	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26378065	chr17:18585709	ZNF286B	-0.44	-5.58	-0.34	6.22e-8	Educational attainment (years of education);
KIRP	cis	rs4356932	0.967	rs6532161	chr4:76978366	G/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08331219	chr15:49429402	COPS2	-0.42	-6.62	-0.39	2.28e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg15103050	chr10:90582504	ANKRD22	-0.55	-6.33	-0.37	1.13e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs981844	0.885	rs72731673	chr4:154667446	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.85	11.51	0.59	8.31e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05220968	chr6:146057943	EPM2A	-0.4	-5.28	-0.32	2.82e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829661	1.000	rs829672	chr2:30712016	C/T	cg10949345	chr2:30726833	LCLAT1	0.69	9.66	0.52	6.38e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs526231	0.511	rs26255	chr5:102554100	T/A	cg23492399	chr5:102201601	PAM	-0.49	-5.29	-0.32	2.64e-7	Primary biliary cholangitis;
KIRP	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.65	6.97	0.41	2.9e-11	Response to diuretic therapy;
KIRP	cis	rs669446	0.533	rs3791041	chr1:44202991	A/G	cg12599982	chr1:44399894	ARTN	0.43	5.16	0.31	5.12e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg04374321	chr14:90722782	PSMC1	0.57	6.93	0.4	3.7e-11	Longevity;
KIRP	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg03970086	chr16:88974840	CBFA2T3	-0.49	-6.32	-0.37	1.19e-9	Social autistic-like traits;
KIRP	cis	rs6504340	0.739	rs4793938	chr17:46665229	T/G	cg04904318	chr17:46607828	HOXB1	-0.55	-5.61	-0.34	5.48e-8	Primary tooth development (number of teeth);
KIRP	cis	rs9488822	0.676	rs1556857	chr6:116325559	T/C	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.91	15.66	0.71	8.28e-39	Menarche (age at onset);
KIRP	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg03959625	chr15:84868606	LOC388152	0.47	5.5	0.33	9.44e-8	Schizophrenia;
KIRP	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg04989706	chr14:50066350	PPIL5	-0.49	-6.04	-0.36	5.66e-9	Carotid intima media thickness;
KIRP	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.61	-6.54	-0.38	3.58e-10	DNA methylation (variation);
KIRP	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	9.95	0.54	7.97e-20	Chronic sinus infection;
KIRP	cis	rs2073300	1.000	rs6132629	chr20:23451251	G/A	cg12062639	chr20:23401060	NAPB	0.79	6.85	0.4	5.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg27147174	chr7:100797783	AP1S1	-0.6	-7.83	-0.45	1.44e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg18350739	chr11:68623251	NA	0.45	7.29	0.42	4.23e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg25338242	chr13:114786047	RASA3	0.42	5.0	0.3	1.11e-6	Schizophrenia;
KIRP	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.99	-0.3	1.15e-6	Schizophrenia;
KIRP	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.95	14.18	0.67	9.61e-34	Response to bleomycin (chromatid breaks);
KIRP	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg23307798	chr14:103986281	CKB	-0.51	-6.83	-0.4	6.6e-11	Coronary artery disease;
KIRP	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.9	0.3	1.76e-6	Cognitive test performance;
KIRP	cis	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.85e-9	Leprosy;
KIRP	cis	rs17001868	0.881	rs12484358	chr22:40774660	G/A	cg07138101	chr22:40742427	ADSL	0.73	6.17	0.37	2.82e-9	Mammographic density (dense area);
KIRP	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2151522	0.544	rs12173960	chr6:127130999	A/G	cg21431617	chr6:127135037	NA	0.34	6.16	0.37	2.97e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.9	12.12	0.61	8.24e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs6486730	0.508	rs7133440	chr12:129269244	A/C	cg09035930	chr12:129282057	SLC15A4	-0.54	-6.6	-0.39	2.54e-10	Systemic lupus erythematosus;
KIRP	cis	rs6142102	0.961	rs2284386	chr20:32644396	G/A	cg08999081	chr20:33150536	PIGU	0.51	6.7	0.39	1.4e-10	Skin pigmentation;
KIRP	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-5.91	-0.35	1.15e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22496380	chr5:211416	CCDC127	-0.67	-5.44	-0.33	1.26e-7	Asthma (childhood onset);
KIRP	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26314531	chr2:26401878	FAM59B	-0.56	-6.11	-0.36	3.89e-9	Gut microbiome composition (summer);
KIRP	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.49	7.2	0.42	7.27e-12	Schizophrenia;
KIRP	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.76	0.34	2.51e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2979489	0.891	rs2979498	chr8:30375251	T/A	cg26383811	chr8:30366931	RBPMS	-0.46	-6.31	-0.37	1.32e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.63	8.63	0.48	7.62e-16	Mean corpuscular volume;
KIRP	cis	rs2249694	0.572	rs9418984	chr10:135322356	C/G	cg20169779	chr10:135381914	SYCE1	-0.66	-7.55	-0.43	8.3e-13	Obesity-related traits;
KIRP	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2802372	0.653	rs1250541	chr10:81034913	C/G	cg18688392	chr10:81059414	ZMIZ1	-0.42	-5.68	-0.34	3.83e-8	Granulocyte count;
KIRP	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg23188430	chr6:125850052	NA	-0.32	-4.92	-0.3	1.62e-6	Brugada syndrome;
KIRP	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07570687	chr10:102243282	WNT8B	-0.53	-7.27	-0.42	4.68e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11225247	1.000	rs11547916	chr11:102267820	C/T	cg06323957	chr11:102217781	BIRC2	0.98	6.08	0.36	4.57e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.62	8.68	0.48	5.44e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.32	-0.37	1.24e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	trans	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs9810890	1.000	rs73196988	chr3:128453467	G/A	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs2071403	0.966	rs11686524	chr2:1412244	T/G	cg07083862	chr2:1417248	TPO	0.33	5.27	0.32	2.93e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs12476592	0.571	rs190519	chr2:63858425	T/A	cg17519650	chr2:63277830	OTX1	-0.43	-4.88	-0.3	1.95e-6	Childhood ear infection;
KIRP	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-5.41	-0.33	1.46e-7	Alzheimer's disease (late onset);
KIRP	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.76	-10.66	-0.56	4.72e-22	Caffeine consumption;
KIRP	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.75	-0.4	1.03e-10	Joint mobility (Beighton score);
KIRP	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.6	12.36	0.62	1.27e-27	Diabetic kidney disease;
KIRP	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.58	-0.34	6.3e-8	IgG glycosylation;
KIRP	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.69	9.28	0.51	9.21e-18	Life satisfaction;
KIRP	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg15676125	chr6:33679581	C6orf125	0.38	5.04	0.31	9.11e-7	Plateletcrit;
KIRP	cis	rs6693567	0.565	rs6685252	chr1:150259945	T/A	cg09579323	chr1:150459698	TARS2	-0.41	-5.18	-0.31	4.69e-7	Migraine;
KIRP	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	cis	rs11673344	0.864	rs8104919	chr19:37503783	G/A	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.18	-0.31	4.64e-7	Obesity-related traits;
KIRP	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg19683494	chr5:74908142	NA	-0.46	-5.0	-0.3	1.09e-6	Age-related disease endophenotypes;
KIRP	cis	rs4742903	0.967	rs7023085	chr9:106904265	C/T	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	1.98e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-8.31	-0.47	6.64e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18252515	chr7:66147081	NA	0.42	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.7	9.63	0.52	7.61e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg02887458	chr19:19495540	GATAD2A	-0.45	-5.06	-0.31	8.29e-7	Bipolar disorder;
KIRP	cis	rs494562	0.892	rs632163	chr6:86122062	C/T	cg27039625	chr6:86159096	NT5E	0.43	5.64	0.34	4.67e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.65	-0.34	4.53e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg18402987	chr7:1209562	NA	0.46	5.28	0.32	2.87e-7	Longevity;Endometriosis;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.64e-16	Life satisfaction;
KIRP	cis	rs7766436	0.885	rs4712698	chr6:22592807	C/T	cg13666174	chr6:22585274	NA	-0.47	-6.72	-0.39	1.27e-10	Coronary artery disease;
KIRP	cis	rs2273669	0.667	rs28504359	chr6:109330417	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	trans	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-6.3	-0.37	1.39e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs41264869	0.689	rs3862948	chr1:205099959	A/C	cg21214746	chr1:205091277	RBBP5	-0.45	-5.31	-0.32	2.45e-7	Blood protein levels;
KIRP	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.66	12.53	0.62	3.41e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-6.61	-0.39	2.39e-10	Gut microbiome composition (summer);
KIRP	cis	rs7119038	0.818	rs10892289	chr11:118646003	C/T	cg19308663	chr11:118741387	NA	0.57	8.73	0.49	4.02e-16	Sjögren's syndrome;
KIRP	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.16	-0.31	5.2e-7	Mood instability;
KIRP	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.02	13.82	0.66	1.58e-32	Corneal structure;
KIRP	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.93	-15.79	-0.71	3.04e-39	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.45	1.59e-13	Morning vs. evening chronotype;
KIRP	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.53	6.73	0.39	1.16e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.62	8.91	0.49	1.18e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.78	12.46	0.62	6.02e-28	Breast cancer;
KIRP	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg07701084	chr6:150067640	NUP43	0.63	8.0	0.45	4.9e-14	Lung cancer;
KIRP	cis	rs4236601	0.927	rs4730745	chr7:116160259	A/T	cg05166801	chr7:116143459	CAV2	0.48	5.95	0.35	9.23e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs236907	0.859	rs1801898	chr1:171765964	A/G	cg01410279	chr1:171621941	MYOC	-0.47	-5.41	-0.33	1.52e-7	Mean platelet volume;
KIRP	cis	rs12984174	0.877	rs408484	chr19:18139771	C/T	cg21649277	chr19:18117794	ARRDC2	0.65	5.43	0.33	1.34e-7	Pulmonary function in asthmatics;
KIRP	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.6	-7.98	-0.45	5.68e-14	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg08992911	chr2:238395768	MLPH	0.46	5.74	0.34	2.83e-8	Prostate cancer;
KIRP	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17409876	chr11:66436470	RBM4B	-0.45	-6.39	-0.38	8.02e-10	Inflammatory biomarkers;
KIRP	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg23752985	chr2:85803571	VAMP8	0.55	7.69	0.44	3.61e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs7246760	0.867	rs34648216	chr19:9850690	T/A	cg02900749	chr2:68251473	NA	-1.2	-10.05	-0.54	3.86e-20	Pursuit maintenance gain;
KIRP	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	0.69	9.64	0.52	7.11e-19	Cognitive test performance;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01128800	chr10:69644938	SIRT1	0.45	6.35	0.38	1.05e-9	Survival in pancreatic cancer;
KIRP	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg22654517	chr2:96458247	NA	0.32	5.03	0.31	9.62e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.71	-0.34	3.21e-8	Neuroticism;
KIRP	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg26207909	chr14:103986467	CKB	-0.43	-5.28	-0.32	2.86e-7	Coronary artery disease;
KIRP	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.25	-5.27	-0.32	3.01e-7	Menarche (age at onset);
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg05562828	chr17:3906858	NA	0.77	16.33	0.72	4.28e-41	Type 2 diabetes;
KIRP	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.5	-6.88	-0.4	4.81e-11	Schizophrenia;
KIRP	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.38	-5.93	-0.35	1.04e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.68	9.78	0.53	2.67e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.45	5.65	0.34	4.44e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.84	11.76	0.6	1.28e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18252515	chr7:66147081	NA	0.46	5.51	0.33	9.21e-8	Aortic root size;
KIRP	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg08890418	chr1:21044141	KIF17	-0.43	-6.52	-0.38	4.01e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs684232	0.901	rs1741275	chr17:630363	C/G	cg04370829	chr17:406249	NA	0.38	4.96	0.3	1.3e-6	Prostate cancer;
KIRP	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg24631222	chr15:78858424	CHRNA5	0.73	8.51	0.48	1.73e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg07395648	chr5:131743802	NA	-0.58	-8.06	-0.46	3.42e-14	Acylcarnitine levels;
KIRP	cis	rs2494663	0.610	rs11588942	chr1:154044543	T/G	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.33	-4.85	-0.3	2.19e-6	Mean platelet volume;
KIRP	cis	rs258892	0.895	rs9293443	chr5:72055622	T/C	cg21869765	chr5:72125136	TNPO1	-0.52	-5.66	-0.34	4.17e-8	Small cell lung carcinoma;
KIRP	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg04935436	chr20:30431758	NA	0.47	5.99	0.36	7.28e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.07	-0.64	5.21e-30	Chronic sinus infection;
KIRP	cis	rs735539	1.000	rs1888001	chr13:21285906	C/G	cg02792322	chr13:21280448	IL17D	-0.32	-5.35	-0.32	2e-7	Dental caries;
KIRP	cis	rs12200782	0.722	rs12194095	chr6:26364520	C/T	cg00631329	chr6:26305371	NA	-0.87	-5.04	-0.31	8.82e-7	Small cell lung carcinoma;
KIRP	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg24558204	chr6:135376177	HBS1L	-0.6	-7.71	-0.44	3.15e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.97	-14.6	-0.68	3.35e-35	Coronary artery disease;
KIRP	cis	rs4903604	0.581	rs11159279	chr14:78036358	C/T	cg18872420	chr14:78023429	SPTLC2	0.36	5.55	0.33	7.4e-8	Gut microbiome composition (winter);
KIRP	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg10047753	chr17:41438598	NA	1.13	17.91	0.75	1.78e-46	Menopause (age at onset);
KIRP	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.5	7.03	0.41	2.01e-11	Lewy body disease;
KIRP	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg00031303	chr3:195681400	NA	0.7	7.88	0.45	1.07e-13	Pancreatic cancer;
KIRP	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.44	-0.47	2.8e-15	Mood instability;
KIRP	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs6901250	0.655	rs1398404	chr6:117126345	A/C	cg12892004	chr6:117198278	RFX6	0.42	6.93	0.4	3.64e-11	C-reactive protein levels;
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.45	-6.39	-0.38	8.39e-10	Testicular germ cell tumor;
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg06009432	chr2:178483847	TTC30A	0.5	6.23	0.37	2.02e-9	Body mass index in non-asthmatics;
KIRP	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg00531865	chr16:30841666	NA	0.36	4.93	0.3	1.53e-6	Dementia with Lewy bodies;
KIRP	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg15234197	chr11:68924956	NA	0.35	5.12	0.31	6.24e-7	Blond vs. brown hair color;
KIRP	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg06740227	chr12:86229804	RASSF9	0.47	5.66	0.34	4.17e-8	Major depressive disorder;
KIRP	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg00405596	chr8:11794950	NA	0.39	5.0	0.3	1.09e-6	Retinal vascular caliber;
KIRP	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	7.5	0.43	1.13e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4690686	0.769	rs11133146	chr4:177278878	C/T	cg17059388	chr4:177262070	NA	-0.53	-7.22	-0.42	6.37e-12	Essential tremor;
KIRP	cis	rs7116495	0.786	rs1892919	chr11:71712175	G/A	cg26138937	chr11:71823887	C11orf51	-0.68	-5.38	-0.32	1.76e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2077654	0.908	rs7926934	chr11:17433088	A/C	cg25308976	chr11:17434268	ABCC8	1.04	10.83	0.57	1.29e-22	Gout;
KIRP	cis	rs7870753	0.838	rs1590971	chr9:99246217	C/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.65	-9.38	-0.51	4.54e-18	Retinal vascular caliber;
KIRP	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.9	9.28	0.51	9.39e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23903597	chr17:61704154	MAP3K3	0.54	6.46	0.38	5.51e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.86	-0.49	1.62e-16	Response to antipsychotic treatment;
KIRP	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.86	-0.4	5.66e-11	Obesity-related traits;
KIRP	trans	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.03	-0.41	2.01e-11	Diabetic kidney disease;
KIRP	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg10189774	chr4:17578691	LAP3	0.47	5.49	0.33	9.88e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	4.94	0.3	1.47e-6	Renal cell carcinoma;
KIRP	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.93	0.4	3.72e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25468554	chr19:16739491	MED26	0.51	6.32	0.37	1.19e-9	Parkinson's disease;
KIRP	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg19875535	chr5:140030758	IK	0.64	8.78	0.49	2.77e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs72789687	chr10:35372489	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs787274	0.850	rs10733599	chr9:115634234	A/T	cg13803584	chr9:115635662	SNX30	-0.71	-5.99	-0.36	7.27e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg01689657	chr7:91764605	CYP51A1	0.41	5.78	0.35	2.26e-8	Breast cancer;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.45	-0.52	2.87e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3126085	0.515	rs10788838	chr1:152363201	A/C	cg26876637	chr1:152193138	HRNR	-0.57	-6.57	-0.39	2.91e-10	Atopic dermatitis;
KIRP	trans	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.35	-0.38	1.01e-9	Neuroticism;
KIRP	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs8113308	0.810	rs17695737	chr19:52445536	C/T	cg24732339	chr19:52471368	ZNF350	-0.45	-4.88	-0.3	1.91e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg12591125	chr7:1885375	MAD1L1	0.54	5.42	0.33	1.42e-7	Bipolar disorder;
KIRP	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg07777115	chr5:623756	CEP72	-0.57	-5.82	-0.35	1.86e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.03	0.41	2.08e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.62	9.43	0.52	3.18e-18	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.14	-0.31	5.7e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6723108	1.000	rs6723108	chr2:135479980	G/T	cg12500956	chr2:135428796	TMEM163	0.45	5.61	0.34	5.37e-8	Type 2 diabetes;
KIRP	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06846819	chr11:68850022	TPCN2	0.47	5.33	0.32	2.17e-7	Hair color;
KIRP	cis	rs9311676	0.656	rs12496906	chr3:58390490	A/C	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs1712517	0.566	rs7076274	chr10:105046007	G/A	cg04362960	chr10:104952993	NT5C2	-0.59	-7.31	-0.42	3.85e-12	Migraine;
KIRP	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.86	9.25	0.51	1.1e-17	Alzheimer's disease;
KIRP	cis	rs57024841	0.819	rs908839	chr9:139856639	C/G	cg00693599	chr9:139836323	FBXW5	-0.46	-5.99	-0.36	7.58e-9	Beta-trace protein levels;
KIRP	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg18306943	chr3:40428807	ENTPD3	0.39	5.48	0.33	1.05e-7	Renal cell carcinoma;
KIRP	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg13206674	chr6:150067644	NUP43	-0.57	-8.31	-0.47	6.58e-15	Lung cancer;
KIRP	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg18944383	chr4:111397179	ENPEP	-0.71	-12.88	-0.63	2.34e-29	Coronary artery disease;
KIRP	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs4363385	0.510	rs6689510	chr1:153048039	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-6.19	-0.37	2.46e-9	Inflammatory skin disease;
KIRP	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg10254082	chr7:997346	NA	0.5	5.59	0.34	5.97e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.68	8.76	0.49	3.18e-16	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07138452	chr17:17141020	FLCN	-0.46	-6.7	-0.39	1.41e-10	Metabolic traits;
KIRP	cis	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.94	-13.91	-0.66	7.87e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.92	12.65	0.63	1.39e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-0.74	-6.45	-0.38	5.78e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.8	13.12	0.64	3.66e-30	Vitiligo;
KIRP	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.29	15.46	0.7	4.06e-38	Uric acid levels;
KIRP	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-10.82	-0.57	1.38e-22	Colorectal cancer;
KIRP	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg26576206	chr19:1064938	ABCA7	0.37	5.03	0.31	9.38e-7	Alzheimer's disease (late onset);
KIRP	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-8.6	-0.48	9.76e-16	Mean corpuscular volume;
KIRP	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg20387954	chr3:183756860	HTR3D	0.64	9.46	0.52	2.61e-18	Anterior chamber depth;
KIRP	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg05768032	chr16:30646687	NA	0.48	5.82	0.35	1.85e-8	Multiple myeloma;
KIRP	cis	rs6142102	0.961	rs1555075	chr20:32610401	T/C	cg08999081	chr20:33150536	PIGU	0.5	5.92	0.35	1.07e-8	Skin pigmentation;
KIRP	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg22705602	chr4:152727874	NA	-0.54	-9.64	-0.52	7.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs8018808	1.000	rs4575469	chr14:77860543	G/A	cg20045696	chr14:77926864	AHSA1	-0.41	-5.08	-0.31	7.35e-7	Myeloid white cell count;
KIRP	cis	rs9715521	0.691	rs60007977	chr4:59847637	T/C	cg11281224	chr4:60001000	NA	-0.4	-4.96	-0.3	1.33e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs112591243	0.685	rs2839366	chr21:48026443	A/T	cg26904215	chr21:47823096	PCNT	0.72	6.09	0.36	4.4e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.55	-7.14	-0.41	1.06e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg21698718	chr17:80085957	CCDC57	-0.33	-4.97	-0.3	1.28e-6	Life satisfaction;
KIRP	cis	rs4523957	0.928	rs12943566	chr17:2157774	A/G	cg16513277	chr17:2031491	SMG6	0.57	7.62	0.44	5.59e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.05	-8.12	-0.46	2.22e-14	Mitochondrial DNA levels;
KIRP	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.62	7.09	0.41	1.39e-11	Platelet count;
KIRP	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.71	10.29	0.55	6.77e-21	Lymphocyte counts;
KIRP	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.48	-7.15	-0.41	1e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg01391022	chr12:122360665	WDR66	-0.37	-5.35	-0.32	1.98e-7	Mean corpuscular volume;
KIRP	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg10253484	chr15:75165896	SCAMP2	-0.54	-6.35	-0.38	1.05e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg10047753	chr17:41438598	NA	0.81	11.2	0.58	8.28e-24	Menopause (age at onset);
KIRP	cis	rs2635047	0.638	rs9961383	chr18:44604001	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.22	0.37	2.15e-9	Educational attainment;
KIRP	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg12560992	chr17:57184187	TRIM37	0.59	5.61	0.34	5.32e-8	Cognitive test performance;
KIRP	trans	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.23	-0.37	2.05e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.03	0.64	7.35e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg01403660	chr11:68851641	TPCN2	0.69	6.8	0.4	8.02e-11	Blond vs. brown hair color;
KIRP	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg21360079	chr12:107162445	NA	0.67	9.62	0.52	8.65e-19	Heart rate;
KIRP	cis	rs112990264	1.000	rs56300028	chr1:212943796	C/T	cg01785514	chr1:212988523	TATDN3	0.92	5.74	0.34	2.8e-8	Itch intensity from mosquito bite;
KIRP	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.27	5.8	0.35	2.03e-8	Cutaneous nevi;
KIRP	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs11170631	0.504	rs10128880	chr12:53927783	T/C	cg16917193	chr12:54089295	NA	0.66	10.62	0.56	6.07e-22	Height;
KIRP	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg03342759	chr3:160939853	NMD3	-0.54	-6.88	-0.4	4.96e-11	Morning vs. evening chronotype;
KIRP	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.21	-32.13	-0.9	5.1e-90	Myeloid white cell count;
KIRP	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	11.19	0.58	9.39e-24	Total body bone mineral density;
KIRP	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.35	-0.38	1.04e-9	Blood pressure;
KIRP	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.93	16.27	0.72	6.71e-41	Mortality in heart failure;
KIRP	cis	rs734999	0.505	rs4278312	chr1:2539555	A/G	cg20673091	chr1:2541236	MMEL1	0.79	12.8	0.63	4.42e-29	Ulcerative colitis;
KIRP	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.38	-0.59	2.22e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.64	-9.26	-0.51	1.05e-17	Plateletcrit;Platelet count;
KIRP	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.91	-0.66	7.57e-33	Primary sclerosing cholangitis;
KIRP	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.4	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs981844	1.000	rs2251900	chr4:154654145	C/T	cg14289246	chr4:154710475	SFRP2	0.67	7.51	0.43	1.07e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg05044414	chr3:183734942	ABCC5	0.34	5.03	0.31	9.41e-7	Anterior chamber depth;
KIRP	cis	rs4268898	0.552	rs4665663	chr2:24372139	G/C	cg20701182	chr2:24300061	SF3B14	-0.4	-5.13	-0.31	5.94e-7	Asthma;
KIRP	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	0.93	8.18	0.46	1.51e-14	Blood protein levels;
KIRP	cis	rs17092148	1.000	rs6088594	chr20:33343157	A/G	cg16810054	chr20:33298113	TP53INP2	0.46	5.66	0.34	4.23e-8	Neuroticism;
KIRP	cis	rs7084402	0.967	rs1593674	chr10:60291908	A/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs970548	0.643	rs7080474	chr10:45931899	C/T	cg15590007	chr10:45870220	ALOX5	0.46	5.22	0.32	3.79e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg25547332	chr5:131281432	NA	-0.46	-5.14	-0.31	5.52e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.68	-0.34	3.74e-8	Response to antipsychotic treatment;
KIRP	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	5.67	0.34	3.97e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.94	-0.4	3.46e-11	Acne (severe);
KIRP	cis	rs782590	0.875	rs62165175	chr2:55745810	T/A	cg18811423	chr2:55921094	PNPT1	0.87	14.25	0.67	5.25e-34	Metabolic syndrome;
KIRP	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg01677386	chr11:118938358	VPS11	-0.51	-5.95	-0.35	9.07e-9	Coronary artery disease;
KIRP	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.75	12.38	0.62	1.06e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg22974920	chr21:40686053	BRWD1	0.51	6.12	0.36	3.58e-9	Cognitive function;
KIRP	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg24253500	chr15:84953950	NA	0.59	6.87	0.4	5.21e-11	Schizophrenia;
KIRP	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.92e-31	Eye color traits;
KIRP	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-7.23	-0.42	6.16e-12	Common traits (Other);
KIRP	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs1014246	1.000	rs1014246	chr10:118466042	C/T	cg14919929	chr10:118506882	NA	0.57	7.09	0.41	1.43e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.35	6.2	0.37	2.4e-9	Refractive error;
KIRP	cis	rs7084402	0.967	rs1593672	chr10:60294379	T/C	cg05938607	chr10:60274200	BICC1	-0.43	-10.36	-0.55	4.14e-21	Refractive error;
KIRP	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg00800038	chr16:89945340	TCF25	-0.83	-6.15	-0.36	3.16e-9	Skin colour saturation;
KIRP	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	5.29	0.32	2.75e-7	Renal cell carcinoma;
KIRP	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg11970804	chr8:8084126	NA	-0.36	-5.33	-0.32	2.27e-7	Mood instability;
KIRP	cis	rs2346160	0.932	rs2026993	chr6:167661034	T/C	cg04673565	chr6:167680447	NA	0.43	5.74	0.34	2.84e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs9926664	0.584	rs8046526	chr16:85951635	C/T	cg04597312	chr16:85933163	IRF8	-0.54	-4.84	-0.3	2.25e-6	Sum basophil neutrophil counts;Neutrophil count;
KIRP	cis	rs2932538	0.583	rs2932537	chr1:113230394	C/T	cg22162597	chr1:113214053	CAPZA1	0.69	7.54	0.43	8.83e-13	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg09597638	chr17:3907349	NA	0.83	16.74	0.73	1.67e-42	Type 2 diabetes;
KIRP	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.84	-12.14	-0.61	6.84e-27	Morning vs. evening chronotype;
KIRP	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg04935436	chr20:30431758	NA	0.47	6.15	0.36	3.18e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg03647239	chr10:116582469	FAM160B1	0.52	6.06	0.36	5.06e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1832871	0.711	rs56043101	chr6:158682277	A/G	cg07215822	chr6:158701037	NA	-0.61	-7.13	-0.41	1.09e-11	Height;
KIRP	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4849845	0.637	rs4849851	chr2:121055910	A/C	cg24070213	chr2:121070622	NA	0.39	5.96	0.35	8.93e-9	Mean platelet volume;
KIRP	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.57	-0.48	1.16e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7819412	0.502	rs34440473	chr8:10906841	A/T	cg09559047	chr8:10916868	XKR6	-0.4	-5.48	-0.33	1.06e-7	Triglycerides;
KIRP	cis	rs7923609	1.000	rs7073746	chr10:64904071	A/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.48	-0.33	1.08e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs11199874	0.741	rs1873450	chr10:123006274	T/G	cg03091752	chr19:51221605	SHANK1	-0.52	-6.1	-0.36	4.12e-9	Prostate cancer;
KIRP	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.2	-0.46	1.38e-14	Monocyte percentage of white cells;
KIRP	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg08890418	chr1:21044141	KIF17	0.36	5.4	0.33	1.61e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg21064579	chr19:49206444	FUT2	0.56	8.34	0.47	5.22e-15	Dietary macronutrient intake;
KIRP	cis	rs7011049	0.915	rs12375408	chr8:53868662	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.65	-5.9	-0.35	1.18e-8	Height;
KIRP	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg12560992	chr17:57184187	TRIM37	0.63	6.74	0.39	1.13e-10	Testicular germ cell tumor;
KIRP	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.71	-8.05	-0.46	3.45e-14	Body mass index;
KIRP	cis	rs494562	0.892	rs573737	chr6:86118233	A/G	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs72772090	1.000	rs11738135	chr5:96048336	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.54	-5.34	-0.32	2.11e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06850241	chr22:41845214	NA	-0.46	-5.59	-0.34	5.96e-8	Vitiligo;
KIRP	cis	rs904251	0.686	rs1224128	chr6:37415676	C/A	cg08126542	chr6:37504118	NA	-0.52	-5.5	-0.33	9.69e-8	Cognitive performance;
KIRP	cis	rs7221595	0.877	rs35321558	chr17:3892909	G/A	cg09695851	chr17:3907499	NA	0.6	5.91	0.35	1.13e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs78487399	0.908	rs17031079	chr2:43804933	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.86	-0.3	2.1e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg27411982	chr8:10470053	RP1L1	0.38	4.94	0.3	1.43e-6	Morning vs. evening chronotype;
KIRP	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.64	8.02	0.46	4.35e-14	Menarche (age at onset);
KIRP	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg21132104	chr15:45694354	SPATA5L1	0.58	7.1	0.41	1.34e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg23335576	chr14:104009727	NA	0.38	5.61	0.34	5.35e-8	Body mass index;
KIRP	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg18753928	chr3:113234510	CCDC52	-0.52	-6.66	-0.39	1.8e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.65	8.99	0.5	6.69e-17	Blood protein levels;
KIRP	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg00864860	chr1:7907996	UTS2	-0.47	-5.43	-0.33	1.36e-7	Crohn's disease;
KIRP	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg03627880	chr6:151815985	C6orf97	-0.4	-4.85	-0.3	2.15e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg18306943	chr3:40428807	ENTPD3	0.46	6.05	0.36	5.36e-9	Renal cell carcinoma;
KIRP	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.58	-0.48	1.08e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.9	-0.45	9.23e-14	Type 2 diabetes;
KIRP	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.43	-5.24	-0.32	3.48e-7	Diastolic blood pressure;
KIRP	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.46	-4.96	-0.3	1.33e-6	Psoriasis;
KIRP	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg00677455	chr12:58241039	CTDSP2	0.98	12.84	0.63	3.12e-29	Multiple sclerosis;
KIRP	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg00106254	chr7:1943704	MAD1L1	-0.59	-6.39	-0.38	8.06e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26002218	chr14:103986227	CKB	-0.35	-7.14	-0.41	1.03e-11	Body mass index;
KIRP	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg00576331	chr11:65640516	EFEMP2	-0.51	-5.58	-0.34	6.29e-8	Crohn's disease;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.78	6.81	0.4	7.57e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1355223	0.867	rs2281908	chr11:34683578	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-4.93	-0.3	1.51e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.46	6.27	0.37	1.59e-9	Dupuytren's disease;
KIRP	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg10631289	chr15:39006617	NA	-0.8	-8.72	-0.49	4.18e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs7084402	0.565	rs4948522	chr10:60334575	T/C	cg05938607	chr10:60274200	BICC1	-0.37	-8.05	-0.46	3.44e-14	Refractive error;
KIRP	cis	rs45535039	0.506	rs2511856	chr11:119144148	A/C	cg16724696	chr11:118992527	HINFP	-0.61	-8.88	-0.49	1.42e-16	Plateletcrit;
KIRP	cis	rs6546886	0.957	rs6546887	chr2:74250781	C/G	cg14702570	chr2:74259524	NA	-0.33	-6.74	-0.39	1.1e-10	Dialysis-related mortality;
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.67	6.21	0.37	2.18e-9	Alzheimer's disease;
KIRP	cis	rs58688157	0.572	rs936472	chr11:593453	T/C	cg12989344	chr11:534232	HRAS	0.36	4.86	0.3	2.06e-6	Systemic lupus erythematosus;
KIRP	trans	rs1801222	0.564	rs2356823	chr10:17127240	C/T	cg20419291	chr11:124767974	ROBO4	0.48	6.02	0.36	6.35e-9	Folate pathway vitamin levels;Vitamin B levels in ischemic stroke;Homocysteine levels;
KIRP	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.89	12.83	0.63	3.53e-29	Height;
KIRP	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg04374321	chr14:90722782	PSMC1	-0.9	-13.6	-0.66	8.67e-32	Mortality in heart failure;
KIRP	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.46	-0.38	5.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.53	7.24	0.42	5.58e-12	Schizophrenia;
KIRP	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.64	-0.39	1.97e-10	Bipolar disorder;
KIRP	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.06	-0.31	8.37e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00857998	chr1:205179979	DSTYK	0.66	8.56	0.48	1.27e-15	Red blood cell count;
KIRP	cis	rs8060686	0.920	rs73597578	chr16:67679348	C/T	cg04539111	chr16:67997858	SLC12A4	-0.5	-5.07	-0.31	7.85e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.64	-8.62	-0.48	8.22e-16	Coronary artery disease;
KIRP	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.63	9.39	0.51	4.14e-18	Endometriosis;
KIRP	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg18305652	chr10:134549665	INPP5A	0.47	7.07	0.41	1.62e-11	Migraine;
KIRP	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.56	-6.43	-0.38	6.58e-10	Vitiligo;
KIRP	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	1.06	15.46	0.7	4.06e-38	Menopause (age at onset);
KIRP	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.02	-0.36	6.19e-9	IgG glycosylation;
KIRP	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.68	-8.97	-0.5	7.83e-17	Personality dimensions;
KIRP	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.47	6.09	0.36	4.42e-9	Monocyte count;
KIRP	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.39	-0.38	8.29e-10	Coronary artery disease;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-1.1	-21.59	-0.81	1.01e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6504622	0.545	rs10853087	chr17:45006112	C/G	cg16759221	chr17:45003025	GOSR2	0.35	5.25	0.32	3.34e-7	Orofacial clefts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03578886	chr8:94928855	PDP1	0.48	6.36	0.38	9.9e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-16.63	-0.73	4.1e-42	Height;
KIRP	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23281280	chr6:28129359	ZNF389	0.45	4.93	0.3	1.53e-6	Depression;
KIRP	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.75	5.75	0.34	2.65e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.75	-0.34	2.59e-8	Colorectal cancer;
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg21698718	chr17:80085957	CCDC57	-0.34	-4.88	-0.3	1.89e-6	Life satisfaction;
KIRP	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	1.0	13.52	0.65	1.57e-31	Menopause (age at onset);
KIRP	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-8.75	-0.49	3.42e-16	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.59	-9.57	-0.52	1.21e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.79	-10.16	-0.54	1.8e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11987759	chr7:65425863	GUSB	-0.66	-9.3	-0.51	8.01e-18	Calcium levels;
KIRP	cis	rs6701037	1.000	rs6702010	chr1:175123858	C/A	cg00958927	chr1:175162553	KIAA0040	-0.28	-4.86	-0.3	2.11e-6	Alcohol dependence;
KIRP	cis	rs7119167	0.950	rs7935204	chr11:73219181	G/A	cg17517138	chr11:73019481	ARHGEF17	0.47	4.88	0.3	1.94e-6	Blood protein levels;
KIRP	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2908197	0.737	rs6465096	chr7:75972872	T/G	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.3	-5.0	-0.3	1.07e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.85	-11.5	-0.59	8.67e-25	Cocaine dependence;
KIRP	trans	rs7999699	0.967	rs2077433	chr13:48333991	A/G	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	6.82e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs490608	0.628	rs678157	chr1:155658341	T/C	cg02153340	chr1:155202674	NA	-0.43	-5.71	-0.34	3.31e-8	Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02976575	chr7:97835841	LMTK2	-0.47	-6.22	-0.37	2.09e-9	Parkinson's disease;
KIRP	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg13147721	chr7:65941812	NA	1.04	7.43	0.43	1.73e-12	Diabetic kidney disease;
KIRP	cis	rs2712184	0.756	rs2024487	chr2:217663271	C/T	cg05032264	chr2:217675019	NA	0.43	6.35	0.38	1.01e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.3	0.58	4.05e-24	Cognitive test performance;
KIRP	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.59	-0.48	1.04e-15	Response to antipsychotic treatment;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg01832266	chr21:34144059	C21orf66;C21orf49	0.5	6.32	0.37	1.2e-9	DNA methylation (variation);
KIRP	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs9443189	1.000	rs1280047	chr6:76527791	A/G	cg01950844	chr6:76311363	SENP6	0.53	5.28	0.32	2.79e-7	Prostate cancer;
KIRP	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	cg21523751	chr1:182988639	NA	0.46	7.04	0.41	1.94e-11	Colorectal cancer;
KIRP	cis	rs1620921	0.967	rs1247557	chr6:161189670	A/G	cg01280913	chr6:161186852	NA	-0.44	-6.3	-0.37	1.35e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.01	16.95	0.73	3.09e-43	Testicular germ cell tumor;
KIRP	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.5	-6.58	-0.39	2.74e-10	Schizophrenia;
KIRP	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg12598211	chr12:123634384	NA	-0.41	-5.07	-0.31	7.97e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.47	5.63	0.34	4.87e-8	Glycated hemoglobin levels;
KIRP	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs9302635	0.745	rs35909200	chr16:72156666	T/G	cg01557791	chr16:72042693	DHODH	-0.67	-6.37	-0.38	9.28e-10	Blood protein levels;
KIRP	cis	rs11628318	0.805	rs749543	chr14:103057250	C/A	cg01864069	chr14:103024347	NA	-0.68	-8.76	-0.49	3.28e-16	Platelet count;
KIRP	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.48	-0.52	2.32e-18	Personality dimensions;
KIRP	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg20701182	chr2:24300061	SF3B14	-0.47	-4.92	-0.3	1.55e-6	Asthma;
KIRP	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg07777115	chr5:623756	CEP72	-0.59	-5.9	-0.35	1.22e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg10755058	chr3:40428713	ENTPD3	0.49	6.67	0.39	1.63e-10	Renal cell carcinoma;
KIRP	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.3	-0.32	2.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs960902	0.818	rs4353628	chr2:37739512	A/G	cg25341268	chr2:37734390	NA	-0.61	-8.46	-0.47	2.35e-15	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.96	-0.35	8.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.65	6.62	0.39	2.26e-10	Graves' disease;
KIRP	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs3784262	0.709	rs4080	chr15:58201341	C/G	cg12031962	chr15:58353849	ALDH1A2	0.39	5.48	0.33	1.03e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg07451762	chr16:28383216	NA	0.43	5.63	0.34	4.98e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.39	5.0	0.3	1.11e-6	Leprosy;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03437886	chr1:178698946	RALGPS2	0.39	6.26	0.37	1.73e-9	C-reactive protein;
KIRP	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9488822	0.676	rs11153593	chr6:116335131	C/A	cg15226275	chr6:116381976	FRK	0.22	6.04	0.36	5.77e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17554472	chr22:41940697	POLR3H	0.69	7.08	0.41	1.48e-11	Vitiligo;
KIRP	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17376030	chr22:41985996	PMM1	0.47	5.44	0.33	1.28e-7	Vitiligo;
KIRP	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs4742903	0.967	rs3739737	chr9:106858192	A/G	cg14250997	chr9:106856677	SMC2	0.4	5.18	0.31	4.7e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.39	-5.44	-0.33	1.26e-7	Neuroticism;
KIRP	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg08917208	chr2:24149416	ATAD2B	0.56	4.97	0.3	1.26e-6	Lymphocyte counts;
KIRP	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.39	-5.48	-0.33	1.03e-7	Mean corpuscular volume;
KIRP	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.89	0.4	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.35	-5.5	-0.33	9.39e-8	Body mass index;
KIRP	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg22903471	chr2:27725779	GCKR	-0.44	-5.17	-0.31	4.74e-7	Blood metabolite levels;
KIRP	cis	rs1524927	0.566	rs12704876	chr7:96366342	C/T	cg03808172	chr7:96339361	SHFM1	0.44	6.1	0.36	4.18e-9	Total body bone mineral density;
KIRP	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg08992911	chr2:238395768	MLPH	0.55	5.4	0.33	1.56e-7	Prostate cancer;
KIRP	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.69	-9.91	-0.53	1.06e-19	Extrinsic epigenetic age acceleration;
KIRP	cis	rs909341	0.810	rs2427529	chr20:62359564	T/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.79	-0.4	8.47e-11	Atopic dermatitis;
KIRP	cis	rs6681460	0.634	rs4142763	chr1:66998036	A/G	cg02459107	chr1:67143332	SGIP1	0.39	5.41	0.33	1.47e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs3091242	0.967	rs3093614	chr1:25677844	T/A	cg02931644	chr1:25747376	RHCE	-0.37	-6.73	-0.39	1.16e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.72	10.01	0.54	5.38e-20	Height;
KIRP	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg08799069	chr10:126477246	METTL10	-0.48	-6.48	-0.38	5.07e-10	Asthma;
KIRP	cis	rs4865169	0.560	rs1277312	chr4:57902945	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	9.23	0.51	1.29e-17	Breast cancer;
KIRP	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.48	-6.79	-0.4	8.21e-11	Height;
KIRP	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18364779	chr6:26104403	HIST1H4C	0.49	5.55	0.33	7.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9372498	0.536	rs72952793	chr6:118892979	T/A	cg21191810	chr6:118973309	C6orf204	-0.44	-4.89	-0.3	1.84e-6	Diastolic blood pressure;
KIRP	cis	rs7688540	0.771	rs74984113	chr4:250522	G/A	cg17891759	chr4:299121	NA	-0.5	-5.2	-0.31	4.29e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs9815354	1.000	rs1607908	chr3:41905196	T/G	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg11839771	chr15:80205821	ST20	-0.39	-5.46	-0.33	1.19e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.6	-7.87	-0.45	1.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.52	-0.38	4.05e-10	Lung cancer;
KIRP	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.95	-0.3	1.38e-6	Schizophrenia;
KIRP	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.23	-0.46	1.12e-14	Mean corpuscular volume;
KIRP	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg23505145	chr19:12996616	KLF1	0.57	8.41	0.47	3.42e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.5	-0.43	1.17e-12	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg24253500	chr15:84953950	NA	0.52	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs4474465	0.831	rs10899510	chr11:78170841	G/A	cg02023728	chr11:77925099	USP35	0.36	5.66	0.34	4.15e-8	Alzheimer's disease (survival time);
KIRP	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.6	-5.19	-0.31	4.45e-7	Narcolepsy;
KIRP	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.52	-6.41	-0.38	7.32e-10	Menarche (age at onset);
KIRP	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	8.99	0.5	6.71e-17	Motion sickness;
KIRP	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.41	-5.13	-0.31	5.78e-7	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23309257	chr8:144679350	EEF1D;TIGD5	0.5	6.3	0.37	1.34e-9	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg15445000	chr17:37608096	MED1	0.46	5.46	0.33	1.18e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.71e-31	Diabetic retinopathy;
KIRP	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg04025307	chr7:1156635	C7orf50	-0.47	-5.03	-0.31	9.6e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs73198271	0.628	rs76079102	chr8:8591553	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10102274	1.000	rs75280382	chr8:91797890	C/A	cg16814680	chr8:91681699	NA	-0.8	-4.86	-0.3	2.13e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.56	-0.39	3.19e-10	Response to antipsychotic treatment;
KIRP	cis	rs17539620	0.808	rs62434163	chr6:154874692	G/C	cg20019720	chr6:154832845	CNKSR3	0.34	5.21	0.32	3.97e-7	Lipoprotein (a) levels;
KIRP	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.68	-7.86	-0.45	1.2e-13	Corneal astigmatism;
KIRP	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.64	0.34	4.58e-8	Breast cancer;
KIRP	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.56	-0.39	3.18e-10	Diastolic blood pressure;
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.45	6.87	0.4	5.22e-11	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22336774	chr19:7600718	PNPLA6	0.49	6.44	0.38	6.11e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg22437258	chr11:111473054	SIK2	0.63	7.68	0.44	3.81e-13	Primary sclerosing cholangitis;
KIRP	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-6.63	-0.39	2.13e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	6.8	0.4	7.89e-11	Menarche (age at onset);
KIRP	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg13397359	chr6:42928475	GNMT	0.44	4.92	0.3	1.55e-6	Blood protein levels;
KIRP	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	7.84	0.45	1.32e-13	Menarche (age at onset);
KIRP	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg23625390	chr15:77176239	SCAPER	0.5	6.59	0.39	2.73e-10	Blood metabolite levels;
KIRP	cis	rs17221829	0.733	rs35757457	chr11:89358250	T/A	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.2	-0.31	4.21e-7	Anxiety in major depressive disorder;
KIRP	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs9371601	0.798	rs550070	chr6:152717505	A/G	cg05529123	chr2:66910386	NA	-0.46	-6.2	-0.37	2.37e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.91	0.53	1.11e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.62	-7.97	-0.45	5.99e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.75	7.56	0.43	8.2e-13	Bipolar disorder;
KIRP	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg16141378	chr3:129829833	LOC729375	0.49	6.2	0.37	2.33e-9	Schizophrenia;
KIRP	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.52	6.38	0.38	8.69e-10	Subjective well-being;
KIRP	cis	rs4742903	0.527	rs10991112	chr9:106878906	C/T	cg14250997	chr9:106856677	SMC2	0.43	5.88	0.35	1.35e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs918629	0.798	rs6877821	chr5:95289502	C/T	cg16656078	chr5:95278638	ELL2	-0.47	-6.78	-0.4	8.68e-11	IgG glycosylation;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.74	6.7	0.39	1.39e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7937840	0.581	rs4963286	chr11:61887232	C/A	cg01969543	chr11:61895209	INCENP	-0.46	-6.06	-0.36	4.95e-9	Breast cancer;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg23257110	chr1:153935815	SLC39A1	0.47	6.47	0.38	5.25e-10	Coronary artery disease;
KIRP	cis	rs6545883	0.929	rs2256615	chr2:61679894	C/G	cg15711740	chr2:61764176	XPO1	-0.61	-7.78	-0.44	1.97e-13	Tuberculosis;
KIRP	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.49	6.4	0.38	7.63e-10	HDL cholesterol levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09326324	chr1:161123937	UFC1	0.46	6.18	0.37	2.64e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg07775547	chr4:1625484	NA	0.44	4.93	0.3	1.5e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.52	-6.48	-0.38	4.92e-10	Total body bone mineral density;
KIRP	trans	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.26	0.37	1.68e-9	Mean corpuscular volume;
KIRP	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	cg21523751	chr1:182988639	NA	0.41	6.34	0.37	1.08e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.75e-15	Aortic root size;
KIRP	cis	rs4523957	0.533	rs216216	chr17:2145046	A/G	cg16513277	chr17:2031491	SMG6	0.5	5.53	0.33	8.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-5.94	-0.35	9.91e-9	Gut microbiome composition (summer);
KIRP	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-7.43	-0.43	1.75e-12	Tonsillectomy;
KIRP	cis	rs6580649	0.941	rs726354	chr12:48500334	G/A	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.67	-7.74	-0.44	2.53e-13	Pancreatic cancer;
KIRP	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg20712883	chr12:51590929	POU6F1	0.58	7.15	0.41	1e-11	Cisplatin-induced ototoxicity;
KIRP	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7534824	0.625	rs61780287	chr1:101382744	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.84	7.19	0.42	7.58e-12	Refractive astigmatism;
KIRP	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.64	8.34	0.47	5.51e-15	Height;
KIRP	cis	rs5753037	0.869	rs2189802	chr22:30294173	A/G	cg27665648	chr22:30112403	NA	0.39	5.48	0.33	1.04e-7	Type 1 diabetes;
KIRP	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.73	-7.18	-0.42	8.44e-12	Psoriasis vulgaris;
KIRP	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg22951263	chr5:87985283	NA	-0.48	-6.83	-0.4	6.68e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg10167378	chr1:228756711	NA	0.52	5.93	0.35	1.01e-8	Diastolic blood pressure;
KIRP	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg00409905	chr10:38381863	ZNF37A	0.55	5.78	0.35	2.25e-8	Obesity (extreme);
KIRP	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg23594656	chr7:65796392	TPST1	-0.51	-8.06	-0.46	3.3e-14	Aortic root size;
KIRP	cis	rs7246657	0.550	rs9941475	chr19:38064517	C/T	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs17221829	0.589	rs7930747	chr11:89377160	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.76e-7	Life satisfaction;
KIRP	cis	rs253959	0.545	rs712596	chr5:115657911	A/G	cg23108291	chr5:115420582	COMMD10	-0.52	-5.7	-0.34	3.4e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg08975724	chr8:8085496	FLJ10661	0.67	8.56	0.48	1.24e-15	Neuroticism;
KIRP	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg20628663	chr10:43360327	NA	0.55	6.43	0.38	6.48e-10	Blood protein levels;
KIRP	cis	rs7215564	0.908	rs1471788	chr17:78672153	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.14	0.31	5.6e-7	Myopia (pathological);
KIRP	cis	rs9372498	0.536	rs55697388	chr6:118891544	C/T	cg21191810	chr6:118973309	C6orf204	-0.42	-4.89	-0.3	1.86e-6	Diastolic blood pressure;
KIRP	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg14458575	chr2:238380390	NA	0.57	5.6	0.34	5.63e-8	Prostate cancer;
KIRP	cis	rs1971762	0.527	rs11170590	chr12:53938913	G/A	cg16917193	chr12:54089295	NA	0.66	10.62	0.56	6.15e-22	Height;
KIRP	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.77	-0.35	2.34e-8	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.2	12.85	0.63	2.93e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	6.38	0.38	8.93e-10	Personality dimensions;
KIRP	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg12591125	chr7:1885375	MAD1L1	0.61	5.96	0.36	8.64e-9	Bipolar disorder;
KIRP	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.4	-0.55	3.12e-21	Hypospadias;
KIRP	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg14541582	chr5:601475	NA	0.57	6.46	0.38	5.63e-10	Obesity-related traits;
KIRP	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.53	5.8	0.35	2.06e-8	Lung cancer;
KIRP	cis	rs965513	1.000	rs1561962	chr9:100546219	C/T	cg13688889	chr9:100608707	NA	-0.59	-7.52	-0.43	1.02e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.44	0.52	2.95e-18	Morning vs. evening chronotype;
KIRP	cis	rs10488172	0.655	rs1541710	chr7:133565784	C/G	cg10665199	chr7:133106180	EXOC4	-0.47	-4.89	-0.3	1.81e-6	Tonometry;
KIRP	cis	rs9309473	1.000	rs58603761	chr2:73726605	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.49	-0.33	9.97e-8	Metabolite levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00110724	chr8:144885851	SCRIB	0.47	6.14	0.36	3.21e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.52	7.53	0.43	9.81e-13	Obesity-related traits;
KIRP	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	0.76	7.97	0.45	5.94e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.44	0.38	6.39e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Hypertriglyceridemia;
KIRP	cis	rs12900413	0.687	rs12906905	chr15:90315399	A/G	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.66e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs60871478	0.636	rs61441144	chr7:897784	C/T	cg13798912	chr7:905769	UNC84A	-0.75	-6.95	-0.41	3.27e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.47	0.38	5.35e-10	Putamen volume;
KIRP	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	6.73	0.39	1.19e-10	Menarche (age at onset);
KIRP	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.78	8.63	0.48	7.89e-16	Exhaled nitric oxide output;
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.98	10.97	0.57	4.7e-23	Alzheimer's disease;
KIRP	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg02023728	chr11:77925099	USP35	0.34	5.41	0.33	1.52e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg18882449	chr10:104885122	NT5C2	-0.42	-5.36	-0.32	1.9e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg22325292	chr17:80708367	FN3K	0.37	4.91	0.3	1.65e-6	Glycated hemoglobin levels;
KIRP	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg27205649	chr11:78285834	NARS2	-0.66	-8.24	-0.47	1.01e-14	Alzheimer's disease (survival time);
KIRP	cis	rs10499694	0.697	rs3779074	chr7:50612202	A/G	cg00647317	chr7:50633725	DDC	0.41	6.02	0.36	6.16e-9	Body mass index;
KIRP	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.08	0.31	7.54e-7	Childhood ear infection;
KIRP	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.01	-0.3	1.03e-6	Obesity-related traits;
KIRP	cis	rs997295	0.675	rs12912974	chr15:67974379	G/C	cg24579218	chr15:68104479	NA	0.35	4.97	0.3	1.25e-6	Motion sickness;
KIRP	cis	rs7923609	0.936	rs10761778	chr10:65273782	A/G	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.16e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.22	-5.19	-0.31	4.45e-7	Coronary artery disease;
KIRP	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg03834567	chr2:218808745	TNS1	0.47	5.66	0.34	4.16e-8	Ulcerative colitis;
KIRP	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	cg04338863	chr8:33670619	NA	0.4	5.43	0.33	1.36e-7	Body mass index;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18989174	chr7:149470820	ZNF467	0.52	6.33	0.37	1.14e-9	Lung cancer in ever smokers;
KIRP	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.82	0.81	1.91e-59	Prudent dietary pattern;
KIRP	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-8.17	-0.46	1.58e-14	Total body bone mineral density;
KIRP	cis	rs1978968	0.956	rs7291304	chr22:18421821	C/A	cg03078520	chr22:18463400	MICAL3	-0.66	-7.52	-0.43	1.03e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	5.79	0.35	2.15e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11987759	chr7:65425863	GUSB	-0.45	-5.61	-0.34	5.56e-8	Aortic root size;
KIRP	cis	rs2860975	0.620	rs7095531	chr10:96811841	A/G	cg09036531	chr10:96991505	NA	-0.48	-5.88	-0.35	1.32e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs1298908	0.897	rs2573326	chr10:82013146	T/C	cg13429435	chr10:81271195	EIF5AL1	-0.33	-5.0	-0.3	1.09e-6	Diabetic kidney disease;
KIRP	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg17146150	chr15:56657437	TEX9	0.47	6.36	0.38	9.52e-10	Ischemic stroke;
KIRP	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.56	7.43	0.43	1.74e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-4.91	-0.3	1.67e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg00094735	chr5:1949198	NA	0.45	5.56	0.33	6.98e-8	Gut microbiome composition (winter);
KIRP	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.5	5.44	0.33	1.27e-7	Type 2 diabetes;
KIRP	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.62	8.08	0.46	3.01e-14	Platelet distribution width;
KIRP	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.72	9.23	0.51	1.26e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.91	-0.3	1.67e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg01338139	chr15:38987640	C15orf53	-0.56	-6.28	-0.37	1.55e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-4.86	-0.3	2.11e-6	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg01763666	chr17:80159506	CCDC57	-0.38	-5.16	-0.31	5.13e-7	Life satisfaction;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.76	-9.62	-0.52	8.29e-19	Longevity;Endometriosis;
KIRP	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.95	-0.35	9.19e-9	Educational attainment;
KIRP	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg07884673	chr3:53033167	SFMBT1	0.59	5.03	0.31	9.52e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.59	5.66	0.34	4.22e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.33	-0.32	2.26e-7	Life satisfaction;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.32	-0.37	1.22e-9	Height;
KIRP	cis	rs4356932	1.000	rs6811301	chr4:76970579	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.63	7.93	0.45	7.46e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg26174226	chr8:58114915	NA	-0.49	-4.94	-0.3	1.45e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-11.78	-0.6	1.11e-25	Height;
KIRP	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.84	12.02	0.61	1.73e-26	Total body bone mineral density;
KIRP	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02034447	chr16:89574710	SPG7	0.39	4.96	0.3	1.3e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg05973401	chr12:123451056	ABCB9	0.57	6.57	0.39	2.94e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.87	10.47	0.56	1.91e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.68	7.7	0.44	3.31e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.03	-0.67	3.08e-33	Primary sclerosing cholangitis;
KIRP	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.68	-7.18	-0.42	8.44e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.06	-0.5	4.22e-17	Chronic sinus infection;
KIRP	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg22951263	chr5:87985283	NA	-0.48	-6.83	-0.4	6.68e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.05	0.41	1.8e-11	Caffeine consumption;
KIRP	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.24	-0.32	3.46e-7	Blood metabolite levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24419099	chr11:47270565	NR1H3;ACP2	0.54	6.26	0.37	1.7e-9	Smoking initiation;
KIRP	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg19610905	chr11:61596333	FADS2	-0.52	-5.84	-0.35	1.61e-8	Neutrophil count;Sum basophil neutrophil counts;
KIRP	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.4	-0.43	2.19e-12	Morning vs. evening chronotype;
KIRP	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.67	-0.34	4.04e-8	Diastolic blood pressure;
KIRP	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg13173536	chr2:3403300	TTC15	-0.36	-4.89	-0.3	1.86e-6	Obesity-related traits;
KIRP	cis	rs882732	0.576	rs12895360	chr14:95038922	T/C	cg05186455	chr14:95027692	SERPINA4	-0.34	-5.18	-0.31	4.53e-7	Blood protein levels;
KIRP	trans	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	8.87	0.49	1.5e-16	Exhaled nitric oxide output;
KIRP	cis	rs6662572	0.737	rs9429179	chr1:46514198	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.63	0.34	4.96e-8	Blood protein levels;
KIRP	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.58	-0.34	6.24e-8	Height;
KIRP	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.4	-5.31	-0.32	2.47e-7	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.7	-11.45	-0.59	1.28e-24	Menopause (age at onset);
KIRP	cis	rs1443512	0.812	rs1561987	chr12:54335268	C/T	cg17410650	chr12:54324560	NA	-0.46	-6.01	-0.36	6.77e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg16558253	chr16:72132732	DHX38	-0.42	-5.24	-0.32	3.43e-7	Blood protein levels;
KIRP	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg19500275	chr17:80737654	TBCD	0.45	5.09	0.31	7.18e-7	Glycated hemoglobin levels;
KIRP	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.59	-8.12	-0.46	2.22e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-6.89	-0.4	4.6e-11	Electroencephalogram traits;
KIRP	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.66	-8.19	-0.46	1.4e-14	IgG glycosylation;
KIRP	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.19	-0.31	4.44e-7	Height;
KIRP	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-7.08	-0.41	1.49e-11	Coffee consumption (cups per day);
KIRP	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.95e-8	Endometrial cancer;
KIRP	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg26876637	chr1:152193138	HRNR	0.7	9.06	0.5	4.19e-17	Atopic dermatitis;
KIRP	cis	rs7692976	0.868	rs6824594	chr4:110904448	A/G	cg06981781	chr4:110842888	EGF	0.23	5.04	0.31	9.18e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg11833968	chr6:79620685	NA	-0.39	-5.67	-0.34	3.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4903604	0.505	rs11623595	chr14:78037547	A/G	cg18872420	chr14:78023429	SPTLC2	0.32	4.96	0.3	1.3e-6	Gut microbiome composition (winter);
KIRP	cis	rs2882667	0.690	rs11750163	chr5:138041609	T/C	cg04439458	chr5:138467593	SIL1	-0.37	-5.37	-0.32	1.82e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.41	-6.28	-0.37	1.53e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs7402982	0.625	rs4966008	chr15:99203445	A/G	cg03437748	chr15:99193247	IGF1R	-0.75	-9.03	-0.5	5.24e-17	Birth weight;
KIRP	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg19338460	chr6:170058176	WDR27	-0.52	-5.85	-0.35	1.56e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg20991723	chr1:152506922	NA	-0.46	-5.52	-0.33	8.46e-8	Hair morphology;
KIRP	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg04727924	chr7:799746	HEATR2	0.66	6.54	0.38	3.54e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs897080	0.515	rs698818	chr2:44709769	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.86	0.35	1.52e-8	Height;
KIRP	cis	rs10207628	0.943	rs10207708	chr2:127852056	G/A	cg06223080	chr2:127868745	NA	-0.61	-8.25	-0.47	9.93e-15	Psychosis and Alzheimer's disease;
KIRP	cis	rs11955398	0.585	rs4447941	chr5:60022211	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.28	-0.32	2.85e-7	Life satisfaction;
KIRP	cis	rs16828019	0.929	rs8179465	chr1:41701747	C/T	cg24596898	chr1:41849189	NA	0.61	4.99	0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.79	-9.71	-0.53	4.38e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8084125	1.000	rs72978662	chr18:74951872	G/A	cg18461021	chr18:74961002	GALR1	0.64	6.07	0.36	4.77e-9	Obesity-related traits;
KIRP	cis	rs11997175	0.655	rs72630922	chr8:33662401	G/A	cg04338863	chr8:33670619	NA	0.41	5.39	0.33	1.62e-7	Body mass index;
KIRP	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7224685	0.569	rs12950730	chr17:3994225	G/T	cg11204139	chr17:3907470	NA	0.51	5.05	0.31	8.7e-7	Type 2 diabetes;
KIRP	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.56	-6.29	-0.37	1.44e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.55	6.45	0.38	5.86e-10	Blood protein levels;
KIRP	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg25019033	chr10:957182	NA	-0.72	-9.05	-0.5	4.47e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg04662567	chr6:169592167	NA	-0.78	-6.82	-0.4	6.97e-11	Pulse pressure;
KIRP	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.61	-6.15	-0.36	3.15e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6696846	0.936	rs12134724	chr1:205039288	T/C	cg21545522	chr1:205238299	TMCC2	0.4	5.19	0.31	4.49e-7	Red blood cell count;
KIRP	cis	rs7760535	0.764	rs2343614	chr6:111705158	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.49	-6.5	-0.38	4.52e-10	Metabolic traits;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg25533220	chr19:2328480	SPPL2B;LSM7	0.68	6.47	0.38	5.17e-10	Lung function (FEV1);
KIRP	cis	rs4409675	0.913	rs4908375	chr1:28251898	T/A	cg23691781	chr1:28212827	C1orf38	-0.34	-7.12	-0.41	1.21e-11	Corneal astigmatism;
KIRP	cis	rs6565681	1.000	rs6565681	chr17:78348494	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.71	-7.0	-0.41	2.49e-11	Moyamoya disease;
KIRP	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.83	-0.4	6.72e-11	Aortic root size;
KIRP	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14448850	chr7:22860191	TOMM7	-0.49	-6.07	-0.36	4.82e-9	Inflammatory biomarkers;
KIRP	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.6	-6.4	-0.38	7.87e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.87	9.68	0.53	5.5e-19	Gut microbiome composition (summer);
KIRP	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.75	10.39	0.55	3.37e-21	Leprosy;
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg08662619	chr6:150070041	PCMT1	-0.33	-5.26	-0.32	3.19e-7	Lung cancer;
KIRP	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.74	11.68	0.6	2.22e-25	Calcium levels;
KIRP	cis	rs13424612	0.839	rs4854063	chr2:240914090	T/C	cg19172429	chr2:240878313	NA	0.3	4.91	0.3	1.62e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg18850127	chr7:39170497	POU6F2	0.27	5.2	0.31	4.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6088813	0.645	rs7263431	chr20:34014192	G/A	cg14752227	chr20:34000481	UQCC	0.47	5.23	0.32	3.66e-7	Height;
KIRP	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg23752985	chr2:85803571	VAMP8	0.6	9.13	0.5	2.61e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.1	-0.31	6.84e-7	Myopia (pathological);
KIRP	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg13114125	chr14:105738426	BRF1	-0.75	-10.34	-0.55	4.82e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.57	-7.98	-0.45	5.42e-14	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg23307798	chr14:103986281	CKB	0.76	13.08	0.64	4.77e-30	Bone mineral density;
KIRP	cis	rs17739794	0.557	rs7823906	chr8:814710	A/G	cg01971667	chr8:817044	NA	-0.39	-5.5	-0.33	9.53e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.5	0.43	1.13e-12	Aortic root size;
KIRP	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs501120	1.000	rs527785	chr10:44762686	G/A	cg09554077	chr10:44749378	NA	0.7	10.74	0.57	2.53e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg06212747	chr3:49208901	KLHDC8B	0.66	7.82	0.45	1.5700000000000001e-13	Menarche (age at onset);
KIRP	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg03929089	chr4:120376271	NA	0.68	6.09	0.36	4.22e-9	Axial length;
KIRP	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.76	-6.83	-0.4	6.48e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7301016	0.948	rs11174498	chr12:62865345	T/C	cg01804193	chr12:63026212	NA	0.54	5.68	0.34	3.88e-8	IgG glycosylation;
KIRP	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg05709478	chr1:6581295	PLEKHG5	0.61	6.64	0.39	1.98e-10	Body mass index;
KIRP	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.03	-16.7	-0.73	2.23e-42	Dilated cardiomyopathy;
KIRP	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06544989	chr22:39130855	UNC84B	0.5	7.49	0.43	1.24e-12	Menopause (age at onset);
KIRP	cis	rs4356932	0.967	rs6532159	chr4:76978124	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.96	10.14	0.54	2.05e-20	Schizophrenia;
KIRP	cis	rs9912468	1.000	rs9912468	chr17:64318357	C/G	cg19474267	chr17:64306194	PRKCA	0.65	9.46	0.52	2.54e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg09788416	chr12:39539408	NA	0.42	5.22	0.32	3.83e-7	Morning vs. evening chronotype;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg08805041	chr16:621841	PIGQ	-0.36	-4.94	-0.3	1.42e-6	Height;
KIRP	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.67	-9.09	-0.5	3.35e-17	Type 2 diabetes;
KIRP	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08280861	chr8:58055591	NA	0.71	5.65	0.34	4.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	cis	rs375066	0.620	rs349049	chr19:44301400	T/C	cg11993925	chr19:44307056	LYPD5	-0.36	-5.01	-0.3	1.06e-6	Breast cancer;
KIRP	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.54	-7.31	-0.42	3.81e-12	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.46	-0.33	1.19e-7	Life satisfaction;
KIRP	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg25281562	chr12:121454272	C12orf43	0.45	4.87	0.3	2.02e-6	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
KIRP	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg17372223	chr3:52568218	NT5DC2	0.32	4.97	0.3	1.28e-6	Electroencephalogram traits;
KIRP	cis	rs6662572	0.737	rs72677550	chr1:46589276	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.42	0.33	1.42e-7	Blood protein levels;
KIRP	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-7.26	-0.42	5.08e-12	Monocyte percentage of white cells;
KIRP	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.47	6.0	0.36	7.09e-9	Motion sickness;
KIRP	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg23711669	chr6:146136114	FBXO30	0.68	9.42	0.51	3.51e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.71	-9.21	-0.51	1.46e-17	Mean platelet volume;
KIRP	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg19875535	chr5:140030758	IK	-0.7	-9.86	-0.53	1.56e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs1620921	0.524	rs12194271	chr6:161195895	A/G	cg01280913	chr6:161186852	NA	-0.68	-9.51	-0.52	1.8e-18	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg23442198	chr4:187126114	CYP4V2	0.76	6.66	0.39	1.74e-10	Blood protein levels;
KIRP	cis	rs17321999	1.000	rs13386455	chr2:30480865	A/G	cg05247661	chr2:30472410	LBH	0.63	7.02	0.41	2.12e-11	Systemic lupus erythematosus;
KIRP	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg06671706	chr8:8559999	CLDN23	0.59	6.7	0.39	1.44e-10	Obesity-related traits;
KIRP	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.14	-0.31	5.53e-7	Pulmonary function;
KIRP	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.67	8.26	0.47	8.94e-15	Dilated cardiomyopathy;
KIRP	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-6.86	-0.4	5.68e-11	Mean platelet volume;
KIRP	cis	rs10761482	0.500	rs7098650	chr10:62277679	C/T	cg01186212	chr10:62110162	ANK3	-0.31	-5.05	-0.31	8.63e-7	Schizophrenia;
KIRP	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	8.47	0.48	2.22e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6142102	0.602	rs4911399	chr20:32623418	C/A	cg08999081	chr20:33150536	PIGU	0.38	4.91	0.3	1.63e-6	Skin pigmentation;
KIRP	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.63	-6.98	-0.41	2.77e-11	Gut microbiome composition (summer);
KIRP	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	8.33	0.47	5.84e-15	Response to antipsychotic treatment;
KIRP	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.69	9.05	0.5	4.38e-17	Morning vs. evening chronotype;
KIRP	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg05650719	chr12:132293520	NA	-0.55	-7.53	-0.43	9.67e-13	Migraine;
KIRP	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.89	9.98	0.54	6.56e-20	Corneal structure;
KIRP	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	cis	rs3755132	0.929	rs976016	chr2:15772865	A/G	cg12888861	chr2:15731646	DDX1	0.4	5.5	0.33	9.27e-8	Wilms tumor;
KIRP	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg14541582	chr5:601475	NA	-0.54	-5.94	-0.35	9.55e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-6.44	-0.38	6.05e-10	Chronic sinus infection;
KIRP	cis	rs6684428	1.000	rs6693526	chr1:56349764	G/A	cg11651538	chr1:56320950	NA	-0.87	-10.37	-0.55	3.99e-21	Airflow obstruction;
KIRP	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.19	-0.37	2.53e-9	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10263973	chr15:65822718	PTPLAD1	0.49	6.36	0.38	9.63e-10	Parkinson's disease;
KIRP	cis	rs6005807	0.719	rs9625512	chr22:29020756	G/C	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg26338869	chr17:61819248	STRADA	0.54	6.31	0.37	1.32e-9	Prudent dietary pattern;
KIRP	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg27624424	chr6:160112604	SOD2	0.46	4.92	0.3	1.61e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.8	10.5	0.56	1.5e-21	Mood instability;
KIRP	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg11784071	chr10:104629166	AS3MT	-0.38	-5.37	-0.32	1.8e-7	Arsenic metabolism;
KIRP	cis	rs13385	0.723	rs28722951	chr5:139609952	T/G	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.58	-6.67	-0.39	1.72e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg17294928	chr15:75287854	SCAMP5	0.64	5.52	0.33	8.44e-8	Lung cancer;
KIRP	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.56	-5.49	-0.33	1.02e-7	Ulcerative colitis;
KIRP	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.89	-0.35	1.29e-8	Pulmonary function;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12413365	chr12:12510412	LOH12CR1;LOH12CR2	0.54	6.28	0.37	1.5e-9	Smoking initiation;
KIRP	cis	rs7945718	0.934	rs11022478	chr11:12741104	T/C	cg25843174	chr11:12811716	TEAD1	0.35	6.55	0.39	3.3e-10	Educational attainment (years of education);
KIRP	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-7.42	-0.43	1.91e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg19077165	chr18:44547161	KATNAL2	0.47	5.87	0.35	1.43e-8	Personality dimensions;
KIRP	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg13385521	chr17:29058706	SUZ12P	0.82	6.3	0.37	1.39e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	1.23	12.6	0.63	2.01e-28	Red blood cell traits;
KIRP	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.45	-0.47	2.65e-15	Response to antipsychotic treatment;
KIRP	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.69	0.48	5.14e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs4774899	0.902	rs12912210	chr15:57471823	A/G	cg13626582	chr15:57592083	LOC283663	-0.2	-4.86	-0.3	2.1e-6	Urinary tract infection frequency;
KIRP	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.54	8.14	0.46	1.94e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg23985595	chr17:80112537	CCDC57	0.34	5.1	0.31	6.8e-7	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10779184	chr7:92462706	CDK6	0.45	6.28	0.37	1.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg23505145	chr19:12996616	KLF1	0.58	8.53	0.48	1.5e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.61	0.39	2.34e-10	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.45	-0.52	2.82e-18	Aortic root size;
KIRP	cis	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg25276700	chr6:44698697	NA	0.35	4.98	0.3	1.21e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg25019722	chr6:37503610	NA	-0.89	-12.88	-0.63	2.29e-29	Cognitive performance;
KIRP	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.6	8.77	0.49	2.95e-16	Systemic lupus erythematosus;
KIRP	cis	rs2573652	1.000	rs2581362	chr15:100513524	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.69	-10.31	-0.55	6.12e-21	Height;
KIRP	cis	rs2377585	0.653	rs10770955	chr12:8842752	C/T	cg03761649	chr12:8850719	RIMKLB	0.51	5.0	0.3	1.07e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs922182	0.547	rs6494458	chr15:64271095	A/C	cg24729988	chr15:64271149	DAPK2	-0.34	-5.03	-0.31	9.38e-7	Blood protein levels;
KIRP	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.44	-5.45	-0.33	1.23e-7	Bipolar disorder;
KIRP	trans	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg16141378	chr3:129829833	LOC729375	0.58	6.85	0.4	6.01e-11	Neuroticism;
KIRP	cis	rs883565	0.684	rs811971	chr3:39168283	C/T	cg01426195	chr3:39028469	NA	-0.6	-9.15	-0.5	2.3e-17	Handedness;
KIRP	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg21747090	chr2:27597821	SNX17	0.45	6.07	0.36	4.92e-9	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14126493	chr5:176831297	F12	0.44	6.1	0.36	4.05e-9	Parkinson's disease;
KIRP	cis	rs365132	0.791	rs55954117	chr5:176454075	A/G	cg16309518	chr5:176445507	NA	-0.8	-12.04	-0.61	1.45e-26	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs2327429	0.767	rs12190287	chr6:134214525	C/G	cg08368617	chr6:134217040	NA	-0.47	-5.95	-0.35	8.94e-9	Coronary artery disease;
KIRP	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg14289826	chr9:140003911	NA	0.49	9.17	0.5	1.94e-17	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg20243544	chr17:37824526	PNMT	0.53	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs4523957	0.928	rs216189	chr17:2187401	A/G	cg16513277	chr17:2031491	SMG6	-0.57	-8.21	-0.46	1.23e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10208940	0.920	rs10211211	chr2:68718191	G/C	cg12452813	chr2:68675892	NA	0.47	5.07	0.31	7.97e-7	Urate levels in lean individuals;
KIRP	cis	rs7520050	0.966	rs6672898	chr1:46290588	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.58	8.66	0.48	6.23e-16	Fat distribution (HIV);
KIRP	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26207909	chr14:103986467	CKB	0.52	6.93	0.4	3.73e-11	Body mass index;
KIRP	cis	rs7546668	1.000	rs3795759	chr1:15853628	C/T	cg21858823	chr1:15850916	CASP9	0.47	5.19	0.31	4.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg08125733	chr17:73851984	WBP2	0.54	6.77	0.4	9.33e-11	White matter hyperintensity burden;
KIRP	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs4692589	0.556	rs13133562	chr4:170965709	C/T	cg19918862	chr4:170955249	NA	0.57	6.16	0.37	2.99e-9	Anxiety disorder;
KIRP	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.85	9.83	0.53	1.87e-19	Obesity-related traits;
KIRP	trans	rs12517041	1.000	rs2217309	chr5:23313736	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.45	6.33	0.37	1.16e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.19	0.46	1.4e-14	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg02287279	chr5:89814120	LYSMD3	0.41	6.42	0.38	6.99e-10	C-reactive protein;
KIRP	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.6	9.32	0.51	6.75e-18	IgA nephropathy;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.49	-6.18	-0.37	2.6e-9	Longevity;Endometriosis;
KIRP	cis	rs4713675	0.584	rs4713666	chr6:33679061	A/G	cg15676125	chr6:33679581	C6orf125	0.42	5.45	0.33	1.25e-7	Plateletcrit;
KIRP	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.83	12.96	0.64	1.24e-29	Ulcerative colitis;
KIRP	cis	rs72848980	1.000	rs72848976	chr10:105312536	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.61	6.78	0.4	8.84e-11	White matter hyperintensity burden;
KIRP	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg07384165	chr1:10488281	NA	-0.41	-5.39	-0.33	1.61e-7	Breast size;
KIRP	cis	rs2154427	0.872	rs80098814	chr21:34133002	C/T	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.66	-5.41	-0.33	1.48e-7	Bilirubin levels;
KIRP	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.71	9.65	0.52	6.72e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.53e-22	Coronary artery disease;
KIRP	cis	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg24110177	chr3:50126178	RBM5	-0.42	-5.36	-0.32	1.9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.13	0.31	5.8e-7	Neuroticism;
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.41	-5.05	-0.31	8.67e-7	Longevity;Endometriosis;
KIRP	cis	rs35740288	0.770	rs11638379	chr15:86111290	G/T	cg17133734	chr15:86042851	AKAP13	-0.51	-5.54	-0.33	7.72e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.89	0.45	1.02e-13	Coffee consumption (cups per day);
KIRP	trans	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg24644049	chr4:85504048	CDS1	1.03	6.73	0.39	1.15e-10	Skin colour saturation;
KIRP	cis	rs6142102	0.517	rs8119076	chr20:32525715	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	5.46	0.33	1.18e-7	Skin pigmentation;
KIRP	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg16127683	chr15:40268777	EIF2AK4	0.48	5.55	0.33	7.27e-8	Corneal curvature;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg08254913	chr15:41836464	RPAP1	-0.47	-6.36	-0.38	9.51e-10	Morning vs. evening chronotype;
KIRP	cis	rs17039065	0.920	rs9790677	chr4:109443588	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.53	4.85	0.3	2.24e-6	Gut microbiome composition (summer);
KIRP	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg12369402	chr1:90227771	NA	-0.36	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7429990	0.901	rs6442102	chr3:48152562	A/G	cg11946769	chr3:48343235	NME6	-0.44	-5.35	-0.32	2.01e-7	Educational attainment (years of education);
KIRP	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	1.16	9.29	0.51	8.59e-18	LDL cholesterol;
KIRP	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg20415053	chr1:26527928	CATSPER4	-0.43	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs12982744	0.613	rs2238608	chr19:2145330	A/G	cg09261902	chr19:2140048	AP3D1	0.43	5.48	0.33	1.07e-7	Osteoarthritis;Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23031518	chr14:88851898	SPATA7	0.44	6.04	0.36	5.71e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.85	12.16	0.61	6.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	10.0	0.54	5.58e-20	Bone mineral density;
KIRP	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	4.85	0.3	2.17e-6	Renal cell carcinoma;
KIRP	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg03806693	chr22:41940476	POLR3H	-0.45	-5.37	-0.32	1.86e-7	Neuroticism;
KIRP	trans	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.61	6.81	0.4	7.33e-11	Obesity-related traits;
KIRP	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg13256891	chr4:100009986	ADH5	0.52	6.58	0.39	2.79e-10	Alcohol dependence;
KIRP	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.66	7.99	0.45	5.37e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.75	0.44	2.48e-13	Coffee consumption (cups per day);
KIRP	cis	rs2120243	0.539	rs7617727	chr3:157105558	A/C	cg24825693	chr3:157122686	VEPH1	0.57	9.43	0.52	3.31e-18	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.34	5.34	0.32	2.13e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.43	0.65	3.36e-31	Platelet count;
KIRP	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.55	5.58	0.34	6.23e-8	Platelet count;
KIRP	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg15320075	chr8:145703422	NA	0.67	8.68	0.48	5.54e-16	Age at first birth;
KIRP	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg09491104	chr22:46646882	C22orf40	-0.59	-7.73	-0.44	2.82e-13	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12113898	chr17:41150213	RPL27	-0.45	-6.19	-0.37	2.53e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.59e-8	Aortic root size;
KIRP	cis	rs2574975	0.708	rs2574981	chr10:52131568	C/T	cg10034176	chr10:52120283	SGMS1	-0.53	-7.23	-0.42	5.95e-12	Response to amphetamines;
KIRP	cis	rs8060686	0.858	rs6499143	chr16:67874264	T/C	cg26727032	chr16:67993705	SLC12A4	-0.8	-9.59	-0.52	1.07e-18	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg00938859	chr5:1591904	SDHAP3	0.58	7.71	0.44	3.1e-13	Breast cancer;
KIRP	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg00656387	chr3:40428638	ENTPD3	-0.37	-5.07	-0.31	7.92e-7	Renal cell carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11595155	chr19:37960414	ZNF570	0.43	6.5	0.38	4.5e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-0.9	-6.7	-0.39	1.45e-10	Mitochondrial DNA levels;
KIRP	cis	rs712039	0.652	rs11656503	chr17:35772021	G/T	cg16670864	chr17:35848621	DUSP14	0.47	5.78	0.35	2.3e-8	Tuberculosis;
KIRP	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.18	21.34	0.81	6.98e-58	Cognitive function;
KIRP	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg21427119	chr20:30132790	HM13	-0.53	-6.0	-0.36	6.93e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg19680485	chr15:31195859	MTMR15	0.4	5.17	0.31	4.96e-7	Huntington's disease progression;
KIRP	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg00405596	chr8:11794950	NA	-0.48	-6.27	-0.37	1.63e-9	Retinal vascular caliber;
KIRP	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.56	7.32	0.42	3.48e-12	Aortic root size;
KIRP	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.15	12.19	0.61	4.69e-27	Nonalcoholic fatty liver disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00213967	chr3:12851900	CAND2	0.45	6.37	0.38	9.37e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg00405596	chr8:11794950	NA	0.58	8.2	0.46	1.31e-14	Neuroticism;
KIRP	cis	rs6772849	0.930	rs1962040	chr3:128324161	G/A	cg08795948	chr3:128337044	NA	0.5	6.11	0.36	3.86e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05086178	chr16:2588345	PDPK1	0.5	6.44	0.38	6.26e-10	Parkinson's disease;
KIRP	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.52	-7.3	-0.42	3.95e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs62056376	0.736	rs2215185	chr17:32633902	C/T	cg17635953	chr13:28535085	NA	0.64	6.55	0.39	3.32e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.51	0.33	9.1e-8	Educational attainment;
KIRP	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07570687	chr10:102243282	WNT8B	0.51	6.26	0.37	1.74e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg21775007	chr8:11205619	TDH	-0.46	-5.76	-0.34	2.45e-8	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26463908	chr19:5680975	HSD11B1L;C19orf70	0.54	6.58	0.39	2.77e-10	Parkinson's disease;
KIRP	cis	rs12982744	0.613	rs25672	chr19:2138654	G/T	cg09261902	chr19:2140048	AP3D1	-0.44	-5.62	-0.34	5.04e-8	Osteoarthritis;Height;
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.79	-13.98	-0.67	4.42e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs16936870	0.543	rs9298156	chr8:71088548	C/T	cg14232793	chr8:71155543	NCOA2	-0.53	-6.13	-0.36	3.41e-9	QT interval;
KIRP	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.38	0.47	4.2e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1018697	1.000	rs1018697	chr10:104549224	C/A	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	15.0	0.69	1.47e-36	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.64	8.36	0.47	4.82e-15	Motion sickness;
KIRP	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.79	-12.21	-0.61	4.11e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg05484376	chr2:27715224	FNDC4	0.32	5.06	0.31	8.33e-7	Total body bone mineral density;
KIRP	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.91	14.59	0.68	3.81e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9810890	1.000	rs116772388	chr3:128453215	A/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg20169779	chr10:135381914	SYCE1	-0.55	-5.47	-0.33	1.09e-7	Gout;
KIRP	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg00277334	chr10:82204260	NA	0.56	5.19	0.31	4.42e-7	Post bronchodilator FEV1;
KIRP	cis	rs2411233	0.837	rs1897738	chr15:39261480	G/A	cg02291532	chr15:39874776	THBS1	0.47	6.11	0.36	3.97e-9	Platelet count;
KIRP	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg04672837	chr16:48644449	N4BP1	0.48	6.45	0.38	6.01e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-5.64	-0.34	4.71e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7590368	0.683	rs56121730	chr2:10960866	C/T	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg24807547	chr6:37504484	NA	0.48	7.15	0.42	9.6e-12	Cognitive performance;
KIRP	cis	rs12900413	0.562	rs2118849	chr15:90302399	G/T	cg24650279	chr15:90327240	NA	-0.41	-5.08	-0.31	7.51e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.99	0.36	7.31e-9	Motion sickness;
KIRP	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg08999081	chr20:33150536	PIGU	-0.4	-5.23	-0.32	3.56e-7	Height;
KIRP	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.46	0.52	2.63e-18	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	cg21523751	chr1:182988639	NA	0.42	6.43	0.38	6.44e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs3755132	0.929	rs16862799	chr2:15742260	G/A	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg17401720	chr7:158221031	PTPRN2	0.32	4.86	0.3	2.05e-6	Obesity-related traits;
KIRP	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.57	6.7	0.39	1.37e-10	Schizophrenia;
KIRP	cis	rs4523957	0.928	rs9899193	chr17:2156917	G/A	cg16513277	chr17:2031491	SMG6	0.58	8.04	0.46	3.74e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg00405596	chr8:11794950	NA	-0.41	-5.11	-0.31	6.5e-7	Triglycerides;
KIRP	cis	rs3026101	0.624	rs1058398	chr17:5288760	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.51	-6.64	-0.39	2.02e-10	Body mass index;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03518179	chr1:156470915	MEF2D	-0.47	-6.22	-0.37	2.11e-9	Myopia;
KIRP	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg21466736	chr12:48725269	NA	-0.53	-6.62	-0.39	2.28e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.6	-9.7	-0.53	4.91e-19	Lymphocyte counts;
KIRP	cis	rs2072732	0.861	rs12409277	chr1:2957600	A/G	cg11731671	chr1:2995604	PRDM16	-0.44	-5.49	-0.33	9.94e-8	Plateletcrit;
KIRP	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.54	6.35	0.38	1.04e-9	Obesity-related traits;
KIRP	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg02367144	chr2:237146137	ASB18	0.41	5.29	0.32	2.69e-7	Educational attainment;
KIRP	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.74	6.53	0.38	3.8e-10	Cognitive function;
KIRP	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	7.63	0.44	5.04e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg25173405	chr17:45401733	C17orf57	-0.45	-5.71	-0.34	3.28e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.4	-5.69	-0.34	3.65e-8	Renal function-related traits (BUN);
KIRP	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg17366294	chr4:99064904	C4orf37	-0.35	-4.93	-0.3	1.52e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.74	10.95	0.57	5.41e-23	Prudent dietary pattern;
KIRP	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.81	-0.35	1.95e-8	Height;
KIRP	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg10117171	chr1:25599238	RHD	0.38	5.21	0.32	4.01e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.52	0.48	1.58e-15	IgG glycosylation;
KIRP	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg00103785	chr1:155043322	NA	0.33	6.04	0.36	5.77e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.55	0.48	1.36e-15	Prudent dietary pattern;
KIRP	trans	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17183009	chr3:120277827	NA	0.52	6.04	0.36	5.72e-9	Corneal astigmatism;
KIRP	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.66	-8.96	-0.5	8.4e-17	Ear protrusion;
KIRP	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg01256987	chr12:42539512	GXYLT1	-0.45	-5.97	-0.36	8.15e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-0.85	-9.13	-0.5	2.55e-17	Gut microbiome composition (summer);
KIRP	cis	rs600806	0.672	rs1144593	chr1:110030945	A/G	cg23032129	chr1:109941072	SORT1	0.3	5.25	0.32	3.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg19847130	chr8:10466454	RP1L1	-0.34	-5.25	-0.32	3.37e-7	Neuroticism;
KIRP	cis	rs4006360	0.522	rs11871050	chr17:39236997	A/T	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.66	-0.48	6.38e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	1.03	14.21	0.67	7.47e-34	Menopause (age at onset);
KIRP	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg00278547	chr2:177037212	HOXD3	-0.37	-4.92	-0.3	1.57e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs712039	0.652	rs829160	chr17:35763091	T/A	cg16670864	chr17:35848621	DUSP14	0.42	5.03	0.31	9.52e-7	Tuberculosis;
KIRP	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg01620082	chr3:125678407	NA	-0.88	-6.43	-0.38	6.75e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.89e-31	Eye color traits;
KIRP	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg21466736	chr12:48725269	NA	-0.42	-5.18	-0.31	4.68e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.22	0.37	2.11e-9	Personality dimensions;
KIRP	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg15839431	chr19:19639596	YJEFN3	-0.47	-5.14	-0.31	5.63e-7	Bipolar disorder;
KIRP	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.7	-7.66	-0.44	4.2e-13	DNA methylation (variation);
KIRP	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg02551604	chr5:131831745	NA	-0.37	-5.01	-0.3	1.03e-6	Breast cancer;Mosquito bite size;
KIRP	cis	rs7113874	0.545	rs72855149	chr11:8607707	T/C	cg08015107	chr11:8618950	NA	-0.73	-8.74	-0.49	3.77e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00523012	chr19:13264324	IER2	-0.47	-6.02	-0.36	6.38e-9	Myopia;
KIRP	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg13047869	chr3:10149882	C3orf24	0.55	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.73	10.4	0.55	3.11e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.39	7.18	0.42	8.1e-12	Refractive error;
KIRP	cis	rs240764	0.658	rs10872634	chr6:101199579	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-5.47	-0.33	1.11e-7	Neuroticism;
KIRP	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-5.12	-0.31	6.31e-7	Vitiligo;
KIRP	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg25801113	chr15:45476975	SHF	-0.44	-8.18	-0.46	1.54e-14	Uric acid levels;
KIRP	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.59	7.72	0.44	2.88e-13	Height;
KIRP	cis	rs72634030	0.536	rs2309381	chr17:5268712	A/G	cg20802942	chr17:5185005	RABEP1	0.5	5.02	0.3	9.88e-7	Rheumatoid arthritis;
KIRP	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.49	-6.05	-0.36	5.4e-9	Menarche (age at onset);
KIRP	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg10223061	chr2:219282414	VIL1	-0.36	-5.98	-0.36	7.92e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg07827796	chr19:33622959	WDR88	0.42	4.92	0.3	1.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.41	-4.86	-0.3	2.12e-6	Resistin levels;
KIRP	cis	rs1215050	0.874	rs2167893	chr4:99048464	A/T	cg17366294	chr4:99064904	C4orf37	0.38	5.08	0.31	7.56e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.39	2.67e-10	Bipolar disorder;
KIRP	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.67	9.5	0.52	1.95e-18	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12163131	chr10:125754386	NA	0.58	7.28	0.42	4.5e-12	Parkinson's disease;
KIRP	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23598886	chr18:12777645	NA	0.74	6.09	0.36	4.28e-9	Inflammatory skin disease;
KIRP	cis	rs2150410	0.915	rs9978591	chr21:40620127	T/G	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	11.36	0.59	2.64e-24	Personality dimensions;
KIRP	cis	rs7923609	0.935	rs10995477	chr10:65010672	T/C	cg01631684	chr10:65280961	REEP3	-0.49	-5.73	-0.34	2.96e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	0.82	9.08	0.5	3.67e-17	Gut microbiome composition (summer);
KIRP	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	9.13	0.5	2.52e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.66	8.28	0.47	7.68e-15	Breast cancer;
KIRP	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.06	-16.75	-0.73	1.54e-42	Height;
KIRP	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg10255544	chr17:80519551	FOXK2	0.57	8.39	0.47	3.87e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs6893300	0.961	rs11744616	chr5:179209113	G/T	cg14593053	chr5:179126677	CANX	-0.56	-6.41	-0.38	7.21e-10	Resting heart rate;
KIRP	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg17507749	chr15:85114479	UBE2QP1	0.89	9.91	0.53	1.08e-19	Schizophrenia;
KIRP	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.65	-8.07	-0.46	3.19e-14	Multiple sclerosis;
KIRP	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	7.91	0.45	8.93e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs6601327	0.641	rs10096462	chr8:9614993	C/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.43	0.43	1.74e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg17764715	chr19:33622953	WDR88	0.61	7.52	0.43	9.97e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.76	-0.44	2.26e-13	Body mass index;
KIRP	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs6977660	0.714	rs10232870	chr7:19818040	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg05156742	chr15:59063176	FAM63B	0.52	6.16	0.37	2.9e-9	Schizophrenia;
KIRP	cis	rs74181299	0.520	rs11684110	chr2:65368290	A/G	cg05010058	chr2:65284262	CEP68	-0.46	-6.14	-0.36	3.33e-9	Pulse pressure;
KIRP	cis	rs1359582	0.813	rs1555840	chr10:90382790	G/T	cg15661332	chr10:90342814	RNLS	0.57	6.18	0.37	2.67e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2976388	0.935	rs2920284	chr8:143756919	A/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.53	-0.38	3.83e-10	Urinary tract infection frequency;
KIRP	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	6.18	0.37	2.58e-9	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.51	-0.43	1.12e-12	Life satisfaction;
KIRP	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.18	0.37	2.69e-9	Ovarian reserve;
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.79	-13.15	-0.64	2.89e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.57	7.52	0.43	1.02e-12	Mean corpuscular volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16866257	chr17:61905183	FTSJ3;PSMC5	0.53	6.34	0.37	1.07e-9	Smoking initiation;
KIRP	cis	rs6815814	0.904	rs67712706	chr4:38820616	A/G	cg06935464	chr4:38784597	TLR10	0.5	5.21	0.32	4.06e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18253101	chr19:709325	PALM	0.51	6.52	0.38	3.94e-10	Parkinson's disease;
KIRP	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02807482	chr3:125708958	NA	-0.57	-5.25	-0.32	3.22e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-7.48	-0.43	1.34e-12	Lymphocyte counts;
KIRP	cis	rs8032158	0.963	rs1912402	chr15:56161919	C/T	cg02198044	chr15:56286336	NEDD4	-0.41	-4.89	-0.3	1.84e-6	Keloid;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22091297	chr13:24153504	TNFRSF19	0.48	6.04	0.36	5.66e-9	Parkinson's disease;
KIRP	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.39	8.29	0.47	7.54e-15	IgG glycosylation;
KIRP	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.39	-4.89	-0.3	1.83e-6	Neutrophil percentage of white cells;
KIRP	trans	rs2048656	0.578	rs925610	chr8:9681836	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.44	-0.43	1.65e-12	Schizophrenia;
KIRP	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg00277334	chr10:82204260	NA	-0.45	-5.1	-0.31	6.73e-7	Post bronchodilator FEV1;
KIRP	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg02336718	chr17:17403227	NA	-0.36	-5.35	-0.32	1.99e-7	Total body bone mineral density;
KIRP	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg15128208	chr22:42549153	NA	0.52	5.22	0.32	3.88e-7	Birth weight;
KIRP	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg08885076	chr2:99613938	TSGA10	-0.45	-6.66	-0.39	1.78e-10	Fear of minor pain;
KIRP	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg12315302	chr6:26189340	HIST1H4D	1.04	6.11	0.36	3.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.84	-12.73	-0.63	7.36e-29	Monocyte percentage of white cells;
KIRP	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.73	9.39	0.51	4.37e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.37	0.65	5.21e-31	Platelet count;
KIRP	cis	rs3857747	0.931	rs11767708	chr7:40364316	A/G	cg00420559	chr7:40367873	C7orf10	-0.6	-8.46	-0.47	2.37e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.47	-6.99	-0.41	2.59e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.82	13.6	0.66	8.84e-32	Longevity;
KIRP	cis	rs9311676	0.656	rs10866016	chr3:58390844	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	trans	rs263156	0.903	rs263126	chr6:142935915	T/C	cg01789478	chr2:182545485	NEUROD1	0.35	6.09	0.36	4.21e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs8062405	0.721	rs151303	chr16:28492510	C/A	cg00931491	chr16:28608288	SULT1A2	-0.26	-4.93	-0.3	1.51e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18743034	chr11:124539453	SIAE	0.44	6.06	0.36	5.13e-9	Interleukin-4 levels;
KIRP	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	-0.65	-4.95	-0.3	1.41e-6	Childhood ear infection;
KIRP	cis	rs631288	0.655	rs4245679	chr1:146710504	C/A	cg25205988	chr1:146714368	CHD1L	0.86	5.11	0.31	6.56e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.47	5.32	0.32	2.38e-7	Schizophrenia;
KIRP	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg18833306	chr6:118973337	C6orf204	0.39	4.93	0.3	1.51e-6	Electrocardiographic conduction measures;
KIRP	cis	rs7173743	1.000	rs4438276	chr15:79138565	A/G	cg00079375	chr15:79125835	NA	-0.41	-5.87	-0.35	1.37e-8	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.84	0.35	1.63e-8	Aortic root size;
KIRP	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.64	7.24	0.42	5.65e-12	Corneal astigmatism;
KIRP	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg00631329	chr6:26305371	NA	-0.73	-9.26	-0.51	1.06e-17	Educational attainment;
KIRP	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.0	-0.57	3.62e-23	Height;
KIRP	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg05692746	chr2:100937584	LONRF2	-0.39	-5.03	-0.31	9.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8077577	0.747	rs11867895	chr17:18146721	A/C	cg18869244	chr17:18121946	NA	0.47	5.28	0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg21186296	chr8:27182909	PTK2B	0.48	6.18	0.37	2.57e-9	Neuroticism;
KIRP	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg11965913	chr1:205819406	PM20D1	-0.61	-5.98	-0.36	7.75e-9	Menarche (age at onset);
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg04025307	chr7:1156635	C7orf50	0.74	7.59	0.44	6.57e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg21784768	chr11:537496	LRRC56	-0.59	-4.97	-0.3	1.24e-6	Body mass index;
KIRP	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.66	0.39	1.81e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg00645731	chr22:42541494	CYP2D7P1	-0.5	-5.42	-0.33	1.45e-7	Birth weight;
KIRP	cis	rs6601327	0.600	rs10103925	chr8:9652211	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-4.92	-0.3	1.6e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17554472	chr22:41940697	POLR3H	0.57	6.27	0.37	1.61e-9	Vitiligo;
KIRP	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.2	-0.51	1.6e-17	Chronic sinus infection;
KIRP	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg04780086	chr2:111875790	ACOXL	0.46	6.33	0.37	1.14e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.58	7.24	0.42	5.83e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7538876	0.967	rs6678552	chr1:17720391	G/A	cg07965774	chr1:17746286	RCC2	0.28	4.89	0.3	1.81e-6	Basal cell carcinoma;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg06577604	chr3:184279443	EPHB3	0.51	6.39	0.38	8.44e-10	Sleep duration;
KIRP	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg24315340	chr6:146058215	EPM2A	-0.38	-4.99	-0.3	1.17e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg15896084	chr13:114927664	NA	0.45	6.18	0.37	2.61e-9	Schizophrenia;
KIRP	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.56	-6.8	-0.4	7.87e-11	Uric acid levels;
KIRP	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15750696	chr6:56507601	DST	0.39	6.04	0.36	5.71e-9	Survival in pancreatic cancer;
KIRP	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.52	6.75	0.4	1.06e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.73	8.98	0.5	7.44e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-4.99	-0.3	1.15e-6	Height;
KIRP	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg25182066	chr10:30743637	MAP3K8	-0.64	-8.7	-0.49	4.72e-16	Inflammatory bowel disease;
KIRP	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg03678062	chr6:149772716	ZC3H12D	0.36	5.62	0.34	5.27e-8	Dupuytren's disease;
KIRP	cis	rs4700695	0.841	rs706681	chr5:65317913	G/T	cg21114390	chr5:65439923	SFRS12	0.55	5.31	0.32	2.47e-7	Facial morphology (factor 19);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg08492707	chr21:34696952	IFNAR1	-0.45	-6.47	-0.38	5.11e-10	Morning vs. evening chronotype;
KIRP	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.63	-0.34	4.83e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.62	-0.66	7.52e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.44	7.73	0.44	2.79e-13	Systemic lupus erythematosus;
KIRP	cis	rs970548	0.606	rs12355888	chr10:45931564	G/T	cg15590007	chr10:45870220	ALOX5	0.71	6.48	0.38	4.99e-10	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06481639	chr22:41940642	POLR3H	0.68	6.9	0.4	4.29e-11	Vitiligo;
KIRP	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg00319359	chr11:70116639	PPFIA1	0.8	6.97	0.41	2.93e-11	Coronary artery disease;
KIRP	cis	rs7116495	1.000	rs1939245	chr11:71742532	C/T	cg18441811	chr11:71824068	C11orf51	-0.63	-5.07	-0.31	7.7e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.68	-9.79	-0.53	2.5e-19	Lymphocyte counts;
KIRP	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.39	5.52	0.33	8.42e-8	Bipolar disorder;
KIRP	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-6.6	-0.39	2.51e-10	Systemic lupus erythematosus;
KIRP	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.66	7.97	0.45	5.85e-14	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.73	-9.29	-0.51	8.71e-18	Life satisfaction;
KIRP	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	1.0	14.34	0.67	2.59e-34	Monocyte count;
KIRP	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg00507259	chr4:95128692	SMARCAD1	0.4	5.12	0.31	6.06e-7	QT interval;
KIRP	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg25281562	chr12:121454272	C12orf43	0.55	6.07	0.36	4.81e-9	N-glycan levels;
KIRP	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg22563815	chr15:78856949	CHRNA5	-0.46	-6.91	-0.4	4.15e-11	Sudden cardiac arrest;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.45	-5.68	-0.34	3.86e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.38	-0.32	1.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg16590910	chr6:42928470	GNMT	-0.41	-5.78	-0.35	2.25e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.63	-0.39	2.16e-10	Body mass index;
KIRP	cis	rs6580649	0.941	rs4760677	chr12:48449163	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.5	-6.5	-0.38	4.45e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg19547200	chr22:42896249	SERHL	-0.4	-6.19	-0.37	2.44e-9	Ischemic stroke;
KIRP	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.12	-0.36	3.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.58	8.01	0.45	4.57e-14	Brugada syndrome;
KIRP	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	5.02	0.3	9.96e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg24881330	chr22:46731750	TRMU	0.74	5.22	0.32	3.87e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.89	-12.91	-0.64	1.9e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg09137382	chr11:130731461	NA	0.5	7.18	0.42	8.3e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg09873164	chr1:152488093	CRCT1	0.57	7.21	0.42	7.06e-12	Hair morphology;
KIRP	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg12560992	chr17:57184187	TRIM37	0.58	5.07	0.31	7.87e-7	Cognitive test performance;
KIRP	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12292205	chr6:26970375	C6orf41	-0.61	-6.88	-0.4	4.8e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.52	6.55	0.39	3.34e-10	Migraine;
KIRP	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	1.0	18.67	0.77	4.88e-49	Parkinson's disease;
KIRP	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg19875535	chr5:140030758	IK	-0.56	-6.97	-0.41	2.9100000000000002e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg26751094	chr13:95954534	ABCC4	-0.7	-9.74	-0.53	3.65e-19	Blood metabolite levels;
KIRP	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg00684032	chr4:1343700	KIAA1530	0.46	5.44	0.33	1.26e-7	Longevity;
KIRP	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	8.04	0.46	3.85e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg13607699	chr17:42295918	UBTF	0.47	5.87	0.35	1.41e-8	Total body bone mineral density;
KIRP	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg01280390	chr8:19363452	CSGALNACT1	0.45	6.11	0.36	3.94e-9	Oropharynx cancer;
KIRP	cis	rs4849845	0.704	rs4848580	chr2:121001117	A/G	cg24070213	chr2:121070622	NA	-0.37	-5.58	-0.34	6.17e-8	Mean platelet volume;
KIRP	cis	rs7542091	0.648	rs688464	chr1:209992539	C/T	cg23166289	chr1:210001082	C1orf107	0.41	5.26	0.32	3.17e-7	Monobrow;
KIRP	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.76	6.52	0.38	4.05e-10	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg15226275	chr6:116381976	FRK	0.21	5.92	0.35	1.09e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg10018233	chr7:150070692	REPIN1	0.58	7.48	0.43	1.29e-12	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs9309473	0.898	rs9807961	chr2:73694043	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.31	-0.37	1.27e-9	Metabolite levels;
KIRP	cis	rs6466055	0.591	rs67505443	chr7:104893335	C/T	cg04380332	chr7:105027541	SRPK2	0.38	5.21	0.32	3.92e-7	Schizophrenia;
KIRP	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg00792783	chr2:198669748	PLCL1	0.45	5.05	0.31	8.78e-7	Dermatomyositis;
KIRP	cis	rs2483519	0.806	rs1041623	chr10:116377998	C/T	cg13761818	chr10:116473420	NA	0.42	4.96	0.3	1.33e-6	Paclitaxel disposition in epithelial ovarian cancer;
KIRP	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	trans	rs877282	0.583	rs12356155	chr10:823940	C/T	cg22713356	chr15:30763199	NA	0.86	8.39	0.47	3.9e-15	Uric acid levels;
KIRP	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg03808351	chr9:123631620	PHF19	0.45	6.31	0.37	1.3e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.43	-5.31	-0.32	2.51e-7	Aortic root size;
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.46	0.7	4.07e-38	Platelet count;
KIRP	cis	rs12643440	0.960	rs2056391	chr4:17204014	C/G	cg22650099	chr4:17144496	NA	-0.5	-6.05	-0.36	5.22e-9	Metabolite levels (Pyroglutamine);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg10586903	chr19:41221192	ADCK4	0.66	6.13	0.36	3.44e-9	Lung function (FEV1);
KIRP	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.77	9.49	0.52	2.18e-18	Birth weight;
KIRP	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.09	-15.02	-0.69	1.26e-36	Body mass index;
KIRP	cis	rs7546094	0.875	rs7522288	chr1:113151205	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	5.73	0.34	2.96e-8	Platelet distribution width;
KIRP	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.39	8.23	0.46	1.08e-14	Body mass index;
KIRP	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.1	0.31	6.85e-7	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg08662619	chr6:150070041	PCMT1	0.37	6.07	0.36	4.72e-9	Lung cancer;
KIRP	cis	rs4363385	0.510	rs6689510	chr1:153048039	G/A	cg07796016	chr1:152779584	LCE1C	-0.46	-5.89	-0.35	1.3e-8	Inflammatory skin disease;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.36	-0.51	5.35e-18	Platelet count;
KIRP	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.81	-10.09	-0.54	2.89e-20	Coronary artery disease;
KIRP	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-1.03	-19.46	-0.78	1.05e-51	Height;
KIRP	cis	rs7927370	0.541	rs7932242	chr11:55617171	T/A	cg07850316	chr11:56344833	OR5M10;OR8U8	0.69	5.26	0.32	3.07e-7	Systemic lupus erythematosus;
KIRP	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.6	5.37	0.32	1.85e-7	Alzheimer's disease;
KIRP	trans	rs7863100	0.711	rs13286662	chr9:18650137	C/T	cg13196806	chr10:133996309	JAKMIP3	0.6	6.11	0.36	3.93e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg18357526	chr6:26021779	HIST1H4A	0.43	5.75	0.34	2.64e-8	Height;
KIRP	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg15848620	chr12:58087721	OS9	-0.5	-5.77	-0.35	2.38e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg20387954	chr3:183756860	HTR3D	0.46	6.54	0.38	3.48e-10	Anterior chamber depth;
KIRP	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.54	7.63	0.44	4.99e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg24375607	chr4:120327624	NA	0.57	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.77	0.44	2.12e-13	Aortic root size;
KIRP	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	cg04338863	chr8:33670619	NA	0.47	6.22	0.37	2.17e-9	Body mass index;
KIRP	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg23307798	chr14:103986281	CKB	0.78	13.92	0.66	7.09e-33	Body mass index;
KIRP	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.71	10.43	0.55	2.52e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	1.01	11.03	0.58	3.07e-23	Blood protein levels;
KIRP	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.98	9.31	0.51	7.56e-18	Cognitive function;
KIRP	cis	rs6987853	0.901	rs2974344	chr8:42400732	T/G	cg09913449	chr8:42400586	C8orf40	0.37	4.9	0.3	1.75e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05232067	chr8:26240888	BNIP3L	0.56	6.73	0.39	1.18e-10	Smoking initiation;
KIRP	cis	rs16986825	0.714	rs5762857	chr22:29247097	A/G	cg02153584	chr22:29168773	CCDC117	0.59	5.09	0.31	7.27e-7	Pancreatic cancer;
KIRP	cis	rs7577293	1.000	rs7603438	chr2:85935182	A/G	cg19805943	chr2:85933069	NA	-0.42	-5.25	-0.32	3.24e-7	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg07701084	chr6:150067640	NUP43	0.53	6.82	0.4	7.21e-11	Lung cancer;
KIRP	cis	rs1962073	0.529	rs13258627	chr8:10274578	T/C	cg19847130	chr8:10466454	RP1L1	-0.36	-5.12	-0.31	6.28e-7	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg13010199	chr12:38710504	ALG10B	0.47	6.11	0.36	3.85e-9	Morning vs. evening chronotype;
KIRP	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.43	5.47	0.33	1.11e-7	High light scatter reticulocyte count;
KIRP	cis	rs7336332	0.517	rs9581842	chr13:27978953	G/C	cg22138327	chr13:27999177	GTF3A	0.8	7.13	0.41	1.09e-11	Weight;
KIRP	cis	rs612683	0.536	rs12042531	chr1:100965942	G/A	cg09408571	chr1:101003634	GPR88	-0.31	-7.5	-0.43	1.19e-12	Breast cancer;
KIRP	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	4.91	0.3	1.66e-6	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26598388	chr17:16284909	UBB	0.46	6.26	0.37	1.69e-9	Survival in pancreatic cancer;
KIRP	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.37	0.65	5.08e-31	Personality dimensions;
KIRP	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg11833968	chr6:79620685	NA	-0.45	-7.0	-0.41	2.44e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11987759	chr7:65425863	GUSB	-0.61	-8.08	-0.46	2.89e-14	Aortic root size;
KIRP	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg05973401	chr12:123451056	ABCB9	-0.55	-6.34	-0.37	1.1e-9	Neutrophil percentage of white cells;
KIRP	cis	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg08496016	chr9:99181722	ZNF367	-0.49	-4.95	-0.3	1.37e-6	Neuroticism;
KIRP	cis	rs9826463	0.582	rs73238155	chr3:142073145	G/A	cg20824294	chr3:142316082	PLS1	0.43	6.23	0.37	2.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.99	-20.65	-0.8	1.27e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.53	-0.43	9.91e-13	Response to antipsychotic treatment;
KIRP	cis	rs9912468	0.933	rs35105653	chr17:64321521	G/A	cg19474267	chr17:64306194	PRKCA	0.65	8.95	0.5	8.83e-17	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg24060327	chr5:131705240	SLC22A5	-0.55	-7.33	-0.42	3.34e-12	Acylcarnitine levels;
KIRP	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.84	0.4	6.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4006360	0.553	rs71383383	chr17:39318172	T/A	cg25341923	chr17:39239918	KRTAP4-7	0.41	5.76	0.34	2.46e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07421028	chr16:30406949	ZNF48	0.51	6.39	0.38	8.05e-10	Parkinson's disease;
KIRP	trans	rs913655	0.777	rs2495845	chr10:19127973	C/G	cg27106950	chr16:11367916	PRM3	-0.56	-6.14	-0.36	3.3e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
KIRP	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.74	9.87	0.53	1.4e-19	Squamous cell carcinoma;
KIRP	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg08847533	chr14:75593920	NEK9	0.52	6.2	0.37	2.36e-9	IgG glycosylation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23359706	chr19:11491839	EPOR	0.52	6.7	0.39	1.41e-10	Smoking initiation;
KIRP	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.95	-16.52	-0.73	9.05e-42	Multiple myeloma;
KIRP	cis	rs2387326	0.717	rs10829340	chr10:129943941	G/T	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.39	-0.51	4.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7542091	0.704	rs7550330	chr1:210044587	G/A	cg05527609	chr1:210001259	C1orf107	-0.37	-4.95	-0.3	1.41e-6	Monobrow;
KIRP	cis	rs7520050	0.966	rs785492	chr1:46583607	G/A	cg03146154	chr1:46216737	IPP	-0.41	-5.25	-0.32	3.22e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.58	-0.44	7.11e-13	Bladder cancer;
KIRP	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.84	-14.17	-0.67	9.71e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.55	7.22	0.42	6.32e-12	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs2916247	1.000	rs13250170	chr8:93035331	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.54	-0.48	1.42e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg04369109	chr6:150039330	LATS1	-0.65	-8.57	-0.48	1.14e-15	Lung cancer;
KIRP	cis	rs17020663	0.771	rs10451616	chr2:101613603	G/A	cg15506514	chr2:101638852	TBC1D8	-0.54	-5.25	-0.32	3.33e-7	Pulse pressure;
KIRP	cis	rs4740619	0.682	rs1887664	chr9:16003597	A/G	cg14451791	chr9:16040625	NA	-0.4	-5.12	-0.31	6.12e-7	Body mass index;
KIRP	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg19116668	chr7:99932089	PMS2L1	0.47	5.5	0.33	9.53e-8	Coronary artery disease;
KIRP	cis	rs2151522	0.603	rs9372849	chr6:127196571	T/C	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs654128	0.614	rs72963952	chr6:117131164	G/A	cg12892004	chr6:117198278	RFX6	0.52	5.27	0.32	2.92e-7	Telomere length;
KIRP	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06544989	chr22:39130855	UNC84B	0.5	8.85	0.49	1.72e-16	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs4789452	0.902	rs4789454	chr17:75375199	C/T	cg02320862	chr17:75370284	SEPT9	-0.36	-5.01	-0.3	1.04e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg00631329	chr6:26305371	NA	-0.65	-8.32	-0.47	6.18e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.59	-8.1	-0.46	2.64e-14	Diastolic blood pressure;
KIRP	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.07	0.31	7.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg02820040	chr2:241836501	C2orf54	0.25	5.3	0.32	2.52e-7	Urinary metabolites;
KIRP	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg14228332	chr4:119757509	SEC24D	0.76	4.86	0.3	2.09e-6	Cannabis dependence symptom count;
KIRP	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.02	-0.36	6.39e-9	Triglycerides;
KIRP	cis	rs1254309	1	rs1254309	chr14:60890422	A/G	cg27398547	chr14:60952738	C14orf39	-0.39	-5.19	-0.31	4.32e-7	Menarche (age at onset);
KIRP	trans	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg01620082	chr3:125678407	NA	-0.93	-6.7	-0.39	1.45e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg16926213	chr1:1841314	NA	0.31	5.29	0.32	2.7e-7	Body mass index;
KIRP	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.95e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs896543	1.000	rs896543	chr2:237509207	A/G	cg25295825	chr2:237489920	CXCR7	-0.67	-10.01	-0.54	5.33e-20	Alcohol dependence (age at onset);
KIRP	cis	rs4740619	0.590	rs10810519	chr9:16029411	G/C	cg14451791	chr9:16040625	NA	-0.41	-5.39	-0.33	1.61e-7	Body mass index;
KIRP	cis	rs2041895	0.565	rs10861679	chr12:107322915	T/C	cg15890332	chr12:107067104	RFX4	0.36	5.13	0.31	5.99e-7	Glaucoma (low intraocular pressure);
KIRP	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.6	-7.4	-0.43	2.16e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.3	-0.37	1.4e-9	IgG glycosylation;
KIRP	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg26068271	chr17:76253126	NA	0.65	8.26	0.47	8.81e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs12042938	0.507	rs1655303	chr1:231731439	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.04	-0.54	4.11e-20	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.83	11.73	0.6	1.59e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg13512537	chr8:22265999	SLC39A14	-0.44	-6.05	-0.36	5.25e-9	Verbal declarative memory;
KIRP	cis	rs2033732	0.601	rs12681446	chr8:85033238	G/A	cg05716166	chr8:85095498	RALYL	0.51	4.86	0.3	2.13e-6	Body mass index;
KIRP	cis	rs580438	1.000	rs580438	chr3:13345450	C/T	cg10657019	chr3:13328039	NA	0.71	9.27	0.51	9.59e-18	Myringotomy;
KIRP	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg26248373	chr2:1572462	NA	-0.62	-5.82	-0.35	1.86e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs12517041	1.000	rs71611219	chr5:23280981	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.86	-7.94	-0.45	7.27e-14	Calcium levels;
KIRP	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.65	-10.11	-0.54	2.55e-20	Hip circumference;Waist circumference;
KIRP	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.54	-6.87	-0.4	5.13e-11	White blood cell count;
KIRP	cis	rs2072732	0.861	rs3795262	chr1:2938697	A/C	cg11731671	chr1:2995604	PRDM16	-0.43	-4.99	-0.3	1.14e-6	Plateletcrit;
KIRP	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg27211696	chr2:191398769	TMEM194B	-0.74	-8.8	-0.49	2.41e-16	Diastolic blood pressure;
KIRP	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg05340658	chr4:99064831	C4orf37	-0.56	-6.76	-0.4	9.73e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs490234	0.812	rs13286111	chr9:128429951	A/T	cg14078157	chr9:128172775	NA	-0.63	-7.67	-0.44	4.13e-13	Mean arterial pressure;
KIRP	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.27e-12	Prudent dietary pattern;
KIRP	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.18	-0.31	4.66e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.88	-0.63	2.4e-29	Electrocardiographic conduction measures;
KIRP	cis	rs7615316	0.603	rs13091966	chr3:141956613	T/C	cg20824294	chr3:142316082	PLS1	0.23	5.2	0.31	4.18e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7224685	0.569	rs35586982	chr17:4001993	G/A	cg09695851	chr17:3907499	NA	0.54	5.14	0.31	5.72e-7	Type 2 diabetes;
KIRP	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg06027949	chr8:82754900	SNX16	0.61	6.6	0.39	2.56e-10	Diastolic blood pressure;
KIRP	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg02297831	chr4:17616191	MED28	0.59	7.54	0.43	8.98e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.57	0.48	1.13e-15	Motion sickness;
KIRP	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg24009623	chr19:33667908	NA	0.47	5.73	0.34	2.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg17554472	chr22:41940697	POLR3H	-0.56	-6.15	-0.36	3.19e-9	Vitiligo;
KIRP	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg25664220	chr3:72788482	NA	-0.35	-5.13	-0.31	6e-7	Motion sickness;
KIRP	cis	rs796364	0.616	rs769955	chr2:200692595	C/T	cg17644776	chr2:200775616	C2orf69	0.57	5.29	0.32	2.7e-7	Schizophrenia;
KIRP	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.44	-9.03	-0.5	5.14e-17	Longevity;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11342046	chr2:242641489	ING5	0.52	6.72	0.39	1.24e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.1	0.61	9.51e-27	Bone mineral density;
KIRP	cis	rs77688320	0.517	rs12623282	chr2:202247457	G/C	cg06431681	chr2:202330990	STRADB	0.51	6.78	0.4	9.02e-11	Breast cancer;
KIRP	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27297192	chr10:134578999	INPP5A	0.63	7.66	0.44	4.3e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.02	0.36	6.19e-9	Mean platelet volume;
KIRP	cis	rs4664293	0.867	rs4665110	chr2:160587525	C/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.78	0.35	2.28e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg24476569	chr13:95954382	ABCC4	-0.6	-9.23	-0.51	1.26e-17	Blood metabolite levels;
KIRP	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26879891	chr1:152191343	HRNR	-0.48	-6.78	-0.4	8.7e-11	Inflammatory skin disease;
KIRP	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs55788414	0.932	rs2317119	chr16:81182854	T/C	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs62413470	0.872	rs12212998	chr6:55939530	C/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs16854884	1.000	rs34639473	chr3:143821293	T/A	cg06585982	chr3:143692056	C3orf58	0.48	4.95	0.3	1.35e-6	Economic and political preferences (feminism/equality);
KIRP	cis	rs11673344	0.526	rs73035160	chr19:38146036	G/A	cg14683738	chr19:37701593	ZNF585B	-0.44	-5.34	-0.32	2.12e-7	Obesity-related traits;
KIRP	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00149659	chr3:10157352	C3orf10	0.58	7.03	0.41	1.97e-11	Alzheimer's disease;
KIRP	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.88	10.41	0.55	2.81e-21	Gut microbiome composition (summer);
KIRP	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-9.14	-0.5	2.37e-17	Resting heart rate;
KIRP	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.55	-6.99	-0.41	2.53e-11	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04293876	chr10:99400850	PI4K2A	0.51	6.24	0.37	1.9e-9	Parkinson's disease;
KIRP	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg04490037	chr7:50633773	DDC	0.36	4.91	0.3	1.65e-6	Body mass index;
KIRP	cis	rs9303542	0.559	rs12938390	chr17:46614722	T/C	cg04904318	chr17:46607828	HOXB1	-0.62	-6.7	-0.39	1.38e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1978968	0.763	rs35276871	chr22:18459040	C/T	cg03078520	chr22:18463400	MICAL3	-0.8	-10.23	-0.55	1.04e-20	Presence of antiphospholipid antibodies;
KIRP	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.57	7.23	0.42	5.97e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg06012730	chr15:75315579	PPCDC	-0.4	-4.99	-0.3	1.13e-6	Blood trace element (Zn levels);
KIRP	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg08501292	chr6:25962987	TRIM38	1.12	8.07	0.46	3.2e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs988913	1.000	rs6929930	chr6:54812710	G/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.57	-0.33	6.59e-8	Menarche (age at onset);
KIRP	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.54	-0.33	7.68e-8	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14676166	chr22:38245522	EIF3L	0.47	6.22	0.37	2.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg23682824	chr7:23144976	KLHL7	0.54	6.5	0.38	4.48e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	12.98	0.64	1.06e-29	Platelet count;
KIRP	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.68	0.48	5.5e-16	Prudent dietary pattern;
KIRP	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg04865290	chr3:52927548	TMEM110	-0.62	-6.82	-0.4	6.98e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07145255	chr5:59995354	DEPDC1B	0.63	7.71	0.44	3.09e-13	Smoking initiation;
KIRP	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.74	9.23	0.51	1.29e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.49	6.43	0.38	6.53e-10	High light scatter reticulocyte count;
KIRP	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg17133734	chr15:86042851	AKAP13	-0.46	-5.84	-0.35	1.6e-8	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg05562828	chr17:3906858	NA	-0.54	-5.51	-0.33	9.16e-8	Type 2 diabetes;
KIRP	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	6.97	0.41	2.9e-11	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.67	-9.9	-0.53	1.17e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.21	-0.51	1.5e-17	Retinal vascular caliber;
KIRP	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.42	-4.98	-0.3	1.22e-6	Crohn's disease;
KIRP	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.78	11.53	0.59	7.11e-25	Total body bone mineral density;
KIRP	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg24879335	chr3:133465180	TF	-0.32	-5.03	-0.31	9.67e-7	Iron status biomarkers;
KIRP	cis	rs9603616	0.719	rs6563737	chr13:40233966	C/A	cg26701198	chr13:40229707	COG6	0.44	5.25	0.32	3.24e-7	Rheumatoid arthritis;
KIRP	cis	rs7188697	0.882	rs37054	chr16:58558989	C/T	cg21335942	chr16:58549945	SETD6	0.46	5.13	0.31	5.89e-7	QT interval;
KIRP	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-0.97	-8.96	-0.5	8.39e-17	Blood pressure (smoking interaction);
KIRP	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg09455208	chr3:40491958	NA	0.35	6.12	0.36	3.58e-9	Renal cell carcinoma;
KIRP	trans	rs10825741	0.756	rs2002031	chr10:57954989	A/G	cg09141856	chr16:5498227	NA	0.54	6.59	0.39	2.59e-10	Night sleep phenotypes;
KIRP	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg00852783	chr1:26633632	UBXN11	0.54	7.77	0.44	2.18e-13	Obesity-related traits;
KIRP	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg00579200	chr11:133705235	NA	0.4	5.11	0.31	6.57e-7	Childhood ear infection;
KIRP	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg00321850	chr1:175162397	KIAA0040	0.3	5.27	0.32	3.01e-7	Alcohol dependence;
KIRP	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.77	9.15	0.5	2.26e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs12200560	0.505	rs12192623	chr6:97081432	A/G	cg06623918	chr6:96969491	KIAA0776	-0.53	-6.7	-0.39	1.44e-10	Coronary heart disease;
KIRP	cis	rs505401	0.504	rs114349183	chr19:6119517	G/A	cg18109231	chr19:6110877	RFX2	0.83	5.34	0.32	2.08e-7	Mean platelet volume;
KIRP	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg00405596	chr8:11794950	NA	0.47	5.85	0.35	1.57e-8	Retinal vascular caliber;
KIRP	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg21132104	chr15:45694354	SPATA5L1	0.59	7.27	0.42	4.71e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg07274523	chr3:49395745	GPX1	0.72	8.8	0.49	2.55e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19314403	chr19:35225114	ZNF181	0.52	6.64	0.39	1.94e-10	Parkinson's disease;
KIRP	cis	rs4689642	0.756	rs4689091	chr4:7226892	G/A	cg21353189	chr4:7228343	SORCS2	0.42	5.54	0.33	7.89e-8	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg22604316	chr1:46958801	NA	-0.35	-5.08	-0.31	7.42e-7	Monobrow;
KIRP	cis	rs9653442	0.545	rs1821826	chr2:100764711	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs17065868	1.000	rs9533906	chr13:45129094	G/A	cg10246903	chr13:45222710	NA	0.69	6.47	0.38	5.38e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs7289126	1.000	rs8142686	chr22:38634266	C/T	cg25457927	chr22:38595422	NA	-0.31	-6.85	-0.4	5.83e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg27211696	chr2:191398769	TMEM194B	-0.54	-6.45	-0.38	5.83e-10	Diastolic blood pressure;
KIRP	cis	rs10029851	0.704	rs1436506	chr4:109630951	C/T	cg16525761	chr4:109541525	LOC285456;RPL34	-0.49	-5.44	-0.33	1.3e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9913711	0.899	rs9913936	chr17:70074148	A/G	cg09344028	chr17:70110421	NA	0.38	7.52	0.43	1.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2644899	0.715	rs2607415	chr19:41262687	C/G	cg24958765	chr19:41283667	RAB4B	-0.62	-7.01	-0.41	2.33e-11	Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03765846	chr3:160681137	PPM1L	0.47	6.83	0.4	6.77e-11	Interleukin-4 levels;
KIRP	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg21253087	chr9:139290292	SNAPC4	-0.47	-6.57	-0.39	3.01e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.35e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.6	-0.34	5.67e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs10540	0.541	rs7482356	chr11:437088	T/C	cg19913688	chr11:428466	ANO9	0.93	8.24	0.47	1.01e-14	Body mass index;
KIRP	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.69	-8.0	-0.45	4.92e-14	Hirschsprung disease;
KIRP	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.85	12.89	0.63	2.18e-29	Total body bone mineral density;
KIRP	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.71e-36	Prostate cancer;
KIRP	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.82	-0.35	1.82e-8	Menarche (age at onset);
KIRP	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.62	-8.92	-0.49	1.1e-16	Weight;
KIRP	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg10047753	chr17:41438598	NA	1.12	17.9	0.75	1.83e-46	Menopause (age at onset);
KIRP	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.47	-6.44	-0.38	6.18e-10	Testicular germ cell tumor;
KIRP	cis	rs7404928	1.000	rs3826258	chr16:23903552	C/T	cg21745164	chr16:23765304	CHP2	-0.36	-5.16	-0.31	4.99e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs2425143	0.514	rs8114246	chr20:34581979	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-5.18	-0.31	4.53e-7	Blood protein levels;
KIRP	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg10932868	chr11:921992	NA	0.56	6.93	0.4	3.73e-11	Alzheimer's disease (late onset);
KIRP	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.62	-7.52	-0.43	1.01e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg26373071	chr5:1325741	CLPTM1L	0.52	7.15	0.41	9.76e-12	Lung cancer;
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg09699651	chr6:150184138	LRP11	0.47	6.21	0.37	2.24e-9	Lung cancer;
KIRP	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg00074818	chr8:8560427	CLDN23	0.36	6.0	0.36	7.04e-9	Obesity-related traits;
KIRP	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.53	-0.43	9.59e-13	Eye color traits;
KIRP	cis	rs8077577	0.945	rs62073608	chr17:18071448	T/C	cg18869244	chr17:18121946	NA	0.48	5.45	0.33	1.2e-7	Obesity-related traits;
KIRP	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.38	-0.47	3.98e-15	Total cholesterol levels;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg15040075	chr2:232379222	C2orf52	-1.08	-6.03	-0.36	6.04e-9	Thrombomodulin levels in ischemic stroke;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26687565	chr4:141072046	MAML3	0.44	6.02	0.36	6.4e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-9.45	-0.52	2.72e-18	Platelet count;
KIRP	trans	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg10756647	chr7:56101905	PSPH	1.02	7.46	0.43	1.53e-12	Diabetic kidney disease;
KIRP	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.73	0.34	2.92e-8	Lung cancer;
KIRP	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg18944383	chr4:111397179	ENPEP	-0.52	-6.24	-0.37	1.95e-9	Axial length;
KIRP	cis	rs7709377	0.597	rs10066026	chr5:115518568	A/G	cg23108291	chr5:115420582	COMMD10	0.4	4.85	0.3	2.15e-6	Metabolite levels  (X-11787);
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.41	8.43	0.47	2.9e-15	Vitiligo;
KIRP	cis	rs564148	1.000	rs581379	chr1:34171768	G/T	cg25772827	chr1:34632573	C1orf94;CSMD2	0.43	4.87	0.3	1.96e-6	Response to amphetamines;
KIRP	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.85	8.68	0.48	5.36e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2625529	0.586	rs11639282	chr15:72435260	G/A	cg16672083	chr15:72433130	SENP8	0.4	5.69	0.34	3.59e-8	Red blood cell count;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07154063	chr2:175664535	CHN1	-0.5	-6.02	-0.36	6.45e-9	Bladder cancer;
KIRP	cis	rs72634258	0.503	rs34177663	chr1:7833228	A/G	cg26816564	chr1:7831052	VAMP3	0.96	8.48	0.48	2.14e-15	Inflammatory bowel disease;
KIRP	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.98	-16.73	-0.73	1.84e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6708331	0.517	rs12999042	chr2:70366811	C/T	cg01613454	chr2:70366299	NA	0.41	5.55	0.33	7.21e-8	Obesity-related traits;
KIRP	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs714027	0.605	rs5763775	chr22:30503007	G/T	cg27665648	chr22:30112403	NA	-0.45	-6.3	-0.37	1.38e-9	Lymphocyte counts;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.13	-21.08	-0.8	4.71e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.44	6.2	0.37	2.42e-9	Coronary artery disease;
KIRP	cis	rs2637030	0.533	rs7731940	chr5:52863638	A/T	cg06476337	chr5:52856530	NDUFS4	0.54	5.86	0.35	1.46e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg22681709	chr2:178499509	PDE11A	-0.46	-5.55	-0.33	7.33e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg05627522	chr15:75251581	NA	0.35	5.1	0.31	6.78e-7	Caffeine consumption;
KIRP	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs3744061	0.520	rs4322697	chr17:74648642	C/T	cg27546012	chr17:74684504	MXRA7	-0.53	-6.72	-0.39	1.26e-10	Retinal arteriolar caliber;
KIRP	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg15841412	chr13:111365552	ING1	0.5	5.79	0.35	2.12e-8	Coronary artery disease;
KIRP	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.52	-7.51	-0.43	1.09e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	0.94	14.58	0.68	3.88e-35	Breast cancer;
KIRP	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg09473613	chr1:24152604	HMGCL	-0.45	-5.93	-0.35	1.04e-8	Immature fraction of reticulocytes;
KIRP	cis	rs14403	1.000	rs12406958	chr1:243662190	T/C	cg21452805	chr1:244014465	NA	0.53	5.2	0.31	4.29e-7	Schizophrenia;
KIRP	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.5	6.95	0.41	3.26e-11	Mean corpuscular volume;
KIRP	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.45	7.26	0.42	5.05e-12	Testicular germ cell tumor;
KIRP	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg16482183	chr6:26056742	HIST1H1C	0.44	5.54	0.33	7.85e-8	Schizophrenia;
KIRP	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg26084005	chr2:241760190	KIF1A	-0.51	-6.87	-0.4	5.36e-11	Urinary metabolites;
KIRP	cis	rs7267005	0.661	rs60828070	chr20:34431747	G/A	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7301016	1.000	rs7301016	chr12:62886123	A/G	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs17023223	0.537	rs2645292	chr1:119573194	C/T	cg18261050	chr1:119551319	NA	0.52	6.89	0.4	4.64e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg15181151	chr6:150070149	PCMT1	0.29	4.88	0.3	1.9e-6	Lung cancer;
KIRP	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.8	8.16	0.46	1.74e-14	Eosinophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25375290	chr22:40766683	SGSM3	0.5	6.36	0.38	9.93e-10	Parkinson's disease;
KIRP	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.61	-6.36	-0.38	9.52e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg16497661	chr14:103986332	CKB	0.49	6.61	0.39	2.35e-10	Body mass index;
KIRP	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	1.05	9.16	0.5	2.07e-17	Fat distribution (HIV);
KIRP	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.83	0.4	6.7e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.64	-8.94	-0.5	9.73e-17	Breast cancer;
KIRP	cis	rs12431939	1.000	rs67628731	chr14:51662708	C/G	cg23942311	chr14:51606299	NA	-0.49	-5.0	-0.3	1.09e-6	Cancer;
KIRP	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.88	-0.53	1.34e-19	Neuroticism;
KIRP	cis	rs4783244	0.897	rs4597315	chr16:82652931	T/C	cg09415485	chr16:82663111	CDH13	-0.29	-5.48	-0.33	1.06e-7	Adiponectin levels;
KIRP	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg11815105	chr2:239148849	HES6	-0.41	-4.9	-0.3	1.76e-6	Phospholipid levels (plasma);
KIRP	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg12549451	chr6:135224345	NA	0.4	5.3	0.32	2.59e-7	Red blood cell count;
KIRP	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg08885076	chr2:99613938	TSGA10	-0.35	-5.85	-0.35	1.54e-8	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00603356	chr7:107382211	NA	-0.44	-6.26	-0.37	1.74e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.56	-0.39	3.07e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg06671706	chr8:8559999	CLDN23	0.52	6.24	0.37	1.91e-9	Obesity-related traits;
KIRP	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg07777115	chr5:623756	CEP72	-0.57	-5.74	-0.34	2.83e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg21734707	chr17:3908241	ZZEF1	-0.63	-9.5	-0.52	1.94e-18	Type 2 diabetes;
KIRP	cis	rs11877825	0.737	rs6505572	chr18:10579366	T/C	cg25239095	chr18:10589360	NA	0.41	4.87	0.3	1.97e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.61	7.2	0.42	7.45e-12	Osteoporosis;
KIRP	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04650786	chr6:108395545	OSTM1	0.49	6.45	0.38	5.92e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg18234130	chr8:27182889	PTK2B	-0.55	-7.1	-0.41	1.3e-11	Neuroticism;
KIRP	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg12435725	chr3:58293450	RPP14	-0.54	-5.67	-0.34	4e-8	Cholesterol, total;
KIRP	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.57	0.52	1.21e-18	Coffee consumption (cups per day);
KIRP	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.29	0.37	1.45e-9	Uric acid levels;
KIRP	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.16	15.72	0.71	4.92e-39	Lymphocyte percentage of white cells;
KIRP	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.65	7.73	0.44	2.71e-13	Cognitive test performance;
KIRP	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.72	7.48	0.43	1.35e-12	Migraine;Coronary artery disease;
KIRP	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.38	-7.09	-0.41	1.39e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg27411982	chr8:10470053	RP1L1	-0.53	-7.0	-0.41	2.45e-11	Neuroticism;
KIRP	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.91	15.23	0.7	2.37e-37	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg16141378	chr3:129829833	LOC729375	0.51	6.42	0.38	7.05e-10	Neuroticism;
KIRP	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg01028140	chr2:1542097	TPO	-0.48	-5.47	-0.33	1.13e-7	IgG glycosylation;
KIRP	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg02336718	chr17:17403227	NA	0.33	5.23	0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg16586182	chr3:47516702	SCAP	-0.73	-10.34	-0.55	4.96e-21	Colorectal cancer;
KIRP	cis	rs909341	0.909	rs2236510	chr20:62368804	C/T	cg03999872	chr20:62272968	STMN3	-0.59	-6.83	-0.4	6.8e-11	Atopic dermatitis;
KIRP	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg09163369	chr1:210001066	C1orf107	0.56	6.99	0.41	2.64e-11	Orofacial clefts;
KIRP	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg08632701	chr21:37451849	NA	0.47	5.97	0.36	8.28e-9	Mitral valve prolapse;
KIRP	cis	rs7127900	0.821	rs10743180	chr11:2229573	G/T	cg25635251	chr11:2234043	NA	0.53	8.0	0.45	4.9e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg21161173	chr5:140098174	VTRNA1-2	-0.39	-4.97	-0.3	1.25e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs228437	0.913	rs1535117	chr6:134911816	G/A	cg24504307	chr6:134963096	NA	-0.44	-6.94	-0.4	3.53e-11	Melanoma;
KIRP	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg27494647	chr7:150038898	RARRES2	0.43	6.22	0.37	2.1e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.99	8.47	0.47	2.33e-15	Systolic blood pressure;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	14.25	0.67	5.16e-34	Lymphocyte counts;
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg00343986	chr7:65444356	GUSB	-0.48	-5.78	-0.35	2.29e-8	Aortic root size;
KIRP	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.32	-0.32	2.37e-7	Red blood cell count;
KIRP	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg04374321	chr14:90722782	PSMC1	0.99	17.8	0.75	4.22e-46	Mortality in heart failure;
KIRP	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	0.66	5.85	0.35	1.55e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.74	10.7	0.56	3.38e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg06169648	chr16:85646832	KIAA0182	0.52	6.43	0.38	6.73e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-6.42	-0.38	7.11e-10	Uric acid levels;
KIRP	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.67	-0.56	4.21e-22	Menopause (age at onset);
KIRP	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs4589502	0.841	rs56401320	chr15:67140517	C/G	cg09911534	chr15:67153556	NA	-0.5	-5.09	-0.31	7.19e-7	Lung cancer (smoking interaction);
KIRP	cis	rs12760731	0.668	rs10913548	chr1:178372286	G/A	cg00404053	chr1:178313656	RASAL2	0.65	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26647736	chr12:100593455	ACTR6	-0.56	-6.24	-0.37	1.91e-9	Menopause (age at onset);
KIRP	cis	rs6800768	0.633	rs60706278	chr3:24101424	T/A	cg10674438	chr3:24145617	LOC152024	-0.43	-5.82	-0.35	1.87e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	0.96	8.46	0.47	2.42e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.51	-7.74	-0.44	2.53e-13	Lung cancer;
KIRP	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.32	1.9e-7	Menopause (age at onset);
KIRP	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.7	-7.88	-0.45	1.06e-13	Menarche (age at onset);
KIRP	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg23100626	chr2:96804247	ASTL	0.46	6.52	0.38	3.93e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg27211696	chr2:191398769	TMEM194B	-0.77	-8.96	-0.5	8.16e-17	Diastolic blood pressure;
KIRP	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg10167378	chr1:228756711	NA	0.52	5.84	0.35	1.65e-8	Diastolic blood pressure;
KIRP	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.45	-5.8	-0.35	2.08e-8	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13773948	chr10:43277913	BMS1	0.55	6.98	0.41	2.73e-11	Parkinson's disease;
KIRP	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.92	-0.49	1.09e-16	Triglycerides;
KIRP	cis	rs2030114	0.531	rs4783838	chr16:51594238	G/A	cg03758633	chr16:51611768	NA	0.24	4.84	0.3	2.26e-6	Blood pressure measurement (high sodium and potassium intervention);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06887283	chr1:235972393	LYST	-0.39	-6.22	-0.37	2.13e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-10.1	-0.54	2.83e-20	Neuroticism;
KIRP	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.52	0.43	1.01e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg26681399	chr22:41777847	TEF	-0.45	-5.0	-0.3	1.11e-6	Neuroticism;
KIRP	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.15	0.67	1.14e-33	Platelet count;
KIRP	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.9	-8.67	-0.48	6.05e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg08700190	chr5:6636046	SRD5A1	-0.39	-4.93	-0.3	1.48e-6	Response to amphetamines;
KIRP	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.49	6.5	0.38	4.35e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13385	0.769	rs34266577	chr5:139547797	C/T	cg01860693	chr5:139557145	C5orf32	0.49	5.1	0.31	6.86e-7	Atrial fibrillation;
KIRP	cis	rs11874712	0.545	rs9955008	chr18:43658888	A/G	cg26436583	chr18:43649176	PSTPIP2	0.36	5.35	0.32	2.01e-7	Migraine - clinic-based;
KIRP	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.73	0.34	2.88e-8	Personality dimensions;
KIRP	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.71	6.09	0.36	4.35e-9	Crohn's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10277546	chr21:34960952	DONSON	0.48	6.25	0.37	1.79e-9	Myopia (pathological);
KIRP	cis	rs96067	0.805	rs12033824	chr1:36600307	C/T	cg27506609	chr1:36549197	TEKT2	-0.5	-6.04	-0.36	5.54e-9	Corneal structure;
KIRP	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg13679303	chr9:96623674	NA	0.45	5.9	0.35	1.19e-8	DNA methylation (variation);
KIRP	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.63	-10.04	-0.54	4.15e-20	Prostate cancer;
KIRP	trans	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.03	-0.41	2.08e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.52	0.33	8.7e-8	Diisocyanate-induced asthma;
KIRP	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.45	5.83	0.35	1.75e-8	Crohn's disease;
KIRP	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.76	8.37	0.47	4.51e-15	Corneal astigmatism;
KIRP	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg26554054	chr8:600488	NA	0.66	5.28	0.32	2.84e-7	IgG glycosylation;
KIRP	cis	rs9359856	0.564	rs1036853	chr6:90499502	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.8	-7.89	-0.45	1.01e-13	Bipolar disorder;
KIRP	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	1.1	17.77	0.75	5.43e-46	Cognitive function;
KIRP	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg16306078	chr6:126000798	NA	0.26	4.91	0.3	1.69e-6	Endometrial cancer;
KIRP	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg16988262	chr1:15930761	NA	0.4	5.13	0.31	6.02e-7	Systolic blood pressure;
KIRP	cis	rs7246657	0.722	rs10404031	chr19:38035954	A/G	cg23950597	chr19:37808831	NA	-0.61	-6.66	-0.39	1.79e-10	Coronary artery calcification;
KIRP	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00933542	chr6:150070202	PCMT1	0.26	5.02	0.3	9.82e-7	Lung cancer;
KIRP	cis	rs3739821	0.793	rs7023663	chr9:130714930	T/C	cg21181453	chr9:130700954	DPM2	0.48	7.23	0.42	6.07e-12	Glaucoma (primary angle closure);
KIRP	trans	rs12449568	0.904	rs11079221	chr17:54412108	C/G	cg04456437	chr3:119217424	C3orf1	0.49	6.14	0.36	3.27e-9	Height;
KIRP	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg00666640	chr1:248458726	OR2T12	0.45	6.15	0.37	3.09e-9	Common traits (Other);
KIRP	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.7	7.78	0.44	1.97e-13	Tourette syndrome;
KIRP	cis	rs2307121	0.700	rs10065173	chr5:64712004	A/C	cg11190754	chr5:64858552	CENPK;PPWD1	0.42	5.33	0.32	2.26e-7	Corneal structure;
KIRP	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-5.05	-0.31	8.53e-7	Skin colour saturation;
KIRP	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	9.51	0.52	1.84e-18	Renal function-related traits (BUN);
KIRP	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg16482183	chr6:26056742	HIST1H1C	0.95	10.16	0.54	1.75e-20	Iron status biomarkers;
KIRP	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs4671400	0.571	rs4672429	chr2:61495469	G/C	cg15711740	chr2:61764176	XPO1	0.63	6.9	0.4	4.32e-11	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg21174375	chr14:64681225	SYNE2	0.67	9.37	0.51	4.77e-18	Atrial fibrillation;
KIRP	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.64	-9.63	-0.52	8.11e-19	Educational attainment;
KIRP	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.4	-4.92	-0.3	1.62e-6	Educational attainment;
KIRP	cis	rs17681684	0.565	rs12150167	chr17:9764244	C/A	cg26853458	chr17:9805074	RCVRN	0.54	5.08	0.31	7.55e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs9644630	0.932	rs4273861	chr8:19352703	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.39	-5.29	-0.32	2.75e-7	Oropharynx cancer;
KIRP	cis	rs9309473	0.950	rs13391258	chr2:73848933	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.59	-0.34	6.03e-8	Metabolite levels;
KIRP	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.69	8.33	0.47	5.52e-15	Aortic root size;
KIRP	cis	rs6988636	0.710	rs17315999	chr8:124153763	A/G	cg15893493	chr8:124194847	FAM83A	0.89	7.24	0.42	5.67e-12	Urinary uromodulin levels;
KIRP	cis	rs6256	1.000	rs10832054	chr11:13550220	G/T	cg11976911	chr11:13509032	NA	0.65	5.48	0.33	1.07e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg02336718	chr17:17403227	NA	0.33	5.23	0.32	3.63e-7	Total body bone mineral density;
KIRP	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.64	7.59	0.44	6.73e-13	Testicular germ cell tumor;
KIRP	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.86	-12.42	-0.62	8.11e-28	Body mass index (adult);
KIRP	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.17	0.42	8.68e-12	Mean corpuscular volume;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.5	6.68	0.39	1.55e-10	Breast cancer;
KIRP	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.87	12.22	0.61	3.86e-27	Menopause (age at onset);
KIRP	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.01	0.5	5.77e-17	Menopause (age at onset);
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg05255149	chr17:80675120	FN3KRP	0.47	5.13	0.31	5.77e-7	Glycated hemoglobin levels;
KIRP	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.26	-0.37	1.67e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg06521331	chr12:34319734	NA	-0.47	-5.95	-0.35	9.41e-9	Morning vs. evening chronotype;
KIRP	cis	rs785830	0.521	rs553489	chr9:259990	G/C	cg14500300	chr9:211689	NA	0.36	4.98	0.3	1.17e-6	Platelet distribution width;
KIRP	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.59e-8	Aortic root size;
KIRP	cis	rs882732	1.000	rs10139277	chr14:95035060	C/T	cg08495878	chr14:95027859	SERPINA4	-0.42	-5.03	-0.31	9.52e-7	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg17822266	chr1:2720087	NA	-0.44	-6.09	-0.36	4.38e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.74	11.33	0.59	3.08e-24	Type 2 diabetes;
KIRP	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.53	-6.51	-0.38	4.26e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.11	-0.61	8.87e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03866757	chr5:172484412	C5orf41	0.48	6.56	0.39	3.22e-10	Parkinson's disease;
KIRP	cis	rs9399135	0.773	rs949895	chr6:135405359	C/T	cg24558204	chr6:135376177	HBS1L	0.42	5.34	0.32	2.11e-7	Red blood cell count;
KIRP	cis	rs35883536	0.967	rs1984134	chr1:101109307	A/G	cg06223162	chr1:101003688	GPR88	0.32	6.58	0.39	2.73e-10	Monocyte count;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg23298564	chr19:41256395	C19orf54;SNRPA	0.51	6.06	0.36	4.96e-9	Educational attainment;
KIRP	cis	rs7078219	0.543	rs10786557	chr10:101283328	C/G	cg07044859	chr10:101282883	NA	-0.32	-5.67	-0.34	3.95e-8	Dental caries;
KIRP	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-8.77	-0.49	3.09e-16	Personality dimensions;
KIRP	cis	rs4658101	0.815	rs906633	chr1:92047004	T/C	cg09075522	chr1:92031145	NA	0.46	5.51	0.33	8.83e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg25486957	chr4:152246857	NA	-0.42	-5.02	-0.3	9.95e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03579738	chr19:2900714	ZNF57	-0.48	-6.11	-0.36	3.9e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1440410	0.571	rs72719141	chr4:144028568	G/A	cg01719995	chr4:144104893	USP38	-0.46	-5.8	-0.35	2.02e-8	Ischemic stroke;
KIRP	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.56	-0.33	6.97e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs714027	0.605	rs5763779	chr22:30504652	A/G	cg01021169	chr22:30184971	ASCC2	0.48	5.93	0.35	1.05e-8	Lymphocyte counts;
KIRP	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.69	-8.5	-0.48	1.8e-15	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.68e-8	Life satisfaction;
KIRP	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg21918786	chr6:109611834	NA	0.35	5.17	0.31	4.87e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	7.02	0.41	2.17e-11	Menarche (age at onset);
KIRP	cis	rs6681460	0.649	rs10889625	chr1:67007235	T/C	cg02459107	chr1:67143332	SGIP1	0.35	4.93	0.3	1.52e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs73198271	0.628	rs11777908	chr8:8590437	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.81	12.17	0.61	5.64e-27	Prudent dietary pattern;
KIRP	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.51	6.36	0.38	9.91e-10	Total body bone mineral density;
KIRP	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg08773314	chr2:239334832	ASB1	0.31	5.33	0.32	2.22e-7	Multiple system atrophy;
KIRP	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg10761708	chr20:43804764	PI3	0.49	5.19	0.31	4.43e-7	Blood protein levels;
KIRP	cis	rs6681460	1.000	rs4655647	chr1:67106077	C/G	cg13052034	chr1:66999238	SGIP1	0.4	5.47	0.33	1.09e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9972944	0.902	rs9972956	chr17:63771092	T/C	cg07283582	chr17:63770753	CCDC46	0.48	7.94	0.45	7.1e-14	Total body bone mineral density;
KIRP	cis	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.13	0.31	5.88e-7	Leprosy;
KIRP	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.86	12.4	0.62	9.61e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13359291	0.596	rs1422278	chr5:122467417	G/T	cg16368670	chr5:122501738	PRDM6	-0.48	-5.39	-0.33	1.64e-7	Systolic blood pressure;
KIRP	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	12.97	0.64	1.18e-29	Smoking behavior;
KIRP	cis	rs8084125	1.000	rs62105185	chr18:74954808	G/A	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.43	-5.67	-0.34	3.89e-8	Parkinson's disease;
KIRP	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.85	12.91	0.64	1.88e-29	Height;
KIRP	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	7.04	0.41	1.86e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs8135828	0.955	rs468254	chr22:29962077	A/G	cg23204276	chr22:29729285	AP1B1;SNORD125	-0.45	-4.99	-0.3	1.16e-6	Lipid traits;
KIRP	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs8012145	0.543	rs7150245	chr14:55186005	C/T	cg19913537	chr14:55186044	SAMD4A	0.33	5.03	0.31	9.56e-7	Plateletcrit;
KIRP	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg19468946	chr17:37922297	IKZF3	-0.47	-6.45	-0.38	5.97e-10	Self-reported allergy;
KIRP	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg19554555	chr3:13937349	NA	-0.47	-6.39	-0.38	8.22e-10	Ovarian reserve;
KIRP	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg10253484	chr15:75165896	SCAMP2	-0.59	-6.89	-0.4	4.76e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg26248373	chr2:1572462	NA	-0.62	-5.82	-0.35	1.86e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.71	-9.74	-0.53	3.55e-19	Ear protrusion;
KIRP	cis	rs2274273	0.686	rs66782529	chr14:55587867	C/T	cg10130446	chr14:55658398	DLGAP5	-0.43	-4.93	-0.3	1.54e-6	Protein biomarker;
KIRP	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.84	12.49	0.62	4.71e-28	Eosinophil percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15627593	chr17:17457836	PEMT	-0.45	-6.22	-0.37	2.14e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1325195	0.507	rs10798652	chr1:179061427	A/G	cg11624085	chr17:8464688	MYH10	0.46	6.39	0.38	8.05e-10	IgE grass sensitization;
KIRP	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.04	14.87	0.69	4.14e-36	Cognitive ability;
KIRP	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg13334819	chr7:99746414	C7orf59	0.46	5.01	0.3	1.03e-6	Alzheimer's disease (late onset);
KIRP	cis	rs1620921	0.711	rs2802356	chr6:161238215	G/A	cg01280913	chr6:161186852	NA	-0.38	-5.14	-0.31	5.52e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	7.37	0.43	2.55e-12	Neuroticism;
KIRP	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.84	-12.21	-0.61	3.91e-27	Nonalcoholic fatty liver disease;
KIRP	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg00701064	chr4:6280414	WFS1	0.36	7.12	0.41	1.15e-11	Cisplatin-induced ototoxicity;
KIRP	cis	rs4356932	0.935	rs115828298	chr4:76967941	G/T	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-6.83	-0.4	6.73e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-7.93	-0.45	7.78e-14	Response to antipsychotic treatment;
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg26134248	chr17:3907702	NA	-0.54	-7.94	-0.45	7.28e-14	Type 2 diabetes;
KIRP	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.58	7.72	0.44	3.01e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2073300	1.000	rs112057098	chr20:23448901	C/T	cg12480562	chr20:23434244	CST11	0.6	5.99	0.36	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.94	12.18	0.61	5e-27	Breast cancer;
KIRP	cis	rs1215050	0.791	rs684210	chr4:98678740	G/C	cg05340658	chr4:99064831	C4orf37	0.49	6.02	0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs13323323	0.652	rs9825080	chr3:44251270	C/T	cg02073558	chr3:44770973	ZNF501	0.48	5.85	0.35	1.55e-8	IgG glycosylation;
KIRP	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.88	-0.3	1.92e-6	Cervical cancer;
KIRP	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.52	-0.48	1.63e-15	Mean corpuscular volume;
KIRP	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg09184832	chr6:79620586	NA	-0.53	-7.57	-0.43	7.4e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.72	10.73	0.56	2.7e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24768113	chr11:26996054	NA	0.38	6.33	0.37	1.15e-9	Survival in pancreatic cancer;
KIRP	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3857747	0.578	rs10281352	chr7:40383936	T/C	cg00420559	chr7:40367873	C7orf10	-0.45	-6.39	-0.38	8.32e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1971762	0.563	rs4759279	chr12:54064888	C/T	cg16917193	chr12:54089295	NA	0.77	13.34	0.65	6.34e-31	Height;
KIRP	cis	rs17023223	0.509	rs7542832	chr1:119762729	T/C	cg05756136	chr1:119680316	WARS2	-0.57	-7.62	-0.44	5.6e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.89e-10	Bipolar disorder;
KIRP	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.79	10.14	0.54	2.03e-20	Menopause (age at onset);
KIRP	cis	rs732716	0.504	rs9352	chr19:4442336	C/T	cg03719555	chr19:4455413	UBXN6	0.29	4.98	0.3	1.22e-6	Mean corpuscular volume;
KIRP	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.69	-0.53	5.1e-19	Neuroticism;
KIRP	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg14914422	chr1:46958856	NA	-0.41	-5.15	-0.31	5.3e-7	Monobrow;
KIRP	cis	rs17030434	0.784	rs4696486	chr4:154651354	T/C	cg14289246	chr4:154710475	SFRP2	-0.59	-7.74	-0.44	2.59e-13	Electrocardiographic conduction measures;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.82	-13.28	-0.65	1.06e-30	Prostate cancer;
KIRP	cis	rs12042938	0.935	rs823159	chr1:231777168	T/C	cg24499839	chr1:231762238	TSNAX-DISC1;DISC1	-0.37	-5.22	-0.32	3.85e-7	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs13401104	0.587	rs56146026	chr2:237145629	A/G	cg26422059	chr2:237146110	ASB18	0.46	5.27	0.32	3.03e-7	Educational attainment;
KIRP	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.62	-8.21	-0.46	1.25e-14	Height;
KIRP	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg06219351	chr7:158114137	PTPRN2	0.58	8.37	0.47	4.5e-15	Calcium levels;
KIRP	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.01	13.97	0.67	4.9e-33	Cognitive ability;
KIRP	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg17390301	chr11:111250093	POU2AF1	0.35	5.67	0.34	4.07e-8	Primary biliary cholangitis;
KIRP	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.63	8.18	0.46	1.48e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg00745463	chr17:30367425	LRRC37B	-0.87	-6.77	-0.4	9.33e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg05043794	chr9:111880884	C9orf5	-0.24	-5.11	-0.31	6.55e-7	Menarche (age at onset);
KIRP	cis	rs4750440	0.523	rs4565800	chr10:14032326	G/C	cg27542038	chr10:14027202	FRMD4A	-0.51	-6.62	-0.39	2.17e-10	Adiponectin levels;
KIRP	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.1	-0.41	1.29e-11	Joint mobility (Beighton score);
KIRP	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.75	-0.44	2.43e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3784262	0.643	rs12916872	chr15:58375741	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-5.07	-0.31	7.83e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.53	-6.52	-0.38	4.03e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.65	-0.56	4.87e-22	Height;
KIRP	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.89	-0.45	1.02e-13	Alzheimer's disease;
KIRP	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.13	-0.46	2.12e-14	Migraine;Coronary artery disease;
KIRP	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.79	-11.07	-0.58	2.24e-23	Dental caries;
KIRP	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg16586182	chr3:47516702	SCAP	-0.75	-10.65	-0.56	4.9e-22	Colorectal cancer;
KIRP	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.62	-8.33	-0.47	5.75e-15	Glaucoma (primary open-angle);
KIRP	cis	rs6142618	0.555	rs6061153	chr20:30662247	A/C	cg09796376	chr20:30640595	HCK	-0.41	-5.7	-0.34	3.37e-8	Inflammatory bowel disease;
KIRP	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.38	4.94	0.3	1.48e-6	Blood protein levels;
KIRP	cis	rs35995292	0.963	rs2240555	chr7:38949424	T/C	cg19327137	chr7:38886074	VPS41	0.51	6.04	0.36	5.81e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.2	0.46	1.3e-14	IgG glycosylation;
KIRP	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.96e-7	Body mass index;
KIRP	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg19575753	chr5:1948995	NA	-0.43	-5.1	-0.31	6.78e-7	Gut microbiome composition (winter);
KIRP	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.61	7.26	0.42	5.05e-12	Height;
KIRP	cis	rs36715	0.953	rs36706	chr5:127556698	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	8.81	0.49	2.26e-16	Breast cancer;
KIRP	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-7.22	-0.42	6.28e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.26	-0.42	5.2e-12	Aortic root size;
KIRP	cis	rs73416724	0.544	rs732691	chr6:43240390	C/T	cg02694972	chr6:43249501	TTBK1	-0.57	-4.94	-0.3	1.42e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23629032	chr21:30302708	RNF160	-0.41	-6.45	-0.38	5.87e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg08885076	chr2:99613938	TSGA10	-0.48	-6.23	-0.37	1.96e-9	Chronic sinus infection;
KIRP	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.68	7.09	0.41	1.42e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg27487796	chr7:28973253	NA	-0.23	-5.2	-0.31	4.2e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg25664220	chr3:72788482	NA	0.41	5.9	0.35	1.2e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06050784	chr16:88016603	BANP	0.42	5.1	0.31	6.68e-7	Menopause (age at onset);
KIRP	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.26e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3126085	0.560	rs2065954	chr1:152321344	T/G	cg26876637	chr1:152193138	HRNR	-0.57	-6.43	-0.38	6.58e-10	Atopic dermatitis;
KIRP	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.11	0.41	1.28e-11	Height;
KIRP	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.41	-0.33	1.51e-7	Life satisfaction;
KIRP	cis	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg02972257	chr16:68554789	NA	-0.55	-5.89	-0.35	1.25e-8	Ulcerative colitis;
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.51	-6.57	-0.39	2.94e-10	Testicular germ cell tumor;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24534381	chr11:77348924	CLNS1A	-0.48	-6.17	-0.37	2.75e-9	Myopia;
KIRP	trans	rs2472591	0.852	rs73489861	chr13:50511364	C/T	cg04548715	chr7:99598775	NA	0.59	6.43	0.38	6.63e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.63	7.07	0.41	1.62e-11	Neutrophil percentage of white cells;
KIRP	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.58	7.34	0.42	3.1e-12	Aortic root size;
KIRP	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg04374321	chr14:90722782	PSMC1	0.92	15.44	0.7	4.6e-38	Mortality in heart failure;
KIRP	cis	rs7584330	0.541	rs10202181	chr2:238352099	A/G	cg11271282	chr2:238384023	NA	0.51	5.8	0.35	2.05e-8	Prostate cancer;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16581360	chr16:8962069	CARHSP1	0.59	6.53	0.38	3.78e-10	Lung cancer in ever smokers;
KIRP	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.22	32.47	0.9	6.31e-91	Myeloid white cell count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06518714	chr8:9870454	NA	-0.39	-6.14	-0.36	3.29e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg06871246	chr4:1363661	KIAA1530	-0.58	-7.21	-0.42	6.77e-12	Longevity;
KIRP	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs4389656	0.857	rs274676	chr5:6754762	T/C	cg10857441	chr5:6722123	POLS	-0.43	-5.95	-0.35	9.19e-9	Coronary artery disease;
KIRP	cis	rs3857747	0.827	rs1532722	chr7:40438667	T/A	cg00420559	chr7:40367873	C7orf10	-0.58	-7.99	-0.45	5.2e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg24955955	chr5:415729	AHRR	0.72	6.09	0.36	4.38e-9	Fat distribution (HIV);
KIRP	cis	rs40363	0.953	rs39730	chr16:3509665	T/G	cg22508957	chr16:3507546	NAT15	0.53	7.0	0.41	2.41e-11	Tuberculosis;
KIRP	cis	rs7572644	0.656	rs34096628	chr2:28060990	A/C	cg27432699	chr2:27873401	GPN1	0.46	5.66	0.34	4.29e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg00852783	chr1:26633632	UBXN11	-0.52	-5.57	-0.33	6.55e-8	Obesity-related traits;
KIRP	cis	rs6539288	0.803	rs2374651	chr12:107328124	A/G	cg21360079	chr12:107162445	NA	-0.38	-5.01	-0.3	1.02e-6	Total body bone mineral density;
KIRP	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.12	-0.31	6.04e-7	Post bronchodilator FEV1;
KIRP	cis	rs4959799	0.557	rs9503516	chr6:3272065	G/A	cg03657281	chr6:3270030	SLC22A23	0.78	6.03	0.36	6.04e-9	Survival in rectal cancer;
KIRP	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg12856521	chr11:46389249	DGKZ	0.54	6.9	0.4	4.3e-11	Crohn's disease;
KIRP	cis	rs17453880	0.853	rs60025184	chr5:151965130	G/A	cg12297329	chr5:152029980	NA	-0.68	-10.16	-0.54	1.74e-20	Subjective well-being;
KIRP	cis	rs7221595	0.825	rs8078629	chr17:3983964	A/C	cg09597638	chr17:3907349	NA	0.56	5.87	0.35	1.42e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.64	-9.38	-0.51	4.44e-18	Body mass index;
KIRP	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-0.39	-4.88	-0.3	1.94e-6	Type 2 diabetes;
KIRP	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.77	8.68	0.48	5.52e-16	Corneal astigmatism;
KIRP	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.8	12.39	0.62	1.04e-27	Prostate cancer;
KIRP	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.51	-7.28	-0.42	4.49e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-7.5	-0.43	1.14e-12	Electroencephalogram traits;
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00689492	chr4:1303491	MAEA	0.3	5.18	0.31	4.69e-7	Obesity-related traits;
KIRP	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg24375607	chr4:120327624	NA	0.52	6.13	0.36	3.51e-9	Corneal astigmatism;
KIRP	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg22875332	chr1:76189707	ACADM	-0.35	-5.15	-0.31	5.26e-7	Daytime sleep phenotypes;
KIRP	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.75	-8.7	-0.49	4.82e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.04	-0.31	8.92e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.08	-0.31	7.6e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.85	10.08	0.54	3.18e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7520050	0.778	rs2991985	chr1:46080530	T/C	cg24296786	chr1:45957014	TESK2	0.47	6.22	0.37	2.08e-9	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	1.16	14.34	0.67	2.67e-34	Type 2 diabetes nephropathy;
KIRP	cis	rs193541	0.632	rs173481	chr5:122254552	G/A	cg19412675	chr5:122181750	SNX24	0.61	6.34	0.37	1.07e-9	Glucose homeostasis traits;
KIRP	cis	rs2282032	1.000	rs115667214	chr14:90733890	A/G	cg04374321	chr14:90722782	PSMC1	0.56	5.34	0.32	2.1e-7	Longevity;
KIRP	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg21775007	chr8:11205619	TDH	0.53	7.4	0.43	2.13e-12	Retinal vascular caliber;
KIRP	cis	rs9290877	0.667	rs9833602	chr3:188462284	A/G	cg17392043	chr3:188495102	LPP	-0.52	-6.79	-0.4	8.29e-11	IgE levels;
KIRP	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg17885191	chr8:135476712	NA	0.52	6.0	0.36	7.15e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14598338	chr9:96623480	NA	0.6	9.2	0.51	1.56e-17	DNA methylation (variation);
KIRP	cis	rs2071403	0.933	rs11685159	chr2:1412282	A/C	cg06500727	chr2:1417164	TPO	0.47	7.45	0.43	1.6e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.56	9.68	0.53	5.6e-19	Bone mineral density;
KIRP	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-5.99	-0.36	7.25e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg11031976	chr2:198649780	BOLL	-0.52	-4.99	-0.3	1.15e-6	Ulcerative colitis;
KIRP	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg00343986	chr7:65444356	GUSB	-0.4	-4.98	-0.3	1.22e-6	Aortic root size;
KIRP	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	11.52	0.59	7.7e-25	Monocyte percentage of white cells;
KIRP	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.47	0.38	5.25e-10	Bipolar disorder;
KIRP	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg22875332	chr1:76189707	ACADM	-0.34	-4.87	-0.3	1.99e-6	Daytime sleep phenotypes;
KIRP	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg08923669	chr16:420230	MRPL28	-0.45	-5.15	-0.31	5.45e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs9303542	0.559	rs12602539	chr17:46617459	T/A	cg04904318	chr17:46607828	HOXB1	-0.61	-6.66	-0.39	1.73e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.13	-0.31	5.83e-7	Inflammatory skin disease;
KIRP	cis	rs13161895	1.000	rs6873994	chr5:179436696	T/G	cg02702477	chr5:179499311	RNF130	-0.69	-5.36	-0.32	1.95e-7	LDL cholesterol;
KIRP	cis	rs4654899	0.865	rs957163	chr1:21416181	G/T	cg05370193	chr1:21551575	ECE1	0.45	5.61	0.34	5.3e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg10018233	chr7:150070692	REPIN1	0.65	7.6	0.44	6.04e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-0.79	-7.7	-0.44	3.32e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg00857998	chr1:205179979	DSTYK	0.58	7.03	0.41	1.97e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs12210905	0.688	rs72845027	chr6:27528199	T/C	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.4e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01616529	chr11:638424	DRD4	-0.4	-5.2	-0.31	4.17e-7	Systemic lupus erythematosus;
KIRP	cis	rs394563	0.967	rs420099	chr6:149794290	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.9	-0.3	1.76e-6	Dupuytren's disease;
KIRP	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg05347473	chr6:146136440	FBXO30	0.5	7.14	0.41	1.07e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.92	-0.49	1.1e-16	Retinal vascular caliber;
KIRP	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.43	5.7	0.34	3.38e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.89	12.31	0.62	1.86e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs7005380	0.581	rs13265513	chr8:120919926	C/T	cg21645572	chr8:120931649	DEPDC6	-0.52	-7.22	-0.42	6.55e-12	Interstitial lung disease;
KIRP	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg23602478	chr1:26503979	CNKSR1	0.44	6.35	0.38	1.02e-9	Height;
KIRP	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg19197139	chr17:4613644	ARRB2	-0.64	-6.94	-0.4	3.52e-11	Lymphocyte counts;
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.31	-0.32	2.49e-7	Breast cancer;
KIRP	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21659725	chr3:3221576	CRBN	-0.55	-6.5	-0.38	4.4e-10	Educational attainment;
KIRP	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.46	-5.89	-0.35	1.27e-8	Retinal vascular caliber;
KIRP	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.33	10.11	0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	cis	rs6772849	0.930	rs55987729	chr3:128340110	T/C	cg08795948	chr3:128337044	NA	0.49	6.09	0.36	4.36e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg23216685	chr1:86174607	ZNHIT6	0.55	6.32	0.37	1.23e-9	Urate levels in overweight individuals;
KIRP	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.95	0.41	3.31e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.74	6.5	0.38	4.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg18478394	chr8:109455254	TTC35	0.51	6.26	0.37	1.71e-9	Dupuytren's disease;
KIRP	cis	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.42	5.35	0.32	1.97e-7	Leprosy;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg06871246	chr4:1363661	KIAA1530	-0.52	-6.5	-0.38	4.48e-10	Longevity;
KIRP	cis	rs9596863	0.898	rs68056413	chr13:54375907	G/T	ch.13.53330881F	chr13:54432880	NA	0.62	6.09	0.36	4.22e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs883565	0.655	rs4676649	chr3:39064948	T/C	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	cis	rs4789452	0.595	rs7359497	chr17:75352173	C/T	cg01320579	chr17:75405842	SEPT9	0.34	5.78	0.35	2.21e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.95	0.41	3.28e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.63	-0.39	2.14e-10	Axial length;
KIRP	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.38	4.9	0.3	1.73e-6	Melanoma;
KIRP	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	6.97	0.41	2.84e-11	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.35	-4.94	-0.3	1.41e-6	Monocyte count;
KIRP	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.5	6.66	0.39	1.8e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs3743714	1	rs3743714	chr16:66583705	T/C	cg03448915	chr16:66583078	TK2	-0.51	-4.94	-0.3	1.42e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.65	-5.96	-0.36	8.69e-9	Tuberculosis;
KIRP	cis	rs56161922	0.818	rs4437879	chr1:207875977	G/A	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg04691961	chr3:161091175	C3orf57	-0.49	-7.33	-0.42	3.24e-12	Morning vs. evening chronotype;
KIRP	cis	rs12311304	1.000	rs7297771	chr12:15376420	A/G	cg08258403	chr12:15378311	NA	0.34	5.04	0.31	8.86e-7	Behavioural disinhibition (generation interaction);
KIRP	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg21724239	chr8:58056113	NA	0.51	4.9	0.3	1.76e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6545883	0.929	rs778140	chr2:61682976	C/T	cg15711740	chr2:61764176	XPO1	-0.6	-7.78	-0.44	1.97e-13	Tuberculosis;
KIRP	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg15252951	chr6:33757062	LEMD2	0.46	5.4	0.33	1.59e-7	Crohn's disease;
KIRP	cis	rs4262150	0.846	rs72799161	chr5:152129607	T/C	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg24449463	chr1:168025552	DCAF6	-0.42	-4.97	-0.3	1.24e-6	Schizophrenia;
KIRP	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg00361562	chr2:198649771	BOLL	-0.5	-5.12	-0.31	6.03e-7	Ulcerative colitis;
KIRP	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.16	-0.37	2.9e-9	Breast cancer;
KIRP	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg24747557	chr10:131355152	MGMT	0.4	5.23	0.32	3.56e-7	Response to temozolomide;
KIRP	cis	rs4363385	0.510	rs2068678	chr1:152906956	G/A	cg07796016	chr1:152779584	LCE1C	-0.46	-5.7	-0.34	3.34e-8	Inflammatory skin disease;
KIRP	cis	rs11264213	0.591	rs274732	chr1:36488199	T/G	cg27506609	chr1:36549197	TEKT2	-1.19	-7.55	-0.43	8.47e-13	Schizophrenia;
KIRP	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg17366294	chr4:99064904	C4orf37	0.37	5.19	0.31	4.48e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg18132916	chr6:79620363	NA	0.53	7.35	0.42	2.89e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg03808351	chr9:123631620	PHF19	0.46	6.38	0.38	8.64e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs11644362	0.966	rs976011	chr16:12992910	C/T	cg06890432	chr16:12997467	SHISA9	-0.41	-6.45	-0.38	6e-10	Positive affect;Subjective well-being;
KIRP	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs28489187	0.706	rs18582	chr1:85794819	A/G	cg16011679	chr1:85725395	C1orf52	0.51	6.27	0.37	1.64e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	7.5	0.43	1.15e-12	Neuroticism;
KIRP	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg22437258	chr11:111473054	SIK2	0.52	6.12	0.36	3.63e-9	Primary sclerosing cholangitis;
KIRP	cis	rs6838801	0.930	rs6532535	chr4:77562538	T/A	cg17476223	chr4:77663285	SHROOM3	-0.43	-5.92	-0.35	1.1e-8	Cleft lip with or without cleft palate;
KIRP	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg13010199	chr12:38710504	ALG10B	0.49	6.27	0.37	1.64e-9	Morning vs. evening chronotype;
KIRP	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.48	-6.07	-0.36	4.91e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.42	-0.59	1.63e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg23815491	chr16:72088622	HP	0.54	7.69	0.44	3.44e-13	Blood protein levels;
KIRP	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg01864069	chr14:103024347	NA	-0.96	-12.79	-0.63	4.59e-29	Platelet count;
KIRP	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg25281562	chr12:121454272	C12orf43	-0.46	-4.96	-0.3	1.32e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	cis	rs6001982	0.667	rs6001910	chr22:40824009	T/C	cg07138101	chr22:40742427	ADSL	0.64	4.99	0.3	1.14e-6	Breast cancer;
KIRP	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg25447019	chr17:19030144	GRAPL	0.54	7.56	0.43	7.76e-13	Schizophrenia;
KIRP	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg24631222	chr15:78858424	CHRNA5	1.03	13.01	0.64	8.73e-30	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.46	5.73	0.34	2.95e-8	Longevity;
KIRP	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.54	-6.88	-0.4	4.91e-11	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg01280390	chr8:19363452	CSGALNACT1	0.38	4.96	0.3	1.35e-6	Oropharynx cancer;
KIRP	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	11.99	0.61	2.24e-26	Mean platelet volume;
KIRP	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.72	-10.78	-0.57	1.9e-22	Idiopathic membranous nephropathy;
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.83	0.63	3.31e-29	Platelet count;
KIRP	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg08600765	chr20:34638493	LOC647979	-0.66	-6.56	-0.39	3.11e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg12315302	chr6:26189340	HIST1H4D	0.66	4.93	0.3	1.53e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg22633769	chr20:60982531	CABLES2	0.41	5.18	0.31	4.53e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg16898833	chr6:26189333	HIST1H4D	0.97	5.87	0.35	1.38e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.13e-8	Common traits (Other);
KIRP	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.43	7.22	0.42	6.33e-12	Renal cell carcinoma;
KIRP	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19717773	chr7:2847554	GNA12	-0.3	-4.97	-0.3	1.25e-6	Height;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg00444019	chr10:14646244	FAM107B	0.58	7.2	0.42	7.36e-12	Educational attainment;
KIRP	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg14683738	chr19:37701593	ZNF585B	0.52	5.2	0.31	4.13e-7	Coronary artery calcification;
KIRP	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.88	13.83	0.66	1.42e-32	Menarche (age at onset);
KIRP	cis	rs3206736	0.732	rs329557	chr7:35103469	A/G	cg06685737	chr7:35301730	NA	0.47	7.06	0.41	1.7e-11	Diastolic blood pressure;
KIRP	cis	rs28493229	0.737	rs2288450	chr19:41209177	C/T	cg21869046	chr19:41225005	ITPKC	0.56	6.55	0.39	3.31e-10	Kawasaki disease;
KIRP	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.41	-5.26	-0.32	3.2e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.75	7.98	0.45	5.71e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.8	-0.4	7.98e-11	Diabetic kidney disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18347040	chr19:11639830	ECSIT	0.49	6.04	0.36	5.7e-9	Parkinson's disease;
KIRP	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg14343924	chr8:8086146	FLJ10661	0.5	5.86	0.35	1.47e-8	Mood instability;
KIRP	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.71	9.06	0.5	4.12e-17	Vitiligo;
KIRP	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg21419209	chr3:44054225	NA	-0.75	-8.93	-0.49	1.05e-16	Coronary artery disease;
KIRP	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.73	-0.39	1.17e-10	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26327118	chr6:39693366	KIF6	0.46	6.07	0.36	4.9e-9	Parkinson's disease;
KIRP	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg01475377	chr6:109611718	NA	-0.37	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.04	-0.64	6.65e-30	Exhaled nitric oxide output;
KIRP	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.19	-0.46	1.4e-14	Total cholesterol levels;
KIRP	cis	rs10186029	0.509	rs7592621	chr2:213941177	C/T	cg08319019	chr2:214017104	IKZF2	-0.45	-5.34	-0.32	2.06e-7	Systemic sclerosis;
KIRP	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.41	-0.43	2.08e-12	Type 2 diabetes;
KIRP	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg26531700	chr6:26746687	NA	0.4	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1961637	0.960	rs1899039	chr2:223910943	A/G	cg02552189	chr2:223891284	NA	-0.37	-5.1	-0.31	6.79e-7	Oropharynx cancer;
KIRP	cis	rs1823913	0.599	rs13015653	chr2:192171539	T/C	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.65e-12	Obesity-related traits;
KIRP	cis	rs2380205	0.967	rs7099029	chr10:5899188	C/A	cg27141509	chr10:5886111	NA	-0.37	-5.35	-0.32	2.01e-7	Breast cancer;
KIRP	trans	rs1912785	0.545	rs3843364	chr3:146503157	C/T	cg23398323	chr19:49122587	RPL18;SPHK2	0.49	6.06	0.36	4.98e-9	Barrett's esophagus;
KIRP	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.68	-7.81	-0.45	1.63e-13	Alcohol dependence;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.63	-8.47	-0.48	2.26e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.62	9.46	0.52	2.6e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2916247	0.954	rs990132	chr8:93106039	A/G	cg10183463	chr8:93005414	RUNX1T1	0.5	6.14	0.36	3.28e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg26149184	chr10:133730230	NA	0.42	4.9	0.3	1.75e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6684428	0.536	rs6660000	chr1:56399554	G/C	cg11651538	chr1:56320950	NA	-0.56	-7.88	-0.45	1.06e-13	Airflow obstruction;
KIRP	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.88	0.53	1.29e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.74	-11.17	-0.58	1.05e-23	Longevity;
KIRP	cis	rs9399401	0.961	rs6909857	chr6:142701158	A/G	cg03128060	chr6:142623767	GPR126	0.32	5.17	0.31	4.83e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs11249608	0.789	rs7700958	chr5:178436617	G/A	cg21905437	chr5:178450457	ZNF879	0.48	5.65	0.34	4.43e-8	Pubertal anthropometrics;
KIRP	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs7011049	0.778	rs113964834	chr8:53866524	T/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs4683702	0.932	rs55940906	chr3:142612091	C/T	cg22826874	chr3:142608218	PCOLCE2	-0.37	-5.4	-0.33	1.54e-7	Blood protein levels;
KIRP	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg26874164	chr19:58962979	ZNF324B	0.47	5.53	0.33	8.13e-8	Uric acid clearance;
KIRP	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg23625390	chr15:77176239	SCAPER	0.53	6.97	0.41	2.82e-11	Blood metabolite levels;
KIRP	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.99	-15.46	-0.7	4e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs7113874	0.797	rs4503528	chr11:8664454	A/G	cg08015107	chr11:8618950	NA	0.42	5.97	0.36	8.22e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9972944	0.656	rs10083855	chr17:63773139	T/C	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs16828019	0.929	rs12037037	chr1:41698256	C/T	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg04317338	chr11:64019027	PLCB3	0.8	5.96	0.36	8.64e-9	Mean platelet volume;
KIRP	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.45	5.44	0.33	1.29e-7	Height;
KIRP	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg08822215	chr16:89438651	ANKRD11	-0.6	-7.75	-0.44	2.39e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg14593290	chr7:50529359	DDC	0.8	9.99	0.54	5.94e-20	Malaria;
KIRP	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg08283408	chr3:49949060	MON1A	-0.41	-5.32	-0.32	2.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs909341	0.678	rs6011018	chr20:62303622	T/G	cg11503966	chr20:62272292	STMN3	0.42	5.82	0.35	1.84e-8	Atopic dermatitis;
KIRP	cis	rs11825685	0.607	rs61327677	chr11:134552340	C/A	cg06603561	chr11:134479413	NA	-0.58	-5.71	-0.34	3.18e-8	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-10.03	-0.54	4.49e-20	Gut microbiome composition (summer);
KIRP	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18252515	chr7:66147081	NA	0.47	5.71	0.34	3.3e-8	Aortic root size;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg22695372	chr1:94354654	GCLM	0.45	6.75	0.4	1.08e-10	C-reactive protein;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16414762	chr1:6845247	CAMTA1	0.5	6.43	0.38	6.71e-10	Parkinson's disease;
KIRP	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg23602478	chr1:26503979	CNKSR1	0.46	6.3	0.37	1.36e-9	Height;
KIRP	cis	rs13102973	0.640	rs6857995	chr4:135834193	G/A	cg14419869	chr4:135874104	NA	0.5	8.37	0.47	4.25e-15	Subjective well-being;
KIRP	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.54	-6.9	-0.4	4.43e-11	Longevity;
KIRP	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.93	10.09	0.54	2.91e-20	Type 2 diabetes nephropathy;
KIRP	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.42	-0.38	6.79e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg20587970	chr11:113659929	NA	-1.11	-10.35	-0.55	4.64e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.96	8.96	0.5	8.24e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg15691649	chr6:25882328	NA	-0.43	-5.29	-0.32	2.74e-7	Blood metabolite levels;
KIRP	trans	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg18335740	chr13:41363409	SLC25A15	0.52	7.67	0.44	3.97e-13	Lewy body disease;
KIRP	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg27490568	chr2:178487706	NA	0.51	6.84	0.4	6.09e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg04132472	chr17:19861366	AKAP10	0.39	5.0	0.3	1.07e-6	Schizophrenia;
KIRP	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs4262150	0.883	rs55737372	chr5:152097562	T/C	cg12297329	chr5:152029980	NA	-0.52	-6.76	-0.4	9.78e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08280861	chr8:58055591	NA	0.69	6.41	0.38	7.56e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14396505	chr17:19552141	ALDH3A2	-0.46	-6.3	-0.37	1.35e-9	Metabolic traits;
KIRP	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	cg21523751	chr1:182988639	NA	0.34	4.98	0.3	1.19e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg26061582	chr7:22766209	IL6	1.03	7.43	0.43	1.83e-12	Tonsillectomy;
KIRP	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.51	-6.2	-0.37	2.41e-9	Systemic lupus erythematosus;
KIRP	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.73	5.29	0.32	2.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7712401	0.601	rs30045	chr5:122271619	C/T	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26002218	chr14:103986227	CKB	0.29	5.96	0.36	8.73e-9	Body mass index;
KIRP	cis	rs7224685	0.569	rs35586982	chr17:4001993	G/A	cg09597638	chr17:3907349	NA	0.52	5.22	0.32	3.81e-7	Type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13198984	chr17:80129470	CCDC57	0.59	8.84	0.49	1.88e-16	Life satisfaction;
KIRP	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs9393813	0.529	rs2393964	chr6:27475144	A/C	cg03332623	chr6:27441972	ZNF184	-0.39	-5.54	-0.33	7.58e-8	Bipolar disorder;
KIRP	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg10755058	chr3:40428713	ENTPD3	-0.4	-5.8	-0.35	1.99e-8	Renal cell carcinoma;
KIRP	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16318349	chr1:154917307	PBXIP1	-0.29	-5.14	-0.31	5.72e-7	Prostate cancer;
KIRP	cis	rs1318772	0.932	rs35274088	chr5:112872958	G/T	cg12552261	chr5:112820674	MCC	0.77	5.36	0.32	1.89e-7	F-cell distribution;
KIRP	cis	rs3824347	0.839	rs12553648	chr9:77570716	A/G	cg01251476	chr9:77566080	C9orf40	-0.3	-4.89	-0.3	1.82e-6	Urinary magnesium-to-creatinine ratio;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00933542	chr6:150070202	PCMT1	0.3	6.05	0.36	5.5e-9	Lung cancer;
KIRP	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg10189774	chr4:17578691	LAP3	0.48	5.77	0.35	2.35e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg15469184	chr8:337539	NA	0.62	6.96	0.41	3e-11	Obesity-related traits;
KIRP	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.93	0.3	1.5e-6	Tonsillectomy;
KIRP	cis	rs7274811	0.516	rs3213141	chr20:32274380	G/A	cg21523528	chr20:32077966	CBFA2T2	0.51	5.02	0.3	9.83e-7	Height;
KIRP	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg04731861	chr2:219085781	ARPC2	0.26	6.59	0.39	2.71e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19354750	chr17:61554413	ACE	0.48	6.89	0.4	4.64e-11	Parkinson's disease;
KIRP	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg21466736	chr12:48725269	NA	-0.45	-5.87	-0.35	1.39e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg13699009	chr12:122356056	WDR66	-0.54	-7.41	-0.43	2.07e-12	Mean corpuscular volume;
KIRP	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg02336718	chr17:17403227	NA	0.34	5.33	0.32	2.27e-7	Total body bone mineral density;
KIRP	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.79	10.0	0.54	5.64e-20	Corneal astigmatism;
KIRP	trans	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg08400319	chr2:242004533	SNED1	0.45	6.25	0.37	1.76e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.74	7.48	0.43	1.3e-12	Type 2 diabetes nephropathy;
KIRP	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.72	9.51	0.52	1.85e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.77	9.81	0.53	2.16e-19	Corneal astigmatism;
KIRP	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	1.09	9.05	0.5	4.58e-17	Severe influenza A (H1N1) infection;
KIRP	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg22903471	chr2:27725779	GCKR	0.41	5.63	0.34	4.85e-8	Oral cavity cancer;
KIRP	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.64	-0.34	4.54e-8	Multiple sclerosis;
KIRP	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.17	-0.42	8.95e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg07308232	chr7:1071921	C7orf50	-0.57	-5.37	-0.32	1.8e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.7	-0.63	9.44e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg00647317	chr7:50633725	DDC	0.4	5.94	0.35	9.66e-9	Body mass index;
KIRP	cis	rs8067545	1.000	rs8065337	chr17:19941879	C/A	cg13482628	chr17:19912719	NA	0.65	9.9	0.53	1.12e-19	Schizophrenia;
KIRP	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.81	0.35	1.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.8	10.03	0.54	4.65e-20	Breast cancer;
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg11859384	chr17:80120422	CCDC57	0.46	5.84	0.35	1.67e-8	Life satisfaction;
KIRP	cis	rs7542091	0.748	rs2357231	chr1:210028454	A/C	cg09163369	chr1:210001066	C1orf107	0.49	6.3	0.37	1.4e-9	Monobrow;
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg08989290	chr16:615782	NHLRC4	0.43	6.37	0.38	9.3e-10	Height;
KIRP	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-7.46	-0.43	1.51e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2076028	0.506	rs9611007	chr22:39077058	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	6.82	0.4	7.1e-11	Resting heart rate;
KIRP	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.4	-6.2	-0.37	2.32e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.45	7.52	0.43	1.04e-12	Testicular germ cell tumor;
KIRP	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg23587288	chr2:27483067	SLC30A3	-0.57	-7.2	-0.42	7.47e-12	Blood metabolite levels;
KIRP	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg07395648	chr5:131743802	NA	-0.45	-6.33	-0.37	1.15e-9	Blood metabolite levels;
KIRP	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.92	9.92	0.53	1.02e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg26513180	chr16:89883248	FANCA	-0.61	-8.51	-0.48	1.71e-15	Vitiligo;
KIRP	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	cg04338863	chr8:33670619	NA	0.41	5.32	0.32	2.34e-7	Body mass index;
KIRP	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.6	-7.84	-0.45	1.38e-13	Pulse pressure;
KIRP	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.61	-7.25	-0.42	5.52e-12	Menarche (age at onset);
KIRP	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg14458575	chr2:238380390	NA	0.61	6.54	0.38	3.5e-10	Prostate cancer;
KIRP	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	10.91	0.57	7.33e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.54	5.29	0.32	2.72e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.69	-0.44	3.48e-13	Lung cancer;
KIRP	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.45	-6.65	-0.39	1.87e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs2274273	0.967	rs8013027	chr14:55610940	C/G	cg04306507	chr14:55594613	LGALS3	0.46	7.28	0.42	4.46e-12	Protein biomarker;
KIRP	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.68	-9.45	-0.52	2.79e-18	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1009181	0.965	rs1059490	chr6:26171250	T/C	cg13736514	chr6:26305472	NA	-0.49	-5.8	-0.35	2.04e-8	Childhood ear infection;
KIRP	cis	rs2944755	0.959	rs2977491	chr8:141574277	A/G	cg26074100	chr8:141568712	EIF2C2	0.45	6.07	0.36	4.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.82	-0.35	1.85e-8	Colorectal cancer;
KIRP	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.6	8.39	0.47	3.84e-15	Breast cancer;
KIRP	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.99	10.56	0.56	9.76e-22	Bronchopulmonary dysplasia;
KIRP	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg22256960	chr15:77711686	NA	-0.46	-5.81	-0.35	1.97e-8	Type 2 diabetes;
KIRP	cis	rs7715811	1.000	rs12153762	chr5:13778890	A/G	cg07548982	chr5:13769939	DNAH5	-0.55	-6.74	-0.4	1.09e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs290268	0.845	rs290266	chr9:93537952	T/A	cg02608019	chr9:93564028	SYK	0.78	10.48	0.56	1.68e-21	Platelet count;
KIRP	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg19116668	chr7:99932089	PMS2L1	0.41	5.03	0.31	9.43e-7	Coronary artery disease;
KIRP	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.15	-0.41	9.93e-12	Migraine;Coronary artery disease;
KIRP	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.44	6.09	0.36	4.34e-9	Coronary artery disease;
KIRP	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.71	6.73	0.39	1.21e-10	Multiple sclerosis;
KIRP	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.68	8.18	0.46	1.51e-14	Height;
KIRP	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.55	7.1	0.41	1.31e-11	Age at first birth;
KIRP	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.46	5.27	0.32	3.05e-7	Schizophrenia;
KIRP	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-7.56	-0.43	8.04e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs12930096	1.000	rs12445222	chr16:11677687	G/A	cg07439791	chr16:11680400	LITAF	0.71	6.1	0.36	4.07e-9	QT interval;
KIRP	cis	rs73198271	0.603	rs546606	chr8:8595843	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-5.29	-0.32	2.71e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11584989	chr19:19387371	SF4	0.57	6.2	0.37	2.42e-9	Bipolar disorder;
KIRP	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.68	-12.52	-0.62	3.62e-28	White blood cell count (basophil);
KIRP	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-8.96	-0.5	8.54e-17	Brugada syndrome;
KIRP	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.08	-19.01	-0.77	3.48e-50	Exhaled nitric oxide output;
KIRP	cis	rs11677416	1.000	rs1878318	chr2:113545185	A/G	cg23974023	chr2:113544294	IL1A	-0.33	-5.13	-0.31	5.87e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	10.07	0.54	3.31e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13939156	chr17:80058883	NA	0.51	7.72	0.44	2.9e-13	Life satisfaction;
KIRP	cis	rs2075064	0.903	rs7034780	chr9:126788935	A/G	cg14112217	chr9:126806003	NA	0.35	5.03	0.31	9.62e-7	Waist circumference;
KIRP	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.63	8.94	0.5	9.71e-17	Multiple system atrophy;
KIRP	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.87	-14.78	-0.69	8.11e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.35	-0.32	1.98e-7	Cervical cancer;
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13047869	chr3:10149882	C3orf24	0.6	5.82	0.35	1.79e-8	Alzheimer's disease;
KIRP	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.89	-12.97	-0.64	1.13e-29	Dupuytren's disease;
KIRP	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.73	11.75	0.6	1.32e-25	Cancer;
KIRP	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg25547332	chr5:131281432	NA	-0.47	-5.28	-0.32	2.91e-7	Life satisfaction;
KIRP	trans	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.0	-0.41	2.39e-11	Diabetic kidney disease;
KIRP	cis	rs4750440	0.706	rs61837399	chr10:14016047	G/A	cg27542038	chr10:14027202	FRMD4A	-0.49	-6.59	-0.39	2.6e-10	Adiponectin levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg26594331	chr5:178053244	CLK4	0.97	6.35	0.38	1.02e-9	P wave terminal force;
KIRP	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg06533319	chr4:3265114	C4orf44	-0.58	-7.28	-0.42	4.51e-12	Parental longevity (mother's age at death);
KIRP	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg12658694	chr1:38397304	INPP5B	0.69	9.31	0.51	7.18e-18	Coronary artery disease;
KIRP	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.56	5.26	0.32	3.08e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-5.02	-0.3	1e-6	Metabolite levels;
KIRP	cis	rs11016883	1.000	rs7086923	chr10:131498414	A/G	cg14312783	chr10:131504572	MGMT	0.41	5.03	0.31	9.26e-7	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.69	9.22	0.51	1.4e-17	Morning vs. evening chronotype;
KIRP	cis	rs6738627	1.000	rs6753142	chr2:165544071	T/C	cg03182029	chr2:165697222	COBLL1	0.39	5.06	0.31	8.09e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.47	4.92	0.3	1.6e-6	Initial pursuit acceleration;
KIRP	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg01616529	chr11:638424	DRD4	-0.37	-5.07	-0.31	7.7300000000000005e-07	Systemic lupus erythematosus;
KIRP	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.48	7.04	0.41	1.96e-11	Major depressive disorder;
KIRP	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8177876	0.822	rs9926174	chr16:81111436	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.51	6.93	0.4	3.67e-11	Coronary artery disease;
KIRP	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.64	-9.06	-0.5	4.13e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.42	-0.55	2.74e-21	Hemoglobin concentration;
KIRP	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg23281280	chr6:28129359	ZNF389	0.49	5.35	0.32	2.05e-7	Parkinson's disease;
KIRP	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.82	0.63	3.63e-29	Platelet count;
KIRP	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg16989719	chr2:238392110	NA	-0.51	-6.55	-0.39	3.42e-10	Prostate cancer;
KIRP	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg06307176	chr5:131281290	NA	0.54	5.87	0.35	1.42e-8	Life satisfaction;
KIRP	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.95	-14.56	-0.68	4.84e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg07606381	chr6:8435919	SLC35B3	-0.45	-5.58	-0.34	6.24e-8	Motion sickness;
KIRP	trans	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg06521331	chr12:34319734	NA	-0.6	-6.93	-0.4	3.76e-11	Morning vs. evening chronotype;
KIRP	cis	rs9547996	0.879	rs61957469	chr13:38133006	C/T	cg13634560	chr13:38173852	POSTN	-0.41	-5.66	-0.34	4.15e-8	Diastolic blood pressure;
KIRP	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.64	8.16	0.46	1.74e-14	Lung cancer;
KIRP	cis	rs918629	0.798	rs10052503	chr5:95283658	A/C	cg16656078	chr5:95278638	ELL2	-0.47	-6.8	-0.4	7.93e-11	IgG glycosylation;
KIRP	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg18016565	chr1:150552671	MCL1	0.34	5.3	0.32	2.56e-7	Tonsillectomy;
KIRP	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.07	0.41	1.6e-11	Mean platelet volume;
KIRP	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.46	6.36	0.38	9.97e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg18709589	chr6:96969512	KIAA0776	-0.42	-4.99	-0.3	1.16e-6	Migraine;Coronary artery disease;
KIRP	cis	rs2412459	1.000	rs2412459	chr15:40295959	C/T	cg10636054	chr15:40330586	SRP14	0.67	6.45	0.38	5.92e-10	Response to haloperidol in psychosis;
KIRP	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.21	0.51	1.45e-17	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.9	13.19	0.64	2.1000000000000002e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10929159	0.928	rs3738994	chr2:236918539	T/C	cg20128773	chr2:236923534	AGAP1	0.3	5.06	0.31	8.12e-7	Parkinson's disease;
KIRP	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.44	-6.05	-0.36	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg09507567	chr10:124027408	NA	-0.3	-5.43	-0.33	1.37e-7	Total body bone mineral density;
KIRP	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.61	-0.39	2.34e-10	Neutrophil percentage of white cells;
KIRP	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.16	0.37	3.03e-9	Morning vs. evening chronotype;
KIRP	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg16105309	chr15:79090380	ADAMTS7	0.59	7.21	0.42	6.78e-12	Schizophrenia;
KIRP	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.55	-6.98	-0.41	2.74e-11	Coronary artery disease;
KIRP	cis	rs12913538	0.962	rs4775517	chr15:62885173	A/G	cg09983546	chr15:62884068	NA	0.61	8.75	0.49	3.39e-16	Sleep depth;
KIRP	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg05220968	chr6:146057943	EPM2A	-0.39	-4.93	-0.3	1.54e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg10756647	chr7:56101905	PSPH	-0.86	-7.63	-0.44	5.06e-13	Diabetic kidney disease;
KIRP	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg13939156	chr17:80058883	NA	-0.46	-5.42	-0.33	1.41e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg23034840	chr1:205782522	SLC41A1	-0.57	-5.18	-0.31	4.53e-7	Prostate-specific antigen levels;
KIRP	cis	rs78487399	0.520	rs7609256	chr2:43672499	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.32	-0.32	2.29e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-7.69	-0.44	3.56e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs9469913	0.799	rs3800457	chr6:34663598	C/T	cg14254433	chr6:34482411	PACSIN1	0.41	5.13	0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00969787	chr1:45956256	TESK2	0.9	6.27	0.37	1.58e-9	P wave terminal force;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.16	-21.15	-0.8	2.89e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg11833968	chr6:79620685	NA	0.47	6.75	0.4	1.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10344404	chr17:35969756	SYNRG	0.89	6.41	0.38	7.54e-10	P wave terminal force;
KIRP	cis	rs2299587	0.729	rs6586676	chr8:17857445	T/C	cg01800426	chr8:17659068	MTUS1	-0.41	-4.92	-0.3	1.56e-6	Economic and political preferences;
KIRP	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg23791538	chr6:167370224	RNASET2	0.44	5.54	0.33	7.64e-8	Crohn's disease;
KIRP	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg17376030	chr22:41985996	PMM1	0.61	6.39	0.38	8.4e-10	Vitiligo;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10322419	chr1:4470956	LOC284661	0.45	6.2	0.37	2.31e-9	Interleukin-4 levels;
KIRP	cis	rs6708331	0.517	rs6546572	chr2:70373642	C/T	cg01613454	chr2:70366299	NA	0.37	4.91	0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg04369109	chr6:150039330	LATS1	-0.41	-4.92	-0.3	1.57e-6	Lung cancer;
KIRP	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.56	-6.86	-0.4	5.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.47	-0.43	1.44e-12	Bipolar disorder;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg06815112	chr8:27182871	PTK2B	0.54	6.93	0.4	3.72e-11	Neuroticism;
KIRP	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	8.61	0.48	8.7e-16	Myopia (pathological);
KIRP	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg05315796	chr3:52349193	DNAH1	0.56	8.42	0.47	3.13e-15	Bipolar disorder;
KIRP	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.43	5.18	0.31	4.63e-7	Resistin levels;
KIRP	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11987759	chr7:65425863	GUSB	-0.69	-9.72	-0.53	4.23e-19	Calcium levels;
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.85	11.41	0.59	1.69e-24	Longevity;
KIRP	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg10047753	chr17:41438598	NA	1.08	17.23	0.74	3.69e-44	Menopause (age at onset);
KIRP	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg09231725	chr11:64357281	SLC22A12	0.6	7.89	0.45	1.01e-13	Urate levels in obese individuals;
KIRP	cis	rs1440410	0.798	rs11727441	chr4:144163755	C/T	cg01719995	chr4:144104893	USP38	0.42	5.72	0.34	3.12e-8	Ischemic stroke;
KIRP	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg04731861	chr2:219085781	ARPC2	-0.21	-5.03	-0.31	9.37e-7	Colorectal cancer;
KIRP	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg25797454	chr6:150327115	RAET1K	0.37	6.88	0.4	5.04e-11	Alopecia areata;
KIRP	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg23594656	chr7:65796392	TPST1	0.46	7.29	0.42	4.31e-12	Aortic root size;
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.53	-6.9	-0.4	4.36e-11	Testicular germ cell tumor;
KIRP	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.6	-7.48	-0.43	1.33e-12	Gut microbiome composition (summer);
KIRP	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.36	-0.32	1.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.62	6.8	0.4	7.83e-11	Gut microbiome composition (summer);
KIRP	trans	rs10864302	0.515	rs6679411	chr1:7458393	G/A	cg24761882	chr9:96214934	FAM120AOS;FAM120A	-0.6	-6.32	-0.37	1.19e-9	Photic sneeze reflex;
KIRP	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.58	7.91	0.45	8.8e-14	Prostate cancer;
KIRP	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg14092571	chr14:90743983	NA	0.41	5.04	0.31	8.84e-7	Mortality in heart failure;
KIRP	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	8.87	0.49	1.49e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg08499158	chr17:42289980	UBTF	-0.64	-8.64	-0.48	7.37e-16	Total body bone mineral density;
KIRP	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg18461458	chr19:21324796	ZNF431	-0.48	-4.96	-0.3	1.29e-6	Pain;
KIRP	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg04058563	chr4:185651563	MLF1IP	-0.51	-7.07	-0.41	1.58e-11	Kawasaki disease;
KIRP	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg18209359	chr17:80159595	CCDC57	-0.4	-5.26	-0.32	3.15e-7	Life satisfaction;
KIRP	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-7.6	-0.44	6.14e-13	Coffee consumption (cups per day);
KIRP	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg00383909	chr3:49044727	WDR6	0.44	4.86	0.3	2.05e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8067545	1.000	rs7218708	chr17:19926836	A/G	cg04132472	chr17:19861366	AKAP10	0.39	5.32	0.32	2.3e-7	Schizophrenia;
KIRP	cis	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg21546286	chr11:48923668	NA	-0.48	-6.11	-0.36	3.82e-9	HDL cholesterol;
KIRP	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg14664628	chr15:75095509	CSK	0.44	5.51	0.33	8.9e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1832871	0.672	rs9457361	chr6:158771750	G/A	cg07215822	chr6:158701037	NA	-0.63	-7.32	-0.42	3.45e-12	Height;
KIRP	cis	rs6142102	0.602	rs1054534	chr20:32605327	G/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.75	0.34	2.65e-8	Skin pigmentation;
KIRP	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	1.06	20.02	0.79	1.53e-53	Heart rate;
KIRP	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg09323728	chr8:95962352	TP53INP1	0.28	5.86	0.35	1.44e-8	Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg25174290	chr11:3078921	CARS	-0.57	-6.11	-0.36	3.89e-9	Calcium levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg26439238	chr13:45563672	NUFIP1;KIAA1704	0.97	6.47	0.38	5.14e-10	P wave terminal force;
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	1.0	12.09	0.61	1e-26	Post bronchodilator FEV1;
KIRP	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7589728	0.858	rs1914734	chr2:88529509	T/C	cg04511125	chr2:88470314	THNSL2	0.56	5.12	0.31	6.16e-7	Plasma clusterin levels;
KIRP	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.76e-8	Type 2 diabetes;
KIRP	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg25319279	chr11:5960081	NA	0.52	5.47	0.33	1.13e-7	DNA methylation (variation);
KIRP	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg04691961	chr3:161091175	C3orf57	-0.65	-10.53	-0.56	1.19e-21	Morning vs. evening chronotype;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg25018755	chr22:43506952	BIK	0.67	6.25	0.37	1.77e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg05043794	chr9:111880884	C9orf5	-0.27	-5.44	-0.33	1.28e-7	Menarche (age at onset);
KIRP	cis	rs4356932	1.000	rs11097223	chr4:76987496	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.13	0.31	5.75e-7	Blood protein levels;
KIRP	cis	rs4302748	0.862	rs60346569	chr7:36184201	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg03609598	chr5:56110824	MAP3K1	0.48	5.46	0.33	1.15e-7	Initial pursuit acceleration;
KIRP	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.54	5.98	0.36	7.61e-9	Diisocyanate-induced asthma;
KIRP	cis	rs10924970	0.967	rs10754589	chr1:235439755	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.44	-0.52	2.97e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg10047753	chr17:41438598	NA	1.14	17.79	0.75	4.34e-46	Menopause (age at onset);
KIRP	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg15660573	chr17:549704	VPS53	-0.94	-15.05	-0.69	9.79e-37	Prostate cancer;
KIRP	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.29	0.47	7.2e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.9	13.33	0.65	7.32e-31	Coronary artery disease;
KIRP	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg04935436	chr20:30431758	NA	0.49	6.54	0.39	3.46e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4919044	0.808	rs835279	chr10:94809809	A/T	cg05127821	chr10:94822908	CYP26C1	-1.05	-11.03	-0.58	3.03e-23	Coronary artery disease;
KIRP	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.68	8.73	0.49	3.83e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs741677	1.000	rs741677	chr17:463843	C/T	cg06217071	chr17:408420	NA	-0.51	-7.36	-0.43	2.67e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13082711	0.911	rs13081368	chr3:27521998	G/T	cg02860705	chr3:27208620	NA	0.55	7.49	0.43	1.26e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs5995756	0.736	rs8140185	chr22:40010806	A/G	cg03390717	chr22:39966585	CACNA1I	0.29	5.16	0.31	5.02e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg24642439	chr20:33292090	TP53INP2	-0.61	-7.86	-0.45	1.19e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.93	-0.45	7.81e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.720	rs72670225	chr4:119302167	C/T	cg21605333	chr4:119757512	SEC24D	1.01	6.82	0.4	7e-11	Cannabis dependence symptom count;
KIRP	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.43	6.57	0.39	2.94e-10	Schizophrenia;
KIRP	cis	rs4805272	0.962	rs2870544	chr19:29324733	C/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.25e-10	Hepatitis;
KIRP	cis	rs11209185	0.503	rs4655573	chr1:68438778	C/T	cg22082780	chr1:68452167	NA	-0.39	-5.56	-0.33	6.85e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7560272	0.538	rs17434655	chr2:73923089	C/T	cg20560298	chr2:73613845	ALMS1	-0.51	-6.02	-0.36	6.22e-9	Schizophrenia;
KIRP	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.51	-8.01	-0.45	4.51e-14	IgG glycosylation;
KIRP	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg02569458	chr12:86230093	RASSF9	0.38	5.52	0.33	8.68e-8	Major depressive disorder;
KIRP	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	1.11	17.91	0.75	1.81e-46	Homoarginine levels;
KIRP	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16798694	chr8:141557712	EIF2C2	0.46	6.24	0.37	1.88e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.56	-7.66	-0.44	4.39e-13	Prostate cancer;
KIRP	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.44	6.02	0.36	6.28e-9	Total body bone mineral density;
KIRP	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.5	-6.05	-0.36	5.31e-9	Alzheimer's disease biomarkers;
KIRP	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.72	-8.38	-0.47	4.06e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7692976	0.868	rs882471	chr4:110904973	C/T	cg06981781	chr4:110842888	EGF	-0.22	-4.99	-0.3	1.17e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.71	8.93	0.49	1.05e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1165472	1.000	rs6700588	chr1:56099371	A/C	cg11523071	chr1:56160889	NA	0.41	5.23	0.32	3.71e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15369054	chr17:80825471	TBCD	0.68	5.8	0.35	2e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03903647	chr4:40058344	N4BP2;LOC344967	0.49	6.23	0.37	1.98e-9	Myopia (pathological);
KIRP	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg07701084	chr6:150067640	NUP43	0.61	7.85	0.45	1.25e-13	Lung cancer;
KIRP	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg26876637	chr1:152193138	HRNR	0.73	10.08	0.54	3.26e-20	Atopic dermatitis;
KIRP	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.51	5.36	0.32	1.87e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-7.69	-0.44	3.47e-13	Lung cancer;
KIRP	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11987759	chr7:65425863	GUSB	0.49	6.24	0.37	1.85e-9	Aortic root size;
KIRP	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.57	8.23	0.46	1.13e-14	Ovarian reserve;
KIRP	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.87	-12.09	-0.61	1.02e-26	Obesity-related traits;
KIRP	cis	rs7175404	0.938	rs7174235	chr15:94052854	G/A	cg23502883	chr15:93959149	NA	0.51	5.14	0.31	5.68e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs4919687	0.544	rs34269636	chr10:104410599	T/C	cg04362960	chr10:104952993	NT5C2	0.55	5.64	0.34	4.61e-8	Colorectal cancer;
KIRP	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg04287289	chr16:89883240	FANCA	0.76	11.93	0.61	3.39e-26	Schizophrenia;
KIRP	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.32	5.29	0.32	2.69e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg26022315	chr17:47021804	SNF8	0.43	5.52	0.33	8.45e-8	Type 2 diabetes;
KIRP	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.43e-11	Response to antipsychotic treatment;
KIRP	cis	rs597583	0.806	rs12224853	chr11:117394822	A/G	cg27161313	chr11:117392002	DSCAML1	0.57	6.37	0.38	9.23e-10	Putamen volume;
KIRP	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.6	-9.07	-0.5	3.99e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs6991838	0.584	rs4388482	chr8:66496203	T/G	cg13398993	chr8:66546079	ARMC1	-0.47	-5.37	-0.32	1.85e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1106684	1.000	rs11764453	chr7:131452984	C/T	cg13607082	chr12:122652224	LRRC43	-0.68	-7.24	-0.42	5.87e-12	Body mass index;
KIRP	cis	rs10518128	1.000	rs7672884	chr4:75707822	G/A	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.71	-0.39	1.36e-10	Type 2 diabetes;
KIRP	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.69	-10.21	-0.55	1.23e-20	Bladder cancer;
KIRP	cis	rs1816854	1.000	rs10880569	chr12:44201636	C/G	cg20956634	chr12:44200518	TWF1	0.53	5.74	0.34	2.72e-8	Inflammatory bowel disease;
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.99	14.17	0.67	1.02e-33	Cognitive function;
KIRP	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg17470723	chr8:74884337	TCEB1	0.57	7.35	0.42	2.86e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg00579200	chr11:133705235	NA	-0.38	-4.99	-0.3	1.15e-6	Childhood ear infection;
KIRP	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.01	-0.3	1.04e-6	Rheumatoid arthritis;
KIRP	cis	rs6855629	1.000	rs2647257	chr4:106199505	A/T	cg08924430	chr4:106067052	TET2	-0.35	-4.85	-0.3	2.23e-6	Height;
KIRP	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.44	6.47	0.38	5.37e-10	Reticulocyte fraction of red cells;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11688874	chr10:28822482	WAC	0.48	6.36	0.38	9.71e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9290877	0.667	rs9816134	chr3:188462321	T/G	cg17392043	chr3:188495102	LPP	-0.48	-6.2	-0.37	2.38e-9	IgE levels;
KIRP	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg22875332	chr1:76189707	ACADM	-0.34	-4.92	-0.3	1.61e-6	Daytime sleep phenotypes;
KIRP	cis	rs4721295	0.540	rs59134428	chr7:2195445	G/A	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.58	-0.33	6.47e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.53	0.33	8.27e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.67	-8.66	-0.48	6.29e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg04727924	chr7:799746	HEATR2	-0.78	-8.85	-0.49	1.8e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs494562	0.892	rs683218	chr6:86118584	A/G	cg21730993	chr6:86159210	NT5E	0.51	5.19	0.31	4.35e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6496044	0.963	rs7165300	chr15:86070069	G/C	cg17133734	chr15:86042851	AKAP13	-0.44	-5.22	-0.32	3.86e-7	Interstitial lung disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15208375	chr19:31841555	TSHZ3	0.47	6.37	0.38	9.11e-10	Parkinson's disease;
KIRP	trans	rs12517041	1.000	rs4374724	chr5:23309672	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.43	4.91	0.3	1.66e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs10777332	0.675	rs10859209	chr12:92204429	C/T	cg04275566	chr13:113512395	ATP11A	0.63	6.02	0.36	6.34e-9	Biochemical measures;
KIRP	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.78	-8.76	-0.49	3.16e-16	Platelet count;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18713687	chr3:195489789	MUC4	-0.71	-6.25	-0.37	1.84e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg21573476	chr21:45109991	RRP1B	-0.51	-6.8	-0.4	7.77e-11	Mean corpuscular volume;
KIRP	cis	rs9649213	0.574	rs60077733	chr7:97970137	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.35	0.32	1.99e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.5	6.13	0.36	3.54e-9	Type 2 diabetes;
KIRP	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.84	11.93	0.61	3.52e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.23	0.46	1.13e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.54	-0.43	9e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg18404041	chr3:52824283	ITIH1	0.36	5.21	0.32	3.91e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.79	11.36	0.59	2.6e-24	Monocyte count;
KIRP	trans	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg17712092	chr4:129076599	LARP1B	-0.6	-7.61	-0.44	5.97e-13	Eosinophil percentage of white cells;
KIRP	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.86	0.6	5.98e-26	Cannabis dependence symptom count;
KIRP	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.93	-12.89	-0.64	2.08e-29	Cognitive function;
KIRP	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.97	13.14	0.64	3.05e-30	Multiple sclerosis;
KIRP	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg17554472	chr22:41940697	POLR3H	-0.45	-5.31	-0.32	2.43e-7	Neuroticism;
KIRP	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.31	-0.32	2.39e-7	Electroencephalogram traits;
KIRP	cis	rs4566357	1.000	rs7577005	chr2:227921573	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.06	-0.31	8.14e-7	Coronary artery disease;
KIRP	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.61	7.02	0.41	2.15e-11	Testicular germ cell tumor;
KIRP	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs9828933	0.766	rs704372	chr3:63867453	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.95	9.52	0.52	1.67e-18	Type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09477006	chr4:6711267	MRFAP1L1	-0.46	-6.46	-0.38	5.42e-10	Metabolic traits;
KIRP	cis	rs9443189	1.000	rs6906615	chr6:76489774	A/G	cg01950844	chr6:76311363	SENP6	0.5	4.96	0.3	1.35e-6	Prostate cancer;
KIRP	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg02415014	chr8:143852576	LYNX1	-0.31	-5.03	-0.31	9.61e-7	Urinary tract infection frequency;
KIRP	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.8	7.69	0.44	3.45e-13	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.7	8.46	0.47	2.48e-15	Post bronchodilator FEV1;
KIRP	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg23594656	chr7:65796392	TPST1	0.36	5.36	0.32	1.94e-7	Corneal structure;
KIRP	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05025164	chr4:1340916	KIAA1530	-0.5	-6.53	-0.38	3.82e-10	Obesity-related traits;
KIRP	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg04369109	chr6:150039330	LATS1	-0.65	-7.86	-0.45	1.23e-13	Lung cancer;
KIRP	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.56	-7.57	-0.43	7.4e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs73200209	0.744	rs17426676	chr12:116595512	T/C	cg01776926	chr12:116560359	MED13L	-0.52	-5.84	-0.35	1.62e-8	Total body bone mineral density;
KIRP	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg26022315	chr17:47021804	SNF8	0.4	5.1	0.31	6.81e-7	Type 2 diabetes;
KIRP	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.85e-7	Diabetic retinopathy;
KIRP	cis	rs860295	0.702	rs2025669	chr1:155357609	G/A	cg02153340	chr1:155202674	NA	-0.55	-7.45	-0.43	1.56e-12	Body mass index;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg17232254	chr10:64927353	JMJD1C	0.43	6.12	0.36	3.66e-9	Migraine with aura;
KIRP	cis	rs4765905	1.000	rs11062170	chr12:2348844	G/C	cg10668781	chr12:2307325	CACNA1C	-0.29	-5.22	-0.32	3.75e-7	Schizophrenia;
KIRP	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.07e-12	Blood protein levels;
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg16341495	chr8:142228727	SLC45A4	-0.4	-4.92	-0.3	1.58e-6	Immature fraction of reticulocytes;
KIRP	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.46e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	5.9	0.35	1.18e-8	Mean corpuscular volume;
KIRP	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg01566213	chr4:1579287	NA	-0.4	-5.65	-0.34	4.48e-8	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg05785598	chr3:49045655	WDR6	0.27	4.89	0.3	1.83e-6	Parkinson's disease;
KIRP	cis	rs9905704	0.633	rs2632506	chr17:56467408	G/T	cg12560992	chr17:57184187	TRIM37	-0.56	-5.44	-0.33	1.26e-7	Testicular germ cell tumor;
KIRP	cis	rs7267005	1.000	rs58481463	chr20:34537994	G/T	cg17201900	chr20:34330562	RBM39	0.92	5.16	0.31	5.14e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.79	-0.35	2.14e-8	Aortic root size;
KIRP	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg25039879	chr17:56429692	SUPT4H1	0.59	5.17	0.31	4.82e-7	Cognitive test performance;
KIRP	cis	rs2708977	0.637	rs676007	chr2:97075052	G/A	cg01950434	chr2:97203154	ARID5A	-0.41	-5.04	-0.31	8.89e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs35000415	0.873	rs62478615	chr7:128684316	G/C	cg19972273	chr7:128594194	NA	0.86	6.34	0.37	1.12e-9	Systemic lupus erythematosus;
KIRP	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26306683	chr17:18585705	ZNF286B	0.6	7.81	0.45	1.64e-13	Educational attainment (years of education);
KIRP	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg09163369	chr1:210001066	C1orf107	0.51	6.63	0.39	2.07e-10	Orofacial clefts;
KIRP	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.43	8.55	0.48	1.33e-15	Mean corpuscular volume;
KIRP	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	trans	rs7999699	0.934	rs1924803	chr13:48337255	T/A	cg23237801	chr1:16476620	EPHA2	0.51	6.34	0.37	1.1e-9	Colorectal cancer (diet interaction);
KIRP	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.62	-6.36	-0.38	9.71e-10	Axial length;
KIRP	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.85	-9.24	-0.51	1.23e-17	Osteoarthritis;
KIRP	cis	rs4704187	0.687	rs4340901	chr5:74404905	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs11628318	0.950	rs4356406	chr14:103050106	G/A	cg12046867	chr14:103022105	NA	-0.45	-6.23	-0.37	2.02e-9	Platelet count;
KIRP	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg08738300	chr3:44038990	NA	0.69	9.74	0.53	3.69e-19	Coronary artery disease;
KIRP	cis	rs1006703	0.544	rs8068346	chr17:3838717	T/C	cg06463185	chr17:3833770	ATP2A3	-0.65	-5.96	-0.36	8.88e-9	Glucose homeostasis traits;
KIRP	cis	rs9479482	0.686	rs2184452	chr6:150384827	T/C	cg03788504	chr6:150331562	NA	-0.32	-5.77	-0.35	2.34e-8	Alopecia areata;
KIRP	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg01689657	chr7:91764605	CYP51A1	0.46	6.83	0.4	6.75e-11	Breast cancer;
KIRP	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.5	-7.97	-0.45	6.03e-14	Platelet distribution width;
KIRP	cis	rs2071426	1.000	rs2071426	chr10:96828323	T/C	cg09036531	chr10:96991505	NA	-0.7	-8.33	-0.47	5.79e-15	Blood metabolite levels;
KIRP	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.04	-0.58	2.71e-23	Height;
KIRP	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg11498726	chr8:26250323	BNIP3L	-0.53	-7.88	-0.45	1.03e-13	Red cell distribution width;
KIRP	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.65	-6.08	-0.36	4.62e-9	Breast cancer;
KIRP	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg06647332	chr5:131281008	NA	-0.46	-5.01	-0.3	1.05e-6	Life satisfaction;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg18612461	chr15:75251733	NA	0.33	5.12	0.31	6.14e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs10203711	0.681	rs10202058	chr2:239607772	T/C	cg14580085	chr2:239553406	NA	0.41	5.34	0.32	2.09e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg18478394	chr8:109455254	TTC35	0.5	6.17	0.37	2.8e-9	Dupuytren's disease;
KIRP	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	9.75	0.53	3.25e-19	Mean platelet volume;
KIRP	cis	rs3126085	0.515	rs4322234	chr1:152353768	A/G	cg26876637	chr1:152193138	HRNR	-0.55	-6.91	-0.4	4.15e-11	Atopic dermatitis;
KIRP	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.62	-9.01	-0.5	5.72e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.62	6.76	0.4	9.8e-11	Corneal astigmatism;
KIRP	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg19767477	chr5:127420684	SLC12A2	-0.34	-4.87	-0.3	2.02e-6	Ileal carcinoids;
KIRP	cis	rs8077889	0.750	rs80053172	chr17:41936843	C/T	cg26893861	chr17:41843967	DUSP3	0.85	8.88	0.49	1.46e-16	Triglycerides;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09172752	chr15:77197536	NA	-0.56	-6.09	-0.36	4.23e-9	Menopause (age at onset);
KIRP	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg21696256	chr3:125484277	NA	0.48	5.52	0.33	8.8e-8	Blood pressure (smoking interaction);
KIRP	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.14	-10.14	-0.54	2.12e-20	Body mass index;
KIRP	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.52	-6.92	-0.4	3.87e-11	Total body bone mineral density;
KIRP	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.55	7.33	0.42	3.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs507080	0.769	rs527290	chr11:118515616	C/T	cg04173919	chr11:118528438	PHLDB1	0.36	5.08	0.31	7.53e-7	Serum metabolite levels;
KIRP	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.43	6.93	0.4	3.64e-11	Type 2 diabetes;
KIRP	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg24060327	chr5:131705240	SLC22A5	-0.62	-7.62	-0.44	5.35e-13	Blood metabolite levels;
KIRP	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs5753037	0.803	rs131263	chr22:30133045	C/T	cg01021169	chr22:30184971	ASCC2	-0.39	-4.93	-0.3	1.54e-6	Type 1 diabetes;
KIRP	cis	rs282587	0.597	rs1278659	chr13:113386497	G/T	cg04656015	chr13:113407548	ATP11A	0.67	8.12	0.46	2.29e-14	Glycated hemoglobin levels;
KIRP	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg12560992	chr17:57184187	TRIM37	0.61	5.47	0.33	1.11e-7	Cognitive test performance;
KIRP	cis	rs7221595	0.825	rs62072392	chr17:3910125	A/G	cg21851534	chr17:3907994	ZZEF1	0.57	5.49	0.33	9.93e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10568689	chr11:73591256	PAAF1	-0.5	-6.31	-0.37	1.25e-9	Inflammatory biomarkers;
KIRP	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.05	0.41	1.77e-11	Mean corpuscular volume;
KIRP	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.47	-6.83	-0.4	6.75e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.58	-6.92	-0.4	3.95e-11	Menopause (age at onset);
KIRP	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg20295408	chr7:1910781	MAD1L1	-0.55	-6.81	-0.4	7.26e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg09904177	chr6:26538194	HMGN4	-0.56	-5.17	-0.31	4.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.55	-5.12	-0.31	6.25e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg05926928	chr17:57297772	GDPD1	-0.79	-7.61	-0.44	5.71e-13	Opioid sensitivity;
KIRP	cis	rs7809615	0.901	rs10273424	chr7:99196073	T/A	cg12290671	chr7:99195819	NA	-0.67	-6.32	-0.37	1.21e-9	Blood metabolite ratios;
KIRP	trans	rs7246760	0.867	rs55914342	chr19:9824447	A/T	cg02900749	chr2:68251473	NA	-1.19	-10.02	-0.54	4.82e-20	Pursuit maintenance gain;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg12692727	chr7:1102344	C7orf50	0.48	5.12	0.31	6.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8177876	0.822	rs56119129	chr16:81118266	C/T	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs12517041	1.000	rs1366453	chr5:23283409	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.45	-0.47	2.58e-15	Calcium levels;
KIRP	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.33	-0.32	2.26e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.22	-24.51	-0.84	5.66e-68	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00889227	chr1:205173544	DSTYK	-0.36	-4.87	-0.3	2.03e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2574704	1.000	rs7433453	chr3:11647416	C/T	cg07643000	chr3:11666825	VGLL4	-0.39	-5.67	-0.34	3.98e-8	Body mass index;
KIRP	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg18944383	chr4:111397179	ENPEP	-0.47	-7.68	-0.44	3.87e-13	Coronary artery disease;
KIRP	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.37e-10	Subjective well-being;
KIRP	cis	rs4812048	0.649	rs3761258	chr20:57618596	C/G	cg14073986	chr20:57617431	SLMO2	-0.65	-5.72	-0.34	3.11e-8	Mean platelet volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15437457	chr12:1100385	ERC1	0.51	6.22	0.37	2.17e-9	Parkinson's disease;
KIRP	cis	rs10858047	0.824	rs222502	chr1:115165472	T/A	cg12756093	chr1:115239321	AMPD1	-0.68	-6.41	-0.38	7.39e-10	Autism;
KIRP	trans	rs12709013	0.591	rs4410065	chr16:58834872	A/G	cg12115882	chr11:133449267	NA	-0.44	-6.04	-0.36	5.59e-9	Blood metabolite ratios;
KIRP	cis	rs787274	1.000	rs787276	chr9:115551891	T/C	cg13803584	chr9:115635662	SNX30	-0.74	-8.38	-0.47	4e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.52	-0.33	8.75e-8	Total body bone mineral density;
KIRP	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg00204512	chr16:28754710	NA	0.45	5.88	0.35	1.36e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.72	-8.5	-0.48	1.9e-15	Corneal astigmatism;
KIRP	cis	rs13161895	1.000	rs34882290	chr5:179463836	C/A	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg12046867	chr14:103022105	NA	-0.54	-7.13	-0.41	1.08e-11	Platelet count;
KIRP	cis	rs4728302	0.869	rs2042455	chr7:133580545	A/G	cg10665199	chr7:133106180	EXOC4	0.47	5.71	0.34	3.32e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7246865	0.510	rs2305757	chr19:17169758	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	6.33	0.37	1.14e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.86	13.04	0.64	6.53e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3105593	1.000	rs11070800	chr15:50907347	C/T	cg08437265	chr15:50716283	USP8	0.39	4.93	0.3	1.48e-6	QT interval;
KIRP	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg23505145	chr19:12996616	KLF1	0.6	8.97	0.5	7.86e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.84	-0.4	6.35e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	11.39	0.59	2.09e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.5	-6.38	-0.38	8.88e-10	Schizophrenia;
KIRP	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg06115741	chr20:33292138	TP53INP2	0.39	5.25	0.32	3.32e-7	Coronary artery disease;
KIRP	cis	rs7577696	0.524	rs805831	chr2:32484228	C/G	cg02381751	chr2:32503542	YIPF4	0.52	5.27	0.32	2.96e-7	Inflammatory biomarkers;
KIRP	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg03563238	chr19:33554763	RHPN2	-0.32	-5.67	-0.34	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.56	6.75	0.4	1.06e-10	Monocyte count;
KIRP	cis	rs10203711	1.000	rs907108	chr2:239566285	T/C	cg14580085	chr2:239553406	NA	0.37	4.94	0.3	1.45e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08392591	chr16:89556376	ANKRD11	0.53	7.42	0.43	1.92e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.73	10.57	0.56	8.76e-22	Hip circumference;
KIRP	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.48	-5.02	-0.3	9.98e-7	Fibroblast growth factor basic levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17217741	chr8:56788346	NA	0.44	6.05	0.36	5.28e-9	Interleukin-4 levels;
KIRP	cis	rs36715	0.868	rs2546147	chr5:127552590	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.58	6.78	0.4	8.73e-11	Breast cancer;
KIRP	cis	rs7940866	0.874	rs11222406	chr11:130814093	A/G	cg12179176	chr11:130786555	SNX19	0.61	7.06	0.41	1.69e-11	Schizophrenia;
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg04804543	chr8:142233427	SLC45A4	-1.02	-17.81	-0.75	3.95e-46	Immature fraction of reticulocytes;
KIRP	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg12369402	chr1:90227771	NA	-0.35	-5.04	-0.31	8.94e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.73	10.09	0.54	2.85e-20	Plateletcrit;Platelet count;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg05941025	chr16:89927596	SPIRE2	-0.32	-5.09	-0.31	7.04e-7	Vitiligo;
KIRP	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg16434002	chr17:42200994	HDAC5	-0.52	-6.49	-0.38	4.61e-10	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12452788	chr2:206597271	NRP2	0.47	6.53	0.38	3.67e-10	Survival in pancreatic cancer;
KIRP	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9682041	0.561	rs7643214	chr3:170144281	C/T	cg11886554	chr3:170076028	SKIL	0.5	4.97	0.3	1.25e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.43	-0.38	6.74e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs858239	0.600	rs61292332	chr7:23131862	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.47	0.33	1.08e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.78	-7.66	-0.44	4.34e-13	Bipolar disorder;
KIRP	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg08999081	chr20:33150536	PIGU	0.46	4.91	0.3	1.7e-6	Protein C levels;
KIRP	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg11972305	chr2:233791962	NGEF	-0.38	-4.9	-0.3	1.74e-6	Schizophrenia;
KIRP	cis	rs3007729	0.509	rs6665151	chr1:18800247	A/G	cg13507429	chr1:18807550	KLHDC7A	0.24	6.44	0.38	6.06e-10	Diabetic retinopathy;
KIRP	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg15557168	chr22:42548783	NA	0.41	5.72	0.34	3.1e-8	Cognitive function;
KIRP	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg19468946	chr17:37922297	IKZF3	-0.46	-6.74	-0.39	1.11e-10	Asthma;
KIRP	cis	rs7635838	0.892	rs2880897	chr3:11494544	A/G	cg00170343	chr3:11313890	ATG7	0.47	5.94	0.35	9.87e-9	HDL cholesterol;
KIRP	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.69	9.39	0.51	4.37e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs793571	0.650	rs12899638	chr15:58920275	G/A	cg05156742	chr15:59063176	FAM63B	0.58	7.47	0.43	1.43e-12	Schizophrenia;
KIRP	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.73	9.08	0.5	3.67e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.03	-0.64	7.39e-30	Height;
KIRP	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.87	9.57	0.52	1.21e-18	Gut microbiome composition (summer);
KIRP	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg02297831	chr4:17616191	MED28	0.53	6.6	0.39	2.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg03060546	chr3:49711283	APEH	-0.61	-6.06	-0.36	5.06e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg06565975	chr8:143823917	SLURP1	0.48	7.37	0.43	2.62e-12	Urinary tract infection frequency;
KIRP	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.5	-7.84	-0.45	1.33e-13	Huntington's disease progression;
KIRP	cis	rs4748857	0.853	rs6482261	chr10:23584488	T/C	cg12804278	chr10:23633326	C10orf67	0.43	5.4	0.33	1.6e-7	Systemic lupus erythematosus;
KIRP	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.72	-0.39	1.26e-10	Diastolic blood pressure;
KIRP	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg08501292	chr6:25962987	TRIM38	0.71	4.85	0.3	2.22e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.84	10.96	0.57	4.9e-23	Menarche (age at onset);
KIRP	cis	rs9311676	0.656	rs66793022	chr3:58391565	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs6125597	0.967	rs6063380	chr20:47881581	A/C	cg03212862	chr20:47662828	CSE1L	-0.41	-5.24	-0.32	3.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6743226	0.934	rs6704615	chr2:242228733	A/G	cg10021735	chr2:242295487	FARP2	-0.49	-6.07	-0.36	4.77e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs73108077	0.736	rs73104088	chr20:29898913	G/T	cg19241311	chr20:30028893	DEFB123	0.73	5.04	0.31	9.21e-7	Red blood cell density in sickle cell anemia;
KIRP	cis	rs4704187	0.687	rs6885071	chr5:74460045	A/G	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.53	-6.84	-0.4	6.21e-11	Rheumatoid arthritis;
KIRP	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg21187068	chr8:144659627	NAPRT1	0.72	4.92	0.3	1.6e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.18e-19	Prudent dietary pattern;
KIRP	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.83	8.26	0.47	9.3e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10909502	chr6:71122960	FAM135A	0.52	7.07	0.41	1.62e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg23625390	chr15:77176239	SCAPER	0.54	7.13	0.41	1.12e-11	Blood metabolite levels;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg16497661	chr14:103986332	CKB	0.75	11.17	0.58	1.07e-23	Body mass index;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07256732	chr16:621771	PIGQ	-0.47	-6.56	-0.39	3.21e-10	Height;
KIRP	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.49	-7.44	-0.43	1.7e-12	Immature fraction of reticulocytes;
KIRP	cis	rs10982256	0.817	rs10817628	chr9:117259538	A/C	cg13636371	chr9:117264095	DFNB31	-0.41	-5.31	-0.32	2.48e-7	Bipolar disorder;
KIRP	cis	rs2411233	0.811	rs3910264	chr15:39262124	A/G	cg02291532	chr15:39874776	THBS1	0.46	6.18	0.37	2.71e-9	Platelet count;
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg24747557	chr10:131355152	MGMT	-0.47	-6.51	-0.38	4.3e-10	Response to temozolomide;
KIRP	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg05044414	chr3:183734942	ABCC5	0.38	5.75	0.34	2.68e-8	Anterior chamber depth;
KIRP	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.23	-0.32	3.69e-7	Menarche (age at onset);
KIRP	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.84	-6.84	-0.4	6.16e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs68170813	0.617	rs6964395	chr7:107080667	G/C	cg02696742	chr7:106810147	HBP1	-0.68	-6.0	-0.36	7.04e-9	Coronary artery disease;
KIRP	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs4778581	0.569	rs870994	chr15:80364246	G/A	cg08257866	chr15:80351198	ZFAND6	0.5	5.35	0.32	2.06e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg00334542	chr7:100209784	MOSPD3	-0.79	-6.74	-0.4	1.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	0.89	7.64	0.44	4.81e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10979	0.571	rs7764231	chr6:143919151	C/G	cg25407410	chr6:143891975	LOC285740	-0.52	-5.39	-0.33	1.62e-7	Hypospadias;
KIRP	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg00405596	chr8:11794950	NA	-0.44	-5.56	-0.33	7.07e-8	Retinal vascular caliber;
KIRP	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	5.13	0.31	5.99e-7	Ovarian reserve;
KIRP	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.14	-0.54	2.03e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs2281603	0.951	rs58893738	chr14:64985811	G/A	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.7	8.27	0.47	8.44e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2688608	0.967	rs2675663	chr10:75660270	T/G	cg23231163	chr10:75533350	FUT11	-0.33	-5.05	-0.31	8.71e-7	Inflammatory bowel disease;
KIRP	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	ch.8.33884649F	chr8:33765107	NA	0.56	7.28	0.42	4.46e-12	Body mass index;
KIRP	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg11569703	chr11:65557185	OVOL1	0.37	5.78	0.35	2.21e-8	Eosinophil percentage of white cells;
KIRP	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.03e-12	Blood protein levels;
KIRP	trans	rs7614311	0.689	rs73122704	chr3:63841228	C/T	cg19155932	chr20:56725873	C20orf85	-0.55	-6.1	-0.36	4.16e-9	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs732765	0.648	rs8019391	chr14:75409682	T/C	cg06637938	chr14:75390232	RPS6KL1	0.42	4.96	0.3	1.3e-6	Non-small cell lung cancer;
KIRP	cis	rs6005807	0.719	rs28818228	chr22:29042025	G/A	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.45	-5.58	-0.34	6.36e-8	Non-small cell lung cancer;
KIRP	cis	rs72820985	1.000	rs35690046	chr16:80844222	G/A	cg04448709	chr16:81349954	GAN	-0.5	-5.07	-0.31	7.99e-7	Breast cancer;
KIRP	cis	rs6693295	0.729	rs2185073	chr1:246213341	G/A	cg11798871	chr1:246315928	SMYD3	-0.42	-5.17	-0.31	4.92e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg04025307	chr7:1156635	C7orf50	0.74	7.73	0.44	2.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.11	-0.36	3.84e-9	Monocyte count;
KIRP	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.57	6.81	0.4	7.29e-11	HDL cholesterol;
KIRP	trans	rs6601327	0.635	rs10112972	chr8:9655218	T/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.26	-0.42	5.17e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg19077165	chr18:44547161	KATNAL2	0.42	5.18	0.31	4.57e-7	Educational attainment;
KIRP	cis	rs1858037	0.836	rs2576923	chr2:65633884	A/G	cg08085232	chr2:65598271	SPRED2	0.54	6.43	0.38	6.55e-10	Rheumatoid arthritis;
KIRP	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.64	7.34	0.42	3.07e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg20169779	chr10:135381914	SYCE1	0.43	5.03	0.31	9.54e-7	Obesity-related traits;
KIRP	cis	rs1863824	0.625	rs11202024	chr10:88168024	C/A	cg07322936	chr10:88137208	NA	-0.53	-5.26	-0.32	3.16e-7	Schizophrenia;
KIRP	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	6.77	0.4	9.26e-11	Coronary artery disease;
KIRP	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.91	-12.07	-0.61	1.19e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg12560992	chr17:57184187	TRIM37	0.63	5.71	0.34	3.25e-8	Cognitive test performance;
KIRP	cis	rs6693567	0.565	rs8006	chr1:150280801	G/C	cg07843065	chr1:150265600	MRPS21	-0.5	-7.29	-0.42	4.32e-12	Migraine;
KIRP	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-5.03	-0.31	9.63e-7	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00833344	chr2:150426294	MMADHC	-0.46	-7.61	-0.44	5.65e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg23995753	chr2:160760732	LY75	-0.41	-5.5	-0.33	9.55e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.52	-4.88	-0.3	1.91e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07985704	chr6:108395859	OSTM1	-0.5	-6.49	-0.38	4.7e-10	Metabolic traits;
KIRP	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.55	14.18	0.67	9.49e-34	Airflow obstruction;
KIRP	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.7	9.57	0.52	1.17e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs600806	0.714	rs12137189	chr1:110013215	A/G	cg02175308	chr1:109941060	SORT1	-0.28	-5.19	-0.31	4.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2274273	0.805	rs28612464	chr14:55816411	T/C	cg04306507	chr14:55594613	LGALS3	0.43	6.56	0.39	3.14e-10	Protein biomarker;
KIRP	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.73	-8.14	-0.46	1.98e-14	Pursuit maintenance gain;
KIRP	trans	rs17079247	0.841	rs9575842	chr13:85807670	G/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.68	-9.19	-0.51	1.67e-17	Hypospadias;
KIRP	cis	rs986417	1.000	rs1262174	chr14:60887194	C/T	cg27398547	chr14:60952738	C14orf39	0.58	6.25	0.37	1.78e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg03651054	chr13:50194643	NA	0.61	8.58	0.48	1.07e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg25547332	chr5:131281432	NA	0.47	5.36	0.32	1.92e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-6.16	-0.37	2.94e-9	Gut microbiome composition (summer);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13265914	chr8:21999630	REEP4	0.57	6.64	0.39	1.95e-10	Smoking initiation;
KIRP	cis	rs3790645	1.000	rs35245195	chr1:26884039	C/G	cg23229016	chr1:26872525	RPS6KA1	0.22	5.69	0.34	3.6e-8	Glucose homeostasis traits;
KIRP	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7113874	0.592	rs10840057	chr11:8498228	C/A	cg08015107	chr11:8618950	NA	-0.7	-8.44	-0.47	2.72e-15	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs6561151	0.957	rs7995004	chr13:44478820	C/T	cg12856521	chr11:46389249	DGKZ	0.5	6.83	0.4	6.44e-11	Crohn's disease;
KIRP	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg23594656	chr7:65796392	TPST1	0.37	5.29	0.32	2.73e-7	Aortic root size;
KIRP	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	7.82	0.45	1.5700000000000001e-13	Personality dimensions;
KIRP	cis	rs394563	0.591	rs237018	chr6:149743930	A/G	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.45	-0.33	1.24e-7	Dupuytren's disease;
KIRP	cis	rs71597109	0.599	rs10446682	chr4:102723839	G/A	cg14855874	chr4:102712397	BANK1	0.4	5.35	0.32	2e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-5.05	-0.31	8.66e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs1497828	0.956	rs2646814	chr1:217523440	A/G	cg04411442	chr1:217543379	NA	-0.41	-6.26	-0.37	1.72e-9	Dialysis-related mortality;
KIRP	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4805272	0.962	rs1363325	chr19:29325666	A/G	cg15000279	chr19:29285009	NA	-0.37	-5.27	-0.32	2.96e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg24838063	chr12:130822603	PIWIL1	-0.5	-6.6	-0.39	2.56e-10	Menopause (age at onset);
KIRP	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg00806126	chr19:22604979	ZNF98	0.69	7.28	0.42	4.38e-12	Pain;
KIRP	cis	rs6601327	0.600	rs7828039	chr8:9654757	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-5.0	-0.3	1.09e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg00599163	chr2:162100495	NA	0.42	4.85	0.3	2.23e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.58	-7.93	-0.45	7.52e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.47	5.27	0.32	2.99e-7	Schizophrenia;
KIRP	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-7.07	-0.41	1.55e-11	Prudent dietary pattern;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Blood metabolite levels;
KIRP	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.43	5.44	0.33	1.31e-7	Common traits (Other);
KIRP	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.94	-0.61	3.24e-26	Idiopathic membranous nephropathy;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10698098	chr6:160148397	WTAP	-0.61	-6.75	-0.4	1.06e-10	Menopause (age at onset);
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	6.52	0.38	4.04e-10	Lymphocyte counts;
KIRP	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.76	-8.04	-0.46	3.77e-14	Asthma;
KIRP	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.59	-0.34	5.87e-8	Parkinson's disease;
KIRP	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.6	-9.21	-0.51	1.51e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.6	-7.39	-0.43	2.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7615316	1.000	rs9856302	chr3:142336361	T/C	cg20824294	chr3:142316082	PLS1	0.23	5.04	0.31	9.04e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-7.48	-0.43	1.31e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg11502198	chr6:26597334	ABT1	-0.78	-5.33	-0.32	2.23e-7	Small cell lung carcinoma;
KIRP	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	0.93	6.35	0.38	1.05e-9	Major depressive disorder;
KIRP	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg23601095	chr6:26197514	HIST1H3D	0.98	8.24	0.47	1.01e-14	Gout;Renal underexcretion gout;
KIRP	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12923728	chr3:195709715	SDHAP1	-0.76	-8.78	-0.49	2.86e-16	Pancreatic cancer;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20018267	chr7:138145918	TRIM24	0.48	6.05	0.36	5.35e-9	Parkinson's disease;
KIRP	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.75	-6.84	-0.4	6.16e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3931020	0.772	rs11485555	chr1:75186509	C/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.39	4.92	0.3	1.62e-6	Resistin levels;
KIRP	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg06636001	chr8:8085503	FLJ10661	0.67	8.56	0.48	1.21e-15	Retinal vascular caliber;
KIRP	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.53	6.92	0.4	4e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.56	-6.47	-0.38	5.2e-10	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.05	-0.31	8.74e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg07701084	chr6:150067640	NUP43	0.56	6.86	0.4	5.41e-11	Testicular germ cell tumor;
KIRP	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.57	-7.4	-0.43	2.14e-12	Lung cancer;
KIRP	cis	rs10982256	0.567	rs11791072	chr9:117238655	C/T	cg13636371	chr9:117264095	DFNB31	0.53	7.21	0.42	6.82e-12	Bipolar disorder;
KIRP	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg17133734	chr15:86042851	AKAP13	0.46	5.93	0.35	1.01e-8	Coronary artery disease;
KIRP	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.73	-8.4	-0.47	3.62e-15	Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03804985	chr9:130159694	SLC2A8	0.51	6.54	0.38	3.47e-10	Parkinson's disease;
KIRP	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2712184	0.756	rs2541395	chr2:217647675	C/T	cg05032264	chr2:217675019	NA	-0.45	-6.59	-0.39	2.67e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.15	0.37	3.09e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg05973401	chr12:123451056	ABCB9	0.57	6.58	0.39	2.74e-10	Neutrophil percentage of white cells;
KIRP	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.18	15.55	0.7	1.95e-38	Corneal structure;
KIRP	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.81	8.3	0.47	6.91e-15	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12762547	chr2:217277354	SMARCAL1	0.49	6.36	0.38	9.96e-10	Parkinson's disease;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg08989290	chr16:615782	NHLRC4	0.38	5.59	0.34	6.07e-8	Height;
KIRP	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.27e-21	Educational attainment;
KIRP	cis	rs7224685	1.000	rs8074454	chr17:3981148	G/C	cg09695851	chr17:3907499	NA	0.64	8.63	0.48	7.71e-16	Type 2 diabetes;
KIRP	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg27411982	chr8:10470053	RP1L1	-0.43	-5.55	-0.33	7.46e-8	Neuroticism;
KIRP	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg17105886	chr17:28927953	LRRC37B2	0.53	5.4	0.33	1.55e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg13753209	chr17:57696993	CLTC	0.57	5.64	0.34	4.71e-8	Obesity-related traits;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg21186296	chr8:27182909	PTK2B	0.51	6.45	0.38	6.01e-10	Neuroticism;
KIRP	cis	rs17321999	1.000	rs72787722	chr2:30489941	T/C	cg05247661	chr2:30472410	LBH	0.7	6.82	0.4	7.04e-11	Systemic lupus erythematosus;
KIRP	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10755512	chr3:44666543	ZNF197	0.5	6.37	0.38	9.32e-10	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.38	0.59	2.23e-24	Height;
KIRP	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.71	10.06	0.54	3.74e-20	Caffeine consumption;
KIRP	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.97	11.68	0.6	2.3e-25	Corneal astigmatism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24918798	chr2:103432687	TMEM182	0.38	6.39	0.38	8.42e-10	C-reactive protein;
KIRP	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg12559939	chr2:27858050	GPN1	0.43	5.52	0.33	8.71e-8	Oral cavity cancer;
KIRP	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9346649	0.654	rs12527055	chr6:168492655	C/T	cg09211372	chr6:168490623	NA	-0.37	-6.3	-0.37	1.36e-9	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg18016565	chr1:150552671	MCL1	-0.34	-5.22	-0.32	3.84e-7	Tonsillectomy;
KIRP	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.58	-9.37	-0.51	4.77e-18	C-reactive protein levels;
KIRP	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.58	0.39	2.83e-10	Aortic root size;
KIRP	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg06640241	chr16:89574553	SPG7	0.63	7.8	0.45	1.76e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs7011507	1.000	rs75026238	chr8:49182358	G/T	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs780094	0.500	rs4665991	chr2:27766284	G/A	cg05484376	chr2:27715224	FNDC4	-0.38	-5.24	-0.32	3.4e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19081843	chr11:68606654	CPT1A	0.43	6.09	0.36	4.31e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02652125	chr6:99857406	SFRS18	-0.44	-6.7	-0.39	1.4e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13323323	0.842	rs56377787	chr3:44293513	A/G	cg02073558	chr3:44770973	ZNF501	0.46	5.38	0.32	1.76e-7	IgG glycosylation;
KIRP	cis	rs6960043	1.000	rs6960043	chr7:15052860	C/T	cg19272540	chr7:15055459	NA	0.19	5.21	0.32	3.93e-7	Type 2 diabetes;
KIRP	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.72	-7.08	-0.41	1.46e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4704187	0.687	rs9293650	chr5:74497084	C/T	cg03227963	chr5:74354835	NA	0.43	6.18	0.37	2.57e-9	Response to amphetamines;
KIRP	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	1.08	19.39	0.78	1.85e-51	Leprosy;
KIRP	cis	rs40363	0.953	rs39730	chr16:3509665	T/G	cg00484396	chr16:3507460	NAT15	0.53	5.79	0.35	2.12e-8	Tuberculosis;
KIRP	cis	rs939574	0.676	rs10166888	chr2:220136836	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.65	-7.13	-0.41	1.13e-11	Platelet distribution width;
KIRP	cis	rs11718455	0.585	rs6789465	chr3:43932045	G/A	cg08738300	chr3:44038990	NA	0.58	7.5	0.43	1.15e-12	Coronary artery disease;
KIRP	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.39	2.66e-10	Bipolar disorder;
KIRP	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs16828019	0.929	rs12037037	chr1:41698256	C/T	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.19	-0.31	4.32e-7	Height;
KIRP	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.6	-0.34	5.64e-8	Bipolar disorder;
KIRP	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	0.98	13.83	0.66	1.46e-32	Alcohol dependence;
KIRP	cis	rs3849570	0.555	rs4481177	chr3:81996817	A/T	cg07356753	chr3:81810745	GBE1	0.54	6.64	0.39	2.03e-10	Waist circumference;Body mass index;
KIRP	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.61	8.59	0.48	1.04e-15	Schizophrenia;
KIRP	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.13e-6	Bladder cancer;
KIRP	cis	rs12643440	0.538	rs4299576	chr4:17140108	G/A	cg22650099	chr4:17144496	NA	-0.7	-8.78	-0.49	2.83e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.73	6.09	0.36	4.39e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.92	13.42	0.65	3.47e-31	Bladder cancer;
KIRP	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.6	7.9	0.45	9.44e-14	Selective IgA deficiency;
KIRP	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg05347473	chr6:146136440	FBXO30	-0.64	-9.32	-0.51	6.8e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11955175	1.000	rs78855960	chr5:40657221	C/G	cg04002187	chr5:40835754	RPL37	0.65	5.26	0.32	3.09e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15128208	chr22:42549153	NA	-0.44	-5.69	-0.34	3.53e-8	Cognitive function;
KIRP	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg01864069	chr14:103024347	NA	-0.86	-10.14	-0.54	2.04e-20	Platelet count;
KIRP	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.8	13.64	0.66	6.41e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.66	-8.07	-0.46	3.17e-14	Obesity-related traits;
KIRP	cis	rs2505998	0.957	rs2506005	chr10:43581980	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.5	-5.19	-0.31	4.31e-7	Hirschsprung disease;
KIRP	cis	rs12431939	0.598	rs10873047	chr14:51727239	G/T	cg23942311	chr14:51606299	NA	0.43	4.93	0.3	1.53e-6	Cancer;
KIRP	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.59	-6.94	-0.4	3.56e-11	Corneal astigmatism;
KIRP	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.69	8.92	0.49	1.1e-16	Resting heart rate;
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg00122941	chr17:4613640	ARRB2	0.79	8.59	0.48	1.04e-15	Lymphocyte counts;
KIRP	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.75	-7.02	-0.41	2.21e-11	Skin colour saturation;
KIRP	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1051424	0.642	rs115869798	chr17:57892829	T/A	cg02344993	chr17:57696989	CLTC	0.61	5.93	0.35	1e-8	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06045408	chr11:20385389	HTATIP2	0.44	6.29	0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.58	-7.43	-0.43	1.84e-12	Cognitive test performance;
KIRP	cis	rs2865126	0.644	rs8098584	chr18:10736934	G/A	cg21165219	chr18:10698044	FAM38B	-0.54	-4.86	-0.3	2.06e-6	Metabolite levels (5-HIAA/ MHPG Ratio);
KIRP	cis	rs7011049	0.841	rs6473775	chr8:53875047	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg24633833	chr3:10029261	TMEM111	0.56	5.44	0.33	1.26e-7	Alzheimer's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13840032	chr18:46385379	KIAA0427	0.51	6.99	0.41	2.53e-11	Survival in pancreatic cancer;
KIRP	cis	rs14057	0.864	rs11122118	chr1:6764807	T/C	cg16431369	chr1:6694556	THAP3;DNAJC11	-0.42	-4.99	-0.3	1.14e-6	Systolic blood pressure;
KIRP	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg03161606	chr19:29218774	NA	0.65	6.27	0.37	1.57e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg01631408	chr1:248437212	OR2T33	0.44	5.78	0.35	2.27e-8	Common traits (Other);
KIRP	cis	rs2271404	0.506	rs10197366	chr2:111996785	C/T	cg23466623	chr2:111982296	NA	-0.68	-9.31	-0.51	7.48e-18	Atopic dermatitis;
KIRP	cis	rs4601821	0.895	rs1055075	chr11:113239512	T/C	cg14159747	chr11:113255604	NA	0.36	5.18	0.31	4.72e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs4971059	0.654	rs4971052	chr1:155126018	C/T	cg02153340	chr1:155202674	NA	-0.43	-6.14	-0.36	3.21e-9	Breast cancer;
KIRP	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg04662567	chr6:169592167	NA	-0.54	-7.35	-0.42	2.93e-12	Pulse pressure;
KIRP	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13385	0.813	rs6859064	chr5:139663301	A/T	cg01860693	chr5:139557145	C5orf32	0.47	4.89	0.3	1.81e-6	Atrial fibrillation;
KIRP	cis	rs2979489	0.891	rs2915590	chr8:30393334	A/G	cg26383811	chr8:30366931	RBPMS	-0.46	-6.48	-0.38	5.07e-10	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg04166393	chr7:2884313	GNA12	0.66	7.93	0.45	7.54e-14	Height;
KIRP	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.83	-11.65	-0.6	2.81e-25	Height;
KIRP	trans	rs2048656	0.561	rs11776236	chr8:9545167	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.66	-0.39	1.81e-10	Schizophrenia;
KIRP	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.28	-0.37	1.53e-9	Retinal vascular caliber;
KIRP	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg18316498	chr11:111250196	POU2AF1	0.41	6.43	0.38	6.56e-10	Primary biliary cholangitis;
KIRP	cis	rs113835537	0.627	rs4630309	chr11:66333072	A/C	cg26679405	chr11:66247800	DPP3	0.61	5.58	0.34	6.44e-8	Airway imaging phenotypes;
KIRP	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.91	8.86	0.49	1.65e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg08885076	chr2:99613938	TSGA10	-0.43	-6.45	-0.38	6e-10	Bipolar disorder;
KIRP	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.21	0.37	2.21e-9	Ovarian reserve;
KIRP	cis	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg06521331	chr12:34319734	NA	-0.44	-5.18	-0.31	4.67e-7	Resting heart rate;
KIRP	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.53	0.7	2.24e-38	Chronic sinus infection;
KIRP	trans	rs7999699	0.902	rs9526393	chr13:48316743	G/C	cg23237801	chr1:16476620	EPHA2	0.49	6.18	0.37	2.67e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg05785598	chr3:49045655	WDR6	0.31	5.56	0.33	7.18e-8	Parkinson's disease;
KIRP	cis	rs240764	0.604	rs9377234	chr6:101263035	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.5	0.33	9.69e-8	Neuroticism;
KIRP	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.64	9.21	0.51	1.47e-17	Resting heart rate;
KIRP	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg12573791	chr2:3828286	NA	0.41	5.72	0.34	3.01e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.56	-6.71	-0.39	1.35e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.73	-10.16	-0.54	1.75e-20	Hypospadias;
KIRP	cis	rs447921	0.817	rs11077823	chr17:74456001	C/T	cg16776035	chr17:74542680	NA	-0.48	-5.09	-0.31	7.24e-7	Mitochondrial DNA levels;
KIRP	cis	rs787274	0.764	rs786965	chr9:115448195	A/C	cg13803584	chr9:115635662	SNX30	0.54	5.65	0.34	4.46e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	0.48	4.96	0.3	1.31e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg18154014	chr19:37997991	ZNF793	-0.53	-6.01	-0.36	6.5e-9	Coronary artery calcification;
KIRP	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	0.84	11.75	0.6	1.3e-25	Primary sclerosing cholangitis;
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.68	-6.51	-0.38	4.08e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	5.96	0.35	8.93e-9	Height;
KIRP	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg23594656	chr7:65796392	TPST1	0.39	5.87	0.35	1.43e-8	Aortic root size;
KIRP	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.91	12.82	0.63	3.65e-29	Morning vs. evening chronotype;
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg19923238	chr8:142232952	SLC45A4	-0.42	-4.91	-0.3	1.67e-6	Immature fraction of reticulocytes;
KIRP	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg06392426	chr19:10676186	KRI1	0.38	4.93	0.3	1.54e-6	Red cell distribution width;
KIRP	cis	rs507080	0.961	rs520543	chr11:118538157	G/A	cg04173919	chr11:118528438	PHLDB1	0.34	4.85	0.3	2.18e-6	Serum metabolite levels;
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.47	-0.33	1.08e-7	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19736369	chr19:12949639	MAST1	0.46	6.02	0.36	6.22e-9	Parkinson's disease;
KIRP	cis	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg07460842	chr6:66804631	NA	-0.48	-5.9	-0.35	1.2e-8	Blood trace element (Cu levels);
KIRP	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.34	-0.55	4.76e-21	Hemoglobin concentration;
KIRP	cis	rs62229266	0.839	rs11088335	chr21:37470335	C/T	cg08632701	chr21:37451849	NA	-0.42	-5.12	-0.31	6.12e-7	Mitral valve prolapse;
KIRP	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.42	-5.44	-0.33	1.26e-7	Blood metabolite levels;
KIRP	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg19847130	chr8:10466454	RP1L1	0.42	6.08	0.36	4.66e-9	Joint mobility (Beighton score);
KIRP	cis	rs4363385	0.510	rs12083211	chr1:153032131	A/T	cg13444842	chr1:152974279	SPRR3	0.43	6.19	0.37	2.46e-9	Inflammatory skin disease;
KIRP	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg11005552	chr10:105648138	OBFC1	0.41	5.9	0.35	1.2e-8	Coronary artery disease;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg01763666	chr17:80159506	CCDC57	0.38	5.22	0.32	3.88e-7	Life satisfaction;
KIRP	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.59	0.52	1.05e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.46	5.85	0.35	1.58e-8	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs526231	0.511	rs55741939	chr5:102372688	T/C	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.43e-29	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg10617943	chr7:1981403	MAD1L1	-0.39	-5.31	-0.32	2.45e-7	Neuroticism;
KIRP	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-4.9	-0.3	1.7e-6	Crohn's disease;
KIRP	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.86	-0.3	2.05e-6	Crohn's disease;
KIRP	cis	rs2249694	0.960	rs7084391	chr10:135412344	A/C	cg20169779	chr10:135381914	SYCE1	-0.42	-4.98	-0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg17691542	chr6:26056736	HIST1H1C	0.39	5.29	0.32	2.71e-7	Schizophrenia;
KIRP	cis	rs8103278	0.701	rs116959973	chr19:46252333	A/T	cg14061069	chr19:46274453	DMPK	-0.56	-6.64	-0.39	1.98e-10	Coronary artery disease;
KIRP	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.17	0.46	1.59e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg03959625	chr15:84868606	LOC388152	0.66	8.03	0.46	3.94e-14	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.4	-5.46	-0.33	1.16e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg16558253	chr16:72132732	DHX38	-0.64	-9.66	-0.52	6.3e-19	Fibrinogen levels;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs17123764	0.818	rs75222486	chr12:50009762	T/G	cg02054252	chr12:50078554	FMNL3	0.48	5.06	0.31	8.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.02	-0.46	4.25e-14	Monocyte percentage of white cells;
KIRP	cis	rs2223471	0.624	rs6927620	chr6:50734984	A/G	cg03432817	chr6:50765336	NA	-0.35	-5.09	-0.31	7.05e-7	Subcutaneous adipose tissue;
KIRP	cis	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.85e-9	Leprosy;
KIRP	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg15147215	chr3:52552868	STAB1	-0.29	-4.89	-0.3	1.78e-6	Electroencephalogram traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17286790	chr17:80096513	CCDC57	0.48	6.21	0.37	2.26e-9	Interleukin-4 levels;
KIRP	cis	rs7172677	0.737	rs12914536	chr15:75437715	C/T	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.4	-0.55	3.03e-21	Response to antipsychotic treatment;
KIRP	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.57	5.6	0.34	5.84e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2494938	0.730	rs417399	chr6:40516762	A/C	cg14084896	chr6:40530702	LRFN2	-0.46	-6.0	-0.36	6.87e-9	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.72	-0.49	4.31e-16	Mood instability;
KIRP	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	2.04e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4950322	0.542	rs3766519	chr1:146686372	C/T	cg22381352	chr1:146742008	CHD1L	-0.42	-5.01	-0.3	1.04e-6	Protein quantitative trait loci;
KIRP	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	10.02	0.54	4.96e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg22676075	chr6:135203613	NA	0.44	6.48	0.38	4.95e-10	Red blood cell count;
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.31	-0.32	2.45e-7	Lung cancer;
KIRP	cis	rs732716	0.740	rs62129356	chr19:4400314	C/T	cg21720385	chr19:4455239	UBXN6	0.71	8.5	0.48	1.88e-15	Mean corpuscular volume;
KIRP	cis	rs8114671	0.647	rs1124511	chr20:33736697	A/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.0	0.36	6.88e-9	Height;
KIRP	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.94	-0.4	3.44e-11	Hemoglobin concentration;
KIRP	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.48	6.34	0.37	1.09e-9	IgG glycosylation;
KIRP	trans	rs2068824	0.573	rs11588215	chr1:201599304	C/T	cg24700485	chr15:53090546	NA	0.79	6.08	0.36	4.64e-9	Celiac disease;
KIRP	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg10950524	chr7:2139216	MAD1L1	0.32	5.1	0.31	6.85e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg04609801	chr16:28609176	SULT1A2	-0.55	-5.3	-0.32	2.56e-7	Platelet distribution width;
KIRP	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.5	-7.14	-0.41	1.06e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	cg21523751	chr1:182988639	NA	0.37	5.38	0.32	1.75e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs11608355	0.508	rs1469944	chr12:109847587	A/T	cg19025524	chr12:109796872	NA	-0.51	-6.18	-0.37	2.68e-9	Neuroticism;
KIRP	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.91	13.15	0.64	2.99e-30	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.33	-5.09	-0.31	7.15e-7	Blood metabolite levels;
KIRP	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg16586182	chr3:47516702	SCAP	0.81	11.1	0.58	1.79e-23	Colorectal cancer;
KIRP	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.41	-6.32	-0.37	1.25e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg24130564	chr14:104152367	KLC1	-0.49	-6.53	-0.38	3.8e-10	Body mass index;
KIRP	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	5.85	0.35	1.57e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1152591	0.643	rs3020449	chr14:64773392	C/T	cg21174375	chr14:64681225	SYNE2	-0.37	-4.94	-0.3	1.43e-6	Atrial fibrillation;
KIRP	cis	rs6580649	0.941	rs60681522	chr12:48464195	T/C	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.85	-13.56	-0.65	1.15e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.5	-0.33	9.66e-8	Lung cancer;
KIRP	cis	rs2573652	0.722	rs12914189	chr15:100544429	A/T	cg09918751	chr15:100517450	ADAMTS17	0.5	6.96	0.41	3.07e-11	Height;
KIRP	cis	rs7116495	0.609	rs12290931	chr11:71553570	G/C	cg10381502	chr11:71823885	C11orf51	0.79	5.38	0.32	1.76e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg05562828	chr17:3906858	NA	0.8	17.25	0.74	3.12e-44	Type 2 diabetes;
KIRP	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.88	12.26	0.62	2.79e-27	Breast cancer;
KIRP	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg03929089	chr4:120376271	NA	0.93	6.78	0.4	8.74e-11	Myopia (pathological);
KIRP	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg16989719	chr2:238392110	NA	-0.58	-5.85	-0.35	1.56e-8	Prostate cancer;
KIRP	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	7.22	0.42	6.3e-12	Eye color traits;
KIRP	cis	rs7258465	1.000	rs271621	chr19:18631332	C/A	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.63	-0.34	4.86e-8	Breast cancer;
KIRP	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.71	-9.03	-0.5	5.18e-17	Coronary artery disease;
KIRP	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-9.42	-0.51	3.5e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs16936870	0.543	rs7837694	chr8:71225278	C/T	cg14232793	chr8:71155543	NCOA2	0.59	7.2	0.42	7.2e-12	QT interval;
KIRP	trans	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg00405596	chr8:11794950	NA	-0.47	-6.32	-0.37	1.24e-9	Mood instability;
KIRP	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.32	-0.42	3.56e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23980196	chr14:91007859	TTC7B	0.47	6.21	0.37	2.22e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26207909	chr14:103986467	CKB	0.75	11.62	0.6	3.54e-25	Body mass index;
KIRP	cis	rs55788414	0.932	rs12102691	chr16:81181460	G/T	cg06400318	chr16:81190750	PKD1L2	-0.85	-7.85	-0.45	1.27e-13	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg10523679	chr1:76189770	ACADM	-0.5	-7.08	-0.41	1.46e-11	Daytime sleep phenotypes;
KIRP	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg06740227	chr12:86229804	RASSF9	0.5	6.47	0.38	5.27e-10	Major depressive disorder;
KIRP	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg16329197	chr12:53359506	NA	-0.54	-5.01	-0.3	1.04e-6	Prostate cancer;
KIRP	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13939156	chr17:80058883	NA	0.53	8.54	0.48	1.39e-15	Life satisfaction;
KIRP	cis	rs1847505	0.609	rs75871412	chr13:61496028	C/G	cg25164009	chr13:61490935	NA	0.53	5.54	0.33	7.59e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs2905347	0.520	rs1858936	chr7:22647553	G/C	cg23521230	chr7:22704884	NA	0.44	5.13	0.31	5.92e-7	Major depression and alcohol dependence;
KIRP	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg00319359	chr11:70116639	PPFIA1	0.78	6.93	0.4	3.73e-11	Coronary artery disease;
KIRP	cis	rs2425143	1.000	rs45595739	chr20:34320759	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs1978968	0.957	rs55865752	chr22:18444227	G/A	cg02610425	chr22:18483192	MICAL3	0.37	5.11	0.31	6.52e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.96	9.7	0.53	4.73e-19	Bronchopulmonary dysplasia;
KIRP	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.84	12.0	0.61	1.99e-26	Itch intensity from mosquito bite;
KIRP	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg16486109	chr11:613632	IRF7	0.43	5.3	0.32	2.52e-7	Systemic lupus erythematosus;
KIRP	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.74	-8.58	-0.48	1.11e-15	Monocyte count;
KIRP	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.42	5.34	0.32	2.16e-7	Melanoma;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.55	-8.88	-0.49	1.4e-16	Lymphocyte counts;
KIRP	cis	rs9815354	1.000	rs6768542	chr3:41865474	G/A	cg03022575	chr3:42003672	ULK4	0.54	5.94	0.35	9.53e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs55871839	0.643	rs7004274	chr8:59810378	T/A	cg07426533	chr8:59803705	TOX	-0.5	-8.43	-0.47	2.87e-15	Pneumonia;
KIRP	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.63	-7.18	-0.42	8.26e-12	Body mass index;
KIRP	cis	rs31771	0.525	rs2132523	chr5:165518271	C/T	cg13976338	chr5:165423657	NA	0.48	4.98	0.3	1.2e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.04	-0.46	3.89e-14	Triglycerides;
KIRP	cis	rs8044995	0.925	rs9928653	chr16:68252079	T/C	cg26727032	chr16:67993705	SLC12A4	-0.75	-8.93	-0.49	1.02e-16	Schizophrenia;
KIRP	cis	rs1355223	0.557	rs7936076	chr11:34724672	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.13	-0.36	3.42e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg24644049	chr4:85504048	CDS1	1.03	6.89	0.4	4.56e-11	Skin colour saturation;
KIRP	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg08499158	chr17:42289980	UBTF	0.48	5.94	0.35	9.8e-9	Total body bone mineral density;
KIRP	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.53	-7.62	-0.44	5.52e-13	Bipolar disorder;
KIRP	cis	rs4523957	0.928	rs216209	chr17:2195130	A/G	cg16513277	chr17:2031491	SMG6	0.61	8.39	0.47	3.93e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg15358701	chr1:161410459	NA	-0.6	-5.76	-0.34	2.56e-8	Rheumatoid arthritis;
KIRP	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg06521331	chr12:34319734	NA	0.62	7.45	0.43	1.6e-12	Morning vs. evening chronotype;
KIRP	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs7246865	0.954	rs3745348	chr19:17212410	C/T	cg18440316	chr19:18077727	KCNN1	-0.41	-5.67	-0.34	4.03e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg01689657	chr7:91764605	CYP51A1	0.37	5.4	0.33	1.55e-7	Breast cancer;
KIRP	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.75	9.6	0.52	9.41e-19	Coronary artery disease;
KIRP	cis	rs16958440	1.000	rs62096471	chr18:44643814	T/C	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs7630877	0.886	rs57823511	chr3:179624521	A/G	cg18765712	chr3:179670323	PEX5L	0.56	6.87	0.4	5.24e-11	Type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01112927	chr2:71357293	MCEE;MPHOSPH10	-0.43	-6.03	-0.36	6.13e-9	Metabolic traits;
KIRP	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.95	0.4	3.32e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg22963979	chr7:1858916	MAD1L1	-0.52	-6.79	-0.4	8.22e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs3931020	0.508	rs4145871	chr1:75218704	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.44	5.46	0.33	1.16e-7	Resistin levels;
KIRP	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.75	7.61	0.44	5.87e-13	Gut microbiome composition (summer);
KIRP	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg08508325	chr11:3079039	CARS	0.33	6.04	0.36	5.55e-9	Calcium levels;
KIRP	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25517755	chr10:38738941	LOC399744	-0.52	-7.14	-0.41	1.05e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-5.21	-0.32	4.04e-7	Retinal vascular caliber;
KIRP	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg06917634	chr15:78832804	PSMA4	-0.57	-5.94	-0.35	9.9e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.59	-5.42	-0.33	1.45e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.67	6.61	0.39	2.43e-10	Axial length;
KIRP	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.58	-4.92	-0.3	1.59e-6	Lung cancer;
KIRP	cis	rs7084402	0.967	rs1658458	chr10:60301382	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.87	-0.57	1.02e-22	Refractive error;
KIRP	cis	rs1832871	0.711	rs7747669	chr6:158664345	A/G	cg07215822	chr6:158701037	NA	-0.64	-7.41	-0.43	2.03e-12	Height;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08233864	chr13:113631110	MCF2L	0.42	6.23	0.37	1.98e-9	Pancreatic cancer;
KIRP	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg02187348	chr16:89574699	SPG7	0.45	5.59	0.34	6.16e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.94	15.52	0.7	2.46e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.68	-7.05	-0.41	1.75e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-5.0	-0.3	1.09e-6	Obesity-related traits;
KIRP	cis	rs3126085	1.000	rs11588170	chr1:152286032	C/T	cg26876637	chr1:152193138	HRNR	-0.83	-8.38	-0.47	4.04e-15	Atopic dermatitis;
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.13	0.46	2.15e-14	Longevity;Endometriosis;
KIRP	cis	rs9513627	1.000	rs3928270	chr13:100184268	A/G	cg25919922	chr13:100150906	NA	0.66	5.13	0.31	5.82e-7	Obesity-related traits;
KIRP	cis	rs3774830	0.776	rs195126	chr4:5429872	T/C	cg26943120	chr4:5472116	STK32B	-0.23	-5.49	-0.33	1.02e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2882667	0.660	rs11951084	chr5:138461547	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-5.54	-0.33	7.88e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7096127	1.000	rs11013971	chr10:24500777	C/T	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.88	0.3	1.91e-6	Lobe attachment (rater scored);
KIRP	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg07636037	chr3:49044803	WDR6	-0.7	-7.45	-0.43	1.57e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00520540	chr10:14880887	CDNF;HSPA14	0.49	6.32	0.37	1.19e-9	Parkinson's disease;
KIRP	cis	rs4780401	0.546	rs3743588	chr16:11836508	G/A	cg01061890	chr16:11836724	TXNDC11	0.81	8.8	0.49	2.55e-16	Rheumatoid arthritis;
KIRP	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.87	-0.4	5.28e-11	Aortic root size;
KIRP	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.61	7.48	0.43	1.35e-12	Dialysis-related mortality;
KIRP	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg19847130	chr8:10466454	RP1L1	-0.34	-5.19	-0.31	4.38e-7	Retinal vascular caliber;
KIRP	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg02640540	chr1:67518911	SLC35D1	-0.4	-4.98	-0.3	1.2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.75	-0.34	2.68e-8	Parkinson's disease;
KIRP	cis	rs7246657	0.891	rs2279149	chr19:38024367	T/C	cg23950597	chr19:37808831	NA	-0.76	-7.91	-0.45	8.99e-14	Coronary artery calcification;
KIRP	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.46	0.7	3.95e-38	Gut microbiome composition (summer);
KIRP	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Hypertriglyceridemia;
KIRP	cis	rs6504622	0.537	rs1618989	chr17:44993708	T/C	cg16759221	chr17:45003025	GOSR2	-0.41	-6.1	-0.36	3.99e-9	Orofacial clefts;
KIRP	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-1.19	-15.3	-0.7	1.41e-37	Response to hepatitis C treatment;
KIRP	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg02336718	chr17:17403227	NA	0.38	5.81	0.35	1.88e-8	Total body bone mineral density;
KIRP	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.71	10.55	0.56	1.01e-21	Dupuytren's disease;
KIRP	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.19	0.31	4.38e-7	Renal cell carcinoma;
KIRP	cis	rs9534288	0.797	rs4337200	chr13:46531749	G/A	cg15192986	chr13:46630673	CPB2	-0.65	-7.93	-0.45	7.69e-14	Blood protein levels;
KIRP	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.45	-6.61	-0.39	2.34e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.49	6.0	0.36	6.87e-9	Initial pursuit acceleration;
KIRP	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.8	11.17	0.58	1.09e-23	Aortic root size;
KIRP	cis	rs2151522	0.762	rs59540076	chr6:127178125	T/C	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg04824913	chr4:887549	GAK	0.59	5.01	0.3	1.05e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg22777020	chr22:31556080	RNF185	-0.51	-5.4	-0.33	1.56e-7	Colorectal cancer;
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg02696790	chr15:75250997	RPP25	0.32	5.64	0.34	4.71e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.5	-4.85	-0.3	2.18e-6	Recombination rate (females);
KIRP	cis	rs6959887	0.962	rs10264933	chr7:35297019	C/T	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	cg04338863	chr8:33670619	NA	0.48	6.31	0.37	1.31e-9	Body mass index;
KIRP	trans	rs7246760	0.867	rs67539464	chr19:9832424	C/G	cg02900749	chr2:68251473	NA	-1.08	-8.92	-0.49	1.09e-16	Pursuit maintenance gain;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17321999	1.000	rs13389106	chr2:30480750	T/G	cg05247661	chr2:30472410	LBH	0.7	7.72	0.44	2.88e-13	Systemic lupus erythematosus;
KIRP	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.14	0.36	3.26e-9	Breast cancer;
KIRP	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.59	8.68	0.48	5.59e-16	Systemic lupus erythematosus;
KIRP	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.92	-15.65	-0.71	8.71e-39	Metabolic syndrome;
KIRP	cis	rs72960926	0.744	rs2352083	chr6:75023176	A/G	cg03266952	chr6:74778945	NA	-0.69	-4.96	-0.3	1.33e-6	Metabolite levels (MHPG);
KIRP	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.72	8.38	0.47	4.19e-15	Corneal astigmatism;
KIRP	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6540559	1.000	rs4844895	chr1:209958580	T/C	cg25204440	chr1:209979598	IRF6	0.5	5.03	0.31	9.53e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg04132472	chr17:19861366	AKAP10	0.41	5.52	0.33	8.61e-8	Schizophrenia;
KIRP	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg11845111	chr2:191398756	TMEM194B	-0.94	-10.39	-0.55	3.25e-21	Diastolic blood pressure;
KIRP	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.62	-7.8	-0.45	1.79e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-4.98	-0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg18016565	chr1:150552671	MCL1	-0.38	-5.76	-0.34	2.52e-8	Tonsillectomy;
KIRP	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.7	9.95	0.54	8.14e-20	Obesity-related traits;
KIRP	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-12.87	-0.63	2.47e-29	Vitiligo;
KIRP	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg05085585	chr16:30420623	ZNF771	-0.35	-5.45	-0.33	1.23e-7	Tonsillectomy;
KIRP	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg02567788	chr10:71992279	PPA1	0.74	7.06	0.41	1.65e-11	Lung function (FEV1);
KIRP	cis	rs10129255	0.500	rs1024350	chr14:107141122	C/T	cg23076370	chr14:107095027	NA	-0.43	-5.43	-0.33	1.38e-7	Kawasaki disease;
KIRP	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.45	-5.19	-0.31	4.36e-7	Total body bone mineral density;
KIRP	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.45	0.52	2.82e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.35	-6.07	-0.36	4.81e-9	Height;
KIRP	cis	rs12643440	0.538	rs56290948	chr4:17138950	C/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	0.83	7.44	0.43	1.7e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.96	-13.06	-0.64	5.8e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15676371	chr5:176518013	FGFR4	0.47	6.39	0.38	8.2e-10	Survival in pancreatic cancer;
KIRP	cis	rs9815354	0.767	rs60943892	chr3:41852307	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.52	6.85	0.4	5.97e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.65	-7.44	-0.43	1.66e-12	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.9	-12.41	-0.62	9.06e-28	Schizophrenia;
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.78	12.95	0.64	1.33e-29	Vitiligo;
KIRP	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg20731937	chr12:48336164	NA	0.42	5.34	0.32	2.16e-7	Longevity (90 years and older);
KIRP	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg04374321	chr14:90722782	PSMC1	0.99	18.13	0.76	3.17e-47	Mortality in heart failure;
KIRP	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.63	-0.52	7.91e-19	Joint mobility (Beighton score);
KIRP	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg23307798	chr14:103986281	CKB	0.74	11.56	0.59	5.47e-25	Body mass index;
KIRP	cis	rs35883536	0.525	rs2647321	chr1:101032006	T/G	cg06223162	chr1:101003688	GPR88	0.47	9.65	0.52	6.7e-19	Monocyte count;
KIRP	cis	rs643506	1.000	rs643506	chr11:111636627	T/G	cg09085632	chr11:111637200	PPP2R1B	0.53	5.96	0.36	8.62e-9	Breast cancer;
KIRP	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.61	-8.63	-0.48	8e-16	Colorectal cancer;
KIRP	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	1.02	18.36	0.76	5.48e-48	Breast cancer;
KIRP	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.56	-5.07	-0.31	7.74e-7	Blood pressure (smoking interaction);
KIRP	cis	rs17401966	0.522	rs6541085	chr1:10285709	A/G	cg19773385	chr1:10388646	KIF1B	-0.44	-6.51	-0.38	4.28e-10	Hepatocellular carcinoma;
KIRP	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs575018	0.836	rs4367275	chr5:100584022	T/C	cg03848127	chr5:100126093	NA	-0.42	-4.91	-0.3	1.69e-6	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-5.33	-0.32	2.25e-7	Height;
KIRP	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg02574844	chr11:5959923	NA	-0.58	-5.97	-0.36	8.15e-9	DNA methylation (variation);
KIRP	cis	rs3818717	0.538	rs752579	chr17:17660347	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.42	-5.09	-0.31	7.05e-7	Lymphocyte counts;
KIRP	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg06781948	chr3:72941472	GXYLT2	0.48	6.4	0.38	7.64e-10	Motion sickness;
KIRP	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.18	0.42	8.11e-12	Vitiligo;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg13713052	chr3:122102218	FAM162A;CCDC58	0.64	6.09	0.36	4.27e-9	Lung function (FEV1);
KIRP	trans	rs933360	0.585	rs7785908	chr7:50833567	T/C	cg20003124	chr12:4557277	NA	0.53	6.46	0.38	5.69e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg02336718	chr17:17403227	NA	-0.37	-5.45	-0.33	1.24e-7	Total body bone mineral density;
KIRP	cis	rs113084984	0.718	rs12620490	chr2:11682796	A/T	cg07314298	chr2:11723111	GREB1	0.39	5.17	0.31	4.76e-7	Breast cancer;
KIRP	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.56	0.39	3.18e-10	Major depressive disorder;
KIRP	cis	rs997295	0.713	rs17243334	chr15:68013079	A/G	cg24579218	chr15:68104479	NA	0.35	4.97	0.3	1.25e-6	Motion sickness;
KIRP	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg07747251	chr5:1868357	NA	0.42	5.52	0.33	8.74e-8	Cardiovascular disease risk factors;
KIRP	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg05721485	chr17:44071124	MAPT	-0.55	-7.56	-0.43	8.12e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11209185	0.509	rs2419044	chr1:68421087	C/T	cg22082780	chr1:68452167	NA	0.4	5.66	0.34	4.27e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.73	6.45	0.38	5.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18364779	chr6:26104403	HIST1H4C	0.4	5.34	0.32	2.13e-7	Schizophrenia;
KIRP	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.53	7.31	0.42	3.82e-12	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.4	0.62	9.2e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.19	0.51	1.65e-17	Colorectal cancer;
KIRP	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg07274523	chr3:49395745	GPX1	0.71	8.75	0.49	3.41e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg01294253	chr9:136912663	BRD3	0.44	5.65	0.34	4.39e-8	Platelet distribution width;
KIRP	cis	rs7520050	0.966	rs4660321	chr1:46366760	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.26	-0.32	3.2e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2562456	0.833	rs11671609	chr19:21525571	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.5	-8.01	-0.45	4.68e-14	Height;
KIRP	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.98	-0.3	1.21e-6	Pulmonary function;
KIRP	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg12560992	chr17:57184187	TRIM37	0.7	6.76	0.4	9.88e-11	Cognitive test performance;
KIRP	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg23387468	chr7:139079360	LUC7L2	0.3	5.23	0.32	3.68e-7	Diisocyanate-induced asthma;
KIRP	cis	rs775227	0.574	rs60279293	chr3:113096087	T/G	cg18753928	chr3:113234510	CCDC52	-0.55	-5.48	-0.33	1.04e-7	Dental caries;
KIRP	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg18016565	chr1:150552671	MCL1	0.4	5.86	0.35	1.49e-8	Melanoma;
KIRP	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.81	-0.53	2.22e-19	Triglycerides;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15480897	chr4:151505467	LRBA;MAB21L2	0.6	7.95	0.45	6.62e-14	Interleukin-4 levels;
KIRP	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.09	0.46	2.69e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs1497828	1.000	rs2810765	chr1:217565100	T/C	cg04411442	chr1:217543379	NA	0.3	4.86	0.3	2.13e-6	Dialysis-related mortality;
KIRP	cis	rs6662572	0.901	rs28484896	chr1:46184200	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.31	0.32	2.5e-7	Blood protein levels;
KIRP	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.62	-7.0	-0.41	2.45e-11	Coronary artery disease;
KIRP	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.32	-0.62	1.68e-27	Ulcerative colitis;
KIRP	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.42	-7.01	-0.41	2.27e-11	Type 2 diabetes;
KIRP	cis	rs988913	0.957	rs72645372	chr6:54788822	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.38	-0.32	1.77e-7	Menarche (age at onset);
KIRP	cis	rs3105593	0.635	rs3131567	chr15:50757930	A/T	cg08437265	chr15:50716283	USP8	0.36	4.93	0.3	1.5e-6	QT interval;
KIRP	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.2	-0.37	2.39e-9	QT interval;
KIRP	cis	rs2712184	0.868	rs1548946	chr2:217665368	C/T	cg05032264	chr2:217675019	NA	-0.52	-7.83	-0.45	1.43e-13	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.11	-0.36	3.93e-9	Schizophrenia;
KIRP	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg10047753	chr17:41438598	NA	1.16	18.75	0.77	2.5e-49	Menopause (age at onset);
KIRP	cis	rs6088813	1.000	rs1540927	chr20:33931344	A/G	cg14752227	chr20:34000481	UQCC	-0.5	-6.62	-0.39	2.21e-10	Height;
KIRP	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.53	-6.29	-0.37	1.45e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs6466055	0.625	rs17707802	chr7:104866472	T/A	cg04380332	chr7:105027541	SRPK2	0.37	5.14	0.31	5.61e-7	Schizophrenia;
KIRP	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg16434002	chr17:42200994	HDAC5	-0.62	-7.7	-0.44	3.24e-13	Total body bone mineral density;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.21	0.37	2.22e-9	Aortic root size;
KIRP	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg25319279	chr11:5960081	NA	-0.59	-6.12	-0.36	3.73e-9	DNA methylation (variation);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19541688	chr19:46289559	DMWD	0.53	6.49	0.38	4.73e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.88e-18	Height;
KIRP	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.37	-5.28	-0.32	2.79e-7	Plateletcrit;
KIRP	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.57	-11.5	-0.59	9.06e-25	Diabetic kidney disease;
KIRP	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.0	0.36	6.91e-9	Schizophrenia;
KIRP	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05901451	chr6:126070800	HEY2	0.41	5.73	0.34	3e-8	Endometrial cancer;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.68	-10.38	-0.55	3.57e-21	Menarche (age at onset);
KIRP	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.47	0.43	1.4e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2979489	0.786	rs62508366	chr8:30369499	G/A	cg26383811	chr8:30366931	RBPMS	-0.46	-6.29	-0.37	1.41e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs2346160	1.000	rs7753298	chr6:167664193	G/A	cg04673565	chr6:167680447	NA	0.39	5.19	0.31	4.49e-7	Parental extreme longevity (95 years and older);
KIRP	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg23791538	chr6:167370224	RNASET2	-0.48	-5.59	-0.34	5.91e-8	Primary biliary cholangitis;
KIRP	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.81	-8.46	-0.47	2.41e-15	Gut microbiome composition (summer);
KIRP	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.69	-0.34	3.69e-8	Breast cancer;
KIRP	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.07	0.5	3.94e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1712517	0.844	rs1163074	chr10:105021762	C/T	cg05636881	chr10:105038444	INA	0.42	6.37	0.38	9.41e-10	Migraine;
KIRP	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.45	-6.29	-0.37	1.42e-9	Dupuytren's disease;
KIRP	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg20243544	chr17:37824526	PNMT	0.52	7.5	0.43	1.13e-12	Asthma;
KIRP	trans	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg19694781	chr19:47549865	TMEM160	0.58	7.82	0.45	1.53e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.81	10.84	0.57	1.26e-22	Total body bone mineral density;
KIRP	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg07701084	chr6:150067640	NUP43	0.61	8.03	0.46	4.09e-14	Lung cancer;
KIRP	cis	rs9900972	0.918	rs8082515	chr17:76876769	C/A	cg20937029	chr17:76870563	TIMP2	0.44	5.06	0.31	8.11e-7	Obesity-related traits;
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg10231116	chr7:157982364	PTPRN2	0.45	5.89	0.35	1.29e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04527057	chr20:5107457	CDS2;PCNA	0.47	6.3	0.37	1.38e-9	Survival in pancreatic cancer;
KIRP	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	0.72	9.65	0.52	6.87e-19	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15212821	chr22:44395017	PARVB	0.53	6.78	0.4	8.73e-11	Interleukin-4 levels;
KIRP	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	11.23	0.58	6.76e-24	Response to antipsychotic treatment;
KIRP	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg25664220	chr3:72788482	NA	-0.33	-5.0	-0.3	1.1e-6	Motion sickness;
KIRP	cis	rs412050	0.696	rs41283227	chr22:22275524	C/T	cg17089214	chr22:22089827	YPEL1	0.57	5.52	0.33	8.44e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	0.98	8.32	0.47	6.08e-15	Arsenic metabolism;
KIRP	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23281280	chr6:28129359	ZNF389	0.44	4.87	0.3	2.01e-6	Depression;
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg17441377	chr17:3906640	NA	0.55	8.28	0.47	7.81e-15	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.12	-0.5	2.68e-17	Retinal vascular caliber;
KIRP	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg10755058	chr3:40428713	ENTPD3	0.48	6.59	0.39	2.63e-10	Renal cell carcinoma;
KIRP	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg04080417	chr5:1859792	NA	-0.54	-6.68	-0.39	1.55e-10	Cardiovascular disease risk factors;
KIRP	cis	rs4812048	0.696	rs6070694	chr20:57591126	G/A	cg14073986	chr20:57617431	SLMO2	0.62	4.89	0.3	1.86e-6	Mean platelet volume;
KIRP	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.3	1e-6	Initial pursuit acceleration;
KIRP	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-5.49	-0.33	1.01e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg25482853	chr8:67687455	SGK3	0.71	6.44	0.38	6.14e-10	Obesity-related traits;
KIRP	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.75	-6.58	-0.39	2.8e-10	Body mass index;
KIRP	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg03808351	chr9:123631620	PHF19	0.4	5.37	0.32	1.8e-7	Rheumatoid arthritis;
KIRP	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg09754948	chr16:28834200	ATXN2L	0.5	5.66	0.34	4.28e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs35100037	0.803	rs10068886	chr5:128612886	G/A	cg23338408	chr14:31289523	NA	-0.61	-6.23	-0.37	2.02e-9	Ankle injury;
KIRP	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.77	6.33	0.37	1.14e-9	Mortality in heart failure;
KIRP	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12579753	0.642	rs11115072	chr12:82284991	T/A	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.48	-0.33	1.07e-7	Resting heart rate;
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.9	0.35	1.17e-8	Platelet count;
KIRP	cis	rs12143943	0.966	rs4950953	chr1:204575481	A/G	cg20240347	chr1:204465584	NA	-0.33	-6.03	-0.36	6.12e-9	Cognitive performance;
KIRP	trans	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg06521331	chr12:34319734	NA	-0.57	-7.02	-0.41	2.15e-11	Bladder cancer;
KIRP	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.91e-9	Response to antipsychotic treatment;
KIRP	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs981844	0.857	rs62325141	chr4:154716407	A/G	cg14289246	chr4:154710475	SFRP2	0.67	8.11	0.46	2.47e-14	Response to statins (LDL cholesterol change);
KIRP	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.69	-0.34	3.59e-8	Life satisfaction;
KIRP	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.48	-5.58	-0.34	6.21e-8	Schizophrenia;
KIRP	cis	rs1014246	0.826	rs1900509	chr10:118470942	T/C	cg14919929	chr10:118506882	NA	-0.57	-7.46	-0.43	1.47e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.74	0.71	4.32e-39	Bipolar disorder;
KIRP	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.42	-0.33	1.39e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-9.16	-0.5	2.12e-17	Triglycerides;
KIRP	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg10523679	chr1:76189770	ACADM	-0.49	-6.78	-0.4	8.75e-11	Daytime sleep phenotypes;
KIRP	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.75	7.77	0.44	2.12e-13	Corneal astigmatism;
KIRP	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg23594656	chr7:65796392	TPST1	0.49	7.65	0.44	4.65e-13	Aortic root size;
KIRP	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.96	-12.69	-0.63	1.01e-28	Platelet distribution width;
KIRP	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.05	12.94	0.64	1.42e-29	Smoking behavior;
KIRP	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg05333889	chr7:157238977	NA	0.46	5.92	0.35	1.1e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg21698718	chr17:80085957	CCDC57	0.36	5.16	0.31	5.15e-7	Life satisfaction;
KIRP	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.18	0.54	1.5e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.47	5.84	0.35	1.66e-8	Height;
KIRP	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg11965913	chr1:205819406	PM20D1	0.44	5.07	0.31	7.85e-7	White blood cell types;
KIRP	trans	rs2504916	0.784	rs2504919	chr6:160773378	G/A	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	0.59	6.18	0.37	2.71e-9	Response to hepatitis C treatment;
KIRP	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.58	6.7	0.39	1.43e-10	Schizophrenia;
KIRP	cis	rs580438	0.529	rs6797729	chr3:13430234	C/T	cg10657019	chr3:13328039	NA	-0.47	-6.07	-0.36	4.81e-9	Myringotomy;
KIRP	cis	rs7834588	0.678	rs72658324	chr8:63912086	G/A	cg04220482	chr8:63952370	GGH	0.52	5.5	0.33	9.5e-8	Response to Vitamin E supplementation;
KIRP	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	5.77	0.35	2.35e-8	Vitiligo;
KIRP	cis	rs1981331	1.000	rs75843712	chr21:47976115	A/G	cg17243659	chr21:48055224	PRMT2	1.11	6.52	0.38	4.06e-10	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.85	9.04	0.5	4.82e-17	Cognitive test performance;
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05025164	chr4:1340916	KIAA1530	0.56	7.41	0.43	2.05e-12	Obesity-related traits;
KIRP	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.5	-7.13	-0.41	1.09e-11	Adiponectin levels;
KIRP	cis	rs6681460	0.966	rs7519747	chr1:67140723	T/C	cg13052034	chr1:66999238	SGIP1	0.46	6.43	0.38	6.6e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.56	-0.33	6.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-7.97	-0.45	5.87e-14	Personality dimensions;
KIRP	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg05625103	chr10:2543513	NA	0.38	4.99	0.3	1.17e-6	Age-related hearing impairment;
KIRP	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg04013166	chr16:89971882	TCF25	0.67	5.64	0.34	4.54e-8	Skin colour saturation;
KIRP	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.79	-7.68	-0.44	3.7e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10633931	chr6:34164263	NA	-0.47	-6.76	-0.4	9.86e-11	Metabolic traits;
KIRP	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	1.0	13.33	0.65	7.31e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	6.45	0.38	5.96e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs2411233	1.000	rs8034449	chr15:39278940	C/A	cg02291532	chr15:39874776	THBS1	0.39	5.3	0.32	2.62e-7	Platelet count;
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.7	-9.07	-0.5	3.8e-17	Obesity-related traits;
KIRP	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.08	-9.61	-0.52	8.76e-19	Plateletcrit;
KIRP	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.75	10.4	0.55	3.07e-21	Parkinson's disease;
KIRP	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg12591125	chr7:1885375	MAD1L1	-0.55	-5.37	-0.32	1.82e-7	Bipolar disorder;
KIRP	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg05775895	chr3:12838266	CAND2	0.37	5.68	0.34	3.77e-8	QRS complex (12-leadsum);
KIRP	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg06243866	chr13:111019493	COL4A2	-0.8	-12.4	-0.62	9.14e-28	White matter hyperintensity burden;
KIRP	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg01428437	chr1:1852164	TMEM52	0.28	4.86	0.3	2.12e-6	Body mass index;
KIRP	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-7.61	-0.44	5.89e-13	Lung cancer;
KIRP	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.62	-7.52	-0.43	1.01e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2412208	0.608	rs11120823	chr1:7113247	G/A	cg20434152	chr1:7120926	CAMTA1	-0.39	-5.22	-0.32	3.79e-7	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs6681460	0.565	rs1536112	chr1:67107225	C/T	cg02459107	chr1:67143332	SGIP1	-0.37	-5.17	-0.31	4.86e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.03	0.64	7.39e-30	Exhaled nitric oxide output;
KIRP	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.51	-8.01	-0.45	4.51e-14	IgG glycosylation;
KIRP	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.91	0.3	1.69e-6	Coronary artery calcification;
KIRP	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg00405596	chr8:11794950	NA	-0.42	-5.09	-0.31	7.06e-7	Retinal vascular caliber;
KIRP	cis	rs7640424	0.721	rs326356	chr3:107824563	C/T	cg09227934	chr3:107805635	CD47	-0.28	-4.87	-0.3	2.02e-6	Body mass index;
KIRP	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg04539111	chr16:67997858	SLC12A4	-0.51	-5.0	-0.3	1.11e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs10875746	0.579	rs10875778	chr12:48624655	T/C	cg24011408	chr12:48396354	COL2A1	-0.45	-5.19	-0.31	4.45e-7	Longevity (90 years and older);
KIRP	trans	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg25288420	chr1:78511713	GIPC2	0.44	6.17	0.37	2.74e-9	Obesity-related traits;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.38	-5.84	-0.35	1.66e-8	Lymphocyte counts;
KIRP	cis	rs1712517	0.873	rs1163083	chr10:105038455	T/A	cg05636881	chr10:105038444	INA	0.44	6.41	0.38	7.34e-10	Migraine;
KIRP	cis	rs829661	0.793	rs2609958	chr2:30872771	T/G	cg10949345	chr2:30726833	LCLAT1	1.09	13.36	0.65	5.56e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2733310	0.895	rs1657930	chr15:57120989	G/A	cg13626582	chr15:57592083	LOC283663	-0.25	-5.58	-0.34	6.44e-8	Mean platelet volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16397071	chr2:15731827	DDX1	0.48	6.48	0.38	5.08e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	0.91	11.68	0.6	2.23e-25	Vitiligo;
KIRP	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	ch.8.33884649F	chr8:33765107	NA	0.61	7.67	0.44	3.9e-13	Body mass index;
KIRP	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg08461772	chr7:95026248	PON3	0.41	6.0	0.36	7.12e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.81	10.72	0.56	3.07e-22	Breast cancer;
KIRP	cis	rs860295	0.871	rs6696888	chr1:155508882	G/A	cg02153340	chr1:155202674	NA	0.39	5.26	0.32	3.1e-7	Body mass index;
KIRP	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg21174375	chr14:64681225	SYNE2	0.57	7.27	0.42	4.68e-12	Atrial fibrillation;
KIRP	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.81	-0.57	1.52e-22	Menopause (age at onset);
KIRP	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.63	-7.52	-0.43	1.03e-12	Menarche (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07008962	chr6:138478542	NA	-0.42	-6.61	-0.39	2.33e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg06521331	chr12:34319734	NA	-0.54	-6.73	-0.39	1.18e-10	Heart rate;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.81	0.35	1.95e-8	Educational attainment;
KIRP	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.57	7.57	0.43	7.58e-13	Blood protein levels;
KIRP	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.51	-0.38	4.19e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.72	-8.1	-0.46	2.54e-14	Pursuit maintenance gain;
KIRP	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.85	0.35	1.56e-8	Total cholesterol levels;
KIRP	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg08499158	chr17:42289980	UBTF	0.62	7.96	0.45	6.38e-14	Total body bone mineral density;
KIRP	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg21605333	chr4:119757512	SEC24D	1.58	10.75	0.57	2.33e-22	Cannabis dependence symptom count;
KIRP	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg19468946	chr17:37922297	IKZF3	-0.45	-6.31	-0.37	1.31e-9	Eosinophil percentage of white cells;
KIRP	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.97	0.3	1.24e-6	Coronary artery calcification;
KIRP	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg09184832	chr6:79620586	NA	-0.51	-7.07	-0.41	1.58e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-4.99	-0.3	1.13e-6	Schizophrenia;
KIRP	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.66	8.28	0.47	8.02e-15	Platelet count;
KIRP	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg19847130	chr8:10466454	RP1L1	0.38	5.27	0.32	2.97e-7	Retinal vascular caliber;
KIRP	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg00857998	chr1:205179979	DSTYK	0.58	7.05	0.41	1.76e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11987759	chr7:65425863	GUSB	-0.52	-6.84	-0.4	6.06e-11	Aortic root size;
KIRP	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg12315302	chr6:26189340	HIST1H4D	0.75	5.07	0.31	7.67e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4750440	0.702	rs4750444	chr10:14029068	C/T	cg27542038	chr10:14027202	FRMD4A	-0.48	-6.6	-0.39	2.5e-10	Adiponectin levels;
KIRP	cis	rs1143633	0.615	rs11687403	chr2:113643638	G/A	cg06156847	chr2:113672199	IL1F7	0.43	5.66	0.34	4.22e-8	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg05973401	chr12:123451056	ABCB9	-0.5	-5.51	-0.33	9.18e-8	Neutrophil percentage of white cells;
KIRP	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg03571507	chr19:53239146	ZNF611	0.24	5.86	0.35	1.48e-8	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.87	-11.78	-0.6	1.06e-25	Blood protein levels;
KIRP	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg24253500	chr15:84953950	NA	0.67	7.81	0.45	1.69e-13	Schizophrenia;
KIRP	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.65	-7.43	-0.43	1.82e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.91	-0.45	8.52e-14	Homocysteine levels;
KIRP	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	1.3	9.0	0.5	6.34e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	5.68	0.34	3.85e-8	Renal cell carcinoma;
KIRP	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs28595532	0.668	rs72670237	chr4:119320937	T/C	cg21605333	chr4:119757512	SEC24D	1.04	7.42	0.43	1.88e-12	Cannabis dependence symptom count;
KIRP	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	6.66	0.39	1.73e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.38	-0.47	4.18e-15	Retinal vascular caliber;
KIRP	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.78	-10.09	-0.54	2.93e-20	Total body bone mineral density;
KIRP	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.59	7.8	0.45	1.76e-13	Response to temozolomide;
KIRP	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg04896959	chr15:78267971	NA	0.52	6.78	0.4	8.91e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg14675211	chr2:100938903	LONRF2	-0.49	-6.38	-0.38	8.73e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16516785	chr7:100291438	NA	-0.53	-6.2	-0.37	2.32e-9	Menopause (age at onset);
KIRP	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.83	12.55	0.62	3e-28	Longevity;
KIRP	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg09596252	chr17:78655493	RPTOR	0.6	7.86	0.45	1.21e-13	Obesity;
KIRP	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg13607699	chr17:42295918	UBTF	0.48	6.06	0.36	5.18e-9	Total body bone mineral density;
KIRP	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	8.02e-13	Bipolar disorder;
KIRP	cis	rs909341	0.909	rs1291207	chr20:62329412	G/A	cg03999872	chr20:62272968	STMN3	-0.56	-6.58	-0.39	2.79e-10	Atopic dermatitis;
KIRP	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3126085	0.935	rs12405678	chr1:152195308	C/G	cg26876637	chr1:152193138	HRNR	-0.85	-8.44	-0.47	2.82e-15	Atopic dermatitis;
KIRP	cis	rs4262150	0.767	rs6579993	chr5:152329479	C/T	cg12297329	chr5:152029980	NA	0.44	5.94	0.35	9.86e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.0	-7.77	-0.44	2.17e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs954108	0.522	rs7983818	chr13:29383182	A/C	cg11788234	chr13:29393811	NA	-0.57	-7.17	-0.42	8.55e-12	Obesity-related traits;
KIRP	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg16586182	chr3:47516702	SCAP	0.74	9.94	0.54	8.55e-20	Colorectal cancer;
KIRP	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.46	6.01	0.36	6.7e-9	Response to temozolomide;
KIRP	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg18367735	chr17:79674897	NA	0.54	6.55	0.39	3.24e-10	Dental caries;
KIRP	cis	rs258892	0.841	rs266425	chr5:72132531	T/C	cg21869765	chr5:72125136	TNPO1	0.58	6.48	0.38	4.87e-10	Small cell lung carcinoma;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	6.95e-7	Life satisfaction;
KIRP	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05025164	chr4:1340916	KIAA1530	0.43	5.36	0.32	1.9e-7	Obesity-related traits;
KIRP	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg05887092	chr17:76393375	PGS1	0.52	7.09	0.41	1.41e-11	HDL cholesterol levels;
KIRP	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.64	9.2	0.51	1.6e-17	Colorectal cancer;
KIRP	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg26554054	chr8:600488	NA	0.68	4.9	0.3	1.74e-6	IgG glycosylation;
KIRP	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.63	-8.17	-0.46	1.64e-14	Inhibitory control;
KIRP	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.92	-10.67	-0.56	4.43e-22	Diastolic blood pressure;
KIRP	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg03128060	chr6:142623767	GPR126	0.36	5.21	0.32	4.07e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.71	6.5	0.38	4.42e-10	Methadone dose in opioid dependence;
KIRP	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.51	6.22	0.37	2.11e-9	Coffee consumption (cups per day);
KIRP	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.9	-0.3	1.78e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg02524346	chr8:600233	NA	0.86	6.13	0.36	3.55e-9	IgG glycosylation;
KIRP	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg05347473	chr6:146136440	FBXO30	0.46	6.58	0.39	2.84e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	15.92	0.71	1.09e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05220968	chr6:146057943	EPM2A	-0.39	-5.14	-0.31	5.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs526231	0.543	rs246913	chr5:102560370	G/C	cg23492399	chr5:102201601	PAM	-0.47	-4.96	-0.3	1.33e-6	Primary biliary cholangitis;
KIRP	cis	rs2441986	0.821	rs10792146	chr11:57984071	G/C	cg19752551	chr11:57585705	CTNND1	0.36	4.89	0.3	1.81e-6	Systolic blood pressure;
KIRP	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08109568	chr15:31115862	NA	-0.77	-9.28	-0.51	9.02e-18	Huntington's disease progression;
KIRP	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg21684588	chr1:67600265	NA	0.51	5.89	0.35	1.23e-8	Psoriasis;
KIRP	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg04865290	chr3:52927548	TMEM110	0.56	6.79	0.4	8.51e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs13082711	0.863	rs35797268	chr3:27418862	T/C	cg02860705	chr3:27208620	NA	0.57	7.71	0.44	3.06e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6545883	0.811	rs2921718	chr2:61795267	C/A	cg15711740	chr2:61764176	XPO1	-0.6	-8.19	-0.46	1.45e-14	Tuberculosis;
KIRP	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg26681399	chr22:41777847	TEF	-0.42	-4.9	-0.3	1.76e-6	Neuroticism;
KIRP	cis	rs2790457	0.958	rs2790454	chr10:28842032	A/G	cg05705492	chr10:28955341	NA	-0.54	-8.17	-0.46	1.64e-14	Multiple myeloma;
KIRP	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs73198271	0.562	rs76702427	chr8:8660141	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.19	-0.31	4.46e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.38	-0.51	4.47e-18	Personality dimensions;
KIRP	cis	rs2150410	0.703	rs2410104	chr21:40564464	T/C	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs28829049	0.597	rs12563386	chr1:19455205	T/C	cg13387374	chr1:19411106	UBR4	0.41	4.89	0.3	1.78e-6	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4959270	0.780	rs4339511	chr6:451895	T/C	cg13299325	chr6:447777	NA	0.27	5.35	0.32	1.99e-7	Limited cutaneous systemic scleroderma;
KIRP	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg04731861	chr2:219085781	ARPC2	0.29	7.5	0.43	1.12e-12	Colorectal cancer;
KIRP	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.59	6.87	0.4	5.14e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg00933542	chr6:150070202	PCMT1	0.26	4.98	0.3	1.22e-6	Testicular germ cell tumor;
KIRP	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg18016565	chr1:150552671	MCL1	0.39	5.9	0.35	1.19e-8	Melanoma;
KIRP	cis	rs7520050	0.966	rs1707321	chr1:46505309	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.48	-0.33	1.05e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg11635098	chr7:100497156	NA	-0.67	-7.23	-0.42	6.1e-12	Resting heart rate;
KIRP	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg00990874	chr7:1149470	C7orf50	-0.71	-6.79	-0.4	8.45e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs57994353	0.570	rs10870139	chr9:139303269	G/A	cg21253087	chr9:139290292	SNAPC4	0.54	5.42	0.33	1.45e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	trans	rs8112211	0.637	rs2270094	chr19:38840139	T/C	cg09817427	chr6:85474313	TBX18	0.54	6.08	0.36	4.63e-9	Blood protein levels;
KIRP	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.45	-5.31	-0.32	2.41e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.1	0.5	3.09e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.85	0.49	1.7e-16	Bipolar disorder;
KIRP	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg16926213	chr1:1841314	NA	0.31	5.37	0.32	1.79e-7	Body mass index;
KIRP	cis	rs867371	0.820	rs12443224	chr15:82495610	C/T	cg06066596	chr15:83166174	LOC80154	-0.48	-5.44	-0.33	1.28e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs35934224	0.783	rs7287073	chr22:19864335	G/A	cg11182965	chr22:19864308	TXNRD2	-0.47	-5.76	-0.34	2.54e-8	Glaucoma (primary open-angle);
KIRP	cis	rs9328573	0.967	rs2581381	chr15:100509498	T/C	cg09918751	chr15:100517450	ADAMTS17	0.37	5.0	0.3	1.09e-6	Urate levels in lean individuals;
KIRP	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg07936489	chr17:37558343	FBXL20	-0.5	-6.27	-0.37	1.61e-9	Asthma;
KIRP	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg21427119	chr20:30132790	HM13	-0.43	-5.18	-0.31	4.55e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	6.38	0.38	8.86e-10	Cognitive test performance;
KIRP	cis	rs2034088	0.931	rs7217763	chr17:421437	A/G	cg13332499	chr17:408570	NA	0.63	8.53	0.48	1.47e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg13978929	chr19:21580086	ZNF493	-0.52	-5.09	-0.31	7.27e-7	Pain;
KIRP	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-7.51	-0.43	1.12e-12	Body mass index;
KIRP	cis	rs2820315	1.000	rs1517810	chr1:201850057	T/C	cg11586189	chr1:201857591	SHISA4	-0.39	-5.54	-0.33	7.59e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg19773385	chr1:10388646	KIF1B	-0.69	-9.06	-0.5	4.29e-17	Hepatocellular carcinoma;
KIRP	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg07843065	chr1:150265600	MRPS21	-0.5	-7.14	-0.41	1.05e-11	Migraine;
KIRP	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.56	-0.33	6.86e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.71	-10.45	-0.55	2.11e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.57	7.65	0.44	4.51e-13	Obesity-related traits;
KIRP	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg19875535	chr5:140030758	IK	0.64	8.75	0.49	3.4e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10073892	0.667	rs28481357	chr5:101610918	A/G	cg19774478	chr5:101632501	SLCO4C1	0.6	6.17	0.37	2.72e-9	Cognitive decline (age-related);
KIRP	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.97	-12.36	-0.62	1.28e-27	Platelet distribution width;
KIRP	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg11569703	chr11:65557185	OVOL1	0.5	7.47	0.43	1.36e-12	Breast cancer;
KIRP	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg26876637	chr1:152193138	HRNR	-0.76	-8.66	-0.48	6.34e-16	Atopic dermatitis;
KIRP	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.93	13.72	0.66	3.47e-32	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg02353165	chr6:42928485	GNMT	0.44	4.95	0.3	1.36e-6	Blood protein levels;
KIRP	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg03060546	chr3:49711283	APEH	0.46	6.22	0.37	2.16e-9	Parkinson's disease;
KIRP	cis	rs911119	1.000	rs3787498	chr20:23616781	C/T	cg09631192	chr20:23583594	CST9	-0.6	-5.68	-0.34	3.81e-8	Chronic kidney disease;
KIRP	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26378065	chr17:18585709	ZNF286B	0.53	6.83	0.4	6.44e-11	Educational attainment (years of education);
KIRP	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.32	5.29	0.32	2.69e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.7	7.85	0.45	1.25e-13	Obesity-related traits;
KIRP	cis	rs4645881	0.748	rs1010103	chr19:49461211	T/G	cg26673286	chr19:49458596	BAX	0.57	4.94	0.3	1.44e-6	Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.52	-7.04	-0.41	1.87e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs490234	0.841	rs513568	chr9:128411854	G/A	cg14078157	chr9:128172775	NA	-0.42	-5.25	-0.32	3.34e-7	Mean arterial pressure;
KIRP	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.87	6.13	0.36	3.49e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9359856	0.564	rs17735590	chr6:90330268	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-8.15	-0.46	1.84e-14	Bipolar disorder;
KIRP	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg09873164	chr1:152488093	CRCT1	0.61	8.03	0.46	3.93e-14	Hair morphology;
KIRP	cis	rs9436747	0.605	rs7526141	chr1:65975275	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.53	-5.43	-0.33	1.36e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg11569703	chr11:65557185	OVOL1	0.5	7.47	0.43	1.36e-12	Breast cancer;
KIRP	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.82	-12.8	-0.63	4.27e-29	Blood metabolite levels;
KIRP	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.65	0.48	6.58e-16	Motion sickness;
KIRP	cis	rs9653442	0.564	rs4851253	chr2:100762786	T/G	cg17356467	chr2:100759845	AFF3	0.43	6.18	0.37	2.63e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.75	-0.49	3.42e-16	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs35000415	0.688	rs12536719	chr7:128717740	C/T	cg19972273	chr7:128594194	NA	0.61	5.04	0.31	9.2e-7	Systemic lupus erythematosus;
KIRP	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-8.83	-0.49	2.06e-16	Asthma;
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg21475434	chr5:93447410	FAM172A	0.77	6.9	0.4	4.46e-11	Diabetic retinopathy;
KIRP	cis	rs61884328	0.733	rs17197710	chr11:47225996	C/T	cg23433285	chr11:47201945	PACSIN3	-0.63	-4.85	-0.3	2.16e-6	Total body bone mineral density (age over 60);
KIRP	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17507749	chr15:85114479	UBE2QP1	0.7	7.87	0.45	1.14e-13	Schizophrenia;
KIRP	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.64	5.23	0.32	3.64e-7	Schizophrenia;
KIRP	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.69	8.21	0.46	1.27e-14	Blood protein levels;
KIRP	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg26338869	chr17:61819248	STRADA	0.52	6.19	0.37	2.57e-9	Prudent dietary pattern;
KIRP	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.49	6.27	0.37	1.63e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg00405596	chr8:11794950	NA	-0.46	-6.15	-0.37	3.19e-9	Mood instability;
KIRP	cis	rs6430538	0.671	rs13390951	chr2:135582128	A/G	cg25422880	chr2:135218333	TMEM163	-0.4	-5.46	-0.33	1.17e-7	Parkinson's disease;
KIRP	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.79	8.08	0.46	2.95e-14	Hip geometry;
KIRP	cis	rs4711336	0.935	rs3818529	chr6:33661106	T/C	cg15676125	chr6:33679581	C6orf125	0.42	5.65	0.34	4.31e-8	Height;
KIRP	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.67	9.24	0.51	1.21e-17	Morning vs. evening chronotype;
KIRP	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.59	-6.89	-0.4	4.79e-11	Response to antineoplastic agents;
KIRP	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.29	-0.78	4.04e-51	Schizophrenia;
KIRP	cis	rs16828019	0.929	rs11209734	chr1:41698074	C/T	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.75	10.87	0.57	1.01e-22	Prudent dietary pattern;
KIRP	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	0.9	14.06	0.67	2.36e-33	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	10.51	0.56	1.39e-21	Exhaled nitric oxide output;
KIRP	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.42	-6.66	-0.39	1.82e-10	Body mass index;
KIRP	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg07395648	chr5:131743802	NA	-0.38	-5.59	-0.34	6.13e-8	Acylcarnitine levels;
KIRP	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg12560992	chr17:57184187	TRIM37	0.62	5.4	0.33	1.6e-7	Cognitive test performance;
KIRP	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	1.09	8.04	0.46	3.69e-14	Skin colour saturation;
KIRP	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg22117172	chr7:91764530	CYP51A1	-0.44	-5.91	-0.35	1.15e-8	Breast cancer;
KIRP	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.86	-12.8	-0.63	4.2e-29	Height;
KIRP	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-4.98	-0.3	1.19e-6	Life satisfaction;
KIRP	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg25866889	chr13:114914595	NA	-0.4	-5.42	-0.33	1.41e-7	Schizophrenia;
KIRP	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg05555928	chr11:63887634	MACROD1	-0.57	-5.33	-0.32	2.23e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.73	10.5	0.56	1.54e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	0.95	8.11	0.46	2.34e-14	Arsenic metabolism;
KIRP	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2061333	0.557	rs8105860	chr19:44606928	A/G	cg21636353	chr19:44617292	ZNF225	-0.49	-5.08	-0.31	7.29e-7	Alzheimer's disease;
KIRP	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06544989	chr22:39130855	UNC84B	-0.52	-9.15	-0.5	2.22e-17	Menopause (age at onset);
KIRP	cis	rs55986470	0.817	rs10177049	chr2:239422169	G/T	cg08773314	chr2:239334832	ASB1	-0.38	-5.05	-0.31	8.74e-7	Chronotype;
KIRP	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.27	0.32	2.92e-7	Coronary artery disease;
KIRP	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg00738919	chr7:1100172	C7orf50	0.39	4.93	0.3	1.49e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.84	11.2	0.58	8.35e-24	Type 2 diabetes;
KIRP	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg21573476	chr21:45109991	RRP1B	-0.67	-10.02	-0.54	4.75e-20	Mean corpuscular volume;
KIRP	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg12435725	chr3:58293450	RPP14	-0.5	-5.41	-0.33	1.48e-7	Cholesterol, total;
KIRP	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Urinary tract infection frequency;
KIRP	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg00857998	chr1:205179979	DSTYK	0.49	6.03	0.36	5.95e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg26513180	chr16:89883248	FANCA	0.75	5.3	0.32	2.58e-7	Skin colour saturation;
KIRP	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	5.66	0.34	4.24e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs372883	0.869	rs2027605	chr21:30726773	A/G	cg24692254	chr21:30365293	RNF160	0.41	5.22	0.32	3.86e-7	Pancreatic cancer;
KIRP	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.47	0.38	5.23e-10	Birth weight;
KIRP	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.33	-0.51	6.46e-18	Coronary artery disease;
KIRP	cis	rs743757	1.000	rs9835537	chr3:50464335	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	5.62	0.34	5.05e-8	Diastolic blood pressure;
KIRP	cis	rs10861342	1.000	rs1444608	chr12:105559157	A/G	cg23923672	chr12:105501055	KIAA1033	0.85	6.88	0.4	5e-11	IgG glycosylation;
KIRP	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.13	-0.5	2.54e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1461503	0.934	rs930982	chr11:122834378	C/T	cg27398637	chr11:122830231	C11orf63	-0.67	-8.64	-0.48	7.17e-16	Menarche (age at onset);
KIRP	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg25251562	chr2:3704773	ALLC	-0.41	-5.4	-0.33	1.55e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7814319	0.727	rs3808386	chr8:97273543	G/A	cg20787634	chr8:97240163	UQCRB	-0.58	-7.65	-0.44	4.62e-13	Lung function (FVC);
KIRP	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	0.61	5.17	0.31	4.91e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg23601095	chr6:26197514	HIST1H3D	0.58	5.73	0.34	2.91e-8	Gout;Renal underexcretion gout;
KIRP	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.54	7.23	0.42	6.12e-12	Blood metabolite levels;
KIRP	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg21684588	chr1:67600265	NA	0.43	5.06	0.31	8.23e-7	Psoriasis;
KIRP	cis	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg07460842	chr6:66804631	NA	-0.49	-6.0	-0.36	6.94e-9	Blood trace element (Cu levels);
KIRP	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.57	0.43	7.7e-13	White blood cell count;
KIRP	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	0.91	12.67	0.63	1.22e-28	Monocyte percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21620608	chr2:139259466	SPOPL	0.51	6.95	0.41	3.28e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.63	8.04	0.46	3.81e-14	Body mass index;
KIRP	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7215564	0.818	rs1126064	chr17:78610388	A/G	cg06153925	chr17:78755379	RPTOR	0.39	5.75	0.34	2.64e-8	Myopia (pathological);
KIRP	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs6832769	0.961	rs2412646	chr4:56318772	T/C	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.5	5.91	0.35	1.16e-8	Diastolic blood pressure;
KIRP	cis	rs6684514	1.000	rs3806408	chr1:156252137	C/A	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs737693	0.607	rs654600	chr11:102729174	A/C	cg19620758	chr11:102826565	MMP13	0.52	5.45	0.33	1.24e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.83	-11.53	-0.59	7.24e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2191566	0.576	rs420584	chr19:44495257	C/T	cg18700516	chr19:44507157	ZNF230	0.42	4.85	0.3	2.23e-6	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12952179	chr4:111866981	NA	0.42	6.41	0.38	7.58e-10	Cancer;
KIRP	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.45	7.96	0.45	6.32e-14	Height;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg15487600	chr1:155113158	DPM3	-0.45	-6.12	-0.36	3.65e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs7870753	0.838	rs10820682	chr9:99241587	T/G	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Body mass index;
KIRP	cis	rs986417	0.818	rs4901993	chr14:61081453	G/A	cg27398547	chr14:60952738	C14orf39	0.55	5.26	0.32	3.07e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	5.63	0.34	4.92e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4356932	0.935	rs10336	chr4:76922988	A/G	cg00809888	chr4:76862425	NAAA	0.46	6.49	0.38	4.73e-10	Blood protein levels;
KIRP	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg13939156	chr17:80058883	NA	0.47	5.54	0.33	7.83e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg17691542	chr6:26056736	HIST1H1C	0.42	5.6	0.34	5.65e-8	Schizophrenia;
KIRP	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg15442037	chr11:69286293	NA	0.52	6.57	0.39	2.9e-10	Breast cancer (early onset);
KIRP	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg13010199	chr12:38710504	ALG10B	0.62	7.71	0.44	3.18e-13	Morning vs. evening chronotype;
KIRP	cis	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg00806126	chr19:22604979	ZNF98	0.64	7.07	0.41	1.6e-11	Pain;
KIRP	cis	rs2562456	0.876	rs2359144	chr19:21590636	C/T	cg18461458	chr19:21324796	ZNF431	-0.54	-5.15	-0.31	5.22e-7	Pain;
KIRP	cis	rs7127900	1.000	rs7127900	chr11:2233574	A/G	cg25635251	chr11:2234043	NA	0.52	7.86	0.45	1.23e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs4262150	0.764	rs2961756	chr5:151936155	T/A	cg12297329	chr5:152029980	NA	-0.54	-6.81	-0.4	7.32e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs2278796	0.639	rs4950976	chr1:204970243	C/T	cg04862289	chr1:204966208	NFASC	-0.65	-9.26	-0.51	1.08e-17	Mean platelet volume;
KIRP	trans	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg00938859	chr5:1591904	SDHAP3	0.52	6.58	0.39	2.77e-10	Breast cancer;
KIRP	cis	rs7560272	0.501	rs17350188	chr2:73964842	C/G	cg20560298	chr2:73613845	ALMS1	-0.5	-5.96	-0.36	8.54e-9	Schizophrenia;
KIRP	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.57	7.57	0.43	7.38e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.53	6.49	0.38	4.63e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.5	6.98	0.41	2.73e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.57	5.35	0.32	1.98e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17123764	0.818	rs7970241	chr12:49948759	C/T	cg20471783	chr12:50157085	TMBIM6	0.31	4.87	0.3	1.98e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.62	-8.45	-0.47	2.65e-15	Total body bone mineral density;
KIRP	cis	rs10073892	0.664	rs924679	chr5:101880715	T/G	cg19774478	chr5:101632501	SLCO4C1	0.6	5.91	0.35	1.16e-8	Cognitive decline (age-related);
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs212524	0.544	rs2038089	chr1:21551457	C/T	cg21184320	chr1:21044207	KIF17	-0.37	-5.63	-0.34	4.87e-8	Height;
KIRP	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.97	-13.63	-0.66	6.66e-32	Alcohol dependence;
KIRP	cis	rs5753037	0.813	rs9614100	chr22:30288339	A/T	cg27665648	chr22:30112403	NA	0.42	5.77	0.35	2.41e-8	Type 1 diabetes;
KIRP	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg07972983	chr1:205091412	RBBP5	0.4	4.88	0.3	1.87e-6	Red blood cell count;
KIRP	cis	rs698833	0.926	rs1065786	chr2:44660616	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-6.25	-0.37	1.78e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7923609	0.841	rs10740131	chr10:65271488	A/T	cg01631684	chr10:65280961	REEP3	-0.51	-6.08	-0.36	4.61e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.24	0.58	6.2e-24	Alzheimer's disease;
KIRP	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.75	-10.17	-0.54	1.6e-20	Plateletcrit;Platelet count;
KIRP	cis	rs6546324	0.625	rs2902025	chr2:67842424	A/G	cg15745817	chr2:67799979	NA	-0.69	-7.44	-0.43	1.72e-12	Endometriosis;
KIRP	trans	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg06521331	chr12:34319734	NA	-0.62	-7.27	-0.42	4.86e-12	Bladder cancer;
KIRP	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.65	9.81	0.53	2.13e-19	Height;
KIRP	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.4	-5.25	-0.32	3.29e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs490234	0.805	rs517064	chr9:128348486	C/T	cg14078157	chr9:128172775	NA	0.39	4.88	0.3	1.92e-6	Mean arterial pressure;
KIRP	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg01631408	chr1:248437212	OR2T33	-0.65	-8.35	-0.47	5.06e-15	Common traits (Other);
KIRP	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg07541023	chr7:19748670	TWISTNB	0.63	5.52	0.33	8.71e-8	Thyroid stimulating hormone;
KIRP	cis	rs4774899	0.966	rs12910556	chr15:57493210	C/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.39	-0.32	1.65e-7	Urinary tract infection frequency;
KIRP	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	6.07	0.36	4.88e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09647110	chr2:44772303	C2orf34	0.4	6.17	0.37	2.72e-9	Warfarin maintenance dose;
KIRP	cis	rs7654585	1.000	rs4692025	chr4:25949759	A/C	cg10409131	chr4:25915609	C4orf52	-0.46	-5.25	-0.32	3.25e-7	Obesity-related traits;
KIRP	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.85	8.0	0.45	4.86e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.49	7.21	0.42	6.94e-12	Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19629710	chr18:33647533	RPRD1A	-0.45	-6.07	-0.36	4.83e-9	Metabolic traits;
KIRP	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg09264619	chr17:80180166	NA	0.51	6.07	0.36	4.76e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg00405596	chr8:11794950	NA	-0.49	-6.47	-0.38	5.26e-10	Retinal vascular caliber;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16221875	chr6:21588597	NA	0.58	6.8	0.4	7.69e-11	Smoking initiation;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.44	-5.15	-0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg03433033	chr1:76189801	ACADM	-0.43	-6.42	-0.38	6.98e-10	Daytime sleep phenotypes;
KIRP	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	8.65	0.48	6.79e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg05072774	chr3:49840536	C3orf54	-0.38	-4.89	-0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg03465714	chr1:152285911	FLG	-0.42	-4.94	-0.3	1.48e-6	Atopic dermatitis;
KIRP	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.91	10.19	0.54	1.38e-20	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg07274523	chr3:49395745	GPX1	0.69	8.33	0.47	5.52e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.35	-4.9	-0.3	1.71e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs6750047	0.605	rs2121260	chr2:38268763	T/G	cg07380506	chr2:38303506	CYP1B1	0.45	5.88	0.35	1.31e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11987759	chr7:65425863	GUSB	-0.47	-5.62	-0.34	5.13e-8	Aortic root size;
KIRP	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs909341	0.909	rs914559	chr20:62369300	C/G	cg11503966	chr20:62272292	STMN3	0.4	5.36	0.32	1.95e-7	Atopic dermatitis;
KIRP	cis	rs12042938	1.000	rs823158	chr1:231782650	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	6.87	0.4	5.22e-11	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.24	-0.37	1.91e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2273156	1.000	rs35106382	chr14:35434291	T/C	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.65	-0.34	4.31e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg17524265	chr8:144659883	NAPRT1	0.79	5.05	0.31	8.75e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs2120243	0.592	rs7618502	chr3:157095544	C/G	cg24825693	chr3:157122686	VEPH1	-0.49	-7.96	-0.45	6.17e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.69	9.4	0.51	3.93e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs1076160	0.811	rs438369	chr9:135690294	G/A	cg04648087	chr9:135819397	TSC1	-0.4	-4.89	-0.3	1.83e-6	Psoriasis;
KIRP	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.72	-9.02	-0.5	5.62e-17	Blood trace element (Zn levels);
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.78e-8	Lung cancer;
KIRP	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.99	0.41	2.55e-11	Mean platelet volume;
KIRP	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.13e-20	Dupuytren's disease;
KIRP	cis	rs35661897	1.000	rs35661897	chr2:227333838	A/G	cg03426602	chr2:227312417	NA	-0.56	-6.48	-0.38	4.94e-10	Urinary tract infection frequency;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05837253	chr5:42424075	GHR	0.51	7.07	0.41	1.62e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.5	0.33	9.67e-8	Height;
KIRP	cis	rs1823913	0.599	rs34840299	chr2:192145105	G/C	cg12404831	chr2:192114017	MYO1B	0.48	6.78	0.4	8.68e-11	Obesity-related traits;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.45	6.06	0.36	5.14e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg05347473	chr6:146136440	FBXO30	0.57	7.82	0.45	1.51e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg12384639	chr17:618140	VPS53	0.47	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	1.02	9.52	0.52	1.68e-18	Cognitive function;
KIRP	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg21775007	chr8:11205619	TDH	-0.51	-6.71	-0.39	1.3100000000000001e-10	Triglycerides;
KIRP	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.42	0.62	7.93e-28	Smoking behavior;
KIRP	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg20701182	chr2:24300061	SF3B14	0.49	5.08	0.31	7.48e-7	Asthma;
KIRP	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg25019722	chr6:37503610	NA	-0.77	-10.79	-0.57	1.73e-22	Cognitive performance;
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	trans	rs2302464	1.000	rs10939630	chr4:15658481	A/G	cg24908198	chr11:128812992	TP53AIP1	0.37	6.05	0.36	5.3300000000000004e-09	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg21775007	chr8:11205619	TDH	-0.44	-5.8	-0.35	2.07e-8	Neuroticism;
KIRP	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07570687	chr10:102243282	WNT8B	0.49	6.05	0.36	5.28e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg01403660	chr11:68851641	TPCN2	0.66	6.36	0.38	9.63e-10	Blond vs. brown hair color;
KIRP	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.68	7.03	0.41	2.03e-11	Vitiligo;
KIRP	cis	rs258892	0.947	rs266436	chr5:72174553	G/A	cg21869765	chr5:72125136	TNPO1	0.58	6.4	0.38	7.9e-10	Small cell lung carcinoma;
KIRP	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.02	-0.3	1.01e-6	Inflammatory skin disease;
KIRP	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg07777115	chr5:623756	CEP72	-0.53	-5.73	-0.34	2.91e-8	Obesity-related traits;
KIRP	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg05756136	chr1:119680316	WARS2	-0.61	-8.4	-0.47	3.7e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg25281562	chr12:121454272	C12orf43	0.5	5.63	0.34	4.94e-8	N-glycan levels;
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg14221460	chr8:27183342	PTK2B	-0.51	-6.59	-0.39	2.7e-10	Neuroticism;
KIRP	cis	rs8067354	0.645	rs2173120	chr17:57892640	A/T	cg02344993	chr17:57696989	CLTC	0.55	5.1	0.31	6.94e-7	Hemoglobin concentration;
KIRP	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-1.29	-13.51	-0.65	1.7e-31	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.8	-0.4	7.98e-11	Diabetic kidney disease;
KIRP	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg12046867	chr14:103022105	NA	0.53	6.32	0.37	1.22e-9	Platelet count;
KIRP	cis	rs78487399	0.908	rs75597324	chr2:43811239	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.46	-0.33	1.19e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10883723	0.641	rs80146619	chr10:104405850	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	6.62	0.39	2.21e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs6723108	0.738	rs6430538	chr2:135539967	A/G	cg12500956	chr2:135428796	TMEM163	-0.49	-6.33	-0.37	1.14e-9	Type 2 diabetes;
KIRP	cis	rs6545883	0.894	rs4672436	chr2:61603357	A/C	cg15711740	chr2:61764176	XPO1	0.6	7.75	0.44	2.39e-13	Tuberculosis;
KIRP	cis	rs4664293	0.867	rs12623283	chr2:160593470	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg13395646	chr4:1353034	KIAA1530	-0.4	-5.17	-0.31	4.82e-7	Longevity;
KIRP	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.46	5.68	0.34	3.73e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3540	0.538	rs2074585	chr15:91009484	G/A	cg10434728	chr15:90938212	IQGAP1	0.39	7.06	0.41	1.68e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9393813	0.626	rs2393926	chr6:27320744	G/C	cg18711553	chr6:27366782	ZNF391	0.4	5.47	0.33	1.09e-7	Bipolar disorder;
KIRP	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.74	6.81	0.4	7.33e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg18944383	chr4:111397179	ENPEP	0.53	9.05	0.5	4.43e-17	Coronary artery disease;
KIRP	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.46	-5.11	-0.31	6.4e-7	Bipolar disorder;
KIRP	cis	rs17209837	1.000	rs2072383	chr7:87081349	A/G	cg00919237	chr7:87102261	ABCB4	-0.71	-7.14	-0.41	1.02e-11	Gallbladder cancer;
KIRP	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	6.73	0.39	1.19e-10	Menarche (age at onset);
KIRP	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg00129232	chr17:37814104	STARD3	-0.51	-6.67	-0.39	1.68e-10	Self-reported allergy;
KIRP	cis	rs26232	0.583	rs154258	chr5:102363623	G/A	cg23492399	chr5:102201601	PAM	0.45	4.89	0.3	1.83e-6	Rheumatoid arthritis;
KIRP	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.9	-0.45	9.34e-14	Triglycerides;
KIRP	cis	rs7005380	0.556	rs7813263	chr8:120938931	C/T	cg21645572	chr8:120931649	DEPDC6	-0.42	-4.99	-0.3	1.13e-6	Interstitial lung disease;
KIRP	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg25664220	chr3:72788482	NA	-0.43	-6.39	-0.38	8.4e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3736485	0.899	rs7183479	chr15:51942207	C/G	cg14296394	chr15:51910925	DMXL2	-0.34	-5.01	-0.3	1.05e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs732716	0.889	rs62129355	chr19:4397034	T/C	cg03719555	chr19:4455413	UBXN6	0.52	7.92	0.45	8.42e-14	Mean corpuscular volume;
KIRP	cis	rs7534824	0.625	rs61780284	chr1:101355166	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.1	0.41	1.3e-11	Refractive astigmatism;
KIRP	cis	rs12049351	0.774	rs6671385	chr1:229642652	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.87	-0.35	1.44e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs1050631	0.536	rs1785928	chr18:33725931	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.43	-5.43	-0.33	1.35e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg13978929	chr19:21580086	ZNF493	0.51	4.95	0.3	1.35e-6	Pain;
KIRP	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.28	7.44	0.43	1.72e-12	Primary biliary cholangitis;
KIRP	cis	rs752864	0.580	rs17613475	chr15:52607262	C/T	cg25063058	chr15:52860530	ARPP19	-0.45	-5.38	-0.32	1.74e-7	Number of common colds;
KIRP	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.34	-5.58	-0.34	6.18e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg26138937	chr11:71823887	C11orf51	-0.7	-5.59	-0.34	5.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg12405258	chr13:114927641	NA	0.48	6.96	0.41	3.02e-11	Schizophrenia;
KIRP	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.72	-11.24	-0.58	6.35e-24	Hepatocellular carcinoma;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17762617	chr12:118573850	PEBP1	0.71	6.1	0.36	4.2e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs10786764	0.516	rs1884279	chr10:83632817	A/C	cg05499890	chr1:115238213	AMPD1	-0.53	-6.11	-0.36	3.91e-9	Basal metabolic rate;
KIRP	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.58	-0.56	8.35e-22	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs6601327	0.670	rs6601338	chr8:9438928	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.96	0.41	3.07e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg25801113	chr15:45476975	SHF	0.49	9.56	0.52	1.31e-18	Uric acid levels;
KIRP	cis	rs12145833	0.596	rs1060643	chr1:243429976	G/C	cg02356786	chr1:243265016	LOC731275	0.91	6.31	0.37	1.26e-9	Obesity (early onset extreme);
KIRP	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.43	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.01	0.45	4.72e-14	Height;
KIRP	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15237819	chr2:19558375	OSR1	-0.4	-6.02	-0.36	6.21e-9	Metabolic traits;
KIRP	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-7.28	-0.42	4.53e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg03115019	chr17:80708279	FN3K	0.41	4.88	0.3	1.9e-6	Glycated hemoglobin levels;
KIRP	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.68	7.2	0.42	7.27e-12	Lymphocyte counts;
KIRP	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg16141378	chr3:129829833	LOC729375	0.49	6.33	0.37	1.18e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.42	-6.25	-0.37	1.82e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.93	-14.3	-0.67	3.47e-34	Lung cancer;
KIRP	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.92	-0.4	3.94e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7096127	1.000	rs4074063	chr10:24502794	T/C	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.93	0.3	1.55e-6	Lobe attachment (rater scored);
KIRP	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26816363	chr19:46295874	DMWD	0.49	6.6	0.39	2.53e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35771425	1.000	rs12733930	chr1:211603026	C/A	cg10512769	chr1:211675356	NA	-0.52	-5.15	-0.31	5.31e-7	Educational attainment (years of education);
KIRP	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.35	1.16e-8	Total cholesterol levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05509352	chr5:142092851	NA	0.51	7.45	0.43	1.61e-12	Parkinson's disease;
KIRP	cis	rs754423	0.515	rs1956292	chr14:52555693	T/C	cg05884192	chr14:52515736	NID2	0.47	5.18	0.31	4.57e-7	Craniofacial microsomia;
KIRP	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg01872077	chr2:219646372	CYP27A1	0.42	5.45	0.33	1.2e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.81	7.07	0.41	1.55e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1403694	0.966	rs1656910	chr3:186438993	A/C	cg12454167	chr3:186435060	KNG1	0.5	8.78	0.49	2.91e-16	Blood protein levels;
KIRP	cis	rs9381107	0.505	rs9394957	chr6:9484928	C/G	cg14735645	chr6:9486422	NA	-0.56	-7.73	-0.44	2.72e-13	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.6	-0.66	8.64e-32	Response to antipsychotic treatment;
KIRP	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg01689657	chr7:91764605	CYP51A1	0.35	5.07	0.31	7.85e-7	Breast cancer;
KIRP	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg01422370	chr2:73384389	NA	0.41	5.52	0.33	8.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg26531700	chr6:26746687	NA	0.43	5.81	0.35	1.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg11906718	chr8:101322791	RNF19A	0.48	6.38	0.38	8.95e-10	Atrioventricular conduction;
KIRP	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg10760299	chr15:45669010	GATM	0.34	5.07	0.31	7.83e-7	Homoarginine levels;
KIRP	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.86	13.5	0.65	1.85e-31	Height;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08555112	chr17:48942811	TOB1	-0.45	-6.03	-0.36	5.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg09165964	chr15:75287851	SCAMP5	-0.37	-4.99	-0.3	1.13e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4268898	0.552	rs35331966	chr2:24367828	C/T	cg20701182	chr2:24300061	SF3B14	-0.41	-5.26	-0.32	3.15e-7	Asthma;
KIRP	cis	rs509477	1.000	rs531558	chr18:32575286	A/T	cg23791764	chr18:32556832	MAPRE2	-0.5	-6.34	-0.37	1.07e-9	Cerebrospinal fluid AB1-42 levels;
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg13880726	chr7:1868755	MAD1L1	0.51	5.6	0.34	5.58e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg08847533	chr14:75593920	NEK9	0.51	6.08	0.36	4.5e-9	Platelet count;
KIRP	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.55	-9.71	-0.53	4.33e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg09873164	chr1:152488093	CRCT1	0.6	7.79	0.45	1.82e-13	Hair morphology;
KIRP	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg26207909	chr14:103986467	CKB	0.56	7.67	0.44	3.95e-13	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02965039	chr14:77648199	TMEM63C	0.47	6.09	0.36	4.26e-9	Parkinson's disease;
KIRP	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	1.04	15.83	0.71	2.1e-39	Homoarginine levels;
KIRP	cis	rs9398803	0.865	rs9398809	chr6:126789144	C/T	cg19875578	chr6:126661172	C6orf173	0.51	6.63	0.39	2.1e-10	Male-pattern baldness;
KIRP	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg06223162	chr1:101003688	GPR88	-0.43	-8.57	-0.48	1.13e-15	Monocyte count;
KIRP	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.42	5.21	0.32	3.99e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00422248	chr19:16653661	CHERP	0.52	6.48	0.38	5.07e-10	Parkinson's disease;
KIRP	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.08	-0.36	4.67e-9	Colorectal cancer;
KIRP	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.5	-5.46	-0.33	1.15e-7	Total body bone mineral density;
KIRP	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.7	-11.45	-0.59	1.28e-24	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	7.46	0.43	1.44e-12	Height;
KIRP	cis	rs911119	1.000	rs3088162	chr20:23607752	C/A	cg16589663	chr20:23618590	CST3	0.57	5.78	0.35	2.23e-8	Chronic kidney disease;
KIRP	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.78	9.49	0.52	2.04e-18	Corneal astigmatism;
KIRP	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg05234568	chr11:5960015	NA	-0.6	-6.18	-0.37	2.71e-9	DNA methylation (variation);
KIRP	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg07843065	chr1:150265600	MRPS21	0.4	5.45	0.33	1.23e-7	Migraine;
KIRP	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg11266682	chr4:10021025	SLC2A9	-0.38	-4.97	-0.3	1.26e-6	Schizophrenia (age at onset);
KIRP	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg05756136	chr1:119680316	WARS2	-0.61	-8.4	-0.47	3.7e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs13343954	0.575	rs10402158	chr19:33527784	G/C	cg17764715	chr19:33622953	WDR88	0.7	7.86	0.45	1.23e-13	Colorectal cancer;
KIRP	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.37	-0.43	2.63e-12	Morning vs. evening chronotype;
KIRP	cis	rs6782228	0.606	rs6807019	chr3:128405934	G/A	cg18648031	chr3:128330563	NA	0.25	5.16	0.31	5.08e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg25347419	chr2:177043501	NA	0.45	6.28	0.37	1.48e-9	IgG glycosylation;
KIRP	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-7.66	-0.44	4.31e-13	Total body bone mineral density;
KIRP	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg17279839	chr7:150038598	RARRES2	0.43	6.01	0.36	6.55e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.65	-0.34	4.32e-8	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24045810	chr14:76127290	C14orf1;TTLL5	-0.55	-6.55	-0.39	3.4e-10	Interleukin-4 levels;
KIRP	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg18527119	chr7:66119851	NA	-0.45	-4.92	-0.3	1.59e-6	Aortic root size;
KIRP	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg08885076	chr2:99613938	TSGA10	-0.55	-9.67	-0.52	6.06e-19	Chronic sinus infection;
KIRP	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.69	-0.48	5.3e-16	Common traits (Other);
KIRP	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg00495681	chr13:53174319	NA	0.4	5.4	0.33	1.53e-7	Lewy body disease;
KIRP	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.8	-10.57	-0.56	9.26e-22	Body mass index;
KIRP	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg11031976	chr2:198649780	BOLL	-0.52	-5.03	-0.31	9.29e-7	Ulcerative colitis;
KIRP	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	0.94	9.95	0.54	8.26e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg07384165	chr1:10488281	NA	-0.38	-4.89	-0.3	1.79e-6	Breast size;
KIRP	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.39	0.38	8.34e-10	Diabetic retinopathy;
KIRP	cis	rs981844	1.000	rs2251997	chr4:154654067	A/G	cg14289246	chr4:154710475	SFRP2	-0.67	-7.68	-0.44	3.83e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs1823913	0.599	rs34691559	chr2:192172414	T/C	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.65e-12	Obesity-related traits;
KIRP	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg03060546	chr3:49711283	APEH	0.54	7.33	0.42	3.32e-12	Menarche (age at onset);
KIRP	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.41	-4.92	-0.3	1.6e-6	Facial morphology (factor 20);
KIRP	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-11.7	-0.6	1.96e-25	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14021555	chr22:43485536	TTLL1	0.6	7.31	0.42	3.78e-12	Smoking initiation;
KIRP	trans	rs12517041	1.000	rs10052113	chr5:23287871	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.68	-0.48	5.57e-16	Calcium levels;
KIRP	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06481639	chr22:41940642	POLR3H	-0.47	-5.61	-0.34	5.37e-8	Vitiligo;
KIRP	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg14952266	chr13:112191215	NA	0.46	6.68	0.39	1.57e-10	Hepatitis;
KIRP	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.36	6.17e-9	Morning vs. evening chronotype;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.45	5.59	0.34	6.1e-8	Longevity;
KIRP	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg00129232	chr17:37814104	STARD3	-0.54	-6.89	-0.4	4.71e-11	Self-reported allergy;
KIRP	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-8.62	-0.48	8.16e-16	Coronary artery disease;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg19893067	chr17:80732956	TBCD	0.35	4.86	0.3	2.1e-6	Glycated hemoglobin levels;
KIRP	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.09	-0.41	1.43e-11	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15480897	chr4:151505467	LRBA;MAB21L2	0.47	6.61	0.39	2.39e-10	Survival in pancreatic cancer;
KIRP	cis	rs7923609	0.875	rs10761741	chr10:65066186	G/T	cg01631684	chr10:65280961	REEP3	-0.48	-5.57	-0.33	6.71e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3931020	0.705	rs28482086	chr1:75226252	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.41	4.9	0.3	1.77e-6	Resistin levels;
KIRP	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.65	-7.58	-0.44	7.16e-13	IgG glycosylation;
KIRP	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.51	7.37	0.43	2.63e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs2688608	0.967	rs72814394	chr10:75656325	C/T	cg19442545	chr10:75533431	FUT11	-0.36	-4.9	-0.3	1.72e-6	Inflammatory bowel disease;
KIRP	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.32e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg07212818	chr11:638076	DRD4	-0.42	-5.39	-0.33	1.61e-7	Systemic lupus erythematosus;
KIRP	cis	rs4950322	0.570	rs113498894	chr1:146790598	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg26681399	chr22:41777847	TEF	0.48	5.31	0.32	2.5e-7	Vitiligo;
KIRP	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg11608241	chr8:8085544	FLJ10661	0.44	5.81	0.35	1.9e-8	Mood instability;
KIRP	cis	rs4688759	0.764	rs2023953	chr3:50103917	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.78	-6.14	-0.36	3.34e-9	Blood protein levels;
KIRP	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg25801113	chr15:45476975	SHF	0.49	9.69	0.53	4.96e-19	Uric acid levels;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg00261534	chr10:3826854	KLF6	0.54	6.65	0.39	1.87e-10	Asthma;
KIRP	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.46	6.3	0.37	1.36e-9	Dupuytren's disease;
KIRP	cis	rs12460243	0.938	rs17160128	chr19:8132698	A/G	cg26754826	chr19:8657410	ADAMTS10	0.52	5.15	0.31	5.31e-7	Neurocognitive impairment in HIV-1 infection (continuous);
KIRP	cis	rs12760731	0.720	rs2175254	chr1:178319105	G/A	cg00404053	chr1:178313656	RASAL2	0.65	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs6504340	0.790	rs35825473	chr17:46645394	G/A	cg04904318	chr17:46607828	HOXB1	-0.58	-6.17	-0.37	2.78e-9	Primary tooth development (number of teeth);
KIRP	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs2346160	0.867	rs2989556	chr6:167704404	T/A	cg04673565	chr6:167680447	NA	-0.36	-4.86	-0.3	2.11e-6	Parental extreme longevity (95 years and older);
KIRP	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg04362960	chr10:104952993	NT5C2	0.65	7.62	0.44	5.48e-13	Arsenic metabolism;
KIRP	cis	rs2286379	1.000	rs7294540	chr12:1899714	A/C	cg05227549	chr12:1770782	NA	-0.31	-5.0	-0.3	1.09e-6	Blood pressure (smoking interaction);
KIRP	cis	rs2904967	0.929	rs503277	chr11:65078626	G/A	cg09225861	chr11:65069680	NA	0.44	5.81	0.35	1.91e-8	Mean corpuscular volume;
KIRP	cis	rs42648	0.837	rs10262603	chr7:89909442	G/A	cg25739043	chr7:89950458	NA	-0.47	-7.49	-0.43	1.21e-12	Homocysteine levels;
KIRP	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.99	0.41	2.58e-11	Coffee consumption (cups per day);
KIRP	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg04490037	chr7:50633773	DDC	-0.42	-5.09	-0.31	7.24e-7	Malaria;
KIRP	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg08462924	chr1:41848221	NA	-0.5	-7.02	-0.41	2.17e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg10890403	chr12:132336407	NA	-0.41	-5.3	-0.32	2.6e-7	Migraine;
KIRP	cis	rs2371030	1.000	rs2371026	chr2:211565999	G/T	cg18417063	chr2:211583084	NA	-0.52	-7.54	-0.43	9.15e-13	Non-small cell lung cancer;
KIRP	cis	rs7252505	0.772	rs10411210	chr19:33532300	C/T	cg17764715	chr19:33622953	WDR88	0.58	4.88	0.3	1.9e-6	Colorectal cancer;
KIRP	cis	rs4345220	0.553	rs4860999	chr4:41649717	G/C	cg15232654	chr4:41643107	LIMCH1	0.39	5.13	0.31	6.01e-7	Migraine with aura;
KIRP	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg21890820	chr11:65308645	LTBP3	0.58	5.6	0.34	5.79e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg02612397	chr6:125855124	NA	-0.33	-4.87	-0.3	2.03e-6	Brugada syndrome;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg17422427	chr2:241507521	RNPEPL1	0.51	6.08	0.36	4.45e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11650494	0.634	rs8072520	chr17:47466640	T/G	cg08112188	chr17:47440006	ZNF652	1.06	6.58	0.39	2.76e-10	Prostate cancer;
KIRP	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	trans	rs11165623	0.602	rs4127309	chr1:97006892	T/C	cg04515677	chr7:112090494	IFRD1	0.47	6.19	0.37	2.45e-9	Hip circumference;Waist circumference;
KIRP	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg19445457	chr11:5799446	OR52N5	-0.42	-5.01	-0.3	1.05e-6	DNA methylation (variation);
KIRP	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg04374321	chr14:90722782	PSMC1	-0.83	-11.42	-0.59	1.59e-24	Mortality in heart failure;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.85	14.85	0.69	4.88e-36	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg20744362	chr22:50050164	C22orf34	0.31	4.89	0.3	1.83e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs714515	0.934	rs2227199	chr1:172359780	A/G	cg01573306	chr1:172330400	DNM3	0.44	5.79	0.35	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.23	-22.76	-0.82	1.78e-62	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2307121	0.512	rs2047066	chr5:64734172	T/C	cg11190754	chr5:64858552	CENPK;PPWD1	0.38	5.11	0.31	6.47e-7	Corneal structure;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18369257	chr11:61520258	C11orf9	-0.58	-6.29	-0.37	1.41e-9	Menopause (age at onset);
KIRP	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23422044	chr7:1970798	MAD1L1	-0.71	-7.31	-0.42	3.71e-12	Bipolar disorder;
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.57	0.33	6.54e-8	Lung cancer;
KIRP	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.23	12.16	0.61	5.79e-27	Diabetic retinopathy;
KIRP	cis	rs7395662	0.593	rs8188975	chr11:48891877	A/G	cg21546286	chr11:48923668	NA	0.47	5.97	0.36	8.17e-9	HDL cholesterol;
KIRP	cis	rs4363506	0.635	rs1931737	chr10:129281900	G/T	cg07804728	chr10:129284050	NA	0.47	5.92	0.35	1.07e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.75	-0.4	1.04e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.88	-0.49	1.44e-16	Neuroticism;
KIRP	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.59	5.18	0.31	4.52e-7	Major depressive disorder;
KIRP	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.51	5.48	0.33	1.04e-7	Type 2 diabetes;
KIRP	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.45	5.7	0.34	3.47e-8	Multiple sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15347004	chr20:37590907	DHX35	0.49	6.32	0.37	1.24e-9	Parkinson's disease;
KIRP	cis	rs17065868	1.000	rs9595157	chr13:45144344	A/G	cg10246903	chr13:45222710	NA	0.64	6.83	0.4	6.75e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7224685	0.569	rs10521129	chr17:4008820	C/T	cg09597638	chr17:3907349	NA	0.45	4.89	0.3	1.83e-6	Type 2 diabetes;
KIRP	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg21775007	chr8:11205619	TDH	-0.45	-5.87	-0.35	1.4e-8	Triglycerides;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg01798813	chr17:3906674	NA	0.52	7.28	0.42	4.5e-12	Type 2 diabetes;
KIRP	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.53	0.75	3.39e-45	Cognitive function;
KIRP	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg01877450	chr7:97915802	BRI3	-0.57	-7.46	-0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1823913	0.538	rs6732537	chr2:192211481	C/T	cg12404831	chr2:192114017	MYO1B	0.47	6.14	0.36	3.25e-9	Obesity-related traits;
KIRP	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg08847533	chr14:75593920	NEK9	0.42	5.05	0.31	8.56e-7	Caffeine consumption;
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg17207736	chr8:142237307	SLC45A4	-0.5	-6.43	-0.38	6.5e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg19847130	chr8:10466454	RP1L1	0.34	4.9	0.3	1.74e-6	Triglycerides;
KIRP	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg26566898	chr11:117069891	TAGLN	0.42	4.94	0.3	1.46e-6	Blood protein levels;
KIRP	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs4908768	0.657	rs4908510	chr1:8806345	C/G	cg03610117	chr1:8450231	RERE	0.45	5.42	0.33	1.4e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9653442	0.527	rs12712064	chr2:100756548	C/T	cg17356467	chr2:100759845	AFF3	0.42	5.65	0.34	4.34e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6142102	0.961	rs2235596	chr20:32684309	A/G	cg08999081	chr20:33150536	PIGU	-0.5	-6.59	-0.39	2.7e-10	Skin pigmentation;
KIRP	cis	rs6466055	0.661	rs17640508	chr7:104842643	C/T	cg04380332	chr7:105027541	SRPK2	0.35	5.02	0.31	9.73e-7	Schizophrenia;
KIRP	cis	rs10875746	0.951	rs4760690	chr12:48563653	G/A	cg26205652	chr12:48591994	NA	0.78	10.56	0.56	9.85e-22	Longevity (90 years and older);
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg24209194	chr3:40518798	ZNF619	-0.39	-4.94	-0.3	1.44e-6	Renal cell carcinoma;
KIRP	cis	rs4959270	0.904	rs4467819	chr6:452138	G/A	cg13299325	chr6:447777	NA	0.25	5.03	0.31	9.27e-7	Limited cutaneous systemic scleroderma;
KIRP	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.13	-0.31	5.98e-7	Pulmonary function;
KIRP	cis	rs6142102	0.961	rs2284378	chr20:32588095	T/C	cg08999081	chr20:33150536	PIGU	0.49	5.83	0.35	1.7e-8	Skin pigmentation;
KIRP	cis	rs7188697	0.922	rs9926577	chr16:58613431	C/T	cg21335942	chr16:58549945	SETD6	-0.46	-5.12	-0.31	6.31e-7	QT interval;
KIRP	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.47	-5.68	-0.34	3.75e-8	Carotid intima media thickness;
KIRP	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	1.09	17.34	0.74	1.51e-44	Homoarginine levels;
KIRP	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7116495	1.000	rs7128317	chr11:71701367	C/T	cg26138937	chr11:71823887	C11orf51	0.73	5.94	0.35	9.87e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs7404095	0.695	rs11074583	chr16:23866913	A/G	cg21745164	chr16:23765304	CHP2	-0.35	-5.11	-0.31	6.33e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg11645453	chr3:52864694	ITIH4	0.34	5.24	0.32	3.44e-7	Body mass index;
KIRP	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg06115741	chr20:33292138	TP53INP2	0.41	4.94	0.3	1.41e-6	Height;
KIRP	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.49	-5.47	-0.33	1.09e-7	Neuroticism;
KIRP	cis	rs2548003	0.518	rs2548006	chr5:28732126	C/T	cg22863700	chr5:28928346	NA	-0.57	-5.85	-0.35	1.53e-8	Hip geometry;
KIRP	cis	rs9488822	0.676	rs13194714	chr6:116394819	T/A	cg26893134	chr6:116381904	FRK	0.19	5.14	0.31	5.55e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg23920097	chr1:209922102	NA	-0.46	-5.52	-0.33	8.78e-8	Red blood cell count;
KIRP	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.71	-10.28	-0.55	7.34e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs45535039	1.000	rs7104210	chr11:119073886	T/G	cg16724696	chr11:118992527	HINFP	0.41	4.99	0.3	1.15e-6	Plateletcrit;
KIRP	cis	rs732716	0.813	rs760369	chr19:4449287	C/T	cg19820705	chr19:4455316	UBXN6	-0.65	-8.25	-0.47	9.81e-15	Mean corpuscular volume;
KIRP	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.31e-34	Breast cancer;
KIRP	trans	rs10016562	0.505	rs11724166	chr4:122968164	T/C	cg19254152	chr7:1083473	C7orf50	-0.4	-6.06	-0.36	5.04e-9	Emphysema imaging phenotypes;
KIRP	cis	rs6684514	1.000	rs12132919	chr1:156318141	C/A	cg16558208	chr1:156270281	VHLL	-0.42	-5.35	-0.32	2.05e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.61	5.24	0.32	3.38e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.5	6.93	0.4	3.78e-11	Glioblastoma;Glioma;
KIRP	cis	rs12220238	1.000	rs10824151	chr10:76092179	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.78	0.4	8.62e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.39	9.44	0.52	2.95e-18	Corneal astigmatism;
KIRP	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.95	0.54	8.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16318349	chr1:154917307	PBXIP1	-0.28	-5.03	-0.31	9.61e-7	Prostate cancer;
KIRP	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg05340658	chr4:99064831	C4orf37	-0.59	-7.27	-0.42	4.86e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.97	14.92	0.69	2.82e-36	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg03585969	chr10:35415529	CREM	0.84	9.99	0.54	5.87e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg00999904	chr2:3704751	ALLC	-0.74	-7.83	-0.45	1.43e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg00800038	chr16:89945340	TCF25	-0.53	-5.65	-0.34	4.41e-8	Skin colour saturation;
KIRP	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg10556349	chr10:835070	NA	-0.42	-5.53	-0.33	7.98e-8	Survival in rectal cancer;
KIRP	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg12315302	chr6:26189340	HIST1H4D	0.73	5.11	0.31	6.41e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg23166289	chr1:210001082	C1orf107	0.44	5.52	0.33	8.51e-8	Orofacial clefts;
KIRP	cis	rs2151522	0.563	rs9388521	chr6:127120238	T/C	cg21431617	chr6:127135037	NA	0.33	6.0	0.36	7.06e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg13206674	chr6:150067644	NUP43	0.52	7.41	0.43	1.96e-12	Testicular germ cell tumor;
KIRP	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg16141378	chr3:129829833	LOC729375	-0.5	-6.7	-0.39	1.38e-10	Retinal vascular caliber;
KIRP	cis	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg02972257	chr16:68554789	NA	0.5	4.92	0.3	1.6e-6	Colorectal cancer;
KIRP	cis	rs9921338	0.961	rs7191093	chr16:11442279	A/G	cg00044050	chr16:11439710	C16orf75	-0.55	-5.74	-0.34	2.77e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.46	6.67	0.39	1.63e-10	Urate levels in lean individuals;
KIRP	trans	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.08	0.36	4.63e-9	Retinal vascular caliber;
KIRP	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg20243544	chr17:37824526	PNMT	-0.5	-7.37	-0.43	2.57e-12	Asthma;
KIRP	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg25319279	chr11:5960081	NA	-0.59	-6.12	-0.36	3.73e-9	DNA methylation (variation);
KIRP	cis	rs2295359	1.000	rs4655524	chr1:67629469	G/A	cg11235152	chr1:67600687	NA	0.65	9.78	0.53	2.7e-19	Psoriasis;
KIRP	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.94	15.49	0.7	3.06e-38	Ulcerative colitis;
KIRP	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	cg04338863	chr8:33670619	NA	0.42	5.39	0.32	1.66e-7	Body mass index;
KIRP	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg12463550	chr7:65579703	CRCP	-0.43	-4.95	-0.3	1.37e-6	Aortic root size;
KIRP	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg15485101	chr11:133734466	NA	0.44	5.88	0.35	1.3e-8	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25294785	chr12:44152807	IRAK4;PUS7L	0.53	6.9	0.4	4.48e-11	Parkinson's disease;
KIRP	cis	rs12210905	1.000	rs10946906	chr6:27252780	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.8	-5.91	-0.35	1.13e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg02811702	chr13:24901961	NA	0.43	5.73	0.34	2.89e-8	Obesity-related traits;
KIRP	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.75	-8.59	-0.48	1.03e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.48	7.43	0.43	1.84e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2278796	0.789	rs1078719	chr1:204962405	A/G	cg17449235	chr1:204966235	NFASC	0.62	8.4	0.47	3.69e-15	Mean platelet volume;
KIRP	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg06565975	chr8:143823917	SLURP1	0.45	6.95	0.41	3.2e-11	Urinary tract infection frequency;
KIRP	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.46	-6.17	-0.37	2.81e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg07884673	chr3:53033167	SFMBT1	-0.63	-5.87	-0.35	1.4e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg07810366	chr2:100720526	AFF3	-0.35	-6.45	-0.38	6.01e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.33	-0.37	1.18e-9	Neuroticism;
KIRP	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.32e-12	Uric acid levels;
KIRP	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg12718519	chr1:2058417	PRKCZ	-0.2	-5.69	-0.34	3.62e-8	Height;
KIRP	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.61	7.75	0.44	2.35e-13	Iron status biomarkers;
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18713687	chr3:195489789	MUC4	0.67	6.22	0.37	2.13e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.52	6.8	0.4	7.81e-11	Longevity;Endometriosis;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg17294928	chr15:75287854	SCAMP5	0.58	7.8	0.45	1.74e-13	Breast cancer;
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg07169003	chr6:111999442	FYN	0.43	6.15	0.37	3.03e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs6539288	0.677	rs11113144	chr12:107323422	T/C	cg21360079	chr12:107162445	NA	-0.44	-5.52	-0.33	8.74e-8	Total body bone mineral density;
KIRP	cis	rs13385	0.769	rs156082	chr5:139544562	G/A	cg01860693	chr5:139557145	C5orf32	0.49	5.36	0.32	1.95e-7	Atrial fibrillation;
KIRP	trans	rs1859156	0.812	rs72669099	chr4:95813591	C/A	cg24204951	chr2:239172084	PER2	0.27	6.06	0.36	5.09e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.15	15.1	0.69	6.59e-37	Gut microbiome composition (summer);
KIRP	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg11150807	chr10:43354902	NA	-0.68	-7.56	-0.43	8.09e-13	Blood protein levels;
KIRP	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-4.95	-0.3	1.36e-6	Psoriasis;
KIRP	cis	rs4149423	1.000	rs12620050	chr2:108919798	G/A	cg06795125	chr2:108905320	SULT1C2	-0.55	-9.49	-0.52	2.14e-18	Lobe size;
KIRP	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.57	-6.96	-0.41	3.16e-11	Aortic root size;
KIRP	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.75	7.34	0.42	3.13e-12	Lung function (FEV1/FVC);
KIRP	trans	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg16141378	chr3:129829833	LOC729375	-0.48	-6.4	-0.38	7.91e-10	Joint mobility (Beighton score);
KIRP	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.23	0.51	1.31e-17	Colorectal cancer;
KIRP	cis	rs4728302	0.838	rs10264922	chr7:133598975	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs400736	0.602	rs11121090	chr1:8168634	A/G	cg25007680	chr1:8021821	PARK7	0.41	5.26	0.32	3.1e-7	Response to antidepressants and depression;
KIRP	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg24699146	chr1:24152579	HMGCL	-0.48	-6.94	-0.4	3.55e-11	Immature fraction of reticulocytes;
KIRP	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg02002194	chr4:3960332	NA	0.43	6.23	0.37	1.96e-9	Triglycerides;
KIRP	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.47	6.16	0.37	2.93e-9	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
KIRP	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.98	-0.41	2.8e-11	Response to antipsychotic treatment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10504751	chr16:56390830	GNAO1	0.45	6.24	0.37	1.95e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00864083	chr1:42671478	FOXJ3	0.43	6.9	0.4	4.4e-11	C-reactive protein;
KIRP	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.52	6.57	0.39	2.91e-10	Eye color traits;
KIRP	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg07870213	chr5:140052090	DND1	-0.62	-7.71	-0.44	3.1e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-5.54	-0.33	7.85e-8	Response to antipsychotic treatment;
KIRP	cis	rs58688157	0.921	rs35600572	chr11:617214	A/G	cg01616529	chr11:638424	DRD4	-0.37	-5.0	-0.3	1.08e-6	Systemic lupus erythematosus;
KIRP	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06173319	chr16:90148775	NA	0.56	5.26	0.32	3.15e-7	Skin colour saturation;
KIRP	cis	rs7688540	0.771	rs11248009	chr4:220149	T/C	cg17891759	chr4:299121	NA	-0.51	-5.17	-0.31	4.83e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs17123764	0.892	rs7953412	chr12:50140266	A/G	cg20471783	chr12:50157085	TMBIM6	0.41	5.87	0.35	1.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.37	-0.38	9.02e-10	Hemoglobin concentration;
KIRP	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.3	-0.42	3.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg22705602	chr4:152727874	NA	-0.55	-9.35	-0.51	5.47e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	0.95	7.79	0.44	1.9e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6963495	0.546	rs2697020	chr7:105150046	C/T	cg13798780	chr7:105162888	PUS7	0.4	4.93	0.3	1.52e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.19e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07836600	chr6:165384599	NA	0.45	6.97	0.41	2.82e-11	Survival in pancreatic cancer;
KIRP	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.17	-0.37	2.79e-9	Parkinson's disease;
KIRP	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-0.8	-6.45	-0.38	5.74e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs9309473	0.950	rs6546859	chr2:73842055	C/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.5	-0.33	9.6e-8	Metabolite levels;
KIRP	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.13	0.36	3.5e-9	Joint mobility (Beighton score);
KIRP	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.85	-0.35	1.58e-8	Body mass index;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg21647170	chr7:56119546	CCT6A;PSPH	-0.51	-6.42	-0.38	6.79e-10	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16570129	chr5:179004739	RUFY1	0.44	6.15	0.37	3.16e-9	Survival in pancreatic cancer;
KIRP	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17507749	chr15:85114479	UBE2QP1	-0.7	-8.04	-0.46	3.69e-14	Schizophrenia;
KIRP	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.23	13.96	0.66	5.01e-33	Platelet count;
KIRP	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.25	-0.47	9.36e-15	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.71	8.29	0.47	7.38e-15	Corneal astigmatism;
KIRP	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg19025524	chr12:109796872	NA	-0.57	-8.15	-0.46	1.85e-14	Neuroticism;
KIRP	cis	rs6753739	0.871	rs6436113	chr2:219984898	C/T	cg01749213	chr2:219906749	CCDC108	0.45	5.59	0.34	5.87e-8	Height;
KIRP	cis	rs8060686	0.623	rs6499162	chr16:68239460	T/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-7.54	-0.43	8.87e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg02640540	chr1:67518911	SLC35D1	0.4	4.98	0.3	1.21e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg26207909	chr14:103986467	CKB	-0.44	-5.39	-0.32	1.65e-7	Coronary artery disease;
KIRP	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.99	-10.2	-0.55	1.29e-20	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.13	-0.5	2.52e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2522056	1.000	rs2706381	chr5:131810619	C/T	cg07395648	chr5:131743802	NA	0.52	6.22	0.37	2.08e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.5	6.17	0.37	2.77e-9	Urinary tract infection frequency;
KIRP	cis	rs17122278	0.613	rs477106	chr11:118363424	A/C	cg06090739	chr11:118230722	UBE4A	-0.51	-5.22	-0.32	3.8e-7	Total cholesterol levels;
KIRP	cis	rs2548003	0.518	rs2554904	chr5:28726189	T/A	cg22863700	chr5:28928346	NA	0.61	6.34	0.37	1.1e-9	Hip geometry;
KIRP	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg17788362	chr6:86352627	SYNCRIP	-0.46	-6.05	-0.36	5.49e-9	Smooth-surface caries;
KIRP	cis	rs6142102	0.923	rs6059635	chr20:32613493	A/T	cg08999081	chr20:33150536	PIGU	0.52	6.54	0.39	3.44e-10	Skin pigmentation;
KIRP	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	7.45	0.43	1.58e-12	Coffee consumption (cups per day);
KIRP	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	6.36	0.38	1e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs12517041	1.000	rs1428618	chr5:23282263	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.7	-9.21	-0.51	1.45e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11878675	chr2:74211845	NA	-0.5	-6.75	-0.4	1.02e-10	Myopia;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	15.69	0.71	6.64e-39	Platelet count;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg23736307	chr8:27182930	PTK2B	0.54	6.85	0.4	5.94e-11	Neuroticism;
KIRP	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	0.89	12.0	0.61	1.99e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-1.08	-14.73	-0.68	1.23e-35	Alopecia areata;
KIRP	cis	rs4692589	0.581	rs62344678	chr4:170961308	G/A	cg19918862	chr4:170955249	NA	0.58	6.32	0.37	1.25e-9	Anxiety disorder;
KIRP	cis	rs1505368	0.543	rs13413590	chr2:213292329	C/T	cg16329650	chr2:213403929	ERBB4	0.38	4.91	0.3	1.69e-6	Symmetrical dimethylarginine levels;
KIRP	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg12435725	chr3:58293450	RPP14	-0.46	-5.34	-0.32	2.14e-7	Cholesterol, total;
KIRP	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg21361702	chr7:150065534	REPIN1	0.62	6.52	0.38	3.99e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6670533	0.571	rs6697800	chr1:24867540	G/A	cg07475527	chr1:24864545	NA	-1.05	-8.54	-0.48	1.46e-15	Fasting blood insulin (BMI interaction);
KIRP	cis	rs8077577	0.708	rs3889544	chr17:18133788	C/T	cg18869244	chr17:18121946	NA	-0.42	-4.85	-0.3	2.16e-6	Obesity-related traits;
KIRP	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	6.94	0.4	3.49e-11	Bipolar disorder;
KIRP	cis	rs8114671	0.647	rs1415771	chr20:33734493	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	6.0	0.36	6.87e-9	Height;
KIRP	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg02725872	chr8:58115012	NA	-0.43	-5.09	-0.31	7.19e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21659725	chr3:3221576	CRBN	0.72	8.6	0.48	9.43e-16	Resting heart rate;
KIRP	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.94	0.3	1.46e-6	Rheumatoid arthritis;
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02725872	chr8:58115012	NA	-0.74	-7.44	-0.43	1.7e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs1823913	1.000	rs6704784	chr2:192109558	T/G	cg12404831	chr2:192114017	MYO1B	-0.5	-6.8	-0.4	8.01e-11	Obesity-related traits;
KIRP	trans	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	9.06	0.5	4.29e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00230869	chr2:70418140	C2orf42	0.47	6.07	0.36	4.85e-9	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.39	-0.38	8.44e-10	Myopia (pathological);
KIRP	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.46	5.51	0.33	9.17e-8	Height;
KIRP	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs78049276	0.688	rs61075980	chr4:148374767	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.72	-7.59	-0.44	6.56e-13	Pulse pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21252859	chr9:124076247	GSN	-0.51	-6.51	-0.38	4.11e-10	Parkinson's disease;
KIRP	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg11833968	chr6:79620685	NA	-0.41	-5.97	-0.36	8.03e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.76e-11	Diabetic kidney disease;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Visceral adipose tissue adjusted for BMI;
KIRP	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg12661370	chr5:149340060	SLC26A2	0.45	5.44	0.33	1.27e-7	HIV-1 control;
KIRP	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.54	-6.94	-0.4	3.43e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25235380	chr17:4167449	ANKFY1	0.6	6.76	0.4	9.86e-11	Lung cancer in ever smokers;
KIRP	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg12081754	chr8:22256438	SLC39A14	0.78	9.3	0.51	8.1e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21108553	chr6:28357838	ZSCAN12	0.45	6.14	0.36	3.31e-9	Survival in pancreatic cancer;
KIRP	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg17517138	chr11:73019481	ARHGEF17	0.76	6.43	0.38	6.68e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.46	5.22	0.32	3.87e-7	Schizophrenia;
KIRP	cis	rs12230513	0.732	rs4130004	chr12:55860773	G/T	cg11794356	chr12:55725991	OR6C3	-0.53	-6.46	-0.38	5.66e-10	Contrast sensitivity;
KIRP	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg12826209	chr6:26865740	GUSBL1	0.78	5.26	0.32	3.16e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17030434	0.654	rs10021631	chr4:154646675	A/G	cg14289246	chr4:154710475	SFRP2	-0.65	-7.5	-0.43	1.16e-12	Electrocardiographic conduction measures;
KIRP	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.63	0.48	7.63e-16	Prudent dietary pattern;
KIRP	cis	rs3126085	1.000	rs6661167	chr1:152312870	A/G	cg26876637	chr1:152193138	HRNR	-0.81	-7.83	-0.45	1.43e-13	Atopic dermatitis;
KIRP	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg01097406	chr16:89675127	NA	0.5	8.91	0.49	1.19e-16	Vitiligo;
KIRP	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.44	-5.93	-0.35	1.03e-8	Ankylosing spondylitis;
KIRP	cis	rs28595532	0.748	rs72670249	chr4:119336823	G/T	cg21605333	chr4:119757512	SEC24D	1.1	8.23	0.46	1.06e-14	Cannabis dependence symptom count;
KIRP	trans	rs10923574	0.576	rs1146315	chr1:119024403	C/G	cg22418565	chr22:24114690	MMP11	-0.34	-6.53	-0.38	3.71e-10	Breast cancer;Folding of antihelix;
KIRP	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.96	-14.41	-0.68	1.47e-34	Cognitive function;
KIRP	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	0.96	11.83	0.6	7.19e-26	Corneal structure;
KIRP	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg12062639	chr20:23401060	NAPB	0.84	7.25	0.42	5.29e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.24	0.42	5.72e-12	Rheumatoid arthritis;
KIRP	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg17554472	chr22:41940697	POLR3H	0.66	7.04	0.41	1.89e-11	Vitiligo;
KIRP	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg09555818	chr19:45449301	APOC2	0.5	7.26	0.42	4.94e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.71	-0.34	3.19e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg08992911	chr2:238395768	MLPH	0.55	4.98	0.3	1.17e-6	Prostate cancer;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg06988368	chr1:147142773	ACP6	-0.44	-6.32	-0.37	1.24e-9	Blood metabolite levels;
KIRP	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18324126	chr8:30890620	WRN;PURG	-0.5	-6.04	-0.36	5.56e-9	Interleukin-4 levels;
KIRP	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.38	7.44e-10	Height;
KIRP	cis	rs2898681	0.837	rs2017237	chr4:53748515	A/G	cg00791764	chr4:53727839	RASL11B	0.37	5.31	0.32	2.44e-7	Optic nerve measurement (cup area);
KIRP	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	Myopia (pathological);
KIRP	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg01304814	chr3:48885189	PRKAR2A	0.59	5.27	0.32	2.94e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.55	-5.94	-0.35	9.52e-9	Blood pressure (smoking interaction);
KIRP	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.06	0.36	4.95e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg05315796	chr3:52349193	DNAH1	0.42	6.34	0.37	1.07e-9	Bipolar disorder;
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg14221460	chr8:27183342	PTK2B	0.5	6.54	0.38	3.63e-10	Neuroticism;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17422427	chr2:241507521	RNPEPL1	0.7	6.5	0.38	4.42e-10	Lung function (FEV1);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19733847	chr19:8571072	NA	0.47	6.05	0.36	5.3e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01728866	chr1:43638014	WDR65;EBNA1BP2	0.48	6.24	0.37	1.92e-9	Parkinson's disease;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.68	-8.54	-0.48	1.44e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg22563815	chr15:78856949	CHRNA5	0.44	5.9	0.35	1.22e-8	Sudden cardiac arrest;
KIRP	cis	rs34779708	0.897	rs4934716	chr10:35369299	A/G	cg04310649	chr10:35416472	CREM	-0.6	-7.19	-0.42	7.74e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg05347473	chr6:146136440	FBXO30	0.63	8.94	0.5	9.41e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-6.65	-0.39	1.92e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.38	-4.98	-0.3	1.19e-6	Multiple myeloma;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg09820084	chr6:18387507	RNF144B	0.52	6.05	0.36	5.39e-9	Sleep duration;
KIRP	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.36	-0.32	1.89e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg25512537	chr17:76250053	NA	0.48	7.25	0.42	5.38e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.64	7.24	0.42	5.84e-12	Gut microbiome composition (summer);
KIRP	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg06153925	chr17:78755379	RPTOR	-0.53	-7.41	-0.43	2.07e-12	Myopia (pathological);
KIRP	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg23534315	chr17:78082725	GAA	0.38	5.22	0.32	3.83e-7	Yeast infection;
KIRP	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.63	8.6	0.48	9.34e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.61	8.98	0.5	7.32e-17	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	cis	rs75064307	0.734	rs6779094	chr3:108081277	G/T	cg14703454	chr3:108065259	HHLA2	0.5	6.12	0.36	3.62e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18357526	chr6:26021779	HIST1H4A	0.46	6.36	0.38	9.79e-10	Schizophrenia;
KIRP	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.1	-0.41	1.32e-11	Joint mobility (Beighton score);
KIRP	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg10189774	chr4:17578691	LAP3	0.5	5.95	0.35	9.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13384711	1	rs13384711	chr2:136176540	T/C	cg07169764	chr2:136633963	MCM6	0.49	5.49	0.33	9.97e-8	Mosquito bite size;
KIRP	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.84	0.81	1.56e-59	Prudent dietary pattern;
KIRP	cis	rs2625529	0.824	rs12592364	chr15:72284647	C/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.12e-9	Red blood cell count;
KIRP	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs11673344	0.797	rs3745768	chr19:37488809	A/G	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.2	-0.31	4.16e-7	Obesity-related traits;
KIRP	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg00310523	chr12:86230176	RASSF9	0.39	5.98	0.36	7.77e-9	Major depressive disorder;
KIRP	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg13332499	chr17:408570	NA	0.59	8.76	0.49	3.18e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.92	16.03	0.71	4.29e-40	Headache;
KIRP	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-5.1	-0.31	6.86e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg08890418	chr1:21044141	KIF17	0.33	4.94	0.3	1.43e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	9.38	0.51	4.44e-18	Schizophrenia;
KIRP	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	0.64	5.78	0.35	2.29e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs12580194	0.593	rs61957941	chr12:55748058	G/A	cg19537932	chr12:55886519	OR6C68	-0.5	-6.47	-0.38	5.14e-10	Cancer;
KIRP	cis	rs7106204	0.534	rs77470639	chr11:24250082	C/T	ch.11.24196551F	chr11:24239977	NA	0.73	4.97	0.3	1.25e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.97	-12.77	-0.63	5.42e-29	Bipolar disorder and schizophrenia;
KIRP	cis	rs7017914	0.934	rs13274062	chr8:71737087	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg11905131	chr22:24372483	LOC391322	-0.54	-5.67	-0.34	4.07e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-11.87	-0.6	5.56e-26	Monocyte percentage of white cells;
KIRP	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06360820	chr2:242988706	NA	-0.9	-8.84	-0.49	1.87e-16	Obesity-related traits;
KIRP	cis	rs6466055	0.669	rs1142	chr7:104756326	C/T	cg04380332	chr7:105027541	SRPK2	-0.63	-9.68	-0.53	5.4e-19	Schizophrenia;
KIRP	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	9.61	0.52	9.16e-19	Total body bone mineral density;
KIRP	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-7.59	-0.44	6.62e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs2071426	0.959	rs2185571	chr10:96824975	C/T	cg09036531	chr10:96991505	NA	-0.65	-7.18	-0.42	8.27e-12	Blood metabolite levels;
KIRP	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg24498760	chr8:49746867	NA	0.4	4.88	0.3	1.92e-6	Blood metabolite ratios;
KIRP	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-8.94	-0.5	9.44e-17	Colorectal cancer;
KIRP	cis	rs1408799	0.521	rs2733834	chr9:12708910	C/G	cg05274944	chr9:12693694	TYRP1	0.45	6.83	0.4	6.46e-11	Eye color;Blue vs. green eyes;
KIRP	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg09658497	chr7:2847517	GNA12	-0.37	-5.03	-0.31	9.33e-7	Height;
KIRP	cis	rs4671458	0.762	rs17618045	chr2:63793255	T/C	cg17519650	chr2:63277830	OTX1	-0.51	-5.14	-0.31	5.67e-7	Subjective well-being;
KIRP	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg10326726	chr10:51549505	MSMB	0.53	7.6	0.44	6.07e-13	Prostate-specific antigen levels;
KIRP	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg08313168	chr12:7315531	NA	0.74	6.67	0.39	1.72e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.76	-10.47	-0.56	1.82e-21	Blood metabolite levels;
KIRP	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.78	10.17	0.54	1.67e-20	Menopause (age at onset);
KIRP	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg24315340	chr6:146058215	EPM2A	-0.43	-5.45	-0.33	1.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.7	9.18	0.51	1.77e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.75	9.53	0.52	1.64e-18	Coronary artery disease;
KIRP	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.18	-0.31	4.66e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.48	-6.29	-0.37	1.47e-9	Blood metabolite levels;
KIRP	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.83	8.5	0.48	1.83e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11264213	0.681	rs72659694	chr1:36301803	G/A	cg27506609	chr1:36549197	TEKT2	0.96	5.32	0.32	2.29e-7	Schizophrenia;
KIRP	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg25809561	chr17:30822961	MYO1D	0.51	6.63	0.39	2.15e-10	Schizophrenia;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-8.74	-0.49	3.82e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06022373	chr22:39101656	GTPBP1	0.9	11.18	0.58	9.52e-24	Menopause (age at onset);
KIRP	cis	rs1829883	0.835	rs2460664	chr5:98802442	C/T	cg08333243	chr5:99726346	NA	-0.39	-5.14	-0.31	5.51e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-0.77	-11.04	-0.58	2.72e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs785830	0.523	rs2484966	chr9:216493	T/C	cg14500300	chr9:211689	NA	0.44	6.17	0.37	2.8e-9	Platelet distribution width;
KIRP	trans	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.61	0.39	2.36e-10	Mean corpuscular volume;
KIRP	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.32	8.13	0.46	2.05e-14	Primary biliary cholangitis;
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg26516362	chr5:178986906	RUFY1	0.38	6.2	0.37	2.37e-9	Lung cancer;
KIRP	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.55	-0.33	7.49e-8	Depression;
KIRP	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.63	8.81	0.49	2.27e-16	Schizophrenia;
KIRP	cis	rs6545883	0.524	rs2694618	chr2:61536984	A/G	cg15711740	chr2:61764176	XPO1	-0.46	-5.79	-0.35	2.12e-8	Tuberculosis;
KIRP	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.24	5.11	0.31	6.39e-7	Height;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.89	14.49	0.68	8.18e-35	Menarche (age at onset);
KIRP	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.85	-11.28	-0.58	4.58e-24	Type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06740311	chr18:12699646	CEP76	-0.44	-6.51	-0.38	4.25e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs656319	0.629	rs11774276	chr8:10070309	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.19	-0.42	7.96e-12	Myopia (pathological);
KIRP	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.52	-7.26	-0.42	5.16e-12	Menarche (age at onset);
KIRP	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg19847130	chr8:10466454	RP1L1	-0.42	-6.14	-0.36	3.26e-9	Retinal vascular caliber;
KIRP	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-10.04	-0.54	4.09e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6901250	0.523	rs641338	chr6:117086265	C/A	cg05399210	chr6:117082661	FAM162B	-0.48	-6.92	-0.4	3.83e-11	C-reactive protein levels;
KIRP	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.91	12.61	0.63	1.83e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs10782582	0.617	rs1146587	chr1:76229326	T/C	cg03433033	chr1:76189801	ACADM	0.36	5.61	0.34	5.44e-8	Daytime sleep phenotypes;
KIRP	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg06307176	chr5:131281290	NA	-0.55	-6.43	-0.38	6.65e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg05370193	chr1:21551575	ECE1	-0.38	-5.19	-0.31	4.41e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	0.65	9.58	0.52	1.09e-18	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs9513627	1.000	rs6491512	chr13:100199741	C/T	cg25919922	chr13:100150906	NA	0.7	5.37	0.32	1.78e-7	Obesity-related traits;
KIRP	cis	rs17401966	0.522	rs17396973	chr1:10334924	C/T	cg19773385	chr1:10388646	KIF1B	-0.44	-6.49	-0.38	4.59e-10	Hepatocellular carcinoma;
KIRP	cis	rs12912251	0.591	rs3102119	chr15:39003601	C/T	cg10631289	chr15:39006617	NA	0.67	7.4	0.43	2.2e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs4783244	0.827	rs28597883	chr16:82647566	G/C	cg09415485	chr16:82663111	CDH13	-0.26	-4.89	-0.3	1.86e-6	Adiponectin levels;
KIRP	cis	rs8179	0.552	rs2888877	chr7:92228400	C/T	cg15732164	chr7:92237376	CDK6	-0.62	-6.66	-0.39	1.73e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-5.62	-0.34	5.09e-8	Menarche (age at onset);
KIRP	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	1.04	19.59	0.78	3.86e-52	Heart rate;
KIRP	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	0.41	4.92	0.3	1.59e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg12181417	chr19:49337499	HSD17B14	-0.47	-5.06	-0.31	8.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.62	-6.8	-0.4	7.76e-11	DNA methylation (variation);
KIRP	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs3925075	1.000	rs3925074	chr16:31347807	G/A	cg02846316	chr16:31340340	ITGAM	0.6	9.3	0.51	8.2e-18	IgA nephropathy;
KIRP	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.56	-6.68	-0.39	1.62e-10	HDL cholesterol;
KIRP	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.82	-8.93	-0.49	1.04e-16	Exhaled nitric oxide output;
KIRP	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg12405258	chr13:114927641	NA	0.5	7.32	0.42	3.58e-12	Schizophrenia;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg20821713	chr7:1055600	C7orf50	-0.35	-5.4	-0.33	1.54e-7	Longevity;Endometriosis;
KIRP	cis	rs6977660	0.652	rs10254427	chr7:19816240	C/T	cg07541023	chr7:19748670	TWISTNB	0.5	5.03	0.31	9.46e-7	Thyroid stimulating hormone;
KIRP	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg12718519	chr1:2058417	PRKCZ	0.22	4.94	0.3	1.42e-6	Height;
KIRP	cis	rs7552404	0.731	rs7523573	chr1:76372020	G/T	cg10523679	chr1:76189770	ACADM	0.73	9.35	0.51	5.46e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg06365898	chr1:16533907	ARHGEF19	0.48	6.71	0.39	1.36e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg00784671	chr22:46762841	CELSR1	-0.67	-8.5	-0.48	1.81e-15	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg21086891	chr3:192635035	C3orf59	0.67	6.23	0.37	2.02e-9	Lung function (FEV1);
KIRP	cis	rs6752107	0.967	rs2880080	chr2:234154139	G/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.51	6.75	0.4	1.08e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2559856	1.000	rs2559854	chr12:102090246	C/T	cg12924262	chr12:102091054	CHPT1	0.44	5.57	0.33	6.68e-8	Blood protein levels;
KIRP	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg07862535	chr7:139043722	LUC7L2	-0.48	-5.4	-0.33	1.58e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	5.64	0.34	4.57e-8	Coronary artery disease;
KIRP	cis	rs1891498	0.703	rs10900397	chr1:147243153	G/A	cg27546670	chr1:147246839	GJA5	-0.82	-10.45	-0.55	2.1e-21	Cognitive performance;
KIRP	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs6450176	1.000	rs4311394	chr5:53300662	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.43	-0.59	1.54e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2979489	0.891	rs2915594	chr8:30401367	T/C	cg26383811	chr8:30366931	RBPMS	-0.45	-6.18	-0.37	2.63e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	trans	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg00938859	chr5:1591904	SDHAP3	0.57	6.93	0.4	3.7e-11	Breast cancer;
KIRP	cis	rs11718455	0.548	rs11918413	chr3:43902518	C/A	cg08738300	chr3:44038990	NA	-0.43	-6.19	-0.37	2.45e-9	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.88	-16.33	-0.72	4.22e-41	Body mass index;
KIRP	trans	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.68	8.81	0.49	2.23e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg01677386	chr11:118938358	VPS11	-0.55	-6.64	-0.39	2.02e-10	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.78	6.84	0.4	6.26e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.74	-8.47	-0.48	2.21e-15	Longevity;Endometriosis;
KIRP	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.71	-7.87	-0.45	1.13e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs992157	0.764	rs2015863	chr2:219185161	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-6.39	-0.38	8.29e-10	Colorectal cancer;
KIRP	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.62	-7.56	-0.43	8.16e-13	Longevity;
KIRP	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-9.4	-0.51	3.82e-18	Chronic sinus infection;
KIRP	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.46	6.26	0.37	1.69e-9	Endometrial cancer;
KIRP	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.74	8.82	0.49	2.17e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg05315796	chr3:52349193	DNAH1	0.4	5.19	0.31	4.35e-7	Schizophrenia;
KIRP	cis	rs7180079	0.620	rs11071803	chr15:64965815	G/T	cg15337035	chr15:64978493	NA	0.5	5.47	0.33	1.11e-7	Monocyte count;
KIRP	trans	rs12659622	0.850	rs4702087	chr5:15609920	A/G	cg25746134	chr1:202129865	PTPN7	0.48	6.06	0.36	5.1e-9	Obesity-related traits;
KIRP	cis	rs4460629	0.712	rs11264313	chr1:155076505	A/G	cg02153340	chr1:155202674	NA	-0.37	-5.27	-0.32	3.02e-7	Serum magnesium levels;
KIRP	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04013166	chr16:89971882	TCF25	-0.71	-7.68	-0.44	3.85e-13	Skin colour saturation;
KIRP	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	0.99	16.22	0.72	9.76e-41	Schizophrenia;
KIRP	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17554472	chr22:41940697	POLR3H	-0.65	-6.16	-0.37	2.94e-9	Vitiligo;
KIRP	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-9.86	-0.53	1.51e-19	Schizophrenia;
KIRP	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.5	-0.33	9.46e-8	Pulmonary function;
KIRP	cis	rs6546324	0.625	rs980227	chr2:67864258	T/G	cg15745817	chr2:67799979	NA	-0.65	-7.12	-0.41	1.21e-11	Endometriosis;
KIRP	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg08885076	chr2:99613938	TSGA10	-0.39	-5.65	-0.34	4.4e-8	Fear of minor pain;
KIRP	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.77	-0.44	2.19e-13	Total cholesterol levels;
KIRP	cis	rs4400599	0.600	rs12095767	chr1:154188028	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.4	-5.96	-0.36	8.62e-9	Platelet distribution width;
KIRP	cis	rs17123764	0.892	rs12307828	chr12:50139060	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.99	0.36	7.49e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg23172400	chr8:95962367	TP53INP1	0.31	6.07	0.36	4.72e-9	Type 2 diabetes;
KIRP	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg17507749	chr15:85114479	UBE2QP1	0.81	9.36	0.51	5.22e-18	Schizophrenia;
KIRP	cis	rs2224391	0.590	rs2145372	chr6:5245070	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.59	-0.39	2.6e-10	Height;
KIRP	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11893307	0.507	rs1465304	chr2:191585398	A/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-4.87	-0.3	1.97e-6	Mean platelet volume;
KIRP	cis	rs258892	0.947	rs250517	chr5:72200626	G/C	cg21869765	chr5:72125136	TNPO1	0.58	6.39	0.38	8.43e-10	Small cell lung carcinoma;
KIRP	trans	rs6601327	0.540	rs4841225	chr8:9669164	T/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.32	-0.37	1.2e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg05785598	chr3:49045655	WDR6	0.28	5.2	0.31	4.18e-7	Parkinson's disease;
KIRP	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.03	0.36	5.94e-9	Joint mobility (Beighton score);
KIRP	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.8	8.19	0.46	1.43e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-7.28	-0.42	4.42e-12	Vitiligo;
KIRP	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.88	8.66	0.48	6.43e-16	Fibroblast growth factor basic levels;
KIRP	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg26408565	chr15:76604113	ETFA	0.48	6.69	0.39	1.47e-10	Blood metabolite levels;
KIRP	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.62	6.72	0.39	1.28e-10	Gut microbiome composition (summer);
KIRP	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-4.92	-0.3	1.59e-6	Mean platelet volume;
KIRP	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.96	-14.99	-0.69	1.55e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17308493	chr10:30634469	MTPAP	-0.46	-6.31	-0.37	1.29e-9	Inflammatory biomarkers;
KIRP	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg16497661	chr14:103986332	CKB	0.84	14.23	0.67	6.25e-34	Body mass index;
KIRP	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.33	-7.19	-0.42	7.62e-12	Cutaneous nevi;
KIRP	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.58	-0.44	6.92e-13	Initial pursuit acceleration;
KIRP	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg27205649	chr11:78285834	NARS2	0.58	6.64	0.39	2.02e-10	Testicular germ cell tumor;
KIRP	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	7.43	0.43	1.74e-12	Schizophrenia;
KIRP	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.0	-0.3	1.09e-6	Cervical cancer;
KIRP	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.74	9.02	0.5	5.59e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg23161317	chr6:28129485	ZNF389	0.48	5.2	0.31	4.27e-7	Depression;
KIRP	cis	rs3822411	0.565	rs2930055	chr5:10710147	T/C	cg14521931	chr5:10832172	NA	0.46	5.39	0.33	1.62e-7	Sum eosinophil basophil counts;
KIRP	cis	rs6102059	0.525	rs4810296	chr20:39192317	A/G	cg22477343	chr20:39312069	NA	-0.52	-6.66	-0.39	1.76e-10	LDL cholesterol;
KIRP	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.83	10.94	0.57	5.91e-23	Menopause (age at onset);
KIRP	cis	rs7106204	0.748	rs6484031	chr11:24237115	A/C	ch.11.24196551F	chr11:24239977	NA	0.79	9.48	0.52	2.31e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.43	-5.64	-0.34	4.62e-8	Menarche (age at onset);
KIRP	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs10875746	0.903	rs11168401	chr12:48481519	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs9400271	0.609	rs9386782	chr6:109588643	G/T	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg06521331	chr12:34319734	NA	-0.5	-6.34	-0.37	1.12e-9	Morning vs. evening chronotype;
KIRP	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.52	5.98	0.36	7.79e-9	Aortic root size;
KIRP	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06544989	chr22:39130855	UNC84B	0.51	8.31	0.47	6.6e-15	Menopause (age at onset);
KIRP	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.55	7.51	0.43	1.08e-12	Motion sickness;
KIRP	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg05973401	chr12:123451056	ABCB9	0.62	7.23	0.42	5.95e-12	Platelet count;
KIRP	cis	rs10465746	0.967	rs11163879	chr1:84444051	T/C	cg10977910	chr1:84465055	TTLL7	0.48	5.82	0.35	1.82e-8	Obesity-related traits;
KIRP	cis	rs5753037	0.803	rs131263	chr22:30133045	C/T	cg27665648	chr22:30112403	NA	0.43	6.22	0.37	2.15e-9	Type 1 diabetes;
KIRP	cis	rs3768617	0.782	rs12146099	chr1:182968079	G/A	cg21523751	chr1:182988639	NA	0.35	4.91	0.3	1.67e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg17764715	chr19:33622953	WDR88	0.66	8.29	0.47	7.25e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.49	-0.43	1.21e-12	Life satisfaction;
KIRP	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.92e-18	Morning vs. evening chronotype;
KIRP	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg00405596	chr8:11794950	NA	0.49	6.03	0.36	5.88e-9	Neuroticism;
KIRP	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg01557791	chr16:72042693	DHODH	-0.51	-6.35	-0.38	1.05e-9	Fibrinogen levels;
KIRP	cis	rs12282928	0.917	rs1601046	chr11:48337656	A/G	cg26585981	chr11:48327164	OR4S1	0.52	6.28	0.37	1.54e-9	Migraine - clinic-based;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22987188	chr3:101559865	NFKBIZ	0.52	7.0	0.41	2.4e-11	Interleukin-4 levels;
KIRP	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg23032129	chr1:109941072	SORT1	0.29	4.94	0.3	1.42e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Bladder cancer;
KIRP	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.59	7.52	0.43	1.02e-12	Aortic root size;
KIRP	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-6.09	-0.36	4.39e-9	Self-reported allergy;
KIRP	cis	rs7129556	0.775	rs12286317	chr11:77389020	T/C	cg12586386	chr11:77299805	AQP11	0.43	5.67	0.34	4.01e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs231513	0.954	rs231505	chr17:41970268	A/T	cg26893861	chr17:41843967	DUSP3	0.48	5.0	0.3	1.09e-6	Cognitive function;
KIRP	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-9.75	-0.53	3.33e-19	Myopia (pathological);
KIRP	cis	rs2391754	0.697	rs13227449	chr7:29338501	T/A	cg00901138	chr7:29329370	CHN2	-0.43	-5.3	-0.32	2.54e-7	CSF tryptophan concentration in tuberculous meningitis;
KIRP	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg05564831	chr3:52568323	NT5DC2	0.34	5.54	0.33	7.69e-8	Bipolar disorder;
KIRP	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.93	0.53	9.44e-20	Ileal carcinoids;
KIRP	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg01877450	chr7:97915802	BRI3	-0.57	-7.37	-0.43	2.67e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.56	6.82	0.4	7.09e-11	Aortic root size;
KIRP	cis	rs12210905	1.000	rs9379965	chr6:27227061	C/T	cg11502198	chr6:26597334	ABT1	-0.71	-4.94	-0.3	1.42e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs72772090	0.710	rs113710451	chr5:96060306	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.67	-5.81	-0.35	1.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20135002	chr11:47629003	NA	-0.48	-5.83	-0.35	1.73e-8	Subjective well-being;
KIRP	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs4704187	0.617	rs7356697	chr5:74354542	A/G	cg03227963	chr5:74354835	NA	0.42	6.26	0.37	1.74e-9	Response to amphetamines;
KIRP	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.78	0.49	2.87e-16	Motion sickness;
KIRP	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg16141378	chr3:129829833	LOC729375	-0.54	-6.71	-0.39	1.34e-10	Morning vs. evening chronotype;
KIRP	cis	rs9815354	0.638	rs73075241	chr3:42058045	C/T	cg03022575	chr3:42003672	ULK4	0.78	7.11	0.41	1.29e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.68	9.41	0.51	3.71e-18	Multiple sclerosis;
KIRP	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-7.57	-0.43	7.33e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-10.0	-0.54	5.62e-20	Eye color traits;
KIRP	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg16558253	chr16:72132732	DHX38	-0.37	-4.97	-0.3	1.24e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg18461458	chr19:21324796	ZNF431	0.47	4.9	0.3	1.74e-6	Pain;
KIRP	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.18	-0.31	4.73e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.07	-0.58	2.23e-23	Height;
KIRP	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg03060546	chr3:49711283	APEH	-0.58	-5.04	-0.31	8.92e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6568686	0.786	rs4458728	chr6:111840562	A/C	cg22127309	chr6:111907043	TRAF3IP2	0.53	4.93	0.3	1.5e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	trans	rs7044246	0.924	rs7048083	chr9:134858097	A/G	cg11308549	chr19:42348902	LYPD4;DMRTC2	0.47	6.05	0.36	5.44e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg25019722	chr6:37503610	NA	-0.78	-10.59	-0.56	7.84e-22	Cognitive performance;
KIRP	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg07395648	chr5:131743802	NA	-0.35	-5.11	-0.31	6.52e-7	Blood metabolite levels;
KIRP	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.22	13.44	0.65	3.07e-31	Corneal structure;
KIRP	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.53	5.01	0.3	1.04e-6	Height;
KIRP	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.06	0.36	5.13e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.29e-7	Red blood cell count;
KIRP	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-16.01	-0.71	5.08e-40	Coronary artery disease;
KIRP	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.58	7.58	0.44	7e-13	Lung cancer;
KIRP	trans	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg24644049	chr4:85504048	CDS1	1.1	7.25	0.42	5.49e-12	Skin colour saturation;
KIRP	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-1.04	-13.79	-0.66	1.9e-32	Body mass index;
KIRP	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.85	-0.63	2.89e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs34779708	0.736	rs34195979	chr10:35549817	T/C	cg03585969	chr10:35415529	CREM	0.57	6.59	0.39	2.66e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.58	-7.22	-0.42	6.46e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.92	12.96	0.64	1.22e-29	Bladder cancer;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.83	-12.08	-0.61	1.07e-26	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.94	12.25	0.62	2.93e-27	Menopause (age at onset);
KIRP	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.44	-0.55	2.34e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg16358155	chr3:195490169	MUC4	-0.53	-5.03	-0.31	9.25e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg05991184	chr2:219186017	PNKD	-0.35	-4.99	-0.3	1.16e-6	Colorectal cancer;
KIRP	trans	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.36	-4.9	-0.3	1.77e-6	Bipolar disorder;
KIRP	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.54	-8.73	-0.49	4.01e-16	Prostate cancer;
KIRP	trans	rs3779273	0.776	rs1829989	chr7:77830751	A/C	cg05596911	chr5:118502651	DMXL1	-0.42	-6.79	-0.4	8.47e-11	Body mass index;
KIRP	cis	rs2598107	0.542	rs6965395	chr7:37950115	C/T	cg25225232	chr7:37962694	EPDR1	-0.44	-5.03	-0.31	9.3e-7	Dupuytren's disease;
KIRP	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.42	5.11	0.31	6.42e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.68	8.0	0.45	5.04e-14	Late-onset Alzheimer's disease;
KIRP	trans	rs7558233	0.614	rs4665214	chr2:23678795	A/G	cg13319488	chr13:44361064	ENOX1	0.58	6.21	0.37	2.24e-9	Cannabis use (initiation);
KIRP	cis	rs7707921	0.602	rs10514231	chr5:81307412	C/T	cg15871215	chr5:81402204	ATG10	0.53	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg18261050	chr1:119551319	NA	0.52	6.76	0.4	1.02e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.82	9.99	0.54	5.96e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.7	-0.34	3.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg05555928	chr11:63887634	MACROD1	-0.57	-5.27	-0.32	3.02e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26039092	chr1:231473538	EXOC8;C1orf124	0.52	6.6	0.39	2.57e-10	Parkinson's disease;
KIRP	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-6.62	-0.39	2.26e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg16141378	chr3:129829833	LOC729375	0.53	6.99	0.41	2.6e-11	Retinal vascular caliber;
KIRP	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-0.55	-7.95	-0.45	6.64e-14	Coronary artery disease;
KIRP	cis	rs4253772	0.515	rs9615968	chr22:46772695	A/G	cg18190219	chr22:46762943	CELSR1	-0.95	-6.82	-0.4	7.17e-11	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg25827112	chr1:45956773	TESK2	0.51	6.08	0.36	4.63e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	Neuroticism;
KIRP	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.81	-9.46	-0.52	2.51e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg13906792	chr15:75199810	C15orf17	-0.38	-5.54	-0.33	7.63e-8	Breast cancer;
KIRP	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.62	7.92	0.45	8.27e-14	Total body bone mineral density;
KIRP	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg19875535	chr5:140030758	IK	-0.68	-9.65	-0.52	6.74e-19	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs669484	0.541	rs10959082	chr9:10378865	A/G	cg25509871	chr19:40871557	PLD3	-0.65	-6.3	-0.37	1.38e-9	Gestational age at birth (child effect);
KIRP	cis	rs7523050	0.730	rs72984628	chr1:109460808	G/A	cg08274380	chr1:109419600	GPSM2	0.81	7.38	0.43	2.44e-12	Fat distribution (HIV);
KIRP	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19717773	chr7:2847554	GNA12	-0.34	-4.91	-0.3	1.7e-6	Height;
KIRP	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12963246	chr6:28129442	ZNF389	-0.45	-5.37	-0.32	1.8e-7	Parkinson's disease;
KIRP	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	5.72	0.34	3.11e-8	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg00405596	chr8:11794950	NA	-0.53	-7.2	-0.42	7.24e-12	Mood instability;
KIRP	cis	rs2916247	1.000	rs9297902	chr8:93036884	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.61	-8.03	-0.46	4.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15664640	chr17:80829946	TBCD	0.8	8.97	0.5	7.62e-17	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26330133	chr20:35089838	DLGAP4	0.51	6.88	0.4	4.96e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09509739	chr16:31129199	MYST1	0.5	6.29	0.37	1.42e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.58	-0.34	6.4e-8	Life satisfaction;
KIRP	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg19116668	chr7:99932089	PMS2L1	-0.56	-6.31	-0.37	1.29e-9	Coronary artery disease;
KIRP	cis	rs6539288	0.803	rs7307895	chr12:107332126	A/C	cg21360079	chr12:107162445	NA	-0.37	-4.96	-0.3	1.34e-6	Total body bone mineral density;
KIRP	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.48	-6.83	-0.4	6.52e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg13010199	chr12:38710504	ALG10B	0.64	7.93	0.45	7.79e-14	Morning vs. evening chronotype;
KIRP	cis	rs11673344	0.566	rs256735	chr19:37866043	A/G	cg14683738	chr19:37701593	ZNF585B	0.46	5.41	0.33	1.47e-7	Obesity-related traits;
KIRP	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg20573242	chr4:122745356	CCNA2	0.41	5.11	0.31	6.54e-7	Type 2 diabetes;
KIRP	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.5	0.38	4.39e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1147199	0.531	rs1147195	chr9:87273174	T/C	cg22402007	chr9:87282823	NTRK2	-0.4	-4.98	-0.3	1.22e-6	Body mass index;
KIRP	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	15.62	0.71	1.11e-38	Electrocardiographic conduction measures;
KIRP	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23903597	chr17:61704154	MAP3K3	-0.64	-8.31	-0.47	6.42e-15	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs11877825	0.826	rs3748426	chr18:10581732	G/A	cg07277756	chr18:10589357	NA	0.51	6.19	0.37	2.54e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.42	-0.38	7.12e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.88	-9.93	-0.53	9.35e-20	Gut microbiome composition (summer);
KIRP	trans	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg16011800	chr17:1958478	HIC1	-0.53	-6.13	-0.36	3.49e-9	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg09559047	chr8:10916868	XKR6	0.38	5.6	0.34	5.7e-8	Triglycerides;
KIRP	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.4	-5.62	-0.34	5.26e-8	Coronary artery disease;
KIRP	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	6.2	0.37	2.35e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.78	12.08	0.61	1.1e-26	Colorectal cancer;
KIRP	cis	rs73105738	0.590	rs78349188	chr5:73286900	G/A	cg26653990	chr5:72510846	NA	-0.49	-5.37	-0.32	1.86e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs6681460	0.898	rs2483704	chr1:67195353	C/T	cg02459107	chr1:67143332	SGIP1	-0.38	-5.44	-0.33	1.31e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01073178	chr12:117537710	TESC	-0.46	-6.68	-0.39	1.59e-10	Metabolic traits;
KIRP	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg01990225	chr2:97406019	LMAN2L	-1.12	-7.37	-0.43	2.52e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg14345882	chr6:26364793	BTN3A2	0.54	4.98	0.3	1.21e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	13.52	0.65	1.57e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.76e-11	Bipolar disorder;
KIRP	cis	rs4148660	1.000	rs4148655	chr12:22063353	A/C	cg14669847	chr12:22099120	NA	-0.34	-5.79	-0.35	2.08e-8	Gout;
KIRP	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.64	9.2	0.51	1.6e-17	Colorectal cancer;
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg08662619	chr6:150070041	PCMT1	0.37	5.77	0.35	2.32e-8	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03933341	chr8:33346060	MAK16	0.43	6.02	0.36	6.33e-9	Interleukin-4 levels;
KIRP	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.41	4.98	0.3	1.22e-6	Diabetic retinopathy;
KIRP	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	5.41	0.33	1.5e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg03929089	chr4:120376271	NA	-0.58	-6.81	-0.4	7.59e-11	Coronary artery disease;
KIRP	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	7.4	0.43	2.12e-12	Neuroticism;
KIRP	cis	rs4742903	0.935	rs7872034	chr9:106896809	G/A	cg14250997	chr9:106856677	SMC2	0.38	5.01	0.3	1.06e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs12823128	0.766	rs12582081	chr12:26929913	A/G	cg14081884	chr12:26986758	ITPR2	0.4	5.01	0.3	1.02e-6	Birth weight;
KIRP	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.33	-0.62	1.64e-27	Exhaled nitric oxide output;
KIRP	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg07596299	chr11:71824057	C11orf51	0.85	5.51	0.33	9.22e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2916247	1.000	rs28550757	chr8:93047087	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.97	-0.45	5.94e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.76	8.4	0.47	3.61e-15	Uric acid levels;
KIRP	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs9880211	0.898	rs9866840	chr3:136029258	G/C	cg15507776	chr3:136538369	TMEM22	0.45	4.85	0.3	2.19e-6	Body mass index;Height;
KIRP	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg02336718	chr17:17403227	NA	-0.34	-5.15	-0.31	5.32e-7	Total body bone mineral density;
KIRP	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.74	11.07	0.58	2.17e-23	Blood metabolite ratios;
KIRP	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.71	10.11	0.54	2.59e-20	Bladder cancer;
KIRP	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg03468072	chr12:39539422	NA	0.41	5.97	0.36	8.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.46	7.62	0.44	5.37e-13	Testicular germ cell tumor;
KIRP	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg27205649	chr11:78285834	NARS2	-0.51	-4.88	-0.3	1.9e-6	Testicular germ cell tumor;
KIRP	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.95	15.66	0.71	7.99e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg13482628	chr17:19912719	NA	0.55	7.75	0.44	2.47e-13	Schizophrenia;
KIRP	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg05802129	chr4:122689817	NA	-0.56	-6.78	-0.4	9.06e-11	Type 2 diabetes;
KIRP	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg25019722	chr6:37503610	NA	0.68	8.16	0.46	1.78e-14	Cognitive performance;
KIRP	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg21926883	chr2:100939477	LONRF2	-0.56	-7.52	-0.43	1.03e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.78	8.39	0.47	3.86e-15	Cholesterol, total;
KIRP	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg09873164	chr1:152488093	CRCT1	0.57	7.25	0.42	5.28e-12	Hair morphology;
KIRP	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg20503657	chr10:835505	NA	-0.51	-6.1	-0.36	4.11e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4356932	0.691	rs2242474	chr4:76878982	T/C	cg19388996	chr4:76862389	NAAA	-0.42	-5.37	-0.32	1.8e-7	Blood protein levels;
KIRP	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg16586182	chr3:47516702	SCAP	0.67	9.5	0.52	1.91e-18	Colorectal cancer;
KIRP	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg25338242	chr13:114786047	RASA3	0.43	5.01	0.3	1.06e-6	Schizophrenia;
KIRP	cis	rs4363385	0.747	rs6689609	chr1:152967588	G/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.05	-0.31	8.68e-7	Inflammatory skin disease;
KIRP	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.35	-0.51	5.61e-18	Myopia (pathological);
KIRP	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg19847130	chr8:10466454	RP1L1	-0.34	-5.08	-0.31	7.34e-7	Retinal vascular caliber;
KIRP	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg19847866	chr10:1019161	NA	-0.61	-5.59	-0.34	6.17e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg01557791	chr16:72042693	DHODH	-0.43	-5.3	-0.32	2.55e-7	Fibrinogen levels;
KIRP	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05220968	chr6:146057943	EPM2A	0.39	4.93	0.3	1.52e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg13798912	chr7:905769	UNC84A	-0.76	-7.08	-0.41	1.48e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg06618935	chr21:46677482	NA	-0.45	-5.55	-0.33	7.22e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.96	11.16	0.58	1.1e-23	Corneal astigmatism;
KIRP	cis	rs405956	1.000	rs9486037	chr6:105561560	C/A	cg22580625	chr6:105627791	POPDC3	-0.61	-6.6	-0.39	2.58e-10	QT interval;
KIRP	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.34	0.42	3.17e-12	Bipolar disorder;
KIRP	cis	rs10411936	0.626	rs8109817	chr19:16587889	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.34	0.32	2.07e-7	White blood cell count;Multiple sclerosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10006721	chr19:55825820	TMEM150B	0.48	6.03	0.36	6e-9	Interleukin-4 levels;
KIRP	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.48	6.21	0.37	2.29e-9	Blood protein levels;
KIRP	cis	rs4765905	0.610	rs10848629	chr12:2312897	C/T	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs151997	1.000	rs251043	chr5:50215997	A/G	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs3733418	0.860	rs72697987	chr4:165953917	G/A	cg10852876	chr4:165953100	TRIM60	-0.52	-5.57	-0.33	6.77e-8	Obesity-related traits;
KIRP	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg05347473	chr6:146136440	FBXO30	-0.56	-7.78	-0.44	1.94e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17428704	0.510	rs16903375	chr5:14302488	A/G	cg26595256	chr5:14380529	TRIO	-0.88	-5.19	-0.31	4.42e-7	Electroencephalogram traits;
KIRP	trans	rs3858145	0.588	rs61854833	chr10:70037327	C/G	cg04882175	chr6:131122610	NA	-0.59	-6.95	-0.41	3.35e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg06204229	chr3:52865917	ITIH4	0.55	7.79	0.44	1.9e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg14784868	chr12:69753453	YEATS4	0.51	5.22	0.32	3.82e-7	Response to diuretic therapy;
KIRP	cis	rs2273669	0.915	rs12191613	chr6:109289203	G/A	cg05315195	chr6:109294784	ARMC2	-0.47	-5.26	-0.32	3.13e-7	Prostate cancer;
KIRP	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg13939156	chr17:80058883	NA	0.48	5.62	0.34	5.08e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg02811702	chr13:24901961	NA	0.42	5.51	0.33	9.11e-8	Obesity-related traits;
KIRP	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg08603382	chr10:743973	NA	0.47	6.83	0.4	6.5e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs2274273	0.653	rs1209087	chr14:55493220	C/T	cg04306507	chr14:55594613	LGALS3	-0.44	-6.66	-0.39	1.74e-10	Protein biomarker;
KIRP	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.52e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs12049351	0.675	rs754024	chr1:229637414	C/T	cg11742688	chr1:229674241	ABCB10	-0.37	-5.7	-0.34	3.49e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6832769	1.000	rs7667849	chr4:56388199	A/G	cg09317128	chr4:56265301	TMEM165	-0.56	-7.13	-0.41	1.11e-11	Personality dimensions;
KIRP	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.85	-10.16	-0.54	1.83e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01622965	chr7:98476371	TRRAP	0.6	6.97	0.41	2.89e-11	Smoking initiation;
KIRP	trans	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.31	0.37	1.31e-9	Schizophrenia;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.43	5.24	0.32	3.52e-7	Longevity;Endometriosis;
KIRP	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.72	-7.17	-0.42	8.9e-12	Menarche (age at onset);
KIRP	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg04306507	chr14:55594613	LGALS3	0.48	7.42	0.43	1.89e-12	Protein biomarker;
KIRP	cis	rs838721	0.574	rs11681192	chr2:234258064	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	4.93	0.3	1.49e-6	Total body bone mineral density;
KIRP	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg08807892	chr2:162101083	NA	0.45	5.39	0.32	1.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.71	8.47	0.48	2.29e-15	Blood metabolite levels;
KIRP	cis	rs9296736	0.961	rs9370260	chr6:53921674	T/C	cg04374786	chr6:53939321	C6orf142	0.38	4.98	0.3	1.22e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg00405596	chr8:11794950	NA	0.57	7.87	0.45	1.15e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06481639	chr22:41940642	POLR3H	0.69	7.43	0.43	1.76e-12	Vitiligo;
KIRP	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.67	9.11	0.5	3.01e-17	Eye color traits;
KIRP	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg21605333	chr4:119757512	SEC24D	1.37	10.3	0.55	6.55e-21	Cannabis dependence symptom count;
KIRP	cis	rs2274459	1.000	rs877187	chr6:33706211	A/G	cg06253072	chr6:33679850	C6orf125	-0.5	-5.1	-0.31	6.74e-7	Obesity (extreme);
KIRP	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg17654217	chr7:100282651	GIGYF1	0.52	4.96	0.3	1.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-16.12	-0.72	2.21e-40	Chronic sinus infection;
KIRP	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04374321	chr14:90722782	PSMC1	-0.89	-14.61	-0.68	3.13e-35	Mortality in heart failure;
KIRP	cis	rs6882046	0.513	rs618298	chr5:88038390	A/G	cg22951263	chr5:87985283	NA	-0.48	-6.78	-0.4	8.82e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.78	8.95	0.5	8.89e-17	Corneal astigmatism;
KIRP	cis	rs888194	0.677	rs10774696	chr12:109875753	C/T	cg19025524	chr12:109796872	NA	-0.37	-5.08	-0.31	7.37e-7	Neuroticism;
KIRP	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.56	8.2	0.46	1.37e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	12.85	0.63	2.91e-29	Mean platelet volume;
KIRP	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg16296679	chr22:42394374	WBP2NL	-0.36	-4.84	-0.3	2.26e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs10924309	0.889	rs10802248	chr1:245858554	A/C	cg00036263	chr1:245852353	KIF26B	-0.5	-6.59	-0.39	2.72e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg08461772	chr7:95026248	PON3	0.41	5.79	0.35	2.11e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg03877680	chr5:178157825	ZNF354A	1.04	13.61	0.66	7.79e-32	Neutrophil percentage of white cells;
KIRP	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.58	-8.1	-0.46	2.62e-14	Motion sickness;
KIRP	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03934478	chr11:495069	RNH1	0.87	6.95	0.4	3.34e-11	Body mass index;
KIRP	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg04691961	chr3:161091175	C3orf57	-0.58	-9.52	-0.52	1.69e-18	Morning vs. evening chronotype;
KIRP	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	0.94	8.35	0.47	4.91e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	9.95	0.54	8.11e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9436747	0.626	rs17412403	chr1:65942266	T/C	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-4.85	-0.3	2.14e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg25319279	chr11:5960081	NA	-0.57	-5.88	-0.35	1.32e-8	DNA methylation (variation);
KIRP	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.74	-10.8	-0.57	1.68e-22	Height;
KIRP	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.75	-9.84	-0.53	1.81e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18098774	chr2:107084802	RGPD3	-0.46	-6.51	-0.38	4.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67385638	0.802	rs11036635	chr11:5308896	C/T	cg12559170	chr11:5275217	HBG2	0.51	7.4	0.43	2.09e-12	Hemoglobin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08427575	chr7:75988356	YWHAG	0.53	7.43	0.43	1.81e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3815700	0.688	rs259252	chr19:33149991	G/C	cg02997394	chr19:33096574	ANKRD27	1.28	8.07	0.46	3.02e-14	Eosinophilic esophagitis;
KIRP	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg23815491	chr16:72088622	HP	-0.36	-5.9	-0.35	1.22e-8	Prostate cancer;
KIRP	cis	rs2445762	0.548	rs2445781	chr15:51653260	A/C	cg00184732	chr15:51633821	GLDN	0.28	4.87	0.3	1.99e-6	Hormone measurements;
KIRP	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.28	-0.32	2.87e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg25319279	chr11:5960081	NA	-0.53	-5.19	-0.31	4.46e-7	DNA methylation (variation);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15604682	chr7:102105781	ALKBH4;LRWD1	-0.5	-6.82	-0.4	6.89e-11	Myopia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26558510	chr4:178531944	NA	-0.43	-6.46	-0.38	5.58e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.48	-6.7	-0.39	1.45e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	1.03	11.14	0.58	1.31e-23	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg25042112	chr7:64838748	ZNF92	-0.6	-6.34	-0.37	1.1e-9	Pain;
KIRP	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.51	6.4	0.38	7.68e-10	Obesity-related traits;
KIRP	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg13679303	chr9:96623674	NA	0.44	5.76	0.34	2.53e-8	DNA methylation (variation);
KIRP	cis	rs78487399	0.808	rs7567535	chr2:43668261	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg23719950	chr11:63933701	MACROD1	-0.6	-6.03	-0.36	5.84e-9	Mean platelet volume;
KIRP	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg21395723	chr22:39101663	GTPBP1	0.44	5.39	0.33	1.63e-7	Menopause (age at onset);
KIRP	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	10.15	0.54	1.88e-20	Exhaled nitric oxide levels;
KIRP	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg07862535	chr7:139043722	LUC7L2	0.48	5.28	0.32	2.81e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4664293	0.867	rs11681565	chr2:160616873	C/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs834811	0.863	rs834821	chr7:135895713	A/T	cg01726295	chr7:135938950	NA	0.38	5.47	0.33	1.09e-7	Post-traumatic stress disorder;
KIRP	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs1519814	0.696	rs6985424	chr8:121062976	C/T	cg22335954	chr8:121166405	COL14A1	-0.5	-4.88	-0.3	1.94e-6	Breast cancer;
KIRP	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg15848620	chr12:58087721	OS9	-0.48	-5.49	-0.33	9.96e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg08807892	chr2:162101083	NA	0.64	8.8	0.49	2.5e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	5.49	0.33	1.01e-7	Longevity;
KIRP	trans	rs7710178	0.938	rs194144	chr5:155964872	T/C	cg23165310	chr3:181422217	SOX2OT	0.74	6.18	0.37	2.71e-9	Airway responsiveness in chronic obstructive pulmonary disease;
KIRP	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg18646521	chr2:111875858	NA	0.41	5.91	0.35	1.14e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg26134248	chr17:3907702	NA	0.56	8.24	0.47	1.01e-14	Type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs3779635	0.742	rs1045510	chr8:27255128	T/C	cg18234130	chr8:27182889	PTK2B	0.54	6.84	0.4	6.07e-11	Neuroticism;
KIRP	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.91	-0.66	7.57e-33	Primary sclerosing cholangitis;
KIRP	cis	rs2151522	0.762	rs9372845	chr6:127150997	T/C	cg21431617	chr6:127135037	NA	0.3	5.39	0.33	1.64e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.4	-0.33	1.55e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.76	-13.33	-0.65	7.03e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.55	7.47	0.43	1.4e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	7.97	0.45	6.09e-14	Parkinson's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21156684	chr1:6411612	ACOT7	0.44	6.25	0.37	1.84e-9	Survival in pancreatic cancer;
KIRP	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.61	0.56	6.76e-22	Cognitive test performance;
KIRP	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.98	14.06	0.67	2.39e-33	Platelet distribution width;
KIRP	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08439880	chr3:133502540	NA	0.57	7.12	0.41	1.22e-11	Iron status biomarkers;
KIRP	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg23533419	chr12:54090519	NA	-0.32	-5.06	-0.31	8.09e-7	Height;
KIRP	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.87	-0.4	5.28e-11	Aortic root size;
KIRP	cis	rs812925	0.537	rs10196146	chr2:61605379	C/A	cg15711740	chr2:61764176	XPO1	0.45	5.58	0.34	6.18e-8	Immature fraction of reticulocytes;
KIRP	cis	rs4594175	0.926	rs114230179	chr14:51601974	C/T	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04540959	chr5:89687197	NA	0.47	6.44	0.38	6.31e-10	Survival in pancreatic cancer;
KIRP	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg06766960	chr11:133703094	NA	-0.6	-7.82	-0.45	1.56e-13	Childhood ear infection;
KIRP	cis	rs8068544	0.606	rs8082153	chr17:40172467	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.19	-9.3	-0.51	7.92e-18	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.63	-7.9	-0.45	9.14e-14	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03512643	chr14:74486160	C14orf45;ENTPD5	-0.45	-6.03	-0.36	6.03e-9	Myopia;
KIRP	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg07395648	chr5:131743802	NA	-0.36	-4.95	-0.3	1.4e-6	Blood metabolite levels;
KIRP	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	14.84	0.69	5.14e-36	Chronic sinus infection;
KIRP	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg20140201	chr2:241835670	C2orf54	-0.31	-4.92	-0.3	1.59e-6	Urinary metabolites;
KIRP	cis	rs7078219	0.743	rs17094148	chr10:101280279	A/G	cg07044859	chr10:101282883	NA	-0.36	-5.58	-0.34	6.42e-8	Dental caries;
KIRP	cis	rs9400467	0.528	rs457492	chr6:111641850	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.4	-5.21	-0.32	3.92e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12476592	0.571	rs166384	chr2:63863630	G/T	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg00666640	chr1:248458726	OR2T12	0.45	6.04	0.36	5.79e-9	Common traits (Other);
KIRP	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.44	-5.32	-0.32	2.35e-7	Ulcerative colitis;
KIRP	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg15103426	chr22:29168792	CCDC117	0.47	6.24	0.37	1.91e-9	Red cell distribution width;
KIRP	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.16	0.46	1.73e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18500431	chr7:1709489	NA	-0.42	-6.03	-0.36	6.1e-9	Pancreatic cancer;
KIRP	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.42	5.49	0.33	9.8e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1712517	0.566	rs7917388	chr10:105054963	C/T	cg04362960	chr10:104952993	NT5C2	-0.58	-7.29	-0.42	4.12e-12	Migraine;
KIRP	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg07382826	chr16:28625726	SULT1A1	0.48	5.35	0.32	2.06e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg07382826	chr16:28625726	SULT1A1	0.47	5.49	0.33	9.99e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.83	-9.66	-0.52	6.47e-19	Exhaled nitric oxide output;
KIRP	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	6.47	0.38	5.37e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg05768032	chr16:30646687	NA	0.42	5.06	0.31	8.19e-7	Multiple myeloma;
KIRP	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.88	0.35	1.32e-8	Motion sickness;
KIRP	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.6	8.07	0.46	3.22e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4711350	0.765	rs2395446	chr6:33743264	C/T	cg25922239	chr6:33757077	LEMD2	0.53	6.01	0.36	6.5e-9	Schizophrenia;
KIRP	trans	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg06521331	chr12:34319734	NA	-0.51	-6.16	-0.37	2.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.79	-0.4	8.16e-11	Mood instability;
KIRP	cis	rs4728302	0.869	rs2042456	chr7:133580447	G/A	cg10665199	chr7:133106180	EXOC4	0.47	5.71	0.34	3.32e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.47	5.89	0.35	1.23e-8	Initial pursuit acceleration;
KIRP	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.52	7.08	0.41	1.47e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.69	-7.06	-0.41	1.65e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.58	7.38	0.43	2.4e-12	Aortic root size;
KIRP	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg02487422	chr3:49467188	NICN1	0.36	5.08	0.31	7.41e-7	Parkinson's disease;
KIRP	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18252515	chr7:66147081	NA	0.47	5.72	0.34	3.1e-8	Aortic root size;
KIRP	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.77	-0.4	9.6e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg05315796	chr3:52349193	DNAH1	0.4	5.19	0.31	4.35e-7	Schizophrenia;
KIRP	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.7	0.49	4.71e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.4	5.14	0.31	5.72e-7	Leprosy;
KIRP	cis	rs10982256	0.935	rs1555700	chr9:117256375	T/C	cg13636371	chr9:117264095	DFNB31	0.6	8.42	0.47	3.25e-15	Bipolar disorder;
KIRP	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg16141378	chr3:129829833	LOC729375	0.61	8.26	0.47	8.84e-15	Triglycerides;
KIRP	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12463550	chr7:65579703	CRCP	0.75	4.88	0.3	1.9e-6	Diabetic kidney disease;
KIRP	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg24796726	chr7:884288	UNC84A	-0.59	-5.46	-0.33	1.17e-7	Initial pursuit acceleration;
KIRP	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs10129255	0.500	rs8014529	chr14:107192302	G/A	cg23076370	chr14:107095027	NA	-0.4	-4.87	-0.3	2e-6	Kawasaki disease;
KIRP	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.89	10.59	0.56	7.9e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg16988262	chr1:15930761	NA	0.38	4.9	0.3	1.77e-6	Systolic blood pressure;
KIRP	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.89e-31	Eye color traits;
KIRP	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.56	0.52	1.28e-18	Prudent dietary pattern;
KIRP	cis	rs4786125	0.512	rs55694271	chr16:6930378	G/A	cg03623568	chr16:6915990	A2BP1	-0.44	-5.26	-0.32	3.11e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-0.93	-9.31	-0.51	7.37e-18	Developmental language disorder (linguistic errors);
KIRP	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.55	-15.72	-0.71	5e-39	Hip circumference adjusted for BMI;
KIRP	cis	rs9443189	0.502	rs3798431	chr6:76596220	G/C	cg01950844	chr6:76311363	SENP6	-0.76	-4.87	-0.3	1.98e-6	Prostate cancer;
KIRP	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.46	-5.78	-0.35	2.29e-8	Blood metabolite levels;
KIRP	cis	rs9304742	0.962	rs12461778	chr19:53454963	T/A	cg09915433	chr19:53449742	NA	-0.38	-5.51	-0.33	9.15e-8	Psoriasis;
KIRP	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg13180566	chr4:1052158	NA	-0.52	-5.34	-0.32	2.1e-7	Recombination rate (females);
KIRP	cis	rs4262150	0.726	rs4958567	chr5:152015597	T/G	cg12297329	chr5:152029980	NA	-0.63	-8.16	-0.46	1.78e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2033908	0.558	rs6486064	chr11:12869509	T/C	cg25843174	chr11:12811716	TEAD1	-0.31	-5.82	-0.35	1.87e-8	Sitting height ratio;
KIRP	cis	rs34421088	0.531	rs2245232	chr8:11400944	G/T	cg00405596	chr8:11794950	NA	-0.46	-5.71	-0.34	3.17e-8	Neuroticism;
KIRP	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.67	9.33	0.51	6.5e-18	Red blood cell count;
KIRP	cis	rs448720	0.554	rs2127162	chr15:68090824	A/C	cg24579218	chr15:68104479	NA	0.48	7.59	0.44	6.51e-13	Cognitive performance;
KIRP	cis	rs7116495	1.000	rs10751193	chr11:71785356	A/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-9.15	-0.5	2.18e-17	Hepatocellular carcinoma;
KIRP	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg22771759	chr13:24902376	NA	0.39	5.01	0.3	1.02e-6	Obesity-related traits;
KIRP	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg10761708	chr20:43804764	PI3	0.51	5.22	0.32	3.8e-7	Blood protein levels;
KIRP	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.61	9.76	0.53	3.07e-19	HDL cholesterol levels;
KIRP	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg08662619	chr6:150070041	PCMT1	0.32	5.1	0.31	6.77e-7	Testicular germ cell tumor;
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.26	-0.37	1.73e-9	Longevity;
KIRP	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.64	-0.39	1.96e-10	Mean platelet volume;
KIRP	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.68	-7.72	-0.44	2.99e-13	Schizophrenia;
KIRP	cis	rs9603616	1.000	rs7319041	chr13:40345356	G/A	cg26701198	chr13:40229707	COG6	-0.46	-5.14	-0.31	5.53e-7	Rheumatoid arthritis;
KIRP	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.78	9.15	0.5	2.29e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.4	6.85	0.4	5.94e-11	Mean corpuscular volume;
KIRP	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.46	6.48	0.38	4.83e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-8.97	-0.5	7.95e-17	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18605135	chr13:39346236	FREM2	-0.38	-6.15	-0.37	3.19e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg19767477	chr5:127420684	SLC12A2	-0.35	-4.85	-0.3	2.19e-6	Ileal carcinoids;
KIRP	cis	rs6442310	0.534	rs1151997	chr3:12446004	A/G	cg02700894	chr3:12045449	SYN2	0.41	5.59	0.34	5.9e-8	Hematocrit;
KIRP	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-6.28	-0.37	1.56e-9	Menopause (age at onset);
KIRP	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg10760299	chr15:45669010	GATM	0.35	5.13	0.31	5.79e-7	Homoarginine levels;
KIRP	cis	rs12049351	0.774	rs10799533	chr1:229656562	C/T	cg11742688	chr1:229674241	ABCB10	-0.36	-5.36	-0.32	1.93e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg24747557	chr10:131355152	MGMT	-0.46	-6.47	-0.38	5.17e-10	Response to temozolomide;
KIRP	cis	rs4742903	0.846	rs4743699	chr9:107002261	T/A	cg14250997	chr9:106856677	SMC2	0.39	5.27	0.32	3.05e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg27411982	chr8:10470053	RP1L1	0.4	4.85	0.3	2.18e-6	Neuroticism;
KIRP	cis	rs7172677	0.737	rs12442410	chr15:75437510	G/A	cg14664628	chr15:75095509	CSK	-0.55	-6.08	-0.36	4.55e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7534824	0.543	rs60978318	chr1:101400413	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.83	0.35	1.7e-8	Refractive astigmatism;
KIRP	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.42	-0.51	3.5e-18	Response to antipsychotic treatment;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10571824	chr7:1963144	MAD1L1	0.45	6.12	0.36	3.61e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6142102	0.961	rs4911389	chr20:32565041	A/G	cg08999081	chr20:33150536	PIGU	0.48	5.63	0.34	4.97e-8	Skin pigmentation;
KIRP	cis	rs61935443	0.720	rs10859785	chr12:95295081	A/T	cg21533806	chr12:95267307	NA	0.63	6.16	0.37	2.94e-9	Schizophrenia;
KIRP	cis	rs7582180	0.934	rs2309824	chr2:100901661	A/G	cg14675211	chr2:100938903	LONRF2	-0.54	-6.36	-0.38	9.62e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21171335	chr12:122356390	WDR66	0.63	8.66	0.48	6.3e-16	Mean corpuscular volume;
KIRP	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.6	5.49	0.33	1.02e-7	Lung function (FEV1/FVC);
KIRP	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05776053	chr2:74358815	NA	0.65	6.2	0.37	2.32e-9	Gestational age at birth (maternal effect);
KIRP	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-11.92	-0.6	3.77e-26	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg13939156	chr17:80058883	NA	-0.52	-7.77	-0.44	2.07e-13	Life satisfaction;
KIRP	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg07827796	chr19:33622959	WDR88	0.43	5.05	0.31	8.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg08901578	chr4:187885870	NA	-0.44	-6.6	-0.39	2.45e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.08	12.75	0.63	6.18e-29	Vitiligo;
KIRP	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.83	-13.85	-0.66	1.22e-32	Brugada syndrome;
KIRP	cis	rs10214930	0.697	rs2110528	chr7:27643019	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.99	0.3	1.16e-6	Hypospadias;
KIRP	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.59	-6.31	-0.37	1.31e-9	Pancreatic cancer;
KIRP	trans	rs10129666	0.817	rs7145947	chr14:78687035	A/G	cg01530981	chr1:209756892	CAMK1G	-0.36	-6.06	-0.36	5.12e-9	Electrodermal activity;
KIRP	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07151155	chr5:1473589	LPCAT1	-0.42	-5.6	-0.34	5.67e-8	Breast cancer;
KIRP	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16421803	chr2:25194856	DNAJC27	0.51	6.09	0.36	4.31e-9	Myopia (pathological);
KIRP	cis	rs1981331	0.609	rs3088287	chr21:48079669	G/A	cg17243659	chr21:48055224	PRMT2	0.86	6.28	0.37	1.53e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs17065868	0.892	rs9525980	chr13:45119719	A/G	cg10246903	chr13:45222710	NA	0.72	6.4	0.38	7.86e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg05084668	chr3:125655381	ALG1L	-0.5	-5.58	-0.34	6.34e-8	Blood pressure (smoking interaction);
KIRP	trans	rs6887317	0.585	rs2158099	chr5:11362268	C/G	cg10195962	chr10:47656369	NA	0.39	6.14	0.36	3.25e-9	Lewy body disease;
KIRP	cis	rs7640424	0.649	rs35876429	chr3:107928557	C/T	cg09227934	chr3:107805635	CD47	-0.35	-5.91	-0.35	1.15e-8	Body mass index;
KIRP	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.52	-5.5	-0.33	9.45e-8	Blood pressure (smoking interaction);
KIRP	cis	rs8027181	1.000	rs3850986	chr15:73091283	G/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.37	4.86	0.3	2.06e-6	Triglyceride levels;
KIRP	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.07	11.94	0.61	3.29e-26	Vitiligo;
KIRP	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.1	0.41	1.35e-11	Prudent dietary pattern;
KIRP	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg04727924	chr7:799746	HEATR2	-0.66	-6.61	-0.39	2.39e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Bipolar disorder;
KIRP	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	7.54	0.43	8.87e-13	Retinal vascular caliber;
KIRP	cis	rs7975161	0.608	rs10861169	chr12:104610640	C/T	cg25273343	chr12:104657179	TXNRD1	-0.46	-5.28	-0.32	2.8e-7	Toenail selenium levels;
KIRP	cis	rs9403317	0.960	rs9373314	chr6:141820687	A/T	cg15052665	chr6:141804349	NA	0.41	4.93	0.3	1.5e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829661	0.793	rs2593474	chr2:30856936	A/T	cg10949345	chr2:30726833	LCLAT1	-1.14	-14.0	-0.67	3.94e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg19468946	chr17:37922297	IKZF3	-0.41	-5.8	-0.35	2.03e-8	Asthma;
KIRP	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7084402	0.905	rs1649031	chr10:60279742	G/A	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27447131	chr15:66198458	MEGF11	0.41	6.5	0.38	4.35e-10	Survival in pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25494665	chr13:42623369	DGKH	0.46	6.25	0.37	1.83e-9	Parkinson's disease;
KIRP	cis	rs3829109	0.502	rs4320648	chr9:139294271	G/A	cg14169450	chr9:139327907	INPP5E	0.45	5.47	0.33	1.13e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.54	0.33	7.9e-8	Homoarginine levels;
KIRP	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08439880	chr3:133502540	NA	-0.5	-6.22	-0.37	2.09e-9	Iron status biomarkers;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg12486944	chr17:80159399	CCDC57	-0.41	-5.54	-0.33	7.74e-8	Life satisfaction;
KIRP	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg17757837	chr7:157058334	UBE3C	-0.81	-11.17	-0.58	1.02e-23	Body mass index;
KIRP	trans	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg21734707	chr17:3908241	ZZEF1	-0.63	-9.66	-0.52	6.55e-19	Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg00745463	chr17:30367425	LRRC37B	-0.64	-6.56	-0.39	3.22e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.92	0.4	3.88e-11	Aortic root size;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-0.83	-14.36	-0.68	2.22e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs27434	0.583	rs34764	chr5:96155229	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1e-7	Ankylosing spondylitis;
KIRP	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg25486957	chr4:152246857	NA	-0.48	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05508315	chr3:122605312	LOC100129550	0.43	6.54	0.38	3.49e-10	Survival in pancreatic cancer;
KIRP	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.83	0.49	1.95e-16	Neuroticism;
KIRP	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.38	6.36	0.38	9.7e-10	Total body bone mineral density;
KIRP	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.59	7.67	0.44	3.89e-13	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12120238	chr6:155054535	RBM16	0.53	6.64	0.39	1.96e-10	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.28	-0.32	2.81e-7	Morning vs. evening chronotype;
KIRP	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg04935436	chr20:30431758	NA	0.46	5.89	0.35	1.24e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs9547996	0.836	rs61957483	chr13:38147504	T/C	cg13634560	chr13:38173852	POSTN	-0.41	-5.62	-0.34	5.23e-8	Diastolic blood pressure;
KIRP	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.78	0.35	2.27e-8	Menopause (age at onset);
KIRP	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg12559939	chr2:27858050	GPN1	0.47	5.9	0.35	1.22e-8	Oral cavity cancer;
KIRP	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs8179	0.761	rs42035	chr7:92239531	A/G	cg15732164	chr7:92237376	CDK6	-0.54	-6.73	-0.39	1.15e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg05347473	chr6:146136440	FBXO30	-0.64	-9.41	-0.51	3.8e-18	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04312406	chr1:226497240	LIN9	0.51	6.73	0.39	1.18e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.58	-6.48	-0.38	4.94e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05181186	chr4:85504391	CDS1	-0.55	-6.11	-0.36	3.77e-9	Menopause (age at onset);
KIRP	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg03714773	chr7:91764589	CYP51A1	0.35	5.27	0.32	2.95e-7	Breast cancer;
KIRP	cis	rs6693295	1.000	rs6693295	chr1:246223120	C/T	cg11798871	chr1:246315928	SMYD3	-0.44	-5.26	-0.32	3.09e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.44	5.92	0.35	1.09e-8	Hypertriglyceridemia;
KIRP	cis	rs17125944	0.615	rs7146915	chr14:53316039	C/T	cg00686598	chr14:53173677	PSMC6	-0.74	-6.92	-0.4	3.98e-11	Alzheimer's disease (late onset);
KIRP	cis	rs897080	0.589	rs1085448	chr2:44663805	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.7	0.34	3.38e-8	Height;
KIRP	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.62	9.21	0.51	1.46e-17	Carotid intima media thickness;
KIRP	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg02503808	chr4:7069936	GRPEL1	-0.85	-5.11	-0.31	6.35e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg01304814	chr3:48885189	PRKAR2A	0.56	4.95	0.3	1.4e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg13962347	chr6:5174647	LYRM4	-0.62	-8.48	-0.48	2.04e-15	Height;
KIRP	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.82	-8.76	-0.49	3.16e-16	Hair shape;
KIRP	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.23e-7	Obesity-related traits;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06973293	chr4:77135005	SCARB2	0.49	6.19	0.37	2.51e-9	Myopia (pathological);
KIRP	cis	rs10849893	0.535	rs7965954	chr12:121918732	G/T	cg01154721	chr12:121881891	KDM2B	0.43	5.47	0.33	1.13e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.55	-5.48	-0.33	1.06e-7	Gut microbiome composition (summer);
KIRP	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.36	-0.32	1.91e-7	Cholesterol, total;
KIRP	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg01304814	chr3:48885189	PRKAR2A	0.73	5.61	0.34	5.33e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs494562	0.892	rs544408	chr6:86119110	A/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs2882667	0.898	rs6863347	chr5:138361135	C/T	cg04439458	chr5:138467593	SIL1	-0.38	-6.41	-0.38	7.26e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12101261	0.556	rs2300516	chr14:81446908	A/G	cg06600135	chr14:81408086	NA	0.4	5.02	0.3	1e-6	Graves' disease;
KIRP	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.96	13.67	0.66	4.87e-32	Cognitive function;
KIRP	cis	rs1124376	0.688	rs11715447	chr3:20140129	A/C	cg05072819	chr3:20081367	KAT2B	0.67	4.95	0.3	1.38e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.44	8.42	0.47	3.2e-15	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg10756647	chr7:56101905	PSPH	1.02	7.73	0.44	2.72e-13	Diabetic kidney disease;
KIRP	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.4	5.65	0.34	4.51e-8	Obesity-related traits;
KIRP	cis	rs6987853	0.966	rs2974359	chr8:42434194	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.16	0.31	5.2e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9308731	0.583	rs7596789	chr2:111932616	G/A	cg04780086	chr2:111875790	ACOXL	0.44	5.9	0.35	1.2e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	1.09	8.04	0.46	3.69e-14	Skin colour saturation;
KIRP	cis	rs4478858	0.735	rs6425736	chr1:31784376	T/A	cg00250761	chr1:31883323	NA	-0.3	-5.3	-0.32	2.61e-7	Alcohol dependence;
KIRP	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.6	-6.67	-0.39	1.66e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs12230513	0.732	rs7957446	chr12:55839631	G/C	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs2591576	0.809	rs152271	chr5:165412347	C/T	cg13976338	chr5:165423657	NA	-0.81	-12.55	-0.62	2.97e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs909341	0.909	rs6122158	chr20:62363096	G/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.74	-0.39	1.1e-10	Atopic dermatitis;
KIRP	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03076246	chr16:67906784	EDC4	0.49	6.48	0.38	4.89e-10	Asthma;
KIRP	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.15	-0.31	5.35e-7	Menarche (age at onset);
KIRP	cis	rs6725041	0.547	rs1394784	chr2:213209325	G/A	cg16329650	chr2:213403929	ERBB4	-0.39	-4.93	-0.3	1.5e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.08	0.61	1.11e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.56	7.58	0.43	7.17e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	0.97	10.62	0.56	6.45e-22	Blood protein levels;
KIRP	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg15873301	chr3:12045459	SYN2	0.4	5.45	0.33	1.22e-7	Plateletcrit;Lymphocyte counts;White blood cell count;
KIRP	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.96	12.71	0.63	8.63e-29	Platelet distribution width;
KIRP	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.49	5.76	0.34	2.51e-8	Longevity;Endometriosis;
KIRP	cis	rs2820315	0.867	rs2820319	chr1:201878650	G/A	cg11586189	chr1:201857591	SHISA4	-0.4	-5.71	-0.34	3.24e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	trans	rs972578	0.791	rs738538	chr22:43281879	A/G	cg15321293	chr3:36422198	STAC	-0.47	-6.07	-0.36	4.84e-9	Mean platelet volume;
KIRP	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg02023728	chr11:77925099	USP35	-0.31	-5.36	-0.32	1.89e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.7	0.68	1.59e-35	Platelet count;
KIRP	trans	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg06521331	chr12:34319734	NA	-0.6	-6.99	-0.41	2.59e-11	Bladder cancer;
KIRP	cis	rs71403859	0.554	rs12920245	chr16:72029069	C/A	cg09488090	chr16:72319766	NA	-0.56	-5.16	-0.31	5.14e-7	Post bronchodilator FEV1;
KIRP	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg18944383	chr4:111397179	ENPEP	-0.57	-10.9	-0.57	8.02e-23	Height;
KIRP	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.85	-13.21	-0.64	1.81e-30	Height;
KIRP	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg23903597	chr17:61704154	MAP3K3	-0.56	-6.83	-0.4	6.5500000000000006e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.29	-0.42	4.1e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg19913688	chr11:428466	ANO9	-0.75	-5.53	-0.33	7.98e-8	Body mass index;
KIRP	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.83	0.53	1.86e-19	Corneal astigmatism;
KIRP	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg19920283	chr7:105172520	RINT1	0.41	4.96	0.3	1.32e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.46	5.88	0.35	1.33e-8	Blood protein levels;
KIRP	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg11130432	chr3:121712080	ILDR1	-0.46	-5.41	-0.33	1.5e-7	Multiple sclerosis;
KIRP	cis	rs1200821	0.701	rs1200820	chr10:37559479	C/G	cg00409905	chr10:38381863	ZNF37A	-0.39	-5.22	-0.32	3.83e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg12560992	chr17:57184187	TRIM37	0.6	5.57	0.33	6.5e-8	Cognitive test performance;
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg18402987	chr7:1209562	NA	0.42	4.88	0.3	1.89e-6	Longevity;Endometriosis;
KIRP	cis	rs11239930	0.517	rs493000	chr1:146549527	C/T	cg16700924	chr1:146552102	NA	-0.44	-4.86	-0.3	2.06e-6	AIDS progression;
KIRP	cis	rs11673344	0.864	rs11670216	chr19:37503428	G/C	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.18	-0.31	4.64e-7	Obesity-related traits;
KIRP	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg07621104	chr11:117668040	DSCAML1	0.48	7.32	0.42	3.54e-12	Myopia;
KIRP	cis	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-5.19	-0.31	4.31e-7	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.28	-0.37	1.49e-9	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.2e-8	Life satisfaction;
KIRP	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.22	-0.37	2.14e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	6.25	0.37	1.81e-9	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00292435	chr9:91925643	CKS2	0.56	6.72	0.39	1.28e-10	Smoking initiation;
KIRP	cis	rs6959887	0.926	rs4723402	chr7:35278424	G/A	cg06685737	chr7:35301730	NA	0.45	6.56	0.39	3.12e-10	Birth weight;
KIRP	cis	rs2737618	1.000	rs2737618	chr1:200107425	C/T	cg21825944	chr1:200113062	NR5A2	-0.6	-7.72	-0.44	2.99e-13	Uric acid levels;
KIRP	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	1.11	9.29	0.51	8.26e-18	Red blood cell traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11184682	chr3:50365769	TUSC2	0.53	6.12	0.36	3.68e-9	Smoking initiation;
KIRP	cis	rs2625529	0.824	rs12916694	chr15:72298140	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.12e-9	Red blood cell count;
KIRP	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.8	-0.35	2.06e-8	Vitiligo;
KIRP	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.88	13.06	0.64	5.61e-30	Eosinophil percentage of white cells;
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.64	9.52	0.52	1.76e-18	Vitiligo;
KIRP	cis	rs4776059	1.000	rs11070909	chr15:52931601	A/G	cg25063058	chr15:52860530	ARPP19	0.53	5.83	0.35	1.7e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00944808	chr15:42264708	EHD4	0.48	6.21	0.37	2.24e-9	Parkinson's disease;
KIRP	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg03585969	chr10:35415529	CREM	0.66	8.31	0.47	6.71e-15	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg11608241	chr8:8085544	FLJ10661	0.55	6.67	0.39	1.68e-10	Neuroticism;
KIRP	cis	rs35740288	0.770	rs4843086	chr15:86162874	G/A	cg17133734	chr15:86042851	AKAP13	-0.55	-5.54	-0.33	7.84e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.64	-7.09	-0.41	1.43e-11	Neuroticism;
KIRP	trans	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.51	6.16	0.37	2.98e-9	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg10756647	chr7:56101905	PSPH	0.92	6.69	0.39	1.47e-10	Diabetic kidney disease;
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	cis	rs526231	0.543	rs152123	chr5:102531919	A/G	cg23492399	chr5:102201601	PAM	0.5	5.47	0.33	1.1e-7	Primary biliary cholangitis;
KIRP	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08822215	chr16:89438651	ANKRD11	-0.45	-6.13	-0.36	3.54e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.96	0.5	8.07e-17	Motion sickness;
KIRP	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg08917208	chr2:24149416	ATAD2B	1.04	8.08	0.46	2.89e-14	Lymphocyte counts;
KIRP	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg10223061	chr2:219282414	VIL1	-0.33	-5.34	-0.32	2.1e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg13010199	chr12:38710504	ALG10B	0.51	6.51	0.38	4.22e-10	Morning vs. evening chronotype;
KIRP	trans	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg20243544	chr17:37824526	PNMT	0.5	7.27	0.42	4.88e-12	Asthma;
KIRP	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.51	-7.22	-0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.5e-13	Coffee consumption (cups per day);
KIRP	cis	rs9815354	0.680	rs73073301	chr3:42028777	T/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	cg21523751	chr1:182988639	NA	-0.4	-6.33	-0.37	1.14e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11688874	chr10:28822482	WAC	0.59	7.06	0.41	1.73e-11	Smoking initiation;
KIRP	trans	rs7999699	0.902	rs34159337	chr13:48308983	T/A	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs96067	0.652	rs274137	chr1:36577945	A/G	cg27506609	chr1:36549197	TEKT2	-0.7	-5.42	-0.33	1.39e-7	Corneal structure;
KIRP	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	6.61	0.39	2.35e-10	Tonsillectomy;
KIRP	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.72	0.44	2.91e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.41	6.21	0.37	2.2e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.13	-0.36	3.44e-9	Arsenic metabolism;
KIRP	cis	rs112591243	1.000	rs112591243	chr21:47718796	G/A	cg26904215	chr21:47823096	PCNT	-0.69	-5.48	-0.33	1.05e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.72	-0.49	4.18e-16	Morning vs. evening chronotype;
KIRP	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.68	-7.83	-0.45	1.45e-13	Pancreatic cancer;
KIRP	cis	rs12282928	0.918	rs1018136	chr11:48241821	G/A	cg26585981	chr11:48327164	OR4S1	-0.52	-6.15	-0.37	3.04e-9	Migraine - clinic-based;
KIRP	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg13147721	chr7:65941812	NA	-1.02	-6.71	-0.39	1.29e-10	Diabetic kidney disease;
KIRP	cis	rs12496230	0.794	rs9813067	chr3:66862644	T/C	cg17646820	chr3:66848679	NA	0.4	6.51	0.38	4.19e-10	Type 2 diabetes;
KIRP	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.81	9.6	0.52	9.51e-19	Corneal astigmatism;
KIRP	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04374321	chr14:90722782	PSMC1	0.96	17.02	0.74	1.91e-43	Mortality in heart failure;
KIRP	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08048268	chr3:133502702	NA	-0.4	-4.97	-0.3	1.23e-6	Iron status biomarkers;
KIRP	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg06223162	chr1:101003688	GPR88	-0.42	-8.67	-0.48	6.04e-16	Monocyte count;
KIRP	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.71	10.4	0.55	3e-21	Prudent dietary pattern;
KIRP	cis	rs4073416	0.518	rs8022053	chr14:65867947	T/G	cg03016385	chr14:66212404	NA	-0.55	-6.6	-0.39	2.53e-10	N-glycan levels;
KIRP	cis	rs16828019	0.852	rs34386859	chr1:41564024	C/T	cg08144172	chr1:41849203	NA	0.63	5.16	0.31	5.03e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4936891	0.563	rs78294880	chr11:123890006	C/T	cg22125253	chr11:123886957	OR10G4	0.63	8.82	0.49	2.18e-16	Male fertility;
KIRP	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.44	-5.85	-0.35	1.54e-8	Monocyte count;
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg02696790	chr15:75250997	RPP25	0.31	5.22	0.32	3.81e-7	Caffeine consumption;
KIRP	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.22	-0.51	1.34e-17	Response to antipsychotic treatment;
KIRP	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.88e-7	Aortic root size;
KIRP	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg24747557	chr10:131355152	MGMT	-0.4	-5.46	-0.33	1.16e-7	Response to temozolomide;
KIRP	cis	rs57590327	0.644	rs7624045	chr3:81510799	A/G	cg07356753	chr3:81810745	GBE1	-0.53	-5.75	-0.34	2.57e-8	Extraversion;
KIRP	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg05347473	chr6:146136440	FBXO30	0.61	8.91	0.49	1.14e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6988636	0.792	rs62521803	chr8:124152970	A/C	cg23067535	chr8:124195133	FAM83A	-0.66	-5.55	-0.33	7.38e-8	Urinary uromodulin levels;
KIRP	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs4595586	0.655	rs11831499	chr12:39310114	A/T	cg26384229	chr12:38710491	ALG10B	0.49	6.37	0.38	9.21e-10	Morning vs. evening chronotype;
KIRP	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12311346	chr5:56204834	C5orf35	-0.49	-6.61	-0.39	2.34e-10	Coronary artery disease;
KIRP	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	1.08	20.35	0.79	1.19e-54	Height;
KIRP	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg21395723	chr22:39101663	GTPBP1	0.49	6.49	0.38	4.66e-10	Menopause (age at onset);
KIRP	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg06647332	chr5:131281008	NA	0.46	5.07	0.31	7.92e-7	Life satisfaction;
KIRP	cis	rs12220238	0.915	rs11001014	chr10:76128832	A/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.72	-6.98	-0.41	2.71e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.56	5.16	0.31	5.08e-7	Other erythrocyte phenotypes;
KIRP	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg07511934	chr16:89386912	ANKRD11	0.42	5.46	0.33	1.17e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg02487422	chr3:49467188	NICN1	-0.43	-5.45	-0.33	1.24e-7	Menarche (age at onset);
KIRP	cis	rs137887	0.817	rs137888	chr22:50464496	G/A	cg17558497	chr22:50464837	TTLL8	0.48	7.2	0.42	7.43e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg00405596	chr8:11794950	NA	0.57	7.97	0.45	6.1e-14	Neuroticism;
KIRP	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg15893493	chr8:124194847	FAM83A	-0.92	-7.97	-0.45	5.98e-14	Urinary uromodulin levels;
KIRP	cis	rs7870753	0.838	rs10991348	chr9:99247827	C/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg16898833	chr6:26189333	HIST1H4D	0.75	5.29	0.32	2.67e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg10223061	chr2:219282414	VIL1	0.44	7.0	0.41	2.49e-11	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg16141378	chr3:129829833	LOC729375	-0.6	-8.3	-0.47	7.05e-15	Retinal vascular caliber;
KIRP	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08280861	chr8:58055591	NA	0.69	4.92	0.3	1.55e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.86	9.92	0.53	9.71e-20	Corneal astigmatism;
KIRP	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.85	0.4	5.95e-11	Neuroticism;
KIRP	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs17123764	0.892	rs12313354	chr12:50138667	T/C	cg20471783	chr12:50157085	TMBIM6	0.42	5.99	0.36	7.49e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-7.33	-0.42	3.27e-12	Menopause (age at onset);
KIRP	cis	rs6662572	0.737	rs4434876	chr1:46270129	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.4e-8	Blood protein levels;
KIRP	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.37	-0.43	2.67e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.72	8.31	0.47	6.31e-15	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg25547332	chr5:131281432	NA	0.46	5.1	0.31	6.63e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.65e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg15234197	chr11:68924956	NA	0.34	4.92	0.3	1.59e-6	Blond vs. brown hair color;
KIRP	cis	rs3931020	0.688	rs455032	chr1:75196488	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.46	-5.57	-0.33	6.56e-8	Resistin levels;
KIRP	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02887679	chr6:36410977	PXT1;KCTD20	0.49	6.1	0.36	4.14e-9	Parkinson's disease;
KIRP	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.42	-4.98	-0.3	1.23e-6	Facial morphology (factor 20);
KIRP	cis	rs1978968	0.763	rs8137857	chr22:18465616	T/C	cg02610425	chr22:18483192	MICAL3	0.37	5.56	0.33	6.98e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.62	8.99	0.5	6.55e-17	Colorectal cancer;
KIRP	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg17133734	chr15:86042851	AKAP13	-0.41	-5.13	-0.31	5.97e-7	Interstitial lung disease;
KIRP	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.73	8.26	0.47	9.03e-15	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg05768032	chr16:30646687	NA	0.43	5.58	0.33	6.45e-8	Dementia with Lewy bodies;
KIRP	cis	rs8018808	0.935	rs11625365	chr14:77908588	A/G	cg18872420	chr14:78023429	SPTLC2	0.37	5.39	0.33	1.61e-7	Myeloid white cell count;
KIRP	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.19	-0.37	2.49e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	trans	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Bladder cancer;
KIRP	cis	rs35955747	0.777	rs5997895	chr22:31566173	T/G	cg02404636	chr22:31891804	SFI1	-0.4	-5.29	-0.32	2.66e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs6540556	0.834	rs6700223	chr1:209935031	G/A	cg23920097	chr1:209922102	NA	-0.4	-5.47	-0.33	1.11e-7	Red blood cell count;
KIRP	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	5.84	0.35	1.67e-8	Personality dimensions;
KIRP	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	10.59	0.56	7.84e-22	Blood protein levels;
KIRP	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.57	-7.63	-0.44	5.28e-13	Multiple sclerosis;
KIRP	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg17644776	chr2:200775616	C2orf69	0.4	4.85	0.3	2.22e-6	Asthma (bronchodilator response);
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg03289416	chr15:75166202	SCAMP2	0.53	7.18	0.42	8.02e-12	Breast cancer;
KIRP	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs17221829	0.627	rs7130892	chr11:89386606	T/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.36	5.19	0.31	4.33e-7	Calcium levels;
KIRP	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg23533419	chr12:54090519	NA	-0.31	-4.84	-0.3	2.27e-6	Height;
KIRP	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.78	-10.96	-0.57	4.97e-23	Morning vs. evening chronotype;
KIRP	cis	rs9469913	0.799	rs9462007	chr6:34715341	C/T	cg17674042	chr6:34482479	PACSIN1	-0.39	-5.27	-0.32	2.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg06742321	chr12:123595122	PITPNM2	0.44	5.44	0.33	1.29e-7	Platelet count;
KIRP	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg01420254	chr6:26195488	NA	1.21	7.7	0.44	3.29e-13	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.74	6.91	0.4	4.07e-11	Eosinophil percentage of granulocytes;
KIRP	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.12	-0.36	3.6e-9	Triglycerides;
KIRP	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.81	10.05	0.54	3.85e-20	Menopause (age at onset);
KIRP	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg05802129	chr4:122689817	NA	-0.47	-6.77	-0.4	9.23e-11	Type 2 diabetes;
KIRP	cis	rs829883	0.872	rs1641641	chr12:98896018	A/C	cg25150519	chr12:98850993	NA	0.86	12.97	0.64	1.12e-29	Colorectal adenoma (advanced);
KIRP	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg06781948	chr3:72941472	GXYLT2	0.49	6.32	0.37	1.2e-9	Motion sickness;
KIRP	cis	rs13102973	0.710	rs4428340	chr4:135886451	C/T	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs73198271	1.000	rs4841030	chr8:8607011	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.04	-0.31	8.91e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8177876	0.822	rs12444137	chr16:81110351	A/T	cg08591886	chr16:81111003	C16orf46	-0.72	-5.65	-0.34	4.44e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2594989	0.733	rs6777022	chr3:11577636	G/A	cg01796438	chr3:11312864	ATG7	0.44	5.72	0.34	3.05e-8	Circulating chemerin levels;
KIRP	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.88	0.4	4.84e-11	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.54	-0.52	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	1.08	7.76	0.44	2.31e-13	Skin colour saturation;
KIRP	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.53	-6.98	-0.41	2.79e-11	Schizophrenia;
KIRP	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg05991184	chr2:219186017	PNKD	-0.4	-5.63	-0.34	5.03e-8	Colorectal cancer;
KIRP	cis	rs2304069	0.542	rs3020829	chr5:149426966	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.1	7.48	0.43	1.28e-12	HIV-1 control;
KIRP	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-4.91	-0.3	1.65e-6	Coronary artery disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg25998860	chr5:126853954	PRRC1	0.53	6.25	0.37	1.84e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs367943	0.799	rs10478135	chr5:112976905	C/A	cg12552261	chr5:112820674	MCC	0.6	6.45	0.38	6.03e-10	Type 2 diabetes;
KIRP	cis	rs2908197	0.806	rs6465098	chr7:75972947	T/C	cg22830091	chr7:75961684	YWHAG	-0.36	-4.88	-0.3	1.89e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10267417	0.603	rs2390196	chr7:19864026	G/A	cg05791153	chr7:19748676	TWISTNB	0.52	5.12	0.31	6.26e-7	Night sleep phenotypes;
KIRP	cis	rs4950322	0.543	rs2883324	chr1:146788870	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs2279817	0.863	rs871089	chr1:18017704	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.68	9.03	0.5	5.04e-17	Neuroticism;
KIRP	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg12292205	chr6:26970375	C6orf41	0.34	4.86	0.3	2.09e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg17822266	chr1:2720087	NA	0.43	6.05	0.36	5.4e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.85	14.06	0.67	2.29e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7808935	0.789	rs2040668	chr7:27958773	G/T	cg22168087	chr7:27702803	HIBADH	-0.65	-7.03	-0.41	2.07e-11	Prostate cancer;
KIRP	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.89	0.35	1.25e-8	Motion sickness;
KIRP	cis	rs7267005	0.661	rs17093084	chr20:34369997	T/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4936894	0.519	rs4272792	chr11:124109058	C/G	cg27160556	chr11:124181099	OR8D1	-0.39	-5.85	-0.35	1.56e-8	Aging (time to death);
KIRP	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.79	10.28	0.55	7.62e-21	Platelet count;
KIRP	cis	rs7225151	0.634	rs76253980	chr17:5209510	C/A	cg24500398	chr17:5266808	RABEP1	-0.57	-5.66	-0.34	4.14e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.63	8.12	0.46	2.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.6	-6.69	-0.39	1.47e-10	Obesity-related traits;
KIRP	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.84	-0.4	6.38e-11	Hemoglobin concentration;
KIRP	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.44	8.41	0.47	3.44e-15	Coronary artery disease;
KIRP	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.68	4.86	0.3	2.1e-6	Schizophrenia;
KIRP	cis	rs1971762	0.527	rs1247956	chr12:53963814	G/T	cg16917193	chr12:54089295	NA	-0.84	-14.0	-0.67	3.82e-33	Height;
KIRP	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.51	7.07	0.41	1.58e-11	Mean corpuscular volume;
KIRP	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg01849466	chr14:104193079	ZFYVE21	0.42	5.17	0.31	4.79e-7	Schizophrenia;
KIRP	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.85	-0.35	1.56e-8	IgG glycosylation;
KIRP	trans	rs330071	0.515	rs12545193	chr8:9251880	G/A	cg08975724	chr8:8085496	FLJ10661	0.59	7.97	0.45	6.1e-14	Acne (severe);
KIRP	cis	rs2562456	0.833	rs11670815	chr19:21539317	T/C	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg11266682	chr4:10021025	SLC2A9	0.35	4.94	0.3	1.42e-6	Psychosis and Alzheimer's disease;
KIRP	cis	rs35740288	0.721	rs17637276	chr15:86243520	T/C	cg17133734	chr15:86042851	AKAP13	-0.5	-5.44	-0.33	1.29e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	5.69	0.34	3.63e-8	Schizophrenia;
KIRP	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.68	-12.52	-0.62	3.62e-28	White blood cell count (basophil);
KIRP	cis	rs9912468	0.933	rs35512343	chr17:64310575	T/A	cg19474267	chr17:64306194	PRKCA	0.57	8.08	0.46	2.85e-14	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.49	-8.71	-0.49	4.58e-16	Vitiligo;
KIRP	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg09699651	chr6:150184138	LRP11	0.53	7.19	0.42	7.8e-12	Testicular germ cell tumor;
KIRP	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.69	-8.62	-0.48	8.42e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9913156	0.670	rs4416072	chr17:4570036	C/T	cg00122941	chr17:4613640	ARRB2	0.62	6.84	0.4	6.2e-11	Lymphocyte counts;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg05562828	chr17:3906858	NA	0.56	8.64	0.48	7.02e-16	Type 2 diabetes;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg06659073	chr6:158589307	SERAC1;GTF2H5	-0.56	-6.05	-0.36	5.36e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs9783347	0.925	rs3802968	chr11:18343878	A/G	cg15585147	chr11:18324498	HPS5	0.44	5.95	0.35	9.4e-9	Pancreatic cancer;
KIRP	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg15038512	chr6:170123185	PHF10	0.48	5.42	0.33	1.45e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9843304	0.624	rs13061914	chr3:149202132	A/C	cg08667024	chr3:149219783	TM4SF4	-0.43	-6.6	-0.39	2.51e-10	Gallstone disease;
KIRP	cis	rs5753618	0.583	rs2273249	chr22:31836486	T/C	cg02404636	chr22:31891804	SFI1	0.51	6.04	0.36	5.51e-9	Colorectal cancer;
KIRP	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.45	0.65	2.74e-31	Bladder cancer;
KIRP	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.92	6.9	0.4	4.37e-11	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18882091	chr7:99058544	ATP5J2	0.44	6.54	0.38	3.56e-10	Survival in pancreatic cancer;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg23736307	chr8:27182930	PTK2B	0.53	6.77	0.4	9.54e-11	Neuroticism;
KIRP	cis	rs2387326	0.717	rs77277629	chr10:129944462	C/T	cg16087940	chr10:129947807	NA	-0.51	-6.58	-0.39	2.78e-10	Select biomarker traits;
KIRP	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg08501292	chr6:25962987	TRIM38	1.06	8.07	0.46	3.07e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.7	-0.34	3.5e-8	Obesity-related traits;
KIRP	cis	rs9815354	1.000	rs6805880	chr3:41865397	A/G	cg03022575	chr3:42003672	ULK4	0.54	5.94	0.35	9.53e-9	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.56	6.18	0.37	2.64e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg13373371	chr19:49828787	SLC6A16	0.4	4.89	0.3	1.86e-6	Multiple sclerosis;
KIRP	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg04691961	chr3:161091175	C3orf57	0.34	4.92	0.3	1.55e-6	Kawasaki disease;
KIRP	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.38	7.23	0.42	6.15e-12	Height;
KIRP	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs2411233	0.846	rs11632819	chr15:39263049	G/C	cg19287857	chr15:39890699	NA	0.42	5.91	0.35	1.14e-8	Platelet count;
KIRP	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.77	8.58	0.48	1.09e-15	Corneal astigmatism;
KIRP	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-5.03	-0.31	9.45e-7	Neuroticism;
KIRP	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.96	13.14	0.64	3.08e-30	Cognitive function;
KIRP	cis	rs17253792	0.822	rs10483646	chr14:56103872	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.94	6.02	0.36	6.22e-9	Putamen volume;
KIRP	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg03959625	chr15:84868606	LOC388152	0.54	6.55	0.39	3.42e-10	Schizophrenia;
KIRP	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.19	27.43	0.87	8.49e-77	Schizophrenia;
KIRP	cis	rs12200782	1.000	rs12208390	chr6:26437106	C/T	cg11502198	chr6:26597334	ABT1	-0.73	-4.9	-0.3	1.74e-6	Small cell lung carcinoma;
KIRP	cis	rs2172802	0.584	rs6857007	chr4:62510516	T/G	cg04118610	chr4:62707027	LPHN3	-0.44	-5.4	-0.33	1.58e-7	Partial epilepsies;
KIRP	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.87	-11.87	-0.6	5.54e-26	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg14829360	chr17:73884958	NA	-0.44	-5.84	-0.35	1.67e-8	White matter hyperintensity burden;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.88	-9.09	-0.5	3.38e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg16497661	chr14:103986332	CKB	-0.79	-12.69	-0.63	1.02e-28	Bone mineral density;
KIRP	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.2	0.46	1.38e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	0.74	10.26	0.55	8.63e-21	Red blood cell count;
KIRP	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.87	12.27	0.62	2.55e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs6693295	0.938	rs34718543	chr1:246224085	A/G	cg11798871	chr1:246315928	SMYD3	-0.45	-5.36	-0.32	1.89e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12580194	0.593	rs61071395	chr12:55721228	G/C	cg11794356	chr12:55725991	OR6C3	-0.61	-8.62	-0.48	8.4e-16	Cancer;
KIRP	cis	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.75	0.49	3.42e-16	Neuroticism;
KIRP	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg03929089	chr4:120376271	NA	-0.69	-6.25	-0.37	1.82e-9	Axial length;
KIRP	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.31	5.01	0.3	1.03e-6	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg06815112	chr8:27182871	PTK2B	-0.49	-5.94	-0.35	9.42e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05220968	chr6:146057943	EPM2A	-0.41	-5.18	-0.31	4.64e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10924309	0.737	rs1538957	chr1:245855639	A/G	cg00036263	chr1:245852353	KIF26B	-0.53	-7.48	-0.43	1.34e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs2412208	0.565	rs11120822	chr1:7113112	G/C	cg20434152	chr1:7120926	CAMTA1	-0.42	-5.93	-0.35	1.04e-8	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.38	0.32	1.72e-7	Personality dimensions;
KIRP	trans	rs1973993	0.561	rs3851275	chr1:96990823	G/A	cg10631902	chr5:14652156	NA	-0.55	-6.82	-0.4	6.84e-11	Weight;
KIRP	trans	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17183009	chr3:120277827	NA	0.56	6.57	0.39	3.06e-10	Corneal astigmatism;
KIRP	cis	rs7084402	0.967	rs1649033	chr10:60279634	T/C	cg05938607	chr10:60274200	BICC1	0.46	11.06	0.58	2.41e-23	Refractive error;
KIRP	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg00745463	chr17:30367425	LRRC37B	1.02	6.72	0.39	1.25e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg16898833	chr6:26189333	HIST1H4D	0.7	5.57	0.33	6.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.51	-6.79	-0.4	8.3e-11	Facial morphology (factor 20);
KIRP	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg00250761	chr1:31883323	NA	-0.3	-5.29	-0.32	2.7e-7	Alcohol dependence;
KIRP	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.49	6.12	0.36	3.7e-9	Height;
KIRP	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7246657	0.722	rs10403173	chr19:38078680	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.94	-14.19	-0.67	8.84e-34	Tonsillectomy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02538199	chr9:37034277	PAX5	0.5	6.92	0.4	3.81e-11	Smoking initiation;
KIRP	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg07384165	chr1:10488281	NA	-0.43	-5.48	-0.33	1.03e-7	Breast size;
KIRP	cis	rs889398	0.802	rs8051168	chr16:69887274	T/A	cg09409435	chr16:70099608	PDXDC2	0.43	5.29	0.32	2.74e-7	Body mass index;
KIRP	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.87	0.35	1.39e-8	Morning vs. evening chronotype;
KIRP	cis	rs714027	0.526	rs73164755	chr22:30590015	A/G	cg27665648	chr22:30112403	NA	0.51	7.5	0.43	1.18e-12	Lymphocyte counts;
KIRP	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs10875746	0.807	rs12297004	chr12:48453820	A/G	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.78	-12.88	-0.63	2.29e-29	Corneal structure;
KIRP	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-0.99	-16.4	-0.72	2.39e-41	Height;
KIRP	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.61	8.81	0.49	2.37e-16	Obesity-related traits;
KIRP	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg27205649	chr11:78285834	NARS2	-0.67	-8.41	-0.47	3.33e-15	Alzheimer's disease (survival time);
KIRP	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg00074818	chr8:8560427	CLDN23	0.4	6.3	0.37	1.34e-9	Obesity-related traits;
KIRP	cis	rs8177876	0.597	rs1048194	chr16:81064702	A/G	cg08591886	chr16:81111003	C16orf46	0.63	5.09	0.31	7.19e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.13e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16875169	chr19:49617695	LIN7B	0.51	6.47	0.38	5.28e-10	Parkinson's disease;
KIRP	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.73	-9.69	-0.53	4.97e-19	Morning vs. evening chronotype;
KIRP	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21643547	chr1:205240462	TMCC2	-0.76	-12.33	-0.62	1.58e-27	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2669010	1.000	rs1512501	chr12:76964435	A/T	cg14998926	chr12:77026162	NA	0.42	5.49	0.33	9.89e-8	Systemic lupus erythematosus;
KIRP	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg17143192	chr8:8559678	CLDN23	0.53	6.2	0.37	2.41e-9	Obesity-related traits;
KIRP	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg05791153	chr7:19748676	TWISTNB	0.73	6.08	0.36	4.49e-9	Thyroid stimulating hormone;
KIRP	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.69	-9.32	-0.51	6.84e-18	Hypospadias;
KIRP	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg05666200	chr11:89790683	NA	-0.47	-4.96	-0.3	1.31e-6	White blood cell types;
KIRP	cis	rs6120849	0.950	rs6088732	chr20:33744134	A/G	cg24642439	chr20:33292090	TP53INP2	-0.59	-6.41	-0.38	7.53e-10	Protein C levels;
KIRP	cis	rs9488822	0.676	rs1338667	chr6:116323910	T/A	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.54	-7.58	-0.44	6.86e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg13319975	chr6:146136371	FBXO30	-0.45	-5.97	-0.36	8.34e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg22139774	chr2:100720529	AFF3	-0.41	-5.07	-0.31	7.93e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.82	12.21	0.61	3.98e-27	IgG glycosylation;
KIRP	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.41	0.55	3e-21	Dupuytren's disease;
KIRP	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg02807482	chr3:125708958	NA	-0.54	-5.14	-0.31	5.58e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.94	16.03	0.71	4.34e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg15556689	chr8:8085844	FLJ10661	0.58	7.46	0.43	1.51e-12	Mood instability;
KIRP	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.26	-0.42	5.22e-12	Menopause (age at onset);
KIRP	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-0.6	-8.37	-0.47	4.32e-15	Ulcerative colitis;
KIRP	trans	rs12709013	0.591	rs899375	chr16:58826229	C/A	cg12115882	chr11:133449267	NA	-0.44	-6.08	-0.36	4.68e-9	Blood metabolite ratios;
KIRP	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs2625529	0.730	rs1481860	chr15:72241857	T/C	cg16672083	chr15:72433130	SENP8	0.47	6.52	0.38	4.07e-10	Red blood cell count;
KIRP	cis	rs1620921	0.967	rs1247551	chr6:161187517	T/C	cg01280913	chr6:161186852	NA	-0.42	-6.07	-0.36	4.91e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7665939	1.000	rs72727637	chr4:190106678	G/T	cg09826759	chr4:190284978	NA	-0.75	-5.09	-0.31	7.17e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03952484	chr1:149899818	SF3B4	0.57	6.73	0.39	1.2e-10	Smoking initiation;
KIRP	cis	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg00614314	chr15:82944287	LOC80154	0.55	6.41	0.38	7.31e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.48	-4.96	-0.3	1.33e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs11574514	1.000	rs28367503	chr16:67854534	A/G	cg26727032	chr16:67993705	SLC12A4	-0.68	-5.57	-0.33	6.61e-8	Crohn's disease;
KIRP	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg25547332	chr5:131281432	NA	0.47	5.31	0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.42	5.5	0.33	9.54e-8	Alzheimer's disease (late onset);
KIRP	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg01620082	chr3:125678407	NA	-0.94	-6.42	-0.38	6.78e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6568686	0.786	rs2181356	chr6:111815604	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.53	-4.96	-0.3	1.33e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs539514	0.690	rs2761398	chr13:76316933	C/A	cg04757411	chr13:76259545	LMO7	-0.36	-5.06	-0.31	8.07e-7	Type 1 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06938235	chr12:56498303	PA2G4	0.45	6.05	0.36	5.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg00938859	chr5:1591904	SDHAP3	0.53	6.26	0.37	1.69e-9	Breast cancer;
KIRP	cis	rs4700695	0.841	rs152935	chr5:65358593	A/G	cg21114390	chr5:65439923	SFRS12	-0.58	-5.34	-0.32	2.13e-7	Facial morphology (factor 19);
KIRP	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.36	-0.42	2.69e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs909341	0.710	rs6011016	chr20:62302650	C/G	cg11503966	chr20:62272292	STMN3	0.44	6.13	0.36	3.54e-9	Atopic dermatitis;
KIRP	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.58	8.39	0.47	3.96e-15	Educational attainment;
KIRP	trans	rs2048656	0.605	rs34592740	chr8:9651096	G/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.37	0.38	9.15e-10	Schizophrenia;
KIRP	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.8	-12.28	-0.62	2.33e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6028335	0.674	rs6028234	chr20:37607869	A/C	cg16355469	chr20:37678765	NA	0.52	5.15	0.31	5.43e-7	Alcohol and nicotine co-dependence;
KIRP	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.58	-6.81	-0.4	7.31e-11	Aortic root size;
KIRP	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg23815491	chr16:72088622	HP	0.44	6.0	0.36	7.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.9	-9.96	-0.54	7.5e-20	Bipolar disorder and schizophrenia;
KIRP	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg10223061	chr2:219282414	VIL1	-0.37	-6.13	-0.36	3.39e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.66	-0.39	1.73e-10	Joint mobility (Beighton score);
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg03388025	chr16:89894329	SPIRE2	0.37	6.93	0.4	3.67e-11	Vitiligo;
KIRP	cis	rs6708331	0.517	rs2028879	chr2:70354637	C/T	cg01613454	chr2:70366299	NA	0.37	4.92	0.3	1.55e-6	Obesity-related traits;
KIRP	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg08313168	chr12:7315531	NA	0.69	6.29	0.37	1.48e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.78	14.55	0.68	5e-35	Lymphocyte counts;
KIRP	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.59	7.23	0.42	6.23e-12	Body mass index;
KIRP	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg04132472	chr17:19861366	AKAP10	-0.41	-5.33	-0.32	2.19e-7	Schizophrenia;
KIRP	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-5.55	-0.33	7.28e-8	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24873593	chr5:139944080	APBB3;SLC35A4	0.49	6.27	0.37	1.57e-9	Parkinson's disease;
KIRP	cis	rs3764563	0.935	rs622886	chr19:15698696	C/T	cg20725493	chr19:15740067	CYP4F8	0.88	6.23	0.37	2.01e-9	Inflammatory biomarkers;
KIRP	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg06637938	chr14:75390232	RPS6KL1	0.45	6.21	0.37	2.3e-9	Height;
KIRP	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg03834567	chr2:218808745	TNS1	0.41	5.17	0.31	4.79e-7	Ulcerative colitis;
KIRP	cis	rs3857747	0.537	rs7782189	chr7:40472892	G/T	cg00420559	chr7:40367873	C7orf10	-0.36	-4.99	-0.3	1.16e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9810890	0.850	rs73198858	chr3:128514061	T/G	cg15033153	chr3:128514015	RAB7A	0.76	6.21	0.37	2.28e-9	Dental caries;
KIRP	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg13514129	chr1:39547527	MACF1	0.53	7.67	0.44	3.93e-13	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg00792783	chr2:198669748	PLCL1	0.45	5.05	0.31	8.78e-7	Dermatomyositis;
KIRP	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.51	-6.44	-0.38	6.3e-10	Verbal declarative memory;
KIRP	cis	rs13161895	1.000	rs1102191	chr5:179416210	C/T	cg02702477	chr5:179499311	RNF130	0.65	5.04	0.31	9.08e-7	LDL cholesterol;
KIRP	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.67	10.75	0.57	2.4e-22	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg00325661	chr8:49890786	NA	-0.45	-5.72	-0.34	3.11e-8	Sudden cardiac arrest;
KIRP	trans	rs13170463	0.579	rs116508029	chr5:8044805	G/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg17366294	chr4:99064904	C4orf37	0.38	4.87	0.3	2e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg21546286	chr11:48923668	NA	-0.47	-5.9	-0.35	1.2e-8	HDL cholesterol;
KIRP	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg00784671	chr22:46762841	CELSR1	-0.8	-8.3	-0.47	6.72e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg01304814	chr3:48885189	PRKAR2A	0.61	5.44	0.33	1.27e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13573178	chr1:90463746	ZNF326	0.42	6.5	0.38	4.54e-10	C-reactive protein;
KIRP	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg01631408	chr1:248437212	OR2T33	-0.44	-6.15	-0.37	3.08e-9	Common traits (Other);
KIRP	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	8.47	0.48	2.25e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.8	10.77	0.57	2.06e-22	Systemic lupus erythematosus;
KIRP	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.56	5.04	0.31	9.06e-7	Initial pursuit acceleration;
KIRP	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.62	5.94	0.35	9.76e-9	Breast cancer;
KIRP	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.68	6.9	0.4	4.38e-11	Corneal astigmatism;
KIRP	cis	rs4073221	0.654	rs7372790	chr3:18297289	C/T	cg07694806	chr3:18168406	NA	-0.67	-6.1	-0.36	4.14e-9	Parkinson's disease;
KIRP	cis	rs7221595	0.778	rs2290439	chr17:3924306	A/G	cg21851534	chr17:3907994	ZZEF1	0.53	6.03	0.36	6e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7818345	0.967	rs10107416	chr8:19286253	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.44	-6.53	-0.38	3.65e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg21970626	chr13:21893289	NA	-0.42	-5.88	-0.35	1.35e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	1.06	20.28	0.79	2.1e-54	Height;
KIRP	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-7.1	-0.41	1.31e-11	Skin colour saturation;
KIRP	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-9.33	-0.51	6.64e-18	Chronic sinus infection;
KIRP	cis	rs42648	0.564	rs7777170	chr7:89822282	A/T	cg25739043	chr7:89950458	NA	-0.37	-5.87	-0.35	1.42e-8	Homocysteine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20994703	chr7:149542110	ZNF862	0.5	6.07	0.36	4.91e-9	Interleukin-4 levels;
KIRP	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.2	13.91	0.66	7.79e-33	Sexual dysfunction (female);
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.34	-0.37	1.1e-9	Alcohol dependence;
KIRP	cis	rs9616064	0.740	rs6520049	chr22:46996309	C/T	cg25730555	chr22:47059586	GRAMD4	0.54	6.8	0.4	7.69e-11	Urate levels in obese individuals;
KIRP	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.68	9.92	0.53	1.03e-19	Oral cavity cancer;
KIRP	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg01879757	chr17:41196368	BRCA1	-0.62	-8.32	-0.47	6.09e-15	Menopause (age at onset);
KIRP	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.55	0.52	1.37e-18	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs16976116	0.951	rs3759862	chr15:55483104	C/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.52	0.43	1.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg01616529	chr11:638424	DRD4	-0.52	-6.73	-0.39	1.16e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.71	-8.2	-0.46	1.31e-14	Alcohol dependence;
KIRP	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg11846333	chr4:119757529	SEC24D	0.92	5.77	0.35	2.38e-8	Cannabis dependence symptom count;
KIRP	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.39	-5.52	-0.33	8.4e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg08700190	chr5:6636046	SRD5A1	-0.49	-5.94	-0.35	9.6e-9	Response to amphetamines;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7084783	0.538	rs3781367	chr10:105337294	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.46	5.79	0.35	2.15e-8	Fear of pain;
KIRP	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-5.73	-0.34	2.93e-8	Morning vs. evening chronotype;
KIRP	cis	rs4742903	0.904	rs1507512	chr9:107004948	A/G	cg14250997	chr9:106856677	SMC2	0.38	5.07	0.31	7.77e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg05973401	chr12:123451056	ABCB9	0.58	6.6	0.39	2.53e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7923609	0.846	rs10740115	chr10:65094990	G/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.48e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2625529	0.627	rs12902661	chr15:72480158	T/G	cg16672083	chr15:72433130	SENP8	-0.46	-5.59	-0.34	5.88e-8	Red blood cell count;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.17	0.46	1.65e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4356932	0.967	rs5005109	chr4:76986342	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-1.02	-9.64	-0.52	7.27e-19	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.66	7.67	0.44	4.08e-13	Type 2 diabetes;
KIRP	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg04226714	chr8:49833948	SNAI2	-0.53	-7.05	-0.41	1.79e-11	Life satisfaction;
KIRP	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg08533674	chr1:46993347	NA	-0.48	-5.95	-0.35	9.06e-9	Monobrow;
KIRP	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.91	15.73	0.71	4.57e-39	Menarche (age at onset);
KIRP	cis	rs16976116	0.803	rs7168737	chr15:55501344	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10818894	0.571	rs4838068	chr9:126316354	G/A	cg16191174	chr9:126692580	DENND1A	0.51	5.75	0.34	2.67e-8	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
KIRP	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.45	6.01	0.36	6.8e-9	Red blood cell count;
KIRP	cis	rs4750440	0.585	rs10508470	chr10:14021822	G/A	cg27542038	chr10:14027202	FRMD4A	-0.59	-7.43	-0.43	1.82e-12	Adiponectin levels;
KIRP	cis	rs7766436	0.885	rs13200219	chr6:22595428	C/T	cg13666174	chr6:22585274	NA	-0.47	-6.38	-0.38	8.83e-10	Coronary artery disease;
KIRP	cis	rs876084	0.505	rs9969404	chr8:121107102	A/C	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15480897	chr4:151505467	LRBA;MAB21L2	-0.49	-6.48	-0.38	4.83e-10	Inflammatory biomarkers;
KIRP	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg18806716	chr10:30721971	MAP3K8	-0.34	-5.03	-0.31	9.26e-7	Inflammatory bowel disease;
KIRP	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.99	-14.0	-0.67	3.78e-33	Ulcerative colitis;
KIRP	cis	rs2119480	0.701	rs1193458	chr13:111302922	T/C	cg24331049	chr13:111365604	ING1	-0.46	-5.45	-0.33	1.21e-7	Diastolic blood pressure;
KIRP	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.5	-6.51	-0.38	4.27e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg07274523	chr3:49395745	GPX1	0.58	5.45	0.33	1.2e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9309473	0.519	rs13022145	chr2:73863473	G/A	cg20560298	chr2:73613845	ALMS1	0.48	5.84	0.35	1.64e-8	Metabolite levels;
KIRP	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.76	-6.35	-0.38	1.02e-9	Blood pressure (smoking interaction);
KIRP	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.59	8.25	0.47	9.36e-15	Multiple system atrophy;
KIRP	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.53	7.46	0.43	1.5e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg09631192	chr20:23583594	CST9	-0.52	-5.2	-0.31	4.27e-7	Chronic kidney disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19997236	chr12:121790271	ANAPC5	0.57	6.62	0.39	2.27e-10	Smoking initiation;
KIRP	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.76	10.57	0.56	9.02e-22	Dental caries;
KIRP	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg24009623	chr19:33667908	NA	0.47	6.08	0.36	4.67e-9	Bone properties (heel);
KIRP	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16346588	chr10:242978	ZMYND11	0.45	5.44	0.33	1.27e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs2882667	0.690	rs11954103	chr5:138269148	G/A	cg04439458	chr5:138467593	SIL1	-0.38	-5.14	-0.31	5.71e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13418717	1.000	rs10496658	chr2:127663497	C/T	cg25501666	chr2:127640322	NA	0.83	6.17	0.37	2.73e-9	Heart failure;
KIRP	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.9	-0.3	1.73e-6	Pulmonary function;
KIRP	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.74	0.39	1.12e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-5.19	-0.31	4.41e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.86	11.37	0.59	2.43e-24	Gestational age at birth (maternal effect);
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	12.48	0.62	4.94e-28	Platelet count;
KIRP	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.77	11.96	0.61	2.75e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3857067	0.839	rs12505694	chr4:95042940	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.04	-0.31	8.98e-7	QT interval;
KIRP	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg19847130	chr8:10466454	RP1L1	-0.36	-5.3	-0.32	2.55e-7	Retinal vascular caliber;
KIRP	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-14.43	-0.68	1.29e-34	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.79	-0.4	8.43e-11	Lung cancer;
KIRP	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	7.49	0.43	1.23e-12	Height;
KIRP	cis	rs7789940	0.817	rs6946310	chr7:75936099	T/C	cg10167463	chr7:75959203	YWHAG	-0.37	-4.92	-0.3	1.58e-6	Multiple sclerosis;
KIRP	cis	rs61935443	0.720	rs10859784	chr12:95288926	G/A	cg21533806	chr12:95267307	NA	0.64	6.32	0.37	1.22e-9	Schizophrenia;
KIRP	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg15655495	chr12:38532458	NA	-0.25	-4.84	-0.3	2.26e-6	Heart rate;
KIRP	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04802407	chr22:21356391	THAP7;FLJ39582	0.51	6.93	0.4	3.75e-11	Survival in pancreatic cancer;
KIRP	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg00076555	chr3:49705435	BSN	-0.28	-4.85	-0.3	2.18e-6	Body mass index;
KIRP	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.58	-6.66	-0.39	1.82e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.65	-0.39	1.92e-10	Joint mobility (Beighton score);
KIRP	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg08499158	chr17:42289980	UBTF	-0.58	-7.39	-0.43	2.29e-12	Total body bone mineral density;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg11301795	chr4:187892539	NA	-1.03	-18.26	-0.76	1.19e-47	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.61	12.42	0.62	7.9e-28	Diabetic kidney disease;
KIRP	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg09455208	chr3:40491958	NA	-0.31	-5.53	-0.33	8.32e-8	Renal cell carcinoma;
KIRP	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18932078	chr1:2524107	MMEL1	0.46	6.39	0.38	8.24e-10	Ulcerative colitis;
KIRP	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.97	9.42	0.51	3.43e-18	Eosinophilic esophagitis;
KIRP	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17554472	chr22:41940697	POLR3H	0.74	7.54	0.43	9.26e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.46	-7.04	-0.41	1.89e-11	Coronary artery disease;
KIRP	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.03	-12.5	-0.62	4.51e-28	Alzheimer's disease;
KIRP	cis	rs10208940	0.920	rs35118992	chr2:68699460	G/A	cg12452813	chr2:68675892	NA	0.47	5.07	0.31	7.97e-7	Urate levels in lean individuals;
KIRP	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	7.34	0.42	3.04e-12	Menarche (age at onset);
KIRP	cis	rs96067	0.805	rs3767705	chr1:36602044	A/T	cg24686825	chr1:36642396	MAP7D1	-0.53	-5.83	-0.35	1.69e-8	Corneal structure;
KIRP	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg22705602	chr4:152727874	NA	-0.61	-9.29	-0.51	8.33e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7252981	0.632	rs8113682	chr19:19743730	T/G	cg11584989	chr19:19387371	SF4	-0.48	-5.67	-0.34	4.02e-8	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.76	12.23	0.61	3.53e-27	Dupuytren's disease;
KIRP	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.65	0.48	6.75e-16	Motion sickness;
KIRP	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	1.09	10.8	0.57	1.6e-22	Blood protein levels;
KIRP	cis	rs4704187	0.687	rs1477934	chr5:74423243	A/T	cg03227963	chr5:74354835	NA	0.41	5.93	0.35	9.96e-9	Response to amphetamines;
KIRP	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	6.91	0.4	4.12e-11	Menarche (age at onset);
KIRP	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.78	11.52	0.59	7.61e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.54	6.45	0.38	5.75e-10	Obesity-related traits;
KIRP	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.58	0.39	2.87e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg15117754	chr3:10150083	C3orf24	0.55	5.16	0.31	5.13e-7	Alzheimer's disease;
KIRP	cis	rs72627123	0.531	rs3742806	chr14:74532523	A/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	5.24	0.32	3.4e-7	Morning vs. evening chronotype;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05665937	chr4:1216051	CTBP1	0.44	6.13	0.36	3.46e-9	Obesity-related traits;
KIRP	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	0.95	16.11	0.72	2.32e-40	Ulcerative colitis;
KIRP	trans	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.4	-0.38	7.74e-10	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12869820	chr12:125478231	BRI3BP	0.51	6.79	0.4	8.44e-11	Parkinson's disease;
KIRP	cis	rs10875746	0.669	rs10875792	chr12:48697423	T/A	cg24011408	chr12:48396354	COL2A1	-0.45	-5.06	-0.31	8.26e-7	Longevity (90 years and older);
KIRP	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	1.16	9.04	0.5	4.78e-17	LDL cholesterol;
KIRP	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.67	0.34	3.94e-8	Lung cancer;
KIRP	cis	rs6662572	0.737	rs4518839	chr1:46376690	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.35e-8	Blood protein levels;
KIRP	cis	rs6466055	0.777	rs41562	chr7:104845094	C/T	cg04380332	chr7:105027541	SRPK2	0.58	8.98	0.5	7.36e-17	Schizophrenia;
KIRP	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-1.16	-12.09	-0.61	1e-26	Red blood cell traits;
KIRP	cis	rs1978968	0.717	rs5992934	chr22:18457119	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.75	-10.47	-0.56	1.9e-21	Presence of antiphospholipid antibodies;
KIRP	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg24110177	chr3:50126178	RBM5	0.44	5.63	0.34	5.01e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7870753	0.786	rs7031099	chr9:99245690	T/C	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg00684032	chr4:1343700	KIAA1530	0.45	5.44	0.33	1.31e-7	Longevity;
KIRP	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.61	7.7	0.44	3.24e-13	Breast cancer;
KIRP	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg17133734	chr15:86042851	AKAP13	0.43	5.35	0.32	2e-7	Coronary artery disease;
KIRP	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.76	10.06	0.54	3.7799999999999997e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg01378222	chr16:28622494	SULT1A1	-0.55	-6.06	-0.36	5.08e-9	Platelet distribution width;
KIRP	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.41	-5.87	-0.35	1.39e-8	Blood metabolite levels;
KIRP	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21545522	chr1:205238299	TMCC2	0.5	6.57	0.39	3.02e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.44	5.41	0.33	1.52e-7	Common traits (Other);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19763319	chr19:50316468	FUZ	0.51	6.94	0.4	3.4e-11	Parkinson's disease;
KIRP	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.65	-7.17	-0.42	8.84e-12	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.85	13.04	0.64	6.5e-30	Menarche (age at onset);
KIRP	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.67	7.81	0.45	1.62e-13	Breast cancer;
KIRP	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg16296679	chr22:42394374	WBP2NL	0.36	4.99	0.3	1.15e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg22705602	chr4:152727874	NA	0.52	8.34	0.47	5.47e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.95	12.86	0.63	2.69e-29	Breast cancer;
KIRP	cis	rs1983891	0.955	rs9381076	chr6:41517564	G/A	cg20194872	chr6:41519635	FOXP4	0.55	6.97	0.41	2.89e-11	Prostate cancer;
KIRP	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01616529	chr11:638424	DRD4	-0.42	-5.67	-0.34	3.97e-8	Systemic lupus erythematosus;
KIRP	cis	rs6466055	0.777	rs917114	chr7:104907507	C/T	cg04380332	chr7:105027541	SRPK2	0.65	9.76	0.53	3.19e-19	Schizophrenia;
KIRP	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.37	0.59	2.42e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06130950	chr11:123612538	ZNF202	-0.52	-6.54	-0.38	3.54e-10	Interleukin-4 levels;
KIRP	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg01631408	chr1:248437212	OR2T33	-0.64	-8.5	-0.48	1.87e-15	Common traits (Other);
KIRP	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg25482853	chr8:67687455	SGK3	0.82	7.19	0.42	7.77e-12	Obesity-related traits;
KIRP	cis	rs1971762	1.000	rs10876481	chr12:54066743	T/C	cg09709951	chr12:54017699	ATF7	0.45	5.65	0.34	4.31e-8	Height;
KIRP	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.02	-0.57	3.22e-23	Height;
KIRP	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs12725198	0.507	rs41393951	chr1:16053493	C/T	cg18133145	chr1:16060689	PLEKHM2	-0.74	-9.84	-0.53	1.82e-19	Cardiac Troponin-T levels;
KIRP	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg02151108	chr14:50098012	C14orf104	-0.46	-5.89	-0.35	1.28e-8	Carotid intima media thickness;
KIRP	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.62	-0.34	5.06e-8	Ulcerative colitis;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02902865	chr1:12679132	DHRS3	-0.46	-6.33	-0.37	1.18e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4148660	0.697	rs7137730	chr12:22039180	A/C	cg14669847	chr12:22099120	NA	0.36	5.93	0.35	1.01e-8	Gout;
KIRP	cis	rs2970992	0.764	rs925577	chr2:101324948	C/T	cg01042948	chr2:101319752	NA	-0.43	-6.47	-0.38	5.32e-10	Educational attainment;
KIRP	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg03714773	chr7:91764589	CYP51A1	0.33	4.92	0.3	1.55e-6	Breast cancer;
KIRP	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.38	5.84	0.35	1.67e-8	Fractional excretion of uric acid;
KIRP	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.58	-7.29	-0.42	4.19e-12	Fibrinogen levels;
KIRP	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.54	7.85	0.45	1.29e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg25019033	chr10:957182	NA	-0.69	-8.82	-0.49	2.11e-16	Eosinophil percentage of granulocytes;
KIRP	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05192639	chr6:26864778	GUSBL1	-0.23	-4.9	-0.3	1.72e-6	Educational attainment;
KIRP	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.46	-5.27	-0.32	3.02e-7	Osteoporosis;
KIRP	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.97	12.93	0.64	1.57e-29	Vitamin D levels;
KIRP	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7084402	0.967	rs1658436	chr10:60326910	G/A	cg05938607	chr10:60274200	BICC1	-0.38	-8.82	-0.49	2.16e-16	Refractive error;
KIRP	cis	rs1978968	1.000	rs5013012	chr22:18450149	A/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.57	-0.43	7.33e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.57	7.35	0.42	2.9e-12	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.66e-9	Colorectal cancer;
KIRP	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg23933602	chr10:16859644	RSU1	0.52	5.57	0.33	6.52e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg17294928	chr15:75287854	SCAMP5	0.56	7.15	0.42	9.6e-12	Caffeine consumption;
KIRP	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.48	7.58	0.43	7.26e-13	Testicular germ cell tumor;
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg00684032	chr4:1343700	KIAA1530	0.56	7.59	0.44	6.8e-13	Obesity-related traits;
KIRP	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.54	13.45	0.65	2.86e-31	Airflow obstruction;
KIRP	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	7.58	0.44	6.84e-13	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.85	10.33	0.55	5.22e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	1.05	19.01	0.77	3.34e-50	Bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15941779	chr14:56649615	PELI2	-0.43	-6.34	-0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-13.82	-0.66	1.5e-32	Heart rate;
KIRP	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.28	-0.37	1.53e-9	Total bilirubin levels in HIV-1 infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07349045	chr8:70745597	SLCO5A1	0.48	6.04	0.36	5.6e-9	Smoking initiation;
KIRP	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg07636037	chr3:49044803	WDR6	0.65	6.31	0.37	1.3e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.61	-7.28	-0.42	4.5e-12	Aortic root size;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20841906	chr3:160822911	B3GALNT1	0.48	6.48	0.38	4.86e-10	Parkinson's disease;
KIRP	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.78	-10.23	-0.55	1.05e-20	Iron status biomarkers;
KIRP	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.7	10.31	0.55	6e-21	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13047869	chr3:10149882	C3orf24	0.52	4.91	0.3	1.69e-6	Alzheimer's disease;
KIRP	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.75	0.44	2.49e-13	Coffee consumption (cups per day);
KIRP	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg26441486	chr22:50317300	CRELD2	-0.39	-5.47	-0.33	1.09e-7	Schizophrenia;
KIRP	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs2191566	0.881	rs1996408	chr19:44532732	G/A	cg18700516	chr19:44507157	ZNF230	-0.43	-4.87	-0.3	2e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.94	10.54	0.56	1.14e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs4414128	0.832	rs4601655	chr10:5680738	A/G	cg12223502	chr10:5658492	NA	0.48	5.51	0.33	9.17e-8	Breast cancer;
KIRP	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-5.74	-0.34	2.72e-8	Chronic sinus infection;
KIRP	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg07451762	chr16:28383216	NA	0.38	4.99	0.3	1.16e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg16497424	chr10:135191798	PAOX	0.58	6.53	0.38	3.73e-10	Response to statin therapy;
KIRP	cis	rs2191566	0.960	rs2270196	chr19:44506623	A/G	cg18700516	chr19:44507157	ZNF230	0.48	5.7	0.34	3.49e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.97	-14.63	-0.68	2.65e-35	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2554380	0.843	rs2562779	chr15:84390975	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.5	-7.12	-0.41	1.21e-11	Height;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg11079969	chr15:82339920	NA	0.47	6.34	0.37	1.1e-9	Sleep duration;
KIRP	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.71	9.92	0.53	1e-19	Mean corpuscular volume;
KIRP	cis	rs501120	0.584	rs1704228	chr10:44673050	C/T	cg09554077	chr10:44749378	NA	0.58	6.12	0.36	3.75e-9	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs2594989	0.733	rs2616538	chr3:11581076	G/T	cg02538783	chr10:35102505	PARD3	-0.32	-6.15	-0.37	3.17e-9	Circulating chemerin levels;
KIRP	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-4.91	-0.3	1.62e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg02023728	chr11:77925099	USP35	0.32	5.41	0.33	1.46e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg09579323	chr1:150459698	TARS2	0.4	5.07	0.31	7.86e-7	Migraine;
KIRP	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.17	0.64	2.54e-30	Eye color traits;
KIRP	cis	rs62413470	1.000	rs12197951	chr6:55946916	T/A	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.31	6.32	0.37	1.24e-9	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12315302	chr6:26189340	HIST1H4D	0.61	5.04	0.31	9.17e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg05861140	chr6:150128134	PCMT1	-0.5	-7.06	-0.41	1.71e-11	Lung cancer;
KIRP	cis	rs58688157	0.960	rs34449380	chr11:617221	T/G	cg16486109	chr11:613632	IRF7	0.41	4.96	0.3	1.33e-6	Systemic lupus erythematosus;
KIRP	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg08222618	chr4:941054	TMEM175	-0.6	-5.34	-0.32	2.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg12011299	chr4:100065546	ADH4	-0.58	-7.84	-0.45	1.39e-13	HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs3857067	0.740	rs10024198	chr4:95060602	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-5.85	-0.35	1.59e-8	QT interval;
KIRP	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.51	-6.38	-0.38	8.56e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.06	-0.61	1.24e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.74	8.74	0.49	3.67e-16	Cognitive test performance;
KIRP	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.65	-8.81	-0.49	2.28e-16	Ear protrusion;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.7	-10.94	-0.57	5.69e-23	Menarche (age at onset);
KIRP	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.97	0.3	1.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	1.09	17.26	0.74	2.9e-44	Homoarginine levels;
KIRP	cis	rs2718058	0.606	rs2718054	chr7:37835854	T/A	cg15028436	chr7:37888078	TXNDC3	0.48	5.79	0.35	2.14e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg07621104	chr11:117668040	DSCAML1	0.4	5.76	0.34	2.53e-8	Myopia;
KIRP	cis	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg23307798	chr14:103986281	CKB	-0.45	-5.27	-0.32	3.05e-7	Monocyte count;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg25750404	chr12:6579648	VAMP1	0.52	6.34	0.37	1.07e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.45	-0.52	2.82e-18	Rheumatoid arthritis;
KIRP	cis	rs7721647	0.777	rs1583907	chr5:90844272	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.2	0.31	4.2e-7	Breast cancer;
KIRP	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-8.22	-0.46	1.16e-14	Chronic sinus infection;
KIRP	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.7e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	1.04	14.34	0.67	2.7200000000000002e-34	Menopause (age at onset);
KIRP	cis	rs34976449	1	rs34976449	chr1:8498326	T/TG	cg03610117	chr1:8450231	RERE	0.38	5.39	0.33	1.65e-7	Lymphocyte counts;
KIRP	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.61	-0.34	5.34e-8	Bipolar disorder;
KIRP	cis	rs11825064	0.666	rs58623219	chr11:134494910	C/T	cg06603561	chr11:134479413	NA	-0.73	-5.99	-0.36	7.33e-9	Seasonality;
KIRP	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs3733418	0.929	rs72697952	chr4:165900928	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.49	-4.86	-0.3	2.1e-6	Obesity-related traits;
KIRP	cis	rs7714584	1.000	rs11740172	chr5:150300278	A/G	cg22134413	chr5:150180641	NA	0.82	6.59	0.39	2.68e-10	Crohn's disease;
KIRP	cis	rs490234	0.812	rs4838268	chr9:128280315	G/T	cg14078157	chr9:128172775	NA	-0.44	-5.7	-0.34	3.38e-8	Mean arterial pressure;
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg05861140	chr6:150128134	PCMT1	-0.53	-7.6	-0.44	6.36e-13	Lung cancer;
KIRP	cis	rs8018808	0.935	rs12433766	chr14:77930293	C/T	cg20045696	chr14:77926864	AHSA1	0.46	5.61	0.34	5.39e-8	Myeloid white cell count;
KIRP	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg08885076	chr2:99613938	TSGA10	-0.43	-6.31	-0.37	1.32e-9	Bipolar disorder;
KIRP	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg25801113	chr15:45476975	SHF	-0.45	-8.24	-0.47	1.03e-14	Uric acid levels;
KIRP	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg15929201	chr5:31531945	RNASEN;C5orf22	0.46	6.37	0.38	9.11e-10	Ischemic stroke;
KIRP	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.3	6.05	0.36	5.3300000000000004e-09	Schizophrenia;
KIRP	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.85	-0.35	1.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17286411	0.836	rs4538017	chr16:71900907	C/T	cg04254540	chr16:71951199	KIAA0174	-0.39	-5.09	-0.31	7.2e-7	Blood protein levels;
KIRP	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg18944383	chr4:111397179	ENPEP	0.47	7.46	0.43	1.46e-12	Coronary artery disease;
KIRP	cis	rs732765	0.734	rs1057500	chr14:75205116	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.05	-0.31	8.51e-7	Non-small cell lung cancer;
KIRP	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs4006360	0.635	rs1848811	chr17:39235963	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.67	-0.48	5.75e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg14086599	chr2:241536098	CAPN10	0.42	4.9	0.3	1.7e-6	Bipolar disorder;
KIRP	cis	rs4363385	0.510	rs11488175	chr1:153039778	A/G	cg13444842	chr1:152974279	SPRR3	0.42	5.91	0.35	1.13e-8	Inflammatory skin disease;
KIRP	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07570687	chr10:102243282	WNT8B	0.51	6.69	0.39	1.5e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.39	-8.47	-0.48	2.31e-15	Body mass index;
KIRP	cis	rs7852872	0.965	rs10817897	chr9:119245955	G/A	cg13792444	chr9:119245443	ASTN2	0.48	6.77	0.4	9.55e-11	Hippocampal volume;
KIRP	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg08283408	chr3:49949060	MON1A	-0.44	-5.97	-0.36	8.37e-9	Body mass index;
KIRP	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08704250	chr15:31115839	NA	-0.58	-8.14	-0.46	1.92e-14	Huntington's disease progression;
KIRP	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	1.04	11.22	0.58	7.18e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.48	-5.97	-0.36	8.46e-9	Heschl's gyrus morphology;
KIRP	cis	rs2273669	0.667	rs12215736	chr6:109330367	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.75	-6.91	-0.4	4.11e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg16141378	chr3:129829833	LOC729375	0.56	7.65	0.44	4.6e-13	Mood instability;
KIRP	trans	rs9329221	0.539	rs35060302	chr8:10264771	C/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.28	0.37	1.53e-9	Neuroticism;
KIRP	cis	rs2230307	0.572	rs621212	chr1:100559281	T/C	cg24955406	chr1:100503596	HIAT1	0.58	6.27	0.37	1.58e-9	Carotid intima media thickness;
KIRP	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.54	-0.39	3.45e-10	Joint mobility (Beighton score);
KIRP	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	0.93	12.04	0.61	1.5e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs911119	0.955	rs4815224	chr20:23594112	C/G	cg16589663	chr20:23618590	CST3	0.65	6.13	0.36	3.4e-9	Chronic kidney disease;
KIRP	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13198984	chr17:80129470	CCDC57	-0.46	-7.01	-0.41	2.27e-11	Life satisfaction;
KIRP	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.99	-13.33	-0.65	7e-31	Cognitive ability;
KIRP	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.49	-0.33	1e-7	Neutrophil percentage of white cells;
KIRP	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.62	0.39	2.2e-10	Breast cancer;
KIRP	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg04935436	chr20:30431758	NA	0.48	5.86	0.35	1.48e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg05650719	chr12:132293520	NA	-0.49	-6.28	-0.37	1.49e-9	Migraine;
KIRP	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.93	0.57	6.37e-23	Cognitive test performance;
KIRP	cis	rs815815	0.583	rs11125126	chr2:47395379	C/T	cg17724938	chr2:46727096	NA	-0.43	-5.36	-0.32	1.92e-7	Dialysis-related mortality;
KIRP	cis	rs6732160	0.845	rs10203125	chr2:73361151	C/G	cg01422370	chr2:73384389	NA	0.4	5.27	0.32	2.92e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08155953	chr20:32031801	SNTA1	0.45	6.61	0.39	2.36e-10	Myopia (pathological);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03433549	chr12:56498817	PA2G4	0.57	6.72	0.39	1.25e-10	Smoking initiation;
KIRP	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.0	0.3	1.1e-6	Schizophrenia;
KIRP	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.57	6.08	0.36	4.51e-9	Uric acid levels;
KIRP	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.56	-6.85	-0.4	5.79e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.11	-0.46	2.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg13736514	chr6:26305472	NA	0.66	8.83	0.49	1.95e-16	Educational attainment;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg13453750	chr1:205783389	SLC41A1	-0.46	-7.13	-0.41	1.09e-11	Menarche (age at onset);
KIRP	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.52	-13.79	-0.66	1.95e-32	Hip circumference adjusted for BMI;
KIRP	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.39	-9.34	-0.51	6.09e-18	Asthma (sex interaction);
KIRP	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.89	15.12	0.69	5.59e-37	Mortality in heart failure;
KIRP	cis	rs5747327	0.839	rs7291752	chr22:18180911	T/C	cg19898043	chr22:18121309	BCL2L13	-0.42	-5.31	-0.32	2.42e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs4262150	0.726	rs4958569	chr5:152016105	A/G	cg12297329	chr5:152029980	NA	-0.63	-8.16	-0.46	1.78e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.49	5.7	0.34	3.5e-8	Platelet distribution width;
KIRP	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.26	-17.25	-0.74	2.96e-44	Breast cancer;
KIRP	cis	rs2273156	0.500	rs75741665	chr14:35566040	A/T	cg09327582	chr14:35236912	BAZ1A	-0.68	-6.09	-0.36	4.25e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs72829446	0.530	rs17732878	chr17:7362359	C/T	cg17788227	chr17:7347145	FGF11;CHRNB1	-0.49	-5.07	-0.31	8.01e-7	Androgen levels;
KIRP	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	1.07	11.92	0.61	3.66e-26	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg13736514	chr6:26305472	NA	0.52	6.58	0.39	2.88e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.71	-7.22	-0.42	6.65e-12	Vitiligo;
KIRP	cis	rs7119038	0.774	rs11217001	chr11:118607046	G/A	cg19308663	chr11:118741387	NA	0.54	8.27	0.47	8.48e-15	Sjögren's syndrome;
KIRP	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg07827796	chr19:33622959	WDR88	0.42	4.98	0.3	1.21e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg10932868	chr11:921992	NA	0.51	6.08	0.36	4.57e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg01557791	chr16:72042693	DHODH	-0.54	-6.05	-0.36	5.22e-9	Blood protein levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00810945	chr16:21964237	UQCRC2	-0.49	-6.42	-0.38	7.11e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg02375832	chr11:62437615	C11orf48	-0.4	-4.93	-0.3	1.53e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.62	8.68	0.48	5.55e-16	Menarche (age at onset);
KIRP	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.78	-10.17	-0.54	1.61e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg13271783	chr10:134563150	INPP5A	-0.62	-8.0	-0.45	4.8e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.73	6.99	0.41	2.52e-11	Arsenic metabolism;
KIRP	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01616529	chr11:638424	DRD4	-0.42	-5.59	-0.34	5.93e-8	Systemic lupus erythematosus;
KIRP	trans	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.49	-0.43	1.21e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg18888403	chr1:24152774	HMGCL	0.35	5.1	0.31	6.83e-7	Immature fraction of reticulocytes;
KIRP	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg13119609	chr19:45449297	APOC2	0.39	5.03	0.31	9.52e-7	Blood protein levels;
KIRP	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	6.29	0.37	1.44e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg19338460	chr6:170058176	WDR27	-1.16	-9.38	-0.51	4.67e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.79	9.97	0.54	6.99e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.55e-10	Morning vs. evening chronotype;
KIRP	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.55	8.34	0.47	5.32e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26314531	chr2:26401878	FAM59B	0.47	5.13	0.31	5.84e-7	Gut microbiome composition (summer);
KIRP	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg06634786	chr22:41940651	POLR3H	-0.47	-5.77	-0.35	2.31e-8	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05269534	chr2:162062429	TANK	-0.42	-6.78	-0.4	9.08e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09372778	chr14:24702290	GMPR2;NEDD8	0.58	7.13	0.41	1.11e-11	Smoking initiation;
KIRP	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg17385448	chr1:15911702	AGMAT	0.26	5.25	0.32	3.24e-7	Systolic blood pressure;
KIRP	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.71	10.32	0.55	5.41e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.86	-0.45	1.2e-13	Aortic root size;
KIRP	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.69	8.55	0.48	1.36e-15	Multiple sclerosis;
KIRP	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg01411142	chr8:19674711	INTS10	0.49	5.3	0.32	2.63e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg05802129	chr4:122689817	NA	-0.5	-6.64	-0.39	2.03e-10	Type 2 diabetes;
KIRP	cis	rs10140922	0.966	rs10083387	chr14:35823669	G/A	cg07166546	chr14:35805898	NA	-0.26	-6.46	-0.38	5.45e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	5.75	0.34	2.7e-8	Breast cancer;
KIRP	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg15556689	chr8:8085844	FLJ10661	0.53	6.96	0.41	3.11e-11	Retinal vascular caliber;
KIRP	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg06212747	chr3:49208901	KLHDC8B	0.62	5.8	0.35	2e-8	Menarche (age at onset);
KIRP	cis	rs4664293	0.867	rs6432558	chr2:160601908	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs2124969	0.506	rs10497209	chr2:160985586	A/C	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.32	-0.37	1.22e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.52	6.29	0.37	1.45e-9	Uric acid levels;
KIRP	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.75	7.84	0.45	1.34e-13	White matter hyperintensity burden;
KIRP	cis	rs4908768	0.906	rs12409937	chr1:8538302	G/C	cg03610117	chr1:8450231	RERE	-0.48	-5.19	-0.31	4.43e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00857998	chr1:205179979	DSTYK	0.68	8.69	0.48	5.19e-16	Red blood cell count;
KIRP	cis	rs4006360	0.575	rs436266	chr17:39313798	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.42	-6.02	-0.36	6.28e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg11839771	chr15:80205821	ST20	-0.37	-5.43	-0.33	1.34e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs2862064	1.000	rs1910053	chr5:156463063	G/A	cg12943317	chr5:156479607	HAVCR1	-0.91	-8.12	-0.46	2.27e-14	Platelet count;
KIRP	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.42	5.34	0.32	2.15e-7	Age at first birth;
KIRP	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15369054	chr17:80825471	TBCD	0.65	5.67	0.34	3.9e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs2979489	0.945	rs11992441	chr8:30313649	A/G	cg26383811	chr8:30366931	RBPMS	0.4	5.43	0.33	1.38e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs687432	0.851	rs12804093	chr11:57734088	C/T	cg19752551	chr11:57585705	CTNND1	0.55	7.73	0.44	2.72e-13	Parkinson's disease;
KIRP	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg23587288	chr2:27483067	SLC30A3	-0.64	-7.16	-0.42	9.08e-12	Blood metabolite levels;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.69	9.73	0.53	3.82e-19	Renal function-related traits (BUN);
KIRP	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	0.84	7.02	0.41	2.15e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6832769	1.000	rs11931061	chr4:56338793	G/A	cg09317128	chr4:56265301	TMEM165	0.55	7.44	0.43	1.63e-12	Personality dimensions;
KIRP	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.62	8.92	0.49	1.07e-16	Resting heart rate;
KIRP	cis	rs1847505	0.574	rs112031726	chr13:61475108	C/T	cg25164009	chr13:61490935	NA	0.55	5.68	0.34	3.86e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.77	-9.22	-0.51	1.36e-17	Pancreatic cancer;
KIRP	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.55	-0.33	7.47e-8	Educational attainment;
KIRP	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.57	7.18	0.42	8.42e-12	Chronic lymphocytic leukemia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01219382	chr4:184328462	NA	0.5	6.62	0.39	2.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-5.18	-0.31	4.62e-7	Triglycerides;
KIRP	cis	rs7175404	1.000	rs28698970	chr15:94036807	G/C	cg23502883	chr15:93959149	NA	0.53	5.69	0.34	3.61e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.72	10.22	0.55	1.16e-20	Lewy body disease;
KIRP	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg17133734	chr15:86042851	AKAP13	-0.46	-5.89	-0.35	1.26e-8	Coronary artery disease;
KIRP	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg05519781	chr21:40033154	ERG	0.66	8.97	0.5	7.59e-17	Coronary artery disease;
KIRP	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg13147721	chr7:65941812	NA	0.97	7.1	0.41	1.32e-11	Gout;
KIRP	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.79	-11.57	-0.59	5.34e-25	Caffeine consumption;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08523029	chr5:130500466	HINT1	0.47	6.05	0.36	5.43e-9	Parkinson's disease;
KIRP	cis	rs10924309	0.737	rs3766648	chr1:245852388	C/T	cg00036263	chr1:245852353	KIF26B	-0.54	-7.62	-0.44	5.52e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs7692976	0.578	rs2881559	chr4:110840946	A/G	cg06981781	chr4:110842888	EGF	-0.23	-5.13	-0.31	5.93e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19828298	chr1:3713105	LRRC47	0.51	6.77	0.4	9.23e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.57	-0.48	1.13e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7011049	0.841	rs66726879	chr8:53866586	T/C	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg23594656	chr7:65796392	TPST1	0.47	7.48	0.43	1.34e-12	Aortic root size;
KIRP	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.77	-11.44	-0.59	1.42e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.46e-11	Colorectal cancer;
KIRP	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg15664640	chr17:80829946	TBCD	-0.7	-6.02	-0.36	6.16e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	14.59	0.68	3.59e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01528063	chr19:1249902	MIDN	0.55	6.7	0.39	1.42e-10	Parkinson's disease;
KIRP	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.41	5.69	0.34	3.55e-8	Endometrial cancer;
KIRP	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg25319279	chr11:5960081	NA	-0.55	-5.58	-0.34	6.28e-8	DNA methylation (variation);
KIRP	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.45	4.94	0.3	1.42e-6	Platelet count;
KIRP	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg15839431	chr19:19639596	YJEFN3	0.51	5.23	0.32	3.62e-7	Bipolar disorder;
KIRP	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.34	-0.42	3.07e-12	Aortic root size;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg11641102	chr8:27183873	PTK2B	0.47	6.13	0.36	3.42e-9	Neuroticism;
KIRP	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg22800045	chr5:56110881	MAP3K1	-0.69	-6.85	-0.4	5.97e-11	Initial pursuit acceleration;
KIRP	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg05527609	chr1:210001259	C1orf107	-0.51	-5.58	-0.34	6.2e-8	Red blood cell count;
KIRP	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.08e-11	Blood metabolite levels;
KIRP	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg21452805	chr1:244014465	NA	0.7	6.5	0.38	4.47e-10	RR interval (heart rate);
KIRP	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg08885076	chr2:99613938	TSGA10	0.51	8.88	0.49	1.41e-16	Chronic sinus infection;
KIRP	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08392591	chr16:89556376	ANKRD11	0.41	5.15	0.31	5.32e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg17810781	chr1:201082982	CACNA1S	-0.45	-7.17	-0.42	8.78e-12	Permanent tooth development;
KIRP	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.88	13.06	0.64	5.65e-30	Longevity;
KIRP	trans	rs263156	0.903	rs2077836	chr6:142922061	T/C	cg01789478	chr2:182545485	NEUROD1	0.35	6.06	0.36	5.03e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	6.99	0.41	2.62e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-7.18	-0.42	8.42e-12	Self-reported allergy;
KIRP	cis	rs965513	1.000	rs4743130	chr9:100546040	C/T	cg13688889	chr9:100608707	NA	-0.6	-7.65	-0.44	4.42e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg20999797	chr1:1681921	NA	0.51	7.83	0.45	1.5e-13	Body mass index;
KIRP	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.76	7.75	0.44	2.41e-13	Iron status biomarkers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21815882	chr7:26241064	CBX3;HNRNPA2B1	0.6	7.07	0.41	1.63e-11	Smoking initiation;
KIRP	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.49	6.18	0.37	2.69e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs7236492	0.748	rs8092987	chr18:77208141	C/T	cg15644404	chr18:77186268	NFATC1	-0.94	-7.77	-0.44	2.11e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2224391	0.628	rs2753236	chr6:5252214	G/A	cg13962347	chr6:5174647	LYRM4	-0.72	-10.23	-0.55	1.07e-20	Height;
KIRP	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.03	-14.95	-0.69	2.15e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.58	7.52	0.43	1.01e-12	Aortic root size;
KIRP	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.56	-0.7	1.85e-38	Gut microbiome composition (summer);
KIRP	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.6e-25	Morning vs. evening chronotype;
KIRP	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg13736514	chr6:26305472	NA	-0.46	-5.17	-0.31	4.81e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.91	-10.52	-0.56	1.28e-21	Neuroticism;
KIRP	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg04310649	chr10:35416472	CREM	-0.53	-6.09	-0.36	4.23e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.25	-5.03	-0.31	9.48e-7	Lymphocyte counts;
KIRP	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06544989	chr22:39130855	UNC84B	-0.38	-6.03	-0.36	5.98e-9	Menopause (age at onset);
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg24642844	chr7:1081250	C7orf50	-0.38	-5.13	-0.31	5.8e-7	Longevity;Endometriosis;
KIRP	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg07689907	chr11:61582574	FADS1	0.48	6.01	0.36	6.59e-9	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.67	8.19	0.46	1.47e-14	Testicular germ cell tumor;
KIRP	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.64	5.36	0.32	1.87e-7	Diabetic retinopathy;
KIRP	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg05072774	chr3:49840536	C3orf54	-0.41	-5.37	-0.32	1.86e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.41	0.55	2.95e-21	Cognitive test performance;
KIRP	cis	rs6577655	0.517	rs6998749	chr8:135584316	A/G	cg17885191	chr8:135476712	NA	-0.7	-6.7	-0.39	1.4e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2241685	0.621	rs11127305	chr2:1902562	A/G	cg22511877	chr2:1942942	MYT1L	-0.58	-5.37	-0.32	1.86e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg01557791	chr16:72042693	DHODH	-0.42	-5.14	-0.31	5.62e-7	Fibrinogen levels;
KIRP	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs7833787	1.000	rs7844500	chr8:18703343	A/G	cg17701159	chr8:18705777	PSD3	-0.37	-6.99	-0.41	2.6e-11	Obesity-related traits;
KIRP	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.63	-7.71	-0.44	3.21e-13	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.66	0.34	4.22e-8	Menopause (age at onset);
KIRP	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg02415014	chr8:143852576	LYNX1	-0.33	-5.26	-0.32	3.18e-7	Urinary tract infection frequency;
KIRP	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-1.1	-17.98	-0.75	1.05e-46	Strep throat;
KIRP	cis	rs259282	0.605	rs36107586	chr19:33109674	G/A	cg02997394	chr19:33096574	ANKRD27	-0.47	-5.35	-0.32	2.02e-7	Schizophrenia;
KIRP	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg26875233	chr11:93583750	C11orf90	-0.41	-7.7	-0.44	3.21e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6495367	1.000	rs4778634	chr15:79380822	C/T	cg17916960	chr15:79447300	NA	0.31	5.18	0.31	4.65e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg23978390	chr7:1156363	C7orf50	0.49	5.13	0.31	5.87e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg16989719	chr2:238392110	NA	-0.56	-5.99	-0.36	7.27e-9	Prostate cancer;
KIRP	trans	rs76288851	0.799	rs73209608	chr3:126638038	G/A	cg13821433	chr2:26726535	OTOF	0.58	6.44	0.38	6.29e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.76	11.14	0.58	1.35e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18876405	chr7:65276391	NA	0.42	5.11	0.31	6.49e-7	Aortic root size;
KIRP	cis	rs5752326	0.510	rs5761547	chr22:26863093	C/T	cg20819150	chr22:26891497	TFIP11	0.54	5.08	0.31	7.36e-7	Ischemic stroke;
KIRP	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.26	-0.32	3.08e-7	Iron status biomarkers;
KIRP	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg25019033	chr10:957182	NA	0.71	9.11	0.5	2.94e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.19	-22.68	-0.82	3.18e-62	Ulcerative colitis;
KIRP	trans	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg15469184	chr8:337539	NA	0.56	6.01	0.36	6.49e-9	Obesity-related traits;
KIRP	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.49	5.48	0.33	1.08e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.98	0.36	7.81e-9	Motion sickness;
KIRP	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.44	-0.43	1.68e-12	Body mass index;
KIRP	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.37	-0.32	1.86e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs13385	0.769	rs7722986	chr5:139617386	G/A	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.46	4.99	0.3	1.14e-6	HDL cholesterol;
KIRP	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.44	5.14	0.31	5.6e-7	Schizophrenia;
KIRP	cis	rs7520050	0.966	rs61783200	chr1:46297403	T/C	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.64	12.3	0.62	1.99e-27	Bone mineral density;
KIRP	cis	rs7941030	0.902	rs10892873	chr11:122535333	C/G	cg20555462	chr11:122535518	UBASH3B	0.48	5.95	0.35	9.4e-9	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	13.8	0.66	1.79e-32	Smoking behavior;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07343612	chr16:622815	PIGQ	-0.89	-13.45	-0.65	2.68e-31	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01334186	chr1:151372572	PSMB4	0.6	7.44	0.43	1.71e-12	Smoking initiation;
KIRP	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg01877450	chr7:97915802	BRI3	0.39	5.27	0.32	3.04e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg00405596	chr8:11794950	NA	-0.53	-6.63	-0.39	2.08e-10	Triglycerides;
KIRP	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.43	-5.71	-0.34	3.26e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg02696742	chr7:106810147	HBP1	-0.78	-8.38	-0.47	4.05e-15	Coronary artery disease;
KIRP	cis	rs918629	0.530	rs3777185	chr5:95259862	C/T	cg16656078	chr5:95278638	ELL2	-0.36	-5.52	-0.33	8.42e-8	IgG glycosylation;
KIRP	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.43	0.47	2.86e-15	Motion sickness;
KIRP	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.7	8.78	0.49	2.89e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs921943	1.000	rs7709757	chr5:78315329	T/C	cg26802063	chr5:78281964	ARSB	0.5	6.21	0.37	2.22e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg17443007	chr1:101659419	NA	-0.42	-5.89	-0.35	1.25e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.53	6.52	0.38	4.07e-10	Monocyte count;
KIRP	cis	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg26585981	chr11:48327164	OR4S1	-0.51	-6.28	-0.37	1.56e-9	Migraine - clinic-based;
KIRP	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs10046574	0.519	rs7781819	chr7:135205700	A/T	cg27474649	chr7:135195673	CNOT4	0.55	5.18	0.31	4.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.69	8.14	0.46	2.01e-14	Alcohol dependence;
KIRP	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg23387468	chr7:139079360	LUC7L2	-0.29	-5.02	-0.31	9.71e-7	Diisocyanate-induced asthma;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06747863	chr12:118810789	TAOK3	0.51	6.74	0.39	1.11e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.8200000000000003e-11	Hypertriglyceridemia;
KIRP	cis	rs61935443	0.666	rs11107780	chr12:95299142	G/A	cg21533806	chr12:95267307	NA	0.59	5.24	0.32	3.44e-7	Schizophrenia;
KIRP	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12311346	chr5:56204834	C5orf35	-0.41	-5.39	-0.33	1.64e-7	Coronary artery disease;
KIRP	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.63	-6.84	-0.4	6.13e-11	YKL-40 levels;
KIRP	cis	rs6545883	0.929	rs2593627	chr2:61618574	T/C	cg15711740	chr2:61764176	XPO1	0.6	7.98	0.45	5.54e-14	Tuberculosis;
KIRP	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg16141378	chr3:129829833	LOC729375	0.6	7.72	0.44	2.87e-13	Morning vs. evening chronotype;
KIRP	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.82	-12.52	-0.62	3.85e-28	Prostate cancer;
KIRP	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.83	11.25	0.58	5.89e-24	Breast cancer;
KIRP	cis	rs2224391	0.518	rs17736611	chr6:5283821	A/G	cg13962347	chr6:5174647	LYRM4	-0.73	-6.73	-0.39	1.15e-10	Height;
KIRP	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg06204229	chr3:52865917	ITIH4	0.51	7.5	0.43	1.16e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1215050	0.765	rs181521	chr4:98745728	A/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.45	-0.38	5.91e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.7	-12.88	-0.63	2.42e-29	Body mass index;
KIRP	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.55	6.46	0.38	5.62e-10	Mean corpuscular volume;
KIRP	cis	rs1978968	0.912	rs12157484	chr22:18455122	C/T	cg02610425	chr22:18483192	MICAL3	0.37	5.01	0.3	1.02e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs9398803	0.687	rs1340952	chr6:126951510	C/T	cg19875578	chr6:126661172	C6orf173	0.38	4.97	0.3	1.27e-6	Male-pattern baldness;
KIRP	cis	rs12780845	0.964	rs7912064	chr10:17233916	C/T	cg01003015	chr10:17271136	VIM	0.46	4.96	0.3	1.32e-6	Homocysteine levels;
KIRP	cis	rs4664293	0.867	rs12692562	chr2:160595710	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.8	-11.74	-0.6	1.45e-25	Heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05451573	chr3:97691096	MINA	0.52	6.54	0.38	3.54e-10	Parkinson's disease;
KIRP	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg13206674	chr6:150067644	NUP43	0.56	7.98	0.45	5.44e-14	Lung cancer;
KIRP	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg27422857	chr2:105853526	NA	-0.43	-5.67	-0.34	4.03e-8	Type 2 diabetes;
KIRP	cis	rs17023223	0.537	rs2765530	chr1:119584396	G/A	cg05756136	chr1:119680316	WARS2	-0.57	-7.72	-0.44	2.85e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.61	-10.01	-0.54	5.32e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg05887749	chr16:88097594	BANP	0.49	6.02	0.36	6.21e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs12120353	0.529	rs55956326	chr1:4623889	C/T	cg12065138	chr1:4771201	AJAP1	-0.68	-5.71	-0.34	3.16e-8	Anxiety disorder;
KIRP	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.54	-6.96	-0.41	3.03e-11	Body mass index;
KIRP	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.56	7.09	0.41	1.43e-11	Obesity-related traits;
KIRP	cis	rs7814319	0.600	rs111300519	chr8:97262939	G/A	cg20787634	chr8:97240163	UQCRB	-0.57	-7.65	-0.44	4.68e-13	Lung function (FVC);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19694134	chr7:82388134	PCLO	-0.41	-6.45	-0.38	5.98e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg00579200	chr11:133705235	NA	0.43	5.65	0.34	4.42e-8	Childhood ear infection;
KIRP	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg23594656	chr7:65796392	TPST1	-0.47	-7.41	-0.43	1.97e-12	Aortic root size;
KIRP	cis	rs6684428	0.536	rs6670350	chr1:56391806	C/T	cg11651538	chr1:56320950	NA	0.58	8.32	0.47	6.11e-15	Airflow obstruction;
KIRP	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.71	-7.27	-0.42	4.86e-12	Blood pressure (smoking interaction);
KIRP	cis	rs9826463	0.582	rs73238161	chr3:142081981	A/C	cg20824294	chr3:142316082	PLS1	0.44	6.35	0.38	1.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.72	-7.79	-0.44	1.92e-13	Blood pressure (smoking interaction);
KIRP	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg20542592	chr8:11973495	FAM66D	0.39	4.87	0.3	1.99e-6	Triglycerides;
KIRP	cis	rs4629710	0.545	rs3777477	chr6:131534374	T/C	cg12606694	chr6:131520996	AKAP7	0.52	6.64	0.39	2.01e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14589563	chr11:63438716	ATL3	0.46	6.38	0.38	8.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.53	-0.38	3.66e-10	Cardiac Troponin-T levels;
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg18209359	chr17:80159595	CCDC57	0.41	5.4	0.33	1.57e-7	Life satisfaction;
KIRP	cis	rs2882667	0.628	rs13173618	chr5:138139780	T/G	cg04439458	chr5:138467593	SIL1	-0.4	-5.21	-0.32	4.01e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg22676075	chr6:135203613	NA	0.51	7.44	0.43	1.67e-12	Red blood cell count;
KIRP	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.91	14.66	0.68	2.15e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg05692746	chr2:100937584	LONRF2	0.42	5.25	0.32	3.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28489187	0.617	rs11161606	chr1:85853902	T/C	cg16011679	chr1:85725395	C1orf52	0.46	5.68	0.34	3.75e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.0	-0.36	6.87e-9	Personality dimensions;
KIRP	cis	rs8079658	1.000	rs72831444	chr17:63815666	A/G	cg18091269	chr17:63822838	CCDC46	-0.56	-7.77	-0.44	2.06e-13	Post bronchodilator FEV1;
KIRP	cis	rs3736485	0.934	rs11634999	chr15:51871461	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.53e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg18306943	chr3:40428807	ENTPD3	0.46	6.2	0.37	2.43e-9	Renal cell carcinoma;
KIRP	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.89	0.4	4.64e-11	Blood metabolite levels;
KIRP	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.64	-6.26	-0.37	1.72e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg00031303	chr3:195681400	NA	0.65	7.48	0.43	1.32e-12	Pancreatic cancer;
KIRP	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg07001201	chr5:642380	CEP72	0.66	6.6	0.39	2.44e-10	Obesity-related traits;
KIRP	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg04202892	chr2:111875749	ACOXL	0.44	6.09	0.36	4.31e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs1656402	1.000	rs3021411	chr2:233425224	G/A	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg00587304	chr3:172468157	NA	0.49	6.04	0.36	5.54e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.81	-0.49	2.28e-16	Response to antipsychotic treatment;
KIRP	cis	rs13034020	0.790	rs13026050	chr2:61136013	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.59	4.86	0.3	2.13e-6	Hodgkin's lymphoma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25253773	chr2:74942436	NA	-0.53	-6.19	-0.37	2.45e-9	Interleukin-4 levels;
KIRP	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg24009623	chr19:33667908	NA	0.47	6.15	0.37	3.03e-9	Bone properties (heel);
KIRP	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg26965718	chr17:79658957	HGS	-0.61	-5.91	-0.35	1.17e-8	Dental caries;
KIRP	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14442939	chr10:27389572	ANKRD26	0.62	6.39	0.38	8.08e-10	Breast cancer;
KIRP	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	0.84	6.59	0.39	2.67e-10	Mitochondrial DNA levels;
KIRP	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	5.73	0.34	3e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03535862	chr6:139348428	C6orf115	-0.41	-6.35	-0.38	1.05e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.72	8.68	0.48	5.52e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7945718	0.934	rs11022478	chr11:12741104	T/C	ch.11.340609R	chr11:12831013	TEAD1	-0.44	-5.64	-0.34	4.72e-8	Educational attainment (years of education);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10135532	chr3:58477573	KCTD6	0.49	6.24	0.37	1.87e-9	Parkinson's disease;
KIRP	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg04865290	chr3:52927548	TMEM110	-0.64	-6.76	-0.4	1.01e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.72	9.91	0.53	1.08e-19	Ulcerative colitis;
KIRP	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.26	4.87	0.3	2.02e-6	Coronary artery disease;
KIRP	cis	rs62070183	1.000	rs62070183	chr17:31164367	T/C	cg05781649	chr17:31146240	MYO1D	-0.51	-5.13	-0.31	5.78e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs2637030	0.515	rs449160	chr5:53005969	A/G	cg06476337	chr5:52856530	NDUFS4	0.56	6.3	0.37	1.34e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg17376030	chr22:41985996	PMM1	0.42	5.08	0.31	7.44e-7	Vitiligo;
KIRP	cis	rs7560272	0.723	rs7609249	chr2:73813820	G/A	cg20560298	chr2:73613845	ALMS1	-0.41	-5.02	-0.3	9.93e-7	Schizophrenia;
KIRP	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg24642844	chr7:1081250	C7orf50	-0.9	-7.59	-0.44	6.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	12.02	0.61	1.69e-26	Ileal carcinoids;
KIRP	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.56	7.48	0.43	1.35e-12	Bladder cancer;
KIRP	cis	rs10924970	0.967	rs4659654	chr1:235383188	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg24375607	chr4:120327624	NA	0.48	5.61	0.34	5.47e-8	Corneal astigmatism;
KIRP	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	7.21	0.42	6.97e-12	Lung function (FEV1/FVC);
KIRP	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg26408565	chr15:76604113	ETFA	-0.44	-5.83	-0.35	1.72e-8	Blood metabolite levels;
KIRP	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs17453880	0.895	rs7730088	chr5:152028536	T/G	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.57	6.96	0.41	3.02e-11	Iron status biomarkers;
KIRP	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.07	8.84	0.49	1.91e-16	Mitochondrial DNA levels;
KIRP	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.66	-6.18	-0.37	2.58e-9	Schizophrenia;
KIRP	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg24375607	chr4:120327624	NA	-0.46	-5.51	-0.33	9.02e-8	Corneal astigmatism;
KIRP	cis	rs240764	0.578	rs6927598	chr6:101232729	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.22	0.32	3.85e-7	Neuroticism;
KIRP	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.47	-0.33	1.11e-7	Autism;
KIRP	cis	rs72843166	0.592	rs112829995	chr17:61528361	C/T	cg19683800	chr17:61518354	CYB561	-0.46	-5.87	-0.35	1.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06481639	chr22:41940642	POLR3H	0.45	5.46	0.33	1.19e-7	Vitiligo;
KIRP	trans	rs783540	0.934	rs8043401	chr15:83356259	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.44	-6.06	-0.36	4.99e-9	Schizophrenia;
KIRP	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	0.91	14.45	0.68	1.12e-34	Stearic acid (18:0) levels;
KIRP	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg10578777	chr12:7781093	NA	0.61	6.31	0.37	1.32e-9	HDL cholesterol levels;
KIRP	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.95	13.39	0.65	4.33e-31	Platelet distribution width;
KIRP	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg10223061	chr2:219282414	VIL1	-0.4	-6.39	-0.38	8.07e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3099143	0.901	rs28405838	chr15:77226053	C/G	cg21673338	chr15:77095150	SCAPER	-0.52	-5.42	-0.33	1.4e-7	Recalcitrant atopic dermatitis;
KIRP	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg05692746	chr2:100937584	LONRF2	-0.39	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg00125455	chr20:44574271	PCIF1	0.45	8.78	0.49	2.79e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.77	0.35	2.39e-8	Menopause (age at onset);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.49	6.45	0.38	5.82e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.79	-9.7	-0.53	4.67e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg16586182	chr3:47516702	SCAP	0.82	11.63	0.6	3.25e-25	Colorectal cancer;
KIRP	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg03959625	chr15:84868606	LOC388152	0.59	6.99	0.41	2.63e-11	Schizophrenia;
KIRP	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs17286411	0.836	rs4788448	chr16:71921979	C/A	cg04254540	chr16:71951199	KIAA0174	-0.39	-5.16	-0.31	5.16e-7	Blood protein levels;
KIRP	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg05044414	chr3:183734942	ABCC5	0.37	5.58	0.34	6.36e-8	Anterior chamber depth;
KIRP	trans	rs783540	0.500	rs7163840	chr15:83398303	A/G	cg16105309	chr15:79090380	ADAMTS7	0.61	7.3	0.42	3.86e-12	Schizophrenia;
KIRP	cis	rs7615316	0.678	rs12639042	chr3:142061286	A/C	cg20824294	chr3:142316082	PLS1	0.27	5.36	0.32	1.95e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg14664628	chr15:75095509	CSK	-0.62	-7.33	-0.42	3.3e-12	Caffeine consumption;
KIRP	trans	rs1391576	1	rs1391576	chr11:51394932	C/T	cg26562691	chr16:23850404	PRKCB	0.61	6.11	0.36	3.96e-9	Body mass index;
KIRP	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.83	11.69	0.6	2.1e-25	Coronary artery disease;
KIRP	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.65	-9.03	-0.5	5.13e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.78	11.69	0.6	2.11e-25	Total body bone mineral density;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg04369109	chr6:150039330	LATS1	-0.49	-6.24	-0.37	1.9e-9	Lung cancer;
KIRP	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.7	-0.34	3.4e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4700695	0.534	rs153373	chr5:65426159	G/A	cg21114390	chr5:65439923	SFRS12	-0.75	-6.65	-0.39	1.84e-10	Facial morphology (factor 19);
KIRP	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg26876637	chr1:152193138	HRNR	0.72	9.79	0.53	2.54e-19	Atopic dermatitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19536404	chr3:184971825	EHHADH	0.52	6.74	0.39	1.1e-10	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs427941	0.669	rs417013	chr7:101820155	G/A	cg06246474	chr7:101738831	CUX1	0.51	6.1	0.36	4.04e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg03713592	chr11:72463424	ARAP1	0.55	6.01	0.36	6.58e-9	Body mass index;
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-4.96	-0.3	1.31e-6	Life satisfaction;
KIRP	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18255839	chr2:239335447	ASB1	0.44	5.19	0.31	4.45e-7	Multiple system atrophy;
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.68	-0.44	3.65e-13	Platelet count;
KIRP	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.49	-11.44	-0.59	1.39e-24	Diabetic kidney disease;
KIRP	cis	rs2071403	0.966	rs11686524	chr2:1412244	T/G	cg06500727	chr2:1417164	TPO	0.47	7.45	0.43	1.6e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.11	-0.54	2.63e-20	Response to antipsychotic treatment;
KIRP	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	1.04	12.24	0.62	3.12e-27	Breast cancer;
KIRP	cis	rs367943	0.712	rs1607159	chr5:112681044	C/A	cg12552261	chr5:112820674	MCC	0.49	5.73	0.34	2.91e-8	Type 2 diabetes;
KIRP	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.52	6.22	0.37	2.07e-9	Menopause (age at onset);
KIRP	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg19338460	chr6:170058176	WDR27	-1.22	-9.65	-0.52	6.62e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	15.05	0.69	1.03e-36	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15034081	chr19:38893816	FAM98C	0.57	7.2	0.42	7.34e-12	Parkinson's disease;
KIRP	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.37	0.32	1.86e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg21775007	chr8:11205619	TDH	0.47	6.52	0.38	4.03e-10	Neuroticism;
KIRP	cis	rs2151522	0.624	rs1543705	chr6:127197108	A/G	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg16141378	chr3:129829833	LOC729375	0.56	7.75	0.44	2.44e-13	Neuroticism;
KIRP	cis	rs735539	0.645	rs3825444	chr13:21173926	A/G	cg27499820	chr13:21296301	IL17D	0.34	4.96	0.3	1.3e-6	Dental caries;
KIRP	cis	rs62413470	0.935	rs4469280	chr6:55946228	A/C	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg09596252	chr17:78655493	RPTOR	0.59	7.74	0.44	2.61e-13	Obesity;
KIRP	cis	rs367615	0.959	rs4957830	chr5:108911758	G/T	cg17395555	chr5:108820864	NA	0.5	5.36	0.32	1.96e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg20387954	chr3:183756860	HTR3D	0.59	8.57	0.48	1.19e-15	Anterior chamber depth;
KIRP	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00585698	chr12:123750864	CDK2AP1	-0.5	-6.3	-0.37	1.33e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg11752832	chr7:134001865	SLC35B4	0.45	5.39	0.33	1.63e-7	Mean platelet volume;
KIRP	cis	rs61884328	0.852	rs74713772	chr11:47070915	C/T	cg23433285	chr11:47201945	PACSIN3	0.77	6.26	0.37	1.67e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs42648	1.000	rs42648	chr7:89977760	A/G	cg25739043	chr7:89950458	NA	-0.47	-7.69	-0.44	3.51e-13	Homocysteine levels;
KIRP	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.41	0.38	7.49e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05665937	chr4:1216051	CTBP1	0.52	7.26	0.42	5.12e-12	Obesity-related traits;
KIRP	cis	rs282587	0.569	rs390657	chr13:113415085	A/G	cg04656015	chr13:113407548	ATP11A	0.58	6.36	0.38	9.68e-10	Glycated hemoglobin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16117910	chr2:109745648	SH3RF3;LOC100287216	0.54	6.86	0.4	5.69e-11	Parkinson's disease;
KIRP	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg08501292	chr6:25962987	TRIM38	1.0	7.71	0.44	3.21e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg17554472	chr22:41940697	POLR3H	0.59	6.41	0.38	7.48e-10	Vitiligo;
KIRP	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15073248	chr7:102715559	ARMC10;FBXL13	0.54	6.7	0.39	1.41e-10	Parkinson's disease;
KIRP	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	cg21523751	chr1:182988639	NA	0.45	7.18	0.42	8.12e-12	Colorectal cancer;
KIRP	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	cg04338863	chr8:33670619	NA	0.43	5.02	0.3	9.99e-7	Body mass index;
KIRP	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg26876637	chr1:152193138	HRNR	-0.81	-9.96	-0.54	7.27e-20	Atopic dermatitis;
KIRP	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg19849509	chr2:175204996	NA	-0.53	-6.34	-0.37	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg09699651	chr6:150184138	LRP11	0.47	6.38	0.38	8.95e-10	Lung cancer;
KIRP	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.22	-11.4	-0.59	1.85e-24	Diabetic retinopathy;
KIRP	cis	rs963731	0.649	rs2924710	chr2:39302757	G/C	cg04010122	chr2:39346883	SOS1	-0.93	-6.33	-0.37	1.18e-9	Corticobasal degeneration;
KIRP	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.93	16.09	0.72	2.85e-40	Breast cancer;
KIRP	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	11.46	0.59	1.2e-24	Mean corpuscular hemoglobin;
KIRP	cis	rs4690686	0.500	rs11728314	chr4:177268373	G/A	cg17059388	chr4:177262070	NA	0.88	12.75	0.63	6.44e-29	Essential tremor;
KIRP	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.72	-0.49	4.2e-16	Morning vs. evening chronotype;
KIRP	cis	rs698813	0.604	rs12712917	chr2:44482190	A/G	cg04920474	chr2:44395004	PPM1B	0.36	4.86	0.3	2.11e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg27432699	chr2:27873401	GPN1	-0.46	-5.89	-0.35	1.27e-8	Total body bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00035980	chr13:113600332	NA	0.48	6.27	0.37	1.61e-9	Interleukin-4 levels;
KIRP	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.61	-0.34	5.36e-8	Coronary artery disease;
KIRP	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs4664293	0.867	rs6720304	chr2:160643832	G/A	cg08347373	chr2:160653686	CD302	-0.44	-6.53	-0.38	3.83e-10	Monocyte percentage of white cells;
KIRP	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg12573791	chr2:3828286	NA	0.38	5.13	0.31	6.02e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg07843065	chr1:150265600	MRPS21	-0.47	-6.66	-0.39	1.82e-10	Migraine;
KIRP	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.43	7.52	0.43	1.01e-12	Renal cell carcinoma;
KIRP	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg22437258	chr11:111473054	SIK2	0.51	5.66	0.34	4.12e-8	Primary sclerosing cholangitis;
KIRP	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.05	0.36	5.49e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.73	11.69	0.6	2.19e-25	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.7	7.32	0.42	3.54e-12	Bipolar disorder;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20066782	chr7:102574504	FBXL13;LRRC17	0.51	6.02	0.36	6.16e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.61	12.42	0.62	7.9e-28	Diabetic kidney disease;
KIRP	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	1.1	23.36	0.83	2.19e-64	Parkinson's disease;
KIRP	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.68	-0.34	3.87e-8	Parkinson's disease;
KIRP	cis	rs17221829	0.733	rs12421371	chr11:89381008	T/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.23e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2278796	0.697	rs4951150	chr1:204952849	C/A	cg17947172	chr1:204966197	NFASC	0.4	5.5	0.33	9.74e-8	Mean platelet volume;
KIRP	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	10.64	0.56	5.5e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.36	0.32	1.94e-7	Coronary artery disease;
KIRP	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.23	-0.51	1.3e-17	Triglycerides;
KIRP	cis	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg25547332	chr5:131281432	NA	0.46	4.99	0.3	1.15e-6	Life satisfaction;
KIRP	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14893161	chr1:205819251	PM20D1	-0.52	-6.08	-0.36	4.53e-9	Parkinson's disease;
KIRP	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg04727924	chr7:799746	HEATR2	0.6	5.57	0.33	6.65e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10782582	0.609	rs5745543	chr1:76365111	A/T	cg03433033	chr1:76189801	ACADM	-0.47	-6.88	-0.4	5.06e-11	Daytime sleep phenotypes;
KIRP	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	7.92e-7	Electrocardiographic conduction measures;
KIRP	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.13	-0.41	1.11e-11	Bipolar disorder;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18043078	chr13:114898210	RASA3	0.51	6.07	0.36	4.86e-9	Obesity-related traits;
KIRP	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.52	-5.75	-0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs12580194	0.554	rs12579852	chr12:55716569	T/A	cg11794356	chr12:55725991	OR6C3	-0.55	-7.11	-0.41	1.23e-11	Cancer;
KIRP	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.58	8.53	0.48	1.52e-15	Blood metabolite levels;
KIRP	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.48	6.09	0.36	4.39e-9	Age at first birth;
KIRP	cis	rs2072732	0.861	rs16823392	chr1:2953833	C/G	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg16989719	chr2:238392110	NA	-0.53	-5.97	-0.36	8.03e-9	Prostate cancer;
KIRP	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11264213	0.686	rs645383	chr1:36373823	C/G	cg27506609	chr1:36549197	TEKT2	-0.97	-8.29	-0.47	7.26e-15	Schizophrenia;
KIRP	cis	rs7175404	0.583	rs17708748	chr15:94071414	A/G	cg23502883	chr15:93959149	NA	0.49	4.91	0.3	1.65e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs11671005	0.735	rs11668420	chr19:58937836	G/A	cg13877915	chr19:58951672	ZNF132	0.6	5.91	0.35	1.12e-8	Mean platelet volume;
KIRP	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg18944383	chr4:111397179	ENPEP	0.49	8.13	0.46	2.13e-14	Coronary artery disease;
KIRP	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg00012203	chr2:219082015	ARPC2	0.66	8.66	0.48	6.27e-16	Colorectal cancer;
KIRP	cis	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.93	0.3	1.49e-6	Leprosy;
KIRP	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg24375607	chr4:120327624	NA	-0.52	-6.11	-0.36	3.93e-9	Corneal astigmatism;
KIRP	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.6	8.03	0.46	4.13e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg08992911	chr2:238395768	MLPH	0.43	4.9	0.3	1.72e-6	Prostate cancer;
KIRP	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.44e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12214534	chr11:64851506	CDCA5;ZFPL1	0.52	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.71	9.04	0.5	4.73e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg00621247	chr5:1949277	NA	0.48	5.38	0.32	1.73e-7	Gut microbiome composition (winter);
KIRP	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-7.83	-0.45	1.47e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.87	15.17	0.7	3.81e-37	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs34779708	0.897	rs4934529	chr10:35302376	T/A	cg03585969	chr10:35415529	CREM	0.83	9.93	0.53	9.33e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13177180	0.671	rs10079000	chr5:114940200	A/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.3	4.99	0.3	1.12e-6	Conotruncal heart defects (inherited effects);
KIRP	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg24304309	chr1:154577895	ADAR	0.36	5.87	0.35	1.43e-8	Blood protein levels;
KIRP	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.78	11.18	0.58	9.95e-24	Bladder cancer;
KIRP	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.37	0.43	2.55e-12	Retinal vascular caliber;
KIRP	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg08975724	chr8:8085496	FLJ10661	0.58	7.09	0.41	1.43e-11	Retinal vascular caliber;
KIRP	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.59	-7.34	-0.42	3.12e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.31	-0.32	2.5e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg15848620	chr12:58087721	OS9	-0.43	-4.9	-0.3	1.75e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg19875535	chr5:140030758	IK	-0.59	-7.65	-0.44	4.44e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26314531	chr2:26401878	FAM59B	0.47	4.9	0.3	1.75e-6	Gut microbiome composition (summer);
KIRP	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.51	-11.6	-0.59	4.35e-25	Diabetic kidney disease;
KIRP	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.71	10.64	0.56	5.21e-22	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2290419	0.730	rs76291348	chr11:68944514	T/G	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg18240653	chr6:144019428	PHACTR2	0.46	4.88	0.3	1.88e-6	Obesity-related traits;
KIRP	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.7	7.81	0.45	1.68e-13	Obesity-related traits;
KIRP	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg03653399	chr8:142233436	SLC45A4	0.65	8.83	0.49	2.02e-16	Immature fraction of reticulocytes;
KIRP	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg10434728	chr15:90938212	IQGAP1	0.29	4.91	0.3	1.65e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.61	6.73	0.39	1.22e-10	Aortic root size;
KIRP	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg19847130	chr8:10466454	RP1L1	0.37	5.57	0.33	6.65e-8	Neuroticism;
KIRP	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.8	-10.0	-0.54	5.58e-20	Blood protein levels;
KIRP	cis	rs7929679	0.602	rs10836311	chr11:34809166	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.34e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg02536541	chr18:77568900	NA	-0.72	-10.82	-0.57	1.43e-22	Schizophrenia;
KIRP	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.11	-0.41	1.22e-11	Neuroticism;
KIRP	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.65	8.59	0.48	1.03e-15	Personality dimensions;
KIRP	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg03605463	chr16:89740564	NA	0.48	6.16	0.37	2.92e-9	Vitiligo;
KIRP	cis	rs7011507	1.000	rs79246395	chr8:49188885	G/A	cg15325961	chr8:49183143	NA	0.61	5.2	0.31	4.17e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs911119	0.913	rs6048929	chr20:23588855	T/C	cg09631192	chr20:23583594	CST9	-0.51	-5.34	-0.32	2.07e-7	Chronic kidney disease;
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.21e-8	Life satisfaction;
KIRP	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.51	0.59	8.51e-25	Bladder cancer;
KIRP	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.51e-7	Life satisfaction;
KIRP	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.44	-5.22	-0.32	3.78e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs798766	1.000	rs7682402	chr4:1743343	G/A	cg07775547	chr4:1625484	NA	-0.45	-5.38	-0.32	1.73e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs7712401	0.601	rs27976	chr5:122206460	C/T	cg19412675	chr5:122181750	SNX24	-0.52	-5.65	-0.34	4.5e-8	Mean platelet volume;
KIRP	cis	rs684232	0.805	rs2360737	chr17:506163	C/T	cg15660573	chr17:549704	VPS53	-0.52	-6.68	-0.39	1.58e-10	Prostate cancer;
KIRP	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg04310649	chr10:35416472	CREM	-0.55	-6.24	-0.37	1.93e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7937612	1.000	rs10750174	chr11:120292097	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.15	-0.41	1.01e-11	Intraocular pressure;
KIRP	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg23625390	chr15:77176239	SCAPER	0.52	6.89	0.4	4.64e-11	Blood metabolite levels;
KIRP	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.56	7.24	0.42	5.71e-12	Pulse pressure;
KIRP	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.6	8.84	0.49	1.84e-16	Cancer;
KIRP	cis	rs2150410	0.764	rs7282724	chr21:40659961	A/C	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.63	7.73	0.44	2.68e-13	Height;
KIRP	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-11.32	-0.59	3.5e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg23307798	chr14:103986281	CKB	-0.51	-6.93	-0.4	3.73e-11	Coronary artery disease;
KIRP	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.13	-0.46	2.11e-14	Coffee consumption (cups per day);
KIRP	cis	rs9815354	0.680	rs73073262	chr3:42018443	G/T	cg03022575	chr3:42003672	ULK4	0.75	6.98	0.41	2.68e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg24579218	chr15:68104479	NA	-0.47	-7.68	-0.44	3.77e-13	Restless legs syndrome;
KIRP	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg05709478	chr1:6581295	PLEKHG5	-0.62	-6.21	-0.37	2.26e-9	Body mass index;
KIRP	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg16141378	chr3:129829833	LOC729375	0.52	6.44	0.38	6.27e-10	Joint mobility (Beighton score);
KIRP	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.81	10.38	0.55	3.67e-21	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Bladder cancer;
KIRP	cis	rs7084402	1.000	rs7073504	chr10:60271987	C/T	cg05938607	chr10:60274200	BICC1	0.42	10.12	0.54	2.44e-20	Refractive error;
KIRP	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.71	8.98	0.5	7.23e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6987853	0.966	rs2974338	chr8:42391945	A/G	cg09913449	chr8:42400586	C8orf40	0.4	5.05	0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.69	9.24	0.51	1.24e-17	Systemic lupus erythematosus;
KIRP	cis	rs78579285	0.589	rs113010486	chr16:88798398	A/G	cg09054528	chr16:88821542	FAM38A	-0.66	-5.34	-0.32	2.09e-7	Joint mobility (Beighton score);
KIRP	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.81	11.42	0.59	1.63e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg05484376	chr2:27715224	FNDC4	0.34	5.47	0.33	1.12e-7	Total body bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19445734	chr2:55566679	CCDC88A	-0.46	-6.79	-0.4	8.39e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17893934	chr10:858817	LARP4B	0.47	6.09	0.36	4.4e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs16912285	0.591	rs7929025	chr11:24363324	A/C	ch.11.24196551F	chr11:24239977	NA	0.67	6.35	0.38	1.03e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg23307798	chr14:103986281	CKB	0.74	12.04	0.61	1.43e-26	Body mass index;
KIRP	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-1.04	-9.62	-0.52	8.15e-19	Diabetic kidney disease;
KIRP	trans	rs2048656	0.570	rs7814635	chr8:9646620	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.07	0.36	4.77e-9	Schizophrenia;
KIRP	cis	rs889398	0.741	rs7192213	chr16:69926280	G/A	cg09409435	chr16:70099608	PDXDC2	0.41	5.07	0.31	7.69e-7	Body mass index;
KIRP	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	7.14e-8	Breast cancer;
KIRP	trans	rs9650657	0.648	rs6601512	chr8:10585596	G/A	cg16141378	chr3:129829833	LOC729375	0.46	6.08	0.36	4.44e-9	Neuroticism;
KIRP	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg13939156	chr17:80058883	NA	-0.48	-7.28	-0.42	4.54e-12	Life satisfaction;
KIRP	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg21605333	chr4:119757512	SEC24D	1.56	11.04	0.58	2.74e-23	Cannabis dependence symptom count;
KIRP	cis	rs2278796	1.000	rs2278796	chr1:204951209	C/T	cg04862289	chr1:204966208	NFASC	0.65	9.19	0.51	1.74e-17	Mean platelet volume;
KIRP	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.3	-0.55	6.5e-21	Neuroticism;
KIRP	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	1.01	11.46	0.59	1.24e-24	Educational attainment;
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.9	16.33	0.72	4.29e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg20243544	chr17:37824526	PNMT	-0.4	-4.93	-0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs447	1.000	rs7785708	chr7:83752668	C/T	cg22846510	chr7:83753280	SEMA3A	-0.42	-4.93	-0.3	1.54e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4955124	0.558	rs12629793	chr3:32024251	C/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.76	6.87	0.4	5.16e-11	Schizophrenia;
KIRP	cis	rs2625529	0.617	rs8557	chr15:72115733	T/C	cg16672083	chr15:72433130	SENP8	-0.48	-6.75	-0.4	1.07e-10	Red blood cell count;
KIRP	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg23649088	chr2:200775458	C2orf69	-0.59	-5.02	-0.3	9.91e-7	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg20965017	chr5:231967	SDHA	-0.46	-5.19	-0.31	4.41e-7	Breast cancer;
KIRP	cis	rs812925	0.502	rs2084318	chr2:61652601	C/T	cg15711740	chr2:61764176	XPO1	0.46	5.87	0.35	1.39e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7106204	0.609	rs12788438	chr11:24284068	G/T	ch.11.24196551F	chr11:24239977	NA	0.69	5.39	0.33	1.64e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7771547	0.605	rs659726	chr6:36467791	C/G	cg07856975	chr6:36356162	ETV7	0.36	5.19	0.31	4.36e-7	Platelet distribution width;
KIRP	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.29	0.62	2.25e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.97	-0.64	1.18e-29	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-8.94	-0.5	9.2e-17	Retinal vascular caliber;
KIRP	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.17	-0.37	2.84e-9	Response to antipsychotic treatment;
KIRP	cis	rs273573	0.643	rs10767879	chr11:30874669	C/T	cg14844989	chr11:31128820	NA	0.34	4.88	0.3	1.92e-6	Total body bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08907819	chr7:70255804	AUTS2	0.48	6.16	0.37	2.89e-9	Interleukin-4 levels;
KIRP	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.67	-5.18	-0.31	4.68e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg00262122	chr8:11665843	FDFT1	0.41	5.16	0.31	5.06e-7	Neuroticism;
KIRP	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg18209359	chr17:80159595	CCDC57	0.36	4.91	0.3	1.69e-6	Life satisfaction;
KIRP	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.51	-0.62	3.91e-28	Chronic sinus infection;
KIRP	cis	rs5753618	0.561	rs4820043	chr22:31647094	A/G	cg02404636	chr22:31891804	SFI1	-0.47	-5.16	-0.31	5.02e-7	Colorectal cancer;
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.68	0.34	3.7e-8	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26480413	chr15:90233593	WDR93;PEX11A	0.44	6.5	0.38	4.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg01864069	chr14:103024347	NA	-0.97	-13.01	-0.64	8.43e-30	Platelet count;
KIRP	cis	rs3892630	0.558	rs4588103	chr19:33352770	G/A	cg22980127	chr19:33182716	NUDT19	0.98	10.02	0.54	4.87e-20	Red blood cell traits;
KIRP	trans	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.83	9.93	0.53	9.49e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-1.01	-19.52	-0.78	6.54e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg06565975	chr8:143823917	SLURP1	0.47	7.39	0.43	2.23e-12	Urinary tract infection frequency;
KIRP	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.91	7.68	0.44	3.65e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg26769984	chr7:1090371	C7orf50	0.67	5.86	0.35	1.45e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg21775007	chr8:11205619	TDH	0.43	5.62	0.34	5.27e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2033711	0.905	rs893186	chr19:58969179	C/A	cg26874164	chr19:58962979	ZNF324B	0.46	5.35	0.32	2.04e-7	Uric acid clearance;
KIRP	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	1.04	14.46	0.68	1.05e-34	Menopause (age at onset);
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	0.81	7.18	0.42	8.19e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7923609	1.000	rs4400684	chr10:65012687	A/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.67	-0.34	4.04e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg04691961	chr3:161091175	C3orf57	-0.4	-5.4	-0.33	1.59e-7	Educational attainment (years of education);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14347670	chr6:41908995	CCND3	0.59	7.01	0.41	2.32e-11	Smoking initiation;
KIRP	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg15117754	chr3:10150083	C3orf24	0.54	5.06	0.31	8.26e-7	Alzheimer's disease;
KIRP	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg08807101	chr21:30365312	RNF160	-0.55	-5.42	-0.33	1.43e-7	Cognitive test performance;
KIRP	cis	rs4959270	0.874	rs4311550	chr6:451925	A/G	cg13299325	chr6:447777	NA	-0.26	-5.13	-0.31	5.88e-7	Limited cutaneous systemic scleroderma;
KIRP	cis	rs7809615	0.901	rs10226310	chr7:99118320	G/A	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite ratios;
KIRP	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg05526886	chr2:227700861	RHBDD1	0.45	5.43	0.33	1.35e-7	Pulmonary function;
KIRP	trans	rs7980799	0.905	rs4244866	chr12:33511983	G/C	cg26384229	chr12:38710491	ALG10B	-0.53	-6.43	-0.38	6.6e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg00334542	chr7:100209784	MOSPD3	-0.58	-5.53	-0.33	8.21e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg15839431	chr19:19639596	YJEFN3	-0.5	-5.25	-0.32	3.22e-7	Bipolar disorder;
KIRP	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.58	0.52	1.1e-18	Corneal astigmatism;
KIRP	cis	rs1982963	0.639	rs2749875	chr14:52503396	G/A	cg10843707	chr14:52510701	NID2	-0.32	-5.58	-0.33	6.45e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13132184	0.507	rs13118113	chr4:38035396	A/G	cg14409701	chr4:38048871	TBC1D1	-0.79	-7.61	-0.44	5.78e-13	Verbal declarative memory;
KIRP	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	0.92	12.03	0.61	1.55e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg14664628	chr15:75095509	CSK	0.45	5.63	0.34	4.8e-8	Caffeine consumption;
KIRP	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.54	-7.07	-0.41	1.63e-11	Alcohol dependence;
KIRP	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg26149184	chr10:133730230	NA	0.42	4.98	0.3	1.21e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs17301259	0.524	rs3890882	chr7:88405722	C/T	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.3	-4.92	-0.3	1.57e-6	Heschl's gyrus morphology;
KIRP	trans	rs1864585	0.520	rs11995539	chr8:10659850	C/T	cg26278703	chr11:58910052	FAM111A	0.64	6.5	0.38	4.31e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg14703610	chr5:56206110	C5orf35	0.45	5.87	0.35	1.37e-8	Coronary artery disease;
KIRP	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg00094735	chr5:1949198	NA	0.45	5.44	0.33	1.3e-7	Gut microbiome composition (winter);
KIRP	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg24315340	chr6:146058215	EPM2A	0.44	5.59	0.34	6.15e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg03315344	chr16:75512273	CHST6	-0.56	-5.4	-0.33	1.56e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.83	0.35	1.77e-8	Motion sickness;
KIRP	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	0.72	7.83	0.45	1.5e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg07653901	chr22:50250238	ZBED4	0.47	5.56	0.33	6.85e-8	Schizophrenia;
KIRP	cis	rs960902	0.747	rs7595792	chr2:37729623	T/C	cg25341268	chr2:37734390	NA	0.63	8.49	0.48	2.03e-15	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.82	-0.49	2.09e-16	Height;
KIRP	cis	rs10981012	0.554	rs4978464	chr9:114581117	C/T	cg14428669	chr9:114659192	UGCG	-0.47	-5.06	-0.31	8.23e-7	Coronary artery disease;
KIRP	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs12496230	0.794	rs7645370	chr3:66862893	T/G	cg04995300	chr3:66848608	NA	0.44	6.81	0.4	7.28e-11	Type 2 diabetes;
KIRP	cis	rs2213920	0.569	rs6478170	chr9:118246331	G/A	cg13918206	chr9:118159781	DEC1	1.01	10.09	0.54	2.97e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.83	15.52	0.7	2.44e-38	Anterior chamber depth;
KIRP	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.79	11.21	0.58	7.97e-24	Mood instability;
KIRP	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	13.18	0.64	2.28e-30	Platelet count;
KIRP	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	0.83	12.49	0.62	4.86e-28	Body mass index;
KIRP	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-10.87	-0.57	9.85e-23	Exhaled nitric oxide output;
KIRP	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.46	9.5	0.52	2.02e-18	Schizophrenia;
KIRP	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs6467136	0.765	rs11767380	chr7:127209302	T/C	cg08586737	chr7:127225949	GCC1	-0.38	-4.86	-0.3	2.1e-6	Type 2 diabetes;
KIRP	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.76	-10.82	-0.57	1.44e-22	Waist circumference;Body mass index;
KIRP	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg21605333	chr4:119757512	SEC24D	1.13	8.43	0.47	3.01e-15	Cannabis dependence symptom count;
KIRP	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	6.69	0.39	1.5e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.99	0.45	5.12e-14	Iron status biomarkers;
KIRP	cis	rs17123764	0.605	rs7967624	chr12:50159519	A/C	cg20471783	chr12:50157085	TMBIM6	0.32	5.01	0.3	1.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.52	-7.52	-0.43	1.01e-12	Daytime sleep phenotypes;
KIRP	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.9	-10.89	-0.57	8.71e-23	Response to antipsychotic treatment;
KIRP	cis	rs9815354	0.767	rs73071337	chr3:41822518	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4006360	0.629	rs7214220	chr17:39236627	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.67	-9.37	-0.51	4.83e-18	Bipolar disorder and schizophrenia;
KIRP	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25517755	chr10:38738941	LOC399744	-0.39	-5.53	-0.33	7.99e-8	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06634786	chr22:41940651	POLR3H	0.46	5.13	0.31	5.92e-7	Vitiligo;
KIRP	cis	rs1832871	0.711	rs62439861	chr6:158700531	A/G	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs4356932	1.000	rs4359937	chr4:76972155	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.12	0.31	6.24e-7	Blood protein levels;
KIRP	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.69	-7.81	-0.45	1.64e-13	Lung cancer;
KIRP	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg17554472	chr22:41940697	POLR3H	0.44	5.24	0.32	3.4e-7	Vitiligo;
KIRP	cis	rs17286411	0.806	rs56309616	chr16:71862448	A/G	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.21	-0.32	3.97e-7	Blood protein levels;
KIRP	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg03571507	chr19:53239146	ZNF611	0.22	5.48	0.33	1.03e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.65	-0.34	4.4e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.63	0.52	8.08e-19	Bipolar disorder;
KIRP	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.83	-12.5	-0.62	4.41e-28	Body mass index;
KIRP	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg14343924	chr8:8086146	FLJ10661	0.49	5.56	0.33	6.98e-8	Mood instability;
KIRP	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.66	8.62	0.48	8.39e-16	Schizophrenia;
KIRP	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.58	8.19	0.46	1.43e-14	Longevity;Endometriosis;
KIRP	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.4	-5.16	-0.31	5.17e-7	IgG glycosylation;
KIRP	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg01879757	chr17:41196368	BRCA1	-0.78	-10.94	-0.57	5.77e-23	Menopause (age at onset);
KIRP	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg19731401	chr7:2775893	GNA12	0.68	6.43	0.38	6.56e-10	Childhood ear infection;
KIRP	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg14541582	chr5:601475	NA	-0.53	-5.67	-0.34	3.94e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-5.63	-0.34	4.92e-8	Neuroticism;
KIRP	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.86	9.81	0.53	2.19e-19	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12659159	chr3:197463876	KIAA0226	0.55	6.9	0.4	4.35e-11	Parkinson's disease;
KIRP	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.83	8.59	0.48	1.02e-15	Cerebrospinal P-tau181p levels;
KIRP	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg03929089	chr4:120376271	NA	0.97	6.95	0.41	3.17e-11	Myopia (pathological);
KIRP	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.53	-7.11	-0.41	1.27e-11	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs12496230	0.794	rs7645370	chr3:66862893	T/G	cg17646820	chr3:66848679	NA	0.4	6.62	0.39	2.27e-10	Type 2 diabetes;
KIRP	cis	rs17221829	0.710	rs12421890	chr11:89391799	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.75	9.21	0.51	1.45e-17	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs6910061	1.000	rs6456868	chr6:11115183	G/A	cg27233058	chr6:11094804	LOC221710	0.56	5.76	0.34	2.49e-8	Diabetic kidney disease;
KIRP	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.34	-4.85	-0.3	2.16e-6	Monocyte count;
KIRP	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.51	6.99	0.41	2.62e-11	Gout;
KIRP	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg11941060	chr3:133502564	NA	-0.39	-5.17	-0.31	4.85e-7	Iron status biomarkers;
KIRP	cis	rs2404602	0.735	rs4886800	chr15:76678692	A/G	cg23625390	chr15:77176239	SCAPER	-0.61	-8.01	-0.45	4.65e-14	Blood metabolite levels;
KIRP	cis	rs4073416	0.595	rs10131715	chr14:66157373	T/C	cg03016385	chr14:66212404	NA	-0.41	-5.27	-0.32	2.98e-7	N-glycan levels;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg25319279	chr11:5960081	NA	-0.57	-5.93	-0.35	1.03e-8	DNA methylation (variation);
KIRP	cis	rs9914544	1.000	rs1634409	chr17:18836177	C/T	cg26378065	chr17:18585709	ZNF286B	0.6	7.24	0.42	5.79e-12	Educational attainment (years of education);
KIRP	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Corneal astigmatism;
KIRP	cis	rs4936894	0.519	rs3905280	chr11:124149820	A/C	cg27160556	chr11:124181099	OR8D1	-0.38	-5.66	-0.34	4.25e-8	Aging (time to death);
KIRP	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.23	-0.51	1.26e-17	Bone mineral density;
KIRP	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg20542592	chr8:11973495	FAM66D	0.4	4.99	0.3	1.14e-6	Neuroticism;
KIRP	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.46	0.68	1.07e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15851274	chr15:75748063	SIN3A	0.5	6.78	0.4	8.72e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.71	-6.89	-0.4	4.73e-11	Ulcerative colitis;
KIRP	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	4.93	0.3	1.49e-6	Renal cell carcinoma;
KIRP	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg18944383	chr4:111397179	ENPEP	0.64	10.71	0.56	3.16e-22	Coronary artery disease;
KIRP	cis	rs10121009	0.635	rs10972430	chr9:35323238	A/G	cg15271616	chr9:35490515	RUSC2	0.4	5.3	0.32	2.51e-7	Parkinson's disease;
KIRP	cis	rs12476592	0.602	rs262479	chr2:63872479	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.04	-0.31	9.19e-7	Childhood ear infection;
KIRP	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.71	0.39	1.35e-10	Retinal vascular caliber;
KIRP	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.71	11.05	0.58	2.56e-23	Resting heart rate;
KIRP	cis	rs7116495	1.000	rs2511116	chr11:71802160	G/A	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg08975724	chr8:8085496	FLJ10661	-0.73	-10.66	-0.56	4.58e-22	Neuroticism;
KIRP	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg16049864	chr8:95962084	TP53INP1	-0.37	-5.96	-0.35	8.91e-9	Type 2 diabetes;
KIRP	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.57	6.16	0.37	2.91e-9	Type 2 diabetes;
KIRP	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.45	-0.43	1.62e-12	Bipolar disorder;
KIRP	cis	rs1978968	0.707	rs13058527	chr22:18412929	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-7.57	-0.43	7.57e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs4285214	0.715	rs12515071	chr5:124031011	C/T	cg15082166	chr5:124005151	ZNF608	0.42	5.22	0.32	3.88e-7	Survival in pancreatic cancer;
KIRP	cis	rs12643440	0.538	rs4698538	chr4:17150001	T/G	cg22650099	chr4:17144496	NA	-0.73	-8.66	-0.48	6.22e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.89	12.48	0.62	5.25e-28	Coronary artery disease;
KIRP	cis	rs11800820	0.605	rs1890158	chr1:246687278	G/A	cg16700716	chr1:246684329	NA	-0.52	-5.44	-0.33	1.27e-7	Obesity-related traits;
KIRP	cis	rs9826463	0.582	rs11719737	chr3:142164017	A/G	cg20824294	chr3:142316082	PLS1	0.41	6.22	0.37	2.09e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7236492	0.572	rs7244366	chr18:77179746	C/T	cg15644404	chr18:77186268	NFATC1	-1.01	-6.48	-0.38	4.95e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg02336718	chr17:17403227	NA	-0.32	-4.85	-0.3	2.24e-6	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07156959	chr12:121975669	KDM2B	0.49	6.66	0.39	1.74e-10	Survival in pancreatic cancer;
KIRP	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.87	14.41	0.68	1.47e-34	Multiple myeloma;
KIRP	cis	rs400736	0.671	rs2131630	chr1:7990367	G/A	cg25007680	chr1:8021821	PARK7	-0.51	-6.97	-0.41	2.9e-11	Response to antidepressants and depression;
KIRP	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.43	0.43	1.77e-12	Neuroticism;
KIRP	cis	rs28489187	0.683	rs6704103	chr1:85868657	C/A	cg16011679	chr1:85725395	C1orf52	-0.5	-6.11	-0.36	3.82e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg08461772	chr7:95026248	PON3	0.41	5.82	0.35	1.78e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs9948	1.000	rs12172	chr2:97500852	C/G	cg20312557	chr2:97357134	FER1L5	-0.75	-5.44	-0.33	1.31e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs12043259	0.730	rs11801063	chr1:204809143	T/C	cg11485465	chr5:54518469	NA	0.34	6.07	0.36	4.75e-9	Addiction;
KIRP	cis	rs17253792	0.545	rs35230683	chr14:56012493	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.77	5.06	0.31	8.12e-7	Putamen volume;
KIRP	cis	rs9826463	1.000	rs2177397	chr3:142343980	C/T	cg20824294	chr3:142316082	PLS1	-0.31	-5.51	-0.33	9.23e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.86	-0.53	1.55e-19	Height;
KIRP	cis	rs2224391	0.518	rs11757927	chr6:5282573	A/C	cg24031505	chr6:4779396	CDYL	0.62	4.95	0.3	1.39e-6	Height;
KIRP	cis	rs6838801	0.630	rs6853053	chr4:77489645	A/G	cg17476223	chr4:77663285	SHROOM3	0.42	5.22	0.32	3.82e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg07636037	chr3:49044803	WDR6	-0.58	-5.43	-0.33	1.34e-7	Menarche (age at onset);
KIRP	cis	rs3126085	0.935	rs4511111	chr1:152211624	C/G	cg26876637	chr1:152193138	HRNR	-0.86	-8.85	-0.49	1.76e-16	Atopic dermatitis;
KIRP	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03996677	chr3:167817329	NA	0.4	6.55	0.39	3.38e-10	C-reactive protein;
KIRP	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	16.05	0.72	3.66e-40	Homoarginine levels;
KIRP	cis	rs6733011	0.628	rs4263159	chr2:99456151	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-6.01	-0.36	6.78e-9	Bipolar disorder;
KIRP	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.34	-6.9	-0.4	4.29e-11	Diastolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27525876	chr16:89294245	ZNF778	-0.45	-6.56	-0.39	3.1e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg04025307	chr7:1156635	C7orf50	0.55	8.09	0.46	2.78e-14	Longevity;Endometriosis;
KIRP	cis	rs9972944	0.729	rs1421033	chr17:63766714	A/C	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.62	8.42	0.47	3.18e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.3	-0.47	6.89e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg17554472	chr22:41940697	POLR3H	-0.5	-5.61	-0.34	5.34e-8	Neuroticism;
KIRP	cis	rs2448490	0.642	rs507859	chr11:65471982	G/A	cg11569703	chr11:65557185	OVOL1	-0.35	-5.63	-0.34	4.79e-8	Platelet count;
KIRP	cis	rs7178909	0.872	rs3931863	chr15:90433913	T/G	cg19708238	chr15:90437601	AP3S2	0.57	7.82	0.45	1.59e-13	Common traits (Other);
KIRP	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.41	-0.33	1.47e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg27205649	chr11:78285834	NARS2	0.62	8.05	0.46	3.61e-14	Alzheimer's disease (survival time);
KIRP	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.83	9.97	0.54	6.87e-20	Corneal astigmatism;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg16590910	chr6:42928470	GNMT	0.44	6.39	0.38	8.27e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg07827796	chr19:33622959	WDR88	0.53	7.07	0.41	1.59e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.19e-7	Life satisfaction;
KIRP	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg17294928	chr15:75287854	SCAMP5	-0.65	-5.61	-0.34	5.34e-8	Lung cancer;
KIRP	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	5.72	0.34	3.11e-8	Total body bone mineral density;
KIRP	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.18	-0.37	2.65e-9	Schizophrenia;
KIRP	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg03959625	chr15:84868606	LOC388152	0.52	6.24	0.37	1.95e-9	Schizophrenia;
KIRP	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25722142	chr6:139695762	CITED2	0.54	6.25	0.37	1.78e-9	Smoking initiation;
KIRP	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.2	-0.42	7.13e-12	Type 2 diabetes;
KIRP	cis	rs4302748	0.862	rs11980735	chr7:36183683	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.7	-7.75	-0.44	2.38e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.52	6.62	0.39	2.25e-10	Blood protein levels;
KIRP	cis	rs7601312	0.903	rs6436789	chr2:229291543	G/A	cg02542817	chr2:229291442	NA	-0.54	-8.35	-0.47	4.84e-15	Schizophrenia;
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.21	-22.62	-0.82	5.03e-62	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.62	6.19	0.37	2.54e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg11569703	chr11:65557185	OVOL1	-0.48	-8.57	-0.48	1.18e-15	Acne (severe);
KIRP	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.47	7.23	0.42	6.02e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs35079168	0.923	rs12115573	chr9:137288782	G/A	cg13941235	chr9:137270186	RXRA	-0.24	-5.16	-0.31	5.02e-7	Intelligence;
KIRP	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-6.9	-0.4	4.31e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg16586182	chr3:47516702	SCAP	0.82	11.65	0.6	2.96e-25	Colorectal cancer;
KIRP	cis	rs3755132	0.929	rs2302935	chr2:15753482	C/G	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs6740322	0.748	rs6544635	chr2:43486704	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.84	-11.33	-0.59	3.22e-24	Coronary artery disease;
KIRP	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.69	-12.52	-0.62	3.61e-28	White blood cell count (basophil);
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.58	-6.46	-0.38	5.69e-10	Obesity-related traits;
KIRP	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.78	11.25	0.58	6.03e-24	Blood metabolite ratios;
KIRP	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.4	0.62	9.35e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg02415014	chr8:143852576	LYNX1	-0.31	-5.07	-0.31	7.74e-7	Urinary tract infection frequency;
KIRP	cis	rs8014252	0.803	rs56328037	chr14:71045341	A/C	cg11204974	chr14:71022665	NA	-0.73	-7.13	-0.41	1.09e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg03609598	chr5:56110824	MAP3K1	-0.42	-4.94	-0.3	1.41e-6	Coronary artery disease;
KIRP	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg13010199	chr12:38710504	ALG10B	0.62	7.86	0.45	1.2e-13	Morning vs. evening chronotype;
KIRP	cis	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg19680485	chr15:31195859	MTMR15	-0.52	-4.95	-0.3	1.37e-6	Hypertriglyceridemia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09235385	chr13:114825451	RASA3	0.48	6.21	0.37	2.19e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs1079204	1.000	rs1017697	chr2:219170462	C/T	cg05728596	chr2:219128475	GPBAR1	0.72	5.4	0.33	1.58e-7	Smooth-surface caries;
KIRP	cis	rs5770917	1.000	rs1056964	chr22:51017476	A/G	cg25309564	chr22:51001381	C22orf41	0.74	5.17	0.31	4.9e-7	Narcolepsy;
KIRP	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg03060546	chr3:49711283	APEH	0.43	5.43	0.33	1.38e-7	Parkinson's disease;
KIRP	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.51	7.22	0.42	6.37e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg00689492	chr4:1303491	MAEA	0.29	5.22	0.32	3.87e-7	Longevity;
KIRP	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.32	1.66e-7	Aortic root size;
KIRP	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg02640540	chr1:67518911	SLC35D1	-0.41	-4.96	-0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg22643751	chr7:855365	UNC84A	-0.36	-5.21	-0.32	3.92e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs2742417	0.904	rs2373047	chr3:45747497	C/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg05721485	chr17:44071124	MAPT	-0.55	-7.56	-0.43	8.12e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs17742757	0.522	rs899364	chr8:11329544	G/T	cg21775007	chr8:11205619	TDH	-0.44	-5.33	-0.32	2.18e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg19743168	chr1:23544995	NA	0.52	7.29	0.42	4.27e-12	Height;
KIRP	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg24488311	chr11:68621650	NA	0.48	5.7	0.34	3.36e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg08822215	chr16:89438651	ANKRD11	-0.43	-5.85	-0.35	1.59e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs1050631	0.592	rs1632169	chr18:33709762	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.48	6.12	0.36	3.73e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.44	6.23	0.37	2.05e-9	Testicular germ cell tumor;
KIRP	trans	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.28	-0.51	9.06e-18	Triglycerides;
KIRP	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17376030	chr22:41985996	PMM1	0.71	7.59	0.44	6.55e-13	Vitiligo;
KIRP	cis	rs2380205	0.689	rs12779398	chr10:5896625	G/T	cg27141509	chr10:5886111	NA	-0.42	-5.82	-0.35	1.78e-8	Breast cancer;
KIRP	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.77	-0.49	3.01e-16	Neuroticism;
KIRP	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.64	-9.1	-0.5	3.23e-17	Schizophrenia;
KIRP	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2535633	0.631	rs2710313	chr3:52969529	T/A	cg11645453	chr3:52864694	ITIH4	-0.35	-5.39	-0.32	1.66e-7	Body mass index;
KIRP	cis	rs6453429	0.720	rs626105	chr5:78369901	A/G	cg06501366	chr5:78365687	BHMT2;DMGDH	-0.34	-5.96	-0.36	8.49e-9	Urinary metabolites;
KIRP	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	5.06	0.31	8.18e-7	Menarche (age at onset);
KIRP	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.33	0.37	1.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.79	-11.74	-0.6	1.45e-25	Obesity-related traits;
KIRP	cis	rs4950322	0.543	rs4568882	chr1:146788598	T/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg09936142	chr19:10668400	KRI1	-0.42	-4.9	-0.3	1.71e-6	Inflammatory skin disease;
KIRP	trans	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg10756647	chr7:56101905	PSPH	1.02	7.73	0.44	2.72e-13	Diabetic kidney disease;
KIRP	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-0.82	-9.14	-0.5	2.4e-17	Gut microbiome composition (summer);
KIRP	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.76	-0.44	2.32e-13	Lung cancer;
KIRP	cis	rs2481665	0.510	rs2481676	chr1:62627675	C/T	cg18591186	chr1:62594603	INADL	-0.67	-10.43	-0.55	2.47e-21	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs490234	0.783	rs10119855	chr9:128271123	A/T	cg14078157	chr9:128172775	NA	-0.58	-6.84	-0.4	6.2e-11	Mean arterial pressure;
KIRP	cis	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.0	-0.3	1.09e-6	Cervical cancer;
KIRP	cis	rs6988636	0.792	rs62521803	chr8:124152970	A/C	cg22384356	chr8:124195192	FAM83A	-0.54	-4.89	-0.3	1.82e-6	Urinary uromodulin levels;
KIRP	cis	rs834603	0.547	rs1704966	chr7:47469948	G/A	cg09696706	chr7:47479511	TNS3	0.43	5.01	0.3	1.04e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.55	-7.36	-0.42	2.83e-12	Morning vs. evening chronotype;
KIRP	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.54	-6.2	-0.37	2.43e-9	Blood metabolite levels;
KIRP	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.1e-14	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg08619932	chr19:49200058	FUT2	0.35	5.25	0.32	3.32e-7	Dietary macronutrient intake;
KIRP	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.43	-5.08	-0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	0.97	12.93	0.64	1.55e-29	Menopause (age at onset);
KIRP	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg00204512	chr16:28754710	NA	0.43	5.69	0.34	3.67e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.65	8.99	0.5	6.75e-17	Blood protein levels;
KIRP	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.88	-11.51	-0.59	8.54e-25	Cognitive function;
KIRP	trans	rs12517041	0.872	rs1896723	chr5:23303194	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs6753739	0.871	rs6436114	chr2:220002834	A/C	cg01749213	chr2:219906749	CCDC108	0.43	5.4	0.33	1.55e-7	Height;
KIRP	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06481639	chr22:41940642	POLR3H	0.65	7.03	0.41	2.05e-11	Vitiligo;
KIRP	cis	rs1816752	0.783	rs7317439	chr13:24985077	A/T	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07341141	chr7:102098004	ALKBH4	0.46	6.13	0.36	3.49e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg16898833	chr6:26189333	HIST1H4D	0.72	5.13	0.31	5.76e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg25554036	chr4:6271136	WFS1	0.4	5.67	0.34	3.93e-8	Cisplatin-induced ototoxicity;
KIRP	cis	rs4409675	1.000	rs11247726	chr1:28260180	A/G	cg23691781	chr1:28212827	C1orf38	-0.34	-7.3	-0.42	3.98e-12	Corneal astigmatism;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg13453750	chr1:205783389	SLC41A1	-0.46	-7.13	-0.41	1.09e-11	Menarche (age at onset);
KIRP	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	-0.76	-9.75	-0.53	3.44e-19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg27121462	chr16:89883253	FANCA	0.49	6.1	0.36	4.08e-9	Vitiligo;
KIRP	cis	rs3755132	0.929	rs6431717	chr2:15740570	C/T	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	trans	rs763014	0.931	rs1981483	chr16:630665	G/A	cg00950418	chr7:105029125	SRPK2	-0.52	-6.46	-0.38	5.47e-10	Height;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.33	0.47	5.68e-15	Electroencephalogram traits;
KIRP	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.43	5.92	0.35	1.06e-8	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.92	12.51	0.62	4.12e-28	Menopause (age at onset);
KIRP	cis	rs4711336	1.000	rs2296742	chr6:33659793	G/A	cg15676125	chr6:33679581	C6orf125	0.41	5.5	0.33	9.33e-8	Height;
KIRP	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.84	8.99	0.5	6.56e-17	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.73	9.46	0.52	2.55e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg13160058	chr8:26243215	BNIP3L	-0.47	-7.02	-0.41	2.15e-11	Red cell distribution width;
KIRP	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.79	-0.35	2.19e-8	Electroencephalogram traits;
KIRP	cis	rs1555895	0.622	rs7703	chr10:858394	C/T	cg10017260	chr10:834428	NA	-0.38	-5.54	-0.33	7.81e-8	Survival in rectal cancer;
KIRP	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.91	15.74	0.71	4.27e-39	Headache;
KIRP	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.61	7.86	0.45	1.2e-13	Height;
KIRP	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs587242	1.000	rs7543590	chr1:96892216	T/C	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-5.75	-0.34	2.68e-8	Body mass index;
KIRP	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	13.67	0.66	4.84e-32	Electrocardiographic conduction measures;
KIRP	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Bipolar disorder;
KIRP	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.45	5.86	0.35	1.48e-8	Longevity;Endometriosis;
KIRP	cis	rs2839627	0.561	rs6586248	chr21:44257812	C/T	cg03543861	chr21:44258195	NA	0.53	6.15	0.37	3.1e-9	Information processing speed;
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02475777	chr4:1388615	CRIPAK	0.42	5.63	0.34	4.9e-8	Obesity-related traits;
KIRP	cis	rs754466	0.561	rs72806025	chr10:79707026	C/T	cg17075019	chr10:79541650	NA	-0.72	-5.69	-0.34	3.51e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7945071	0.515	rs6589128	chr11:110231723	A/G	cg04157658	chr11:110243994	NA	0.35	5.03	0.31	9.5e-7	Cognitive function;
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-1.04	-20.44	-0.79	6.04e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4908768	0.906	rs55858268	chr1:8554696	C/T	cg03610117	chr1:8450231	RERE	-0.48	-5.2	-0.31	4.18e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs1546924	0.570	rs197419	chr1:112315450	G/T	cg23955903	chr1:112298873	DDX20;C1orf183	-0.44	-5.43	-0.33	1.38e-7	Body mass index;
KIRP	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.92	10.5	0.56	1.46e-21	Triglycerides;
KIRP	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.64	8.61	0.48	8.81e-16	Total body bone mineral density;
KIRP	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg15162869	chr22:32027605	PISD	-0.72	-4.86	-0.3	2.12e-6	Age-related hearing impairment;
KIRP	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs9905704	0.681	rs4793948	chr17:56562062	G/A	cg12560992	chr17:57184187	TRIM37	-0.53	-5.03	-0.31	9.48e-7	Testicular germ cell tumor;
KIRP	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg09117114	chr16:67998030	SLC12A4	-0.5	-5.17	-0.31	4.81e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg16396542	chr1:89473148	GBP3	0.4	5.49	0.33	9.82e-8	Carotid intima media thickness;
KIRP	cis	rs4776059	0.876	rs2414163	chr15:52897478	T/C	cg22715398	chr15:52968154	KIAA1370	-0.66	-8.1	-0.46	2.62e-14	Schizophrenia;
KIRP	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.61	0.44	5.99e-13	Obesity-related traits;
KIRP	trans	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs16828019	0.929	rs10524	chr1:41726473	T/C	cg03387723	chr1:41708464	SCMH1	-0.77	-6.8	-0.4	7.68e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs4523957	0.928	rs12949991	chr17:2197185	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.31	0.47	6.45e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.93	-0.4	3.67e-11	Eye color traits;
KIRP	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-5.24	-0.32	3.46e-7	Blood metabolite levels;
KIRP	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	1.05	20.44	0.79	5.89e-55	Breast cancer;
KIRP	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg00204512	chr16:28754710	NA	0.46	5.91	0.35	1.14e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.56	8.02	0.46	4.24e-14	Bone mineral density;
KIRP	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg03468072	chr12:39539422	NA	0.38	5.65	0.34	4.4e-8	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.26e-18	Bladder cancer;
KIRP	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.76	-0.4	9.87e-11	Superior crus of antihelix expression;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13713052	chr3:122102218	FAM162A;CCDC58	0.56	6.74	0.39	1.13e-10	Smoking initiation;
KIRP	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg08662619	chr6:150070041	PCMT1	0.37	5.97	0.36	8.37e-9	Lung cancer;
KIRP	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs7084402	0.967	rs1649060	chr10:60310480	C/G	cg05938607	chr10:60274200	BICC1	0.38	9.15	0.5	2.29e-17	Refractive error;
KIRP	cis	rs4363506	0.625	rs10765116	chr10:129284869	T/C	cg07804728	chr10:129284050	NA	0.42	5.78	0.35	2.25e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00255919	chr5:131827918	IRF1	0.27	5.73	0.34	3e-8	Asthma (sex interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04421424	chr19:57791681	ZNF460	0.54	6.33	0.37	1.13e-9	Smoking initiation;
KIRP	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg07511934	chr16:89386912	ANKRD11	0.41	5.05	0.31	8.57e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg10326726	chr10:51549505	MSMB	-0.61	-8.96	-0.5	8.13e-17	Prostate-specific antigen levels;
KIRP	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.53	-0.43	9.91e-13	Response to antipsychotic treatment;
KIRP	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.61	7.1	0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg17366294	chr4:99064904	C4orf37	0.38	5.06	0.31	8.07e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.92	10.53	0.56	1.2e-21	Corneal astigmatism;
KIRP	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg07511934	chr16:89386912	ANKRD11	0.4	5.09	0.31	7.09e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg04132472	chr17:19861366	AKAP10	0.39	5.02	0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.78	6.79	0.4	8.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14937228	chr10:14562035	FAM107B	0.47	6.03	0.36	5.98e-9	Interleukin-4 levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg25018755	chr22:43506952	BIK	0.47	6.91	0.4	4.14e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1978968	0.763	rs5992943	chr22:18465756	A/C	cg02610425	chr22:18483192	MICAL3	0.38	5.31	0.32	2.4e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06647332	chr5:131281008	NA	-0.45	-4.92	-0.3	1.58e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.83	-0.57	1.33e-22	Height;
KIRP	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg16141378	chr3:129829833	LOC729375	-0.47	-6.06	-0.36	5.01e-9	Triglycerides;
KIRP	cis	rs7005380	0.581	rs7005888	chr8:120931611	C/T	cg21645572	chr8:120931649	DEPDC6	0.48	6.71	0.39	1.34e-10	Interstitial lung disease;
KIRP	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.85	-0.35	1.53e-8	Diastolic blood pressure;
KIRP	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.78	-0.35	2.26e-8	Educational attainment;
KIRP	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.22	-0.7	2.51e-37	Chronic sinus infection;
KIRP	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg27205649	chr11:78285834	NARS2	0.68	9.16	0.5	2.04e-17	Alzheimer's disease (survival time);
KIRP	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	12.31	0.62	1.88e-27	Smoking behavior;
KIRP	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.72	-0.34	3.13e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	5.87	0.35	1.44e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2071403	0.799	rs11211643	chr2:1402588	A/G	cg06500727	chr2:1417164	TPO	0.46	6.96	0.41	3.11e-11	Thyroid peroxidase antibody positivity;
KIRP	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.06	-0.5	4.22e-17	Chronic sinus infection;
KIRP	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg23950597	chr19:37808831	NA	-0.68	-6.02	-0.36	6.23e-9	Coronary artery calcification;
KIRP	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.69	10.01	0.54	5.42e-20	Retinal vascular caliber;
KIRP	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg10018233	chr7:150070692	REPIN1	0.63	7.38	0.43	2.39e-12	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs4356932	0.935	rs4380549	chr4:76979082	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs17384381	0.953	rs12139958	chr1:85842112	A/G	cg16011679	chr1:85725395	C1orf52	0.84	8.39	0.47	3.93e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.38	-5.77	-0.35	2.34e-8	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg15131784	chr3:139108705	COPB2	0.37	4.9	0.3	1.74e-6	Obesity-related traits;
KIRP	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg21695830	chr1:89457462	RBMXL1;CCBL2	0.36	4.9	0.3	1.77e-6	Carotid intima media thickness;
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.62	9.45	0.52	2.72e-18	Lung cancer;
KIRP	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-8.69	-0.48	5.32e-16	Platelet count;
KIRP	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg12591125	chr7:1885375	MAD1L1	0.58	5.68	0.34	3.85e-8	Bipolar disorder;
KIRP	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3105593	1.000	rs3131587	chr15:50845101	T/G	cg05456662	chr15:50716270	USP8	0.42	5.25	0.32	3.31e-7	QT interval;
KIRP	cis	rs7534824	0.625	rs12563134	chr1:101468558	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.89	-7.03	-0.41	2.08e-11	Refractive astigmatism;
KIRP	cis	rs10861342	1.000	rs10861358	chr12:105559563	G/A	cg23923672	chr12:105501055	KIAA1033	0.86	8.57	0.48	1.17e-15	IgG glycosylation;
KIRP	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.84e-11	Hypertriglyceridemia;
KIRP	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.68	-10.12	-0.54	2.29e-20	Dupuytren's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08422456	chr4:88720194	IBSP	-0.43	-6.75	-0.4	1.03e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.65	0.52	6.99e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7084402	0.934	rs1158212	chr10:60318276	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-11.15	-0.58	1.21e-23	Refractive error;
KIRP	cis	rs4423214	0.592	rs11234027	chr11:71234107	G/A	cg05163923	chr11:71159392	DHCR7	-0.72	-6.99	-0.41	2.52e-11	Vitamin D levels;
KIRP	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.7	9.02	0.5	5.65e-17	Blood metabolite levels;
KIRP	cis	rs13385	0.769	rs72798805	chr5:139568054	C/A	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.41	-6.37	-0.38	9.32e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs815815	0.636	rs815817	chr2:47396558	C/T	cg17724938	chr2:46727096	NA	-0.42	-5.05	-0.31	8.59e-7	Dialysis-related mortality;
KIRP	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.78e-11	Gut microbiome composition (summer);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21194723	chr11:60681294	TMEM109	0.58	6.31	0.37	1.28e-9	Lung cancer in ever smokers;
KIRP	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg03571507	chr19:53239146	ZNF611	0.23	5.64	0.34	4.64e-8	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.89	-9.97	-0.54	7.11e-20	Gut microbiome composition (summer);
KIRP	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	ch.11.42038R	chr11:967971	AP2A2	0.45	5.92	0.35	1.07e-8	Alzheimer's disease (late onset);
KIRP	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.58	6.78	0.4	8.67e-11	Corneal astigmatism;
KIRP	cis	rs4073221	0.585	rs13093950	chr3:18325997	C/T	cg07694806	chr3:18168406	NA	-0.68	-5.91	-0.35	1.12e-8	Parkinson's disease;
KIRP	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg16338278	chr11:67432957	ALDH3B2	0.4	5.09	0.31	7.01e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg27205649	chr11:78285834	NARS2	-0.6	-7.23	-0.42	6.09e-12	Alzheimer's disease (survival time);
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg23693289	chr8:27183097	PTK2B	0.57	7.26	0.42	5.22e-12	Neuroticism;
KIRP	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.6	-7.18	-0.42	7.99e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-11.83	-0.6	7.28e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs2457480	0.733	rs1545845	chr10:44679802	A/C	cg09554077	chr10:44749378	NA	0.51	6.75	0.4	1.08e-10	Coronary artery disease;
KIRP	cis	rs12900413	0.631	rs62023455	chr15:90301999	G/A	cg24650279	chr15:90327240	NA	-0.41	-5.08	-0.31	7.51e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg01097406	chr16:89675127	NA	-0.3	-4.96	-0.3	1.35e-6	Vitiligo;
KIRP	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.58	8.13	0.46	2.12e-14	Lymphocyte counts;
KIRP	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg13939156	chr17:80058883	NA	0.51	5.97	0.36	8.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg08873628	chr1:175162347	KIAA0040	0.44	6.5	0.38	4.31e-10	Alcohol dependence;
KIRP	cis	rs17123764	0.892	rs4641552	chr12:50047182	A/C	cg20471783	chr12:50157085	TMBIM6	-0.39	-5.41	-0.33	1.51e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.97	-0.45	6.05e-14	Systolic blood pressure;
KIRP	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.6	-0.44	6.16e-13	Triglycerides;
KIRP	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg21827317	chr3:136751795	NA	0.37	5.09	0.31	7.1e-7	Neuroticism;
KIRP	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-0.99	-15.27	-0.7	1.73e-37	Dilated cardiomyopathy;
KIRP	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.42	6.24	0.37	1.9e-9	Schizophrenia;
KIRP	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.46	6.36	0.38	9.78e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg00484396	chr16:3507460	NAT15	0.53	5.35	0.32	2.06e-7	Tuberculosis;
KIRP	trans	rs2048656	0.578	rs2090061	chr8:9680978	C/T	cg16141378	chr3:129829833	LOC729375	0.47	6.18	0.37	2.58e-9	Schizophrenia;
KIRP	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.66	7.65	0.44	4.42e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg14703610	chr5:56206110	C5orf35	-0.47	-6.48	-0.38	4.9e-10	Coronary artery disease;
KIRP	cis	rs787274	1.000	rs2185769	chr9:115462594	A/G	cg13803584	chr9:115635662	SNX30	0.61	6.13	0.36	3.48e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-6.7	-0.39	1.41e-10	Morning vs. evening chronotype;
KIRP	cis	rs11583043	0.546	rs6688545	chr1:101590335	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.57	5.63	0.34	4.83e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg03877680	chr5:178157825	ZNF354A	0.95	12.47	0.62	5.51e-28	Neutrophil percentage of white cells;
KIRP	cis	rs6450176	0.904	rs4351101	chr5:53300591	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.46	-0.59	1.19e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.77	8.68	0.48	5.52e-16	Corneal astigmatism;
KIRP	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg09873164	chr1:152488093	CRCT1	0.55	7.08	0.41	1.49e-11	Hair morphology;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg26655764	chr16:89657805	CPNE7	-0.41	-6.03	-0.36	6.04e-9	Bladder cancer;
KIRP	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	6.18	0.37	2.61e-9	Mean platelet volume;
KIRP	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs56161922	1.000	rs72468035	chr1:207812405	C/T	cg09557387	chr1:207818395	CR1L	1.08	6.51	0.38	4.2e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.78	-0.35	2.31e-8	IgG glycosylation;
KIRP	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.63	-8.47	-0.48	2.2e-15	Colorectal cancer;
KIRP	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.76	11.3	0.58	4.04e-24	Monocyte percentage of white cells;
KIRP	cis	rs8038465	0.662	rs12594595	chr15:73986347	A/G	cg15420318	chr15:73925796	NPTN	0.48	5.96	0.35	8.89e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.67	0.39	1.69e-10	Electroencephalogram traits;
KIRP	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.81	11.19	0.58	9.21e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28374715	0.510	rs28468975	chr15:41564592	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.76	-9.61	-0.52	9.2e-19	Ulcerative colitis;
KIRP	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	8.68	0.48	5.49e-16	Resting heart rate;
KIRP	cis	rs986417	1.000	rs1272688	chr14:60920718	T/C	cg27398547	chr14:60952738	C14orf39	-0.74	-7.44	-0.43	1.69e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.18	0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-7.39	-0.43	2.32e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.3	7.28	0.42	4.39e-12	Primary biliary cholangitis;
KIRP	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.43	8.47	0.48	2.31e-15	Coronary artery disease;
KIRP	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.73	10.95	0.57	5.62e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.07	0.36	4.92e-9	Hypertriglyceridemia;
KIRP	cis	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.02	0.75	7.41e-47	Chronic sinus infection;
KIRP	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs501120	0.584	rs545025	chr10:44736544	C/T	cg09554077	chr10:44749378	NA	0.66	7.0	0.41	2.4e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9815354	1.000	rs1717011	chr3:41980199	T/C	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg25173405	chr17:45401733	C17orf57	0.46	6.11	0.36	3.82e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs6601327	0.543	rs11249948	chr8:9648686	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.57	0.39	2.92e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19548283	chr14:58764383	FLJ31306;ARID4A	0.48	6.59	0.39	2.71e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs859767	0.812	rs842355	chr2:135344881	G/C	cg12500956	chr2:135428796	TMEM163	0.38	4.93	0.3	1.54e-6	Neuroticism;
KIRP	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.78	7.81	0.45	1.6e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.55	5.81	0.35	1.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.43	5.54	0.33	7.69e-8	Neutrophil percentage of white cells;
KIRP	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.91	-14.81	-0.69	6.41e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg01428437	chr1:1852164	TMEM52	0.29	5.05	0.31	8.42e-7	Body mass index;
KIRP	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.69	8.99	0.5	6.64e-17	Multiple sclerosis;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg03188948	chr7:1209495	NA	0.49	5.47	0.33	1.09e-7	Longevity;Endometriosis;
KIRP	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	1.06	19.85	0.78	5.41e-53	Height;
KIRP	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-6.75	-0.4	1.07e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.57	8.47	0.48	2.26e-15	Personality dimensions;
KIRP	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.58	-0.39	2.74e-10	Renal cell carcinoma;
KIRP	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.92	14.72	0.68	1.32e-35	Blood protein levels;
KIRP	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg08501292	chr6:25962987	TRIM38	1.05	7.98	0.45	5.54e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.42	-6.94	-0.4	3.44e-11	Type 2 diabetes;
KIRP	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.15	-0.77	1.19e-50	Height;
KIRP	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.58	6.84	0.4	6.13e-11	Height;
KIRP	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.67	-9.29	-0.51	8.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9372498	0.536	rs2356501	chr6:118942371	C/A	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs953387	0.910	rs4954397	chr2:136946433	A/G	cg05194412	chr2:137003533	NA	-0.38	-4.93	-0.3	1.49e-6	Arthritis (juvenile idiopathic);
KIRP	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.41	-4.92	-0.3	1.6e-6	Coronary artery disease;
KIRP	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg13114125	chr14:105738426	BRF1	-0.71	-9.74	-0.53	3.65e-19	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.41	-5.33	-0.32	2.2e-7	Body mass index;
KIRP	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.66	6.21	0.37	2.27e-9	Cognitive function;
KIRP	cis	rs13006833	0.668	rs291466	chr2:191184475	A/G	cg27211696	chr2:191398769	TMEM194B	0.39	5.46	0.33	1.16e-7	Urinary metabolites;
KIRP	cis	rs56079296	1.000	rs3792802	chr5:121403659	G/A	cg05256605	chr5:121412184	LOX	-0.48	-5.67	-0.34	4.09e-8	Coronary artery disease;
KIRP	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02725872	chr8:58115012	NA	-0.78	-7.79	-0.44	1.92e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs654128	0.920	rs339364	chr6:117171919	T/C	cg12892004	chr6:117198278	RFX6	-0.49	-5.47	-0.33	1.09e-7	Telomere length;
KIRP	cis	rs7870753	0.578	rs80024379	chr9:99100250	C/T	cg25260653	chr9:99212216	HABP4	0.53	4.88	0.3	1.87e-6	Height;
KIRP	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.76	-0.4	9.76e-11	Response to antipsychotic treatment;
KIRP	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	1.04	11.09	0.58	1.94e-23	Nonalcoholic fatty liver disease;
KIRP	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.22	14.11	0.67	1.61e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg10760299	chr15:45669010	GATM	0.33	4.85	0.3	2.21e-6	Homoarginine levels;
KIRP	cis	rs3849570	0.643	rs1969433	chr3:81968869	T/C	cg07356753	chr3:81810745	GBE1	-0.55	-7.38	-0.43	2.45e-12	Waist circumference;Body mass index;
KIRP	cis	rs73200209	0.744	rs56350518	chr12:116556775	A/G	cg01776926	chr12:116560359	MED13L	-0.54	-6.03	-0.36	5.82e-9	Total body bone mineral density;
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19346786	chr7:2764209	NA	-0.29	-5.0	-0.3	1.07e-6	Height;
KIRP	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg16558253	chr16:72132732	DHX38	-0.56	-7.74	-0.44	2.54e-13	Fibrinogen levels;
KIRP	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.59	-7.15	-0.41	9.72e-12	Mosquito bite size;
KIRP	cis	rs939574	0.512	rs6730612	chr2:220146196	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.55	5.91	0.35	1.11e-8	Platelet distribution width;
KIRP	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.43	0.52	3.16e-18	IgG glycosylation;
KIRP	cis	rs754423	0.515	rs1956286	chr14:52553691	G/T	cg05884192	chr14:52515736	NID2	0.46	5.04	0.31	9.23e-7	Craniofacial microsomia;
KIRP	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-7.65	-0.44	4.59e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.63	-7.53	-0.43	9.77e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	8.96	0.5	8.12e-17	Resting heart rate;
KIRP	cis	rs806215	1.000	rs712700	chr7:127250907	T/C	cg25922125	chr7:127225783	GCC1	0.47	5.05	0.31	8.61e-7	Type 2 diabetes;
KIRP	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.98	-14.95	-0.69	2.16e-36	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.28	-0.32	2.91e-7	Primary biliary cholangitis;
KIRP	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.64	-7.29	-0.42	4.15e-12	Bone mineral density;
KIRP	cis	rs12143943	0.866	rs10458588	chr1:204505487	T/C	cg20240347	chr1:204465584	NA	-0.36	-6.52	-0.38	4.01e-10	Cognitive performance;
KIRP	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.73	9.1	0.5	3.17e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.39	0.38	8.1e-10	Neuroticism;
KIRP	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-7.69	-0.44	3.51e-13	Coronary artery disease;
KIRP	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.67	9.21	0.51	1.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg07414643	chr4:187882934	NA	0.38	4.99	0.3	1.16e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.14	0.31	5.66e-7	Body mass index;
KIRP	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	1.01	11.5	0.59	8.86e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg25554036	chr4:6271136	WFS1	0.41	5.77	0.35	2.41e-8	Cisplatin-induced ototoxicity;
KIRP	cis	rs4332428	0.892	rs35056421	chr10:4967533	C/T	cg19648686	chr10:5044992	AKR1C2	-0.98	-8.19	-0.46	1.38e-14	Height;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15749322	chr11:82905199	ANKRD42	1.06	6.92	0.4	3.9e-11	P wave terminal force;
KIRP	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.8	0.45	1.71e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09093137	chr7:105028539	SRPK2	0.69	8.44	0.47	2.79e-15	Smoking initiation;
KIRP	cis	rs3106136	0.872	rs2059605	chr4:95255212	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-4.92	-0.3	1.57e-6	Capecitabine sensitivity;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04782396	chr11:65819908	SF3B2	0.5	6.69	0.39	1.49e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg08499158	chr17:42289980	UBTF	0.7	9.46	0.52	2.68e-18	Total body bone mineral density;
KIRP	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	4.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	7.68	0.44	3.8e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs859767	0.501	rs11898465	chr2:135431449	G/T	cg12500956	chr2:135428796	TMEM163	-0.41	-5.59	-0.34	6.16e-8	Neuroticism;
KIRP	trans	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.78	0.4	8.98e-11	Retinal vascular caliber;
KIRP	trans	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg06521331	chr12:34319734	NA	-0.54	-6.68	-0.39	1.55e-10	Heart rate;
KIRP	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	14.17	0.67	1.02e-33	Alzheimer's disease;
KIRP	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.62	-7.53	-0.43	9.81e-13	Systemic lupus erythematosus;
KIRP	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3774830	0.748	rs58854245	chr4:5466134	G/A	cg26943120	chr4:5472116	STK32B	0.24	5.9	0.35	1.19e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.73	0.49	3.91e-16	Prudent dietary pattern;
KIRP	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.18	12.71	0.63	8.91e-29	Eosinophil percentage of granulocytes;
KIRP	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg02175308	chr1:109941060	SORT1	-0.29	-5.48	-0.33	1.06e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.44	-5.45	-0.33	1.24e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.38	-5.57	-0.33	6.55e-8	Body mass index;
KIRP	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.66	6.28	0.37	1.49e-9	Mean platelet volume;
KIRP	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.53	-6.71	-0.39	1.36e-10	QT interval (drug interaction);
KIRP	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.13	-0.41	1.13e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.73	-8.86	-0.49	1.65e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg04569364	chr19:57922590	ZNF17	0.66	6.15	0.37	3.08e-9	Lung function (FEV1);
KIRP	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.9	11.39	0.59	1.99e-24	Platelet distribution width;
KIRP	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg14972814	chr11:95582409	MTMR2	0.34	5.91	0.35	1.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.74	-9.62	-0.52	8.39e-19	Aortic root size;
KIRP	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg00784671	chr22:46762841	CELSR1	-0.64	-6.68	-0.39	1.56e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	7.86	0.45	1.2e-13	Systemic lupus erythematosus;
KIRP	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg24044564	chr13:99115944	STK24	0.59	6.8	0.4	7.75e-11	Obesity-related traits;
KIRP	cis	rs16912285	0.585	rs7950920	chr11:24356464	G/A	ch.11.24196551F	chr11:24239977	NA	0.61	5.46	0.33	1.18e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.62	-8.32	-0.47	6.08e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.72	-7.98	-0.45	5.5e-14	Response to bleomycin (chromatid breaks);
KIRP	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.07	0.36	4.7e-9	Monocyte count;
KIRP	trans	rs921874	0.585	rs2512389	chr11:86790339	C/T	cg20852851	chr2:240168848	HDAC4	0.5	6.04	0.36	5.6e-9	Total body bone mineral density;
KIRP	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.32	5.08	0.31	7.31e-7	Testicular germ cell tumor;
KIRP	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.6	8.09	0.46	2.68e-14	Bladder cancer;
KIRP	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16346588	chr10:242978	ZMYND11	0.47	5.75	0.34	2.65e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg09788416	chr12:39539408	NA	0.42	5.15	0.31	5.43e-7	Morning vs. evening chronotype;
KIRP	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-7.23	-0.42	5.93e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.52	6.71	0.39	1.35e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.85	9.52	0.52	1.7e-18	Cisplatin-induced ototoxicity;
KIRP	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.3	1e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg02725872	chr8:58115012	NA	-0.56	-6.14	-0.36	3.27e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.54	8.62	0.48	8.28e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs564148	1.000	rs501501	chr1:34170786	G/A	cg25772827	chr1:34632573	C1orf94;CSMD2	0.43	4.87	0.3	1.96e-6	Response to amphetamines;
KIRP	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg21573476	chr21:45109991	RRP1B	-0.55	-7.53	-0.43	9.81e-13	Mean corpuscular volume;
KIRP	cis	rs72653721	0.730	rs9468288	chr6:11035853	G/A	cg13562911	chr6:11044106	ELOVL2	0.52	5.15	0.31	5.4e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs259842	0.669	rs6433810	chr2:180694237	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.41	-5.51	-0.33	8.91e-8	Blood protein levels;
KIRP	cis	rs12042938	0.507	rs1765775	chr1:231731446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.04	-0.54	4.11e-20	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.67	-7.42	-0.43	1.87e-12	Gut microbiome composition (summer);
KIRP	cis	rs10751667	0.560	rs10902265	chr11:1003642	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-5.61	-0.34	5.51e-8	Alzheimer's disease (late onset);
KIRP	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg07415687	chr6:7910841	TXNDC5	-1.06	-6.07	-0.36	4.77e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg07382826	chr16:28625726	SULT1A1	0.44	5.12	0.31	6.24e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.76	-9.64	-0.52	7.24e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6580649	0.769	rs60629297	chr12:48438290	T/A	cg26205652	chr12:48591994	NA	-0.48	-5.59	-0.34	6.06e-8	Lung cancer;
KIRP	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.69	10.2	0.55	1.29e-20	Prostate cancer;
KIRP	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg19650706	chr5:140594406	PCDHB13	0.44	4.87	0.3	2e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg17845761	chr1:175162550	KIAA0040	0.33	6.35	0.38	1.02e-9	Alcohol dependence;
KIRP	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs55728055	0.661	rs62237849	chr22:32029807	T/C	cg01338084	chr22:32026380	PISD	1.04	6.57	0.39	3.01e-10	Age-related hearing impairment;
KIRP	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.81	11.26	0.58	5.21e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00789793	chr3:141329863	RASA2	0.4	6.17	0.37	2.82e-9	C-reactive protein;
KIRP	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg06219351	chr7:158114137	PTPRN2	0.59	8.73	0.49	4.04e-16	Calcium levels;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.64	9.8	0.53	2.3e-19	Immature fraction of reticulocytes;
KIRP	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg01620082	chr3:125678407	NA	-0.87	-6.36	-0.38	9.83e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.63	8.04	0.46	3.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.76	0.34	2.51e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs365132	0.846	rs812246	chr5:176327644	G/A	cg16309518	chr5:176445507	NA	-0.81	-12.67	-0.63	1.19e-28	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg02023728	chr11:77925099	USP35	0.44	7.02	0.41	2.09e-11	Testicular germ cell tumor;
KIRP	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	7.13	0.41	1.11e-11	Aortic root size;
KIRP	cis	rs860295	0.702	rs34124416	chr1:155578049	C/G	cg02153340	chr1:155202674	NA	-0.48	-6.64	-0.39	1.97e-10	Body mass index;
KIRP	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	cis	rs7712401	0.715	rs401226	chr5:122347726	G/A	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg07843065	chr1:150265600	MRPS21	0.45	6.25	0.37	1.75e-9	Migraine;
KIRP	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13382275	0.544	rs10188791	chr2:952234	T/C	cg10902693	chr2:875509	NA	0.61	6.87	0.4	5.29e-11	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg16255804	chr6:135334527	HBS1L	-0.34	-5.42	-0.33	1.43e-7	Red blood cell count;
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg09355771	chr2:177043147	NA	0.47	6.03	0.36	5.84e-9	IgG glycosylation;
KIRP	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg14703610	chr5:56206110	C5orf35	0.42	5.52	0.33	8.69e-8	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs427941	1.000	rs6465852	chr7:101846898	A/G	cg06246474	chr7:101738831	CUX1	0.5	5.9	0.35	1.23e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg17279839	chr7:150038598	RARRES2	0.43	5.56	0.33	6.93e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6500395	0.588	rs12918232	chr16:48690695	C/A	cg04672837	chr16:48644449	N4BP1	-0.38	-5.24	-0.32	3.53e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	0.98	7.07	0.41	1.55e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.79	9.43	0.52	3.23e-18	Red cell distribution width;
KIRP	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.47	7.96	0.45	6.52e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-7.37	-0.43	2.53e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.22	-0.37	2.16e-9	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.51e-15	Mortality in heart failure;
KIRP	cis	rs882732	1.000	rs10134935	chr14:95037079	T/C	cg08495878	chr14:95027859	SERPINA4	-0.44	-5.2	-0.31	4.15e-7	Blood protein levels;
KIRP	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg15252951	chr6:33757062	LEMD2	0.43	5.07	0.31	7.95e-7	Crohn's disease;
KIRP	cis	rs7011507	1.000	rs55738586	chr8:49138753	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05351201	chr14:89029602	ZC3H14	0.52	6.77	0.4	9.44e-11	Myopia (pathological);
KIRP	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg13512537	chr8:22265999	SLC39A14	-0.42	-5.81	-0.35	1.93e-8	Verbal declarative memory;
KIRP	cis	rs1215050	0.791	rs165237	chr4:98712029	T/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-7.6	-0.44	6.3e-13	Monocyte percentage of white cells;
KIRP	trans	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.06	-0.41	1.65e-11	Bladder cancer;
KIRP	cis	rs397969	0.646	rs17604987	chr17:19867331	A/T	cg04132472	chr17:19861366	AKAP10	-0.53	-6.53	-0.38	3.63e-10	Platelet count;
KIRP	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.45e-21	Diabetic kidney disease;
KIRP	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.72	0.49	4.16e-16	Motion sickness;
KIRP	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg13385521	chr17:29058706	SUZ12P	0.56	5.73	0.34	2.86e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs17834760	0.955	rs3899648	chr6:62069344	C/T	cg08476511	chr6:168435923	KIF25	-0.53	-6.15	-0.37	3.19e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs8177876	0.822	rs9929586	chr16:81113021	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.23	-0.37	1.96e-9	Obesity-related traits;
KIRP	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.83	-13.02	-0.64	8.14e-30	Dental caries;
KIRP	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg08662619	chr6:150070041	PCMT1	0.34	5.53	0.33	8.06e-8	Lung cancer;
KIRP	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg19507638	chr5:93509721	C5orf36	-0.61	-5.59	-0.34	6.09e-8	Diabetic retinopathy;
KIRP	cis	rs9400467	0.500	rs1361425	chr6:111472243	A/T	cg15721981	chr6:111408429	SLC16A10	-0.58	-7.83	-0.45	1.46e-13	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg10223061	chr2:219282414	VIL1	-0.4	-6.5	-0.38	4.44e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.7	9.73	0.53	3.75e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs7124676	0.966	rs4930426	chr11:64315914	C/G	cg09127371	chr11:64313507	NA	0.36	4.94	0.3	1.46e-6	Obesity-related traits;
KIRP	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.91	12.79	0.63	4.5e-29	Response to antipsychotic treatment;
KIRP	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.52	0.33	8.66e-8	Lung cancer;
KIRP	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.45	-4.87	-0.3	1.97e-6	Platelet distribution width;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg15089892	chr3:101568188	NFKBIZ	0.53	6.51	0.38	4.11e-10	Educational attainment;
KIRP	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.74	-8.54	-0.48	1.37e-15	Ulcerative colitis;
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg14338887	chr6:42928500	GNMT	0.47	6.87	0.4	5.32e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	10.02	0.54	4.72e-20	Bone mineral density;
KIRP	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.94	-13.18	-0.64	2.35e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6005807	0.640	rs12171099	chr22:29076637	G/A	cg12565055	chr22:29076175	TTC28	0.59	5.04	0.31	9.23e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.96	-0.36	8.57e-9	Menarche (age at onset);
KIRP	cis	rs883565	0.528	rs6599271	chr3:38970730	A/G	cg01426195	chr3:39028469	NA	0.48	7.23	0.42	6.03e-12	Handedness;
KIRP	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg04013166	chr16:89971882	TCF25	0.57	5.97	0.36	8.24e-9	Skin colour saturation;
KIRP	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg22681709	chr2:178499509	PDE11A	-0.63	-8.8	-0.49	2.45e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.36	-5.49	-0.33	1e-7	Body mass index;
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg17264618	chr3:40429014	ENTPD3	-0.36	-5.52	-0.33	8.41e-8	Renal cell carcinoma;
KIRP	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.56	7.67	0.44	4.04e-13	Schizophrenia;
KIRP	cis	rs7944584	0.502	rs10769256	chr11:47378396	C/T	cg20307385	chr11:47447363	PSMC3	0.74	9.83	0.53	1.95e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs3105593	1.000	rs57002197	chr15:50873760	C/T	cg08437265	chr15:50716283	USP8	0.39	4.94	0.3	1.42e-6	QT interval;
KIRP	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.91	-0.49	1.15e-16	Triglycerides;
KIRP	cis	rs2505998	1.000	rs2435357	chr10:43582056	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-5.42	-0.33	1.43e-7	Hirschsprung disease;
KIRP	cis	rs743757	1.000	rs2236965	chr3:50453456	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.5	4.94	0.3	1.46e-6	Diastolic blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10500570	chr8:100549776	MIR599;VPS13B;MIR875	-0.46	-6.84	-0.4	6.16e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs1497828	0.956	rs2815230	chr1:217536114	T/C	cg04411442	chr1:217543379	NA	-0.43	-6.56	-0.39	3.14e-10	Dialysis-related mortality;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24867180	chr15:42120426	JMJD7-PLA2G4B;JMJD7	0.5	6.41	0.38	7.54e-10	Parkinson's disease;
KIRP	cis	rs1018836	0.700	rs4735201	chr8:91528313	C/T	cg16814680	chr8:91681699	NA	-0.61	-6.91	-0.4	4.02e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.84	12.16	0.61	5.94e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.8	-10.36	-0.55	4.24e-21	Blood metabolite levels;
KIRP	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.36	-0.32	1.94e-7	Height;
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg15181151	chr6:150070149	PCMT1	0.31	5.32	0.32	2.38e-7	Lung cancer;
KIRP	cis	rs151997	1.000	rs373030	chr5:50215836	G/A	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs3007168	0.953	rs35556623	chr14:51679717	T/A	cg23942311	chr14:51606299	NA	0.53	5.55	0.33	7.27e-8	Cancer;
KIRP	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg02073558	chr3:44770973	ZNF501	0.47	5.49	0.33	1.01e-7	IgG glycosylation;
KIRP	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.77	9.17	0.5	1.95e-17	Adiposity;
KIRP	cis	rs9653442	0.564	rs2309756	chr2:100780269	G/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.19	-0.31	4.35e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs9653442	0.527	rs2164712	chr2:100745404	C/G	cg22139774	chr2:100720529	AFF3	-0.29	-4.9	-0.3	1.72e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs858239	0.539	rs6965833	chr7:23192366	T/C	cg23682824	chr7:23144976	KLHL7	0.55	6.55	0.39	3.42e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.77	-10.85	-0.57	1.18e-22	Waist circumference;Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17004212	chr13:50656130	DLEU1;DLEU2	-0.55	-8.42	-0.47	3.06e-15	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.88	-0.45	1.04e-13	Mood instability;
KIRP	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg11498726	chr8:26250323	BNIP3L	-0.57	-8.11	-0.46	2.41e-14	Red cell distribution width;
KIRP	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18357526	chr6:26021779	HIST1H4A	0.53	7.29	0.42	4.19e-12	Height;
KIRP	cis	rs2737618	0.651	rs2816975	chr1:200081159	A/G	cg21825944	chr1:200113062	NR5A2	-0.55	-7.91	-0.45	8.47e-14	Uric acid levels;
KIRP	cis	rs4805272	1.000	rs10419348	chr19:29320387	T/C	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.16	-0.31	5.18e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14969320	chr1:3731835	KIAA0562	0.44	6.09	0.36	4.42e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.69	-8.11	-0.46	2.46e-14	Menarche (age at onset);
KIRP	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.82	9.06	0.5	4.12e-17	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13198984	chr17:80129470	CCDC57	0.55	8.39	0.47	3.73e-15	Life satisfaction;
KIRP	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg10189774	chr4:17578691	LAP3	0.42	4.99	0.3	1.16e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg01403660	chr11:68851641	TPCN2	0.68	6.64	0.39	2.02e-10	Blond vs. brown hair color;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg25566285	chr7:158114605	PTPRN2	0.79	13.07	0.64	5.34e-30	Calcium levels;
KIRP	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg10326726	chr10:51549505	MSMB	-0.55	-7.81	-0.45	1.62e-13	Prostate-specific antigen levels;
KIRP	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	0.96	14.9	0.69	3.34e-36	Schizophrenia;
KIRP	cis	rs737008	0.922	rs28567501	chr16:11378928	C/A	cg00044050	chr16:11439710	C16orf75	-0.65	-7.89	-0.45	9.82e-14	Obesity-related traits;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg04458869	chr2:169312687	LASS6	0.52	6.26	0.37	1.68e-9	Educational attainment;
KIRP	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.87	-0.4	5.27e-11	Myopia (pathological);
KIRP	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.42	-5.18	-0.31	4.54e-7	Aortic root size;
KIRP	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs732716	0.785	rs62130978	chr19:4429007	C/T	cg03719555	chr19:4455413	UBXN6	0.48	7.4	0.43	2.12e-12	Mean corpuscular volume;
KIRP	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg27462398	chr1:86174642	ZNHIT6	-0.59	-8.79	-0.49	2.62e-16	Urate levels in overweight individuals;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25439992	chr11:126173954	DCPS	0.49	6.3	0.37	1.39e-9	Myopia (pathological);
KIRP	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-9.25	-0.51	1.09e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg24826892	chr11:71159390	DHCR7	0.44	5.06	0.31	8.04e-7	Vitamin D levels;
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg04804543	chr8:142233427	SLC45A4	-1.03	-17.97	-0.75	1.07e-46	Immature fraction of reticulocytes;
KIRP	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg17554472	chr22:41940697	POLR3H	-0.43	-5.33	-0.32	2.27e-7	Neuroticism;
KIRP	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	24.76	0.84	9.26e-69	Chronic sinus infection;
KIRP	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.65	8.39	0.47	3.87e-15	Prudent dietary pattern;
KIRP	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.88	13.73	0.66	3.08e-32	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18252515	chr7:66147081	NA	0.47	5.71	0.34	3.23e-8	Aortic root size;
KIRP	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.85	-9.03	-0.5	5.3e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11270192	chr12:30849015	IPO8	-0.46	-6.18	-0.37	2.64e-9	Myopia;
KIRP	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.63	6.03	0.36	5.96e-9	Psoriasis;
KIRP	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.95	-0.3	1.39e-6	Metabolite levels;
KIRP	cis	rs3206736	0.634	rs329546	chr7:35111358	T/C	cg06685737	chr7:35301730	NA	0.42	5.94	0.35	9.65e-9	Diastolic blood pressure;
KIRP	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.67	-6.93	-0.4	3.74e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.72	7.42	0.43	1.86e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.86	14.34	0.67	2.65e-34	Prostate cancer;
KIRP	cis	rs17030434	0.906	rs12641631	chr4:154665279	A/G	cg14289246	chr4:154710475	SFRP2	-0.78	-9.05	-0.5	4.42e-17	Electrocardiographic conduction measures;
KIRP	cis	rs17065868	1.000	rs9525964	chr13:45065549	A/G	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.62	6.99	0.41	2.63e-11	Aortic root size;
KIRP	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-6.88	-0.4	4.99e-11	Gut microbiome composition (summer);
KIRP	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10282345	chr14:75745684	FOS	0.5	6.15	0.37	3.16e-9	Parkinson's disease;
KIRP	cis	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg03511173	chr18:77590860	NA	-0.46	-4.95	-0.3	1.35e-6	Opioid sensitivity;
KIRP	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg10701640	chr17:43249399	NA	0.47	9.7	0.53	4.81e-19	Height;
KIRP	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg09238746	chr17:78121135	EIF4A3	0.47	6.1	0.36	4.11e-9	Yeast infection;
KIRP	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg15247329	chr7:2764246	NA	-0.35	-4.98	-0.3	1.18e-6	Height;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01020399	chr1:249153122	ZNF692	0.5	6.26	0.37	1.69e-9	Myopia (pathological);
KIRP	cis	rs2380205	0.967	rs4567357	chr10:5899283	A/T	cg27141509	chr10:5886111	NA	-0.35	-5.12	-0.31	6.2e-7	Breast cancer;
KIRP	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.46	-5.74	-0.34	2.73e-8	Childhood ear infection;
KIRP	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.08	-0.31	7.32e-7	Parkinson's disease;
KIRP	cis	rs9400467	0.537	rs12191266	chr6:111528041	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10802346	0.636	rs1614456	chr1:246412327	G/T	cg15962031	chr1:246363574	SMYD3	0.76	5.57	0.33	6.66e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.75	7.52	0.43	1.02e-12	Vitiligo;
KIRP	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg05220968	chr6:146057943	EPM2A	0.4	5.07	0.31	7.89e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.55	7.11	0.41	1.27e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1067327	1	rs1067327	chr2:44628529	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.02	0.36	6.18e-9	Anxiety disorder (factor score);
KIRP	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.09	-0.46	2.76e-14	Monocyte percentage of white cells;
KIRP	cis	rs2267137	0.903	rs5752903	chr22:29769306	G/T	cg07256473	chr22:29710276	RASL10A	0.46	6.78	0.4	9.08e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.51	0.59	8.52e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22794795	chr12:113623087	C12orf52;DDX54	-0.46	-6.57	-0.39	2.92e-10	Metabolic traits;
KIRP	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg03060546	chr3:49711283	APEH	-0.66	-6.19	-0.37	2.5e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs3126085	0.560	rs11204986	chr1:152342059	T/C	cg26876637	chr1:152193138	HRNR	-0.73	-6.93	-0.4	3.73e-11	Atopic dermatitis;
KIRP	cis	rs7107174	0.688	rs3740677	chr11:77928036	A/C	cg02023728	chr11:77925099	USP35	0.34	5.57	0.33	6.63e-8	Testicular germ cell tumor;
KIRP	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg21775007	chr8:11205619	TDH	-0.42	-5.63	-0.34	4.79e-8	Triglycerides;
KIRP	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.72	0.49	4.16e-16	Motion sickness;
KIRP	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg19116668	chr7:99932089	PMS2L1	-0.54	-6.15	-0.36	3.17e-9	Coronary artery disease;
KIRP	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg04731861	chr2:219085781	ARPC2	0.26	6.44	0.38	6.35e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg24692254	chr21:30365293	RNF160	-0.69	-9.31	-0.51	7.4e-18	Pancreatic cancer;
KIRP	cis	rs4132509	0.779	rs3006936	chr1:243674772	A/G	cg25706552	chr1:244017396	NA	0.49	6.96	0.41	3.07e-11	RR interval (heart rate);
KIRP	cis	rs11779988	0.545	rs208763	chr8:17806482	G/A	cg01800426	chr8:17659068	MTUS1	-0.64	-6.51	-0.38	4.29e-10	Breast cancer;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg12692727	chr7:1102344	C7orf50	0.45	4.89	0.3	1.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1459104	0.866	rs67929427	chr11:54824182	C/T	cg26562691	chr16:23850404	PRKCB	0.61	6.04	0.36	5.55e-9	Body mass index;
KIRP	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg21427119	chr20:30132790	HM13	-0.43	-5.18	-0.31	4.55e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.64	-9.16	-0.5	2.14e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.35	-4.94	-0.3	1.42e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs8177876	0.822	rs55939311	chr16:81109098	G/C	cg08591886	chr16:81111003	C16orf46	-0.76	-5.89	-0.35	1.25e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.27	-0.37	1.62e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10795061	0.576	rs12219804	chr10:3710626	C/T	cg22632523	chr10:3711048	NA	0.39	6.13	0.36	3.44e-9	Subjective well-being;
KIRP	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg00343986	chr7:65444356	GUSB	0.5	6.09	0.36	4.22e-9	Calcium levels;
KIRP	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.07e-11	Bipolar disorder;
KIRP	cis	rs7809615	0.901	rs10808111	chr7:99070884	T/A	cg12290671	chr7:99195819	NA	-0.75	-6.99	-0.41	2.57e-11	Blood metabolite ratios;
KIRP	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg17524265	chr8:144659883	NAPRT1	0.83	5.36	0.32	1.88e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.48	0.65	2.21e-31	Electrocardiographic conduction measures;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09657378	chr3:101232109	SENP7	0.45	6.03	0.36	5.95e-9	Survival in pancreatic cancer;
KIRP	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg17724175	chr1:150552817	MCL1	0.36	6.11	0.36	3.82e-9	Melanoma;
KIRP	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.64	-9.11	-0.5	2.91e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg05347473	chr6:146136440	FBXO30	-0.58	-8.33	-0.47	5.74e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2120243	0.539	rs722484	chr3:157100627	C/T	cg24825693	chr3:157122686	VEPH1	-0.56	-9.02	-0.5	5.62e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg16141378	chr3:129829833	LOC729375	-0.5	-6.73	-0.39	1.16e-10	Retinal vascular caliber;
KIRP	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.75	-6.79	-0.4	8.51e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg20991723	chr1:152506922	NA	-0.47	-5.43	-0.33	1.32e-7	Hair morphology;
KIRP	cis	rs2882667	0.898	rs6882330	chr5:138382182	A/G	cg04439458	chr5:138467593	SIL1	-0.45	-7.55	-0.43	8.33e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg23543263	chr13:22245177	FGF9	0.52	6.46	0.38	5.54e-10	Educational attainment;
KIRP	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg01864069	chr14:103024347	NA	-0.85	-10.08	-0.54	3.14e-20	Platelet count;
KIRP	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.58	-9.04	-0.5	4.81e-17	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9400467	0.528	rs455335	chr6:111675516	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg12573791	chr2:3828286	NA	0.41	5.68	0.34	3.69e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.6	6.64	0.39	2e-10	Interstitial lung disease;
KIRP	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.69	9.12	0.5	2.84e-17	Schizophrenia;
KIRP	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-0.61	-8.19	-0.46	1.44e-14	Post bronchodilator FEV1;
KIRP	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.43	5.31	0.32	2.49e-7	Aortic root size;
KIRP	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs6723108	0.654	rs669759	chr2:135291135	C/T	cg12500956	chr2:135428796	TMEM163	0.42	5.14	0.31	5.61e-7	Type 2 diabetes;
KIRP	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg19025524	chr12:109796872	NA	-0.41	-5.25	-0.32	3.27e-7	Neuroticism;
KIRP	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg14675211	chr2:100938903	LONRF2	0.45	6.12	0.36	3.75e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01559031	chr1:180374455	ACBD6	0.42	6.45	0.38	6e-10	C-reactive protein;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.46	5.74	0.34	2.71e-8	Longevity;
KIRP	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.45	-0.47	2.62e-15	Total cholesterol levels;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.78	6.79	0.4	8.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.45	7.52	0.43	1.04e-12	Testicular germ cell tumor;
KIRP	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg03128945	chr5:622914	CEP72	-0.41	-6.08	-0.36	4.51e-9	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14181387	chr1:36022775	NCDN;KIAA0319L	0.56	7.29	0.42	4.27e-12	Parkinson's disease;
KIRP	cis	rs6001982	0.748	rs6001942	chr22:40893866	A/G	cg07138101	chr22:40742427	ADSL	0.72	5.81	0.35	1.9e-8	Breast cancer;
KIRP	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.72	-0.39	1.24e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg04132472	chr17:19861366	AKAP10	0.44	6.05	0.36	5.25e-9	Schizophrenia;
KIRP	cis	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg06521331	chr12:34319734	NA	-0.56	-6.87	-0.4	5.14e-11	Morning vs. evening chronotype;
KIRP	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.87	11.07	0.58	2.27e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg12705353	chr12:122356852	WDR66	0.42	5.41	0.33	1.47e-7	Mean corpuscular volume;
KIRP	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.49	5.75	0.34	2.66e-8	Glycated hemoglobin levels;
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07157834	chr1:205819609	PM20D1	0.68	9.02	0.5	5.53e-17	Monocyte percentage of white cells;
KIRP	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.61	-7.44	-0.43	1.65e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg01097406	chr16:89675127	NA	0.53	9.19	0.51	1.73e-17	Vitiligo;
KIRP	cis	rs712039	0.652	rs736424	chr17:35789362	T/C	cg16670864	chr17:35848621	DUSP14	0.38	5.12	0.31	6.07e-7	Tuberculosis;
KIRP	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg18944383	chr4:111397179	ENPEP	0.51	8.99	0.5	6.59e-17	Height;
KIRP	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.54	6.95	0.41	3.26e-11	Crohn's disease;
KIRP	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg10018233	chr7:150070692	REPIN1	0.79	9.93	0.54	9.14e-20	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.8	9.87	0.53	1.42e-19	Lymphocyte percentage of white cells;
KIRP	cis	rs858239	0.511	rs10256996	chr7:23145295	G/T	cg23682824	chr7:23144976	KLHL7	-0.47	-5.85	-0.35	1.59e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-11.29	-0.58	4.36e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg09873164	chr1:152488093	CRCT1	0.58	7.74	0.44	2.59e-13	Hair morphology;
KIRP	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg04990556	chr1:26633338	UBXN11	-0.57	-6.9	-0.4	4.41e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.69	-11.91	-0.6	4.1e-26	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.96	16.0	0.71	5.7e-40	Colorectal cancer;
KIRP	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs11955175	1.000	rs111310950	chr5:40641951	G/T	cg04002187	chr5:40835754	RPL37	0.65	5.26	0.32	3.09e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	4.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.75	-6.88	-0.4	4.89e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg19257562	chr1:2043853	PRKCZ	-0.35	-5.2	-0.31	4.25e-7	Height;
KIRP	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg03684893	chr10:554711	DIP2C	0.37	5.18	0.31	4.69e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs12986413	0.781	rs2864419	chr19:2183175	A/C	cg09261902	chr19:2140048	AP3D1	-0.6	-8.86	-0.49	1.69e-16	Height;
KIRP	cis	rs4141404	0.818	rs6518737	chr22:31582662	A/G	cg02404636	chr22:31891804	SFI1	-0.5	-6.51	-0.38	4.1e-10	Paclitaxel-induced neuropathy;
KIRP	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg24110177	chr3:50126178	RBM5	0.64	8.21	0.46	1.27e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.6	-6.69	-0.39	1.48e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs1823913	0.637	rs13382985	chr2:192171061	A/C	cg12404831	chr2:192114017	MYO1B	-0.49	-6.73	-0.39	1.19e-10	Obesity-related traits;
KIRP	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg25019722	chr6:37503610	NA	-0.69	-8.82	-0.49	2.14e-16	Cognitive performance;
KIRP	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	1.02	10.64	0.56	5.45e-22	Eosinophilic esophagitis;
KIRP	cis	rs8038465	0.615	rs62004616	chr15:73961176	C/T	cg15420318	chr15:73925796	NPTN	0.65	9.34	0.51	5.9e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4478137	0.931	rs7665672	chr4:164236875	G/A	cg06758707	chr4:164254230	NPY1R	0.7	9.03	0.5	5.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg01200585	chr1:228362443	C1orf69	0.45	5.45	0.33	1.23e-7	Diastolic blood pressure;
KIRP	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.38	-0.38	8.94e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs933360	0.585	rs2876846	chr7:50840056	C/G	cg20003124	chr12:4557277	NA	-0.55	-6.7	-0.39	1.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17470531	chr2:55646984	CCDC88A	0.46	6.22	0.37	2.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23422044	chr7:1970798	MAD1L1	-0.71	-7.36	-0.42	2.68e-12	Bipolar disorder;
KIRP	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg07884673	chr3:53033167	SFMBT1	-0.65	-5.61	-0.34	5.48e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.8	-7.78	-0.44	1.95e-13	Systemic lupus erythematosus;
KIRP	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.41	-6.32	-0.37	1.19e-9	Body mass index;
KIRP	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg11608241	chr8:8085544	FLJ10661	-0.47	-6.23	-0.37	2.05e-9	Retinal vascular caliber;
KIRP	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-0.75	-9.28	-0.51	9.13e-18	Blood trace element (Zn levels);
KIRP	cis	rs2625529	0.627	rs12898585	chr15:72473928	T/C	cg16672083	chr15:72433130	SENP8	-0.45	-5.48	-0.33	1.06e-7	Red blood cell count;
KIRP	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg19773385	chr1:10388646	KIF1B	-0.43	-6.36	-0.38	9.85e-10	Hepatocellular carcinoma;
KIRP	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.42	5.01	0.3	1.02e-6	Common traits (Other);
KIRP	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02725872	chr8:58115012	NA	-0.56	-6.43	-0.38	6.65e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.27	-0.32	2.99e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12986413	0.789	rs12985980	chr19:2165197	C/G	cg09261902	chr19:2140048	AP3D1	0.44	5.3	0.32	2.63e-7	Height;
KIRP	cis	rs10782582	0.569	rs1770892	chr1:76389359	T/C	cg03433033	chr1:76189801	ACADM	-0.46	-6.6	-0.39	2.5e-10	Daytime sleep phenotypes;
KIRP	cis	rs151997	0.853	rs6882235	chr5:50260139	T/C	cg06027927	chr5:50259733	NA	0.6	7.86	0.45	1.18e-13	Callous-unemotional behaviour;
KIRP	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18357526	chr6:26021779	HIST1H4A	0.56	7.52	0.43	1.01e-12	Height;
KIRP	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg11465639	chr17:19241549	NA	0.39	4.88	0.3	1.94e-6	Schizophrenia;
KIRP	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.25	-0.32	3.3e-7	Parkinson's disease;
KIRP	cis	rs870825	0.655	rs6552812	chr4:185653568	C/T	cg04058563	chr4:185651563	MLF1IP	-0.92	-11.61	-0.59	3.98e-25	Blood protein levels;
KIRP	trans	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg24644049	chr4:85504048	CDS1	1.03	6.78	0.4	8.61e-11	Skin colour saturation;
KIRP	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg09137382	chr11:130731461	NA	-0.54	-7.66	-0.44	4.32e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4849845	0.777	rs3931841	chr2:121041314	A/G	cg24070213	chr2:121070622	NA	0.36	5.05	0.31	8.75e-7	Mean platelet volume;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.61	8.94	0.5	9.34e-17	Lung cancer;
KIRP	cis	rs35883536	1.000	rs17403857	chr1:101105216	A/C	cg06223162	chr1:101003688	GPR88	0.32	6.65	0.39	1.9e-10	Monocyte count;
KIRP	cis	rs9400467	0.537	rs1150081	chr6:111479016	A/G	cg15721981	chr6:111408429	SLC16A10	0.78	7.12	0.41	1.2e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6500395	0.569	rs12934452	chr16:48706139	C/T	cg04672837	chr16:48644449	N4BP1	-0.38	-5.24	-0.32	3.53e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.56	7.45	0.43	1.53e-12	Mean corpuscular volume;
KIRP	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg11584989	chr19:19387371	SF4	-0.44	-5.32	-0.32	2.38e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.68	-8.84	-0.49	1.93e-16	Personality dimensions;
KIRP	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.3	-6.97	-0.41	2.84e-11	Mean corpuscular volume;
KIRP	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.91	0.3	1.67e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg00631329	chr6:26305371	NA	-0.69	-8.86	-0.49	1.59e-16	Mosquito bite size;
KIRP	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.7	9.22	0.51	1.37e-17	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.9	-0.57	7.6e-23	Height;
KIRP	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg19899395	chr1:46959349	NA	-0.4	-5.05	-0.31	8.6e-7	Monobrow;
KIRP	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.55	-0.43	8.42e-13	Bone mineral density;
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg01721255	chr8:58191610	C8orf71	0.63	5.61	0.34	5.55e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.66	9.47	0.52	2.39e-18	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.74	9.87	0.53	1.48e-19	Parkinson's disease;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg13922124	chr7:105221991	EFCAB10	0.5	6.24	0.37	1.86e-9	Sleep duration;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs7973683	0.541	rs57078519	chr12:124388784	G/A	cg12597309	chr12:124393772	DNAH10	0.42	5.42	0.33	1.4e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.31	-0.42	3.71e-12	Type 2 diabetes;
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22168489	chr12:122356033	WDR66	0.57	8.68	0.48	5.44e-16	Mean corpuscular volume;
KIRP	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.42	-0.51	3.35e-18	Neuroticism;
KIRP	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs11638352	1.000	rs2615294	chr15:44412620	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-5.11	-0.31	6.36e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg23034840	chr1:205782522	SLC41A1	0.54	6.43	0.38	6.6e-10	Menarche (age at onset);
KIRP	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg23682824	chr7:23144976	KLHL7	0.47	5.66	0.34	4.13e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg17425144	chr1:10567563	PEX14	0.49	9.0	0.5	6.5e-17	Breast size;
KIRP	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.53	7.1	0.41	1.31e-11	HDL cholesterol;
KIRP	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.0	0.36	7.06e-9	Platelet count;
KIRP	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg18402987	chr7:1209562	NA	0.7	4.88	0.3	1.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg06565975	chr8:143823917	SLURP1	0.45	6.91	0.4	4.07e-11	Urinary tract infection frequency;
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.73	0.34	2.86e-8	Platelet count;
KIRP	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.53	0.38	3.73e-10	Mean platelet volume;
KIRP	cis	rs9815354	0.812	rs77047799	chr3:41958895	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.78	0.49	2.89e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.39	-0.47	3.71e-15	Type 2 diabetes;
KIRP	cis	rs7561273	0.586	rs13418279	chr2:24349218	G/T	cg20701182	chr2:24300061	SF3B14	0.49	6.0	0.36	6.99e-9	Quantitative traits;
KIRP	cis	rs10073892	0.703	rs2123131	chr5:101640178	T/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-11.29	-0.58	4.25e-24	Body mass index;
KIRP	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg27147174	chr7:100797783	AP1S1	-0.59	-7.73	-0.44	2.75e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs17453880	0.926	rs6885111	chr5:152027557	T/C	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.3	-0.32	2.52e-7	Aortic root size;
KIRP	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg08992911	chr2:238395768	MLPH	0.41	5.28	0.32	2.83e-7	Prostate cancer;
KIRP	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs986417	0.901	rs7160405	chr14:60970004	G/C	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg00631329	chr6:26305371	NA	-0.68	-8.39	-0.47	3.83e-15	Height;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg00931877	chr10:13672646	PRPF18	-0.43	-6.14	-0.36	3.29e-9	Select biomarker traits;
KIRP	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.57	-0.33	6.5e-8	Personality dimensions;
KIRP	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg04226714	chr8:49833948	SNAI2	-0.54	-7.2	-0.42	7.48e-12	Life satisfaction;
KIRP	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.2	0.37	2.3e-9	Retinal vascular caliber;
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.43	5.52	0.33	8.44e-8	Vitiligo;
KIRP	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg09455208	chr3:40491958	NA	0.29	4.86	0.3	2.13e-6	Renal cell carcinoma;
KIRP	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-7.07	-0.41	1.62e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs520865	0.786	rs581431	chr5:80348949	T/C	cg17330048	chr5:80257322	RASGRF2	-0.45	-6.6	-0.39	2.56e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Educational attainment;
KIRP	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.87	16.51	0.72	1.03e-41	Anterior chamber depth;
KIRP	cis	rs986417	0.748	rs1955691	chr14:61004128	G/A	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg04398451	chr17:18023971	MYO15A	-0.7	-9.5	-0.52	1.92e-18	Total body bone mineral density;
KIRP	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.53	6.83	0.4	6.74e-11	Tonsillectomy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20049927	chr15:45777254	SLC30A4	-0.46	-7.11	-0.41	1.25e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.12	12.2	0.61	4.53e-27	Eosinophil percentage of granulocytes;
KIRP	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg09555818	chr19:45449301	APOC2	0.41	5.33	0.32	2.25e-7	Blood protein levels;
KIRP	cis	rs1894292	0.715	rs1957660	chr4:74471944	T/C	cg12566645	chr4:74483141	RASSF6	0.36	4.9	0.3	1.78e-6	Prostate cancer;
KIRP	cis	rs2997447	0.846	rs61775422	chr1:26395898	C/T	cg19633962	chr1:26362018	EXTL1	-0.74	-6.24	-0.37	1.95e-9	QRS complex (12-leadsum);
KIRP	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	9.32	0.51	6.79e-18	Alzheimer's disease;
KIRP	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg18761221	chr20:60518478	NA	0.5	5.59	0.34	6e-8	Obesity-related traits;
KIRP	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg11189052	chr15:85197271	WDR73	0.48	4.99	0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.67	-8.2	-0.46	1.33e-14	Prudent dietary pattern;
KIRP	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.91	10.97	0.57	4.59e-23	Menarche (age at onset);
KIRP	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-13.28	-0.65	1.02e-30	Vitiligo;
KIRP	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.71	9.9	0.53	1.12e-19	Mean corpuscular volume;
KIRP	trans	rs526821	0.595	rs532278	chr11:55344983	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-6.19	-0.37	2.48e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.16	-0.37	2.91e-9	Cardiac Troponin-T levels;
KIRP	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.78	-11.42	-0.59	1.63e-24	Menarche (age at onset);
KIRP	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7809615	0.901	rs12535424	chr7:99053816	G/A	cg12290671	chr7:99195819	NA	-0.67	-5.67	-0.34	4.02e-8	Blood metabolite ratios;
KIRP	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg11839771	chr15:80205821	ST20	-0.38	-5.52	-0.33	8.71e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg02795151	chr17:7402630	POLR2A	0.78	8.03	0.46	4.11e-14	Height;
KIRP	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.36	0.38	9.55e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12765878	0.812	rs2475214	chr10:105660986	T/C	cg11005552	chr10:105648138	OBFC1	-0.42	-5.76	-0.34	2.54e-8	Coronary artery disease;
KIRP	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs2820315	1.000	rs2820310	chr1:201838107	G/A	cg11586189	chr1:201857591	SHISA4	-0.39	-5.46	-0.33	1.14e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11987759	chr7:65425863	GUSB	-0.67	-9.18	-0.51	1.79e-17	Aortic root size;
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.66	-7.76	-0.44	2.21e-13	Longevity;Endometriosis;
KIRP	cis	rs1823913	0.599	rs13001899	chr2:192150168	C/T	cg12404831	chr2:192114017	MYO1B	0.53	7.33	0.42	3.32e-12	Obesity-related traits;
KIRP	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.36	-0.51	5.23e-18	Triglycerides;
KIRP	cis	rs10073892	0.620	rs10440757	chr5:101929477	T/C	cg19774478	chr5:101632501	SLCO4C1	0.53	5.27	0.32	2.94e-7	Cognitive decline (age-related);
KIRP	cis	rs8177876	1.000	rs8177876	chr16:81124275	G/A	cg08591886	chr16:81111003	C16orf46	-0.69	-5.19	-0.31	4.48e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg25797454	chr6:150327115	RAET1K	0.32	6.03	0.36	6.11e-9	Alopecia areata;
KIRP	trans	rs3863381	0.764	rs79880109	chr12:106105839	G/C	cg00615913	chr20:37063096	LOC388796;SNORA71D	-0.67	-6.15	-0.37	3.07e-9	Night sleep phenotypes;
KIRP	cis	rs2273156	1.000	rs74046408	chr14:35467135	T/C	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.37	-0.32	1.87e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.35	-0.32	2.04e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs883565	0.569	rs784514	chr3:39164622	A/G	cg01426195	chr3:39028469	NA	0.52	8.31	0.47	6.35e-15	Handedness;
KIRP	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.28	7.45	0.43	1.54e-12	Primary biliary cholangitis;
KIRP	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg05340658	chr4:99064831	C4orf37	0.55	6.75	0.4	1.03e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.93	10.75	0.57	2.34e-22	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.63	0.44	5.13e-13	Triglycerides;
KIRP	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.66	-0.34	4.26e-8	Colorectal cancer;
KIRP	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.76	9.16	0.5	2.1e-17	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.52	-4.87	-0.3	2e-6	Narcolepsy;
KIRP	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg24579218	chr15:68104479	NA	-0.58	-9.24	-0.51	1.21e-17	Restless legs syndrome;
KIRP	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.87	10.46	0.55	2.04e-21	Alzheimer's disease;
KIRP	cis	rs7822232	0.710	rs13256214	chr8:145149823	G/T	cg27454946	chr8:145133526	EXOSC4	-0.62	-5.53	-0.33	8.01e-8	Blood metabolite levels;
KIRP	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg05315796	chr3:52349193	DNAH1	0.42	6.42	0.38	7.11e-10	Bipolar disorder;
KIRP	cis	rs10489525	0.583	rs6660550	chr1:115650850	C/G	cg01522456	chr1:115632236	TSPAN2	0.78	10.75	0.57	2.45e-22	Autism;
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.53	8.26	0.47	9.05e-15	Lung cancer;
KIRP	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-1.24	-11.57	-0.59	5.18e-25	Diabetic retinopathy;
KIRP	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.87	0.3	2.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	9.78	0.53	2.71e-19	Total body bone mineral density;
KIRP	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg11131117	chr7:1891496	MAD1L1	0.4	4.85	0.3	2.19e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg06742321	chr12:123595122	PITPNM2	0.42	5.21	0.32	3.94e-7	Platelet count;
KIRP	cis	rs4073221	0.584	rs56058600	chr3:18295064	T/C	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.4e-9	Parkinson's disease;
KIRP	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-5.52	-0.33	8.75e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	trans	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Bladder cancer;
KIRP	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.57	-7.35	-0.42	2.93e-12	Aortic root size;
KIRP	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg13482628	chr17:19912719	NA	0.61	8.68	0.48	5.61e-16	Schizophrenia;
KIRP	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.58	8.02	0.46	4.26e-14	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10020600	chr19:39397911	NFKBIB	0.54	6.29	0.37	1.47e-9	Interleukin-4 levels;
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg02475777	chr4:1388615	CRIPAK	0.36	4.86	0.3	2.11e-6	Obesity-related traits;
KIRP	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.08	-0.36	4.67e-9	Colorectal cancer;
KIRP	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg00531865	chr16:30841666	NA	-0.39	-5.07	-0.31	7.89e-7	Multiple myeloma;
KIRP	cis	rs3026101	0.624	rs1058400	chr17:5288794	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.91	0.35	1.11e-8	Body mass index;
KIRP	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.79	10.63	0.56	5.77e-22	Systemic lupus erythematosus;
KIRP	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg03647239	chr10:116582469	FAM160B1	0.49	5.61	0.34	5.32e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.75	11.28	0.58	4.77e-24	Blood metabolite ratios;
KIRP	cis	rs12210905	1.000	rs72838266	chr6:27015052	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.61	-0.39	2.31e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.62	9.47	0.52	2.42e-18	Hip circumference;Waist circumference;
KIRP	cis	rs4664308	0.694	rs4665140	chr2:160890710	T/A	cg03641300	chr2:160917029	PLA2R1	-0.64	-9.97	-0.54	6.74e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.32	0.55	5.5e-21	Cognitive test performance;
KIRP	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.48	13.92	0.66	7.13e-33	Opioid sensitivity;
KIRP	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-8.5	-0.48	1.9e-15	Response to antipsychotic treatment;
KIRP	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg10755058	chr3:40428713	ENTPD3	-0.44	-6.47	-0.38	5.23e-10	Renal cell carcinoma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06047995	chr3:129035211	H1FX;C3orf47	0.44	6.07	0.36	4.71e-9	Survival in pancreatic cancer;
KIRP	cis	rs6001982	0.665	rs17001943	chr22:40862613	A/G	cg07138101	chr22:40742427	ADSL	0.73	5.15	0.31	5.41e-7	Breast cancer;
KIRP	cis	rs478304	0.530	rs11568300	chr11:65425167	C/G	cg27068330	chr11:65405492	SIPA1	-0.43	-5.69	-0.34	3.57e-8	Acne (severe);
KIRP	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg12940923	chr8:10282607	MSRA	-0.38	-5.02	-0.3	9.93e-7	Triglycerides;
KIRP	cis	rs3026101	0.671	rs1806258	chr17:5314956	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.48e-8	Body mass index;
KIRP	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg12573791	chr2:3828286	NA	0.48	6.97	0.41	2.93e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs17221829	0.863	rs11018739	chr11:89427654	A/G	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.03	-0.31	9.34e-7	Anxiety in major depressive disorder;
KIRP	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs55665837	0.701	rs12787709	chr11:14639257	G/A	cg04446326	chr11:14613845	PSMA1	-0.41	-5.21	-0.32	4e-7	Vitamin D levels;
KIRP	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg10117171	chr1:25599238	RHD	0.38	5.19	0.31	4.39e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs687432	0.924	rs1510420	chr11:57701198	T/C	cg19752551	chr11:57585705	CTNND1	-0.7	-9.24	-0.51	1.2e-17	Parkinson's disease;
KIRP	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	cis	rs6442310	0.534	rs1822825	chr3:12449963	G/A	cg15873301	chr3:12045459	SYN2	-0.41	-5.55	-0.33	7.28e-8	Hematocrit;
KIRP	cis	rs258892	0.895	rs266424	chr5:72122660	G/A	cg21869765	chr5:72125136	TNPO1	-0.57	-6.32	-0.37	1.22e-9	Small cell lung carcinoma;
KIRP	cis	rs8113308	0.515	rs4986770	chr19:52468034	G/A	cg25782003	chr19:52490127	ZNF350	0.85	6.15	0.37	3.05e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	0.99	10.06	0.54	3.59e-20	Height;
KIRP	trans	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg25042112	chr7:64838748	ZNF92	-0.61	-6.26	-0.37	1.72e-9	Pain;
KIRP	cis	rs35661897	0.920	rs4522589	chr2:227328729	G/A	cg03426602	chr2:227312417	NA	-0.53	-6.82	-0.4	6.9e-11	Urinary tract infection frequency;
KIRP	trans	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg19274270	chr17:78178856	CARD14	-0.36	-6.67	-0.39	1.66e-10	Kawasaki disease;
KIRP	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06634786	chr22:41940651	POLR3H	-0.54	-6.27	-0.37	1.57e-9	Neuroticism;
KIRP	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.49	-5.07	-0.31	7.8e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.65	8.85	0.49	1.81e-16	Alcohol dependence;
KIRP	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	8.31	0.47	6.53e-15	Bone mineral density;
KIRP	cis	rs427941	0.632	rs201522	chr7:101771546	C/T	cg06246474	chr7:101738831	CUX1	0.47	5.56	0.33	6.86e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.3	0.32	2.61e-7	Bipolar disorder;
KIRP	cis	rs77688320	0.517	rs10931949	chr2:202324453	C/T	cg06431681	chr2:202330990	STRADB	0.53	7.16	0.42	9.17e-12	Breast cancer;
KIRP	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.72	8.73	0.49	3.99e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.78	10.83	0.57	1.31e-22	Coronary artery disease;
KIRP	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.25	0.62	3.02e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg25039879	chr17:56429692	SUPT4H1	0.57	5.11	0.31	6.58e-7	Cognitive test performance;
KIRP	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg08392591	chr16:89556376	ANKRD11	0.4	5.23	0.32	3.61e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg25482853	chr8:67687455	SGK3	0.79	6.99	0.41	2.64e-11	Obesity-related traits;
KIRP	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg18164611	chr1:46958628	NA	0.42	5.22	0.32	3.86e-7	Monobrow;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15720156	chr1:233430398	PCNXL2	0.52	7.17	0.42	8.67e-12	Interleukin-4 levels;
KIRP	cis	rs78545713	0.892	rs113432940	chr6:26256324	T/A	cg01420254	chr6:26195488	NA	0.61	4.86	0.3	2.05e-6	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs1318772	1.000	rs414475	chr5:112808617	A/T	cg12552261	chr5:112820674	MCC	-0.8	-5.11	-0.31	6.49e-7	F-cell distribution;
KIRP	cis	rs7709909	0.720	rs408626	chr5:79951133	T/C	cg24059623	chr5:79951536	MSH3;DHFR	0.39	5.39	0.32	1.67e-7	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs7973719	1.000	rs7973719	chr12:7334813	C/T	cg07052231	chr12:7363540	PEX5	0.4	5.09	0.31	7.11e-7	IgG glycosylation;
KIRP	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg16141378	chr3:129829833	LOC729375	0.56	7.74	0.44	2.52e-13	Neuroticism;
KIRP	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg02476566	chr12:106696527	TCP11L2	-0.5	-4.84	-0.3	2.26e-6	Tourette syndrome;
KIRP	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.51	-5.53	-0.33	8.06e-8	Total body bone mineral density;
KIRP	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.26	14.07	0.67	2.15e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.25	7.05	0.41	1.76e-11	Type 2 diabetes;
KIRP	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.62	0.52	8.19e-19	Morning vs. evening chronotype;
KIRP	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.47	5.68	0.34	3.77e-8	Common traits (Other);
KIRP	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.52	0.38	3.99e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg00074818	chr8:8560427	CLDN23	0.41	5.99	0.36	7.25e-9	Obesity-related traits;
KIRP	trans	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.15	-0.37	3.06e-9	Joint mobility (Beighton score);
KIRP	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg00405596	chr8:11794950	NA	-0.45	-5.59	-0.34	6.13e-8	Neuroticism;
KIRP	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.52	7.07	0.41	1.56e-11	Heart rate;
KIRP	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg14092571	chr14:90743983	NA	0.41	5.53	0.33	8.26e-8	Mortality in heart failure;
KIRP	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg25036284	chr2:26402008	FAM59B	-0.51	-5.37	-0.32	1.85e-7	Gut microbiome composition (summer);
KIRP	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.54	6.26	0.37	1.67e-9	Schizophrenia;
KIRP	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.54	-0.62	3.12e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg26138937	chr11:71823887	C11orf51	-1.01	-6.96	-0.41	3.01e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs6893300	0.826	rs7734102	chr5:179153797	A/G	cg14593053	chr5:179126677	CANX	0.59	7.3	0.42	3.97e-12	Resting heart rate;
KIRP	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.99	-0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-5.71	-0.34	3.24e-8	Personality dimensions;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg16453206	chr5:36877216	NIPBL	-0.5	-6.83	-0.4	6.76e-11	Migraine with aura;
KIRP	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg05802129	chr4:122689817	NA	-0.7	-9.43	-0.52	3.24e-18	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25912827	chr2:162930805	DPP4	0.42	6.15	0.37	3.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.07	12.87	0.63	2.44e-29	Vitiligo;
KIRP	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.76	-0.34	2.44e-8	Coronary artery disease;
KIRP	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg12923728	chr3:195709715	SDHAP1	-0.8	-8.93	-0.49	9.91e-17	Pancreatic cancer;
KIRP	cis	rs5995756	0.712	rs9611205	chr22:40010521	G/A	cg10455938	chr22:40058150	CACNA1I	-0.59	-8.71	-0.49	4.5e-16	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.65	-9.83	-0.53	1.96e-19	Menarche (age at onset);
KIRP	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23903597	chr17:61704154	MAP3K3	0.48	5.6	0.34	5.65e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.69	-0.53	5.3e-19	Neuroticism;
KIRP	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.39e-9	Neuroticism;
KIRP	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg17108064	chr15:78857060	CHRNA5	0.34	4.84	0.3	2.27e-6	Sudden cardiac arrest;
KIRP	cis	rs17065868	1.000	rs9533873	chr13:45060304	T/C	cg10246903	chr13:45222710	NA	0.66	6.33	0.37	1.12e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.65	12.14	0.61	6.98e-27	Blood protein levels;
KIRP	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.64	8.03	0.46	4.06e-14	Body mass index;
KIRP	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.47	-5.97	-0.36	8.33e-9	Crohn's disease;
KIRP	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg01214346	chr17:406501	NA	0.45	5.81	0.35	1.96e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.31e-9	Parkinson's disease;
KIRP	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.96	-0.5	8.41e-17	Platelet count;
KIRP	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.37e-10	Aortic root size;
KIRP	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.65	12.15	0.61	6.45e-27	Blood protein levels;
KIRP	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.61	-8.28	-0.47	7.9e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-6.5	-0.38	4.41e-10	Urinary tract infection frequency;
KIRP	cis	rs748404	0.588	rs506120	chr15:43802024	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.6	7.42	0.43	1.86e-12	Lung cancer;
KIRP	cis	rs9596863	0.898	rs7995039	chr13:54382214	G/A	ch.13.53330881F	chr13:54432880	NA	0.62	6.16	0.37	2.96e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg11693508	chr17:37793320	STARD3	0.5	6.86	0.4	5.59e-11	Bipolar disorder;
KIRP	trans	rs977145	0.855	rs11209780	chr1:71876652	A/G	cg13566436	chr1:25240865	RUNX3	-0.38	-6.08	-0.36	4.6e-9	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks);
KIRP	cis	rs7665939	0.860	rs72709255	chr4:190129201	C/T	cg09826759	chr4:190284978	NA	-0.81	-5.66	-0.34	4.27e-8	Amyotrophic lateral sclerosis;
KIRP	cis	rs6545883	0.929	rs9679557	chr2:61709349	C/A	cg15711740	chr2:61764176	XPO1	-0.6	-7.97	-0.45	6.09e-14	Tuberculosis;
KIRP	cis	rs12986413	0.967	rs2108524	chr19:2170764	A/G	cg09261902	chr19:2140048	AP3D1	0.62	9.78	0.53	2.72e-19	Height;
KIRP	cis	rs838147	0.844	rs8105137	chr19:49249888	G/A	cg13540341	chr19:49222985	MAMSTR	0.31	5.09	0.31	6.97e-7	Dietary macronutrient intake;
KIRP	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.24	26.31	0.86	1.87e-73	IgG glycosylation;
KIRP	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.81	-9.18	-0.51	1.81e-17	Pancreatic cancer;
KIRP	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg19554555	chr3:13937349	NA	-0.45	-6.25	-0.37	1.84e-9	Ovarian reserve;
KIRP	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.56	5.09	0.31	7.05e-7	Bipolar disorder;
KIRP	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.44	-0.65	3.06e-31	Height;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03637447	chr2:99061186	INPP4A	0.68	7.61	0.44	5.83e-13	Lung cancer in ever smokers;
KIRP	cis	rs9912468	0.647	rs9895261	chr17:64240436	A/G	cg19474267	chr17:64306194	PRKCA	-0.47	-5.96	-0.36	8.73e-9	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.46	5.89	0.35	1.26e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs738722	0.514	rs695567	chr22:28889735	C/A	cg16849201	chr22:29715310	NA	-0.31	-5.03	-0.31	9.39e-7	Optic cup area;Esophageal cancer and gastric cancer;
KIRP	cis	rs3767633	0.925	rs10733044	chr1:161903534	A/G	cg09175582	chr1:161736000	ATF6	-0.72	-5.88	-0.35	1.34e-8	IgG glycosylation;
KIRP	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24110177	chr3:50126178	RBM5	-0.43	-5.5	-0.33	9.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.27	0.32	3.01e-7	Coronary artery disease;
KIRP	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	trans	rs35100037	0.803	rs28886668	chr5:128638752	A/G	cg23338408	chr14:31289523	NA	-0.6	-6.16	-0.37	2.88e-9	Ankle injury;
KIRP	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg08885076	chr2:99613938	TSGA10	-0.38	-5.52	-0.33	8.54e-8	Bipolar disorder;
KIRP	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.67	0.44	4.01e-13	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs6601327	0.635	rs7821575	chr8:9665955	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.8	-0.4	7.74e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg23601095	chr6:26197514	HIST1H3D	1.02	8.6	0.48	9.47e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs832187	0.704	rs832195	chr3:63864612	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.47	5.25	0.32	3.21e-7	Schizophrenia;
KIRP	cis	rs73200209	0.744	rs56187732	chr12:116688042	C/T	cg01776926	chr12:116560359	MED13L	-0.56	-6.27	-0.37	1.64e-9	Total body bone mineral density;
KIRP	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg02980000	chr4:1222292	CTBP1	0.8	9.24	0.51	1.17e-17	Systolic blood pressure;
KIRP	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.41	-4.92	-0.3	1.56e-6	IgG glycosylation;
KIRP	cis	rs2016266	0.784	rs7308162	chr12:53654956	G/A	cg16917193	chr12:54089295	NA	0.42	5.11	0.31	6.52e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.79	0.35	2.08e-8	Lung cancer;
KIRP	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.35	0.38	1.06e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.87	-0.57	9.97e-23	Chronic sinus infection;
KIRP	cis	rs10211205	1.000	rs10173638	chr2:236613478	G/A	cg02339850	chr2:236586191	AGAP1	-0.55	-5.62	-0.34	5.28e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg00405596	chr8:11794950	NA	-0.48	-6.71	-0.39	1.33e-10	Triglycerides;
KIRP	cis	rs1823913	0.503	rs34716486	chr2:192208061	C/T	cg12404831	chr2:192114017	MYO1B	0.51	7.01	0.41	2.3e-11	Obesity-related traits;
KIRP	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.11	0.67	1.54e-33	Tonsillectomy;
KIRP	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.65	5.51	0.33	9.18e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.57	0.56	9.26e-22	Cognitive test performance;
KIRP	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.17	-22.83	-0.82	1.04e-62	Exhaled nitric oxide output;
KIRP	cis	rs300890	0.710	rs3846235	chr4:144227841	C/T	cg19876092	chr4:144208277	NA	0.37	5.37	0.32	1.79e-7	Nasopharyngeal carcinoma;
KIRP	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.33	0.37	1.17e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7523273	0.597	rs66532523	chr1:207983745	A/C	cg22525895	chr1:207977042	MIR29B2	-0.62	-5.95	-0.35	9.14e-9	Schizophrenia;
KIRP	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.83	-12.01	-0.61	1.85e-26	Educational attainment;
KIRP	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-4.9	-0.3	1.77e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.66	8.37	0.47	4.24e-15	Body mass index;
KIRP	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.68	10.22	0.55	1.12e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20089095	chr3:185303988	SENP2	0.43	6.04	0.36	5.59e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27297192	chr10:134578999	INPP5A	0.64	8.0	0.45	5.02e-14	Migraine;
KIRP	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.6	-5.56	-0.33	6.89e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg00677455	chr12:58241039	CTDSP2	0.59	6.76	0.4	9.97e-11	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	1.0	10.31	0.55	5.86e-21	Alzheimer's disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15642758	chr15:83876612	HDGFRP3	0.96	6.3	0.37	1.39e-9	P wave terminal force;
KIRP	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg26681399	chr22:41777847	TEF	-0.52	-4.94	-0.3	1.46e-6	Vitiligo;
KIRP	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.06	-0.41	1.71e-11	Diabetic kidney disease;
KIRP	cis	rs240764	0.658	rs705584	chr6:101261553	C/T	cg09795085	chr6:101329169	ASCC3	0.48	5.69	0.34	3.55e-8	Neuroticism;
KIRP	cis	rs735539	0.645	rs9552253	chr13:21202350	T/C	cg04906043	chr13:21280425	IL17D	-0.49	-5.6	-0.34	5.68e-8	Dental caries;
KIRP	cis	rs5742915	0.513	rs7183908	chr15:74329193	T/C	cg17221444	chr15:74284820	STOML1	-0.43	-5.05	-0.31	8.45e-7	Height;Paget's disease;
KIRP	cis	rs10858047	0.883	rs7556270	chr1:115178041	T/C	cg12756093	chr1:115239321	AMPD1	-0.67	-6.46	-0.38	5.42e-10	Autism;
KIRP	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.86	11.95	0.61	2.92e-26	Systolic blood pressure;
KIRP	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.42	-5.35	-0.32	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.71	0.49	4.42e-16	Motion sickness;
KIRP	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg05973401	chr12:123451056	ABCB9	0.56	4.99	0.3	1.15e-6	Neutrophil percentage of white cells;
KIRP	cis	rs394563	0.591	rs237035	chr6:149710848	C/T	cg16235748	chr6:149772707	ZC3H12D	-0.32	-5.45	-0.33	1.19e-7	Dupuytren's disease;
KIRP	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg26876637	chr1:152193138	HRNR	-0.77	-10.38	-0.55	3.52e-21	Atopic dermatitis;
KIRP	cis	rs17453880	0.750	rs2964240	chr5:151924531	T/C	cg12297329	chr5:152029980	NA	-0.5	-7.11	-0.41	1.29e-11	Subjective well-being;
KIRP	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg13147721	chr7:65941812	NA	1.04	7.43	0.43	1.73e-12	Diabetic kidney disease;
KIRP	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.46	4.93	0.3	1.5e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.04	15.25	0.7	2.07e-37	Primary sclerosing cholangitis;
KIRP	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.62	-8.2	-0.46	1.31e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg23682824	chr7:23144976	KLHL7	0.54	6.58	0.39	2.88e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.34	-0.47	5.25e-15	Mood instability;
KIRP	cis	rs2191566	0.576	rs381091	chr19:44495315	G/A	cg18700516	chr19:44507157	ZNF230	0.42	4.85	0.3	2.23e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6142102	0.646	rs2223553	chr20:32709444	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	5.25	0.32	3.22e-7	Skin pigmentation;
KIRP	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg15485101	chr11:133734466	NA	0.48	6.28	0.37	1.56e-9	Childhood ear infection;
KIRP	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.76	-11.27	-0.58	5.14e-24	Endometriosis;
KIRP	cis	rs7116495	1.000	rs7103210	chr11:71648966	G/C	cg26138937	chr11:71823887	C11orf51	-0.64	-5.25	-0.32	3.28e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg05315796	chr3:52349193	DNAH1	0.42	6.45	0.38	5.77e-10	Bipolar disorder;
KIRP	cis	rs12580194	0.593	rs3935215	chr12:55792401	T/A	cg11794356	chr12:55725991	OR6C3	-0.53	-6.95	-0.4	3.32e-11	Cancer;
KIRP	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg15556689	chr8:8085844	FLJ10661	0.64	8.02	0.46	4.2e-14	Neuroticism;
KIRP	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.5	-7.15	-0.41	1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9443645	0.611	rs10943616	chr6:79823541	G/A	cg11833968	chr6:79620685	NA	-0.36	-5.08	-0.31	7.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.89	13.85	0.66	1.21e-32	Mean corpuscular volume;
KIRP	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.69	-0.39	1.49e-10	Immature fraction of reticulocytes;
KIRP	cis	rs743757	1.000	rs2282754	chr3:50436827	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.47	5.17	0.31	4.95e-7	Diastolic blood pressure;
KIRP	cis	rs42648	0.536	rs13242882	chr7:89800053	A/T	cg25739043	chr7:89950458	NA	-0.34	-5.29	-0.32	2.7e-7	Homocysteine levels;
KIRP	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	1.08	8.07	0.46	3.05e-14	Skin colour saturation;
KIRP	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	0.85	5.15	0.31	5.39e-7	Height;
KIRP	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.69	10.09	0.54	2.97e-20	Dupuytren's disease;
KIRP	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.65	-9.2	-0.51	1.64e-17	Retinal vascular caliber;
KIRP	cis	rs597583	0.806	rs2276339	chr11:117395481	G/A	cg27161313	chr11:117392002	DSCAML1	-0.55	-6.09	-0.36	4.33e-9	Putamen volume;
KIRP	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg17108064	chr15:78857060	CHRNA5	0.36	4.9	0.3	1.75e-6	Sudden cardiac arrest;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10659575	chr11:102188233	BIRC3	0.54	7.43	0.43	1.74e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.85	-0.4	6.05e-11	Type 2 diabetes;
KIRP	cis	rs7769051	0.522	rs7769354	chr6:133146865	G/T	cg22852734	chr6:133119734	C6orf192	0.93	4.99	0.3	1.16e-6	Type 2 diabetes nephropathy;
KIRP	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg10189774	chr4:17578691	LAP3	-0.45	-5.25	-0.32	3.3e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05479791	chr8:146228139	ZNF252;C8orf77	-0.55	-6.09	-0.36	4.28e-9	Menopause (age at onset);
KIRP	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg16558253	chr16:72132732	DHX38	-0.6	-9.18	-0.51	1.79e-17	Fibrinogen levels;
KIRP	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg18404041	chr3:52824283	ITIH1	0.41	5.36	0.32	1.95e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05776053	chr2:74358815	NA	0.55	5.74	0.34	2.74e-8	Gestational age at birth (maternal effect);
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.54	-7.28	-0.42	4.35e-12	Glycated hemoglobin levels;
KIRP	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.65	9.39	0.51	4.21e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs35100037	0.803	rs13166431	chr5:128643955	A/T	cg23338408	chr14:31289523	NA	0.57	6.11	0.36	3.98e-9	Ankle injury;
KIRP	cis	rs2976388	1.000	rs2920280	chr8:143761144	G/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.33	-0.37	1.17e-9	Urinary tract infection frequency;
KIRP	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	cis	rs8177876	0.822	rs4324142	chr16:81114903	G/C	cg08591886	chr16:81111003	C16orf46	-0.59	-5.76	-0.34	2.45e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.22	-0.46	1.2e-14	Monocyte percentage of white cells;
KIRP	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg24879335	chr3:133465180	TF	0.51	8.32	0.47	6.18e-15	Iron status biomarkers;
KIRP	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg16482183	chr6:26056742	HIST1H1C	0.45	5.68	0.34	3.78e-8	Height;
KIRP	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.85	-0.3	2.17e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs1505368	0.563	rs1394798	chr2:213230641	G/A	cg20637307	chr2:213403960	ERBB4	0.5	6.68	0.39	1.59e-10	Symmetrical dimethylarginine levels;
KIRP	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.39	-5.07	-0.31	7.7e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.78	-9.25	-0.51	1.12e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.66	-0.52	6.29e-19	Response to antipsychotic treatment;
KIRP	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.7	7.87	0.45	1.15e-13	Asthma;
KIRP	cis	rs1440410	0.835	rs10016850	chr4:144056847	T/C	cg19876092	chr4:144208277	NA	0.29	4.88	0.3	1.88e-6	Ischemic stroke;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg19851384	chr11:48001835	PTPRJ	-0.41	-6.19	-0.37	2.44e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-8.27	-0.47	8.36e-15	Personality dimensions;
KIRP	cis	rs6684514	1.000	rs10908498	chr1:156278175	T/C	cg16558208	chr1:156270281	VHLL	-0.43	-5.79	-0.35	2.13e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6594499	0.807	rs6594497	chr5:110415868	A/T	cg04022379	chr5:110408740	TSLP	0.47	7.16	0.42	9.31e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs8179	0.645	rs12531820	chr7:92257392	A/G	cg15732164	chr7:92237376	CDK6	-0.39	-5.18	-0.31	4.63e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg22974920	chr21:40686053	BRWD1	0.51	6.14	0.36	3.23e-9	Cognitive function;
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg05562828	chr17:3906858	NA	-0.72	-13.75	-0.66	2.61e-32	Type 2 diabetes;
KIRP	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg09231725	chr11:64357281	SLC22A12	0.62	8.26	0.47	8.79e-15	Urate levels in obese individuals;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.49	6.59	0.39	2.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs867371	0.502	rs3759800	chr15:82532963	A/C	cg00614314	chr15:82944287	LOC80154	-0.4	-5.04	-0.31	9.04e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs9650657	0.771	rs12542888	chr8:10662555	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.03	-0.36	5.89e-9	Neuroticism;
KIRP	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13877915	chr19:58951672	ZNF132	0.39	4.93	0.3	1.5e-6	Uric acid clearance;
KIRP	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg08975724	chr8:8085496	FLJ10661	0.66	8.19	0.46	1.44e-14	Parkinson's disease;
KIRP	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	9.52	0.52	1.68e-18	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15627593	chr17:17457836	PEMT	0.53	6.36	0.38	9.65e-10	Interleukin-4 levels;
KIRP	cis	rs241257	0.643	rs241270	chr1:4625189	A/T	cg02837536	chr1:4771682	AJAP1	0.28	5.02	0.3	9.95e-7	Anxiety disorder;
KIRP	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg06219351	chr7:158114137	PTPRN2	-0.56	-7.73	-0.44	2.71e-13	Calcium levels;
KIRP	trans	rs2594989	0.831	rs6803125	chr3:11583228	A/G	cg02538783	chr10:35102505	PARD3	0.36	6.1	0.36	4.09e-9	Circulating chemerin levels;
KIRP	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.74	7.0	0.41	2.42e-11	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.57	-0.39	3.01e-10	Lung cancer;
KIRP	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg19898043	chr22:18121309	BCL2L13	0.62	7.04	0.41	1.93e-11	Sum neutrophil eosinophil counts;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.98	-11.77	-0.6	1.19e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	1.05	17.76	0.75	5.55e-46	Bone mineral density;
KIRP	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.68	7.94	0.45	7.15e-14	Diabetic retinopathy;
KIRP	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.68	5.0	0.3	1.11e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg05964544	chr11:70165517	PPFIA1	-0.53	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs4474465	0.850	rs7938816	chr11:78266227	T/C	cg27205649	chr11:78285834	NARS2	0.72	7.86	0.45	1.2e-13	Alzheimer's disease (survival time);
KIRP	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05220968	chr6:146057943	EPM2A	0.4	5.22	0.32	3.74e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs918629	0.530	rs11739652	chr5:95238582	C/G	cg16656078	chr5:95278638	ELL2	-0.39	-5.87	-0.35	1.38e-8	IgG glycosylation;
KIRP	cis	rs13427251	0.653	rs11123787	chr2:100156940	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-6.29	-0.37	1.4e-9	Chronic sinus infection;
KIRP	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-7.15	-0.41	9.85e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	9.01	0.5	5.69e-17	Personality dimensions;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg18209359	chr17:80159595	CCDC57	0.42	5.47	0.33	1.1e-7	Life satisfaction;
KIRP	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg15147215	chr3:52552868	STAB1	-0.27	-4.87	-0.3	1.99e-6	Bipolar disorder;
KIRP	cis	rs6429082	0.623	rs7547849	chr1:235564254	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.74	-9.18	-0.51	1.79e-17	Adiposity;
KIRP	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.49	-5.48	-0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.74	7.31	0.42	3.66e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg25930673	chr12:123319894	HIP1R	-0.72	-6.47	-0.38	5.29e-10	Schizophrenia;
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg06654118	chr4:1303317	MAEA	0.29	5.17	0.31	4.92e-7	Obesity-related traits;
KIRP	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	trans	rs12043259	1.000	rs11240296	chr1:204825286	C/T	cg11485465	chr5:54518469	NA	0.4	6.31	0.37	1.26e-9	Addiction;
KIRP	cis	rs7084402	0.934	rs1649051	chr10:60321997	A/G	cg05938607	chr10:60274200	BICC1	-0.48	-11.78	-0.6	1.09e-25	Refractive error;
KIRP	cis	rs10207060	0.500	rs10181238	chr2:240709496	G/A	cg20333904	chr2:240724165	NA	-0.51	-6.02	-0.36	6.36e-9	Obesity-related traits;
KIRP	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.43	-5.5	-0.33	9.55e-8	Aortic root size;
KIRP	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.5	-6.59	-0.39	2.69e-10	IgG glycosylation;
KIRP	trans	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg19694781	chr19:47549865	TMEM160	-0.51	-6.23	-0.37	1.97e-9	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs1076160	0.811	rs10117989	chr9:135710625	C/T	cg04648087	chr9:135819397	TSC1	-0.39	-4.85	-0.3	2.21e-6	Psoriasis;
KIRP	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	1.08	19.52	0.78	6.89e-52	Systemic lupus erythematosus;
KIRP	cis	rs687432	0.737	rs7948507	chr11:57913108	G/T	cg19752551	chr11:57585705	CTNND1	-0.58	-7.53	-0.43	9.39e-13	Parkinson's disease;
KIRP	cis	rs13102973	0.932	rs7656273	chr4:135852678	G/A	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.12e-16	Subjective well-being;
KIRP	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.57	-6.29	-0.37	1.41e-9	Colorectal adenoma (advanced);
KIRP	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg10223061	chr2:219282414	VIL1	-0.34	-5.35	-0.32	1.97e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg05861140	chr6:150128134	PCMT1	-0.45	-6.45	-0.38	5.99e-10	Lung cancer;
KIRP	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.46	5.39	0.32	1.69e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs883115	0.791	rs7532595	chr1:224794237	T/C	cg01808320	chr1:224927238	CNIH3	-0.37	-5.23	-0.32	3.56e-7	Cancer;
KIRP	cis	rs7662987	0.793	rs7684735	chr4:99991506	C/T	cg13256891	chr4:100009986	ADH5	-0.65	-5.59	-0.34	5.93e-8	Smoking initiation;
KIRP	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.46	-5.6	-0.34	5.57e-8	Diastolic blood pressure;
KIRP	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.29	6.72	0.39	1.25e-10	IgG glycosylation;
KIRP	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-1.05	-12.85	-0.63	2.89e-29	Exhaled nitric oxide output;
KIRP	trans	rs6993813	0.678	rs6469792	chr8:120008371	T/C	cg22961513	chr11:14280813	SPON1	0.36	6.08	0.36	4.45e-9	Bone mineral density (hip);
KIRP	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.7	10.63	0.56	5.58e-22	Blood metabolite ratios;
KIRP	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.75	-0.34	2.7e-8	Educational attainment;
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.8	0.35	2.02e-8	Lung cancer;
KIRP	trans	rs3128341	0.818	rs12144335	chr1:72828183	T/C	cg16299813	chr17:79632380	C17orf90;CCDC137	-0.34	-6.06	-0.36	4.97e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	8.11	0.46	2.39e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.59	7.32	0.42	3.49e-12	Arsenic metabolism;
KIRP	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg24060327	chr5:131705240	SLC22A5	-0.48	-6.23	-0.37	1.97e-9	Blood metabolite levels;
KIRP	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.56	-6.79	-0.4	8.22e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg00405596	chr8:11794950	NA	0.57	7.88	0.45	1.03e-13	Myopia (pathological);
KIRP	cis	rs73036520	0.646	rs11666411	chr19:45798195	C/T	cg01416317	chr19:45737208	EXOC3L2	0.42	4.97	0.3	1.23e-6	Monocyte percentage of white cells;
KIRP	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg10223061	chr2:219282414	VIL1	-0.3	-4.91	-0.3	1.64e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.24	-0.42	5.59e-12	Menopause (age at onset);
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.98	10.97	0.57	4.7e-23	Alzheimer's disease;
KIRP	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.57	7.44	0.43	1.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg05220968	chr6:146057943	EPM2A	-0.42	-5.61	-0.34	5.45e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3774830	0.748	rs17367445	chr4:5464903	C/T	cg26943120	chr4:5472116	STK32B	0.24	5.87	0.35	1.4e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.55	-6.8	-0.4	7.92e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.86	-11.98	-0.61	2.34e-26	Primary sclerosing cholangitis;
KIRP	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg05791153	chr7:19748676	TWISTNB	0.62	5.79	0.35	2.18e-8	Thyroid stimulating hormone;
KIRP	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg06742321	chr12:123595122	PITPNM2	0.56	6.83	0.4	6.69e-11	Neutrophil percentage of white cells;
KIRP	cis	rs16828019	0.852	rs12044539	chr1:41661732	A/C	cg03387723	chr1:41708464	SCMH1	-0.81	-6.91	-0.4	4.15e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.91	-0.35	1.12e-8	LDL cholesterol levels;
KIRP	cis	rs11203032	0.831	rs11203027	chr10:90956290	T/A	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs7638909	0.512	rs6793245	chr3:38599037	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.44	5.52	0.33	8.64e-8	Electrocardiographic conduction measures;
KIRP	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg05973401	chr12:123451056	ABCB9	-0.58	-6.78	-0.4	9.04e-11	Neutrophil percentage of white cells;
KIRP	cis	rs17301259	0.564	rs10248441	chr7:88416536	T/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-5.38	-0.32	1.76e-7	Heschl's gyrus morphology;
KIRP	cis	rs4713675	0.565	rs4713668	chr6:33690796	C/T	cg14003231	chr6:33640908	ITPR3	0.28	5.09	0.31	6.96e-7	Plateletcrit;
KIRP	cis	rs6430538	0.671	rs6740829	chr2:135573264	A/G	cg25422880	chr2:135218333	TMEM163	-0.44	-6.18	-0.37	2.63e-9	Parkinson's disease;
KIRP	cis	rs9815354	0.857	rs6798152	chr3:42023558	A/T	cg03022575	chr3:42003672	ULK4	0.72	7.12	0.41	1.22e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.65	-8.02	-0.46	4.28e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4363385	0.510	rs11577384	chr1:152899728	C/T	cg07796016	chr1:152779584	LCE1C	-0.46	-5.78	-0.35	2.24e-8	Inflammatory skin disease;
KIRP	cis	rs714031	0.730	rs5757766	chr22:40069490	T/C	cg21377881	chr22:40064566	CACNA1I	-0.66	-10.33	-0.55	5.22e-21	Schizophrenia;
KIRP	cis	rs6547631	0.502	rs77067405	chr2:85927739	G/T	cg24620635	chr2:85921963	GNLY	0.33	5.19	0.31	4.51e-7	Blood protein levels;
KIRP	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-1.06	-12.34	-0.62	1.45e-27	Height;
KIRP	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg03887218	chr1:16534349	ARHGEF19	0.56	7.5	0.43	1.13e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs151997	0.569	rs10035173	chr5:50276059	C/G	cg06027927	chr5:50259733	NA	0.53	6.63	0.39	2.11e-10	Callous-unemotional behaviour;
KIRP	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.58	-7.57	-0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs28834970	0.675	rs6557994	chr8:27232018	A/G	cg21186296	chr8:27182909	PTK2B	-0.41	-4.86	-0.3	2.11e-6	Alzheimer's disease (late onset);
KIRP	cis	rs4748857	0.853	rs7095016	chr10:23610272	C/G	cg12804278	chr10:23633326	C10orf67	-0.47	-5.74	-0.34	2.72e-8	Systemic lupus erythematosus;
KIRP	cis	rs4132509	1.000	rs6681863	chr1:243982709	C/G	cg21452805	chr1:244014465	NA	0.58	5.6	0.34	5.68e-8	RR interval (heart rate);
KIRP	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs7688540	0.771	rs4582105	chr4:246342	T/C	cg17891759	chr4:299121	NA	-0.49	-5.0	-0.3	1.09e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg02996583	chr8:142237188	SLC45A4	-0.49	-6.02	-0.36	6.38e-9	Immature fraction of reticulocytes;
KIRP	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20135002	chr11:47629003	NA	-0.47	-5.27	-0.32	2.97e-7	Subjective well-being;
KIRP	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.42	4.85	0.3	2.15e-6	Menopause (age at onset);
KIRP	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23161317	chr6:28129485	ZNF389	0.46	5.36	0.32	1.89e-7	Depression;
KIRP	cis	rs10510057	0.614	rs10787982	chr10:121324883	C/G	cg06765389	chr10:121379685	NA	-0.48	-7.51	-0.43	1.07e-12	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg27411982	chr8:10470053	RP1L1	0.41	5.37	0.32	1.86e-7	Retinal vascular caliber;
KIRP	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.6	8.12	0.46	2.2e-14	Motion sickness;
KIRP	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg14689365	chr7:158441557	NCAPG2	0.49	6.24	0.37	1.9e-9	Height;
KIRP	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.77	7.76	0.44	2.24e-13	Bipolar disorder;
KIRP	cis	rs9469913	0.551	rs9469864	chr6:34739932	G/A	cg17674042	chr6:34482479	PACSIN1	-0.38	-5.17	-0.31	4.73e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1318772	1.000	rs68189049	chr5:112690255	C/T	cg12552261	chr5:112820674	MCC	0.68	5.03	0.31	9.41e-7	F-cell distribution;
KIRP	cis	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg02681480	chr8:81490484	NA	0.4	5.03	0.31	9.58e-7	Bladder cancer;
KIRP	cis	rs3026101	0.671	rs28409881	chr17:5319100	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.36	5.22	0.32	3.81e-7	Coronary artery disease;
KIRP	cis	rs8077577	0.895	rs11655797	chr17:18107850	C/T	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.59	-6.48	-0.38	4.83e-10	Vitiligo;
KIRP	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg01843034	chr6:37503916	NA	-0.69	-7.95	-0.45	6.59e-14	Cognitive performance;
KIRP	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.39	-4.89	-0.3	1.83e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.57	7.71	0.44	3.06e-13	Plateletcrit;Platelet count;
KIRP	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.45e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10322419	chr1:4470956	LOC284661	0.42	6.46	0.38	5.59e-10	Survival in pancreatic cancer;
KIRP	cis	rs9653442	0.545	rs10496344	chr2:100764125	C/T	cg17356467	chr2:100759845	AFF3	-0.42	-5.71	-0.34	3.22e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.75	7.75	0.44	2.43e-13	Lung function (FEV1/FVC);
KIRP	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.55	-6.31	-0.37	1.29e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.43	-6.31	-0.37	1.31e-9	Personality dimensions;
KIRP	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg24253500	chr15:84953950	NA	-0.62	-6.61	-0.39	2.35e-10	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.73	-9.24	-0.51	1.19e-17	Aortic root size;
KIRP	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.95	12.77	0.63	5.44e-29	Breast cancer;
KIRP	cis	rs13102973	0.867	rs4521398	chr4:135906934	T/G	cg14419869	chr4:135874104	NA	0.48	7.44	0.43	1.67e-12	Subjective well-being;
KIRP	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.67	9.87	0.53	1.47e-19	Dupuytren's disease;
KIRP	cis	rs31771	0.690	rs31763	chr5:165501892	G/T	cg13976338	chr5:165423657	NA	0.55	4.98	0.3	1.18e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg12756093	chr1:115239321	AMPD1	0.53	7.1	0.41	1.31e-11	Autism;
KIRP	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs6032067	1.000	rs6032060	chr20:43852454	A/T	cg10761708	chr20:43804764	PI3	0.51	5.22	0.32	3.78e-7	Blood protein levels;
KIRP	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.1	-0.36	4.01e-9	Ulcerative colitis;
KIRP	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.63	9.04	0.5	4.88e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs3935685	0.874	rs11072663	chr15:77999542	A/G	cg25212270	chr15:78015279	NA	0.58	7.62	0.44	5.54e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.546	rs9993299	chr4:98815976	G/A	cg17366294	chr4:99064904	C4orf37	0.38	4.87	0.3	2e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.85	13.58	0.65	9.82e-32	Multiple myeloma (IgH translocation);
KIRP	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.4	4.88	0.3	1.88e-6	Vitiligo;
KIRP	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21302194	chr4:155412348	DCHS2	0.86	6.25	0.37	1.82e-9	P wave terminal force;
KIRP	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.61	7.14	0.41	1.07e-11	Blood metabolite levels;
KIRP	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.56	-6.86	-0.4	5.55e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs860295	0.702	rs12746592	chr1:155505967	G/A	cg02153340	chr1:155202674	NA	-0.56	-7.68	-0.44	3.7e-13	Body mass index;
KIRP	cis	rs10214930	0.813	rs2391444	chr7:27642420	G/A	cg22168087	chr7:27702803	HIBADH	0.52	5.07	0.31	7.7e-7	Hypospadias;
KIRP	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg01633841	chr1:54872108	SSBP3	0.53	6.83	0.4	6.68e-11	Colorectal cancer;
KIRP	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.82	9.94	0.54	8.63e-20	Neutrophil percentage of white cells;
KIRP	cis	rs7937682	0.564	rs7115263	chr11:111379054	C/A	cg09085632	chr11:111637200	PPP2R1B	0.54	7.14	0.41	1.03e-11	Primary sclerosing cholangitis;
KIRP	cis	rs4073221	0.789	rs13092771	chr3:18213426	C/T	cg07694806	chr3:18168406	NA	-0.71	-6.16	-0.37	2.91e-9	Parkinson's disease;
KIRP	cis	rs4713118	1.000	rs9468195	chr6:27676309	A/G	cg20933634	chr6:27740509	NA	0.39	4.91	0.3	1.64e-6	Parkinson's disease;
KIRP	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg23335576	chr14:104009727	NA	0.4	5.49	0.33	1.02e-7	Body mass index;
KIRP	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23161317	chr6:28129485	ZNF389	-0.46	-5.42	-0.33	1.4e-7	Depression;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg18504358	chr14:23340787	LRP10	-0.46	-6.05	-0.36	5.51e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.68	-8.22	-0.46	1.18e-14	Corneal astigmatism;
KIRP	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg11522683	chr6:37501428	NA	-0.39	-5.04	-0.31	9.14e-7	Cognitive performance;
KIRP	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.43	-6.15	-0.36	3.19e-9	Coronary artery disease;
KIRP	cis	rs7615316	0.671	rs9816377	chr3:142357223	C/G	cg20824294	chr3:142316082	PLS1	-0.25	-5.24	-0.32	3.53e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16047490	chr17:73717197	ITGB4	0.51	6.65	0.39	1.92e-10	Parkinson's disease;
KIRP	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	12.79	0.63	4.52e-29	Ileal carcinoids;
KIRP	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs6832769	1.000	rs726967	chr4:56421713	A/T	cg05960024	chr4:56376020	CLOCK	-0.69	-8.63	-0.48	7.72e-16	Personality dimensions;
KIRP	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg02487422	chr3:49467188	NICN1	0.41	5.78	0.35	2.23e-8	Menarche (age at onset);
KIRP	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.74	-10.6	-0.56	7e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs8077577	0.747	rs62072537	chr17:18216100	G/A	cg18869244	chr17:18121946	NA	0.45	5.06	0.31	8.19e-7	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.66	-12.19	-0.61	4.87e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg11410718	chr7:27170412	HOXA4	-0.38	-5.35	-0.32	2.02e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-6.37	-0.38	9.01e-10	IgG glycosylation;
KIRP	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.4	-9.91	-0.53	1.1e-19	Corneal astigmatism;
KIRP	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg07621104	chr11:117668040	DSCAML1	0.43	6.42	0.38	7.03e-10	Myopia;
KIRP	cis	rs2729354	0.502	rs2848641	chr11:57263068	G/C	cg24343310	chr11:57249947	NA	0.24	5.18	0.31	4.55e-7	Blood protein levels;
KIRP	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.48	7.22	0.42	6.61e-12	Breast cancer;
KIRP	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg23682824	chr7:23144976	KLHL7	0.59	7.25	0.42	5.37e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9921338	0.924	rs72773831	chr16:11412927	G/A	cg00044050	chr16:11439710	C16orf75	-0.53	-5.65	-0.34	4.47e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg26149184	chr10:133730230	NA	0.42	4.97	0.3	1.24e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg01879757	chr17:41196368	BRCA1	-0.79	-10.89	-0.57	8.2000000000000006e-23	Menopause (age at onset);
KIRP	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9653442	0.527	rs11690905	chr2:100761473	C/T	cg07810366	chr2:100720526	AFF3	0.32	5.25	0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg01422370	chr2:73384389	NA	0.46	6.2	0.37	2.32e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20003050	chr2:58029503	NA	-0.45	-6.66	-0.39	1.73e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg04006718	chr10:1068667	C10orf110;IDI2	-0.71	-4.97	-0.3	1.25e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.4	0.33	1.54e-7	Neuroticism;
KIRP	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.75	-7.61	-0.44	6.01e-13	Bipolar disorder;
KIRP	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.53	-0.33	8.2e-8	Schizophrenia;
KIRP	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.45	5.4	0.33	1.59e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.98	11.18	0.58	9.52e-24	Pulmonary function decline;
KIRP	cis	rs3126085	0.560	rs72698932	chr1:152355520	C/T	cg26876637	chr1:152193138	HRNR	-0.65	-6.67	-0.39	1.67e-10	Atopic dermatitis;
KIRP	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-1.27	-12.8	-0.63	4.19e-29	Post bronchodilator FEV1;
KIRP	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.44	-6.39	-0.38	8.27e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.92	-10.65	-0.56	4.91e-22	White matter hyperintensity burden;
KIRP	cis	rs7621025	0.500	rs12629000	chr3:136643571	T/A	cg15507776	chr3:136538369	TMEM22	0.78	10.81	0.57	1.58e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.9	-0.49	1.27e-16	Resting heart rate;
KIRP	cis	rs10140922	0.931	rs4982262	chr14:35822193	C/T	cg07166546	chr14:35805898	NA	-0.27	-6.71	-0.39	1.29e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.57	8.17	0.46	1.66e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg10253484	chr15:75165896	SCAMP2	0.66	7.37	0.43	2.64e-12	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg25486957	chr4:152246857	NA	-0.42	-5.02	-0.31	9.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.733	rs60553075	chr10:35542462	T/A	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg23032965	chr3:12705835	RAF1	0.73	8.02	0.46	4.27e-14	Cholesterol, total;
KIRP	cis	rs11673344	0.526	rs55754546	chr19:38043762	T/A	cg14683738	chr19:37701593	ZNF585B	-0.44	-5.31	-0.32	2.4e-7	Obesity-related traits;
KIRP	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg24955955	chr5:415729	AHRR	0.77	6.27	0.37	1.59e-9	Fat distribution (HIV);
KIRP	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.59	7.45	0.43	1.6e-12	Menarche (age at onset);
KIRP	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg02378861	chr5:212933	CCDC127	-0.69	-5.51	-0.33	8.88e-8	Fat distribution (HIV);
KIRP	cis	rs6568686	0.786	rs2181356	chr6:111815604	A/G	cg15721981	chr6:111408429	SLC16A10	-0.7	-6.25	-0.37	1.8e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg22800045	chr5:56110881	MAP3K1	0.57	6.14	0.36	3.2e-9	Type 2 diabetes;
KIRP	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg21926883	chr2:100939477	LONRF2	-0.52	-6.87	-0.4	5.35e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13939156	chr17:80058883	NA	-0.49	-7.36	-0.42	2.8e-12	Life satisfaction;
KIRP	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.83	12.5	0.62	4.38e-28	Body mass index;
KIRP	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.39	-0.32	1.68e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9687846	0.877	rs13173241	chr5:55861359	G/A	cg15001016	chr5:55860904	NA	-0.29	-5.3	-0.32	2.53e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg02807482	chr3:125708958	NA	-0.5	-5.17	-0.31	4.82e-7	Blood pressure (smoking interaction);
KIRP	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg23625390	chr15:77176239	SCAPER	0.54	7.53	0.43	9.68e-13	Blood metabolite levels;
KIRP	cis	rs12282928	1.000	rs10838858	chr11:48301755	C/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.9e-9	Migraine - clinic-based;
KIRP	cis	rs4594175	0.926	rs4131365	chr14:51622444	C/T	cg23942311	chr14:51606299	NA	0.51	6.74	0.39	1.13e-10	Cancer;
KIRP	cis	rs687432	0.774	rs7945154	chr11:57912638	G/A	cg19752551	chr11:57585705	CTNND1	-0.67	-8.54	-0.48	1.38e-15	Parkinson's disease;
KIRP	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00938859	chr5:1591904	SDHAP3	0.59	7.95	0.45	6.54e-14	Breast cancer;
KIRP	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.76	7.72	0.44	3e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg00343986	chr7:65444356	GUSB	0.46	5.38	0.32	1.74e-7	Aortic root size;
KIRP	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg09175582	chr1:161736000	ATF6	0.72	5.83	0.35	1.74e-8	IgG glycosylation;
KIRP	trans	rs263156	0.934	rs263113	chr6:142882361	G/A	cg01789478	chr2:182545485	NEUROD1	-0.36	-6.34	-0.37	1.08e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.43	-5.02	-0.31	9.73e-7	Body mass index;
KIRP	cis	rs1165472	0.639	rs1514134	chr1:56116513	T/C	cg11523071	chr1:56160889	NA	-0.43	-6.26	-0.37	1.71e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg13334819	chr7:99746414	C7orf59	-0.44	-4.93	-0.3	1.53e-6	Coronary artery disease;
KIRP	trans	rs1106684	1.000	rs10954328	chr7:131458025	A/G	cg13607082	chr12:122652224	LRRC43	0.64	6.46	0.38	5.67e-10	Body mass index;
KIRP	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.57	7.41	0.43	2.08e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg18753928	chr3:113234510	CCDC52	-0.57	-5.67	-0.34	3.97e-8	Dental caries;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24858140	chr15:80189322	MTHFS	0.56	7.63	0.44	5.18e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg08131204	chr22:41487073	MIR1281	-0.43	-4.98	-0.3	1.2e-6	Neuroticism;
KIRP	cis	rs13279522	0.536	rs9298110	chr8:67016106	A/C	cg04041976	chr8:67085823	TRIM55	-0.43	-5.34	-0.32	2.1e-7	Coronary heart disease event reduction (statin therapy interaction);
KIRP	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.33	-6.67	-0.39	1.66e-10	Diastolic blood pressure;
KIRP	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg11663144	chr21:46675770	NA	-0.59	-8.66	-0.48	6.43e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs5753037	0.809	rs997913	chr22:30374621	T/A	cg01021169	chr22:30184971	ASCC2	-0.39	-5.19	-0.31	4.5e-7	Type 1 diabetes;
KIRP	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.35	-0.32	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	1.09	17.61	0.75	1.78e-45	Cognitive function;
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.6	-7.89	-0.45	1.02e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg11945507	chr8:142233382	SLC45A4	-0.47	-6.28	-0.37	1.51e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	0.99	11.44	0.59	1.45e-24	Corneal structure;
KIRP	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	4.87	0.3	1.97e-6	Bipolar disorder;
KIRP	trans	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg12560992	chr17:57184187	TRIM37	0.62	6.59	0.39	2.6e-10	Testicular germ cell tumor;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.49	5.83	0.35	1.7e-8	Longevity;Endometriosis;
KIRP	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.29	0.32	2.65e-7	Diisocyanate-induced asthma;
KIRP	cis	rs921943	0.957	rs727674	chr5:78327621	A/T	cg26802063	chr5:78281964	ARSB	0.43	5.37	0.32	1.85e-7	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.42	-7.01	-0.41	2.31e-11	Testicular germ cell tumor;
KIRP	trans	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.76	9.59	0.52	1.07e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01765077	chr12:122356316	WDR66	0.45	6.04	0.36	5.77e-9	Mean corpuscular volume;
KIRP	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg10047753	chr17:41438598	NA	0.87	12.59	0.63	2.23e-28	Menopause (age at onset);
KIRP	cis	rs5753618	0.509	rs2413033	chr22:31574213	A/G	cg22777020	chr22:31556080	RNF185	-0.48	-5.08	-0.31	7.38e-7	Colorectal cancer;
KIRP	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.75	-8.96	-0.5	8.29e-17	Post bronchodilator FEV1;
KIRP	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.74	-9.39	-0.51	4.16e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs12134040	0.514	rs61833977	chr1:236526726	C/A	cg21399712	chr1:236511386	NA	-0.49	-6.52	-0.38	3.99e-10	Urate levels (BMI interaction);
KIRP	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg14541582	chr5:601475	NA	-0.55	-6.14	-0.36	3.3e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs16958440	0.581	rs11872531	chr18:44689234	C/A	cg17192377	chr18:44677553	HDHD2	0.65	6.32	0.37	1.22e-9	Sitting height ratio;
KIRP	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg22676075	chr6:135203613	NA	0.52	7.54	0.43	8.95e-13	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02025192	chr11:115375385	CADM1	0.44	6.49	0.38	4.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.66	9.25	0.51	1.13e-17	Mood instability;
KIRP	cis	rs1978968	1.000	rs1978968	chr22:18448113	A/G	cg02610425	chr22:18483192	MICAL3	-0.41	-5.51	-0.33	8.88e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg25214090	chr10:38739885	LOC399744	0.63	7.44	0.43	1.67e-12	Educational attainment;
KIRP	cis	rs4356932	0.875	rs6826408	chr4:76973564	A/C	cg19388996	chr4:76862389	NAAA	0.4	5.15	0.31	5.31e-7	Blood protein levels;
KIRP	cis	rs554111	0.510	rs10916863	chr1:21120592	C/T	cg08890418	chr1:21044141	KIF17	0.57	8.96	0.5	8.18e-17	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.52	-7.94	-0.45	7.07e-14	Huntington's disease progression;
KIRP	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg03342759	chr3:160939853	NMD3	-0.5	-5.49	-0.33	1e-7	Parkinson's disease;
KIRP	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg27462398	chr1:86174642	ZNHIT6	0.53	6.85	0.4	6.02e-11	Urate levels in overweight individuals;
KIRP	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.38	0.38	8.62e-10	Mean platelet volume;
KIRP	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg06766960	chr11:133703094	NA	-0.45	-5.7	-0.34	3.43e-8	Childhood ear infection;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.9	0.35	1.17e-8	Platelet count;
KIRP	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg05315796	chr3:52349193	DNAH1	0.4	5.98	0.36	7.88e-9	Bipolar disorder;
KIRP	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16434002	chr17:42200994	HDAC5	-0.55	-6.91	-0.4	4.21e-11	Total body bone mineral density;
KIRP	cis	rs8084125	0.832	rs62105168	chr18:74944848	T/C	cg26065057	chr18:74961000	GALR1	0.61	6.15	0.37	3.07e-9	Obesity-related traits;
KIRP	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg03808351	chr9:123631620	PHF19	0.38	5.22	0.32	3.81e-7	Rheumatoid arthritis;
KIRP	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-0.94	-11.35	-0.59	2.81e-24	Vitiligo;
KIRP	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.07e-9	Cognitive function;
KIRP	trans	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg06521331	chr12:34319734	NA	-0.58	-7.01	-0.41	2.26e-11	Bladder cancer;
KIRP	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16524936	chr4:1340807	KIAA1530	-0.46	-5.83	-0.35	1.76e-8	Longevity;
KIRP	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.93	-12.78	-0.63	4.93e-29	Platelet distribution width;
KIRP	cis	rs55863869	1.000	rs12465449	chr2:179681814	A/G	cg02880032	chr2:179629472	TTN	-0.74	-5.77	-0.35	2.41e-8	QT interval;
KIRP	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg12292205	chr6:26970375	C6orf41	0.33	4.92	0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.79	9.24	0.51	1.17e-17	Obesity-related traits;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09732510	chr15:72978892	HIGD2B;BBS4	-0.51	-6.48	-0.38	5e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	15.43	0.7	5.12e-38	Chronic sinus infection;
KIRP	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg23484912	chr5:273055	PDCD6	0.58	7.28	0.42	4.53e-12	Pancreatic cancer;
KIRP	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.72	-8.64	-0.48	7.3e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.8	0.4	7.8e-11	Coffee consumption (cups per day);
KIRP	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg16482183	chr6:26056742	HIST1H1C	0.42	4.88	0.3	1.93e-6	Iron status biomarkers;
KIRP	trans	rs7230711	1.000	rs7230928	chr18:48683484	C/G	cg09299053	chr7:57509762	ZNF716	-0.82	-6.11	-0.36	3.94e-9	Immune response to anthrax vaccine;
KIRP	cis	rs2172802	0.598	rs13115278	chr4:62539481	A/G	cg04118610	chr4:62707027	LPHN3	-0.45	-5.54	-0.33	7.95e-8	Partial epilepsies;
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg11814155	chr7:99998594	ZCWPW1	0.57	5.31	0.32	2.47e-7	Platelet count;
KIRP	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.39	5.09	0.31	7.14e-7	Aortic root size;
KIRP	cis	rs28680850	0.541	rs4876041	chr8:1370441	T/C	cg06035437	chr8:1398411	NA	-0.8	-8.71	-0.49	4.61e-16	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15869694	chr12:6643747	GAPDH	0.51	6.29	0.37	1.42e-9	Parkinson's disease;
KIRP	cis	rs2274273	0.712	rs17832311	chr14:55534466	A/G	cg04306507	chr14:55594613	LGALS3	0.44	6.67	0.39	1.7e-10	Protein biomarker;
KIRP	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg13010199	chr12:38710504	ALG10B	0.49	6.43	0.38	6.66e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs904251	0.523	rs2797799	chr6:37483620	T/G	cg25019722	chr6:37503610	NA	-0.95	-15.11	-0.69	6.09e-37	Cognitive performance;
KIRP	trans	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg24644049	chr4:85504048	CDS1	0.99	6.58	0.39	2.83e-10	Skin colour saturation;
KIRP	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg02415014	chr8:143852576	LYNX1	0.32	5.12	0.31	6.07e-7	Urinary tract infection frequency;
KIRP	cis	rs2224391	0.518	rs72815613	chr6:5289798	A/G	cg13962347	chr6:5174647	LYRM4	-0.7	-6.28	-0.37	1.49e-9	Height;
KIRP	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	11.48	0.59	1.04e-24	Exhaled nitric oxide levels;
KIRP	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.49	-0.65	1.97e-31	Tonsillectomy;
KIRP	cis	rs7017914	0.967	rs13257800	chr8:71714133	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.15	-0.31	5.35e-7	Bone mineral density;
KIRP	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.29	-0.32	2.67e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-9.74	-0.53	3.52e-19	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2658782	0.906	rs2658791	chr11:93198983	T/C	cg15737290	chr11:93063684	CCDC67	0.87	9.14	0.5	2.35e-17	Pulmonary function decline;
KIRP	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-0.73	-10.58	-0.56	8.62e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.63	-9.34	-0.51	5.84e-18	Body mass index;
KIRP	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	trans	rs13170463	0.579	rs11749510	chr5:8051900	A/G	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg26750617	chr12:132293702	NA	-0.51	-7.05	-0.41	1.8e-11	Migraine;
KIRP	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg18944383	chr4:111397179	ENPEP	0.43	6.77	0.4	9.63e-11	Coronary artery disease;
KIRP	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg05361325	chr10:32636312	EPC1	-0.67	-6.39	-0.38	8.44e-10	Sexual dysfunction (female);
KIRP	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.47	-6.8	-0.4	7.69e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg17294928	chr15:75287854	SCAMP5	-0.68	-5.12	-0.31	6.13e-7	Lung cancer;
KIRP	cis	rs12580194	0.593	rs61957933	chr12:55744710	T/G	cg19537932	chr12:55886519	OR6C68	-0.48	-6.36	-0.38	9.58e-10	Cancer;
KIRP	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.57	-0.39	2.95e-10	Daytime sleep phenotypes;
KIRP	cis	rs2688608	0.967	rs2688609	chr10:75658181	A/G	cg23231163	chr10:75533350	FUT11	0.34	5.14	0.31	5.7e-7	Inflammatory bowel disease;
KIRP	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.63	8.04	0.46	3.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs651907	0.967	rs641432	chr3:101587566	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.11	0.31	6.4e-7	Colorectal cancer;
KIRP	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg23625390	chr15:77176239	SCAPER	0.5	6.9	0.4	4.4e-11	Blood metabolite levels;
KIRP	cis	rs17123764	0.579	rs55637397	chr12:50014181	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.64	0.34	4.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26314531	chr2:26401878	FAM59B	-0.5	-5.41	-0.33	1.51e-7	Gut microbiome composition (summer);
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg03289416	chr15:75166202	SCAMP2	0.48	6.34	0.37	1.08e-9	Breast cancer;
KIRP	cis	rs7799006	0.723	rs33922585	chr7:2285178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-4.85	-0.3	2.16e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.88	11.82	0.6	7.68e-26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs34779708	0.931	rs9663401	chr10:35278849	G/T	cg03585969	chr10:35415529	CREM	0.84	10.14	0.54	2.08e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg00784671	chr22:46762841	CELSR1	-0.67	-8.5	-0.48	1.81e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs301161	0.915	rs4843788	chr16:85819521	A/G	cg03249995	chr16:85819513	COX4NB	0.59	5.18	0.31	4.59e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.37	-0.38	9.46e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	7.9	0.45	9.47e-14	Personality dimensions;
KIRP	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17376030	chr22:41985996	PMM1	-0.69	-7.61	-0.44	5.93e-13	Vitiligo;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.49	-5.45	-0.33	1.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.71	8.77	0.49	3.11e-16	Monocyte count;
KIRP	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg07541023	chr7:19748670	TWISTNB	0.61	5.47	0.33	1.1e-7	Thyroid stimulating hormone;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11143857	chr1:202559755	SYT2	0.51	7.5	0.43	1.16e-12	Survival in pancreatic cancer;
KIRP	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-7.1	-0.41	1.36e-11	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12056000	chr1:16259191	SPEN	0.45	6.15	0.37	3.1e-9	Interleukin-4 levels;
KIRP	trans	rs28573326	0.606	rs1438120	chr4:166348471	A/G	cg13437084	chr2:26467494	HADHB;HADHA	-0.48	-6.71	-0.39	1.3e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.41	11.11	0.58	1.7e-23	Prostate cancer;
KIRP	cis	rs7615316	1.000	rs1357530	chr3:142350756	C/T	cg20824294	chr3:142316082	PLS1	0.25	5.41	0.33	1.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6662572	0.703	rs10789482	chr1:46396704	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.55e-8	Blood protein levels;
KIRP	cis	rs5756391	0.546	rs4239882	chr22:37314008	A/G	cg16356956	chr22:37317934	CSF2RB	0.37	5.05	0.31	8.53e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg08076091	chr2:203926405	NBEAL1	0.93	10.0	0.54	5.66e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.05	-0.36	5.36e-9	Response to antipsychotic treatment;
KIRP	cis	rs7246657	0.551	rs4806413	chr19:37617716	A/T	cg18154014	chr19:37997991	ZNF793	0.6	5.11	0.31	6.52e-7	Coronary artery calcification;
KIRP	cis	rs7172809	0.599	rs75323552	chr15:77421943	A/T	cg05673287	chr15:77411982	SGK269	0.41	4.85	0.3	2.22e-6	Glucose homeostasis traits;
KIRP	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg00576331	chr11:65640516	EFEMP2	0.51	5.67	0.34	4.05e-8	Crohn's disease;
KIRP	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.48	6.27	0.37	1.6e-9	Menopause (age at onset);
KIRP	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.59	5.53	0.33	7.98e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.73	6.84	0.4	6.27e-11	Mean platelet volume;
KIRP	trans	rs17079247	0.841	rs1927722	chr13:85810862	A/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.6	7.66	0.44	4.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg00360474	chr6:37504404	NA	-0.44	-6.32	-0.37	1.22e-9	Cognitive performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16260274	chr17:35849812	DUSP14	0.5	6.33	0.37	1.14e-9	Parkinson's disease;
KIRP	cis	rs6545883	0.931	rs778756	chr2:61781994	A/G	cg15711740	chr2:61764176	XPO1	-0.58	-7.56	-0.43	7.92e-13	Tuberculosis;
KIRP	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	9.81	0.53	2.18e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-9.45	-0.52	2.8e-18	Gut microbiome composition (summer);
KIRP	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	1.05	13.54	0.65	1.4e-31	Exhaled nitric oxide output;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22803407	chr19:6733691	GPR108	-0.44	-6.24	-0.37	1.94e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.91	13.59	0.65	9.23e-32	Mean platelet volume;
KIRP	cis	rs793571	0.502	rs688756	chr15:59076272	A/C	cg05156742	chr15:59063176	FAM63B	0.68	9.23	0.51	1.3e-17	Schizophrenia;
KIRP	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg20701182	chr2:24300061	SF3B14	0.51	5.32	0.32	2.34e-7	Asthma;
KIRP	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.63	-8.34	-0.47	5.18e-15	Alzheimer's disease;
KIRP	cis	rs2742417	0.935	rs1468543	chr3:45776900	A/G	cg04037228	chr3:45636386	LIMD1	0.36	5.26	0.32	3.11e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21507487	chr14:71941057	NA	0.4	6.03	0.36	5.93e-9	C-reactive protein;
KIRP	cis	rs10904908	1.000	rs7903259	chr10:17259642	C/G	cg01003015	chr10:17271136	VIM	0.42	5.09	0.31	6.98e-7	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.33	0.42	3.35e-12	Lung cancer;
KIRP	cis	rs17428704	0.571	rs11949756	chr5:14388686	C/G	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.43	-0.33	1.35e-7	Renal cell carcinoma;
KIRP	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg16141378	chr3:129829833	LOC729375	-0.6	-8.22	-0.46	1.18e-14	Triglycerides;
KIRP	cis	rs2479724	0.870	rs6913232	chr6:41915143	C/T	cg17623882	chr6:41773611	USP49	0.43	5.3	0.32	2.61e-7	Menarche (age at onset);
KIRP	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg18882449	chr10:104885122	NT5C2	-0.38	-4.94	-0.3	1.44e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8177876	0.731	rs74878296	chr16:81105545	C/G	cg08591886	chr16:81111003	C16orf46	-0.68	-5.3	-0.32	2.63e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg00852783	chr1:26633632	UBXN11	0.53	7.61	0.44	5.99e-13	Obesity-related traits;
KIRP	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg22903471	chr2:27725779	GCKR	-0.46	-4.92	-0.3	1.57e-6	Blood metabolite levels;
KIRP	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.68	-0.34	3.87e-8	Parkinson's disease;
KIRP	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg22903471	chr2:27725779	GCKR	0.45	6.32	0.37	1.21e-9	Oral cavity cancer;
KIRP	cis	rs9311676	0.656	rs62258102	chr3:58378784	T/C	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.62	-6.76	-0.4	1.01e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg26134248	chr17:3907702	NA	0.58	8.63	0.48	8e-16	Type 2 diabetes;
KIRP	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05585630	chr7:157510462	PTPRN2	-0.54	-8.05	-0.46	3.6e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.74	-11.39	-0.59	1.99e-24	Idiopathic membranous nephropathy;
KIRP	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.5	-7.0	-0.41	2.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.04	-0.46	3.87e-14	Monocyte percentage of white cells;
KIRP	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.81	0.49	2.35e-16	Cognitive function;
KIRP	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg11382394	chr1:2564504	MMEL1	0.38	4.88	0.3	1.89e-6	Ulcerative colitis;
KIRP	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07402062	chr16:89894098	SPIRE2	0.34	6.96	0.41	3.05e-11	Vitiligo;
KIRP	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg24253500	chr15:84953950	NA	0.62	6.95	0.41	3.31e-11	Schizophrenia;
KIRP	cis	rs17123764	0.892	rs12304796	chr12:50123466	T/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.9	0.3	1.74e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs78579285	0.510	rs78759106	chr16:88788535	T/C	cg09786329	chr16:88821445	FAM38A	-0.61	-4.93	-0.3	1.51e-6	Joint mobility (Beighton score);
KIRP	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	0.99	16.4	0.72	2.4e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg11846333	chr4:119757529	SEC24D	0.99	6.0	0.36	7.02e-9	Cannabis dependence symptom count;
KIRP	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.49	-6.58	-0.39	2.79e-10	Multiple sclerosis;
KIRP	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08280861	chr8:58055591	NA	0.78	6.28	0.37	1.51e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg21253087	chr9:139290292	SNAPC4	0.49	6.93	0.4	3.67e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg21360079	chr12:107162445	NA	-0.69	-9.97	-0.54	7.01e-20	Heart rate;
KIRP	cis	rs9314323	0.708	rs1594829	chr8:26206077	C/T	cg11498726	chr8:26250323	BNIP3L	0.56	7.07	0.41	1.56e-11	Red cell distribution width;
KIRP	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.57	-7.38	-0.43	2.36e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs3752645	1.000	rs112953061	chr7:106718508	G/T	cg02696742	chr7:106810147	HBP1	-0.76	-5.44	-0.33	1.26e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs7264396	0.563	rs11698796	chr20:34248134	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.43	-0.38	6.63e-10	Total cholesterol levels;
KIRP	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-1.07	-20.03	-0.79	1.36e-53	Height;
KIRP	cis	rs4474465	0.850	rs4945287	chr11:78226521	C/T	cg27205649	chr11:78285834	NARS2	0.62	7.75	0.44	2.45e-13	Alzheimer's disease (survival time);
KIRP	cis	rs2073499	1.000	rs77217288	chr3:50393676	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.69	4.91	0.3	1.67e-6	Schizophrenia;
KIRP	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg04398451	chr17:18023971	MYO15A	0.69	8.99	0.5	6.68e-17	Total body bone mineral density;
KIRP	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg15839431	chr19:19639596	YJEFN3	0.51	5.23	0.32	3.62e-7	Bipolar disorder;
KIRP	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.91	9.01	0.5	5.93e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg15655495	chr12:38532458	NA	-0.28	-5.1	-0.31	6.67e-7	Morning vs. evening chronotype;
KIRP	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.72	9.57	0.52	1.16e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.71	9.17	0.5	2e-17	Endometriosis;
KIRP	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.56	8.59	0.48	9.9e-16	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg00656387	chr3:40428638	ENTPD3	-0.35	-4.86	-0.3	2.07e-6	Renal cell carcinoma;
KIRP	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.5	7.19	0.42	7.66e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.36	-5.7	-0.34	3.39e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs988913	0.958	rs9475078	chr6:54809589	T/A	cg03513858	chr6:54763001	FAM83B	-0.37	-5.22	-0.32	3.77e-7	Menarche (age at onset);
KIRP	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.65	7.63	0.44	5.13e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.71	9.52	0.52	1.75e-18	Post bronchodilator FEV1;
KIRP	cis	rs3099143	0.901	rs1611866	chr15:77236291	A/C	cg21673338	chr15:77095150	SCAPER	-0.52	-5.36	-0.32	1.95e-7	Recalcitrant atopic dermatitis;
KIRP	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg06647332	chr5:131281008	NA	-0.44	-4.93	-0.3	1.54e-6	Life satisfaction;
KIRP	cis	rs7721647	0.853	rs6867266	chr5:90873294	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.41	5.04	0.31	8.88e-7	Breast cancer;
KIRP	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg10755058	chr3:40428713	ENTPD3	0.45	6.57	0.39	3.04e-10	Renal cell carcinoma;
KIRP	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.34	-4.85	-0.3	2.21e-6	Monocyte count;
KIRP	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.48	-7.15	-0.41	1e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.71	9.08	0.5	3.71e-17	Bladder cancer;
KIRP	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg22284058	chr8:142237359	SLC45A4	-0.43	-5.4	-0.33	1.59e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs28719689	0.504	rs17669535	chr8:1244224	C/G	cg22761795	chr8:1265118	NA	0.84	6.1	0.36	4.07e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.42	-0.43	1.85e-12	Bipolar disorder;
KIRP	cis	rs4720118	0.508	rs6944723	chr7:33423960	A/T	cg22798885	chr7:33102694	NT5C3	-0.41	-5.19	-0.31	4.4e-7	Leprosy;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg18234130	chr8:27182889	PTK2B	0.57	7.43	0.43	1.84e-12	Neuroticism;
KIRP	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	5.0	0.3	1.1e-6	Renal cell carcinoma;
KIRP	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.62	0.44	5.35e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4728302	0.869	rs6954712	chr7:133618853	G/A	cg10665199	chr7:133106180	EXOC4	0.43	5.25	0.32	3.22e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.56	8.2	0.46	1.35e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs745080	0.519	rs67565529	chr14:52914315	A/G	cg23333723	chr14:53022898	GPR137C	-0.4	-5.2	-0.31	4.25e-7	Orofacial clefts;
KIRP	cis	rs7221595	0.825	rs12942967	chr17:3921834	C/T	cg09597638	chr17:3907349	NA	0.56	6.02	0.36	6.23e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg21546286	chr11:48923668	NA	-0.47	-6.16	-0.37	3e-9	HDL cholesterol;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23142935	chr16:22385308	CDR2	0.72	6.64	0.39	1.96e-10	Lung function (FEV1);
KIRP	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg25600027	chr14:23388339	RBM23	-0.54	-6.62	-0.39	2.17e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs1215050	0.791	rs592053	chr4:98732220	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1142	0.507	rs2470937	chr7:104579775	T/A	cg04380332	chr7:105027541	SRPK2	-0.47	-6.82	-0.4	6.87e-11	Advanced age-related macular degeneration;
KIRP	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg18350739	chr11:68623251	NA	-0.48	-7.68	-0.44	3.69e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6973256	0.865	rs11975290	chr7:133335144	C/A	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg15252951	chr6:33757062	LEMD2	0.44	5.19	0.31	4.36e-7	Crohn's disease;
KIRP	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg17279839	chr7:150038598	RARRES2	0.42	5.92	0.35	1.06e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.65	9.61	0.52	8.87e-19	Schizophrenia;
KIRP	cis	rs7534824	0.625	rs61780327	chr1:101449810	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.43	0.33	1.38e-7	Refractive astigmatism;
KIRP	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg24375607	chr4:120327624	NA	0.59	6.4	0.38	7.92e-10	Corneal astigmatism;
KIRP	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.45e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.41	6.3	0.37	1.4e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.32	0.55	5.63e-21	Dupuytren's disease;
KIRP	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg03678062	chr6:149772716	ZC3H12D	-0.39	-6.37	-0.38	9.08e-10	Dupuytren's disease;
KIRP	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg04310649	chr10:35416472	CREM	-0.58	-6.81	-0.4	7.5e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.05e-8	Lung cancer;
KIRP	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.26	-0.42	4.96e-12	Aortic root size;
KIRP	cis	rs1629083	0.967	rs1104542	chr11:118129340	C/T	cg18857871	chr11:118064634	AMICA1	0.61	8.04	0.46	3.77e-14	Lung cancer;
KIRP	cis	rs57590327	0.503	rs9874464	chr3:81505488	C/G	cg07356753	chr3:81810745	GBE1	-0.51	-6.36	-0.38	9.51e-10	Extraversion;
KIRP	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.8	7.34	0.42	3.06e-12	Methadone dose in opioid dependence;
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	5.89	0.35	1.28e-8	Platelet count;
KIRP	cis	rs1485395	0.945	rs11611695	chr12:54053761	G/T	cg16917193	chr12:54089295	NA	-0.54	-5.15	-0.31	5.27e-7	Migraine without aura;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00005306	chr16:30709566	SRCAP	-0.46	-6.08	-0.36	4.44e-9	Metabolic traits;
KIRP	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg12311346	chr5:56204834	C5orf35	-0.37	-5.0	-0.3	1.12e-6	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23422044	chr7:1970798	MAD1L1	-0.71	-7.31	-0.42	3.8e-12	Bipolar disorder;
KIRP	cis	rs2858942	0.575	rs2858011	chr16:247938	C/T	cg08400316	chr16:204221	HBZ	0.41	4.85	0.3	2.21e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg11130432	chr3:121712080	ILDR1	-0.44	-4.96	-0.3	1.3e-6	Multiple sclerosis;
KIRP	cis	rs7010267	0.687	rs13264791	chr8:120013090	A/G	cg01975934	chr8:119970761	NA	-0.39	-4.92	-0.3	1.59e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg17279839	chr7:150038598	RARRES2	0.46	6.21	0.37	2.2e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.56	-0.33	6.92e-8	Life satisfaction;
KIRP	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg06204229	chr3:52865917	ITIH4	0.47	5.45	0.33	1.23e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-1.14	-18.9	-0.77	8.09e-50	Strep throat;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27105224	chr19:7587465	MCOLN1	0.52	6.35	0.38	1.03e-9	Parkinson's disease;
KIRP	cis	rs963731	0.649	rs10172714	chr2:39197543	C/G	cg04010122	chr2:39346883	SOS1	-0.84	-5.7	-0.34	3.36e-8	Corticobasal degeneration;
KIRP	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.35	-0.32	2e-7	Aortic root size;
KIRP	cis	rs1784581	0.722	rs1621456	chr6:162399985	C/T	cg17173639	chr6:162384350	PARK2	-0.59	-9.4	-0.51	3.99e-18	Itch intensity from mosquito bite;
KIRP	cis	rs2299587	0.545	rs12543739	chr8:17756229	C/T	cg01800426	chr8:17659068	MTUS1	-0.42	-4.99	-0.3	1.13e-6	Economic and political preferences;
KIRP	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4400599	0.618	rs1194582	chr1:154215973	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.99	-0.36	7.38e-9	Platelet distribution width;
KIRP	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg21466736	chr12:48725269	NA	-0.41	-5.43	-0.33	1.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg01804193	chr12:63026212	NA	0.58	6.28	0.37	1.52e-9	IgG glycosylation;
KIRP	cis	rs7523050	1.000	rs7523050	chr1:109417679	C/A	cg08274380	chr1:109419600	GPSM2	0.62	6.15	0.37	3.06e-9	Fat distribution (HIV);
KIRP	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg12315302	chr6:26189340	HIST1H4D	0.89	6.2	0.37	2.39e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11987759	chr7:65425863	GUSB	0.58	7.39	0.43	2.36e-12	Aortic root size;
KIRP	cis	rs1800932	0.544	rs2047681	chr2:48056231	G/A	cg09607915	chr2:48124557	FBXO11	-0.58	-5.04	-0.31	9.15e-7	Menopause (age at onset);
KIRP	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.33	-0.32	2.22e-7	Breast cancer;
KIRP	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg17644776	chr2:200775616	C2orf69	-0.56	-5.32	-0.32	2.38e-7	Schizophrenia;
KIRP	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.06	-17.57	-0.75	2.48e-45	Exhaled nitric oxide levels;
KIRP	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg08885076	chr2:99613938	TSGA10	-0.46	-6.8	-0.4	7.82e-11	Fear of minor pain;
KIRP	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.68	7.13	0.41	1.1e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00399650	chr7:141402322	KIAA1147	-0.48	-6.02	-0.36	6.34e-9	Neuroticism;
KIRP	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.59	0.39	2.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.41	4.98	0.3	1.22e-6	Diabetic retinopathy;
KIRP	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.55	-7.14	-0.41	1.03e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.7	-8.48	-0.48	2.12e-15	Cognitive function;
KIRP	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg07148914	chr20:33460835	GGT7	-0.52	-6.97	-0.41	2.81e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.63	-9.29	-0.51	8.49e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.48	5.04	0.31	9.17e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.94	12.83	0.63	3.46e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26002218	chr14:103986227	CKB	0.28	5.81	0.35	1.96e-8	Body mass index;
KIRP	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg11522683	chr6:37501428	NA	-0.4	-5.22	-0.32	3.83e-7	Cognitive performance;
KIRP	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg07378217	chr19:58662286	ZNF329	-0.58	-5.36	-0.32	1.94e-7	Cholesterol, total;
KIRP	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.78	0.4	8.91e-11	Coffee consumption (cups per day);
KIRP	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	10.33	0.55	5.07e-21	Monocyte percentage of white cells;
KIRP	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg00405596	chr8:11794950	NA	0.6	8.61	0.48	9.06e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.68	8.45	0.47	2.52e-15	Dilated cardiomyopathy;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18350866	chr20:39766189	PLCG1	-0.53	-6.05	-0.36	5.43e-9	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05147328	chr17:79849438	ANAPC11;THOC4	0.58	6.59	0.39	2.7e-10	Smoking initiation;
KIRP	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg12559939	chr2:27858050	GPN1	-0.41	-5.15	-0.31	5.35e-7	Oral cavity cancer;
KIRP	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.87	16.52	0.73	9.05e-42	Anterior chamber depth;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23518257	chr19:4791542	FEM1A	0.46	6.02	0.36	6.46e-9	Parkinson's disease;
KIRP	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	1.03	18.97	0.77	4.87e-50	Heart rate;
KIRP	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	1.02	13.42	0.65	3.58e-31	Response to hepatitis C treatment;
KIRP	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg04935436	chr20:30431758	NA	0.47	5.74	0.34	2.82e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.75	10.85	0.57	1.12e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18747265	chr6:57306409	PRIM2	0.44	6.14	0.36	3.23e-9	Interleukin-4 levels;
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg21851534	chr17:3907994	ZZEF1	0.74	12.34	0.62	1.45e-27	Type 2 diabetes;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13561592	chr9:118916976	PAPPA	-0.51	-6.18	-0.37	2.62e-9	Menopause (age at onset);
KIRP	cis	rs2017305	0.834	rs12250707	chr10:70779436	C/T	cg01024728	chr10:70782572	NA	0.68	5.56	0.33	7.03e-8	Depression (quantitative trait);
KIRP	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg17724175	chr1:150552817	MCL1	0.43	7.11	0.41	1.27e-11	Urate levels;
KIRP	trans	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	6.82	0.4	6.92e-11	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24734865	chr13:22178329	EFHA1	0.52	6.53	0.38	3.72e-10	Parkinson's disease;
KIRP	trans	rs7729273	0.956	rs12521891	chr5:7185208	A/G	cg13850847	chr9:136131739	ABO	0.5	6.4	0.38	7.77e-10	Cognitive performance;
KIRP	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg03929089	chr4:120376271	NA	0.71	7.01	0.41	2.22e-11	Axial length;
KIRP	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.36	-5.19	-0.31	4.42e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26684050	chr8:74514105	STAU2	-0.41	-6.39	-0.38	8.1e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg12692727	chr7:1102344	C7orf50	0.45	4.9	0.3	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg06027949	chr8:82754900	SNX16	-0.56	-7.09	-0.41	1.41e-11	Diastolic blood pressure;
KIRP	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-9.94	-0.54	8.85e-20	Schizophrenia;
KIRP	cis	rs7112043	0.838	rs11032839	chr11:34777725	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.49	5.65	0.34	4.33e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.63	8.96	0.5	8.32e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7404928	0.718	rs12443784	chr16:23860837	G/A	cg05497750	chr16:23765381	CHP2	-0.53	-5.83	-0.35	1.76e-8	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.76	12.23	0.62	3.39e-27	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs3755132	0.929	rs7594392	chr2:15750852	A/G	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs10073892	0.789	rs62371036	chr5:101840103	C/A	cg19774478	chr5:101632501	SLCO4C1	0.65	6.49	0.38	4.73e-10	Cognitive decline (age-related);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06053805	chr11:108093413	ATM;NPAT	-0.49	-6.47	-0.38	5.39e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.15	-0.37	3.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg00310523	chr12:86230176	RASSF9	0.54	8.6	0.48	9.32e-16	Major depressive disorder;
KIRP	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.58	6.71	0.39	1.32e-10	Aortic root size;
KIRP	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	6.06	0.36	5.17e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg00990874	chr7:1149470	C7orf50	-0.67	-7.35	-0.42	2.86e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg05802129	chr4:122689817	NA	-0.64	-8.14	-0.46	1.97e-14	Type 2 diabetes;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg12560992	chr17:57184187	TRIM37	0.59	5.43	0.33	1.33e-7	Cognitive test performance;
KIRP	cis	rs77688320	0.553	rs2249868	chr2:202277226	A/G	cg06431681	chr2:202330990	STRADB	-0.47	-5.48	-0.33	1.05e-7	Breast cancer;
KIRP	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.83	-0.45	1.48e-13	Triglycerides;
KIRP	cis	rs9400467	0.506	rs79788276	chr6:111599214	C/T	cg15721981	chr6:111408429	SLC16A10	0.75	6.87	0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.04	-0.41	1.95e-11	Blood pressure;
KIRP	cis	rs9362426	0.708	rs4707367	chr6:88101188	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.38	-5.02	-0.31	9.76e-7	Depressive episodes in bipolar disorder;
KIRP	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg06417478	chr19:12876846	HOOK2	-0.49	-5.88	-0.35	1.33e-8	Mean corpuscular volume;
KIRP	cis	rs7082209	0.938	rs11238983	chr10:44810205	C/T	cg09554077	chr10:44749378	NA	0.42	5.22	0.32	3.77e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg09307838	chr4:120376055	NA	0.69	7.86	0.45	1.18e-13	Corneal astigmatism;
KIRP	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	9.71	0.53	4.44e-19	Cognitive test performance;
KIRP	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-9.77	-0.53	3.01e-19	Coronary artery disease;
KIRP	cis	rs9409565	0.658	rs2809768	chr9:97128369	G/A	cg04523069	chr9:97136363	HIATL1	-0.47	-6.24	-0.37	1.92e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs7714584	1.000	rs17800987	chr5:150323428	A/G	cg22134413	chr5:150180641	NA	0.66	5.62	0.34	5.09e-8	Crohn's disease;
KIRP	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	8.1	0.46	2.57e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08280861	chr8:58055591	NA	0.52	4.85	0.3	2.21e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg27140938	chr4:25235459	PI4K2B	-0.47	-6.12	-0.36	3.66e-9	Myopia;
KIRP	cis	rs7116495	1.000	rs679926	chr11:71769936	A/G	cg26138937	chr11:71823887	C11orf51	0.69	5.56	0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs75920871	0.925	rs7112191	chr11:116902056	G/A	cg23684410	chr11:116897558	SIK3	0.51	5.59	0.34	6.01e-8	Subjective well-being;
KIRP	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg11833968	chr6:79620685	NA	-0.44	-6.68	-0.39	1.61e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs73017046	0.557	rs66519049	chr6:148895186	T/C	cg08280468	chr16:12997534	SHISA9	-0.7	-6.38	-0.38	8.88e-10	Major depression and alcohol dependence;
KIRP	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg03929089	chr4:120376271	NA	0.75	6.8	0.4	7.83e-11	Axial length;
KIRP	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.01	-0.54	5.16e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.44	9.93	0.53	9.52e-20	Alzheimer's disease (late onset);
KIRP	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.15	-0.46	1.89e-14	Systemic lupus erythematosus;
KIRP	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.74	0.34	2.79e-8	Menopause (age at onset);
KIRP	cis	rs12311304	1.000	rs16910711	chr12:15395799	C/T	cg08258403	chr12:15378311	NA	0.38	5.64	0.34	4.6e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.38	-15.16	-0.7	4.02e-37	Schizophrenia;
KIRP	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.47	6.54	0.39	3.46e-10	Sitting height ratio;
KIRP	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05472934	chr7:22766657	IL6	0.81	10.52	0.56	1.34e-21	Lung cancer;
KIRP	cis	rs6496667	0.779	rs10220750	chr15:90939294	G/C	cg10434728	chr15:90938212	IQGAP1	0.42	5.38	0.32	1.78e-7	Rheumatoid arthritis;
KIRP	cis	rs73206853	0.764	rs73205079	chr12:110599953	C/T	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.51	-0.43	1.12e-12	Life satisfaction;
KIRP	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg07928363	chr10:1254425	ADARB2	0.38	5.02	0.3	1.01e-6	Migraine;
KIRP	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.5	-5.6	-0.34	5.86e-8	Breast cancer;
KIRP	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg08126542	chr6:37504118	NA	-0.57	-6.83	-0.4	6.61e-11	Cognitive performance;
KIRP	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-9.04	-0.5	4.65e-17	Total cholesterol levels;
KIRP	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.49	-5.54	-0.33	7.85e-8	White matter hyperintensity burden;
KIRP	cis	rs9359856	0.518	rs12662171	chr6:90193898	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.56	-5.98	-0.36	7.67e-9	Bipolar disorder;
KIRP	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.27	0.37	1.63e-9	Rheumatoid arthritis;
KIRP	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.81	10.69	0.56	3.72e-22	Osteoporosis;
KIRP	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg05182265	chr7:156933206	UBE3C	0.33	6.98	0.41	2.75e-11	Body mass index;
KIRP	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg26408565	chr15:76604113	ETFA	-0.42	-5.7	-0.34	3.35e-8	Blood metabolite levels;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg14664628	chr15:75095509	CSK	-0.61	-7.48	-0.43	1.29e-12	Breast cancer;
KIRP	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg18110333	chr6:292329	DUSP22	-0.58	-6.77	-0.4	9.45e-11	Menopause (age at onset);
KIRP	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.65	8.4	0.47	3.48e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.35	-4.93	-0.3	1.5e-6	Monocyte count;
KIRP	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.51	-6.98	-0.41	2.71e-11	Dilated cardiomyopathy;
KIRP	cis	rs4236601	0.720	rs11980719	chr7:116142808	T/A	cg12739419	chr7:116140593	CAV2	0.47	5.9	0.35	1.21e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs787274	0.718	rs10739379	chr9:115640976	C/G	cg13803584	chr9:115635662	SNX30	-0.75	-8.06	-0.46	3.38e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6750047	0.585	rs4670235	chr2:38272528	C/T	cg07380506	chr2:38303506	CYP1B1	0.45	5.92	0.35	1.1e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.82	11.37	0.59	2.43e-24	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
KIRP	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg13147721	chr7:65941812	NA	-0.91	-6.56	-0.39	3.19e-10	Diabetic kidney disease;
KIRP	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg06740227	chr12:86229804	RASSF9	0.41	5.25	0.32	3.34e-7	Major depressive disorder;
KIRP	cis	rs12681288	0.782	rs2600497	chr8:1026220	A/G	cg08648136	chr8:956695	NA	0.4	5.43	0.33	1.35e-7	Schizophrenia;
KIRP	cis	rs56307353	0.781	rs10425937	chr19:1959021	A/G	cg01980928	chr19:1952821	C19orf34;CSNK1G2	-0.47	-5.33	-0.32	2.2e-7	Coronary artery disease;
KIRP	cis	rs1448094	0.967	rs7961782	chr12:86326461	T/C	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.34	3.27e-8	Major depressive disorder;
KIRP	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg01528321	chr10:82214614	TSPAN14	0.61	7.99	0.45	5.28e-14	Post bronchodilator FEV1;
KIRP	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-6.85	-0.4	5.97e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg18306943	chr3:40428807	ENTPD3	0.46	5.96	0.36	8.83e-9	Renal cell carcinoma;
KIRP	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.99	-0.3	1.12e-6	Monocyte percentage of white cells;
KIRP	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.43	-6.16	-0.37	2.96e-9	Height;
KIRP	cis	rs7909074	0.531	rs879344	chr10:45400667	G/C	cg05187965	chr10:45406764	TMEM72	-0.25	-5.52	-0.33	8.59e-8	Mean corpuscular volume;
KIRP	cis	rs7267005	0.661	rs111433174	chr20:34378058	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg16586182	chr3:47516702	SCAP	-0.74	-10.5	-0.56	1.49e-21	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.37	-0.32	1.81e-7	Renal cell carcinoma;
KIRP	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.66	9.56	0.52	1.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg24631222	chr15:78858424	CHRNA5	0.76	9.08	0.5	3.53e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs870825	0.932	rs13136635	chr4:185574807	C/T	cg04058563	chr4:185651563	MLF1IP	-0.95	-10.5	-0.56	1.5e-21	Blood protein levels;
KIRP	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.08	-0.31	7.29e-7	Schizophrenia;
KIRP	cis	rs7614311	0.636	rs66818634	chr3:63913222	G/A	cg22134162	chr3:63841271	THOC7	-0.43	-5.18	-0.31	4.61e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.5	-6.7	-0.39	1.43e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs992157	0.764	rs4552182	chr2:219184872	G/T	cg05991184	chr2:219186017	PNKD	-0.43	-6.26	-0.37	1.74e-9	Colorectal cancer;
KIRP	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.42e-13	Morning vs. evening chronotype;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19850565	chr19:35168394	ZNF302	0.66	6.24	0.37	1.92e-9	Lung function (FEV1);
KIRP	trans	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.17	-0.37	2.82e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05665937	chr4:1216051	CTBP1	0.51	7.03	0.41	2.03e-11	Obesity-related traits;
KIRP	cis	rs73200209	0.744	rs1865787	chr12:116429689	A/G	cg01776926	chr12:116560359	MED13L	-0.48	-5.23	-0.32	3.66e-7	Total body bone mineral density;
KIRP	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg11693508	chr17:37793320	STARD3	0.69	7.17	0.42	8.69e-12	Bipolar disorder;
KIRP	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	11.21	0.58	8.11e-24	Mean corpuscular hemoglobin;
KIRP	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg08648136	chr8:956695	NA	0.44	5.77	0.35	2.41e-8	Schizophrenia;
KIRP	cis	rs9815354	1.000	rs6599176	chr3:41788492	G/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.57	-0.33	6.71e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg18190219	chr22:46762943	CELSR1	-0.7	-5.95	-0.35	9.02e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.51	-0.62	3.91e-28	Chronic sinus infection;
KIRP	cis	rs6832769	0.961	rs13152650	chr4:56357858	T/C	cg09317128	chr4:56265301	TMEM165	0.54	7.08	0.41	1.48e-11	Personality dimensions;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg15841415	chr5:36606520	SLC1A3	-0.47	-6.48	-0.38	4.97e-10	Obesity-related traits;
KIRP	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs60311166	1.000	rs764636	chr3:52766697	G/A	cg13174197	chr3:52720522	GNL3;PBRM1	0.93	6.1	0.36	4.11e-9	CTACK levels;
KIRP	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-5.09	-0.31	7.1e-7	Large artery stroke;
KIRP	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg11815991	chr20:30193098	ID1	-0.5	-5.07	-0.31	7.7e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.72	5.75	0.34	2.57e-8	Diabetic retinopathy;
KIRP	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.68	-10.02	-0.54	5e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.59	7.44	0.43	1.73e-12	Tonsillectomy;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14383545	chr9:104161489	MRPL50;ZNF189	0.5	6.04	0.36	5.59e-9	Inflammatory biomarkers;
KIRP	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.48	-0.43	1.34e-12	Type 2 diabetes;
KIRP	cis	rs838147	0.760	rs281408	chr19:49233406	A/C	cg08619932	chr19:49200058	FUT2	0.35	5.22	0.32	3.73e-7	Dietary macronutrient intake;
KIRP	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.54	6.58	0.39	2.88e-10	Mean platelet volume;
KIRP	cis	rs7737355	1.000	rs40396	chr5:130708044	C/G	cg06647332	chr5:131281008	NA	-0.48	-5.34	-0.32	2.09e-7	Life satisfaction;
KIRP	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.44	-0.38	6.25e-10	Daytime sleep phenotypes;
KIRP	cis	rs2273669	0.915	rs6908104	chr6:109293973	T/C	cg05315195	chr6:109294784	ARMC2	-0.5	-5.69	-0.34	3.66e-8	Prostate cancer;
KIRP	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg21573476	chr21:45109991	RRP1B	-0.51	-6.71	-0.39	1.34e-10	Mean corpuscular volume;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19280121	chr17:21117780	TMEM11	0.5	6.8	0.4	7.85e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-6.31	-0.37	1.27e-9	Daytime sleep phenotypes;
KIRP	cis	rs6585424	1.000	rs10466226	chr10:81924055	C/T	cg27417294	chr10:81904244	PLAC9	-0.51	-5.16	-0.31	5.07e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg03474202	chr17:45855739	NA	0.37	5.64	0.34	4.59e-8	IgG glycosylation;
KIRP	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.85	12.22	0.61	3.62e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-7.61	-0.44	5.89e-13	Lung cancer;
KIRP	cis	rs11166927	1.000	rs12549587	chr8:140804310	G/A	cg16909799	chr8:140841666	TRAPPC9	0.71	10.31	0.55	5.82e-21	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.23	10.43	0.55	2.45e-21	Diabetic kidney disease;
KIRP	cis	rs2273669	0.667	rs12374658	chr6:109345930	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs4664293	0.642	rs6732598	chr2:160646881	G/A	cg08347373	chr2:160653686	CD302	0.36	5.75	0.34	2.6e-8	Monocyte percentage of white cells;
KIRP	cis	rs11997175	0.838	rs7836762	chr8:33667153	A/G	cg04338863	chr8:33670619	NA	0.42	5.61	0.34	5.56e-8	Body mass index;
KIRP	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.29	-0.42	4.14e-12	Retinal vascular caliber;
KIRP	cis	rs897080	0.552	rs698799	chr2:44690618	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.16	0.37	3e-9	Height;
KIRP	trans	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg13565492	chr6:43139072	SRF	-0.94	-8.67	-0.48	5.79e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg18132916	chr6:79620363	NA	-0.39	-5.41	-0.33	1.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg25902810	chr10:99078978	FRAT1	0.59	7.28	0.42	4.39e-12	Monocyte count;
KIRP	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	10.57	0.56	9.01e-22	Breast cancer;
KIRP	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.74	-8.74	-0.49	3.66e-16	Diabetic retinopathy;
KIRP	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg17644776	chr2:200775616	C2orf69	0.56	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg25753631	chr6:25732923	NA	-0.27	-5.36	-0.32	1.94e-7	Iron status biomarkers;
KIRP	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg25547332	chr5:131281432	NA	0.47	5.41	0.33	1.52e-7	Life satisfaction;
KIRP	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.81	-11.52	-0.59	7.88e-25	Dental caries;
KIRP	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.69	9.37	0.51	4.82e-18	Crohn's disease;
KIRP	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.05	-14.59	-0.68	3.63e-35	Breast cancer;
KIRP	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.84	10.62	0.56	6.04e-22	Gestational age at birth (maternal effect);
KIRP	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg10932868	chr11:921992	NA	0.67	9.13	0.5	2.59e-17	Alzheimer's disease (late onset);
KIRP	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg19875535	chr5:140030758	IK	0.64	8.75	0.49	3.4e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4664304	0.629	rs17239981	chr2:160847667	C/T	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.28	-0.32	2.82e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg18477163	chr1:228402036	OBSCN	0.34	6.32	0.37	1.21e-9	Diastolic blood pressure;
KIRP	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg07212818	chr11:638076	DRD4	-0.38	-4.93	-0.3	1.51e-6	Systemic lupus erythematosus;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg17074969	chr3:14220346	LSM3;XPC	-0.47	-6.23	-0.37	2.06e-9	Morning vs. evening chronotype;
KIRP	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg07451762	chr16:28383216	NA	0.39	5.02	0.3	9.79e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg20240347	chr1:204465584	NA	-0.41	-7.92	-0.45	8.19e-14	Schizophrenia;
KIRP	cis	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.64	-0.34	4.59e-8	Monocyte count;
KIRP	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs10465746	0.780	rs10874424	chr1:84424033	C/T	cg10977910	chr1:84465055	TTLL7	0.57	7.26	0.42	5.09e-12	Obesity-related traits;
KIRP	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.51	0.33	9.06e-8	Schizophrenia;
KIRP	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg12741994	chr3:170137321	CLDN11	-0.48	-4.9	-0.3	1.71e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg24315340	chr6:146058215	EPM2A	-0.48	-5.97	-0.36	8.06e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.81	0.35	1.9e-8	Body mass index;
KIRP	cis	rs3784262	0.839	rs8033270	chr15:58217789	G/C	cg12031962	chr15:58353849	ALDH1A2	0.45	6.16	0.37	2.87e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.44	5.96	0.36	8.51e-9	Red blood cell count;
KIRP	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg16141378	chr3:129829833	LOC729375	-0.52	-6.38	-0.38	8.52e-10	Neuroticism;
KIRP	cis	rs4704187	0.687	rs4361493	chr5:74405097	A/G	cg03227963	chr5:74354835	NA	0.4	5.79	0.35	2.09e-8	Response to amphetamines;
KIRP	cis	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg21625330	chr8:9911636	MSRA	0.37	4.85	0.3	2.16e-6	Neuroticism;
KIRP	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg09555818	chr19:45449301	APOC2	0.38	4.89	0.3	1.86e-6	Blood protein levels;
KIRP	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg04374321	chr14:90722782	PSMC1	0.99	18.21	0.76	1.71e-47	Mortality in heart failure;
KIRP	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.58	7.58	0.44	7.08e-13	Retinal vascular caliber;
KIRP	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.3	-0.32	2.52e-7	Neuroticism;
KIRP	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg06636001	chr8:8085503	FLJ10661	0.6	8.04	0.46	3.81e-14	Myopia (pathological);
KIRP	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg18089426	chr14:101175970	NA	-0.64	-5.92	-0.35	1.05e-8	Plateletcrit;
KIRP	cis	rs10421328	0.784	rs12983292	chr19:19787767	G/A	cg03709012	chr19:19516395	GATAD2A	0.49	5.61	0.34	5.41e-8	Parental longevity (combined parental age at death);
KIRP	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-7.24	-0.42	5.66e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg13611997	chr5:233750	SDHA	-0.41	-4.92	-0.3	1.58e-6	Breast cancer;
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg08901578	chr4:187885870	NA	-0.48	-7.3	-0.42	3.87e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.61	-7.28	-0.42	4.43e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs17123764	0.818	rs3887728	chr12:49972332	G/A	cg02054252	chr12:50078554	FMNL3	0.43	5.19	0.31	4.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg03342759	chr3:160939853	NMD3	0.43	5.27	0.32	3.01e-7	Morning vs. evening chronotype;
KIRP	cis	rs8177876	0.731	rs10514512	chr16:81113955	C/G	cg08591886	chr16:81111003	C16orf46	-0.72	-5.65	-0.34	4.43e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6681460	0.966	rs6588215	chr1:67141949	A/G	cg02459107	chr1:67143332	SGIP1	0.51	7.41	0.43	2.03e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg03806693	chr22:41940476	POLR3H	-0.46	-5.53	-0.33	8.23e-8	Neuroticism;
KIRP	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.73	9.27	0.51	1e-17	Corneal astigmatism;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-6.12	-0.36	3.76e-9	Longevity;
KIRP	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg11005552	chr10:105648138	OBFC1	0.4	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs7520050	0.966	rs785479	chr1:46492144	C/T	cg03146154	chr1:46216737	IPP	-0.43	-5.45	-0.33	1.24e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg06064525	chr11:970664	AP2A2	-0.37	-7.47	-0.43	1.44e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7258015	1.000	rs7258015	chr19:10449358	T/C	cg25279553	chr19:10444815	RAVER1;ICAM3	0.48	6.21	0.37	2.28e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.49	-5.12	-0.31	6.29e-7	Obesity (extreme);
KIRP	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.15	0.31	5.35e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.06	-0.36	5.18e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg02527881	chr3:46936655	PTH1R	-0.44	-6.29	-0.37	1.43e-9	Colorectal cancer;
KIRP	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11029668	chr17:45918458	SCRN2	0.5	6.38	0.38	8.85e-10	Parkinson's disease;
KIRP	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.59e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.44	6.49	0.38	4.57e-10	Major depressive disorder;
KIRP	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.88	10.56	0.56	9.83e-22	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7116495	1.000	rs7116495	chr11:71762085	C/T	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg27490568	chr2:178487706	NA	0.66	8.96	0.5	8.4e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg00933542	chr6:150070202	PCMT1	0.27	5.34	0.32	2.13e-7	Lung cancer;
KIRP	cis	rs151997	1.000	rs62367382	chr5:50246715	T/C	cg06027927	chr5:50259733	NA	0.58	6.82	0.4	6.91e-11	Callous-unemotional behaviour;
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.88	-0.45	1.07e-13	Platelet count;
KIRP	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.97	-16.73	-0.73	1.87e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7572644	0.713	rs4233718	chr2:28066360	A/G	cg27432699	chr2:27873401	GPN1	0.45	5.01	0.3	1.06e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.76	8.72	0.49	4.13e-16	Diastolic blood pressure;
KIRP	cis	rs9914988	0.613	rs2277664	chr17:27286662	C/G	cg10538030	chr17:27276405	PHF12	0.65	5.63	0.34	4.81e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg07216194	chr8:27182965	PTK2B	0.46	5.76	0.34	2.47e-8	Neuroticism;
KIRP	cis	rs116726256	1.000	rs6744209	chr2:1839087	A/T	cg07855242	chr2:1841068	MYT1L	-0.63	-5.98	-0.36	7.77e-9	Interleukin-8 levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04389422	chr12:24715564	SOX5	0.6	7.71	0.44	3.2e-13	Smoking initiation;
KIRP	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg04289385	chr6:36355825	ETV7	-0.48	-7.55	-0.43	8.51e-13	Platelet distribution width;
KIRP	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.03e-7	Coronary artery disease;
KIRP	cis	rs3849570	0.615	rs6766011	chr3:81986136	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-7.21	-0.42	6.85e-12	Waist circumference;Body mass index;
KIRP	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg25019722	chr6:37503610	NA	-0.98	-15.29	-0.7	1.55e-37	Cognitive performance;
KIRP	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg11459648	chr5:138714337	SLC23A1	-0.52	-7.48	-0.43	1.3e-12	Esophageal squamous cell carcinoma;
KIRP	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg09754948	chr16:28834200	ATXN2L	0.46	5.1	0.31	6.72e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs35740288	0.770	rs10520592	chr15:86114142	G/C	cg17133734	chr15:86042851	AKAP13	-0.5	-5.64	-0.34	4.73e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.61	-8.28	-0.47	7.9e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg01522456	chr1:115632236	TSPAN2	-0.43	-6.03	-0.36	6.07e-9	Autism;
KIRP	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg06640241	chr16:89574553	SPG7	0.64	8.4	0.47	3.65e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.68	7.75	0.44	2.38e-13	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15817923	chr19:39881719	PAF1;MED29	0.55	7.05	0.41	1.77e-11	Parkinson's disease;
KIRP	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.53	7.18	0.42	8.1e-12	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
KIRP	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	5.81	0.35	1.94e-8	Mean platelet volume;
KIRP	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.45	8.58	0.48	1.11e-15	Educational attainment (years of education);
KIRP	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.8	-8.96	-0.5	8.29e-17	Coronary artery disease;
KIRP	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	5.99	0.36	7.53e-9	Depressive symptoms;
KIRP	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg26513180	chr16:89883248	FANCA	0.81	5.5	0.33	9.37e-8	Skin colour saturation;
KIRP	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg13385521	chr17:29058706	SUZ12P	0.78	6.54	0.38	3.48e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg20701182	chr2:24300061	SF3B14	0.58	5.08	0.31	7.59e-7	Lymphocyte counts;
KIRP	cis	rs13014235	0.667	rs2540328	chr2:202249060	C/T	cg06431681	chr2:202330990	STRADB	-0.48	-5.65	-0.34	4.4e-8	Basal cell carcinoma;
KIRP	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg09344028	chr17:70110421	NA	0.43	9.32	0.51	6.72e-18	Thyroid hormone levels;
KIRP	cis	rs6681460	0.966	rs10889642	chr1:67143334	T/G	cg02459107	chr1:67143332	SGIP1	0.53	7.54	0.43	9.13e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.34	-0.32	2.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4363506	0.635	rs1931736	chr10:129281859	G/C	cg07804728	chr10:129284050	NA	0.46	5.74	0.34	2.73e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg21475434	chr5:93447410	FAM172A	0.43	4.96	0.3	1.32e-6	Diabetic retinopathy;
KIRP	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.83	11.14	0.58	1.32e-23	Platelet count;
KIRP	cis	rs7760949	0.963	rs9475771	chr6:13914869	A/G	cg27413430	chr6:13925136	RNF182	-0.37	-4.88	-0.3	1.92e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg02725872	chr8:58115012	NA	-0.43	-5.09	-0.31	7.19e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12379764	chr21:47803548	PCNT	-0.42	-5.0	-0.3	1.09e-6	Testicular germ cell tumor;
KIRP	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.5	-0.48	1.87e-15	Triglycerides;
KIRP	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg14675211	chr2:100938903	LONRF2	0.52	6.65	0.39	1.92e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.31	0.32	2.46e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs71520386	0.607	rs4308627	chr7:22879904	C/T	cg15401507	chr7:22894281	NA	0.4	5.03	0.31	9.42e-7	Fibrinogen levels;
KIRP	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.65	-7.88	-0.45	1.05e-13	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9815354	0.556	rs55953604	chr3:42004428	A/G	cg03022575	chr3:42003672	ULK4	0.79	8.37	0.47	4.39e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6142618	0.516	rs242601	chr20:30665834	G/T	cg09796376	chr20:30640595	HCK	0.38	5.28	0.32	2.82e-7	Inflammatory bowel disease;
KIRP	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.45	5.17	0.31	4.83e-7	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg02733842	chr7:1102375	C7orf50	0.43	5.03	0.31	9.45e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8093481	1.000	rs9955127	chr18:10693407	A/G	cg21165219	chr18:10698044	FAM38B	-0.44	-5.49	-0.33	9.81e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.7	-0.68	1.58e-35	Height;
KIRP	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg02367723	chr1:46378857	MAST2	0.42	4.89	0.3	1.86e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.76	0.34	2.52e-8	Breast cancer;
KIRP	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg15448220	chr1:150897856	SETDB1	0.4	5.16	0.31	5e-7	Melanoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14232643	chr2:97481853	CNNM3	0.53	6.66	0.39	1.76e-10	Parkinson's disease;
KIRP	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.33	6.19	0.37	2.57e-9	Total body bone mineral density;
KIRP	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4273100	0.512	rs2233072	chr17:19281828	T/G	cg25447019	chr17:19030144	GRAPL	0.59	8.01	0.46	4.45e-14	Schizophrenia;
KIRP	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17376030	chr22:41985996	PMM1	-0.58	-6.51	-0.38	4.25e-10	Vitiligo;
KIRP	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-7.71	-0.44	3.02e-13	Colorectal cancer;
KIRP	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg04013166	chr16:89971882	TCF25	0.63	5.52	0.33	8.5e-8	Skin colour saturation;
KIRP	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.3	0.62	2.03e-27	Bipolar disorder;
KIRP	cis	rs883565	0.568	rs4381879	chr3:39028460	G/C	cg01426195	chr3:39028469	NA	-0.77	-13.74	-0.66	2.82e-32	Handedness;
KIRP	cis	rs2281603	0.520	rs9323452	chr14:64972144	T/C	cg01860774	chr14:64969374	ZBTB25	0.35	5.65	0.34	4.35e-8	Lymphocyte counts;
KIRP	trans	rs1424233	1.000	rs1424233	chr16:79682751	T/C	cg11120865	chr14:21853037	SUPT16H	0.37	6.3	0.37	1.37e-9	Obesity;
KIRP	cis	rs2742417	1.000	rs2245705	chr3:45749722	A/G	cg04037228	chr3:45636386	LIMD1	0.33	4.89	0.3	1.82e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.88	12.15	0.61	6.33e-27	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10819733	chr22:24237672	NA	0.33	4.93	0.3	1.55e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.47	-6.36	-0.38	9.71e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7072216	0.770	rs3830020	chr10:100176615	C/G	cg26618903	chr10:100175079	PYROXD2	0.34	4.88	0.3	1.94e-6	Metabolite levels;
KIRP	cis	rs7809950	0.906	rs10248717	chr7:107056795	A/G	cg23024343	chr7:107201750	COG5	-0.44	-6.78	-0.4	9.06e-11	Coronary artery disease;
KIRP	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.72	8.34	0.47	5.2e-15	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg18538332	chr22:24372958	LOC391322	0.61	6.51	0.38	4.17e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg00012203	chr2:219082015	ARPC2	-0.66	-8.19	-0.46	1.42e-14	Colorectal cancer;
KIRP	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.56	-7.04	-0.41	1.91e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg04370829	chr17:406249	NA	0.39	4.86	0.3	2.11e-6	Prostate cancer;
KIRP	cis	rs72781680	0.560	rs111310684	chr2:24265682	C/G	cg08917208	chr2:24149416	ATAD2B	0.64	5.8	0.35	2.02e-8	Lymphocyte counts;
KIRP	cis	rs4253772	0.872	rs45528736	chr22:46638312	A/G	cg00784671	chr22:46762841	CELSR1	-0.51	-5.71	-0.34	3.19e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.09e-22	Coronary artery disease;
KIRP	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.37	0.38	9.08e-10	Neuroticism;
KIRP	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.86	-0.35	1.44e-8	Colorectal cancer;
KIRP	cis	rs7646881	0.812	rs59192661	chr3:158459027	T/C	cg19483011	chr3:158453295	NA	-0.56	-5.97	-0.36	8.22e-9	Tetralogy of Fallot;
KIRP	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg00125455	chr20:44574271	PCIF1	0.42	8.38	0.47	4.11e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg11518657	chr1:67396239	MIER1	-0.6	-5.91	-0.35	1.17e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg00310523	chr12:86230176	RASSF9	0.39	6.02	0.36	6.29e-9	Major depressive disorder;
KIRP	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg18350739	chr11:68623251	NA	-0.51	-7.96	-0.45	6.4e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6959887	0.962	rs17675131	chr7:35288068	G/A	cg06685737	chr7:35301730	NA	0.43	6.16	0.37	3e-9	Birth weight;
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg23736307	chr8:27182930	PTK2B	0.55	6.95	0.41	3.27e-11	Neuroticism;
KIRP	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.15	-0.31	5.3e-7	Neuroticism;
KIRP	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.84	13.94	0.66	6.14e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs8113308	0.810	rs73582180	chr19:52446537	G/A	cg24732339	chr19:52471368	ZNF350	-0.44	-4.92	-0.3	1.57e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs4805834	0.719	rs111484921	chr19:33277648	C/T	cg07201929	chr19:33182834	NUDT19	-0.63	-5.31	-0.32	2.45e-7	Creatinine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22478328	chr22:32340140	C22orf24;YWHAH	0.57	6.77	0.4	9.31e-11	Smoking initiation;
KIRP	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.86	-0.4	5.6e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	0.96	18.62	0.76	6.85e-49	Dental caries;
KIRP	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.67	8.85	0.49	1.71e-16	Coronary artery disease;
KIRP	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.8	9.12	0.5	2.69e-17	Vitamin D levels;
KIRP	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	cg21523751	chr1:182988639	NA	-0.44	-7.12	-0.41	1.16e-11	Colorectal cancer;
KIRP	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.01	0.3	1.06e-6	Educational attainment;
KIRP	cis	rs2281603	0.951	rs17101896	chr14:64992923	G/A	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.47	-0.33	1.11e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.51	6.46	0.38	5.43e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs17453880	0.963	rs6872161	chr5:151947543	T/A	cg12297329	chr5:152029980	NA	-0.71	-10.03	-0.54	4.49e-20	Subjective well-being;
KIRP	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg03115019	chr17:80708279	FN3K	0.41	4.9	0.3	1.78e-6	Glycated hemoglobin levels;
KIRP	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg00042356	chr1:8021962	PARK7	0.73	6.23	0.37	2.04e-9	Inflammatory bowel disease;
KIRP	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg02012338	chr4:187126139	CYP4V2	0.61	5.72	0.34	3.04e-8	Blood protein levels;
KIRP	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.69	-6.35	-0.38	1.05e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13095912	0.785	rs6791954	chr3:185335709	C/T	cg11274856	chr3:185301563	NA	-0.62	-8.1	-0.46	2.5e-14	Systolic blood pressure;
KIRP	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg09264619	chr17:80180166	NA	0.5	6.01	0.36	6.69e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.27	-7.01	-0.41	2.3e-11	Primary biliary cholangitis;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg12705353	chr12:122356852	WDR66	0.52	6.84	0.4	6.38e-11	Mean corpuscular volume;
KIRP	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.76	7.04	0.41	1.9e-11	Mean platelet volume;
KIRP	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg15896084	chr13:114927664	NA	0.46	6.11	0.36	3.8e-9	Schizophrenia;
KIRP	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg26116260	chr4:7069785	GRPEL1	0.52	6.02	0.36	6.44e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-5.11	-0.31	6.36e-7	Height;
KIRP	cis	rs74181299	0.684	rs6741255	chr2:65306905	C/T	cg05010058	chr2:65284262	CEP68	-0.41	-5.7	-0.34	3.45e-8	Pulse pressure;
KIRP	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.82	11.88	0.6	4.97e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg14086599	chr2:241536098	CAPN10	-0.49	-5.69	-0.34	3.58e-8	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.92	12.96	0.64	1.22e-29	Bladder cancer;
KIRP	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.53	6.52	0.38	4.05e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.85	-13.85	-0.66	1.22e-32	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs1973993	0.967	rs2181375	chr1:96940119	A/G	cg10631902	chr5:14652156	NA	0.65	10.05	0.54	3.91e-20	Weight;
KIRP	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.48	6.44	0.38	6.18e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11628318	0.950	rs4356406	chr14:103050106	G/A	cg01864069	chr14:103024347	NA	-0.67	-8.7	-0.48	4.95e-16	Platelet count;
KIRP	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg17366294	chr4:99064904	C4orf37	0.47	5.86	0.35	1.5e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-1.01	-12.68	-0.63	1.07e-28	Platelet distribution width;
KIRP	cis	rs10782582	0.758	rs5745554	chr1:76379197	A/C	cg10523679	chr1:76189770	ACADM	-0.36	-5.12	-0.31	6.27e-7	Daytime sleep phenotypes;
KIRP	cis	rs6707387	0.686	rs6716478	chr2:214480346	C/A	cg08319019	chr2:214017104	IKZF2	0.49	5.67	0.34	4.09e-8	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-5.01	-0.3	1.02e-6	Breast cancer;
KIRP	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg12756093	chr1:115239321	AMPD1	0.54	7.31	0.42	3.65e-12	Autism;
KIRP	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg12369402	chr1:90227771	NA	0.38	5.45	0.33	1.25e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3736485	0.966	rs4775944	chr15:51775610	T/C	cg14296394	chr15:51910925	DMXL2	-0.36	-5.42	-0.33	1.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.85	-12.15	-0.61	6.23e-27	Height;
KIRP	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	8.31	0.47	6.44e-15	Metabolite levels;
KIRP	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.86	13.13	0.64	3.24e-30	IgG glycosylation;
KIRP	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.95	12.25	0.62	3.01e-27	Homoarginine levels;
KIRP	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17376030	chr22:41985996	PMM1	0.76	7.72	0.44	2.93e-13	Vitiligo;
KIRP	cis	rs2985684	0.557	rs2985689	chr14:50098031	C/A	cg02151108	chr14:50098012	C14orf104	-0.77	-10.39	-0.55	3.29e-21	Carotid intima media thickness;
KIRP	cis	rs8049040	0.524	rs34538886	chr16:71423487	C/T	cg08717414	chr16:71523259	ZNF19	-0.59	-6.8	-0.4	7.72e-11	Blood protein levels;
KIRP	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg09029085	chr17:47094198	IGF2BP1	0.25	5.72	0.34	3.07e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7224685	0.569	rs12947597	chr17:3999199	A/G	cg09597638	chr17:3907349	NA	-0.5	-4.87	-0.3	2.01e-6	Type 2 diabetes;
KIRP	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-1.01	-17.13	-0.74	7.97e-44	Height;
KIRP	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.27	0.37	1.6e-9	Height;
KIRP	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.46	7.13	0.41	1.12e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.5	-6.74	-0.39	1.13e-10	Mean corpuscular volume;
KIRP	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg16586182	chr3:47516702	SCAP	-0.71	-9.91	-0.53	1.05e-19	Colorectal cancer;
KIRP	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.66	9.68	0.53	5.6e-19	Dupuytren's disease;
KIRP	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg19338460	chr6:170058176	WDR27	-0.58	-6.87	-0.4	5.26e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg09788416	chr12:39539408	NA	0.42	5.32	0.32	2.28e-7	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.68	0.39	1.56e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.68	9.64	0.52	7.23e-19	Alcohol dependence;
KIRP	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg16497661	chr14:103986332	CKB	-0.88	-15.48	-0.7	3.39e-38	Body mass index;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	1.04	11.27	0.58	4.88e-24	Alzheimer's disease;
KIRP	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs6723108	0.534	rs1016120	chr2:135547289	G/A	cg12500956	chr2:135428796	TMEM163	0.43	5.38	0.32	1.76e-7	Type 2 diabetes;
KIRP	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg26022315	chr17:47021804	SNF8	0.44	5.69	0.34	3.57e-8	Type 2 diabetes;
KIRP	cis	rs6723226	0.593	rs176401	chr2:32636511	A/T	cg02381751	chr2:32503542	YIPF4	-0.83	-10.79	-0.57	1.81e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.85	0.3	2.15e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg11266582	chr15:64275853	DAPK2	0.4	6.52	0.38	3.95e-10	Serum protein levels (sST2);
KIRP	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg11522683	chr6:37501428	NA	-0.4	-5.15	-0.31	5.41e-7	Cognitive performance;
KIRP	trans	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.36	-0.42	2.72e-12	Neuroticism;
KIRP	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg26681399	chr22:41777847	TEF	0.45	4.85	0.3	2.19e-6	Vitiligo;
KIRP	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs56079296	0.929	rs10045728	chr5:121277101	A/G	cg01191064	chr5:121408893	LOX	-0.46	-5.08	-0.31	7.45e-7	Coronary artery disease;
KIRP	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg07828024	chr6:149772892	ZC3H12D	-0.29	-5.11	-0.31	6.6e-7	Dupuytren's disease;
KIRP	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg14664628	chr15:75095509	CSK	0.52	6.16	0.37	2.89e-9	Systemic lupus erythematosus;
KIRP	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs220519	0.736	rs220511	chr20:37289738	T/C	cg24308336	chr20:37270989	C20orf95	0.23	4.87	0.3	1.98e-6	Schizophrenia;
KIRP	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg23335576	chr14:104009727	NA	0.39	5.71	0.34	3.25e-8	Body mass index;
KIRP	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.58	7.91	0.45	8.8e-14	Prostate cancer;
KIRP	cis	rs8054556	0.787	rs12325400	chr16:30023786	C/G	cg06326092	chr16:30034487	C16orf92	0.44	5.92	0.35	1.1e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs9398803	0.678	rs3861456	chr6:126898660	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.41	0.33	1.47e-7	Male-pattern baldness;
KIRP	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04578738	chr17:34136331	TAF15	0.56	6.64	0.39	1.99e-10	Smoking initiation;
KIRP	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.46	-0.43	1.52e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg19507638	chr5:93509721	C5orf36	-0.59	-5.29	-0.32	2.71e-7	Diabetic retinopathy;
KIRP	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg15128208	chr22:42549153	NA	0.4	5.2	0.31	4.12e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg11206763	chr12:56521692	ESYT1	0.55	6.6	0.39	2.52e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg10434728	chr15:90938212	IQGAP1	0.42	8.05	0.46	3.44e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.96	15.85	0.71	1.79e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.84	13.49	0.65	1.98e-31	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs1712517	0.836	rs7093039	chr10:105149547	A/G	cg05636881	chr10:105038444	INA	0.44	6.22	0.37	2.06e-9	Migraine;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12349858	chr3:160822545	B3GALNT1	0.41	5.66	0.34	4.27e-8	Parkinson's disease;
KIRP	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.77	-7.41	-0.43	2.08e-12	Psoriasis vulgaris;
KIRP	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.58	6.31	0.37	1.28e-9	Gut microbiome composition (summer);
KIRP	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.85	0.35	1.6e-8	Total cholesterol levels;
KIRP	cis	rs17123764	0.892	rs78616783	chr12:50143363	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.5	0.33	9.61e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	cg12689670	chr1:183009347	LAMC1	0.49	7.02	0.41	2.16e-11	Hypertriglyceridemia;
KIRP	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-8.58	-0.48	1.08e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs629922	1.000	rs624452	chr11:114068183	C/G	cg25009965	chr11:114031120	ZBTB16	0.43	5.44	0.33	1.26e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.66	-0.39	1.74e-10	Aortic root size;
KIRP	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.61	-0.44	5.94e-13	Retinal vascular caliber;
KIRP	trans	rs2230307	0.706	rs12127209	chr1:100562955	T/C	cg05735639	chr17:49021875	NA	-0.68	-6.48	-0.38	4.93e-10	Carotid intima media thickness;
KIRP	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg10523679	chr1:76189770	ACADM	-0.47	-6.6	-0.39	2.53e-10	Daytime sleep phenotypes;
KIRP	cis	rs834811	0.831	rs834810	chr7:135879825	T/C	cg01726295	chr7:135938950	NA	0.35	4.86	0.3	2.09e-6	Post-traumatic stress disorder;
KIRP	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.65	-7.94	-0.45	7.32e-14	Aortic root size;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg04369109	chr6:150039330	LATS1	-0.5	-6.41	-0.38	7.48e-10	Lung cancer;
KIRP	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.25	0.51	1.14e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs12311304	0.965	rs1382803	chr12:15372662	A/G	cg08258403	chr12:15378311	NA	0.35	5.01	0.3	1.02e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs1874124	0.577	rs2807872	chr1:221040250	C/T	cg22888665	chr1:221052729	HLX	0.5	5.06	0.31	8.3e-7	Cholesterol, total;
KIRP	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.1	0.72	2.48e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.5	0.38	4.35e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26207909	chr14:103986467	CKB	0.77	11.97	0.61	2.57e-26	Body mass index;
KIRP	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.9	-12.67	-0.63	1.16e-28	Tonsillectomy;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-5.43	-0.33	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg10547527	chr2:198650123	BOLL	-0.5	-4.92	-0.3	1.58e-6	Ulcerative colitis;
KIRP	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg05484376	chr2:27715224	FNDC4	0.38	6.23	0.37	1.95e-9	Total body bone mineral density;
KIRP	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	11.09	0.58	1.94e-23	Nonalcoholic fatty liver disease;
KIRP	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg11833968	chr6:79620685	NA	-0.45	-6.9	-0.4	4.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg02319466	chr17:76381040	PGS1	-0.52	-7.11	-0.41	1.25e-11	HDL cholesterol levels;
KIRP	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	9.51	0.52	1.84e-18	Cognitive ability;
KIRP	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg05347473	chr6:146136440	FBXO30	0.57	8.07	0.46	3.11e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs11997175	0.503	rs7013967	chr8:33826107	T/G	ch.8.33884649F	chr8:33765107	NA	0.55	6.87	0.4	5.27e-11	Body mass index;
KIRP	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.34	0.37	1.1e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7615316	0.779	rs9826786	chr3:142146261	A/C	cg20824294	chr3:142316082	PLS1	0.24	5.35	0.32	1.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs76693355	0.512	rs10790381	chr11:120257495	C/T	cg24566217	chr11:120254723	ARHGEF12	0.43	5.64	0.34	4.56e-8	Intraocular pressure;
KIRP	cis	rs2273669	0.667	rs11153148	chr6:109304084	C/T	cg05315195	chr6:109294784	ARMC2	-0.61	-6.08	-0.36	4.65e-9	Prostate cancer;
KIRP	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.47	5.84	0.35	1.66e-8	Height;
KIRP	cis	rs4683142	0.518	rs7653682	chr3:46029271	A/G	cg18004856	chr3:46029278	FYCO1	0.48	6.52	0.38	4.05e-10	Methadone dose in opioid dependence;
KIRP	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.06	0.36	5.03e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg22117172	chr7:91764530	CYP51A1	0.42	5.98	0.36	7.64e-9	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17701921	chr19:537170	CDC34	0.48	6.18	0.37	2.7e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg12560992	chr17:57184187	TRIM37	0.47	5.58	0.33	6.49e-8	Cognitive test performance;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.22	-22.52	-0.82	1.04e-61	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6545883	0.602	rs11125871	chr2:61470126	C/T	cg15711740	chr2:61764176	XPO1	0.6	7.65	0.44	4.54e-13	Tuberculosis;
KIRP	cis	rs116726256	0.744	rs75597163	chr2:1843569	T/A	cg07855242	chr2:1841068	MYT1L	0.61	5.8	0.35	2.07e-8	Interleukin-8 levels;
KIRP	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg00277334	chr10:82204260	NA	-0.44	-4.85	-0.3	2.18e-6	Post bronchodilator FEV1;
KIRP	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.22	-0.32	3.82e-7	Bipolar disorder;
KIRP	cis	rs3105593	1.000	rs2292174	chr15:50924956	A/G	cg08437265	chr15:50716283	USP8	0.41	5.13	0.31	5.89e-7	QT interval;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19014214	chr11:122230364	NA	0.46	6.17	0.37	2.86e-9	Interleukin-4 levels;
KIRP	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.09	0.31	6.99e-7	Parkinson's disease;
KIRP	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg00684032	chr4:1343700	KIAA1530	0.52	6.6	0.39	2.52e-10	Obesity-related traits;
KIRP	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg22117172	chr7:91764530	CYP51A1	0.44	6.05	0.36	5.23e-9	Breast cancer;
KIRP	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg23845249	chr11:68861649	NA	0.57	8.22	0.46	1.18e-14	Blond vs. brown hair color;
KIRP	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.86	9.7	0.53	4.77e-19	Reticulocyte fraction of red cells;
KIRP	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg00042356	chr1:8021962	PARK7	0.6	4.85	0.3	2.22e-6	Inflammatory bowel disease;
KIRP	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg12908607	chr1:44402522	ARTN	-0.37	-5.47	-0.33	1.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18357526	chr6:26021779	HIST1H4A	0.62	6.88	0.4	4.89e-11	Urate levels;
KIRP	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.71	11.1	0.58	1.75e-23	Resting heart rate;
KIRP	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs2072732	0.861	rs66693767	chr1:2955930	A/G	cg11731671	chr1:2995604	PRDM16	-0.45	-5.68	-0.34	3.8e-8	Plateletcrit;
KIRP	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Electroencephalogram traits;
KIRP	cis	rs9596863	0.898	rs17088922	chr13:54375033	T/C	ch.13.53330881F	chr13:54432880	NA	0.61	6.03	0.36	6.02e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs988913	1.000	rs9475099	chr6:54839070	A/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.53	-0.33	8.11e-8	Menarche (age at onset);
KIRP	cis	rs55788414	0.932	rs35326835	chr16:81190413	T/C	cg06400318	chr16:81190750	PKD1L2	-1.06	-8.53	-0.48	1.55e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.83	-0.49	2.01e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.59	-7.4	-0.43	2.18e-12	Fibrinogen levels;
KIRP	cis	rs7122257	0.507	rs10840585	chr11:11163672	C/T	cg16931664	chr11:11169707	NA	-0.45	-6.2	-0.37	2.35e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6893300	0.560	rs1019443	chr5:179207547	A/G	cg14593053	chr5:179126677	CANX	-0.69	-10.52	-0.56	1.29e-21	Resting heart rate;
KIRP	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-1.1	-8.78	-0.49	2.78e-16	Atopic dermatitis;
KIRP	cis	rs4654899	0.802	rs6426648	chr1:21179527	A/G	cg05370193	chr1:21551575	ECE1	0.41	5.23	0.32	3.58e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-5.11	-0.31	6.39e-7	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-7.11	-0.41	1.24e-11	Lung cancer;
KIRP	cis	rs1420338	0.967	rs10272282	chr7:34172073	C/T	cg01275685	chr7:34179230	BMPER	-0.52	-7.71	-0.44	3.04e-13	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.54	0.48	1.43e-15	Coffee consumption (cups per day);
KIRP	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.29	0.47	7.23e-15	IgG glycosylation;
KIRP	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00889227	chr1:205173544	DSTYK	-0.36	-4.88	-0.3	1.89e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg10503236	chr1:231470652	EXOC8	-0.53	-7.4	-0.43	2.16e-12	Hemoglobin concentration;
KIRP	cis	rs12643440	0.538	rs4698536	chr4:17142175	C/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9649213	0.593	rs6963210	chr7:97944986	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.96	0.36	8.88e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg06223162	chr1:101003688	GPR88	0.41	7.64	0.44	4.97e-13	Breast cancer;
KIRP	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg18357526	chr6:26021779	HIST1H4A	0.54	7.23	0.42	5.98e-12	Height;
KIRP	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs193541	0.545	rs12518979	chr5:122181787	G/T	cg19412675	chr5:122181750	SNX24	-0.58	-6.29	-0.37	1.43e-9	Glucose homeostasis traits;
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg06654118	chr4:1303317	MAEA	0.28	5.22	0.32	3.89e-7	Longevity;
KIRP	cis	rs2224391	0.554	rs2224392	chr6:5261136	G/A	cg13962347	chr6:5174647	LYRM4	-0.77	-10.86	-0.57	1.09e-22	Height;
KIRP	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg01879757	chr17:41196368	BRCA1	-0.54	-7.17	-0.42	8.9e-12	Menopause (age at onset);
KIRP	cis	rs6546886	1.000	rs4328662	chr2:74244037	A/C	cg14702570	chr2:74259524	NA	-0.29	-5.71	-0.34	3.19e-8	Dialysis-related mortality;
KIRP	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.64	-8.69	-0.48	5.27e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg03808351	chr9:123631620	PHF19	0.42	5.56	0.33	7.07e-8	Rheumatoid arthritis;
KIRP	cis	rs7534824	0.625	rs61780327	chr1:101449810	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.03	0.41	2.07e-11	Refractive astigmatism;
KIRP	cis	rs6956675	1.000	rs1879843	chr7:62586129	A/G	cg08930214	chr7:62859557	LOC100287834	0.48	5.58	0.34	6.35e-8	Obesity-related traits;
KIRP	cis	rs12615966	0.932	rs72830462	chr2:105394600	C/T	cg16465502	chr2:105461796	NA	0.62	5.65	0.34	4.35e-8	Pancreatic cancer;
KIRP	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.75	8.21	0.46	1.26e-14	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.63	-0.39	2.16e-10	Neuroticism;
KIRP	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.84e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10517025	0.673	rs73235559	chr4:42419622	G/C	cg11065575	chr4:42403471	SHISA3	0.45	4.97	0.3	1.25e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.48e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg10104451	chr8:143696006	ARC	-0.68	-7.54	-0.43	9.23e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.71	7.97	0.45	6.09e-14	Corneal astigmatism;
KIRP	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.4	4.98	0.3	1.22e-6	Response to temozolomide;
KIRP	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.95	0.54	8.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg03959625	chr15:84868606	LOC388152	0.54	6.55	0.39	3.42e-10	Schizophrenia;
KIRP	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	1.04	19.9	0.79	3.56e-53	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg01620082	chr3:125678407	NA	-1.03	-6.64	-0.39	1.97e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7072216	0.555	rs2296433	chr10:100184062	C/A	cg11203827	chr10:100175560	PYROXD2	-0.37	-4.87	-0.3	1.96e-6	Metabolite levels;
KIRP	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00361562	chr2:198649771	BOLL	-0.5	-5.3	-0.32	2.51e-7	Ulcerative colitis;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg00689492	chr4:1303491	MAEA	0.29	5.36	0.32	1.92e-7	Longevity;
KIRP	cis	rs6429082	0.509	rs2803846	chr1:235521054	C/G	cg26050004	chr1:235667680	B3GALNT2	0.41	4.9	0.3	1.74e-6	Adiposity;
KIRP	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg06204229	chr3:52865917	ITIH4	0.47	5.4	0.33	1.59e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg22676075	chr6:135203613	NA	0.5	7.18	0.42	8.21e-12	Red blood cell count;
KIRP	cis	rs7258015	0.909	rs3176769	chr19:10447034	A/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.48	6.21	0.37	2.24e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.92	12.57	0.63	2.49e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17608500	chr1:154955711	FLAD1	0.46	6.04	0.36	5.63e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.64	0.39	2.04e-10	Electroencephalogram traits;
KIRP	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg12315302	chr6:26189340	HIST1H4D	1.08	6.42	0.38	7.16e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	trans	rs242364	0.530	rs13047360	chr21:28851580	C/T	cg01278232	chr17:17606846	RAI1	0.6	6.83	0.4	6.65e-11	Daytime sleep phenotypes;
KIRP	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.53	6.27	0.37	1.6e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.96	0.36	8.85e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs4919044	0.866	rs11187263	chr10:94816817	T/C	cg05127821	chr10:94822908	CYP26C1	-0.98	-7.06	-0.41	1.68e-11	Coronary artery disease;
KIRP	cis	rs8179	1.000	rs42031	chr7:92237396	A/T	cg15732164	chr7:92237376	CDK6	-0.66	-8.39	-0.47	3.76e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg07148914	chr20:33460835	GGT7	-0.41	-5.07	-0.31	7.84e-7	Height;
KIRP	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.9	13.99	0.67	4.02e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13065560	0.594	rs4234133	chr3:38888021	T/C	cg01426195	chr3:39028469	NA	-0.45	-7.21	-0.42	6.67e-12	Interleukin-18 levels;
KIRP	cis	rs7027203	0.576	rs4415381	chr9:96554603	A/G	cg14598338	chr9:96623480	NA	0.46	7.15	0.41	9.67e-12	DNA methylation (variation);
KIRP	cis	rs6594499	0.872	rs6859041	chr5:110435231	G/A	cg04022379	chr5:110408740	TSLP	0.46	7.11	0.41	1.25e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg14403583	chr14:105418241	AHNAK2	0.68	9.47	0.52	2.38e-18	Rheumatoid arthritis;
KIRP	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg15691649	chr6:25882328	NA	0.41	4.96	0.3	1.33e-6	Blood metabolite levels;
KIRP	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.42	5.53	0.33	8.27e-8	Height;
KIRP	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.33	0.32	2.25e-7	Menopause (age at onset);
KIRP	cis	rs787274	0.764	rs4979157	chr9:115571791	T/C	cg13803584	chr9:115635662	SNX30	-0.72	-6.55	-0.39	3.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg00982548	chr2:198649783	BOLL	-0.59	-5.55	-0.33	7.48e-8	Ulcerative colitis;
KIRP	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg00310523	chr12:86230176	RASSF9	0.38	5.8	0.35	2.01e-8	Major depressive disorder;
KIRP	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg07701084	chr6:150067640	NUP43	0.61	7.79	0.44	1.87e-13	Lung cancer;
KIRP	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg01246520	chr17:17644344	RAI1	0.47	8.1	0.46	2.52e-14	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.89	-8.45	-0.47	2.64e-15	Rheumatoid arthritis;
KIRP	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg21851534	chr17:3907994	ZZEF1	0.42	4.86	0.3	2.12e-6	Type 2 diabetes;
KIRP	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg02811702	chr13:24901961	NA	0.4	5.35	0.32	2e-7	Obesity-related traits;
KIRP	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19524238	chr7:2802976	GNA12	-0.35	-4.86	-0.3	2.13e-6	Height;
KIRP	cis	rs7010876	0.568	rs7357575	chr8:89230024	A/G	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.9	-10.47	-0.56	1.87e-21	White matter hyperintensity burden;
KIRP	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.81	8.73	0.49	3.85e-16	Prostate cancer;
KIRP	cis	rs637571	0.524	rs674363	chr11:65699134	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.47	5.88	0.35	1.35e-8	Eosinophil percentage of white cells;
KIRP	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg01620082	chr3:125678407	NA	-1.23	-7.82	-0.45	1.58e-13	Depression;
KIRP	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg26876637	chr1:152193138	HRNR	0.72	9.53	0.52	1.61e-18	Atopic dermatitis;
KIRP	cis	rs6256	0.860	rs74932445	chr11:13500645	G/A	cg11976911	chr11:13509032	NA	-0.62	-5.18	-0.31	4.55e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs11809443	0.569	rs11800309	chr1:228391808	G/T	cg07830794	chr1:228460260	OBSCN	-0.7	-7.53	-0.43	9.7e-13	Coronary artery disease;
KIRP	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.75	10.43	0.55	2.42e-21	Diastolic blood pressure;
KIRP	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-5.28	-0.32	2.88e-7	Schizophrenia (age at onset);
KIRP	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.65	-8.32	-0.47	6.29e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs754423	0.703	rs753436	chr14:52519839	G/A	cg05884192	chr14:52515736	NID2	-0.66	-7.94	-0.45	7.24e-14	Craniofacial microsomia;
KIRP	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg14343924	chr8:8086146	FLJ10661	0.52	6.25	0.37	1.82e-9	Neuroticism;
KIRP	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg00361562	chr2:198649771	BOLL	-0.52	-5.45	-0.33	1.2e-7	Ulcerative colitis;
KIRP	trans	rs12517041	1.000	rs6874000	chr5:23304235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.87	7.81	0.45	1.67e-13	Calcium levels;
KIRP	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	0.65	8.28	0.47	7.76e-15	Red blood cell count;
KIRP	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	11.66	0.6	2.59e-25	Smoking behavior;
KIRP	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.45	-5.27	-0.32	3.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg14784868	chr12:69753453	YEATS4	0.54	5.71	0.34	3.22e-8	Response to diuretic therapy;
KIRP	cis	rs4936894	0.500	rs10790660	chr11:124146135	A/G	cg27160556	chr11:124181099	OR8D1	-0.47	-6.68	-0.39	1.6e-10	Aging (time to death);
KIRP	cis	rs28830936	0.934	rs3959569	chr15:42115747	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.41	-0.38	7.44e-10	Diastolic blood pressure;
KIRP	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.65	0.34	4.34e-8	Total cholesterol levels;
KIRP	cis	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg24110177	chr3:50126178	RBM5	0.67	8.99	0.5	6.65e-17	Menarche (age at onset);
KIRP	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.68	9.38	0.51	4.68e-18	Obesity-related traits;
KIRP	cis	rs258892	0.895	rs153320	chr5:72138452	C/T	cg21869765	chr5:72125136	TNPO1	-0.61	-6.96	-0.41	3.01e-11	Small cell lung carcinoma;
KIRP	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.71	-8.29	-0.47	7.2e-15	Resting heart rate;
KIRP	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg06204229	chr3:52865917	ITIH4	0.56	6.74	0.39	1.11e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6815814	0.861	rs4543123	chr4:38792524	A/G	cg06935464	chr4:38784597	TLR10	0.49	5.86	0.35	1.46e-8	Breast cancer;
KIRP	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg00343986	chr7:65444356	GUSB	0.46	5.63	0.34	4.99e-8	Calcium levels;
KIRP	cis	rs6684428	0.536	rs4927275	chr1:56396564	A/G	cg11651538	chr1:56320950	NA	0.55	8.09	0.46	2.76e-14	Airflow obstruction;
KIRP	cis	rs7630877	0.719	rs73057311	chr3:179664197	A/G	cg18765712	chr3:179670323	PEX5L	0.83	9.55	0.52	1.41e-18	Type 2 diabetes;
KIRP	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.77	10.71	0.56	3.2800000000000002e-22	Red blood cell count;
KIRP	cis	rs965513	1.000	rs10983761	chr9:100553957	A/C	cg13688889	chr9:100608707	NA	-0.59	-7.4	-0.43	2.15e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs988913	0.581	rs3125269	chr6:54858449	G/C	cg03513858	chr6:54763001	FAM83B	-0.34	-4.9	-0.3	1.76e-6	Menarche (age at onset);
KIRP	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.6	0.52	9.84e-19	Prudent dietary pattern;
KIRP	cis	rs2997447	0.846	rs3008232	chr1:26402621	A/G	cg19633962	chr1:26362018	EXTL1	-0.51	-5.05	-0.31	8.48e-7	QRS complex (12-leadsum);
KIRP	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg08126542	chr6:37504118	NA	-0.59	-7.04	-0.41	1.92e-11	Cognitive performance;
KIRP	trans	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg16141378	chr3:129829833	LOC729375	0.52	6.3	0.37	1.34e-9	Mood instability;
KIRP	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.87	-8.47	-0.48	2.19e-15	Monocyte percentage of white cells;
KIRP	cis	rs28655083	0.956	rs7184198	chr16:77069490	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.55	-6.3	-0.37	1.34e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2599510	0.783	rs62136349	chr2:32827504	G/A	cg02381751	chr2:32503542	YIPF4	0.45	5.12	0.31	6.21e-7	Interleukin-18 levels;
KIRP	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.96	-0.3	1.34e-6	Obesity-related traits;
KIRP	cis	rs526231	0.543	rs75913944	chr5:102479503	G/C	cg23492399	chr5:102201601	PAM	-0.5	-5.44	-0.33	1.26e-7	Primary biliary cholangitis;
KIRP	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.87	-0.4	5.09e-11	Eye color traits;
KIRP	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.93	14.76	0.69	9.36e-36	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.49	5.72	0.34	3.14e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs4006360	0.646	rs6503602	chr17:39301175	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.82	-0.45	1.5700000000000001e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs12220238	0.915	rs10824164	chr10:76137032	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.67	0.39	1.65e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-5.67	-0.34	3.92e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg14675211	chr2:100938903	LONRF2	0.54	7.32	0.42	3.59e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs959260	1.000	rs9900002	chr17:73382018	T/A	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.66	-0.48	6.24e-16	Mood instability;
KIRP	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg06565975	chr8:143823917	SLURP1	-0.57	-7.84	-0.45	1.35e-13	Urinary tract infection frequency;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.89	-0.3	1.83e-6	Life satisfaction;
KIRP	cis	rs654384	0.864	rs651245	chr7:4167336	C/T	cg21882563	chr7:4172065	SDK1	0.39	5.06	0.31	8.21e-7	Positive affect;
KIRP	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.09	15.9	0.71	1.23e-39	Total cholesterol levels;
KIRP	cis	rs8084125	1.000	rs7237781	chr18:74953527	C/T	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg07843065	chr1:150265600	MRPS21	0.44	6.0	0.36	6.98e-9	Migraine;
KIRP	cis	rs4363385	0.510	rs56241316	chr1:152901748	A/G	cg07796016	chr1:152779584	LCE1C	-0.46	-5.71	-0.34	3.26e-8	Inflammatory skin disease;
KIRP	cis	rs911119	0.913	rs6048926	chr20:23580987	C/A	cg16589663	chr20:23618590	CST3	0.48	4.85	0.3	2.18e-6	Chronic kidney disease;
KIRP	cis	rs1448094	0.817	rs10863121	chr12:86343834	A/C	cg06740227	chr12:86229804	RASSF9	-0.43	-5.44	-0.33	1.29e-7	Major depressive disorder;
KIRP	cis	rs13102973	0.965	rs6535051	chr4:135874869	G/A	cg14419869	chr4:135874104	NA	-0.62	-11.11	-0.58	1.64e-23	Subjective well-being;
KIRP	cis	rs1006703	0.544	rs8082265	chr17:3838761	C/T	cg06463185	chr17:3833770	ATP2A3	-0.65	-6.01	-0.36	6.66e-9	Glucose homeostasis traits;
KIRP	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.96	13.53	0.65	1.49e-31	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.79	8.99	0.5	6.85e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg00094735	chr5:1949198	NA	-0.47	-5.35	-0.32	2.06e-7	Gut microbiome composition (winter);
KIRP	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.03	-0.5	5.09e-17	Retinal vascular caliber;
KIRP	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg18932078	chr1:2524107	MMEL1	0.4	5.43	0.33	1.37e-7	Ulcerative colitis;
KIRP	cis	rs1978968	1.000	rs2099945	chr22:18438642	G/C	cg03078520	chr22:18463400	MICAL3	-0.61	-7.66	-0.44	4.15e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.79	-11.53	-0.59	7.18e-25	Mean platelet volume;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg09699651	chr6:150184138	LRP11	0.48	6.28	0.37	1.52e-9	Lung cancer;
KIRP	cis	rs6132905	0.590	rs2092655	chr20:2626050	G/A	cg24848351	chr20:2622020	TMC2	-0.64	-5.85	-0.35	1.52e-8	Mumps;
KIRP	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.4	5.75	0.34	2.69e-8	Testicular germ cell tumor;
KIRP	cis	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg21546286	chr11:48923668	NA	-0.47	-5.99	-0.36	7.59e-9	HDL cholesterol;
KIRP	cis	rs3755132	0.929	rs976233	chr2:15774115	C/T	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg21466736	chr12:48725269	NA	-0.5	-6.21	-0.37	2.25e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	8.34	0.47	5.47e-15	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.44	0.38	6.28e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg00074818	chr8:8560427	CLDN23	0.4	6.19	0.37	2.55e-9	Obesity-related traits;
KIRP	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.46	5.7	0.34	3.41e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.47	-0.38	5.35e-10	Neutrophil percentage of white cells;
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg25703541	chr22:24373054	LOC391322	-0.58	-6.24	-0.37	1.89e-9	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.74	-10.29	-0.55	6.84e-21	Childhood ear infection;
KIRP	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg18755752	chr8:142205143	DENND3	0.42	5.6	0.34	5.79e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.88e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2625529	0.668	rs35206011	chr15:72539494	T/C	cg16672083	chr15:72433130	SENP8	-0.47	-5.73	-0.34	3e-8	Red blood cell count;
KIRP	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.58	-0.34	6.27e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.59	-0.52	1.02e-18	Body mass index;
KIRP	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.5	-0.38	4.33e-10	Glomerular filtration rate;
KIRP	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	cg21523751	chr1:182988639	NA	0.41	6.32	0.37	1.22e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6832769	1.000	rs28582059	chr4:56408404	G/C	cg09317128	chr4:56265301	TMEM165	-0.55	-7.35	-0.42	2.89e-12	Personality dimensions;
KIRP	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.3	-0.32	2.63e-7	Coronary artery disease;
KIRP	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.69	8.12	0.46	2.2e-14	Corneal astigmatism;
KIRP	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	1.24	11.54	0.59	6.79e-25	Diabetic retinopathy;
KIRP	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	cis	rs427941	0.703	rs201441	chr7:101737327	A/C	cg06246474	chr7:101738831	CUX1	0.53	6.63	0.39	2.13e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4356932	1.000	rs4304003	chr4:76995463	A/G	cg00809888	chr4:76862425	NAAA	-0.42	-5.96	-0.36	8.67e-9	Blood protein levels;
KIRP	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg07810366	chr2:100720526	AFF3	-0.31	-4.87	-0.3	2.01e-6	Educational attainment;
KIRP	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-10.04	-0.54	4.3e-20	Morning vs. evening chronotype;
KIRP	cis	rs7520050	0.966	rs946529	chr1:46485548	G/T	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.08e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.53	-0.56	1.23e-21	Menopause (age at onset);
KIRP	cis	rs4389656	0.857	rs416847	chr5:6739567	A/G	cg10857441	chr5:6722123	POLS	-0.47	-6.63	-0.39	2.17e-10	Coronary artery disease;
KIRP	cis	rs7714584	1.000	rs61270113	chr5:150226263	G/A	cg22134413	chr5:150180641	NA	0.6	5.21	0.32	4.07e-7	Crohn's disease;
KIRP	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.43	8.47	0.48	2.31e-15	Coronary artery disease;
KIRP	cis	rs7096127	1.000	rs11013970	chr10:24500718	A/T	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.88	0.3	1.91e-6	Lobe attachment (rater scored);
KIRP	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19346786	chr7:2764209	NA	-0.45	-7.43	-0.43	1.79e-12	Height;
KIRP	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.88	-12.72	-0.63	8.32e-29	Coronary artery disease;
KIRP	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.85	13.72	0.66	3.5e-32	Multiple myeloma (IgH translocation);
KIRP	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs3784262	0.742	rs28379349	chr15:58202494	A/G	cg12031962	chr15:58353849	ALDH1A2	0.38	5.36	0.32	1.89e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.84	13.7	0.66	3.93e-32	Itch intensity from mosquito bite;
KIRP	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.63	7.03	0.41	2.04e-11	Aortic root size;
KIRP	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.47	6.0	0.36	7.05e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg06627628	chr2:24431161	ITSN2	0.6	5.31	0.32	2.46e-7	Lymphocyte counts;
KIRP	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg22903471	chr2:27725779	GCKR	-0.37	-5.16	-0.31	5.2e-7	Oral cavity cancer;
KIRP	cis	rs732716	0.785	rs55660045	chr19:4425305	T/G	cg21720385	chr19:4455239	UBXN6	0.71	8.82	0.49	2.21e-16	Mean corpuscular volume;
KIRP	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-6.24	-0.37	1.94e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.79	-0.57	1.74e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6499755	0.712	rs31085	chr16:55362502	G/A	cg05099576	chr16:55362342	IRX6	0.31	6.49	0.38	4.66e-10	Hypospadias;
KIRP	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.43	-5.51	-0.33	9.2e-8	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.01	0.3	1.03e-6	Breast cancer;
KIRP	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg04132472	chr17:19861366	AKAP10	0.66	9.97	0.54	6.78e-20	Schizophrenia;
KIRP	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15554466	chr19:39936040	SUPT5H	0.45	6.31	0.37	1.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.59	-12.11	-0.61	8.67e-27	Diabetic kidney disease;
KIRP	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg00361562	chr2:198649771	BOLL	-0.5	-5.03	-0.31	9.36e-7	Ulcerative colitis;
KIRP	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.7	-8.39	-0.47	3.94e-15	Obesity-related traits;
KIRP	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.6	11.32	0.59	3.38e-24	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20810993	chr1:116250018	CASQ2	-0.43	-6.2	-0.37	2.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs12517041	1.000	rs6880744	chr5:23299825	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.96	-0.5	8.24e-17	Calcium levels;
KIRP	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.11	0.31	6.53e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1318772	0.932	rs3763141	chr5:112896576	C/G	cg12552261	chr5:112820674	MCC	0.78	5.46	0.33	1.17e-7	F-cell distribution;
KIRP	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-7.55	-0.43	8.53e-13	Response to antipsychotic treatment;
KIRP	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg12042659	chr19:58951599	ZNF132	0.49	6.05	0.36	5.28e-9	Uric acid clearance;
KIRP	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs865483	0.860	rs853220	chr17:35787666	C/T	cg06716730	chr17:35851459	DUSP14	0.25	5.99	0.36	7.52e-9	Monocyte count;
KIRP	cis	rs282587	0.569	rs377748	chr13:113405482	C/T	cg04656015	chr13:113407548	ATP11A	0.6	6.52	0.38	3.85e-10	Glycated hemoglobin levels;
KIRP	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.35	5.0	0.3	1.08e-6	Mean corpuscular volume;
KIRP	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.01	17.09	0.74	1.06e-43	Testicular germ cell tumor;
KIRP	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.69	9.27	0.51	9.48e-18	Crohn's disease;
KIRP	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.74	-10.29	-0.55	6.83e-21	Anterior chamber depth;
KIRP	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.05e-8	Common traits (Other);
KIRP	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg07777115	chr5:623756	CEP72	-0.57	-5.82	-0.35	1.86e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg04672837	chr16:48644449	N4BP1	0.51	7.1	0.41	1.3e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.86	9.44	0.52	3.07e-18	Platelet count;
KIRP	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg00262122	chr8:11665843	FDFT1	-0.42	-5.15	-0.31	5.33e-7	Retinal vascular caliber;
KIRP	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg01843034	chr6:37503916	NA	-0.71	-8.36	-0.47	4.8e-15	Cognitive performance;
KIRP	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg00684032	chr4:1343700	KIAA1530	0.47	6.07	0.36	4.75e-9	Obesity-related traits;
KIRP	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.78	0.66	2.12e-32	Alzheimer's disease;
KIRP	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg16917193	chr12:54089295	NA	0.85	16.34	0.72	3.89e-41	Height;
KIRP	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.7	-0.34	3.46e-8	Fear of minor pain;
KIRP	cis	rs8177876	0.822	rs1412	chr16:81115842	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	0.96	9.61	0.52	8.89e-19	Lung cancer;
KIRP	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.51	0.33	8.88e-8	Renal cell carcinoma;
KIRP	cis	rs9398235	1.000	rs9398235	chr6:110732116	A/G	cg01119278	chr6:110721349	DDO	-0.44	-4.93	-0.3	1.53e-6	Systemic lupus erythematosus;
KIRP	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-6.72	-0.39	1.24e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs752010	0.967	rs4083593	chr1:42099583	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	9.67	0.52	5.89e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg20253172	chr1:3107290	PRDM16	-0.5	-6.29	-0.37	1.42e-9	Migraine;
KIRP	cis	rs2554380	0.628	rs6602993	chr15:84482362	C/G	cg14598478	chr15:84363061	ADAMTSL3	-0.3	-5.02	-0.3	1e-6	Height;
KIRP	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg00982548	chr2:198649783	BOLL	0.59	5.46	0.33	1.17e-7	Ulcerative colitis;
KIRP	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg26898376	chr11:64110657	CCDC88B	0.58	4.9	0.3	1.77e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs490234	0.691	rs1250505	chr9:128193456	G/T	cg14078157	chr9:128172775	NA	-0.41	-5.01	-0.3	1.06e-6	Mean arterial pressure;
KIRP	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg16141378	chr3:129829833	LOC729375	0.53	6.99	0.41	2.62e-11	Retinal vascular caliber;
KIRP	cis	rs11790388	0.505	rs2025955	chr9:129750103	A/G	cg13970942	chr9:129673409	NA	0.38	5.0	0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs1847505	0.609	rs78738196	chr13:61511592	C/T	cg25164009	chr13:61490935	NA	0.54	5.67	0.34	3.94e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg04490037	chr7:50633773	DDC	0.36	4.91	0.3	1.65e-6	Body mass index;
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg21186296	chr8:27182909	PTK2B	0.51	6.45	0.38	5.83e-10	Neuroticism;
KIRP	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9659323	0.612	rs10923721	chr1:119542187	A/G	cg18261050	chr1:119551319	NA	0.42	5.95	0.35	9.29e-9	Body mass index;
KIRP	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.65	-7.05	-0.41	1.78e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.48	-5.17	-0.31	4.78e-7	Initial pursuit acceleration;
KIRP	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.75	-11.93	-0.61	3.5e-26	Resting heart rate;
KIRP	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg11344533	chr11:111475393	SIK2	-0.29	-4.97	-0.3	1.24e-6	Primary sclerosing cholangitis;
KIRP	cis	rs4845875	0.557	rs4846054	chr1:11869230	C/T	cg24844545	chr1:11908347	NPPA	0.35	4.95	0.3	1.35e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.66	9.17	0.5	1.92e-17	Prostate cancer;
KIRP	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.64	-9.44	-0.52	3.02e-18	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg00405596	chr8:11794950	NA	-0.54	-7.37	-0.43	2.52e-12	Mood instability;
KIRP	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.68	8.53	0.48	1.54e-15	Aortic root size;
KIRP	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg18498241	chr11:69286352	NA	-0.54	-6.52	-0.38	3.96e-10	Breast cancer (early onset);
KIRP	cis	rs244293	0.730	rs12951898	chr17:53035602	C/T	cg07707039	chr17:53042137	COX11	-0.41	-5.27	-0.32	2.94e-7	Menarche (age at onset);
KIRP	cis	rs10875746	0.903	rs10875735	chr12:48463806	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg07395648	chr5:131743802	NA	-0.35	-5.15	-0.31	5.41e-7	Blood metabolite levels;
KIRP	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.48	0.33	1.05e-7	Ovarian reserve;
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07308232	chr7:1071921	C7orf50	-0.8	-11.45	-0.59	1.27e-24	Longevity;Endometriosis;
KIRP	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.2	22.07	0.82	3.02e-60	Cognitive function;
KIRP	cis	rs11264213	0.901	rs663163	chr1:36390527	A/G	cg27506609	chr1:36549197	TEKT2	0.96	10.23	0.55	1.04e-20	Schizophrenia;
KIRP	cis	rs1050631	0.574	rs1789507	chr18:33732354	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.65	0.34	4.4e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.53	6.68	0.39	1.6e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.89	-12.93	-0.64	1.63e-29	Tonsillectomy;
KIRP	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg27205649	chr11:78285834	NARS2	0.82	11.43	0.59	1.51e-24	Alzheimer's disease (survival time);
KIRP	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06544989	chr22:39130855	UNC84B	-0.51	-8.42	-0.47	3.16e-15	Menopause (age at onset);
KIRP	trans	rs702634	0.959	rs1664781	chr5:53276301	A/G	cg02663137	chr19:6745717	TRIP10	0.52	6.15	0.37	3.12e-9	Type 2 diabetes;High light scatter reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs73193808	0.666	rs7276548	chr21:30552839	A/G	cg03476357	chr21:30257390	N6AMT1	0.43	5.03	0.31	9.42e-7	Coronary artery disease;
KIRP	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.34	-0.42	3.13e-12	Body mass index;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg27189623	chr16:705930	WDR90	0.44	6.13	0.36	3.55e-9	Height;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19828298	chr1:3713105	LRRC47	0.62	6.85	0.4	5.88e-11	Lung cancer in ever smokers;
KIRP	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg18306943	chr3:40428807	ENTPD3	-0.44	-5.74	-0.34	2.73e-8	Renal cell carcinoma;
KIRP	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.46	-5.02	-0.3	1e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs9790314	0.613	rs1447619	chr3:160616077	A/T	cg04691961	chr3:161091175	C3orf57	0.42	6.18	0.37	2.65e-9	Morning vs. evening chronotype;
KIRP	cis	rs10463316	0.817	rs10476770	chr5:150777720	G/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-5.91	-0.35	1.16e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.67	7.09	0.41	1.39e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.15	24.03	0.84	1.81e-66	Schizophrenia;
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.46	-0.33	1.19e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2617583	0.967	rs2652509	chr5:1448247	A/G	cg07151155	chr5:1473589	LPCAT1	-0.42	-5.77	-0.35	2.33e-8	Breast cancer;
KIRP	cis	rs4901847	0.609	rs11158198	chr14:58576320	G/T	cg15908186	chr14:58618357	C14orf37	-0.56	-6.81	-0.4	7.32e-11	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg22681709	chr2:178499509	PDE11A	-0.62	-9.12	-0.5	2.68e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8067545	1.000	rs8067545	chr17:19912710	T/C	cg04132472	chr17:19861366	AKAP10	0.48	6.84	0.4	6.16e-11	Schizophrenia;
KIRP	cis	rs7011507	1.000	rs7004976	chr8:49134742	G/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.58	-7.11	-0.41	1.22e-11	Glomerular filtration rate;
KIRP	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4704187	0.687	rs1363579	chr5:74510353	G/T	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.74e-8	Response to amphetamines;
KIRP	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.45	5.84	0.35	1.62e-8	Initial pursuit acceleration;
KIRP	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	1.03	14.28	0.67	4.08e-34	Cognitive function;
KIRP	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.19	-0.37	2.56e-9	Total body bone mineral density;
KIRP	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.71	-0.34	3.29e-8	Morning vs. evening chronotype;
KIRP	cis	rs17023223	0.537	rs1343723	chr1:119605054	A/T	cg18261050	chr1:119551319	NA	0.49	6.56	0.39	3.12e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22253541	chr12:65385603	NA	-0.42	-6.15	-0.37	3.05e-9	Inflammatory biomarkers;
KIRP	cis	rs4908768	0.906	rs12568293	chr1:8540912	C/T	cg03610117	chr1:8450231	RERE	0.5	5.46	0.33	1.15e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg07395648	chr5:131743802	NA	-0.48	-6.57	-0.39	2.99e-10	Blood metabolite levels;
KIRP	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.25	-0.47	9.62e-15	Total cholesterol levels;
KIRP	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.78	7.24	0.42	5.81e-12	Mean platelet volume;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg18234130	chr8:27182889	PTK2B	-0.56	-7.12	-0.41	1.15e-11	Neuroticism;
KIRP	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg04202892	chr2:111875749	ACOXL	0.5	7.0	0.41	2.47e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs17767294	1.000	rs17767294	chr6:28054198	A/G	cg08851530	chr6:28072375	NA	0.73	5.16	0.31	4.99e-7	Parkinson's disease;
KIRP	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg02487422	chr3:49467188	NICN1	0.39	5.45	0.33	1.21e-7	Parkinson's disease;
KIRP	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21747090	chr2:27597821	SNX17	-0.46	-6.28	-0.37	1.49e-9	Total body bone mineral density;
KIRP	cis	rs77633900	0.614	rs2469241	chr15:76873908	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-7.75	-0.44	2.42e-13	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.74	9.95	0.54	7.98e-20	Parkinson's disease;
KIRP	cis	rs9534288	0.751	rs2806920	chr13:46514506	T/C	cg15192986	chr13:46630673	CPB2	0.62	7.41	0.43	2.02e-12	Blood protein levels;
KIRP	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	8.07e-13	Bipolar disorder;
KIRP	cis	rs8077577	0.895	rs16960996	chr17:18110559	A/G	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg24253500	chr15:84953950	NA	0.67	7.81	0.45	1.69e-13	Schizophrenia;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg22515201	chr22:38577827	PLA2G6	-0.44	-6.03	-0.36	6.06e-9	Serum protein levels (sST2);
KIRP	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg12756093	chr1:115239321	AMPD1	0.55	7.49	0.43	1.21e-12	Autism;
KIRP	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	1.23	12.71	0.63	8.51e-29	Red blood cell traits;
KIRP	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	0.94	7.67	0.44	4.06e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15334456	chr3:10290272	TATDN2	0.49	6.26	0.37	1.71e-9	Parkinson's disease;
KIRP	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg23791538	chr6:167370224	RNASET2	0.44	5.54	0.33	7.81e-8	Crohn's disease;
KIRP	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	6.09	0.36	4.34e-9	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs930036	0.550	rs3770442	chr2:171786239	C/T	cg12801329	chr2:171670795	NA	0.43	4.88	0.3	1.9e-6	Menopause (age at onset);
KIRP	cis	rs77688320	0.500	rs7603584	chr2:202305145	C/T	cg06431681	chr2:202330990	STRADB	0.57	7.74	0.44	2.51e-13	Breast cancer;
KIRP	cis	rs12712073	0.845	rs6729966	chr2:100781566	A/G	cg17356467	chr2:100759845	AFF3	0.37	5.09	0.31	7.06e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	5.18	0.31	4.63e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg19752551	chr11:57585705	CTNND1	-0.82	-13.58	-0.65	1.02e-31	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg12692727	chr7:1102344	C7orf50	0.48	5.18	0.31	4.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg10755058	chr3:40428713	ENTPD3	0.49	6.75	0.4	1.06e-10	Renal cell carcinoma;
KIRP	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.08	-0.31	7.29e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg01304814	chr3:48885189	PRKAR2A	0.71	5.63	0.34	4.97e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg04733989	chr22:42467013	NAGA	0.55	7.55	0.43	8.72e-13	Cognitive function;
KIRP	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg17517138	chr11:73019481	ARHGEF17	0.76	6.43	0.38	6.45e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7005380	0.556	rs11984773	chr8:120936586	C/G	cg21645572	chr8:120931649	DEPDC6	-0.43	-5.25	-0.32	3.23e-7	Interstitial lung disease;
KIRP	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.96	12.94	0.64	1.46e-29	Cognitive function;
KIRP	cis	rs526231	0.543	rs34832	chr5:102444595	T/C	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.35	1.27e-8	Primary biliary cholangitis;
KIRP	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.52	-5.84	-0.35	1.62e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.68	0.66	4.8e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4783244	0.897	rs12598679	chr16:82651205	G/A	cg09415485	chr16:82663111	CDH13	-0.26	-5.05	-0.31	8.79e-7	Adiponectin levels;
KIRP	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.73	0.6	1.62e-25	Heart rate;
KIRP	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.46	-5.45	-0.33	1.23e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	0.96	11.2	0.58	8.39e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg01251548	chr11:17372745	DKFZp686O24166	-0.38	-4.97	-0.3	1.27e-6	Type 2 diabetes;
KIRP	cis	rs11718455	0.585	rs17076170	chr3:43917946	C/T	cg08738300	chr3:44038990	NA	0.56	7.01	0.41	2.26e-11	Coronary artery disease;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg13995169	chr10:72142516	LRRC20	0.49	6.04	0.36	5.59e-9	Beard thickness;
KIRP	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	13.41	0.65	3.93e-31	Menopause (age at onset);
KIRP	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.44	5.7	0.34	3.36e-8	Childhood ear infection;
KIRP	cis	rs7143963	0.609	rs11846158	chr14:103292959	A/G	cg24154132	chr14:103367632	TRAF3	0.3	5.72	0.34	3.15e-8	Body mass index;
KIRP	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.73	10.06	0.54	3.72e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.55	-0.39	3.38e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg25309564	chr22:51001381	C22orf41	0.77	5.36	0.32	1.94e-7	Narcolepsy;
KIRP	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.69	9.9	0.53	1.19e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.24e-10	Hypertriglyceridemia;
KIRP	cis	rs6499255	0.951	rs16959025	chr16:69695589	G/T	cg15192750	chr16:69999425	NA	-0.49	-5.21	-0.32	4.01e-7	IgE levels;
KIRP	cis	rs7009516	0.766	rs13279289	chr8:24232368	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.32	-6.69	-0.39	1.46e-10	Hair greying;
KIRP	cis	rs11603020	0.950	rs28362949	chr11:57371911	G/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.53	-0.52	1.63e-18	Blood protein levels;
KIRP	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.18	0.46	1.52e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06544989	chr22:39130855	UNC84B	0.43	7.42	0.43	1.95e-12	Menopause (age at onset);
KIRP	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.79	-11.79	-0.6	9.65e-26	Hip circumference;
KIRP	cis	rs2637030	0.586	rs12521381	chr5:52846195	C/T	cg06476337	chr5:52856530	NDUFS4	0.55	5.91	0.35	1.11e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.91	-0.4	4.14e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.69	8.89	0.49	1.31e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12210905	1.000	rs12192320	chr6:27090305	G/A	cg11502198	chr6:26597334	ABT1	-0.76	-4.97	-0.3	1.24e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs13315871	1.000	rs13315871	chr3:58381287	G/A	cg12435725	chr3:58293450	RPP14	-0.48	-5.12	-0.31	6.19e-7	Cholesterol, total;
KIRP	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.62	-7.13	-0.41	1.11e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16435858	chr3:129158884	IFT122;MBD4	-0.47	-6.15	-0.37	3.19e-9	Metabolic traits;
KIRP	cis	rs6738627	0.710	rs10195252	chr2:165513091	T/C	cg03182029	chr2:165697222	COBLL1	0.37	4.93	0.3	1.53e-6	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.12	-14.02	-0.67	3.25e-33	IgG glycosylation;
KIRP	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.78	11.83	0.6	7.34e-26	Electrocardiographic conduction measures;
KIRP	cis	rs2562456	0.833	rs62110428	chr19:21613656	C/T	cg00806126	chr19:22604979	ZNF98	-0.58	-5.33	-0.32	2.22e-7	Pain;
KIRP	trans	rs4349753	0.904	rs248567	chr5:144184301	T/A	cg16033277	chr17:80885358	TBCD	0.4	6.24	0.37	1.89e-9	Photic sneeze reflex;
KIRP	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.38	5.39	0.32	1.66e-7	Plateletcrit;
KIRP	cis	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg04691961	chr3:161091175	C3orf57	0.48	6.97	0.41	2.84e-11	Morning vs. evening chronotype;
KIRP	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg13263691	chr18:77568018	NA	0.49	6.73	0.39	1.2e-10	Schizophrenia;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.6	8.42	0.47	3.08e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg02367723	chr1:46378857	MAST2	0.43	4.99	0.3	1.16e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-1.06	-13.2	-0.64	1.97e-30	Exhaled nitric oxide output;
KIRP	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.58	0.39	2.84e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7246657	0.722	rs2972430	chr19:38182111	C/T	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	trans	rs7999699	0.902	rs12585275	chr13:48317513	C/T	cg23237801	chr1:16476620	EPHA2	0.5	6.3	0.37	1.33e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs3109167	0.666	rs2255872	chr7:83113683	C/T	cg14519356	chr7:83097669	SEMA3E	-0.45	-6.28	-0.37	1.49e-9	Blood protein levels;
KIRP	cis	rs2304069	0.826	rs184960	chr5:149343370	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.74	-8.09	-0.46	2.72e-14	HIV-1 control;
KIRP	cis	rs61884328	0.852	rs61896124	chr11:47092682	C/T	cg23433285	chr11:47201945	PACSIN3	0.71	5.85	0.35	1.54e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.47	-5.0	-0.3	1.1e-6	Initial pursuit acceleration;
KIRP	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg14458575	chr2:238380390	NA	0.56	6.16	0.37	2.9e-9	Prostate cancer;
KIRP	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.33	4.86	0.3	2.06e-6	Electroencephalogram traits;
KIRP	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.29	-0.55	6.9299999999999992e-21	Chronic sinus infection;
KIRP	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.65	-12.0	-0.61	1.95e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Systolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.59	6.98	0.41	2.69e-11	Smoking initiation;
KIRP	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	1.15	6.98	0.41	2.71e-11	LDL cholesterol;
KIRP	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.09	-0.31	7.13e-7	Type 2 diabetes;
KIRP	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg11833968	chr6:79620685	NA	-0.36	-5.17	-0.31	4.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15556689	chr8:8085844	FLJ10661	0.81	10.56	0.56	9.36e-22	Mood instability;
KIRP	cis	rs13185784	0.667	rs4454029	chr5:179645325	C/T	cg23221052	chr5:179740743	GFPT2	0.47	4.85	0.3	2.16e-6	TRAIL levels;
KIRP	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-4.87	-0.3	2.03e-6	Myopia (pathological);
KIRP	cis	rs7849270	0.959	rs10988233	chr9:131915926	C/A	cg13538475	chr9:131942899	NA	-0.35	-5.63	-0.34	4.89e-8	Blood metabolite ratios;
KIRP	cis	rs4356932	0.935	rs4380549	chr4:76979082	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs240764	0.631	rs9386250	chr6:101204126	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-5.24	-0.32	3.52e-7	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05450262	chr10:3371481	NA	0.49	6.89	0.4	4.52e-11	Interleukin-4 levels;
KIRP	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.45	-6.25	-0.37	1.8e-9	Lewy body disease;
KIRP	cis	rs2635047	0.615	rs2137287	chr18:44751856	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	6.87	0.4	5.13e-11	Educational attainment;
KIRP	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.26	-0.32	3.17e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	cis	rs9488822	0.585	rs7768026	chr6:116274313	A/G	cg26893134	chr6:116381904	FRK	-0.2	-5.25	-0.32	3.32e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.53	-6.71	-0.39	1.3100000000000001e-10	White blood cell count;
KIRP	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.09	0.46	2.69e-14	Response to bleomycin (chromatid breaks);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg03398387	chr6:160114178	SOD2	0.58	6.68	0.39	1.56e-10	Sleep duration;
KIRP	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg05527609	chr1:210001259	C1orf107	-0.53	-6.02	-0.36	6.31e-9	Red blood cell count;
KIRP	cis	rs1858037	0.867	rs6727013	chr2:65558375	C/A	cg08085232	chr2:65598271	SPRED2	-0.51	-6.09	-0.36	4.25e-9	Rheumatoid arthritis;
KIRP	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-1.06	-18.84	-0.77	1.33e-49	Monocyte count;
KIRP	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs13185784	0.703	rs55756747	chr5:179675052	C/A	cg23221052	chr5:179740743	GFPT2	0.53	5.12	0.31	6.18e-7	TRAIL levels;
KIRP	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg22676075	chr6:135203613	NA	0.52	7.67	0.44	4.01e-13	Red blood cell count;
KIRP	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.45	6.3	0.37	1.37e-9	Dupuytren's disease;
KIRP	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg23306229	chr2:178417860	TTC30B	0.56	5.12	0.31	6.16e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg04369109	chr6:150039330	LATS1	-0.63	-8.15	-0.46	1.8e-14	Lung cancer;
KIRP	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	5.58	0.34	6.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18252515	chr7:66147081	NA	0.47	5.57	0.33	6.7e-8	Aortic root size;
KIRP	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	10.41	0.55	2.87e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7951870	0.945	rs11038973	chr11:46728952	G/C	cg19486271	chr11:47235900	DDB2	0.49	5.06	0.31	8.04e-7	Schizophrenia;
KIRP	cis	rs9398803	0.723	rs853983	chr6:127046153	G/A	cg19875578	chr6:126661172	C6orf173	-0.43	-5.56	-0.33	6.93e-8	Male-pattern baldness;
KIRP	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg06115741	chr20:33292138	TP53INP2	0.39	5.2	0.31	4.17e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg27121462	chr16:89883253	FANCA	-0.5	-6.47	-0.38	5.21e-10	Vitiligo;
KIRP	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.12	0.46	2.21e-14	Colorectal cancer;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09332650	chr19:50120000	PRR12	0.56	6.18	0.37	2.63e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg13639189	chr17:80606880	WDR45L	0.45	6.02	0.36	6.29e-9	Breast cancer;
KIRP	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.74	8.24	0.47	1.01e-14	Schizophrenia;
KIRP	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg15440763	chr7:158190612	PTPRN2	0.43	5.52	0.33	8.46e-8	Obesity-related traits;
KIRP	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg08603382	chr10:743973	NA	-0.52	-7.75	-0.44	2.44e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs2000999	0.514	rs36061252	chr16:72217613	T/G	cg04254540	chr16:71951199	KIAA0174	-0.72	-5.2	-0.31	4.2e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.52	6.29	0.37	1.43e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs712039	0.652	rs829163	chr17:35766026	G/C	cg16670864	chr17:35848621	DUSP14	0.44	5.3	0.32	2.52e-7	Tuberculosis;
KIRP	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg18132916	chr6:79620363	NA	-0.36	-4.97	-0.3	1.24e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	9.16	0.5	2.13e-17	Smoking behavior;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14522873	chr20:21283801	XRN2	-0.53	-6.25	-0.37	1.77e-9	Interleukin-4 levels;
KIRP	trans	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg00938859	chr5:1591904	SDHAP3	0.59	7.81	0.45	1.64e-13	Breast cancer;
KIRP	cis	rs241257	0.643	rs241274	chr1:4627482	A/C	cg12065138	chr1:4771201	AJAP1	-0.34	-4.93	-0.3	1.5e-6	Anxiety disorder;
KIRP	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.92	13.09	0.64	4.75e-30	Bladder cancer;
KIRP	cis	rs77633900	0.772	rs2957612	chr15:76703688	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-5.56	-0.33	6.91e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.53	6.72	0.39	1.23e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.19	-0.37	2.45e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg20891283	chr12:69753455	YEATS4	0.63	6.47	0.38	5.21e-10	Response to diuretic therapy;
KIRP	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	5.38	0.32	1.72e-7	Iron status biomarkers;
KIRP	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-5.14	-0.31	5.67e-7	Menarche (age at onset);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg09618674	chr2:142629557	LRP1B	0.42	6.17	0.37	2.84e-9	Migraine with aura;
KIRP	cis	rs2299587	0.729	rs7825899	chr8:17857880	A/C	cg01800426	chr8:17659068	MTUS1	-0.41	-5.03	-0.31	9.37e-7	Economic and political preferences;
KIRP	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.59	-7.03	-0.41	2.09e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs2860975	1.000	rs11188133	chr10:96772015	G/A	cg09036531	chr10:96991505	NA	-0.54	-6.86	-0.4	5.41e-11	Immune response to smallpox vaccine (IL-6);
KIRP	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg13010199	chr12:38710504	ALG10B	0.62	7.71	0.44	3.18e-13	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.6	-0.39	2.46e-10	Neutrophil percentage of white cells;
KIRP	cis	rs1971762	0.527	rs7976398	chr12:54028862	T/C	cg16917193	chr12:54089295	NA	0.85	15.01	0.69	1.32e-36	Height;
KIRP	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg24315340	chr6:146058215	EPM2A	-0.37	-4.89	-0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg17646820	chr3:66848679	NA	0.77	9.49	0.52	2.11e-18	Type 2 diabetes;
KIRP	trans	rs10782582	0.758	rs5745523	chr1:76361041	C/T	cg10283277	chr11:111472630	SIK2	-0.31	-6.25	-0.37	1.77e-9	Daytime sleep phenotypes;
KIRP	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.39	5.62	0.34	5.05e-8	Body mass index;
KIRP	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg00507259	chr4:95128692	SMARCAD1	0.41	5.31	0.32	2.42e-7	QT interval;
KIRP	cis	rs12282928	0.959	rs1503168	chr11:48272696	A/G	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	8.06	0.46	3.36e-14	Myopia (pathological);
KIRP	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.53	7.01	0.41	2.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg11886554	chr3:170076028	SKIL	0.53	5.19	0.31	4.47e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.58	-6.17	-0.37	2.76e-9	Glomerular filtration rate;
KIRP	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.85	11.36	0.59	2.56e-24	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg25019722	chr6:37503610	NA	-0.78	-10.59	-0.56	7.84e-22	Cognitive performance;
KIRP	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	1.04	15.95	0.71	8.01e-40	Homoarginine levels;
KIRP	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.34	-4.91	-0.3	1.64e-6	Coronary artery disease;
KIRP	cis	rs2446066	0.605	rs7302835	chr12:53955066	C/T	cg16917193	chr12:54089295	NA	0.62	5.77	0.35	2.34e-8	Red blood cell count;
KIRP	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.95	14.82	0.69	5.99e-36	Systemic lupus erythematosus;
KIRP	cis	rs9323205	1.000	rs12589519	chr14:51596684	C/G	cg23942311	chr14:51606299	NA	-0.57	-5.96	-0.36	8.81e-9	Cancer;
KIRP	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg10253484	chr15:75165896	SCAMP2	0.66	7.37	0.43	2.64e-12	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.54	-8.84	-0.49	1.86e-16	Total body bone mineral density;
KIRP	cis	rs385076	0.503	rs212702	chr2:32444250	A/G	cg02381751	chr2:32503542	YIPF4	0.61	5.8	0.35	2.01e-8	Interleukin-18 levels;
KIRP	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.03	-0.31	9.42e-7	Bladder cancer;
KIRP	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.74	11.21	0.58	7.78e-24	Orofacial clefts;
KIRP	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg11833968	chr6:79620685	NA	-0.47	-7.12	-0.41	1.21e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg13514129	chr1:39547527	MACF1	-0.52	-7.78	-0.44	1.97e-13	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs4356932	1.000	rs8878	chr4:76942300	C/T	cg00809888	chr4:76862425	NAAA	-0.45	-6.3	-0.37	1.39e-9	Blood protein levels;
KIRP	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg01879757	chr17:41196368	BRCA1	-0.76	-10.55	-0.56	1.02e-21	Menopause (age at onset);
KIRP	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.75	12.1	0.61	9.61e-27	Vitiligo;
KIRP	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.72	-10.13	-0.54	2.25e-20	Plateletcrit;Platelet count;
KIRP	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.62	-7.29	-0.42	4.17e-12	Menopause (age at onset);
KIRP	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.68	8.13	0.46	2.08e-14	Height;
KIRP	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7590368	0.715	rs12475790	chr2:10957907	A/C	cg15705551	chr2:10952987	PDIA6	0.6	5.49	0.33	1.01e-7	Educational attainment (years of education);
KIRP	cis	rs853679	0.506	rs1150693	chr6:28174590	T/C	cg23281280	chr6:28129359	ZNF389	0.49	5.39	0.32	1.65e-7	Depression;
KIRP	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.81	7.29	0.42	4.17e-12	Obesity-related traits;
KIRP	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.39	-5.04	-0.31	8.97e-7	IgG glycosylation;
KIRP	cis	rs883565	0.543	rs784497	chr3:39179909	G/A	cg01426195	chr3:39028469	NA	0.54	8.48	0.48	2.08e-15	Handedness;
KIRP	cis	rs13315871	0.858	rs4075404	chr3:58411419	C/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.59	7.11	0.41	1.28e-11	Schizophrenia;
KIRP	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.65	8.9	0.49	1.28e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg04013166	chr16:89971882	TCF25	0.7	7.61	0.44	5.88e-13	Skin colour saturation;
KIRP	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg27398547	chr14:60952738	C14orf39	0.68	6.7	0.39	1.42e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	10.28	0.55	7.3e-21	Lymphocyte counts;
KIRP	trans	rs270421	0.636	rs55868519	chr16:79249161	C/T	cg26284735	chr3:5065165	NA	0.25	6.41	0.38	7.33e-10	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.4	-0.38	7.99e-10	Blood pressure;
KIRP	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.7	-6.39	-0.38	8.09e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg21775007	chr8:11205619	TDH	-0.42	-5.58	-0.34	6.35e-8	Triglycerides;
KIRP	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg21132104	chr15:45694354	SPATA5L1	0.54	6.35	0.38	1.04e-9	Glomerular filtration rate;
KIRP	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg14675211	chr2:100938903	LONRF2	0.55	7.13	0.41	1.11e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs16912285	0.688	rs12276587	chr11:24280656	C/G	ch.11.24196551F	chr11:24239977	NA	-0.84	-10.05	-0.54	3.83e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2051773	0.567	rs7924495	chr11:17038728	G/T	cg15432903	chr11:17409602	KCNJ11	0.51	6.04	0.36	5.58e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs7582180	0.809	rs7590008	chr2:100894115	T/C	cg14675211	chr2:100938903	LONRF2	0.5	6.1	0.36	4.14e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8054556	1.000	rs4318227	chr16:29984839	C/G	cg06326092	chr16:30034487	C16orf92	0.34	4.85	0.3	2.2e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg25019722	chr6:37503610	NA	-0.76	-8.66	-0.48	6.14e-16	Cognitive performance;
KIRP	cis	rs236907	0.859	rs10913684	chr1:171758758	A/G	cg01410279	chr1:171621941	MYOC	-0.49	-5.57	-0.33	6.83e-8	Mean platelet volume;
KIRP	cis	rs273573	0.643	rs897605	chr11:30881001	T/C	cg14844989	chr11:31128820	NA	0.35	5.0	0.3	1.07e-6	Total body bone mineral density;
KIRP	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg07148914	chr20:33460835	GGT7	-0.5	-6.88	-0.4	5.02e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg21466736	chr12:48725269	NA	-0.45	-5.93	-0.35	1e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg27494647	chr7:150038898	RARRES2	0.42	6.37	0.38	9.16e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg04374321	chr14:90722782	PSMC1	0.49	5.37	0.32	1.83e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.66	-8.05	-0.46	3.64e-14	Pancreatic cancer;
KIRP	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg20090143	chr19:45452003	APOC2	0.33	5.32	0.32	2.31e-7	Blood protein levels;
KIRP	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12963246	chr6:28129442	ZNF389	-0.49	-6.01	-0.36	6.76e-9	Depression;
KIRP	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg18944383	chr4:111397179	ENPEP	-0.53	-6.21	-0.37	2.29e-9	Axial length;
KIRP	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg06204229	chr3:52865917	ITIH4	-0.42	-5.16	-0.31	5.12e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.55	-8.1	-0.46	2.5e-14	Blood metabolite levels;
KIRP	cis	rs35883536	0.565	rs2647322	chr1:101031962	G/T	cg06223162	chr1:101003688	GPR88	0.46	9.7	0.53	4.89e-19	Monocyte count;
KIRP	cis	rs4132509	1.000	rs10927043	chr1:243762208	C/T	cg21452805	chr1:244014465	NA	0.53	5.45	0.33	1.24e-7	RR interval (heart rate);
KIRP	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg02775129	chr4:119771670	NA	-0.83	-5.22	-0.32	3.84e-7	Cannabis dependence symptom count;
KIRP	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.3	13.35	0.65	6.19e-31	Diabetic retinopathy;
KIRP	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg05347473	chr6:146136440	FBXO30	0.65	9.39	0.51	4.17e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg03609598	chr5:56110824	MAP3K1	0.46	5.37	0.32	1.82e-7	Initial pursuit acceleration;
KIRP	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.72	7.57	0.43	7.68e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs375066	0.592	rs349048	chr19:44300937	C/T	cg11993925	chr19:44307056	LYPD5	-0.35	-5.01	-0.3	1.06e-6	Breast cancer;
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.47	5.94	0.35	9.78e-9	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.52	0.33	8.38e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23905618	chr14:32546466	ARHGAP5;C14orf128	0.47	6.84	0.4	6.11e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11937541	chr2:170441360	PPIG	0.49	6.06	0.36	5.15e-9	Parkinson's disease;
KIRP	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	9.95	0.54	8.25e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg16255804	chr6:135334527	HBS1L	-0.31	-4.91	-0.3	1.64e-6	Red blood cell count;
KIRP	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs66561647	0.563	rs4733580	chr8:128932677	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.41	5.2	0.31	4.26e-7	Hemoglobin concentration;
KIRP	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.64	-10.37	-0.55	3.9e-21	Morning vs. evening chronotype;
KIRP	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.49	-5.84	-0.35	1.63e-8	Carotid intima media thickness;
KIRP	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg16141378	chr3:129829833	LOC729375	0.57	7.5	0.43	1.16e-12	Neuroticism;
KIRP	cis	rs2380205	0.967	rs9732607	chr10:5895101	T/C	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.54e-8	Breast cancer;
KIRP	cis	rs6594499	0.872	rs6880351	chr5:110451664	C/G	cg04022379	chr5:110408740	TSLP	0.48	7.37	0.43	2.59e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.39	-5.45	-0.33	1.2e-7	Monocyte count;
KIRP	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-8.37	-0.47	4.39e-15	Morning vs. evening chronotype;
KIRP	cis	rs9815354	0.812	rs17215988	chr3:41851320	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6693295	0.536	rs12132151	chr1:246229264	C/T	cg11798871	chr1:246315928	SMYD3	-0.67	-7.31	-0.42	3.68e-12	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.49	-0.33	1.01e-7	Lung cancer;
KIRP	cis	rs3120667	0.789	rs11204993	chr1:152356333	C/T	cg26876637	chr1:152193138	HRNR	-0.71	-7.13	-0.41	1.1e-11	Eating disorders;
KIRP	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.96	10.72	0.56	3.05e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.88	-0.77	9.72e-50	Schizophrenia;
KIRP	cis	rs78487399	0.808	rs6757251	chr2:43734847	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.18	-0.31	4.66e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7116495	1.000	rs10751190	chr11:71680757	C/T	cg26138937	chr11:71823887	C11orf51	-0.72	-5.85	-0.35	1.53e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg13565492	chr6:43139072	SRF	-0.94	-8.64	-0.48	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1215050	0.791	rs783969	chr4:98906504	C/T	cg17366294	chr4:99064904	C4orf37	0.37	4.87	0.3	2e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-4.86	-0.3	2.12e-6	Platelet distribution width;
KIRP	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg22800045	chr5:56110881	MAP3K1	0.72	7.71	0.44	3.04e-13	Initial pursuit acceleration;
KIRP	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg05220968	chr6:146057943	EPM2A	0.39	4.94	0.3	1.44e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg06204229	chr3:52865917	ITIH4	0.55	7.79	0.44	1.9e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.75	-8.96	-0.5	8.34e-17	Diastolic blood pressure;
KIRP	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.51	-6.59	-0.39	2.66e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2273669	0.667	rs76747161	chr6:109305456	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-6.4	-0.38	7.84e-10	Prostate cancer;
KIRP	cis	rs7252981	0.632	rs8101679	chr19:19733877	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.49	-5.2	-0.31	4.27e-7	Perceived unattractiveness to mosquitoes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27209110	chr19:53662353	ZNF347	0.47	6.11	0.36	3.94e-9	Parkinson's disease;
KIRP	cis	rs8093481	1.000	rs8093481	chr18:10695157	A/G	cg21165219	chr18:10698044	FAM38B	-0.43	-5.39	-0.32	1.68e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15777606	chr6:15496615	JARID2	0.47	6.39	0.38	8.09e-10	Survival in pancreatic cancer;
KIRP	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg02336718	chr17:17403227	NA	-0.35	-5.37	-0.32	1.82e-7	Total body bone mineral density;
KIRP	trans	rs3741489	1.000	rs11147098	chr12:133406374	G/A	cg24132527	chr5:140019269	TMCO6	0.95	6.5	0.38	4.43e-10	Cognitive function;
KIRP	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.6	7.3	0.42	3.91e-12	Pancreatic cancer;
KIRP	cis	rs755109	0.934	rs3780420	chr9:100677166	T/C	cg13688889	chr9:100608707	NA	-0.47	-5.47	-0.33	1.09e-7	Quantitative traits;
KIRP	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.75	5.61	0.34	5.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg04022379	chr5:110408740	TSLP	0.72	10.65	0.56	4.93e-22	Eosinophilic esophagitis;
KIRP	cis	rs6091737	1.000	rs6091737	chr20:52349892	A/G	cg11837293	chr20:52356911	NA	-0.39	-4.97	-0.3	1.23e-6	Calcium levels;
KIRP	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg23815491	chr16:72088622	HP	0.49	6.94	0.4	3.53e-11	Blood protein levels;
KIRP	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.44	5.24	0.32	3.38e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg23565292	chr14:50234668	KLHDC2	0.45	5.39	0.32	1.68e-7	Carotid intima media thickness;
KIRP	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg09455208	chr3:40491958	NA	0.33	5.99	0.36	7.42e-9	Renal cell carcinoma;
KIRP	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.48	-0.65	2.24e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6450176	1.000	rs3776703	chr5:53305259	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.4	-0.59	1.95e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.43	-6.15	-0.37	3.03e-9	Reticulocyte fraction of red cells;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06876404	chr16:30941527	FBXL19	0.5	6.13	0.36	3.51e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.69	8.98	0.5	7.35e-17	Dilated cardiomyopathy;
KIRP	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.78e-7	Aortic root size;
KIRP	cis	rs2594989	0.831	rs7651886	chr3:11572728	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-7.21	-0.42	6.99e-12	Circulating chemerin levels;
KIRP	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.48	10.95	0.57	5.39e-23	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs2290402	0.536	rs4690340	chr4:848280	G/T	cg21249729	chr9:138392748	C9orf116;MRPS2	0.61	6.1	0.36	4.19e-9	Type 2 diabetes;
KIRP	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.4	6.51	0.38	4.14e-10	Testicular germ cell tumor;
KIRP	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.65	-6.12	-0.36	3.62e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.67	-9.19	-0.51	1.76e-17	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09332650	chr19:50120000	PRR12	0.54	6.81	0.4	7.4e-11	Interleukin-4 levels;
KIRP	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg21919602	chr1:242011447	EXO1	-0.47	-6.09	-0.36	4.42e-9	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.43	7.49	0.43	1.22e-12	Renal cell carcinoma;
KIRP	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg19468946	chr17:37922297	IKZF3	-0.47	-6.48	-0.38	4.99e-10	Self-reported allergy;
KIRP	cis	rs9614461	0.702	rs3788648	chr22:45727180	G/A	cg23503501	chr22:45809793	SMC1B;RIBC2	0.59	5.54	0.33	7.93e-8	Tonsillectomy;
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg03152288	chr2:177042942	NA	0.64	9.05	0.5	4.38e-17	IgG glycosylation;
KIRP	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06544989	chr22:39130855	UNC84B	0.51	8.37	0.47	4.3e-15	Menopause (age at onset);
KIRP	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg00543991	chr22:32367038	NA	0.54	5.43	0.33	1.33e-7	Childhood ear infection;
KIRP	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.72	6.6	0.39	2.44e-10	Cognitive function;
KIRP	cis	rs13102973	0.829	rs55951114	chr4:135897925	T/C	cg14419869	chr4:135874104	NA	0.48	7.48	0.43	1.33e-12	Subjective well-being;
KIRP	cis	rs7116495	1.000	rs73539529	chr11:71815596	T/C	cg26138937	chr11:71823887	C11orf51	0.7	5.59	0.34	6.11e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.92	12.34	0.62	1.47e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg05370193	chr1:21551575	ECE1	-0.37	-5.04	-0.31	9.19e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs4716602	0.596	rs13221649	chr7:156160793	G/A	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs1076160	1.000	rs2106346	chr9:135784169	A/C	cg04648087	chr9:135819397	TSC1	-0.42	-5.49	-0.33	9.83e-8	Psoriasis;
KIRP	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.84	-0.35	1.63e-8	Height;
KIRP	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.51	5.69	0.34	3.68e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs42648	1.000	rs42658	chr7:89981915	T/A	cg25739043	chr7:89950458	NA	-0.44	-7.01	-0.41	2.28e-11	Homocysteine levels;
KIRP	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg12369402	chr1:90227771	NA	-0.36	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.37	-0.43	2.51e-12	Blood pressure;
KIRP	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.9	15.57	0.7	1.62e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.68	8.19	0.46	1.4e-14	Type 2 diabetes;
KIRP	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.42	-5.56	-0.33	6.94e-8	Renal function-related traits (BUN);
KIRP	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.65	0.48	6.69e-16	Prudent dietary pattern;
KIRP	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.35	-0.42	2.98e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.45	-6.02	-0.36	6.33e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.83	7.03	0.41	2.06e-11	Alzheimer's disease;
KIRP	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	0.95	12.16	0.61	6e-27	Blood protein levels;
KIRP	cis	rs4356975	0.563	rs62296936	chr4:69948621	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	4.95	0.3	1.4e-6	Obesity-related traits;
KIRP	cis	rs4631830	0.897	rs4304716	chr10:51544587	G/A	cg10326726	chr10:51549505	MSMB	0.58	8.12	0.46	2.23e-14	Prostate-specific antigen levels;
KIRP	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.76	9.87	0.53	1.47e-19	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.41	-4.86	-0.3	2.13e-6	Neuroticism;
KIRP	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-9.21	-0.51	1.51e-17	Morning vs. evening chronotype;
KIRP	cis	rs6959887	0.962	rs715112	chr7:35282343	A/C	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg11859384	chr17:80120422	CCDC57	0.45	6.08	0.36	4.49e-9	Life satisfaction;
KIRP	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg00631329	chr6:26305371	NA	-0.73	-9.17	-0.5	1.95e-17	Educational attainment;
KIRP	cis	rs7224685	0.569	rs12950310	chr17:4001980	T/C	cg09597638	chr17:3907349	NA	0.52	5.22	0.32	3.81e-7	Type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.97	-0.69	1.83e-36	Alzheimer's disease;
KIRP	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg25486957	chr4:152246857	NA	-0.48	-5.39	-0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7624766	0.555	rs9866566	chr3:160543742	G/C	cg22637730	chr3:160473554	PPM1L	0.44	5.4	0.33	1.54e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.73	6.01	0.36	6.5e-9	Crohn's disease;
KIRP	cis	rs4363385	0.510	rs7543689	chr1:153046803	A/T	cg13444842	chr1:152974279	SPRR3	-0.43	-6.19	-0.37	2.46e-9	Inflammatory skin disease;
KIRP	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg25037394	chr1:24152592	HMGCL	0.39	5.22	0.32	3.8e-7	Immature fraction of reticulocytes;
KIRP	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg16605745	chr12:48099745	RPAP3	-0.45	-6.05	-0.36	5.4e-9	Vertical cup-disc ratio;
KIRP	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.71	-10.06	-0.54	3.66e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg01238044	chr22:24384105	GSTT1	-0.73	-9.73	-0.53	3.87e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26345971	chr12:85430215	TSPAN19;LRRIQ1	0.46	6.61	0.39	2.37e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12049351	0.774	rs35464914	chr1:229690232	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.53	-0.33	8.32e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.75	9.49	0.52	2.12e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.39	0.51	4.36e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg22139774	chr2:100720529	AFF3	-0.39	-4.88	-0.3	1.89e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg06627628	chr2:24431161	ITSN2	-0.52	-4.89	-0.3	1.84e-6	Lymphocyte counts;
KIRP	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.86	12.89	0.63	2.18e-29	Longevity;
KIRP	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg08632701	chr21:37451849	NA	-0.54	-7.68	-0.44	3.88e-13	Mitral valve prolapse;
KIRP	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-8.66	-0.48	6.27e-16	Alzheimer's disease;
KIRP	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.49	6.93	0.4	3.7e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	4.86	0.3	2.1e-6	Schizophrenia;
KIRP	cis	rs1891275	0.515	rs7092745	chr10:93483820	C/T	cg07889827	chr10:93443413	NA	-0.43	-7.33	-0.42	3.3e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7010267	0.596	rs12682278	chr8:120032328	C/T	cg01975934	chr8:119970761	NA	0.4	5.08	0.31	7.31e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.76	-11.62	-0.6	3.64e-25	Prostate cancer;
KIRP	cis	rs7614311	0.731	rs6445387	chr3:63962678	C/G	cg22134162	chr3:63841271	THOC7	-0.39	-5.46	-0.33	1.18e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs12693043	0.727	rs9789707	chr2:175412112	G/C	cg11778734	chr2:175439522	WIPF1	-0.58	-8.22	-0.46	1.16e-14	Urate levels (BMI interaction);
KIRP	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.94	-6.95	-0.41	3.28e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2346160	0.899	rs1736585	chr6:167688325	G/A	cg27333441	chr6:167680455	NA	-0.41	-5.55	-0.33	7.53e-8	Parental extreme longevity (95 years and older);
KIRP	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.74	0.49	3.8e-16	Morning vs. evening chronotype;
KIRP	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-5.03	-0.31	9.5e-7	Ulcerative colitis;
KIRP	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg26513180	chr16:89883248	FANCA	0.82	5.61	0.34	5.48e-8	Skin colour saturation;
KIRP	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg16497661	chr14:103986332	CKB	-0.51	-6.67	-0.39	1.69e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.69	-0.34	3.65e-8	Type 2 diabetes;
KIRP	cis	rs2671245	0.966	rs1165480	chr1:56168564	A/T	cg11523071	chr1:56160889	NA	0.41	6.31	0.37	1.27e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-7.02	-0.41	2.14e-11	Mean corpuscular volume;
KIRP	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15664640	chr17:80829946	TBCD	0.55	5.47	0.33	1.09e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg00405596	chr8:11794950	NA	0.57	7.87	0.45	1.1e-13	Monocyte count;
KIRP	cis	rs75229567	0.618	rs75389984	chr12:70212879	A/G	cg10114359	chr12:70132523	RAB3IP	1.21	8.66	0.48	6.54e-16	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg13736514	chr6:26305472	NA	-0.69	-8.68	-0.48	5.51e-16	Educational attainment;
KIRP	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs981844	1.000	rs1116636	chr4:154657151	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.83	11.91	0.6	4.01e-26	Platelet distribution width;
KIRP	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.21	0.32	4.03e-7	Tonsillectomy;
KIRP	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	13.14	0.64	3.15e-30	Menopause (age at onset);
KIRP	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.17	-0.42	9e-12	Response to antipsychotic treatment;
KIRP	cis	rs35883536	1.000	rs6681906	chr1:101086414	C/T	cg06223162	chr1:101003688	GPR88	0.32	6.49	0.38	4.58e-10	Monocyte count;
KIRP	cis	rs2213920	0.516	rs6415818	chr9:118210588	A/G	cg13918206	chr9:118159781	DEC1	1.01	10.2	0.55	1.3e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-5.08	-0.31	7.62e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.42	5.29	0.32	2.68e-7	Longevity;
KIRP	cis	rs7180079	0.620	rs3935716	chr15:65035979	A/G	cg15337035	chr15:64978493	NA	-0.52	-5.73	-0.34	2.87e-8	Monocyte count;
KIRP	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11987759	chr7:65425863	GUSB	0.49	6.21	0.37	2.22e-9	Aortic root size;
KIRP	cis	rs6142102	0.924	rs6059662	chr20:32675727	C/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-5.66	-0.34	4.16e-8	Skin pigmentation;
KIRP	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.03	-0.31	9.64e-7	Coronary artery disease;
KIRP	cis	rs9896933	0.895	rs6416854	chr17:80899811	T/A	cg20578329	chr17:80767326	TBCD	0.77	7.36	0.42	2.74e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.87	0.81	1.26e-59	Prudent dietary pattern;
KIRP	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg21452805	chr1:244014465	NA	0.72	6.11	0.36	3.86e-9	RR interval (heart rate);
KIRP	cis	rs6681460	0.898	rs1032635	chr1:67195184	C/G	cg13052034	chr1:66999238	SGIP1	-0.37	-5.1	-0.31	6.9e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	cg21523751	chr1:182988639	NA	0.45	6.97	0.41	2.86e-11	Colorectal cancer;
KIRP	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.58	7.99	0.45	5.14e-14	Height;
KIRP	cis	rs911119	1.000	rs734801	chr20:23612791	A/G	cg16589663	chr20:23618590	CST3	0.63	6.17	0.37	2.83e-9	Chronic kidney disease;
KIRP	cis	rs4664293	0.867	rs7579206	chr2:160572503	A/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs13315871	1.000	rs11719273	chr3:58462014	G/T	cg12435725	chr3:58293450	RPP14	-0.48	-4.96	-0.3	1.31e-6	Cholesterol, total;
KIRP	cis	rs11673344	0.566	rs256733	chr19:37875631	C/T	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.35	-0.32	2.04e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.21	0.61	4.01e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.49	-5.83	-0.35	1.73e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg01721255	chr8:58191610	C8orf71	0.5	5.37	0.32	1.86e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00485849	chr4:74486170	RASSF6	-0.51	-6.61	-0.39	2.42e-10	Interleukin-4 levels;
KIRP	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg20312557	chr2:97357134	FER1L5	-0.72	-5.26	-0.32	3.18e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs8084125	0.832	rs62105182	chr18:74951407	T/C	cg05528293	chr18:74961138	GALR1	0.55	6.01	0.36	6.7e-9	Obesity-related traits;
KIRP	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg00409905	chr10:38381863	ZNF37A	0.58	6.36	0.38	9.51e-10	Obesity (extreme);
KIRP	cis	rs7113874	1.000	rs4929927	chr11:8658485	A/G	cg08015107	chr11:8618950	NA	0.35	4.94	0.3	1.46e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg08901578	chr4:187885870	NA	-0.45	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16464735	chr14:57700226	EXOC5	-0.46	-6.72	-0.39	1.23e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9644630	0.930	rs4921655	chr8:19366608	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.38	4.99	0.3	1.13e-6	Oropharynx cancer;
KIRP	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.32e-9	Obesity-related traits;
KIRP	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg15934090	chr1:100435551	SLC35A3	0.53	6.62	0.39	2.26e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg26924012	chr15:45694286	SPATA5L1	0.68	9.06	0.5	4.31e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12282928	1.000	rs10838845	chr11:48280299	C/T	cg26585981	chr11:48327164	OR4S1	0.47	5.25	0.32	3.35e-7	Migraine - clinic-based;
KIRP	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg24203234	chr3:128598194	ACAD9	0.43	4.87	0.3	1.99e-6	IgG glycosylation;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg05564831	chr3:52568323	NT5DC2	0.35	5.57	0.33	6.74e-8	Bipolar disorder;
KIRP	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06481639	chr22:41940642	POLR3H	0.49	5.82	0.35	1.86e-8	Vitiligo;
KIRP	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.98	9.31	0.51	7.46e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg18477163	chr1:228402036	OBSCN	-0.32	-6.74	-0.39	1.1e-10	Diastolic blood pressure;
KIRP	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.89	15.89	0.71	1.36e-39	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg05805236	chr11:65401703	PCNXL3	-0.56	-7.27	-0.42	4.63e-12	Acne (severe);
KIRP	cis	rs10794720	0.748	rs11250275	chr10:1171823	A/G	cg08668510	chr10:1095578	IDI1	-0.83	-5.61	-0.34	5.49e-8	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
KIRP	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.6	-7.41	-0.43	2.04e-12	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8177876	0.731	rs4889227	chr16:81109181	T/C	cg08591886	chr16:81111003	C16orf46	0.56	5.43	0.33	1.37e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs10875746	0.729	rs11168357	chr12:48412138	G/A	cg26205652	chr12:48591994	NA	0.78	10.08	0.54	3.11e-20	Longevity (90 years and older);
KIRP	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg08668510	chr10:1095578	IDI1	0.91	6.22	0.37	2.08e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg06115741	chr20:33292138	TP53INP2	-0.38	-5.0	-0.3	1.09e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs501120	0.564	rs11238907	chr10:44687780	T/G	cg09554077	chr10:44749378	NA	0.47	6.44	0.38	6.12e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg01320579	chr17:75405842	SEPT9	0.46	7.22	0.42	6.53e-12	Airflow obstruction;
KIRP	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.64	7.71	0.44	3.1400000000000003e-13	Pancreatic cancer;
KIRP	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg05085585	chr16:30420623	ZNF771	0.36	5.58	0.34	6.23e-8	Tonsillectomy;
KIRP	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19717773	chr7:2847554	GNA12	-0.34	-6.05	-0.36	5.41e-9	Height;
KIRP	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg03959625	chr15:84868606	LOC388152	0.4	5.04	0.31	9.15e-7	Schizophrenia;
KIRP	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	6.16	0.37	2.89e-9	Total body bone mineral density;
KIRP	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg18944383	chr4:111397179	ENPEP	0.46	7.39	0.43	2.31e-12	Coronary artery disease;
KIRP	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg14768367	chr16:72042858	DHODH	0.44	5.35	0.32	2.05e-7	Fibrinogen levels;
KIRP	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.64	-6.89	-0.4	4.55e-11	Response to diuretic therapy;
KIRP	cis	rs13401104	0.587	rs62190972	chr2:237145164	T/C	cg19324714	chr2:237145437	ASB18	0.56	6.52	0.38	3.97e-10	Educational attainment;
KIRP	cis	rs920590	0.921	rs4922099	chr8:19648486	T/C	cg03894339	chr8:19674705	INTS10	0.48	5.91	0.35	1.12e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3936840	0.548	rs1190545	chr14:102904179	G/C	cg10241871	chr14:102965420	TECPR2	0.44	5.2	0.31	4.24e-7	Plateletcrit;
KIRP	cis	rs2033908	0.619	rs10765994	chr11:12850819	A/G	cg25843174	chr11:12811716	TEAD1	0.39	7.34	0.42	3.06e-12	Sitting height ratio;
KIRP	cis	rs892085	0.681	rs873016	chr19:10894728	G/A	cg17710535	chr19:10819994	QTRT1	0.47	6.02	0.36	6.41e-9	Psoriasis vulgaris;Psoriasis;
KIRP	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg16989719	chr2:238392110	NA	-0.65	-6.57	-0.39	2.96e-10	Prostate cancer;
KIRP	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg03468072	chr12:39539422	NA	0.42	6.06	0.36	4.99e-9	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-7.49	-0.43	1.27e-12	Menarche (age at onset);
KIRP	cis	rs11225247	0.772	rs61895376	chr11:102227892	A/G	cg06323957	chr11:102217781	BIRC2	0.77	5.0	0.3	1.11e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.81	-11.33	-0.59	3.15e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs77633900	0.614	rs113557153	chr15:76994445	A/G	cg21673338	chr15:77095150	SCAPER	-0.62	-6.23	-0.37	2.01e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg22117172	chr7:91764530	CYP51A1	0.37	5.08	0.31	7.32e-7	Breast cancer;
KIRP	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg12560992	chr17:57184187	TRIM37	0.63	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11908202	chr17:41456347	LOC100130581	0.49	6.75	0.4	1.03e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.6	-7.94	-0.45	7.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25948154	chr15:40763247	CHST14	-0.48	-6.41	-0.38	7.53e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg20261243	chr20:44718728	NCOA5	0.66	6.1	0.36	4.09e-9	Lung function (FEV1);
KIRP	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.53	-7.78	-0.44	1.94e-13	Lewy body disease;
KIRP	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.19	14.32	0.67	3.19e-34	Corneal structure;
KIRP	cis	rs9905704	0.633	rs2680687	chr17:56491966	T/C	cg12560992	chr17:57184187	TRIM37	0.56	5.24	0.32	3.44e-7	Testicular germ cell tumor;
KIRP	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg22732515	chr19:44031385	ETHE1	0.63	8.94	0.5	9.43e-17	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs6539288	0.677	rs2287163	chr12:107349294	C/T	cg15890332	chr12:107067104	RFX4	0.37	6.02	0.36	6.47e-9	Total body bone mineral density;
KIRP	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.83	-7.12	-0.41	1.17e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13471184	chr18:44702735	IER3IP1	0.53	7.18	0.42	8.43e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg14675211	chr2:100938903	LONRF2	0.48	6.21	0.37	2.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs829880	0.558	rs249820	chr12:98897473	A/G	cg25150519	chr12:98850993	NA	0.51	5.54	0.33	7.62e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.59	7.76	0.44	2.29e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6708331	0.517	rs7579922	chr2:70361913	A/G	cg05298696	chr2:70188691	ASPRV1	-0.44	-5.88	-0.35	1.35e-8	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg13147721	chr7:65941812	NA	0.92	7.14	0.41	1.02e-11	Diabetic kidney disease;
KIRP	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.56	-7.35	-0.42	2.94e-12	Hip circumference;
KIRP	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.16	-0.31	5.18e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05620814	chr16:74640948	GLG1	0.45	6.09	0.36	4.36e-9	Cancer;
KIRP	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06481639	chr22:41940642	POLR3H	0.75	7.45	0.43	1.57e-12	Vitiligo;
KIRP	cis	rs1448094	0.717	rs60713909	chr12:86294469	C/G	cg02569458	chr12:86230093	RASSF9	0.37	5.37	0.32	1.86e-7	Major depressive disorder;
KIRP	cis	rs2280630	0.529	rs6599010	chr3:39153222	C/T	cg01426195	chr3:39028469	NA	-0.6	-9.81	-0.53	2.12e-19	Verbal declarative memory;
KIRP	cis	rs1816752	0.792	rs7330956	chr13:24987312	A/G	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.34	-4.85	-0.3	2.21e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs4363385	0.574	rs61813182	chr1:152943868	T/A	cg07796016	chr1:152779584	LCE1C	-0.48	-6.05	-0.36	5.42e-9	Inflammatory skin disease;
KIRP	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00338735	chr4:53728038	RASL11B	0.5	5.97	0.36	8.38e-9	Optic nerve measurement (cup area);
KIRP	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg25039879	chr17:56429692	SUPT4H1	0.61	5.25	0.32	3.33e-7	Cognitive test performance;
KIRP	cis	rs7951870	0.617	rs7932354	chr11:46722221	T/C	cg16389345	chr11:46697382	NA	0.43	5.24	0.32	3.52e-7	Schizophrenia;
KIRP	cis	rs1978968	0.830	rs11089210	chr22:18445692	A/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.24e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.56	7.75	0.44	2.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.07	-0.31	7.66e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs1200821	0.738	rs1926128	chr10:37654620	C/T	cg00409905	chr10:38381863	ZNF37A	0.48	6.2	0.37	2.32e-9	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2288884	0.559	rs61287503	chr19:52521192	A/C	cg05974498	chr19:52599256	ZNF841	0.35	5.06	0.31	8.19e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
KIRP	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg09163369	chr1:210001066	C1orf107	-0.62	-7.22	-0.42	6.57e-12	Orofacial clefts;
KIRP	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.04	-0.58	2.88e-23	Height;
KIRP	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.48	-0.38	5.06e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.13	0.41	1.12e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg02820901	chr13:113351484	ATP11A	0.75	6.99	0.41	2.55e-11	Glycated hemoglobin levels;
KIRP	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.48	8.07	0.46	3.15e-14	Multiple sclerosis;
KIRP	cis	rs2916247	1.000	rs7002565	chr8:93057196	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.7	-0.44	3.24e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg22563815	chr15:78856949	CHRNA5	-0.47	-7.39	-0.43	2.33e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs1448094	0.617	rs10863162	chr12:86474122	C/T	cg00310523	chr12:86230176	RASSF9	-0.42	-6.19	-0.37	2.55e-9	Major depressive disorder;
KIRP	trans	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.74	0.39	1.09e-10	Mean corpuscular volume;
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13198984	chr17:80129470	CCDC57	-0.54	-8.16	-0.46	1.76e-14	Life satisfaction;
KIRP	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg22947322	chr17:47091978	IGF2BP1	0.42	5.49	0.33	1.02e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.78	-9.99	-0.54	5.96e-20	Coronary artery disease;
KIRP	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg03396347	chr1:1875803	NA	-0.62	-9.37	-0.51	4.91e-18	Body mass index;
KIRP	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg10167378	chr1:228756711	NA	0.52	5.91	0.35	1.11e-8	Diastolic blood pressure;
KIRP	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg12046867	chr14:103022105	NA	-0.5	-6.09	-0.36	4.36e-9	Platelet count;
KIRP	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7127900	0.519	rs7112959	chr11:2233609	G/A	cg25635251	chr11:2234043	NA	0.44	6.95	0.4	3.32e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg16482183	chr6:26056742	HIST1H1C	0.6	6.83	0.4	6.5e-11	Iron status biomarkers;
KIRP	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.32e-9	Obesity-related traits;
KIRP	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-7.26	-0.42	5.14e-12	Longevity;Endometriosis;
KIRP	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.71	5.98	0.36	7.64e-9	Diabetic retinopathy;
KIRP	cis	rs10073892	0.789	rs56028821	chr5:101776400	C/G	cg19774478	chr5:101632501	SLCO4C1	0.67	6.49	0.38	4.62e-10	Cognitive decline (age-related);
KIRP	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.83	8.59	0.48	1.03e-15	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.56	7.54	0.43	9.28e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.18	-0.31	4.67e-7	Calcium levels;
KIRP	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	1.29	13.3	0.65	8.86e-31	Diabetic retinopathy;
KIRP	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04374321	chr14:90722782	PSMC1	0.9	14.5	0.68	7.76e-35	Mortality in heart failure;
KIRP	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.04	-0.31	8.88e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6959887	0.962	rs1833127	chr7:35279796	G/A	cg06685737	chr7:35301730	NA	0.43	6.29	0.37	1.47e-9	Birth weight;
KIRP	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg22676075	chr6:135203613	NA	0.5	7.21	0.42	7.07e-12	Red blood cell count;
KIRP	trans	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17095355	1.000	rs12242642	chr10:111724213	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.28	-0.32	2.9e-7	Biliary atresia;
KIRP	cis	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.95	0.3	1.38e-6	Leprosy;
KIRP	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.46	0.33	1.13e-7	Educational attainment;
KIRP	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.1	-0.36	4.18e-9	Triglycerides;
KIRP	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg16797656	chr11:68205561	LRP5	0.37	4.95	0.3	1.37e-6	Total body bone mineral density;
KIRP	cis	rs1873147	1.000	rs1873149	chr15:63312428	A/C	cg12160578	chr15:63334699	TPM1	0.45	5.49	0.33	9.93e-8	Orofacial clefts;
KIRP	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs73198271	1.000	rs11784958	chr8:8607781	C/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.61	-0.34	5.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg05973401	chr12:123451056	ABCB9	0.6	5.52	0.33	8.46e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9816226	0.591	rs77805826	chr3:185798025	C/T	cg00760338	chr3:185826511	ETV5	-0.75	-6.48	-0.38	4.86e-10	Obesity;Body mass index;
KIRP	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.53	5.6	0.34	5.64e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg13819577	chr1:248512075	OR14C36	-0.39	-5.06	-0.31	8.11e-7	Common traits (Other);
KIRP	cis	rs10782582	0.609	rs5745430	chr1:76332994	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.34	-0.37	1.09e-9	Daytime sleep phenotypes;
KIRP	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg05370193	chr1:21551575	ECE1	-0.36	-4.91	-0.3	1.65e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg21546286	chr11:48923668	NA	-0.48	-6.11	-0.36	3.96e-9	HDL cholesterol;
KIRP	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.96	14.71	0.68	1.48e-35	Personality dimensions;
KIRP	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg02462569	chr6:150064036	NUP43	-0.42	-6.32	-0.37	1.21e-9	Lung cancer;
KIRP	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg25019722	chr6:37503610	NA	-0.75	-8.66	-0.48	6.27e-16	Cognitive performance;
KIRP	cis	rs72730918	0.590	rs897581	chr15:51973438	A/G	cg14296394	chr15:51910925	DMXL2	-0.74	-10.0	-0.54	5.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.89	0.3	1.85e-6	Tonsillectomy;
KIRP	cis	rs11203032	0.831	rs11203024	chr10:90955239	G/T	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs375066	0.935	rs396973	chr19:44399306	C/T	cg08633290	chr19:44405433	NA	0.39	4.95	0.3	1.4e-6	Breast cancer;
KIRP	cis	rs4363385	0.510	rs11576797	chr1:153049417	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-6.04	-0.36	5.62e-9	Inflammatory skin disease;
KIRP	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg03060546	chr3:49711283	APEH	0.45	5.81	0.35	1.95e-8	Parkinson's disease;
KIRP	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.48	-7.7	-0.44	3.23e-13	Height;
KIRP	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg14078157	chr9:128172775	NA	-0.41	-5.08	-0.31	7.42e-7	Resting heart rate;
KIRP	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg22508957	chr16:3507546	NAT15	0.59	7.33	0.42	3.3e-12	Tuberculosis;
KIRP	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg03999872	chr20:62272968	STMN3	0.53	6.45	0.38	5.73e-10	Atopic dermatitis;
KIRP	cis	rs60871478	1.000	rs62432223	chr7:787959	A/G	cg13798912	chr7:905769	UNC84A	0.57	5.74	0.34	2.77e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg15051221	chr5:177434457	FAM153C	0.37	5.14	0.31	5.55e-7	Methadone dose in opioid dependence;
KIRP	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.58	-0.44	7.09e-13	Neuroticism;
KIRP	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.95	15.56	0.7	1.77e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg17764715	chr19:33622953	WDR88	0.58	4.99	0.3	1.14e-6	Bone properties (heel);
KIRP	cis	rs6445967	1.000	rs62258069	chr3:58315263	A/T	cg16569813	chr3:58235849	ABHD6	-0.34	-5.04	-0.31	9.08e-7	Platelet count;
KIRP	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg02836325	chr17:76403955	PGS1	0.4	6.82	0.4	6.97e-11	HDL cholesterol levels;
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.62	-7.34	-0.42	3.15e-12	Menopause (age at onset);
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.73	-9.74	-0.53	3.63e-19	Longevity;Endometriosis;
KIRP	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.88	-12.94	-0.64	1.44e-29	Monocyte count;
KIRP	cis	rs16976116	0.901	rs56328329	chr15:55502977	A/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg00495681	chr13:53174319	NA	0.42	5.66	0.34	4.1e-8	Lewy body disease;
KIRP	cis	rs1209950	0.866	rs1734587	chr21:40180884	A/G	cg01359822	chr21:40176597	ETS2	0.36	5.79	0.35	2.15e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs4775041	0.961	rs62001736	chr15:58674051	G/A	cg02971627	chr15:59042282	ADAM10	0.45	4.88	0.3	1.92e-6	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.44	5.76	0.34	2.52e-8	Monocyte count;
KIRP	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.41	4.97	0.3	1.28e-6	Tonsillectomy;
KIRP	cis	rs2151522	0.762	rs62436793	chr6:127163549	G/A	cg21431617	chr6:127135037	NA	0.29	5.14	0.31	5.67e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg16576597	chr16:28551801	NUPR1	0.37	5.31	0.32	2.49e-7	Body mass index;
KIRP	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.69	8.15	0.46	1.83e-14	Diabetic retinopathy;
KIRP	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg08975724	chr8:8085496	FLJ10661	0.48	6.3	0.37	1.38e-9	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg10189774	chr4:17578691	LAP3	0.54	6.81	0.4	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.42	-0.47	3.12e-15	Neuroticism;
KIRP	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.48e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-0.4	-5.07	-0.31	7.68e-7	Type 2 diabetes;
KIRP	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg05692746	chr2:100937584	LONRF2	-0.38	-5.06	-0.31	8.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6589219	0.954	rs3802840	chr11:111171646	G/T	cg25129781	chr11:111156908	C11orf53	0.5	6.43	0.38	6.46e-10	Colorectal cancer;
KIRP	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.73	9.24	0.51	1.18e-17	Coronary artery disease;
KIRP	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.5	-0.52	1.96e-18	Colorectal cancer;
KIRP	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg18164611	chr1:46958628	NA	0.44	5.47	0.33	1.08e-7	Monobrow;
KIRP	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.58	11.12	0.58	1.52e-23	Bone mineral density;
KIRP	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.6	-9.56	-0.52	1.27e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.16	-0.37	2.9e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	4.92	0.3	1.59e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs501120	0.564	rs1509931	chr10:44682080	C/T	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1656402	0.953	rs1190456	chr2:233435104	T/C	cg03852847	chr2:233439513	NA	-0.68	-9.29	-0.51	8.46e-18	Non-small cell lung cancer (survival);
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	6.88	0.4	4.86e-11	Longevity;
KIRP	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.77	11.46	0.59	1.22e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6585424	1.000	rs34162901	chr10:81946856	A/C	cg27417294	chr10:81904244	PLAC9	0.53	5.04	0.31	8.98e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg15790184	chr11:494944	RNH1	0.4	5.14	0.31	5.73e-7	Systemic lupus erythematosus;
KIRP	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.35	-0.38	1.05e-9	Schizophrenia;
KIRP	trans	rs587242	1.000	rs61786491	chr1:96904651	G/C	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs2671245	0.933	rs2819489	chr1:56164391	G/T	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.53e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.71	-9.18	-0.5	1.87e-17	Menopause (age at onset);
KIRP	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.56	0.39	3.08e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.0	0.36	7e-9	Schizophrenia;
KIRP	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-7.36	-0.42	2.77e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg10756647	chr7:56101905	PSPH	1.01	7.6	0.44	6.29e-13	Diabetic kidney disease;
KIRP	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.19	-0.46	1.39e-14	Monocyte percentage of white cells;
KIRP	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.58	-7.28	-0.42	4.47e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	5.18	0.31	4.52e-7	Schizophrenia;
KIRP	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.63	6.12	0.36	3.66e-9	Menarche (age at onset);
KIRP	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.95	-0.35	9.24e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs1062177	0.855	rs62395861	chr5:151269270	A/G	cg00977110	chr5:151150581	G3BP1	0.6	6.04	0.36	5.6e-9	Preschool internalizing problems;
KIRP	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.75	0.4	1.06e-10	Colorectal cancer;
KIRP	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	trans	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03602288	chr17:46641863	HOXB3	0.45	6.15	0.37	3.09e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.3	-6.01	-0.36	6.71e-9	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20922377	chr15:48623205	DUT	0.48	6.61	0.39	2.37e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.81	-11.45	-0.59	1.29e-24	Total body bone mineral density;
KIRP	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.83	12.57	0.63	2.62e-28	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21454656	chr22:41347267	RBX1	0.48	6.7	0.39	1.44e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1511802	0.501	rs7661323	chr4:187115996	T/G	cg24794857	chr4:187113578	CYP4V2	0.4	5.49	0.33	1e-7	Blood protein levels;
KIRP	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.4	-5.17	-0.31	4.91e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs4132509	0.744	rs7519673	chr1:243993123	A/G	cg21452805	chr1:244014465	NA	0.69	5.6	0.34	5.71e-8	RR interval (heart rate);
KIRP	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.64	8.05	0.46	3.52e-14	Diastolic blood pressure;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09093137	chr7:105028539	SRPK2	0.47	6.16	0.37	2.89e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.72	9.5	0.52	2.01e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14159672	chr1:205819179	PM20D1	0.51	5.64	0.34	4.69e-8	Parkinson's disease;
KIRP	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.71	-8.76	-0.49	3.19e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2288912	0.807	rs7251501	chr19:45455706	C/T	cg10169327	chr19:45448959	APOC2	0.33	4.93	0.3	1.53e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12823128	0.766	rs7315217	chr12:26936764	T/C	cg14081884	chr12:26986758	ITPR2	0.41	5.12	0.31	6.18e-7	Birth weight;
KIRP	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.67	9.26	0.51	1.07e-17	Multiple sclerosis;
KIRP	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.82e-7	Cognitive function;
KIRP	cis	rs8060686	0.668	rs2418739	chr16:68092850	G/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-7.97	-0.45	5.76e-14	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.12	0.36	3.59e-9	Height;
KIRP	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.56	7.56	0.43	8.09e-13	Blood metabolite levels;
KIRP	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg06740227	chr12:86229804	RASSF9	0.51	6.7	0.39	1.44e-10	Major depressive disorder;
KIRP	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.62	8.29	0.47	7.25e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.86	-0.35	1.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.73	10.15	0.54	1.95e-20	Lung cancer;
KIRP	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs10782582	0.967	rs5745512	chr1:76357752	A/C	cg10523679	chr1:76189770	ACADM	-0.36	-5.31	-0.32	2.46e-7	Daytime sleep phenotypes;
KIRP	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	trans	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.51	6.13	0.36	3.54e-9	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	1.14	20.17	0.79	4.61e-54	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs829661	0.793	rs829681	chr2:30708932	A/C	cg10949345	chr2:30726833	LCLAT1	1.0	14.11	0.67	1.66e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.39	0.83	1.77e-64	Chronic sinus infection;
KIRP	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg07701084	chr6:150067640	NUP43	-0.49	-5.38	-0.32	1.76e-7	Lung cancer;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18212924	chr14:105608474	JAG2	0.48	6.1	0.36	4.16e-9	Interleukin-4 levels;
KIRP	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg00857998	chr1:205179979	DSTYK	0.6	7.31	0.42	3.83e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.52	-5.8	-0.35	2.04e-8	Breast cancer;
KIRP	cis	rs732716	0.889	rs11666856	chr19:4437450	A/G	cg03719555	chr19:4455413	UBXN6	0.49	7.54	0.43	9.18e-13	Mean corpuscular volume;
KIRP	cis	rs7923609	1.000	rs2393969	chr10:65140440	A/C	cg01631684	chr10:65280961	REEP3	-0.5	-5.93	-0.35	1.04e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4517514	0.509	rs12276499	chr11:89855565	C/G	cg06174606	chr11:89959870	NA	-0.55	-5.41	-0.33	1.47e-7	Trans fatty acid levels;
KIRP	cis	rs13401104	0.587	rs56146026	chr2:237145629	A/G	cg19324714	chr2:237145437	ASB18	0.56	6.52	0.38	3.97e-10	Educational attainment;
KIRP	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.46	6.07	0.36	4.69e-9	Alzheimer's disease (late onset);
KIRP	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg21854759	chr1:92012499	NA	-0.47	-6.09	-0.36	4.38e-9	Breast cancer;
KIRP	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.32	-0.32	2.28e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-14.11	-0.67	1.64e-33	Electrocardiographic conduction measures;
KIRP	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.58	7.66	0.44	4.15e-13	Smoking behavior;
KIRP	cis	rs17123764	0.892	rs13906	chr12:49952394	C/T	cg02054252	chr12:50078554	FMNL3	0.43	5.36	0.32	1.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg11965913	chr1:205819406	PM20D1	0.48	5.47	0.33	1.13e-7	Parkinson's disease;
KIRP	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.45	5.23	0.32	3.7e-7	Schizophrenia;
KIRP	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg00656387	chr3:40428638	ENTPD3	-0.38	-5.18	-0.31	4.7e-7	Renal cell carcinoma;
KIRP	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.77	9.15	0.5	2.32e-17	Vitiligo;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16696730	chr21:43916444	RSPH1	0.93	6.24	0.37	1.88e-9	P wave terminal force;
KIRP	trans	rs933360	0.503	rs2329554	chr7:50875030	A/G	cg20003124	chr12:4557277	NA	0.51	6.03	0.36	6.1e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs4363385	0.626	rs6667103	chr1:153064438	A/G	cg07796016	chr1:152779584	LCE1C	-0.43	-4.99	-0.3	1.16e-6	Inflammatory skin disease;
KIRP	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.53	6.83	0.4	6.68e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	Neuroticism;
KIRP	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.67	-8.4	-0.47	3.48e-15	Obesity-related traits;
KIRP	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.92	11.4	0.59	1.88e-24	Response to antineoplastic agents;
KIRP	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg24375607	chr4:120327624	NA	0.59	6.16	0.37	2.9e-9	Corneal astigmatism;
KIRP	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg00684032	chr4:1343700	KIAA1530	0.43	5.57	0.33	6.78e-8	Longevity;
KIRP	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.6	-0.34	5.66e-8	Life satisfaction;
KIRP	cis	rs3105593	0.933	rs2003359	chr15:50833113	A/G	cg05456662	chr15:50716270	USP8	0.39	5.09	0.31	7.17e-7	QT interval;
KIRP	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.65	6.06	0.36	5.17e-9	Diisocyanate-induced asthma;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.74	9.74	0.53	3.71e-19	Longevity;Endometriosis;
KIRP	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg19743168	chr1:23544995	NA	0.56	7.76	0.44	2.32e-13	Height;
KIRP	cis	rs986417	0.688	rs6573321	chr14:61101710	A/G	cg27398547	chr14:60952738	C14orf39	0.62	5.64	0.34	4.76e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg21972741	chr5:435613	AHRR	0.5	6.26	0.37	1.71e-9	Cystic fibrosis severity;
KIRP	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.82	0.35	1.78e-8	Menopause (age at onset);
KIRP	cis	rs9815354	0.723	rs12152489	chr3:42060402	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.09	0.41	1.39e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.02	-0.36	6.17e-9	Personality dimensions;
KIRP	cis	rs7584330	0.554	rs6729415	chr2:238429943	C/G	cg15120555	chr2:238296405	COL6A3	0.42	4.85	0.3	2.2e-6	Prostate cancer;
KIRP	cis	rs6901004	0.803	rs1150083	chr6:111510767	C/T	cg15721981	chr6:111408429	SLC16A10	-0.58	-7.98	-0.45	5.45e-14	Blood metabolite levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03705947	chr1:68152081	GADD45A	0.79	6.76	0.4	9.71e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.6	-7.26	-0.42	5.14e-12	Red cell distribution width;
KIRP	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.17e-25	Corneal astigmatism;
KIRP	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.73	-0.39	1.21e-10	Neuroticism;
KIRP	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg05347473	chr6:146136440	FBXO30	0.61	8.63	0.48	7.62e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg20362242	chr5:692897	TPPP	0.57	4.95	0.3	1.39e-6	Obesity-related traits;
KIRP	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-6.92	-0.4	3.85e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs2979489	0.891	rs2915624	chr8:30381245	T/C	cg26383811	chr8:30366931	RBPMS	-0.45	-6.12	-0.36	3.68e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs9625935	0.518	rs713718	chr22:30314092	A/C	cg01021169	chr22:30184971	ASCC2	0.46	6.53	0.38	3.72e-10	Tonsillectomy;
KIRP	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-5.18	-0.31	4.53e-7	Colorectal cancer;
KIRP	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17507749	chr15:85114479	UBE2QP1	0.71	7.82	0.45	1.51e-13	Schizophrenia;
KIRP	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.37	-0.32	1.78e-7	Neutrophil percentage of white cells;
KIRP	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg03678062	chr6:149772716	ZC3H12D	0.32	5.3	0.32	2.62e-7	Dupuytren's disease;
KIRP	trans	rs2290402	0.536	rs58429160	chr4:875266	G/A	cg21249729	chr9:138392748	C9orf116;MRPS2	0.62	6.27	0.37	1.59e-9	Type 2 diabetes;
KIRP	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg05973401	chr12:123451056	ABCB9	0.59	6.94	0.4	3.44e-11	Neutrophil percentage of white cells;
KIRP	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.37	0.59	2.41e-24	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12636447	chr8:56652350	TMEM68	-0.4	-6.23	-0.37	1.96e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg00784671	chr22:46762841	CELSR1	-0.5	-6.94	-0.4	3.53e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10143866	1.000	rs77965541	chr14:52876841	G/A	cg26085721	chr14:52473044	NID2	0.66	5.03	0.31	9.41e-7	Smooth-surface caries;
KIRP	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg13736514	chr6:26305472	NA	-0.7	-8.84	-0.49	1.82e-16	Educational attainment;
KIRP	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg08668510	chr10:1095578	IDI1	0.76	5.2	0.31	4.14e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg17691542	chr6:26056736	HIST1H1C	0.67	7.94	0.45	6.98e-14	Iron status biomarkers;
KIRP	cis	rs909341	0.909	rs1151624	chr20:62369895	A/G	cg11503966	chr20:62272292	STMN3	0.42	5.77	0.35	2.32e-8	Atopic dermatitis;
KIRP	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg02487422	chr3:49467188	NICN1	0.5	7.51	0.43	1.11e-12	Resting heart rate;
KIRP	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.86	9.0	0.5	6.45e-17	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs2172802	0.570	rs11931258	chr4:62533602	A/G	cg04118610	chr4:62707027	LPHN3	0.44	5.47	0.33	1.08e-7	Partial epilepsies;
KIRP	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.57	7.83	0.45	1.43e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7860634	1.000	rs7860634	chr9:139089679	C/T	cg04455058	chr9:139085579	NA	0.66	9.74	0.53	3.71e-19	Thyroid hormone levels;
KIRP	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs282587	0.597	rs450351	chr13:113394987	C/T	cg04656015	chr13:113407548	ATP11A	0.61	6.59	0.39	2.7e-10	Glycated hemoglobin levels;
KIRP	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	8.48	0.48	2.06e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.9	-13.14	-0.64	3.14e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg09795085	chr6:101329169	ASCC3	-0.5	-6.02	-0.36	6.24e-9	Neuroticism;
KIRP	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18255839	chr2:239335447	ASB1	0.41	4.91	0.3	1.63e-6	Multiple system atrophy;
KIRP	cis	rs259842	0.584	rs7601013	chr2:180693037	G/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.43	-5.83	-0.35	1.69e-8	Blood protein levels;
KIRP	cis	rs4812048	0.793	rs6070693	chr20:57589516	C/T	cg14073986	chr20:57617431	SLMO2	0.57	5.18	0.31	4.52e-7	Mean platelet volume;
KIRP	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg17279839	chr7:150038598	RARRES2	0.44	5.71	0.34	3.32e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs11785693	0.789	rs11776268	chr8:4985852	C/T	cg14573268	chr5:165063158	NA	0.44	6.25	0.37	1.81e-9	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg09455208	chr3:40491958	NA	0.36	6.48	0.38	5.01e-10	Renal cell carcinoma;
KIRP	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-12.18	-0.61	5.07e-27	Chronic sinus infection;
KIRP	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg08392591	chr16:89556376	ANKRD11	0.53	7.17	0.42	8.54e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17183009	chr3:120277827	NA	0.53	6.29	0.37	1.41e-9	Corneal astigmatism;
KIRP	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.52	-6.52	-0.38	4.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.49	-5.33	-0.32	2.27e-7	Urate levels;
KIRP	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.45	9.82	0.53	2.02e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs55788414	0.505	rs7190949	chr16:81189583	C/T	cg06400318	chr16:81190750	PKD1L2	0.76	9.58	0.52	1.14e-18	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg22089800	chr15:90895588	ZNF774	0.43	5.12	0.31	6.28e-7	Rheumatoid arthritis;
KIRP	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22903657	chr4:1355424	KIAA1530	-0.5	-7.1	-0.41	1.33e-11	Obesity-related traits;
KIRP	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.86	-0.3	2.09e-6	Breast cancer;
KIRP	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg27205649	chr11:78285834	NARS2	-0.66	-7.57	-0.43	7.66e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9815354	0.812	rs73071338	chr3:41824328	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.69	-0.44	3.6e-13	Type 2 diabetes;
KIRP	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	8.68	0.48	5.42e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.55	-5.56	-0.33	7.07e-8	Subjective well-being;
KIRP	cis	rs1021993	0.672	rs2800929	chr1:209491968	T/C	cg06155620	chr1:209527581	NA	0.35	4.87	0.3	1.97e-6	Gut microbiome composition (winter);
KIRP	trans	rs61904987	0.631	rs2428014	chr11:113708131	T/C	cg02842869	chr17:79921131	NA	0.37	6.31	0.37	1.28e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00639286	chr5:151138064	ATOX1	0.49	6.29	0.37	1.46e-9	Parkinson's disease;
KIRP	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07570687	chr10:102243282	WNT8B	0.51	6.73	0.39	1.19e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg07810366	chr2:100720526	AFF3	0.33	6.07	0.36	4.91e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.97	11.68	0.6	2.3e-25	Corneal astigmatism;
KIRP	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg27147174	chr7:100797783	AP1S1	-0.71	-9.09	-0.5	3.47e-17	Life satisfaction;
KIRP	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.64e-15	Mortality in heart failure;
KIRP	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	11.71	0.6	1.82e-25	Bipolar disorder;
KIRP	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs231513	0.954	rs231512	chr17:41965831	G/A	cg26893861	chr17:41843967	DUSP3	-0.58	-5.06	-0.31	8.04e-7	Cognitive function;
KIRP	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12292205	chr6:26970375	C6orf41	-0.56	-6.09	-0.36	4.41e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.34	-0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.55	-0.33	7.32e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.2	0.37	2.32e-9	Menopause (age at onset);
KIRP	trans	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00950418	chr7:105029125	SRPK2	-0.53	-6.59	-0.39	2.6200000000000003e-10	Height;
KIRP	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	1.0	17.41	0.74	8.79e-45	Breast cancer;
KIRP	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.43	5.62	0.34	5.19e-8	Birth weight;
KIRP	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06544989	chr22:39130855	UNC84B	0.5	8.84	0.49	1.82e-16	Menopause (age at onset);
KIRP	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.89	-10.64	-0.56	5.27e-22	White matter hyperintensity burden;
KIRP	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.58	-7.69	-0.44	3.57e-13	Left ventricular obstructive tract defect (inherited effect);
KIRP	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-5.34	-0.32	2.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.65	-8.1	-0.46	2.5e-14	Vitiligo;
KIRP	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg15128208	chr22:42549153	NA	-0.41	-5.1	-0.31	6.94e-7	Cognitive function;
KIRP	cis	rs16976116	0.855	rs11856010	chr15:55495008	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs253959	0.842	rs9326986	chr5:115427056	A/C	cg23108291	chr5:115420582	COMMD10	0.41	5.04	0.31	8.84e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-8.27	-0.47	8.33e-15	Urinary metabolites;
KIRP	cis	rs6832769	0.925	rs2412663	chr4:56455816	C/A	cg05960024	chr4:56376020	CLOCK	-0.71	-9.27	-0.51	9.66e-18	Personality dimensions;
KIRP	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg02527881	chr3:46936655	PTH1R	-0.42	-6.02	-0.36	6.46e-9	Colorectal cancer;
KIRP	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.05e-8	Common traits (Other);
KIRP	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg08885076	chr2:99613938	TSGA10	-0.61	-11.01	-0.57	3.38e-23	Chronic sinus infection;
KIRP	cis	rs12823128	0.766	rs7298744	chr12:26936608	C/T	cg14081884	chr12:26986758	ITPR2	0.41	5.12	0.31	6.18e-7	Birth weight;
KIRP	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg26585981	chr11:48327164	OR4S1	0.49	6.1	0.36	4.12e-9	Migraine - clinic-based;
KIRP	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg14914422	chr1:46958856	NA	0.42	5.25	0.32	3.32e-7	Monobrow;
KIRP	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg20333904	chr2:240724165	NA	0.42	5.82	0.35	1.86e-8	Obesity-related traits;
KIRP	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs12190007	0.604	rs7382308	chr6:169732276	A/C	cg16388071	chr6:169726476	NA	-0.47	-6.96	-0.41	3.13e-11	Obesity-related traits;
KIRP	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.72	9.06	0.5	4.04e-17	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15030756	chr15:74907746	CLK3	0.51	6.28	0.37	1.5e-9	Parkinson's disease;
KIRP	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg14972814	chr11:95582409	MTMR2	0.36	5.82	0.35	1.83e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg07701084	chr6:150067640	NUP43	0.71	10.08	0.54	3.25e-20	Lung cancer;
KIRP	cis	rs12318506	1.000	rs35383953	chr12:75660182	A/G	cg04728562	chr12:75699417	CAPS2	-1.04	-7.26	-0.42	5.02e-12	Coronary artery calcification;
KIRP	cis	rs9400467	0.506	rs17756732	chr6:111580154	A/G	cg15721981	chr6:111408429	SLC16A10	0.75	6.87	0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg18441811	chr11:71824068	C11orf51	-0.78	-5.17	-0.31	4.82e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.51	6.72	0.39	1.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.74	-0.39	1.14e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2236918	0.932	rs1776178	chr1:242011534	C/T	cg17736920	chr1:242011382	EXO1	-0.76	-10.3	-0.55	6.5e-21	Menopause (age at onset);
KIRP	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg02336718	chr17:17403227	NA	0.33	5.03	0.31	9.32e-7	Total body bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08906898	chr20:34319899	RBM39	0.49	6.14	0.36	3.25e-9	Interleukin-4 levels;
KIRP	cis	rs8084125	0.765	rs62105164	chr18:74944367	C/T	cg18461021	chr18:74961002	GALR1	0.55	5.48	0.33	1.05e-7	Obesity-related traits;
KIRP	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg24631222	chr15:78858424	CHRNA5	0.4	4.94	0.3	1.47e-6	Sudden cardiac arrest;
KIRP	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs911119	0.955	rs6048952	chr20:23607257	A/G	cg16589663	chr20:23618590	CST3	0.47	5.0	0.3	1.09e-6	Chronic kidney disease;
KIRP	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-0.8	-6.51	-0.38	4.28e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.4	-5.25	-0.32	3.36e-7	Oropharynx cancer;
KIRP	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16553338	chr16:2242886	CASKIN1	0.49	6.21	0.37	2.27e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg19583211	chr2:162273185	TBR1	0.53	6.04	0.36	5.58e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7084402	0.967	rs1649027	chr10:60280911	T/G	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.47	-0.52	2.41e-18	Personality dimensions;
KIRP	cis	rs35740288	0.822	rs34734963	chr15:86217644	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-4.95	-0.3	1.37e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.51	5.96	0.36	8.86e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9938149	0.705	rs7405095	chr16:88307825	C/T	cg05435882	chr16:88311214	NA	0.43	5.17	0.31	4.97e-7	Corneal structure;Central corneal thickness;
KIRP	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg16127683	chr15:40268777	EIF2AK4	-0.56	-6.51	-0.38	4.08e-10	Corneal curvature;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04264477	chr4:185655235	MLF1IP	0.51	6.27	0.37	1.62e-9	Parkinson's disease;
KIRP	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.64	7.61	0.44	5.9e-13	Age at first birth;
KIRP	cis	rs4268898	0.552	rs12620938	chr2:24367122	C/A	cg06627628	chr2:24431161	ITSN2	0.48	5.76	0.34	2.46e-8	Asthma;
KIRP	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg05315796	chr3:52349193	DNAH1	0.44	6.77	0.4	9.16e-11	Bipolar disorder;
KIRP	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	trans	rs6995541	0.553	rs11986013	chr8:10699992	C/T	cg01434694	chr16:88837185	FAM38A	0.34	6.28	0.37	1.54e-9	Triglyceride levels;
KIRP	cis	rs4704187	0.687	rs1422696	chr5:74464415	T/C	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.64	7.61	0.44	5.8e-13	Testicular germ cell tumor;
KIRP	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg02820901	chr13:113351484	ATP11A	0.65	6.13	0.36	3.49e-9	Glycated hemoglobin levels;
KIRP	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg05315796	chr3:52349193	DNAH1	0.4	6.34	0.37	1.1e-9	Electroencephalogram traits;
KIRP	trans	rs2302464	1.000	rs10939631	chr4:15658569	G/A	cg19145858	chr7:129781681	NA	-0.66	-6.44	-0.38	6.35e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg19847130	chr8:10466454	RP1L1	-0.35	-5.04	-0.31	9.16e-7	Retinal vascular caliber;
KIRP	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-8.59	-0.48	1.02e-15	Triglycerides;
KIRP	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.84	11.09	0.58	1.91e-23	Coronary artery disease or large artery stroke;
KIRP	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.94	-0.64	1.46e-29	Exhaled nitric oxide output;
KIRP	cis	rs1546924	0.692	rs197374	chr1:112289983	C/T	cg23955903	chr1:112298873	DDX20;C1orf183	0.47	5.95	0.35	9.01e-9	Body mass index;
KIRP	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	12.95	0.64	1.31e-29	Smoking behavior;
KIRP	cis	rs3812111	0.510	rs9372456	chr6:116592956	A/G	cg18828861	chr6:116576566	TSPYL4	0.42	4.87	0.3	1.98e-6	Age-related macular degeneration;
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg11168104	chr5:1857477	NA	-0.39	-4.96	-0.3	1.3e-6	Cardiovascular disease risk factors;
KIRP	cis	rs4356932	1.000	rs4356932	chr4:76955194	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.28	5.65	0.34	4.35e-8	Asthma (sex interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12059848	chr1:117577902	CD101	-0.43	-6.45	-0.38	6.03e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6450176	1.000	rs3776706	chr5:53304933	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.4	-0.59	1.95e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.5	-8.54	-0.48	1.41e-15	Refractive error;
KIRP	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.94	15.13	0.69	5.14e-37	Menopause (age at onset);
KIRP	cis	rs2562456	0.755	rs11670868	chr19:21556415	T/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs6102059	0.692	rs6129647	chr20:39229982	A/G	cg06665391	chr20:39312290	NA	-0.4	-5.04	-0.31	9.07e-7	LDL cholesterol;
KIRP	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg16606324	chr3:10149918	C3orf24	0.71	5.99	0.36	7.39e-9	Alzheimer's disease;
KIRP	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.72	-9.74	-0.53	3.55e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs4262150	0.544	rs10045463	chr5:151920194	C/T	cg12297329	chr5:152029980	NA	-0.64	-7.86	-0.45	1.19e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7523050	0.730	rs72984614	chr1:109435848	T/C	cg08274380	chr1:109419600	GPSM2	1.16	10.22	0.55	1.14e-20	Fat distribution (HIV);
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg00738919	chr7:1100172	C7orf50	0.44	5.1	0.31	6.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs134594	0.569	rs134559	chr22:29458441	C/T	cg02913918	chr1:181767609	CACNA1E	-0.42	-6.05	-0.36	5.24e-9	Birth weight;
KIRP	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg08501292	chr6:25962987	TRIM38	1.15	6.85	0.4	6.04e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg13147721	chr7:65941812	NA	-1.0	-6.94	-0.4	3.48e-11	Diabetic kidney disease;
KIRP	cis	rs7709377	0.595	rs254171	chr5:115623186	G/A	cg23108291	chr5:115420582	COMMD10	-0.44	-5.34	-0.32	2.12e-7	Metabolite levels  (X-11787);
KIRP	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-9.33	-0.51	6.47e-18	Morning vs. evening chronotype;
KIRP	cis	rs4073221	0.546	rs13069372	chr3:18234144	A/C	cg07694806	chr3:18168406	NA	-0.61	-5.54	-0.33	7.94e-8	Parkinson's disease;
KIRP	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg25554036	chr4:6271136	WFS1	0.47	7.03	0.41	2.03e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg01798813	chr17:3906674	NA	0.56	7.93	0.45	7.45e-14	Type 2 diabetes;
KIRP	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.42	-6.18	-0.37	2.69e-9	Colorectal cancer;
KIRP	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg13444842	chr1:152974279	SPRR3	-0.43	-6.18	-0.37	2.65e-9	Inflammatory skin disease;
KIRP	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg12131826	chr15:77904385	NA	-0.44	-5.89	-0.35	1.24e-8	Type 2 diabetes;
KIRP	cis	rs9826463	0.938	rs7622648	chr3:142346132	A/C	cg20824294	chr3:142316082	PLS1	0.32	5.4	0.33	1.58e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	9.28	0.51	9.23e-18	Hip circumference;
KIRP	cis	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.37	4.9	0.3	1.73e-6	Birth weight;
KIRP	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg17133734	chr15:86042851	AKAP13	0.47	6.0	0.36	6.98e-9	Coronary artery disease;
KIRP	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg13798780	chr7:105162888	PUS7	0.66	6.1	0.36	4.09e-9	Bipolar disorder (body mass index interaction);
KIRP	trans	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	7.11	0.41	1.27e-11	Electroencephalogram traits;
KIRP	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.88	-11.46	-0.59	1.18e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.96	-0.45	6.18e-14	Retinal vascular caliber;
KIRP	cis	rs447921	0.861	rs117544870	chr17:74415206	T/G	cg17201438	chr17:74438067	UBE2O	0.44	4.96	0.3	1.29e-6	Mitochondrial DNA levels;
KIRP	cis	rs2290402	0.572	rs3775119	chr4:893712	C/T	cg14517359	chr4:903473	GAK	-0.58	-5.63	-0.34	4.87e-8	Type 2 diabetes;
KIRP	cis	rs9400467	0.537	rs584937	chr6:111481577	T/G	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.05	0.31	8.59e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.59	8.32	0.47	6.07e-15	Myopia (pathological);
KIRP	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg01620082	chr3:125678407	NA	-1.04	-6.81	-0.4	7.58e-11	Depression;
KIRP	trans	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.4e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7317038	1.000	rs7317038	chr13:114012898	C/T	cg24344662	chr13:114018021	GRTP1	-0.58	-7.7	-0.44	3.38e-13	Mean platelet volume;
KIRP	cis	rs1018697	1.000	rs2150928	chr10:104550985	G/A	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.78	6.81	0.4	7.57e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-0.99	-11.51	-0.59	8.5e-25	White matter hyperintensity burden;
KIRP	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg23127183	chr11:57508653	C11orf31	-0.44	-5.9	-0.35	1.18e-8	Schizophrenia;
KIRP	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.93	10.0	0.54	5.44e-20	Alzheimer's disease;
KIRP	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.91	0.35	1.16e-8	Total cholesterol levels;
KIRP	trans	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg01311341	chr22:25575246	KIAA1671	0.65	7.49	0.43	1.25e-12	Atopic dermatitis;
KIRP	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00585698	chr12:123750864	CDK2AP1	0.44	5.53	0.33	8.13e-8	Platelet count;
KIRP	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.55	0.33	7.4e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg17376030	chr22:41985996	PMM1	-0.49	-5.91	-0.35	1.12e-8	Vitiligo;
KIRP	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.57	7.0	0.41	2.47e-11	Longevity;
KIRP	cis	rs7542091	0.813	rs2049999	chr1:210031331	A/G	cg05527609	chr1:210001259	C1orf107	-0.5	-6.95	-0.41	3.22e-11	Monobrow;
KIRP	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.64	0.71	9.35e-39	Bipolar disorder;
KIRP	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg24315340	chr6:146058215	EPM2A	0.43	5.36	0.32	1.92e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	11.03	0.58	2.99e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.28	-5.26	-0.32	3.2e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1223629	0.826	rs56131311	chr10:96041167	G/T	cg03387497	chr20:17680945	BANF2	0.73	6.48	0.38	4.98e-10	Glucose homeostasis traits;
KIRP	cis	rs4132509	0.793	rs10803161	chr1:243990770	T/C	cg21452805	chr1:244014465	NA	0.56	5.3	0.32	2.63e-7	RR interval (heart rate);
KIRP	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg06483076	chr3:194406458	FAM43A	0.45	6.81	0.4	7.3e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg03342759	chr3:160939853	NMD3	-0.49	-6.36	-0.38	9.92e-10	Morning vs. evening chronotype;
KIRP	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21643547	chr1:205240462	TMCC2	-0.83	-12.79	-0.63	4.54e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08692423	chr21:45148864	PDXK	0.59	6.08	0.36	4.62e-9	Lung function (FEV1);
KIRP	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.08	-0.31	7.55e-7	Pulmonary function;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27189623	chr16:705930	WDR90	0.44	6.23	0.37	1.99e-9	Height;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.5	-0.52	2.03e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.5	5.92	0.35	1.06e-8	Schizophrenia;
KIRP	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg18025133	chr1:46111528	RPS15AP10;GPBP1L1	0.36	4.9	0.3	1.73e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9506514	0.617	rs9509352	chr13:21295149	A/G	cg04906043	chr13:21280425	IL17D	0.43	5.62	0.34	5.14e-8	Coronary artery calcification;
KIRP	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.83	13.35	0.65	5.93e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.62	-9.31	-0.51	7.61e-18	Body mass index;
KIRP	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg17376030	chr22:41985996	PMM1	-0.52	-6.32	-0.37	1.2e-9	Vitiligo;
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg08805041	chr16:621841	PIGQ	-0.36	-4.86	-0.3	2.12e-6	Height;
KIRP	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14998457	chr2:114514532	SLC35F5	0.43	6.26	0.37	1.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1080500	1.000	rs1080500	chr3:53175017	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg27624424	chr6:160112604	SOD2	0.47	4.98	0.3	1.17e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.74	0.39	1.15e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg17443007	chr1:101659419	NA	0.4	5.74	0.34	2.75e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg00717180	chr2:96193071	NA	-0.5	-6.17	-0.37	2.73e-9	Coronary artery disease;
KIRP	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg22920501	chr2:26401640	FAM59B	-0.49	-5.97	-0.36	8.43e-9	Gut microbiome composition (summer);
KIRP	cis	rs9905704	0.552	rs8071623	chr17:56621286	G/T	cg12560992	chr17:57184187	TRIM37	-0.54	-5.12	-0.31	6.1e-7	Testicular germ cell tumor;
KIRP	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs2219968	0.961	rs2200014	chr8:78956394	A/T	cg00738934	chr8:78996279	NA	-0.42	-5.74	-0.34	2.76e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg21858823	chr1:15850916	CASP9	0.52	5.57	0.33	6.62e-8	Systolic blood pressure;
KIRP	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.7	-0.63	9.56e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.62	-7.97	-0.45	5.99e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.66	-8.01	-0.45	4.7e-14	Aortic root size;
KIRP	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs1318772	0.932	rs66838021	chr5:112898834	G/T	cg12552261	chr5:112820674	MCC	0.78	5.46	0.33	1.17e-7	F-cell distribution;
KIRP	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg16512390	chr1:228756714	NA	0.74	6.08	0.36	4.55e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg06742321	chr12:123595122	PITPNM2	0.44	5.41	0.33	1.49e-7	Platelet count;
KIRP	cis	rs16937956	0.597	rs11822608	chr11:8401664	A/C	cg08015107	chr11:8618950	NA	-0.54	-7.05	-0.41	1.84e-11	Body mass index;
KIRP	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg15839431	chr19:19639596	YJEFN3	0.47	5.05	0.31	8.72e-7	Bipolar disorder;
KIRP	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.58	-6.08	-0.36	4.5e-9	Obesity-related traits;
KIRP	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg15556689	chr8:8085844	FLJ10661	-0.68	-8.73	-0.49	3.95e-16	Joint mobility (Beighton score);
KIRP	cis	rs6696846	0.630	rs11240373	chr1:205135600	A/C	cg00889227	chr1:205173544	DSTYK	-0.38	-5.23	-0.32	3.62e-7	Red blood cell count;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02983885	chr19:42772892	NA	0.53	6.67	0.39	1.65e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg26513180	chr16:89883248	FANCA	0.65	8.77	0.49	3.09e-16	Vitiligo;
KIRP	cis	rs9682041	0.569	rs4955724	chr3:170146532	A/G	cg11886554	chr3:170076028	SKIL	0.5	5.07	0.31	7.99e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13198984	chr17:80129470	CCDC57	0.59	8.94	0.5	9.61e-17	Life satisfaction;
KIRP	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs33912345	0.750	rs1268620	chr14:60920776	T/C	cg27398547	chr14:60952738	C14orf39	-0.38	-5.03	-0.31	9.43e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg02297831	chr4:17616191	MED28	0.5	5.72	0.34	3.04e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg15556689	chr8:8085844	FLJ10661	0.64	8.27	0.47	8.5e-15	Retinal vascular caliber;
KIRP	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg09596252	chr17:78655493	RPTOR	0.48	6.17	0.37	2.8e-9	Obesity;
KIRP	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05220968	chr6:146057943	EPM2A	0.39	5.0	0.3	1.11e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.66	-10.6	-0.56	7.28e-22	Menopause (age at onset);
KIRP	cis	rs7688540	0.771	rs12505835	chr4:297525	G/C	cg17891759	chr4:299121	NA	-0.5	-4.97	-0.3	1.25e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.31	-0.37	1.28e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06481639	chr22:41940642	POLR3H	0.74	7.18	0.42	8.26e-12	Vitiligo;
KIRP	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.4	7.67	0.44	4.13e-13	Height;
KIRP	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg01411142	chr8:19674711	INTS10	0.61	6.62	0.39	2.25e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg23748340	chr12:48592721	NA	-0.43	-4.89	-0.3	1.82e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs7558233	0.614	rs6544858	chr2:23676071	C/T	cg00747342	chr2:23700632	KLHL29	-0.56	-5.06	-0.31	8.23e-7	Cannabis use (initiation);
KIRP	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg12549451	chr6:135224345	NA	-0.43	-5.33	-0.32	2.17e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.52	-6.51	-0.38	4.28e-10	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg23594656	chr7:65796392	TPST1	0.39	5.74	0.34	2.72e-8	Aortic root size;
KIRP	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	1.17	8.24	0.47	1.02e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9488822	0.585	rs529574	chr6:116268158	T/A	cg05304507	chr6:116381966	FRK	-0.21	-5.59	-0.34	6.11e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.71	0.34	3.26e-8	Lung cancer;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg06090383	chr4:174292579	SAP30	-0.49	-6.61	-0.39	2.42e-10	Serum protein levels (sST2);
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.72	-10.62	-0.56	6.26e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs12615966	1.000	rs12618379	chr2:105386854	C/T	cg16465502	chr2:105461796	NA	0.54	5.15	0.31	5.41e-7	Pancreatic cancer;
KIRP	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.43	-6.37	-0.38	9.06e-10	Bone mineral density;
KIRP	cis	rs2574975	0.531	rs1203392	chr10:52204993	C/T	cg10034176	chr10:52120283	SGMS1	-0.39	-5.54	-0.33	7.86e-8	Response to amphetamines;
KIRP	trans	rs429017	1.000	rs407963	chr5:41265016	G/A	cg06122825	chr1:203488764	NA	0.41	6.06	0.36	5.03e-9	Blood protein levels;
KIRP	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.67	-11.0	-0.57	3.73e-23	Lung function (FVC);
KIRP	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.72	7.81	0.45	1.62e-13	Small cell lung carcinoma;
KIRP	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.12	0.54	2.37e-20	Total body bone mineral density;
KIRP	cis	rs7267005	0.661	rs17093099	chr20:34387463	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs4363506	1.000	rs4363507	chr10:129274942	T/C	cg07804728	chr10:129284050	NA	0.41	5.83	0.35	1.73e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs2273669	0.915	rs7753554	chr6:109292133	G/C	cg05315195	chr6:109294784	ARMC2	-0.48	-5.44	-0.33	1.27e-7	Prostate cancer;
KIRP	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg14541582	chr5:601475	NA	-0.57	-6.34	-0.37	1.09e-9	Obesity-related traits;
KIRP	cis	rs1010254	0.510	rs72806361	chr5:151685160	C/T	cg12297329	chr5:152029980	NA	-0.66	-6.58	-0.39	2.83e-10	Optic nerve measurement (cup area);
KIRP	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg07395648	chr5:131743802	NA	-0.36	-5.01	-0.3	1.06e-6	Blood metabolite levels;
KIRP	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.08	0.36	4.58e-9	Colorectal cancer;
KIRP	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.56	6.98	0.41	2.68e-11	Chronic sinus infection;
KIRP	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs13401104	0.796	rs10929172	chr2:237116600	C/G	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.52	-6.94	-0.4	3.55e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg00483446	chr3:67048774	KBTBD8	-0.55	-6.32	-0.37	1.23e-9	Corneal astigmatism;
KIRP	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.69	8.43	0.47	2.9e-15	Neutrophil percentage of white cells;
KIRP	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.5	5.85	0.35	1.55e-8	Parkinson's disease;
KIRP	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.96	11.02	0.58	3.13e-23	Corneal astigmatism;
KIRP	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.7	-0.39	1.44e-10	Response to antipsychotic treatment;
KIRP	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg00079375	chr15:79125835	NA	0.42	6.13	0.36	3.5e-9	Coronary artery disease;
KIRP	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg04132472	chr17:19861366	AKAP10	0.38	4.9	0.3	1.77e-6	Schizophrenia;
KIRP	cis	rs6005807	0.719	rs16986398	chr22:28815629	A/C	cg12565055	chr22:29076175	TTC28	0.6	5.07	0.31	7.81e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9783347	0.754	rs4757637	chr11:18307575	G/T	cg15585147	chr11:18324498	HPS5	0.35	5.11	0.31	6.5e-7	Pancreatic cancer;
KIRP	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.59	7.25	0.42	5.35e-12	Mean corpuscular volume;
KIRP	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.5	5.02	0.31	9.77e-7	Initial pursuit acceleration;
KIRP	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.67	11.63	0.6	3.3e-25	Coronary artery disease;
KIRP	cis	rs138229	0.506	rs138233	chr22:50559953	G/A	cg26190233	chr22:50609610	PANX2	-0.36	-4.98	-0.3	1.17e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg19899395	chr1:46959349	NA	0.45	5.54	0.33	7.95e-8	Monobrow;
KIRP	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs2387326	0.717	rs11016101	chr10:129945003	C/T	cg16087940	chr10:129947807	NA	-0.37	-5.07	-0.31	7.87e-7	Select biomarker traits;
KIRP	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.0	16.92	0.73	4.15e-43	Schizophrenia;
KIRP	cis	rs1823913	1.000	rs11681777	chr2:192121467	G/A	cg12404831	chr2:192114017	MYO1B	-0.51	-6.89	-0.4	4.74e-11	Obesity-related traits;
KIRP	cis	rs9475752	0.793	rs13218276	chr6:56815154	T/A	cg22880620	chr6:56820808	BEND6;DST	0.5	5.17	0.31	4.96e-7	Menarche (age at onset);
KIRP	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg21360079	chr12:107162445	NA	-0.69	-9.89	-0.53	1.27e-19	Heart rate;
KIRP	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.87	0.35	1.37e-8	Educational attainment;
KIRP	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg13010199	chr12:38710504	ALG10B	0.54	6.8	0.4	7.76e-11	Morning vs. evening chronotype;
KIRP	cis	rs17023223	0.581	rs11811859	chr1:119707680	A/G	cg05756136	chr1:119680316	WARS2	-0.62	-8.34	-0.47	5.27e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2725236	0.563	rs11097180	chr4:88880830	A/C	cg00088885	chr4:88896634	SPP1	-0.43	-5.09	-0.31	7.1e-7	Caffeine consumption;
KIRP	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg09264619	chr17:80180166	NA	-0.4	-5.96	-0.36	8.55e-9	Life satisfaction;
KIRP	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	10.25	0.55	9.48e-21	Lymphocyte counts;
KIRP	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg19875535	chr5:140030758	IK	-0.62	-8.92	-0.49	1.1e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.03	-0.31	9.47e-7	Longevity;
KIRP	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.21	0.32	4.04e-7	Childhood ear infection;
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg23985595	chr17:80112537	CCDC57	-0.35	-5.17	-0.31	4.82e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg11859384	chr17:80120422	CCDC57	-0.42	-5.42	-0.33	1.45e-7	Life satisfaction;
KIRP	cis	rs28489187	0.643	rs233054	chr1:85840191	T/G	cg16011679	chr1:85725395	C1orf52	0.55	6.66	0.39	1.82e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg26174226	chr8:58114915	NA	-0.63	-7.37	-0.43	2.51e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg24009623	chr19:33667908	NA	-0.46	-5.91	-0.35	1.11e-8	Bone properties (heel);
KIRP	cis	rs1318878	0.519	rs56060060	chr12:15505312	T/C	cg08258403	chr12:15378311	NA	0.37	4.9	0.3	1.75e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.36	5.19	0.31	4.36e-7	Calcium levels;
KIRP	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	trans	rs933360	0.585	rs2074720	chr7:50823221	A/G	cg20003124	chr12:4557277	NA	0.51	6.2	0.37	2.31e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs12982744	0.613	rs3786969	chr19:2141110	A/C	cg09261902	chr19:2140048	AP3D1	0.43	5.52	0.33	8.63e-8	Osteoarthritis;Height;
KIRP	cis	rs10211205	1.000	rs10190985	chr2:236611155	C/G	cg02339850	chr2:236586191	AGAP1	-0.53	-5.46	-0.33	1.14e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs399593	0.767	rs2245061	chr10:30891731	G/C	cg02831383	chr1:3329820	PRDM16	0.6	6.18	0.37	2.65e-9	Dental caries;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg16010370	chr3:53290200	TKT	-0.61	-6.25	-0.37	1.83e-9	Response to statin therapy;
KIRP	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.72e-15	Prudent dietary pattern;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05650458	chr1:228270764	ARF1	-0.57	-6.55	-0.39	3.28e-10	Interleukin-4 levels;
KIRP	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg00122941	chr17:4613640	ARRB2	-0.69	-7.64	-0.44	4.86e-13	Lymphocyte counts;
KIRP	cis	rs1009181	0.560	rs9379829	chr6:26172219	C/T	cg13736514	chr6:26305472	NA	-0.59	-5.94	-0.35	9.75e-9	Childhood ear infection;
KIRP	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.42	5.43	0.33	1.35e-7	Hypertriglyceridemia;
KIRP	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg27494647	chr7:150038898	RARRES2	0.43	6.26	0.37	1.69e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9938149	0.706	rs6540220	chr16:88315515	G/C	cg05435882	chr16:88311214	NA	-0.49	-5.87	-0.35	1.42e-8	Corneal structure;Central corneal thickness;
KIRP	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg25356066	chr3:128598488	ACAD9	0.56	6.43	0.38	6.48e-10	IgG glycosylation;
KIRP	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg18402987	chr7:1209562	NA	0.7	4.88	0.3	1.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10626959	chr7:4800797	FOXK1	1.13	6.63	0.39	2.12e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs4971059	0.654	rs7364524	chr1:155121922	A/G	cg02153340	chr1:155202674	NA	-0.43	-6.14	-0.36	3.21e-9	Breast cancer;
KIRP	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.69	8.66	0.48	6.49e-16	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs4764487	0.735	rs11612258	chr12:6360683	G/T	cg08284733	chr12:6341482	CD9	0.57	9.65	0.52	6.76e-19	Mean platelet volume;
KIRP	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.75	-9.89	-0.53	1.21e-19	Blood metabolite levels;
KIRP	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.12	0.58	1.56e-23	Cognitive test performance;
KIRP	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs10875746	0.669	rs11168459	chr12:48596241	A/G	cg20731937	chr12:48336164	NA	0.44	5.86	0.35	1.46e-8	Longevity (90 years and older);
KIRP	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg11845111	chr2:191398756	TMEM194B	-0.95	-10.56	-0.56	9.36e-22	Diastolic blood pressure;
KIRP	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.12	-0.46	2.31e-14	Monocyte percentage of white cells;
KIRP	trans	rs1941687	0.831	rs35740221	chr18:31387714	T/G	cg27147174	chr7:100797783	AP1S1	-0.55	-6.74	-0.39	1.14e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs300890	0.760	rs7655782	chr4:144206248	T/C	cg19876092	chr4:144208277	NA	0.42	6.86	0.4	5.41e-11	Nasopharyngeal carcinoma;
KIRP	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26207909	chr14:103986467	CKB	0.57	7.8	0.45	1.73e-13	Body mass index;
KIRP	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg00800038	chr16:89945340	TCF25	-0.79	-5.46	-0.33	1.14e-7	Skin colour saturation;
KIRP	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg11673840	chr17:47092156	IGF2BP1	-0.4	-5.01	-0.3	1.06e-6	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg11642891	chr2:3452563	TTC15	-0.53	-6.84	-0.4	6.07e-11	Obesity-related traits;
KIRP	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.65	7.99	0.45	5.09e-14	Height;
KIRP	cis	rs12580194	0.593	rs60873827	chr12:55717769	T/C	cg19537932	chr12:55886519	OR6C68	-0.51	-6.29	-0.37	1.47e-9	Cancer;
KIRP	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-4.89	-0.3	1.84e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.34	0.55	4.65e-21	Cognitive test performance;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20783806	chr2:419684	NA	-0.45	-6.32	-0.37	1.21e-9	Inflammatory biomarkers;
KIRP	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg09491104	chr22:46646882	C22orf40	-0.53	-5.17	-0.31	4.73e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21214630	chr9:127631857	ARPC5L	-0.45	-6.25	-0.37	1.78e-9	Metabolic traits;
KIRP	trans	rs7555006	0.621	rs2453729	chr1:51463805	C/T	cg17804635	chr8:37554071	ZNF703	-0.48	-6.04	-0.36	5.56e-9	Headache;
KIRP	cis	rs7665939	1.000	rs72709223	chr4:190119797	G/T	cg09826759	chr4:190284978	NA	-0.69	-4.92	-0.3	1.61e-6	Amyotrophic lateral sclerosis;
KIRP	cis	rs287982	1.000	rs287977	chr2:9970018	T/C	cg10881225	chr2:9984929	TAF1B	-0.4	-4.91	-0.3	1.63e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.72	9.58	0.52	1.15e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.37	-0.59	2.43e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6546324	0.921	rs1430788	chr2:67868412	C/T	cg15745817	chr2:67799979	NA	-0.45	-5.96	-0.36	8.58e-9	Endometriosis;
KIRP	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-6.56	-0.39	3.07e-10	Body mass index;
KIRP	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg11833968	chr6:79620685	NA	-0.45	-6.74	-0.4	1.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.12	-0.5	2.82e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.71	-0.39	1.33e-10	Dilated cardiomyopathy;
KIRP	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.34	11.5	0.59	8.67e-25	Diabetic retinopathy;
KIRP	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg15691649	chr6:25882328	NA	0.39	5.01	0.3	1.03e-6	Blood metabolite levels;
KIRP	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg01557791	chr16:72042693	DHODH	-0.4	-4.97	-0.3	1.23e-6	Fibrinogen levels;
KIRP	cis	rs6009824	0.891	rs11090995	chr22:50085210	G/A	cg27029450	chr22:50098074	NA	0.62	6.2	0.37	2.37e-9	Natriuretic peptide levels;
KIRP	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg26681399	chr22:41777847	TEF	-0.54	-5.38	-0.32	1.77e-7	Vitiligo;
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.54	7.19	0.42	7.66e-12	Blood metabolite levels;
KIRP	cis	rs7116495	1.000	rs28504107	chr11:71832519	G/A	cg26138937	chr11:71823887	C11orf51	0.64	5.14	0.31	5.63e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21760146	chr6:167275781	RPS6KA2	0.42	6.17	0.37	2.73e-9	Parkinson's disease;
KIRP	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.79	13.4	0.65	4.14e-31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19524238	chr7:2802976	GNA12	-0.37	-4.98	-0.3	1.21e-6	Height;
KIRP	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-7.57	-0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.55	-5.63	-0.34	4.8e-8	DNA methylation (variation);
KIRP	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6707387	0.686	rs13004439	chr2:214486662	A/C	cg08319019	chr2:214017104	IKZF2	0.47	5.48	0.33	1.03e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs888194	0.677	rs7956194	chr12:109877825	C/T	cg19025524	chr12:109796872	NA	-0.37	-5.06	-0.31	8.02e-7	Neuroticism;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	1.02	11.31	0.58	3.73e-24	Alzheimer's disease;
KIRP	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13409248	chr3:40428643	ENTPD3	0.37	5.08	0.31	7.62e-7	Renal cell carcinoma;
KIRP	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg11569703	chr11:65557185	OVOL1	-0.49	-8.79	-0.49	2.55e-16	Acne (severe);
KIRP	cis	rs965513	0.965	rs10759944	chr9:100556972	A/G	cg13688889	chr9:100608707	NA	-0.59	-7.4	-0.43	2.15e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs735539	0.645	rs7326068	chr13:21209512	A/G	cg04906043	chr13:21280425	IL17D	0.49	5.58	0.34	6.44e-8	Dental caries;
KIRP	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.55	5.9	0.35	1.19e-8	Diisocyanate-induced asthma;
KIRP	cis	rs904251	0.686	rs1224128	chr6:37415676	C/A	cg01843034	chr6:37503916	NA	-0.61	-6.27	-0.37	1.59e-9	Cognitive performance;
KIRP	cis	rs2230307	0.536	rs580611	chr1:100622925	G/A	cg24955406	chr1:100503596	HIAT1	-0.6	-6.39	-0.38	8.23e-10	Carotid intima media thickness;
KIRP	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-8.85	-0.49	1.78e-16	Schizophrenia;
KIRP	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs5753037	0.869	rs2301402	chr22:30234045	G/A	cg27665648	chr22:30112403	NA	0.5	6.41	0.38	7.39e-10	Type 1 diabetes;
KIRP	cis	rs7209700	0.821	rs4642	chr17:45369777	A/G	cg25173405	chr17:45401733	C17orf57	0.41	4.89	0.3	1.8e-6	IgG glycosylation;
KIRP	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	cg12689670	chr1:183009347	LAMC1	0.43	6.16	0.37	3e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs10782582	0.609	rs78748984	chr1:76340467	G/A	cg10523679	chr1:76189770	ACADM	-0.44	-6.04	-0.36	5.61e-9	Daytime sleep phenotypes;
KIRP	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.6	7.63	0.44	5.07e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	0.72	6.53	0.38	3.81e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3762637	0.943	rs3817040	chr3:122254769	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-6.64	-0.39	1.98e-10	LDL cholesterol levels;
KIRP	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg00631329	chr6:26305371	NA	-0.6	-7.75	-0.44	2.35e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.43	-5.62	-0.34	5.09e-8	IgG glycosylation;
KIRP	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00149659	chr3:10157352	C3orf10	0.81	8.9	0.49	1.21e-16	Alzheimer's disease;
KIRP	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg21573476	chr21:45109991	RRP1B	0.62	8.51	0.48	1.71e-15	Mean corpuscular volume;
KIRP	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs28834970	0.675	rs17057051	chr8:27227554	C/T	cg23693289	chr8:27183097	PTK2B	0.51	5.71	0.34	3.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg03999872	chr20:62272968	STMN3	-0.47	-4.9	-0.3	1.77e-6	Glioblastoma;
KIRP	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.49	6.41	0.38	7.55e-10	Blood metabolite levels;
KIRP	cis	rs2220004	0.642	rs11227494	chr11:55969836	T/C	cg01505312	chr11:56258856	OR5M8;OR8U8	0.49	5.4	0.33	1.59e-7	Odorant perception (&beta-damascenone);
KIRP	cis	rs239198	0.602	rs4840157	chr6:101326375	C/T	cg09795085	chr6:101329169	ASCC3	-0.5	-5.79	-0.35	2.15e-8	Menarche (age at onset);
KIRP	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.26	0.42	4.96e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg26754761	chr2:177040938	NA	-0.46	-7.9	-0.45	9.54e-14	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.65	-7.58	-0.44	7.15e-13	Systemic lupus erythematosus;
KIRP	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg13319975	chr6:146136371	FBXO30	-0.39	-5.13	-0.31	5.81e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6593803	0.622	rs1001193	chr1:147166377	A/G	cg27546670	chr1:147246839	GJA5	-0.56	-5.56	-0.33	6.91e-8	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs2077654	0.822	rs1805036	chr11:17434284	G/A	cg25308976	chr11:17434268	ABCC8	1.04	10.83	0.57	1.29e-22	Gout;
KIRP	cis	rs9400271	0.632	rs9372205	chr6:109588401	A/T	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.41	-7.03	-0.41	1.98e-11	Heart rate;
KIRP	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg22117172	chr7:91764530	CYP51A1	-0.41	-5.76	-0.34	2.52e-8	Breast cancer;
KIRP	cis	rs9393813	0.868	rs2393963	chr6:27475100	G/C	cg18711553	chr6:27366782	ZNF391	-0.43	-6.32	-0.37	1.23e-9	Bipolar disorder;
KIRP	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg05340658	chr4:99064831	C4orf37	-0.54	-6.7	-0.39	1.41e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg25486957	chr4:152246857	NA	-0.45	-5.42	-0.33	1.43e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.92	13.13	0.64	3.37e-30	Bladder cancer;
KIRP	cis	rs6840360	0.901	rs6826799	chr4:152455700	G/A	cg25486957	chr4:152246857	NA	-0.46	-5.33	-0.32	2.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-5.98	-0.36	7.64e-9	Lung cancer;
KIRP	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.77	8.7	0.49	4.7e-16	Corneal astigmatism;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.71	-6.21	-0.37	2.22e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.68	8.16	0.46	1.78e-14	Schizophrenia;
KIRP	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg13180566	chr4:1052158	NA	-0.54	-5.46	-0.33	1.19e-7	Recombination rate (females);
KIRP	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.84	-12.46	-0.62	5.75e-28	Height;
KIRP	cis	rs4774899	1.000	rs12914425	chr15:57476285	C/G	cg13626582	chr15:57592083	LOC283663	-0.21	-4.97	-0.3	1.28e-6	Urinary tract infection frequency;
KIRP	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	4.04e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.63	-6.44	-0.38	6.29e-10	Gout;
KIRP	cis	rs17030434	0.906	rs5020754	chr4:154670444	T/C	cg14289246	chr4:154710475	SFRP2	-0.75	-8.87	-0.49	1.55e-16	Electrocardiographic conduction measures;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12113561	chr17:36860216	NA	-0.43	-6.33	-0.37	1.12e-9	Metabolic traits;
KIRP	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.74e-11	Vitiligo;
KIRP	trans	rs6866721	0.904	rs7704264	chr5:116224153	A/G	cg12737536	chr10:5227162	AKR1CL1	0.45	6.31	0.37	1.26e-9	Body mass index;
KIRP	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs8054556	0.730	rs4788190	chr16:29948401	G/A	cg05445914	chr16:30134068	MAPK3	0.39	4.98	0.3	1.2e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg04310649	chr10:35416472	CREM	-0.58	-6.87	-0.4	5.13e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.69	7.14	0.41	1.03e-11	Lung function (FEV1/FVC);
KIRP	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg12560992	chr17:57184187	TRIM37	0.58	5.23	0.32	3.69e-7	Cognitive test performance;
KIRP	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	7.62	0.44	5.54e-13	Parkinson's disease;
KIRP	cis	rs860295	0.702	rs10908471	chr1:155542942	A/G	cg02153340	chr1:155202674	NA	-0.55	-7.41	-0.43	1.97e-12	Body mass index;
KIRP	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.78	8.67	0.48	5.75e-16	Corneal astigmatism;
KIRP	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg23594656	chr7:65796392	TPST1	0.4	5.76	0.34	2.52e-8	Aortic root size;
KIRP	cis	rs11608355	0.557	rs759971	chr12:109826046	A/T	cg19025524	chr12:109796872	NA	-0.51	-7.05	-0.41	1.84e-11	Neuroticism;
KIRP	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.1	-0.31	6.91e-7	Coronary artery disease;
KIRP	trans	rs1941687	0.764	rs4799357	chr18:31366442	T/C	cg04226714	chr8:49833948	SNAI2	-0.51	-7.11	-0.41	1.24e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg07843065	chr1:150265600	MRPS21	0.46	6.06	0.36	4.95e-9	Migraine;
KIRP	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.1	0.5	3.22e-17	Lung cancer in ever smokers;
KIRP	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs698833	0.859	rs17580340	chr2:44602554	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.17	0.31	4.9e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07818431	chr1:228291118	C1orf35	-0.49	-6.59	-0.39	2.66e-10	Myopia;
KIRP	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg18709589	chr6:96969512	KIAA0776	0.34	5.18	0.31	4.59e-7	Headache;
KIRP	cis	rs10802346	0.588	rs12038849	chr1:246359987	C/T	cg15962031	chr1:246363574	SMYD3	0.79	5.91	0.35	1.15e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs12594515	0.600	rs12903858	chr15:45972166	A/G	cg01629716	chr15:45996671	NA	0.32	5.24	0.32	3.48e-7	Waist circumference;Weight;
KIRP	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.68	-12.9	-0.64	1.98e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs58649573	0.509	rs917784	chr9:126790201	T/C	cg14112217	chr9:126806003	NA	0.38	5.29	0.32	2.66e-7	Post-traumatic stress disorder;
KIRP	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.92	12.54	0.62	3.16e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg24807547	chr6:37504484	NA	-0.61	-9.26	-0.51	1.02e-17	Cognitive performance;
KIRP	cis	rs629922	0.642	rs615119	chr11:114072224	T/C	cg25009965	chr11:114031120	ZBTB16	0.43	5.18	0.31	4.53e-7	Paneth cell defects in Crohn's disease;
KIRP	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.64	-0.39	2.01e-10	Neuroticism;
KIRP	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.85	13.61	0.66	8.17e-32	Dental caries;
KIRP	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.77	0.49	2.92e-16	IgG glycosylation;
KIRP	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.57	-6.24	-0.37	1.9e-9	DNA methylation (variation);
KIRP	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg23479056	chr15:41276147	INO80	-0.35	-4.87	-0.3	2e-6	Menopause (age at onset);
KIRP	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	10.22	0.55	1.13e-20	Calcium levels;
KIRP	cis	rs9682041	0.877	rs6804688	chr3:170071191	T/G	cg11886554	chr3:170076028	SKIL	0.5	5.52	0.33	8.54e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs76693355	0.512	rs11217857	chr11:120270170	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.03	-0.36	5.85e-9	Intraocular pressure;
KIRP	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg16584290	chr5:462447	EXOC3	0.39	5.06	0.31	8.26e-7	Cystic fibrosis severity;
KIRP	cis	rs2414059	0.518	rs3098171	chr15:50771511	C/G	cg05456662	chr15:50716270	USP8	-0.41	-5.73	-0.34	3e-8	QT interval;
KIRP	cis	rs2120243	0.647	rs60676003	chr3:157147939	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.38	5.45	0.33	1.22e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg08662619	chr6:150070041	PCMT1	0.37	6.1	0.36	4e-9	Lung cancer;
KIRP	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.9	-0.35	1.22e-8	Type 2 diabetes;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10681804	chr20:33433114	GGT7	1.17	7.1	0.41	1.33e-11	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg23992470	chr4:843637	GAK	0.63	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4728302	0.607	rs6954537	chr7:133585612	T/C	cg10665199	chr7:133106180	EXOC4	0.42	4.98	0.3	1.21e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg27205649	chr11:78285834	NARS2	-0.61	-6.93	-0.4	3.62e-11	Testicular germ cell tumor;
KIRP	cis	rs732716	0.853	rs12459922	chr19:4455862	A/G	cg19820705	chr19:4455316	UBXN6	0.68	8.47	0.47	2.33e-15	Mean corpuscular volume;
KIRP	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg08779649	chr13:50194554	NA	0.49	6.61	0.39	2.32e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.97	-0.64	1.18e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs73198271	0.583	rs11781985	chr8:8589783	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	5.79	0.35	2.19e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg16736954	chr20:23401023	NAPB	0.63	5.0	0.3	1.08e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs9831754	0.756	rs7653140	chr3:78419340	C/G	cg06138941	chr3:78371609	NA	-0.8	-11.01	-0.57	3.38e-23	Calcium levels;
KIRP	cis	rs6442310	0.534	rs2938392	chr3:12434608	G/A	cg15873301	chr3:12045459	SYN2	0.41	5.59	0.34	5.91e-8	Hematocrit;
KIRP	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg01557791	chr16:72042693	DHODH	-0.53	-5.99	-0.36	7.56e-9	Blood protein levels;
KIRP	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg01721255	chr8:58191610	C8orf71	0.54	5.24	0.32	3.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg19077165	chr18:44547161	KATNAL2	-0.39	-4.99	-0.3	1.14e-6	Educational attainment;
KIRP	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg26874164	chr19:58962979	ZNF324B	0.48	5.82	0.35	1.84e-8	Uric acid clearance;
KIRP	cis	rs6125597	0.967	rs6125611	chr20:47904734	G/T	cg03212862	chr20:47662828	CSE1L	-0.41	-5.29	-0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1106684	1.000	rs1592697	chr7:131464699	A/G	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg04369109	chr6:150039330	LATS1	-0.67	-8.85	-0.49	1.71e-16	Lung cancer;
KIRP	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.75	-8.37	-0.47	4.45e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg06521331	chr12:34319734	NA	-0.45	-5.28	-0.32	2.77e-7	Resting heart rate;
KIRP	cis	rs40363	0.594	rs250626	chr16:3511892	G/A	cg22508957	chr16:3507546	NAT15	0.44	6.71	0.39	1.33e-10	Tuberculosis;
KIRP	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.8	11.04	0.58	2.81e-23	Aortic root size;
KIRP	cis	rs4262150	0.774	rs4958564	chr5:152005941	T/C	cg12297329	chr5:152029980	NA	-0.63	-7.9	-0.45	9.53e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4774899	1.000	rs2583108	chr15:57245778	A/G	cg13626582	chr15:57592083	LOC283663	-0.2	-4.87	-0.3	2.04e-6	Urinary tract infection frequency;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13521891	chr12:95466445	NR2C1	0.54	6.18	0.37	2.68e-9	Lung cancer in ever smokers;
KIRP	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs597583	0.709	rs7940527	chr11:117398202	C/G	cg27161313	chr11:117392002	DSCAML1	0.48	5.36	0.32	1.91e-7	Putamen volume;
KIRP	cis	rs4561483	0.583	rs11075032	chr16:12004450	C/T	cg08843971	chr16:11963173	GSPT1	0.53	7.54	0.43	9.09e-13	Testicular germ cell tumor;
KIRP	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.86	10.9	0.57	7.83e-23	Coronary artery disease;
KIRP	cis	rs1978968	0.731	rs9605463	chr22:18459889	C/T	cg03078520	chr22:18463400	MICAL3	-0.85	-12.25	-0.62	3.04e-27	Presence of antiphospholipid antibodies;
KIRP	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-7.77	-0.44	2.09e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.21	-0.37	2.26e-9	Neuroticism;
KIRP	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg02951883	chr7:2050386	MAD1L1	-0.52	-5.82	-0.35	1.87e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg03161606	chr19:29218774	NA	0.83	8.02	0.46	4.43e-14	Methadone dose in opioid dependence;
KIRP	cis	rs714027	0.545	rs41161	chr22:30407652	T/C	cg01021169	chr22:30184971	ASCC2	0.42	5.25	0.32	3.24e-7	Lymphocyte counts;
KIRP	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg16989719	chr2:238392110	NA	-0.53	-7.07	-0.41	1.55e-11	Prostate cancer;
KIRP	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.58	-6.06	-0.36	5.02e-9	Ulcerative colitis;
KIRP	cis	rs17123764	1.000	rs56743994	chr12:49950408	G/A	cg20471783	chr12:50157085	TMBIM6	0.4	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg16141378	chr3:129829833	LOC729375	0.48	6.15	0.37	3.1e-9	Neuroticism;
KIRP	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00495681	chr13:53174319	NA	0.37	5.02	0.3	9.82e-7	Lewy body disease;
KIRP	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.63e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10128251	0.743	rs2386636	chr10:5712087	G/T	cg11519256	chr10:5708881	ASB13	0.46	5.71	0.34	3.2e-8	Childhood ear infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03685910	chr17:39844834	EIF1	0.63	7.53	0.43	9.32e-13	Smoking initiation;
KIRP	cis	rs494562	0.892	rs575477	chr6:86118064	A/G	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.27	-5.23	-0.32	3.67e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.32	-0.37	1.25e-9	Neuroticism;
KIRP	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg09455208	chr3:40491958	NA	-0.37	-6.67	-0.39	1.69e-10	Renal cell carcinoma;
KIRP	cis	rs4273100	0.541	rs7501702	chr17:19293727	C/T	cg18093559	chr17:18951025	GRAP	0.45	5.38	0.32	1.76e-7	Schizophrenia;
KIRP	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs7113850	0.541	rs7927067	chr11:24232604	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	8.37	0.47	4.29e-15	Bone fracture in osteoporosis;
KIRP	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg07451762	chr16:28383216	NA	0.42	5.5	0.33	9.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg02811702	chr13:24901961	NA	-0.42	-5.55	-0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.78	8.78	0.49	2.85e-16	Corneal astigmatism;
KIRP	cis	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg27411982	chr8:10470053	RP1L1	-0.38	-4.87	-0.3	2.02e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg15839431	chr19:19639596	YJEFN3	0.46	4.96	0.3	1.32e-6	Bipolar disorder;
KIRP	cis	rs2282032	1.000	rs75722521	chr14:90760478	T/C	cg04374321	chr14:90722782	PSMC1	0.56	5.27	0.32	2.93e-7	Longevity;
KIRP	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs4845459	0.967	rs477392	chr1:152555176	C/G	cg07796016	chr1:152779584	LCE1C	-0.49	-6.03	-0.36	5.84e-9	Psoriasis;
KIRP	cis	rs9398803	0.687	rs9388507	chr6:126970895	G/T	cg19875578	chr6:126661172	C6orf173	0.42	5.4	0.33	1.57e-7	Male-pattern baldness;
KIRP	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg09455208	chr3:40491958	NA	-0.38	-7.01	-0.41	2.25e-11	Renal cell carcinoma;
KIRP	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.49	5.72	0.34	3.14e-8	Intraocular pressure;
KIRP	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg05914723	chr15:78953907	NA	0.57	5.52	0.33	8.79e-8	Post bronchodilator FEV1;
KIRP	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.48	8.36	0.47	4.64e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs58688157	0.960	rs61877856	chr11:617378	C/T	cg02461776	chr11:598696	PHRF1	0.51	5.41	0.33	1.49e-7	Systemic lupus erythematosus;
KIRP	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.38	-5.29	-0.32	2.72e-7	Blood metabolite levels;
KIRP	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs986417	1.000	rs1018531	chr14:60970844	C/T	cg27398547	chr14:60952738	C14orf39	0.73	7.26	0.42	5.21e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.74	-0.34	2.84e-8	IgG glycosylation;
KIRP	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg12591125	chr7:1885375	MAD1L1	0.67	6.28	0.37	1.51e-9	Bipolar disorder;
KIRP	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.38	5.66	0.34	4.23e-8	Platelet distribution width;
KIRP	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.75	8.49	0.48	2.02e-15	Corneal astigmatism;
KIRP	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg03315344	chr16:75512273	CHST6	-0.57	-5.43	-0.33	1.35e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg01304814	chr3:48885189	PRKAR2A	0.7	5.43	0.33	1.33e-7	Cognitive function;
KIRP	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.42	0.38	7e-10	Breast cancer;
KIRP	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.49	6.19	0.37	2.44e-9	Multiple sclerosis;
KIRP	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.31	0.37	1.29e-9	Systolic blood pressure;
KIRP	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.78	-0.35	2.21e-8	Schizophrenia;
KIRP	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg09184832	chr6:79620586	NA	-0.52	-7.43	-0.43	1.77e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.41	-4.88	-0.3	1.9e-6	Iron status biomarkers;
KIRP	cis	rs7517126	1.000	rs35881325	chr1:196876879	C/T	cg13441112	chr1:196844364	NA	0.42	4.87	0.3	1.97e-6	Blood protein levels;
KIRP	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.9	-10.35	-0.55	4.38e-21	Neuroticism;
KIRP	cis	rs9581857	0.685	rs60787915	chr13:28022298	C/T	cg22138327	chr13:27999177	GTF3A	0.67	5.69	0.34	3.62e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.81	10.74	0.56	2.61e-22	Breast cancer;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.68	-0.34	3.83e-8	Life satisfaction;
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg16341495	chr8:142228727	SLC45A4	0.41	5.04	0.31	8.98e-7	Immature fraction of reticulocytes;
KIRP	cis	rs41005	0.967	rs6752776	chr2:8104594	A/G	cg03155496	chr2:8117019	LOC339788	0.53	8.65	0.48	6.78e-16	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.09	-0.31	7.28e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4363385	0.626	rs1108410	chr1:153005662	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-6.1	-0.36	4.05e-9	Inflammatory skin disease;
KIRP	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg24747557	chr10:131355152	MGMT	-0.38	-5.11	-0.31	6.36e-7	Response to temozolomide;
KIRP	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg10645314	chr2:3704589	ALLC	-0.65	-7.05	-0.41	1.8e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg09408571	chr1:101003634	GPR88	-0.24	-5.52	-0.33	8.56e-8	Monocyte count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03522510	chr10:63424588	C10orf107	-0.39	-6.62	-0.39	2.24e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4523957	0.620	rs9912385	chr17:2062591	T/G	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg07274523	chr3:49395745	GPX1	0.69	8.34	0.47	5.4e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.64	0.44	4.73e-13	Height;
KIRP	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13047869	chr3:10149882	C3orf24	0.57	5.56	0.33	7.15e-8	Alzheimer's disease;
KIRP	cis	rs7319311	0.565	rs9588148	chr13:111021081	G/T	cg06243866	chr13:111019493	COL4A2	0.55	6.32	0.37	1.2e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg00129232	chr17:37814104	STARD3	-0.45	-5.88	-0.35	1.36e-8	Self-reported allergy;
KIRP	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	8.88	0.49	1.42e-16	Retinal vascular caliber;
KIRP	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg15432903	chr11:17409602	KCNJ11	0.75	11.07	0.58	2.22e-23	Type 2 diabetes;
KIRP	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12560992	chr17:57184187	TRIM37	0.61	6.68	0.39	1.6e-10	Testicular germ cell tumor;
KIRP	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.62	0.73	4.4e-42	Breast cancer;
KIRP	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.17	0.67	1.01e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.06	0.36	4.96e-9	Lipoprotein (a) levels;
KIRP	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-13.11	-0.64	3.81e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.1	-0.41	1.31e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2562456	0.833	rs4644962	chr19:21520927	C/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.93	-0.3	1.49e-6	Pain;
KIRP	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.64	9.94	0.54	8.6e-20	Neuroticism;
KIRP	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg13334819	chr7:99746414	C7orf59	-0.55	-6.2	-0.37	2.33e-9	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19900371	chr14:53417241	FERMT2	0.48	6.34	0.37	1.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6662572	1.000	rs72688460	chr1:46111094	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.5	5.68	0.34	3.84e-8	Blood protein levels;
KIRP	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg19257562	chr1:2043853	PRKCZ	0.38	6.29	0.37	1.43e-9	Height;
KIRP	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.69	10.3	0.55	6.6e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg02475777	chr4:1388615	CRIPAK	0.53	5.0	0.3	1.09e-6	Recombination rate (females);
KIRP	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg06076350	chr7:157294107	NA	0.41	5.4	0.33	1.59e-7	Inattentive symptoms;
KIRP	cis	rs6539288	0.630	rs10778519	chr12:107357329	A/G	cg15890332	chr12:107067104	RFX4	0.33	5.21	0.31	4.09e-7	Total body bone mineral density;
KIRP	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.45	-0.38	5.92e-10	Joint mobility (Beighton score);
KIRP	cis	rs2717559	0.622	rs13255523	chr8:143887054	A/G	cg17252645	chr8:143867129	LY6D	-0.42	-7.22	-0.42	6.52e-12	Urinary tract infection frequency;
KIRP	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.0	14.87	0.69	4.08e-36	Orofacial clefts;
KIRP	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05601917	chr6:125855416	NA	0.34	4.9	0.3	1.7e-6	Endometrial cancer;
KIRP	cis	rs5753037	0.809	rs740041	chr22:30200099	A/G	cg01021169	chr22:30184971	ASCC2	-0.4	-4.95	-0.3	1.35e-6	Type 1 diabetes;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg18582965	chr2:241401686	GPC1	0.43	6.51	0.38	4.23e-10	Serum protein levels (sST2);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27552081	chr17:25621774	WSB1	0.63	7.54	0.43	8.86e-13	Smoking initiation;
KIRP	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-8.12	-0.46	2.31e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs838147	0.844	rs12611201	chr19:49248255	G/A	cg13540341	chr19:49222985	MAMSTR	0.35	5.63	0.34	4.86e-8	Dietary macronutrient intake;
KIRP	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg14343924	chr8:8086146	FLJ10661	0.42	4.88	0.3	1.87e-6	Mood instability;
KIRP	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12826209	chr6:26865740	GUSBL1	-0.64	-5.02	-0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs75920871	0.800	rs723953	chr11:116924978	A/C	cg23684410	chr11:116897558	SIK3	0.44	4.93	0.3	1.5e-6	Subjective well-being;
KIRP	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg26516362	chr5:178986906	RUFY1	0.47	8.35	0.47	5.02e-15	Lung cancer;
KIRP	cis	rs806215	1.000	rs712701	chr7:127251188	T/G	cg25922125	chr7:127225783	GCC1	0.46	5.0	0.3	1.1e-6	Type 2 diabetes;
KIRP	cis	rs4886920	0.894	rs7182697	chr15:78118624	G/T	cg10461261	chr15:78109450	NA	-0.34	-5.56	-0.33	7.01e-8	Neuroticism;
KIRP	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.47e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.5	5.15	0.31	5.39e-7	Smoking behavior;
KIRP	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.39	6.69	0.39	1.46e-10	Heart rate;
KIRP	cis	rs55882075	0.535	rs67484565	chr5:179110574	G/T	cg14593053	chr5:179126677	CANX	0.55	6.73	0.39	1.18e-10	Monocyte percentage of white cells;
KIRP	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg18944383	chr4:111397179	ENPEP	-0.71	-13.7	-0.66	3.91e-32	Coronary artery disease;
KIRP	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.66	-9.43	-0.52	3.23e-18	Colorectal cancer;
KIRP	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.79	9.94	0.54	8.83e-20	Mean platelet volume;
KIRP	cis	rs13424612	0.930	rs4149545	chr2:240942818	G/T	cg01812947	chr2:240904978	NDUFA10	0.5	6.34	0.37	1.09e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.89	-0.35	1.27e-8	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15754548	chr17:8192281	SLC25A35;RANGRF	0.58	7.51	0.43	1.09e-12	Parkinson's disease;
KIRP	cis	rs10518128	1.000	rs10011543	chr4:75711122	C/T	cg20122727	chr4:75719957	BTC	-0.52	-5.3	-0.32	2.52e-7	Electroencephalogram traits;
KIRP	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.81	0.4	7.64e-11	Bipolar disorder;
KIRP	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	7.32	0.42	3.52e-12	Menarche (age at onset);
KIRP	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg23601095	chr6:26197514	HIST1H3D	0.98	8.26	0.47	9.26e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs9900062	0.546	rs2676289	chr17:62705738	A/G	cg02097616	chr17:62675921	NA	-0.49	-6.01	-0.36	6.72e-9	QT interval;
KIRP	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.97	0.88	2.9e-81	Chronic sinus infection;
KIRP	cis	rs2219968	0.701	rs7015968	chr8:78995994	A/G	cg00738934	chr8:78996279	NA	0.42	5.64	0.34	4.69e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.69	6.85	0.4	5.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.63	7.58	0.44	6.99e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17067123	0.614	rs72712852	chr4:180066270	T/C	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg06636001	chr8:8085503	FLJ10661	0.61	8.24	0.47	1.04e-14	Joint mobility (Beighton score);
KIRP	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-5.18	-0.31	4.57e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.67	9.02	0.5	5.49e-17	Multiple sclerosis;
KIRP	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.47	-5.73	-0.34	2.93e-8	Refractive error;
KIRP	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.67	7.86	0.45	1.24e-13	Height;
KIRP	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02711726	chr17:80685570	FN3KRP	-0.51	-6.98	-0.41	2.79e-11	Glycated hemoglobin levels;
KIRP	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05776053	chr2:74358815	NA	0.64	6.51	0.38	4.23e-10	Gestational age at birth (maternal effect);
KIRP	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg05791153	chr7:19748676	TWISTNB	0.67	6.69	0.39	1.46e-10	Thyroid stimulating hormone;
KIRP	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg17554472	chr22:41940697	POLR3H	-0.43	-5.22	-0.32	3.74e-7	Neuroticism;
KIRP	cis	rs1978968	0.957	rs34486385	chr22:18444290	C/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs78487399	0.710	rs74382177	chr2:43528057	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-4.89	-0.3	1.79e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1978968	0.763	rs13055106	chr22:18465208	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.71	-8.82	-0.49	2.09e-16	Presence of antiphospholipid antibodies;
KIRP	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg26207909	chr14:103986467	CKB	0.42	4.89	0.3	1.85e-6	Monocyte count;
KIRP	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.59	-7.44	-0.43	1.65e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7534824	0.860	rs74591599	chr1:101604889	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	5.49	0.33	1.01e-7	Refractive astigmatism;
KIRP	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.99	9.11	0.5	2.86e-17	Post bronchodilator FEV1;
KIRP	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1950626	0.743	rs1956734	chr14:101399830	A/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.64	-7.1	-0.41	1.36e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg25319279	chr11:5960081	NA	-0.51	-5.08	-0.31	7.48e-7	DNA methylation (variation);
KIRP	cis	rs12145833	0.538	rs9803701	chr1:243391634	T/C	cg02356786	chr1:243265016	LOC731275	-0.72	-5.55	-0.33	7.46e-8	Obesity (early onset extreme);
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg23884241	chr7:27169957	HOXA4	-0.32	-5.14	-0.31	5.59e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.74	-10.15	-0.54	1.86e-20	Blood metabolite levels;
KIRP	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg05756136	chr1:119680316	WARS2	-0.61	-8.48	-0.48	2.18e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2637030	0.501	rs375956	chr5:52883715	C/G	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg04362960	chr10:104952993	NT5C2	0.61	7.12	0.41	1.16e-11	Arsenic metabolism;
KIRP	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	cg21523751	chr1:182988639	NA	0.34	4.96	0.3	1.35e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg11569703	chr11:65557185	OVOL1	0.55	9.03	0.5	5.27e-17	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg27165867	chr14:105738592	BRF1	-0.42	-4.96	-0.3	1.35e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg05585630	chr7:157510462	PTPRN2	-0.5	-6.63	-0.39	2.05e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.58	-5.01	-0.3	1.02e-6	Putamen volume;
KIRP	cis	rs397969	0.646	rs1638527	chr17:19845393	A/G	cg04132472	chr17:19861366	AKAP10	-0.56	-6.69	-0.39	1.53e-10	Platelet count;
KIRP	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg08648136	chr8:956695	NA	0.46	6.32	0.37	1.21e-9	Schizophrenia;
KIRP	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg03647239	chr10:116582469	FAM160B1	0.45	5.36	0.32	1.93e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	cg12689670	chr1:183009347	LAMC1	0.46	6.58	0.39	2.77e-10	Hypertriglyceridemia;
KIRP	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg08499158	chr17:42289980	UBTF	-0.64	-8.52	-0.48	1.58e-15	Total body bone mineral density;
KIRP	cis	rs1629083	0.967	rs73024604	chr11:118120351	C/T	cg18857871	chr11:118064634	AMICA1	0.63	8.52	0.48	1.65e-15	Lung cancer;
KIRP	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.75e-15	Aortic root size;
KIRP	cis	rs748404	0.560	rs2255663	chr15:43829008	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.53	-6.46	-0.38	5.47e-10	Lung cancer;
KIRP	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg14972814	chr11:95582409	MTMR2	0.36	6.1	0.36	4.14e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9693857	0.501	rs67985496	chr8:9263128	T/C	cg12253571	chr8:8283032	NA	0.4	4.85	0.3	2.2e-6	Systolic blood pressure;
KIRP	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.08	-0.36	4.68e-9	Myopia (pathological);
KIRP	cis	rs28489187	0.706	rs233069	chr1:85805466	C/T	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.79	-0.4	8.12e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.57	-5.22	-0.32	3.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-9.43	-0.52	3.26e-18	Response to antipsychotic treatment;
KIRP	cis	rs3096299	0.809	rs3096325	chr16:89421678	A/G	cg08822215	chr16:89438651	ANKRD11	-0.52	-6.83	-0.4	6.71e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.91	15.47	0.7	3.53e-38	Headache;
KIRP	cis	rs7084402	0.934	rs1658455	chr10:60306089	G/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg15655495	chr12:38532458	NA	0.27	5.0	0.3	1.08e-6	Bladder cancer;
KIRP	cis	rs77688320	0.535	rs1019299	chr2:202337730	A/G	cg06431681	chr2:202330990	STRADB	0.52	6.59	0.39	2.65e-10	Breast cancer;
KIRP	cis	rs4849845	0.889	rs4849846	chr2:121026891	T/C	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.37	-0.32	1.8e-7	Obesity-related traits;
KIRP	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.88	13.9	0.66	8.48e-33	Height;
KIRP	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs4938330	0.608	rs12418744	chr11:117084537	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.94	-0.3	1.44e-6	Blood protein levels;
KIRP	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg19507638	chr5:93509721	C5orf36	-0.61	-5.62	-0.34	5.27e-8	Diabetic retinopathy;
KIRP	trans	rs2856321	0.874	rs2856324	chr12:11876589	A/G	cg10155026	chr12:4553029	FGF6	0.42	6.04	0.36	5.65e-9	Height;
KIRP	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.98	14.12	0.67	1.43e-33	Platelet distribution width;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14457918	chr22:50608509	PANX2	-0.5	-6.8	-0.4	7.96e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7084402	0.967	rs1427222	chr10:60290970	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs3774830	0.533	rs3774846	chr4:5414131	C/T	cg26943120	chr4:5472116	STK32B	-0.25	-6.0	-0.36	6.95e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17065868	0.803	rs9595151	chr13:45126626	G/A	cg10246903	chr13:45222710	NA	0.53	5.73	0.34	2.88e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs12220238	0.915	rs10824197	chr10:76282793	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.34	0.37	1.1e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.27	-0.47	8.63e-15	Triglycerides;
KIRP	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg09914555	chr8:142094789	NA	0.44	6.04	0.36	5.59e-9	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg14092988	chr3:52407081	DNAH1	0.34	5.89	0.35	1.24e-8	Bipolar disorder;
KIRP	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg01689657	chr7:91764605	CYP51A1	0.33	4.9	0.3	1.71e-6	Breast cancer;
KIRP	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg02570527	chr1:10970165	NA	0.4	4.94	0.3	1.46e-6	Body mass index;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-4.92	-0.3	1.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.54	-7.64	-0.44	4.82e-13	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.43	5.64	0.34	4.7e-8	Motion sickness;
KIRP	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg04226714	chr8:49833948	SNAI2	-0.56	-7.72	-0.44	2.95e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg08975724	chr8:8085496	FLJ10661	0.53	6.58	0.39	2.81e-10	Neuroticism;
KIRP	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg14835575	chr10:16859367	RSU1	0.6	8.04	0.46	3.77e-14	Platelet distribution width;
KIRP	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg25753631	chr6:25732923	NA	0.25	5.01	0.3	1.03e-6	Iron status biomarkers;
KIRP	cis	rs7215564	0.908	rs8080789	chr17:78735202	A/G	cg06153925	chr17:78755379	RPTOR	-0.33	-5.71	-0.34	3.2e-8	Myopia (pathological);
KIRP	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.93	13.12	0.64	3.53e-30	Menopause (age at onset);
KIRP	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg26373071	chr5:1325741	CLPTM1L	0.57	7.5	0.43	1.19e-12	Lung cancer;
KIRP	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Colorectal cancer;
KIRP	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg19847130	chr8:10466454	RP1L1	-0.34	-4.85	-0.3	2.17e-6	Neuroticism;
KIRP	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs559928	0.502	rs4963223	chr11:64193418	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.47	5.03	0.31	9.47e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.8	9.18	0.5	1.87e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	1.34	11.3	0.58	3.99e-24	Sexual dysfunction (female);
KIRP	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.32	-5.39	-0.33	1.64e-7	Monocyte count;
KIRP	cis	rs4356975	0.545	rs62296944	chr4:69960210	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs2882667	0.822	rs13187096	chr5:138404088	C/A	cg04439458	chr5:138467593	SIL1	-0.51	-7.79	-0.44	1.85e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs5753037	0.585	rs5752962	chr22:30188245	A/C	cg01021169	chr22:30184971	ASCC2	-0.51	-7.2	-0.42	7.11e-12	Type 1 diabetes;
KIRP	cis	rs250677	0.524	rs183140	chr5:148438803	G/T	cg12140854	chr5:148520817	ABLIM3	-0.44	-5.67	-0.34	3.94e-8	Breast cancer;
KIRP	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	0.93	13.46	0.65	2.64e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8028182	0.636	rs7171507	chr15:75737287	T/C	cg20655648	chr15:75932815	IMP3	0.52	6.48	0.38	4.93e-10	Sudden cardiac arrest;
KIRP	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg17133734	chr15:86042851	AKAP13	-0.48	-5.97	-0.36	8.23e-9	Coronary artery disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg27431859	chr19:531042	CDC34	0.69	6.14	0.36	3.24e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg07395648	chr5:131743802	NA	-0.36	-4.94	-0.3	1.45e-6	Blood metabolite levels;
KIRP	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg16512390	chr1:228756714	NA	0.74	6.02	0.36	6.23e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg06740227	chr12:86229804	RASSF9	0.42	5.2	0.31	4.15e-7	Major depressive disorder;
KIRP	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.39	0.32	1.68e-7	Initial pursuit acceleration;
KIRP	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs2249694	0.960	rs4556495	chr10:135422209	C/T	cg20169779	chr10:135381914	SYCE1	-0.41	-4.88	-0.3	1.95e-6	Obesity-related traits;
KIRP	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg12435725	chr3:58293450	RPP14	-0.45	-5.11	-0.31	6.35e-7	Cholesterol, total;
KIRP	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.8	0.4	7.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9361491	0.508	rs7773448	chr6:79417356	C/T	cg11833968	chr6:79620685	NA	-0.36	-5.03	-0.31	9.43e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.02	-10.85	-0.57	1.18e-22	Alzheimer's disease;
KIRP	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg11752832	chr7:134001865	SLC35B4	0.43	4.91	0.3	1.64e-6	Mean platelet volume;
KIRP	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.72	9.15	0.5	2.28e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4845459	0.967	rs4845452	chr1:152591647	A/G	cg07796016	chr1:152779584	LCE1C	-0.49	-6.0	-0.36	7.03e-9	Psoriasis;
KIRP	cis	rs61884328	0.852	rs17790306	chr11:47089690	C/T	cg23433285	chr11:47201945	PACSIN3	0.79	6.35	0.38	1.04e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg05315796	chr3:52349193	DNAH1	-0.39	-5.13	-0.31	5.83e-7	Schizophrenia;
KIRP	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg04058563	chr4:185651563	MLF1IP	-0.5	-6.94	-0.4	3.54e-11	Kawasaki disease;
KIRP	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg13482628	chr17:19912719	NA	0.68	10.34	0.55	4.76e-21	Schizophrenia;
KIRP	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	cis	rs4594175	0.926	rs4901084	chr14:51634131	G/A	cg23942311	chr14:51606299	NA	0.53	7.12	0.41	1.2e-11	Cancer;
KIRP	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.47	-6.09	-0.36	4.37e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.34	0.37	1.11e-9	Aortic root size;
KIRP	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.45	5.66	0.34	4.21e-8	Platelet count;
KIRP	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06481639	chr22:41940642	POLR3H	0.43	5.11	0.31	6.57e-7	Vitiligo;
KIRP	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg18657303	chr4:1051139	NA	-0.54	-4.9	-0.3	1.71e-6	Recombination rate (females);
KIRP	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg04166393	chr7:2884313	GNA12	0.48	6.19	0.37	2.51e-9	Height;
KIRP	cis	rs28834970	0.925	rs6987305	chr8:27208126	G/A	cg23693289	chr8:27183097	PTK2B	-0.45	-5.6	-0.34	5.62e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg08662619	chr6:150070041	PCMT1	0.37	6.02	0.36	6.4e-9	Lung cancer;
KIRP	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg16083429	chr3:49237500	CCDC36	-0.39	-4.98	-0.3	1.22e-6	Menarche (age at onset);
KIRP	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.62	-6.96	-0.41	3.12e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-1.03	-9.49	-0.52	2.15e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg11214544	chr1:2391121	NA	-0.49	-5.2	-0.31	4.15e-7	Non-obstructive azoospermia;
KIRP	cis	rs17539620	0.808	rs6904264	chr6:154878380	C/G	cg20019720	chr6:154832845	CNKSR3	-0.34	-5.32	-0.32	2.39e-7	Lipoprotein (a) levels;
KIRP	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.5	7.02	0.41	2.16e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.37	0.43	2.62e-12	Lymphocyte counts;
KIRP	cis	rs33912345	0.750	rs28543014	chr14:60985004	C/T	cg27398547	chr14:60952738	C14orf39	0.38	4.98	0.3	1.19e-6	Glaucoma (high intraocular pressure);
KIRP	cis	rs7615316	0.902	rs6770155	chr3:142308691	A/G	cg20824294	chr3:142316082	PLS1	0.23	5.0	0.3	1.09e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg23594656	chr7:65796392	TPST1	0.37	5.33	0.32	2.27e-7	Aortic root size;
KIRP	cis	rs9815354	1.000	rs9846634	chr3:41894049	G/A	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.91	13.16	0.64	2.72e-30	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs12580194	0.593	rs11171431	chr12:55757609	G/T	cg19537932	chr12:55886519	OR6C68	-0.47	-6.22	-0.37	2.12e-9	Cancer;
KIRP	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-16.64	-0.73	3.6e-42	Height;
KIRP	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	0.54	6.59	0.39	2.71e-10	Prudent dietary pattern;
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg04804543	chr8:142233427	SLC45A4	1.02	16.98	0.73	2.45e-43	Immature fraction of reticulocytes;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	1.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1865760	0.929	rs9461224	chr6:25936402	G/T	cg16482183	chr6:26056742	HIST1H1C	0.42	5.29	0.32	2.74e-7	Height;
KIRP	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	0.74	10.25	0.55	9.31e-21	Verbal declarative memory;
KIRP	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.37	1.98e-9	Aortic root size;
KIRP	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.33	-5.14	-0.31	5.54e-7	Blood metabolite levels;
KIRP	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg22852734	chr6:133119734	C6orf192	0.98	7.14	0.41	1.07e-11	Type 2 diabetes nephropathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00117825	chr1:57004017	PPAP2B	0.52	6.66	0.39	1.75e-10	Interleukin-4 levels;
KIRP	cis	rs7188697	0.885	rs246194	chr16:58573901	G/A	cg21335942	chr16:58549945	SETD6	0.46	5.11	0.31	6.47e-7	QT interval;
KIRP	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.38	5.16	0.31	5.1e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7215564	0.730	rs1125587	chr17:78581696	A/G	cg06153925	chr17:78755379	RPTOR	0.33	5.39	0.32	1.66e-7	Myopia (pathological);
KIRP	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05472934	chr7:22766657	IL6	0.81	10.34	0.55	4.95e-21	Lung cancer;
KIRP	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.11e-7	Breast cancer;
KIRP	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.85	-0.35	1.55e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6499755	0.932	rs9302665	chr16:55340567	C/G	cg05099576	chr16:55362342	IRX6	-0.28	-5.74	-0.34	2.71e-8	Hypospadias;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06626759	chr14:36009109	RALGAPA1	0.4	6.23	0.37	2.06e-9	C-reactive protein;
KIRP	trans	rs1424233	0.875	rs12448419	chr16:79680195	C/G	cg11120865	chr14:21853037	SUPT16H	0.38	6.27	0.37	1.62e-9	Obesity;
KIRP	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.59	0.39	2.67e-10	Educational attainment;
KIRP	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg19197139	chr17:4613644	ARRB2	0.76	7.78	0.44	1.98e-13	Lymphocyte counts;
KIRP	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	cis	rs3736594	0.513	rs6751087	chr2:27778016	T/C	cg27432699	chr2:27873401	GPN1	0.58	6.35	0.38	1.06e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17467752	chr17:38218738	THRA	-0.54	-6.81	-0.4	7.44e-11	White blood cell count;
KIRP	trans	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg10241871	chr14:102965420	TECPR2	-0.55	-6.28	-0.37	1.55e-9	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.89	-0.35	1.3e-8	Parkinson's disease;
KIRP	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.9	-0.35	1.2e-8	Fear of minor pain;
KIRP	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.58	10.63	0.56	5.91e-22	Bone mineral density;
KIRP	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg26665480	chr2:98280029	ACTR1B	-0.59	-5.09	-0.31	7.1e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9986765	0.881	rs73452602	chr7:142828331	A/T	cg11323483	chr7:142828068	PIP	-0.54	-4.98	-0.3	1.2e-6	Cancer;Dermatomyositis;
KIRP	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00149659	chr3:10157352	C3orf10	-0.56	-6.57	-0.39	2.92e-10	Alzheimer's disease;
KIRP	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03647317	chr4:187891568	NA	-0.79	-13.24	-0.65	1.43e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12752838	0.730	rs6661010	chr1:8910542	C/T	cg06972019	chr1:8937448	ENO1	-0.33	-4.96	-0.3	1.32e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs748404	0.518	rs2927085	chr15:43989530	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.36	0.38	9.67e-10	Lung cancer;
KIRP	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg12658694	chr1:38397304	INPP5B	0.63	8.2	0.46	1.35e-14	Coronary artery disease;
KIRP	cis	rs9815354	1.000	rs17063584	chr3:41861463	A/G	cg03022575	chr3:42003672	ULK4	0.6	6.9	0.4	4.36e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg23752985	chr2:85803571	VAMP8	0.59	8.51	0.48	1.72e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.68	9.05	0.5	4.35e-17	Coronary artery disease;
KIRP	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.73	-9.9	-0.53	1.16e-19	Personality dimensions;
KIRP	trans	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.51	0.43	1.08e-12	Diabetic kidney disease;
KIRP	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	cis	rs12693043	0.790	rs2033310	chr2:175409060	A/C	cg11778734	chr2:175439522	WIPF1	-0.54	-7.55	-0.43	8.25e-13	Urate levels (BMI interaction);
KIRP	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg06042504	chr8:55087323	NA	-0.53	-6.31	-0.37	1.32e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg21684588	chr1:67600265	NA	0.56	5.98	0.36	7.66e-9	Psoriasis;
KIRP	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg05347473	chr6:146136440	FBXO30	-0.62	-9.15	-0.5	2.21e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7903847	0.620	rs9787454	chr10:99155561	A/T	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg23307798	chr14:103986281	CKB	-0.37	-5.04	-0.31	8.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17023223	0.537	rs6662165	chr1:119614071	T/G	cg18261050	chr1:119551319	NA	0.55	7.18	0.42	8.21e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg00553149	chr7:99775558	STAG3;GPC2	-0.42	-5.01	-0.3	1.04e-6	Coronary artery disease;
KIRP	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg04672837	chr16:48644449	N4BP1	0.51	7.1	0.41	1.3e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.53	7.12	0.41	1.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.44	5.77	0.35	2.36e-8	Blood metabolite levels;
KIRP	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.26	-0.47	8.97e-15	Response to antipsychotic treatment;
KIRP	cis	rs1847505	0.693	rs7989616	chr13:61587706	G/A	cg25164009	chr13:61490935	NA	-0.58	-6.93	-0.4	3.57e-11	Polychlorinated biphenyl levels;
KIRP	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.74	-0.34	2.8e-8	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02956372	chr4:967467	DGKQ	0.6	7.87	0.45	1.11e-13	Parkinson's disease;
KIRP	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	6.33	0.37	1.17e-9	Menopause (age at onset);
KIRP	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg14650228	chr8:144573510	ZC3H3	-0.7	-4.96	-0.3	1.31e-6	Attention deficit hyperactivity disorder;
KIRP	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.47	-0.56	1.9e-21	Triglycerides;
KIRP	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg09455208	chr3:40491958	NA	-0.38	-7.02	-0.41	2.19e-11	Renal cell carcinoma;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02745719	chr5:112251076	REEP5	-0.49	-6.83	-0.4	6.77e-11	Select biomarker traits;
KIRP	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.63	7.14	0.41	1.03e-11	Aortic root size;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02457644	chr19:36245325	LIN37	0.52	6.16	0.37	2.97e-9	Interleukin-4 levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24250450	chr4:40058375	N4BP2;LOC344967	-0.46	-6.2	-0.37	2.36e-9	Metabolic traits;
KIRP	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg18477163	chr1:228402036	OBSCN	0.48	5.01	0.3	1.06e-6	Major depressive disorder;
KIRP	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.68	-7.93	-0.45	7.47e-14	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg26875233	chr11:93583750	C11orf90	-0.36	-6.66	-0.39	1.75e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.49	-7.47	-0.43	1.44e-12	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg02972257	chr16:68554789	NA	0.5	4.92	0.3	1.6e-6	Colorectal cancer;
KIRP	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg19610905	chr11:61596333	FADS2	-0.68	-6.69	-0.39	1.52e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.59	-0.48	1.04e-15	Response to antipsychotic treatment;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24809958	chr1:6662478	KLHL21	0.53	6.03	0.36	6.05e-9	Smoking initiation;
KIRP	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.74	-9.38	-0.51	4.43e-18	Aortic root size;
KIRP	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.9	-0.71	1.23e-39	Chronic sinus infection;
KIRP	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg11995313	chr8:8860691	ERI1	0.41	5.4	0.33	1.54e-7	Joint mobility (Beighton score);
KIRP	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.42	-7.37	-0.43	2.56e-12	Refractive error;
KIRP	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg10434728	chr15:90938212	IQGAP1	0.42	7.31	0.42	3.76e-12	Rheumatoid arthritis;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg03188948	chr7:1209495	NA	0.46	5.22	0.32	3.85e-7	Longevity;Endometriosis;
KIRP	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg12435725	chr3:58293450	RPP14	-0.5	-5.43	-0.33	1.36e-7	Cholesterol, total;
KIRP	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.84	-0.45	1.39e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	0.76	6.92	0.4	3.87e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.45	-5.29	-0.32	2.76e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6681460	1.000	rs6656550	chr1:67122552	C/T	cg02459107	chr1:67143332	SGIP1	0.51	7.24	0.42	5.64e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs73416724	0.544	rs80320191	chr6:43238395	C/T	cg02694972	chr6:43249501	TTBK1	-0.56	-4.91	-0.3	1.64e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs71636778	0.543	rs10493037	chr1:27248645	A/G	cg12203394	chr1:27248618	NUDC	0.61	5.37	0.32	1.82e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.94	-13.13	-0.64	3.29e-30	Cognitive function;
KIRP	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.2	-0.31	4.11e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg09571762	chr12:39539558	NA	-0.34	-5.01	-0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs12444156	1	rs12444156	chr16:71841257	C/T	cg08717414	chr16:71523259	ZNF19	-0.98	-8.39	-0.47	3.8e-15	Post bronchodilator FEV1;
KIRP	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg21419209	chr3:44054225	NA	-0.74	-9.23	-0.51	1.31e-17	Coronary artery disease;
KIRP	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg12207922	chr5:74063060	GFM2;NSA2	-0.43	-6.03	-0.36	5.86e-9	Warfarin maintenance dose;
KIRP	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg24253500	chr15:84953950	NA	0.61	6.62	0.39	2.28e-10	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62355272	0.965	rs10067863	chr5:35832177	A/G	cg13894535	chr5:35919491	CAPSL	-0.4	-5.09	-0.31	7.03e-7	Lymphocyte counts;
KIRP	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.72	-0.34	3.13e-8	Bipolar disorder;
KIRP	cis	rs867371	1.000	rs4778982	chr15:82475272	T/G	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7113850	0.541	rs11826483	chr11:24237730	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.41	0.47	3.28e-15	Bone fracture in osteoporosis;
KIRP	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	1.07	17.7	0.75	8.89e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.43	0.38	6.58e-10	Aortic root size;
KIRP	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	cis	rs412050	0.594	rs113463481	chr22:22097230	G/A	cg17089214	chr22:22089827	YPEL1	0.69	6.67	0.39	1.64e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg16006841	chr5:176797999	RGS14	0.82	10.41	0.55	2.96e-21	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs1883415	0.534	rs2253794	chr6:24479642	C/A	cg20631270	chr6:24437470	GPLD1	0.39	4.99	0.3	1.13e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2594989	0.733	rs2616539	chr3:11580371	C/A	cg02538783	chr10:35102505	PARD3	-0.32	-6.07	-0.36	4.92e-9	Circulating chemerin levels;
KIRP	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.49	-0.33	9.99e-8	Pulmonary function;
KIRP	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg19338460	chr6:170058176	WDR27	-0.64	-7.56	-0.43	8.19e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg00484396	chr16:3507460	NAT15	0.54	5.71	0.34	3.31e-8	Tuberculosis;
KIRP	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.8	10.73	0.56	2.75e-22	Platelet count;
KIRP	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.61	7.77	0.44	2.11e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg10505658	chr17:80084571	CCDC57	-0.28	-5.17	-0.31	4.95e-7	Life satisfaction;
KIRP	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.01	-0.3	1.06e-6	Bladder cancer;
KIRP	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.64	7.43	0.43	1.82e-12	Height;
KIRP	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.92	-8.56	-0.48	1.21e-15	Rheumatoid arthritis;
KIRP	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg24289452	chr6:170231220	NA	-0.74	-4.86	-0.3	2.07e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg06647332	chr5:131281008	NA	-0.45	-4.96	-0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17554472	chr22:41940697	POLR3H	-0.67	-6.86	-0.4	5.54e-11	Vitiligo;
KIRP	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg11410718	chr7:27170412	HOXA4	-0.36	-5.31	-0.32	2.41e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.4	0.47	3.67e-15	Motion sickness;
KIRP	cis	rs6009824	0.891	rs11090995	chr22:50085210	G/A	cg18178197	chr22:50098317	NA	0.63	7.21	0.42	6.75e-12	Natriuretic peptide levels;
KIRP	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.61	7.05	0.41	1.76e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4356932	1.000	rs7699624	chr4:76962631	G/T	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06028808	chr11:68637592	NA	-0.65	-7.84	-0.45	1.39e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs2224391	0.628	rs9504365	chr6:5256116	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.52	-0.38	4.06e-10	Height;
KIRP	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.37	-5.29	-0.32	2.76e-7	Coronary artery disease;
KIRP	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg05044414	chr3:183734942	ABCC5	0.38	5.8	0.35	2.07e-8	Anterior chamber depth;
KIRP	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	cis	rs8070740	0.579	rs28429022	chr17:5354471	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.19	0.37	2.44e-9	Menopause (age at onset);
KIRP	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.5	7.28	0.42	4.39e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg05717871	chr11:638507	DRD4	-0.38	-5.49	-0.33	1.02e-7	Systemic lupus erythematosus;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg05370193	chr1:21551575	ECE1	0.42	5.97	0.36	8.41e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18110333	chr6:292329	DUSP22	-0.61	-7.1	-0.41	1.35e-11	Menopause (age at onset);
KIRP	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg03340356	chr1:67600835	NA	0.4	4.93	0.3	1.48e-6	Psoriasis;
KIRP	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11987759	chr7:65425863	GUSB	-0.63	-8.48	-0.48	2.07e-15	Aortic root size;
KIRP	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.3	13.35	0.65	6.19e-31	Diabetic retinopathy;
KIRP	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg23682824	chr7:23144976	KLHL7	0.55	6.79	0.4	8.46e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7404928	1.000	rs3785396	chr16:23903156	G/T	cg21745164	chr16:23765304	CHP2	-0.36	-5.27	-0.32	2.96e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08305263	chr15:38764405	FAM98B	-0.42	-6.43	-0.38	6.59e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs290268	0.669	rs10448310	chr9:93556174	A/G	cg02608019	chr9:93564028	SYK	0.68	9.04	0.5	4.75e-17	Platelet count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg24786176	chr4:113153431	AP1AR	0.53	7.04	0.41	1.85e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00531823	chr4:77870745	SEPT11	0.58	7.28	0.42	4.45e-12	Parkinson's disease;
KIRP	cis	rs12823128	0.766	rs34606914	chr12:26927054	A/C	cg14081884	chr12:26986758	ITPR2	0.39	4.9	0.3	1.76e-6	Birth weight;
KIRP	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.27	-0.32	2.94e-7	Total body bone mineral density;
KIRP	trans	rs6601327	0.670	rs6601338	chr8:9438928	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.17	0.42	8.86e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.98	14.09	0.67	1.86e-33	Cognitive function;
KIRP	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	9.94	0.54	8.46e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs4073221	0.654	rs56267653	chr3:18271910	T/C	cg07694806	chr3:18168406	NA	-0.68	-6.04	-0.36	5.67e-9	Parkinson's disease;
KIRP	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg26138937	chr11:71823887	C11orf51	-1.04	-7.1	-0.41	1.3e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.47	-5.74	-0.34	2.71e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.78	10.61	0.56	6.5e-22	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-8.54	-0.48	1.46e-15	Cognitive function;
KIRP	cis	rs6987853	0.787	rs10958722	chr8:42425487	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.37	0.32	1.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs12620999	0.774	rs6711726	chr2:238101795	C/T	cg23555395	chr2:238036564	NA	-0.42	-5.1	-0.31	6.82e-7	Systemic lupus erythematosus;
KIRP	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.55	-6.29	-0.37	1.48e-9	Diabetic retinopathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18783160	chr5:78100628	ARSB	0.5	6.08	0.36	4.6e-9	Interleukin-4 levels;
KIRP	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	5.27	0.32	2.93e-7	Renal cell carcinoma;
KIRP	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.39	-4.86	-0.3	2.08e-6	Carotid intima media thickness;
KIRP	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.5	-6.44	-0.38	6.1e-10	QT interval;
KIRP	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.31	-0.42	3.68e-12	Alzheimer's disease (late onset);
KIRP	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg01028140	chr2:1542097	TPO	-0.51	-5.84	-0.35	1.65e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4774899	1.000	rs2116066	chr15:57254778	A/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.12	-0.31	6.27e-7	Urinary tract infection frequency;
KIRP	cis	rs1018697	1.000	rs4919677	chr10:104554304	G/A	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	trans	rs9944715	0.954	rs4890317	chr18:43770510	A/G	cg01718231	chr17:29326311	RNF135	-0.51	-6.07	-0.36	4.85e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs58688157	0.960	rs34449380	chr11:617221	T/G	cg02461776	chr11:598696	PHRF1	0.52	5.48	0.33	1.05e-7	Systemic lupus erythematosus;
KIRP	cis	rs1215050	0.904	rs1727285	chr4:98978821	G/A	cg17366294	chr4:99064904	C4orf37	-0.38	-4.98	-0.3	1.17e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg05973401	chr12:123451056	ABCB9	0.5	5.4	0.33	1.58e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.54	7.26	0.42	4.99e-12	Blood metabolite levels;
KIRP	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	9.41	0.51	3.67e-18	Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4262150	0.727	rs6876403	chr5:151929221	A/G	cg12297329	chr5:152029980	NA	-0.59	-7.42	-0.43	1.93e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.82	8.1	0.46	2.62e-14	Lung function (FEV1/FVC);
KIRP	cis	rs9815354	1.000	rs9869282	chr3:41756064	A/G	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.33e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.69	10.19	0.54	1.48e-20	Dupuytren's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15367021	chr18:30050896	FAM59A	0.46	6.02	0.36	6.21e-9	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.85	-0.63	3.04e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.46	5.72	0.34	3.03e-8	Asthma;
KIRP	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg20169779	chr10:135381914	SYCE1	-0.41	-4.9	-0.3	1.71e-6	Obesity-related traits;
KIRP	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg01721255	chr8:58191610	C8orf71	0.48	5.18	0.31	4.69e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	9.11e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17384381	1.000	rs1608536	chr1:85885836	C/T	cg16011679	chr1:85725395	C1orf52	0.82	8.04	0.46	3.71e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.5	6.72	0.39	1.23e-10	Breast cancer;
KIRP	trans	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg11693508	chr17:37793320	STARD3	0.8	8.04	0.46	3.88e-14	Neuroticism;
KIRP	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-0.82	-8.95	-0.5	9.14e-17	Post bronchodilator FEV1;
KIRP	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg05775895	chr3:12838266	CAND2	0.46	7.59	0.44	6.73e-13	QRS complex (12-leadsum);
KIRP	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	8.65	0.48	6.67e-16	Mean corpuscular hemoglobin;
KIRP	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.69	-7.16	-0.42	9.32e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.78	9.21	0.51	1.46e-17	Mean platelet volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17885579	chr8:59572218	NSMAF	0.53	7.87	0.45	1.16e-13	Survival in pancreatic cancer;
KIRP	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg02660097	chr11:68866761	NA	0.38	5.27	0.32	2.98e-7	Blond vs. brown hair color;
KIRP	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	14.43	0.68	1.31e-34	Gut microbiome composition (summer);
KIRP	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.54	-0.38	3.52e-10	Morning vs. evening chronotype;
KIRP	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.4	-5.32	-0.32	2.33e-7	Blood protein levels;
KIRP	cis	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	4.95	0.3	1.39e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4722404	0.556	rs765728	chr7:3153564	A/G	cg19214707	chr7:3157722	NA	-0.43	-5.5	-0.33	9.38e-8	Atopic dermatitis;
KIRP	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.85	11.17	0.58	1.1e-23	Monocyte count;
KIRP	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs7113850	0.541	rs74702708	chr11:24226866	T/C	ch.11.24196551F	chr11:24239977	NA	0.94	7.74	0.44	2.65e-13	Bone fracture in osteoporosis;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg07511934	chr16:89386912	ANKRD11	0.42	5.38	0.32	1.7e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.19	-0.46	1.4e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17031493	chr1:186343755	C1orf27;TPR;MIR548F1	0.43	6.29	0.37	1.45e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.54	6.37	0.38	9.03e-10	Dialysis-related mortality;
KIRP	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg09873164	chr1:152488093	CRCT1	-0.56	-7.11	-0.41	1.24e-11	Hair morphology;
KIRP	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.84	-0.45	1.39e-13	Tonsillectomy;
KIRP	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.95	-16.06	-0.72	3.57e-40	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09011746	chr16:71316773	FTSJD1	0.45	6.64	0.39	2.01e-10	Interleukin-4 levels;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.36	5.09	0.31	6.99e-7	Vitiligo;
KIRP	cis	rs1190552	0.841	rs56144019	chr14:102949731	G/A	cg10241871	chr14:102965420	TECPR2	-0.53	-6.13	-0.36	3.4e-9	Blood protein levels;
KIRP	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.91	15.74	0.71	4.27e-39	Headache;
KIRP	cis	rs757081	0.667	rs214933	chr11:17194584	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-4.86	-0.3	2.1e-6	Systolic blood pressure;
KIRP	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	5.18	0.31	4.69e-7	Schizophrenia;
KIRP	cis	rs4780401	0.703	rs7193637	chr16:11764920	C/T	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.2	-0.31	4.12e-7	Rheumatoid arthritis;
KIRP	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg02153584	chr22:29168773	CCDC117	0.48	5.2	0.31	4.12e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	7.63	0.44	5.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10782582	0.609	rs5745485	chr1:76349534	C/G	cg10523679	chr1:76189770	ACADM	-0.46	-6.38	-0.38	8.87e-10	Daytime sleep phenotypes;
KIRP	cis	rs7709377	0.597	rs10051072	chr5:115488499	C/T	cg23108291	chr5:115420582	COMMD10	0.43	5.24	0.32	3.45e-7	Metabolite levels  (X-11787);
KIRP	cis	rs2204008	0.630	rs7314669	chr12:38203602	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-5.7	-0.34	3.35e-8	Bladder cancer;
KIRP	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.86	-0.4	5.63e-11	Aortic root size;
KIRP	cis	rs7919006	0.793	rs11816422	chr10:76765477	G/C	cg01390419	chr10:76803856	DUPD1	0.52	5.84	0.35	1.69e-8	Weight;
KIRP	cis	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg19847130	chr8:10466454	RP1L1	0.34	5.16	0.31	5.19e-7	Morning vs. evening chronotype;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04929736	chr8:27472395	CLU	0.47	6.2	0.37	2.36e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs687432	0.924	rs66813766	chr11:57698254	G/T	cg19752551	chr11:57585705	CTNND1	-0.72	-9.49	-0.52	2.08e-18	Parkinson's disease;
KIRP	cis	rs860295	0.702	rs12081067	chr1:155358982	A/G	cg02153340	chr1:155202674	NA	-0.55	-7.45	-0.43	1.56e-12	Body mass index;
KIRP	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.35	-0.32	2.06e-7	Schizophrenia;
KIRP	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg05304507	chr6:116381966	FRK	0.21	5.6	0.34	5.64e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13198984	chr17:80129470	CCDC57	0.58	8.68	0.48	5.38e-16	Life satisfaction;
KIRP	cis	rs7213347	0.780	rs7209564	chr17:2168233	C/T	cg15816464	chr17:2026533	SMG6	0.34	4.89	0.3	1.83e-6	Total body bone mineral density;
KIRP	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	0.81	7.09	0.41	1.39e-11	Obesity-related traits;
KIRP	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg13147721	chr7:65941812	NA	-1.03	-6.94	-0.4	3.39e-11	Gout;
KIRP	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	cg21523751	chr1:182988639	NA	0.41	6.36	0.38	9.61e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.64	8.84	0.49	1.92e-16	Longevity;Endometriosis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13984515	chr1:86046961	CYR61	-0.46	-6.15	-0.37	3.06e-9	Metabolic traits;
KIRP	trans	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg16141378	chr3:129829833	LOC729375	0.47	6.13	0.36	3.45e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.92	-11.74	-0.6	1.48e-25	Monocyte percentage of white cells;
KIRP	cis	rs4791746	1.000	rs2101939	chr17:8620648	A/G	cg03115937	chr17:8649504	CCDC42	-0.5	-6.43	-0.38	6.49e-10	Heroin dependence;
KIRP	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.33	-0.7	1.09e-37	Headache;
KIRP	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-7.55	-0.43	8.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg06740227	chr12:86229804	RASSF9	0.41	5.25	0.32	3.22e-7	Major depressive disorder;
KIRP	cis	rs4690686	0.538	rs6855882	chr4:177261061	T/G	cg17059388	chr4:177262070	NA	0.85	11.58	0.59	4.73e-25	Essential tremor;
KIRP	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.74	-0.44	2.56e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg18209359	chr17:80159595	CCDC57	0.38	5.03	0.31	9.43e-7	Life satisfaction;
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg04025307	chr7:1156635	C7orf50	0.54	7.61	0.44	5.88e-13	Longevity;Endometriosis;
KIRP	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg23625390	chr15:77176239	SCAPER	0.52	7.15	0.41	9.88e-12	Blood metabolite levels;
KIRP	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.58	-0.48	1.07e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12143943	0.866	rs3789051	chr1:204494436	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.43	-0.38	6.64e-10	Cognitive performance;
KIRP	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.64	-8.27	-0.47	8.7e-15	Prudent dietary pattern;
KIRP	cis	rs6681460	0.837	rs6669023	chr1:67171868	G/T	cg02459107	chr1:67143332	SGIP1	0.39	5.66	0.34	4.16e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs9790314	0.613	rs56665329	chr3:160590858	T/A	cg19274270	chr17:78178856	CARD14	0.35	6.02	0.36	6.38e-9	Morning vs. evening chronotype;
KIRP	cis	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg12315302	chr6:26189340	HIST1H4D	0.97	5.81	0.35	1.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs11644362	0.903	rs2014726	chr16:12992849	T/C	cg06890432	chr16:12997467	SHISA9	-0.41	-6.45	-0.38	6e-10	Positive affect;Subjective well-being;
KIRP	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.05e-8	Common traits (Other);
KIRP	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.87	13.84	0.66	1.31e-32	Blood protein levels;
KIRP	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	0.85	7.43	0.43	1.74e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-4.86	-0.3	2.11e-6	Schizophrenia;
KIRP	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg22117172	chr7:91764530	CYP51A1	0.47	6.53	0.38	3.64e-10	Breast cancer;
KIRP	cis	rs10267417	0.603	rs7796434	chr7:19945825	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	5.24	0.32	3.43e-7	Night sleep phenotypes;
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-7.19	-0.42	7.62e-12	Platelet count;
KIRP	cis	rs300890	1.000	rs300904	chr4:144239825	C/T	cg19876092	chr4:144208277	NA	-0.45	-7.38	-0.43	2.46e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg16590910	chr6:42928470	GNMT	0.42	5.9	0.35	1.17e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs865483	0.860	rs860468	chr17:35793286	G/C	cg06716730	chr17:35851459	DUSP14	0.25	5.99	0.36	7.52e-9	Monocyte count;
KIRP	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12893428	chr3:195717962	SDHAP1	0.42	5.21	0.32	4.03e-7	Pancreatic cancer;
KIRP	trans	rs7786808	0.552	rs35809824	chr7:158185067	C/T	cg02030672	chr11:45687055	CHST1	0.64	8.27	0.47	8.41e-15	Obesity-related traits;
KIRP	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.53	7.91	0.45	8.52e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg23625390	chr15:77176239	SCAPER	-0.52	-6.87	-0.4	5.18e-11	Blood metabolite levels;
KIRP	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.55	7.56	0.43	8.21e-13	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22373415	chr15:66996361	SMAD6	0.46	6.04	0.36	5.68e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.63	-7.91	-0.45	8.97e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs5747327	0.775	rs5747308	chr22:18133500	A/C	cg19898043	chr22:18121309	BCL2L13	-0.42	-4.97	-0.3	1.24e-6	Myeloid white cell count;Granulocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16624187	chr3:139108582	COPB2	0.5	6.11	0.36	3.97e-9	Parkinson's disease;
KIRP	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs2411233	0.967	rs7169140	chr15:39271265	G/A	cg02291532	chr15:39874776	THBS1	0.4	5.42	0.33	1.39e-7	Platelet count;
KIRP	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.6	-6.91	-0.4	4.15e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13198984	chr17:80129470	CCDC57	0.57	8.63	0.48	8e-16	Life satisfaction;
KIRP	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.57	-6.42	-0.38	7.01e-10	Iron status biomarkers;
KIRP	cis	rs1823913	0.614	rs6755243	chr2:192134536	A/G	cg12404831	chr2:192114017	MYO1B	-0.47	-6.31	-0.37	1.28e-9	Obesity-related traits;
KIRP	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.58	7.99	0.45	5.19e-14	Height;
KIRP	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.43	5.65	0.34	4.51e-8	Testicular germ cell tumor;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg18234130	chr8:27182889	PTK2B	0.56	7.24	0.42	5.71e-12	Neuroticism;
KIRP	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg23587288	chr2:27483067	SLC30A3	-0.59	-7.24	-0.42	5.69e-12	Blood metabolite levels;
KIRP	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg10189774	chr4:17578691	LAP3	0.47	5.6	0.34	5.6e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg05362011	chr13:21860987	NA	-0.5	-5.42	-0.33	1.44e-7	White matter hyperintensity burden;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg06268701	chr1:110091083	GNAI3	-0.47	-6.69	-0.39	1.51e-10	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11955175	1.000	rs73080591	chr5:40634687	T/C	cg17351974	chr5:40835760	RPL37	0.6	5.46	0.33	1.14e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	15.64	0.71	9.9e-39	Platelet count;
KIRP	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.86	10.73	0.56	2.78e-22	Coronary artery disease;
KIRP	cis	rs1538970	0.924	rs10890327	chr1:45891458	C/T	cg05343316	chr1:45956843	TESK2	0.71	8.03	0.46	4.02e-14	Platelet count;
KIRP	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.87	12.91	0.64	1.88e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg26695010	chr11:65641043	EFEMP2	0.51	5.1	0.31	6.88e-7	Crohn's disease;
KIRP	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.77	9.19	0.51	1.66e-17	Red cell distribution width;
KIRP	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg02487422	chr3:49467188	NICN1	0.45	5.78	0.35	2.26e-8	Resting heart rate;
KIRP	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21545522	chr1:205238299	TMCC2	0.5	6.56	0.39	3.21e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.57	-6.49	-0.38	4.62e-10	Menarche (age at onset);
KIRP	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg20090143	chr19:45452003	APOC2	0.34	5.42	0.33	1.41e-7	Blood protein levels;
KIRP	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg15556689	chr8:8085844	FLJ10661	0.65	8.32	0.47	6.14e-15	Retinal vascular caliber;
KIRP	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.83	11.92	0.61	3.61e-26	Coronary artery disease;
KIRP	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.65	6.13	0.36	3.41e-9	Gut microbiome composition (summer);
KIRP	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg20673841	chr7:107026890	COG5	0.41	5.13	0.31	6.02e-7	Coronary artery disease;
KIRP	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg18016565	chr1:150552671	MCL1	-0.49	-7.64	-0.44	4.8e-13	Tonsillectomy;
KIRP	trans	rs7980799	0.772	rs6488162	chr12:33593127	T/C	cg26384229	chr12:38710491	ALG10B	-0.57	-7.06	-0.41	1.66e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.91	11.19	0.58	9.28e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-9.78	-0.53	2.77e-19	Morning vs. evening chronotype;
KIRP	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.56	7.38	0.43	2.47e-12	Blood trace element (Cu levels);
KIRP	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.71	8.98	0.5	7.23e-17	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs1422110	0.774	rs1017200	chr5:85506455	G/A	cg01787110	chr1:109008453	NBPF6	0.68	8.16	0.46	1.7e-14	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg23736307	chr8:27182930	PTK2B	0.52	6.72	0.39	1.25e-10	Neuroticism;
KIRP	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg22903657	chr4:1355424	KIAA1530	-0.43	-6.16	-0.37	2.88e-9	Obesity-related traits;
KIRP	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.44	5.44	0.33	1.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.27	6.34	0.37	1.09e-9	IgG glycosylation;
KIRP	cis	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.34	-0.32	2.07e-7	Triglycerides;
KIRP	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg27205649	chr11:78285834	NARS2	0.69	9.1	0.5	3.17e-17	Alzheimer's disease (survival time);
KIRP	cis	rs7481584	0.962	rs756692	chr11:2973244	G/A	cg25174290	chr11:3078921	CARS	-0.54	-6.03	-0.36	5.89e-9	Calcium levels;
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.45	6.38	0.38	8.5e-10	Testicular germ cell tumor;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg09763865	chr1:36615143	TRAPPC3	-0.59	-6.06	-0.36	5.02e-9	Response to statin therapy;
KIRP	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg07274523	chr3:49395745	GPX1	0.56	5.14	0.31	5.69e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.46	-5.89	-0.35	1.27e-8	Retinal vascular caliber;
KIRP	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg23127183	chr11:57508653	C11orf31	0.46	6.25	0.37	1.83e-9	Schizophrenia;
KIRP	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg08533674	chr1:46993347	NA	0.41	5.2	0.31	4.29e-7	Monobrow;
KIRP	cis	rs12900413	0.687	rs62023459	chr15:90308231	A/T	cg24650279	chr15:90327240	NA	-0.41	-5.27	-0.32	2.93e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg21253087	chr9:139290292	SNAPC4	0.39	5.02	0.3	1.01e-6	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7520050	0.807	rs3013595	chr1:46153203	G/A	cg24296786	chr1:45957014	TESK2	-0.41	-5.11	-0.31	6.37e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.78	10.14	0.54	2.04e-20	Gestational age at birth (maternal effect);
KIRP	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg23950597	chr19:37808831	NA	0.62	6.66	0.39	1.81e-10	Coronary artery calcification;
KIRP	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg22117172	chr7:91764530	CYP51A1	0.43	6.1	0.36	3.98e-9	Breast cancer;
KIRP	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs1957429	0.520	rs230718	chr14:65318943	A/G	cg23373153	chr14:65346875	NA	-0.58	-4.92	-0.3	1.61e-6	Pediatric areal bone mineral density (radius);
KIRP	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.82	-0.49	2.16e-16	Neuroticism;
KIRP	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.58	-7.11	-0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.84	0.49	1.87e-16	Motion sickness;
KIRP	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.94	-0.61	3.24e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-5.78	-0.35	2.2e-8	Blood metabolite levels;
KIRP	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.78	10.64	0.56	5.33e-22	Coronary artery disease;
KIRP	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg11901034	chr3:128598214	ACAD9	-0.45	-5.61	-0.34	5.51e-8	IgG glycosylation;
KIRP	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg16482183	chr6:26056742	HIST1H1C	0.41	5.25	0.32	3.3e-7	Schizophrenia;
KIRP	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg24315340	chr6:146058215	EPM2A	-0.46	-5.8	-0.35	2.06e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.97	0.45	6.01e-14	Iron status biomarkers;
KIRP	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03605463	chr16:89740564	NA	0.59	7.7	0.44	3.28e-13	Vitiligo;
KIRP	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg24972876	chr7:65420302	NA	-0.4	-5.48	-0.33	1.05e-7	Aortic root size;
KIRP	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg23594656	chr7:65796392	TPST1	0.34	4.93	0.3	1.48e-6	Aortic root size;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg13906792	chr15:75199810	C15orf17	-0.37	-5.37	-0.32	1.8e-7	Breast cancer;
KIRP	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.49	5.98	0.36	7.99e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7940866	0.745	rs1368853	chr11:130866084	A/G	cg12179176	chr11:130786555	SNX19	0.63	7.32	0.42	3.48e-12	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01415527	chr19:1110591	SBNO2	0.44	6.13	0.36	3.54e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg22532475	chr10:104410764	TRIM8	-0.29	-5.02	-0.3	1e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6977660	0.714	rs6945753	chr7:19814255	A/G	cg07541023	chr7:19748670	TWISTNB	0.56	5.36	0.32	1.88e-7	Thyroid stimulating hormone;
KIRP	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg18850929	chr19:1828978	REXO1	0.45	5.3	0.32	2.62e-7	Bipolar disorder;
KIRP	cis	rs4704187	0.687	rs4447960	chr5:74361857	C/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	1.02	18.28	0.76	9.53e-48	Heart rate;
KIRP	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.77	9.31	0.51	7.4e-18	Response to antipsychotic treatment;
KIRP	cis	rs13315871	0.929	rs13077539	chr3:58267846	T/C	cg12435725	chr3:58293450	RPP14	-0.42	-4.96	-0.3	1.31e-6	Cholesterol, total;
KIRP	cis	rs933360	0.535	rs10226937	chr7:50845718	G/A	cg14997413	chr7:51384937	COBL	0.31	4.87	0.3	1.95e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg19875535	chr5:140030758	IK	0.63	8.56	0.48	1.2e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2574704	1.000	rs11711892	chr3:11650787	T/C	cg07643000	chr3:11666825	VGLL4	0.37	5.44	0.33	1.28e-7	Body mass index;
KIRP	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg11833968	chr6:79620685	NA	-0.47	-7.1	-0.41	1.3e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg14851346	chr12:38532713	NA	-0.39	-4.88	-0.3	1.94e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	0.79	8.28	0.47	8.09e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07678449	chr4:171011395	AADAT	0.45	6.36	0.38	9.95e-10	Parkinson's disease;
KIRP	cis	rs7635838	0.927	rs13082150	chr3:11437813	T/C	cg00170343	chr3:11313890	ATG7	0.45	5.67	0.34	4e-8	HDL cholesterol;
KIRP	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg03959625	chr15:84868606	LOC388152	0.71	8.47	0.48	2.22e-15	Schizophrenia;
KIRP	trans	rs2270927	0.510	rs246813	chr5:75599605	G/T	cg13563193	chr19:33072644	PDCD5	0.89	6.72	0.39	1.29e-10	Mean corpuscular volume;
KIRP	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26002218	chr14:103986227	CKB	0.26	4.96	0.3	1.33e-6	Body mass index;
KIRP	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20135002	chr11:47629003	NA	-0.48	-5.76	-0.34	2.56e-8	Subjective well-being;
KIRP	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.81	12.03	0.61	1.63e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.86	-11.47	-0.59	1.09e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-5.95	-0.35	9.27e-9	Blood metabolite levels;
KIRP	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.25	-0.32	3.36e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3733418	1.000	rs3733419	chr4:165878170	A/G	cg10852876	chr4:165953100	TRIM60	-0.47	-5.28	-0.32	2.81e-7	Obesity-related traits;
KIRP	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-6.24	-0.37	1.88e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg26084005	chr2:241760190	KIF1A	-0.51	-6.88	-0.4	4.82e-11	Urinary metabolites;
KIRP	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	10.45	0.55	2.12e-21	Hip circumference;
KIRP	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.74	-8.06	-0.46	3.26e-14	Diastolic blood pressure;
KIRP	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg00094735	chr5:1949198	NA	0.46	5.52	0.33	8.53e-8	Gut microbiome composition (winter);
KIRP	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.47	-6.41	-0.38	7.21e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg03929089	chr4:120376271	NA	0.7	6.75	0.4	1.05e-10	Axial length;
KIRP	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg06115741	chr20:33292138	TP53INP2	-0.36	-4.96	-0.3	1.29e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.55	7.61	0.44	5.67e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.66	-6.78	-0.4	8.75e-11	Menarche (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05902531	chr12:58239324	CTDSP2	0.48	6.41	0.38	7.35e-10	Survival in pancreatic cancer;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.79	6.89	0.4	4.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.57	0.56	9.26e-22	Cognitive test performance;
KIRP	cis	rs12044355	0.827	rs11586191	chr1:231831781	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.48	6.12	0.36	3.6e-9	Alzheimer's disease;
KIRP	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.67	-0.44	4.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	10.2	0.55	1.34e-20	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00852783	chr1:26633632	UBXN11	0.57	7.6	0.44	6.29e-13	Monocyte percentage of white cells;
KIRP	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg26335602	chr6:28129616	ZNF389	-0.45	-5.11	-0.31	6.54e-7	Depression;
KIRP	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs10982213	0.830	rs10982212	chr9:117187976	C/G	cg00969271	chr9:117093052	ORM2	0.41	5.09	0.31	7.01e-7	Interleukin-6 levels;
KIRP	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.62	-6.6	-0.39	2.54e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-9.44	-0.52	2.89e-18	Monocyte percentage of white cells;
KIRP	cis	rs1497828	0.913	rs2646836	chr1:217550020	A/T	cg04411442	chr1:217543379	NA	0.41	6.19	0.37	2.53e-9	Dialysis-related mortality;
KIRP	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01911352	chr22:38302090	MICALL1	-0.51	-6.67	-0.39	1.66e-10	Myopia;
KIRP	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg20430773	chr1:16534157	ARHGEF19	0.61	7.55	0.43	8.57e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs757647	0.503	rs10038448	chr5:137515781	C/G	cg27119451	chr5:137514611	BRD8;KIF20A	-0.45	-5.05	-0.31	8.71e-7	Menarche (age at onset);
KIRP	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.47	5.75	0.34	2.66e-8	Kawasaki disease;
KIRP	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.33	5.24	0.32	3.5e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.52	0.48	1.6e-15	Type 2 diabetes;
KIRP	cis	rs7274811	0.711	rs291680	chr20:32022251	A/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.44	5.35	0.32	1.97e-7	Height;
KIRP	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.89	-11.65	-0.6	2.84e-25	Type 2 diabetes;
KIRP	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.55	6.84	0.4	6.25e-11	Body mass index;
KIRP	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg09473613	chr1:24152604	HMGCL	-0.46	-6.01	-0.36	6.47e-9	Immature fraction of reticulocytes;
KIRP	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.39	0.47	3.84e-15	Motion sickness;
KIRP	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.71	5.98	0.36	7.64e-9	Diabetic retinopathy;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs3784262	0.669	rs4646609	chr15:58274989	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.36	-5.08	-0.31	7.3e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.55	5.81	0.35	1.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs1448094	0.617	rs1502800	chr12:86476255	A/G	cg06740227	chr12:86229804	RASSF9	0.41	5.14	0.31	5.67e-7	Major depressive disorder;
KIRP	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.43	-0.55	2.44e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs96067	0.643	rs274133	chr1:36581792	G/A	cg27506609	chr1:36549197	TEKT2	-0.84	-7.28	-0.42	4.48e-12	Corneal structure;
KIRP	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg00042356	chr1:8021962	PARK7	-0.49	-4.88	-0.3	1.94e-6	Inflammatory bowel disease;
KIRP	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg09473613	chr1:24152604	HMGCL	0.48	6.51	0.38	4.2e-10	Immature fraction of reticulocytes;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg05518842	chr16:1823291	MRPS34;EME2	-0.44	-6.02	-0.36	6.4e-9	Migraine with aura;
KIRP	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg22705602	chr4:152727874	NA	0.58	10.16	0.54	1.73e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.91	15.13	0.69	5.31e-37	Menarche (age at onset);
KIRP	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13409248	chr3:40428643	ENTPD3	0.38	5.1	0.31	6.9e-7	Renal cell carcinoma;
KIRP	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg13293535	chr8:11597251	GATA4	0.39	5.07	0.31	7.7300000000000005e-07	Retinal vascular caliber;
KIRP	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.22	23.48	0.83	9.19e-65	Schizophrenia;
KIRP	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg24807547	chr6:37504484	NA	0.51	7.8	0.45	1.72e-13	Cognitive performance;
KIRP	cis	rs1961637	0.524	rs895771	chr2:223894051	C/T	cg02552189	chr2:223891284	NA	-0.42	-6.07	-0.36	4.87e-9	Oropharynx cancer;
KIRP	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27654615	chr5:138674135	NA	0.44	6.35	0.38	1.04e-9	Interleukin-4 levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16721845	chr11:68518800	MTL5	0.43	6.52	0.38	3.88e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.22	0.37	2.11e-9	Bipolar disorder;
KIRP	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs55871839	0.559	rs4737527	chr8:59823491	A/G	cg07426533	chr8:59803705	TOX	0.53	7.32	0.42	3.55e-12	Pneumonia;
KIRP	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg21926883	chr2:100939477	LONRF2	-0.54	-7.33	-0.42	3.21e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	1.000	rs5992928	chr22:18451438	A/C	cg03078520	chr22:18463400	MICAL3	-0.61	-7.22	-0.42	6.51e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.79	10.38	0.55	3.51e-21	Body mass index;
KIRP	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.8	-12.9	-0.64	1.96e-29	Prostate cancer;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg14673194	chr17:80132900	CCDC57	0.77	8.68	0.48	5.63e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1045714	0.848	rs73033686	chr7:2635085	C/G	cg20813462	chr7:2646259	IQCE	0.67	6.26	0.37	1.69e-9	Urate levels in lean individuals;
KIRP	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.84	-6.84	-0.4	6.16e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs981844	0.857	rs41320045	chr4:154720615	A/T	cg14289246	chr4:154710475	SFRP2	-0.66	-7.66	-0.44	4.23e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs883565	0.771	rs1053530	chr3:39138082	A/G	cg01426195	chr3:39028469	NA	0.7	11.35	0.59	2.79e-24	Handedness;
KIRP	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg07274523	chr3:49395745	GPX1	0.72	8.76	0.49	3.15e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.56	-5.59	-0.34	6.14e-8	Type 2 diabetes;
KIRP	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.46	6.71	0.39	1.3e-10	Testicular germ cell tumor;
KIRP	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg21926883	chr2:100939477	LONRF2	0.4	4.98	0.3	1.22e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.52	6.25	0.37	1.77e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.44	5.03	0.31	9.61e-7	Exhaled nitric oxide output;
KIRP	cis	rs10936797	0.775	rs13062427	chr3:174222659	G/A	cg17069914	chr3:174162456	NA	-0.33	-4.96	-0.3	1.3e-6	Obesity-related traits;
KIRP	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg00484396	chr16:3507460	NAT15	0.53	5.28	0.32	2.81e-7	Tuberculosis;
KIRP	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.73	0.49	3.94e-16	Electroencephalogram traits;
KIRP	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg20387954	chr3:183756860	HTR3D	0.62	9.08	0.5	3.66e-17	Anterior chamber depth;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg09698166	chr20:21106763	PLK1S1	0.73	6.02	0.36	6.46e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg13615516	chr5:77269221	NA	0.53	8.38	0.47	4.1e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7937840	0.581	rs4963462	chr11:61886672	A/T	cg01969543	chr11:61895209	INCENP	0.46	5.96	0.36	8.56e-9	Breast cancer;
KIRP	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.56	6.45	0.38	5.85e-10	Vitiligo;
KIRP	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.55	-0.39	3.34e-10	Joint mobility (Beighton score);
KIRP	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.41	-5.08	-0.31	7.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg16497661	chr14:103986332	CKB	-0.52	-6.85	-0.4	5.9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg25039879	chr17:56429692	SUPT4H1	0.6	5.27	0.32	3.02e-7	Cognitive test performance;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-1.1	-21.78	-0.81	2.57e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.31	-0.42	3.85e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg24009623	chr19:33667908	NA	0.47	6.12	0.36	3.76e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg14593290	chr7:50529359	DDC	0.38	4.88	0.3	1.95e-6	Malaria;
KIRP	cis	rs4566357	0.790	rs4389330	chr2:227957483	C/G	cg11843606	chr2:227700838	RHBDD1	0.48	5.94	0.35	9.74e-9	Coronary artery disease;
KIRP	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.94	10.83	0.57	1.28e-22	Breast cancer;
KIRP	cis	rs6504950	0.800	rs8065361	chr17:53008853	A/T	cg26251398	chr17:52985966	TOM1L1	0.45	6.04	0.36	5.68e-9	Breast cancer;
KIRP	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg19016782	chr12:123741754	C12orf65	0.4	4.94	0.3	1.45e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7084402	0.967	rs1658439	chr10:60325986	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.9	-0.57	7.95e-23	Refractive error;
KIRP	cis	rs4262150	0.689	rs72795371	chr5:151924995	G/A	cg12297329	chr5:152029980	NA	-0.7	-8.43	-0.47	2.88e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.79	-10.33	-0.55	5.28e-21	Parkinson's disease;
KIRP	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.57	-0.48	1.16e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs77633900	0.772	rs284898	chr15:76750695	A/G	cg21673338	chr15:77095150	SCAPER	-0.62	-5.93	-0.35	1.03e-8	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-6.67	-0.39	1.64e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg24009623	chr19:33667908	NA	0.49	6.29	0.37	1.47e-9	Colorectal cancer;
KIRP	cis	rs11650494	0.570	rs9901650	chr17:47513127	A/G	cg08112188	chr17:47440006	ZNF652	0.79	5.14	0.31	5.68e-7	Prostate cancer;
KIRP	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	13.95	0.66	5.46e-33	Tonsillectomy;
KIRP	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9398803	0.865	rs1578060	chr6:126712247	G/C	cg19875578	chr6:126661172	C6orf173	0.5	6.35	0.38	1.02e-9	Male-pattern baldness;
KIRP	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg04719120	chr6:96025338	MANEA	-0.61	-5.72	-0.34	3.08e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg05484376	chr2:27715224	FNDC4	0.33	5.46	0.33	1.17e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25019777	chr4:53525403	USP46	0.53	6.57	0.39	3e-10	Parkinson's disease;
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.21	21.78	0.81	2.54e-59	Cognitive function;
KIRP	cis	rs2273156	1.000	rs17102923	chr14:35449839	G/A	cg09327582	chr14:35236912	BAZ1A	-0.48	-5.24	-0.32	3.51e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.43	5.14	0.31	5.5e-7	Aortic root size;
KIRP	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.6	-0.44	6.2e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg02733842	chr7:1102375	C7orf50	0.52	5.46	0.33	1.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9381040	0.869	rs9357347	chr6:41150591	A/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.64	-6.66	-0.39	1.82e-10	Alzheimer's disease (late onset);
KIRP	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-9.24	-0.51	1.23e-17	Heart rate;
KIRP	cis	rs10814247	0.702	rs12685290	chr9:35219053	G/A	cg15271616	chr9:35490515	RUSC2	-0.37	-5.2	-0.31	4.26e-7	Psoriasis;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.67	6.21	0.37	2.18e-9	Alzheimer's disease;
KIRP	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg27490568	chr2:178487706	NA	0.96	10.8	0.57	1.62e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.61	4.87	0.3	1.99e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.49	-0.33	9.77e-8	Electroencephalogram traits;
KIRP	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg12549451	chr6:135224345	NA	0.44	5.48	0.33	1.07e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.49	-6.15	-0.37	3.09e-9	Post bronchodilator FEV1;
KIRP	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	0.99	15.72	0.71	5.19e-39	Triglycerides;
KIRP	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21659725	chr3:3221576	CRBN	0.78	9.18	0.51	1.87e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg06521331	chr12:34319734	NA	-0.64	-7.79	-0.45	1.82e-13	Morning vs. evening chronotype;
KIRP	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.31	0.32	2.48e-7	Lung cancer;
KIRP	cis	rs4236601	1.000	rs4236601	chr7:116162729	G/A	cg05166801	chr7:116143459	CAV2	0.48	5.95	0.35	9.23e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg03854865	chr6:26224070	HIST1H3E	0.62	4.85	0.3	2.16e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs1079204	1.000	rs10178462	chr2:219083353	G/T	cg05728596	chr2:219128475	GPBAR1	0.85	6.61	0.39	2.33e-10	Smooth-surface caries;
KIRP	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.38	-4.94	-0.3	1.43e-6	Educational attainment (years of education);
KIRP	cis	rs2712184	0.756	rs2024489	chr2:217661530	A/G	cg05032264	chr2:217675019	NA	-0.46	-6.82	-0.4	6.88e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs7565981	1.000	rs17024770	chr2:101421316	C/T	cg02232089	chr2:101440696	NPAS2	-0.59	-5.01	-0.3	1.05e-6	Creutzfeldt-Jakob disease (variant);
KIRP	trans	rs353116	0.737	rs699478	chr2:166130894	G/A	cg23361659	chr2:28914775	NA	0.34	6.66	0.39	1.73e-10	Parkinson's disease;
KIRP	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.6	-5.56	-0.33	6.89e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.33	5.45	0.33	1.2e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg17595323	chr11:93583763	C11orf90	-0.3	-5.15	-0.31	5.31e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.63	-6.2	-0.37	2.36e-9	White matter integrity;
KIRP	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.29	0.47	7.19e-15	Motion sickness;
KIRP	trans	rs1106684	1.000	rs67506721	chr7:131457071	C/T	cg13607082	chr12:122652224	LRRC43	-0.6	-6.32	-0.37	1.24e-9	Body mass index;
KIRP	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.84	-10.84	-0.57	1.27e-22	Menopause (age at onset);
KIRP	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.35	-0.32	2.03e-7	Retinal vascular caliber;
KIRP	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	0.86	9.31	0.51	7.44e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.03	-0.31	9.66e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11997175	0.603	rs7462153	chr8:33814607	C/T	cg04338863	chr8:33670619	NA	0.4	5.09	0.31	7.22e-7	Body mass index;
KIRP	cis	rs62051538	0.524	rs2454909	chr16:31410948	C/T	cg13439730	chr16:31146999	PRSS8	0.32	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg24125890	chr12:21654287	RECQL;GOLT1B	-0.49	-6.29	-0.37	1.4e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.68	-6.43	-0.38	6.66e-10	Neutrophil percentage of white cells;
KIRP	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg13147721	chr7:65941812	NA	-0.97	-6.87	-0.4	5.29e-11	Diabetic kidney disease;
KIRP	cis	rs12360000	0.932	rs10508219	chr10:1899620	A/G	cg26364871	chr10:1889757	NA	-0.59	-7.13	-0.41	1.08e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.63	9.72	0.53	4.05e-19	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4443656	0.870	rs6586997	chr8:21549018	C/G	cg03964515	chr8:21588527	GFRA2	-0.35	-4.98	-0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7191868	1	rs7191868	chr16:536090	G/C	cg00676925	chr16:540266	RAB11FIP3	-0.7	-6.51	-0.38	4.25e-10	Platelet distribution width;
KIRP	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Hypertriglyceridemia;
KIRP	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg12315302	chr6:26189340	HIST1H4D	0.96	6.8	0.4	8.09e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-1.07	-15.9	-0.71	1.19e-39	Blood protein levels;
KIRP	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	1.0	15.93	0.71	9.67e-40	Vitamin D levels;
KIRP	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11638352	1.000	rs2412853	chr15:44295257	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.82	-5.56	-0.33	7.01e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.67	8.02	0.46	4.31e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	1.35	10.37	0.55	3.93e-21	Prostate cancer;
KIRP	cis	rs2274273	0.686	rs66842809	chr14:55630571	T/C	cg04306507	chr14:55594613	LGALS3	0.41	5.77	0.35	2.42e-8	Protein biomarker;
KIRP	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.05	-0.31	8.75e-7	Personality dimensions;
KIRP	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	7.4	0.43	2.17e-12	Neuroticism;
KIRP	cis	rs1056053	0.514	rs3127334	chr6:166574246	G/A	cg11088901	chr6:166572345	T	-0.52	-7.31	-0.42	3.83e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10982256	0.905	rs4979417	chr9:117263878	C/T	cg13636371	chr9:117264095	DFNB31	0.57	7.68	0.44	3.78e-13	Bipolar disorder;
KIRP	cis	rs4683702	0.932	rs1470121	chr3:142625778	C/T	cg22826874	chr3:142608218	PCOLCE2	-0.35	-5.21	-0.32	4.07e-7	Blood protein levels;
KIRP	cis	rs526231	0.578	rs6860588	chr5:102280302	A/G	cg23492399	chr5:102201601	PAM	0.48	5.36	0.32	1.94e-7	Primary biliary cholangitis;
KIRP	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	11.01	0.57	3.37e-23	Cognitive test performance;
KIRP	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.46	5.87	0.35	1.41e-8	Aortic root size;
KIRP	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.64	9.35	0.51	5.52e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg16434002	chr17:42200994	HDAC5	-0.47	-5.53	-0.33	8.18e-8	Total body bone mineral density;
KIRP	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-9.83	-0.53	1.93e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.77	-12.36	-0.62	1.27e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg13798912	chr7:905769	UNC84A	0.78	7.38	0.43	2.4e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7870753	0.730	rs10122517	chr9:99175456	T/C	cg25260653	chr9:99212216	HABP4	0.53	5.87	0.35	1.39e-8	Height;
KIRP	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg25902810	chr10:99078978	FRAT1	0.62	7.89	0.45	9.82e-14	Monocyte count;
KIRP	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.5	-0.33	9.6e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.82	8.53	0.48	1.56e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.55	7.98	0.45	5.67e-14	Carotid intima media thickness;
KIRP	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.48	-0.33	1.03e-7	Neuroticism;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg05340658	chr4:99064831	C4orf37	-0.53	-6.43	-0.38	6.67e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.65	-8.94	-0.5	9.49e-17	Breast cancer;
KIRP	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg12310025	chr6:25882481	NA	0.39	5.24	0.32	3.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.58	7.97	0.45	5.93e-14	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.96	11.68	0.6	2.22e-25	Response to antineoplastic agents;
KIRP	cis	rs7523273	0.565	rs11118451	chr1:207887493	A/G	cg22525895	chr1:207977042	MIR29B2	0.45	5.79	0.35	2.14e-8	Schizophrenia;
KIRP	trans	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg16141378	chr3:129829833	LOC729375	0.53	6.36	0.38	9.54e-10	Mood instability;
KIRP	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.26	-0.32	3.09e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-10.23	-0.55	1.06e-20	Total body bone mineral density;
KIRP	cis	rs7666738	0.519	rs13136069	chr4:98819568	C/T	cg05340658	chr4:99064831	C4orf37	0.67	7.63	0.44	5.19e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.67	9.17	0.5	1.89e-17	Lymphocyte counts;
KIRP	cis	rs2997447	0.761	rs61776576	chr1:26429898	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.56	-0.33	7.02e-8	QRS complex (12-leadsum);
KIRP	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.39	-7.56	-0.43	7.86e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg22715398	chr15:52968154	KIAA1370	-0.67	-8.03	-0.46	4.01e-14	Schizophrenia;
KIRP	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.8	-12.77	-0.63	5.27e-29	Prostate cancer;
KIRP	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.79	11.39	0.59	2.05e-24	Heart rate;
KIRP	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg14829360	chr17:73884958	NA	-0.47	-6.39	-0.38	8.39e-10	White matter hyperintensity burden;
KIRP	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.25	0.42	5.26e-12	Vitiligo;
KIRP	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.52	0.43	1.02e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg10950524	chr7:2139216	MAD1L1	0.3	5.23	0.32	3.59e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.61	0.48	8.74e-16	Bipolar disorder;
KIRP	cis	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg19171272	chr22:38449367	NA	-0.64	-9.72	-0.53	4.05e-19	Glioblastoma;Glioma;
KIRP	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg21775007	chr8:11205619	TDH	-0.52	-6.66	-0.39	1.81e-10	Neuroticism;
KIRP	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.65	-9.63	-0.52	7.7e-19	Educational attainment;
KIRP	cis	rs12608504	0.503	rs12610691	chr19:18398335	A/C	cg02790458	chr19:18386421	KIAA1683	0.43	6.16	0.37	3.02e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.21	0.46	1.24e-14	Lung cancer;
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg24874828	chr4:187887005	NA	-0.57	-9.27	-0.51	9.47e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8141529	0.551	rs16986864	chr22:29350911	G/T	cg02153584	chr22:29168773	CCDC117	0.57	5.24	0.32	3.51e-7	Lymphocyte counts;
KIRP	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	9.18	0.51	1.78e-17	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs7999699	0.902	rs4942692	chr13:48319958	A/T	cg23237801	chr1:16476620	EPHA2	0.51	6.36	0.38	9.82e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.49	7.63	0.44	5.06e-13	Testicular germ cell tumor;
KIRP	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.85	10.62	0.56	6.2e-22	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.45e-8	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18936471	chr4:99186446	RAP1GDS1	0.43	6.36	0.38	9.77e-10	Interleukin-4 levels;
KIRP	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs853679	0.546	rs200981	chr6:27833174	A/G	cg26587870	chr6:27730563	NA	-0.64	-4.98	-0.3	1.17e-6	Depression;
KIRP	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.59	5.82	0.35	1.78e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.32e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10861342	1.000	rs11112371	chr12:105499021	T/C	cg23923672	chr12:105501055	KIAA1033	0.85	6.55	0.39	3.35e-10	IgG glycosylation;
KIRP	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.45	-6.76	-0.4	9.84e-11	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg13482628	chr17:19912719	NA	0.53	6.82	0.4	6.89e-11	Schizophrenia;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.62	-8.87	-0.49	1.57e-16	Longevity;Endometriosis;
KIRP	cis	rs35000415	0.688	rs13222044	chr7:128716525	C/T	cg19972273	chr7:128594194	NA	0.61	5.1	0.31	6.67e-7	Systemic lupus erythematosus;
KIRP	cis	rs6681460	0.608	rs10889624	chr1:67005807	A/G	cg02459107	chr1:67143332	SGIP1	0.37	5.22	0.32	3.82e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.64	-7.75	-0.44	2.37e-13	Facial morphology (factor 19);
KIRP	cis	rs138055607	1	rs138055607	chr10:75450901	C/G	cg04833713	chr10:74871078	NUDT13	0.49	5.81	0.35	1.9e-8	Initial pursuit acceleration;
KIRP	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.16	0.37	2.92e-9	Ovarian reserve;
KIRP	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.99	18.52	0.76	1.47e-48	Colorectal adenoma (advanced);
KIRP	cis	rs1538970	0.884	rs781226	chr1:45872662	T/C	cg05343316	chr1:45956843	TESK2	-0.62	-7.29	-0.42	4.25e-12	Platelet count;
KIRP	cis	rs2072732	0.904	rs717795	chr1:2970464	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.74	-0.34	2.79e-8	Plateletcrit;
KIRP	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	5.01	0.3	1.04e-6	Lung function (FEV1/FVC);
KIRP	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.87	-12.49	-0.62	4.79e-28	Total body bone mineral density;
KIRP	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.41	5.48	0.33	1.03e-7	Homoarginine levels;
KIRP	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.42e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.63	8.6	0.48	9.47e-16	Colorectal cancer;
KIRP	trans	rs7830939	0.586	rs10108359	chr8:9327086	C/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.08	-0.36	4.46e-9	Neuroticism;
KIRP	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	12.18	0.61	5.07e-27	Exhaled nitric oxide output;
KIRP	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.82	10.2	0.54	1.38e-20	Post bronchodilator FEV1;
KIRP	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.85	12.42	0.62	8.26e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	6.19	0.37	2.52e-9	Personality dimensions;
KIRP	trans	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Diabetic kidney disease;
KIRP	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg24747557	chr10:131355152	MGMT	0.39	5.25	0.32	3.33e-7	Response to temozolomide;
KIRP	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	0.96	10.41	0.55	2.96e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs77688320	0.553	rs6722889	chr2:202304082	C/T	cg06431681	chr2:202330990	STRADB	-0.46	-5.27	-0.32	3.01e-7	Breast cancer;
KIRP	cis	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg00262122	chr8:11665843	FDFT1	-0.45	-5.25	-0.32	3.24e-7	Triglycerides;
KIRP	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.43	5.62	0.34	5.29e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs3105593	1.000	rs56118429	chr15:50923849	T/A	cg08437265	chr15:50716283	USP8	0.39	4.97	0.3	1.28e-6	QT interval;
KIRP	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.66	7.76	0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs712039	0.652	rs67879888	chr17:35795312	A/G	cg16670864	chr17:35848621	DUSP14	0.43	5.39	0.32	1.68e-7	Tuberculosis;
KIRP	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	19.77	0.78	9.67e-53	Prudent dietary pattern;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20527647	chr6:75994873	TMEM30A	-0.45	-6.11	-0.36	3.78e-9	Cancer;
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.14	14.6	0.68	3.5e-35	Platelet count;
KIRP	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-8.05	-0.46	3.52e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6585424	1.000	rs34386571	chr10:81939432	C/T	cg27417294	chr10:81904244	PLAC9	0.53	5.04	0.31	8.98e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.82	0.4	6.86e-11	Educational attainment;
KIRP	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.85	11.96	0.61	2.68e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12636108	chr5:176036956	GPRIN1	0.45	6.69	0.39	1.51e-10	Survival in pancreatic cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08917060	chr1:197872294	C1orf53	0.44	6.36	0.38	9.61e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.33	-0.42	3.4e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	1.09	17.85	0.75	2.83e-46	Cognitive function;
KIRP	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg17340268	chr14:105411764	AHNAK2	-0.38	-4.94	-0.3	1.43e-6	Rheumatoid arthritis;
KIRP	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.51	-0.33	9.03e-8	Schizophrenia;
KIRP	cis	rs6783573	0.894	rs939408	chr3:46599079	C/A	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.49	-5.83	-0.35	1.71e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.68	-0.44	3.81e-13	Joint mobility (Beighton score);
KIRP	cis	rs2387326	0.672	rs12254264	chr10:129945519	C/T	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg15369054	chr17:80825471	TBCD	0.64	5.5	0.33	9.66e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg26422059	chr2:237146110	ASB18	0.45	5.01	0.3	1.02e-6	Educational attainment;
KIRP	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg01304814	chr3:48885189	PRKAR2A	0.72	5.45	0.33	1.22e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg04369109	chr6:150039330	LATS1	0.61	7.8	0.45	1.75e-13	Lung cancer;
KIRP	cis	rs56146971	0.763	rs45490092	chr14:91845143	A/G	cg10511902	chr14:91842949	CCDC88C	0.5	5.31	0.32	2.49e-7	Alzheimer disease and age of onset;
KIRP	cis	rs2671245	0.933	rs2767509	chr1:56156041	A/G	cg11523071	chr1:56160889	NA	0.41	6.74	0.39	1.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77861329	0.748	rs735768	chr3:52174970	A/C	cg08692210	chr3:52188851	WDR51A	0.62	6.3	0.37	1.39e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs11760067	1.000	rs11760067	chr6:135094272	C/T	cg16001689	chr6:135042205	NA	0.36	4.99	0.3	1.13e-6	Coronary artery calcification;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-1.08	-21.46	-0.81	2.78e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg00262122	chr8:11665843	FDFT1	0.5	6.17	0.37	2.83e-9	Morning vs. evening chronotype;
KIRP	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14298792	chr15:30685198	CHRFAM7A	0.51	6.22	0.37	2.07e-9	Huntington's disease progression;
KIRP	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg12292205	chr6:26970375	C6orf41	0.48	6.96	0.41	3.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs883565	0.682	rs7623850	chr3:39053311	C/T	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg14930904	chr10:32216787	ARHGAP12	0.36	4.91	0.3	1.68e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs3752645	0.881	rs77363449	chr7:106716778	C/G	cg02696742	chr7:106810147	HBP1	-0.74	-5.63	-0.34	4.8e-8	Bladder cancer (smoking interaction);
KIRP	cis	rs7011507	1.000	rs77708136	chr8:49133590	C/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03270197	chr6:166796579	BRP44L	0.64	7.66	0.44	4.3e-13	Smoking initiation;
KIRP	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg26681399	chr22:41777847	TEF	-0.43	-5.13	-0.31	5.79e-7	Vitiligo;
KIRP	cis	rs2117029	0.556	rs1057725	chr12:49522578	T/C	cg24176009	chr12:49580217	TUBA1A	-0.38	-5.15	-0.31	5.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.68	10.05	0.54	3.98e-20	Dupuytren's disease;
KIRP	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.56	7.72	0.44	2.85e-13	Mood instability;
KIRP	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.6	6.2	0.37	2.3e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.31	6.37	0.38	9.43e-10	Schizophrenia;
KIRP	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg08999081	chr20:33150536	PIGU	-0.4	-5.13	-0.31	5.96e-7	Height;
KIRP	cis	rs10518128	1.000	rs6848411	chr4:75715789	G/A	cg20122727	chr4:75719957	BTC	0.56	5.69	0.34	3.55e-8	Electroencephalogram traits;
KIRP	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.3900000000000007e-08	Blood protein levels;
KIRP	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.95	16.74	0.73	1.7e-42	Breast cancer;
KIRP	cis	rs17123764	0.892	rs1993398	chr12:50105414	A/G	cg20471783	chr12:50157085	TMBIM6	0.4	5.31	0.32	2.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg18306943	chr3:40428807	ENTPD3	0.43	5.91	0.35	1.16e-8	Renal cell carcinoma;
KIRP	cis	rs7714670	1.000	rs6871548	chr5:73076024	C/T	cg04480106	chr5:72934606	RGNEF	-0.37	-4.86	-0.3	2.06e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg25182066	chr10:30743637	MAP3K8	0.61	7.44	0.43	1.67e-12	Inflammatory bowel disease;
KIRP	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.29	-0.32	2.7e-7	Blood pressure;
KIRP	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.45	6.15	0.36	3.14e-9	Testicular germ cell tumor;
KIRP	cis	rs883565	0.531	rs813668	chr3:39180867	G/T	cg01426195	chr3:39028469	NA	0.37	5.21	0.32	3.9e-7	Handedness;
KIRP	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	6.92	0.4	3.83e-11	Menarche (age at onset);
KIRP	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.67	-9.14	-0.5	2.44e-17	Hemoglobin concentration;
KIRP	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg26513180	chr16:89883248	FANCA	0.83	5.68	0.34	3.73e-8	Skin colour saturation;
KIRP	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.85	12.47	0.62	5.72e-28	Height;
KIRP	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg27165867	chr14:105738592	BRF1	-0.42	-4.95	-0.3	1.39e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs57994353	0.793	rs12552167	chr9:139322927	C/T	cg14169450	chr9:139327907	INPP5E	0.58	6.93	0.4	3.75e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.94	0.5	9.6e-17	Lymphocyte percentage of white cells;
KIRP	cis	rs2882667	0.893	rs10054796	chr5:138294344	G/A	cg04439458	chr5:138467593	SIL1	-0.39	-5.97	-0.36	8.33e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg13010199	chr12:38710504	ALG10B	0.68	8.82	0.49	2.21e-16	Morning vs. evening chronotype;
KIRP	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg11498726	chr8:26250323	BNIP3L	-0.43	-6.38	-0.38	8.51e-10	Height;
KIRP	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	1.1	20.49	0.79	4.18e-55	Height;
KIRP	cis	rs2150410	0.915	rs6517537	chr21:40653957	A/C	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.45	-5.87	-0.35	1.43e-8	Longevity;Endometriosis;
KIRP	cis	rs17453880	0.750	rs10067084	chr5:151927189	A/T	cg12297329	chr5:152029980	NA	-0.53	-7.75	-0.44	2.46e-13	Subjective well-being;
KIRP	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg04691961	chr3:161091175	C3orf57	-0.43	-6.62	-0.39	2.28e-10	Morning vs. evening chronotype;
KIRP	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg26727032	chr16:67993705	SLC12A4	-0.7	-6.22	-0.37	2.08e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.13	0.64	3.26e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6921919	0.583	rs1124131	chr6:28380248	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1355223	0.902	rs286858	chr11:34717357	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.6	0.34	5.85e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2712184	0.967	rs2541385	chr2:217669595	C/T	cg05032264	chr2:217675019	NA	-0.53	-8.0	-0.45	4.91e-14	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.09	-11.96	-0.61	2.77e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg01629716	chr15:45996671	NA	0.37	6.59	0.39	2.73e-10	Waist circumference;Weight;
KIRP	cis	rs33912345	0.643	rs1254297	chr14:60871338	G/C	cg27398547	chr14:60952738	C14orf39	-0.39	-5.12	-0.31	6.22e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs61935443	1.000	rs4761691	chr12:95248171	C/G	cg21533806	chr12:95267307	NA	0.53	5.28	0.32	2.78e-7	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08680417	chr15:50716372	USP8	-0.52	-6.21	-0.37	2.2e-9	Interleukin-4 levels;
KIRP	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	ch.8.33884649F	chr8:33765107	NA	0.5	6.0	0.36	6.91e-9	Body mass index;
KIRP	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.76	-0.34	2.52e-8	Height;
KIRP	cis	rs2412819	0.542	rs62018894	chr15:43912987	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.35	0.38	1.05e-9	Lung cancer;
KIRP	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.68	7.99	0.45	5.06e-14	Cocaine dependence;
KIRP	cis	rs6841333	0.857	rs9994667	chr4:76955248	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.44	-4.85	-0.3	2.22e-6	Monokine induced by gamma interferon levels;
KIRP	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.47	0.38	5.31e-10	Reticulocyte count;High light scatter reticulocyte count;
KIRP	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.44	-0.33	1.3e-7	Renal cell carcinoma;
KIRP	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg00321850	chr1:175162397	KIAA0040	-0.31	-5.27	-0.32	2.99e-7	Alcohol dependence;
KIRP	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.6	0.44	6.25e-13	Colorectal cancer;
KIRP	cis	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg26587870	chr6:27730563	NA	-0.65	-5.14	-0.31	5.58e-7	Breast cancer;
KIRP	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.56	5.94	0.35	9.81e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9972944	0.756	rs6504357	chr17:63770621	C/T	cg07283582	chr17:63770753	CCDC46	-0.42	-7.16	-0.42	9.19e-12	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-10.59	-0.56	7.76e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1858037	0.867	rs1039765	chr2:65614362	A/T	cg08085232	chr2:65598271	SPRED2	0.54	6.34	0.37	1.1e-9	Rheumatoid arthritis;
KIRP	trans	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg26043149	chr18:55253948	FECH	0.51	6.23	0.37	2e-9	Bone mineral density;
KIRP	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg22705602	chr4:152727874	NA	-0.55	-9.69	-0.53	5.24e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg08508325	chr11:3079039	CARS	0.33	6.05	0.36	5.31e-9	Calcium levels;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.23	-24.07	-0.84	1.28e-66	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-11.17	-0.58	1.02e-23	Colorectal cancer;
KIRP	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-10.84	-0.57	1.27e-22	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg13395646	chr4:1353034	KIAA1530	0.4	5.39	0.33	1.64e-7	Obesity-related traits;
KIRP	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg13731523	chr4:3047190	NA	-0.39	-6.36	-0.38	9.97e-10	Serum sulfate level;
KIRP	cis	rs1971762	1.000	rs1971762	chr12:54058238	C/T	cg09709951	chr12:54017699	ATF7	0.45	5.7	0.34	3.35e-8	Height;
KIRP	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs8018808	0.935	rs2091916	chr14:77914752	A/G	cg20045696	chr14:77926864	AHSA1	0.46	5.46	0.33	1.17e-7	Myeloid white cell count;
KIRP	cis	rs6973256	0.605	rs7792396	chr7:133345526	T/C	cg10665199	chr7:133106180	EXOC4	0.51	6.52	0.38	3.85e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg02175308	chr1:109941060	SORT1	-0.31	-5.79	-0.35	2.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.79	-10.35	-0.55	4.59e-21	Body mass index;
KIRP	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.62	-0.39	2.23e-10	Coronary artery calcification;
KIRP	cis	rs397969	0.646	rs6813	chr17:19808445	C/T	cg13482628	chr17:19912719	NA	-0.43	-5.54	-0.33	7.7e-8	Platelet count;
KIRP	cis	rs4663866	0.901	rs71426512	chr2:239187128	C/T	cg17283117	chr2:239148619	HES6	0.71	5.08	0.31	7.33e-7	Irritable bowel syndrome;
KIRP	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	13.01	0.64	8.25e-30	Electrocardiographic conduction measures;
KIRP	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg20744362	chr22:50050164	C22orf34	0.32	4.89	0.3	1.83e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs35955747	0.902	rs140074	chr22:31725634	C/G	cg02404636	chr22:31891804	SFI1	0.38	5.23	0.32	3.68e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg00738919	chr7:1100172	C7orf50	0.42	5.08	0.31	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9381107	0.860	rs35811970	chr6:9415320	T/C	cg14735645	chr6:9486422	NA	-0.49	-5.28	-0.32	2.86e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs66561647	0.794	rs2278176	chr8:128951805	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.53	6.81	0.4	7.27e-11	Hemoglobin concentration;
KIRP	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.47	-6.61	-0.39	2.31e-10	IgG glycosylation;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg24654547	chr16:68057165	DUS2L;DDX28	1.02	6.79	0.4	8.12e-11	P wave terminal force;
KIRP	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.45	6.45	0.38	5.94e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.22	-0.32	3.73e-7	Triglycerides;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg00338893	chr7:140714614	MRPS33	0.53	6.61	0.39	2.43e-10	Educational attainment;
KIRP	cis	rs258892	0.895	rs6452657	chr5:72022918	G/C	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	14.15	0.67	1.21e-33	Cognitive ability;
KIRP	cis	rs2412208	0.509	rs7546792	chr1:7124346	C/T	cg20434152	chr1:7120926	CAMTA1	-0.47	-6.79	-0.4	8.45e-11	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25555424	chr11:2950735	PHLDA2	0.51	7.26	0.42	5.22e-12	Parkinson's disease;
KIRP	cis	rs4363385	0.531	rs11205188	chr1:153053645	A/T	cg07796016	chr1:152779584	LCE1C	-0.44	-5.42	-0.33	1.44e-7	Inflammatory skin disease;
KIRP	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs10203711	1.000	rs10203711	chr2:239553368	C/T	cg14580085	chr2:239553406	NA	0.4	5.23	0.32	3.63e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2236918	0.965	rs2488472	chr1:242019919	T/C	cg17736920	chr1:242011382	EXO1	0.71	9.1	0.5	3.17e-17	Menopause (age at onset);
KIRP	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.43	5.46	0.33	1.14e-7	Mean platelet volume;
KIRP	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.61	-7.95	-0.45	6.9e-14	Uric acid clearance;
KIRP	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg26138937	chr11:71823887	C11orf51	1.12	7.14	0.41	1.07e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.6	6.6	0.39	2.56e-10	Interstitial lung disease;
KIRP	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.39	4.98	0.3	1.21e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-7.72	-0.44	2.86e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.87	-0.4	5.16e-11	Hemoglobin concentration;
KIRP	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg24315340	chr6:146058215	EPM2A	-0.43	-5.3	-0.32	2.61e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7536201	1.000	rs11249221	chr1:25300541	T/C	cg23273869	chr1:25296894	NA	-0.4	-5.85	-0.35	1.55e-8	Psoriasis vulgaris;
KIRP	cis	rs752010	0.715	rs11807117	chr1:42101206	C/T	cg06885757	chr1:42089581	HIVEP3	0.88	14.68	0.68	1.85e-35	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs10465746	0.905	rs11163875	chr1:84429605	T/G	cg10977910	chr1:84465055	TTLL7	0.48	5.82	0.35	1.82e-8	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13489987	chr14:67292488	GPHN	-0.48	-7.68	-0.44	3.68e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2067663	0.786	rs662230	chr5:88035068	A/C	cg18498987	chr5:88179539	MEF2C	-0.4	-5.26	-0.32	3.08e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs7640424	0.929	rs327139	chr3:107822481	G/C	cg09227934	chr3:107805635	CD47	0.33	5.43	0.33	1.33e-7	Body mass index;
KIRP	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg19507638	chr5:93509721	C5orf36	-0.62	-5.72	-0.34	3.05e-8	Diabetic retinopathy;
KIRP	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg17810781	chr1:201082982	CACNA1S	-0.4	-6.24	-0.37	1.87e-9	Permanent tooth development;
KIRP	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.64	7.91	0.45	8.57e-14	Response to antipsychotic treatment;
KIRP	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.7	9.89	0.53	1.24e-19	Mood instability;
KIRP	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg26566898	chr11:117069891	TAGLN	0.39	4.96	0.3	1.34e-6	Blood protein levels;
KIRP	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11622362	chr11:34938112	PDHX;APIP	-0.47	-5.81	-0.35	1.9e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg00094735	chr5:1949198	NA	-0.44	-5.3	-0.32	2.55e-7	Gut microbiome composition (winter);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10355708	chr8:145618298	ADCK5	-0.49	-6.17	-0.37	2.72e-9	Inflammatory biomarkers;
KIRP	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.34	0.47	5.42e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg02336718	chr17:17403227	NA	0.34	5.19	0.31	4.3e-7	Total body bone mineral density;
KIRP	cis	rs7534824	0.625	rs17449022	chr1:101442367	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.43	0.33	1.38e-7	Refractive astigmatism;
KIRP	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg01246520	chr17:17644344	RAI1	0.35	5.8	0.35	2.01e-8	Lymphocyte counts;
KIRP	cis	rs754423	0.582	rs67640320	chr14:52511596	C/G	cg05884192	chr14:52515736	NID2	0.56	5.95	0.35	8.95e-9	Craniofacial microsomia;
KIRP	cis	rs12210905	0.688	rs72843151	chr6:27359268	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg11861562	chr11:117069780	TAGLN	0.42	5.45	0.33	1.24e-7	Blood protein levels;
KIRP	cis	rs273573	0.643	rs9300006	chr11:30916680	A/G	cg14844989	chr11:31128820	NA	0.34	4.85	0.3	2.17e-6	Total body bone mineral density;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03787326	chr3:48130820	MAP4	-0.46	-6.03	-0.36	5.98e-9	Myopia;
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.87	0.3	1.98e-6	Lymphocyte counts;
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.41	5.51	0.33	9.18e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	0.94	11.19	0.58	9.06e-24	Vitiligo;
KIRP	cis	rs9912468	0.933	rs17633401	chr17:64301363	C/T	cg19474267	chr17:64306194	PRKCA	0.6	8.29	0.47	7.27e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.76	9.49	0.52	2.07e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg11987759	chr7:65425863	GUSB	0.6	8.36	0.47	4.53e-15	Calcium levels;
KIRP	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg04132472	chr17:19861366	AKAP10	-0.38	-4.98	-0.3	1.18e-6	Schizophrenia;
KIRP	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.03	-10.95	-0.57	5.51e-23	Vitiligo;
KIRP	cis	rs6832769	1.000	rs7677526	chr4:56349908	A/T	cg09317128	chr4:56265301	TMEM165	0.55	7.34	0.42	3.13e-12	Personality dimensions;
KIRP	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.26	-0.42	5.21e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.62	-10.24	-0.55	1e-20	Obesity-related traits;
KIRP	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.36	5.28	0.32	2.86e-7	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.49	-0.52	2.07e-18	Chronic sinus infection;
KIRP	cis	rs6684514	1.000	rs12117951	chr1:156305286	G/A	cg16558208	chr1:156270281	VHLL	-0.44	-5.9	-0.35	1.19e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.45	5.37	0.32	1.85e-7	Personality dimensions;
KIRP	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.39	0.38	8.39e-10	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08235889	chr16:1660574	IFT140	0.55	7.18	0.42	8.26e-12	Parkinson's disease;
KIRP	cis	rs986417	0.748	rs4899011	chr14:60986698	A/G	cg27398547	chr14:60952738	C14orf39	0.67	6.7	0.39	1.41e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.24e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg23936098	chr10:103911881	NOLC1	0.41	4.97	0.3	1.25e-6	Educational attainment;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-0.52	-5.87	-0.35	1.37e-8	Acne (severe);
KIRP	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.52	-0.33	8.41e-8	Pulmonary function;
KIRP	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg08847533	chr14:75593920	NEK9	0.51	6.1	0.36	4.04e-9	IgG glycosylation;
KIRP	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs6969780	0.722	rs983185	chr7:27188607	G/A	cg19142026	chr7:27170394	HOXA4	-0.35	-5.32	-0.32	2.31e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.42	-5.25	-0.32	3.29e-7	Aortic root size;
KIRP	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg01879757	chr17:41196368	BRCA1	-0.75	-9.95	-0.54	8.23e-20	Menopause (age at onset);
KIRP	cis	rs4851254	0.961	rs13000759	chr2:100753903	A/T	cg22139774	chr2:100720529	AFF3	0.35	4.84	0.3	2.25e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg24315340	chr6:146058215	EPM2A	0.4	5.14	0.31	5.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg12664940	chr5:140430875	PCDHB1	-0.43	-6.11	-0.36	3.79e-9	Obesity-related traits;
KIRP	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12292205	chr6:26970375	C6orf41	-0.39	-5.17	-0.31	4.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.88	-0.49	1.4e-16	Resting heart rate;
KIRP	cis	rs13185784	0.667	rs4700924	chr5:179645870	A/C	cg23248424	chr5:179741104	GFPT2	-0.5	-5.27	-0.32	3e-7	TRAIL levels;
KIRP	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg23422044	chr7:1970798	MAD1L1	-0.66	-6.22	-0.37	2.07e-9	Neuroticism;
KIRP	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.1	-0.69	6.59e-37	Gut microbiome composition (summer);
KIRP	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.58	7.58	0.44	6.99e-13	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg23161317	chr6:28129485	ZNF389	0.48	5.52	0.33	8.75e-8	Depression;
KIRP	cis	rs73198271	0.694	rs113694763	chr8:8647076	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.44	-0.38	6.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs656319	0.580	rs13279701	chr8:9969450	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.48	-0.48	2.08e-15	Myopia (pathological);
KIRP	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg14458575	chr2:238380390	NA	0.7	7.15	0.41	9.69e-12	Prostate cancer;
KIRP	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23903597	chr17:61704154	MAP3K3	-0.59	-6.62	-0.39	2.28e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4560672	0.808	rs2363779	chr6:158621011	G/C	cg14029994	chr6:158589857	SERAC1;GTF2H5	-0.59	-5.12	-0.31	6.11e-7	Smoking quantity;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03666205	chr15:67812280	C15orf61	0.5	6.16	0.37	2.98e-9	Interleukin-4 levels;
KIRP	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.56	-6.98	-0.41	2.73e-11	Metabolite levels;
KIRP	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.65	-0.48	6.74e-16	Blood protein levels;
KIRP	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg14972814	chr11:95582409	MTMR2	0.37	6.12	0.36	3.7e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg10818794	chr15:86012489	AKAP13	-0.49	-7.08	-0.41	1.48e-11	Coronary artery disease;
KIRP	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.56	6.82	0.4	6.91e-11	Eosinophil percentage of white cells;
KIRP	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.58	-6.77	-0.4	9.25e-11	DNA methylation (variation);
KIRP	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2219968	0.717	rs4610733	chr8:78914112	T/G	cg00738934	chr8:78996279	NA	-0.37	-4.96	-0.3	1.29e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.62	9.41	0.51	3.74e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs6707387	0.623	rs10166400	chr2:214312551	A/G	cg08319019	chr2:214017104	IKZF2	0.42	4.9	0.3	1.77e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg26695010	chr11:65641043	EFEMP2	0.45	5.22	0.32	3.86e-7	Eosinophil percentage of white cells;
KIRP	cis	rs12282928	0.513	rs7948537	chr11:48342072	T/A	cg26585981	chr11:48327164	OR4S1	0.52	6.26	0.37	1.7e-9	Migraine - clinic-based;
KIRP	cis	rs16828019	0.852	rs34286980	chr1:41608389	A/G	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs71277158	0.688	rs73879164	chr3:169770924	T/C	cg04067573	chr3:169899625	PHC3	0.54	5.11	0.31	6.39e-7	Prostate cancer;
KIRP	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.58	7.24	0.42	5.79e-12	Arsenic metabolism;
KIRP	cis	rs4849845	0.925	rs934726	chr2:121012911	A/G	cg24070213	chr2:121070622	NA	0.38	5.12	0.31	6.19e-7	Mean platelet volume;
KIRP	cis	rs2862064	0.872	rs1393209	chr5:156477540	G/A	cg12943317	chr5:156479607	HAVCR1	-0.91	-8.14	-0.46	2.04e-14	Platelet count;
KIRP	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg10047753	chr17:41438598	NA	1.01	12.72	0.63	7.94e-29	Menopause (age at onset);
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg18209359	chr17:80159595	CCDC57	0.38	5.12	0.31	6.08e-7	Life satisfaction;
KIRP	cis	rs4805272	1.000	rs9304626	chr19:29320254	A/C	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.16e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg02297831	chr4:17616191	MED28	0.52	6.44	0.38	6.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs6466055	0.611	rs3213742	chr7:104643230	C/A	cg04380332	chr7:105027541	SRPK2	-0.62	-9.21	-0.51	1.45e-17	Schizophrenia;
KIRP	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg09904177	chr6:26538194	HMGN4	-0.42	-5.17	-0.31	4.84e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7394190	0.748	rs4114992	chr10:75566829	A/G	cg04833713	chr10:74871078	NUDT13	0.44	4.93	0.3	1.54e-6	Incident atrial fibrillation;
KIRP	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.15	-0.46	1.89e-14	Body mass index;
KIRP	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	1.0	14.35	0.68	2.35e-34	Cognitive function;
KIRP	cis	rs13361707	0.920	rs1692252	chr5:40722822	G/A	cg01087697	chr5:40835557	RPL37	-0.47	-5.42	-0.33	1.43e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.94	-0.35	9.5e-9	Parkinson's disease;
KIRP	cis	rs883115	0.846	rs6697510	chr1:224810687	T/C	cg01808320	chr1:224927238	CNIH3	-0.36	-5.06	-0.31	8.08e-7	Cancer;
KIRP	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.29	-0.37	1.43e-9	Arsenic metabolism;
KIRP	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg17507749	chr15:85114479	UBE2QP1	0.71	7.33	0.42	3.35e-12	Schizophrenia;
KIRP	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg15655495	chr12:38532458	NA	-0.28	-5.14	-0.31	5.67e-7	Bladder cancer;
KIRP	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg06115741	chr20:33292138	TP53INP2	-0.38	-5.14	-0.31	5.66e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg12311346	chr5:56204834	C5orf35	-0.36	-4.93	-0.3	1.52e-6	Coronary artery disease;
KIRP	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg12573674	chr2:1569213	NA	-0.56	-5.05	-0.31	8.42e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	0.41	5.12	0.31	6.04e-7	Carotid intima media thickness;
KIRP	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.51	6.73	0.39	1.21e-10	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.52	0.65	1.65e-31	Platelet count;
KIRP	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.78	9.55	0.52	1.36e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs912330	0.517	rs1890064	chr13:99182295	T/C	cg07423050	chr13:99094983	FARP1	-0.34	-5.09	-0.31	6.97e-7	Alzheimer's disease;
KIRP	cis	rs12210905	0.920	rs9379975	chr6:27295808	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.59	-0.39	2.64e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg01763666	chr17:80159506	CCDC57	0.36	4.88	0.3	1.87e-6	Life satisfaction;
KIRP	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.61	-7.62	-0.44	5.64e-13	Coronary artery disease;
KIRP	cis	rs35955747	0.738	rs2012451	chr22:31844373	A/C	cg02404636	chr22:31891804	SFI1	-0.41	-5.73	-0.34	2.99e-8	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.61	-0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-9.24	-0.51	1.21e-17	Retinal vascular caliber;
KIRP	cis	rs4716602	0.596	rs4997808	chr7:156158734	C/G	cg16983916	chr7:156159713	NA	-0.44	-5.55	-0.33	7.5e-8	Anti-saccade response;
KIRP	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.24	-0.42	5.82e-12	Aortic root size;
KIRP	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.36	5.14	0.31	5.69e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs25645	0.502	rs17609240	chr17:38110689	T/G	cg17344932	chr17:38183730	MED24;SNORD124	-0.33	-4.91	-0.3	1.69e-6	Myeloid white cell count;
KIRP	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg03289416	chr15:75166202	SCAMP2	0.52	7.05	0.41	1.76e-11	Breast cancer;
KIRP	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.8	-0.4	7.97e-11	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23281280	chr6:28129359	ZNF389	0.48	5.17	0.31	4.94e-7	Depression;
KIRP	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg02811702	chr13:24901961	NA	0.43	5.76	0.34	2.52e-8	Obesity-related traits;
KIRP	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg19197139	chr17:4613644	ARRB2	-0.64	-6.94	-0.4	3.52e-11	Lymphocyte counts;
KIRP	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-14.9	-0.69	3.13e-36	Chronic sinus infection;
KIRP	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07905888	chr1:36023245	NCDN;KIAA0319L	0.52	6.64	0.39	1.97e-10	Parkinson's disease;
KIRP	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg12549451	chr6:135224345	NA	0.41	5.03	0.31	9.55e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.72	-7.17	-0.42	8.9e-12	Menarche (age at onset);
KIRP	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.48	6.77	0.4	9.51e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2048656	0.523	rs13270801	chr8:9543651	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.44	-0.38	6.09e-10	Schizophrenia;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.22e-7	Life satisfaction;
KIRP	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	5.73	0.34	2.99e-8	Mean platelet volume;
KIRP	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg00319359	chr11:70116639	PPFIA1	0.64	6.25	0.37	1.81e-9	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20161985	chr11:66112762	BRMS1	0.51	6.57	0.39	2.97e-10	Parkinson's disease;
KIRP	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.72	-8.47	-0.48	2.19e-15	Diabetic retinopathy;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.43	-5.38	-0.32	1.7e-7	Longevity;Endometriosis;
KIRP	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg06740227	chr12:86229804	RASSF9	-0.45	-5.39	-0.32	1.68e-7	Major depressive disorder;
KIRP	cis	rs9815354	1.000	rs2371627	chr3:41839219	A/G	cg03022575	chr3:42003672	ULK4	0.5	5.79	0.35	2.15e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg22265988	chr12:53895176	TARBP2	-0.55	-6.1	-0.36	4.07e-9	Menopause (age at onset);
KIRP	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12826209	chr6:26865740	GUSBL1	0.67	6.17	0.37	2.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	0.85	7.75	0.44	2.43e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.55	5.59	0.34	6e-8	Gut microbiome composition (summer);
KIRP	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg05805236	chr11:65401703	PCNXL3	-0.52	-6.56	-0.39	3.15e-10	Acne (severe);
KIRP	cis	rs2273156	0.570	rs2143950	chr14:35572357	C/T	cg09327582	chr14:35236912	BAZ1A	-0.5	-4.99	-0.3	1.12e-6	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.54	-7.52	-0.43	1.03e-12	Bipolar disorder;
KIRP	cis	rs524023	0.914	rs11231845	chr11:64407419	G/A	cg09231725	chr11:64357281	SLC22A12	0.61	8.03	0.46	3.98e-14	Urate levels in obese individuals;
KIRP	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.31	0.42	3.73e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	1.15	10.99	0.57	3.9699999999999997e-23	Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.79	12.14	0.61	6.73e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073416	0.542	rs2183277	chr14:66035429	T/C	cg03016385	chr14:66212404	NA	-0.51	-6.08	-0.36	4.46e-9	N-glycan levels;
KIRP	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.79	-11.97	-0.61	2.51e-26	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.66	9.74	0.53	3.67e-19	Blood metabolite levels;
KIRP	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.23	-0.32	3.71e-7	Autism;
KIRP	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.06	-0.5	4.11e-17	Personality dimensions;
KIRP	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.62e-8	Aortic root size;
KIRP	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	6.96	0.41	3.1e-11	Bipolar disorder;
KIRP	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	1.08	20.53	0.79	3.08e-55	Height;
KIRP	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.74	-13.18	-0.64	2.33e-30	Obesity-related traits;
KIRP	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.53	6.63	0.39	2.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.4	-5.03	-0.31	9.48e-7	Common traits (Other);
KIRP	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.57	-0.39	2.95e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	trans	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg02900749	chr2:68251473	NA	-1.15	-9.35	-0.51	5.5e-18	Pursuit maintenance gain;
KIRP	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg25418670	chr11:30344373	C11orf46	-0.6	-5.02	-0.3	1e-6	Morning vs. evening chronotype;
KIRP	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	trans	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg06521331	chr12:34319734	NA	-0.52	-6.39	-0.38	8.16e-10	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs9944715	0.954	rs9807157	chr18:43817755	T/C	cg01718231	chr17:29326311	RNF135	-0.5	-6.04	-0.36	5.61e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs2267137	0.903	rs2072051	chr22:29755888	C/T	cg07256473	chr22:29710276	RASL10A	-0.45	-7.18	-0.42	8.41e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg25418670	chr11:30344373	C11orf46	-0.61	-5.14	-0.31	5.64e-7	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	6.83	0.4	6.5e-11	Iron status biomarkers;
KIRP	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg08923054	chr8:41654455	ANK1	0.7	7.6	0.44	6.04e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.48	-7.3	-0.42	3.91e-12	Coronary artery disease;
KIRP	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg20243544	chr17:37824526	PNMT	0.4	4.93	0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs12282928	0.876	rs1158898	chr11:48273246	G/A	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs258892	0.895	rs34660	chr5:72151858	T/A	cg21869765	chr5:72125136	TNPO1	0.57	6.27	0.37	1.59e-9	Small cell lung carcinoma;
KIRP	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.58	7.24	0.42	5.72e-12	Coronary artery disease;
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg16268157	chr7:99778414	STAG3	-0.45	-5.34	-0.32	2.09e-7	Lung function (FEV1/FVC);
KIRP	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.56	7.53	0.43	9.53e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4950322	0.570	rs72692917	chr1:146776087	A/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.41	-0.33	1.52e-7	Protein quantitative trait loci;
KIRP	cis	rs4148660	1.000	rs11046235	chr12:22073563	T/A	cg14669847	chr12:22099120	NA	-0.32	-5.43	-0.33	1.34e-7	Gout;
KIRP	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.7	8.99	0.5	6.8e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.62	-9.16	-0.5	2.08e-17	Brugada syndrome;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg07283152	chr11:8284997	LMO1	-0.4	-6.04	-0.36	5.73e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.75	10.96	0.57	5.2e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs6601327	0.665	rs10113186	chr8:9655426	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.77	-0.4	9.13e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1318772	0.932	rs11744710	chr5:112932318	A/C	cg12552261	chr5:112820674	MCC	0.73	5.14	0.31	5.56e-7	F-cell distribution;
KIRP	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg07395648	chr5:131743802	NA	0.35	4.94	0.3	1.48e-6	Acylcarnitine levels;
KIRP	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.45	5.52	0.33	8.56e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.48	0.33	1.04e-7	Parkinson's disease;
KIRP	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.59	15.62	0.71	1.11e-38	Airflow obstruction;
KIRP	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.46	-0.43	1.52e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.56	-5.98	-0.36	7.86e-9	Body mass index;
KIRP	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.89	-12.44	-0.62	6.94e-28	Menopause (age at onset);
KIRP	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.58	-6.69	-0.39	1.53e-10	Blood trace element (Cu levels);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19586645	chr17:73266642	MIF4GD	0.52	6.04	0.36	5.61e-9	Smoking initiation;
KIRP	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18252515	chr7:66147081	NA	0.46	5.62	0.34	5.17e-8	Aortic root size;
KIRP	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24549020	chr5:56110836	MAP3K1	0.6	5.51	0.33	8.83e-8	Type 2 diabetes;
KIRP	cis	rs580438	0.529	rs9836501	chr3:13426046	T/G	cg10657019	chr3:13328039	NA	-0.51	-6.68	-0.39	1.59e-10	Myringotomy;
KIRP	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg03161606	chr19:29218774	NA	0.62	5.45	0.33	1.2e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.5	6.28	0.37	1.49e-9	Mean platelet volume;
KIRP	cis	rs6956675	0.915	rs6977279	chr7:62630625	C/G	cg08930214	chr7:62859557	LOC100287834	0.44	5.31	0.32	2.41e-7	Obesity-related traits;
KIRP	cis	rs3818717	0.538	rs4925108	chr17:17649423	C/T	cg02336718	chr17:17403227	NA	-0.33	-5.17	-0.31	4.85e-7	Lymphocyte counts;
KIRP	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.88	-0.4	4.82e-11	Joint mobility (Beighton score);
KIRP	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg11362935	chr11:111250201	POU2AF1	0.41	6.91	0.4	4.02e-11	Primary biliary cholangitis;
KIRP	cis	rs2014572	1.000	rs2014572	chr19:57760018	G/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.15	-0.36	3.19e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg07775547	chr4:1625484	NA	-0.42	-5.12	-0.31	6.24e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.89	-11.65	-0.6	2.9e-25	Coronary artery disease;
KIRP	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2625529	0.526	rs1035744	chr15:72566615	C/T	cg16672083	chr15:72433130	SENP8	0.41	5.76	0.34	2.51e-8	Red blood cell count;
KIRP	cis	rs9815354	1.000	rs1016669	chr3:41894440	T/C	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg11693508	chr17:37793320	STARD3	0.79	7.69	0.44	3.63e-13	Neuroticism;
KIRP	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg14250997	chr9:106856677	SMC2	0.43	5.93	0.35	1.03e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg23649088	chr2:200775458	C2orf69	-0.67	-5.85	-0.35	1.53e-8	Schizophrenia;
KIRP	trans	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00938859	chr5:1591904	SDHAP3	0.62	8.44	0.47	2.67e-15	Breast cancer;
KIRP	cis	rs1008375	0.872	rs2315552	chr4:17627294	A/G	cg02297831	chr4:17616191	MED28	0.57	7.11	0.41	1.28e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg17425144	chr1:10567563	PEX14	0.48	9.47	0.52	2.5e-18	Breast size;
KIRP	cis	rs2434422	0.708	rs62108271	chr19:52839821	C/T	cg17271561	chr19:52839334	ZNF610	-0.84	-6.59	-0.39	2.65e-10	Cannabis use (initiation);
KIRP	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23903597	chr17:61704154	MAP3K3	-0.55	-6.74	-0.39	1.12e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.33	-0.74	1.68e-44	Coronary artery disease;
KIRP	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg27490568	chr2:178487706	NA	0.49	6.64	0.39	2.03e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.43	5.25	0.32	3.33e-7	Iron status biomarkers;
KIRP	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.56	8.0	0.45	5.05e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15533453	chr10:2542242	NA	0.29	5.11	0.31	6.57e-7	Age-related hearing impairment;
KIRP	cis	rs2625529	0.824	rs16953769	chr15:72463325	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.06	-0.61	1.28e-26	Electrocardiographic conduction measures;
KIRP	cis	rs526231	0.543	rs72785717	chr5:102333105	C/T	cg23492399	chr5:102201601	PAM	-0.6	-6.7	-0.39	1.44e-10	Primary biliary cholangitis;
KIRP	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14169450	chr9:139327907	INPP5E	0.53	7.73	0.44	2.68e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg00204512	chr16:28754710	NA	0.42	4.95	0.3	1.37e-6	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17791489	chr3:193339109	OPA1	-0.43	-7.03	-0.41	2.04e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	1.0	7.17	0.42	8.91e-12	IgG glycosylation;
KIRP	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg17443007	chr1:101659419	NA	0.37	5.08	0.31	7.45e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg10756647	chr7:56101905	PSPH	0.99	6.85	0.4	5.74e-11	Diabetic kidney disease;
KIRP	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.06	-0.36	5.15e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs17321999	0.516	rs72787730	chr2:30497632	T/C	cg05247661	chr2:30472410	LBH	0.69	5.18	0.31	4.52e-7	Systemic lupus erythematosus;
KIRP	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg18944383	chr4:111397179	ENPEP	-0.71	-13.3	-0.65	9.3e-31	Coronary artery disease;
KIRP	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.62	-6.65	-0.39	1.86e-10	Bipolar disorder;
KIRP	cis	rs1011728	0.531	rs10862975	chr12:85749398	C/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	0.39	5.27	0.32	3.04e-7	Bone mineral density (Ward's triangle area);
KIRP	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg05768032	chr16:30646687	NA	0.53	6.61	0.39	2.35e-10	Multiple myeloma;
KIRP	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg20913747	chr6:44695427	NA	-0.38	-4.9	-0.3	1.77e-6	Total body bone mineral density;
KIRP	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Body mass index;
KIRP	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.09	0.61	1.01e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17739794	0.517	rs4439155	chr8:781047	C/T	cg11667643	chr8:748456	NA	-0.42	-4.84	-0.3	2.26e-6	Clozapine-induced cytotoxicity;
KIRP	cis	rs2150410	0.915	rs11910971	chr21:40612466	T/C	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg10223061	chr2:219282414	VIL1	0.43	6.8	0.4	7.67e-11	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg27284088	chr4:84031130	PLAC8	0.47	6.02	0.36	6.34e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs16912285	0.688	rs35683920	chr11:24358521	A/G	ch.11.24196551F	chr11:24239977	NA	0.61	5.46	0.33	1.18e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.53	-7.53	-0.43	9.4e-13	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.43	1.36e-12	Body mass index;
KIRP	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg14703610	chr5:56206110	C5orf35	0.49	6.68	0.39	1.59e-10	Breast cancer;Breast cancer (early onset);
KIRP	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.36	-0.38	9.71e-10	Myopia (pathological);
KIRP	cis	rs9815354	0.812	rs56183581	chr3:41848492	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.57	0.48	1.16e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.15	0.58	1.22e-23	Cognitive test performance;
KIRP	cis	rs67385638	0.802	rs72872555	chr11:5310169	G/A	cg12559170	chr11:5275217	HBG2	0.48	6.65	0.39	1.92e-10	Hemoglobin levels;
KIRP	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.77	0.35	2.37e-8	Blood protein levels;
KIRP	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.77	0.49	2.99e-16	Heart rate;
KIRP	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.65	8.47	0.48	2.29e-15	Coronary artery disease;
KIRP	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg06138931	chr13:21896616	NA	0.54	5.54	0.33	7.87e-8	White matter hyperintensity burden;
KIRP	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs2908668	0.932	rs2972288	chr16:5069960	T/C	cg00849365	chr16:5074999	NAGPA	-0.42	-5.17	-0.31	4.9e-7	Cancer;
KIRP	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg12317470	chr15:67143691	NA	-0.49	-5.4	-0.33	1.56e-7	Lung cancer (smoking interaction);
KIRP	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.85	12.16	0.61	6.01e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.87	12.24	0.62	3.17e-27	Schizophrenia;
KIRP	cis	rs501120	0.850	rs642222	chr10:44770473	A/G	cg09554077	chr10:44749378	NA	0.71	10.94	0.57	6.01e-23	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.62	7.61	0.44	5.93e-13	Extraversion;
KIRP	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg27490568	chr2:178487706	NA	0.59	7.97	0.45	6.02e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.96	14.81	0.69	6.74e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-10.93	-0.57	6.32e-23	Colorectal cancer;
KIRP	cis	rs2219968	0.638	rs10504672	chr8:78995199	G/C	cg00738934	chr8:78996279	NA	0.44	5.87	0.35	1.4e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7279771	0.768	rs11702354	chr21:35884525	A/G	cg03797705	chr17:79604227	NPLOC4	0.55	6.32	0.37	1.23e-9	Cancer;
KIRP	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.78	8.61	0.48	8.66e-16	Bipolar disorder;
KIRP	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg02461776	chr11:598696	PHRF1	0.63	6.69	0.39	1.49e-10	Systemic lupus erythematosus;
KIRP	cis	rs17655565	0.537	rs1732276	chr12:52761469	A/C	cg07925835	chr12:52762777	KRT85	0.51	5.81	0.35	1.95e-8	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.69	8.82	0.49	2.21e-16	Bladder cancer;
KIRP	cis	rs2150410	0.790	rs2183575	chr21:40594360	A/G	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.37	1.58e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12580194	0.593	rs55659159	chr12:55747754	C/T	cg19537932	chr12:55886519	OR6C68	-0.48	-6.36	-0.38	9.58e-10	Cancer;
KIRP	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.74	8.96	0.5	8.31e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.52	12.6	0.63	2.03e-28	Airflow obstruction;
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.7	0.66	3.81e-32	Platelet count;
KIRP	cis	rs10493773	0.775	rs6667672	chr1:86171072	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.43	-5.21	-0.32	4.05e-7	Urate levels in overweight individuals;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.58	-7.91	-0.45	8.47e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.57	6.83	0.4	6.53e-11	Height;
KIRP	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.99	18.52	0.76	1.47e-48	Colorectal adenoma (advanced);
KIRP	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg18944383	chr4:111397179	ENPEP	-0.72	-13.65	-0.66	5.82e-32	Coronary artery disease;
KIRP	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg10223061	chr2:219282414	VIL1	-0.36	-6.0	-0.36	7.02e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4917385	1	rs4917385	chr10:105003721	T/G	cg04362960	chr10:104952993	NT5C2	0.59	7.35	0.42	2.98e-12	Systemic lupus erythematosus;
KIRP	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.05	0.36	5.44e-9	Hypertriglyceridemia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24306779	chr16:58060336	MMP15	0.55	6.27	0.37	1.64e-9	Smoking initiation;
KIRP	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-11.45	-0.59	1.33e-24	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27599033	chr16:2802711	SRRM2;LOC100128788	0.46	6.07	0.36	4.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.66	-8.6	-0.48	9.23e-16	Body mass index;
KIRP	cis	rs6750047	0.585	rs62136319	chr2:38272950	G/A	cg07380506	chr2:38303506	CYP1B1	0.43	5.68	0.34	3.81e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs7225151	0.710	rs111676379	chr17:5247005	G/A	cg24500398	chr17:5266808	RABEP1	-0.58	-5.79	-0.35	2.09e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs4776059	0.876	rs2414163	chr15:52897478	T/C	cg25063058	chr15:52860530	ARPP19	0.6	6.69	0.39	1.46e-10	Schizophrenia;
KIRP	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg00101154	chr16:420108	MRPL28	-0.45	-5.44	-0.33	1.31e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs62355272	0.861	rs62355269	chr5:35843746	T/C	cg13894535	chr5:35919491	CAPSL	-0.51	-5.67	-0.34	4.05e-8	Lymphocyte counts;
KIRP	cis	rs1978968	0.763	rs5992136	chr22:18453103	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.72	-9.76	-0.53	3.21e-19	Presence of antiphospholipid antibodies;
KIRP	cis	rs5753618	0.583	rs5753615	chr22:31828027	T/C	cg02404636	chr22:31891804	SFI1	0.51	5.87	0.35	1.38e-8	Colorectal cancer;
KIRP	cis	rs4805272	0.962	rs8101324	chr19:29331529	A/G	cg04546413	chr19:29218101	NA	0.44	4.99	0.3	1.17e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.74	-9.48	-0.52	2.19e-18	Aortic root size;
KIRP	cis	rs3206736	0.664	rs3909150	chr7:35117736	T/A	cg06685737	chr7:35301730	NA	0.48	7.18	0.42	8.2e-12	Diastolic blood pressure;
KIRP	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg00343986	chr7:65444356	GUSB	0.43	5.1	0.31	6.89e-7	Aortic root size;
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg10207240	chr12:122356781	WDR66	-0.57	-7.85	-0.45	1.29e-13	Mean corpuscular volume;
KIRP	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.86	12.48	0.62	4.99e-28	Glomerular filtration rate (creatinine);
KIRP	cis	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg21775007	chr8:11205619	TDH	-0.47	-6.09	-0.36	4.3e-9	Triglycerides;
KIRP	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg13615516	chr5:77269221	NA	0.51	7.87	0.45	1.1e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.75	-8.79	-0.49	2.69e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03188948	chr7:1209495	NA	0.46	5.42	0.33	1.42e-7	Longevity;Endometriosis;
KIRP	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg16141378	chr3:129829833	LOC729375	-0.5	-6.42	-0.38	6.93e-10	Systolic blood pressure;
KIRP	trans	rs12517041	1.000	rs1428629	chr5:23311989	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.91	-0.45	8.59e-14	Calcium levels;
KIRP	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-7.28	-0.42	4.49e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18876405	chr7:65276391	NA	0.41	5.05	0.31	8.81e-7	Aortic root size;
KIRP	cis	rs8028313	0.529	rs16951358	chr15:68153732	G/C	cg24579218	chr15:68104479	NA	-0.42	-6.1	-0.36	4.18e-9	Obesity;
KIRP	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg06121193	chr1:90282411	NA	-0.48	-6.94	-0.4	3.55e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg03465714	chr1:152285911	FLG	-0.42	-4.94	-0.3	1.48e-6	Atopic dermatitis;
KIRP	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.76	-8.38	-0.47	4.08e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7017914	0.967	rs35115527	chr8:71643009	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg03834567	chr2:218808745	TNS1	0.45	5.54	0.33	7.77e-8	Ulcerative colitis;
KIRP	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26378065	chr17:18585709	ZNF286B	0.54	6.75	0.4	1.06e-10	Educational attainment (years of education);
KIRP	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg00898013	chr13:113819073	PROZ	-0.58	-6.03	-0.36	5.96e-9	Platelet distribution width;
KIRP	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.7	-8.84	-0.49	1.92e-16	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7520050	0.933	rs12045165	chr1:46256022	C/A	cg24296786	chr1:45957014	TESK2	0.39	4.91	0.3	1.65e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs56146971	0.714	rs55709253	chr14:91853363	T/C	cg16433844	chr14:91963127	SMEK1	-0.51	-4.86	-0.3	2.07e-6	Alzheimer disease and age of onset;
KIRP	cis	rs1570884	0.684	rs7326825	chr13:50113450	G/A	cg08779649	chr13:50194554	NA	0.53	7.43	0.43	1.84e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg06204229	chr3:52865917	ITIH4	0.56	6.56	0.39	3.2e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6701037	1.000	rs6683533	chr1:175125440	G/A	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.19	-0.31	4.39e-7	Alcohol dependence;
KIRP	cis	rs7011507	0.838	rs78358172	chr8:49189118	A/G	cg15325961	chr8:49183143	NA	0.61	5.21	0.32	3.92e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg09264619	chr17:80180166	NA	-0.4	-5.96	-0.36	8.47e-9	Life satisfaction;
KIRP	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg00981070	chr1:2046702	PRKCZ	0.41	5.86	0.35	1.5e-8	Height;
KIRP	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg04166393	chr7:2884313	GNA12	0.64	7.29	0.42	4.22e-12	Height;
KIRP	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg15997130	chr1:24165203	NA	-0.58	-8.17	-0.46	1.64e-14	Immature fraction of reticulocytes;
KIRP	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.38	-5.19	-0.31	4.43e-7	Coronary artery disease;
KIRP	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.64	-11.94	-0.61	3.06e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs7551222	0.716	rs10494852	chr1:204457786	A/G	cg20240347	chr1:204465584	NA	0.42	7.66	0.44	4.28e-13	Schizophrenia;
KIRP	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.77	-8.47	-0.48	2.2e-15	HIV-1 control;
KIRP	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.62	-7.12	-0.41	1.2e-11	Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.45	-0.52	2.87e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg26187514	chr1:212458738	PPP2R5A	-0.65	-7.56	-0.43	8.17e-13	Brain structure;
KIRP	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.36	5.29	0.32	2.75e-7	Mean corpuscular volume;
KIRP	cis	rs12912251	1.000	rs12912251	chr15:38986368	G/T	cg01338139	chr15:38987640	C15orf53	-0.52	-5.88	-0.35	1.35e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs10073892	0.743	rs13360644	chr5:101651672	A/T	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs1712517	0.771	rs11191654	chr10:105077124	C/A	cg05636881	chr10:105038444	INA	0.43	6.19	0.37	2.45e-9	Migraine;
KIRP	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs7225151	0.614	rs80172399	chr17:5194249	A/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.72	-0.34	3.06e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4262150	0.544	rs4613693	chr5:151898365	G/T	cg12297329	chr5:152029980	NA	-0.72	-8.9	-0.49	1.21e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.56	7.28	0.42	4.6e-12	Prostate cancer;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	0.97	16.81	0.73	9.85e-43	Menarche (age at onset);
KIRP	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.9	-0.45	9.08e-14	Acne (severe);
KIRP	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg14169450	chr9:139327907	INPP5E	0.58	7.04	0.41	1.93e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.93	12.48	0.62	4.92e-28	Coronary artery disease;
KIRP	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	trans	rs909341	0.909	rs6122159	chr20:62370732	G/T	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.89	-0.4	4.75e-11	Atopic dermatitis;
KIRP	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg10017260	chr10:834428	NA	-0.55	-5.43	-0.33	1.35e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs62229266	0.835	rs998384	chr21:37445526	G/C	cg12218747	chr21:37451666	NA	-0.46	-5.6	-0.34	5.73e-8	Mitral valve prolapse;
KIRP	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg02297831	chr4:17616191	MED28	0.6	7.66	0.44	4.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg02462569	chr6:150064036	NUP43	-0.34	-5.31	-0.32	2.45e-7	Lung cancer;
KIRP	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg08283408	chr3:49949060	MON1A	-0.43	-5.74	-0.34	2.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	0.83	8.88	0.49	1.44e-16	Gut microbiome composition (summer);
KIRP	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.63	-7.5	-0.43	1.17e-12	Systemic lupus erythematosus;
KIRP	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.59	-0.68	3.79e-35	Primary sclerosing cholangitis;
KIRP	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg27624424	chr6:160112604	SOD2	0.48	5.08	0.31	7.55e-7	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1116547	0.602	rs11750488	chr5:112792948	G/C	cg12552261	chr5:112820674	MCC	-0.5	-5.63	-0.34	4.85e-8	Cerebral amyloid angiopathy;
KIRP	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.68	-6.91	-0.4	4.06e-11	Body mass index;
KIRP	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.64	8.04	0.46	3.68e-14	Tonsillectomy;
KIRP	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.8	10.02	0.54	4.71e-20	Corneal astigmatism;
KIRP	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.45	-5.71	-0.34	3.17e-8	Iron status biomarkers;
KIRP	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.16	-0.42	9.27e-12	Neuroticism;
KIRP	cis	rs6693567	0.565	rs543179	chr1:150274610	G/A	cg07843065	chr1:150265600	MRPS21	-0.48	-6.9	-0.4	4.36e-11	Migraine;
KIRP	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.52	-0.43	1.05e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg10223061	chr2:219282414	VIL1	-0.34	-5.27	-0.32	2.94e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.58	7.63	0.44	5.09e-13	Endometrial cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23848541	chr22:30722865	TBC1D10A	-0.47	-6.37	-0.38	8.97e-10	Metabolic traits;
KIRP	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg26513180	chr16:89883248	FANCA	0.75	5.3	0.32	2.58e-7	Skin colour saturation;
KIRP	cis	rs2172802	0.570	rs6820960	chr4:62518033	A/T	cg04118610	chr4:62707027	LPHN3	-0.45	-5.55	-0.33	7.27e-8	Partial epilepsies;
KIRP	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.67	9.5	0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs55863869	0.748	rs74805196	chr2:179619400	T/C	cg02880032	chr2:179629472	TTN	0.67	5.49	0.33	9.95e-8	QT interval;
KIRP	cis	rs763512	0.504	rs853216	chr17:35863008	G/A	cg16670864	chr17:35848621	DUSP14	0.48	5.97	0.36	8.03e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg20534287	chr10:135191450	PAOX	0.53	5.55	0.33	7.29e-8	Lifespan;
KIRP	cis	rs6142102	0.961	rs2284378	chr20:32588095	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	6.69	0.39	1.46e-10	Skin pigmentation;
KIRP	cis	rs72960926	0.744	rs11755740	chr6:74934131	C/T	cg03266952	chr6:74778945	NA	-0.73	-5.34	-0.32	2.11e-7	Metabolite levels (MHPG);
KIRP	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17507749	chr15:85114479	UBE2QP1	0.72	8.1	0.46	2.53e-14	Schizophrenia;
KIRP	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg04132472	chr17:19861366	AKAP10	0.38	4.87	0.3	2.04e-6	Schizophrenia;
KIRP	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg00792783	chr2:198669748	PLCL1	0.45	5.01	0.3	1.04e-6	Intracranial aneurysm;
KIRP	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg17366294	chr4:99064904	C4orf37	-0.35	-4.93	-0.3	1.52e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg03714773	chr7:91764589	CYP51A1	0.37	5.56	0.33	6.97e-8	Breast cancer;
KIRP	cis	rs9367716	0.917	rs1013147	chr6:57124881	C/T	cg03371099	chr6:57305889	PRIM2	-0.45	-5.96	-0.36	8.54e-9	Coronary artery disease;
KIRP	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.85	11.19	0.58	8.84e-24	Menarche (age at onset);
KIRP	cis	rs4774899	0.966	rs11071305	chr15:57371178	A/G	cg13626582	chr15:57592083	LOC283663	-0.2	-4.91	-0.3	1.69e-6	Urinary tract infection frequency;
KIRP	cis	rs6987853	0.931	rs3099936	chr8:42384331	C/T	cg09913449	chr8:42400586	C8orf40	-0.4	-5.05	-0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.8	12.38	0.62	1.09e-27	Skin aging (microtopography measurement);
KIRP	cis	rs9962915	1.000	rs1539812	chr18:5596091	T/C	cg12967001	chr18:5544089	EPB41L3	-0.43	-5.34	-0.32	2.07e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17321999	0.516	rs7563661	chr2:30497757	G/A	cg05247661	chr2:30472410	LBH	0.67	5.54	0.33	7.58e-8	Systemic lupus erythematosus;
KIRP	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-8.23	-0.46	1.07e-14	Colorectal cancer;
KIRP	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.89	12.78	0.63	5.21e-29	Bladder cancer;
KIRP	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg18477163	chr1:228402036	OBSCN	0.27	5.17	0.31	4.81e-7	Diastolic blood pressure;
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.78	-13.08	-0.64	5.02e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.65	-7.25	-0.42	5.4e-12	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs1420338	0.967	rs1014581	chr7:34164677	T/G	cg01275685	chr7:34179230	BMPER	-0.51	-7.39	-0.43	2.35e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	1.02	10.37	0.55	3.86e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1215050	0.791	rs2123100	chr4:98803747	T/C	cg05340658	chr4:99064831	C4orf37	0.53	6.43	0.38	6.71e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg17674042	chr6:34482479	PACSIN1	-0.62	-6.7	-0.39	1.4e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs9398803	0.678	rs1155938	chr6:126866472	C/A	cg19875578	chr6:126661172	C6orf173	0.39	4.98	0.3	1.18e-6	Male-pattern baldness;
KIRP	cis	rs11250097	0.506	rs34365278	chr8:11309780	G/A	cg21775007	chr8:11205619	TDH	-0.43	-5.02	-0.3	1.01e-6	Neuroticism;
KIRP	cis	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg06521331	chr12:34319734	NA	-0.47	-5.75	-0.34	2.63e-8	Morning vs. evening chronotype;
KIRP	cis	rs501120	1.000	rs534079	chr10:44752558	G/T	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.95	14.76	0.69	9.83e-36	Menopause (age at onset);
KIRP	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.79	7.17	0.42	8.52e-12	Alzheimer's disease;
KIRP	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.77	9.17	0.5	1.95e-17	Adiposity;
KIRP	cis	rs9815354	1.000	rs6796210	chr3:41851718	T/C	cg03022575	chr3:42003672	ULK4	0.5	5.83	0.35	1.75e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.78	0.4	8.66e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.9	-12.36	-0.62	1.27e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.73	10.71	0.56	3.24e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.31	-0.42	3.79e-12	Bladder cancer;
KIRP	cis	rs4713675	0.565	rs4713674	chr6:33708169	C/T	cg15676125	chr6:33679581	C6orf125	-0.41	-5.21	-0.32	3.92e-7	Plateletcrit;
KIRP	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.34	-0.47	5.48e-15	Life satisfaction;
KIRP	cis	rs2458413	0.542	rs2853146	chr8:105370179	G/A	cg08657449	chr8:105351661	TM7SF4	-0.34	-5.62	-0.34	5.06e-8	Paget's disease;
KIRP	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.14	16.52	0.73	9.43e-42	Breast cancer;
KIRP	cis	rs4762326	0.584	rs3816838	chr12:95668437	G/T	cg07737802	chr12:95537812	FGD6	0.39	5.21	0.32	3.95e-7	Endometriosis;
KIRP	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg13819577	chr1:248512075	OR14C36	0.35	5.05	0.31	8.62e-7	Common traits (Other);
KIRP	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	10.7	0.56	3.5e-22	Coronary artery disease;
KIRP	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg05791153	chr7:19748676	TWISTNB	0.69	6.04	0.36	5.59e-9	Thyroid stimulating hormone;
KIRP	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.73	-9.17	-0.5	1.95e-17	Blood pressure (smoking interaction);
KIRP	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.41	-0.38	7.44e-10	Aortic root size;
KIRP	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.49	6.38	0.38	8.56e-10	Blood metabolite levels;
KIRP	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg20999797	chr1:1681921	NA	0.5	7.54	0.43	9e-13	Body mass index;
KIRP	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.26	-5.62	-0.34	5.16e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs8103278	0.706	rs3810333	chr19:46318691	T/C	cg14061069	chr19:46274453	DMPK	-0.41	-5.93	-0.35	9.99e-9	Coronary artery disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg20540327	chr15:72668275	HEXA;C15orf34	0.56	6.92	0.4	3.86e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.83	-0.35	1.7e-8	Breast cancer;
KIRP	cis	rs12282928	1.000	rs12292297	chr11:48329794	C/A	cg26585981	chr11:48327164	OR4S1	0.5	6.09	0.36	4.28e-9	Migraine - clinic-based;
KIRP	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.77	13.08	0.64	5.07e-30	Cancer;
KIRP	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg20999797	chr1:1681921	NA	0.5	7.4	0.43	2.14e-12	Body mass index;
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	0.84	14.36	0.68	2.24e-34	Vitiligo;
KIRP	trans	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.2	-0.37	2.38e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.59	6.05	0.36	5.46e-9	Vitiligo;
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.76	-0.34	2.54e-8	Life satisfaction;
KIRP	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.72	-7.68	-0.44	3.7e-13	Gut microbiome composition (summer);
KIRP	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-6.82	-0.4	7.01e-11	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs5753618	0.539	rs4820962	chr22:31689951	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.33	-0.32	2.18e-7	Colorectal cancer;
KIRP	cis	rs17221829	0.733	rs10765228	chr11:89385132	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg24009623	chr19:33667908	NA	0.49	6.28	0.37	1.52e-9	Colorectal cancer;
KIRP	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg25811766	chr13:21894605	NA	-0.6	-5.82	-0.35	1.79e-8	White matter hyperintensity burden;
KIRP	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg25251562	chr2:3704773	ALLC	-0.51	-6.0	-0.36	7.07e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg17252645	chr8:143867129	LY6D	-0.31	-4.98	-0.3	1.21e-6	Urinary tract infection frequency;
KIRP	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.68	9.13	0.5	2.64e-17	Personality dimensions;
KIRP	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg22029157	chr1:209979665	IRF6	0.39	6.0	0.36	6.98e-9	Monobrow;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg13789711	chr9:139743225	PHPT1	0.76	6.55	0.39	3.27e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1511802	0.666	rs3817184	chr4:187122304	C/T	cg24794857	chr4:187113578	CYP4V2	0.38	5.28	0.32	2.8e-7	Blood protein levels;
KIRP	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.58	-7.23	-0.42	6.09e-12	Neuroticism;
KIRP	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17554472	chr22:41940697	POLR3H	-0.58	-6.5	-0.38	4.52e-10	Vitiligo;
KIRP	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.64	8.91	0.49	1.2e-16	Blood protein levels;
KIRP	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg16989719	chr2:238392110	NA	-0.49	-5.38	-0.32	1.73e-7	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20994490	chr1:63988814	ITGB3BP;EFCAB7	0.43	6.16	0.37	2.87e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg24315340	chr6:146058215	EPM2A	0.45	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-1.01	-15.73	-0.71	4.63e-39	Coronary artery disease;
KIRP	cis	rs4805834	0.764	rs2404712	chr19:33461848	A/G	cg07201929	chr19:33182834	NUDT19	0.66	5.22	0.32	3.84e-7	Creatinine levels;
KIRP	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18252515	chr7:66147081	NA	-0.45	-5.25	-0.32	3.3e-7	Aortic root size;
KIRP	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg11168104	chr5:1857477	NA	-0.38	-4.91	-0.3	1.66e-6	Cardiovascular disease risk factors;
KIRP	cis	rs2554380	0.943	rs2585042	chr15:84341748	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.64	-8.79	-0.49	2.6e-16	Height;
KIRP	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg03647239	chr10:116582469	FAM160B1	-0.52	-5.79	-0.35	2.14e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-6.02	-0.36	6.16e-9	Lung cancer;
KIRP	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2625529	0.642	rs2200056	chr15:72302667	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-5.98	-0.36	7.69e-9	Red blood cell count;
KIRP	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg10845886	chr2:3471009	TTC15	-0.52	-7.4	-0.43	2.16e-12	Neurofibrillary tangles;
KIRP	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Hypertriglyceridemia;
KIRP	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.71	9.26	0.51	1.02e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4400599	0.618	rs1194599	chr1:154236452	C/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.58	-0.33	6.49e-8	Platelet distribution width;
KIRP	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg13319975	chr6:146136371	FBXO30	0.39	5.26	0.32	3.14e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.7	-10.37	-0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-1.03	-11.77	-0.6	1.16e-25	Platelet distribution width;
KIRP	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.79	11.44	0.59	1.35e-24	IgG glycosylation;
KIRP	cis	rs911119	0.837	rs2208289	chr20:23579526	A/G	cg09631192	chr20:23583594	CST9	0.45	4.87	0.3	1.99e-6	Chronic kidney disease;
KIRP	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15320075	chr8:145703422	NA	0.66	8.49	0.48	2.03e-15	Age at first birth;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00689492	chr4:1303491	MAEA	0.3	5.18	0.31	4.69e-7	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg03929089	chr4:120376271	NA	-0.54	-6.63	-0.39	2.15e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg04087571	chr11:116723030	SIK3	-0.27	-5.66	-0.34	4.16e-8	Subjective well-being;
KIRP	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg22138327	chr13:27999177	GTF3A	0.93	7.11	0.41	1.24e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs199950	0.911	rs12071300	chr1:181599089	T/G	cg04237608	chr1:18659049	IGSF21	-0.38	-6.17	-0.37	2.81e-9	Body mass index (change over time);
KIRP	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.14	0.46	1.92e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-4.85	-0.3	2.21e-6	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.7	-6.6	-0.39	2.57e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.12	0.5	2.82e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.64	-6.78	-0.4	9e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg01324507	chr7:1177794	C7orf50	0.52	4.87	0.3	1.96e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs7688540	0.771	rs11723615	chr4:276983	A/G	cg17891759	chr4:299121	NA	-0.47	-4.87	-0.3	1.99e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.63	-8.57	-0.48	1.16e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg04289385	chr6:36355825	ETV7	0.45	7.24	0.42	5.89e-12	Platelet distribution width;
KIRP	cis	rs362296	0.698	rs362266	chr4:3259632	C/G	cg06533319	chr4:3265114	C4orf44	0.57	6.69	0.39	1.52e-10	Parental longevity (mother's age at death);
KIRP	cis	rs1440410	0.798	rs7684430	chr4:144054344	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.26e-10	Ischemic stroke;
KIRP	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg27490568	chr2:178487706	NA	0.47	6.29	0.37	1.47e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00500522	chr12:57504387	STAT6	0.46	6.3	0.37	1.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.11	-0.36	3.84e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg18164611	chr1:46958628	NA	0.43	5.39	0.32	1.68e-7	Monobrow;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16752925	chr8:145235335	HEATR7A	0.45	6.11	0.36	3.77e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs5766691	1.000	rs5766691	chr22:47532396	A/G	cg15757745	chr22:47558489	TBC1D22A	-0.42	-5.16	-0.31	5.05e-7	Longevity;
KIRP	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg17207736	chr8:142237307	SLC45A4	-0.46	-5.6	-0.34	5.6e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.81	8.76	0.49	3.34e-16	Exhaled nitric oxide output;
KIRP	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25517755	chr10:38738941	LOC399744	-0.37	-5.07	-0.31	7.92e-7	Extrinsic epigenetic age acceleration;
KIRP	trans	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	9.03	0.5	5.27e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.17	-0.42	8.78e-12	Myopia (pathological);
KIRP	cis	rs17123764	0.818	rs57916875	chr12:49989336	G/A	cg20471783	chr12:50157085	TMBIM6	0.4	5.69	0.34	3.64e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg03714773	chr7:91764589	CYP51A1	0.4	5.97	0.36	8.12e-9	Breast cancer;
KIRP	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg13731523	chr4:3047190	NA	-0.39	-6.15	-0.36	3.19e-9	Serum sulfate level;
KIRP	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg10523679	chr1:76189770	ACADM	-0.45	-6.39	-0.38	8.41e-10	Daytime sleep phenotypes;
KIRP	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.91	15.07	0.69	8.55e-37	Menarche (age at onset);
KIRP	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	8.1e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77861329	1.000	rs9843299	chr3:52137469	G/T	cg08692210	chr3:52188851	WDR51A	0.84	5.86	0.35	1.48e-8	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.78	-0.4	9.03e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs1712790	0.702	rs10502192	chr11:114622352	C/T	cg19465033	chr11:114479364	NA	0.39	5.17	0.31	4.82e-7	Urinary albumin excretion;
KIRP	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg21401794	chr1:90099060	LRRC8C	0.7	9.8	0.53	2.4e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.46	6.96	0.41	3.07e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg20744362	chr22:50050164	C22orf34	0.31	4.88	0.3	1.91e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07837717	chr19:2841006	ZNF555	-0.44	-6.09	-0.36	4.42e-9	Metabolic traits;
KIRP	cis	rs4356932	0.656	rs11732759	chr4:76856440	T/A	cg00809888	chr4:76862425	NAAA	-0.41	-5.65	-0.34	4.53e-8	Blood protein levels;
KIRP	cis	rs6723108	0.654	rs520449	chr2:135295619	C/T	cg25422880	chr2:135218333	TMEM163	-0.41	-5.52	-0.33	8.41e-8	Type 2 diabetes;
KIRP	cis	rs1978968	1.000	rs5013014	chr22:18449927	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.69	-0.39	1.46e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs9596863	1.000	rs1379833	chr13:54443167	C/T	ch.13.53330881F	chr13:54432880	NA	0.56	5.72	0.34	3e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4765905	0.580	rs4765668	chr12:2312826	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.92	0.53	9.72e-20	Lung cancer;
KIRP	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.61	6.26	0.37	1.68e-9	Axial length;
KIRP	cis	rs2120243	0.508	rs4435581	chr3:157096217	G/A	cg24825693	chr3:157122686	VEPH1	-0.56	-9.04	-0.5	4.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.95	10.93	0.57	6.13e-23	Corneal astigmatism;
KIRP	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg09173681	chr1:183549694	NCF2	-0.83	-11.29	-0.58	4.18e-24	Systemic lupus erythematosus;
KIRP	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-4.94	-0.3	1.42e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.84	-11.41	-0.59	1.78e-24	Longevity;Endometriosis;
KIRP	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg09517075	chr8:22133004	PIWIL2	0.45	5.96	0.36	8.56e-9	Hypertriglyceridemia;
KIRP	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.61	9.52	0.52	1.68e-18	Coronary artery disease;
KIRP	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-1.19	-15.36	-0.7	8.39e-38	Platelet distribution width;
KIRP	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.75	0.44	2.42e-13	Height;
KIRP	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	0.83	9.05	0.5	4.46e-17	Gut microbiome composition (summer);
KIRP	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg03959625	chr15:84868606	LOC388152	0.56	6.76	0.4	9.99e-11	Schizophrenia;
KIRP	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.4	-0.33	1.6e-7	Bladder cancer;
KIRP	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.78	13.89	0.66	8.83e-33	Height;
KIRP	cis	rs10802346	0.636	rs12027922	chr1:246423532	G/A	cg15962031	chr1:246363574	SMYD3	0.79	5.92	0.35	1.07e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs34779708	0.966	rs11010135	chr10:35518063	A/G	cg04310649	chr10:35416472	CREM	-0.53	-5.79	-0.35	2.1e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg08799069	chr10:126477246	METTL10	0.42	5.79	0.35	2.19e-8	Asthma;
KIRP	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.31	5.66	0.34	4.16e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs3026101	0.671	rs1806239	chr17:5295528	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg00405596	chr8:11794950	NA	0.47	5.73	0.34	2.94e-8	Monocyte count;
KIRP	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg06121193	chr1:90282411	NA	-0.48	-6.94	-0.4	3.55e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg21851534	chr17:3907994	ZZEF1	-0.48	-6.33	-0.37	1.17e-9	Type 2 diabetes;
KIRP	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.62	-0.34	5.11e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg05156742	chr15:59063176	FAM63B	0.5	5.83	0.35	1.78e-8	Schizophrenia;
KIRP	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg01864069	chr14:103024347	NA	-1.0	-13.02	-0.64	8.19e-30	Platelet count;
KIRP	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08704250	chr15:31115839	NA	-0.58	-8.16	-0.46	1.71e-14	Huntington's disease progression;
KIRP	cis	rs3764563	0.935	rs623700	chr19:15698544	C/T	cg20725493	chr19:15740067	CYP4F8	0.88	6.23	0.37	2.01e-9	Inflammatory biomarkers;
KIRP	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.48	-6.16	-0.37	2.96e-9	Schizophrenia;
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg05941025	chr16:89927596	SPIRE2	0.38	6.01	0.36	6.77e-9	Vitiligo;
KIRP	cis	rs1978968	0.956	rs5992925	chr22:18447697	G/A	cg03078520	chr22:18463400	MICAL3	-0.64	-7.61	-0.44	5.68e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg24796726	chr7:884288	UNC84A	0.62	5.49	0.33	1.02e-7	Initial pursuit acceleration;
KIRP	cis	rs575018	0.774	rs4509001	chr5:100592381	T/C	cg03848127	chr5:100126093	NA	-0.45	-5.42	-0.33	1.41e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7808935	0.581	rs6968704	chr7:27966984	C/T	cg22168087	chr7:27702803	HIBADH	0.55	6.4	0.38	7.71e-10	Prostate cancer;
KIRP	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	1.05	22.79	0.82	1.45e-62	Multiple myeloma;
KIRP	cis	rs35883536	1.000	rs1832121	chr1:101159476	A/G	cg06223162	chr1:101003688	GPR88	0.35	7.33	0.42	3.35e-12	Monocyte count;
KIRP	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg10381502	chr11:71823885	C11orf51	-1.11	-7.75	-0.44	2.41e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs10170310	1.000	rs10170310	chr2:139278922	C/T	cg10095539	chr2:139258744	SPOPL	0.34	5.44	0.33	1.3e-7	Response to antipsychotic treatment;
KIRP	cis	rs1971762	0.966	rs11170631	chr12:54041192	T/C	cg16917193	chr12:54089295	NA	0.69	9.48	0.52	2.23e-18	Height;
KIRP	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg03714773	chr7:91764589	CYP51A1	0.34	5.12	0.31	6.17e-7	Breast cancer;
KIRP	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg07701084	chr6:150067640	NUP43	0.58	7.33	0.42	3.36e-12	Testicular germ cell tumor;
KIRP	cis	rs12220238	0.778	rs10824216	chr10:76409210	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.12	0.36	3.61e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg16584676	chr17:46985605	UBE2Z	0.45	5.64	0.34	4.58e-8	Type 2 diabetes;
KIRP	cis	rs1420338	0.933	rs10253869	chr7:34149922	A/G	cg01275685	chr7:34179230	BMPER	-0.51	-7.35	-0.42	2.84e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs4728302	0.869	rs13233715	chr7:133617471	C/T	cg10665199	chr7:133106180	EXOC4	0.45	5.46	0.33	1.19e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg27411982	chr8:10470053	RP1L1	0.41	5.02	0.3	1.01e-6	Retinal vascular caliber;
KIRP	cis	rs10073892	0.687	rs924681	chr5:101877499	A/T	cg19774478	chr5:101632501	SLCO4C1	0.51	5.77	0.35	2.4e-8	Cognitive decline (age-related);
KIRP	cis	rs7927771	0.793	rs3740686	chr11:47376363	A/G	cg20307385	chr11:47447363	PSMC3	0.5	5.3	0.32	2.61e-7	Subjective well-being;
KIRP	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	0.9	13.14	0.64	3.03e-30	Dupuytren's disease;
KIRP	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.68	9.01	0.5	5.71e-17	Bladder cancer;
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.71	0.34	3.33e-8	Lung cancer;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.55	-7.2	-0.42	7.09e-12	Migraine;
KIRP	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.65	7.97	0.45	5.76e-14	Obesity-related traits;
KIRP	trans	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10838634	1.000	rs9667108	chr11:46935185	G/C	cg25873214	chr11:47587499	PTPMT1	-0.59	-4.86	-0.3	2.07e-6	Schizophrenia;
KIRP	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg04725166	chr1:7887271	PER3	0.35	5.52	0.33	8.42e-8	Crohn's disease;
KIRP	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg23950597	chr19:37808831	NA	-0.75	-7.59	-0.44	6.43e-13	Coronary artery calcification;
KIRP	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.52e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9462846	0.959	rs10456518	chr6:42830484	G/A	cg02353165	chr6:42928485	GNMT	0.44	5.03	0.31	9.4e-7	Blood protein levels;
KIRP	cis	rs7116495	0.609	rs11235444	chr11:71831859	G/A	cg07596299	chr11:71824057	C11orf51	0.86	5.26	0.32	3.18e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg04058563	chr4:185651563	MLF1IP	0.43	5.3	0.32	2.54e-7	Kawasaki disease;
KIRP	cis	rs992157	0.932	rs4672884	chr2:219182481	G/A	cg00012203	chr2:219082015	ARPC2	-0.73	-9.67	-0.52	6.12e-19	Colorectal cancer;
KIRP	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.89	-0.35	1.23e-8	Response to antipsychotic treatment;
KIRP	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg03808351	chr9:123631620	PHF19	0.41	5.59	0.34	6.15e-8	Rheumatoid arthritis;
KIRP	cis	rs8179	0.627	rs17688839	chr7:92263350	A/T	cg15732164	chr7:92237376	CDK6	-0.47	-5.24	-0.32	3.46e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg04166393	chr7:2884313	GNA12	0.39	5.07	0.31	7.95e-7	Height;
KIRP	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Colorectal cancer;
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	14.41	0.68	1.5e-34	Platelet count;
KIRP	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg12131826	chr15:77904385	NA	0.42	4.86	0.3	2.12e-6	Type 2 diabetes;
KIRP	cis	rs6539288	0.677	rs10778515	chr12:107332481	A/G	cg21360079	chr12:107162445	NA	-0.44	-5.52	-0.33	8.49e-8	Total body bone mineral density;
KIRP	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs734999	0.967	rs6667605	chr1:2502780	C/T	cg20673091	chr1:2541236	MMEL1	0.42	5.97	0.36	8.24e-9	Ulcerative colitis;
KIRP	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	0.97	12.77	0.63	5.65e-29	Breast cancer;
KIRP	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.39	0.33	1.64e-7	Diisocyanate-induced asthma;
KIRP	cis	rs12425451	0.552	rs10848765	chr12:3141495	C/T	cg01521688	chr12:3131390	TEAD4	-0.48	-6.11	-0.36	3.79e-9	Narcolepsy with cataplexy;
KIRP	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.6	-0.44	6.17e-13	Joint mobility (Beighton score);
KIRP	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.69	8.87	0.49	1.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg10503236	chr1:231470652	EXOC8	0.49	7.17	0.42	8.91e-12	Hemoglobin concentration;
KIRP	cis	rs4903604	0.581	rs4899658	chr14:78035392	A/T	cg18872420	chr14:78023429	SPTLC2	-0.37	-5.71	-0.34	3.32e-8	Gut microbiome composition (winter);
KIRP	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.41	-7.39	-0.43	2.29e-12	Refractive error;
KIRP	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg22778903	chr21:42741698	MX2	-0.61	-8.35	-0.47	5.02e-15	Melanoma;
KIRP	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	0.89	8.99	0.5	6.98e-17	Methadone dose in opioid dependence;
KIRP	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11613427	chr3:52932208	TMEM110	-0.3	-4.86	-0.3	2.06e-6	Schizophrenia;
KIRP	trans	rs9693857	0.505	rs2085640	chr8:9265464	A/C	cg08975724	chr8:8085496	FLJ10661	0.5	6.32	0.37	1.19e-9	Systolic blood pressure;
KIRP	cis	rs539514	0.516	rs2273996	chr13:76410725	A/G	cg04757411	chr13:76259545	LMO7	0.47	6.62	0.39	2.18e-10	Type 1 diabetes;
KIRP	cis	rs9604529	0.759	rs113010684	chr13:114615754	G/A	cg13259177	chr13:114761607	RASA3	-0.71	-5.83	-0.35	1.72e-8	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg11621586	chr10:70884670	VPS26A	1.14	15.32	0.7	1.18e-37	Left atrial antero-posterior diameter;
KIRP	cis	rs1712790	0.651	rs12270926	chr11:114619805	G/A	cg19465033	chr11:114479364	NA	0.4	5.32	0.32	2.37e-7	Urinary albumin excretion;
KIRP	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg05043794	chr9:111880884	C9orf5	-0.25	-4.86	-0.3	2.09e-6	Menarche (age at onset);
KIRP	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.43	6.24	0.37	1.94e-9	Tuberculosis;
KIRP	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg22963979	chr7:1858916	MAD1L1	0.39	5.32	0.32	2.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.89	-0.3	1.85e-6	Obesity-related traits;
KIRP	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-0.73	-6.5	-0.38	4.32e-10	Obesity-related traits;
KIRP	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.18	14.1	0.67	1.78e-33	Corneal structure;
KIRP	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg05347473	chr6:146136440	FBXO30	0.48	6.87	0.4	5.16e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6496044	0.507	rs8034676	chr15:86159262	C/T	cg10818794	chr15:86012489	AKAP13	-0.42	-5.72	-0.34	3.03e-8	Interstitial lung disease;
KIRP	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.52	-6.34	-0.37	1.07e-9	Response to antidepressants in depression;
KIRP	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg03609598	chr5:56110824	MAP3K1	0.68	6.67	0.39	1.69e-10	Initial pursuit acceleration;
KIRP	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.85	0.35	1.58e-8	Total cholesterol levels;
KIRP	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg09795085	chr6:101329169	ASCC3	0.47	5.68	0.34	3.69e-8	Neuroticism;
KIRP	cis	rs12476592	0.602	rs7563623	chr2:63720210	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-4.9	-0.3	1.74e-6	Childhood ear infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10226419	chr13:45914925	LOC100190939;TPT1	0.45	6.2	0.37	2.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs8027181	0.839	rs2277598	chr15:73027478	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.53	7.79	0.44	1.92e-13	Triglyceride levels;
KIRP	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18252515	chr7:66147081	NA	-0.47	-5.56	-0.33	6.98e-8	Aortic root size;
KIRP	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg17691542	chr6:26056736	HIST1H1C	0.44	5.76	0.34	2.45e-8	Schizophrenia;
KIRP	cis	rs13095912	0.962	rs11916386	chr3:185308069	G/T	cg11274856	chr3:185301563	NA	0.51	6.67	0.39	1.63e-10	Systolic blood pressure;
KIRP	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.21	-0.32	3.93e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg18944383	chr4:111397179	ENPEP	0.43	6.97	0.41	2.96e-11	Coronary artery disease;
KIRP	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.19	-0.42	7.69e-12	Joint mobility (Beighton score);
KIRP	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.51	6.57	0.39	2.91e-10	Height;
KIRP	cis	rs7590368	0.961	rs13431852	chr2:10960410	T/C	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg03342759	chr3:160939853	NMD3	-0.45	-5.56	-0.33	6.98e-8	Morning vs. evening chronotype;
KIRP	cis	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs2479106	0.727	rs10986139	chr9:126689150	C/G	cg16191174	chr9:126692580	DENND1A	0.49	5.73	0.34	2.93e-8	Polycystic ovary syndrome;
KIRP	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg03171003	chr2:111875934	NA	0.39	5.34	0.32	2.1e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs2970992	0.692	rs7558366	chr2:101324705	T/C	cg01042948	chr2:101319752	NA	0.42	6.34	0.37	1.07e-9	Educational attainment;
KIRP	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.83	-0.49	2.06e-16	Chronic sinus infection;
KIRP	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06079273	chr8:97247865	UQCRB	0.45	6.48	0.38	4.98e-10	Survival in pancreatic cancer;
KIRP	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.1	0.36	4.09e-9	Ovarian reserve;
KIRP	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg12140854	chr5:148520817	ABLIM3	-0.41	-5.1	-0.31	6.76e-7	Breast cancer;
KIRP	cis	rs754423	0.548	rs7155552	chr14:52569547	T/C	cg05884192	chr14:52515736	NID2	-0.48	-5.38	-0.32	1.74e-7	Craniofacial microsomia;
KIRP	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.91	0.4	4.19e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.83	-14.11	-0.67	1.55e-33	Brugada syndrome;
KIRP	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs17321999	0.857	rs1962588	chr2:30465122	T/G	cg05247661	chr2:30472410	LBH	0.76	7.29	0.42	4.09e-12	Systemic lupus erythematosus;
KIRP	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.37	-0.32	1.82e-7	Breast cancer;
KIRP	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.77	10.62	0.56	6.11e-22	Monocyte count;
KIRP	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.61	-6.82	-0.4	6.87e-11	Gut microbiome composition (summer);
KIRP	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08905701	chr5:35232164	PRLR	0.44	6.05	0.36	5.25e-9	Interleukin-4 levels;
KIRP	cis	rs7267005	1.000	rs76009645	chr20:34493255	T/C	cg17201900	chr20:34330562	RBM39	0.87	4.9	0.3	1.71e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg02151108	chr14:50098012	C14orf104	-0.58	-8.24	-0.46	1.05e-14	Carotid intima media thickness;
KIRP	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg08975724	chr8:8085496	FLJ10661	0.72	8.38	0.47	4.23e-15	Red cell distribution width;
KIRP	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	6.83	0.4	6.6e-11	Initial pursuit acceleration;
KIRP	cis	rs6450176	0.859	rs3776719	chr5:53298684	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.1	-0.58	1.78e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.82	-0.35	1.82e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg22800045	chr5:56110881	MAP3K1	0.67	7.31	0.42	3.68e-12	Initial pursuit acceleration;
KIRP	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg04315214	chr1:2043799	PRKCZ	-0.35	-5.58	-0.33	6.45e-8	Height;
KIRP	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.14	-0.31	5.61e-7	Height;
KIRP	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg01422370	chr2:73384389	NA	0.42	5.55	0.33	7.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2415984	0.622	rs12434073	chr14:46921265	G/A	cg14871534	chr14:47121158	RPL10L	-0.45	-5.37	-0.32	1.86e-7	Number of children ever born;
KIRP	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26002218	chr14:103986227	CKB	0.27	5.13	0.31	6e-7	Body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18618936	chr12:122255346	SETD1B	0.5	6.58	0.39	2.83e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.83	11.98	0.61	2.32e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9816226	0.591	rs57912727	chr3:185804583	A/C	cg00760338	chr3:185826511	ETV5	-0.73	-6.4	-0.38	7.82e-10	Obesity;Body mass index;
KIRP	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.76	9.24	0.51	1.17e-17	Response to bleomycin (chromatid breaks);
KIRP	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.79	7.45	0.43	1.56e-12	Obesity-related traits;
KIRP	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.54	-5.36	-0.32	1.93e-7	Obesity-related traits;
KIRP	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.84	10.6	0.56	7.28e-22	Multiple sclerosis;
KIRP	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.5	5.6	0.34	5.58e-8	Subjective well-being;
KIRP	cis	rs714027	0.605	rs2412976	chr22:30567907	C/G	cg27665648	chr22:30112403	NA	0.45	6.4	0.38	7.73e-10	Lymphocyte counts;
KIRP	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.16	0.42	9.43e-12	Height;
KIRP	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs1355223	0.934	rs11602669	chr11:34695114	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.33	-0.32	2.18e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.98	10.59	0.56	7.67e-22	HIV-1 control;
KIRP	cis	rs4356932	0.790	rs6532130	chr4:76969190	A/G	cg00809888	chr4:76862425	NAAA	0.43	5.93	0.35	1.02e-8	Blood protein levels;
KIRP	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	1.18	12.94	0.64	1.41e-29	Psoriasis;
KIRP	trans	rs4498364	0.541	rs1206155	chr6:97549206	C/T	cg01048931	chr7:55639931	VOPP1	-0.52	-6.31	-0.37	1.28e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.47	0.72	1.44e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs838147	0.508	rs507711	chr19:49208564	C/T	cg21064579	chr19:49206444	FUT2	0.54	7.7	0.44	3.26e-13	Dietary macronutrient intake;
KIRP	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg17294928	chr15:75287854	SCAMP5	-0.66	-5.87	-0.35	1.38e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14199148	chr13:52158669	WDFY2	0.48	6.47	0.38	5.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg08131204	chr22:41487073	MIR1281	-0.44	-5.13	-0.31	6e-7	Neuroticism;
KIRP	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.1	-0.36	4.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.13	-0.31	5.85e-7	Cholesterol, total;
KIRP	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg18753928	chr3:113234510	CCDC52	-0.6	-5.76	-0.34	2.49e-8	Dental caries;
KIRP	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26314531	chr2:26401878	FAM59B	-0.48	-5.08	-0.31	7.3e-7	Gut microbiome composition (summer);
KIRP	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06173319	chr16:90148775	NA	0.59	5.44	0.33	1.28e-7	Skin colour saturation;
KIRP	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.75	11.83	0.6	7.54e-26	Calcium levels;
KIRP	cis	rs66696671	0.559	rs11199037	chr10:121357825	G/T	cg06765389	chr10:121379685	NA	-0.4	-5.4	-0.33	1.58e-7	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.58	11.96	0.61	2.68e-26	Diabetic kidney disease;
KIRP	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg02725872	chr8:58115012	NA	-0.45	-5.33	-0.32	2.26e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg07402062	chr16:89894098	SPIRE2	0.32	6.54	0.38	3.5e-10	Vitiligo;
KIRP	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg12315302	chr6:26189340	HIST1H4D	1.0	6.82	0.4	6.86e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.54	-0.39	3.45e-10	Lung cancer;
KIRP	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg18383594	chr14:62263120	SNAPC1	-0.44	-5.72	-0.34	3e-8	Select biomarker traits;
KIRP	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg04865290	chr3:52927548	TMEM110	-0.43	-5.19	-0.31	4.35e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg02462569	chr6:150064036	NUP43	-0.34	-5.01	-0.3	1.04e-6	Lung cancer;
KIRP	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.78	-0.49	2.78e-16	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.62	7.5	0.43	1.14e-12	Coronary artery disease;
KIRP	cis	rs834603	0.575	rs1704970	chr7:47466512	C/T	cg09696706	chr7:47479511	TNS3	0.43	4.89	0.3	1.8e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs61867294	0.597	rs4917433	chr10:106693002	A/G	cg11455642	chr10:106494954	SORCS3	0.34	4.96	0.3	1.33e-6	Schizophrenia;
KIRP	cis	rs1050631	0.592	rs1785921	chr18:33737196	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.88	0.35	1.36e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	9.1	0.5	3.1e-17	Smoking behavior;
KIRP	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.65	-5.46	-0.33	1.17e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg04691961	chr3:161091175	C3orf57	-0.66	-11.15	-0.58	1.2e-23	Morning vs. evening chronotype;
KIRP	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.51	0.48	1.77e-15	Prudent dietary pattern;
KIRP	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs11628318	1.000	rs12892184	chr14:103040300	C/A	cg01864069	chr14:103024347	NA	-0.74	-9.58	-0.52	1.1e-18	Platelet count;
KIRP	cis	rs10114408	0.959	rs7847426	chr9:96642908	A/T	cg14598338	chr9:96623480	NA	-0.33	-4.85	-0.3	2.24e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg18190219	chr22:46762943	CELSR1	-0.7	-5.94	-0.35	9.52e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6191	0.838	rs6877893	chr5:142727193	C/T	cg08845721	chr5:142780693	NR3C1	-0.39	-5.52	-0.33	8.44e-8	Night sleep phenotypes;
KIRP	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg08873628	chr1:175162347	KIAA0040	0.44	6.5	0.38	4.31e-10	Diastolic blood pressure;
KIRP	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.59	7.79	0.44	1.91e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg02733842	chr7:1102375	C7orf50	0.58	5.92	0.35	1.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.18	18.9	0.77	7.88e-50	Height;
KIRP	cis	rs785830	0.600	rs535550	chr9:245752	C/T	cg14500300	chr9:211689	NA	-0.45	-5.88	-0.35	1.31e-8	Platelet distribution width;
KIRP	cis	rs17221829	0.733	rs11018728	chr11:89415942	G/A	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.26	-0.32	3.08e-7	Anxiety in major depressive disorder;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.72	11.28	0.58	4.75e-24	Menarche (age at onset);
KIRP	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.76	-0.34	2.53e-8	Neuroticism;
KIRP	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	14.21	0.67	7.44e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-6.03	-0.36	6.03e-9	Chronic sinus infection;
KIRP	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg26893134	chr6:116381904	FRK	0.21	5.76	0.34	2.46e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1559088	0.847	rs3760891	chr19:33599708	C/T	cg24009623	chr19:33667908	NA	0.48	6.1	0.36	3.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.81	12.88	0.63	2.35e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg05044414	chr3:183734942	ABCC5	0.32	5.02	0.3	1e-6	Anterior chamber depth;
KIRP	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.66	7.33	0.42	3.33e-12	Initial pursuit acceleration;
KIRP	cis	rs10465746	0.967	rs28445286	chr1:84430483	A/G	cg10977910	chr1:84465055	TTLL7	0.48	5.81	0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.41	5.36	0.32	1.88e-7	Cardiovascular disease risk factors;
KIRP	cis	rs11997175	0.545	rs5005657	chr8:33668913	C/G	ch.8.33884649F	chr8:33765107	NA	0.5	5.97	0.36	8.25e-9	Body mass index;
KIRP	cis	rs1881396	0.891	rs2141372	chr2:27827196	G/T	cg27432699	chr2:27873401	GPN1	0.57	6.71	0.39	1.32e-10	Nonalcoholic fatty liver disease;
KIRP	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14169450	chr9:139327907	INPP5E	-0.55	-6.19	-0.37	2.44e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-7.03	-0.41	1.97e-11	Response to antipsychotic treatment;
KIRP	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.63	7.07	0.41	1.57e-11	Aortic root size;
KIRP	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.81	-0.49	2.28e-16	Response to antipsychotic treatment;
KIRP	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.6	-6.85	-0.4	5.85e-11	Menarche (age at onset);
KIRP	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.44	6.08	0.36	4.57e-9	Total body bone mineral density;
KIRP	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg05973401	chr12:123451056	ABCB9	0.63	6.75	0.4	1.08e-10	Neutrophil percentage of white cells;
KIRP	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.21	0.51	1.46e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.04	-0.31	9.14e-7	Menarche (age at onset);
KIRP	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg14675211	chr2:100938903	LONRF2	0.55	7.07	0.41	1.58e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14893161	chr1:205819251	PM20D1	-0.55	-5.47	-0.33	1.11e-7	Menarche (age at onset);
KIRP	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25517755	chr10:38738941	LOC399744	0.39	5.13	0.31	5.97e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs42648	0.869	rs1015404	chr7:89913946	G/C	cg25739043	chr7:89950458	NA	-0.47	-7.36	-0.42	2.7e-12	Homocysteine levels;
KIRP	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg11970804	chr8:8084126	NA	-0.39	-5.07	-0.31	8e-7	Mood instability;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18811621	chr2:208207188	NA	0.46	6.08	0.36	4.52e-9	Interleukin-4 levels;
KIRP	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.73	9.44	0.52	3.04e-18	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02128655	chr19:17186722	MYO9B;HAUS8	0.48	6.17	0.37	2.85e-9	Parkinson's disease;
KIRP	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.6	0.34	5.71e-8	Personality dimensions;
KIRP	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg09165964	chr15:75287851	SCAMP5	-1.08	-7.23	-0.42	6.02e-12	Lung cancer;
KIRP	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.53	7.47	0.43	1.38e-12	Metabolite levels;
KIRP	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.62	-10.35	-0.55	4.61e-21	Sense of smell;
KIRP	cis	rs5752326	0.510	rs4820682	chr22:26884039	G/A	cg20819150	chr22:26891497	TFIP11	0.6	5.49	0.33	1.02e-7	Ischemic stroke;
KIRP	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg12384639	chr17:618140	VPS53	0.49	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg04306507	chr14:55594613	LGALS3	0.52	8.24	0.47	1.01e-14	Protein biomarker;
KIRP	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.73	0.53	3.99e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg10207240	chr12:122356781	WDR66	0.47	6.19	0.37	2.47e-9	Mean corpuscular volume;
KIRP	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.05e-17	Retinal vascular caliber;
KIRP	cis	rs71403859	0.730	rs12447672	chr16:71715131	G/A	cg08717414	chr16:71523259	ZNF19	-1.07	-8.82	-0.49	2.15e-16	Post bronchodilator FEV1;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06320134	chr1:6663664	KLHL21	-0.47	-6.26	-0.37	1.71e-9	Interleukin-4 levels;
KIRP	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.62	7.95	0.45	6.63e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4236601	1.000	rs6950964	chr7:116161671	T/C	cg05166801	chr7:116143459	CAV2	0.48	5.95	0.35	9.23e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg13512537	chr8:22265999	SLC39A14	-0.44	-6.02	-0.36	6.28e-9	Verbal declarative memory;
KIRP	cis	rs2411233	0.811	rs2033544	chr15:39262972	G/T	cg05886626	chr15:39873553	THBS1	-0.33	-5.03	-0.31	9.57e-7	Platelet count;
KIRP	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.43	5.13	0.31	5.94e-7	Melanoma;
KIRP	cis	rs11696739	1.000	rs11696739	chr20:1600925	A/G	cg02198625	chr20:1600641	SIRPB1	-0.35	-5.07	-0.31	7.76e-7	Mean platelet volume;
KIRP	cis	rs3799379	0.550	rs77631260	chr6:26379440	A/T	cg12826209	chr6:26865740	GUSBL1	0.47	5.84	0.35	1.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg01320579	chr17:75405842	SEPT9	0.48	7.81	0.45	1.66e-13	Airflow obstruction;
KIRP	cis	rs9914988	0.560	rs8066347	chr17:27244473	G/A	cg20469991	chr17:27169893	C17orf63	-0.63	-5.21	-0.32	3.92e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.68	-8.01	-0.45	4.54e-14	Schizophrenia;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.52	-5.74	-0.34	2.78e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3744061	0.557	rs9889862	chr17:74647976	A/G	cg27546012	chr17:74684504	MXRA7	-0.45	-5.79	-0.35	2.12e-8	Retinal arteriolar caliber;
KIRP	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg24296786	chr1:45957014	TESK2	-0.57	-7.13	-0.41	1.12e-11	High light scatter reticulocyte count;
KIRP	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-8.49	-0.48	1.96e-15	Brugada syndrome;
KIRP	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.61	0.66	8.26e-32	Bladder cancer;
KIRP	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.82	-0.4	6.93e-11	Hemoglobin concentration;
KIRP	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.42	0.43	1.86e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg19507638	chr5:93509721	C5orf36	-0.62	-5.19	-0.31	4.5e-7	Diabetic retinopathy;
KIRP	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs732716	0.889	rs11085074	chr19:4386352	A/G	cg19820705	chr19:4455316	UBXN6	0.67	8.28	0.47	8.17e-15	Mean corpuscular volume;
KIRP	cis	rs6681460	0.933	rs7554101	chr1:67156472	A/G	cg02459107	chr1:67143332	SGIP1	-0.41	-5.89	-0.35	1.29e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.0	-0.3	1.09e-6	Life satisfaction;
KIRP	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.67	0.34	4.08e-8	Total cholesterol levels;
KIRP	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.75	-8.27	-0.47	8.62e-15	Parkinson's disease;
KIRP	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg22903471	chr2:27725779	GCKR	0.4	5.5	0.33	9.27e-8	Oral cavity cancer;
KIRP	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02034447	chr16:89574710	SPG7	0.5	6.67	0.39	1.65e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs8030485	0.730	rs57488047	chr15:79403002	T/C	cg17916960	chr15:79447300	NA	0.36	6.36	0.38	9.5e-10	Left ventricle wall thickness;
KIRP	cis	rs2688608	0.967	rs9971040	chr10:75661162	G/C	cg23231163	chr10:75533350	FUT11	-0.33	-5.05	-0.31	8.72e-7	Inflammatory bowel disease;
KIRP	cis	rs2281603	0.570	rs10132969	chr14:64953580	T/A	cg01860774	chr14:64969374	ZBTB25	0.33	5.4	0.33	1.58e-7	Lymphocyte counts;
KIRP	cis	rs3733418	1.000	rs3733418	chr4:165878335	A/G	cg10852876	chr4:165953100	TRIM60	-0.51	-5.74	-0.34	2.79e-8	Obesity-related traits;
KIRP	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg04731861	chr2:219085781	ARPC2	-0.19	-4.89	-0.3	1.82e-6	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-5.99	-0.36	7.54e-9	Neuroticism;
KIRP	cis	rs3026101	0.671	rs56344067	chr17:5316459	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.48e-8	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16136187	chr2:179058025	OSBPL6	0.51	6.24	0.37	1.87e-9	Interleukin-4 levels;
KIRP	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-7.01	-0.41	2.32e-11	Bladder cancer;
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg03115019	chr17:80708279	FN3K	0.5	6.73	0.39	1.21e-10	Glycated hemoglobin levels;
KIRP	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.85	10.23	0.55	1.1e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.66	9.73	0.53	3.81e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.38	0.32	1.7e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7590368	1.000	rs7590368	chr2:10961474	T/C	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.83	-9.19	-0.51	1.71e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.36	-0.32	1.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.87	12.64	0.63	1.51e-28	Morning vs. evening chronotype;
KIRP	cis	rs76793172	0.588	rs8110017	chr19:46289392	G/C	cg00442267	chr19:46317840	RSPH6A	0.64	5.63	0.34	4.93e-8	Eosinophil counts;
KIRP	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.28	-0.32	2.87e-7	Aortic root size;
KIRP	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg07636037	chr3:49044803	WDR6	-0.79	-7.89	-0.45	9.97e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg22974920	chr21:40686053	BRWD1	0.48	5.47	0.33	1.08e-7	Cognitive function;
KIRP	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg18646521	chr2:111875858	NA	0.41	5.88	0.35	1.35e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.76	-0.53	3.16e-19	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg10254082	chr7:997346	NA	0.46	4.93	0.3	1.49e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.73e-10	Prudent dietary pattern;
KIRP	cis	rs2742417	1.000	rs2251954	chr3:45731784	A/G	cg04837898	chr3:45731254	SACM1L	-0.38	-5.26	-0.32	3.2e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg10223061	chr2:219282414	VIL1	-0.33	-5.46	-0.33	1.14e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg04731861	chr2:219085781	ARPC2	-0.23	-5.92	-0.35	1.08e-8	Colorectal cancer;
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.61	8.87	0.49	1.58e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.68	8.61	0.48	9.09e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	trans	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.14	-0.41	1.06e-11	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	0.95	11.41	0.59	1.8e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs897080	0.516	rs1067393	chr2:44638832	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.88	0.35	1.33e-8	Height;
KIRP	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-8.47	-0.48	2.25e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg23307798	chr14:103986281	CKB	0.41	5.69	0.34	3.52e-8	Body mass index;
KIRP	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.5	5.8	0.35	2.07e-8	Platelet distribution width;
KIRP	cis	rs62413470	1.000	rs62404896	chr6:55962092	A/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.22e-8	Retinal vascular caliber;
KIRP	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg23625390	chr15:77176239	SCAPER	0.54	7.13	0.41	1.12e-11	Blood metabolite levels;
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg23985595	chr17:80112537	CCDC57	0.37	5.44	0.33	1.28e-7	Life satisfaction;
KIRP	cis	rs2299587	0.622	rs12334522	chr8:17889773	G/C	cg01800426	chr8:17659068	MTUS1	-0.42	-5.04	-0.31	9.01e-7	Economic and political preferences;
KIRP	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.66	-9.41	-0.51	3.65e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18831045	chr5:137667989	CDC25C	0.48	6.2	0.37	2.41e-9	Parkinson's disease;
KIRP	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.99	10.27	0.55	7.88e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11644362	1.000	rs4505301	chr16:12989467	A/G	cg06890432	chr16:12997467	SHISA9	-0.39	-6.04	-0.36	5.8e-9	Positive affect;Subjective well-being;
KIRP	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.39	4.85	0.3	2.14e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.35	-5.12	-0.31	6.22e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs3755605	0.520	rs546950	chr3:169944100	C/T	cg02973263	chr3:169940162	PRKCI	0.44	4.99	0.3	1.17e-6	Testicular germ cell tumor;
KIRP	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.45	-0.33	1.23e-7	Total body bone mineral density;
KIRP	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg02574844	chr11:5959923	NA	-0.52	-5.58	-0.33	6.48e-8	DNA methylation (variation);
KIRP	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	8.19	0.46	1.41e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg19901468	chr14:105411992	AHNAK2	-0.76	-12.05	-0.61	1.33e-26	Systemic lupus erythematosus;
KIRP	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.73	-0.44	2.71e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4728302	0.607	rs1963841	chr7:133607535	A/G	cg10665199	chr7:133106180	EXOC4	0.41	4.86	0.3	2.14e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs6558530	0.640	rs4875889	chr8:1695291	C/G	cg08198773	chr8:1697536	NA	0.53	6.56	0.39	3.09e-10	Systolic blood pressure;
KIRP	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.78	-10.36	-0.55	4.27e-21	Dental caries;
KIRP	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.99	-0.36	7.31e-9	Breast cancer;
KIRP	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-5.99	-0.36	7.37e-9	Bladder cancer;
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg01283332	chr5:1856932	NA	-0.49	-6.3	-0.37	1.37e-9	Cardiovascular disease risk factors;
KIRP	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg02376097	chr19:46275166	DMPK	-0.39	-5.01	-0.3	1.03e-6	Coronary artery disease;
KIRP	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg04287289	chr16:89883240	FANCA	-0.42	-5.34	-0.32	2.14e-7	Vitiligo;
KIRP	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg01620082	chr3:125678407	NA	0.87	6.25	0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.58	-8.22	-0.46	1.18e-14	Obesity-related traits;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg06654118	chr4:1303317	MAEA	0.29	5.18	0.31	4.7e-7	Obesity-related traits;
KIRP	cis	rs7727544	0.514	rs3846728	chr5:131436217	G/A	cg07395648	chr5:131743802	NA	-0.36	-4.89	-0.3	1.84e-6	Blood metabolite levels;
KIRP	cis	rs5753037	0.838	rs1076135	chr22:30238317	A/T	cg01021169	chr22:30184971	ASCC2	-0.38	-4.98	-0.3	1.21e-6	Type 1 diabetes;
KIRP	cis	rs7147624	0.573	rs10148699	chr14:66199662	G/A	cg03016385	chr14:66212404	NA	-0.95	-9.45	-0.52	2.88e-18	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.69	6.5	0.38	4.39e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.6	-7.36	-0.43	2.67e-12	Neuroticism;
KIRP	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.55	0.39	3.32e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.49	-5.25	-0.32	3.3e-7	Urate levels in overweight individuals;
KIRP	cis	rs2411233	1.000	rs8040312	chr15:39280103	C/T	cg02291532	chr15:39874776	THBS1	-0.39	-5.37	-0.32	1.79e-7	Platelet count;
KIRP	cis	rs7172677	1.000	rs8032208	chr15:75431245	A/G	cg14664628	chr15:75095509	CSK	-0.48	-5.2	-0.31	4.24e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9914578	1.000	rs9914578	chr17:2005136	C/G	cg16513277	chr17:2031491	SMG6	-0.72	-8.68	-0.48	5.64e-16	Body mass index;
KIRP	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.61	8.68	0.48	5.56e-16	Colorectal cancer;
KIRP	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.8	-10.92	-0.57	6.58e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	7.8	0.45	1.75e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-0.8	-12.19	-0.61	4.83e-27	Multiple myeloma;
KIRP	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-5.27	-0.32	2.98e-7	Neuroticism;
KIRP	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-0.78	-10.98	-0.57	4.27e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg17105886	chr17:28927953	LRRC37B2	0.55	5.65	0.34	4.45e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.51	6.04	0.36	5.63e-9	Interleukin-18 levels;
KIRP	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	0.44	6.03	0.36	6.07e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg18132916	chr6:79620363	NA	-0.36	-4.98	-0.3	1.19e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg20302533	chr7:39170763	POU6F2	0.29	5.82	0.35	1.87e-8	IgG glycosylation;
KIRP	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.44	5.31	0.32	2.5e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6901250	0.569	rs594940	chr6:117090358	C/T	cg05399210	chr6:117082661	FAM162B	-0.48	-6.82	-0.4	7.08e-11	C-reactive protein levels;
KIRP	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg18882449	chr10:104885122	NT5C2	-0.42	-5.41	-0.33	1.49e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg18944383	chr4:111397179	ENPEP	-0.6	-10.37	-0.55	3.94e-21	Coronary artery disease;
KIRP	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.56	6.0	0.36	6.91e-9	Type 2 diabetes;
KIRP	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg01097406	chr16:89675127	NA	-0.35	-5.35	-0.32	2.01e-7	Vitiligo;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg20996164	chr8:81490377	NA	0.46	6.06	0.36	5.22e-9	DNA methylation (variation);
KIRP	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg12559939	chr2:27858050	GPN1	-0.41	-5.21	-0.32	3.95e-7	Oral cavity cancer;
KIRP	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.18	-0.67	9.44e-34	Alzheimer's disease;
KIRP	cis	rs35176054	0.730	rs12772158	chr10:105502410	G/C	cg00730670	chr10:105510713	SH3PXD2A	-0.54	-5.0	-0.3	1.11e-6	Atrial fibrillation;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00689492	chr4:1303491	MAEA	0.32	5.44	0.33	1.28e-7	Obesity-related traits;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-9.41	-0.51	3.79e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs40363	0.951	rs40223	chr16:3503738	C/T	cg21433313	chr16:3507492	NAT15	0.66	7.2	0.42	7.35e-12	Tuberculosis;
KIRP	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.73	-8.56	-0.48	1.28e-15	Resting heart rate;
KIRP	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-0.53	-7.24	-0.42	5.56e-12	Coronary artery disease;
KIRP	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.81	10.9	0.57	7.97e-23	Morning vs. evening chronotype;
KIRP	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg18825076	chr15:78729989	IREB2	0.44	5.35	0.32	1.99e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs2278796	0.639	rs6661266	chr1:204971452	C/T	cg17947172	chr1:204966197	NFASC	-0.65	-8.7	-0.49	4.84e-16	Mean platelet volume;
KIRP	cis	rs860295	0.557	rs12091730	chr1:155556971	G/A	cg02153340	chr1:155202674	NA	-0.56	-6.83	-0.4	6.64e-11	Body mass index;
KIRP	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.32e-15	Life satisfaction;
KIRP	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.8	9.27	0.51	1e-17	Pulmonary function decline;
KIRP	cis	rs4132509	0.895	rs6674314	chr1:243920895	A/G	cg25706552	chr1:244017396	NA	0.59	7.46	0.43	1.48e-12	RR interval (heart rate);
KIRP	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.44	-5.15	-0.31	5.45e-7	Metabolite levels;
KIRP	cis	rs4845459	0.935	rs4845449	chr1:152591024	A/T	cg07796016	chr1:152779584	LCE1C	-0.48	-5.92	-0.35	1.09e-8	Psoriasis;
KIRP	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.16	-0.42	9.06e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18364779	chr6:26104403	HIST1H4C	-0.51	-5.51	-0.33	8.89e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg07701084	chr6:150067640	NUP43	0.71	10.03	0.54	4.66e-20	Lung cancer;
KIRP	cis	rs11997175	0.525	rs67217084	chr8:33888133	T/C	ch.8.33884649F	chr8:33765107	NA	0.47	5.21	0.32	4.07e-7	Body mass index;
KIRP	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg00277334	chr10:82204260	NA	-0.5	-5.71	-0.34	3.28e-8	Post bronchodilator FEV1;
KIRP	cis	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.35	-0.32	2.05e-7	Leprosy;
KIRP	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg26681399	chr22:41777847	TEF	-0.49	-4.94	-0.3	1.43e-6	Vitiligo;
KIRP	cis	rs4776059	1.000	rs2288271	chr15:52886466	A/G	cg22715398	chr15:52968154	KIAA1370	-0.68	-8.25	-0.47	9.59e-15	Schizophrenia;
KIRP	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.66	-0.44	4.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.56	0.65	1.14e-31	Smoking behavior;
KIRP	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg13615516	chr5:77269221	NA	0.5	7.71	0.44	3.18e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.24	-0.32	3.42e-7	Bipolar disorder;
KIRP	trans	rs353116	0.697	rs353122	chr2:166129087	A/T	cg23361659	chr2:28914775	NA	-0.33	-6.37	-0.38	9.32e-10	Parkinson's disease;
KIRP	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.53	-6.54	-0.39	3.47e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.66	8.62	0.48	8.49e-16	Alcohol dependence;
KIRP	cis	rs72772090	0.908	rs72772091	chr5:96040122	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.52	-4.95	-0.3	1.38e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg09526685	chr4:187126073	CYP4V2	0.7	6.31	0.37	1.3e-9	Blood protein levels;
KIRP	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg21775007	chr8:11205619	TDH	0.47	6.21	0.37	2.26e-9	Joint mobility (Beighton score);
KIRP	cis	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg21546286	chr11:48923668	NA	-0.47	-6.15	-0.36	3.17e-9	HDL cholesterol;
KIRP	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.48	6.81	0.4	7.38e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10017167	chr16:30683065	NA	0.56	6.35	0.38	1.04e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg19554555	chr3:13937349	NA	-0.47	-6.39	-0.38	8.22e-10	Ovarian reserve;
KIRP	cis	rs9815354	0.680	rs78402272	chr3:42028425	G/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.66	8.43	0.47	3.02e-15	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20274824	chr1:36638199	MAP7D1	0.51	7.13	0.41	1.14e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg26681399	chr22:41777847	TEF	0.54	5.23	0.32	3.69e-7	Vitiligo;
KIRP	cis	rs17033621	0.902	rs12622491	chr2:107605590	A/G	cg17818308	chr2:107502146	ST6GAL2	-0.37	-4.89	-0.3	1.81e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs1866706	0.865	rs17488051	chr11:12861994	C/T	cg25843174	chr11:12811716	TEAD1	-0.34	-5.61	-0.34	5.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.99	15.83	0.71	2.17e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.49	6.61	0.39	2.41e-10	Testicular germ cell tumor;
KIRP	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.36	-0.38	9.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2554380	0.628	rs4843156	chr15:84457345	G/T	cg14598478	chr15:84363061	ADAMTSL3	-0.34	-5.04	-0.31	9.21e-7	Height;
KIRP	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg05035280	chr1:1909092	KIAA1751	-0.38	-5.31	-0.32	2.4e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.64	9.51	0.52	1.85e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs712039	0.652	rs853200	chr17:35804114	G/A	cg16670864	chr17:35848621	DUSP14	0.41	4.91	0.3	1.67e-6	Tuberculosis;
KIRP	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.58	7.84	0.45	1.39e-13	Mean corpuscular volume;
KIRP	cis	rs597583	0.671	rs506836	chr11:117412453	C/T	cg27161313	chr11:117392002	DSCAML1	-0.58	-5.31	-0.32	2.45e-7	Putamen volume;
KIRP	cis	rs1448094	0.706	rs10863149	chr12:86425498	A/T	cg06740227	chr12:86229804	RASSF9	0.39	4.89	0.3	1.86e-6	Major depressive disorder;
KIRP	cis	rs3206736	0.530	rs329553	chr7:35105062	G/A	cg06685737	chr7:35301730	NA	0.47	7.06	0.41	1.7e-11	Diastolic blood pressure;
KIRP	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.24	-0.47	1.03e-14	Blood metabolite levels;
KIRP	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg19500275	chr17:80737654	TBCD	0.47	5.63	0.34	4.95e-8	Glycated hemoglobin levels;
KIRP	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg06740227	chr12:86229804	RASSF9	0.49	5.91	0.35	1.15e-8	Major depressive disorder;
KIRP	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg19025524	chr12:109796872	NA	-0.38	-4.99	-0.3	1.15e-6	Neuroticism;
KIRP	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.62	7.69	0.44	3.48e-13	Height;
KIRP	trans	rs17079247	0.749	rs9602692	chr13:85806267	A/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg00405596	chr8:11794950	NA	-0.45	-5.52	-0.33	8.69e-8	Neuroticism;
KIRP	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.16	-0.31	4.98e-7	Metabolite levels;
KIRP	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.77	8.25	0.47	9.48e-15	Bipolar disorder;
KIRP	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg04691961	chr3:161091175	C3orf57	-0.37	-5.73	-0.34	2.94e-8	Morning vs. evening chronotype;
KIRP	cis	rs9788682	0.948	rs28498264	chr15:78837673	C/T	cg24631222	chr15:78858424	CHRNA5	0.97	12.76	0.63	5.98e-29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg25650185	chr19:21324782	ZNF431	0.49	5.18	0.31	4.54e-7	Pain;
KIRP	cis	rs4237845	0.591	rs10431506	chr12:58311524	G/A	cg00677455	chr12:58241039	CTDSP2	0.68	7.61	0.44	5.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.14	0.31	5.5e-7	Renal cell carcinoma;
KIRP	cis	rs4656940	0.550	rs12072399	chr1:160762293	A/T	cg17331569	chr1:160788135	LY9	-0.49	-5.78	-0.35	2.23e-8	Crohn's disease;
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg01656853	chr19:49199172	FUT2	0.34	4.86	0.3	2.07e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs2916247	1.000	rs6991006	chr8:93064270	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.72	9.08	0.5	3.57e-17	Resting heart rate;
KIRP	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg03468072	chr12:39539422	NA	0.43	5.92	0.35	1.07e-8	Morning vs. evening chronotype;
KIRP	cis	rs7707921	0.767	rs862245	chr5:81585737	A/C	cg07807695	chr5:81608485	ATP6AP1L	0.45	5.81	0.35	1.94e-8	Breast cancer;
KIRP	cis	rs751728	0.588	rs7774620	chr6:33736285	T/A	cg25922239	chr6:33757077	LEMD2	0.54	6.71	0.39	1.32e-10	Crohn's disease;
KIRP	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.8	-5.3	-0.32	2.63e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	cg21523751	chr1:182988639	NA	0.35	4.91	0.3	1.67e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.56	7.6	0.44	6.18e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs9398803	0.965	rs4895807	chr6:126686513	C/G	cg19875578	chr6:126661172	C6orf173	0.48	6.48	0.38	4.89e-10	Male-pattern baldness;
KIRP	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg01378222	chr16:28622494	SULT1A1	-0.62	-5.34	-0.32	2.06e-7	Platelet distribution width;
KIRP	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.31	0.32	2.43e-7	Homoarginine levels;
KIRP	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	1.14	9.01	0.5	5.81e-17	Parkinson's disease;
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg11168104	chr5:1857477	NA	-0.45	-5.72	-0.34	3.07e-8	Cardiovascular disease risk factors;
KIRP	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg11584989	chr19:19387371	SF4	-0.41	-5.28	-0.32	2.81e-7	Tonsillectomy;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03710119	chr20:44509748	ZSWIM1	0.48	6.25	0.37	1.8e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.63	7.85	0.45	1.31e-13	Alcohol dependence;
KIRP	cis	rs2239815	0.515	rs5762848	chr22:29236308	A/G	cg15103426	chr22:29168792	CCDC117	0.53	5.1	0.31	6.68e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.45	5.92	0.35	1.08e-8	Height;
KIRP	cis	rs2737618	0.677	rs2253771	chr1:200068658	C/T	cg21825944	chr1:200113062	NR5A2	-0.54	-6.56	-0.39	3.08e-10	Uric acid levels;
KIRP	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.82	13.34	0.65	6.5e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg08501292	chr6:25962987	TRIM38	0.91	6.48	0.38	5.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12282928	1.000	rs10769338	chr11:48294256	A/G	cg26585981	chr11:48327164	OR4S1	-0.47	-5.2	-0.31	4.15e-7	Migraine - clinic-based;
KIRP	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.88	-9.81	-0.53	2.15e-19	Gut microbiome composition (summer);
KIRP	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-8.23	-0.46	1.07e-14	Colorectal cancer;
KIRP	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.41	-0.51	3.67e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg26248373	chr2:1572462	NA	-0.63	-5.75	-0.34	2.61e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4919044	0.799	rs56024810	chr10:94753313	G/A	cg05127821	chr10:94822908	CYP26C1	-1.03	-8.32	-0.47	6.01e-15	Coronary artery disease;
KIRP	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg27487796	chr7:28973253	NA	-0.22	-4.96	-0.3	1.32e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg14345882	chr6:26364793	BTN3A2	0.34	5.59	0.34	5.93e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7809615	0.901	rs10230784	chr7:99113672	G/A	cg24024660	chr7:99195788	NA	-0.54	-4.92	-0.3	1.57e-6	Blood metabolite ratios;
KIRP	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.93	-0.35	1.02e-8	IgG glycosylation;
KIRP	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.9	-11.66	-0.6	2.57e-25	Cognitive function;
KIRP	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg24579218	chr15:68104479	NA	-0.36	-5.31	-0.32	2.46e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg19847130	chr8:10466454	RP1L1	-0.33	-5.21	-0.32	3.92e-7	Neuroticism;
KIRP	trans	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.75	9.5	0.52	2.03e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.07	23.72	0.83	1.58e-65	Multiple myeloma;
KIRP	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg18306943	chr3:40428807	ENTPD3	0.4	5.23	0.32	3.64e-7	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07981475	chr11:110167594	RDX	0.59	7.53	0.43	9.66e-13	Parkinson's disease;
KIRP	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.68	9.15	0.5	2.29e-17	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	4.78e-8	Lung cancer;
KIRP	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg07775547	chr4:1625484	NA	-0.45	-5.28	-0.32	2.79e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs909341	0.909	rs1741708	chr20:62372041	G/T	cg03999872	chr20:62272968	STMN3	-0.56	-6.36	-0.38	9.85e-10	Atopic dermatitis;
KIRP	cis	rs6921919	0.583	rs6928771	chr6:28375209	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.48	-6.93	-0.4	3.6e-11	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.9	-0.45	9.19e-14	Neuroticism;
KIRP	cis	rs1971256	0.500	rs6925359	chr6:151798783	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	4.93	0.3	1.52e-6	Endometriosis;
KIRP	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.38	0.32	1.76e-7	Homoarginine levels;
KIRP	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg04731861	chr2:219085781	ARPC2	-0.23	-5.62	-0.34	5.07e-8	Colorectal cancer;
KIRP	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg16926213	chr1:1841314	NA	0.31	5.38	0.32	1.75e-7	Body mass index;
KIRP	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.54	-4.96	-0.3	1.29e-6	Body mass index (adult);
KIRP	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg06042504	chr8:55087323	NA	-0.54	-6.68	-0.39	1.6e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.57	-6.38	-0.38	8.9e-10	Coronary artery disease;
KIRP	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.79	13.0	0.64	9.54e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.42	5.73	0.34	2.95e-8	Red blood cell count;
KIRP	cis	rs7011507	0.945	rs78980858	chr8:49136621	T/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg20503657	chr10:835505	NA	0.53	6.34	0.37	1.1e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg07636037	chr3:49044803	WDR6	-0.74	-5.37	-0.32	1.82e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.9	0.45	9.29e-14	Height;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg02301978	chr19:7069707	ZNF557	0.46	6.81	0.4	7.63e-11	Bladder cancer;
KIRP	cis	rs1829883	0.737	rs56662472	chr5:98910544	G/A	cg08333243	chr5:99726346	NA	0.42	5.35	0.32	1.98e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.27	-5.5	-0.33	9.4e-8	Menarche (age at onset);
KIRP	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg12131826	chr15:77904385	NA	0.5	6.02	0.36	6.28e-9	Type 2 diabetes;
KIRP	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.12	0.41	1.19e-11	Neuroticism;
KIRP	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.71	-9.34	-0.51	6.15e-18	Personality dimensions;
KIRP	cis	rs73200209	0.912	rs11609898	chr12:116638445	G/T	cg01776926	chr12:116560359	MED13L	0.44	5.4	0.33	1.54e-7	Total body bone mineral density;
KIRP	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg17691542	chr6:26056736	HIST1H1C	0.66	8.0	0.45	4.77e-14	Iron status biomarkers;
KIRP	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.54	0.52	1.49e-18	Corneal astigmatism;
KIRP	cis	rs554111	0.858	rs10916855	chr1:21056382	T/C	cg21184320	chr1:21044207	KIF17	0.43	6.36	0.38	9.72e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg00204512	chr16:28754710	NA	-0.41	-5.06	-0.31	8.29e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.38	4.84	0.3	2.27e-6	Melanoma;
KIRP	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg03959625	chr15:84868606	LOC388152	0.59	6.55	0.39	3.38e-10	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16332283	chr21:45139805	PDXK	0.51	6.46	0.38	5.54e-10	Parkinson's disease;
KIRP	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.6	-5.61	-0.34	5.55e-8	Schizophrenia;
KIRP	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg22356347	chr1:167427500	CD247	-0.4	-5.62	-0.34	5.26e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.85	10.53	0.56	1.21e-21	Breast cancer;
KIRP	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg09455208	chr3:40491958	NA	0.32	5.59	0.34	6.05e-8	Renal cell carcinoma;
KIRP	cis	rs11603020	0.904	rs11606677	chr11:57383377	G/A	cg23127183	chr11:57508653	C11orf31	-0.46	-5.35	-0.32	1.99e-7	Blood protein levels;
KIRP	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	6.2	0.37	2.41e-9	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7106204	0.688	rs7131103	chr11:24219299	A/G	ch.11.24196551F	chr11:24239977	NA	0.82	8.27	0.47	8.57e-15	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg13565492	chr6:43139072	SRF	-0.94	-8.58	-0.48	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg26816564	chr1:7831052	VAMP3	0.97	8.51	0.48	1.73e-15	Inflammatory bowel disease;
KIRP	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-4.84	-0.3	2.25e-6	Breast cancer;
KIRP	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	11.23	0.58	6.9e-24	Lung cancer in ever smokers;
KIRP	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg09231725	chr11:64357281	SLC22A12	-0.64	-8.57	-0.48	1.2e-15	Urate levels in obese individuals;
KIRP	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg26924012	chr15:45694286	SPATA5L1	0.66	8.73	0.49	3.83e-16	Response to fenofibrate (adiponectin levels);
KIRP	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.51	-0.78	7.36e-52	Height;
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07308232	chr7:1071921	C7orf50	-0.7	-8.87	-0.49	1.54e-16	Longevity;Endometriosis;
KIRP	cis	rs4594175	0.926	rs60234748	chr14:51630102	T/C	cg23942311	chr14:51606299	NA	0.53	7.01	0.41	2.31e-11	Cancer;
KIRP	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg17470723	chr8:74884337	TCEB1	0.64	8.17	0.46	1.6e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.8	-0.4	7.81e-11	Joint mobility (Beighton score);
KIRP	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg27494647	chr7:150038898	RARRES2	0.41	6.27	0.37	1.65e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.2	0.42	7.27e-12	Aortic root size;
KIRP	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.83	-12.92	-0.64	1.78e-29	Asthma;
KIRP	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.54	-11.4	-0.59	1.87e-24	Diabetic kidney disease;
KIRP	cis	rs2380205	0.967	rs4294487	chr10:5898405	G/A	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.22e-8	Breast cancer;
KIRP	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.66	6.47	0.38	5.17e-10	Axial length;
KIRP	cis	rs427941	0.703	rs201445	chr7:101737921	G/T	cg06246474	chr7:101738831	CUX1	0.56	6.94	0.4	3.37e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.42	-0.38	7.11e-10	Uric acid levels;
KIRP	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-10.0	-0.54	5.57e-20	Eye color traits;
KIRP	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.53e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829661	0.689	rs829694	chr2:30648577	T/A	cg10949345	chr2:30726833	LCLAT1	1.05	12.88	0.63	2.33e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs11710088	0.634	rs13095959	chr3:149207196	T/A	cg08667024	chr3:149219783	TM4SF4	-0.48	-7.07	-0.41	1.59e-11	QRS duration;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg10254082	chr7:997346	NA	0.48	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg02023728	chr11:77925099	USP35	-0.32	-5.6	-0.34	5.84e-8	Alzheimer's disease (survival time);
KIRP	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg18350739	chr11:68623251	NA	0.5	7.84	0.45	1.38e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1355223	0.506	rs6484738	chr11:34860858	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.5	6.05	0.36	5.39e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.32	-0.32	2.29e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6429082	0.510	rs6699644	chr1:235495476	G/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.66e-7	Adiposity;
KIRP	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.41	5.15	0.31	5.3e-7	Lung cancer;
KIRP	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg27211696	chr2:191398769	TMEM194B	-0.53	-6.46	-0.38	5.42e-10	Diastolic blood pressure;
KIRP	cis	rs2051773	0.567	rs7935677	chr11:17039832	A/G	cg15432903	chr11:17409602	KCNJ11	-0.51	-6.03	-0.36	6.04e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.04	-0.36	5.72e-9	Neuroticism;
KIRP	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg17788227	chr17:7347145	FGF11;CHRNB1	0.49	5.08	0.31	7.58e-7	Androgen levels;
KIRP	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg17376030	chr22:41985996	PMM1	0.61	6.39	0.38	8.4e-10	Vitiligo;
KIRP	cis	rs644148	0.693	rs2686772	chr19:44999729	T/C	cg15540054	chr19:45004280	ZNF180	-0.67	-7.59	-0.44	6.61e-13	Personality dimensions;
KIRP	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg16141378	chr3:129829833	LOC729375	0.49	6.44	0.38	6.17e-10	Neuroticism;
KIRP	cis	rs1009181	0.585	rs2183947	chr6:26159356	G/A	cg13736514	chr6:26305472	NA	-0.51	-5.33	-0.32	2.24e-7	Childhood ear infection;
KIRP	cis	rs4262150	0.526	rs4309960	chr5:151971852	A/G	cg12297329	chr5:152029980	NA	-0.71	-10.65	-0.56	4.9e-22	Bipolar disorder and schizophrenia;
KIRP	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.24	13.65	0.66	5.98e-32	Uric acid levels;
KIRP	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.56	4.92	0.3	1.56e-6	Smoking behavior;
KIRP	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.89	-12.05	-0.61	1.34e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19671926	chr4:122722719	EXOSC9	0.46	5.52	0.33	8.41e-8	Type 2 diabetes;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10357841	chr11:450288	PTDSS2	-0.59	-6.35	-0.38	1.01e-9	Menopause (age at onset);
KIRP	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.54	8.33	0.47	5.75e-15	Bone mineral density;
KIRP	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.88	13.76	0.66	2.54e-32	Mean corpuscular volume;
KIRP	cis	rs1829883	0.701	rs1817358	chr5:99002595	G/A	cg08333243	chr5:99726346	NA	0.38	4.91	0.3	1.67e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06873352	chr17:61820015	STRADA	0.67	8.72	0.49	4.12e-16	Prudent dietary pattern;
KIRP	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg03235661	chr20:60525775	NA	-0.31	-5.25	-0.32	3.37e-7	Body mass index;
KIRP	cis	rs77972916	0.609	rs72790903	chr2:43561985	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-6.37	-0.38	9.24e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg02725872	chr8:58115012	NA	-0.53	-5.87	-0.35	1.42e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs9987353	0.876	rs329993	chr8:9123438	T/C	cg19847130	chr8:10466454	RP1L1	0.43	6.4	0.38	7.6e-10	Recombination measurement;
KIRP	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.73	-9.27	-0.51	9.54e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	0.95	6.67	0.39	1.64e-10	IgG glycosylation;
KIRP	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.87	-14.78	-0.69	8.11e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.82	-0.35	1.8e-8	Pulmonary function;
KIRP	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg08890418	chr1:21044141	KIF17	-0.41	-6.24	-0.37	1.89e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs13315871	0.929	rs11716580	chr3:58228695	G/C	cg20936604	chr3:58311152	NA	-0.75	-5.63	-0.34	4.97e-8	Cholesterol, total;
KIRP	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg18064842	chr5:14874549	NA	-0.52	-8.0	-0.45	4.9e-14	Blood metabolite levels;
KIRP	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.57	-7.84	-0.45	1.36e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.52	-0.62	3.63e-28	Primary sclerosing cholangitis;
KIRP	cis	rs9611198	0.846	rs5757731	chr22:39967785	C/G	cg10455938	chr22:40058150	CACNA1I	-0.44	-6.3	-0.37	1.34e-9	Schizophrenia;
KIRP	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.41	-5.13	-0.31	5.77e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.59	-7.21	-0.42	6.71e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs867371	0.519	rs1566559	chr15:82524461	T/C	cg00614314	chr15:82944287	LOC80154	0.42	5.49	0.33	9.85e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs7520050	0.807	rs4353138	chr1:46219803	C/T	cg15605315	chr1:45957053	TESK2	0.44	5.34	0.32	2.11e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg16898833	chr6:26189333	HIST1H4D	0.72	5.13	0.31	5.76e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg08975724	chr8:8085496	FLJ10661	-0.73	-9.45	-0.52	2.76e-18	Triglycerides;
KIRP	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.26	0.37	1.68e-9	Menarche (age at onset);
KIRP	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.5	0.33	9.72e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.42	-0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg10932868	chr11:921992	NA	0.64	8.58	0.48	1.1e-15	Alzheimer's disease (late onset);
KIRP	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.55	5.55	0.33	7.3900000000000007e-08	Schizophrenia;
KIRP	cis	rs2070997	0.527	rs11244139	chr9:133660799	C/T	cg13397898	chr9:133768931	QRFP	0.36	5.28	0.32	2.82e-7	Response to amphetamines;
KIRP	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.58	-6.12	-0.36	3.68e-9	Obesity-related traits;
KIRP	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.68	9.09	0.5	3.31e-17	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.76	9.49	0.52	2.07e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg23479056	chr15:41276147	INO80	-0.38	-5.17	-0.31	4.8e-7	Menopause (age at onset);
KIRP	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg06636001	chr8:8085503	FLJ10661	0.69	8.85	0.49	1.78e-16	Parkinson's disease;
KIRP	cis	rs1712517	0.526	rs113528138	chr10:105125451	C/A	cg04362960	chr10:104952993	NT5C2	-0.58	-7.3	-0.42	3.9e-12	Migraine;
KIRP	cis	rs2554380	0.628	rs12914377	chr15:84460693	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.34	-5.61	-0.34	5.5e-8	Height;
KIRP	cis	rs2057178	0.745	rs12280757	chr11:32353264	G/A	cg05837727	chr11:32355149	NA	0.42	5.04	0.31	8.94e-7	Tuberculosis;
KIRP	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.85	-0.3	2.17e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.62	-8.29	-0.47	7.52e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.51	-7.03	-0.41	2.03e-11	Glycated hemoglobin levels;
KIRP	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.96	-12.01	-0.61	1.85e-26	Alzheimer's disease;
KIRP	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12893428	chr3:195717962	SDHAP1	0.48	6.44	0.38	6.18e-10	Pancreatic cancer;
KIRP	cis	rs17401966	0.931	rs12408430	chr1:10323339	T/A	cg19773385	chr1:10388646	KIF1B	-0.72	-11.17	-0.58	1.08e-23	Hepatocellular carcinoma;
KIRP	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.77	-8.94	-0.5	9.71e-17	Platelet distribution width;
KIRP	cis	rs4691139	0.582	rs9993113	chr4:165940728	G/C	cg10852876	chr4:165953100	TRIM60	-0.35	-4.87	-0.3	1.96e-6	Ovarian cancer in BRCA1 mutation carriers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25104716	chr18:45936047	NA	0.46	6.13	0.36	3.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs6563842	0.563	rs9603786	chr13:41316364	G/A	cg21288729	chr13:41239152	FOXO1	0.54	7.2	0.42	7.4e-12	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
KIRP	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.45	6.2	0.37	2.33e-9	Sitting height ratio;
KIRP	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.38	5.26	0.32	3.06e-7	Gout;
KIRP	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.74	10.02	0.54	4.81e-20	Depressive symptoms;
KIRP	cis	rs834603	0.575	rs1534137	chr7:47482719	T/C	cg09696706	chr7:47479511	TNS3	0.42	4.86	0.3	2.08e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.63	5.19	0.31	4.44e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14893161	chr1:205819251	PM20D1	-0.59	-5.83	-0.35	1.74e-8	Menarche (age at onset);
KIRP	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg10351095	chr21:47802916	PCNT	0.41	5.03	0.31	9.56e-7	Testicular germ cell tumor;
KIRP	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg06740227	chr12:86229804	RASSF9	-0.42	-5.4	-0.33	1.54e-7	Major depressive disorder;
KIRP	cis	rs13418717	1.000	rs13393833	chr2:127653076	C/T	cg25501666	chr2:127640322	NA	1.09	7.44	0.43	1.65e-12	Heart failure;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg20957975	chr19:18392540	JUND	-1.12	-6.22	-0.37	2.14e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs56146971	0.763	rs34854034	chr14:91870677	A/G	cg16433844	chr14:91963127	SMEK1	-0.57	-5.32	-0.32	2.3e-7	Alzheimer disease and age of onset;
KIRP	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.67	-0.44	4.08e-13	Morning vs. evening chronotype;
KIRP	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	1.03	14.12	0.67	1.52e-33	Menopause (age at onset);
KIRP	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg16701003	chr16:89028210	CBFA2T3	0.48	6.41	0.38	7.2e-10	Social autistic-like traits;
KIRP	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg00129232	chr17:37814104	STARD3	-0.52	-6.42	-0.38	7.15e-10	Self-reported allergy;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17461670	chr17:66926513	ABCA8	0.38	6.02	0.36	6.26e-9	C-reactive protein;
KIRP	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.0	-0.3	1.1e-6	Bipolar disorder;
KIRP	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.45	6.34	0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg11608241	chr8:8085544	FLJ10661	-0.48	-5.8	-0.35	2.07e-8	Joint mobility (Beighton score);
KIRP	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.82	-10.67	-0.56	4.45e-22	Type 2 diabetes;
KIRP	cis	rs2786865	0.529	rs2744777	chr1:26012517	A/C	cg22943243	chr1:26232311	STMN1	-0.71	-4.84	-0.3	2.25e-6	Facial morphology (factor 11, projection of the nose);
KIRP	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.74	10.54	0.56	1.1e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg21475434	chr5:93447410	FAM172A	0.78	6.71	0.39	1.37e-10	Diabetic retinopathy;
KIRP	cis	rs10486003	0.881	rs73402253	chr7:97203464	C/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.58	-5.19	-0.31	4.43e-7	Response to platinum-based agents;
KIRP	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.63	-7.07	-0.41	1.56e-11	Cisplatin-induced ototoxicity;
KIRP	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.51	-5.68	-0.34	3.84e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.46	5.74	0.34	2.79e-8	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.41	-5.08	-0.31	7.32e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	6.01	0.36	6.71e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.47	-0.43	1.36e-12	Body mass index;
KIRP	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.57	-6.89	-0.4	4.65e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs12143943	0.934	rs12027855	chr1:204595544	C/A	cg20240347	chr1:204465584	NA	-0.32	-5.56	-0.33	7.13e-8	Cognitive performance;
KIRP	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	1.05	8.34	0.47	5.5e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.56e-25	Diabetic kidney disease;
KIRP	cis	rs6450176	0.909	rs10940353	chr5:53299959	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.1	-0.58	1.78e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg01786151	chr1:41347977	NA	-0.43	-6.07	-0.36	4.77e-9	Colorectal cancer;
KIRP	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11987759	chr7:65425863	GUSB	-0.44	-5.32	-0.32	2.34e-7	Aortic root size;
KIRP	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg06995285	chr7:2418615	EIF3B	0.82	8.54	0.48	1.39e-15	Multiple sclerosis;
KIRP	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.59	-0.52	1.04e-18	Asthma;
KIRP	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg22117172	chr7:91764530	CYP51A1	0.5	6.98	0.41	2.7e-11	Breast cancer;
KIRP	trans	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg20993868	chr7:22813445	NA	0.62	9.0	0.5	6.36e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9469913	0.688	rs2814985	chr6:34548296	C/T	cg17674042	chr6:34482479	PACSIN1	-0.53	-6.6	-0.39	2.54e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg12486944	chr17:80159399	CCDC57	-0.38	-5.08	-0.31	7.39e-7	Life satisfaction;
KIRP	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.95	7.7	0.44	3.24e-13	Body mass index;
KIRP	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.89	-13.61	-0.66	7.78e-32	Height;
KIRP	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.65	-7.82	-0.45	1.58e-13	Exhaled nitric oxide output;
KIRP	trans	rs1462872	0.673	rs327344	chr8:31794882	T/C	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.86	0.35	1.45e-8	Menopause (age at onset);
KIRP	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.76	12.55	0.62	3.09e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg23594656	chr7:65796392	TPST1	-0.43	-6.0	-0.36	6.91e-9	Aortic root size;
KIRP	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.6	-7.25	-0.42	5.44e-12	Glomerular filtration rate;
KIRP	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13939156	chr17:80058883	NA	0.53	8.43	0.47	3.01e-15	Life satisfaction;
KIRP	cis	rs1983891	0.673	rs9369296	chr6:41570251	A/G	cg20194872	chr6:41519635	FOXP4	0.48	6.32	0.37	1.2e-9	Prostate cancer;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26360961	chr12:7282931	CLSTN3;RBP5	0.53	6.73	0.39	1.19e-10	Myopia (pathological);
KIRP	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10053473	chr17:62856997	LRRC37A3	0.69	7.48	0.43	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.68	-0.44	3.78e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	trans	rs2055729	0.710	rs112406488	chr8:9736362	T/C	cg06636001	chr8:8085503	FLJ10661	0.56	6.16	0.37	2.96e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4262150	1.000	rs4262150	chr5:152288453	G/T	cg12297329	chr5:152029980	NA	-0.43	-5.89	-0.35	1.24e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg27398817	chr8:82754497	SNX16	-0.74	-8.15	-0.46	1.89e-14	Diastolic blood pressure;
KIRP	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23544223	chr18:12777786	NA	0.76	6.46	0.38	5.61e-10	Inflammatory skin disease;
KIRP	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg21775007	chr8:11205619	TDH	-0.4	-5.05	-0.31	8.71e-7	Neuroticism;
KIRP	cis	rs904092	0.720	rs1230027	chr4:100183423	T/C	cg12011299	chr4:100065546	ADH4	0.49	4.94	0.3	1.42e-6	Alcohol dependence;
KIRP	cis	rs7572644	0.699	rs6731650	chr2:28261163	C/A	cg27432699	chr2:27873401	GPN1	-0.44	-5.28	-0.32	2.83e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs829661	0.739	rs2602792	chr2:30867800	T/C	cg10949345	chr2:30726833	LCLAT1	0.83	10.23	0.55	1.09e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	7.09	0.41	1.42e-11	Eye color traits;
KIRP	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.34	-0.32	2.13e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7180079	0.686	rs654820	chr15:64779046	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.5	-6.25	-0.37	1.84e-9	Facial morphology (factor 20);
KIRP	cis	rs1978968	0.912	rs5992932	chr22:18456254	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-7.05	-0.41	1.8e-11	Presence of antiphospholipid antibodies;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10057841	chr11:129996244	APLP2	0.51	6.74	0.39	1.12e-10	Survival in pancreatic cancer;
KIRP	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	0.99	18.45	0.76	2.6e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg14456004	chr13:21872349	NA	-1.11	-13.94	-0.66	6.04e-33	White matter hyperintensity burden;
KIRP	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg06212747	chr3:49208901	KLHDC8B	0.48	4.86	0.3	2.14e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.57	-0.48	1.14e-15	Coronary artery disease;
KIRP	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.55e-20	Dupuytren's disease;
KIRP	cis	rs2997447	0.706	rs55657303	chr1:26421012	A/G	cg19633962	chr1:26362018	EXTL1	-0.7	-5.93	-0.35	1.03e-8	QRS complex (12-leadsum);
KIRP	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05025164	chr4:1340916	KIAA1530	0.42	5.24	0.32	3.5e-7	Obesity-related traits;
KIRP	cis	rs4702718	0.519	rs2918386	chr5:10734647	G/A	cg14521931	chr5:10832172	NA	0.52	5.49	0.33	1.02e-7	Obesity-related traits;
KIRP	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg08668510	chr10:1095578	IDI1	0.9	6.65	0.39	1.86e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.6	-7.19	-0.42	7.77e-12	Initial pursuit acceleration;
KIRP	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.41	8.81	0.49	2.25e-16	Mean corpuscular volume;
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.56	-5.46	-0.33	1.14e-7	Platelet count;
KIRP	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26207909	chr14:103986467	CKB	0.74	10.53	0.56	1.19e-21	Body mass index;
KIRP	cis	rs61884328	0.866	rs12575721	chr11:46823681	T/C	cg23433285	chr11:47201945	PACSIN3	0.74	4.93	0.3	1.53e-6	Total body bone mineral density (age over 60);
KIRP	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01616529	chr11:638424	DRD4	-0.42	-5.68	-0.34	3.71e-8	Systemic lupus erythematosus;
KIRP	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg07636037	chr3:49044803	WDR6	0.53	6.27	0.37	1.58e-9	Resting heart rate;
KIRP	cis	rs9400467	0.506	rs12198788	chr6:111686791	C/G	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-7.38	-0.43	2.46e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg08999081	chr20:33150536	PIGU	0.41	4.87	0.3	2.02e-6	Height;
KIRP	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg21919602	chr1:242011447	EXO1	-0.47	-6.09	-0.36	4.42e-9	Menopause (age at onset);
KIRP	cis	rs7534824	0.860	rs7411264	chr1:101606449	G/A	cg17443007	chr1:101659419	NA	0.65	5.36	0.32	1.93e-7	Refractive astigmatism;
KIRP	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.62	0.34	5.1e-8	Personality dimensions;
KIRP	cis	rs2505998	1.000	rs2435362	chr10:43578779	A/C	cg15436174	chr10:43711423	RASGEF1A	-0.47	-4.98	-0.3	1.22e-6	Hirschsprung disease;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.72	11.4	0.59	1.85e-24	Mean corpuscular volume;
KIRP	cis	rs3789045	0.837	rs57450685	chr1:204580832	A/T	cg08641003	chr1:204589008	LRRN2	-0.56	-6.06	-0.36	5.18e-9	Educational attainment (college completion);
KIRP	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg20493526	chr2:3714936	ALLC	0.42	5.01	0.3	1.02e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.18	0.31	4.71e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg16586182	chr3:47516702	SCAP	0.8	11.15	0.58	1.27e-23	Colorectal cancer;
KIRP	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.62	0.56	6.35e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.85	-9.75	-0.53	3.3e-19	Osteoarthritis;
KIRP	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.75	-10.54	-0.56	1.15e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02018176	chr4:1364513	KIAA1530	0.36	4.92	0.3	1.59e-6	Longevity;
KIRP	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.64	8.54	0.48	1.46e-15	Lymphocyte counts;
KIRP	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg04727924	chr7:799746	HEATR2	-0.7	-7.21	-0.42	6.79e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg24881330	chr22:46731750	TRMU	0.74	5.52	0.33	8.76e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg04990556	chr1:26633338	UBXN11	0.68	6.67	0.39	1.72e-10	Obesity-related traits;
KIRP	cis	rs4666002	0.665	rs2305929	chr2:28113911	A/G	cg05484376	chr2:27715224	FNDC4	-0.48	-5.26	-0.32	3.17e-7	Phospholipid levels (plasma);
KIRP	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg13010199	chr12:38710504	ALG10B	0.5	6.43	0.38	6.5e-10	Morning vs. evening chronotype;
KIRP	cis	rs12282928	1.000	rs11039657	chr11:48320979	A/G	cg26585981	chr11:48327164	OR4S1	0.51	6.22	0.37	2.09e-9	Migraine - clinic-based;
KIRP	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.73	9.46	0.52	2.58e-18	Menopause (age at onset);
KIRP	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs76793172	1.000	rs56006974	chr19:46330636	C/A	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.12	-0.36	3.65e-9	Eosinophil counts;
KIRP	cis	rs72792276	1.000	rs56657382	chr5:127387338	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	5.96	0.36	8.68e-9	Red cell distribution width;
KIRP	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.52	6.36	0.38	9.75e-10	Subjective well-being;
KIRP	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.7	-9.11	-0.5	3.06e-17	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg06636001	chr8:8085503	FLJ10661	0.75	10.61	0.56	6.47e-22	Mood instability;
KIRP	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.8	7.86	0.45	1.23e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs6783573	0.510	rs11718490	chr3:46628763	C/T	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.34	-4.94	-0.3	1.45e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	3e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.54	7.23	0.42	6.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg15045943	chr5:171614719	STK10	0.71	6.18	0.37	2.65e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4791641	1.000	rs4791641	chr17:8161149	C/T	cg06726167	chr17:8076949	TMEM107	0.48	5.67	0.34	3.98e-8	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
KIRP	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.51	-7.19	-0.42	7.7e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2219968	0.798	rs4739185	chr8:78879189	A/G	cg00738934	chr8:78996279	NA	-0.39	-5.24	-0.32	3.4e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.73	10.26	0.55	8.38e-21	Lung cancer;
KIRP	cis	rs75216060	0.731	rs73212363	chr8:13826987	A/G	cg12665059	chr8:13787749	NA	0.35	5.43	0.33	1.36e-7	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg22325292	chr17:80708367	FN3K	0.35	4.86	0.3	2.07e-6	Glycated hemoglobin levels;
KIRP	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.86	13.94	0.66	5.83e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs55962025	0.842	rs362272	chr4:3234980	C/T	cg06533319	chr4:3265114	C4orf44	0.51	5.37	0.32	1.84e-7	Parental longevity (mother's age at death);
KIRP	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.35	-0.38	1.05e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04740258	chr3:138553760	NA	-0.43	-6.06	-0.36	5.13e-9	Metabolic traits;
KIRP	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.52	-0.43	1.03e-12	Neuroticism;
KIRP	cis	rs12049351	0.774	rs12140727	chr1:229626891	C/G	cg11742688	chr1:229674241	ABCB10	0.39	5.79	0.35	2.17e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.95	0.61	2.94e-26	Alzheimer's disease;
KIRP	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.09	-13.01	-0.64	8.32e-30	Vitiligo;
KIRP	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg23719950	chr11:63933701	MACROD1	-0.6	-5.86	-0.35	1.44e-8	Mean platelet volume;
KIRP	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg26875233	chr11:93583750	C11orf90	-0.36	-6.75	-0.4	1.08e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.55	-7.34	-0.42	3.06e-12	Urate levels in overweight individuals;
KIRP	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg10223061	chr2:219282414	VIL1	-0.4	-6.41	-0.38	7.18e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.26	-0.32	3.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg09699651	chr6:150184138	LRP11	0.45	6.03	0.36	5.83e-9	Lung cancer;
KIRP	cis	rs2741335	1.000	rs2741335	chr8:27337791	A/C	cg00421144	chr8:27336675	CHRNA2	-0.31	-5.07	-0.31	7.93e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.54	6.39	0.38	8.13e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	-0.52	-5.78	-0.35	2.26e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.92e-34	Menopause (age at onset);
KIRP	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06481639	chr22:41940642	POLR3H	0.73	7.11	0.41	1.23e-11	Vitiligo;
KIRP	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg13165212	chr22:42675999	NA	0.3	5.27	0.32	2.99e-7	Cognitive function;
KIRP	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg13010199	chr12:38710504	ALG10B	0.63	7.82	0.45	1.59e-13	Morning vs. evening chronotype;
KIRP	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg17885191	chr8:135476712	NA	0.53	6.08	0.36	4.51e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.32	-0.32	2.3e-7	Renal cell carcinoma;
KIRP	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg06766960	chr11:133703094	NA	-0.43	-5.34	-0.32	2.06e-7	Childhood ear infection;
KIRP	cis	rs4750440	0.523	rs4565801	chr10:14032358	G/A	cg27542038	chr10:14027202	FRMD4A	-0.51	-6.62	-0.39	2.17e-10	Adiponectin levels;
KIRP	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.57	6.84	0.4	6.22e-11	Eosinophil percentage of white cells;
KIRP	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.99	10.64	0.56	5.26e-22	Blood protein levels;
KIRP	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg01304814	chr3:48885189	PRKAR2A	0.57	5.22	0.32	3.78e-7	Cognitive function;
KIRP	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg05347473	chr6:146136440	FBXO30	0.58	8.04	0.46	3.68e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23838308	chr17:57785056	PTRH2;TMEM49	0.46	6.1	0.36	4.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg10104451	chr8:143696006	ARC	-0.65	-7.24	-0.42	5.74e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.61	-7.81	-0.45	1.68e-13	Obesity-related traits;
KIRP	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg21918786	chr6:109611834	NA	-0.42	-5.94	-0.35	9.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	13.96	0.66	5.25e-33	Platelet count;
KIRP	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs7551222	0.752	rs4951389	chr1:204475834	G/T	cg20240347	chr1:204465584	NA	-0.42	-7.95	-0.45	6.76e-14	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23269605	chr13:77675444	MYCBP2	0.39	6.11	0.36	3.86e-9	C-reactive protein;
KIRP	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.84	-0.4	6.08e-11	Diabetic kidney disease;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1497828	1.000	rs2810777	chr1:217559619	A/C	cg04411442	chr1:217543379	NA	0.32	5.11	0.31	6.33e-7	Dialysis-related mortality;
KIRP	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg09455208	chr3:40491958	NA	0.35	6.03	0.36	5.82e-9	Renal cell carcinoma;
KIRP	cis	rs7129556	0.737	rs7950873	chr11:77412851	A/G	cg12586386	chr11:77299805	AQP11	0.45	5.02	0.31	9.72e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs9581857	0.547	rs17753763	chr13:28077734	A/G	cg22138327	chr13:27999177	GTF3A	0.85	6.62	0.39	2.24e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7523050	0.643	rs34572569	chr1:109401856	A/T	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg01990225	chr2:97406019	LMAN2L	0.85	6.85	0.4	5.81e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg18477163	chr1:228402036	OBSCN	-0.31	-6.52	-0.38	4.05e-10	Diastolic blood pressure;
KIRP	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.79	11.22	0.58	7.28e-24	Bladder cancer;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.73	6.44	0.38	6.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg19743168	chr1:23544995	NA	0.56	7.76	0.44	2.32e-13	Height;
KIRP	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	cg21523751	chr1:182988639	NA	0.35	5.32	0.32	2.33e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-1.08	-13.22	-0.64	1.72e-30	Exhaled nitric oxide output;
KIRP	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg18016565	chr1:150552671	MCL1	0.38	5.8	0.35	2.01e-8	Tonsillectomy;
KIRP	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.77	-10.33	-0.55	5.19e-21	Total body bone mineral density;
KIRP	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.61	8.24	0.47	1.01e-14	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14753042	chr7:55714413	LOC442308	0.52	6.18	0.37	2.68e-9	Interleukin-4 levels;
KIRP	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.78	9.76	0.53	3.1e-19	Iron status biomarkers;
KIRP	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	1.07	19.54	0.78	6.01e-52	Systemic lupus erythematosus;
KIRP	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg00262122	chr8:11665843	FDFT1	0.39	4.91	0.3	1.62e-6	Neuroticism;
KIRP	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg16898833	chr6:26189333	HIST1H4D	0.74	5.11	0.31	6.5e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs12517041	0.938	rs10039693	chr5:23272411	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.64	-6.54	-0.38	3.46e-10	Calcium levels;
KIRP	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.84	-12.73	-0.63	7.28e-29	Height;
KIRP	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.39	5.99	0.36	7.39e-9	Hypertriglyceridemia;
KIRP	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg22676075	chr6:135203613	NA	0.49	7.15	0.41	9.97e-12	Red blood cell count;
KIRP	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg24154853	chr7:158122151	PTPRN2	0.39	5.56	0.33	7.17e-8	Calcium levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg02723399	chr22:19420170	HIRA;MRPL40	0.49	6.24	0.37	1.91e-9	Myopia (pathological);
KIRP	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.77	-0.4	9.65e-11	Joint mobility (Beighton score);
KIRP	cis	rs897080	0.515	rs1067345	chr2:44618897	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.29	0.37	1.47e-9	Height;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.45	-5.57	-0.33	6.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg27624424	chr6:160112604	SOD2	0.47	4.95	0.3	1.4e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg24101359	chr6:42928495	GNMT	0.6	8.59	0.48	1.04e-15	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.45	-5.55	-0.33	7.56e-8	Leprosy;
KIRP	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.19e-9	Body mass index;
KIRP	cis	rs9972944	0.756	rs6504353	chr17:63768013	T/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.08e-13	Total body bone mineral density;
KIRP	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg19761014	chr17:28927070	LRRC37B2	0.5	4.86	0.3	2.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12826942	0.876	rs17548889	chr12:42722219	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	4.95	0.3	1.39e-6	Coronary artery disease;
KIRP	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.9	-13.95	-0.66	5.48e-33	Primary sclerosing cholangitis;
KIRP	cis	rs35000415	0.688	rs17340542	chr7:128720045	C/T	cg19972273	chr7:128594194	NA	-0.57	-4.93	-0.3	1.54e-6	Systemic lupus erythematosus;
KIRP	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg13180566	chr4:1052158	NA	-0.53	-5.4	-0.33	1.56e-7	Recombination rate (females);
KIRP	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg06108461	chr20:60628389	TAF4	-0.63	-7.66	-0.44	4.24e-13	Body mass index;
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg23985595	chr17:80112537	CCDC57	0.34	4.96	0.3	1.29e-6	Life satisfaction;
KIRP	cis	rs78487399	0.710	rs80147536	chr2:43698028	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.14	-0.31	5.69e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.51	6.41	0.38	7.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg11189052	chr15:85197271	WDR73	0.48	4.96	0.3	1.31e-6	Schizophrenia;
KIRP	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.7	-9.59	-0.52	1.01e-18	Coronary artery disease;
KIRP	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21747090	chr2:27597821	SNX17	-0.51	-6.78	-0.4	8.97e-11	Menopause (age at onset);
KIRP	cis	rs2594989	0.733	rs9882513	chr3:11558377	T/C	cg01796438	chr3:11312864	ATG7	0.41	5.36	0.32	1.92e-7	Circulating chemerin levels;
KIRP	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg06637938	chr14:75390232	RPS6KL1	0.55	7.85	0.45	1.3e-13	Height;
KIRP	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.96	13.67	0.66	4.87e-32	Cognitive function;
KIRP	cis	rs829661	0.793	rs829639	chr2:30703247	A/G	cg10949345	chr2:30726833	LCLAT1	1.13	15.94	0.71	9.14e-40	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9890032	0.618	rs55872374	chr17:29149881	C/T	cg13385521	chr17:29058706	SUZ12P	0.44	5.22	0.32	3.79e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs427941	0.667	rs34247954	chr7:101740993	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.27e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.55	6.17	0.37	2.76e-9	Lung cancer;
KIRP	cis	rs2219968	1.000	rs16939594	chr8:78969920	T/A	cg00738934	chr8:78996279	NA	0.39	4.92	0.3	1.57e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.55	-6.27	-0.37	1.6e-9	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.44	4.99	0.3	1.14e-6	Alzheimer's disease (late onset);
KIRP	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	1.15	14.12	0.67	1.53e-33	IgG glycosylation;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07287682	chr7:2281772	NUDT1;FTSJ2	-0.48	-6.02	-0.36	6.42e-9	Myopia;
KIRP	cis	rs10128264	0.902	rs2802360	chr10:80971196	C/T	cg18737081	chr10:80999807	ZMIZ1	-0.32	-5.94	-0.35	9.91e-9	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.21	0.37	2.21e-9	Ovarian reserve;
KIRP	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg18190219	chr22:46762943	CELSR1	-0.84	-6.5	-0.38	4.38e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.46	-6.26	-0.37	1.68e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.62	-7.14	-0.41	1.05e-11	Platelet count;
KIRP	cis	rs55788414	0.932	rs2317122	chr16:81182819	A/G	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.34	-0.47	5.31e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg08501292	chr6:25962987	TRIM38	1.04	8.34	0.47	5.33e-15	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2208049	0.947	rs1106978	chr20:41678428	C/T	cg10074813	chr8:144637872	GSDMD	0.48	6.42	0.38	6.8e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs714027	0.605	rs1468176	chr22:30544516	G/A	cg27665648	chr22:30112403	NA	-0.45	-6.4	-0.38	7.73e-10	Lymphocyte counts;
KIRP	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg13010199	chr12:38710504	ALG10B	0.52	6.71	0.39	1.36e-10	Morning vs. evening chronotype;
KIRP	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg19116668	chr7:99932089	PMS2L1	0.43	5.1	0.31	6.71e-7	Coronary artery disease;
KIRP	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs4650994	0.544	rs6664493	chr1:178494428	C/T	cg05059571	chr16:84539110	KIAA1609	-0.72	-10.32	-0.55	5.57e-21	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs7939886	0.920	rs2054610	chr11:56087942	T/G	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.7	-9.04	-0.5	4.75e-17	Glomerular filtration rate;
KIRP	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.44	0.33	1.27e-7	Menopause (age at onset);
KIRP	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg17554472	chr22:41940697	POLR3H	-0.67	-6.96	-0.41	3.07e-11	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18813448	chr3:137893807	DBR1	0.54	6.66	0.39	1.78e-10	Parkinson's disease;
KIRP	cis	rs7590368	0.715	rs56263234	chr2:10959160	A/G	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21717879	chr19:572359	BSG	0.58	7.36	0.42	2.71e-12	Parkinson's disease;
KIRP	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00495681	chr13:53174319	NA	0.4	5.39	0.33	1.61e-7	Lewy body disease;
KIRP	cis	rs6815814	0.898	rs115807384	chr4:38851585	A/C	cg06935464	chr4:38784597	TLR10	0.53	5.39	0.32	1.65e-7	Breast cancer;
KIRP	cis	rs612683	0.862	rs12760924	chr1:100898600	A/T	cg06223162	chr1:101003688	GPR88	0.43	7.82	0.45	1.56e-13	Breast cancer;
KIRP	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.24e-6	Depression;
KIRP	cis	rs1971762	0.545	rs3864905	chr12:54058324	C/T	cg23533419	chr12:54090519	NA	-0.36	-5.49	-0.33	1e-7	Height;
KIRP	cis	rs33912345	0.695	rs1254262	chr14:60837827	C/T	cg27398547	chr14:60952738	C14orf39	-0.42	-5.63	-0.34	4.9e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-6.38	-0.38	8.96e-10	Bladder cancer;
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg12486944	chr17:80159399	CCDC57	-0.41	-5.44	-0.33	1.28e-7	Life satisfaction;
KIRP	cis	rs4409675	0.957	rs6656506	chr1:28255000	C/T	cg23691781	chr1:28212827	C1orf38	-0.34	-7.3	-0.42	3.98e-12	Corneal astigmatism;
KIRP	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.93	-15.66	-0.71	8.08e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.61	-6.29	-0.37	1.41e-9	Platelet distribution width;
KIRP	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	0.83	12.49	0.62	4.86e-28	Body mass index;
KIRP	cis	rs2637030	0.559	rs2636991	chr5:52943067	T/G	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs7221595	0.778	rs8077986	chr17:3902951	A/G	cg11204139	chr17:3907470	NA	0.58	5.72	0.34	3.1e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg06873352	chr17:61820015	STRADA	-0.58	-7.33	-0.42	3.26e-12	Prudent dietary pattern;
KIRP	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-6.86	-0.4	5.64e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.38e-51	Height;
KIRP	cis	rs687432	0.885	rs7949741	chr11:57759767	C/T	cg19752551	chr11:57585705	CTNND1	-0.65	-8.25	-0.47	9.76e-15	Parkinson's disease;
KIRP	cis	rs4638749	0.501	rs4322804	chr2:108744939	G/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.91	-0.3	1.64e-6	Blood pressure;
KIRP	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9556958	0.588	rs9556964	chr13:99159306	T/C	cg20750642	chr13:99100586	FARP1	0.52	6.96	0.41	3.12e-11	Educational attainment (years of education);
KIRP	cis	rs1165472	0.543	rs1399137	chr1:56137624	A/G	cg11523071	chr1:56160889	NA	-0.55	-6.35	-0.38	1.02e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.68	10.3	0.55	6.43e-21	Menarche (age at onset);
KIRP	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.77	-7.23	-0.42	6.19e-12	Chronic sinus infection;
KIRP	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg11569703	chr11:65557185	OVOL1	-0.49	-8.79	-0.49	2.55e-16	Acne (severe);
KIRP	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.47	6.7	0.39	1.42e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.3	18.85	0.77	1.15e-49	Corneal structure;
KIRP	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.94	-0.3	1.45e-6	Prostate cancer;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.46	6.3	0.37	1.36e-9	Mean corpuscular volume;
KIRP	cis	rs981844	0.775	rs17371274	chr4:154738713	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.65	6.5	0.38	4.51e-10	Gastritis;
KIRP	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.77	6.98	0.41	2.69e-11	Alzheimer's disease;
KIRP	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.67	-10.18	-0.54	1.58e-20	Coronary artery disease;
KIRP	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg10792982	chr14:105748885	BRF1	0.86	12.8	0.63	4.26e-29	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-8.26	-0.47	9.29e-15	Myopia (pathological);
KIRP	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg09231725	chr11:64357281	SLC22A12	-0.5	-5.61	-0.34	5.56e-8	Body mass index;Urate levels;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg22000725	chr19:8478147	MARCH2	0.51	6.28	0.37	1.5e-9	Educational attainment;
KIRP	cis	rs6910061	1.000	rs13214666	chr6:11103537	C/A	cg27233058	chr6:11094804	LOC221710	0.56	5.59	0.34	6.05e-8	Diabetic kidney disease;
KIRP	cis	rs9398803	0.830	rs1361109	chr6:126771143	C/T	cg19875578	chr6:126661172	C6orf173	0.45	5.9	0.35	1.18e-8	Male-pattern baldness;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10230308	chr17:61678218	TACO1	0.5	6.12	0.36	3.73e-9	Inflammatory biomarkers;
KIRP	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg00852783	chr1:26633632	UBXN11	-0.53	-7.63	-0.44	5.04e-13	Obesity-related traits;
KIRP	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.48	-5.94	-0.35	9.49e-9	Renal function-related traits (BUN);
KIRP	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.61	-9.58	-0.52	1.15e-18	C-reactive protein levels;
KIRP	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17554472	chr22:41940697	POLR3H	-0.64	-6.79	-0.4	8.54e-11	Vitiligo;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06568401	chr4:42089384	SLC30A9	-0.47	-7.33	-0.42	3.28e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	10.24	0.55	1.02e-20	Cognitive test performance;
KIRP	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.42	5.47	0.33	1.11e-7	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27525248	chr2:134877576	NA	-0.45	-6.2	-0.37	2.36e-9	Metabolic traits;
KIRP	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg08923054	chr8:41654455	ANK1	0.75	8.81	0.49	2.24e-16	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7221595	0.778	rs57625058	chr17:3914513	T/G	cg21734707	chr17:3908241	ZZEF1	0.53	4.86	0.3	2.13e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-5.78	-0.35	2.23e-8	Body mass index;
KIRP	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs9815354	0.812	rs4264702	chr3:41952539	T/A	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs42648	0.596	rs194507	chr7:89843560	A/C	cg25739043	chr7:89950458	NA	0.41	6.6	0.39	2.55e-10	Homocysteine levels;
KIRP	cis	rs1629083	0.967	rs17092740	chr11:118117614	G/A	cg18857871	chr11:118064634	AMICA1	0.64	8.53	0.48	1.51e-15	Lung cancer;
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg07701084	chr6:150067640	NUP43	0.71	9.65	0.52	6.77e-19	Lung cancer;
KIRP	cis	rs137887	0.845	rs4838877	chr22:50464740	G/C	cg17558497	chr22:50464837	TTLL8	0.51	7.71	0.44	3.1400000000000003e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg10189774	chr4:17578691	LAP3	0.42	5.11	0.31	6.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.73	10.21	0.55	1.2e-20	Body mass index;
KIRP	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.45	6.69	0.39	1.49e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs73198271	0.960	rs11778970	chr8:8609334	G/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-5.76	-0.34	2.44e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg25174290	chr11:3078921	CARS	-0.59	-6.25	-0.37	1.81e-9	Calcium levels;
KIRP	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.74	10.62	0.56	6.18e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20887711	chr4:1340912	KIAA1530	0.42	5.4	0.33	1.6e-7	Obesity-related traits;
KIRP	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs2594989	0.887	rs2442797	chr3:11555935	C/T	cg01796438	chr3:11312864	ATG7	-0.64	-7.48	-0.43	1.34e-12	Circulating chemerin levels;
KIRP	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.39	1.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	0.61	6.44	0.38	6.18e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg05528293	chr18:74961138	GALR1	0.54	6.01	0.36	6.78e-9	Obesity-related traits;
KIRP	cis	rs7809615	0.901	rs11973801	chr7:99102911	A/G	cg24024660	chr7:99195788	NA	-0.59	-5.15	-0.31	5.26e-7	Blood metabolite ratios;
KIRP	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg04310649	chr10:35416472	CREM	-0.58	-6.88	-0.4	4.88e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7103648	0.569	rs10769282	chr11:47626492	T/G	cg20307385	chr11:47447363	PSMC3	0.88	9.87	0.53	1.45e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg12935359	chr14:103987150	CKB	-0.36	-5.8	-0.35	2.05e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12153243	0.714	rs17402447	chr5:142916732	G/T	cg13907255	chr5:142895549	NA	0.37	4.96	0.3	1.32e-6	Migraine;
KIRP	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.65	8.56	0.48	1.23e-15	Morning vs. evening chronotype;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09736950	chr15:62938334	MGC15885;TLN2	0.53	6.09	0.36	4.27e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg13700000	chr13:67570127	PCDH9	0.39	6.25	0.37	1.76e-9	Migraine with aura;
KIRP	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg09754948	chr16:28834200	ATXN2L	0.47	5.32	0.32	2.34e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04036009	chr2:27434710	C2orf28;SLC5A6	0.51	6.65	0.39	1.9e-10	Parkinson's disease;
KIRP	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg11608241	chr8:8085544	FLJ10661	-0.42	-5.32	-0.32	2.38e-7	Mood instability;
KIRP	cis	rs4804368	0.607	rs8106700	chr19:7200558	A/G	cg09377704	chr19:7936683	NA	0.46	5.11	0.31	6.38e-7	Renal cell carcinoma;
KIRP	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.71	-8.62	-0.48	8.15e-16	Blood pressure (smoking interaction);
KIRP	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg02367723	chr1:46378857	MAST2	0.44	5.06	0.31	8.12e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10988449	1.000	rs68145693	chr9:132371505	G/A	cg18327994	chr9:132372705	NA	-0.58	-5.36	-0.32	1.94e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.18	-0.37	2.65e-9	Schizophrenia;
KIRP	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Bladder cancer;
KIRP	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.74	-0.34	2.75e-8	Fear of minor pain;
KIRP	cis	rs9328573	1.000	rs12903084	chr15:100510081	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.4	-5.42	-0.33	1.39e-7	Urate levels in lean individuals;
KIRP	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.52	-6.42	-0.38	6.87e-10	Coronary artery disease;
KIRP	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg16898833	chr6:26189333	HIST1H4D	0.81	5.81	0.35	1.95e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.46	5.87	0.35	1.4e-8	Initial pursuit acceleration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12684684	chr2:219082027	ARPC2	0.51	6.86	0.4	5.65e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.97	-0.41	2.98e-11	Monocyte percentage of white cells;
KIRP	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.91	-14.68	-0.68	1.85e-35	IgG glycosylation;
KIRP	cis	rs3857747	0.578	rs12701818	chr7:40367581	T/A	cg00420559	chr7:40367873	C7orf10	-0.47	-6.65	-0.39	1.92e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg13334819	chr7:99746414	C7orf59	0.55	6.21	0.37	2.25e-9	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg00629928	chr5:358741	AHRR	0.51	4.97	0.3	1.27e-6	Breast cancer;
KIRP	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14598338	chr9:96623480	NA	-0.68	-11.68	-0.6	2.21e-25	DNA methylation (variation);
KIRP	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26002218	chr14:103986227	CKB	-0.33	-6.74	-0.39	1.15e-10	Body mass index;
KIRP	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.68	-8.66	-0.48	6.51e-16	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs981844	0.683	rs1105495	chr4:154756867	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs17286411	0.836	rs4788567	chr16:71893498	G/A	cg04254540	chr16:71951199	KIAA0174	-0.4	-5.25	-0.32	3.35e-7	Blood protein levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08330404	chr6:166419593	NA	-0.41	-6.08	-0.36	4.67e-9	Metabolic traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06925236	chr11:68039653	C11orf24	0.52	6.13	0.36	3.53e-9	Smoking initiation;
KIRP	cis	rs7215564	0.908	rs34135683	chr17:78652903	G/T	cg06153925	chr17:78755379	RPTOR	0.34	5.42	0.33	1.45e-7	Myopia (pathological);
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09549240	chr15:75250560	RPP25	0.29	5.02	0.3	1.01e-6	Breast cancer;
KIRP	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.45	9.5	0.52	1.92e-18	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.57	7.24	0.42	5.85e-12	Aortic root size;
KIRP	cis	rs17221829	0.673	rs56004718	chr11:89413190	A/G	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.29	-0.32	2.71e-7	Anxiety in major depressive disorder;
KIRP	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.85	0.4	5.8e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06481639	chr22:41940642	POLR3H	0.59	6.43	0.38	6.4e-10	Vitiligo;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24379599	chr1:186369020	OCLM;C1orf27;MIR548F1	-0.42	-6.84	-0.4	6.26e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18600419	chr15:57719252	CGNL1	-0.49	-6.4	-0.38	7.72e-10	Inflammatory biomarkers;
KIRP	cis	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-4.92	-0.3	1.6e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg08999081	chr20:33150536	PIGU	-0.4	-5.17	-0.31	4.94e-7	Height;
KIRP	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg16898833	chr6:26189333	HIST1H4D	0.67	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26913058	chr16:419975	MRPL28	0.47	5.88	0.35	1.3e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.45	5.78	0.35	2.27e-8	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs7215564	0.908	rs35878324	chr17:78677530	C/T	cg08454507	chr17:78755406	RPTOR	0.32	4.9	0.3	1.77e-6	Myopia (pathological);
KIRP	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.83	-0.66	1.38e-32	Ulcerative colitis;
KIRP	cis	rs2274273	0.686	rs66782529	chr14:55587867	C/T	cg04306507	chr14:55594613	LGALS3	0.43	6.03	0.36	5.85e-9	Protein biomarker;
KIRP	cis	rs12931792	0.782	rs12927190	chr16:30169393	C/G	cg17640201	chr16:30407289	ZNF48	0.46	5.16	0.31	5.15e-7	Tonsillectomy;
KIRP	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg21361702	chr7:150065534	REPIN1	0.61	6.05	0.36	5.42e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.98	15.85	0.71	1.83e-39	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.08	-15.4	-0.7	6.16e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg22974920	chr21:40686053	BRWD1	0.46	5.42	0.33	1.42e-7	Cognitive function;
KIRP	cis	rs6738028	0.524	rs7565445	chr2:111935461	C/T	cg04202892	chr2:111875749	ACOXL	0.43	5.65	0.34	4.49e-8	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.99	7.72	0.44	2.95e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12731740	1.000	rs35720264	chr1:208004782	G/A	cg22525895	chr1:207977042	MIR29B2	-0.64	-4.9	-0.3	1.74e-6	Biomedical quantitative traits;
KIRP	trans	rs7493138	0.900	rs35341183	chr14:28998981	A/T	cg08496086	chr5:2176142	NA	0.45	6.1	0.36	4.14e-9	Longevity;
KIRP	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.67	-9.39	-0.51	4.11e-18	Retinal vascular caliber;
KIRP	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.75	10.59	0.56	7.49e-22	Colorectal cancer;
KIRP	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07648498	chr16:89883185	FANCA	0.39	5.09	0.31	7.27e-7	Vitiligo;
KIRP	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg15507776	chr3:136538369	TMEM22	0.51	7.17	0.42	9e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6568686	0.786	rs6911772	chr6:111857638	G/C	cg22127309	chr6:111907043	TRAF3IP2	-0.56	-5.45	-0.33	1.22e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg02073558	chr3:44770973	ZNF501	0.6	8.31	0.47	6.54e-15	Depressive symptoms;
KIRP	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.15	-0.31	5.37e-7	Red blood cell count;
KIRP	trans	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg13565492	chr6:43139072	SRF	-0.94	-8.58	-0.48	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	6.69	0.39	1.52e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.75	11.04	0.58	2.82e-23	Prudent dietary pattern;
KIRP	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.62	-7.56	-0.43	7.87e-13	Mosquito bite size;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-1.02	-17.35	-0.74	1.44e-44	Height;
KIRP	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18252515	chr7:66147081	NA	0.45	5.3	0.32	2.61e-7	Aortic root size;
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-7.75	-0.44	2.48e-13	Lung cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06577604	chr3:184279443	EPHB3	0.61	6.03	0.36	5.84e-9	Lung function (FEV1);
KIRP	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	8.04	0.46	3.81e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06544989	chr22:39130855	UNC84B	0.49	8.1	0.46	2.55e-14	Menopause (age at onset);
KIRP	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg04731861	chr2:219085781	ARPC2	0.23	5.53	0.33	8.03e-8	Colorectal cancer;
KIRP	cis	rs1190552	0.846	rs1061924	chr14:102975655	C/T	cg10241871	chr14:102965420	TECPR2	-0.54	-6.08	-0.36	4.44e-9	Blood protein levels;
KIRP	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg12560992	chr17:57184187	TRIM37	0.63	6.07	0.36	4.79e-9	Cognitive test performance;
KIRP	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs4950322	0.570	rs4950399	chr1:146791020	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-0.88	-9.29	-0.51	8.46e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.47	-0.33	1.11e-7	Fear of minor pain;
KIRP	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.61	6.82	0.4	7.11e-11	Schizophrenia;
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.65	-10.82	-0.57	1.43e-22	Lung cancer;
KIRP	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg19847866	chr10:1019161	NA	-0.47	-5.45	-0.33	1.24e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg06795125	chr2:108905320	SULT1C2	-0.54	-9.17	-0.5	1.95e-17	Lobe size;
KIRP	cis	rs7005380	0.531	rs7388491	chr8:120925877	G/A	cg21645572	chr8:120931649	DEPDC6	0.42	5.08	0.31	7.61e-7	Interstitial lung disease;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg13939156	chr17:80058883	NA	-0.48	-7.24	-0.42	5.68e-12	Life satisfaction;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18718189	chr14:20902347	KLHL33	-0.46	-6.21	-0.37	2.3e-9	Inflammatory biomarkers;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02784696	chr2:24270586	C2orf44	-0.46	-6.54	-0.38	3.53e-10	Serum protein levels (sST2);
KIRP	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.03	0.41	2.04e-11	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7737355	0.812	rs2158294	chr5:130878215	A/G	cg06307176	chr5:131281290	NA	0.42	5.03	0.31	9.64e-7	Life satisfaction;
KIRP	cis	rs4356932	1.000	rs6532172	chr4:76996958	G/A	cg00809888	chr4:76862425	NAAA	0.42	6.0	0.36	7.08e-9	Blood protein levels;
KIRP	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-1.05	-19.29	-0.78	4.13e-51	Height;
KIRP	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	6.26	0.37	1.7e-9	Prudent dietary pattern;
KIRP	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg08501292	chr6:25962987	TRIM38	1.07	7.84	0.45	1.41e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg00405596	chr8:11794950	NA	-0.46	-5.9	-0.35	1.17e-8	Retinal vascular caliber;
KIRP	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.74	9.81	0.53	2.18e-19	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6601327	0.635	rs7821575	chr8:9665955	G/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.09	-0.31	7.12e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1035491	0.715	rs3846479	chr5:63922013	C/T	cg01791865	chr5:63954708	NA	0.33	5.21	0.32	4.06e-7	Body mass index;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg08901578	chr4:187885870	NA	-0.45	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18749629	chr8:144566769	ZC3H3	0.54	6.69	0.39	1.5e-10	Interleukin-4 levels;
KIRP	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg23625390	chr15:77176239	SCAPER	0.5	6.69	0.39	1.46e-10	Blood metabolite levels;
KIRP	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg15839431	chr19:19639596	YJEFN3	-0.53	-5.39	-0.32	1.65e-7	Bipolar disorder;
KIRP	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20135002	chr11:47629003	NA	-0.44	-5.03	-0.31	9.39e-7	Subjective well-being;
KIRP	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.77	-8.38	-0.47	4.17e-15	Corneal astigmatism;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg06983586	chr4:184320034	NA	0.51	6.4	0.38	7.74e-10	Plasma plasminogen activator levels;
KIRP	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11622362	chr11:34938112	PDHX;APIP	-0.45	-5.61	-0.34	5.55e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg26816564	chr1:7831052	VAMP3	0.61	5.37	0.32	1.82e-7	Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17811228	chr5:139175116	PSD2	0.47	6.34	0.37	1.07e-9	Parkinson's disease;
KIRP	cis	rs258892	0.895	rs7702660	chr5:72044687	A/G	cg21869765	chr5:72125136	TNPO1	-0.5	-5.64	-0.34	4.56e-8	Small cell lung carcinoma;
KIRP	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-4.89	-0.3	1.8e-6	Educational attainment (years of education);
KIRP	cis	rs17065868	0.892	rs9533912	chr13:45139961	T/C	cg10246903	chr13:45222710	NA	0.75	6.67	0.39	1.72e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.75	-6.29	-0.37	1.46e-9	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07047347	chr8:96281113	C8orf37	0.5	6.61	0.39	2.38e-10	Parkinson's disease;
KIRP	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.56	7.17	0.42	8.63e-12	Longevity;
KIRP	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.57	7.19	0.42	7.57e-12	Arsenic metabolism;
KIRP	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg11130432	chr3:121712080	ILDR1	-0.46	-5.07	-0.31	7.95e-7	Multiple sclerosis;
KIRP	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	12.0	0.61	2.04e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs4589502	0.920	rs77518050	chr15:67138089	T/C	cg12317470	chr15:67143691	NA	0.73	5.1	0.31	6.9e-7	Lung cancer (smoking interaction);
KIRP	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs28489187	0.577	rs729655	chr1:85844617	A/C	cg16011679	chr1:85725395	C1orf52	0.46	5.71	0.34	3.29e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.91	-10.18	-0.54	1.49e-20	Blood protein levels;
KIRP	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg12560992	chr17:57184187	TRIM37	0.63	5.66	0.34	4.22e-8	Cognitive test performance;
KIRP	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.09e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.84	-0.45	1.39e-13	Retinal vascular caliber;
KIRP	cis	rs10518128	1.000	rs7654271	chr4:75708071	A/G	cg20122727	chr4:75719957	BTC	0.62	6.2	0.37	2.42e-9	Electroencephalogram traits;
KIRP	cis	rs6496667	1.000	rs7162175	chr15:90897473	A/G	cg10434728	chr15:90938212	IQGAP1	0.38	5.01	0.3	1.03e-6	Rheumatoid arthritis;
KIRP	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg26874164	chr19:58962979	ZNF324B	0.47	5.58	0.33	6.45e-8	Uric acid clearance;
KIRP	cis	rs2929278	0.617	rs693919	chr15:44102328	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-6.31	-0.37	1.26e-9	Schizophrenia;
KIRP	cis	rs3789045	0.774	rs12039365	chr1:204488687	A/G	cg18185008	chr1:204589407	LRRN2	-0.6	-6.54	-0.38	3.53e-10	Educational attainment (college completion);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20949959	chr2:43453251	ZFP36L2;LOC100129726	-0.48	-6.46	-0.38	5.64e-10	Metabolic traits;
KIRP	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.78	10.56	0.56	9.92e-22	Monocyte count;
KIRP	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg19592336	chr6:28129416	ZNF389	0.48	5.54	0.33	7.96e-8	Depression;
KIRP	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.78	9.71	0.53	4.39e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg05861140	chr6:150128134	PCMT1	-0.39	-5.23	-0.32	3.61e-7	Lung cancer;
KIRP	cis	rs17293817	0.625	rs10794748	chr10:1421516	A/G	cg02851212	chr10:1451418	ADARB2	-0.36	-5.33	-0.32	2.19e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.7	-0.39	1.42e-10	Dilated cardiomyopathy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21970794	chr5:114517423	TRIM36	-0.44	-6.95	-0.41	3.27e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg03161606	chr19:29218774	NA	0.74	6.64	0.39	1.98e-10	Methadone dose in opioid dependence;
KIRP	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg26681399	chr22:41777847	TEF	-0.5	-5.48	-0.33	1.03e-7	Vitiligo;
KIRP	cis	rs7172677	0.732	rs55655136	chr15:75285114	G/A	cg10253484	chr15:75165896	SCAMP2	0.68	7.41	0.43	2.07e-12	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.92	14.03	0.67	3.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4356975	0.522	rs12647681	chr4:69963160	A/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.83	-11.55	-0.59	5.94e-25	Schizophrenia;
KIRP	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-9.18	-0.5	1.88e-17	QRS duration;
KIRP	cis	rs394563	0.726	rs366905	chr6:149735097	T/A	cg03678062	chr6:149772716	ZC3H12D	-0.32	-5.1	-0.31	6.92e-7	Dupuytren's disease;
KIRP	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg00147788	chr6:125855365	NA	-0.34	-5.22	-0.32	3.85e-7	Brugada syndrome;
KIRP	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg09699651	chr6:150184138	LRP11	0.41	5.24	0.32	3.38e-7	Lung cancer;
KIRP	trans	rs1056053	0.514	rs3127329	chr6:166572362	G/A	cg17428496	chr19:2151817	AP3D1	-0.54	-6.06	-0.36	5.1e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg13607699	chr17:42295918	UBTF	0.43	5.28	0.32	2.79e-7	Total body bone mineral density;
KIRP	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.43	5.65	0.34	4.4e-8	Coronary artery disease;
KIRP	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg24253500	chr15:84953950	NA	0.54	6.23	0.37	1.96e-9	Schizophrenia;
KIRP	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.86	-0.53	1.55e-19	Height;
KIRP	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs78487399	0.908	rs6749617	chr2:43845329	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	5.44	0.33	1.27e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.52	5.72	0.34	3.14e-8	Exhaled nitric oxide output;
KIRP	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.91	10.41	0.55	2.94e-21	Corneal astigmatism;
KIRP	cis	rs7937682	0.593	rs1944123	chr11:111356407	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.73	0.34	2.94e-8	Primary sclerosing cholangitis;
KIRP	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg02336718	chr17:17403227	NA	0.3	4.86	0.3	2.14e-6	Total body bone mineral density;
KIRP	cis	rs10518128	1.000	rs60126902	chr4:75710822	A/G	cg20122727	chr4:75719957	BTC	0.59	5.95	0.35	9.23e-9	Electroencephalogram traits;
KIRP	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.13	0.61	7.44e-27	Smoking behavior;
KIRP	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.4	-4.9	-0.3	1.78e-6	Renal cell carcinoma;
KIRP	cis	rs10129255	0.518	rs7143784	chr14:107143294	A/G	cg23076370	chr14:107095027	NA	-0.42	-5.35	-0.32	2.02e-7	Kawasaki disease;
KIRP	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.46	-6.19	-0.37	2.53e-9	Schizophrenia;
KIRP	cis	rs2274273	0.624	rs10143136	chr14:55743528	G/A	cg04306507	chr14:55594613	LGALS3	0.41	5.57	0.33	6.66e-8	Protein biomarker;
KIRP	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg26554054	chr8:600488	NA	0.67	5.12	0.31	6.22e-7	IgG glycosylation;
KIRP	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-18.85	-0.77	1.16e-49	Height;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.69	-11.46	-0.59	1.19e-24	Mean corpuscular volume;
KIRP	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg19906672	chr4:6918868	TBC1D14	0.51	5.33	0.32	2.22e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2398893	0.889	rs7872984	chr9:96782447	T/C	cg14459158	chr9:96720562	NA	0.29	5.19	0.31	4.4e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.78	0.49	2.81e-16	Life satisfaction;
KIRP	cis	rs600806	0.813	rs4970759	chr1:109982213	C/A	cg02175308	chr1:109941060	SORT1	-0.26	-5.0	-0.3	1.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.64	-10.68	-0.56	3.87e-22	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11661265	chr4:36068080	ARAP2	-0.39	-6.12	-0.36	3.69e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg21918786	chr6:109611834	NA	-0.41	-5.76	-0.34	2.51e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17499981	chr11:809742	RPLP2	-0.47	-6.06	-0.36	5.17e-9	Metabolic traits;
KIRP	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-4.99	-0.3	1.13e-6	Schizophrenia;
KIRP	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.67	-9.21	-0.51	1.43e-17	Crohn's disease;
KIRP	cis	rs2241685	0.646	rs4557005	chr2:1919696	C/G	cg22511877	chr2:1942942	MYT1L	0.48	5.32	0.32	2.34e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg08999081	chr20:33150536	PIGU	0.46	6.13	0.36	3.4e-9	Height;
KIRP	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs10267417	0.603	rs13245108	chr7:19910053	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg20022511	chr1:948740	ISG15	-0.52	-6.03	-0.36	5.97e-9	Corneal astigmatism;
KIRP	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg14541582	chr5:601475	NA	-0.49	-5.47	-0.33	1.11e-7	Lung disease severity in cystic fibrosis;
KIRP	trans	rs7939886	0.920	rs78674679	chr11:56070898	A/G	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg05973401	chr12:123451056	ABCB9	0.59	5.34	0.32	2.16e-7	Neutrophil percentage of white cells;
KIRP	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg15147215	chr3:52552868	STAB1	-0.28	-5.05	-0.31	8.72e-7	Bipolar disorder;
KIRP	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs10214930	0.781	rs974883	chr7:27588734	T/C	cg22168087	chr7:27702803	HIBADH	0.52	5.08	0.31	7.46e-7	Hypospadias;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25026957	chr14:74416582	FAM161B;COQ6	0.6	6.62	0.39	2.22e-10	Lung cancer in ever smokers;
KIRP	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg14675211	chr2:100938903	LONRF2	0.52	6.78	0.4	8.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg10932868	chr11:921992	NA	0.63	8.07	0.46	3.19e-14	Alzheimer's disease (late onset);
KIRP	cis	rs9525562	0.536	rs61732602	chr13:42617616	C/T	cg07025593	chr13:42613794	NA	0.46	5.21	0.32	4.05e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7116495	1.000	rs4944242	chr11:71667141	G/T	cg26138937	chr11:71823887	C11orf51	-0.71	-5.72	-0.34	3.08e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4478137	0.931	rs12509756	chr4:164237464	A/T	cg06758707	chr4:164254230	NPY1R	0.76	10.13	0.54	2.14e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg00990874	chr7:1149470	C7orf50	-0.7	-7.12	-0.41	1.16e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-0.84	-9.31	-0.51	7.67e-18	Gut microbiome composition (summer);
KIRP	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg11621586	chr10:70884670	VPS26A	1.23	16.95	0.73	3.27e-43	Left atrial antero-posterior diameter;
KIRP	cis	rs8523	0.774	rs2147041	chr6:11050523	C/T	cg13562911	chr6:11044106	ELOVL2	-0.37	-4.9	-0.3	1.77e-6	Red blood cell fatty acid levels;
KIRP	cis	rs4262150	0.846	rs55830548	chr5:152188126	C/T	cg12297329	chr5:152029980	NA	-0.66	-8.53	-0.48	1.55e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg01304814	chr3:48885189	PRKAR2A	0.71	5.63	0.34	4.97e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.76	6.36	0.38	9.65e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.58	-7.43	-0.43	1.84e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg01629716	chr15:45996671	NA	-0.37	-6.68	-0.39	1.57e-10	Waist circumference;Weight;
KIRP	cis	rs9534288	0.699	rs1409433	chr13:46655501	T/C	cg15192986	chr13:46630673	CPB2	-0.79	-9.58	-0.52	1.09e-18	Blood protein levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05379127	chr19:12885939	HOOK2	0.55	6.11	0.36	3.81e-9	Lung cancer in ever smokers;
KIRP	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.34	-0.47	5.37e-15	Total cholesterol levels;
KIRP	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.38	4.91	0.3	1.68e-6	Melanoma;
KIRP	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.06	-0.36	4.95e-9	IgG glycosylation;
KIRP	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg17105886	chr17:28927953	LRRC37B2	0.54	5.56	0.33	6.94e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg21253087	chr9:139290292	SNAPC4	-0.39	-5.11	-0.31	6.36e-7	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08040740	chr19:11925285	ZNF440	0.5	6.04	0.36	5.64e-9	Parkinson's disease;
KIRP	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	ch.8.33884649F	chr8:33765107	NA	0.6	7.55	0.43	8.37e-13	Body mass index;
KIRP	cis	rs17221829	0.702	rs72971023	chr11:89363934	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2012796	1.000	rs10450894	chr14:81825172	T/A	cg02996355	chr14:81879375	NA	0.4	5.48	0.33	1.08e-7	Night sleep phenotypes;
KIRP	cis	rs981844	0.775	rs72733610	chr4:154732336	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.91	-0.35	1.15e-8	Breast cancer;
KIRP	cis	rs72730918	0.590	rs12901452	chr15:51990247	C/T	cg14296394	chr15:51910925	DMXL2	0.75	10.53	0.56	1.24e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08045932	chr20:61659980	NA	0.54	6.83	0.4	6.63e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07234876	chr8:600039	NA	-0.96	-6.25	-0.37	1.8e-9	IgG glycosylation;
KIRP	cis	rs11955398	0.716	rs2061250	chr5:59917678	C/A	cg02684056	chr5:59996105	DEPDC1B	0.43	5.17	0.31	4.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg03060546	chr3:49711283	APEH	-0.65	-6.64	-0.39	1.98e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg26875233	chr11:93583750	C11orf90	-0.4	-7.52	-0.43	9.94e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25555424	chr11:2950735	PHLDA2	-0.52	-6.54	-0.38	3.48e-10	Menopause (age at onset);
KIRP	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-8.42	-0.47	3.17e-15	Alzheimer's disease;
KIRP	cis	rs28834970	0.571	rs12679874	chr8:27230819	A/G	cg18234130	chr8:27182889	PTK2B	-0.46	-5.59	-0.34	6.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs494562	0.892	rs547963	chr6:86118743	T/C	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-18.86	-0.77	1.12e-49	Height;
KIRP	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.68	-7.87	-0.45	1.14e-13	DNA methylation (variation);
KIRP	cis	rs34779708	0.931	rs79749947	chr10:35277081	A/T	cg03585969	chr10:35415529	CREM	0.84	10.14	0.54	2.08e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	1.11	15.87	0.71	1.58e-39	Breast cancer;
KIRP	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg00334542	chr7:100209784	MOSPD3	-0.78	-6.62	-0.39	2.25e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4356975	0.563	rs4540108	chr4:69949332	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs9308731	0.591	rs6542350	chr2:111944740	C/T	cg04202892	chr2:111875749	ACOXL	0.41	5.61	0.34	5.31e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.92	13.42	0.65	3.47e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs4474465	0.850	rs10899536	chr11:78216992	C/A	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.47e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg25233709	chr10:116636983	FAM160B1	0.35	5.3	0.32	2.59e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1971762	0.730	rs7963016	chr12:54072819	T/A	cg09709951	chr12:54017699	ATF7	0.4	5.11	0.31	6.45e-7	Height;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.76	6.78	0.4	9.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11264213	0.892	rs16822339	chr1:36220558	A/C	cg27506609	chr1:36549197	TEKT2	-0.74	-6.62	-0.39	2.24e-10	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.94	0.57	6.02e-23	Personality dimensions;
KIRP	cis	rs13361707	1.000	rs59338019	chr5:40780786	A/G	cg01087697	chr5:40835557	RPL37	-0.45	-5.24	-0.32	3.48e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.46	-0.52	2.57e-18	Chronic sinus infection;
KIRP	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.85	9.18	0.51	1.86e-17	Alzheimer's disease;
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg04025307	chr7:1156635	C7orf50	0.77	7.76	0.44	2.33e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7923609	1.000	rs7923609	chr10:65133822	A/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.55	-0.33	7.35e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12615966	0.651	rs72830473	chr2:105411202	C/A	cg16465502	chr2:105461796	NA	0.95	7.89	0.45	1e-13	Pancreatic cancer;
KIRP	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.68	7.97	0.45	6.02e-14	Height;
KIRP	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg02297831	chr4:17616191	MED28	0.62	7.7	0.44	3.39e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg02725872	chr8:58115012	NA	0.73	7.9	0.45	9.59e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg11150807	chr10:43354902	NA	0.63	6.68	0.39	1.58e-10	Blood protein levels;
KIRP	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.53	-7.6	-0.44	6.26e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg16077055	chr2:106428750	NCK2	0.29	5.85	0.35	1.53e-8	Addiction;
KIRP	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.81	12.06	0.61	1.29e-26	Menarche (age at onset);
KIRP	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.61	6.84	0.4	6.19e-11	Aortic root size;
KIRP	cis	rs5995756	0.627	rs3788568	chr22:40011273	G/T	cg21377881	chr22:40064566	CACNA1I	-0.38	-5.04	-0.31	8.87e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg17279839	chr7:150038598	RARRES2	0.46	6.08	0.36	4.62e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs748404	0.723	rs565658	chr15:43556307	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.35	0.42	2.92e-12	Lung cancer;
KIRP	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.31	5.48	0.33	1.05e-7	Monocyte count;
KIRP	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg17182837	chr8:41585554	ANK1	-0.48	-6.59	-0.39	2.61e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs1011108	0.561	rs1053807	chr2:26800422	G/A	cg18742855	chr2:26800399	C2orf70	0.38	5.68	0.34	3.76e-8	Periodontal microbiota;
KIRP	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.7	9.23	0.51	1.33e-17	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg02733842	chr7:1102375	C7orf50	0.48	5.1	0.31	6.72e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07570687	chr10:102243282	WNT8B	0.51	6.24	0.37	1.86e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10465746	0.725	rs980417	chr1:84365331	C/A	cg10977910	chr1:84465055	TTLL7	0.55	7.0	0.41	2.39e-11	Obesity-related traits;
KIRP	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.36	5.06	0.31	8.11e-7	Calcium levels;
KIRP	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.71	-0.53	4.57e-19	Coronary artery disease;
KIRP	cis	rs7635838	0.892	rs9823197	chr3:11503133	A/T	cg00170343	chr3:11313890	ATG7	0.46	5.78	0.35	2.26e-8	HDL cholesterol;
KIRP	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-7.33	-0.42	3.28e-12	Coffee consumption (cups per day);
KIRP	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg08533674	chr1:46993347	NA	-0.41	-5.35	-0.32	2.06e-7	Monobrow;
KIRP	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg01620082	chr3:125678407	NA	-1.27	-8.04	-0.46	3.81e-14	Depression;
KIRP	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.64	-7.42	-0.43	1.85e-12	Gut microbiome composition (summer);
KIRP	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg24253500	chr15:84953950	NA	0.51	5.86	0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.75	-11.07	-0.58	2.3e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.46	-0.33	1.14e-7	Morning vs. evening chronotype;
KIRP	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17507749	chr15:85114479	UBE2QP1	0.7	7.86	0.45	1.23e-13	Schizophrenia;
KIRP	cis	rs2411233	0.935	rs2164011	chr15:39289029	G/A	cg02291532	chr15:39874776	THBS1	0.42	5.72	0.34	3.1e-8	Platelet count;
KIRP	cis	rs9469913	0.866	rs2744942	chr6:34643752	T/C	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.28	-0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg09408571	chr1:101003634	GPR88	-0.22	-5.04	-0.31	9.2e-7	Monocyte count;
KIRP	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.86	9.7	0.53	4.77e-19	High light scatter reticulocyte count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02945294	chr17:2206979	SRR;SMG6	-0.47	-6.06	-0.36	5.08e-9	Metabolic traits;
KIRP	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg05479556	chr5:449004	EXOC3	-0.43	-5.21	-0.32	3.94e-7	Fat distribution (HIV);
KIRP	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Bladder cancer;
KIRP	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg01444801	chr10:135216882	MTG1	-0.55	-6.23	-0.37	2.01e-9	Systemic lupus erythematosus;
KIRP	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.79	-10.09	-0.54	3.02e-20	Menopause (age at onset);
KIRP	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg13880726	chr7:1868755	MAD1L1	0.53	6.32	0.37	1.19e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13985868	chr9:116102304	WDR31	0.57	7.18	0.42	8.3e-12	Parkinson's disease;
KIRP	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.45	-6.02	-0.36	6.46e-9	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg05528293	chr18:74961138	GALR1	0.52	5.78	0.35	2.24e-8	Obesity-related traits;
KIRP	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.61	7.9	0.45	9.37e-14	Vitiligo;
KIRP	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.7	-10.73	-0.56	2.72e-22	Height;
KIRP	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.87	10.13	0.54	2.16e-20	Osteoarthritis;
KIRP	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg10845886	chr2:3471009	TTC15	-0.52	-7.61	-0.44	5.79e-13	Neurofibrillary tangles;
KIRP	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.73	9.86	0.53	1.53e-19	Multiple sclerosis;
KIRP	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	1.01	17.98	0.75	1e-46	Leprosy;
KIRP	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.44	-5.62	-0.34	5.1e-8	Neutrophil percentage of white cells;
KIRP	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.42	-5.12	-0.31	6.09e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.95	0.3	1.36e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.81	11.18	0.58	9.58e-24	Blood metabolite levels;
KIRP	cis	rs9426935	0.932	rs2252508	chr1:153913770	A/G	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.29	-4.95	-0.3	1.4e-6	Lentiform nucleus volume;
KIRP	cis	rs2904967	0.778	rs116742819	chr11:65099893	A/C	cg12562828	chr11:65076843	NA	0.94	12.28	0.62	2.39e-27	Mean corpuscular volume;
KIRP	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.57	7.45	0.43	1.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.9	-10.08	-0.54	3.17e-20	Corneal astigmatism;
KIRP	cis	rs11997175	0.692	rs6995075	chr8:33673816	G/A	cg04338863	chr8:33670619	NA	0.43	5.77	0.35	2.33e-8	Body mass index;
KIRP	cis	rs4924590	0.531	rs2114477	chr15:42227441	C/T	cg20935245	chr15:42234343	EHD4	-0.5	-7.9	-0.45	9.58e-14	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
KIRP	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg08499158	chr17:42289980	UBTF	0.49	6.28	0.37	1.5e-9	Total body bone mineral density;
KIRP	cis	rs9325144	0.723	rs35749392	chr12:39170874	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.03	-0.41	2.07e-11	Morning vs. evening chronotype;
KIRP	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg13373371	chr19:49828787	SLC6A16	0.4	4.94	0.3	1.43e-6	Multiple sclerosis;
KIRP	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg04733989	chr22:42467013	NAGA	-0.54	-5.77	-0.35	2.43e-8	Schizophrenia;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.46	0.43	1.47e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg04310649	chr10:35416472	CREM	-0.6	-7.16	-0.42	9.16e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.11	-0.36	3.81e-9	Systolic blood pressure;
KIRP	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.05	20.16	0.79	5.05e-54	Testicular germ cell tumor;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg20360273	chr2:70056711	GMCL1	0.58	6.7	0.39	1.39e-10	Plasma plasminogen activator levels;
KIRP	cis	rs1461503	1.000	rs1461499	chr11:122843987	C/A	cg27398637	chr11:122830231	C11orf63	-0.68	-8.99	-0.5	6.86e-17	Menarche (age at onset);
KIRP	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	cg21523751	chr1:182988639	NA	0.41	6.3	0.37	1.37e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05472934	chr7:22766657	IL6	0.73	10.37	0.55	3.74e-21	Lung cancer;
KIRP	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.81	10.46	0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7084402	1.000	rs6481401	chr10:60268880	A/C	cg05938607	chr10:60274200	BICC1	0.41	9.98	0.54	6.68e-20	Refractive error;
KIRP	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.59	-7.52	-0.43	1.03e-12	Sudden cardiac arrest;
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	4.96	0.3	1.29e-6	Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04535371	chr3:49066825	IMPDH2	0.53	6.76	0.4	9.72e-11	Parkinson's disease;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.58	-9.1	-0.5	3.26e-17	Lymphocyte counts;
KIRP	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08393972	chr4:2372832	ZFYVE28	-0.46	-6.22	-0.37	2.08e-9	Parkinson's disease;
KIRP	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.41	-0.47	3.35e-15	Mood instability;
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02018176	chr4:1364513	KIAA1530	0.45	5.65	0.34	4.33e-8	Longevity;
KIRP	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.98	11.16	0.58	1.16e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13047869	chr3:10149882	C3orf24	0.6	5.48	0.33	1.06e-7	Alzheimer's disease;
KIRP	cis	rs7851660	0.805	rs7038998	chr9:100662396	C/G	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg18882449	chr10:104885122	NT5C2	-0.5	-6.44	-0.38	6.1e-10	Arsenic metabolism;
KIRP	cis	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.4	-4.97	-0.3	1.24e-6	Leprosy;
KIRP	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.78	9.43	0.52	3.26e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg13010199	chr12:38710504	ALG10B	-0.43	-5.3	-0.32	2.64e-7	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9815354	1.000	rs1717001	chr3:41934949	G/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.25	-0.32	3.36e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg25730555	chr22:47059586	GRAMD4	-0.5	-6.09	-0.36	4.27e-9	Urate levels in obese individuals;
KIRP	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.89	13.36	0.65	5.82e-31	Coronary artery disease;
KIRP	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.27	-0.47	8.45e-15	Myopia (pathological);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14121472	chr12:2934143	ITFG2	0.49	6.38	0.38	8.63e-10	Interleukin-4 levels;
KIRP	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg13271783	chr10:134563150	INPP5A	-0.61	-7.96	-0.45	6.15e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-5.99	-0.36	7.48e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4790312	0.729	rs9912392	chr17:1995611	G/C	cg24156229	chr17:1948635	NA	-0.45	-6.08	-0.36	4.66e-9	Left atrial antero-posterior diameter;
KIRP	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.37	0.38	9.01e-10	Aortic root size;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.48	-8.81	-0.49	2.28e-16	Lung cancer;
KIRP	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.65	-9.27	-0.51	9.96e-18	Retinal vascular caliber;
KIRP	cis	rs3736485	0.899	rs6493505	chr15:51845172	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.17	-0.31	4.79e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3126085	0.935	rs11584427	chr1:152299788	A/G	cg26876637	chr1:152193138	HRNR	-0.82	-8.03	-0.46	4.1e-14	Atopic dermatitis;
KIRP	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg19743168	chr1:23544995	NA	0.55	7.74	0.44	2.51e-13	Height;
KIRP	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06481639	chr22:41940642	POLR3H	-0.65	-7.24	-0.42	5.59e-12	Vitiligo;
KIRP	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.06e-6	Aortic root size;
KIRP	cis	rs6738627	0.840	rs6717858	chr2:165539661	C/T	cg03182029	chr2:165697222	COBLL1	-0.39	-5.14	-0.31	5.64e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg27432699	chr2:27873401	GPN1	-0.55	-7.09	-0.41	1.42e-11	Total body bone mineral density;
KIRP	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26207909	chr14:103986467	CKB	0.78	12.3	0.62	1.97e-27	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19209225	chr10:102756912	LZTS2	0.55	7.06	0.41	1.74e-11	Parkinson's disease;
KIRP	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg18016565	chr1:150552671	MCL1	0.35	5.38	0.32	1.72e-7	Tonsillectomy;
KIRP	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.58	-7.41	-0.43	2.05e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.55	6.95	0.41	3.3e-11	HDL cholesterol;
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg07402062	chr16:89894098	SPIRE2	0.33	6.72	0.39	1.24e-10	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.48	6.81	0.4	7.62e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1524927	1.000	rs11765843	chr7:96341168	T/A	cg03808172	chr7:96339361	SHFM1	0.37	4.9	0.3	1.74e-6	Total body bone mineral density;
KIRP	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.23	12.16	0.61	5.79e-27	Diabetic retinopathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03971828	chr1:25071582	CLIC4	-0.55	-6.27	-0.37	1.6e-9	Interleukin-4 levels;
KIRP	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.54	-0.43	9.21e-13	Acne (severe);
KIRP	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg17595323	chr11:93583763	C11orf90	-0.41	-6.79	-0.4	8.59e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs6662572	0.950	rs56093189	chr1:46234323	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.43	4.85	0.3	2.18e-6	Blood protein levels;
KIRP	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.49	-0.52	2.14e-18	Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg19847130	chr8:10466454	RP1L1	0.35	4.86	0.3	2.05e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg14673194	chr17:80132900	CCDC57	0.78	8.71	0.49	4.38e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.7	8.72	0.49	4.13e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs587242	1.000	rs1830868	chr1:96895906	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.32	8.58	0.48	1.08e-15	Crohn's disease;
KIRP	cis	rs9896052	0.608	rs9797247	chr17:73445814	C/T	cg25649188	chr17:73499917	CASKIN2	0.46	5.87	0.35	1.4e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg25182066	chr10:30743637	MAP3K8	0.61	7.49	0.43	1.25e-12	Inflammatory bowel disease;
KIRP	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.71	8.06	0.46	3.24e-14	Corneal astigmatism;
KIRP	cis	rs9325144	0.794	rs7963855	chr12:38914187	T/C	cg26384229	chr12:38710491	ALG10B	-0.54	-6.38	-0.38	8.91e-10	Morning vs. evening chronotype;
KIRP	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg21395723	chr22:39101663	GTPBP1	0.49	6.49	0.38	4.66e-10	Menopause (age at onset);
KIRP	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg27165867	chr14:105738592	BRF1	0.42	4.96	0.3	1.29e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.04	-0.31	8.94e-7	Pulmonary function;
KIRP	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.66	0.34	4.22e-8	Personality dimensions;
KIRP	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg16586182	chr3:47516702	SCAP	-0.76	-10.94	-0.57	5.82e-23	Colorectal cancer;
KIRP	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.76	-9.17	-0.5	1.96e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Hypertriglyceridemia;
KIRP	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.56	8.2	0.46	1.34e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs1858037	0.867	rs72621551	chr2:65615221	C/T	cg08085232	chr2:65598271	SPRED2	-0.54	-6.4	-0.38	7.9e-10	Rheumatoid arthritis;
KIRP	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.41	5.31	0.32	2.42e-7	Response to temozolomide;
KIRP	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg18944383	chr4:111397179	ENPEP	0.52	9.1	0.5	3.07e-17	Height;
KIRP	cis	rs7577696	0.597	rs212751	chr2:32418808	T/A	cg02381751	chr2:32503542	YIPF4	0.55	5.58	0.34	6.19e-8	Inflammatory biomarkers;
KIRP	cis	rs10073892	0.660	rs10477820	chr5:101946548	C/G	cg19774478	chr5:101632501	SLCO4C1	-0.53	-5.54	-0.33	7.6e-8	Cognitive decline (age-related);
KIRP	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg26138937	chr11:71823887	C11orf51	-1.12	-7.83	-0.45	1.49e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg18196295	chr10:418757	DIP2C	0.4	4.92	0.3	1.62e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.93e-10	Hypertriglyceridemia;
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.79	-0.4	8.15e-11	Immature fraction of reticulocytes;
KIRP	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg10504392	chr12:110044639	NA	0.27	5.31	0.32	2.49e-7	Neuroticism;
KIRP	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.45	-11.3	-0.58	4.1e-24	Diabetic kidney disease;
KIRP	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg18964960	chr10:1102726	WDR37	0.58	6.46	0.38	5.6e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.74	10.44	0.55	2.29e-21	Red blood cell count;
KIRP	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.69	8.78	0.49	2.78e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg08501292	chr6:25962987	TRIM38	0.76	5.11	0.31	6.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7578199	0.924	rs11693454	chr2:242358940	G/A	cg01632474	chr2:242799312	PDCD1	0.38	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs17604090	0.938	rs850027	chr7:29675792	G/T	cg19413766	chr7:29689036	LOC646762	-0.57	-5.29	-0.32	2.73e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
KIRP	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg06636001	chr8:8085503	FLJ10661	0.82	11.09	0.58	1.9e-23	Neuroticism;
KIRP	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg02023728	chr11:77925099	USP35	-0.28	-4.87	-0.3	1.96e-6	Alzheimer's disease (survival time);
KIRP	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg03465714	chr1:152285911	FLG	-0.43	-6.24	-0.37	1.9e-9	Inflammatory skin disease;
KIRP	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.58	7.17	0.42	8.89e-12	Arsenic metabolism;
KIRP	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.6	-0.39	2.46e-10	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-0.78	-7.74	-0.44	2.65e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.81	10.9	0.57	7.97e-23	Morning vs. evening chronotype;
KIRP	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg23625390	chr15:77176239	SCAPER	0.51	6.7	0.39	1.43e-10	Blood metabolite levels;
KIRP	cis	rs4789452	0.716	rs1105410	chr17:75383942	C/T	cg12985929	chr17:75370611	SEPT9	-0.36	-5.04	-0.31	8.88e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.51	7.21	0.42	6.68e-12	Systemic lupus erythematosus;
KIRP	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.59	-6.59	-0.39	2.66e-10	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.4	5.68	0.34	3.86e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg24060327	chr5:131705240	SLC22A5	0.53	6.39	0.38	8.26e-10	Blood metabolite levels;
KIRP	cis	rs9914266	1	rs9914266	chr17:2133250	T/C	cg16513277	chr17:2031491	SMG6	-0.68	-9.43	-0.52	3.2e-18	Myocardial infarction;
KIRP	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27286337	chr10:134555280	INPP5A	0.91	10.77	0.57	2.06e-22	Migraine;
KIRP	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.61	8.11	0.46	2.48e-14	Menarche (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21914187	chr7:92465743	CDK6	0.42	6.24	0.37	1.88e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.45	-6.14	-0.36	3.35e-9	Monocyte count;
KIRP	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.84	-13.66	-0.66	5.49e-32	Prostate cancer;
KIRP	cis	rs662064	0.962	rs660725	chr1:10557544	A/G	cg07384165	chr1:10488281	NA	-0.41	-5.08	-0.31	7.63e-7	Asthma;
KIRP	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	6.82	0.4	6.89e-11	Height;
KIRP	cis	rs2882667	0.858	rs11242447	chr5:138426173	T/C	cg04439458	chr5:138467593	SIL1	-0.54	-8.07	-0.46	3.16e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg11774413	chr4:56412743	CLOCK	0.48	6.17	0.37	2.79e-9	Myopia (pathological);
KIRP	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Bladder cancer;
KIRP	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	5.56	0.33	6.92e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.09	0.64	4.57e-30	Bladder cancer;
KIRP	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.82	10.69	0.56	3.86e-22	Total cholesterol levels;
KIRP	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg22437258	chr11:111473054	SIK2	-0.62	-6.48	-0.38	4.84e-10	Primary sclerosing cholangitis;
KIRP	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs12282928	0.959	rs871249	chr11:48284477	G/A	cg26585981	chr11:48327164	OR4S1	0.47	5.2	0.31	4.15e-7	Migraine - clinic-based;
KIRP	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.33	0.47	5.72e-15	Bipolar disorder;
KIRP	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.55	-0.33	7.54e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-0.69	-9.81	-0.53	2.16e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.58	5.49	0.33	9.87e-8	Alzheimer's disease;
KIRP	cis	rs75200691	0.748	rs28733113	chr8:13035434	A/C	cg26244164	chr8:12987449	DLC1	-0.35	-5.05	-0.31	8.7e-7	Emphysema imaging phenotypes;
KIRP	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg02725872	chr8:58115012	NA	-0.47	-5.6	-0.34	5.72e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.76	11.46	0.59	1.24e-24	Oral cavity cancer;
KIRP	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.81	-8.38	-0.47	3.99e-15	Gut microbiome composition (summer);
KIRP	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg09029085	chr17:47094198	IGF2BP1	0.23	5.39	0.33	1.64e-7	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	trans	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.2	0.42	7.48e-12	Mean corpuscular volume;
KIRP	cis	rs12143943	0.966	rs6669246	chr1:204557561	A/G	cg20240347	chr1:204465584	NA	-0.36	-6.66	-0.39	1.82e-10	Cognitive performance;
KIRP	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-18.99	-0.77	3.87e-50	Schizophrenia;
KIRP	cis	rs73206853	0.688	rs56691704	chr12:110568623	A/G	cg12870014	chr12:110450643	ANKRD13A	0.57	5.75	0.34	2.62e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.79	-8.92	-0.49	1.06e-16	Platelet count;
KIRP	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg04989706	chr14:50066350	PPIL5	-0.44	-5.16	-0.31	5.14e-7	Carotid intima media thickness;
KIRP	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg08999081	chr20:33150536	PIGU	0.42	5.29	0.32	2.65e-7	Height;
KIRP	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg10755058	chr3:40428713	ENTPD3	0.41	5.72	0.34	3.03e-8	Renal cell carcinoma;
KIRP	cis	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg11266682	chr4:10021025	SLC2A9	0.39	4.95	0.3	1.39e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs6568686	0.786	rs4145457	chr6:111821182	T/C	cg15721981	chr6:111408429	SLC16A10	-0.69	-5.96	-0.36	8.63e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.75	9.99	0.54	5.89e-20	Breast cancer;
KIRP	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.74	9.09	0.5	3.36e-17	Monocyte count;
KIRP	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg07636037	chr3:49044803	WDR6	0.46	5.55	0.33	7.33e-8	Resting heart rate;
KIRP	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.55	6.02	0.36	6.39e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg12598211	chr12:123634384	NA	-0.4	-5.03	-0.31	9.48e-7	Platelet count;
KIRP	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-9.05	-0.5	4.45e-17	Menarche (age at onset);
KIRP	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg00393435	chr22:39052596	LOC646851;CBY1	0.52	6.09	0.36	4.25e-9	Electroencephalogram traits;
KIRP	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg13679303	chr9:96623674	NA	-0.5	-6.99	-0.41	2.6e-11	DNA methylation (variation);
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.66	-8.81	-0.49	2.23e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs155346	0.625	rs264349	chr5:139361203	G/A	cg24724630	chr5:139362307	NRG2	-0.41	-5.49	-0.33	1.02e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg03684893	chr10:554711	DIP2C	-0.37	-5.07	-0.31	7.71e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.39	6.49	0.38	4.82e-10	Testicular germ cell tumor;
KIRP	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.59	-7.38	-0.43	2.38e-12	Iron status biomarkers;
KIRP	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg26207909	chr14:103986467	CKB	0.41	5.27	0.32	3.05e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	13.32	0.65	7.49e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg19318889	chr4:1322082	MAEA	0.47	5.39	0.32	1.67e-7	Longevity;
KIRP	cis	rs7179456	0.593	rs514049	chr15:59042363	A/C	cg05156742	chr15:59063176	FAM63B	-0.66	-8.82	-0.49	2.11e-16	Asperger disorder;
KIRP	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg04998671	chr14:104000505	TRMT61A	0.72	7.29	0.42	4.24e-12	Coronary artery disease;
KIRP	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.3	-5.74	-0.34	2.82e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg18461458	chr19:21324796	ZNF431	0.48	5.0	0.3	1.1e-6	Pain;
KIRP	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg13373371	chr19:49828787	SLC6A16	0.41	5.05	0.31	8.73e-7	Multiple sclerosis;
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13939156	chr17:80058883	NA	0.5	7.49	0.43	1.2e-12	Life satisfaction;
KIRP	trans	rs1497266	1.000	rs1497266	chr3:139283462	A/C	cg00834536	chr16:4013537	ADCY9	-0.26	-6.48	-0.38	4.84e-10	Gut microbiota (functional units);
KIRP	cis	rs4132509	1.000	rs6660534	chr1:243791642	A/C	cg21452805	chr1:244014465	NA	0.53	5.44	0.33	1.29e-7	RR interval (heart rate);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10187365	chr21:34860956	DNAJC28	0.46	6.3	0.37	1.4e-9	Survival in pancreatic cancer;
KIRP	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.56	-6.92	-0.4	3.84e-11	Diastolic blood pressure;
KIRP	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-8.85	-0.49	1.79e-16	Eye color traits;
KIRP	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg24531977	chr5:56204891	C5orf35	-0.42	-5.39	-0.33	1.64e-7	Coronary artery disease;
KIRP	trans	rs1056053	0.514	rs1056051	chr6:166571579	T/G	cg17428496	chr19:2151817	AP3D1	-0.56	-6.31	-0.37	1.31e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16702774	chr17:77771036	CBX8	0.54	7.6	0.44	6.08e-13	Survival in pancreatic cancer;
KIRP	trans	rs12690897	0.704	rs10231543	chr7:85337016	G/T	cg03355690	chr6:35265616	DEF6	-0.31	-6.03	-0.36	5.86e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.9	13.32	0.65	7.41e-31	Mean platelet volume;
KIRP	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg06223162	chr1:101003688	GPR88	-0.4	-7.78	-0.44	1.96e-13	Monocyte count;
KIRP	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.4	-0.33	1.6e-7	Coronary artery disease;
KIRP	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.84	10.1	0.54	2.71e-20	Homoarginine levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14163061	chr2:44223239	LRPPRC	0.52	6.58	0.39	2.78e-10	Inflammatory biomarkers;
KIRP	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.99	0.5	6.59e-17	Colorectal cancer;
KIRP	trans	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.76e-11	Diabetic kidney disease;
KIRP	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	11.15	0.58	1.2e-23	Alzheimer's disease;
KIRP	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.9	-0.49	1.23e-16	Total cholesterol levels;
KIRP	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11779988	0.545	rs375203	chr8:17769054	T/A	cg01800426	chr8:17659068	MTUS1	-0.59	-6.21	-0.37	2.28e-9	Breast cancer;
KIRP	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg08501292	chr6:25962987	TRIM38	0.8	5.38	0.32	1.71e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.97	13.93	0.66	6.33e-33	Alcohol dependence;
KIRP	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.16	0.37	2.92e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11225247	0.772	rs11225222	chr11:102230129	T/A	cg06323957	chr11:102217781	BIRC2	0.77	5.0	0.3	1.11e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg00981070	chr1:2046702	PRKCZ	0.39	6.58	0.39	2.79e-10	Height;
KIRP	cis	rs7998202	0.567	rs914019	chr13:113352911	A/G	cg04656015	chr13:113407548	ATP11A	-0.53	-5.71	-0.34	3.27e-8	Glycated hemoglobin levels;
KIRP	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	cg04338863	chr8:33670619	NA	0.46	6.0	0.36	6.93e-9	Body mass index;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg21285383	chr16:89894308	SPIRE2	0.3	5.62	0.34	5.19e-8	Vitiligo;
KIRP	cis	rs7833787	1.000	rs12546946	chr8:18703078	C/G	cg17701159	chr8:18705777	PSD3	-0.38	-7.15	-0.41	9.98e-12	Obesity-related traits;
KIRP	cis	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.22e-12	Morning vs. evening chronotype;
KIRP	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg22875332	chr1:76189707	ACADM	-0.34	-4.99	-0.3	1.16e-6	Daytime sleep phenotypes;
KIRP	cis	rs4356932	1.000	rs4484329	chr4:76978692	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg21851534	chr17:3907994	ZZEF1	-0.51	-7.15	-0.41	9.86e-12	Type 2 diabetes;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07402062	chr16:89894098	SPIRE2	0.34	6.99	0.41	2.53e-11	Vitiligo;
KIRP	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25951256	chr10:38645740	HSD17B7P2	-0.41	-4.94	-0.3	1.43e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.65	-0.39	1.92e-10	Axial length;
KIRP	cis	rs758324	0.947	rs1604080	chr5:131176644	A/G	cg06307176	chr5:131281290	NA	-0.53	-5.8	-0.35	2.02e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15557168	chr22:42548783	NA	-0.45	-5.73	-0.34	2.96e-8	Cognitive function;
KIRP	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.77	-0.35	2.35e-8	Breast cancer;
KIRP	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.03	15.24	0.7	2.16e-37	Primary sclerosing cholangitis;
KIRP	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.6	-9.59	-0.52	1.03e-18	Neuroticism;
KIRP	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	6.48	0.38	5.01e-10	Total body bone mineral density;
KIRP	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg23032965	chr3:12705835	RAF1	0.74	8.02	0.46	4.33e-14	Cholesterol, total;
KIRP	cis	rs7646881	1.000	rs59918529	chr3:158452705	T/C	cg19483011	chr3:158453295	NA	-0.51	-5.97	-0.36	8.31e-9	Tetralogy of Fallot;
KIRP	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.66	9.28	0.51	9.23e-18	Lymphocyte counts;
KIRP	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg17554472	chr22:41940697	POLR3H	-0.7	-7.05	-0.41	1.79e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-12.0	-0.61	1.96e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs17065868	1.000	rs55717372	chr13:45219605	G/A	cg10246903	chr13:45222710	NA	0.72	7.11	0.41	1.27e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-6.69	-0.39	1.53e-10	Response to antipsychotic treatment;
KIRP	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.83	11.51	0.59	7.97e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2839627	0.513	rs7282879	chr21:44286525	C/T	cg03543861	chr21:44258195	NA	0.52	5.73	0.34	3e-8	Information processing speed;
KIRP	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.74	6.78	0.4	8.73e-11	Diabetic retinopathy;
KIRP	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.83	0.66	1.47e-32	Bladder cancer;
KIRP	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg23587288	chr2:27483067	SLC30A3	-0.64	-7.18	-0.42	8.46e-12	Blood metabolite levels;
KIRP	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg04287289	chr16:89883240	FANCA	0.59	7.49	0.43	1.26e-12	Vitiligo;
KIRP	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21643547	chr1:205240462	TMCC2	-0.91	-14.5	-0.68	7.52e-35	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8049040	0.609	rs7188858	chr16:71468895	T/C	cg08717414	chr16:71523259	ZNF19	-0.57	-6.71	-0.39	1.37e-10	Blood protein levels;
KIRP	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs7624766	0.555	rs1851378	chr3:160513520	G/T	cg22637730	chr3:160473554	PPM1L	-0.44	-5.44	-0.33	1.29e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.56	-6.16	-0.37	2.96e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00889227	chr1:205173544	DSTYK	0.37	5.04	0.31	8.94e-7	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.97	11.5	0.59	9.04e-25	Exhaled nitric oxide levels;
KIRP	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg27205649	chr11:78285834	NARS2	-0.67	-8.29	-0.47	7.38e-15	Alzheimer's disease (survival time);
KIRP	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.05	0.46	3.44e-14	Menarche (age at onset);
KIRP	cis	rs838147	0.537	rs485073	chr19:49207255	A/G	cg08619932	chr19:49200058	FUT2	0.39	6.02	0.36	6.22e-9	Dietary macronutrient intake;
KIRP	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg08975724	chr8:8085496	FLJ10661	0.48	6.29	0.37	1.46e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs56146971	0.763	rs77450079	chr14:91863924	A/C	cg16433844	chr14:91963127	SMEK1	-0.58	-5.47	-0.33	1.08e-7	Alzheimer disease and age of onset;
KIRP	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.33	-0.37	1.15e-9	Blood pressure;
KIRP	cis	rs13034020	0.522	rs12996059	chr2:61245551	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.29	0.37	1.44e-9	Hodgkin's lymphoma;
KIRP	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.26	0.42	5.15e-12	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23841903	chr1:21058444	SH2D5	0.46	6.18	0.37	2.67e-9	Parkinson's disease;
KIRP	cis	rs7143963	0.580	rs3783385	chr14:103367667	G/A	cg24154132	chr14:103367632	TRAF3	0.29	5.55	0.33	7.51e-8	Body mass index;
KIRP	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23903597	chr17:61704154	MAP3K3	0.44	5.16	0.31	4.98e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs992157	0.932	rs10203039	chr2:219187367	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.38	0.38	8.6e-10	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01777187	chr21:40721343	HMGN1	0.48	6.38	0.38	8.5e-10	Parkinson's disease;
KIRP	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs15676	0.783	rs2280845	chr9:131583170	T/C	cg00228799	chr9:131580591	ENDOG	0.53	5.92	0.35	1.1e-8	Blood metabolite levels;
KIRP	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.89	-12.97	-0.64	1.13e-29	Dupuytren's disease;
KIRP	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg05043794	chr9:111880884	C9orf5	-0.25	-5.37	-0.32	1.82e-7	Menarche (age at onset);
KIRP	cis	rs735539	0.593	rs2818997	chr13:21369315	C/T	cg04906043	chr13:21280425	IL17D	-0.42	-4.96	-0.3	1.34e-6	Dental caries;
KIRP	cis	rs16828019	0.852	rs12759023	chr1:41603978	T/C	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.55	7.61	0.44	5.83e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs10181042	0.535	rs2441465	chr2:61311187	C/T	cg15711740	chr2:61764176	XPO1	-0.39	-5.08	-0.31	7.53e-7	Crohn's disease;
KIRP	trans	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg14791747	chr16:20752902	THUMPD1	0.69	9.64	0.52	7.11e-19	Cognitive test performance;
KIRP	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg11130432	chr3:121712080	ILDR1	-0.46	-5.4	-0.33	1.58e-7	Multiple sclerosis;
KIRP	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg00125455	chr20:44574271	PCIF1	-0.44	-8.68	-0.48	5.53e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg02336718	chr17:17403227	NA	-0.32	-4.91	-0.3	1.7e-6	Total body bone mineral density;
KIRP	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.43	0.38	6.58e-10	Aortic root size;
KIRP	cis	rs16858210	0.648	rs57604063	chr3:183578689	A/T	cg25686905	chr3:183603175	PARL	-0.43	-4.86	-0.3	2.13e-6	Menopause (age at onset);
KIRP	cis	rs4886920	0.862	rs4886531	chr15:78144742	A/G	cg10461261	chr15:78109450	NA	-0.32	-5.21	-0.32	3.95e-7	Neuroticism;
KIRP	cis	rs16828019	0.777	rs34502739	chr1:41459146	A/G	cg03387723	chr1:41708464	SCMH1	-0.75	-6.08	-0.36	4.5e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14185104	chr9:128649813	PBX3	0.42	6.02	0.36	6.34e-9	C-reactive protein;
KIRP	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.49	7.01	0.41	2.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg10547527	chr2:198650123	BOLL	-0.55	-4.97	-0.3	1.23e-6	Ulcerative colitis;
KIRP	cis	rs17123764	0.710	rs7688	chr12:50157071	T/C	cg20471783	chr12:50157085	TMBIM6	0.32	5.01	0.3	1.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg13206674	chr6:150067644	NUP43	0.52	7.4	0.43	2.22e-12	Testicular germ cell tumor;
KIRP	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg13906792	chr15:75199810	C15orf17	-0.37	-5.68	-0.34	3.73e-8	Breast cancer;
KIRP	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.18	13.53	0.65	1.53e-31	Sexual dysfunction (female);
KIRP	cis	rs9938149	0.736	rs28716598	chr16:88324563	C/G	cg05435882	chr16:88311214	NA	-0.47	-5.52	-0.33	8.59e-8	Corneal structure;Central corneal thickness;
KIRP	cis	rs72781680	0.611	rs74661620	chr2:24365260	C/A	cg20701182	chr2:24300061	SF3B14	0.95	10.25	0.55	9.19e-21	Lymphocyte counts;
KIRP	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg05370193	chr1:21551575	ECE1	-0.36	-4.96	-0.3	1.32e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs13418717	1.000	rs951816	chr2:127665049	A/G	cg25501666	chr2:127640322	NA	0.88	5.79	0.35	2.11e-8	Heart failure;
KIRP	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg24315340	chr6:146058215	EPM2A	0.42	5.2	0.31	4.1e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.65	7.02	0.41	2.21e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs73105738	0.590	rs59572799	chr5:73286433	G/A	cg26653990	chr5:72510846	NA	-0.49	-5.37	-0.32	1.86e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg22681709	chr2:178499509	PDE11A	-0.59	-8.51	-0.48	1.72e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg00977110	chr5:151150581	G3BP1	-0.61	-6.2	-0.37	2.4e-9	Preschool internalizing problems;
KIRP	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-5.04	-0.31	9.11e-7	Ulcerative colitis;
KIRP	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2594989	0.837	rs7642031	chr3:11453754	G/A	cg01796438	chr3:11312864	ATG7	-0.72	-8.66	-0.48	6.32e-16	Circulating chemerin levels;
KIRP	cis	rs57994353	0.568	rs4400498	chr9:139305007	C/T	cg21253087	chr9:139290292	SNAPC4	0.52	5.71	0.34	3.19e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.78	9.9	0.53	1.12e-19	Cognitive function;
KIRP	trans	rs6601327	0.632	rs4841220	chr8:9656059	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.66	-0.44	4.39e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.99	10.89	0.57	8.69e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg26827852	chr1:89887630	LOC400759	0.44	6.04	0.36	5.75e-9	Carotid intima media thickness;
KIRP	trans	rs12681366	0.663	rs10216902	chr8:95479978	A/G	cg18054943	chr17:7283897	TNK1	-0.26	-6.45	-0.38	5.78e-10	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-1.01	-16.87	-0.73	5.9e-43	Height;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.82	-12.69	-0.63	1.03e-28	Asthma;
KIRP	cis	rs13102973	0.864	rs7442176	chr4:135899575	C/A	cg14419869	chr4:135874104	NA	-0.49	-7.71	-0.44	3.04e-13	Subjective well-being;
KIRP	cis	rs6753739	0.745	rs1455838	chr2:219912629	A/G	cg01749213	chr2:219906749	CCDC108	0.43	5.09	0.31	7.2e-7	Height;
KIRP	cis	rs17123764	0.818	rs7970241	chr12:49948759	C/T	cg02054252	chr12:50078554	FMNL3	0.43	5.25	0.32	3.36e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00938859	chr5:1591904	SDHAP3	0.54	6.28	0.37	1.53e-9	Breast cancer;
KIRP	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.73	12.13	0.61	7.41e-27	Metabolite levels;
KIRP	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg24296786	chr1:45957014	TESK2	-0.5	-5.56	-0.33	6.94e-8	Homocysteine levels;
KIRP	cis	rs9584850	0.834	rs3803253	chr13:99117149	G/A	cg20750642	chr13:99100586	FARP1	-0.52	-6.1	-0.36	4.03e-9	Neuroticism;
KIRP	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg11621586	chr10:70884670	VPS26A	1.07	9.71	0.53	4.31e-19	Left atrial antero-posterior diameter;
KIRP	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.63	8.59	0.48	9.81e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg15181151	chr6:150070149	PCMT1	0.29	4.94	0.3	1.42e-6	Lung cancer;
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-5.81	-0.35	1.96e-8	Lung cancer;
KIRP	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.72	-0.53	4.23e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg23188430	chr6:125850052	NA	-0.31	-4.85	-0.3	2.21e-6	Brugada syndrome;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg05567628	chr11:12462992	PARVA	0.4	6.18	0.37	2.64e-9	Warfarin maintenance dose;
KIRP	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20135002	chr11:47629003	NA	-0.46	-5.17	-0.31	4.76e-7	Subjective well-being;
KIRP	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.13	22.04	0.81	3.62e-60	Testicular germ cell tumor;
KIRP	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.41	5.23	0.32	3.55e-7	Neutrophil percentage of white cells;
KIRP	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.63	-8.15	-0.46	1.82e-14	Colorectal cancer;
KIRP	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.81	-0.35	1.96e-8	Glomerular filtration rate;
KIRP	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-20.29	-0.79	1.88e-54	Heart rate;
KIRP	cis	rs3099143	0.901	rs78020233	chr15:77107050	T/G	cg21673338	chr15:77095150	SCAPER	-0.59	-5.93	-0.35	1.04e-8	Recalcitrant atopic dermatitis;
KIRP	cis	rs9815354	0.812	rs13084436	chr3:42017537	T/A	cg03022575	chr3:42003672	ULK4	-0.55	-6.07	-0.36	4.76e-9	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22564026	chr6:163608419	PACRG	-0.43	-6.31	-0.37	1.32e-9	Parkinson's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07312556	chr10:61666263	CCDC6	-0.5	-6.71	-0.39	1.32e-10	Myopia;
KIRP	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.65	6.7	0.39	1.38e-10	Vitiligo;
KIRP	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg09571762	chr12:39539558	NA	0.35	5.23	0.32	3.67e-7	Morning vs. evening chronotype;
KIRP	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.32	4.86	0.3	2.11e-6	Body mass index;
KIRP	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	1.05	6.67	0.39	1.66e-10	Type 2 diabetes nephropathy;
KIRP	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.58	-8.54	-0.48	1.38e-15	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22995356	chr3:184081109	POLR2H	0.53	6.87	0.4	5.13e-11	Parkinson's disease;
KIRP	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.36	-0.32	1.92e-7	Chronic sinus infection;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23738548	chr7:622318	PRKAR1B	0.47	6.06	0.36	5.03e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs1978968	1.000	rs1079576	chr22:18446318	C/A	cg03078520	chr22:18463400	MICAL3	-0.64	-7.63	-0.44	5.29e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.68	9.09	0.5	3.5e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs889512	0.642	rs8048529	chr16:75275630	C/T	cg03315344	chr16:75512273	CHST6	-0.66	-5.03	-0.31	9.38e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs17221829	0.549	rs9666894	chr11:89358359	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.19	-0.31	4.48e-7	Anxiety in major depressive disorder;
KIRP	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg15358701	chr1:161410459	NA	-0.59	-5.66	-0.34	4.11e-8	Rheumatoid arthritis;
KIRP	cis	rs6929812	0.967	rs2893916	chr6:27396658	C/A	cg03332623	chr6:27441972	ZNF184	-0.37	-5.2	-0.31	4.19e-7	Neuroticism (multi-trait analysis);
KIRP	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19717773	chr7:2847554	GNA12	-0.36	-6.32	-0.37	1.19e-9	Height;
KIRP	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.75e-12	Bipolar disorder;
KIRP	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.4	5.02	0.3	9.81e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.13	-0.61	7.34e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07544984	chr3:42845911	HIGD1A	0.47	6.26	0.37	1.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-5.07	-0.31	7.65e-7	Ulcerative colitis;
KIRP	trans	rs12517041	1.000	rs28600340	chr5:23301774	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg00908189	chr16:619842	PIGQ	0.84	11.51	0.59	8.39e-25	Height;
KIRP	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26002218	chr14:103986227	CKB	0.29	6.13	0.36	3.5e-9	Body mass index;
KIRP	cis	rs554111	0.891	rs531044	chr1:21057011	T/C	cg08890418	chr1:21044141	KIF17	0.61	9.76	0.53	3.09e-19	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs362296	0.671	rs3095074	chr4:3261152	G/A	cg06533319	chr4:3265114	C4orf44	0.55	6.33	0.37	1.15e-9	Parental longevity (mother's age at death);
KIRP	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05555928	chr11:63887634	MACROD1	0.43	6.1	0.36	3.99e-9	Platelet count;
KIRP	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg19554555	chr3:13937349	NA	0.54	7.82	0.45	1.51e-13	Ovarian reserve;
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg09264619	chr17:80180166	NA	-0.37	-5.43	-0.33	1.38e-7	Life satisfaction;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19573567	chr10:90751252	ACTA2;FAS	-0.43	-6.09	-0.36	4.41e-9	Migraine with aura;
KIRP	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg10223061	chr2:219282414	VIL1	-0.34	-5.35	-0.32	2.04e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs787274	1.000	rs787286	chr9:115534336	T/C	cg13803584	chr9:115635662	SNX30	-0.72	-6.34	-0.37	1.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg01114163	chr5:1856713	NA	-0.43	-5.13	-0.31	5.86e-7	Cardiovascular disease risk factors;
KIRP	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg18154014	chr19:37997991	ZNF793	0.73	7.78	0.44	1.97e-13	Coronary artery calcification;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19224656	chr3:72897546	SHQ1	0.52	6.61	0.39	2.31e-10	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23283236	chr19:39616406	PAK4	0.48	6.56	0.39	3.11e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2652822	0.530	rs7165016	chr15:63439590	T/A	cg02713581	chr15:63449717	RPS27L	0.51	5.47	0.33	1.11e-7	Metabolic traits;
KIRP	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03517284	chr6:25882590	NA	0.41	5.46	0.33	1.19e-7	Height;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.76	11.55	0.59	6.07e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	0.99	18.16	0.76	2.53e-47	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12986413	0.624	rs2238601	chr19:2140374	G/T	cg09261902	chr19:2140048	AP3D1	0.71	11.71	0.6	1.77e-25	Height;
KIRP	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg10755058	chr3:40428713	ENTPD3	0.44	6.16	0.37	3.01e-9	Renal cell carcinoma;
KIRP	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.47	-0.43	1.41e-12	Neuroticism;
KIRP	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg10756647	chr7:56101905	PSPH	1.09	8.55	0.48	1.29e-15	Diabetic kidney disease;
KIRP	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.06	13.06	0.64	5.76e-30	Platelet count;
KIRP	cis	rs6541297	0.699	rs1555290	chr1:230294989	A/C	cg20703242	chr1:230279135	GALNT2	-0.34	-5.44	-0.33	1.31e-7	Coronary artery disease;
KIRP	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.89	8.72	0.49	4.33e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26314531	chr2:26401878	FAM59B	0.46	4.89	0.3	1.8e-6	Gut microbiome composition (summer);
KIRP	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg25281562	chr12:121454272	C12orf43	-0.49	-5.31	-0.32	2.48e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.43	-5.98	-0.36	8.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	1.0	13.46	0.65	2.54e-31	Vitamin D levels;
KIRP	cis	rs7119167	0.762	rs11823923	chr11:73061734	T/C	cg17517138	chr11:73019481	ARHGEF17	0.48	5.12	0.31	6.12e-7	Blood protein levels;
KIRP	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg18850127	chr7:39170497	POU6F2	-0.34	-6.41	-0.38	7.43e-10	IgG glycosylation;
KIRP	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg20573242	chr4:122745356	CCNA2	0.4	5.0	0.3	1.08e-6	Type 2 diabetes;
KIRP	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.59	-7.58	-0.44	6.89e-13	Diastolic blood pressure;
KIRP	cis	rs4409675	0.912	rs11247730	chr1:28270737	A/G	cg23691781	chr1:28212827	C1orf38	-0.31	-5.89	-0.35	1.24e-8	Corneal astigmatism;
KIRP	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs9859260	0.925	rs3761717	chr3:195797947	G/C	cg12923728	chr3:195709715	SDHAP1	-0.43	-5.02	-0.3	9.94e-7	Mean corpuscular volume;
KIRP	cis	rs6681460	0.932	rs665319	chr1:67175488	A/G	cg13052034	chr1:66999238	SGIP1	0.36	5.16	0.31	5.08e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.59	8.11	0.46	2.43e-14	Coronary artery disease;
KIRP	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.5	-7.2	-0.42	7.42e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.67	7.12	0.41	1.15e-11	Lymphocyte counts;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.84	-12.52	-0.62	3.86e-28	Height;
KIRP	cis	rs9905704	0.918	rs444393	chr17:56709222	A/G	cg12560992	chr17:57184187	TRIM37	0.62	6.62	0.39	2.17e-10	Testicular germ cell tumor;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14868726	chr18:2571660	METTL4;NDC80	0.46	6.14	0.36	3.22e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.9	14.23	0.67	6.04e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.41	5.23	0.32	3.54e-7	Melanoma;
KIRP	cis	rs55675132	0.548	rs3911879	chr1:115378032	C/T	cg12756093	chr1:115239321	AMPD1	0.51	5.08	0.31	7.53e-7	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03934478	chr11:495069	RNH1	0.75	5.98	0.36	7.81e-9	Body mass index;
KIRP	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.85	10.3	0.55	6.46e-21	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg05025164	chr4:1340916	KIAA1530	0.47	5.67	0.34	3.93e-8	Obesity-related traits;
KIRP	cis	rs7709377	0.570	rs9326987	chr5:115436407	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7084402	0.967	rs1658479	chr10:60289398	C/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.96	-0.57	5.09e-23	Refractive error;
KIRP	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	1.0	8.16	0.46	1.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.96	11.9	0.6	4.35e-26	Platelet distribution width;
KIRP	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.63	-9.2	-0.51	1.6e-17	Heart rate;
KIRP	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg06565975	chr8:143823917	SLURP1	-0.57	-8.0	-0.45	4.88e-14	Urinary tract infection frequency;
KIRP	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg05340658	chr4:99064831	C4orf37	0.53	6.59	0.39	2.61e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.47	6.09	0.36	4.21e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg21860029	chr14:82000536	SEL1L	0.55	6.09	0.36	4.42e-9	Schizophrenia;
KIRP	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-0.88	-8.74	-0.49	3.59e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.15	15.1	0.69	6.59e-37	Gut microbiome composition (summer);
KIRP	cis	rs597583	0.715	rs11216437	chr11:117394685	A/G	cg27161313	chr11:117392002	DSCAML1	0.72	7.56	0.43	8.07e-13	Putamen volume;
KIRP	cis	rs1823913	1.000	rs4853565	chr2:192123746	C/T	cg12404831	chr2:192114017	MYO1B	-0.5	-6.77	-0.4	9.57e-11	Obesity-related traits;
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg07216194	chr8:27182965	PTK2B	0.48	5.87	0.35	1.4e-8	Neuroticism;
KIRP	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs2594989	0.836	rs347609	chr3:11269999	G/C	cg01796438	chr3:11312864	ATG7	-0.63	-7.43	-0.43	1.84e-12	Circulating chemerin levels;
KIRP	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.63	8.5	0.48	1.88e-15	Total body bone mineral density;
KIRP	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.26	0.47	8.87e-15	Lung cancer in ever smokers;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14870128	chr10:70931312	VPS26A	0.53	6.72	0.39	1.29e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.84	8.53	0.48	1.47e-15	Gastritis;
KIRP	cis	rs7945718	0.781	rs11022513	chr11:12840986	C/T	ch.11.340609R	chr11:12831013	TEAD1	0.44	5.64	0.34	4.69e-8	Educational attainment (years of education);
KIRP	cis	rs13102973	0.899	rs7442212	chr4:135899800	A/G	cg14419869	chr4:135874104	NA	-0.49	-7.71	-0.44	3.04e-13	Subjective well-being;
KIRP	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg11845111	chr2:191398756	TMEM194B	-0.94	-10.55	-0.56	1.02e-21	Diastolic blood pressure;
KIRP	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg21643547	chr1:205240462	TMCC2	-0.54	-7.86	-0.45	1.23e-13	Red blood cell count;
KIRP	cis	rs7005380	0.581	rs869341	chr8:120932805	G/C	cg21645572	chr8:120931649	DEPDC6	-0.52	-7.24	-0.42	5.77e-12	Interstitial lung disease;
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg21734707	chr17:3908241	ZZEF1	-0.62	-9.31	-0.51	7.48e-18	Type 2 diabetes;
KIRP	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.55	7.61	0.44	5.67e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs593531	0.571	rs6592557	chr11:74086642	T/C	cg18195628	chr11:73498948	MRPL48	-0.42	-4.9	-0.3	1.72e-6	Neuroticism;
KIRP	cis	rs13343954	0.825	rs11084698	chr19:33534174	A/G	cg27124370	chr19:33622961	WDR88	0.62	6.85	0.4	5.77e-11	Colorectal cancer;
KIRP	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.67	8.14	0.46	1.99e-14	Blood metabolite levels;
KIRP	cis	rs12949688	0.627	rs4793572	chr17:55834387	A/G	cg12582317	chr17:55822272	NA	0.44	6.2	0.37	2.41e-9	Schizophrenia;
KIRP	cis	rs35000415	0.938	rs17339836	chr7:128681062	C/T	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg03714773	chr7:91764589	CYP51A1	0.34	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.8	0.49	2.45e-16	Motion sickness;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18751573	chr3:16924903	NA	-0.46	-6.26	-0.37	1.74e-9	Inflammatory biomarkers;
KIRP	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.76	11.77	0.6	1.16e-25	Total body bone mineral density;
KIRP	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.11	0.64	4.03e-30	Exhaled nitric oxide output;
KIRP	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.63	-7.04	-0.41	1.91e-11	Menarche (age at onset);
KIRP	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.07	0.41	1.57e-11	Iron status biomarkers;
KIRP	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg07930552	chr6:133119739	C6orf192	0.98	6.32	0.37	1.22e-9	Type 2 diabetes nephropathy;
KIRP	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.38	5.16	0.31	5.07e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg15892785	chr1:6309343	GPR153	-0.48	-6.65	-0.39	1.91e-10	Resting heart rate;
KIRP	cis	rs33912345	0.695	rs1254305	chr14:60887415	G/A	cg27398547	chr14:60952738	C14orf39	-0.4	-5.4	-0.33	1.56e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.89	-13.01	-0.64	8.45e-30	Total body bone mineral density;
KIRP	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.73	-0.44	2.74e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9381107	0.615	rs7757541	chr6:9432485	A/C	cg14735645	chr6:9486422	NA	-0.37	-4.9	-0.3	1.76e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg10755058	chr3:40428713	ENTPD3	0.36	5.14	0.31	5.49e-7	Renal cell carcinoma;
KIRP	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.56	-15.32	-0.7	1.14e-37	Hip circumference adjusted for BMI;
KIRP	trans	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg24644049	chr4:85504048	CDS1	0.93	6.88	0.4	4.86e-11	Skin colour saturation;
KIRP	cis	rs6988636	0.710	rs73339621	chr8:124138936	C/T	cg23067535	chr8:124195133	FAM83A	-0.66	-5.55	-0.33	7.38e-8	Urinary uromodulin levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09675001	chr1:89616557	GBP7	-0.43	-6.41	-0.38	7.52e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs501120	0.929	rs528668	chr10:44762584	G/A	cg09554077	chr10:44749378	NA	0.7	10.73	0.56	2.84e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg21573476	chr21:45109991	RRP1B	-0.58	-7.83	-0.45	1.44e-13	Mean corpuscular volume;
KIRP	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg13385521	chr17:29058706	SUZ12P	0.54	5.29	0.32	2.69e-7	Body mass index;
KIRP	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.45	-7.35	-0.42	2.84e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg14221460	chr8:27183342	PTK2B	0.54	7.06	0.41	1.69e-11	Neuroticism;
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.66	-5.87	-0.35	1.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.29	-0.47	7.44e-15	Total cholesterol levels;
KIRP	cis	rs11628318	0.851	rs4243734	chr14:103023569	T/C	cg12046867	chr14:103022105	NA	-0.59	-7.25	-0.42	5.48e-12	Platelet count;
KIRP	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.65	-0.39	1.89e-10	Height;
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.56	-7.55	-0.43	8.58e-13	Mean corpuscular volume;
KIRP	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	cis	rs9596863	0.898	rs9568904	chr13:54330100	A/G	ch.13.53330881F	chr13:54432880	NA	0.6	5.79	0.35	2.16e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg23594656	chr7:65796392	TPST1	0.47	7.37	0.43	2.61e-12	Aortic root size;
KIRP	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	0.99	18.16	0.76	2.45e-47	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg10932868	chr11:921992	NA	0.61	8.17	0.46	1.65e-14	Alzheimer's disease (late onset);
KIRP	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg00204512	chr16:28754710	NA	0.41	5.26	0.32	3.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02636234	chr1:212781466	ATF3	0.44	6.33	0.37	1.13e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.38	-0.32	1.7e-7	Multiple sclerosis;
KIRP	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg04306507	chr14:55594613	LGALS3	0.46	7.21	0.42	6.88e-12	Protein biomarker;
KIRP	cis	rs62117911	1	rs62117911	chr19:16241886	G/A	cg07665718	chr19:16244068	HSH2D;RAB8A	0.84	7.46	0.43	1.48e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9828933	0.626	rs73119018	chr3:63975328	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.87	-7.31	-0.42	3.8e-12	Type 2 diabetes;
KIRP	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.45	6.32	0.37	1.19e-9	Dupuytren's disease;
KIRP	cis	rs7849270	0.921	rs6478864	chr9:131880630	C/G	cg13538475	chr9:131942899	NA	-0.31	-4.98	-0.3	1.21e-6	Blood metabolite ratios;
KIRP	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg15068132	chr12:102092402	CHPT1	-0.39	-5.09	-0.31	7.26e-7	Blood protein levels;
KIRP	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.54	-7.41	-0.43	1.97e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs12693043	0.845	rs13004727	chr2:175376648	A/C	cg11778734	chr2:175439522	WIPF1	-0.45	-6.05	-0.36	5.39e-9	Urate levels (BMI interaction);
KIRP	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20135002	chr11:47629003	NA	-0.47	-5.25	-0.32	3.22e-7	Subjective well-being;
KIRP	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg12315302	chr6:26189340	HIST1H4D	0.69	5.45	0.33	1.22e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7546094	0.846	rs6537749	chr1:113218503	T/C	cg22162597	chr1:113214053	CAPZA1	-0.44	-5.72	-0.34	3.05e-8	Platelet distribution width;
KIRP	cis	rs1215050	0.791	rs503863	chr4:98707663	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.8	9.25	0.51	1.12e-17	Pulmonary function decline;
KIRP	cis	rs687432	0.924	rs11605267	chr11:57699402	C/T	cg19752551	chr11:57585705	CTNND1	-0.52	-7.18	-0.42	8.26e-12	Parkinson's disease;
KIRP	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg01028140	chr2:1542097	TPO	-0.78	-6.95	-0.41	3.3e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs17079247	0.722	rs1038735	chr13:85805836	T/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.43	-0.38	6.53e-10	Bipolar disorder (mania);
KIRP	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.35	-4.87	-0.3	2.02e-6	High light scatter reticulocyte count;
KIRP	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.78	-10.54	-0.56	1.12e-21	Aortic root size;
KIRP	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg05340658	chr4:99064831	C4orf37	0.61	7.68	0.44	3.88e-13	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg00852783	chr1:26633632	UBXN11	0.61	7.81	0.45	1.6e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg11204139	chr17:3907470	NA	-0.53	-5.19	-0.31	4.4e-7	Type 2 diabetes;
KIRP	cis	rs17123764	0.710	rs12299505	chr12:50019894	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.88	0.3	1.87e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11997175	0.902	rs7462610	chr8:33693318	A/T	ch.8.33884649F	chr8:33765107	NA	0.47	5.91	0.35	1.16e-8	Body mass index;
KIRP	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.68	-7.83	-0.45	1.43e-13	Pancreatic cancer;
KIRP	cis	rs501120	0.568	rs471451	chr10:44754785	G/C	cg09554077	chr10:44749378	NA	0.68	6.26	0.37	1.68e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg05973401	chr12:123451056	ABCB9	0.55	6.26	0.37	1.69e-9	Neutrophil percentage of white cells;
KIRP	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.74	-0.68	1.1e-35	Alzheimer's disease;
KIRP	cis	rs4908768	0.594	rs11121227	chr1:8830640	C/T	cg25722041	chr1:8623473	RERE	0.64	8.03	0.46	4.14e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9547692	1.000	rs9547691	chr13:37468588	T/C	cg01493522	chr13:37497338	NA	-0.43	-5.35	-0.32	2.04e-7	Coronary artery disease;
KIRP	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg23460707	chr10:133558971	NA	0.35	5.4	0.33	1.59e-7	Survival in rectal cancer;
KIRP	cis	rs2224391	0.534	rs2753229	chr6:5246633	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.17	-0.37	2.75e-9	Height;
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg04804543	chr8:142233427	SLC45A4	-1.03	-17.86	-0.75	2.64e-46	Immature fraction of reticulocytes;
KIRP	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.34	0.55	4.65e-21	Cognitive test performance;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg27532560	chr4:187881888	NA	-0.74	-12.39	-0.62	9.92e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg07451762	chr16:28383216	NA	0.42	5.4	0.33	1.53e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1355223	0.902	rs1773908	chr11:34743380	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs42648	0.596	rs6465251	chr7:89847881	C/G	cg25739043	chr7:89950458	NA	-0.42	-6.75	-0.4	1.06e-10	Homocysteine levels;
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.38	0.51	4.7e-18	Lung cancer;
KIRP	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.88	9.88	0.53	1.32e-19	Corneal astigmatism;
KIRP	cis	rs17401966	0.522	rs7368073	chr1:10314962	G/T	cg17425144	chr1:10567563	PEX14	-0.32	-5.5	-0.33	9.49e-8	Hepatocellular carcinoma;
KIRP	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-6.4	-0.38	7.73e-10	Gut microbiome composition (summer);
KIRP	cis	rs904251	0.523	rs10947675	chr6:37479972	G/A	cg00360474	chr6:37504404	NA	-0.46	-6.4	-0.38	7.72e-10	Cognitive performance;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06738889	chr1:150208936	ANP32E	0.67	8.47	0.48	2.21e-15	Smoking initiation;
KIRP	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs7011507	1.000	rs7816954	chr8:49165238	T/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.61	7.57	0.43	7.26e-13	Personality dimensions;
KIRP	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.89	0.35	1.26e-8	Multiple sclerosis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00735239	chr22:50708947	MAPK11	-0.46	-6.31	-0.37	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg26513180	chr16:89883248	FANCA	-0.41	-5.05	-0.31	8.68e-7	Vitiligo;
KIRP	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.81	-8.35	-0.47	5e-15	Schizophrenia;
KIRP	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.79	6.36	0.38	9.85e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Corneal astigmatism;
KIRP	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs7665939	0.860	rs72709255	chr4:190129201	C/T	cg14840187	chr4:190284988	NA	-0.95	-7.13	-0.41	1.09e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs240764	0.817	rs239232	chr6:101103038	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.57	0.33	6.63e-8	Neuroticism;
KIRP	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.6	6.8	0.4	7.7e-11	Bipolar disorder;
KIRP	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg02073558	chr3:44770973	ZNF501	0.61	8.71	0.49	4.64e-16	Depressive symptoms;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22559218	chr3:14989381	NR2C2	0.48	6.14	0.36	3.28e-9	Parkinson's disease;
KIRP	cis	rs12431939	0.626	rs8015848	chr14:51715021	G/A	cg23942311	chr14:51606299	NA	0.45	5.1	0.31	6.79e-7	Cancer;
KIRP	cis	rs6594499	0.872	rs7702774	chr5:110460851	G/T	cg04022379	chr5:110408740	TSLP	0.47	7.11	0.41	1.27e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.09	-19.43	-0.78	1.39e-51	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg13147721	chr7:65941812	NA	-0.97	-6.87	-0.4	5.09e-11	Diabetic kidney disease;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	8.64	0.48	7.36e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg22617819	chr1:44378782	ST3GAL3	-0.32	-4.9	-0.3	1.7e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.67	0.34	4.01e-8	Breast cancer;
KIRP	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg11131117	chr7:1891496	MAD1L1	0.4	4.85	0.3	2.19e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg23100626	chr2:96804247	ASTL	0.45	6.4	0.38	7.89e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.63	7.26	0.42	5.22e-12	Obesity-related traits;
KIRP	cis	rs1903068	1.000	rs1903068	chr4:56008477	A/G	cg20092376	chr4:56023423	NA	0.42	5.22	0.32	3.79e-7	Endometriosis;
KIRP	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.24	13.57	0.65	1.13e-31	Uric acid levels;
KIRP	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.4	-6.1	-0.36	4.09e-9	Body mass index;
KIRP	trans	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg11693508	chr17:37793320	STARD3	0.81	9.72	0.53	4.01e-19	Neuroticism;
KIRP	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.5e-20	Coffee consumption (cups per day);
KIRP	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	0.79	11.31	0.58	3.64e-24	Intelligence (multi-trait analysis);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg06586915	chr7:65958596	NA	0.5	6.11	0.36	3.9e-9	Asthma;
KIRP	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg23477460	chr3:66848765	NA	0.74	7.88	0.45	1.05e-13	Type 2 diabetes;
KIRP	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg18646521	chr2:111875858	NA	0.4	5.72	0.34	3.12e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.49	6.68	0.39	1.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	7.6	0.44	6.11e-13	Personality dimensions;
KIRP	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.67	9.24	0.51	1.22e-17	Morning vs. evening chronotype;
KIRP	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.58	-11.9	-0.6	4.44e-26	Diabetic kidney disease;
KIRP	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21643547	chr1:205240462	TMCC2	-0.87	-14.03	-0.67	2.99e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	8.54	0.48	1.44e-15	Platelet distribution width;
KIRP	cis	rs7246657	0.654	rs10407568	chr19:38123009	A/T	cg18154014	chr19:37997991	ZNF793	0.62	6.68	0.39	1.6e-10	Coronary artery calcification;
KIRP	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.87	-0.45	1.13e-13	Homocysteine levels;
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.58	0.34	6.24e-8	Lung cancer;
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg07216194	chr8:27182965	PTK2B	0.45	5.62	0.34	5.2100000000000003e-08	Neuroticism;
KIRP	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg16141378	chr3:129829833	LOC729375	0.61	8.4	0.47	3.58e-15	Triglycerides;
KIRP	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.15	-0.46	1.87e-14	Total cholesterol levels;
KIRP	cis	rs2882667	0.894	rs1433008	chr5:138333664	T/C	cg04439458	chr5:138467593	SIL1	-0.44	-7.35	-0.42	2.84e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs12545912	0.739	rs12541617	chr8:9539099	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.55	-0.39	3.26e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg15676125	chr6:33679581	C6orf125	0.39	5.11	0.31	6.43e-7	Plateletcrit;
KIRP	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg08975724	chr8:8085496	FLJ10661	0.55	7.43	0.43	1.77e-12	Neuroticism;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06873606	chr13:20625618	ZMYM2	0.42	6.29	0.37	1.45e-9	Migraine with aura;
KIRP	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg25281562	chr12:121454272	C12orf43	0.5	5.63	0.34	4.94e-8	N-glycan levels;
KIRP	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	10.33	0.55	5.06e-21	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.83	-0.4	6.61e-11	Coronary artery disease;
KIRP	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.44	-8.69	-0.48	5.32e-16	Urinary metabolites;
KIRP	cis	rs1043099	0.556	rs737723	chr22:30802029	C/G	cg03868770	chr22:30783737	RNF215	-0.43	-4.86	-0.3	2.06e-6	Rheumatoid arthritis;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06722353	chr7:99236244	NA	0.39	6.16	0.37	2.92e-9	Cancer;
KIRP	cis	rs1355223	0.902	rs865070	chr11:34742497	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.05	-0.31	8.75e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg12935359	chr14:103987150	CKB	-0.35	-5.43	-0.33	1.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2282032	0.527	rs60971518	chr14:90765745	A/G	cg04374321	chr14:90722782	PSMC1	0.57	6.9	0.4	4.3e-11	Longevity;
KIRP	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	6.42	0.38	6.93e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg08992911	chr2:238395768	MLPH	-0.51	-5.8	-0.35	1.99e-8	Prostate cancer;
KIRP	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	1.01	15.92	0.71	1.02e-39	Sudden cardiac arrest;
KIRP	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg00666640	chr1:248458726	OR2T12	0.47	5.76	0.34	2.48e-8	Common traits (Other);
KIRP	cis	rs7546094	1.000	rs11102497	chr1:113109274	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.9	-13.33	-0.65	7.34e-31	Height;
KIRP	cis	rs10518128	1.000	rs9997663	chr4:75705378	T/C	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg23340505	chr13:114927933	NA	0.31	4.87	0.3	2.04e-6	Schizophrenia;
KIRP	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.62	-8.35	-0.47	5.01e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg22705602	chr4:152727874	NA	-0.54	-9.35	-0.51	5.57e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs11138902	0.635	rs1475641	chr9:72112444	A/G	cg14397918	chr9:72078829	APBA1	0.34	5.53	0.33	8.25e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7181230	1.000	rs11638521	chr15:40360314	T/C	cg00868766	chr15:40364524	NA	-0.39	-6.19	-0.37	2.52e-9	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg01721255	chr8:58191610	C8orf71	0.64	5.58	0.34	6.39e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg05779272	chr9:33168018	B4GALT1	0.37	4.88	0.3	1.9e-6	IgG glycosylation;
KIRP	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-6.27	-0.37	1.59e-9	Lung cancer;
KIRP	cis	rs1440410	0.571	rs9993291	chr4:144028173	T/C	cg01719995	chr4:144104893	USP38	0.46	6.03	0.36	5.82e-9	Ischemic stroke;
KIRP	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.54	6.57	0.39	2.97e-10	Colorectal cancer;
KIRP	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg07511934	chr16:89386912	ANKRD11	-0.48	-6.01	-0.36	6.77e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.64	6.82	0.4	6.99e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg07005513	chr11:61595956	FADS2	-0.59	-4.91	-0.3	1.67e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.82	11.21	0.58	7.98e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.16	-0.31	5.07e-7	Colorectal cancer;
KIRP	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg15181151	chr6:150070149	PCMT1	0.29	4.87	0.3	1.97e-6	Lung cancer;
KIRP	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.79	-12.19	-0.61	4.8e-27	Asthma;
KIRP	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg13319975	chr6:146136371	FBXO30	0.46	6.35	0.38	1.05e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.506	rs12452569	chr17:4023667	T/A	cg09695851	chr17:3907499	NA	0.55	5.15	0.31	5.29e-7	Type 2 diabetes;
KIRP	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg06565975	chr8:143823917	SLURP1	0.48	7.6	0.44	6.33e-13	Urinary tract infection frequency;
KIRP	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	1.22	15.42	0.7	5.47e-38	Night sleep phenotypes;
KIRP	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-1.03	-11.27	-0.58	5.11e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1958560	0.932	rs9972106	chr14:66023131	A/T	cg03016385	chr14:66212404	NA	-0.45	-5.69	-0.34	3.62e-8	Menarche (age at onset);
KIRP	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg24488311	chr11:68621650	NA	0.49	6.01	0.36	6.55e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-7.12	-0.41	1.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs240764	0.817	rs12193960	chr6:101150326	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.52	-0.33	8.75e-8	Neuroticism;
KIRP	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.71	8.13	0.46	2.12e-14	Pancreatic cancer;
KIRP	trans	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.34e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg04202892	chr2:111875749	ACOXL	0.5	6.96	0.41	3.13e-11	Chronic lymphocytic leukemia;
KIRP	trans	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg12819144	chr4:165953018	TRIM60	0.4	6.22	0.37	2.09e-9	Response to bleomycin (chromatid breaks);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg26519745	chr21:43639879	ABCG1	0.43	6.44	0.38	6.07e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Hypertriglyceridemia;
KIRP	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1923539	1.000	rs1923539	chr10:81694950	G/A	cg24613050	chr10:81743128	NA	0.36	4.85	0.3	2.2e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2635047	0.638	rs55730206	chr18:44608230	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	6.05	0.36	5.28e-9	Educational attainment;
KIRP	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	6.28	0.37	1.55e-9	Rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09266468	chr1:45241580	SNORD46;SNORD55;RPS8	0.45	6.15	0.37	3.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg07001201	chr5:642380	CEP72	0.51	6.13	0.36	3.47e-9	Obesity-related traits;
KIRP	cis	rs10425738	0.830	rs3843043	chr19:41433931	C/T	cg09508736	chr19:41385865	CYP2A7	-0.48	-5.24	-0.32	3.49e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.69	0.34	3.52e-8	Renal cell carcinoma;
KIRP	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg03929089	chr4:120376271	NA	-0.54	-6.58	-0.39	2.88e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg10932868	chr11:921992	NA	0.65	8.77	0.49	3.03e-16	Alzheimer's disease (late onset);
KIRP	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.54	-6.41	-0.38	7.42e-10	Macular telangiectasia type 2;
KIRP	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg00361562	chr2:198649771	BOLL	-0.51	-4.92	-0.3	1.55e-6	Ulcerative colitis;
KIRP	cis	rs7215564	0.908	rs35434628	chr17:78714760	C/T	cg06153925	chr17:78755379	RPTOR	0.35	5.69	0.34	3.63e-8	Myopia (pathological);
KIRP	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg14914422	chr1:46958856	NA	0.43	5.35	0.32	1.97e-7	Monobrow;
KIRP	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.63	8.41	0.47	3.45e-15	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20270863	chr1:210407484	C1orf133;SERTAD4	0.48	6.04	0.36	5.8e-9	Parkinson's disease;
KIRP	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	11.24	0.58	6.41e-24	Birth weight;
KIRP	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.73	8.89	0.49	1.31e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs1448094	0.872	rs1026085	chr12:86355735	A/G	cg00310523	chr12:86230176	RASSF9	0.4	6.22	0.37	2.15e-9	Major depressive disorder;
KIRP	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07308232	chr7:1071921	C7orf50	-0.87	-12.04	-0.61	1.54e-26	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.8	0.4	8.02e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.22	-0.51	1.36e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6539288	0.677	rs2216221	chr12:107327231	A/T	cg15890332	chr12:107067104	RFX4	0.35	5.61	0.34	5.34e-8	Total body bone mineral density;
KIRP	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg03465714	chr1:152285911	FLG	-0.43	-5.15	-0.31	5.4e-7	Atopic dermatitis;
KIRP	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.92	-0.4	3.83e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8010715	0.816	rs1134340	chr14:24594213	C/T	cg23112188	chr14:24563095	PCK2	-0.33	-4.85	-0.3	2.23e-6	IgG glycosylation;
KIRP	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18876405	chr7:65276391	NA	0.37	4.93	0.3	1.52e-6	Aortic root size;
KIRP	cis	rs14168	1.000	rs1045767	chr10:53455408	A/G	cg18823846	chr10:53459691	PRKG1;CSTF2T	0.66	5.85	0.35	1.53e-8	Mammographic density (non-dense area);
KIRP	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.12	-0.69	5.91e-37	Headache;
KIRP	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18252515	chr7:66147081	NA	0.46	5.68	0.34	3.88e-8	Aortic root size;
KIRP	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg19683494	chr5:74908142	NA	0.43	5.02	0.3	9.9e-7	Age-related disease endophenotypes;
KIRP	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.62	0.34	5.07e-8	Diisocyanate-induced asthma;
KIRP	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg10505658	chr17:80084571	CCDC57	-0.26	-4.86	-0.3	2.1e-6	Life satisfaction;
KIRP	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg13482628	chr17:19912719	NA	0.66	9.87	0.53	1.46e-19	Schizophrenia;
KIRP	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs11638352	1.000	rs8038096	chr15:44367290	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.7	-5.89	-0.35	1.29e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.24	-34.95	-0.91	2.24e-97	Myeloid white cell count;
KIRP	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.44	5.64	0.34	4.72e-8	Motion sickness;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-8.36	-0.47	4.55e-15	Obesity-related traits;
KIRP	cis	rs501120	0.810	rs513391	chr10:44749708	A/C	cg09554077	chr10:44749378	NA	0.73	12.09	0.61	9.91e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs72772090	0.710	rs10515244	chr5:96078337	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.66	-5.77	-0.35	2.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg24488311	chr11:68621650	NA	0.5	6.1	0.36	4.16e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9815354	0.767	rs73069245	chr3:41951452	G/A	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg13319975	chr6:146136371	FBXO30	0.47	6.37	0.38	9.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8084125	0.832	rs7238522	chr18:74948730	A/C	cg15443732	chr18:74961078	GALR1	-0.57	-5.83	-0.35	1.77e-8	Obesity-related traits;
KIRP	cis	rs1559088	0.948	rs7247748	chr19:33594023	T/C	cg27124370	chr19:33622961	WDR88	0.56	6.94	0.4	3.53e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg10189774	chr4:17578691	LAP3	0.48	5.57	0.33	6.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg19171272	chr22:38449367	NA	0.63	9.26	0.51	1.05e-17	Glioblastoma;Glioma;
KIRP	cis	rs3790645	1.000	rs34062688	chr1:26887150	A/G	cg23229016	chr1:26872525	RPS6KA1	0.22	5.89	0.35	1.26e-8	Glucose homeostasis traits;
KIRP	cis	rs4728302	0.607	rs1025074	chr7:133615559	G/A	cg10665199	chr7:133106180	EXOC4	0.42	4.89	0.3	1.85e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg07001201	chr5:642380	CEP72	0.68	6.38	0.38	8.52e-10	Obesity-related traits;
KIRP	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg22117172	chr7:91764530	CYP51A1	0.48	6.78	0.4	8.76e-11	Breast cancer;
KIRP	cis	rs4654899	0.643	rs12145181	chr1:21086046	C/A	cg05370193	chr1:21551575	ECE1	0.37	5.17	0.31	4.79e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07215822	chr6:158701037	NA	-0.65	-7.44	-0.43	1.65e-12	Height;
KIRP	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.77	9.23	0.51	1.28e-17	Testicular germ cell tumor;
KIRP	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-7.03	-0.41	2.08e-11	Hyperactive-impulsive symptoms;
KIRP	cis	rs11638352	0.661	rs2706491	chr15:44423829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-4.92	-0.3	1.59e-6	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.77	-0.4	9.47e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.73	0.53	3.99e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09225295	chr7:95405749	DYNC1I1	0.45	6.2	0.37	2.43e-9	Interleukin-4 levels;
KIRP	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.02	-0.36	6.29e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.29	-12.11	-0.61	8.37e-27	Diabetic retinopathy;
KIRP	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg25124228	chr12:125621409	AACS	-0.54	-7.71	-0.44	3.05e-13	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10875746	0.624	rs7297298	chr12:48672306	C/G	cg20731937	chr12:48336164	NA	0.48	5.89	0.35	1.29e-8	Longevity (90 years and older);
KIRP	cis	rs9372498	0.536	rs62663261	chr6:118900553	T/C	cg21191810	chr6:118973309	C6orf204	-0.44	-4.89	-0.3	1.84e-6	Diastolic blood pressure;
KIRP	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.6	7.85	0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs7808935	0.914	rs10807843	chr7:27992390	T/C	cg22168087	chr7:27702803	HIBADH	0.77	7.85	0.45	1.26e-13	Prostate cancer;
KIRP	cis	rs8028182	0.636	rs7163907	chr15:75845097	T/C	cg20655648	chr15:75932815	IMP3	0.53	6.77	0.4	9.58e-11	Sudden cardiac arrest;
KIRP	trans	rs7980799	0.935	rs7312012	chr12:33517984	A/G	cg26384229	chr12:38710491	ALG10B	-0.53	-6.56	-0.39	3.19e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	1.08	20.53	0.79	3.04e-55	Height;
KIRP	cis	rs2071426	0.594	rs7900980	chr10:96784778	A/C	cg09036531	chr10:96991505	NA	-0.45	-5.27	-0.32	3.04e-7	Blood metabolite levels;
KIRP	cis	rs9886651	0.776	rs12155669	chr8:128779931	A/G	cg24514600	chr8:128805414	PVT1	0.69	11.82	0.6	7.84e-26	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg20592017	chr15:40364740	NA	0.35	5.27	0.32	3.04e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.88	0.3	1.94e-6	Menopause (age at onset);
KIRP	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	cg12689670	chr1:183009347	LAMC1	0.5	7.19	0.42	7.83e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	8.54	0.48	1.4e-15	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-12.8	-0.63	4.27e-29	Blood metabolite levels;
KIRP	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.83	14.94	0.69	2.27e-36	Anterior chamber depth;
KIRP	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.6	-7.32	-0.42	3.51e-12	Pancreatic cancer;
KIRP	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.46	5.63	0.34	4.78e-8	Longevity;
KIRP	cis	rs4664293	0.967	rs7597482	chr2:160547091	T/A	cg08347373	chr2:160653686	CD302	-0.39	-5.94	-0.35	9.93e-9	Monocyte percentage of white cells;
KIRP	cis	rs778371	0.788	rs778355	chr2:233784749	T/G	cg11972305	chr2:233791962	NGEF	-0.45	-5.66	-0.34	4.27e-8	Schizophrenia;
KIRP	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.14	0.5	2.46e-17	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-0.82	-9.2	-0.51	1.6e-17	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.28	0.47	8.07e-15	Aortic root size;
KIRP	cis	rs7534824	0.625	rs61780288	chr1:101389945	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	5.71	0.34	3.27e-8	Refractive astigmatism;
KIRP	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.18	0.42	8.26e-12	White blood cell count;
KIRP	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg06289844	chr6:126071538	HEY2	0.45	6.71	0.39	1.33e-10	Brugada syndrome;
KIRP	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05220968	chr6:146057943	EPM2A	0.39	4.85	0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs654950	0.875	rs116747365	chr1:41994792	C/T	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.47	-0.38	5.23e-10	Airway imaging phenotypes;
KIRP	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.54	0.38	3.52e-10	Atrioventricular conduction;
KIRP	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.02	0.5	5.61e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.8	11.03	0.58	2.99e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1712517	0.771	rs11191645	chr10:105059308	G/T	cg05636881	chr10:105038444	INA	0.43	6.19	0.37	2.51e-9	Migraine;
KIRP	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-11.96	-0.61	2.77e-26	Vitiligo;
KIRP	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg13902645	chr11:5959945	NA	-0.6	-6.31	-0.37	1.26e-9	DNA methylation (variation);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26579311	chr8:119124103	EXT1	-0.63	-6.97	-0.41	2.94e-11	Menopause (age at onset);
KIRP	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.19	0.31	4.46e-7	Educational attainment;
KIRP	cis	rs17030434	0.954	rs10000558	chr4:154766835	A/T	cg14289246	chr4:154710475	SFRP2	-0.73	-8.85	-0.49	1.76e-16	Electrocardiographic conduction measures;
KIRP	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.03	-0.41	2.05e-11	Glomerular filtration rate;
KIRP	cis	rs9815354	0.761	rs12186051	chr3:41836919	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2073300	1.000	rs6114126	chr20:23452127	A/T	cg12062639	chr20:23401060	NAPB	0.79	6.85	0.4	5.84e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11408622	chr5:176514005	FGFR4	0.49	6.32	0.37	1.2e-9	Parkinson's disease;
KIRP	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.76	10.55	0.56	1.04e-21	Parkinson's disease;
KIRP	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-1.08	-20.34	-0.79	1.34e-54	Gut microbiome composition (winter);
KIRP	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.97	12.58	0.63	2.3e-28	Breast cancer;
KIRP	cis	rs10875746	0.855	rs12296244	chr12:48441479	C/G	cg20731937	chr12:48336164	NA	0.41	5.23	0.32	3.61e-7	Longevity (90 years and older);
KIRP	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.62	-0.39	2.23e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02698620	chr7:45026579	C7orf40;SNORA9	0.53	6.26	0.37	1.72e-9	Smoking initiation;
KIRP	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.11	-0.46	2.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg18016565	chr1:150552671	MCL1	-0.47	-7.15	-0.42	9.57e-12	Tonsillectomy;
KIRP	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg00405596	chr8:11794950	NA	-0.47	-6.0	-0.36	7.16e-9	Triglycerides;
KIRP	cis	rs7011507	0.891	rs56252522	chr8:49158730	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg10130564	chr11:117069849	TAGLN	0.41	5.08	0.31	7.51e-7	Blood protein levels;
KIRP	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg07395648	chr5:131743802	NA	-0.48	-6.64	-0.39	2e-10	Blood metabolite levels;
KIRP	cis	rs4751006	0.543	rs76245329	chr10:128773697	T/C	cg05702161	chr10:128779687	DOCK1	-1.18	-9.55	-0.52	1.4e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg00310523	chr12:86230176	RASSF9	0.42	6.56	0.39	3.23e-10	Major depressive disorder;
KIRP	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg17279839	chr7:150038598	RARRES2	0.56	7.1	0.41	1.35e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7180079	0.620	rs2593698	chr15:64910003	A/G	cg15337035	chr15:64978493	NA	-0.48	-5.1	-0.31	6.89e-7	Monocyte count;
KIRP	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg18225595	chr11:63971243	STIP1	0.64	5.85	0.35	1.54e-8	Mean platelet volume;
KIRP	cis	rs7312774	0.881	rs7309260	chr12:107313254	T/A	cg16260113	chr12:107380972	MTERFD3	0.72	6.53	0.38	3.79e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.29	-5.16	-0.31	5.13e-7	Sarcoidosis;
KIRP	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.41	0.33	1.48e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	1.27	9.18	0.51	1.77e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-10.08	-0.54	3.06e-20	Coronary artery disease;
KIRP	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg19507638	chr5:93509721	C5orf36	-0.53	-4.95	-0.3	1.38e-6	Diabetic retinopathy;
KIRP	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg10645314	chr2:3704589	ALLC	-0.42	-5.08	-0.31	7.41e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.82	11.11	0.58	1.6e-23	Lung cancer;
KIRP	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg19025524	chr12:109796872	NA	-0.51	-6.35	-0.38	1.02e-9	Neuroticism;
KIRP	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.5	-0.43	1.13e-12	Triglycerides;
KIRP	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.65	-7.93	-0.45	7.79e-14	Aortic root size;
KIRP	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg00677455	chr12:58241039	CTDSP2	0.8	10.65	0.56	5.11e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg13165212	chr22:42675999	NA	0.28	5.02	0.3	1e-6	Cognitive function;
KIRP	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.11e-10	Prudent dietary pattern;
KIRP	cis	rs1519814	1.000	rs6983133	chr8:121166682	T/G	cg22335954	chr8:121166405	COL14A1	-0.66	-6.41	-0.38	7.38e-10	Breast cancer;
KIRP	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.55	6.04	0.36	5.77e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7224685	0.515	rs7207986	chr17:3979949	G/A	cg21734707	chr17:3908241	ZZEF1	0.54	5.02	0.3	1e-6	Type 2 diabetes;
KIRP	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.78	-10.74	-0.57	2.53e-22	Waist circumference;Body mass index;
KIRP	cis	rs4409675	1.000	rs71642219	chr1:28259338	C/T	cg23691781	chr1:28212827	C1orf38	0.3	5.59	0.34	5.96e-8	Corneal astigmatism;
KIRP	cis	rs10203711	0.932	rs4502365	chr2:239597792	G/A	cg14580085	chr2:239553406	NA	0.39	5.16	0.31	5.2e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg05304507	chr6:116381966	FRK	0.2	5.45	0.33	1.19e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4789452	0.538	rs2627207	chr17:75353160	A/G	cg05865280	chr17:75406074	SEPT9	-0.26	-5.68	-0.34	3.82e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs55962025	0.960	rs7659144	chr4:3098321	C/G	cg06533319	chr4:3265114	C4orf44	0.45	5.38	0.32	1.69e-7	Parental longevity (mother's age at death);
KIRP	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg04990556	chr1:26633338	UBXN11	0.62	5.99	0.36	7.35e-9	Obesity-related traits;
KIRP	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.78	-11.56	-0.59	5.61e-25	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	6.3	0.37	1.33e-9	Personality dimensions;
KIRP	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs4638749	0.680	rs12612935	chr2:108818409	A/G	cg23163573	chr2:108905468	SULT1C2	-0.32	-5.09	-0.31	7.11e-7	Blood pressure;
KIRP	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.55	7.07	0.41	1.62e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg16797656	chr11:68205561	LRP5	0.37	4.96	0.3	1.34e-6	Total body bone mineral density;
KIRP	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.66	-0.73	3.11e-42	Height;
KIRP	cis	rs3822411	0.529	rs7715399	chr5:10682230	T/C	cg14521931	chr5:10832172	NA	0.41	5.45	0.33	1.21e-7	Sum eosinophil basophil counts;
KIRP	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.73	6.99	0.41	2.52e-11	Arsenic metabolism;
KIRP	cis	rs7719624	0.756	rs13188659	chr5:135396468	T/A	cg00308130	chr5:135415190	NA	0.32	5.04	0.31	9.17e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.69	10.81	0.57	1.52e-22	Cancer;
KIRP	cis	rs909341	1.000	rs909341	chr20:62328742	C/T	cg11503966	chr20:62272292	STMN3	-0.41	-5.86	-0.35	1.45e-8	Atopic dermatitis;
KIRP	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs494562	0.892	rs1665787	chr6:86115187	C/A	cg27039625	chr6:86159096	NT5E	0.42	5.1	0.31	6.65e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs4955124	0.558	rs62244396	chr3:32023779	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.81	6.52	0.38	4.02e-10	Schizophrenia;
KIRP	cis	rs370915	0.890	rs1425952	chr4:187833545	A/G	cg19519643	chr4:187840862	NA	-0.55	-7.53	-0.43	9.87e-13	Gout;
KIRP	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg13072238	chr3:49761600	GMPPB	-0.51	-4.98	-0.3	1.17e-6	Menarche (age at onset);
KIRP	cis	rs4006360	0.604	rs1976318	chr17:39250906	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs16975963	0.639	rs112997435	chr19:38204631	C/T	cg18030218	chr19:38865513	PSMD8	0.56	4.98	0.3	1.19e-6	Longevity;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg25636833	chr22:41864805	PHF5A;ACO2	1.12	7.54	0.43	9e-13	P wave terminal force;
KIRP	cis	rs7584330	0.518	rs78358347	chr2:238413566	C/T	cg16989719	chr2:238392110	NA	-0.72	-5.94	-0.35	9.74e-9	Prostate cancer;
KIRP	cis	rs11264213	0.591	rs274755	chr1:36544237	T/C	cg27506609	chr1:36549197	TEKT2	-1.09	-7.91	-0.45	8.48e-14	Schizophrenia;
KIRP	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.28	-0.32	2.8e-7	Aortic root size;
KIRP	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	13.0	0.64	9.41e-30	Smoking behavior;
KIRP	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.59	6.34	0.37	1.09e-9	Type 2 diabetes;
KIRP	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg16586182	chr3:47516702	SCAP	0.65	8.64	0.48	7.06e-16	Colorectal cancer;
KIRP	cis	rs11239930	0.517	rs2477569	chr1:146547809	G/T	cg16700924	chr1:146552102	NA	0.44	4.93	0.3	1.54e-6	AIDS progression;
KIRP	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.57	7.04	0.41	1.95e-11	Aortic root size;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27556913	chr4:1341059	KIAA1530	-0.44	-6.37	-0.38	9e-10	Metabolic traits;
KIRP	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.45	6.22	0.37	2.15e-9	Coronary artery disease;
KIRP	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	1.04	19.91	0.79	3.37e-53	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1355223	0.902	rs448016	chr11:34706593	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.49	5.82	0.35	1.8e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.66	9.28	0.51	9.06e-18	Morning vs. evening chronotype;
KIRP	cis	rs4132509	1.000	rs9782883	chr1:243892532	A/G	cg21452805	chr1:244014465	NA	0.57	5.74	0.34	2.81e-8	RR interval (heart rate);
KIRP	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg08999081	chr20:33150536	PIGU	-0.39	-5.01	-0.3	1.03e-6	Height;
KIRP	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg03128534	chr1:43423976	SLC2A1	0.61	7.04	0.41	1.9e-11	Red cell distribution width;
KIRP	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21643547	chr1:205240462	TMCC2	-0.69	-10.38	-0.55	3.62e-21	Red blood cell count;
KIRP	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.15	0.36	3.18e-9	Colorectal cancer;
KIRP	cis	rs7084402	0.967	rs2577392	chr10:60329183	A/G	cg05938607	chr10:60274200	BICC1	-0.44	-10.41	-0.55	2.88e-21	Refractive error;
KIRP	cis	rs13385	0.769	rs7710268	chr5:139576347	T/C	cg01860693	chr5:139557145	C5orf32	0.49	5.38	0.32	1.75e-7	Atrial fibrillation;
KIRP	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg24009623	chr19:33667908	NA	0.5	6.19	0.37	2.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg22903471	chr2:27725779	GCKR	0.41	5.67	0.34	4.04e-8	Oral cavity cancer;
KIRP	cis	rs13102973	0.965	rs4629509	chr4:135872410	C/T	cg14419869	chr4:135874104	NA	-0.61	-11.08	-0.58	2.01e-23	Subjective well-being;
KIRP	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.64	-7.97	-0.45	5.8e-14	Breast size;
KIRP	cis	rs72829446	0.556	rs12936464	chr17:7403942	A/C	cg17788227	chr17:7347145	FGF11;CHRNB1	-0.46	-4.87	-0.3	2e-6	Androgen levels;
KIRP	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7254827	0.737	rs2305753	chr19:17180033	C/T	cg19418318	chr19:17219073	MYO9B	-0.54	-5.03	-0.31	9.29e-7	Mean platelet volume;
KIRP	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25833597	chr17:30823145	MYO1D	0.45	5.59	0.34	5.97e-8	Schizophrenia;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.57	-4.91	-0.3	1.62e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8028182	0.636	rs7163451	chr15:75861076	G/T	cg20655648	chr15:75932815	IMP3	0.57	7.28	0.42	4.53e-12	Sudden cardiac arrest;
KIRP	cis	rs6684428	0.572	rs10888946	chr1:56375197	G/A	cg11651538	chr1:56320950	NA	-0.46	-6.5	-0.38	4.55e-10	Airflow obstruction;
KIRP	cis	rs1009181	0.585	rs4486004	chr6:26167710	G/T	cg00631329	chr6:26305371	NA	-0.62	-6.98	-0.41	2.76e-11	Childhood ear infection;
KIRP	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02725872	chr8:58115012	NA	-0.65	-6.29	-0.37	1.47e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg24069376	chr3:38537580	EXOG	0.3	4.92	0.3	1.55e-6	Electrocardiographic conduction measures;
KIRP	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg02569458	chr12:86230093	RASSF9	0.36	5.18	0.31	4.71e-7	Major depressive disorder;
KIRP	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.49	0.33	1e-7	Blood protein levels;
KIRP	cis	rs1816752	0.905	rs8002309	chr13:24976355	C/T	cg02811702	chr13:24901961	NA	0.41	5.32	0.32	2.3e-7	Obesity-related traits;
KIRP	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg02002194	chr4:3960332	NA	0.46	6.83	0.4	6.78e-11	Neuroticism;
KIRP	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.58	0.39	2.83e-10	Height;
KIRP	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg21919602	chr1:242011447	EXO1	-0.46	-5.92	-0.35	1.09e-8	Menopause (age at onset);
KIRP	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.19	-0.42	7.77e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg05315796	chr3:52349193	DNAH1	0.42	5.49	0.33	1.01e-7	Schizophrenia;
KIRP	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	4.97	0.3	1.25e-6	Diisocyanate-induced asthma;
KIRP	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg23324259	chr8:82754387	SNX16	-0.44	-4.88	-0.3	1.9e-6	Diastolic blood pressure;
KIRP	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg27494647	chr7:150038898	RARRES2	0.38	5.67	0.34	3.95e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.49	-5.72	-0.34	3.09e-8	Body mass index;
KIRP	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.36	-0.32	1.93e-7	Neuroticism;
KIRP	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg00262122	chr8:11665843	FDFT1	-0.45	-5.48	-0.33	1.04e-7	Retinal vascular caliber;
KIRP	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.43	5.91	0.35	1.12e-8	Sitting height ratio;
KIRP	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg10755058	chr3:40428713	ENTPD3	0.49	6.65	0.39	1.9e-10	Renal cell carcinoma;
KIRP	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg09165964	chr15:75287851	SCAMP5	-0.94	-8.38	-0.47	4.2e-15	Lung cancer;
KIRP	cis	rs11608355	0.532	rs7968387	chr12:109788019	A/C	cg19025524	chr12:109796872	NA	-0.51	-6.71	-0.39	1.34e-10	Neuroticism;
KIRP	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.49	-6.11	-0.36	3.89e-9	Motion sickness;
KIRP	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg02574844	chr11:5959923	NA	-0.54	-5.31	-0.32	2.44e-7	DNA methylation (variation);
KIRP	cis	rs8027181	0.839	rs998020	chr15:72999635	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.53	7.8	0.45	1.79e-13	Triglyceride levels;
KIRP	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg02336718	chr17:17403227	NA	0.34	5.33	0.32	2.27e-7	Total body bone mineral density;
KIRP	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.57	-6.78	-0.4	8.67e-11	Mosquito bite size;
KIRP	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg03006477	chr6:74432658	CD109	0.24	5.06	0.31	8.14e-7	Blood protein levels;Calcium levels;
KIRP	cis	rs7084783	0.500	rs4918024	chr10:105341860	G/C	cg00126946	chr10:105363258	SH3PXD2A	0.46	5.8	0.35	2.07e-8	Fear of pain;
KIRP	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.65	-7.11	-0.41	1.27e-11	DNA methylation (variation);
KIRP	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.86	11.65	0.6	2.79e-25	Coronary artery disease or large artery stroke;
KIRP	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg17425144	chr1:10567563	PEX14	0.31	5.33	0.32	2.24e-7	Hepatocellular carcinoma;
KIRP	trans	rs2281597	0.664	rs10753290	chr1:34291781	C/T	cg19991458	chr15:67417651	SMAD3	-0.49	-6.46	-0.38	5.47e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg05991184	chr2:219186017	PNKD	0.36	5.06	0.31	8.39e-7	Colorectal cancer;
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs7221595	0.825	rs12601931	chr17:3986097	T/C	cg21851534	chr17:3907994	ZZEF1	0.52	5.01	0.3	1.04e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7665939	1.000	rs7665939	chr4:190123318	C/T	cg09826759	chr4:190284978	NA	-0.7	-5.01	-0.3	1.05e-6	Amyotrophic lateral sclerosis;
KIRP	cis	rs8044868	0.530	rs8060770	chr16:72155694	C/A	cg16558253	chr16:72132732	DHX38	-0.41	-5.53	-0.33	8.21e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs4356932	0.967	rs4859586	chr4:76943235	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg18357526	chr6:26021779	HIST1H4A	0.39	5.14	0.31	5.62e-7	Height;
KIRP	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg24009623	chr19:33667908	NA	0.47	5.68	0.34	3.89e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.37	6.4	0.38	7.86e-10	Heart rate;
KIRP	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18252515	chr7:66147081	NA	-0.45	-5.49	-0.33	9.78e-8	Aortic root size;
KIRP	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg15655495	chr12:38532458	NA	0.27	5.34	0.32	2.1e-7	Bladder cancer;
KIRP	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg26338869	chr17:61819248	STRADA	0.54	6.41	0.38	7.37e-10	Prudent dietary pattern;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.65	-7.49	-0.43	1.26e-12	Menopause (age at onset);
KIRP	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg18016565	chr1:150552671	MCL1	-0.48	-7.48	-0.43	1.3e-12	Tonsillectomy;
KIRP	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg02023728	chr11:77925099	USP35	-0.32	-5.1	-0.31	6.93e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg13047869	chr3:10149882	C3orf24	0.58	4.88	0.3	1.93e-6	Alzheimer's disease;
KIRP	cis	rs9832740	1.000	rs4677151	chr3:72394027	G/A	cg05607079	chr3:72387937	NA	0.33	4.91	0.3	1.65e-6	Height;
KIRP	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg10223061	chr2:219282414	VIL1	0.42	6.42	0.38	6.8e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg17182837	chr8:41585554	ANK1	-0.49	-6.93	-0.4	3.78e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs4664304	0.620	rs12692569	chr2:160723579	C/G	cg03641300	chr2:160917029	PLA2R1	0.39	5.93	0.35	9.95e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1978968	0.956	rs8135939	chr22:18434284	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-7.73	-0.44	2.71e-13	Presence of antiphospholipid antibodies;
KIRP	trans	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg02030672	chr11:45687055	CHST1	-0.56	-7.43	-0.43	1.74e-12	Obesity-related traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02632274	chr1:154973402	NA	-0.48	-6.41	-0.38	7.46e-10	Myopia;
KIRP	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14757267	chr19:17970559	RPL18AP3;RPL18A	0.45	6.04	0.36	5.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs72781680	0.611	rs72783619	chr2:24311607	G/A	cg20701182	chr2:24300061	SF3B14	0.99	10.84	0.57	1.19e-22	Lymphocyte counts;
KIRP	cis	rs7216064	0.861	rs12449312	chr17:65829358	A/C	cg12091567	chr17:66097778	LOC651250	-0.78	-8.49	-0.48	1.95e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.96	10.72	0.56	3.05e-22	Eosinophil percentage of granulocytes;
KIRP	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-6.94	-0.4	3.43e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8053891	0.615	rs34042070	chr16:72101525	C/G	cg16558253	chr16:72132732	DHX38	-0.57	-6.18	-0.37	2.65e-9	Coronary artery disease;
KIRP	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-7.47	-0.43	1.42e-12	Platelet distribution width;
KIRP	cis	rs7408868	0.563	rs11085949	chr19:15296917	G/T	cg14696996	chr19:15285081	NOTCH3	0.73	6.81	0.4	7.52e-11	Pulse pressure;
KIRP	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.53	6.1	0.36	4.04e-9	Inhibitory control;
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg09695851	chr17:3907499	NA	0.69	11.12	0.58	1.57e-23	Type 2 diabetes;
KIRP	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.27	0.37	1.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.62	-7.79	-0.44	1.89e-13	Dental caries;
KIRP	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg22963979	chr7:1858916	MAD1L1	-0.58	-7.61	-0.44	5.68e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs2425143	1.000	rs111597121	chr20:34371913	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-4.95	-0.3	1.39e-6	Blood protein levels;
KIRP	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.34	6.08	0.36	4.44e-9	Renal cell carcinoma;
KIRP	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.76	-0.44	2.29e-13	Total cholesterol levels;
KIRP	trans	rs561341	0.843	rs879944	chr17:30242803	A/G	cg20587970	chr11:113659929	NA	-0.92	-9.53	-0.52	1.62e-18	Hip circumference adjusted for BMI;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18802601	chr5:34698640	RAI14	0.49	6.35	0.38	1.01e-9	Interleukin-4 levels;
KIRP	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.81e-7	Cognitive function;
KIRP	cis	rs7712401	0.601	rs246328	chr5:122287628	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg04202892	chr2:111875749	ACOXL	0.46	6.49	0.38	4.63e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg01763666	chr17:80159506	CCDC57	-0.38	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg17443007	chr1:101659419	NA	0.4	5.66	0.34	4.17e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg07884673	chr3:53033167	SFMBT1	0.81	6.35	0.38	1.02e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-9.65	-0.52	6.99e-19	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.86	9.79	0.53	2.51e-19	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1010254	0.559	rs114133296	chr5:151730255	G/A	cg12297329	chr5:152029980	NA	-0.66	-6.71	-0.39	1.29e-10	Optic nerve measurement (cup area);
KIRP	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.47	-4.97	-0.3	1.23e-6	Platelet distribution width;
KIRP	cis	rs17767294	0.541	rs72845050	chr6:27610070	A/C	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.42e-7	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05889321	chr10:97416837	ALDH18A1	0.58	7.1	0.41	1.29e-11	Smoking initiation;
KIRP	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg10645314	chr2:3704589	ALLC	-1.12	-12.33	-0.62	1.67e-27	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07375912	chr16:12009839	GSPT1	0.49	6.11	0.36	3.91e-9	Parkinson's disease;
KIRP	cis	rs7709377	0.570	rs10075063	chr5:115452613	A/T	cg23108291	chr5:115420582	COMMD10	0.41	4.94	0.3	1.43e-6	Metabolite levels  (X-11787);
KIRP	cis	rs7560272	0.538	rs2012574	chr2:73928366	G/C	cg20560298	chr2:73613845	ALMS1	0.53	6.49	0.38	4.77e-10	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg00666640	chr1:248458726	OR2T12	0.46	6.17	0.37	2.74e-9	Common traits (Other);
KIRP	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02807482	chr3:125708958	NA	-0.51	-5.22	-0.32	3.81e-7	Blood pressure (smoking interaction);
KIRP	cis	rs10761482	0.566	rs4505011	chr10:62200308	T/C	cg01186212	chr10:62110162	ANK3	-0.32	-5.37	-0.32	1.84e-7	Schizophrenia;
KIRP	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.64	-8.93	-0.49	1.04e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg24315340	chr6:146058215	EPM2A	0.45	5.63	0.34	4.79e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.37	0.43	2.56e-12	Aortic root size;
KIRP	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.74	-9.45	-0.52	2.76e-18	Facial morphology (factor 19);
KIRP	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg15676125	chr6:33679581	C6orf125	0.4	5.22	0.32	3.84e-7	Plateletcrit;
KIRP	cis	rs2274459	0.841	rs12205398	chr6:33701543	C/T	cg06253072	chr6:33679850	C6orf125	0.53	5.54	0.33	7.87e-8	Obesity (extreme);
KIRP	cis	rs62413470	1.000	rs62404867	chr6:55957970	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.07	-0.41	1.62e-11	Response to antipsychotic treatment;
KIRP	cis	rs7534824	0.543	rs60978318	chr1:101400413	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.25	0.42	5.24e-12	Refractive astigmatism;
KIRP	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg21775007	chr8:11205619	TDH	0.44	5.82	0.35	1.81e-8	Neuroticism;
KIRP	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.75	-10.35	-0.55	4.56e-21	Childhood ear infection;
KIRP	cis	rs6504340	0.741	rs34822124	chr17:46648679	G/T	cg04904318	chr17:46607828	HOXB1	-0.58	-6.09	-0.36	4.27e-9	Primary tooth development (number of teeth);
KIRP	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	7.6	0.44	6.29e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg04733989	chr22:42467013	NAGA	0.61	8.17	0.46	1.68e-14	Cognitive function;
KIRP	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.73e-8	Tonsillectomy;
KIRP	cis	rs2880765	0.546	rs36098649	chr15:86056807	C/T	cg17133734	chr15:86042851	AKAP13	-0.62	-7.27	-0.42	4.73e-12	Coronary artery disease;
KIRP	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.47	0.43	1.4e-12	HDL cholesterol levels;
KIRP	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg05484376	chr2:27715224	FNDC4	0.3	4.85	0.3	2.22e-6	Oral cavity cancer;
KIRP	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	trans	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg09872104	chr7:134855509	C7orf49	-0.91	-6.67	-0.39	1.72e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16851402	chr8:90636522	NA	0.45	6.38	0.38	8.8e-10	Interleukin-4 levels;
KIRP	cis	rs7546668	0.947	rs4645989	chr1:15850343	A/G	cg21858823	chr1:15850916	CASP9	0.47	5.19	0.31	4.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg09344028	chr17:70110421	NA	0.4	7.91	0.45	8.94e-14	Thyroid hormone levels;
KIRP	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-1.01	-13.13	-0.64	3.27e-30	Platelet distribution width;
KIRP	cis	rs4389656	0.883	rs34338480	chr5:6712854	T/C	cg10857441	chr5:6722123	POLS	0.45	5.63	0.34	4.82e-8	Coronary artery disease;
KIRP	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.76	11.34	0.59	2.93e-24	Blood metabolite ratios;
KIRP	cis	rs1364705	0.910	rs13274578	chr8:120314864	T/C	cg09273054	chr8:120220131	MAL2	0.54	6.31	0.37	1.29e-9	Hippocampal atrophy;
KIRP	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	17.69	0.75	9.93e-46	Chronic sinus infection;
KIRP	cis	rs9517302	0.615	rs3752973	chr13:99097509	G/A	cg24044564	chr13:99115944	STK24	0.54	6.3	0.37	1.38e-9	Obesity-related traits;
KIRP	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.69	8.15	0.46	1.83e-14	Diabetic retinopathy;
KIRP	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg02951883	chr7:2050386	MAD1L1	-0.51	-5.6	-0.34	5.58e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.54	7.5	0.43	1.17e-12	Oral cavity cancer;
KIRP	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.68	8.61	0.48	9.03e-16	Multiple sclerosis;
KIRP	cis	rs4474465	1.000	rs2063728	chr11:78185636	G/C	cg27205649	chr11:78285834	NARS2	-0.65	-7.33	-0.42	3.39e-12	Alzheimer's disease (survival time);
KIRP	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg02336718	chr17:17403227	NA	-0.31	-4.86	-0.3	2.09e-6	Total body bone mineral density;
KIRP	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-5.19	-0.31	4.45e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg16524733	chr11:117070046	TAGLN	0.4	5.18	0.31	4.56e-7	Blood protein levels;
KIRP	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg01631408	chr1:248437212	OR2T33	-0.72	-9.56	-0.52	1.25e-18	Common traits (Other);
KIRP	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg17108064	chr15:78857060	CHRNA5	0.37	5.37	0.32	1.8e-7	Sudden cardiac arrest;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.62	0.68	3.03e-35	Alzheimer's disease;
KIRP	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg19774624	chr17:42201019	HDAC5	0.66	8.85	0.49	1.73e-16	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	cis	rs1950626	0.743	rs12887333	chr14:101462612	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.32	0.37	1.2e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7951870	1.000	rs11819869	chr11:46560680	C/T	cg16389345	chr11:46697382	NA	-0.49	-5.56	-0.33	7.13e-8	Schizophrenia;
KIRP	cis	rs4671458	0.626	rs72806004	chr2:63729432	A/G	cg17519650	chr2:63277830	OTX1	-0.49	-4.93	-0.3	1.54e-6	Subjective well-being;
KIRP	cis	rs7116495	0.609	rs10501408	chr11:71680590	C/T	cg18441811	chr11:71824068	C11orf51	-0.82	-5.5	-0.33	9.51e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.51	6.7	0.39	1.44e-10	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00933542	chr6:150070202	PCMT1	0.3	5.85	0.35	1.58e-8	Lung cancer;
KIRP	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.94	12.26	0.62	2.8e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9905704	0.633	rs72841019	chr17:56496346	G/A	cg12560992	chr17:57184187	TRIM37	0.53	4.95	0.3	1.37e-6	Testicular germ cell tumor;
KIRP	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.68	8.18	0.46	1.49e-14	Corneal astigmatism;
KIRP	cis	rs7903847	0.527	rs11189221	chr10:99198217	C/T	cg07052063	chr10:99255236	MMS19	0.46	5.16	0.31	5.1e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs62355272	0.828	rs7725599	chr5:35821747	C/T	cg13894535	chr5:35919491	CAPSL	-0.42	-5.05	-0.31	8.48e-7	Lymphocyte counts;
KIRP	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.55	6.25	0.37	1.81e-9	Hypospadias;
KIRP	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg12315302	chr6:26189340	HIST1H4D	0.67	4.99	0.3	1.14e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.98	0.3	1.19e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2071426	0.959	rs1934982	chr10:96802124	A/C	cg09036531	chr10:96991505	NA	-0.65	-7.1	-0.41	1.37e-11	Blood metabolite levels;
KIRP	trans	rs933360	0.585	rs10254782	chr7:50825281	C/A	cg20003124	chr12:4557277	NA	0.55	6.7	0.39	1.44e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.38	5.71	0.34	3.18e-8	Neuroticism;
KIRP	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg13180566	chr4:1052158	NA	-0.52	-5.34	-0.32	2.13e-7	Recombination rate (females);
KIRP	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21171335	chr12:122356390	WDR66	0.61	8.13	0.46	2.1e-14	Mean corpuscular volume;
KIRP	cis	rs11235843	0.602	rs7106773	chr11:73383174	C/G	cg18195628	chr11:73498948	MRPL48	-0.5	-5.07	-0.31	7.93e-7	Hand grip strength;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15710681	chr11:30348418	C11orf46	0.41	6.67	0.39	1.65e-10	C-reactive protein;
KIRP	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.55	-0.33	7.51e-8	Pulmonary function;
KIRP	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.46	5.89	0.35	1.29e-8	Neutrophil percentage of white cells;
KIRP	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26207909	chr14:103986467	CKB	0.74	10.53	0.56	1.19e-21	Body mass index;
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg14221460	chr8:27183342	PTK2B	0.5	6.53	0.38	3.74e-10	Neuroticism;
KIRP	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.59	-8.4	-0.47	3.64e-15	Diastolic blood pressure;
KIRP	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg02297831	chr4:17616191	MED28	0.59	7.62	0.44	5.45e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg11814155	chr7:99998594	ZCWPW1	0.56	5.46	0.33	1.17e-7	Platelet count;
KIRP	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.79	-0.4	8.16e-11	Aortic root size;
KIRP	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg10792982	chr14:105748885	BRF1	0.89	13.66	0.66	5.41e-32	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.71	7.56	0.43	8.05e-13	Lymphocyte counts;
KIRP	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs9494145	0.590	rs9376090	chr6:135411228	T/C	cg22676075	chr6:135203613	NA	0.44	4.92	0.3	1.58e-6	Mean platelet volume;Platelet count;Fetal hemoglobin levels in sickle cell anemia;Red blood cell traits;
KIRP	cis	rs1461503	0.511	rs4129007	chr11:122811812	T/C	cg27398637	chr11:122830231	C11orf63	-0.68	-9.07	-0.5	4e-17	Menarche (age at onset);
KIRP	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.72	-8.74	-0.49	3.82e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs807029	0.577	rs7903239	chr10:102758337	G/T	cg04662943	chr10:102668895	NA	0.46	5.05	0.31	8.51e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.45	5.15	0.31	5.46e-7	Schizophrenia;
KIRP	cis	rs16976116	0.901	rs7172108	chr15:55501551	C/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	8.47	0.48	2.31e-15	Alzheimer's disease;
KIRP	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.69	-0.48	5.22e-16	Coronary artery disease;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg00597055	chr15:41523239	CHP;EXD1	-0.59	-6.22	-0.37	2.11e-9	Response to statin therapy;
KIRP	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.81	0.4	7.29e-11	Colorectal cancer;
KIRP	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg23920097	chr1:209922102	NA	-0.47	-6.26	-0.37	1.73e-9	Red blood cell count;
KIRP	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	1.02	13.2	0.64	2.02e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.28	-0.42	4.43e-12	Retinal vascular caliber;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16524936	chr4:1340807	KIAA1530	-0.51	-6.56	-0.39	3.09e-10	Longevity;
KIRP	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.98	-11.89	-0.6	4.55e-26	Dilated cardiomyopathy;
KIRP	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.48e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	10.97	0.57	4.77e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg21523564	chr15:75251491	NA	0.37	6.25	0.37	1.77e-9	Breast cancer;
KIRP	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.11	0.36	3.9e-9	Menopause (age at onset);
KIRP	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.8	11.3	0.58	4e-24	Eosinophil percentage of white cells;
KIRP	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.75	12.22	0.61	3.65e-27	Longevity;Endometriosis;
KIRP	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg12940439	chr1:67600707	NA	0.4	6.01	0.36	6.81e-9	Psoriasis;
KIRP	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.39	-0.32	1.66e-7	Bipolar disorder;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg01114163	chr5:1856713	NA	-0.43	-5.31	-0.32	2.46e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Crohn's disease;
KIRP	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg16339924	chr4:17578868	LAP3	-0.43	-5.57	-0.33	6.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.7	-9.05	-0.5	4.48e-17	Glomerular filtration rate;
KIRP	cis	rs9653442	0.527	rs11690905	chr2:100761473	C/T	cg17356467	chr2:100759845	AFF3	-0.42	-5.69	-0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11997175	0.603	rs7464053	chr8:33786938	C/A	cg04338863	chr8:33670619	NA	0.4	5.02	0.3	9.98e-7	Body mass index;
KIRP	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	7.99	0.45	5.34e-14	Personality dimensions;
KIRP	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.33	5.96	0.36	8.52e-9	Renal cell carcinoma;
KIRP	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.66	8.1	0.46	2.55e-14	Pancreatic cancer;
KIRP	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.48	-7.65	-0.44	4.56e-13	Huntington's disease progression;
KIRP	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg07701084	chr6:150067640	NUP43	0.59	7.38	0.43	2.41e-12	Lung cancer;
KIRP	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.78	10.29	0.55	6.76e-21	Aortic root size;
KIRP	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg13165212	chr22:42675999	NA	0.29	5.28	0.32	2.82e-7	Cognitive function;
KIRP	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.42	-4.96	-0.3	1.32e-6	Height;
KIRP	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.74	-10.89	-0.57	8.28e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg08283408	chr3:49949060	MON1A	-0.42	-5.7	-0.34	3.33e-8	Body mass index;
KIRP	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.37	0.38	9.43e-10	Retinal vascular caliber;
KIRP	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17376030	chr22:41985996	PMM1	-0.78	-8.02	-0.46	4.18e-14	Cannabis dependence symptom count;
KIRP	cis	rs13385	0.769	rs2053058	chr5:139563483	T/C	cg01860693	chr5:139557145	C5orf32	0.49	5.34	0.32	2.15e-7	Atrial fibrillation;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.09	-0.41	1.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.25	-0.37	1.81e-9	Educational attainment;
KIRP	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.93	0.64	1.63e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs9600079	0.720	rs7332697	chr13:73713875	A/C	cg01054891	chr19:57352729	PEG3;ZIM2;MIMT1	-0.46	-6.02	-0.36	6.19e-9	Prostate cancer;
KIRP	cis	rs73242632	0.881	rs55734441	chr4:57833717	G/A	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	4.86	0.3	2.13e-6	Congenital heart disease (maternal effect);
KIRP	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.65	8.33	0.47	5.62e-15	Colorectal cancer;
KIRP	cis	rs9400467	0.537	rs12213673	chr6:111544839	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.57	5.32	0.32	2.37e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10423674	0.526	rs2023878	chr19:18834124	A/G	cg11464615	chr19:18717783	CRLF1	-0.46	-5.02	-0.3	9.89e-7	Menarche (age at onset);
KIRP	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg14952266	chr13:112191215	NA	0.45	6.73	0.39	1.18e-10	Hepatitis;
KIRP	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.7	8.45	0.47	2.64e-15	Aortic root size;
KIRP	cis	rs4132509	1.000	rs10927059	chr1:243852079	T/C	cg21452805	chr1:244014465	NA	0.54	5.48	0.33	1.03e-7	RR interval (heart rate);
KIRP	cis	rs876084	0.630	rs2037342	chr8:121019872	A/G	cg22335954	chr8:121166405	COL14A1	0.38	4.88	0.3	1.92e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg19875535	chr5:140030758	IK	0.57	7.18	0.42	8.31e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg13939156	chr17:80058883	NA	0.48	5.6	0.34	5.58e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg03060546	chr3:49711283	APEH	-0.61	-6.06	-0.36	5.06e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.38	8.01	0.45	4.65e-14	IgG glycosylation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05889681	chr14:38605532	NA	-0.42	-6.33	-0.37	1.17e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6708331	0.540	rs9677885	chr2:70381819	A/G	cg05298696	chr2:70188691	ASPRV1	-0.46	-6.1	-0.36	4.14e-9	Obesity-related traits;
KIRP	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.07	-0.41	1.64e-11	Joint mobility (Beighton score);
KIRP	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.66	-8.68	-0.48	5.54e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	0.92	7.78	0.44	2e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs10782582	0.609	rs2029680	chr1:76363505	A/C	cg10523679	chr1:76189770	ACADM	-0.49	-6.92	-0.4	3.95e-11	Daytime sleep phenotypes;
KIRP	cis	rs17121403	1.000	rs114469102	chr1:100560264	A/T	cg24955406	chr1:100503596	HIAT1	0.76	5.0	0.3	1.09e-6	Pulmonary function decline;
KIRP	cis	rs4700695	0.925	rs4700692	chr5:65396279	T/C	cg21114390	chr5:65439923	SFRS12	-0.53	-5.87	-0.35	1.42e-8	Facial morphology (factor 19);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13636373	chr6:57037092	BAG2	0.47	6.49	0.38	4.81e-10	Parkinson's disease;
KIRP	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.84	0.35	1.63e-8	Total cholesterol levels;
KIRP	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.5	7.18	0.42	8.01e-12	Birth weight;
KIRP	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg16077055	chr2:106428750	NCK2	0.31	6.19	0.37	2.54e-9	Addiction;
KIRP	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.91	-11.98	-0.61	2.29e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg06121193	chr1:90282411	NA	-0.48	-6.98	-0.41	2.73e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg26531700	chr6:26746687	NA	0.45	6.44	0.38	6.24e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	6.21	0.37	2.26e-9	Ulcerative colitis;
KIRP	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00376283	chr12:123451042	ABCB9	-0.65	-6.12	-0.36	3.6e-9	Lymphocyte percentage of white cells;
KIRP	cis	rs12760731	0.720	rs12048834	chr1:178353998	A/G	cg00404053	chr1:178313656	RASAL2	0.65	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs754423	0.515	rs7143508	chr14:52555124	C/T	cg05884192	chr14:52515736	NID2	0.47	5.21	0.32	4.05e-7	Craniofacial microsomia;
KIRP	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.24e-10	Hypertriglyceridemia;
KIRP	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg06521331	chr12:34319734	NA	-0.64	-7.58	-0.44	6.9e-13	Morning vs. evening chronotype;
KIRP	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.55	-6.04	-0.36	5.75e-9	Coronary artery disease;
KIRP	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.82	-9.42	-0.51	3.55e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.28	0.62	2.46e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg07460842	chr6:66804631	NA	0.48	5.69	0.34	3.66e-8	Metabolite levels;
KIRP	cis	rs12210905	1.000	rs9368499	chr6:27254332	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.8	-5.91	-0.35	1.13e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg07596299	chr11:71824057	C11orf51	-0.88	-5.44	-0.33	1.26e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg23920097	chr1:209922102	NA	-0.48	-5.73	-0.34	2.95e-8	Red blood cell count;
KIRP	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg25664220	chr3:72788482	NA	-0.42	-5.59	-0.34	6.11e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs2070997	1.000	rs6597645	chr9:133745487	A/G	cg13397898	chr9:133768931	QRFP	0.28	4.87	0.3	2.04e-6	Response to amphetamines;
KIRP	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg23920097	chr1:209922102	NA	-0.44	-5.9	-0.35	1.21e-8	Red blood cell count;
KIRP	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg21775007	chr8:11205619	TDH	-0.44	-5.8	-0.35	2.03e-8	Triglycerides;
KIRP	cis	rs2483058	0.796	rs11120291	chr1:206616101	G/A	cg19452316	chr1:206680966	RASSF5	0.42	5.61	0.34	5.46e-8	Cholesterol and Triglycerides;
KIRP	cis	rs2400749	0.830	rs6575733	chr14:100031377	G/A	cg19965031	chr14:100038389	CCDC85C	0.45	5.44	0.33	1.32e-7	Alzheimer's disease (survival time);
KIRP	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.6	6.03	0.36	5.97e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4141404	0.640	rs9606854	chr22:31930567	C/T	cg02404636	chr22:31891804	SFI1	0.57	5.84	0.35	1.63e-8	Paclitaxel-induced neuropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05368115	chr19:901123	C19orf22	-0.45	-6.08	-0.36	4.67e-9	Parkinson's disease;
KIRP	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg11833968	chr6:79620685	NA	-0.47	-6.99	-0.41	2.63e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7005606	0.905	rs2439304	chr8:32430371	A/G	cg04912273	chr1:27461082	SLC9A1	0.43	6.19	0.37	2.46e-9	Hirschsprung disease;
KIRP	cis	rs9400271	0.632	rs9374071	chr6:109588681	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg21775007	chr8:11205619	TDH	-0.4	-5.41	-0.33	1.48e-7	Morning vs. evening chronotype;
KIRP	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.27	0.42	4.7e-12	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.39	-0.43	2.23e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.85	-12.78	-0.63	4.97e-29	Strep throat;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.63	9.55	0.52	1.35e-18	Lung cancer;
KIRP	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg13072238	chr3:49761600	GMPPB	0.57	5.13	0.31	5.8e-7	Menarche (age at onset);
KIRP	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-7.67	-0.44	4.1e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg10755058	chr3:40428713	ENTPD3	0.44	5.6	0.34	5.74e-8	Renal cell carcinoma;
KIRP	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.5	8.35	0.47	4.88e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg16898833	chr6:26189333	HIST1H4D	1.0	5.91	0.35	1.15e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.51	-0.33	9.05e-8	Breast cancer;
KIRP	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.74	-8.17	-0.46	1.63e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg11650704	chr1:154556575	ADAR	-0.41	-5.0	-0.3	1.11e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg04289385	chr6:36355825	ETV7	0.46	7.04	0.41	1.85e-11	Platelet distribution width;
KIRP	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.74	-0.49	3.66e-16	Mean corpuscular volume;
KIRP	cis	rs12210905	1.000	rs10946906	chr6:27252780	G/A	cg11502198	chr6:26597334	ABT1	-0.85	-4.86	-0.3	2.09e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7534824	0.625	rs55693426	chr1:101466859	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.43	0.33	1.38e-7	Refractive astigmatism;
KIRP	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	11.98	0.61	2.37e-26	Lymphocyte percentage of white cells;
KIRP	cis	rs7202877	0.519	rs4887811	chr16:75307251	C/T	cg03315344	chr16:75512273	CHST6	0.54	5.48	0.33	1.05e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.48	-5.02	-0.3	9.98e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.65	-8.81	-0.49	2.28e-16	Ear protrusion;
KIRP	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.5	-0.33	9.36e-8	Menarche (age at onset);
KIRP	cis	rs5743890	0.591	rs2056083	chr11:1369555	C/T	cg06066251	chr11:1309984	TOLLIP	0.61	5.68	0.34	3.73e-8	Idiopathic pulmonary fibrosis;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.61	9.03	0.5	5.02e-17	Menarche (age at onset);
KIRP	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.08e-11	Blood metabolite levels;
KIRP	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.66	9.22	0.51	1.4e-17	Blood protein levels;
KIRP	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.96e-18	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.5	6.8	0.4	7.71e-11	Migraine;
KIRP	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1971762	0.563	rs4759285	chr12:54079513	G/T	cg16917193	chr12:54089295	NA	1.02	22.17	0.82	1.34e-60	Height;
KIRP	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg03788504	chr6:150331562	NA	-0.34	-6.29	-0.37	1.46e-9	Alopecia areata;
KIRP	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg18646521	chr2:111875858	NA	0.36	5.12	0.31	6.23e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.13	-0.36	3.43e-9	Type 2 diabetes;
KIRP	cis	rs2274273	0.870	rs8021583	chr14:55749607	G/A	cg04306507	chr14:55594613	LGALS3	0.44	6.79	0.4	8.49e-11	Protein biomarker;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.52	6.09	0.36	4.3e-9	Lung cancer;
KIRP	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.56	6.83	0.4	6.6e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6681460	0.966	rs9659879	chr1:67121434	T/C	cg13052034	chr1:66999238	SGIP1	0.45	6.31	0.37	1.28e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs4690686	0.500	rs4690429	chr4:177263983	G/A	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.42	-0.43	1.85e-12	Daytime sleep phenotypes;
KIRP	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg10645314	chr2:3704589	ALLC	-0.39	-4.93	-0.3	1.54e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17376030	chr22:41985996	PMM1	0.73	7.82	0.45	1.55e-13	Vitiligo;
KIRP	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg04369109	chr6:150039330	LATS1	-0.61	-7.86	-0.45	1.22e-13	Lung cancer;
KIRP	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	0.99	13.21	0.64	1.77e-30	Dilated cardiomyopathy;
KIRP	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg00262122	chr8:11665843	FDFT1	0.4	4.84	0.3	2.25e-6	Retinal vascular caliber;
KIRP	cis	rs4740619	0.590	rs10756735	chr9:16027606	T/G	cg14451791	chr9:16040625	NA	-0.39	-5.08	-0.31	7.47e-7	Body mass index;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg18234130	chr8:27182889	PTK2B	0.57	7.43	0.43	1.84e-12	Neuroticism;
KIRP	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.86	0.35	1.45e-8	Monocyte percentage of white cells;
KIRP	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg00647317	chr7:50633725	DDC	-0.41	-5.44	-0.33	1.31e-7	Malaria;
KIRP	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.6	7.48	0.43	1.29e-12	Tonsillectomy;
KIRP	cis	rs17065868	1.000	rs9533938	chr13:45222796	T/A	cg10246903	chr13:45222710	NA	0.77	8.28	0.47	7.71e-15	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg00334542	chr7:100209784	MOSPD3	-0.53	-5.06	-0.31	8.11e-7	Other erythrocyte phenotypes;
KIRP	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg04731861	chr2:219085781	ARPC2	-0.21	-5.15	-0.31	5.3e-7	Colorectal cancer;
KIRP	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg02980000	chr4:1222292	CTBP1	-0.79	-9.38	-0.51	4.69e-18	Systolic blood pressure;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg02733842	chr7:1102375	C7orf50	0.56	5.81	0.35	1.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs55882075	0.967	rs12656648	chr5:179152106	C/A	cg14593053	chr5:179126677	CANX	0.65	8.47	0.48	2.19e-15	Monocyte percentage of white cells;
KIRP	cis	rs7395581	0.918	rs10838693	chr11:47350553	G/C	cg25783544	chr11:47291846	MADD	0.43	4.91	0.3	1.63e-6	HDL cholesterol;
KIRP	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg05938607	chr10:60274200	BICC1	0.41	10.01	0.54	5.21e-20	Refractive error;
KIRP	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg26681399	chr22:41777847	TEF	0.51	5.19	0.31	4.41e-7	Vitiligo;
KIRP	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.02	-13.89	-0.66	9.01e-33	Alzheimer's disease;
KIRP	cis	rs56399783	0.901	rs11761804	chr7:2792524	C/T	cg19731401	chr7:2775893	GNA12	0.65	6.19	0.37	2.45e-9	Childhood ear infection;
KIRP	cis	rs7572644	0.699	rs7595847	chr2:28173043	T/A	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg26513180	chr16:89883248	FANCA	0.79	5.5	0.33	9.64e-8	Skin colour saturation;
KIRP	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg04519387	chr11:65556438	OVOL1	0.35	5.35	0.32	2.02e-7	Acne (severe);
KIRP	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.66	-8.38	-0.47	4.09e-15	Tonsillectomy;
KIRP	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	6.99	0.41	2.64e-11	Menarche (age at onset);
KIRP	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.6	8.95	0.5	8.85e-17	Testicular germ cell tumor;
KIRP	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg00629941	chr15:75287862	SCAMP5	-0.5	-5.25	-0.32	3.27e-7	Blood trace element (Zn levels);
KIRP	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-6.93	-0.4	3.66e-11	Morning vs. evening chronotype;
KIRP	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg08761264	chr16:28874980	SH2B1	-0.51	-5.9	-0.35	1.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.61	-7.45	-0.43	1.61e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs877426	0.681	rs7317994	chr13:114817068	C/T	cg00571178	chr13:114841904	RASA3	-0.49	-5.17	-0.31	4.92e-7	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg01843034	chr6:37503916	NA	-0.83	-12.01	-0.61	1.9e-26	Cognitive performance;
KIRP	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg03714773	chr7:91764589	CYP51A1	0.39	5.79	0.35	2.1e-8	Breast cancer;
KIRP	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg13206674	chr6:150067644	NUP43	0.55	7.8	0.45	1.74e-13	Lung cancer;
KIRP	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-7.83	-0.45	1.47e-13	Platelet distribution width;
KIRP	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg23594656	chr7:65796392	TPST1	-0.43	-5.95	-0.35	9e-9	Aortic root size;
KIRP	cis	rs6582630	0.538	rs2320582	chr12:38284992	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-5.41	-0.33	1.47e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.43	4.87	0.3	2.04e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.46	5.85	0.35	1.59e-8	Coronary artery disease;
KIRP	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg03834567	chr2:218808745	TNS1	0.41	5.17	0.31	4.79e-7	Ulcerative colitis;
KIRP	trans	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg24644049	chr4:85504048	CDS1	0.9	6.64	0.39	2e-10	Skin colour saturation;
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg13906792	chr15:75199810	C15orf17	-0.36	-5.09	-0.31	7.03e-7	Breast cancer;
KIRP	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.5	-6.97	-0.41	2.83e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs2219968	1.000	rs13263569	chr8:78954480	A/G	cg00738934	chr8:78996279	NA	0.41	5.12	0.31	6.21e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.49	6.7	0.39	1.42e-10	Mean corpuscular volume;
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg05025164	chr4:1340916	KIAA1530	0.58	8.03	0.46	4.14e-14	Longevity;
KIRP	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.86e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs34286592	1.000	rs4787480	chr16:29857316	G/A	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	4.86	0.3	2.14e-6	Multiple sclerosis;
KIRP	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg18154014	chr19:37997991	ZNF793	0.61	6.68	0.39	1.57e-10	Coronary artery calcification;
KIRP	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.79	6.86	0.4	5.44e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23903597	chr17:61704154	MAP3K3	-0.57	-6.78	-0.4	8.86e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.07	18.52	0.76	1.54e-48	Schizophrenia;
KIRP	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg00405596	chr8:11794950	NA	0.62	8.71	0.49	4.42e-16	Neuroticism;
KIRP	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	trans	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg19894588	chr14:64061835	NA	-0.64	-7.51	-0.43	1.08e-12	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg12751644	chr20:60527061	NA	-0.4	-4.91	-0.3	1.65e-6	Body mass index;
KIRP	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs812925	0.519	rs2463099	chr2:61618311	T/C	cg15711740	chr2:61764176	XPO1	0.48	6.16	0.37	2.9e-9	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg13319975	chr6:146136371	FBXO30	0.43	5.67	0.34	3.99e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg03609598	chr5:56110824	MAP3K1	0.58	5.69	0.34	3.58e-8	Initial pursuit acceleration;
KIRP	cis	rs9430161	0.645	rs12081186	chr1:11034195	T/C	cg02454025	chr1:11042201	C1orf127	0.9	14.42	0.68	1.39e-34	Ewing sarcoma;
KIRP	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg11130432	chr3:121712080	ILDR1	-0.43	-5.09	-0.31	7.24e-7	Multiple sclerosis;
KIRP	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs28655083	0.636	rs61117898	chr16:77050736	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.61	-5.57	-0.33	6.57e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6142102	1.000	rs6059681	chr20:32723341	T/C	cg08999081	chr20:33150536	PIGU	0.5	5.94	0.35	9.73e-9	Skin pigmentation;
KIRP	cis	rs9652601	0.845	rs7184615	chr16:11165542	G/C	cg04616529	chr16:11181986	CLEC16A	0.37	4.92	0.3	1.55e-6	Systemic lupus erythematosus;
KIRP	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg16141378	chr3:129829833	LOC729375	0.53	6.45	0.38	6.01e-10	Neuroticism;
KIRP	trans	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg24644049	chr4:85504048	CDS1	1.01	6.58	0.39	2.79e-10	Skin colour saturation;
KIRP	cis	rs11718455	0.563	rs6809096	chr3:43902494	G/C	cg08738300	chr3:44038990	NA	0.51	6.77	0.4	9.47e-11	Coronary artery disease;
KIRP	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg06627628	chr2:24431161	ITSN2	-0.57	-5.11	-0.31	6.49e-7	Lymphocyte counts;
KIRP	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg20534287	chr10:135191450	PAOX	0.57	7.09	0.41	1.38e-11	Lifespan;
KIRP	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.1	-0.31	6.83e-7	Blood metabolite levels;
KIRP	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg10505658	chr17:80084571	CCDC57	-0.26	-4.86	-0.3	2.13e-6	Life satisfaction;
KIRP	cis	rs9311676	0.656	rs55913214	chr3:58388026	A/G	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg22764044	chr5:178986830	RUFY1	-0.46	-6.9	-0.4	4.44e-11	Lung cancer;
KIRP	cis	rs2901460	0.527	rs10167456	chr2:62112839	G/A	cg02183531	chr2:62113199	CCT4	-0.49	-4.98	-0.3	1.18e-6	Mean corpuscular volume;
KIRP	cis	rs2274273	0.712	rs1002054	chr14:55528913	A/C	cg04306507	chr14:55594613	LGALS3	0.4	6.05	0.36	5.46e-9	Protein biomarker;
KIRP	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg23505145	chr19:12996616	KLF1	0.58	8.38	0.47	3.99e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.38	4.88	0.3	1.92e-6	Testicular germ cell tumor;
KIRP	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg21605333	chr4:119757512	SEC24D	0.73	5.72	0.34	3.03e-8	Cannabis dependence symptom count;
KIRP	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.46	5.72	0.34	3.02e-8	Height;
KIRP	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.67	8.51	0.48	1.71e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.4	-0.65	4.21e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.38	6.38	0.38	8.91e-10	Heart rate;
KIRP	cis	rs364477	0.761	rs166790	chr9:958746	A/T	cg13952963	chr9:998547	NA	0.58	5.93	0.35	1.02e-8	Major depressive disorder;
KIRP	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.76	10.28	0.55	7.56e-21	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4925114	0.568	rs11656775	chr17:17654319	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-6.52	-0.38	4.05e-10	Body mass index;
KIRP	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg16141378	chr3:129829833	LOC729375	0.54	6.99	0.41	2.58e-11	Mood instability;
KIRP	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.62	-7.75	-0.44	2.48e-13	Longevity;Endometriosis;
KIRP	trans	rs12517041	0.935	rs10053181	chr5:23293265	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.75	-0.4	1.07e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg19554555	chr3:13937349	NA	-0.46	-6.25	-0.37	1.76e-9	Ovarian reserve;
KIRP	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg17470723	chr8:74884337	TCEB1	0.63	8.1	0.46	2.49e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg04733989	chr22:42467013	NAGA	-0.53	-6.47	-0.38	5.25e-10	Cognitive function;
KIRP	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.64	-7.63	-0.44	5.03e-13	Bone mineral density;
KIRP	cis	rs11718455	0.585	rs11719257	chr3:43914854	A/T	cg08738300	chr3:44038990	NA	0.56	7.28	0.42	4.37e-12	Coronary artery disease;
KIRP	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.64	-6.75	-0.4	1.04e-10	Obesity-related traits;
KIRP	cis	rs6540559	1.000	rs6659367	chr1:209982408	G/T	cg25204440	chr1:209979598	IRF6	0.44	4.92	0.3	1.6e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.61	-7.93	-0.45	7.55e-14	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.63	8.11	0.46	2.33e-14	Prudent dietary pattern;
KIRP	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-13.05	-0.64	6.16e-30	Vitiligo;
KIRP	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.36	-0.32	1.87e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7923609	0.967	rs3999089	chr10:65203808	C/T	cg01631684	chr10:65280961	REEP3	0.51	6.01	0.36	6.81e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg11846333	chr4:119757529	SEC24D	1.04	6.0	0.36	7.19e-9	Cannabis dependence symptom count;
KIRP	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	1.01	18.06	0.76	5.5e-47	Leprosy;
KIRP	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg24565620	chr2:194026	NA	0.69	5.18	0.31	4.63e-7	Blood protein levels;
KIRP	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.44	6.24	0.37	1.9e-9	Menarche (age at onset);
KIRP	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.26	17.69	0.75	9.67e-46	Atopic dermatitis;
KIRP	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.4	5.51	0.33	9.24e-8	Total body bone mineral density;
KIRP	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21643547	chr1:205240462	TMCC2	-0.72	-11.02	-0.57	3.28e-23	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2425143	0.915	rs74355238	chr20:34441541	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-4.94	-0.3	1.46e-6	Blood protein levels;
KIRP	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg17372223	chr3:52568218	NT5DC2	-0.3	-4.87	-0.3	2.03e-6	Bipolar disorder;
KIRP	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.75	-0.34	2.59e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4774899	0.933	rs2053472	chr15:57217618	A/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.15	-0.31	5.28e-7	Urinary tract infection frequency;
KIRP	cis	rs2979489	0.624	rs62505275	chr8:30437639	C/T	cg26383811	chr8:30366931	RBPMS	-0.36	-4.97	-0.3	1.25e-6	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.78	11.95	0.61	2.91e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg07395648	chr5:131743802	NA	-0.34	-4.9	-0.3	1.71e-6	Breast cancer;
KIRP	cis	rs9323205	0.953	rs11623710	chr14:51694261	C/T	cg23942311	chr14:51606299	NA	-0.58	-6.1	-0.36	4.06e-9	Cancer;
KIRP	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg25319279	chr11:5960081	NA	-0.59	-6.12	-0.36	3.73e-9	DNA methylation (variation);
KIRP	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.94	-13.29	-0.65	9.53e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg06740227	chr12:86229804	RASSF9	0.45	5.91	0.35	1.14e-8	Major depressive disorder;
KIRP	cis	rs11874712	0.965	rs8085444	chr18:43652203	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.43	-5.86	-0.35	1.49e-8	Migraine - clinic-based;
KIRP	cis	rs922692	0.715	rs2277546	chr15:79083376	C/A	cg04896959	chr15:78267971	NA	0.52	6.86	0.4	5.39e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg27121462	chr16:89883253	FANCA	-0.53	-7.4	-0.43	2.11e-12	Vitiligo;
KIRP	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.8	11.02	0.58	3.14e-23	Aortic root size;
KIRP	cis	rs4704187	0.687	rs2112871	chr5:74469853	G/A	cg03227963	chr5:74354835	NA	0.4	6.0	0.36	7.09e-9	Response to amphetamines;
KIRP	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-19.37	-0.78	2.09e-51	Ulcerative colitis;
KIRP	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.7	7.91	0.45	8.49e-14	High light scatter reticulocyte count;
KIRP	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	7.28	0.42	4.41e-12	Myopia (pathological);
KIRP	cis	rs883565	0.569	rs784513	chr3:39164915	G/A	cg01426195	chr3:39028469	NA	0.52	8.31	0.47	6.35e-15	Handedness;
KIRP	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.79	-8.98	-0.5	7.26e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	7.59	0.44	6.76e-13	Height;
KIRP	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06544989	chr22:39130855	UNC84B	-0.49	-8.05	-0.46	3.56e-14	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg23594656	chr7:65796392	TPST1	0.52	8.28	0.47	8.07e-15	Aortic root size;
KIRP	cis	rs10073892	0.660	rs10477821	chr5:101946610	T/C	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg00745463	chr17:30367425	LRRC37B	-0.62	-5.66	-0.34	4.13e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs17023223	0.537	rs7525871	chr1:119621894	T/C	cg18261050	chr1:119551319	NA	0.56	7.52	0.43	9.99e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg06154544	chr16:764854	METRN	-0.52	-6.48	-0.38	4.93e-10	Height;
KIRP	cis	rs7520050	0.931	rs7526678	chr1:46374159	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.32	-0.32	2.37e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg09137382	chr11:130731461	NA	0.56	8.23	0.46	1.12e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.97	13.94	0.66	6.19e-33	Platelet distribution width;
KIRP	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.81	-8.81	-0.49	2.31e-16	Coronary artery disease;
KIRP	cis	rs1843834	0.688	rs2396149	chr2:225601985	G/A	cg22509189	chr2:225307070	NA	-0.45	-5.41	-0.33	1.53e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg26681399	chr22:41777847	TEF	-0.5	-5.48	-0.33	1.03e-7	Vitiligo;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg07185648	chr2:216946617	PECR;TMEM169	0.51	6.24	0.37	1.93e-9	DNA methylation (variation);
KIRP	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.73	-9.18	-0.51	1.78e-17	Aortic root size;
KIRP	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg05082376	chr22:42548792	NA	0.46	5.8	0.35	2.01e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.53	6.22	0.37	2.18e-9	Schizophrenia;
KIRP	trans	rs12545912	0.770	rs12114182	chr8:9537635	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.15	-0.37	3.16e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg01081584	chr15:40268610	EIF2AK4	-0.56	-6.86	-0.4	5.5e-11	Corneal curvature;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02028540	chr16:67193883	TRADD;FBXL8	-0.47	-6.22	-0.37	2.15e-9	Myopia;
KIRP	cis	rs1823913	1.000	rs4853561	chr2:192107706	T/C	cg12404831	chr2:192114017	MYO1B	-0.49	-6.73	-0.39	1.19e-10	Obesity-related traits;
KIRP	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg13798780	chr7:105162888	PUS7	0.66	6.09	0.36	4.31e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg05304507	chr6:116381966	FRK	0.21	5.86	0.35	1.51e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg04267008	chr7:1944627	MAD1L1	-0.51	-5.35	-0.32	2.03e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11967485	0.609	rs72998904	chr6:157164875	C/T	cg23222435	chr6:157204239	ARID1B	-0.74	-5.18	-0.31	4.63e-7	Calcium levels;
KIRP	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs3736594	0.959	rs6547796	chr2:27975394	T/C	cg27432699	chr2:27873401	GPN1	-0.57	-7.32	-0.42	3.46e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg15047889	chr8:124780837	FAM91A1	-0.48	-4.86	-0.3	2.12e-6	Pancreatic cancer;
KIRP	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.95	0.3	1.4e-6	Tonsillectomy;
KIRP	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg27494647	chr7:150038898	RARRES2	0.35	5.0	0.3	1.07e-6	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17809895	chr20:51589197	TSHZ2	0.48	6.17	0.37	2.87e-9	Myopia (pathological);
KIRP	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.57	-6.48	-0.38	4.97e-10	Hypospadias;
KIRP	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg07382826	chr16:28625726	SULT1A1	0.46	5.17	0.31	4.92e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.43	0.33	1.34e-7	Putamen volume;
KIRP	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.35	-0.47	5.08e-15	Retinal vascular caliber;
KIRP	cis	rs737008	0.960	rs11640295	chr16:11390728	C/G	cg00044050	chr16:11439710	C16orf75	0.57	6.96	0.41	3.06e-11	Obesity-related traits;
KIRP	cis	rs7017914	0.967	rs12680166	chr8:71678638	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.38e-7	Bone mineral density;
KIRP	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.7	10.56	0.56	9.83e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.73e-8	Aortic root size;
KIRP	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.42	5.49	0.33	9.81e-8	Neutrophil percentage of white cells;
KIRP	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.38	-0.38	8.56e-10	Monocyte percentage of white cells;
KIRP	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.88	9.81	0.53	2.15e-19	Gut microbiome composition (summer);
KIRP	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg18225595	chr11:63971243	STIP1	0.61	5.6	0.34	5.66e-8	Mean platelet volume;
KIRP	cis	rs1723838	0.510	rs45523540	chr11:73692990	G/A	cg10064339	chr11:73693792	UCP2	0.89	5.72	0.34	3.09e-8	Obesity-related traits;
KIRP	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.53	6.59	0.39	2.68e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.18	-0.46	1.53e-14	Response to antipsychotic treatment;
KIRP	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg22643751	chr7:855365	UNC84A	0.38	5.34	0.32	2.13e-7	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs883115	0.846	rs4654057	chr1:224796339	A/G	cg01808320	chr1:224927238	CNIH3	-0.37	-5.28	-0.32	2.89e-7	Cancer;
KIRP	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.71	8.18	0.46	1.5e-14	Dialysis-related mortality;
KIRP	cis	rs2898681	0.581	rs731073	chr4:53680090	A/G	cg00338735	chr4:53728038	RASL11B	0.43	5.42	0.33	1.42e-7	Optic nerve measurement (cup area);
KIRP	cis	rs6662572	0.737	rs6429590	chr1:46457250	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.46	0.33	1.17e-7	Blood protein levels;
KIRP	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.89	15.21	0.7	2.71e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15519465	chr1:8738385	RERE	0.42	6.23	0.37	1.98e-9	C-reactive protein;
KIRP	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.59	7.74	0.44	2.61e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22744368	chr20:61273372	SLCO4A1	0.51	6.58	0.39	2.88e-10	Parkinson's disease;
KIRP	cis	rs6832769	0.961	rs11947623	chr4:56349190	C/A	cg05960024	chr4:56376020	CLOCK	0.63	8.17	0.46	1.65e-14	Personality dimensions;
KIRP	cis	rs3741151	1.000	rs1892856	chr11:73017971	G/C	cg17517138	chr11:73019481	ARHGEF17	1.21	8.26	0.47	9.27e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.7	-7.39	-0.43	2.29e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9400271	0.632	rs9384705	chr6:109588244	T/C	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9843304	0.721	rs13062142	chr3:149201983	C/T	cg08667024	chr3:149219783	TM4SF4	-0.35	-5.02	-0.3	9.82e-7	Gallstone disease;
KIRP	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.51	-5.71	-0.34	3.29e-8	Adiposity;
KIRP	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	9.64	0.52	7.4e-19	Bipolar disorder;
KIRP	cis	rs17123764	0.892	rs10506287	chr12:50156640	T/C	cg20471783	chr12:50157085	TMBIM6	0.42	5.5	0.33	9.61e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19524238	chr7:2802976	GNA12	-0.35	-4.86	-0.3	2.13e-6	Height;
KIRP	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg10223061	chr2:219282414	VIL1	-0.33	-5.37	-0.32	1.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18110333	chr6:292329	DUSP22	-0.61	-7.1	-0.41	1.35e-11	Menopause (age at onset);
KIRP	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg05370193	chr1:21551575	ECE1	0.44	6.27	0.37	1.65e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1215050	0.791	rs783959	chr4:98893476	C/T	cg05340658	chr4:99064831	C4orf37	-0.57	-7.0	-0.41	2.48e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12484756	chr19:10764617	ILF3;LOC147727	0.47	6.04	0.36	5.63e-9	Parkinson's disease;
KIRP	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg16141378	chr3:129829833	LOC729375	0.61	7.77	0.44	2.13e-13	Neuroticism;
KIRP	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.21	-0.46	1.27e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.29	-0.51	8.26e-18	Mean corpuscular volume;
KIRP	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg17425144	chr1:10567563	PEX14	0.46	8.43	0.47	2.87e-15	Breast size;
KIRP	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.63	-9.36	-0.51	5.08e-18	Age-related hearing impairment;
KIRP	cis	rs675026	0.963	rs648007	chr6:154422611	A/G	cg07813322	chr6:154414604	OPRM1	-0.5	-6.43	-0.38	6.76e-10	Hypertension;
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg17441377	chr17:3906640	NA	0.55	8.28	0.47	7.81e-15	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26293310	chr5:133968572	SAR1B	0.49	6.3	0.37	1.36e-9	Parkinson's disease;
KIRP	cis	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg21775007	chr8:11205619	TDH	-0.42	-5.21	-0.31	4.09e-7	Triglycerides;
KIRP	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-11.2	-0.58	8.33e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg07395648	chr5:131743802	NA	-0.36	-5.29	-0.32	2.71e-7	Acylcarnitine levels;
KIRP	cis	rs11148252	0.535	rs11616459	chr13:53076400	A/T	cg00495681	chr13:53174319	NA	0.71	10.4	0.55	3.11e-21	Lewy body disease;
KIRP	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.95	15.6	0.71	1.27e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg08949428	chr13:98451284	NA	-0.46	-6.19	-0.37	2.51e-9	Inflammatory biomarkers;
KIRP	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg23594656	chr7:65796392	TPST1	-0.43	-6.23	-0.37	1.99e-9	Aortic root size;
KIRP	cis	rs16986825	0.570	rs5762879	chr22:29286180	C/T	cg15103426	chr22:29168792	CCDC117	0.5	5.62	0.34	5.23e-8	Pancreatic cancer;
KIRP	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg10755058	chr3:40428713	ENTPD3	0.47	6.57	0.39	3.01e-10	Renal cell carcinoma;
KIRP	cis	rs494562	0.892	rs9344518	chr6:86125144	T/A	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.5	7.59	0.44	6.65e-13	Testicular germ cell tumor;
KIRP	cis	rs2041895	0.509	rs7976343	chr12:107296028	T/C	cg21360079	chr12:107162445	NA	-0.44	-4.87	-0.3	2e-6	Glaucoma (low intraocular pressure);
KIRP	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg08648136	chr8:956695	NA	0.42	5.67	0.34	3.89e-8	Schizophrenia;
KIRP	cis	rs2274273	0.588	rs17675223	chr14:55862236	G/A	cg04306507	chr14:55594613	LGALS3	0.39	5.41	0.33	1.51e-7	Protein biomarker;
KIRP	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg11663144	chr21:46675770	NA	-0.58	-8.32	-0.47	6.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26526719	chr5:1949144	NA	0.43	5.21	0.31	4.09e-7	Gut microbiome composition (winter);
KIRP	cis	rs240764	0.681	rs12209887	chr6:101156806	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-4.9	-0.3	1.77e-6	Neuroticism;
KIRP	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg01941274	chr14:50234650	KLHDC2	-0.42	-4.99	-0.3	1.17e-6	Carotid intima media thickness;
KIRP	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	10.9	0.57	7.7e-23	Personality dimensions;
KIRP	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs7224685	0.569	rs12452393	chr17:3985427	G/A	cg11204139	chr17:3907470	NA	0.58	5.61	0.34	5.48e-8	Type 2 diabetes;
KIRP	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.49	5.74	0.34	2.71e-8	Mean platelet volume;
KIRP	trans	rs10904290	1.000	rs10904290	chr10:4616862	C/T	cg15971879	chr2:3467236	TTC15	-0.91	-6.05	-0.36	5.26e-9	Major depressive disorder;
KIRP	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg15103426	chr22:29168792	CCDC117	0.53	5.37	0.32	1.83e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs7621025	0.691	rs4678438	chr3:136344920	A/C	cg15507776	chr3:136538369	TMEM22	0.39	5.21	0.32	3.95e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.55	-0.39	3.28e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.85	12.16	0.61	6.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2594989	0.943	rs6442251	chr3:11417477	A/G	cg01796438	chr3:11312864	ATG7	-0.56	-7.27	-0.42	4.63e-12	Circulating chemerin levels;
KIRP	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg09264619	chr17:80180166	NA	-0.4	-5.93	-0.35	1e-8	Life satisfaction;
KIRP	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg13798912	chr7:905769	UNC84A	0.58	5.79	0.35	2.18e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg25182066	chr10:30743637	MAP3K8	-0.63	-7.98	-0.45	5.51e-14	Inflammatory bowel disease;
KIRP	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.21	-12.38	-0.62	1.13e-27	Corneal structure;
KIRP	cis	rs2151522	0.603	rs1930943	chr6:127196776	A/G	cg21431617	chr6:127135037	NA	0.31	5.33	0.32	2.25e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg07384165	chr1:10488281	NA	-0.45	-5.7	-0.34	3.36e-8	Prostate cancer;
KIRP	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg01721255	chr8:58191610	C8orf71	0.52	5.1	0.31	6.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg00543991	chr22:32367038	NA	0.6	5.12	0.31	6.03e-7	Childhood ear infection;
KIRP	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.15	15.72	0.71	5.01e-39	Lymphocyte percentage of white cells;
KIRP	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.4	-5.28	-0.32	2.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.44	-5.56	-0.33	7.05e-8	Longevity;
KIRP	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.58	-0.44	6.9e-13	Mood instability;
KIRP	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	7.16	0.42	9.09e-12	Iron status biomarkers;
KIRP	cis	rs1559088	0.847	rs7254758	chr19:33608047	T/A	cg24009623	chr19:33667908	NA	0.5	6.35	0.38	1.02e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.89	0.49	1.32e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg24315340	chr6:146058215	EPM2A	-0.47	-5.83	-0.35	1.74e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62384625	1.000	rs62384625	chr5:141482269	C/T	cg08523384	chr5:141488047	NDFIP1	-0.37	-5.09	-0.31	7.09e-7	White blood cell count (basophil);
KIRP	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.6	-6.51	-0.38	4.08e-10	Platelet distribution width;
KIRP	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg18016565	chr1:150552671	MCL1	0.4	6.14	0.36	3.22e-9	Melanoma;
KIRP	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg11663144	chr21:46675770	NA	-0.64	-8.81	-0.49	2.25e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs735539	1.000	rs3000676	chr13:21286442	A/T	cg04906043	chr13:21280425	IL17D	-0.66	-9.07	-0.5	3.96e-17	Dental caries;
KIRP	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.5e-10	Bipolar disorder;
KIRP	cis	rs7923609	1.000	rs4400684	chr10:65012687	A/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.66	-0.34	4.21e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg02696790	chr15:75250997	RPP25	0.3	5.11	0.31	6.56e-7	Breast cancer;
KIRP	cis	rs838147	0.844	rs8102032	chr19:49249795	C/T	cg13540341	chr19:49222985	MAMSTR	0.31	5.09	0.31	6.97e-7	Dietary macronutrient intake;
KIRP	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg06145435	chr7:1022769	CYP2W1	0.32	4.88	0.3	1.94e-6	Longevity;Endometriosis;
KIRP	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.42	4.91	0.3	1.66e-6	Lung cancer;
KIRP	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg20637307	chr2:213403960	ERBB4	0.59	7.91	0.45	8.75e-14	Symmetrical dimethylarginine levels;
KIRP	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg01689657	chr7:91764605	CYP51A1	0.44	6.46	0.38	5.65e-10	Breast cancer;
KIRP	cis	rs7766436	0.922	rs11753523	chr6:22602094	G/A	cg13666174	chr6:22585274	NA	-0.47	-6.3	-0.37	1.37e-9	Coronary artery disease;
KIRP	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg24011408	chr12:48396354	COL2A1	-0.39	-5.34	-0.32	2.08e-7	Plateletcrit;
KIRP	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.44	8.65	0.48	6.68e-16	Coronary artery disease;
KIRP	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	6.3	0.37	1.39e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.53	-7.6	-0.44	6.35e-13	Obesity-related traits;
KIRP	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.67	-7.85	-0.45	1.29e-13	Systemic lupus erythematosus;
KIRP	cis	rs7919006	0.590	rs61151518	chr10:76777843	G/A	cg01390419	chr10:76803856	DUPD1	0.51	5.91	0.35	1.13e-8	Weight;
KIRP	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.11	0.64	4.03e-30	Exhaled nitric oxide output;
KIRP	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg08999081	chr20:33150536	PIGU	-0.43	-5.57	-0.33	6.71e-8	Height;
KIRP	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.7	9.46	0.52	2.66e-18	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg21775007	chr8:11205619	TDH	0.49	6.19	0.37	2.44e-9	Mood instability;
KIRP	cis	rs17095355	1.000	rs9630101	chr10:111738451	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.1	-0.36	4.03e-9	Biliary atresia;
KIRP	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg12560992	chr17:57184187	TRIM37	0.58	5.27	0.32	2.94e-7	Cognitive test performance;
KIRP	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg08126542	chr6:37504118	NA	-0.71	-9.96	-0.54	7.49e-20	Cognitive performance;
KIRP	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-0.95	-8.15	-0.46	1.9e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg22800045	chr5:56110881	MAP3K1	0.72	7.71	0.44	3.04e-13	Initial pursuit acceleration;
KIRP	cis	rs7236492	0.532	rs3786184	chr18:77195885	A/C	cg15644404	chr18:77186268	NFATC1	-0.56	-6.03	-0.36	6.11e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.64	8.09	0.46	2.77e-14	Total cholesterol levels;
KIRP	cis	rs9843304	0.500	rs34358037	chr3:149201284	A/G	cg08667024	chr3:149219783	TM4SF4	-0.5	-7.54	-0.43	8.82e-13	Gallstone disease;
KIRP	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18252515	chr7:66147081	NA	0.44	5.26	0.32	3.16e-7	Aortic root size;
KIRP	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.51	6.76	0.4	9.68e-11	Childhood ear infection;
KIRP	cis	rs10021731	0.577	rs34941812	chr4:115594416	C/T	cg22609233	chr4:115518992	UGT8	0.38	5.02	0.3	9.97e-7	Optic disc area;
KIRP	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.98	-0.41	2.8e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.98	11.46	0.59	1.25e-24	Vitiligo;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.57	7.94	0.45	6.99e-14	Longevity;Endometriosis;
KIRP	cis	rs687432	0.885	rs11605988	chr11:57797100	A/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.77	-7.35	-0.42	2.95e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9810890	1.000	rs73208002	chr3:128607468	C/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.9	-0.35	1.17e-8	Breast cancer;
KIRP	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.42	5.34	0.32	2.16e-7	Melanoma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15208573	chr6:44041185	NA	0.42	6.2	0.37	2.36e-9	Survival in pancreatic cancer;
KIRP	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg18132916	chr6:79620363	NA	0.4	5.52	0.33	8.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.78	0.35	2.24e-8	Schizophrenia;
KIRP	cis	rs2230307	0.656	rs114775204	chr1:100463030	T/C	cg24955406	chr1:100503596	HIAT1	0.56	5.57	0.33	6.57e-8	Carotid intima media thickness;
KIRP	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg01689657	chr7:91764605	CYP51A1	0.34	4.9	0.3	1.72e-6	Breast cancer;
KIRP	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg07001201	chr5:642380	CEP72	0.68	6.38	0.38	8.52e-10	Obesity-related traits;
KIRP	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg16898833	chr6:26189333	HIST1H4D	0.65	4.93	0.3	1.48e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	16.77	0.73	1.33e-42	Platelet count;
KIRP	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg27087555	chr16:88793112	FAM38A	-1.19	-7.17	-0.42	8.57e-12	Plateletcrit;
KIRP	cis	rs17121403	0.661	rs12131027	chr1:100511541	T/C	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg02002194	chr4:3960332	NA	-0.43	-6.37	-0.38	8.97e-10	Mood instability;
KIRP	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg13010199	chr12:38710504	ALG10B	-0.48	-5.74	-0.34	2.77e-8	Morning vs. evening chronotype;
KIRP	cis	rs7072216	0.770	rs7909131	chr10:100171471	A/G	cg26618903	chr10:100175079	PYROXD2	-0.34	-4.88	-0.3	1.88e-6	Metabolite levels;
KIRP	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.73	-9.58	-0.52	1.12e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.93e-11	Retinal vascular caliber;
KIRP	cis	rs290268	0.874	rs290991	chr9:93561450	A/C	cg02608019	chr9:93564028	SYK	-0.68	-9.41	-0.51	3.65e-18	Platelet count;
KIRP	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg18944383	chr4:111397179	ENPEP	0.6	11.05	0.58	2.65e-23	Height;
KIRP	cis	rs16830122	0.514	rs67849779	chr1:154611208	G/A	cg24304309	chr1:154577895	ADAR	-0.41	-4.98	-0.3	1.21e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs34734847	0.933	rs998727	chr12:121149064	T/G	cg21892295	chr12:121157589	UNC119B	-0.37	-5.22	-0.32	3.85e-7	Mean corpuscular volume;
KIRP	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-7.04	-0.41	1.89e-11	Daytime sleep phenotypes;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg06815112	chr8:27182871	PTK2B	0.51	6.66	0.39	1.82e-10	Neuroticism;
KIRP	cis	rs9398803	0.931	rs1361262	chr6:126701967	T/C	cg19875578	chr6:126661172	C6orf173	0.5	6.68	0.39	1.61e-10	Male-pattern baldness;
KIRP	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.85	-13.79	-0.66	1.91e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2997447	0.846	rs7520344	chr1:26397286	C/T	cg19633962	chr1:26362018	EXTL1	-0.62	-5.41	-0.33	1.49e-7	QRS complex (12-leadsum);
KIRP	cis	rs71636778	0.631	rs12735407	chr1:27198937	C/G	cg12203394	chr1:27248618	NUDC	0.74	5.79	0.35	2.11e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9815354	1.000	rs7372217	chr3:41990122	G/A	cg03022575	chr3:42003672	ULK4	-0.5	-5.66	-0.34	4.2e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.72	9.43	0.52	3.11e-18	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.61	-0.34	5.41e-8	Breast cancer;
KIRP	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg24110177	chr3:50126178	RBM5	0.64	8.08	0.46	3.01e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg13409248	chr3:40428643	ENTPD3	-0.36	-5.11	-0.31	6.55e-7	Renal cell carcinoma;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.67	9.42	0.51	3.48e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs752045	0.702	rs7007709	chr8:5950706	C/T	cg01837533	chr3:113753924	KIAA1407	0.55	6.13	0.36	3.55e-9	Hand grip strength;
KIRP	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.72	9.54	0.52	1.53e-18	Longevity;
KIRP	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.27	-0.37	1.6e-9	Waist circumference adjusted for body mass index;
KIRP	trans	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg19694781	chr19:47549865	TMEM160	-0.57	-7.46	-0.43	1.46e-12	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs981844	1.000	rs2579918	chr4:154652234	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.02	0.41	2.09e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.23e-8	Life satisfaction;
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.58	-6.76	-0.4	1e-10	Menopause (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12169512	chr17:36831178	C17orf96	-0.49	-6.02	-0.36	6.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg15117754	chr3:10150083	C3orf24	0.51	5.11	0.31	6.46e-7	Alzheimer's disease;
KIRP	trans	rs1937787	0.522	rs12070989	chr1:80841004	G/T	cg12297935	chr1:236902707	ACTN2	0.48	6.68	0.39	1.58e-10	Stroke;
KIRP	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.2	0.46	1.34e-14	Coffee consumption (cups per day);
KIRP	trans	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00950418	chr7:105029125	SRPK2	-0.53	-6.54	-0.38	3.6e-10	Height;
KIRP	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	trans	rs1620921	0.901	rs783182	chr6:161168548	G/A	cg01090089	chr7:6570974	GRID2IP	0.39	6.25	0.37	1.77e-9	Lipoprotein (a) - cholesterol levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01302669	chr3:49824110	IP6K1	0.53	6.15	0.37	3.1e-9	Smoking initiation;
KIRP	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.29	12.38	0.62	1.12e-27	Diabetic retinopathy;
KIRP	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg00262122	chr8:11665843	FDFT1	0.41	5.12	0.31	6.15e-7	Neuroticism;
KIRP	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00290607	chr11:67383545	NA	0.36	5.24	0.32	3.53e-7	Mean corpuscular volume;
KIRP	cis	rs965513	0.524	rs6478413	chr9:100582024	A/G	cg13688889	chr9:100608707	NA	-0.59	-7.17	-0.42	8.72e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.68	-7.91	-0.45	8.72e-14	Lung cancer;
KIRP	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17554472	chr22:41940697	POLR3H	-0.64	-6.74	-0.39	1.13e-10	Vitiligo;
KIRP	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg13798912	chr7:905769	UNC84A	0.57	5.78	0.35	2.22e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs1903068	0.962	rs17773813	chr4:56008969	G/A	cg01777861	chr4:56023843	NA	0.38	4.9	0.3	1.75e-6	Endometriosis;
KIRP	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21659725	chr3:3221576	CRBN	-0.61	-7.27	-0.42	4.77e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg06386533	chr2:46925753	SOCS5	0.46	4.91	0.3	1.7e-6	Height;
KIRP	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg00761755	chr17:1531579	SLC43A2	0.72	6.87	0.4	5.1e-11	Lung function (FEV1);
KIRP	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.97	-0.54	6.91e-20	Response to antipsychotic treatment;
KIRP	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg11995313	chr8:8860691	ERI1	0.37	4.93	0.3	1.51e-6	Joint mobility (Beighton score);
KIRP	cis	rs220519	0.693	rs220526	chr20:37277271	C/T	cg24308336	chr20:37270989	C20orf95	0.22	4.94	0.3	1.47e-6	Schizophrenia;
KIRP	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7520050	0.966	rs34102169	chr1:46424864	G/T	cg03146154	chr1:46216737	IPP	-0.42	-5.38	-0.32	1.72e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg08533674	chr1:46993347	NA	0.44	5.44	0.33	1.3e-7	Monobrow;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23715700	chr19:16188274	TPM4	0.48	6.34	0.37	1.08e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.31	0.62	1.86e-27	Platelet count;
KIRP	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.52	-7.31	-0.42	3.68e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg22676075	chr6:135203613	NA	0.49	6.96	0.41	3.14e-11	Red blood cell count;
KIRP	cis	rs1448094	0.967	rs2405789	chr12:86320466	C/T	cg00310523	chr12:86230176	RASSF9	-0.37	-5.71	-0.34	3.25e-8	Major depressive disorder;
KIRP	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.56	7.29	0.42	4.13e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.44	6.64	0.39	2.04e-10	Major depressive disorder;
KIRP	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg18944383	chr4:111397179	ENPEP	0.47	7.69	0.44	3.6e-13	Coronary artery disease;
KIRP	cis	rs2014572	0.967	rs4801452	chr19:57768066	A/G	cg12963866	chr19:57752005	ZNF805	-0.48	-5.98	-0.36	7.89e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.4	-0.33	1.54e-7	Metabolite levels;
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg18209359	chr17:80159595	CCDC57	-0.41	-5.44	-0.33	1.31e-7	Life satisfaction;
KIRP	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00495681	chr13:53174319	NA	0.45	6.32	0.37	1.19e-9	Lewy body disease;
KIRP	cis	rs830124	0.714	rs658957	chr12:122409664	T/C	cg21171335	chr12:122356390	WDR66	0.54	5.56	0.33	6.85e-8	Urinary metabolites;
KIRP	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg04607699	chr11:48328132	OR4S1	-0.4	-5.75	-0.34	2.62e-8	Migraine - clinic-based;
KIRP	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg11846333	chr4:119757529	SEC24D	0.84	5.2	0.31	4.29e-7	Cannabis dependence symptom count;
KIRP	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.95	-16.1	-0.72	2.48e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.47	7.45	0.43	1.54e-12	Major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13708727	chr12:7282928	CLSTN3;RBP5	0.46	6.13	0.36	3.5e-9	Parkinson's disease;
KIRP	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.43	-5.65	-0.34	4.34e-8	Abdominal aortic aneurysm;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg04369109	chr6:150039330	LATS1	-0.5	-6.39	-0.38	8.26e-10	Lung cancer;
KIRP	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.88	11.13	0.58	1.47e-23	Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08085093	chr17:80250923	NA	-0.47	-6.21	-0.37	2.24e-9	Metabolic traits;
KIRP	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg03235661	chr20:60525775	NA	0.34	4.88	0.3	1.93e-6	Obesity-related traits;
KIRP	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.65	-0.56	4.85e-22	Menopause (age at onset);
KIRP	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	5.99	0.36	7.52e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.71	10.05	0.54	3.99e-20	Mean corpuscular volume;
KIRP	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg19445457	chr11:5799446	OR52N5	-0.47	-5.36	-0.32	1.9e-7	DNA methylation (variation);
KIRP	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs7274811	0.711	rs184110	chr20:31981432	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.42	5.02	0.3	9.95e-7	Height;
KIRP	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.66	-8.6	-0.48	9.59e-16	Colorectal cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02815282	chr11:67141135	LOC100130987;CLCF1	0.99	6.77	0.4	9.49e-11	P wave terminal force;
KIRP	cis	rs2275565	0.872	rs10925250	chr1:237022130	A/G	cg17297354	chr1:237056641	MTR	-0.4	-5.13	-0.31	5.9e-7	Homocysteine levels;
KIRP	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	22.6	0.82	5.83e-62	Schizophrenia;
KIRP	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.63	-11.11	-0.58	1.6e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg24881330	chr22:46731750	TRMU	0.65	4.93	0.3	1.48e-6	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs4742903	0.509	rs10991163	chr9:106967120	T/C	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.21	-0.37	2.21e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs5746492	0.568	rs5747408	chr22:18397120	A/G	cg03078520	chr22:18463400	MICAL3	-0.43	-5.63	-0.34	4.93e-8	Eotaxin levels;
KIRP	cis	rs7809615	0.901	rs10235235	chr7:99075831	T/C	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite ratios;
KIRP	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg19507638	chr5:93509721	C5orf36	-0.6	-5.26	-0.32	3.06e-7	Diabetic retinopathy;
KIRP	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	1.07	20.17	0.79	4.53e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg15117754	chr3:10150083	C3orf24	0.51	5.11	0.31	6.46e-7	Alzheimer's disease;
KIRP	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.13	0.31	5.76e-7	Cognitive test performance;
KIRP	cis	rs67366981	0.800	rs55939042	chr14:77691186	T/A	cg22824376	chr14:77648248	TMEM63C	0.78	6.08	0.36	4.63e-9	Obsessive-compulsive symptoms;
KIRP	cis	rs4750440	0.733	rs2446585	chr10:14028086	C/T	cg27542038	chr10:14027202	FRMD4A	-0.49	-6.77	-0.4	9.43e-11	Adiponectin levels;
KIRP	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg27205649	chr11:78285834	NARS2	0.62	7.38	0.43	2.44e-12	Alzheimer's disease (survival time);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01753731	chr4:903032	GAK	-0.45	-6.91	-0.4	4.1e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4478037	0.822	rs9826234	chr3:33123832	A/C	cg19404215	chr3:33155277	CRTAP	0.57	5.46	0.33	1.15e-7	Major depressive disorder;
KIRP	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg06671706	chr8:8559999	CLDN23	0.52	6.13	0.36	3.4e-9	Obesity-related traits;
KIRP	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9473924	0.632	rs7764992	chr6:50853620	G/T	cg03432817	chr6:50765336	NA	0.35	5.41	0.33	1.52e-7	Body mass index;
KIRP	cis	rs10799590	1.000	rs1603917	chr1:224827532	C/G	cg01808320	chr1:224927238	CNIH3	0.33	4.86	0.3	2.13e-6	Opioid dependence;
KIRP	trans	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Bladder cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21772773	chr1:6880294	CAMTA1	0.42	6.65	0.39	1.92e-10	Interleukin-4 levels;
KIRP	cis	rs1712517	0.844	rs1163075	chr10:105021263	A/G	cg05636881	chr10:105038444	INA	-0.42	-6.37	-0.38	9.27e-10	Migraine;
KIRP	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.63	8.99	0.5	6.72e-17	Plateletcrit;Platelet count;
KIRP	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg27189623	chr16:705930	WDR90	0.45	6.14	0.36	3.33e-9	Height;
KIRP	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg26408565	chr15:76604113	ETFA	-0.43	-5.82	-0.35	1.82e-8	Blood metabolite levels;
KIRP	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	5.55	0.33	7.48e-8	Educational attainment;
KIRP	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg05340658	chr4:99064831	C4orf37	0.66	7.3	0.42	3.94e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2979489	0.891	rs4733495	chr8:30366883	A/G	cg26383811	chr8:30366931	RBPMS	0.49	7.67	0.44	4.02e-13	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg26207909	chr14:103986467	CKB	0.66	7.51	0.43	1.12e-12	Body mass index;
KIRP	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.78	8.99	0.5	6.55e-17	Post bronchodilator FEV1;
KIRP	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs1978968	0.912	rs12157484	chr22:18455122	C/T	cg03078520	chr22:18463400	MICAL3	-0.67	-7.72	-0.44	3e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs1656402	0.954	rs11676436	chr2:233453063	A/G	cg03852847	chr2:233439513	NA	-0.7	-10.3	-0.55	6.31e-21	Non-small cell lung cancer (survival);
KIRP	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg24585782	chr17:78113791	EIF4A3	-0.53	-6.27	-0.37	1.59e-9	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg21100191	chr22:23484243	RTDR1	0.79	11.06	0.58	2.38e-23	Bone mineral density;
KIRP	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.69	-8.53	-0.48	1.56e-15	Schizophrenia;
KIRP	cis	rs193541	0.632	rs34486978	chr5:122312543	G/A	cg19412675	chr5:122181750	SNX24	-0.6	-6.38	-0.38	8.51e-10	Glucose homeostasis traits;
KIRP	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-10.59	-0.56	7.53e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4262150	0.883	rs72802890	chr5:152255145	G/T	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.98e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.43	0.38	6.62e-10	Electroencephalogram traits;
KIRP	cis	rs2625529	0.652	rs2930069	chr15:72226977	G/A	cg16672083	chr15:72433130	SENP8	0.42	6.02	0.36	6.32e-9	Red blood cell count;
KIRP	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg08719095	chr7:1135190	C7orf50	-0.42	-5.02	-0.3	9.85e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs4478858	0.611	rs10914338	chr1:31733782	T/A	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09554701	chr1:180323123	ACBD6	-0.41	-6.89	-0.4	4.53e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg04731861	chr2:219085781	ARPC2	0.3	7.56	0.43	7.99e-13	Colorectal cancer;
KIRP	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22168489	chr12:122356033	WDR66	-0.55	-7.19	-0.42	7.85e-12	Mean corpuscular volume;
KIRP	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.47	-0.43	1.41e-12	Triglycerides;
KIRP	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.4	-5.34	-0.32	2.17e-7	Menarche (age at onset);
KIRP	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.42	5.07	0.31	7.81e-7	HDL cholesterol;
KIRP	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.03	0.31	9.47e-7	Educational attainment;
KIRP	cis	rs4740619	0.587	rs4740632	chr9:16030208	T/G	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	trans	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg00938859	chr5:1591904	SDHAP3	0.54	7.34	0.42	3.1e-12	Breast cancer;
KIRP	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.27	0.37	1.63e-9	Ovarian reserve;
KIRP	cis	rs4595586	0.566	rs7307174	chr12:39368862	A/G	cg26384229	chr12:38710491	ALG10B	0.56	7.22	0.42	6.59e-12	Morning vs. evening chronotype;
KIRP	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.54	7.32	0.42	3.49e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg00677455	chr12:58241039	CTDSP2	0.91	9.41	0.51	3.68e-18	Multiple sclerosis;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16800028	chr3:159943315	LOC401097	0.37	4.95	0.3	1.4e-6	Parkinson's disease;
KIRP	cis	rs520865	0.748	rs508526	chr5:80343852	C/A	cg17330048	chr5:80257322	RASGRF2	-0.46	-6.7	-0.39	1.41e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg04662943	chr10:102668895	NA	0.44	4.87	0.3	1.98e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7481584	0.962	rs11024759	chr11:2982092	T/C	cg25174290	chr11:3078921	CARS	-0.59	-6.54	-0.38	3.5e-10	Calcium levels;
KIRP	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg07395648	chr5:131743802	NA	-0.52	-7.44	-0.43	1.73e-12	Breast cancer;
KIRP	cis	rs11583043	0.708	rs10493942	chr1:101545482	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	5.4	0.33	1.59e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg21573476	chr21:45109991	RRP1B	-0.62	-8.44	-0.47	2.72e-15	Mean corpuscular volume;
KIRP	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-5.22	-0.32	3.74e-7	Tonsillectomy;
KIRP	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs5743618	0.537	rs10020220	chr4:38765867	A/G	cg06935464	chr4:38784597	TLR10	0.4	4.96	0.3	1.34e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.47	7.43	0.43	1.8e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs78487399	0.710	rs28470852	chr2:43593000	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.15	-0.31	5.35e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg26965718	chr17:79658957	HGS	-0.61	-5.92	-0.35	1.09e-8	Dental caries;
KIRP	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.98	14.54	0.68	5.43e-35	Heart rate;
KIRP	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg19731401	chr7:2775893	GNA12	0.82	7.74	0.44	2.59e-13	Childhood ear infection;
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg27106230	chr13:99229068	STK24	-0.56	-6.02	-0.36	6.14e-9	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs7116495	1.000	rs73543633	chr11:71828844	T/C	cg26138937	chr11:71823887	C11orf51	0.7	5.53	0.33	8.01e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.32e-15	Life satisfaction;
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-8.38	-0.47	4.03e-15	Obesity-related traits;
KIRP	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg13010199	chr12:38710504	ALG10B	0.68	8.82	0.49	2.21e-16	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07402800	chr8:145582003	FBXL6;GPR172A	-0.49	-6.47	-0.38	5.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-4.88	-0.3	1.89e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7534824	0.543	rs12569174	chr1:101386179	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	8.08	0.46	2.93e-14	Refractive astigmatism;
KIRP	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-1.04	-12.95	-0.64	1.33e-29	Exhaled nitric oxide output;
KIRP	cis	rs4959799	0.557	rs61246041	chr6:3274406	G/T	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.26	-0.32	3.11e-7	Survival in rectal cancer;
KIRP	cis	rs12580194	0.593	rs7959124	chr12:55726957	A/G	cg11794356	chr12:55725991	OR6C3	-0.54	-7.13	-0.41	1.11e-11	Cancer;
KIRP	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	0.97	14.25	0.67	5.31e-34	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg02297831	chr4:17616191	MED28	0.52	6.45	0.38	5.74e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.86	-10.81	-0.57	1.55e-22	Dupuytren's disease;
KIRP	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg07378217	chr19:58662286	ZNF329	-0.6	-5.63	-0.34	5.02e-8	Cholesterol, total;
KIRP	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg08076091	chr2:203926405	NBEAL1	0.85	8.61	0.48	8.8e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg26566898	chr11:117069891	TAGLN	0.4	5.0	0.3	1.07e-6	Blood protein levels;
KIRP	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.35	-0.32	1.98e-7	Schizophrenia;
KIRP	cis	rs75920871	0.925	rs61903421	chr11:116961802	A/T	cg23684410	chr11:116897558	SIK3	0.52	5.21	0.32	3.94e-7	Subjective well-being;
KIRP	trans	rs7728043	0.609	rs1174918	chr5:5906110	G/A	cg14539658	chr14:21495146	NDRG2	0.38	6.02	0.36	6.45e-9	QT interval;
KIRP	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	7.41	0.43	2.05e-12	Obesity-related traits;
KIRP	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	1.02	12.48	0.62	5.26e-28	Post bronchodilator FEV1;
KIRP	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-12.07	-0.61	1.15e-26	Headache;
KIRP	trans	rs2531992	0.800	rs2601782	chr16:4021051	T/C	cg09155362	chr15:33487289	NA	-0.56	-6.86	-0.4	5.66e-11	Waist circumference;
KIRP	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.54	-0.48	1.42e-15	Common traits (Other);
KIRP	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.5	5.92	0.35	1.05e-8	Uric acid levels;
KIRP	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg10755058	chr3:40428713	ENTPD3	0.48	6.6	0.39	2.56e-10	Renal cell carcinoma;
KIRP	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.05	-0.36	5.25e-9	Morning vs. evening chronotype;
KIRP	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg23791538	chr6:167370224	RNASET2	-0.48	-5.74	-0.34	2.84e-8	Crohn's disease;
KIRP	cis	rs2411233	1.000	rs11856921	chr15:39278107	A/C	cg05886626	chr15:39873553	THBS1	-0.32	-4.91	-0.3	1.64e-6	Platelet count;
KIRP	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs926392	0.666	rs912179	chr20:37710775	G/A	cg16355469	chr20:37678765	NA	0.5	5.91	0.35	1.12e-8	Dialysis-related mortality;
KIRP	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg06671706	chr8:8559999	CLDN23	0.57	6.57	0.39	2.96e-10	Obesity-related traits;
KIRP	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg24375607	chr4:120327624	NA	0.67	7.88	0.45	1.06e-13	Corneal astigmatism;
KIRP	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.81	10.04	0.54	4.33e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.08	-0.36	4.5e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg05784532	chr1:230284198	GALNT2	0.43	6.43	0.38	6.51e-10	Coronary artery disease;
KIRP	cis	rs4268898	0.552	rs12621083	chr2:24367540	C/T	cg06627628	chr2:24431161	ITSN2	0.46	5.6	0.34	5.69e-8	Asthma;
KIRP	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.55	-6.71	-0.39	1.34e-10	Metabolite levels;
KIRP	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg21605333	chr4:119757512	SEC24D	1.65	11.87	0.6	5.44e-26	Cannabis dependence symptom count;
KIRP	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Hypertriglyceridemia;
KIRP	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.74	-0.34	2.74e-8	Breast cancer;
KIRP	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.92	0.49	1.09e-16	Menopause (age at onset);
KIRP	cis	rs9815354	0.953	rs11717170	chr3:42002811	G/C	cg03022575	chr3:42003672	ULK4	-0.49	-5.53	-0.33	8.01e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05288071	chr19:7712539	STXBP2	-0.46	-6.29	-0.37	1.47e-9	Parkinson's disease;
KIRP	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.41	5.11	0.31	6.37e-7	Lung cancer;
KIRP	cis	rs9513627	0.665	rs79036236	chr13:100116405	C/T	cg25919922	chr13:100150906	NA	-0.72	-5.71	-0.34	3.19e-8	Obesity-related traits;
KIRP	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.63e-9	Dilated cardiomyopathy;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04396125	chr19:7580857	ZNF358	-0.46	-6.19	-0.37	2.55e-9	Metabolic traits;
KIRP	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08508325	chr11:3079039	CARS	0.33	6.13	0.36	3.38e-9	Calcium levels;
KIRP	cis	rs9488822	0.662	rs580396	chr6:116263181	T/C	cg05304507	chr6:116381966	FRK	-0.2	-5.38	-0.32	1.75e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.68	-6.71	-0.39	1.32e-10	Asthma;
KIRP	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg25600027	chr14:23388339	RBM23	-0.47	-5.8	-0.35	2.07e-8	Cognitive ability (multi-trait analysis);
KIRP	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.29	-6.22	-0.37	2.1e-9	Asthma (sex interaction);
KIRP	cis	rs11209185	0.509	rs9436356	chr1:68447202	A/G	cg22082780	chr1:68452167	NA	0.38	5.5	0.33	9.36e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg03188948	chr7:1209495	NA	0.49	5.64	0.34	4.7e-8	Longevity;Endometriosis;
KIRP	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.54	7.06	0.41	1.65e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4664304	0.649	rs12692570	chr2:160726599	C/T	cg03641300	chr2:160917029	PLA2R1	0.37	5.74	0.34	2.78e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg24579218	chr15:68104479	NA	-0.44	-7.16	-0.42	9.33e-12	Restless legs syndrome;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07700062	chr1:236767390	HEATR1	-0.49	-6.78	-0.4	8.71e-11	Migraine with aura;
KIRP	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.51	6.99	0.41	2.59e-11	Coronary artery disease;
KIRP	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg02002194	chr4:3960332	NA	-0.45	-6.37	-0.38	9.43e-10	Neuroticism;
KIRP	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.43	5.66	0.34	4.19e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.21	0.37	2.27e-9	Menarche (age at onset);
KIRP	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15556689	chr8:8085844	FLJ10661	0.84	11.58	0.59	4.78e-25	Neuroticism;
KIRP	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.42	5.28	0.32	2.82e-7	Aortic root size;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg26401236	chr17:19881329	AKAP10	-0.53	-6.8	-0.4	7.94e-11	Neuroticism;
KIRP	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.74	10.16	0.54	1.77e-20	Height;
KIRP	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-9.03	-0.5	5.2e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.65	-0.48	6.98e-16	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs365132	0.517	rs6881002	chr5:176336755	T/C	cg16309518	chr5:176445507	NA	0.69	8.35	0.47	4.96e-15	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.4	-5.01	-0.3	1.04e-6	Aortic root size;
KIRP	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg26248373	chr2:1572462	NA	-0.64	-6.16	-0.37	2.97e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.95	9.48	0.52	2.33e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg20701182	chr2:24300061	SF3B14	0.48	5.04	0.31	9.07e-7	Asthma;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.57	-5.18	-0.31	4.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11225247	0.881	rs12274405	chr11:102259295	C/T	cg06323957	chr11:102217781	BIRC2	0.91	5.76	0.34	2.55e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-0.99	-10.48	-0.56	1.79e-21	Mitochondrial DNA levels;
KIRP	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.62	-0.52	8.4e-19	Hemoglobin concentration;
KIRP	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-7.08	-0.41	1.49e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.79	-8.23	-0.46	1.08e-14	Body mass index;
KIRP	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-4.97	-0.3	1.26e-6	Chronic sinus infection;
KIRP	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg23950597	chr19:37808831	NA	-0.64	-6.77	-0.4	9.6e-11	Coronary artery calcification;
KIRP	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg05507819	chr15:63340323	TPM1	0.51	6.33	0.37	1.15e-9	Platelet count;
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07402062	chr16:89894098	SPIRE2	-0.31	-6.4	-0.38	8e-10	Vitiligo;
KIRP	cis	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg07585502	chr8:101912084	NA	-0.63	-8.98	-0.5	7.14e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.67	9.17	0.5	1.94e-17	Colorectal cancer;
KIRP	cis	rs4787491	0.704	rs66467443	chr16:30050494	G/A	cg06326092	chr16:30034487	C16orf92	0.51	7.67	0.44	4.11e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg12042659	chr19:58951599	ZNF132	0.51	6.25	0.37	1.83e-9	Uric acid clearance;
KIRP	cis	rs876084	0.722	rs6469893	chr8:121045000	T/C	cg22335954	chr8:121166405	COL14A1	-0.4	-4.88	-0.3	1.89e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg02023728	chr11:77925099	USP35	0.43	6.98	0.41	2.78e-11	Testicular germ cell tumor;
KIRP	cis	rs6001982	0.584	rs73167034	chr22:40826534	T/C	cg07138101	chr22:40742427	ADSL	0.72	5.15	0.31	5.42e-7	Breast cancer;
KIRP	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.35	-5.31	-0.32	2.43e-7	Headache;
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.42	-0.33	1.44e-7	Life satisfaction;
KIRP	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg01872077	chr2:219646372	CYP27A1	-0.38	-4.85	-0.3	2.22e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg06917634	chr15:78832804	PSMA4	0.47	4.9	0.3	1.78e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg13147721	chr7:65941812	NA	-1.01	-6.86	-0.4	5.43e-11	Diabetic kidney disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03157633	chr12:13154475	HTR7P;HEBP1	0.5	6.74	0.39	1.1e-10	Myopia (pathological);
KIRP	cis	rs6700559	0.740	rs4072551	chr1:200649121	A/G	cg07804481	chr1:200639085	DDX59	0.5	6.6	0.39	2.52e-10	Coronary artery disease;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg00933542	chr6:150070202	PCMT1	-0.26	-5.03	-0.31	9.67e-7	Lung cancer;
KIRP	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg24565620	chr2:194026	NA	0.77	8.64	0.48	7.06e-16	Blood protein levels;
KIRP	cis	rs7124676	0.966	rs34812986	chr11:64314634	G/A	cg09127371	chr11:64313507	NA	0.36	4.94	0.3	1.46e-6	Obesity-related traits;
KIRP	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg03808351	chr9:123631620	PHF19	0.45	6.34	0.37	1.08e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs10518128	1.000	rs7692669	chr4:75712905	T/C	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg04727924	chr7:799746	HEATR2	-0.78	-8.78	-0.49	2.81e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg03808351	chr9:123631620	PHF19	0.45	6.34	0.37	1.08e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg05868516	chr6:26286170	HIST1H4H	0.4	5.32	0.32	2.36e-7	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25701418	chr3:66024556	MAGI1	0.51	6.21	0.37	2.28e-9	Parkinson's disease;
KIRP	cis	rs5995756	0.543	rs136811	chr22:40021256	T/A	cg10455938	chr22:40058150	CACNA1I	0.68	10.83	0.57	1.35e-22	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7923609	0.905	rs7088799	chr10:65016174	T/G	cg01631684	chr10:65280961	REEP3	-0.47	-5.44	-0.33	1.27e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.34	-0.51	6.14e-18	Gut microbiome composition (summer);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24081819	chr8:27348940	EPHX2	0.46	6.04	0.36	5.52e-9	Smoking initiation;
KIRP	cis	rs10129255	0.500	rs988134	chr14:107184937	A/G	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg17425144	chr1:10567563	PEX14	0.41	6.93	0.4	3.78e-11	Hand grip strength;
KIRP	trans	rs13170463	0.579	rs71606013	chr5:8045279	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg07796016	chr1:152779584	LCE1C	-0.45	-5.73	-0.34	2.87e-8	Inflammatory skin disease;
KIRP	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-6.03	-0.36	6.04e-9	Vitiligo;
KIRP	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg25922239	chr6:33757077	LEMD2	0.48	5.7	0.34	3.36e-8	Crohn's disease;
KIRP	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06307176	chr5:131281290	NA	-0.54	-5.9	-0.35	1.23e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.11	-0.46	2.39e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg16989719	chr2:238392110	NA	-0.68	-6.85	-0.4	5.94e-11	Prostate cancer;
KIRP	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.42	6.59	0.39	2.6e-10	Inflammatory bowel disease;
KIRP	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg01620082	chr3:125678407	NA	-1.15	-7.44	-0.43	1.65e-12	Depression;
KIRP	cis	rs7552404	0.731	rs12078299	chr1:76365764	T/A	cg03433033	chr1:76189801	ACADM	0.76	10.98	0.57	4.33e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg24253500	chr15:84953950	NA	0.6	6.32	0.37	1.25e-9	Schizophrenia;
KIRP	cis	rs9831754	0.704	rs9823412	chr3:78457646	T/C	cg06138941	chr3:78371609	NA	-0.8	-10.93	-0.57	6.09e-23	Calcium levels;
KIRP	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26207909	chr14:103986467	CKB	0.8	12.48	0.62	5.12e-28	Body mass index;
KIRP	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg12218747	chr21:37451666	NA	-0.41	-5.02	-0.3	1e-6	Mitral valve prolapse;
KIRP	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg01721255	chr8:58191610	C8orf71	0.69	5.64	0.34	4.7e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9584850	0.540	rs61969457	chr13:99176742	C/T	cg20750642	chr13:99100586	FARP1	-0.55	-5.5	-0.33	9.51e-8	Neuroticism;
KIRP	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg06935464	chr4:38784597	TLR10	0.54	5.42	0.33	1.42e-7	Breast cancer;
KIRP	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.85	12.56	0.63	2.72e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg16524733	chr11:117070046	TAGLN	0.38	4.95	0.3	1.35e-6	Blood protein levels;
KIRP	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg12362517	chr11:133800685	IGSF9B	-0.44	-5.02	-0.3	1.01e-6	Parkinson's disease;
KIRP	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.8	9.81	0.53	2.2e-19	Menarche (age at onset);
KIRP	cis	rs11731606	0.508	rs28501313	chr4:95281023	G/A	cg00507259	chr4:95128692	SMARCAD1	0.66	5.93	0.35	1.04e-8	Mean platelet volume;
KIRP	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.5	8.43	0.47	3.01e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg03468072	chr12:39539422	NA	0.41	5.96	0.36	8.47e-9	Morning vs. evening chronotype;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg17978844	chr19:40854664	PLD3;C19orf47	0.46	6.09	0.36	4.3e-9	Neuroticism;
KIRP	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.18	0.37	2.67e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg25019033	chr10:957182	NA	-0.61	-6.75	-0.4	1.04e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg01631408	chr1:248437212	OR2T33	-0.67	-8.98	-0.5	7.24e-17	Common traits (Other);
KIRP	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg19507638	chr5:93509721	C5orf36	-0.61	-5.27	-0.32	2.94e-7	Diabetic retinopathy;
KIRP	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.62	-0.56	6.31e-22	Gut microbiome composition (summer);
KIRP	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.66	0.39	1.81e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.72	-7.66	-0.44	4.21e-13	Vitiligo;
KIRP	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.35	0.42	2.91e-12	Height;
KIRP	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg08822215	chr16:89438651	ANKRD11	-0.53	-7.07	-0.41	1.55e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg02475777	chr4:1388615	CRIPAK	0.55	5.13	0.31	5.97e-7	Recombination rate (females);
KIRP	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-11.46	-0.59	1.18e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg05347473	chr6:146136440	FBXO30	-0.58	-8.38	-0.47	4.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1440410	0.897	rs9999826	chr4:144036457	A/G	cg01719995	chr4:144104893	USP38	0.47	6.24	0.37	1.86e-9	Ischemic stroke;
KIRP	cis	rs42648	0.564	rs6956980	chr7:89803634	T/C	cg25739043	chr7:89950458	NA	-0.39	-6.04	-0.36	5.57e-9	Homocysteine levels;
KIRP	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.6	-8.14	-0.46	1.98e-14	Homocysteine levels;
KIRP	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg25486957	chr4:152246857	NA	-0.52	-5.74	-0.34	2.84e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	trans	rs7999699	0.902	rs12429282	chr13:48320455	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.33	0.37	1.15e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.52	-0.52	1.72e-18	Gut microbiome composition (summer);
KIRP	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg27147174	chr7:100797783	AP1S1	-0.68	-8.66	-0.48	6.37e-16	Life satisfaction;
KIRP	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.09	18.46	0.76	2.43e-48	Cortisol levels (saliva);
KIRP	cis	rs8054556	1.000	rs4787486	chr16:29977562	A/T	cg06326092	chr16:30034487	C16orf92	0.35	4.97	0.3	1.24e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.95	-16.45	-0.72	1.59e-41	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-8.27	-0.47	8.41e-15	Triglycerides;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	9.62	0.52	8.53e-19	Renal function-related traits (BUN);
KIRP	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg17376030	chr22:41985996	PMM1	0.82	8.82	0.49	2.2e-16	Vitiligo;
KIRP	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.61	-7.98	-0.45	5.56e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6968419	0.755	rs2896180	chr7:115897871	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.05	-0.36	5.26e-9	Intraocular pressure;
KIRP	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg25418670	chr11:30344373	C11orf46	0.61	5.21	0.32	4.08e-7	Morning vs. evening chronotype;
KIRP	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	1.06	13.69	0.66	4.2e-32	Post bronchodilator FEV1;
KIRP	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg11693508	chr17:37793320	STARD3	-0.71	-7.38	-0.43	2.43e-12	Bipolar disorder;
KIRP	cis	rs6750047	0.585	rs4670808	chr2:38267794	A/G	cg07380506	chr2:38303506	CYP1B1	0.43	5.64	0.34	4.63e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.75	-0.4	1.05e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg16497661	chr14:103986332	CKB	0.84	14.31	0.67	3.24e-34	Body mass index;
KIRP	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	6.19	0.37	2.44e-9	Bipolar disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21517261	chr7:38217791	STARD3NL	0.59	7.01	0.41	2.27e-11	Smoking initiation;
KIRP	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.7	8.82	0.49	2.19e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.49	7.78	0.44	1.98e-13	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-6.68	-0.39	1.59e-10	Vitiligo;
KIRP	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.22e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.77	12.51	0.62	3.93e-28	Vitiligo;
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-12.8	-0.63	4.48e-29	Alzheimer's disease;
KIRP	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.09	0.41	1.4e-11	Bipolar disorder;
KIRP	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs6968419	0.755	rs73452247	chr7:115893897	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.82	-0.35	1.83e-8	Intraocular pressure;
KIRP	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg06289844	chr6:126071538	HEY2	0.44	6.51	0.38	4.2e-10	Brugada syndrome;
KIRP	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.55	7.54	0.43	9.01e-13	Colorectal cancer;
KIRP	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg02931644	chr1:25747376	RHCE	-0.36	-6.47	-0.38	5.2e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.64	0.39	1.96e-10	Colorectal cancer;
KIRP	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg25418670	chr11:30344373	C11orf46	0.59	4.97	0.3	1.27e-6	Morning vs. evening chronotype;
KIRP	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.85	0.4	6.01e-11	Blood metabolite levels;
KIRP	cis	rs74181299	0.684	rs6713746	chr2:65324492	G/C	cg05010058	chr2:65284262	CEP68	-0.43	-5.89	-0.35	1.26e-8	Pulse pressure;
KIRP	cis	rs7615316	1.000	rs1916639	chr3:142346764	T/C	cg20824294	chr3:142316082	PLS1	0.25	5.41	0.33	1.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg17376030	chr22:41985996	PMM1	0.61	6.57	0.39	2.92e-10	Vitiligo;
KIRP	cis	rs514024	0.801	rs2988580	chr9:130482966	C/G	cg13643465	chr9:130375613	STXBP1	0.46	5.93	0.35	1.02e-8	Eating disorders (purging via substances);
KIRP	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg00745463	chr17:30367425	LRRC37B	-1.14	-8.67	-0.48	5.84e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs13315871	0.929	rs13097873	chr3:58267924	C/T	cg12435725	chr3:58293450	RPP14	-0.42	-4.96	-0.3	1.31e-6	Cholesterol, total;
KIRP	cis	rs1497828	0.956	rs2810784	chr1:217546406	A/T	cg04411442	chr1:217543379	NA	0.31	5.02	0.3	1e-6	Dialysis-related mortality;
KIRP	cis	rs72843166	0.562	rs17687691	chr17:61481494	C/T	cg19683800	chr17:61518354	CYB561	-0.44	-5.3	-0.32	2.56e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3736485	0.966	rs11070860	chr15:51892654	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.19	-0.31	4.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.75	-10.39	-0.55	3.28e-21	Hypospadias;
KIRP	cis	rs7520050	0.966	rs4376778	chr1:46288846	C/G	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.11	0.41	1.25e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35000415	0.745	rs117944677	chr7:128698185	A/T	cg19972273	chr7:128594194	NA	0.81	6.17	0.37	2.82e-9	Systemic lupus erythematosus;
KIRP	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg14784868	chr12:69753453	YEATS4	0.51	5.22	0.32	3.82e-7	Response to diuretic therapy;
KIRP	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg14343924	chr8:8086146	FLJ10661	0.53	6.31	0.37	1.3e-9	Neuroticism;
KIRP	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg27624424	chr6:160112604	SOD2	0.52	5.83	0.35	1.7e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.89	15.8	0.71	2.68e-39	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg06289844	chr6:126071538	HEY2	0.41	6.09	0.36	4.41e-9	Brugada syndrome;
KIRP	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs6782228	0.606	rs10048945	chr3:128409680	C/T	cg18648031	chr3:128330563	NA	0.25	5.03	0.31	9.28e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg26784012	chr10:32216390	ARHGAP12	0.31	4.98	0.3	1.19e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs41264869	0.657	rs11811115	chr1:205134090	A/G	cg21214746	chr1:205091277	RBBP5	0.52	6.78	0.4	8.83e-11	Blood protein levels;
KIRP	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.55	0.43	8.31e-13	White blood cell count;
KIRP	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.53	-0.33	8.13e-8	Aortic root size;
KIRP	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.41	-0.59	1.76e-24	Monocyte count;
KIRP	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06850241	chr22:41845214	NA	0.42	4.86	0.3	2.13e-6	Vitiligo;
KIRP	cis	rs244731	0.881	rs62397242	chr5:176738538	C/A	cg17509989	chr5:176798049	RGS14	0.71	7.43	0.43	1.83e-12	Urate levels in lean individuals;
KIRP	trans	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg10756647	chr7:56101905	PSPH	0.97	7.18	0.42	8.18e-12	Diabetic kidney disease;
KIRP	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg16574807	chr4:6945745	TBC1D14	0.67	5.98	0.36	7.91e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12282928	0.959	rs11500497	chr11:48304461	A/T	cg26585981	chr11:48327164	OR4S1	0.51	6.24	0.37	1.9e-9	Migraine - clinic-based;
KIRP	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.93	13.18	0.64	2.33e-30	Cognitive function;
KIRP	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg00977110	chr5:151150581	G3BP1	-0.6	-6.01	-0.36	6.81e-9	Preschool internalizing problems;
KIRP	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg24375607	chr4:120327624	NA	0.59	6.85	0.4	5.84e-11	Corneal astigmatism;
KIRP	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg05220968	chr6:146057943	EPM2A	-0.43	-5.37	-0.32	1.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6782228	0.606	rs2253144	chr3:128329920	C/T	cg18648031	chr3:128330563	NA	-0.27	-5.52	-0.33	8.74e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.74	0.44	2.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs6545883	0.524	rs17482440	chr2:61548857	C/T	cg15711740	chr2:61764176	XPO1	0.45	5.49	0.33	1.02e-7	Tuberculosis;
KIRP	cis	rs10029851	0.645	rs893036	chr4:109623350	A/G	cg16525761	chr4:109541525	LOC285456;RPL34	0.48	5.45	0.33	1.2e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.3	-0.72	5.51e-41	Height;
KIRP	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg24060327	chr5:131705240	SLC22A5	-0.56	-6.97	-0.41	2.92e-11	Acylcarnitine levels;
KIRP	cis	rs7828089	0.624	rs7001171	chr8:22270040	T/G	cg12081754	chr8:22256438	SLC39A14	0.44	5.4	0.33	1.55e-7	Verbal declarative memory;
KIRP	trans	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg19223106	chr19:58898630	RPS5	-0.44	-6.53	-0.38	3.83e-10	Breast cancer;
KIRP	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	6.11	0.36	3.81e-9	Height;
KIRP	cis	rs10203711	1.000	rs4331454	chr2:239594474	G/A	cg14580085	chr2:239553406	NA	0.39	5.16	0.31	5.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs3784262	0.692	rs12907125	chr15:58282621	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.85	-0.3	2.15e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.96	12.57	0.63	2.6e-28	Breast cancer;
KIRP	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.21e-12	Morning vs. evening chronotype;
KIRP	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-9.12	-0.5	2.7e-17	Platelet count;
KIRP	trans	rs1422110	0.513	rs1363264	chr5:85450380	G/C	cg01787110	chr1:109008453	NBPF6	0.54	7.17	0.42	8.77e-12	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs10924970	0.781	rs10802589	chr1:235444049	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg02820040	chr2:241836501	C2orf54	-0.24	-5.4	-0.33	1.55e-7	Urinary metabolites;
KIRP	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01973587	chr1:228161476	NA	-0.39	-4.88	-0.3	1.89e-6	Diastolic blood pressure;
KIRP	cis	rs1014246	0.826	rs7921785	chr10:118470658	G/C	cg14919929	chr10:118506882	NA	-0.57	-7.44	-0.43	1.64e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.38	5.04	0.31	8.93e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg13147721	chr7:65941812	NA	-1.01	-7.0	-0.41	2.46e-11	Diabetic kidney disease;
KIRP	cis	rs8177876	0.749	rs79834398	chr16:81090638	G/A	cg08591886	chr16:81111003	C16orf46	-0.65	-5.18	-0.31	4.54e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.4	-0.62	9.69e-28	Glomerular filtration rate (creatinine);
KIRP	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.51	-5.48	-0.33	1.06e-7	Adiposity;
KIRP	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg13271783	chr10:134563150	INPP5A	-0.52	-6.64	-0.39	1.99e-10	Migraine;
KIRP	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	10.9	0.57	8.01e-23	Lung cancer in ever smokers;
KIRP	cis	rs11874712	0.966	rs9962380	chr18:43678706	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.38	-5.2	-0.31	4.18e-7	Migraine - clinic-based;
KIRP	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-6.39	-0.38	8.46e-10	Bipolar disorder;
KIRP	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg24375607	chr4:120327624	NA	0.41	4.91	0.3	1.68e-6	Diastolic blood pressure;
KIRP	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg19637330	chr1:19110922	NA	-0.49	-5.33	-0.32	2.24e-7	Drug-induced liver injury (nitrofurantoin);
KIRP	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs6700896	0.931	rs4655582	chr1:66153363	C/G	cg04111102	chr1:66153794	NA	0.34	5.05	0.31	8.53e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg25482853	chr8:67687455	SGK3	0.81	6.98	0.41	2.68e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.08	0.58	2.11e-23	Primary sclerosing cholangitis;
KIRP	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg00405596	chr8:11794950	NA	-0.49	-6.32	-0.37	1.25e-9	Neuroticism;
KIRP	cis	rs526231	0.697	rs253754	chr5:102631962	T/C	cg23492399	chr5:102201601	PAM	-0.48	-4.93	-0.3	1.52e-6	Primary biliary cholangitis;
KIRP	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	1.05	23.77	0.83	1.12e-65	Multiple myeloma;
KIRP	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.4	5.21	0.32	3.92e-7	Melanoma;
KIRP	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.29	0.37	1.42e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.79	11.17	0.58	1.09e-23	Neuroticism;
KIRP	cis	rs6921919	0.583	rs35599905	chr6:28379663	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-9.37	-0.51	4.96e-18	Coffee consumption (cups per day);
KIRP	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.58	7.99	0.45	5.3e-14	Total body bone mineral density;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg19536664	chr17:6899085	ALOX12	0.46	6.9	0.4	4.39e-11	Tonsillectomy;
KIRP	cis	rs6594499	0.872	rs10055177	chr5:110450584	T/G	cg04022379	chr5:110408740	TSLP	0.49	7.37	0.43	2.53e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.51	7.33	0.42	3.37e-12	Blood protein levels;
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-4.97	-0.3	1.25e-6	Caffeine consumption;
KIRP	cis	rs7712401	0.541	rs6867714	chr5:122382059	T/G	cg19412675	chr5:122181750	SNX24	0.54	5.87	0.35	1.44e-8	Mean platelet volume;
KIRP	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-0.79	-11.12	-0.58	1.48e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg00310523	chr12:86230176	RASSF9	0.47	7.59	0.44	6.6e-13	Major depressive disorder;
KIRP	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.49	6.32	0.37	1.23e-9	Blood metabolite levels;
KIRP	trans	rs2997105	1.000	rs4559812	chr13:56349266	C/G	cg08528735	chr3:184428879	MAGEF1	0.56	6.15	0.37	3.13e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.56	-7.45	-0.43	1.57e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs72843166	0.562	rs72841389	chr17:61437939	A/G	cg19683800	chr17:61518354	CYB561	-0.42	-5.08	-0.31	7.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs56079296	1.000	rs56079296	chr5:121276797	A/G	cg05256605	chr5:121412184	LOX	0.53	5.72	0.34	3.05e-8	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.67	8.67	0.48	5.79e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2882667	0.964	rs12719517	chr5:138305502	C/T	cg04439458	chr5:138467593	SIL1	-0.5	-7.61	-0.44	5.92e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2880765	0.546	rs11637726	chr15:86059271	C/T	cg15340431	chr15:86040528	AKAP13	0.46	5.56	0.33	6.84e-8	Coronary artery disease;
KIRP	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.33	-11.83	-0.6	7.39e-26	Diabetic retinopathy;
KIRP	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-4.85	-0.3	2.22e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05378295	chr18:19284987	ABHD3	0.48	6.39	0.38	8.2e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.4	-5.68	-0.34	3.8e-8	Mean corpuscular volume;
KIRP	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg15083037	chr5:83017644	HAPLN1	0.57	8.76	0.49	3.28e-16	Prostate cancer;
KIRP	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.79	0.4	8.26e-11	Mean corpuscular volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09504196	chr7:148823235	ZNF425;ZNF398	0.58	6.99	0.41	2.51e-11	Smoking initiation;
KIRP	cis	rs2131877	0.913	rs12634646	chr3:194842911	A/G	cg16306870	chr3:194868790	C3orf21	0.24	5.05	0.31	8.5e-7	Non-small cell lung cancer;
KIRP	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	14.56	0.68	4.64e-35	Platelet count;
KIRP	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.63	9.62	0.52	8.47e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg26681399	chr22:41777847	TEF	0.5	5.02	0.3	1.01e-6	Vitiligo;
KIRP	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.75	7.54	0.43	9.29e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.53	7.05	0.41	1.84e-11	Breast cancer;
KIRP	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg08461772	chr7:95026248	PON3	0.41	5.99	0.36	7.38e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	0.62	5.28	0.32	2.89e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs17023223	0.537	rs17023185	chr1:119610787	C/T	cg05756136	chr1:119680316	WARS2	-0.55	-7.22	-0.42	6.27e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4656940	0.574	rs11265485	chr1:160764759	C/T	cg17331569	chr1:160788135	LY9	-0.48	-5.77	-0.35	2.38e-8	Crohn's disease;
KIRP	cis	rs244899	0.967	rs244898	chr5:167918926	T/C	cg06604206	chr5:167912465	RARS	-0.54	-7.6	-0.44	6.22e-13	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg11965913	chr1:205819406	PM20D1	0.82	11.79	0.6	9.97e-26	Monocyte percentage of white cells;
KIRP	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg09238746	chr17:78121135	EIF4A3	-0.4	-4.95	-0.3	1.36e-6	Yeast infection;
KIRP	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.46	6.37	0.38	9.17e-10	Dupuytren's disease;
KIRP	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.86	-0.3	2.1e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs981844	0.796	rs17030437	chr4:154704225	A/C	cg14289246	chr4:154710475	SFRP2	-0.57	-7.15	-0.41	1.01e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.61	-0.34	5.45e-8	Neuroticism;
KIRP	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.9	-10.15	-0.54	1.95e-20	Bipolar disorder and schizophrenia;
KIRP	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	11.91	0.6	3.98e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	trans	rs2048656	0.605	rs11989726	chr8:9648687	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.16	0.37	2.96e-9	Schizophrenia;
KIRP	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.73	-8.01	-0.45	4.69e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg20387954	chr3:183756860	HTR3D	0.61	8.98	0.5	7.18e-17	Anterior chamber depth;
KIRP	cis	rs2219968	1.000	rs2219968	chr8:78956658	G/A	cg00738934	chr8:78996279	NA	0.41	5.18	0.31	4.62e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07372659	chr6:20866952	CDKAL1	0.45	6.41	0.38	7.31e-10	Interleukin-4 levels;
KIRP	cis	rs7712401	0.601	rs30028	chr5:122283269	G/T	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg12598211	chr12:123634384	NA	-0.4	-4.93	-0.3	1.55e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.87	-0.35	1.4e-8	Bipolar disorder;
KIRP	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg20302533	chr7:39170763	POU6F2	0.32	6.81	0.4	7.46e-11	IgG glycosylation;
KIRP	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.0	-12.4	-0.62	9.15e-28	Alzheimer's disease;
KIRP	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.4	-5.14	-0.31	5.58e-7	Parkinson's disease;
KIRP	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	6.33	0.37	1.13e-9	Depressive symptoms;
KIRP	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14598338	chr9:96623480	NA	0.62	9.74	0.53	3.52e-19	DNA methylation (variation);
KIRP	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.68	-9.1	-0.5	3.07e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.91	14.15	0.67	1.13e-33	Ulcerative colitis;
KIRP	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg12441052	chr11:66313700	ZDHHC24;ACTN3	0.49	5.08	0.31	7.48e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg23335576	chr14:104009727	NA	0.65	7.78	0.44	1.98e-13	Body mass index;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	7.3	0.42	3.87e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	9.09	0.5	3.37e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.97	-0.3	1.25e-6	Cognitive function;
KIRP	cis	rs2014572	0.967	rs11667407	chr19:57763122	C/T	cg12963866	chr19:57752005	ZNF805	-0.48	-5.98	-0.36	7.89e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.45	5.95	0.35	8.99e-9	Coronary artery disease;
KIRP	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.41	-0.33	1.51e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.66	-9.53	-0.52	1.62e-18	Prudent dietary pattern;
KIRP	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg11608241	chr8:8085544	FLJ10661	0.43	5.04	0.31	8.96e-7	Mood instability;
KIRP	cis	rs7221595	0.825	rs12938597	chr17:3961200	C/T	cg11204139	chr17:3907470	NA	0.53	5.14	0.31	5.51e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26207909	chr14:103986467	CKB	0.72	10.18	0.54	1.51e-20	Body mass index;
KIRP	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.92	-0.61	3.66e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.84	12.49	0.62	4.64e-28	Colorectal cancer;
KIRP	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg24579218	chr15:68104479	NA	-0.56	-8.94	-0.5	9.36e-17	Restless legs syndrome;
KIRP	cis	rs9810890	1.000	rs115046806	chr3:128607379	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.14	0.31	5.59e-7	Dental caries;
KIRP	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.39	5.62	0.34	5.08e-8	Body mass index;
KIRP	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.63	-8.41	-0.47	3.39e-15	Prostate cancer;
KIRP	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.18	0.42	8.21e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-1.05	-16.93	-0.73	3.86e-43	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	7.84	0.45	1.33e-13	Personality dimensions;
KIRP	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.62	0.34	5.1e-8	Personality dimensions;
KIRP	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg06533319	chr4:3265114	C4orf44	0.58	7.73	0.44	2.74e-13	Parental longevity (mother's age at death);
KIRP	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.55	-15.69	-0.71	6.4e-39	Hip circumference adjusted for BMI;
KIRP	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg25922125	chr7:127225783	GCC1	0.45	4.89	0.3	1.83e-6	Type 2 diabetes;
KIRP	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.57	-6.69	-0.39	1.52e-10	Schizophrenia;
KIRP	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.54	5.5	0.33	9.45e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.65	-9.76	-0.53	3.03e-19	Total body bone mineral density;
KIRP	cis	rs2051773	0.567	rs7934608	chr11:17038917	A/C	cg15432903	chr11:17409602	KCNJ11	-0.49	-5.91	-0.35	1.14e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs8014252	0.803	rs12587714	chr14:71004376	G/C	cg19730268	chr14:71022823	NA	-0.59	-5.61	-0.34	5.33e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.21	-0.32	4.08e-7	Colorectal cancer;
KIRP	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.37	0.43	2.6e-12	Major depressive disorder;
KIRP	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg21643547	chr1:205240462	TMCC2	-0.64	-9.47	-0.52	2.44e-18	Red blood cell count;
KIRP	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18932078	chr1:2524107	MMEL1	0.39	5.17	0.31	4.82e-7	Multiple sclerosis;
KIRP	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs2290159	0.518	rs9843910	chr3:12591589	G/A	cg23032965	chr3:12705835	RAF1	0.67	5.37	0.32	1.84e-7	Cholesterol, total;
KIRP	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.65	10.53	0.56	1.19e-21	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	0.62	5.18	0.31	4.7e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg18501202	chr6:125855421	NA	-0.34	-5.14	-0.31	5.65e-7	Brugada syndrome;
KIRP	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg11555438	chr13:111297484	CARS2	-0.36	-5.83	-0.35	1.72e-8	Coronary artery disease;
KIRP	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg02151108	chr14:50098012	C14orf104	-0.53	-7.16	-0.42	9.14e-12	Carotid intima media thickness;
KIRP	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs76533333	0.915	rs71446622	chr13:113365480	G/A	cg21786786	chr13:113365464	ATP11A	-0.61	-5.17	-0.31	4.87e-7	Red cell distribution width;
KIRP	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.72	8.28	0.47	8.08e-15	Extraversion;
KIRP	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg01522456	chr1:115632236	TSPAN2	0.37	5.03	0.31	9.27e-7	Autism;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20863810	chr6:144164340	LTV1	-0.45	-6.12	-0.36	3.73e-9	Metabolic traits;
KIRP	cis	rs78487399	0.808	rs7573500	chr2:43685625	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.1	-0.31	6.92e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs501120	0.584	rs673354	chr10:44733816	C/A	cg09554077	chr10:44749378	NA	0.7	7.78	0.44	2.03e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	0.9	10.58	0.56	8.24e-22	Testicular germ cell tumor;
KIRP	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.52	-7.61	-0.44	5.66e-13	Daytime sleep phenotypes;
KIRP	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	7.47	0.43	1.4e-12	Coronary artery disease;
KIRP	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.45	6.22	0.37	2.15e-9	Coronary artery disease;
KIRP	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.3	-0.47	7.03e-15	Retinal vascular caliber;
KIRP	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.16	-0.42	9.53e-12	Blood pressure;
KIRP	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.95	13.27	0.65	1.12e-30	Menopause (age at onset);
KIRP	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.68	-0.39	1.59e-10	Response to antipsychotic treatment;
KIRP	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg26398791	chr1:38455867	SF3A3	-0.43	-5.37	-0.32	1.86e-7	Coronary artery disease;
KIRP	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.6	-7.14	-0.41	1.06e-11	Mosquito bite size;
KIRP	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.67	-0.39	1.69e-10	Mood instability;
KIRP	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg10326726	chr10:51549505	MSMB	-0.6	-9.09	-0.5	3.51e-17	Prostate-specific antigen levels;
KIRP	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-6.27	-0.37	1.61e-9	Bladder cancer;
KIRP	cis	rs9876781	0.559	rs11130167	chr3:48400060	A/G	cg11946769	chr3:48343235	NME6	0.41	5.1	0.31	6.67e-7	Longevity;
KIRP	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18932078	chr1:2524107	MMEL1	-0.48	-6.76	-0.4	1.02e-10	Ulcerative colitis;
KIRP	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.73	-9.7	-0.53	4.73e-19	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06481639	chr22:41940642	POLR3H	-0.64	-6.82	-0.4	7.18e-11	Vitiligo;
KIRP	cis	rs860295	0.557	rs12037177	chr1:155877029	C/T	cg02153340	chr1:155202674	NA	0.38	4.92	0.3	1.62e-6	Body mass index;
KIRP	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs9436747	0.874	rs61779814	chr1:65939443	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.44	-5.09	-0.31	6.96e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17554472	chr22:41940697	POLR3H	0.7	7.46	0.43	1.53e-12	Vitiligo;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08555112	chr17:48942811	TOB1	0.63	6.18	0.37	2.68e-9	Lung function (FEV1);
KIRP	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.69	-8.83	-0.49	1.97e-16	Blood metabolite levels;
KIRP	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.57	-0.43	7.48e-13	Total cholesterol levels;
KIRP	trans	rs2975734	0.680	rs1052453	chr8:10108325	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.78	-0.4	8.87e-11	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.49	-0.33	1e-7	Menarche (age at onset);
KIRP	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg18306943	chr3:40428807	ENTPD3	-0.41	-5.7	-0.34	3.42e-8	Renal cell carcinoma;
KIRP	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg18016565	chr1:150552671	MCL1	0.42	6.18	0.37	2.57e-9	Melanoma;
KIRP	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.69	-7.68	-0.44	3.69e-13	Response to antipsychotic treatment;
KIRP	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.11	23.11	0.83	1.38e-63	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg05347473	chr6:146136440	FBXO30	-0.59	-8.76	-0.49	3.16e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.9	0.53	1.18e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1468333	1.000	rs2967784	chr5:137539239	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.38	0.32	1.7e-7	Resting heart rate;
KIRP	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	0.7	6.56	0.39	3.09e-10	Obesity-related traits;
KIRP	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.82	-0.63	3.79e-29	Idiopathic membranous nephropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17648537	chr2:86333281	PTCD3;POLR1A	0.56	6.88	0.4	4.95e-11	Parkinson's disease;
KIRP	cis	rs2268667	0.647	rs11161609	chr1:85862736	G/T	cg16011679	chr1:85725395	C1orf52	-0.41	-5.1	-0.31	6.8e-7	Asymmetrical dimethylarginine levels;
KIRP	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.23	-0.32	3.66e-7	Type 2 diabetes;
KIRP	cis	rs4908768	0.906	rs12145445	chr1:8604370	C/G	cg25722041	chr1:8623473	RERE	0.8	9.87	0.53	1.4e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.67	7.76	0.44	2.3e-13	Primary sclerosing cholangitis;
KIRP	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.69	9.23	0.51	1.3e-17	Breast cancer;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg24699146	chr1:24152579	HMGCL	0.43	5.54	0.33	7.73e-8	Immature fraction of reticulocytes;
KIRP	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.55	-6.75	-0.4	1.08e-10	Calcium levels;
KIRP	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg02931644	chr1:25747376	RHCE	0.45	8.56	0.48	1.23e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs4953911	0.893	rs7606775	chr2:135058175	A/G	cg18482303	chr2:135041380	MGAT5	-0.28	-5.34	-0.32	2.12e-7	Multiple sclerosis (severity);
KIRP	cis	rs6142102	0.961	rs973409	chr20:32536364	A/G	cg08999081	chr20:33150536	PIGU	0.5	5.8	0.35	2.08e-8	Skin pigmentation;
KIRP	cis	rs2067615	0.899	rs4964188	chr12:107100717	T/C	cg21360079	chr12:107162445	NA	-0.43	-5.34	-0.32	2.08e-7	Heart rate;
KIRP	cis	rs7714584	1.000	rs34156253	chr5:150226230	A/G	cg22134413	chr5:150180641	NA	0.6	5.21	0.32	4.07e-7	Crohn's disease;
KIRP	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg08499158	chr17:42289980	UBTF	0.71	9.55	0.52	1.35e-18	Total body bone mineral density;
KIRP	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-6.01	-0.36	6.81e-9	Morning vs. evening chronotype;
KIRP	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18867708	chr6:26865862	GUSBL1	-0.47	-6.03	-0.36	6.13e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg07777115	chr5:623756	CEP72	-0.61	-6.17	-0.37	2.77e-9	Obesity-related traits;
KIRP	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.22	0.32	3.84e-7	Tonsillectomy;
KIRP	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.85	-9.09	-0.5	3.43e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg26681399	chr22:41777847	TEF	-0.49	-4.92	-0.3	1.55e-6	Vitiligo;
KIRP	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg26876637	chr1:152193138	HRNR	-0.7	-9.22	-0.51	1.41e-17	Atopic dermatitis;
KIRP	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.66	7.26	0.42	5.04e-12	Multiple sclerosis;
KIRP	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.79	7.85	0.45	1.28e-13	Methadone dose in opioid dependence;
KIRP	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs9326248	0.515	rs2727793	chr11:116683374	C/T	cg15534755	chr11:117069859	TAGLN	0.4	4.86	0.3	2.08e-6	Blood protein levels;
KIRP	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.39	-5.34	-0.32	2.08e-7	Endometrial cancer;
KIRP	cis	rs6456042	0.893	rs2277093	chr6:166570766	C/T	cg11088901	chr6:166572345	T	-0.34	-5.05	-0.31	8.74e-7	Asthma;
KIRP	trans	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	6.04	0.36	5.52e-9	Aortic root size;
KIRP	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-6.34	-0.37	1.11e-9	Schizophrenia;
KIRP	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.51	6.28	0.37	1.49e-9	Monocyte count;
KIRP	cis	rs68092024	0.731	rs792841	chr3:99471308	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-4.94	-0.3	1.48e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg19743168	chr1:23544995	NA	0.49	6.64	0.39	1.94e-10	Height;
KIRP	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg27411982	chr8:10470053	RP1L1	-0.38	-4.86	-0.3	2.11e-6	Triglycerides;
KIRP	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg04025307	chr7:1156635	C7orf50	0.7	5.49	0.33	1.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.87	13.21	0.64	1.82e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6969780	0.778	rs2428433	chr7:27145517	T/C	cg26364809	chr7:27145159	NA	-0.62	-5.71	-0.34	3.22e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.84e-18	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.11	-0.5	2.93e-17	Platelet count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10000195	chr4:43758625	NA	-0.46	-7.04	-0.41	1.94e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.49	6.22	0.37	2.11e-9	Testicular germ cell tumor;
KIRP	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg14664628	chr15:75095509	CSK	0.47	5.87	0.35	1.42e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg27189623	chr16:705930	WDR90	0.43	5.95	0.35	9.19e-9	Height;
KIRP	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg23950597	chr19:37808831	NA	-0.65	-6.92	-0.4	3.81e-11	Coronary artery calcification;
KIRP	cis	rs3752645	1.000	rs10261881	chr7:106781650	A/G	cg02696742	chr7:106810147	HBP1	-0.6	-5.1	-0.31	6.91e-7	Bladder cancer (smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23974812	chr11:134123664	THYN1;ACAD8	0.57	7.39	0.43	2.22e-12	Parkinson's disease;
KIRP	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.51	-0.52	1.78e-18	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8113308	0.810	rs11881650	chr19:52450139	A/C	cg24732339	chr19:52471368	ZNF350	0.45	5.02	0.3	9.83e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.07	-8.8	-0.49	2.45e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62413470	0.873	rs12194916	chr6:55949309	C/G	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg24804195	chr5:87968844	LOC645323	-0.47	-6.21	-0.37	2.23e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.31	-0.32	2.48e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg27147174	chr7:100797783	AP1S1	0.69	8.98	0.5	7.28e-17	Life satisfaction;
KIRP	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	7.26	0.42	5.05e-12	Bone mineral density;
KIRP	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.67	8.25	0.47	9.49e-15	Mosquito bite size;
KIRP	cis	rs357618	0.581	rs165331	chr5:150875967	A/G	cg22672639	chr5:150884813	FAT2	-0.34	-4.85	-0.3	2.17e-6	Basophil percentage of white cells;
KIRP	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs7536201	1.000	rs12407074	chr1:25299432	T/A	cg23273869	chr1:25296894	NA	-0.39	-5.64	-0.34	4.6e-8	Psoriasis vulgaris;
KIRP	cis	rs7721647	0.810	rs16876880	chr5:90796839	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.45	5.03	0.31	9.65e-7	Breast cancer;
KIRP	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.71	-10.12	-0.54	2.34e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.23	0.37	2.02e-9	Hemoglobin concentration;
KIRP	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg01620082	chr3:125678407	NA	-1.33	-8.35	-0.47	5.13e-15	Depression;
KIRP	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg09231725	chr11:64357281	SLC22A12	0.59	7.79	0.44	1.93e-13	Urate levels in obese individuals;
KIRP	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg11189052	chr15:85197271	WDR73	0.54	5.65	0.34	4.52e-8	Schizophrenia;
KIRP	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.64	-8.08	-0.46	2.84e-14	Vitiligo;
KIRP	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	1.06	15.12	0.69	5.7e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg15674680	chr20:60982522	CABLES2	-0.44	-5.21	-0.32	4.06e-7	Colorectal cancer;
KIRP	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.71	10.81	0.57	1.53e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.42	0.62	8.08e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2387326	0.717	rs10829339	chr10:129943681	C/T	cg16087940	chr10:129947807	NA	-0.36	-5.01	-0.3	1.03e-6	Select biomarker traits;
KIRP	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.58	6.9	0.4	4.35e-11	Aortic root size;
KIRP	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.41	-5.08	-0.31	7.3e-7	Aortic root size;
KIRP	cis	rs3736594	0.918	rs9967838	chr2:27968454	A/C	cg27432699	chr2:27873401	GPN1	-0.59	-7.64	-0.44	4.87e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06508976	chr9:131940586	IER5L	0.55	6.46	0.38	5.66e-10	Smoking initiation;
KIRP	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-0.99	-12.86	-0.63	2.75e-29	Body mass index;
KIRP	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.9	13.98	0.67	4.35e-33	Selective IgA deficiency;
KIRP	cis	rs9309473	0.519	rs12618600	chr2:73890682	T/C	cg20560298	chr2:73613845	ALMS1	0.46	5.77	0.35	2.44e-8	Metabolite levels;
KIRP	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.73	0.39	1.21e-10	Coffee consumption (cups per day);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg26834624	chr7:6662329	ZNF853	-0.48	-6.13	-0.36	3.48e-9	Obesity-related traits;
KIRP	cis	rs7432375	0.523	rs12486911	chr3:136558953	C/G	cg15507776	chr3:136538369	TMEM22	0.44	5.61	0.34	5.57e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5498	0.966	rs2075741	chr19:10401098	G/C	cg10604476	chr19:10403908	ICAM5	0.35	5.43	0.33	1.35e-7	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
KIRP	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.46	-5.69	-0.34	3.66e-8	Diastolic blood pressure;
KIRP	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.75	9.21	0.51	1.44e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs918629	1.000	rs60482707	chr5:95307696	T/C	cg16656078	chr5:95278638	ELL2	-0.44	-6.59	-0.39	2.6e-10	IgG glycosylation;
KIRP	cis	rs554111	0.637	rs604659	chr1:21043913	T/C	cg21184320	chr1:21044207	KIF17	0.38	5.47	0.33	1.08e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg13147721	chr7:65941812	NA	-0.91	-6.56	-0.39	3.19e-10	Diabetic kidney disease;
KIRP	cis	rs3750082	0.817	rs3750078	chr7:32969489	G/A	cg08946731	chr7:32981826	RP9P	-0.35	-5.39	-0.33	1.62e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.08	-0.31	7.41e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7017914	0.967	rs7842851	chr8:71663805	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.12	-0.31	6.05e-7	Bone mineral density;
KIRP	cis	rs151997	0.925	rs26090	chr5:50170071	C/T	cg06027927	chr5:50259733	NA	-0.61	-7.55	-0.43	8.57e-13	Callous-unemotional behaviour;
KIRP	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg14580859	chr9:123691850	NA	0.36	5.24	0.32	3.4e-7	Rheumatoid arthritis;
KIRP	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs12282928	0.959	rs1393791	chr11:48264183	T/G	cg26585981	chr11:48327164	OR4S1	-0.49	-6.07	-0.36	4.86e-9	Migraine - clinic-based;
KIRP	cis	rs6009824	0.891	rs6009820	chr22:50085456	C/T	cg27029450	chr22:50098074	NA	0.56	5.35	0.32	2.06e-7	Natriuretic peptide levels;
KIRP	cis	rs12210905	1.000	rs5030958	chr6:27214257	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.39	-0.38	8.31e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg18646521	chr2:111875858	NA	0.4	5.77	0.35	2.37e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs7601312	0.933	rs12694782	chr2:229323603	T/C	cg02542817	chr2:229291442	NA	-0.55	-8.24	-0.46	1.05e-14	Schizophrenia;
KIRP	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg21905437	chr5:178450457	ZNF879	0.57	6.56	0.39	3.23e-10	Pubertal anthropometrics;
KIRP	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg02336718	chr17:17403227	NA	-0.33	-5.12	-0.31	6.2e-7	Total body bone mineral density;
KIRP	cis	rs9400467	0.506	rs12205046	chr6:111619620	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.07e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12282928	0.959	rs7120768	chr11:48264835	T/A	cg26585981	chr11:48327164	OR4S1	0.46	5.22	0.32	3.83e-7	Migraine - clinic-based;
KIRP	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs3736485	0.966	rs12441167	chr15:51850652	T/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.04	-0.31	8.97e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg21314302	chr13:44204106	ENOX1	-0.58	-6.92	-0.4	3.8e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg10631289	chr15:39006617	NA	-0.78	-8.73	-0.49	3.97e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.53	-7.67	-0.44	4e-13	Sitting height ratio;
KIRP	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	1.22	11.33	0.59	3.24e-24	Lymphocyte counts;
KIRP	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg18306943	chr3:40428807	ENTPD3	-0.41	-5.63	-0.34	4.94e-8	Renal cell carcinoma;
KIRP	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.8	11.0	0.57	3.64e-23	Aortic root size;
KIRP	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg00310523	chr12:86230176	RASSF9	0.55	8.6	0.48	9.5e-16	Major depressive disorder;
KIRP	cis	rs2933343	1.000	rs1680784	chr3:128644458	A/G	cg11901034	chr3:128598214	ACAD9	-0.44	-4.86	-0.3	2.05e-6	IgG glycosylation;
KIRP	cis	rs61990749	0.571	rs4903655	chr14:78306326	C/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.74	6.08	0.36	4.47e-9	Fibroblast growth factor basic levels;
KIRP	cis	rs11874712	1.000	rs56181324	chr18:43678024	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.44	-6.09	-0.36	4.43e-9	Migraine - clinic-based;
KIRP	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.02	0.3	9.8e-7	Menopause (age at onset);
KIRP	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.33	0.55	5.23e-21	Coffee consumption (cups per day);
KIRP	cis	rs2273156	0.570	rs28399702	chr14:35625217	G/T	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.18	-0.31	4.62e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg27170947	chr2:26402098	FAM59B	0.56	5.44	0.33	1.27e-7	Gut microbiome composition (summer);
KIRP	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-8.29	-0.47	7.38e-15	Alzheimer's disease (survival time);
KIRP	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg09408571	chr1:101003634	GPR88	-0.3	-7.3	-0.42	3.94e-12	Breast cancer;
KIRP	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.63	8.05	0.46	3.52e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2387326	0.671	rs11016103	chr10:129946285	A/G	cg16087940	chr10:129947807	NA	-0.42	-5.79	-0.35	2.14e-8	Select biomarker traits;
KIRP	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.69	11.08	0.58	2.01e-23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4262150	0.641	rs4958586	chr5:152248567	G/A	cg12297329	chr5:152029980	NA	0.47	6.6	0.39	2.48e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs714027	0.585	rs2007446	chr22:30388601	C/T	cg27665648	chr22:30112403	NA	0.41	5.62	0.34	5.2e-8	Lymphocyte counts;
KIRP	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs12643440	0.538	rs66857912	chr4:17146347	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.37	-0.47	4.51e-15	Coronary artery disease;
KIRP	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.61	-10.01	-0.54	5.32e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.67	-8.2	-0.46	1.38e-14	Body mass index;
KIRP	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-1.08	-11.61	-0.59	3.94e-25	Exhaled nitric oxide output;
KIRP	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.69	0.48	5.25e-16	Motion sickness;
KIRP	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22168489	chr12:122356033	WDR66	0.64	9.56	0.52	1.32e-18	Mean corpuscular volume;
KIRP	cis	rs2072732	0.904	rs2993480	chr1:2973322	A/G	cg11731671	chr1:2995604	PRDM16	0.43	5.94	0.35	9.45e-9	Plateletcrit;
KIRP	cis	rs2733201	1.000	rs2733208	chr15:44437692	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	5.51	0.33	9.22e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg00405596	chr8:11794950	NA	-0.49	-6.47	-0.38	5.26e-10	Retinal vascular caliber;
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg08126542	chr6:37504118	NA	-0.72	-10.4	-0.55	3.17e-21	Cognitive performance;
KIRP	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg24296786	chr1:45957014	TESK2	0.49	6.36	0.38	9.67e-10	Red blood cell count;Reticulocyte count;
KIRP	trans	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg09872104	chr7:134855509	C7orf49	-0.86	-6.21	-0.37	2.28e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.4e-12	Bipolar disorder;
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03647317	chr4:187891568	NA	-0.8	-13.28	-0.65	1.07e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05450629	chr15:90627448	IDH2	0.47	6.3	0.37	1.36e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs60311166	1.000	rs57757646	chr3:52636808	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.91	5.6	0.34	5.58e-8	CTACK levels;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg02696790	chr15:75250997	RPP25	0.32	5.53	0.33	8.01e-8	Breast cancer;
KIRP	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg09517075	chr8:22133004	PIWIL2	0.46	6.16	0.37	2.88e-9	Hypertriglyceridemia;
KIRP	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06108461	chr20:60628389	TAF4	-0.55	-6.89	-0.4	4.55e-11	Body mass index;
KIRP	cis	rs7172677	0.711	rs8027552	chr15:75439393	A/G	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-0.69	-7.05	-0.41	1.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg00319359	chr11:70116639	PPFIA1	0.64	6.27	0.37	1.57e-9	Coronary artery disease;
KIRP	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg24747557	chr10:131355152	MGMT	0.38	5.26	0.32	3.2e-7	Response to temozolomide;
KIRP	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.33	-0.42	3.25e-12	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.57	0.75	2.58e-45	Chronic sinus infection;
KIRP	cis	rs7534824	0.625	rs6692186	chr1:101470217	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	6.99	0.41	2.59e-11	Refractive astigmatism;
KIRP	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.57	8.27	0.47	8.62e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.3	-6.97	-0.41	2.95e-11	Corneal astigmatism;
KIRP	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.66	8.22	0.46	1.21e-14	Multiple sclerosis;
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg11945507	chr8:142233382	SLC45A4	0.94	16.89	0.73	5.15e-43	Immature fraction of reticulocytes;
KIRP	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.5	-0.38	4.42e-10	Aortic root size;
KIRP	cis	rs897080	0.515	rs1067319	chr2:44633458	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.02	0.36	6.29e-9	Height;
KIRP	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.17	-0.37	2.8e-9	Alcohol dependence;
KIRP	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg00806126	chr19:22604979	ZNF98	0.68	7.04	0.41	1.94e-11	Pain;
KIRP	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	8.3	0.47	6.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4356932	0.691	rs9995007	chr4:76897791	T/A	cg19388996	chr4:76862389	NAAA	0.43	5.39	0.33	1.63e-7	Blood protein levels;
KIRP	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.77	-8.92	-0.49	1.06e-16	Diastolic blood pressure;
KIRP	cis	rs687432	0.737	rs11600060	chr11:57898867	C/T	cg19752551	chr11:57585705	CTNND1	-0.66	-8.51	-0.48	1.7e-15	Parkinson's disease;
KIRP	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.49	-9.16	-0.5	2.08e-17	Cystic fibrosis severity;
KIRP	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg08514558	chr10:81106712	PPIF	0.4	5.49	0.33	9.81e-8	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07850407	chr2:67387038	NA	-0.39	-6.18	-0.37	2.63e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11987759	chr7:65425863	GUSB	-0.58	-7.56	-0.43	7.85e-13	Aortic root size;
KIRP	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24549020	chr5:56110836	MAP3K1	0.63	5.63	0.34	4.94e-8	Type 2 diabetes;
KIRP	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg00405596	chr8:11794950	NA	0.52	6.49	0.38	4.67e-10	Neuroticism;
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.5	6.94	0.4	3.4e-11	Testicular germ cell tumor;
KIRP	cis	rs6838801	0.823	rs13139112	chr4:77584089	G/A	cg17476223	chr4:77663285	SHROOM3	0.54	7.76	0.44	2.22e-13	Cleft lip with or without cleft palate;
KIRP	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.51	9.2	0.51	1.56e-17	Bone mineral density;
KIRP	cis	rs526231	0.511	rs62362545	chr5:102347452	A/G	cg23492399	chr5:102201601	PAM	-0.45	-5.04	-0.31	9.02e-7	Primary biliary cholangitis;
KIRP	cis	rs12425451	0.544	rs3741951	chr12:3147080	A/G	cg05389053	chr12:3131226	TEAD4	0.45	5.45	0.33	1.21e-7	Narcolepsy with cataplexy;
KIRP	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs12681288	0.782	rs12544713	chr8:1026697	C/T	cg08648136	chr8:956695	NA	0.4	5.53	0.33	8.32e-8	Schizophrenia;
KIRP	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.59	-9.53	-0.52	1.58e-18	Neuroticism;
KIRP	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.05	0.41	1.75e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg15507776	chr3:136538369	TMEM22	0.39	5.26	0.32	3.09e-7	Neuroticism;
KIRP	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	8.21	0.46	1.27e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.39e-12	Morning vs. evening chronotype;
KIRP	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.18	0.42	7.99e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-5.46	-0.33	1.15e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.84	0.35	1.62e-8	Menopause (age at onset);
KIRP	cis	rs35883536	0.528	rs10783138	chr1:101031061	C/T	cg06223162	chr1:101003688	GPR88	0.47	9.72	0.53	4.01e-19	Monocyte count;
KIRP	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg00405596	chr8:11794950	NA	-0.4	-5.14	-0.31	5.72e-7	Retinal vascular caliber;
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg08662619	chr6:150070041	PCMT1	0.37	6.24	0.37	1.93e-9	Lung cancer;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs17095355	1.000	rs12267714	chr10:111722052	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.28	-0.32	2.9e-7	Biliary atresia;
KIRP	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.68	-7.58	-0.44	6.93e-13	Menarche (age at onset);
KIRP	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg14061069	chr19:46274453	DMPK	-0.57	-8.48	-0.48	2.12e-15	Coronary artery disease;
KIRP	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg18586891	chr4:952366	TMEM175	0.59	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6589219	0.753	rs4548657	chr11:111140043	C/G	cg25129781	chr11:111156908	C11orf53	-0.4	-5.11	-0.31	6.58e-7	Colorectal cancer;
KIRP	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.92	-0.35	1.06e-8	Breast cancer;
KIRP	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.42	-5.66	-0.34	4.3e-8	HIV-1 susceptibility;
KIRP	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	0.93	10.34	0.55	4.76e-21	Triglycerides;
KIRP	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.48	-0.33	1.06e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14598338	chr9:96623480	NA	-0.67	-11.44	-0.59	1.38e-24	DNA methylation (variation);
KIRP	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.64	7.98	0.45	5.65e-14	Multiple sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18179849	chr3:185541973	IGF2BP2	0.43	6.68	0.39	1.55e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22007632	chr19:17186265	MYO9B;HAUS8	0.55	7.01	0.41	2.27e-11	Parkinson's disease;
KIRP	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg23307798	chr14:103986281	CKB	-0.5	-6.74	-0.39	1.13e-10	Coronary artery disease;
KIRP	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.66	6.84	0.4	6.21e-11	Corneal astigmatism;
KIRP	cis	rs33912345	0.722	rs8015263	chr14:60958880	C/T	cg27398547	chr14:60952738	C14orf39	0.37	4.93	0.3	1.5e-6	Glaucoma (high intraocular pressure);
KIRP	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.96	8.81	0.49	2.25e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg08499158	chr17:42289980	UBTF	0.51	6.39	0.38	8.08e-10	Total body bone mineral density;
KIRP	trans	rs10782582	0.758	rs5745554	chr1:76379197	A/C	cg10283277	chr11:111472630	SIK2	-0.31	-6.21	-0.37	2.23e-9	Daytime sleep phenotypes;
KIRP	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.49	-5.8	-0.35	2.01e-8	Body mass index;
KIRP	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.4	-6.34	-0.37	1.08e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.72	8.65	0.48	6.98e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs1546924	0.570	rs197413	chr1:112308972	G/A	cg23955903	chr1:112298873	DDX20;C1orf183	0.45	5.6	0.34	5.82e-8	Body mass index;
KIRP	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.74	-0.39	1.1e-10	Diastolic blood pressure;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg10254082	chr7:997346	NA	0.47	4.9	0.3	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8067354	0.609	rs1292066	chr17:57932314	T/A	cg13753209	chr17:57696993	CLTC	0.51	5.21	0.32	3.94e-7	Hemoglobin concentration;
KIRP	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.47	6.03	0.36	5.97e-9	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27026673	chr2:39664343	MAP4K3	0.57	7.26	0.42	5.2e-12	Parkinson's disease;
KIRP	cis	rs8014252	0.803	rs57598551	chr14:71068401	G/A	cg19730268	chr14:71022823	NA	-0.72	-6.4	-0.38	7.89e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.79	9.68	0.53	5.56e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs72781680	0.611	rs2303289	chr2:24342242	C/G	cg20701182	chr2:24300061	SF3B14	-1.01	-10.86	-0.57	1.04e-22	Lymphocyte counts;
KIRP	cis	rs12986413	0.651	rs2238612	chr19:2149694	C/T	cg09261902	chr19:2140048	AP3D1	-0.68	-10.51	-0.56	1.36e-21	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27570636	chr1:214454189	SMYD2	0.54	6.43	0.38	6.72e-10	Smoking initiation;
KIRP	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.39	-5.0	-0.3	1.11e-6	Parkinson's disease;
KIRP	cis	rs10761482	0.601	rs1954117	chr10:62210588	A/C	cg01186212	chr10:62110162	ANK3	-0.31	-5.21	-0.32	3.9e-7	Schizophrenia;
KIRP	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	5.74	0.34	2.74e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.54	6.84	0.4	6.15e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs78487399	0.808	rs113373412	chr2:43762987	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.93	-0.3	1.48e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6466055	0.589	rs17708070	chr7:104959297	G/A	cg04380332	chr7:105027541	SRPK2	0.37	5.08	0.31	7.34e-7	Schizophrenia;
KIRP	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg16434002	chr17:42200994	HDAC5	-0.6	-7.35	-0.42	3.01e-12	Total body bone mineral density;
KIRP	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.54	-5.07	-0.31	7.82e-7	Narcolepsy;
KIRP	trans	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.82	-0.4	7.14e-11	Bladder cancer;
KIRP	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg04944784	chr2:26401820	FAM59B	-0.66	-7.21	-0.42	6.85e-12	Gut microbiome composition (summer);
KIRP	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.79	7.61	0.44	5.76e-13	Diisocyanate-induced asthma;
KIRP	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg03060546	chr3:49711283	APEH	-0.58	-5.07	-0.31	7.88e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.45	-0.43	1.6e-12	Monocyte count;
KIRP	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.76	-5.19	-0.31	4.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6142102	0.778	rs4911374	chr20:32516001	T/C	cg08999081	chr20:33150536	PIGU	0.47	5.46	0.33	1.18e-7	Skin pigmentation;
KIRP	cis	rs4356975	0.563	rs4455491	chr4:69960933	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs300890	0.679	rs1027852	chr4:144298243	T/C	cg01601573	chr4:144256835	GAB1	-0.34	-4.89	-0.3	1.8e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg15128208	chr22:42549153	NA	0.37	4.89	0.3	1.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg15117754	chr3:10150083	C3orf24	0.54	5.34	0.32	2.08e-7	Alzheimer's disease;
KIRP	cis	rs4478858	0.611	rs1007012	chr1:31710068	G/A	cg00250761	chr1:31883323	NA	-0.32	-5.63	-0.34	4.87e-8	Alcohol dependence;
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13198984	chr17:80129470	CCDC57	-0.51	-7.56	-0.43	7.95e-13	Life satisfaction;
KIRP	cis	rs34286592	0.929	rs11864180	chr16:29830829	T/C	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	5.1	0.31	6.78e-7	Multiple sclerosis;
KIRP	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs11239930	0.538	rs630630	chr1:146551926	T/C	cg16700924	chr1:146552102	NA	-0.44	-4.87	-0.3	2e-6	AIDS progression;
KIRP	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.09	18.71	0.77	3.48e-49	Cortisol levels (saliva);
KIRP	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg08992911	chr2:238395768	MLPH	0.55	4.98	0.3	1.17e-6	Prostate cancer;
KIRP	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.43	7.54	0.43	9.11e-13	Renal cell carcinoma;
KIRP	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg04935436	chr20:30431758	NA	0.56	6.86	0.4	5.47e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg02487422	chr3:49467188	NICN1	0.41	4.86	0.3	2.05e-6	Menarche (age at onset);
KIRP	cis	rs2172802	0.570	rs57415754	chr4:62544758	A/G	cg04118610	chr4:62707027	LPHN3	0.44	5.49	0.33	9.8e-8	Partial epilepsies;
KIRP	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.54	6.44	0.38	6.13e-10	Height;
KIRP	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.53	-6.46	-0.38	5.6e-10	Metabolite levels;
KIRP	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg04132472	chr17:19861366	AKAP10	0.42	5.68	0.34	3.72e-8	Schizophrenia;
KIRP	cis	rs13424612	1.000	rs4149547	chr2:240933308	C/T	cg01812947	chr2:240904978	NDUFA10	0.49	6.33	0.37	1.16e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.67	9.86	0.53	1.56e-19	Lymphocyte counts;
KIRP	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11276456	chr10:74856846	P4HA1	0.56	7.87	0.45	1.11e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs859767	0.519	rs11688414	chr2:135420237	G/A	cg25422880	chr2:135218333	TMEM163	0.42	6.05	0.36	5.42e-9	Neuroticism;
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg00343986	chr7:65444356	GUSB	0.42	5.05	0.31	8.57e-7	Aortic root size;
KIRP	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg26681399	chr22:41777847	TEF	0.52	5.36	0.32	1.91e-7	Vitiligo;
KIRP	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg25019722	chr6:37503610	NA	-0.92	-13.19	-0.64	2.03e-30	Cognitive performance;
KIRP	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs9914544	0.545	rs2386403	chr17:18769600	A/G	cg26378065	chr17:18585709	ZNF286B	0.4	5.2	0.31	4.14e-7	Educational attainment (years of education);
KIRP	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.64	-8.12	-0.46	2.25e-14	Facial morphology (factor 19);
KIRP	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg04166393	chr7:2884313	GNA12	0.64	8.28	0.47	7.96e-15	Height;
KIRP	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg17796960	chr10:135278976	LOC619207	-0.54	-6.0	-0.36	7.18e-9	Systemic lupus erythematosus;
KIRP	cis	rs1983891	0.706	rs913077	chr6:41569157	G/A	cg20194872	chr6:41519635	FOXP4	0.48	6.3	0.37	1.38e-9	Prostate cancer;
KIRP	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg08738300	chr3:44038990	NA	0.66	9.13	0.5	2.65e-17	Coronary artery disease;
KIRP	cis	rs2718058	0.630	rs2722227	chr7:37858610	G/A	cg15028436	chr7:37888078	TXNDC3	0.48	5.1	0.31	6.94e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg05347473	chr6:146136440	FBXO30	-0.63	-9.22	-0.51	1.43e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg07309820	chr7:148901717	ZNF282	-0.38	-4.96	-0.3	1.29e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg24558204	chr6:135376177	HBS1L	-0.63	-8.17	-0.46	1.66e-14	Red blood cell count;
KIRP	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg16482183	chr6:26056742	HIST1H1C	0.45	5.55	0.33	7.27e-8	Height;
KIRP	cis	rs60311166	1.000	rs1987234	chr3:52598359	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.9	5.55	0.33	7.28e-8	CTACK levels;
KIRP	cis	rs72960926	0.744	rs3898077	chr6:74959122	G/A	cg03266952	chr6:74778945	NA	-0.73	-5.37	-0.32	1.8e-7	Metabolite levels (MHPG);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06621132	chr4:25623424	NA	0.49	6.93	0.4	3.66e-11	Survival in pancreatic cancer;
KIRP	cis	rs9826463	1.000	rs7647497	chr3:142322333	G/A	cg20824294	chr3:142316082	PLS1	0.31	5.27	0.32	3.05e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.6	7.85	0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs7113850	0.541	rs7102578	chr11:24244671	G/T	ch.11.24196551F	chr11:24239977	NA	0.91	8.5	0.48	1.89e-15	Bone fracture in osteoporosis;
KIRP	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.04	-0.41	1.9e-11	Systolic blood pressure;
KIRP	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg14456004	chr13:21872349	NA	-1.11	-13.8	-0.66	1.77e-32	White matter hyperintensity burden;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.67	8.81	0.49	2.3e-16	Bladder cancer;
KIRP	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg00601450	chr5:74908170	NA	-0.47	-5.38	-0.32	1.71e-7	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
KIRP	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.13	0.31	5.91e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg08499158	chr17:42289980	UBTF	0.5	6.13	0.36	3.57e-9	Total body bone mineral density;
KIRP	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.55	7.38	0.43	2.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.64	7.81	0.45	1.65e-13	Vitiligo;
KIRP	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg09201719	chr10:104596890	CYP17A1	0.36	5.05	0.31	8.74e-7	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg06606381	chr12:133084897	FBRSL1	-1.09	-6.41	-0.38	7.21e-10	Depression;
KIRP	cis	rs526231	0.511	rs58344084	chr5:102378212	C/T	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg01559446	chr3:44596178	ZNF167	-0.38	-5.35	-0.32	2.01e-7	Depressive symptoms;
KIRP	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.73	0.49	3.99e-16	Colorectal cancer;
KIRP	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg02175308	chr1:109941060	SORT1	-0.3	-5.76	-0.34	2.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7017914	0.934	rs10504479	chr8:71577515	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14507002	chr2:73089775	NA	-0.54	-6.36	-0.38	9.51e-10	Interleukin-4 levels;
KIRP	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg21161173	chr5:140098174	VTRNA1-2	-0.37	-4.87	-0.3	1.99e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.58	-0.34	6.43e-8	Parkinson's disease;
KIRP	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg21775007	chr8:11205619	TDH	0.44	5.71	0.34	3.31e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1010254	0.559	rs56261934	chr5:151750431	C/A	cg12297329	chr5:152029980	NA	-0.66	-6.75	-0.4	1.09e-10	Optic nerve measurement (cup area);
KIRP	cis	rs2224391	1.000	rs9504370	chr6:5261601	T/C	cg13962347	chr6:5174647	LYRM4	-0.62	-8.48	-0.48	2.13e-15	Height;
KIRP	cis	rs6693567	0.565	rs4926395	chr1:150405298	T/C	cg07843065	chr1:150265600	MRPS21	0.46	6.51	0.38	4.12e-10	Migraine;
KIRP	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.77	9.93	0.53	9.38e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg10932868	chr11:921992	NA	-0.65	-8.7	-0.48	4.95e-16	Alzheimer's disease (late onset);
KIRP	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-6.86	-0.4	5.59e-11	Tonsillectomy;
KIRP	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.01	0.5	5.77e-17	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.77	-9.9	-0.53	1.12e-19	Aortic root size;
KIRP	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg06212747	chr3:49208901	KLHDC8B	0.63	8.76	0.49	3.24e-16	Resting heart rate;
KIRP	cis	rs78487399	0.710	rs7607777	chr2:43629931	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.01	-0.3	1.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg26022315	chr17:47021804	SNF8	0.41	5.19	0.31	4.48e-7	Type 2 diabetes;
KIRP	cis	rs11718455	0.960	rs3843372	chr3:43997666	C/T	cg21419209	chr3:44054225	NA	-0.73	-9.0	-0.5	6.18e-17	Coronary artery disease;
KIRP	cis	rs3026101	0.671	rs2871210	chr17:5305027	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.66	-7.88	-0.45	1.03e-13	IgG glycosylation;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18845289	chr12:121124611	MLEC	0.73	6.92	0.4	3.89e-11	Lung function (FEV1);
KIRP	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg16898833	chr6:26189333	HIST1H4D	0.74	5.3	0.32	2.52e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.68	5.47	0.33	1.1e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2051211	0.895	rs2300670	chr3:38555815	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-9.12	-0.5	2.74e-17	QRS duration;
KIRP	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg16486109	chr11:613632	IRF7	0.43	5.35	0.32	2.04e-7	Systemic lupus erythematosus;
KIRP	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.6	8.46	0.47	2.38e-15	Obesity-related traits;
KIRP	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.7e-7	Neutrophil percentage of white cells;
KIRP	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.59	7.84	0.45	1.41e-13	Mean corpuscular volume;
KIRP	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg02415014	chr8:143852576	LYNX1	0.31	4.98	0.3	1.21e-6	Urinary tract infection frequency;
KIRP	cis	rs662064	0.925	rs669701	chr1:10544725	A/G	cg17425144	chr1:10567563	PEX14	0.32	5.39	0.33	1.63e-7	Asthma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13034654	chr5:64859130	CENPK;PPWD1	-0.45	-6.03	-0.36	6.12e-9	Interleukin-4 levels;
KIRP	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.58	6.69	0.39	1.49e-10	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs6968419	0.714	rs17138472	chr7:115892738	A/G	cg02561103	chr7:115862891	TES	-0.42	-5.98	-0.36	7.87e-9	Intraocular pressure;
KIRP	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-0.66	-5.71	-0.34	3.19e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.97	12.64	0.63	1.43e-28	Exhaled nitric oxide output;
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg03188948	chr7:1209495	NA	0.45	5.16	0.31	5.18e-7	Longevity;Endometriosis;
KIRP	cis	rs10861342	1.000	rs10861356	chr12:105526965	G/T	cg23923672	chr12:105501055	KIAA1033	0.9	9.17	0.5	1.95e-17	IgG glycosylation;
KIRP	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg11608241	chr8:8085544	FLJ10661	-0.47	-5.81	-0.35	1.94e-8	Joint mobility (Beighton score);
KIRP	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg17133734	chr15:86042851	AKAP13	-0.45	-5.62	-0.34	5.07e-8	Interstitial lung disease;
KIRP	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.51	-0.38	4.14e-10	Aortic root size;
KIRP	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	cg04338863	chr8:33670619	NA	0.49	6.64	0.39	2.02e-10	Body mass index;
KIRP	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.44	-0.52	3.05e-18	Chronic sinus infection;
KIRP	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg22961513	chr11:14280813	SPON1	0.3	4.94	0.3	1.46e-6	Mitochondrial DNA levels;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07308232	chr7:1071921	C7orf50	-0.6	-7.56	-0.43	7.89e-13	Longevity;Endometriosis;
KIRP	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg12718519	chr1:2058417	PRKCZ	0.23	5.17	0.31	4.82e-7	Height;
KIRP	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.58	-6.15	-0.36	3.16e-9	Prostate cancer;
KIRP	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.46	7.9	0.45	9.29e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	0.76	8.0	0.45	4.96e-14	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.69	-0.48	5.02e-16	Joint mobility (Beighton score);
KIRP	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg17356467	chr2:100759845	AFF3	0.54	5.52	0.33	8.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	0.691	rs2242474	chr4:76878982	T/C	cg00809888	chr4:76862425	NAAA	-0.5	-7.0	-0.41	2.45e-11	Blood protein levels;
KIRP	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.58	7.35	0.42	2.92e-12	Aortic root size;
KIRP	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.55	7.25	0.42	5.33e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.89	11.89	0.6	4.62e-26	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09011162	chr16:961353	LMF1	0.49	6.12	0.36	3.73e-9	Interleukin-4 levels;
KIRP	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.72	6.24	0.37	1.91e-9	Diabetic retinopathy;
KIRP	cis	rs12540874	0.524	rs7804365	chr7:50637148	A/C	cg00647317	chr7:50633725	DDC	0.49	7.29	0.42	4.31e-12	Systemic sclerosis;
KIRP	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg04731861	chr2:219085781	ARPC2	0.3	7.61	0.44	5.73e-13	Colorectal cancer;
KIRP	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.4	0.7	6.37e-38	Gut microbiome composition (summer);
KIRP	cis	rs1978968	0.826	rs5992946	chr22:18466111	G/T	cg02610425	chr22:18483192	MICAL3	0.4	5.04	0.31	9.15e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	1.09	8.9	0.49	1.26e-16	Plasma clusterin levels;
KIRP	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg10755058	chr3:40428713	ENTPD3	0.36	4.85	0.3	2.14e-6	Renal cell carcinoma;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.66	10.87	0.57	1.01e-22	Lymphocyte counts;
KIRP	cis	rs612683	0.862	rs12760924	chr1:100898600	A/T	cg09408571	chr1:101003634	GPR88	0.28	5.89	0.35	1.26e-8	Breast cancer;
KIRP	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg13010199	chr12:38710504	ALG10B	0.41	5.35	0.32	2e-7	Heart rate;
KIRP	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	7.16	0.42	9.14e-12	Aortic root size;
KIRP	cis	rs42648	0.935	rs42651	chr7:89978590	A/G	cg25739043	chr7:89950458	NA	-0.47	-7.74	-0.44	2.59e-13	Homocysteine levels;
KIRP	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.57	7.69	0.44	3.51e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg04369109	chr6:150039330	LATS1	-0.46	-5.55	-0.33	7.25e-8	Lung cancer;
KIRP	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.75	6.14	0.36	3.25e-9	Diabetic retinopathy;
KIRP	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.62	-7.8	-0.45	1.79e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7903847	0.667	rs7096801	chr10:99140969	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.79	-0.4	8.21e-11	Daytime sleep phenotypes;
KIRP	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg14580859	chr9:123691850	NA	0.35	5.0	0.3	1.08e-6	Rheumatoid arthritis;
KIRP	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	13.0	0.64	9.48e-30	Alzheimer's disease;
KIRP	cis	rs4908768	0.581	rs2784739	chr1:8497558	T/G	cg25722041	chr1:8623473	RERE	0.46	5.63	0.34	4.81e-8	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.2	0.31	4.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-0.66	-7.73	-0.44	2.79e-13	Initial pursuit acceleration;
KIRP	cis	rs7258465	1.000	rs8109573	chr19:18617151	G/T	cg10790698	chr19:18539756	SSBP4	-0.34	-7.41	-0.43	2.02e-12	Breast cancer;
KIRP	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg07972983	chr1:205091412	RBBP5	0.41	4.89	0.3	1.82e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7424096	0.582	rs12105781	chr2:37221567	T/C	cg14987922	chr2:37194071	STRN	0.57	5.92	0.35	1.05e-8	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg17145862	chr1:211918768	LPGAT1	0.65	6.37	0.38	9.11e-10	Crohn's disease;
KIRP	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg16141378	chr3:129829833	LOC729375	0.53	7.1	0.41	1.31e-11	Morning vs. evening chronotype;
KIRP	cis	rs9634489	0.511	rs9584361	chr13:97019134	C/T	cg02571835	chr13:96230311	CLDN10	0.36	4.86	0.3	2.06e-6	Body mass index;
KIRP	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg06647332	chr5:131281008	NA	-0.45	-4.98	-0.3	1.19e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg24633833	chr3:10029261	TMEM111	0.52	5.29	0.32	2.75e-7	Alzheimer's disease;
KIRP	cis	rs6539288	0.674	rs989560	chr12:107285751	T/C	cg21360079	chr12:107162445	NA	-0.5	-7.02	-0.41	2.13e-11	Total body bone mineral density;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.23	-0.37	1.98e-9	Longevity;Endometriosis;
KIRP	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	0.71	6.92	0.4	3.91e-11	Methadone dose in opioid dependence;
KIRP	cis	rs3105593	0.933	rs11633404	chr15:50899309	C/A	cg05456662	chr15:50716270	USP8	0.38	4.95	0.3	1.36e-6	QT interval;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16232504	chr1:99127707	SNX7	0.98	6.46	0.38	5.63e-10	P wave terminal force;
KIRP	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.41	5.8	0.35	2.04e-8	Ovarian reserve;
KIRP	cis	rs11638352	1.000	rs4924737	chr15:44364901	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.75	-5.15	-0.31	5.43e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg24253500	chr15:84953950	NA	0.54	6.17	0.37	2.75e-9	Schizophrenia;
KIRP	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg03959625	chr15:84868606	LOC388152	0.5	5.74	0.34	2.83e-8	Schizophrenia;
KIRP	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	cg21523751	chr1:182988639	NA	0.44	6.8	0.4	8e-11	Colorectal cancer;
KIRP	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg00933542	chr6:150070202	PCMT1	0.27	5.32	0.32	2.35e-7	Lung cancer;
KIRP	cis	rs7224685	0.569	rs35977026	chr17:4036528	G/A	cg11204139	chr17:3907470	NA	0.55	5.05	0.31	8.5e-7	Type 2 diabetes;
KIRP	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.6	7.27	0.42	4.72e-12	Platelet count;
KIRP	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19373090	chr19:797215	PTBP1	0.48	6.36	0.38	9.75e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	cg12689670	chr1:183009347	LAMC1	0.58	8.17	0.46	1.63e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg22244940	chr12:132335942	MMP17	0.47	5.87	0.35	1.37e-8	Migraine;
KIRP	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg21108841	chr4:24914750	CCDC149	0.46	5.73	0.34	2.86e-8	Heschl's gyrus morphology;
KIRP	trans	rs7679673	0.813	rs2007403	chr4:106131210	A/G	cg11223512	chr8:143615353	BAI1	-0.44	-6.02	-0.36	6.16e-9	Cancer (pleiotropy);Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Prostate cancer;Myeloid white cell count;Sum neutrophil eosinophil counts;Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.28	4.89	0.3	1.85e-6	Renal function-related traits (BUN);
KIRP	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.9	14.46	0.68	1.04e-34	Mean corpuscular volume;
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg04660111	chr19:49199234	FUT2	0.36	5.54	0.33	7.8e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs7027203	0.576	rs11792101	chr9:96535470	C/T	cg14598338	chr9:96623480	NA	0.45	6.85	0.4	5.91e-11	DNA methylation (variation);
KIRP	cis	rs9463078	0.547	rs2038555	chr6:44744033	A/G	cg25276700	chr6:44698697	NA	0.34	4.94	0.3	1.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs8067545	0.532	rs12946508	chr17:19952059	A/T	cg04132472	chr17:19861366	AKAP10	0.42	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	trans	rs4352251	0.673	rs4851420	chr2:101956124	C/T	cg01941881	chr14:105793310	PACS2	-0.65	-6.48	-0.38	4.87e-10	Adiponectin levels (BMI-adjusted);Adiponectin levels;
KIRP	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-1.07	-7.18	-0.42	8.42e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg17810781	chr1:201082982	CACNA1S	0.4	6.29	0.37	1.42e-9	Permanent tooth development;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17864619	chr19:45971158	FOSB	0.46	6.04	0.36	5.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.62	-7.57	-0.43	7.66e-13	Mosquito bite size;
KIRP	cis	rs6973256	0.897	rs10236819	chr7:133345983	A/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.39	-0.38	8.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-0.88	-13.71	-0.66	3.59e-32	Total body bone mineral density;
KIRP	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.54	-7.58	-0.44	6.99e-13	Schizophrenia;
KIRP	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.64	-9.26	-0.51	1.04e-17	Educational attainment;
KIRP	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg02002194	chr4:3960332	NA	-0.44	-6.65	-0.39	1.85e-10	Mood instability;
KIRP	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg12432903	chr7:1882776	MAD1L1	0.52	4.86	0.3	2.13e-6	Bipolar disorder;
KIRP	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.29	0.55	6.71e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg13565492	chr6:43139072	SRF	-0.93	-8.6	-0.48	9.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.82	-8.52	-0.48	1.58e-15	Vitamin D levels;
KIRP	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg23188430	chr6:125850052	NA	-0.35	-5.5	-0.33	9.51e-8	Brugada syndrome;
KIRP	cis	rs10463554	0.759	rs34815	chr5:102434265	C/T	cg23492399	chr5:102201601	PAM	-0.5	-5.44	-0.33	1.26e-7	Parkinson's disease;
KIRP	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	10.94	0.57	5.81e-23	Personality dimensions;
KIRP	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs11645898	0.687	rs11075919	chr16:72106906	T/C	cg14768367	chr16:72042858	DHODH	-0.63	-7.49	-0.43	1.22e-12	Blood protein levels;
KIRP	cis	rs2281845	0.859	rs58364051	chr1:201077667	A/G	cg17810781	chr1:201082982	CACNA1S	0.41	6.37	0.38	9.45e-10	Permanent tooth development;
KIRP	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg09699651	chr6:150184138	LRP11	0.4	5.23	0.32	3.65e-7	Lung cancer;
KIRP	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.7	-9.85	-0.53	1.61e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg05044414	chr3:183734942	ABCC5	0.36	5.32	0.32	2.32e-7	Anterior chamber depth;
KIRP	cis	rs9972944	0.651	rs8080916	chr17:63816368	G/C	cg07283582	chr17:63770753	CCDC46	-0.5	-7.92	-0.45	7.95e-14	Total body bone mineral density;
KIRP	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg18306943	chr3:40428807	ENTPD3	0.46	6.05	0.36	5.36e-9	Renal cell carcinoma;
KIRP	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04827379	chr10:118083701	C10orf96	-0.45	-7.29	-0.42	4.17e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.27	5.52	0.33	8.61e-8	Height;
KIRP	cis	rs55692468	0.848	rs2346206	chr2:153362979	G/A	cg04681845	chr2:153283485	FMNL2	0.47	5.95	0.35	9.29e-9	Intraocular pressure;
KIRP	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg22437258	chr11:111473054	SIK2	0.61	7.12	0.41	1.16e-11	Primary sclerosing cholangitis;
KIRP	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17376030	chr22:41985996	PMM1	0.7	7.58	0.43	7.19e-13	Vitiligo;
KIRP	cis	rs11610422	1.000	rs12824459	chr12:31414435	C/T	cg14306366	chr12:31406441	NA	-0.57	-5.88	-0.35	1.36e-8	Coronary artery disease;
KIRP	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.71	-10.51	-0.56	1.41e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg09264619	chr17:80180166	NA	0.51	6.07	0.36	4.88e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2574704	0.961	rs11712416	chr3:11649334	G/A	cg07643000	chr3:11666825	VGLL4	0.38	5.51	0.33	9e-8	Body mass index;
KIRP	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.45	-6.87	-0.4	5.14e-11	Schizophrenia;
KIRP	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.6e-6	Total body bone mineral density;
KIRP	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.59	-7.44	-0.43	1.7e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg05991184	chr2:219186017	PNKD	-0.36	-5.07	-0.31	7.79e-7	Colorectal cancer;
KIRP	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg02297831	chr4:17616191	MED28	0.53	6.58	0.39	2.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4523957	0.579	rs903160	chr17:2091765	C/T	cg16513277	chr17:2031491	SMG6	-0.71	-10.28	-0.55	7.24e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12480562	chr20:23434244	CST11	0.64	5.09	0.31	7.02e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.0	-0.3	1.1e-6	Coronary artery disease;
KIRP	cis	rs1448094	0.791	rs61929395	chr12:86331584	A/T	cg02569458	chr12:86230093	RASSF9	0.36	5.27	0.32	3.03e-7	Major depressive disorder;
KIRP	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.69	10.09	0.54	2.93e-20	Dupuytren's disease;
KIRP	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.16	0.42	9.55e-12	Lung cancer;
KIRP	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg02297831	chr4:17616191	MED28	0.5	6.07	0.36	4.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs687432	0.924	rs61905309	chr11:57746574	G/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.04	-0.5	4.95e-17	Parkinson's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	ch.1.69949640R	chr1:70177052	NA	-0.43	-6.2	-0.37	2.41e-9	C-reactive protein;
KIRP	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.68	6.06	0.36	4.98e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg22563815	chr15:78856949	CHRNA5	0.51	7.45	0.43	1.57e-12	Sudden cardiac arrest;
KIRP	cis	rs4654899	0.643	rs651538	chr1:21097866	A/G	cg08890418	chr1:21044141	KIF17	0.34	5.16	0.31	5.12e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	1.05	9.36	0.51	5.4e-18	Type 2 diabetes;
KIRP	trans	rs62056376	0.688	rs62056378	chr17:32671362	G/A	cg17635953	chr13:28535085	NA	-0.68	-6.7	-0.39	1.41e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2458413	0.500	rs2458415	chr8:105351998	A/C	cg08657449	chr8:105351661	TM7SF4	-0.38	-6.0	-0.36	7.11e-9	Paget's disease;
KIRP	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.8	0.35	2.04e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.49	6.34	0.37	1.1e-9	Blood metabolite levels;
KIRP	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.84	-7.07	-0.41	1.63e-11	Obesity-related traits;
KIRP	cis	rs4865169	0.871	rs9918067	chr4:57870544	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.46	-5.51	-0.33	8.9e-8	Breast cancer;
KIRP	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg10223061	chr2:219282414	VIL1	0.42	6.53	0.38	3.74e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17936460	chr4:1872235	WHSC1	0.51	6.51	0.38	4.11e-10	Parkinson's disease;
KIRP	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs240764	0.658	rs2132169	chr6:101177663	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.57	-0.33	6.53e-8	Neuroticism;
KIRP	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-5.68	-0.34	3.75e-8	Schizophrenia;
KIRP	cis	rs3104707	0.588	rs2650432	chr16:10069081	A/G	cg06299307	chr16:10133466	GRIN2A	0.43	4.91	0.3	1.68e-6	Subjective well-being;
KIRP	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.82	13.41	0.65	3.93e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.53	7.42	0.43	1.85e-12	Mean corpuscular volume;
KIRP	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.02	13.28	0.65	1.07e-30	Exhaled nitric oxide output;
KIRP	cis	rs6496667	0.779	rs7175476	chr15:91027184	G/C	cg10434728	chr15:90938212	IQGAP1	0.36	5.0	0.3	1.07e-6	Rheumatoid arthritis;
KIRP	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.64	8.24	0.47	9.97e-15	Prudent dietary pattern;
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg21734707	chr17:3908241	ZZEF1	0.68	10.35	0.55	4.53e-21	Type 2 diabetes;
KIRP	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.5	0.65	1.84e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg25039879	chr17:56429692	SUPT4H1	0.59	5.17	0.31	4.9e-7	Cognitive test performance;
KIRP	trans	rs4733781	1.000	rs4733781	chr8:131296767	A/C	cg26979473	chr7:137028389	PTN	-0.47	-6.29	-0.37	1.45e-9	Tuberculosis;
KIRP	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.38	7.71	0.44	3.04e-13	IgG glycosylation;
KIRP	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.87	-0.4	5.28e-11	Aortic root size;
KIRP	cis	rs72960926	0.744	rs6933439	chr6:75006170	T/C	cg03266952	chr6:74778945	NA	-0.65	-5.83	-0.35	1.74e-8	Metabolite levels (MHPG);
KIRP	cis	rs9549328	0.879	rs12428058	chr13:113636504	G/A	cg17524180	chr13:113633600	MCF2L	-0.28	-5.15	-0.31	5.22e-7	Systolic blood pressure;
KIRP	cis	rs6952809	0.961	rs7796798	chr7:2450794	T/A	cg25507518	chr7:2405875	EIF3B	0.37	5.17	0.31	4.95e-7	Multiple sclerosis;
KIRP	cis	rs754423	0.515	rs34973015	chr14:52552690	T/C	cg05884192	chr14:52515736	NID2	0.47	5.2	0.31	4.29e-7	Craniofacial microsomia;
KIRP	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	0.84	7.39	0.43	2.33e-12	Lung disease severity in cystic fibrosis;
KIRP	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	7.97	0.45	5.96e-14	Neuroticism;
KIRP	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	0.83	12.39	0.62	9.95e-28	Dupuytren's disease;
KIRP	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.81	10.69	0.56	3.73e-22	Height;
KIRP	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.03	0.31	9.45e-7	Axial length;
KIRP	cis	rs9815354	0.767	rs61283393	chr3:41854135	T/G	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs28489187	0.617	rs2840319	chr1:85886224	C/T	cg16011679	chr1:85725395	C1orf52	-0.43	-5.35	-0.32	2.05e-7	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.93	-0.4	3.61e-11	Systolic blood pressure;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg25547332	chr5:131281432	NA	0.46	5.11	0.31	6.52e-7	Life satisfaction;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-1.05	-20.72	-0.8	7.03e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6855629	0.667	rs6533181	chr4:106074826	T/G	cg08924430	chr4:106067052	TET2	0.36	5.25	0.32	3.29e-7	Height;
KIRP	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg21775007	chr8:11205619	TDH	0.45	5.97	0.36	8.05e-9	Myopia (pathological);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg24294544	chr10:43866966	FXYD4	-0.36	-6.84	-0.4	6.21e-11	Bladder cancer;
KIRP	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-10.11	-0.54	2.5e-20	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg04166393	chr7:2884313	GNA12	0.64	7.48	0.43	1.35e-12	Height;
KIRP	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg13047869	chr3:10149882	C3orf24	0.54	5.31	0.32	2.44e-7	Alzheimer's disease;
KIRP	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg12962167	chr3:53033115	SFMBT1	0.71	5.36	0.32	1.95e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.59	7.27	0.42	4.89e-12	Schizophrenia;
KIRP	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.52	0.52	1.7e-18	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg08901578	chr4:187885870	NA	-0.51	-7.86	-0.45	1.22e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs2458413	0.542	rs2458430	chr8:105367785	C/T	cg08657449	chr8:105351661	TM7SF4	0.33	5.57	0.33	6.6e-8	Paget's disease;
KIRP	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs1165472	0.755	rs9326037	chr1:56163458	G/A	cg11523071	chr1:56160889	NA	-0.62	-8.13	-0.46	2.07e-14	Paclitaxel-induced neuropathy;
KIRP	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg09888468	chr15:81410853	NA	-0.49	-6.31	-0.37	1.29e-9	QT interval (drug interaction);
KIRP	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg13206674	chr6:150067644	NUP43	0.48	6.72	0.39	1.26e-10	Lung cancer;
KIRP	cis	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg21204522	chr6:27730016	NA	-0.61	-5.17	-0.31	4.87e-7	Lung cancer in ever smokers;
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg16867584	chr19:49200180	FUT2	0.31	4.95	0.3	1.4e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.59	-7.71	-0.44	3.1400000000000003e-13	Multiple myeloma (IgH translocation);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09838262	chr17:37921981	IKZF3	0.55	7.33	0.42	3.38e-12	Interleukin-4 levels;
KIRP	cis	rs7317038	0.869	rs61966631	chr13:114015702	T/C	cg18412546	chr13:114005154	GRTP1	-0.37	-5.55	-0.33	7.55e-8	Mean platelet volume;
KIRP	cis	rs6910061	1.000	rs34846077	chr6:11096561	G/A	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	cis	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg06521331	chr12:34319734	NA	-0.58	-7.13	-0.41	1.08e-11	Morning vs. evening chronotype;
KIRP	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg21475434	chr5:93447410	FAM172A	0.67	5.54	0.33	7.77e-8	Diabetic retinopathy;
KIRP	cis	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg16898833	chr6:26189333	HIST1H4D	0.7	5.57	0.33	6.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg05187965	chr10:45406764	TMEM72	-0.3	-6.9	-0.4	4.36e-11	Mean corpuscular volume;
KIRP	cis	rs55962025	0.842	rs2269477	chr4:3184464	G/T	cg06533319	chr4:3265114	C4orf44	0.47	4.99	0.3	1.13e-6	Parental longevity (mother's age at death);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14021714	chr12:3757418	EFCAB4B	0.47	6.06	0.36	5.19e-9	Interleukin-4 levels;
KIRP	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.69	7.1	0.41	1.3e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.64	-6.61	-0.39	2.39e-10	Gut microbiome composition (summer);
KIRP	cis	rs7709377	0.597	rs12657249	chr5:115520736	A/C	cg23108291	chr5:115420582	COMMD10	0.44	5.35	0.32	1.98e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.57	-6.52	-0.38	3.95e-10	Menarche (age at onset);
KIRP	cis	rs4262150	0.764	rs17452991	chr5:151938965	C/G	cg12297329	chr5:152029980	NA	0.66	8.06	0.46	3.23e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg19847130	chr8:10466454	RP1L1	0.37	5.41	0.33	1.49e-7	Neuroticism;
KIRP	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.66	0.34	4.1e-8	Total cholesterol levels;
KIRP	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg14952266	chr13:112191215	NA	-0.43	-6.24	-0.37	1.9e-9	Hepatitis;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg08306513	chr11:120040083	NA	0.67	6.33	0.37	1.12e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg24874828	chr4:187887005	NA	0.48	7.16	0.42	9.31e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9886651	0.869	rs11779374	chr8:128792310	G/A	cg24514600	chr8:128805414	PVT1	-0.73	-12.54	-0.62	3.2e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg19773385	chr1:10388646	KIF1B	-0.73	-11.71	-0.6	1.84e-25	Hepatocellular carcinoma;
KIRP	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-5.32	-0.32	2.31e-7	Crohn's disease;
KIRP	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg06636001	chr8:8085503	FLJ10661	0.61	8.34	0.47	5.19e-15	Neuroticism;
KIRP	cis	rs5750854	0.530	rs5750863	chr22:40026948	A/T	cg21377881	chr22:40064566	CACNA1I	-0.37	-4.95	-0.3	1.4e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg18404041	chr3:52824283	ITIH1	0.41	5.23	0.32	3.61e-7	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.64	5.36	0.32	1.95e-7	Putamen volume;
KIRP	cis	rs10875746	0.669	rs10783244	chr12:48664989	A/C	cg26205652	chr12:48591994	NA	0.62	8.09	0.46	2.76e-14	Longevity (90 years and older);
KIRP	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21643547	chr1:205240462	TMCC2	-0.87	-14.21	-0.67	7.11e-34	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.9	-0.53	1.14e-19	Retinal vascular caliber;
KIRP	cis	rs77688320	0.500	rs6755428	chr2:202295766	T/A	cg06431681	chr2:202330990	STRADB	0.57	7.72	0.44	2.86e-13	Breast cancer;
KIRP	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.8200000000000003e-11	Hypertriglyceridemia;
KIRP	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.08	0.31	7.29e-7	Schizophrenia;
KIRP	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.48	-0.43	1.35e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.78	-0.35	2.26e-8	Educational attainment;
KIRP	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.89	13.89	0.66	8.94e-33	Colorectal cancer;
KIRP	trans	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.66	-9.18	-0.51	1.85e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg11569703	chr11:65557185	OVOL1	-0.48	-8.45	-0.47	2.5e-15	Acne (severe);
KIRP	cis	rs8084125	0.765	rs72981157	chr18:74944238	A/G	cg05528293	chr18:74961138	GALR1	0.5	5.35	0.32	2.03e-7	Obesity-related traits;
KIRP	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.62	9.04	0.5	4.72e-17	Resting heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14266050	chr4:2845671	ADD1	0.51	6.78	0.4	8.63e-11	Parkinson's disease;
KIRP	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.93	16.11	0.72	2.28e-40	Menarche (age at onset);
KIRP	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.76	8.8	0.49	2.46e-16	High light scatter reticulocyte count;
KIRP	cis	rs6866344	0.569	rs56027952	chr5:178150181	C/A	cg03877680	chr5:178157825	ZNF354A	1.03	13.17	0.64	2.44e-30	Neutrophil percentage of white cells;
KIRP	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.68	5.78	0.35	2.24e-8	Diabetic retinopathy;
KIRP	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.57	-7.01	-0.41	2.26e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24977338	chr2:113188963	RGPD8;RGPD5	0.69	6.15	0.36	3.17e-9	Yeast infection;
KIRP	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.44	-0.62	6.87e-28	Primary sclerosing cholangitis;
KIRP	cis	rs501120	0.584	rs61857482	chr10:44716905	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7700895	0.729	rs3777182	chr5:95263752	T/A	cg16656078	chr5:95278638	ELL2	-0.38	-5.61	-0.34	5.38e-8	IgG glycosylation;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.81	-12.3	-0.62	2.08e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.4	3.46e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.99	13.46	0.65	2.62e-31	Ulcerative colitis;
KIRP	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg18657303	chr4:1051139	NA	0.53	4.87	0.3	2.02e-6	Recombination rate (females);
KIRP	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.67	9.99	0.54	5.93e-20	Pulse pressure;
KIRP	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.02	-0.36	6.39e-9	Breast cancer;
KIRP	cis	rs61884328	0.852	rs61896125	chr11:47097298	C/T	cg23433285	chr11:47201945	PACSIN3	0.71	5.85	0.35	1.54e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.81	9.01	0.5	6.02e-17	Platelet count;
KIRP	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg26585981	chr11:48327164	OR4S1	0.49	6.18	0.37	2.63e-9	Migraine - clinic-based;
KIRP	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.78	10.41	0.55	2.97e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg03161606	chr19:29218774	NA	0.74	6.58	0.39	2.74e-10	Methadone dose in opioid dependence;
KIRP	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.48	-0.33	1.06e-7	Neuroticism;
KIRP	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.15	12.4	0.62	9.58e-28	Mitochondrial DNA levels;
KIRP	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.7	8.1	0.46	2.59e-14	Pediatric autoimmune diseases;
KIRP	trans	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg00938859	chr5:1591904	SDHAP3	-0.59	-7.9	-0.45	9.53e-14	Breast cancer;
KIRP	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08045932	chr20:61659980	NA	0.47	4.92	0.3	1.59e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs448720	0.840	rs10775195	chr15:68186641	C/T	cg24579218	chr15:68104479	NA	0.35	5.1	0.31	6.85e-7	Cognitive performance;
KIRP	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg00343986	chr7:65444356	GUSB	0.48	5.77	0.35	2.32e-8	Aortic root size;
KIRP	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg12317470	chr15:67143691	NA	-0.54	-5.2	-0.31	4.12e-7	Lung cancer (smoking interaction);
KIRP	cis	rs7937612	1.000	rs7937612	chr11:120278688	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.27	-0.42	4.73e-12	Intraocular pressure;
KIRP	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.4	-0.43	2.14e-12	Retinal vascular caliber;
KIRP	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg17863274	chr19:49399704	TULP2	-0.41	-5.85	-0.35	1.57e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7011049	0.841	rs12375409	chr8:53868886	G/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs7923609	0.935	rs10995477	chr10:65010672	T/C	cg08743896	chr10:65200160	JMJD1C	-0.39	-5.74	-0.34	2.77e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.3	-5.53	-0.33	8.21e-8	Monocyte percentage of white cells;
KIRP	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg10503236	chr1:231470652	EXOC8	-0.53	-7.44	-0.43	1.69e-12	Hemoglobin concentration;
KIRP	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.46	-5.33	-0.32	2.25e-7	Cognitive test performance;
KIRP	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.59	8.24	0.47	1.03e-14	Economic and political preferences (feminism/equality);
KIRP	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.72	10.18	0.54	1.54e-20	Parkinson's disease;
KIRP	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16386425	chr10:429943	DIP2C	-0.53	-7.34	-0.42	3.02e-12	Psychosis in Alzheimer's disease;
KIRP	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.65	-8.8	-0.49	2.48e-16	Huntington's disease progression;
KIRP	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	11.65	0.6	2.91e-25	Schizophrenia;
KIRP	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.63	-0.34	4.87e-8	Aortic root size;
KIRP	cis	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs2033908	0.620	rs1440272	chr11:12852309	G/A	cg25843174	chr11:12811716	TEAD1	-0.29	-5.5	-0.33	9.72e-8	Sitting height ratio;
KIRP	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs986417	0.901	rs1024224	chr14:60926942	C/G	cg27398547	chr14:60952738	C14orf39	0.74	7.43	0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg00405596	chr8:11794950	NA	-0.45	-5.96	-0.36	8.53e-9	Triglycerides;
KIRP	cis	rs1345301	1.000	rs10200410	chr2:102870871	G/A	cg12451869	chr2:102867685	NA	0.4	5.82	0.35	1.87e-8	Waist circumference;
KIRP	cis	rs4783244	0.862	rs4782721	chr16:82656995	A/G	cg09415485	chr16:82663111	CDH13	0.28	5.39	0.32	1.66e-7	Adiponectin levels;
KIRP	cis	rs11997175	0.531	rs113627999	chr8:33737335	G/T	ch.8.33884649F	chr8:33765107	NA	0.58	6.76	0.4	9.84e-11	Body mass index;
KIRP	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.58	7.77	0.44	2.1e-13	Blood protein levels;
KIRP	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.86	7.53	0.43	9.79e-13	Exhaled nitric oxide output;
KIRP	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.72	0.34	3.1e-8	Homoarginine levels;
KIRP	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg04166393	chr7:2884313	GNA12	0.66	7.66	0.44	4.19e-13	Height;
KIRP	cis	rs7656342	0.599	rs6852425	chr4:9856859	G/T	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.89	-0.35	1.24e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.53	6.74	0.39	1.13e-10	Tonsillectomy;
KIRP	cis	rs57561814	1.000	rs57561814	chr7:22753675	G/C	cg26061582	chr7:22766209	IL6	0.82	6.16	0.37	2.87e-9	Tonsillectomy;
KIRP	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.3	0.32	2.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.53e-11	Iron status biomarkers;
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg25486957	chr4:152246857	NA	-0.5	-5.29	-0.32	2.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.39	5.55	0.33	7.48e-8	Body mass index;
KIRP	cis	rs1448094	0.842	rs7978562	chr12:86451478	A/G	cg02569458	chr12:86230093	RASSF9	0.35	5.07	0.31	7.9e-7	Major depressive disorder;
KIRP	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.65	-7.06	-0.41	1.7e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg06742321	chr12:123595122	PITPNM2	0.45	5.5	0.33	9.3e-8	Platelet count;
KIRP	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	1.02	19.46	0.78	1.06e-51	Breast cancer;
KIRP	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6772849	0.768	rs9820741	chr3:128416080	G/A	cg08795948	chr3:128337044	NA	0.43	5.09	0.31	7.06e-7	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.78	0.4	9.07e-11	Bipolar disorder;
KIRP	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.45	5.33	0.32	2.27e-7	Colorectal cancer;
KIRP	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-10.89	-0.57	8.67e-23	Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13038030	chr17:73267041	MIF4GD	0.64	7.5	0.43	1.17e-12	Smoking initiation;
KIRP	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg13293535	chr8:11597251	GATA4	-0.41	-5.32	-0.32	2.35e-7	Retinal vascular caliber;
KIRP	cis	rs17221829	0.764	rs7945447	chr11:89386070	A/G	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.83	0.57	1.34e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	8.42	0.47	3.09e-15	Response to antipsychotic treatment;
KIRP	cis	rs7246967	0.611	rs62120457	chr19:22958519	A/G	cg03230154	chr19:22817176	ZNF492	0.5	4.93	0.3	1.51e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs240764	0.604	rs9373590	chr6:101212001	A/T	cg09795085	chr6:101329169	ASCC3	0.45	5.21	0.32	4.06e-7	Neuroticism;
KIRP	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg01420254	chr6:26195488	NA	1.14	10.18	0.54	1.59e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg27532560	chr4:187881888	NA	-0.74	-12.28	-0.62	2.33e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.48	-6.78	-0.4	8.73e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4908768	0.817	rs11577530	chr1:8743444	C/T	cg25722041	chr1:8623473	RERE	0.78	8.68	0.48	5.5e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6662572	0.723	rs72677543	chr1:46565329	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.79	0.35	2.11e-8	Blood protein levels;
KIRP	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.64	-7.05	-0.41	1.78e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.44	5.68	0.34	3.87e-8	Cardiovascular disease risk factors;
KIRP	cis	rs4700695	1.000	rs12518359	chr5:65397909	T/C	cg21114390	chr5:65439923	SFRS12	-0.48	-5.67	-0.34	4.03e-8	Facial morphology (factor 19);
KIRP	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.75	-8.98	-0.5	7.06e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-10.86	-0.57	1.05e-22	Sense of smell;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.68e-8	Life satisfaction;
KIRP	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.53	9.25	0.51	1.15e-17	Vitiligo;
KIRP	cis	rs1656402	0.953	rs10933398	chr2:233440544	G/A	cg03852847	chr2:233439513	NA	-0.68	-8.97	-0.5	7.96e-17	Non-small cell lung cancer (survival);
KIRP	cis	rs787274	0.619	rs1475293	chr9:115619587	C/T	cg13803584	chr9:115635662	SNX30	0.61	6.82	0.4	7.21e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg13615516	chr5:77269221	NA	0.51	8.03	0.46	4.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.49	5.98	0.36	7.76e-9	Height;
KIRP	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07570687	chr10:102243282	WNT8B	0.5	6.5	0.38	4.36e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6832769	0.925	rs6829182	chr4:56454156	C/T	cg05960024	chr4:56376020	CLOCK	0.61	7.74	0.44	2.58e-13	Personality dimensions;
KIRP	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.09	-0.31	7.2e-7	Pulmonary function;
KIRP	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.63	6.81	0.4	7.45e-11	Gut microbiome composition (summer);
KIRP	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.49	-5.94	-0.35	9.7e-9	Asthma (sex interaction);
KIRP	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg21064579	chr19:49206444	FUT2	0.53	7.56	0.43	8.04e-13	Dietary macronutrient intake;
KIRP	cis	rs4886920	0.862	rs35020526	chr15:78137862	G/T	cg10461261	chr15:78109450	NA	-0.32	-5.21	-0.32	4.05e-7	Neuroticism;
KIRP	cis	rs9525562	0.513	rs73468973	chr13:42613890	G/A	cg07025593	chr13:42613794	NA	0.46	5.21	0.32	4.05e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2014572	0.967	rs11084492	chr19:57756026	A/T	cg12963866	chr19:57752005	ZNF805	-0.49	-6.28	-0.37	1.53e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs9469913	0.604	rs2764203	chr6:34708901	A/G	cg17674042	chr6:34482479	PACSIN1	-0.39	-5.37	-0.32	1.84e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.73e-8	Life satisfaction;
KIRP	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.98	-10.48	-0.56	1.75e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg08807101	chr21:30365312	RNF160	-0.44	-5.27	-0.32	2.92e-7	Pancreatic cancer;
KIRP	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.88e-16	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg13319975	chr6:146136371	FBXO30	0.46	6.1	0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16543009	chr15:34331514	AVEN;CHRM5	0.43	6.06	0.36	5.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6988636	0.710	rs62521797	chr8:124134321	A/T	cg15893493	chr8:124194847	FAM83A	0.91	6.74	0.39	1.15e-10	Urinary uromodulin levels;
KIRP	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg00310523	chr12:86230176	RASSF9	0.38	5.85	0.35	1.56e-8	Major depressive disorder;
KIRP	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.26	0.51	1.03e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6693295	0.752	rs2787997	chr1:246233442	G/A	cg11798871	chr1:246315928	SMYD3	-0.41	-5.27	-0.32	3.01e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-5.11	-0.31	6.45e-7	Birth weight;
KIRP	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12826209	chr6:26865740	GUSBL1	0.45	5.61	0.34	5.32e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	0.42	5.58	0.34	6.36e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.98	17.99	0.75	9.26e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.7	-0.34	3.38e-8	Height;
KIRP	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg03929089	chr4:120376271	NA	0.76	6.7	0.39	1.43e-10	Intraocular pressure;
KIRP	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	1.09	17.49	0.74	4.85e-45	Cognitive function;
KIRP	cis	rs654950	0.841	rs2759247	chr1:41991756	G/C	cg06885757	chr1:42089581	HIVEP3	-0.46	-6.45	-0.38	5.81e-10	Airway imaging phenotypes;
KIRP	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.76	9.48	0.52	2.3e-18	Height;
KIRP	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg00042356	chr1:8021962	PARK7	0.84	7.16	0.42	9.46e-12	Inflammatory bowel disease;
KIRP	cis	rs6546886	0.833	rs12713804	chr2:74238709	C/T	cg14702570	chr2:74259524	NA	-0.26	-4.86	-0.3	2.07e-6	Dialysis-related mortality;
KIRP	cis	rs10203711	0.933	rs11885493	chr2:239584919	G/T	cg14580085	chr2:239553406	NA	0.4	5.13	0.31	5.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	14.02	0.67	3.17e-33	Smoking behavior;
KIRP	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg19866673	chr12:132237789	SFRS8	-0.34	-4.94	-0.3	1.47e-6	Migraine;
KIRP	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg21858823	chr1:15850916	CASP9	0.53	5.74	0.34	2.84e-8	Systolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06914050	chr7:56119237	PSPH;CCT6A	0.52	6.38	0.38	8.96e-10	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23665147	chr14:93760360	BTBD7	0.45	6.04	0.36	5.75e-9	Myopia (pathological);
KIRP	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18932078	chr1:2524107	MMEL1	0.43	5.99	0.36	7.39e-9	Ulcerative colitis;
KIRP	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.48	-5.11	-0.31	6.5e-7	Platelet distribution width;
KIRP	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.92	-12.38	-0.62	1.08e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs8084125	0.832	rs62105171	chr18:74945663	G/A	cg05528293	chr18:74961138	GALR1	0.5	5.29	0.32	2.75e-7	Obesity-related traits;
KIRP	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg00677455	chr12:58241039	CTDSP2	-0.5	-6.08	-0.36	4.57e-9	Multiple sclerosis;
KIRP	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg27068330	chr11:65405492	SIPA1	-0.42	-5.42	-0.33	1.43e-7	Acne (severe);
KIRP	cis	rs1881396	0.947	rs77350364	chr2:27866139	A/G	cg27432699	chr2:27873401	GPN1	0.62	6.93	0.4	3.73e-11	Nonalcoholic fatty liver disease;
KIRP	cis	rs1858037	0.765	rs67404371	chr2:65597271	C/A	cg08085232	chr2:65598271	SPRED2	-0.54	-6.45	-0.38	5.78e-10	Rheumatoid arthritis;
KIRP	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.79	-11.54	-0.59	6.38e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg20701182	chr2:24300061	SF3B14	0.48	4.98	0.3	1.2e-6	Asthma;
KIRP	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg24253500	chr15:84953950	NA	0.52	5.99	0.36	7.33e-9	Schizophrenia;
KIRP	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.61	6.24	0.37	1.9e-9	Menarche (age at onset);
KIRP	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.54	-5.15	-0.31	5.35e-7	Narcolepsy;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg22491279	chr19:8008671	TIMM44	-1.14	-6.45	-0.38	5.79e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.75	9.4	0.51	3.96e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.17	0.7	3.81e-37	Platelet count;
KIRP	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.54	-7.22	-0.42	6.64e-12	Total body bone mineral density;
KIRP	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg15893493	chr8:124194847	FAM83A	0.93	8.13	0.46	2.14e-14	Urinary uromodulin levels;
KIRP	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.51	6.8	0.4	7.75e-11	Coronary artery disease;
KIRP	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.4	-0.33	1.54e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.02	13.28	0.65	1.07e-30	Exhaled nitric oxide output;
KIRP	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.73e-10	Diabetic kidney disease;
KIRP	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs830233	0.732	rs7700903	chr5:165436872	T/C	cg13976338	chr5:165423657	NA	-0.73	-7.85	-0.45	1.29e-13	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg13206674	chr6:150067644	NUP43	0.69	10.52	0.56	1.31e-21	Lung cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg22099404	chr17:4458623	MYBBP1A	-0.56	-6.68	-0.39	1.55e-10	Menopause (age at onset);
KIRP	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg21926883	chr2:100939477	LONRF2	-0.56	-7.6	-0.44	6.23e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9810890	1.000	rs41266497	chr3:128526207	A/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs6539288	0.677	rs10778518	chr12:107343950	C/T	cg15890332	chr12:107067104	RFX4	-0.38	-6.59	-0.39	2.67e-10	Total body bone mineral density;
KIRP	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.73	-12.43	-0.62	7.3e-28	Itch intensity from mosquito bite;
KIRP	cis	rs7404928	0.645	rs10852255	chr16:23850580	C/T	cg21745164	chr16:23765304	CHP2	-0.72	-8.32	-0.47	6.15e-15	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg27144592	chr16:783916	NARFL	0.35	4.93	0.3	1.53e-6	Height;
KIRP	cis	rs2395528	0.514	rs2559537	chr10:80122446	A/G	cg08356028	chr10:80217969	NA	0.32	4.99	0.3	1.14e-6	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs6909279	0.933	rs6557149	chr6:151876413	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.47	-6.19	-0.37	2.43e-9	Bone mineral density;
KIRP	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.72	0.44	2.93e-13	Coronary artery calcification;
KIRP	cis	rs7289126	1.000	rs4820328	chr22:38635679	C/T	cg25457927	chr22:38595422	NA	-0.32	-7.05	-0.41	1.84e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.92	-12.77	-0.63	5.29e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.5	-4.85	-0.3	2.21e-6	IFN-related cytopenia;
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.63	5.9	0.35	1.2e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.29	5.89	0.35	1.27e-8	Schizophrenia;
KIRP	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.24	-0.32	3.42e-7	Inflammatory bowel disease;
KIRP	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.64	-0.39	2e-10	Blood pressure;
KIRP	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.67	8.83	0.49	1.97e-16	Breast cancer;
KIRP	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg15436174	chr10:43711423	RASGEF1A	0.78	8.37	0.47	4.24e-15	Hirschsprung disease;
KIRP	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg25124228	chr12:125621409	AACS	-0.51	-5.93	-0.35	9.96e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-8.36	-0.47	4.55e-15	Obesity-related traits;
KIRP	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg23803603	chr1:2058230	PRKCZ	0.36	5.7	0.34	3.36e-8	Height;
KIRP	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg21775007	chr8:11205619	TDH	-0.44	-5.93	-0.35	1.01e-8	Triglycerides;
KIRP	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg15841412	chr13:111365552	ING1	-0.51	-5.82	-0.35	1.86e-8	Coronary artery disease;
KIRP	cis	rs7084402	0.967	rs1658477	chr10:60289607	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.68	6.56	0.39	3.19e-10	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.66	-9.03	-0.5	5.24e-17	Hypospadias;
KIRP	cis	rs1497828	0.956	rs2646819	chr1:217525691	T/G	cg04411442	chr1:217543379	NA	-0.41	-6.19	-0.37	2.45e-9	Dialysis-related mortality;
KIRP	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	7.52	0.43	1.01e-12	Caffeine consumption;
KIRP	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-8.81	-0.49	2.35e-16	Mitochondrial DNA levels;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.73	6.47	0.38	5.27e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg21605333	chr4:119757512	SEC24D	1.48	9.55	0.52	1.36e-18	Cannabis dependence symptom count;
KIRP	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.51	6.61	0.39	2.35e-10	Aortic root size;
KIRP	cis	rs2061333	0.557	rs10410306	chr19:44601537	T/C	cg21636353	chr19:44617292	ZNF225	-0.48	-4.97	-0.3	1.24e-6	Alzheimer's disease;
KIRP	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.49	-5.12	-0.31	6.29e-7	Obesity (extreme);
KIRP	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.81	-0.4	7.63e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.51	7.27	0.42	4.7e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11155671	0.530	rs9371504	chr6:150184080	A/T	cg13206674	chr6:150067644	NUP43	0.55	7.79	0.45	1.82e-13	Testicular germ cell tumor;
KIRP	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg26965718	chr17:79658957	HGS	-0.51	-4.94	-0.3	1.42e-6	Dental caries;
KIRP	cis	rs9398803	0.687	rs9375450	chr6:126985351	G/A	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.89e-7	Male-pattern baldness;
KIRP	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg01097406	chr16:89675127	NA	-0.35	-5.53	-0.33	8.12e-8	Vitiligo;
KIRP	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.01	14.92	0.69	2.75e-36	Orofacial clefts;
KIRP	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.55	0.43	8.32e-13	Prudent dietary pattern;
KIRP	cis	rs4671458	0.626	rs2278718	chr2:63815801	A/C	cg17519650	chr2:63277830	OTX1	-0.5	-5.14	-0.31	5.65e-7	Subjective well-being;
KIRP	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.82	-8.16	-0.46	1.71e-14	Systemic lupus erythematosus;
KIRP	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.85	-14.55	-0.68	5.23e-35	Heart rate;
KIRP	cis	rs9972944	0.756	rs6416945	chr17:63763942	G/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.84	-0.45	1.35e-13	Total body bone mineral density;
KIRP	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.12	-0.31	6.11e-7	Tonsillectomy;
KIRP	cis	rs501120	0.584	rs61855740	chr10:44679810	A/G	cg09554077	chr10:44749378	NA	0.57	5.95	0.35	9.05e-9	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg10756647	chr7:56101905	PSPH	1.02	7.45	0.43	1.61e-12	Diabetic kidney disease;
KIRP	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs6959887	0.962	rs17675142	chr7:35288133	G/A	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg17863274	chr19:49399704	TULP2	-0.4	-5.72	-0.34	3.12e-8	Red cell distribution width;
KIRP	cis	rs2279817	0.818	rs34036216	chr1:17986046	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-7.98	-0.45	5.71e-14	Neuroticism;
KIRP	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-1.07	-19.18	-0.77	8.97e-51	Migraine;
KIRP	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg02023728	chr11:77925099	USP35	0.36	5.58	0.33	6.46e-8	Alzheimer's disease (survival time);
KIRP	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13067350	chr1:221274025	NA	0.48	6.61	0.39	2.42e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.79	-0.35	2.16e-8	Pulmonary function;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.9.31239617R	chr9:31249617	NA	0.47	6.61	0.39	2.39e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72960926	0.590	rs72959617	chr6:74993963	G/A	cg03266952	chr6:74778945	NA	-0.76	-5.78	-0.35	2.28e-8	Metabolite levels (MHPG);
KIRP	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.56	0.65	1.14e-31	Smoking behavior;
KIRP	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.9	0.3	1.76e-6	Menopause (age at onset);
KIRP	cis	rs357618	0.965	rs357621	chr5:150847554	T/C	cg22672639	chr5:150884813	FAT2	0.35	5.34	0.32	2.15e-7	Basophil percentage of white cells;
KIRP	cis	rs7215564	0.818	rs901063	chr17:78595696	A/T	cg06153925	chr17:78755379	RPTOR	-0.48	-6.11	-0.36	3.88e-9	Myopia (pathological);
KIRP	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	1.08	21.56	0.81	1.27e-58	Height;
KIRP	cis	rs1538970	0.851	rs61788285	chr1:45919234	A/C	cg03146154	chr1:46216737	IPP	0.46	4.86	0.3	2.07e-6	Platelet count;
KIRP	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.73	-0.44	2.68e-13	Height;
KIRP	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg25486957	chr4:152246857	NA	-0.42	-5.06	-0.31	8.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6142102	0.961	rs1007090	chr20:32582871	T/C	cg08999081	chr20:33150536	PIGU	0.49	5.83	0.35	1.7e-8	Skin pigmentation;
KIRP	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.49	5.09	0.31	7.07e-7	Menopause (age at onset);
KIRP	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.58	7.36	0.42	2.83e-12	Aortic root size;
KIRP	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg22437258	chr11:111473054	SIK2	-0.58	-6.44	-0.38	6.4e-10	Primary sclerosing cholangitis;
KIRP	cis	rs4774899	0.966	rs12914418	chr15:57506355	C/G	cg13626582	chr15:57592083	LOC283663	-0.21	-5.04	-0.31	8.88e-7	Urinary tract infection frequency;
KIRP	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.19	-0.61	4.82e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.43	-6.91	-0.4	4.03e-11	Testicular germ cell tumor;
KIRP	cis	rs12580194	0.593	rs61957936	chr12:55745719	A/G	cg11794356	chr12:55725991	OR6C3	-0.6	-8.62	-0.48	8.4e-16	Cancer;
KIRP	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg15832292	chr6:96025679	MANEA	0.68	5.3	0.32	2.52e-7	Behavioural disinhibition (generation interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg05491852	chr1:3663832	KIAA0495	0.7	6.37	0.38	9.34e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.93	-0.49	1.04e-16	Resting heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20467168	chr1:76081408	NA	0.49	6.99	0.41	2.53e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg05083358	chr7:2394359	EIF3B	-0.7	-6.92	-0.4	3.88e-11	Multiple sclerosis;
KIRP	cis	rs778371	0.749	rs2675965	chr2:233793736	C/T	cg08000102	chr2:233561755	GIGYF2	-0.45	-4.97	-0.3	1.24e-6	Schizophrenia;
KIRP	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.55	7.93	0.45	7.5e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg19196401	chr6:110721138	DDO	-0.43	-6.55	-0.39	3.38e-10	Platelet distribution width;
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg06815112	chr8:27182871	PTK2B	0.53	6.89	0.4	4.73e-11	Neuroticism;
KIRP	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg18900838	chr17:28804337	GOSR1	0.47	6.02	0.36	6.17e-9	Beard thickness;
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg10253484	chr15:75165896	SCAMP2	-0.44	-4.99	-0.3	1.16e-6	Caffeine consumption;
KIRP	cis	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg04608330	chr12:45269318	NELL2	-0.42	-5.94	-0.35	9.46e-9	Gut microbiome composition (summer);
KIRP	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.47	-5.5	-0.33	9.43e-8	Urate levels in overweight individuals;
KIRP	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.51	-7.06	-0.41	1.74e-11	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14409850	chr12:27091377	C12orf11;FGFR1OP2	0.44	6.13	0.36	3.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.68	-8.94	-0.5	9.58e-17	Huntington's disease progression;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18879646	chr1:89990278	LRRC8B	-0.56	-6.13	-0.36	3.42e-9	Menopause (age at onset);
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg01765077	chr12:122356316	WDR66	0.62	8.55	0.48	1.3e-15	Mean corpuscular volume;
KIRP	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.69	8.91	0.49	1.17e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8113308	0.810	rs17695737	chr19:52445536	C/T	cg25782003	chr19:52490127	ZNF350	0.57	5.19	0.31	4.31e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg11846333	chr4:119757529	SEC24D	1.17	7.18	0.42	8.23e-12	Cannabis dependence symptom count;
KIRP	cis	rs17123764	1.000	rs56743994	chr12:49950408	G/A	cg02054252	chr12:50078554	FMNL3	0.5	5.01	0.3	1.05e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04085025	chr7:30029442	SCRN1	-0.47	-6.28	-0.37	1.55e-9	Myopia;
KIRP	trans	rs12449568	0.806	rs759109	chr17:54408802	T/C	cg04456437	chr3:119217424	C3orf1	0.48	6.12	0.36	3.66e-9	Height;
KIRP	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.51	-6.14	-0.36	3.28e-9	Parkinson's disease;
KIRP	cis	rs2241685	0.621	rs11127304	chr2:1902622	G/A	cg22511877	chr2:1942942	MYT1L	-0.59	-5.44	-0.33	1.26e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.51e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg08076091	chr2:203926405	NBEAL1	0.85	8.63	0.48	7.88e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4356932	0.967	rs28642977	chr4:76972731	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.17	0.37	2.77e-9	Blood protein levels;
KIRP	cis	rs9815354	0.716	rs73828280	chr3:41833907	A/T	cg03022575	chr3:42003672	ULK4	0.58	6.55	0.39	3.41e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8016982	0.674	rs28890880	chr14:81708031	A/G	cg01989461	chr14:81687754	GTF2A1	0.71	10.51	0.56	1.41e-21	Schizophrenia;
KIRP	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.55	6.75	0.4	1.04e-10	Arsenic metabolism;
KIRP	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00857998	chr1:205179979	DSTYK	-0.67	-8.64	-0.48	7.49e-16	Red blood cell count;
KIRP	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg05991184	chr2:219186017	PNKD	0.36	5.05	0.31	8.64e-7	Colorectal cancer;
KIRP	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	5.94	0.35	9.53e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	0.731	rs9605464	chr22:18459922	C/T	cg03078520	chr22:18463400	MICAL3	-0.85	-12.25	-0.62	3.04e-27	Presence of antiphospholipid antibodies;
KIRP	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	1.03	13.23	0.64	1.54e-30	Post bronchodilator FEV1;
KIRP	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg13402656	chr8:1511478	DLGAP2	-0.76	-11.6	-0.59	4.23e-25	Lung cancer;
KIRP	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.56	-5.03	-0.31	9.42e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-7.84	-0.45	1.37e-13	Bipolar disorder;
KIRP	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.46	-4.95	-0.3	1.39e-6	Parkinson's disease;
KIRP	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.88	12.65	0.63	1.41e-28	Total body bone mineral density;
KIRP	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.54	-0.52	1.49e-18	Mood instability;
KIRP	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.73	9.36	0.51	5.07e-18	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.08e-17	Retinal vascular caliber;
KIRP	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg16558253	chr16:72132732	DHX38	-0.6	-8.95	-0.5	8.84e-17	Fibrinogen levels;
KIRP	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.62	-0.52	8.34e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6681460	0.649	rs1947083	chr1:67004801	G/A	cg13052034	chr1:66999238	SGIP1	0.42	5.95	0.35	9.12e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg02660097	chr11:68866761	NA	0.38	4.96	0.3	1.3e-6	Blond vs. brown hair color;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-1.05	-20.37	-0.79	1.02e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.74	11.44	0.59	1.35e-24	Longevity;Endometriosis;
KIRP	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg19554555	chr3:13937349	NA	0.53	7.94	0.45	7.38e-14	Ovarian reserve;
KIRP	cis	rs6988985	0.765	rs6471581	chr8:143986919	C/T	cg10324643	chr8:143916377	GML	0.43	4.94	0.3	1.42e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg08873628	chr1:175162347	KIAA0040	-0.38	-5.57	-0.33	6.75e-8	Alcohol dependence;
KIRP	cis	rs4073221	0.654	rs34591568	chr3:18288424	C/T	cg07694806	chr3:18168406	NA	-0.64	-5.91	-0.35	1.15e-8	Parkinson's disease;
KIRP	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.31e-9	Depression;
KIRP	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg16141378	chr3:129829833	LOC729375	-0.53	-6.34	-0.37	1.06e-9	Retinal vascular caliber;
KIRP	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg18904891	chr8:8559673	CLDN23	0.69	7.72	0.44	3.01e-13	Obesity-related traits;
KIRP	cis	rs4713675	0.565	rs9348924	chr6:33705436	A/G	cg15676125	chr6:33679581	C6orf125	0.41	5.25	0.32	3.26e-7	Plateletcrit;
KIRP	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg02336718	chr17:17403227	NA	0.35	5.39	0.32	1.67e-7	Total body bone mineral density;
KIRP	cis	rs6840360	0.901	rs6826799	chr4:152455700	G/A	cg22705602	chr4:152727874	NA	-0.39	-5.88	-0.35	1.32e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01498384	chr19:47551847	TMEM160	0.47	6.17	0.37	2.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.41	5.27	0.32	3.02e-7	Aortic root size;
KIRP	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.45	-5.2	-0.31	4.21e-7	Total body bone mineral density;
KIRP	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.86	9.7	0.53	4.77e-19	High light scatter reticulocyte count;
KIRP	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00585698	chr12:123750864	CDK2AP1	-0.38	-4.85	-0.3	2.16e-6	Platelet count;
KIRP	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.7	9.14	0.5	2.37e-17	Height;
KIRP	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.98	-15.87	-0.71	1.58e-39	Monocyte count;
KIRP	cis	rs4886920	0.672	rs11072680	chr15:78130580	C/G	cg10461261	chr15:78109450	NA	0.33	5.49	0.33	9.8e-8	Neuroticism;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.76	7.03	0.41	2e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg06647332	chr5:131281008	NA	0.47	5.06	0.31	8.12e-7	Life satisfaction;
KIRP	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	4.89	0.3	1.82e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg15488143	chr7:128924101	AHCYL2	0.57	6.23	0.37	2.05e-9	White matter hyperintensity burden;
KIRP	cis	rs12367572	0.501	rs7975969	chr12:45468749	T/C	cg04608330	chr12:45269318	NELL2	-0.45	-5.76	-0.34	2.56e-8	Gut microbiome composition (summer);
KIRP	cis	rs17095355	1.000	rs12254785	chr10:111699607	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.52	-0.38	3.89e-10	Biliary atresia;
KIRP	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs4262150	0.883	rs4958579	chr5:152184970	G/C	cg12297329	chr5:152029980	NA	-0.63	-8.3	-0.47	6.89e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs4786125	0.636	rs9932626	chr16:6917014	C/G	cg03623568	chr16:6915990	A2BP1	-0.4	-4.91	-0.3	1.69e-6	Heart rate variability traits (SDNN);
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.29	0.51	8.32e-18	Cognitive test performance;
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg08668510	chr10:1095578	IDI1	0.81	5.69	0.34	3.64e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02475777	chr4:1388615	CRIPAK	0.38	4.89	0.3	1.8e-6	Longevity;
KIRP	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg02378861	chr5:212933	CCDC127	-0.71	-5.6	-0.34	5.82e-8	Fat distribution (HIV);
KIRP	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg04317338	chr11:64019027	PLCB3	-0.39	-4.91	-0.3	1.69e-6	Platelet count;
KIRP	cis	rs4865169	0.560	rs1277311	chr4:57902761	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.69	9.17	0.5	2e-17	Breast cancer;
KIRP	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg08807101	chr21:30365312	RNF160	0.66	8.09	0.46	2.74e-14	Cognitive test performance;
KIRP	cis	rs7560272	0.512	rs2421677	chr2:73965917	G/T	cg20560298	chr2:73613845	ALMS1	0.43	5.01	0.3	1.03e-6	Schizophrenia;
KIRP	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.3	-6.11	-0.36	3.98e-9	Breast cancer;
KIRP	cis	rs889398	0.741	rs7193038	chr16:69926134	T/G	cg09409435	chr16:70099608	PDXDC2	0.41	5.05	0.31	8.49e-7	Body mass index;
KIRP	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.56	5.45	0.33	1.23e-7	Skin colour saturation;
KIRP	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.94	-0.3	1.44e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg03653399	chr8:142233436	SLC45A4	-0.64	-7.86	-0.45	1.18e-13	Immature fraction of reticulocytes;
KIRP	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg06115741	chr20:33292138	TP53INP2	0.38	5.12	0.31	6.18e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs3126085	0.515	rs10788835	chr1:152330945	T/C	cg26876637	chr1:152193138	HRNR	-0.55	-6.82	-0.4	7.03e-11	Atopic dermatitis;
KIRP	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-1.0	-15.2	-0.7	2.96e-37	Chronic sinus infection;
KIRP	cis	rs55962025	0.842	rs73193303	chr4:3192200	A/G	cg13731523	chr4:3047190	NA	0.32	4.99	0.3	1.13e-6	Parental longevity (mother's age at death);
KIRP	trans	rs12659622	0.850	rs6892081	chr5:15636890	G/A	cg09887955	chr1:202129854	PTPN7	-0.53	-6.15	-0.37	3.18e-9	Obesity-related traits;
KIRP	cis	rs7221595	0.825	rs4790552	chr17:3923366	G/A	cg09597638	chr17:3907349	NA	0.6	6.79	0.4	8.6e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.62	7.74	0.44	2.63e-13	Mosquito bite size;
KIRP	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.49	-5.22	-0.32	3.82e-7	Corneal structure;
KIRP	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg02038168	chr22:39784481	NA	-0.43	-5.1	-0.31	6.75e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.47	-4.94	-0.3	1.46e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs796364	0.616	rs1523818	chr2:200684704	G/T	cg17644776	chr2:200775616	C2orf69	0.57	5.23	0.32	3.56e-7	Schizophrenia;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.66	-6.79	-0.4	8.54e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17376030	chr22:41985996	PMM1	-0.84	-9.12	-0.5	2.7e-17	Vitiligo;
KIRP	cis	rs4700695	0.841	rs417152	chr5:65316205	G/A	cg21114390	chr5:65439923	SFRS12	0.58	6.28	0.37	1.5e-9	Facial morphology (factor 19);
KIRP	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg12598211	chr12:123634384	NA	-0.44	-5.45	-0.33	1.21e-7	Neutrophil percentage of white cells;
KIRP	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-0.86	-6.5	-0.38	4.55e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.64	0.34	4.58e-8	Lung cancer;
KIRP	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg03465714	chr1:152285911	FLG	0.47	5.12	0.31	6.14e-7	Atopic dermatitis;
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg21186296	chr8:27182909	PTK2B	0.51	6.45	0.38	5.83e-10	Neuroticism;
KIRP	cis	rs2033732	0.674	rs1866087	chr8:85071289	T/A	cg05716166	chr8:85095498	RALYL	0.54	6.13	0.36	3.39e-9	Body mass index;
KIRP	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg26924012	chr15:45694286	SPATA5L1	0.68	9.0	0.5	6.32e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-1.04	-20.97	-0.8	1.08e-56	Height;
KIRP	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	7.79	0.44	1.84e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg21782813	chr7:2030301	MAD1L1	0.55	6.86	0.4	5.41e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9314323	0.501	rs6557911	chr8:26189230	G/T	cg13160058	chr8:26243215	BNIP3L	-0.45	-6.5	-0.38	4.46e-10	Red cell distribution width;
KIRP	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg17425144	chr1:10567563	PEX14	0.31	5.2	0.31	4.2e-7	Hepatocellular carcinoma;
KIRP	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.89	-0.4	4.75e-11	Blood metabolite levels;
KIRP	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg01721255	chr8:58191610	C8orf71	-0.65	-5.76	-0.34	2.5e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.45	10.14	0.54	2.05e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.5	5.66	0.34	4.18e-8	Immune response to smallpox vaccine (IL-6);
KIRP	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.49e-13	Morning vs. evening chronotype;
KIRP	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	0.87	7.25	0.42	5.44e-12	Severe influenza A (H1N1) infection;
KIRP	trans	rs6810798	0.731	rs1429139	chr4:148284104	A/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.51	-6.02	-0.36	6.2e-9	Coronary artery disease;
KIRP	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.6	7.93	0.45	7.74e-14	Retinal vascular caliber;
KIRP	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg07395648	chr5:131743802	NA	-0.37	-5.15	-0.31	5.38e-7	Acylcarnitine levels;
KIRP	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg13395646	chr4:1353034	KIAA1530	-0.38	-5.05	-0.31	8.48e-7	Longevity;
KIRP	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg06121193	chr1:90282411	NA	-0.45	-6.37	-0.38	9.35e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11350889	chr5:34656553	RAI14	0.51	6.24	0.37	1.88e-9	Parkinson's disease;
KIRP	cis	rs11195062	0.693	rs950232	chr10:111988373	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.32	-5.17	-0.31	4.86e-7	Multiple myeloma;
KIRP	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg25037394	chr1:24152592	HMGCL	0.38	5.16	0.31	5e-7	Immature fraction of reticulocytes;
KIRP	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12463550	chr7:65579703	CRCP	-0.69	-4.9	-0.3	1.71e-6	Diabetic kidney disease;
KIRP	cis	rs17321999	1.000	rs6732241	chr2:30479927	C/T	cg05247661	chr2:30472410	LBH	0.74	8.27	0.47	8.73e-15	Systemic lupus erythematosus;
KIRP	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg04935436	chr20:30431758	NA	0.5	6.84	0.4	6.4e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg04317338	chr11:64019027	PLCB3	0.79	7.26	0.42	5.05e-12	Mean platelet volume;
KIRP	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.42	-0.38	6.78e-10	Hemoglobin concentration;
KIRP	cis	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg11502198	chr6:26597334	ABT1	-0.87	-5.32	-0.32	2.33e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg00684032	chr4:1343700	KIAA1530	0.57	7.65	0.44	4.4e-13	Obesity-related traits;
KIRP	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.98	-0.5	7.09e-17	Triglycerides;
KIRP	cis	rs1318772	0.932	rs34554590	chr5:112892277	A/G	cg12552261	chr5:112820674	MCC	0.78	5.46	0.33	1.17e-7	F-cell distribution;
KIRP	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.81	9.78	0.53	2.8e-19	Corneal astigmatism;
KIRP	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.98	10.44	0.55	2.31e-21	Blood protein levels;
KIRP	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.87	-0.45	1.1e-13	Neuroticism;
KIRP	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.64	-7.25	-0.42	5.26e-12	Menarche (age at onset);
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg22284058	chr8:142237359	SLC45A4	-0.5	-6.29	-0.37	1.46e-9	Immature fraction of reticulocytes;
KIRP	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg16296679	chr22:42394374	WBP2NL	0.36	4.95	0.3	1.38e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7583236	0.500	rs6728352	chr2:70343432	G/A	cg19638749	chr2:70312615	NA	0.46	4.94	0.3	1.45e-6	Obesity-related traits;
KIRP	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.17	0.37	2.85e-9	Aortic root size;
KIRP	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.37	-6.2	-0.37	2.4e-9	Height;
KIRP	cis	rs1208285	0.564	rs2327427	chr6:134203517	G/A	cg06643013	chr6:134217242	NA	-0.44	-5.11	-0.31	6.54e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs7155454	0.815	rs11627485	chr14:65487694	T/C	cg11161011	chr14:65562177	MAX	-0.43	-5.3	-0.32	2.55e-7	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
KIRP	cis	rs7714584	1.000	rs1896708	chr5:150245076	A/T	cg22134413	chr5:150180641	NA	0.74	6.49	0.38	4.74e-10	Crohn's disease;
KIRP	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.61	-0.34	5.54e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.89	-0.57	8.2000000000000006e-23	Menopause (age at onset);
KIRP	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg10434728	chr15:90938212	IQGAP1	0.41	7.08	0.41	1.55e-11	Rheumatoid arthritis;
KIRP	cis	rs9308731	0.591	rs60982612	chr2:111940939	C/T	cg04202892	chr2:111875749	ACOXL	0.42	5.7	0.34	3.34e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.63	-8.48	-0.48	2.1e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2916247	0.954	rs1126063	chr8:93120861	C/T	cg10183463	chr8:93005414	RUNX1T1	0.43	5.05	0.31	8.54e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg05802129	chr4:122689817	NA	-0.6	-7.55	-0.43	8.56e-13	Type 2 diabetes;
KIRP	cis	rs2213920	0.619	rs7870511	chr9:118196904	A/G	cg13918206	chr9:118159781	DEC1	1.0	10.34	0.55	4.68e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg23594656	chr7:65796392	TPST1	0.53	8.32	0.47	6.19e-15	Aortic root size;
KIRP	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.28	-0.37	1.53e-9	Hyperactive-impulsive symptoms;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20624538	chr11:118662171	DDX6	0.47	6.76	0.4	9.97e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg13607699	chr17:42295918	UBTF	0.46	5.7	0.34	3.39e-8	Total body bone mineral density;
KIRP	cis	rs2239815	0.515	rs5762839	chr22:29231447	C/T	cg15103426	chr22:29168792	CCDC117	0.52	5.24	0.32	3.38e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg07460842	chr6:66804631	NA	-0.57	-7.34	-0.42	3.12e-12	Blood trace element (Cu levels);
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.67	0.34	3.99e-8	Lung cancer;
KIRP	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.45	-5.91	-0.35	1.11e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs6593803	0.774	rs12032789	chr1:147220045	C/A	cg27546670	chr1:147246839	GJA5	-0.69	-7.93	-0.45	7.57e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.65	10.64	0.56	5.2e-22	Pulse pressure;
KIRP	trans	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg10756647	chr7:56101905	PSPH	1.08	8.58	0.48	1.08e-15	Diabetic kidney disease;
KIRP	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.45	-6.82	-0.4	6.91e-11	Total body bone mineral density;
KIRP	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.38	-0.43	2.5e-12	Aortic root size;
KIRP	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg04935436	chr20:30431758	NA	0.49	6.54	0.39	3.46e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7939886	0.920	rs11231885	chr11:55804022	T/A	cg15704280	chr7:45808275	SEPT13	0.82	6.03	0.36	5.87e-9	Myopia (pathological);
KIRP	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg04112845	chr2:172379619	CYBRD1	0.48	6.43	0.38	6.44e-10	DNA methylation (variation);
KIRP	cis	rs7903847	0.642	rs11189196	chr10:99155079	A/G	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs10772939	0.535	rs10744123	chr12:16587185	A/G	cg20863947	chr2:120124202	DBI;C2orf76	-0.49	-6.06	-0.36	4.97e-9	Economic and political preferences;
KIRP	cis	rs4400599	0.618	rs1194580	chr1:154219485	G/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.95	-0.35	8.97e-9	Platelet distribution width;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg16139199	chr18:19180362	ESCO1	0.53	6.22	0.37	2.11e-9	Sleep duration;
KIRP	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg14675211	chr2:100938903	LONRF2	0.57	7.13	0.41	1.13e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12780845	0.540	rs10795451	chr10:17179195	T/C	cg01003015	chr10:17271136	VIM	-0.49	-6.15	-0.36	3.18e-9	Homocysteine levels;
KIRP	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.93	13.15	0.64	2.98e-30	Height;
KIRP	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28595532	0.702	rs72670252	chr4:119337546	A/C	cg21605333	chr4:119757512	SEC24D	1.1	8.23	0.46	1.06e-14	Cannabis dependence symptom count;
KIRP	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg02980000	chr4:1222292	CTBP1	0.82	8.54	0.48	1.4e-15	Systolic blood pressure;
KIRP	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.48e-6	Red blood cell count;
KIRP	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.56	7.31	0.42	3.84e-12	Breast cancer;
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.62	-9.32	-0.51	7.03e-18	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.75	-11.12	-0.58	1.53e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.81	-11.68	-0.6	2.3e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11997175	0.575	rs56942690	chr8:33820308	G/A	ch.8.33884649F	chr8:33765107	NA	0.55	6.87	0.4	5.27e-11	Body mass index;
KIRP	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.22	-0.42	6.41e-12	Neuroticism;
KIRP	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg07843065	chr1:150265600	MRPS21	0.44	5.99	0.36	7.26e-9	Migraine;
KIRP	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg25037394	chr1:24152592	HMGCL	-0.38	-5.23	-0.32	3.58e-7	Immature fraction of reticulocytes;
KIRP	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.86	-0.4	5.52e-11	Joint mobility (Beighton score);
KIRP	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.81	10.64	0.56	5.33e-22	Osteoporosis;
KIRP	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg07511934	chr16:89386912	ANKRD11	0.44	5.51	0.33	8.91e-8	Multiple myeloma (IgH translocation);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22776125	chr6:167041314	RPS6KA2	0.46	6.14	0.36	3.24e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18252515	chr7:66147081	NA	-0.45	-5.5	-0.33	9.59e-8	Aortic root size;
KIRP	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg24253500	chr15:84953950	NA	0.65	7.22	0.42	6.53e-12	Schizophrenia;
KIRP	cis	rs240764	0.658	rs9390679	chr6:101216102	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.26	-0.32	3.14e-7	Neuroticism;
KIRP	cis	rs703970	0.522	rs2802363	chr10:80988837	A/G	cg18737081	chr10:80999807	ZMIZ1	-0.29	-4.97	-0.3	1.25e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg04731861	chr2:219085781	ARPC2	-0.27	-6.99	-0.41	2.61e-11	Colorectal cancer;
KIRP	cis	rs6442310	0.534	rs1151998	chr3:12446492	A/G	cg22839075	chr3:12045461	SYN2	0.39	5.48	0.33	1.07e-7	Hematocrit;
KIRP	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18252515	chr7:66147081	NA	0.49	5.66	0.34	4.12e-8	Cotinine glucuronidation;
KIRP	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg01988459	chr11:68622903	NA	-0.37	-5.4	-0.33	1.57e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs35740288	0.752	rs11636138	chr15:86287547	T/A	cg10818794	chr15:86012489	AKAP13	-0.44	-5.15	-0.31	5.37e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs12659622	0.764	rs2914762	chr5:15611733	T/G	cg09887955	chr1:202129854	PTPN7	-0.53	-6.18	-0.37	2.63e-9	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12963246	chr6:28129442	ZNF389	0.49	6.03	0.36	5.99e-9	Depression;
KIRP	cis	rs17123764	0.818	rs73305008	chr12:49958911	G/A	cg02054252	chr12:50078554	FMNL3	0.43	5.19	0.31	4.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.98	0.36	7.91e-9	Bipolar disorder;
KIRP	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg22138327	chr13:27999177	GTF3A	0.89	7.04	0.41	1.88e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9309473	0.950	rs6546860	chr2:73844249	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.62	-0.34	5.19e-8	Metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21155063	chr1:193074287	GLRX2	0.43	6.09	0.36	4.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs26232	0.521	rs3776856	chr5:102358806	T/C	cg23492399	chr5:102201601	PAM	-0.46	-5.06	-0.31	8.13e-7	Rheumatoid arthritis;
KIRP	cis	rs1656402	1.000	rs3108615	chr2:233429700	C/A	cg03852847	chr2:233439513	NA	0.72	12.12	0.61	8.32e-27	Non-small cell lung cancer (survival);
KIRP	cis	rs1971762	0.527	rs7952858	chr12:54039692	C/G	cg23533419	chr12:54090519	NA	-0.33	-4.92	-0.3	1.58e-6	Height;
KIRP	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.7	-0.34	3.49e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7180079	0.620	rs486330	chr15:64803250	C/T	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.65	7.71	0.44	3.02e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	cis	rs11578119	0.902	rs2183372	chr1:170504019	G/A	cg09767346	chr1:170501363	GORAB	-0.35	-4.87	-0.3	2e-6	Male-pattern baldness;
KIRP	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.57	5.28	0.32	2.87e-7	Major depressive disorder;
KIRP	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg15103426	chr22:29168792	CCDC117	0.66	9.54	0.52	1.48e-18	Lymphocyte counts;
KIRP	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg06808227	chr14:105710500	BRF1	-0.78	-9.33	-0.51	6.56e-18	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7688540	0.771	rs11248013	chr4:311425	T/C	cg10134910	chr4:1076041	RNF212	-0.25	-5.0	-0.3	1.08e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-5.37	-0.32	1.85e-7	Neuroticism;
KIRP	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.85	-0.53	1.69e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg14458575	chr2:238380390	NA	0.57	5.88	0.35	1.32e-8	Prostate cancer;
KIRP	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	cg12689670	chr1:183009347	LAMC1	0.54	7.04	0.41	1.94e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	13.57	0.65	1.08e-31	Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.15	-0.31	5.29e-7	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.0	0.3	1.09e-6	Renal cell carcinoma;
KIRP	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.35	-0.32	1.99e-7	Bipolar disorder;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07308232	chr7:1071921	C7orf50	-0.66	-8.59	-0.48	1.03e-15	Longevity;Endometriosis;
KIRP	cis	rs6707387	0.662	rs6435777	chr2:214325979	A/G	cg08319019	chr2:214017104	IKZF2	0.44	5.02	0.3	9.78e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs2738048	0.545	rs2738045	chr8:6823568	T/C	cg24860332	chr8:6827800	DEFA10P	-0.39	-5.09	-0.31	7.1e-7	IgA nephropathy;
KIRP	cis	rs17253792	0.545	rs12886406	chr14:56027605	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.51	0.33	8.98e-8	Putamen volume;
KIRP	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.73	9.48	0.52	2.23e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.29	0.37	1.47e-9	Red blood cell count;
KIRP	cis	rs9914544	0.678	rs28374894	chr17:18761659	C/A	cg26378065	chr17:18585709	ZNF286B	0.38	4.92	0.3	1.57e-6	Educational attainment (years of education);
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.6	8.96	0.5	8.18e-17	Lung cancer;
KIRP	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg02073558	chr3:44770973	ZNF501	0.72	11.45	0.59	1.33e-24	Depressive symptoms;
KIRP	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-6.11	-0.36	3.93e-9	Response to antipsychotic treatment;
KIRP	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.89	0.4	4.62e-11	Height;
KIRP	cis	rs3750082	0.632	rs7811630	chr7:32960718	C/A	cg06627557	chr7:32535165	LSM5;AVL9	-0.47	-5.16	-0.31	5.19e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg26248373	chr2:1572462	NA	-0.57	-5.31	-0.32	2.48e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-4.87	-0.3	2.01e-6	Myopia (pathological);
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg23803311	chr5:147763284	FBXO38	-0.51	-7.04	-0.41	1.91e-11	Breast cancer;
KIRP	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.72	-8.51	-0.48	1.72e-15	Resting heart rate;
KIRP	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg03128060	chr6:142623767	GPR126	0.37	5.12	0.31	6.12e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg07884673	chr3:53033167	SFMBT1	0.88	7.01	0.41	2.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.58	-8.98	-0.5	7.16e-17	Lymphocyte counts;
KIRP	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.36	-0.62	1.3e-27	Blood trace element (Zn levels);
KIRP	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg15252951	chr6:33757062	LEMD2	0.45	5.19	0.31	4.31e-7	Crohn's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09735598	chr1:183603895	ARPC5;RGL1	0.45	6.07	0.36	4.68e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6676180	0.555	rs871665	chr1:119772663	C/T	cg05756136	chr1:119680316	WARS2	-0.5	-7.17	-0.42	8.73e-12	Monobrow;
KIRP	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.0	0.61	2.06e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	0.84	11.02	0.57	3.25e-23	Primary sclerosing cholangitis;
KIRP	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg16989719	chr2:238392110	NA	-0.58	-5.89	-0.35	1.28e-8	Prostate cancer;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg22764044	chr5:178986830	RUFY1	0.51	7.68	0.44	3.74e-13	Lung cancer;
KIRP	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.54	-6.84	-0.4	6.22e-11	Dental caries;
KIRP	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.54	-6.29	-0.37	1.48e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg12435725	chr3:58293450	RPP14	-0.55	-5.67	-0.34	3.92e-8	Cholesterol, total;
KIRP	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg02023728	chr11:77925099	USP35	-0.32	-5.6	-0.34	5.84e-8	Alzheimer's disease (survival time);
KIRP	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-6.24	-0.37	1.89e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9309473	1.000	rs10193972	chr2:73717656	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.8	-0.35	2e-8	Metabolite levels;
KIRP	cis	rs6684428	0.706	rs10888942	chr1:56335432	C/G	cg11651538	chr1:56320950	NA	-0.93	-12.57	-0.63	2.48e-28	Airflow obstruction;
KIRP	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg17252645	chr8:143867129	LY6D	-0.31	-4.98	-0.3	1.21e-6	Urinary tract infection frequency;
KIRP	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-16.94	-0.73	3.57e-43	Coronary artery disease;
KIRP	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13047869	chr3:10149882	C3orf24	0.51	4.86	0.3	2.05e-6	Alzheimer's disease;
KIRP	trans	rs7012814	1	rs7012814	chr8:9173358	G/A	cg08975724	chr8:8085496	FLJ10661	0.5	6.18	0.37	2.61e-9	Fibrinogen levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05768582	chr16:30934727	NCRNA00095;FBXL19	0.51	6.25	0.37	1.78e-9	Parkinson's disease;
KIRP	cis	rs2694528	0.609	rs1379112	chr5:59995742	C/A	cg11474532	chr5:59995715	DEPDC1B	0.84	6.27	0.37	1.64e-9	Parkinson's disease;
KIRP	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.76	10.4	0.55	3.12e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	26.01	0.86	1.52e-72	Chronic sinus infection;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.46	6.65	0.39	1.87e-10	Sitting height ratio;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.67	-8.41	-0.47	3.32e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.44	6.15	0.37	3.09e-9	Plateletcrit;Platelet count;
KIRP	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg21905437	chr5:178450457	ZNF879	0.56	6.54	0.38	3.59e-10	Pubertal anthropometrics;
KIRP	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18876405	chr7:65276391	NA	0.49	6.06	0.36	5.06e-9	Corneal structure;
KIRP	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg00147788	chr6:125855365	NA	-0.32	-4.98	-0.3	1.18e-6	Brugada syndrome;
KIRP	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.89e-6	Neutrophil percentage of white cells;
KIRP	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.46	0.43	1.46e-12	Aortic root size;
KIRP	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09012708	chr2:42068177	NA	0.42	6.14	0.36	3.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.74	9.74	0.53	3.73e-19	Coronary artery disease;
KIRP	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs56161922	1.000	rs41274776	chr1:207812791	A/G	cg09557387	chr1:207818395	CR1L	1.08	6.51	0.38	4.2e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.3	0.47	6.88e-15	Personality dimensions;
KIRP	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg18461458	chr19:21324796	ZNF431	0.47	4.88	0.3	1.87e-6	Pain;
KIRP	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.16e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg25486957	chr4:152246857	NA	-0.42	-5.07	-0.31	7.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg05717871	chr11:638507	DRD4	-0.37	-5.19	-0.31	4.4e-7	Systemic lupus erythematosus;
KIRP	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.86	-10.93	-0.57	6.31e-23	Parkinson's disease;
KIRP	cis	rs1021993	0.597	rs17014320	chr1:209512173	T/C	cg24446417	chr1:209558027	NA	-0.49	-4.96	-0.3	1.32e-6	Gut microbiome composition (winter);
KIRP	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg02160872	chr5:212506	CCDC127	-0.63	-5.25	-0.32	3.27e-7	Asthma (childhood onset);
KIRP	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg02804510	chr19:49199965	FUT2	0.34	4.87	0.3	2.01e-6	Dietary macronutrient intake;
KIRP	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.66	9.79	0.53	2.46e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs17020663	0.552	rs8179740	chr2:101653528	C/T	cg17494863	chr2:101638916	TBC1D8	-0.49	-5.4	-0.33	1.56e-7	Pulse pressure;
KIRP	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.86	-0.35	1.5e-8	Breast cancer;
KIRP	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg24826892	chr11:71159390	DHCR7	0.43	5.19	0.31	4.37e-7	Vitamin D levels;
KIRP	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.73	9.5	0.52	1.98e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.85	-12.96	-0.64	1.29e-29	Selective IgA deficiency;
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05165339	chr4:1420672	NA	-0.3	-4.85	-0.3	2.22e-6	Longevity;
KIRP	cis	rs9616064	0.520	rs875559	chr22:47034838	T/C	cg05621596	chr22:47072043	GRAMD4	-0.72	-8.69	-0.48	5.03e-16	Urate levels in obese individuals;
KIRP	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	8.57	0.48	1.16e-15	Platelet distribution width;
KIRP	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.43	-5.38	-0.32	1.72e-7	Aortic root size;
KIRP	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3126085	0.515	rs11204996	chr1:152364612	C/A	cg26876637	chr1:152193138	HRNR	-0.61	-6.87	-0.4	5.28e-11	Atopic dermatitis;
KIRP	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg07395648	chr5:131743802	NA	-0.55	-8.07	-0.46	3.08e-14	Blood metabolite levels;
KIRP	cis	rs4805272	1.000	rs56131999	chr19:29319597	T/C	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg05484376	chr2:27715224	FNDC4	0.38	6.32	0.37	1.2e-9	Total body bone mineral density;
KIRP	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.21e-6	Pulmonary function;
KIRP	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.09	-0.41	1.42e-11	Glomerular filtration rate;
KIRP	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg02070118	chr4:952128	TMEM175	0.6	5.05	0.31	8.48e-7	Parkinson's disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg11422045	chr11:43701985	HSD17B12	0.98	7.06	0.41	1.69e-11	P wave terminal force;
KIRP	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg01283332	chr5:1856932	NA	-0.44	-5.51	-0.33	8.93e-8	Cardiovascular disease risk factors;
KIRP	cis	rs6563943	1.000	rs6563943	chr16:83639335	A/G	cg01935413	chr16:83636749	CDH13	-0.4	-5.84	-0.35	1.65e-8	Height;
KIRP	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-7.92	-0.45	8.35e-14	Fibrinogen levels;
KIRP	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg14416269	chr4:6271139	WFS1	0.34	5.09	0.31	7.04e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg02023728	chr11:77925099	USP35	0.3	5.12	0.31	6.02e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg18882449	chr10:104885122	NT5C2	-0.42	-5.4	-0.33	1.58e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.4	-5.16	-0.31	5.2e-7	IgG glycosylation;
KIRP	cis	rs2741335	0.876	rs2565055	chr8:27337380	G/T	cg00421144	chr8:27336675	CHRNA2	-0.33	-4.96	-0.3	1.34e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.74	-10.25	-0.55	8.98e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs1021993	0.672	rs2254757	chr1:209491993	G/T	cg06155620	chr1:209527581	NA	0.35	4.87	0.3	1.97e-6	Gut microbiome composition (winter);
KIRP	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg27205649	chr11:78285834	NARS2	0.83	12.16	0.61	6.12e-27	Alzheimer's disease (survival time);
KIRP	trans	rs12517041	1.000	rs58571178	chr5:23294196	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs6997458	0.785	rs2432083	chr8:86340608	C/T	cg02393479	chr8:86352350	CA3	-0.32	-4.95	-0.3	1.36e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.76	-9.91	-0.53	1.05e-19	Pancreatic cancer;
KIRP	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.67	-0.34	3.95e-8	Parkinson's disease;
KIRP	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg03465714	chr1:152285911	FLG	0.49	5.0	0.3	1.11e-6	Atopic dermatitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05677249	chr15:77158041	SCAPER	-0.46	-6.33	-0.37	1.15e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-6.56	-0.39	3.1e-10	Chronic sinus infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14178837	chr14:39639234	TRAPPC6B	-0.56	-6.63	-0.39	2.16e-10	Interleukin-4 levels;
KIRP	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-8.52	-0.48	1.59e-15	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg18657303	chr4:1051139	NA	0.55	5.08	0.31	7.44e-7	Recombination rate (females);
KIRP	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg11833968	chr6:79620685	NA	-0.45	-6.74	-0.4	1.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26769984	chr7:1090371	C7orf50	0.77	7.26	0.42	4.93e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18252515	chr7:66147081	NA	0.46	5.63	0.34	4.98e-8	Aortic root size;
KIRP	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg14458575	chr2:238380390	NA	0.49	5.32	0.32	2.3e-7	Prostate cancer;
KIRP	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg07068956	chr7:100330872	ZAN	0.4	5.39	0.32	1.67e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs11124272	0.543	rs11676456	chr2:32331511	A/G	cg02381751	chr2:32503542	YIPF4	-0.55	-5.02	-0.3	9.84e-7	Interleukin-18 levels;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03306564	chr11:64902099	SYVN1	0.53	6.66	0.39	1.81e-10	Asthma;
KIRP	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg11266682	chr4:10021025	SLC2A9	0.34	4.95	0.3	1.35e-6	Blood metabolite levels;
KIRP	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg26531700	chr6:26746687	NA	0.39	5.22	0.32	3.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.44	5.61	0.34	5.42e-8	Crohn's disease;
KIRP	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg26876637	chr1:152193138	HRNR	-0.68	-8.56	-0.48	1.28e-15	Atopic dermatitis;
KIRP	cis	rs76793172	1.000	rs16980059	chr19:46353634	C/T	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.26	-0.37	1.69e-9	Eosinophil counts;
KIRP	cis	rs7555523	0.887	rs7518099	chr1:165736880	C/T	cg24409356	chr1:165738333	TMCO1	0.73	6.29	0.37	1.44e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs12044355	0.927	rs11585981	chr1:231833962	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.47	5.91	0.35	1.11e-8	Alzheimer's disease;
KIRP	cis	rs267939	0.521	rs267954	chr5:10740624	A/T	cg14521931	chr5:10832172	NA	-0.54	-6.95	-0.41	3.17e-11	Gut microbiota (functional units);Ulcerative colitis;
KIRP	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18255839	chr2:239335447	ASB1	-0.42	-5.08	-0.31	7.34e-7	Multiple system atrophy;
KIRP	cis	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.54	-6.06	-0.36	4.98e-9	Menarche (age at onset);
KIRP	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.68	8.26	0.47	8.76e-15	Aortic root size;
KIRP	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg26513180	chr16:89883248	FANCA	0.79	5.6	0.34	5.64e-8	Skin colour saturation;
KIRP	cis	rs11658311	1.000	rs8071007	chr17:17506892	C/T	cg01246520	chr17:17644344	RAI1	0.55	5.07	0.31	7.99e-7	Obsessive-compulsive symptoms;
KIRP	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19671926	chr4:122722719	EXOSC9	0.5	5.93	0.35	1.04e-8	Type 2 diabetes;
KIRP	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg17691542	chr6:26056736	HIST1H1C	-0.54	-6.66	-0.39	1.8e-10	Iron status biomarkers;
KIRP	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg05673287	chr15:77411982	SGK269	-0.38	-4.88	-0.3	1.94e-6	Type 2 diabetes;
KIRP	cis	rs4765905	0.609	rs2238046	chr12:2299998	A/C	cg10668781	chr12:2307325	CACNA1C	-0.35	-7.01	-0.41	2.31e-11	Schizophrenia;
KIRP	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	13.54	0.65	1.39e-31	Menopause (age at onset);
KIRP	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.28	-6.0	-0.36	7.14e-9	Type 2 diabetes;
KIRP	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.76	0.4	1.02e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg01475377	chr6:109611718	NA	-0.38	-5.44	-0.33	1.31e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.54	-7.58	-0.43	7.24e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1448094	0.935	rs11117119	chr12:86336432	A/T	cg06740227	chr12:86229804	RASSF9	0.4	4.99	0.3	1.15e-6	Major depressive disorder;
KIRP	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg23484912	chr5:273055	PDCD6	0.6	7.48	0.43	1.31e-12	Pancreatic cancer;
KIRP	trans	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg16141378	chr3:129829833	LOC729375	-0.51	-6.39	-0.38	8.41e-10	Mood instability;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg16246294	chr17:34122769	MMP28	-0.43	-6.05	-0.36	5.49e-9	Blood metabolite levels;
KIRP	cis	rs4849845	0.925	rs10180681	chr2:121012029	A/G	cg24070213	chr2:121070622	NA	0.39	5.24	0.32	3.41e-7	Mean platelet volume;
KIRP	cis	rs35123781	0.654	rs356443	chr5:139077829	G/C	cg10513866	chr5:139070639	NA	0.54	7.67	0.44	4.01e-13	Schizophrenia;
KIRP	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.57	6.61	0.39	2.4e-10	HDL cholesterol;
KIRP	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg14703610	chr5:56206110	C5orf35	0.49	6.9	0.4	4.47e-11	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05993778	chr9:37590960	TOMM5	0.35	6.14	0.36	3.23e-9	Survival in pancreatic cancer;
KIRP	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.39	6.69	0.39	1.46e-10	Heart rate;
KIRP	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	4.95	0.3	1.37e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2270927	0.510	rs10942765	chr5:75591324	G/A	cg13563193	chr19:33072644	PDCD5	0.94	6.67	0.39	1.72e-10	Mean corpuscular volume;
KIRP	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	5.15	0.31	5.42e-7	Rheumatoid arthritis;
KIRP	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg06640241	chr16:89574553	SPG7	0.67	8.72	0.49	4.22e-16	Multiple myeloma (IgH translocation);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06178387	chr17:17585774	RAI1	-0.47	-6.29	-0.37	1.42e-9	Myopia;
KIRP	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg18833306	chr6:118973337	C6orf204	0.42	5.3	0.32	2.61e-7	Electrocardiographic conduction measures;
KIRP	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.49	5.7	0.34	3.34e-8	Diastolic blood pressure;
KIRP	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg03060546	chr3:49711283	APEH	-0.64	-6.03	-0.36	5.86e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.97	11.63	0.6	3.41e-25	Exhaled nitric oxide levels;
KIRP	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg21419209	chr3:44054225	NA	-0.71	-8.9	-0.49	1.28e-16	Coronary artery disease;
KIRP	cis	rs504918	0.524	rs2272486	chr3:123988039	T/C	cg05766129	chr3:123988013	KALRN	0.5	7.23	0.42	6.04e-12	Schizophrenia;
KIRP	trans	rs1422110	0.513	rs1422105	chr5:85448371	A/C	cg01787110	chr1:109008453	NBPF6	0.54	7.16	0.42	9.51e-12	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg19847130	chr8:10466454	RP1L1	-0.35	-4.94	-0.3	1.47e-6	Neuroticism;
KIRP	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.43	-0.43	1.81e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1847505	0.609	rs9538998	chr13:61571160	A/G	cg25164009	chr13:61490935	NA	-0.6	-7.45	-0.43	1.59e-12	Polychlorinated biphenyl levels;
KIRP	cis	rs4849845	0.925	rs10168224	chr2:121011660	C/G	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg05564831	chr3:52568323	NT5DC2	0.35	5.41	0.33	1.51e-7	Electroencephalogram traits;
KIRP	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg11189052	chr15:85197271	WDR73	0.56	5.89	0.35	1.25e-8	Schizophrenia;
KIRP	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs11138902	0.649	rs11139289	chr9:72164537	A/G	cg14123607	chr9:72164709	APBA1	-0.41	-5.22	-0.32	3.84e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg13147721	chr7:65941812	NA	-1.02	-7.06	-0.41	1.71e-11	Diabetic kidney disease;
KIRP	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.8	9.8	0.53	2.41e-19	Breast cancer;
KIRP	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg10434728	chr15:90938212	IQGAP1	0.36	6.86	0.4	5.68e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	1.35	9.86	0.53	1.54e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	7.57	0.43	7.56e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg18016565	chr1:150552671	MCL1	0.4	6.01	0.36	6.53e-9	Melanoma;
KIRP	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.58	-6.88	-0.4	4.93e-11	Mosquito bite size;
KIRP	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.89	16.18	0.72	1.37e-40	Heart rate;
KIRP	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.82	-12.68	-0.63	1.08e-28	Asthma;
KIRP	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.38	5.02	0.3	9.83e-7	Type 2 diabetes;
KIRP	cis	rs10486003	1.000	rs77479653	chr7:97222930	G/A	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.64	-5.01	-0.3	1.03e-6	Response to platinum-based agents;
KIRP	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-6.54	-0.39	3.44e-10	Colorectal cancer;
KIRP	cis	rs10861661	0.963	rs12424054	chr12:107186747	A/G	cg21360079	chr12:107162445	NA	0.66	6.32	0.37	1.23e-9	Triglyceride levels;
KIRP	cis	rs4728302	1.000	rs4728302	chr7:133630463	C/T	cg10665199	chr7:133106180	EXOC4	-0.41	-5.03	-0.31	9.39e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs282587	0.560	rs399153	chr13:113417592	C/T	cg04656015	chr13:113407548	ATP11A	0.59	5.85	0.35	1.54e-8	Glycated hemoglobin levels;
KIRP	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.83	-0.45	1.48e-13	Mood instability;
KIRP	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg21905437	chr5:178450457	ZNF879	0.56	6.54	0.38	3.48e-10	Pubertal anthropometrics;
KIRP	cis	rs17101923	1.000	rs12810758	chr12:66328027	C/T	cg06712651	chr12:66351869	HMGA2	-0.58	-6.63	-0.39	2.15e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.28	0.32	2.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4902647	0.728	rs10142466	chr14:69271784	A/G	cg03189333	chr14:69283534	NA	0.4	4.95	0.3	1.38e-6	Multiple sclerosis;
KIRP	trans	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.76	-0.4	1.02e-10	Retinal vascular caliber;
KIRP	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	11.99	0.61	2.1e-26	Smoking behavior;
KIRP	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.54	-0.43	9.3e-13	Neuroticism;
KIRP	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.48	-0.48	2.11e-15	Coronary artery disease;
KIRP	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg00852783	chr1:26633632	UBXN11	0.52	7.51	0.43	1.09e-12	Obesity-related traits;
KIRP	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg08648136	chr8:956695	NA	-0.45	-6.21	-0.37	2.25e-9	Schizophrenia;
KIRP	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg17764715	chr19:33622953	WDR88	0.67	8.33	0.47	5.54e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4774830	0.744	rs62046379	chr15:56299233	G/A	cg24530489	chr15:56299380	NA	-0.88	-5.35	-0.32	2.01e-7	Delta-5 desaturase activity;
KIRP	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	6.21	0.37	2.24e-9	HIV-1 control;
KIRP	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.43	-0.47	2.94e-15	Coronary artery disease;
KIRP	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.89	12.37	0.62	1.22e-27	Response to antipsychotic treatment;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.75	11.84	0.6	6.63e-26	Longevity;Endometriosis;
KIRP	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.29	0.42	4.28e-12	Vitiligo;
KIRP	cis	rs357618	1.000	rs357623	chr5:150848500	G/A	cg22672639	chr5:150884813	FAT2	0.35	5.34	0.32	2.15e-7	Basophil percentage of white cells;
KIRP	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.48	9.89	0.53	1.28e-19	Multiple system atrophy;
KIRP	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg03609598	chr5:56110824	MAP3K1	0.47	5.4	0.33	1.57e-7	Initial pursuit acceleration;
KIRP	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.85	-12.92	-0.64	1.72e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs2559856	0.967	rs2559863	chr12:102087108	C/T	cg12924262	chr12:102091054	CHPT1	0.49	6.42	0.38	7e-10	Blood protein levels;
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg09549240	chr15:75250560	RPP25	0.27	5.01	0.3	1.04e-6	Breast cancer;
KIRP	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.82	-11.21	-0.58	7.92e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.54	-6.41	-0.38	7.23e-10	Iron status biomarkers;
KIRP	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs13108043	0.605	rs62306509	chr4:87957073	T/G	cg11209507	chr4:87813803	C4orf36	0.47	4.97	0.3	1.27e-6	Red blood cell count;
KIRP	cis	rs7903847	0.620	rs17112676	chr10:99122288	G/A	cg20016023	chr10:99160130	RRP12	-0.41	-5.56	-0.33	6.99e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7520050	0.966	rs61102033	chr1:46382441	G/T	cg03146154	chr1:46216737	IPP	-0.42	-5.31	-0.32	2.43e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg01620082	chr3:125678407	NA	-1.07	-6.21	-0.37	2.28e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg10189774	chr4:17578691	LAP3	0.54	6.77	0.4	9.15e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7129556	0.954	rs10793255	chr11:77267611	A/G	cg12586386	chr11:77299805	AQP11	0.41	5.47	0.33	1.11e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	1.1	17.82	0.75	3.47e-46	Cognitive function;
KIRP	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs1440410	0.866	rs13139457	chr4:144113800	T/A	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg17736920	chr1:242011382	EXO1	0.45	5.62	0.34	5.09e-8	Menopause (age at onset);
KIRP	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.94	14.57	0.68	4.18e-35	Blood protein levels;
KIRP	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.67	9.3	0.51	7.81e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1320333	0.772	rs2867136	chr2:701455	T/C	cg27237671	chr2:676223	TMEM18	0.42	5.24	0.32	3.45e-7	Obesity-related traits;
KIRP	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.56	-0.56	9.51e-22	Breast cancer;
KIRP	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.85	-0.4	5.85e-11	Morning vs. evening chronotype;
KIRP	cis	rs9473924	0.542	rs9473946	chr6:50892950	G/A	cg14470998	chr6:50812995	TFAP2B	0.81	7.63	0.44	5.28e-13	Body mass index;
KIRP	trans	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs6832769	0.922	rs60797008	chr4:56388672	A/T	cg09317128	chr4:56265301	TMEM165	-0.56	-7.18	-0.42	8.07e-12	Personality dimensions;
KIRP	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	7.07	0.41	1.56e-11	Menarche (age at onset);
KIRP	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg14703610	chr5:56206110	C5orf35	0.5	6.78	0.4	8.61e-11	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs6662572	0.737	rs6693222	chr1:46461178	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.64	0.34	4.72e-8	Blood protein levels;
KIRP	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.54	7.65	0.44	4.5e-13	Metabolite levels;
KIRP	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg00262122	chr8:11665843	FDFT1	-0.41	-5.09	-0.31	7.13e-7	Morning vs. evening chronotype;
KIRP	cis	rs8062405	0.756	rs151182	chr16:28495752	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	5.37	0.32	1.83e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs35740288	0.822	rs17637142	chr15:86240503	T/C	cg10818794	chr15:86012489	AKAP13	-0.41	-4.86	-0.3	2.09e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09321620	chr14:59954414	JKAMP	0.38	6.12	0.36	3.6e-9	C-reactive protein;
KIRP	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg04310649	chr10:35416472	CREM	-0.57	-6.51	-0.38	4.29e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.84	-12.73	-0.63	7.48e-29	Height;
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg16867584	chr19:49200180	FUT2	0.31	4.94	0.3	1.45e-6	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg00343986	chr7:65444356	GUSB	0.39	4.87	0.3	2.02e-6	Aortic root size;
KIRP	cis	rs3800461	0.544	rs41312309	chr6:34498328	C/T	cg17674042	chr6:34482479	PACSIN1	-0.62	-6.7	-0.39	1.4e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs10788264	0.544	rs9630083	chr10:124017423	C/T	cg09507567	chr10:124027408	NA	0.31	5.72	0.34	3.12e-8	Total body bone mineral density;
KIRP	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg26378065	chr17:18585709	ZNF286B	0.4	5.07	0.31	7.66e-7	Educational attainment (years of education);
KIRP	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.09	19.23	0.77	6.29e-51	Colorectal cancer;
KIRP	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.79	-7.32	-0.42	3.58e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.68	-10.06	-0.54	3.6e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs2224391	0.628	rs766340	chr6:5243521	C/T	cg13962347	chr6:5174647	LYRM4	-0.75	-10.35	-0.55	4.41e-21	Height;
KIRP	cis	rs10818894	0.772	rs10120705	chr9:126692600	T/G	cg16191174	chr9:126692580	DENND1A	0.71	8.9	0.49	1.25e-16	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
KIRP	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.42	0.52	3.34e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg02023728	chr11:77925099	USP35	-0.31	-5.25	-0.32	3.23e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1448094	0.874	rs10779219	chr12:86322643	T/G	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.34	3.27e-8	Major depressive disorder;
KIRP	cis	rs3733606	1.000	rs3733606	chr4:6883012	A/G	cg05012661	chr4:6891264	NA	-0.48	-6.44	-0.38	6.11e-10	Platelet count;
KIRP	cis	rs883565	0.569	rs784489	chr3:39173426	T/C	cg01426195	chr3:39028469	NA	0.53	8.37	0.47	4.52e-15	Handedness;
KIRP	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.13	0.36	3.49e-9	Coronary artery disease;
KIRP	cis	rs1519814	1.000	rs4871041	chr8:121136584	C/T	cg22335954	chr8:121166405	COL14A1	-0.62	-6.35	-0.38	1.03e-9	Breast cancer;
KIRP	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.51	7.4	0.43	2.21e-12	Blood protein levels;
KIRP	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg18132916	chr6:79620363	NA	-0.4	-5.48	-0.33	1.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.59	7.96	0.45	6.52e-14	Airway imaging phenotypes;
KIRP	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.75	9.31	0.51	7.22e-18	Prostate cancer;
KIRP	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-9.68	-0.53	5.66e-19	Coronary artery disease;
KIRP	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg12346351	chr4:152330392	FAM160A1	0.54	6.16	0.37	2.92e-9	Sleep duration;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05972308	chr16:31476161	ARMC5	0.52	6.27	0.37	1.64e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16110940	chr22:21400158	LOC400891	0.41	6.16	0.37	2.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04132851	chr1:85155548	SSX2IP	0.52	6.43	0.38	6.65e-10	Smoking initiation;
KIRP	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg03315344	chr16:75512273	CHST6	-0.59	-5.75	-0.34	2.66e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.26	-0.42	5.06e-12	Body mass index;
KIRP	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.74	10.26	0.55	8.65e-21	Red blood cell count;
KIRP	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.57	-0.48	1.15e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg03468072	chr12:39539422	NA	0.39	5.7	0.34	3.46e-8	Morning vs. evening chronotype;
KIRP	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs12594515	0.694	rs2068295	chr15:45985546	T/C	cg01629716	chr15:45996671	NA	0.36	6.28	0.37	1.51e-9	Waist circumference;Weight;
KIRP	cis	rs7760535	0.711	rs240959	chr6:111620013	C/A	cg15721981	chr6:111408429	SLC16A10	-0.44	-5.6	-0.34	5.78e-8	Metabolic traits;
KIRP	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21545522	chr1:205238299	TMCC2	0.45	5.82	0.35	1.79e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.63	0.52	8.08e-19	Bipolar disorder;
KIRP	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.48	6.22	0.37	2.09e-9	Blood metabolite levels;
KIRP	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.11	-0.46	2.44e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.89	13.92	0.66	7.16e-33	Longevity;
KIRP	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.79	10.7	0.56	3.44e-22	Body mass index;
KIRP	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg05347473	chr6:146136440	FBXO30	0.62	8.75	0.49	3.47e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg00321850	chr1:175162397	KIAA0040	-0.42	-7.61	-0.44	5.75e-13	Diastolic blood pressure;
KIRP	cis	rs7527798	1.000	rs2147021	chr1:207849214	A/G	cg09232269	chr1:207846808	CR1L	-0.43	-5.09	-0.31	7.11e-7	Erythrocyte sedimentation rate;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg24003225	chr3:184870891	C3orf70	0.49	6.1	0.36	4.15e-9	Electroencephalogram traits;
KIRP	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.43	0.38	6.5e-10	Breast cancer;
KIRP	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.81	11.44	0.59	1.4e-24	Body mass index;
KIRP	cis	rs2165468	0.901	rs12217619	chr10:3504081	C/T	cg11503287	chr10:3498567	NA	0.76	5.17	0.31	4.78e-7	Bone mineral density;
KIRP	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg20701182	chr2:24300061	SF3B14	0.48	4.94	0.3	1.43e-6	Asthma;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.69	10.4	0.55	3.2e-21	Menarche (age at onset);
KIRP	trans	rs12214131	0.569	rs72931583	chr6:106250743	G/C	cg09763439	chr6:3473380	NA	-0.48	-6.55	-0.39	3.32e-10	Male-pattern baldness;
KIRP	cis	rs73198271	0.562	rs55657655	chr8:8675491	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.18	-0.31	4.52e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-5.77	-0.35	2.38e-8	Neuroticism;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.62	0.34	5.05e-8	Life satisfaction;
KIRP	cis	rs55871839	0.547	rs3780001	chr8:59872615	G/T	cg07426533	chr8:59803705	TOX	-0.48	-6.74	-0.39	1.1e-10	Pneumonia;
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg13453750	chr1:205783389	SLC41A1	-0.51	-7.53	-0.43	9.43e-13	Menarche (age at onset);
KIRP	cis	rs12261331	1	rs12261331	chr10:82287527	C/T	cg01528321	chr10:82214614	TSPAN14	-0.92	-7.94	-0.45	7.26e-14	Post bronchodilator FEV1;
KIRP	cis	rs9660180	0.967	rs66701417	chr1:1698092	A/G	cg23982607	chr1:1823379	GNB1	-0.85	-14.89	-0.69	3.38e-36	Body mass index;
KIRP	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	15.59	0.7	1.37e-38	Colorectal cancer;
KIRP	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.21	-0.32	4.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17253792	0.545	rs12883972	chr14:56018020	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	6.74	0.39	1.15e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.42	-5.21	-0.32	4.07e-7	Diastolic blood pressure;
KIRP	cis	rs490234	0.651	rs13291556	chr9:128240922	T/C	cg14078157	chr9:128172775	NA	-0.63	-7.45	-0.43	1.54e-12	Mean arterial pressure;
KIRP	cis	rs17121403	0.661	rs12144561	chr1:100465405	A/G	cg24955406	chr1:100503596	HIAT1	0.78	5.08	0.31	7.35e-7	Pulmonary function decline;
KIRP	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.24	-0.42	5.78e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20785715	chr8:144718023	ZNF623	-0.6	-6.52	-0.38	3.97e-10	Menopause (age at onset);
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.86	14.51	0.68	6.89e-35	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs76693355	0.512	rs10502235	chr11:120212423	C/T	cg24566217	chr11:120254723	ARHGEF12	0.41	5.2	0.31	4.3e-7	Intraocular pressure;
KIRP	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	1.04	13.26	0.65	1.2e-30	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.59	0.39	2.67e-10	Neuroticism;
KIRP	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs559928	0.502	rs10897504	chr11:64190137	C/G	cg05555928	chr11:63887634	MACROD1	-0.42	-5.02	-0.3	9.79e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24307225	chr16:58231550	CSNK2A2	-0.45	-6.05	-0.36	5.24e-9	Metabolic traits;
KIRP	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17344932	chr17:38183730	MED24;SNORD124	0.47	7.56	0.43	7.9e-13	White blood cell count;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08336733	chr16:5148730	FAM86A	-0.5	-6.35	-0.38	1.01e-9	Myopia;
KIRP	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg27211696	chr2:191398769	TMEM194B	-0.57	-6.9	-0.4	4.51e-11	Diastolic blood pressure;
KIRP	cis	rs7714584	1.000	rs17800886	chr5:150309539	C/G	cg22134413	chr5:150180641	NA	0.68	5.48	0.33	1.05e-7	Crohn's disease;
KIRP	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21643547	chr1:205240462	TMCC2	-0.81	-12.85	-0.63	3.01e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg19862616	chr7:65841803	NCRNA00174	0.59	7.19	0.42	7.87e-12	Eotaxin levels;
KIRP	cis	rs7520050	0.966	rs785471	chr1:46518677	T/C	cg03146154	chr1:46216737	IPP	-0.42	-5.35	-0.32	2.03e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg05721485	chr17:44071124	MAPT	-0.35	-5.02	-0.3	9.93e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs17401966	0.518	rs10864453	chr1:10407169	T/G	cg19773385	chr1:10388646	KIF1B	-0.42	-6.03	-0.36	5.98e-9	Hepatocellular carcinoma;
KIRP	trans	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Bladder cancer;
KIRP	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg20701182	chr2:24300061	SF3B14	0.5	4.93	0.3	1.55e-6	Lymphocyte counts;
KIRP	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg10932868	chr11:921992	NA	0.65	8.54	0.48	1.45e-15	Alzheimer's disease (late onset);
KIRP	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.5	0.38	4.39e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg24060327	chr5:131705240	SLC22A5	-0.46	-5.95	-0.35	9.13e-9	Breast cancer;
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10373780	chr19:8455179	RAB11B	0.57	7.14	0.41	1.03e-11	Parkinson's disease;
KIRP	cis	rs11155671	0.530	rs9371505	chr6:150184148	A/C	cg09699651	chr6:150184138	LRP11	0.59	8.13	0.46	2.08e-14	Testicular germ cell tumor;
KIRP	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.63	-8.11	-0.46	2.34e-14	Homocysteine levels;
KIRP	cis	rs8077577	0.708	rs3829590	chr17:18134265	C/A	cg18869244	chr17:18121946	NA	-0.43	-4.95	-0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs13088645	0.532	rs12695613	chr3:134166572	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	6.48	0.38	5e-10	Coronary artery disease;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.71	-7.54	-0.43	9.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs240764	0.658	rs9322182	chr6:101223295	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.56	6.89	0.4	4.57e-11	Aortic root size;
KIRP	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.84	5.65	0.34	4.37e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2073300	1.000	rs6137980	chr20:23466726	G/T	cg12062639	chr20:23401060	NAPB	1.08	7.12	0.41	1.21e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg19773385	chr1:10388646	KIF1B	-0.7	-9.9	-0.53	1.18e-19	Hepatocellular carcinoma;
KIRP	cis	rs9308731	0.583	rs6726007	chr2:111932122	A/T	cg04202892	chr2:111875749	ACOXL	0.48	6.48	0.38	4.85e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs859767	0.540	rs6739706	chr2:135407409	A/C	cg25422880	chr2:135218333	TMEM163	0.35	5.13	0.31	5.83e-7	Neuroticism;
KIRP	cis	rs7923609	1.000	rs10761727	chr10:64995493	C/T	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.61	-0.34	5.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	10.15	0.54	1.88e-20	Exhaled nitric oxide levels;
KIRP	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg27624424	chr6:160112604	SOD2	0.47	4.97	0.3	1.23e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.34	-5.57	-0.33	6.8e-8	Height;
KIRP	cis	rs796364	0.577	rs7574287	chr2:200680999	C/T	cg17644776	chr2:200775616	C2orf69	0.57	5.23	0.32	3.56e-7	Schizophrenia;
KIRP	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg08992911	chr2:238395768	MLPH	0.56	5.23	0.32	3.66e-7	Prostate cancer;
KIRP	trans	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17712092	chr4:129076599	LARP1B	-0.54	-6.16	-0.37	2.95e-9	Breast cancer;
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg11168104	chr5:1857477	NA	-0.4	-5.18	-0.31	4.73e-7	Cardiovascular disease risk factors;
KIRP	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.4	-8.42	-0.47	3.08e-15	Body mass index;
KIRP	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-5.45	-0.33	1.25e-7	Aortic root size;
KIRP	cis	rs1635	0.655	rs10484542	chr6:28309753	C/T	cg15743358	chr6:28303923	ZNF323	-0.75	-6.1	-0.36	4.01e-9	Schizophrenia;
KIRP	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg09911534	chr15:67153556	NA	0.42	5.18	0.31	4.62e-7	Lung cancer (smoking interaction);
KIRP	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.62	7.63	0.44	5.18e-13	Mosquito bite size;
KIRP	cis	rs490234	0.812	rs2416971	chr9:128466113	A/G	cg14078157	chr9:128172775	NA	-0.39	-4.86	-0.3	2.12e-6	Mean arterial pressure;
KIRP	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.5	-0.43	1.19e-12	Blood pressure;
KIRP	cis	rs13095912	0.785	rs6783023	chr3:185330189	A/G	cg11274856	chr3:185301563	NA	0.69	8.88	0.49	1.41e-16	Systolic blood pressure;
KIRP	cis	rs714027	0.605	rs193475	chr22:30450492	T/C	cg27665648	chr22:30112403	NA	-0.43	-5.89	-0.35	1.26e-8	Lymphocyte counts;
KIRP	cis	rs2150410	0.915	rs6517540	chr21:40679803	C/A	cg11890956	chr21:40555474	PSMG1	0.8	5.67	0.34	4.07e-8	Temperament (bipolar disorder);
KIRP	cis	rs11264213	0.901	rs72661628	chr1:36406547	A/G	cg27506609	chr1:36549197	TEKT2	1.15	6.84	0.4	6.2e-11	Schizophrenia;
KIRP	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Body mass index;
KIRP	cis	rs1485395	0.891	rs11170624	chr12:54030238	G/T	cg16917193	chr12:54089295	NA	0.57	5.51	0.33	8.91e-8	Migraine without aura;
KIRP	cis	rs9659323	1.000	rs10923715	chr1:119535334	A/T	cg18261050	chr1:119551319	NA	-0.38	-5.53	-0.33	8.1e-8	Body mass index;
KIRP	cis	rs829661	0.690	rs2609948	chr2:30869475	A/T	cg10949345	chr2:30726833	LCLAT1	1.08	13.31	0.65	8.61e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs7582720	1.000	rs6705330	chr2:203662197	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.16	10.03	0.54	4.61e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg23533926	chr12:111358616	MYL2	-0.53	-7.13	-0.41	1.13e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.68	10.41	0.55	2.8e-21	Heart rate;
KIRP	cis	rs6882046	0.513	rs34318	chr5:88027149	G/A	cg24804195	chr5:87968844	LOC645323	-0.44	-5.83	-0.35	1.77e-8	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.57	-6.51	-0.38	4.22e-10	Menarche (age at onset);
KIRP	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.21	0.42	7.04e-12	Height;
KIRP	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs6832769	0.961	rs28445925	chr4:56435849	T/C	cg05960024	chr4:56376020	CLOCK	-0.7	-9.04	-0.5	4.78e-17	Personality dimensions;
KIRP	cis	rs6968419	0.585	rs9692117	chr7:115927959	G/T	cg20172156	chr7:115970652	NA	-0.32	-4.95	-0.3	1.4e-6	Intraocular pressure;
KIRP	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg13072238	chr3:49761600	GMPPB	0.58	5.38	0.32	1.73e-7	Menarche (age at onset);
KIRP	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.43	0.33	1.37e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs16828019	0.852	rs12022978	chr1:41554088	A/G	cg24596898	chr1:41849189	NA	0.63	5.19	0.31	4.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.74	10.64	0.56	5.56e-22	Psoriasis;
KIRP	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.58	5.55	0.33	7.48e-8	Skin colour saturation;
KIRP	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg12606694	chr6:131520996	AKAP7	-0.49	-6.14	-0.36	3.23e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg01631408	chr1:248437212	OR2T33	-0.59	-7.97	-0.45	5.92e-14	Common traits (Other);
KIRP	cis	rs7546094	0.967	rs1006298	chr1:113061959	G/C	cg22162597	chr1:113214053	CAPZA1	0.45	6.44	0.38	6.39e-10	Platelet distribution width;
KIRP	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.85	12.78	0.63	5.02e-29	Height;
KIRP	cis	rs785830	0.523	rs529045	chr9:217397	C/T	cg14500300	chr9:211689	NA	0.44	6.05	0.36	5.48e-9	Platelet distribution width;
KIRP	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg02336718	chr17:17403227	NA	-0.32	-4.89	-0.3	1.81e-6	Total body bone mineral density;
KIRP	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg21775007	chr8:11205619	TDH	-0.49	-6.66	-0.39	1.77e-10	Mood instability;
KIRP	cis	rs2625529	0.816	rs8025504	chr15:72294757	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.03	-0.36	6.06e-9	Red blood cell count;
KIRP	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg08992911	chr2:238395768	MLPH	0.68	6.56	0.39	3.11e-10	Prostate cancer;
KIRP	cis	rs6684514	0.961	rs68170055	chr1:156332331	C/G	cg16558208	chr1:156270281	VHLL	-0.43	-5.38	-0.32	1.73e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg01631408	chr1:248437212	OR2T33	-0.37	-5.14	-0.31	5.67e-7	Common traits (Other);
KIRP	cis	rs892085	0.681	rs7246673	chr19:10876841	T/G	cg17710535	chr19:10819994	QTRT1	0.49	6.34	0.37	1.07e-9	Psoriasis vulgaris;Psoriasis;
KIRP	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	0.84	11.53	0.59	7.22e-25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg25486957	chr4:152246857	NA	-0.44	-4.96	-0.3	1.3e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs62056376	0.688	rs1476759	chr17:32600150	A/G	cg17635953	chr13:28535085	NA	0.6	6.12	0.36	3.63e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs6088813	1.000	rs6141548	chr20:33971085	A/G	cg14752227	chr20:34000481	UQCC	-0.52	-6.88	-0.4	4.97e-11	Height;
KIRP	trans	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg03060546	chr3:49711283	APEH	0.66	6.62	0.39	2.26e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.63	8.53	0.48	1.47e-15	Prostate cancer;
KIRP	cis	rs2746347	0.722	rs2796522	chr1:57130503	A/G	cg09935045	chr1:57111199	PRKAA2	0.5	5.26	0.32	3.1e-7	Lymphocyte counts;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg10434728	chr15:90938212	IQGAP1	0.43	8.22	0.46	1.16e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.74	11.5	0.59	9.13e-25	Neuroticism;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.37	4.99	0.3	1.17e-6	Vitiligo;
KIRP	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	8.5	0.48	1.82e-15	Total body bone mineral density;
KIRP	trans	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg19274270	chr17:78178856	CARD14	-0.36	-6.47	-0.38	5.29e-10	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg18657303	chr4:1051139	NA	0.58	5.05	0.31	8.8e-7	Recombination rate (females);
KIRP	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.08	-0.5	3.71e-17	Rheumatoid arthritis;
KIRP	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.53	-8.01	-0.45	4.66e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg15038512	chr6:170123185	PHF10	-0.56	-8.4	-0.47	3.68e-15	Obesity-related traits;
KIRP	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	0.93	14.16	0.67	1.11e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg13819577	chr1:248512075	OR14C36	-0.39	-5.22	-0.32	3.79e-7	Common traits (Other);
KIRP	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs501120	0.584	rs11238927	chr10:44704112	C/T	cg09554077	chr10:44749378	NA	0.56	5.95	0.35	9.34e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg08280861	chr8:58055591	NA	0.53	5.01	0.3	1.05e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18402987	chr7:1209562	NA	0.53	5.04	0.31	8.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg12591125	chr7:1885375	MAD1L1	0.64	6.14	0.36	3.22e-9	Bipolar disorder;
KIRP	cis	rs9834373	0.853	rs3923272	chr3:78488245	A/G	cg06138941	chr3:78371609	NA	-0.38	-5.04	-0.31	9.08e-7	Protein quantitative trait loci;
KIRP	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg05072774	chr3:49840536	C3orf54	0.43	5.47	0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg12573674	chr2:1569213	NA	-0.52	-5.15	-0.31	5.37e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg12140854	chr5:148520817	ABLIM3	-0.57	-6.46	-0.38	5.51e-10	Breast cancer;
KIRP	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.57	-6.07	-0.36	4.9e-9	Obesity-related traits;
KIRP	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.78	0.44	2.06e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-6.11	-0.36	3.78e-9	Lung cancer;
KIRP	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	4.04e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs986417	0.748	rs4400969	chr14:61013298	A/C	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg13160058	chr8:26243215	BNIP3L	-0.45	-6.94	-0.4	3.42e-11	Red cell distribution width;
KIRP	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.57	6.74	0.39	1.12e-10	Height;
KIRP	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-5.09	-0.31	6.96e-7	Neuroticism;
KIRP	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.84	-9.76	-0.53	3.17e-19	Vitamin D levels;
KIRP	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.93	0.45	7.7e-14	Morning vs. evening chronotype;
KIRP	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4740619	0.619	rs4741559	chr9:16041982	G/A	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs9513627	0.915	rs73556173	chr13:100121766	C/T	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.61	9.13	0.5	2.66e-17	Itch intensity from mosquito bite;
KIRP	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg10351095	chr21:47802916	PCNT	-0.44	-5.55	-0.33	7.28e-8	Testicular germ cell tumor;
KIRP	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	4.95	0.3	1.4e-6	Bipolar disorder;
KIRP	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.51	-0.33	9.16e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg21523564	chr15:75251491	NA	0.37	6.37	0.38	9.26e-10	Breast cancer;
KIRP	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.7	8.2	0.46	1.32e-14	Breast cancer;
KIRP	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg05072774	chr3:49840536	C3orf54	-0.38	-4.89	-0.3	1.79e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg03388025	chr16:89894329	SPIRE2	-0.42	-8.71	-0.49	4.38e-16	Vitiligo;
KIRP	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg00074818	chr8:8560427	CLDN23	0.43	6.4	0.38	7.61e-10	Obesity-related traits;
KIRP	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg00262122	chr8:11665843	FDFT1	-0.42	-5.1	-0.31	6.84e-7	Neuroticism;
KIRP	cis	rs2859741	0.608	rs532719	chr1:37477380	C/T	cg09363841	chr1:37513479	NA	0.57	9.19	0.51	1.76e-17	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg21827317	chr3:136751795	NA	0.37	5.13	0.31	5.91e-7	Neuroticism;
KIRP	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.79	13.14	0.64	3.07e-30	Heart rate;
KIRP	cis	rs7534824	0.543	rs61780300	chr1:101403601	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.83	0.35	1.7e-8	Refractive astigmatism;
KIRP	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.28	-0.32	2.85e-7	Bladder cancer;
KIRP	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg02073558	chr3:44770973	ZNF501	0.73	11.56	0.59	5.82e-25	Depressive symptoms;
KIRP	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.4	-5.12	-0.31	6.21e-7	Parkinson's disease;
KIRP	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg10547527	chr2:198650123	BOLL	-0.52	-4.88	-0.3	1.9e-6	Ulcerative colitis;
KIRP	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.06	18.24	0.76	1.32e-47	Multiple system atrophy;
KIRP	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.34	-6.91	-0.4	4.11e-11	Urinary metabolites;
KIRP	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-7.96	-0.45	6.25e-14	Fibrinogen levels;
KIRP	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg26384229	chr12:38710491	ALG10B	0.65	8.55	0.48	1.35e-15	Resting heart rate;
KIRP	cis	rs6466055	0.669	rs10953468	chr7:104741842	A/T	cg04380332	chr7:105027541	SRPK2	-0.64	-9.73	-0.53	3.79e-19	Schizophrenia;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg16341495	chr8:142228727	SLC45A4	-0.4	-5.0	-0.3	1.07e-6	Immature fraction of reticulocytes;
KIRP	cis	rs2224391	0.628	rs2773309	chr6:5248916	C/T	cg13962347	chr6:5174647	LYRM4	-0.72	-9.91	-0.53	1.1e-19	Height;
KIRP	cis	rs7818345	1.000	rs7011602	chr8:19308915	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.36	5.18	0.31	4.71e-7	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.72	9.31	0.51	7.62e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.51	0.52	1.89e-18	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22824647	chr19:17830645	MAP1S	0.49	6.41	0.38	7.52e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12476592	0.602	rs262477	chr2:63870959	A/C	cg17519650	chr2:63277830	OTX1	-0.45	-5.02	-0.3	9.98e-7	Childhood ear infection;
KIRP	cis	rs17095355	0.901	rs12240333	chr10:111743972	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.37	-5.2	-0.31	4.15e-7	Biliary atresia;
KIRP	cis	rs1903068	1.000	rs1903068	chr4:56008477	A/G	cg01777861	chr4:56023843	NA	0.38	4.9	0.3	1.75e-6	Endometriosis;
KIRP	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg06521331	chr12:34319734	NA	0.47	5.95	0.35	9.2e-9	Morning vs. evening chronotype;
KIRP	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-7.72	-0.44	3.01e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.88	-12.49	-0.62	4.79e-28	Dental caries;
KIRP	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.54	6.29	0.37	1.45e-9	Body mass index (adult);
KIRP	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg24296786	chr1:45957014	TESK2	0.6	7.51	0.43	1.11e-12	High light scatter reticulocyte count;
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg05552183	chr6:42928497	GNMT	0.82	13.51	0.65	1.8e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	1.08	21.19	0.8	2.1e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2979489	0.891	rs3824107	chr8:30353412	A/G	cg26383811	chr8:30366931	RBPMS	0.37	5.2	0.31	4.19e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg20821713	chr7:1055600	C7orf50	-0.35	-5.21	-0.32	4.02e-7	Longevity;Endometriosis;
KIRP	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	1.08	21.88	0.81	1.16e-59	Height;
KIRP	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.7	-10.31	-0.55	5.99e-21	Retinal vascular caliber;
KIRP	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg04398451	chr17:18023971	MYO15A	-0.7	-9.5	-0.52	1.92e-18	Total body bone mineral density;
KIRP	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.64	8.26	0.47	8.85e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.33	-0.51	6.6e-18	Platelet count;
KIRP	cis	rs2151522	0.724	rs13196855	chr6:127126146	T/C	cg21431617	chr6:127135037	NA	0.31	5.66	0.34	4.25e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg00106254	chr7:1943704	MAD1L1	-0.51	-5.35	-0.32	1.97e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9612	1.000	rs28373139	chr19:44246706	A/G	cg08581076	chr19:44259116	C19orf61	0.63	6.81	0.4	7.56e-11	Exhaled nitric oxide output;
KIRP	cis	rs42648	0.935	rs42624	chr7:89957541	C/G	cg25739043	chr7:89950458	NA	-0.47	-7.3	-0.42	3.87e-12	Homocysteine levels;
KIRP	cis	rs7870753	0.838	rs7039472	chr9:99245574	C/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.81	7.41	0.43	1.97e-12	Obesity-related traits;
KIRP	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.46e-9	Obesity-related traits;
KIRP	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg21775007	chr8:11205619	TDH	-0.41	-5.21	-0.32	3.91e-7	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.68	9.74	0.53	3.54e-19	Lymphocyte counts;
KIRP	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg26681399	chr22:41777847	TEF	0.54	5.14	0.31	5.59e-7	Vitiligo;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.58	-6.53	-0.38	3.81e-10	Menarche (age at onset);
KIRP	cis	rs33912345	0.695	rs1270509	chr14:60898568	T/A	cg27398547	chr14:60952738	C14orf39	-0.45	-6.0	-0.36	7.07e-9	Glaucoma (high intraocular pressure);
KIRP	cis	rs1250566	0.506	rs4993728	chr10:81040338	G/T	cg18688392	chr10:81059414	ZMIZ1	-0.45	-5.65	-0.34	4.53e-8	Inflammatory bowel disease;
KIRP	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg20430773	chr1:16534157	ARHGEF19	0.52	6.42	0.38	7.14e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg11584989	chr19:19387371	SF4	-0.42	-5.33	-0.32	2.18e-7	Tonsillectomy;
KIRP	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.63	5.38	0.32	1.78e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7084402	0.967	rs7098326	chr10:60276906	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.3	0.58	3.95e-24	Refractive error;
KIRP	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.17	0.74	5.82e-44	Cognitive function;
KIRP	cis	rs4974559	0.501	rs1250093	chr4:1240911	G/A	cg02980000	chr4:1222292	CTBP1	-0.94	-9.99	-0.54	6.04e-20	Systolic blood pressure;
KIRP	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	1.02	19.46	0.78	1.08e-51	Breast cancer;
KIRP	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.53	6.12	0.36	3.68e-9	Inhibitory control;
KIRP	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-14.39	-0.68	1.83e-34	Chronic sinus infection;
KIRP	trans	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg25214090	chr10:38739885	LOC399744	0.49	6.19	0.37	2.46e-9	Diastolic blood pressure;
KIRP	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7017914	0.967	rs1471114	chr8:71675547	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	0.85	6.84	0.4	6.07e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03467501	chr4:39481691	LOC401127	-0.44	-6.11	-0.36	3.83e-9	Select biomarker traits;
KIRP	cis	rs40363	0.645	rs37838	chr16:3509754	G/A	cg21433313	chr16:3507492	NAT15	0.53	7.16	0.42	9.27e-12	Tuberculosis;
KIRP	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg09137382	chr11:130731461	NA	0.56	8.25	0.47	9.79e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg01304814	chr3:48885189	PRKAR2A	0.75	5.71	0.34	3.25e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.48	-11.09	-0.58	1.9e-23	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg19847130	chr8:10466454	RP1L1	-0.35	-5.16	-0.31	5.02e-7	Retinal vascular caliber;
KIRP	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-6.69	-0.39	1.47e-10	Menarche (age at onset);
KIRP	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.58	-6.99	-0.41	2.55e-11	Aortic root size;
KIRP	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.68	9.37	0.51	5.05e-18	Body mass index;
KIRP	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.21	0.61	4.08e-27	Bipolar disorder;
KIRP	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.46	-5.91	-0.35	1.11e-8	Motion sickness;
KIRP	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg03808351	chr9:123631620	PHF19	0.38	5.12	0.31	6.04e-7	Rheumatoid arthritis;
KIRP	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.55	-6.34	-0.37	1.1e-9	Initial pursuit acceleration;
KIRP	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	6.59	0.39	2.59e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-8.1	-0.46	2.53e-14	Vitiligo;
KIRP	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg08975724	chr8:8085496	FLJ10661	-0.73	-9.46	-0.52	2.66e-18	Triglycerides;
KIRP	cis	rs9381040	1.000	rs9394767	chr6:41159905	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.6	-6.45	-0.38	5.89e-10	Alzheimer's disease (late onset);
KIRP	cis	rs2294693	0.891	rs4714421	chr6:40992837	C/T	cg14769373	chr6:40998127	UNC5CL	-0.54	-5.96	-0.36	8.89e-9	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg18586891	chr4:952366	TMEM175	-0.61	-5.55	-0.33	7.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06850241	chr22:41845214	NA	0.43	4.93	0.3	1.5e-6	Vitiligo;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22788252	chr4:143050435	INPP4B	0.49	6.09	0.36	4.33e-9	Interleukin-4 levels;
KIRP	cis	rs3617	0.521	rs11713763	chr3:53160360	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	5.87	0.35	1.44e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs963731	0.649	rs79431889	chr2:39358410	G/A	cg04010122	chr2:39346883	SOS1	0.88	5.57	0.33	6.61e-8	Corticobasal degeneration;
KIRP	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.35	-0.32	2.05e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg14345882	chr6:26364793	BTN3A2	0.32	5.0	0.3	1.1e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.67	9.43	0.52	3.16e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.69	-8.34	-0.47	5.25e-15	Extraversion;
KIRP	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg15655495	chr12:38532458	NA	0.25	4.93	0.3	1.49e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.3	0.37	1.36e-9	Lipoprotein (a) levels;
KIRP	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.53	7.3	0.42	4.09e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.63	8.59	0.48	1.02e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg18306943	chr3:40428807	ENTPD3	0.48	6.54	0.38	3.54e-10	Renal cell carcinoma;
KIRP	cis	rs6832769	0.961	rs13128582	chr4:56328944	C/G	cg05960024	chr4:56376020	CLOCK	0.63	8.17	0.46	1.65e-14	Personality dimensions;
KIRP	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.92	-14.45	-0.68	1.16e-34	Bladder cancer;
KIRP	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg01629716	chr15:45996671	NA	0.37	6.59	0.39	2.73e-10	Waist circumference;Weight;
KIRP	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg23682824	chr7:23144976	KLHL7	0.55	6.62	0.39	2.24e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18255839	chr2:239335447	ASB1	0.42	4.95	0.3	1.37e-6	Multiple system atrophy;
KIRP	cis	rs10207060	0.771	rs4852124	chr2:240680022	C/T	cg20333904	chr2:240724165	NA	-0.46	-6.24	-0.37	1.91e-9	Obesity-related traits;
KIRP	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.51	-0.33	8.87e-8	Breast cancer;
KIRP	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.23	-0.32	3.65e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.74	0.34	2.71e-8	Asthma (sex interaction);
KIRP	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.41	8.2	0.46	1.3e-14	Multiple system atrophy;
KIRP	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.81	13.1	0.64	4.12e-30	Metabolic syndrome;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15979172	chr19:15490570	AKAP8	-0.56	-6.18	-0.37	2.68e-9	Menopause (age at onset);
KIRP	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.43	4.96	0.3	1.33e-6	Menopause (age at onset);
KIRP	cis	rs2625529	0.824	rs2415130	chr15:72242554	G/A	cg16672083	chr15:72433130	SENP8	-0.48	-5.96	-0.36	8.83e-9	Red blood cell count;
KIRP	cis	rs6102059	0.503	rs7268642	chr20:39176878	T/C	cg22477343	chr20:39312069	NA	0.4	5.09	0.31	7e-7	LDL cholesterol;
KIRP	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.86	0.35	1.52e-8	Educational attainment;
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg05562828	chr17:3906858	NA	-0.71	-13.58	-0.65	1.05e-31	Type 2 diabetes;
KIRP	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	1.15	10.33	0.55	5.23e-21	Hip circumference adjusted for BMI;
KIRP	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.75	-0.44	2.42e-13	Retinal vascular caliber;
KIRP	cis	rs2904967	0.866	rs8638	chr11:65064918	C/G	cg12562828	chr11:65076843	NA	0.49	7.33	0.42	3.3e-12	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06270244	chr15:78933407	CHRNB4	0.43	6.61	0.39	2.34e-10	Parkinson's disease;
KIRP	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7091068	0.507	rs913046	chr10:95408484	A/C	cg20715218	chr10:95462985	C10orf4	0.52	5.92	0.35	1.08e-8	Urinary tract infection frequency;
KIRP	cis	rs2033908	0.620	rs1992335	chr11:12851717	A/C	cg25843174	chr11:12811716	TEAD1	-0.3	-5.65	-0.34	4.45e-8	Sitting height ratio;
KIRP	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	0.75	10.92	0.57	6.64e-23	Prudent dietary pattern;
KIRP	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.99	17.08	0.74	1.15e-43	Breast cancer;
KIRP	cis	rs17095355	1.000	rs11194917	chr10:111692552	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.45	-0.38	5.95e-10	Biliary atresia;
KIRP	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs136211	0.640	rs9306310	chr22:36758258	G/A	cg21778268	chr22:36877729	TXN2	-0.41	-5.13	-0.31	5.84e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.56	7.61	0.44	5.77e-13	Ulcerative colitis;
KIRP	cis	rs6662572	0.737	rs11211211	chr1:46340554	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.98	-0.36	7.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg22681709	chr2:178499509	PDE11A	-0.49	-6.72	-0.39	1.26e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.15	-0.37	3.11e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2904967	0.852	rs668735	chr11:65045725	G/T	cg09225861	chr11:65069680	NA	0.44	5.77	0.35	2.41e-8	Mean corpuscular volume;
KIRP	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg14289246	chr4:154710475	SFRP2	-0.52	-6.83	-0.4	6.5e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.05	11.79	0.6	9.77e-26	Vitiligo;
KIRP	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg17764715	chr19:33622953	WDR88	0.67	8.38	0.47	4.1e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	cis	rs702485	0.933	rs836559	chr7:6448763	C/G	cg22104063	chr7:6435090	RAC1	-0.36	-4.91	-0.3	1.66e-6	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg23534315	chr17:78082725	GAA	0.39	5.6	0.34	5.75e-8	Yeast infection;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06943149	chr12:77157476	ZDHHC17	0.71	6.31	0.37	1.27e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.34	-0.32	2.09e-7	Life satisfaction;
KIRP	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Parkinson's disease;
KIRP	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg18586891	chr4:952366	TMEM175	0.63	5.02	0.3	1.01e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.77	-10.34	-0.55	4.92e-21	Obesity-related traits;
KIRP	cis	rs988913	1.000	rs9382402	chr6:54809493	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.43	-0.33	1.37e-7	Menarche (age at onset);
KIRP	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	cg04338863	chr8:33670619	NA	0.48	6.21	0.37	2.27e-9	Body mass index;
KIRP	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.45	-0.33	1.2e-7	Obesity-related traits;
KIRP	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.65	-7.81	-0.45	1.63e-13	Height;
KIRP	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.78	-0.4	8.95e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.59	7.0	0.41	2.43e-11	Height;
KIRP	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.68	8.23	0.46	1.11e-14	Type 2 diabetes;
KIRP	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg16497661	chr14:103986332	CKB	-0.5	-6.37	-0.38	9.4e-10	Coronary artery disease;
KIRP	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg26022315	chr17:47021804	SNF8	0.42	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs13385	0.769	rs7703595	chr5:139611190	A/C	cg01860693	chr5:139557145	C5orf32	0.45	4.97	0.3	1.27e-6	Atrial fibrillation;
KIRP	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg23127183	chr11:57508653	C11orf31	0.49	6.57	0.39	2.91e-10	Schizophrenia;
KIRP	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.43	-7.83	-0.45	1.43e-13	Urinary metabolites;
KIRP	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.78	-8.81	-0.49	2.25e-16	Diastolic blood pressure;
KIRP	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.98	17.53	0.75	3.48e-45	Parkinson's disease;
KIRP	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	7.18	0.42	8.17e-12	Height;
KIRP	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg13010199	chr12:38710504	ALG10B	0.69	8.89	0.49	1.3e-16	Morning vs. evening chronotype;
KIRP	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs2034088	0.828	rs2289620	chr17:415667	T/C	cg13332499	chr17:408570	NA	0.57	7.97	0.45	6.07e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs17592366	0.517	rs10145350	chr14:35279109	A/C	cg09327582	chr14:35236912	BAZ1A	0.59	5.94	0.35	9.92e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs8084125	0.935	rs7238336	chr18:74953540	A/G	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg23505145	chr19:12996616	KLF1	0.55	7.95	0.45	6.81e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2411233	1.000	rs11070161	chr15:39270193	G/C	cg02291532	chr15:39874776	THBS1	0.39	5.3	0.32	2.56e-7	Platelet count;
KIRP	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg24747557	chr10:131355152	MGMT	-0.41	-5.49	-0.33	1.01e-7	Response to temozolomide;
KIRP	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.81	9.21	0.51	1.53e-17	High light scatter reticulocyte count;
KIRP	trans	rs7999699	0.871	rs6650373	chr13:48303361	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg05973401	chr12:123451056	ABCB9	-0.59	-5.37	-0.32	1.84e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.34	0.47	5.19e-15	Motion sickness;
KIRP	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg16006841	chr5:176797999	RGS14	0.67	7.37	0.43	2.58e-12	Urate levels in lean individuals;
KIRP	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	5.94	0.35	9.78e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2594989	0.943	rs7622627	chr3:11357419	T/C	cg01796438	chr3:11312864	ATG7	-0.69	-7.86	-0.45	1.18e-13	Circulating chemerin levels;
KIRP	cis	rs4716602	0.622	rs57131976	chr7:156167072	A/C	cg16983916	chr7:156159713	NA	-0.47	-6.19	-0.37	2.47e-9	Anti-saccade response;
KIRP	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.62	-9.1	-0.5	3.13e-17	Schizophrenia;
KIRP	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26002218	chr14:103986227	CKB	0.3	6.12	0.36	3.77e-9	Body mass index;
KIRP	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg06917634	chr15:78832804	PSMA4	0.48	4.95	0.3	1.38e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg01864069	chr14:103024347	NA	0.8	9.78	0.53	2.65e-19	Platelet count;
KIRP	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.51	-6.21	-0.37	2.29e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg02725872	chr8:58115012	NA	-0.46	-5.33	-0.32	2.17e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	1.01	11.42	0.59	1.65e-24	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.7	-8.55	-0.48	1.3e-15	Aortic root size;
KIRP	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg07271561	chr3:50359363	HYAL2	0.37	5.15	0.31	5.25e-7	Diastolic blood pressure;
KIRP	cis	rs2071403	0.901	rs9711204	chr2:1406012	C/T	cg07083862	chr2:1417248	TPO	0.34	5.5	0.33	9.74e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	1.1	20.46	0.79	5.36e-55	Bone mineral density;
KIRP	cis	rs1546924	0.549	rs127204	chr1:112277693	A/C	cg23955903	chr1:112298873	DDX20;C1orf183	0.44	5.53	0.33	7.96e-8	Body mass index;
KIRP	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.59	-7.71	-0.44	3.1400000000000003e-13	Childhood ear infection;
KIRP	cis	rs2997447	0.846	rs61775427	chr1:26408768	G/A	cg19633962	chr1:26362018	EXTL1	-0.65	-5.47	-0.33	1.12e-7	QRS complex (12-leadsum);
KIRP	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-5.3	-0.32	2.61e-7	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21897413	chr5:176944084	DDX41	0.49	6.09	0.36	4.25e-9	Parkinson's disease;
KIRP	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.91	13.63	0.66	6.66e-32	Mean platelet volume;
KIRP	cis	rs2737618	0.551	rs2816992	chr1:200069216	C/T	cg21825944	chr1:200113062	NR5A2	0.49	6.41	0.38	7.31e-10	Uric acid levels;
KIRP	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	1.06	15.61	0.71	1.24e-38	Menopause (age at onset);
KIRP	cis	rs6540559	0.673	rs11803382	chr1:209986426	G/A	cg22029157	chr1:209979665	IRF6	0.52	5.9	0.35	1.21e-8	Cleft lip with or without cleft palate;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07832834	chr1:2457954	PANK4	-0.47	-6.33	-0.37	1.18e-9	Myopia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg09096430	chr3:52444765	PHF7;BAP1	0.51	6.26	0.37	1.66e-9	Myopia (pathological);
KIRP	cis	rs6832769	0.961	rs10009593	chr4:56436681	C/A	cg05960024	chr4:56376020	CLOCK	-0.7	-9.04	-0.5	4.93e-17	Personality dimensions;
KIRP	cis	rs76793172	0.588	rs659444	chr19:46284947	T/C	cg11657440	chr19:46296263	DMWD	0.71	5.19	0.31	4.5e-7	Eosinophil counts;
KIRP	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.7	5.99	0.36	7.48e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.56	7.24	0.42	5.71e-12	Pulse pressure;
KIRP	cis	rs2267137	0.574	rs5752910	chr22:29803493	A/G	cg07256473	chr22:29710276	RASL10A	0.41	6.3	0.37	1.38e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg20887711	chr4:1340912	KIAA1530	-0.44	-5.47	-0.33	1.09e-7	Obesity-related traits;
KIRP	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.53	6.6	0.39	2.51e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01116491	chr4:102715139	BANK1	-0.45	-7.04	-0.41	1.86e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.85	-8.49	-0.48	2.03e-15	Coronary artery calcification;
KIRP	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.47	6.41	0.38	7.44e-10	Dupuytren's disease;
KIRP	cis	rs4787491	0.679	rs12933575	chr16:30022564	A/G	cg06326092	chr16:30034487	C16orf92	0.47	7.07	0.41	1.6e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10875746	0.903	rs2158516	chr12:48490834	T/A	cg20731937	chr12:48336164	NA	0.41	5.25	0.32	3.23e-7	Longevity (90 years and older);
KIRP	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.69	5.95	0.35	9.16e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs494562	0.892	rs618448	chr6:86121324	G/A	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.4	-5.78	-0.35	2.31e-8	Height;
KIRP	cis	rs11676348	0.808	rs4674261	chr2:219005009	G/C	cg00012203	chr2:219082015	ARPC2	-0.4	-4.98	-0.3	1.18e-6	Ulcerative colitis;
KIRP	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.48	7.25	0.42	5.47e-12	Total body bone mineral density;
KIRP	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	1.11	16.42	0.72	2.13e-41	Breast cancer;
KIRP	cis	rs981844	0.775	rs55986083	chr4:154765640	A/C	cg14289246	chr4:154710475	SFRP2	0.66	7.62	0.44	5.32e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg05315796	chr3:52349193	DNAH1	0.41	6.51	0.38	4.17e-10	Bipolar disorder;
KIRP	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.91	0.3	1.7e-6	Childhood ear infection;
KIRP	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.77	-9.2	-0.51	1.54e-17	Corneal structure;
KIRP	cis	rs7084402	0.967	rs7921371	chr10:60330531	G/C	cg05938607	chr10:60274200	BICC1	0.37	8.68	0.48	5.37e-16	Refractive error;
KIRP	cis	rs34746873	1.000	rs34746873	chr8:62898949	G/A	cg01509237	chr8:63160509	NKAIN3	0.44	5.64	0.34	4.73e-8	Neurofibrillary tangles;
KIRP	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.51	6.51	0.38	4.28e-10	HDL cholesterol levels;
KIRP	cis	rs2916247	0.954	rs6992101	chr8:93152048	C/A	cg10183463	chr8:93005414	RUNX1T1	0.43	5.1	0.31	6.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	1.000	rs8068804	chr17:3985864	G/A	cg21734707	chr17:3908241	ZZEF1	0.47	5.92	0.35	1.07e-8	Type 2 diabetes;
KIRP	cis	rs78545713	0.649	rs77362785	chr6:26232351	G/A	cg23601095	chr6:26197514	HIST1H3D	0.88	5.24	0.32	3.43e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg15443732	chr18:74961078	GALR1	0.54	5.38	0.32	1.75e-7	Obesity-related traits;
KIRP	cis	rs960902	0.620	rs11681193	chr2:37724917	C/T	cg25341268	chr2:37734390	NA	-0.56	-7.26	-0.42	5.21e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.52	0.62	3.89e-28	Menopause (age at onset);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg15769409	chr9:138372274	KIAA0649	0.51	6.25	0.37	1.76e-9	Asthma;
KIRP	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.2	16.75	0.73	1.55e-42	Lymphocyte percentage of white cells;
KIRP	cis	rs6684428	1.000	rs59959484	chr1:56345876	C/T	cg11651538	chr1:56320950	NA	-0.89	-10.77	-0.57	2.13e-22	Airflow obstruction;
KIRP	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.77	-11.28	-0.58	4.59e-24	Height;
KIRP	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg13010199	chr12:38710504	ALG10B	0.47	5.63	0.34	4.84e-8	Morning vs. evening chronotype;
KIRP	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs78579285	0.622	rs4782322	chr16:88797669	T/G	cg09054528	chr16:88821542	FAM38A	-0.61	-4.95	-0.3	1.41e-6	Joint mobility (Beighton score);
KIRP	cis	rs72829446	0.556	rs9907042	chr17:7402985	A/G	cg02795151	chr17:7402630	POLR2A	-0.77	-7.85	-0.45	1.25e-13	Androgen levels;
KIRP	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg19847866	chr10:1019161	NA	-0.63	-5.78	-0.35	2.28e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg01206211	chr2:36825736	FEZ2	0.6	8.15	0.46	1.91e-14	Height;
KIRP	cis	rs1823913	0.576	rs13011608	chr2:192131823	C/T	cg12404831	chr2:192114017	MYO1B	0.53	7.37	0.43	2.55e-12	Obesity-related traits;
KIRP	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.01	-0.3	1.03e-6	Iron status biomarkers;
KIRP	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg05082376	chr22:42548792	NA	0.37	4.85	0.3	2.2e-6	Cognitive function;
KIRP	cis	rs7213347	0.610	rs8077194	chr17:2119475	A/G	cg15816464	chr17:2026533	SMG6	0.37	5.38	0.32	1.77e-7	Total body bone mineral density;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg25703541	chr22:24373054	LOC391322	-0.65	-9.16	-0.5	2.08e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20091187	chr13:93979371	GPC6	-0.34	-6.15	-0.37	3.07e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg13385521	chr17:29058706	SUZ12P	0.57	5.61	0.34	5.35e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs883565	0.606	rs883349	chr3:39067925	T/C	cg01426195	chr3:39028469	NA	-0.65	-10.59	-0.56	7.94e-22	Handedness;
KIRP	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg18882449	chr10:104885122	NT5C2	-0.43	-5.51	-0.33	9e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.48	6.16	0.37	3e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4356932	1.000	rs6828596	chr4:76961373	A/G	cg00809888	chr4:76862425	NAAA	0.42	5.94	0.35	9.58e-9	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25925331	chr15:94774753	NA	0.49	6.27	0.37	1.63e-9	Parkinson's disease;
KIRP	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-1.1	-13.89	-0.66	8.79e-33	Lymphocyte counts;
KIRP	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.58e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.28	0.42	4.35e-12	Menarche (age at onset);
KIRP	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg09137382	chr11:130731461	NA	0.55	8.13	0.46	2.13e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6466055	0.748	rs6962856	chr7:104953466	A/T	cg04380332	chr7:105027541	SRPK2	-0.59	-8.83	-0.49	1.98e-16	Schizophrenia;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.76	-10.81	-0.57	1.58e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4262150	0.508	rs2961741	chr5:151919607	T/C	cg12297329	chr5:152029980	NA	-0.58	-7.23	-0.42	6.2e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg18306943	chr3:40428807	ENTPD3	0.44	5.74	0.34	2.72e-8	Renal cell carcinoma;
KIRP	cis	rs189798	0.738	rs330911	chr8:8996273	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	5.89	0.35	1.27e-8	Myopia (pathological);
KIRP	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.6	-9.76	-0.53	3.19e-19	Prostate cancer;
KIRP	cis	rs2278796	0.639	rs4950977	chr1:204970777	T/A	cg17449235	chr1:204966235	NFASC	0.57	7.86	0.45	1.17e-13	Mean platelet volume;
KIRP	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.48	0.38	5.07e-10	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05482956	chr11:16635016	NA	-0.39	-6.18	-0.37	2.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21866054	chr4:103748674	UBE2D3	0.59	6.87	0.4	5.27e-11	Smoking initiation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21144940	chr19:1993265	BTBD2	0.5	6.1	0.36	4.14e-9	Interleukin-4 levels;
KIRP	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg00677455	chr12:58241039	CTDSP2	-0.5	-5.64	-0.34	4.7e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs959260	1.000	rs2033607	chr17:73367288	A/G	cg20590849	chr17:73267439	MIF4GD	-0.61	-6.57	-0.39	2.97e-10	Systemic lupus erythematosus;
KIRP	cis	rs12586317	0.576	rs10146115	chr14:35631184	C/G	cg07166546	chr14:35805898	NA	-0.27	-6.49	-0.38	4.59e-10	Psoriasis;
KIRP	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg26850624	chr5:429559	AHRR	-0.39	-6.4	-0.38	7.84e-10	Cystic fibrosis severity;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg05562828	chr17:3906858	NA	0.78	16.23	0.72	9.28e-41	Type 2 diabetes;
KIRP	cis	rs3764563	1.000	rs4239612	chr19:15727442	A/G	cg20725493	chr19:15740067	CYP4F8	-0.96	-6.44	-0.38	6.29e-10	Inflammatory biomarkers;
KIRP	cis	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg00405596	chr8:11794950	NA	-0.49	-6.58	-0.39	2.89e-10	Monocyte count;
KIRP	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg24747557	chr10:131355152	MGMT	0.48	6.46	0.38	5.7e-10	Response to temozolomide;
KIRP	cis	rs77688320	0.535	rs11691859	chr2:202271991	T/C	cg06431681	chr2:202330990	STRADB	0.52	6.92	0.4	3.96e-11	Breast cancer;
KIRP	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.7	10.2	0.55	1.37e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.68	8.09	0.46	2.75e-14	Pancreatic cancer;
KIRP	cis	rs737008	0.821	rs28671554	chr16:11403753	A/G	cg00044050	chr16:11439710	C16orf75	0.52	6.21	0.37	2.2e-9	Obesity-related traits;
KIRP	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg21366198	chr4:185655624	MLF1IP	0.38	5.23	0.32	3.57e-7	Kawasaki disease;
KIRP	cis	rs4560672	1.000	rs1951543	chr6:158555641	A/G	cg14029994	chr6:158589857	SERAC1;GTF2H5	0.56	5.0	0.3	1.11e-6	Smoking quantity;
KIRP	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.51	7.21	0.42	6.98e-12	Hematocrit;
KIRP	cis	rs1816752	0.783	rs7139527	chr13:24985512	G/A	cg02811702	chr13:24901961	NA	0.39	5.08	0.31	7.53e-7	Obesity-related traits;
KIRP	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.58	7.17	0.42	8.84e-12	Arsenic metabolism;
KIRP	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.55	-6.74	-0.39	1.11e-10	Longevity;
KIRP	cis	rs8084125	0.832	rs62105166	chr18:74944518	A/G	cg05528293	chr18:74961138	GALR1	0.5	5.35	0.32	2.03e-7	Obesity-related traits;
KIRP	cis	rs2791713	0.591	rs12129638	chr1:207161286	T/C	cg24040043	chr1:207224982	YOD1	0.28	4.87	0.3	1.96e-6	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg14048686	chr9:138304510	NA	0.52	6.23	0.37	2.03e-9	DNA methylation (variation);
KIRP	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-1.05	-18.25	-0.76	1.21e-47	Height;
KIRP	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	5.38	0.32	1.71e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg27432699	chr2:27873401	GPN1	-0.43	-5.54	-0.33	7.95e-8	Total body bone mineral density;
KIRP	cis	rs2242116	0.896	rs724449	chr3:46935681	C/T	cg23352942	chr3:46931381	PTH1R	-0.51	-7.04	-0.41	1.87e-11	Birth weight;
KIRP	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg05721485	chr17:44071124	MAPT	0.43	6.45	0.38	5.96e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13998988	chr14:58063727	SLC35F4	0.49	6.91	0.4	4.21e-11	Interleukin-4 levels;
KIRP	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg23950597	chr19:37808831	NA	-0.64	-6.8	-0.4	7.8e-11	Coronary artery calcification;
KIRP	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.77	-0.35	2.32e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg21184320	chr1:21044207	KIF17	0.36	5.47	0.33	1.09e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	1.18	9.68	0.53	5.45e-19	Lymphocyte counts;
KIRP	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg18451016	chr1:38461880	NA	0.4	5.52	0.33	8.73e-8	Coronary artery disease;
KIRP	cis	rs9653442	0.527	rs13003982	chr2:100759078	T/C	cg17356467	chr2:100759845	AFF3	0.45	5.91	0.35	1.11e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.15	0.64	2.78e-30	Platelet count;
KIRP	cis	rs71525726	1	rs71525726	chr8:6190359	A/G	cg23549331	chr8:6189008	NA	0.85	8.65	0.48	6.92e-16	Alcoholic chronic pancreatitis;
KIRP	cis	rs72634258	0.679	rs7523227	chr1:8180097	G/A	cg00042356	chr1:8021962	PARK7	0.5	4.97	0.3	1.23e-6	Inflammatory bowel disease;
KIRP	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.51	0.52	1.8e-18	Coffee consumption (cups per day);
KIRP	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.51	-7.46	-0.43	1.52e-12	Bipolar disorder;
KIRP	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg23024343	chr7:107201750	COG5	-0.47	-7.25	-0.42	5.27e-12	Coronary artery disease;
KIRP	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.7	8.5	0.48	1.81e-15	Neutrophil percentage of white cells;
KIRP	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.73	10.62	0.56	6.18e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.87	-10.66	-0.56	4.68e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg07596299	chr11:71824057	C11orf51	-0.85	-5.76	-0.34	2.54e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg23161317	chr6:28129485	ZNF389	0.39	4.87	0.3	1.98e-6	Cardiac Troponin-T levels;
KIRP	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.97	10.43	0.55	2.57e-21	Blood protein levels;
KIRP	trans	rs9650657	0.740	rs6980805	chr8:10679842	G/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.4	-0.38	7.64e-10	Neuroticism;
KIRP	cis	rs6752107	0.967	rs56049444	chr2:234157688	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.13	0.46	2.05e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-5.5	-0.33	9.56e-8	Schizophrenia;
KIRP	cis	rs11169552	0.510	rs7138604	chr12:50952797	T/C	cg12884762	chr12:50931848	DIP2B	-0.44	-5.22	-0.32	3.72e-7	Colorectal cancer;
KIRP	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	14.89	0.69	3.63e-36	Chronic sinus infection;
KIRP	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.35	0.55	4.48e-21	Ileal carcinoids;
KIRP	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg06636001	chr8:8085503	FLJ10661	0.76	10.18	0.54	1.49e-20	Systolic blood pressure;
KIRP	cis	rs1014246	0.541	rs2011695	chr10:118507219	A/C	cg14919929	chr10:118506882	NA	-0.86	-12.28	-0.62	2.34e-27	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	trans	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-6.83	-0.4	6.47e-11	Mean corpuscular volume;
KIRP	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg24375607	chr4:120327624	NA	0.52	6.13	0.36	3.51e-9	Corneal astigmatism;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.89	-10.17	-0.54	1.64e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg16865965	chr2:85811662	VAMP5	0.33	5.01	0.3	1.03e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2219968	0.961	rs2128016	chr8:78964507	C/T	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.66	6.27	0.37	1.6e-9	Lung function (FEV1/FVC);
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.62	-9.65	-0.52	6.84e-19	Paraoxonase activity;
KIRP	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.96	-0.41	2.99e-11	Hemoglobin concentration;
KIRP	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg14664628	chr15:75095509	CSK	-0.43	-5.34	-0.32	2.11e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.77	-0.35	2.34e-8	Parkinson's disease;
KIRP	cis	rs9400467	0.506	rs12200641	chr6:111622758	C/T	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.54	-0.38	3.53e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.35	-4.91	-0.3	1.66e-6	Motion sickness;
KIRP	cis	rs703970	0.560	rs2802361	chr10:80971640	G/C	cg18737081	chr10:80999807	ZMIZ1	-0.3	-5.12	-0.31	6.13e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs787274	0.867	rs786968	chr9:115449110	C/T	cg13803584	chr9:115635662	SNX30	0.49	5.23	0.32	3.61e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6693295	0.877	rs6426278	chr1:246284163	C/T	cg11798871	chr1:246315928	SMYD3	-0.54	-6.71	-0.39	1.29e-10	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg05785598	chr3:49045655	WDR6	0.31	5.56	0.33	7.18e-8	Parkinson's disease;
KIRP	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg02151108	chr14:50098012	C14orf104	-0.51	-7.08	-0.41	1.47e-11	Carotid intima media thickness;
KIRP	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	5.99	0.36	7.23e-9	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg00933542	chr6:150070202	PCMT1	-0.28	-5.21	-0.32	3.93e-7	Lung cancer;
KIRP	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.33	0.47	5.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.62	8.9	0.49	1.27e-16	Coronary artery disease;
KIRP	cis	rs2290419	0.730	rs75139917	chr11:68944768	A/G	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg07827796	chr19:33622959	WDR88	0.49	6.31	0.37	1.31e-9	Bone properties (heel);
KIRP	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.56	6.46	0.38	5.43e-10	Initial pursuit acceleration;
KIRP	cis	rs9972944	0.508	rs35919548	chr17:63857548	T/C	cg07283582	chr17:63770753	CCDC46	-0.44	-6.82	-0.4	7.18e-11	Total body bone mineral density;
KIRP	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.63	-8.37	-0.47	4.42e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.66	8.15	0.46	1.88e-14	Alcohol dependence;
KIRP	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.68	-8.07	-0.46	3.21e-14	Diabetic retinopathy;
KIRP	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg12963246	chr6:28129442	ZNF389	0.53	6.43	0.38	6.49e-10	Depression;
KIRP	cis	rs7737355	0.947	rs6895586	chr5:130588008	C/A	cg25547332	chr5:131281432	NA	0.46	5.16	0.31	5.11e-7	Life satisfaction;
KIRP	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.62	-0.52	8.4e-19	Hemoglobin concentration;
KIRP	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.79	0.49	2.56e-16	Bladder cancer;
KIRP	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.6	-0.66	8.64e-32	Response to antipsychotic treatment;
KIRP	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	1.03	20.4	0.79	8.35e-55	Breast cancer;
KIRP	cis	rs992157	0.672	rs2382829	chr2:219184617	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.15	0.36	3.18e-9	Colorectal cancer;
KIRP	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.55	-6.71	-0.39	1.3100000000000001e-10	Uric acid clearance;
KIRP	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg18357526	chr6:26021779	HIST1H4A	0.42	5.1	0.31	6.72e-7	Blood metabolite levels;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg25184507	chr17:7760147	CYB5D1;LSMD1	0.67	6.61	0.39	2.4e-10	Lung function (FEV1);
KIRP	cis	rs735539	0.521	rs12430409	chr13:21349667	A/G	cg04906043	chr13:21280425	IL17D	-0.43	-4.97	-0.3	1.26e-6	Dental caries;
KIRP	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02398342	chr17:80708632	TBCD;FN3K	-0.5	-6.13	-0.36	3.45e-9	Glycated hemoglobin levels;
KIRP	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs17209837	1.000	rs4148805	chr7:87106365	G/A	cg00919237	chr7:87102261	ABCB4	-0.67	-7.29	-0.42	4.33e-12	Gallbladder cancer;
KIRP	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.37	5.17	0.31	4.81e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	6.63	0.39	2.06e-10	Bipolar disorder;
KIRP	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg17724175	chr1:150552817	MCL1	0.35	5.97	0.36	8.07e-9	Melanoma;
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg27532560	chr4:187881888	NA	-0.76	-12.74	-0.63	7.09e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.87	16.54	0.73	8.26e-42	Anterior chamber depth;
KIRP	cis	rs1062177	0.756	rs2964592	chr5:151115688	A/G	cg00977110	chr5:151150581	G3BP1	-0.53	-5.49	-0.33	9.89e-8	Preschool internalizing problems;
KIRP	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg03735888	chr19:58951602	ZNF132	0.47	5.84	0.35	1.63e-8	Uric acid clearance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08516262	chr3:101292886	PCNP	0.5	6.42	0.38	6.94e-10	Parkinson's disease;
KIRP	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.47	-4.87	-0.3	1.95e-6	Smoking behavior;
KIRP	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.94	-0.3	1.44e-6	Blood metabolite levels;
KIRP	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg22676075	chr6:135203613	NA	0.48	6.97	0.41	2.89e-11	Red blood cell count;
KIRP	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.74	10.7	0.56	3.48e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.59	7.89	0.45	1e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22307029	chr19:49891270	CCDC155	0.68	6.3	0.37	1.37e-9	Multiple sclerosis;
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-7.56	-0.43	8.21e-13	Lung cancer;
KIRP	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.36	-5.17	-0.31	4.85e-7	Monocyte count;
KIRP	cis	rs7635838	0.826	rs9867963	chr3:11469126	C/T	cg00170343	chr3:11313890	ATG7	0.41	4.94	0.3	1.41e-6	HDL cholesterol;
KIRP	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.52	-6.6	-0.39	2.44e-10	Neurofibrillary tangles;
KIRP	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg00343986	chr7:65444356	GUSB	0.49	5.92	0.35	1.08e-8	Aortic root size;
KIRP	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00889227	chr1:205173544	DSTYK	0.38	5.48	0.33	1.06e-7	Red blood cell count;
KIRP	trans	rs2270927	0.510	rs13188781	chr5:75580409	C/A	cg13563193	chr19:33072644	PDCD5	0.94	6.81	0.4	7.48e-11	Mean corpuscular volume;
KIRP	cis	rs7215564	0.558	rs4889876	chr17:78657071	T/G	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs73200209	0.662	rs17426872	chr12:116636915	T/C	cg01776926	chr12:116560359	MED13L	-0.57	-6.18	-0.37	2.63e-9	Total body bone mineral density;
KIRP	trans	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg10756647	chr7:56101905	PSPH	1.01	7.54	0.43	9.29e-13	Diabetic kidney disease;
KIRP	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.17	-0.31	4.88e-7	Pulmonary function;
KIRP	cis	rs8135828	1.000	rs2247753	chr22:30022936	A/G	cg23204276	chr22:29729285	AP1B1;SNORD125	0.44	4.92	0.3	1.55e-6	Lipid traits;
KIRP	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg21605333	chr4:119757512	SEC24D	1.52	11.4	0.59	1.92e-24	Cannabis dependence symptom count;
KIRP	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	0.84	7.54	0.43	8.76e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.55	-7.43	-0.43	1.74e-12	Type 2 diabetes;
KIRP	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.91	14.04	0.67	2.87e-33	Selective IgA deficiency;
KIRP	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.42	5.49	0.33	9.81e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9612	1.000	rs1059	chr19:44268348	C/T	cg08581076	chr19:44259116	C19orf61	0.5	5.43	0.33	1.37e-7	Exhaled nitric oxide output;
KIRP	cis	rs6546324	0.580	rs4410279	chr2:67850620	A/C	cg15745817	chr2:67799979	NA	-0.69	-7.5	-0.43	1.15e-12	Endometriosis;
KIRP	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.59	7.72	0.44	2.99e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2071403	0.933	rs10183390	chr2:1404885	T/C	cg06500727	chr2:1417164	TPO	0.49	7.79	0.44	1.86e-13	Thyroid peroxidase antibody positivity;
KIRP	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.84	11.91	0.6	4.04e-26	Body mass index;
KIRP	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg06740227	chr12:86229804	RASSF9	-0.46	-5.59	-0.34	6.17e-8	Major depressive disorder;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.28	-0.32	2.79e-7	Life satisfaction;
KIRP	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs11765649	1	rs11765649	chr7:23479013	T/C	cg08153160	chr7:23508734	IGF2BP3	-0.45	-5.04	-0.31	8.93e-7	Birth weight;
KIRP	cis	rs2014572	0.901	rs35658377	chr19:57755627	T/G	cg12963866	chr19:57752005	ZNF805	-0.49	-6.24	-0.37	1.91e-9	Hyperactive-impulsive symptoms;
KIRP	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg18944383	chr4:111397179	ENPEP	0.61	11.17	0.58	1.03e-23	Height;
KIRP	cis	rs9948	1.000	rs62152793	chr2:97484948	C/T	cg20312557	chr2:97357134	FER1L5	-0.73	-5.31	-0.32	2.46e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs654128	0.640	rs339339	chr6:117214866	A/C	cg12892004	chr6:117198278	RFX6	-0.45	-5.84	-0.35	1.64e-8	Telomere length;
KIRP	cis	rs17092148	1.000	rs1884432	chr20:33342439	A/G	cg16810054	chr20:33298113	TP53INP2	-0.46	-5.73	-0.34	2.89e-8	Neuroticism;
KIRP	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg10517650	chr3:113235015	CCDC52	-0.41	-5.08	-0.31	7.45e-7	Dental caries;
KIRP	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.39	-0.33	1.61e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs1858037	0.867	rs4671660	chr2:65576436	C/A	cg08085232	chr2:65598271	SPRED2	-0.49	-5.83	-0.35	1.76e-8	Rheumatoid arthritis;
KIRP	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.71	-9.42	-0.51	3.45e-18	Personality dimensions;
KIRP	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.69	9.7	0.53	4.74e-19	Post bronchodilator FEV1;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00386034	chr6:44191288	SLC29A1	-0.68	-7.99	-0.45	5.11e-14	Menopause (age at onset);
KIRP	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	8.94	0.5	9.43e-17	Mood instability;
KIRP	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.55	-0.33	7.44e-8	Depression;
KIRP	cis	rs59868192	0.925	rs72726027	chr15:42248826	T/C	cg20935245	chr15:42234343	EHD4	-0.52	-5.11	-0.31	6.38e-7	White blood cell count;
KIRP	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg02820901	chr13:113351484	ATP11A	0.68	6.34	0.37	1.08e-9	Glycated hemoglobin levels;
KIRP	cis	rs112591243	0.685	rs2839341	chr21:47990008	A/G	cg26904215	chr21:47823096	PCNT	0.81	6.47	0.38	5.21e-10	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.57	-6.15	-0.37	3.09e-9	Pancreatic cancer;
KIRP	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.3	0.47	7.09e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-5.24	-0.32	3.49e-7	Lung cancer;
KIRP	cis	rs9393813	0.506	rs4713105	chr6:27434920	T/C	cg03332623	chr6:27441972	ZNF184	-0.35	-5.1	-0.31	6.92e-7	Bipolar disorder;
KIRP	cis	rs17023223	0.537	rs12086	chr1:119573860	T/C	cg05756136	chr1:119680316	WARS2	-0.54	-6.25	-0.37	1.81e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.68	6.81	0.4	7.3e-11	Bronchopulmonary dysplasia;
KIRP	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg07341007	chr3:195489909	MUC4	-0.72	-6.63	-0.39	2.1e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7011049	1.000	rs72648407	chr8:53857144	C/T	cg26025543	chr8:53854495	NA	0.75	7.78	0.44	2.06e-13	Systolic blood pressure;
KIRP	cis	rs1010254	0.559	rs115672114	chr5:151749774	G/T	cg12297329	chr5:152029980	NA	-0.62	-6.36	-0.38	9.89e-10	Optic nerve measurement (cup area);
KIRP	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.55	6.7	0.39	1.41e-10	Arsenic metabolism;
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg14221460	chr8:27183342	PTK2B	0.53	6.79	0.4	8.33e-11	Neuroticism;
KIRP	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg15655495	chr12:38532458	NA	0.25	5.0	0.3	1.11e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg18490616	chr2:88469792	THNSL2	0.65	5.03	0.31	9.4e-7	Plasma clusterin levels;
KIRP	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg02336718	chr17:17403227	NA	0.36	5.4	0.33	1.59e-7	Total body bone mineral density;
KIRP	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.37	-0.59	2.42e-24	Chronic sinus infection;
KIRP	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg16926213	chr1:1841314	NA	0.34	5.72	0.34	3.02e-8	Body mass index;
KIRP	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.46	-0.43	1.52e-12	Alzheimer's disease (late onset);
KIRP	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg13736514	chr6:26305472	NA	-0.69	-8.6	-0.48	9.52e-16	Educational attainment;
KIRP	cis	rs6788895	1.000	rs16862842	chr3:150484844	A/G	cg09723797	chr3:150481914	SIAH2	0.76	4.96	0.3	1.32e-6	Breast cancer;
KIRP	cis	rs1829883	0.739	rs1829882	chr5:98728778	G/A	cg08333243	chr5:99726346	NA	0.38	5.0	0.3	1.08e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs10495907	0.591	rs13412831	chr2:43960043	A/C	cg11659317	chr2:43863985	PLEKHH2	-0.42	-5.01	-0.3	1.03e-6	Coronary artery disease;
KIRP	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.57	7.0	0.41	2.37e-11	Total body bone mineral density;
KIRP	cis	rs4666002	0.956	rs4665383	chr2:27791555	C/G	cg05484376	chr2:27715224	FNDC4	-0.37	-5.25	-0.32	3.27e-7	Phospholipid levels (plasma);
KIRP	cis	rs7536201	1.000	rs10903122	chr1:25303576	A/G	cg23273869	chr1:25296894	NA	-0.41	-6.02	-0.36	6.29e-9	Psoriasis vulgaris;
KIRP	cis	rs16828019	0.777	rs35044078	chr1:41474400	C/G	cg18742814	chr1:41828276	NA	0.62	5.52	0.33	8.65e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.87	12.58	0.63	2.45e-28	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10929159	0.928	rs7565059	chr2:236926347	A/G	cg20128773	chr2:236923534	AGAP1	0.29	5.0	0.3	1.07e-6	Parkinson's disease;
KIRP	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.57	6.54	0.38	3.56e-10	Primary sclerosing cholangitis;
KIRP	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.7	-0.39	1.41e-10	Response to antipsychotic treatment;
KIRP	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.84	-0.35	1.62e-8	Bone mineral density;
KIRP	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.65	8.76	0.49	3.22e-16	Total body bone mineral density;
KIRP	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	7.65	0.44	4.42e-13	Tonsillectomy;
KIRP	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.19	-0.31	4.34e-7	Neutrophil percentage of white cells;
KIRP	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08822215	chr16:89438651	ANKRD11	-0.47	-6.47	-0.38	5.16e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs732716	0.785	rs62130978	chr19:4429007	C/T	cg21720385	chr19:4455239	UBXN6	0.71	8.82	0.49	2.12e-16	Mean corpuscular volume;
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg10351095	chr21:47802916	PCNT	0.44	5.56	0.33	7.16e-8	Testicular germ cell tumor;
KIRP	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.12	0.41	1.2e-11	Bipolar disorder;
KIRP	cis	rs1461503	0.548	rs7114175	chr11:122813983	A/T	cg27398637	chr11:122830231	C11orf63	-0.6	-8.13	-0.46	2.09e-14	Menarche (age at onset);
KIRP	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg02160872	chr5:212506	CCDC127	-0.61	-5.15	-0.31	5.46e-7	Asthma (childhood onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06717289	chr15:75978121	CSPG4	-0.4	-6.33	-0.37	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs145358377	1	rs145358377	chr1:6272136	GA/G	cg01517656	chr1:6272055	RNF207	-0.69	-4.97	-0.3	1.24e-6	Resting heart rate;
KIRP	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.32e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg23067535	chr8:124195133	FAM83A	-0.82	-8.32	-0.47	5.92e-15	Urinary uromodulin levels;
KIRP	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	1.13	8.22	0.46	1.2e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1829883	0.689	rs2511979	chr5:98828142	A/T	cg08333243	chr5:99726346	NA	-0.42	-5.41	-0.33	1.52e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	7.47	0.43	1.43e-12	Lymphocyte counts;
KIRP	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.54	-0.43	9.31e-13	Type 2 diabetes;
KIRP	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.88	-12.83	-0.63	3.48e-29	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg10503236	chr1:231470652	EXOC8	-0.47	-6.36	-0.38	9.56e-10	Hemoglobin concentration;
KIRP	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.92	10.7	0.56	3.42e-22	Corneal astigmatism;
KIRP	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg09699651	chr6:150184138	LRP11	0.59	8.18	0.46	1.55e-14	Testicular germ cell tumor;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	8.89e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16094925	chr1:193028456	TROVE2;UCHL5	0.46	6.96	0.41	3.05e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7523273	0.505	rs34277355	chr1:207881491	C/A	cg22525895	chr1:207977042	MIR29B2	0.48	5.78	0.35	2.2e-8	Schizophrenia;
KIRP	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14598338	chr9:96623480	NA	0.61	9.35	0.51	5.5e-18	DNA methylation (variation);
KIRP	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg21187068	chr8:144659627	NAPRT1	0.74	5.05	0.31	8.49e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.89	13.0	0.64	8.85e-30	Body mass index (adult);
KIRP	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.83	-0.57	1.36e-22	Height;
KIRP	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg09455208	chr3:40491958	NA	-0.37	-6.71	-0.39	1.3100000000000001e-10	Renal cell carcinoma;
KIRP	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.92	10.56	0.56	9.34e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg21433313	chr16:3507492	NAT15	0.65	7.22	0.42	6.56e-12	Tuberculosis;
KIRP	cis	rs8060686	0.841	rs56374641	chr16:67908713	G/T	cg09117114	chr16:67998030	SLC12A4	-0.49	-5.17	-0.31	4.87e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.73	-0.44	2.82e-13	Mood instability;
KIRP	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.22	0.37	2.16e-9	Ovarian reserve;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10607599	chr11:120382422	NA	0.46	6.45	0.38	5.8e-10	Parkinson's disease;
KIRP	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.25	-0.42	5.38e-12	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.63	8.19	0.46	1.43e-14	Mood instability;
KIRP	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg06565975	chr8:143823917	SLURP1	-0.43	-6.54	-0.38	3.57e-10	Urinary tract infection frequency;
KIRP	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.62	-0.44	5.53e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14169450	chr9:139327907	INPP5E	0.51	7.32	0.42	3.46e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11645898	0.504	rs79169855	chr16:71950201	A/G	cg14768367	chr16:72042858	DHODH	-0.77	-6.78	-0.4	8.78e-11	Blood protein levels;
KIRP	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg16434002	chr17:42200994	HDAC5	-0.45	-5.34	-0.32	2.17e-7	Total body bone mineral density;
KIRP	cis	rs11722228	0.790	rs13126729	chr4:9974186	G/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-6.22	-0.37	2.08e-9	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.89	12.96	0.64	1.29e-29	Monocyte count;
KIRP	cis	rs10203711	0.933	rs1810139	chr2:239568154	A/C	cg14580085	chr2:239553406	NA	0.39	5.13	0.31	5.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs728478	1.000	rs11079376	chr17:57453489	G/T	cg16535752	chr17:57448097	YPEL2	-0.22	-5.26	-0.32	3.16e-7	QT interval;
KIRP	cis	rs7937612	0.965	rs10790378	chr11:120220268	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.55	-0.39	3.3e-10	Intraocular pressure;
KIRP	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.68	-0.53	5.57e-19	Mean corpuscular volume;
KIRP	cis	rs3112255	0.647	rs10175405	chr2:101319712	G/T	cg01042948	chr2:101319752	NA	-0.51	-7.29	-0.42	4.21e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg13736514	chr6:26305472	NA	-0.72	-9.28	-0.51	9e-18	Educational attainment;
KIRP	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.77	10.2	0.55	1.33e-20	Resting heart rate;
KIRP	cis	rs13095912	0.785	rs35637544	chr3:185329958	A/G	cg11274856	chr3:185301563	NA	0.66	8.4	0.47	3.67e-15	Systolic blood pressure;
KIRP	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg04310649	chr10:35416472	CREM	-0.5	-5.87	-0.35	1.43e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11987759	chr7:65425863	GUSB	0.51	6.88	0.4	4.83e-11	Aortic root size;
KIRP	cis	rs13082711	1.000	rs73050029	chr3:27514760	C/A	cg02860705	chr3:27208620	NA	0.57	7.58	0.44	7.02e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.37	5.63	0.34	4.94e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.54	5.49	0.33	9.96e-8	Birth weight;
KIRP	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	12.69	0.63	1.01e-28	Personality dimensions;
KIRP	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.34	12.3	0.62	2.1e-27	Diabetic retinopathy;
KIRP	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.74	10.98	0.57	4.31e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg25019033	chr10:957182	NA	-0.61	-7.2	-0.42	7.49e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.45	-5.48	-0.33	1.05e-7	IgG glycosylation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00050984	chr2:210288967	MAP2	0.46	6.29	0.37	1.48e-9	Survival in pancreatic cancer;
KIRP	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.52	-5.74	-0.34	2.73e-8	Platelet distribution width;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.46	6.85	0.4	5.78e-11	Lymphocyte counts;
KIRP	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-1.07	-13.56	-0.65	1.18e-31	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1341267	1.000	rs6492725	chr13:95285580	A/C	cg11945895	chr13:95253670	GPR180	-0.26	-4.89	-0.3	1.86e-6	Triglyceride levels;
KIRP	cis	rs1558375	0.679	rs31676	chr7:87069880	T/C	cg00919237	chr7:87102261	ABCB4	0.54	6.88	0.4	4.96e-11	Gallbladder cancer;
KIRP	cis	rs2573652	0.755	rs1469830	chr15:100517403	G/T	cg09918751	chr15:100517450	ADAMTS17	0.84	14.85	0.69	4.91e-36	Height;
KIRP	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.69	8.12	0.46	2.32e-14	Cocaine dependence;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06427957	chr5:81601203	ATP6AP1L	0.48	7.11	0.41	1.28e-11	Migraine with aura;
KIRP	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	5.18	0.31	4.51e-7	Bipolar disorder;
KIRP	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg22117172	chr7:91764530	CYP51A1	0.5	7.22	0.42	6.34e-12	Breast cancer;
KIRP	cis	rs9400271	0.632	rs9487020	chr6:109587672	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg26338869	chr17:61819248	STRADA	0.54	6.59	0.39	2.59e-10	Prudent dietary pattern;
KIRP	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.84	-12.46	-0.62	5.75e-28	Height;
KIRP	trans	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg10756647	chr7:56101905	PSPH	0.97	6.94	0.4	3.51e-11	Diabetic kidney disease;
KIRP	cis	rs1659258	0.568	rs1713941	chr2:88629360	C/T	cg00685853	chr2:88648947	NA	-0.49	-5.75	-0.34	2.6e-8	Visceral fat;
KIRP	cis	rs4728302	0.607	rs6956135	chr7:133589608	A/C	cg10665199	chr7:133106180	EXOC4	-0.43	-5.05	-0.31	8.79e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg14673194	chr17:80132900	CCDC57	0.77	8.91	0.49	1.18e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.22	14.11	0.67	1.55e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg08738300	chr3:44038990	NA	0.66	8.97	0.5	7.81e-17	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	1.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.94	15.66	0.71	8.22e-39	Ulcerative colitis;
KIRP	cis	rs1034435	0.792	rs2338719	chr22:48879639	C/T	cg05992904	chr22:48892994	FAM19A5	-0.58	-6.69	-0.39	1.51e-10	Late-onset Alzheimer's disease;
KIRP	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.56	-6.97	-0.41	2.85e-11	Uric acid clearance;
KIRP	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.1	-0.36	4e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg00933542	chr6:150070202	PCMT1	0.27	5.0	0.3	1.08e-6	Testicular germ cell tumor;
KIRP	cis	rs6546324	1.000	rs6546324	chr2:67856490	A/C	cg15745817	chr2:67799979	NA	-0.44	-5.76	-0.34	2.51e-8	Endometriosis;
KIRP	cis	rs77633900	0.772	rs506000	chr15:76817788	T/C	cg21673338	chr15:77095150	SCAPER	-0.63	-5.81	-0.35	1.98e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg23034840	chr1:205782522	SLC41A1	-0.67	-6.05	-0.36	5.45e-9	Prostate-specific antigen levels;
KIRP	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs2594989	0.836	rs1546231	chr3:11513678	T/G	cg01796438	chr3:11312864	ATG7	-0.62	-7.62	-0.44	5.55e-13	Circulating chemerin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05353415	chr7:42276004	GLI3	0.56	6.65	0.39	1.93e-10	Smoking initiation;
KIRP	cis	rs4517514	0.509	rs10830434	chr11:89912652	T/C	cg06174606	chr11:89959870	NA	-0.57	-5.91	-0.35	1.11e-8	Trans fatty acid levels;
KIRP	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs7560272	0.502	rs13013228	chr2:73925216	G/A	cg20560298	chr2:73613845	ALMS1	0.55	6.66	0.39	1.77e-10	Schizophrenia;
KIRP	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05890377	chr2:74357713	NA	0.86	10.97	0.57	4.56e-23	Gestational age at birth (maternal effect);
KIRP	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-13.1	-0.64	4.33e-30	Chronic sinus infection;
KIRP	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg13798780	chr7:105162888	PUS7	0.62	5.65	0.34	4.32e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.92	10.45	0.55	2.23e-21	Corneal astigmatism;
KIRP	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.55	-6.45	-0.38	5.8e-10	Longevity;Endometriosis;
KIRP	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.78	9.64	0.52	7.28e-19	Blood trace element (Cu levels);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02467765	chr4:78978708	FRAS1	-0.46	-6.24	-0.37	1.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	1.07	20.91	0.8	1.77e-56	Height;
KIRP	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.69	-5.26	-0.32	3.13e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.46	4.86	0.3	2.13e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs137699	0.959	rs5757631	chr22:39755953	T/C	cg11247378	chr22:39784982	NA	-0.34	-4.92	-0.3	1.57e-6	IgG glycosylation;
KIRP	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.08	0.41	1.48e-11	Bipolar disorder;
KIRP	cis	rs2307121	0.700	rs12187081	chr5:64756859	T/G	cg00944502	chr5:64858997	PPWD1;CENPK	0.41	4.86	0.3	2.05e-6	Corneal structure;
KIRP	cis	rs10129255	0.500	rs8021941	chr14:107189727	C/T	cg23076370	chr14:107095027	NA	-0.42	-5.17	-0.31	4.89e-7	Kawasaki disease;
KIRP	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.81	-9.19	-0.51	1.7e-17	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.53	0.33	8.04e-8	Putamen volume;
KIRP	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.69	7.88	0.45	1.04e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg05347473	chr6:146136440	FBXO30	0.61	8.68	0.48	5.69e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1712790	0.614	rs4938126	chr11:114633560	G/A	cg19465033	chr11:114479364	NA	0.4	5.31	0.32	2.41e-7	Urinary albumin excretion;
KIRP	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16524936	chr4:1340807	KIAA1530	-0.47	-5.84	-0.35	1.62e-8	Longevity;
KIRP	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.6	-9.43	-0.52	3.31e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.53	-8.83	-0.49	2.01e-16	Eye color traits;
KIRP	cis	rs311392	0.554	rs376765	chr8:55097188	A/G	cg20636351	chr8:55087400	NA	-0.53	-6.43	-0.38	6.74e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.2	0.72	1.19e-40	Lymphocyte percentage of white cells;
KIRP	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.56	0.39	3.17e-10	Morning vs. evening chronotype;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg23736307	chr8:27182930	PTK2B	0.52	6.63	0.39	2.09e-10	Neuroticism;
KIRP	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.74	10.85	0.57	1.12e-22	Body mass index;
KIRP	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg22676075	chr6:135203613	NA	0.5	7.18	0.42	8.21e-12	Reticulocyte count;High light scatter reticulocyte count;
KIRP	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.55	7.54	0.43	9.01e-13	Colorectal cancer;
KIRP	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21643547	chr1:205240462	TMCC2	-0.85	-14.21	-0.67	7.23e-34	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg11650704	chr1:154556575	ADAR	-0.38	-4.97	-0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00149659	chr3:10157352	C3orf10	0.7	7.53	0.43	9.49e-13	Alzheimer's disease;
KIRP	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg09959495	chr2:237029385	AGAP1	0.42	6.04	0.36	5.75e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.77	8.34	0.47	5.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.81	10.85	0.57	1.17e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.67	-6.55	-0.39	3.35e-10	Bipolar disorder;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg13395646	chr4:1353034	KIAA1530	-0.44	-6.12	-0.36	3.62e-9	Longevity;
KIRP	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.14	-0.31	5.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.85e-9	Leprosy;
KIRP	cis	rs13102973	0.899	rs13122646	chr4:135906123	T/C	cg14419869	chr4:135874104	NA	0.48	7.44	0.43	1.67e-12	Subjective well-being;
KIRP	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.63	8.05	0.46	3.5e-14	Anxiety disorder;
KIRP	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.64	9.2	0.51	1.6e-17	Colorectal cancer;
KIRP	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg13628971	chr7:2884303	GNA12	0.44	5.93	0.35	1.02e-8	Height;
KIRP	cis	rs7116495	1.000	rs2298456	chr11:71730715	A/T	cg26138937	chr11:71823887	C11orf51	0.66	5.2	0.31	4.21e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.81	0.35	1.95e-8	Lung cancer;
KIRP	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg00383909	chr3:49044727	WDR6	0.45	4.97	0.3	1.24e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg21775007	chr8:11205619	TDH	0.48	6.36	0.38	9.88e-10	Mood instability;
KIRP	cis	rs2290402	0.505	rs9328759	chr4:882845	C/T	cg00846425	chr4:957561	DGKQ	0.52	5.36	0.32	1.95e-7	Type 2 diabetes;
KIRP	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg03289416	chr15:75166202	SCAMP2	-0.4	-5.58	-0.34	6.26e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-9.65	-0.52	6.98e-19	Chronic sinus infection;
KIRP	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.25	6.85	0.4	5.77e-11	Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15888849	chr15:76094525	NA	0.44	6.03	0.36	5.87e-9	Survival in pancreatic cancer;
KIRP	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.22	-0.37	2.09e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23545105	chr4:48908833	OCIAD2	0.55	7.28	0.42	4.36e-12	Parkinson's disease;
KIRP	cis	rs66696671	0.559	rs12217200	chr10:121357196	A/G	cg06765389	chr10:121379685	NA	-0.42	-5.68	-0.34	3.87e-8	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.61	0.68	3.15e-35	Platelet count;
KIRP	cis	rs7555523	0.830	rs6426936	chr1:165684707	C/T	cg24409356	chr1:165738333	TMCO1	-0.67	-5.18	-0.31	4.57e-7	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	trans	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg25288420	chr1:78511713	GIPC2	0.48	6.35	0.38	1.05e-9	Obesity-related traits;
KIRP	cis	rs2502731	0.583	rs3003579	chr9:130995751	C/G	cg09976142	chr9:130955436	CIZ1	0.4	5.99	0.36	7.6e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg23477460	chr3:66848765	NA	-0.52	-6.45	-0.38	6.05e-10	Type 2 diabetes;
KIRP	cis	rs13418717	1.000	rs4452092	chr2:127655112	G/A	cg25501666	chr2:127640322	NA	1.07	7.35	0.42	2.95e-12	Heart failure;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.55	-5.77	-0.35	2.43e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.62	-7.53	-0.43	9.38e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9584850	0.834	rs7339274	chr13:99120272	A/G	cg20750642	chr13:99100586	FARP1	0.54	6.39	0.38	8.05e-10	Neuroticism;
KIRP	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg04132472	chr17:19861366	AKAP10	0.39	4.96	0.3	1.3e-6	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26218983	chr11:109964223	ZC3H12C	0.55	6.85	0.4	5.83e-11	Parkinson's disease;
KIRP	cis	rs9614461	0.826	rs9614649	chr22:45746097	C/A	cg13318129	chr22:45737514	FAM118A	0.6	6.98	0.41	2.75e-11	Tonsillectomy;
KIRP	cis	rs7688540	0.771	rs11722521	chr4:276765	A/T	cg10134910	chr4:1076041	RNF212	-0.24	-4.85	-0.3	2.19e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs1344555	0.808	rs7620590	chr3:169285609	T/G	cg17499719	chr20:17588410	DSTN	-0.53	-6.04	-0.36	5.7e-9	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg08501292	chr6:25962987	TRIM38	1.09	6.11	0.36	3.85e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11264213	0.786	rs72659678	chr1:36258190	T/C	cg27506609	chr1:36549197	TEKT2	0.91	5.51	0.33	9.03e-8	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg08662619	chr6:150070041	PCMT1	0.37	5.92	0.35	1.08e-8	Lung cancer;
KIRP	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.85	0.49	1.79e-16	Motion sickness;
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.63	9.28	0.51	8.86e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.28	-0.37	1.49e-9	Neutrophil percentage of white cells;
KIRP	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.48	-8.24	-0.46	1.04e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.03	-0.5	5.24e-17	Rheumatoid arthritis;
KIRP	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg00405596	chr8:11794950	NA	0.52	6.91	0.4	4.21e-11	Mood instability;
KIRP	cis	rs757081	0.533	rs56030184	chr11:17067849	C/T	cg15432903	chr11:17409602	KCNJ11	-0.53	-6.03	-0.36	5.94e-9	Systolic blood pressure;
KIRP	cis	rs2071426	0.959	rs11572093	chr10:96824406	C/T	cg09036531	chr10:96991505	NA	-0.56	-6.41	-0.38	7.26e-10	Blood metabolite levels;
KIRP	cis	rs11627756	0.915	rs11850368	chr14:103131770	G/C	cg01864069	chr14:103024347	NA	0.55	6.43	0.38	6.55e-10	Mean platelet volume;
KIRP	cis	rs6450176	1.000	rs58369491	chr5:53297295	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.33	-0.59	3.2e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6973256	0.637	rs12707116	chr7:133424909	C/T	cg10665199	chr7:133106180	EXOC4	-0.48	-6.05	-0.36	5.47e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg26174226	chr8:58114915	NA	-0.57	-6.27	-0.37	1.59e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg17376030	chr22:41985996	PMM1	0.58	6.46	0.38	5.54e-10	Vitiligo;
KIRP	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.83	9.79	0.53	2.56e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs42235	0.683	rs60814640	chr7:92286918	A/G	cg15732164	chr7:92237376	CDK6	-0.37	-5.13	-0.31	5.99e-7	Hip circumference adjusted for BMI;Height;
KIRP	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg25811766	chr13:21894605	NA	-0.63	-6.25	-0.37	1.79e-9	White matter hyperintensity burden;
KIRP	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	5.13	0.31	5.99e-7	Ovarian reserve;
KIRP	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-5.31	-0.32	2.51e-7	Neuroticism;
KIRP	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.97	-6.38	-0.38	8.5e-10	LDL cholesterol;
KIRP	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-11.92	-0.61	3.58e-26	Prostate cancer;
KIRP	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg02297831	chr4:17616191	MED28	0.59	7.54	0.43	8.97e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.25	0.47	9.85e-15	Motion sickness;
KIRP	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.89	10.57	0.56	9.13e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs6088813	1.000	rs4911491	chr20:33947285	C/G	cg14752227	chr20:34000481	UQCC	-0.51	-6.87	-0.4	5.22e-11	Height;
KIRP	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs9398803	0.723	rs853971	chr6:127066190	T/C	cg19875578	chr6:126661172	C6orf173	-0.42	-5.5	-0.33	9.28e-8	Male-pattern baldness;
KIRP	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.61	-7.61	-0.44	5.87e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.64	0.52	7.35e-19	Bipolar disorder;
KIRP	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.45	5.23	0.32	3.7e-7	Schizophrenia;
KIRP	cis	rs4356932	0.790	rs6848620	chr4:76973549	G/C	cg00809888	chr4:76862425	NAAA	0.44	6.2	0.37	2.42e-9	Blood protein levels;
KIRP	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg00310523	chr12:86230176	RASSF9	0.46	7.17	0.42	8.72e-12	Major depressive disorder;
KIRP	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-9.14	-0.5	2.38e-17	Neuroticism;
KIRP	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg24315340	chr6:146058215	EPM2A	0.4	4.97	0.3	1.24e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10861661	0.963	rs3782707	chr12:107185187	G/A	cg21360079	chr12:107162445	NA	-0.59	-6.61	-0.39	2.39e-10	Triglyceride levels;
KIRP	cis	rs7130144	0.541	rs78212960	chr11:130446126	G/A	cg26307797	chr11:130446613	NA	-0.64	-5.14	-0.31	5.5e-7	Urate levels in lean individuals;
KIRP	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.36	5.13	0.31	5.9e-7	Body mass index;
KIRP	cis	rs6464929	0.956	rs10272564	chr7:148705490	G/A	cg05518778	chr7:148730143	NA	-0.42	-5.28	-0.32	2.86e-7	Pediatric bone mineral content (hip);
KIRP	cis	rs754423	0.515	rs768021	chr14:52553563	G/A	cg10149976	chr14:52535953	NID2	-0.37	-5.23	-0.32	3.61e-7	Craniofacial microsomia;
KIRP	cis	rs41278232	0.920	rs7265923	chr20:62677395	G/C	cg03065311	chr20:62601662	ZNF512B	0.33	4.93	0.3	1.49e-6	Tonsillectomy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26872475	chr11:119039430	NLRX1	0.54	6.25	0.37	1.78e-9	Smoking initiation;
KIRP	cis	rs7224685	0.569	rs8067427	chr17:3997517	C/T	cg05562828	chr17:3906858	NA	0.54	5.67	0.34	3.94e-8	Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21225450	chr8:98656257	MTDH	0.52	6.11	0.36	3.96e-9	Inflammatory biomarkers;
KIRP	trans	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg16141378	chr3:129829833	LOC729375	0.47	6.29	0.37	1.45e-9	Mood instability;
KIRP	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg14851346	chr12:38532713	NA	-0.39	-4.85	-0.3	2.15e-6	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.88	0.49	1.46e-16	Neuroticism;
KIRP	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg00074818	chr8:8560427	CLDN23	0.41	6.61	0.39	2.42e-10	Obesity-related traits;
KIRP	cis	rs78487399	0.808	rs6746632	chr2:43712163	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.99	-0.3	1.14e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	1.04	14.46	0.68	1.05e-34	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg19847130	chr8:10466454	RP1L1	-0.34	-4.92	-0.3	1.58e-6	Retinal vascular caliber;
KIRP	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.28	0.58	4.68e-24	Alzheimer's disease;
KIRP	cis	rs35934224	0.891	rs34249993	chr22:19872170	G/T	cg11182965	chr22:19864308	TXNRD2	-0.41	-5.67	-0.34	3.9e-8	Glaucoma (primary open-angle);
KIRP	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg15557168	chr22:42548783	NA	-0.38	-5.37	-0.32	1.82e-7	Cognitive function;
KIRP	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg11645453	chr3:52864694	ITIH4	0.47	5.91	0.35	1.12e-8	Schizophrenia;
KIRP	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.62	-0.34	5.24e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-11.42	-0.59	1.63e-24	Alzheimer's disease;
KIRP	cis	rs714027	0.585	rs41157	chr22:30405151	T/C	cg01021169	chr22:30184971	ASCC2	0.4	5.02	0.3	1e-6	Lymphocyte counts;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.73	10.94	0.57	6.06e-23	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06529453	chr1:54955046	NA	0.52	6.07	0.36	4.88e-9	Smoking initiation;
KIRP	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg19678392	chr7:94953810	PON1	-0.43	-5.07	-0.31	7.81e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03466841	chr7:24663627	MPP6	-0.43	-6.82	-0.4	7.01e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.59	-7.55	-0.43	8.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.76	9.65	0.52	6.9e-19	Neutrophil percentage of white cells;
KIRP	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.65	-8.6	-0.48	9.770000000000001e-16	Obesity-related traits;
KIRP	cis	rs66530629	0.958	rs4543739	chr1:25049680	A/C	cg07201717	chr1:25031947	NA	0.33	4.96	0.3	1.34e-6	Plateletcrit;
KIRP	cis	rs9912468	0.933	rs67700546	chr17:64301081	C/T	cg19474267	chr17:64306194	PRKCA	0.6	8.29	0.47	7.27e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs7209700	0.962	rs56327427	chr17:45354746	C/T	cg08085267	chr17:45401833	C17orf57	0.42	4.94	0.3	1.45e-6	IgG glycosylation;
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg11131117	chr7:1891496	MAD1L1	0.41	5.03	0.31	9.55e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg18585693	chr11:117668161	DSCAML1	0.31	5.01	0.3	1.02e-6	Myopia;
KIRP	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs12980942	0.591	rs11879435	chr19:41757603	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.68	5.53	0.33	8.21e-8	Coronary artery disease;
KIRP	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.79	9.45	0.52	2.81e-18	Corneal astigmatism;
KIRP	cis	rs9473924	0.505	rs7756058	chr6:50904438	G/A	cg14470998	chr6:50812995	TFAP2B	0.85	7.85	0.45	1.25e-13	Body mass index;
KIRP	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg09137382	chr11:130731461	NA	-0.56	-8.23	-0.46	1.1e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.79	13.14	0.64	3.14e-30	Calcium levels;
KIRP	cis	rs9972944	0.756	rs7220733	chr17:63764890	A/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.7	-0.44	3.39e-13	Total body bone mineral density;
KIRP	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg02461776	chr11:598696	PHRF1	0.5	5.3	0.32	2.57e-7	Systemic lupus erythematosus;
KIRP	cis	rs9815354	1.000	rs9834098	chr3:41833493	A/G	cg03022575	chr3:42003672	ULK4	0.49	5.46	0.33	1.16e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs741677	0.826	rs12938729	chr17:475780	T/C	cg13332499	chr17:408570	NA	0.39	5.08	0.31	7.52e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.99	-0.54	6.03e-20	Asthma;
KIRP	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Bipolar disorder;
KIRP	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	0.61	5.72	0.34	3.05e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs400736	0.602	rs4601608	chr1:8168808	A/G	cg25007680	chr1:8021821	PARK7	-0.41	-5.37	-0.32	1.83e-7	Response to antidepressants and depression;
KIRP	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.6	-6.72	-0.39	1.25e-10	Aortic root size;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.86	15.55	0.7	1.95e-38	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.66	-10.4	-0.55	3.07e-21	Hip circumference;Waist circumference;
KIRP	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.52	-6.81	-0.4	7.33e-11	Aortic root size;
KIRP	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.57	5.22	0.32	3.75e-7	Major depressive disorder;
KIRP	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg23594656	chr7:65796392	TPST1	0.39	5.75	0.34	2.66e-8	Aortic root size;
KIRP	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg25457927	chr22:38595422	NA	-0.25	-5.3	-0.32	2.55e-7	Cutaneous nevi;
KIRP	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg03060546	chr3:49711283	APEH	0.48	6.32	0.37	1.2e-9	Parkinson's disease;
KIRP	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.2	21.77	0.81	2.68e-59	Cognitive function;
KIRP	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-0.77	-8.95	-0.5	8.63e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs12042938	0.837	rs1417584	chr1:231819050	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-6.42	-0.38	6.95e-10	Neuranatomic and neurocognitive phenotypes;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10020600	chr19:39397911	NFKBIB	0.59	6.07	0.36	4.87e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg03146154	chr1:46216737	IPP	0.56	5.89	0.35	1.3e-8	Platelet count;
KIRP	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg08890418	chr1:21044141	KIF17	0.34	5.01	0.3	1.04e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs981844	0.583	rs62323859	chr4:154629690	G/A	cg14289246	chr4:154710475	SFRP2	0.58	5.48	0.33	1.03e-7	Response to statins (LDL cholesterol change);
KIRP	cis	rs6977660	0.660	rs13225400	chr7:19817016	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.49	5.95	0.35	9.11e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg05361325	chr10:32636312	EPC1	-0.66	-6.27	-0.37	1.64e-9	Sexual dysfunction (female);
KIRP	cis	rs35740288	0.929	rs1978391	chr15:86311695	A/G	cg17133734	chr15:86042851	AKAP13	0.49	5.39	0.33	1.63e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-5.45	-0.33	1.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.6	9.34	0.51	6.13e-18	Prostate cancer;
KIRP	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.33e-11	Aortic root size;
KIRP	cis	rs4891159	0.790	rs4891161	chr18:74142683	A/G	cg24786174	chr18:74118243	ZNF516	-0.71	-9.76	-0.53	3.02e-19	Longevity;
KIRP	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg04725166	chr1:7887271	PER3	-0.34	-5.37	-0.32	1.87e-7	Crohn's disease;
KIRP	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.23	-0.32	3.64e-7	Schizophrenia;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Blood metabolite levels;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg06815112	chr8:27182871	PTK2B	0.49	6.36	0.38	9.96e-10	Neuroticism;
KIRP	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg18225595	chr11:63971243	STIP1	0.62	5.61	0.34	5.38e-8	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-5.68	-0.34	3.79e-8	Lung cancer;
KIRP	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.59	-8.46	-0.47	2.44e-15	Diastolic blood pressure;
KIRP	cis	rs4972539	0.784	rs11690597	chr2:174085741	A/G	cg04505972	chr2:173508040	NA	-0.46	-5.53	-0.33	7.99e-8	Parental longevity (mother's age at death);
KIRP	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19671926	chr4:122722719	EXOSC9	0.5	6.03	0.36	6.06e-9	Type 2 diabetes;
KIRP	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	ch.11.42038R	chr11:967971	AP2A2	0.45	5.82	0.35	1.83e-8	Alzheimer's disease (late onset);
KIRP	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg10017260	chr10:834428	NA	-0.58	-5.56	-0.33	7e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	8.69	0.48	5.34e-16	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.11	0.36	3.79e-9	Lung cancer;
KIRP	cis	rs3736485	0.578	rs2305716	chr15:51981291	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.01	-0.3	1.02e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg02336718	chr17:17403227	NA	-0.33	-5.29	-0.32	2.74e-7	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10561983	chr2:23454432	NA	-0.41	-6.64	-0.39	1.98e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.84	-10.71	-0.56	3.25e-22	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg11846333	chr4:119757529	SEC24D	1.11	5.88	0.35	1.37e-8	Cannabis dependence symptom count;
KIRP	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg00405596	chr8:11794950	NA	-0.5	-6.58	-0.39	2.87e-10	Retinal vascular caliber;
KIRP	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.8	7.51	0.43	1.12e-12	Type 2 diabetes;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg17316185	chr17:43045884	C1QL1	-0.5	-6.32	-0.37	1.22e-9	Blood metabolite levels;
KIRP	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg13679303	chr9:96623674	NA	0.45	6.0	0.36	6.97e-9	DNA methylation (variation);
KIRP	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg24642439	chr20:33292090	TP53INP2	0.56	6.66	0.39	1.77e-10	Height;
KIRP	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.48	-0.48	2.11e-15	Coronary artery disease;
KIRP	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.52	-6.16	-0.37	2.87e-9	Ulcerative colitis;
KIRP	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.57	7.44	0.43	1.67e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-7.2	-0.42	7.29e-12	Vitiligo;
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	5.71	0.34	3.29e-8	Platelet count;
KIRP	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.46	0.38	5.65e-10	Personality dimensions;
KIRP	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-8.2	-0.46	1.36e-14	Neuroticism;
KIRP	cis	rs2554380	0.891	rs1896816	chr15:84299371	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.56	-0.48	1.25e-15	Height;
KIRP	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.58	7.64	0.44	4.96e-13	White matter hyperintensity burden;
KIRP	cis	rs238295	0.805	rs1983694	chr20:5574134	T/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-5.14	-0.31	5.53e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs10465746	0.780	rs11163866	chr1:84367123	A/G	cg10977910	chr1:84465055	TTLL7	0.53	6.68	0.39	1.56e-10	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08180261	chr2:86668980	KDM3A	0.45	6.54	0.38	3.51e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg01629716	chr15:45996671	NA	0.37	6.74	0.39	1.15e-10	Waist circumference;Weight;
KIRP	trans	rs12030196	0.788	rs10889125	chr1:59417116	A/G	cg09326324	chr1:161123937	UFC1	-0.53	-6.08	-0.36	4.52e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs72781680	0.652	rs72794281	chr2:23893265	G/A	cg08917208	chr2:24149416	ATAD2B	1.04	8.14	0.46	2e-14	Lymphocyte counts;
KIRP	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.68	-4.94	-0.3	1.42e-6	Coronary artery disease;
KIRP	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg22138327	chr13:27999177	GTF3A	0.88	6.67	0.39	1.68e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg13010199	chr12:38710504	ALG10B	0.44	5.68	0.34	3.75e-8	Morning vs. evening chronotype;
KIRP	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.51	6.26	0.37	1.67e-9	HIV-1 control;
KIRP	trans	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg10756647	chr7:56101905	PSPH	-0.98	-7.0	-0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.59	-0.34	6.11e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg08132940	chr7:1081526	C7orf50	-0.7	-7.04	-0.41	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4262150	0.883	rs55967446	chr5:152207140	G/T	cg12297329	chr5:152029980	NA	-0.62	-8.05	-0.46	3.49e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg17143192	chr8:8559678	CLDN23	0.36	4.86	0.3	2.07e-6	Mood instability;
KIRP	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.42	-0.38	7.04e-10	Hemoglobin concentration;
KIRP	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06481639	chr22:41940642	POLR3H	0.63	6.99	0.41	2.61e-11	Vitiligo;
KIRP	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg09936142	chr19:10668400	KRI1	-0.44	-5.14	-0.31	5.63e-7	Inflammatory skin disease;
KIRP	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg21775007	chr8:11205619	TDH	-0.49	-6.51	-0.38	4.09e-10	Retinal vascular caliber;
KIRP	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg12173498	chr6:36355764	ETV7	0.3	4.94	0.3	1.46e-6	Platelet distribution width;
KIRP	cis	rs507080	0.922	rs654792	chr11:118552996	A/C	cg04173919	chr11:118528438	PHLDB1	-0.37	-5.33	-0.32	2.18e-7	Serum metabolite levels;
KIRP	cis	rs9393813	0.529	rs73395360	chr6:27457317	A/C	cg03332623	chr6:27441972	ZNF184	-0.39	-5.52	-0.33	8.38e-8	Bipolar disorder;
KIRP	cis	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg11783602	chr8:55087084	NA	-0.55	-6.63	-0.39	2.14e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.44	5.54	0.33	7.94e-8	Testicular germ cell tumor;
KIRP	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-1.06	-18.12	-0.76	3.49e-47	Intelligence (multi-trait analysis);
KIRP	cis	rs10203711	1.000	rs907100	chr2:239563579	G/C	cg14580085	chr2:239553406	NA	0.39	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2637030	0.559	rs1490768	chr5:53018495	C/G	cg06476337	chr5:52856530	NDUFS4	0.52	5.75	0.34	2.65e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-7.98	-0.45	5.6e-14	Alcohol dependence;
KIRP	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.43	-5.79	-0.35	2.1e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.69	-8.86	-0.49	1.6e-16	Vitiligo;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09123989	chr12:125093710	NA	-0.44	-6.39	-0.38	8.04e-10	Survival in pancreatic cancer;
KIRP	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.58	7.0	0.41	2.37e-11	Schizophrenia;
KIRP	cis	rs859767	0.501	rs10193171	chr2:135403199	C/T	cg12500956	chr2:135428796	TMEM163	0.38	5.18	0.31	4.65e-7	Neuroticism;
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg13206674	chr6:150067644	NUP43	0.59	8.6	0.48	9.21e-16	Lung cancer;
KIRP	cis	rs1978968	0.717	rs1072405	chr22:18406068	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-6.0	-0.36	6.87e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg05333889	chr7:157238977	NA	-0.4	-5.54	-0.33	7.79e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs10861661	1.000	rs10861661	chr12:107174646	A/C	cg15890332	chr12:107067104	RFX4	0.37	5.54	0.33	7.6e-8	Triglyceride levels;
KIRP	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.08	-0.41	1.47e-11	Menopause (age at onset);
KIRP	cis	rs6832769	1.000	rs11726609	chr4:56400869	A/T	cg05960024	chr4:56376020	CLOCK	0.68	8.29	0.47	7.34e-15	Personality dimensions;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg18234130	chr8:27182889	PTK2B	0.54	7.06	0.41	1.67e-11	Neuroticism;
KIRP	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-4.95	-0.3	1.38e-6	Cognitive function;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15907819	chr5:27119093	NA	0.46	7.79	0.44	1.93e-13	Survival in pancreatic cancer;
KIRP	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.17	0.37	2.77e-9	Personality dimensions;
KIRP	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg25664220	chr3:72788482	NA	-0.36	-5.07	-0.31	7.8e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1978968	0.956	rs7290762	chr22:18449130	C/G	cg03078520	chr22:18463400	MICAL3	-0.64	-7.57	-0.43	7.6e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.68	-0.34	3.8e-8	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14238081	chr14:65438743	RAB15	0.52	6.33	0.37	1.16e-9	Parkinson's disease;
KIRP	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.45e-9	Depression;
KIRP	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.5	-0.33	9.37e-8	Life satisfaction;
KIRP	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg21775007	chr8:11205619	TDH	-0.39	-5.18	-0.31	4.57e-7	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg14186256	chr22:23484241	RTDR1	0.52	5.07	0.31	7.99e-7	Serum parathyroid hormone levels;
KIRP	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.64	-5.96	-0.36	8.57e-9	Narcolepsy;
KIRP	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg25233709	chr10:116636983	FAM160B1	0.34	5.07	0.31	7.99e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg06156847	chr2:113672199	IL1F7	-0.43	-6.07	-0.36	4.92e-9	Pulmonary function;
KIRP	cis	rs3789045	0.729	rs12039968	chr1:204490674	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.27	-0.37	1.59e-9	Educational attainment (college completion);
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.4	-0.33	1.55e-7	Life satisfaction;
KIRP	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg23950597	chr19:37808831	NA	-0.68	-5.94	-0.35	9.55e-9	Coronary artery calcification;
KIRP	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg03929089	chr4:120376271	NA	-0.57	-6.65	-0.39	1.84e-10	HDL cholesterol;
KIRP	cis	rs1010254	0.559	rs1592896	chr5:151746085	G/T	cg12297329	chr5:152029980	NA	-0.62	-6.36	-0.38	9.89e-10	Optic nerve measurement (cup area);
KIRP	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg16926213	chr1:1841314	NA	0.33	5.55	0.33	7.3e-8	Body mass index;
KIRP	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26002218	chr14:103986227	CKB	0.29	6.13	0.36	3.5e-9	Body mass index;
KIRP	cis	rs7084402	1.000	rs7910442	chr10:60270260	T/G	cg05938607	chr10:60274200	BICC1	0.42	10.11	0.54	2.53e-20	Refractive error;
KIRP	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg00792783	chr2:198669748	PLCL1	0.46	4.97	0.3	1.26e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs9815354	1.000	rs56207540	chr3:41976627	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.48	1.5e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs13082711	0.954	rs35523848	chr3:27552800	A/C	cg02860705	chr3:27208620	NA	0.58	7.19	0.42	7.67e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg24881330	chr22:46731750	TRMU	0.6	5.95	0.35	8.96e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg07701084	chr6:150067640	NUP43	0.7	9.48	0.52	2.19e-18	Lung cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16331972	chr17:8791471	PIK3R5	0.5	6.35	0.38	1.01e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.51	-6.49	-0.38	4.58e-10	Calcium levels;
KIRP	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.87	-13.84	-0.66	1.33e-32	Prostate cancer;
KIRP	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.44	0.38	6.13e-10	Neuroticism;
KIRP	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg25547332	chr5:131281432	NA	0.47	5.34	0.32	2.15e-7	Life satisfaction;
KIRP	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg02187348	chr16:89574699	SPG7	0.43	5.14	0.31	5.48e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09015484	chr9:96929106	NA	-0.49	-6.13	-0.36	3.54e-9	Neuroticism;
KIRP	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg17366294	chr4:99064904	C4orf37	0.36	4.89	0.3	1.84e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	15.94	0.71	9.22e-40	Electrocardiographic conduction measures;
KIRP	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg05775895	chr3:12838266	CAND2	0.34	5.3	0.32	2.61e-7	QRS complex (12-leadsum);
KIRP	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg00405596	chr8:11794950	NA	-0.48	-6.32	-0.37	1.22e-9	Neuroticism;
KIRP	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.02	0.5	5.33e-17	Exhaled nitric oxide output;
KIRP	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs2131877	0.619	rs6794540	chr3:194867162	C/T	cg21937377	chr3:194868750	C3orf21	0.2	4.89	0.3	1.83e-6	Non-small cell lung cancer;
KIRP	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.04	15.44	0.7	4.5e-38	Primary sclerosing cholangitis;
KIRP	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.11	0.41	1.22e-11	Vitiligo;
KIRP	cis	rs732716	0.819	rs12459919	chr19:4434503	C/T	cg03719555	chr19:4455413	UBXN6	0.49	7.43	0.43	1.83e-12	Mean corpuscular volume;
KIRP	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.85	-11.94	-0.61	3.22e-26	Total body bone mineral density;
KIRP	cis	rs2573652	1.000	rs2727196	chr15:100513529	C/T	cg09918751	chr15:100517450	ADAMTS17	-0.69	-10.31	-0.55	6.12e-21	Height;
KIRP	cis	rs12980942	0.591	rs2304232	chr19:41762525	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.63	5.1	0.31	6.92e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16746770	chr12:15580907	PTPRO	-0.39	-6.3	-0.37	1.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2910162	0.865	rs4921142	chr5:159917215	C/T	cg03306240	chr5:159912455	MIR146A	0.45	6.67	0.39	1.64e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	10.93	0.57	6.29e-23	Platelet count;
KIRP	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.79	10.82	0.57	1.44e-22	Aortic root size;
KIRP	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	1.17	9.19	0.51	1.65e-17	Cannabis dependence symptom count;
KIRP	cis	rs1829883	0.583	rs115209822	chr5:98915203	G/A	cg08333243	chr5:99726346	NA	0.39	4.93	0.3	1.48e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.42	5.24	0.32	3.53e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg19923238	chr8:142232952	SLC45A4	0.42	5.04	0.31	8.87e-7	Immature fraction of reticulocytes;
KIRP	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-6.16	-0.37	2.99e-9	Retinal vascular caliber;
KIRP	cis	rs193541	0.621	rs898391	chr5:122082166	T/C	cg19412675	chr5:122181750	SNX24	0.51	5.42	0.33	1.4e-7	Glucose homeostasis traits;
KIRP	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg10755058	chr3:40428713	ENTPD3	0.36	5.2	0.31	4.13e-7	Renal cell carcinoma;
KIRP	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03762994	chr17:6899332	ALOX12	-0.28	-4.88	-0.3	1.95e-6	Tonsillectomy;
KIRP	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs400736	0.671	rs2472862	chr1:7991203	G/A	cg25007680	chr1:8021821	PARK7	-0.51	-7.02	-0.41	2.11e-11	Response to antidepressants and depression;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16254375	chr4:93105176	NA	-0.41	-6.41	-0.38	7.54e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10761482	0.861	rs10740027	chr10:62159661	T/C	cg01186212	chr10:62110162	ANK3	-0.29	-4.87	-0.3	2.04e-6	Schizophrenia;
KIRP	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg23102388	chr7:1867652	MAD1L1	-0.46	-6.18	-0.37	2.7e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.63	-6.77	-0.4	9.14e-11	Gut microbiome composition (summer);
KIRP	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg11508081	chr17:41442227	NA	0.36	4.89	0.3	1.81e-6	Menopause (age at onset);
KIRP	cis	rs2591576	0.718	rs7733193	chr5:165435775	T/C	cg13976338	chr5:165423657	NA	-0.71	-10.38	-0.55	3.7e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs7129556	0.863	rs11237225	chr11:77283561	A/T	cg12586386	chr11:77299805	AQP11	0.47	5.67	0.34	4.07e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs71597109	0.681	rs17266357	chr4:102721809	T/C	cg14855874	chr4:102712397	BANK1	0.4	5.33	0.32	2.27e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	7.36	0.42	2.75e-12	Height;
KIRP	cis	rs10858047	0.883	rs12040830	chr1:115108738	T/C	cg12756093	chr1:115239321	AMPD1	0.64	6.15	0.37	3.05e-9	Autism;
KIRP	cis	rs9810890	1.000	rs73198844	chr3:128503044	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11141711	chr14:99947712	SETD3;CCNK	0.48	6.29	0.37	1.45e-9	Survival in pancreatic cancer;
KIRP	cis	rs300890	0.544	rs17686361	chr4:144207686	G/A	cg19876092	chr4:144208277	NA	0.41	6.48	0.38	5.05e-10	Nasopharyngeal carcinoma;
KIRP	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg23752985	chr2:85803571	VAMP8	0.56	8.12	0.46	2.27e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs4073416	0.542	rs8011224	chr14:65969670	T/A	cg03016385	chr14:66212404	NA	-0.53	-6.62	-0.39	2.26e-10	N-glycan levels;
KIRP	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.25	4.87	0.3	1.98e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg01304814	chr3:48885189	PRKAR2A	0.5	5.28	0.32	2.85e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6088813	0.922	rs6088800	chr20:33934437	T/A	cg14752227	chr20:34000481	UQCC	-0.5	-6.63	-0.39	2.12e-10	Height;
KIRP	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.69	8.43	0.47	2.9e-15	Neutrophil percentage of white cells;
KIRP	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.48	0.52	2.21e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6732160	0.596	rs7605923	chr2:73402333	T/C	cg01422370	chr2:73384389	NA	0.4	5.33	0.32	2.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg00614314	chr15:82944287	LOC80154	0.56	6.43	0.38	6.42e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-1.0	-12.76	-0.63	6.06e-29	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg11906718	chr8:101322791	RNF19A	0.54	7.26	0.42	5.17e-12	Atrioventricular conduction;
KIRP	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg07775547	chr4:1625484	NA	-0.43	-5.28	-0.32	2.87e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs6142102	0.625	rs6142068	chr20:32557172	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-4.95	-0.3	1.4e-6	Skin pigmentation;
KIRP	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	cg21523751	chr1:182988639	NA	0.42	6.67	0.39	1.69e-10	Colorectal cancer;
KIRP	trans	rs4742903	0.509	rs1889286	chr9:106962928	A/G	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.1	-0.36	4.04e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27085584	chr5:61699286	DIMT1L	0.45	6.79	0.4	8.18e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.81	-11.34	-0.59	2.98e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11997175	0.543	rs115681590	chr8:33761157	G/T	cg04338863	chr8:33670619	NA	0.43	5.35	0.32	1.97e-7	Body mass index;
KIRP	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.08	-0.41	1.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg23594656	chr7:65796392	TPST1	-0.49	-7.42	-0.43	1.9e-12	Aortic root size;
KIRP	cis	rs494562	0.892	rs9344518	chr6:86125144	T/A	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg19752551	chr11:57585705	CTNND1	-0.81	-13.01	-0.64	8.8e-30	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08065241	chr3:56502265	ERC2	0.53	6.48	0.38	5.02e-10	Parkinson's disease;
KIRP	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.45	5.73	0.34	2.98e-8	Iron status biomarkers;
KIRP	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg08975724	chr8:8085496	FLJ10661	0.7	9.12	0.5	2.7e-17	Mood instability;
KIRP	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg02038168	chr22:39784481	NA	-0.43	-4.99	-0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6466055	0.553	rs10228174	chr7:104691505	C/T	cg04380332	chr7:105027541	SRPK2	-0.4	-5.48	-0.33	1.03e-7	Schizophrenia;
KIRP	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-6.85	-0.4	6.04e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs6102059	0.748	rs6129648	chr20:39231118	A/G	cg22477343	chr20:39312069	NA	0.5	6.6	0.39	2.54e-10	LDL cholesterol;
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.56	-0.33	7.11e-8	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg17845761	chr1:175162550	KIAA0040	-0.34	-6.5	-0.38	4.51e-10	Alcohol dependence;
KIRP	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.8	9.83	0.53	1.86e-19	Corneal astigmatism;
KIRP	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg18132916	chr6:79620363	NA	-0.41	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.68	-0.39	1.61e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg11764359	chr7:65958608	NA	0.43	5.07	0.31	7.91e-7	Calcium levels;
KIRP	trans	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.76	7.15	0.41	1.01e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.75	9.97	0.54	6.96e-20	Systemic lupus erythematosus;
KIRP	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.64e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.6	8.81	0.49	2.27e-16	Mean corpuscular volume;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23704689	chr12:110906840	GPN3;C12orf24	-0.49	-6.25	-0.37	1.84e-9	Myopia;
KIRP	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23854747	chr20:62612705	PRPF6	-0.49	-6.21	-0.37	2.27e-9	Interleukin-4 levels;
KIRP	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-7.22	-0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.81	8.67	0.48	5.74e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.18	21.23	0.8	1.54e-57	Cognitive function;
KIRP	cis	rs6662572	0.703	rs7556472	chr1:46339811	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.27	5.48	0.33	1.05e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg25356066	chr3:128598488	ACAD9	0.5	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.02	-0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.89	0.49	1.38e-16	Motion sickness;
KIRP	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.64	-6.42	-0.38	7.1e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs17123764	0.710	rs57191490	chr12:50064889	G/A	cg20471783	chr12:50157085	TMBIM6	0.39	5.39	0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.28	-5.42	-0.33	1.39e-7	Diastolic blood pressure;
KIRP	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg26876637	chr1:152193138	HRNR	-0.78	-9.79	-0.53	2.54e-19	Atopic dermatitis;
KIRP	cis	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg08773314	chr2:239334832	ASB1	-0.54	-5.48	-0.33	1.07e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.55	-0.33	7.49e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4786125	0.665	rs6500857	chr16:6903364	C/T	cg03623568	chr16:6915990	A2BP1	-0.44	-5.32	-0.32	2.3e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs4363385	0.531	rs11205188	chr1:153053645	A/T	cg13444842	chr1:152974279	SPRR3	-0.44	-6.16	-0.37	2.88e-9	Inflammatory skin disease;
KIRP	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.6	6.74	0.4	1.09e-10	Subjective well-being;
KIRP	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	7.99	0.45	5.14e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.3	15.7	0.71	5.97e-39	Uric acid levels;
KIRP	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.11	-0.36	3.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4356932	0.967	rs6837830	chr4:76980179	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.87	12.27	0.62	2.55e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.5	6.78	0.4	9e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg22800045	chr5:56110881	MAP3K1	0.67	7.31	0.42	3.8e-12	Initial pursuit acceleration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14862791	chr5:34839623	TTC23L	0.5	6.14	0.36	3.2e-9	Smoking initiation;
KIRP	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg02297831	chr4:17616191	MED28	-0.6	-7.53	-0.43	9.5e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.13e-15	Menarche (age at onset);
KIRP	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-15.44	-0.7	4.46e-38	Height;
KIRP	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg01493522	chr13:37497338	NA	-0.45	-5.51	-0.33	9.04e-8	Coronary artery disease;
KIRP	cis	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg07460842	chr6:66804631	NA	-0.48	-5.83	-0.35	1.76e-8	Blood trace element (Cu levels);
KIRP	cis	rs1635	0.655	rs59598126	chr6:28303600	A/C	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.28	0.32	2.83e-7	Schizophrenia;
KIRP	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	trans	rs1859156	0.812	rs3775009	chr4:95821404	A/G	cg24204951	chr2:239172084	PER2	0.28	6.58	0.39	2.74e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.98	-0.41	2.76e-11	Blood pressure;
KIRP	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.92	10.48	0.56	1.74e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.5	-6.24	-0.37	1.94e-9	Post bronchodilator FEV1;
KIRP	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.95	16.41	0.72	2.24e-41	Metabolic syndrome;
KIRP	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	3e-14	Migraine;Coronary artery disease;
KIRP	cis	rs3774830	0.714	rs7688517	chr4:5466392	A/C	cg26943120	chr4:5472116	STK32B	0.25	6.18	0.37	2.65e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs829661	0.652	rs56322420	chr2:30824543	T/A	cg10949345	chr2:30726833	LCLAT1	1.1	13.65	0.66	5.65e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs1408799	0.550	rs7025812	chr9:12721554	T/C	cg05274944	chr9:12693694	TYRP1	0.35	5.17	0.31	4.8e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.82	-6.81	-0.4	7.35e-11	Obesity-related traits;
KIRP	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg06453172	chr10:134556979	INPP5A	-0.53	-6.36	-0.38	9.73e-10	Migraine;
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg01763666	chr17:80159506	CCDC57	0.37	5.13	0.31	5.75e-7	Life satisfaction;
KIRP	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.53	7.07	0.41	1.63e-11	Colorectal cancer;
KIRP	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-8.36	-0.47	4.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs4141404	0.923	rs2413035	chr22:31600460	A/G	cg22777020	chr22:31556080	RNF185	-0.51	-5.45	-0.33	1.21e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-6.87	-0.4	5.31e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1971762	1.000	rs916134	chr12:54069803	A/G	cg16917193	chr12:54089295	NA	0.66	8.89	0.49	1.3e-16	Height;
KIRP	cis	rs3109167	0.596	rs2255715	chr7:83115464	G/C	cg14519356	chr7:83097669	SEMA3E	0.38	5.23	0.32	3.67e-7	Blood protein levels;
KIRP	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.45	0.38	5.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg00319359	chr11:70116639	PPFIA1	0.82	7.63	0.44	5.02e-13	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.73	0.34	2.9e-8	Lung cancer;
KIRP	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg09911534	chr15:67153556	NA	-0.5	-5.09	-0.31	7.19e-7	Lung cancer (smoking interaction);
KIRP	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.13	15.15	0.69	4.51e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1538970	1.000	rs2492840	chr1:45849792	C/A	cg05343316	chr1:45956843	TESK2	0.63	7.3	0.42	3.86e-12	Platelet count;
KIRP	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.71	-10.15	-0.54	1.84e-20	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg05754148	chr16:3507555	NAT15	0.5	4.94	0.3	1.43e-6	Tuberculosis;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg23736307	chr8:27182930	PTK2B	0.52	6.66	0.39	1.76e-10	Neuroticism;
KIRP	cis	rs838147	0.844	rs8102032	chr19:49249795	C/T	cg08619932	chr19:49200058	FUT2	-0.34	-5.27	-0.32	2.97e-7	Dietary macronutrient intake;
KIRP	cis	rs7084402	0.934	rs1658426	chr10:60331542	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs2000999	0.524	rs12933482	chr16:72189604	A/G	cg04254540	chr16:71951199	KIAA0174	-0.83	-5.54	-0.33	7.7e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg10756647	chr7:56101905	PSPH	0.98	6.96	0.41	3.1e-11	Gout;
KIRP	cis	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg08501292	chr6:25962987	TRIM38	1.1	6.4	0.38	7.74e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.48	6.36	0.38	9.71e-10	Height;
KIRP	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18252515	chr7:66147081	NA	0.45	5.56	0.33	6.89e-8	Aortic root size;
KIRP	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.23	0.61	3.54e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-5.47	-0.33	1.12e-7	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.75	9.59	0.52	1.05e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2274471	0.591	rs7034539	chr9:5081585	C/T	cg03390472	chr9:5043263	JAK2	0.46	5.04	0.31	9.22e-7	Crohn's disease;
KIRP	cis	rs259842	0.858	rs259844	chr2:180735788	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.84	-0.35	1.66e-8	Blood protein levels;
KIRP	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.03	-0.31	9.58e-7	Pulmonary function;
KIRP	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.03	-0.36	5.98e-9	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01468426	chr8:41896277	MYST3	-0.46	-7.42	-0.43	1.88e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg10381502	chr11:71823885	C11orf51	-1.15	-8.05	-0.46	3.47e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.79	-11.78	-0.6	1.06e-25	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.88	0.53	1.35e-19	Lung cancer;
KIRP	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg08975724	chr8:8085496	FLJ10661	0.63	8.41	0.47	3.3e-15	Retinal vascular caliber;
KIRP	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg23894439	chr1:183413866	NA	-0.41	-5.34	-0.32	2.16e-7	Systemic lupus erythematosus;
KIRP	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg15247329	chr7:2764246	NA	-0.35	-4.9	-0.3	1.71e-6	Height;
KIRP	cis	rs62413470	1.000	rs17218309	chr6:55935196	G/A	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs4812048	0.649	rs6100319	chr20:57626568	A/C	cg14073986	chr20:57617431	SLMO2	0.65	5.78	0.35	2.22e-8	Mean platelet volume;
KIRP	cis	rs2932538	0.883	rs6537740	chr1:113080084	T/G	cg22162597	chr1:113214053	CAPZA1	0.94	12.2	0.61	4.36e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.88	9.88	0.53	1.32e-19	Corneal astigmatism;
KIRP	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.97	0.3	1.26e-6	Lung cancer;
KIRP	cis	rs1190552	0.639	rs3742446	chr14:102975572	C/T	cg18135206	chr14:102964638	TECPR2	0.46	5.0	0.3	1.09e-6	Blood protein levels;
KIRP	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg14673194	chr17:80132900	CCDC57	-0.77	-8.68	-0.48	5.51e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.72	0.34	3.1e-8	Putamen volume;
KIRP	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg07274523	chr3:49395745	GPX1	0.71	8.63	0.48	7.65e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27659841	chr2:192109995	MYO1B	-0.44	-6.06	-0.36	5.15e-9	Metabolic traits;
KIRP	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	1.06	15.24	0.7	2.16e-37	Menopause (age at onset);
KIRP	trans	rs972578	0.791	rs5751392	chr22:43261694	T/G	cg15321293	chr3:36422198	STAC	-0.48	-6.23	-0.37	2.01e-9	Mean platelet volume;
KIRP	cis	rs1050631	0.564	rs589213	chr18:33743610	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.62	0.34	5.14e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs4700695	1.000	rs153319	chr5:65419423	C/T	cg21114390	chr5:65439923	SFRS12	-0.5	-5.57	-0.33	6.72e-8	Facial morphology (factor 19);
KIRP	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg06873352	chr17:61820015	STRADA	-0.5	-6.08	-0.36	4.44e-9	Prudent dietary pattern;
KIRP	cis	rs4711350	0.734	rs7739273	chr6:33758065	G/A	cg25922239	chr6:33757077	LEMD2	0.58	6.17	0.37	2.87e-9	Schizophrenia;
KIRP	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.47	-0.52	2.49e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.2e-11	Morning vs. evening chronotype;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.76	10.49	0.56	1.6e-21	Menarche (age at onset);
KIRP	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.9	-14.88	-0.69	3.89e-36	Mortality in heart failure;
KIRP	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg13010199	chr12:38710504	ALG10B	0.63	7.76	0.44	2.27e-13	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	7.34	0.42	3.04e-12	Bipolar disorder;
KIRP	cis	rs365132	0.517	rs7706790	chr5:176359136	C/T	cg06783121	chr5:176314628	HK3	0.51	5.85	0.35	1.57e-8	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg07810366	chr2:100720526	AFF3	-0.4	-7.29	-0.42	4.09e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7523273	0.586	rs7518047	chr1:207899332	T/C	cg22525895	chr1:207977042	MIR29B2	-0.46	-5.9	-0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg00405596	chr8:11794950	NA	0.54	6.91	0.4	4.2e-11	Neuroticism;
KIRP	cis	rs7709377	0.597	rs13159102	chr5:115519105	C/T	cg23108291	chr5:115420582	COMMD10	0.4	4.85	0.3	2.15e-6	Metabolite levels  (X-11787);
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.56	-0.43	7.81e-13	Life satisfaction;
KIRP	cis	rs7113874	0.802	rs10769936	chr11:8654528	C/T	cg08015107	chr11:8618950	NA	-0.44	-5.95	-0.35	9.12e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9426935	0.580	rs2841102	chr1:154017501	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.1	-0.31	6.88e-7	Lentiform nucleus volume;
KIRP	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.95	12.76	0.63	6.01e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg25753631	chr6:25732923	NA	-0.28	-5.3	-0.32	2.61e-7	Iron status biomarkers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17677112	chr7:77428730	PHTF2;TMEM60	0.6	7.06	0.41	1.68e-11	Smoking initiation;
KIRP	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg18190219	chr22:46762943	CELSR1	-0.53	-5.17	-0.31	4.81e-7	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.1	-0.54	2.73e-20	Colorectal cancer;
KIRP	cis	rs10465746	0.935	rs6687372	chr1:84447634	C/T	cg10977910	chr1:84465055	TTLL7	0.48	5.84	0.35	1.67e-8	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg15181151	chr6:150070149	PCMT1	0.32	5.4	0.33	1.56e-7	Lung cancer;
KIRP	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.25	7.11	0.41	1.25e-11	Type 2 diabetes;
KIRP	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg04455712	chr21:45112962	RRP1B	-0.39	-5.07	-0.31	7.7300000000000005e-07	Mean corpuscular volume;
KIRP	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg25319279	chr11:5960081	NA	-0.57	-5.78	-0.35	2.25e-8	DNA methylation (variation);
KIRP	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.6	-6.68	-0.39	1.61e-10	Menarche (age at onset);
KIRP	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.63	7.24	0.42	5.62e-12	Caffeine consumption;
KIRP	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	6.24	0.37	1.89e-9	Eotaxin levels;
KIRP	cis	rs4711336	1.000	rs4711336	chr6:33659046	A/G	cg14003231	chr6:33640908	ITPR3	-0.27	-4.96	-0.3	1.31e-6	Height;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.56	6.7	0.39	1.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4791641	0.792	rs12051691	chr17:8149787	C/T	cg06726167	chr17:8076949	TMEM107	0.55	6.81	0.4	7.43e-11	LDL cholesterol levels;Hematocrit;Hemoglobin concentration;Red blood cell count;LDL cholesterol;
KIRP	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.21	-0.42	6.8e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.53	6.16	0.37	3.02e-9	Bone mineral density (spine);
KIRP	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg00291366	chr1:12616550	NA	0.45	6.44	0.38	6.08e-10	Optic cup area;
KIRP	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg09626299	chr10:82213104	TSPAN14	-0.33	-5.04	-0.31	8.86e-7	Post bronchodilator FEV1;
KIRP	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs8018808	0.935	rs958463	chr14:77886721	G/T	cg18872420	chr14:78023429	SPTLC2	0.33	4.91	0.3	1.63e-6	Myeloid white cell count;
KIRP	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.67	9.99	0.54	5.89e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg17654217	chr7:100282651	GIGYF1	0.52	5.05	0.31	8.81e-7	Other erythrocyte phenotypes;
KIRP	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg02461776	chr11:598696	PHRF1	0.6	6.58	0.39	2.82e-10	Systemic lupus erythematosus;
KIRP	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg11663144	chr21:46675770	NA	-0.58	-8.37	-0.47	4.35e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	0.76	7.8	0.45	1.74e-13	Type 2 diabetes nephropathy;
KIRP	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.51	7.44	0.43	1.66e-12	Bipolar disorder;
KIRP	cis	rs6005807	0.719	rs12165715	chr22:29005595	T/C	cg12565055	chr22:29076175	TTC28	0.58	4.99	0.3	1.14e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg16141378	chr3:129829833	LOC729375	0.59	7.4	0.43	2.17e-12	Triglycerides;
KIRP	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.79	-10.35	-0.55	4.43e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg04731861	chr2:219085781	ARPC2	-0.21	-5.01	-0.3	1.04e-6	Colorectal cancer;
KIRP	cis	rs7129556	0.737	rs56218634	chr11:77464834	A/G	cg12586386	chr11:77299805	AQP11	0.44	5.2	0.31	4.19e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs2387326	0.767	rs11016086	chr10:129939145	C/T	cg16087940	chr10:129947807	NA	-0.48	-6.06	-0.36	5.18e-9	Select biomarker traits;
KIRP	cis	rs8077577	0.895	rs62073602	chr17:18057907	A/G	cg18869244	chr17:18121946	NA	0.43	5.05	0.31	8.55e-7	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.57	-7.14	-0.41	1.08e-11	Coronary artery disease;
KIRP	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.81	-12.39	-0.62	9.83e-28	Breast cancer;
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.56	-7.72	-0.44	2.99e-13	Electroencephalogram traits;
KIRP	trans	rs12659622	0.764	rs891195	chr5:15605947	C/A	cg09887955	chr1:202129854	PTPN7	0.52	6.09	0.36	4.42e-9	Obesity-related traits;
KIRP	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg16434002	chr17:42200994	HDAC5	0.44	5.46	0.33	1.17e-7	Total body bone mineral density;
KIRP	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.81	8.38	0.47	4.01e-15	Triglycerides;
KIRP	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg23791538	chr6:167370224	RNASET2	0.44	5.59	0.34	6.04e-8	Crohn's disease;
KIRP	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01256987	chr12:42539512	GXYLT1	-0.44	-5.81	-0.35	1.94e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.69	8.74	0.49	3.6e-16	Resting heart rate;
KIRP	cis	rs4908768	1.000	rs12134896	chr1:8656227	G/A	cg03610117	chr1:8450231	RERE	-0.49	-4.97	-0.3	1.27e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	cg21523751	chr1:182988639	NA	0.44	6.06	0.36	5.14e-9	Colorectal cancer;
KIRP	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.58	8.31	0.47	6.43e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6500395	0.962	rs1872652	chr16:48642928	C/A	cg04672837	chr16:48644449	N4BP1	0.49	6.68	0.39	1.6e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg25281562	chr12:121454272	C12orf43	0.51	5.76	0.34	2.49e-8	N-glycan levels;
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.51	-0.33	8.9e-8	Lung cancer;
KIRP	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.64	-7.15	-0.42	9.6e-12	Blood trace element (Cu levels);
KIRP	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.28	-0.37	1.55e-9	Coronary artery disease;
KIRP	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.4	-5.61	-0.34	5.43e-8	Renal function-related traits (BUN);
KIRP	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.85	-0.4	5.9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs894344	0.812	rs894360	chr8:135601194	T/C	cg09855544	chr8:135498122	ZFAT	0.42	5.47	0.33	1.1e-7	Systolic blood pressure;
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.38	0.32	1.74e-7	Lung cancer;
KIRP	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.55	7.25	0.42	5.34e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg06636001	chr8:8085503	FLJ10661	0.74	10.07	0.54	3.39e-20	Joint mobility (Beighton score);
KIRP	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.27	-0.42	4.89e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9788682	0.747	rs4887053	chr15:78712699	A/C	cg24631222	chr15:78858424	CHRNA5	-0.94	-10.5	-0.56	1.5e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.18	-0.31	4.68e-7	Ulcerative colitis;
KIRP	cis	rs9308731	0.966	rs3827536	chr2:111920741	G/T	cg23466623	chr2:111982296	NA	-0.45	-5.55	-0.33	7.43e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.57	-8.66	-0.48	6.4e-16	Obesity-related traits;
KIRP	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg18132916	chr6:79620363	NA	-0.4	-5.49	-0.33	1.01e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4409675	0.871	rs10902678	chr1:28268573	C/T	cg23691781	chr1:28212827	C1orf38	-0.34	-6.56	-0.39	3.07e-10	Corneal astigmatism;
KIRP	cis	rs2274273	0.588	rs9919923	chr14:55813899	A/G	cg04306507	chr14:55594613	LGALS3	0.39	5.32	0.32	2.35e-7	Protein biomarker;
KIRP	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg16584676	chr17:46985605	UBE2Z	0.46	5.69	0.34	3.61e-8	Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg21546286	chr11:48923668	NA	0.4	4.87	0.3	2e-6	HDL cholesterol;
KIRP	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	7.75	0.44	2.44e-13	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.62	4.91	0.3	1.65e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg19530576	chr14:99947768	SETD3;CCNK	0.55	6.12	0.36	3.64e-9	Plasma plasminogen activator levels;
KIRP	cis	rs2033732	0.613	rs10101678	chr8:85060063	G/T	cg05716166	chr8:85095498	RALYL	0.5	5.63	0.34	4.82e-8	Body mass index;
KIRP	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg14664628	chr15:75095509	CSK	-0.49	-5.88	-0.35	1.34e-8	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2708977	0.867	rs12717782	chr2:97254116	G/A	cg01950434	chr2:97203154	ARID5A	0.54	6.29	0.37	1.47e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	9.65	0.52	6.63e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg23752985	chr2:85803571	VAMP8	0.6	9.13	0.5	2.61e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.95	-0.3	1.4e-6	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.1	0.31	6.74e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg11972305	chr2:233791962	NGEF	-0.44	-5.25	-0.32	3.37e-7	Schizophrenia;
KIRP	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	10.02	0.54	4.98e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg00079375	chr15:79125835	NA	0.37	5.39	0.33	1.64e-7	Coronary artery disease;
KIRP	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.73	6.01	0.36	6.8e-9	Diabetic retinopathy;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11436430	chr6:41514104	FOXP4	-0.63	-6.99	-0.41	2.56e-11	Menopause (age at onset);
KIRP	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.27	-0.47	8.4e-15	Mean corpuscular volume;
KIRP	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.65	-8.49	-0.48	2.01e-15	Metabolic syndrome;
KIRP	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg08885076	chr2:99613938	TSGA10	-0.42	-6.22	-0.37	2.14e-9	Bipolar disorder;
KIRP	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.63	9.25	0.51	1.16e-17	Vitiligo;
KIRP	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg06212747	chr3:49208901	KLHDC8B	0.72	10.02	0.54	4.71e-20	Parkinson's disease;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.04	0.36	5.65e-9	Platelet count;
KIRP	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.68	-7.51	-0.43	1.1e-12	Bronchopulmonary dysplasia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22024508	chr19:16771032	TMEM38A;C19orf42	-0.49	-6.25	-0.37	1.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	9.47	0.52	2.44e-18	Renal function-related traits (BUN);
KIRP	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.47	6.88	0.4	4.97e-11	Coronary artery disease;
KIRP	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.9	-0.3	1.72e-6	Obesity-related traits;
KIRP	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg21361702	chr7:150065534	REPIN1	0.55	5.92	0.35	1.1e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14992154	chr4:20701870	PACRGL	0.42	6.2	0.37	2.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6137287	0.722	rs1007226	chr20:21103987	A/G	cg04219410	chr20:21106687	PLK1S1	0.4	4.95	0.3	1.36e-6	Height;
KIRP	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.96	-0.35	8.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.29	0.42	4.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg12685995	chr10:126849062	CTBP2	0.49	6.16	0.37	2.92e-9	Colorectal cancer;
KIRP	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.73	-0.39	1.17e-10	Aortic root size;
KIRP	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs1816752	0.811	rs9507337	chr13:24984945	A/T	cg22771759	chr13:24902376	NA	0.38	4.87	0.3	2.02e-6	Obesity-related traits;
KIRP	cis	rs35123781	0.502	rs195674	chr5:138927219	G/A	cg12205435	chr5:138714322	SLC23A1	-0.39	-5.23	-0.32	3.54e-7	Schizophrenia;
KIRP	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.62	8.59	0.48	1e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.96	-9.8	-0.53	2.27e-19	Systemic lupus erythematosus;
KIRP	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg19731401	chr7:2775893	GNA12	-0.7	-6.83	-0.4	6.66e-11	Childhood ear infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06660842	chr3:93733689	ARL13B;STX19	-0.46	-6.81	-0.4	7.29e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg11833968	chr6:79620685	NA	0.46	7.03	0.41	2.09e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg07741184	chr6:167504864	NA	-0.21	-5.46	-0.33	1.18e-7	Graves' disease;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-8.45	-0.47	2.51e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg08885076	chr2:99613938	TSGA10	0.52	8.9	0.49	1.26e-16	Chronic sinus infection;
KIRP	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.74	-9.66	-0.52	6.3e-19	Coronary artery disease;
KIRP	cis	rs2412208	0.796	rs6693136	chr1:7066567	G/A	cg20434152	chr1:7120926	CAMTA1	-0.39	-4.84	-0.3	2.26e-6	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs7178572	0.657	rs4886873	chr15:77829176	A/G	cg12131826	chr15:77904385	NA	-0.46	-4.89	-0.3	1.82e-6	Type 2 diabetes;
KIRP	cis	rs17407555	0.657	rs12505144	chr4:10270919	G/C	cg11266682	chr4:10021025	SLC2A9	0.35	5.28	0.32	2.79e-7	Schizophrenia (age at onset);
KIRP	cis	rs7116495	0.786	rs10736785	chr11:71718912	C/A	cg11196788	chr11:71737549	NUMA1	0.56	5.05	0.31	8.46e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	1.02	10.66	0.56	4.48e-22	Exhaled nitric oxide output;
KIRP	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.0	0.3	1.08e-6	Educational attainment;
KIRP	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	0.73	6.77	0.4	9.4e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.5	5.22	0.32	3.88e-7	Subjective well-being;
KIRP	cis	rs7712401	0.601	rs431878	chr5:122261791	G/T	cg19412675	chr5:122181750	SNX24	-0.48	-5.24	-0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.37	-7.52	-0.43	1.02e-12	Arsenic metabolism;
KIRP	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg20295408	chr7:1910781	MAD1L1	0.47	5.55	0.33	7.41e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9928842	0.771	rs2870471	chr16:75274282	A/G	cg09066997	chr16:75300724	BCAR1	-0.53	-5.02	-0.3	1e-6	Alcoholic chronic pancreatitis;
KIRP	cis	rs75064307	0.734	rs13079759	chr3:108088078	G/C	cg03329597	chr3:108125523	MYH15	-0.51	-5.02	-0.3	9.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.28	-0.32	2.82e-7	Pulmonary function;
KIRP	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg05342945	chr12:48394962	COL2A1	-0.46	-4.99	-0.3	1.16e-6	Lung cancer;
KIRP	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs698833	0.892	rs1067363	chr2:44658401	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	5.17	0.31	4.94e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg23625390	chr15:77176239	SCAPER	0.48	6.42	0.38	7.01e-10	Blood metabolite levels;
KIRP	cis	rs8084125	0.832	rs884472	chr18:74946087	A/G	cg15443732	chr18:74961078	GALR1	0.54	5.39	0.32	1.68e-7	Obesity-related traits;
KIRP	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg08131204	chr22:41487073	MIR1281	0.44	5.23	0.32	3.57e-7	Neuroticism;
KIRP	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-6.48	-0.38	4.87e-10	Colorectal cancer;
KIRP	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.79	0.66	1.93e-32	Cognitive function;
KIRP	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14598338	chr9:96623480	NA	-0.67	-11.49	-0.59	9.68e-25	DNA methylation (variation);
KIRP	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs6499766	1.000	rs4784549	chr16:55612918	A/T	cg12196692	chr5:41071405	HEATR7B2	-0.41	-6.03	-0.36	5.92e-9	Thyroid hormone levels;
KIRP	cis	rs490234	0.841	rs497531	chr9:128314664	C/T	cg14078157	chr9:128172775	NA	0.4	5.07	0.31	7.87e-7	Mean arterial pressure;
KIRP	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.51	-7.08	-0.41	1.47e-11	Mean corpuscular volume;
KIRP	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.5	-0.38	4.42e-10	Aortic root size;
KIRP	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg26138937	chr11:71823887	C11orf51	1.02	6.8	0.4	8.02e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.63	0.34	4.88e-8	Motion sickness;
KIRP	cis	rs5742915	0.513	rs9479	chr15:74328576	A/G	cg17221444	chr15:74284820	STOML1	-0.43	-5.05	-0.31	8.64e-7	Height;Paget's disease;
KIRP	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	1.07	22.86	0.82	8.78e-63	Parkinson's disease;
KIRP	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.79	-6.42	-0.38	7.07e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.67	-12.32	-0.62	1.74e-27	White blood cell count (basophil);
KIRP	cis	rs62380364	0.602	rs589544	chr5:88064462	T/C	cg22951263	chr5:87985283	NA	-0.45	-6.26	-0.37	1.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12580194	0.556	rs7955088	chr12:55732963	G/T	cg19537932	chr12:55886519	OR6C68	-0.48	-6.4	-0.38	7.95e-10	Cancer;
KIRP	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.45	0.43	1.62e-12	Aortic root size;
KIRP	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg16524733	chr11:117070046	TAGLN	0.39	5.0	0.3	1.07e-6	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.73	-9.78	-0.53	2.72e-19	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11608355	0.521	rs7972346	chr12:109808771	C/G	cg19025524	chr12:109796872	NA	0.49	6.87	0.4	5.2e-11	Neuroticism;
KIRP	cis	rs6142102	0.625	rs6142067	chr20:32556572	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	5.62	0.34	5.2e-8	Skin pigmentation;
KIRP	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	12.13	0.61	7.7e-27	Smoking behavior;
KIRP	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg23100626	chr2:96804247	ASTL	0.44	5.61	0.34	5.41e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.95	0.54	7.98e-20	Lung cancer;
KIRP	cis	rs6732160	0.845	rs6752507	chr2:73385158	C/G	cg01422370	chr2:73384389	NA	0.44	5.94	0.35	9.71e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.73	6.45	0.38	5.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.5	6.81	0.4	7.6e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs7015630	0.657	rs12155807	chr8:90847712	T/C	cg18493113	chr8:90847772	NA	-0.53	-5.93	-0.35	1.02e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9905704	0.633	rs2680697	chr17:56478711	T/A	cg12560992	chr17:57184187	TRIM37	-0.57	-5.45	-0.33	1.22e-7	Testicular germ cell tumor;
KIRP	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2273669	0.748	rs114830980	chr6:109297857	A/T	cg05315195	chr6:109294784	ARMC2	-0.49	-5.59	-0.34	6.1e-8	Prostate cancer;
KIRP	cis	rs96067	0.528	rs274131	chr1:36582925	C/T	cg27506609	chr1:36549197	TEKT2	-0.89	-7.33	-0.42	3.32e-12	Corneal structure;
KIRP	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg12435725	chr3:58293450	RPP14	-0.47	-5.07	-0.31	7.85e-7	Cholesterol, total;
KIRP	cis	rs867371	0.929	rs7176075	chr15:82471339	C/G	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.35	-0.51	5.68e-18	Personality dimensions;
KIRP	cis	rs7116495	1.000	rs3814721	chr11:71709272	C/T	cg26138937	chr11:71823887	C11orf51	-0.63	-5.25	-0.32	3.31e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg02709834	chr1:75198841	CRYZ;TYW3	0.4	4.86	0.3	2.05e-6	Resistin levels;
KIRP	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.68	-0.48	5.69e-16	Neuroticism;
KIRP	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.57	-5.91	-0.35	1.16e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs80130819	0.688	rs10783233	chr12:48590899	C/G	cg26205652	chr12:48591994	NA	0.48	5.39	0.33	1.61e-7	Prostate cancer;
KIRP	cis	rs17123764	0.681	rs74086911	chr12:50015942	G/A	cg02054252	chr12:50078554	FMNL3	0.5	5.03	0.31	9.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3736594	0.513	rs62138971	chr2:27840754	G/A	cg27432699	chr2:27873401	GPN1	0.56	6.36	0.38	9.63e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-12.94	-0.64	1.44e-29	Dental caries;
KIRP	cis	rs2625529	0.652	rs2899775	chr15:72268354	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.36	0.38	9.72e-10	Red blood cell count;
KIRP	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.46	-5.89	-0.35	1.24e-8	Osteoporosis;
KIRP	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.7	8.18	0.46	1.55e-14	Breast cancer;
KIRP	cis	rs67385638	1.000	rs10837697	chr11:5281018	G/C	cg12559170	chr11:5275217	HBG2	0.55	8.04	0.46	3.78e-14	Hemoglobin levels;
KIRP	cis	rs6692729	0.814	rs2246221	chr1:227075402	C/T	cg08708961	chr1:227070630	PSEN2	0.38	4.98	0.3	1.2e-6	Electrodermal activity;
KIRP	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-9.2	-0.51	1.58e-17	Morning vs. evening chronotype;
KIRP	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg24807547	chr6:37504484	NA	-0.61	-9.26	-0.51	1.02e-17	Cognitive performance;
KIRP	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10174797	chr19:8464628	RAB11B	0.5	6.22	0.37	2.07e-9	HDL cholesterol;
KIRP	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg02931644	chr1:25747376	RHCE	-0.36	-6.64	-0.39	1.94e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.78	6.54	0.38	3.58e-10	Fat distribution (HIV);
KIRP	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13409248	chr3:40428643	ENTPD3	0.38	5.02	0.3	9.93e-7	Renal cell carcinoma;
KIRP	cis	rs4494114	1.000	rs2147914	chr1:39352271	G/T	cg25970120	chr1:39325951	RRAGC	-0.39	-4.97	-0.3	1.24e-6	Blood protein levels;
KIRP	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg19847866	chr10:1019161	NA	0.5	5.94	0.35	9.44e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs2230307	0.505	rs571579	chr1:100617372	G/A	cg24955406	chr1:100503596	HIAT1	-0.57	-6.15	-0.37	3.1e-9	Carotid intima media thickness;
KIRP	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs732716	0.853	rs72990643	chr19:4454736	C/T	cg21720385	chr19:4455239	UBXN6	0.7	8.71	0.49	4.61e-16	Mean corpuscular volume;
KIRP	cis	rs2278796	0.639	rs6661266	chr1:204971452	C/T	cg04862289	chr1:204966208	NFASC	-0.66	-9.23	-0.51	1.3e-17	Mean platelet volume;
KIRP	cis	rs66530629	0.874	rs6600274	chr1:25162444	T/G	cg22509179	chr1:25234806	RUNX3	-0.39	-5.13	-0.31	6e-7	Plateletcrit;
KIRP	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg23093090	chr10:104574429	C10orf26	0.37	5.91	0.35	1.12e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.6	7.75	0.44	2.45e-13	Colorectal cancer;
KIRP	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.71	9.4	0.51	4.03e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	14.74	0.68	1.12e-35	Smoking behavior;
KIRP	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.57	7.72	0.44	2.83e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.52	7.05	0.41	1.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg02030672	chr11:45687055	CHST1	-0.53	-6.65	-0.39	1.87e-10	Obesity-related traits;
KIRP	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs36715	0.953	rs36700	chr5:127551273	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.7	0.49	4.72e-16	Breast cancer;
KIRP	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23161317	chr6:28129485	ZNF389	0.48	5.77	0.35	2.33e-8	Depression;
KIRP	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.62	-6.89	-0.4	4.53e-11	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	0.84	10.38	0.55	3.53e-21	Prostate cancer;
KIRP	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg13072238	chr3:49761600	GMPPB	-0.59	-5.64	-0.34	4.58e-8	Menarche (age at onset);
KIRP	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.45	6.5	0.38	4.38e-10	Plateletcrit;Platelet count;
KIRP	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg11382394	chr1:2564504	MMEL1	-0.4	-5.03	-0.31	9.32e-7	Ulcerative colitis;
KIRP	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.63	-7.02	-0.41	2.16e-11	Vitiligo;
KIRP	cis	rs7225151	0.614	rs56117162	chr17:5182430	G/A	cg24500398	chr17:5266808	RABEP1	-0.57	-5.76	-0.34	2.47e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7551222	0.749	rs2887429	chr1:204565012	G/T	cg20240347	chr1:204465584	NA	-0.4	-7.76	-0.44	2.24e-13	Schizophrenia;
KIRP	cis	rs6479891	0.630	rs4545434	chr10:64875745	T/C	cg25356468	chr10:64875536	NA	0.45	5.02	0.3	9.88e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.29	-0.37	1.45e-9	Alzheimer's disease (late onset);
KIRP	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.82	-0.35	1.81e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	0.98	12.8	0.63	4.21e-29	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg03315344	chr16:75512273	CHST6	0.65	9.74	0.53	3.69e-19	Dupuytren's disease;
KIRP	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg23594656	chr7:65796392	TPST1	0.51	7.91	0.45	8.88e-14	Aortic root size;
KIRP	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg00204512	chr16:28754710	NA	0.46	6.05	0.36	5.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18299363	chr10:103816089	C10orf76	0.93	6.24	0.37	1.95e-9	P wave terminal force;
KIRP	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg23978390	chr7:1156363	C7orf50	0.56	5.88	0.35	1.3e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs11676676	0.593	rs891421	chr2:109776566	A/G	cg01741688	chr2:109781768	SH3RF3	-0.47	-4.91	-0.3	1.69e-6	Pediatric bone mineral density (spine);
KIRP	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg06671706	chr8:8559999	CLDN23	0.56	6.53	0.38	3.65e-10	Obesity-related traits;
KIRP	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg07777115	chr5:623756	CEP72	-0.6	-6.0	-0.36	7.09e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.53	7.69	0.44	3.62e-13	Pubertal anthropometrics;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg10295955	chr4:187884368	NA	-1.16	-19.42	-0.78	1.43e-51	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00889227	chr1:205173544	DSTYK	-0.39	-5.6	-0.34	5.67e-8	Red blood cell count;
KIRP	cis	rs10739695	0.572	rs1318074	chr9:130380101	A/G	cg13643465	chr9:130375613	STXBP1	0.36	5.06	0.31	8.2e-7	Monocyte percentage of white cells;
KIRP	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg16989719	chr2:238392110	NA	-0.65	-6.24	-0.37	1.92e-9	Prostate cancer;
KIRP	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.74	-9.39	-0.51	4.1e-18	Colorectal cancer;
KIRP	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg26338869	chr17:61819248	STRADA	-0.47	-5.67	-0.34	3.97e-8	Prudent dietary pattern;
KIRP	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.83	0.35	1.73e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg22617819	chr1:44378782	ST3GAL3	0.38	6.22	0.37	2.13e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9473924	0.542	rs2857482	chr6:50790642	C/T	cg14470998	chr6:50812995	TFAP2B	1.02	9.0	0.5	6.45e-17	Body mass index;
KIRP	cis	rs72730918	1.000	rs72730918	chr15:51926808	G/T	cg14296394	chr15:51910925	DMXL2	0.84	7.22	0.42	6.51e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.611	rs2111884	chr2:24289472	A/T	cg06627628	chr2:24431161	ITSN2	-0.56	-4.94	-0.3	1.48e-6	Lymphocyte counts;
KIRP	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.71	9.62	0.52	8.3e-19	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08250273	chr7:116593366	ST7;ST7OT4;ST7OT1	0.48	6.35	0.38	1.05e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.29	-5.14	-0.31	5.62e-7	Monocyte percentage of white cells;
KIRP	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.37	-5.03	-0.31	9.55e-7	Neuroticism;
KIRP	cis	rs7937612	0.965	rs10892570	chr11:120274501	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.99	-0.41	2.52e-11	Intraocular pressure;
KIRP	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg06598631	chr6:88300029	RARS2;ORC3L	-0.4	-4.86	-0.3	2.1e-6	Monocyte percentage of white cells;
KIRP	cis	rs1456297	0.513	rs12905903	chr15:51997737	G/A	cg14296394	chr15:51910925	DMXL2	0.72	9.36	0.51	5.07e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs10929159	0.928	rs12053257	chr2:236920174	C/T	cg20128773	chr2:236923534	AGAP1	0.3	5.18	0.31	4.51e-7	Parkinson's disease;
KIRP	cis	rs6910061	1.000	rs9468436	chr6:11112626	C/G	cg27233058	chr6:11094804	LOC221710	0.57	5.73	0.34	2.91e-8	Diabetic kidney disease;
KIRP	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.25	-0.32	3.35e-7	Inflammatory bowel disease;
KIRP	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.88	-14.57	-0.68	4.28e-35	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg24315340	chr6:146058215	EPM2A	0.42	5.21	0.32	4.04e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	1.000	rs9327608	chr5:130650134	G/A	cg25547332	chr5:131281432	NA	0.48	5.36	0.32	1.94e-7	Life satisfaction;
KIRP	cis	rs7215564	0.908	rs34547024	chr17:78661373	C/G	cg06153925	chr17:78755379	RPTOR	0.34	5.42	0.33	1.42e-7	Myopia (pathological);
KIRP	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	5.27	0.32	2.92e-7	Personality dimensions;
KIRP	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	cg12689670	chr1:183009347	LAMC1	-0.42	-6.22	-0.37	2.17e-9	Colorectal cancer;
KIRP	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.41	6.21	0.37	2.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg10556349	chr10:835070	NA	-0.42	-5.56	-0.33	6.88e-8	Survival in rectal cancer;
KIRP	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg08738300	chr3:44038990	NA	0.68	9.32	0.51	7.15e-18	Coronary artery disease;
KIRP	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs806215	1.000	rs327512	chr7:127257251	G/A	cg25922125	chr7:127225783	GCC1	0.44	4.98	0.3	1.2e-6	Type 2 diabetes;
KIRP	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.44	5.81	0.35	1.9e-8	Height;
KIRP	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.92	-0.9	4.05e-92	Myeloid white cell count;
KIRP	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.71	9.04	0.5	4.91e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	0.94	17.32	0.74	1.79e-44	Dental caries;
KIRP	cis	rs1978968	0.956	rs1110661	chr22:18444734	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-7.2	-0.42	7.08e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.87	13.36	0.65	5.42e-31	Testicular germ cell tumor;
KIRP	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg13047869	chr3:10149882	C3orf24	0.54	5.24	0.32	3.48e-7	Alzheimer's disease;
KIRP	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg06092702	chr1:163392909	NA	0.32	5.02	0.3	1.01e-6	Motion sickness;
KIRP	cis	rs9905704	0.718	rs758377	chr17:56607124	T/C	cg12560992	chr17:57184187	TRIM37	-0.56	-5.36	-0.32	1.91e-7	Testicular germ cell tumor;
KIRP	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg20573242	chr4:122745356	CCNA2	0.41	5.07	0.31	7.84e-7	Type 2 diabetes;
KIRP	cis	rs72960926	0.590	rs72959619	chr6:74995975	A/G	cg03266952	chr6:74778945	NA	-0.76	-5.78	-0.35	2.28e-8	Metabolite levels (MHPG);
KIRP	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.44	-12.93	-0.64	1.57e-29	Hip circumference adjusted for BMI;
KIRP	cis	rs154659	1.000	rs154659	chr16:89667337	C/T	cg01710450	chr16:89662404	CPNE7	0.54	7.07	0.41	1.55e-11	Tanning;
KIRP	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.89	13.54	0.65	1.38e-31	Selective IgA deficiency;
KIRP	cis	rs7017914	0.934	rs17689585	chr8:71818801	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.18	0.31	4.69e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.58	-7.43	-0.43	1.83e-12	Aortic root size;
KIRP	cis	rs4006360	0.646	rs917635	chr17:39302683	A/G	cg25341923	chr17:39239918	KRTAP4-7	0.63	8.74	0.49	3.81e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg23601095	chr6:26197514	HIST1H3D	0.98	8.28	0.47	8.02e-15	Gout;Renal underexcretion gout;
KIRP	trans	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg10756647	chr7:56101905	PSPH	-0.98	-6.96	-0.41	3.06e-11	Diabetic kidney disease;
KIRP	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-4.96	-0.3	1.34e-6	Skin colour saturation;
KIRP	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	9.3	0.51	7.95e-18	Cognitive test performance;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-9.01	-0.5	5.91e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6977660	0.660	rs10269891	chr7:19816063	T/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.5	0.33	9.73e-8	Thyroid stimulating hormone;
KIRP	cis	rs11874712	0.965	rs11661945	chr18:43672194	T/A	cg26436583	chr18:43649176	PSTPIP2	-0.45	-6.47	-0.38	5.2400000000000005e-10	Migraine - clinic-based;
KIRP	cis	rs7113874	1.000	rs10840100	chr11:8669437	C/T	cg08015107	chr11:8618950	NA	-0.34	-4.84	-0.3	2.26e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7572644	0.723	rs12473400	chr2:28024024	G/T	cg27432699	chr2:27873401	GPN1	0.49	5.52	0.33	8.75e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg00310523	chr12:86230176	RASSF9	0.56	8.69	0.48	5.29e-16	Major depressive disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05831673	chr14:53196918	STYX	-0.49	-6.06	-0.36	5e-9	Survival in pancreatic cancer;
KIRP	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.63	8.5	0.48	1.88e-15	Total body bone mineral density;
KIRP	cis	rs7851660	0.874	rs7860144	chr9:100626884	A/G	cg13688889	chr9:100608707	NA	-0.67	-8.83	-0.49	1.97e-16	Strep throat;
KIRP	cis	rs2625529	0.878	rs2929511	chr15:72231682	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.31	0.37	1.27e-9	Red blood cell count;
KIRP	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg11189052	chr15:85197271	WDR73	0.51	5.42	0.33	1.45e-7	Schizophrenia;
KIRP	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06173319	chr16:90148775	NA	0.55	5.01	0.3	1.03e-6	Skin colour saturation;
KIRP	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg17764715	chr19:33622953	WDR88	0.8	11.51	0.59	8.49e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg05072774	chr3:49840536	C3orf54	-0.41	-5.14	-0.31	5.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	1.36	11.79	0.6	1.01e-25	Sexual dysfunction (female);
KIRP	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.44	5.69	0.34	3.59e-8	LDL cholesterol levels;LDL cholesterol;
KIRP	cis	rs2652822	0.525	rs2899691	chr15:63519088	T/A	cg02713581	chr15:63449717	RPS27L	0.45	4.99	0.3	1.15e-6	Metabolic traits;
KIRP	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.86	8.86	0.49	1.62e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4936894	0.500	rs10893193	chr11:124140263	C/T	cg27160556	chr11:124181099	OR8D1	-0.46	-6.62	-0.39	2.25e-10	Aging (time to death);
KIRP	cis	rs4006360	0.546	rs6416912	chr17:39253337	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.66	-0.52	6.47e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.72	10.45	0.55	2.12e-21	Hip circumference;
KIRP	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg10761708	chr20:43804764	PI3	0.5	5.25	0.32	3.22e-7	Blood protein levels;
KIRP	cis	rs7082209	1.000	rs12265306	chr10:44811617	C/G	cg09554077	chr10:44749378	NA	0.44	5.36	0.32	1.93e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg14004847	chr7:1930337	MAD1L1	-0.44	-5.07	-0.31	7.93e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs735539	0.645	rs1411038	chr13:21248431	A/G	cg04906043	chr13:21280425	IL17D	-0.52	-6.35	-0.38	1.04e-9	Dental caries;
KIRP	cis	rs6693567	0.545	rs4451552	chr1:150455854	C/G	cg07843065	chr1:150265600	MRPS21	0.5	6.67	0.39	1.68e-10	Migraine;
KIRP	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.71	7.39	0.43	2.27e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs829883	1.000	rs249839	chr12:98872364	T/C	cg25150519	chr12:98850993	NA	0.87	13.15	0.64	2.97e-30	Colorectal adenoma (advanced);
KIRP	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg01620082	chr3:125678407	NA	-1.22	-7.76	-0.44	2.22e-13	Depression;
KIRP	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.6	-7.09	-0.41	1.44e-11	Menarche (age at onset);
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12016809	chr21:47604291	C21orf56	0.49	7.13	0.41	1.15e-11	Testicular germ cell tumor;
KIRP	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg12131826	chr15:77904385	NA	0.42	5.55	0.33	7.31e-8	Type 2 diabetes;
KIRP	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.49	5.38	0.32	1.69e-7	Lung cancer (smoking interaction);
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.03	-0.41	2.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.18	21.28	0.8	1.05e-57	Cognitive function;
KIRP	cis	rs1978968	1.000	rs7285566	chr22:18445288	G/A	cg03078520	chr22:18463400	MICAL3	-0.76	-8.8	-0.49	2.4e-16	Presence of antiphospholipid antibodies;
KIRP	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg18904891	chr8:8559673	CLDN23	0.67	7.38	0.43	2.41e-12	Obesity-related traits;
KIRP	cis	rs4805272	1.000	rs10412433	chr19:29320163	C/G	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs367943	0.666	rs10074214	chr5:112702214	A/G	cg12552261	chr5:112820674	MCC	0.55	6.51	0.38	4.18e-10	Type 2 diabetes;
KIRP	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg11502198	chr6:26597334	ABT1	-0.56	-7.21	-0.42	6.73e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-5.03	-0.31	9.49e-7	Menarche (age at onset);
KIRP	cis	rs4956211	0.542	rs55929207	chr4:109703549	C/G	cg07086381	chr4:109682776	AGXT2L1	-0.4	-5.15	-0.31	5.41e-7	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.66	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.67	-8.04	-0.46	3.87e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg26752003	chr8:145688521	CYHR1	-0.55	-6.55	-0.39	3.43e-10	Age at first birth;
KIRP	cis	rs807669	0.525	rs738904	chr22:19167385	C/A	cg02655711	chr22:19163373	SLC25A1	0.53	7.46	0.43	1.51e-12	Metabolite levels;
KIRP	cis	rs981844	0.921	rs2606336	chr4:154656792	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs524023	0.874	rs7105665	chr11:64396568	T/C	cg09231725	chr11:64357281	SLC22A12	0.59	7.89	0.45	9.83e-14	Urate levels in obese individuals;
KIRP	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg21419209	chr3:44054225	NA	-0.75	-9.31	-0.51	7.16e-18	Coronary artery disease;
KIRP	cis	rs4262150	0.883	rs72802883	chr5:152246607	A/C	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg17863274	chr19:49399704	TULP2	-0.41	-5.82	-0.35	1.85e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg00405596	chr8:11794950	NA	-0.44	-5.37	-0.32	1.83e-7	Neuroticism;
KIRP	cis	rs78487399	0.731	rs6747229	chr2:43712610	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.43	-0.33	1.33e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs448720	0.811	rs1996121	chr15:68181578	G/T	cg24579218	chr15:68104479	NA	-0.38	-5.45	-0.33	1.21e-7	Cognitive performance;
KIRP	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg00852783	chr1:26633632	UBXN11	0.53	7.69	0.44	3.5e-13	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03526905	chr17:6554842	C17orf100;MED31	-0.45	-6.08	-0.36	4.5e-9	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.44	5.44	0.33	1.27e-7	Aortic root size;
KIRP	cis	rs73086581	0.687	rs16989002	chr20:3850703	G/C	cg02187196	chr20:3869020	PANK2	0.6	5.47	0.33	1.1e-7	Response to antidepressants in depression;
KIRP	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.62	-0.39	2.22e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.73	9.24	0.51	1.18e-17	Coronary artery disease;
KIRP	cis	rs9652601	0.677	rs35732840	chr16:11228355	T/G	cg04616529	chr16:11181986	CLEC16A	0.38	4.9	0.3	1.72e-6	Systemic lupus erythematosus;
KIRP	cis	rs4481887	0.504	rs6587439	chr1:248376070	A/G	cg00666640	chr1:248458726	OR2T12	-0.42	-4.89	-0.3	1.79e-6	Common traits (Other);
KIRP	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg25039879	chr17:56429692	SUPT4H1	0.57	5.11	0.31	6.58e-7	Cognitive test performance;
KIRP	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg21919602	chr1:242011447	EXO1	-0.47	-6.09	-0.36	4.39e-9	Menopause (age at onset);
KIRP	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg24807547	chr6:37504484	NA	-0.57	-8.51	-0.48	1.72e-15	Cognitive performance;
KIRP	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.95	10.16	0.54	1.79e-20	Corneal astigmatism;
KIRP	cis	rs7246865	0.724	rs10424674	chr19:17183185	G/A	cg18440316	chr19:18077727	KCNN1	-0.39	-5.42	-0.33	1.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg06226150	chr20:62369956	SLC2A4RG;LIME1	-0.35	-5.44	-0.33	1.27e-7	Prostate cancer;
KIRP	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg16558253	chr16:72132732	DHX38	-0.37	-4.87	-0.3	1.99e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13424732	chr7:72722590	NSUN5	0.48	6.4	0.38	7.72e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.68	10.13	0.54	2.14e-20	Dupuytren's disease;
KIRP	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg15556689	chr8:8085844	FLJ10661	0.46	5.62	0.34	5.13e-8	Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg23985595	chr17:80112537	CCDC57	0.4	6.13	0.36	3.49e-9	Life satisfaction;
KIRP	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	0.88	7.14	0.41	1.03e-11	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26986584	chr19:2819738	ZNF554	0.59	7.62	0.44	5.54e-13	Parkinson's disease;
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg11859384	chr17:80120422	CCDC57	-0.41	-5.13	-0.31	5.75e-7	Life satisfaction;
KIRP	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.56	6.68	0.39	1.6e-10	Ulcerative colitis;
KIRP	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9790314	0.613	rs56665329	chr3:160590858	T/A	cg04691961	chr3:161091175	C3orf57	0.45	6.33	0.37	1.16e-9	Morning vs. evening chronotype;
KIRP	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-12.09	-0.61	1.02e-26	Systemic lupus erythematosus;
KIRP	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg15068132	chr12:102092402	CHPT1	-0.41	-5.3	-0.32	2.63e-7	Blood protein levels;
KIRP	cis	rs2851682	1.000	rs2845574	chr11:61601872	C/T	cg07689907	chr11:61582574	FADS1	0.63	4.9	0.3	1.73e-6	Gestational age at birth (child effect);Trans fatty acid levels;
KIRP	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg27124370	chr19:33622961	WDR88	0.73	10.38	0.55	3.64e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg11621586	chr10:70884670	VPS26A	1.02	13.06	0.64	5.85e-30	Left atrial antero-posterior diameter;
KIRP	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.4	8.28	0.47	7.84e-15	IgG glycosylation;
KIRP	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.61	-8.68	-0.48	5.57e-16	Colorectal cancer;
KIRP	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg05315796	chr3:52349193	DNAH1	0.37	5.67	0.34	3.97e-8	Bipolar disorder;
KIRP	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2976388	0.647	rs2920288	chr8:143753289	C/T	cg02415014	chr8:143852576	LYNX1	-0.32	-5.0	-0.3	1.07e-6	Urinary tract infection frequency;
KIRP	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg26149184	chr10:133730230	NA	0.42	5.08	0.31	7.4e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-0.83	-14.75	-0.69	1.01e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg09455208	chr3:40491958	NA	0.34	5.95	0.35	9.36e-9	Renal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.75	7.57	0.43	7.5e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4595586	1.000	rs4595586	chr12:39225991	A/T	cg26384229	chr12:38710491	ALG10B	-0.38	-4.89	-0.3	1.85e-6	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.14e-11	Obesity-related traits;
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg05457628	chr5:178986728	RUFY1	0.55	8.56	0.48	1.21e-15	Lung cancer;
KIRP	cis	rs1978968	0.912	rs1110666	chr22:18457720	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	0.56	6.46	0.38	5.52e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.66	5.13	0.31	6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.82	-8.69	-0.48	5.29e-16	Lung cancer in ever smokers;
KIRP	trans	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg04702396	chr17:15466718	FAM18B2	0.52	6.58	0.39	2.83e-10	Educational attainment (years of education);
KIRP	cis	rs2150410	0.915	rs55885019	chr21:40517875	T/G	cg11890956	chr21:40555474	PSMG1	-0.77	-5.55	-0.33	7.56e-8	Temperament (bipolar disorder);
KIRP	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg15282417	chr9:129245246	FAM125B	-0.42	-7.16	-0.42	9.21e-12	Intraocular pressure;
KIRP	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.78	-12.38	-0.62	1.09e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg27205649	chr11:78285834	NARS2	-0.66	-8.6	-0.48	9.5e-16	Alzheimer's disease (survival time);
KIRP	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg19292749	chr17:79650816	ARL16;HGS	0.52	4.87	0.3	2.04e-6	Dental caries;
KIRP	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23161317	chr6:28129485	ZNF389	0.43	5.04	0.31	9.21e-7	Depression;
KIRP	cis	rs17221829	0.645	rs10830325	chr11:89389068	G/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg14952266	chr13:112191215	NA	0.46	6.8	0.4	8.08e-11	Hepatitis;
KIRP	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.72	0.39	1.23e-10	Colorectal cancer;
KIRP	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg20578329	chr17:80767326	TBCD	0.52	6.35	0.38	1.01e-9	Breast cancer;
KIRP	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.81	-6.89	-0.4	4.55e-11	Obesity-related traits;
KIRP	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	1.22	9.26	0.51	1.01e-17	Prostate cancer;
KIRP	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.76	5.65	0.34	4.44e-8	Economic and political preferences (immigration/crime);
KIRP	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.72	9.32	0.51	7.1e-18	Chronic sinus infection;
KIRP	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg21395723	chr22:39101663	GTPBP1	0.43	5.89	0.35	1.23e-8	Menopause (age at onset);
KIRP	cis	rs2380205	0.875	rs10795593	chr10:5895756	C/A	cg27141509	chr10:5886111	NA	-0.38	-5.53	-0.33	8.2e-8	Breast cancer;
KIRP	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-4.99	-0.3	1.14e-6	Colorectal cancer;
KIRP	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg25173405	chr17:45401733	C17orf57	0.46	6.18	0.37	2.59e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.03	-0.31	9.57e-7	Schizophrenia;
KIRP	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.31	5.73	0.34	2.97e-8	Calcium levels;
KIRP	cis	rs501120	1.000	rs554568	chr10:44755446	C/T	cg09554077	chr10:44749378	NA	0.74	12.09	0.61	1.02e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	1.13	10.15	0.54	1.9e-20	Post bronchodilator FEV1;
KIRP	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.19	-22.19	-0.82	1.23e-60	Cognitive function;
KIRP	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.49	-6.15	-0.37	3.09e-9	Post bronchodilator FEV1;
KIRP	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg23894439	chr1:183413866	NA	-0.42	-5.55	-0.33	7.3e-8	Systemic lupus erythematosus;
KIRP	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.48	-5.41	-0.33	1.47e-7	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.56	0.48	1.21e-15	Motion sickness;
KIRP	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18252515	chr7:66147081	NA	0.46	5.69	0.34	3.58e-8	Aortic root size;
KIRP	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg23752985	chr2:85803571	VAMP8	0.56	8.02	0.46	4.32e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs193541	0.593	rs30042	chr5:122272641	A/G	cg19412675	chr5:122181750	SNX24	0.59	6.15	0.36	3.16e-9	Glucose homeostasis traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04568842	chr12:6875453	PTMS	0.53	6.8	0.4	8.11e-11	Parkinson's disease;
KIRP	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.22	-5.82	-0.35	1.81e-8	Mean corpuscular volume;
KIRP	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.57	-5.04	-0.31	9e-7	Mosquito bite size;
KIRP	cis	rs714515	0.586	rs2032530	chr1:172451886	C/T	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs35883536	0.935	rs12409832	chr1:101107725	A/G	cg06223162	chr1:101003688	GPR88	0.32	6.58	0.39	2.73e-10	Monocyte count;
KIRP	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.74	-0.34	2.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.66	-9.24	-0.51	1.17e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.52	5.23	0.32	3.71e-7	Alzheimer's disease;
KIRP	cis	rs2380205	0.967	rs10905316	chr10:5898740	C/T	cg27141509	chr10:5886111	NA	-0.39	-5.65	-0.34	4.36e-8	Breast cancer;
KIRP	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg18964960	chr10:1102726	WDR37	-0.49	-5.76	-0.34	2.55e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg06647332	chr5:131281008	NA	-0.45	-4.98	-0.3	1.19e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.71	-8.65	-0.48	6.98e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.8	9.94	0.54	8.73e-20	Platelet distribution width;
KIRP	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	1.06	14.88	0.69	3.66e-36	Menopause (age at onset);
KIRP	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg16329650	chr2:213403929	ERBB4	0.39	5.44	0.33	1.27e-7	Symmetrical dimethylarginine levels;
KIRP	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg24110177	chr3:50126178	RBM5	0.62	7.83	0.45	1.44e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.78	10.45	0.55	2.18e-21	Aortic root size;
KIRP	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg18190219	chr22:46762943	CELSR1	-0.68	-7.63	-0.44	5.02e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.49	-6.55	-0.39	3.31e-10	Multiple sclerosis;
KIRP	cis	rs3784262	0.669	rs2414530	chr15:58356362	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.85	-0.3	2.2e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.17	0.5	1.91e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9625935	0.957	rs5763674	chr22:30386358	C/T	cg01021169	chr22:30184971	ASCC2	-0.43	-4.87	-0.3	2e-6	Tonsillectomy;
KIRP	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg25922239	chr6:33757077	LEMD2	0.7	9.03	0.5	5.05e-17	Crohn's disease;
KIRP	cis	rs9879311	0.522	rs6442169	chr3:10430862	A/G	cg11030744	chr3:10328490	GHRL;GHRLOS	0.44	5.29	0.32	2.65e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg23698023	chr8:27181813	PTK2B	0.35	5.21	0.32	3.96e-7	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14022322	chr14:104206702	PPP1R13B	-0.44	-6.3	-0.37	1.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-4.94	-0.3	1.46e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs60843830	0.517	rs58416198	chr2:175580	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.59	6.1	0.36	4.14e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.85	-12.33	-0.62	1.63e-27	Calcium levels;
KIRP	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.49	6.77	0.4	9.16e-11	Red blood cell count;
KIRP	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-6.94	-0.4	3.44e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.09	12.5	0.62	4.5e-28	Uric acid levels;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg15028436	chr7:37888078	TXNDC3	0.53	6.22	0.37	2.15e-9	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg20503657	chr10:835505	NA	-0.56	-6.8	-0.4	7.96e-11	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.66	-8.56	-0.48	1.24e-15	Iron status biomarkers;
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg15117754	chr3:10150083	C3orf24	0.52	5.02	0.3	9.87e-7	Alzheimer's disease;
KIRP	cis	rs743757	1.000	rs2236987	chr3:50504546	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.54	-5.48	-0.33	1.06e-7	Diastolic blood pressure;
KIRP	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.59	5.47	0.33	1.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4561483	0.743	rs28653099	chr16:12009150	C/A	cg08843971	chr16:11963173	GSPT1	0.55	7.66	0.44	4.2e-13	Testicular germ cell tumor;
KIRP	trans	rs6810798	0.780	rs2562869	chr4:148247353	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	0.53	6.29	0.37	1.44e-9	Coronary artery disease;
KIRP	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.44	5.48	0.33	1.08e-7	IgG glycosylation;
KIRP	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.86	-12.27	-0.62	2.63e-27	Cocaine dependence;
KIRP	cis	rs1629083	1.000	rs1629083	chr11:118126576	C/T	cg18857871	chr11:118064634	AMICA1	0.67	9.51	0.52	1.8e-18	Lung cancer;
KIRP	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	0.77	10.44	0.55	2.29e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7849270	1.000	rs7849270	chr9:131874641	A/G	cg13538475	chr9:131942899	NA	-0.32	-5.15	-0.31	5.36e-7	Blood metabolite ratios;
KIRP	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg02336718	chr17:17403227	NA	0.33	5.2	0.31	4.1e-7	Total body bone mineral density;
KIRP	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	1.02	22.11	0.82	2.18e-60	Multiple myeloma;
KIRP	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.84	-13.57	-0.65	1.1e-31	Blood metabolite levels;
KIRP	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg18944383	chr4:111397179	ENPEP	0.47	8.06	0.46	3.22e-14	Height;
KIRP	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg27494647	chr7:150038898	RARRES2	0.43	6.27	0.37	1.64e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs1538970	0.924	rs6657284	chr1:45879088	T/C	cg05343316	chr1:45956843	TESK2	0.69	8.0	0.45	5.03e-14	Platelet count;
KIRP	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-6.87	-0.4	5.22e-11	Mean platelet volume;
KIRP	cis	rs675026	0.926	rs505340	chr6:154451287	T/C	cg07813322	chr6:154414604	OPRM1	-0.45	-5.97	-0.36	8.23e-9	Hypertension;
KIRP	cis	rs2072732	0.904	rs72629496	chr1:2953143	G/A	cg11731671	chr1:2995604	PRDM16	-0.59	-6.77	-0.4	9.65e-11	Plateletcrit;
KIRP	cis	rs73198271	1.000	rs73198279	chr8:8608504	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-5.61	-0.34	5.45e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2279817	0.735	rs34571066	chr1:18002777	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.52	-0.48	1.61e-15	Neuroticism;
KIRP	trans	rs10078397	0.626	rs62360007	chr5:107859418	T/G	cg20207829	chr8:110132541	NA	0.49	6.27	0.37	1.64e-9	Neuroticism;
KIRP	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.74	9.45	0.52	2.73e-18	N-glycan levels;
KIRP	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.34	5.62	0.34	5.05e-8	Monocyte count;
KIRP	cis	rs2019216	0.967	rs2342216	chr17:21910379	A/C	cg22648282	chr17:21454238	C17orf51	-0.38	-5.13	-0.31	5.85e-7	Pelvic organ prolapse;
KIRP	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.34	4.87	0.3	2.04e-6	Hepatitis;
KIRP	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg25182066	chr10:30743637	MAP3K8	-0.67	-8.68	-0.48	5.6e-16	Inflammatory bowel disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07693037	chr3:128216748	NA	0.52	6.84	0.4	6.24e-11	Smoking initiation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09441579	chr5:9066649	SEMA5A	0.51	6.38	0.38	8.67e-10	Interleukin-4 levels;
KIRP	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg04691961	chr3:161091175	C3orf57	0.45	7.1	0.41	1.31e-11	Morning vs. evening chronotype;
KIRP	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg22906224	chr7:99728672	NA	-0.5	-6.12	-0.36	3.58e-9	Coronary artery disease;
KIRP	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg19847130	chr8:10466454	RP1L1	0.37	5.46	0.33	1.13e-7	Retinal vascular caliber;
KIRP	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.21	-0.37	2.3e-9	Aortic root size;
KIRP	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-5.96	-0.36	8.58e-9	Fear of minor pain;
KIRP	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg06740227	chr12:86229804	RASSF9	-0.45	-5.6	-0.34	5.73e-8	Major depressive disorder;
KIRP	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.59	-0.48	1.04e-15	Response to antipsychotic treatment;
KIRP	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg21775007	chr8:11205619	TDH	-0.38	-4.91	-0.3	1.68e-6	Neuroticism;
KIRP	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg03563238	chr19:33554763	RHPN2	-0.34	-6.25	-0.37	1.76e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.48	5.92	0.35	1.07e-8	HDL cholesterol;
KIRP	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg22437258	chr11:111473054	SIK2	0.61	7.13	0.41	1.11e-11	Primary sclerosing cholangitis;
KIRP	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.59	-8.71	-0.49	4.4e-16	Carotid intima media thickness;
KIRP	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.04	11.8	0.6	9.34e-26	Vitiligo;
KIRP	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg17425144	chr1:10567563	PEX14	0.48	8.98	0.5	7.07e-17	Breast size;
KIRP	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.61	6.8	0.4	7.94e-11	Exhaled nitric oxide output;
KIRP	cis	rs238295	0.805	rs6085211	chr20:5552847	G/C	cg24001556	chr20:5591874	RP5-1022P6.2	-0.5	-5.08	-0.31	7.56e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18252515	chr7:66147081	NA	-0.46	-5.56	-0.33	7.09e-8	Aortic root size;
KIRP	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg15655495	chr12:38532458	NA	-0.28	-5.27	-0.32	2.93e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6700559	0.716	rs12140579	chr1:200624496	T/C	cg07804481	chr1:200639085	DDX59	0.51	6.59	0.39	2.6200000000000003e-10	Coronary artery disease;
KIRP	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.35	-5.3	-0.32	2.63e-7	Headache;
KIRP	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18364779	chr6:26104403	HIST1H4C	-0.48	-5.42	-0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.64	-0.39	1.94e-10	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.24	-0.37	1.9e-9	Lung cancer;
KIRP	cis	rs11997175	0.545	rs66584807	chr8:33667609	A/G	cg04338863	chr8:33670619	NA	0.43	5.47	0.33	1.11e-7	Body mass index;
KIRP	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg00204512	chr16:28754710	NA	0.45	5.99	0.36	7.31e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs2135232	0.881	rs10518142	chr4:76842874	G/T	cg06564900	chr2:164592568	FIGN	0.41	6.13	0.36	3.49e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4656940	0.574	rs579589	chr1:160787725	T/C	cg17331569	chr1:160788135	LY9	0.41	4.92	0.3	1.57e-6	Crohn's disease;
KIRP	cis	rs7221595	0.825	rs9896963	chr17:3966591	T/C	cg21734707	chr17:3908241	ZZEF1	0.58	5.76	0.34	2.47e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.91	-0.53	1.07e-19	Retinal vascular caliber;
KIRP	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.65	-11.88	-0.6	5.01e-26	White blood cell count (basophil);
KIRP	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-5.92	-0.35	1.05e-8	Neuroticism;
KIRP	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.78	-9.39	-0.51	4.19e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.66	7.15	0.41	9.62e-12	Huntington's disease progression;
KIRP	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.36	-0.42	2.78e-12	Menopause (age at onset);
KIRP	trans	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg14791747	chr16:20752902	THUMPD1	0.63	6.95	0.41	3.21e-11	Cognitive test performance;
KIRP	cis	rs1519814	0.956	rs7827008	chr8:121130281	A/T	cg22335954	chr8:121166405	COL14A1	-0.47	-4.94	-0.3	1.43e-6	Breast cancer;
KIRP	cis	rs687432	0.851	rs7927022	chr11:57733923	T/C	cg19752551	chr11:57585705	CTNND1	-0.55	-7.78	-0.44	2.01e-13	Parkinson's disease;
KIRP	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.12e-8	Life satisfaction;
KIRP	cis	rs2820315	0.867	rs2819351	chr1:201885157	C/T	cg11586189	chr1:201857591	SHISA4	-0.4	-5.65	-0.34	4.46e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs7264396	0.561	rs6142474	chr20:34574914	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.53	5.85	0.35	1.57e-8	Total cholesterol levels;
KIRP	cis	rs1448094	0.740	rs4919774	chr12:86337560	G/T	cg00310523	chr12:86230176	RASSF9	0.41	6.28	0.37	1.55e-9	Major depressive disorder;
KIRP	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg20578329	chr17:80767326	TBCD	-0.93	-8.8	-0.49	2.51e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.94	13.93	0.66	6.56e-33	Tonsillectomy;
KIRP	cis	rs7551222	0.647	rs3014606	chr1:204464150	C/G	cg20240347	chr1:204465584	NA	0.36	5.82	0.35	1.78e-8	Schizophrenia;
KIRP	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg16255804	chr6:135334527	HBS1L	-0.34	-5.45	-0.33	1.24e-7	Red blood cell count;
KIRP	cis	rs300890	0.760	rs12643013	chr4:144206948	T/C	cg19876092	chr4:144208277	NA	0.42	6.98	0.41	2.71e-11	Nasopharyngeal carcinoma;
KIRP	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs7590368	0.961	rs12474895	chr2:10957848	A/C	cg15705551	chr2:10952987	PDIA6	0.46	5.03	0.31	9.68e-7	Educational attainment (years of education);
KIRP	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	cis	rs9921338	0.887	rs9926136	chr16:11437275	A/G	cg00044050	chr16:11439710	C16orf75	-0.54	-5.77	-0.35	2.35e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg13198984	chr17:80129470	CCDC57	0.57	8.66	0.48	6.46e-16	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.33	0.37	1.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg05527609	chr1:210001259	C1orf107	0.47	5.27	0.32	2.92e-7	Red blood cell count;
KIRP	cis	rs8028182	0.636	rs4564532	chr15:75706296	C/G	cg20655648	chr15:75932815	IMP3	0.53	6.87	0.4	5.13e-11	Sudden cardiac arrest;
KIRP	cis	rs3764563	1.000	rs623675	chr19:15705115	G/A	cg20725493	chr19:15740067	CYP4F8	0.88	5.89	0.35	1.28e-8	Inflammatory biomarkers;
KIRP	cis	rs2019216	0.872	rs6565384	chr17:21897456	T/C	cg22648282	chr17:21454238	C17orf51	-0.38	-5.06	-0.31	8.07e-7	Pelvic organ prolapse;
KIRP	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg07451762	chr16:28383216	NA	0.39	5.03	0.31	9.54e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-0.83	-9.6	-0.52	9.95e-19	Gut microbiome composition (summer);
KIRP	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.56	7.18	0.42	8.23e-12	Resting heart rate;
KIRP	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg18404041	chr3:52824283	ITIH1	0.33	4.85	0.3	2.21e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1076160	0.846	rs717141	chr9:135737271	T/C	cg04648087	chr9:135819397	TSC1	-0.4	-4.88	-0.3	1.9e-6	Psoriasis;
KIRP	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg08600765	chr20:34638493	LOC647979	-0.66	-6.41	-0.38	7.5e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	13.81	0.66	1.69e-32	Platelet count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23080060	chr5:61028303	NA	0.48	6.4	0.38	7.82e-10	Survival in pancreatic cancer;
KIRP	cis	rs12580194	0.593	rs11171435	chr12:55758053	T/C	cg11794356	chr12:55725991	OR6C3	-0.54	-7.62	-0.44	5.34e-13	Cancer;
KIRP	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg27494647	chr7:150038898	RARRES2	0.4	6.07	0.36	4.69e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs918629	0.567	rs13361341	chr5:95250273	A/T	cg16656078	chr5:95278638	ELL2	-0.35	-5.37	-0.32	1.85e-7	IgG glycosylation;
KIRP	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg06647332	chr5:131281008	NA	-0.44	-4.9	-0.3	1.75e-6	Life satisfaction;
KIRP	cis	rs6977660	0.619	rs71526305	chr7:19785374	G/C	cg05791153	chr7:19748676	TWISTNB	0.53	5.55	0.33	7.49e-8	Thyroid stimulating hormone;
KIRP	cis	rs9815354	0.857	rs73073252	chr3:42016891	C/T	cg03022575	chr3:42003672	ULK4	0.69	6.83	0.4	6.77e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg15128208	chr22:42549153	NA	0.67	7.65	0.44	4.59e-13	Birth weight;
KIRP	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.52	-7.93	-0.45	7.65e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs526231	0.511	rs17154965	chr5:102359566	C/A	cg23492399	chr5:102201601	PAM	-0.46	-5.09	-0.31	6.97e-7	Primary biliary cholangitis;
KIRP	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg04013166	chr16:89971882	TCF25	0.56	5.8	0.35	2.07e-8	Skin colour saturation;
KIRP	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-1.0	-12.92	-0.64	1.65e-29	Platelet distribution width;
KIRP	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.53	0.38	3.63e-10	Prudent dietary pattern;
KIRP	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-7.51	-0.43	1.06e-12	Glycated hemoglobin levels;
KIRP	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.27	12.9	0.64	1.95e-29	Diabetic retinopathy;
KIRP	cis	rs490234	0.812	rs13288963	chr9:128295198	G/A	cg14078157	chr9:128172775	NA	-0.59	-7.07	-0.41	1.63e-11	Mean arterial pressure;
KIRP	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg13010199	chr12:38710504	ALG10B	0.51	6.43	0.38	6.54e-10	Morning vs. evening chronotype;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.86	-0.3	2.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-5.97	-0.36	8.43e-9	Acne (severe);
KIRP	cis	rs10875746	1.000	rs10875746	chr12:48518264	A/C	cg26205652	chr12:48591994	NA	0.63	8.35	0.47	5.15e-15	Longevity (90 years and older);
KIRP	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.5	7.11	0.41	1.26e-11	Metabolite levels;
KIRP	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.98	-15.97	-0.71	7.23e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.37	1.57e-9	Bladder cancer;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs2273156	1.000	rs8014327	chr14:35434736	C/T	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.72	-0.34	3.05e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs3849570	0.533	rs6785385	chr3:81989850	A/G	cg07356753	chr3:81810745	GBE1	-0.52	-6.77	-0.4	9.28e-11	Waist circumference;Body mass index;
KIRP	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.9	13.52	0.65	1.56e-31	Mean platelet volume;
KIRP	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00940812	chr8:91960827	NECAB1	0.43	6.3	0.37	1.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	1.28	9.22	0.51	1.39e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-5.0	-0.3	1.08e-6	Cognitive function;
KIRP	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg15744005	chr10:104629667	AS3MT	-0.27	-5.23	-0.32	3.6e-7	Arsenic metabolism;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21930229	chr1:32758033	HDAC1	0.52	6.14	0.36	3.32e-9	Lung cancer in ever smokers;
KIRP	cis	rs909341	0.909	rs2872881	chr20:62342801	G/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.77	-0.35	2.32e-8	Atopic dermatitis;
KIRP	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.84	-0.4	6.26e-11	Hemoglobin concentration;
KIRP	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-1.01	-13.87	-0.66	1.05e-32	Alopecia areata;
KIRP	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg09904177	chr6:26538194	HMGN4	0.51	5.43	0.33	1.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.548	rs17710668	chr17:3880546	C/G	cg09695851	chr17:3907499	NA	0.61	6.48	0.38	4.92e-10	Type 2 diabetes;
KIRP	cis	rs10782582	0.609	rs11584577	chr1:76242378	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.49	-0.38	4.69e-10	Daytime sleep phenotypes;
KIRP	cis	rs2131877	0.573	rs58370605	chr3:194842877	A/G	cg19775763	chr3:194786989	NA	-0.4	-4.85	-0.3	2.2e-6	Non-small cell lung cancer;
KIRP	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg16898833	chr6:26189333	HIST1H4D	0.85	5.92	0.35	1.06e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4950322	0.748	rs56392137	chr1:146824196	A/G	cg22381352	chr1:146742008	CHD1L	-0.44	-5.0	-0.3	1.09e-6	Protein quantitative trait loci;
KIRP	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg02228329	chr11:64053129	BAD;GPR137	0.89	10.91	0.57	7.25e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg14346243	chr4:90757452	SNCA	-0.37	-4.86	-0.3	2.09e-6	Neuroticism;
KIRP	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-5.12	-0.31	6.09e-7	Blood metabolite levels;
KIRP	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.76	5.62	0.34	5.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg18404041	chr3:52824283	ITIH1	0.36	5.02	0.3	1.01e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.42	-0.43	1.85e-12	Daytime sleep phenotypes;
KIRP	cis	rs712039	0.652	rs853224	chr17:35791328	A/T	cg16670864	chr17:35848621	DUSP14	0.48	5.86	0.35	1.46e-8	Tuberculosis;
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.78	12.95	0.64	1.32e-29	Vitiligo;
KIRP	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-8.64	-0.48	7.42e-16	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.16e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs78579285	0.545	rs79311053	chr16:88785206	C/T	cg09054528	chr16:88821542	FAM38A	-0.56	-5.03	-0.31	9.67e-7	Joint mobility (Beighton score);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13648088	chr10:124768538	ACADSB;IKZF5	0.45	6.33	0.37	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6601327	0.603	rs10095171	chr8:9669885	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-5.13	-0.31	5.74e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4566357	1.000	rs6705989	chr2:227923320	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.07	-0.31	7.96e-7	Coronary artery disease;
KIRP	cis	rs55728055	0.661	rs5753700	chr22:31971258	C/T	cg01338084	chr22:32026380	PISD	0.83	5.04	0.31	9.07e-7	Age-related hearing impairment;
KIRP	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	0.8	6.2	0.37	2.39e-9	Fat distribution (HIV);
KIRP	cis	rs4073221	0.520	rs13067391	chr3:18191929	C/T	cg07694806	chr3:18168406	NA	-0.88	-7.53	-0.43	9.91e-13	Parkinson's disease;
KIRP	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg06935464	chr4:38784597	TLR10	0.52	5.27	0.32	3.02e-7	Breast cancer;
KIRP	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg23815491	chr16:72088622	HP	0.34	4.96	0.3	1.29e-6	Blood protein levels;
KIRP	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg19468946	chr17:37922297	IKZF3	-0.46	-6.54	-0.38	3.6e-10	Asthma;
KIRP	cis	rs78487399	0.808	rs13409687	chr2:43701151	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.02	-0.3	9.94e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg04369109	chr6:150039330	LATS1	-0.51	-6.45	-0.38	5.92e-10	Lung cancer;
KIRP	cis	rs7187994	0.848	rs12920732	chr16:84780613	C/T	cg11201751	chr16:85158047	NA	0.47	4.9	0.3	1.75e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.99	-12.37	-0.62	1.17e-27	Response to antineoplastic agents;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02902865	chr1:12679132	DHRS3	0.47	6.77	0.4	9.59e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.78	-11.17	-0.58	1.06e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7582720	0.945	rs72932722	chr2:203647598	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	9.63	0.52	8.09e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.38	5.74	0.34	2.73e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs909341	0.909	rs1151622	chr20:62365556	A/G	cg03999872	chr20:62272968	STMN3	-0.59	-6.83	-0.4	6.8e-11	Atopic dermatitis;
KIRP	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.9	13.9	0.66	8.1e-33	Blood protein levels;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg21734707	chr17:3908241	ZZEF1	0.68	10.39	0.55	3.28e-21	Type 2 diabetes;
KIRP	cis	rs8054556	1.000	rs12921996	chr16:30011618	C/T	cg06326092	chr16:30034487	C16orf92	0.36	4.97	0.3	1.25e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.83	-12.85	-0.63	2.97e-29	Blood metabolite levels;
KIRP	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.51	-6.6	-0.39	2.52e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.74	10.68	0.56	3.87e-22	Hip circumference;
KIRP	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.86	14.37	0.68	2.15e-34	Prostate cancer;
KIRP	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.35	5.75	0.34	2.66e-8	Lymphocyte counts;
KIRP	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.51	6.38	0.38	8.59e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.56	-6.21	-0.37	2.28e-9	Total cholesterol levels;
KIRP	cis	rs72781680	0.611	rs72781699	chr2:24277709	G/A	cg08917208	chr2:24149416	ATAD2B	0.63	5.65	0.34	4.41e-8	Lymphocyte counts;
KIRP	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg23601095	chr6:26197514	HIST1H3D	0.94	7.7	0.44	3.23e-13	Gout;Renal underexcretion gout;
KIRP	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	8.16	0.46	1.76e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg24202620	chr15:23034457	NIPA2	0.46	6.07	0.36	4.7e-9	Colorectal cancer;
KIRP	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.43	5.08	0.31	7.63e-7	Airway imaging phenotypes;
KIRP	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.85	14.41	0.68	1.58e-34	Vitiligo;
KIRP	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.91	7.62	0.44	5.54e-13	Alzheimer's disease (late onset);
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg14338887	chr6:42928500	GNMT	0.47	7.04	0.41	1.93e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs35000415	0.688	rs35429892	chr7:128713630	G/A	cg19972273	chr7:128594194	NA	0.61	5.0	0.3	1.07e-6	Systemic lupus erythematosus;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08704250	chr15:31115839	NA	0.51	8.12	0.46	2.31e-14	Huntington's disease progression;
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg18234130	chr8:27182889	PTK2B	0.56	7.15	0.41	9.68e-12	Neuroticism;
KIRP	cis	rs35955747	0.659	rs11704494	chr22:31913271	G/A	cg02404636	chr22:31891804	SFI1	-0.4	-5.24	-0.32	3.38e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	6.94	0.4	3.5e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11834862	0.770	rs10444603	chr12:132694910	C/G	cg05229598	chr12:132699923	GALNT9	-0.58	-6.36	-0.38	9.7e-10	Anti-saccade response;
KIRP	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg07382826	chr16:28625726	SULT1A1	0.54	5.97	0.36	8.29e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs5753037	0.809	rs2079338	chr22:30203842	G/A	cg01021169	chr22:30184971	ASCC2	-0.4	-4.9	-0.3	1.72e-6	Type 1 diabetes;
KIRP	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg16586182	chr3:47516702	SCAP	-0.71	-9.98	-0.54	6.39e-20	Colorectal cancer;
KIRP	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.78	7.95	0.45	6.88e-14	Coronary artery calcification;
KIRP	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.52	5.52	0.33	8.76e-8	Alzheimer's disease;
KIRP	cis	rs4356932	1.000	rs6857372	chr4:76974727	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg25019033	chr10:957182	NA	-0.58	-7.19	-0.42	7.94e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg09890400	chr1:26503858	CNKSR1	-0.43	-6.03	-0.36	6.06e-9	Height;
KIRP	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.54	5.13	0.31	5.93e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.43	-0.43	1.81e-12	Mood instability;
KIRP	cis	rs7903847	0.656	rs7895695	chr10:99167255	A/G	cg20016023	chr10:99160130	RRP12	0.39	5.11	0.31	6.33e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.57	-6.5	-0.38	4.47e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg04398451	chr17:18023971	MYO15A	-0.69	-9.56	-0.52	1.25e-18	Total body bone mineral density;
KIRP	cis	rs2067663	0.786	rs627464	chr5:88060321	G/A	cg18498987	chr5:88179539	MEF2C	-0.42	-5.45	-0.33	1.21e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs7721647	0.821	rs332523	chr5:90830449	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.4	4.91	0.3	1.65e-6	Breast cancer;
KIRP	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg01988459	chr11:68622903	NA	0.39	5.48	0.33	1.04e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18932078	chr1:2524107	MMEL1	0.45	6.22	0.37	2.13e-9	Ulcerative colitis;
KIRP	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.47	5.95	0.35	9.28e-9	Recombination rate (males);
KIRP	cis	rs909341	0.859	rs3208008	chr20:62326110	A/C	cg11503966	chr20:62272292	STMN3	0.41	5.88	0.35	1.35e-8	Atopic dermatitis;
KIRP	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs3087591	0.708	rs3785956	chr17:29647707	C/A	cg24425628	chr17:29625626	OMG;NF1	0.63	9.23	0.51	1.27e-17	Hip circumference;
KIRP	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.64	8.34	0.47	5.32e-15	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs405956	0.769	rs2001119	chr6:105562120	G/A	cg22580625	chr6:105627791	POPDC3	-0.48	-5.33	-0.32	2.23e-7	QT interval;
KIRP	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.54	-0.38	3.54e-10	Neuroticism;
KIRP	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	9.59	0.52	1.07e-18	Cognitive test performance;
KIRP	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.5	-0.33	9.29e-8	Neuroticism;
KIRP	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.64	0.34	4.61e-8	Educational attainment;
KIRP	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg12501888	chr15:85177176	SCAND2	-0.43	-5.33	-0.32	2.23e-7	P wave terminal force;
KIRP	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.65	-4.97	-0.3	1.26e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs10934753	0.632	rs4350878	chr3:125914214	C/G	cg01346077	chr3:125931526	NA	0.42	6.61	0.39	2.37e-10	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg27532560	chr4:187881888	NA	0.73	12.43	0.62	7.38e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.56	-6.69	-0.39	1.5e-10	Age at first birth;
KIRP	cis	rs7429990	0.931	rs62262084	chr3:47653822	C/T	cg11946769	chr3:48343235	NME6	0.5	5.13	0.31	5.96e-7	Educational attainment (years of education);
KIRP	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.85	12.08	0.61	1.06e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg22138327	chr13:27999177	GTF3A	0.89	7.04	0.41	1.88e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.59	7.74	0.44	2.58e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12435854	chr1:70691524	SFRS11	-0.38	-6.07	-0.36	4.79e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.67	0.63	1.15e-28	Morning vs. evening chronotype;
KIRP	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg25174290	chr11:3078921	CARS	-0.69	-8.98	-0.5	7.09e-17	Calcium levels;
KIRP	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.27	-0.32	2.94e-7	Aortic root size;
KIRP	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-8.67	-0.48	5.93e-16	Platelet count;
KIRP	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.56	-0.39	3.19e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.65	8.26	0.47	9.08e-15	Height;
KIRP	cis	rs4664308	0.618	rs35771982	chr2:160885418	G/C	cg03641300	chr2:160917029	PLA2R1	-0.66	-10.41	-0.55	2.92e-21	Idiopathic membranous nephropathy;
KIRP	cis	rs8033133	0.881	rs4344720	chr15:25324141	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.51	-6.04	-0.36	5.54e-9	Blood osmolality (transformed sodium);
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg09033563	chr22:24373618	LOC391322	-0.42	-5.47	-0.33	1.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg11895451	chr1:16533891	ARHGEF19	0.43	5.96	0.36	8.72e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg21515243	chr18:21033072	RIOK3	-0.5	-6.26	-0.37	1.73e-9	Neuroticism;
KIRP	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg21684588	chr1:67600265	NA	-0.5	-5.85	-0.35	1.58e-8	Psoriasis;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg10207240	chr12:122356781	WDR66	0.62	8.02	0.46	4.33e-14	Mean corpuscular volume;
KIRP	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.56	0.43	8.03e-13	Lung cancer;
KIRP	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25517755	chr10:38738941	LOC399744	-0.36	-4.94	-0.3	1.45e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17376030	chr22:41985996	PMM1	0.75	7.85	0.45	1.32e-13	Vitiligo;
KIRP	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg13147721	chr7:65941812	NA	-0.93	-6.78	-0.4	8.84e-11	Diabetic kidney disease;
KIRP	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	0.96	12.18	0.61	5.1e-27	Testicular germ cell tumor;
KIRP	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.57	8.68	0.48	5.47e-16	Personality dimensions;
KIRP	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18252515	chr7:66147081	NA	0.45	5.27	0.32	3.04e-7	Aortic root size;
KIRP	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.51	-6.03	-0.36	6.02e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2147904	0.704	rs783628	chr1:42361102	G/A	cg26038582	chr1:42384390	HIVEP3	0.24	5.05	0.31	8.55e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.6	-7.78	-0.44	2.03e-13	Breast cancer;
KIRP	cis	rs904251	0.605	rs4257849	chr6:37410969	T/G	cg08126542	chr6:37504118	NA	-0.52	-5.54	-0.33	7.62e-8	Cognitive performance;
KIRP	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.39	0.43	2.28e-12	Coffee consumption (cups per day);
KIRP	cis	rs17384381	1.000	rs12123745	chr1:85884772	T/C	cg16011679	chr1:85725395	C1orf52	0.82	8.04	0.46	3.71e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg00629928	chr5:358741	AHRR	0.5	4.86	0.3	2.09e-6	Breast cancer;
KIRP	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg01721255	chr8:58191610	C8orf71	0.66	5.64	0.34	4.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3736485	0.934	rs11635216	chr15:51871947	A/G	cg14296394	chr15:51910925	DMXL2	0.36	5.24	0.32	3.48e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9547996	0.837	rs1924298	chr13:38183502	A/G	cg13634560	chr13:38173852	POSTN	-0.4	-5.55	-0.33	7.2e-8	Diastolic blood pressure;
KIRP	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg15655495	chr12:38532458	NA	-0.31	-5.33	-0.32	2.21e-7	Bladder cancer;
KIRP	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.56	5.59	0.34	6.09e-8	Initial pursuit acceleration;
KIRP	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.65	8.02	0.46	4.38e-14	Aortic root size;
KIRP	cis	rs10129255	0.518	rs8004895	chr14:107193377	T/C	cg23076370	chr14:107095027	NA	-0.4	-4.87	-0.3	2.01e-6	Kawasaki disease;
KIRP	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.98	0.41	2.72e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	0.84	7.52	0.43	1.02e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1981331	0.609	rs7279368	chr21:48065999	A/G	cg23283320	chr21:48055893	PRMT2	1.45	9.12	0.5	2.82e-17	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7551222	0.750	rs898387	chr1:204579373	A/G	cg20240347	chr1:204465584	NA	0.3	5.35	0.32	2.02e-7	Schizophrenia;
KIRP	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.43	5.7	0.34	3.34e-8	Childhood ear infection;
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg08662619	chr6:150070041	PCMT1	0.38	6.19	0.37	2.44e-9	Lung cancer;
KIRP	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg23307798	chr14:103986281	CKB	-0.54	-7.06	-0.41	1.73e-11	Coronary artery disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02002494	chr3:119013045	CDGAP	0.53	7.36	0.42	2.81e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13047869	chr3:10149882	C3orf24	0.55	5.26	0.32	3.09e-7	Alzheimer's disease;
KIRP	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg16497661	chr14:103986332	CKB	-0.53	-7.09	-0.41	1.43e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7558233	0.614	rs4665213	chr2:23678781	A/G	cg00747342	chr2:23700632	KLHL29	0.58	5.35	0.32	1.97e-7	Cannabis use (initiation);
KIRP	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg18944383	chr4:111397179	ENPEP	0.53	9.44	0.52	2.9e-18	Height;
KIRP	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg05802129	chr4:122689817	NA	-0.47	-6.93	-0.4	3.72e-11	Type 2 diabetes;
KIRP	cis	rs4702718	0.587	rs4702722	chr5:10677339	A/G	cg14521931	chr5:10832172	NA	0.41	5.51	0.33	9.22e-8	Obesity-related traits;
KIRP	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg08890418	chr1:21044141	KIF17	-0.43	-6.52	-0.38	4.01e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg09165964	chr15:75287851	SCAMP5	-1.08	-7.37	-0.43	2.64e-12	Lung cancer;
KIRP	cis	rs4356932	0.597	rs7679177	chr4:76853790	C/G	cg00809888	chr4:76862425	NAAA	-0.42	-5.71	-0.34	3.22e-8	Blood protein levels;
KIRP	cis	rs60871478	0.898	rs62432225	chr7:789433	G/A	cg05535760	chr7:792225	HEATR2	0.89	9.01	0.5	5.87e-17	Cerebrospinal P-tau181p levels;
KIRP	cis	rs8014252	0.803	rs12586441	chr14:70988062	T/C	cg19730268	chr14:71022823	NA	-0.76	-6.46	-0.38	5.46e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.62	5.3	0.32	2.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23161317	chr6:28129485	ZNF389	0.43	5.06	0.31	8.25e-7	Depression;
KIRP	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.86	-9.07	-0.5	3.95e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9323205	0.871	rs8008599	chr14:51670057	A/G	cg23942311	chr14:51606299	NA	0.59	6.85	0.4	5.79e-11	Cancer;
KIRP	cis	rs4700695	0.686	rs27075	chr5:65370379	C/T	cg21114390	chr5:65439923	SFRS12	-0.53	-4.99	-0.3	1.14e-6	Facial morphology (factor 19);
KIRP	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.21	14.0	0.67	3.86e-33	Sexual dysfunction (female);
KIRP	cis	rs10982256	0.811	rs10759713	chr9:117254214	G/A	cg13636371	chr9:117264095	DFNB31	0.59	8.2	0.46	1.31e-14	Bipolar disorder;
KIRP	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs27434	0.583	rs468130	chr5:96156029	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.49	-0.33	1.01e-7	Ankylosing spondylitis;
KIRP	cis	rs1950626	0.699	rs12880855	chr14:101468382	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.34	0.37	1.07e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.8	9.94	0.54	8.81e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15684116	chr1:153700070	INTS3	0.62	6.11	0.36	3.78e-9	Lung function (FEV1);
KIRP	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg08662619	chr6:150070041	PCMT1	0.37	6.01	0.36	6.56e-9	Lung cancer;
KIRP	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg15755662	chr7:2671535	TTYH3	0.42	4.89	0.3	1.8e-6	Schizophrenia;
KIRP	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.5	-0.38	4.51e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	7.21	0.42	7.01e-12	Mean corpuscular hemoglobin;
KIRP	trans	rs2302464	1.000	rs10011868	chr4:15660828	T/A	cg24908198	chr11:128812992	TP53AIP1	0.42	6.04	0.36	5.69e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg19875535	chr5:140030758	IK	-0.71	-10.43	-0.55	2.49e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.81	-10.77	-0.57	2.01e-22	Pancreatic cancer;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.73	0.44	2.69e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs796364	0.616	rs769956	chr2:200693720	C/T	cg17644776	chr2:200775616	C2orf69	-0.53	-4.9	-0.3	1.73e-6	Schizophrenia;
KIRP	cis	rs2742417	1.000	rs1877933	chr3:45753487	C/T	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg15676125	chr6:33679581	C6orf125	0.39	5.03	0.31	9.43e-7	Height;
KIRP	cis	rs12615966	0.932	rs1947308	chr2:105391930	G/A	cg16465502	chr2:105461796	NA	0.62	5.62	0.34	5.13e-8	Pancreatic cancer;
KIRP	cis	rs9488822	0.585	rs7756746	chr6:116239881	C/T	cg15226275	chr6:116381976	FRK	-0.26	-6.09	-0.36	4.43e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg25486957	chr4:152246857	NA	-0.53	-5.68	-0.34	3.78e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.61	8.89	0.49	1.3e-16	Systemic lupus erythematosus;
KIRP	cis	rs2072732	0.861	rs34408665	chr1:2950067	A/G	cg11731671	chr1:2995604	PRDM16	-0.43	-5.42	-0.33	1.41e-7	Plateletcrit;
KIRP	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.38e-8	Life satisfaction;
KIRP	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg06740227	chr12:86229804	RASSF9	0.44	5.58	0.34	6.37e-8	Major depressive disorder;
KIRP	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg02297831	chr4:17616191	MED28	-0.49	-5.96	-0.36	8.73e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg10760299	chr15:45669010	GATM	-0.35	-5.19	-0.31	4.33e-7	Homoarginine levels;
KIRP	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg00079375	chr15:79125835	NA	0.37	5.4	0.33	1.54e-7	Coronary artery disease;
KIRP	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg00262122	chr8:11665843	FDFT1	-0.41	-5.05	-0.31	8.47e-7	Retinal vascular caliber;
KIRP	cis	rs2904967	0.703	rs4149813	chr11:65082673	G/A	cg12562828	chr11:65076843	NA	0.48	7.32	0.42	3.42e-12	Mean corpuscular volume;
KIRP	cis	rs220519	0.811	rs220513	chr20:37284222	T/A	cg24308336	chr20:37270989	C20orf95	0.24	5.21	0.32	4.02e-7	Schizophrenia;
KIRP	cis	rs661054	0.784	rs7122337	chr11:114397499	T/C	cg19465033	chr11:114479364	NA	0.43	5.15	0.31	5.3e-7	Ulcerative colitis;
KIRP	trans	rs6601327	0.665	rs12543369	chr8:9655915	C/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.76	-0.4	9.86e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.78	-11.12	-0.58	1.54e-23	Blood metabolite levels;
KIRP	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.45	0.33	1.21e-7	Educational attainment;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg01798813	chr17:3906674	NA	-0.53	-7.43	-0.43	1.74e-12	Type 2 diabetes;
KIRP	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.45	0.43	1.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs763512	0.504	rs1051838	chr17:35870833	G/A	cg16670864	chr17:35848621	DUSP14	0.45	5.34	0.32	2.16e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07151155	chr5:1473589	LPCAT1	-0.43	-5.79	-0.35	2.1e-8	Breast cancer;
KIRP	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg18404041	chr3:52824283	ITIH1	0.35	4.91	0.3	1.68e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg23985595	chr17:80112537	CCDC57	0.36	5.31	0.32	2.46e-7	Life satisfaction;
KIRP	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.78	-0.35	2.27e-8	Bipolar disorder;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.35	0.38	1.02e-9	Vitiligo;
KIRP	cis	rs4389656	0.740	rs274706	chr5:6726629	T/C	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg22138327	chr13:27999177	GTF3A	-1.02	-12.61	-0.63	1.81e-28	Body mass index;
KIRP	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.44	5.35	0.32	2.05e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs311392	0.554	rs2671798	chr8:55104495	C/T	cg11783602	chr8:55087084	NA	-0.47	-5.69	-0.34	3.64e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg00319359	chr11:70116639	PPFIA1	0.64	6.21	0.37	2.23e-9	Coronary artery disease;
KIRP	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs61884328	0.852	rs4572092	chr11:47094546	G/A	cg23433285	chr11:47201945	PACSIN3	0.83	6.28	0.37	1.5e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg02070118	chr4:952128	TMEM175	0.61	5.24	0.32	3.54e-7	Parkinson's disease;
KIRP	cis	rs12431939	0.948	rs12435916	chr14:51665858	T/G	cg23942311	chr14:51606299	NA	-0.57	-5.64	-0.34	4.66e-8	Cancer;
KIRP	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	1.08	8.09	0.46	2.72e-14	Skin colour saturation;
KIRP	cis	rs12153243	0.714	rs6895860	chr5:142913679	C/T	cg13907255	chr5:142895549	NA	-0.38	-4.85	-0.3	2.15e-6	Migraine;
KIRP	cis	rs580438	0.529	rs6806404	chr3:13374490	T/C	cg10657019	chr3:13328039	NA	-0.46	-6.16	-0.37	2.91e-9	Myringotomy;
KIRP	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.42	-6.95	-0.41	3.25e-11	Type 2 diabetes;
KIRP	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.71	9.02	0.5	5.38e-17	Coronary artery disease;
KIRP	cis	rs6847149	0.789	rs62324954	chr4:110751691	G/A	cg07850274	chr4:110748770	RRH	-0.47	-5.65	-0.34	4.42e-8	Exercise treadmill test traits;
KIRP	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.66	7.98	0.45	5.68e-14	Post bronchodilator FEV1;
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg23156509	chr2:114033830	PAX8;LOC440839	-0.36	-5.38	-0.32	1.74e-7	Lymphocyte counts;
KIRP	cis	rs3789045	0.560	rs4553256	chr1:204411144	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.9	-8.35	-0.47	5.05e-15	Educational attainment (college completion);
KIRP	cis	rs259842	0.764	rs357711	chr2:180667840	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.34	-4.88	-0.3	1.91e-6	Blood protein levels;
KIRP	cis	rs11779988	0.545	rs422746	chr8:17784486	C/A	cg01800426	chr8:17659068	MTUS1	-0.58	-5.8	-0.35	1.99e-8	Breast cancer;
KIRP	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.44	5.75	0.34	2.66e-8	Blood metabolite levels;
KIRP	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15557168	chr22:42548783	NA	-0.45	-5.87	-0.35	1.39e-8	Cognitive function;
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg22907277	chr7:1156413	C7orf50	0.68	8.35	0.47	5.01e-15	Longevity;Endometriosis;
KIRP	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.43	-5.98	-0.36	7.73e-9	Monocyte count;
KIRP	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg20701182	chr2:24300061	SF3B14	0.6	5.3	0.32	2.59e-7	Lymphocyte counts;
KIRP	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.57	-7.42	-0.43	1.85e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg03388025	chr16:89894329	SPIRE2	-0.34	-6.29	-0.37	1.47e-9	Vitiligo;
KIRP	cis	rs73058052	1.000	rs73057994	chr19:50091273	C/A	cg09250473	chr19:50168907	IRF3;BCL2L12	0.64	7.18	0.42	8.23e-12	Fibrinogen levels;
KIRP	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.24	-0.37	1.9e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg06636001	chr8:8085503	FLJ10661	0.68	9.25	0.51	1.12e-17	Retinal vascular caliber;
KIRP	cis	rs311392	0.833	rs6473917	chr8:55090430	A/G	cg20636351	chr8:55087400	NA	-0.61	-7.49	-0.43	1.22e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg05785598	chr3:49045655	WDR6	0.28	5.08	0.31	7.59e-7	Parkinson's disease;
KIRP	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg04731861	chr2:219085781	ARPC2	0.2	5.08	0.31	7.5e-7	Colorectal cancer;
KIRP	cis	rs1620921	0.967	rs1247552	chr6:161187744	G/T	cg01280913	chr6:161186852	NA	-0.42	-6.0	-0.36	6.86e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs10491083	1.000	rs10491083	chr17:6558557	A/G	cg13067509	chr17:6538498	KIAA0753	0.69	6.98	0.41	2.76e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7033996	0.822	rs56383937	chr9:35912719	T/C	cg00918944	chr9:35908117	LOC158376	0.39	5.18	0.31	4.71e-7	Urate levels (BMI interaction);
KIRP	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.0	0.36	7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.77	9.6	0.52	1e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg06742321	chr12:123595122	PITPNM2	-0.44	-5.45	-0.33	1.19e-7	Platelet count;
KIRP	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg18944383	chr4:111397179	ENPEP	0.54	9.46	0.52	2.52e-18	Height;
KIRP	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg14580859	chr9:123691850	NA	0.36	5.15	0.31	5.36e-7	Rheumatoid arthritis;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg05315796	chr3:52349193	DNAH1	0.45	6.97	0.41	2.98e-11	Electroencephalogram traits;
KIRP	trans	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg16141378	chr3:129829833	LOC729375	0.51	6.28	0.37	1.54e-9	Mood instability;
KIRP	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	1.02	13.1	0.64	4.16e-30	IgG glycosylation;
KIRP	trans	rs79538733	1.000	rs3104056	chr10:71510039	A/G	cg15644727	chr11:116134539	NA	0.58	6.02	0.36	6.25e-9	Alzheimer disease and age of onset;
KIRP	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.58	8.87	0.49	1.49e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.63	0.39	2.1e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.55	-7.35	-0.42	3e-12	Blood metabolite levels;
KIRP	trans	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg01656853	chr19:49199172	FUT2	0.34	4.93	0.3	1.5e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs4862307	0.720	rs12650935	chr4:184989565	G/A	cg06737308	chr4:185021514	ENPP6	0.53	6.64	0.39	2.01e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs10073892	0.661	rs13358421	chr5:101651958	C/T	cg19774478	chr5:101632501	SLCO4C1	0.65	6.67	0.39	1.68e-10	Cognitive decline (age-related);
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg22907277	chr7:1156413	C7orf50	0.86	8.16	0.46	1.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg23307798	chr14:103986281	CKB	0.44	6.21	0.37	2.2e-9	Body mass index;
KIRP	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.73	7.7	0.44	3.24e-13	Vitiligo;
KIRP	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.9	11.46	0.59	1.16e-24	Homoarginine levels;
KIRP	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.72	8.1	0.46	2.61e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.58	-7.82	-0.45	1.53e-13	Dilated cardiomyopathy;
KIRP	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg03060546	chr3:49711283	APEH	-0.69	-6.93	-0.4	3.7e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.75	-0.4	1.07e-10	Neuroticism;
KIRP	cis	rs2574975	0.679	rs2255853	chr10:52131941	C/T	cg10034176	chr10:52120283	SGMS1	-0.53	-7.22	-0.42	6.53e-12	Response to amphetamines;
KIRP	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.69	-7.17	-0.42	8.49e-12	Diabetic retinopathy;
KIRP	cis	rs7175404	0.583	rs12592543	chr15:94076455	G/A	cg23502883	chr15:93959149	NA	0.49	4.9	0.3	1.7e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs17030434	0.784	rs17370965	chr4:154650948	C/T	cg14289246	chr4:154710475	SFRP2	-0.63	-7.65	-0.44	4.48e-13	Electrocardiographic conduction measures;
KIRP	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg04132472	chr17:19861366	AKAP10	0.5	7.16	0.42	9.02e-12	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.74	-5.43	-0.33	1.36e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3733418	0.929	rs7657444	chr4:165886559	G/C	cg10852876	chr4:165953100	TRIM60	-0.51	-5.69	-0.34	3.64e-8	Obesity-related traits;
KIRP	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.72	8.83	0.49	1.96e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs8002861	0.515	rs9525846	chr13:44390857	A/G	cg17145862	chr1:211918768	LPGAT1	-0.7	-9.06	-0.5	4.05e-17	Leprosy;
KIRP	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	8.26	0.47	9.09e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4654899	0.931	rs10799679	chr1:21341776	A/G	cg05370193	chr1:21551575	ECE1	0.4	5.34	0.32	2.15e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7267005	0.661	rs7272885	chr20:34227153	A/C	cg17201900	chr20:34330562	RBM39	1.11	6.08	0.36	4.48e-9	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg00262122	chr8:11665843	FDFT1	0.44	5.51	0.33	9.16e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg04539111	chr16:67997858	SLC12A4	0.56	4.95	0.3	1.37e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs73198271	1.000	rs4840356	chr8:8607527	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-5.91	-0.35	1.16e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11734570	0.581	rs73811714	chr4:38588327	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.56	5.71	0.34	3.2e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg04780086	chr2:111875790	ACOXL	0.47	6.48	0.38	4.98e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.8	11.04	0.58	2.76e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.66	7.72	0.44	2.9e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg03060546	chr3:49711283	APEH	0.44	5.81	0.35	1.9e-8	Parkinson's disease;
KIRP	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.86	12.75	0.63	6.15e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19717773	chr7:2847554	GNA12	-0.38	-5.8	-0.35	2.03e-8	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25643782	chr11:118978198	C2CD2L	-0.45	-6.16	-0.37	2.9e-9	Metabolic traits;
KIRP	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg01147727	chr14:105363015	KIAA0284	-0.45	-5.85	-0.35	1.52e-8	IgG glycosylation;
KIRP	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27297192	chr10:134578999	INPP5A	0.62	7.92	0.45	8.12e-14	Migraine;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.59	8.85	0.49	1.78e-16	Lung cancer;
KIRP	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.88	-0.35	1.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.39	5.08	0.31	7.59e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-8.13	-0.46	2.13e-14	Personality dimensions;
KIRP	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg26876637	chr1:152193138	HRNR	-0.72	-9.7	-0.53	4.9e-19	Atopic dermatitis;
KIRP	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg17264618	chr3:40429014	ENTPD3	-0.34	-5.28	-0.32	2.81e-7	Renal cell carcinoma;
KIRP	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	1.05	13.2	0.64	1.89e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg26876637	chr1:152193138	HRNR	0.71	9.65	0.52	7.04e-19	Atopic dermatitis;
KIRP	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg00800038	chr16:89945340	TCF25	-0.66	-5.42	-0.33	1.4e-7	Skin colour saturation;
KIRP	cis	rs6546886	0.957	rs4853005	chr2:74258049	G/C	cg14702570	chr2:74259524	NA	-0.33	-6.74	-0.39	1.1e-10	Dialysis-related mortality;
KIRP	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.47	6.07	0.36	4.88e-9	Menopause (age at onset);
KIRP	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.62	-6.72	-0.39	1.28e-10	DNA methylation (variation);
KIRP	cis	rs3733418	0.929	rs13149738	chr4:165905697	T/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.5	-4.96	-0.3	1.3e-6	Obesity-related traits;
KIRP	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.73	9.42	0.51	3.55e-18	Coronary artery disease;
KIRP	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.88	11.27	0.58	4.94e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.48	-4.99	-0.3	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.93	13.37	0.65	5.21e-31	Coronary artery disease;
KIRP	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.68	8.81	0.49	2.27e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.7	9.68	0.53	5.52e-19	Plateletcrit;Platelet count;
KIRP	cis	rs1014246	0.541	rs887195	chr10:118507976	G/A	cg14919929	chr10:118506882	NA	-0.88	-12.79	-0.63	4.51e-29	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs12580194	0.630	rs60586348	chr12:55745151	A/T	cg11794356	chr12:55725991	OR6C3	-0.53	-7.09	-0.41	1.41e-11	Cancer;
KIRP	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg18357645	chr12:58087776	OS9	0.68	8.68	0.48	5.48e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4638749	0.501	rs1000173	chr2:108762878	A/G	cg25838818	chr2:108905173	SULT1C2	-0.34	-5.01	-0.3	1.05e-6	Blood pressure;
KIRP	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg00629941	chr15:75287862	SCAMP5	-0.51	-5.36	-0.32	1.9e-7	Blood trace element (Zn levels);
KIRP	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.39	-5.52	-0.33	8.6e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	10.38	0.55	3.66e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6594499	0.872	rs6881147	chr5:110451936	G/C	cg04022379	chr5:110408740	TSLP	0.49	7.37	0.43	2.52e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg16341495	chr8:142228727	SLC45A4	-0.4	-4.93	-0.3	1.5e-6	Immature fraction of reticulocytes;
KIRP	cis	rs6973256	0.828	rs62471409	chr7:133371246	C/T	cg10665199	chr7:133106180	EXOC4	-0.5	-5.83	-0.35	1.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6546324	0.625	rs2861681	chr2:67830139	A/G	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.7e-13	Endometriosis;
KIRP	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.81	-13.06	-0.64	5.7e-30	Heart rate;
KIRP	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.63	-9.32	-0.51	6.93e-18	Heart rate;
KIRP	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	1.1	12.0	0.61	1.94e-26	Corneal structure;
KIRP	cis	rs11874712	0.623	rs3753069	chr18:43678035	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.38	-5.55	-0.33	7.42e-8	Migraine - clinic-based;
KIRP	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.55	-0.39	3.34e-10	Joint mobility (Beighton score);
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.46	6.54	0.38	3.56e-10	Lymphocyte counts;
KIRP	cis	rs1723838	0.510	rs17132534	chr11:73691774	A/G	cg10064339	chr11:73693792	UCP2	0.74	5.6	0.34	5.71e-8	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02858413	chr17:38474509	RARA	-0.5	-6.72	-0.39	1.27e-10	Metabolic traits;
KIRP	cis	rs13361707	0.920	rs10071679	chr5:40743061	G/A	cg01087697	chr5:40835557	RPL37	-0.49	-5.57	-0.33	6.64e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2267137	0.776	rs2267145	chr22:29805407	C/T	cg07256473	chr22:29710276	RASL10A	-0.38	-5.84	-0.35	1.67e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22399232	chr2:33824342	FAM98A	0.49	6.9	0.4	4.43e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.65	7.35	0.42	2.86e-12	Body mass index;
KIRP	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.71	-10.56	-0.56	9.75e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg06636001	chr8:8085503	FLJ10661	-0.81	-11.51	-0.59	8.3e-25	Triglycerides;
KIRP	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg21360079	chr12:107162445	NA	-0.68	-9.44	-0.52	3.01e-18	Heart rate;
KIRP	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.28e-7	Schizophrenia;
KIRP	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg05973401	chr12:123451056	ABCB9	0.57	6.53	0.38	3.76e-10	Neutrophil percentage of white cells;
KIRP	cis	rs6832769	0.961	rs3805147	chr4:56306730	C/T	cg09317128	chr4:56265301	TMEM165	0.54	6.94	0.4	3.37e-11	Personality dimensions;
KIRP	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	16.09	0.72	2.72e-40	Electrocardiographic conduction measures;
KIRP	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.77e-10	Protein C levels;
KIRP	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	5.72	0.34	3.11e-8	Iron status biomarkers;
KIRP	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07570687	chr10:102243282	WNT8B	0.5	6.48	0.38	5.07e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.42	-0.47	3.08e-15	Morning vs. evening chronotype;
KIRP	cis	rs4148660	1.000	rs4148650	chr12:22069114	G/T	cg14669847	chr12:22099120	NA	0.33	5.63	0.34	5e-8	Gout;
KIRP	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg04132472	chr17:19861366	AKAP10	0.38	4.85	0.3	2.22e-6	Schizophrenia;
KIRP	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.88	-0.53	1.32e-19	Hemoglobin concentration;
KIRP	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.69	9.69	0.53	5.08e-19	Blood protein levels;
KIRP	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.88	6.62	0.39	2.25e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	5.86	0.35	1.46e-8	Schizophrenia;
KIRP	cis	rs3126085	0.515	rs11204995	chr1:152359168	C/T	cg26876637	chr1:152193138	HRNR	-0.54	-6.93	-0.4	3.6e-11	Atopic dermatitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25847484	chr1:47069653	MKNK1	0.52	6.52	0.38	3.89e-10	Parkinson's disease;
KIRP	trans	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg10756647	chr7:56101905	PSPH	1.08	8.57	0.48	1.15e-15	Diabetic kidney disease;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.69	11.88	0.6	4.95e-26	Cardiovascular disease risk factors;
KIRP	cis	rs12143943	0.866	rs12030639	chr1:204530924	C/T	cg20240347	chr1:204465584	NA	-0.35	-6.24	-0.37	1.88e-9	Cognitive performance;
KIRP	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.36	-0.32	1.92e-7	Aortic root size;
KIRP	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24830367	chr12:108083606	PWP1	0.54	6.74	0.39	1.14e-10	Interleukin-4 levels;
KIRP	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.03	-11.57	-0.59	5.19e-25	Response to antipsychotic treatment;
KIRP	cis	rs921943	0.881	rs6877698	chr5:78319710	C/G	cg26802063	chr5:78281964	ARSB	0.48	5.91	0.35	1.12e-8	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg23649088	chr2:200775458	C2orf69	-0.6	-5.39	-0.32	1.69e-7	Schizophrenia;
KIRP	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.39	5.04	0.31	9.13e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs9853921	0.564	rs1880115	chr3:117983768	T/C	cg15509235	chr3:117715573	NA	-0.33	-4.99	-0.3	1.13e-6	JT interval (sulfonylurea treatment interaction);
KIRP	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.38	-0.62	1.12e-27	Exhaled nitric oxide output;
KIRP	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg07810366	chr2:100720526	AFF3	-0.37	-6.8	-0.4	7.96e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.47	5.76	0.34	2.48e-8	Common traits (Other);
KIRP	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.86	-0.35	1.51e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg09695851	chr17:3907499	NA	-0.81	-14.69	-0.68	1.7000000000000001e-35	Type 2 diabetes;
KIRP	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg06115741	chr20:33292138	TP53INP2	0.4	5.31	0.32	2.43e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg23625390	chr15:77176239	SCAPER	-0.53	-6.99	-0.41	2.59e-11	Blood metabolite levels;
KIRP	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	trans	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg24644049	chr4:85504048	CDS1	1.03	6.73	0.39	1.15e-10	Skin colour saturation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01279709	chr13:28196083	POLR1D;LNX2	0.58	6.74	0.39	1.1e-10	Smoking initiation;
KIRP	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg14664628	chr15:75095509	CSK	0.56	6.09	0.36	4.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs714515	0.835	rs2001127	chr1:172361516	C/T	cg01573306	chr1:172330400	DNM3	0.38	4.88	0.3	1.92e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg14061069	chr19:46274453	DMPK	0.72	12.91	0.64	1.87e-29	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.02	0.36	6.19e-9	Menopause (age at onset);
KIRP	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg04374321	chr14:90722782	PSMC1	-0.83	-11.94	-0.61	3.19e-26	Mortality in heart failure;
KIRP	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.72	0.34	3.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4683702	0.896	rs62278541	chr3:142631909	A/G	cg22826874	chr3:142608218	PCOLCE2	-0.37	-5.47	-0.33	1.12e-7	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.48e-6	Life satisfaction;
KIRP	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.45	-5.7	-0.34	3.41e-8	Blood metabolite levels;
KIRP	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.76	0.71	3.8e-39	Chronic sinus infection;
KIRP	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.63	-8.79	-0.49	2.63e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.13	-0.5	2.6e-17	Retinal vascular caliber;
KIRP	cis	rs6142102	1.000	rs6059681	chr20:32723341	T/C	cg24642439	chr20:33292090	TP53INP2	0.55	6.05	0.36	5.37e-9	Skin pigmentation;
KIRP	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	trans	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg09125723	chr2:122096106	CLASP1	-0.53	-6.53	-0.38	3.81e-10	Protein C levels;
KIRP	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.7	-8.87	-0.49	1.56e-16	Response to temozolomide;
KIRP	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg21905437	chr5:178450457	ZNF879	-0.49	-5.7	-0.34	3.43e-8	Pubertal anthropometrics;
KIRP	cis	rs447921	0.861	rs56248611	chr17:74448255	G/A	cg16776035	chr17:74542680	NA	-0.61	-4.96	-0.3	1.33e-6	Mitochondrial DNA levels;
KIRP	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	9.16	0.5	2.13e-17	Smoking behavior;
KIRP	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.93	-0.3	1.48e-6	Retinal vascular caliber;
KIRP	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg04917615	chr1:193074429	GLRX2	0.53	6.56	0.39	3.1e-10	Educational attainment;
KIRP	cis	rs6832769	0.961	rs7684810	chr4:56352794	C/T	cg09317128	chr4:56265301	TMEM165	0.52	6.49	0.38	4.74e-10	Personality dimensions;
KIRP	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.63	7.61	0.44	5.99e-13	Obesity-related traits;
KIRP	cis	rs2483058	0.739	rs3860302	chr1:206624643	C/G	cg19452316	chr1:206680966	RASSF5	0.41	5.53	0.33	7.98e-8	Cholesterol and Triglycerides;
KIRP	trans	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03602288	chr17:46641863	HOXB3	0.45	6.16	0.37	2.9e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.24e-8	Life satisfaction;
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.65	-0.34	4.33e-8	Life satisfaction;
KIRP	cis	rs4236601	1.000	rs62469005	chr7:116155968	A/G	cg05166801	chr7:116143459	CAV2	0.5	6.08	0.36	4.48e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.82	0.49	2.21e-16	Eosinophil percentage of white cells;
KIRP	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg10761708	chr20:43804764	PI3	0.52	5.47	0.33	1.09e-7	Blood protein levels;
KIRP	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg25797454	chr6:150327115	RAET1K	0.32	5.94	0.35	9.46e-9	Alopecia areata;
KIRP	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.6	-7.8	-0.45	1.77e-13	Hip circumference;
KIRP	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg07636037	chr3:49044803	WDR6	0.94	10.56	0.56	9.57e-22	Menarche (age at onset);
KIRP	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.51	5.72	0.34	3.05e-8	Diisocyanate-induced asthma;
KIRP	cis	rs7215564	0.730	rs34579757	chr17:78700077	G/A	cg08454507	chr17:78755406	RPTOR	0.33	5.12	0.31	6.3e-7	Myopia (pathological);
KIRP	cis	rs9303542	0.559	rs1042822	chr17:46620095	G/T	cg05487507	chr17:46671861	LOC404266;HOXB5	0.42	4.84	0.3	2.25e-6	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs6142102	1.000	rs2378078	chr20:32714728	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	4.98	0.3	1.18e-6	Skin pigmentation;
KIRP	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.3	-6.02	-0.36	6.21e-9	Schizophrenia;
KIRP	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.73	9.27	0.51	9.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-0.88	-12.62	-0.63	1.7e-28	Dupuytren's disease;
KIRP	trans	rs62056376	0.736	rs62054939	chr17:32645165	T/C	cg12726354	chr15:28342256	OCA2	-0.54	-6.04	-0.36	5.76e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.61	-8.73	-0.49	3.96e-16	Bipolar disorder;
KIRP	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.49e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6973256	0.865	rs2909225	chr7:133331952	C/T	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3766606	0.505	rs72633047	chr1:7935440	G/A	cg26816564	chr1:7831052	VAMP3	0.58	4.85	0.3	2.2e-6	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.72	13.55	0.65	1.26e-31	Body mass index;
KIRP	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.47	6.12	0.36	3.64e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.66	-9.71	-0.53	4.43e-19	Calcium levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03041046	chr12:53473136	SPRYD3	0.45	6.13	0.36	3.46e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg24296786	chr1:45957014	TESK2	0.53	6.31	0.37	1.27e-9	Homocysteine levels;
KIRP	cis	rs710987	1.000	rs710986	chr5:3529660	C/T	cg14530963	chr5:3489551	NA	-0.4	-4.89	-0.3	1.82e-6	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg24375607	chr4:120327624	NA	0.39	4.85	0.3	2.17e-6	Diastolic blood pressure;
KIRP	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.1	18.65	0.77	5.42e-49	Cortisol levels (saliva);
KIRP	cis	rs7572644	0.679	rs4447576	chr2:28076248	T/C	cg27432699	chr2:27873401	GPN1	0.48	5.78	0.35	2.26e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.61	-9.95	-0.54	7.88e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg00343986	chr7:65444356	GUSB	0.49	5.9	0.35	1.2e-8	Aortic root size;
KIRP	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.37	0.32	1.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs56146971	0.714	rs55709253	chr14:91853363	T/C	cg10511902	chr14:91842949	CCDC88C	0.53	5.89	0.35	1.27e-8	Alzheimer disease and age of onset;
KIRP	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg21419209	chr3:44054225	NA	-0.73	-9.05	-0.5	4.45e-17	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01519350	chr3:137906342	ARMC8	0.55	6.33	0.37	1.14e-9	Smoking initiation;
KIRP	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.24	0.51	1.22e-17	Colorectal cancer;
KIRP	trans	rs7951870	1.000	rs1489192	chr11:46509344	T/C	cg01183821	chr12:46123850	ARID2	-0.63	-6.16	-0.37	3e-9	Schizophrenia;
KIRP	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg05791153	chr7:19748676	TWISTNB	0.59	5.84	0.35	1.67e-8	Thyroid stimulating hormone;
KIRP	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg04362960	chr10:104952993	NT5C2	0.63	7.09	0.41	1.41e-11	Arsenic metabolism;
KIRP	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg03060546	chr3:49711283	APEH	-0.7	-5.07	-0.31	7.85e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10150615	chr22:24372951	LOC391322	-0.41	-5.04	-0.31	9.12e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.11	-15.83	-0.71	2.14e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7719624	0.692	rs2237065	chr5:135367220	C/T	cg16684184	chr5:135415129	NA	-0.39	-5.97	-0.36	8.02e-9	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.56	7.38	0.43	2.37e-12	Obesity-related traits;
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.7	9.55	0.52	1.33e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg11833968	chr6:79620685	NA	-0.47	-7.05	-0.41	1.83e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs514024	0.672	rs578997	chr9:130489189	C/T	cg13643465	chr9:130375613	STXBP1	0.43	5.76	0.34	2.51e-8	Eating disorders (purging via substances);
KIRP	trans	rs933360	0.585	rs11238315	chr7:50835549	A/G	cg20003124	chr12:4557277	NA	0.53	6.46	0.38	5.69e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00290607	chr11:67383545	NA	0.36	5.15	0.31	5.37e-7	Mean corpuscular volume;
KIRP	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.03e-12	Bipolar disorder;
KIRP	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg13180566	chr4:1052158	NA	-0.54	-5.43	-0.33	1.36e-7	Recombination rate (females);
KIRP	cis	rs6681460	1.000	rs6656912	chr1:67083671	A/G	cg02459107	chr1:67143332	SGIP1	0.46	6.19	0.37	2.47e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-6.86	-0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.5	5.89	0.35	1.25e-8	Metabolite levels;
KIRP	cis	rs4805272	1.000	rs888827	chr19:29325356	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.27	-0.32	2.96e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.75	-10.57	-0.56	9.15e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.61	8.4	0.47	3.54e-15	Lymphocyte counts;
KIRP	cis	rs17123764	0.892	rs56737983	chr12:50138465	T/G	cg20471783	chr12:50157085	TMBIM6	0.42	5.47	0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.67	8.58	0.48	1.07e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Colorectal cancer;
KIRP	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg25019033	chr10:957182	NA	-0.61	-6.41	-0.38	7.42e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs10940138	0.501	rs6898808	chr5:67249637	T/G	ch.5.1281357F	chr5:67228439	NA	-0.5	-7.4	-0.43	2.19e-12	Menarche (age at onset);
KIRP	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg10756647	chr7:56101905	PSPH	0.9	7.06	0.41	1.65e-11	Diabetic kidney disease;
KIRP	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	6.22	0.37	2.1e-9	Schizophrenia;
KIRP	cis	rs6746896	0.734	rs7608661	chr2:97459920	A/G	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.49	-0.43	1.2e-12	Bipolar disorder;
KIRP	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.81	0.45	1.63e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1345301	1.000	rs1345301	chr2:102875587	A/G	cg12451869	chr2:102867685	NA	0.39	5.7	0.34	3.37e-8	Waist circumference;
KIRP	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.78	10.79	0.57	1.83e-22	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.71	-9.76	-0.53	3.19e-19	Plateletcrit;Platelet count;
KIRP	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.37e-8	Motion sickness;
KIRP	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3007168	1.000	rs3007068	chr14:51597196	T/C	cg23942311	chr14:51606299	NA	0.48	5.09	0.31	7.14e-7	Cancer;
KIRP	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs7715811	1.000	rs7446025	chr5:13773800	T/A	cg07548982	chr5:13769939	DNAH5	-0.54	-6.63	-0.39	2.05e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs2273156	1.000	rs7141293	chr14:35462910	T/A	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.39	-0.33	1.64e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg05669848	chr5:237993	SDHA	-0.5	-5.19	-0.31	4.39e-7	Breast cancer;
KIRP	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg13206674	chr6:150067644	NUP43	0.52	7.4	0.43	2.17e-12	Testicular germ cell tumor;
KIRP	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg22532475	chr10:104410764	TRIM8	-0.29	-5.02	-0.3	1e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.29e-16	Prudent dietary pattern;
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18918831	chr3:195489782	MUC4	0.7	6.49	0.38	4.68e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.48	-9.73	-0.53	3.9e-19	Longevity;
KIRP	cis	rs2391754	0.596	rs3793300	chr7:29339788	C/T	cg00901138	chr7:29329370	CHN2	-0.42	-5.32	-0.32	2.32e-7	CSF tryptophan concentration in tuberculous meningitis;
KIRP	cis	rs9308433	0.553	rs11120299	chr1:214509407	C/A	cg06198575	chr1:214491504	SMYD2	0.46	5.81	0.35	1.9e-8	IgG glycosylation;
KIRP	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-9.05	-0.5	4.45e-17	Resting heart rate;
KIRP	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg04236735	chr4:71658722	RUFY3	-0.47	-6.47	-0.38	5.13e-10	Select biomarker traits;
KIRP	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.72	10.14	0.54	2.01e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg23188430	chr6:125850052	NA	-0.34	-5.32	-0.32	2.38e-7	Brugada syndrome;
KIRP	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg18586891	chr4:952366	TMEM175	0.62	5.53	0.33	8.14e-8	Parkinson's disease;
KIRP	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.72	-8.69	-0.48	5.26e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg06740227	chr12:86229804	RASSF9	0.44	5.58	0.34	6.37e-8	Major depressive disorder;
KIRP	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-4.86	-0.3	2.07e-6	Mean platelet volume;
KIRP	cis	rs732505	1.000	rs4807790	chr19:5584614	A/G	cg26242866	chr19:5711310	LONP1	0.69	5.04	0.31	9.22e-7	vWF and FVIII levels;
KIRP	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg24241305	chr13:114826075	RASA3	-0.84	-8.87	-0.49	1.5e-16	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg25706552	chr1:244017396	NA	0.57	6.61	0.39	2.43e-10	RR interval (heart rate);
KIRP	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.82	12.28	0.62	2.41e-27	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08882882	chr6:84937375	KIAA1009	-0.44	-6.16	-0.37	2.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4664293	0.867	rs3771718	chr2:160636908	A/G	cg08347373	chr2:160653686	CD302	-0.42	-6.43	-0.38	6.58e-10	Monocyte percentage of white cells;
KIRP	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg02503808	chr4:7069936	GRPEL1	0.45	5.92	0.35	1.09e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.72	-0.34	3.13e-8	Bipolar disorder;
KIRP	cis	rs4236601	1.000	rs10281637	chr7:116151338	T/C	cg05166801	chr7:116143459	CAV2	0.48	5.72	0.34	3.1e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.46	5.83	0.35	1.75e-8	Recombination rate (males);
KIRP	cis	rs10267417	0.603	rs10226787	chr7:19946542	A/G	cg05791153	chr7:19748676	TWISTNB	0.51	5.12	0.31	6.3e-7	Night sleep phenotypes;
KIRP	cis	rs78487399	0.710	rs7561114	chr2:43701951	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.02	-0.3	9.94e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs787274	0.867	rs786978	chr9:115460239	A/G	cg13803584	chr9:115635662	SNX30	-0.58	-7.17	-0.42	8.8e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg07810366	chr2:100720526	AFF3	-0.4	-7.16	-0.42	9.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2926702	0.810	rs11776606	chr8:71320297	C/A	cg21651000	chr8:71129472	NCOA2	-0.49	-5.05	-0.31	8.45e-7	Non-small cell lung cancer;
KIRP	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.75	9.23	0.51	1.32e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.09	-0.31	7.09e-7	Life satisfaction;
KIRP	cis	rs10832963	1.000	rs10832963	chr11:18664241	T/G	cg09201001	chr11:18656081	SPTY2D1	0.94	14.38	0.68	1.94e-34	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01573732	chr11:47236904	DDB2	0.48	6.34	0.37	1.1e-9	Parkinson's disease;
KIRP	cis	rs4006360	0.628	rs6416911	chr17:39253311	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.59	-8.19	-0.46	1.41e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg10755058	chr3:40428713	ENTPD3	-0.43	-6.31	-0.37	1.32e-9	Renal cell carcinoma;
KIRP	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg18709589	chr6:96969512	KIAA0776	-0.39	-5.08	-0.31	7.64e-7	Migraine;Coronary artery disease;
KIRP	cis	rs1950626	0.833	rs1951025	chr14:101406022	T/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.83	0.4	6.72e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.75	-0.34	2.7e-8	Glomerular filtration rate;
KIRP	cis	rs35892873	0.920	rs3890851	chr3:126093700	G/T	cg15490784	chr3:126061950	KLF15	0.52	6.57	0.39	2.95e-10	Male-pattern baldness;
KIRP	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.81	7.21	0.42	6.94e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.61	5.86	0.35	1.45e-8	Plateletcrit;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10561989	chr14:35408569	C14orf19	0.52	6.56	0.39	3.13e-10	Interleukin-4 levels;
KIRP	cis	rs9296736	0.890	rs9370258	chr6:53910988	T/G	cg04374786	chr6:53939321	C6orf142	0.39	5.18	0.31	4.64e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg01864069	chr14:103024347	NA	0.99	13.29	0.65	9.95e-31	Platelet count;
KIRP	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.94	-0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg09990169	chr2:241835740	C2orf54	-0.45	-6.23	-0.37	1.96e-9	Urinary metabolites;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08330404	chr6:166419593	NA	0.46	6.27	0.37	1.61e-9	Parkinson's disease;
KIRP	cis	rs8133932	0.654	rs375971	chr21:47338854	C/G	cg11214348	chr21:47283868	PCBP3	-0.47	-5.38	-0.32	1.76e-7	Schizophrenia;
KIRP	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg27494647	chr7:150038898	RARRES2	0.41	6.34	0.37	1.09e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	1.08	17.56	0.75	2.67e-45	Cognitive function;
KIRP	cis	rs11191270	0.554	rs3781293	chr10:104166257	T/C	cg15320455	chr10:103880129	LDB1	0.87	6.66	0.39	1.76e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg18306943	chr3:40428807	ENTPD3	0.45	5.78	0.35	2.25e-8	Renal cell carcinoma;
KIRP	cis	rs1062746	0.502	rs76128303	chr16:87339236	T/C	cg02258303	chr16:87377426	FBXO31	-0.41	-5.13	-0.31	5.85e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs798766	0.909	rs11724531	chr4:1753424	A/G	cg07775547	chr4:1625484	NA	-0.45	-5.28	-0.32	2.82e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	10.08	0.54	3.1e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg15655495	chr12:38532458	NA	0.27	5.23	0.32	3.66e-7	Bladder cancer;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	1.11	21.45	0.81	2.87e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg16346588	chr10:242978	ZMYND11	-0.42	-5.05	-0.31	8.62e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg03959625	chr15:84868606	LOC388152	-0.63	-7.04	-0.41	1.86e-11	Schizophrenia;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.58	7.77	0.44	2.07e-13	Longevity;
KIRP	cis	rs10267417	0.603	rs10243346	chr7:19862365	G/A	cg05791153	chr7:19748676	TWISTNB	0.55	5.25	0.32	3.3e-7	Night sleep phenotypes;
KIRP	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-9.5	-0.52	1.95e-18	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-9.14	-0.5	2.36e-17	Platelet count;
KIRP	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.65	0.48	6.69e-16	Prudent dietary pattern;
KIRP	trans	rs12517041	1.000	rs2081953	chr5:23295682	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs1318878	0.565	rs12317051	chr12:15428939	A/G	cg08258403	chr12:15378311	NA	0.36	5.1	0.31	6.93e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg04058563	chr4:185651563	MLF1IP	-0.5	-6.88	-0.4	4.91e-11	Kawasaki disease;
KIRP	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.38	-4.89	-0.3	1.84e-6	Mean platelet volume;
KIRP	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg01475377	chr6:109611718	NA	0.36	4.93	0.3	1.51e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05845435	chr10:25273116	ENKUR	-0.39	-6.14	-0.36	3.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2882667	0.824	rs13189485	chr5:138475401	C/T	cg04439458	chr5:138467593	SIL1	-0.52	-7.72	-0.44	2.9e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.88e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.67	-7.91	-0.45	8.79e-14	Blood protein levels;
KIRP	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg07843065	chr1:150265600	MRPS21	0.41	5.33	0.32	2.17e-7	Migraine;
KIRP	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg11211951	chr8:145729740	GPT	0.45	7.27	0.42	4.75e-12	Age at first birth;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg11410718	chr7:27170412	HOXA4	-0.46	-6.23	-0.37	1.96e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg00677455	chr12:58241039	CTDSP2	-0.53	-6.47	-0.38	5.35e-10	Multiple sclerosis;
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg01324507	chr7:1177794	C7orf50	0.51	4.99	0.3	1.13e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg10755058	chr3:40428713	ENTPD3	0.47	6.57	0.39	3.01e-10	Renal cell carcinoma;
KIRP	cis	rs7175404	0.793	rs6497079	chr15:94033348	C/T	cg23502883	chr15:93959149	NA	0.47	5.52	0.33	8.4e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.85	12.89	0.63	2.21e-29	Height;
KIRP	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg25356066	chr3:128598488	ACAD9	0.52	5.97	0.36	8.35e-9	IgG glycosylation;
KIRP	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg26531700	chr6:26746687	NA	0.45	6.05	0.36	5.5e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.31	-0.37	1.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15286784	chr20:47895175	C20orf199;SNORD12C;ZNFX1	0.98	6.4	0.38	7.86e-10	P wave terminal force;
KIRP	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-6.86	-0.4	5.47e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.1	0.69	6.82e-37	Platelet count;
KIRP	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-7.71	-0.44	3.2e-13	Monocyte percentage of white cells;
KIRP	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.44	-6.05	-0.36	5.5e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.29	13.07	0.64	5.15e-30	Diabetic retinopathy;
KIRP	cis	rs4073416	0.508	rs2898818	chr14:65972584	G/C	cg03016385	chr14:66212404	NA	-0.52	-6.27	-0.37	1.62e-9	N-glycan levels;
KIRP	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg23625390	chr15:77176239	SCAPER	0.56	7.45	0.43	1.54e-12	Blood metabolite levels;
KIRP	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.31e-34	Breast cancer;
KIRP	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg04989706	chr14:50066350	PPIL5	-0.49	-5.76	-0.34	2.44e-8	Carotid intima media thickness;
KIRP	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-6.23	-0.37	2.04e-9	Educational attainment (years of education);
KIRP	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.82	-10.04	-0.54	4.12e-20	Blood protein levels;
KIRP	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-1.2	-11.08	-0.58	2.01e-23	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.74	9.16	0.5	2.16e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.06	-0.36	5.19e-9	Response to antipsychotic treatment;
KIRP	cis	rs7224685	0.548	rs17710668	chr17:3880546	C/G	cg17441377	chr17:3906640	NA	0.49	5.04	0.31	9.1e-7	Type 2 diabetes;
KIRP	cis	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03270197	chr6:166796579	BRP44L	0.49	6.02	0.36	6.47e-9	Asthma;
KIRP	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.5	-0.33	9.56e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.85	-0.3	2.2e-6	Resting heart rate;
KIRP	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2851682	1.000	rs2845573	chr11:61601908	C/T	cg07689907	chr11:61582574	FADS1	-0.62	-4.89	-0.3	1.86e-6	Gestational age at birth (child effect);Trans fatty acid levels;
KIRP	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24473518	chr4:159816397	FNIP2;C4orf45	0.4	6.06	0.36	4.98e-9	C-reactive protein;
KIRP	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg05973401	chr12:123451056	ABCB9	0.66	7.97	0.45	5.76e-14	Platelet count;
KIRP	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	0.98	15.97	0.71	7e-40	Testicular germ cell tumor;
KIRP	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.89	12.6	0.63	2.07e-28	Morning vs. evening chronotype;
KIRP	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.41	-5.68	-0.34	3.84e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.5	7.25	0.42	5.37e-12	Schizophrenia;
KIRP	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.49	-8.04	-0.46	3.9e-14	Longevity;
KIRP	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.41	-0.59	1.76e-24	Monocyte count;
KIRP	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg02375832	chr11:62437615	C11orf48	-0.41	-5.16	-0.31	5.18e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.03	0.61	1.66e-26	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19475689	chr2:28789802	PLB1	0.48	6.21	0.37	2.21e-9	Parkinson's disease;
KIRP	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg21734707	chr17:3908241	ZZEF1	0.63	9.46	0.52	2.59e-18	Type 2 diabetes;
KIRP	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg03647239	chr10:116582469	FAM160B1	0.52	5.96	0.36	8.71e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg04691961	chr3:161091175	C3orf57	-0.66	-10.72	-0.56	2.9e-22	Morning vs. evening chronotype;
KIRP	cis	rs1823913	0.599	rs55786000	chr2:192149226	A/G	cg12404831	chr2:192114017	MYO1B	0.52	7.27	0.42	4.69e-12	Obesity-related traits;
KIRP	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.87	12.47	0.62	5.48e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg14458575	chr2:238380390	NA	0.6	6.45	0.38	5.96e-10	Prostate cancer;
KIRP	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg08501292	chr6:25962987	TRIM38	1.03	8.22	0.46	1.18e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg22681709	chr2:178499509	PDE11A	-0.69	-9.69	-0.53	5.25e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg11693508	chr17:37793320	STARD3	0.81	8.12	0.46	2.24e-14	Neuroticism;
KIRP	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg24972876	chr7:65420302	NA	0.4	5.56	0.33	7.19e-8	Calcium levels;
KIRP	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg06212747	chr3:49208901	KLHDC8B	0.69	8.14	0.46	2e-14	Menarche (age at onset);
KIRP	cis	rs7560272	0.588	rs4852965	chr2:73911169	T/C	cg20560298	chr2:73613845	ALMS1	0.5	6.23	0.37	2.05e-9	Schizophrenia;
KIRP	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg03959625	chr15:84868606	LOC388152	0.66	7.97	0.45	6.05e-14	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg01620082	chr3:125678407	NA	-1.21	-7.83	-0.45	1.46e-13	Depression;
KIRP	cis	rs490234	0.932	rs577026	chr9:128341023	C/T	cg14078157	chr9:128172775	NA	-0.43	-5.39	-0.32	1.67e-7	Mean arterial pressure;
KIRP	cis	rs300890	0.544	rs13136521	chr4:144205564	A/G	cg01719995	chr4:144104893	USP38	-0.43	-4.97	-0.3	1.23e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.22	0.37	2.08e-9	Lung cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27001534	chr5:443220	C5orf55;EXOC3	-0.44	-6.05	-0.36	5.43e-9	Metabolic traits;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07650554	chr16:30457408	SEPHS2	0.56	6.14	0.36	3.3e-9	Lung cancer in ever smokers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03065822	chr2:152266375	RIF1	0.43	6.02	0.36	6.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg14221460	chr8:27183342	PTK2B	-0.52	-6.72	-0.39	1.28e-10	Neuroticism;
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg07747251	chr5:1868357	NA	0.42	5.49	0.33	1.02e-7	Cardiovascular disease risk factors;
KIRP	cis	rs17023223	0.537	rs12086	chr1:119573860	T/C	cg18261050	chr1:119551319	NA	0.58	6.77	0.4	9.32e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02724401	chr12:78542637	NAV3	-0.44	-7.32	-0.42	3.53e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25018755	chr22:43506952	BIK	0.48	6.06	0.36	5.08e-9	Smoking initiation;
KIRP	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg14092571	chr14:90743983	NA	0.44	5.77	0.35	2.36e-8	Mortality in heart failure;
KIRP	cis	rs9843304	0.528	rs9860963	chr3:149197465	A/G	cg08667024	chr3:149219783	TM4SF4	0.57	8.74	0.49	3.6e-16	Gallstone disease;
KIRP	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg08992911	chr2:238395768	MLPH	0.55	5.31	0.32	2.44e-7	Prostate cancer;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00619915	chr2:44497795	NA	0.48	6.91	0.4	4.17e-11	Cancer;
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg01763666	chr17:80159506	CCDC57	-0.36	-5.05	-0.31	8.47e-7	Life satisfaction;
KIRP	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg17554472	chr22:41940697	POLR3H	-0.45	-5.56	-0.33	7.1e-8	Vitiligo;
KIRP	cis	rs35883536	0.967	rs4908091	chr1:101138171	G/A	cg06223162	chr1:101003688	GPR88	0.31	6.32	0.37	1.22e-9	Monocyte count;
KIRP	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.48	-5.45	-0.33	1.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1950626	0.577	rs61991118	chr14:101441974	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.54	6.15	0.36	3.15e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs832187	0.629	rs59971314	chr3:63914618	G/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.52	-5.98	-0.36	7.79e-9	Schizophrenia;
KIRP	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.62	-7.76	-0.44	2.23e-13	Dental caries;
KIRP	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.72	-6.19	-0.37	2.54e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.56e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-8.17	-0.46	1.59e-14	Coronary artery disease;
KIRP	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.62	-0.39	2.19e-10	Mood instability;
KIRP	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.46	-5.74	-0.34	2.78e-8	IgG glycosylation;
KIRP	cis	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg07585502	chr8:101912084	NA	-0.66	-8.45	-0.47	2.54e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02756545	chr1:94884060	ABCD3	0.63	7.46	0.43	1.47e-12	Smoking initiation;
KIRP	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.58	-0.8	2.03e-55	Height;
KIRP	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.67	-9.29	-0.51	8.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg11204139	chr17:3907470	NA	-0.81	-14.65	-0.68	2.28e-35	Type 2 diabetes;
KIRP	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.46	-5.55	-0.33	7.49e-8	Testicular germ cell tumor;
KIRP	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg14338887	chr6:42928500	GNMT	0.46	6.59	0.39	2.6e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs42648	0.935	rs42627	chr7:89961876	C/T	cg25739043	chr7:89950458	NA	-0.45	-7.11	-0.41	1.28e-11	Homocysteine levels;
KIRP	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7715811	1.000	rs2173980	chr5:13767116	A/T	cg07548982	chr5:13769939	DNAH5	-0.52	-6.32	-0.37	1.2e-9	Subclinical atherosclerosis traits (other);
KIRP	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg03388025	chr16:89894329	SPIRE2	0.3	5.65	0.34	4.46e-8	Vitiligo;
KIRP	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.53	6.87	0.4	5.37e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.65	7.88	0.45	1.03e-13	Coronary artery disease;
KIRP	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg26875233	chr11:93583750	C11orf90	-0.41	-7.73	-0.44	2.77e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg24826892	chr11:71159390	DHCR7	0.44	4.89	0.3	1.81e-6	Vitamin D levels;
KIRP	trans	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg06311355	chr22:24577269	SUSD2	-0.3	-6.12	-0.36	3.67e-9	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09511724	chr1:10804939	CASZ1	0.47	6.74	0.39	1.13e-10	Interleukin-4 levels;
KIRP	cis	rs7404928	1.000	rs7190694	chr16:23900245	G/C	cg21745164	chr16:23765304	CHP2	-0.5	-6.49	-0.38	4.79e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.38	-0.32	1.7e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.69	9.42	0.51	3.4e-18	Mean corpuscular volume;
KIRP	cis	rs6939532	0.648	rs9379862	chr6:26370707	T/C	cg14345882	chr6:26364793	BTN3A2	0.34	5.13	0.31	5.82e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.99	17.44	0.74	7.08e-45	Breast cancer;
KIRP	trans	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg00938859	chr5:1591904	SDHAP3	0.55	6.32	0.37	1.22e-9	Breast cancer;
KIRP	trans	rs7939886	0.841	rs10501349	chr11:56021284	G/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg22117172	chr7:91764530	CYP51A1	-0.44	-6.0	-0.36	6.84e-9	Breast cancer;
KIRP	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg11608241	chr8:8085544	FLJ10661	0.4	4.98	0.3	1.19e-6	Neuroticism;
KIRP	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg20487152	chr13:99095054	FARP1	0.39	5.65	0.34	4.39e-8	Educational attainment (years of education);
KIRP	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	6.68	0.39	1.61e-10	Mood instability;
KIRP	cis	rs12367572	0.501	rs7964644	chr12:45473723	A/G	cg04608330	chr12:45269318	NELL2	-0.43	-5.48	-0.33	1.08e-7	Gut microbiome composition (summer);
KIRP	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg03714773	chr7:91764589	CYP51A1	-0.34	-4.9	-0.3	1.72e-6	Breast cancer;
KIRP	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.61	0.39	2.43e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6541297	0.699	rs966333	chr1:230305477	T/C	cg05784532	chr1:230284198	GALNT2	0.44	5.54	0.33	7.86e-8	Coronary artery disease;
KIRP	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.67	-10.14	-0.54	2.1e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.87	-0.35	1.4e-8	Bipolar disorder;
KIRP	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg05361325	chr10:32636312	EPC1	-0.59	-5.63	-0.34	4.91e-8	Sexual dysfunction (female);
KIRP	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.45	6.32	0.37	1.19e-9	Dupuytren's disease;
KIRP	cis	rs7851660	0.809	rs7048255	chr9:100665698	A/G	cg13688889	chr9:100608707	NA	-0.68	-8.66	-0.48	6.18e-16	Strep throat;
KIRP	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-8.4	-0.47	3.49e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg08313168	chr12:7315531	NA	0.68	6.18	0.37	2.61e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg17264618	chr3:40429014	ENTPD3	-0.32	-5.02	-0.3	1.01e-6	Renal cell carcinoma;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25751266	chr3:38495385	LOC100128640;ACVR2B	-0.48	-6.08	-0.36	4.58e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg01081584	chr15:40268610	EIF2AK4	-0.56	-8.18	-0.46	1.56e-14	Response to haloperidol in psychosis;
KIRP	cis	rs6669919	0.933	rs10863899	chr1:211666218	A/G	cg10512769	chr1:211675356	NA	-0.67	-10.32	-0.55	5.63e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-5.69	-0.34	3.62e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg08501292	chr6:25962987	TRIM38	0.8	5.39	0.32	1.66e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-7.47	-0.43	1.39e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg02640540	chr1:67518911	SLC35D1	0.4	4.9	0.3	1.78e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs6968419	0.755	rs3807983	chr7:115898991	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.93	-0.35	1e-8	Intraocular pressure;
KIRP	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg16482183	chr6:26056742	HIST1H1C	0.66	7.65	0.44	4.68e-13	Height;
KIRP	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.43e-12	Obesity-related traits;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg19332832	chr2:153191675	FMNL2	0.47	6.36	0.38	9.76e-10	Cancer;
KIRP	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-1.01	-16.2	-0.72	1.16e-40	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.13	-0.31	5.83e-7	Inflammatory skin disease;
KIRP	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg09163369	chr1:210001066	C1orf107	0.64	7.2	0.42	7.44e-12	Orofacial clefts;
KIRP	cis	rs6546324	0.625	rs2861703	chr2:67861053	T/C	cg15745817	chr2:67799979	NA	-0.63	-6.98	-0.41	2.76e-11	Endometriosis;
KIRP	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.62	-0.66	7.52e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.78e-11	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.95e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12765107	chr7:90315680	NA	-0.42	-6.45	-0.38	6e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	cg12689670	chr1:183009347	LAMC1	0.58	8.07	0.46	3.15e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.64	-0.34	4.64e-8	Lung cancer;
KIRP	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.5	-6.12	-0.36	3.63e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.68	7.26	0.42	4.99e-12	Lymphocyte counts;
KIRP	cis	rs8044868	0.530	rs9932951	chr16:72075341	A/G	cg16558253	chr16:72132732	DHX38	-0.42	-5.64	-0.34	4.64e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	12.86	0.63	2.62e-29	Personality dimensions;
KIRP	cis	rs11785693	0.730	rs62489552	chr8:4956801	T/C	cg26367366	chr8:4980734	NA	0.56	4.93	0.3	1.53e-6	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs6091737	0.954	rs6022697	chr20:52343011	A/T	cg20178976	chr20:52357117	NA	-0.45	-5.43	-0.33	1.35e-7	Calcium levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16300524	chr1:46269324	MAST2	-0.46	-6.09	-0.36	4.4e-9	Metabolic traits;
KIRP	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg03060546	chr3:49711283	APEH	-0.62	-6.13	-0.36	3.55e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-6.87	-0.4	5.23e-11	Colorectal cancer;
KIRP	cis	rs7116495	1.000	rs1573502	chr11:71747428	C/T	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	5.25	0.32	3.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.59	6.51	0.38	4.12e-10	Aortic root size;
KIRP	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.67	-0.34	4.01e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.31	-0.37	1.29e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8093481	0.965	rs9957910	chr18:10690758	T/C	cg21165219	chr18:10698044	FAM38B	-0.46	-5.69	-0.34	3.53e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg00405596	chr8:11794950	NA	-0.43	-5.58	-0.34	6.44e-8	Triglycerides;
KIRP	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.83	-0.53	1.91e-19	Total body bone mineral density;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09938079	chr11:3862089	RHOG	-0.45	-6.04	-0.36	5.53e-9	Metabolic traits;
KIRP	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.62	8.77	0.49	3.04e-16	Schizophrenia;
KIRP	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.52	-6.77	-0.4	9.52e-11	Schizophrenia;
KIRP	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6707387	0.686	rs6435791	chr2:214570513	G/T	cg08319019	chr2:214017104	IKZF2	0.44	4.88	0.3	1.91e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs654128	0.640	rs339348	chr6:117220253	T/C	cg12892004	chr6:117198278	RFX6	-0.39	-5.15	-0.31	5.27e-7	Telomere length;
KIRP	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.49	6.31	0.37	1.29e-9	IgG glycosylation;
KIRP	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.25	-0.47	9.4e-15	Neuroticism;
KIRP	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.64	6.7	0.39	1.41e-10	Platelet distribution width;
KIRP	trans	rs78049276	0.688	rs56024659	chr4:148378604	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.77	-9.79	-0.53	2.61e-19	Pulse pressure;
KIRP	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.59	7.79	0.45	1.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03657573	chr3:182972326	MCF2L2;B3GNT5	0.48	6.12	0.36	3.57e-9	Parkinson's disease;
KIRP	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg21918786	chr6:109611834	NA	0.34	4.98	0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs2235573	0.805	rs59414277	chr22:38500126	C/T	cg19171272	chr22:38449367	NA	0.61	8.39	0.47	3.77e-15	Glioblastoma;Glioma;
KIRP	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg02151108	chr14:50098012	C14orf104	-0.47	-6.08	-0.36	4.51e-9	Carotid intima media thickness;
KIRP	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg11995313	chr8:8860691	ERI1	0.41	5.62	0.34	5.24e-8	Joint mobility (Beighton score);
KIRP	cis	rs2671245	1.000	rs2819479	chr1:56155251	A/C	cg11523071	chr1:56160889	NA	0.41	6.31	0.37	1.27e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.66	-9.86	-0.53	1.49e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18252515	chr7:66147081	NA	0.45	5.3	0.32	2.59e-7	Aortic root size;
KIRP	cis	rs240764	0.658	rs7753317	chr6:101220433	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs7582720	0.836	rs72938315	chr2:204121063	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.97	8.59	0.48	9.95e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.96	12.68	0.63	1.12e-28	Homoarginine levels;
KIRP	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.47	0.48	2.19e-15	IgG glycosylation;
KIRP	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.41	11.11	0.58	1.7e-23	Prostate cancer;
KIRP	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg04935436	chr20:30431758	NA	0.48	6.42	0.38	6.79e-10	Mean corpuscular volume;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09238106	chr11:64242796	NA	1.06	6.28	0.37	1.55e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.31e-11	Aortic root size;
KIRP	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.02	-16.16	-0.72	1.58e-40	Dilated cardiomyopathy;
KIRP	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.35	6.69	0.39	1.46e-10	Educational attainment (years of education);
KIRP	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.63	-0.34	4.91e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs372883	0.530	rs2832226	chr21:30532986	A/G	cg24692254	chr21:30365293	RNF160	-0.49	-5.91	-0.35	1.14e-8	Pancreatic cancer;
KIRP	cis	rs62355272	0.541	rs11955657	chr5:35920564	C/A	cg13894535	chr5:35919491	CAPSL	-0.39	-5.25	-0.32	3.23e-7	Lymphocyte counts;
KIRP	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg18882449	chr10:104885122	NT5C2	0.38	4.9	0.3	1.77e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.96	11.24	0.58	6.27e-24	Neuroticism;
KIRP	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg16988262	chr1:15930761	NA	0.39	4.99	0.3	1.12e-6	Systolic blood pressure;
KIRP	cis	rs3820928	0.709	rs10178202	chr2:227914561	C/T	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.13	-0.31	5.89e-7	Pulmonary function;
KIRP	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.46	-6.48	-0.38	4.87e-10	Coronary artery disease;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.54	6.89	0.4	4.75e-11	Menarche (age at onset);
KIRP	cis	rs10992471	0.528	rs10115290	chr9:95195858	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-4.97	-0.3	1.25e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10838532	1.000	rs10838532	chr11:45947464	C/G	cg24204282	chr11:45944920	GYLTL1B	0.39	4.92	0.3	1.61e-6	Axial length;
KIRP	cis	rs2151522	0.563	rs62439174	chr6:127204928	A/C	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	1.06	19.57	0.78	4.51e-52	Height;
KIRP	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06544989	chr22:39130855	UNC84B	0.43	6.77	0.4	9.54e-11	Menopause (age at onset);
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.6	8.78	0.49	2.9e-16	Menarche (age at onset);
KIRP	cis	rs12615966	1.000	rs17030284	chr2:105380921	A/G	cg16465502	chr2:105461796	NA	-0.56	-5.45	-0.33	1.2e-7	Pancreatic cancer;
KIRP	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.21	-0.32	4.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg04226714	chr8:49833948	SNAI2	-0.49	-6.44	-0.38	6.18e-10	Life satisfaction;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg20578329	chr17:80767326	TBCD	0.45	5.19	0.31	4.37e-7	Glycated hemoglobin levels;
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-1.05	-23.1	-0.83	1.43e-63	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9603616	0.719	rs4566029	chr13:40238387	T/C	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.56	-15.24	-0.7	2.15e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg17133734	chr15:86042851	AKAP13	-0.47	-5.93	-0.35	1e-8	Coronary artery disease;
KIRP	cis	rs3008870	0.727	rs2862729	chr1:67500828	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.6	7.94	0.45	7.41e-14	Lymphocyte percentage of white cells;
KIRP	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg04990556	chr1:26633338	UBXN11	0.66	6.14	0.36	3.26e-9	Obesity-related traits;
KIRP	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15874270	chr4:123161078	KIAA1109	0.47	6.98	0.41	2.66e-11	Survival in pancreatic cancer;
KIRP	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg17133734	chr15:86042851	AKAP13	0.45	5.56	0.33	6.91e-8	Interstitial lung disease;
KIRP	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg08859206	chr1:53392774	SCP2	0.49	6.45	0.38	5.99e-10	Monocyte count;
KIRP	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs1978968	0.912	rs5992932	chr22:18456254	C/T	cg03078520	chr22:18463400	MICAL3	-0.66	-7.65	-0.44	4.42e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.93	-11.6	-0.59	4.06e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-7.04	-0.41	1.93e-11	Mood instability;
KIRP	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg24375607	chr4:120327624	NA	0.48	5.61	0.34	5.47e-8	Educational attainment;
KIRP	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-7.39	-0.43	2.31e-12	Longevity;Endometriosis;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10476260	chr2:74682101	INO80B	-0.45	-6.28	-0.37	1.51e-9	Morning vs. evening chronotype;
KIRP	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.67	7.98	0.45	5.61e-14	Blood metabolite levels;
KIRP	trans	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg06521331	chr12:34319734	NA	-0.51	-6.35	-0.38	1.01e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.58	7.83	0.45	1.45e-13	Height;
KIRP	cis	rs3105593	1.000	rs62017189	chr15:50922032	T/A	cg05456662	chr15:50716270	USP8	0.42	5.14	0.31	5.54e-7	QT interval;
KIRP	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.82	-12.78	-0.63	5.15e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.78	10.61	0.56	6.53e-22	Coronary artery disease;
KIRP	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg26408565	chr15:76604113	ETFA	-0.45	-6.12	-0.36	3.68e-9	Blood metabolite levels;
KIRP	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg03788504	chr6:150331562	NA	-0.33	-6.27	-0.37	1.64e-9	Alopecia areata;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.72	10.76	0.57	2.15e-22	Menarche (age at onset);
KIRP	cis	rs4936894	0.500	rs10790665	chr11:124175973	C/T	cg27160556	chr11:124181099	OR8D1	-0.45	-6.41	-0.38	7.5e-10	Aging (time to death);
KIRP	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.39	0.59	2.02e-24	Longevity;
KIRP	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg14458575	chr2:238380390	NA	0.55	5.76	0.34	2.45e-8	Prostate cancer;
KIRP	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.48	6.43	0.38	6.54e-10	Dilated cardiomyopathy;
KIRP	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11644362	1.000	rs12934970	chr16:12988077	G/C	cg06890432	chr16:12997467	SHISA9	-0.39	-6.04	-0.36	5.8e-9	Positive affect;Subjective well-being;
KIRP	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18364779	chr6:26104403	HIST1H4C	-0.38	-5.12	-0.31	6.11e-7	Schizophrenia;
KIRP	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg00405596	chr8:11794950	NA	-0.38	-5.05	-0.31	8.48e-7	Neuroticism;
KIRP	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.84	14.02	0.67	3.2e-33	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.03	-0.31	9.66e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg21466736	chr12:48725269	NA	-0.45	-5.79	-0.35	2.09e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.58	7.24	0.42	5.79e-12	Arsenic metabolism;
KIRP	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg17133734	chr15:86042851	AKAP13	-0.46	-5.76	-0.34	2.57e-8	Coronary artery disease;
KIRP	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.55	-6.64	-0.39	1.98e-10	Corneal curvature;
KIRP	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10451253	chr17:32907705	TMEM132E;C17orf102	0.46	6.08	0.36	4.61e-9	Parkinson's disease;
KIRP	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.37	-0.51	4.81e-18	Gut microbiome composition (summer);
KIRP	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	cg21523751	chr1:182988639	NA	0.39	5.99	0.36	7.53e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7721647	0.810	rs72771538	chr5:90797727	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.45	4.98	0.3	1.2e-6	Breast cancer;
KIRP	cis	rs7630877	0.719	rs73057366	chr3:179672470	C/G	cg18765712	chr3:179670323	PEX5L	0.85	9.79	0.53	2.6e-19	Type 2 diabetes;
KIRP	cis	rs259842	0.759	rs183079	chr2:180676223	C/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.36	-0.32	1.93e-7	Blood protein levels;
KIRP	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg00677455	chr12:58241039	CTDSP2	-0.49	-5.61	-0.34	5.41e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10465746	0.570	rs11163887	chr1:84474718	C/T	cg10977910	chr1:84465055	TTLL7	0.44	5.42	0.33	1.4e-7	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11874712	0.527	rs7359798	chr18:43648999	A/C	cg26436583	chr18:43649176	PSTPIP2	0.5	7.4	0.43	2.11e-12	Migraine - clinic-based;
KIRP	cis	rs13178130	0.515	rs329304	chr5:133897829	A/G	cg06019726	chr5:133897654	PHF15	-0.41	-6.06	-0.36	5.14e-9	Menarche (age at onset);
KIRP	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-6.35	-0.38	1.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg21535247	chr6:8435926	SLC35B3	-0.51	-6.63	-0.39	2.13e-10	Motion sickness;
KIRP	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg11783602	chr8:55087084	NA	-0.57	-7.02	-0.41	2.13e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg08992911	chr2:238395768	MLPH	0.42	4.96	0.3	1.34e-6	Prostate cancer;
KIRP	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg06223162	chr1:101003688	GPR88	0.43	8.4	0.47	3.48e-15	Breast cancer;
KIRP	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11987759	chr7:65425863	GUSB	-0.44	-5.32	-0.32	2.34e-7	Aortic root size;
KIRP	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg13165212	chr22:42675999	NA	0.4	7.0	0.41	2.37e-11	Cognitive function;
KIRP	cis	rs12519773	1.000	rs12519773	chr5:92464416	A/G	cg18783429	chr5:92414398	NA	0.29	5.07	0.31	7.72e-7	Migraine;
KIRP	cis	rs8067287	0.645	rs55770108	chr17:16841424	A/G	cg26910001	chr17:16838321	NA	-0.63	-6.02	-0.36	6.26e-9	Diabetic kidney disease;
KIRP	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	0.96	16.16	0.72	1.62e-40	Ulcerative colitis;
KIRP	cis	rs9815354	0.953	rs1716641	chr3:41921681	C/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.43	-0.33	1.34e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04978709	chr7:75101039	POM121C	0.51	7.28	0.42	4.39e-12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs743757	1.000	rs743756	chr3:50481717	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	5.65	0.34	4.5e-8	Diastolic blood pressure;
KIRP	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.41	-0.43	2.06e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg03810516	chr4:655893	PDE6B	0.39	6.19	0.37	2.46e-9	Serum protein levels (sST2);
KIRP	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.68	-9.67	-0.52	6.06e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2591576	0.789	rs830232	chr5:165403424	A/T	cg13976338	chr5:165423657	NA	-0.72	-10.68	-0.56	4.14e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	trans	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.6	6.1	0.36	4.19e-9	Ulcerative colitis;
KIRP	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg02072170	chr3:194406190	FAM43A	0.38	5.93	0.35	1.02e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.27	-0.37	1.65e-9	Breast cancer;
KIRP	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg13289132	chr10:30722225	MAP3K8	-0.4	-5.14	-0.31	5.72e-7	Inflammatory bowel disease;
KIRP	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.63	7.2	0.42	7.18e-12	Height;
KIRP	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.8	8.71	0.49	4.53e-16	Gestational age at birth (maternal effect);
KIRP	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.58	-6.69	-0.39	1.46e-10	Menarche (age at onset);
KIRP	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	1.0	18.01	0.75	7.98e-47	Leprosy;
KIRP	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg05347473	chr6:146136440	FBXO30	-0.49	-6.86	-0.4	5.49e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	8.6	0.48	9.28e-16	Neuroticism;
KIRP	cis	rs4262150	0.544	rs4958555	chr5:151903379	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.79	-0.49	2.7e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.2	-0.31	4.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.46	-5.98	-0.36	7.92e-9	Ulcerative colitis;
KIRP	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg04691961	chr3:161091175	C3orf57	-0.44	-6.4	-0.38	8.01e-10	Morning vs. evening chronotype;
KIRP	cis	rs4664293	1.000	rs10204535	chr2:160463692	C/T	cg08347373	chr2:160653686	CD302	-0.38	-5.8	-0.35	1.98e-8	Monocyte percentage of white cells;
KIRP	cis	rs7106204	0.534	rs7928616	chr11:24296060	T/C	ch.11.24196551F	chr11:24239977	NA	0.77	8.86	0.49	1.61e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21962204	chr1:217604232	GPATCH2	-0.36	-6.37	-0.38	9.13e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.72	-10.15	-0.54	1.95e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs66561647	0.634	rs7387606	chr8:128929371	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.42	5.32	0.32	2.32e-7	Hemoglobin concentration;
KIRP	cis	rs8113308	0.810	rs8105910	chr19:52447068	A/G	cg25782003	chr19:52490127	ZNF350	0.53	4.97	0.3	1.23e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9972944	0.702	rs6416946	chr17:63763967	C/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.84	-0.45	1.35e-13	Total body bone mineral density;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11981744	chr15:56285484	NEDD4	-0.53	-6.41	-0.38	7.23e-10	Menopause (age at onset);
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.63	9.01	0.5	5.82e-17	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.33	-0.42	3.39e-12	Bone mineral density;
KIRP	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.27	-0.32	2.96e-7	Body mass index;
KIRP	cis	rs7083	0.935	rs2509211	chr11:117137633	C/T	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg15128208	chr22:42549153	NA	0.44	5.77	0.35	2.34e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs7520050	0.808	rs11211196	chr1:46282296	A/T	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.53e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg24874828	chr4:187887005	NA	-0.5	-7.55	-0.43	8.55e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg00405596	chr8:11794950	NA	-0.46	-5.69	-0.34	3.69e-8	Neuroticism;
KIRP	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	1.09	17.49	0.74	4.85e-45	Cognitive function;
KIRP	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg12315302	chr6:26189340	HIST1H4D	0.89	6.03	0.36	6e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.19	0.37	2.46e-9	Axial length;
KIRP	cis	rs193541	0.632	rs152038	chr5:122195846	G/A	cg19412675	chr5:122181750	SNX24	0.6	6.4	0.38	7.67e-10	Glucose homeostasis traits;
KIRP	cis	rs10267417	0.603	rs10281428	chr7:19857374	G/A	cg05791153	chr7:19748676	TWISTNB	0.54	5.15	0.31	5.33e-7	Night sleep phenotypes;
KIRP	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	5.95	0.35	9.41e-9	Menarche (age at onset);
KIRP	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.7	8.58	0.48	1.08e-15	Aortic root size;
KIRP	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.64	-7.21	-0.42	6.96e-12	Blood pressure (smoking interaction);
KIRP	cis	rs7221595	0.825	rs61442612	chr17:3961019	C/T	cg11204139	chr17:3907470	NA	0.53	5.14	0.31	5.51e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs13401104	0.587	rs62190974	chr2:237145263	C/T	cg02367144	chr2:237146137	ASB18	0.4	5.21	0.32	4.04e-7	Educational attainment;
KIRP	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.51	6.57	0.39	3.02e-10	HDL cholesterol levels;
KIRP	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.49	7.22	0.42	6.54e-12	Testicular germ cell tumor;
KIRP	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	8.58	0.48	1.06e-15	Personality dimensions;
KIRP	cis	rs2033732	0.706	rs12679039	chr8:85064095	G/A	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg21479132	chr6:26055353	NA	0.75	5.03	0.31	9.56e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11225247	0.881	rs7113906	chr11:102253670	C/T	cg06323957	chr11:102217781	BIRC2	0.9	5.63	0.34	4.79e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg18478394	chr8:109455254	TTC35	0.57	7.06	0.41	1.68e-11	Dupuytren's disease;
KIRP	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.8	0.49	2.5e-16	Morning vs. evening chronotype;
KIRP	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg20749741	chr2:264178	ACP1;SH3YL1	0.44	4.87	0.3	2.01e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.58	6.58	0.39	2.77e-10	Educational attainment;
KIRP	cis	rs13108043	0.605	rs62306511	chr4:87962705	G/A	cg11209507	chr4:87813803	C4orf36	0.47	5.01	0.3	1.05e-6	Red blood cell count;
KIRP	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.54	-0.43	9.02e-13	Bipolar disorder;
KIRP	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.67	10.12	0.54	2.29e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.84	9.96	0.54	7.68e-20	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00517218	chr7:111846502	DOCK4;ZNF277	0.49	6.03	0.36	5.96e-9	Parkinson's disease;
KIRP	cis	rs7178572	0.524	rs12904088	chr15:77399397	C/G	cg12131826	chr15:77904385	NA	0.42	5.5	0.33	9.71e-8	Type 2 diabetes;
KIRP	cis	rs687432	0.688	rs61902769	chr11:57892659	G/A	cg19752551	chr11:57585705	CTNND1	-0.61	-8.22	-0.46	1.17e-14	Parkinson's disease;
KIRP	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg14696996	chr19:15285081	NOTCH3	0.67	7.3	0.42	4.04e-12	Pulse pressure;
KIRP	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.78	7.65	0.44	4.42e-13	Blood protein levels;
KIRP	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg01721255	chr8:58191610	C8orf71	0.56	4.92	0.3	1.6e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg18154014	chr19:37997991	ZNF793	-0.69	-7.5	-0.43	1.18e-12	Coronary artery calcification;
KIRP	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.65	7.88	0.45	1.05e-13	Calcium levels;
KIRP	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	1.05	19.5	0.78	8.2e-52	Height;
KIRP	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.33	5.24	0.32	3.46e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs6987853	0.814	rs2923447	chr8:42439848	G/T	cg09913449	chr8:42400586	C8orf40	0.4	5.32	0.32	2.29e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs137699	0.604	rs137702	chr22:39750158	T/C	cg11247378	chr22:39784982	NA	-0.47	-5.9	-0.35	1.19e-8	IgG glycosylation;
KIRP	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.7	9.21	0.51	1.47e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-5.15	-0.31	5.29e-7	Total body bone mineral density;
KIRP	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.83	11.94	0.61	3.18e-26	Colorectal cancer;
KIRP	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.39	-5.99	-0.36	7.5e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16933664	chr11:67085326	LOC100130987	0.5	6.02	0.36	6.21e-9	Parkinson's disease;
KIRP	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg08029281	chr1:67600428	NA	0.34	4.87	0.3	1.98e-6	Psoriasis;
KIRP	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg13264159	chr8:625131	ERICH1	0.86	6.09	0.36	4.24e-9	IgG glycosylation;
KIRP	cis	rs834811	0.829	rs834818	chr7:135895070	A/G	cg01726295	chr7:135938950	NA	0.37	5.03	0.31	9.36e-7	Post-traumatic stress disorder;
KIRP	cis	rs6545883	0.507	rs2442025	chr2:61571445	G/A	cg15711740	chr2:61764176	XPO1	0.45	5.43	0.33	1.33e-7	Tuberculosis;
KIRP	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Visceral adipose tissue adjusted for BMI;
KIRP	cis	rs4356932	1.000	rs7377856	chr4:76964096	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs911119	0.913	rs13043266	chr20:23588127	C/T	cg09631192	chr20:23583594	CST9	-0.63	-6.12	-0.36	3.63e-9	Chronic kidney disease;
KIRP	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.7	10.02	0.54	4.91e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.51	7.16	0.42	9.15e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg14343924	chr8:8086146	FLJ10661	0.43	5.25	0.32	3.37e-7	Systolic blood pressure;
KIRP	cis	rs7845219	0.525	rs6471501	chr8:95922491	A/G	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.2	-0.37	2.35e-9	Type 2 diabetes;
KIRP	cis	rs4919044	0.808	rs55856996	chr10:94808618	T/G	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg19507638	chr5:93509721	C5orf36	-0.54	-5.08	-0.31	7.32e-7	Diabetic retinopathy;
KIRP	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.81	-11.04	-0.58	2.72e-23	Multiple sclerosis;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg03133777	chr2:170361364	BBS5	0.42	6.44	0.38	6.07e-10	Cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12560154	chr19:11925149	ZNF440	0.58	6.91	0.4	4.04e-11	Smoking initiation;
KIRP	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.94	0.4	3.44e-11	Schizophrenia;
KIRP	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12379764	chr21:47803548	PCNT	-0.41	-5.0	-0.3	1.07e-6	Testicular germ cell tumor;
KIRP	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg05484376	chr2:27715224	FNDC4	0.35	5.57	0.33	6.8e-8	Total body bone mineral density;
KIRP	cis	rs4262150	0.883	rs72802841	chr5:152205965	C/G	cg12297329	chr5:152029980	NA	-0.62	-8.05	-0.46	3.49e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs33912345	0.750	rs1254337	chr14:60920525	A/T	cg27398547	chr14:60952738	C14orf39	-0.38	-5.03	-0.31	9.43e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-9.49	-0.52	2.08e-18	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.08	-0.58	2e-23	Chronic sinus infection;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.74	9.89	0.53	1.25e-19	Longevity;Endometriosis;
KIRP	cis	rs9608946	1.000	rs17670707	chr22:30877936	G/A	cg23383138	chr22:30885012	SEC14L4	0.4	4.88	0.3	1.92e-6	Red cell distribution width;
KIRP	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.69	9.58	0.52	1.08e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.77	-11.5	-0.59	8.67e-25	Obesity-related traits;
KIRP	trans	rs1864585	0.520	rs7838335	chr8:10589913	C/T	cg26278703	chr11:58910052	FAM111A	0.58	6.06	0.36	5.11e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.63	7.52	0.43	1.04e-12	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.6	-5.3	-0.32	2.61e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13034020	0.641	rs34230978	chr2:61221523	A/T	cg18625361	chr2:61244694	PEX13;PUS10	0.55	4.96	0.3	1.31e-6	Hodgkin's lymphoma;
KIRP	cis	rs877426	0.681	rs7317369	chr13:114816738	C/G	cg00571178	chr13:114841904	RASA3	-0.49	-5.18	-0.31	4.61e-7	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.8	-0.35	2e-8	Parkinson's disease;
KIRP	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.66	6.02	0.36	6.15e-9	Alzheimer's disease;
KIRP	cis	rs17221829	0.733	rs11018726	chr11:89413265	T/C	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.14	-0.31	5.69e-7	Anxiety in major depressive disorder;
KIRP	cis	rs981844	1.000	rs2405431	chr4:154656396	A/G	cg14289246	chr4:154710475	SFRP2	0.64	6.85	0.4	5.88e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.26	0.47	9.29e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg01238044	chr22:24384105	GSTT1	-0.55	-7.36	-0.42	2.75e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21545522	chr1:205238299	TMCC2	0.55	7.31	0.42	3.76e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.15	0.31	5.23e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-6.03	-0.36	5.97e-9	Fear of minor pain;
KIRP	cis	rs4671458	1.000	rs4671461	chr2:63406800	T/C	cg17519650	chr2:63277830	OTX1	-0.56	-5.63	-0.34	4.82e-8	Subjective well-being;
KIRP	cis	rs12995491	0.731	rs13019346	chr2:88509321	A/G	cg04511125	chr2:88470314	THNSL2	-0.45	-5.61	-0.34	5.55e-8	Response to metformin (IC50);
KIRP	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg22356347	chr1:167427500	CD247	-0.45	-6.2	-0.37	2.38e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10519155	chr20:60757898	GTPBP5	-0.48	-6.19	-0.37	2.5e-9	Myopia;
KIRP	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.38	0.43	2.49e-12	Retinal vascular caliber;
KIRP	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg27490568	chr2:178487706	NA	0.5	6.55	0.39	3.37e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1050631	0.592	rs948417	chr18:33711274	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.48	6.05	0.36	5.45e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg14092571	chr14:90743983	NA	-0.42	-5.19	-0.31	4.5e-7	Mortality in heart failure;
KIRP	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.66	-8.17	-0.46	1.6e-14	Aortic root size;
KIRP	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.84	-12.73	-0.63	7.28e-29	Height;
KIRP	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.99	-0.3	1.15e-6	Coronary artery disease;
KIRP	trans	rs6601327	0.613	rs7835002	chr8:9455045	G/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.58	0.39	2.77e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6691722	0.503	rs6656485	chr1:24707685	A/G	cg18323236	chr1:24743029	NIPAL3	0.44	6.31	0.37	1.3e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs4671458	1.000	rs11125949	chr2:63357876	T/C	cg17519650	chr2:63277830	OTX1	-0.54	-5.45	-0.33	1.21e-7	Subjective well-being;
KIRP	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.45	-5.15	-0.31	5.28e-7	Subjective well-being;
KIRP	cis	rs6132905	0.590	rs113218623	chr20:2613606	C/T	cg24848351	chr20:2622020	TMC2	-0.57	-5.09	-0.31	7.21e-7	Mumps;
KIRP	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.21	-0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg06307176	chr5:131281290	NA	-0.46	-5.47	-0.33	1.12e-7	Life satisfaction;
KIRP	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.58	-7.55	-0.43	8.37e-13	Lymphocyte counts;
KIRP	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.93	15.73	0.71	4.6e-39	Height;
KIRP	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg09594475	chr20:60884601	LAMA5	0.39	6.05	0.36	5.44e-9	Pelvic organ prolapse;
KIRP	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg06521331	chr12:34319734	NA	0.57	7.02	0.41	2.14e-11	Morning vs. evening chronotype;
KIRP	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg20387954	chr3:183756860	HTR3D	0.62	9.09	0.5	3.44e-17	Anterior chamber depth;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26122815	chr7:127948739	NA	-0.47	-6.36	-0.38	9.72e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma (childhood onset);
KIRP	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.3	-6.99	-0.41	2.62e-11	Mean corpuscular volume;
KIRP	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg00784671	chr22:46762841	CELSR1	-0.88	-8.42	-0.47	3.24e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg18882449	chr10:104885122	NT5C2	-0.5	-6.44	-0.38	6.1e-10	Arsenic metabolism;
KIRP	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg13880726	chr7:1868755	MAD1L1	0.49	5.83	0.35	1.7e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg15839431	chr19:19639596	YJEFN3	0.51	5.23	0.32	3.62e-7	Bipolar disorder;
KIRP	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.19	0.37	2.54e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16360182	chr14:104314518	PPP1R13B	0.48	6.65	0.39	1.93e-10	Parkinson's disease;
KIRP	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg10547527	chr2:198650123	BOLL	-0.56	-5.06	-0.31	8.05e-7	Ulcerative colitis;
KIRP	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11987759	chr7:65425863	GUSB	0.5	6.47	0.38	5.22e-10	Aortic root size;
KIRP	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg26373071	chr5:1325741	CLPTM1L	-0.58	-7.73	-0.44	2.7e-13	Lung cancer;
KIRP	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg18944383	chr4:111397179	ENPEP	0.54	9.51	0.52	1.79e-18	Height;
KIRP	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-5.32	-0.32	2.31e-7	Crohn's disease;
KIRP	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.5	6.32	0.37	1.22e-9	Mean platelet volume;
KIRP	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.59	6.71	0.39	1.35e-10	Vitiligo;
KIRP	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg13798912	chr7:905769	UNC84A	0.64	6.33	0.37	1.17e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.42	0.33	1.41e-7	Educational attainment;
KIRP	trans	rs9841504	1.000	rs1290894	chr3:114353140	A/G	cg24348448	chr19:55493930	NLRP2	-0.74	-6.52	-0.38	3.94e-10	Gastric cancer;
KIRP	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-5.31	-0.32	2.4e-7	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12919135	chr15:65903447	C15orf44	0.55	7.11	0.41	1.24e-11	Parkinson's disease;
KIRP	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg13397359	chr6:42928475	GNMT	0.42	4.95	0.3	1.41e-6	Blood protein levels;
KIRP	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.72	9.43	0.52	3.28e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg12140854	chr5:148520817	ABLIM3	0.43	4.98	0.3	1.22e-6	Breast cancer;
KIRP	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.06	0.31	8.14e-7	Diabetic retinopathy;
KIRP	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.57	7.03	0.41	1.97e-11	Total body bone mineral density;
KIRP	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg08807101	chr21:30365312	RNF160	-0.59	-7.25	-0.42	5.28e-12	Cognitive test performance;
KIRP	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	5.63	0.34	5.01e-8	Coronary artery disease;
KIRP	cis	rs8018808	0.935	rs7146784	chr14:77932111	A/G	cg20045696	chr14:77926864	AHSA1	0.45	5.46	0.33	1.18e-7	Myeloid white cell count;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09253211	chr11:63438586	ATL3	-0.47	-6.44	-0.38	6.31e-10	Myopia;
KIRP	trans	rs6432860	0.733	rs2116546	chr2:166723533	T/C	cg13971571	chr8:6693247	XKR5	0.52	6.42	0.38	7.08e-10	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;
KIRP	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.38	-0.43	2.46e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs8014252	0.803	rs12586441	chr14:70988062	T/C	cg11204974	chr14:71022665	NA	-0.76	-7.22	-0.42	6.38e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg09408571	chr1:101003634	GPR88	0.24	5.41	0.33	1.5e-7	Monocyte count;
KIRP	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg01304814	chr3:48885189	PRKAR2A	-0.68	-4.93	-0.3	1.48e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg13206674	chr6:150067644	NUP43	0.7	10.55	0.56	1.05e-21	Lung cancer;
KIRP	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.75	-0.63	6.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6142102	0.502	rs58393429	chr20:32545802	C/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.77	0.35	2.4e-8	Skin pigmentation;
KIRP	cis	rs41264869	0.600	rs73083129	chr1:205186206	T/C	cg21214746	chr1:205091277	RBBP5	0.39	4.94	0.3	1.43e-6	Blood protein levels;
KIRP	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.59	7.32	0.42	3.55e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.72	-10.25	-0.55	9.54e-21	Glaucoma (primary open-angle);
KIRP	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg09491104	chr22:46646882	C22orf40	-0.53	-5.81	-0.35	1.96e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10073892	0.830	rs10057361	chr5:101602741	T/G	cg19774478	chr5:101632501	SLCO4C1	0.65	6.3	0.37	1.33e-9	Cognitive decline (age-related);
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg26618056	chr16:25043323	NA	-0.54	-6.22	-0.37	2.15e-9	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs8084125	0.832	rs56301307	chr18:74942711	A/G	cg15443732	chr18:74961078	GALR1	0.52	4.97	0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.66	9.11	0.5	2.86e-17	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16791186	chr15:67134971	NA	0.48	6.15	0.37	3.09e-9	Parkinson's disease;
KIRP	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg26513180	chr16:89883248	FANCA	0.62	5.24	0.32	3.39e-7	Skin colour saturation;
KIRP	cis	rs2671245	0.586	rs2671238	chr1:56150704	C/T	cg11523071	chr1:56160889	NA	-0.43	-6.3	-0.37	1.4e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17401966	0.540	rs6674949	chr1:10458480	A/G	cg17425144	chr1:10567563	PEX14	-0.31	-5.26	-0.32	3.16e-7	Hepatocellular carcinoma;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.32	-0.32	2.31e-7	Life satisfaction;
KIRP	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.5	6.38	0.38	8.88e-10	Schizophrenia;
KIRP	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg08514558	chr10:81106712	PPIF	0.39	5.33	0.32	2.24e-7	Height;
KIRP	cis	rs887829	0.508	rs1104892	chr2:234620272	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-6.01	-0.36	6.64e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	9.87	0.53	1.47e-19	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.54	-6.03	-0.36	5.82e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.56	7.63	0.44	5.13e-13	Tuberculosis;
KIRP	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg25037394	chr1:24152592	HMGCL	-0.38	-4.95	-0.3	1.35e-6	Immature fraction of reticulocytes;
KIRP	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.51	6.04	0.36	5.66e-9	Prudent dietary pattern;
KIRP	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.09	0.5	3.48e-17	Colorectal cancer;
KIRP	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.55	-6.81	-0.4	7.23e-11	Uric acid clearance;
KIRP	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.72	7.03	0.41	2.07e-11	Prostate cancer;
KIRP	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg21395723	chr22:39101663	GTPBP1	-0.41	-5.05	-0.31	8.55e-7	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.96	0.36	8.69e-9	Morning vs. evening chronotype;
KIRP	cis	rs72634258	0.786	rs9434993	chr1:8179744	G/C	cg00042356	chr1:8021962	PARK7	0.51	5.11	0.31	6.39e-7	Inflammatory bowel disease;
KIRP	cis	rs859767	0.501	rs6724777	chr2:135407292	C/T	cg12500956	chr2:135428796	TMEM163	-0.42	-5.68	-0.34	3.78e-8	Neuroticism;
KIRP	trans	rs7246760	1.000	rs17849496	chr19:9922223	G/A	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.46e-20	Pursuit maintenance gain;
KIRP	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg04691961	chr3:161091175	C3orf57	-0.49	-7.31	-0.42	3.8e-12	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg01689657	chr7:91764605	CYP51A1	0.39	5.46	0.33	1.16e-7	Breast cancer;
KIRP	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg10047753	chr17:41438598	NA	1.17	19.27	0.78	4.52e-51	Menopause (age at onset);
KIRP	cis	rs2273799	1.000	rs2273799	chr11:33913568	C/T	cg15356966	chr11:33913187	LMO2	0.34	4.85	0.3	2.23e-6	Red blood cell count;Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg23594656	chr7:65796392	TPST1	0.35	5.15	0.31	5.23e-7	Aortic root size;
KIRP	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg06212747	chr3:49208901	KLHDC8B	0.7	7.72	0.44	2.86e-13	Menarche (age at onset);
KIRP	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg23173402	chr1:227635558	NA	-0.64	-5.28	-0.32	2.87e-7	Major depressive disorder;
KIRP	cis	rs11255291	1.000	rs10905219	chr10:7738411	C/T	cg26051552	chr10:7670683	ITIH5	0.43	5.55	0.33	7.35e-8	Ovarian reserve;
KIRP	cis	rs2172802	0.560	rs996208	chr4:62559531	A/C	cg04118610	chr4:62707027	LPHN3	-0.46	-5.63	-0.34	4.97e-8	Partial epilepsies;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24126187	chr3:46923546	PTH1R	0.45	6.13	0.36	3.53e-9	Parkinson's disease;
KIRP	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.35	-4.97	-0.3	1.23e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.67	-8.77	-0.49	3e-16	Iron status biomarkers;
KIRP	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.95	-0.3	1.39e-6	Metabolite levels;
KIRP	cis	rs1440410	0.835	rs7670439	chr4:144080267	T/C	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	cis	rs7215564	0.908	rs35071767	chr17:78652575	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.21	0.32	3.97e-7	Myopia (pathological);
KIRP	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.65	6.44	0.38	6.09e-10	Height;
KIRP	cis	rs1215050	0.791	rs2123099	chr4:98803456	A/G	cg17366294	chr4:99064904	C4orf37	0.36	4.97	0.3	1.28e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg07271561	chr3:50359363	HYAL2	-0.35	-4.93	-0.3	1.49e-6	Diastolic blood pressure;
KIRP	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.56	-0.39	3.2e-10	Initial pursuit acceleration;
KIRP	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg05315796	chr3:52349193	DNAH1	0.4	5.26	0.32	3.17e-7	Schizophrenia;
KIRP	cis	rs7715806	0.500	rs58968428	chr5:75004107	A/G	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-7.6	-0.44	6.29e-13	Coronary artery disease;
KIRP	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg25036284	chr2:26402008	FAM59B	0.52	5.46	0.33	1.14e-7	Gut microbiome composition (summer);
KIRP	trans	rs6902257	0.590	rs2503727	chr6:81310817	G/A	cg06063519	chr15:99274532	IGF1R	-0.62	-6.05	-0.36	5.47e-9	Obesity-related traits;
KIRP	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.92	13.2	0.64	1.96e-30	Bladder cancer;
KIRP	cis	rs507080	0.961	rs4938522	chr11:118548671	A/T	cg04173919	chr11:118528438	PHLDB1	0.33	4.87	0.3	1.98e-6	Serum metabolite levels;
KIRP	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.84	0.45	1.41e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg13606994	chr1:44402422	ARTN	-0.33	-6.55	-0.39	3.36e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg14221460	chr8:27183342	PTK2B	0.53	7.01	0.41	2.23e-11	Neuroticism;
KIRP	cis	rs2808510	0.521	rs12131135	chr1:200418613	G/T	cg10889502	chr1:200398670	NA	-0.31	-4.87	-0.3	2e-6	Myopia;
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	8.9e-8	Life satisfaction;
KIRP	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08280861	chr8:58055591	NA	0.7	5.07	0.31	7.72e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.79	10.59	0.56	7.48e-22	Aortic root size;
KIRP	trans	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg13628156	chr9:140380767	PNPLA7	0.41	6.32	0.37	1.24e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6840360	0.617	rs2724564	chr4:152349962	G/T	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2307121	0.700	rs10471661	chr5:64746627	A/G	cg00944502	chr5:64858997	PPWD1;CENPK	0.41	4.86	0.3	2.05e-6	Corneal structure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08897759	chr5:178415944	GRM6	-0.41	-6.11	-0.36	3.82e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.53	7.2	0.42	7.38e-12	Schizophrenia;
KIRP	cis	rs950776	0.678	rs12910237	chr15:78956338	C/T	cg22563815	chr15:78856949	CHRNA5	0.41	5.57	0.33	6.51e-8	Sudden cardiac arrest;
KIRP	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	7.02	0.41	2.17e-11	Menarche (age at onset);
KIRP	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.72	-0.34	3.15e-8	Coronary artery disease;
KIRP	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg15556689	chr8:8085844	FLJ10661	-0.68	-8.73	-0.49	3.95e-16	Joint mobility (Beighton score);
KIRP	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.57	7.9	0.45	9.06e-14	Prostate cancer;
KIRP	cis	rs1538970	0.924	rs2088100	chr1:45877575	C/T	cg05343316	chr1:45956843	TESK2	0.67	7.73	0.44	2.69e-13	Platelet count;
KIRP	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg01557791	chr16:72042693	DHODH	-0.51	-6.38	-0.38	8.64e-10	Fibrinogen levels;
KIRP	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	8.23	0.46	1.11e-14	Lymphocyte percentage of white cells;
KIRP	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.75	-7.05	-0.41	1.81e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.42	-0.51	3.52e-18	Response to antipsychotic treatment;
KIRP	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg21573476	chr21:45109991	RRP1B	-0.64	-8.72	-0.49	4.2e-16	Mean corpuscular volume;
KIRP	cis	rs6968419	0.674	rs1918911	chr7:115906748	G/T	cg02561103	chr7:115862891	TES	-0.4	-5.6	-0.34	5.82e-8	Intraocular pressure;
KIRP	cis	rs6840360	0.582	rs6535796	chr4:152304728	G/A	cg25486957	chr4:152246857	NA	-0.42	-4.88	-0.3	1.87e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.9	-12.54	-0.62	3.27e-28	Schizophrenia;
KIRP	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg25482853	chr8:67687455	SGK3	0.79	6.99	0.41	2.64e-11	Obesity-related traits;
KIRP	cis	rs8060686	0.858	rs2008173	chr16:67856240	A/G	cg04539111	chr16:67997858	SLC12A4	-0.42	-5.01	-0.3	1.04e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg20243544	chr17:37824526	PNMT	0.47	6.13	0.36	3.44e-9	Asthma;
KIRP	cis	rs9596863	0.898	rs9568915	chr13:54341214	T/C	ch.13.53330881F	chr13:54432880	NA	0.49	4.95	0.3	1.39e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10213059	chr13:70369137	KLHL1	-0.39	-6.22	-0.37	2.17e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg16434002	chr17:42200994	HDAC5	-0.57	-6.95	-0.41	3.24e-11	Total body bone mineral density;
KIRP	cis	rs1832871	0.672	rs9457337	chr6:158726292	C/T	cg07215822	chr6:158701037	NA	-0.65	-7.44	-0.43	1.65e-12	Height;
KIRP	cis	rs9473924	0.632	rs4711962	chr6:50862960	C/T	cg03432817	chr6:50765336	NA	0.35	5.41	0.33	1.52e-7	Body mass index;
KIRP	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.08	-0.41	1.49e-11	Fear of minor pain;
KIRP	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.56	-7.08	-0.41	1.5e-11	Lung cancer;
KIRP	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.72	-10.64	-0.56	5.29e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6593803	0.729	rs10900394	chr1:147202386	G/A	cg27546670	chr1:147246839	GJA5	0.63	7.09	0.41	1.45e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.52	6.84	0.4	6.19e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs10875746	0.768	rs12305182	chr12:48421407	G/T	cg26205652	chr12:48591994	NA	0.74	10.0	0.54	5.55e-20	Longevity (90 years and older);
KIRP	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	1.0	13.92	0.66	7.03e-33	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2273799	1.000	rs10836129	chr11:33912448	T/G	cg15356966	chr11:33913187	LMO2	-0.35	-4.87	-0.3	1.99e-6	Red blood cell count;Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6601327	0.600	rs4841219	chr8:9654185	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.08	-0.31	7.64e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg13482628	chr17:19912719	NA	-0.52	-6.76	-0.4	1.01e-10	Schizophrenia;
KIRP	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-8.47	-0.48	2.3e-15	Coronary artery disease;
KIRP	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.39	-0.47	3.84e-15	Systemic lupus erythematosus;
KIRP	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.71	-12.25	-0.62	2.99e-27	Urate levels in overweight individuals;
KIRP	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.96	13.83	0.66	1.42e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6546886	0.912	rs12713808	chr2:74292779	T/C	cg14702570	chr2:74259524	NA	-0.28	-5.53	-0.33	8.29e-8	Dialysis-related mortality;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-8.8	-0.49	2.4e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg06636001	chr8:8085503	FLJ10661	0.56	7.69	0.44	3.46e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-0.58	-8.9	-0.49	1.22e-16	Trans fatty acid levels;
KIRP	cis	rs7756236	0.521	rs6936993	chr6:36626322	C/T	cg08179530	chr6:36648295	CDKN1A	-0.43	-5.64	-0.34	4.58e-8	QRS duration;
KIRP	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.44	-6.58	-0.39	2.8e-10	Tuberculosis;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00933542	chr6:150070202	PCMT1	0.29	5.67	0.34	3.97e-8	Lung cancer;
KIRP	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg14403583	chr14:105418241	AHNAK2	-0.7	-9.79	-0.53	2.49e-19	Rheumatoid arthritis;
KIRP	trans	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg10756647	chr7:56101905	PSPH	1.09	8.55	0.48	1.29e-15	Diabetic kidney disease;
KIRP	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.77	10.9	0.57	7.82e-23	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg15997130	chr1:24165203	NA	-0.6	-8.38	-0.47	4.02e-15	Immature fraction of reticulocytes;
KIRP	cis	rs10818894	0.515	rs10818831	chr9:126312791	C/T	cg16191174	chr9:126692580	DENND1A	0.56	6.16	0.37	2.9e-9	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
KIRP	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.73	7.98	0.45	5.66e-14	Corneal astigmatism;
KIRP	cis	rs72820985	1.000	rs12446476	chr16:80841931	C/T	cg04448709	chr16:81349954	GAN	0.51	5.2	0.31	4.1e-7	Breast cancer;
KIRP	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg00094735	chr5:1949198	NA	0.46	5.2	0.31	4.1e-7	Gut microbiome composition (winter);
KIRP	cis	rs6963495	0.556	rs711427	chr7:105161755	T/G	cg19920283	chr7:105172520	RINT1	0.54	6.09	0.36	4.34e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6788895	1.000	rs6795396	chr3:150510227	C/T	cg09723797	chr3:150481914	SIAH2	0.71	5.67	0.34	3.98e-8	Breast cancer;
KIRP	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg12598211	chr12:123634384	NA	-0.43	-5.17	-0.31	4.94e-7	Neutrophil percentage of white cells;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg01324507	chr7:1177794	C7orf50	0.42	5.06	0.31	8.19e-7	Longevity;Endometriosis;
KIRP	cis	rs7712401	0.580	rs439739	chr5:122318421	G/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.42	5.08	0.31	7.52e-7	Tonsillectomy;
KIRP	cis	rs55962025	0.711	rs4690072	chr4:3122507	T/G	cg06533319	chr4:3265114	C4orf44	0.4	5.03	0.31	9.56e-7	Parental longevity (mother's age at death);
KIRP	cis	rs2273156	0.929	rs8017225	chr14:35470049	G/A	cg09327582	chr14:35236912	BAZ1A	-0.47	-5.18	-0.31	4.62e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs4400599	0.618	rs9803862	chr1:154192143	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.45	6.78	0.4	8.85e-11	Platelet distribution width;
KIRP	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg04374321	chr14:90722782	PSMC1	-0.89	-13.29	-0.65	9.44e-31	Mortality in heart failure;
KIRP	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg16586182	chr3:47516702	SCAP	-0.72	-10.12	-0.54	2.45e-20	Colorectal cancer;
KIRP	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg02038168	chr22:39784481	NA	-0.46	-5.57	-0.33	6.72e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.46	-6.86	-0.4	5.5e-11	Vitamin D levels;
KIRP	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.48	5.95	0.35	9.12e-9	Subjective well-being;
KIRP	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.16	0.42	9.12e-12	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg17264618	chr3:40429014	ENTPD3	0.33	4.99	0.3	1.14e-6	Renal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.72e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13305883	chr1:145438423	TXNIP	0.46	6.06	0.36	5.11e-9	Parkinson's disease;
KIRP	cis	rs1829883	1.000	rs1916599	chr5:98774240	C/G	cg08333243	chr5:99726346	NA	-0.38	-5.07	-0.31	7.66e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs9832454	1.000	rs9832454	chr3:50217558	C/T	cg03060546	chr3:49711283	APEH	-0.63	-4.93	-0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.7	-6.34	-0.37	1.09e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg12131826	chr15:77904385	NA	0.45	5.97	0.36	8.07e-9	Type 2 diabetes;
KIRP	cis	rs5753618	0.555	rs5749286	chr22:31900359	G/T	cg02404636	chr22:31891804	SFI1	0.57	6.82	0.4	7.1e-11	Colorectal cancer;
KIRP	cis	rs7590368	0.715	rs56162318	chr2:10958936	A/C	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-9.39	-0.51	4.37e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg16898833	chr6:26189333	HIST1H4D	0.84	5.93	0.35	1.03e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6969780	0.915	rs3807597	chr7:27189195	C/T	cg19142026	chr7:27170394	HOXA4	-0.43	-5.53	-0.33	8.08e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.51	-0.38	4.28e-10	Joint mobility (Beighton score);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06646757	chr2:175211131	NA	0.35	6.02	0.36	6.31e-9	Migraine with aura;
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.66	0.68	2.07e-35	Platelet count;
KIRP	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg15488143	chr7:128924101	AHCYL2	-0.57	-6.39	-0.38	8.48e-10	White matter hyperintensity burden;
KIRP	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg21360079	chr12:107162445	NA	-0.68	-9.53	-0.52	1.64e-18	Heart rate;
KIRP	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.34	0.32	2.06e-7	Height;
KIRP	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.47	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4664293	0.867	rs6432554	chr2:160579084	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23281280	chr6:28129359	ZNF389	-0.5	-5.59	-0.34	6.1e-8	Depression;
KIRP	trans	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4356932	1.000	rs6829896	chr4:76970739	C/T	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26314531	chr2:26401878	FAM59B	0.48	5.2	0.31	4.17e-7	Gut microbiome composition (summer);
KIRP	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs11225247	0.772	rs34104132	chr11:102232160	T/G	cg06323957	chr11:102217781	BIRC2	0.77	4.97	0.3	1.27e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-15.73	-0.71	4.78e-39	Coronary artery disease;
KIRP	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.42	5.69	0.34	3.62e-8	Type 2 diabetes;
KIRP	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg18190219	chr22:46762943	CELSR1	-0.62	-5.64	-0.34	4.66e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs66696671	0.516	rs4752335	chr10:121340908	A/G	cg06765389	chr10:121379685	NA	-0.39	-5.28	-0.32	2.78e-7	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.79	9.62	0.52	8.68e-19	Corneal astigmatism;
KIRP	trans	rs6731373	0.651	rs13029910	chr2:68434345	A/C	cg21762695	chr7:36022695	NA	-0.41	-6.02	-0.36	6.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.33	0.42	3.21e-12	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23092844	chr2:169103738	STK39	0.52	6.42	0.38	6.78e-10	Parkinson's disease;
KIRP	cis	rs31771	0.564	rs6881378	chr5:165512904	G/C	cg13976338	chr5:165423657	NA	0.45	4.97	0.3	1.25e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.08	-0.36	4.59e-9	Lung cancer;
KIRP	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.53	-6.23	-0.37	1.99e-9	Corneal curvature;
KIRP	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg10818794	chr15:86012489	AKAP13	-0.47	-6.62	-0.39	2.26e-10	Interstitial lung disease;
KIRP	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg11965913	chr1:205819406	PM20D1	0.51	5.46	0.33	1.14e-7	Parkinson's disease;
KIRP	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg21926883	chr2:100939477	LONRF2	-0.6	-7.66	-0.44	4.33e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs7819412	0.593	rs11778398	chr8:10974243	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.77	-0.44	2.14e-13	Triglycerides;
KIRP	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16524936	chr4:1340807	KIAA1530	-0.43	-5.4	-0.33	1.55e-7	Longevity;
KIRP	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.16	0.37	3e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2224391	0.628	rs2753237	chr6:5252675	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.51	-0.38	4.15e-10	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00520540	chr10:14880887	CDNF;HSPA14	0.45	6.28	0.37	1.5e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2904967	0.852	rs668735	chr11:65045725	G/T	cg12562828	chr11:65076843	NA	0.48	7.21	0.42	6.74e-12	Mean corpuscular volume;
KIRP	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.56	-0.39	3.16e-10	Obesity-related traits;
KIRP	cis	rs17453880	0.929	rs4958571	chr5:152030714	A/C	cg12297329	chr5:152029980	NA	0.72	11.15	0.58	1.2e-23	Subjective well-being;
KIRP	cis	rs17123764	0.818	rs12321819	chr12:49941997	T/C	cg02054252	chr12:50078554	FMNL3	0.43	5.25	0.32	3.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12973672	1.000	rs12973672	chr19:35767866	A/G	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.5	-8.47	-0.48	2.19e-15	Pneumonia;
KIRP	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.01	0.54	5.35e-20	Lymphocyte counts;
KIRP	cis	rs4791746	1.000	rs7225052	chr17:8618804	A/G	cg03115937	chr17:8649504	CCDC42	-0.53	-6.33	-0.37	1.14e-9	Heroin dependence;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.47	-5.96	-0.36	8.8e-9	Longevity;Endometriosis;
KIRP	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.79	-0.4	8.4e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.5	-7.07	-0.41	1.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs9535307	0.929	rs942032	chr13:50251145	T/G	cg04663916	chr13:50265991	EBPL	0.73	7.66	0.44	4.35e-13	Obesity-related traits;
KIRP	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.42	5.99	0.36	7.26e-9	Sitting height ratio;
KIRP	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Parkinson's disease;
KIRP	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.62	-0.48	8.09e-16	Triglycerides;
KIRP	cis	rs6433857	0.536	rs7557023	chr2:181350474	G/A	cg23363182	chr2:181467187	NA	-0.37	-5.25	-0.32	3.32e-7	Body mass index;
KIRP	cis	rs829661	0.793	rs2593461	chr2:30872317	C/G	cg10949345	chr2:30726833	LCLAT1	1.02	12.55	0.62	2.87e-28	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7646501	0.677	rs1511543	chr3:24068751	G/C	cg21910673	chr3:24143257	LOC152024	0.39	5.35	0.32	2.05e-7	Cognitive ability;Intelligence;
KIRP	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg07001201	chr5:642380	CEP72	0.61	5.8	0.35	2e-8	Obesity-related traits;
KIRP	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg07653901	chr22:50250238	ZBED4	-0.47	-5.16	-0.31	5e-7	Schizophrenia;
KIRP	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-7.62	-0.44	5.64e-13	Extraversion;
KIRP	cis	rs7143963	0.666	rs11847989	chr14:103303514	T/C	cg24154132	chr14:103367632	TRAF3	0.32	5.92	0.35	1.08e-8	Body mass index;
KIRP	trans	rs3858145	0.588	rs731063	chr10:70043190	A/G	cg04882175	chr6:131122610	NA	0.59	6.81	0.4	7.39e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.46	6.25	0.37	1.82e-9	Menopause (age at onset);
KIRP	cis	rs1209950	0.901	rs1209953	chr21:40180383	T/A	cg01359822	chr21:40176597	ETS2	0.36	5.83	0.35	1.77e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg13180566	chr4:1052158	NA	-0.5	-5.14	-0.31	5.62e-7	Recombination rate (females);
KIRP	cis	rs9815354	1.000	rs9838965	chr3:41927938	C/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.47	-0.33	1.11e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11491207	chr11:32914638	QSER1	-0.61	-6.6	-0.39	2.53e-10	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg23594656	chr7:65796392	TPST1	0.48	7.56	0.43	8.04e-13	Aortic root size;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.81	-14.29	-0.67	3.91e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	17.25	0.74	3.06e-44	Platelet count;
KIRP	cis	rs7188697	0.883	rs4485352	chr16:58601410	A/G	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg03806693	chr22:41940476	POLR3H	-0.47	-5.68	-0.34	3.7e-8	Neuroticism;
KIRP	cis	rs4262150	0.883	rs4484413	chr5:152165140	A/T	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7572644	0.723	rs3935148	chr2:28020966	T/A	cg27432699	chr2:27873401	GPN1	0.48	5.31	0.32	2.42e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	7.42	0.43	1.9e-12	Mean platelet volume;
KIRP	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	0.95	14.84	0.69	5.01e-36	Breast cancer;
KIRP	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.41	-0.38	7.56e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg25418670	chr11:30344373	C11orf46	-0.6	-5.02	-0.3	1e-6	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15219393	chr5:149109878	PPARGC1B	0.49	6.33	0.37	1.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.72	8.7	0.48	4.95e-16	Tonsillectomy;
KIRP	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg19507638	chr5:93509721	C5orf36	-0.59	-5.07	-0.31	7.92e-7	Diabetic retinopathy;
KIRP	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	cis	rs11605924	0.967	rs7121611	chr11:45864142	A/T	cg23097878	chr11:45879730	CRY2	0.31	6.43	0.38	6.55e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg24579218	chr15:68104479	NA	0.57	9.28	0.51	9.42e-18	Restless legs syndrome;
KIRP	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg13615516	chr5:77269221	NA	0.52	8.15	0.46	1.87e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg17366294	chr4:99064904	C4orf37	0.44	6.38	0.38	8.94e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.55	7.44	0.43	1.64e-12	Blood metabolite levels;
KIRP	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg10117171	chr1:25599238	RHD	0.39	5.22	0.32	3.77e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg25019033	chr10:957182	NA	-0.67	-6.83	-0.4	6.71e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg04455712	chr21:45112962	RRP1B	0.5	6.79	0.4	8.32e-11	Mean corpuscular volume;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg10360139	chr7:1886902	MAD1L1	-0.44	-4.88	-0.3	1.91e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg08717414	chr16:71523259	ZNF19	0.57	6.85	0.4	5.74e-11	Blood protein levels;
KIRP	cis	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg19847130	chr8:10466454	RP1L1	0.36	5.17	0.31	4.85e-7	Neuroticism;
KIRP	cis	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg19847130	chr8:10466454	RP1L1	-0.35	-4.93	-0.3	1.54e-6	Neuroticism;
KIRP	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg15117754	chr3:10150083	C3orf24	0.48	4.94	0.3	1.42e-6	Alzheimer's disease;
KIRP	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.6	8.25	0.47	9.44e-15	Menarche (age at onset);
KIRP	cis	rs11169552	0.543	rs11169481	chr12:50926485	C/A	cg12884762	chr12:50931848	DIP2B	-0.44	-5.04	-0.31	9.21e-7	Colorectal cancer;
KIRP	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg10189774	chr4:17578691	LAP3	0.51	6.23	0.37	2.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3925075	0.531	rs56392848	chr16:31360892	A/G	cg02846316	chr16:31340340	ITGAM	0.48	5.68	0.34	3.79e-8	IgA nephropathy;
KIRP	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg11522683	chr6:37501428	NA	-0.38	-5.04	-0.31	9.06e-7	Cognitive performance;
KIRP	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg04166393	chr7:2884313	GNA12	0.45	5.89	0.35	1.29e-8	Height;
KIRP	cis	rs300774	1.000	rs300692	chr2:181415	C/T	cg21211680	chr2:198530	NA	-0.59	-6.22	-0.37	2.18e-9	Suicide attempts in bipolar disorder;
KIRP	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	9.88	0.53	1.32e-19	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg17470449	chr10:769945	NA	0.57	6.02	0.36	6.37e-9	Uric acid levels;
KIRP	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.83	-13.85	-0.66	1.22e-32	Brugada syndrome;
KIRP	cis	rs6832769	0.961	rs6817663	chr4:56447215	A/G	cg05960024	chr4:56376020	CLOCK	-0.71	-9.36	-0.51	5.25e-18	Personality dimensions;
KIRP	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.5	6.81	0.4	7.36e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg09165964	chr15:75287851	SCAMP5	0.44	5.52	0.33	8.6e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	4.93e-23	Prudent dietary pattern;
KIRP	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.72	-9.14	-0.5	2.4e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.91	-0.3	1.67e-6	Breast cancer;
KIRP	cis	rs7590368	0.673	rs56140102	chr2:10943256	T/C	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	cis	rs6102059	0.667	rs6124254	chr20:39218023	C/G	cg06665391	chr20:39312290	NA	0.41	5.28	0.32	2.86e-7	LDL cholesterol;
KIRP	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07234876	chr8:600039	NA	0.78	6.22	0.37	2.15e-9	IgG glycosylation;
KIRP	cis	rs7246967	0.673	rs55744741	chr19:22959973	C/T	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.78e-11	Diabetic kidney disease;
KIRP	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.29	5.72	0.34	3.01e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg21360079	chr12:107162445	NA	-0.65	-9.08	-0.5	3.76e-17	Total body bone mineral density;
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-1.1	-22.07	-0.82	2.91e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-5.1	-0.31	6.64e-7	Ulcerative colitis;
KIRP	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.77	0.49	3.08e-16	Bipolar disorder;
KIRP	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.53	5.04	0.31	9.23e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg15147215	chr3:52552868	STAB1	-0.32	-5.74	-0.34	2.78e-8	Electroencephalogram traits;
KIRP	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.54	7.11	0.41	1.25e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs4849845	0.889	rs1065518	chr2:121050989	T/A	cg24070213	chr2:121070622	NA	0.41	5.66	0.34	4.22e-8	Mean platelet volume;
KIRP	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.63	9.18	0.51	1.8e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.6	-6.88	-0.4	4.94e-11	Iron status biomarkers;
KIRP	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg07402062	chr16:89894098	SPIRE2	-0.32	-6.55	-0.39	3.33e-10	Vitiligo;
KIRP	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-7.89	-0.45	1.02e-13	Personality dimensions;
KIRP	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg17724175	chr1:150552817	MCL1	0.36	6.24	0.37	1.87e-9	Melanoma;
KIRP	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg12427896	chr2:111880694	BCL2L11	0.76	7.1	0.41	1.36e-11	Lung function (FEV1);
KIRP	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg17788362	chr6:86352627	SYNCRIP	0.49	6.26	0.37	1.69e-9	Smooth-surface caries;
KIRP	cis	rs1417569	0.519	rs61845674	chr10:31115766	C/T	cg00428179	chr10:31322131	ZNF438	-0.5	-5.48	-0.33	1.06e-7	Tuberculosis;
KIRP	cis	rs9603616	0.719	rs9548872	chr13:40238483	G/A	cg26701198	chr13:40229707	COG6	0.45	5.35	0.32	1.98e-7	Rheumatoid arthritis;
KIRP	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.66	8.88	0.49	1.48e-16	Male sexual orientation;
KIRP	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.49	-7.29	-0.42	4.15e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.41	-0.78	1.56e-51	Schizophrenia;
KIRP	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.26	0.42	4.92e-12	Prudent dietary pattern;
KIRP	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg06647332	chr5:131281008	NA	0.44	5.01	0.3	1.06e-6	Life satisfaction;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09256448	chr16:638327	NA	0.36	5.08	0.31	7.6e-7	Height;
KIRP	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.52	-7.33	-0.42	3.32e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg00079375	chr15:79125835	NA	0.37	5.33	0.32	2.27e-7	Coronary artery disease;
KIRP	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.23	0.42	6.24e-12	Bipolar disorder;
KIRP	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg26876637	chr1:152193138	HRNR	-0.74	-8.39	-0.47	3.8e-15	Atopic dermatitis;
KIRP	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg26965718	chr17:79658957	HGS	-0.61	-5.66	-0.34	4.12e-8	Dental caries;
KIRP	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26207909	chr14:103986467	CKB	0.75	11.54	0.59	6.72e-25	Body mass index;
KIRP	cis	rs4664293	0.747	rs7600347	chr2:160657492	C/G	cg08347373	chr2:160653686	CD302	-0.41	-6.04	-0.36	5.74e-9	Monocyte percentage of white cells;
KIRP	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg17507749	chr15:85114479	UBE2QP1	0.89	9.87	0.53	1.44e-19	Schizophrenia;
KIRP	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	0.85	10.51	0.56	1.35e-21	Prostate cancer;
KIRP	trans	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs629922	0.507	rs633767	chr11:114053886	T/A	cg01914181	chr11:114070210	ZBTB16	-0.47	-4.87	-0.3	2.02e-6	Paneth cell defects in Crohn's disease;
KIRP	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-8.04	-0.46	3.69e-14	Total body bone mineral density;
KIRP	cis	rs6137287	0.883	rs2252714	chr20:21223498	A/T	cg04219410	chr20:21106687	PLK1S1	0.39	4.93	0.3	1.54e-6	Height;
KIRP	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	trans	rs7939886	0.844	rs17150088	chr11:55894862	T/G	cg03929089	chr4:120376271	NA	0.93	6.78	0.4	8.74e-11	Myopia (pathological);
KIRP	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg04306507	chr14:55594613	LGALS3	0.46	7.04	0.41	1.97e-11	Protein biomarker;
KIRP	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg18196295	chr10:418757	DIP2C	0.4	5.03	0.31	9.25e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.66	7.52	0.43	1.04e-12	Corneal astigmatism;
KIRP	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg05714579	chr10:131428358	MGMT	0.49	6.39	0.38	8.02e-10	Response to temozolomide;
KIRP	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.67	9.81	0.53	2.11e-19	Lymphocyte counts;
KIRP	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.83	0.57	1.3e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.06	-0.31	8.08e-7	Neuroticism;
KIRP	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.8	8.04	0.46	3.77e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs9815354	1.000	rs6599170	chr3:41772718	C/G	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.33	8.71e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18252515	chr7:66147081	NA	0.43	5.03	0.31	9.5e-7	Aortic root size;
KIRP	cis	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg02972257	chr16:68554789	NA	-0.55	-5.55	-0.33	7.5e-8	Ulcerative colitis;
KIRP	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg00852783	chr1:26633632	UBXN11	-0.53	-5.29	-0.32	2.69e-7	Obesity-related traits;
KIRP	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	5.61	0.34	5.41e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.68	6.6	0.39	2.46e-10	Axial length;
KIRP	cis	rs921943	1.000	rs2364143	chr5:78316227	A/C	cg26802063	chr5:78281964	ARSB	0.51	6.38	0.38	8.85e-10	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.59	-5.28	-0.32	2.89e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg16369786	chr1:63153804	DOCK7	0.8	6.9	0.4	4.45e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs11825685	0.708	rs73044092	chr11:134546621	G/A	cg06603561	chr11:134479413	NA	-0.56	-5.69	-0.34	3.57e-8	IgG glycosylation;
KIRP	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg05340658	chr4:99064831	C4orf37	0.61	6.26	0.37	1.68e-9	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.68	-0.39	1.55e-10	Heart rate;
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.79	-11.27	-0.58	4.87e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg03563238	chr19:33554763	RHPN2	-0.33	-5.67	-0.34	4.06e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg02297831	chr4:17616191	MED28	0.51	6.0	0.36	7.08e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18252515	chr7:66147081	NA	-0.44	-5.41	-0.33	1.48e-7	Aortic root size;
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.92	0.4	3.8e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10346111	chr3:10326661	GHRLOS;C3orf42	0.57	6.25	0.37	1.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs921943	1.000	rs1805074	chr5:78324352	A/G	cg26802063	chr5:78281964	ARSB	0.49	6.08	0.36	4.56e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.85	11.17	0.58	1.08e-23	Myopia (pathological);
KIRP	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.79	10.78	0.57	1.93e-22	Alcohol dependence (age at onset);
KIRP	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg09873164	chr1:152488093	CRCT1	0.51	6.43	0.38	6.44e-10	Hair morphology;
KIRP	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.78	8.97	0.5	7.76e-17	Corneal astigmatism;
KIRP	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.74	10.77	0.57	2.05e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7714584	1.000	rs4958426	chr5:150278346	A/C	cg22134413	chr5:150180641	NA	1.04	7.35	0.42	2.85e-12	Crohn's disease;
KIRP	cis	rs259842	0.729	rs1486233	chr2:180704481	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.46	-0.33	1.17e-7	Blood protein levels;
KIRP	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg18478394	chr8:109455254	TTC35	0.6	7.47	0.43	1.4e-12	Dupuytren's disease;
KIRP	cis	rs3087591	0.683	rs7502556	chr17:29642430	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	9.84	0.53	1.76e-19	Hip circumference;
KIRP	cis	rs7923609	0.967	rs6479896	chr10:65126832	T/C	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.53	-0.33	8.01e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.66	8.31	0.47	6.45e-15	Resting heart rate;
KIRP	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	5.99	0.36	7.4e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07650554	chr16:30457408	SEPHS2	0.58	6.78	0.4	8.61e-11	Smoking initiation;
KIRP	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg23307798	chr14:103986281	CKB	0.48	6.73	0.39	1.22e-10	Body mass index;
KIRP	cis	rs981844	1.000	rs56331473	chr4:154668052	C/A	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.71	-10.4	-0.55	3.12e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg14082893	chr15:75400931	NA	0.38	5.53	0.33	8.27e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.43	5.94	0.35	9.53e-9	Coronary artery disease;
KIRP	cis	rs9815354	0.767	rs60764195	chr3:41812522	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.68	7.83	0.45	1.49e-13	Plateletcrit;
KIRP	cis	rs7721647	0.853	rs2919809	chr5:90860165	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.41	5.04	0.31	8.88e-7	Breast cancer;
KIRP	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05220968	chr6:146057943	EPM2A	-0.37	-5.03	-0.31	9.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.67	-10.15	-0.54	1.8899999999999998e-20	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-5.95	-0.35	9.32e-9	Aortic root size;
KIRP	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.4	5.27	0.32	2.94e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Blood metabolite levels;
KIRP	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.3	0.37	1.36e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.56	-6.82	-0.4	7.1e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs490234	0.702	rs4838277	chr9:128367886	C/T	cg14078157	chr9:128172775	NA	-0.59	-6.86	-0.4	5.46e-11	Mean arterial pressure;
KIRP	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.48	-6.12	-0.36	3.68e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs2071403	0.933	rs10180405	chr2:1404850	A/G	cg07083862	chr2:1417248	TPO	0.36	5.81	0.35	1.9e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg00800038	chr16:89945340	TCF25	-0.79	-5.46	-0.33	1.14e-7	Skin colour saturation;
KIRP	cis	rs2151522	0.563	rs2143679	chr6:127107582	A/G	cg21431617	chr6:127135037	NA	0.32	5.96	0.36	8.85e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.98	-16.51	-0.73	1.01e-41	Breast cancer;
KIRP	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.43	5.9	0.35	1.21e-8	Total body bone mineral density;
KIRP	cis	rs904251	0.504	rs12202664	chr6:37481198	A/G	cg08126542	chr6:37504118	NA	-0.82	-12.24	-0.62	3.23e-27	Cognitive performance;
KIRP	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.74	9.26	0.51	1.08e-17	Eye color traits;
KIRP	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.21	-0.32	4.07e-7	Putamen volume;
KIRP	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	12.08	0.61	1.12e-26	Chronic sinus infection;
KIRP	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	1.19	11.87	0.6	5.25e-26	Red blood cell traits;
KIRP	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.53	6.98	0.41	2.75e-11	Tuberculosis;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg08989290	chr16:615782	NHLRC4	0.4	5.84	0.35	1.66e-8	Height;
KIRP	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg21479132	chr6:26055353	NA	0.73	4.89	0.3	1.83e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.71	-0.6	1.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.39	-5.03	-0.31	9.6e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg22437258	chr11:111473054	SIK2	0.57	6.55	0.39	3.25e-10	Primary sclerosing cholangitis;
KIRP	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs151997	0.962	rs27256	chr5:50190264	G/C	cg06027927	chr5:50259733	NA	0.59	7.37	0.43	2.57e-12	Callous-unemotional behaviour;
KIRP	cis	rs151997	1.000	rs152690	chr5:50213584	A/T	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg18198730	chr1:247681584	NA	0.59	5.51	0.33	9.02e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg14664628	chr15:75095509	CSK	-0.66	-8.39	-0.47	3.78e-15	Breast cancer;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01126855	chr4:183727586	NA	0.49	6.24	0.37	1.87e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7851660	0.809	rs12004762	chr9:100652755	A/G	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs6662572	1.000	rs7517111	chr1:46122140	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.57	0.33	6.65e-8	Blood protein levels;
KIRP	cis	rs2904967	0.929	rs482842	chr11:65045278	T/G	cg12562828	chr11:65076843	NA	0.6	8.91	0.49	1.19e-16	Mean corpuscular volume;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.64	9.8	0.53	2.3e-19	Immature fraction of reticulocytes;
KIRP	cis	rs2289700	0.561	rs16970223	chr15:79194286	T/A	cg04896959	chr15:78267971	NA	-0.59	-5.37	-0.32	1.81e-7	Bipolar disorder;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg22903657	chr4:1355424	KIAA1530	-0.35	-5.05	-0.31	8.72e-7	Longevity;
KIRP	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.66	-7.32	-0.42	3.53e-12	Alcohol dependence;
KIRP	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg22029157	chr1:209979665	IRF6	0.5	6.52	0.38	3.86e-10	Cleft lip with or without cleft palate;
KIRP	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg00405596	chr8:11794950	NA	-0.5	-6.63	-0.39	2.06e-10	Mood instability;
KIRP	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg06204229	chr3:52865917	ITIH4	-0.42	-5.33	-0.32	2.26e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg17252645	chr8:143867129	LY6D	-0.3	-4.92	-0.3	1.58e-6	Urinary tract infection frequency;
KIRP	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg00784671	chr22:46762841	CELSR1	-0.86	-8.07	-0.46	3.06e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg25319279	chr11:5960081	NA	-0.59	-5.87	-0.35	1.43e-8	DNA methylation (variation);
KIRP	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg21926883	chr2:100939477	LONRF2	-0.51	-6.89	-0.4	4.59e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.65	8.9	0.49	1.27e-16	Longevity;
KIRP	cis	rs11731606	0.712	rs17378658	chr4:95390157	A/G	cg20625393	chr4:95128694	SMARCAD1	-0.55	-5.09	-0.31	7.01e-7	Mean platelet volume;
KIRP	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg16325326	chr1:53192061	ZYG11B	0.78	11.22	0.58	7.44e-24	Monocyte count;
KIRP	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.59	7.68	0.44	3.69e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg07001201	chr5:642380	CEP72	0.66	6.06	0.36	4.99e-9	Obesity-related traits;
KIRP	cis	rs1355223	0.902	rs836466	chr11:34737366	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13198984	chr17:80129470	CCDC57	-0.49	-7.52	-0.43	1.01e-12	Life satisfaction;
KIRP	trans	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.28	-0.37	1.56e-9	Neuroticism;
KIRP	cis	rs7590368	0.715	rs12471725	chr2:10958119	C/T	cg15705551	chr2:10952987	PDIA6	0.58	5.0	0.3	1.11e-6	Educational attainment (years of education);
KIRP	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg08738300	chr3:44038990	NA	0.71	9.72	0.53	4.25e-19	Coronary artery disease;
KIRP	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10875746	0.855	rs73102065	chr12:48492607	T/C	cg26205652	chr12:48591994	NA	0.77	10.12	0.54	2.33e-20	Longevity (90 years and older);
KIRP	cis	rs35883536	0.565	rs2809813	chr1:101032003	A/C	cg09408571	chr1:101003634	GPR88	0.24	5.53	0.33	8.18e-8	Monocyte count;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg21523564	chr15:75251491	NA	0.4	6.52	0.38	3.86e-10	Breast cancer;
KIRP	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.82	6.95	0.4	3.33e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.67	6.62	0.39	2.21e-10	Axial length;
KIRP	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg23682824	chr7:23144976	KLHL7	0.47	5.65	0.34	4.36e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg24315340	chr6:146058215	EPM2A	0.45	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	13.45	0.65	2.73e-31	Electrocardiographic conduction measures;
KIRP	cis	rs500492	0.542	rs400354	chr16:1074526	T/G	cg09791621	chr16:1078722	NA	0.44	4.99	0.3	1.12e-6	Polycystic ovary syndrome;
KIRP	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.12	-0.31	6.27e-7	Rheumatoid arthritis;
KIRP	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.65	9.36	0.51	5.37e-18	Dupuytren's disease;
KIRP	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg13264159	chr8:625131	ERICH1	0.76	6.78	0.4	8.94e-11	IgG glycosylation;
KIRP	cis	rs6005807	0.719	rs73430168	chr22:28985428	C/T	cg12565055	chr22:29076175	TTC28	0.59	5.06	0.31	8.4e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg03060546	chr3:49711283	APEH	-0.64	-6.23	-0.37	2e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg00405596	chr8:11794950	NA	-0.42	-5.41	-0.33	1.51e-7	Triglycerides;
KIRP	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.53	5.73	0.34	2.93e-8	Inflammatory bowel disease;
KIRP	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.6	7.43	0.43	1.77e-12	Arsenic metabolism;
KIRP	cis	rs7289126	1.000	rs5750571	chr22:38640312	A/G	cg25457927	chr22:38595422	NA	-0.32	-6.91	-0.4	4.14e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs9815354	0.638	rs76276404	chr3:41931770	A/G	cg03022575	chr3:42003672	ULK4	0.77	7.99	0.45	5.18e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.63	-7.38	-0.43	2.38e-12	Menarche (age at onset);
KIRP	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.91	0.4	4.15e-11	Menarche (age at onset);
KIRP	cis	rs17767294	0.541	rs72845042	chr6:27568734	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-5.85	-0.35	1.57e-8	Parkinson's disease;
KIRP	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10910200	0.583	rs780208	chr1:233651277	T/C	cg23054119	chr1:233659267	NA	-0.38	-5.2	-0.31	4.25e-7	Diabetic retinopathy;
KIRP	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-6.7	-0.39	1.42e-10	Chronic sinus infection;
KIRP	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-6.89	-0.4	4.77e-11	Platelet count;
KIRP	cis	rs73157695	0.676	rs7277160	chr21:47333235	A/G	cg12162886	chr21:47318899	PCBP3	-0.35	-4.92	-0.3	1.6e-6	Myopia;
KIRP	cis	rs6740322	0.748	rs6756625	chr2:43489313	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.79	10.85	0.57	1.14e-22	Coronary artery disease;
KIRP	cis	rs10751667	0.600	rs10902266	chr11:1005697	G/T	cg10932868	chr11:921992	NA	0.51	5.8	0.35	2.03e-8	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.57	-7.43	-0.43	1.84e-12	Aortic root size;
KIRP	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.43	-6.12	-0.36	3.74e-9	Mean corpuscular volume;
KIRP	cis	rs13385	0.724	rs10039051	chr5:139565146	A/G	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.81	8.85	0.49	1.81e-16	Corneal astigmatism;
KIRP	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.2	-0.37	2.39e-9	QT interval;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg21616051	chr4:987303	IDUA;SLC26A1	-0.23	-5.56	-0.33	6.87e-8	Sjögren's syndrome;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22319618	chr22:45562946	NUP50	0.5	6.93	0.4	3.63e-11	Interleukin-4 levels;
KIRP	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg08773314	chr2:239334832	ASB1	0.41	7.26	0.42	5.03e-12	Multiple system atrophy;
KIRP	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg17644776	chr2:200775616	C2orf69	-0.58	-6.07	-0.36	4.94e-9	Schizophrenia;
KIRP	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.74	9.01	0.5	5.72e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	8.13	0.46	2.15e-14	Educational attainment;
KIRP	cis	rs6504622	0.537	rs1662596	chr17:44993118	C/T	cg16759221	chr17:45003025	GOSR2	-0.41	-6.24	-0.37	1.88e-9	Orofacial clefts;
KIRP	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	5.41	0.33	1.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.75	6.14	0.36	3.25e-9	Diabetic retinopathy;
KIRP	cis	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg12315302	chr6:26189340	HIST1H4D	1.11	6.23	0.37	1.99e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg18200741	chr2:33780366	RASGRP3	-0.21	-6.15	-0.37	3.07e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg01684248	chr16:86536239	NA	-0.45	-6.14	-0.36	3.29e-9	Morning vs. evening chronotype;
KIRP	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.85	-8.42	-0.47	3.25e-15	Obesity-related traits;
KIRP	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg10935138	chr17:73851978	WBP2	-0.45	-5.31	-0.32	2.47e-7	White matter hyperintensity burden;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13445258	chr3:128369860	RPN1	0.58	6.87	0.4	5.22e-11	Smoking initiation;
KIRP	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg09873164	chr1:152488093	CRCT1	0.56	6.98	0.41	2.73e-11	Hair morphology;
KIRP	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.57	6.67	0.39	1.72e-10	Corneal astigmatism;
KIRP	cis	rs16828019	0.852	rs35190461	chr1:41543135	T/C	cg08144172	chr1:41849203	NA	0.62	5.13	0.31	5.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9469913	0.799	rs2492859	chr6:34645266	A/G	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.13	-0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18802818	chr6:146875866	RAB32	0.44	6.22	0.37	2.08e-9	Interleukin-4 levels;
KIRP	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-8.53	-0.48	1.55e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.45	-5.56	-0.33	7.01e-8	Resistin levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22981555	chr4:80138126	NA	0.54	7.28	0.42	4.39e-12	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14073663	chr11:33722324	C11orf91	0.5	6.87	0.4	5.28e-11	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.73	11.21	0.58	7.9e-24	Menarche (age at onset);
KIRP	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg20333904	chr2:240724165	NA	-0.43	-5.89	-0.35	1.24e-8	Obesity-related traits;
KIRP	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg10503236	chr1:231470652	EXOC8	-0.52	-7.5	-0.43	1.14e-12	Hemoglobin concentration;
KIRP	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg13206674	chr6:150067644	NUP43	0.58	8.09	0.46	2.65e-14	Lung cancer;
KIRP	trans	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg05890785	chr19:53811704	NA	-0.47	-6.07	-0.36	4.76e-9	Lung cancer (smoking interaction);
KIRP	cis	rs1620921	0.505	rs1344731	chr6:161205037	G/A	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-0.91	-8.95	-0.5	9.07e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg23748340	chr12:48592721	NA	0.42	4.91	0.3	1.66e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.65	-9.45	-0.52	2.82e-18	Brugada syndrome;
KIRP	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg11031976	chr2:198649780	BOLL	0.56	5.32	0.32	2.37e-7	Ulcerative colitis;
KIRP	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg16898833	chr6:26189333	HIST1H4D	0.66	5.22	0.32	3.85e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952808	0.578	rs6949478	chr7:1841342	A/G	cg10360139	chr7:1886902	MAD1L1	0.52	6.21	0.37	2.27e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.44	6.81	0.4	7.42e-11	Platelet distribution width;
KIRP	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg08662619	chr6:150070041	PCMT1	0.34	5.18	0.31	4.7e-7	Lung cancer;
KIRP	cis	rs9513627	1.000	rs73556165	chr13:100120317	C/T	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg19761014	chr17:28927070	LRRC37B2	0.67	4.91	0.3	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg25214090	chr10:38739885	LOC399744	-0.58	-6.67	-0.39	1.69e-10	Corneal astigmatism;
KIRP	cis	rs4253772	0.872	rs14843	chr22:46639462	A/T	cg18190219	chr22:46762943	CELSR1	-0.7	-5.95	-0.35	9.02e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg16482183	chr6:26056742	HIST1H1C	0.4	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.0	13.96	0.66	5.03e-33	Response to antipsychotic treatment;
KIRP	cis	rs9400467	0.506	rs17756732	chr6:111580154	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs9217	1.000	rs55749333	chr17:7371932	C/T	cg08566640	chr11:64091735	NA	0.52	6.42	0.38	7.05e-10	Height;
KIRP	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.56	-5.98	-0.36	7.86e-9	Body mass index;
KIRP	cis	rs35091702	1	rs35091702	chr8:30279470	CAAAAAAG/C	cg26383811	chr8:30366931	RBPMS	0.36	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7553864	0.966	rs4529687	chr1:87614083	T/C	cg17420885	chr1:87600446	LOC339524	-0.48	-6.4	-0.38	7.97e-10	Smoking behavior;
KIRP	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	0.99	9.87	0.53	1.39e-19	Blood pressure (smoking interaction);
KIRP	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.74	10.81	0.57	1.51e-22	Gut microbiome composition (winter);
KIRP	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg04166393	chr7:2884313	GNA12	0.64	7.68	0.44	3.68e-13	Height;
KIRP	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg26022315	chr17:47021804	SNF8	0.45	5.86	0.35	1.47e-8	Coronary heart disease;
KIRP	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.74	10.94	0.57	5.95e-23	Hip circumference;
KIRP	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.2	0.31	4.12e-7	Parkinson's disease;
KIRP	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	4.94	0.3	1.45e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs741702	0.928	rs2974749	chr19:13038791	A/G	cg11738485	chr19:12877000	HOOK2	0.4	4.86	0.3	2.12e-6	Red blood cell traits;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.62	-9.2	-0.51	1.58e-17	Immature fraction of reticulocytes;
KIRP	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.68	8.69	0.48	5.22e-16	Alzheimer's disease;
KIRP	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.28	-0.37	1.55e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.65	-8.63	-0.48	7.79e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg17863274	chr19:49399704	TULP2	-0.4	-5.66	-0.34	4.14e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.45	5.88	0.35	1.31e-8	Height;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.48	-6.28	-0.37	1.52e-9	Longevity;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg04559178	chr12:29301719	NA	0.46	6.1	0.36	4.07e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg11693508	chr17:37793320	STARD3	0.69	7.25	0.42	5.4e-12	Bipolar disorder;
KIRP	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg03396347	chr1:1875803	NA	-0.62	-9.14	-0.5	2.41e-17	Body mass index;
KIRP	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.6	9.92	0.53	9.99e-20	Total body bone mineral density;
KIRP	trans	rs9371601	0.892	rs549720	chr6:152718591	C/G	cg05529123	chr2:66910386	NA	-0.46	-6.25	-0.37	1.77e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7221595	0.778	rs36054194	chr17:3900280	C/T	cg09695851	chr17:3907499	NA	0.57	6.03	0.36	5.82e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg16141378	chr3:129829833	LOC729375	0.57	7.68	0.44	3.66e-13	Joint mobility (Beighton score);
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg08533424	chr17:37009973	RPL23;SNORA21	-0.47	-6.25	-0.37	1.83e-9	Platelet-derived growth factor BB levels;
KIRP	cis	rs9372498	0.536	rs9489452	chr6:118910868	G/C	cg18833306	chr6:118973337	C6orf204	-0.47	-4.97	-0.3	1.23e-6	Diastolic blood pressure;
KIRP	cis	rs1978968	0.717	rs5992934	chr22:18457119	C/T	cg02610425	chr22:18483192	MICAL3	0.37	5.67	0.34	3.99e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.05	0.31	8.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg12623918	chr2:306882	NA	0.46	5.82	0.35	1.78e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg22562194	chr17:72209580	TTYH2;MGC16275	0.47	6.11	0.36	3.97e-9	Educational attainment;
KIRP	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.98	13.57	0.65	1.12e-31	Menopause (age at onset);
KIRP	cis	rs7572644	0.699	rs937812	chr2:28255302	C/T	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg21656824	chr11:76494942	TSKU	0.49	6.15	0.37	3.18e-9	Myopia (pathological);
KIRP	cis	rs838147	0.844	rs8111399	chr19:49247963	G/T	cg13540341	chr19:49222985	MAMSTR	0.35	5.62	0.34	5.06e-8	Dietary macronutrient intake;
KIRP	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.8	9.3	0.51	7.88e-18	Post bronchodilator FEV1;
KIRP	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg13010199	chr12:38710504	ALG10B	0.41	5.35	0.32	2e-7	Heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18541417	chr15:38856528	RASGRP1	0.5	6.14	0.36	3.36e-9	Parkinson's disease;
KIRP	cis	rs282587	0.569	rs282595	chr13:113379930	A/G	cg04656015	chr13:113407548	ATP11A	-0.66	-8.0	-0.45	4.8e-14	Glycated hemoglobin levels;
KIRP	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg00376283	chr12:123451042	ABCB9	-0.63	-6.58	-0.39	2.78e-10	Neutrophil percentage of white cells;
KIRP	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.41	5.32	0.32	2.3e-7	Childhood ear infection;
KIRP	cis	rs4363385	0.626	rs1108410	chr1:153005662	T/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.33	-0.37	1.15e-9	Inflammatory skin disease;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	7.79	0.44	1.87e-13	Cognitive test performance;
KIRP	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg23188430	chr6:125850052	NA	-0.34	-5.37	-0.32	1.85e-7	Brugada syndrome;
KIRP	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	0.91	6.98	0.41	2.76e-11	IgG glycosylation;
KIRP	cis	rs12643440	0.538	rs6852278	chr4:17138490	A/C	cg22650099	chr4:17144496	NA	0.74	9.28	0.51	9.05e-18	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.98	14.09	0.67	1.85e-33	Cognitive function;
KIRP	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg08632701	chr21:37451849	NA	-0.43	-5.48	-0.33	1.06e-7	Mitral valve prolapse;
KIRP	cis	rs4664293	0.867	rs6432560	chr2:160607269	G/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg00405596	chr8:11794950	NA	0.53	6.95	0.41	3.23e-11	Mood instability;
KIRP	cis	rs8077577	0.747	rs2290505	chr17:18137141	A/G	cg18869244	chr17:18121946	NA	-0.46	-5.25	-0.32	3.33e-7	Obesity-related traits;
KIRP	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.69	-7.78	-0.44	2e-13	Adiposity;
KIRP	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.75	-9.76	-0.53	3.08e-19	Facial morphology (factor 19);
KIRP	cis	rs7560272	0.695	rs780393	chr2:73701669	T/A	cg20560298	chr2:73613845	ALMS1	0.39	4.88	0.3	1.88e-6	Schizophrenia;
KIRP	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.42	-5.5	-0.33	9.41e-8	Body mass index;
KIRP	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.46	6.53	0.38	3.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7792596	0.861	rs6970279	chr7:94014889	A/C	cg20814616	chr7:94014465	NA	0.38	6.23	0.37	1.99e-9	Intelligence;
KIRP	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.58	7.51	0.43	1.12e-12	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	1.11	17.36	0.74	1.28e-44	Homoarginine levels;
KIRP	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.96	-14.01	-0.67	3.38e-33	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.62	10.22	0.55	1.16e-20	Lung cancer;
KIRP	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11987759	chr7:65425863	GUSB	0.45	5.32	0.32	2.34e-7	Aortic root size;
KIRP	trans	rs13170463	0.579	rs6883798	chr5:8036310	C/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg16898833	chr6:26189333	HIST1H4D	0.7	5.57	0.33	6.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-6.58	-0.39	2.86e-10	Monocyte count;
KIRP	cis	rs2151522	0.563	rs9388524	chr6:127122647	A/T	cg21431617	chr6:127135037	NA	0.33	6.01	0.36	6.73e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.61	-0.34	5.39e-8	Schizophrenia;
KIRP	cis	rs8054556	1.000	rs7190185	chr16:29962352	A/G	cg06326092	chr16:30034487	C16orf92	0.36	5.08	0.31	7.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.71	9.53	0.52	1.61e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.0	0.36	6.85e-9	Hemoglobin concentration;
KIRP	cis	rs13095912	0.752	rs62291883	chr3:185313842	T/C	cg11274856	chr3:185301563	NA	0.59	7.58	0.44	6.87e-13	Systolic blood pressure;
KIRP	cis	rs6815814	0.950	rs4540055	chr4:38803255	A/T	cg06935464	chr4:38784597	TLR10	0.49	5.56	0.33	7.12e-8	Breast cancer;
KIRP	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.71	-10.45	-0.55	2.11e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.67	-0.44	4e-13	Myopia (pathological);
KIRP	cis	rs2502731	0.539	rs3003614	chr9:130994736	G/A	cg13642260	chr9:130955380	CIZ1	0.41	5.5	0.33	9.6e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs4764487	0.710	rs7964366	chr12:6346478	T/C	cg08284733	chr12:6341482	CD9	0.6	10.4	0.55	3.05e-21	Mean platelet volume;
KIRP	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg04166393	chr7:2884313	GNA12	0.63	7.44	0.43	1.72e-12	Height;
KIRP	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.88	9.74	0.53	3.53e-19	Pulmonary function decline;
KIRP	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.53	0.33	8.27e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.76	-8.98	-0.5	7.02e-17	Pancreatic cancer;
KIRP	cis	rs2733201	1.000	rs2706472	chr15:44433292	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.06	-0.36	5.1e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.85	-14.39	-0.68	1.79e-34	Prostate cancer;
KIRP	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.84	11.37	0.59	2.3e-24	Morning vs. evening chronotype;
KIRP	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg07701084	chr6:150067640	NUP43	0.55	6.98	0.41	2.7e-11	Testicular germ cell tumor;
KIRP	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.9	-0.73	4.59e-43	Height;
KIRP	cis	rs911119	0.913	rs6048928	chr20:23585988	A/G	cg09631192	chr20:23583594	CST9	-0.66	-6.49	-0.38	4.73e-10	Chronic kidney disease;
KIRP	cis	rs714515	0.967	rs9425590	chr1:172358664	A/C	cg01573306	chr1:172330400	DNM3	0.44	5.79	0.35	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs2270927	0.790	rs4613682	chr5:75576455	G/C	cg13563193	chr19:33072644	PDCD5	0.76	7.16	0.42	9.47e-12	Mean corpuscular volume;
KIRP	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.78	-0.35	2.24e-8	Height;
KIRP	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.03	0.41	2.04e-11	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.68	-0.53	5.64e-19	Response to antipsychotic treatment;
KIRP	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs2274273	0.870	rs10145203	chr14:55784458	A/C	cg04306507	chr14:55594613	LGALS3	0.44	6.56	0.39	3.08e-10	Protein biomarker;
KIRP	cis	rs1829883	0.698	rs7720921	chr5:98986307	A/C	cg08333243	chr5:99726346	NA	0.41	5.2	0.31	4.17e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11625487	0.609	rs78677337	chr14:77966223	G/A	cg20045696	chr14:77926864	AHSA1	-0.75	-5.46	-0.33	1.16e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs2072732	0.821	rs10909864	chr1:2948178	T/C	cg06792538	chr1:2954250	NA	0.39	4.87	0.3	2.01e-6	Plateletcrit;
KIRP	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.84	11.37	0.59	2.43e-24	Morning vs. evening chronotype;
KIRP	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	4.96	0.3	1.34e-6	Tonsillectomy;
KIRP	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg17595323	chr11:93583763	C11orf90	-0.3	-5.14	-0.31	5.47e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg09873164	chr1:152488093	CRCT1	0.5	6.36	0.38	9.97e-10	Hair morphology;
KIRP	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg24324837	chr19:49891574	CCDC155	-0.42	-4.97	-0.3	1.26e-6	Multiple sclerosis;
KIRP	cis	rs2964802	0.617	rs13174269	chr5:10804759	C/T	cg14521931	chr5:10832172	NA	-0.46	-6.39	-0.38	8.09e-10	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs1978968	0.912	rs34156568	chr22:18444261	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg03653399	chr8:142233436	SLC45A4	-0.51	-6.06	-0.36	5.07e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.31	-0.32	2.49e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1010254	0.510	rs72806379	chr5:151701942	C/T	cg12297329	chr5:152029980	NA	-0.66	-6.73	-0.39	1.19e-10	Optic nerve measurement (cup area);
KIRP	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs400736	0.729	rs1546846	chr1:8004259	C/T	cg25007680	chr1:8021821	PARK7	-0.56	-7.27	-0.42	4.7e-12	Response to antidepressants and depression;
KIRP	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg10047753	chr17:41438598	NA	1.15	18.22	0.76	1.51e-47	Menopause (age at onset);
KIRP	cis	rs10266483	1.000	rs10266483	chr7:63733331	A/G	cg04636841	chr7:63768139	NA	-0.38	-4.85	-0.3	2.18e-6	Response to statin therapy;
KIRP	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.83	11.58	0.59	4.72e-25	Body mass index;
KIRP	cis	rs27434	0.583	rs149431	chr5:96157541	T/C	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.06e-8	Ankylosing spondylitis;
KIRP	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.95	10.0	0.54	5.49e-20	Cognitive test performance;
KIRP	cis	rs2882667	0.964	rs12055237	chr5:138307306	A/G	cg04439458	chr5:138467593	SIL1	-0.42	-6.37	-0.38	9.24e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg27170947	chr2:26402098	FAM59B	0.52	5.79	0.35	2.12e-8	Gut microbiome composition (summer);
KIRP	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.83	7.87	0.45	1.14e-13	Menopause (age at onset);
KIRP	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.47	-0.48	2.24e-15	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg21905437	chr5:178450457	ZNF879	0.58	6.76	0.4	9.92e-11	Pubertal anthropometrics;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.75	10.51	0.56	1.42e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.78	14.36	0.68	2.23e-34	Lymphocyte counts;
KIRP	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.7	0.39	1.44e-10	Aortic root size;
KIRP	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg11641102	chr8:27183873	PTK2B	0.47	6.11	0.36	3.89e-9	Neuroticism;
KIRP	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg10504392	chr12:110044639	NA	0.24	4.91	0.3	1.64e-6	Neuroticism;
KIRP	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg00262122	chr8:11665843	FDFT1	0.4	5.07	0.31	7.98e-7	Myopia (pathological);
KIRP	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg13180566	chr4:1052158	NA	-0.54	-5.43	-0.33	1.36e-7	Recombination rate (females);
KIRP	trans	rs225245	0.817	rs225302	chr17:33922396	C/T	cg19694781	chr19:47549865	TMEM160	-0.53	-6.49	-0.38	4.74e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26617929	chr16:1858877	NA	-0.71	-5.91	-0.35	1.11e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.53	7.35	0.42	2.9e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.5	-7.71	-0.44	3.12e-13	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-0.78	-9.08	-0.5	3.54e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.52	-6.23	-0.37	2.05e-9	Ulcerative colitis;
KIRP	cis	rs4356932	0.817	rs6826406	chr4:76973557	A/C	cg00809888	chr4:76862425	NAAA	0.44	6.2	0.37	2.42e-9	Blood protein levels;
KIRP	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.62	-8.52	-0.48	1.65e-15	Blood protein levels;
KIRP	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg06654118	chr4:1303317	MAEA	0.28	5.36	0.32	1.93e-7	Obesity-related traits;
KIRP	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.53	11.52	0.59	7.39e-25	Diabetic kidney disease;
KIRP	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.37e-10	Aortic root size;
KIRP	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.71	-0.39	1.36e-10	Testicular germ cell tumor;
KIRP	cis	rs2764980	1.000	rs2764978	chr10:3283385	C/G	cg11630169	chr10:3283847	NA	-0.45	-6.12	-0.36	3.58e-9	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs1629083	0.875	rs17121871	chr11:118073344	A/G	cg18857871	chr11:118064634	AMICA1	0.66	9.15	0.5	2.17e-17	Lung cancer;
KIRP	cis	rs7937612	1.000	rs1892894	chr11:120254684	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.49	-7.43	-0.43	1.81e-12	Intraocular pressure;
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg02462569	chr6:150064036	NUP43	0.44	6.77	0.4	9.2e-11	Lung cancer;
KIRP	cis	rs4638749	0.501	rs13391411	chr2:108789053	A/G	cg06795125	chr2:108905320	SULT1C2	-0.3	-5.44	-0.33	1.28e-7	Blood pressure;
KIRP	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg27147174	chr7:100797783	AP1S1	0.57	7.42	0.43	1.9e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.62	0.44	5.56e-13	Height;
KIRP	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg22817719	chr11:130068300	ST14	0.42	6.54	0.38	3.62e-10	Serum protein levels (sST2);
KIRP	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.82	-9.67	-0.52	5.73e-19	Neutrophil percentage of white cells;
KIRP	cis	rs7560272	0.538	rs4852972	chr2:73916672	C/T	cg20560298	chr2:73613845	ALMS1	0.51	6.13	0.36	3.53e-9	Schizophrenia;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.54	8.15	0.46	1.84e-14	Lung cancer;
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.63	0.34	4.83e-8	Schizophrenia;
KIRP	cis	rs9583531	0.660	rs80030913	chr13:111336866	G/C	cg24331049	chr13:111365604	ING1	-0.84	-5.8	-0.35	2e-8	Coronary artery disease;
KIRP	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.08	21.43	0.81	3.47e-58	Platelet distribution width;
KIRP	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.77	-0.69	9.15e-36	Height;
KIRP	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.65	6.43	0.38	6.63e-10	Height;
KIRP	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.5	-0.33	9.32e-8	Body mass index;
KIRP	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17344932	chr17:38183730	MED24;SNORD124	0.45	7.24	0.42	5.57e-12	White blood cell count;
KIRP	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg14593290	chr7:50529359	DDC	0.65	7.83	0.45	1.49e-13	Malaria;
KIRP	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.61	6.74	0.39	1.15e-10	Height;
KIRP	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg16586182	chr3:47516702	SCAP	-0.69	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.2	0.31	4.12e-7	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11653758	chr19:507511	C19orf20	0.53	6.96	0.41	3.01e-11	Parkinson's disease;
KIRP	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.11e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7602568	1.000	rs2338440	chr2:28587656	G/C	cg27432699	chr2:27873401	GPN1	-0.47	-5.17	-0.31	4.93e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.77	-11.22	-0.58	7.28e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.63	8.04	0.46	3.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7719624	0.870	rs1990199	chr5:135395543	G/C	cg16684184	chr5:135415129	NA	0.35	5.25	0.32	3.23e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg22437258	chr11:111473054	SIK2	0.55	6.3	0.37	1.38e-9	Primary sclerosing cholangitis;
KIRP	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	0.81	7.09	0.41	1.39e-11	Obesity-related traits;
KIRP	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.46	5.83	0.35	1.76e-8	Blood metabolite levels;
KIRP	cis	rs4262150	0.810	rs72797211	chr5:151959517	T/A	cg12297329	chr5:152029980	NA	-0.68	-8.33	-0.47	5.86e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg10326726	chr10:51549505	MSMB	0.56	7.96	0.45	6.4e-14	Prostate-specific antigen levels;
KIRP	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.63	10.64	0.56	5.4e-22	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg09873164	chr1:152488093	CRCT1	-0.56	-7.19	-0.42	7.81e-12	Hair morphology;
KIRP	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.91	-14.96	-0.69	2.06e-36	Breast cancer;
KIRP	cis	rs8067545	0.532	rs17759609	chr17:19992514	C/G	cg13482628	chr17:19912719	NA	0.47	5.34	0.32	2.11e-7	Schizophrenia;
KIRP	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-7.35	-0.42	2.96e-12	Platelet count;
KIRP	cis	rs6593803	0.622	rs12747247	chr1:147166010	A/C	cg27546670	chr1:147246839	GJA5	-0.55	-5.37	-0.32	1.83e-7	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs1468333	1.000	rs17171770	chr5:137514815	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.47	5.25	0.32	3.27e-7	Resting heart rate;
KIRP	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg10189774	chr4:17578691	LAP3	0.44	5.32	0.32	2.31e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4474465	1.000	rs10793319	chr11:78217237	G/A	cg02023728	chr11:77925099	USP35	-0.32	-5.41	-0.33	1.47e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7224685	0.569	rs12453798	chr17:4017079	C/T	cg09695851	chr17:3907499	NA	0.54	5.05	0.31	8.69e-7	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	6.33	0.37	1.17e-9	Menopause (age at onset);
KIRP	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.56	5.6	0.34	5.61e-8	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7404928	0.718	rs72777934	chr16:23871621	C/T	cg21745164	chr16:23765304	CHP2	-0.55	-6.44	-0.38	6.3e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg18209359	chr17:80159595	CCDC57	0.41	5.5	0.33	9.46e-8	Life satisfaction;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14145653	chr9:5184772	INSL6	0.56	6.14	0.36	3.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.77	-10.92	-0.57	6.86e-23	Asthma;
KIRP	cis	rs6669919	1.000	rs6669919	chr1:211674383	T/C	cg10512769	chr1:211675356	NA	-0.63	-10.08	-0.54	3.23e-20	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21449926	chr8:110253782	NUDCD1	-0.41	-6.3	-0.37	1.36e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.93	13.19	0.64	2.07e-30	Bladder cancer;
KIRP	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.61e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg25214090	chr10:38739885	LOC399744	0.47	6.16	0.37	2.89e-9	Diastolic blood pressure;
KIRP	cis	rs8177876	0.822	rs9938965	chr16:81113163	G/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.32	-0.37	1.2e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12292205	chr6:26970375	C6orf41	-0.68	-7.3	-0.42	4.05e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.53	-0.38	3.77e-10	Joint mobility (Beighton score);
KIRP	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg10503236	chr1:231470652	EXOC8	-0.49	-6.78	-0.4	8.94e-11	Hemoglobin concentration;
KIRP	cis	rs3735025	0.963	rs161336	chr7:137052399	G/A	cg13839563	chr7:136910420	NA	0.39	4.93	0.3	1.52e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg22532475	chr10:104410764	TRIM8	-0.32	-5.23	-0.32	3.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.35	0.42	3e-12	Aortic root size;
KIRP	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg05347473	chr6:146136440	FBXO30	0.41	5.66	0.34	4.23e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62070183	0.808	rs79957065	chr17:31142749	C/T	cg05781649	chr17:31146240	MYO1D	-0.5	-4.9	-0.3	1.71e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.63	0.34	4.79e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg15744005	chr10:104629667	AS3MT	-0.31	-5.97	-0.36	8.05e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.68	8.59	0.48	1.02e-15	Body mass index;
KIRP	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg25706552	chr1:244017396	NA	0.63	6.73	0.39	1.18e-10	RR interval (heart rate);
KIRP	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.85	9.42	0.51	3.43e-18	Iron status biomarkers;
KIRP	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg12697442	chr11:101981167	YAP1	-0.45	-6.1	-0.36	4.09e-9	Vertical cup-disc ratio;
KIRP	cis	rs364477	0.794	rs10123824	chr9:958073	G/A	cg13952963	chr9:998547	NA	0.51	5.01	0.3	1.03e-6	Major depressive disorder;
KIRP	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.89	14.08	0.67	2e-33	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg12756093	chr1:115239321	AMPD1	0.59	7.54	0.43	9.31e-13	Autism;
KIRP	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg13147721	chr7:65941812	NA	-1.0	-6.72	-0.39	1.25e-10	Diabetic kidney disease;
KIRP	cis	rs1538970	0.924	rs12037201	chr1:45941349	G/T	cg03146154	chr1:46216737	IPP	0.49	5.17	0.31	4.77e-7	Platelet count;
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.6	-0.34	5.66e-8	Life satisfaction;
KIRP	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.87	-0.45	1.09e-13	Sudden cardiac arrest;
KIRP	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.51	7.36	0.42	2.74e-12	Testicular germ cell tumor;
KIRP	cis	rs4363385	0.720	rs1415967	chr1:152965585	C/T	cg13444842	chr1:152974279	SPRR3	-0.35	-4.93	-0.3	1.53e-6	Inflammatory skin disease;
KIRP	cis	rs6504622	0.875	rs4968250	chr17:45045351	C/G	cg24703533	chr17:45055318	NA	0.39	5.53	0.33	8.33e-8	Orofacial clefts;
KIRP	cis	rs3736594	0.722	rs12993377	chr2:27952767	G/C	cg27432699	chr2:27873401	GPN1	-0.61	-7.85	-0.45	1.27e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.07	0.36	4.83e-9	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg13512537	chr8:22265999	SLC39A14	-0.41	-5.35	-0.32	2.05e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg25482853	chr8:67687455	SGK3	0.78	7.41	0.43	2.08e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6708331	0.517	rs11692018	chr2:70369154	A/C	cg01613454	chr2:70366299	NA	0.39	5.23	0.32	3.68e-7	Obesity-related traits;
KIRP	trans	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00950418	chr7:105029125	SRPK2	-0.55	-6.75	-0.4	1.04e-10	Height;
KIRP	cis	rs11166927	1.000	rs13256625	chr8:140805003	G/T	cg16909799	chr8:140841666	TRAPPC9	0.73	10.71	0.56	3.26e-22	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03346523	chr11:32951061	QSER1	-0.48	-7.72	-0.44	2.91e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.55	4.85	0.3	2.16e-6	Bipolar disorder;
KIRP	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-6.65	-0.39	1.87e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.17e-37	Height;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.47	-0.33	1.09e-7	Lung cancer;
KIRP	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg20503657	chr10:835505	NA	0.91	9.27	0.51	1e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.71	-0.56	3.18e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg22974920	chr21:40686053	BRWD1	-0.41	-4.89	-0.3	1.79e-6	Cognitive function;
KIRP	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg05315796	chr3:52349193	DNAH1	0.41	6.47	0.38	5.32e-10	Electroencephalogram traits;
KIRP	cis	rs16976116	0.901	rs2899582	chr15:55491734	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs17221829	0.733	rs2388105	chr11:89355317	A/G	cg02982614	chr11:89391479	FOLH1B	0.3	4.91	0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7923609	0.870	rs10822156	chr10:65080727	T/C	cg01631684	chr10:65280961	REEP3	-0.51	-5.99	-0.36	7.29e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.18	-0.51	1.83e-17	Colorectal cancer;
KIRP	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.61	-7.02	-0.41	2.11e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2591576	0.718	rs115321012	chr5:165396290	T/C	cg13976338	chr5:165423657	NA	-0.65	-8.78	-0.49	2.78e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg04691961	chr3:161091175	C3orf57	-0.57	-8.58	-0.48	1.08e-15	Morning vs. evening chronotype;
KIRP	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg06671706	chr8:8559999	CLDN23	0.53	6.06	0.36	4.98e-9	Obesity-related traits;
KIRP	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23161317	chr6:28129485	ZNF389	0.42	4.92	0.3	1.57e-6	Depression;
KIRP	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.83	11.8	0.6	9.19e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg16497661	chr14:103986332	CKB	-0.5	-5.05	-0.31	8.46e-7	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.81	0.35	1.91e-8	Renal cell carcinoma;
KIRP	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg01631408	chr1:248437212	OR2T33	-0.41	-4.96	-0.3	1.31e-6	Common traits (Other);
KIRP	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg17207736	chr8:142237307	SLC45A4	-0.46	-5.55	-0.33	7.52e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg05507819	chr15:63340323	TPM1	-0.51	-6.35	-0.38	1.02e-9	Platelet count;
KIRP	cis	rs10849893	0.557	rs6489812	chr12:121913559	T/A	cg01154721	chr12:121881891	KDM2B	0.45	6.03	0.36	5.95e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg07115304	chr20:361903	TRIB3	0.51	6.21	0.37	2.27e-9	Educational attainment;
KIRP	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.95	-0.35	9.19e-9	Educational attainment;
KIRP	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.75	7.25	0.42	5.43e-12	Arsenic metabolism;
KIRP	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	trans	rs1941687	0.831	rs28402875	chr18:31351506	G/A	cg27147174	chr7:100797783	AP1S1	-0.56	-6.92	-0.4	3.88e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.68	10.01	0.54	5.41e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12615966	0.932	rs17020857	chr2:105401306	A/G	cg16465502	chr2:105461796	NA	-0.64	-5.43	-0.33	1.34e-7	Pancreatic cancer;
KIRP	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs9513627	1.000	rs9582302	chr13:100125985	A/T	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.49	-6.94	-0.4	3.5e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.86	11.21	0.58	7.72e-24	Monocyte count;
KIRP	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg15733309	chr7:157513707	PTPRN2	0.42	6.39	0.38	8.12e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs4561483	0.619	rs12597429	chr16:12062396	A/G	cg08843971	chr16:11963173	GSPT1	-0.47	-6.38	-0.38	8.6e-10	Testicular germ cell tumor;
KIRP	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.69	-5.46	-0.33	1.16e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.46	-5.48	-0.33	1.06e-7	P wave terminal force;
KIRP	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	1.03	18.15	0.76	2.76e-47	Leprosy;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.32	5.32	0.32	2.36e-7	Iron status biomarkers;
KIRP	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11987759	chr7:65425863	GUSB	-0.45	-5.48	-0.33	1.05e-7	Aortic root size;
KIRP	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg03161606	chr19:29218774	NA	0.83	8.02	0.46	4.43e-14	Methadone dose in opioid dependence;
KIRP	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.46	5.83	0.35	1.7e-8	Coronary artery disease;
KIRP	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-6.72	-0.39	1.24e-10	Aortic root size;
KIRP	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.49	6.5	0.38	4.35e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.555	rs11504385	chr12:38285085	G/A	cg26384229	chr12:38710491	ALG10B	-0.42	-5.41	-0.33	1.47e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg02462569	chr6:150064036	NUP43	-0.34	-5.34	-0.32	2.15e-7	Lung cancer;
KIRP	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15358743	chr18:56807035	SEC11C	0.52	6.12	0.36	3.74e-9	Smoking initiation;
KIRP	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-8.26	-0.47	8.85e-15	Resting heart rate;
KIRP	trans	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs4236601	1.000	rs67933359	chr7:116143862	C/A	cg05166801	chr7:116143459	CAV2	0.46	5.55	0.33	7.23e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg00204512	chr16:28754710	NA	0.39	5.09	0.31	7.25e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg13699009	chr12:122356056	WDR66	0.72	11.6	0.59	4.08e-25	Mean corpuscular volume;
KIRP	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.88	-0.77	9.72e-50	Schizophrenia;
KIRP	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg23594656	chr7:65796392	TPST1	0.51	7.89	0.45	9.9e-14	Aortic root size;
KIRP	cis	rs2562456	0.833	rs76646508	chr19:21518049	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs7551222	0.680	rs2169137	chr1:204497913	G/C	cg20240347	chr1:204465584	NA	-0.37	-6.26	-0.37	1.66e-9	Schizophrenia;
KIRP	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg23594656	chr7:65796392	TPST1	-0.37	-5.36	-0.32	1.92e-7	Aortic root size;
KIRP	cis	rs742134	0.915	rs742136	chr22:43518822	A/G	cg26453588	chr22:43506021	BIK	0.38	5.33	0.32	2.18e-7	Prostate cancer;
KIRP	cis	rs73200209	0.744	rs61939680	chr12:116493867	G/A	cg01776926	chr12:116560359	MED13L	-0.56	-6.13	-0.36	3.38e-9	Total body bone mineral density;
KIRP	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.35	-0.42	2.9e-12	Neuroticism;
KIRP	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.75	-7.99	-0.45	5.27e-14	Corneal astigmatism;
KIRP	cis	rs11203032	0.831	rs10788638	chr10:90950683	A/G	cg16672925	chr10:90967113	CH25H	0.44	5.35	0.32	2.03e-7	Heart failure;
KIRP	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg06197360	chr20:60970103	CABLES2	-0.48	-5.41	-0.33	1.48e-7	Colorectal cancer;
KIRP	cis	rs2494938	0.655	rs846531	chr6:40552132	A/C	cg14084896	chr6:40530702	LRFN2	-0.41	-4.93	-0.3	1.53e-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg27211696	chr2:191398769	TMEM194B	-0.55	-6.72	-0.39	1.23e-10	Diastolic blood pressure;
KIRP	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.44	-5.93	-0.35	1.02e-8	Refractive error;
KIRP	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	12.09	0.61	1.03e-26	Lymphocyte percentage of white cells;
KIRP	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.3	-0.51	8.19e-18	Brugada syndrome;
KIRP	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14169450	chr9:139327907	INPP5E	0.5	7.32	0.42	3.5e-12	Monocyte percentage of white cells;
KIRP	cis	rs9847710	0.566	rs2564951	chr3:53060449	C/T	cg05315796	chr3:52349193	DNAH1	-0.37	-4.88	-0.3	1.9e-6	Ulcerative colitis;
KIRP	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg21775007	chr8:11205619	TDH	0.47	6.25	0.37	1.78e-9	Triglycerides;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg21186296	chr8:27182909	PTK2B	0.51	6.44	0.38	6.34e-10	Neuroticism;
KIRP	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg11952622	chr19:58962976	ZNF324B	-0.43	-5.1	-0.31	6.7e-7	Uric acid clearance;
KIRP	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.62	-7.71	-0.44	3.04e-13	Iron status biomarkers;
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg07216194	chr8:27182965	PTK2B	0.43	5.34	0.32	2.09e-7	Neuroticism;
KIRP	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg01338084	chr22:32026380	PISD	-0.93	-7.33	-0.42	3.28e-12	Age-related hearing impairment;
KIRP	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.48	-7.22	-0.42	6.59e-12	Vitamin D levels;
KIRP	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg23985595	chr17:80112537	CCDC57	0.38	5.91	0.35	1.15e-8	Life satisfaction;
KIRP	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.47	5.3	0.32	2.53e-7	Schizophrenia;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg08805041	chr16:621841	PIGQ	-0.41	-5.53	-0.33	8.32e-8	Height;
KIRP	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.99	14.84	0.69	5.31e-36	Monocyte count;
KIRP	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.06	-0.36	5.07e-9	Breast cancer;
KIRP	cis	rs17401966	0.540	rs11121566	chr1:10472848	C/G	cg17425144	chr1:10567563	PEX14	-0.32	-5.35	-0.32	1.97e-7	Hepatocellular carcinoma;
KIRP	cis	rs55675132	0.510	rs6696332	chr1:115300370	T/C	cg12756093	chr1:115239321	AMPD1	0.66	6.31	0.37	1.27e-9	Schizophrenia;
KIRP	cis	rs6442310	0.534	rs1151998	chr3:12446492	A/G	cg15873301	chr3:12045459	SYN2	0.4	5.35	0.32	2.03e-7	Hematocrit;
KIRP	cis	rs7849270	0.725	rs59012667	chr9:131850481	G/T	cg13538475	chr9:131942899	NA	-0.36	-5.65	-0.34	4.37e-8	Blood metabolite ratios;
KIRP	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.49	0.33	1.01e-7	Platelet count;
KIRP	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.69	8.04	0.46	3.78e-14	Smoking initiation;
KIRP	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19717773	chr7:2847554	GNA12	0.35	5.34	0.32	2.07e-7	Height;
KIRP	cis	rs7845219	0.544	rs9643350	chr8:95917276	C/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.03	-0.36	5.87e-9	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08903422	chr17:7328532	C17orf74	0.45	6.34	0.37	1.07e-9	Interleukin-4 levels;
KIRP	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg19752551	chr11:57585705	CTNND1	0.68	11.44	0.59	1.4e-24	Schizophrenia;
KIRP	trans	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg24644049	chr4:85504048	CDS1	0.76	6.47	0.38	5.37e-10	Skin colour saturation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25778220	chr18:48556359	SMAD4	0.49	6.39	0.38	8.42e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-7.22	-0.42	6.63e-12	Coronary artery disease;
KIRP	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05220968	chr6:146057943	EPM2A	0.42	5.32	0.32	2.35e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17346426	chr2:216946392	TMEM169;PECR	-0.59	-6.94	-0.4	3.46e-11	Interleukin-4 levels;
KIRP	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs7580658	0.545	rs885276	chr2:127950904	A/T	cg16751203	chr2:127950803	CYP27C1	0.42	5.78	0.35	2.28e-8	Protein C levels;
KIRP	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg19077165	chr18:44547161	KATNAL2	0.46	5.69	0.34	3.61e-8	Personality dimensions;
KIRP	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.63	-0.39	2.14e-10	Axial length;
KIRP	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.58	-0.39	2.75e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03934478	chr11:495069	RNH1	0.78	6.19	0.37	2.43e-9	Body mass index;
KIRP	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.42	-0.38	7.05e-10	Retinal vascular caliber;
KIRP	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.84	9.53	0.52	1.54e-18	Iron status biomarkers;
KIRP	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	1.08	19.39	0.78	1.85e-51	Leprosy;
KIRP	cis	rs2790457	0.958	rs2790444	chr10:28825689	C/T	cg05705492	chr10:28955341	NA	-0.54	-8.25	-0.47	9.35e-15	Multiple myeloma;
KIRP	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.52	-0.59	7.55e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs8054556	1.000	rs4788209	chr16:30013266	C/T	cg06326092	chr16:30034487	C16orf92	0.36	5.02	0.3	9.92e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12422267	0.702	rs4072972	chr12:132602748	T/C	cg26561844	chr12:132562101	EP400	-0.58	-5.21	-0.32	3.92e-7	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	22.33	0.82	4.14e-61	Chronic sinus infection;
KIRP	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.44	4.88	0.3	1.94e-6	Platelet count;
KIRP	cis	rs4805272	0.962	rs1363327	chr19:29325571	A/C	cg15000279	chr19:29285009	NA	-0.4	-5.85	-0.35	1.59e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.56	-0.43	8.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg23307798	chr14:103986281	CKB	0.48	6.89	0.4	4.52e-11	Body mass index;
KIRP	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04374321	chr14:90722782	PSMC1	0.93	15.9	0.71	1.27e-39	Mortality in heart failure;
KIRP	cis	rs2635047	0.631	rs2668778	chr18:44745185	A/C	cg19077165	chr18:44547161	KATNAL2	-0.4	-5.09	-0.31	7.11e-7	Educational attainment;
KIRP	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg24253500	chr15:84953950	NA	-0.4	-5.02	-0.3	9.84e-7	P wave terminal force;
KIRP	cis	rs2594989	0.779	rs56053623	chr3:11592153	T/C	cg01796438	chr3:11312864	ATG7	0.43	5.6	0.34	5.84e-8	Circulating chemerin levels;
KIRP	cis	rs3741798	1.000	rs17303178	chr12:12485351	G/A	cg08615371	chr12:12503544	MANSC1	0.94	8.28	0.47	7.84e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.21	0.42	6.82e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	0.85	7.78	0.44	2.05e-13	Gut microbiota (bacterial taxa);
KIRP	cis	rs4566357	1.000	rs2251223	chr2:227914975	T/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.28	-0.32	2.88e-7	Coronary artery disease;
KIRP	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg16586182	chr3:47516702	SCAP	-0.54	-6.49	-0.38	4.63e-10	Birth weight;
KIRP	cis	rs2299587	0.527	rs7843715	chr8:17733526	C/A	cg01800426	chr8:17659068	MTUS1	-0.42	-5.15	-0.31	5.36e-7	Economic and political preferences;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23931836	chr19:47615988	ZC3H4	0.51	6.23	0.37	2.01e-9	Parkinson's disease;
KIRP	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.41	6.19	0.37	2.54e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02146966	chr17:18967117	NA	0.96	6.92	0.4	3.79e-11	P wave terminal force;
KIRP	trans	rs1941687	0.797	rs12963024	chr18:31389547	A/G	cg04226714	chr8:49833948	SNAI2	-0.44	-6.02	-0.36	6.23e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07737236	chr3:161089327	C3orf57	0.41	5.35	0.32	2.06e-7	Parkinson's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07937555	chr14:59365905	NA	0.4	6.21	0.37	2.3e-9	C-reactive protein;
KIRP	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.57	7.7	0.44	3.32e-13	Schizophrenia;
KIRP	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg15038512	chr6:170123185	PHF10	0.48	5.39	0.33	1.62e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-1.13	-12.07	-0.61	1.19e-26	Atopic dermatitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21156006	chr9:129455121	LMX1B	0.45	6.67	0.39	1.71e-10	Survival in pancreatic cancer;
KIRP	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg14993813	chr1:46806288	NSUN4	-0.48	-5.52	-0.33	8.5e-8	Menopause (age at onset);
KIRP	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.8	0.35	2.07e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6700559	0.692	rs2809342	chr1:200597650	C/T	cg07804481	chr1:200639085	DDX59	-0.41	-5.16	-0.31	5.19e-7	Coronary artery disease;
KIRP	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.9	-13.19	-0.64	2.18e-30	Height;
KIRP	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg18306943	chr3:40428807	ENTPD3	0.46	6.35	0.38	1.01e-9	Renal cell carcinoma;
KIRP	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.56	-7.23	-0.42	6.26e-12	Colorectal cancer;
KIRP	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.75	12.1	0.61	9.41e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.68	-0.34	3.72e-8	Aortic root size;
KIRP	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.45	5.84	0.35	1.61e-8	Neutrophil percentage of white cells;
KIRP	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.98	-0.54	6.72e-20	Triglycerides;
KIRP	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg22771759	chr13:24902376	NA	0.42	5.33	0.32	2.19e-7	Obesity-related traits;
KIRP	trans	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg06521331	chr12:34319734	NA	-0.54	-6.76	-0.4	9.91e-11	Bladder cancer;
KIRP	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13686307	chr2:232651122	COPS7B	-0.47	-6.19	-0.37	2.45e-9	Metabolic traits;
KIRP	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.79	0.35	2.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.18	-0.37	2.65e-9	Breast cancer;
KIRP	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.84e-11	Hypertriglyceridemia;
KIRP	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.69	-9.15	-0.5	2.24e-17	Dilated cardiomyopathy;
KIRP	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg17971929	chr21:40555470	PSMG1	-0.59	-6.45	-0.38	5.96e-10	Menarche (age at onset);
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.69	10.97	0.57	4.53e-23	Lung cancer;
KIRP	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.78	-0.44	2.03e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.67	-0.48	6e-16	Neuroticism;
KIRP	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg11031976	chr2:198649780	BOLL	-0.47	-4.89	-0.3	1.82e-6	Ulcerative colitis;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.83	12.35	0.62	1.34e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.17	17.93	0.75	1.48e-46	Cognitive function;
KIRP	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.7	-9.29	-0.51	8.57e-18	Glomerular filtration rate;
KIRP	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-0.39	-4.96	-0.3	1.34e-6	Type 2 diabetes;
KIRP	cis	rs12643440	0.538	rs2041442	chr4:17137895	C/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7267005	0.661	rs74768850	chr20:34419847	G/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.77	-9.17	-0.5	2.02e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.43	-5.63	-0.34	4.92e-8	Height;
KIRP	cis	rs7127900	1.000	rs6579001	chr11:2232056	A/G	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg16867584	chr19:49200180	FUT2	0.31	4.93	0.3	1.52e-6	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs12579753	0.719	rs4418885	chr12:82275845	A/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.18	-0.37	2.57e-9	Resting heart rate;
KIRP	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.65	-9.31	-0.51	7.25e-18	Neuroticism;
KIRP	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	1.1	8.25	0.47	9.63e-15	Skin colour saturation;
KIRP	cis	rs6882046	0.513	rs185291	chr5:88006764	T/C	cg22951263	chr5:87985283	NA	-0.44	-6.24	-0.37	1.89e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.89	-13.94	-0.66	6.02e-33	Breast cancer;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.9	-0.3	1.77e-6	Life satisfaction;
KIRP	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg21395723	chr22:39101663	GTPBP1	0.44	5.33	0.32	2.19e-7	Menopause (age at onset);
KIRP	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.92	-0.4	3.82e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg12826209	chr6:26865740	GUSBL1	0.71	5.0	0.3	1.07e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.56	-5.39	-0.32	1.66e-7	Narcolepsy;
KIRP	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.95	-14.08	-0.67	2.08e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25019898	chr10:1118816	WDR37	0.42	6.44	0.38	6.15e-10	Migraine with aura;
KIRP	cis	rs17101923	1.000	rs35084099	chr12:66340703	A/C	cg06712651	chr12:66351869	HMGA2	-0.58	-6.49	-0.38	4.74e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.37	-0.43	2.6e-12	Bipolar disorder;
KIRP	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.1	0.61	9.17e-27	Monocyte percentage of white cells;
KIRP	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15557168	chr22:42548783	NA	-0.47	-6.15	-0.36	3.16e-9	Cognitive function;
KIRP	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.68	8.73	0.49	3.83e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs11673344	0.864	rs7256213	chr19:37511491	T/C	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.18	-0.31	4.64e-7	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.43	0.62	7.33e-28	Bladder cancer;
KIRP	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.5	7.3	0.42	3.96e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs12476592	0.602	rs262504	chr2:63861235	C/G	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg23719950	chr11:63933701	MACROD1	-0.69	-6.71	-0.39	1.36e-10	Mean platelet volume;
KIRP	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.9	15.27	0.7	1.82e-37	Coronary artery disease;
KIRP	cis	rs72730918	0.564	rs956171	chr15:51837138	C/T	cg14296394	chr15:51910925	DMXL2	-0.76	-10.53	-0.56	1.23e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs7572644	0.640	rs34181670	chr2:28019856	T/C	cg27432699	chr2:27873401	GPN1	0.49	5.55	0.33	7.41e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.82	-0.45	1.51e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.77	-10.92	-0.57	6.89e-23	Fibrinogen levels;
KIRP	cis	rs10788972	0.620	rs34764952	chr1:54483694	C/T	cg25741118	chr1:54482237	LDLRAD1	-0.29	-4.99	-0.3	1.17e-6	Parkinson disease and lewy body pathology;
KIRP	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg23484912	chr5:273055	PDCD6	-0.57	-7.22	-0.42	6.44e-12	Pancreatic cancer;
KIRP	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.9	8.41	0.47	3.26e-15	Systolic blood pressure;
KIRP	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.77	-11.35	-0.59	2.85e-24	Hip circumference;
KIRP	cis	rs7933455	0.502	rs1385850	chr11:12234595	C/T	cg10383724	chr11:12228521	MICAL2	0.53	5.34	0.32	2.17e-7	Cold sores;
KIRP	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.88	12.59	0.63	2.22e-28	Mean platelet volume;
KIRP	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg12218747	chr21:37451666	NA	-0.45	-5.59	-0.34	6e-8	Mitral valve prolapse;
KIRP	cis	rs3733418	0.860	rs869867	chr4:165930747	C/G	cg10852876	chr4:165953100	TRIM60	-0.48	-5.03	-0.31	9.65e-7	Obesity-related traits;
KIRP	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg10167463	chr7:75959203	YWHAG	-0.52	-6.73	-0.39	1.16e-10	Multiple sclerosis;
KIRP	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.91	-0.4	4.23e-11	Aortic root size;
KIRP	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.17	0.42	8.89e-12	Obesity-related traits;
KIRP	cis	rs7539409	0.651	rs7521788	chr1:84309320	G/T	cg10977910	chr1:84465055	TTLL7	0.6	5.49	0.33	9.97e-8	Alzheimer's disease;
KIRP	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.71	-9.92	-0.53	9.63e-20	Brugada syndrome;
KIRP	cis	rs918629	0.679	rs56002885	chr5:95269602	A/G	cg16656078	chr5:95278638	ELL2	-0.47	-6.62	-0.39	2.28e-10	IgG glycosylation;
KIRP	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26306683	chr17:18585705	ZNF286B	-0.45	-5.69	-0.34	3.66e-8	Educational attainment (years of education);
KIRP	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.27	-0.37	1.59e-9	Cardiac Troponin-T levels;
KIRP	trans	rs1422110	0.641	rs12514639	chr5:85523929	C/T	cg01787110	chr1:109008453	NBPF6	-0.76	-9.13	-0.5	2.51e-17	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg12288994	chr5:1860383	NA	0.54	7.49	0.43	1.23e-12	Cardiovascular disease risk factors;
KIRP	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg05964544	chr11:70165517	PPFIA1	-0.53	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17346426	chr2:216946392	TMEM169;PECR	0.53	6.42	0.38	6.84e-10	Inflammatory biomarkers;
KIRP	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.6	8.02	0.46	4.32e-14	Multiple sclerosis;
KIRP	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	1.08	7.22	0.42	6.42e-12	Severe influenza A (H1N1) infection;
KIRP	trans	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.61	0.39	2.36e-10	Mean corpuscular volume;
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg10318148	chr7:1024673	CYP2W1	0.34	4.9	0.3	1.75e-6	Longevity;Endometriosis;
KIRP	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.34e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg16339924	chr4:17578868	LAP3	0.6	7.9	0.45	9.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	9.66	0.52	6.17e-19	Alzheimer's disease;
KIRP	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg19507638	chr5:93509721	C5orf36	-0.52	-4.96	-0.3	1.32e-6	Diabetic retinopathy;
KIRP	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00933542	chr6:150070202	PCMT1	0.27	5.23	0.32	3.66e-7	Lung cancer;
KIRP	cis	rs11581903	0.568	rs11590859	chr1:53073838	G/T	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.9	7.47	0.43	1.36e-12	Joint mobility (Beighton score);
KIRP	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.69	9.04	0.5	4.96e-17	Cognitive function;
KIRP	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg07117364	chr1:16154769	NA	-0.4	-4.85	-0.3	2.18e-6	Dilated cardiomyopathy;
KIRP	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05665937	chr4:1216051	CTBP1	-0.44	-5.45	-0.33	1.24e-7	Obesity-related traits;
KIRP	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.95	13.44	0.65	2.97e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.21	-0.42	7.04e-12	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg11859384	chr17:80120422	CCDC57	-0.41	-5.19	-0.31	4.3e-7	Life satisfaction;
KIRP	cis	rs17221829	0.537	rs7933470	chr11:89376963	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.89	-0.3	1.81e-6	Anxiety in major depressive disorder;
KIRP	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.57	6.81	0.4	7.63e-11	Obesity-related traits;
KIRP	trans	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.72	-0.39	1.27e-10	Neuroticism;
KIRP	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg01721255	chr8:58191610	C8orf71	0.56	5.75	0.34	2.67e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.76	7.27	0.42	4.66e-12	Pediatric areal bone mineral density (radius);
KIRP	cis	rs752010	0.967	rs10890151	chr1:42101843	C/A	cg06885757	chr1:42089581	HIVEP3	0.5	7.39	0.43	2.29e-12	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs62056376	0.736	rs2215185	chr17:32633902	C/T	cg13554086	chr5:76507100	PDE8B	0.54	6.32	0.37	1.21e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs4262150	0.810	rs72799126	chr5:152084873	T/C	cg12297329	chr5:152029980	NA	-0.67	-8.13	-0.46	2.08e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22341533	chr12:2066003	DCP1B	-0.41	-6.26	-0.37	1.67e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg26566898	chr11:117069891	TAGLN	0.41	5.38	0.32	1.75e-7	Blood protein levels;
KIRP	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.53	7.29	0.42	4.31e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs5753037	0.629	rs140138	chr22:30164628	T/G	cg27665648	chr22:30112403	NA	0.46	6.29	0.37	1.46e-9	Type 1 diabetes;
KIRP	cis	rs7011049	0.778	rs117805592	chr8:53865778	A/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.35e-10	Systolic blood pressure;
KIRP	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.27	0.55	7.99e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg18357526	chr6:26021779	HIST1H4A	0.51	6.82	0.4	7.14e-11	Height;
KIRP	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	8.03	0.46	3.97e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15910486	chr5:142783621	NR3C1	0.48	6.71	0.39	1.34e-10	Parkinson's disease;
KIRP	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg15557168	chr22:42548783	NA	-0.4	-5.54	-0.33	7.86e-8	Cognitive function;
KIRP	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.11	-0.41	1.26e-11	Retinal vascular caliber;
KIRP	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg10326726	chr10:51549505	MSMB	-0.6	-8.94	-0.5	9.67e-17	Prostate-specific antigen levels;
KIRP	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.82	11.1	0.58	1.75e-23	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg22468803	chr18:9136381	ANKRD12	0.94	6.4	0.38	7.64e-10	P wave terminal force;
KIRP	cis	rs2494663	0.560	rs11265036	chr1:154054426	C/T	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.98	-0.3	1.21e-6	Mean platelet volume;
KIRP	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg10381502	chr11:71823885	C11orf51	-1.03	-7.17	-0.42	8.64e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg26875233	chr11:93583750	C11orf90	-0.4	-7.55	-0.43	8.25e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.93	-0.3	1.5e-6	Neuroticism;
KIRP	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg03289416	chr15:75166202	SCAMP2	-0.4	-5.58	-0.34	6.26e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg09408571	chr1:101003634	GPR88	0.26	5.83	0.35	1.74e-8	Monocyte count;
KIRP	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg16558253	chr16:72132732	DHX38	-0.41	-4.86	-0.3	2.12e-6	Blood protein levels;
KIRP	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17376030	chr22:41985996	PMM1	0.67	7.02	0.41	2.09e-11	Vitiligo;
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-7.8	-0.45	1.72e-13	Platelet count;
KIRP	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg03468072	chr12:39539422	NA	0.39	5.7	0.34	3.47e-8	Morning vs. evening chronotype;
KIRP	cis	rs7520050	0.966	rs10890354	chr1:46305347	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs12043302	0.529	rs12755217	chr1:6923003	G/A	cg26765385	chr7:2611244	IQCE	-0.81	-6.07	-0.36	4.88e-9	Gestational age at birth in labor-initiated deliveries (child effect);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17981648	chr6:133422365	LOC285735	-0.43	-6.68	-0.39	1.56e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs803923	0.545	rs756118	chr9:119487330	A/G	cg13792444	chr9:119245443	ASTN2	-0.34	-5.39	-0.33	1.62e-7	Lung function (FEV1/FVC);
KIRP	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg16141378	chr3:129829833	LOC729375	-0.57	-7.77	-0.44	2.1e-13	Retinal vascular caliber;
KIRP	cis	rs11553699	0.765	rs11615667	chr12:122399173	C/A	cg22168489	chr12:122356033	WDR66	0.61	4.88	0.3	1.87e-6	Mean platelet volume;Platelet count;Platelet distribution width;Reticulocyte fraction of red cells;Plateletcrit;
KIRP	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.01	-0.5	5.93e-17	Retinal vascular caliber;
KIRP	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg04865290	chr3:52927548	TMEM110	-0.44	-5.4	-0.33	1.55e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg09695851	chr17:3907499	NA	-0.82	-14.77	-0.69	8.75e-36	Type 2 diabetes;
KIRP	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg03289416	chr15:75166202	SCAMP2	0.45	6.32	0.37	1.24e-9	Breast cancer;
KIRP	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-8.0	-0.45	4.86e-14	Personality dimensions;
KIRP	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.97	0.54	7.08e-20	Lung cancer;
KIRP	cis	rs710216	0.917	rs2297977	chr1:43415288	G/T	cg03128534	chr1:43423976	SLC2A1	0.5	4.98	0.3	1.17e-6	Red cell distribution width;
KIRP	cis	rs829661	0.793	rs2602791	chr2:30868179	A/G	cg10949345	chr2:30726833	LCLAT1	-1.04	-12.66	-0.63	1.23e-28	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07402062	chr16:89894098	SPIRE2	0.31	6.44	0.38	6.2e-10	Vitiligo;
KIRP	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.23	-0.32	3.69e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg19853194	chr18:9913725	VAPA	0.49	6.2	0.37	2.42e-9	Asthma;
KIRP	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg23100626	chr2:96804247	ASTL	-0.53	-7.71	-0.44	3.02e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.96	6.91	0.4	4.17e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-5.95	-0.35	9.19e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06360820	chr2:242988706	NA	-0.81	-7.19	-0.42	7.75e-12	Obesity-related traits;
KIRP	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg06740227	chr12:86229804	RASSF9	0.48	6.31	0.37	1.31e-9	Major depressive disorder;
KIRP	cis	rs9290877	0.704	rs9846404	chr3:188412997	T/A	cg17392043	chr3:188495102	LPP	-0.4	-4.98	-0.3	1.21e-6	IgE levels;
KIRP	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg05527609	chr1:210001259	C1orf107	-0.47	-5.12	-0.31	6.06e-7	Red blood cell count;
KIRP	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg01657329	chr11:68192670	LRP5	-0.51	-5.43	-0.33	1.38e-7	Total body bone mineral density;
KIRP	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.79	-8.88	-0.49	1.39e-16	Pancreatic cancer;
KIRP	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg01028140	chr2:1542097	TPO	-0.62	-7.06	-0.41	1.65e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7221595	0.778	rs2727072	chr17:3918585	C/G	cg11204139	chr17:3907470	NA	0.68	8.36	0.47	4.78e-15	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.7	-7.53	-0.43	9.65e-13	Platelet count;
KIRP	cis	rs59698941	0.550	rs11748063	chr5:132200943	C/T	cg14825688	chr5:132208181	LEAP2	-0.37	-4.87	-0.3	1.96e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	1.09	9.73	0.53	3.88e-19	Pulse pressure;
KIRP	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.41	-5.54	-0.33	7.77e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.69	10.51	0.56	1.42e-21	Hip circumference;
KIRP	cis	rs710913	0.717	rs2243761	chr1:40051616	T/C	cg27567593	chr1:39956653	BMP8A	0.34	4.94	0.3	1.46e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	4.9	0.3	1.74e-6	Cognitive test performance;
KIRP	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24549020	chr5:56110836	MAP3K1	0.5	5.13	0.31	5.96e-7	Initial pursuit acceleration;
KIRP	cis	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg07460842	chr6:66804631	NA	0.48	5.64	0.34	4.69e-8	Metabolite levels;
KIRP	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.5	5.83	0.35	1.73e-8	Uric acid levels;
KIRP	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg11833968	chr6:79620685	NA	-0.47	-6.99	-0.41	2.63e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg21775007	chr8:11205619	TDH	0.51	6.79	0.4	8.24e-11	Mood instability;
KIRP	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.47	5.8	0.35	1.98e-8	Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25028639	chr11:9884897	SBF2	0.37	6.24	0.37	1.88e-9	Survival in pancreatic cancer;
KIRP	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05315796	chr3:52349193	DNAH1	0.41	6.28	0.37	1.52e-9	Hemoglobin concentration;
KIRP	trans	rs921874	0.586	rs2001411	chr11:86771583	A/G	cg22937172	chr2:240168862	HDAC4	0.51	6.57	0.39	2.89e-10	Total body bone mineral density;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-0.59	-7.9	-0.45	9.46e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs73198271	0.603	rs570364	chr8:8593638	G/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.15	-0.31	5.44e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9488822	0.662	rs495565	chr6:116262976	G/A	cg15226275	chr6:116381976	FRK	-0.2	-5.43	-0.33	1.38e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00585698	chr12:123750864	CDK2AP1	0.41	5.28	0.32	2.88e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.68	0.34	3.73e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	0.643	rs12145181	chr1:21086046	C/A	cg08890418	chr1:21044141	KIF17	0.33	4.92	0.3	1.6e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg06647332	chr5:131281008	NA	0.45	5.08	0.31	7.58e-7	Life satisfaction;
KIRP	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg15028436	chr7:37888078	TXNDC3	0.6	6.95	0.41	3.31e-11	Alzheimer's disease (late onset);
KIRP	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	11.82	0.6	7.95e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7681423	0.951	rs6050	chr4:155507590	C/T	cg20735720	chr4:155535218	FGG	0.52	6.9	0.4	4.46e-11	Fibrinogen;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19248656	chr17:48712198	ABCC3	0.49	6.26	0.37	1.66e-9	Parkinson's disease;
KIRP	cis	rs7951870	0.945	rs12574918	chr11:46724068	G/C	cg19486271	chr11:47235900	DDB2	0.53	5.0	0.3	1.09e-6	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg15660573	chr17:549704	VPS53	-0.95	-15.04	-0.69	1.04e-36	Prostate cancer;
KIRP	cis	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg20368463	chr18:77673604	PQLC1	-0.46	-5.77	-0.35	2.33e-8	Schizophrenia;
KIRP	cis	rs7594645	1.000	rs74957607	chr2:207583731	A/T	cg17160730	chr2:207629934	MDH1B;FASTKD2	-0.85	-5.08	-0.31	7.41e-7	Episodic memory;
KIRP	cis	rs714515	0.586	rs4916264	chr1:172450760	C/T	cg01573306	chr1:172330400	DNM3	0.4	5.04	0.31	9.2e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.92	-0.4	3.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg23479056	chr15:41276147	INO80	-0.39	-5.41	-0.33	1.51e-7	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10200728	chr6:80816267	BCKDHB	0.47	6.88	0.4	5.04e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13047869	chr3:10149882	C3orf24	0.55	5.31	0.32	2.43e-7	Alzheimer's disease;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.65	-9.54	-0.52	1.45e-18	Vitiligo;
KIRP	cis	rs34375054	1.000	rs3751178	chr12:125664357	C/T	cg25124228	chr12:125621409	AACS	0.41	5.02	0.3	9.97e-7	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg21775007	chr8:11205619	TDH	0.44	5.41	0.33	1.49e-7	Monocyte count;
KIRP	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.48	5.86	0.35	1.5e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg04362960	chr10:104952993	NT5C2	-0.42	-4.97	-0.3	1.23e-6	Colorectal cancer;
KIRP	cis	rs9815354	0.857	rs1474219	chr3:42000913	G/A	cg03022575	chr3:42003672	ULK4	-0.49	-5.53	-0.33	8.01e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.98	-15.38	-0.7	7.22e-38	Ulcerative colitis;
KIRP	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg24503407	chr1:205819492	PM20D1	-0.4	-4.84	-0.3	2.26e-6	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.43	-0.33	1.35e-7	Pulmonary function;
KIRP	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06544989	chr22:39130855	UNC84B	0.52	9.09	0.5	3.42e-17	Menopause (age at onset);
KIRP	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.44	-0.33	1.29e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.61	-9.48	-0.52	2.29e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg00409905	chr10:38381863	ZNF37A	-0.56	-6.61	-0.39	2.31e-10	Obesity (extreme);
KIRP	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.49	6.07	0.36	4.8e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6707387	0.686	rs7560793	chr2:214408201	C/T	cg08319019	chr2:214017104	IKZF2	0.46	5.33	0.32	2.22e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg04691961	chr3:161091175	C3orf57	0.49	7.31	0.42	3.81e-12	Morning vs. evening chronotype;
KIRP	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg22325292	chr17:80708367	FN3K	0.37	4.92	0.3	1.58e-6	Glycated hemoglobin levels;
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.68	-10.85	-0.57	1.16e-22	Mean corpuscular volume;
KIRP	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg13010199	chr12:38710504	ALG10B	0.63	7.81	0.45	1.63e-13	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09904774	chr17:3539754	CTNS;SHPK	0.53	6.81	0.4	7.23e-11	Parkinson's disease;
KIRP	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	23.7	0.83	1.96e-65	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25516151	chr8:18413889	PSD3	0.49	6.44	0.38	6.29e-10	Interleukin-4 levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01191660	chr1:11024083	C1orf127	0.53	7.15	0.41	9.61e-12	Interleukin-4 levels;
KIRP	cis	rs4654899	0.655	rs4654883	chr1:21213708	C/T	cg08890418	chr1:21044141	KIF17	-0.34	-5.06	-0.31	8.15e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10214930	0.813	rs2160125	chr7:27688286	G/A	cg22168087	chr7:27702803	HIBADH	0.51	5.13	0.31	5.91e-7	Hypospadias;
KIRP	cis	rs258892	0.843	rs155431	chr5:72120916	A/T	cg21869765	chr5:72125136	TNPO1	-0.57	-6.33	-0.37	1.15e-9	Small cell lung carcinoma;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01079118	chr10:131567828	NA	0.47	6.13	0.36	3.54e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.12	-0.5	2.82e-17	Mood instability;
KIRP	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	0.47	6.11	0.36	3.82e-9	Systemic lupus erythematosus;
KIRP	cis	rs7523273	1.000	rs7541230	chr1:207957555	T/C	cg22525895	chr1:207977042	MIR29B2	-0.68	-8.65	-0.48	6.96e-16	Schizophrenia;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Blood metabolite levels;
KIRP	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg08283408	chr3:49949060	MON1A	-0.38	-5.06	-0.31	8.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg10792982	chr14:105748885	BRF1	0.89	13.66	0.66	5.41e-32	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.83	-10.6	-0.56	7.29e-22	Longevity;Endometriosis;
KIRP	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg16141378	chr3:129829833	LOC729375	0.54	7.08	0.41	1.52e-11	Triglycerides;
KIRP	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.66	-9.95	-0.54	7.94e-20	Educational attainment;
KIRP	cis	rs34779708	0.733	rs4444023	chr10:35548354	G/A	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2274273	0.638	rs11622636	chr14:55647840	C/T	cg04306507	chr14:55594613	LGALS3	0.41	5.36	0.32	1.96e-7	Protein biomarker;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg19770292	chr5:1868693	NA	0.39	5.11	0.31	6.53e-7	Cardiovascular disease risk factors;
KIRP	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg00603274	chr11:61596626	FADS2	-0.65	-6.5	-0.38	4.48e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	1.03	13.42	0.65	3.53e-31	Neutrophil percentage of white cells;
KIRP	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-10.06	-0.54	3.54e-20	Exhaled nitric oxide output;
KIRP	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg06212747	chr3:49208901	KLHDC8B	0.67	6.31	0.37	1.27e-9	Menarche (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23133153	chr13:115000275	CDC16	-0.54	-6.12	-0.36	3.72e-9	Interleukin-4 levels;
KIRP	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.68	-0.39	1.55e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00004939	chr14:69261661	C14orf181	0.56	6.83	0.4	6.63e-11	Lung cancer in ever smokers;
KIRP	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg11815991	chr20:30193098	ID1	-0.45	-4.87	-0.3	2.02e-6	Mean corpuscular hemoglobin;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24478420	chr1:80923103	NA	0.37	6.06	0.36	5.19e-9	Migraine with aura;
KIRP	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.45	6.25	0.37	1.82e-9	Sitting height ratio;
KIRP	cis	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs526231	0.543	rs17154913	chr5:102328490	C/G	cg23492399	chr5:102201601	PAM	-0.48	-5.55	-0.33	7.24e-8	Primary biliary cholangitis;
KIRP	cis	rs988913	1.000	rs1503135	chr6:54841672	C/T	cg03513858	chr6:54763001	FAM83B	-0.37	-5.44	-0.33	1.27e-7	Menarche (age at onset);
KIRP	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.68	10.02	0.54	4.93e-20	Dupuytren's disease;
KIRP	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.77	-11.07	-0.58	2.18e-23	Height;
KIRP	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg07689907	chr11:61582574	FADS1	0.49	6.09	0.36	4.24e-9	Trans fatty acid levels;
KIRP	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06481639	chr22:41940642	POLR3H	0.58	6.6	0.39	2.51e-10	Vitiligo;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04937561	chr11:57103057	SSRP1	-0.56	-6.17	-0.37	2.84e-9	Menopause (age at onset);
KIRP	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.6	7.83	0.45	1.49e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.59	7.34	0.42	3.04e-12	Alzheimer's disease;
KIRP	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg16482183	chr6:26056742	HIST1H1C	0.61	7.2	0.42	7.34e-12	Iron status biomarkers;
KIRP	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.53	6.57	0.39	2.93e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16576597	chr16:28551801	NUPR1	0.36	5.47	0.33	1.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2637030	0.559	rs256105	chr5:53013889	T/C	cg06476337	chr5:52856530	NDUFS4	0.5	5.32	0.32	2.28e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg08885076	chr2:99613938	TSGA10	-0.54	-7.36	-0.43	2.67e-12	Chronic sinus infection;
KIRP	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.66	-7.8	-0.45	1.8e-13	Aortic root size;
KIRP	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg26587870	chr6:27730563	NA	-0.65	-4.92	-0.3	1.56e-6	Breast cancer;
KIRP	cis	rs9815354	1.000	rs1615243	chr3:41965234	C/T	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.98	15.96	0.71	7.84e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg21523564	chr15:75251491	NA	0.41	6.63	0.39	2.15e-10	Breast cancer;
KIRP	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.19	-0.31	4.35e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	17.44	0.74	6.86e-45	Electrocardiographic conduction measures;
KIRP	cis	rs4663866	0.901	rs2304672	chr2:239186589	C/G	cg17283117	chr2:239148619	HES6	-0.7	-5.17	-0.31	4.76e-7	Irritable bowel syndrome;
KIRP	cis	rs11800820	0.619	rs73136168	chr1:246673948	G/A	cg16700716	chr1:246684329	NA	0.61	5.9	0.35	1.19e-8	Obesity-related traits;
KIRP	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.3	-6.2	-0.37	2.43e-9	Breast cancer;
KIRP	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.71	-12.9	-0.64	2e-29	Body mass index;
KIRP	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-0.62	-5.13	-0.31	5.79e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.49	-6.15	-0.37	3.09e-9	Post bronchodilator FEV1;
KIRP	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg12560992	chr17:57184187	TRIM37	0.58	5.07	0.31	7.87e-7	Cognitive test performance;
KIRP	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.69	0.53	4.95e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg01294253	chr9:136912663	BRD3	0.41	5.34	0.32	2.09e-7	Platelet distribution width;
KIRP	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-6.22	-0.37	2.11e-9	Axial length;
KIRP	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.99	14.25	0.67	5.16e-34	Cognitive function;
KIRP	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg04990556	chr1:26633338	UBXN11	0.66	6.48	0.38	5e-10	Obesity-related traits;
KIRP	cis	rs876084	0.505	rs4431629	chr8:121108668	C/T	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg14139633	chr9:131103210	SLC27A4	0.52	6.08	0.36	4.51e-9	Electroencephalogram traits;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	4.9	0.3	1.71e-6	Longevity;
KIRP	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.84	10.18	0.54	1.54e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg10326726	chr10:51549505	MSMB	0.54	7.65	0.44	4.6e-13	Prostate-specific antigen levels;
KIRP	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs2249694	0.878	rs2987792	chr10:135371466	T/C	cg20169779	chr10:135381914	SYCE1	0.44	5.19	0.31	4.37e-7	Obesity-related traits;
KIRP	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.79	13.73	0.66	3.08e-32	Anterior chamber depth;
KIRP	cis	rs4671400	0.571	rs62152275	chr2:61502238	C/A	cg15711740	chr2:61764176	XPO1	0.62	6.7	0.39	1.38e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg08901578	chr4:187885870	NA	-0.51	-7.77	-0.44	2.15e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	8.1	0.46	2.57e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs231513	1.000	rs231518	chr17:41961451	C/T	cg26893861	chr17:41843967	DUSP3	0.58	5.06	0.31	8.04e-7	Cognitive function;
KIRP	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg15556689	chr8:8085844	FLJ10661	0.64	8.44	0.47	2.72e-15	Retinal vascular caliber;
KIRP	cis	rs600806	0.742	rs12753439	chr1:110015519	G/A	cg02175308	chr1:109941060	SORT1	-0.28	-5.18	-0.31	4.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.68	8.03	0.46	4.08e-14	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg13482628	chr17:19912719	NA	0.5	6.43	0.38	6.43e-10	Schizophrenia;
KIRP	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.4	-0.38	7.89e-10	Vitiligo;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg13906792	chr15:75199810	C15orf17	-0.38	-5.56	-0.33	6.85e-8	Breast cancer;
KIRP	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg04691961	chr3:161091175	C3orf57	-0.5	-6.94	-0.4	3.42e-11	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.6	-7.41	-0.43	2.05e-12	Neuroticism;
KIRP	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg22070880	chr22:50098194	NA	0.71	8.06	0.46	3.33e-14	Natriuretic peptide levels;
KIRP	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg01444801	chr10:135216882	MTG1	-0.56	-6.24	-0.37	1.9e-9	Systemic lupus erythematosus;
KIRP	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	cis	rs910873	0.505	rs6058089	chr20:33194257	C/T	cg24642439	chr20:33292090	TP53INP2	-0.61	-5.22	-0.32	3.88e-7	Melanoma;
KIRP	cis	rs17023223	0.537	rs2765534	chr1:119597792	A/C	cg05756136	chr1:119680316	WARS2	-0.53	-7.21	-0.42	6.83e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	1.07	21.33	0.81	7.14e-58	Platelet distribution width;
KIRP	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg09163369	chr1:210001066	C1orf107	0.65	7.4	0.43	2.1e-12	Orofacial clefts;
KIRP	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.2	-0.37	2.4e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg18234130	chr8:27182889	PTK2B	0.54	6.97	0.41	2.89e-11	Neuroticism;
KIRP	cis	rs4742903	0.904	rs10114234	chr9:107003646	C/T	cg14250997	chr9:106856677	SMC2	-0.38	-5.12	-0.31	6.06e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.33	0.37	1.17e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-7.58	-0.44	7.04e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs35771425	1.000	rs35699165	chr1:211594287	G/C	cg10512769	chr1:211675356	NA	-0.51	-5.1	-0.31	6.66e-7	Educational attainment (years of education);
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg03115019	chr17:80708279	FN3K	0.42	4.88	0.3	1.91e-6	Glycated hemoglobin levels;
KIRP	cis	rs62344088	1.000	rs7710931	chr5:152286	C/T	cg22857025	chr5:266934	NA	-0.73	-5.0	-0.3	1.09e-6	Asthma (childhood onset);
KIRP	trans	rs3741489	1.000	rs3741489	chr12:133417802	A/G	cg24132527	chr5:140019269	TMCO6	1.04	6.64	0.39	2.03e-10	Cognitive function;
KIRP	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-0.62	-6.88	-0.4	4.86e-11	Initial pursuit acceleration;
KIRP	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.84	0.3	2.25e-6	Menarche (age at onset);
KIRP	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg02175503	chr12:58329896	NA	0.51	5.46	0.33	1.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg17595323	chr11:93583763	C11orf90	-0.38	-6.34	-0.37	1.1e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg13010199	chr12:38710504	ALG10B	0.48	6.4	0.38	7.97e-10	Morning vs. evening chronotype;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg18538332	chr22:24372958	LOC391322	-0.58	-7.35	-0.42	2.87e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg10818794	chr15:86012489	AKAP13	-0.49	-7.05	-0.41	1.77e-11	Coronary artery disease;
KIRP	cis	rs41264869	0.657	rs3183297	chr1:205113833	A/G	cg21214746	chr1:205091277	RBBP5	0.51	6.66	0.39	1.77e-10	Blood protein levels;
KIRP	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.37	-0.38	9.26e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1018697	0.966	rs1953930	chr10:104549461	G/A	cg04362960	chr10:104952993	NT5C2	0.5	6.03	0.36	6.09e-9	Colorectal adenoma (advanced);
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg21366198	chr4:185655624	MLF1IP	-0.42	-5.64	-0.34	4.59e-8	Kawasaki disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24804652	chr7:29234082	CHN2	0.44	6.02	0.36	6.44e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.39	1.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg26681399	chr22:41777847	TEF	-0.51	-5.34	-0.32	2.15e-7	Vitiligo;
KIRP	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-9.34	-0.51	6.05e-18	Coronary artery disease;
KIRP	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg23281280	chr6:28129359	ZNF389	0.49	5.47	0.33	1.08e-7	Depression;
KIRP	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg16586182	chr3:47516702	SCAP	0.67	9.26	0.51	1.02e-17	Colorectal cancer;
KIRP	cis	rs6681460	0.898	rs1032634	chr1:67195192	C/G	cg13052034	chr1:66999238	SGIP1	-0.35	-4.91	-0.3	1.66e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.93	16.03	0.71	4.53e-40	Breast cancer;
KIRP	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.56	-7.05	-0.41	1.83e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-10.45	-0.55	2.16e-21	Colorectal cancer;
KIRP	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg24315340	chr6:146058215	EPM2A	0.45	5.63	0.34	4.89e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg23978513	chr4:39979310	PDS5A	-0.56	-6.18	-0.37	2.64e-9	Menopause (age at onset);
KIRP	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg01872077	chr2:219646372	CYP27A1	0.42	5.45	0.33	1.2e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9434723	0.844	rs9435148	chr1:9300962	G/C	cg04199779	chr1:9294473	H6PD	0.44	5.39	0.32	1.66e-7	Height;
KIRP	cis	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.48	6.01	0.36	6.54e-9	Height;
KIRP	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.78	-0.49	2.78e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.88	13.71	0.66	3.7e-32	Mean corpuscular volume;
KIRP	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg08719095	chr7:1135190	C7orf50	-0.41	-4.91	-0.3	1.67e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg02336718	chr17:17403227	NA	-0.36	-5.31	-0.32	2.5e-7	Total body bone mineral density;
KIRP	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.61	6.03	0.36	5.94e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.46	5.84	0.35	1.65e-8	Aortic root size;
KIRP	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg08807101	chr21:30365312	RNF160	-0.59	-5.77	-0.35	2.4e-8	Cognitive test performance;
KIRP	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs11707575	chr3:53113762	G/T	cg04865290	chr3:52927548	TMEM110	-0.39	-5.05	-0.31	8.44e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg22508957	chr16:3507546	NAT15	0.47	6.04	0.36	5.67e-9	Body mass index (adult);
KIRP	cis	rs41005	0.967	rs41002	chr2:8113921	C/T	cg03155496	chr2:8117019	LOC339788	0.65	11.53	0.59	7.27e-25	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs8070740	0.898	rs4442872	chr17:5324236	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.29	0.42	4.3e-12	Menopause (age at onset);
KIRP	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg14673194	chr17:80132900	CCDC57	-0.78	-8.84	-0.49	1.91e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs73086581	0.787	rs67724338	chr20:3869057	A/G	cg02187196	chr20:3869020	PANK2	0.58	5.36	0.32	1.94e-7	Response to antidepressants in depression;
KIRP	cis	rs17095355	1.000	rs11194920	chr10:111695412	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.45	-6.51	-0.38	4.17e-10	Biliary atresia;
KIRP	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.44	5.59	0.34	5.89e-8	Hypertriglyceridemia;
KIRP	cis	rs9900972	0.918	rs8065102	chr17:76876735	T/C	cg20937029	chr17:76870563	TIMP2	0.43	4.91	0.3	1.67e-6	Obesity-related traits;
KIRP	trans	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.52	0.52	1.7e-18	Monocyte percentage of white cells;
KIRP	cis	rs2976388	0.967	rs2976397	chr8:143764613	G/T	cg06565975	chr8:143823917	SLURP1	-0.45	-6.59	-0.39	2.7e-10	Urinary tract infection frequency;
KIRP	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-8.97	-0.5	7.83e-17	Systemic lupus erythematosus;
KIRP	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg22676075	chr6:135203613	NA	0.51	7.28	0.42	4.47e-12	Red blood cell count;
KIRP	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	15.29	0.7	1.53e-37	Colorectal cancer;
KIRP	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.39	-5.03	-0.31	9.45e-7	Monocyte percentage of white cells;
KIRP	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg06219351	chr7:158114137	PTPRN2	0.55	6.91	0.4	4.14e-11	Response to amphetamines;
KIRP	cis	rs9625935	0.536	rs9608819	chr22:30260809	A/C	cg01021169	chr22:30184971	ASCC2	0.45	6.3	0.37	1.36e-9	Tonsillectomy;
KIRP	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.72	-8.55	-0.48	1.31e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	1.12	8.09	0.46	2.78e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7224685	0.569	rs8070737	chr17:3981066	G/T	cg09597638	chr17:3907349	NA	0.56	5.63	0.34	4.82e-8	Type 2 diabetes;
KIRP	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.36	-0.42	2.76e-12	Morning vs. evening chronotype;
KIRP	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.75	6.4	0.38	7.94e-10	Body mass index;
KIRP	trans	rs6838801	0.857	rs903044	chr4:77578750	A/G	cg25171389	chr7:44055869	POLR2J4	-0.47	-6.11	-0.36	3.91e-9	Cleft lip with or without cleft palate;
KIRP	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.63	7.03	0.41	2.06e-11	Neutrophil percentage of white cells;
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg25173405	chr17:45401733	C17orf57	0.5	6.59	0.39	2.61e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.4	-4.84	-0.3	2.27e-6	Parkinson's disease;
KIRP	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg08975724	chr8:8085496	FLJ10661	0.57	7.52	0.43	1.01e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	1.03	16.4	0.72	2.5e-41	Blood trace element (Zn levels);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01015416	chr7:77166650	PTPN12	0.48	6.89	0.4	4.52e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.86e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.41	-5.53	-0.33	8.18e-8	Homoarginine levels;
KIRP	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg20560298	chr2:73613845	ALMS1	0.44	5.37	0.32	1.83e-7	Metabolite levels;
KIRP	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Parkinson's disease;
KIRP	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.61	-7.53	-0.43	9.46e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg15103426	chr22:29168792	CCDC117	0.54	5.55	0.33	7.54e-8	Pancreatic cancer;
KIRP	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.59	5.85	0.35	1.53e-8	Urate levels in lean individuals;
KIRP	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	8.63	0.48	7.88e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg24060327	chr5:131705240	SLC22A5	-0.52	-6.17	-0.37	2.84e-9	Blood metabolite levels;
KIRP	cis	rs4356975	0.563	rs7439792	chr4:69959599	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg23307798	chr14:103986281	CKB	0.47	6.72	0.39	1.25e-10	Body mass index;
KIRP	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg11833968	chr6:79620685	NA	-0.47	-7.1	-0.41	1.3e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg13047869	chr3:10149882	C3orf24	0.6	5.11	0.31	6.61e-7	Alzheimer's disease;
KIRP	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.7	-8.11	-0.46	2.44e-14	Bone mineral density;
KIRP	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg07250515	chr12:56618133	OBFC2B	-0.61	-5.68	-0.34	3.84e-8	Psoriasis vulgaris;
KIRP	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-12.01	-0.61	1.84e-26	Ulcerative colitis;
KIRP	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg01872077	chr2:219646372	CYP27A1	0.38	4.98	0.3	1.19e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs26232	0.551	rs26431	chr5:102365794	G/C	cg23492399	chr5:102201601	PAM	0.45	4.89	0.3	1.83e-6	Rheumatoid arthritis;
KIRP	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.74	-10.49	-0.56	1.62e-21	Red blood cell count;
KIRP	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg22800045	chr5:56110881	MAP3K1	0.69	7.25	0.42	5.28e-12	Initial pursuit acceleration;
KIRP	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg08603382	chr10:743973	NA	-0.49	-7.47	-0.43	1.38e-12	Psychosis in Alzheimer's disease;
KIRP	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23848055	chr1:44240621	ST3GAL3	-0.4	-6.08	-0.36	4.54e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.44	-0.43	1.68e-12	Height;
KIRP	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.77	-9.99	-0.54	6.17e-20	Iron status biomarkers;
KIRP	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg11945507	chr8:142233382	SLC45A4	-0.5	-6.58	-0.39	2.84e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg15655495	chr12:38532458	NA	-0.27	-5.31	-0.32	2.41e-7	Heart rate;
KIRP	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.73e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.16	0.31	5.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08392591	chr16:89556376	ANKRD11	0.53	7.2	0.42	7.17e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.17	-0.31	4.79e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.63	6.76	0.4	9.69e-11	Gut microbiome composition (summer);
KIRP	cis	rs13161895	1.000	rs864482	chr5:179427873	A/G	cg02702477	chr5:179499311	RNF130	0.67	5.19	0.31	4.34e-7	LDL cholesterol;
KIRP	cis	rs73200209	0.744	rs7314858	chr12:116565050	T/C	cg01776926	chr12:116560359	MED13L	-0.54	-6.06	-0.36	5.13e-9	Total body bone mineral density;
KIRP	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.28	-0.51	9.04e-18	Body mass index;
KIRP	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-14.4	-0.68	1.68e-34	Gut microbiome composition (summer);
KIRP	cis	rs10073892	0.664	rs2400806	chr5:101893436	C/T	cg19774478	chr5:101632501	SLCO4C1	0.56	5.6	0.34	5.73e-8	Cognitive decline (age-related);
KIRP	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg05347473	chr6:146136440	FBXO30	-0.58	-8.35	-0.47	5.07e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18617219	chr2:122325428	CLASP1	0.38	6.03	0.36	5.88e-9	C-reactive protein;
KIRP	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.27	0.32	2.92e-7	Coronary artery disease;
KIRP	trans	rs6432860	0.701	rs749773	chr2:166733738	A/G	cg13971571	chr8:6693247	XKR5	0.49	6.2	0.37	2.35e-9	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;
KIRP	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg02725872	chr8:58115012	NA	-0.55	-6.35	-0.38	1.05e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7520050	0.966	rs4660898	chr1:46402171	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.65	8.27	0.47	8.28e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs113084984	0.684	rs4669745	chr2:11681572	A/G	cg07314298	chr2:11723111	GREB1	0.41	5.31	0.32	2.46e-7	Breast cancer;
KIRP	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg22974920	chr21:40686053	BRWD1	0.51	6.09	0.36	4.27e-9	Cognitive function;
KIRP	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg07511934	chr16:89386912	ANKRD11	0.4	5.29	0.32	2.74e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.21	-0.32	3.99e-7	Alcohol dependence;
KIRP	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg09754948	chr16:28834200	ATXN2L	-0.45	-5.26	-0.32	3.21e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg04362960	chr10:104952993	NT5C2	-0.43	-4.88	-0.3	1.9e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg16497661	chr14:103986332	CKB	0.56	7.29	0.42	4.12e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg05315796	chr3:52349193	DNAH1	0.56	8.4	0.47	3.7e-15	Bipolar disorder;
KIRP	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	1.03	19.59	0.78	4.07e-52	Height;
KIRP	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg27205649	chr11:78285834	NARS2	-0.64	-8.25	-0.47	9.47e-15	Alzheimer's disease (survival time);
KIRP	cis	rs72843166	0.947	rs72843175	chr17:61144586	G/T	cg19683800	chr17:61518354	CYB561	-0.4	-4.94	-0.3	1.42e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.76	-10.16	-0.54	1.8e-20	Schizophrenia;
KIRP	cis	rs882732	1.000	rs10139745	chr14:95035374	C/T	cg05186455	chr14:95027692	SERPINA4	-0.36	-4.98	-0.3	1.2e-6	Blood protein levels;
KIRP	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.47	-0.33	1.11e-7	Bipolar disorder;
KIRP	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	0.86	14.67	0.68	1.95e-35	Vitiligo;
KIRP	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.67	8.93	0.49	1.03e-16	Breast cancer;
KIRP	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg12349571	chr15:70364359	TLE3	-0.56	-5.0	-0.3	1.07e-6	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.1	-0.41	1.3e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg05941025	chr16:89927596	SPIRE2	0.35	5.4	0.33	1.57e-7	Vitiligo;
KIRP	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-8.1	-0.46	2.53e-14	Vitiligo;
KIRP	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg02297831	chr4:17616191	MED28	0.63	7.96	0.45	6.33e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4148660	1.000	rs2277405	chr12:22078838	T/G	cg14669847	chr12:22099120	NA	0.35	5.93	0.35	9.97e-9	Gout;
KIRP	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg26893134	chr6:116381904	FRK	0.21	5.88	0.35	1.37e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs11638352	1.000	rs2555380	chr15:44412635	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-5.11	-0.31	6.36e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs6132905	0.520	rs2422823	chr20:2646333	C/A	cg19137662	chr20:2633362	NOP56;MIR1292;SNORD110	0.45	5.28	0.32	2.86e-7	Mumps;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.9	-10.73	-0.56	2.73e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg15841412	chr13:111365552	ING1	0.51	6.16	0.37	3.02e-9	Educational attainment;
KIRP	cis	rs6693295	0.761	rs10924507	chr1:246268829	G/C	cg11798871	chr1:246315928	SMYD3	-0.44	-5.32	-0.32	2.35e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.66	-8.45	-0.47	2.5e-15	Hypospadias;
KIRP	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg08648136	chr8:956695	NA	0.43	5.81	0.35	1.88e-8	Schizophrenia;
KIRP	cis	rs2625529	0.526	rs62022789	chr15:72564492	C/T	cg16672083	chr15:72433130	SENP8	0.39	5.5	0.33	9.42e-8	Red blood cell count;
KIRP	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg18016565	chr1:150552671	MCL1	0.39	5.98	0.36	7.65e-9	Melanoma;
KIRP	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.07	-0.5	4.01e-17	Blood metabolite levels;
KIRP	cis	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.37	-0.32	1.78e-7	Joint mobility (Beighton score);
KIRP	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg05347473	chr6:146136440	FBXO30	0.47	6.93	0.4	3.72e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8054556	0.787	rs35105141	chr16:30057148	C/T	cg06326092	chr16:30034487	C16orf92	0.45	6.03	0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs73200209	0.843	rs73200232	chr12:116646821	C/T	cg01776926	chr12:116560359	MED13L	-0.37	-4.89	-0.3	1.83e-6	Total body bone mineral density;
KIRP	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.5	6.76	0.4	9.92e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg14541582	chr5:601475	NA	-0.58	-6.59	-0.39	2.73e-10	Obesity-related traits;
KIRP	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg08992911	chr2:238395768	MLPH	0.64	5.75	0.34	2.67e-8	Prostate cancer;
KIRP	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.22	0.37	2.16e-9	Ovarian reserve;
KIRP	cis	rs7520050	0.751	rs2230657	chr1:46073489	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.33	1.63e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.72	-10.08	-0.54	3.16e-20	Schizophrenia;
KIRP	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg20936604	chr3:58311152	NA	-0.59	-4.9	-0.3	1.73e-6	Cholesterol, total;
KIRP	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11997175	0.766	rs4733178	chr8:33691899	A/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.84	0.35	1.65e-8	Body mass index;
KIRP	cis	rs7258465	1.000	rs10409483	chr19:18590223	C/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.91	-0.35	1.12e-8	Breast cancer;
KIRP	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg12218747	chr21:37451666	NA	-0.59	-8.6	-0.48	9.770000000000001e-16	Mitral valve prolapse;
KIRP	trans	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg10756647	chr7:56101905	PSPH	-0.85	-7.16	-0.42	9.08e-12	Diabetic kidney disease;
KIRP	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.5	6.21	0.37	2.24e-9	HIV-1 control;
KIRP	cis	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.43	-5.55	-0.33	7.31e-8	Leprosy;
KIRP	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg25650185	chr19:21324782	ZNF431	-0.49	-5.16	-0.31	4.97e-7	Pain;
KIRP	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.97	-10.54	-0.56	1.1e-21	Blood protein levels;
KIRP	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg12369402	chr1:90227771	NA	-0.37	-5.3	-0.32	2.56e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.61	-7.56	-0.43	8.1e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1829883	0.898	rs1879360	chr5:98775330	G/A	cg08333243	chr5:99726346	NA	-0.41	-5.45	-0.33	1.23e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2191566	0.821	rs62119173	chr19:44518073	G/A	cg18700516	chr19:44507157	ZNF230	-0.44	-5.14	-0.31	5.6e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25517755	chr10:38738941	LOC399744	-0.52	-7.18	-0.42	8.46e-12	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11710845	1.000	rs11710139	chr3:150059342	G/A	cg21175685	chr3:99378032	COL8A1;MIR548G	0.37	6.02	0.36	6.38e-9	Intraocular pressure;
KIRP	cis	rs2594989	0.779	rs2447603	chr3:11590261	T/C	cg01796438	chr3:11312864	ATG7	0.44	5.6	0.34	5.58e-8	Circulating chemerin levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21117373	chr7:74071882	GTF2I	-0.47	-6.17	-0.37	2.84e-9	Metabolic traits;
KIRP	cis	rs1023500	1.000	rs10154646	chr22:42331409	G/C	cg04733989	chr22:42467013	NAGA	-0.53	-5.71	-0.34	3.2e-8	Schizophrenia;
KIRP	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg10189774	chr4:17578691	LAP3	0.42	4.86	0.3	2.1e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs904251	0.561	rs4714070	chr6:37473198	C/T	cg08126542	chr6:37504118	NA	-0.72	-9.87	-0.53	1.4e-19	Cognitive performance;
KIRP	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.49	6.73	0.39	1.18e-10	Red blood cell count;
KIRP	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23544223	chr18:12777786	NA	0.76	6.42	0.38	6.9e-10	Inflammatory skin disease;
KIRP	cis	rs6669384	0.547	rs2745979	chr1:208018219	G/C	cg22525895	chr1:207977042	MIR29B2	-0.51	-5.9	-0.35	1.21e-8	Immune response to measles vaccine (measles-specific neutralising antibody titre);
KIRP	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.3	13.35	0.65	6.19e-31	Diabetic retinopathy;
KIRP	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg10241871	chr14:102965420	TECPR2	-0.58	-6.83	-0.4	6.61e-11	Blood protein levels;
KIRP	cis	rs7116495	0.609	rs7924834	chr11:71644333	C/T	cg18441811	chr11:71824068	C11orf51	0.72	5.21	0.32	3.98e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs587242	1.000	rs12727152	chr1:96915548	G/A	cg10631902	chr5:14652156	NA	0.53	6.11	0.36	3.91e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg16034541	chr3:195490309	MUC4	0.59	5.52	0.33	8.59e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10203711	0.933	rs4994754	chr2:239567218	A/G	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs76793172	1.000	rs76793172	chr19:46359794	C/T	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.26	-0.37	1.69e-9	Eosinophil counts;
KIRP	cis	rs2172802	0.659	rs4484334	chr4:62499841	C/T	cg04118610	chr4:62707027	LPHN3	0.58	7.24	0.42	5.74e-12	Partial epilepsies;
KIRP	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg15507776	chr3:136538369	TMEM22	0.38	5.21	0.32	3.93e-7	Neuroticism;
KIRP	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.73	-0.44	2.68e-13	Height;
KIRP	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg17724175	chr1:150552817	MCL1	0.36	6.16	0.37	2.94e-9	Tonsillectomy;
KIRP	cis	rs77633900	0.772	rs2469224	chr15:76651327	T/G	cg21673338	chr15:77095150	SCAPER	-0.6	-5.53	-0.33	7.98e-8	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg23533926	chr12:111358616	MYL2	-0.53	-7.13	-0.41	1.13e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7508	0.546	rs382752	chr8:17898383	A/G	cg01800426	chr8:17659068	MTUS1	0.45	5.01	0.3	1.02e-6	Atrial fibrillation;
KIRP	cis	rs1408799	0.550	rs910	chr9:12710035	A/C	cg05274944	chr9:12693694	TYRP1	0.39	5.68	0.34	3.75e-8	Eye color;Blue vs. green eyes;
KIRP	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg07636037	chr3:49044803	WDR6	0.65	6.73	0.39	1.19e-10	Menarche (age at onset);
KIRP	cis	rs2820315	0.867	rs2820321	chr1:201880296	G/C	cg11586189	chr1:201857591	SHISA4	-0.4	-5.66	-0.34	4.26e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg18209359	chr17:80159595	CCDC57	0.42	5.51	0.33	9.25e-8	Life satisfaction;
KIRP	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.82	0.35	1.86e-8	Renal cell carcinoma;
KIRP	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg16586182	chr3:47516702	SCAP	-0.71	-10.05	-0.54	4.03e-20	Colorectal cancer;
KIRP	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.49	0.43	1.24e-12	Corneal astigmatism;
KIRP	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.02	0.3	9.8e-7	Menopause (age at onset);
KIRP	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12606694	chr6:131520996	AKAP7	0.51	6.53	0.38	3.81e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs882732	1.000	rs7159121	chr14:95040935	G/T	cg05186455	chr14:95027692	SERPINA4	-0.4	-5.1	-0.31	6.68e-7	Blood protein levels;
KIRP	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg00933542	chr6:150070202	PCMT1	0.26	4.98	0.3	1.2e-6	Testicular germ cell tumor;
KIRP	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.83	0.49	2.06e-16	Motion sickness;
KIRP	cis	rs7010876	0.568	rs28678551	chr8:89243644	A/C	cg08624180	chr8:89339080	MMP16	-0.53	-5.16	-0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs79349575	0.756	rs62078385	chr17:47045009	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	5.98	0.36	7.88e-9	Type 2 diabetes;
KIRP	cis	rs9928842	0.823	rs11149811	chr16:75300708	C/G	cg09066997	chr16:75300724	BCAR1	0.63	5.37	0.32	1.78e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg04455712	chr21:45112962	RRP1B	0.44	5.84	0.35	1.66e-8	Mean corpuscular volume;
KIRP	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg13395646	chr4:1353034	KIAA1530	0.37	4.89	0.3	1.84e-6	Obesity-related traits;
KIRP	cis	rs9473924	0.505	rs7738924	chr6:50850600	C/T	cg14470998	chr6:50812995	TFAP2B	0.84	7.77	0.44	2.07e-13	Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17309711	chr11:45826527	SLC35C1	0.58	6.74	0.39	1.09e-10	Smoking initiation;
KIRP	trans	rs2270927	0.510	rs35966882	chr5:75577716	A/G	cg13563193	chr19:33072644	PDCD5	0.88	6.85	0.4	5.95e-11	Mean corpuscular volume;
KIRP	cis	rs7084402	0.967	rs1658438	chr10:60326583	A/G	cg05938607	chr10:60274200	BICC1	0.45	11.05	0.58	2.68e-23	Refractive error;
KIRP	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.52	6.46	0.38	5.71e-10	Lymphocyte counts;
KIRP	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.03	14.59	0.68	3.75e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.65	-5.7	-0.34	3.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3736485	0.966	rs2124876	chr15:51906162	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.16e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg04374321	chr14:90722782	PSMC1	0.84	12.57	0.63	2.62e-28	Mortality in heart failure;
KIRP	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg10017260	chr10:834428	NA	-0.51	-5.24	-0.32	3.47e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg05347473	chr6:146136440	FBXO30	0.61	8.63	0.48	7.62e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.4	-5.77	-0.34	2.44e-8	Temporomandibular joint disorder;
KIRP	cis	rs2412819	0.597	rs78282429	chr15:43922003	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.59	0.39	2.73e-10	Lung cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17017335	chr3:97540665	NA	0.69	6.36	0.38	9.79e-10	Lung function (FEV1);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12334811	chr6:28045602	ZNF165	0.44	6.84	0.4	6.21e-11	Survival in pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02683085	chr20:10655461	JAG1	0.51	6.52	0.38	3.88e-10	Parkinson's disease;
KIRP	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg16586182	chr3:47516702	SCAP	0.83	11.69	0.6	2.05e-25	Colorectal cancer;
KIRP	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs9381107	0.932	rs13198509	chr6:9479610	C/T	cg14735645	chr6:9486422	NA	-0.56	-6.88	-0.4	4.87e-11	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.59e-11	Tonsillectomy;
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs4523957	0.579	rs2307143	chr17:2089754	G/A	cg16513277	chr17:2031491	SMG6	-0.72	-10.41	-0.55	2.81e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs9650657	0.812	rs7834466	chr8:10634805	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.4	-0.38	7.81e-10	Neuroticism;
KIRP	cis	rs35883536	0.935	rs1577510	chr1:101114295	G/A	cg06223162	chr1:101003688	GPR88	-0.33	-6.64	-0.39	1.96e-10	Monocyte count;
KIRP	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08704250	chr15:31115839	NA	-0.56	-8.02	-0.46	4.18e-14	Huntington's disease progression;
KIRP	cis	rs4523957	0.786	rs216213	chr17:2134225	G/A	cg16513277	chr17:2031491	SMG6	0.69	9.57	0.52	1.24e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs10875746	0.951	rs10875748	chr12:48526360	A/G	cg26205652	chr12:48591994	NA	0.77	10.39	0.55	3.28e-21	Longevity (90 years and older);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16248795	chr3:182698009	DCUN1D1	-0.57	-6.06	-0.36	5.13e-9	Menopause (age at onset);
KIRP	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg07884673	chr3:53033167	SFMBT1	0.75	6.11	0.36	3.91e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.47	0.38	5.34e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17183009	chr3:120277827	NA	0.56	6.45	0.38	5.9e-10	Corneal astigmatism;
KIRP	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg05347473	chr6:146136440	FBXO30	-0.51	-7.16	-0.42	9.47e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.46	5.59	0.34	6.08e-8	Menopause (age at onset);
KIRP	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.88	-14.11	-0.67	1.64e-33	Urate levels in lean individuals;
KIRP	cis	rs12210905	1.000	rs12214848	chr6:27063348	G/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.11	-0.31	6.54e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1829883	0.668	rs3905720	chr5:98985826	C/T	cg08333243	chr5:99726346	NA	0.4	5.05	0.31	8.79e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-0.84	-7.73	-0.44	2.75e-13	Opioid sensitivity;
KIRP	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	8.41	0.47	3.27e-15	Lung cancer in ever smokers;
KIRP	trans	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg00022858	chr4:55096616	PDGFRA	-0.45	-6.25	-0.37	1.82e-9	Protein C levels;
KIRP	cis	rs9640161	0.658	rs57888387	chr7:150004244	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.59	-7.09	-0.41	1.4e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg09491104	chr22:46646882	C22orf40	-0.5	-5.57	-0.33	6.64e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7849270	1.000	rs10988214	chr9:131883752	A/G	cg13538475	chr9:131942899	NA	-0.31	-5.04	-0.31	9.09e-7	Blood metabolite ratios;
KIRP	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	9.3	0.51	7.74e-18	Cognitive test performance;
KIRP	cis	rs7630877	0.719	rs1524514	chr3:179673066	T/C	cg18765712	chr3:179670323	PEX5L	0.85	9.84	0.53	1.78e-19	Type 2 diabetes;
KIRP	cis	rs10203711	1.000	rs13028091	chr2:239569723	C/T	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	5.05	0.31	8.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs4262150	0.883	rs4958583	chr5:152223531	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.16e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg26898376	chr11:64110657	CCDC88B	0.46	5.17	0.31	4.88e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4704846	0.614	rs2862718	chr5:156500626	G/A	cg12943317	chr5:156479607	HAVCR1	-0.51	-4.88	-0.3	1.89e-6	Blood protein levels;
KIRP	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg26876637	chr1:152193138	HRNR	-0.77	-9.21	-0.51	1.53e-17	Atopic dermatitis;
KIRP	trans	rs2856321	0.874	rs2724645	chr12:11892263	G/A	cg10155026	chr12:4553029	FGF6	0.42	6.3	0.37	1.37e-9	Height;
KIRP	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs10875746	0.669	rs11168499	chr12:48662670	A/G	cg26205652	chr12:48591994	NA	0.81	10.26	0.55	8.42e-21	Longevity (90 years and older);
KIRP	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.71	0.53	4.51e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg16989719	chr2:238392110	NA	-0.56	-6.04	-0.36	5.79e-9	Prostate cancer;
KIRP	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.81	-8.72	-0.49	4.24e-16	Asthma;
KIRP	cis	rs6058796	1.000	rs6141333	chr20:31263324	C/A	cg13636640	chr20:31349939	DNMT3B	0.59	5.25	0.32	3.36e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14651505	chr19:47987460	KPTN	0.56	7.28	0.42	4.56e-12	Parkinson's disease;
KIRP	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg08873628	chr1:175162347	KIAA0040	0.35	5.01	0.3	1.02e-6	Alcohol dependence;
KIRP	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.08	-0.46	2.88e-14	Aortic root size;
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg06871246	chr4:1363661	KIAA1530	-0.56	-6.98	-0.41	2.75e-11	Longevity;
KIRP	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.6	-8.03	-0.46	4.1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6578185	0.575	rs10102492	chr8:142484621	A/G	cg07762003	chr8:142452454	FLJ43860	0.4	4.99	0.3	1.13e-6	Endometriosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20727052	chr4:107224533	TBCK	0.4	6.29	0.37	1.44e-9	Interleukin-4 levels;
KIRP	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.39	5.34	0.32	2.12e-7	Lewy body disease;
KIRP	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.48	6.09	0.36	4.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11112613	0.818	rs73184093	chr12:106010066	G/C	cg03607813	chr12:105948248	NA	0.48	5.1	0.31	6.93e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs2014572	0.967	rs10426174	chr19:57756055	G/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.28	-0.37	1.53e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg18888403	chr1:24152774	HMGCL	0.37	5.23	0.32	3.67e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6601327	0.602	rs11249956	chr8:9658194	G/C	cg27411982	chr8:10470053	RP1L1	-0.39	-4.95	-0.3	1.36e-6	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.56	-15.48	-0.7	3.24e-38	Hip circumference adjusted for BMI;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25565998	chr19:56166418	U2AF2	-0.57	-6.37	-0.38	9.17e-10	Menopause (age at onset);
KIRP	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg14703610	chr5:56206110	C5orf35	-0.5	-7.07	-0.41	1.59e-11	Coronary artery disease;
KIRP	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.46	-0.33	1.17e-7	Huntington's disease progression;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04371633	chr14:65381025	CHURC1	0.59	7.06	0.41	1.64e-11	Smoking initiation;
KIRP	cis	rs2675399	0.607	rs7422239	chr2:189425664	C/T	cg00872532	chr2:189168448	GULP1	0.51	5.99	0.36	7.26e-9	Obesity-related traits;
KIRP	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg05973401	chr12:123451056	ABCB9	0.57	6.57	0.39	2.94e-10	Neutrophil percentage of white cells;
KIRP	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.48	-5.99	-0.36	7.48e-9	Monocyte count;
KIRP	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.82	0.35	1.86e-8	Total cholesterol levels;
KIRP	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs2055942	0.599	rs2229940	chr4:46995366	G/T	cg09812070	chr4:46995689	GABRA4	0.46	6.0	0.36	6.87e-9	Type 2 diabetes;
KIRP	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	15.18	0.7	3.67e-37	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23864376	chr10:26986384	PDSS1	0.53	6.59	0.39	2.61e-10	Parkinson's disease;
KIRP	cis	rs17221829	0.590	rs10830300	chr11:89363066	A/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg24565620	chr2:194026	NA	0.64	7.13	0.41	1.11e-11	Blood protein levels;
KIRP	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg13198984	chr17:80129470	CCDC57	0.59	8.96	0.5	8.46e-17	Life satisfaction;
KIRP	cis	rs6540556	0.517	rs61820570	chr1:209884953	C/T	cg23920097	chr1:209922102	NA	-0.48	-5.4	-0.33	1.54e-7	Red blood cell count;
KIRP	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.04	13.17	0.64	2.53e-30	Mitochondrial DNA levels;
KIRP	cis	rs580438	0.548	rs1048650	chr3:13358204	G/A	cg10657019	chr3:13328039	NA	0.6	7.88	0.45	1.08e-13	Myringotomy;
KIRP	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.51	4.95	0.3	1.4e-6	Yeast infection;
KIRP	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.62	-8.39	-0.47	3.72e-15	Total body bone mineral density;
KIRP	cis	rs6457821	1.000	rs73407614	chr6:35155339	A/G	cg06087101	chr6:35551932	FKBP5	0.55	4.91	0.3	1.68e-6	Height;
KIRP	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs2898857	0.524	rs2906100	chr17:47372764	C/T	cg11430096	chr6:110968061	CDK19	0.54	6.65	0.39	1.9e-10	Cancer;
KIRP	cis	rs9596863	0.750	rs1971924	chr13:54432432	T/G	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.64	-0.34	4.68e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4356975	0.522	rs6600888	chr4:69969859	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.48	0.33	1.06e-7	Obesity-related traits;
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg01391022	chr12:122360665	WDR66	-0.39	-5.62	-0.34	5.16e-8	Mean corpuscular volume;
KIRP	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg18478394	chr8:109455254	TTC35	0.52	6.55	0.39	3.32e-10	Dupuytren's disease;
KIRP	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg26681399	chr22:41777847	TEF	-0.52	-5.14	-0.31	5.63e-7	Vitiligo;
KIRP	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg24579218	chr15:68104479	NA	0.52	7.7	0.44	3.36e-13	Restless legs syndrome;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.79	6.85	0.4	5.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs684232	0.583	rs10521106	chr17:510707	C/T	cg15660573	chr17:549704	VPS53	-0.88	-13.39	-0.65	4.47e-31	Prostate cancer;
KIRP	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-1.05	-9.49	-0.52	2.04e-18	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.95	-13.82	-0.66	1.55e-32	Coronary artery disease;
KIRP	cis	rs240764	0.658	rs4463266	chr6:101223997	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.79	11.28	0.58	4.57e-24	Bladder cancer;
KIRP	cis	rs858239	0.536	rs6961109	chr7:23252413	C/T	cg23682824	chr7:23144976	KLHL7	0.43	4.9	0.3	1.7e-6	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.61	7.01	0.41	2.34e-11	Aortic root size;
KIRP	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.48	6.68	0.39	1.55e-10	Coronary artery disease;
KIRP	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs754423	0.621	rs10137158	chr14:52509858	C/T	cg05884192	chr14:52515736	NID2	0.53	5.83	0.35	1.71e-8	Craniofacial microsomia;
KIRP	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg20302533	chr7:39170763	POU6F2	-0.26	-5.31	-0.32	2.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-0.6	-7.94	-0.45	6.99e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.55	-6.7	-0.39	1.44e-10	Smoking behavior;
KIRP	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	12.08	0.61	1.11e-26	Monocyte percentage of white cells;
KIRP	cis	rs2414059	0.518	rs56398519	chr15:50773432	A/G	cg05456662	chr15:50716270	USP8	-0.44	-5.9	-0.35	1.18e-8	QT interval;
KIRP	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg25753631	chr6:25732923	NA	-0.29	-5.25	-0.32	3.32e-7	Iron status biomarkers;
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.39e-10	Bipolar disorder;
KIRP	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.23	0.58	6.77e-24	Bladder cancer;
KIRP	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg10935138	chr17:73851978	WBP2	0.45	5.34	0.32	2.09e-7	White matter hyperintensity burden;
KIRP	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg05347473	chr6:146136440	FBXO30	0.6	8.47	0.48	2.19e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.53	-0.38	3.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4742903	0.935	rs10991186	chr9:106996153	C/T	cg14250997	chr9:106856677	SMC2	-0.36	-4.92	-0.3	1.56e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	6.97	0.41	2.92e-11	Bipolar disorder;
KIRP	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.52	6.33	0.37	1.13e-9	Monocyte count;
KIRP	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg15655495	chr12:38532458	NA	-0.27	-5.18	-0.31	4.69e-7	Bladder cancer;
KIRP	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg09491104	chr22:46646882	C22orf40	-0.58	-6.85	-0.4	5.87e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs4409675	0.549	rs72872888	chr1:28239809	G/A	cg23691781	chr1:28212827	C1orf38	0.4	9.67	0.52	5.96e-19	Corneal astigmatism;
KIRP	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg03060546	chr3:49711283	APEH	-0.68	-5.0	-0.3	1.1e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs62229266	0.804	rs998383	chr21:37445739	C/G	cg08632701	chr21:37451849	NA	-0.48	-6.0	-0.36	7e-9	Mitral valve prolapse;
KIRP	cis	rs7119038	0.818	rs10892293	chr11:118665575	A/T	cg19308663	chr11:118741387	NA	0.53	7.9	0.45	9.06e-14	Sjögren's syndrome;
KIRP	cis	rs7589728	1.000	rs75309929	chr2:88524377	T/C	cg04511125	chr2:88470314	THNSL2	0.7	5.46	0.33	1.17e-7	Plasma clusterin levels;
KIRP	cis	rs767764	0.932	rs59738387	chr8:13200212	G/A	cg20744108	chr8:13131569	DLC1	-0.49	-4.99	-0.3	1.17e-6	Nose size;
KIRP	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs28595532	0.748	rs55949457	chr4:119336174	A/G	cg21605333	chr4:119757512	SEC24D	0.93	7.13	0.41	1.08e-11	Cannabis dependence symptom count;
KIRP	cis	rs7130144	0.541	rs57851196	chr11:130465218	T/C	cg26307797	chr11:130446613	NA	-0.63	-5.19	-0.31	4.36e-7	Urate levels in lean individuals;
KIRP	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg13271783	chr10:134563150	INPP5A	-0.56	-7.12	-0.41	1.21e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg17554472	chr22:41940697	POLR3H	0.42	5.19	0.31	4.3e-7	Vitiligo;
KIRP	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg26876637	chr1:152193138	HRNR	-0.75	-8.52	-0.48	1.6e-15	Atopic dermatitis;
KIRP	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.21	14.22	0.67	6.91e-34	Corneal structure;
KIRP	cis	rs7113850	0.541	rs7933381	chr11:24237534	T/C	ch.11.24196551F	chr11:24239977	NA	0.9	8.41	0.47	3.28e-15	Bone fracture in osteoporosis;
KIRP	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.78	-11.56	-0.59	5.52e-25	Neurofibrillary tangles;
KIRP	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-4.95	-0.3	1.36e-6	Neuroticism;
KIRP	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.48	-6.36	-0.38	9.93e-10	Survival in pancreatic cancer;
KIRP	cis	rs1570884	0.714	rs2038881	chr13:50135177	A/G	cg03651054	chr13:50194643	NA	0.58	8.27	0.47	8.3e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg03714773	chr7:91764589	CYP51A1	0.4	5.82	0.35	1.81e-8	Breast cancer;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.52	-0.43	1e-12	Blood pressure;
KIRP	cis	rs883565	0.502	rs11129810	chr3:38946064	C/T	cg01426195	chr3:39028469	NA	-0.47	-7.27	-0.42	4.73e-12	Handedness;
KIRP	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg24253500	chr15:84953950	NA	0.53	6.0	0.36	6.92e-9	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.13	-0.36	3.54e-9	Lung cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08316941	chr5:133984937	SEC24A	0.49	6.3	0.37	1.33e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4849845	0.889	rs4849847	chr2:121034530	A/G	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.45	0.47	2.53e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.68	7.81	0.45	1.65e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg11784071	chr10:104629166	AS3MT	-0.37	-5.15	-0.31	5.32e-7	Arsenic metabolism;
KIRP	trans	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs4356932	0.967	rs13113632	chr4:76972516	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.05	0.36	5.3e-9	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg02733842	chr7:1102375	C7orf50	0.54	5.68	0.34	3.76e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs2904967	1.000	rs2904967	chr11:65091609	G/A	cg09225861	chr11:65069680	NA	0.43	5.23	0.32	3.64e-7	Mean corpuscular volume;
KIRP	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.49	5.74	0.34	2.85e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg08722104	chr11:47448306	PSMC3	-0.49	-6.28	-0.37	1.55e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.18	-0.31	4.69e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.7	10.44	0.55	2.39e-21	Lewy body disease;
KIRP	cis	rs72843166	0.562	rs17760469	chr17:61428957	G/A	cg19683800	chr17:61518354	CYB561	-0.42	-5.22	-0.32	3.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.43	-5.57	-0.33	6.81e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.52	-6.07	-0.36	4.89e-9	Schizophrenia;
KIRP	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-12.34	-0.62	1.44e-27	Chronic sinus infection;
KIRP	cis	rs62109865	0.655	rs62111820	chr19:12607949	G/A	cg19721055	chr19:12753329	NA	-0.84	-4.94	-0.3	1.48e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17065868	0.881	rs9590837	chr13:45145355	G/T	cg10246903	chr13:45222710	NA	0.69	6.56	0.39	3.1e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	7.41	0.43	2.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg12315302	chr6:26189340	HIST1H4D	0.97	6.82	0.4	7.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg13611997	chr5:233750	SDHA	-0.44	-5.26	-0.32	3.15e-7	Breast cancer;
KIRP	cis	rs11638352	0.661	rs2733213	chr15:44462954	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	4.84	0.3	2.27e-6	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02985724	chr1:159915429	IGSF9	-0.43	-6.55	-0.39	3.34e-10	Metabolic traits;
KIRP	cis	rs6442310	0.545	rs2972163	chr3:12438022	G/A	cg22839075	chr3:12045461	SYN2	0.37	5.32	0.32	2.31e-7	Hematocrit;
KIRP	cis	rs35995292	0.500	rs7776996	chr7:38919762	G/C	cg19327137	chr7:38886074	VPS41	0.79	12.15	0.61	6.35e-27	Subjective well-being (multi-trait analysis);
KIRP	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.61	6.93	0.4	3.75e-11	Height;
KIRP	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	0.98	10.41	0.55	2.97e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6510725	1.000	rs6510725	chr19:348743	C/T	cg27103937	chr19:348210	NA	0.43	4.93	0.3	1.53e-6	Non-small cell lung cancer;
KIRP	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.6	7.27	0.42	4.82e-12	Metabolite levels;
KIRP	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg24253500	chr15:84953950	NA	0.46	5.14	0.31	5.63e-7	Schizophrenia;
KIRP	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.73	-7.98	-0.45	5.56e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg23748340	chr12:48592721	NA	-0.43	-5.01	-0.3	1.02e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.64	7.61	0.44	5.8e-13	Testicular germ cell tumor;
KIRP	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.81	-0.63	4.05e-29	Extrinsic epigenetic age acceleration;
KIRP	trans	rs12444979	0.507	rs8062735	chr16:19839538	C/T	cg12228919	chr15:44955936	SPG11	0.5	6.02	0.36	6.39e-9	Body mass index;
KIRP	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs10849893	0.576	rs7134248	chr12:121897052	T/C	cg01154721	chr12:121881891	KDM2B	-0.43	-5.7	-0.34	3.39e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg14517863	chr17:44321492	NA	0.51	6.44	0.38	6.22e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2033908	0.620	rs10765993	chr11:12849185	C/G	cg25843174	chr11:12811716	TEAD1	-0.37	-7.08	-0.41	1.48e-11	Sitting height ratio;
KIRP	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.34	-0.55	4.76e-21	Heart rate;
KIRP	cis	rs17123764	0.892	rs74089564	chr12:49952042	T/G	cg20471783	chr12:50157085	TMBIM6	0.43	5.38	0.32	1.74e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15963230	chr19:11485746	C19orf39	0.5	6.39	0.38	8.14e-10	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25663178	chr15:66161981	RAB11A	0.42	6.17	0.37	2.74e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg00074818	chr8:8560427	CLDN23	0.41	6.57	0.39	3.02e-10	Obesity-related traits;
KIRP	cis	rs1448094	0.842	rs12809288	chr12:86455427	C/T	cg00310523	chr12:86230176	RASSF9	-0.4	-6.15	-0.36	3.16e-9	Major depressive disorder;
KIRP	cis	rs28587833	1	rs28587833	chr17:78511327	C/G	cg08122114	chr17:78444702	NPTX1	-0.45	-4.91	-0.3	1.69e-6	Schizophrenia;
KIRP	cis	rs12210905	0.688	rs72839479	chr6:27332910	G/A	cg08851530	chr6:28072375	NA	0.89	5.14	0.31	5.55e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9400467	0.509	rs463853	chr6:111673211	C/G	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg05457628	chr5:178986728	RUFY1	0.64	10.45	0.55	2.11e-21	Lung cancer;
KIRP	cis	rs2742234	0.955	rs2503865	chr10:43659536	C/T	cg02780029	chr10:43622663	RET	-0.33	-4.86	-0.3	2.12e-6	Hirschsprung disease;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.27	-0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.17	-0.37	2.83e-9	Bladder cancer;
KIRP	cis	rs714027	0.566	rs4820827	chr22:30477589	T/C	cg27665648	chr22:30112403	NA	-0.45	-6.31	-0.37	1.31e-9	Lymphocyte counts;
KIRP	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.42	-0.43	1.89e-12	Mood instability;
KIRP	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.82	-0.45	1.54e-13	Calcium levels;
KIRP	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.93	0.35	1.02e-8	Total cholesterol levels;
KIRP	cis	rs4804368	0.674	rs4804377	chr19:7194976	A/G	cg09377704	chr19:7936683	NA	0.44	4.91	0.3	1.68e-6	Renal cell carcinoma;
KIRP	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg24881330	chr22:46731750	TRMU	0.61	5.09	0.31	7.01e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.59	7.33	0.42	3.27e-12	Breast cancer;
KIRP	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.65	-0.52	6.81e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg01864069	chr14:103024347	NA	-0.69	-8.06	-0.46	3.3e-14	Platelet count;
KIRP	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09318721	chr1:101534815	NA	-0.45	-7.08	-0.41	1.48e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.74	11.68	0.6	2.29e-25	Resting heart rate;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07308232	chr7:1071921	C7orf50	-0.51	-6.49	-0.38	4.79e-10	Longevity;Endometriosis;
KIRP	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	5.92	0.35	1.06e-8	Bipolar disorder;
KIRP	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.24	-0.32	3.5e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.78	-9.16	-0.5	2.11e-17	Schizophrenia;
KIRP	cis	rs1062177	0.855	rs6892117	chr5:151264985	C/T	cg00977110	chr5:151150581	G3BP1	-0.55	-5.84	-0.35	1.68e-8	Preschool internalizing problems;
KIRP	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg12856521	chr11:46389249	DGKZ	0.6	7.19	0.42	7.69e-12	Crohn's disease;
KIRP	cis	rs9443189	0.813	rs2133191	chr6:76440761	C/T	cg01950844	chr6:76311363	SENP6	-0.58	-6.26	-0.37	1.71e-9	Prostate cancer;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14905665	chr2:206661494	NRP2	0.53	6.06	0.36	5.01e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs17023223	0.509	rs6668960	chr1:119600812	C/T	cg18261050	chr1:119551319	NA	0.5	6.6	0.39	2.55e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.24	-0.37	1.9e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.47	4.99	0.3	1.13e-6	Breast cancer;
KIRP	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.52	0.33	8.79e-8	Platelet count;
KIRP	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg06766960	chr11:133703094	NA	-0.55	-6.8	-0.4	7.68e-11	Childhood ear infection;
KIRP	cis	rs12580194	0.593	rs11171435	chr12:55758053	T/C	cg19537932	chr12:55886519	OR6C68	-0.47	-6.31	-0.37	1.27e-9	Cancer;
KIRP	cis	rs2033732	0.826	rs2196617	chr8:85089394	G/A	cg05716166	chr8:85095498	RALYL	0.51	5.96	0.36	8.7e-9	Body mass index;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03399598	chr4:174091002	GALNT7	-0.52	-6.69	-0.39	1.5e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3007168	1.000	rs2999362	chr14:51605265	A/G	cg23942311	chr14:51606299	NA	0.53	5.54	0.33	7.84e-8	Cancer;
KIRP	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.78	9.49	0.52	2.04e-18	Corneal astigmatism;
KIRP	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg00405596	chr8:11794950	NA	-0.49	-6.45	-0.38	5.86e-10	Retinal vascular caliber;
KIRP	cis	rs4006360	0.610	rs7503043	chr17:39295561	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-8.68	-0.48	5.54e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg02415014	chr8:143852576	LYNX1	-0.31	-5.07	-0.31	7.74e-7	Urinary tract infection frequency;
KIRP	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.97	-0.5	7.57e-17	Hirschsprung disease;
KIRP	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg08076091	chr2:203926405	NBEAL1	0.85	8.77	0.49	3.08e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs61776719	0.520	rs17465651	chr1:38418496	C/T	cg18451016	chr1:38461880	NA	0.48	6.58	0.39	2.83e-10	Coronary artery disease;
KIRP	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	8.04	0.46	3.81e-14	Resting heart rate;
KIRP	cis	rs6584283	0.716	rs10786558	chr10:101287610	G/A	cg07044859	chr10:101282883	NA	-0.28	-4.9	-0.3	1.7e-6	Ulcerative colitis;
KIRP	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg00310523	chr12:86230176	RASSF9	-0.48	-7.66	-0.44	4.28e-13	Major depressive disorder;
KIRP	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21028142	chr17:79581711	NPLOC4	0.33	4.85	0.3	2.16e-6	Eye color traits;
KIRP	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.64	-0.34	4.68e-8	Type 2 diabetes;
KIRP	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg26022315	chr17:47021804	SNF8	0.44	5.69	0.34	3.57e-8	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.79	9.64	0.52	7.2e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs16828019	0.852	rs71648540	chr1:41722295	G/A	cg03387723	chr1:41708464	SCMH1	-0.77	-6.8	-0.4	7.68e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg22974920	chr21:40686053	BRWD1	0.49	5.9	0.35	1.19e-8	Cognitive function;
KIRP	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.82	11.49	0.59	9.7e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.0	16.42	0.72	2e-41	Multiple system atrophy;
KIRP	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.54	-6.46	-0.38	5.41e-10	Ulcerative colitis;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.61	-8.18	-0.46	1.52e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg00343986	chr7:65444356	GUSB	0.43	5.12	0.31	6.05e-7	Aortic root size;
KIRP	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-8.67	-0.48	6.04e-16	Personality dimensions;
KIRP	cis	rs12190007	0.747	rs2981942	chr6:169792659	T/G	cg15038512	chr6:170123185	PHF10	-0.41	-5.56	-0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.54	-6.28	-0.37	1.49e-9	Menarche (age at onset);
KIRP	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg03060546	chr3:49711283	APEH	0.53	7.23	0.42	6.07e-12	Menarche (age at onset);
KIRP	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.42	0.33	1.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.32	0.62	1.76e-27	Platelet count;
KIRP	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg13736514	chr6:26305472	NA	-0.66	-8.71	-0.49	4.66e-16	Educational attainment;
KIRP	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg06012730	chr15:75315579	PPCDC	-0.41	-5.06	-0.31	8.21e-7	Blood trace element (Zn levels);
KIRP	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg00405596	chr8:11794950	NA	0.44	5.69	0.34	3.51e-8	Myopia (pathological);
KIRP	cis	rs8014252	0.803	rs17113651	chr14:71061836	T/C	cg11204974	chr14:71022665	NA	-0.68	-7.12	-0.41	1.21e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4919044	0.756	rs7073161	chr10:94826465	C/G	cg05127821	chr10:94822908	CYP26C1	0.67	6.84	0.4	6.27e-11	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16791424	chr14:27068093	NOVA1	0.48	7.32	0.42	3.48e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.35	-0.32	2e-7	Lung cancer;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg08935602	chr16:2509817	C16orf59	0.52	6.27	0.37	1.62e-9	Sleep duration;
KIRP	cis	rs6772849	0.830	rs7633674	chr3:128355026	G/A	cg08795948	chr3:128337044	NA	0.48	6.1	0.36	4.15e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg16691251	chr5:66510806	NA	0.46	6.04	0.36	5.59e-9	Breast cancer;
KIRP	cis	rs300890	0.642	rs3805252	chr4:144295659	A/G	cg01719995	chr4:144104893	USP38	-0.41	-5.16	-0.31	5.12e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg21479132	chr6:26055353	NA	0.76	4.88	0.3	1.95e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg16235748	chr6:149772707	ZC3H12D	0.3	5.09	0.31	7.29e-7	Dupuytren's disease;
KIRP	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	8.73	0.49	3.87e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.52	-5.46	-0.33	1.19e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	1.11	16.31	0.72	4.73e-41	Breast cancer;
KIRP	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.25	0.32	3.33e-7	Lung cancer;
KIRP	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.7	-9.44	-0.52	3.02e-18	Morning vs. evening chronotype;
KIRP	cis	rs3540	0.513	rs2589957	chr15:90903311	A/G	cg10434728	chr15:90938212	IQGAP1	0.4	7.42	0.43	1.95e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.39	-0.38	8.2e-10	Axial length;
KIRP	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17507749	chr15:85114479	UBE2QP1	0.7	7.86	0.45	1.23e-13	Schizophrenia;
KIRP	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	Neuroticism;
KIRP	cis	rs4959799	0.655	rs9503518	chr6:3273457	A/G	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.25	-0.32	3.34e-7	Survival in rectal cancer;
KIRP	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.49	-5.07	-0.31	7.8e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg06521331	chr12:34319734	NA	-0.61	-7.35	-0.42	2.93e-12	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	6.31	0.37	1.29e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	9.38	0.51	4.44e-18	Schizophrenia;
KIRP	cis	rs6832769	0.961	rs11133382	chr4:56316980	T/G	cg05960024	chr4:56376020	CLOCK	0.59	7.64	0.44	4.7e-13	Personality dimensions;
KIRP	cis	rs6707387	0.617	rs10180751	chr2:214334092	G/A	cg08319019	chr2:214017104	IKZF2	0.43	4.93	0.3	1.5e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs8033133	0.958	rs6420956	chr15:25309559	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.57	-6.66	-0.39	1.8e-10	Blood osmolality (transformed sodium);
KIRP	cis	rs7078219	0.543	rs4919342	chr10:101282553	G/C	cg07044859	chr10:101282883	NA	-0.31	-5.67	-0.34	4.09e-8	Dental caries;
KIRP	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Schizophrenia;
KIRP	cis	rs7615316	1.000	rs6440098	chr3:142355410	A/C	cg20824294	chr3:142316082	PLS1	-0.23	-5.1	-0.31	6.77e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs9659323	0.804	rs10923722	chr1:119543486	C/T	cg18261050	chr1:119551319	NA	0.41	5.78	0.35	2.2e-8	Body mass index;
KIRP	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.13	-0.36	3.46e-9	Daytime sleep phenotypes;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg08132940	chr7:1081526	C7orf50	-0.62	-6.29	-0.37	1.42e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg09264619	chr17:80180166	NA	-0.39	-5.64	-0.34	4.6e-8	Life satisfaction;
KIRP	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg10770023	chr22:51016644	CPT1B;CHKB-CPT1B	-0.53	-4.9	-0.3	1.75e-6	Narcolepsy;
KIRP	cis	rs11622475	0.953	rs6576012	chr14:104400159	T/C	cg20488157	chr14:104394430	TDRD9	-0.77	-10.71	-0.56	3.18e-22	Bipolar disorder;
KIRP	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.9	11.2	0.58	8.71e-24	Smoking behavior;
KIRP	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg21775007	chr8:11205619	TDH	0.48	6.39	0.38	8.17e-10	Mood instability;
KIRP	cis	rs6142102	1.000	rs4911409	chr20:32710710	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.39	0.38	8.42e-10	Skin pigmentation;
KIRP	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg08283408	chr3:49949060	MON1A	0.36	4.85	0.3	2.22e-6	Body mass index;
KIRP	cis	rs12282928	1.000	rs10838840	chr11:48258010	C/A	cg26585981	chr11:48327164	OR4S1	0.47	5.34	0.32	2.15e-7	Migraine - clinic-based;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg12705353	chr12:122356852	WDR66	0.53	7.22	0.42	6.29e-12	Mean corpuscular volume;
KIRP	cis	rs783147	0.652	rs1782627	chr6:161196800	A/G	cg01280913	chr6:161186852	NA	0.48	6.42	0.38	7.03e-10	Lp (a) levels;
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg01324507	chr7:1177794	C7orf50	0.55	5.0	0.3	1.07e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs4791746	1.000	rs7225030	chr17:8618763	A/G	cg03115937	chr17:8649504	CCDC42	-0.52	-6.29	-0.37	1.43e-9	Heroin dependence;
KIRP	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-0.95	-13.26	-0.65	1.23e-30	Blood trace element (Zn levels);
KIRP	cis	rs7520050	1.000	rs12143096	chr1:46469763	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.21e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.56	7.73	0.44	2.8e-13	Blood metabolite levels;
KIRP	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg01872077	chr2:219646372	CYP27A1	0.38	5.32	0.32	2.34e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.59	8.59	0.48	1.02e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg26338869	chr17:61819248	STRADA	-0.52	-6.21	-0.37	2.29e-9	Prudent dietary pattern;
KIRP	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg16898833	chr6:26189333	HIST1H4D	0.95	5.77	0.35	2.35e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.66	-9.73	-0.53	3.94e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2279817	0.743	rs3766309	chr1:17977378	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.39	-5.59	-0.34	6.04e-8	Neuroticism;
KIRP	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg11895451	chr1:16533891	ARHGEF19	0.43	5.88	0.35	1.3e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26207909	chr14:103986467	CKB	0.56	7.51	0.43	1.06e-12	Body mass index;
KIRP	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.47	9.75	0.53	3.36e-19	Schizophrenia;
KIRP	cis	rs72827839	0.793	rs112296021	chr17:46101460	G/A	cg03171361	chr17:47075758	IGF2BP1	-0.49	-4.95	-0.3	1.38e-6	Ease of getting up in the morning;
KIRP	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.49	7.06	0.41	1.68e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2671245	0.933	rs1183736	chr1:56183163	A/C	cg11523071	chr1:56160889	NA	0.36	5.42	0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.66	-8.55	-0.48	1.3e-15	Longevity;
KIRP	cis	rs986417	1.000	rs1254287	chr14:60861774	C/T	cg27398547	chr14:60952738	C14orf39	-0.74	-7.41	-0.43	2.01e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.4	-5.55	-0.33	7.3e-8	Blood metabolite levels;
KIRP	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg11234688	chr2:1609660	NA	0.58	5.28	0.32	2.79e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.42	-5.19	-0.31	4.42e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg06618935	chr21:46677482	NA	-0.47	-5.94	-0.35	9.42e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11987759	chr7:65425863	GUSB	-0.49	-6.32	-0.37	1.22e-9	Aortic root size;
KIRP	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.94	0.81	7.68e-60	Prudent dietary pattern;
KIRP	cis	rs2519796	0.529	rs2073885	chr9:136814491	T/C	cg13751417	chr9:136814406	VAV2	-0.46	-5.23	-0.32	3.71e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.19	-0.37	2.53e-9	Hemoglobin concentration;
KIRP	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg15839431	chr19:19639596	YJEFN3	0.5	5.14	0.31	5.57e-7	Bipolar disorder;
KIRP	cis	rs3026101	0.671	rs2871203	chr17:5298490	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.41	-5.24	-0.32	3.53e-7	Aortic root size;
KIRP	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.56	-4.86	-0.3	2.09e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs6681460	0.576	rs7354930	chr1:66986377	T/C	cg13052034	chr1:66999238	SGIP1	0.41	5.43	0.33	1.33e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg00241281	chr14:105779794	PACS2	-0.36	-4.9	-0.3	1.77e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	13.35	0.65	6.08e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.49	0.65	2.07e-31	Smoking behavior;
KIRP	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.45	-0.33	1.25e-7	Bipolar disorder;
KIRP	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg04976154	chr16:1532411	NA	0.63	9.34	0.51	5.92e-18	Bone mineral density;
KIRP	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26314531	chr2:26401878	FAM59B	-0.52	-5.66	-0.34	4.12e-8	Gut microbiome composition (summer);
KIRP	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.52	-5.98	-0.36	7.96e-9	Migraine;
KIRP	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.73	10.01	0.54	5.28e-20	Mood instability;
KIRP	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg16482183	chr6:26056742	HIST1H1C	0.63	7.38	0.43	2.4e-12	Iron status biomarkers;
KIRP	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg05805236	chr11:65401703	PCNXL3	-0.58	-6.71	-0.39	1.34e-10	Acne (severe);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13648088	chr10:124768538	ACADSB;IKZF5	-0.5	-6.82	-0.4	7.09e-11	Myopia;
KIRP	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.66	9.63	0.52	8.06e-19	Metabolite levels;
KIRP	cis	rs13108043	0.639	rs34140562	chr4:87945401	G/T	cg11209507	chr4:87813803	C4orf36	0.46	4.89	0.3	1.78e-6	Red blood cell count;
KIRP	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	cg21523751	chr1:182988639	NA	0.45	7.1	0.41	1.36e-11	Colorectal cancer;
KIRP	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.13e-6	Aortic root size;
KIRP	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.79	-11.04	-0.58	2.86e-23	Educational attainment;
KIRP	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.68	-9.31	-0.51	7.57e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.5	7.16	0.42	9.46e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg12623918	chr2:306882	NA	0.46	5.83	0.35	1.73e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.47	6.86	0.4	5.69e-11	Coronary artery disease;
KIRP	cis	rs7809799	0.571	rs67546174	chr7:98938254	C/T	cg12290671	chr7:99195819	NA	-0.71	-5.37	-0.32	1.86e-7	Ulcerative colitis;
KIRP	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06481639	chr22:41940642	POLR3H	0.45	5.46	0.33	1.19e-7	Vitiligo;
KIRP	cis	rs66530629	1.000	rs12043858	chr1:25047459	C/T	cg07201717	chr1:25031947	NA	0.33	4.96	0.3	1.29e-6	Plateletcrit;
KIRP	cis	rs5753037	0.702	rs140143	chr22:30173109	G/T	cg01021169	chr22:30184971	ASCC2	-0.44	-5.54	-0.33	7.63e-8	Type 1 diabetes;
KIRP	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07525857	chr15:44955958	SPG11	0.49	6.17	0.37	2.74e-9	Parkinson's disease;
KIRP	cis	rs2150410	0.748	rs13050583	chr21:40574080	C/T	cg11890956	chr21:40555474	PSMG1	0.75	5.38	0.32	1.77e-7	Temperament (bipolar disorder);
KIRP	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg24296786	chr1:45957014	TESK2	-0.42	-5.28	-0.32	2.79e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15508776	chr22:40054056	CACNA1I	0.45	6.07	0.36	4.93e-9	Survival in pancreatic cancer;
KIRP	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg27205649	chr11:78285834	NARS2	-0.68	-9.06	-0.5	4.22e-17	Alzheimer's disease (survival time);
KIRP	cis	rs6840360	0.541	rs4696251	chr4:152266326	T/C	cg25486957	chr4:152246857	NA	-0.48	-6.03	-0.36	5.86e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg16141378	chr3:129829833	LOC729375	0.57	7.71	0.44	3.21e-13	Mood instability;
KIRP	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg02336718	chr17:17403227	NA	-0.34	-5.29	-0.32	2.7e-7	Total body bone mineral density;
KIRP	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg05082376	chr22:42548792	NA	0.46	5.8	0.35	2.01e-8	Schizophrenia;
KIRP	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.75	-7.53	-0.43	9.38e-13	Vitiligo;
KIRP	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg05768032	chr16:30646687	NA	0.45	5.87	0.35	1.37e-8	Dementia with Lewy bodies;
KIRP	cis	rs9398803	1.000	rs9398803	chr6:126683594	A/G	cg19875578	chr6:126661172	C6orf173	0.47	6.15	0.37	3.1e-9	Male-pattern baldness;
KIRP	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.92	13.43	0.65	3.31e-31	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg01338084	chr22:32026380	PISD	0.98	6.81	0.4	7.26e-11	Age-related hearing impairment;
KIRP	cis	rs7721647	0.853	rs1822167	chr5:90864497	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.41	5.14	0.31	5.7e-7	Breast cancer;
KIRP	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.57	7.88	0.45	1.03e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs933688	0.775	rs10434640	chr5:90578301	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-5.55	-0.33	7.33e-8	Smoking behavior;
KIRP	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs7116495	1.000	rs642573	chr11:71780854	G/C	cg26138937	chr11:71823887	C11orf51	-0.67	-5.26	-0.32	3.16e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.57	7.2	0.42	7.15e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg19847130	chr8:10466454	RP1L1	0.34	5.09	0.31	7e-7	Triglycerides;
KIRP	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg06138931	chr13:21896616	NA	0.6	6.12	0.36	3.69e-9	White matter hyperintensity burden;
KIRP	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.69	0.34	3.57e-8	Bipolar disorder;
KIRP	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg17264618	chr3:40429014	ENTPD3	0.33	4.93	0.3	1.49e-6	Renal cell carcinoma;
KIRP	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg26513180	chr16:89883248	FANCA	0.62	5.31	0.32	2.49e-7	Skin colour saturation;
KIRP	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.77	-0.77	2.27e-49	Schizophrenia;
KIRP	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.41	-0.43	2.03e-12	Bipolar disorder;
KIRP	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.06	-0.36	5.07e-9	Breast cancer;
KIRP	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	0.6	5.13	0.31	6.01e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs11997175	0.562	rs58955533	chr8:33829692	C/T	ch.8.33884649F	chr8:33765107	NA	0.51	6.18	0.37	2.69e-9	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05041984	chr10:52145861	SGMS1	-0.42	-6.59	-0.39	2.69e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.43	-4.97	-0.3	1.26e-6	Educational attainment (years of education);
KIRP	cis	rs13102973	0.899	rs4546304	chr4:135902382	G/A	cg14419869	chr4:135874104	NA	0.48	7.52	0.43	1.02e-12	Subjective well-being;
KIRP	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	7.9	0.45	9.22e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg12573674	chr2:1569213	NA	-0.52	-5.15	-0.31	5.37e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6540556	0.682	rs2282741	chr1:209900609	G/C	cg23920097	chr1:209922102	NA	-0.4	-5.47	-0.33	1.09e-7	Red blood cell count;
KIRP	cis	rs11074306	0.561	rs2311468	chr15:28069041	G/A	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.59e-6	Uveal melanoma;
KIRP	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.63	8.53	0.48	1.47e-15	Colorectal cancer;
KIRP	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	1.0	13.46	0.65	2.54e-31	Vitamin D levels;
KIRP	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs3789045	1.000	rs3789045	chr1:204586812	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.54	-5.42	-0.33	1.42e-7	Educational attainment (college completion);
KIRP	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg03315344	chr16:75512273	CHST6	-0.55	-5.42	-0.33	1.45e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs7809950	0.724	rs1858888	chr7:107046062	T/A	cg23024343	chr7:107201750	COG5	-0.56	-8.06	-0.46	3.24e-14	Coronary artery disease;
KIRP	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.75	-8.97	-0.5	7.87e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-7.53	-0.43	9.45e-13	Neuroticism;
KIRP	cis	rs1165472	0.543	rs78592388	chr1:56140576	A/C	cg11523071	chr1:56160889	NA	-0.54	-6.35	-0.38	1.03e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-8.66	-0.48	6.51e-16	Renal function-related traits (BUN);
KIRP	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.08	0.5	3.62e-17	Bipolar disorder;
KIRP	trans	rs909341	0.909	rs1741708	chr20:62372041	G/T	cg01311341	chr22:25575246	KIAA1671	-0.58	-6.67	-0.39	1.63e-10	Atopic dermatitis;
KIRP	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.78	-10.36	-0.55	4.27e-21	Dental caries;
KIRP	cis	rs367943	0.712	rs9326888	chr5:112731133	A/C	cg12552261	chr5:112820674	MCC	0.58	6.89	0.4	4.75e-11	Type 2 diabetes;
KIRP	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg02591564	chr12:125578355	AACS	-0.43	-4.91	-0.3	1.65e-6	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg08392591	chr16:89556376	ANKRD11	0.43	5.43	0.33	1.32e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs8054556	0.787	rs1140239	chr16:30021402	C/T	cg13500354	chr6:168617491	NA	0.33	6.04	0.36	5.65e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.61	5.5	0.33	9.67e-8	Alzheimer's disease;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg22907277	chr7:1156413	C7orf50	0.82	7.69	0.44	3.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.25	-0.37	1.76e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg11235152	chr1:67600687	NA	-0.74	-10.97	-0.57	4.75e-23	Psoriasis;
KIRP	cis	rs960902	0.714	rs11890793	chr2:37715860	T/C	cg25341268	chr2:37734390	NA	-0.55	-7.12	-0.41	1.2e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg19274270	chr17:78178856	CARD14	-0.35	-6.37	-0.38	9.22e-10	Kawasaki disease;
KIRP	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	1.14	8.89	0.49	1.31e-16	Lymphocyte counts;
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-6.11	-0.36	3.93e-9	Lung cancer;
KIRP	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.92	15.64	0.71	9.43e-39	Menarche (age at onset);
KIRP	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg18164611	chr1:46958628	NA	-0.41	-5.01	-0.3	1.04e-6	Monobrow;
KIRP	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg06289844	chr6:126071538	HEY2	0.4	5.88	0.35	1.33e-8	Brugada syndrome;
KIRP	cis	rs1656402	0.953	rs1550099	chr2:233428147	A/G	cg03852847	chr2:233439513	NA	0.69	11.26	0.58	5.58e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	5.34	0.32	2.09e-7	Personality dimensions;
KIRP	cis	rs4453791	1.000	rs4453791	chr3:38882519	T/C	cg23654821	chr3:39188656	CSRNP1	0.49	4.97	0.3	1.24e-6	Social communication problems;
KIRP	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg00405596	chr8:11794950	NA	0.47	5.78	0.35	2.23e-8	Retinal vascular caliber;
KIRP	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.89	-0.35	1.23e-8	Response to antipsychotic treatment;
KIRP	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.68	9.82	0.53	2.01e-19	Dupuytren's disease;
KIRP	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	5.01	0.3	1.06e-6	Bipolar disorder;
KIRP	cis	rs977987	0.864	rs40446	chr16:75496658	T/C	cg03315344	chr16:75512273	CHST6	-0.7	-10.54	-0.56	1.1e-21	Dupuytren's disease;
KIRP	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg18350739	chr11:68623251	NA	-0.49	-7.65	-0.44	4.65e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4638749	0.501	rs9653451	chr2:108781858	A/G	cg06795125	chr2:108905320	SULT1C2	-0.31	-5.63	-0.34	4.95e-8	Blood pressure;
KIRP	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs847851	1.000	rs4646926	chr6:34852253	G/T	cg25473981	chr6:34433676	PACSIN1	0.41	4.89	0.3	1.85e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2562456	0.833	rs62110429	chr19:21613786	C/T	cg00806126	chr19:22604979	ZNF98	-0.58	-5.32	-0.32	2.38e-7	Pain;
KIRP	cis	rs698833	0.852	rs4953089	chr2:44565024	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.6	0.34	5.6e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03354744	chr4:185655229	MLF1IP	0.51	6.2	0.37	2.34e-9	Parkinson's disease;
KIRP	trans	rs2191566	0.600	rs11883068	chr19:44516964	C/T	cg17494585	chr1:117705743	VTCN1	0.32	6.23	0.37	2e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.52	7.03	0.41	2.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs12049351	0.774	rs12125125	chr1:229627666	A/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.58	-0.34	6.24e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.56	-7.16	-0.42	9.56e-12	Platelet count;
KIRP	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg07701084	chr6:150067640	NUP43	0.65	8.36	0.47	4.64e-15	Lung cancer;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16524936	chr4:1340807	KIAA1530	-0.52	-6.76	-0.4	9.74e-11	Longevity;
KIRP	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.19	-0.77	8.29e-51	Height;
KIRP	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.45	-6.6	-0.39	2.46e-10	Vitamin D levels;
KIRP	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.58	7.82	0.45	1.55e-13	White matter hyperintensity burden;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22795345	chr13:111935508	ARHGEF7	0.44	6.03	0.36	5.96e-9	Interleukin-4 levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12461364	chr10:12084985	UPF2	0.46	6.31	0.37	1.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11961642	chr12:124272362	DNAH10	-0.42	-6.38	-0.38	8.95e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.24	-6.34	-0.37	1.12e-9	Crohn's disease;
KIRP	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.88	0.4	4.87e-11	Lung cancer;
KIRP	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06544989	chr22:39130855	UNC84B	0.48	7.96	0.45	6.4e-14	Menopause (age at onset);
KIRP	cis	rs35883536	0.933	rs1409419	chr1:101183396	T/C	cg06223162	chr1:101003688	GPR88	0.33	6.78	0.4	9.06e-11	Monocyte count;
KIRP	cis	rs11631955	1	rs11631955	chr15:79085915	A/G	cg04896959	chr15:78267971	NA	0.51	6.67	0.39	1.68e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.56	7.38	0.43	2.44e-12	Height;
KIRP	cis	rs1322639	0.614	rs7768154	chr6:169565470	A/G	cg04662567	chr6:169592167	NA	-0.64	-5.45	-0.33	1.2e-7	Pulse pressure;
KIRP	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.7	10.9	0.57	7.85e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.76	9.48	0.52	2.28e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg02975922	chr3:195473998	MUC4	-0.48	-5.23	-0.32	3.69e-7	Pancreatic cancer;
KIRP	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.43	-5.75	-0.34	2.66e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs4363385	0.647	rs56412380	chr1:153000705	T/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.3	-0.37	1.33e-9	Inflammatory skin disease;
KIRP	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg16144293	chr14:75469539	EIF2B2	-0.47	-5.45	-0.33	1.22e-7	Height;
KIRP	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.41	-0.43	2.02e-12	Retinal vascular caliber;
KIRP	cis	rs595982	0.702	rs609985	chr19:49370648	A/G	cg21252483	chr19:49399788	TULP2	-0.31	-5.92	-0.35	1.05e-8	Red cell distribution width;
KIRP	cis	rs2494663	0.610	rs11265082	chr1:154075076	A/G	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.93	-0.3	1.5e-6	Mean platelet volume;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.81	-14.62	-0.68	3.03e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7520050	0.807	rs3013594	chr1:46138000	T/C	cg03146154	chr1:46216737	IPP	0.41	4.99	0.3	1.12e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06481639	chr22:41940642	POLR3H	0.68	6.9	0.4	4.29e-11	Vitiligo;
KIRP	cis	rs1250566	0.784	rs1250573	chr10:81042475	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.63	-7.21	-0.42	6.77e-12	Inflammatory bowel disease;
KIRP	cis	rs1570884	0.857	rs4942848	chr13:50141345	A/G	cg03651054	chr13:50194643	NA	-0.54	-6.66	-0.39	1.83e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.51	7.35	0.42	2.85e-12	Testicular germ cell tumor;
KIRP	cis	rs34779708	0.931	rs12773169	chr10:35366462	G/C	cg04310649	chr10:35416472	CREM	-0.58	-6.87	-0.4	5.33e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.85	8.89	0.49	1.38e-16	Pulmonary function decline;
KIRP	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg03929089	chr4:120376271	NA	0.69	6.06	0.36	5.12e-9	Axial length;
KIRP	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.64	-7.97	-0.45	5.8e-14	Breast size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13053783	chr1:1334803	CCNL2;LOC148413	0.47	6.23	0.37	1.97e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg11395062	chr17:14139857	CDRT15	0.58	7.75	0.44	2.41e-13	Temperament;
KIRP	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	26.97	0.86	1.94e-75	Chronic sinus infection;
KIRP	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg05370193	chr1:21551575	ECE1	0.47	6.26	0.37	1.71e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg11814155	chr7:99998594	ZCWPW1	0.52	5.04	0.31	9.14e-7	Platelet count;
KIRP	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.68	7.39	0.43	2.31e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs33912345	0.750	rs11158285	chr14:60945203	G/A	cg27398547	chr14:60952738	C14orf39	0.37	4.93	0.3	1.5e-6	Glaucoma (high intraocular pressure);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10800082	chr10:112631596	LOC282997;PDCD4	0.44	6.04	0.36	5.7e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9815354	0.767	rs6805140	chr3:41995791	A/G	cg03022575	chr3:42003672	ULK4	0.8	8.6	0.48	9.38e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1359582	0.793	rs750508	chr10:90400677	T/C	cg15661332	chr10:90342814	RNLS	0.58	6.59	0.39	2.65e-10	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs4262150	0.667	rs11740655	chr5:152258232	A/G	cg12297329	chr5:152029980	NA	0.46	6.52	0.38	4.02e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg25019033	chr10:957182	NA	-0.64	-7.62	-0.44	5.34e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.46	-0.33	1.15e-7	Multiple sclerosis;
KIRP	cis	rs2019216	0.564	rs1518053	chr17:21924272	G/T	cg22648282	chr17:21454238	C17orf51	-0.5	-6.49	-0.38	4.78e-10	Pelvic organ prolapse;
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg03289416	chr15:75166202	SCAMP2	0.5	6.71	0.39	1.3e-10	Breast cancer;
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg07701084	chr6:150067640	NUP43	0.71	10.3	0.55	6.43e-21	Lung cancer;
KIRP	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.44	7.78	0.44	1.97e-13	Systemic lupus erythematosus;
KIRP	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg05333889	chr7:157238977	NA	-0.44	-6.01	-0.36	6.56e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-6.02	-0.36	6.24e-9	Lung cancer;
KIRP	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.62	7.42	0.43	1.93e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.88	-11.1	-0.58	1.75e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.3	-0.32	2.62e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.12	20.4	0.79	8.23e-55	Colorectal cancer;
KIRP	cis	rs4805834	0.719	rs17206212	chr19:33315613	A/G	cg07201929	chr19:33182834	NUDT19	0.57	4.93	0.3	1.51e-6	Creatinine levels;
KIRP	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg02951883	chr7:2050386	MAD1L1	-0.5	-5.58	-0.34	6.18e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.77	0.49	2.96e-16	Colorectal cancer;
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg26134248	chr17:3907702	NA	0.57	8.52	0.48	1.66e-15	Type 2 diabetes;
KIRP	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg13393036	chr8:95962371	TP53INP1	0.35	7.14	0.41	1.04e-11	Type 2 diabetes;
KIRP	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	11.17	0.58	1.03e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.8	11.04	0.58	2.71e-23	Body mass index;
KIRP	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg09163369	chr1:210001066	C1orf107	0.49	6.17	0.37	2.75e-9	Orofacial clefts;
KIRP	cis	rs35740288	0.929	rs11635081	chr15:86304260	G/A	cg17133734	chr15:86042851	AKAP13	-0.5	-5.44	-0.33	1.3e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg06204229	chr3:52865917	ITIH4	0.54	7.61	0.44	5.96e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9815354	1.000	rs9830469	chr3:41762535	A/G	cg03022575	chr3:42003672	ULK4	0.48	5.33	0.32	2.18e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.78	-0.44	2.02e-13	Migraine;Coronary artery disease;
KIRP	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-9.45	-0.52	2.87e-18	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg10756647	chr7:56101905	PSPH	-0.92	-6.42	-0.38	7.07e-10	Diabetic kidney disease;
KIRP	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg21095983	chr6:86352623	SYNCRIP	0.5	6.44	0.38	6.2e-10	Smooth-surface caries;
KIRP	cis	rs6681460	1.000	rs4655647	chr1:67106077	C/G	cg02459107	chr1:67143332	SGIP1	0.47	6.57	0.39	2.93e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg15733309	chr7:157513707	PTPRN2	0.42	6.32	0.37	1.2e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs72799341	1.000	rs7185007	chr16:30927509	C/T	cg00531865	chr16:30841666	NA	-0.45	-4.98	-0.3	1.22e-6	Diastolic blood pressure;
KIRP	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13126279	chr21:47581558	C21orf56	-0.41	-4.96	-0.3	1.3e-6	Testicular germ cell tumor;
KIRP	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	1.15	17.39	0.74	1.02e-44	Monocyte percentage of white cells;
KIRP	trans	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg22037779	chr5:139682734	PFDN1	-0.53	-6.32	-0.37	1.21e-9	Mean platelet volume;
KIRP	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg01620082	chr3:125678407	NA	-1.1	-7.44	-0.43	1.7e-12	Depression;
KIRP	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg03834567	chr2:218808745	TNS1	0.44	5.29	0.32	2.67e-7	Ulcerative colitis;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg23985595	chr17:80112537	CCDC57	0.34	5.1	0.31	6.8e-7	Life satisfaction;
KIRP	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.85	0.45	1.3e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9783347	1.000	rs4150566	chr11:18355599	C/G	cg15585147	chr11:18324498	HPS5	0.37	4.97	0.3	1.27e-6	Pancreatic cancer;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.62	-8.2	-0.46	1.38e-14	Aortic root size;
KIRP	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.45	6.62	0.39	2.18e-10	Major depressive disorder;
KIRP	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs72720396	0.803	rs114328297	chr1:91190854	T/G	cg13456504	chr1:91191583	NA	0.57	6.16	0.37	2.9e-9	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs367943	0.666	rs7700413	chr5:112704435	T/C	cg12552261	chr5:112820674	MCC	0.55	6.51	0.38	4.22e-10	Type 2 diabetes;
KIRP	cis	rs11718455	0.548	rs9824340	chr3:43902170	A/G	cg21419209	chr3:44054225	NA	-0.45	-5.86	-0.35	1.46e-8	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.95	-0.61	2.92e-26	Eye color traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18974903	chr8:9621167	TNKS	-0.43	-6.53	-0.38	3.74e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.83	-12.09	-0.61	1.04e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6893807	1.000	rs13163336	chr5:87943710	C/A	cg24804195	chr5:87968844	LOC645323	0.53	5.59	0.34	5.96e-8	Body mass index;
KIRP	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg14835575	chr10:16859367	RSU1	0.57	7.34	0.42	3.03e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg05784532	chr1:230284198	GALNT2	0.41	6.2	0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	5.94	0.35	9.88e-9	Schizophrenia;
KIRP	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.72	-9.86	-0.53	1.52e-19	Schizophrenia;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	6.69	0.39	1.52e-10	Longevity;
KIRP	cis	rs10904908	1.000	rs7903402	chr10:17259772	C/T	cg01003015	chr10:17271136	VIM	-0.43	-5.22	-0.32	3.75e-7	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	9.04e-8	Life satisfaction;
KIRP	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.9	-0.3	1.77e-6	Neuroticism;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20831041	chr11:464554	PTDSS2	0.47	6.73	0.39	1.19e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2290402	0.536	rs2279175	chr4:852013	G/A	cg14517359	chr4:903473	GAK	-0.57	-6.22	-0.37	2.18e-9	Type 2 diabetes;
KIRP	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.38	6.0	0.36	7.06e-9	QRS complex (12-leadsum);
KIRP	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.46	6.38	0.38	8.81e-10	Coronary artery disease;
KIRP	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.4	5.07	0.31	7.94e-7	Childhood ear infection;
KIRP	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg21926883	chr2:100939477	LONRF2	-0.49	-5.81	-0.35	1.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs714031	0.934	rs5757764	chr22:40067818	C/T	cg21377881	chr22:40064566	CACNA1I	-0.67	-10.5	-0.56	1.48e-21	Schizophrenia;
KIRP	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg21775007	chr8:11205619	TDH	-0.48	-6.44	-0.38	6.37e-10	Mood instability;
KIRP	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13401104	0.716	rs10204147	chr2:237130344	A/C	cg19324714	chr2:237145437	ASB18	0.5	6.09	0.36	4.3e-9	Educational attainment;
KIRP	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.62	-8.16	-0.46	1.7e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg06654118	chr4:1303317	MAEA	0.3	5.4	0.33	1.6e-7	Obesity-related traits;
KIRP	cis	rs380904	0.519	rs1377663	chr8:144644787	T/A	cg21643262	chr8:144646939	NA	-0.51	-5.23	-0.32	3.57e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.63	9.66	0.52	6.31e-19	Lung cancer;
KIRP	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs959260	1.000	rs2117563	chr17:73368985	A/G	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.9	10.39	0.55	3.28e-21	Blood protein levels;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg04371633	chr14:65381025	CHURC1	0.53	6.18	0.37	2.68e-9	Sleep duration;
KIRP	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.52	6.66	0.39	1.81e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.69	-9.44	-0.52	3.08e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10861342	1.000	rs10861346	chr12:105473245	G/T	cg23923672	chr12:105501055	KIAA1033	0.77	5.75	0.34	2.65e-8	IgG glycosylation;
KIRP	cis	rs9816784	0.525	rs555412	chr3:195804918	T/C	cg01351295	chr3:195700735	SDHAP1	-0.45	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs10992471	0.603	rs2094281	chr9:95290654	C/G	cg13798575	chr9:95087839	CENPP;NOL8	0.49	5.78	0.35	2.3e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg10464454	chr21:35014241	ITSN1;CRYZL1	0.51	6.04	0.36	5.65e-9	Beard thickness;
KIRP	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.48	6.51	0.38	4.29e-10	Coronary artery disease;
KIRP	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.23	-0.46	1.07e-14	Mood instability;
KIRP	trans	rs12431410	0.536	rs1957998	chr14:60148800	C/G	cg20601314	chr10:104179541	FBXL15;PSD	0.56	6.32	0.37	1.2e-9	Schizophrenia;
KIRP	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-5.35	-0.32	2.01e-7	Primary biliary cholangitis;
KIRP	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.09	0.54	3e-20	Total body bone mineral density;
KIRP	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg24253500	chr15:84953950	NA	0.48	5.49	0.33	9.92e-8	Schizophrenia;
KIRP	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	10.64	0.56	5.3e-22	Hip circumference;
KIRP	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.7	8.2	0.46	1.34e-14	Corneal astigmatism;
KIRP	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg02600515	chr11:62521696	ZBTB3	-0.47	-4.96	-0.3	1.34e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs6910061	0.956	rs61185321	chr6:11103103	T/G	cg27233058	chr6:11094804	LOC221710	0.58	5.91	0.35	1.16e-8	Diabetic kidney disease;
KIRP	cis	rs4236601	1.000	rs4385407	chr7:116162988	G/A	cg05166801	chr7:116143459	CAV2	0.51	6.18	0.37	2.71e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs7116495	1.000	rs7128317	chr11:71701367	C/T	cg11196788	chr11:71737549	NUMA1	-0.55	-5.01	-0.3	1.04e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs654950	1.000	rs621680	chr1:41984584	C/T	cg06885757	chr1:42089581	HIVEP3	-0.43	-6.2	-0.37	2.42e-9	Airway imaging phenotypes;
KIRP	cis	rs13006833	0.739	rs291429	chr2:191197941	G/A	cg27211696	chr2:191398769	TMEM194B	0.4	5.67	0.34	4.09e-8	Urinary metabolites;
KIRP	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.5	5.73	0.34	2.86e-8	Breast cancer;
KIRP	cis	rs7635838	0.892	rs9838141	chr3:11488639	C/T	cg00170343	chr3:11313890	ATG7	0.46	6.09	0.36	4.24e-9	HDL cholesterol;
KIRP	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.75	-0.44	2.42e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg06565975	chr8:143823917	SLURP1	-0.5	-7.29	-0.42	4.22e-12	Urinary tract infection frequency;
KIRP	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.3	0.42	3.93e-12	Menarche (age at onset);
KIRP	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg26248373	chr2:1572462	NA	-0.68	-7.21	-0.42	6.93e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.4	-8.48	-0.48	2.15e-15	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-11.03	-0.58	3.06e-23	Colorectal cancer;
KIRP	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg26874164	chr19:58962979	ZNF324B	0.51	5.96	0.36	8.7e-9	Uric acid clearance;
KIRP	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21984481	chr17:79567631	NPLOC4	-0.39	-6.11	-0.36	3.94e-9	Eye color traits;
KIRP	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.54	-8.2	-0.46	1.37e-14	Itch intensity from mosquito bite;
KIRP	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.33	-0.37	1.18e-9	Joint mobility (Beighton score);
KIRP	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs155346	0.571	rs264339	chr5:139353502	A/G	cg24724630	chr5:139362307	NRG2	-0.38	-5.02	-0.3	9.79e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg06219351	chr7:158114137	PTPRN2	0.58	8.37	0.47	4.5e-15	Calcium levels;
KIRP	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05601917	chr6:125855416	NA	-0.35	-5.24	-0.32	3.41e-7	Brugada syndrome;
KIRP	cis	rs10892173	0.846	rs2298647	chr11:117671641	A/T	cg21014159	chr11:117668035	DSCAML1	0.41	6.21	0.37	2.23e-9	Myopia;
KIRP	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg16691251	chr5:66510806	NA	0.43	5.62	0.34	5.03e-8	Breast cancer;
KIRP	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.16	0.42	9.21e-12	Bipolar disorder;
KIRP	cis	rs12049351	0.774	rs16849844	chr1:229620396	A/G	cg11742688	chr1:229674241	ABCB10	0.39	5.79	0.35	2.17e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs897080	0.552	rs1067383	chr2:44645911	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.87	0.35	1.41e-8	Height;
KIRP	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.44e-7	Breast cancer;
KIRP	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	7.75	0.44	2.37e-13	Menarche (age at onset);
KIRP	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.77	0.49	2.96e-16	Colorectal cancer;
KIRP	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.55	-0.39	3.3e-10	Neuroticism;
KIRP	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs6575793	0.553	rs61993004	chr14:101030579	G/A	cg18516195	chr14:101012996	BEGAIN	0.49	5.69	0.34	3.68e-8	Menarche (age at onset);
KIRP	trans	rs61931739	0.546	rs7297354	chr12:33700556	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.09	-0.36	4.24e-9	Morning vs. evening chronotype;
KIRP	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg19468946	chr17:37922297	IKZF3	-0.55	-7.61	-0.44	5.86e-13	Self-reported allergy;
KIRP	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13047869	chr3:10149882	C3orf24	0.52	4.91	0.3	1.69e-6	Alzheimer's disease;
KIRP	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg26061582	chr7:22766209	IL6	0.42	5.04	0.31	9.04e-7	Lung cancer;
KIRP	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg08501292	chr6:25962987	TRIM38	1.11	6.5	0.38	4.44e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg05785598	chr3:49045655	WDR6	0.32	5.64	0.34	4.58e-8	Parkinson's disease;
KIRP	trans	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg24644049	chr4:85504048	CDS1	0.93	6.88	0.4	4.86e-11	Skin colour saturation;
KIRP	cis	rs2296225	0.722	rs900037	chr1:21057788	C/T	cg14666476	chr1:21112556	HP1BP3	0.68	6.23	0.37	2e-9	Eosinophilic esophagitis;
KIRP	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.24	-0.37	1.92e-9	Personality dimensions;
KIRP	cis	rs55986470	0.670	rs6730810	chr2:239416329	C/T	cg18131467	chr2:239335373	ASB1	-0.53	-5.1	-0.31	6.89e-7	Chronotype;
KIRP	cis	rs6504622	0.577	rs197925	chr17:45010721	C/T	cg16759221	chr17:45003025	GOSR2	-0.32	-4.86	-0.3	2.1e-6	Orofacial clefts;
KIRP	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.1	0.46	2.56e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg12560992	chr17:57184187	TRIM37	0.53	6.15	0.36	3.17e-9	Cognitive test performance;
KIRP	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg04362960	chr10:104952993	NT5C2	0.56	6.87	0.4	5.24e-11	Arsenic metabolism;
KIRP	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.71	-7.4	-0.43	2.14e-12	DNA methylation (variation);
KIRP	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	10.15	0.54	1.88e-20	Exhaled nitric oxide levels;
KIRP	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.45	-9.09	-0.5	3.36e-17	Rheumatoid arthritis;
KIRP	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21643547	chr1:205240462	TMCC2	-0.87	-13.89	-0.66	9.11e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs10463554	0.759	rs461609	chr5:102447305	G/A	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Parkinson's disease;
KIRP	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg01804193	chr12:63026212	NA	0.59	6.35	0.38	1e-9	IgG glycosylation;
KIRP	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.68	-0.34	3.74e-8	Response to antipsychotic treatment;
KIRP	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.48	6.65	0.39	1.89e-10	Red blood cell count;
KIRP	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg23335576	chr14:104009727	NA	0.36	5.14	0.31	5.7e-7	Body mass index;
KIRP	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.41	-5.23	-0.32	3.69e-7	IgG glycosylation;
KIRP	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.21	0.61	3.98e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg05562828	chr17:3906858	NA	0.53	5.59	0.34	5.87e-8	Type 2 diabetes;
KIRP	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg23422044	chr7:1970798	MAD1L1	-0.68	-6.83	-0.4	6.79e-11	Bipolar disorder;
KIRP	cis	rs13315871	0.929	rs11717700	chr3:58250876	T/A	cg20936604	chr3:58311152	NA	-0.73	-5.26	-0.32	3.19e-7	Cholesterol, total;
KIRP	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.6	0.34	5.71e-8	Personality dimensions;
KIRP	cis	rs12541635	0.677	rs1496183	chr8:107024445	C/T	cg10147462	chr8:107024639	NA	0.33	4.96	0.3	1.33e-6	Age of smoking initiation;
KIRP	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-5.87	-0.35	1.4e-8	IgG glycosylation;
KIRP	cis	rs12313068	0.709	rs11064912	chr12:110505699	A/T	cg12870014	chr12:110450643	ANKRD13A	-0.54	-7.11	-0.41	1.25e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg06636001	chr8:8085503	FLJ10661	0.7	9.07	0.5	3.79e-17	Retinal vascular caliber;
KIRP	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.78	-0.35	2.29e-8	Breast cancer;
KIRP	cis	rs228437	1.000	rs6934385	chr6:134916471	A/G	cg24504307	chr6:134963096	NA	-0.53	-7.51	-0.43	1.1e-12	Melanoma;
KIRP	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.54	-0.52	1.53e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg07274523	chr3:49395745	GPX1	0.69	8.45	0.47	2.56e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.39	5.03	0.31	9.47e-7	Aortic root size;
KIRP	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg10792982	chr14:105748885	BRF1	0.86	13.33	0.65	7.25e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11605275	0.901	rs79690581	chr11:20026110	G/C	cg14835545	chr11:20032148	NAV2	-0.75	-5.69	-0.34	3.54e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.61	-0.59	3.93e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.98	13.53	0.65	1.45e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg18306943	chr3:40428807	ENTPD3	0.45	5.96	0.36	8.66e-9	Renal cell carcinoma;
KIRP	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.36	0.38	9.66e-10	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14840081	chr7:152551660	ACTR3B	-0.47	-6.56	-0.39	3.11e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg17376030	chr22:41985996	PMM1	0.55	6.5	0.38	4.44e-10	Vitiligo;
KIRP	cis	rs10875746	0.859	rs3782910	chr12:48483507	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.76	11.12	0.58	1.49e-23	Heart rate;
KIRP	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.71	9.18	0.51	1.86e-17	Corneal astigmatism;
KIRP	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.31	-0.65	8.15e-31	Extrinsic epigenetic age acceleration;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg11153328	chr22:36877737	TXN2	0.52	6.33	0.37	1.12e-9	Obesity-related traits;
KIRP	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg03808351	chr9:123631620	PHF19	0.45	6.16	0.37	2.97e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.56	0.48	1.22e-15	Neuroticism;
KIRP	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs6732160	0.588	rs28626211	chr2:73378522	G/A	cg01422370	chr2:73384389	NA	0.51	6.86	0.4	5.64e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg16141378	chr3:129829833	LOC729375	0.61	8.28	0.47	7.75e-15	Triglycerides;
KIRP	trans	rs2975734	0.736	rs4841300	chr8:10112595	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.74	-0.39	1.13e-10	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg00261534	chr10:3826854	KLF6	0.85	7.24	0.42	5.89e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9359856	0.636	rs1980878	chr6:90314749	A/C	cg13799429	chr6:90582589	CASP8AP2	0.59	6.35	0.38	1.03e-9	Bipolar disorder;
KIRP	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.72	-0.39	1.24e-10	Neuroticism;
KIRP	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.11e-8	Melanoma;
KIRP	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18364779	chr6:26104403	HIST1H4C	0.38	5.05	0.31	8.6e-7	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.52	0.48	1.66e-15	Personality dimensions;
KIRP	cis	rs7224685	0.569	rs7213885	chr17:4018489	T/A	cg09695851	chr17:3907499	NA	0.55	5.12	0.31	6.27e-7	Type 2 diabetes;
KIRP	cis	rs2299587	0.554	rs3739404	chr8:17739843	C/A	cg01800426	chr8:17659068	MTUS1	-0.43	-5.3	-0.32	2.58e-7	Economic and political preferences;
KIRP	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.95	10.43	0.55	2.56e-21	Corneal astigmatism;
KIRP	cis	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.49	-0.33	1.02e-7	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15059257	chr1:43147884	YBX1	0.52	6.58	0.39	2.78e-10	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15728439	chr2:208793660	PLEKHM3	0.47	6.02	0.36	6.32e-9	Interleukin-4 levels;
KIRP	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.69	9.12	0.5	2.85e-17	Bladder cancer;
KIRP	cis	rs9362426	1.000	rs414013	chr6:88085866	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	5.54	0.33	7.61e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg04780086	chr2:111875790	ACOXL	0.47	6.5	0.38	4.54e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs2859741	1.000	rs2795009	chr1:37509494	C/T	cg09363841	chr1:37513479	NA	-0.67	-11.52	-0.59	7.72e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.84	-7.65	-0.44	4.59e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6585424	1.000	rs12411386	chr10:81926231	T/A	cg27417294	chr10:81904244	PLAC9	0.55	5.39	0.32	1.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2708977	0.637	rs654224	chr2:97080123	A/C	cg01950434	chr2:97203154	ARID5A	-0.43	-5.32	-0.32	2.28e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.55e-13	Life satisfaction;
KIRP	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg22617819	chr1:44378782	ST3GAL3	-0.37	-5.78	-0.35	2.24e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7116495	1.000	rs73543633	chr11:71828844	T/C	cg11196788	chr11:71737549	NUMA1	-0.56	-5.03	-0.31	9.65e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg21479132	chr6:26055353	NA	0.76	4.88	0.3	1.95e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg21191810	chr6:118973309	C6orf204	-0.44	-4.89	-0.3	1.84e-6	Diastolic blood pressure;
KIRP	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.44	5.64	0.34	4.67e-8	Motion sickness;
KIRP	cis	rs2274273	0.686	rs57033289	chr14:55623317	C/A	cg04306507	chr14:55594613	LGALS3	0.42	5.54	0.33	7.86e-8	Protein biomarker;
KIRP	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg19041857	chr6:27730383	NA	-0.62	-5.1	-0.31	6.69e-7	Breast cancer;
KIRP	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg14458575	chr2:238380390	NA	0.6	8.03	0.46	4.15e-14	Prostate cancer;
KIRP	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-5.08	-0.31	7.29e-7	Colorectal cancer;
KIRP	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg05340658	chr4:99064831	C4orf37	-0.59	-7.3	-0.42	3.86e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.82	-11.62	-0.6	3.58e-25	Breast cancer;
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.37	-5.04	-0.31	9.02e-7	Electroencephalogram traits;
KIRP	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.68	10.94	0.57	5.85e-23	Pulse pressure;
KIRP	cis	rs7172677	0.960	rs11072526	chr15:75432517	T/C	cg14082893	chr15:75400931	NA	0.36	5.11	0.31	6.56e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs661054	1.000	rs648541	chr11:114429934	A/G	cg19465033	chr11:114479364	NA	0.35	4.85	0.3	2.23e-6	Ulcerative colitis;
KIRP	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.84	-12.27	-0.62	2.61e-27	Systemic lupus erythematosus;
KIRP	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	0.84	6.53	0.38	3.66e-10	Mitochondrial DNA levels;
KIRP	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.87	13.8	0.66	1.76e-32	Blood protein levels;
KIRP	cis	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs2573652	0.722	rs968412	chr15:100544512	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.4	-5.37	-0.32	1.83e-7	Height;
KIRP	cis	rs6684514	1.000	rs10752615	chr1:156248609	T/C	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg21892295	chr12:121157589	UNC119B	-0.4	-5.73	-0.34	2.98e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg21905437	chr5:178450457	ZNF879	0.58	6.71	0.39	1.33e-10	Pubertal anthropometrics;
KIRP	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg10503236	chr1:231470652	EXOC8	0.52	7.41	0.43	2.03e-12	Hemoglobin concentration;
KIRP	cis	rs4889855	0.530	rs8072592	chr17:78615361	A/C	cg09596252	chr17:78655493	RPTOR	-0.51	-5.85	-0.35	1.56e-8	Fractional excretion of uric acid;
KIRP	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.53	7.03	0.41	2e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg00405596	chr8:11794950	NA	0.41	5.28	0.32	2.8e-7	Retinal vascular caliber;
KIRP	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.49	-6.85	-0.4	5.87e-11	Obesity-related traits;
KIRP	cis	rs714515	0.511	rs9425301	chr1:172363815	A/C	cg01573306	chr1:172330400	DNM3	0.42	5.4	0.33	1.59e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs6496667	0.779	rs2074582	chr15:91009177	A/G	cg10434728	chr15:90938212	IQGAP1	0.37	5.02	0.3	9.79e-7	Rheumatoid arthritis;
KIRP	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	6.64	0.39	1.95e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	5.64	0.34	4.63e-8	Bipolar disorder;
KIRP	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg16590910	chr6:42928470	GNMT	0.41	5.71	0.34	3.17e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8014252	0.803	rs8006487	chr14:71011934	G/A	cg11204974	chr14:71022665	NA	-0.61	-6.46	-0.38	5.41e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	1.14	20.98	0.8	1.03e-56	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs7831492	0.564	rs60792897	chr8:41609623	C/T	cg17182837	chr8:41585554	ANK1	-0.51	-7.04	-0.41	1.88e-11	Colorectal cancer;
KIRP	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.46	8.37	0.47	4.39e-15	Superior crus of antihelix expression;
KIRP	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.73	-8.4	-0.47	3.64e-15	Adiposity;
KIRP	cis	rs7523273	0.925	rs6540443	chr1:208002010	T/A	cg22525895	chr1:207977042	MIR29B2	-0.66	-8.28	-0.47	8.09e-15	Schizophrenia;
KIRP	cis	rs220324	0.683	rs220323	chr21:43586658	C/G	cg15319517	chr21:43638949	ABCG1	-0.38	-5.25	-0.32	3.32e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	trans	rs6601327	0.670	rs6601338	chr8:9438928	C/T	cg16141378	chr3:129829833	LOC729375	-0.47	-6.03	-0.36	5.89e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg13770153	chr20:60521292	NA	-0.42	-4.99	-0.3	1.15e-6	Body mass index;
KIRP	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	9.26	0.51	1.08e-17	Resting heart rate;
KIRP	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.74	-0.39	1.14e-10	Morning vs. evening chronotype;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg06815112	chr8:27182871	PTK2B	0.54	6.97	0.41	2.94e-11	Neuroticism;
KIRP	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs72634030	0.536	rs7222662	chr17:5190617	A/G	cg20802942	chr17:5185005	RABEP1	0.51	4.94	0.3	1.45e-6	Rheumatoid arthritis;
KIRP	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg04132472	chr17:19861366	AKAP10	0.66	10.25	0.55	9.5e-21	Schizophrenia;
KIRP	cis	rs12930096	1.000	rs8050192	chr16:11678582	C/T	cg07439791	chr16:11680400	LITAF	0.71	5.92	0.35	1.08e-8	QT interval;
KIRP	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg11150807	chr10:43354902	NA	-0.66	-6.78	-0.4	8.96e-11	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg05340658	chr4:99064831	C4orf37	0.59	7.42	0.43	1.87e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4926611	0.863	rs2177957	chr1:54082487	C/T	cg08927728	chr1:54059983	GLIS1	0.28	6.09	0.36	4.36e-9	Hand grip strength;
KIRP	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg25547332	chr5:131281432	NA	0.5	6.12	0.36	3.6e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg04691961	chr3:161091175	C3orf57	-0.48	-7.15	-0.41	9.9e-12	Morning vs. evening chronotype;
KIRP	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	1.2	10.11	0.54	2.57e-20	Corneal curvature;
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.85	0.3	2.14e-6	Lung cancer;
KIRP	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs72627123	0.656	rs76479281	chr14:74564609	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.91	0.3	1.7e-6	Morning vs. evening chronotype;
KIRP	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.46	5.7	0.34	3.39e-8	Resistin levels;
KIRP	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg14972814	chr11:95582409	MTMR2	0.34	5.5	0.33	9.42e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4646404	0.643	rs897453	chr17:17425631	C/T	cg01246520	chr17:17644344	RAI1	-0.33	-5.27	-0.32	3.04e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg00800038	chr16:89945340	TCF25	-0.69	-5.05	-0.31	8.53e-7	Skin colour saturation;
KIRP	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	cg04338863	chr8:33670619	NA	0.42	5.41	0.33	1.5e-7	Body mass index;
KIRP	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.46	5.8	0.35	1.99e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg20503657	chr10:835505	NA	-0.51	-6.1	-0.36	4.11e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.45	-0.33	1.2e-7	Bipolar disorder;
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg12486944	chr17:80159399	CCDC57	0.39	5.2	0.31	4.19e-7	Life satisfaction;
KIRP	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	10.94	0.57	5.74e-23	Personality dimensions;
KIRP	cis	rs16933812	0.510	rs7854114	chr9:36989004	T/C	cg13738729	chr9:36989127	PAX5	0.36	4.89	0.3	1.8e-6	Obesity-related traits;
KIRP	trans	rs12043259	0.730	rs57482207	chr1:204813922	C/T	cg11485465	chr5:54518469	NA	0.38	6.58	0.39	2.78e-10	Addiction;
KIRP	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg02038168	chr22:39784481	NA	0.42	5.16	0.31	5.09e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.7	-6.87	-0.4	5.2e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7221595	0.778	rs12946045	chr17:3904307	G/C	cg05562828	chr17:3906858	NA	0.63	7.86	0.45	1.22e-13	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg11906718	chr8:101322791	RNF19A	-0.65	-8.3	-0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs2274459	1.000	rs35274562	chr6:33716831	C/T	cg06253072	chr6:33679850	C6orf125	0.51	5.05	0.31	8.48e-7	Obesity (extreme);
KIRP	cis	rs9815354	1.000	rs1716657	chr3:41918456	C/T	cg03022575	chr3:42003672	ULK4	-0.47	-5.31	-0.32	2.42e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.61	8.89	0.49	1.31e-16	Immature fraction of reticulocytes;
KIRP	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg07796016	chr1:152779584	LCE1C	0.47	5.92	0.35	1.08e-8	Inflammatory skin disease;
KIRP	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg02002194	chr4:3960332	NA	-0.45	-6.59	-0.39	2.7e-10	Triglycerides;
KIRP	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg07636037	chr3:49044803	WDR6	-0.58	-5.41	-0.33	1.48e-7	Menarche (age at onset);
KIRP	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg05082376	chr22:42548792	NA	-0.46	-5.31	-0.32	2.49e-7	Schizophrenia;
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg07701084	chr6:150067640	NUP43	-0.71	-9.51	-0.52	1.87e-18	Lung cancer;
KIRP	cis	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg07585502	chr8:101912084	NA	-0.65	-8.47	-0.48	2.24e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	13.77	0.66	2.3e-32	Monocyte percentage of white cells;
KIRP	cis	rs2273669	0.588	rs111773102	chr6:109306480	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-6.36	-0.38	1e-9	Prostate cancer;
KIRP	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.7	8.33	0.47	5.75e-15	Schizophrenia;
KIRP	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg23649088	chr2:200775458	C2orf69	-0.4	-5.15	-0.31	5.27e-7	Asthma (bronchodilator response);
KIRP	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.68	0.48	5.5e-16	Prudent dietary pattern;
KIRP	cis	rs7523273	0.927	rs1891423	chr1:207931913	G/A	cg22525895	chr1:207977042	MIR29B2	0.64	8.3	0.47	6.74e-15	Schizophrenia;
KIRP	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.87	12.88	0.63	2.38e-29	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03915846	chr12:112451028	ERP29;TMEM116	0.52	6.53	0.38	3.71e-10	Parkinson's disease;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg18234130	chr8:27182889	PTK2B	0.54	7.06	0.41	1.73e-11	Neuroticism;
KIRP	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	4.85	0.3	2.21e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg14091149	chr1:16273971	ZBTB17	0.4	6.11	0.36	3.85e-9	Dilated cardiomyopathy;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00984602	chr6:43139692	SRF	-0.64	-7.1	-0.41	1.37e-11	Menopause (age at onset);
KIRP	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-4.95	-0.3	1.39e-6	Coronary artery disease;
KIRP	cis	rs4713675	0.584	rs7739505	chr6:33670370	G/A	cg15676125	chr6:33679581	C6orf125	0.41	5.41	0.33	1.5e-7	Plateletcrit;
KIRP	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.69	-0.39	1.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg15507776	chr3:136538369	TMEM22	0.55	7.83	0.45	1.44e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.54	-6.99	-0.41	2.59e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1941687	0.800	rs1845387	chr18:31358940	T/G	cg27147174	chr7:100797783	AP1S1	-0.57	-6.91	-0.4	4.04e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08881995	chr1:1051895	C1orf159	0.46	6.14	0.36	3.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.43	5.14	0.31	5.5e-7	Aortic root size;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16048942	chr17:1953617	MIR132;MIR212	-0.47	-6.35	-0.38	1.03e-9	Metabolic traits;
KIRP	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	0.96	11.68	0.6	2.26e-25	Vitiligo;
KIRP	cis	rs11874712	1.000	rs9783886	chr18:43651270	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.51	-0.33	9.06e-8	Migraine - clinic-based;
KIRP	cis	rs6987853	0.787	rs2923441	chr8:42429937	G/T	cg09913449	chr8:42400586	C8orf40	-0.39	-5.2	-0.31	4.12e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs6445035	0.582	rs35282201	chr3:165738235	C/T	cg23267042	chr1:70671309	LRRC40;SFRS11	0.52	6.24	0.37	1.91e-9	Aspirin hydrolysis (plasma);
KIRP	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg18944383	chr4:111397179	ENPEP	-0.42	-6.73	-0.39	1.21e-10	Coronary artery disease;
KIRP	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg04935436	chr20:30431758	NA	0.48	5.29	0.32	2.69e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs12936587	0.633	rs12939598	chr17:17508878	C/G	cg01246520	chr17:17644344	RAI1	-0.38	-5.75	-0.34	2.65e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17252645	chr8:143867129	LY6D	-0.53	-9.55	-0.52	1.37e-18	Urinary tract infection frequency;
KIRP	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg10397082	chr2:1609832	NA	0.56	5.09	0.31	7.15e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13301069	chr11:6624877	ILK;RRP8	0.49	6.35	0.38	1.06e-9	Parkinson's disease;
KIRP	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.96	15.39	0.7	7.03e-38	Uric acid clearance;
KIRP	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg11965913	chr1:205819406	PM20D1	-0.6	-5.91	-0.35	1.13e-8	Menarche (age at onset);
KIRP	cis	rs1847505	0.520	rs717048	chr13:61497414	T/C	cg25164009	chr13:61490935	NA	0.65	8.34	0.47	5.33e-15	Polychlorinated biphenyl levels;
KIRP	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg00977110	chr5:151150581	G3BP1	0.6	6.1	0.36	4.03e-9	Preschool internalizing problems;
KIRP	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.47	-0.38	5.16e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.36	-0.32	1.9e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.49	6.54	0.39	3.44e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.4	5.08	0.31	7.3e-7	Lung cancer;
KIRP	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg13512537	chr8:22265999	SLC39A14	-0.45	-5.89	-0.35	1.26e-8	Verbal declarative memory;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22976360	chr2:70528671	FAM136A	-0.49	-6.34	-0.37	1.06e-9	Myopia;
KIRP	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg17554472	chr22:41940697	POLR3H	0.42	5.06	0.31	8.16e-7	Vitiligo;
KIRP	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.71	8.98	0.5	7.45e-17	Bladder cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg01685689	chr11:126081170	FAM118B;RPUSD4	0.53	6.45	0.38	5.99e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.73	11.52	0.59	7.64e-25	Brugada syndrome;
KIRP	cis	rs2548003	0.518	rs967080	chr5:28755831	T/C	cg22863700	chr5:28928346	NA	0.56	5.8	0.35	2.01e-8	Hip geometry;
KIRP	cis	rs7937682	0.593	rs4598705	chr11:111345840	G/A	cg09085632	chr11:111637200	PPP2R1B	0.45	5.8	0.35	1.98e-8	Primary sclerosing cholangitis;
KIRP	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.68	-7.4	-0.43	2.13e-12	DNA methylation (variation);
KIRP	trans	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg00405596	chr8:11794950	NA	-0.47	-6.37	-0.38	9.15e-10	Mood instability;
KIRP	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.45	6.29	0.37	1.42e-9	Dupuytren's disease;
KIRP	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	5.86	0.35	1.51e-8	Thyroid stimulating hormone;
KIRP	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	1.09	20.49	0.79	4.03e-55	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.7	10.86	0.57	1.04e-22	Resting heart rate;
KIRP	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg00981070	chr1:2046702	PRKCZ	0.4	5.85	0.35	1.56e-8	Height;
KIRP	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.68	8.46	0.47	2.44e-15	Coronary artery disease;
KIRP	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg07636037	chr3:49044803	WDR6	-0.71	-6.53	-0.38	3.66e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.31	-0.37	1.29e-9	Triglycerides;
KIRP	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.73	9.16	0.5	2.17e-17	Coronary artery disease;
KIRP	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg06027949	chr8:82754900	SNX16	0.46	5.64	0.34	4.61e-8	Diastolic blood pressure;
KIRP	cis	rs10782582	1.000	rs1021462	chr1:76376154	G/A	cg10523679	chr1:76189770	ACADM	-0.38	-5.64	-0.34	4.62e-8	Daytime sleep phenotypes;
KIRP	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg20430773	chr1:16534157	ARHGEF19	0.52	6.45	0.38	5.96e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26207909	chr14:103986467	CKB	-0.79	-12.34	-0.62	1.52e-27	Body mass index;
KIRP	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.2	0.51	1.62e-17	Prudent dietary pattern;
KIRP	cis	rs6032067	0.929	rs6032049	chr20:43825556	C/T	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs7224685	0.501	rs781823	chr17:3966280	G/C	cg01798813	chr17:3906674	NA	0.52	7.25	0.42	5.22e-12	Type 2 diabetes;
KIRP	cis	rs601339	1.000	rs7969523	chr12:123168636	T/G	cg18578876	chr12:123200353	GPR109B	0.5	4.9	0.3	1.72e-6	Adiponectin levels;
KIRP	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	cg04338863	chr8:33670619	NA	0.41	5.24	0.32	3.42e-7	Body mass index;
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.79	9.88	0.53	1.37e-19	Corneal astigmatism;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-1.09	-21.19	-0.8	2.11e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg17376030	chr22:41985996	PMM1	0.44	5.19	0.31	4.3e-7	Vitiligo;
KIRP	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg05636881	chr10:105038444	INA	0.66	5.53	0.33	8.19e-8	Arsenic metabolism;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg10318148	chr7:1024673	CYP2W1	0.35	5.11	0.31	6.43e-7	Longevity;Endometriosis;
KIRP	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.04	13.3	0.65	8.61e-31	Body mass index;
KIRP	cis	rs2594989	0.943	rs346068	chr3:11302933	A/G	cg01796438	chr3:11312864	ATG7	-0.64	-7.59	-0.44	6.6e-13	Circulating chemerin levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26749475	chr10:89580388	CFLP1	-0.4	-6.48	-0.38	4.85e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg23594656	chr7:65796392	TPST1	0.37	5.14	0.31	5.55e-7	Aortic root size;
KIRP	cis	rs2033711	0.905	rs1077420	chr19:58968875	A/C	cg00825309	chr19:58991885	ZNF446	-0.61	-7.52	-0.43	1.05e-12	Uric acid clearance;
KIRP	cis	rs7534824	0.625	rs55693426	chr1:101466859	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.03	0.41	2.07e-11	Refractive astigmatism;
KIRP	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg09655341	chr17:79618100	PDE6G	-0.31	-4.85	-0.3	2.21e-6	Eye color traits;
KIRP	cis	rs12190007	0.846	rs9505962	chr6:169726667	A/G	cg16388071	chr6:169726476	NA	0.39	5.66	0.34	4.19e-8	Obesity-related traits;
KIRP	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.54	7.11	0.41	1.22e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.7	0.53	4.92e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg06640241	chr16:89574553	SPG7	0.67	9.17	0.5	1.94e-17	Multiple myeloma (IgH translocation);
KIRP	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.72	-12.25	-0.62	2.95e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.69	9.8	0.53	2.39e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs56161922	0.915	rs12563415	chr1:207856666	G/T	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg25319279	chr11:5960081	NA	-0.59	-6.26	-0.37	1.7e-9	DNA methylation (variation);
KIRP	cis	rs4148660	0.895	rs2900493	chr12:22078245	G/C	cg14669847	chr12:22099120	NA	0.33	5.63	0.34	4.81e-8	Gout;
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg05861140	chr6:150128134	PCMT1	-0.45	-6.3	-0.37	1.35e-9	Lung cancer;
KIRP	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg01563465	chr5:72512441	NA	-0.31	-6.05	-0.36	5.3e-9	Brain volume in infants (cerebrospinal fluid);
KIRP	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg22617819	chr1:44378782	ST3GAL3	-0.32	-5.12	-0.31	6.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3789045	0.729	rs61817460	chr1:204543579	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.21	-0.37	2.22e-9	Educational attainment (college completion);
KIRP	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.68	8.77	0.49	2.94e-16	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1448094	0.872	rs10863147	chr12:86408441	G/C	cg02569458	chr12:86230093	RASSF9	0.35	5.01	0.3	1.02e-6	Major depressive disorder;
KIRP	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.65	-8.28	-0.47	7.7e-15	Obesity-related traits;
KIRP	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.09	0.31	7.05e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20201566	chr12:110011335	MMAB;MVK	0.49	6.07	0.36	4.88e-9	Parkinson's disease;
KIRP	cis	rs4771122	0.728	rs7992289	chr13:28036430	G/A	cg22138327	chr13:27999177	GTF3A	-0.63	-6.5	-0.38	4.5e-10	Body mass index;
KIRP	cis	rs9653442	0.510	rs13415583	chr2:100764087	T/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24873593	chr5:139944080	APBB3;SLC35A4	0.49	6.85	0.4	5.86e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2519796	0.509	rs471882	chr9:136825399	C/G	cg13751417	chr9:136814406	VAV2	0.48	6.28	0.37	1.52e-9	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg16584676	chr17:46985605	UBE2Z	0.5	6.13	0.36	3.56e-9	Type 2 diabetes;
KIRP	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.72	-9.94	-0.54	8.86e-20	Blood metabolite levels;
KIRP	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg21466736	chr12:48725269	NA	-0.44	-5.55	-0.33	7.41e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg00677455	chr12:58241039	CTDSP2	0.63	7.65	0.44	4.65e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg08662619	chr6:150070041	PCMT1	0.36	5.77	0.35	2.33e-8	Lung cancer;
KIRP	cis	rs988913	0.706	rs11753587	chr6:54950698	T/C	cg03513858	chr6:54763001	FAM83B	-0.36	-5.12	-0.31	6.28e-7	Menarche (age at onset);
KIRP	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.18	-0.42	8.45e-12	Aortic root size;
KIRP	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg04609801	chr16:28609176	SULT1A2	-0.5	-5.47	-0.33	1.11e-7	Platelet distribution width;
KIRP	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2307121	0.512	rs2367496	chr5:64712122	T/C	cg00944502	chr5:64858997	PPWD1;CENPK	0.42	5.36	0.32	1.87e-7	Corneal structure;
KIRP	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.63	-8.57	-0.48	1.19e-15	Lymphocyte counts;
KIRP	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg12598211	chr12:123634384	NA	-0.4	-4.93	-0.3	1.55e-6	Neutrophil percentage of white cells;
KIRP	cis	rs1270639	0.778	rs1796271	chr7:157438129	T/G	cg13357408	chr7:157437802	PTPRN2	0.6	6.09	0.36	4.37e-9	Colorectal cancer;
KIRP	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.54	7.28	0.42	4.54e-12	Blood protein levels;
KIRP	cis	rs7116495	1.000	rs6592453	chr11:71683231	C/G	cg18441811	chr11:71824068	C11orf51	-0.63	-5.11	-0.31	6.4e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2742417	1.000	rs2742436	chr3:45741397	T/C	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	2.95e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23794135	chr12:81190974	NA	-0.4	-6.51	-0.38	4.26e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7916968	0.708	rs72776414	chr10:767235	C/A	cg25053142	chr10:775353	NA	0.51	5.17	0.31	4.86e-7	Migraine;
KIRP	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg01616529	chr11:638424	DRD4	-0.37	-4.95	-0.3	1.4e-6	Systemic lupus erythematosus;
KIRP	cis	rs4638749	0.501	rs13421955	chr2:108748076	A/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.92	-0.3	1.57e-6	Blood pressure;
KIRP	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.62	-8.11	-0.46	2.38e-14	Inhibitory control;
KIRP	cis	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg12315302	chr6:26189340	HIST1H4D	0.74	5.19	0.31	4.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12282928	1.000	rs10769336	chr11:48292339	T/C	cg26585981	chr11:48327164	OR4S1	-0.47	-5.34	-0.32	2.15e-7	Migraine - clinic-based;
KIRP	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.76	-7.5	-0.43	1.18e-12	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00675324	chr4:37688114	RELL1	0.54	6.69	0.39	1.54e-10	Parkinson's disease;
KIRP	cis	rs7258465	0.931	rs8107347	chr19:18612748	G/A	cg10790698	chr19:18539756	SSBP4	-0.33	-7.16	-0.42	9.26e-12	Breast cancer;
KIRP	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg04998671	chr14:104000505	TRMT61A	-0.49	-5.63	-0.34	4.92e-8	Coronary artery disease;
KIRP	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.69	-8.19	-0.46	1.43e-14	Blood trace element (Cu levels);
KIRP	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg19847130	chr8:10466454	RP1L1	0.34	5.09	0.31	7.25e-7	Triglycerides;
KIRP	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg07382826	chr16:28625726	SULT1A1	0.52	6.09	0.36	4.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1973993	0.717	rs56209707	chr1:96972973	C/A	cg10631902	chr5:14652156	NA	-0.58	-8.37	-0.47	4.32e-15	Weight;
KIRP	cis	rs61884328	0.852	rs61899293	chr11:47038066	A/G	cg23433285	chr11:47201945	PACSIN3	0.75	6.06	0.36	5.16e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg18032289	chr17:61959525	GH2	-0.43	-5.03	-0.31	9.35e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.6	7.76	0.44	2.21e-13	Height;
KIRP	cis	rs11955175	1.000	rs111310950	chr5:40641951	G/T	cg05478818	chr5:40835740	RPL37	0.68	5.32	0.32	2.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1035491	0.715	rs7726365	chr5:63922274	T/C	cg01791865	chr5:63954708	NA	0.34	5.4	0.33	1.53e-7	Body mass index;
KIRP	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.02	0.31	9.71e-7	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24622205	chr11:6625060	ILK;RRP8	0.57	7.2	0.42	7.23e-12	Parkinson's disease;
KIRP	cis	rs4936894	0.500	rs4936919	chr11:124180082	C/T	cg27160556	chr11:124181099	OR8D1	0.46	6.43	0.38	6.67e-10	Aging (time to death);
KIRP	cis	rs6580649	0.941	rs1018973	chr12:48441692	C/G	cg26205652	chr12:48591994	NA	0.5	5.89	0.35	1.24e-8	Lung cancer;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg07414643	chr4:187882934	NA	0.42	5.62	0.34	5.18e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.62	8.31	0.47	6.7e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg04935436	chr20:30431758	NA	0.53	6.49	0.38	4.72e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg22508957	chr16:3507546	NAT15	0.58	7.13	0.41	1.13e-11	Tuberculosis;
KIRP	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.12	22.87	0.82	7.95e-63	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.55	7.68	0.44	3.81e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26862148	chr16:21610851	METTL9	0.52	6.47	0.38	5.17e-10	Parkinson's disease;
KIRP	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.56	5.88	0.35	1.3e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.0	0.36	6.88e-9	Ovarian reserve;
KIRP	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.55	-6.97	-0.41	2.82e-11	Insulin-like growth factors;
KIRP	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.66	7.2	0.42	7.27e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	1.16	11.0	0.57	3.82e-23	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg16917193	chr12:54089295	NA	0.87	16.58	0.73	5.66e-42	Height;
KIRP	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.54	6.01	0.36	6.55e-9	Bipolar disorder;
KIRP	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.75	10.88	0.57	9.34e-23	Total body bone mineral density;
KIRP	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.92	10.71	0.56	3.26e-22	Eosinophil percentage of granulocytes;
KIRP	trans	rs7246760	1.000	rs28441975	chr19:9897631	C/A	cg02900749	chr2:68251473	NA	-0.96	-8.75	-0.49	3.55e-16	Pursuit maintenance gain;
KIRP	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg13010199	chr12:38710504	ALG10B	0.44	5.67	0.34	4.08e-8	Morning vs. evening chronotype;
KIRP	trans	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg15371732	chr17:78194151	SLC26A11;SGSH	0.57	6.43	0.38	6.58e-10	Cystic fibrosis severity;
KIRP	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.4	6.64	0.39	1.99e-10	Renal cell carcinoma;
KIRP	cis	rs4700695	0.841	rs153367	chr5:65419170	G/A	cg21114390	chr5:65439923	SFRS12	-0.47	-5.06	-0.31	8.4e-7	Facial morphology (factor 19);
KIRP	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07570687	chr10:102243282	WNT8B	0.52	6.84	0.4	6.22e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.83	12.27	0.62	2.56e-27	Eye color traits;
KIRP	cis	rs7009516	0.669	rs12674766	chr8:24241732	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.32	-6.69	-0.39	1.49e-10	Hair greying;
KIRP	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.39	-5.78	-0.35	2.23e-8	Pubertal anthropometrics;
KIRP	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08439880	chr3:133502540	NA	-0.56	-6.8	-0.4	7.7e-11	Iron status biomarkers;
KIRP	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.87	14.71	0.68	1.46e-35	Prostate cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15732812	chr1:206808946	DYRK3	-0.48	-6.11	-0.36	3.89e-9	Myopia;
KIRP	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs13418717	0.793	rs57113328	chr2:127667120	G/A	cg25501666	chr2:127640322	NA	0.79	6.29	0.37	1.44e-9	Heart failure;
KIRP	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.53	-7.43	-0.43	1.76e-12	Lung cancer;
KIRP	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.95	16.65	0.73	3.3e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.6	-0.34	5.81e-8	Metabolite levels;
KIRP	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.82	11.85	0.6	6.1e-26	Heart rate;
KIRP	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-8.93	-0.49	1.03e-16	Resting heart rate;
KIRP	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	1.04	15.4	0.7	6.41e-38	Homoarginine levels;
KIRP	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg27462398	chr1:86174642	ZNHIT6	-0.58	-8.52	-0.48	1.65e-15	Urate levels in overweight individuals;
KIRP	cis	rs1619661	0.530	rs7909598	chr10:44688935	T/C	cg09554077	chr10:44749378	NA	0.44	6.5	0.38	4.49e-10	QT interval (ambient particulate matter interaction);
KIRP	trans	rs6464816	0.668	rs2074712	chr7:147259728	C/T	cg16063617	chr5:128430663	ISOC1	-0.64	-6.25	-0.37	1.83e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.78	-0.4	8.89e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-1.1	-14.41	-0.68	1.46e-34	Post bronchodilator FEV1;
KIRP	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg11021082	chr4:95130006	SMARCAD1	0.49	6.28	0.37	1.54e-9	QT interval;
KIRP	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg12591125	chr7:1885375	MAD1L1	0.67	6.21	0.37	2.2e-9	Bipolar disorder;
KIRP	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs12282928	1.000	rs7107408	chr11:48291558	T/A	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg19445457	chr11:5799446	OR52N5	-0.5	-5.59	-0.34	5.96e-8	DNA methylation (variation);
KIRP	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.79	-0.4	8.21e-11	Daytime sleep phenotypes;
KIRP	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-5.05	-0.31	8.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg00631329	chr6:26305371	NA	-0.74	-9.59	-0.52	1.07e-18	Educational attainment;
KIRP	cis	rs9467711	0.559	rs13214027	chr6:26573631	C/G	cg12826209	chr6:26865740	GUSBL1	0.61	4.93	0.3	1.53e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.23	0.37	2.05e-9	Tonsillectomy;
KIRP	cis	rs6438504	0.885	rs34549395	chr3:118957544	C/A	cg25372693	chr3:118959985	B4GALT4	0.33	5.44	0.33	1.26e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg00977110	chr5:151150581	G3BP1	0.6	6.06	0.36	5.08e-9	Preschool internalizing problems;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14795281	chr19:13953361	NA	0.46	6.09	0.36	4.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.8	-9.87	-0.53	1.41e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06544989	chr22:39130855	UNC84B	0.5	8.79	0.49	2.66e-16	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08560604	chr13:90014813	NA	0.45	6.58	0.39	2.86e-10	Interleukin-4 levels;
KIRP	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.81	-8.31	-0.47	6.57e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.05	-0.31	8.62e-7	Bladder cancer;
KIRP	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg05535760	chr7:792225	HEATR2	1.03	9.9	0.53	1.14e-19	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.51	-0.38	4.16e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.52	7.3	0.42	3.89e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg03653399	chr8:142233436	SLC45A4	-0.48	-5.89	-0.35	1.24e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs13326165	0.585	rs3886875	chr3:52454262	T/G	cg01348873	chr3:52349823	DNAH1	0.69	5.15	0.31	5.33e-7	HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	1.11	10.39	0.55	3.27e-21	Lymphocyte counts;
KIRP	cis	rs975752	1.000	rs4919429	chr10:101938630	G/C	cg13817732	chr10:102046368	BLOC1S2	0.72	5.94	0.35	9.65e-9	Schizophrenia;
KIRP	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg07653901	chr22:50250238	ZBED4	0.43	4.98	0.3	1.19e-6	Schizophrenia;
KIRP	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.6	7.54	0.43	9.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.48	-7.13	-0.41	1.12e-11	Lung cancer;
KIRP	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.42	-5.95	-0.35	9.4e-9	Endometrial cancer;
KIRP	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg03929089	chr4:120376271	NA	0.67	6.28	0.37	1.53e-9	Intraocular pressure;
KIRP	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.02	0.3	9.91e-7	Axial length;
KIRP	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.72	-9.49	-0.52	2.09e-18	Childhood ear infection;
KIRP	cis	rs3829109	0.564	rs11145891	chr9:139293912	T/C	cg21253087	chr9:139290292	SNAPC4	0.47	5.4	0.33	1.59e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.88	0.4	4.88e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7005380	0.581	rs6469876	chr8:120935251	G/T	cg21645572	chr8:120931649	DEPDC6	-0.5	-6.76	-0.4	9.94e-11	Interstitial lung disease;
KIRP	cis	rs6088813	0.857	rs1886692	chr20:33986549	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-6.84	-0.4	6.1e-11	Height;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg09699651	chr6:150184138	LRP11	0.47	6.22	0.37	2.15e-9	Lung cancer;
KIRP	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.63	-0.63	1.58e-28	Exhaled nitric oxide output;
KIRP	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg00405596	chr8:11794950	NA	-0.5	-6.58	-0.39	2.87e-10	Retinal vascular caliber;
KIRP	cis	rs1858037	0.867	rs1553675	chr2:65570307	C/T	cg08085232	chr2:65598271	SPRED2	0.53	6.36	0.38	9.6e-10	Rheumatoid arthritis;
KIRP	cis	rs12049351	0.774	rs4925457	chr1:229633571	C/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.43	-0.33	1.32e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg24747557	chr10:131355152	MGMT	0.36	4.98	0.3	1.22e-6	Response to temozolomide;
KIRP	cis	rs11645898	0.515	rs61747473	chr16:72258743	C/T	cg14768367	chr16:72042858	DHODH	-0.7	-6.79	-0.4	8.55e-11	Blood protein levels;
KIRP	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.52	5.99	0.36	7.47e-9	Alzheimer's disease (late onset);
KIRP	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg01620082	chr3:125678407	NA	-1.11	-7.23	-0.42	6.11e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21972741	chr5:435613	AHRR	0.53	7.04	0.41	1.88e-11	Cystic fibrosis severity;
KIRP	cis	rs17065868	1.000	rs61947967	chr13:45076773	G/A	cg10246903	chr13:45222710	NA	0.6	6.1	0.36	4.2e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.52	6.87	0.4	5.12e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.29	0.32	2.67e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11138902	0.649	rs11139224	chr9:72155195	G/T	cg14397918	chr9:72078829	APBA1	0.3	4.91	0.3	1.64e-6	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg16898833	chr6:26189333	HIST1H4D	0.72	5.12	0.31	6.31e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.6	7.57	0.43	7.36e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.49	6.19	0.37	2.47e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs17401966	0.577	rs6661326	chr1:10242231	T/C	cg19773385	chr1:10388646	KIF1B	-0.48	-6.96	-0.41	3.12e-11	Hepatocellular carcinoma;
KIRP	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	0.83	12.51	0.62	3.92e-28	Body mass index;
KIRP	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.28	-0.42	4.44e-12	Response to antipsychotic treatment;
KIRP	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs732716	0.740	rs78869060	chr19:4444742	A/G	cg21720385	chr19:4455239	UBXN6	0.71	8.88	0.49	1.47e-16	Mean corpuscular volume;
KIRP	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-5.35	-0.32	1.97e-7	Fear of minor pain;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15432938	chr10:99078812	FRAT1	0.52	6.23	0.37	1.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	6.92	0.4	3.81e-11	Aortic root size;
KIRP	cis	rs6467136	0.818	rs2157751	chr7:127171291	A/G	cg08586737	chr7:127225949	GCC1	-0.38	-4.99	-0.3	1.14e-6	Type 2 diabetes;
KIRP	cis	rs9826463	0.759	rs1403726	chr3:142360913	C/G	cg20824294	chr3:142316082	PLS1	0.4	5.72	0.34	3.11e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26850624	chr5:429559	AHRR	0.33	6.03	0.36	5.82e-9	Cystic fibrosis severity;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23052039	chr6:647366	EXOC2	0.44	6.13	0.36	3.45e-9	Interleukin-4 levels;
KIRP	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg23188684	chr11:67383651	NA	0.42	5.44	0.33	1.29e-7	Mean corpuscular volume;
KIRP	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.22	14.11	0.67	1.61e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg07395648	chr5:131743802	NA	-0.36	-5.13	-0.31	5.94e-7	Blood metabolite levels;
KIRP	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.81	0.49	2.34e-16	Bipolar disorder;
KIRP	cis	rs7312774	0.618	rs7953088	chr12:107334539	G/C	cg16260113	chr12:107380972	MTERFD3	0.77	6.81	0.4	7.58e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg04037228	chr3:45636386	LIMD1	0.36	5.33	0.32	2.18e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.57	-0.48	1.13e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-1.13	-21.08	-0.8	4.6e-57	Monocyte count;
KIRP	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg17108064	chr15:78857060	CHRNA5	0.35	5.05	0.31	8.74e-7	Sudden cardiac arrest;
KIRP	cis	rs61542988	0.570	rs10950919	chr7:22833821	A/G	cg11367502	chr7:22862612	TOMM7	0.51	5.6	0.34	5.59e-8	Fibrinogen levels;
KIRP	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg03894339	chr8:19674705	INTS10	0.54	6.73	0.39	1.18e-10	Breast cancer;
KIRP	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06634786	chr22:41940651	POLR3H	-0.45	-5.4	-0.33	1.55e-7	Vitiligo;
KIRP	cis	rs7017914	0.967	rs34042354	chr8:71730961	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs3026101	0.671	rs14231	chr17:5294976	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs4073221	0.654	rs13071665	chr3:18308095	T/C	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	cis	rs2718058	0.560	rs2709109	chr7:37832852	G/A	cg15028436	chr7:37888078	TXNDC3	0.5	5.4	0.33	1.59e-7	Alzheimer's disease (late onset);
KIRP	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg23505145	chr19:12996616	KLF1	0.55	7.95	0.45	6.81e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2219968	1.000	rs4333586	chr8:78971965	C/T	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg18586891	chr4:952366	TMEM175	0.59	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg22117172	chr7:91764530	CYP51A1	-0.44	-6.0	-0.36	6.84e-9	Breast cancer;
KIRP	cis	rs10465746	0.967	rs6670658	chr1:84461268	A/G	cg10977910	chr1:84465055	TTLL7	0.48	5.83	0.35	1.73e-8	Obesity-related traits;
KIRP	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.57	-7.6	-0.44	6.14e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.78	-9.96	-0.54	7.5e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.51	-0.38	4.25e-10	Morning vs. evening chronotype;
KIRP	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.52	0.52	1.7e-18	Monocyte percentage of white cells;
KIRP	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg23649088	chr2:200775458	C2orf69	0.53	5.08	0.31	7.37e-7	Schizophrenia;
KIRP	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg11952622	chr19:58962976	ZNF324B	0.44	5.25	0.32	3.28e-7	Uric acid clearance;
KIRP	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.66	8.19	0.46	1.44e-14	Alcohol dependence;
KIRP	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg16068336	chr17:48637367	CACNA1G	-0.4	-5.24	-0.32	3.53e-7	Type 2 diabetes;
KIRP	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg24972876	chr7:65420302	NA	0.41	5.6	0.34	5.65e-8	Aortic root size;
KIRP	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-8.63	-0.48	7.79e-16	Response to antipsychotic treatment;
KIRP	cis	rs754423	0.515	rs12587906	chr14:52553959	T/G	cg05884192	chr14:52515736	NID2	0.48	5.64	0.34	4.77e-8	Craniofacial microsomia;
KIRP	cis	rs714515	0.934	rs10752943	chr1:172354992	C/T	cg01573306	chr1:172330400	DNM3	0.45	5.83	0.35	1.69e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg17724175	chr1:150552817	MCL1	0.32	5.33	0.32	2.25e-7	Melanoma;
KIRP	cis	rs1559088	0.847	rs8110181	chr19:33605939	G/A	cg07827796	chr19:33622959	WDR88	0.4	4.87	0.3	2.03e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs4950322	0.634	rs7542951	chr1:146812058	C/T	cg22381352	chr1:146742008	CHD1L	-0.43	-5.0	-0.3	1.07e-6	Protein quantitative trait loci;
KIRP	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg06636001	chr8:8085503	FLJ10661	0.59	7.84	0.45	1.33e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.58	7.76	0.44	2.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.53	0.43	9.33e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.79	-0.35	2.16e-8	Pulmonary function;
KIRP	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg00982548	chr2:198649783	BOLL	0.57	5.37	0.32	1.79e-7	Ulcerative colitis;
KIRP	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg18225595	chr11:63971243	STIP1	0.59	5.42	0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg02475777	chr4:1388615	CRIPAK	0.51	4.87	0.3	2.02e-6	Recombination rate (females);
KIRP	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg02569458	chr12:86230093	RASSF9	0.36	5.25	0.32	3.23e-7	Major depressive disorder;
KIRP	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg27129171	chr3:47204927	SETD2	0.74	10.87	0.57	9.58e-23	Colorectal cancer;
KIRP	cis	rs1538970	0.961	rs884962	chr1:45847981	G/A	cg05343316	chr1:45956843	TESK2	0.65	7.45	0.43	1.58e-12	Platelet count;
KIRP	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.41	-4.95	-0.3	1.41e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7577293	1.000	rs12151621	chr2:85934499	A/C	cg19805943	chr2:85933069	NA	0.42	5.24	0.32	3.45e-7	Blood protein levels;
KIRP	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.69	-7.98	-0.45	5.44e-14	Pancreatic cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11407540	chr4:110833060	EGF	0.52	6.98	0.41	2.8e-11	Interleukin-4 levels;
KIRP	cis	rs7084402	0.967	rs1649085	chr10:60292042	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.63	-8.1	-0.46	2.5e-14	Colorectal cancer;
KIRP	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg15028436	chr7:37888078	TXNDC3	0.6	6.95	0.41	3.25e-11	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	9.04e-8	Life satisfaction;
KIRP	cis	rs2213920	0.679	rs6415820	chr9:118231832	A/C	cg13918206	chr9:118159781	DEC1	1.01	10.16	0.54	1.72e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg00094735	chr5:1949198	NA	-0.43	-5.21	-0.32	4e-7	Gut microbiome composition (winter);
KIRP	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.71	9.53	0.52	1.61e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg26876637	chr1:152193138	HRNR	-0.82	-8.34	-0.47	5.26e-15	Atopic dermatitis;
KIRP	cis	rs8067354	0.645	rs11079389	chr17:57887952	G/A	cg02344993	chr17:57696989	CLTC	0.56	5.12	0.31	6.07e-7	Hemoglobin concentration;
KIRP	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg27129171	chr3:47204927	SETD2	0.77	11.54	0.59	6.55e-25	Colorectal cancer;
KIRP	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.47	5.91	0.35	1.13e-8	Blood metabolite levels;
KIRP	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.16	23.66	0.83	2.51e-65	Schizophrenia;
KIRP	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg24296786	chr1:45957014	TESK2	-0.43	-5.5	-0.33	9.41e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4955124	0.558	rs12631369	chr3:32026387	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.75	6.77	0.4	9.29e-11	Schizophrenia;
KIRP	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg25037394	chr1:24152592	HMGCL	-0.35	-4.9	-0.3	1.76e-6	Immature fraction of reticulocytes;
KIRP	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg08501292	chr6:25962987	TRIM38	0.99	5.91	0.35	1.16e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.58	0.34	6.35e-8	Coronary artery disease;
KIRP	cis	rs290268	0.647	rs1333637	chr9:93557066	C/T	cg02608019	chr9:93564028	SYK	-0.68	-8.58	-0.48	1.07e-15	Platelet count;
KIRP	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg05784532	chr1:230284198	GALNT2	-0.42	-6.71	-0.39	1.37e-10	Coronary artery disease;
KIRP	cis	rs2882667	0.931	rs10038799	chr5:138362283	C/T	cg04439458	chr5:138467593	SIL1	-0.44	-7.47	-0.43	1.38e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6707387	0.662	rs6744533	chr2:214384998	A/G	cg08319019	chr2:214017104	IKZF2	0.44	5.12	0.31	6.26e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	4.95	0.3	1.36e-6	Multiple sclerosis;
KIRP	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg22800045	chr5:56110881	MAP3K1	0.61	7.03	0.41	2.06e-11	Initial pursuit acceleration;
KIRP	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-12.83	-0.63	3.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25845431	chr1:44412572	IPO13	0.55	6.77	0.4	9.55e-11	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13711144	chr7:107218933	BCAP29;DUS4L	0.46	6.3	0.37	1.39e-9	Interleukin-4 levels;
KIRP	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg10755058	chr3:40428713	ENTPD3	0.38	5.18	0.31	4.6e-7	Renal cell carcinoma;
KIRP	cis	rs12476592	0.602	rs11125978	chr2:63809602	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-4.95	-0.3	1.36e-6	Childhood ear infection;
KIRP	cis	rs12786942	0.530	rs6590855	chr11:101277610	A/C	cg03942599	chr11:101341554	TRPC6	0.38	4.91	0.3	1.63e-6	Facial depth;
KIRP	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.62	-7.77	-0.44	2.14e-13	Dental caries;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg25320221	chr1:183440909	SMG7	-0.58	-6.05	-0.36	5.41e-9	Response to statin therapy;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg09699651	chr6:150184138	LRP11	0.46	5.95	0.35	9.27e-9	Lung cancer;
KIRP	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg12501888	chr15:85177176	SCAND2	-0.43	-5.33	-0.32	2.18e-7	P wave terminal force;
KIRP	cis	rs151997	0.962	rs39955	chr5:50187501	C/A	cg06027927	chr5:50259733	NA	0.58	7.27	0.42	4.89e-12	Callous-unemotional behaviour;
KIRP	cis	rs9815354	0.767	rs73079325	chr3:41864565	G/A	cg03022575	chr3:42003672	ULK4	0.6	7.01	0.41	2.28e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg09408571	chr1:101003634	GPR88	0.23	5.2	0.31	4.21e-7	Monocyte count;
KIRP	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.5	0.33	9.56e-8	Menopause (age at onset);
KIRP	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.4	4.95	0.3	1.35e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.67	-0.34	3.96e-8	HDL cholesterol;
KIRP	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg26441486	chr22:50317300	CRELD2	0.42	6.68	0.39	1.56e-10	Schizophrenia;
KIRP	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg18154014	chr19:37997991	ZNF793	0.74	6.75	0.4	1.05e-10	Coronary artery calcification;
KIRP	cis	rs11731606	0.508	rs28501313	chr4:95281023	G/A	cg20625393	chr4:95128694	SMARCAD1	0.66	5.74	0.34	2.72e-8	Mean platelet volume;
KIRP	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08280861	chr8:58055591	NA	0.72	5.92	0.35	1.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.88	10.49	0.56	1.57e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4594175	0.962	rs8008182	chr14:51608357	C/T	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs6859018	1.000	rs4921442	chr5:158694100	C/G	cg26646896	chr5:158686746	NA	-0.36	-5.17	-0.31	4.9e-7	Serum sulfate level;
KIRP	cis	rs12982744	0.613	rs35288362	chr19:2141982	T/C	cg09261902	chr19:2140048	AP3D1	0.43	5.49	0.33	1.01e-7	Osteoarthritis;Height;
KIRP	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.76	-7.33	-0.42	3.22e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.1	-9.16	-0.5	2.04e-17	Body mass index;
KIRP	cis	rs12579753	0.667	rs7485826	chr12:82301554	C/T	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.49	-0.33	1e-7	Resting heart rate;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23063879	chr4:89881374	FAM13A	0.45	6.58	0.39	2.76e-10	Interleukin-4 levels;
KIRP	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg00784671	chr22:46762841	CELSR1	-0.61	-6.64	-0.39	1.99e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-6.04	-0.36	5.77e-9	Bipolar disorder;
KIRP	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.65	-0.39	1.92e-10	Diastolic blood pressure;
KIRP	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.64	-8.54	-0.48	1.43e-15	Motion sickness;
KIRP	cis	rs4356975	0.545	rs35749478	chr4:69949580	A/T	cg27372994	chr4:70080453	UGT2B11	0.37	4.94	0.3	1.44e-6	Obesity-related traits;
KIRP	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.47	-0.33	1.11e-7	Fear of minor pain;
KIRP	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.55	6.96	0.41	3.15e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg02931644	chr1:25747376	RHCE	-0.35	-6.34	-0.37	1.12e-9	Erythrocyte sedimentation rate;
KIRP	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg09137382	chr11:130731461	NA	0.56	8.16	0.46	1.71e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.52	0.7	2.49e-38	Bipolar disorder;
KIRP	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg26338869	chr17:61819248	STRADA	0.54	6.45	0.38	5.91e-10	Prudent dietary pattern;
KIRP	cis	rs13095912	0.925	rs11924016	chr3:185307879	A/T	cg11274856	chr3:185301563	NA	0.52	6.46	0.38	5.53e-10	Systolic blood pressure;
KIRP	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.66	-6.18	-0.37	2.58e-9	Schizophrenia;
KIRP	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.62	-0.52	8.4e-19	Hemoglobin concentration;
KIRP	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-1.11	-9.13	-0.5	2.5e-17	Body mass index;
KIRP	cis	rs4660306	1.000	rs6429569	chr1:46001330	A/C	cg24296786	chr1:45957014	TESK2	0.52	6.23	0.37	1.99e-9	Homocysteine levels;
KIRP	trans	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg07817883	chr1:32538562	TMEM39B	1.26	8.05	0.46	3.62e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6088813	1.000	rs2425066	chr20:33927006	A/C	cg14752227	chr20:34000481	UQCC	0.5	6.62	0.39	2.21e-10	Height;
KIRP	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06481639	chr22:41940642	POLR3H	-0.68	-7.15	-0.42	9.61e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11249608	0.789	rs6868425	chr5:178446708	A/G	cg21905437	chr5:178450457	ZNF879	0.52	5.9	0.35	1.2e-8	Pubertal anthropometrics;
KIRP	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg06885757	chr1:42089581	HIVEP3	0.49	7.11	0.41	1.25e-11	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.03	0.41	2e-11	Arsenic metabolism;
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.83	0.63	3.31e-29	Platelet count;
KIRP	cis	rs4794202	0.629	rs7212099	chr17:45925890	A/G	cg02219949	chr17:45927392	SP6	0.55	5.06	0.31	8.19e-7	Alzheimer's disease (cognitive decline);
KIRP	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg03605463	chr16:89740564	NA	0.49	5.69	0.34	3.66e-8	Vitiligo;
KIRP	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.93e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.79	11.63	0.6	3.35e-25	Mood instability;
KIRP	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19524238	chr7:2802976	GNA12	-0.38	-5.13	-0.31	5.76e-7	Height;
KIRP	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg15507776	chr3:136538369	TMEM22	0.51	7.62	0.44	5.34e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg00334542	chr7:100209784	MOSPD3	-0.51	-5.38	-0.32	1.75e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg17182837	chr8:41585554	ANK1	-0.47	-6.69	-0.39	1.5e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg23307798	chr14:103986281	CKB	0.79	13.82	0.66	1.51e-32	Body mass index;
KIRP	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.76	-9.39	-0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg05340658	chr4:99064831	C4orf37	0.61	7.64	0.44	4.78e-13	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg22508957	chr16:3507546	NAT15	-0.45	-6.09	-0.36	4.21e-9	Tuberculosis;
KIRP	cis	rs714515	0.934	rs9425297	chr1:172358816	A/G	cg01573306	chr1:172330400	DNM3	0.44	5.79	0.35	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.79	9.45	0.52	2.81e-18	Corneal astigmatism;
KIRP	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.9	-14.7	-0.68	1.54e-35	Breast cancer;
KIRP	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg27211696	chr2:191398769	TMEM194B	-0.62	-7.38	-0.43	2.51e-12	Diastolic blood pressure;
KIRP	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.03	-0.67	3.08e-33	Primary sclerosing cholangitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00332822	chr7:115897974	TES	0.48	6.39	0.38	8.23e-10	Interleukin-4 levels;
KIRP	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18364779	chr6:26104403	HIST1H4C	0.38	5.12	0.31	6.11e-7	Schizophrenia;
KIRP	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.63	8.4	0.47	3.52e-15	Motion sickness;
KIRP	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13047869	chr3:10149882	C3orf24	0.49	4.87	0.3	2e-6	Alzheimer's disease;
KIRP	cis	rs1050631	0.564	rs10153377	chr18:33727984	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.44	5.67	0.34	3.91e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs6450176	0.638	rs11746856	chr5:53291295	A/C	ch.5.1024479R	chr5:53302184	ARL15	-1.2	-15.21	-0.7	2.72e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.65	-7.31	-0.42	3.67e-12	Menarche (age at onset);
KIRP	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.5	0.33	9.67e-8	Height;
KIRP	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	1.0	11.1	0.58	1.73e-23	Iron status biomarkers;
KIRP	cis	rs4704187	0.663	rs9654428	chr5:74466884	A/C	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg18016565	chr1:150552671	MCL1	-0.34	-5.22	-0.32	3.87e-7	Tonsillectomy;
KIRP	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.82	-0.49	2.09e-16	Resting heart rate;
KIRP	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg18586891	chr4:952366	TMEM175	-0.59	-5.27	-0.32	3.06e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-6.98	-0.41	2.68e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7635838	0.819	rs2454482	chr3:11534031	C/T	cg00170343	chr3:11313890	ATG7	0.47	5.93	0.35	9.97e-9	HDL cholesterol;
KIRP	cis	rs78487399	0.808	rs74600494	chr2:43743491	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.85	-0.3	2.2e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs12478665	1	rs12478665	chr2:210123032	C/T	cg26685596	chr2:210074359	NA	0.4	5.17	0.31	4.94e-7	Hippocampal volume;
KIRP	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24110177	chr3:50126178	RBM5	-0.65	-8.93	-0.49	1.04e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.73	7.11	0.41	1.22e-11	Vitiligo;
KIRP	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.79	11.48	0.59	1.02e-24	Morning vs. evening chronotype;
KIRP	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.72	8.69	0.48	5.33e-16	Tonsillectomy;
KIRP	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg15764593	chr10:829463	NA	-0.8	-8.63	-0.48	7.51e-16	Uric acid levels;
KIRP	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg15103426	chr22:29168792	CCDC117	0.46	6.24	0.37	1.92e-9	Red cell distribution width;
KIRP	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.12	0.61	8.3e-27	Platelet count;
KIRP	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg07862535	chr7:139043722	LUC7L2	0.46	5.16	0.31	4.99e-7	Diisocyanate-induced asthma;
KIRP	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs7929679	0.602	rs11032866	chr11:34803432	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.34e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg10818794	chr15:86012489	AKAP13	-0.5	-7.09	-0.41	1.4e-11	Coronary artery disease;
KIRP	cis	rs3857067	0.806	rs9307137	chr4:95135712	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-5.75	-0.34	2.67e-8	QT interval;
KIRP	cis	rs2273156	0.570	rs28365850	chr14:35591316	G/A	cg09327582	chr14:35236912	BAZ1A	-0.54	-5.36	-0.32	1.95e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs929596	0.958	rs17862873	chr2:234646722	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-8.07	-0.46	3.15e-14	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.75	6.4	0.38	7.94e-10	Body mass index;
KIRP	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg25251562	chr2:3704773	ALLC	-0.36	-4.88	-0.3	1.92e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs830233	0.525	rs62382144	chr5:165340408	C/T	cg13976338	chr5:165423657	NA	-0.55	-5.48	-0.33	1.07e-7	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg27205649	chr11:78285834	NARS2	-0.66	-8.54	-0.48	1.46e-15	Alzheimer's disease (survival time);
KIRP	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg27211696	chr2:191398769	TMEM194B	-0.75	-9.17	-0.5	1.95e-17	Diastolic blood pressure;
KIRP	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg13271783	chr10:134563150	INPP5A	0.61	8.19	0.46	1.46e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9905704	0.918	rs302852	chr17:56685214	C/T	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04633409	chr12:44195947	TWF1	-0.39	-6.04	-0.36	5.79e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs986417	0.892	rs11628559	chr14:61038153	G/C	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg17724175	chr1:150552817	MCL1	0.36	5.96	0.36	8.8e-9	Melanoma;
KIRP	cis	rs981844	1.000	rs116588966	chr4:154664794	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04402966	chr7:87505783	SLC25A40;DBF4	0.48	6.8	0.4	8.09e-11	Survival in pancreatic cancer;
KIRP	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg14829360	chr17:73884958	NA	-0.74	-6.22	-0.37	2.07e-9	Psoriasis;
KIRP	cis	rs1468333	1.000	rs2864	chr5:137523430	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.48	5.42	0.33	1.41e-7	Resting heart rate;
KIRP	cis	rs4006360	0.522	rs72625953	chr17:39237157	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.64	-0.48	7.14e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs1978968	1.000	rs2099943	chr22:18438559	A/G	cg02610425	chr22:18483192	MICAL3	0.39	5.88	0.35	1.32e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg12756093	chr1:115239321	AMPD1	0.59	7.55	0.43	8.29e-13	Autism;
KIRP	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg17376030	chr22:41985996	PMM1	-0.53	-6.06	-0.36	5.14e-9	Vitiligo;
KIRP	cis	rs9400467	0.537	rs12197886	chr6:111491405	C/G	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg19731401	chr7:2775893	GNA12	0.77	7.25	0.42	5.43e-12	Childhood ear infection;
KIRP	cis	rs6430538	0.671	rs13390951	chr2:135582128	A/G	cg12500956	chr2:135428796	TMEM163	0.4	4.94	0.3	1.43e-6	Parkinson's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15072735	chr9:72375102	PTAR1	0.53	6.27	0.37	1.62e-9	Smoking initiation;
KIRP	cis	rs16858210	0.874	rs6792309	chr3:183607661	C/T	cg25686905	chr3:183603175	PARL	-0.43	-5.57	-0.33	6.68e-8	Menopause (age at onset);
KIRP	cis	rs9972944	0.756	rs4791132	chr17:63769124	T/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.16e-13	Total body bone mineral density;
KIRP	cis	rs35740288	0.770	rs62023931	chr15:86132752	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs11138902	0.673	rs13291843	chr9:72162011	C/T	cg14123607	chr9:72164709	APBA1	-0.41	-5.18	-0.31	4.56e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.63	-7.36	-0.42	2.75e-12	Dental caries;
KIRP	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg24803719	chr17:45855879	NA	0.45	6.12	0.36	3.73e-9	IgG glycosylation;
KIRP	cis	rs16828019	0.852	rs71648535	chr1:41613750	G/A	cg18742814	chr1:41828276	NA	0.66	5.77	0.35	2.37e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg07451762	chr16:28383216	NA	0.39	5.02	0.3	9.79e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	1.05	16.06	0.72	3.62e-40	Menopause (age at onset);
KIRP	cis	rs3092073	0.624	rs7275164	chr20:44604822	G/A	cg27529037	chr20:44575021	PCIF1	0.51	6.07	0.36	4.93e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg05025164	chr4:1340916	KIAA1530	0.47	5.67	0.34	3.93e-8	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09274402	chr7:77166647	PTPN12	0.45	6.35	0.38	1.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.4	4.85	0.3	2.16e-6	Renal cell carcinoma;
KIRP	cis	rs876084	0.604	rs4621850	chr8:121014873	C/T	cg22335954	chr8:121166405	COL14A1	-0.4	-4.99	-0.3	1.14e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.55e-10	Morning vs. evening chronotype;
KIRP	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg05991184	chr2:219186017	PNKD	0.36	5.03	0.31	9.37e-7	Colorectal cancer;
KIRP	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg09163369	chr1:210001066	C1orf107	0.49	6.17	0.37	2.77e-9	Orofacial clefts;
KIRP	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.7	-12.88	-0.63	2.42e-29	Body mass index;
KIRP	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.53	-7.41	-0.43	2.08e-12	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.18	0.42	8.07e-12	Aortic root size;
KIRP	cis	rs17826219	0.500	rs117560728	chr17:29070938	A/C	cg13385521	chr17:29058706	SUZ12P	0.97	6.64	0.39	1.98e-10	Body mass index;
KIRP	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg08648136	chr8:956695	NA	0.39	5.64	0.34	4.63e-8	Schizophrenia;
KIRP	cis	rs10131728	0.892	rs12891828	chr14:81654524	A/G	cg01989461	chr14:81687754	GTF2A1	-0.73	-5.54	-0.33	7.71e-8	IgG glycosylation;
KIRP	cis	rs4389656	0.857	rs274680	chr5:6749085	T/G	cg10857441	chr5:6722123	POLS	-0.46	-6.45	-0.38	5.8e-10	Coronary artery disease;
KIRP	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg18646521	chr2:111875858	NA	0.4	5.83	0.35	1.69e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs7809950	0.731	rs4730238	chr7:107054787	G/A	cg23024343	chr7:107201750	COG5	-0.56	-8.01	-0.45	4.6e-14	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.45	-5.62	-0.34	5.29e-8	Aortic root size;
KIRP	cis	rs2562456	0.793	rs78467454	chr19:21504732	T/C	cg18461458	chr19:21324796	ZNF431	-0.52	-5.04	-0.31	8.96e-7	Pain;
KIRP	cis	rs6968419	0.747	rs6957561	chr7:115888339	G/A	cg02561103	chr7:115862891	TES	-0.42	-6.04	-0.36	5.73e-9	Intraocular pressure;
KIRP	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.72	10.02	0.54	4.76e-20	Multiple sclerosis;
KIRP	cis	rs2273669	0.504	rs77043922	chr6:109488896	G/A	cg05315195	chr6:109294784	ARMC2	-0.51	-4.85	-0.3	2.18e-6	Prostate cancer;
KIRP	cis	rs1018697	0.966	rs1475643	chr10:104546467	C/T	cg04362960	chr10:104952993	NT5C2	0.48	5.72	0.34	3.05e-8	Colorectal adenoma (advanced);
KIRP	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg07701084	chr6:150067640	NUP43	0.59	7.58	0.44	7.04e-13	Lung cancer;
KIRP	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.52	-5.78	-0.35	2.26e-8	Multiple sclerosis;
KIRP	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.92	13.86	0.66	1.15e-32	Body mass index;
KIRP	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.42	-5.21	-0.32	3.91e-7	Aortic root size;
KIRP	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg11845111	chr2:191398756	TMEM194B	0.94	10.22	0.55	1.13e-20	Diastolic blood pressure;
KIRP	cis	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-8.73	-0.49	3.92e-16	Asthma;
KIRP	cis	rs28489187	0.617	rs233097	chr1:85825473	G/C	cg16011679	chr1:85725395	C1orf52	0.45	5.67	0.34	3.95e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21768436	chr8:67341108	RRS1	0.43	6.03	0.36	6.05e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9469913	0.799	rs2815005	chr6:34638847	G/A	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.17	-0.31	4.74e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	0.83	11.97	0.61	2.51e-26	Lewy body disease;
KIRP	cis	rs3739034	0.759	rs4430991	chr2:135491932	C/T	cg15546071	chr2:135691756	CCNT2	-0.52	-4.93	-0.3	1.5e-6	Gut microbiome composition (winter);
KIRP	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg26116260	chr4:7069785	GRPEL1	-0.8	-6.56	-0.39	3.2e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	cis	rs1448094	0.935	rs11117108	chr12:86322310	T/A	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.34	3.27e-8	Major depressive disorder;
KIRP	cis	rs6973256	0.865	rs4728295	chr7:133322680	A/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.55	-0.39	3.33e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.7	-0.34	3.35e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs684232	0.712	rs2955626	chr17:618100	C/G	cg12384639	chr17:618140	VPS53	-0.47	-6.01	-0.36	6.79e-9	Prostate cancer;
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg26134248	chr17:3907702	NA	0.44	6.14	0.36	3.36e-9	Type 2 diabetes;
KIRP	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg26354017	chr1:205819088	PM20D1	-0.56	-5.66	-0.34	4.22e-8	Menarche (age at onset);
KIRP	cis	rs9506514	0.712	rs11838795	chr13:21258328	T/C	cg04906043	chr13:21280425	IL17D	-0.4	-5.13	-0.31	5.83e-7	Coronary artery calcification;
KIRP	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.48	-5.69	-0.34	3.55e-8	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26947572	chr2:10442852	HPCAL1	0.53	6.77	0.4	9.19e-11	Parkinson's disease;
KIRP	cis	rs7180079	0.620	rs1385950	chr15:65051190	C/T	cg15337035	chr15:64978493	NA	-0.5	-5.5	-0.33	9.37e-8	Monocyte count;
KIRP	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	ch.8.33884649F	chr8:33765107	NA	0.64	8.15	0.46	1.81e-14	Body mass index;
KIRP	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.58	7.76	0.44	2.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.25	-0.37	1.82e-9	Lung cancer;
KIRP	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg13010199	chr12:38710504	ALG10B	-0.46	-5.81	-0.35	1.91e-8	Morning vs. evening chronotype;
KIRP	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg20578329	chr17:80767326	TBCD	0.67	7.63	0.44	5.15e-13	Breast cancer;
KIRP	cis	rs75216060	0.861	rs73212357	chr8:13825875	G/T	cg12665059	chr8:13787749	NA	0.32	4.96	0.3	1.29e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs7845219	0.506	rs12548999	chr8:95929843	C/T	cg23172400	chr8:95962367	TP53INP1	-0.29	-5.65	-0.34	4.39e-8	Type 2 diabetes;
KIRP	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg16586182	chr3:47516702	SCAP	-0.75	-10.44	-0.55	2.3e-21	Colorectal cancer;
KIRP	cis	rs501120	1.000	rs479596	chr10:44760473	C/T	cg09554077	chr10:44749378	NA	0.72	10.49	0.56	1.64e-21	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.22	-0.42	6.41e-12	Triglycerides;
KIRP	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12292205	chr6:26970375	C6orf41	-0.65	-7.27	-0.42	4.63e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs28489187	0.706	rs233057	chr1:85798855	T/C	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.83	0.53	1.86e-19	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07052390	chr11:133827076	IGSF9B	0.5	6.6	0.39	2.51e-10	Parkinson's disease;
KIRP	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.42	5.34	0.32	2.15e-7	Age at first birth;
KIRP	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.63	7.41	0.43	2.03e-12	Platelet count;
KIRP	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg24579218	chr15:68104479	NA	-0.36	-5.19	-0.31	4.42e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	cis	rs1524927	1.000	rs13310130	chr7:96346088	T/G	cg00227355	chr7:96336147	SHFM1	-0.32	-4.88	-0.3	1.91e-6	Total body bone mineral density;
KIRP	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	1.05	9.41	0.51	3.73e-18	Pulse pressure;
KIRP	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.59	-8.36	-0.47	4.68e-15	Diastolic blood pressure;
KIRP	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.21	-5.5	-0.33	9.74e-8	Mean corpuscular volume;
KIRP	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-6.02	-0.36	6.44e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs7808935	0.589	rs38513	chr7:28028227	G/A	cg22168087	chr7:27702803	HIBADH	-0.56	-5.31	-0.32	2.4e-7	Prostate cancer;
KIRP	cis	rs4656940	0.574	rs575217	chr1:160788217	T/A	cg17331569	chr1:160788135	LY9	0.41	4.93	0.3	1.48e-6	Crohn's disease;
KIRP	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs687432	0.586	rs2443441	chr11:57903862	A/C	cg19752551	chr11:57585705	CTNND1	-0.37	-5.09	-0.31	7.16e-7	Parkinson's disease;
KIRP	cis	rs137699	0.604	rs137702	chr22:39750158	T/C	cg24399712	chr22:39784796	NA	-0.61	-7.26	-0.42	5.22e-12	IgG glycosylation;
KIRP	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg26695010	chr11:65641043	EFEMP2	-0.5	-4.99	-0.3	1.12e-6	Crohn's disease;
KIRP	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg07701084	chr6:150067640	NUP43	0.68	8.36	0.47	4.56e-15	Lung cancer;
KIRP	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.93	-15.35	-0.7	9.49e-38	Breast cancer;
KIRP	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg25174290	chr11:3078921	CARS	-0.69	-8.96	-0.5	8.26e-17	Calcium levels;
KIRP	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.95	-13.46	-0.65	2.51e-31	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.86	14.4	0.68	1.65e-34	Alcohol dependence (age at onset);
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg15595755	chr5:1867978	NA	0.41	5.4	0.33	1.59e-7	Cardiovascular disease risk factors;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01926858	chr14:53619558	DDHD1	0.51	6.36	0.38	9.63e-10	Parkinson's disease;
KIRP	cis	rs11628318	0.805	rs4906229	chr14:103057511	A/C	cg12046867	chr14:103022105	NA	-0.38	-5.03	-0.31	9.42e-7	Platelet count;
KIRP	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.98	10.85	0.57	1.17e-22	IgG glycosylation;
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg11814155	chr7:99998594	ZCWPW1	0.54	5.41	0.33	1.49e-7	Platelet count;
KIRP	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg17376030	chr22:41985996	PMM1	-0.53	-6.03	-0.36	6.11e-9	Vitiligo;
KIRP	cis	rs6684428	0.536	rs12744110	chr1:56396309	T/C	cg11651538	chr1:56320950	NA	0.54	7.98	0.45	5.59e-14	Airflow obstruction;
KIRP	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.78	-10.34	-0.55	4.96e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg18016565	chr1:150552671	MCL1	0.41	6.1	0.36	4.14e-9	Tonsillectomy;
KIRP	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg17133734	chr15:86042851	AKAP13	-0.46	-5.89	-0.35	1.26e-8	Coronary artery disease;
KIRP	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05025164	chr4:1340916	KIAA1530	0.4	5.23	0.32	3.67e-7	Obesity-related traits;
KIRP	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.74	-9.79	-0.53	2.48e-19	Pancreatic cancer;
KIRP	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.57	7.66	0.44	4.38e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.68	-12.52	-0.62	3.62e-28	White blood cell count (basophil);
KIRP	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.81	9.23	0.51	1.33e-17	Bipolar disorder;
KIRP	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.62	-6.86	-0.4	5.39e-11	Urate levels in lean individuals;
KIRP	cis	rs6684514	1.000	rs6800	chr1:156262653	A/C	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg06204229	chr3:52865917	ITIH4	0.53	5.94	0.35	9.49e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12789259	chr4:151605776	LRBA	-0.4	-6.19	-0.37	2.5e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg05861140	chr6:150128134	PCMT1	0.42	5.78	0.35	2.2e-8	Lung cancer;
KIRP	cis	rs2294369	0.906	rs136854	chr22:40058999	C/T	cg10455938	chr22:40058150	CACNA1I	0.44	5.33	0.32	2.19e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg26876637	chr1:152193138	HRNR	-0.7	-9.58	-0.52	1.14e-18	Atopic dermatitis;
KIRP	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.83	-8.74	-0.49	3.64e-16	Hair shape;
KIRP	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.9	10.65	0.56	5.17e-22	Exhaled nitric oxide levels;
KIRP	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.12	7.69	0.44	3.59e-13	Age-related hearing impairment;
KIRP	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.71	8.09	0.46	2.66e-14	Corneal astigmatism;
KIRP	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.14	-0.41	1.04e-11	Aortic root size;
KIRP	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-7.85	-0.45	1.31e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg19875535	chr5:140030758	IK	-0.73	-10.5	-0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs74181299	0.684	rs1420184	chr2:65315880	G/C	cg05010058	chr2:65284262	CEP68	-0.42	-5.78	-0.35	2.24e-8	Pulse pressure;
KIRP	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-4.93	-0.3	1.5e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	cis	rs7017914	0.967	rs34508469	chr8:71628463	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.73	-0.44	2.71e-13	Mood instability;
KIRP	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.35	8.04	0.46	3.67e-14	Cutaneous nevi;
KIRP	cis	rs7221595	0.825	rs8069643	chr17:3971237	C/T	cg21851534	chr17:3907994	ZZEF1	0.57	6.06	0.36	5.14e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs16957091	0.909	rs8034447	chr15:43014165	C/T	cg24196017	chr15:43021976	CDAN1	-0.54	-7.11	-0.41	1.22e-11	MGMT methylation in smokers;
KIRP	cis	rs494562	0.892	rs547052	chr6:86118840	G/A	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-10.22	-0.55	1.11e-20	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg07148914	chr20:33460835	GGT7	-0.54	-7.07	-0.41	1.62e-11	Height;
KIRP	cis	rs2411233	0.837	rs1368803	chr15:39256705	C/T	cg02291532	chr15:39874776	THBS1	0.48	6.32	0.37	1.23e-9	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23335269	chr10:6130793	RBM17	0.48	6.82	0.4	7.16e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg27205649	chr11:78285834	NARS2	0.67	7.2	0.42	7.33e-12	Alzheimer's disease (survival time);
KIRP	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.11	-0.31	6.37e-7	Bladder cancer;
KIRP	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	1.03	16.05	0.72	3.82e-40	Homoarginine levels;
KIRP	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg05775895	chr3:12838266	CAND2	0.48	8.29	0.47	7.25e-15	QRS complex (12-leadsum);
KIRP	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.45	5.07	0.31	7.79e-7	Schizophrenia;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.5	5.73	0.34	2.89e-8	Lung cancer;
KIRP	cis	rs9826463	0.582	rs73238187	chr3:142143674	T/C	cg20824294	chr3:142316082	PLS1	0.41	5.98	0.36	7.98e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg07884673	chr3:53033167	SFMBT1	0.8	6.41	0.38	7.38e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg21466736	chr12:48725269	NA	0.42	5.18	0.31	4.64e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg13319975	chr6:146136371	FBXO30	-0.4	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6005807	0.563	rs9620811	chr22:29058409	T/C	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs28834970	0.925	rs2322599	chr8:27211910	G/A	cg06815112	chr8:27182871	PTK2B	-0.43	-5.56	-0.33	6.88e-8	Alzheimer's disease (late onset);
KIRP	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg10117171	chr1:25599238	RHD	-0.39	-5.28	-0.32	2.83e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs4363385	0.530	rs61815714	chr1:152921380	C/T	cg07796016	chr1:152779584	LCE1C	-0.46	-5.81	-0.35	1.98e-8	Inflammatory skin disease;
KIRP	cis	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg00405596	chr8:11794950	NA	-0.48	-6.18	-0.37	2.64e-9	Monocyte count;
KIRP	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg06742321	chr12:123595122	PITPNM2	-0.4	-4.88	-0.3	1.87e-6	Neutrophil percentage of white cells;
KIRP	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.48	5.79	0.35	2.17e-8	Menarche (age at onset);
KIRP	cis	rs807029	0.577	rs701834	chr10:102761801	C/T	cg04662943	chr10:102668895	NA	0.47	5.03	0.31	9.25e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11766298	0.702	rs10249336	chr7:128964149	G/C	cg06809055	chr7:129142284	NA	0.68	4.84	0.3	2.26e-6	Response to fenofibrate;
KIRP	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg27205649	chr11:78285834	NARS2	-0.49	-5.34	-0.32	2.06e-7	Testicular germ cell tumor;
KIRP	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.9	14.74	0.68	1.13e-35	Dental caries;
KIRP	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg07395648	chr5:131743802	NA	-0.59	-8.34	-0.47	5.19e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg23682824	chr7:23144976	KLHL7	0.47	5.63	0.34	4.91e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.57	6.68	0.39	1.55e-10	Aortic root size;
KIRP	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.68	-9.92	-0.53	9.73e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.46	5.45	0.33	1.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2230307	0.536	rs640030	chr1:100574992	C/T	cg24955406	chr1:100503596	HIAT1	-0.66	-7.46	-0.43	1.49e-12	Carotid intima media thickness;
KIRP	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.06	-0.36	4.97e-9	Systolic blood pressure;
KIRP	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.53	-6.26	-0.37	1.74e-9	Bone mineral density;
KIRP	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs7428	1.000	rs72840063	chr2:85550396	T/A	cg24342717	chr2:85555507	TGOLN2	-0.53	-6.02	-0.36	6.16e-9	Ear protrusion;
KIRP	cis	rs10518128	1.000	rs112795376	chr4:75716413	G/A	cg20122727	chr4:75719957	BTC	0.6	6.03	0.36	5.86e-9	Electroencephalogram traits;
KIRP	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg18657303	chr4:1051139	NA	0.55	5.03	0.31	9.44e-7	Recombination rate (females);
KIRP	cis	rs16957091	0.909	rs12912064	chr15:43004170	C/T	cg24196017	chr15:43021976	CDAN1	-0.46	-6.14	-0.36	3.2e-9	MGMT methylation in smokers;
KIRP	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.91	9.32	0.51	7.08e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7267005	0.661	rs77779232	chr20:34400409	T/G	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg13736514	chr6:26305472	NA	-0.65	-7.95	-0.45	6.76e-14	Educational attainment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07358015	chr8:28748218	INTS9;HMBOX1	0.42	6.38	0.38	8.96e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg02297831	chr4:17616191	MED28	-0.58	-7.46	-0.43	1.48e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.17	16.65	0.73	3.32e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.52	6.29	0.37	1.45e-9	Uric acid levels;
KIRP	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.07	-0.36	4.92e-9	Lung cancer;
KIRP	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.36	0.38	9.93e-10	Lung cancer;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.4	-0.33	1.59e-7	Life satisfaction;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25877054	chr1:95700082	RWDD3	0.47	6.1	0.36	4.15e-9	Myopia (pathological);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23055707	chr2:1681153	PXDN	-0.42	-6.27	-0.37	1.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg12549451	chr6:135224345	NA	0.41	5.0	0.3	1.07e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg08975724	chr8:8085496	FLJ10661	0.59	7.89	0.45	9.63e-14	Neuroticism;
KIRP	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	1.08	8.09	0.46	2.72e-14	Skin colour saturation;
KIRP	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.66	8.51	0.48	1.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	1.31	9.58	0.52	1.11e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.52	-7.24	-0.42	5.87e-12	Menarche (age at onset);
KIRP	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg10397082	chr2:1609832	NA	0.56	5.08	0.31	7.57e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.68	6.8	0.4	8.04e-11	Vitiligo;
KIRP	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.58	-0.43	7.26e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs3752645	1.000	rs10248105	chr7:106760498	C/T	cg02696742	chr7:106810147	HBP1	-0.57	-4.91	-0.3	1.7e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs539514	0.637	rs552030	chr13:76322065	G/T	cg04757411	chr13:76259545	LMO7	-0.43	-6.1	-0.36	4.15e-9	Type 1 diabetes;
KIRP	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-1.11	-18.49	-0.76	1.97e-48	Strep throat;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14443694	chr20:5107453	CDS2;PCNA	0.46	6.1	0.36	3.98e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4671458	0.626	rs72806055	chr2:63835971	C/A	cg17519650	chr2:63277830	OTX1	-0.5	-5.14	-0.31	5.65e-7	Subjective well-being;
KIRP	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg22508957	chr16:3507546	NAT15	0.59	7.29	0.42	4.27e-12	Tuberculosis;
KIRP	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.56	6.54	0.38	3.51e-10	Corneal astigmatism;
KIRP	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.5	-5.75	-0.34	2.68e-8	Coronary artery disease;
KIRP	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-8.78	-0.49	2.77e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg07395648	chr5:131743802	NA	-0.54	-7.56	-0.43	8.07e-13	Breast cancer;
KIRP	cis	rs7534824	0.625	rs61782085	chr1:101518270	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.32	0.32	2.37e-7	Refractive astigmatism;
KIRP	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-4.85	-0.3	2.16e-6	Aortic root size;
KIRP	cis	rs2718058	0.630	rs2722292	chr7:37824581	A/G	cg15028436	chr7:37888078	TXNDC3	0.5	5.27	0.32	2.95e-7	Alzheimer's disease (late onset);
KIRP	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.78	12.44	0.62	6.84e-28	Coronary artery disease;
KIRP	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg22604316	chr1:46958801	NA	0.46	6.55	0.39	3.42e-10	Monobrow;
KIRP	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.89	-11.23	-0.58	6.86e-24	Breast cancer;
KIRP	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg16586182	chr3:47516702	SCAP	-0.69	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg02725872	chr8:58115012	NA	0.75	7.87	0.45	1.16e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg08132940	chr7:1081526	C7orf50	-0.46	-5.28	-0.32	2.86e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2692947	0.644	rs772154	chr2:97021664	G/T	cg23100626	chr2:96804247	ASTL	0.5	6.76	0.4	9.86e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.65	-9.85	-0.53	1.59e-19	Total body bone mineral density;
KIRP	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.79	-8.75	-0.49	3.42e-16	Bipolar disorder;
KIRP	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg17279839	chr7:150038598	RARRES2	0.4	5.12	0.31	6.25e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.58	6.73	0.39	1.19e-10	Mean corpuscular volume;
KIRP	cis	rs9826463	0.702	rs73230564	chr3:142409393	T/C	cg20824294	chr3:142316082	PLS1	0.39	5.46	0.33	1.18e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	8.01	0.45	4.49e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg20818283	chr2:191399100	TMEM194B	-0.51	-6.54	-0.38	3.52e-10	Pulse pressure;
KIRP	cis	rs8084125	0.832	rs62105168	chr18:74944848	T/C	cg18461021	chr18:74961002	GALR1	0.52	5.3	0.32	2.59e-7	Obesity-related traits;
KIRP	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-11.73	-0.6	1.61e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.5	6.91	0.4	4.16e-11	Red blood cell count;
KIRP	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	6.48	0.38	5.04e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.37	-0.32	1.78e-7	Life satisfaction;
KIRP	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	1.12	21.43	0.81	3.36e-58	Monocyte count;
KIRP	cis	rs7828089	1.000	rs7828089	chr8:22264334	T/G	cg13512537	chr8:22265999	SLC39A14	-0.44	-6.01	-0.36	6.67e-9	Verbal declarative memory;
KIRP	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.69	8.25	0.47	9.79e-15	Cocaine dependence;
KIRP	cis	rs4692589	1.000	rs4321597	chr4:170934424	C/T	cg19918862	chr4:170955249	NA	0.42	5.11	0.31	6.49e-7	Anxiety disorder;
KIRP	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.6	-9.27	-0.51	1.01e-17	Coronary artery disease;
KIRP	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.53	-0.38	3.66e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06782748	chr10:35416372	CREM	0.45	6.15	0.37	3.19e-9	Survival in pancreatic cancer;
KIRP	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg12615879	chr12:58013172	SLC26A10	0.47	7.4	0.43	2.12e-12	Multiple sclerosis;
KIRP	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.77e-17	Corneal astigmatism;
KIRP	cis	rs12135191	0.771	rs7540548	chr1:236498406	G/A	cg21399712	chr1:236511386	NA	-0.48	-6.16	-0.37	2.98e-9	Urate levels (BMI interaction);
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.75	-11.24	-0.58	6.33e-24	Prostate cancer;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg14221460	chr8:27183342	PTK2B	0.54	7.08	0.41	1.54e-11	Neuroticism;
KIRP	cis	rs13064411	0.518	rs1471884	chr3:113212041	G/A	cg18753928	chr3:113234510	CCDC52	-0.49	-6.26	-0.37	1.72e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26376749	chr17:30677620	ZNF207	0.61	7.24	0.42	5.65e-12	Smoking initiation;
KIRP	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg25547332	chr5:131281432	NA	-0.47	-5.26	-0.32	3.15e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.64	-8.18	-0.46	1.53e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg14345882	chr6:26364793	BTN3A2	-0.55	-5.05	-0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7011049	0.778	rs6994249	chr8:53866215	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.63	-8.72	-0.49	4.34e-16	Autism;
KIRP	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.48	6.87	0.4	5.28e-11	Sitting height ratio;
KIRP	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.57	-8.08	-0.46	2.95e-14	Testicular germ cell tumor;
KIRP	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.81	11.25	0.58	5.76e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg12861170	chr19:19639553	YJEFN3	0.48	4.9	0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.71	-8.26	-0.47	8.82e-15	Menarche (age at onset);
KIRP	cis	rs4356932	0.967	rs4432767	chr4:76981312	A/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.71	11.1	0.58	1.75e-23	Resting heart rate;
KIRP	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.88	-7.0	-0.41	2.41e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.61	6.99	0.41	2.51e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10137155	chr3:67049254	KBTBD8	-0.45	-6.15	-0.37	3.03e-9	Survival in pancreatic cancer;
KIRP	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.45	-5.35	-0.32	1.99e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg06223162	chr1:101003688	GPR88	-0.42	-8.64	-0.48	7.19e-16	Monocyte count;
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.88	15.23	0.7	2.5e-37	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.66	0.39	1.75e-10	Height;
KIRP	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1971762	1.000	rs10876481	chr12:54066743	T/C	cg16917193	chr12:54089295	NA	0.68	9.08	0.5	3.77e-17	Height;
KIRP	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.83	-11.65	-0.6	2.81e-25	Height;
KIRP	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.76	-0.34	2.51e-8	Breast cancer;
KIRP	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-6.92	-0.4	3.91e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg25182066	chr10:30743637	MAP3K8	-0.63	-7.98	-0.45	5.51e-14	Inflammatory bowel disease;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg21843114	chr4:26334859	RBPJ	0.43	6.84	0.4	6.13e-11	Serum protein levels (sST2);
KIRP	cis	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg08798685	chr6:27730294	NA	-0.55	-4.86	-0.3	2.08e-6	Lung cancer in ever smokers;
KIRP	cis	rs10737909	0.728	rs1780588	chr1:15554229	T/G	cg21012057	chr1:15538911	TMEM51	-0.52	-6.8	-0.4	7.98e-11	Migraine;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02267838	chr4:26862852	STIM2	-0.5	-6.37	-0.38	9.19e-10	Myopia;
KIRP	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.67e-19	Gut microbiome composition (summer);
KIRP	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs7188697	0.922	rs4471670	chr16:58601365	G/A	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21643547	chr1:205240462	TMCC2	-0.82	-12.74	-0.63	6.83e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7224685	0.530	rs7221574	chr17:4007543	T/C	cg09597638	chr17:3907349	NA	0.52	5.22	0.32	3.81e-7	Type 2 diabetes;
KIRP	cis	rs4780355	0.776	rs9936459	chr16:11437779	C/T	cg00044050	chr16:11439710	C16orf75	-0.53	-6.36	-0.38	9.99e-10	Crohn's disease and psoriasis;
KIRP	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg24315340	chr6:146058215	EPM2A	-0.39	-4.85	-0.3	2.23e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg06871246	chr4:1363661	KIAA1530	-0.56	-6.93	-0.4	3.6e-11	Longevity;
KIRP	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.21e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.57e-10	Colorectal cancer;
KIRP	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.62	8.24	0.47	1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	9.6	0.52	9.46e-19	Schizophrenia;
KIRP	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.78	11.37	0.59	2.42e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17123764	1.000	rs75278574	chr12:50000945	C/T	cg20471783	chr12:50157085	TMBIM6	0.42	5.64	0.34	4.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg10402321	chr1:26617780	UBXN11	-0.42	-5.55	-0.33	7.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.44	5.75	0.34	2.7e-8	Hypertriglyceridemia;
KIRP	cis	rs7317038	1.000	rs7317038	chr13:114012898	C/T	cg18412546	chr13:114005154	GRTP1	-0.37	-5.72	-0.34	3.03e-8	Mean platelet volume;
KIRP	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.2	-0.31	4.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7721647	0.853	rs10043890	chr5:90867639	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg24503407	chr1:205819492	PM20D1	0.51	5.4	0.33	1.57e-7	Parkinson's disease;
KIRP	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg21775007	chr8:11205619	TDH	-0.41	-5.43	-0.33	1.35e-7	Neuroticism;
KIRP	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15320075	chr8:145703422	NA	-0.62	-8.28	-0.47	7.84e-15	Age at first birth;
KIRP	cis	rs9398803	0.865	rs9398810	chr6:126815604	C/A	cg19875578	chr6:126661172	C6orf173	0.49	6.37	0.38	9.29e-10	Male-pattern baldness;
KIRP	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg13798912	chr7:905769	UNC84A	0.54	5.48	0.33	1.05e-7	Cerebrospinal P-tau181p levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15432938	chr10:99078812	FRAT1	0.57	6.69	0.39	1.45e-10	Smoking initiation;
KIRP	cis	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg21546286	chr11:48923668	NA	-0.48	-6.12	-0.36	3.64e-9	HDL cholesterol;
KIRP	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs16976116	0.643	rs12440420	chr15:55517432	C/T	cg11288833	chr15:55489084	RSL24D1	-0.47	-5.44	-0.33	1.31e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg08901578	chr4:187885870	NA	0.5	7.43	0.43	1.84e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9815354	1.000	rs7616844	chr3:41874343	A/G	cg03022575	chr3:42003672	ULK4	0.52	6.05	0.36	5.38e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg14456004	chr13:21872349	NA	-1.11	-13.86	-0.66	1.12e-32	White matter hyperintensity burden;
KIRP	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.3	-0.47	7.1e-15	Myopia (pathological);
KIRP	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg19847130	chr8:10466454	RP1L1	0.37	5.57	0.33	6.68e-8	Neuroticism;
KIRP	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg04369109	chr6:150039330	LATS1	-0.64	-7.63	-0.44	5.03e-13	Lung cancer;
KIRP	cis	rs397969	0.646	rs203478	chr17:19829842	G/C	cg04132472	chr17:19861366	AKAP10	0.58	6.99	0.41	2.59e-11	Platelet count;
KIRP	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg07689907	chr11:61582574	FADS1	0.6	7.14	0.41	1.08e-11	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	7.84	0.45	1.33e-13	Bipolar disorder;
KIRP	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.76	-8.47	-0.48	2.22e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg13978929	chr19:21580086	ZNF493	0.49	4.99	0.3	1.17e-6	Pain;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18986451	chr3:100428869	TFG	0.74	6.5	0.38	4.5e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-1.02	-17.32	-0.74	1.81e-44	Height;
KIRP	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg24375607	chr4:120327624	NA	0.49	5.72	0.34	3.11e-8	Corneal astigmatism;
KIRP	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.52	7.47	0.43	1.41e-12	Night sleep phenotypes;
KIRP	cis	rs2290419	0.730	rs116683298	chr11:68943571	G/A	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg10223061	chr2:219282414	VIL1	-0.37	-6.09	-0.36	4.34e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4919044	1.000	rs10509649	chr10:94768166	A/T	cg05127821	chr10:94822908	CYP26C1	-0.87	-5.87	-0.35	1.39e-8	Coronary artery disease;
KIRP	cis	rs9826463	0.757	rs2229032	chr3:142178144	A/G	cg20824294	chr3:142316082	PLS1	-0.39	-6.24	-0.37	1.86e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2594989	0.887	rs7643330	chr3:11442093	A/G	cg01796438	chr3:11312864	ATG7	-0.58	-7.47	-0.43	1.41e-12	Circulating chemerin levels;
KIRP	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg27124370	chr19:33622961	WDR88	0.61	7.43	0.43	1.75e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	6.61	0.39	2.4e-10	Systemic lupus erythematosus;
KIRP	trans	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.98e-12	Bladder cancer;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg26876637	chr1:152193138	HRNR	-0.78	-8.7	-0.49	4.86e-16	Atopic dermatitis;
KIRP	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.39	9.74	0.53	3.49e-19	Corneal astigmatism;
KIRP	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg21775007	chr8:11205619	TDH	0.45	5.73	0.34	2.9e-8	Monocyte count;
KIRP	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg08648136	chr8:956695	NA	-0.41	-5.9	-0.35	1.19e-8	Schizophrenia;
KIRP	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg06521852	chr22:38141419	TRIOBP	-0.42	-5.88	-0.35	1.36e-8	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.65	8.02	0.46	4.28e-14	Aortic root size;
KIRP	cis	rs4925386	0.808	rs1741634	chr20:60925979	A/C	cg24112000	chr20:60950667	NA	0.6	9.01	0.5	6.08e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.78	-10.56	-0.56	9.4e-22	Aortic root size;
KIRP	cis	rs3931020	0.657	rs277376	chr1:75242246	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.49	-5.7	-0.34	3.42e-8	Resistin levels;
KIRP	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg14972814	chr11:95582409	MTMR2	0.35	5.69	0.34	3.64e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.61	8.68	0.48	5.56e-16	Colorectal cancer;
KIRP	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.89	-8.72	-0.49	4.2e-16	Monocyte percentage of white cells;
KIRP	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg19116668	chr7:99932089	PMS2L1	-0.54	-6.17	-0.37	2.84e-9	Coronary artery disease;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg10884052	chr2:135475971	TMEM163	-0.45	-6.3	-0.37	1.35e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.59	7.3	0.42	3.93e-12	Blood metabolite levels;
KIRP	cis	rs829661	0.793	rs2602786	chr2:30870429	T/C	cg10949345	chr2:30726833	LCLAT1	1.08	13.23	0.64	1.55e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs4253772	0.938	rs41329344	chr22:46636930	C/T	cg18190219	chr22:46762943	CELSR1	-0.7	-5.94	-0.35	9.52e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg12257156	chr7:158823799	VIPR2	0.33	4.85	0.3	2.2e-6	Facial morphology (factor 20);
KIRP	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.49	6.81	0.4	7.35e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg14683738	chr19:37701593	ZNF585B	0.48	4.99	0.3	1.14e-6	Coronary artery calcification;
KIRP	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg26061582	chr7:22766209	IL6	0.41	5.12	0.31	6.24e-7	Lung cancer;
KIRP	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg04080417	chr5:1859792	NA	-0.63	-8.16	-0.46	1.77e-14	Cardiovascular disease risk factors;
KIRP	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.8	0.4	7.72e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs72960926	0.744	rs11759133	chr6:74932518	A/G	cg03266952	chr6:74778945	NA	-0.6	-5.12	-0.31	6.2e-7	Metabolite levels (MHPG);
KIRP	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.65	9.68	0.53	5.48e-19	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg02297831	chr4:17616191	MED28	0.52	6.52	0.38	4.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6782228	0.675	rs9841987	chr3:128385142	G/T	cg18648031	chr3:128330563	NA	0.27	5.49	0.33	9.91e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg09695851	chr17:3907499	NA	-0.82	-15.0	-0.69	1.42e-36	Type 2 diabetes;
KIRP	cis	rs4789452	1.000	rs35971812	chr17:75373362	C/A	cg02320862	chr17:75370284	SEPT9	-0.39	-5.27	-0.32	2.99e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.66	9.03	0.5	5.01e-17	Mean corpuscular volume;
KIRP	cis	rs997295	0.868	rs3784699	chr15:68007591	T/C	cg14210607	chr15:68128175	NA	-0.31	-5.06	-0.31	8.37e-7	Motion sickness;
KIRP	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg01864069	chr14:103024347	NA	0.87	10.16	0.54	1.81e-20	Platelet count;
KIRP	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg02297831	chr4:17616191	MED28	0.55	6.9	0.4	4.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7010267	0.773	rs13439134	chr8:119918868	G/C	cg01975934	chr8:119970761	NA	0.41	5.25	0.32	3.25e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs11166927	1.000	rs11166927	chr8:140796420	T/C	cg16909799	chr8:140841666	TRAPPC9	0.69	9.9	0.53	1.18e-19	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.82	11.91	0.6	3.85e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.61	-6.53	-0.38	3.82e-10	Vitiligo;
KIRP	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.19e-9	Body mass index;
KIRP	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.39	-5.08	-0.31	7.47e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.75e-7	Coronary artery disease;
KIRP	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg00343986	chr7:65444356	GUSB	0.49	5.91	0.35	1.13e-8	Aortic root size;
KIRP	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.39e-10	Diabetic retinopathy;
KIRP	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.59	-0.34	5.99e-8	Height;
KIRP	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg18441811	chr11:71824068	C11orf51	-0.77	-5.13	-0.31	5.88e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-5.08	-0.31	7.5e-7	Axial length;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.75	-10.89	-0.57	8.69e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2904967	0.929	rs3016001	chr11:65008771	G/A	cg12562828	chr11:65076843	NA	-0.48	-7.17	-0.42	8.95e-12	Mean corpuscular volume;
KIRP	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.53	-0.38	3.82e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs10140922	0.966	rs10140133	chr14:35819834	C/G	cg07166546	chr14:35805898	NA	-0.25	-5.98	-0.36	8.01e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg14593290	chr7:50529359	DDC	-0.8	-10.11	-0.54	2.51e-20	Malaria;
KIRP	cis	rs12580194	0.593	rs12581916	chr12:55764409	A/C	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.7	10.17	0.54	1.64e-20	Blood metabolite levels;
KIRP	cis	rs7809950	0.954	rs2712229	chr7:107295326	T/A	cg23024343	chr7:107201750	COG5	0.43	6.56	0.39	3.07e-10	Coronary artery disease;
KIRP	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg06212747	chr3:49208901	KLHDC8B	0.49	5.62	0.34	5.2e-8	Resting heart rate;
KIRP	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.96	15.14	0.69	4.97e-37	Systemic lupus erythematosus;
KIRP	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg15445000	chr17:37608096	MED1	0.48	5.65	0.34	4.41e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.3e-10	Blood metabolite levels;
KIRP	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.47	0.33	1.12e-7	Tonsillectomy;
KIRP	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.82	0.35	1.84e-8	Total cholesterol levels;
KIRP	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.78	11.58	0.59	4.77e-25	Heart rate;
KIRP	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg00495681	chr13:53174319	NA	0.38	5.05	0.31	8.42e-7	Lewy body disease;
KIRP	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.42	-5.36	-0.32	1.91e-7	Blood metabolite levels;
KIRP	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.57	-0.39	2.95e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-0.93	-8.33	-0.47	5.64e-15	Lung cancer;
KIRP	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-1.07	-19.46	-0.78	1.11e-51	Height;
KIRP	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2391754	0.695	rs17686617	chr7:29346518	C/T	cg00901138	chr7:29329370	CHN2	-0.39	-4.95	-0.3	1.36e-6	CSF tryptophan concentration in tuberculous meningitis;
KIRP	trans	rs9841504	1.000	rs73857635	chr3:114356783	T/C	cg24348448	chr19:55493930	NLRP2	-0.76	-6.09	-0.36	4.24e-9	Gastric cancer;
KIRP	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg08890418	chr1:21044141	KIF17	-0.4	-6.06	-0.36	5.1e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.47	-0.38	5.37e-10	Coronary artery disease;
KIRP	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.6	-0.59	4.29e-25	Caffeine consumption;
KIRP	cis	rs2742417	1.000	rs2673038	chr3:45748632	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.5	-6.46	-0.38	5.41e-10	Testicular germ cell tumor;
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg07402062	chr16:89894098	SPIRE2	-0.33	-6.91	-0.4	4.16e-11	Vitiligo;
KIRP	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9364220	0.623	rs6940507	chr6:168493719	T/C	cg09211372	chr6:168490623	NA	0.28	4.85	0.3	2.23e-6	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg05941025	chr16:89927596	SPIRE2	0.34	5.34	0.32	2.11e-7	Vitiligo;
KIRP	cis	rs11718455	0.591	rs6765212	chr3:43931484	C/T	cg21419209	chr3:44054225	NA	-0.55	-6.54	-0.39	3.45e-10	Coronary artery disease;
KIRP	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg22800045	chr5:56110881	MAP3K1	-0.75	-7.35	-0.42	2.98e-12	Initial pursuit acceleration;
KIRP	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	6.15	0.36	3.16e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.71	9.78	0.53	2.73e-19	Mean corpuscular volume;
KIRP	cis	rs72772090	0.539	rs11742261	chr5:96167608	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.7	-5.98	-0.36	7.85e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.68	-8.39	-0.47	3.9e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1209950	0.866	rs1734587	chr21:40180884	A/G	cg02119577	chr21:40195074	ETS2	-0.35	-5.25	-0.32	3.22e-7	Non-small cell lung cancer (survival);
KIRP	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-6.53	-0.38	3.8e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.01	-0.45	4.51e-14	Monocyte percentage of white cells;
KIRP	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.66	8.15	0.46	1.86e-14	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.16e-7	Life satisfaction;
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.75	-9.41	-0.51	3.77e-18	Longevity;Endometriosis;
KIRP	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.24	-0.37	1.9e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg10189774	chr4:17578691	LAP3	0.49	5.95	0.35	9.25e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg17736920	chr1:242011382	EXO1	0.47	5.75	0.34	2.68e-8	Menopause (age at onset);
KIRP	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg02375832	chr11:62437615	C11orf48	-0.44	-5.61	-0.34	5.56e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.67	10.21	0.55	1.24e-20	Retinal vascular caliber;
KIRP	cis	rs6102059	0.525	rs6093367	chr20:39193406	C/T	cg22477343	chr20:39312069	NA	-0.44	-5.69	-0.34	3.53e-8	LDL cholesterol;
KIRP	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg26205652	chr12:48591994	NA	0.46	5.33	0.32	2.23e-7	Lung cancer;
KIRP	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.59	6.47	0.38	5.3e-10	Subjective well-being;
KIRP	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg01620082	chr3:125678407	NA	-1.02	-6.59	-0.39	2.65e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg24375607	chr4:120327624	NA	0.48	5.67	0.34	3.96e-8	Corneal astigmatism;
KIRP	cis	rs6681460	0.604	rs11208920	chr1:67075312	C/A	cg13052034	chr1:66999238	SGIP1	0.37	5.13	0.31	5.74e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg23602478	chr1:26503979	CNKSR1	-0.43	-6.28	-0.37	1.54e-9	Height;
KIRP	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.82	-14.45	-0.68	1.15e-34	Post bronchodilator FEV1;
KIRP	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg16497661	chr14:103986332	CKB	0.51	7.11	0.41	1.27e-11	Body mass index;
KIRP	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.6	7.69	0.44	3.56e-13	Resting heart rate;
KIRP	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg06521331	chr12:34319734	NA	-0.61	-7.36	-0.42	2.74e-12	Morning vs. evening chronotype;
KIRP	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg13147721	chr7:65941812	NA	-1.08	-7.64	-0.44	4.82e-13	Diabetic kidney disease;
KIRP	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	6.04	0.36	5.55e-9	Response to antipsychotic treatment;
KIRP	cis	rs9398803	0.865	rs1490388	chr6:126835655	C/T	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.15e-10	Male-pattern baldness;
KIRP	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg04990556	chr1:26633338	UBXN11	0.66	6.19	0.37	2.48e-9	Obesity-related traits;
KIRP	cis	rs7582720	0.945	rs72932707	chr2:203639395	T/C	cg08076091	chr2:203926405	NBEAL1	0.83	8.27	0.47	8.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs62413470	0.938	rs12207719	chr6:55931228	G/A	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02761497	chr5:6712440	NA	-0.48	-6.24	-0.37	1.87e-9	Myopia;
KIRP	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg10434728	chr15:90938212	IQGAP1	-0.37	-6.94	-0.4	3.44e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.97	-0.45	5.87e-14	Gut microbiome composition (summer);
KIRP	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.43	-6.28	-0.37	1.5e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs34779708	0.931	rs12261654	chr10:35322024	G/A	cg04310649	chr10:35416472	CREM	-0.59	-7.14	-0.41	1.06e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06156847	chr2:113672199	IL1F7	0.42	5.45	0.33	1.22e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg08989290	chr16:615782	NHLRC4	0.42	6.11	0.36	3.88e-9	Height;
KIRP	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg00677455	chr12:58241039	CTDSP2	-0.63	-7.33	-0.42	3.31e-12	Multiple sclerosis;
KIRP	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.5	7.37	0.43	2.54e-12	Schizophrenia;
KIRP	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg02725872	chr8:58115012	NA	-0.53	-6.0	-0.36	6.84e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6973256	0.897	rs4728296	chr7:133344566	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.46	-0.38	5.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2191566	1.000	rs10418363	chr19:44525463	A/G	cg20607764	chr19:44506953	ZNF230	-0.42	-4.97	-0.3	1.27e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.97	11.35	0.59	2.71e-24	Corneal astigmatism;
KIRP	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-16.23	-0.72	9.17e-41	Height;
KIRP	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17691542	chr6:26056736	HIST1H1C	0.78	8.32	0.47	6.04e-15	Iron status biomarkers;
KIRP	cis	rs624899	0.655	rs73514607	chr19:11632207	G/A	cg20127191	chr19:12306497	NA	-0.69	-5.05	-0.31	8.79e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05347473	chr6:146136440	FBXO30	0.49	7.05	0.41	1.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.12	13.78	0.66	2.13e-32	Gut microbiome composition (summer);
KIRP	cis	rs7809615	0.901	rs11973801	chr7:99102911	A/G	cg12290671	chr7:99195819	NA	-0.76	-7.04	-0.41	1.91e-11	Blood metabolite ratios;
KIRP	cis	rs981844	1.000	rs2606337	chr4:154656845	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs6450176	1.000	rs59061738	chr5:53296557	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.33	-0.59	3.2e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.9	13.11	0.64	3.81e-30	Diastolic blood pressure;Systolic blood pressure;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg24714147	chr19:14629240	DNAJB1	-0.52	-6.66	-0.39	1.78e-10	Myopia;
KIRP	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg25706552	chr1:244017396	NA	0.55	6.69	0.39	1.51e-10	RR interval (heart rate);
KIRP	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.62	9.43	0.52	3.25e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.92	10.5	0.56	1.46e-21	Triglycerides;
KIRP	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.44	-10.43	-0.55	2.49e-21	Diastolic blood pressure;
KIRP	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.52	-7.81	-0.45	1.61e-13	Coronary artery disease;
KIRP	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-5.4	-0.33	1.55e-7	Vitiligo;
KIRP	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06481639	chr22:41940642	POLR3H	0.65	7.14	0.41	1.04e-11	Vitiligo;
KIRP	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg12384639	chr17:618140	VPS53	0.49	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	cg21523751	chr1:182988639	NA	0.41	6.31	0.37	1.31e-9	Colorectal cancer;
KIRP	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.37	-0.32	1.8e-7	Schizophrenia;
KIRP	cis	rs28489187	0.706	rs72724606	chr1:85850246	T/C	cg16011679	chr1:85725395	C1orf52	0.5	6.16	0.37	2.87e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1971256	0.500	rs3912290	chr6:151818297	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	4.91	0.3	1.68e-6	Endometriosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14311108	chr9:139377450	C9orf163;SEC16A	0.52	6.9	0.4	4.39e-11	Parkinson's disease;
KIRP	cis	rs12431939	0.598	rs12437085	chr14:51728941	G/T	cg23942311	chr14:51606299	NA	0.43	5.05	0.31	8.76e-7	Cancer;
KIRP	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11987759	chr7:65425863	GUSB	0.43	5.08	0.31	7.44e-7	Aortic root size;
KIRP	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg09596252	chr17:78655493	RPTOR	0.53	6.07	0.36	4.86e-9	Fractional excretion of uric acid;
KIRP	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	1.17	10.23	0.55	1.06e-20	Skin colour saturation;
KIRP	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg25319279	chr11:5960081	NA	-0.59	-6.22	-0.37	2.1e-9	DNA methylation (variation);
KIRP	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10518128	1.000	rs1452311	chr4:75715017	C/T	cg20122727	chr4:75719957	BTC	0.6	6.0	0.36	7.03e-9	Electroencephalogram traits;
KIRP	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	11.26	0.58	5.32e-24	Menopause (age at onset);
KIRP	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg20003494	chr4:90757398	SNCA	-0.37	-4.9	-0.3	1.75e-6	Neuroticism;
KIRP	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg24315340	chr6:146058215	EPM2A	-0.47	-5.89	-0.35	1.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	10.01	0.54	5.11e-20	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg24315340	chr6:146058215	EPM2A	0.45	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-11.97	-0.61	2.55e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6977660	0.714	rs6959039	chr7:19818182	T/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01813649	chr6:116421855	NT5DC1	0.53	6.92	0.4	3.92e-11	Parkinson's disease;
KIRP	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg13319975	chr6:146136371	FBXO30	-0.43	-5.98	-0.36	7.76e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72829446	0.530	rs3853820	chr17:7396781	A/T	cg02795151	chr17:7402630	POLR2A	0.75	7.89	0.45	9.98e-14	Androgen levels;
KIRP	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.29	7.41	0.43	1.99e-12	Primary biliary cholangitis;
KIRP	cis	rs490234	0.812	rs7875713	chr9:128268903	G/T	cg14078157	chr9:128172775	NA	-0.44	-5.68	-0.34	3.76e-8	Mean arterial pressure;
KIRP	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg13010199	chr12:38710504	ALG10B	0.69	8.88	0.49	1.45e-16	Morning vs. evening chronotype;
KIRP	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.81	8.15	0.46	1.8e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs9398803	0.830	rs4053271	chr6:126830512	T/C	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.15e-10	Male-pattern baldness;
KIRP	cis	rs2224391	0.628	rs2753238	chr6:5252795	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.59	-0.39	2.58e-10	Height;
KIRP	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.57	7.45	0.43	1.59e-12	Height;
KIRP	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg05895507	chr15:77155635	SCAPER	0.31	5.62	0.34	5.06e-8	Blood metabolite levels;
KIRP	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Smoking initiation;
KIRP	cis	rs4656940	0.574	rs3856334	chr1:160778982	C/T	cg17331569	chr1:160788135	LY9	-0.48	-5.94	-0.35	9.73e-9	Crohn's disease;
KIRP	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg15247329	chr7:2764246	NA	-0.42	-5.99	-0.36	7.55e-9	Height;
KIRP	cis	rs3857067	1.000	rs899133	chr4:95019609	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.02	-0.3	9.95e-7	QT interval;
KIRP	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.6	-7.65	-0.44	4.61e-13	Vitiligo;
KIRP	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.72	0.39	1.23e-10	Aortic root size;
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs3736485	0.932	rs2278988	chr15:51915234	A/C	cg14296394	chr15:51910925	DMXL2	-0.34	-5.16	-0.31	5.12e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.74	10.38	0.55	3.54e-21	Diastolic blood pressure;
KIRP	trans	rs7692299	0.636	rs72929781	chr4:124670568	T/G	cg21282663	chr1:221053904	HLX	0.55	6.12	0.36	3.61e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	0.79	8.8	0.49	2.46e-16	Left atrial antero-posterior diameter;
KIRP	cis	rs17123764	0.892	rs74903123	chr12:50113129	C/G	cg20471783	chr12:50157085	TMBIM6	0.4	5.31	0.32	2.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	0.94	12.37	0.62	1.17e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19717773	chr7:2847554	GNA12	-0.41	-6.01	-0.36	6.53e-9	Height;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11653675	chr2:46811648	RHOQ;PIGF	0.38	6.23	0.37	2e-9	Migraine with aura;
KIRP	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.65	7.03	0.41	2.07e-11	Gut microbiome composition (summer);
KIRP	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.53	-0.43	9.82e-13	Height;
KIRP	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg04362960	chr10:104952993	NT5C2	0.44	5.52	0.33	8.56e-8	Waist circumference;Hip circumference;
KIRP	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.24	-0.42	5.84e-12	Morning vs. evening chronotype;
KIRP	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	1.12	8.94	0.5	9.36e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.63	-10.72	-0.56	3.02e-22	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.68	9.53	0.52	1.6e-18	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	4.91	0.3	1.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg23594656	chr7:65796392	TPST1	-0.52	-8.09	-0.46	2.71e-14	Aortic root size;
KIRP	cis	rs1417569	0.517	rs2994627	chr10:31200884	C/T	cg00428179	chr10:31322131	ZNF438	-0.37	-5.57	-0.33	6.77e-8	Tuberculosis;
KIRP	cis	rs4006360	0.657	rs12939793	chr17:39233537	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.59	-8.17	-0.46	1.58e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg07870213	chr5:140052090	DND1	0.67	8.72	0.49	4.37e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-6.13	-0.36	3.44e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg01448562	chr3:133502909	NA	-0.49	-5.91	-0.35	1.16e-8	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21824413	chr3:23987438	NR1D2	0.51	6.56	0.39	3.21e-10	Parkinson's disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg07775675	chr17:74379922	SPHK1	0.66	6.15	0.37	3.13e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09614580	chr10:5682262	ASB13	0.5	6.07	0.36	4.73e-9	Interleukin-4 levels;
KIRP	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg15655495	chr12:38532458	NA	-0.25	-4.92	-0.3	1.6e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.66	-9.1	-0.5	3.1e-17	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg08499158	chr17:42289980	UBTF	-0.74	-9.91	-0.53	1.08e-19	Total body bone mineral density;
KIRP	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11987759	chr7:65425863	GUSB	0.47	6.04	0.36	5.68e-9	Aortic root size;
KIRP	cis	rs2916247	0.954	rs13252280	chr8:93088151	C/T	cg10183463	chr8:93005414	RUNX1T1	0.52	6.85	0.4	5.95e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.9	-15.67	-0.71	7.48e-39	Menarche (age at onset);
KIRP	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.69	-0.34	3.64e-8	Breast cancer;Mosquito bite size;
KIRP	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.75	10.4	0.55	3.14e-21	Metabolic syndrome;
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.51	5.35	0.32	2.03e-7	Lung function (FEV1/FVC);
KIRP	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-1.08	-12.5	-0.62	4.31e-28	Educational attainment;
KIRP	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.4	-6.03	-0.36	5.98e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg05784532	chr1:230284198	GALNT2	0.51	7.16	0.42	9.36e-12	Coronary artery disease;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg09699651	chr6:150184138	LRP11	0.51	6.77	0.4	9.49e-11	Lung cancer;
KIRP	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg03342759	chr3:160939853	NMD3	0.48	5.8	0.35	2.01e-8	Morning vs. evening chronotype;
KIRP	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-5.36	-0.32	1.89e-7	Ovarian reserve;
KIRP	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg04990556	chr1:26633338	UBXN11	0.64	6.14	0.36	3.33e-9	Obesity-related traits;
KIRP	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg03388025	chr16:89894329	SPIRE2	-0.33	-6.23	-0.37	1.99e-9	Vitiligo;
KIRP	cis	rs2463822	0.583	rs72917379	chr11:62026112	T/C	cg06239285	chr11:62104954	ASRGL1	-0.89	-6.7	-0.39	1.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24700222	chr1:86622682	COL24A1	-0.41	-6.26	-0.37	1.66e-9	Interleukin-4 levels;
KIRP	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.43	-5.17	-0.31	4.9e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg12257156	chr7:158823799	VIPR2	0.34	4.94	0.3	1.48e-6	Facial morphology (factor 20);
KIRP	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	0.96	14.57	0.68	4.2e-35	Eosinophil percentage of white cells;
KIRP	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.42	5.81	0.35	1.95e-8	Endometrial cancer;
KIRP	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs587242	1.000	rs509588	chr1:96891552	G/C	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	4.93e-11	Blood metabolite levels;
KIRP	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-0.72	-6.35	-0.38	1.01e-9	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs740698	0.522	rs1024653	chr17:60791818	A/C	cg00648184	chr17:60828157	MARCH10	-0.3	-5.06	-0.31	8.05e-7	Pulse pressure;
KIRP	cis	rs4671458	0.656	rs72821631	chr2:63700164	G/A	cg17519650	chr2:63277830	OTX1	-0.49	-4.97	-0.3	1.25e-6	Subjective well-being;
KIRP	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.84	12.5	0.62	4.48e-28	Mean corpuscular volume;
KIRP	cis	rs77505915	0.512	rs12921808	chr16:75383984	T/C	cg03315344	chr16:75512273	CHST6	-0.4	-4.93	-0.3	1.49e-6	Migraine;
KIRP	cis	rs4722166	0.599	rs7776857	chr7:22754768	G/T	cg05472934	chr7:22766657	IL6	0.74	8.22	0.46	1.14e-14	Lung cancer;
KIRP	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.29	-4.85	-0.3	2.16e-6	Monocyte count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00120358	chr1:100615552	LRRC39;CCDC76	-0.46	-7.09	-0.41	1.41e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24685071	chr2:27592886	EIF2B4;SNX17	0.52	6.63	0.39	2.09e-10	Parkinson's disease;
KIRP	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg09549813	chr16:4587862	C16orf5	-0.32	-4.86	-0.3	2.07e-6	Schizophrenia;
KIRP	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg03647239	chr10:116582469	FAM160B1	0.52	5.95	0.35	9.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg20936604	chr3:58311152	NA	-0.7	-5.81	-0.35	1.93e-8	Cholesterol, total;
KIRP	cis	rs4690686	0.509	rs13147303	chr4:177256126	G/A	cg17059388	chr4:177262070	NA	0.77	8.21	0.46	1.25e-14	Essential tremor;
KIRP	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.9	-10.89	-0.57	8.71e-23	Type 2 diabetes;
KIRP	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg15848620	chr12:58087721	OS9	-0.47	-5.43	-0.33	1.38e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.84	-11.61	-0.59	3.98e-25	Autism;
KIRP	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.81	-10.33	-0.55	5.3e-21	Systolic blood pressure;
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg00689492	chr4:1303491	MAEA	0.31	5.69	0.34	3.61e-8	Longevity;
KIRP	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.46	6.73	0.39	1.19e-10	Urate levels in lean individuals;
KIRP	cis	rs3857747	0.578	rs4598149	chr7:40379073	A/G	cg00420559	chr7:40367873	C7orf10	-0.45	-6.41	-0.38	7.23e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg23625390	chr15:77176239	SCAPER	0.52	6.91	0.4	4.12e-11	Blood metabolite levels;
KIRP	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01962937	chr10:124221066	HTRA1	0.5	6.53	0.38	3.79e-10	Myopia (pathological);
KIRP	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.44	-4.89	-0.3	1.86e-6	White matter hyperintensity burden;
KIRP	cis	rs4262150	0.883	rs72801026	chr5:152203902	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.1	-0.46	2.64e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15773090	chr12:42632129	YAF2	-0.57	-6.17	-0.37	2.78e-9	Menopause (age at onset);
KIRP	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.63	8.95	0.5	8.99e-17	Schizophrenia;
KIRP	cis	rs12208915	0.945	rs12201183	chr6:79570120	A/G	cg18132916	chr6:79620363	NA	0.56	4.99	0.3	1.15e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg05220968	chr6:146057943	EPM2A	0.41	5.18	0.31	4.55e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.42	-7.63	-0.44	5.17e-13	Refractive error;
KIRP	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.42	5.48	0.33	1.04e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.24e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg19913688	chr11:428466	ANO9	-0.76	-6.1	-0.36	4.09e-9	Body mass index;
KIRP	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.75	8.33	0.47	5.85e-15	Cholesterol, total;
KIRP	cis	rs804280	0.535	rs10435719	chr8:11776904	C/T	cg00262122	chr8:11665843	FDFT1	0.44	5.42	0.33	1.41e-7	Myopia (pathological);
KIRP	cis	rs6973256	0.897	rs2430769	chr7:133349149	A/G	cg10665199	chr7:133106180	EXOC4	0.49	6.21	0.37	2.24e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg01872077	chr2:219646372	CYP27A1	-0.38	-4.85	-0.3	2.2e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg05347473	chr6:146136440	FBXO30	0.56	8.26	0.47	8.88e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg10664184	chr19:17420304	DDA1	0.79	9.03	0.5	5e-17	Systemic lupus erythematosus;
KIRP	cis	rs1883415	0.534	rs2817208	chr6:24481373	T/A	cg20631270	chr6:24437470	GPLD1	0.4	5.08	0.31	7.3e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2594989	0.887	rs2443717	chr3:11521493	T/C	cg01796438	chr3:11312864	ATG7	-0.63	-7.68	-0.44	3.83e-13	Circulating chemerin levels;
KIRP	cis	rs7221595	0.877	rs35321558	chr17:3892909	G/A	cg09597638	chr17:3907349	NA	0.56	5.86	0.35	1.5e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-7.76	-0.44	2.31e-13	Lung cancer;
KIRP	cis	rs12580194	0.593	rs61957899	chr12:55731971	C/T	cg11794356	chr12:55725991	OR6C3	-0.62	-8.87	-0.49	1.49e-16	Cancer;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	8.89e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.74	-9.05	-0.5	4.33e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg23594656	chr7:65796392	TPST1	0.47	7.46	0.43	1.51e-12	Aortic root size;
KIRP	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg11150807	chr10:43354902	NA	-0.66	-7.27	-0.42	4.69e-12	Blood protein levels;
KIRP	cis	rs13361707	0.920	rs6873054	chr5:40719543	T/C	cg01087697	chr5:40835557	RPL37	-0.47	-5.37	-0.32	1.84e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2279817	0.865	rs35255680	chr1:17981184	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-8.41	-0.47	3.32e-15	Neuroticism;
KIRP	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg03929089	chr4:120376271	NA	-0.61	-6.3	-0.37	1.34e-9	Axial length;
KIRP	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg05043794	chr9:111880884	C9orf5	-0.27	-5.41	-0.33	1.53e-7	Menarche (age at onset);
KIRP	cis	rs7119038	0.865	rs11217044	chr11:118696022	T/C	cg19308663	chr11:118741387	NA	0.55	9.34	0.51	6.04e-18	Sjögren's syndrome;
KIRP	cis	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs9400271	0.632	rs6930844	chr6:109590286	C/A	cg21918786	chr6:109611834	NA	-0.36	-5.33	-0.32	2.23e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.84	-0.53	1.77e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg14517863	chr17:44321492	NA	0.49	5.62	0.34	5.24e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.58	-0.39	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg04660111	chr19:49199234	FUT2	0.33	4.91	0.3	1.66e-6	Dietary macronutrient intake;
KIRP	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.37	6.79	0.4	8.51e-11	Refractive error;
KIRP	cis	rs10426930	0.607	rs2613762	chr19:5064948	T/G	cg18473234	chr19:5097819	KDM4B	-0.59	-6.49	-0.38	4.65e-10	Monocyte percentage of white cells;
KIRP	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.45	5.22	0.32	3.79e-7	Schizophrenia;
KIRP	cis	rs2860975	0.666	rs1891073	chr10:96804911	G/A	cg09036531	chr10:96991505	NA	-0.48	-5.87	-0.35	1.4e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.5	0.43	1.17e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg06740227	chr12:86229804	RASSF9	0.49	6.3	0.37	1.38e-9	Major depressive disorder;
KIRP	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg17595323	chr11:93583763	C11orf90	-0.42	-7.04	-0.41	1.85e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg13819577	chr1:248512075	OR14C36	-0.37	-4.85	-0.3	2.17e-6	Common traits (Other);
KIRP	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg06121193	chr1:90282411	NA	-0.51	-7.36	-0.42	2.77e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02694990	chr2:197001634	STK17B	-0.39	-6.07	-0.36	4.77e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.55	6.34	0.37	1.09e-9	Bone mineral density (spine);
KIRP	cis	rs7127900	1.000	rs7109474	chr11:2233219	G/A	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg11859384	chr17:80120422	CCDC57	0.45	6.0	0.36	6.98e-9	Life satisfaction;
KIRP	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.74	10.16	0.54	1.75e-20	Multiple sclerosis;
KIRP	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.01	-0.3	1.05e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg04132472	chr17:19861366	AKAP10	-0.4	-5.13	-0.31	5.87e-7	Schizophrenia;
KIRP	cis	rs9398803	0.678	rs9372841	chr6:126898541	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.41	0.33	1.47e-7	Male-pattern baldness;
KIRP	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg26507422	chr16:88990409	CBFA2T3	-0.34	-4.93	-0.3	1.49e-6	Social autistic-like traits;
KIRP	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.67	9.14	0.5	2.37e-17	Neuroticism;
KIRP	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-13.22	-0.64	1.66e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg10017260	chr10:834428	NA	-0.49	-5.1	-0.31	6.74e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.81	13.9	0.66	8.61e-33	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2652822	0.555	rs77171305	chr15:63536230	C/A	cg02713581	chr15:63449717	RPS27L	0.53	5.8	0.35	2.04e-8	Metabolic traits;
KIRP	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg14952266	chr13:112191215	NA	0.46	6.67	0.39	1.69e-10	Hepatitis;
KIRP	cis	rs4363385	0.747	rs1413849	chr1:152970233	C/A	cg13444842	chr1:152974279	SPRR3	-0.36	-4.92	-0.3	1.6e-6	Inflammatory skin disease;
KIRP	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.32	-0.32	2.3e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs13102973	0.899	rs13104662	chr4:135904615	C/T	cg14419869	chr4:135874104	NA	0.48	7.5	0.43	1.13e-12	Subjective well-being;
KIRP	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg16586182	chr3:47516702	SCAP	-0.7	-9.37	-0.51	4.86e-18	Colorectal cancer;
KIRP	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg05220968	chr6:146057943	EPM2A	-0.38	-4.89	-0.3	1.85e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg18306943	chr3:40428807	ENTPD3	0.47	6.14	0.36	3.24e-9	Renal cell carcinoma;
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg05564831	chr3:52568323	NT5DC2	0.45	7.29	0.42	4.24e-12	Electroencephalogram traits;
KIRP	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.96	13.01	0.64	8.29e-30	Menopause (age at onset);
KIRP	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.78	6.54	0.38	3.58e-10	Fat distribution (HIV);
KIRP	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg05272587	chr13:111038400	COL4A2	-0.37	-5.51	-0.33	8.96e-8	White matter hyperintensity burden;
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-0.89	-13.79	-0.66	1.9e-32	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg19847130	chr8:10466454	RP1L1	0.34	5.09	0.31	7.09e-7	Neuroticism;
KIRP	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.08	-0.36	4.68e-9	Menarche (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06509661	chr1:234614745	TARBP1	0.47	6.71	0.39	1.36e-10	Survival in pancreatic cancer;
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg04080417	chr5:1859792	NA	-0.53	-6.37	-0.38	9.05e-10	Cardiovascular disease risk factors;
KIRP	cis	rs11877825	0.762	rs9676152	chr18:10571440	C/T	cg07277756	chr18:10589357	NA	0.51	6.17	0.37	2.84e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6707387	0.598	rs8179764	chr2:214332297	C/T	cg08319019	chr2:214017104	IKZF2	0.43	4.95	0.3	1.41e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs4430311	0.723	rs12735854	chr1:243748184	G/C	cg25706552	chr1:244017396	NA	-0.62	-10.71	-0.56	3.24e-22	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg00321850	chr1:175162397	KIAA0040	-0.31	-5.22	-0.32	3.87e-7	Alcohol dependence;
KIRP	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg16586182	chr3:47516702	SCAP	-0.63	-8.75	-0.49	3.37e-16	Colorectal cancer;
KIRP	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg09904177	chr6:26538194	HMGN4	-0.44	-5.82	-0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs4006360	0.543	rs937403	chr17:39296016	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.58	-7.56	-0.43	7.91e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.57	8.38	0.47	4.1e-15	Monocyte percentage of white cells;
KIRP	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-7.82	-0.45	1.58e-13	Colorectal cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20548564	chr13:28240073	POLR1D	0.49	6.38	0.38	8.66e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg23693289	chr8:27183097	PTK2B	0.56	7.06	0.41	1.65e-11	Neuroticism;
KIRP	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs362272	0.525	rs2798286	chr4:3046173	A/G	cg13731523	chr4:3047190	NA	-0.36	-7.07	-0.41	1.56e-11	Serum sulfate level;
KIRP	cis	rs9535307	0.719	rs1198319	chr13:50376858	T/C	cg04663916	chr13:50265991	EBPL	-0.56	-6.05	-0.36	5.39e-9	Obesity-related traits;
KIRP	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg25811766	chr13:21894605	NA	-0.63	-6.16	-0.37	2.95e-9	White matter hyperintensity burden;
KIRP	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	10.14	0.54	2.06e-20	Schizophrenia;
KIRP	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg08461772	chr7:95026248	PON3	0.41	5.85	0.35	1.53e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.96	0.5	8.26e-17	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs10129255	0.536	rs10139058	chr14:107141916	C/T	cg23076370	chr14:107095027	NA	-0.42	-5.37	-0.32	1.86e-7	Kawasaki disease;
KIRP	cis	rs17221829	0.627	rs12421880	chr11:89391713	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs9815354	1.000	rs1716987	chr3:41970516	A/G	cg03022575	chr3:42003672	ULK4	-0.57	-6.68	-0.39	1.6e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	8.4	0.47	3.6e-15	Total body bone mineral density;
KIRP	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg23307798	chr14:103986281	CKB	0.52	6.96	0.41	3.06e-11	Coronary artery disease;
KIRP	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.64	5.19	0.31	4.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4664293	0.867	rs3732289	chr2:160585398	G/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.92	0.3	1.59e-6	Renal cell carcinoma;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg02441831	chr11:64901569	SYVN1	0.56	7.0	0.41	2.39e-11	Myopia (pathological);
KIRP	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.35	-0.32	2.02e-7	Bipolar disorder;
KIRP	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.55	4.97	0.3	1.26e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg23108931	chr8:105342351	NA	-0.35	-4.91	-0.3	1.66e-6	Paget's disease;
KIRP	cis	rs6746896	0.683	rs6576983	chr2:97454650	T/G	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.45	-0.43	1.59e-12	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20208648	chr7:44163237	POLD2	0.48	6.64	0.39	1.98e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.57	7.69	0.44	3.48e-13	Testicular germ cell tumor;
KIRP	cis	rs559555	0.523	rs11124270	chr2:32003345	G/A	cg02381751	chr2:32503542	YIPF4	-0.52	-4.99	-0.3	1.12e-6	Blood metabolite ratios;Blood metabolite levels;
KIRP	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.5	5.27	0.32	2.93e-7	Breast cancer;
KIRP	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.65	9.43	0.52	3.13e-18	Dupuytren's disease;
KIRP	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg06937882	chr20:24974362	C20orf3	0.43	5.0	0.3	1.08e-6	Blood protein levels;
KIRP	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.66	-0.39	1.82e-10	Colorectal cancer;
KIRP	cis	rs12049351	0.665	rs10449251	chr1:229640911	A/G	cg11742688	chr1:229674241	ABCB10	0.37	5.4	0.33	1.59e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs35740288	0.770	rs1871285	chr15:86152487	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.42	-0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12208915	0.848	rs12203336	chr6:79518315	G/T	cg18132916	chr6:79620363	NA	0.54	5.1	0.31	6.69e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg00191853	chr8:101177733	SPAG1	0.43	6.96	0.41	3.02e-11	Atrioventricular conduction;
KIRP	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.75	10.77	0.57	2.05e-22	Menopause (age at onset);
KIRP	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	0.67	7.42	0.43	1.96e-12	Dental caries;
KIRP	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg03060546	chr3:49711283	APEH	-0.54	-7.49	-0.43	1.25e-12	Menarche (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.4.80657279F	chr4:80438255	NA	0.41	6.08	0.36	4.54e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11225247	0.881	rs11605573	chr11:102259959	G/T	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs3755132	0.929	rs976015	chr2:15772546	C/G	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	1.07	19.29	0.78	3.88e-51	Leprosy;
KIRP	cis	rs7011507	1.000	rs56267309	chr8:49137698	A/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs12995491	0.731	rs17435433	chr2:88509616	A/G	cg04511125	chr2:88470314	THNSL2	-0.45	-5.57	-0.33	6.62e-8	Response to metformin (IC50);
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.74	0.39	1.13e-10	Neuroticism;
KIRP	cis	rs72829446	0.530	rs7210231	chr17:7357864	C/A	cg17788227	chr17:7347145	FGF11;CHRNB1	0.49	5.13	0.31	5.76e-7	Androgen levels;
KIRP	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.89	8.69	0.48	5.13e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.67	-9.24	-0.51	1.22e-17	Schizophrenia;
KIRP	cis	rs1832871	0.541	rs10945546	chr6:158892209	A/G	cg07215822	chr6:158701037	NA	-0.51	-5.68	-0.34	3.88e-8	Height;
KIRP	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.63	-9.37	-0.51	4.87e-18	Menopause (age at onset);
KIRP	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	12.52	0.62	3.89e-28	Menopause (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09793700	chr6:150244020	RAET1G	-0.41	-6.32	-0.37	1.25e-9	Metabolic traits;
KIRP	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg15896084	chr13:114927664	NA	0.44	5.78	0.35	2.29e-8	Schizophrenia;
KIRP	cis	rs504918	0.783	rs17289013	chr3:124120040	C/T	cg05766129	chr3:123988013	KALRN	-0.4	-4.91	-0.3	1.67e-6	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.74	0.49	3.71e-16	Motion sickness;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.86	-0.3	2.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg00800038	chr16:89945340	TCF25	-0.78	-5.24	-0.32	3.43e-7	Skin colour saturation;
KIRP	cis	rs9381107	0.932	rs116221613	chr6:9445051	G/A	cg14735645	chr6:9486422	NA	-0.45	-5.36	-0.32	1.88e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.84	-9.06	-0.5	4.06e-17	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16672108	chr2:132250124	FAM128A;LOC150776	0.48	6.6	0.39	2.47e-10	Survival in pancreatic cancer;
KIRP	cis	rs2230307	0.536	rs473759	chr1:100557282	C/G	cg24955406	chr1:100503596	HIAT1	0.58	6.27	0.37	1.58e-9	Carotid intima media thickness;
KIRP	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.54	-5.99	-0.36	7.23e-9	Menarche (age at onset);
KIRP	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-5.58	-0.34	6.35e-8	Height;
KIRP	cis	rs16976116	0.901	rs3759861	chr15:55473192	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	6.9	0.4	4.47e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1832871	0.711	rs9459887	chr6:158696479	C/T	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs7601312	0.844	rs1469181	chr2:229269825	A/C	cg02542817	chr2:229291442	NA	-0.56	-8.6	-0.48	9.27e-16	Schizophrenia;
KIRP	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.45	-5.79	-0.35	2.15e-8	Coronary artery disease;
KIRP	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.0	-0.3	1.09e-6	Coronary artery disease;
KIRP	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg06636001	chr8:8085503	FLJ10661	0.63	7.92	0.45	8.31e-14	Neuroticism;
KIRP	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg08134877	chr2:44394819	PPM1B	-0.43	-5.29	-0.32	2.64e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.14	-0.31	5.54e-7	Breast cancer;
KIRP	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11987759	chr7:65425863	GUSB	0.45	5.37	0.32	1.79e-7	Aortic root size;
KIRP	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg15704280	chr7:45808275	SEPT13	-0.56	-6.35	-0.38	1e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.48	-5.62	-0.34	5.04e-8	Carotid intima media thickness;
KIRP	cis	rs17023223	0.537	rs1343723	chr1:119605054	A/T	cg05756136	chr1:119680316	WARS2	-0.53	-7.21	-0.42	6.83e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.96	11.28	0.58	4.81e-24	Corneal astigmatism;
KIRP	cis	rs6466055	0.720	rs1204066	chr7:104971987	G/T	cg04380332	chr7:105027541	SRPK2	0.62	9.35	0.51	5.73e-18	Schizophrenia;
KIRP	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-18.72	-0.77	3.15e-49	Schizophrenia;
KIRP	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	8.42	0.47	3.11e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs1829883	0.775	rs2548098	chr5:98921515	G/A	cg08333243	chr5:99726346	NA	0.43	5.58	0.34	6.27e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.45	6.39	0.38	8.12e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	9.09	0.5	3.29e-17	Resting heart rate;
KIRP	cis	rs6832769	1.000	rs59804446	chr4:56429541	A/C	cg09317128	chr4:56265301	TMEM165	-0.52	-6.42	-0.38	6.99e-10	Personality dimensions;
KIRP	cis	rs8018808	1.000	rs176767	chr14:77865614	A/G	cg20045696	chr14:77926864	AHSA1	0.42	5.16	0.31	5.09e-7	Myeloid white cell count;
KIRP	cis	rs7929679	0.551	rs10836303	chr11:34792702	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg04727924	chr7:799746	HEATR2	0.63	5.81	0.35	1.93e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg19731401	chr7:2775893	GNA12	0.77	7.26	0.42	5.04e-12	Childhood ear infection;
KIRP	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg17644776	chr2:200775616	C2orf69	0.47	5.21	0.32	3.91e-7	Osteoporosis;
KIRP	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg00531865	chr16:30841666	NA	-0.43	-6.13	-0.36	3.55e-9	Dementia with Lewy bodies;
KIRP	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.71	10.5	0.56	1.49e-21	Lewy body disease;
KIRP	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.66	8.1	0.46	2.51e-14	Blood metabolite levels;
KIRP	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.98	13.0	0.64	9.55e-30	Vitamin D levels;
KIRP	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.65	8.36	0.47	4.58e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg08992911	chr2:238395768	MLPH	0.67	6.48	0.38	4.85e-10	Prostate cancer;
KIRP	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg07148914	chr20:33460835	GGT7	-0.58	-7.62	-0.44	5.4e-13	Height;
KIRP	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg01557791	chr16:72042693	DHODH	-0.65	-7.3	-0.42	3.94e-12	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.93	15.89	0.71	1.31e-39	Breast cancer;
KIRP	trans	rs877282	0.520	rs12360072	chr10:813082	C/T	cg22713356	chr15:30763199	NA	0.53	6.44	0.38	6.19e-10	Uric acid levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14625450	chr2:32449528	NLRC4	0.41	6.07	0.36	4.69e-9	Migraine with aura;
KIRP	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.72	-7.79	-0.44	1.92e-13	Blood pressure (smoking interaction);
KIRP	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05347473	chr6:146136440	FBXO30	0.49	7.12	0.41	1.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16725865	chr1:92546135	BTBD8	0.57	6.69	0.39	1.51e-10	Smoking initiation;
KIRP	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.09	-0.5	3.37e-17	Neuroticism;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.04e-7	Life satisfaction;
KIRP	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.44	6.09	0.36	4.33e-9	Systolic blood pressure;
KIRP	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.56	7.49	0.43	1.27e-12	Bladder cancer;
KIRP	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-5.83	-0.35	1.75e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.86	15.96	0.71	7.99e-40	Anterior chamber depth;
KIRP	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg15534755	chr11:117069859	TAGLN	-0.39	-4.92	-0.3	1.55e-6	Blood protein levels;
KIRP	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg16497277	chr3:49208875	KLHDC8B	0.43	5.68	0.34	3.76e-8	Menarche (age at onset);
KIRP	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg19507638	chr5:93509721	C5orf36	-0.53	-5.01	-0.3	1.02e-6	Diabetic retinopathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15051795	chr19:1816298	MIR1909;REXO1	-0.53	-6.6	-0.39	2.47e-10	Parkinson's disease;
KIRP	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg25866889	chr13:114914595	NA	-0.38	-5.26	-0.32	3.06e-7	Schizophrenia;
KIRP	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.51	0.48	1.7e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.66	0.39	1.75e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1823913	1.000	rs4853568	chr2:192126190	G/A	cg12404831	chr2:192114017	MYO1B	-0.47	-6.27	-0.37	1.61e-9	Obesity-related traits;
KIRP	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg25174290	chr11:3078921	CARS	-0.68	-8.85	-0.49	1.71e-16	Calcium levels;
KIRP	cis	rs6546324	0.625	rs2861698	chr2:67854808	A/G	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs9462846	1.000	rs9471950	chr6:42869040	G/A	cg02353165	chr6:42928485	GNMT	0.45	5.02	0.3	1.01e-6	Blood protein levels;
KIRP	cis	rs4262150	0.810	rs4246033	chr5:152009417	T/C	cg12297329	chr5:152029980	NA	-0.63	-7.9	-0.45	9.53e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg17145862	chr1:211918768	LPGAT1	-0.9	-13.2	-0.64	2e-30	Leprosy;
KIRP	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.23	0.67	6.15e-34	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg10223061	chr2:219282414	VIL1	-0.33	-5.4	-0.33	1.54e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg26554054	chr8:600488	NA	-0.62	-5.14	-0.31	5.61e-7	IgG glycosylation;
KIRP	cis	rs12362504	0.532	rs4910076	chr11:9925352	G/A	cg07197493	chr11:9884649	SBF2	-0.37	-5.02	-0.3	9.88e-7	Survival in pancreatic cancer;
KIRP	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.87	9.78	0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.79	-11.27	-0.58	4.87e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs55962025	0.842	rs362306	chr4:3242100	C/T	cg06533319	chr4:3265114	C4orf44	0.48	5.13	0.31	5.75e-7	Parental longevity (mother's age at death);
KIRP	trans	rs747782	0.537	rs10838835	chr11:48246457	C/T	cg03929089	chr4:120376271	NA	-0.67	-6.16	-0.37	2.9e-9	Intraocular pressure;
KIRP	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.09	-21.04	-0.8	6.69e-57	Prudent dietary pattern;
KIRP	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg02993010	chr8:124780839	FAM91A1	-0.58	-6.09	-0.36	4.36e-9	Pancreatic cancer;
KIRP	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg11498726	chr8:26250323	BNIP3L	-0.58	-8.09	-0.46	2.77e-14	Red cell distribution width;
KIRP	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	1.1	8.32	0.47	6.03e-15	Cognitive function;
KIRP	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg12131826	chr15:77904385	NA	0.43	5.09	0.31	7.11e-7	Type 2 diabetes;
KIRP	trans	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-6.89	-0.4	4.65e-11	Obesity-related traits;
KIRP	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	8.01e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.23	0.51	1.31e-17	Colorectal cancer;
KIRP	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs13108043	0.511	rs34881728	chr4:87759088	G/C	cg11209507	chr4:87813803	C4orf36	0.51	5.35	0.32	2.05e-7	Red blood cell count;
KIRP	cis	rs580438	0.529	rs7618989	chr3:13435352	A/G	cg10657019	chr3:13328039	NA	-0.49	-6.36	-0.38	9.94e-10	Myringotomy;
KIRP	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.71	7.11	0.41	1.22e-11	Chronic kidney disease;
KIRP	cis	rs6959887	0.926	rs73099190	chr7:35293417	A/G	cg06685737	chr7:35301730	NA	0.45	6.46	0.38	5.57e-10	Birth weight;
KIRP	cis	rs2120243	0.508	rs1456106	chr3:157123456	T/C	cg24825693	chr3:157122686	VEPH1	-0.56	-9.38	-0.51	4.65e-18	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg16497661	chr14:103986332	CKB	0.43	5.78	0.35	2.22e-8	Body mass index;
KIRP	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.71	-10.07	-0.54	3.29e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs34779708	0.931	rs34304999	chr10:35365705	C/T	cg03585969	chr10:35415529	CREM	0.79	9.56	0.52	1.32e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs501120	0.584	rs11238898	chr10:44679016	T/A	cg09554077	chr10:44749378	NA	0.57	5.95	0.35	9.05e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg11584989	chr19:19387371	SF4	-0.4	-5.06	-0.31	8.31e-7	Tonsillectomy;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.45	7.08	0.41	1.51e-11	Lung cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14322427	chr6:110501706	WASF1;CDC40	-0.45	-6.39	-0.38	8.03e-10	Migraine with aura;
KIRP	cis	rs7267005	0.661	rs79966869	chr20:34373232	T/G	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg15448220	chr1:150897856	SETDB1	-0.39	-5.04	-0.31	9.01e-7	Tonsillectomy;
KIRP	cis	rs12620999	0.941	rs2875690	chr2:237977737	G/A	cg23555395	chr2:238036564	NA	0.46	5.33	0.32	2.25e-7	Systemic lupus erythematosus;
KIRP	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg08975724	chr8:8085496	FLJ10661	0.56	7.24	0.42	5.84e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.9	-14.3	-0.67	3.64e-34	Calcium levels;
KIRP	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs10875746	0.537	rs4760625	chr12:48673743	A/T	cg20731937	chr12:48336164	NA	0.48	5.99	0.36	7.55e-9	Longevity (90 years and older);
KIRP	cis	rs3126085	0.560	rs11204987	chr1:152342869	G/A	cg26876637	chr1:152193138	HRNR	-0.57	-6.22	-0.37	2.11e-9	Atopic dermatitis;
KIRP	cis	rs1823913	0.526	rs35340557	chr2:192203414	G/C	cg12404831	chr2:192114017	MYO1B	0.51	7.02	0.41	2.18e-11	Obesity-related traits;
KIRP	cis	rs6688613	0.694	rs12562794	chr1:166828957	A/G	cg07049167	chr1:166818506	POGK	0.62	7.32	0.42	3.55e-12	Refractive astigmatism;
KIRP	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.68	8.68	0.48	5.41e-16	Resting heart rate;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg01864069	chr14:103024347	NA	0.94	10.18	0.54	1.51e-20	Platelet count;
KIRP	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs6438504	0.922	rs4422293	chr3:118948618	G/C	cg25372693	chr3:118959985	B4GALT4	0.33	5.67	0.34	3.95e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs35661897	0.764	rs67648943	chr2:227259665	C/A	cg03426602	chr2:227312417	NA	-0.55	-6.43	-0.38	6.73e-10	Urinary tract infection frequency;
KIRP	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.82	-10.47	-0.56	1.85e-21	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21393421	chr1:6259179	RPL22	0.48	6.65	0.39	1.85e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2236918	0.901	rs1776132	chr1:242024473	C/G	cg17736920	chr1:242011382	EXO1	0.73	9.44	0.52	2.98e-18	Menopause (age at onset);
KIRP	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.41	-0.43	2.06e-12	Mood instability;
KIRP	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.77	-8.33	-0.47	5.82e-15	Vitiligo;
KIRP	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.69	-8.57	-0.48	1.13e-15	Hypospadias;
KIRP	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg15147215	chr3:52552868	STAB1	-0.27	-4.95	-0.3	1.4e-6	Bipolar disorder;
KIRP	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.12	-0.31	6.16e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg13482628	chr17:19912719	NA	0.53	6.82	0.4	6.89e-11	Schizophrenia;
KIRP	cis	rs9398803	0.865	rs2050644	chr6:126805255	A/G	cg19875578	chr6:126661172	C6orf173	0.51	6.6	0.39	2.47e-10	Male-pattern baldness;
KIRP	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1595825	0.891	rs16823385	chr2:198602101	G/A	cg10547527	chr2:198650123	BOLL	-0.54	-4.97	-0.3	1.23e-6	Ulcerative colitis;
KIRP	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.61	-0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs6969780	1.000	rs6976129	chr7:27177746	C/T	cg26364809	chr7:27145159	NA	-0.59	-5.19	-0.31	4.37e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg06115741	chr20:33292138	TP53INP2	0.42	5.7	0.34	3.47e-8	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09449449	chr16:14357888	MKL2	0.46	6.12	0.36	3.57e-9	Survival in pancreatic cancer;
KIRP	trans	rs4111	0.519	rs11924873	chr3:55947628	C/T	cg26376025	chr3:67060217	KBTBD8	-0.41	-6.04	-0.36	5.63e-9	Sense of smell;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.73	6.46	0.38	5.44e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg00343986	chr7:65444356	GUSB	-0.45	-5.42	-0.33	1.46e-7	Aortic root size;
KIRP	cis	rs16854884	0.657	rs62268458	chr3:143736219	T/C	cg06585982	chr3:143692056	C3orf58	0.58	7.53	0.43	9.84e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs2348418	0.715	rs11049719	chr12:28720379	A/T	cg13890972	chr12:28721907	NA	-0.33	-5.16	-0.31	5.04e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg26681399	chr22:41777847	TEF	0.5	5.26	0.32	3.19e-7	Vitiligo;
KIRP	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg16482183	chr6:26056742	HIST1H1C	0.43	5.49	0.33	9.78e-8	Height;
KIRP	cis	rs11203032	0.831	rs11203017	chr10:90948709	C/T	cg16672925	chr10:90967113	CH25H	0.78	8.07	0.46	3.2e-14	Heart failure;
KIRP	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.86	13.17	0.64	2.49e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	7.13	0.41	1.09e-11	Iron status biomarkers;
KIRP	cis	rs3761218	0.714	rs1968648	chr20:3763349	C/T	cg25011176	chr20:3776985	CDC25B	0.4	5.03	0.31	9.4e-7	Bipolar disorder;
KIRP	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.24	-0.32	3.37e-7	Coronary artery disease;
KIRP	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg21360079	chr12:107162445	NA	-0.66	-9.26	-0.51	1.07e-17	Heart rate;
KIRP	cis	rs2591576	0.935	rs830229	chr5:165400696	T/G	cg13976338	chr5:165423657	NA	-0.63	-8.67	-0.48	6.08e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.37	-0.51	4.78e-18	Personality dimensions;
KIRP	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg14403583	chr14:105418241	AHNAK2	-0.75	-10.68	-0.56	4.15e-22	Rheumatoid arthritis;
KIRP	cis	rs4780401	0.632	rs8059262	chr16:11784129	G/T	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.17	-0.31	4.82e-7	Rheumatoid arthritis;
KIRP	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.74	10.94	0.57	5.95e-23	Hip circumference;
KIRP	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.54	-7.37	-0.43	2.65e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4776059	0.916	rs4774636	chr15:52968193	A/C	cg22715398	chr15:52968154	KIAA1370	-0.68	-7.95	-0.45	6.87e-14	Schizophrenia;
KIRP	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg24611264	chr11:120008944	TRIM29	-0.29	-5.27	-0.32	2.99e-7	Stroke (pediatric);
KIRP	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg04025307	chr7:1156635	C7orf50	0.64	5.0	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4494114	0.936	rs9439092	chr1:39375157	T/G	cg25970120	chr1:39325951	RRAGC	-0.41	-5.24	-0.32	3.41e-7	Blood protein levels;
KIRP	cis	rs1858037	0.867	rs9789444	chr2:65569227	T/C	cg08085232	chr2:65598271	SPRED2	-0.52	-6.17	-0.37	2.85e-9	Rheumatoid arthritis;
KIRP	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.35	-7.22	-0.42	6.57e-12	Type 2 diabetes;
KIRP	cis	rs34779708	0.832	rs6481946	chr10:35529114	A/G	cg03585969	chr10:35415529	CREM	0.77	9.26	0.51	1.05e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.72	6.29	0.37	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs78487399	0.808	rs7599799	chr2:43685493	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.1	-0.31	6.92e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs501120	0.584	rs1704223	chr10:44677014	C/T	cg09554077	chr10:44749378	NA	0.57	5.95	0.35	9.05e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.49	0.68	8.39e-35	Alzheimer's disease;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg07118243	chr12:94853994	CCDC41;LOC144486	0.51	6.58	0.39	2.79e-10	Asthma;
KIRP	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.54	0.33	7.73e-8	Educational attainment;
KIRP	cis	rs5753037	0.809	rs2074707	chr22:30210356	G/A	cg27665648	chr22:30112403	NA	0.47	6.47	0.38	5.25e-10	Type 1 diabetes;
KIRP	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	1.11	7.84	0.45	1.34e-13	Skin colour saturation;
KIRP	cis	rs10782582	0.609	rs1770882	chr1:76411549	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-6.34	-0.37	1.07e-9	Daytime sleep phenotypes;
KIRP	cis	rs4523957	0.651	rs9894613	chr17:2071058	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-11.44	-0.59	1.4e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.8	13.06	0.64	5.71e-30	Schizophrenia;
KIRP	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.74	7.47	0.43	1.43e-12	Resting heart rate;
KIRP	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg03146154	chr1:46216737	IPP	0.43	5.35	0.32	1.98e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2224391	0.704	rs9504371	chr6:5261608	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.94	-0.4	3.55e-11	Height;
KIRP	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.49	-5.79	-0.35	2.16e-8	Parkinson's disease;
KIRP	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.61	-7.72	-0.44	2.88e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.66	-8.32	-0.47	6.2e-15	Facial morphology (factor 19);
KIRP	cis	rs4671400	0.543	rs2290324	chr2:61448776	A/C	cg15711740	chr2:61764176	XPO1	0.62	6.8	0.4	7.73e-11	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg02775129	chr4:119771670	NA	-0.83	-4.85	-0.3	2.19e-6	Cannabis dependence symptom count;
KIRP	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg05347473	chr6:146136440	FBXO30	-0.51	-6.95	-0.41	3.25e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg23505145	chr19:12996616	KLF1	0.55	7.95	0.45	6.81e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg26876637	chr1:152193138	HRNR	0.76	9.9	0.53	1.17e-19	Atopic dermatitis;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12639763	chr10:97321104	SORBS1	0.51	6.24	0.37	1.87e-9	Myopia (pathological);
KIRP	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg05800321	chr8:143867799	LY6D	-0.31	-4.97	-0.3	1.27e-6	Urinary tract infection frequency;
KIRP	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.66	8.89	0.49	1.35e-16	Schizophrenia;
KIRP	cis	rs2380205	0.967	rs9663697	chr10:5897906	C/T	cg27141509	chr10:5886111	NA	-0.38	-5.53	-0.33	8.01e-8	Breast cancer;
KIRP	cis	rs950881	0.867	rs56179005	chr2:102974328	G/A	cg01254707	chr2:102953421	IL1RL1	-0.5	-4.91	-0.3	1.65e-6	Allergy;
KIRP	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.28	-0.32	2.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg11859384	chr17:80120422	CCDC57	-0.4	-5.05	-0.31	8.5e-7	Life satisfaction;
KIRP	cis	rs9581857	0.512	rs9652091	chr13:28073509	G/A	cg22138327	chr13:27999177	GTF3A	0.83	7.41	0.43	2.08e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6001982	0.584	rs73167076	chr22:40879843	C/T	cg07138101	chr22:40742427	ADSL	0.72	4.91	0.3	1.64e-6	Breast cancer;
KIRP	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11987759	chr7:65425863	GUSB	0.51	6.85	0.4	5.8200000000000003e-11	Aortic root size;
KIRP	cis	rs10899021	0.920	rs76121309	chr11:74343921	A/T	cg25880958	chr11:74394337	NA	-0.59	-4.92	-0.3	1.62e-6	Response to metformin (IC50);
KIRP	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.88	-14.69	-0.68	1.66e-35	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg08017634	chr8:144659831	NAPRT1	0.81	5.24	0.32	3.39e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.03	-13.14	-0.64	2.99e-30	Exhaled nitric oxide output;
KIRP	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.85	-0.3	2.19e-6	Pulmonary function;
KIRP	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.33	-0.32	2.22e-7	Height;
KIRP	cis	rs33912345	0.695	rs1254272	chr14:60843493	G/A	cg27398547	chr14:60952738	C14orf39	-0.41	-5.55	-0.33	7.33e-8	Glaucoma (high intraocular pressure);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg00124920	chr1:178515751	C1orf220	0.4	6.43	0.38	6.57e-10	Serum protein levels (sST2);
KIRP	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg13010199	chr12:38710504	ALG10B	0.38	5.0	0.3	1.1e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.42	0.33	1.41e-7	Coronary artery disease;
KIRP	cis	rs9488822	0.662	rs496311	chr6:116274730	A/G	cg26893134	chr6:116381904	FRK	0.21	5.74	0.34	2.78e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.74	10.14	0.54	1.99e-20	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs332034	0.546	rs28581487	chr8:8696342	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-5.01	-0.3	1.05e-6	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg10729496	chr3:10149963	C3orf24	0.54	5.02	0.31	9.71e-7	Alzheimer's disease;
KIRP	cis	rs4474465	0.850	rs7938816	chr11:78266227	T/C	cg02023728	chr11:77925099	USP35	-0.33	-4.86	-0.3	2.08e-6	Alzheimer's disease (survival time);
KIRP	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg08499158	chr17:42289980	UBTF	-0.66	-8.71	-0.49	4.44e-16	Total body bone mineral density;
KIRP	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg23752985	chr2:85803571	VAMP8	0.59	8.78	0.49	2.79e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7188697	0.922	rs37040	chr16:58578262	T/C	cg21335942	chr16:58549945	SETD6	0.46	5.08	0.31	7.6e-7	QT interval;
KIRP	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg07843065	chr1:150265600	MRPS21	-0.51	-7.36	-0.42	2.76e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs180358	0.588	rs1263167	chr11:116677723	A/G	cg08985259	chr11:116699649	APOC3	0.53	6.21	0.37	2.24e-9	Multiple sclerosis (severity);
KIRP	cis	rs1559088	0.600	rs10421769	chr19:33605312	T/C	cg07827796	chr19:33622959	WDR88	0.53	7.07	0.41	1.59e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg13939156	chr17:80058883	NA	0.55	8.82	0.49	2.09e-16	Life satisfaction;
KIRP	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.61	0.44	5.82e-13	Calcium levels;
KIRP	cis	rs300774	0.920	rs378161	chr2:192983	A/T	cg21211680	chr2:198530	NA	0.57	5.88	0.35	1.32e-8	Suicide attempts in bipolar disorder;
KIRP	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.31	0.32	2.51e-7	Type 2 diabetes;
KIRP	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.08	-0.36	4.51e-9	Height;
KIRP	cis	rs45535039	1.000	rs2276083	chr11:119145274	A/G	cg16724696	chr11:118992527	HINFP	0.39	4.84	0.3	2.26e-6	Plateletcrit;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg09699651	chr6:150184138	LRP11	0.46	5.97	0.36	8.17e-9	Lung cancer;
KIRP	cis	rs2400749	0.712	rs6575731	chr14:100023927	A/G	cg19965031	chr14:100038389	CCDC85C	-0.4	-4.92	-0.3	1.56e-6	Alzheimer's disease (survival time);
KIRP	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg21174375	chr14:64681225	SYNE2	0.46	5.22	0.32	3.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg13147721	chr7:65941812	NA	-0.89	-6.36	-0.38	9.62e-10	Diabetic kidney disease;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg07689907	chr11:61582574	FADS1	0.48	6.04	0.36	5.58e-9	Trans fatty acid levels;
KIRP	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.64	-8.95	-0.5	9.14e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21548772	chr3:47422338	PTPN23	0.5	6.1	0.36	4.06e-9	Parkinson's disease;
KIRP	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.45	-5.04	-0.31	8.87e-7	Tuberculosis;
KIRP	cis	rs6684514	1.000	rs12027741	chr1:156248148	T/G	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg22676075	chr6:135203613	NA	0.52	7.54	0.43	8.95e-13	Red blood cell count;
KIRP	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg16736954	chr20:23401023	NAPB	0.65	5.06	0.31	8.22e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	6.0	0.36	7e-9	Schizophrenia;
KIRP	cis	rs55962025	0.804	rs2269499	chr4:3239702	C/T	cg13731523	chr4:3047190	NA	0.31	4.96	0.3	1.32e-6	Parental longevity (mother's age at death);
KIRP	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.61	-7.49	-0.43	1.27e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.83	8.9	0.49	1.22e-16	Alzheimer's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg05195393	chr14:69865263	SLC39A9;ERH	-0.46	-6.07	-0.36	4.79e-9	Interleukin-4 levels;
KIRP	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.56	7.61	0.44	5.78e-13	Gout;
KIRP	cis	rs742071	0.527	rs7541614	chr1:18951811	G/A	cg22389438	chr1:18926496	NA	-0.37	-5.53	-0.33	8.23e-8	Nonsyndromic cleft lip with cleft palate;Orofacial clefts;
KIRP	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg27124370	chr19:33622961	WDR88	0.7	9.59	0.52	1.05e-18	Bone properties (heel);
KIRP	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.39	4.94	0.3	1.45e-6	Blood metabolite levels;
KIRP	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-8.87	-0.49	1.54e-16	Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08953461	chr5:157158882	THG1L	0.55	6.55	0.39	3.32e-10	Smoking initiation;
KIRP	cis	rs6956675	0.881	rs1829737	chr7:62576000	G/A	cg08930214	chr7:62859557	LOC100287834	0.5	5.65	0.34	4.49e-8	Obesity-related traits;
KIRP	cis	rs62012628	0.527	rs12437868	chr15:79088460	T/C	cg22753661	chr15:79092743	ADAMTS7	-0.47	-5.38	-0.32	1.7e-7	Diastolic blood pressure;
KIRP	cis	rs57590327	0.644	rs62265393	chr3:81526075	G/C	cg07356753	chr3:81810745	GBE1	-0.53	-5.66	-0.34	4.1e-8	Extraversion;
KIRP	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.58	7.24	0.42	5.79e-12	Arsenic metabolism;
KIRP	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.75	-9.41	-0.51	3.76e-18	Aortic root size;
KIRP	cis	rs28489187	0.660	rs6576767	chr1:85876316	G/A	cg16011679	chr1:85725395	C1orf52	-0.5	-6.16	-0.37	2.89e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15009525	chr17:79253888	SLC38A10	-0.45	-6.17	-0.37	2.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg18192325	chr2:105854051	NA	-0.38	-5.22	-0.32	3.73e-7	Type 2 diabetes;
KIRP	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg11812906	chr14:75593930	NEK9	0.71	8.55	0.48	1.36e-15	Height;
KIRP	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg26513180	chr16:89883248	FANCA	0.83	5.62	0.34	5.22e-8	Skin colour saturation;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg18350739	chr11:68623251	NA	-0.51	-7.8	-0.45	1.81e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.73	9.65	0.52	6.87e-19	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg21996137	chr6:16761906	ATXN1	-0.58	-6.05	-0.36	5.32e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.74	-0.34	2.74e-8	Bipolar disorder;
KIRP	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.71	7.89	0.45	9.87e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg06935464	chr4:38784597	TLR10	0.52	5.95	0.35	9.41e-9	Breast cancer;
KIRP	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.42	5.38	0.32	1.73e-7	Aortic root size;
KIRP	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.32	8.54	0.48	1.37e-15	Crohn's disease;
KIRP	cis	rs7630877	0.962	rs73060761	chr3:179660724	T/C	cg18765712	chr3:179670323	PEX5L	0.51	6.2	0.37	2.34e-9	Type 2 diabetes;
KIRP	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg01522456	chr1:115632236	TSPAN2	-0.37	-5.03	-0.31	9.55e-7	Autism;
KIRP	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-5.27	-0.32	2.98e-7	Triglycerides;
KIRP	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.97	-16.74	-0.73	1.72e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.65	-9.31	-0.51	7.64e-18	Retinal vascular caliber;
KIRP	cis	rs62229266	0.771	rs62230790	chr21:37388911	A/G	cg08632701	chr21:37451849	NA	-0.45	-5.56	-0.33	6.84e-8	Mitral valve prolapse;
KIRP	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs909341	0.808	rs2263805	chr20:62351150	T/C	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.95	-0.41	3.29e-11	Atopic dermatitis;
KIRP	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.41	-5.57	-0.33	6.55e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22821358	chr1:198828005	MIR181B1	-0.42	-6.23	-0.37	2.01e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7760949	0.963	rs4142889	chr6:13918461	T/A	cg27413430	chr6:13925136	RNF182	0.42	5.38	0.32	1.72e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13198984	chr17:80129470	CCDC57	-0.54	-8.15	-0.46	1.81e-14	Life satisfaction;
KIRP	cis	rs4356932	0.905	rs7679394	chr4:76985890	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg27490568	chr2:178487706	NA	0.57	7.65	0.44	4.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01426354	chr20:33999881	UQCC	0.44	6.09	0.36	4.25e-9	Survival in pancreatic cancer;
KIRP	cis	rs748404	0.560	rs1060939	chr15:43816917	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.43	0.38	6.72e-10	Lung cancer;
KIRP	cis	rs7187994	0.848	rs3751759	chr16:84778222	G/A	cg11201751	chr16:85158047	NA	0.47	4.85	0.3	2.22e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg27205649	chr11:78285834	NARS2	-0.55	-6.2	-0.37	2.43e-9	Testicular germ cell tumor;
KIRP	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.6	-0.39	2.46e-10	Neutrophil percentage of white cells;
KIRP	cis	rs6120849	0.754	rs6088667	chr20:33566722	A/C	cg24642439	chr20:33292090	TP53INP2	0.57	5.94	0.35	9.77e-9	Protein C levels;
KIRP	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.43	5.52	0.33	8.52e-8	Melanoma;
KIRP	cis	rs11209002	0.592	rs4655672	chr1:67553543	C/T	cg02640540	chr1:67518911	SLC35D1	0.59	6.59	0.39	2.63e-10	Crohn's disease;
KIRP	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.0	-0.36	7.18e-9	Parkinson's disease;
KIRP	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.51	6.19	0.37	2.52e-9	Glycated hemoglobin levels;
KIRP	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg08871354	chr16:85723489	GINS2	-0.46	-4.96	-0.3	1.31e-6	Platelet distribution width;
KIRP	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.56e-8	Colorectal cancer;
KIRP	cis	rs7615316	0.751	rs6772400	chr3:142152477	T/A	cg20824294	chr3:142316082	PLS1	0.24	5.38	0.32	1.72e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.65	7.77	0.44	2.11e-13	Corneal astigmatism;
KIRP	cis	rs6466055	0.589	rs17342493	chr7:105010684	G/A	cg04380332	chr7:105027541	SRPK2	0.36	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs17023223	0.537	rs10802073	chr1:119604655	T/C	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	2.94e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg18944383	chr4:111397179	ENPEP	0.48	7.73	0.44	2.81e-13	Coronary artery disease;
KIRP	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	11.63	0.6	3.39e-25	Smoking behavior;
KIRP	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.71	8.22	0.46	1.17e-14	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.64	8.59	0.48	1e-15	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg09658497	chr7:2847517	GNA12	0.36	5.09	0.31	7.07e-7	Height;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11399891	chr19:56652352	ZNF444	-0.52	-6.75	-0.4	1.04e-10	Neuroticism;
KIRP	cis	rs2224391	0.628	rs2773313	chr6:5252213	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.5	-0.38	4.34e-10	Height;
KIRP	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg15896084	chr13:114927664	NA	0.47	6.35	0.38	1.05e-9	Schizophrenia;
KIRP	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.48	-7.92	-0.45	8.02e-14	Multiple sclerosis;
KIRP	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-5.94	-0.35	9.56e-9	Breast cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg22481606	chr17:56429567	SUPT4H1	0.8	6.68	0.39	1.6e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4262150	0.658	rs2964223	chr5:151940822	C/T	cg12297329	chr5:152029980	NA	-0.43	-5.56	-0.33	6.91e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg08280861	chr8:58055591	NA	0.55	5.21	0.32	3.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4566357	1.000	rs6436649	chr2:227923952	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.27	-0.32	2.98e-7	Coronary artery disease;
KIRP	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.47	6.42	0.38	7.11e-10	Testicular germ cell tumor;
KIRP	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.41	8.11	0.46	2.33e-14	Multiple system atrophy;
KIRP	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.24	-0.32	3.48e-7	Red blood cell count;
KIRP	cis	rs9400467	0.537	rs55643604	chr6:111490648	T/G	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.73	-0.44	2.8e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.7	0.66	3.81e-32	Platelet count;
KIRP	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-6.88	-0.4	4.96e-11	Mean platelet volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg16436509	chr12:120875898	COX6A1	1.04	6.92	0.4	3.89e-11	P wave terminal force;
KIRP	cis	rs193541	0.632	rs6878609	chr5:122095549	C/G	cg19412675	chr5:122181750	SNX24	0.56	5.79	0.35	2.16e-8	Glucose homeostasis traits;
KIRP	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg08738300	chr3:44038990	NA	0.68	9.56	0.52	1.28e-18	Coronary artery disease;
KIRP	cis	rs6088813	1.000	rs6088813	chr20:33975181	C/A	cg14752227	chr20:34000481	UQCC	-0.52	-6.86	-0.4	5.42e-11	Height;
KIRP	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.7	8.48	0.48	2.12e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg07051648	chr19:49177693	NTN5;SEC1	0.48	6.13	0.36	3.54e-9	Dietary macronutrient intake;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10392504	chr7:5464594	TNRC18	0.54	6.26	0.37	1.65e-9	Smoking initiation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27008780	chr6:3093488	RIPK1	-0.45	-6.32	-0.37	1.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11024102	0.925	rs7123383	chr11:17002985	G/A	cg15378786	chr11:17036137	PLEKHA7	0.49	4.9	0.3	1.73e-6	Glaucoma (primary angle closure);
KIRP	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg09873164	chr1:152488093	CRCT1	0.56	7.01	0.41	2.24e-11	Hair morphology;
KIRP	cis	rs2120243	0.539	rs1840668	chr3:157098721	T/C	cg24825693	chr3:157122686	VEPH1	-0.56	-9.03	-0.5	5.22e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.8	-10.59	-0.56	7.86e-22	Breast cancer;
KIRP	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.86	10.79	0.57	1.77e-22	Coronary artery disease;
KIRP	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.65	7.92	0.45	7.97e-14	Obesity-related traits;
KIRP	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.27	-0.32	2.98e-7	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs7481311	0.956	rs1873078	chr11:27548003	C/G	cg18117895	chr11:27722066	BDNF	0.46	5.09	0.31	7.22e-7	Body mass index;Weight;
KIRP	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	5.22	0.32	3.79e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.24	-26.04	-0.86	1.17e-72	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6693295	0.536	rs55912974	chr1:246225155	C/T	cg11798871	chr1:246315928	SMYD3	-0.66	-7.27	-0.42	4.74e-12	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg07451762	chr16:28383216	NA	0.42	5.5	0.33	9.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.46	-6.25	-0.37	1.76e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9912468	1.000	rs4577128	chr17:64308473	A/G	cg19474267	chr17:64306194	PRKCA	-0.64	-9.11	-0.5	2.88e-17	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08048620	chr17:72209716	MGC16275;TTYH2	0.45	6.26	0.37	1.69e-9	Parkinson's disease;
KIRP	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg03788504	chr6:150331562	NA	-0.34	-6.11	-0.36	3.88e-9	Alopecia areata;
KIRP	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.92	13.32	0.65	7.85e-31	Menopause (age at onset);
KIRP	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	0.95	17.16	0.74	6.35e-44	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7923609	0.967	rs7085018	chr10:65286667	T/C	cg01631684	chr10:65280961	REEP3	-0.5	-5.9	-0.35	1.17e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9394841	0.667	rs9394831	chr6:41753084	C/T	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21051989	chr6:90121833	RRAGD	-0.46	-6.39	-0.38	8.29e-10	Metabolic traits;
KIRP	cis	rs10465746	0.967	rs942849	chr1:84427499	G/A	cg10977910	chr1:84465055	TTLL7	0.48	5.81	0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs7084402	0.967	rs1649015	chr10:60289031	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.31	17.35	0.74	1.41e-44	Corneal structure;
KIRP	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg23601095	chr6:26197514	HIST1H3D	0.97	8.23	0.46	1.08e-14	Gout;Renal underexcretion gout;
KIRP	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19717773	chr7:2847554	GNA12	-0.36	-5.68	-0.34	3.86e-8	Height;
KIRP	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg12559939	chr2:27858050	GPN1	0.42	5.36	0.32	1.95e-7	Oral cavity cancer;
KIRP	cis	rs9810890	0.850	rs73207992	chr3:128593484	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.82	-0.35	1.85e-8	Height;
KIRP	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg19468946	chr17:37922297	IKZF3	-0.42	-5.63	-0.34	4.79e-8	Asthma;
KIRP	cis	rs17406451	0.587	rs6544646	chr2:43576997	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.4	-5.15	-0.31	5.42e-7	Mitochondrial DNA levels;
KIRP	cis	rs501120	0.584	rs11238894	chr10:44671851	T/C	cg09554077	chr10:44749378	NA	0.58	6.11	0.36	3.96e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.5	7.6	0.44	6.32e-13	Total body bone mineral density;
KIRP	cis	rs965469	0.895	rs6139124	chr20:3398144	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-4.9	-0.3	1.78e-6	IFN-related cytopenia;
KIRP	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06481639	chr22:41940642	POLR3H	-0.7	-6.83	-0.4	6.74e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13859861	chr7:44163228	POLD2	0.47	6.22	0.37	2.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg05692746	chr2:100937584	LONRF2	-0.41	-5.47	-0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg20307385	chr11:47447363	PSMC3	0.62	7.46	0.43	1.48e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg16989719	chr2:238392110	NA	0.56	6.11	0.36	3.91e-9	Prostate cancer;
KIRP	cis	rs2380205	0.967	rs11255558	chr10:5896392	G/A	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.52e-8	Breast cancer;
KIRP	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg06598544	chr20:61472147	COL9A3	-1.01	-5.64	-0.34	4.77e-8	Obesity-related traits;
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg17294928	chr15:75287854	SCAMP5	0.55	7.35	0.42	2.96e-12	Breast cancer;
KIRP	cis	rs7615316	0.789	rs6440082	chr3:142114406	A/G	cg20824294	chr3:142316082	PLS1	-0.21	-4.89	-0.3	1.85e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.33	-0.32	2.23e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.4	5.96	0.36	8.55e-9	Testicular germ cell tumor;
KIRP	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg16497661	chr14:103986332	CKB	0.66	7.24	0.42	5.56e-12	Body mass index;
KIRP	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg08461772	chr7:95026248	PON3	0.42	5.71	0.34	3.23e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.83	11.84	0.6	6.81e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs504918	0.556	rs11706831	chr3:124021252	C/T	cg05766129	chr3:123988013	KALRN	0.44	5.75	0.34	2.7e-8	Schizophrenia;
KIRP	cis	rs6546886	0.912	rs10191539	chr2:74269926	T/C	cg14702570	chr2:74259524	NA	-0.34	-6.75	-0.4	1.09e-10	Dialysis-related mortality;
KIRP	cis	rs6466055	0.661	rs56132497	chr7:104933707	G/C	cg04380332	chr7:105027541	SRPK2	0.37	4.99	0.3	1.16e-6	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16645202	chr15:92397488	SLCO3A1	0.57	7.7	0.44	3.25e-13	Parkinson's disease;
KIRP	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg07653901	chr22:50250238	ZBED4	-0.48	-5.73	-0.34	2.92e-8	Schizophrenia;
KIRP	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.46	5.13	0.31	5.98e-7	Schizophrenia;
KIRP	cis	rs62413470	0.935	rs10807507	chr6:55950432	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.4	-0.43	2.09e-12	Type 2 diabetes;
KIRP	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg13444842	chr1:152974279	SPRR3	-0.35	-4.92	-0.3	1.56e-6	Inflammatory skin disease;
KIRP	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.35	-6.19	-0.37	2.53e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg06259557	chr10:133751219	PPP2R2D	0.37	6.07	0.36	4.89e-9	Serum protein levels (sST2);
KIRP	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg12486944	chr17:80159399	CCDC57	0.38	5.05	0.31	8.41e-7	Life satisfaction;
KIRP	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.68	-6.35	-0.38	1.01e-9	White matter integrity;
KIRP	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.74	11.1	0.58	1.81e-23	Blood metabolite ratios;
KIRP	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg08975724	chr8:8085496	FLJ10661	-0.69	-8.92	-0.49	1.09e-16	Joint mobility (Beighton score);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17859659	chr15:43785369	TP53BP1	0.46	6.54	0.38	3.51e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.86	-0.3	2.05e-6	Crohn's disease;
KIRP	cis	rs13385	0.769	rs2337131	chr5:139571288	G/A	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs9815354	0.812	rs73081383	chr3:41920614	A/G	cg03022575	chr3:42003672	ULK4	0.8	8.15	0.46	1.88e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21643547	chr1:205240462	TMCC2	-0.79	-12.05	-0.61	1.42e-26	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg17470449	chr10:769945	NA	0.57	6.02	0.36	6.37e-9	Uric acid levels;
KIRP	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg21427119	chr20:30132790	HM13	-0.55	-6.26	-0.37	1.73e-9	Mean corpuscular hemoglobin;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15115365	chr5:88384656	NA	0.42	6.26	0.37	1.69e-9	Survival in pancreatic cancer;
KIRP	cis	rs4474465	0.850	rs4579956	chr11:78232445	G/C	cg27205649	chr11:78285834	NARS2	0.71	7.88	0.45	1.07e-13	Alzheimer's disease (survival time);
KIRP	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg26338869	chr17:61819248	STRADA	0.54	6.48	0.38	5e-10	Prudent dietary pattern;
KIRP	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.41	-6.39	-0.38	8.45e-10	Hypertriglyceridemia;
KIRP	cis	rs76025697	1	rs76025697	chr5:179184488	G/A	cg14593053	chr5:179126677	CANX	0.64	8.63	0.48	7.98e-16	Granulocyte percentage of myeloid white cells;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Granulocyte count;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17437033	chr5:132072786	KIF3A	0.54	6.51	0.38	4.16e-10	Inflammatory biomarkers;
KIRP	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.2	-0.61	4.44e-27	Ulcerative colitis;
KIRP	trans	rs17772222	0.606	rs1955598	chr14:88823655	C/T	cg17518899	chr12:50017006	PRPF40B	-0.49	-6.02	-0.36	6.41e-9	Coronary artery calcification;
KIRP	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg21475434	chr5:93447410	FAM172A	-0.45	-5.19	-0.31	4.48e-7	Diabetic retinopathy;
KIRP	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg18306943	chr3:40428807	ENTPD3	0.45	5.88	0.35	1.33e-8	Renal cell carcinoma;
KIRP	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.69	7.25	0.42	5.24e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.85	12.21	0.61	4.03e-27	Body mass index (adult);
KIRP	cis	rs9815354	0.812	rs55916959	chr3:41849130	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg25036284	chr2:26402008	FAM59B	-0.48	-5.07	-0.31	8.01e-7	Gut microbiome composition (summer);
KIRP	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs5995756	0.666	rs5750857	chr22:40000221	A/C	cg10455938	chr22:40058150	CACNA1I	-0.38	-5.33	-0.32	2.2e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.49	-0.33	1.01e-7	Depression;
KIRP	cis	rs7712401	0.601	rs154500	chr5:122211991	T/G	cg19412675	chr5:122181750	SNX24	0.48	5.32	0.32	2.31e-7	Mean platelet volume;
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.53	7.91	0.45	8.52e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg11262906	chr1:85462892	MCOLN2	-0.48	-5.34	-0.32	2.07e-7	Serum sulfate level;
KIRP	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg22676075	chr6:135203613	NA	0.51	7.3	0.42	3.87e-12	Red blood cell count;
KIRP	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.65	-0.34	4.41e-8	Testicular germ cell tumor;
KIRP	cis	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg06521331	chr12:34319734	NA	-0.48	-5.86	-0.35	1.47e-8	Morning vs. evening chronotype;
KIRP	cis	rs80130819	0.688	rs4760692	chr12:48587549	T/C	cg26205652	chr12:48591994	NA	0.49	5.54	0.33	7.57e-8	Prostate cancer;
KIRP	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.04	-0.36	5.54e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg26681399	chr22:41777847	TEF	0.42	4.84	0.3	2.27e-6	Vitiligo;
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg03724423	chr7:27170755	HOXA4	-0.35	-5.2	-0.31	4.23e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs12476592	0.602	rs1446563	chr2:63898124	T/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.94	-0.3	1.41e-6	Childhood ear infection;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16008457	chr7:6865886	C7orf28B	-0.55	-6.09	-0.36	4.3e-9	Menopause (age at onset);
KIRP	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.41	-5.0	-0.3	1.09e-6	Neurofibrillary tangles;
KIRP	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.79	-7.98	-0.45	5.51e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.58	-5.97	-0.36	8.37e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	7.79	0.44	1.93e-13	Mean platelet volume;
KIRP	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.62	-0.44	5.49e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00585698	chr12:123750864	CDK2AP1	0.54	6.98	0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg08773314	chr2:239334832	ASB1	-0.55	-5.68	-0.34	3.7e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg07636037	chr3:49044803	WDR6	-0.76	-5.8	-0.35	1.98e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.56	-6.65	-0.39	1.88e-10	Systemic lupus erythematosus;
KIRP	cis	rs8113308	0.810	rs10411484	chr19:52443405	T/C	cg25782003	chr19:52490127	ZNF350	0.56	5.04	0.31	9.09e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21775007	chr8:11205619	TDH	-0.4	-5.27	-0.32	2.92e-7	Retinal vascular caliber;
KIRP	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg24642439	chr20:33292090	TP53INP2	0.46	5.45	0.33	1.24e-7	Height;
KIRP	cis	rs4656940	0.550	rs6656939	chr1:160773346	C/G	cg17331569	chr1:160788135	LY9	-0.46	-5.62	-0.34	5.16e-8	Crohn's disease;
KIRP	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.48	-6.68	-0.39	1.55e-10	Schizophrenia;
KIRP	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg08133631	chr1:26527909	CATSPER4	-0.46	-5.05	-0.31	8.42e-7	Obesity-related traits;
KIRP	cis	rs9653442	0.545	rs12712067	chr2:100763900	A/C	cg07810366	chr2:100720526	AFF3	0.33	5.2	0.31	4.16e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.68	-0.56	3.94e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg01872077	chr2:219646372	CYP27A1	0.39	5.08	0.31	7.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg24803719	chr17:45855879	NA	-0.41	-5.49	-0.33	9.75e-8	IgG glycosylation;
KIRP	cis	rs812925	0.537	rs778146	chr2:61606475	A/G	cg15711740	chr2:61764176	XPO1	0.47	5.89	0.35	1.24e-8	Immature fraction of reticulocytes;
KIRP	cis	rs6991838	0.584	rs2048650	chr8:66537899	A/G	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs1359582	0.757	rs1555842	chr10:90403071	G/A	cg15661332	chr10:90342814	RNLS	0.56	5.94	0.35	9.84e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.5	-0.33	9.66e-8	Lung cancer;
KIRP	cis	rs10982256	1.000	rs4979414	chr9:117260185	C/T	cg13636371	chr9:117264095	DFNB31	0.58	8.09	0.46	2.81e-14	Bipolar disorder;
KIRP	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg22654517	chr2:96458247	NA	0.34	5.09	0.31	7.2e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs539514	0.586	rs552441	chr13:76377129	G/A	cg04757411	chr13:76259545	LMO7	-0.35	-4.89	-0.3	1.85e-6	Type 1 diabetes;
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.74	-10.69	-0.56	3.63e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.34	-6.16	-0.37	2.92e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-20.07	-0.79	1e-53	Height;
KIRP	cis	rs860295	0.812	rs7556519	chr1:155827546	T/C	cg02153340	chr1:155202674	NA	-0.41	-5.57	-0.33	6.8e-8	Body mass index;
KIRP	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg20991723	chr1:152506922	NA	0.46	5.5	0.33	9.59e-8	Hair morphology;
KIRP	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg06307176	chr5:131281290	NA	-0.53	-5.78	-0.35	2.24e-8	Life satisfaction;
KIRP	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg21466736	chr12:48725269	NA	0.4	4.94	0.3	1.43e-6	Glycated hemoglobin levels;
KIRP	cis	rs2625529	0.689	rs12898728	chr15:72112853	C/T	cg16672083	chr15:72433130	SENP8	-0.48	-6.73	-0.39	1.15e-10	Red blood cell count;
KIRP	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-10.98	-0.57	4.35e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1843834	0.721	rs1601730	chr2:225590153	G/A	cg22455342	chr2:225449267	CUL3	0.46	5.25	0.32	3.31e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.5	7.22	0.42	6.42e-12	Testicular germ cell tumor;
KIRP	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg11150807	chr10:43354902	NA	-0.68	-7.41	-0.43	2e-12	Blood protein levels;
KIRP	cis	rs6430538	0.597	rs4954181	chr2:135570372	T/C	cg12500956	chr2:135428796	TMEM163	0.4	5.17	0.31	4.82e-7	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.62	9.31	0.51	7.46e-18	Lung cancer;
KIRP	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg00814883	chr7:100076585	TSC22D4	-0.5	-4.91	-0.3	1.66e-6	Lung function (FEV1/FVC);
KIRP	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.61	-8.03	-0.46	3.94e-14	Inhibitory control;
KIRP	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.58	7.76	0.44	2.28e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs10874322	0.867	rs4662141	chr1:83029720	C/T	cg12753787	chr1:3239712	PRDM16	0.66	6.67	0.39	1.66e-10	Response to taxane treatment (docetaxel);
KIRP	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.68	-9.01	-0.5	6.07e-17	Glomerular filtration rate;
KIRP	cis	rs711830	1.000	rs6433571	chr2:177039578	G/T	cg13092806	chr2:177043255	NA	0.64	6.7	0.39	1.38e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	11.37	0.59	2.3e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs5167	0.566	rs7253458	chr19:45482570	C/T	cg13119609	chr19:45449297	APOC2	0.39	4.86	0.3	2.14e-6	Blood protein levels;
KIRP	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg16077055	chr2:106428750	NCK2	0.29	5.83	0.35	1.75e-8	Addiction;
KIRP	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.49e-9	Depression;
KIRP	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg05340658	chr4:99064831	C4orf37	0.62	7.71	0.44	3.1e-13	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.85	-9.56	-0.52	1.25e-18	Exhaled nitric oxide output;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06074314	chr2:70475575	TIA1	0.58	6.76	0.4	9.67e-11	Smoking initiation;
KIRP	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.54	-5.96	-0.36	8.61e-9	Platelet distribution width;
KIRP	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.6	-7.65	-0.44	4.65e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs829661	1.000	rs829582	chr2:30678057	C/T	cg10949345	chr2:30726833	LCLAT1	0.73	10.31	0.55	6.05e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.48	6.24	0.37	1.89e-9	Childhood ear infection;
KIRP	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.45	-0.47	2.59e-15	Personality dimensions;
KIRP	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.53	-5.82	-0.35	1.8e-8	Platelet distribution width;
KIRP	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg00106254	chr7:1943704	MAD1L1	-0.43	-4.94	-0.3	1.44e-6	Schizophrenia;
KIRP	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg21361702	chr7:150065534	REPIN1	0.62	6.06	0.36	4.96e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.58	-7.41	-0.43	1.99e-12	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.68	10.02	0.54	4.85e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg08126542	chr6:37504118	NA	-0.7	-9.8	-0.53	2.28e-19	Cognitive performance;
KIRP	cis	rs35740288	0.770	rs34058174	chr15:86174462	G/T	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.32	-0.37	1.21e-9	Axial length;
KIRP	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg10756647	chr7:56101905	PSPH	-0.93	-7.05	-0.41	1.82e-11	Gout;
KIRP	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14996935	chr7:91875850	KRIT1;ANKIB1	0.59	7.29	0.42	4.28e-12	Smoking initiation;
KIRP	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg22916017	chr11:64110731	CCDC88B	0.57	6.68	0.39	1.61e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg18404041	chr3:52824283	ITIH1	-0.47	-5.79	-0.35	2.09e-8	Schizophrenia;
KIRP	cis	rs6690583	0.623	rs74689037	chr1:85439268	C/T	cg22153463	chr1:85462885	MCOLN2	0.62	5.13	0.31	5.95e-7	Serum sulfate level;
KIRP	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.58	-0.39	2.81e-10	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-1.0	-15.61	-0.71	1.19e-38	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg10756647	chr7:56101905	PSPH	0.98	7.0	0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16414030	chr3:133502952	NA	-0.48	-5.48	-0.33	1.04e-7	Iron status biomarkers;
KIRP	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-1.0	-11.23	-0.58	6.88e-24	Exhaled nitric oxide output;
KIRP	cis	rs2273669	0.504	rs77107907	chr6:109436345	C/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.14	-0.31	5.53e-7	Prostate cancer;
KIRP	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12615966	0.932	rs58391435	chr2:105368520	A/G	cg16465502	chr2:105461796	NA	0.68	6.11	0.36	3.89e-9	Pancreatic cancer;
KIRP	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg20991723	chr1:152506922	NA	-0.46	-5.62	-0.34	5.04e-8	Hair morphology;
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.69	6.28	0.37	1.49e-9	Lung function (FEV1/FVC);
KIRP	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg04731861	chr2:219085781	ARPC2	0.28	7.26	0.42	4.97e-12	Colorectal cancer;
KIRP	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	0.9	10.85	0.57	1.14e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg21573476	chr21:45109991	RRP1B	-0.64	-8.7	-0.48	4.94e-16	Mean corpuscular volume;
KIRP	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg00677455	chr12:58241039	CTDSP2	0.71	8.46	0.47	2.48e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg09699651	chr6:150184138	LRP11	0.4	5.23	0.32	3.65e-7	Lung cancer;
KIRP	cis	rs9828933	0.832	rs3774723	chr3:63962339	G/A	cg17941049	chr3:63904683	ATXN7	0.51	5.2	0.31	4.24e-7	Type 2 diabetes;
KIRP	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.67	8.51	0.48	1.68e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg12598211	chr12:123634384	NA	-0.44	-5.37	-0.32	1.8e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.38	4.99	0.3	1.12e-6	Neuroticism;
KIRP	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.74	0.6	1.41e-25	Alzheimer's disease;
KIRP	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1448094	0.838	rs11834294	chr12:86311958	C/T	cg00310523	chr12:86230176	RASSF9	0.4	6.05	0.36	5.37e-9	Major depressive disorder;
KIRP	cis	rs16976116	0.901	rs1061824	chr15:55495963	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7404928	0.794	rs3826260	chr16:23877229	C/T	cg21745164	chr16:23765304	CHP2	-0.51	-6.08	-0.36	4.5e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs8018808	0.935	rs4903584	chr14:77934758	A/G	cg18872420	chr14:78023429	SPTLC2	0.36	5.24	0.32	3.52e-7	Myeloid white cell count;
KIRP	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg05082376	chr22:42548792	NA	-0.46	-5.94	-0.35	9.71e-9	Schizophrenia;
KIRP	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00993674	chr21:45661322	ICOSLG	-0.47	-6.33	-0.37	1.14e-9	Neuroticism;
KIRP	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg24110177	chr3:50126178	RBM5	-0.67	-7.52	-0.43	1e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.38	0.38	8.89e-10	Depression;
KIRP	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.51	5.95	0.35	9.39e-9	Tonsillectomy;
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg02711726	chr17:80685570	FN3KRP	-0.53	-7.29	-0.42	4.17e-12	Glycated hemoglobin levels;
KIRP	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.97	15.0	0.69	1.45e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg05709478	chr1:6581295	PLEKHG5	0.63	6.29	0.37	1.44e-9	Body mass index;
KIRP	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.85	-10.75	-0.57	2.41e-22	Cognitive function;
KIRP	cis	rs12541635	0.677	rs6997487	chr8:106965511	A/C	cg10147462	chr8:107024639	NA	0.34	5.11	0.31	6.39e-7	Age of smoking initiation;
KIRP	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg19468946	chr17:37922297	IKZF3	-0.47	-6.5	-0.38	4.51e-10	Self-reported allergy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07051257	chr19:39897430	ZFP36	0.55	7.51	0.43	1.1e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.8	0.66	1.85e-32	Cognitive function;
KIRP	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.16	0.58	1.18e-23	Bipolar disorder;
KIRP	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08439880	chr3:133502540	NA	0.53	7.05	0.41	1.8e-11	Iron status biomarkers;
KIRP	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg13332499	chr17:408570	NA	0.63	9.22	0.51	1.34e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg22549504	chr19:17448937	GTPBP3	0.49	5.1	0.31	6.83e-7	Systemic lupus erythematosus;
KIRP	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg00129232	chr17:37814104	STARD3	-0.54	-6.92	-0.4	3.94e-11	Self-reported allergy;
KIRP	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg05805236	chr11:65401703	PCNXL3	-0.53	-7.36	-0.42	2.75e-12	Acne (severe);
KIRP	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg03128060	chr6:142623767	GPR126	0.36	5.2	0.31	4.21e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg14458575	chr2:238380390	NA	0.75	7.23	0.42	6.24e-12	Prostate cancer;
KIRP	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05347473	chr6:146136440	FBXO30	0.57	8.14	0.46	1.94e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2964802	0.505	rs13164697	chr5:10831212	C/T	cg14521931	chr5:10832172	NA	-0.74	-10.87	-0.57	9.62e-23	Major depressive disorder;Recurrent major depressive disorder;
KIRP	trans	rs6601327	0.665	rs9286060	chr8:9653145	A/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.55	-0.39	3.35e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.57	0.33	6.68e-8	Skin colour saturation;
KIRP	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.3	-0.32	2.54e-7	Colorectal cancer;
KIRP	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.43	5.56	0.33	6.85e-8	Blood metabolite levels;
KIRP	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	1.04	14.41	0.68	1.47e-34	Menopause (age at onset);
KIRP	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg24315340	chr6:146058215	EPM2A	0.45	5.73	0.34	2.91e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg11783602	chr8:55087084	NA	-0.51	-6.41	-0.38	7.53e-10	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs804280	0.535	rs10435719	chr8:11776904	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.98	0.41	2.75e-11	Myopia (pathological);
KIRP	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26002218	chr14:103986227	CKB	0.26	5.1	0.31	6.89e-7	Body mass index;
KIRP	cis	rs2415984	0.622	rs17672908	chr14:46934527	T/C	cg14871534	chr14:47121158	RPL10L	-0.43	-5.17	-0.31	4.88e-7	Number of children ever born;
KIRP	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.66	0.52	6.51e-19	Prudent dietary pattern;
KIRP	cis	rs1215050	0.791	rs165239	chr4:98682549	C/T	cg05340658	chr4:99064831	C4orf37	0.49	6.02	0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg20302533	chr7:39170763	POU6F2	0.3	6.54	0.38	3.57e-10	IgG glycosylation;
KIRP	trans	rs12517041	1.000	rs10066885	chr5:23296872	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6545883	0.525	rs1177274	chr2:61368532	T/G	cg15711740	chr2:61764176	XPO1	-0.59	-7.53	-0.43	9.61e-13	Tuberculosis;
KIRP	cis	rs2299587	0.623	rs7009476	chr8:17770376	T/C	cg01800426	chr8:17659068	MTUS1	-0.52	-6.19	-0.37	2.47e-9	Economic and political preferences;
KIRP	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.62	-6.94	-0.4	3.45e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.61	-7.42	-0.43	1.91e-12	Corneal astigmatism;
KIRP	cis	rs71403859	0.568	rs12149489	chr16:71813780	G/T	cg08717414	chr16:71523259	ZNF19	-0.88	-7.63	-0.44	5.14e-13	Post bronchodilator FEV1;
KIRP	trans	rs4775041	0.920	rs80123226	chr15:58676032	A/T	cg21369679	chr16:47007757	DNAJA2	0.56	6.32	0.37	1.2e-9	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	trans	rs7939886	0.920	rs12221509	chr11:56045987	C/T	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg21546286	chr11:48923668	NA	0.43	5.4	0.33	1.57e-7	HDL cholesterol;
KIRP	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.42	6.15	0.37	3.05e-9	Lipoprotein (a) levels;
KIRP	cis	rs4006360	0.540	rs9915780	chr17:39301074	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.47	-7.18	-0.42	8.21e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	9.14	0.5	2.33e-17	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-7.59	-0.44	6.43e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg03235661	chr20:60525775	NA	-0.37	-5.64	-0.34	4.68e-8	Body mass index;
KIRP	cis	rs11638352	0.661	rs2706488	chr15:44389897	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.68	-5.68	-0.34	3.76e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg05082376	chr22:42548792	NA	-0.46	-5.49	-0.33	1.01e-7	Schizophrenia;
KIRP	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-1.0	-16.63	-0.73	4.09e-42	Height;
KIRP	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-7.69	-0.44	3.48e-13	Bladder cancer;
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg06665941	chr21:34602869	IFNAR2	0.48	6.42	0.38	6.88e-10	Plasma plasminogen activator levels;
KIRP	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg18882449	chr10:104885122	NT5C2	-0.4	-5.16	-0.31	5.03e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2733310	0.948	rs2703594	chr15:57488790	C/G	cg13626582	chr15:57592083	LOC283663	-0.33	-7.71	-0.44	3.17e-13	Mean platelet volume;
KIRP	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs926392	0.692	rs6028259	chr20:37696977	T/A	cg16355469	chr20:37678765	NA	0.54	6.39	0.38	8.06e-10	Dialysis-related mortality;
KIRP	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.45	6.46	0.38	5.67e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06850241	chr22:41845214	NA	-0.42	-4.92	-0.3	1.57e-6	Vitiligo;
KIRP	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg01422370	chr2:73384389	NA	0.49	6.62	0.39	2.3e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.53	6.84	0.4	6.23e-11	IgG glycosylation;
KIRP	cis	rs35740288	1.000	rs35740288	chr15:86297085	T/A	cg17133734	chr15:86042851	AKAP13	-0.43	-4.88	-0.3	1.95e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs76693355	0.512	rs10892575	chr11:120291137	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.12	-0.36	3.62e-9	Intraocular pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18941831	chr1:120272766	PHGDH	0.45	6.19	0.37	2.52e-9	Interleukin-4 levels;
KIRP	cis	rs77688320	0.517	rs7573536	chr2:202334399	A/G	cg06431681	chr2:202330990	STRADB	0.53	7.22	0.42	6.38e-12	Breast cancer;
KIRP	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-0.72	-6.35	-0.38	1.01e-9	Obesity-related traits;
KIRP	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.01	-0.3	1.05e-6	Neuroticism;
KIRP	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg01631408	chr1:248437212	OR2T33	-0.64	-8.5	-0.48	1.87e-15	Common traits (Other);
KIRP	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9649213	0.574	rs62478236	chr7:98030377	G/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.22	-0.42	6.41e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg12046867	chr14:103022105	NA	-0.57	-7.06	-0.41	1.72e-11	Platelet count;
KIRP	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg20673091	chr1:2541236	MMEL1	-0.65	-9.48	-0.52	2.31e-18	Ulcerative colitis;
KIRP	cis	rs785830	1.000	rs785830	chr9:246357	A/G	cg14500300	chr9:211689	NA	0.57	7.62	0.44	5.52e-13	Platelet distribution width;
KIRP	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg17652424	chr22:38574118	PLA2G6	-0.24	-4.9	-0.3	1.72e-6	Cutaneous nevi;
KIRP	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.42	-0.47	3.17e-15	Systolic blood pressure;
KIRP	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg20991723	chr1:152506922	NA	0.46	5.66	0.34	4.15e-8	Hair morphology;
KIRP	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.59	6.8	0.4	7.68e-11	Educational attainment;
KIRP	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.57	-6.26	-0.37	1.74e-9	Menarche (age at onset);
KIRP	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.63	6.56	0.39	3.15e-10	Response to diuretic therapy;
KIRP	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.35	6.31	0.37	1.26e-9	Erythrocyte sedimentation rate;
KIRP	cis	rs10875746	0.624	rs10875777	chr12:48622071	T/C	cg26205652	chr12:48591994	NA	0.66	8.7	0.49	4.86e-16	Longevity (90 years and older);
KIRP	cis	rs2290402	0.536	rs56253935	chr4:853871	A/T	cg14517359	chr4:903473	GAK	-0.56	-6.03	-0.36	5.92e-9	Type 2 diabetes;
KIRP	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15664640	chr17:80829946	TBCD	-0.72	-6.37	-0.38	9.42e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.65	7.51	0.43	1.11e-12	Osteoporosis;
KIRP	cis	rs6568686	0.786	rs6927920	chr6:111820382	A/T	cg22127309	chr6:111907043	TRAF3IP2	-0.58	-5.29	-0.32	2.66e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	cis	rs6001982	0.667	rs73167053	chr22:40851728	G/A	cg07138101	chr22:40742427	ADSL	0.73	5.16	0.31	5.09e-7	Breast cancer;
KIRP	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.46	6.49	0.38	4.57e-10	Dupuytren's disease;
KIRP	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.72	-10.56	-0.56	9.63e-22	Neuroticism;
KIRP	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.2	0.46	1.32e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19197905	chr10:98716488	LCOR	0.39	6.21	0.37	2.23e-9	C-reactive protein;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04272560	chr4:925854	TMEM175;GAK	0.5	6.23	0.37	1.98e-9	Parkinson's disease;
KIRP	cis	rs2274273	0.840	rs17674463	chr14:55824863	A/T	cg04306507	chr14:55594613	LGALS3	0.46	7.31	0.42	3.7e-12	Protein biomarker;
KIRP	cis	rs74181299	0.571	rs6728523	chr2:65282708	G/C	cg05010058	chr2:65284262	CEP68	0.42	5.3	0.32	2.58e-7	Pulse pressure;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07939768	chr17:27621433	NUFIP2	0.96	6.52	0.38	3.86e-10	P wave terminal force;
KIRP	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.62	5.01	0.3	1.06e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs4262150	0.695	rs72804798	chr5:152329436	G/T	cg12297329	chr5:152029980	NA	-0.54	-6.49	-0.38	4.6e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg12317470	chr15:67143691	NA	0.61	5.58	0.34	6.34e-8	Lung cancer (smoking interaction);
KIRP	cis	rs4363385	0.510	rs11205182	chr1:153045748	C/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.18	-0.31	4.65e-7	Inflammatory skin disease;
KIRP	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg20493526	chr2:3714936	ALLC	0.51	6.63	0.39	2.06e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.41	5.29	0.32	2.65e-7	Aortic root size;
KIRP	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.78	7.65	0.44	4.59e-13	Neuroblastoma;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07196835	chr1:113217837	MOV10	-0.52	-6.68	-0.39	1.57e-10	Myopia;
KIRP	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	7.88	0.45	1.04e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs858239	0.539	rs10270695	chr7:23188988	C/T	cg23682824	chr7:23144976	KLHL7	-0.49	-5.82	-0.35	1.87e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-5.42	-0.33	1.39e-7	Triglycerides;
KIRP	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg17595323	chr11:93583763	C11orf90	-0.36	-6.1	-0.36	4.01e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.66	9.34	0.51	6.22e-18	Obesity-related traits;
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.95	17.65	0.75	1.39e-45	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg09904177	chr6:26538194	HMGN4	-0.56	-5.15	-0.31	5.43e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	6.69	0.39	1.5e-10	Monocyte percentage of white cells;
KIRP	cis	rs9581857	0.579	rs9581846	chr13:27987953	A/G	cg22138327	chr13:27999177	GTF3A	0.99	7.54	0.43	9.27e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs10221833	0.636	rs355890	chr2:165634976	T/G	cg03182029	chr2:165697222	COBLL1	0.44	4.84	0.3	2.25e-6	Response to statin therapy;
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.69	9.19	0.51	1.68e-17	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.5	0.38	4.47e-10	Personality dimensions;
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg09264619	chr17:80180166	NA	-0.39	-5.57	-0.33	6.55e-8	Life satisfaction;
KIRP	cis	rs2692947	0.666	rs7566050	chr2:96626030	T/C	cg23100626	chr2:96804247	ASTL	0.43	5.83	0.35	1.77e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg16497661	chr14:103986332	CKB	0.83	14.16	0.67	1.06e-33	Body mass index;
KIRP	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.76e-11	Aortic root size;
KIRP	cis	rs9398803	0.835	rs59698523	chr6:126733094	T/C	cg19875578	chr6:126661172	C6orf173	0.47	6.09	0.36	4.42e-9	Male-pattern baldness;
KIRP	cis	rs2708977	0.966	rs2708978	chr2:97202243	A/C	cg01950434	chr2:97203154	ARID5A	-0.57	-7.16	-0.42	9.11e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs17453880	0.929	rs12522239	chr5:152054873	C/G	cg12297329	chr5:152029980	NA	-0.66	-9.81	-0.53	2.24e-19	Subjective well-being;
KIRP	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.63	-0.34	4.87e-8	Aortic root size;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg23857200	chr19:39882127	MED29;PAF1	0.5	6.02	0.36	6.36e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.62	6.23	0.37	1.98e-9	Ulcerative colitis;
KIRP	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs8084125	1.000	rs62105169	chr18:74945193	A/G	cg05528293	chr18:74961138	GALR1	0.5	4.92	0.3	1.61e-6	Obesity-related traits;
KIRP	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg24498760	chr8:49746867	NA	0.42	5.03	0.31	9.34e-7	Blood metabolite ratios;
KIRP	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs2150410	0.915	rs7276698	chr21:40657043	C/T	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	cis	rs11203032	0.614	rs11203025	chr10:90955474	A/C	cg16672925	chr10:90967113	CH25H	0.79	8.14	0.46	2.03e-14	Heart failure;
KIRP	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg13271783	chr10:134563150	INPP5A	-0.61	-7.81	-0.45	1.66e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg07636037	chr3:49044803	WDR6	0.69	7.05	0.41	1.78e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2236918	0.932	rs1776131	chr1:242024245	T/A	cg17736920	chr1:242011382	EXO1	0.76	10.01	0.54	5.37e-20	Menopause (age at onset);
KIRP	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.9	-15.54	-0.7	2.08e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg14664628	chr15:75095509	CSK	0.55	6.01	0.36	6.82e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg16306078	chr6:126000798	NA	-0.27	-5.09	-0.31	7.03e-7	Endometrial cancer;
KIRP	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.71	-8.21	-0.46	1.28e-14	Adiposity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03136486	chr8:89048264	NA	-0.39	-6.02	-0.36	6.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs2463822	0.547	rs72917373	chr11:62024403	C/A	cg06239285	chr11:62104954	ASRGL1	-0.89	-6.7	-0.39	1.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs12282928	1.000	rs2128677	chr11:48319974	G/A	cg26585981	chr11:48327164	OR4S1	0.5	6.04	0.36	5.75e-9	Migraine - clinic-based;
KIRP	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-1.03	-18.65	-0.77	5.72e-49	Height;
KIRP	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.96	11.68	0.6	2.22e-25	Response to antineoplastic agents;
KIRP	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg10017260	chr10:834428	NA	-0.43	-6.41	-0.38	7.43e-10	Survival in rectal cancer;
KIRP	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg11253592	chr11:95992166	MAML2	-0.41	-6.06	-0.36	5.04e-9	Select biomarker traits;
KIRP	cis	rs11673344	0.583	rs7247090	chr19:38013411	T/A	cg14683738	chr19:37701593	ZNF585B	-0.51	-6.16	-0.37	2.94e-9	Obesity-related traits;
KIRP	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.54	8.35	0.47	4.98e-15	Lung cancer;
KIRP	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	8.33	0.47	5.87e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg14593290	chr7:50529359	DDC	0.43	5.46	0.33	1.18e-7	Malaria;
KIRP	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-6.83	-0.4	6.68e-11	Height;
KIRP	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg05527609	chr1:210001259	C1orf107	0.6	6.94	0.4	3.48e-11	Red blood cell count;
KIRP	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.36	6.27	0.37	1.61e-9	Coronary artery disease;
KIRP	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg04865290	chr3:52927548	TMEM110	-0.46	-4.89	-0.3	1.82e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.09	-0.64	4.49e-30	Blood protein levels;
KIRP	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.14	0.72	1.8e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1805008	0.535	rs4785621	chr16:90130735	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.61	-6.04	-0.36	5.75e-9	Skin colour saturation;
KIRP	cis	rs4955124	0.558	rs12485595	chr3:32018354	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.79	7.37	0.43	2.59e-12	Schizophrenia;
KIRP	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.48	-6.13	-0.36	3.52e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs526231	0.543	rs158400	chr5:102413332	T/C	cg23492399	chr5:102201601	PAM	-0.49	-5.41	-0.33	1.48e-7	Primary biliary cholangitis;
KIRP	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.78	9.87	0.53	1.38e-19	Corneal astigmatism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18269457	chr1:98383686	DPYD	0.45	7.0	0.41	2.46e-11	C-reactive protein;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12476298	chr19:58426697	ZNF417	-0.4	-6.16	-0.37	2.92e-9	Survival in pancreatic cancer;
KIRP	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.9	15.28	0.7	1.69e-37	Metabolic syndrome;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.94	0.3	1.46e-6	Lung cancer;
KIRP	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg15128208	chr22:42549153	NA	-0.43	-5.34	-0.32	2.08e-7	Cognitive function;
KIRP	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs714031	0.934	rs2235342	chr22:40068853	T/C	cg21377881	chr22:40064566	CACNA1I	-0.66	-10.2	-0.55	1.36e-20	Schizophrenia;
KIRP	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg23307798	chr14:103986281	CKB	-0.51	-6.89	-0.4	4.59e-11	Coronary artery disease;
KIRP	cis	rs28489187	0.558	rs12044537	chr1:85846385	T/A	cg16011679	chr1:85725395	C1orf52	0.44	5.52	0.33	8.66e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	14.87	0.69	4.2e-36	Platelet count;
KIRP	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg15358701	chr1:161410459	NA	-0.63	-5.87	-0.35	1.43e-8	Rheumatoid arthritis;
KIRP	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.94	-14.67	-0.68	1.98e-35	Height;
KIRP	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.83	-8.54	-0.48	1.42e-15	Schizophrenia;
KIRP	cis	rs9948	1.000	rs62152793	chr2:97484948	C/T	cg01990225	chr2:97406019	LMAN2L	-1.07	-7.64	-0.44	4.8e-13	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg26441486	chr22:50317300	CRELD2	0.52	7.71	0.44	3.08e-13	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22117172	chr7:91764530	CYP51A1	0.45	6.16	0.37	2.94e-9	Breast cancer;
KIRP	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg04554929	chr8:105342491	NA	-0.4	-5.84	-0.35	1.61e-8	Paget's disease;
KIRP	cis	rs714027	0.585	rs9306468	chr22:30374281	T/C	cg27665648	chr22:30112403	NA	0.4	5.18	0.31	4.68e-7	Lymphocyte counts;
KIRP	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg08648136	chr8:956695	NA	0.45	6.33	0.37	1.13e-9	Schizophrenia;
KIRP	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg21399703	chr1:247681439	NA	-0.52	-5.22	-0.32	3.84e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9653442	0.510	rs13415583	chr2:100764087	T/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.53	6.69	0.39	1.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg18394090	chr19:14247419	ASF1B	-0.49	-6.56	-0.39	3.16e-10	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.73	11.29	0.58	4.2e-24	Neuroticism;
KIRP	cis	rs7552404	0.731	rs11161857	chr1:76370228	G/C	cg22875332	chr1:76189707	ACADM	0.59	7.65	0.44	4.56e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.71	11.1	0.58	1.75e-23	Resting heart rate;
KIRP	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.86	8.79	0.49	2.64e-16	Methadone dose in opioid dependence;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.2.1448966F	chr2:63344642	NA	0.44	6.32	0.37	1.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg24579218	chr15:68104479	NA	-0.57	-9.25	-0.51	1.1e-17	Restless legs syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03404102	chr3:122103036	FAM162A;CCDC58	0.49	6.12	0.36	3.58e-9	Parkinson's disease;
KIRP	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg03801030	chr11:6440781	APBB1	0.48	6.02	0.36	6.26e-9	Educational attainment;
KIRP	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg01849789	chr22:41697279	ZC3H7B	-0.51	-5.74	-0.34	2.74e-8	Neuroticism;
KIRP	cis	rs72634030	0.536	rs72634016	chr17:5185204	C/T	cg27093376	chr17:5185073	RABEP1	0.52	5.04	0.31	8.95e-7	Rheumatoid arthritis;
KIRP	cis	rs6142102	0.961	rs4911407	chr20:32683565	C/A	cg24642439	chr20:33292090	TP53INP2	0.58	6.54	0.39	3.46e-10	Skin pigmentation;
KIRP	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg08999081	chr20:33150536	PIGU	0.47	6.29	0.37	1.48e-9	Height;
KIRP	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.11e-7	Breast cancer;
KIRP	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	11.8	0.6	9.08e-26	Monocyte count;
KIRP	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	8.81	0.49	2.3e-16	Menarche (age at onset);
KIRP	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.44	-5.41	-0.33	1.47e-7	Diastolic blood pressure;
KIRP	cis	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.15	-0.37	3.07e-9	Small cell lung carcinoma;
KIRP	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.97	0.54	7.01e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.53	-7.19	-0.42	7.6e-12	Blood metabolite levels;
KIRP	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	6.6	0.39	2.57e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9815354	1.000	rs9826058	chr3:41762062	A/G	cg03022575	chr3:42003672	ULK4	0.48	5.34	0.32	2.1e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs526231	0.543	rs183752	chr5:102507812	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.58	-0.34	6.21e-8	Primary biliary cholangitis;
KIRP	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg11801959	chr13:50123613	RCBTB1	-0.35	-4.97	-0.3	1.26e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg04398451	chr17:18023971	MYO15A	-0.62	-8.35	-0.47	5.05e-15	Total body bone mineral density;
KIRP	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.59	5.47	0.33	1.11e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04353131	chr6:88755259	NA	0.35	6.07	0.36	4.75e-9	C-reactive protein;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.59	-8.39	-0.47	3.89e-15	Testicular germ cell tumor;
KIRP	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg07827796	chr19:33622959	WDR88	0.4	4.87	0.3	2.03e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg06481639	chr22:41940642	POLR3H	-0.41	-4.93	-0.3	1.52e-6	Vitiligo;
KIRP	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	trans	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg24644049	chr4:85504048	CDS1	1.03	6.73	0.39	1.15e-10	Skin colour saturation;
KIRP	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg05527609	chr1:210001259	C1orf107	-0.51	-5.58	-0.34	6.2e-8	Red blood cell count;
KIRP	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg03605463	chr16:89740564	NA	0.55	7.21	0.42	6.83e-12	Vitiligo;
KIRP	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg21427119	chr20:30132790	HM13	-0.54	-6.4	-0.38	7.95e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3857747	0.519	rs12701819	chr7:40370405	C/T	cg00420559	chr7:40367873	C7orf10	-0.45	-6.49	-0.38	4.58e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs4742903	0.509	rs1605445	chr9:106958484	C/A	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	2.04e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	0.94	7.96	0.45	6.32e-14	Schizophrenia;
KIRP	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.52	-5.75	-0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs13034020	0.522	rs62150978	chr2:61256222	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.58	6.44	0.38	6.33e-10	Hodgkin's lymphoma;
KIRP	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	1.02	13.96	0.66	5.07e-33	Neutrophil percentage of white cells;
KIRP	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	8.93	0.49	1.01e-16	Cognitive test performance;
KIRP	cis	rs7520050	0.966	rs1768816	chr1:46528599	T/C	cg03146154	chr1:46216737	IPP	-0.41	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg18350739	chr11:68623251	NA	-0.53	-7.99	-0.45	5.17e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg24812749	chr6:127587940	RNF146	0.82	9.99	0.54	6.04e-20	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22684387	chr10:105916443	C10orf79	0.41	6.11	0.36	3.95e-9	Interleukin-4 levels;
KIRP	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg02336718	chr17:17403227	NA	0.33	5.19	0.31	4.3e-7	Total body bone mineral density;
KIRP	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg23335576	chr14:104009727	NA	0.38	5.32	0.32	2.35e-7	Body mass index;
KIRP	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg26335602	chr6:28129616	ZNF389	-0.45	-4.86	-0.3	2.05e-6	Parkinson's disease;
KIRP	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2279817	0.731	rs11203435	chr1:18010233	T/A	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-9.59	-0.52	1.04e-18	Neuroticism;
KIRP	cis	rs7714584	1.000	rs6874560	chr5:150182713	A/C	cg22134413	chr5:150180641	NA	1.05	7.58	0.44	6.99e-13	Crohn's disease;
KIRP	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.74	10.76	0.57	2.29e-22	Dupuytren's disease;
KIRP	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.64	8.76	0.49	3.13e-16	Myopia (pathological);
KIRP	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.59	-9.16	-0.5	2.15e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.69	0.34	3.65e-8	Lung cancer;
KIRP	cis	rs9603616	0.719	rs4941940	chr13:40253901	A/G	cg26701198	chr13:40229707	COG6	0.44	5.18	0.31	4.54e-7	Rheumatoid arthritis;
KIRP	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg20573242	chr4:122745356	CCNA2	0.41	5.07	0.31	7.84e-7	Type 2 diabetes;
KIRP	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.81	7.54	0.43	8.79e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	9.0	0.5	6.5e-17	Eosinophil percentage of white cells;
KIRP	cis	rs4908768	0.906	rs10492965	chr1:8598127	G/A	cg03610117	chr1:8450231	RERE	-0.5	-5.22	-0.32	3.72e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg14037413	chr11:9482594	ZNF143	1.04	7.4	0.43	2.09e-12	P wave terminal force;
KIRP	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.75	10.49	0.56	1.61e-21	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26608221	chr2:74692293	MOGS	0.54	7.21	0.42	6.86e-12	Parkinson's disease;
KIRP	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg22508957	chr16:3507546	NAT15	0.58	7.12	0.41	1.19e-11	Tuberculosis;
KIRP	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Dermatomyositis;
KIRP	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.94e-19	Corneal astigmatism;
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.6	-7.33	-0.42	3.29e-12	Breast cancer;
KIRP	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.48	-0.56	1.68e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg10018233	chr7:150070692	REPIN1	0.69	8.13	0.46	2.12e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg06917634	chr15:78832804	PSMA4	-0.68	-7.38	-0.43	2.37e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg16482183	chr6:26056742	HIST1H1C	0.63	7.16	0.42	9.09e-12	Iron status biomarkers;
KIRP	cis	rs9309473	0.528	rs11898362	chr2:73565293	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.19	-0.37	2.48e-9	Metabolite levels;
KIRP	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.59	-8.8	-0.49	2.51e-16	Platelet distribution width;
KIRP	cis	rs2411233	1.000	rs9920185	chr15:39273575	C/A	cg05886626	chr15:39873553	THBS1	0.33	4.98	0.3	1.22e-6	Platelet count;
KIRP	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg06937882	chr20:24974362	C20orf3	-0.43	-4.88	-0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs829883	0.646	rs249836	chr12:98878342	T/C	cg25150519	chr12:98850993	NA	0.57	7.74	0.44	2.64e-13	Colorectal adenoma (advanced);
KIRP	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.9	0.4	4.29e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12496230	0.794	rs7638057	chr3:66862718	C/T	cg04995300	chr3:66848608	NA	0.45	6.8	0.4	7.91e-11	Type 2 diabetes;
KIRP	cis	rs7221595	0.756	rs35102999	chr17:3892700	G/A	cg09597638	chr17:3907349	NA	0.54	5.65	0.34	4.38e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs16828019	0.852	rs12022978	chr1:41554088	A/G	cg03387723	chr1:41708464	SCMH1	-0.76	-6.71	-0.39	1.36e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.79	6.4	0.38	7.75e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg04998671	chr14:104000505	TRMT61A	0.48	5.86	0.35	1.45e-8	Coronary artery disease;
KIRP	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg00656387	chr3:40428638	ENTPD3	-0.37	-5.05	-0.31	8.42e-7	Renal cell carcinoma;
KIRP	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	1.08	11.02	0.58	3.16e-23	Nonalcoholic fatty liver disease;
KIRP	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg20578329	chr17:80767326	TBCD	0.47	6.19	0.37	2.44e-9	Breast cancer;
KIRP	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.69	-8.23	-0.46	1.11e-14	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23636324	chr1:92351686	TGFBR3	0.53	6.52	0.38	4.03e-10	Parkinson's disease;
KIRP	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg16988262	chr1:15930761	NA	-0.38	-5.03	-0.31	9.47e-7	Systolic blood pressure;
KIRP	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.2	26.56	0.86	3.19e-74	Schizophrenia;
KIRP	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.55	6.36	0.38	9.61e-10	Aortic root size;
KIRP	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.63	6.81	0.4	7.56e-11	Exhaled nitric oxide output;
KIRP	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	6.41	0.38	7.56e-10	Height;
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg23736307	chr8:27182930	PTK2B	0.53	6.79	0.4	8.25e-11	Neuroticism;
KIRP	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-6.38	-0.38	8.6e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.82	0.35	1.8e-8	Morning vs. evening chronotype;
KIRP	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2411233	0.967	rs2035061	chr15:39287286	C/T	cg02291532	chr15:39874776	THBS1	0.37	5.02	0.3	9.9e-7	Platelet count;
KIRP	cis	rs7078219	0.965	rs10883358	chr10:101273857	C/T	cg17888390	chr10:101282816	NA	-0.3	-4.94	-0.3	1.47e-6	Dental caries;
KIRP	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs12681366	0.663	rs2043987	chr8:95469693	G/C	cg13257157	chr8:95487014	RAD54B	0.41	5.05	0.31	8.78e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.88	-10.66	-0.56	4.71e-22	Lung cancer in ever smokers;
KIRP	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.26	-0.32	3.07e-7	Pulmonary function;
KIRP	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg19592336	chr6:28129416	ZNF389	0.44	4.94	0.3	1.44e-6	Parkinson's disease;
KIRP	cis	rs4073416	0.510	rs10873190	chr14:65981439	G/T	cg03016385	chr14:66212404	NA	-0.53	-6.48	-0.38	5.04e-10	N-glycan levels;
KIRP	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.9	-12.58	-0.63	2.32e-28	Coronary artery disease;
KIRP	cis	rs506338	0.517	rs12269736	chr11:64471986	T/C	cg09231725	chr11:64357281	SLC22A12	-0.45	-5.03	-0.31	9.35e-7	Body mass index;Urate levels;
KIRP	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.42	8.7	0.48	5e-16	Coronary artery disease;
KIRP	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.67	9.42	0.51	3.4e-18	Multiple sclerosis;
KIRP	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg23974023	chr2:113544294	IL1A	-0.33	-4.91	-0.3	1.68e-6	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Systolic blood pressure;
KIRP	cis	rs2151522	0.762	rs13201789	chr6:127151751	T/A	cg21431617	chr6:127135037	NA	0.3	5.41	0.33	1.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg17470723	chr8:74884337	TCEB1	0.62	7.92	0.45	8.29e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.67	-0.39	1.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8179	0.553	rs42377	chr7:92243672	G/A	cg15732164	chr7:92237376	CDK6	-0.5	-6.88	-0.4	4.96e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.68	-8.5	-0.48	1.83e-15	Extraversion;
KIRP	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.97	-0.36	8.05e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg00383909	chr3:49044727	WDR6	0.64	5.84	0.35	1.69e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.89	14.49	0.68	8.18e-35	Breast cancer;
KIRP	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg21360079	chr12:107162445	NA	-0.67	-9.7	-0.53	4.79e-19	Heart rate;
KIRP	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.4	0.38	7.75e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6662572	0.737	rs7533750	chr1:46558434	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.51	0.33	8.96e-8	Blood protein levels;
KIRP	cis	rs6142102	0.961	rs2235597	chr20:32665614	G/T	cg24642439	chr20:33292090	TP53INP2	0.6	6.71	0.39	1.3e-10	Skin pigmentation;
KIRP	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg23815491	chr16:72088622	HP	0.52	7.45	0.43	1.57e-12	Blood protein levels;
KIRP	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg25019033	chr10:957182	NA	-0.66	-7.78	-0.44	2.02e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs9400467	0.528	rs11153292	chr6:111722379	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.71	-0.34	3.22e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4566357	1.000	rs12612535	chr2:227926998	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	trans	rs979961	0.568	rs75902665	chr4:117919636	A/C	cg02574033	chr7:141398961	KIAA1147	0.88	6.14	0.36	3.22e-9	Ulcerative colitis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg22478328	chr22:32340140	C22orf24;YWHAH	0.46	6.1	0.36	3.98e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg00938859	chr5:1591904	SDHAP3	0.53	6.26	0.37	1.69e-9	Breast cancer;
KIRP	cis	rs5753037	0.653	rs140121	chr22:30138689	C/T	cg01021169	chr22:30184971	ASCC2	-0.42	-5.84	-0.35	1.67e-8	Type 1 diabetes;
KIRP	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11688628	chr1:26146208	FAM54B	-0.46	-6.16	-0.37	2.94e-9	Metabolic traits;
KIRP	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.13	0.69	5.33e-37	Platelet count;
KIRP	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.68	-0.53	5.64e-19	Response to antipsychotic treatment;
KIRP	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.1	0.36	4.19e-9	Ovarian reserve;
KIRP	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.74	9.96	0.54	7.57e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7937612	0.965	rs10892563	chr11:120224544	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.65	-0.39	1.88e-10	Intraocular pressure;
KIRP	cis	rs2033732	0.706	rs1866086	chr8:85071556	G/C	cg05716166	chr8:85095498	RALYL	0.54	6.13	0.36	3.39e-9	Body mass index;
KIRP	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-6.96	-0.41	2.98e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.7	-7.72	-0.44	2.86e-13	Menarche (age at onset);
KIRP	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg00405596	chr8:11794950	NA	-0.5	-6.54	-0.38	3.49e-10	Neuroticism;
KIRP	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.56	7.95	0.45	6.75e-14	Breast cancer;
KIRP	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	14.02	0.67	3.36e-33	Post bronchodilator FEV1;
KIRP	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg01620082	chr3:125678407	NA	-1.04	-6.89	-0.4	4.54e-11	Depression;
KIRP	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.68	10.05	0.54	3.98e-20	Dupuytren's disease;
KIRP	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg07636037	chr3:49044803	WDR6	0.58	5.52	0.33	8.68e-8	Menarche (age at onset);
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.69	-9.01	-0.5	5.94e-17	Longevity;Endometriosis;
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg05255149	chr17:80675120	FN3KRP	0.5	5.34	0.32	2.14e-7	Glycated hemoglobin levels;
KIRP	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg05973401	chr12:123451056	ABCB9	0.49	5.71	0.34	3.3e-8	Neutrophil percentage of white cells;
KIRP	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.44	5.53	0.33	8.07e-8	Huntington's disease progression;
KIRP	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-1.0	-12.92	-0.64	1.65e-29	Platelet distribution width;
KIRP	cis	rs6838801	0.754	rs7669852	chr4:77542398	A/G	cg17476223	chr4:77663285	SHROOM3	-0.36	-5.24	-0.32	3.51e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.74	11.93	0.61	3.53e-26	Sjögren's syndrome;
KIRP	cis	rs8067545	0.532	rs56371654	chr17:19960362	G/T	cg13482628	chr17:19912719	NA	0.47	5.3	0.32	2.56e-7	Schizophrenia;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09414673	chr7:1022797	CYP2W1	0.38	5.08	0.31	7.31e-7	Longevity;Endometriosis;
KIRP	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.33	0.32	2.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg22437258	chr11:111473054	SIK2	-0.6	-7.15	-0.41	9.96e-12	Primary sclerosing cholangitis;
KIRP	cis	rs1619661	0.530	rs1627329	chr10:44691633	A/G	cg09554077	chr10:44749378	NA	0.43	6.29	0.37	1.44e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.98	-13.72	-0.66	3.27e-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	5.63	0.34	4.89e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9479482	0.686	rs13199618	chr6:150384648	C/A	cg03788504	chr6:150331562	NA	-0.31	-5.52	-0.33	8.54e-8	Alopecia areata;
KIRP	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg21204522	chr6:27730016	NA	-0.78	-6.11	-0.36	3.85e-9	Breast cancer;
KIRP	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg06795125	chr2:108905320	SULT1C2	-0.48	-8.34	-0.47	5.27e-15	Blood pressure;
KIRP	cis	rs7317038	0.869	rs61966631	chr13:114015702	T/C	cg24344662	chr13:114018021	GRTP1	-0.57	-7.25	-0.42	5.26e-12	Mean platelet volume;
KIRP	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg21191810	chr6:118973309	C6orf204	0.39	5.58	0.34	6.18e-8	Electrocardiographic conduction measures;
KIRP	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg00405596	chr8:11794950	NA	-0.41	-5.45	-0.33	1.22e-7	Neuroticism;
KIRP	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.81	-9.16	-0.5	2.12e-17	Blood pressure (smoking interaction);
KIRP	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.85	10.4	0.55	3.21e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg11150807	chr10:43354902	NA	-0.62	-5.38	-0.32	1.74e-7	Blood protein levels;
KIRP	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.96	17.61	0.75	1.76e-45	Colorectal adenoma (advanced);
KIRP	cis	rs3790645	1.000	rs392814	chr1:26892009	T/C	cg23229016	chr1:26872525	RPS6KA1	0.23	6.07	0.36	4.83e-9	Glucose homeostasis traits;
KIRP	cis	rs2019216	0.542	rs8073228	chr17:21909838	C/G	cg22648282	chr17:21454238	C17orf51	-0.52	-6.68	-0.39	1.58e-10	Pelvic organ prolapse;
KIRP	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.98	-17.29	-0.74	2.18e-44	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.77	5.98	0.36	7.94e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22811668	chr19:2046303	MKNK2	0.49	6.48	0.38	4.96e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-6.12	-0.36	3.61e-9	Chronic sinus infection;
KIRP	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.29	-0.42	4.14e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.18	-0.46	1.49e-14	Mean corpuscular volume;
KIRP	cis	rs1971762	0.509	rs784567	chr12:53894465	C/T	cg16917193	chr12:54089295	NA	-0.75	-12.32	-0.62	1.69e-27	Height;
KIRP	cis	rs4363506	0.635	rs10830101	chr10:129285555	C/T	cg07804728	chr10:129284050	NA	0.47	6.25	0.37	1.81e-9	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg22563815	chr15:78856949	CHRNA5	0.5	7.87	0.45	1.14e-13	Sudden cardiac arrest;
KIRP	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.6	-8.42	-0.47	3.23e-15	Diastolic blood pressure;
KIRP	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.17	-0.46	1.59e-14	Bone mineral density;
KIRP	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg00405596	chr8:11794950	NA	-0.51	-6.66	-0.39	1.79e-10	Retinal vascular caliber;
KIRP	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg00310523	chr12:86230176	RASSF9	0.41	6.32	0.37	1.23e-9	Major depressive disorder;
KIRP	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.14	16.52	0.73	9.43e-42	Breast cancer;
KIRP	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg21918786	chr6:109611834	NA	0.37	5.17	0.31	4.74e-7	Reticulocyte fraction of red cells;
KIRP	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	0.93	14.18	0.67	9.09e-34	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9547692	1.000	rs527929	chr13:37478506	C/T	cg01493522	chr13:37497338	NA	-0.41	-5.44	-0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.68	7.2	0.42	7.44e-12	Lymphocyte counts;
KIRP	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg05865280	chr17:75406074	SEPT9	0.52	12.6	0.63	2.03e-28	Airflow obstruction;
KIRP	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg17105886	chr17:28927953	LRRC37B2	0.5	5.22	0.32	3.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-6.4	-0.38	7.91e-10	Longevity;Endometriosis;
KIRP	cis	rs1030268	0.640	rs12707092	chr7:133188145	C/G	cg10665199	chr7:133106180	EXOC4	0.56	5.54	0.33	7.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.42	9.06	0.5	4.13e-17	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg23594656	chr7:65796392	TPST1	-0.52	-8.18	-0.46	1.54e-14	Aortic root size;
KIRP	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.48	-5.02	-0.3	1e-6	Psoriasis;
KIRP	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.71	9.96	0.54	7.48e-20	Mean corpuscular volume;
KIRP	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.58	-6.93	-0.4	3.68e-11	Bone mineral density;
KIRP	cis	rs96067	0.805	rs2296268	chr1:36603165	G/A	cg24686825	chr1:36642396	MAP7D1	-0.43	-5.08	-0.31	7.44e-7	Corneal structure;
KIRP	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-7.16	-0.42	9.15e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.18	-0.31	4.51e-7	Life satisfaction;
KIRP	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs6753739	0.745	rs4674356	chr2:219914633	A/C	cg01749213	chr2:219906749	CCDC108	0.44	5.2	0.31	4.24e-7	Height;
KIRP	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg01877450	chr7:97915802	BRI3	-0.38	-5.13	-0.31	5.81e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.29	-0.37	1.41e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs526231	0.511	rs12109860	chr5:102393112	A/T	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg22081084	chr1:89990230	LRRC8B	0.69	6.26	0.37	1.7e-9	Lung function (FEV1);
KIRP	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.84	-10.71	-0.56	3.25e-22	Parkinson's disease;
KIRP	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg22916017	chr11:64110731	CCDC88B	0.55	6.1	0.36	4.1e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.36	-8.12	-0.46	2.29e-14	Cutaneous nevi;
KIRP	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	5.8	0.35	2.04e-8	Lung cancer;
KIRP	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.74	8.28	0.47	7.83e-15	Corneal astigmatism;
KIRP	trans	rs10435719	0.746	rs58007588	chr8:11794969	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.34	0.42	3.16e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.0	-0.36	7.17e-9	Breast cancer;
KIRP	cis	rs2273156	0.929	rs4573843	chr14:35391769	A/G	cg09327582	chr14:35236912	BAZ1A	-0.56	-6.17	-0.37	2.78e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.29	-0.62	2.2e-27	Blood trace element (Zn levels);
KIRP	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.37	-6.41	-0.38	7.44e-10	Heart rate;
KIRP	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg18132916	chr6:79620363	NA	0.47	6.19	0.37	2.51e-9	Left atrial antero-posterior diameter;
KIRP	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.19	0.51	1.75e-17	Colorectal cancer;
KIRP	cis	rs4713675	0.624	rs482786	chr6:33707599	T/C	cg25922239	chr6:33757077	LEMD2	-0.5	-5.31	-0.32	2.46e-7	Plateletcrit;
KIRP	cis	rs988913	1.000	rs9396007	chr6:54807622	T/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.33	-0.32	2.19e-7	Menarche (age at onset);
KIRP	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg23594656	chr7:65796392	TPST1	-0.45	-7.41	-0.43	2.04e-12	Aortic root size;
KIRP	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.41	-0.38	7.28e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg23594656	chr7:65796392	TPST1	0.39	5.9	0.35	1.2e-8	Aortic root size;
KIRP	cis	rs754423	0.631	rs904060	chr14:52519254	A/G	cg05884192	chr14:52515736	NID2	-0.55	-6.91	-0.4	4.09e-11	Craniofacial microsomia;
KIRP	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg10047753	chr17:41438598	NA	1.13	17.69	0.75	9.76e-46	Menopause (age at onset);
KIRP	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg23625390	chr15:77176239	SCAPER	0.53	7.05	0.41	1.8e-11	Blood metabolite levels;
KIRP	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg25173405	chr17:45401733	C17orf57	-0.43	-5.61	-0.34	5.39e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg04657146	chr19:12876947	HOOK2	-0.48	-5.69	-0.34	3.6e-8	Mean corpuscular volume;
KIRP	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.66	-0.48	6.51e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs1864729	1.000	rs2853318	chr8:98283509	A/T	cg08679828	chr8:102218111	ZNF706	-0.73	-6.66	-0.39	1.78e-10	Estradiol plasma levels (breast cancer);
KIRP	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg18944383	chr4:111397179	ENPEP	0.53	9.44	0.52	2.9e-18	Height;
KIRP	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.84	-0.4	6.2e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.41e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.59	-7.16	-0.42	9.09e-12	Aortic root size;
KIRP	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.69	7.88	0.45	1.09e-13	Obesity-related traits;
KIRP	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg08822215	chr16:89438651	ANKRD11	-0.54	-7.28	-0.42	4.39e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg22903471	chr2:27725779	GCKR	-0.47	-4.94	-0.3	1.46e-6	Blood metabolite levels;
KIRP	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg11693508	chr17:37793320	STARD3	0.73	7.83	0.45	1.49e-13	Bipolar disorder;
KIRP	cis	rs258892	0.895	rs155433	chr5:72139664	G/C	cg21869765	chr5:72125136	TNPO1	0.58	6.37	0.38	9.1e-10	Small cell lung carcinoma;
KIRP	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.97	16.02	0.71	4.62e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg21132104	chr15:45694354	SPATA5L1	0.76	10.09	0.54	2.96e-20	Homoarginine levels;
KIRP	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-6.85	-0.4	6.01e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.46	6.13	0.36	3.4e-9	Vitiligo;
KIRP	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs921874	0.553	rs12419551	chr11:86784665	A/G	cg20852851	chr2:240168848	HDAC4	0.47	6.08	0.36	4.54e-9	Total body bone mineral density;
KIRP	cis	rs16936870	0.543	rs12676045	chr8:71259947	C/T	cg14232793	chr8:71155543	NCOA2	0.54	6.24	0.37	1.95e-9	QT interval;
KIRP	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg03209412	chr4:183728196	NA	0.46	5.97	0.36	8.42e-9	Pediatric autoimmune diseases;
KIRP	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.93	-0.4	3.67e-11	Eye color traits;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg26876637	chr1:152193138	HRNR	-0.7	-8.81	-0.49	2.34e-16	Atopic dermatitis;
KIRP	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.44	-0.55	2.25e-21	Hypospadias;
KIRP	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg02570527	chr1:10970165	NA	-0.42	-5.12	-0.31	6.11e-7	Body mass index;
KIRP	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.8	0.57	1.62e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg09343402	chr19:24216269	NA	-0.49	-6.27	-0.37	1.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	6.51	0.38	4.21e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.72	-7.33	-0.42	3.23e-12	Bipolar disorder;
KIRP	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg12591125	chr7:1885375	MAD1L1	0.6	6.03	0.36	6.03e-9	Bipolar disorder;
KIRP	cis	rs1440410	0.835	rs7656276	chr4:144097549	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.26e-10	Ischemic stroke;
KIRP	cis	rs2860975	1.000	rs7920659	chr10:96767924	T/C	cg09036531	chr10:96991505	NA	-0.54	-6.96	-0.41	3.15e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg16497661	chr14:103986332	CKB	0.75	11.17	0.58	1.07e-23	Body mass index;
KIRP	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.69	7.97	0.45	5.82e-14	Monocyte count;
KIRP	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg09060608	chr5:178986726	RUFY1	0.53	8.01	0.45	4.62e-14	Lung cancer;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg17441377	chr17:3906640	NA	0.52	7.68	0.44	3.82e-13	Type 2 diabetes;
KIRP	cis	rs250677	0.652	rs250675	chr5:148438565	A/C	cg12140854	chr5:148520817	ABLIM3	0.58	5.94	0.35	9.46e-9	Breast cancer;
KIRP	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg04370829	chr17:406249	NA	0.4	4.97	0.3	1.27e-6	Prostate cancer;
KIRP	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.65	7.22	0.42	6.39e-12	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs2458413	0.542	rs1810113	chr8:105364594	C/T	cg08657449	chr8:105351661	TM7SF4	0.34	5.58	0.34	6.25e-8	Paget's disease;
KIRP	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-6.14	-0.36	3.29e-9	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg04804543	chr8:142233427	SLC45A4	-0.77	-10.86	-0.57	1.07e-22	Immature fraction of reticulocytes;
KIRP	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.5	5.31	0.32	2.42e-7	Alzheimer's disease;
KIRP	cis	rs12579753	0.667	rs11495227	chr12:82302032	C/T	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.56	-0.33	6.93e-8	Resting heart rate;
KIRP	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.12	-0.36	3.66e-9	Total body bone mineral density;
KIRP	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.44e-9	Breast cancer;
KIRP	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.69	10.33	0.55	5.26e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.38	-0.47	4.2e-15	Retinal vascular caliber;
KIRP	cis	rs367943	0.799	rs2115209	chr5:112973494	A/G	cg12552261	chr5:112820674	MCC	0.57	6.18	0.37	2.58e-9	Type 2 diabetes;
KIRP	cis	rs8113308	1.000	rs8113308	chr19:52445386	T/C	cg25782003	chr19:52490127	ZNF350	0.51	5.02	0.3	9.97e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9826463	0.759	rs17623058	chr3:142344039	G/A	cg20824294	chr3:142316082	PLS1	0.46	6.42	0.38	6.85e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	cg04338863	chr8:33670619	NA	0.47	6.16	0.37	2.87e-9	Body mass index;
KIRP	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.46	5.61	0.34	5.41e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs580438	0.529	rs3796322	chr3:13418327	C/T	cg10657019	chr3:13328039	NA	-0.53	-6.85	-0.4	5.94e-11	Myringotomy;
KIRP	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs8126001	0.573	rs6090043	chr20:62717930	C/T	cg13277040	chr20:62716332	OPRL1;C20orf201	0.27	4.87	0.3	2.03e-6	Pulse pressure;Mean corpuscular volume;
KIRP	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg22676075	chr6:135203613	NA	0.49	7.06	0.41	1.72e-11	Red blood cell count;
KIRP	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.75	11.31	0.58	3.75e-24	Blood metabolite ratios;
KIRP	cis	rs7520050	0.778	rs3014216	chr1:46035760	A/T	cg03146154	chr1:46216737	IPP	0.39	4.87	0.3	2.02e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.26	-0.37	1.68e-9	Response to antipsychotic treatment;
KIRP	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.82	9.81	0.53	2.17e-19	Corneal astigmatism;
KIRP	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg16512390	chr1:228756714	NA	0.45	5.04	0.31	8.95e-7	Diastolic blood pressure;
KIRP	trans	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg10756647	chr7:56101905	PSPH	0.74	6.37	0.38	9.17e-10	Diabetic kidney disease;
KIRP	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg18944383	chr4:111397179	ENPEP	0.48	7.68	0.44	3.65e-13	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.58	-0.34	6.28e-8	Lung cancer;
KIRP	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.01	0.36	6.83e-9	Total body bone mineral density;
KIRP	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.49	-6.17	-0.37	2.78e-9	Menopause (age at onset);
KIRP	cis	rs2219968	0.962	rs1471585	chr8:78945590	C/T	cg00738934	chr8:78996279	NA	-0.38	-5.02	-0.3	1e-6	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.18	-0.42	8.42e-12	Bladder cancer;
KIRP	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.13	0.69	5.33e-37	Platelet count;
KIRP	cis	rs2017305	0.834	rs12266901	chr10:70783522	T/C	cg01024728	chr10:70782572	NA	0.63	5.22	0.32	3.78e-7	Depression (quantitative trait);
KIRP	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.53	7.23	0.42	6.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12963246	chr6:28129442	ZNF389	0.52	6.38	0.38	8.64e-10	Depression;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25699199	chr4:737005	PCGF3	0.5	6.32	0.37	1.25e-9	Interleukin-4 levels;
KIRP	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg00255919	chr5:131827918	IRF1	-0.3	-6.51	-0.38	4.09e-10	Asthma (sex interaction);
KIRP	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7916697	0.588	rs10823165	chr10:70008026	G/A	cg06988349	chr10:69991859	ATOH7	-0.42	-5.15	-0.31	5.36e-7	Optic disc area;
KIRP	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.47	-0.38	5.19e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg23335576	chr14:104009727	NA	0.36	5.21	0.32	3.93e-7	Body mass index;
KIRP	cis	rs13102973	0.931	rs4608864	chr4:135883488	G/A	cg14419869	chr4:135874104	NA	0.52	8.52	0.48	1.64e-15	Subjective well-being;
KIRP	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.75	0.4	1.06e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg00206168	chr11:65308501	LTBP3	0.8	4.93	0.3	1.54e-6	Height;
KIRP	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.32	0.32	2.32e-7	Educational attainment;
KIRP	cis	rs2562456	0.754	rs58338799	chr19:21521811	G/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.45	5.78	0.35	2.23e-8	Initial pursuit acceleration;
KIRP	cis	rs6832769	0.857	rs61072181	chr4:56483377	C/G	cg05960024	chr4:56376020	CLOCK	-0.6	-7.15	-0.41	9.76e-12	Personality dimensions;
KIRP	cis	rs17321999	0.909	rs17009315	chr2:30491392	A/G	cg05247661	chr2:30472410	LBH	0.55	6.07	0.36	4.9e-9	Systemic lupus erythematosus;
KIRP	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg24807547	chr6:37504484	NA	-0.62	-10.06	-0.54	3.77e-20	Cognitive performance;
KIRP	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.37	5.13	0.31	5.82e-7	Coronary artery disease;
KIRP	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	8.58	0.48	1.06e-15	Personality dimensions;
KIRP	cis	rs1448094	0.791	rs7303256	chr12:86333217	C/T	cg00310523	chr12:86230176	RASSF9	-0.39	-6.15	-0.36	3.18e-9	Major depressive disorder;
KIRP	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg15703646	chr7:100209939	MOSPD3	-0.53	-6.04	-0.36	5.55e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03375212	chr4:39368138	RFC1	0.47	6.86	0.4	5.58e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg24498760	chr8:49746867	NA	0.4	4.86	0.3	2.08e-6	Blood metabolite ratios;
KIRP	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg24088639	chr11:34937564	PDHX;APIP	0.43	5.05	0.31	8.79e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2916247	1.000	rs2976512	chr8:93013459	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.94	-0.45	7.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg15038512	chr6:170123185	PHF10	-0.56	-8.42	-0.47	3.08e-15	Obesity-related traits;
KIRP	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.96	0.36	8.76e-9	Breast cancer;
KIRP	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.29	-0.51	8.48e-18	Mean corpuscular volume;
KIRP	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.55	-5.18	-0.31	4.66e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23161317	chr6:28129485	ZNF389	-0.5	-5.9	-0.35	1.18e-8	Depression;
KIRP	cis	rs1847202	0.859	rs6805260	chr3:72933767	C/T	cg06781948	chr3:72941472	GXYLT2	0.5	6.27	0.37	1.65e-9	Motion sickness;
KIRP	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-4.96	-0.3	1.34e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg19581696	chr11:59522087	STX3	-0.43	-6.05	-0.36	5.41e-9	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.7	9.22	0.51	1.43e-17	Morning vs. evening chronotype;
KIRP	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.94	13.43	0.65	3.23e-31	Height;
KIRP	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg06565975	chr8:143823917	SLURP1	0.43	6.31	0.37	1.29e-9	Urinary tract infection frequency;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06730340	chr3:9811714	CAMK1	0.49	6.32	0.37	1.2e-9	Parkinson's disease;
KIRP	cis	rs7692976	0.549	rs116513354	chr4:110857783	T/G	cg06981781	chr4:110842888	EGF	-0.24	-5.4	-0.33	1.54e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7078219	1.000	rs61872688	chr10:101273546	G/A	cg17888390	chr10:101282816	NA	-0.3	-4.84	-0.3	2.25e-6	Dental caries;
KIRP	cis	rs2380205	1.000	rs2380205	chr10:5886734	C/T	cg27141509	chr10:5886111	NA	-0.36	-5.07	-0.31	7.76e-7	Breast cancer;
KIRP	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.41	-0.38	7.46e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4819052	0.851	rs11558445	chr21:46685175	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	5.79	0.35	2.15e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg01114163	chr5:1856713	NA	-0.44	-5.38	-0.32	1.71e-7	Cardiovascular disease risk factors;
KIRP	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.64	6.42	0.38	6.89e-10	Gastritis;
KIRP	cis	rs12431939	0.626	rs10138856	chr14:51712712	G/A	cg23942311	chr14:51606299	NA	0.43	5.04	0.31	8.82e-7	Cancer;
KIRP	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg00405596	chr8:11794950	NA	0.57	8.01	0.45	4.54e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg05234568	chr11:5960015	NA	-0.61	-6.27	-0.37	1.62e-9	DNA methylation (variation);
KIRP	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.85	16.16	0.72	1.64e-40	Anterior chamber depth;
KIRP	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.5	-6.87	-0.4	5.34e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.59	5.47	0.33	1.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg10932868	chr11:921992	NA	0.56	7.12	0.41	1.21e-11	Alzheimer's disease (late onset);
KIRP	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.67e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg26754761	chr2:177040938	NA	0.31	5.47	0.33	1.09e-7	IgG glycosylation;
KIRP	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.48	-6.67	-0.39	1.65e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9517302	0.512	rs9517305	chr13:99097910	G/C	cg24044564	chr13:99115944	STK24	0.56	6.4	0.38	7.6e-10	Obesity-related traits;
KIRP	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.84	-0.45	1.39e-13	Systolic blood pressure;
KIRP	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.73	-7.8	-0.45	1.71e-13	Blood pressure (smoking interaction);
KIRP	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.49	-0.33	1.01e-7	Aortic root size;
KIRP	cis	rs6832769	0.961	rs10026692	chr4:56452706	C/T	cg05960024	chr4:56376020	CLOCK	-0.62	-8.12	-0.46	2.2e-14	Personality dimensions;
KIRP	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.9	-14.29	-0.67	4.03e-34	Dental caries;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg02462569	chr6:150064036	NUP43	-0.36	-5.52	-0.33	8.43e-8	Lung cancer;
KIRP	cis	rs7011507	1.000	rs7829495	chr8:49164850	C/A	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22044401	chr12:113405926	OAS3	0.42	6.02	0.36	6.2e-9	Survival in pancreatic cancer;
KIRP	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.61	6.7	0.39	1.39e-10	Corneal structure;
KIRP	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-9.02	-0.5	5.47e-17	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.79e-15	Prudent dietary pattern;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg22105103	chr4:187893119	NA	0.72	10.8	0.57	1.71e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.69	-10.23	-0.55	1.09e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.82	10.37	0.55	3.82e-21	Menopause (age at onset);
KIRP	cis	rs7312774	0.748	rs7295619	chr12:107316934	T/A	cg16260113	chr12:107380972	MTERFD3	0.73	6.57	0.39	2.98e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.73	8.67	0.48	5.83e-16	Blood protein levels;
KIRP	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.66	0.34	4.29e-8	Educational attainment;
KIRP	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg26554054	chr8:600488	NA	0.66	5.32	0.32	2.31e-7	IgG glycosylation;
KIRP	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg23335576	chr14:104009727	NA	0.4	5.47	0.33	1.11e-7	Body mass index;
KIRP	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg05973401	chr12:123451056	ABCB9	0.62	7.27	0.42	4.73e-12	Platelet count;
KIRP	trans	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06437703	chr8:37914619	EIF4EBP1	0.6	8.11	0.46	2.35e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg17441377	chr17:3906640	NA	0.58	8.74	0.49	3.62e-16	Type 2 diabetes;
KIRP	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.35	0.38	1.05e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg15556689	chr8:8085844	FLJ10661	-0.67	-9.86	-0.53	1.53e-19	Triglycerides;
KIRP	cis	rs13161895	0.941	rs3797764	chr5:179439345	A/G	cg02702477	chr5:179499311	RNF130	-0.69	-5.36	-0.32	1.95e-7	LDL cholesterol;
KIRP	cis	rs5167	0.504	rs4803779	chr19:45456497	T/C	cg10169327	chr19:45448959	APOC2	0.33	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.55	5.95	0.35	9.1e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.59	8.12	0.46	2.28e-14	Menarche (age at onset);
KIRP	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.79	-11.95	-0.61	3.06e-26	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05800723	chr4:79103126	FRAS1	-0.51	-6.36	-0.38	9.58e-10	Smoking initiation;
KIRP	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.56	7.72	0.44	2.86e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26585770	chr6:43027623	KLC4;MRPL2	0.51	6.58	0.39	2.81e-10	Parkinson's disease;
KIRP	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg19468946	chr17:37922297	IKZF3	-0.47	-6.63	-0.39	2.13e-10	Asthma;
KIRP	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg15556689	chr8:8085844	FLJ10661	0.61	7.51	0.43	1.09e-12	Neuroticism;
KIRP	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg11645453	chr3:52864694	ITIH4	-0.35	-5.32	-0.32	2.29e-7	Body mass index;
KIRP	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg04226714	chr8:49833948	SNAI2	-0.46	-6.58	-0.39	2.78e-10	Life satisfaction;
KIRP	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.07	0.36	4.8e-9	Menopause (age at onset);
KIRP	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.73	10.64	0.56	5.57e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg06636001	chr8:8085503	FLJ10661	0.59	7.73	0.44	2.69e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.49	-6.49	-0.38	4.71e-10	IgG glycosylation;
KIRP	cis	rs12580194	0.593	rs60142559	chr12:55719192	A/G	cg11794356	chr12:55725991	OR6C3	-0.6	-8.56	-0.48	1.23e-15	Cancer;
KIRP	cis	rs7011049	1.000	rs117708010	chr8:53844026	G/A	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	13.03	0.64	7.32e-30	Platelet count;
KIRP	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4073416	0.542	rs9323460	chr14:65933199	T/G	cg03016385	chr14:66212404	NA	-0.57	-6.94	-0.4	3.48e-11	N-glycan levels;
KIRP	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.91	15.74	0.71	4.27e-39	Headache;
KIRP	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.85e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs8113308	0.810	rs7254930	chr19:52451527	G/T	cg25782003	chr19:52490127	ZNF350	0.54	5.11	0.31	6.44e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg13789015	chr9:136890014	NCRNA00094	-0.65	-5.85	-0.35	1.59e-8	Mosquito bite size;
KIRP	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.4	-5.62	-0.34	5.26e-8	Coronary artery disease;
KIRP	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.03	-0.46	4e-14	Mood instability;
KIRP	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg03060546	chr3:49711283	APEH	-0.63	-6.26	-0.37	1.74e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg25288420	chr1:78511713	GIPC2	0.56	7.48	0.43	1.29e-12	Obesity-related traits;
KIRP	cis	rs6541297	0.699	rs1555290	chr1:230294989	A/C	cg05784532	chr1:230284198	GALNT2	-0.45	-5.97	-0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.45	5.81	0.35	1.93e-8	Crohn's disease;
KIRP	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg22633769	chr20:60982531	CABLES2	-0.51	-6.51	-0.38	4.27e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2191566	0.960	rs11083733	chr19:44520919	G/C	cg18700516	chr19:44507157	ZNF230	-0.44	-5.14	-0.31	5.67e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg04733989	chr22:42467013	NAGA	0.63	7.9	0.45	9.35e-14	Schizophrenia;
KIRP	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg24881330	chr22:46731750	TRMU	0.8	5.49	0.33	1e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9469890	0.604	rs11758426	chr6:34503338	A/G	cg17674042	chr6:34482479	PACSIN1	-0.4	-4.89	-0.3	1.83e-6	Pubertal anthropometrics;Coronary artery disease;
KIRP	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.28	-0.37	1.54e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.68	8.3	0.47	7.15e-15	Aortic root size;
KIRP	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg16479474	chr6:28041457	NA	0.44	4.9	0.3	1.73e-6	Depression;
KIRP	cis	rs12900413	0.687	rs13343250	chr15:90311410	T/C	cg24650279	chr15:90327240	NA	-0.41	-5.23	-0.32	3.7e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg19847130	chr8:10466454	RP1L1	0.43	6.23	0.37	1.96e-9	Joint mobility (Beighton score);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05284480	chr16:2318642	RNPS1	0.48	6.33	0.37	1.16e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	0.64	5.75	0.34	2.59e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-1.04	-19.26	-0.78	4.97e-51	Height;
KIRP	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.66	8.35	0.47	5.12e-15	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10844884	chr10:45498904	ZNF22	-0.48	-6.66	-0.39	1.83e-10	Parkinson's disease;
KIRP	cis	rs909341	0.909	rs1151622	chr20:62365556	A/G	cg11503966	chr20:62272292	STMN3	-0.42	-5.77	-0.35	2.32e-8	Atopic dermatitis;
KIRP	cis	rs4700695	0.841	rs428880	chr5:65245133	C/A	cg21114390	chr5:65439923	SFRS12	0.54	5.67	0.34	4.07e-8	Facial morphology (factor 19);
KIRP	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.54	7.16	0.42	9.01e-12	Morning vs. evening chronotype;
KIRP	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.63	0.48	7.68e-16	Bipolar disorder;
KIRP	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg26384229	chr12:38710491	ALG10B	0.67	8.96	0.5	8.57e-17	Morning vs. evening chronotype;
KIRP	trans	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.36	10.15	0.54	1.88e-20	Diabetic kidney disease;
KIRP	cis	rs300890	0.642	rs13101346	chr4:144283155	C/T	cg01719995	chr4:144104893	USP38	-0.44	-5.46	-0.33	1.14e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg08461772	chr7:95026248	PON3	-0.38	-5.34	-0.32	2.13e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs6456042	0.893	rs1134482	chr6:166571157	G/A	cg11088901	chr6:166572345	T	-0.34	-5.03	-0.31	9.69e-7	Asthma;
KIRP	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg04034577	chr2:241836375	C2orf54	0.28	5.42	0.33	1.42e-7	Urinary metabolites;
KIRP	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs2658782	0.547	rs6483244	chr11:93197935	A/G	cg15737290	chr11:93063684	CCDC67	0.45	5.0	0.3	1.09e-6	Pulmonary function decline;
KIRP	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.7	-9.25	-0.51	1.16e-17	Glomerular filtration rate;
KIRP	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.31	-7.21	-0.42	7.04e-12	Mean corpuscular volume;
KIRP	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.73e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1559088	0.895	rs13345542	chr19:33586739	G/C	cg03563238	chr19:33554763	RHPN2	-0.32	-5.67	-0.34	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.59	-0.39	2.73e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.13e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073416	0.508	rs10152007	chr14:66047434	A/T	cg03016385	chr14:66212404	NA	-0.51	-6.18	-0.37	2.59e-9	N-glycan levels;
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg07701084	chr6:150067640	NUP43	0.63	8.17	0.46	1.62e-14	Lung cancer;
KIRP	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg23166289	chr1:210001082	C1orf107	-0.52	-5.93	-0.35	9.98e-9	Orofacial clefts;
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg11410718	chr7:27170412	HOXA4	0.39	5.44	0.33	1.31e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg01721255	chr8:58191610	C8orf71	0.46	4.98	0.3	1.2e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4762326	0.966	rs7966079	chr12:95699240	T/C	cg07737802	chr12:95537812	FGD6	0.46	6.49	0.38	4.59e-10	Endometriosis;
KIRP	cis	rs4671400	0.571	rs4672428	chr2:61478497	C/T	cg15711740	chr2:61764176	XPO1	0.6	6.52	0.38	3.98e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.74	10.02	0.54	4.73e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg00129232	chr17:37814104	STARD3	-0.5	-6.02	-0.36	6.46e-9	Self-reported allergy;
KIRP	cis	rs2273669	0.748	rs59883302	chr6:109377033	C/A	cg05315195	chr6:109294784	ARMC2	-0.46	-4.9	-0.3	1.72e-6	Prostate cancer;
KIRP	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg07068956	chr7:100330872	ZAN	0.4	5.41	0.33	1.47e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.86	-0.63	2.63e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg00361562	chr2:198649771	BOLL	-0.49	-5.04	-0.31	9.11e-7	Ulcerative colitis;
KIRP	trans	rs1424233	1.000	rs11150183	chr16:79680556	G/T	cg11120865	chr14:21853037	SUPT16H	0.37	6.18	0.37	2.67e-9	Obesity;
KIRP	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03576123	chr11:487126	PTDSS2	-1.05	-8.57	-0.48	1.12e-15	Body mass index;
KIRP	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	0.97	5.89	0.35	1.24e-8	Height;
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18404041	chr3:52824283	ITIH1	-0.35	-4.85	-0.3	2.18e-6	Electroencephalogram traits;
KIRP	trans	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg24644049	chr4:85504048	CDS1	1.09	6.63	0.39	2.06e-10	Skin colour saturation;
KIRP	cis	rs300890	0.513	rs11100775	chr4:144073912	A/G	cg01719995	chr4:144104893	USP38	-0.43	-5.51	-0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.06	-0.31	8.16e-7	Neutrophil percentage of white cells;
KIRP	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg13010199	chr12:38710504	ALG10B	0.53	6.74	0.39	1.09e-10	Morning vs. evening chronotype;
KIRP	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.45	5.34	0.32	2.07e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2904967	0.929	rs1783486	chr11:65008917	A/G	cg12562828	chr11:65076843	NA	-0.61	-8.96	-0.5	8.45e-17	Mean corpuscular volume;
KIRP	cis	rs4654899	0.772	rs10916892	chr1:21201325	A/G	cg05370193	chr1:21551575	ECE1	0.47	5.37	0.32	1.84e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs10435736	0.673	rs4879523	chr9:31534673	A/G	cg26105015	chr3:122745099	SEMA5B	-0.47	-6.03	-0.36	5.83e-9	Metabolite levels  (X-11787);
KIRP	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.01	-0.57	3.38e-23	Height;
KIRP	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.63	-6.98	-0.41	2.69e-11	Neuroticism;
KIRP	cis	rs17221829	0.702	rs72969198	chr11:89357607	T/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.09	-0.31	7.04e-7	Anxiety in major depressive disorder;
KIRP	cis	rs1943345	0.530	rs501155	chr11:82919893	G/T	cg07047830	chr11:82868014	PCF11	0.43	4.97	0.3	1.26e-6	Obesity-related traits;
KIRP	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.7	9.69	0.53	5.19e-19	Mean corpuscular volume;
KIRP	cis	rs17123764	0.710	rs7137976	chr12:50099067	A/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.89	0.3	1.83e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1012068	0.541	rs11703587	chr22:32322414	A/C	cg15333674	chr22:32435499	NA	-0.47	-5.37	-0.32	1.81e-7	Chronic hepatitis C infection;
KIRP	cis	rs2905347	0.757	rs2905318	chr7:22696653	A/C	cg23521230	chr7:22704884	NA	-0.4	-5.12	-0.31	6.11e-7	Major depression and alcohol dependence;
KIRP	cis	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg06521331	chr12:34319734	NA	-0.47	-5.75	-0.34	2.63e-8	Morning vs. evening chronotype;
KIRP	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-5.2	-0.31	4.17e-7	Neuroticism;
KIRP	cis	rs471756	0.618	rs511364	chr9:264265	A/G	cg14500300	chr9:211689	NA	0.41	5.84	0.35	1.67e-8	Mean platelet volume;
KIRP	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.39	-5.45	-0.33	1.2e-7	Monocyte count;
KIRP	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg21775007	chr8:11205619	TDH	0.44	5.88	0.35	1.31e-8	Neuroticism;
KIRP	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.74	-9.9	-0.53	1.18e-19	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs853679	0.505	rs200992	chr6:27814677	A/G	cg21204522	chr6:27730016	NA	-0.71	-5.2	-0.31	4.13e-7	Depression;
KIRP	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.43	5.58	0.33	6.45e-8	Obesity-related traits;
KIRP	cis	rs4704187	0.532	rs75392670	chr5:74394968	A/G	cg03227963	chr5:74354835	NA	0.42	6.08	0.36	4.44e-9	Response to amphetamines;
KIRP	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg01448562	chr3:133502909	NA	-0.45	-6.11	-0.36	3.85e-9	Iron status biomarkers;
KIRP	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.29	0.67	4.03e-34	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19770116	chr3:57199524	IL17RD	0.5	6.36	0.38	9.72e-10	Parkinson's disease;
KIRP	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg17133734	chr15:86042851	AKAP13	-0.45	-5.7	-0.34	3.4e-8	Coronary artery disease;
KIRP	cis	rs7534824	0.625	rs7414132	chr1:101526413	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.32	0.32	2.37e-7	Refractive astigmatism;
KIRP	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg23484912	chr5:273055	PDCD6	0.58	7.33	0.42	3.32e-12	Pancreatic cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13784866	chr9:139269562	CARD9	0.47	6.29	0.37	1.4e-9	Survival in pancreatic cancer;
KIRP	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.87	-0.35	1.37e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.82	-0.45	1.58e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04238871	chr10:126431886	FAM53B	0.68	6.35	0.38	1.05e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.43	11.63	0.6	3.22e-25	Diabetic kidney disease;
KIRP	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg13444842	chr1:152974279	SPRR3	-0.38	-5.47	-0.33	1.1e-7	Inflammatory skin disease;
KIRP	cis	rs13161895	1.000	rs4129403	chr5:179476610	A/G	cg02702477	chr5:179499311	RNF130	0.73	5.82	0.35	1.82e-8	LDL cholesterol;
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-5.64	-0.34	4.61e-8	Lung cancer;
KIRP	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.83	-0.45	1.45e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.31	-0.42	3.63e-12	Colorectal cancer;
KIRP	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg19324714	chr2:237145437	ASB18	0.56	6.47	0.38	5.2e-10	Educational attainment;
KIRP	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.68	8.62	0.48	8.03e-16	Blood metabolite levels;
KIRP	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	0.99	11.78	0.6	1.05e-25	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg02353165	chr6:42928485	GNMT	0.45	5.02	0.3	1.01e-6	Blood protein levels;
KIRP	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg17145862	chr1:211918768	LPGAT1	0.75	10.38	0.55	3.64e-21	Leprosy;
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.42e-6	Life satisfaction;
KIRP	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	1.17	10.24	0.55	1e-20	Skin colour saturation;
KIRP	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg09911534	chr15:67153556	NA	-0.49	-5.27	-0.32	2.92e-7	Lung cancer (smoking interaction);
KIRP	cis	rs73200209	0.912	rs59509739	chr12:116573496	A/G	cg01776926	chr12:116560359	MED13L	-0.45	-5.46	-0.33	1.18e-7	Total body bone mineral density;
KIRP	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg07827796	chr19:33622959	WDR88	0.42	4.98	0.3	1.21e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg26752003	chr8:145688521	CYHR1	0.76	10.4	0.55	3.08e-21	Age at first birth;
KIRP	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg01420254	chr6:26195488	NA	1.16	10.2	0.55	1.31e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.74	-0.39	1.15e-10	Bladder cancer;
KIRP	cis	rs11169552	0.510	rs876079	chr12:51030709	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-4.96	-0.3	1.32e-6	Colorectal cancer;
KIRP	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.72	11.76	0.6	1.22e-25	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	5.02	0.31	9.73e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg23161317	chr6:28129485	ZNF389	0.41	5.06	0.31	8.09e-7	Cardiac Troponin-T levels;
KIRP	cis	rs6959887	0.609	rs4723398	chr7:35272923	C/T	cg06685737	chr7:35301730	NA	0.61	9.9	0.53	1.15e-19	Birth weight;
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg23985595	chr17:80112537	CCDC57	-0.34	-5.14	-0.31	5.53e-7	Life satisfaction;
KIRP	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	0.41	5.0	0.3	1.08e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	cis	rs12208915	0.731	rs9443630	chr6:79661777	G/T	cg09184832	chr6:79620586	NA	0.47	5.2	0.31	4.15e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg10047753	chr17:41438598	NA	1.15	18.14	0.76	2.88e-47	Menopause (age at onset);
KIRP	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg24375607	chr4:120327624	NA	0.5	5.48	0.33	1.04e-7	Corneal astigmatism;
KIRP	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg02811702	chr13:24901961	NA	0.44	5.83	0.35	1.75e-8	Obesity-related traits;
KIRP	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23903597	chr17:61704154	MAP3K3	-0.45	-5.63	-0.34	5.01e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6120849	0.901	rs13037296	chr20:33749228	T/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.04	0.36	5.59e-9	Protein C levels;
KIRP	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.55	5.01	0.3	1.05e-6	Skin colour saturation;
KIRP	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg09640425	chr7:158790006	NA	0.4	4.99	0.3	1.13e-6	Facial morphology (factor 20);
KIRP	cis	rs6669119	0.668	rs17354622	chr1:19087996	G/T	cg19637330	chr1:19110922	NA	0.63	5.55	0.33	7.3e-8	Percentage gas trapping;
KIRP	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg27205649	chr11:78285834	NARS2	-0.66	-7.67	-0.44	3.96e-13	Alzheimer's disease (survival time);
KIRP	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg19847130	chr8:10466454	RP1L1	-0.36	-5.45	-0.33	1.21e-7	Retinal vascular caliber;
KIRP	cis	rs7646881	0.812	rs61696028	chr3:158455703	A/C	cg19483011	chr3:158453295	NA	-0.56	-5.94	-0.35	9.55e-9	Tetralogy of Fallot;
KIRP	cis	rs1519814	0.915	rs10808507	chr8:121166429	G/A	cg22335954	chr8:121166405	COL14A1	-0.7	-7.54	-0.43	9.12e-13	Breast cancer;
KIRP	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.7	-0.44	3.39e-13	Mean platelet volume;
KIRP	cis	rs960902	0.747	rs115003310	chr2:37719263	A/C	cg25341268	chr2:37734390	NA	0.64	8.51	0.48	1.75e-15	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.76	-12.01	-0.61	1.92e-26	Rheumatoid arthritis;
KIRP	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17507749	chr15:85114479	UBE2QP1	0.71	8.0	0.45	4.82e-14	Schizophrenia;
KIRP	cis	rs963731	0.649	rs297149	chr2:39324469	G/C	cg04010122	chr2:39346883	SOS1	-0.91	-6.52	-0.38	3.88e-10	Corticobasal degeneration;
KIRP	cis	rs3733606	0.503	rs11731274	chr4:6891455	T/G	cg05012661	chr4:6891264	NA	0.55	7.34	0.42	3.05e-12	Platelet count;
KIRP	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.56	7.96	0.45	6.16e-14	Dupuytren's disease;
KIRP	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.06	0.41	1.68e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08280861	chr8:58055591	NA	0.62	5.05	0.31	8.56e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg00129232	chr17:37814104	STARD3	-0.49	-6.15	-0.36	3.13e-9	Eosinophil percentage of white cells;
KIRP	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.34	12.3	0.62	2.1e-27	Diabetic retinopathy;
KIRP	cis	rs10465746	0.809	rs2389617	chr1:84437652	A/T	cg10977910	chr1:84465055	TTLL7	0.57	7.26	0.42	5.19e-12	Obesity-related traits;
KIRP	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72772090	0.710	rs11739280	chr5:96074147	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.66	5.93	0.35	1.02e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2505998	0.833	rs2505533	chr10:43594453	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.53	-5.71	-0.34	3.3e-8	Hirschsprung disease;
KIRP	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg05887092	chr17:76393375	PGS1	0.54	7.49	0.43	1.22e-12	HDL cholesterol levels;
KIRP	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg08741688	chr4:3415352	RGS12	-0.46	-5.13	-0.31	5.95e-7	Serum sulfate level;
KIRP	cis	rs1440410	0.795	rs9308169	chr4:144184743	A/G	cg01719995	chr4:144104893	USP38	-0.38	-4.85	-0.3	2.17e-6	Ischemic stroke;
KIRP	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg20965017	chr5:231967	SDHA	-0.5	-5.64	-0.34	4.66e-8	Breast cancer;
KIRP	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	0.89	10.03	0.54	4.64e-20	Corneal structure;
KIRP	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg13206674	chr6:150067644	NUP43	-0.47	-5.9	-0.35	1.18e-8	Lung cancer;
KIRP	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.91	14.69	0.68	1.68e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.82	0.66	1.51e-32	Alzheimer's disease;
KIRP	cis	rs10073892	0.662	rs10059790	chr5:101643293	C/T	cg19774478	chr5:101632501	SLCO4C1	0.63	6.38	0.38	8.59e-10	Cognitive decline (age-related);
KIRP	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg25486957	chr4:152246857	NA	-0.53	-5.83	-0.35	1.71e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.89	-0.45	9.74e-14	Retinal vascular caliber;
KIRP	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.1	0.46	2.6e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg12131826	chr15:77904385	NA	0.47	6.36	0.38	9.62e-10	Type 2 diabetes;
KIRP	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.67	-11.02	-0.57	3.35e-23	Urate levels in overweight individuals;
KIRP	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.56	7.08	0.41	1.55e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.86	9.7	0.53	4.77e-19	High light scatter reticulocyte count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13789711	chr9:139743225	PHPT1	0.51	6.74	0.39	1.14e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs80282103	0.717	rs74117685	chr10:1100410	A/G	cg08668510	chr10:1095578	IDI1	1.12	6.82	0.4	7.16e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs4919044	0.866	rs11187265	chr10:94824166	G/A	cg05127821	chr10:94822908	CYP26C1	-0.92	-6.71	-0.39	1.36e-10	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17063962	chr7:91808500	NA	0.65	10.49	0.56	1.56e-21	Breast cancer;
KIRP	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.63	0.44	5.2e-13	IgG glycosylation;
KIRP	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.09	0.36	4.3e-9	Alzheimer's disease (late onset);
KIRP	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24783234	chr19:1104508	GPX4	0.59	7.4	0.43	2.12e-12	Parkinson's disease;
KIRP	cis	rs9535307	0.929	rs9526593	chr13:50288777	T/C	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-0.86	-9.53	-0.52	1.53e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27280396	chr15:61521715	RORA	-0.45	-6.2	-0.37	2.36e-9	Metabolic traits;
KIRP	cis	rs921943	1.000	rs731124	chr5:78317413	C/T	cg26802063	chr5:78281964	ARSB	0.49	6.1	0.36	4.1e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg25276700	chr6:44698697	NA	0.35	4.98	0.3	1.21e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.32	8.17	0.46	1.64e-14	Primary biliary cholangitis;
KIRP	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg06915872	chr16:87998081	BANP	0.5	5.1	0.31	6.63e-7	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18813170	chr20:25677664	ZNF337	0.52	6.49	0.38	4.74e-10	Parkinson's disease;
KIRP	cis	rs2371030	0.833	rs2371034	chr2:211578153	G/A	cg18417063	chr2:211583084	NA	-0.46	-6.55	-0.39	3.41e-10	Non-small cell lung cancer;
KIRP	cis	rs2742417	0.967	rs2742439	chr3:45744248	G/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg26384229	chr12:38710491	ALG10B	0.72	9.56	0.52	1.29e-18	Morning vs. evening chronotype;
KIRP	cis	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19171272	chr22:38449367	NA	0.54	7.96	0.45	6.25e-14	Glioblastoma;Glioma;
KIRP	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg27143246	chr3:169489583	MYNN	-0.42	-6.34	-0.37	1.11e-9	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.81	-0.45	1.62e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.69	-9.87	-0.53	1.38e-19	Inflammatory bowel disease;
KIRP	cis	rs77972171	0.558	rs75877446	chr7:123358754	T/C	cg03229431	chr7:123269106	ASB15	-0.58	-4.93	-0.3	1.53e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.63	7.33	0.42	3.29e-12	Obesity-related traits;
KIRP	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00338735	chr4:53728038	RASL11B	0.42	5.3	0.32	2.57e-7	Optic nerve measurement (cup area);
KIRP	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.64	8.43	0.47	2.92e-15	Alcohol dependence;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12867853	chr22:44351301	SAMM50	-0.44	-6.09	-0.36	4.39e-9	Metabolic traits;
KIRP	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.3	1.44e-6	Cognitive test performance;
KIRP	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg16141378	chr3:129829833	LOC729375	0.57	7.64	0.44	4.78e-13	Neuroticism;
KIRP	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg26384229	chr12:38710491	ALG10B	0.54	7.26	0.42	5.06e-12	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13949487	chr9:98637884	C9orf130;C9orf102	0.46	6.16	0.37	3.02e-9	Parkinson's disease;
KIRP	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.69	-9.14	-0.5	2.45e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23903597	chr17:61704154	MAP3K3	-0.55	-6.69	-0.39	1.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7084402	0.967	rs1649036	chr10:60331878	C/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.5	-0.56	1.45e-21	Refractive error;
KIRP	cis	rs4236601	0.720	rs6466580	chr7:116154726	T/C	cg05166801	chr7:116143459	CAV2	0.48	5.97	0.36	8.16e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.78	9.21	0.51	1.5e-17	Corneal astigmatism;
KIRP	cis	rs11779988	0.545	rs454692	chr8:17789298	T/C	cg01800426	chr8:17659068	MTUS1	-0.6	-5.97	-0.36	8.16e-9	Breast cancer;
KIRP	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.61	0.39	2.39e-10	Menarche (age at onset);
KIRP	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg05220968	chr6:146057943	EPM2A	-0.39	-5.07	-0.31	7.88e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.6	0.44	6.11e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.82	9.73	0.53	3.82e-19	Corneal astigmatism;
KIRP	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg03713592	chr11:72463424	ARAP1	0.55	6.01	0.36	6.58e-9	Body mass index;
KIRP	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg18261050	chr1:119551319	NA	0.49	6.11	0.36	3.78e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs7939886	0.920	rs76934983	chr11:55993334	A/C	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg18932078	chr1:2524107	MMEL1	0.4	5.45	0.33	1.23e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-1.01	-16.87	-0.73	5.9e-43	Height;
KIRP	cis	rs2880765	0.546	rs11637726	chr15:86059271	C/T	cg17133734	chr15:86042851	AKAP13	0.6	7.16	0.42	9.35e-12	Coronary artery disease;
KIRP	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.66	9.31	0.51	7.26e-18	Lymphocyte counts;
KIRP	cis	rs11731606	0.508	rs28497379	chr4:95283789	G/T	cg20625393	chr4:95128694	SMARCAD1	0.69	6.0	0.36	6.99e-9	Mean platelet volume;
KIRP	cis	rs6466055	0.720	rs4730072	chr7:104832260	A/T	cg04380332	chr7:105027541	SRPK2	-0.62	-9.45	-0.52	2.7e-18	Schizophrenia;
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.86	-0.4	5.62e-11	Longevity;Endometriosis;
KIRP	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg14703610	chr5:56206110	C5orf35	0.5	6.94	0.4	3.4e-11	Coronary artery disease;
KIRP	cis	rs55962025	0.883	rs59613878	chr4:3139152	C/T	cg13731523	chr4:3047190	NA	0.32	4.95	0.3	1.36e-6	Parental longevity (mother's age at death);
KIRP	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg10760299	chr15:45669010	GATM	0.34	5.24	0.32	3.54e-7	Homoarginine levels;
KIRP	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg06671706	chr8:8559999	CLDN23	0.57	6.42	0.38	6.81e-10	Obesity-related traits;
KIRP	cis	rs74181299	0.684	rs10185243	chr2:65355744	G/T	cg05010058	chr2:65284262	CEP68	-0.49	-6.54	-0.38	3.55e-10	Pulse pressure;
KIRP	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg16255804	chr6:135334527	HBS1L	-0.34	-5.38	-0.32	1.7e-7	Red blood cell count;
KIRP	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.09	-0.46	2.71e-14	Aortic root size;
KIRP	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg23791538	chr6:167370224	RNASET2	-0.4	-5.05	-0.31	8.76e-7	Crohn's disease;
KIRP	cis	rs6723226	0.708	rs2710627	chr2:32758627	A/G	cg02381751	chr2:32503542	YIPF4	0.79	9.55	0.52	1.34e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg21433313	chr16:3507492	NAT15	0.65	7.18	0.42	8.17e-12	Tuberculosis;
KIRP	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg00656387	chr3:40428638	ENTPD3	0.38	4.86	0.3	2.08e-6	Renal cell carcinoma;
KIRP	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg16083429	chr3:49237500	CCDC36	-0.39	-5.01	-0.3	1.06e-6	Menarche (age at onset);
KIRP	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.66	-12.4	-0.62	9.49e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9398803	0.687	rs7743860	chr6:126927717	T/G	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.56	-0.33	7e-8	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18818321	chr7:16793256	TSPAN13	0.43	6.46	0.38	5.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01727434	chr2:152118530	RBM43	-0.48	-6.6	-0.39	2.53e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.97	11.53	0.59	7.29e-25	Corneal astigmatism;
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.73	10.4	0.55	3e-21	Lung cancer;
KIRP	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg24375607	chr4:120327624	NA	0.59	6.42	0.38	6.89e-10	Corneal astigmatism;
KIRP	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs661054	1.000	rs11215037	chr11:114403674	G/A	cg19465033	chr11:114479364	NA	0.39	5.26	0.32	3.15e-7	Ulcerative colitis;
KIRP	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg00129232	chr17:37814104	STARD3	-0.64	-6.97	-0.41	2.93e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs17209837	1.000	rs2302385	chr7:87091826	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-7.48	-0.43	1.35e-12	Gallbladder cancer;
KIRP	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	10.14	0.54	2.08e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.69	8.71	0.49	4.47e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Colorectal cancer;
KIRP	cis	rs1185460	1.000	rs1799993	chr11:118958127	A/C	cg01677386	chr11:118938358	VPS11	0.48	5.61	0.34	5.36e-8	Coronary artery disease;
KIRP	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.36	-0.32	1.93e-7	Metabolite levels;
KIRP	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.44	4.99	0.3	1.17e-6	Type 2 diabetes;
KIRP	cis	rs7084402	0.967	rs1649023	chr10:60285820	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.54	-0.56	1.12e-21	Refractive error;
KIRP	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06481639	chr22:41940642	POLR3H	0.7	7.18	0.42	8.11e-12	Vitiligo;
KIRP	cis	rs7712401	0.601	rs39819	chr5:122301676	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs1021993	0.545	rs1006317	chr1:209552636	G/T	cg24446417	chr1:209558027	NA	-0.5	-5.07	-0.31	8.01e-7	Gut microbiome composition (winter);
KIRP	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg08992911	chr2:238395768	MLPH	0.49	5.01	0.3	1.02e-6	Prostate cancer;
KIRP	cis	rs300890	0.513	rs72719179	chr4:144061433	C/T	cg01719995	chr4:144104893	USP38	-0.43	-5.51	-0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs35661897	0.539	rs7580876	chr2:227345846	T/A	cg03426602	chr2:227312417	NA	-0.33	-4.85	-0.3	2.18e-6	Urinary tract infection frequency;
KIRP	trans	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg14791747	chr16:20752902	THUMPD1	-0.57	-6.3	-0.37	1.37e-9	Cognitive test performance;
KIRP	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg12179176	chr11:130786555	SNX19	-0.62	-7.79	-0.44	1.83e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg26384229	chr12:38710491	ALG10B	0.61	8.41	0.47	3.36e-15	Morning vs. evening chronotype;
KIRP	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.55	-7.21	-0.42	6.98e-12	Migraine;
KIRP	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.64	8.35	0.47	4.91e-15	Total body bone mineral density;
KIRP	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.71	6.83	0.4	6.69e-11	Type 2 diabetes;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg01593552	chr13:22185680	NA	0.4	6.58	0.39	2.79e-10	Serum protein levels (sST2);
KIRP	cis	rs7929679	0.571	rs10768099	chr11:34797334	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.36e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg18016565	chr1:150552671	MCL1	0.38	5.81	0.35	1.97e-8	Melanoma;
KIRP	cis	rs17789174	0.523	rs35006889	chr16:85077196	C/T	cg16671652	chr16:85009995	ZDHHC7	0.46	5.38	0.32	1.7e-7	Dysphagia;
KIRP	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg25486957	chr4:152246857	NA	-0.42	-5.09	-0.31	7.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10518128	1.000	rs28647657	chr4:75713724	A/G	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs6832769	0.961	rs2412647	chr4:56319105	C/T	cg05960024	chr4:56376020	CLOCK	0.73	9.43	0.52	3.31e-18	Personality dimensions;
KIRP	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.69	-9.2	-0.51	1.56e-17	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07558682	chr1:43148835	YBX1	0.45	6.13	0.36	3.41e-9	Survival in pancreatic cancer;
KIRP	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.97	13.78	0.66	2.18e-32	Cognitive function;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg11859384	chr17:80120422	CCDC57	-0.45	-5.83	-0.35	1.72e-8	Life satisfaction;
KIRP	cis	rs6662572	0.686	rs72677541	chr1:46561560	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.51	0.33	8.96e-8	Blood protein levels;
KIRP	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg10047753	chr17:41438598	NA	1.16	18.83	0.77	1.42e-49	Menopause (age at onset);
KIRP	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.71	-0.39	1.35e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1476670	0.565	rs2108201	chr1:44514883	G/C	cg09470012	chr1:44509516	NA	0.34	5.8	0.35	2.04e-8	Eotaxin levels;
KIRP	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg00800038	chr16:89945340	TCF25	-0.76	-5.19	-0.31	4.41e-7	Skin colour saturation;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4356932	0.935	rs6532160	chr4:76978199	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs4908768	0.906	rs55860300	chr1:8596335	G/A	cg25722041	chr1:8623473	RERE	0.71	9.15	0.5	2.29e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs311392	1.000	rs2666871	chr8:55089184	C/T	cg06042504	chr8:55087323	NA	-0.61	-7.5	-0.43	1.13e-12	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06415087	chr7:12726571	ARL4A	-0.46	-6.86	-0.4	5.46e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs62056376	0.736	rs2215185	chr17:32633902	C/T	cg06688323	chr4:4858340	NA	0.61	6.38	0.38	8.72e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs7429990	0.932	rs12486714	chr3:48148700	C/G	cg11946769	chr3:48343235	NME6	-0.43	-5.16	-0.31	4.97e-7	Educational attainment (years of education);
KIRP	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.59	0.39	2.73e-10	Breast cancer;
KIRP	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.53	5.41	0.33	1.49e-7	Tuberculosis;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg04369109	chr6:150039330	LATS1	-0.5	-6.38	-0.38	8.8e-10	Lung cancer;
KIRP	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg20243544	chr17:37824526	PNMT	-0.4	-4.93	-0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.84	-10.03	-0.54	4.45e-20	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-15.54	-0.7	2.09e-38	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg08847533	chr14:75593920	NEK9	-0.43	-5.28	-0.32	2.84e-7	Caffeine consumption;
KIRP	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.98	-15.39	-0.7	7.1e-38	Personality dimensions;
KIRP	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.43	4.9	0.3	1.77e-6	Schizophrenia;
KIRP	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.6	7.72	0.44	2.93e-13	Coronary artery disease;
KIRP	cis	rs42648	0.738	rs13247172	chr7:89889204	A/C	cg25739043	chr7:89950458	NA	-0.38	-5.03	-0.31	9.48e-7	Homocysteine levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04235519	chr10:102505365	PAX2	-0.43	-6.1	-0.36	4.2e-9	Metabolic traits;
KIRP	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg13147721	chr7:65941812	NA	-0.96	-6.78	-0.4	8.76e-11	Diabetic kidney disease;
KIRP	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.26	0.37	1.68e-9	Neuroticism;
KIRP	cis	rs2279817	0.954	rs12143113	chr1:18018857	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.66	9.92	0.53	1.02e-19	Neuroticism;
KIRP	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg23555395	chr2:238036564	NA	0.48	5.31	0.32	2.42e-7	Systemic lupus erythematosus;
KIRP	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.39	5.15	0.31	5.22e-7	Reticulocyte fraction of red cells;
KIRP	trans	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg24644049	chr4:85504048	CDS1	1.03	6.89	0.4	4.56e-11	Skin colour saturation;
KIRP	cis	rs16828019	0.850	rs12027691	chr1:41462032	C/T	cg03387723	chr1:41708464	SCMH1	-0.75	-6.0	-0.36	6.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg08501292	chr6:25962987	TRIM38	0.77	5.36	0.32	1.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg09699651	chr6:150184138	LRP11	0.46	6.2	0.37	2.37e-9	Lung cancer;
KIRP	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg05082376	chr22:42548792	NA	0.46	5.81	0.35	1.93e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs61629263	0.531	rs11867362	chr17:41938082	A/T	cg18439195	chr17:41980192	MPP2	0.36	5.12	0.31	6.14e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs1823913	0.599	rs34100174	chr2:192148305	G/C	cg12404831	chr2:192114017	MYO1B	0.53	7.41	0.43	2.02e-12	Obesity-related traits;
KIRP	cis	rs1757171	0.542	rs3818985	chr6:37484214	G/T	cg00360474	chr6:37504404	NA	-0.47	-6.6	-0.39	2.52e-10	Cognitive performance;
KIRP	cis	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.93	0.3	1.49e-6	Leprosy;
KIRP	cis	rs1134634	0.520	rs3822298	chr4:15556403	A/G	cg16509355	chr4:15471240	CC2D2A	-0.3	-5.0	-0.3	1.1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7215564	0.818	rs35929483	chr17:78635944	C/A	cg06153925	chr17:78755379	RPTOR	0.39	5.54	0.33	7.68e-8	Myopia (pathological);
KIRP	cis	rs6496667	0.908	rs12592935	chr15:90852437	T/C	cg10434728	chr15:90938212	IQGAP1	0.4	5.28	0.32	2.84e-7	Rheumatoid arthritis;
KIRP	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs9659323	1.000	rs9658899	chr1:119504543	G/A	cg18261050	chr1:119551319	NA	0.35	4.91	0.3	1.66e-6	Body mass index;
KIRP	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.83	9.96	0.54	7.25e-20	Corneal astigmatism;
KIRP	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.51	5.98	0.36	7.85e-9	Menopause (age at onset);
KIRP	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13334819	chr7:99746414	C7orf59	0.61	6.67	0.39	1.66e-10	Coronary artery disease;
KIRP	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg16988262	chr1:15930761	NA	0.4	5.29	0.32	2.74e-7	Systolic blood pressure;
KIRP	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.28	0.47	7.89e-15	Lung cancer in ever smokers;
KIRP	cis	rs2997447	0.761	rs17163588	chr1:26450009	C/T	cg19633962	chr1:26362018	EXTL1	-0.53	-4.92	-0.3	1.57e-6	QRS complex (12-leadsum);
KIRP	cis	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg06521331	chr12:34319734	NA	-0.45	-5.17	-0.31	4.94e-7	Resting heart rate;
KIRP	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg01559446	chr3:44596178	ZNF167	-0.36	-5.17	-0.31	4.76e-7	Depressive symptoms;
KIRP	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.49	6.27	0.37	1.59e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.75	11.66	0.6	2.72e-25	Longevity;Endometriosis;
KIRP	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg04310649	chr10:35416472	CREM	-0.59	-6.92	-0.4	3.93e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.88	10.57	0.56	8.78e-22	Response to antineoplastic agents;
KIRP	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg05991184	chr2:219186017	PNKD	0.36	5.05	0.31	8.61e-7	Colorectal cancer;
KIRP	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg23533419	chr12:54090519	NA	-0.33	-5.11	-0.31	6.49e-7	Height;
KIRP	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg25319279	chr11:5960081	NA	-0.57	-5.77	-0.35	2.33e-8	DNA methylation (variation);
KIRP	trans	rs330071	0.549	rs11785593	chr8:9256324	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	6.74	0.39	1.1e-10	Acne (severe);
KIRP	cis	rs12022452	0.591	rs1001400	chr1:40998902	A/G	cg25568243	chr1:40974465	DEM1	0.53	5.73	0.34	2.9e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.55	-4.94	-0.3	1.46e-6	Other erythrocyte phenotypes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16189024	chr3:101568236	NFKBIZ	-0.47	-6.25	-0.37	1.78e-9	Metabolic traits;
KIRP	cis	rs6815814	0.948	rs73236649	chr4:38873332	C/T	cg06935464	chr4:38784597	TLR10	0.52	5.32	0.32	2.34e-7	Breast cancer;
KIRP	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.47	-5.63	-0.34	4.93e-8	Diastolic blood pressure;
KIRP	cis	rs2070997	1.000	rs6597645	chr9:133745487	A/G	cg03924115	chr9:133768966	QRFP	0.34	5.04	0.31	9.23e-7	Response to amphetamines;
KIRP	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.45	5.11	0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs8060686	0.920	rs73591976	chr16:67811590	C/A	cg04539111	chr16:67997858	SLC12A4	-0.6	-5.98	-0.36	7.69e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.52	-0.33	8.41e-8	Neuroticism;
KIRP	cis	rs35740288	1.000	rs35740288	chr15:86297085	T/A	cg20737812	chr15:86336631	KLHL25	-0.37	-4.98	-0.3	1.2e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.15	-0.37	3.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs2274459	0.841	rs12661400	chr6:33696477	C/T	cg06253072	chr6:33679850	C6orf125	0.54	5.57	0.33	6.65e-8	Obesity (extreme);
KIRP	cis	rs798766	0.903	rs798726	chr4:1685211	C/T	cg01566213	chr4:1579287	NA	0.42	5.98	0.36	7.63e-9	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.7	-12.48	-0.62	4.95e-28	Lung cancer;
KIRP	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.85	11.84	0.6	6.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9612	1.000	rs61002661	chr19:44269032	T/A	cg08581076	chr19:44259116	C19orf61	0.51	5.57	0.33	6.75e-8	Exhaled nitric oxide output;
KIRP	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.84	11.83	0.6	7.4e-26	Multiple sclerosis;
KIRP	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg07424592	chr7:64974309	NA	-0.76	-4.93	-0.3	1.5e-6	Diabetic kidney disease;
KIRP	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.22	0.61	3.66e-27	Bone mineral density;
KIRP	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg15282417	chr9:129245246	FAM125B	0.43	7.25	0.42	5.55e-12	Intraocular pressure;
KIRP	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	9.33	0.51	6.29e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs72934535	0.722	rs16839813	chr2:204324094	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.74	5.59	0.34	6.04e-8	Coronary artery disease;
KIRP	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.89	-0.35	1.29e-8	Neutrophil percentage of white cells;
KIRP	cis	rs78761021	0.755	rs75458334	chr17:9795535	C/T	cg26853458	chr17:9805074	RCVRN	0.51	4.93	0.3	1.5e-6	Type 2 diabetes;
KIRP	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-1.01	-16.87	-0.73	5.9e-43	Height;
KIRP	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	6.83	0.4	6.45e-11	Neuroticism;
KIRP	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs911119	0.913	rs3810575	chr20:23583392	G/A	cg09631192	chr20:23583594	CST9	-0.49	-5.07	-0.31	7.82e-7	Chronic kidney disease;
KIRP	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.54	-6.66	-0.39	1.77e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg23335576	chr14:104009727	NA	0.4	5.48	0.33	1.05e-7	Body mass index;
KIRP	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg06521331	chr12:34319734	NA	-0.62	-7.5	-0.43	1.17e-12	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	cis	rs6684428	0.536	rs11583130	chr1:56400111	A/G	cg11651538	chr1:56320950	NA	-0.56	-7.93	-0.45	7.83e-14	Airflow obstruction;
KIRP	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg25797454	chr6:150327115	RAET1K	0.36	6.56	0.39	3.13e-10	Alopecia areata;
KIRP	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg20637307	chr2:213403960	ERBB4	0.93	16.28	0.72	6.22e-41	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg15147215	chr3:52552868	STAB1	-0.29	-4.96	-0.3	1.3e-6	Electroencephalogram traits;
KIRP	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg12131826	chr15:77904385	NA	-0.41	-5.31	-0.32	2.49e-7	Type 2 diabetes;
KIRP	cis	rs4523957	0.620	rs9894215	chr17:2070698	G/A	cg16513277	chr17:2031491	SMG6	-0.86	-12.82	-0.63	3.79e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs11169552	0.510	rs3935869	chr12:50964076	A/G	cg12884762	chr12:50931848	DIP2B	-0.44	-5.07	-0.31	7.83e-7	Colorectal cancer;
KIRP	cis	rs6547631	0.635	rs934773	chr2:85898094	A/G	cg24620635	chr2:85921963	GNLY	0.37	5.43	0.33	1.34e-7	Blood protein levels;
KIRP	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.61	7.64	0.44	4.72e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.39	9.74	0.53	3.5e-19	Corneal astigmatism;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-9.43	-0.52	3.25e-18	Longevity;Endometriosis;
KIRP	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg04025307	chr7:1156635	C7orf50	0.64	5.08	0.31	7.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg17366294	chr4:99064904	C4orf37	0.37	4.97	0.3	1.28e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7215564	0.908	rs34267318	chr17:78664619	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs17739167	0.532	rs8035074	chr15:42239779	C/T	cg20935245	chr15:42234343	EHD4	0.44	6.97	0.41	2.95e-11	Monocyte count;
KIRP	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.05	-0.64	6.44e-30	Height;
KIRP	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1832871	0.711	rs9459826	chr6:158680396	C/G	cg07215822	chr6:158701037	NA	0.62	7.13	0.41	1.12e-11	Height;
KIRP	cis	rs7221595	0.778	rs8077986	chr17:3902951	A/G	cg09695851	chr17:3907499	NA	0.61	5.97	0.36	8.03e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	5.03	0.31	9.68e-7	Systolic blood pressure;
KIRP	cis	rs3741151	0.686	rs7935948	chr11:73219118	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.63	-5.7	-0.34	3.35e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs2278796	1.000	rs12124296	chr1:204945618	G/A	cg17947172	chr1:204966197	NFASC	0.67	8.92	0.49	1.06e-16	Mean platelet volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10106091	chr12:117176294	C12orf49;RNFT2	0.98	6.56	0.39	3.08e-10	P wave terminal force;
KIRP	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-0.87	-9.23	-0.51	1.3e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg11846333	chr4:119757529	SEC24D	0.96	6.73	0.39	1.16e-10	Cannabis dependence symptom count;
KIRP	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15209934	chr19:52800385	ZNF480	0.47	6.97	0.41	2.9e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3752645	1.000	rs11762123	chr7:106748079	T/C	cg02696742	chr7:106810147	HBP1	-0.59	-5.11	-0.31	6.61e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs17030434	0.953	rs11099906	chr4:154691690	A/T	cg14289246	chr4:154710475	SFRP2	-0.83	-9.73	-0.53	3.81e-19	Electrocardiographic conduction measures;
KIRP	cis	rs9308731	0.505	rs10169613	chr2:111934977	C/T	cg03171003	chr2:111875934	NA	0.41	5.82	0.35	1.78e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.45	6.95	0.41	3.28e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg04132472	chr17:19861366	AKAP10	0.48	6.91	0.4	4.1e-11	Schizophrenia;
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.82	-12.19	-0.61	4.6e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg05220968	chr6:146057943	EPM2A	-0.37	-5.03	-0.31	9.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.16	0.42	9.15e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg16586182	chr3:47516702	SCAP	-0.69	-9.79	-0.53	2.49e-19	Colorectal cancer;
KIRP	cis	rs6832769	0.961	rs3805147	chr4:56306730	C/T	cg05960024	chr4:56376020	CLOCK	0.73	9.33	0.51	6.62e-18	Personality dimensions;
KIRP	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg09137382	chr11:130731461	NA	0.55	8.13	0.46	2.13e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1134634	0.520	rs4393989	chr4:15615899	T/G	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.79	-0.35	2.18e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.67	-5.04	-0.31	9.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-9.01	-0.5	5.97e-17	Schizophrenia;
KIRP	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg05669848	chr5:237993	SDHA	0.47	4.86	0.3	2.08e-6	Breast cancer;
KIRP	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.42	-0.38	6.92e-10	Recombination measurement;
KIRP	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.33	5.0	0.3	1.1e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.45	5.05	0.31	8.6e-7	Schizophrenia;
KIRP	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.83e-26	Heart rate;
KIRP	cis	rs2299587	0.519	rs3850746	chr8:17787536	C/T	cg01800426	chr8:17659068	MTUS1	0.63	7.5	0.43	1.13e-12	Economic and political preferences;
KIRP	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.64	-9.37	-0.51	4.81e-18	Red cell distribution width;
KIRP	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-0.89	-8.88	-0.49	1.4e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg00405596	chr8:11794950	NA	0.46	5.94	0.35	9.63e-9	Retinal vascular caliber;
KIRP	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg10381502	chr11:71823885	C11orf51	-1.03	-7.17	-0.42	8.64e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.49	0.52	2.13e-18	Cognitive test performance;
KIRP	cis	rs2637030	0.559	rs256095	chr5:52972669	C/T	cg06476337	chr5:52856530	NDUFS4	-0.54	-5.95	-0.35	9.23e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.62	-7.16	-0.42	9.28e-12	Height;
KIRP	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.73	6.22	0.37	2.07e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg12963246	chr6:28129442	ZNF389	0.52	6.4	0.38	7.66e-10	Depression;
KIRP	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.52	-5.1	-0.31	6.89e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs7822232	0.710	rs13256214	chr8:145149823	G/T	cg06495924	chr8:145149574	CYC1	0.56	4.95	0.3	1.35e-6	Blood metabolite levels;
KIRP	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg01620082	chr3:125678407	NA	-1.19	-7.59	-0.44	6.51e-13	Depression;
KIRP	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg17691542	chr6:26056736	HIST1H1C	0.69	8.29	0.47	7.66e-15	Iron status biomarkers;
KIRP	cis	rs9303542	0.625	rs9905940	chr17:46614102	A/C	cg04904318	chr17:46607828	HOXB1	0.49	6.09	0.36	4.37e-9	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs7224685	0.569	rs12950730	chr17:3994225	G/T	cg09695851	chr17:3907499	NA	0.52	5.09	0.31	7.13e-7	Type 2 diabetes;
KIRP	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03934478	chr11:495069	RNH1	0.82	6.68	0.39	1.57e-10	Body mass index;
KIRP	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17344932	chr17:38183730	MED24;SNORD124	0.48	7.62	0.44	5.41e-13	White blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12212336	chr2:231577353	CAB39	0.45	6.51	0.38	4.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.91	10.65	0.56	4.83e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.69	-7.62	-0.44	5.48e-13	Vitiligo;
KIRP	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg13206674	chr6:150067644	NUP43	0.56	7.87	0.45	1.11e-13	Lung cancer;
KIRP	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.43	-8.21	-0.46	1.26e-14	Educational attainment (years of education);
KIRP	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg06611532	chr13:114900021	NA	0.22	5.0	0.3	1.1e-6	Schizophrenia;
KIRP	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.59	8.05	0.46	3.49e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg20295408	chr7:1910781	MAD1L1	0.46	5.09	0.31	7.27e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2273669	0.915	rs6928200	chr6:109294164	A/C	cg05315195	chr6:109294784	ARMC2	-0.48	-5.5	-0.33	9.66e-8	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.64	6.29	0.37	1.41e-9	Eotaxin levels;
KIRP	cis	rs11779988	0.629	rs7465361	chr8:17854155	T/C	cg01800426	chr8:17659068	MTUS1	-0.63	-7.38	-0.43	2.38e-12	Breast cancer;
KIRP	cis	rs9816226	1.000	rs9816226	chr3:185834499	A/T	cg00760338	chr3:185826511	ETV5	0.86	8.3	0.47	7.12e-15	Obesity;Body mass index;
KIRP	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg06740227	chr12:86229804	RASSF9	0.49	5.93	0.35	1.04e-8	Major depressive disorder;
KIRP	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.75	-10.45	-0.55	2.12e-21	Hypospadias;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg17260001	chr11:65627869	MUS81	0.48	6.07	0.36	4.69e-9	Colorectal cancer;
KIRP	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.67	7.71	0.44	3.03e-13	Corneal astigmatism;
KIRP	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.85	0.35	1.6e-8	Total cholesterol levels;
KIRP	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg05973401	chr12:123451056	ABCB9	-0.49	-5.38	-0.32	1.75e-7	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg02725872	chr8:58115012	NA	-0.64	-5.84	-0.35	1.69e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.46	-0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs631288	0.793	rs10793659	chr1:146763438	A/G	cg25205988	chr1:146714368	CHD1L	0.93	5.14	0.31	5.51e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	trans	rs13170463	0.737	rs35997483	chr5:8048578	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs7116495	0.786	rs10736785	chr11:71718912	C/A	cg26138937	chr11:71823887	C11orf51	-0.72	-5.81	-0.35	1.95e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg20999797	chr1:1681921	NA	0.53	8.31	0.47	6.32e-15	Body mass index;
KIRP	cis	rs7923609	0.902	rs7897379	chr10:65301725	T/C	cg01631684	chr10:65280961	REEP3	-0.52	-6.17	-0.37	2.84e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg06871246	chr4:1363661	KIAA1530	0.45	5.51	0.33	8.93e-8	Obesity-related traits;
KIRP	cis	rs6089584	0.546	rs6089308	chr20:60583529	C/T	cg13770153	chr20:60521292	NA	-0.49	-5.71	-0.34	3.27e-8	Body mass index;
KIRP	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg01872077	chr2:219646372	CYP27A1	-0.37	-5.1	-0.31	6.78e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	trans	rs1106684	1.000	rs57258901	chr7:131461177	A/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.73	8.92	0.49	1.09e-16	Mammographic density (dense area);
KIRP	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg13072238	chr3:49761600	GMPPB	0.61	5.22	0.32	3.74e-7	Menarche (age at onset);
KIRP	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg17554472	chr22:41940697	POLR3H	-0.7	-6.98	-0.41	2.79e-11	Vitiligo;
KIRP	cis	rs7923609	1.000	rs4379723	chr10:64963449	T/C	cg01631684	chr10:65280961	REEP3	-0.48	-5.67	-0.34	4.07e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg25036284	chr2:26402008	FAM59B	-0.48	-5.07	-0.31	7.96e-7	Gut microbiome composition (summer);
KIRP	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.54	-7.8	-0.45	1.76e-13	Obesity-related traits;
KIRP	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg17133734	chr15:86042851	AKAP13	-0.45	-5.74	-0.34	2.79e-8	Coronary artery disease;
KIRP	cis	rs8093481	0.966	rs868525	chr18:10696333	C/G	cg21165219	chr18:10698044	FAM38B	-0.43	-5.33	-0.32	2.24e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	7.15	0.41	9.65e-12	Hemoglobin concentration;
KIRP	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg19752551	chr11:57585705	CTNND1	-0.82	-13.74	-0.66	2.87e-32	Schizophrenia;
KIRP	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.53	6.91	0.4	4.21e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.94	15.51	0.7	2.56e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	0.74	6.95	0.41	3.29e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2151522	0.545	rs9375457	chr6:127129036	T/A	cg21431617	chr6:127135037	NA	0.34	6.16	0.37	2.97e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg14458575	chr2:238380390	NA	0.55	5.9	0.35	1.2e-8	Prostate cancer;
KIRP	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.54	6.14	0.36	3.28e-9	Coronary artery disease;
KIRP	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg05347473	chr6:146136440	FBXO30	-0.58	-8.48	-0.48	2.16e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.54	0.33	7.86e-8	Lung cancer;
KIRP	cis	rs11877825	0.826	rs9946239	chr18:10567346	A/G	cg07277756	chr18:10589357	NA	-0.45	-5.7	-0.34	3.36e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg22356347	chr1:167427500	CD247	0.44	6.02	0.36	6.29e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg13010199	chr12:38710504	ALG10B	0.49	6.2	0.37	2.32e-9	Morning vs. evening chronotype;
KIRP	cis	rs1971762	0.527	rs6580953	chr12:54021138	T/C	cg23533419	chr12:54090519	NA	-0.35	-5.25	-0.32	3.3e-7	Height;
KIRP	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg00343986	chr7:65444356	GUSB	-0.41	-4.98	-0.3	1.17e-6	Aortic root size;
KIRP	cis	rs2625529	0.591	rs7172158	chr15:72405313	T/C	cg16672083	chr15:72433130	SENP8	0.41	5.5	0.33	9.63e-8	Red blood cell count;
KIRP	cis	rs9826463	0.757	rs73238195	chr3:142171525	A/C	cg20824294	chr3:142316082	PLS1	0.31	5.21	0.32	4.04e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg25547332	chr5:131281432	NA	0.47	5.41	0.33	1.52e-7	Life satisfaction;
KIRP	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg18764771	chr6:116381957	FRK	0.19	5.27	0.32	3.04e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2625529	0.617	rs7175792	chr15:72431883	C/G	cg16672083	chr15:72433130	SENP8	-0.45	-6.19	-0.37	2.52e-9	Red blood cell count;
KIRP	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.53	-5.48	-0.33	1.05e-7	Subjective well-being;
KIRP	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.7	-0.44	3.41e-13	Total cholesterol levels;
KIRP	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg02151108	chr14:50098012	C14orf104	0.52	7.2	0.42	7.44e-12	Carotid intima media thickness;
KIRP	cis	rs10924970	0.967	rs2382617	chr1:235402230	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	4.96	0.3	1.29e-6	Asthma;
KIRP	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.38	-7.08	-0.41	1.53e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.08	-0.61	1.11e-26	Glomerular filtration rate (creatinine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11331988	chr15:40453286	BUB1B	0.45	6.31	0.37	1.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs80282103	0.618	rs59377495	chr10:1157019	C/T	cg08668510	chr10:1095578	IDI1	0.93	6.16	0.37	2.96e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs6967385	0.560	rs10248602	chr7:12347113	G/C	cg20607287	chr7:12443886	VWDE	0.39	5.16	0.31	5.17e-7	Response to taxane treatment (placlitaxel);
KIRP	cis	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.3e-12	Morning vs. evening chronotype;
KIRP	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.49	5.9	0.35	1.21e-8	Diastolic blood pressure;
KIRP	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.94	-13.17	-0.64	2.54e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.71	0.39	1.29e-10	Height;
KIRP	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg09184832	chr6:79620586	NA	-0.52	-7.44	-0.43	1.66e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.97	0.3	1.27e-6	Menopause (age at onset);
KIRP	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.78	-11.1	-0.58	1.76e-23	Asthma;
KIRP	cis	rs1656402	1.000	rs1729252	chr2:233428582	A/G	cg03852847	chr2:233439513	NA	-0.75	-12.69	-0.63	9.9e-29	Non-small cell lung cancer (survival);
KIRP	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg17376030	chr22:41985996	PMM1	-0.51	-6.28	-0.37	1.48e-9	Vitiligo;
KIRP	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.49	6.02	0.36	6.22e-9	Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10022510	chr10:99446788	AVPI1	0.57	7.23	0.42	6.25e-12	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg20673091	chr1:2541236	MMEL1	-0.68	-10.63	-0.56	5.94e-22	Ulcerative colitis;
KIRP	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.77	12.41	0.62	8.7e-28	Menarche (age at onset);
KIRP	cis	rs78487399	0.808	rs17030800	chr2:43671003	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg19592336	chr6:28129416	ZNF389	0.52	5.89	0.35	1.24e-8	Depression;
KIRP	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.68	-7.02	-0.41	2.16e-11	DNA methylation (variation);
KIRP	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg26528668	chr16:1614120	IFT140	0.4	5.04	0.31	8.89e-7	Coronary artery disease;
KIRP	cis	rs5752773	0.564	rs5762670	chr22:28920651	A/G	cg16849201	chr22:29715310	NA	0.3	5.0	0.3	1.1e-6	Vertical cup-disc ratio;
KIRP	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-0.88	-6.19	-0.37	2.44e-9	Inflammatory biomarkers;
KIRP	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.6	-8.62	-0.48	8.11e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11987759	chr7:65425863	GUSB	-0.45	-5.46	-0.33	1.15e-7	Aortic root size;
KIRP	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.52	-7.1	-0.41	1.37e-11	Dilated cardiomyopathy;
KIRP	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.98	10.79	0.57	1.79e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.74	-10.73	-0.56	2.71e-22	Schizophrenia;
KIRP	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg00999904	chr2:3704751	ALLC	0.48	5.77	0.35	2.35e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs6256	1.000	rs12362225	chr11:13548274	G/A	cg11976911	chr11:13509032	NA	-0.62	-5.22	-0.32	3.79e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg05639522	chr1:247681581	NA	0.76	5.04	0.31	8.88e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.58	-7.94	-0.45	7.3e-14	Motion sickness;
KIRP	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.3	7.29	0.42	4.22e-12	IgG glycosylation;
KIRP	cis	rs7078219	0.714	rs60386053	chr10:101288861	G/A	cg07044859	chr10:101282883	NA	-0.33	-4.86	-0.3	2.05e-6	Dental caries;
KIRP	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-5.99	-0.36	7.47e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.66	8.06	0.46	3.39e-14	Calcium levels;
KIRP	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19524238	chr7:2802976	GNA12	-0.38	-5.22	-0.32	3.75e-7	Height;
KIRP	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg02461776	chr11:598696	PHRF1	0.74	7.73	0.44	2.74e-13	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.73	-0.53	3.8e-19	Hemoglobin concentration;
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.71	8.34	0.47	5.17e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg16917193	chr12:54089295	NA	0.86	16.56	0.73	6.7e-42	Height;
KIRP	cis	rs11581903	0.568	rs6686035	chr1:53080008	A/C	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.73	6.27	0.37	1.58e-9	Joint mobility (Beighton score);
KIRP	cis	rs1270639	0.778	rs2906930	chr7:157446453	T/C	cg13357408	chr7:157437802	PTPRN2	0.61	6.1	0.36	4.12e-9	Colorectal cancer;
KIRP	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.07	20.93	0.8	1.43e-56	Schizophrenia;
KIRP	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.96	14.73	0.68	1.19e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.72	7.1	0.41	1.33e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg12131826	chr15:77904385	NA	0.52	6.24	0.37	1.94e-9	Type 2 diabetes;
KIRP	cis	rs55863869	0.892	rs2627041	chr2:179601057	A/G	cg02880032	chr2:179629472	TTN	0.73	5.09	0.31	6.98e-7	QT interval;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03726819	chr1:78277606	FAM73A	-0.4	-6.55	-0.39	3.3e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.43	-5.16	-0.31	5.11e-7	Glycated hemoglobin levels;
KIRP	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.27	-5.44	-0.33	1.28e-7	Menarche (age at onset);
KIRP	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-7.1	-0.41	1.31e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.85	12.78	0.63	5.01e-29	Height;
KIRP	trans	rs656319	0.513	rs3885723	chr8:9991661	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.68	-0.44	3.74e-13	Myopia (pathological);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06159435	chr11:118966351	H2AFX	0.49	6.44	0.38	6.06e-10	Parkinson's disease;
KIRP	cis	rs6442310	0.545	rs2972163	chr3:12438022	G/A	cg02700894	chr3:12045449	SYN2	0.4	5.52	0.33	8.67e-8	Hematocrit;
KIRP	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.2	21.77	0.81	2.68e-59	Cognitive function;
KIRP	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.02	0.36	6.26e-9	Height;
KIRP	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.59	7.67	0.44	4.04e-13	Systemic lupus erythematosus;
KIRP	cis	rs4654899	0.743	rs17409373	chr1:21188871	C/A	cg05370193	chr1:21551575	ECE1	0.41	5.24	0.32	3.45e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20250874	chr13:47127354	LRCH1	0.47	6.43	0.38	6.54e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4523957	0.757	rs216199	chr17:2200871	C/T	cg16513277	chr17:2031491	SMG6	0.55	7.43	0.43	1.79e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.52	-6.39	-0.38	8.1e-10	Mean platelet volume;
KIRP	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg00262122	chr8:11665843	FDFT1	-0.44	-5.33	-0.32	2.25e-7	Retinal vascular caliber;
KIRP	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg10210624	chr19:58662595	ZNF329	0.62	5.66	0.34	4.13e-8	Cholesterol, total;
KIRP	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg23594656	chr7:65796392	TPST1	-0.45	-6.27	-0.37	1.62e-9	Aortic root size;
KIRP	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.58	-0.34	6.27e-8	Aortic root size;
KIRP	cis	rs61472021	1	rs61472021	chr6:26090025	T/C	cg08501292	chr6:25962987	TRIM38	0.63	5.48	0.33	1.07e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg23594656	chr7:65796392	TPST1	-0.44	-6.39	-0.38	8.42e-10	Aortic root size;
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg21734707	chr17:3908241	ZZEF1	-0.58	-8.56	-0.48	1.21e-15	Type 2 diabetes;
KIRP	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg08738300	chr3:44038990	NA	0.68	9.65	0.52	6.79e-19	Coronary artery disease;
KIRP	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	10.23	0.55	1.11e-20	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.66	-0.34	4.1e-8	Yeast infection;
KIRP	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.88	9.96	0.54	7.67e-20	Gut microbiome composition (summer);
KIRP	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-19.96	-0.79	2.38e-53	Heart rate;
KIRP	trans	rs12517041	1.000	rs1428623	chr5:23286659	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.65	-0.48	6.64e-16	Calcium levels;
KIRP	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22878388	chr2:105853796	NA	-0.43	-7.06	-0.41	1.7e-11	Type 2 diabetes;
KIRP	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.62	7.89	0.45	9.91e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg05785598	chr3:49045655	WDR6	0.3	5.46	0.33	1.19e-7	Parkinson's disease;
KIRP	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg04310649	chr10:35416472	CREM	-0.59	-6.94	-0.4	3.39e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg08501292	chr6:25962987	TRIM38	0.83	6.96	0.41	3.09e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9398803	0.865	rs9375439	chr6:126758540	C/G	cg19875578	chr6:126661172	C6orf173	0.5	6.42	0.38	6.87e-10	Male-pattern baldness;
KIRP	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.67	7.34	0.42	3.12e-12	Smoking initiation;
KIRP	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg00086871	chr4:6988644	TBC1D14	0.79	6.69	0.39	1.51e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1505368	0.505	rs2135156	chr2:213259226	C/T	cg16329650	chr2:213403929	ERBB4	0.4	5.54	0.33	7.79e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17554472	chr22:41940697	POLR3H	0.69	7.1	0.41	1.35e-11	Vitiligo;
KIRP	cis	rs7601312	1.000	rs11694614	chr2:229317552	T/G	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.56	-0.33	7.18e-8	Life satisfaction;
KIRP	trans	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.44	-0.38	6.13e-10	Myopia (pathological);
KIRP	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg17764715	chr19:33622953	WDR88	0.68	8.24	0.46	1.05e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg02462569	chr6:150064036	NUP43	-0.38	-5.73	-0.34	2.94e-8	Lung cancer;
KIRP	trans	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.35	-0.42	3e-12	Triglycerides;
KIRP	cis	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg26585981	chr11:48327164	OR4S1	-0.47	-5.67	-0.34	3.96e-8	HDL cholesterol;
KIRP	cis	rs4704187	0.687	rs4621537	chr5:74362222	A/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs2120243	1.000	rs2873258	chr3:157144986	C/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.4	5.46	0.33	1.15e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs12282928	0.959	rs1354293	chr11:48264370	A/G	cg26585981	chr11:48327164	OR4S1	-0.52	-6.33	-0.37	1.17e-9	Migraine - clinic-based;
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13939156	chr17:80058883	NA	-0.48	-7.22	-0.42	6.54e-12	Life satisfaction;
KIRP	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg08499158	chr17:42289980	UBTF	-0.51	-6.5	-0.38	4.39e-10	Total body bone mineral density;
KIRP	cis	rs10875746	0.903	rs12315625	chr12:48472453	G/A	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-11.72	-0.6	1.74e-25	Dental caries;
KIRP	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg00383909	chr3:49044727	WDR6	0.53	5.0	0.3	1.1e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg01294253	chr9:136912663	BRD3	0.4	5.35	0.32	2.05e-7	Platelet distribution width;
KIRP	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	1.07	15.68	0.71	6.8e-39	Menopause (age at onset);
KIRP	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.11	-0.41	1.24e-11	Type 2 diabetes;
KIRP	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg23594656	chr7:65796392	TPST1	0.39	5.81	0.35	1.9e-8	Aortic root size;
KIRP	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14598338	chr9:96623480	NA	-0.64	-11.16	-0.58	1.18e-23	DNA methylation (variation);
KIRP	cis	rs2294369	0.635	rs136829	chr22:40046176	T/C	cg10455938	chr22:40058150	CACNA1I	0.51	5.77	0.35	2.43e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg11906718	chr8:101322791	RNF19A	0.49	6.52	0.38	4.01e-10	Atrioventricular conduction;
KIRP	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg00310523	chr12:86230176	RASSF9	0.4	6.05	0.36	5.37e-9	Major depressive disorder;
KIRP	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg00792783	chr2:198669748	PLCL1	0.48	5.32	0.32	2.38e-7	Intracranial aneurysm;
KIRP	trans	rs62056376	0.736	rs2215185	chr17:32633902	C/T	cg21513437	chr17:39678107	NA	0.49	6.03	0.36	6.07e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2236918	1.000	rs1776137	chr1:242027045	A/G	cg17736920	chr1:242011382	EXO1	0.76	9.95	0.54	7.9e-20	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14638056	chr6:69873409	BAI3	0.42	6.04	0.36	5.68e-9	Interleukin-4 levels;
KIRP	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	6.19	0.37	2.54e-9	Height;
KIRP	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	11.6	0.59	4.1e-25	Retinal vascular caliber;
KIRP	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.55	6.36	0.38	9.59e-10	Aortic root size;
KIRP	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg16329650	chr2:213403929	ERBB4	0.43	6.0	0.36	6.98e-9	Symmetrical dimethylarginine levels;
KIRP	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.37	0.47	4.3e-15	Menopause (age at onset);
KIRP	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg22903471	chr2:27725779	GCKR	-0.4	-5.38	-0.32	1.7e-7	Total body bone mineral density;
KIRP	cis	rs12282928	1.000	rs7130032	chr11:48326963	C/A	cg26585981	chr11:48327164	OR4S1	0.51	6.22	0.37	2.09e-9	Migraine - clinic-based;
KIRP	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.86	-0.49	1.62e-16	Response to antipsychotic treatment;
KIRP	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.53	-7.15	-0.41	1.01e-11	Longevity;Endometriosis;
KIRP	cis	rs6753739	0.784	rs10168527	chr2:219972375	G/C	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	cis	rs892085	0.588	rs4804528	chr19:10886206	G/T	cg17710535	chr19:10819994	QTRT1	-0.48	-5.64	-0.34	4.62e-8	Psoriasis vulgaris;Psoriasis;
KIRP	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg01448562	chr3:133502909	NA	-0.44	-5.42	-0.33	1.39e-7	Iron status biomarkers;
KIRP	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26207909	chr14:103986467	CKB	-0.81	-12.72	-0.63	7.82e-29	Body mass index;
KIRP	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	13.03	0.64	7.02e-30	Platelet count;
KIRP	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg08076091	chr2:203926405	NBEAL1	0.85	8.63	0.48	7.88e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24449302	chr15:66679100	MAP2K1	0.47	6.95	0.41	3.28e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs6687758	0.687	rs12140498	chr1:222098690	C/T	cg11122944	chr17:9924800	GAS7	0.46	6.08	0.36	4.44e-9	Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);Colorectal cancer;
KIRP	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19623624	chr10:135278901	LOC619207	-0.58	-6.37	-0.38	9e-10	Systemic lupus erythematosus;
KIRP	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg07148914	chr20:33460835	GGT7	-0.4	-4.97	-0.3	1.27e-6	Height;
KIRP	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.77	-8.66	-0.48	6.37e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg12756093	chr1:115239321	AMPD1	0.53	7.1	0.41	1.31e-11	Autism;
KIRP	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs587242	1.000	rs1853738	chr1:96895992	A/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-1.05	-20.37	-0.79	1.02e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs4594175	0.926	rs4243570	chr14:51624243	C/T	cg23942311	chr14:51606299	NA	0.52	7.02	0.41	2.2e-11	Cancer;
KIRP	cis	rs4666360	1.000	rs4666295	chr2:20337144	C/T	cg07142377	chr2:20335552	NA	0.27	4.95	0.3	1.37e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
KIRP	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg03465714	chr1:152285911	FLG	-0.43	-6.24	-0.37	1.9e-9	Inflammatory skin disease;
KIRP	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.98	14.09	0.67	1.86e-33	Cognitive function;
KIRP	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11987759	chr7:65425863	GUSB	-0.69	-9.7	-0.53	4.87e-19	Aortic root size;
KIRP	cis	rs17739794	0.557	rs7823711	chr8:814529	A/G	cg01971667	chr8:817044	NA	-0.39	-5.5	-0.33	9.53e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs17453880	0.963	rs6863717	chr5:152027165	G/C	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs4378355	1	rs4378355	chr11:34783417	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.36	0.32	1.95e-7	Prostate-specific antigen levels;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	cg12689670	chr1:183009347	LAMC1	0.44	6.32	0.37	1.25e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4965006	0.915	rs4965004	chr12:132424700	A/G	cg00588090	chr12:132412438	PUS1	0.6	6.28	0.37	1.49e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg03714773	chr7:91764589	CYP51A1	0.39	5.8	0.35	2.06e-8	Breast cancer;
KIRP	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25517755	chr10:38738941	LOC399744	0.39	5.33	0.32	2.17e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06544989	chr22:39130855	UNC84B	0.5	8.92	0.49	1.1e-16	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06706454	chr6:52930286	FBXO9	0.52	6.76	0.4	1.02e-10	Parkinson's disease;
KIRP	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.58	8.72	0.49	4.31e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8103278	1.000	rs62109854	chr19:46350375	A/C	cg14061069	chr19:46274453	DMPK	-0.57	-8.5	-0.48	1.81e-15	Coronary artery disease;
KIRP	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg08133631	chr1:26527909	CATSPER4	-0.45	-4.97	-0.3	1.24e-6	Obesity-related traits;
KIRP	cis	rs16976116	0.901	rs28708989	chr15:55498934	C/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7809950	0.798	rs2701687	chr7:107304628	C/T	cg23024343	chr7:107201750	COG5	0.42	6.45	0.38	5.73e-10	Coronary artery disease;
KIRP	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.54	-0.43	8.95e-13	Bipolar disorder;
KIRP	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.63	8.04	0.46	3.79e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.93	0.4	3.63e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12912184	0.950	rs12905580	chr15:92846847	T/C	cg12155969	chr15:92849000	NA	-0.4	-5.07	-0.31	7.98e-7	Smoking initiation;
KIRP	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-7.72	-0.44	3e-13	Bipolar disorder;
KIRP	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg05484376	chr2:27715224	FNDC4	0.41	6.81	0.4	7.41e-11	Total body bone mineral density;
KIRP	cis	rs12643440	0.538	rs882315	chr4:17149123	A/T	cg22650099	chr4:17144496	NA	-0.72	-8.65	-0.48	6.87e-16	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.71	-9.31	-0.51	7.54e-18	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17376030	chr22:41985996	PMM1	-0.75	-7.98	-0.45	5.53e-14	Vitiligo;
KIRP	cis	rs4930561	0.714	rs7950452	chr11:67962407	C/A	cg16338278	chr11:67432957	ALDH3B2	0.38	4.88	0.3	1.89e-6	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16571354	chr17:36508031	SOCS7	-0.59	-6.44	-0.38	6.1e-10	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11029301	chr3:10206731	IRAK2	0.49	6.58	0.39	2.83e-10	Parkinson's disease;
KIRP	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.93	10.0	0.54	5.44e-20	Alzheimer's disease;
KIRP	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.66	9.65	0.52	7.06e-19	Dupuytren's disease;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.98	-0.3	1.22e-6	Cognitive function;
KIRP	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21643547	chr1:205240462	TMCC2	-0.87	-14.74	-0.68	1.16e-35	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.85	12.17	0.61	5.34e-27	Height;
KIRP	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg08648136	chr8:956695	NA	0.51	8.12	0.46	2.26e-14	Schizophrenia;
KIRP	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg07835443	chr16:89734986	C16orf55	0.2	4.86	0.3	2.13e-6	Vitiligo;
KIRP	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-5.61	-0.34	5.31e-8	Bipolar disorder;
KIRP	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.64	6.77	0.4	9.45e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01946760	chr5:177540738	N4BP3	0.5	6.34	0.37	1.11e-9	Parkinson's disease;
KIRP	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg17390301	chr11:111250093	POU2AF1	0.34	5.25	0.32	3.33e-7	Primary biliary cholangitis;
KIRP	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.92	10.61	0.56	6.5e-22	Cognitive ability;
KIRP	cis	rs9435732	0.778	rs9435665	chr1:17324537	G/A	cg02580006	chr1:16560116	C1orf89	0.42	5.19	0.31	4.34e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in smokers;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23903597	chr17:61704154	MAP3K3	-0.5	-6.06	-0.36	5.07e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.59e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.6	11.94	0.61	3.11e-26	Diabetic kidney disease;
KIRP	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.45	6.49	0.38	4.64e-10	Coronary artery disease;
KIRP	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg00343986	chr7:65444356	GUSB	0.39	4.86	0.3	2.12e-6	Aortic root size;
KIRP	cis	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg03511173	chr18:77590860	NA	-0.57	-7.07	-0.41	1.63e-11	Opioid sensitivity;
KIRP	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.72	-6.6	-0.39	2.47e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26624270	chr17:78184945	SGSH	-0.47	-6.7	-0.39	1.41e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1461503	0.512	rs4259833	chr11:122809205	G/A	cg27398637	chr11:122830231	C11orf63	-0.66	-8.72	-0.49	4.3e-16	Menarche (age at onset);
KIRP	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.46	-5.8	-0.35	2.05e-8	High light scatter reticulocyte count;
KIRP	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg17595323	chr11:93583763	C11orf90	-0.37	-6.29	-0.37	1.48e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.81e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.71	-0.53	4.34e-19	Morning vs. evening chronotype;
KIRP	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.07e-12	Blood protein levels;
KIRP	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.75	-10.15	-0.54	1.91e-20	Aortic root size;
KIRP	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.13	-0.36	3.5e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg15848620	chr12:58087721	OS9	-0.49	-5.66	-0.34	4.3e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs7630877	0.962	rs4146789	chr3:179656495	C/T	cg18765712	chr3:179670323	PEX5L	0.45	5.53	0.33	7.97e-8	Type 2 diabetes;
KIRP	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.0	-0.61	2.05e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg13453750	chr1:205783389	SLC41A1	-0.5	-7.35	-0.42	2.84e-12	Menarche (age at onset);
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg11204139	chr17:3907470	NA	-0.81	-14.58	-0.68	3.97e-35	Type 2 diabetes;
KIRP	trans	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg11693508	chr17:37793320	STARD3	0.8	8.01	0.45	4.48e-14	Neuroticism;
KIRP	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.93	13.66	0.66	5.48e-32	Tonsillectomy;
KIRP	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg14250997	chr9:106856677	SMC2	0.43	5.9	0.35	1.19e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04567173	chr4:25379221	ANAPC4	0.49	6.7	0.39	1.4e-10	Parkinson's disease;
KIRP	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg10207240	chr12:122356781	WDR66	0.6	7.98	0.45	5.74e-14	Mean corpuscular volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10149091	chr2:61404764	AHSA2	-0.56	-6.04	-0.36	5.63e-9	Menopause (age at onset);
KIRP	cis	rs6001982	0.748	rs6001930	chr22:40876234	C/T	cg07138101	chr22:40742427	ADSL	-0.65	-5.04	-0.31	9.16e-7	Breast cancer;
KIRP	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.57	-0.48	1.13e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.38	-0.38	8.92e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-7.85	-0.45	1.31e-13	Dental caries;
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.17	-0.31	4.77e-7	Life satisfaction;
KIRP	cis	rs2274273	0.901	rs12050099	chr14:55764331	G/C	cg04306507	chr14:55594613	LGALS3	0.41	6.02	0.36	6.24e-9	Protein biomarker;
KIRP	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg18093559	chr17:18951025	GRAP	0.51	6.25	0.37	1.75e-9	Schizophrenia;
KIRP	cis	rs3857747	0.931	rs34058459	chr7:40364145	A/G	cg00420559	chr7:40367873	C7orf10	-0.6	-8.46	-0.47	2.37e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2970992	0.741	rs10176355	chr2:101335078	G/A	cg01042948	chr2:101319752	NA	0.41	5.95	0.35	9.4e-9	Educational attainment;
KIRP	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg18944383	chr4:111397179	ENPEP	0.61	10.36	0.55	4.28e-21	Coronary artery disease;
KIRP	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs10073892	0.664	rs10039237	chr5:101911597	A/G	cg19774478	chr5:101632501	SLCO4C1	0.52	4.92	0.3	1.59e-6	Cognitive decline (age-related);
KIRP	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg01689657	chr7:91764605	CYP51A1	0.38	5.49	0.33	1.02e-7	Breast cancer;
KIRP	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg23950597	chr19:37808831	NA	-0.62	-6.76	-0.4	1.02e-10	Coronary artery calcification;
KIRP	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg17507749	chr15:85114479	UBE2QP1	0.8	8.29	0.47	7.24e-15	Schizophrenia;
KIRP	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.81	-11.88	-0.6	5.19e-26	Calcium levels;
KIRP	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg03808351	chr9:123631620	PHF19	0.38	5.13	0.31	5.92e-7	Rheumatoid arthritis;
KIRP	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg25356066	chr3:128598488	ACAD9	0.46	5.2	0.31	4.2e-7	IgG glycosylation;
KIRP	cis	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09973852	chr16:30456960	SEPHS2	0.49	6.1	0.36	4.17e-9	Parkinson's disease;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg03160445	chr3:100120349	LNP1;TOMM70A	0.57	6.92	0.4	3.91e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.98	0.3	1.21e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.73	9.2	0.51	1.57e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-5.5	-0.33	9.46e-8	Height;
KIRP	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.82	11.61	0.59	4.01e-25	Breast cancer;
KIRP	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-9.06	-0.5	4.03e-17	Resting heart rate;
KIRP	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg23974023	chr2:113544294	IL1A	-0.35	-5.24	-0.32	3.38e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs115344852	0.575	rs2531820	chr6:28456719	T/C	cg09682330	chr6:28411287	ZSCAN23	-0.43	-4.88	-0.3	1.92e-6	Epithelial ovarian cancer;
KIRP	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.23	-24.73	-0.84	1.19e-68	IgG glycosylation;
KIRP	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.51	7.24	0.42	5.72e-12	Dupuytren's disease;
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.49	7.14	0.41	1.03e-11	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-12.84	-0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg26876637	chr1:152193138	HRNR	0.76	9.9	0.53	1.17e-19	Atopic dermatitis;
KIRP	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.83	-0.45	1.5e-13	Bipolar disorder;
KIRP	cis	rs17102423	0.559	rs11624169	chr14:65481710	C/G	cg11161011	chr14:65562177	MAX	-0.64	-7.23	-0.42	6.24e-12	Obesity-related traits;
KIRP	cis	rs7116495	1.000	rs6592453	chr11:71683231	C/G	cg11196788	chr11:71737549	NUMA1	0.57	5.15	0.31	5.29e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.82	-11.63	-0.6	3.24e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs9888739	0.591	rs4632147	chr16:31363381	C/T	cg15817542	chr16:31343056	ITGAM	-0.55	-5.76	-0.34	2.51e-8	Systemic lupus erythematosus;
KIRP	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg11707556	chr5:10655725	ANKRD33B	0.52	6.54	0.38	3.5e-10	Coronary artery disease;
KIRP	trans	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg02030672	chr11:45687055	CHST1	-0.53	-6.68	-0.39	1.6e-10	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-8.51	-0.48	1.71e-15	Platelet count;
KIRP	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.46	-6.28	-0.37	1.51e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1832871	0.672	rs62437159	chr6:158697705	C/T	cg07215822	chr6:158701037	NA	-0.64	-7.37	-0.43	2.63e-12	Height;
KIRP	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg11508081	chr17:41442227	NA	-0.37	-4.97	-0.3	1.26e-6	Menopause (age at onset);
KIRP	cis	rs12049351	0.774	rs6661924	chr1:229642740	G/T	cg11742688	chr1:229674241	ABCB10	-0.38	-5.7	-0.34	3.34e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.57	-0.48	1.14e-15	Vitiligo;
KIRP	cis	rs12949688	0.601	rs11079326	chr17:55837207	G/A	cg12582317	chr17:55822272	NA	0.44	6.32	0.37	1.19e-9	Schizophrenia;
KIRP	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.82	11.25	0.58	5.65e-24	Platelet distribution width;
KIRP	cis	rs2708977	0.549	rs6706734	chr2:97429951	T/G	cg26665480	chr2:98280029	ACTR1B	-0.45	-5.38	-0.32	1.71e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05165700	chr1:8021460	PARK7	0.53	6.27	0.37	1.61e-9	Smoking initiation;
KIRP	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg01422370	chr2:73384389	NA	0.42	5.5	0.33	9.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-8.1	-0.46	2.53e-14	Vitiligo;
KIRP	cis	rs7804356	1.000	rs73067472	chr7:26855959	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-4.95	-0.3	1.37e-6	Type 1 diabetes;
KIRP	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.82	11.57	0.59	5.12e-25	Total body bone mineral density;
KIRP	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg04935436	chr20:30431758	NA	0.48	5.86	0.35	1.48e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg03563238	chr19:33554763	RHPN2	-0.34	-5.79	-0.35	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg22974920	chr21:40686053	BRWD1	-0.45	-5.23	-0.32	3.56e-7	Cognitive function;
KIRP	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.05	-0.31	8.7e-7	Coronary artery disease;
KIRP	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.93	10.95	0.57	5.27e-23	Corneal astigmatism;
KIRP	cis	rs11203032	1.000	rs11203033	chr10:90964731	C/G	cg16672925	chr10:90967113	CH25H	-0.88	-9.43	-0.52	3.14e-18	Heart failure;
KIRP	cis	rs10029851	0.560	rs3910459	chr4:109612288	C/G	cg16525761	chr4:109541525	LOC285456;RPL34	-0.47	-5.33	-0.32	2.21e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2307121	0.512	rs2367496	chr5:64712122	T/C	cg11190754	chr5:64858552	CENPK;PPWD1	0.37	4.9	0.3	1.71e-6	Corneal structure;
KIRP	cis	rs870825	0.616	rs10428373	chr4:185639002	A/G	cg21366198	chr4:185655624	MLF1IP	-0.83	-9.9	-0.53	1.16e-19	Blood protein levels;
KIRP	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.74	0.34	2.71e-8	Asthma (sex interaction);
KIRP	cis	rs5752326	0.510	rs3830172	chr22:26873415	G/A	cg20819150	chr22:26891497	TFIP11	0.53	5.0	0.3	1.11e-6	Ischemic stroke;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21727117	chr19:2269525	OAZ1	-0.48	-6.49	-0.38	4.62e-10	Metabolic traits;
KIRP	trans	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.55	0.39	3.29e-10	Neuroticism;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg19462523	chr3:181429908	SOX2;SOX2OT	0.94	6.36	0.38	9.85e-10	P wave terminal force;
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00933542	chr6:150070202	PCMT1	0.27	5.4	0.33	1.61e-7	Lung cancer;
KIRP	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.99	15.92	0.71	1.09e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg19468946	chr17:37922297	IKZF3	-0.56	-7.94	-0.45	7.36e-14	Self-reported allergy;
KIRP	cis	rs34853779	1	rs34853779	chr4:144240024	CT/C	cg01601573	chr4:144256835	GAB1	0.35	4.89	0.3	1.8e-6	Breast cancer;
KIRP	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg21573476	chr21:45109991	RRP1B	-0.85	-13.47	-0.65	2.34e-31	Mean corpuscular volume;
KIRP	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.61	0.34	5.37e-8	Bipolar disorder;
KIRP	cis	rs654384	1.000	rs654384	chr7:4166659	C/T	cg21882563	chr7:4172065	SDK1	0.4	5.02	0.3	9.85e-7	Positive affect;
KIRP	cis	rs9400467	0.506	rs12199656	chr6:111675143	A/C	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.64	0.34	4.72e-8	Breast cancer;
KIRP	cis	rs6832769	1.000	rs35767091	chr4:56346723	G/A	cg09317128	chr4:56265301	TMEM165	0.55	7.12	0.41	1.18e-11	Personality dimensions;
KIRP	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg22563815	chr15:78856949	CHRNA5	-0.5	-7.7	-0.44	3.29e-13	Sudden cardiac arrest;
KIRP	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.56e-15	Lung cancer;
KIRP	cis	rs9381107	0.722	rs11753684	chr6:9450092	A/G	cg14735645	chr6:9486422	NA	-0.45	-5.36	-0.32	1.88e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs7225151	0.710	rs12600505	chr17:5233817	C/T	cg24500398	chr17:5266808	RABEP1	-0.58	-5.71	-0.34	3.23e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.51	-7.42	-0.43	1.85e-12	Daytime sleep phenotypes;
KIRP	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg04166393	chr7:2884313	GNA12	0.48	6.19	0.37	2.51e-9	Height;
KIRP	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg02591564	chr12:125578355	AACS	-0.44	-4.98	-0.3	1.19e-6	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.43	5.69	0.34	3.55e-8	Blood metabolite levels;
KIRP	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg06671706	chr8:8559999	CLDN23	0.57	6.42	0.38	7.1e-10	Obesity-related traits;
KIRP	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.72	0.39	1.28e-10	Height;
KIRP	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.55	6.0	0.36	7.18e-9	Total cholesterol levels;
KIRP	cis	rs8022179	0.580	rs6575977	chr14:103823348	G/T	cg23307798	chr14:103986281	CKB	-0.45	-4.94	-0.3	1.45e-6	Monocyte count;
KIRP	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.66	8.14	0.46	1.94e-14	Breast cancer;
KIRP	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.26	0.37	1.68e-9	Menarche (age at onset);
KIRP	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg06307176	chr5:131281290	NA	0.52	5.73	0.34	2.93e-8	Life satisfaction;
KIRP	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	0.82	12.76	0.63	6.02e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.62	-8.37	-0.47	4.41e-15	Blood trace element (Cu levels);
KIRP	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.93	14.65	0.68	2.27e-35	Testicular germ cell tumor;
KIRP	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.35	-5.13	-0.31	5.79e-7	Body mass index;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg07414643	chr4:187882934	NA	-0.43	-5.78	-0.35	2.26e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.12	-0.31	6.16e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.46	-6.06	-0.36	4.99e-9	Dietary macronutrient intake;
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06028808	chr11:68637592	NA	0.7	8.33	0.47	5.81e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.56	-7.66	-0.44	4.34e-13	Lung cancer;
KIRP	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg21775007	chr8:11205619	TDH	0.44	5.89	0.35	1.29e-8	Neuroticism;
KIRP	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg11833968	chr6:79620685	NA	-0.38	-5.24	-0.32	3.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg02487331	chr1:146550467	NA	-0.47	-5.96	-0.36	8.61e-9	HIV-1 control;
KIRP	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.13	0.46	2.1e-14	Type 2 diabetes;
KIRP	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	10.51	0.56	1.38e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg06521331	chr12:34319734	NA	-0.46	-5.64	-0.34	4.68e-8	Morning vs. evening chronotype;
KIRP	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg18451016	chr1:38461880	NA	0.5	6.97	0.41	2.84e-11	Coronary artery disease;
KIRP	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg19500275	chr17:80737654	TBCD	0.49	5.87	0.35	1.43e-8	Glycated hemoglobin levels;
KIRP	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.38	-0.32	1.72e-7	Life satisfaction;
KIRP	cis	rs367943	0.712	rs26969	chr5:112742436	A/G	cg12552261	chr5:112820674	MCC	0.56	6.69	0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.72	8.66	0.48	6.42e-16	Alcohol dependence;
KIRP	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.69	-9.88	-0.53	1.3e-19	Neurofibrillary tangles;
KIRP	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg17401720	chr7:158221031	PTPRN2	0.35	5.43	0.33	1.37e-7	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07764676	chr5:178286881	ZNF354B	0.45	6.02	0.36	6.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.58	6.38	0.38	8.67e-10	Corneal astigmatism;
KIRP	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	1.09	19.33	0.78	3.01e-51	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06206471	chr16:4364052	NA	-0.52	-6.91	-0.4	4.22e-11	Myopia;
KIRP	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17252645	chr8:143867129	LY6D	-0.54	-9.84	-0.53	1.76e-19	Urinary tract infection frequency;
KIRP	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg06212747	chr3:49208901	KLHDC8B	0.67	6.25	0.37	1.81e-9	Menarche (age at onset);
KIRP	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg26207909	chr14:103986467	CKB	-0.44	-5.35	-0.32	1.98e-7	Coronary artery disease;
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.72	11.24	0.58	6.33e-24	Menarche (age at onset);
KIRP	cis	rs930036	0.526	rs13035460	chr2:171781202	G/A	cg12801329	chr2:171670795	NA	0.46	5.24	0.32	3.44e-7	Menopause (age at onset);
KIRP	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.33	0.47	5.81e-15	Lung cancer in ever smokers;
KIRP	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg27205649	chr11:78285834	NARS2	0.68	8.29	0.47	7.53e-15	Alzheimer's disease (survival time);
KIRP	cis	rs7712401	0.715	rs13163098	chr5:122346536	A/G	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	5.07	0.31	7.93e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6815814	0.851	rs10023850	chr4:38763693	G/A	cg06935464	chr4:38784597	TLR10	0.52	5.37	0.32	1.79e-7	Breast cancer;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05508062	chr3:62110348	ID2B;PTPRG	0.41	6.19	0.37	2.46e-9	Cancer;
KIRP	cis	rs3767633	1.000	rs3767633	chr1:161826615	T/A	cg09175582	chr1:161736000	ATF6	0.73	5.91	0.35	1.13e-8	IgG glycosylation;
KIRP	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg18132916	chr6:79620363	NA	-0.36	-4.98	-0.3	1.19e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.6	6.96	0.41	3.1e-11	Gestational age at birth (maternal effect);
KIRP	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.44	5.05	0.31	8.64e-7	Schizophrenia;
KIRP	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.39	-5.6	-0.34	5.62e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	8.11	0.46	2.46e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.37e-10	Aortic root size;
KIRP	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.66	-9.81	-0.53	2.17e-19	Migraine;
KIRP	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	7.83	0.45	1.41e-13	Type 2 diabetes;
KIRP	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.14	-10.14	-0.54	2.12e-20	Body mass index;
KIRP	cis	rs2400749	0.795	rs8018119	chr14:100034247	A/T	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.43	-0.33	1.34e-7	Alzheimer's disease (survival time);
KIRP	cis	rs59197085	0.515	rs17165191	chr7:128451004	T/C	cg00734629	chr7:128471146	FLNC	0.48	5.71	0.34	3.26e-8	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-5.43	-0.33	1.37e-7	Lung cancer;
KIRP	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg08999081	chr20:33150536	PIGU	-0.44	-5.73	-0.34	2.91e-8	Height;
KIRP	cis	rs714027	0.605	rs5763797	chr22:30530125	T/C	cg27665648	chr22:30112403	NA	-0.43	-5.73	-0.34	2.85e-8	Lymphocyte counts;
KIRP	cis	rs9815354	0.812	rs4299460	chr3:41952445	A/C	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg00800569	chr2:239229395	TRAF3IP1	0.43	5.09	0.31	7.24e-7	Multiple system atrophy;
KIRP	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg05457628	chr5:178986728	RUFY1	-0.39	-5.75	-0.34	2.69e-8	Lung cancer;
KIRP	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.77	-0.53	2.99e-19	Glomerular filtration rate (creatinine);
KIRP	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.19	-0.42	7.7e-12	Systolic blood pressure;
KIRP	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.42	-5.27	-0.32	2.93e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.57	6.68	0.39	1.58e-10	Schizophrenia;
KIRP	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.39	4.9	0.3	1.72e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1413885	0.549	rs9436726	chr1:65853196	T/C	cg13202122	chr1:65886182	LEPROT;LEPR	0.41	4.87	0.3	2.04e-6	Anticoagulant levels;
KIRP	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.69	5.66	0.34	4.18e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	1.03	20.26	0.79	2.38e-54	Breast cancer;
KIRP	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.78	-5.73	-0.34	2.88e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg17822266	chr1:2720087	NA	-0.44	-6.12	-0.36	3.58e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.48	6.51	0.38	4.09e-10	Testicular germ cell tumor;
KIRP	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg03959625	chr15:84868606	LOC388152	0.47	5.54	0.33	7.76e-8	Schizophrenia;
KIRP	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg13319975	chr6:146136371	FBXO30	-0.39	-5.18	-0.31	4.64e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.42	0.43	1.85e-12	Joint mobility (Beighton score);
KIRP	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.6	7.92	0.45	8.22e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs838147	0.873	rs11667321	chr19:49250538	A/G	cg08619932	chr19:49200058	FUT2	-0.35	-5.15	-0.31	5.27e-7	Dietary macronutrient intake;
KIRP	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.99	12.78	0.63	5.02e-29	Exhaled nitric oxide output;
KIRP	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg26875233	chr11:93583750	C11orf90	-0.34	-6.49	-0.38	4.81e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs13385	0.769	rs13178142	chr5:139596552	C/T	cg01860693	chr5:139557145	C5orf32	0.51	5.21	0.32	3.92e-7	Atrial fibrillation;
KIRP	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg19077165	chr18:44547161	KATNAL2	-0.39	-5.02	-0.3	9.92e-7	Educational attainment;
KIRP	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.21	12.45	0.62	6.44e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg01294253	chr9:136912663	BRD3	0.41	5.27	0.32	2.95e-7	Platelet distribution width;
KIRP	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.44	-8.92	-0.49	1.07e-16	Urinary metabolites;
KIRP	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.61	8.16	0.46	1.77e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2299587	0.623	rs7816738	chr8:17768482	A/G	cg01800426	chr8:17659068	MTUS1	-0.54	-6.61	-0.39	2.39e-10	Economic and political preferences;
KIRP	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg04865290	chr3:52927548	TMEM110	-0.66	-6.61	-0.39	2.37e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	5.56	0.33	6.84e-8	Platelet count;
KIRP	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.92	-12.53	-0.62	3.35e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.38	-0.43	2.5e-12	Mood instability;
KIRP	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg01941274	chr14:50234650	KLHDC2	0.4	4.94	0.3	1.47e-6	Carotid intima media thickness;
KIRP	cis	rs7681423	1.000	rs7659024	chr4:155520930	G/A	cg20735720	chr4:155535218	FGG	-0.63	-8.27	-0.47	8.35e-15	Fibrinogen;
KIRP	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.1	0.5	3.22e-17	Lung cancer in ever smokers;
KIRP	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	5.24	0.32	3.51e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.71	-8.65	-0.48	6.61e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.54	-11.59	-0.59	4.46e-25	Diabetic kidney disease;
KIRP	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.71	9.4	0.51	3.87e-18	Morning vs. evening chronotype;
KIRP	cis	rs4886920	0.822	rs8026203	chr15:78105708	C/T	cg10461261	chr15:78109450	NA	-0.33	-5.49	-0.33	1.02e-7	Neuroticism;
KIRP	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.43	7.28	0.42	4.38e-12	Huntington's disease progression;
KIRP	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg12131826	chr15:77904385	NA	0.5	6.22	0.37	2.13e-9	Type 2 diabetes;
KIRP	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.53	7.58	0.43	7.19e-13	Obesity-related traits;
KIRP	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.46	8.78	0.49	2.87e-16	Educational attainment (years of education);
KIRP	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg22974920	chr21:40686053	BRWD1	0.51	6.02	0.36	6.36e-9	Cognitive function;
KIRP	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.69	-8.48	-0.48	2.14e-15	Corneal structure;
KIRP	cis	rs10073892	0.743	rs10076451	chr5:101657522	T/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.15e-10	Cognitive decline (age-related);
KIRP	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg05072774	chr3:49840536	C3orf54	-0.41	-5.14	-0.31	5.59e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02179239	chr10:23002514	PIP4K2A	0.61	7.26	0.42	5.02e-12	Smoking initiation;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.47	6.03	0.36	6.01e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1359582	0.767	rs10749593	chr10:90374057	A/G	cg15661332	chr10:90342814	RNLS	-0.57	-6.28	-0.37	1.54e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs78487399	0.808	rs6544664	chr2:43729108	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.02	-0.3	9.81e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.52	-6.32	-0.37	1.24e-9	Ulcerative colitis;
KIRP	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.83	-12.69	-0.63	1.01e-28	Blood metabolite levels;
KIRP	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07234876	chr8:600039	NA	0.93	6.87	0.4	5.36e-11	IgG glycosylation;
KIRP	cis	rs11627756	0.957	rs11846451	chr14:103131723	T/C	cg01864069	chr14:103024347	NA	0.55	6.43	0.38	6.55e-10	Mean platelet volume;
KIRP	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.93	0.49	1.05e-16	Motion sickness;
KIRP	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.73	0.39	1.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg16434002	chr17:42200994	HDAC5	-0.43	-4.92	-0.3	1.58e-6	Total body bone mineral density;
KIRP	cis	rs698813	0.774	rs786625	chr2:44604156	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.53	0.38	3.74e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.02	-0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg23985595	chr17:80112537	CCDC57	0.37	5.6	0.34	5.66e-8	Life satisfaction;
KIRP	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.62	7.32	0.42	3.43e-12	Obesity-related traits;
KIRP	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	12.93	0.64	1.59e-29	Menopause (age at onset);
KIRP	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg09904177	chr6:26538194	HMGN4	-0.44	-5.43	-0.33	1.32e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	14.0	0.67	3.87e-33	Ulcerative colitis;
KIRP	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg07395648	chr5:131743802	NA	-0.6	-8.33	-0.47	5.54e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.48	-0.43	1.35e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.54	-7.17	-0.42	8.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs137699	0.652	rs137706	chr22:39751400	T/G	cg05872129	chr22:39784769	NA	-0.54	-6.2	-0.37	2.4e-9	IgG glycosylation;
KIRP	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg26681399	chr22:41777847	TEF	0.55	5.35	0.32	1.97e-7	Vitiligo;
KIRP	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg11031976	chr2:198649780	BOLL	-0.48	-4.94	-0.3	1.43e-6	Ulcerative colitis;
KIRP	cis	rs6024905	0.587	rs1579101	chr20:36966334	C/T	cg07053727	chr20:36965646	BPI	0.45	7.33	0.42	3.3e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.44	-0.38	6.2e-10	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17360330	chr4:4459401	STX18	-0.4	-6.02	-0.36	6.24e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11997175	0.545	rs4733457	chr8:33661236	G/A	cg04338863	chr8:33670619	NA	0.44	5.54	0.33	7.73e-8	Body mass index;
KIRP	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.73	7.78	0.44	2.06e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg04398451	chr17:18023971	MYO15A	0.65	8.48	0.48	2.16e-15	Total body bone mineral density;
KIRP	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.45	9.27	0.51	9.61e-18	Ewing sarcoma;
KIRP	cis	rs4356932	1.000	rs6829896	chr4:76970739	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs55962025	0.662	rs2071704	chr4:3240159	C/T	cg06533319	chr4:3265114	C4orf44	0.42	5.4	0.33	1.58e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.63	7.71	0.44	3.11e-13	Coronary artery disease;
KIRP	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.75	-9.46	-0.52	2.61e-18	Colorectal cancer;
KIRP	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg00981070	chr1:2046702	PRKCZ	-0.39	-5.58	-0.33	6.48e-8	Height;
KIRP	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg16672083	chr15:72433130	SENP8	0.42	5.7	0.34	3.44e-8	Red blood cell count;
KIRP	cis	rs2274273	0.682	rs1187876	chr14:55495199	A/T	cg04306507	chr14:55594613	LGALS3	-0.43	-6.5	-0.38	4.37e-10	Protein biomarker;
KIRP	cis	rs2371030	1.000	rs1019393	chr2:211593081	C/G	cg18417063	chr2:211583084	NA	-0.51	-7.24	-0.42	5.63e-12	Non-small cell lung cancer;
KIRP	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.71	-10.93	-0.57	6.26e-23	Height;
KIRP	cis	rs4742903	0.904	rs2417487	chr9:106887581	A/G	cg14250997	chr9:106856677	SMC2	0.4	5.22	0.32	3.81e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.8	11.79	0.6	1.02e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg10932868	chr11:921992	NA	0.68	9.13	0.5	2.63e-17	Alzheimer's disease (late onset);
KIRP	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.67	7.59	0.44	6.76e-13	Height;
KIRP	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.78	7.65	0.44	4.5e-13	Type 2 diabetes;
KIRP	cis	rs11622475	0.677	rs7145372	chr14:104359121	A/G	cg20488157	chr14:104394430	TDRD9	-0.58	-7.24	-0.42	5.73e-12	Bipolar disorder;
KIRP	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	12.17	0.61	5.67e-27	Smoking behavior;
KIRP	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.67	-8.91	-0.49	1.19e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg16576597	chr16:28551801	NUPR1	0.34	5.34	0.32	2.1e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.03	-0.41	1.97e-11	Morning vs. evening chronotype;
KIRP	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	8.64	0.48	7.17e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs35740288	0.770	rs62023931	chr15:86132752	T/C	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.75	6.19	0.37	2.54e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.78	-11.6	-0.59	4.25e-25	Obesity-related traits;
KIRP	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg06636001	chr8:8085503	FLJ10661	0.76	9.04	0.5	4.93e-17	Red cell distribution width;
KIRP	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.58	-7.98	-0.45	5.4e-14	Glycated hemoglobin levels;
KIRP	cis	rs9398803	0.799	rs1538170	chr6:126752874	C/T	cg19875578	chr6:126661172	C6orf173	0.5	6.39	0.38	8.16e-10	Male-pattern baldness;
KIRP	cis	rs4727443	0.899	rs6954978	chr7:99582212	A/G	cg22004693	chr7:99632812	ZKSCAN1	0.37	4.87	0.3	2e-6	Interstitial lung disease;
KIRP	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg02631126	chr6:28058918	ZSCAN12L1	0.44	5.1	0.31	6.63e-7	Cardiac Troponin-T levels;
KIRP	cis	rs3857067	0.967	rs1355240	chr4:95019353	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.02	-0.3	9.95e-7	QT interval;
KIRP	cis	rs4356932	1.000	rs6840980	chr4:76985331	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs2273669	0.667	rs12195836	chr6:109357701	T/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.54	-0.38	3.59e-10	Prostate cancer;
KIRP	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.49	-6.35	-0.38	1.05e-9	Menopause (age at onset);
KIRP	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs2223471	0.652	rs2744488	chr6:50768062	C/A	cg14470998	chr6:50812995	TFAP2B	-0.37	-4.85	-0.3	2.24e-6	Subcutaneous adipose tissue;
KIRP	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg10381502	chr11:71823885	C11orf51	-1.08	-7.52	-0.43	9.99e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	1.15	14.87	0.69	4.21e-36	Response to hepatitis C treatment;
KIRP	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg21905437	chr5:178450457	ZNF879	0.47	5.21	0.32	3.93e-7	Pubertal anthropometrics;
KIRP	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	6.59	0.39	2.63e-10	Response to antipsychotic treatment;
KIRP	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs7951870	0.673	rs13448	chr11:46695414	T/C	cg16389345	chr11:46697382	NA	-0.42	-4.93	-0.3	1.48e-6	Schizophrenia;
KIRP	cis	rs72634258	0.786	rs6682709	chr1:8173796	A/C	cg00042356	chr1:8021962	PARK7	-0.51	-5.11	-0.31	6.56e-7	Inflammatory bowel disease;
KIRP	cis	rs13401104	0.796	rs12471212	chr2:237112191	G/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg05991184	chr2:219186017	PNKD	0.36	5.32	0.32	2.3e-7	Colorectal cancer;
KIRP	cis	rs894344	0.650	rs66669000	chr8:135582895	A/G	cg09855544	chr8:135498122	ZFAT	0.39	4.96	0.3	1.29e-6	Systolic blood pressure;
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg04369109	chr6:150039330	LATS1	-0.45	-5.54	-0.33	7.6e-8	Lung cancer;
KIRP	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg21174375	chr14:64681225	SYNE2	-0.72	-10.11	-0.54	2.6e-20	Atrial fibrillation;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	5.62	0.34	5.15e-8	Platelet count;
KIRP	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.1e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02187348	chr16:89574699	SPG7	0.42	5.11	0.31	6.36e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg09795085	chr6:101329169	ASCC3	0.41	4.9	0.3	1.77e-6	Neuroticism;
KIRP	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg23594656	chr7:65796392	TPST1	0.39	5.87	0.35	1.43e-8	Aortic root size;
KIRP	cis	rs72627509	0.638	rs78933653	chr4:57854840	A/G	cg26694713	chr4:57773883	REST	0.62	5.02	0.31	9.71e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.42	7.48	0.43	1.35e-12	Renal cell carcinoma;
KIRP	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.59	6.9	0.4	4.5e-11	DNA methylation (variation);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07432643	chr22:50247581	ZBED4	0.56	7.27	0.42	4.88e-12	Myopia (pathological);
KIRP	cis	rs9311676	0.656	rs11917591	chr3:58368449	C/T	cg06643156	chr3:58380774	PXK	-0.36	-5.03	-0.31	9.32e-7	Systemic lupus erythematosus;
KIRP	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg07001201	chr5:642380	CEP72	0.67	6.23	0.37	1.99e-9	Obesity-related traits;
KIRP	cis	rs11585357	0.501	rs58620951	chr1:17573965	G/A	cg08277548	chr1:17600880	PADI3	-0.63	-5.33	-0.32	2.17e-7	Hair shape;
KIRP	cis	rs7084402	0.967	rs10763551	chr10:60273898	G/A	cg05938607	chr10:60274200	BICC1	0.42	10.2	0.55	1.35e-20	Refractive error;
KIRP	cis	rs16976116	0.901	rs28508034	chr15:55499010	T/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11671005	0.610	rs3794966	chr19:59068996	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.56	-6.46	-0.38	5.7e-10	Mean platelet volume;
KIRP	cis	rs8133932	0.564	rs452797	chr21:47348455	C/G	cg11214348	chr21:47283868	PCBP3	-0.44	-5.13	-0.31	5.89e-7	Schizophrenia;
KIRP	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.73	10.02	0.54	4.95e-20	Total body bone mineral density;
KIRP	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19882132	chr14:106167949	NA	-0.41	-5.04	-0.31	8.84e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs6842047	0.611	rs4253421	chr4:187204937	C/T	cg02012338	chr4:187126139	CYP4V2	-0.68	-5.27	-0.32	2.91e-7	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26008272	chr19:45574917	ZNF296	-0.44	-6.06	-0.36	5.16e-9	Survival in pancreatic cancer;
KIRP	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.22e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	1.09	21.77	0.81	2.77e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.67	9.69	0.53	5.09e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg25309564	chr22:51001381	C22orf41	0.74	5.17	0.31	4.9e-7	Narcolepsy;
KIRP	cis	rs6807915	0.647	rs310756	chr3:12277612	C/T	cg02700894	chr3:12045449	SYN2	0.4	5.46	0.33	1.18e-7	Leprosy;
KIRP	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.86	-0.53	1.55e-19	Height;
KIRP	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.52	-6.44	-0.38	6.4e-10	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08286218	chr13:115000425	CDC16	-0.55	-6.07	-0.36	4.83e-9	Menopause (age at onset);
KIRP	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.8200000000000003e-11	Hypertriglyceridemia;
KIRP	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg09238746	chr17:78121135	EIF4A3	-0.63	-8.0	-0.45	4.99e-14	Yeast infection;
KIRP	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg26879891	chr1:152191343	HRNR	0.48	5.9	0.35	1.21e-8	Inflammatory skin disease;
KIRP	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg05484376	chr2:27715224	FNDC4	0.41	6.81	0.4	7.41e-11	Total body bone mineral density;
KIRP	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-6.86	-0.4	5.5e-11	Chronic sinus infection;
KIRP	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg23594656	chr7:65796392	TPST1	0.46	7.27	0.42	4.84e-12	Aortic root size;
KIRP	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	1.06	19.83	0.78	6.13e-53	Gut microbiome composition (winter);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10681804	chr20:33433114	GGT7	0.56	6.11	0.36	3.93e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.5	-0.38	4.51e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	trans	rs6601327	0.670	rs6601338	chr8:9438928	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.17	0.37	2.81e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25517755	chr10:38738941	LOC399744	-0.52	-7.14	-0.41	1.05e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.82	-12.99	-0.64	1.01e-29	Blood metabolite levels;
KIRP	cis	rs909341	0.537	rs12481497	chr20:62385541	G/A	cg03999872	chr20:62272968	STMN3	-0.47	-4.9	-0.3	1.72e-6	Atopic dermatitis;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.63	-8.35	-0.47	5.11e-15	Longevity;Endometriosis;
KIRP	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.14	-0.46	1.95e-14	Mean corpuscular volume;
KIRP	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.48	-0.43	1.35e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12425451	0.544	rs28623776	chr12:3147631	C/T	cg05389053	chr12:3131226	TEAD4	-0.46	-5.57	-0.33	6.55e-8	Narcolepsy with cataplexy;
KIRP	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.41	-5.72	-0.34	3.06e-8	Monocyte count;
KIRP	cis	rs10073892	0.744	rs10052881	chr5:101740499	C/T	cg19774478	chr5:101632501	SLCO4C1	0.67	6.49	0.38	4.73e-10	Cognitive decline (age-related);
KIRP	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg07636037	chr3:49044803	WDR6	-0.73	-6.72	-0.39	1.29e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7075426	0.669	rs4934211	chr10:88203735	C/T	cg07322936	chr10:88137208	NA	0.5	5.54	0.33	7.86e-8	Migraine without aura;
KIRP	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.58	6.89	0.4	4.52e-11	Aortic root size;
KIRP	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg14221460	chr8:27183342	PTK2B	0.45	5.84	0.35	1.66e-8	Neuroticism;
KIRP	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs1629083	0.806	rs11600544	chr11:118076954	C/G	cg18857871	chr11:118064634	AMICA1	0.65	8.77	0.49	2.98e-16	Lung cancer;
KIRP	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.61	-7.98	-0.45	5.45e-14	Longevity;
KIRP	cis	rs10073892	0.957	rs61522296	chr5:101858706	T/A	cg19774478	chr5:101632501	SLCO4C1	0.62	6.59	0.39	2.59e-10	Cognitive decline (age-related);
KIRP	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg07001201	chr5:642380	CEP72	0.66	6.05	0.36	5.31e-9	Obesity-related traits;
KIRP	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg25418670	chr11:30344373	C11orf46	0.6	5.15	0.31	5.46e-7	Morning vs. evening chronotype;
KIRP	trans	rs1864585	0.520	rs1549792	chr8:10655620	A/G	cg26278703	chr11:58910052	FAM111A	0.63	6.46	0.38	5.54e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.21	-28.9	-0.88	4.82e-81	Chronic sinus infection;
KIRP	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.81	12.3	0.62	1.99e-27	IgG glycosylation;
KIRP	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.75	-8.31	-0.47	6.37e-15	Parkinson's disease;
KIRP	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.85	-12.58	-0.63	2.44e-28	Total body bone mineral density;
KIRP	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg17294928	chr15:75287854	SCAMP5	-0.57	-5.56	-0.33	7.04e-8	Blood trace element (Zn levels);
KIRP	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	6.34	0.37	1.08e-9	Iron status biomarkers;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.59	-8.24	-0.47	1.04e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg21479132	chr6:26055353	NA	0.78	5.1	0.31	6.89e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs12659622	0.850	rs4510586	chr5:15604978	C/T	cg09887955	chr1:202129854	PTPN7	0.52	6.04	0.36	5.72e-9	Obesity-related traits;
KIRP	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.92	14.56	0.68	4.75e-35	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.27	-0.42	4.91e-12	Mood instability;
KIRP	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg04865290	chr3:52927548	TMEM110	0.59	6.8	0.4	7.69e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg10761708	chr20:43804764	PI3	0.5	5.2	0.31	4.22e-7	Blood protein levels;
KIRP	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	11.79	0.6	1e-25	Bipolar disorder;
KIRP	cis	rs12425451	0.552	rs10848765	chr12:3141495	C/T	cg05389053	chr12:3131226	TEAD4	0.56	6.88	0.4	4.8e-11	Narcolepsy with cataplexy;
KIRP	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.65	7.79	0.44	1.86e-13	Iron status biomarkers;
KIRP	cis	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.39	5.0	0.3	1.11e-6	Leprosy;
KIRP	cis	rs7116495	1.000	rs548961	chr11:71793887	G/A	cg26138937	chr11:71823887	C11orf51	-0.65	-5.06	-0.31	8.15e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg02782426	chr3:40428986	ENTPD3	-0.35	-5.44	-0.33	1.28e-7	Renal cell carcinoma;
KIRP	cis	rs2223471	0.967	rs3765306	chr6:50712784	C/T	cg03432817	chr6:50765336	NA	0.51	8.09	0.46	2.76e-14	Subcutaneous adipose tissue;
KIRP	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.93	9.51	0.52	1.79e-18	Gut microbiome composition (summer);
KIRP	cis	rs142802669	1	rs142802669	chr3:41869427	A/C	cg03022575	chr3:42003672	ULK4	0.51	5.83	0.35	1.75e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.94	-9.5	-0.52	2.03e-18	Body mass index;
KIRP	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.82	-8.15	-0.46	1.9e-14	Asthma;
KIRP	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.01	-0.3	1.06e-6	Life satisfaction;
KIRP	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg09184832	chr6:79620586	NA	-0.54	-7.73	-0.44	2.79e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	5.09	0.31	7.1e-7	Obesity-related traits;
KIRP	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg06565975	chr8:143823917	SLURP1	0.47	7.39	0.43	2.23e-12	Urinary tract infection frequency;
KIRP	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.49	-6.13	-0.36	3.45e-9	Body mass index;
KIRP	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg11584989	chr19:19387371	SF4	0.41	5.28	0.32	2.81e-7	Tonsillectomy;
KIRP	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.65	10.64	0.56	5.2e-22	Pulse pressure;
KIRP	cis	rs7707921	0.767	rs226202	chr5:81571669	C/T	cg07807695	chr5:81608485	ATP6AP1L	-0.41	-5.07	-0.31	7.82e-7	Breast cancer;
KIRP	cis	rs6545883	0.525	rs1729658	chr2:61373520	C/T	cg15711740	chr2:61764176	XPO1	-0.61	-7.8	-0.45	1.73e-13	Tuberculosis;
KIRP	cis	rs448720	0.806	rs47713	chr15:68173855	C/T	cg24579218	chr15:68104479	NA	0.44	6.59	0.39	2.68e-10	Cognitive performance;
KIRP	cis	rs96067	0.607	rs274761	chr1:36574023	C/T	cg27506609	chr1:36549197	TEKT2	-0.78	-5.62	-0.34	5.1e-8	Corneal structure;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg17774305	chr12:50505649	C12orf62	0.51	6.03	0.36	5.99e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-0.97	-9.41	-0.51	3.72e-18	Hip circumference adjusted for BMI;
KIRP	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	1.05	11.75	0.6	1.4e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-6.62	-0.39	2.26e-10	Schizophrenia;
KIRP	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.05	-0.58	2.5e-23	Height;
KIRP	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26423331	chr2:74374909	BOLA3	-0.57	-6.32	-0.37	1.23e-9	Menopause (age at onset);
KIRP	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	1.2	14.63	0.68	2.81e-35	Type 2 diabetes nephropathy;
KIRP	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.46	5.72	0.34	3.13e-8	Lymphocyte counts;
KIRP	cis	rs6725041	0.750	rs1402764	chr2:213096345	T/C	cg20637307	chr2:213403960	ERBB4	-0.4	-5.45	-0.33	1.24e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.84	11.4	0.59	1.83e-24	Mean platelet volume;
KIRP	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-7.11	-0.41	1.24e-11	Testicular germ cell tumor;
KIRP	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	1.09	17.86	0.75	2.52e-46	Cognitive function;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27003571	chr2:145051829	GTDC1	0.44	6.48	0.38	5e-10	Migraine with aura;
KIRP	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	13.39	0.65	4.31e-31	Personality dimensions;
KIRP	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg07423050	chr13:99094983	FARP1	0.3	5.05	0.31	8.6e-7	Longevity;
KIRP	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg15655495	chr12:38532458	NA	-0.28	-5.18	-0.31	4.54e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.82	0.49	2.21e-16	Bladder cancer;
KIRP	cis	rs9653442	0.510	rs12712068	chr2:100764439	A/G	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	6.63	0.39	2.17e-10	Initial pursuit acceleration;
KIRP	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg14972814	chr11:95582409	MTMR2	0.32	5.46	0.33	1.14e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.95	15.33	0.7	1.11e-37	Metabolite levels;
KIRP	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.55	-7.65	-0.44	4.58e-13	Prostate cancer;
KIRP	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg01620082	chr3:125678407	NA	-1.07	-6.74	-0.39	1.09e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1978968	1.000	rs13057203	chr22:18446024	A/G	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6142102	0.961	rs6059651	chr20:32645052	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	6.75	0.4	1.07e-10	Skin pigmentation;
KIRP	cis	rs1215050	0.776	rs1627946	chr4:98844416	G/A	cg17366294	chr4:99064904	C4orf37	-0.36	-4.94	-0.3	1.48e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7009516	0.792	rs13265142	chr8:24229709	T/A	cg01759110	chr8:24241694	ADAMDEC1	-0.3	-6.23	-0.37	2.05e-9	Hair greying;
KIRP	cis	rs4253772	0.591	rs113101219	chr22:46659186	C/A	cg18190219	chr22:46762943	CELSR1	-0.64	-5.82	-0.35	1.79e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg05315796	chr3:52349193	DNAH1	0.44	6.77	0.4	9.16e-11	Bipolar disorder;
KIRP	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.53	-7.43	-0.43	1.82e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg21605333	chr4:119757512	SEC24D	1.34	9.35	0.51	5.52e-18	Cannabis dependence symptom count;
KIRP	cis	rs7534824	0.543	rs6693339	chr1:101424431	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.82	-7.85	-0.45	1.25e-13	Refractive astigmatism;
KIRP	cis	rs4683702	0.932	rs9844878	chr3:142621664	G/C	cg22826874	chr3:142608218	PCOLCE2	-0.34	-5.09	-0.31	7.14e-7	Blood protein levels;
KIRP	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.56	-6.87	-0.4	5.14e-11	Total body bone mineral density;
KIRP	cis	rs13033859	0.794	rs6707786	chr2:166224	G/T	cg10118717	chr2:203439	NA	0.4	6.25	0.37	1.83e-9	Mitochondrial DNA levels;
KIRP	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg19773385	chr1:10388646	KIF1B	-0.66	-10.13	-0.54	2.15e-20	Hepatocellular carcinoma;
KIRP	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.47	-5.14	-0.31	5.52e-7	Tuberculosis;
KIRP	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.57	-7.84	-0.45	1.36e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg04896959	chr15:78267971	NA	0.52	6.81	0.4	7.57e-11	Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11791613	chr1:234614222	TARBP1	0.52	6.6	0.39	2.5e-10	Parkinson's disease;
KIRP	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg00800569	chr2:239229395	TRAF3IP1	0.44	5.36	0.32	1.88e-7	Multiple system atrophy;
KIRP	cis	rs829661	1.000	rs829661	chr2:30726691	T/C	cg10949345	chr2:30726833	LCLAT1	0.69	9.68	0.53	5.44e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg26727032	chr16:67993705	SLC12A4	-0.79	-9.21	-0.51	1.5e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6496667	0.779	rs2074581	chr15:91009147	T/G	cg10434728	chr15:90938212	IQGAP1	0.37	5.02	0.3	9.79e-7	Rheumatoid arthritis;
KIRP	cis	rs151997	0.925	rs27286	chr5:50196324	G/T	cg06027927	chr5:50259733	NA	0.61	7.6	0.44	6.21e-13	Callous-unemotional behaviour;
KIRP	cis	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.2	-0.42	7.35e-12	Morning vs. evening chronotype;
KIRP	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.51	-15.14	-0.69	4.82e-37	Hip circumference adjusted for BMI;
KIRP	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.01	-0.41	2.29e-11	Myopia (pathological);
KIRP	cis	rs755109	1.000	rs7861658	chr9:100679954	A/G	cg13688889	chr9:100608707	NA	-0.42	-4.88	-0.3	1.87e-6	Quantitative traits;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs4650994	0.593	rs2811297	chr1:178551472	C/T	cg12486710	chr1:178512616	C1orf220	-0.25	-5.33	-0.32	2.21e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs12145833	0.665	rs78871868	chr1:243422322	C/T	cg02356786	chr1:243265016	LOC731275	0.89	6.03	0.36	5.82e-9	Obesity (early onset extreme);
KIRP	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.22	-0.32	3.79e-7	Coronary artery disease;
KIRP	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.48	7.52	0.43	1.02e-12	Testicular germ cell tumor;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg18350739	chr11:68623251	NA	-0.51	-7.79	-0.44	1.88e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6545883	0.929	rs2264100	chr2:61670829	G/A	cg15711740	chr2:61764176	XPO1	-0.6	-8.0	-0.45	4.99e-14	Tuberculosis;
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg12419862	chr22:24373484	LOC391322	-0.69	-7.38	-0.43	2.5e-12	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.71	5.98	0.36	7.64e-9	Diabetic retinopathy;
KIRP	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg26876637	chr1:152193138	HRNR	0.71	9.45	0.52	2.71e-18	Atopic dermatitis;
KIRP	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg04733989	chr22:42467013	NAGA	0.56	7.72	0.44	2.89e-13	Cognitive function;
KIRP	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg16482183	chr6:26056742	HIST1H1C	-0.6	-6.88	-0.4	4.94e-11	Iron status biomarkers;
KIRP	cis	rs77688320	0.500	rs10931948	chr2:202323922	G/A	cg06431681	chr2:202330990	STRADB	0.54	6.81	0.4	7.3e-11	Breast cancer;
KIRP	cis	rs4776059	1.000	rs4776066	chr15:52930499	T/C	cg22715398	chr15:52968154	KIAA1370	-0.59	-7.17	-0.42	8.63e-12	Schizophrenia;
KIRP	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.82	0.4	6.88e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg21851534	chr17:3907994	ZZEF1	-0.62	-9.6	-0.52	9.74e-19	Type 2 diabetes;
KIRP	cis	rs253959	0.883	rs6894046	chr5:115428439	T/A	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.47	5.19	0.31	4.43e-7	Schizophrenia;
KIRP	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg26068271	chr17:76253126	NA	0.45	6.52	0.38	4e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	12.08	0.61	1.09e-26	Smoking behavior;
KIRP	cis	rs17065868	1.000	rs61948001	chr13:45167814	G/T	cg10246903	chr13:45222710	NA	0.71	6.6	0.39	2.56e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.76	12.44	0.62	6.96e-28	Vitiligo;
KIRP	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg14458575	chr2:238380390	NA	0.47	5.34	0.32	2.16e-7	Prostate cancer;
KIRP	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23377693	chr6:43597122	MAD2L1BP;GTPBP2	0.53	6.06	0.36	5e-9	Smoking initiation;
KIRP	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg03605463	chr16:89740564	NA	0.55	7.23	0.42	5.95e-12	Vitiligo;
KIRP	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.66	8.88	0.49	1.46e-16	Educational attainment;
KIRP	trans	rs7830939	0.586	rs28586878	chr8:9322144	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.2	-0.37	2.34e-9	Neuroticism;
KIRP	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg07423050	chr13:99094983	FARP1	0.31	5.18	0.31	4.66e-7	Longevity;
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg21186296	chr8:27182909	PTK2B	0.51	6.44	0.38	6.09e-10	Neuroticism;
KIRP	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.85	11.96	0.61	2.68e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg00958927	chr1:175162553	KIAA0040	-0.29	-4.96	-0.3	1.31e-6	Alcohol dependence;
KIRP	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.38	-5.03	-0.31	9.67e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg21747090	chr2:27597821	SNX17	-0.4	-5.38	-0.32	1.71e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg05555928	chr11:63887634	MACROD1	-0.53	-5.59	-0.34	6.05e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.51	-0.33	9.19e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg19077165	chr18:44547161	KATNAL2	0.39	5.03	0.31	9.65e-7	Educational attainment;
KIRP	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.51	-7.61	-0.44	5.88e-13	IgG glycosylation;
KIRP	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.62	-5.9	-0.35	1.2e-8	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24904935	chr17:58740978	PPM1D	0.43	6.11	0.36	3.94e-9	Interleukin-4 levels;
KIRP	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.45	-6.82	-0.4	7.01e-11	Coronary artery disease;
KIRP	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.73	-8.08	-0.46	2.93e-14	Body mass index;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg18861311	chr10:102747418	C10orf2;MRPL43	-0.45	-6.13	-0.36	3.44e-9	Hippocampal sclerosis of aging;
KIRP	cis	rs4664304	0.781	rs3828323	chr2:160808075	C/T	cg03641300	chr2:160917029	PLA2R1	-0.35	-4.92	-0.3	1.62e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg13978929	chr19:21580086	ZNF493	-0.52	-5.1	-0.31	6.94e-7	Pain;
KIRP	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.75	11.4	0.59	1.89e-24	Metabolite levels;
KIRP	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg21360079	chr12:107162445	NA	-0.66	-9.21	-0.51	1.47e-17	Heart rate;
KIRP	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg25838818	chr2:108905173	SULT1C2	0.51	7.58	0.44	6.95e-13	Blood pressure;
KIRP	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg22705602	chr4:152727874	NA	0.58	8.69	0.48	5.27e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg09597638	chr17:3907349	NA	0.8	15.98	0.71	6.8e-40	Type 2 diabetes;
KIRP	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg17376030	chr22:41985996	PMM1	0.61	6.39	0.38	8.4e-10	Vitiligo;
KIRP	cis	rs11825685	0.836	rs56327979	chr11:134588757	A/T	cg06603561	chr11:134479413	NA	-0.57	-5.11	-0.31	6.47e-7	IgG glycosylation;
KIRP	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-7.03	-0.41	2.06e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs600806	0.627	rs2359652	chr1:110008720	T/A	cg02175308	chr1:109941060	SORT1	-0.26	-4.88	-0.3	1.87e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.68	-8.12	-0.46	2.31e-14	Diabetic retinopathy;
KIRP	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.94	12.28	0.62	2.32e-27	Menopause (age at onset);
KIRP	cis	rs8077577	0.895	rs16960986	chr17:18108562	A/G	cg09161412	chr17:18057145	MYO15A	0.37	5.28	0.32	2.85e-7	Obesity-related traits;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-4.86	-0.3	2.14e-6	Longevity;Endometriosis;
KIRP	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg05220968	chr6:146057943	EPM2A	-0.37	-5.03	-0.31	9.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.63	-8.12	-0.46	2.29e-14	Colorectal cancer;
KIRP	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg12559939	chr2:27858050	GPN1	0.44	5.47	0.33	1.09e-7	Oral cavity cancer;
KIRP	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18357526	chr6:26021779	HIST1H4A	0.47	6.29	0.37	1.46e-9	Schizophrenia;
KIRP	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.61	-7.07	-0.41	1.56e-11	Resting heart rate;
KIRP	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.6	-8.38	-0.47	3.99e-15	Brugada syndrome;
KIRP	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg15733309	chr7:157513707	PTPRN2	0.59	8.84	0.49	1.85e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg12140854	chr5:148520817	ABLIM3	0.43	4.93	0.3	1.49e-6	Breast cancer;
KIRP	cis	rs11018874	0.709	rs10765241	chr11:89849316	T/C	cg06174606	chr11:89959870	NA	-0.55	-5.48	-0.33	1.06e-7	White blood cell types;
KIRP	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.79	12.86	0.63	2.62e-29	Dupuytren's disease;
KIRP	cis	rs6832769	0.961	rs3736545	chr4:56310343	C/G	cg05960024	chr4:56376020	CLOCK	0.63	8.05	0.46	3.46e-14	Personality dimensions;
KIRP	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.09e-15	Menarche (age at onset);
KIRP	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.03	-16.7	-0.73	2.23e-42	Dilated cardiomyopathy;
KIRP	cis	rs829661	0.532	rs10205934	chr2:30772783	T/C	cg10949345	chr2:30726833	LCLAT1	0.48	7.16	0.42	9.55e-12	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9462846	0.959	rs9471958	chr6:42883669	C/T	cg13397359	chr6:42928475	GNMT	0.46	5.1	0.31	6.83e-7	Blood protein levels;
KIRP	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg22654517	chr2:96458247	NA	0.34	5.14	0.31	5.69e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.27	0.58	4.95e-24	Smoking behavior;
KIRP	cis	rs2802372	0.678	rs1972346	chr10:81067480	C/G	cg18688392	chr10:81059414	ZMIZ1	-0.57	-7.23	-0.42	5.97e-12	Granulocyte count;
KIRP	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg00812799	chr13:21295612	IL17D	0.39	5.08	0.31	7.35e-7	Dental caries;
KIRP	cis	rs7560272	0.529	rs2421672	chr2:73955540	G/A	cg20560298	chr2:73613845	ALMS1	0.44	5.29	0.32	2.66e-7	Schizophrenia;
KIRP	cis	rs9473924	0.632	rs4141608	chr6:50847242	C/T	cg03432817	chr6:50765336	NA	0.35	5.45	0.33	1.2e-7	Body mass index;
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.67	10.52	0.56	1.26e-21	Lung cancer;
KIRP	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.74	9.85	0.53	1.67e-19	Resting heart rate;
KIRP	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.76	0.4	1.02e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.46	7.07	0.41	1.62e-11	Coronary artery disease;
KIRP	cis	rs6973256	0.762	rs2113336	chr7:133478107	C/A	cg10665199	chr7:133106180	EXOC4	-0.43	-5.06	-0.31	8.17e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06710522	chr17:45908972	MRPL10;LRRC46	0.51	6.36	0.38	9.55e-10	Myopia (pathological);
KIRP	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg20936604	chr3:58311152	NA	-0.66	-5.01	-0.3	1.03e-6	Cholesterol, total;
KIRP	cis	rs10266483	0.741	rs35244017	chr7:63739317	G/A	cg04636841	chr7:63768139	NA	-0.41	-5.38	-0.32	1.77e-7	Response to statin therapy;
KIRP	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.71	7.18	0.42	8.11e-12	Vitiligo;
KIRP	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg05340658	chr4:99064831	C4orf37	-0.54	-6.51	-0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3026101	0.578	rs3026142	chr17:5315089	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.6	0.39	2.48e-10	Body mass index;
KIRP	cis	rs6545883	0.894	rs35292974	chr2:61522047	T/C	cg15711740	chr2:61764176	XPO1	0.6	7.85	0.45	1.3e-13	Tuberculosis;
KIRP	cis	rs747650	0.798	rs11039086	chr11:47116033	G/C	cg16389345	chr11:46697382	NA	0.38	4.98	0.3	1.18e-6	Acne (severe);
KIRP	cis	rs7072216	0.922	rs4539242	chr10:100148058	T/C	cg26618903	chr10:100175079	PYROXD2	-0.34	-4.96	-0.3	1.32e-6	Metabolite levels;
KIRP	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.49	-6.9	-0.4	4.47e-11	Height;
KIRP	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.64	11.0	0.57	3.86e-23	Sense of smell;
KIRP	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.83	12.5	0.62	4.38e-28	Body mass index;
KIRP	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.4	3.46e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7688540	0.800	rs12510827	chr4:252804	G/A	cg17891759	chr4:299121	NA	-0.4	-5.08	-0.31	7.58e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs258892	0.895	rs9293437	chr5:72041905	C/G	cg21869765	chr5:72125136	TNPO1	-0.5	-5.64	-0.34	4.56e-8	Small cell lung carcinoma;
KIRP	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.35	9.02	0.5	5.38e-17	Crohn's disease;
KIRP	cis	rs4253772	0.637	rs41279831	chr22:46651623	T/C	cg18190219	chr22:46762943	CELSR1	-0.66	-5.74	-0.34	2.71e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.51	-7.09	-0.41	1.44e-11	Alcohol dependence;
KIRP	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.76	-7.94	-0.45	7.11e-14	Hair shape;
KIRP	cis	rs8033133	0.560	rs12441340	chr15:25323964	G/T	cg14481604	chr15:25334117	SNORD116-22	-0.4	-4.87	-0.3	2.04e-6	Blood osmolality (transformed sodium);
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg21698718	chr17:80085957	CCDC57	0.36	5.37	0.32	1.81e-7	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg02725872	chr8:58115012	NA	-0.53	-6.03	-0.36	5.81e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9304742	0.962	rs12150933	chr19:53455221	A/G	cg09915433	chr19:53449742	NA	-0.38	-5.51	-0.33	9.15e-8	Psoriasis;
KIRP	cis	rs66561647	0.929	rs67423398	chr8:128972220	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.52	7.21	0.42	7.01e-12	Hemoglobin concentration;
KIRP	cis	rs7011507	1.000	rs79898638	chr8:49184143	C/T	cg15325961	chr8:49183143	NA	0.62	4.98	0.3	1.22e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg01843034	chr6:37503916	NA	0.82	11.66	0.6	2.65e-25	Cognitive performance;
KIRP	cis	rs76917914	0.780	rs6478556	chr9:100842005	A/G	cg03040243	chr9:100819229	NANS	-0.59	-6.42	-0.38	6.81e-10	Immature fraction of reticulocytes;
KIRP	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.68	9.74	0.53	3.63e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.14	-0.36	3.22e-9	Type 2 diabetes;
KIRP	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.43	-8.52	-0.48	1.62e-15	Urinary metabolites;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19307651	chr22:24236434	MIF	0.49	6.89	0.4	4.66e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.02	0.36	6.39e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs42648	0.935	rs7793743	chr7:90031619	G/A	cg25739043	chr7:89950458	NA	0.45	6.98	0.41	2.75e-11	Homocysteine levels;
KIRP	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg05090351	chr10:126851162	NA	0.45	7.52	0.43	1.05e-12	Menarche (age at onset);
KIRP	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.48	-6.13	-0.36	3.43e-9	Obesity-related traits;
KIRP	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs7737355	1.000	rs76753180	chr5:130763701	A/T	cg06307176	chr5:131281290	NA	-0.55	-5.94	-0.35	9.92e-9	Life satisfaction;
KIRP	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg06636001	chr8:8085503	FLJ10661	0.64	8.0	0.45	4.99e-14	Neuroticism;
KIRP	cis	rs372883	0.600	rs2832291	chr21:30734388	C/T	cg24692254	chr21:30365293	RNF160	0.62	8.04	0.46	3.81e-14	Pancreatic cancer;
KIRP	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.47	-6.04	-0.36	5.6e-9	Height;
KIRP	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.85	12.32	0.62	1.74e-27	Eye color traits;
KIRP	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.61	9.5	0.52	1.99e-18	Bone mineral density;
KIRP	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.61	8.79	0.49	2.63e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg12559939	chr2:27858050	GPN1	0.44	5.53	0.33	8.04e-8	Oral cavity cancer;
KIRP	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.97	17.35	0.74	1.36e-44	Breast cancer;
KIRP	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.89	14.11	0.67	1.59e-33	Mean corpuscular volume;
KIRP	cis	rs2479106	0.509	rs4836938	chr9:126367435	G/T	cg16191174	chr9:126692580	DENND1A	0.37	4.96	0.3	1.33e-6	Polycystic ovary syndrome;
KIRP	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72653721	0.715	rs4711162	chr6:10993079	T/A	cg13562911	chr6:11044106	ELOVL2	0.5	4.97	0.3	1.25e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Corneal astigmatism;
KIRP	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.87	13.79	0.66	2.04e-32	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs829883	0.934	rs249814	chr12:98892964	A/G	cg25150519	chr12:98850993	NA	0.86	12.97	0.64	1.12e-29	Colorectal adenoma (advanced);
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg00024416	chr22:24240387	NA	-0.36	-5.19	-0.31	4.51e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-5.27	-0.32	2.91e-7	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg17441377	chr17:3906640	NA	-0.49	-7.14	-0.41	1.02e-11	Type 2 diabetes;
KIRP	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	14.7	0.68	1.54e-35	Height;
KIRP	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg21775007	chr8:11205619	TDH	0.44	5.9	0.35	1.17e-8	Neuroticism;
KIRP	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.54	-0.43	9.14e-13	Migraine;Coronary artery disease;
KIRP	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.38	-0.32	1.74e-7	Coronary artery disease;
KIRP	cis	rs11874712	0.966	rs8094902	chr18:43666774	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.42	-5.94	-0.35	9.42e-9	Migraine - clinic-based;
KIRP	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg17443007	chr1:101659419	NA	-0.41	-5.88	-0.35	1.32e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.73	0.49	3.94e-16	Electroencephalogram traits;
KIRP	cis	rs12765878	0.934	rs11191841	chr10:105639611	C/T	cg11005552	chr10:105648138	OBFC1	-0.43	-6.25	-0.37	1.76e-9	Coronary artery disease;
KIRP	cis	rs4654899	0.802	rs7517642	chr1:21252696	T/C	cg05370193	chr1:21551575	ECE1	0.42	5.44	0.33	1.3e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.68	-8.1	-0.46	2.56e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16405026	chr2:145281942	NA	0.39	6.25	0.37	1.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg11945507	chr8:142233382	SLC45A4	-0.64	-8.38	-0.47	4.11e-15	Immature fraction of reticulocytes;
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.79	9.84	0.53	1.75e-19	Longevity;
KIRP	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg20573242	chr4:122745356	CCNA2	0.4	5.0	0.3	1.08e-6	Type 2 diabetes;
KIRP	trans	rs2997105	0.938	rs7320480	chr13:56359015	C/T	cg08528735	chr3:184428879	MAGEF1	0.57	6.19	0.37	2.54e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-7.04	-0.41	1.95e-11	Daytime sleep phenotypes;
KIRP	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.34	0.55	4.84e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	4.97	0.3	1.26e-6	Diabetic retinopathy;
KIRP	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.52	-6.14	-0.36	3.36e-9	Bone mineral density;
KIRP	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg16141378	chr3:129829833	LOC729375	0.55	7.25	0.42	5.23e-12	Neuroticism;
KIRP	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg11657440	chr19:46296263	DMWD	-0.7	-8.91	-0.49	1.17e-16	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07409897	chr20:13619336	TASP1	0.55	7.2	0.42	7.47e-12	Parkinson's disease;
KIRP	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.31	-0.32	2.4e-7	Headache;
KIRP	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-0.99	-11.59	-0.59	4.61e-25	White matter hyperintensity burden;
KIRP	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs72730918	0.590	rs8027162	chr15:51985147	T/C	cg14296394	chr15:51910925	DMXL2	-0.7	-9.79	-0.53	2.52e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.56	7.27	0.42	4.67e-12	Vitiligo;
KIRP	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg26174226	chr8:58114915	NA	-0.61	-7.15	-0.41	1e-11	Developmental language disorder (linguistic errors);
KIRP	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.62	6.57	0.39	3.01e-10	Eotaxin levels;
KIRP	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.6	-7.66	-0.44	4.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg16346588	chr10:242978	ZMYND11	-0.42	-5.03	-0.31	9.4e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg01320579	chr17:75405842	SEPT9	0.45	7.28	0.42	4.37e-12	Airflow obstruction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17411103	chr17:65241599	HELZ	0.49	6.07	0.36	4.78e-9	Parkinson's disease;
KIRP	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26002218	chr14:103986227	CKB	-0.34	-7.08	-0.41	1.46e-11	Body mass index;
KIRP	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg15605315	chr1:45957053	TESK2	-0.51	-6.45	-0.38	5.88e-10	High light scatter reticulocyte count;
KIRP	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg01777586	chr17:80163174	CCDC57	0.46	4.92	0.3	1.58e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg16586182	chr3:47516702	SCAP	0.82	11.65	0.6	2.96e-25	Colorectal cancer;
KIRP	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg15556689	chr8:8085844	FLJ10661	0.55	7.4	0.43	2.17e-12	Retinal vascular caliber;
KIRP	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg00745463	chr17:30367425	LRRC37B	0.96	6.43	0.38	6.53e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs6596140	0.620	rs7703486	chr5:133029003	T/G	cg08567913	chr11:114082594	ZBTB16	-0.43	-6.08	-0.36	4.55e-9	Hypertension;
KIRP	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg08134877	chr2:44394819	PPM1B	0.49	5.33	0.32	2.27e-7	Height;
KIRP	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg17133734	chr15:86042851	AKAP13	-0.47	-5.93	-0.35	1e-8	Coronary artery disease;
KIRP	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.65	9.23	0.51	1.32e-17	Multiple system atrophy;
KIRP	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.9	-12.04	-0.61	1.45e-26	Cognitive function;
KIRP	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.93	16.12	0.72	2.14e-40	Breast cancer;
KIRP	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17507749	chr15:85114479	UBE2QP1	0.73	8.25	0.47	9.33e-15	Schizophrenia;
KIRP	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.59	-7.97	-0.45	5.9e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs4363385	0.574	rs6671520	chr1:152944156	C/T	cg07796016	chr1:152779584	LCE1C	-0.49	-6.13	-0.36	3.48e-9	Inflammatory skin disease;
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.78	6.69	0.39	1.47e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg24296786	chr1:45957014	TESK2	-0.54	-6.48	-0.38	5.05e-10	Homocysteine levels;
KIRP	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg20573242	chr4:122745356	CCNA2	0.41	5.11	0.31	6.44e-7	Type 2 diabetes;
KIRP	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-7.4	-0.43	2.13e-12	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08894960	chr1:237061516	MTR	0.45	6.1	0.36	4.07e-9	Survival in pancreatic cancer;
KIRP	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg13010199	chr12:38710504	ALG10B	0.53	6.77	0.4	9.46e-11	Morning vs. evening chronotype;
KIRP	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg10503236	chr1:231470652	EXOC8	-0.51	-7.41	-0.43	1.99e-12	Hemoglobin concentration;
KIRP	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg09267113	chr7:98030324	BAIAP2L1	0.42	5.01	0.3	1.06e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg15147215	chr3:52552868	STAB1	-0.28	-4.9	-0.3	1.71e-6	Bipolar disorder;
KIRP	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.4	5.95	0.35	9.12e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7116495	0.609	rs949323	chr11:71714528	T/G	cg26138937	chr11:71823887	C11orf51	-1.11	-7.76	-0.44	2.32e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg13293535	chr8:11597251	GATA4	-0.42	-5.38	-0.32	1.69e-7	Retinal vascular caliber;
KIRP	cis	rs12220238	0.908	rs117056627	chr10:75932657	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	5.94	0.35	9.62e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.85	-11.8	-0.6	9.43e-26	Total body bone mineral density;
KIRP	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.59	10.12	0.54	2.31e-20	Body mass index;
KIRP	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.71	-8.36	-0.47	4.78e-15	Resting heart rate;
KIRP	cis	rs3784262	0.669	rs3742960	chr15:58248088	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-5.35	-0.32	1.99e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg07701084	chr6:150067640	NUP43	-0.73	-9.89	-0.53	1.27e-19	Lung cancer;
KIRP	cis	rs1595825	1.000	rs73058829	chr2:198871145	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-4.98	-0.3	1.18e-6	Ulcerative colitis;
KIRP	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs2241685	0.920	rs59907143	chr2:1934163	T/C	cg22511877	chr2:1942942	MYT1L	-0.64	-5.91	-0.35	1.12e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs6840360	1.000	rs10007167	chr4:152603655	C/T	cg25486957	chr4:152246857	NA	-0.47	-5.49	-0.33	1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	4.92	0.3	1.57e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7169223	0.653	rs3971703	chr15:79092481	G/C	cg21242079	chr15:79101063	ADAMTS7	0.36	4.99	0.3	1.12e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs7236492	0.683	rs59828426	chr18:77204397	T/C	cg15644404	chr18:77186268	NFATC1	-0.67	-6.92	-0.4	3.97e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10267417	0.603	rs7804164	chr7:19905105	G/C	cg05791153	chr7:19748676	TWISTNB	0.51	5.27	0.32	3e-7	Night sleep phenotypes;
KIRP	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27286337	chr10:134555280	INPP5A	0.91	10.95	0.57	5.31e-23	Migraine;
KIRP	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg19899395	chr1:46959349	NA	0.45	5.53	0.33	8.2e-8	Monobrow;
KIRP	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg01879757	chr17:41196368	BRCA1	-0.74	-10.41	-0.55	2.88e-21	Menopause (age at onset);
KIRP	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.39	5.36	0.32	1.93e-7	Lewy body disease;
KIRP	trans	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.73	0.39	1.15e-10	Retinal vascular caliber;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08704884	chr19:59070524	UBE2M;LOC100131691	0.47	6.29	0.37	1.47e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs17253792	0.822	rs78432811	chr14:56051545	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	5.66	0.34	4.22e-8	Putamen volume;
KIRP	cis	rs6450176	1.000	rs67430852	chr5:53290586	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-10.73	-0.56	2.87e-22	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg01831904	chr17:28903510	LRRC37B2	0.76	8.51	0.48	1.72e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs883565	0.569	rs784508	chr3:39166484	C/T	cg01426195	chr3:39028469	NA	0.52	8.34	0.47	5.34e-15	Handedness;
KIRP	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.52	-6.36	-0.38	9.68e-10	Renal function-related traits (BUN);
KIRP	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.39	8.15	0.46	1.88e-14	Body mass index;
KIRP	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg25356066	chr3:128598488	ACAD9	0.58	6.85	0.4	5.8200000000000003e-11	IgG glycosylation;
KIRP	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg15556689	chr8:8085844	FLJ10661	-0.62	-7.81	-0.45	1.61e-13	Systolic blood pressure;
KIRP	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg04733989	chr22:42467013	NAGA	0.85	11.76	0.6	1.25e-25	Schizophrenia;
KIRP	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.68	8.63	0.48	7.61e-16	Resting heart rate;
KIRP	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.57	7.65	0.44	4.51e-13	HDL cholesterol;
KIRP	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	5.65	0.34	4.41e-8	Personality dimensions;
KIRP	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.5	0.38	4.33e-10	Hypertriglyceridemia;
KIRP	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.44	-5.12	-0.31	6.06e-7	Colorectal cancer;
KIRP	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.37	0.51	4.98e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.61	8.68	0.48	5.56e-16	Colorectal cancer;
KIRP	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg15556689	chr8:8085844	FLJ10661	0.61	8.42	0.47	3.05e-15	Retinal vascular caliber;
KIRP	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.4	0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.77	8.81	0.49	2.36e-16	Response to diuretic therapy;
KIRP	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg16497661	chr14:103986332	CKB	0.47	6.34	0.37	1.12e-9	Body mass index;
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg13789711	chr9:139743225	PHPT1	0.48	6.32	0.37	1.23e-9	Plasma plasminogen activator levels;
KIRP	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.29	-0.32	2.75e-7	Mean platelet volume;
KIRP	cis	rs4566357	1.000	rs3769637	chr2:227922623	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.24	-0.32	3.46e-7	Coronary artery disease;
KIRP	trans	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.19	-0.37	2.5e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.58	5.85	0.35	1.57e-8	White matter integrity;
KIRP	cis	rs7975161	0.938	rs4964271	chr12:104652441	T/C	cg25273343	chr12:104657179	TXNRD1	-0.62	-5.55	-0.33	7.23e-8	Toenail selenium levels;
KIRP	cis	rs12580194	0.593	rs61957937	chr12:55746850	G/C	cg11794356	chr12:55725991	OR6C3	-0.53	-7.09	-0.41	1.41e-11	Cancer;
KIRP	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg13180566	chr4:1052158	NA	-0.54	-5.46	-0.33	1.19e-7	Recombination rate (females);
KIRP	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.47	-6.93	-0.4	3.7e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg26875233	chr11:93583750	C11orf90	-0.36	-6.75	-0.4	1.08e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs504918	0.588	rs73188199	chr3:124031871	G/A	cg05766129	chr3:123988013	KALRN	-0.44	-5.57	-0.33	6.58e-8	Schizophrenia;
KIRP	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.56	4.98	0.3	1.21e-6	Bipolar disorder;
KIRP	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-9.29	-0.51	8.71e-18	Triglycerides;
KIRP	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Corneal astigmatism;
KIRP	cis	rs4740619	0.741	rs10756729	chr9:15973712	A/T	cg14451791	chr9:16040625	NA	-0.39	-5.0	-0.3	1.1e-6	Body mass index;
KIRP	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg01721255	chr8:58191610	C8orf71	0.48	5.26	0.32	3.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg04733989	chr22:42467013	NAGA	0.55	7.49	0.43	1.25e-12	Cognitive function;
KIRP	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.98	-0.45	5.51e-14	Neuroticism;
KIRP	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.1e-11	Obesity-related traits;
KIRP	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	13.11	0.64	3.89e-30	Electrocardiographic conduction measures;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg10959786	chr13:74708124	KLF12	0.52	6.17	0.37	2.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1559088	0.948	rs10406916	chr19:33590093	G/A	cg07827796	chr19:33622959	WDR88	0.41	4.94	0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7402982	0.525	rs11247361	chr15:99207392	C/G	cg03437748	chr15:99193247	IGF1R	-0.53	-6.01	-0.36	6.47e-9	Birth weight;
KIRP	cis	rs2411233	0.837	rs11638429	chr15:39260109	C/T	cg19287857	chr15:39890699	NA	0.4	5.54	0.33	7.75e-8	Platelet count;
KIRP	trans	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.17	0.37	2.79e-9	Retinal vascular caliber;
KIRP	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	6.28	0.37	1.49e-9	Axial length;
KIRP	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	4.93e-23	Prudent dietary pattern;
KIRP	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg01879757	chr17:41196368	BRCA1	-0.79	-10.9	-0.57	7.83e-23	Menopause (age at onset);
KIRP	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.3	-0.32	2.63e-7	Colorectal cancer;
KIRP	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-5.6	-0.34	5.58e-8	Menopause (age at onset);
KIRP	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg01304814	chr3:48885189	PRKAR2A	0.6	5.42	0.33	1.42e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.84	10.29	0.55	6.8e-21	Post bronchodilator FEV1;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16818443	chr4:2965195	GRK4;NOP14	0.53	6.9	0.4	4.47e-11	Parkinson's disease;
KIRP	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg07001201	chr5:642380	CEP72	0.68	6.38	0.38	8.52e-10	Obesity-related traits;
KIRP	cis	rs2273156	0.587	rs76767804	chr14:35519367	C/T	cg09327582	chr14:35236912	BAZ1A	-0.47	-4.84	-0.3	2.24e-6	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs7578199	0.924	rs10197237	chr2:242322640	C/T	cg01632474	chr2:242799312	PDCD1	0.38	4.88	0.3	1.93e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.71	-10.48	-0.56	1.7e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-6.2	-0.37	2.37e-9	Bipolar disorder;
KIRP	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06544989	chr22:39130855	UNC84B	0.5	8.27	0.47	8.42e-15	Menopause (age at onset);
KIRP	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg26398791	chr1:38455867	SF3A3	-0.43	-5.45	-0.33	1.25e-7	Coronary artery disease;
KIRP	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05665937	chr4:1216051	CTBP1	0.57	7.72	0.44	2.9e-13	Obesity-related traits;
KIRP	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.44	5.72	0.34	3.01e-8	Motion sickness;
KIRP	cis	rs986417	0.748	rs2179971	chr14:61055466	T/C	cg27398547	chr14:60952738	C14orf39	0.6	5.63	0.34	4.79e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs8022179	0.566	rs959083	chr14:103822687	A/G	cg16497661	chr14:103986332	CKB	0.58	6.15	0.37	3.06e-9	Monocyte count;
KIRP	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg27494647	chr7:150038898	RARRES2	0.47	6.5	0.38	4.4e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.34	-0.42	3.04e-12	Type 2 diabetes;
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg24874828	chr4:187887005	NA	-0.48	-7.07	-0.41	1.56e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1832871	0.711	rs9459877	chr6:158692331	G/A	cg07215822	chr6:158701037	NA	-0.64	-7.51	-0.43	1.1e-12	Height;
KIRP	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg13565492	chr6:43139072	SRF	-0.94	-8.66	-0.48	6.53e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg15888849	chr15:76094525	NA	-0.44	-6.12	-0.36	3.67e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.16	-0.31	5.19e-7	Coronary artery disease;
KIRP	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.18	-0.51	1.78e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg17385448	chr1:15911702	AGMAT	0.26	5.14	0.31	5.67e-7	Systolic blood pressure;
KIRP	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.67	7.37	0.43	2.53e-12	Vitiligo;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08052428	chr9:135996421	RALGDS	0.48	6.58	0.39	2.82e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-1.04	-11.13	-0.58	1.39e-23	Blood protein levels;
KIRP	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.78	-7.98	-0.45	5.64e-14	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.34	0.37	1.09e-9	Mean corpuscular volume;
KIRP	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg01620082	chr3:125678407	NA	-1.09	-6.86	-0.4	5.53e-11	Depression;
KIRP	cis	rs17253792	0.915	rs76957332	chr14:56195370	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.43	0.33	1.34e-7	Putamen volume;
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.07	-8.97	-0.5	7.95e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg02023728	chr11:77925099	USP35	-0.34	-5.09	-0.31	7.12e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2150410	0.915	rs1041439	chr21:40571246	A/G	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.2e-23	Prudent dietary pattern;
KIRP	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg18171855	chr10:2543474	NA	0.55	7.03	0.41	2e-11	Age-related hearing impairment;
KIRP	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.81	9.71	0.53	4.42e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg21535247	chr6:8435926	SLC35B3	-0.49	-6.13	-0.36	3.43e-9	Motion sickness;
KIRP	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.93	14.16	0.67	1.07e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.55	-7.02	-0.41	2.15e-11	Bipolar disorder;
KIRP	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-7.04	-0.41	1.94e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg08126542	chr6:37504118	NA	-0.79	-11.61	-0.59	3.98e-25	Cognitive performance;
KIRP	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg17554472	chr22:41940697	POLR3H	-0.66	-7.38	-0.43	2.46e-12	Vitiligo;
KIRP	cis	rs16973500	0.808	rs1049794	chr16:71950450	C/T	cg00732059	chr16:71740210	PHLPP2	-0.59	-5.61	-0.34	5.5e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	9.15	0.5	2.25e-17	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs34779708	0.931	rs17582416	chr10:35287650	A/C	cg04310649	chr10:35416472	CREM	-0.52	-5.95	-0.35	9.36e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg09455208	chr3:40491958	NA	0.29	4.96	0.3	1.34e-6	Renal cell carcinoma;
KIRP	cis	rs787274	1.000	rs2645994	chr9:115483322	C/T	cg13803584	chr9:115635662	SNX30	0.75	6.78	0.4	8.86e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4236601	0.889	rs59454355	chr7:116156023	C/G	cg05166801	chr7:116143459	CAV2	0.48	5.95	0.35	9.23e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.62	8.45	0.47	2.54e-15	Bladder cancer;
KIRP	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.63	0.48	7.99e-16	Morning vs. evening chronotype;
KIRP	cis	rs1958560	0.897	rs2411356	chr14:66053161	G/A	cg03016385	chr14:66212404	NA	-0.44	-5.48	-0.33	1.04e-7	Menarche (age at onset);
KIRP	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.45	-5.71	-0.34	3.24e-8	Motion sickness;
KIRP	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.72	10.92	0.57	6.76e-23	Orofacial clefts;
KIRP	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.7	10.86	0.57	1.04e-22	Resting heart rate;
KIRP	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.56	-8.3	-0.47	7.11e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.55	-7.66	-0.44	4.38e-13	Motion sickness;
KIRP	cis	rs6978712	0.591	rs60630803	chr7:127077506	G/T	cg24655706	chr7:127078268	NA	0.68	5.36	0.32	1.88e-7	Medication adherence in chronic diseases;
KIRP	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-0.97	-14.02	-0.67	3.28e-33	Blood trace element (Zn levels);
KIRP	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26160460	chr1:198828209	MIR181B1;MIR181A1	-0.41	-6.1	-0.36	4.07e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs743757	0.938	rs6787890	chr3:50520128	T/C	cg07271561	chr3:50359363	HYAL2	-0.42	-5.38	-0.32	1.77e-7	Diastolic blood pressure;
KIRP	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	1.0	10.65	0.56	4.83e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4664293	0.867	rs2059698	chr2:160642416	C/T	cg08347373	chr2:160653686	CD302	0.45	6.55	0.39	3.28e-10	Monocyte percentage of white cells;
KIRP	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs1440410	0.834	rs115904851	chr4:144122227	A/G	cg01719995	chr4:144104893	USP38	0.43	5.48	0.33	1.03e-7	Ischemic stroke;
KIRP	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.25	7.26	0.42	5e-12	Type 2 diabetes;
KIRP	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg19507638	chr5:93509721	C5orf36	-0.59	-5.07	-0.31	7.92e-7	Diabetic retinopathy;
KIRP	cis	rs34779708	0.931	rs3740083	chr10:35320383	C/T	cg03585969	chr10:35415529	CREM	0.77	9.5	0.52	2.02e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg22563815	chr15:78856949	CHRNA5	-0.41	-6.48	-0.38	5.05e-10	Sudden cardiac arrest;
KIRP	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg24058013	chr18:77568902	NA	0.72	10.43	0.55	2.57e-21	Schizophrenia;
KIRP	cis	rs2013441	0.670	rs4924802	chr17:19955895	G/T	cg13482628	chr17:19912719	NA	0.47	5.3	0.32	2.56e-7	Obesity-related traits;
KIRP	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.44	4.96	0.3	1.29e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.66	7.57	0.43	7.58e-13	Corneal astigmatism;
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.79	14.33	0.67	2.94e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg01721255	chr8:58191610	C8orf71	0.6	5.48	0.33	1.06e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg10017260	chr10:834428	NA	-0.49	-5.09	-0.31	7.04e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.39	-5.72	-0.34	3e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.63	7.59	0.44	6.61e-13	Resting heart rate;
KIRP	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs3736485	0.609	rs11631725	chr15:51969474	A/G	cg14296394	chr15:51910925	DMXL2	-0.34	-4.98	-0.3	1.19e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.94	8.93	0.49	9.85e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg06212747	chr3:49208901	KLHDC8B	0.63	8.86	0.49	1.6e-16	Resting heart rate;
KIRP	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.4	4.85	0.3	2.16e-6	Renal cell carcinoma;
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.53	-6.81	-0.4	7.28e-11	Testicular germ cell tumor;
KIRP	cis	rs11779988	0.545	rs208753	chr8:17814915	A/G	cg01800426	chr8:17659068	MTUS1	-0.59	-6.01	-0.36	6.55e-9	Breast cancer;
KIRP	cis	rs7215564	0.908	rs34710385	chr17:78676494	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.14	0.31	5.6e-7	Myopia (pathological);
KIRP	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.85	0.35	1.58e-8	Total cholesterol levels;
KIRP	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.94	10.33	0.55	5.02e-21	Corneal astigmatism;
KIRP	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.84	7.28	0.42	4.41e-12	Fat distribution (HIV);
KIRP	cis	rs838147	0.505	rs1688264	chr19:49209560	T/G	cg16867584	chr19:49200180	FUT2	0.33	5.42	0.33	1.39e-7	Dietary macronutrient intake;
KIRP	cis	rs798554	0.591	rs1636248	chr7:2882030	T/C	cg19717773	chr7:2847554	GNA12	-0.35	-6.04	-0.36	5.6e-9	Height;
KIRP	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.41	-5.19	-0.31	4.3e-7	Platelet count;
KIRP	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	5.46	0.33	1.16e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs5753037	0.834	rs713656	chr22:30212194	C/G	cg27665648	chr22:30112403	NA	0.46	6.38	0.38	8.48e-10	Type 1 diabetes;
KIRP	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.47	5.95	0.35	9.33e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg01849789	chr22:41697279	ZC3H7B	-0.51	-5.8	-0.35	1.98e-8	Neuroticism;
KIRP	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.56	-8.62	-0.48	8.07e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs239198	0.568	rs9404059	chr6:101331497	T/C	cg09795085	chr6:101329169	ASCC3	0.47	5.45	0.33	1.21e-7	Menarche (age at onset);
KIRP	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.91	13.22	0.64	1.61e-30	Tonsillectomy;
KIRP	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.69	8.89	0.49	1.31e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.43	5.13	0.31	5.92e-7	Neuroticism;
KIRP	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg07271561	chr3:50359363	HYAL2	-0.37	-4.94	-0.3	1.42e-6	Schizophrenia;
KIRP	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg23594656	chr7:65796392	TPST1	-0.43	-6.11	-0.36	3.79e-9	Aortic root size;
KIRP	cis	rs7809615	0.901	rs10226310	chr7:99118320	G/A	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite ratios;
KIRP	cis	rs1413885	0.549	rs7545720	chr1:65856443	G/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.73	0.34	2.98e-8	Anticoagulant levels;
KIRP	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg20607798	chr8:58055168	NA	0.54	4.85	0.3	2.15e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.51	7.01	0.41	2.34e-11	Gout;
KIRP	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg02503808	chr4:7069936	GRPEL1	1.02	13.93	0.66	6.48e-33	Monocyte percentage of white cells;
KIRP	cis	rs71277158	0.688	rs16854812	chr3:169774383	T/C	cg04067573	chr3:169899625	PHC3	0.57	5.25	0.32	3.31e-7	Prostate cancer;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.61	-8.38	-0.47	4.11e-15	Longevity;Endometriosis;
KIRP	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.79	-11.15	-0.58	1.27e-23	Bipolar disorder;
KIRP	cis	rs7010267	0.692	rs2073618	chr8:119964052	G/C	cg13268132	chr8:119964037	TNFRSF11B	0.41	4.95	0.3	1.37e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs7078012	0.504	rs117047841	chr10:81665656	G/A	cg24613050	chr10:81743128	NA	-0.56	-5.38	-0.32	1.74e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg12435725	chr3:58293450	RPP14	-0.55	-5.67	-0.34	3.92e-8	Cholesterol, total;
KIRP	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.51	-6.05	-0.36	5.44e-9	Menopause (age at onset);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11970301	chr16:30087888	PPP4C	0.71	6.06	0.36	5.16e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.66	7.54	0.43	8.93e-13	Corneal astigmatism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20255451	chr4:183110156	NA	-0.38	-6.21	-0.37	2.26e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.21	0.31	4.09e-7	Educational attainment (years of education);
KIRP	cis	rs2548003	0.541	rs1895416	chr5:28754530	A/T	cg22863700	chr5:28928346	NA	0.59	6.09	0.36	4.2e-9	Hip geometry;
KIRP	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.06	0.54	3.54e-20	Total body bone mineral density;
KIRP	cis	rs1978968	0.912	rs34156568	chr22:18444261	C/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg13512537	chr8:22265999	SLC39A14	-0.42	-5.81	-0.35	1.93e-8	Verbal declarative memory;
KIRP	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.6	8.0	0.45	4.91e-14	White matter hyperintensity burden;
KIRP	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.37	6.35	0.38	1.01e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg12486944	chr17:80159399	CCDC57	0.39	5.17	0.31	4.75e-7	Life satisfaction;
KIRP	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.93	-12.34	-0.62	1.45e-27	Vitamin D levels;
KIRP	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.93	14.18	0.67	8.93e-34	Mean platelet volume;
KIRP	cis	rs4936894	0.500	rs11219533	chr11:124119298	T/A	cg27160556	chr11:124181099	OR8D1	-0.38	-5.78	-0.35	2.3e-8	Aging (time to death);
KIRP	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.64	-9.66	-0.52	6.39e-19	Fibrinogen levels;
KIRP	cis	rs6500395	0.708	rs9930644	chr16:48555929	G/C	cg04672837	chr16:48644449	N4BP1	0.41	5.48	0.33	1.04e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-6.04	-0.36	5.67e-9	Asthma;
KIRP	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.28	-0.47	7.83e-15	Triglycerides;
KIRP	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.61	-8.73	-0.49	3.99e-16	Bipolar disorder;
KIRP	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg18944383	chr4:111397179	ENPEP	0.55	9.77	0.53	2.84e-19	Height;
KIRP	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.17	-0.42	8.83e-12	Height;
KIRP	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs155346	0.625	rs265170	chr5:139356545	T/C	cg24724630	chr5:139362307	NRG2	-0.38	-4.99	-0.3	1.15e-6	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.21	0.37	2.21e-9	Ovarian reserve;
KIRP	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7615316	0.902	rs6775718	chr3:142203235	G/T	cg20824294	chr3:142316082	PLS1	0.22	4.86	0.3	2.06e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.94	9.31	0.51	7.37e-18	Lymphocyte counts;
KIRP	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.68	-0.53	5.51e-19	Coronary artery disease;
KIRP	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15557168	chr22:42548783	NA	-0.47	-6.06	-0.36	5.05e-9	Cognitive function;
KIRP	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.58	6.42	0.38	7.16e-10	Alcohol dependence;
KIRP	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.41	-5.05	-0.31	8.48e-7	Neurofibrillary tangles;
KIRP	cis	rs12725198	1.000	rs12725833	chr1:16080618	G/A	cg18133145	chr1:16060689	PLEKHM2	-0.58	-6.28	-0.37	1.54e-9	Cardiac Troponin-T levels;
KIRP	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg08662619	chr6:150070041	PCMT1	0.3	4.86	0.3	2.13e-6	Testicular germ cell tumor;
KIRP	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.69	7.05	0.41	1.85e-11	Menarche (age at onset);
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg09597638	chr17:3907349	NA	0.75	14.28	0.67	4.36e-34	Type 2 diabetes;
KIRP	cis	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg02795151	chr17:7402630	POLR2A	0.75	7.46	0.43	1.47e-12	Androgen levels;
KIRP	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg26681399	chr22:41777847	TEF	-0.43	-5.08	-0.31	7.46e-7	Vitiligo;
KIRP	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.45	-5.58	-0.34	6.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6707387	0.662	rs12997815	chr2:214358653	T/C	cg08319019	chr2:214017104	IKZF2	0.47	5.43	0.33	1.37e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg12405258	chr13:114927641	NA	0.48	6.91	0.4	4.11e-11	Schizophrenia;
KIRP	cis	rs507080	0.769	rs645637	chr11:118505090	G/A	cg04173919	chr11:118528438	PHLDB1	0.35	4.99	0.3	1.14e-6	Serum metabolite levels;
KIRP	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg13819577	chr1:248512075	OR14C36	-0.35	-5.03	-0.31	9.61e-7	Common traits (Other);
KIRP	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.38	-5.46	-0.33	1.17e-7	Motion sickness;
KIRP	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.74	-9.89	-0.53	1.22e-19	Age at first birth;
KIRP	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.88	0.53	1.29e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg02775129	chr4:119771670	NA	-0.87	-4.91	-0.3	1.62e-6	Cannabis dependence symptom count;
KIRP	cis	rs3857067	0.806	rs2171379	chr4:95100243	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.12	-0.36	3.68e-9	QT interval;
KIRP	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.64	7.87	0.45	1.14e-13	Crohn's disease;
KIRP	cis	rs6756513	0.520	rs7569566	chr2:70174030	T/C	cg05298696	chr2:70188691	ASPRV1	-0.36	-4.87	-0.3	2e-6	Breast cancer;Platelet count;
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-5.94	-0.35	9.77e-9	Lung cancer;
KIRP	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-5.95	-0.35	9.27e-9	Blood metabolite levels;
KIRP	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-7.73	-0.44	2.74e-13	Obesity-related traits;
KIRP	cis	rs10073892	0.957	rs10479225	chr5:101862866	T/C	cg19774478	chr5:101632501	SLCO4C1	0.62	6.44	0.38	6.33e-10	Cognitive decline (age-related);
KIRP	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.35	-0.38	1.04e-9	Bipolar disorder;
KIRP	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg15128208	chr22:42549153	NA	0.37	4.89	0.3	1.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs35883536	1.000	rs2491822	chr1:101115839	T/C	cg06223162	chr1:101003688	GPR88	-0.33	-6.64	-0.39	1.96e-10	Monocyte count;
KIRP	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs4787491	0.729	rs3814878	chr16:30041966	A/G	cg06326092	chr16:30034487	C16orf92	0.49	7.08	0.41	1.47e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3736485	0.903	rs9944241	chr15:51898058	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.23	-0.32	3.61e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4776059	1.000	rs34431049	chr15:52940538	G/C	cg25063058	chr15:52860530	ARPP19	0.51	5.67	0.34	4.03e-8	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg07382826	chr16:28625726	SULT1A1	0.5	5.86	0.35	1.52e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg23920097	chr1:209922102	NA	-0.47	-5.62	-0.34	5.07e-8	Red blood cell count;
KIRP	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.45	-0.33	1.24e-7	Educational attainment;
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg11814155	chr7:99998594	ZCWPW1	0.54	5.26	0.32	3.13e-7	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19486023	chr11:64085683	PRDX5;TRMT112	0.52	6.5	0.38	4.56e-10	Parkinson's disease;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg19536664	chr17:6899085	ALOX12	0.48	7.52	0.43	1.01e-12	Tonsillectomy;
KIRP	cis	rs2235642	0.582	rs2072990	chr16:1567651	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.2	-4.92	-0.3	1.56e-6	Coronary artery disease;
KIRP	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg26818010	chr10:134567672	INPP5A	-0.64	-7.11	-0.41	1.27e-11	Migraine;
KIRP	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	4.98e-9	Parkinson's disease;
KIRP	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.2	-0.37	2.33e-9	Lung cancer;
KIRP	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	6.29	0.37	1.44e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.2	21.72	0.81	3.85e-59	Cognitive function;
KIRP	cis	rs9826463	0.582	rs73238140	chr3:142046665	T/G	cg20824294	chr3:142316082	PLS1	0.39	5.73	0.34	2.99e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.62	7.32	0.42	3.43e-12	Obesity-related traits;
KIRP	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.74	-0.39	1.15e-10	Morning vs. evening chronotype;
KIRP	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	1.01	13.39	0.65	4.59e-31	Blood protein levels;
KIRP	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.37	-0.38	9.16e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.6	8.17	0.46	1.65e-14	Mood instability;
KIRP	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	7.71	0.44	3.12e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.37	-0.32	1.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14159672	chr1:205819179	PM20D1	-0.56	-5.59	-0.34	6.11e-8	Menarche (age at onset);
KIRP	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.74	-8.58	-0.48	1.11e-15	Monocyte count;
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs3789045	0.560	rs2271424	chr1:204403311	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.87	-8.04	-0.46	3.88e-14	Educational attainment (college completion);
KIRP	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs876084	0.505	rs66488706	chr8:121132894	C/T	cg06265175	chr8:121136014	COL14A1	0.49	6.13	0.36	3.42e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.59	-7.52	-0.43	1.03e-12	Sudden cardiac arrest;
KIRP	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-7.32	-0.42	3.6e-12	Fear of minor pain;
KIRP	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg06637938	chr14:75390232	RPS6KL1	0.51	7.31	0.42	3.63e-12	Height;
KIRP	cis	rs2692947	0.759	rs11687113	chr2:96658588	A/G	cg23100626	chr2:96804247	ASTL	0.47	6.61	0.39	2.36e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs1941687	0.800	rs12968906	chr18:31378307	G/A	cg27147174	chr7:100797783	AP1S1	-0.58	-7.22	-0.42	6.39e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.43	0.33	1.36e-7	Cognitive test performance;
KIRP	cis	rs876084	0.604	rs2271900	chr8:121013770	A/G	cg22335954	chr8:121166405	COL14A1	-0.39	-4.95	-0.3	1.37e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24110177	chr3:50126178	RBM5	-0.43	-5.72	-0.34	3.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.69	-8.45	-0.47	2.58e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg00495681	chr13:53174319	NA	0.37	5.03	0.31	9.63e-7	Lewy body disease;
KIRP	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.42	5.31	0.32	2.45e-7	Brain structure;
KIRP	cis	rs1620921	0.840	rs783177	chr6:161169815	C/T	cg01280913	chr6:161186852	NA	-0.41	-5.73	-0.34	2.95e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1873147	1.000	rs4774470	chr15:63312119	G/A	cg12160578	chr15:63334699	TPM1	-0.47	-5.77	-0.35	2.39e-8	Orofacial clefts;
KIRP	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.98	10.56	0.56	9.78e-22	Cognitive test performance;
KIRP	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	8.85	0.49	1.73e-16	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs7792596	1.000	rs7792596	chr7:94009634	T/C	cg20814616	chr7:94014465	NA	-0.32	-5.35	-0.32	1.99e-7	Intelligence;
KIRP	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.58	6.91	0.4	4.23e-11	Response to antipsychotic treatment;
KIRP	cis	rs970548	0.779	rs11239532	chr10:45964505	C/T	cg15590007	chr10:45870220	ALOX5	0.57	5.82	0.35	1.85e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg16989719	chr2:238392110	NA	-0.54	-7.58	-0.44	7.12e-13	Prostate cancer;
KIRP	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.47	6.47	0.38	5.32e-10	Personality dimensions;
KIRP	cis	rs427941	0.632	rs201498	chr7:101756262	G/A	cg06246474	chr7:101738831	CUX1	0.52	6.34	0.37	1.09e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03398387	chr6:160114178	SOD2	0.62	7.24	0.42	5.61e-12	Smoking initiation;
KIRP	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg25486957	chr4:152246857	NA	-0.45	-5.37	-0.32	1.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26306683	chr17:18585705	ZNF286B	0.61	7.59	0.44	6.79e-13	Educational attainment (years of education);
KIRP	cis	rs34779708	0.931	rs35848945	chr10:35287561	G/T	cg03585969	chr10:35415529	CREM	0.81	9.85	0.53	1.64e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-10.84	-0.57	1.24e-22	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19346786	chr7:2764209	NA	-0.35	-6.07	-0.36	4.86e-9	Height;
KIRP	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.59	6.15	0.37	3.11e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	13.85	0.66	1.22e-32	Platelet count;
KIRP	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg21395723	chr22:39101663	GTPBP1	0.41	5.4	0.33	1.57e-7	Menopause (age at onset);
KIRP	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.81	-0.35	1.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.67	7.62	0.44	5.54e-13	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.74	-0.34	2.71e-8	Triglycerides;
KIRP	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	cg04338863	chr8:33670619	NA	0.49	6.51	0.38	4.26e-10	Body mass index;
KIRP	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg23307798	chr14:103986281	CKB	0.44	6.2	0.37	2.39e-9	Body mass index;
KIRP	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-7.05	-0.41	1.78e-11	Daytime sleep phenotypes;
KIRP	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg10189774	chr4:17578691	LAP3	-0.48	-5.7	-0.34	3.5e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg02336718	chr17:17403227	NA	0.32	5.12	0.31	6.21e-7	Total body bone mineral density;
KIRP	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.16	-0.31	5.07e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg10326726	chr10:51549505	MSMB	-0.56	-8.48	-0.48	2.12e-15	Prostate-specific antigen levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12578287	chr13:42846195	AKAP11	0.46	6.64	0.39	1.95e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs220324	0.657	rs2839474	chr21:43570482	T/C	cg15319517	chr21:43638949	ABCG1	-0.4	-5.04	-0.31	9.05e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.17	0.54	1.7e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4713675	0.584	rs4713661	chr6:33674174	C/A	cg15676125	chr6:33679581	C6orf125	0.42	5.48	0.33	1.07e-7	Plateletcrit;
KIRP	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.89	-10.64	-0.56	5.26e-22	Response to antipsychotic treatment;
KIRP	cis	rs4654899	0.931	rs58762579	chr1:21257831	G/A	cg05370193	chr1:21551575	ECE1	0.41	5.53	0.33	8.12e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.57	-0.43	7.43e-13	Height;
KIRP	cis	rs28595532	0.702	rs72670238	chr4:119322751	C/T	cg21605333	chr4:119757512	SEC24D	0.91	7.62	0.44	5.34e-13	Cannabis dependence symptom count;
KIRP	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg26207909	chr14:103986467	CKB	0.65	6.93	0.4	3.71e-11	Body mass index;
KIRP	cis	rs2290159	0.706	rs7643321	chr3:12663233	A/G	cg23032965	chr3:12705835	RAF1	0.73	7.34	0.42	3.17e-12	Cholesterol, total;
KIRP	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.59	-0.39	2.58e-10	Urinary tract infection frequency;
KIRP	cis	rs597583	1.000	rs521609	chr11:117407301	C/T	cg27161313	chr11:117392002	DSCAML1	-0.54	-6.1	-0.36	4.18e-9	Putamen volume;
KIRP	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	5.32	0.32	2.37e-7	Osteoporosis;
KIRP	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg12179176	chr11:130786555	SNX19	-0.51	-5.83	-0.35	1.74e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs73086581	1.000	rs73086508	chr20:3921715	C/T	cg02187196	chr20:3869020	PANK2	0.5	4.9	0.3	1.7e-6	Response to antidepressants in depression;
KIRP	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	0.96	18.22	0.76	1.57e-47	Dental caries;
KIRP	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.56	-6.98	-0.41	2.73e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.18	0.51	1.78e-17	Bladder cancer;
KIRP	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.6	8.65	0.48	6.73e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.63	0.44	5.07e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.76	8.79	0.49	2.59e-16	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03286899	chr6:36561965	SFRS3	0.49	6.34	0.37	1.1e-9	Parkinson's disease;
KIRP	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg06212747	chr3:49208901	KLHDC8B	0.57	6.37	0.38	9.43e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs75920871	0.800	rs75904569	chr11:116988313	A/G	cg23684410	chr11:116897558	SIK3	0.55	4.97	0.3	1.24e-6	Subjective well-being;
KIRP	cis	rs2072732	0.861	rs67025412	chr1:2951806	T/C	cg11731671	chr1:2995604	PRDM16	-0.46	-5.85	-0.35	1.59e-8	Plateletcrit;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.58	-7.91	-0.45	8.63e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	cis	rs7584330	0.554	rs729388	chr2:238425004	G/C	cg14458575	chr2:238380390	NA	0.51	6.12	0.36	3.57e-9	Prostate cancer;
KIRP	cis	rs1832871	0.672	rs11751553	chr6:158774750	C/T	cg07215822	chr6:158701037	NA	0.61	7.06	0.41	1.65e-11	Height;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.57	-8.87	-0.49	1.53e-16	Lymphocyte counts;
KIRP	cis	rs73200209	0.744	rs17498480	chr12:116558916	A/T	cg01776926	chr12:116560359	MED13L	-0.52	-5.97	-0.36	8.4e-9	Total body bone mineral density;
KIRP	cis	rs7107770	1.000	rs35183670	chr11:125090912	G/A	cg04164023	chr11:125106101	PKNOX2	-0.55	-4.85	-0.3	2.18e-6	Photic sneeze reflex;
KIRP	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.65	-10.09	-0.54	3e-20	Menopause (age at onset);
KIRP	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.69	-7.32	-0.42	3.52e-12	Initial pursuit acceleration;
KIRP	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	0.69	6.19	0.37	2.55e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-6.71	-0.39	1.3e-10	Educational attainment;
KIRP	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Body mass index;
KIRP	cis	rs7940866	0.838	rs7949071	chr11:130877478	T/C	cg12179176	chr11:130786555	SNX19	0.59	6.81	0.4	7.56e-11	Schizophrenia;
KIRP	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.16	-0.37	2.9e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg17554472	chr22:41940697	POLR3H	-0.43	-5.06	-0.31	8.37e-7	Neuroticism;
KIRP	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.89	14.71	0.68	1.49e-35	Prostate cancer;
KIRP	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg25036284	chr2:26402008	FAM59B	-0.47	-4.98	-0.3	1.18e-6	Gut microbiome composition (summer);
KIRP	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.42	4.92	0.3	1.57e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	8.41	0.47	3.44e-15	Neuroticism;
KIRP	cis	rs897080	0.515	rs1067366	chr2:44655094	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	5.67	0.34	4.05e-8	Height;
KIRP	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs1320333	0.685	rs6710875	chr2:699976	A/G	cg27237671	chr2:676223	TMEM18	0.42	5.34	0.32	2.08e-7	Obesity-related traits;
KIRP	cis	rs1858037	0.867	rs4671658	chr2:65561392	A/G	cg08085232	chr2:65598271	SPRED2	0.53	6.43	0.38	6.53e-10	Rheumatoid arthritis;
KIRP	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg10434728	chr15:90938212	IQGAP1	0.38	6.58	0.39	2.83e-10	Rheumatoid arthritis;
KIRP	cis	rs9394841	0.692	rs34073739	chr6:41829970	A/G	cg08135965	chr6:41755394	TOMM6	0.52	5.51	0.33	9.22e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs2278729	0.514	rs10934	chr2:101622728	C/T	cg15506514	chr2:101638852	TBC1D8	0.44	4.9	0.3	1.75e-6	Osteoporosis-related phenotypes;
KIRP	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.35	-5.01	-0.3	1.02e-6	Motion sickness;
KIRP	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.68	0.44	3.81e-13	Corneal astigmatism;
KIRP	cis	rs7113874	0.559	rs34378489	chr11:8429350	G/A	cg08015107	chr11:8618950	NA	-0.66	-7.95	-0.45	6.61e-14	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg10826053	chr4:108641834	PAPSS1	0.54	6.61	0.39	2.32e-10	Beard thickness;
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.92	0.35	1.09e-8	Life satisfaction;
KIRP	cis	rs17065868	1.000	rs9533894	chr13:45102865	T/C	cg10246903	chr13:45222710	NA	0.74	6.77	0.4	9.6e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg00129232	chr17:37814104	STARD3	0.7	8.32	0.47	6.1e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs2147904	0.934	rs783629	chr1:42363275	C/T	cg16685388	chr1:42384056	HIVEP3	0.28	4.88	0.3	1.93e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs6894268	1.000	rs6894268	chr5:179032488	A/G	cg22014891	chr5:179071901	C5orf60	-0.33	-4.97	-0.3	1.26e-6	Eating disorders;
KIRP	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-1.0	-10.86	-0.57	1.07e-22	Lung cancer in ever smokers;
KIRP	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.48	-5.04	-0.31	9.2e-7	Fear of minor pain;
KIRP	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg24315340	chr6:146058215	EPM2A	-0.46	-5.65	-0.34	4.52e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.07	-0.46	3.11e-14	Neuroticism;
KIRP	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	12.4	0.62	9.37e-28	Multiple sclerosis;
KIRP	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg19000871	chr14:103996768	TRMT61A	-0.38	-4.94	-0.3	1.45e-6	Coronary artery disease;
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg21064579	chr19:49206444	FUT2	0.59	8.83	0.49	1.95e-16	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs239198	0.568	rs34555037	chr6:101327153	G/C	cg09795085	chr6:101329169	ASCC3	0.49	5.62	0.34	5.16e-8	Menarche (age at onset);
KIRP	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg05064044	chr6:292385	DUSP22	-0.56	-6.67	-0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.85	-11.94	-0.61	3.22e-26	Total body bone mineral density;
KIRP	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.61	8.42	0.47	3.05e-15	Menarche (age at onset);
KIRP	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.96	-0.45	6.32e-14	Height;
KIRP	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-1.01	-16.89	-0.73	4.99e-43	Height;
KIRP	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.51	6.5	0.38	4.45e-10	Height;
KIRP	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-1.17	-13.05	-0.64	6.01e-30	Pulmonary function decline;
KIRP	trans	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg12575136	chr18:32820987	ZNF397	0.74	11.12	0.58	1.55e-23	White blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18057185	chr3:48342999	NME6	0.45	6.1	0.36	4.03e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.21	-0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg12559939	chr2:27858050	GPN1	0.42	5.35	0.32	2.02e-7	Oral cavity cancer;
KIRP	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.49	0.38	4.71e-10	Bipolar disorder;
KIRP	cis	rs2150410	0.831	rs8131150	chr21:40677315	C/G	cg11890956	chr21:40555474	PSMG1	-0.75	-5.3	-0.32	2.51e-7	Temperament (bipolar disorder);
KIRP	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs1050631	0.924	rs1785918	chr18:33693198	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.49	6.11	0.36	3.88e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2224391	0.628	rs2753224	chr6:5244864	G/T	cg13962347	chr6:5174647	LYRM4	-0.74	-10.18	-0.54	1.59e-20	Height;
KIRP	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.8	-0.45	1.77e-13	Neuroticism;
KIRP	cis	rs6466055	0.612	rs60358227	chr7:104858640	A/G	cg04380332	chr7:105027541	SRPK2	0.38	5.3	0.32	2.53e-7	Schizophrenia;
KIRP	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.69	9.08	0.5	3.72e-17	Bladder cancer;
KIRP	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg24972876	chr7:65420302	NA	-0.36	-4.99	-0.3	1.13e-6	Corneal structure;
KIRP	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.35	0.42	2.98e-12	Vitiligo;
KIRP	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.94	-12.96	-0.64	1.22e-29	Cognitive function;
KIRP	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.9	0.49	1.29e-16	Morning vs. evening chronotype;
KIRP	cis	rs7646881	0.812	rs7635704	chr3:158459720	T/C	cg19483011	chr3:158453295	NA	-0.49	-5.47	-0.33	1.1e-7	Tetralogy of Fallot;
KIRP	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.26	0.32	3.14e-7	Smoking behavior;
KIRP	cis	rs7011507	1.000	rs77547586	chr8:49136987	G/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.43	-6.08	-0.36	4.52e-9	Monocyte count;
KIRP	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs231513	0.822	rs231520	chr17:41956983	T/C	cg26893861	chr17:41843967	DUSP3	-0.48	-4.92	-0.3	1.56e-6	Cognitive function;
KIRP	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg21014159	chr11:117668035	DSCAML1	0.42	6.59	0.39	2.66e-10	Myopia;
KIRP	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7116495	0.737	rs661290	chr11:71766014	A/G	cg18441811	chr11:71824068	C11orf51	-0.72	-4.91	-0.3	1.69e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs73200209	0.744	rs11612907	chr12:116495255	A/G	cg01776926	chr12:116560359	MED13L	-0.55	-6.07	-0.36	4.75e-9	Total body bone mineral density;
KIRP	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.57	8.52	0.48	1.61e-15	Fat distribution (HIV);
KIRP	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.41	0.51	3.62e-18	Morning vs. evening chronotype;
KIRP	cis	rs9400467	0.528	rs462432	chr6:111659755	G/A	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2380205	0.689	rs11255602	chr10:5903717	T/A	cg27141509	chr10:5886111	NA	-0.4	-5.58	-0.34	6.4e-8	Breast cancer;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.67	7.41	0.43	2.02e-12	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.85	0.3	2.2e-6	Menopause (age at onset);
KIRP	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg06197360	chr20:60970103	CABLES2	-0.53	-6.35	-0.38	1.06e-9	Colorectal cancer;
KIRP	cis	rs554111	0.593	rs4654906	chr1:21509642	A/T	cg08890418	chr1:21044141	KIF17	0.43	6.48	0.38	4.89e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1978968	1.000	rs1079576	chr22:18446318	C/A	cg02610425	chr22:18483192	MICAL3	0.36	5.07	0.31	7.72e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2599510	0.811	rs2710628	chr2:32758353	A/C	cg02381751	chr2:32503542	YIPF4	0.43	4.87	0.3	1.96e-6	Interleukin-18 levels;
KIRP	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06850241	chr22:41845214	NA	-0.46	-5.61	-0.34	5.37e-8	Vitiligo;
KIRP	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg17252645	chr8:143867129	LY6D	-0.31	-5.01	-0.3	1.05e-6	Urinary tract infection frequency;
KIRP	cis	rs6540559	1.000	rs2235372	chr1:209960436	A/G	cg22029157	chr1:209979665	IRF6	-0.51	-6.16	-0.37	2.99e-9	Cleft lip with or without cleft palate;
KIRP	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.68	0.44	3.88e-13	Aortic root size;
KIRP	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.55	7.46	0.43	1.51e-12	Mean corpuscular volume;
KIRP	cis	rs11574514	1.000	rs8058835	chr16:67814865	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.99	-0.36	7.54e-9	Crohn's disease;
KIRP	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg24009623	chr19:33667908	NA	0.48	6.1	0.36	3.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4236601	0.745	rs11983864	chr7:116142460	A/C	cg05166801	chr7:116143459	CAV2	0.49	5.95	0.35	9.24e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs1014246	0.848	rs10787716	chr10:118459575	C/A	cg14919929	chr10:118506882	NA	0.7	9.26	0.51	1.02e-17	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.65	-0.34	4.41e-8	HDL cholesterol;
KIRP	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.61	6.7	0.39	1.4e-10	Vitiligo;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg11239120	chr2:7560931	NA	0.49	6.44	0.38	6.22e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.21	-0.32	4.07e-7	Metabolite levels;
KIRP	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg10505658	chr17:80084571	CCDC57	0.27	4.94	0.3	1.43e-6	Life satisfaction;
KIRP	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs28830936	1.000	rs28444909	chr15:41953105	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.26	-5.13	-0.31	5.91e-7	Diastolic blood pressure;
KIRP	cis	rs7215564	0.908	rs74000899	chr17:78653542	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	10.15	0.54	1.87e-20	Monocyte percentage of white cells;
KIRP	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.41	-6.36	-0.38	9.71e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg01689657	chr7:91764605	CYP51A1	0.44	6.43	0.38	6.67e-10	Breast cancer;
KIRP	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.73	8.79	0.49	2.65e-16	Alcohol dependence;
KIRP	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg06740227	chr12:86229804	RASSF9	0.45	5.73	0.34	2.85e-8	Major depressive disorder;
KIRP	cis	rs28595532	0.545	rs17516526	chr4:119259199	C/G	cg21605333	chr4:119757512	SEC24D	0.69	5.84	0.35	1.67e-8	Cannabis dependence symptom count;
KIRP	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06850241	chr22:41845214	NA	0.43	4.96	0.3	1.33e-6	Vitiligo;
KIRP	cis	rs10982213	0.830	rs7861409	chr9:117181190	A/G	cg00969271	chr9:117093052	ORM2	0.4	4.85	0.3	2.16e-6	Interleukin-6 levels;
KIRP	cis	rs3204270	1.000	rs3204270	chr17:79682051	C/T	cg18367735	chr17:79674897	NA	0.68	5.43	0.33	1.37e-7	Dental caries;
KIRP	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.21	-0.46	1.25e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15087147	chr7:127672169	SND1;LRRC4	0.46	6.18	0.37	2.6e-9	Smoking initiation;
KIRP	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.66	8.39	0.47	3.86e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12143943	0.966	rs4951410	chr1:204563817	G/A	cg20240347	chr1:204465584	NA	-0.35	-6.45	-0.38	5.9e-10	Cognitive performance;
KIRP	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19717773	chr7:2847554	GNA12	-0.33	-5.34	-0.32	2.1e-7	Height;
KIRP	trans	rs909341	0.710	rs6010998	chr20:62294402	A/T	cg01311341	chr22:25575246	KIAA1671	0.65	7.52	0.43	1.02e-12	Atopic dermatitis;
KIRP	cis	rs17102423	0.859	rs34184001	chr14:65596027	T/C	cg11161011	chr14:65562177	MAX	-0.61	-7.49	-0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.49	7.35	0.42	2.94e-12	Resting heart rate;
KIRP	cis	rs2219968	1.000	rs6473084	chr8:78972524	T/C	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.09	0.72	2.71e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg22951263	chr5:87985283	NA	-0.48	-6.79	-0.4	8.41e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg17470723	chr8:74884337	TCEB1	0.64	8.3	0.47	7.16e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.51	5.22	0.32	3.72e-7	Alzheimer's disease;
KIRP	cis	rs4704187	1.000	rs4704187	chr5:74480288	T/C	cg03227963	chr5:74354835	NA	0.35	4.91	0.3	1.68e-6	Response to amphetamines;
KIRP	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.37	-7.55	-0.43	8.68e-13	Arsenic metabolism;
KIRP	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg04691961	chr3:161091175	C3orf57	-0.45	-6.88	-0.4	4.91e-11	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg16586182	chr3:47516702	SCAP	0.83	11.91	0.6	4.09e-26	Colorectal cancer;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg25756398	chr11:93474621	C11orf54;TAF1D	0.59	6.34	0.37	1.09e-9	Response to statin therapy;
KIRP	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.38	4.46e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg24498760	chr8:49746867	NA	0.41	4.93	0.3	1.5e-6	Blood metabolite ratios;
KIRP	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.86	9.55	0.52	1.39e-18	High light scatter reticulocyte count;
KIRP	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.22	14.11	0.67	1.61e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.43	-5.88	-0.35	1.35e-8	Migraine;
KIRP	cis	rs11673344	0.864	rs8106386	chr19:37503899	C/T	cg14683738	chr19:37701593	ZNF585B	0.43	5.01	0.3	1.04e-6	Obesity-related traits;
KIRP	cis	rs1440410	0.560	rs300941	chr4:144173540	T/C	cg01719995	chr4:144104893	USP38	0.4	5.15	0.31	5.29e-7	Ischemic stroke;
KIRP	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.66	6.9	0.4	4.45e-11	Bipolar disorder (body mass index interaction);
KIRP	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg04025307	chr7:1156635	C7orf50	0.57	6.19	0.37	2.46e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs7551222	0.681	rs2926533	chr1:204480742	T/A	cg20240347	chr1:204465584	NA	0.37	6.23	0.37	2e-9	Schizophrenia;
KIRP	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg02655711	chr22:19163373	SLC25A1	0.46	6.37	0.38	9.2e-10	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs12949688	0.682	rs1476730	chr17:55838676	G/T	cg12582317	chr17:55822272	NA	-0.43	-6.11	-0.36	3.78e-9	Schizophrenia;
KIRP	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.53	6.1	0.36	4.16e-9	Aortic root size;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.71	8.53	0.48	1.51e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.72	-7.29	-0.42	4.2e-12	Coronary artery calcification;
KIRP	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg20637307	chr2:213403960	ERBB4	0.41	5.49	0.33	9.97e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.55	0.59	6.19e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg16411857	chr16:57023191	NLRC5	-0.63	-6.28	-0.37	1.55e-9	Total cholesterol levels;
KIRP	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg13679303	chr9:96623674	NA	-0.45	-6.14	-0.36	3.2e-9	DNA methylation (variation);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg08679807	chr1:6338594	ACOT7	-0.49	-6.03	-0.36	5.95e-9	Bladder cancer;
KIRP	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.78	-9.02	-0.5	5.47e-17	Parkinson's disease;
KIRP	cis	rs787274	1.000	rs1361720	chr9:115535579	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-8.4	-0.47	3.67e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.58	-8.43	-0.47	2.85e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs8113308	0.515	rs60581730	chr19:52441136	C/T	cg25782003	chr19:52490127	ZNF350	0.66	5.19	0.31	4.3e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs4908768	0.906	rs12145445	chr1:8604370	C/G	cg03610117	chr1:8450231	RERE	-0.5	-5.22	-0.32	3.72e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7119167	0.685	rs2298807	chr11:73068571	T/C	cg17517138	chr11:73019481	ARHGEF17	0.5	5.37	0.32	1.82e-7	Blood protein levels;
KIRP	cis	rs236907	0.859	rs3891278	chr1:171756248	A/C	cg01410279	chr1:171621941	MYOC	-0.49	-5.46	-0.33	1.13e-7	Mean platelet volume;
KIRP	cis	rs6684428	1.000	rs12070494	chr1:56348904	C/T	cg11651538	chr1:56320950	NA	-0.91	-11.85	-0.6	6.31e-26	Airflow obstruction;
KIRP	cis	rs4566357	1.000	rs10933167	chr2:227925969	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg14338887	chr6:42928500	GNMT	-0.44	-4.96	-0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg08076091	chr2:203926405	NBEAL1	0.85	9.18	0.51	1.84e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-5.22	-0.32	3.81e-7	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23493127	chr6:144164392	LTV1	0.47	6.61	0.39	2.33e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.06	0.67	2.32e-33	Platelet count;
KIRP	cis	rs3857067	1.000	rs28840089	chr4:95000403	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.89e-7	QT interval;
KIRP	cis	rs9393813	0.509	rs10946915	chr6:27377830	A/G	cg18711553	chr6:27366782	ZNF391	-0.38	-5.12	-0.31	6.19e-7	Bipolar disorder;
KIRP	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-0.67	-5.53	-0.33	8.22e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs3026101	0.587	rs8066000	chr17:5310033	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg04132472	chr17:19861366	AKAP10	0.68	10.59	0.56	8.04e-22	Schizophrenia;
KIRP	cis	rs12496230	0.794	rs4856827	chr3:66867603	A/G	cg04995300	chr3:66848608	NA	0.43	6.65	0.39	1.87e-10	Type 2 diabetes;
KIRP	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg14250997	chr9:106856677	SMC2	0.44	6.03	0.36	5.88e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg05973401	chr12:123451056	ABCB9	-0.61	-7.17	-0.42	8.7e-12	Platelet count;
KIRP	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.26	5.15	0.31	5.4e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7553864	1.000	rs4626859	chr1:87614020	G/A	cg17420885	chr1:87600446	LOC339524	-0.45	-6.01	-0.36	6.58e-9	Smoking behavior;
KIRP	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-6.97	-0.41	2.9e-11	Bipolar disorder;
KIRP	cis	rs67072384	0.901	rs58076660	chr11:72441495	G/A	cg04827223	chr11:72435913	ARAP1	-0.56	-4.89	-0.3	1.83e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
KIRP	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.33	6.36	0.38	9.79e-10	Alcohol dependence;
KIRP	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	1.23	10.34	0.55	4.97e-21	Gut microbiota (bacterial taxa);
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.65	-8.71	-0.49	4.43e-16	Menarche (age at onset);
KIRP	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg27136344	chr17:80606911	WDR45L	0.48	6.69	0.39	1.48e-10	Breast cancer;
KIRP	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.38	-4.92	-0.3	1.62e-6	Menarche (age at onset);
KIRP	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg16586182	chr3:47516702	SCAP	0.68	9.25	0.51	1.11e-17	Colorectal cancer;
KIRP	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.26	24.25	0.84	3.52e-67	IgG glycosylation;
KIRP	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg08755490	chr11:65554678	OVOL1	0.37	5.27	0.32	3.03e-7	Acne (severe);
KIRP	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.61	-9.6	-0.52	9.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.67	-9.02	-0.5	5.42e-17	Huntington's disease progression;
KIRP	cis	rs6580649	0.941	rs7963934	chr12:48477086	C/G	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17967973	chr11:126139042	FOXRED1;SRPR	0.48	6.12	0.36	3.7e-9	Parkinson's disease;
KIRP	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg11895451	chr1:16533891	ARHGEF19	0.43	5.94	0.35	9.88e-9	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26207909	chr14:103986467	CKB	0.78	12.21	0.61	4.15e-27	Body mass index;
KIRP	cis	rs7258465	1.000	rs10411009	chr19:18606266	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.2	-0.37	2.43e-9	Breast cancer;
KIRP	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	1.26	9.8	0.53	2.37e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.64	8.17	0.46	1.68e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.7	-10.51	-0.56	1.42e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs494003	0.951	rs11227302	chr11:65554502	G/A	cg11569703	chr11:65557185	OVOL1	-0.43	-5.38	-0.32	1.69e-7	Systemic lupus erythematosus;
KIRP	cis	rs7106204	0.609	rs12790279	chr11:24286221	C/G	ch.11.24196551F	chr11:24239977	NA	0.75	6.85	0.4	5.8e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.41	-5.26	-0.32	3.06e-7	QT interval;
KIRP	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg09990169	chr2:241835740	C2orf54	-0.45	-6.57	-0.39	2.9e-10	Urinary metabolites;
KIRP	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01771876	chr2:11886613	LPIN1	0.47	6.38	0.38	8.72e-10	Cancer;
KIRP	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg19683494	chr5:74908142	NA	0.43	5.03	0.31	9.63e-7	Age-related disease endophenotypes;
KIRP	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.7	-0.34	3.41e-8	Menarche (age at onset);
KIRP	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg05756136	chr1:119680316	WARS2	-0.62	-8.35	-0.47	5.11e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.65	5.76	0.34	2.47e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.42	0.47	3.18e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.67	-9.29	-0.51	8.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	5.42	0.33	1.42e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1106684	1.000	rs17165897	chr7:131460437	A/G	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.56	-6.56	-0.39	3.22e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg26043149	chr18:55253948	FECH	0.49	6.06	0.36	5.09e-9	Bone mineral density;
KIRP	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg21360079	chr12:107162445	NA	-0.67	-9.73	-0.53	3.73e-19	Heart rate;
KIRP	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-5.09	-0.31	7.04e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2006771	0.713	rs9606878	chr22:32220680	A/G	cg02404636	chr22:31891804	SFI1	0.45	5.74	0.34	2.72e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6973256	0.897	rs7776986	chr7:133345635	A/G	cg10665199	chr7:133106180	EXOC4	-0.47	-6.15	-0.36	3.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12210905	1.000	rs76889265	chr6:27008835	T/C	cg11502198	chr6:26597334	ABT1	-0.78	-4.98	-0.3	1.18e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs4851254	0.961	rs7583067	chr2:100796850	C/T	cg17356467	chr2:100759845	AFF3	0.58	7.18	0.42	8.13e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4979906	0.920	rs11002239	chr10:79443836	A/C	cg07817648	chr10:79422355	NA	-0.46	-4.96	-0.3	1.32e-6	Mortality in heart failure;
KIRP	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-12.29	-0.62	2.15e-27	Alzheimer's disease;
KIRP	cis	rs6580083	1.000	rs10035725	chr5:153870479	T/G	cg21964928	chr5:153872958	NA	0.42	5.7	0.34	3.43e-8	QRS duration;
KIRP	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.74	10.33	0.55	5.18e-21	Red blood cell count;
KIRP	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg27205649	chr11:78285834	NARS2	-0.53	-5.16	-0.31	5.08e-7	Testicular germ cell tumor;
KIRP	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg11812906	chr14:75593930	NEK9	0.53	5.99	0.36	7.24e-9	Caffeine consumption;
KIRP	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.06	0.67	2.32e-33	Platelet count;
KIRP	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg12963866	chr19:57752005	ZNF805	-0.49	-6.3	-0.37	1.39e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.83	6.38	0.38	8.79e-10	Mean platelet volume;
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.51	-7.15	-0.42	9.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	0.691	rs4282209	chr4:76919536	A/G	cg19388996	chr4:76862389	NAAA	0.43	5.48	0.33	1.06e-7	Blood protein levels;
KIRP	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.99	-0.5	6.7e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9815354	0.556	rs73073276	chr3:42025354	G/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.59	-10.28	-0.55	7.41e-21	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	0.79	8.28	0.47	8.09e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.67	-6.22	-0.37	2.09e-9	Menarche (age at onset);
KIRP	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	5.47	0.33	1.08e-7	Renal cell carcinoma;
KIRP	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg10047753	chr17:41438598	NA	0.9	12.78	0.63	4.95e-29	Menopause (age at onset);
KIRP	cis	rs539514	0.550	rs2328956	chr13:76294595	G/A	cg04757411	chr13:76259545	LMO7	-0.36	-5.04	-0.31	9.05e-7	Type 1 diabetes;
KIRP	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19346786	chr7:2764209	NA	-0.29	-4.98	-0.3	1.17e-6	Height;
KIRP	cis	rs6005807	0.668	rs9620808	chr22:28993331	A/C	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.15	0.41	9.81e-12	Prudent dietary pattern;
KIRP	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg17279839	chr7:150038598	RARRES2	0.52	6.85	0.4	5.97e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-7.88	-0.45	1.08e-13	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg13679303	chr9:96623674	NA	-0.5	-7.16	-0.42	9.34e-12	DNA methylation (variation);
KIRP	cis	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg08798685	chr6:27730294	NA	-0.55	-5.0	-0.3	1.08e-6	Lung cancer in ever smokers;
KIRP	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	cg12689670	chr1:183009347	LAMC1	0.43	6.16	0.37	3e-9	Colorectal cancer;
KIRP	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg17143192	chr8:8559678	CLDN23	0.6	7.06	0.41	1.72e-11	Obesity-related traits;
KIRP	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12292205	chr6:26970375	C6orf41	-0.59	-6.26	-0.37	1.7e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.98	-15.86	-0.71	1.69e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg07741184	chr6:167504864	NA	-0.2	-5.14	-0.31	5.56e-7	Crohn's disease;
KIRP	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg23442198	chr4:187126114	CYP4V2	0.55	5.46	0.33	1.14e-7	Blood protein levels;
KIRP	cis	rs7116495	1.000	rs2460254	chr11:71570110	A/G	cg11196788	chr11:71737549	NUMA1	-0.51	-5.1	-0.31	6.63e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg17554472	chr22:41940697	POLR3H	-0.5	-5.85	-0.35	1.52e-8	Vitiligo;
KIRP	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs220519	0.745	rs220529	chr20:37273910	T/C	cg24308336	chr20:37270989	C20orf95	0.24	5.36	0.32	1.96e-7	Schizophrenia;
KIRP	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.51	7.22	0.42	6.44e-12	Red blood cell count;
KIRP	trans	rs2048656	0.605	rs7837008	chr8:9646506	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	6.59	0.39	2.59e-10	Schizophrenia;
KIRP	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg02462569	chr6:150064036	NUP43	-0.34	-4.94	-0.3	1.46e-6	Lung cancer;
KIRP	cis	rs17057718	1.000	rs6792236	chr3:57149315	T/G	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.36	-4.85	-0.3	2.23e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg05526886	chr2:227700861	RHBDD1	-0.51	-6.05	-0.36	5.38e-9	Pulmonary function;
KIRP	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg25650185	chr19:21324782	ZNF431	0.48	5.08	0.31	7.48e-7	Pain;
KIRP	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.48	7.13	0.41	1.11e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg20243544	chr17:37824526	PNMT	-0.4	-5.0	-0.3	1.11e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs2721195	0.810	rs2721142	chr8:145752467	A/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.83	11.34	0.59	3.01e-24	Age at first birth;
KIRP	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	0.94	8.96	0.5	8.41e-17	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg04369109	chr6:150039330	LATS1	-0.44	-5.46	-0.33	1.17e-7	Lung cancer;
KIRP	cis	rs2820315	0.965	rs8028	chr1:201865763	A/G	cg11586189	chr1:201857591	SHISA4	0.4	5.58	0.34	6.36e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg26354017	chr1:205819088	PM20D1	0.48	5.48	0.33	1.03e-7	Prostate-specific antigen levels;
KIRP	cis	rs10488172	0.857	rs17167144	chr7:133239042	A/G	cg10665199	chr7:133106180	EXOC4	-0.51	-5.43	-0.33	1.33e-7	Tonometry;
KIRP	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.77	7.91	0.45	8.81e-14	Uric acid levels;
KIRP	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.47	4.97	0.3	1.23e-6	Breast cancer;
KIRP	cis	rs12135191	0.771	rs12144786	chr1:236495893	C/T	cg21399712	chr1:236511386	NA	-0.47	-6.05	-0.36	5.26e-9	Urate levels (BMI interaction);
KIRP	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.76	9.76	0.53	3.13e-19	Menopause (age at onset);
KIRP	cis	rs6832769	0.925	rs3817444	chr4:56375981	A/C	cg05960024	chr4:56376020	CLOCK	0.73	9.37	0.51	5.04e-18	Personality dimensions;
KIRP	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg07636037	chr3:49044803	WDR6	-0.77	-7.38	-0.43	2.48e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7258465	1.000	rs10409505	chr19:18590251	C/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.91	-0.35	1.12e-8	Breast cancer;
KIRP	cis	rs1147199	0.585	rs726433	chr9:87247336	C/T	cg22402007	chr9:87282823	NTRK2	0.4	4.96	0.3	1.33e-6	Body mass index;
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.51	5.12	0.31	6.16e-7	Alzheimer's disease;
KIRP	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	10.61	0.56	6.8e-22	Cognitive test performance;
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg21186296	chr8:27182909	PTK2B	0.49	6.26	0.37	1.72e-9	Neuroticism;
KIRP	cis	rs883565	0.569	rs784509	chr3:39166355	G/A	cg01426195	chr3:39028469	NA	0.52	8.34	0.47	5.34e-15	Handedness;
KIRP	cis	rs7998202	0.667	rs282574	chr13:113361310	C/T	cg04656015	chr13:113407548	ATP11A	-0.54	-5.99	-0.36	7.26e-9	Glycated hemoglobin levels;
KIRP	cis	rs2671245	0.933	rs2767507	chr1:56155388	A/G	cg11523071	chr1:56160889	NA	0.41	6.74	0.39	1.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs13161895	0.646	rs77997852	chr5:179504925	T/C	cg02702477	chr5:179499311	RNF130	1.14	6.8	0.4	7.78e-11	LDL cholesterol;
KIRP	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.52	5.08	0.31	7.33e-7	Recombination rate (females);
KIRP	trans	rs8102137	0.550	rs34331990	chr19:30321561	A/C	cg14497545	chr4:140754475	MAML3	-0.42	-6.03	-0.36	5.85e-9	Bladder cancer;
KIRP	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.5	-0.38	4.37e-10	Joint mobility (Beighton score);
KIRP	cis	rs71277158	0.688	rs80038349	chr3:169844718	G/T	cg04067573	chr3:169899625	PHC3	0.58	5.62	0.34	5.23e-8	Prostate cancer;
KIRP	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.8	-11.84	-0.6	6.87e-26	Height;
KIRP	trans	rs10186876	0.543	rs3853705	chr2:44261892	A/G	cg23840823	chr4:1950185	WHSC1	-0.53	-6.26	-0.37	1.69e-9	Hand grip strength;
KIRP	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg18404041	chr3:52824283	ITIH1	0.36	5.15	0.31	5.36e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9596863	0.898	rs28551599	chr13:54342756	T/A	ch.13.53330881F	chr13:54432880	NA	0.54	5.1	0.31	6.66e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7084402	0.967	rs6481404	chr10:60286071	C/G	cg05938607	chr10:60274200	BICC1	0.39	9.21	0.51	1.53e-17	Refractive error;
KIRP	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg23335576	chr14:104009727	NA	0.4	5.48	0.33	1.05e-7	Body mass index;
KIRP	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg13409248	chr3:40428643	ENTPD3	0.39	5.18	0.31	4.65e-7	Renal cell carcinoma;
KIRP	cis	rs17125944	0.615	rs1998777	chr14:53295706	C/T	cg00686598	chr14:53173677	PSMC6	-0.75	-7.49	-0.43	1.21e-12	Alzheimer's disease (late onset);
KIRP	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.75	9.21	0.51	1.43e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7590368	0.600	rs56143168	chr2:10916233	A/G	cg15705551	chr2:10952987	PDIA6	0.61	5.38	0.32	1.77e-7	Educational attainment (years of education);
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg23978390	chr7:1156363	C7orf50	0.63	8.17	0.46	1.59e-14	Longevity;Endometriosis;
KIRP	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.79	12.86	0.63	2.62e-29	Dupuytren's disease;
KIRP	cis	rs17123764	1.000	rs2241418	chr12:49951232	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.87	0.3	1.98e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg02151108	chr14:50098012	C14orf104	0.48	6.16	0.37	2.98e-9	Carotid intima media thickness;
KIRP	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg24488311	chr11:68621650	NA	0.42	5.33	0.32	2.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.63	-7.09	-0.41	1.38e-11	Neuroticism;
KIRP	cis	rs4356932	1.000	rs4309862	chr4:76945981	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs9653442	0.564	rs12992234	chr2:100767886	G/A	cg17356467	chr2:100759845	AFF3	0.42	6.02	0.36	6.33e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.25	-0.32	3.29e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs13095912	1.000	rs6784842	chr3:185342723	C/T	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.25e-11	Systolic blood pressure;
KIRP	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg27422857	chr2:105853526	NA	-0.45	-6.17	-0.37	2.74e-9	Type 2 diabetes;
KIRP	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.23	0.46	1.09e-14	Lung cancer;
KIRP	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.65	8.99	0.5	6.69e-17	Blood protein levels;
KIRP	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg02038168	chr22:39784481	NA	-0.45	-5.52	-0.33	8.47e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.56	6.23	0.37	1.97e-9	Coronary artery disease;
KIRP	cis	rs2274273	0.870	rs8013713	chr14:55841252	A/G	cg04306507	chr14:55594613	LGALS3	-0.45	-7.01	-0.41	2.32e-11	Protein biomarker;
KIRP	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06544989	chr22:39130855	UNC84B	0.49	7.29	0.42	4.16e-12	Menopause (age at onset);
KIRP	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.23	-0.42	6.03e-12	Glomerular filtration rate;
KIRP	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	1.07	18.77	0.77	2.27e-49	Caffeine consumption;
KIRP	cis	rs7172677	0.737	rs6495155	chr15:75437311	G/A	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2274459	0.841	rs10947432	chr6:33676556	A/G	cg06253072	chr6:33679850	C6orf125	-0.5	-5.46	-0.33	1.18e-7	Obesity (extreme);
KIRP	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.96	-0.45	6.18e-14	Mean corpuscular volume;
KIRP	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00585698	chr12:123750864	CDK2AP1	-0.52	-6.69	-0.39	1.46e-10	Neutrophil percentage of white cells;
KIRP	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg02158880	chr13:53174818	NA	0.5	6.5	0.38	4.48e-10	Lewy body disease;
KIRP	trans	rs11165623	0.564	rs6593612	chr1:97002041	C/A	cg10631902	chr5:14652156	NA	-0.5	-6.7	-0.39	1.4e-10	Hip circumference;Waist circumference;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg04025307	chr7:1156635	C7orf50	0.81	8.32	0.47	6.21e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg26248373	chr2:1572462	NA	-0.66	-7.79	-0.44	1.88e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg21132104	chr15:45694354	SPATA5L1	0.58	7.13	0.41	1.09e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs12230513	1.000	rs77755732	chr12:55924293	C/T	cg19537932	chr12:55886519	OR6C68	-0.45	-4.87	-0.3	2.04e-6	Contrast sensitivity;
KIRP	cis	rs883115	0.810	rs10916653	chr1:224785503	G/A	cg01808320	chr1:224927238	CNIH3	-0.36	-5.1	-0.31	6.83e-7	Cancer;
KIRP	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.65	-9.76	-0.53	3.06e-19	Body mass index;
KIRP	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg03609598	chr5:56110824	MAP3K1	0.48	5.48	0.33	1.06e-7	Initial pursuit acceleration;
KIRP	cis	rs2153535	1.000	rs2153535	chr6:8369679	C/G	cg07606381	chr6:8435919	SLC35B3	-0.45	-5.57	-0.33	6.58e-8	Motion sickness;
KIRP	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.11	-0.31	6.34e-7	Schizophrenia;
KIRP	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg18404041	chr3:52824283	ITIH1	0.36	5.09	0.31	7.21e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.54	0.39	3.44e-10	Hypertriglyceridemia;
KIRP	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.84	10.61	0.56	6.85e-22	Menopause (age at onset);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg15325629	chr6:28072465	NA	0.49	6.07	0.36	4.79e-9	Educational attainment;
KIRP	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.56	-0.39	3.17e-10	Joint mobility (Beighton score);
KIRP	cis	rs440932	0.798	rs330942	chr8:9020439	A/C	cg08975724	chr8:8085496	FLJ10661	0.49	5.98	0.36	7.81e-9	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs56146971	0.763	rs75059313	chr14:91847559	T/A	cg10511902	chr14:91842949	CCDC88C	0.5	5.3	0.32	2.64e-7	Alzheimer disease and age of onset;
KIRP	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg12963866	chr19:57752005	ZNF805	-0.48	-5.98	-0.36	7.89e-9	Hyperactive-impulsive symptoms;
KIRP	trans	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.63	-7.19	-0.42	7.61e-12	Colorectal cancer;
KIRP	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs6545883	0.859	rs35760550	chr2:61603865	T/A	cg15711740	chr2:61764176	XPO1	0.6	7.75	0.44	2.39e-13	Tuberculosis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02009255	chr20:58515371	C20orf177;PPP1R3D	-0.49	-6.35	-0.38	1.06e-9	Myopia;
KIRP	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg25650185	chr19:21324782	ZNF431	-0.51	-5.38	-0.32	1.7e-7	Pain;
KIRP	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs13053817	1.000	rs13340033	chr22:29846339	A/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.44	-5.52	-0.33	8.77e-8	Carotid atherosclerosis in HIV infection;
KIRP	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.92	13.66	0.66	5.56e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9826463	0.702	rs56397702	chr3:142304764	C/T	cg20824294	chr3:142316082	PLS1	0.46	6.95	0.4	3.33e-11	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg11641102	chr8:27183873	PTK2B	0.42	5.61	0.34	5.34e-8	Neuroticism;
KIRP	cis	rs911119	0.955	rs4815224	chr20:23594112	C/G	cg09631192	chr20:23583594	CST9	-0.58	-5.53	-0.33	8.08e-8	Chronic kidney disease;
KIRP	cis	rs9815354	0.812	rs7629767	chr3:42043509	T/G	cg03022575	chr3:42003672	ULK4	0.73	7.55	0.43	8.61e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg17425144	chr1:10567563	PEX14	0.42	7.2	0.42	7.43e-12	Hand grip strength;
KIRP	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg07395648	chr5:131743802	NA	-0.47	-6.4	-0.38	7.85e-10	Blood metabolite levels;
KIRP	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	6.76	0.4	1.01e-10	Menarche (age at onset);
KIRP	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg01522456	chr1:115632236	TSPAN2	0.37	4.98	0.3	1.2e-6	Autism;
KIRP	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg11494091	chr17:61959527	GH2	0.47	5.87	0.35	1.42e-8	Height;
KIRP	cis	rs57786342	0.569	rs10139199	chr14:69277800	G/T	cg03189333	chr14:69283534	NA	-0.42	-5.17	-0.31	4.81e-7	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs12496230	0.794	rs34113192	chr3:66863668	A/G	cg17646820	chr3:66848679	NA	0.39	6.37	0.38	9.34e-10	Type 2 diabetes;
KIRP	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg13962347	chr6:5174647	LYRM4	-0.74	-10.29	-0.55	6.84e-21	Height;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg27532560	chr4:187881888	NA	-0.73	-12.12	-0.61	7.87e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-6.76	-0.4	9.74e-11	Menarche (age at onset);
KIRP	cis	rs2274459	0.841	rs35698850	chr6:33700132	A/G	cg06253072	chr6:33679850	C6orf125	0.53	5.55	0.33	7.35e-8	Obesity (extreme);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16910805	chr2:62081285	FAM161A	0.55	6.95	0.41	3.33e-11	Parkinson's disease;
KIRP	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	6.58	0.39	2.86e-10	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01340435	chr15:44487547	FRMD5	0.48	6.48	0.38	4.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	1.99e-8	Lung cancer;
KIRP	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.58	-6.4	-0.38	8.01e-10	Primary sclerosing cholangitis;
KIRP	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg08822215	chr16:89438651	ANKRD11	-0.51	-6.72	-0.39	1.25e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs17065868	1.000	rs73174032	chr13:45205137	T/A	cg10246903	chr13:45222710	NA	0.72	6.36	0.38	9.83e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg05347473	chr6:146136440	FBXO30	0.57	8.12	0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg23594656	chr7:65796392	TPST1	-0.45	-7.09	-0.41	1.44e-11	Aortic root size;
KIRP	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.71	-11.25	-0.58	5.64e-24	Hepatocellular carcinoma;
KIRP	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.97	0.36	8.41e-9	Breast cancer;
KIRP	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.98	-17.55	-0.75	2.89e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.8	0.53	2.4e-19	Corneal astigmatism;
KIRP	trans	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg10756647	chr7:56101905	PSPH	0.99	7.04	0.41	1.9e-11	Diabetic kidney disease;
KIRP	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.63	-7.0	-0.41	2.39e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.69	-13.0	-0.64	9.36e-30	White blood cell count (basophil);
KIRP	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.68	5.47	0.33	1.1e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4474465	1.000	rs7933612	chr11:78209366	G/T	cg02023728	chr11:77925099	USP35	-0.33	-5.36	-0.32	1.92e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	9.12	0.5	2.84e-17	Bone mineral density;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10002088	chr19:9271911	ZNF317	1.1	6.17	0.37	2.74e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.29	-0.51	8.68e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13315871	1.000	rs71311871	chr3:58420613	A/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.17	-0.31	4.79e-7	Cholesterol, total;
KIRP	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.78	-10.36	-0.55	4.27e-21	Dental caries;
KIRP	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg23894439	chr1:183413866	NA	-0.43	-5.62	-0.34	5.27e-8	Systemic lupus erythematosus;
KIRP	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.51	-5.32	-0.32	2.33e-7	Corneal structure;
KIRP	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	7.03	0.41	2.08e-11	Total body bone mineral density;
KIRP	trans	rs4349753	0.904	rs248556	chr5:144177339	C/T	cg16033277	chr17:80885358	TBCD	-0.41	-6.4	-0.38	7.79e-10	Photic sneeze reflex;
KIRP	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.45	-5.41	-0.33	1.48e-7	P wave terminal force;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26661912	chr20:633854	SRXN1	-0.55	-6.14	-0.36	3.28e-9	Menopause (age at onset);
KIRP	trans	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg06521331	chr12:34319734	NA	-0.6	-7.15	-0.41	9.86e-12	Bladder cancer;
KIRP	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg06766960	chr11:133703094	NA	-0.57	-7.16	-0.42	9.48e-12	Childhood ear infection;
KIRP	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg20312557	chr2:97357134	FER1L5	-0.73	-5.35	-0.32	2.05e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	4.95	0.3	1.39e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg25600027	chr14:23388339	RBM23	-0.52	-6.43	-0.38	6.42e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs10073892	0.620	rs55897698	chr5:101935603	C/T	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs10073892	0.664	rs1910288	chr5:101891771	C/T	cg19774478	chr5:101632501	SLCO4C1	0.6	5.86	0.35	1.49e-8	Cognitive decline (age-related);
KIRP	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg19257562	chr1:2043853	PRKCZ	0.46	7.1	0.41	1.34e-11	Height;
KIRP	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.23	-0.32	3.71e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.23	-0.32	3.68e-7	Bipolar disorder;
KIRP	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.56	-9.24	-0.51	1.22e-17	Prostate cancer;
KIRP	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.56	-6.84	-0.4	6.26e-11	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-5.51	-0.33	9.22e-8	Metabolite levels;
KIRP	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg00982548	chr2:198649783	BOLL	-0.53	-4.93	-0.3	1.48e-6	Ulcerative colitis;
KIRP	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.69	7.05	0.41	1.82e-11	Vitiligo;
KIRP	cis	rs9905704	0.914	rs34556895	chr17:56826953	G/T	cg12560992	chr17:57184187	TRIM37	0.57	6.35	0.38	1.03e-9	Testicular germ cell tumor;
KIRP	cis	rs11871801	0.517	rs35635959	chr17:40772288	T/C	cg14558262	chr17:40713999	COASY	0.47	5.05	0.31	8.62e-7	Crohn's disease;
KIRP	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg15147215	chr3:52552868	STAB1	-0.29	-5.25	-0.32	3.25e-7	Electroencephalogram traits;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg13906792	chr15:75199810	C15orf17	-0.36	-5.17	-0.31	4.8e-7	Breast cancer;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.24	-4.99	-0.3	1.14e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11074306	0.561	rs7172907	chr15:28062405	A/G	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.59e-6	Uveal melanoma;
KIRP	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.98	10.91	0.57	7.13e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.39	-4.97	-0.3	1.24e-6	Response to temozolomide;
KIRP	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-10.98	-0.57	4.35e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.59	5.7	0.34	3.46e-8	Schizophrenia;
KIRP	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	0.96	8.75	0.49	3.37e-16	Systolic blood pressure;
KIRP	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg17554472	chr22:41940697	POLR3H	0.47	5.35	0.32	2.04e-7	Vitiligo;
KIRP	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1448094	0.791	rs10863114	chr12:86332325	T/C	cg00310523	chr12:86230176	RASSF9	0.43	6.62	0.39	2.24e-10	Major depressive disorder;
KIRP	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.56	-6.3	-0.37	1.34e-9	Coronary artery disease;
KIRP	cis	rs3789045	0.774	rs4252697	chr1:204501383	C/T	cg18185008	chr1:204589407	LRRN2	-0.62	-6.74	-0.39	1.12e-10	Educational attainment (college completion);
KIRP	cis	rs17641971	0.708	rs1567555	chr8:49900154	G/A	cg00325661	chr8:49890786	NA	0.4	5.04	0.31	8.84e-7	Blood metabolite levels;
KIRP	cis	rs1364705	1.000	rs12676931	chr8:120279927	A/C	cg09273054	chr8:120220131	MAL2	-0.54	-6.29	-0.37	1.43e-9	Hippocampal atrophy;
KIRP	cis	rs7929679	0.521	rs10836307	chr11:34800228	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.36e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg25356066	chr3:128598488	ACAD9	0.56	6.43	0.38	6.48e-10	IgG glycosylation;
KIRP	cis	rs8177876	0.730	rs76656387	chr16:81117467	G/A	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg22139774	chr2:100720529	AFF3	-0.35	-6.39	-0.38	8.43e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.44	7.75	0.44	2.42e-13	Renal cell carcinoma;
KIRP	cis	rs6959887	1.000	rs28561590	chr7:35295780	A/C	cg06685737	chr7:35301730	NA	0.45	6.66	0.39	1.78e-10	Birth weight;
KIRP	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.68	9.18	0.5	1.88e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg13906792	chr15:75199810	C15orf17	-0.38	-5.45	-0.33	1.2e-7	Breast cancer;
KIRP	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg00079375	chr15:79125835	NA	0.37	5.33	0.32	2.27e-7	Coronary artery disease;
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg10295955	chr4:187884368	NA	-1.13	-18.87	-0.77	1.02e-49	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17321999	0.516	rs60827632	chr2:30504629	A/T	cg05247661	chr2:30472410	LBH	0.65	5.35	0.32	1.98e-7	Systemic lupus erythematosus;
KIRP	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.91	13.24	0.64	1.45e-30	Bladder cancer;
KIRP	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg16584676	chr17:46985605	UBE2Z	0.47	5.8	0.35	2.06e-8	Type 2 diabetes;
KIRP	cis	rs6032067	0.683	rs16989763	chr20:43779963	T/C	cg10761708	chr20:43804764	PI3	0.42	4.94	0.3	1.48e-6	Blood protein levels;
KIRP	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.48	-0.43	1.33e-12	Morning vs. evening chronotype;
KIRP	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.74	-8.93	-0.49	9.85e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.76	-10.47	-0.56	1.88e-21	Aortic root size;
KIRP	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18252515	chr7:66147081	NA	0.46	5.72	0.34	3.13e-8	Aortic root size;
KIRP	cis	rs13102973	0.867	rs4543187	chr4:135906850	G/A	cg14419869	chr4:135874104	NA	0.47	7.3	0.42	3.94e-12	Subjective well-being;
KIRP	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg05255149	chr17:80675120	FN3KRP	0.46	4.93	0.3	1.53e-6	Glycated hemoglobin levels;
KIRP	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.66	-10.08	-0.54	3.08e-20	Airway imaging phenotypes;
KIRP	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg22974920	chr21:40686053	BRWD1	-0.43	-5.0	-0.3	1.08e-6	Cognitive function;
KIRP	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.73	10.82	0.57	1.4e-22	Prostate cancer;
KIRP	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg21551340	chr2:1609508	NA	0.52	5.04	0.31	8.99e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg10761708	chr20:43804764	PI3	0.5	5.2	0.31	4.22e-7	Blood protein levels;
KIRP	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.2	-21.82	-0.81	1.9e-59	Ulcerative colitis;
KIRP	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg27205649	chr11:78285834	NARS2	-0.52	-5.9	-0.35	1.2e-8	Testicular germ cell tumor;
KIRP	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-6.1	-0.36	4.03e-9	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg15556689	chr8:8085844	FLJ10661	0.66	9.01	0.5	5.97e-17	Mood instability;
KIRP	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg07395648	chr5:131743802	NA	-0.49	-6.67	-0.39	1.67e-10	Blood metabolite levels;
KIRP	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11584989	chr19:19387371	SF4	0.75	6.9	0.4	4.26e-11	Bipolar disorder;
KIRP	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg14673194	chr17:80132900	CCDC57	0.79	8.81	0.49	2.35e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg23594656	chr7:65796392	TPST1	0.5	7.69	0.44	3.45e-13	Aortic root size;
KIRP	cis	rs6546324	0.559	rs4381768	chr2:67779388	T/C	cg15745817	chr2:67799979	NA	-0.67	-6.74	-0.39	1.09e-10	Endometriosis;
KIRP	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg05347473	chr6:146136440	FBXO30	0.59	8.29	0.47	7.2e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.6	6.71	0.39	1.3e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg07884673	chr3:53033167	SFMBT1	-0.84	-6.55	-0.39	3.35e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7572644	0.553	rs4233717	chr2:28034680	A/T	cg27432699	chr2:27873401	GPN1	0.49	5.59	0.34	6.01e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.35	-0.42	2.98e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg17764715	chr19:33622953	WDR88	0.68	8.25	0.47	9.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.67	9.02	0.5	5.51e-17	Multiple sclerosis;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.1	-0.36	4e-9	Longevity;Endometriosis;
KIRP	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.48	-6.54	-0.38	3.55e-10	Neurofibrillary tangles;
KIRP	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.51	6.94	0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs1035491	0.715	rs6878515	chr5:63925029	G/C	cg01791865	chr5:63954708	NA	0.33	5.21	0.32	4.07e-7	Body mass index;
KIRP	cis	rs684232	0.933	rs866304	chr17:587729	T/C	cg04370829	chr17:406249	NA	0.4	5.23	0.32	3.56e-7	Prostate cancer;
KIRP	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23422044	chr7:1970798	MAD1L1	-0.72	-7.38	-0.43	2.43e-12	Bipolar disorder;
KIRP	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg00792783	chr2:198669748	PLCL1	0.47	5.09	0.31	6.95e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
KIRP	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg19468946	chr17:37922297	IKZF3	-0.48	-6.55	-0.39	3.34e-10	Self-reported allergy;
KIRP	cis	rs12412942	1.000	rs12412942	chr10:2357702	C/T	cg23939236	chr10:2357224	NA	-0.38	-5.96	-0.35	8.92e-9	Schizophrenia;
KIRP	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.93	-14.62	-0.68	2.86e-35	Systemic lupus erythematosus;
KIRP	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.51	5.04	0.31	8.88e-7	Height;
KIRP	cis	rs2275565	0.872	rs3768153	chr1:237053645	C/T	cg17297354	chr1:237056641	MTR	-0.41	-5.24	-0.32	3.39e-7	Homocysteine levels;
KIRP	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.7	6.75	0.4	1.05e-10	Axial length;
KIRP	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg22776125	chr6:167041314	RPS6KA2	0.44	5.57	0.33	6.61e-8	Asthma;
KIRP	cis	rs11212260	0.678	rs11212204	chr11:107267630	G/T	cg25435332	chr11:107328525	CWF19L2	0.84	5.16	0.31	5.14e-7	IgG glycosylation;
KIRP	trans	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-7.46	-0.43	1.46e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg01411142	chr8:19674711	INTS10	0.61	6.62	0.39	2.25e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg12140854	chr5:148520817	ABLIM3	0.54	6.21	0.37	2.22e-9	Breast cancer;
KIRP	cis	rs6684514	0.961	rs11264463	chr1:156242806	A/G	cg16558208	chr1:156270281	VHLL	-0.41	-5.64	-0.34	4.72e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs12900413	0.603	rs7177841	chr15:90302117	C/A	cg24650279	chr15:90327240	NA	-0.42	-5.2	-0.31	4.27e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.88	9.85	0.53	1.64e-19	Gut microbiome composition (summer);
KIRP	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.57	-0.33	6.63e-8	Coronary artery disease;
KIRP	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg07810366	chr2:100720526	AFF3	-0.4	-7.24	-0.42	5.84e-12	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.57	7.62	0.44	5.64e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.7	10.19	0.54	1.45e-20	Lymphocyte counts;
KIRP	cis	rs7011049	0.778	rs113126427	chr8:53867467	T/C	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	1.07	21.56	0.81	1.32e-58	Parkinson's disease;
KIRP	cis	rs3821902	0.691	rs73120936	chr3:64050945	T/C	cg09006292	chr3:64049408	NA	-0.56	-5.99	-0.36	7.28e-9	Breast cancer;
KIRP	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg18806716	chr10:30721971	MAP3K8	-0.38	-5.83	-0.35	1.73e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10484885	0.591	rs72912551	chr6:90178347	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.67	-5.99	-0.36	7.37e-9	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs1514687	0.534	rs11674407	chr2:1464530	G/C	cg13703866	chr2:1479523	TPO	-0.65	-5.18	-0.31	4.7e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg09795085	chr6:101329169	ASCC3	-0.5	-6.02	-0.36	6.24e-9	Neuroticism;
KIRP	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg08501292	chr6:25962987	TRIM38	1.01	8.08	0.46	2.89e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.92	-0.4	3.92e-11	Hemoglobin concentration;
KIRP	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.79	-10.21	-0.55	1.28e-20	Pancreatic cancer;
KIRP	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.61	-0.34	5.3e-8	Coronary artery disease;
KIRP	cis	rs6695223	0.571	rs4907133	chr1:85538947	A/G	cg11262906	chr1:85462892	MCOLN2	-0.51	-5.21	-0.32	4.01e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.38	-0.38	8.59e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.27	6.16	0.37	2.87e-9	IgG glycosylation;
KIRP	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg05340658	chr4:99064831	C4orf37	-0.59	-7.27	-0.42	4.86e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.65	8.82	0.49	2.18e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg05484376	chr2:27715224	FNDC4	0.37	6.08	0.36	4.62e-9	Total body bone mineral density;
KIRP	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	1.0	17.5	0.74	4.43e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg23202291	chr11:1979235	NA	0.41	5.28	0.32	2.81e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg01689657	chr7:91764605	CYP51A1	-0.34	-5.03	-0.31	9.53e-7	Breast cancer;
KIRP	cis	rs526231	0.543	rs3776863	chr5:102327869	G/C	cg23492399	chr5:102201601	PAM	-0.48	-5.55	-0.33	7.24e-8	Primary biliary cholangitis;
KIRP	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.55	-0.39	3.37e-10	Aortic root size;
KIRP	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg17724175	chr1:150552817	MCL1	0.35	5.93	0.35	9.98e-9	Melanoma;
KIRP	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg17167289	chr3:42846087	HIGD1A	-1.08	-6.13	-0.36	3.5e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs11161851	0.901	rs12030917	chr1:75318735	C/G	cg11196437	chr1:75593865	LHX8	-0.4	-5.91	-0.35	1.16e-8	Visceral fat;
KIRP	cis	rs507080	0.769	rs11603616	chr11:118496066	G/A	cg04173919	chr11:118528438	PHLDB1	0.35	5.01	0.3	1.06e-6	Serum metabolite levels;
KIRP	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg11502198	chr6:26597334	ABT1	0.46	4.93	0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.78	7.95	0.45	6.61e-14	Uric acid levels;
KIRP	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.73	9.38	0.51	4.69e-18	Response to antipsychotic treatment;
KIRP	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16524936	chr4:1340807	KIAA1530	-0.48	-6.05	-0.36	5.27e-9	Longevity;
KIRP	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg22906224	chr7:99728672	NA	-0.66	-7.96	-0.45	6.28e-14	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19003646	chr3:184053927	FAM131A	0.65	8.22	0.46	1.2e-14	Parkinson's disease;
KIRP	cis	rs72843166	0.891	rs72839495	chr17:61044550	A/T	cg19683800	chr17:61518354	CYB561	-0.44	-5.07	-0.31	7.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.18e-7	Red blood cell count;
KIRP	cis	rs1371614	0.589	rs935018	chr2:27106625	A/T	cg00617064	chr2:27272375	NA	0.42	4.89	0.3	1.78e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg24488311	chr11:68621650	NA	0.48	5.85	0.35	1.53e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11608355	0.521	rs6606707	chr12:109830241	T/G	cg19025524	chr12:109796872	NA	-0.51	-7.05	-0.41	1.84e-11	Neuroticism;
KIRP	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg04310649	chr10:35416472	CREM	-0.58	-7.12	-0.41	1.21e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs78487399	0.831	rs17031142	chr2:43847646	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.37	-0.32	1.78e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.2	0.42	7.43e-12	Retinal vascular caliber;
KIRP	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.47	-4.85	-0.3	2.17e-6	Initial pursuit acceleration;
KIRP	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.58	-7.32	-0.42	3.54e-12	Uric acid levels;
KIRP	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg13409248	chr3:40428643	ENTPD3	0.39	5.25	0.32	3.24e-7	Renal cell carcinoma;
KIRP	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg26585981	chr11:48327164	OR4S1	-0.5	-6.14	-0.36	3.38e-9	Migraine - clinic-based;
KIRP	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.78	12.22	0.61	3.74e-27	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21219744	chr4:44680344	GUF1	0.51	6.14	0.36	3.21e-9	Smoking initiation;
KIRP	cis	rs35740288	0.770	rs62022867	chr15:86173281	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg14345882	chr6:26364793	BTN3A2	0.54	4.92	0.3	1.56e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg23601095	chr6:26197514	HIST1H3D	0.9	7.35	0.42	3e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.59	-9.48	-0.52	2.34e-18	C-reactive protein levels;
KIRP	trans	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg06521331	chr12:34319734	NA	-0.5	-6.26	-0.37	1.74e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.28	14.58	0.68	4e-35	Eosinophil percentage of granulocytes;
KIRP	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.6	-0.39	2.54e-10	Triglycerides;
KIRP	cis	rs6450176	0.680	rs255756	chr5:53309364	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.18	-15.04	-0.69	1.07e-36	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.81e-31	Diabetic retinopathy;
KIRP	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg03808351	chr9:123631620	PHF19	0.41	5.51	0.33	8.99e-8	Rheumatoid arthritis;
KIRP	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	10.25	0.55	9.12e-21	Mood instability;
KIRP	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.74	10.89	0.57	8.3e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.6	5.8	0.35	2.05e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg15488143	chr7:128924101	AHCYL2	0.64	6.83	0.4	6.72e-11	White matter hyperintensity burden;
KIRP	cis	rs10214930	0.697	rs6462029	chr7:27581495	T/C	cg22168087	chr7:27702803	HIBADH	0.47	4.99	0.3	1.12e-6	Hypospadias;
KIRP	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20887711	chr4:1340912	KIAA1530	-0.45	-5.59	-0.34	5.97e-8	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08971769	chr10:75258327	USP54	0.5	6.13	0.36	3.54e-9	Interleukin-4 levels;
KIRP	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.73	-6.23	-0.37	1.96e-9	Body mass index;
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg07216194	chr8:27182965	PTK2B	0.45	5.51	0.33	9.1e-8	Neuroticism;
KIRP	cis	rs17123764	0.892	rs4641552	chr12:50047182	A/C	cg02054252	chr12:50078554	FMNL3	-0.47	-4.94	-0.3	1.46e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.51	-6.59	-0.39	2.66e-10	Adiposity;
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00802000	chr16:706648	WDR90	-0.39	-4.93	-0.3	1.52e-6	Height;
KIRP	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-8.85	-0.49	1.76e-16	Vitiligo;
KIRP	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16661579	chr10:95462206	C10orf4	0.47	6.14	0.36	3.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg15128208	chr22:42549153	NA	0.38	5.02	0.3	9.96e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs11264213	0.901	rs72661607	chr1:36331411	G/C	cg27506609	chr1:36549197	TEKT2	1.19	7.32	0.42	3.42e-12	Schizophrenia;
KIRP	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg00262122	chr8:11665843	FDFT1	-0.42	-5.23	-0.32	3.57e-7	Triglycerides;
KIRP	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	cis	rs367943	0.712	rs26964	chr5:112738532	T/C	cg12552261	chr5:112820674	MCC	0.56	6.56	0.39	3.21e-10	Type 2 diabetes;
KIRP	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.53	-5.5	-0.33	9.55e-8	Subjective well-being;
KIRP	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00376283	chr12:123451042	ABCB9	-0.66	-6.5	-0.38	4.45e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg12483005	chr1:23474871	LUZP1	-0.41	-4.85	-0.3	2.19e-6	Height;
KIRP	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.67	7.27	0.42	4.82e-12	Vitiligo;
KIRP	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.44	0.43	1.71e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs55962025	0.711	rs82333	chr4:3225389	C/T	cg06533319	chr4:3265114	C4orf44	-0.42	-5.35	-0.32	1.99e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7709377	0.570	rs6594938	chr5:115432472	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs2742417	1.000	rs2673058	chr3:45735618	A/C	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.81	-7.73	-0.44	2.75e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs60871478	0.898	rs34766380	chr7:786862	G/A	cg13798912	chr7:905769	UNC84A	0.6	5.92	0.35	1.07e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	6.41	0.38	7.41e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6540559	0.932	rs764093	chr1:209983331	A/G	cg25204440	chr1:209979598	IRF6	0.44	4.92	0.3	1.6e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.73	9.66	0.52	6.46e-19	Age at first birth;
KIRP	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.59	-7.75	-0.44	2.38e-13	Smoking behavior;
KIRP	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.86	11.61	0.6	3.78e-25	Triglycerides;
KIRP	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.43	5.3	0.32	2.57e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.23	0.46	1.1e-14	Lung cancer;
KIRP	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg09631192	chr20:23583594	CST9	-0.52	-5.2	-0.31	4.27e-7	Chronic kidney disease;
KIRP	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg23752985	chr2:85803571	VAMP8	-0.59	-8.67	-0.48	5.92e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6832769	1.000	rs12646078	chr4:56368204	T/C	cg05960024	chr4:56376020	CLOCK	0.7	8.77	0.49	3.08e-16	Personality dimensions;
KIRP	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.13	-0.46	2.06e-14	Monocyte percentage of white cells;
KIRP	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.55	7.53	0.43	9.33e-13	Colorectal cancer;
KIRP	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19623624	chr10:135278901	LOC619207	-0.53	-5.89	-0.35	1.25e-8	Systemic lupus erythematosus;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19737664	chr11:537435	LRRC56	0.51	6.69	0.39	1.53e-10	Smoking initiation;
KIRP	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.71	-0.44	3.1e-13	Retinal vascular caliber;
KIRP	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg03060546	chr3:49711283	APEH	-0.69	-6.0	-0.36	7.16e-9	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs8077577	0.689	rs62072543	chr17:18243872	G/A	cg18869244	chr17:18121946	NA	0.45	5.06	0.31	8.21e-7	Obesity-related traits;
KIRP	cis	rs2594989	0.779	rs2443702	chr3:11586435	C/T	cg01796438	chr3:11312864	ATG7	0.46	5.84	0.35	1.67e-8	Circulating chemerin levels;
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.26	-5.45	-0.33	1.23e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7077164	0.846	rs1227773	chr10:71579347	C/A	cg20696214	chr10:71583771	COL13A1	-0.41	-5.65	-0.34	4.32e-8	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-7.66	-0.44	4.39e-13	Gut microbiome composition (summer);
KIRP	cis	rs9912468	0.870	rs4433842	chr17:64322683	T/C	cg19474267	chr17:64306194	PRKCA	0.58	8.28	0.47	7.9e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs8028182	0.583	rs9944207	chr15:75912889	A/T	cg20655648	chr15:75932815	IMP3	0.59	7.43	0.43	1.79e-12	Sudden cardiac arrest;
KIRP	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs7246657	0.943	rs10404945	chr19:38022358	T/C	cg18154014	chr19:37997991	ZNF793	0.65	7.44	0.43	1.64e-12	Coronary artery calcification;
KIRP	cis	rs7246865	0.510	rs2305756	chr19:17169936	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.53	6.54	0.38	3.6e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.43	5.63	0.34	5.03e-8	Blood metabolite levels;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg24874828	chr4:187887005	NA	-0.5	-7.54	-0.43	8.92e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.21	-0.32	3.94e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3105593	1.000	rs12439744	chr15:50899211	C/T	cg08437265	chr15:50716283	USP8	0.39	4.93	0.3	1.5e-6	QT interval;
KIRP	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.33	5.2	0.31	4.11e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	4.99	0.3	1.16e-6	Diabetic retinopathy;
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg11168104	chr5:1857477	NA	-0.4	-5.19	-0.31	4.44e-7	Cardiovascular disease risk factors;
KIRP	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.0	-0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.79	11.45	0.59	1.26e-24	Parkinson's disease;
KIRP	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.6	-0.39	2.46e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg00677455	chr12:58241039	CTDSP2	0.98	12.65	0.63	1.36e-28	Multiple sclerosis;
KIRP	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.43	0.33	1.38e-7	Platelet count;
KIRP	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs258892	1.000	rs258886	chr5:72303788	A/T	cg21869765	chr5:72125136	TNPO1	-0.52	-6.34	-0.37	1.07e-9	Small cell lung carcinoma;
KIRP	cis	rs6800768	0.658	rs6764378	chr3:24114668	G/T	cg21910673	chr3:24143257	LOC152024	0.35	4.85	0.3	2.15e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.6	12.3	0.62	2.05e-27	Diabetic kidney disease;
KIRP	cis	rs4936894	0.500	rs4564350	chr11:124108910	T/C	cg27160556	chr11:124181099	OR8D1	-0.39	-5.81	-0.35	1.94e-8	Aging (time to death);
KIRP	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg03929089	chr4:120376271	NA	-0.69	-6.94	-0.4	3.54e-11	Axial length;
KIRP	cis	rs7223966	0.618	rs9906903	chr17:61634508	C/T	cg23903597	chr17:61704154	MAP3K3	-0.43	-5.26	-0.32	3.12e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3779635	0.742	rs17375764	chr8:27251051	T/C	cg18234130	chr8:27182889	PTK2B	0.56	7.28	0.42	4.37e-12	Neuroticism;
KIRP	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-0.84	-9.41	-0.51	3.71e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.61	-0.44	5.7e-13	Initial pursuit acceleration;
KIRP	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.82	13.41	0.65	3.93e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.78	-7.56	-0.43	7.77e-13	Coronary artery calcification;
KIRP	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.44	-5.43	-0.33	1.37e-7	Testicular germ cell tumor;
KIRP	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs879620	0.929	rs2238435	chr16:4014282	C/G	cg09300795	chr16:4042428	ADCY9	0.43	5.39	0.33	1.61e-7	Hip circumference;Body mass index;
KIRP	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg16586182	chr3:47516702	SCAP	-0.75	-10.78	-0.57	1.87e-22	Colorectal cancer;
KIRP	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.16e-16	Resting heart rate;
KIRP	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6545883	0.507	rs59981505	chr2:61580529	G/T	cg15711740	chr2:61764176	XPO1	0.43	5.19	0.31	4.3e-7	Tuberculosis;
KIRP	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg23587288	chr2:27483067	SLC30A3	-0.7	-7.4	-0.43	2.21e-12	Blood metabolite levels;
KIRP	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.06	0.46	3.23e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs1978968	0.763	rs8137857	chr22:18465616	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.78	-10.91	-0.57	7.07e-23	Presence of antiphospholipid antibodies;
KIRP	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.66	-10.19	-0.54	1.43e-20	Total body bone mineral density;
KIRP	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg10253484	chr15:75165896	SCAMP2	-0.53	-6.39	-0.38	8.07e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.71	8.71	0.49	4.49e-16	Neutrophil percentage of white cells;
KIRP	cis	rs4950322	0.571	rs4373796	chr1:146788460	C/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.6	-7.19	-0.42	7.77e-12	Initial pursuit acceleration;
KIRP	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg23845249	chr11:68861649	NA	0.6	8.76	0.49	3.31e-16	Blond vs. brown hair color;
KIRP	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-8.84	-0.49	1.84e-16	Total body bone mineral density;
KIRP	cis	rs3857747	0.827	rs4134194	chr7:40440560	A/G	cg00420559	chr7:40367873	C7orf10	0.55	7.72	0.44	2.97e-13	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg02336718	chr17:17403227	NA	-0.31	-4.87	-0.3	2e-6	Total body bone mineral density;
KIRP	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.0	-0.41	2.43e-11	Response to antipsychotic treatment;
KIRP	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.91	-0.66	7.57e-33	Primary sclerosing cholangitis;
KIRP	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	15.43	0.7	5.18e-38	Electrocardiographic conduction measures;
KIRP	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg17554472	chr22:41940697	POLR3H	0.64	6.63	0.39	2.1e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs735539	0.874	rs9579927	chr13:21270201	C/T	cg04906043	chr13:21280425	IL17D	0.56	7.4	0.43	2.19e-12	Dental caries;
KIRP	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg22117172	chr7:91764530	CYP51A1	-0.43	-6.03	-0.36	6e-9	Breast cancer;
KIRP	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg19875535	chr5:140030758	IK	-0.68	-9.76	-0.53	3.08e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg09888468	chr15:81410853	NA	-0.5	-6.75	-0.4	1.05e-10	QT interval (drug interaction);
KIRP	cis	rs72949976	0.678	rs7573232	chr2:214040425	C/T	cg08319019	chr2:214017104	IKZF2	-0.51	-5.44	-0.33	1.3e-7	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.23	-0.32	3.62e-7	Lung cancer;
KIRP	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.48	-6.09	-0.36	4.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs7712401	0.601	rs246265	chr5:122254950	C/T	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg05347473	chr6:146136440	FBXO30	0.56	8.05	0.46	3.63e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9462846	0.652	rs115953673	chr6:42906243	T/A	cg02353165	chr6:42928485	GNMT	0.64	7.21	0.42	6.91e-12	Blood protein levels;
KIRP	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg24315340	chr6:146058215	EPM2A	0.41	5.12	0.31	6.27e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1165472	0.806	rs67547117	chr1:56148536	A/G	cg11523071	chr1:56160889	NA	-0.64	-8.22	-0.46	1.14e-14	Paclitaxel-induced neuropathy;
KIRP	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.68	-0.34	3.84e-8	Ulcerative colitis;
KIRP	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17507749	chr15:85114479	UBE2QP1	0.68	7.59	0.44	6.6e-13	Schizophrenia;
KIRP	cis	rs17020663	0.713	rs73943418	chr2:101640637	T/C	cg12594615	chr2:101643137	TBC1D8	-0.34	-4.95	-0.3	1.39e-6	Pulse pressure;
KIRP	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg10932868	chr11:921992	NA	0.58	7.33	0.42	3.21e-12	Alzheimer's disease (late onset);
KIRP	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17376030	chr22:41985996	PMM1	-0.44	-5.28	-0.32	2.84e-7	Vitiligo;
KIRP	cis	rs4950322	0.570	rs77118461	chr1:146792436	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.8	8.89	0.49	1.37e-16	Cognitive test performance;
KIRP	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.81	-6.89	-0.4	4.55e-11	Obesity-related traits;
KIRP	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg18261050	chr1:119551319	NA	0.51	6.7	0.39	1.38e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg04681579	chr7:75027559	TRIM73;TRIM74	0.74	9.58	0.52	1.13e-18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg07451762	chr16:28383216	NA	0.38	5.06	0.31	8.23e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11877825	0.826	rs9676161	chr18:10571439	G/A	cg07277756	chr18:10589357	NA	0.51	6.17	0.37	2.84e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06647332	chr5:131281008	NA	0.45	4.97	0.3	1.27e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4281086	0.587	rs56225449	chr8:10365181	C/T	cg01072821	chr8:10382165	T-SP1	-0.36	-5.06	-0.31	8.09e-7	Obesity-related traits;
KIRP	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.37	6.71	0.39	1.32e-10	Refractive error;
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg09163369	chr1:210001066	C1orf107	-0.48	-6.01	-0.36	6.78e-9	Orofacial clefts;
KIRP	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.04e-9	Depression;
KIRP	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.64	8.99	0.5	6.77e-17	Schizophrenia;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02593601	chr10:17707418	STAM	0.43	6.24	0.37	1.94e-9	Migraine with aura;
KIRP	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6701037	0.875	rs6929	chr1:175126721	A/G	cg17845761	chr1:175162550	KIAA0040	-0.3	-5.55	-0.33	7.31e-8	Alcohol dependence;
KIRP	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	6.24	0.37	1.88e-9	Retinal vascular caliber;
KIRP	cis	rs10073892	0.664	rs10051203	chr5:101885772	C/T	cg19774478	chr5:101632501	SLCO4C1	0.6	5.86	0.35	1.49e-8	Cognitive decline (age-related);
KIRP	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.44	7.21	0.42	6.83e-12	Testicular germ cell tumor;
KIRP	cis	rs2483058	0.767	rs2336938	chr1:206618799	A/C	cg19452316	chr1:206680966	RASSF5	0.41	5.52	0.33	8.64e-8	Cholesterol and Triglycerides;
KIRP	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs35661897	0.920	rs12478549	chr2:227329662	T/A	cg03426602	chr2:227312417	NA	-0.57	-6.99	-0.41	2.6e-11	Urinary tract infection frequency;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13850887	chr2:241993303	SNED1	0.58	6.9	0.4	4.42e-11	Interleukin-4 levels;
KIRP	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.21	-0.37	2.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12472274	0.529	rs11677996	chr2:239118007	A/G	cg17459225	chr2:239074497	NA	0.83	8.83	0.49	2.07e-16	Phospholipid levels (plasma);
KIRP	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg24203234	chr3:128598194	ACAD9	0.42	4.86	0.3	2.14e-6	IgG glycosylation;
KIRP	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.35	9.02	0.5	5.38e-17	Crohn's disease;
KIRP	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.66	-9.83	-0.53	1.88e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22819824	chr10:115618670	NHLRC2	-0.42	-6.07	-0.36	4.74e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.66	-7.63	-0.44	5.14e-13	Pancreatic cancer;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.61	5.48	0.33	1.03e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.71	11.08	0.58	2.1e-23	Coronary artery disease;
KIRP	cis	rs8141529	0.600	rs16986838	chr22:29312578	C/T	cg02153584	chr22:29168773	CCDC117	0.62	6.1	0.36	4e-9	Lymphocyte counts;
KIRP	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-0.76	-8.97	-0.5	7.49e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg10505658	chr17:80084571	CCDC57	-0.26	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs6540559	0.740	rs2064163	chr1:210048819	G/T	cg22029157	chr1:209979665	IRF6	0.49	6.08	0.36	4.65e-9	Cleft lip with or without cleft palate;
KIRP	cis	rs332034	0.546	rs28481744	chr8:8696346	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-4.92	-0.3	1.56e-6	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.94	10.92	0.57	6.58e-23	Cognitive ability;
KIRP	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.54	-7.41	-0.43	1.97e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.77	-9.91	-0.53	1.08e-19	Longevity;Endometriosis;
KIRP	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.69	8.52	0.48	1.61e-15	Multiple sclerosis;
KIRP	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	9.28	0.51	9.29e-18	Smoking behavior;
KIRP	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.27	5.48	0.33	1.05e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg17211192	chr8:82754475	SNX16	-0.76	-8.59	-0.48	1.02e-15	Diastolic blood pressure;
KIRP	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg03260781	chr1:16346299	HSPB7	-0.31	-4.96	-0.3	1.29e-6	Systolic blood pressure;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg01866064	chr20:18487951	SEC23B	-0.46	-6.29	-0.37	1.46e-9	Morning vs. evening chronotype;
KIRP	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.7	6.33	0.37	1.15e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-8.64	-0.48	7.42e-16	Morning vs. evening chronotype;
KIRP	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.6	-7.0	-0.41	2.49e-11	Menopause (age at onset);
KIRP	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.52	-7.56	-0.43	7.95e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.46	5.51	0.33	9.24e-8	Resistin levels;
KIRP	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.39e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.57	-9.41	-0.51	3.71e-18	Prostate cancer;
KIRP	cis	rs6430538	0.621	rs2156003	chr2:135569248	C/A	cg12500956	chr2:135428796	TMEM163	0.42	5.28	0.32	2.83e-7	Parkinson's disease;
KIRP	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg22138327	chr13:27999177	GTF3A	0.79	9.0	0.5	6.24e-17	Weight;
KIRP	trans	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg10756647	chr7:56101905	PSPH	1.09	8.64	0.48	7.48e-16	Diabetic kidney disease;
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.57	-8.4	-0.47	3.71e-15	Renal function-related traits (BUN);
KIRP	trans	rs13170463	0.579	rs13173637	chr5:8041532	G/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.7.83698262R	chr7:83860326	NA	0.46	6.38	0.38	8.75e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg22508957	chr16:3507546	NAT15	0.57	7.17	0.42	8.48e-12	Tuberculosis;
KIRP	trans	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.34	-0.37	1.09e-9	Bladder cancer;
KIRP	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.71	8.05	0.46	3.47e-14	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15541040	chr2:3486749	NA	-0.44	-5.21	-0.32	3.96e-7	Neurofibrillary tangles;
KIRP	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg06740227	chr12:86229804	RASSF9	0.47	6.05	0.36	5.4e-9	Major depressive disorder;
KIRP	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.39	10.58	0.56	8.2e-22	Prostate cancer;
KIRP	cis	rs882732	1.000	rs10139277	chr14:95035060	C/T	cg05186455	chr14:95027692	SERPINA4	-0.36	-5.26	-0.32	3.18e-7	Blood protein levels;
KIRP	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	8.27	0.47	8.31e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05203659	chr16:12009378	GSPT1	0.48	6.04	0.36	5.62e-9	Parkinson's disease;
KIRP	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-9.25	-0.51	1.09e-17	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14538441	chr4:89444921	PIGY	0.48	6.15	0.37	3.12e-9	Parkinson's disease;
KIRP	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.86	11.71	0.6	1.78e-25	Coronary artery disease or large artery stroke;
KIRP	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg08885076	chr2:99613938	TSGA10	0.59	10.17	0.54	1.71e-20	Chronic sinus infection;
KIRP	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-1.04	-12.94	-0.64	1.49e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs930036	0.602	rs3755125	chr2:171782864	A/G	cg12801329	chr2:171670795	NA	0.46	5.24	0.32	3.52e-7	Menopause (age at onset);
KIRP	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-7.07	-0.41	1.56e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7116495	1.000	rs17161966	chr11:71815308	T/C	cg18441811	chr11:71824068	C11orf51	0.6	4.87	0.3	2.01e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs1958560	0.932	rs61987993	chr14:66070732	C/G	cg03016385	chr14:66212404	NA	-0.55	-6.76	-0.4	9.94e-11	Menarche (age at onset);
KIRP	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg02023728	chr11:77925099	USP35	-0.32	-5.6	-0.34	5.84e-8	Alzheimer's disease (survival time);
KIRP	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.51	-0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs12210905	1.000	rs3800310	chr6:27206843	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.43	-0.38	6.73e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg16141378	chr3:129829833	LOC729375	0.53	6.53	0.38	3.75e-10	Mood instability;
KIRP	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg02023728	chr11:77925099	USP35	0.32	5.41	0.33	1.46e-7	Alzheimer's disease (survival time);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24449302	chr15:66679100	MAP2K1	0.47	6.48	0.38	4.84e-10	Parkinson's disease;
KIRP	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg23682824	chr7:23144976	KLHL7	0.45	5.13	0.31	5.89e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs35123781	1.000	rs35123781	chr5:139065180	A/G	cg10513866	chr5:139070639	NA	0.35	4.97	0.3	1.23e-6	Schizophrenia;
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg06871246	chr4:1363661	KIAA1530	-0.37	-4.89	-0.3	1.86e-6	Obesity-related traits;
KIRP	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg18657303	chr4:1051139	NA	0.55	5.1	0.31	6.64e-7	Recombination rate (females);
KIRP	trans	rs6506900	0.692	rs8091579	chr18:28902080	C/T	cg10906284	chr12:63544430	AVPR1A	0.37	6.03	0.36	5.83e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00933542	chr6:150070202	PCMT1	0.31	6.11	0.36	3.79e-9	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06047828	chr6:15245231	JARID2	0.49	6.06	0.36	5.15e-9	Parkinson's disease;
KIRP	cis	rs74181299	0.964	rs2723065	chr2:65279414	A/G	cg05010058	chr2:65284262	CEP68	0.45	6.4	0.38	7.88e-10	Pulse pressure;
KIRP	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12580194	0.593	rs73326725	chr12:55749222	G/C	cg19537932	chr12:55886519	OR6C68	-0.5	-6.47	-0.38	5.14e-10	Cancer;
KIRP	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg16797656	chr11:68205561	LRP5	0.4	5.41	0.33	1.48e-7	Total body bone mineral density;
KIRP	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg15556689	chr8:8085844	FLJ10661	0.65	8.61	0.48	9.1e-16	Mood instability;
KIRP	cis	rs4925114	0.568	rs941448	chr17:17654542	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.52	-6.52	-0.38	3.9e-10	Body mass index;
KIRP	cis	rs740160	0.571	rs60577432	chr7:99017281	G/A	cg12290671	chr7:99195819	NA	-0.7	-5.11	-0.31	6.32e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs526231	0.575	rs66730942	chr5:102306779	G/C	cg23492399	chr5:102201601	PAM	-0.49	-5.39	-0.32	1.68e-7	Primary biliary cholangitis;
KIRP	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg04132472	chr17:19861366	AKAP10	0.42	5.81	0.35	1.97e-8	Schizophrenia;
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.64	-9.38	-0.51	4.5e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs5750854	0.503	rs742159	chr22:40024768	C/A	cg10455938	chr22:40058150	CACNA1I	0.41	5.78	0.35	2.26e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.91	-15.93	-0.71	9.69e-40	Ulcerative colitis;
KIRP	cis	rs1832871	0.655	rs4273715	chr6:158722847	T/C	cg07215822	chr6:158701037	NA	-0.65	-7.45	-0.43	1.63e-12	Height;
KIRP	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.95	0.57	5.61e-23	Bladder cancer;
KIRP	cis	rs494562	0.892	rs521005	chr6:86116542	A/G	cg21730993	chr6:86159210	NT5E	0.56	5.32	0.32	2.37e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.42	5.79	0.35	2.19e-8	Coronary artery disease;
KIRP	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00585698	chr12:123750864	CDK2AP1	0.5	5.04	0.31	8.94e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.59	-6.71	-0.39	1.32e-10	Menarche (age at onset);
KIRP	cis	rs13102973	0.965	rs11731021	chr4:135850391	G/T	cg14419869	chr4:135874104	NA	0.52	8.6	0.48	9.21e-16	Subjective well-being;
KIRP	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.55	7.66	0.44	4.14e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.64	0.52	7.44e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25770397	chr18:61034583	KDSR	0.53	6.41	0.38	7.3e-10	Parkinson's disease;
KIRP	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.6	-7.98	-0.45	5.68e-14	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.75	7.28	0.42	4.54e-12	Axial length;
KIRP	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	11.49	0.59	9.79e-25	Lung cancer in ever smokers;
KIRP	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.52	-5.81	-0.35	1.88e-8	Corneal structure;
KIRP	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs580438	0.510	rs6795149	chr3:13390740	T/G	cg10657019	chr3:13328039	NA	-0.6	-7.82	-0.45	1.5700000000000001e-13	Myringotomy;
KIRP	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.23	0.46	1.12e-14	Obesity-related traits;
KIRP	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg19402173	chr7:128379420	CALU	-0.63	-8.2	-0.46	1.32e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg23748340	chr12:48592721	NA	-0.43	-4.94	-0.3	1.47e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.17	-0.42	9e-12	Response to antipsychotic treatment;
KIRP	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9469913	0.674	rs2744965	chr6:34589632	C/T	cg17674042	chr6:34482479	PACSIN1	-0.5	-6.53	-0.38	3.65e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs10936602	0.527	rs9814802	chr3:169532377	A/G	cg08193579	chr3:169529701	LRRC34	0.33	4.87	0.3	2.03e-6	Renal cell carcinoma;
KIRP	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg11945507	chr8:142233382	SLC45A4	-0.92	-15.97	-0.71	7.01e-40	Immature fraction of reticulocytes;
KIRP	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.56	8.98	0.5	7e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.43	-5.29	-0.32	2.69e-7	Neurofibrillary tangles;
KIRP	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.49	6.32	0.37	1.2e-9	Blood metabolite levels;
KIRP	trans	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.51	6.04	0.36	5.55e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg13293535	chr8:11597251	GATA4	0.37	5.01	0.3	1.05e-6	Triglycerides;
KIRP	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg02527881	chr3:46936655	PTH1R	-0.39	-5.59	-0.34	5.92e-8	Colorectal cancer;
KIRP	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.58	7.99	0.45	5.14e-14	Height;
KIRP	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg13962347	chr6:5174647	LYRM4	-0.61	-8.33	-0.47	5.67e-15	Height;
KIRP	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg24250549	chr1:154909240	PMVK	-0.47	-6.12	-0.36	3.67e-9	Prostate cancer;
KIRP	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.51	-5.41	-0.33	1.46e-7	Chronic sinus infection;
KIRP	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.14	16.52	0.73	9.43e-42	Breast cancer;
KIRP	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	9.31	0.51	7.65e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg09264619	chr17:80180166	NA	-0.39	-5.64	-0.34	4.6e-8	Life satisfaction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02932390	chr22:26879615	HPS4;SRRD	-0.53	-6.55	-0.39	3.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2425143	1.000	rs11700256	chr20:34372941	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-4.95	-0.3	1.39e-6	Blood protein levels;
KIRP	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg01304814	chr3:48885189	PRKAR2A	0.6	5.35	0.32	1.99e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.6	-8.05	-0.46	3.59e-14	Asthma;
KIRP	cis	rs6921919	0.583	rs1591913	chr6:28351728	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.35	-0.38	1.05e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.37	-0.43	2.62e-12	Retinal vascular caliber;
KIRP	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18252515	chr7:66147081	NA	0.44	5.11	0.31	6.49e-7	Aortic root size;
KIRP	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.68	10.98	0.57	4.22e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg22031999	chr2:109407014	CCDC138	0.32	4.87	0.3	2.01e-6	Beard thickness;
KIRP	trans	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.28	-0.32	2.77e-7	Life satisfaction;
KIRP	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg03563238	chr19:33554763	RHPN2	-0.29	-4.85	-0.3	2.17e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.5	6.05	0.36	5.46e-9	Coronary artery disease;
KIRP	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.64	8.47	0.47	2.33e-15	Platelet count;
KIRP	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.92	-8.13	-0.46	2.17e-14	Obesity-related traits;
KIRP	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.92	15.2	0.7	3.14e-37	Metabolic syndrome;
KIRP	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.82	11.71	0.6	1.86e-25	Monocyte count;
KIRP	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.73	-0.53	3.8e-19	Hemoglobin concentration;
KIRP	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26207909	chr14:103986467	CKB	0.74	10.61	0.56	6.71e-22	Body mass index;
KIRP	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16083429	chr3:49237500	CCDC36	-0.4	-4.98	-0.3	1.21e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg20673091	chr1:2541236	MMEL1	0.67	10.05	0.54	3.8e-20	Ulcerative colitis;
KIRP	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.99	-16.13	-0.72	1.97e-40	Monocyte count;
KIRP	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.29	-0.47	7.63e-15	Mood instability;
KIRP	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-1.09	-21.75	-0.81	3.21e-59	Height;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.89	-13.8	-0.66	1.81e-32	Height;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.57	-6.63	-0.39	2.16e-10	Menopause (age at onset);
KIRP	cis	rs11585357	0.501	rs72646775	chr1:17592121	T/C	cg08277548	chr1:17600880	PADI3	-0.61	-5.02	-0.3	1.01e-6	Hair shape;
KIRP	cis	rs9815354	1.000	rs1716690	chr3:41922102	T/G	cg03022575	chr3:42003672	ULK4	-0.48	-5.34	-0.32	2.09e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs78487399	0.808	rs75386849	chr2:43723283	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.14	-0.31	5.69e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.82	-8.89	-0.49	1.3e-16	Asthma;
KIRP	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	cg12689670	chr1:183009347	LAMC1	-0.43	-6.17	-0.37	2.74e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08535148	chr4:26321143	RBPJ	0.49	6.05	0.36	5.44e-9	Parkinson's disease;
KIRP	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg05370193	chr1:21551575	ECE1	-0.42	-6.04	-0.36	5.78e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.85	12.01	0.61	1.89e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.68	-0.34	3.75e-8	Cholesterol, total;
KIRP	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg19875535	chr5:140030758	IK	0.56	6.97	0.41	2.85e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8113308	1.000	rs6509600	chr19:52442589	G/T	cg25782003	chr19:52490127	ZNF350	0.54	5.45	0.33	1.21e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs1858037	0.836	rs1396209	chr2:65601234	A/G	cg08085232	chr2:65598271	SPRED2	-0.54	-6.49	-0.38	4.78e-10	Rheumatoid arthritis;
KIRP	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg04990556	chr1:26633338	UBXN11	-0.62	-7.71	-0.44	3.12e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.98e-14	Body mass index;
KIRP	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.64	10.12	0.54	2.44e-20	Bone mineral density;
KIRP	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.77	0.34	2.44e-8	Birth weight;
KIRP	cis	rs71277158	0.688	rs9757709	chr3:169906407	T/G	cg04067573	chr3:169899625	PHC3	0.69	6.48	0.38	4.97e-10	Prostate cancer;
KIRP	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.84	-0.35	1.62e-8	Breast cancer;
KIRP	trans	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg06521331	chr12:34319734	NA	-0.48	-6.05	-0.36	5.46e-9	Bladder cancer;
KIRP	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.14e-21	Alzheimer's disease (late onset);
KIRP	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg26681399	chr22:41777847	TEF	0.53	5.21	0.32	4.08e-7	Vitiligo;
KIRP	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.43	5.38	0.32	1.74e-7	Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25908613	chr15:25436246	SNORD115-9;SNORD115-10;SNORD115-12;SNORD115-5	0.45	6.65	0.39	1.91e-10	Survival in pancreatic cancer;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	7.84	0.45	1.34e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	1.0	10.04	0.54	4.34e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	10.8	0.57	1.68e-22	Electrocardiographic conduction measures;
KIRP	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	6.02	0.36	6.43e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17401966	0.540	rs11121566	chr1:10472848	C/G	cg19773385	chr1:10388646	KIF1B	-0.45	-6.47	-0.38	5.18e-10	Hepatocellular carcinoma;
KIRP	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.31	0.55	6.2e-21	Parkinson's disease;
KIRP	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg06204229	chr3:52865917	ITIH4	0.56	6.56	0.39	3.2e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg10223061	chr2:219282414	VIL1	0.3	4.86	0.3	2.06e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10073892	0.620	rs62369727	chr5:101924235	A/C	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.2	-0.42	7.35e-12	Morning vs. evening chronotype;
KIRP	cis	rs11264213	0.901	rs682686	chr1:36443778	T/A	cg27506609	chr1:36549197	TEKT2	0.97	10.16	0.54	1.81e-20	Schizophrenia;
KIRP	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.66	-8.86	-0.49	1.69e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs9943753	0.508	rs11066422	chr12:109807153	A/G	cg19025524	chr12:109796872	NA	-0.46	-6.32	-0.37	1.25e-9	HDL cholesterol;
KIRP	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-6.9	-0.4	4.31e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg01689657	chr7:91764605	CYP51A1	0.42	6.21	0.37	2.21e-9	Breast cancer;
KIRP	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.76	-9.09	-0.5	3.38e-17	Pancreatic cancer;
KIRP	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4400599	1.000	rs4400599	chr1:154127100	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.39	-5.54	-0.33	7.8e-8	Platelet distribution width;
KIRP	cis	rs6691722	0.543	rs12034846	chr1:24699589	G/A	cg18323236	chr1:24743029	NIPAL3	0.46	6.74	0.39	1.12e-10	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs7007076	0.634	rs971649	chr8:124732275	C/G	cg00283535	chr8:124749564	ANXA13	-0.77	-8.68	-0.48	5.58e-16	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg07216194	chr8:27182965	PTK2B	0.43	5.3	0.32	2.59e-7	Neuroticism;
KIRP	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3789045	1.000	rs3747631	chr1:204587569	G/C	cg17419461	chr1:204415978	PIK3C2B	-0.54	-5.42	-0.33	1.42e-7	Educational attainment (college completion);
KIRP	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs12220238	0.722	rs7921187	chr10:76377501	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.94	0.35	9.84e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.5	-0.33	9.73e-8	IgG glycosylation;
KIRP	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.75	-11.01	-0.57	3.54e-23	Heart rate;
KIRP	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg26727032	chr16:67993705	SLC12A4	-0.65	-5.41	-0.33	1.48e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg12598211	chr12:123634384	NA	0.41	5.05	0.31	8.61e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7681423	1.000	rs7654093	chr4:155545072	A/T	cg20735720	chr4:155535218	FGG	-0.65	-8.51	-0.48	1.69e-15	Fibrinogen;
KIRP	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07570687	chr10:102243282	WNT8B	0.51	6.61	0.39	2.32e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg15448220	chr1:150897856	SETDB1	0.38	5.03	0.31	9.6e-7	Melanoma;
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg26174226	chr8:58114915	NA	-0.56	-6.35	-0.38	1.03e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.57	-0.63	2.59e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.78	-7.04	-0.41	1.86e-11	Platelet count;
KIRP	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	9.16	0.5	2.05e-17	Lymphocyte counts;
KIRP	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg17595323	chr11:93583763	C11orf90	-0.38	-6.42	-0.38	7e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.47	-5.91	-0.35	1.11e-8	Post bronchodilator FEV1;
KIRP	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg02002194	chr4:3960332	NA	-0.45	-6.36	-0.38	9.56e-10	Neuroticism;
KIRP	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs832187	0.813	rs704370	chr3:63868250	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.45	5.25	0.32	3.37e-7	Schizophrenia;
KIRP	cis	rs6539288	0.803	rs7305715	chr12:107326552	G/A	cg21360079	chr12:107162445	NA	-0.38	-5.01	-0.3	1.02e-6	Total body bone mineral density;
KIRP	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg05692746	chr2:100937584	LONRF2	-0.39	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.41	0.38	7.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14315805	chr8:31498947	NRG1	0.39	6.48	0.38	5.1e-10	Survival in pancreatic cancer;
KIRP	cis	rs2574975	0.679	rs2688875	chr10:52131032	G/A	cg10034176	chr10:52120283	SGMS1	-0.52	-6.88	-0.4	5.06e-11	Response to amphetamines;
KIRP	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.04	-0.31	8.83e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.78	11.51	0.59	8.55e-25	Type 2 diabetes;
KIRP	cis	rs889398	0.967	rs35967356	chr16:69581354	C/T	cg09409435	chr16:70099608	PDXDC2	-0.43	-5.09	-0.31	7.16e-7	Body mass index;
KIRP	cis	rs4663866	1.000	rs13033501	chr2:239181860	G/A	cg16914508	chr2:239161102	PER2	0.71	5.2	0.31	4.11e-7	Irritable bowel syndrome;
KIRP	cis	rs524023	0.914	rs80841	chr11:64437490	T/C	cg09231725	chr11:64357281	SLC22A12	0.61	8.03	0.46	3.98e-14	Urate levels in obese individuals;
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.51	-0.48	1.75e-15	Life satisfaction;
KIRP	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.74	8.29	0.47	7.27e-15	Corneal astigmatism;
KIRP	cis	rs830233	0.732	rs62383300	chr5:165435915	G/A	cg13976338	chr5:165423657	NA	-0.73	-7.98	-0.45	5.68e-14	QT interval (sulfonylurea treatment interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11049075	chr17:42199063	HDAC5	-0.38	-6.14	-0.36	3.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-32.82	-0.9	7.76e-92	Myeloid white cell count;
KIRP	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs13102973	0.640	rs13140829	chr4:135838818	T/C	cg14419869	chr4:135874104	NA	0.5	8.26	0.47	9.05e-15	Subjective well-being;
KIRP	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg18944383	chr4:111397179	ENPEP	0.44	7.05	0.41	1.77e-11	Coronary artery disease;
KIRP	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg17077180	chr1:38461687	NA	0.41	5.68	0.34	3.76e-8	Coronary artery disease;
KIRP	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.81	-0.4	7.46e-11	Joint mobility (Beighton score);
KIRP	trans	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.47	-0.38	5.33e-10	Neuroticism;
KIRP	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.88	0.53	1.29e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.98	-0.45	5.58e-14	Retinal vascular caliber;
KIRP	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.72	-0.44	2.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-8.65	-0.48	6.69e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-9.64	-0.52	7.17e-19	Total body bone mineral density;
KIRP	cis	rs3008706	0.790	rs2987040	chr9:16002275	G/C	cg14451791	chr9:16040625	NA	-0.49	-4.98	-0.3	1.21e-6	Bilirubin levels;
KIRP	cis	rs9863706	0.957	rs55877382	chr3:72455273	A/C	cg05607079	chr3:72387937	NA	0.43	4.98	0.3	1.22e-6	Height;
KIRP	cis	rs904251	0.523	rs9369005	chr6:37483109	A/G	cg01843034	chr6:37503916	NA	-0.96	-14.7	-0.68	1.55e-35	Cognitive performance;
KIRP	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	0.97	13.77	0.66	2.3e-32	Total cholesterol levels;
KIRP	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg18815343	chr6:28367644	ZSCAN12	0.45	6.41	0.38	7.31e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg08755490	chr11:65554678	OVOL1	0.38	5.4	0.33	1.58e-7	Acne (severe);
KIRP	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-7.01	-0.41	2.31e-11	Eye color traits;
KIRP	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.65	8.06	0.46	3.24e-14	Schizophrenia;
KIRP	cis	rs2625529	0.590	rs3803471	chr15:72500786	A/G	cg16672083	chr15:72433130	SENP8	-0.47	-5.69	-0.34	3.6e-8	Red blood cell count;
KIRP	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.6	-7.96	-0.45	6.46e-14	Hip circumference;
KIRP	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-7.21	-0.42	6.88e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.09	-0.31	7.12e-7	IgG glycosylation;
KIRP	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg26875137	chr12:53738046	NA	-0.38	-5.29	-0.32	2.7e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.62	-7.55	-0.43	8.63e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.75	-0.44	2.42e-13	Retinal vascular caliber;
KIRP	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.8	10.38	0.55	3.63e-21	Breast cancer;
KIRP	cis	rs151997	1.000	rs32483	chr5:50205230	C/T	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.19	-0.67	8.56e-34	Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03705947	chr1:68152081	GADD45A	0.64	7.7	0.44	3.35e-13	Smoking initiation;
KIRP	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26207909	chr14:103986467	CKB	0.56	7.51	0.43	1.06e-12	Body mass index;
KIRP	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.51	7.74	0.44	2.57e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24802351	chr5:139944046	APBB3;SLC35A4	0.55	7.36	0.42	2.74e-12	Parkinson's disease;
KIRP	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.54	-4.97	-0.3	1.28e-6	Yeast infection;
KIRP	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.84	-12.27	-0.62	2.59e-27	Eye color traits;
KIRP	cis	rs16828019	0.852	rs34979067	chr1:41543084	G/A	cg03387723	chr1:41708464	SCMH1	-0.75	-6.67	-0.39	1.68e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs253959	0.545	rs712579	chr5:115650536	A/C	cg23108291	chr5:115420582	COMMD10	-0.52	-5.93	-0.35	1.01e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg20737812	chr15:86336631	KLHL25	-0.54	-6.96	-0.41	3.13e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.63	-7.0	-0.41	2.39e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs16957091	0.647	rs8026776	chr15:43072559	A/T	cg24196017	chr15:43021976	CDAN1	-0.39	-4.91	-0.3	1.69e-6	MGMT methylation in smokers;
KIRP	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.59	-6.18	-0.37	2.59e-9	Chronic sinus infection;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg03653399	chr8:142233436	SLC45A4	-0.94	-14.68	-0.68	1.89e-35	Immature fraction of reticulocytes;
KIRP	cis	rs6968419	0.708	rs57321537	chr7:115883453	T/G	cg02561103	chr7:115862891	TES	-0.43	-6.15	-0.36	3.16e-9	Intraocular pressure;
KIRP	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.02	-13.14	-0.64	3.02e-30	Lung cancer in ever smokers;
KIRP	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg00800038	chr16:89945340	TCF25	-0.69	-6.97	-0.41	2.84e-11	Skin colour saturation;
KIRP	cis	rs6959887	0.855	rs78661208	chr7:35299016	G/C	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs2802372	0.616	rs1250545	chr10:81032817	G/C	cg18688392	chr10:81059414	ZMIZ1	-0.42	-5.52	-0.33	8.5e-8	Granulocyte count;
KIRP	cis	rs6684428	1.000	rs7540772	chr1:56375368	C/G	cg11651538	chr1:56320950	NA	-0.8	-9.92	-0.53	1.03e-19	Airflow obstruction;
KIRP	cis	rs918629	0.567	rs3777204	chr5:95234350	A/G	cg16656078	chr5:95278638	ELL2	-0.36	-5.51	-0.33	8.97e-8	IgG glycosylation;
KIRP	cis	rs4356975	0.563	rs4292394	chr4:69972949	C/G	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.45	-6.87	-0.4	5.27e-11	Coronary artery disease;
KIRP	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.65	9.44	0.52	2.9e-18	Schizophrenia;
KIRP	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg19899395	chr1:46959349	NA	0.43	5.28	0.32	2.79e-7	Monobrow;
KIRP	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.58	4.96	0.3	1.31e-6	Initial pursuit acceleration;
KIRP	cis	rs514024	0.729	rs2256139	chr9:130486915	T/C	cg13643465	chr9:130375613	STXBP1	0.42	5.62	0.34	5.23e-8	Eating disorders (purging via substances);
KIRP	cis	rs2224391	0.534	rs2753229	chr6:5246633	T/C	cg13962347	chr6:5174647	LYRM4	-0.74	-10.1	-0.54	2.65e-20	Height;
KIRP	cis	rs2275565	0.872	rs7525347	chr1:237022420	T/G	cg17297354	chr1:237056641	MTR	-0.39	-5.05	-0.31	8.52e-7	Homocysteine levels;
KIRP	cis	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg21696256	chr3:125484277	NA	-0.44	-4.84	-0.3	2.24e-6	Blood pressure (smoking interaction);
KIRP	cis	rs6997458	0.785	rs713488	chr8:86342216	T/C	cg02393479	chr8:86352350	CA3	-0.32	-4.95	-0.3	1.36e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26617929	chr16:1858877	NA	-0.66	-5.44	-0.33	1.28e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19346786	chr7:2764209	NA	0.34	6.0	0.36	7.15e-9	Height;
KIRP	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.56	6.68	0.39	1.61e-10	Obesity-related traits;
KIRP	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.75	-9.86	-0.53	1.54e-19	Huntington's disease progression;
KIRP	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.7	7.66	0.44	4.32e-13	Response to bleomycin (chromatid breaks);
KIRP	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg25482853	chr8:67687455	SGK3	0.8	7.02	0.41	2.14e-11	Obesity-related traits;
KIRP	cis	rs10517025	0.673	rs73235560	chr4:42419712	T/C	cg11065575	chr4:42403471	SHISA3	0.44	4.88	0.3	1.89e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg15733309	chr7:157513707	PTPRN2	0.59	8.91	0.49	1.14e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg14458575	chr2:238380390	NA	0.49	5.32	0.32	2.3e-7	Prostate cancer;
KIRP	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg08600765	chr20:34638493	LOC647979	-0.71	-6.27	-0.37	1.63e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	1.0	10.15	0.54	1.88e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	-0.4	-4.94	-0.3	1.46e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg08318506	chr11:34938348	PDHX;APIP	-0.39	-4.85	-0.3	2.15e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4262150	0.883	rs72799201	chr5:152191995	C/T	cg12297329	chr5:152029980	NA	-0.63	-8.1	-0.46	2.54e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs6968419	0.747	rs1004109	chr7:115862296	A/T	cg02561103	chr7:115862891	TES	0.4	5.79	0.35	2.16e-8	Intraocular pressure;
KIRP	cis	rs829661	0.947	rs829575	chr2:30680633	G/T	cg10949345	chr2:30726833	LCLAT1	-0.74	-10.34	-0.55	4.88e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.73	7.05	0.41	1.84e-11	Multiple sclerosis;
KIRP	cis	rs2411233	1.000	rs9920185	chr15:39273575	C/A	cg19287857	chr15:39890699	NA	0.37	5.08	0.31	7.41e-7	Platelet count;
KIRP	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg14993813	chr1:46806288	NSUN4	-0.57	-6.19	-0.37	2.47e-9	Menopause (age at onset);
KIRP	cis	rs4363385	0.574	rs4845503	chr1:152959939	A/G	cg25856811	chr1:152973957	SPRR3	-0.37	-5.16	-0.31	5.08e-7	Inflammatory skin disease;
KIRP	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg11503966	chr20:62272292	STMN3	-0.41	-5.91	-0.35	1.16e-8	Atopic dermatitis;
KIRP	cis	rs6832769	0.767	rs11133394	chr4:56383238	C/T	cg09317128	chr4:56265301	TMEM165	0.48	6.29	0.37	1.47e-9	Personality dimensions;
KIRP	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.29	-0.32	2.68e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.74	-0.39	1.14e-10	Morning vs. evening chronotype;
KIRP	cis	rs1107366	0.513	rs10934761	chr3:125973585	G/T	cg01346077	chr3:125931526	NA	0.43	6.59	0.39	2.63e-10	Metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18781764	chr13:48611842	NUDT15	0.5	6.42	0.38	7.04e-10	Parkinson's disease;
KIRP	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg26695010	chr11:65641043	EFEMP2	0.5	4.99	0.3	1.12e-6	Crohn's disease;
KIRP	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg00405596	chr8:11794950	NA	0.39	4.94	0.3	1.43e-6	Morning vs. evening chronotype;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg00684032	chr4:1343700	KIAA1530	0.55	7.41	0.43	2e-12	Obesity-related traits;
KIRP	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	11.24	0.58	6.13e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.69	-10.24	-0.55	9.77e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7017914	0.967	rs12680988	chr8:71695890	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs4664304	0.629	rs1606117	chr2:160850716	C/T	cg03641300	chr2:160917029	PLA2R1	-0.38	-5.46	-0.33	1.17e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg08822215	chr16:89438651	ANKRD11	-0.61	-8.28	-0.47	7.9e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg24944395	chr17:7166718	CLDN7	-0.31	-5.26	-0.32	3.1e-7	Diastolic blood pressure;
KIRP	cis	rs35123781	0.502	rs2336901	chr5:138919078	A/G	cg11459648	chr5:138714337	SLC23A1	-0.36	-4.9	-0.3	1.71e-6	Schizophrenia;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg08974500	chr6:170863287	PSMB1;TBP	0.53	6.37	0.38	9.42e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.65	0.48	6.71e-16	Life satisfaction;
KIRP	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg27624424	chr6:160112604	SOD2	0.46	4.92	0.3	1.61e-6	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg13010199	chr12:38710504	ALG10B	0.61	7.65	0.44	4.42e-13	Morning vs. evening chronotype;
KIRP	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.02	0.5	5.61e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6467136	0.754	rs10273920	chr7:127158616	T/C	cg08586737	chr7:127225949	GCC1	-0.37	-4.84	-0.3	2.25e-6	Type 2 diabetes;
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg16987848	chr8:356385	FBXO25	-0.46	-6.41	-0.38	7.29e-10	Breast cancer;
KIRP	cis	rs258892	1.000	rs2253215	chr5:72247868	T/C	cg21869765	chr5:72125136	TNPO1	0.51	6.11	0.36	3.96e-9	Small cell lung carcinoma;
KIRP	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg06453172	chr10:134556979	INPP5A	-0.57	-6.57	-0.39	3.04e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs62229266	0.557	rs4817760	chr21:37395301	T/C	cg12218747	chr21:37451666	NA	-0.45	-5.41	-0.33	1.46e-7	Mitral valve prolapse;
KIRP	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg00071950	chr4:10020882	SLC2A9	-0.41	-5.8	-0.35	2.03e-8	Bone mineral density;
KIRP	cis	rs78487399	0.808	rs6544669	chr2:43736171	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.06	-0.31	8.28e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.46	6.21	0.37	2.3e-9	Menopause (age at onset);
KIRP	cis	rs12431939	1.000	rs12432466	chr14:51638873	T/C	cg23942311	chr14:51606299	NA	-0.61	-5.23	-0.32	3.55e-7	Cancer;
KIRP	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.39	0.38	8.19e-10	Neuroticism;
KIRP	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg00507259	chr4:95128692	SMARCAD1	0.4	4.98	0.3	1.22e-6	QT interval;
KIRP	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.02	0.36	6.47e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.3e-12	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04217140	chr17:4613687	ARRB2	0.49	6.03	0.36	5.92e-9	Parkinson's disease;
KIRP	cis	rs1440410	0.835	rs28592151	chr4:144094124	G/A	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.26e-10	Ischemic stroke;
KIRP	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	1.1	8.21	0.46	1.29e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg09873164	chr1:152488093	CRCT1	0.67	8.34	0.47	5.42e-15	Hair morphology;
KIRP	cis	rs7845219	0.544	rs6987400	chr8:95921295	T/C	cg16049864	chr8:95962084	TP53INP1	-0.37	-5.82	-0.35	1.87e-8	Type 2 diabetes;
KIRP	cis	rs2230307	0.536	rs580678	chr1:100483009	C/A	cg24955406	chr1:100503596	HIAT1	0.68	7.8	0.45	1.77e-13	Carotid intima media thickness;
KIRP	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.34	-0.37	1.09e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.95	13.07	0.64	5.53e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.63	-0.39	2.11e-10	Lung cancer;
KIRP	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-12.89	-0.63	2.22e-29	Vitiligo;
KIRP	cis	rs17453880	0.890	rs61070048	chr5:151964713	A/C	cg12297329	chr5:152029980	NA	-0.68	-10.16	-0.54	1.74e-20	Subjective well-being;
KIRP	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg10845886	chr2:3471009	TTC15	-0.52	-7.22	-0.42	6.31e-12	Neurofibrillary tangles;
KIRP	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.95	12.96	0.64	1.28e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.21	-5.66	-0.34	4.1e-8	Mean corpuscular volume;
KIRP	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12360000	0.797	rs11250853	chr10:1909770	A/G	cg26364871	chr10:1889757	NA	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.5	6.0	0.36	7.19e-9	Eosinophil percentage of white cells;
KIRP	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg27462398	chr1:86174642	ZNHIT6	-0.54	-7.47	-0.43	1.37e-12	Urate levels in overweight individuals;
KIRP	trans	rs913655	0.785	rs1844549	chr10:19003295	C/G	cg27106950	chr16:11367916	PRM3	0.57	6.03	0.36	5.91e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15897613	chr1:23418405	LUZP1	0.45	6.66	0.39	1.75e-10	Survival in pancreatic cancer;
KIRP	cis	rs447921	0.861	rs72860804	chr17:74413903	G/A	cg17201438	chr17:74438067	UBE2O	0.45	4.98	0.3	1.17e-6	Mitochondrial DNA levels;
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg07216194	chr8:27182965	PTK2B	0.43	5.37	0.32	1.79e-7	Neuroticism;
KIRP	cis	rs11622475	0.651	rs34982025	chr14:104360431	G/A	cg20488157	chr14:104394430	TDRD9	0.65	8.69	0.48	5.12e-16	Bipolar disorder;
KIRP	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7520050	0.831	rs61783170	chr1:46256329	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.59e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4646404	0.544	rs4646358	chr17:17470708	A/G	cg01246520	chr17:17644344	RAI1	-0.32	-5.5	-0.33	9.71e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs911119	0.955	rs6048946	chr20:23602307	G/T	cg09631192	chr20:23583594	CST9	-0.49	-5.08	-0.31	7.52e-7	Chronic kidney disease;
KIRP	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.6e-10	Morning vs. evening chronotype;
KIRP	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.53	5.43	0.33	1.32e-7	Obesity (extreme);
KIRP	cis	rs7188697	0.743	rs11859781	chr16:58602589	T/A	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.88	13.68	0.66	4.54e-32	Mean corpuscular volume;
KIRP	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg22563815	chr15:78856949	CHRNA5	-0.45	-6.99	-0.41	2.58e-11	Sudden cardiac arrest;
KIRP	cis	rs6028335	0.674	rs59096774	chr20:37603529	A/G	cg16355469	chr20:37678765	NA	0.52	5.15	0.31	5.43e-7	Alcohol and nicotine co-dependence;
KIRP	trans	rs763014	0.931	rs10903017	chr16:627920	T/C	cg00950418	chr7:105029125	SRPK2	-0.51	-6.34	-0.37	1.09e-9	Height;
KIRP	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg18944383	chr4:111397179	ENPEP	0.68	12.19	0.61	4.55e-27	Coronary artery disease;
KIRP	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-11.04	-0.58	2.8e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00300879	chr1:26503847	CNKSR1	0.46	6.63	0.39	2.15e-10	Height;
KIRP	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.5	-0.33	9.36e-8	Total body bone mineral density;
KIRP	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.58	-0.56	8.35e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4132509	0.948	rs7517921	chr1:243856420	T/C	cg25706552	chr1:244017396	NA	0.55	7.21	0.42	6.91e-12	RR interval (heart rate);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06583696	chr2:26101536	ASXL2	0.68	6.27	0.37	1.59e-9	Lung function (FEV1);
KIRP	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg11707556	chr5:10655725	ANKRD33B	0.68	8.78	0.49	2.88e-16	Coronary artery disease;
KIRP	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	0.8	8.45	0.47	2.51e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.56	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg22907277	chr7:1156413	C7orf50	0.65	6.41	0.38	7.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	10.86	0.57	1.04e-22	Calcium levels;
KIRP	cis	rs2554380	0.943	rs4843152	chr15:84363542	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-9.0	-0.5	6.14e-17	Height;
KIRP	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.4	-5.0	-0.3	1.1e-6	Aortic root size;
KIRP	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg17105886	chr17:28927953	LRRC37B2	0.54	5.59	0.34	6.15e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13296485	chr8:61474558	RAB2A	-0.4	-6.22	-0.37	2.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.75	0.4	1.05e-10	Bipolar disorder;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg09033563	chr22:24373618	LOC391322	0.42	5.59	0.34	6.01e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.34	-0.32	2.1e-7	Coronary artery disease;
KIRP	cis	rs10102274	1.000	rs73307295	chr8:91755121	A/G	cg16814680	chr8:91681699	NA	-0.81	-4.88	-0.3	1.92e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.6	-0.39	2.46e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg12317470	chr15:67143691	NA	0.65	7.21	0.42	6.69e-12	Lung cancer (smoking interaction);
KIRP	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.58	8.38	0.47	4.12e-15	Metabolite levels;
KIRP	cis	rs2904967	0.537	rs7116674	chr11:64962958	C/T	cg12562828	chr11:65076843	NA	0.57	6.89	0.4	4.62e-11	Mean corpuscular volume;
KIRP	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.74e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs662064	0.748	rs2506896	chr1:10603716	T/C	cg19773385	chr1:10388646	KIF1B	-0.37	-4.93	-0.3	1.55e-6	Asthma;
KIRP	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.46	-6.2	-0.37	2.39e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs3849570	0.695	rs62265411	chr3:81573660	T/C	cg07356753	chr3:81810745	GBE1	-0.58	-7.27	-0.42	4.83e-12	Waist circumference;Body mass index;
KIRP	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg21827317	chr3:136751795	NA	0.38	5.42	0.33	1.42e-7	Gestational age at birth (child effect);
KIRP	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.9	14.46	0.68	9.93e-35	Ewing sarcoma;
KIRP	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.44e-9	Breast cancer;
KIRP	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg13165212	chr22:42675999	NA	0.29	5.1	0.31	6.67e-7	Cognitive function;
KIRP	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.46	5.15	0.31	5.34e-7	Schizophrenia;
KIRP	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	10.28	0.55	7.59e-21	Birth weight;
KIRP	cis	rs35740288	0.587	rs4843089	chr15:86176136	C/T	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3779635	1.000	rs3779635	chr8:27284692	C/T	cg23693289	chr8:27183097	PTK2B	0.47	5.92	0.35	1.09e-8	Neuroticism;
KIRP	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12524338	chr4:183729343	NA	0.59	5.05	0.31	8.5e-7	Pediatric autoimmune diseases;
KIRP	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg23024343	chr7:107201750	COG5	-0.58	-8.24	-0.47	1.01e-14	Coronary artery disease;
KIRP	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.43	-0.7	4.83e-38	Alzheimer's disease;
KIRP	cis	rs787274	1.000	rs7859175	chr9:115587160	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-6.66	-0.39	1.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-10.7	-0.56	3.39e-22	Morning vs. evening chronotype;
KIRP	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.79	13.11	0.64	3.99e-30	Calcium levels;
KIRP	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17376030	chr22:41985996	PMM1	0.59	6.34	0.37	1.1e-9	Vitiligo;
KIRP	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	cis	rs854765	0.663	rs9906673	chr17:17746197	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.74	-0.53	3.67e-19	Total body bone mineral density;
KIRP	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg08999081	chr20:33150536	PIGU	-0.4	-5.12	-0.31	6.26e-7	Height;
KIRP	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.51	6.52	0.38	4.03e-10	Colorectal cancer;
KIRP	cis	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg02725872	chr8:58115012	NA	-0.82	-7.93	-0.45	7.72e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg20637307	chr2:213403960	ERBB4	0.55	7.65	0.44	4.42e-13	Symmetrical dimethylarginine levels;
KIRP	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.49	-0.33	1.01e-7	Aortic root size;
KIRP	cis	rs7187994	0.848	rs34327141	chr16:84776991	C/T	cg07647771	chr16:84786436	USP10	-0.43	-5.5	-0.33	9.53e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.79	11.19	0.58	8.89e-24	Dental caries;
KIRP	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg05072774	chr3:49840536	C3orf54	-0.39	-4.94	-0.3	1.46e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04188362	chr10:21823475	MLLT10	0.49	7.12	0.41	1.18e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.96	-14.4	-0.68	1.66e-34	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.76	9.31	0.51	7.19e-18	Response to antipsychotic treatment;
KIRP	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.09e-6	Bladder cancer;
KIRP	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.69	10.73	0.56	2.72e-22	Blood metabolite ratios;
KIRP	cis	rs9815354	0.909	rs6794477	chr3:41920401	C/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.34	-0.32	2.09e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg08999081	chr20:33150536	PIGU	0.47	6.29	0.37	1.48e-9	Height;
KIRP	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.64	-7.86	-0.45	1.23e-13	Aortic root size;
KIRP	cis	rs1076160	0.766	rs214636	chr9:135735343	G/A	cg04648087	chr9:135819397	TSC1	-0.4	-4.96	-0.3	1.34e-6	Psoriasis;
KIRP	cis	rs42648	0.617	rs11563435	chr7:89900207	A/C	cg25739043	chr7:89950458	NA	-0.43	-7.02	-0.41	2.21e-11	Homocysteine levels;
KIRP	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg20387954	chr3:183756860	HTR3D	0.6	8.57	0.48	1.17e-15	Anterior chamber depth;
KIRP	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.55	-7.69	-0.44	3.58e-13	Motion sickness;
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-6.03	-0.36	6.1e-9	Lung cancer;
KIRP	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg00204512	chr16:28754710	NA	0.47	6.14	0.36	3.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	10.44	0.55	2.4e-21	Hip circumference;
KIRP	cis	rs8077889	0.750	rs76557360	chr17:41936842	G/A	cg26893861	chr17:41843967	DUSP3	0.85	8.88	0.49	1.46e-16	Triglycerides;
KIRP	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-10.22	-0.55	1.12e-20	Schizophrenia;
KIRP	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02725872	chr8:58115012	NA	-0.56	-6.5	-0.38	4.52e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg09990169	chr2:241835740	C2orf54	-0.44	-6.44	-0.38	6.35e-10	Urinary metabolites;
KIRP	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg23815491	chr16:72088622	HP	0.36	6.06	0.36	5.02e-9	Prostate cancer;
KIRP	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg04490037	chr7:50633773	DDC	0.41	5.01	0.3	1.04e-6	Malaria;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23084441	chr1:67453650	MIER1	-0.4	-6.16	-0.37	2.98e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.91	-0.66	7.57e-33	Primary sclerosing cholangitis;
KIRP	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.93	0.35	1.05e-8	Motion sickness;
KIRP	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.39	5.23	0.32	3.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6580649	0.941	rs757556	chr12:48502493	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg23102388	chr7:1867652	MAD1L1	-0.46	-6.18	-0.37	2.7e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs240764	0.817	rs2036052	chr6:101154909	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-5.52	-0.33	8.75e-8	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25606773	chr6:46110412	ENPP4	-0.46	-7.47	-0.43	1.41e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7221595	0.825	rs9896963	chr17:3966591	T/C	cg11204139	chr17:3907470	NA	0.62	6.43	0.38	6.43e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.85	9.63	0.52	7.69e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08901704	chr4:8023314	ABLIM2	-0.44	-6.2	-0.37	2.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.72	0.34	3.03e-8	Renal cell carcinoma;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.87	-11.91	-0.6	3.95e-26	Longevity;Endometriosis;
KIRP	cis	rs10181042	0.581	rs1177285	chr2:61350137	A/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.25	-0.32	3.31e-7	Crohn's disease;
KIRP	cis	rs7175404	1.000	rs16948116	chr15:94036756	C/T	cg23502883	chr15:93959149	NA	-0.51	-5.51	-0.33	8.86e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg19847130	chr8:10466454	RP1L1	0.37	5.68	0.34	3.86e-8	Neuroticism;
KIRP	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg15327641	chr2:3715039	ALLC	0.42	5.15	0.31	5.4e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg23933602	chr10:16859644	RSU1	0.58	6.33	0.37	1.15e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs9783347	0.857	rs2124374	chr11:18313911	A/C	cg15585147	chr11:18324498	HPS5	0.47	6.36	0.38	9.83e-10	Pancreatic cancer;
KIRP	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.65	0.52	6.61e-19	Prudent dietary pattern;
KIRP	cis	rs4775041	0.842	rs10468017	chr15:58678512	C/T	cg02971627	chr15:59042282	ADAM10	0.48	4.89	0.3	1.86e-6	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-14.46	-0.68	1.03e-34	Coronary artery disease;
KIRP	cis	rs7106204	0.748	rs4636667	chr11:24238615	T/C	ch.11.24196551F	chr11:24239977	NA	0.79	9.48	0.52	2.31e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg16898833	chr6:26189333	HIST1H4D	0.72	5.01	0.3	1.06e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06850241	chr22:41845214	NA	-0.47	-5.36	-0.32	1.96e-7	Vitiligo;
KIRP	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg18850929	chr19:1828978	REXO1	0.43	5.11	0.31	6.53e-7	Bipolar disorder;
KIRP	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.29	5.65	0.34	4.43e-8	Monocyte percentage of white cells;
KIRP	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.26e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg16558253	chr16:72132732	DHX38	0.36	4.91	0.3	1.66e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs1566497	0.791	rs4235021	chr4:169744567	A/G	cg21985951	chr4:169930107	CBR4	0.39	4.97	0.3	1.25e-6	Pulse pressure;
KIRP	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-7.15	-0.41	9.78e-12	Daytime sleep phenotypes;
KIRP	cis	rs9488822	0.585	rs7768026	chr6:116274313	A/G	cg18764771	chr6:116381957	FRK	-0.2	-5.37	-0.32	1.82e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.81	0.66	1.62e-32	Alzheimer's disease;
KIRP	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	8.1	0.46	2.62e-14	Iron status biomarkers;
KIRP	cis	rs753955	0.592	rs1324972	chr13:24348159	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.47	6.17	0.37	2.81e-9	Lung cancer;
KIRP	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.54	6.65	0.39	1.93e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	1.12	12.0	0.61	2.05e-26	Psoriasis;
KIRP	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.67	9.09	0.5	3.43e-17	Multiple sclerosis;
KIRP	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.41	-5.2	-0.31	4.29e-7	Platelet count;
KIRP	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.95	-10.19	-0.54	1.43e-20	Schizophrenia;
KIRP	cis	rs14057	0.832	rs12567649	chr1:6760197	T/C	cg16431369	chr1:6694556	THAP3;DNAJC11	-0.41	-4.95	-0.3	1.35e-6	Systolic blood pressure;
KIRP	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.05	0.61	1.41e-26	Diabetic retinopathy;
KIRP	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs7395581	0.918	rs61896050	chr11:47309063	T/C	cg25783544	chr11:47291846	MADD	0.44	4.97	0.3	1.24e-6	HDL cholesterol;
KIRP	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.73	6.1	0.36	4.03e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.93	-0.4	3.67e-11	Eye color traits;
KIRP	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21643547	chr1:205240462	TMCC2	-0.75	-11.56	-0.59	5.83e-25	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19698099	chr2:189897254	COL5A2	-0.41	-6.62	-0.39	2.17e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs17023223	0.537	rs3934789	chr1:119683063	G/A	cg18261050	chr1:119551319	NA	0.51	6.55	0.39	3.25e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg19274270	chr17:78178856	CARD14	-0.37	-6.59	-0.39	2.59e-10	Morning vs. evening chronotype;
KIRP	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg24631222	chr15:78858424	CHRNA5	0.8	9.7	0.53	4.8e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.3	-6.58	-0.39	2.79e-10	Diastolic blood pressure;
KIRP	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg19847130	chr8:10466454	RP1L1	-0.38	-5.48	-0.33	1.05e-7	Retinal vascular caliber;
KIRP	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	1.07	7.56	0.43	8.02e-13	Skin colour saturation;
KIRP	cis	rs7534824	0.625	rs72736234	chr1:101526098	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.34	0.32	2.06e-7	Refractive astigmatism;
KIRP	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg26681399	chr22:41777847	TEF	-0.51	-5.21	-0.32	3.99e-7	Vitiligo;
KIRP	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg20240347	chr1:204465584	NA	-0.4	-7.65	-0.44	4.51e-13	Schizophrenia;
KIRP	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.13	0.64	3.44e-30	Exhaled nitric oxide output;
KIRP	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.37	-0.38	9.04e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs12431939	1.000	rs60818073	chr14:51696649	T/C	cg23942311	chr14:51606299	NA	-0.58	-5.17	-0.31	4.89e-7	Cancer;
KIRP	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg02297831	chr4:17616191	MED28	0.59	7.22	0.42	6.37e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	8.19	0.46	1.45e-14	Bipolar disorder;
KIRP	cis	rs2400749	0.798	rs12432298	chr14:100032814	T/C	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.44	-0.33	1.32e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.69	-10.0	-0.54	5.65e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.5	-7.03	-0.41	2.08e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4727443	0.866	rs13243708	chr7:99616291	T/C	cg22004693	chr7:99632812	ZKSCAN1	0.39	5.04	0.31	9.15e-7	Interstitial lung disease;
KIRP	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.53	-6.47	-0.38	5.22e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.49	7.55	0.43	8.36e-13	Personality dimensions;
KIRP	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.71	-10.29	-0.55	6.78e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg11707556	chr5:10655725	ANKRD33B	0.67	8.44	0.47	2.8e-15	Coronary artery disease;
KIRP	cis	rs8177876	0.822	rs7204040	chr16:81113493	G/A	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.96	6.55	0.39	3.38e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.52	-6.52	-0.38	3.85e-10	Iron status biomarkers;
KIRP	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11987759	chr7:65425863	GUSB	-0.61	-8.08	-0.46	2.88e-14	Aortic root size;
KIRP	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11779988	0.545	rs10095047	chr8:17750328	T/C	cg01800426	chr8:17659068	MTUS1	-0.43	-5.09	-0.31	7.02e-7	Breast cancer;
KIRP	cis	rs28655083	1.000	rs11863397	chr16:77060388	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-5.69	-0.34	3.52e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.49	6.48	0.38	4.86e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs17123764	1.000	rs17123764	chr12:49947952	C/T	cg20471783	chr12:50157085	TMBIM6	0.4	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.59	8.99	0.5	6.79e-17	Cancer;
KIRP	trans	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs2275620	1.000	rs2275620	chr10:96802598	A/T	cg09036531	chr10:96991505	NA	0.52	6.68	0.39	1.56e-10	Gout;
KIRP	cis	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.96e-12	Morning vs. evening chronotype;
KIRP	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.69	9.9	0.53	1.18e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs9826463	0.582	rs11714528	chr3:142133218	C/T	cg20824294	chr3:142316082	PLS1	0.44	6.35	0.38	1.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs42648	0.564	rs17867585	chr7:89819174	C/T	cg25739043	chr7:89950458	NA	-0.39	-6.05	-0.36	5.51e-9	Homocysteine levels;
KIRP	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.84	10.17	0.54	1.68e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg04374321	chr14:90722782	PSMC1	0.99	18.12	0.76	3.3e-47	Mortality in heart failure;
KIRP	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg24881330	chr22:46731750	TRMU	0.64	5.49	0.33	9.92e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg24807547	chr6:37504484	NA	-0.61	-9.91	-0.53	1.08e-19	Cognitive performance;
KIRP	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.43	5.18	0.31	4.63e-7	Resistin levels;
KIRP	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs4908768	0.680	rs11121225	chr1:8816438	G/A	cg25722041	chr1:8623473	RERE	0.77	7.96	0.45	6.21e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.94	-11.23	-0.58	6.62e-24	White matter hyperintensity burden;
KIRP	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.27e-12	Prudent dietary pattern;
KIRP	cis	rs4750440	0.702	rs7918501	chr10:14029895	C/T	cg27542038	chr10:14027202	FRMD4A	-0.48	-6.7	-0.39	1.39e-10	Adiponectin levels;
KIRP	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg19257562	chr1:2043853	PRKCZ	0.39	6.42	0.38	6.89e-10	Height;
KIRP	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg13271783	chr10:134563150	INPP5A	-0.63	-7.94	-0.45	7.05e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.8	11.96	0.61	2.81e-26	Systolic blood pressure;
KIRP	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.64	-8.47	-0.48	2.19e-15	Blood metabolite levels;
KIRP	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.72	-9.32	-0.51	7.05e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.71	-10.04	-0.54	4.16e-20	Blood metabolite levels;
KIRP	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.76	8.0	0.45	4.94e-14	Uric acid levels;
KIRP	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg00484396	chr16:3507460	NAT15	0.53	5.3	0.32	2.53e-7	Tuberculosis;
KIRP	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.47	-5.67	-0.34	3.95e-8	Initial pursuit acceleration;
KIRP	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg23625390	chr15:77176239	SCAPER	0.5	6.65	0.39	1.83e-10	Blood metabolite levels;
KIRP	cis	rs4319547	0.688	rs6489158	chr12:123110365	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.57	-7.29	-0.42	4.17e-12	Body mass index;
KIRP	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg23280166	chr11:118938394	VPS11	-0.64	-7.76	-0.44	2.33e-13	Coronary artery disease;
KIRP	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg13978929	chr19:21580086	ZNF493	0.49	4.86	0.3	2.06e-6	Pain;
KIRP	cis	rs829661	0.793	rs1869423	chr2:30835134	C/T	cg10949345	chr2:30726833	LCLAT1	1.11	13.58	0.65	1.01e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27297192	chr10:134578999	INPP5A	0.67	8.21	0.46	1.23e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs3789045	0.707	rs61421373	chr1:204560440	C/T	cg18185008	chr1:204589407	LRRN2	-0.6	-7.01	-0.41	2.29e-11	Educational attainment (college completion);
KIRP	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16346588	chr10:242978	ZMYND11	0.47	5.75	0.34	2.65e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17554472	chr22:41940697	POLR3H	-0.66	-6.87	-0.4	5.17e-11	Vitiligo;
KIRP	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.43	-10.87	-0.57	9.88e-23	Diabetic kidney disease;
KIRP	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg15655495	chr12:38532458	NA	-0.29	-4.95	-0.3	1.37e-6	Morning vs. evening chronotype;
KIRP	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-6.88	-0.4	5.03e-11	Myopia (pathological);
KIRP	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.66	-0.34	4.12e-8	Joint mobility (Beighton score);
KIRP	cis	rs960902	0.764	rs1113496	chr2:37732855	T/C	cg25341268	chr2:37734390	NA	-0.51	-7.01	-0.41	2.25e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7923609	0.902	rs7897379	chr10:65301725	T/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.65	-0.34	4.43e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg17691542	chr6:26056736	HIST1H1C	-0.67	-7.88	-0.45	1.08e-13	Iron status biomarkers;
KIRP	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	1.09	8.24	0.47	1.01e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.73	11.46	0.59	1.18e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-11.44	-0.59	1.42e-24	Personality dimensions;
KIRP	cis	rs8054556	1.000	rs11150579	chr16:30000330	T/G	cg06326092	chr16:30034487	C16orf92	0.35	4.87	0.3	2.03e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg00074818	chr8:8560427	CLDN23	0.43	6.48	0.38	4.83e-10	Obesity-related traits;
KIRP	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg27205649	chr11:78285834	NARS2	0.64	8.01	0.45	4.69e-14	Alzheimer's disease (survival time);
KIRP	cis	rs13108043	0.605	rs10489044	chr4:87976387	A/G	cg11209507	chr4:87813803	C4orf36	0.48	5.03	0.31	9.28e-7	Red blood cell count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03258011	chr17:54857409	NA	0.6	7.64	0.44	4.7e-13	Smoking initiation;
KIRP	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.59	5.82	0.35	1.78e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg14375499	chr17:6899207	ALOX12	-0.37	-5.7	-0.34	3.43e-8	Tonsillectomy;
KIRP	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg14675211	chr2:100938903	LONRF2	0.47	6.08	0.36	4.51e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg02725872	chr8:58115012	NA	-0.53	-5.87	-0.35	1.42e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14169450	chr9:139327907	INPP5E	0.54	6.26	0.37	1.68e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.65	5.49	0.33	1.01e-7	Bipolar disorder;
KIRP	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg07810366	chr2:100720526	AFF3	-0.34	-5.86	-0.35	1.46e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	1.11	21.13	0.8	3.19e-57	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs4523957	0.690	rs28505924	chr17:2088838	G/C	cg16513277	chr17:2031491	SMG6	-0.78	-11.16	-0.58	1.11e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4356975	0.509	rs5014975	chr4:69995962	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	4.96	0.3	1.31e-6	Obesity-related traits;
KIRP	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.53	-5.12	-0.31	6.14e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs10267417	0.603	rs10950762	chr7:19912203	A/G	cg05791153	chr7:19748676	TWISTNB	0.48	4.87	0.3	2e-6	Night sleep phenotypes;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg07747251	chr5:1868357	NA	0.45	5.81	0.35	1.93e-8	Cardiovascular disease risk factors;
KIRP	cis	rs9653442	0.527	rs11123812	chr2:100761548	T/C	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4332428	1.000	rs36096746	chr10:4975353	T/G	cg19648686	chr10:5044992	AKR1C2	-0.91	-8.03	-0.46	4.11e-14	Height;
KIRP	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.66	9.29	0.51	8.75e-18	Parkinson's disease;
KIRP	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.56	7.26	0.42	5e-12	Bladder cancer;
KIRP	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg14703610	chr5:56206110	C5orf35	0.46	6.05	0.36	5.4e-9	Coronary artery disease;
KIRP	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.0	0.36	7e-9	Menopause (age at onset);
KIRP	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg23752985	chr2:85803571	VAMP8	0.59	8.47	0.48	2.2e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.41	-0.38	7.25e-10	Longevity;
KIRP	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.78	-11.6	-0.59	4.09e-25	Obesity-related traits;
KIRP	trans	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-6.02	-0.36	6.25e-9	Neuroticism;
KIRP	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs12458462	0.859	rs34242155	chr18:77425192	G/A	cg11879182	chr18:77439856	CTDP1	0.85	10.68	0.56	3.98e-22	Monocyte count;
KIRP	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.48	-9.96	-0.54	7.75e-20	Longevity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11741254	chr8:99129480	POP1;HRSP12	0.48	6.42	0.38	6.78e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg06937882	chr20:24974362	C20orf3	-0.44	-4.86	-0.3	2.11e-6	Blood protein levels;
KIRP	cis	rs4363385	0.588	rs11586559	chr1:153025714	G/A	cg07796016	chr1:152779584	LCE1C	-0.49	-6.35	-0.38	1.02e-9	Inflammatory skin disease;
KIRP	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg14541582	chr5:601475	NA	-0.54	-5.94	-0.35	9.44e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg13206674	chr6:150067644	NUP43	0.5	7.09	0.41	1.43e-11	Lung cancer;
KIRP	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.33	-12.76	-0.63	5.88e-29	Hip circumference adjusted for BMI;
KIRP	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.75	-7.62	-0.44	5.4e-13	Gut microbiome composition (summer);
KIRP	cis	rs7897654	0.571	rs7920697	chr10:104633337	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-5.08	-0.31	7.51e-7	Schizophrenia;
KIRP	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg02297831	chr4:17616191	MED28	0.54	6.84	0.4	6.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.7	9.55	0.52	1.35e-18	Menarche (age at onset);
KIRP	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.63	-0.52	7.74e-19	Triglycerides;
KIRP	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.4	0.59	1.87e-24	Alzheimer's disease;
KIRP	cis	rs7849270	0.801	rs10819474	chr9:131930494	C/T	cg13538475	chr9:131942899	NA	-0.36	-5.12	-0.31	6.1e-7	Blood metabolite ratios;
KIRP	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.35	5.28	0.32	2.91e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6032067	1.000	rs6032059	chr20:43852443	A/T	cg10761708	chr20:43804764	PI3	0.51	5.22	0.32	3.78e-7	Blood protein levels;
KIRP	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs9394841	0.646	rs9471676	chr6:41815192	C/T	cg08135965	chr6:41755394	TOMM6	0.52	5.54	0.33	7.86e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs2997447	0.681	rs11247854	chr1:26399230	C/T	cg08133631	chr1:26527909	CATSPER4	-0.34	-4.9	-0.3	1.7e-6	QRS complex (12-leadsum);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08493338	chr16:354269	AXIN1	0.46	6.2	0.37	2.39e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17539620	0.624	rs62432751	chr6:154841027	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	5.98	0.36	7.62e-9	Lipoprotein (a) levels;
KIRP	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg12131826	chr15:77904385	NA	0.42	5.55	0.33	7.31e-8	Type 2 diabetes;
KIRP	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg02297831	chr4:17616191	MED28	-0.51	-6.1	-0.36	4e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs867371	1.000	rs6495642	chr15:82457497	G/C	cg06066596	chr15:83166174	LOC80154	-0.47	-5.61	-0.34	5.39e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07234876	chr8:600039	NA	1.0	7.08	0.41	1.52e-11	IgG glycosylation;
KIRP	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.32	12.12	0.61	8.01e-27	Diabetic retinopathy;
KIRP	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.5	-5.97	-0.36	8.15e-9	Lung cancer;
KIRP	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg26531700	chr6:26746687	NA	-0.41	-5.47	-0.33	1.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg13962347	chr6:5174647	LYRM4	-0.76	-10.92	-0.57	6.75e-23	Height;
KIRP	cis	rs5747327	0.874	rs5747323	chr22:18163539	G/A	cg19898043	chr22:18121309	BCL2L13	-0.41	-5.06	-0.31	8.32e-7	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7523050	0.643	rs34114412	chr1:109402866	C/T	cg08274380	chr1:109419600	GPSM2	1.06	8.8	0.49	2.54e-16	Fat distribution (HIV);
KIRP	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg00106254	chr7:1943704	MAD1L1	0.44	4.9	0.3	1.77e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs2290402	0.536	rs58429160	chr4:875266	G/A	cg00846425	chr4:957561	DGKQ	-0.47	-5.18	-0.31	4.68e-7	Type 2 diabetes;
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22168489	chr12:122356033	WDR66	0.63	9.38	0.51	4.7e-18	Mean corpuscular volume;
KIRP	cis	rs11577318	0.579	rs11247934	chr1:26695758	A/T	cg00852783	chr1:26633632	UBXN11	-0.45	-5.17	-0.31	4.95e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.67	-7.71	-0.44	3.18e-13	Pancreatic cancer;
KIRP	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.54	-6.64	-0.39	2.03e-10	Iron status biomarkers;
KIRP	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg19257562	chr1:2043853	PRKCZ	0.37	5.48	0.33	1.06e-7	Height;
KIRP	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.15	-17.91	-0.75	1.71e-46	Ulcerative colitis;
KIRP	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.12	-0.31	6.31e-7	Bipolar disorder;
KIRP	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.35	-4.97	-0.3	1.27e-6	Monocyte count;
KIRP	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.58	-0.39	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg04374321	chr14:90722782	PSMC1	-0.97	-17.51	-0.74	4.01e-45	Mortality in heart failure;
KIRP	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg06064525	chr11:970664	AP2A2	-0.29	-5.32	-0.32	2.34e-7	Alzheimer's disease (late onset);
KIRP	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.64	8.11	0.46	2.39e-14	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg14952266	chr13:112191215	NA	0.45	6.62	0.39	2.3e-10	Hepatitis;
KIRP	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs10782582	0.609	rs72979226	chr1:76302222	C/A	cg10523679	chr1:76189770	ACADM	-0.46	-6.38	-0.38	8.52e-10	Daytime sleep phenotypes;
KIRP	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg26784012	chr10:32216390	ARHGAP12	0.32	5.1	0.31	6.74e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.03	0.36	5.9e-9	Height;
KIRP	cis	rs6939532	0.522	rs4712980	chr6:26355758	G/T	cg14345882	chr6:26364793	BTN3A2	-0.33	-5.33	-0.32	2.19e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs33912345	0.695	rs1314343	chr14:60877634	T/G	cg27398547	chr14:60952738	C14orf39	-0.4	-5.44	-0.33	1.3e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs6681460	1.000	rs6670378	chr1:67126585	C/T	cg13052034	chr1:66999238	SGIP1	0.44	6.11	0.36	3.88e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg13902645	chr11:5959945	NA	-0.6	-6.31	-0.37	1.26e-9	DNA methylation (variation);
KIRP	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.82	13.33	0.65	7.21e-31	Schizophrenia;
KIRP	cis	rs7590368	1.000	rs55968911	chr2:10961840	C/T	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17691542	chr6:26056736	HIST1H1C	0.51	6.45	0.38	6e-10	Height;
KIRP	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17554472	chr22:41940697	POLR3H	0.72	7.2	0.42	7.39e-12	Vitiligo;
KIRP	cis	rs13102973	0.965	rs4597893	chr4:135863043	C/T	cg14419869	chr4:135874104	NA	-0.6	-10.5	-0.56	1.45e-21	Subjective well-being;
KIRP	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.68	-12.07	-0.61	1.2e-26	White blood cell count (basophil);
KIRP	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg26965718	chr17:79658957	HGS	-0.61	-4.85	-0.3	2.18e-6	Dental caries;
KIRP	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg26116260	chr4:7069785	GRPEL1	-0.85	-7.19	-0.42	7.84e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.85	8.77	0.49	3.1e-16	Body mass index;
KIRP	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.98	10.73	0.56	2.87e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg18132916	chr6:79620363	NA	-0.4	-5.55	-0.33	7.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	0.94	12.44	0.62	7.19e-28	Homoarginine levels;
KIRP	cis	rs4936894	0.500	rs10893156	chr11:124054741	T/C	cg27160556	chr11:124181099	OR8D1	-0.46	-6.66	-0.39	1.77e-10	Aging (time to death);
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.8	-10.91	-0.57	7.58e-23	Longevity;
KIRP	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg23533926	chr12:111358616	MYL2	-0.49	-6.43	-0.38	6.65e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.58	-0.44	6.96e-13	Sudden cardiac arrest;
KIRP	cis	rs6500602	0.563	rs3810818	chr16:4432029	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	5.06	0.31	8.06e-7	Schizophrenia;
KIRP	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs3764563	0.935	rs585680	chr19:15687802	T/G	cg20725493	chr19:15740067	CYP4F8	0.89	6.38	0.38	8.54e-10	Inflammatory biomarkers;
KIRP	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	1.01	10.66	0.56	4.53e-22	Eosinophilic esophagitis;
KIRP	cis	rs3857536	0.904	rs10806526	chr6:66900531	T/C	cg07460842	chr6:66804631	NA	-0.4	-5.26	-0.32	3.11e-7	Blood trace element (Cu levels);
KIRP	cis	rs16828019	0.852	rs12759023	chr1:41603978	T/C	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg04935436	chr20:30431758	NA	0.48	5.86	0.35	1.48e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs72843166	0.898	rs72843196	chr17:61212553	C/T	cg19683800	chr17:61518354	CYB561	-0.41	-4.93	-0.3	1.53e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg10664184	chr19:17420304	DDA1	0.98	9.57	0.52	1.18e-18	Systemic lupus erythematosus;
KIRP	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.7	-10.22	-0.55	1.14e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-1.01	-17.13	-0.74	8.04e-44	Height;
KIRP	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.44	5.47	0.33	1.12e-7	Aortic root size;
KIRP	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg21466736	chr12:48725269	NA	-0.47	-5.92	-0.35	1.07e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg23815491	chr16:72088622	HP	0.39	6.34	0.37	1.11e-9	Fibrinogen levels;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10802521	chr3:52805072	NEK4	-0.37	-5.08	-0.31	7.49e-7	Bipolar disorder;
KIRP	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20135002	chr11:47629003	NA	-0.44	-5.33	-0.32	2.23e-7	Subjective well-being;
KIRP	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg00981070	chr1:2046702	PRKCZ	0.32	5.53	0.33	8.01e-8	Height;
KIRP	cis	rs11169552	0.510	rs12580051	chr12:51045072	T/A	cg12884762	chr12:50931848	DIP2B	-0.43	-4.9	-0.3	1.72e-6	Colorectal cancer;
KIRP	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg18016565	chr1:150552671	MCL1	0.4	6.11	0.36	3.84e-9	Melanoma;
KIRP	cis	rs661054	0.780	rs10790025	chr11:114439662	C/G	cg19465033	chr11:114479364	NA	0.44	5.27	0.32	2.97e-7	Ulcerative colitis;
KIRP	cis	rs11574514	1.000	rs16957590	chr16:67934725	C/T	cg26727032	chr16:67993705	SLC12A4	0.66	5.36	0.32	1.88e-7	Crohn's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg26151740	chr19:54641525	CNOT3	-0.5	-6.5	-0.38	4.45e-10	Myopia;
KIRP	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18252515	chr7:66147081	NA	0.48	5.58	0.34	6.27e-8	Aortic root size;
KIRP	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg10977910	chr1:84465055	TTLL7	0.45	5.35	0.32	2.02e-7	Obesity-related traits;
KIRP	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg01843034	chr6:37503916	NA	-0.86	-12.0	-0.61	2.08e-26	Cognitive performance;
KIRP	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	trans	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg16141378	chr3:129829833	LOC729375	0.49	6.53	0.38	3.73e-10	Mood instability;
KIRP	cis	rs17095355	1.000	rs7905306	chr10:111712902	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.11	-0.36	3.96e-9	Biliary atresia;
KIRP	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.31	-0.32	2.42e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg22717608	chr11:34937665	PDHX;APIP	-0.42	-5.27	-0.32	2.93e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg12623918	chr2:306882	NA	0.4	5.09	0.31	7.05e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.05	-0.46	3.51e-14	Retinal vascular caliber;
KIRP	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.95	13.04	0.64	6.96e-30	Breast cancer;
KIRP	cis	rs6832769	0.925	rs6554292	chr4:56451110	G/T	cg09317128	chr4:56265301	TMEM165	-0.5	-6.6	-0.39	2.54e-10	Personality dimensions;
KIRP	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg22437258	chr11:111473054	SIK2	0.6	7.06	0.41	1.66e-11	Primary sclerosing cholangitis;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17757281	chr20:44604666	NA	0.4	6.25	0.37	1.76e-9	Cancer;
KIRP	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs4006360	0.505	rs8067313	chr17:39290306	G/T	cg15015397	chr17:39261100	KRTAP4-9	-0.53	-7.15	-0.41	1.01e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.67	8.03	0.46	4.13e-14	Aortic root size;
KIRP	cis	rs4523957	0.583	rs1565763	chr17:2055300	T/C	cg16513277	chr17:2031491	SMG6	-0.85	-12.15	-0.61	6.32e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs12517041	0.938	rs34995120	chr5:23273260	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.65	-6.58	-0.39	2.8e-10	Calcium levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08504905	chr19:54663436	LENG1	0.59	7.07	0.41	1.61e-11	Smoking initiation;
KIRP	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg00977110	chr5:151150581	G3BP1	-0.59	-5.93	-0.35	1.03e-8	Preschool internalizing problems;
KIRP	trans	rs2998286	0.723	rs332186	chr10:28913603	A/G	cg10174683	chr16:85619974	NA	-0.65	-6.05	-0.36	5.45e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.35	-0.51	5.73e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg07148914	chr20:33460835	GGT7	-0.41	-5.09	-0.31	7.26e-7	Height;
KIRP	cis	rs883565	0.740	rs6763016	chr3:39098964	G/A	cg01426195	chr3:39028469	NA	-0.67	-11.18	-0.58	9.53e-24	Handedness;
KIRP	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg07389463	chr12:132296394	NA	-0.53	-8.87	-0.49	1.53e-16	Migraine;
KIRP	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg01879757	chr17:41196368	BRCA1	-0.55	-7.32	-0.42	3.42e-12	Menopause (age at onset);
KIRP	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg07004394	chr14:106090750	NA	-0.46	-4.96	-0.3	1.3e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs2997447	0.739	rs3008224	chr1:26389647	G/A	cg19633962	chr1:26362018	EXTL1	-0.56	-5.25	-0.32	3.24e-7	QRS complex (12-leadsum);
KIRP	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.65	-0.66	5.97e-32	Monocyte count;
KIRP	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg21361702	chr7:150065534	REPIN1	0.55	5.82	0.35	1.78e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.8	13.28	0.65	1.0500000000000001e-30	Menarche (age at onset);
KIRP	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-1.09	-17.66	-0.75	1.22e-45	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg21395723	chr22:39101663	GTPBP1	0.47	6.29	0.37	1.47e-9	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg04369109	chr6:150039330	LATS1	0.64	8.28	0.47	7.72e-15	Lung cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg26890727	chr6:36954138	MTCH1	-0.47	-6.08	-0.36	4.64e-9	Myopia;
KIRP	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.66	6.98	0.41	2.73e-11	Platelet count;
KIRP	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg27211696	chr2:191398769	TMEM194B	-0.76	-8.88	-0.49	1.47e-16	Diastolic blood pressure;
KIRP	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg06042504	chr8:55087323	NA	-0.61	-7.45	-0.43	1.54e-12	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03484853	chr8:93030117	RUNX1T1	-0.41	-6.82	-0.4	7.11e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs12137294	0.829	rs1172154	chr1:205220639	T/G	cg21643547	chr1:205240462	TMCC2	-0.48	-6.83	-0.4	6.8e-11	Red cell distribution width;
KIRP	cis	rs57590327	0.555	rs3821556	chr3:81630790	G/A	cg07356753	chr3:81810745	GBE1	-0.46	-5.34	-0.32	2.07e-7	Extraversion;
KIRP	cis	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg00405596	chr8:11794950	NA	-0.41	-4.93	-0.3	1.49e-6	Morning vs. evening chronotype;
KIRP	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg20362242	chr5:692897	TPPP	0.56	4.86	0.3	2.06e-6	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs3026101	0.671	rs12602061	chr17:5302645	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs1462872	0.669	rs327356	chr8:31800586	T/C	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg26876637	chr1:152193138	HRNR	0.74	9.61	0.52	8.91e-19	Atopic dermatitis;
KIRP	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg11657440	chr19:46296263	DMWD	-0.73	-9.5	-0.52	2.02e-18	Coronary artery disease;
KIRP	trans	rs9650657	0.648	rs6601512	chr8:10585596	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.69	-0.39	1.5e-10	Neuroticism;
KIRP	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg09699651	chr6:150184138	LRP11	0.39	5.01	0.3	1.06e-6	Lung cancer;
KIRP	cis	rs4843185	0.769	rs709805	chr16:85706564	A/G	cg26571870	chr16:85723150	GINS2	0.45	4.85	0.3	2.22e-6	Platelet distribution width;
KIRP	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg01689657	chr7:91764605	CYP51A1	0.44	6.44	0.38	6.21e-10	Breast cancer;
KIRP	cis	rs57590327	0.503	rs12497231	chr3:81519291	A/G	cg07356753	chr3:81810745	GBE1	0.49	6.06	0.36	5.17e-9	Extraversion;
KIRP	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.83	-10.76	-0.57	2.17e-22	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.76	-9.67	-0.52	5.81e-19	Menopause (age at onset);
KIRP	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg13334819	chr7:99746414	C7orf59	0.53	6.01	0.36	6.53e-9	Coronary artery disease;
KIRP	cis	rs4765905	0.610	rs12422554	chr12:2312620	A/C	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs8060686	0.623	rs6499157	chr16:68105474	A/C	cg26727032	chr16:67993705	SLC12A4	-0.74	-9.02	-0.5	5.68e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg06640241	chr16:89574553	SPG7	0.48	6.09	0.36	4.41e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg10523679	chr1:76189770	ACADM	-0.51	-6.92	-0.4	3.95e-11	Daytime sleep phenotypes;
KIRP	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg17554472	chr22:41940697	POLR3H	0.69	7.08	0.41	1.48e-11	Vitiligo;
KIRP	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-7.62	-0.44	5.48e-13	Vitiligo;
KIRP	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.88	10.05	0.54	3.84e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-1.05	-17.81	-0.75	3.97e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg01721255	chr8:58191610	C8orf71	0.5	4.92	0.3	1.58e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs17253792	0.545	rs75276278	chr14:56024341	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.86	12.4	0.62	9.28e-28	Chronic sinus infection;
KIRP	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs9290877	0.667	rs9845169	chr3:188457255	G/T	cg17392043	chr3:188495102	LPP	-0.53	-6.89	-0.4	4.57e-11	IgE levels;
KIRP	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.52	7.16	0.42	9.44e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs4349753	0.904	rs248577	chr5:144202561	A/G	cg16033277	chr17:80885358	TBCD	0.4	6.18	0.37	2.67e-9	Photic sneeze reflex;
KIRP	cis	rs735539	0.521	rs574139	chr13:21425816	T/G	cg04906043	chr13:21280425	IL17D	-0.43	-5.06	-0.31	8.16e-7	Dental caries;
KIRP	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg13147721	chr7:65941812	NA	0.9	6.47	0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-10.25	-0.55	9.2e-21	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.73	5.67	0.34	4.06e-8	Putamen volume;
KIRP	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg16141378	chr3:129829833	LOC729375	0.52	6.47	0.38	5.21e-10	Myopia (pathological);
KIRP	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg16482183	chr6:26056742	HIST1H1C	0.6	6.83	0.4	6.71e-11	Iron status biomarkers;
KIRP	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg02807482	chr3:125708958	NA	-0.53	-4.98	-0.3	1.19e-6	Blood pressure (smoking interaction);
KIRP	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg03959625	chr15:84868606	LOC388152	0.48	5.72	0.34	3.01e-8	Schizophrenia;
KIRP	cis	rs17125944	0.506	rs1998776	chr14:53355590	T/A	cg00686598	chr14:53173677	PSMC6	-0.67	-6.32	-0.37	1.25e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg18132916	chr6:79620363	NA	-0.4	-5.61	-0.34	5.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.5	-7.29	-0.42	4.27e-12	Daytime sleep phenotypes;
KIRP	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.99	10.64	0.56	5.43e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs11169552	0.510	rs7307419	chr12:51007013	T/C	cg12884762	chr12:50931848	DIP2B	-0.42	-5.05	-0.31	8.78e-7	Colorectal cancer;
KIRP	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.61	5.94	0.35	9.93e-9	Tuberculosis;
KIRP	cis	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.04	-0.31	8.9e-7	Neuroticism;
KIRP	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.64	-0.34	4.68e-8	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7546668	1.000	rs6686890	chr1:15835414	C/G	cg21858823	chr1:15850916	CASP9	0.46	5.13	0.31	5.88e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg27566289	chr17:48133890	ITGA3	0.52	6.16	0.37	3.01e-9	Inflammatory biomarkers;
KIRP	cis	rs12431939	0.948	rs12433249	chr14:51669661	T/C	cg23942311	chr14:51606299	NA	-0.51	-5.41	-0.33	1.47e-7	Cancer;
KIRP	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg05805236	chr11:65401703	PCNXL3	0.59	7.7	0.44	3.4e-13	Acne (severe);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23479892	chr3:15469033	METTL6;EAF1	0.5	7.06	0.41	1.74e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.55	6.4	0.38	7.95e-10	Body mass index (adult);
KIRP	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs7224685	0.501	rs781852	chr17:3953102	A/G	cg17441377	chr17:3906640	NA	0.55	8.29	0.47	7.31e-15	Type 2 diabetes;
KIRP	trans	rs2998286	0.723	rs231202	chr10:28849040	A/G	cg10174683	chr16:85619974	NA	-0.65	-6.06	-0.36	5e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs501120	0.513	rs1680639	chr10:44701754	T/G	cg09554077	chr10:44749378	NA	0.52	5.6	0.34	5.67e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2278796	0.639	rs6661381	chr1:204971553	A/G	cg17449235	chr1:204966235	NFASC	0.58	7.92	0.45	8.37e-14	Mean platelet volume;
KIRP	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.87	13.4	0.65	4.2e-31	Total body bone mineral density;
KIRP	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.65	-0.34	4.32e-8	Colorectal cancer;
KIRP	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.92	12.8	0.63	4.45e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.48	5.79	0.35	2.17e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.54	7.09	0.41	1.41e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.44	5.03	0.31	9.48e-7	Resting heart rate;
KIRP	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg17757837	chr7:157058334	UBE3C	0.78	10.52	0.56	1.31e-21	Body mass index;
KIRP	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs7851660	0.874	rs10818175	chr9:100633386	T/C	cg13688889	chr9:100608707	NA	-0.67	-8.78	-0.49	2.74e-16	Strep throat;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg21824413	chr3:23987438	NR1D2	-0.51	-6.74	-0.39	1.14e-10	Myopia;
KIRP	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-10.28	-0.55	7.46e-21	Body mass index;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.43	9.01	0.5	5.96e-17	Vitiligo;
KIRP	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg16497661	chr14:103986332	CKB	0.76	11.26	0.58	5.58e-24	Body mass index;
KIRP	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21545522	chr1:205238299	TMCC2	0.55	7.33	0.42	3.34e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg05791153	chr7:19748676	TWISTNB	0.67	6.03	0.36	6.13e-9	Thyroid stimulating hormone;
KIRP	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.89	13.16	0.64	2.7e-30	Psoriasis;
KIRP	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.63	-0.34	4.85e-8	Coronary artery disease;
KIRP	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01200585	chr1:228362443	C1orf69	0.41	5.14	0.31	5.58e-7	Diastolic blood pressure;
KIRP	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs72627123	0.867	rs73303135	chr14:74495090	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.9	6.66	0.39	1.76e-10	Morning vs. evening chronotype;
KIRP	cis	rs11230563	0.501	rs599856	chr11:60818176	G/A	cg19307003	chr11:60775715	CD6	-0.32	-5.21	-0.32	4.03e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.23	0.42	6.09e-12	Prudent dietary pattern;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	8.65	0.48	6.73e-16	Lung function (FEV1/FVC);
KIRP	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07701084	chr6:150067640	NUP43	0.7	9.22	0.51	1.42e-17	Lung cancer;
KIRP	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.75	-0.73	1.59e-42	Height;
KIRP	trans	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.21	0.37	2.29e-9	Mean corpuscular volume;
KIRP	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.5	0.33	9.56e-8	Menopause (age at onset);
KIRP	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg19767477	chr5:127420684	SLC12A2	-0.37	-5.34	-0.32	2.1e-7	Ileal carcinoids;
KIRP	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg17264618	chr3:40429014	ENTPD3	0.36	5.44	0.33	1.27e-7	Renal cell carcinoma;
KIRP	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg16989719	chr2:238392110	NA	-0.53	-7.12	-0.41	1.18e-11	Prostate cancer;
KIRP	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.9	0.3	1.7e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs4262150	0.667	rs2069117	chr5:152244551	A/C	cg12297329	chr5:152029980	NA	0.47	6.61	0.39	2.3e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.8	11.4	0.59	1.83e-24	Obesity-related traits;
KIRP	cis	rs897080	0.552	rs1067375	chr2:44650118	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.52	-5.62	-0.34	5.27e-8	Height;
KIRP	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06481639	chr22:41940642	POLR3H	0.66	6.72	0.39	1.24e-10	Vitiligo;
KIRP	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.87	0.4	5.2e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs57549656	0.799	rs72980725	chr19:2711083	T/C	cg06609049	chr19:2785107	THOP1	0.53	4.93	0.3	1.52e-6	Schizophrenia;
KIRP	cis	rs9303542	0.559	rs55859232	chr17:46612645	A/G	cg04904318	chr17:46607828	HOXB1	-0.62	-6.66	-0.39	1.75e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.21	15.1	0.69	6.55e-37	Alzheimer's disease;
KIRP	trans	rs12517041	1.000	rs28421903	chr5:23281290	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.87	-8.13	-0.46	2.12e-14	Calcium levels;
KIRP	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.43	-5.69	-0.34	3.51e-8	Melanoma;
KIRP	cis	rs4132509	0.696	rs10927062	chr1:243889364	A/G	cg21452805	chr1:244014465	NA	0.57	5.88	0.35	1.31e-8	RR interval (heart rate);
KIRP	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.73	7.91	0.45	8.93e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.95e-15	Aortic root size;
KIRP	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-7.28	-0.42	4.59e-12	Dental caries;
KIRP	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.97	0.41	2.87e-11	Platelet count;
KIRP	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg13165212	chr22:42675999	NA	0.28	5.03	0.31	9.45e-7	Cognitive function;
KIRP	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.07	-0.36	4.83e-9	Morning vs. evening chronotype;
KIRP	cis	rs4478858	0.611	rs6425721	chr1:31714807	C/T	cg00250761	chr1:31883323	NA	-0.32	-5.66	-0.34	4.31e-8	Alcohol dependence;
KIRP	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg07843065	chr1:150265600	MRPS21	0.46	6.06	0.36	4.95e-9	Migraine;
KIRP	cis	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.35	-0.32	2.05e-7	Leprosy;
KIRP	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.61	7.53	0.43	9.38e-13	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6967385	0.560	rs10254029	chr7:12343148	G/C	cg20607287	chr7:12443886	VWDE	0.4	5.02	0.3	9.84e-7	Response to taxane treatment (placlitaxel);
KIRP	cis	rs4141404	0.604	rs5753625	chr22:31854846	C/T	cg02404636	chr22:31891804	SFI1	-0.48	-6.15	-0.37	3.11e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg10223061	chr2:219282414	VIL1	-0.31	-5.16	-0.31	4.97e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.83	13.66	0.66	5.42e-32	Brugada syndrome;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.73	11.92	0.61	3.76e-26	Longevity;Endometriosis;
KIRP	cis	rs6142102	0.847	rs4911413	chr20:32721775	T/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.35	0.38	1.05e-9	Skin pigmentation;
KIRP	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2224391	0.628	rs2773299	chr6:5242169	C/G	cg13962347	chr6:5174647	LYRM4	-0.73	-10.24	-0.55	9.76e-21	Height;
KIRP	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg06115741	chr20:33292138	TP53INP2	0.41	5.46	0.33	1.18e-7	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.56	6.83	0.4	6.5e-11	Aortic root size;
KIRP	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg06647332	chr5:131281008	NA	-0.44	-4.88	-0.3	1.9e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.42	-4.87	-0.3	1.96e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.6	7.22	0.42	6.43e-12	Uric acid levels;
KIRP	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-1.13	-14.59	-0.68	3.57e-35	Platelet distribution width;
KIRP	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	IgG glycosylation;
KIRP	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.02	-0.36	6.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.28e-8	Aortic root size;
KIRP	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg21573476	chr21:45109991	RRP1B	-0.64	-8.7	-0.48	4.98e-16	Mean corpuscular volume;
KIRP	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	6.07	0.36	4.85e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.14e-13	Alzheimer's disease;
KIRP	cis	rs1816752	0.837	rs57052031	chr13:24983868	T/A	cg22771759	chr13:24902376	NA	0.38	4.89	0.3	1.83e-6	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs6859018	0.951	rs3181218	chr5:158752146	C/T	cg26646896	chr5:158686746	NA	-0.34	-4.95	-0.3	1.36e-6	Serum sulfate level;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00459944	chr3:39148298	TTC21A;GORASP1	0.45	6.57	0.39	2.98e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6750047	0.625	rs59363818	chr2:38261973	A/C	cg07380506	chr2:38303506	CYP1B1	-0.45	-5.95	-0.35	9.25e-9	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg07162820	chr14:24837146	NFATC4	0.4	5.59	0.34	6.11e-8	Height;
KIRP	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg25342872	chr17:79175132	AZI1	-0.59	-7.82	-0.45	1.53e-13	Frontotemporal dementia;
KIRP	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.55	6.99	0.41	2.56e-11	Crohn's disease;
KIRP	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	0.95	8.07	0.46	3.03e-14	Gut microbiota (bacterial taxa);
KIRP	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.96	0.41	3.05e-11	Menarche (age at onset);
KIRP	cis	rs4132509	1.000	rs7514984	chr1:243965623	C/T	cg21452805	chr1:244014465	NA	0.53	5.15	0.31	5.36e-7	RR interval (heart rate);
KIRP	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg12140854	chr5:148520817	ABLIM3	-0.52	-6.25	-0.37	1.8e-9	Breast cancer;
KIRP	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.68	-7.93	-0.45	7.47e-14	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.89	0.45	1.02e-13	Coffee consumption (cups per day);
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.67	6.21	0.37	2.18e-9	Alzheimer's disease;
KIRP	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.47	-6.44	-0.38	6.15e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7084402	0.817	rs7099496	chr10:60265242	G/A	cg05938607	chr10:60274200	BICC1	0.41	9.7	0.53	4.67e-19	Refractive error;
KIRP	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg25838818	chr2:108905173	SULT1C2	0.41	5.98	0.36	7.88e-9	Blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12912869	chr13:114108515	ADPRHL1	-0.39	-6.24	-0.37	1.85e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg12315302	chr6:26189340	HIST1H4D	0.94	5.83	0.35	1.75e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04491365	chr4:144141639	USP38	-0.41	-6.1	-0.36	4.09e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg07169764	chr2:136633963	MCM6	0.54	6.31	0.37	1.32e-9	Mosquito bite size;
KIRP	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.55	9.59	0.52	1.01e-18	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
KIRP	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.95e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs61863818	0.709	rs10786343	chr10:99159465	C/A	cg20016023	chr10:99160130	RRP12	-0.42	-5.78	-0.35	2.25e-8	Monocyte percentage of white cells;
KIRP	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.79e-7	Bladder cancer;
KIRP	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.26	-17.51	-0.74	3.97e-45	Type 1 diabetes nephropathy;
KIRP	cis	rs7551222	0.749	rs6682208	chr1:204566183	T/C	cg20240347	chr1:204465584	NA	-0.4	-7.76	-0.44	2.24e-13	Schizophrenia;
KIRP	cis	rs1318772	0.932	rs11744737	chr5:112932389	T/G	cg12552261	chr5:112820674	MCC	0.75	5.24	0.32	3.4e-7	F-cell distribution;
KIRP	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg11522683	chr6:37501428	NA	-0.36	-4.85	-0.3	2.15e-6	Cognitive performance;
KIRP	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-5.91	-0.35	1.15e-8	Crohn's disease;
KIRP	cis	rs2458413	0.542	rs2002812	chr8:105365234	C/T	cg08657449	chr8:105351661	TM7SF4	-0.34	-5.59	-0.34	6.05e-8	Paget's disease;
KIRP	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg25547332	chr5:131281432	NA	0.46	5.33	0.32	2.19e-7	Life satisfaction;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg01044394	chr3:51422497	MANF	0.5	6.36	0.38	9.7e-10	Colorectal cancer;
KIRP	cis	rs4664308	0.594	rs4665141	chr2:160890795	A/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-9.97	-0.54	6.74e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg26554054	chr8:600488	NA	0.68	4.9	0.3	1.74e-6	IgG glycosylation;
KIRP	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.54	5.96	0.36	8.57e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg01529538	chr14:23388837	RBM23	0.42	5.29	0.32	2.68e-7	Cognitive ability (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-15.63	-0.71	1.02e-38	Height;
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg08989290	chr16:615782	NHLRC4	0.42	6.38	0.38	8.77e-10	Height;
KIRP	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg01304814	chr3:48885189	PRKAR2A	0.81	5.92	0.35	1.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs778371	0.788	rs778355	chr2:233784749	T/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-6.1	-0.36	4.18e-9	Schizophrenia;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.23	-24.64	-0.84	2.17e-68	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg16141378	chr3:129829833	LOC729375	-0.59	-8.24	-0.47	1e-14	Neuroticism;
KIRP	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg16482183	chr6:26056742	HIST1H1C	0.66	7.22	0.42	6.46e-12	Iron status biomarkers;
KIRP	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg00933542	chr6:150070202	PCMT1	0.3	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs34779708	0.966	rs1213392	chr10:35430285	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.76	-0.4	9.83e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3218477	1.000	rs111585335	chr7:152368232	G/A	cg06618968	chr7:152373420	XRCC2	-0.83	-5.38	-0.32	1.69e-7	Mean platelet volume;
KIRP	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Bipolar disorder;
KIRP	cis	rs8038465	0.615	rs62004618	chr15:73962164	A/G	cg15420318	chr15:73925796	NPTN	0.62	8.84	0.49	1.84e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.09	0.31	7.12e-7	Parkinson's disease;
KIRP	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg03342759	chr3:160939853	NMD3	0.45	5.41	0.33	1.52e-7	Morning vs. evening chronotype;
KIRP	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.26	24.21	0.84	4.93e-67	IgG glycosylation;
KIRP	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg23307798	chr14:103986281	CKB	0.78	13.62	0.66	7.28e-32	Body mass index;
KIRP	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.56	-7.71	-0.44	3.08e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2151522	0.762	rs1361832	chr6:127187019	C/T	cg21431617	chr6:127135037	NA	-0.28	-4.89	-0.3	1.81e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.93	0.57	6.37e-23	Cognitive test performance;
KIRP	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg00745463	chr17:30367425	LRRC37B	-0.56	-5.26	-0.32	3.1e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs62355272	0.931	rs1833907	chr5:35904614	A/C	cg13894535	chr5:35919491	CAPSL	0.52	6.21	0.37	2.3e-9	Lymphocyte counts;
KIRP	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.74	-12.17	-0.61	5.39e-27	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.59	7.22	0.42	6.51e-12	Blood metabolite levels;
KIRP	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.67	0.39	1.67e-10	Myopia (pathological);
KIRP	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.58	0.48	1.07e-15	Bipolar disorder;
KIRP	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.53	6.62	0.39	2.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6430538	0.646	rs6430539	chr2:135549730	A/G	cg25422880	chr2:135218333	TMEM163	-0.38	-5.3	-0.32	2.53e-7	Parkinson's disease;
KIRP	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.39	6.01	0.36	6.6e-9	Attention deficit hyperactivity disorder;
KIRP	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.72	-0.56	2.91e-22	Neuroticism;
KIRP	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.57	7.17	0.42	9e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.18	-0.42	8.19e-12	Intelligence (multi-trait analysis);Educational attainment (years of education);
KIRP	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00889227	chr1:205173544	DSTYK	-0.41	-5.81	-0.35	1.92e-8	Red blood cell count;
KIRP	cis	rs3736485	0.873	rs12442725	chr15:51874412	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.57e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4363385	0.720	rs883810	chr1:152941345	T/C	cg13444842	chr1:152974279	SPRR3	-0.36	-4.86	-0.3	2.12e-6	Inflammatory skin disease;
KIRP	cis	rs9488822	0.702	rs10872141	chr6:116323246	C/A	cg15226275	chr6:116381976	FRK	0.22	6.02	0.36	6.32e-9	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-6.64	-0.39	1.94e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02668471	chr12:110011326	MMAB;MVK	0.48	6.19	0.37	2.49e-9	Parkinson's disease;
KIRP	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg11833968	chr6:79620685	NA	-0.46	-7.04	-0.41	1.89e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg09626299	chr10:82213104	TSPAN14	-0.32	-4.88	-0.3	1.94e-6	Post bronchodilator FEV1;
KIRP	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.36	0.59	2.61e-24	Heart rate;
KIRP	cis	rs3981351	0.528	rs12768908	chr10:115443894	C/T	cg24846397	chr10:115438155	CASP7	-0.43	-5.42	-0.33	1.45e-7	Obesity-related traits;
KIRP	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg12560992	chr17:57184187	TRIM37	0.68	6.33	0.37	1.14e-9	Cognitive test performance;
KIRP	cis	rs2644899	0.785	rs2604895	chr19:41292263	T/A	cg24958765	chr19:41283667	RAB4B	-0.6	-6.59	-0.39	2.65e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.53	-7.28	-0.42	4.37e-12	Glioblastoma;Glioma;
KIRP	trans	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.31	-0.37	1.31e-9	Neuroticism;
KIRP	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03605463	chr16:89740564	NA	-0.46	-5.29	-0.32	2.73e-7	Vitiligo;
KIRP	cis	rs2120243	0.647	rs7632702	chr3:157145903	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.37	5.23	0.32	3.59e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.55	-7.58	-0.44	6.89e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14842401	chr3:40566302	ZNF621	-0.47	-6.23	-0.37	1.98e-9	Myopia;
KIRP	cis	rs77861329	0.920	rs9860982	chr3:52096432	T/C	cg08692210	chr3:52188851	WDR51A	0.81	5.51	0.33	8.87e-8	Macrophage inflammatory protein 1b levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18500826	chr12:68716789	MDM1	-0.44	-6.51	-0.38	4.21e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7975161	1.000	rs7960443	chr12:104645363	G/A	cg25273343	chr12:104657179	TXNRD1	-0.6	-6.11	-0.36	3.86e-9	Toenail selenium levels;
KIRP	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg21605333	chr4:119757512	SEC24D	1.36	9.38	0.51	4.61e-18	Cannabis dependence symptom count;
KIRP	trans	rs1864585	0.552	rs73208794	chr8:10681248	C/G	cg26278703	chr11:58910052	FAM111A	0.64	6.41	0.38	7.25e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.04	-0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-5.59	-0.34	6.06e-8	Cognitive function;
KIRP	cis	rs6977660	0.619	rs10223937	chr7:19787697	C/T	cg05791153	chr7:19748676	TWISTNB	0.54	5.6	0.34	5.69e-8	Thyroid stimulating hormone;
KIRP	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg00677455	chr12:58241039	CTDSP2	-0.51	-5.78	-0.35	2.21e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.86	0.6	5.86e-26	Alzheimer's disease;
KIRP	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg17554472	chr22:41940697	POLR3H	0.55	6.08	0.36	4.56e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.46	5.89	0.35	1.27e-8	Dilated cardiomyopathy;
KIRP	cis	rs2737618	0.722	rs2737676	chr1:200086839	T/C	cg21825944	chr1:200113062	NR5A2	-0.57	-7.77	-0.44	2.15e-13	Uric acid levels;
KIRP	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg24009623	chr19:33667908	NA	0.47	6.19	0.37	2.5e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg21918786	chr6:109611834	NA	-0.43	-6.09	-0.36	4.42e-9	Reticulocyte fraction of red cells;
KIRP	trans	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg26811252	chr16:29126840	RRN3P2	0.67	8.59	0.48	1.04e-15	Menopause (age at onset);
KIRP	cis	rs7584330	0.666	rs1574530	chr2:238395708	A/T	cg16989719	chr2:238392110	NA	-0.66	-7.83	-0.45	1.46e-13	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11519710	chr1:2239646	SKI	0.42	6.29	0.37	1.4e-9	Interleukin-4 levels;
KIRP	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.83	10.04	0.54	4.2e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	8.88	0.49	1.47e-16	Platelet count;
KIRP	cis	rs240764	0.717	rs151640	chr6:101111521	A/C	cg09795085	chr6:101329169	ASCC3	0.46	5.51	0.33	8.83e-8	Neuroticism;
KIRP	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs6921919	0.583	rs7749736	chr6:28346031	G/C	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7221595	0.825	rs4790552	chr17:3923366	G/A	cg21851534	chr17:3907994	ZZEF1	0.61	6.53	0.38	3.72e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01668174	chr2:106810661	UXS1	0.53	6.07	0.36	4.87e-9	Smoking initiation;
KIRP	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.76	-0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs2179367	0.959	rs9377212	chr6:149704901	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.3	-4.92	-0.3	1.56e-6	Dupuytren's disease;
KIRP	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03517284	chr6:25882590	NA	-0.4	-5.87	-0.35	1.43e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11645453	chr3:52864694	ITIH4	-0.35	-5.46	-0.33	1.14e-7	Body mass index;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg24809958	chr1:6662478	KLHL21	0.49	6.27	0.37	1.57e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.29	-5.72	-0.34	3.11e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.42	-5.17	-0.31	4.77e-7	Renal function-related traits (BUN);
KIRP	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	cis	rs539514	0.690	rs34545980	chr13:76309637	C/A	cg04757411	chr13:76259545	LMO7	-0.35	-5.02	-0.3	9.94e-7	Type 1 diabetes;
KIRP	cis	rs6088813	1.000	rs6142359	chr20:33960450	T/C	cg14752227	chr20:34000481	UQCC	-0.53	-7.06	-0.41	1.7e-11	Height;
KIRP	cis	rs60871478	0.680	rs34880331	chr7:786833	A/G	cg13798912	chr7:905769	UNC84A	0.7	6.69	0.39	1.5e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg06212747	chr3:49208901	KLHDC8B	0.7	8.25	0.47	9.68e-15	Menarche (age at onset);
KIRP	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12826209	chr6:26865740	GUSBL1	0.77	5.37	0.32	1.82e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	9.42	0.51	3.55e-18	Cognitive test performance;
KIRP	cis	rs9381040	1.000	rs9394766	chr6:41159801	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.64	-6.77	-0.4	9.33e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7923609	0.838	rs7909960	chr10:65239177	T/A	cg01631684	chr10:65280961	REEP3	-0.51	-6.0	-0.36	7.17e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg00806126	chr19:22604979	ZNF98	0.63	6.66	0.39	1.79e-10	Pain;
KIRP	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg08280861	chr8:58055591	NA	0.64	5.86	0.35	1.45e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3820928	1.000	rs4675115	chr2:227769123	C/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.98	-0.3	1.19e-6	Pulmonary function;
KIRP	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg08501292	chr6:25962987	TRIM38	0.88	7.0	0.41	2.43e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.61	10.57	0.56	8.81e-22	Obesity-related traits;
KIRP	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg19847130	chr8:10466454	RP1L1	0.34	4.93	0.3	1.49e-6	Retinal vascular caliber;
KIRP	cis	rs56161922	0.818	rs55638397	chr1:207856040	G/A	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs3784262	0.528	rs8027188	chr15:58334799	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.86	-0.3	2.11e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg22852734	chr6:133119734	C6orf192	1.01	10.92	0.57	6.76e-23	Type 2 diabetes nephropathy;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg20594465	chr13:58246705	PCDH17	0.41	6.28	0.37	1.55e-9	Migraine with aura;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11294835	chr3:48701061	CELSR3	0.46	6.42	0.38	7.08e-10	Smoking initiation;
KIRP	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.35e-9	Myopia (pathological);
KIRP	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg16497661	chr14:103986332	CKB	0.81	13.35	0.65	6.12e-31	Body mass index;
KIRP	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.76	9.91	0.53	1.1e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.61	-0.34	5.55e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs12476592	0.602	rs262524	chr2:63892727	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-4.9	-0.3	1.74e-6	Childhood ear infection;
KIRP	cis	rs9905704	0.709	rs758378	chr17:56607746	G/C	cg12560992	chr17:57184187	TRIM37	-0.56	-5.75	-0.34	2.64e-8	Testicular germ cell tumor;
KIRP	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.58	-7.3	-0.42	3.98e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3755132	0.929	rs3770463	chr2:15749658	T/C	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-7.9	-0.45	9.14e-14	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.98	-17.15	-0.74	6.82e-44	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.79	-11.24	-0.58	6.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9323205	0.911	rs60034431	chr14:51622437	C/A	cg23942311	chr14:51606299	NA	-0.57	-6.2	-0.37	2.36e-9	Cancer;
KIRP	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.83	9.29	0.51	8.35e-18	Alzheimer's disease;
KIRP	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg19773385	chr1:10388646	KIF1B	-0.69	-9.36	-0.51	5.25e-18	Hepatocellular carcinoma;
KIRP	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.79	8.74	0.49	3.69e-16	Pulmonary function decline;
KIRP	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg05527609	chr1:210001259	C1orf107	-0.47	-5.16	-0.31	4.98e-7	Red blood cell count;
KIRP	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.53	8.72	0.49	4.33e-16	Rheumatoid arthritis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07393570	chr1:172863499	NA	0.41	6.38	0.38	8.6e-10	C-reactive protein;
KIRP	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg00409905	chr10:38381863	ZNF37A	0.53	5.81	0.35	1.91e-8	Obesity (extreme);
KIRP	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg25019033	chr10:957182	NA	-0.63	-6.63	-0.39	2.16e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs7172677	1.000	rs2029520	chr15:75415768	A/G	cg14082893	chr15:75400931	NA	0.38	5.54	0.33	7.78e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg21573476	chr21:45109991	RRP1B	-0.7	-10.59	-0.56	7.91e-22	Mean corpuscular volume;
KIRP	trans	rs7246760	0.867	rs3859512	chr19:9932831	C/T	cg02900749	chr2:68251473	NA	-1.1	-9.28	-0.51	8.96e-18	Pursuit maintenance gain;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.2	21.74	0.81	3.52e-59	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10941835	chr20:50419348	SALL4	0.59	7.4	0.43	2.09e-12	Interleukin-4 levels;
KIRP	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.62	-5.93	-0.35	9.99e-9	Breast cancer;
KIRP	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.21	-28.08	-0.87	1.12e-78	Myeloid white cell count;
KIRP	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.51	6.78	0.4	8.87e-11	Childhood ear infection;
KIRP	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg05802129	chr4:122689817	NA	-0.49	-7.01	-0.41	2.29e-11	Type 2 diabetes;
KIRP	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.61	-0.44	5.66e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-7.14	-0.41	1.02e-11	Morning vs. evening chronotype;
KIRP	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg01677386	chr11:118938358	VPS11	-0.56	-6.71	-0.39	1.36e-10	Coronary artery disease;
KIRP	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.62	7.93	0.45	7.59e-14	Coronary artery disease;
KIRP	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	4.96	0.3	1.34e-6	Tonsillectomy;
KIRP	cis	rs3857536	0.904	rs9294684	chr6:66897589	A/C	cg07460842	chr6:66804631	NA	0.4	5.24	0.32	3.38e-7	Blood trace element (Cu levels);
KIRP	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs16857609	0.564	rs1478580	chr2:218291649	C/T	cg15335768	chr2:218268053	DIRC3	-0.52	-6.84	-0.4	6.24e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg09699651	chr6:150184138	LRP11	0.47	6.36	0.38	9.91e-10	Lung cancer;
KIRP	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.51	-0.38	4.22e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.31e-11	Aortic root size;
KIRP	cis	rs4262150	0.883	rs72802856	chr5:152218952	G/A	cg12297329	chr5:152029980	NA	-0.61	-8.22	-0.46	1.2e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	1.14	9.25	0.51	1.1e-17	Plateletcrit;
KIRP	trans	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.45	6.17	0.37	2.75e-9	Leprosy;
KIRP	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.11	0.54	2.48e-20	Total body bone mineral density;
KIRP	cis	rs7523273	0.526	rs733177	chr1:208046384	C/T	cg22525895	chr1:207977042	MIR29B2	0.41	5.08	0.31	7.49e-7	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs656319	0.702	rs587328	chr8:9809722	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.2	-0.37	2.36e-9	Myopia (pathological);
KIRP	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg00933542	chr6:150070202	PCMT1	0.3	5.67	0.34	3.98e-8	Lung cancer;
KIRP	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg00405596	chr8:11794950	NA	-0.4	-4.89	-0.3	1.81e-6	Neuroticism;
KIRP	cis	rs714031	0.867	rs5750868	chr22:40063012	G/A	cg21377881	chr22:40064566	CACNA1I	-0.71	-11.33	-0.59	3.11e-24	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09994773	chr1:9212514	MIR34A	0.52	7.39	0.43	2.25e-12	Survival in pancreatic cancer;
KIRP	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.13	-0.31	5.84e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.69	-10.95	-0.57	5.33e-23	Educational attainment;
KIRP	cis	rs10875746	0.903	rs12301339	chr12:48475233	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs4356932	1.000	rs4241578	chr4:76944491	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs12135191	0.615	rs10802526	chr1:236491969	T/C	cg21399712	chr1:236511386	NA	-0.44	-5.71	-0.34	3.21e-8	Urate levels (BMI interaction);
KIRP	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.35	-0.38	1.01e-9	Alcohol dependence;
KIRP	cis	rs9479482	0.648	rs912557	chr6:150385977	C/T	cg03788504	chr6:150331562	NA	-0.34	-6.14	-0.36	3.28e-9	Alopecia areata;
KIRP	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.63	7.73	0.44	2.68e-13	Height;
KIRP	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg24296786	chr1:45957014	TESK2	0.52	5.74	0.34	2.71e-8	Homocysteine levels;
KIRP	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg27247782	chr7:158767135	NA	-0.39	-4.88	-0.3	1.91e-6	Facial morphology (factor 20);
KIRP	cis	rs4459895	0.762	rs10804914	chr3:187970450	A/G	cg17585528	chr3:187988060	LPP	-0.55	-4.96	-0.3	1.29e-6	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
KIRP	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg13072238	chr3:49761600	GMPPB	0.61	5.58	0.34	6.4e-8	Menarche (age at onset);
KIRP	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.11e-13	Uric acid levels;
KIRP	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.74	10.62	0.56	6.36e-22	Psoriasis;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06665941	chr21:34602869	IFNAR2	-0.48	-6.16	-0.37	2.98e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4073416	0.542	rs7140695	chr14:65929132	T/C	cg03016385	chr14:66212404	NA	-0.53	-6.68	-0.39	1.57e-10	N-glycan levels;
KIRP	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-8.21	-0.46	1.28e-14	Vitiligo;
KIRP	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-1.07	-10.12	-0.54	2.3e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg14664628	chr15:75095509	CSK	-0.56	-6.22	-0.37	2.13e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg05527609	chr1:210001259	C1orf107	-0.49	-5.21	-0.32	4.07e-7	Red blood cell count;
KIRP	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-1.04	-12.83	-0.63	3.43e-29	Breast cancer;
KIRP	cis	rs9473924	0.505	rs9473931	chr6:50851411	C/G	cg14470998	chr6:50812995	TFAP2B	0.83	7.63	0.44	5.26e-13	Body mass index;
KIRP	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14075742	chr18:5539428	EPB41L3	-0.44	-6.79	-0.4	8.31e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.26	-0.32	3.11e-7	Post bronchodilator FEV1;
KIRP	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg11031976	chr2:198649780	BOLL	-0.5	-5.08	-0.31	7.31e-7	Ulcerative colitis;
KIRP	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg09408571	chr1:101003634	GPR88	-0.22	-5.02	-0.3	9.87e-7	Monocyte count;
KIRP	cis	rs2882667	0.898	rs2351465	chr5:138363851	A/C	cg04439458	chr5:138467593	SIL1	-0.44	-7.39	-0.43	2.33e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg10253484	chr15:75165896	SCAMP2	-0.53	-6.42	-0.38	6.78e-10	Breast cancer;
KIRP	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.13e-8	Common traits (Other);
KIRP	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg08807101	chr21:30365312	RNF160	-0.55	-5.38	-0.32	1.72e-7	Cognitive test performance;
KIRP	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.65	8.36	0.47	4.69e-15	Prudent dietary pattern;
KIRP	cis	rs4776059	1.000	rs11070907	chr15:52924231	G/T	cg25063058	chr15:52860530	ARPP19	0.53	5.98	0.36	7.78e-9	Schizophrenia;
KIRP	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.84e-18	Bipolar disorder;
KIRP	cis	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	13.8	0.66	1.79e-32	Smoking behavior;
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.31	-6.55	-0.39	3.29e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7688540	0.771	rs11722197	chr4:281707	A/G	cg17891759	chr4:299121	NA	-0.49	-5.13	-0.31	5.79e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.14e-15	Menarche (age at onset);
KIRP	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg13319975	chr6:146136371	FBXO30	-0.42	-5.75	-0.34	2.6e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	4.93	0.3	1.54e-6	Schizophrenia;
KIRP	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-1.09	-22.01	-0.81	4.7e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.63	-0.34	4.95e-8	Coronary artery disease;
KIRP	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10465746	0.935	rs12758441	chr1:84352034	A/G	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.19e-8	Obesity-related traits;
KIRP	cis	rs6256	1.000	rs11022876	chr11:13572708	A/G	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg19773385	chr1:10388646	KIF1B	-0.69	-9.2	-0.51	1.64e-17	Hepatocellular carcinoma;
KIRP	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg21360079	chr12:107162445	NA	-0.69	-9.82	-0.53	2.03e-19	Heart rate;
KIRP	cis	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg06521331	chr12:34319734	NA	-0.58	-7.14	-0.41	1.07e-11	Morning vs. evening chronotype;
KIRP	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.75	-8.62	-0.48	8.37e-16	Hirschsprung disease;
KIRP	cis	rs6708331	0.540	rs28623550	chr2:70366392	T/C	cg01613454	chr2:70366299	NA	0.41	5.49	0.33	1.02e-7	Obesity-related traits;
KIRP	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.31	5.59	0.34	6.07e-8	Calcium levels;
KIRP	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Body mass index;
KIRP	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2223471	0.624	rs182199	chr6:50669296	A/G	cg03432817	chr6:50765336	NA	0.39	5.99	0.36	7.6e-9	Subcutaneous adipose tissue;
KIRP	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.49	6.56	0.39	3.12e-10	Dupuytren's disease;
KIRP	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg17724175	chr1:150552817	MCL1	-0.31	-5.18	-0.31	4.7e-7	Tonsillectomy;
KIRP	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.89	-12.02	-0.61	1.76e-26	Cognitive function;
KIRP	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg12962167	chr3:53033115	SFMBT1	0.69	5.36	0.32	1.92e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.95	12.34	0.62	1.5e-27	Menopause (age at onset);
KIRP	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg13385521	chr17:29058706	SUZ12P	0.59	5.95	0.35	9.36e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg12861170	chr19:19639553	YJEFN3	0.47	4.9	0.3	1.71e-6	Bipolar disorder;
KIRP	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg03959625	chr15:84868606	LOC388152	0.72	8.62	0.48	8.3e-16	Schizophrenia;
KIRP	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.71	8.88	0.49	1.43e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg04398451	chr17:18023971	MYO15A	-0.67	-8.89	-0.49	1.32e-16	Total body bone mineral density;
KIRP	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.7	9.45	0.52	2.81e-18	Prostate cancer;
KIRP	cis	rs1629083	0.935	rs2368238	chr11:118091761	T/G	cg18857871	chr11:118064634	AMICA1	0.61	8.03	0.46	4.14e-14	Lung cancer;
KIRP	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.63	-0.48	7.87e-16	Blood trace element (Zn levels);
KIRP	cis	rs4666002	0.956	rs13020949	chr2:27836605	C/T	cg05484376	chr2:27715224	FNDC4	-0.37	-5.16	-0.31	5.11e-7	Phospholipid levels (plasma);
KIRP	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.85	0.6	6.19e-26	Smoking behavior;
KIRP	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg15117754	chr3:10150083	C3orf24	0.51	5.06	0.31	8.02e-7	Alzheimer's disease;
KIRP	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg26965718	chr17:79658957	HGS	-0.61	-4.87	-0.3	2e-6	Dental caries;
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.63	10.56	0.56	9.91e-22	Lung cancer;
KIRP	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.82	-11.33	-0.59	3.11e-24	Colorectal cancer;
KIRP	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.7	-11.12	-0.58	1.51e-23	Hepatocellular carcinoma;
KIRP	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.39	5.26	0.32	3.08e-7	Endometrial cancer;
KIRP	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg10617943	chr7:1981403	MAD1L1	-0.4	-5.54	-0.33	7.59e-8	Neuroticism;
KIRP	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg24531977	chr5:56204891	C5orf35	-0.42	-5.57	-0.33	6.64e-8	Coronary artery disease;
KIRP	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs6956675	1.000	rs10280052	chr7:62600311	C/T	cg08930214	chr7:62859557	LOC100287834	0.48	5.52	0.33	8.39e-8	Obesity-related traits;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg06106839	chr12:49620920	NA	0.42	6.45	0.38	5.87e-10	Serum protein levels (sST2);
KIRP	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg09462578	chr12:12878428	APOLD1	-0.7	-7.17	-0.42	8.54e-12	Systemic lupus erythematosus;
KIRP	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg13978929	chr19:21580086	ZNF493	0.5	5.0	0.3	1.11e-6	Pain;
KIRP	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.56	6.76	0.4	1e-10	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12116749	chr10:21245178	NEBL	-0.39	-6.28	-0.37	1.51e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4302748	0.818	rs1882064	chr7:36188616	G/A	cg24442661	chr7:36192818	EEPD1	0.61	6.87	0.4	5.16e-11	Platelet count;
KIRP	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.79	-0.35	2.11e-8	Recombination measurement;
KIRP	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.7	0.48	4.9e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs72653721	0.617	rs57940154	chr6:11035425	C/T	cg13562911	chr6:11044106	ELOVL2	0.52	5.64	0.34	4.76e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02725872	chr8:58115012	NA	-0.7	-8.02	-0.46	4.43e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11613427	chr3:52932208	TMEM110	0.31	5.03	0.31	9.29e-7	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19990483	chr14:51030485	ATL1	0.39	6.47	0.38	5.17e-10	C-reactive protein;
KIRP	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg00629928	chr5:358741	AHRR	0.51	4.97	0.3	1.27e-6	Breast cancer;
KIRP	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.23	0.67	6.32e-34	Electrocardiographic conduction measures;
KIRP	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg25486957	chr4:152246857	NA	-0.51	-5.68	-0.34	3.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.57	0.33	6.52e-8	Ovarian reserve;
KIRP	cis	rs2380205	0.967	rs4293038	chr10:5898159	G/A	cg27141509	chr10:5886111	NA	-0.39	-5.61	-0.34	5.31e-8	Breast cancer;
KIRP	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	5.08	0.31	7.39e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg02023728	chr11:77925099	USP35	-0.32	-5.59	-0.34	6e-8	Alzheimer's disease (survival time);
KIRP	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.99	15.98	0.71	6.51e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.62	0.48	8.29e-16	Prudent dietary pattern;
KIRP	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg08501292	chr6:25962987	TRIM38	0.79	5.43	0.33	1.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs4591494	0.752	rs9829153	chr3:7905601	A/G	cg07227033	chr7:12725802	ARL4A	-0.46	-6.09	-0.36	4.37e-9	Factor VII;
KIRP	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19346786	chr7:2764209	NA	-0.39	-6.5	-0.38	4.46e-10	Height;
KIRP	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-4.96	-0.3	1.33e-6	Coronary artery disease;
KIRP	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg05220968	chr6:146057943	EPM2A	-0.4	-5.07	-0.31	7.68e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10207628	1.000	rs10207628	chr2:127852021	C/G	cg06223080	chr2:127868745	NA	-0.61	-8.2	-0.46	1.34e-14	Psychosis and Alzheimer's disease;
KIRP	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg21452805	chr1:244014465	NA	0.58	5.67	0.34	3.99e-8	RR interval (heart rate);
KIRP	cis	rs3736485	0.966	rs6493510	chr15:51900651	T/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.22	-0.32	3.83e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.65	-9.41	-0.51	3.69e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7215564	0.908	rs34932625	chr17:78653155	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.21	0.32	3.97e-7	Myopia (pathological);
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg16590910	chr6:42928470	GNMT	0.42	5.76	0.34	2.56e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7851660	0.809	rs10984230	chr9:100660284	C/T	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg14689365	chr7:158441557	NCAPG2	-0.4	-4.85	-0.3	2.21e-6	Height;
KIRP	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.7	-8.95	-0.5	8.59e-17	Blood metabolite levels;
KIRP	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg08761264	chr16:28874980	SH2B1	-0.52	-6.03	-0.36	6.09e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs16936870	0.516	rs4738076	chr8:71100634	A/G	cg14232793	chr8:71155543	NCOA2	-0.56	-6.4	-0.38	7.92e-10	QT interval;
KIRP	trans	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg13565492	chr6:43139072	SRF	-0.86	-7.86	-0.45	1.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg08662619	chr6:150070041	PCMT1	0.36	6.09	0.36	4.4e-9	Lung cancer;
KIRP	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg16649577	chr8:11646810	NA	0.38	5.27	0.32	3.04e-7	Retinal vascular caliber;
KIRP	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg03060546	chr3:49711283	APEH	0.74	11.65	0.6	2.86e-25	Resting heart rate;
KIRP	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.21	-5.61	-0.34	5.43e-8	Mean corpuscular volume;
KIRP	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.63	7.48	0.43	1.3e-12	Obesity-related traits;
KIRP	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg04609801	chr16:28609176	SULT1A2	-0.55	-5.3	-0.32	2.56e-7	Platelet distribution width;
KIRP	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.42	-5.26	-0.32	3.2e-7	Aortic root size;
KIRP	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg24699146	chr1:24152579	HMGCL	-0.48	-6.58	-0.39	2.74e-10	Immature fraction of reticulocytes;
KIRP	cis	rs17121403	0.661	rs74888510	chr1:100499059	T/C	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg21775007	chr8:11205619	TDH	-0.67	-9.41	-0.51	3.71e-18	Retinal vascular caliber;
KIRP	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.32	5.06	0.31	8.26e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03398387	chr6:160114178	SOD2	0.81	6.82	0.4	7.12e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg25566285	chr7:158114605	PTPRN2	0.73	8.93	0.49	1.01e-16	Response to amphetamines;
KIRP	cis	rs735539	0.645	rs9550663	chr13:21174053	C/T	cg04906043	chr13:21280425	IL17D	-0.49	-5.57	-0.33	6.72e-8	Dental caries;
KIRP	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs189798	0.807	rs9949	chr8:8994512	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	5.43	0.33	1.32e-7	Myopia (pathological);
KIRP	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.95	10.01	0.54	5.42e-20	HIV-1 control;
KIRP	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg24315340	chr6:146058215	EPM2A	0.39	4.93	0.3	1.51e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg06307176	chr5:131281290	NA	0.55	5.87	0.35	1.42e-8	Life satisfaction;
KIRP	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	8.0	0.45	4.86e-14	Coffee consumption (cups per day);
KIRP	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	1.09	7.86	0.45	1.21e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4682868	0.581	rs4682869	chr3:42923964	A/G	cg21365077	chr3:42922735	NA	0.42	4.86	0.3	2.1e-6	Monocyte percentage of white cells;
KIRP	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	6.14	0.36	3.24e-9	Obesity-related traits;
KIRP	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg09408571	chr1:101003634	GPR88	-0.23	-5.36	-0.32	1.92e-7	Monocyte count;
KIRP	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg00343986	chr7:65444356	GUSB	0.43	5.1	0.31	6.89e-7	Aortic root size;
KIRP	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.73	-0.39	1.18e-10	Bipolar disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14639822	chr9:136131484	ABO	0.44	6.08	0.36	4.65e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg22563815	chr15:78856949	CHRNA5	-0.44	-6.99	-0.41	2.56e-11	Sudden cardiac arrest;
KIRP	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.06e-11	Bipolar disorder;
KIRP	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg02487422	chr3:49467188	NICN1	0.36	5.03	0.31	9.47e-7	Parkinson's disease;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg05627522	chr15:75251581	NA	0.4	6.44	0.38	6.23e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07315006	chr3:174812890	NAALADL2	0.42	6.26	0.37	1.68e-9	Migraine with aura;
KIRP	cis	rs34286592	0.929	rs35901559	chr16:29829615	T/C	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	5.1	0.31	6.78e-7	Multiple sclerosis;
KIRP	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.84	-0.4	6.27e-11	Morning vs. evening chronotype;
KIRP	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg01879757	chr17:41196368	BRCA1	-0.78	-10.64	-0.56	5.55e-22	Menopause (age at onset);
KIRP	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg27490568	chr2:178487706	NA	0.42	5.54	0.33	7.9e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.49e-6	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01735420	chr11:122527139	UBASH3B	0.46	6.23	0.37	1.99e-9	Parkinson's disease;
KIRP	cis	rs55962025	0.842	rs362306	chr4:3242100	C/T	cg13731523	chr4:3047190	NA	0.33	5.21	0.31	4.09e-7	Parental longevity (mother's age at death);
KIRP	cis	rs6681460	1.000	rs1325263	chr1:67129791	C/A	cg02459107	chr1:67143332	SGIP1	0.51	7.32	0.42	3.46e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg22903657	chr4:1355424	KIAA1530	-0.42	-6.05	-0.36	5.3300000000000004e-09	Obesity-related traits;
KIRP	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	1.12	10.28	0.55	7.3e-21	Lymphocyte counts;
KIRP	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.66	9.6	0.52	9.7e-19	Colorectal cancer;
KIRP	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14072140	chr1:98031839	DPYD	-0.43	-6.15	-0.37	3.11e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg23594656	chr7:65796392	TPST1	0.33	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	cis	rs35883536	0.528	rs10783138	chr1:101031061	C/T	cg09408571	chr1:101003634	GPR88	0.24	5.37	0.32	1.8e-7	Monocyte count;
KIRP	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	0.95	7.25	0.42	5.31e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12579753	0.692	rs7397373	chr12:82300010	C/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.56	-0.33	6.93e-8	Resting heart rate;
KIRP	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.62	0.44	5.57e-13	Aortic root size;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.52	-5.68	-0.34	3.73e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17401966	0.558	rs4846218	chr1:10452040	G/T	cg17425144	chr1:10567563	PEX14	-0.31	-5.47	-0.33	1.08e-7	Hepatocellular carcinoma;
KIRP	cis	rs4356932	1.000	rs6532158	chr4:76977964	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-1.03	-12.59	-0.63	2.24e-28	Exhaled nitric oxide output;
KIRP	cis	rs6723108	0.591	rs13399952	chr2:135394404	A/G	cg12500956	chr2:135428796	TMEM163	-0.42	-5.75	-0.34	2.62e-8	Type 2 diabetes;
KIRP	cis	rs6450176	0.909	rs6884760	chr5:53293077	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.0	-0.57	3.88e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7084402	0.967	rs7079648	chr10:60273155	C/A	cg05938607	chr10:60274200	BICC1	0.42	10.2	0.55	1.35e-20	Refractive error;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.79	-13.21	-0.64	1.77e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs76533333	0.605	rs12867229	chr13:113422075	G/A	cg04656015	chr13:113407548	ATP11A	0.65	5.57	0.33	6.62e-8	Red cell distribution width;
KIRP	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	1.3	9.0	0.5	6.34e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7635838	0.859	rs9869977	chr3:11480081	C/A	cg00170343	chr3:11313890	ATG7	0.48	6.11	0.36	3.78e-9	HDL cholesterol;
KIRP	cis	rs7546094	0.871	rs7512948	chr1:113081176	G/A	cg22162597	chr1:113214053	CAPZA1	0.4	5.36	0.32	1.89e-7	Platelet distribution width;
KIRP	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg16434002	chr17:42200994	HDAC5	0.46	5.25	0.32	3.22e-7	Total body bone mineral density;
KIRP	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg22906224	chr7:99728672	NA	-0.49	-6.04	-0.36	5.69e-9	Coronary artery disease;
KIRP	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.43	-5.73	-0.34	2.87e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18610889	chr5:110560172	CAMK4	0.48	6.21	0.37	2.23e-9	Parkinson's disease;
KIRP	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg20701182	chr2:24300061	SF3B14	-0.41	-5.24	-0.32	3.39e-7	Asthma;
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.37	-0.32	1.8e-7	Life satisfaction;
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.72	6.09	0.36	4.36e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg05347473	chr6:146136440	FBXO30	0.48	6.86	0.4	5.43e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12043259	0.730	rs4951127	chr1:204796440	G/A	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs62413470	1.000	rs62404868	chr6:55958119	T/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	trans	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg06521331	chr12:34319734	NA	-0.58	-7.09	-0.41	1.41e-11	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14122300	chr14:69446504	ACTN1	0.65	6.01	0.36	6.48e-9	Lung function (FEV1);
KIRP	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg05347473	chr6:146136440	FBXO30	0.49	6.9	0.4	4.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.58	-5.26	-0.32	3.17e-7	Obesity (extreme);
KIRP	cis	rs687432	0.924	rs7119218	chr11:57717429	C/T	cg19752551	chr11:57585705	CTNND1	-0.54	-7.42	-0.43	1.85e-12	Parkinson's disease;
KIRP	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26207909	chr14:103986467	CKB	0.75	11.35	0.59	2.65e-24	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05650458	chr1:228270764	ARF1	0.53	6.56	0.39	3.2e-10	Parkinson's disease;
KIRP	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg03388025	chr16:89894329	SPIRE2	0.32	5.59	0.34	6.09e-8	Vitiligo;
KIRP	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.79	10.06	0.54	3.7e-20	Menopause (age at onset);
KIRP	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.66	-10.19	-0.54	1.42e-20	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs12143943	0.934	rs868097	chr1:204580139	C/T	cg20240347	chr1:204465584	NA	-0.36	-6.46	-0.38	5.6e-10	Cognitive performance;
KIRP	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg13271783	chr10:134563150	INPP5A	-0.55	-6.88	-0.4	4.93e-11	Migraine;
KIRP	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	0.91	8.47	0.48	2.24e-15	Plateletcrit;
KIRP	trans	rs6601327	0.602	rs12678014	chr8:9649165	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	6.41	0.38	7.53e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.42	6.23	0.37	1.97e-9	Neuroticism;
KIRP	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08045932	chr20:61659980	NA	0.53	6.64	0.39	1.98e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6545883	0.894	rs778158	chr2:61555421	A/G	cg15711740	chr2:61764176	XPO1	0.59	7.8	0.45	1.73e-13	Tuberculosis;
KIRP	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg24879335	chr3:133465180	TF	0.5	7.99	0.45	5.16e-14	Iron status biomarkers;
KIRP	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-8.17	-0.46	1.62e-14	Coronary artery disease;
KIRP	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.73	6.51	0.38	4.24e-10	Diabetic retinopathy;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg13198984	chr17:80129470	CCDC57	0.59	8.9	0.49	1.22e-16	Life satisfaction;
KIRP	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg01522456	chr1:115632236	TSPAN2	-0.43	-5.63	-0.34	4.91e-8	Autism;
KIRP	cis	rs6438504	1.000	rs6438504	chr3:118935999	C/T	cg25372693	chr3:118959985	B4GALT4	-0.29	-5.24	-0.32	3.52e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	2.01e-7	Life satisfaction;
KIRP	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.86	-0.4	5.5e-11	Mood instability;
KIRP	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs17373728	0.739	rs7835101	chr8:76169185	T/C	cg07016329	chr8:76221503	NA	-0.55	-7.33	-0.42	3.22e-12	Diabetic kidney disease;
KIRP	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.87	-13.4	-0.65	4.02e-31	Total body bone mineral density;
KIRP	cis	rs5753037	0.543	rs140122	chr22:30138908	C/G	cg01021169	chr22:30184971	ASCC2	-0.49	-6.47	-0.38	5.19e-10	Type 1 diabetes;
KIRP	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.51	-6.23	-0.37	1.95e-9	HDL cholesterol;
KIRP	cis	rs2562456	0.833	rs2358993	chr19:21558169	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03647317	chr4:187891568	NA	0.79	12.86	0.63	2.62e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg24874828	chr4:187887005	NA	-0.47	-6.79	-0.4	8.6e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs684232	0.644	rs2657613	chr17:623902	T/C	cg12384639	chr17:618140	VPS53	0.47	6.11	0.36	3.91e-9	Prostate cancer;
KIRP	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.94	-0.45	7.19e-14	Eye color traits;
KIRP	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.26	0.7	1.97e-37	Platelet count;
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg14664628	chr15:75095509	CSK	-0.68	-8.1	-0.46	2.54e-14	Caffeine consumption;
KIRP	cis	rs7709377	0.595	rs254172	chr5:115622245	G/A	cg23108291	chr5:115420582	COMMD10	-0.44	-5.4	-0.33	1.58e-7	Metabolite levels  (X-11787);
KIRP	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg20578329	chr17:80767326	TBCD	0.47	6.21	0.37	2.25e-9	Breast cancer;
KIRP	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg25866889	chr13:114914595	NA	-0.4	-5.65	-0.34	4.37e-8	Schizophrenia;
KIRP	cis	rs16936870	0.516	rs10086357	chr8:71135835	C/T	cg14232793	chr8:71155543	NCOA2	-0.56	-6.35	-0.38	1.01e-9	QT interval;
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.19e-7	Life satisfaction;
KIRP	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.83	-10.29	-0.55	6.69e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	trans	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg07837717	chr19:2841006	ZNF555	-0.44	-6.48	-0.38	5.06e-10	Breast cancer;
KIRP	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg24315340	chr6:146058215	EPM2A	0.42	5.29	0.32	2.72e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg09904177	chr6:26538194	HMGN4	-0.57	-7.34	-0.42	3.07e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15557168	chr22:42548783	NA	0.42	5.4	0.33	1.53e-7	Cognitive function;
KIRP	cis	rs2599510	0.693	rs2754514	chr2:32788836	T/A	cg02381751	chr2:32503542	YIPF4	0.48	5.61	0.34	5.34e-8	Interleukin-18 levels;
KIRP	cis	rs2737618	0.698	rs2737681	chr1:200091864	C/T	cg21825944	chr1:200113062	NR5A2	-0.58	-8.12	-0.46	2.19e-14	Uric acid levels;
KIRP	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.41	0.38	7.49e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg08888203	chr3:10149979	C3orf24	0.49	5.07	0.31	7.65e-7	Alzheimer's disease;
KIRP	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg03060546	chr3:49711283	APEH	0.45	5.61	0.34	5.34e-8	Parkinson's disease;
KIRP	cis	rs7870753	1.000	rs1590973	chr9:99246159	C/T	cg25260653	chr9:99212216	HABP4	0.54	6.06	0.36	5.05e-9	Height;
KIRP	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg15691649	chr6:25882328	NA	0.44	5.4	0.33	1.6e-7	Blood metabolite levels;
KIRP	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg20936604	chr3:58311152	NA	-0.66	-5.01	-0.3	1.03e-6	Cholesterol, total;
KIRP	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14598338	chr9:96623480	NA	0.63	9.98	0.54	6.35e-20	DNA methylation (variation);
KIRP	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg00310523	chr12:86230176	RASSF9	0.42	6.69	0.39	1.49e-10	Major depressive disorder;
KIRP	cis	rs236907	0.859	rs12091786	chr1:171768793	A/C	cg01410279	chr1:171621941	MYOC	-0.45	-5.23	-0.32	3.7e-7	Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.61	-9.79	-0.53	2.44e-19	Vitamin D levels;
KIRP	cis	rs1863824	0.625	rs7091192	chr10:88167456	A/G	cg07322936	chr10:88137208	NA	-0.52	-5.22	-0.32	3.89e-7	Schizophrenia;
KIRP	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.89	-12.97	-0.64	1.13e-29	Dupuytren's disease;
KIRP	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.68	-8.01	-0.45	4.6e-14	Diastolic blood pressure;
KIRP	cis	rs8084125	0.765	rs62105165	chr18:74944464	A/G	cg18461021	chr18:74961002	GALR1	0.52	5.3	0.32	2.59e-7	Obesity-related traits;
KIRP	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-11.62	-0.6	3.64e-25	Vitiligo;
KIRP	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.6	-0.34	5.6e-8	Alzheimer's disease (late onset);
KIRP	cis	rs7017914	0.690	rs13263370	chr8:71969534	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.43	-5.09	-0.31	7.1e-7	Bone mineral density;
KIRP	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.69	8.95	0.5	8.69e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-9.12	-0.5	2.7e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg15770687	chr7:76625569	PMS2L11	0.74	6.33	0.37	1.15e-9	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.43	-5.86	-0.35	1.48e-8	Lymphocyte counts;
KIRP	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.11e-13	Uric acid levels;
KIRP	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg09201719	chr10:104596890	CYP17A1	0.39	5.67	0.34	3.91e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.82	11.45	0.59	1.32e-24	Response to antipsychotic treatment;
KIRP	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.79	10.91	0.57	7.56e-23	Aortic root size;
KIRP	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg03924115	chr9:133768966	QRFP	-0.35	-5.14	-0.31	5.66e-7	Bilirubin levels;
KIRP	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg16497661	chr14:103986332	CKB	-0.53	-7.14	-0.41	1.07e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	6.17	0.37	2.82e-9	Schizophrenia;
KIRP	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06505273	chr16:24850292	NA	0.42	5.85	0.35	1.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7084402	0.967	rs2577393	chr10:60286159	C/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs745821	0.660	rs9962245	chr18:48100138	T/A	cg18923635	chr18:48083994	NA	0.43	5.12	0.31	6.19e-7	Diastolic blood pressure;
KIRP	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.58	8.12	0.46	2.24e-14	Blood metabolite levels;
KIRP	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg12826209	chr6:26865740	GUSBL1	0.49	5.45	0.33	1.25e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs41307935	0.596	rs34204245	chr1:27204183	T/C	cg12203394	chr1:27248618	NUDC	0.78	6.01	0.36	6.61e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg10755058	chr3:40428713	ENTPD3	-0.43	-6.21	-0.37	2.22e-9	Renal cell carcinoma;
KIRP	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	cis	rs7565981	1.000	rs6748425	chr2:101425431	C/T	cg02232089	chr2:101440696	NPAS2	-0.58	-5.42	-0.33	1.45e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.8e-8	Schizophrenia;
KIRP	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.68	7.81	0.45	1.66e-13	Carotid intima media thickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27659841	chr2:192109995	MYO1B	0.56	7.42	0.43	1.85e-12	Parkinson's disease;
KIRP	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.76	-0.34	2.5e-8	Electroencephalogram traits;
KIRP	cis	rs73086581	1.000	rs73086505	chr20:3921571	A/G	cg02187196	chr20:3869020	PANK2	0.5	4.9	0.3	1.7e-6	Response to antidepressants in depression;
KIRP	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.18	0.31	4.73e-7	Neuroticism;
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs4728302	0.838	rs10225115	chr7:133591435	C/T	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2151522	0.603	rs1930944	chr6:127196765	C/T	cg21431617	chr6:127135037	NA	0.31	5.33	0.32	2.25e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs12517041	0.935	rs35858834	chr5:23325233	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.82	-7.44	-0.43	1.64e-12	Calcium levels;
KIRP	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs933360	0.557	rs7794299	chr7:50783191	A/G	cg18283321	chr7:50629542	DDC	-0.41	-4.99	-0.3	1.16e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-7.84	-0.45	1.35e-13	Total body bone mineral density;
KIRP	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg00919237	chr7:87102261	ABCB4	-0.75	-9.44	-0.52	3.05e-18	Gallbladder cancer;
KIRP	cis	rs909341	0.868	rs6089961	chr20:62349491	G/A	cg03999872	chr20:62272968	STMN3	-0.56	-6.55	-0.39	3.33e-10	Atopic dermatitis;
KIRP	cis	rs62229266	0.804	rs62230821	chr21:37425116	C/T	cg12218747	chr21:37451666	NA	-0.42	-5.3	-0.32	2.61e-7	Mitral valve prolapse;
KIRP	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg11663144	chr21:46675770	NA	-0.58	-8.15	-0.46	1.84e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg20470467	chr16:30886130	NA	0.49	6.18	0.37	2.71e-9	Asthma;
KIRP	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.62	-0.44	5.58e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	9.87	0.53	1.47e-19	Total body bone mineral density;
KIRP	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg18135555	chr8:22132992	PIWIL2	0.42	6.28	0.37	1.52e-9	Hypertriglyceridemia;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg02072376	chr1:153606637	C1orf77;S100A13	-0.58	-6.25	-0.37	1.77e-9	Response to statin therapy;
KIRP	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg16586182	chr3:47516702	SCAP	0.68	9.25	0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg12692727	chr7:1102344	C7orf50	0.47	5.01	0.3	1.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg20243544	chr17:37824526	PNMT	0.51	7.51	0.43	1.07e-12	Asthma;
KIRP	cis	rs12936587	0.633	rs12946845	chr17:17509010	A/C	cg01246520	chr17:17644344	RAI1	-0.37	-5.63	-0.34	5.01e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.9e-11	Retinal vascular caliber;
KIRP	cis	rs3736594	0.649	rs867282	chr2:27951658	A/G	cg27432699	chr2:27873401	GPN1	-0.59	-7.35	-0.42	2.94e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.61	-8.12	-0.46	2.3e-14	Morning vs. evening chronotype;
KIRP	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg14061069	chr19:46274453	DMPK	0.67	11.63	0.6	3.31e-25	Coronary artery disease;
KIRP	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg16558253	chr16:72132732	DHX38	-0.62	-6.99	-0.41	2.6e-11	Coronary artery disease;
KIRP	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg16583315	chr14:65563665	MAX	-0.34	-5.11	-0.31	6.45e-7	Obesity-related traits;
KIRP	cis	rs9815354	0.812	rs73073355	chr3:41842332	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg02631126	chr6:28058918	ZSCAN12L1	0.47	5.11	0.31	6.52e-7	Depression;
KIRP	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg23803603	chr1:2058230	PRKCZ	-0.41	-6.59	-0.39	2.71e-10	Height;
KIRP	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg18709589	chr6:96969512	KIAA0776	0.33	5.02	0.31	9.76e-7	Headache;
KIRP	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg20503657	chr10:835505	NA	-0.51	-6.37	-0.38	9.2e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.03e-8	Homoarginine levels;
KIRP	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.74	8.95	0.5	8.66e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.54	-7.81	-0.45	1.65e-13	Neurofibrillary tangles;
KIRP	cis	rs918629	0.798	rs3777170	chr5:95284340	T/C	cg16656078	chr5:95278638	ELL2	-0.45	-6.46	-0.38	5.7e-10	IgG glycosylation;
KIRP	cis	rs9715521	0.775	rs62301193	chr4:59844120	C/T	cg11281224	chr4:60001000	NA	-0.4	-4.96	-0.3	1.33e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg01557791	chr16:72042693	DHODH	-0.64	-7.03	-0.41	2.06e-11	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7005380	0.556	rs62528677	chr8:120940874	T/C	cg21645572	chr8:120931649	DEPDC6	-0.42	-4.99	-0.3	1.13e-6	Interstitial lung disease;
KIRP	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.63	-0.44	5.14e-13	Triglycerides;
KIRP	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.05	-0.31	8.72e-7	Heart rate;
KIRP	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg12559939	chr2:27858050	GPN1	0.44	5.52	0.33	8.81e-8	Oral cavity cancer;
KIRP	cis	rs6988636	0.534	rs62521770	chr8:124104070	G/A	cg15893493	chr8:124194847	FAM83A	0.76	5.66	0.34	4.22e-8	Urinary uromodulin levels;
KIRP	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg08392591	chr16:89556376	ANKRD11	0.39	4.89	0.3	1.82e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs12693043	0.727	rs3205060	chr2:175425346	C/T	cg11778734	chr2:175439522	WIPF1	-0.54	-7.43	-0.43	1.83e-12	Urate levels (BMI interaction);
KIRP	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.16	-18.46	-0.76	2.38e-48	Breast cancer;
KIRP	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg04865290	chr3:52927548	TMEM110	-0.65	-6.85	-0.4	6.05e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3105593	0.901	rs3098200	chr15:50821945	G/A	cg05456662	chr15:50716270	USP8	0.38	4.86	0.3	2.09e-6	QT interval;
KIRP	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg04935436	chr20:30431758	NA	0.49	6.53	0.38	3.66e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7246865	0.510	rs7253742	chr19:17171689	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	-0.52	-6.59	-0.39	2.64e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.69	8.15	0.46	1.83e-14	Diabetic retinopathy;
KIRP	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	6.12	0.36	3.59e-9	Neuroticism;
KIRP	cis	rs4073221	0.654	rs13101165	chr3:18311376	T/A	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.29e-9	Parkinson's disease;
KIRP	cis	rs77972916	0.505	rs6756575	chr2:43528519	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.79	-9.74	-0.53	3.51e-19	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-1.01	-12.99	-0.64	1.03e-29	Platelet distribution width;
KIRP	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.33	-0.32	2.21e-7	Aortic root size;
KIRP	cis	rs56399783	0.803	rs17132665	chr7:2802173	T/C	cg19731401	chr7:2775893	GNA12	0.62	6.19	0.37	2.5e-9	Childhood ear infection;
KIRP	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg14092571	chr14:90743983	NA	0.43	5.57	0.33	6.56e-8	Mortality in heart failure;
KIRP	cis	rs7127900	0.561	rs7125026	chr11:2233617	C/T	cg25635251	chr11:2234043	NA	0.43	6.85	0.4	5.78e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg01831904	chr17:28903510	LRRC37B2	0.74	8.33	0.47	5.61e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg03146154	chr1:46216737	IPP	-0.73	-9.25	-0.51	1.13e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3925075	1.000	rs4889543	chr16:31340216	C/T	cg02846316	chr16:31340340	ITGAM	0.61	9.34	0.51	6.01e-18	IgA nephropathy;
KIRP	cis	rs2733201	1.000	rs4923972	chr15:44329256	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-5.76	-0.34	2.49e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.29	-0.37	1.46e-9	Metabolite levels;
KIRP	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg00262122	chr8:11665843	FDFT1	-0.43	-5.39	-0.33	1.63e-7	Morning vs. evening chronotype;
KIRP	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg24955955	chr5:415729	AHRR	0.76	5.76	0.34	2.45e-8	Fat distribution (HIV);
KIRP	cis	rs6496667	0.779	rs28651333	chr15:91021718	C/T	cg10434728	chr15:90938212	IQGAP1	0.36	4.96	0.3	1.3e-6	Rheumatoid arthritis;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.58e-6	Lung cancer;
KIRP	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.36	-0.38	9.51e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs988913	0.957	rs932452	chr6:54801928	C/T	cg03513858	chr6:54763001	FAM83B	-0.39	-5.41	-0.33	1.5e-7	Menarche (age at onset);
KIRP	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg06212747	chr3:49208901	KLHDC8B	0.63	7.11	0.41	1.25e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.33	-0.32	2.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs988913	1.000	rs9382404	chr6:54835218	C/G	cg03513858	chr6:54763001	FAM83B	-0.37	-5.37	-0.32	1.8e-7	Menarche (age at onset);
KIRP	cis	rs2929278	0.617	rs663214	chr15:44113782	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.3	-0.37	1.38e-9	Schizophrenia;
KIRP	cis	rs4132509	1.000	rs10927067	chr1:243923244	C/T	cg25706552	chr1:244017396	NA	0.58	8.01	0.45	4.62e-14	RR interval (heart rate);
KIRP	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.08e-9	Neuroticism;
KIRP	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg18932078	chr1:2524107	MMEL1	0.43	5.98	0.36	7.76e-9	Ulcerative colitis;
KIRP	cis	rs4363385	0.747	rs6668215	chr1:152964498	A/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.9	-0.3	1.75e-6	Inflammatory skin disease;
KIRP	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Parkinson's disease;
KIRP	cis	rs62413470	1.000	rs12196213	chr6:55932547	A/G	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.55	0.43	8.7e-13	IgG glycosylation;
KIRP	cis	rs8133932	0.701	rs2839054	chr21:47328449	A/G	cg11214348	chr21:47283868	PCBP3	0.47	5.36	0.32	1.95e-7	Schizophrenia;
KIRP	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	6.79	0.4	8.59e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.72	9.58	0.52	1.11e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.46e-9	Obesity-related traits;
KIRP	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	1.13	16.94	0.73	3.44e-43	Monocyte percentage of white cells;
KIRP	cis	rs17123764	0.710	rs2278069	chr12:49944508	A/G	cg02054252	chr12:50078554	FMNL3	0.44	5.27	0.32	3.03e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.86	13.89	0.66	8.85e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs1106684	1.000	rs12535113	chr7:131465245	G/A	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg09264619	chr17:80180166	NA	-0.41	-5.93	-0.35	1.02e-8	Life satisfaction;
KIRP	cis	rs9398803	0.865	rs9388495	chr6:126782457	G/A	cg19875578	chr6:126661172	C6orf173	0.45	5.9	0.35	1.19e-8	Male-pattern baldness;
KIRP	trans	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg26043149	chr18:55253948	FECH	0.51	6.12	0.36	3.65e-9	Bone mineral density;
KIRP	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg22604316	chr1:46958801	NA	0.46	6.55	0.39	3.42e-10	Monobrow;
KIRP	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.89	-12.42	-0.62	8.2e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4889855	0.585	rs17848706	chr17:78704618	G/T	cg16591659	chr17:78472290	NA	0.37	5.47	0.33	1.12e-7	Fractional excretion of uric acid;
KIRP	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.43	5.23	0.32	3.62e-7	Lung cancer;
KIRP	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.0	-0.45	4.77e-14	Retinal vascular caliber;
KIRP	cis	rs1431005	0.858	rs11132461	chr4:188430315	A/T	cg13810101	chr4:188427966	NA	0.32	5.15	0.31	5.44e-7	Response to statin therapy;
KIRP	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-9.55	-0.52	1.41e-18	Developmental language disorder (linguistic errors);
KIRP	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.45	-6.17	-0.37	2.83e-9	Coronary artery disease;
KIRP	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12311346	chr5:56204834	C5orf35	0.44	5.97	0.36	8.32e-9	Coronary artery disease;
KIRP	trans	rs7939886	0.920	rs12221615	chr11:55999950	G/C	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs35995292	0.857	rs6946859	chr7:38957432	A/G	cg19327137	chr7:38886074	VPS41	0.5	5.63	0.34	4.9e-8	Subjective well-being (multi-trait analysis);
KIRP	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg27205649	chr11:78285834	NARS2	0.67	8.69	0.48	5.35e-16	Alzheimer's disease (survival time);
KIRP	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.61	10.13	0.54	2.23e-20	Obesity-related traits;
KIRP	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg03808351	chr9:123631620	PHF19	-0.4	-5.35	-0.32	2.03e-7	Rheumatoid arthritis;
KIRP	cis	rs6832769	0.826	rs10462035	chr4:56379178	G/A	cg05960024	chr4:56376020	CLOCK	0.73	9.37	0.51	5.04e-18	Personality dimensions;
KIRP	cis	rs6142102	0.923	rs2268078	chr20:32596704	G/A	cg08999081	chr20:33150536	PIGU	0.47	5.6	0.34	5.71e-8	Skin pigmentation;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16627807	chr19:40596541	ZNF780A	0.46	6.11	0.36	3.87e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg00612595	chr21:47717864	NA	-0.39	-5.13	-0.31	5.99e-7	Testicular germ cell tumor;
KIRP	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.54	6.37	0.38	9.41e-10	Aortic root size;
KIRP	cis	rs12595433	0.522	rs11634593	chr15:63289376	G/A	cg03196360	chr15:63270641	NA	-0.31	-5.69	-0.34	3.61e-8	Obesity-related traits;
KIRP	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg18404041	chr3:52824283	ITIH1	0.37	5.27	0.32	2.95e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg00149659	chr3:10157352	C3orf10	0.61	7.2	0.42	7.32e-12	Alzheimer's disease;
KIRP	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.4	-0.43	2.18e-12	Retinal vascular caliber;
KIRP	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19727059	chr1:209346675	NA	-0.45	-6.3	-0.37	1.35e-9	Survival in pancreatic cancer;
KIRP	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg22089800	chr15:90895588	ZNF774	-0.43	-5.52	-0.33	8.56e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-7.51	-0.43	1.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg24253500	chr15:84953950	NA	0.49	4.85	0.3	2.17e-6	Schizophrenia;
KIRP	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.46	5.39	0.33	1.63e-7	Parkinson's disease;
KIRP	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg11569703	chr11:65557185	OVOL1	0.5	7.55	0.43	8.38e-13	Breast cancer;
KIRP	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg23335576	chr14:104009727	NA	0.39	5.7	0.34	3.5e-8	Bone mineral density;
KIRP	cis	rs904251	0.965	rs1317563	chr6:37451854	G/T	cg25019722	chr6:37503610	NA	-0.69	-9.11	-0.5	2.91e-17	Cognitive performance;
KIRP	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.71	-9.8	-0.53	2.41e-19	Menopause (age at onset);
KIRP	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg08198773	chr8:1697536	NA	-0.51	-6.21	-0.37	2.27e-9	Systolic blood pressure;
KIRP	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg16988262	chr1:15930761	NA	0.4	5.18	0.31	4.59e-7	Systolic blood pressure;
KIRP	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4356975	0.563	rs7668258	chr4:69962078	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.46	-5.43	-0.33	1.36e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg18944383	chr4:111397179	ENPEP	0.54	9.63	0.52	7.98e-19	Height;
KIRP	cis	rs2637030	0.586	rs1030228	chr5:52842569	A/G	cg06476337	chr5:52856530	NDUFS4	0.53	5.59	0.34	6.01e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs1009170	0.794	rs7158971	chr14:92586126	T/A	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.43	0.33	1.37e-7	Dialysis-related mortality;
KIRP	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg18306943	chr3:40428807	ENTPD3	0.47	6.05	0.36	5.4e-9	Renal cell carcinoma;
KIRP	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.61	7.95	0.45	6.9e-14	Pulse pressure;
KIRP	trans	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg10756647	chr7:56101905	PSPH	0.97	7.01	0.41	2.23e-11	Diabetic kidney disease;
KIRP	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-12.2	-0.61	4.28e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.33	-0.32	2.21e-7	Life satisfaction;
KIRP	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.55	6.1	0.36	4.03e-9	Parkinson's disease;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg14221460	chr8:27183342	PTK2B	0.51	6.72	0.39	1.26e-10	Neuroticism;
KIRP	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.89	-0.57	8.58e-23	Exhaled nitric oxide output;
KIRP	cis	rs71636778	0.631	rs113312820	chr1:27213079	A/G	cg12203394	chr1:27248618	NUDC	0.77	6.01	0.36	6.53e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	trans	rs4131099	0.793	rs12448968	chr16:51384572	T/C	cg02207200	chr8:17353980	SLC7A2	0.55	6.08	0.36	4.55e-9	Personality dimensions;
KIRP	cis	rs7779181	0.953	rs215607	chr7:32338337	G/A	cg13207630	chr7:32358064	NA	-0.45	-5.27	-0.32	2.95e-7	Body mass index;
KIRP	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs12496230	0.794	rs7638057	chr3:66862718	C/T	cg17646820	chr3:66848679	NA	0.4	6.53	0.38	3.74e-10	Type 2 diabetes;
KIRP	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg18477163	chr1:228402036	OBSCN	0.35	6.62	0.39	2.29e-10	Diastolic blood pressure;
KIRP	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	1.08	21.56	0.81	1.27e-58	Height;
KIRP	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg13615516	chr5:77269221	NA	0.52	8.12	0.46	2.28e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs2920503	0.659	rs17029006	chr3:12329452	C/T	cg04748988	chr3:12329223	PPARG	0.54	5.49	0.33	1.01e-7	LDL cholesterol;
KIRP	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.81	0.45	1.66e-13	Neuroticism;
KIRP	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg10513866	chr5:139070639	NA	0.54	7.61	0.44	5.77e-13	Schizophrenia;
KIRP	cis	rs7017914	0.934	rs62508771	chr8:71692688	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.45	-6.79	-0.4	8.25e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.59	9.74	0.53	3.59e-19	Schizophrenia;
KIRP	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-1.13	-20.96	-0.8	1.19e-56	Monocyte count;
KIRP	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	6.72	0.39	1.27e-10	Height;
KIRP	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg22676075	chr6:135203613	NA	0.48	7.02	0.41	2.11e-11	Red blood cell count;
KIRP	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg10189774	chr4:17578691	LAP3	0.49	6.03	0.36	5.95e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.66	10.02	0.54	4.98e-20	Lung cancer;
KIRP	cis	rs6929812	0.577	rs2294308	chr6:27483260	T/C	cg03332623	chr6:27441972	ZNF184	-0.33	-4.93	-0.3	1.53e-6	Neuroticism (multi-trait analysis);
KIRP	cis	rs5753037	0.838	rs140149	chr22:30185613	C/T	cg01021169	chr22:30184971	ASCC2	-0.43	-5.3	-0.32	2.63e-7	Type 1 diabetes;
KIRP	cis	rs8060686	0.920	rs1124324	chr16:67897487	C/T	cg04539111	chr16:67997858	SLC12A4	-0.63	-6.53	-0.38	3.71e-10	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg06064525	chr11:970664	AP2A2	0.34	7.12	0.41	1.19e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.44	5.91	0.35	1.11e-8	Coronary artery disease;
KIRP	cis	rs2223471	0.719	rs2744489	chr6:50766781	G/A	cg03432817	chr6:50765336	NA	-0.5	-8.21	-0.46	1.25e-14	Subcutaneous adipose tissue;
KIRP	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-7.24	-0.42	5.76e-12	Vitamin D levels;
KIRP	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.36	-0.32	1.96e-7	Metabolite levels;
KIRP	cis	rs2275565	0.872	rs10925261	chr1:237053186	C/T	cg17297354	chr1:237056641	MTR	-0.42	-5.38	-0.32	1.69e-7	Homocysteine levels;
KIRP	trans	rs1973993	0.651	rs60776572	chr1:96960121	C/T	cg10631902	chr5:14652156	NA	-0.56	-8.16	-0.46	1.69e-14	Weight;
KIRP	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.94	-11.49	-0.59	9.89e-25	Bipolar disorder and schizophrenia;
KIRP	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg25902810	chr10:99078978	FRAT1	0.58	7.21	0.42	6.83e-12	Monocyte count;
KIRP	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.83	-0.49	2.01e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.63	-7.34	-0.42	3.1e-12	Prudent dietary pattern;
KIRP	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg23533926	chr12:111358616	MYL2	-0.48	-6.32	-0.37	1.24e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.67	-0.44	4.05e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.49	-6.67	-0.39	1.63e-10	Type 2 diabetes;
KIRP	cis	rs9400467	0.537	rs449308	chr6:111480395	A/C	cg15721981	chr6:111408429	SLC16A10	-0.78	-7.25	-0.42	5.35e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg22396632	chr1:3079212	PRDM16	-0.37	-4.95	-0.3	1.37e-6	Migraine;
KIRP	cis	rs9810890	1.000	rs73210617	chr3:128645947	A/G	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs17067123	0.614	rs72712853	chr4:180066431	A/G	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg21546286	chr11:48923668	NA	-0.48	-6.11	-0.36	3.96e-9	HDL cholesterol;
KIRP	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg23161317	chr6:28129485	ZNF389	0.49	5.82	0.35	1.84e-8	Depression;
KIRP	cis	rs7729447	0.813	rs7715571	chr5:32690010	A/C	cg16267343	chr5:32710456	NPR3	0.48	5.66	0.34	4.24e-8	Blood pressure;
KIRP	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	0.82	11.28	0.58	4.57e-24	Primary sclerosing cholangitis;
KIRP	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.4	5.44	0.33	1.29e-7	HIV-1 susceptibility;
KIRP	cis	rs6102059	0.692	rs62211684	chr20:39230467	T/C	cg22477343	chr20:39312069	NA	0.49	6.51	0.38	4.18e-10	LDL cholesterol;
KIRP	cis	rs9790314	0.670	rs9864752	chr3:160937591	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-9.81	-0.53	2.24e-19	Morning vs. evening chronotype;
KIRP	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25517755	chr10:38738941	LOC399744	-0.52	-7.16	-0.42	9.35e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg00531865	chr16:30841666	NA	-0.39	-5.07	-0.31	7.89e-7	Multiple myeloma;
KIRP	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.5	7.27	0.42	4.79e-12	Motion sickness;
KIRP	cis	rs7172677	0.793	rs8029712	chr15:75418170	T/A	cg03289416	chr15:75166202	SCAMP2	0.4	4.91	0.3	1.63e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg00204512	chr16:28754710	NA	0.46	6.05	0.36	5.39e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs1847202	0.826	rs7640629	chr3:72925997	C/T	cg06781948	chr3:72941472	GXYLT2	0.46	5.88	0.35	1.34e-8	Motion sickness;
KIRP	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13047869	chr3:10149882	C3orf24	0.53	4.96	0.3	1.33e-6	Alzheimer's disease;
KIRP	cis	rs28680850	0.541	rs28501642	chr8:1379528	G/A	cg09050832	chr8:1365175	NA	-0.62	-5.4	-0.33	1.57e-7	Triglycerides;
KIRP	cis	rs10465746	0.967	rs12732697	chr1:84349283	A/G	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.19e-8	Obesity-related traits;
KIRP	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.58	7.25	0.42	5.25e-12	Monobrow;
KIRP	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.8	-13.14	-0.64	3e-30	Prostate cancer;
KIRP	cis	rs2073300	0.826	rs6048809	chr20:23443788	C/T	cg12062639	chr20:23401060	NAPB	0.79	6.9	0.4	4.27e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.57	-8.6	-0.48	9.41e-16	Coronary artery disease;
KIRP	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Urinary tract infection frequency;
KIRP	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.68	8.14	0.46	1.95e-14	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg09699651	chr6:150184138	LRP11	0.48	6.23	0.37	1.99e-9	Lung cancer;
KIRP	cis	rs10140922	0.966	rs4982259	chr14:35821950	T/C	cg07166546	chr14:35805898	NA	-0.24	-6.04	-0.36	5.6e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.63	-0.44	5.28e-13	Neuroticism;
KIRP	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.33	-5.04	-0.31	8.99e-7	Motion sickness;
KIRP	cis	rs2294693	0.945	rs9462668	chr6:41004194	T/C	cg14769373	chr6:40998127	UNC5CL	-0.52	-5.64	-0.34	4.68e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg12310025	chr6:25882481	NA	-0.39	-5.38	-0.32	1.76e-7	Height;
KIRP	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	1.1	8.4	0.47	3.6e-15	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg20999797	chr1:1681921	NA	0.5	7.32	0.42	3.43e-12	Body mass index;
KIRP	cis	rs42648	0.837	rs6970750	chr7:89938191	G/A	cg25739043	chr7:89950458	NA	-0.45	-7.1	-0.41	1.3e-11	Homocysteine levels;
KIRP	cis	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg04607699	chr11:48328132	OR4S1	-0.35	-4.94	-0.3	1.46e-6	HDL cholesterol;
KIRP	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg10397082	chr2:1609832	NA	0.57	5.15	0.31	5.36e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2191566	0.576	rs402785	chr19:44492236	T/G	cg18700516	chr19:44507157	ZNF230	0.42	4.85	0.3	2.15e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs72843166	0.945	rs72843167	chr17:61099099	G/A	cg19683800	chr17:61518354	CYB561	-0.42	-4.96	-0.3	1.3e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.56	-11.93	-0.61	3.47e-26	Diabetic kidney disease;
KIRP	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	8.65	0.48	6.98e-16	Response to antipsychotic treatment;
KIRP	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.1	0.31	6.87e-7	Parkinson's disease;
KIRP	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.62	7.32	0.42	3.43e-12	Obesity-related traits;
KIRP	cis	rs1982963	0.950	rs2645738	chr14:52513202	G/A	cg10843707	chr14:52510701	NID2	-0.31	-4.88	-0.3	1.92e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.49	6.72	0.39	1.27e-10	Mean corpuscular volume;
KIRP	cis	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs4765905	0.546	rs11062162	chr12:2332104	A/G	cg10668781	chr12:2307325	CACNA1C	-0.26	-4.85	-0.3	2.14e-6	Schizophrenia;
KIRP	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg18657303	chr4:1051139	NA	0.57	5.13	0.31	5.75e-7	Recombination rate (females);
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg01324507	chr7:1177794	C7orf50	0.54	4.87	0.3	1.96e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs11955398	0.585	rs2085409	chr5:60021183	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.8	-0.45	1.81e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21214613	chr1:16344536	HSPB7	0.36	5.14	0.31	5.54e-7	Dilated cardiomyopathy;
KIRP	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.41	-5.36	-0.32	1.94e-7	Renal cell carcinoma;
KIRP	cis	rs9788721	0.842	rs11852372	chr15:78801394	A/C	cg18825076	chr15:78729989	IREB2	-0.49	-5.88	-0.35	1.36e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17760058	chr19:2321626	LSM7	0.43	6.06	0.36	4.95e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg16083429	chr3:49237500	CCDC36	-0.38	-5.05	-0.31	8.8e-7	Menarche (age at onset);
KIRP	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.56	7.43	0.43	1.81e-12	Smoking behavior;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22168489	chr12:122356033	WDR66	0.68	10.23	0.55	1.05e-20	Mean corpuscular volume;
KIRP	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17507749	chr15:85114479	UBE2QP1	0.7	7.94	0.45	7.23e-14	Schizophrenia;
KIRP	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg25418670	chr11:30344373	C11orf46	-0.6	-5.19	-0.31	4.33e-7	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	5.85	0.35	1.54e-8	Total body bone mineral density;
KIRP	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.6	-8.46	-0.47	2.47e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs2929278	0.561	rs62018952	chr15:44080737	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-6.29	-0.37	1.47e-9	Schizophrenia;
KIRP	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg16988262	chr1:15930761	NA	0.38	4.9	0.3	1.77e-6	Systolic blood pressure;
KIRP	cis	rs9308731	0.966	rs1877331	chr2:111906510	G/A	cg23466623	chr2:111982296	NA	-0.44	-5.52	-0.33	8.41e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs4663866	1.000	rs71426510	chr2:239178909	T/G	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg07843065	chr1:150265600	MRPS21	0.43	6.0	0.36	7.03e-9	Migraine;
KIRP	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg08775375	chr8:10454154	NA	-0.37	-5.2	-0.31	4.2e-7	Neuroticism;
KIRP	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.61	-7.53	-0.43	9.46e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-8.3	-0.47	7.14e-15	Cognitive function;
KIRP	cis	rs2273156	0.929	rs34678475	chr14:35451103	T/A	cg09327582	chr14:35236912	BAZ1A	-0.48	-5.24	-0.32	3.51e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg24130564	chr14:104152367	KLC1	-0.5	-6.85	-0.4	5.91e-11	Body mass index;
KIRP	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.6	7.91	0.45	8.53e-14	Diastolic blood pressure;
KIRP	cis	rs4920343	0.698	rs573966	chr1:19087828	A/G	cg19637330	chr1:19110922	NA	0.39	4.86	0.3	2.1e-6	Knee osteoarthritis;
KIRP	cis	rs4356932	0.967	rs4241581	chr4:76962055	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	trans	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg25288420	chr1:78511713	GIPC2	-0.48	-6.43	-0.38	6.57e-10	Obesity-related traits;
KIRP	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.75	-9.56	-0.52	1.27e-18	Facial morphology (factor 19);
KIRP	cis	rs78579285	0.545	rs113385327	chr16:88785242	A/C	cg09786329	chr16:88821445	FAM38A	-0.57	-4.89	-0.3	1.82e-6	Joint mobility (Beighton score);
KIRP	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.99	-0.36	7.46e-9	Morning vs. evening chronotype;
KIRP	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.43	-0.38	6.7e-10	LDL cholesterol levels;
KIRP	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.42	6.18	0.37	2.6e-9	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	1.0	10.19	0.54	1.48e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg10932868	chr11:921992	NA	0.67	9.13	0.5	2.59e-17	Alzheimer's disease (late onset);
KIRP	cis	rs17384381	1.000	rs35193119	chr1:85859265	T/C	cg16011679	chr1:85725395	C1orf52	0.84	8.39	0.47	3.93e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg16141378	chr3:129829833	LOC729375	0.55	7.19	0.42	7.56e-12	Schizophrenia;
KIRP	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	1.0	17.68	0.75	1.07e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9828933	0.938	rs7617036	chr3:64002995	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.7	-7.33	-0.42	3.34e-12	Type 2 diabetes;
KIRP	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg08992911	chr2:238395768	MLPH	0.39	4.9	0.3	1.75e-6	Prostate cancer;
KIRP	cis	rs12738007	0.503	rs1485471	chr1:29194901	A/G	cg06868481	chr1:29192086	NA	0.37	5.44	0.33	1.26e-7	Schizophrenia;
KIRP	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.5	12.81	0.63	4.15e-29	Cutaneous nevi;
KIRP	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg02696790	chr15:75250997	RPP25	0.32	5.57	0.33	6.58e-8	Breast cancer;
KIRP	cis	rs4356975	0.527	rs60423649	chr4:69993670	T/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.06	0.31	8.15e-7	Obesity-related traits;
KIRP	cis	rs16857609	0.628	rs768435	chr2:218343878	C/T	cg15335768	chr2:218268053	DIRC3	-0.39	-5.69	-0.34	3.54e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05025164	chr4:1340916	KIAA1530	0.43	5.27	0.32	3.01e-7	Obesity-related traits;
KIRP	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.45	0.38	6.02e-10	Menarche (age at onset);
KIRP	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.56	-6.26	-0.37	1.67e-9	Breast cancer;
KIRP	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.89	11.93	0.61	3.36e-26	Bipolar disorder;
KIRP	trans	rs2270927	1.000	rs31243	chr5:75594360	A/G	cg13563193	chr19:33072644	PDCD5	0.73	6.51	0.38	4.2e-10	Mean corpuscular volume;
KIRP	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.87	13.75	0.66	2.75e-32	Height;
KIRP	trans	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg06521331	chr12:34319734	NA	-0.54	-6.68	-0.39	1.55e-10	Heart rate;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg23985595	chr17:80112537	CCDC57	-0.35	-5.25	-0.32	3.25e-7	Life satisfaction;
KIRP	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.54	-6.0	-0.36	6.86e-9	Menarche (age at onset);
KIRP	cis	rs698813	0.604	rs11676798	chr2:44479982	G/C	cg04920474	chr2:44395004	PPM1B	0.36	4.9	0.3	1.75e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg13736514	chr6:26305472	NA	-0.66	-8.88	-0.49	1.44e-16	Educational attainment;
KIRP	trans	rs7306455	0.558	rs35249403	chr12:95326743	T/C	cg02647998	chr3:12201096	TIMP4;SYN2	-0.86	-6.08	-0.36	4.57e-9	Coronary artery disease;
KIRP	cis	rs13385	0.769	rs10079286	chr5:139599134	G/A	cg01860693	chr5:139557145	C5orf32	0.48	5.25	0.32	3.33e-7	Atrial fibrillation;
KIRP	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.79	-10.78	-0.57	1.96e-22	Total body bone mineral density;
KIRP	cis	rs1620921	0.505	rs9458030	chr6:161209985	G/A	cg01280913	chr6:161186852	NA	-0.62	-8.39	-0.47	3.77e-15	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.84	11.34	0.59	2.98e-24	Type 2 diabetes;
KIRP	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg01200585	chr1:228362443	C1orf69	-0.4	-4.9	-0.3	1.74e-6	Diastolic blood pressure;
KIRP	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg03806693	chr22:41940476	POLR3H	-0.44	-5.2	-0.31	4.27e-7	Neuroticism;
KIRP	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.22	-0.32	3.79e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg24747557	chr10:131355152	MGMT	-0.47	-6.5	-0.38	4.43e-10	Response to temozolomide;
KIRP	cis	rs6987853	0.787	rs2923405	chr8:42448126	T/G	cg09913449	chr8:42400586	C8orf40	0.41	5.48	0.33	1.05e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.22	-14.75	-0.69	1.02e-35	Eosinophil percentage of granulocytes;
KIRP	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.51	-7.13	-0.41	1.11e-11	Schizophrenia;
KIRP	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg10818794	chr15:86012489	AKAP13	-0.5	-7.12	-0.41	1.21e-11	Coronary artery disease;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg07402062	chr16:89894098	SPIRE2	0.34	7.16	0.42	9.2e-12	Vitiligo;
KIRP	cis	rs7084402	0.967	rs1620404	chr10:60327830	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg03315344	chr16:75512273	CHST6	0.64	5.98	0.36	7.94e-9	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg06243866	chr13:111019493	COL4A2	0.66	8.05	0.46	3.62e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg05370193	chr1:21551575	ECE1	0.42	5.97	0.36	8.41e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4262150	0.764	rs2964231	chr5:151929983	C/T	cg12297329	chr5:152029980	NA	-0.53	-6.69	-0.39	1.47e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg10664184	chr19:17420304	DDA1	0.72	8.36	0.47	4.7e-15	Systemic lupus erythematosus;
KIRP	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg13072238	chr3:49761600	GMPPB	-0.62	-6.04	-0.36	5.76e-9	Menarche (age at onset);
KIRP	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.39	-4.93	-0.3	1.55e-6	Blood protein levels;
KIRP	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg06634786	chr22:41940651	POLR3H	-0.46	-5.01	-0.3	1.04e-6	Neuroticism;
KIRP	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg21361702	chr7:150065534	REPIN1	0.56	5.91	0.35	1.14e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg09904177	chr6:26538194	HMGN4	-0.47	-5.88	-0.35	1.3e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18867708	chr6:26865862	GUSBL1	0.48	6.01	0.36	6.76e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2441986	0.861	rs1584650	chr11:57975237	T/C	cg19752551	chr11:57585705	CTNND1	-0.45	-5.56	-0.33	6.86e-8	Systolic blood pressure;
KIRP	cis	rs4356932	1.000	rs12510335	chr4:76980539	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg04310649	chr10:35416472	CREM	-0.54	-6.18	-0.37	2.68e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg25801113	chr15:45476975	SHF	-0.42	-7.63	-0.44	5.23e-13	Uric acid levels;
KIRP	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg26384229	chr12:38710491	ALG10B	0.66	8.77	0.49	3.07e-16	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18116600	chr6:160210817	MRPL18;TCP1	-0.53	-6.55	-0.39	3.42e-10	Interleukin-4 levels;
KIRP	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.75	-9.76	-0.53	3.08e-19	Facial morphology (factor 19);
KIRP	cis	rs6691722	0.583	rs7535482	chr1:24695114	A/C	cg18323236	chr1:24743029	NIPAL3	0.39	5.48	0.33	1.07e-7	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs490234	0.841	rs626667	chr9:128428404	A/G	cg14078157	chr9:128172775	NA	0.42	5.39	0.33	1.64e-7	Mean arterial pressure;
KIRP	cis	rs3766606	0.505	rs60057745	chr1:7946819	G/A	cg26816564	chr1:7831052	VAMP3	0.6	5.19	0.31	4.45e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg14173624	chr17:72199366	RPL38	0.5	6.04	0.36	5.78e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.87	-10.15	-0.54	1.8899999999999998e-20	White matter hyperintensity burden;
KIRP	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.3	13.48	0.65	2.19e-31	Diabetic retinopathy;
KIRP	trans	rs6918152	1.000	rs12206548	chr6:506231	C/T	cg21824902	chr1:27560832	WDTC1	-0.53	-6.25	-0.37	1.79e-9	Black vs. red hair color;Black vs. blond hair color;
KIRP	cis	rs829661	0.793	rs2609917	chr2:30857157	C/T	cg10949345	chr2:30726833	LCLAT1	1.08	13.27	0.65	1.16e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12143943	0.835	rs12730457	chr1:204548132	C/A	cg20240347	chr1:204465584	NA	-0.35	-6.46	-0.38	5.48e-10	Cognitive performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27583337	chr11:123524786	SCN3B	0.5	6.52	0.38	3.86e-10	Parkinson's disease;
KIRP	cis	rs865483	0.929	rs853215	chr17:35861133	A/G	cg06716730	chr17:35851459	DUSP14	0.23	5.62	0.34	5.16e-8	Monocyte count;
KIRP	cis	rs16986825	0.607	rs5762852	chr22:29242473	T/C	cg02153584	chr22:29168773	CCDC117	0.58	5.5	0.33	9.4e-8	Pancreatic cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06772578	chr4:23796624	PPARGC1A	0.37	6.27	0.37	1.61e-9	C-reactive protein;
KIRP	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.84	11.15	0.58	1.21e-23	Primary sclerosing cholangitis;
KIRP	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg00800038	chr16:89945340	TCF25	-0.71	-5.73	-0.34	2.89e-8	Skin colour saturation;
KIRP	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.81	-9.79	-0.53	2.53e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg26681399	chr22:41777847	TEF	0.5	5.16	0.31	5.07e-7	Vitiligo;
KIRP	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.92	5.2	0.31	4.23e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.69	8.59	0.48	1.05e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs4716602	0.596	rs1996994	chr7:156159694	A/G	cg16983916	chr7:156159713	NA	0.45	5.81	0.35	1.92e-8	Anti-saccade response;
KIRP	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	7.84	0.45	1.38e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7849270	0.760	rs882616	chr9:131940865	C/T	cg13538475	chr9:131942899	NA	0.36	5.12	0.31	6.17e-7	Blood metabolite ratios;
KIRP	cis	rs35160687	0.787	rs10186289	chr2:86512988	G/A	cg10973622	chr2:86423274	IMMT	0.49	6.11	0.36	3.85e-9	Night sleep phenotypes;
KIRP	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg16497661	chr14:103986332	CKB	0.76	11.36	0.59	2.52e-24	Body mass index;
KIRP	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.96	-15.26	-0.7	1.94e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.47	-4.85	-0.3	2.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg08662619	chr6:150070041	PCMT1	0.36	5.73	0.34	2.96e-8	Lung cancer;
KIRP	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg23100626	chr2:96804247	ASTL	0.45	6.25	0.37	1.81e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	16.99	0.73	2.26e-43	Platelet count;
KIRP	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.26	0.55	8.5e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4742903	0.509	rs1857984	chr9:106954979	A/G	cg14250997	chr9:106856677	SMC2	-0.37	-4.94	-0.3	1.47e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	1.08	9.79	0.53	2.5e-19	Pulse pressure;
KIRP	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	1.17	10.24	0.55	1e-20	Skin colour saturation;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19565306	chr22:51222011	RPL23AP82;RABL2B	0.52	6.38	0.38	8.72e-10	Myopia (pathological);
KIRP	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.7	8.23	0.46	1.12e-14	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg09788416	chr12:39539408	NA	0.37	5.09	0.31	7.13e-7	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-16.59	-0.73	5.36e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg04306507	chr14:55594613	LGALS3	0.52	7.93	0.45	7.44e-14	Protein biomarker;
KIRP	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	8.84	0.49	1.89e-16	Response to antipsychotic treatment;
KIRP	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg06671706	chr8:8559999	CLDN23	0.47	5.87	0.35	1.4e-8	Obesity-related traits;
KIRP	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg06521331	chr12:34319734	NA	-0.42	-5.29	-0.32	2.66e-7	Morning vs. evening chronotype;
KIRP	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg15934090	chr1:100435551	SLC35A3	0.5	6.21	0.37	2.22e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg19116668	chr7:99932089	PMS2L1	-0.51	-5.82	-0.35	1.86e-8	Coronary artery disease;
KIRP	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.88	10.56	0.56	9.64e-22	Vitiligo;
KIRP	cis	rs9398803	0.723	rs853968	chr6:127071753	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.5	-0.33	9.37e-8	Male-pattern baldness;
KIRP	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg14092571	chr14:90743983	NA	-0.43	-5.7	-0.34	3.45e-8	Mortality in heart failure;
KIRP	cis	rs911119	0.866	rs4815223	chr20:23577112	C/A	cg09631192	chr20:23583594	CST9	-0.49	-5.2	-0.31	4.26e-7	Chronic kidney disease;
KIRP	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.46	5.37	0.32	1.8e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-5.48	-0.33	1.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg22916017	chr11:64110731	CCDC88B	-0.52	-6.19	-0.37	2.55e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg06815112	chr8:27182871	PTK2B	0.53	6.8	0.4	8.1e-11	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13680054	chr22:28315185	PITPNB;LOC284900	0.5	7.07	0.41	1.56e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2151522	0.563	rs4897190	chr6:127128051	C/T	cg21431617	chr6:127135037	NA	0.34	6.14	0.36	3.37e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.38	-15.16	-0.7	4.02e-37	Schizophrenia;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg20235337	chr6:42981612	MEA1;KLHDC3	-0.5	-6.65	-0.39	1.84e-10	Morning vs. evening chronotype;
KIRP	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.71	0.53	4.56e-19	Multiple sclerosis;
KIRP	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg12042659	chr19:58951599	ZNF132	0.52	6.25	0.37	1.77e-9	Uric acid clearance;
KIRP	trans	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg25214090	chr10:38739885	LOC399744	0.55	6.62	0.39	2.23e-10	Educational attainment;
KIRP	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg26373071	chr5:1325741	CLPTM1L	0.56	7.5	0.43	1.19e-12	Lung cancer;
KIRP	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg04132472	chr17:19861366	AKAP10	-0.48	-6.94	-0.4	3.56e-11	Schizophrenia;
KIRP	cis	rs6545883	0.929	rs1186710	chr2:61688727	T/A	cg15711740	chr2:61764176	XPO1	-0.62	-8.15	-0.46	1.85e-14	Tuberculosis;
KIRP	cis	rs77688320	0.517	rs7605375	chr2:202330630	G/A	cg06431681	chr2:202330990	STRADB	0.53	7.35	0.42	2.97e-12	Breast cancer;
KIRP	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.58	-7.33	-0.42	3.38e-12	Personality dimensions;
KIRP	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg06636001	chr8:8085503	FLJ10661	0.69	8.92	0.49	1.06e-16	Retinal vascular caliber;
KIRP	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	6.97	0.41	2.92e-11	Bipolar disorder;
KIRP	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.63	8.12	0.46	2.22e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.47	0.38	5.34e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.7	0.48	4.93e-16	Motion sickness;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20232060	chr3:141457873	RNF7	0.54	6.11	0.36	3.79e-9	Lung cancer in ever smokers;
KIRP	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.46	5.88	0.35	1.31e-8	Initial pursuit acceleration;
KIRP	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg27205649	chr11:78285834	NARS2	0.64	7.85	0.45	1.28e-13	Alzheimer's disease (survival time);
KIRP	cis	rs6496667	0.779	rs62020734	chr15:90998430	G/C	cg10434728	chr15:90938212	IQGAP1	0.36	4.9	0.3	1.71e-6	Rheumatoid arthritis;
KIRP	cis	rs2479106	0.892	rs549779	chr9:126613028	A/G	cg16191174	chr9:126692580	DENND1A	-0.39	-4.93	-0.3	1.53e-6	Polycystic ovary syndrome;
KIRP	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.34e-8	Platelet count;
KIRP	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg21466736	chr12:48725269	NA	-0.46	-5.88	-0.35	1.32e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg12661370	chr5:149340060	SLC26A2	0.46	5.66	0.34	4.17e-8	HIV-1 control;
KIRP	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.79	-11.95	-0.61	3.06e-26	Height;
KIRP	cis	rs16976116	0.901	rs1061875	chr15:55496278	C/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg04731861	chr2:219085781	ARPC2	-0.21	-5.14	-0.31	5.68e-7	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.44	-5.82	-0.35	1.85e-8	Renal cell carcinoma;
KIRP	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.79	11.35	0.59	2.74e-24	Colorectal cancer;
KIRP	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.8	-8.76	-0.49	3.24e-16	Iron status biomarkers;
KIRP	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg18833306	chr6:118973337	C6orf204	0.41	5.26	0.32	3.2e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9653442	0.564	rs10175599	chr2:100787635	C/T	cg17356467	chr2:100759845	AFF3	0.38	5.35	0.32	2.01e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7017697	1.000	rs7017697	chr8:19685909	G/T	cg03894339	chr8:19674705	INTS10	-0.51	-6.41	-0.38	7.37e-10	Breast cancer;
KIRP	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.79	0.57	1.82e-22	Lung cancer in ever smokers;
KIRP	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.58	-7.37	-0.43	2.59e-12	Morning vs. evening chronotype;
KIRP	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg26876637	chr1:152193138	HRNR	0.71	9.45	0.52	2.71e-18	Atopic dermatitis;
KIRP	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg06481639	chr22:41940642	POLR3H	-0.47	-4.9	-0.3	1.75e-6	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04280677	chr19:10654493	ATG4D	0.52	6.28	0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.97e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	6.85	0.4	5.94e-11	Rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08017156	chr16:21611107	METTL9	0.59	6.95	0.41	3.21e-11	Smoking initiation;
KIRP	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg14132834	chr19:41945861	ATP5SL	-0.63	-8.57	-0.48	1.16e-15	Height;
KIRP	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.59	0.44	6.46e-13	Aortic root size;
KIRP	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg13444842	chr1:152974279	SPRR3	-0.35	-4.97	-0.3	1.28e-6	Inflammatory skin disease;
KIRP	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg24633833	chr3:10029261	TMEM111	0.56	4.99	0.3	1.13e-6	Alzheimer's disease;
KIRP	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg15655495	chr12:38532458	NA	0.27	5.19	0.31	4.45e-7	Morning vs. evening chronotype;
KIRP	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.5e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.42	-0.78	1.45e-51	Schizophrenia;
KIRP	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg09904177	chr6:26538194	HMGN4	0.46	6.2	0.37	2.41e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.26	-0.37	1.66e-9	Educational attainment;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.2	0.46	1.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg10755058	chr3:40428713	ENTPD3	0.47	6.58	0.39	2.78e-10	Renal cell carcinoma;
KIRP	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg21775007	chr8:11205619	TDH	0.49	6.44	0.38	6.26e-10	Neuroticism;
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg07701084	chr6:150067640	NUP43	0.7	9.54	0.52	1.43e-18	Lung cancer;
KIRP	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.6	7.9	0.45	9.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.75	0.44	2.47e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.67	-8.49	-0.48	2.04e-15	Longevity;
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg17372223	chr3:52568218	NT5DC2	0.33	5.08	0.31	7.32e-7	Electroencephalogram traits;
KIRP	cis	rs11997175	0.740	rs4467902	chr8:33693415	G/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.84	0.35	1.65e-8	Body mass index;
KIRP	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.37	-0.32	1.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-0.79	-10.14	-0.54	1.98e-20	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.67	9.92	0.53	1e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg11764359	chr7:65958608	NA	-0.43	-4.96	-0.3	1.33e-6	Calcium levels;
KIRP	cis	rs6782228	0.585	rs6774515	chr3:128415878	C/T	cg18648031	chr3:128330563	NA	0.25	4.99	0.3	1.15e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.23	-21.13	-0.8	3.28e-57	Breast cancer;
KIRP	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg04990556	chr1:26633338	UBXN11	0.62	5.74	0.34	2.75e-8	Obesity-related traits;
KIRP	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg22138327	chr13:27999177	GTF3A	0.78	8.96	0.5	8.06e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.49	-5.53	-0.33	8.09e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.44	5.06	0.31	8.33e-7	Schizophrenia;
KIRP	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg01843524	chr15:80216276	C15orf37;ST20	0.44	5.35	0.32	2e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.42	5.41	0.33	1.52e-7	Childhood ear infection;
KIRP	trans	rs6734238	0.966	rs10188292	chr2:113840443	A/T	cg11332951	chr1:2396472	NA	-0.42	-6.23	-0.37	1.96e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.69	7.18	0.42	8.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.6	-7.17	-0.42	8.71e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs55692468	0.540	rs4664586	chr2:153324071	C/T	cg04681845	chr2:153283485	FMNL2	-0.55	-7.03	-0.41	2.07e-11	Intraocular pressure;
KIRP	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg05973401	chr12:123451056	ABCB9	-0.48	-5.36	-0.32	1.94e-7	Neutrophil percentage of white cells;
KIRP	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg18306943	chr3:40428807	ENTPD3	0.41	5.69	0.34	3.52e-8	Renal cell carcinoma;
KIRP	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	cis	rs490234	0.702	rs35237975	chr9:128313867	A/G	cg14078157	chr9:128172775	NA	-0.63	-7.53	-0.43	9.77e-13	Mean arterial pressure;
KIRP	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg08501292	chr6:25962987	TRIM38	-0.8	-5.5	-0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.62	-7.0	-0.41	2.39e-11	Response to antineoplastic agents;
KIRP	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.2	-0.31	4.14e-7	Pulmonary function;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25689539	chr7:149130015	ZNF777	0.49	6.35	0.38	1.03e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12756686	chr19:29218302	NA	0.87	8.56	0.48	1.25e-15	Methadone dose in opioid dependence;
KIRP	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.51	0.33	8.86e-8	Educational attainment;
KIRP	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg05802129	chr4:122689817	NA	-0.67	-7.63	-0.44	5.11e-13	Type 2 diabetes;
KIRP	cis	rs4118325	0.562	rs4915018	chr1:107703913	G/T	cg01939741	chr1:107680714	NA	-0.56	-5.3	-0.32	2.58e-7	AIDS;
KIRP	cis	rs2282032	1.000	rs79334826	chr14:90744981	G/A	cg04374321	chr14:90722782	PSMC1	0.59	5.64	0.34	4.55e-8	Longevity;
KIRP	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.41	5.84	0.35	1.62e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg02297831	chr4:17616191	MED28	0.57	7.2	0.42	7.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-1.0	-19.06	-0.77	2.41e-50	Breast cancer;
KIRP	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.04	-0.31	9.14e-7	Menarche (age at onset);
KIRP	cis	rs55986470	0.817	rs11883735	chr2:239407644	G/A	cg08773314	chr2:239334832	ASB1	-0.42	-4.91	-0.3	1.63e-6	Chronotype;
KIRP	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg05347473	chr6:146136440	FBXO30	0.51	7.08	0.41	1.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.92	10.56	0.56	9.34e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs755109	1.000	rs17431934	chr9:100695776	T/C	cg13688889	chr9:100608707	NA	-0.42	-4.92	-0.3	1.62e-6	Quantitative traits;
KIRP	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg02527881	chr3:46936655	PTH1R	-0.38	-5.39	-0.33	1.64e-7	Colorectal cancer;
KIRP	cis	rs6504950	0.830	rs8073158	chr17:53028615	C/A	cg26251398	chr17:52985966	TOM1L1	0.43	5.23	0.32	3.58e-7	Breast cancer;
KIRP	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.88	12.59	0.63	2.22e-28	Mean platelet volume;
KIRP	cis	rs2278796	0.639	rs12145998	chr1:204969419	C/T	cg17449235	chr1:204966235	NFASC	0.57	7.83	0.45	1.48e-13	Mean platelet volume;
KIRP	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.14	16.25	0.72	7.84e-41	Lymphocyte percentage of white cells;
KIRP	trans	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg26134248	chr17:3907702	NA	0.57	8.5	0.48	1.83e-15	Type 2 diabetes;
KIRP	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg12962167	chr3:53033115	SFMBT1	0.76	5.68	0.34	3.74e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.51	-7.73	-0.44	2.82e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18204930	chr10:71873599	AIFM2	0.49	6.74	0.39	1.09e-10	Survival in pancreatic cancer;
KIRP	cis	rs7646881	1.000	rs73015649	chr3:158450298	C/G	cg19483011	chr3:158453295	NA	-0.58	-6.35	-0.38	1.03e-9	Tetralogy of Fallot;
KIRP	cis	rs12049351	0.774	rs6673421	chr1:229636388	A/G	cg11742688	chr1:229674241	ABCB10	-0.4	-6.53	-0.38	3.81e-10	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.92	15.98	0.71	6.44e-40	Metabolic syndrome;
KIRP	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg05082376	chr22:42548792	NA	0.46	5.8	0.35	2.01e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10104451	chr8:143696006	ARC	-0.66	-7.28	-0.42	4.56e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg10756647	chr7:56101905	PSPH	0.9	7.06	0.41	1.65e-11	Diabetic kidney disease;
KIRP	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg00405596	chr8:11794950	NA	-0.52	-6.77	-0.4	9.25e-11	Neuroticism;
KIRP	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg02527881	chr3:46936655	PTH1R	-0.57	-8.53	-0.48	1.53e-15	Birth weight;
KIRP	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.91e-9	Response to antipsychotic treatment;
KIRP	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.64	-5.88	-0.35	1.35e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs748404	0.560	rs689797	chr15:43826557	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.38	0.38	8.66e-10	Lung cancer;
KIRP	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.14	-0.31	5.56e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08768569	chr10:106400565	SORCS3	0.49	6.41	0.38	7.43e-10	Parkinson's disease;
KIRP	cis	rs7769051	0.614	rs17061930	chr6:133223799	T/C	cg22852734	chr6:133119734	C6orf192	0.86	5.29	0.32	2.77e-7	Type 2 diabetes nephropathy;
KIRP	cis	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg06521331	chr12:34319734	NA	-0.61	-7.36	-0.42	2.8e-12	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.38	-0.51	4.43e-18	Aortic root size;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg27532560	chr4:187881888	NA	-0.74	-12.72	-0.63	7.95e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.24	-25.04	-0.85	1.29e-69	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.47	6.12	0.36	3.75e-9	Colorectal cancer;
KIRP	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg04989706	chr14:50066350	PPIL5	-0.46	-5.57	-0.33	6.68e-8	Carotid intima media thickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12603476	chr10:82214649	TSPAN14	0.49	6.16	0.37	2.95e-9	Parkinson's disease;
KIRP	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.83	8.6	0.48	9.41e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs3743772	1.000	rs3743772	chr16:53537423	C/A	cg09728985	chr16:53543985	NA	0.64	4.88	0.3	1.93e-6	Depressive symptoms (SSRI exposure interaction);
KIRP	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.08	0.31	7.51e-7	Smoking behavior;
KIRP	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg11266682	chr4:10021025	SLC2A9	-0.36	-5.06	-0.31	8.26e-7	Psychosis and Alzheimer's disease;
KIRP	cis	rs10802346	0.636	rs10802353	chr1:246379680	C/T	cg15962031	chr1:246363574	SMYD3	0.7	5.72	0.34	3.04e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs75920871	0.528	rs12274388	chr11:116946238	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.24	-0.32	3.44e-7	Subjective well-being;
KIRP	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-5.42	-0.33	1.39e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.46	-7.17	-0.42	8.51e-12	Coronary artery disease;
KIRP	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.95	8.26	0.47	8.75e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg15556689	chr8:8085844	FLJ10661	0.74	8.6	0.48	9.17e-16	Red cell distribution width;
KIRP	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg14972814	chr11:95582409	MTMR2	0.34	5.46	0.33	1.15e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	6.08	0.36	4.66e-9	Breast cancer;
KIRP	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.7	5.8	0.35	2.03e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs9826463	0.702	rs73228758	chr3:142320559	A/G	cg20824294	chr3:142316082	PLS1	0.42	6.55	0.39	3.3e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07256732	chr16:621771	PIGQ	-0.44	-6.21	-0.37	2.29e-9	Height;
KIRP	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg20930514	chr14:77499758	NA	0.48	6.09	0.36	4.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg10818794	chr15:86012489	AKAP13	-0.5	-7.15	-0.41	9.9e-12	Coronary artery disease;
KIRP	cis	rs684232	0.568	rs2644714	chr17:633188	G/A	cg01214346	chr17:406501	NA	0.43	5.18	0.31	4.63e-7	Prostate cancer;
KIRP	cis	rs9503598	0.644	rs7774747	chr6:3430996	A/G	cg00476032	chr6:3446245	SLC22A23	-0.39	-5.2	-0.31	4.15e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7923609	0.846	rs9787438	chr10:65038030	G/C	cg01631684	chr10:65280961	REEP3	-0.47	-5.4	-0.33	1.56e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.76	-0.34	2.53e-8	Multiple sclerosis;
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg16590910	chr6:42928470	GNMT	0.42	5.89	0.35	1.27e-8	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.43	-5.17	-0.31	4.88e-7	Testicular germ cell tumor;
KIRP	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg22732515	chr19:44031385	ETHE1	0.64	9.43	0.52	3.25e-18	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25517755	chr10:38738941	LOC399744	0.35	4.97	0.3	1.26e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg03653399	chr8:142233436	SLC45A4	0.51	6.47	0.38	5.33e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7215564	0.908	rs35918698	chr17:78683533	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.39e-7	Myopia (pathological);
KIRP	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs1465370	0.682	rs2239604	chr7:130021331	C/T	cg03229158	chr7:130009420	NA	0.34	4.99	0.3	1.13e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg11833968	chr6:79620685	NA	-0.46	-6.92	-0.4	3.84e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg10932868	chr11:921992	NA	0.64	8.61	0.48	8.76e-16	Alzheimer's disease (late onset);
KIRP	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.75	0.34	2.68e-8	Bipolar disorder;
KIRP	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.34	5.35	0.32	2e-7	Asthma;
KIRP	cis	rs4006360	0.657	rs7225713	chr17:39252092	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg18132916	chr6:79620363	NA	-0.42	-5.67	-0.34	4.07e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.79	8.33	0.47	5.85e-15	Bipolar disorder;
KIRP	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg25182066	chr10:30743637	MAP3K8	-0.63	-8.62	-0.48	8.05e-16	Inflammatory bowel disease;
KIRP	cis	rs2219968	1.000	rs33987699	chr8:78953437	A/C	cg00738934	chr8:78996279	NA	0.48	6.65	0.39	1.87e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs1912785	0.545	rs3843364	chr3:146503157	C/T	cg07377288	chr7:102004298	NA	0.5	6.08	0.36	4.66e-9	Barrett's esophagus;
KIRP	cis	rs9921338	0.887	rs13330151	chr16:11402399	C/T	cg00044050	chr16:11439710	C16orf75	-0.53	-5.5	-0.33	9.44e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg16497661	chr14:103986332	CKB	0.84	14.23	0.67	6.02e-34	Body mass index;
KIRP	trans	rs2834485	1.000	rs5010906	chr21:35818590	G/C	cg07474852	chr4:123073612	NA	0.52	6.22	0.37	2.12e-9	Cancer;
KIRP	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.39	10.58	0.56	8.2e-22	Prostate cancer;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg09695851	chr17:3907499	NA	0.88	17.04	0.74	1.53e-43	Type 2 diabetes;
KIRP	cis	rs1620921	0.505	rs4709467	chr6:161203079	G/A	cg01280913	chr6:161186852	NA	-0.58	-7.79	-0.44	1.85e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg08975724	chr8:8085496	FLJ10661	0.62	8.4	0.47	3.49e-15	Mood instability;
KIRP	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg27124370	chr19:33622961	WDR88	0.57	7.01	0.41	2.33e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs28595532	0.748	rs67928655	chr4:119336525	C/A	cg21605333	chr4:119757512	SEC24D	0.94	7.16	0.42	9.11e-12	Cannabis dependence symptom count;
KIRP	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.53	6.74	0.39	1.1e-10	Tonsillectomy;
KIRP	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg16606324	chr3:10149918	C3orf24	0.57	5.14	0.31	5.61e-7	Alzheimer's disease;
KIRP	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.5	-0.52	2.02e-18	Total body bone mineral density;
KIRP	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12524338	chr4:183729343	NA	0.61	5.08	0.31	7.61e-7	Pediatric autoimmune diseases;
KIRP	cis	rs807669	0.505	rs8142503	chr22:19166717	G/T	cg02655711	chr22:19163373	SLC25A1	0.54	7.53	0.43	9.71e-13	Metabolite levels;
KIRP	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.24	-0.32	3.41e-7	Electroencephalogram traits;
KIRP	cis	rs6681460	0.966	rs10749765	chr1:67150280	C/T	cg13052034	chr1:66999238	SGIP1	0.47	6.41	0.38	7.41e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs10875746	0.951	rs2228500	chr12:48526712	A/G	cg20731937	chr12:48336164	NA	-0.4	-5.09	-0.31	7.06e-7	Longevity (90 years and older);
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.73	6.47	0.38	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-7.72	-0.44	2.92e-13	Bipolar disorder;
KIRP	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.58	7.36	0.42	2.8e-12	Aortic root size;
KIRP	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.95	-13.52	-0.65	1.64e-31	Cognitive function;
KIRP	cis	rs963731	0.649	rs6544191	chr2:39266384	C/T	cg04010122	chr2:39346883	SOS1	-1.06	-7.14	-0.41	1.02e-11	Corticobasal degeneration;
KIRP	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg02336718	chr17:17403227	NA	0.39	5.94	0.35	9.78e-9	Total body bone mineral density;
KIRP	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs4349753	0.904	rs248557	chr5:144177315	A/G	cg16033277	chr17:80885358	TBCD	-0.4	-6.17	-0.37	2.73e-9	Photic sneeze reflex;
KIRP	trans	rs7939886	0.920	rs60087290	chr11:55983527	C/G	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-1.0	-10.72	-0.56	3.05e-22	HIV-1 control;
KIRP	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg16296679	chr22:42394374	WBP2NL	0.36	4.99	0.3	1.15e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6772849	0.896	rs4857859	chr3:128348014	G/T	cg08795948	chr3:128337044	NA	0.5	6.28	0.37	1.53e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs7638995	0.878	rs1995665	chr3:69183140	A/C	cg26574240	chr3:69171822	LMOD3	-0.75	-9.55	-0.52	1.4e-18	Alzheimer's disease (late onset);
KIRP	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.87	11.75	0.6	1.33e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1165472	0.755	rs12239009	chr1:56166508	G/T	cg11523071	chr1:56160889	NA	0.61	8.04	0.46	3.86e-14	Paclitaxel-induced neuropathy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.56	6.48	0.38	5.05e-10	Smoking initiation;
KIRP	cis	rs12022452	0.591	rs11208356	chr1:41006931	A/G	cg25568243	chr1:40974465	DEM1	0.57	6.03	0.36	5.87e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.92	14.28	0.67	4.12e-34	Testicular germ cell tumor;
KIRP	trans	rs9561428	1.000	rs4612931	chr13:94424196	T/G	cg26695444	chr10:42970351	LOC84856	-0.72	-6.02	-0.36	6.39e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg23335576	chr14:104009727	NA	0.4	5.49	0.33	1.02e-7	Body mass index;
KIRP	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.93	-15.06	-0.69	9.21e-37	Height;
KIRP	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.45	-0.33	1.24e-7	Schizophrenia (age at onset);
KIRP	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-7.59	-0.44	6.62e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg17646820	chr3:66848679	NA	0.67	9.71	0.53	4.42e-19	Type 2 diabetes;
KIRP	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.85	-12.67	-0.63	1.15e-28	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10214930	0.697	rs10807841	chr7:27619751	T/C	cg22168087	chr7:27702803	HIBADH	0.47	4.89	0.3	1.84e-6	Hypospadias;
KIRP	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg22284058	chr8:142237359	SLC45A4	-0.4	-4.97	-0.3	1.27e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg24315340	chr6:146058215	EPM2A	0.41	5.24	0.32	3.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14135887	chr4:36266562	NA	-0.42	-6.08	-0.36	4.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg15488143	chr7:128924101	AHCYL2	0.57	6.04	0.36	5.64e-9	White matter hyperintensity burden;
KIRP	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.59	-6.43	-0.38	6.58e-10	Corneal astigmatism;
KIRP	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.56	-6.46	-0.38	5.51e-10	Cardiac Troponin-T levels;
KIRP	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.52e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs11119608	1.000	rs1112269	chr1:210994395	T/C	cg11682528	chr16:751317	FBXL16	-0.47	-6.1	-0.36	4.09e-9	Cancer;
KIRP	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg02023728	chr11:77925099	USP35	0.35	5.46	0.33	1.17e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7116495	1.000	rs55972015	chr11:71642576	C/G	cg26138937	chr11:71823887	C11orf51	-0.7	-5.54	-0.33	7.91e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg10047753	chr17:41438598	NA	1.13	17.96	0.75	1.15e-46	Menopause (age at onset);
KIRP	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.37	-5.08	-0.31	7.56e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.62	-0.34	5.09e-8	Common traits (Other);
KIRP	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.77	7.95	0.45	6.71e-14	Gut microbiome composition (summer);
KIRP	cis	rs9513627	0.920	rs7984052	chr13:100177225	G/A	cg25919922	chr13:100150906	NA	0.67	4.87	0.3	1.99e-6	Obesity-related traits;
KIRP	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.89	7.46	0.43	1.5e-12	Thyroid stimulating hormone;
KIRP	cis	rs7027203	0.538	rs2244395	chr9:96520723	A/G	cg14598338	chr9:96623480	NA	-0.44	-6.69	-0.39	1.49e-10	DNA methylation (variation);
KIRP	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg04287289	chr16:89883240	FANCA	0.7	4.9	0.3	1.72e-6	Skin colour saturation;
KIRP	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg14675211	chr2:100938903	LONRF2	0.55	7.13	0.41	1.11e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg02725872	chr8:58115012	NA	-0.45	-5.24	-0.32	3.44e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg21184320	chr1:21044207	KIF17	-0.35	-5.34	-0.32	2.09e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs889398	0.683	rs8047682	chr16:69913446	G/A	cg09409435	chr16:70099608	PDXDC2	0.41	5.07	0.31	7.98e-7	Body mass index;
KIRP	cis	rs6142102	0.961	rs2284386	chr20:32644396	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	6.82	0.4	7.03e-11	Skin pigmentation;
KIRP	cis	rs42648	0.870	rs7783199	chr7:89999305	G/A	cg25739043	chr7:89950458	NA	0.44	6.91	0.4	4.07e-11	Homocysteine levels;
KIRP	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg17470723	chr8:74884337	TCEB1	0.65	8.44	0.47	2.8e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg01420254	chr6:26195488	NA	1.22	11.16	0.58	1.17e-23	Gout;Renal underexcretion gout;
KIRP	cis	rs12780845	0.505	rs11254419	chr10:17209192	A/C	cg01003015	chr10:17271136	VIM	-0.5	-6.58	-0.39	2.75e-10	Homocysteine levels;
KIRP	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg00405596	chr8:11794950	NA	0.48	6.11	0.36	3.84e-9	Monocyte count;
KIRP	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.92	14.21	0.67	7.56e-34	Metabolite levels;
KIRP	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.22	8.95	0.5	8.7e-17	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.67	8.77	0.49	3.1e-16	Multiple sclerosis;
KIRP	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg14324370	chr2:177042789	NA	-0.73	-8.97	-0.5	7.48e-17	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs2559856	0.967	rs3809260	chr12:102091017	G/T	cg12924262	chr12:102091054	CHPT1	0.46	5.75	0.34	2.61e-8	Blood protein levels;
KIRP	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14169450	chr9:139327907	INPP5E	0.5	6.4	0.38	7.83e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg23594656	chr7:65796392	TPST1	0.45	7.12	0.41	1.17e-11	Aortic root size;
KIRP	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg26139080	chr11:47293733	MADD	-0.42	-5.32	-0.32	2.35e-7	HDL cholesterol;
KIRP	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.51	-5.5	-0.33	9.45e-8	Total body bone mineral density;
KIRP	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg07423050	chr13:99094983	FARP1	0.31	5.18	0.31	4.66e-7	Longevity;
KIRP	trans	rs225245	0.817	rs225255	chr17:33955243	A/G	cg19694781	chr19:47549865	TMEM160	0.51	6.29	0.37	1.41e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs13095912	1.000	rs1823238	chr3:185341970	G/A	cg11274856	chr3:185301563	NA	0.54	6.94	0.4	3.43e-11	Systolic blood pressure;
KIRP	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.36	-0.32	1.87e-7	Pulmonary function;
KIRP	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.17	-0.54	1.6e-20	Coffee consumption (cups per day);
KIRP	cis	rs8179	0.514	rs10269774	chr7:92253972	A/G	cg15732164	chr7:92237376	CDK6	0.44	6.4	0.38	7.73e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.83	11.48	0.59	1.01e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg13334819	chr7:99746414	C7orf59	0.52	6.0	0.36	7.1e-9	Coronary artery disease;
KIRP	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg04935436	chr20:30431758	NA	0.48	5.81	0.35	1.95e-8	Mean corpuscular hemoglobin;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg15149117	chr11:5568008	OR52H1	0.36	6.23	0.37	1.96e-9	Serum protein levels (sST2);
KIRP	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg01620082	chr3:125678407	NA	-1.32	-8.31	-0.47	6.61e-15	Depression;
KIRP	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	12.45	0.62	6.38e-28	Ileal carcinoids;
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg00343986	chr7:65444356	GUSB	-0.45	-5.55	-0.33	7.3900000000000007e-08	Aortic root size;
KIRP	cis	rs10788972	0.933	rs4492560	chr1:54568488	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.3	-5.22	-0.32	3.75e-7	Parkinson disease and lewy body pathology;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.84	12.66	0.63	1.23e-28	Menarche (age at onset);
KIRP	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.26e-9	Obesity-related traits;
KIRP	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg07741184	chr6:167504864	NA	0.22	5.99	0.36	7.24e-9	Crohn's disease;
KIRP	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.38	5.96	0.36	8.56e-9	Information processing speed;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg12263655	chr2:134772833	NA	0.39	6.1	0.36	4.01e-9	C-reactive protein;
KIRP	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg11234688	chr2:1609660	NA	0.53	5.01	0.3	1.05e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg23978390	chr7:1156363	C7orf50	0.4	5.0	0.3	1.1e-6	Longevity;Endometriosis;
KIRP	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	1.02	22.11	0.82	2.18e-60	Multiple myeloma;
KIRP	cis	rs554111	0.891	rs609880	chr1:21055891	A/G	cg21184320	chr1:21044207	KIF17	0.44	6.65	0.39	1.92e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.19	0.42	7.76e-12	Aortic root size;
KIRP	cis	rs7894407	0.856	rs7093667	chr10:105080575	T/C	cg05636881	chr10:105038444	INA	0.39	5.01	0.3	1.04e-6	White matter hyperintensity burden;
KIRP	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.89	-12.44	-0.62	6.82e-28	Height;
KIRP	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27286337	chr10:134555280	INPP5A	0.86	10.25	0.55	9.19e-21	Migraine;
KIRP	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg08662619	chr6:150070041	PCMT1	-0.34	-5.28	-0.32	2.91e-7	Lung cancer;
KIRP	cis	rs9596863	1.000	rs9596862	chr13:54432908	A/G	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg04132472	chr17:19861366	AKAP10	0.42	5.72	0.34	3.09e-8	Schizophrenia;
KIRP	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26207909	chr14:103986467	CKB	0.73	10.31	0.55	6e-21	Body mass index;
KIRP	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.52	6.83	0.4	6.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.14	17.68	0.75	1.07e-45	Cognitive function;
KIRP	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.4	0.33	1.56e-7	Bipolar disorder;
KIRP	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg16414030	chr3:133502952	NA	0.5	5.88	0.35	1.33e-8	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs2279817	0.820	rs12754031	chr1:18006619	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-8.54	-0.48	1.4e-15	Neuroticism;
KIRP	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg20003494	chr4:90757398	SNCA	-0.39	-5.08	-0.31	7.43e-7	Neuroticism;
KIRP	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg00981070	chr1:2046702	PRKCZ	0.41	5.86	0.35	1.5e-8	Height;
KIRP	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.88	-8.48	-0.48	2.09e-15	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.11e-7	Life satisfaction;
KIRP	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg14121845	chr20:25566513	NINL	0.39	5.48	0.33	1.05e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg27432699	chr2:27873401	GPN1	-0.48	-6.2	-0.37	2.42e-9	Total body bone mineral density;
KIRP	cis	rs1712517	0.873	rs1712510	chr10:105009086	A/G	cg05636881	chr10:105038444	INA	-0.4	-5.93	-0.35	1.03e-8	Migraine;
KIRP	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.74	-6.86	-0.4	5.68e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.55	-6.14	-0.36	3.26e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg07843065	chr1:150265600	MRPS21	0.44	5.99	0.36	7.26e-9	Migraine;
KIRP	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.7	-5.25	-0.32	3.26e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.67	-8.02	-0.46	4.19e-14	Pancreatic cancer;
KIRP	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg16558253	chr16:72132732	DHX38	-0.6	-9.04	-0.5	4.93e-17	Fibrinogen levels;
KIRP	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.57	7.47	0.43	1.38e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6594713	0.756	rs10053341	chr5:112784007	G/T	cg12552261	chr5:112820674	MCC	0.62	5.87	0.35	1.39e-8	Brain cytoarchitecture;
KIRP	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.29	-0.32	2.74e-7	Body mass index;
KIRP	cis	rs6681460	0.649	rs10889625	chr1:67007235	T/C	cg13052034	chr1:66999238	SGIP1	0.45	6.39	0.38	8.27e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs59868192	0.925	rs57556178	chr15:42242888	G/A	cg20935245	chr15:42234343	EHD4	-0.54	-5.3	-0.32	2.56e-7	White blood cell count;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12494545	chr19:46057029	OPA3	0.5	6.56	0.39	3.21e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg20570682	chr1:49364711	AGBL4	0.43	6.15	0.37	3.05e-9	Cancer;
KIRP	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.7	-0.34	3.44e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg13206674	chr6:150067644	NUP43	0.5	7.04	0.41	1.95e-11	Testicular germ cell tumor;
KIRP	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg03468072	chr12:39539422	NA	0.41	5.96	0.36	8.79e-9	Morning vs. evening chronotype;
KIRP	trans	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg00405596	chr8:11794950	NA	-0.48	-6.5	-0.38	4.41e-10	Mood instability;
KIRP	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg23202291	chr11:1979235	NA	0.43	5.74	0.34	2.78e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs6466055	0.661	rs2299309	chr7:104838876	T/C	cg04380332	chr7:105027541	SRPK2	0.37	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg21775007	chr8:11205619	TDH	0.7	10.66	0.56	4.74e-22	Retinal vascular caliber;
KIRP	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12654770	chr10:52487693	NA	0.44	6.44	0.38	6.24e-10	Cancer;
KIRP	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.86	10.9	0.57	7.83e-23	Coronary artery disease;
KIRP	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.64	-6.36	-0.38	9.86e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.44	5.02	0.3	1.01e-6	Osteoporosis;
KIRP	cis	rs3789045	0.826	rs55979051	chr1:204567041	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.29	-0.37	1.44e-9	Educational attainment (college completion);
KIRP	cis	rs13424612	1.000	rs10206993	chr2:240900919	C/A	cg01812947	chr2:240904978	NDUFA10	0.42	5.43	0.33	1.34e-7	Odorant perception (isobutyraldehyde);
KIRP	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-9.03	-0.5	5.18e-17	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7106204	0.514	rs2068454	chr11:24256166	C/G	ch.11.24196551F	chr11:24239977	NA	-0.83	-10.07	-0.54	3.41e-20	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs78487399	0.808	rs113377695	chr2:43835359	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-5.05	-0.31	8.43e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.55	7.26	0.42	5.18e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.85	0.4	5.75e-11	Mean corpuscular volume;
KIRP	cis	rs926392	0.640	rs7268716	chr20:37693214	C/T	cg16355469	chr20:37678765	NA	0.53	6.09	0.36	4.38e-9	Dialysis-related mortality;
KIRP	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.9	-12.65	-0.63	1.33e-28	Coronary artery disease;
KIRP	cis	rs16958440	0.867	rs62095427	chr18:44594221	G/A	cg17192377	chr18:44677553	HDHD2	0.67	5.82	0.35	1.79e-8	Sitting height ratio;
KIRP	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg07395648	chr5:131743802	NA	-0.55	-7.67	-0.44	3.97e-13	Breast cancer;Mosquito bite size;
KIRP	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg07930552	chr6:133119739	C6orf192	0.77	7.08	0.41	1.54e-11	Type 2 diabetes nephropathy;
KIRP	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.67	9.21	0.51	1.5e-17	Bladder cancer;
KIRP	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg12560992	chr17:57184187	TRIM37	0.59	5.43	0.33	1.33e-7	Cognitive test performance;
KIRP	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.13	0.31	5.81e-7	Renal cell carcinoma;
KIRP	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg24747557	chr10:131355152	MGMT	-0.41	-5.62	-0.34	5.22e-8	Response to temozolomide;
KIRP	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg11608241	chr8:8085544	FLJ10661	0.5	6.57	0.39	2.99e-10	Retinal vascular caliber;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02318596	chr3:88188181	ZNF654	0.39	6.03	0.36	6.09e-9	Migraine with aura;
KIRP	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.95	0.35	9.25e-9	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg00656387	chr3:40428638	ENTPD3	0.4	5.08	0.31	7.53e-7	Renal cell carcinoma;
KIRP	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.63	-7.04	-0.41	1.91e-11	Menarche (age at onset);
KIRP	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg24747557	chr10:131355152	MGMT	-0.39	-5.14	-0.31	5.5e-7	Response to temozolomide;
KIRP	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.53	6.62	0.39	2.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4664304	0.739	rs66814375	chr2:160716059	C/T	cg06573604	chr2:160760825	LY75	-0.35	-4.93	-0.3	1.53e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26002218	chr14:103986227	CKB	0.26	4.95	0.3	1.36e-6	Body mass index;
KIRP	cis	rs7246967	0.551	rs7248993	chr19:22849152	G/C	cg03230154	chr19:22817176	ZNF492	0.5	4.94	0.3	1.41e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.64	5.29	0.32	2.74e-7	Putamen volume;
KIRP	cis	rs7017914	0.967	rs35960437	chr8:71661960	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs981844	0.796	rs13140722	chr4:154712203	T/A	cg14289246	chr4:154710475	SFRP2	-0.55	-6.8	-0.4	7.71e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1456297	0.651	rs28508455	chr15:52006347	C/T	cg14296394	chr15:51910925	DMXL2	0.73	9.57	0.52	1.21e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	9.37	0.51	4.77e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg16590910	chr6:42928470	GNMT	0.42	5.86	0.35	1.45e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1678542	0.679	rs10783834	chr12:57975953	G/C	cg00677455	chr12:58241039	CTDSP2	0.61	6.42	0.38	6.82e-10	Rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.31e-34	Breast cancer;
KIRP	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.54	-6.63	-0.39	2.11e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.84	11.76	0.6	1.28e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23068124	chr14:58711505	PSMA3	0.76	7.01	0.41	2.32e-11	Lung function (FEV1);
KIRP	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg07148914	chr20:33460835	GGT7	-0.42	-5.19	-0.31	4.45e-7	Height;
KIRP	cis	rs7662987	0.793	rs7669660	chr4:99992602	T/C	cg13256891	chr4:100009986	ADH5	-0.65	-5.59	-0.34	5.93e-8	Smoking initiation;
KIRP	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg25037394	chr1:24152592	HMGCL	-0.38	-5.0	-0.3	1.1e-6	Immature fraction of reticulocytes;
KIRP	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	cis	rs10046574	0.519	rs7810403	chr7:135216172	G/A	cg27474649	chr7:135195673	CNOT4	0.54	4.91	0.3	1.64e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg05347473	chr6:146136440	FBXO30	0.5	7.18	0.42	8.21e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.39	4.91	0.3	1.64e-6	Childhood ear infection;
KIRP	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	10.02	0.54	4.98e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.41	-0.78	1.56e-51	Schizophrenia;
KIRP	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.17	0.64	2.54e-30	Eye color traits;
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.76	12.62	0.63	1.75e-28	Vitiligo;
KIRP	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg15507776	chr3:136538369	TMEM22	0.55	7.83	0.45	1.44e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.68e-11	Hemoglobin concentration;
KIRP	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg27247782	chr7:158767135	NA	-0.42	-4.96	-0.3	1.34e-6	Facial morphology (factor 20);
KIRP	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.61	-0.34	5.53e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs748404	0.578	rs2244746	chr15:43695083	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	6.99	0.41	2.5e-11	Lung cancer;
KIRP	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.56	-8.03	-0.46	4.08e-14	Prostate cancer;
KIRP	trans	rs9420	0.528	rs11229075	chr11:57391023	A/C	cg16592121	chr10:133794558	BNIP3	-0.32	-6.05	-0.36	5.5e-9	Schizophrenia;
KIRP	cis	rs6546324	0.559	rs11126134	chr2:67781064	G/T	cg15745817	chr2:67799979	NA	0.68	6.97	0.41	2.89e-11	Endometriosis;
KIRP	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.56	0.39	3.09e-10	Platelet count;
KIRP	cis	rs735860	0.726	rs209490	chr6:53179047	C/T	cg10236188	chr6:53219634	NA	0.42	5.46	0.33	1.18e-7	Glaucoma;
KIRP	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.58	-4.93	-0.3	1.54e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg27398817	chr8:82754497	SNX16	-0.72	-7.76	-0.44	2.3e-13	Diastolic blood pressure;
KIRP	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.58	-5.71	-0.34	3.25e-8	Ulcerative colitis;
KIRP	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.78	0.4	8.91e-11	Coffee consumption (cups per day);
KIRP	trans	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg02002194	chr4:3960332	NA	0.44	6.34	0.37	1.12e-9	Mood instability;
KIRP	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg16342193	chr10:102329863	NA	-0.38	-4.88	-0.3	1.87e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Bipolar disorder;
KIRP	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.82	-11.26	-0.58	5.6e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7011049	0.749	rs117000605	chr8:53864529	T/G	cg26025543	chr8:53854495	NA	0.59	6.36	0.38	9.51e-10	Systolic blood pressure;
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.51	-5.81	-0.35	1.89e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7246657	0.722	rs8103647	chr19:38100452	C/A	cg23950597	chr19:37808831	NA	-0.59	-6.39	-0.38	8.04e-10	Coronary artery calcification;
KIRP	cis	rs1559088	0.847	rs3786933	chr19:33602881	C/T	cg27124370	chr19:33622961	WDR88	0.56	6.98	0.41	2.77e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg12661370	chr5:149340060	SLC26A2	0.44	5.45	0.33	1.23e-7	HIV-1 control;
KIRP	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.39	5.35	0.32	2.01e-7	Endometrial cancer;
KIRP	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg27490568	chr2:178487706	NA	0.46	6.06	0.36	5.17e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Morning vs. evening chronotype;
KIRP	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.87	-7.72	-0.44	2.89e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10518128	0.850	rs1452309	chr4:75715145	G/A	cg20122727	chr4:75719957	BTC	0.56	5.66	0.34	4.25e-8	Electroencephalogram traits;
KIRP	trans	rs57502260	1.000	rs57502260	chr11:68220905	A/G	cg12549906	chr5:6846268	NA	0.57	6.06	0.36	5.1e-9	Total body bone mineral density (age 45-60);
KIRP	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg04132472	chr17:19861366	AKAP10	0.42	5.68	0.34	3.72e-8	Schizophrenia;
KIRP	cis	rs4356932	1.000	rs4241578	chr4:76944491	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.89e-10	Bipolar disorder;
KIRP	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg00343986	chr7:65444356	GUSB	0.39	4.87	0.3	2.02e-6	Aortic root size;
KIRP	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-10.44	-0.55	2.26e-21	Chronic sinus infection;
KIRP	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.46	5.82	0.35	1.85e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.92	9.88	0.53	1.35e-19	Blood protein levels;
KIRP	cis	rs4481887	0.636	rs6672981	chr1:248407200	C/T	cg01631408	chr1:248437212	OR2T33	-0.5	-5.88	-0.35	1.3e-8	Common traits (Other);
KIRP	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.64	-0.44	4.92e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-11.17	-0.58	1.05e-23	Retinal vascular caliber;
KIRP	cis	rs7837860	0.588	rs16880580	chr8:89287763	A/G	cg08624180	chr8:89339080	MMP16	-0.61	-5.25	-0.32	3.37e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26207909	chr14:103986467	CKB	-0.63	-6.86	-0.4	5.46e-11	Bone mineral density;
KIRP	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg26876637	chr1:152193138	HRNR	0.77	10.13	0.54	2.27e-20	Atopic dermatitis;
KIRP	cis	rs1829883	0.775	rs7717158	chr5:98843529	C/T	cg08333243	chr5:99726346	NA	-0.42	-5.6	-0.34	5.63e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs12580194	0.593	rs73118998	chr12:55736659	T/C	cg11794356	chr12:55725991	OR6C3	-0.61	-8.76	-0.49	3.28e-16	Cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17313118	chr5:127157258	NA	-0.47	-6.22	-0.37	2.07e-9	Inflammatory biomarkers;
KIRP	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs6832769	0.961	rs12647034	chr4:56310622	A/G	cg09317128	chr4:56265301	TMEM165	0.55	7.36	0.42	2.7e-12	Personality dimensions;
KIRP	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.57	6.89	0.4	4.77e-11	Aortic root size;
KIRP	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.07	-0.36	4.84e-9	Triglycerides;
KIRP	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg16797656	chr11:68205561	LRP5	-0.41	-5.85	-0.35	1.54e-8	Bone mineral density (spine);
KIRP	cis	rs3105593	1.000	rs11637228	chr15:50899972	G/T	cg08437265	chr15:50716283	USP8	0.39	4.93	0.3	1.48e-6	QT interval;
KIRP	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-0.62	-6.94	-0.4	3.54e-11	Type 2 diabetes;
KIRP	cis	rs11638352	1.000	rs11632901	chr15:44280253	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.84	-5.59	-0.34	6.03e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27205487	chr21:17961996	C21orf34;MIR125B2	0.35	6.01	0.36	6.48e-9	Survival in pancreatic cancer;
KIRP	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg02887458	chr19:19495540	GATAD2A	0.49	5.9	0.35	1.17e-8	Bipolar disorder;
KIRP	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.8	-12.29	-0.62	2.26e-27	Oral cavity cancer;
KIRP	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.25e-10	Hepatitis;
KIRP	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg23950597	chr19:37808831	NA	-0.64	-6.89	-0.4	4.56e-11	Coronary artery calcification;
KIRP	cis	rs6882076	1.000	rs4704825	chr5:156382308	A/G	cg12943317	chr5:156479607	HAVCR1	-0.55	-6.97	-0.41	2.89e-11	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-7.88	-0.45	1.06e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs1351164	1.000	rs1351164	chr2:218271898	C/T	cg15335768	chr2:218268053	DIRC3	0.53	7.16	0.42	9.52e-12	Height;
KIRP	trans	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg06521331	chr12:34319734	NA	-0.6	-6.99	-0.41	2.59e-11	Bladder cancer;
KIRP	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg17211192	chr8:82754475	SNX16	-0.75	-8.4	-0.47	3.5e-15	Diastolic blood pressure;
KIRP	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg00334542	chr7:100209784	MOSPD3	-0.54	-5.1	-0.31	6.72e-7	Other erythrocyte phenotypes;
KIRP	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg22349387	chr12:9600060	DDX12	-0.34	-4.87	-0.3	2.03e-6	Breast size;
KIRP	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg24375607	chr4:120327624	NA	0.57	6.46	0.38	5.6e-10	Corneal astigmatism;
KIRP	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg18944383	chr4:111397179	ENPEP	0.61	11.1	0.58	1.78e-23	Height;
KIRP	cis	rs6662572	0.703	rs4660909	chr1:46477326	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.35e-8	Blood protein levels;
KIRP	cis	rs370915	1.000	rs370915	chr4:187818256	C/G	cg19519643	chr4:187840862	NA	-0.42	-5.61	-0.34	5.57e-8	Gout;
KIRP	cis	rs8093481	1.000	rs12969695	chr18:10693081	G/A	cg21165219	chr18:10698044	FAM38B	-0.44	-5.49	-0.33	9.81e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.67	6.66	0.39	1.82e-10	Axial length;
KIRP	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21643547	chr1:205240462	TMCC2	-0.7	-10.31	-0.55	5.8e-21	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.51	6.67	0.39	1.69e-10	Calcium levels;
KIRP	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg25730555	chr22:47059586	GRAMD4	0.59	9.11	0.5	2.91e-17	Urate levels in obese individuals;
KIRP	cis	rs7737355	0.812	rs7731773	chr5:130973943	A/G	cg25547332	chr5:131281432	NA	0.41	5.03	0.31	9.49e-7	Life satisfaction;
KIRP	cis	rs2862064	1.000	rs7715467	chr5:156468654	C/G	cg12943317	chr5:156479607	HAVCR1	-0.9	-7.98	-0.45	5.53e-14	Platelet count;
KIRP	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	8.45	0.47	2.61e-15	Response to antipsychotic treatment;
KIRP	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.92	13.68	0.66	4.8e-32	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg26116260	chr4:7069785	GRPEL1	-0.81	-5.21	-0.32	3.99e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1978968	0.731	rs9605469	chr22:18461231	T/C	cg03078520	chr22:18463400	MICAL3	-0.84	-12.08	-0.61	1.07e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs918629	0.530	rs1458019	chr5:95253489	A/G	cg16656078	chr5:95278638	ELL2	-0.37	-5.62	-0.34	5.22e-8	IgG glycosylation;
KIRP	cis	rs2072732	0.861	rs12033927	chr1:2937550	A/G	cg11731671	chr1:2995604	PRDM16	-0.54	-5.84	-0.35	1.66e-8	Plateletcrit;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg19770292	chr5:1868693	NA	0.42	5.44	0.33	1.28e-7	Cardiovascular disease risk factors;
KIRP	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg19743168	chr1:23544995	NA	0.46	6.21	0.37	2.28e-9	Height;
KIRP	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg12140854	chr5:148520817	ABLIM3	-0.56	-5.94	-0.35	9.59e-9	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15008879	chr10:22292810	DNAJC1	0.66	6.06	0.36	5.17e-9	Lung function (FEV1);
KIRP	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.62	-6.2	-0.37	2.32e-9	Chronic sinus infection;
KIRP	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg10117171	chr1:25599238	RHD	-0.37	-5.1	-0.31	6.93e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg06521331	chr12:34319734	NA	-0.4	-5.14	-0.31	5.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs4944092	0.855	rs608747	chr11:75916477	A/G	cg04588336	chr11:75916460	WNT11	-0.45	-6.78	-0.4	8.88e-11	PR interval;
KIRP	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg13266496	chr6:110720918	DDO	-0.37	-5.78	-0.35	2.26e-8	Platelet distribution width;
KIRP	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.48	14.02	0.67	3.17e-33	Opioid sensitivity;
KIRP	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.06	-7.76	-0.44	2.27e-13	Mitochondrial DNA levels;
KIRP	trans	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg24644049	chr4:85504048	CDS1	1.03	6.73	0.39	1.15e-10	Skin colour saturation;
KIRP	cis	rs714027	0.585	rs41171	chr22:30422107	C/G	cg01021169	chr22:30184971	ASCC2	0.42	5.09	0.31	6.98e-7	Lymphocyte counts;
KIRP	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.7	5.01	0.3	1.04e-6	Childhood ear infection;
KIRP	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	7.28	0.42	4.53e-12	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg09873164	chr1:152488093	CRCT1	0.61	8.03	0.46	3.93e-14	Hair morphology;
KIRP	cis	rs9309711	0.736	rs28619526	chr2:3496804	T/C	cg10845886	chr2:3471009	TTC15	-0.69	-9.56	-0.52	1.24e-18	Neurofibrillary tangles;
KIRP	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.69	8.95	0.5	9.07e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.68	-9.28	-0.51	8.85e-18	Colorectal cancer;
KIRP	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.26	7.52	0.43	1.05e-12	Type 2 diabetes;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg12550412	chr1:227730308	NA	0.42	6.16	0.37	2.89e-9	Coronary artery disease;
KIRP	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg00405596	chr8:11794950	NA	-0.49	-6.58	-0.39	2.89e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27019801	chr14:31926776	C14orf126	-0.55	-6.31	-0.37	1.31e-9	Interleukin-4 levels;
KIRP	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.44	-0.47	2.7e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12367572	0.501	rs3858731	chr12:45465934	C/T	cg04608330	chr12:45269318	NELL2	-0.45	-5.76	-0.34	2.53e-8	Gut microbiome composition (summer);
KIRP	cis	rs273573	0.643	rs11031259	chr11:30999824	G/T	cg14844989	chr11:31128820	NA	0.34	4.9	0.3	1.77e-6	Total body bone mineral density;
KIRP	cis	rs4761097	0.537	rs10779132	chr12:85173355	G/A	cg00765312	chr12:85674694	ALX1	0.51	5.85	0.35	1.58e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg20965017	chr5:231967	SDHA	-0.58	-6.87	-0.4	5.09e-11	Breast cancer;
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg14820908	chr5:178986412	RUFY1	-0.47	-7.02	-0.41	2.12e-11	Lung cancer;
KIRP	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.65	-7.22	-0.42	6.64e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7312464	1	rs7312464	chr12:66374247	A/G	cg06712651	chr12:66351869	HMGA2	-0.78	-13.49	-0.65	2.09e-31	Pulse pressure;
KIRP	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg14768367	chr16:72042858	DHODH	0.51	6.33	0.37	1.13e-9	Fibrinogen levels;
KIRP	cis	rs1978968	1.000	rs5992919	chr22:18443855	A/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.23	0.37	1.97e-9	Tonsillectomy;
KIRP	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg20295408	chr7:1910781	MAD1L1	-0.52	-5.35	-0.32	1.98e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs290268	0.838	rs290987	chr9:93563267	T/A	cg02608019	chr9:93564028	SYK	0.82	11.76	0.6	1.24e-25	Platelet count;
KIRP	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg09324608	chr17:30823087	MYO1D	0.41	5.1	0.31	6.75e-7	Schizophrenia;
KIRP	cis	rs259842	0.764	rs357712	chr2:180668778	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.35	-5.03	-0.31	9.67e-7	Blood protein levels;
KIRP	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-7.9	-0.45	9.01e-14	Alzheimer's disease;
KIRP	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg00325661	chr8:49890786	NA	0.4	4.86	0.3	2.13e-6	Sudden cardiac arrest;
KIRP	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.59e-12	Obesity-related traits;
KIRP	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg08890418	chr1:21044141	KIF17	0.35	5.31	0.32	2.43e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	0.87	8.65	0.48	6.93e-16	Methadone dose in opioid dependence;
KIRP	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.74	9.93	0.53	9.35e-20	Mood instability;
KIRP	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.81	-12.34	-0.62	1.48e-27	Breast cancer;
KIRP	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11987759	chr7:65425863	GUSB	-0.53	-6.8	-0.4	7.66e-11	Aortic root size;
KIRP	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.46	-0.38	5.46e-10	Menopause (age at onset);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10175688	chr17:6544015	TXNDC17;KIAA0753	0.51	6.24	0.37	1.91e-9	Myopia (pathological);
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.79	13.32	0.65	7.55e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27171580	chr12:80073676	PAWR	0.4	6.25	0.37	1.75e-9	Migraine with aura;
KIRP	cis	rs7688540	0.771	rs78343340	chr4:267437	G/A	cg10134910	chr4:1076041	RNF212	-0.24	-4.85	-0.3	2.19e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg22974920	chr21:40686053	BRWD1	0.5	6.0	0.36	6.96e-9	Cognitive function;
KIRP	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11954230	chr10:105677556	OBFC1	0.5	6.08	0.36	4.51e-9	Smoking initiation;
KIRP	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg10645314	chr2:3704589	ALLC	-1.04	-11.17	-0.58	1.03e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg16797656	chr11:68205561	LRP5	0.52	8.23	0.46	1.13e-14	Bone mineral density (spine);
KIRP	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.58	6.43	0.38	6.73e-10	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.76	7.79	0.44	1.91e-13	Uric acid levels;
KIRP	cis	rs698833	0.537	rs698826	chr2:44728418	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	4.92	0.3	1.56e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.9e-11	Retinal vascular caliber;
KIRP	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg16672083	chr15:72433130	SENP8	0.45	6.28	0.37	1.56e-9	Red blood cell count;
KIRP	trans	rs2048656	0.578	rs10095236	chr8:9684925	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.92	-0.45	8.01e-14	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03517284	chr6:25882590	NA	-0.38	-5.4	-0.33	1.54e-7	Height;
KIRP	cis	rs7011049	0.687	rs6473770	chr8:53869554	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-1.01	-18.68	-0.77	4.4e-49	Height;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg01798813	chr17:3906674	NA	0.54	7.54	0.43	9.01e-13	Type 2 diabetes;
KIRP	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.59	7.13	0.41	1.1e-11	Response to antipsychotic treatment;
KIRP	cis	rs7103648	0.603	rs3740688	chr11:47380340	G/T	cg20307385	chr11:47447363	PSMC3	0.55	6.37	0.38	9.19e-10	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2019216	0.934	rs7405575	chr17:21936954	T/C	cg22648282	chr17:21454238	C17orf51	-0.37	-4.95	-0.3	1.39e-6	Pelvic organ prolapse;
KIRP	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs2224391	0.590	rs17140068	chr6:5282227	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-5.05	-0.31	8.53e-7	Height;
KIRP	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.44	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.21	0.37	2.27e-9	Leprosy;
KIRP	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg01674679	chr13:27998804	GTF3A	0.57	5.99	0.36	7.45e-9	Body mass index;
KIRP	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.68	9.64	0.52	7.07e-19	Retinal vascular caliber;
KIRP	cis	rs12210905	1.000	rs4636015	chr6:27097316	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.62	-6.9	-0.4	4.28e-11	Neuroticism;
KIRP	cis	rs7224685	0.501	rs2727074	chr17:3994670	A/G	cg21734707	chr17:3908241	ZZEF1	-0.62	-9.29	-0.51	8.4e-18	Type 2 diabetes;
KIRP	cis	rs6466055	0.589	rs10953475	chr7:104961873	A/G	cg04380332	chr7:105027541	SRPK2	0.36	4.99	0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg02151108	chr14:50098012	C14orf104	-0.5	-6.5	-0.38	4.39e-10	Carotid intima media thickness;
KIRP	cis	rs997295	1.000	rs8035675	chr15:67965581	C/T	cg24579218	chr15:68104479	NA	0.36	5.44	0.33	1.26e-7	Motion sickness;
KIRP	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.65	8.02	0.46	4.41e-14	Blood metabolite levels;
KIRP	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg23602478	chr1:26503979	CNKSR1	0.44	6.35	0.38	1.02e-9	Height;
KIRP	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.98	0.41	2.81e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs372883	0.530	rs11088110	chr21:30543373	G/A	cg24692254	chr21:30365293	RNF160	-0.42	-4.93	-0.3	1.48e-6	Pancreatic cancer;
KIRP	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.4	-0.38	7.62e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13976753	chr1:24681532	GRHL3	-0.49	-6.22	-0.37	2.16e-9	Inflammatory biomarkers;
KIRP	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg01721255	chr8:58191610	C8orf71	0.49	5.23	0.32	3.57e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7916697	0.947	rs9783176	chr10:70002393	A/T	cg18338521	chr10:69995036	NA	-0.38	-4.91	-0.3	1.69e-6	Optic disc area;
KIRP	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.62	8.99	0.5	6.88e-17	Colorectal cancer;
KIRP	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.59	0.71	1.4e-38	Lymphocyte percentage of white cells;
KIRP	cis	rs975752	0.867	rs4919440	chr10:102014919	C/T	cg13817732	chr10:102046368	BLOC1S2	0.71	5.98	0.36	7.85e-9	Schizophrenia;
KIRP	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.69	-9.99	-0.54	5.95e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs5753037	0.702	rs81800	chr22:30200362	C/G	cg01021169	chr22:30184971	ASCC2	0.42	5.86	0.35	1.45e-8	Type 1 diabetes;
KIRP	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg06795125	chr2:108905320	SULT1C2	0.38	7.16	0.42	9.45e-12	Blood pressure;
KIRP	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.46	6.78	0.4	9e-11	Gout;
KIRP	cis	rs9815354	0.680	rs73073290	chr3:42027684	T/G	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.42	5.03	0.31	9.68e-7	Eosinophil percentage of white cells;
KIRP	cis	rs1318772	0.932	rs17324474	chr5:112591838	A/T	cg12552261	chr5:112820674	MCC	0.79	4.93	0.3	1.49e-6	F-cell distribution;
KIRP	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.48	6.06	0.36	5.19e-9	Fibrinogen levels;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg17247435	chr13:28713452	PAN3;LOC100288730	-0.45	-6.14	-0.36	3.21e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs933360	0.503	rs10231012	chr7:50876790	G/T	cg14997413	chr7:51384937	COBL	0.31	5.02	0.31	9.7e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg23752985	chr2:85803571	VAMP8	0.46	5.32	0.32	2.34e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.21	-14.49	-0.68	7.98e-35	Platelet count;
KIRP	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	1.05	19.66	0.78	2.35e-52	Height;
KIRP	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg16586182	chr3:47516702	SCAP	0.84	12.02	0.61	1.68e-26	Colorectal cancer;
KIRP	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.73	-9.46	-0.52	2.51e-18	Body mass index;
KIRP	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.14	-0.31	5.56e-7	Gout;Renal underexcretion gout;
KIRP	trans	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs10924970	0.967	rs2382615	chr1:235454955	G/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.73e-7	Asthma;
KIRP	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.64	8.92	0.49	1.08e-16	Lymphocyte counts;
KIRP	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.5	-6.34	-0.37	1.09e-9	IgG glycosylation;
KIRP	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg20387954	chr3:183756860	HTR3D	0.63	9.39	0.51	4.1e-18	Anterior chamber depth;
KIRP	cis	rs734999	0.545	rs10910105	chr1:2538209	G/A	cg20673091	chr1:2541236	MMEL1	0.67	10.05	0.54	3.8e-20	Ulcerative colitis;
KIRP	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-1.31	-13.32	-0.65	7.7e-31	Post bronchodilator FEV1;
KIRP	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.25	0.37	1.77e-9	Total body bone mineral density;
KIRP	cis	rs7221595	0.825	rs8074860	chr17:3986657	C/G	cg11204139	chr17:3907470	NA	0.57	5.55	0.33	7.2e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg14675211	chr2:100938903	LONRF2	0.48	6.23	0.37	1.95e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs846111	1.000	rs846111	chr1:6279370	G/C	cg15892785	chr1:6309343	GPR153	-0.53	-6.3	-0.37	1.4e-9	QT interval;
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.76	-10.2	-0.55	1.29e-20	Longevity;
KIRP	cis	rs4936894	0.500	rs7924537	chr11:124154243	T/C	cg27160556	chr11:124181099	OR8D1	-0.39	-5.75	-0.34	2.65e-8	Aging (time to death);
KIRP	cis	rs10073892	0.662	rs10040933	chr5:101639818	G/A	cg19774478	chr5:101632501	SLCO4C1	0.6	6.23	0.37	2.01e-9	Cognitive decline (age-related);
KIRP	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg07796016	chr1:152779584	LCE1C	-0.47	-5.94	-0.35	9.54e-9	Inflammatory skin disease;
KIRP	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.33	5.09	0.31	7e-7	Type 2 diabetes;
KIRP	cis	rs632111	0.519	rs281380	chr19:49214470	A/G	cg21064579	chr19:49206444	FUT2	-0.39	-5.63	-0.34	4.81e-8	Serum lipase activity;
KIRP	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg25801113	chr15:45476975	SHF	-0.43	-7.61	-0.44	5.77e-13	Uric acid levels;
KIRP	cis	rs9653442	0.527	rs12712064	chr2:100756548	C/T	cg22139774	chr2:100720529	AFF3	-0.33	-5.36	-0.32	1.95e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.63	8.54	0.48	1.46e-15	Schizophrenia;
KIRP	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg20701182	chr2:24300061	SF3B14	0.64	5.53	0.33	8.3e-8	Lymphocyte counts;
KIRP	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	7.45	0.43	1.55e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg04310649	chr10:35416472	CREM	-0.58	-6.77	-0.4	9.43e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg02454025	chr1:11042201	C1orf127	0.9	14.28	0.67	4.12e-34	Ewing sarcoma;
KIRP	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg27121462	chr16:89883253	FANCA	0.49	6.03	0.36	5.91e-9	Vitiligo;
KIRP	cis	rs9400271	0.632	rs9386784	chr6:109591208	C/A	cg01475377	chr6:109611718	NA	-0.36	-5.26	-0.32	3.08e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg17366294	chr4:99064904	C4orf37	0.37	5.1	0.31	6.7e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	1.04	20.33	0.79	1.41e-54	Platelet distribution width;
KIRP	cis	rs71597109	0.608	rs11931087	chr4:102727619	A/G	cg14855874	chr4:102712397	BANK1	0.39	4.89	0.3	1.86e-6	Chronic lymphocytic leukemia;
KIRP	trans	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg23719950	chr11:63933701	MACROD1	-0.68	-6.61	-0.39	2.39e-10	Mean platelet volume;
KIRP	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg19507638	chr5:93509721	C5orf36	-0.61	-5.27	-0.32	2.94e-7	Diabetic retinopathy;
KIRP	cis	rs6504622	0.875	rs11652318	chr17:45041094	T/C	cg24703533	chr17:45055318	NA	0.39	5.52	0.33	8.56e-8	Orofacial clefts;
KIRP	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.09	-19.43	-0.78	1.39e-51	Schizophrenia;
KIRP	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-1.13	-21.0	-0.8	8.58e-57	Monocyte count;
KIRP	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.51	-5.61	-0.34	5.51e-8	Platelet distribution width;
KIRP	cis	rs1298062	0.717	rs78467973	chr19:50995571	T/C	cg11430371	chr19:50961752	MYBPC2	0.36	4.96	0.3	1.33e-6	Age of smoking initiation;
KIRP	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-8.03	-0.46	4.15e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2224391	0.518	rs17736611	chr6:5283821	A/G	cg24031505	chr6:4779396	CDYL	-0.65	-5.09	-0.31	7.13e-7	Height;
KIRP	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.9	10.43	0.55	2.43e-21	Corneal astigmatism;
KIRP	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg18016565	chr1:150552671	MCL1	0.38	5.69	0.34	3.65e-8	Melanoma;
KIRP	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-0.91	-8.42	-0.47	3.12e-15	Lung cancer;
KIRP	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.78	-10.84	-0.57	1.21e-22	Longevity;
KIRP	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs7394190	0.935	rs4746140	chr10:75417249	G/C	cg04833713	chr10:74871078	NUDT13	0.39	5.24	0.32	3.44e-7	Incident atrial fibrillation;
KIRP	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg05669848	chr5:237993	SDHA	-0.48	-4.89	-0.3	1.82e-6	Breast cancer;
KIRP	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-5.73	-0.34	2.97e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6893300	0.961	rs7447159	chr5:179177676	G/C	cg14593053	chr5:179126677	CANX	-0.59	-6.66	-0.39	1.79e-10	Resting heart rate;
KIRP	trans	rs7999699	0.902	rs12429508	chr13:48309257	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.98	-17.49	-0.74	4.56e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.54	-0.33	7.96e-8	Obesity-related traits;
KIRP	cis	rs7709377	0.595	rs41271	chr5:115629354	T/C	cg23108291	chr5:115420582	COMMD10	-0.44	-5.35	-0.32	2e-7	Metabolite levels  (X-11787);
KIRP	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg14972814	chr11:95582409	MTMR2	0.3	5.15	0.31	5.35e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg21433313	chr16:3507492	NAT15	-0.56	-6.92	-0.4	3.96e-11	Tuberculosis;
KIRP	cis	rs42648	0.837	rs7786771	chr7:89924767	G/A	cg25739043	chr7:89950458	NA	-0.45	-6.99	-0.41	2.62e-11	Homocysteine levels;
KIRP	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg04989706	chr14:50066350	PPIL5	-0.49	-5.83	-0.35	1.71e-8	Carotid intima media thickness;
KIRP	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg26384229	chr12:38710491	ALG10B	0.55	7.35	0.42	2.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg00864860	chr1:7907996	UTS2	-0.51	-6.03	-0.36	6.11e-9	Crohn's disease;
KIRP	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23627620	chr6:134273564	TBPL1	0.48	6.67	0.39	1.72e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg25600027	chr14:23388339	RBM23	-0.51	-6.26	-0.37	1.68e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs9840812	0.769	rs3755636	chr3:135968828	G/C	cg15507776	chr3:136538369	TMEM22	0.41	5.3	0.32	2.63e-7	Fibrinogen levels;
KIRP	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg23442198	chr4:187126114	CYP4V2	0.75	6.97	0.41	2.88e-11	Blood protein levels;
KIRP	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	trans	rs2055729	0.677	rs13270146	chr8:9740595	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.08	-0.36	4.47e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10858047	0.831	rs10776787	chr1:115210161	A/T	cg12756093	chr1:115239321	AMPD1	0.62	6.05	0.36	5.44e-9	Autism;
KIRP	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.24	0.37	1.85e-9	Aortic root size;
KIRP	cis	rs447921	0.736	rs28715905	chr17:74448063	A/C	cg16776035	chr17:74542680	NA	0.56	5.16	0.31	5.11e-7	Mitochondrial DNA levels;
KIRP	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg10018233	chr7:150070692	REPIN1	0.59	7.23	0.42	6.13e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.69	-7.8	-0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.84	11.23	0.58	6.79e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg20387954	chr3:183756860	HTR3D	0.41	5.19	0.31	4.3e-7	Anterior chamber depth;
KIRP	cis	rs17065868	0.881	rs9533892	chr13:45099358	T/C	cg10246903	chr13:45222710	NA	0.7	6.85	0.4	5.96e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg18501202	chr6:125855421	NA	-0.34	-5.16	-0.31	5.17e-7	Brugada syndrome;
KIRP	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.84e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	5.1	0.31	6.71e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18678121	chr10:12170807	SEC61A2	0.43	6.54	0.38	3.44e-10	Interleukin-4 levels;
KIRP	cis	rs448720	0.806	rs4306451	chr15:68157881	A/G	cg24579218	chr15:68104479	NA	-0.4	-6.04	-0.36	5.58e-9	Cognitive performance;
KIRP	cis	rs714027	1.000	rs757024	chr22:30471679	G/C	cg27665648	chr22:30112403	NA	-0.38	-5.43	-0.33	1.32e-7	Lymphocyte counts;
KIRP	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.63	6.8	0.4	7.9e-11	Smoking initiation;
KIRP	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.9	0.45	9.31e-14	Iron status biomarkers;
KIRP	cis	rs11997175	0.624	rs66475930	chr8:33752570	G/A	ch.8.33884649F	chr8:33765107	NA	0.57	6.29	0.37	1.45e-9	Body mass index;
KIRP	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.62	7.32	0.42	3.43e-12	Obesity-related traits;
KIRP	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg24324837	chr19:49891574	CCDC155	0.66	8.48	0.48	2.11e-15	Multiple sclerosis;
KIRP	cis	rs2014572	0.933	rs8109882	chr19:57755618	C/G	cg12963866	chr19:57752005	ZNF805	-0.49	-6.24	-0.37	1.91e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs7590368	0.715	rs56141717	chr2:10958989	C/T	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs745080	0.634	rs2065055	chr14:53041549	A/G	cg23333723	chr14:53022898	GPR137C	-0.44	-6.2	-0.37	2.37e-9	Orofacial clefts;
KIRP	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	1.04	10.95	0.57	5.34e-23	Nonalcoholic fatty liver disease;
KIRP	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg17554472	chr22:41940697	POLR3H	0.67	6.94	0.4	3.47e-11	Vitiligo;
KIRP	cis	rs6496044	0.568	rs2880765	chr15:86056462	A/T	cg17133734	chr15:86042851	AKAP13	0.45	5.63	0.34	4.99e-8	Interstitial lung disease;
KIRP	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	8.86	0.49	1.59e-16	Total body bone mineral density;
KIRP	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg09571762	chr12:39539558	NA	0.34	5.04	0.31	8.93e-7	Morning vs. evening chronotype;
KIRP	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.42	-0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.64	8.67	0.48	5.96e-16	Schizophrenia;
KIRP	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg05938607	chr10:60274200	BICC1	-0.4	-9.55	-0.52	1.4e-18	Refractive error;
KIRP	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg20363699	chr7:23626180	CLK2P	0.38	5.17	0.31	4.94e-7	Schizophrenia;
KIRP	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg01631408	chr1:248437212	OR2T33	0.53	7.33	0.42	3.31e-12	Common traits (Other);
KIRP	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.77	-0.35	2.41e-8	Reticulocyte count;
KIRP	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.71	0.44	3.1e-13	Coffee consumption (cups per day);
KIRP	cis	rs17401966	0.540	rs4846199	chr1:10283961	A/G	cg17425144	chr1:10567563	PEX14	-0.28	-4.89	-0.3	1.85e-6	Hepatocellular carcinoma;
KIRP	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg04013166	chr16:89971882	TCF25	0.68	5.68	0.34	3.85e-8	Skin colour saturation;
KIRP	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.23	0.37	2e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.97	13.99	0.67	4.09e-33	Menopause (age at onset);
KIRP	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.63	-7.98	-0.45	5.63e-14	Prudent dietary pattern;
KIRP	cis	rs1318772	0.877	rs34437714	chr5:112703375	G/C	cg12552261	chr5:112820674	MCC	0.62	5.59	0.34	5.9e-8	F-cell distribution;
KIRP	cis	rs13185784	0.667	rs4454029	chr5:179645325	C/T	cg13944838	chr5:179740914	GFPT2	0.48	4.96	0.3	1.31e-6	TRAIL levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01514465	chr4:118004215	NA	-0.47	-6.65	-0.39	1.84e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg01631408	chr1:248437212	OR2T33	-0.52	-7.17	-0.42	8.72e-12	Common traits (Other);
KIRP	cis	rs17453880	0.929	rs4385197	chr5:152047146	G/A	cg12297329	chr5:152029980	NA	-0.71	-10.61	-0.56	6.68e-22	Subjective well-being;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg05665937	chr4:1216051	CTBP1	0.42	5.43	0.33	1.38e-7	Obesity-related traits;
KIRP	cis	rs7929679	0.571	rs2136508	chr11:34796846	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.36e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26002218	chr14:103986227	CKB	0.26	5.1	0.31	6.89e-7	Body mass index;
KIRP	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg05425664	chr17:57184151	TRIM37	0.45	5.71	0.34	3.16e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg25319279	chr11:5960081	NA	0.54	6.02	0.36	6.32e-9	DNA methylation (variation);
KIRP	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.56	7.64	0.44	4.95e-13	Colorectal cancer;
KIRP	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg23601095	chr6:26197514	HIST1H3D	1.02	8.47	0.48	2.24e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs301161	0.790	rs921435	chr16:85821934	A/T	cg03249995	chr16:85819513	COX4NB	0.53	5.52	0.33	8.77e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.52	6.68	0.39	1.6e-10	IgG glycosylation;
KIRP	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.5	-6.96	-0.41	3.1e-11	Asthma;
KIRP	cis	rs507080	0.769	rs483283	chr11:118506402	T/C	cg04173919	chr11:118528438	PHLDB1	0.35	5.01	0.3	1.06e-6	Serum metabolite levels;
KIRP	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.59	7.67	0.44	4.04e-13	Bladder cancer;
KIRP	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg14593290	chr7:50529359	DDC	0.67	8.19	0.46	1.47e-14	Malaria;
KIRP	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg04850286	chr10:81895943	PLAC9	-0.31	-4.93	-0.3	1.49e-6	Sarcoidosis;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.37	-0.51	4.72e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg24998770	chr7:37888106	TXNDC3	0.46	6.15	0.37	3.06e-9	Alzheimer's disease (late onset);
KIRP	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	1.04	21.58	0.81	1.11e-58	Height;
KIRP	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg00919237	chr7:87102261	ABCB4	-0.7	-9.26	-0.51	1.08e-17	Gallbladder cancer;
KIRP	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.55	-6.39	-0.38	8.02e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg19171272	chr22:38449367	NA	-0.66	-9.77	-0.53	2.99e-19	Glioblastoma;Glioma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00199846	chr13:37393246	RFXAP	0.46	6.51	0.38	4.23e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-9.93	-0.53	9.54e-20	Body mass index;
KIRP	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	trans	rs7999699	0.967	rs9534807	chr13:48328664	T/C	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.62	7.33	0.42	3.25e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg25922239	chr6:33757077	LEMD2	0.65	7.97	0.45	6.05e-14	Crohn's disease;
KIRP	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg11608241	chr8:8085544	FLJ10661	-0.48	-6.06	-0.36	4.97e-9	Triglycerides;
KIRP	cis	rs2072732	0.904	rs12044831	chr1:2964397	A/C	cg11731671	chr1:2995604	PRDM16	-0.51	-5.74	-0.34	2.72e-8	Plateletcrit;
KIRP	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg23594656	chr7:65796392	TPST1	-0.45	-7.11	-0.41	1.28e-11	Aortic root size;
KIRP	cis	rs9815354	0.812	rs73069203	chr3:41938767	T/C	cg03022575	chr3:42003672	ULK4	0.77	7.9	0.45	9.42e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2303759	0.958	rs1465697	chr19:49837246	C/T	cg22590775	chr19:49891494	CCDC155	0.67	8.41	0.47	3.4e-15	Multiple sclerosis;
KIRP	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg06212747	chr3:49208901	KLHDC8B	0.66	6.16	0.37	2.89e-9	Menarche (age at onset);
KIRP	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.51	-4.93	-0.3	1.48e-6	Recombination rate (females);
KIRP	cis	rs4805272	1.000	rs60122378	chr19:29321553	C/G	cg15000279	chr19:29285009	NA	-0.36	-5.22	-0.32	3.76e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08511440	chr3:46923503	PTH1R	0.46	6.36	0.38	9.95e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21499685	chr4:1362252	KIAA1530	-0.49	-6.55	-0.39	3.39e-10	Parkinson's disease;
KIRP	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	0.74	10.82	0.57	1.47e-22	Prudent dietary pattern;
KIRP	trans	rs6601327	0.602	rs12678014	chr8:9649165	T/C	cg15556689	chr8:8085844	FLJ10661	0.53	7.03	0.41	2.01e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.63	8.96	0.5	8.55e-17	Schizophrenia;
KIRP	cis	rs5753037	0.585	rs249401	chr22:30216168	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-6.06	-0.36	5.09e-9	Type 1 diabetes;
KIRP	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.35	0.51	5.5e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg23533926	chr12:111358616	MYL2	-0.48	-6.33	-0.37	1.18e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs11779988	0.545	rs4124900	chr8:17785266	A/G	cg01800426	chr8:17659068	MTUS1	-0.61	-6.09	-0.36	4.27e-9	Breast cancer;
KIRP	cis	rs6496667	0.779	rs8041764	chr15:90968264	G/A	cg10434728	chr15:90938212	IQGAP1	0.37	4.96	0.3	1.34e-6	Rheumatoid arthritis;
KIRP	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg02336718	chr17:17403227	NA	0.39	5.92	0.35	1.07e-8	Total body bone mineral density;
KIRP	cis	rs2150410	0.915	rs66519408	chr21:40551119	T/A	cg11890956	chr21:40555474	PSMG1	-0.76	-5.5	-0.33	9.59e-8	Temperament (bipolar disorder);
KIRP	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg13798912	chr7:905769	UNC84A	0.52	5.31	0.32	2.4e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.6	6.63	0.39	2.13e-10	Serum sulfate level;
KIRP	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg06609049	chr19:2785107	THOP1	0.89	11.06	0.58	2.4e-23	Total cholesterol levels;
KIRP	trans	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.26	-0.37	1.72e-9	Triglycerides;
KIRP	cis	rs6681460	0.966	rs11208932	chr1:67097853	T/C	cg13052034	chr1:66999238	SGIP1	0.39	5.35	0.32	2.04e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.69	-6.4	-0.38	7.92e-10	Schizophrenia;
KIRP	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	cis	rs7923609	0.967	rs7085621	chr10:65208926	T/C	cg01631684	chr10:65280961	REEP3	-0.53	-6.19	-0.37	2.54e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9608946	1.000	rs7287003	chr22:30925492	G/C	cg23383138	chr22:30885012	SEC14L4	0.42	4.92	0.3	1.59e-6	Red cell distribution width;
KIRP	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.28e-6	Recombination rate (females);
KIRP	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg01872077	chr2:219646372	CYP27A1	0.42	5.54	0.33	7.81e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg08975724	chr8:8085496	FLJ10661	0.66	8.49	0.48	2.04e-15	Neuroticism;
KIRP	cis	rs72634030	0.536	rs72634025	chr17:5230196	G/A	cg20802942	chr17:5185005	RABEP1	0.52	4.99	0.3	1.17e-6	Rheumatoid arthritis;
KIRP	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.65	6.6	0.39	2.46e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.62	8.91	0.49	1.19e-16	Lung cancer;
KIRP	cis	rs2395528	0.574	rs1863832	chr10:80125238	C/A	cg08356028	chr10:80217969	NA	-0.41	-5.99	-0.36	7.36e-9	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.94e-7	Red blood cell count;
KIRP	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	1.11	17.36	0.74	1.28e-44	Homoarginine levels;
KIRP	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg12861170	chr19:19639553	YJEFN3	-0.47	-4.85	-0.3	2.17e-6	Bipolar disorder;
KIRP	cis	rs988913	0.581	rs1108887	chr6:54857207	C/T	cg03513858	chr6:54763001	FAM83B	0.36	5.22	0.32	3.72e-7	Menarche (age at onset);
KIRP	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.54	-7.52	-0.43	1.04e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	1.15	9.64	0.52	7.28e-19	Prostate cancer;
KIRP	cis	rs7113850	0.541	rs76874215	chr11:24235158	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	8.41	0.47	3.28e-15	Bone fracture in osteoporosis;
KIRP	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg03060546	chr3:49711283	APEH	-0.72	-5.46	-0.33	1.15e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4664293	0.967	rs2357526	chr2:160524596	C/T	cg08347373	chr2:160653686	CD302	0.38	5.94	0.35	9.47e-9	Monocyte percentage of white cells;
KIRP	cis	rs714027	0.605	rs5753025	chr22:30542157	T/C	cg01021169	chr22:30184971	ASCC2	0.44	5.59	0.34	6.05e-8	Lymphocyte counts;
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg11814155	chr7:99998594	ZCWPW1	0.54	5.41	0.33	1.49e-7	Platelet count;
KIRP	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.45	5.54	0.33	7.63e-8	Total body bone mineral density;
KIRP	cis	rs7623687	0.892	rs73074830	chr3:49577017	A/C	cg19401529	chr3:49056140	DALRD3	0.95	6.12	0.36	3.64e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	trans	rs2980439	0.729	rs2955585	chr8:8093511	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.78	-0.4	8.61e-11	Neuroticism;
KIRP	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.58	-7.43	-0.43	1.84e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg23024343	chr7:107201750	COG5	0.4	4.91	0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs2380205	0.967	rs4009521	chr10:5888090	G/T	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.04e-8	Breast cancer;
KIRP	trans	rs12517041	0.872	rs78861527	chr5:23283534	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.87	-8.09	-0.46	2.68e-14	Calcium levels;
KIRP	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg03808351	chr9:123631620	PHF19	0.43	5.95	0.35	8.99e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.59	-7.82	-0.45	1.59e-13	White matter hyperintensity burden;
KIRP	cis	rs3956705	0.762	rs13437980	chr7:32997749	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.41	4.91	0.3	1.69e-6	Red cell distribution width;
KIRP	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg00409905	chr10:38381863	ZNF37A	0.56	5.84	0.35	1.64e-8	Obesity (extreme);
KIRP	cis	rs9900972	0.918	rs4789942	chr17:76877495	T/C	cg00961940	chr17:76876995	TIMP2	0.55	7.18	0.42	8.07e-12	Obesity-related traits;
KIRP	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.65	8.56	0.48	1.26e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-5.44	-0.33	1.27e-7	Crohn's disease;
KIRP	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.62	8.84	0.49	1.83e-16	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.71	9.09	0.5	3.42e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg08657492	chr7:27170832	HOXA4	-0.34	-5.13	-0.31	5.75e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.7	-9.56	-0.52	1.26e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg01097406	chr16:89675127	NA	-0.33	-5.64	-0.34	4.6e-8	Hemoglobin concentration;
KIRP	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg01879757	chr17:41196368	BRCA1	-0.72	-8.87	-0.49	1.53e-16	Menopause (age at onset);
KIRP	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.39	3.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.4	-4.96	-0.3	1.29e-6	Eosinophil percentage of white cells;
KIRP	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	1.01	19.6	0.78	3.57e-52	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24768113	chr11:26996054	NA	0.4	6.05	0.36	5.26e-9	Interleukin-4 levels;
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg01097406	chr16:89675127	NA	-0.3	-4.89	-0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.61	8.35	0.47	5.11e-15	Obesity-related traits;
KIRP	cis	rs9323205	1.000	rs7149022	chr14:51613980	A/C	cg23942311	chr14:51606299	NA	-0.56	-6.12	-0.36	3.62e-9	Cancer;
KIRP	cis	rs2637030	0.559	rs256117	chr5:52916684	G/A	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-8.83	-0.49	2e-16	Platelet distribution width;
KIRP	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg00784671	chr22:46762841	CELSR1	-0.6	-7.31	-0.42	3.76e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg04022379	chr5:110408740	TSLP	0.61	10.04	0.54	4.18e-20	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.66	-8.05	-0.46	3.45e-14	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16351352	chr14:55738545	FBXO34	0.51	6.42	0.38	6.99e-10	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg03834567	chr2:218808745	TNS1	-0.42	-4.97	-0.3	1.25e-6	Ulcerative colitis;
KIRP	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-6.78	-0.4	8.94e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.78	7.39	0.43	2.3e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg08975724	chr8:8085496	FLJ10661	0.79	10.32	0.55	5.72e-21	Mood instability;
KIRP	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.16	-0.31	5.04e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.75	8.34	0.47	5.42e-15	Corneal astigmatism;
KIRP	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs7951870	0.673	rs4606447	chr11:46691737	A/G	cg16389345	chr11:46697382	NA	0.42	5.17	0.31	4.92e-7	Schizophrenia;
KIRP	cis	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg02972257	chr16:68554789	NA	-0.58	-5.69	-0.34	3.6e-8	Ulcerative colitis;
KIRP	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg15128208	chr22:42549153	NA	0.4	5.21	0.31	4.09e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-0.87	-6.7	-0.39	1.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-6.38	-0.38	8.92e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11955398	0.585	rs1117677	chr5:60034675	T/G	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.81	10.75	0.57	2.34e-22	N-glycan levels;
KIRP	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.58	-7.31	-0.42	3.83e-12	Iron status biomarkers;
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg10207240	chr12:122356781	WDR66	0.61	8.08	0.46	2.84e-14	Mean corpuscular volume;
KIRP	cis	rs4845459	0.967	rs4085613	chr1:152550018	T/G	cg07796016	chr1:152779584	LCE1C	-0.48	-5.64	-0.34	4.76e-8	Psoriasis;
KIRP	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.74	9.8	0.53	2.39e-19	Cognitive function;
KIRP	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-7.19	-0.42	7.65e-12	Parkinson's disease;
KIRP	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.99	0.36	7.26e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.96	-12.51	-0.62	3.99e-28	Platelet distribution width;
KIRP	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.51	-0.59	8.44e-25	Body mass index;
KIRP	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	1.04	22.78	0.82	1.58e-62	Multiple myeloma;
KIRP	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.34	-5.77	-0.35	2.31e-8	Height;
KIRP	cis	rs9644630	0.897	rs28671342	chr8:19352420	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.38	4.94	0.3	1.46e-6	Oropharynx cancer;
KIRP	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.8e-8	Body mass index;
KIRP	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg23995753	chr2:160760732	LY75	-0.43	-5.74	-0.34	2.84e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6001982	0.748	rs6001931	chr22:40877514	G/A	cg07138101	chr22:40742427	ADSL	0.7	5.67	0.34	3.92e-8	Breast cancer;
KIRP	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg14689365	chr7:158441557	NCAPG2	0.4	4.94	0.3	1.43e-6	Height;
KIRP	cis	rs244293	0.730	rs12165058	chr17:53022049	T/C	cg07707039	chr17:53042137	COX11	-0.4	-5.07	-0.31	7.85e-7	Menarche (age at onset);
KIRP	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.4	-0.55	3.19e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.31	5.62	0.34	5.13e-8	Renal cell carcinoma;
KIRP	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.79	-0.35	2.11e-8	Breast cancer;
KIRP	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.2	0.46	1.38e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg00079169	chr19:2811669	THOP1	0.55	5.91	0.35	1.13e-8	Total cholesterol levels;
KIRP	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg16141378	chr3:129829833	LOC729375	-0.6	-7.56	-0.43	7.81e-13	Neuroticism;
KIRP	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-4.88	-0.3	1.93e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg09165964	chr15:75287851	SCAMP5	-0.93	-9.07	-0.5	3.92e-17	Lung cancer;
KIRP	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-5.93	-0.35	1.03e-8	Menopause (age at onset);
KIRP	cis	rs12220238	0.915	rs11000945	chr10:76030739	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.3	0.37	1.36e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4728302	0.869	rs10253633	chr7:133590869	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	0.871	rs5746498	chr22:18435794	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	0.47	5.68	0.34	3.76e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.42	-0.33	1.42e-7	Colorectal cancer;
KIRP	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.7	-8.93	-0.49	1.03e-16	Body mass index;
KIRP	cis	rs4671458	0.626	rs72821630	chr2:63696212	C/T	cg17519650	chr2:63277830	OTX1	-0.48	-4.91	-0.3	1.68e-6	Subjective well-being;
KIRP	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.89	-0.3	1.82e-6	Coronary artery disease;
KIRP	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg08283408	chr3:49949060	MON1A	0.36	4.85	0.3	2.22e-6	Body mass index;
KIRP	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg00383909	chr3:49044727	WDR6	0.66	6.0	0.36	6.97e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs33912345	0.669	rs1268619	chr14:60897631	G/A	cg27398547	chr14:60952738	C14orf39	-0.41	-5.59	-0.34	6.13e-8	Glaucoma (high intraocular pressure);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26386846	chr3:118753714	IGSF11	0.5	6.03	0.36	6.07e-9	Parkinson's disease;
KIRP	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg00495681	chr13:53174319	NA	-0.43	-5.92	-0.35	1.06e-8	Lewy body disease;
KIRP	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg18586891	chr4:952366	TMEM175	0.61	5.57	0.33	6.78e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.89	-0.3	1.83e-6	Inflammatory bowel disease;
KIRP	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg22617819	chr1:44378782	ST3GAL3	-0.4	-6.28	-0.37	1.49e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10988449	0.891	rs3088095	chr9:132397239	T/C	cg18327994	chr9:132372705	NA	-0.51	-4.86	-0.3	2.08e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9810890	1.000	rs116142295	chr3:128447372	G/C	cg15033153	chr3:128514015	RAB7A	0.7	4.99	0.3	1.12e-6	Dental caries;
KIRP	cis	rs8084125	0.765	rs72981159	chr18:74945042	A/G	cg15443732	chr18:74961078	GALR1	0.51	4.91	0.3	1.65e-6	Obesity-related traits;
KIRP	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg21366198	chr4:185655624	MLF1IP	-0.4	-5.44	-0.33	1.31e-7	Kawasaki disease;
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg09699651	chr6:150184138	LRP11	0.49	6.38	0.38	8.61e-10	Lung cancer;
KIRP	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	7.11	0.41	1.26e-11	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.68	6.81	0.4	7.3e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs7666738	0.546	rs1863602	chr4:98909304	T/C	cg05340658	chr4:99064831	C4orf37	0.67	7.99	0.45	5.36e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.57	7.7	0.44	3.4e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs62413470	1.000	rs12194192	chr6:55954089	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.52	6.68	0.39	1.61e-10	IgG glycosylation;
KIRP	cis	rs7572644	0.679	rs4666012	chr2:28018293	A/G	cg27432699	chr2:27873401	GPN1	0.47	5.29	0.32	2.64e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.67	-6.14	-0.36	3.28e-9	Schizophrenia;
KIRP	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg08131204	chr22:41487073	MIR1281	-0.44	-5.19	-0.31	4.4e-7	Neuroticism;
KIRP	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.83	-11.2	-0.58	8.63e-24	Morning vs. evening chronotype;
KIRP	cis	rs16912285	0.786	rs76326641	chr11:24253072	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	6.94	0.4	3.5e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15428792	chr12:11151430	PRR4;TAS2R20;PRH1	0.48	6.16	0.37	2.89e-9	Interleukin-4 levels;
KIRP	trans	rs6601327	0.670	rs13259398	chr8:9659935	T/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.75	-0.4	1.08e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.82	-8.36	-0.47	4.55e-15	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.73	0.6	1.6e-25	Total body bone mineral density;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg09699651	chr6:150184138	LRP11	0.45	6.15	0.37	3.08e-9	Lung cancer;
KIRP	cis	rs4845875	0.600	rs4846039	chr1:11836868	A/G	cg24844545	chr1:11908347	NPPA	0.37	4.9	0.3	1.73e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg04310649	chr10:35416472	CREM	-0.54	-6.11	-0.36	3.78e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12826209	chr6:26865740	GUSBL1	0.43	5.37	0.32	1.79e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7712401	0.502	rs30066	chr5:122293702	A/G	cg19412675	chr5:122181750	SNX24	0.6	6.38	0.38	8.51e-10	Mean platelet volume;
KIRP	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg01864069	chr14:103024347	NA	-0.85	-10.1	-0.54	2.75e-20	Platelet count;
KIRP	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg13798912	chr7:905769	UNC84A	0.61	5.95	0.35	9.04e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.74	-9.07	-0.5	3.87e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7534824	0.625	rs61780328	chr1:101458754	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.43	0.33	1.38e-7	Refractive astigmatism;
KIRP	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.74	-10.63	-0.56	5.82e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.66	0.34	4.29e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-1.0	-16.0	-0.71	5.73e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10488172	0.948	rs10488170	chr7:133326002	A/G	cg10665199	chr7:133106180	EXOC4	-0.52	-5.46	-0.33	1.14e-7	Tonometry;
KIRP	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg20302533	chr7:39170763	POU6F2	0.31	6.6	0.39	2.49e-10	IgG glycosylation;
KIRP	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	5.85	0.35	1.57e-8	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs41264869	0.689	rs61822621	chr1:205101554	G/A	cg21214746	chr1:205091277	RBBP5	0.52	6.65	0.39	1.88e-10	Blood protein levels;
KIRP	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.56	7.51	0.43	1.12e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6893300	0.961	rs11741570	chr5:179208910	A/G	cg14593053	chr5:179126677	CANX	-0.56	-6.41	-0.38	7.21e-10	Resting heart rate;
KIRP	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.36	-5.19	-0.31	4.43e-7	Menarche (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22300819	chr8:54755854	ATP6V1H	0.51	6.91	0.4	4.03e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg18350739	chr11:68623251	NA	-0.48	-7.65	-0.44	4.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	0.99	18.16	0.76	2.53e-47	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2944755	0.919	rs2944754	chr8:141574350	A/G	cg26074100	chr8:141568712	EIF2C2	-0.48	-6.41	-0.38	7.33e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg10755058	chr3:40428713	ENTPD3	0.38	5.36	0.32	1.9e-7	Renal cell carcinoma;
KIRP	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg20933634	chr6:27740509	NA	0.42	5.5	0.33	9.7e-8	Parkinson's disease;
KIRP	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg15047889	chr8:124780837	FAM91A1	-0.48	-4.86	-0.3	2.12e-6	Pancreatic cancer;
KIRP	cis	rs7246865	0.510	rs1551551	chr19:17170541	G/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.5	6.3	0.37	1.37e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg18154014	chr19:37997991	ZNF793	0.75	7.66	0.44	4.38e-13	Coronary artery calcification;
KIRP	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg22437258	chr11:111473054	SIK2	0.6	7.05	0.41	1.78e-11	Primary sclerosing cholangitis;
KIRP	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg02462569	chr6:150064036	NUP43	-0.43	-6.49	-0.38	4.69e-10	Lung cancer;
KIRP	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.92	-0.4	4.01e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs1629083	0.935	rs1715453	chr11:118125077	T/C	cg18857871	chr11:118064634	AMICA1	0.69	10.07	0.54	3.38e-20	Lung cancer;
KIRP	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg04865290	chr3:52927548	TMEM110	-0.45	-5.6	-0.34	5.8e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15267010	chr20:42543446	TOX2	-0.55	-6.33	-0.37	1.15e-9	Menopause (age at onset);
KIRP	cis	rs259842	0.585	rs7570985	chr2:180669534	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.23	-0.32	3.55e-7	Blood protein levels;
KIRP	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.75	11.49	0.59	9.37e-25	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.51	-0.38	4.2e-10	Lung cancer;
KIRP	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	1.06	23.28	0.83	3.94e-64	Breast cancer;
KIRP	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg16989719	chr2:238392110	NA	-0.67	-6.75	-0.4	1.03e-10	Prostate cancer;
KIRP	cis	rs62413470	1.000	rs12204789	chr6:55947818	A/C	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.55	-0.33	7.44e-8	Depression;
KIRP	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.25	0.32	3.24e-7	Alzheimer's disease;
KIRP	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-12.14	-0.61	7.18e-27	Height;
KIRP	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.64	-8.17	-0.46	1.59e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs40363	0.953	rs39730	chr16:3509665	T/G	cg21433313	chr16:3507492	NAT15	0.62	7.41	0.43	2.05e-12	Tuberculosis;
KIRP	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.52	7.34	0.42	3.15e-12	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs3087591	0.573	rs731758	chr17:29723000	C/G	cg24425628	chr17:29625626	OMG;NF1	0.51	7.01	0.41	2.25e-11	Hip circumference;
KIRP	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.56	7.48	0.43	1.35e-12	Depressive symptoms;
KIRP	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.6	0.81	1e-58	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16420247	chr2:10442859	HPCAL1	0.49	6.15	0.37	3.07e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg13198984	chr17:80129470	CCDC57	0.57	8.59	0.48	1.02e-15	Life satisfaction;
KIRP	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.58	0.48	1.09e-15	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg03714773	chr7:91764589	CYP51A1	0.43	6.45	0.38	5.79e-10	Breast cancer;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.77	9.63	0.52	7.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.72	-9.16	-0.5	2.07e-17	Dilated cardiomyopathy;
KIRP	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg02158880	chr13:53174818	NA	0.38	5.09	0.31	7.09e-7	Lewy body disease;
KIRP	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg22875332	chr1:76189707	ACADM	-0.34	-5.03	-0.31	9.39e-7	Daytime sleep phenotypes;
KIRP	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg26875233	chr11:93583750	C11orf90	-0.3	-5.57	-0.33	6.56e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs728478	1.000	rs7213014	chr17:57429100	A/G	cg16535752	chr17:57448097	YPEL2	-0.22	-5.25	-0.32	3.3e-7	QT interval;
KIRP	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg02038168	chr22:39784481	NA	-0.41	-4.91	-0.3	1.65e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.23	0.46	1.09e-14	Personality dimensions;
KIRP	trans	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.62	7.32	0.42	3.53e-12	IgG glycosylation;
KIRP	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg05335186	chr13:53173507	NA	0.36	5.64	0.34	4.61e-8	Lewy body disease;
KIRP	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.55	-6.68	-0.39	1.54e-10	Prudent dietary pattern;
KIRP	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-10.92	-0.57	6.82e-23	Height;
KIRP	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.04	-0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.569	rs34540447	chr17:3994413	T/C	cg11204139	chr17:3907470	NA	0.54	5.17	0.31	4.8e-7	Type 2 diabetes;
KIRP	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.5	-0.38	4.31e-10	Height;
KIRP	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg16434002	chr17:42200994	HDAC5	0.48	5.92	0.35	1.1e-8	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg14440974	chr22:39074834	NA	-0.39	-4.91	-0.3	1.64e-6	Menopause (age at onset);
KIRP	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg05868516	chr6:26286170	HIST1H4H	-0.42	-5.51	-0.33	9e-8	Educational attainment;
KIRP	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.19e-15	Retinal vascular caliber;
KIRP	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.84	9.77	0.53	2.87e-19	Platelet count;
KIRP	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg23594656	chr7:65796392	TPST1	-0.45	-6.34	-0.37	1.11e-9	Aortic root size;
KIRP	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg09676129	chr20:60540388	NA	-0.35	-4.95	-0.3	1.36e-6	Body mass index;
KIRP	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg19645103	chr12:69753606	YEATS4	-0.48	-4.96	-0.3	1.32e-6	Response to diuretic therapy;
KIRP	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.66	-7.21	-0.42	6.95e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	4.9	0.3	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.04	0.31	8.95e-7	Menopause (age at onset);
KIRP	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-1.31	-13.32	-0.65	7.7e-31	Post bronchodilator FEV1;
KIRP	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.1	0.31	6.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	8.75	0.49	3.48e-16	Bone mineral density;
KIRP	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.67	10.82	0.57	1.39e-22	Weight;
KIRP	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.41	-6.1	-0.36	4.07e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg05991184	chr2:219186017	PNKD	0.36	5.1	0.31	6.71e-7	Colorectal cancer;
KIRP	cis	rs6942756	0.876	rs6953598	chr7:129033741	A/G	cg02491457	chr7:128862824	NA	0.51	5.66	0.34	4.26e-8	White matter hyperintensity burden;
KIRP	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg05085585	chr16:30420623	ZNF771	0.34	4.94	0.3	1.44e-6	Tonsillectomy;
KIRP	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg10503236	chr1:231470652	EXOC8	-0.52	-7.5	-0.43	1.14e-12	Hemoglobin concentration;
KIRP	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17554472	chr22:41940697	POLR3H	0.66	6.96	0.41	3.09e-11	Vitiligo;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08247611	chr16:71928811	KIAA0174	0.52	6.18	0.37	2.7e-9	Smoking initiation;
KIRP	cis	rs9467711	0.516	rs629444	chr6:25885814	A/G	cg08501292	chr6:25962987	TRIM38	-0.59	-5.46	-0.33	1.16e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.56	0.43	7.85e-13	IgG glycosylation;
KIRP	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg18404041	chr3:52824283	ITIH1	0.36	5.24	0.32	3.5e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4774899	1.000	rs12906042	chr15:57479668	A/C	cg08128148	chr15:57256372	TCF12	-0.34	-4.96	-0.3	1.3e-6	Urinary tract infection frequency;
KIRP	cis	rs2095921	1	rs2095921	chr1:11033322	C/G	cg02454025	chr1:11042201	C1orf127	0.9	14.56	0.68	4.71e-35	Male-pattern baldness;
KIRP	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.33	-0.47	5.59e-15	Retinal vascular caliber;
KIRP	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-1.1	-21.99	-0.81	5.18e-60	Height;
KIRP	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-7.23	-0.42	6.26e-12	Gut microbiome composition (summer);
KIRP	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg21858823	chr1:15850916	CASP9	0.54	5.13	0.31	5.91e-7	Systolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01724006	chr1:43233072	LEPRE1;C1orf50	0.55	6.85	0.4	5.87e-11	Parkinson's disease;
KIRP	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.76	11.36	0.59	2.62e-24	Height;
KIRP	cis	rs2820315	1.000	rs2494114	chr1:201801011	C/G	cg11586189	chr1:201857591	SHISA4	-0.42	-6.03	-0.36	5.96e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.59	-0.59	4.43e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs73086581	1.000	rs73086512	chr20:3922772	C/A	cg02187196	chr20:3869020	PANK2	0.51	4.95	0.3	1.41e-6	Response to antidepressants in depression;
KIRP	cis	rs2562456	0.833	rs56179986	chr19:21520684	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2290159	0.948	rs7956	chr3:12624763	C/T	cg23032965	chr3:12705835	RAF1	-0.68	-7.34	-0.42	3.13e-12	Cholesterol, total;
KIRP	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.64	6.75	0.4	1.06e-10	Response to diuretic therapy;
KIRP	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02187348	chr16:89574699	SPG7	0.52	6.86	0.4	5.69e-11	Multiple myeloma (IgH translocation);
KIRP	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.41	-0.38	7.2e-10	Mood instability;
KIRP	trans	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg17712092	chr4:129076599	LARP1B	-0.62	-7.84	-0.45	1.34e-13	Eosinophil percentage of white cells;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17973462	chr19:6279770	MLLT1	0.53	6.64	0.39	2e-10	Myopia (pathological);
KIRP	trans	rs1864585	0.520	rs73208756	chr8:10657535	C/T	cg26278703	chr11:58910052	FAM111A	0.65	6.48	0.38	5.03e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.55	-0.39	3.31e-10	Neuroticism;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg14221460	chr8:27183342	PTK2B	0.51	6.62	0.39	2.23e-10	Neuroticism;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs6977660	0.619	rs2158379	chr7:19783977	A/G	cg07541023	chr7:19748670	TWISTNB	0.57	5.91	0.35	1.15e-8	Thyroid stimulating hormone;
KIRP	cis	rs9583531	0.714	rs76166228	chr13:111343774	T/C	cg24331049	chr13:111365604	ING1	-0.82	-5.63	-0.34	4.87e-8	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05207227	chr22:29703180	GAS2L1	0.5	6.04	0.36	5.7e-9	Smoking initiation;
KIRP	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg06521331	chr12:34319734	NA	-0.64	-7.58	-0.44	6.9e-13	Morning vs. evening chronotype;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02626152	chr1:52456480	RAB3B	-0.42	-6.14	-0.36	3.33e-9	Serum protein levels (sST2);
KIRP	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.02	-0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs4950322	0.543	rs4950318	chr1:146787953	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg20774646	chr1:149858164	HIST2H2BE;HIST2H2AC	1.03	6.94	0.4	3.48e-11	P wave terminal force;
KIRP	cis	rs6991838	0.612	rs7832407	chr8:66533306	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg19847130	chr8:10466454	RP1L1	0.42	6.15	0.37	3.07e-9	Joint mobility (Beighton score);
KIRP	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg07827796	chr19:33622959	WDR88	0.42	4.99	0.3	1.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	1.06	10.26	0.55	8.89e-21	Opioid sensitivity;
KIRP	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg19773385	chr1:10388646	KIF1B	-0.69	-9.1	-0.5	3.18e-17	Hepatocellular carcinoma;
KIRP	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-1.11	-9.21	-0.51	1.48e-17	Corneal curvature;
KIRP	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04374321	chr14:90722782	PSMC1	0.93	15.93	0.71	9.57e-40	Mortality in heart failure;
KIRP	cis	rs3767633	0.688	rs2490426	chr1:161947385	G/A	cg09175582	chr1:161736000	ATF6	0.77	4.87	0.3	1.96e-6	IgG glycosylation;
KIRP	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg04289385	chr6:36355825	ETV7	0.38	5.0	0.3	1.11e-6	Platelet distribution width;
KIRP	cis	rs3736485	0.966	rs10519312	chr15:51912971	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.42	5.65	0.34	4.5e-8	Melanoma;
KIRP	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.41	-5.56	-0.33	6.92e-8	Blood metabolite levels;
KIRP	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.88	13.84	0.66	1.3e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4650994	0.593	rs10798618	chr1:178519124	A/C	cg12486710	chr1:178512616	C1orf220	-0.25	-5.25	-0.32	3.27e-7	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg10047753	chr17:41438598	NA	1.17	19.34	0.78	2.71e-51	Menopause (age at onset);
KIRP	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg11972305	chr2:233791962	NGEF	0.35	4.89	0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg20701182	chr2:24300061	SF3B14	0.57	5.08	0.31	7.61e-7	Lymphocyte counts;
KIRP	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg19338460	chr6:170058176	WDR27	-0.68	-7.94	-0.45	7.1e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs220519	0.745	rs170217	chr20:37273352	T/C	cg24308336	chr20:37270989	C20orf95	0.24	5.36	0.32	1.96e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	12.36	0.62	1.29e-27	Ileal carcinoids;
KIRP	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	trans	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg21775007	chr8:11205619	TDH	-0.49	-6.6	-0.39	2.5e-10	Mood instability;
KIRP	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.93	-0.45	7.78e-14	Morning vs. evening chronotype;
KIRP	cis	rs494562	0.892	rs490079	chr6:86117599	T/C	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.46	-5.41	-0.33	1.51e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg03563238	chr19:33554763	RHPN2	-0.34	-5.79	-0.35	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs2012796	0.913	rs8010181	chr14:81820125	T/C	cg02996355	chr14:81879375	NA	0.39	5.35	0.32	2.03e-7	Night sleep phenotypes;
KIRP	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg20731937	chr12:48336164	NA	0.41	5.19	0.31	4.46e-7	Longevity (90 years and older);
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	10.57	0.56	8.76e-22	Lymphocyte counts;
KIRP	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg23649088	chr2:200775458	C2orf69	-0.56	-4.99	-0.3	1.14e-6	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.46	-0.47	2.44e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.07	-0.36	4.92e-9	Diastolic blood pressure;
KIRP	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.14	16.25	0.72	7.84e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg16989719	chr2:238392110	NA	-0.57	-6.41	-0.38	7.18e-10	Prostate cancer;
KIRP	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.78	-0.35	2.3e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07541786	chr7:12610355	SCIN	0.51	6.17	0.37	2.79e-9	Smoking initiation;
KIRP	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg02404636	chr22:31891804	SFI1	-0.43	-5.1	-0.31	6.83e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs9372498	0.536	rs72954806	chr6:118899965	C/G	cg18833306	chr6:118973337	C6orf204	-0.48	-4.86	-0.3	2.13e-6	Diastolic blood pressure;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg19142026	chr7:27170394	HOXA4	-0.49	-6.69	-0.39	1.5e-10	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg19847130	chr8:10466454	RP1L1	-0.42	-6.23	-0.37	1.97e-9	Retinal vascular caliber;
KIRP	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	0.64	5.64	0.34	4.63e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.68	8.25	0.47	9.9e-15	Blood protein levels;
KIRP	cis	rs7584330	0.740	rs13425580	chr2:238447168	T/C	cg16989719	chr2:238392110	NA	-0.39	-5.17	-0.31	4.78e-7	Prostate cancer;
KIRP	cis	rs12200782	0.929	rs116018523	chr6:26357234	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.57	-5.27	-0.32	3.01e-7	Small cell lung carcinoma;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.79	-0.4	8.43e-11	Lung cancer;
KIRP	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg12908607	chr1:44402522	ARTN	-0.35	-5.16	-0.31	5.05e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01290068	chr5:162932702	MAT2B	0.48	6.1	0.36	4.06e-9	Parkinson's disease;
KIRP	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg02175503	chr12:58329896	NA	0.59	6.44	0.38	6.05e-10	Multiple sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01800816	chr16:30366694	CD2BP2	0.48	6.42	0.38	6.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg10556349	chr10:835070	NA	0.58	4.91	0.3	1.67e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.49	-7.03	-0.41	2.07e-11	Bipolar disorder;
KIRP	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.51	0.59	8.52e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.42	0.43	1.91e-12	Retinal vascular caliber;
KIRP	cis	rs7258465	1.000	rs4808804	chr19:18585325	A/G	cg06953865	chr19:18549723	ISYNA1	-0.36	-5.21	-0.32	4.01e-7	Breast cancer;
KIRP	cis	rs11679564	0.714	rs4389320	chr2:37172531	T/C	cg14987922	chr2:37194071	STRN	0.49	5.9	0.35	1.19e-8	Immature fraction of reticulocytes;
KIRP	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs7010267	0.583	rs1485303	chr8:119976256	G/A	cg13268132	chr8:119964037	TNFRSF11B	0.41	5.16	0.31	5.02e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs258892	1.000	rs571646	chr5:72367339	A/G	cg21869765	chr5:72125136	TNPO1	0.53	6.29	0.37	1.44e-9	Small cell lung carcinoma;
KIRP	cis	rs66561647	0.634	rs7821856	chr8:128939499	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	5.02	0.31	9.71e-7	Hemoglobin concentration;
KIRP	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10924309	0.737	rs6701023	chr1:245854503	C/G	cg00036263	chr1:245852353	KIF26B	0.54	7.53	0.43	9.41e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.56	-4.86	-0.3	2.06e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.43	-5.34	-0.32	2.13e-7	Acne (severe);
KIRP	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg13906792	chr15:75199810	C15orf17	-0.36	-5.54	-0.33	7.96e-8	Breast cancer;
KIRP	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-6.03	-0.36	6.09e-9	Aortic root size;
KIRP	cis	rs2299587	0.828	rs13258901	chr8:17857028	T/C	cg01800426	chr8:17659068	MTUS1	-0.43	-5.17	-0.31	4.8e-7	Economic and political preferences;
KIRP	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg27131989	chr16:1112322	NA	-0.54	-4.91	-0.3	1.7e-6	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg18888403	chr1:24152774	HMGCL	0.35	4.95	0.3	1.36e-6	Immature fraction of reticulocytes;
KIRP	trans	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg18335740	chr13:41363409	SLC25A15	0.6	8.59	0.48	1.04e-15	Lewy body disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11551902	chr12:2986353	FOXM1;C12orf32	0.57	7.0	0.41	2.48e-11	Parkinson's disease;
KIRP	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.94	11.21	0.58	7.75e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg05721485	chr17:44071124	MAPT	0.6	7.8	0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.68e-11	Type 2 diabetes;
KIRP	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg07382826	chr16:28625726	SULT1A1	0.47	5.33	0.32	2.25e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10465746	0.967	rs5028806	chr1:84329295	G/A	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.13e-8	Obesity-related traits;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg07216194	chr8:27182965	PTK2B	0.47	5.88	0.35	1.34e-8	Neuroticism;
KIRP	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg16144293	chr14:75469539	EIF2B2	-0.46	-5.23	-0.32	3.61e-7	Height;
KIRP	trans	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg03929089	chr4:120376271	NA	0.87	6.25	0.37	1.76e-9	Axial length;
KIRP	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	9.03	0.5	5.01e-17	Cognitive test performance;
KIRP	cis	rs4345220	0.585	rs4861126	chr4:41643057	C/G	cg15232654	chr4:41643107	LIMCH1	0.45	6.06	0.36	4.96e-9	Migraine with aura;
KIRP	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.55	7.76	0.44	2.33e-13	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.41	5.0	0.3	1.08e-6	Response to antipsychotic treatment;
KIRP	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg19418458	chr7:158789849	NA	-0.44	-5.27	-0.32	2.95e-7	Facial morphology (factor 20);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23334298	chr4:78692537	CNOT6L	0.43	6.14	0.36	3.31e-9	Interleukin-4 levels;
KIRP	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.45	-5.29	-0.32	2.72e-7	Asthma (sex interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04579211	chr15:41221939	DLL4	0.54	6.73	0.39	1.21e-10	Smoking initiation;
KIRP	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg26811252	chr16:29126840	RRN3P2	0.66	8.81	0.49	2.38e-16	Menopause (age at onset);
KIRP	cis	rs3800461	0.544	rs6919434	chr6:34498923	C/T	cg14254433	chr6:34482411	PACSIN1	-0.71	-7.36	-0.42	2.68e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg05692746	chr2:100937584	LONRF2	-0.38	-5.06	-0.31	8.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.7	0.53	4.66e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg11204139	chr17:3907470	NA	-0.61	-8.86	-0.49	1.64e-16	Type 2 diabetes;
KIRP	cis	rs7221595	0.778	rs12946045	chr17:3904307	G/C	cg21734707	chr17:3908241	ZZEF1	0.51	5.24	0.32	3.54e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg21775007	chr8:11205619	TDH	0.45	6.14	0.36	3.36e-9	Neuroticism;
KIRP	cis	rs4906332	1.000	rs11541718	chr14:103852164	C/G	cg23307798	chr14:103986281	CKB	-0.5	-6.55	-0.39	3.43e-10	Coronary artery disease;
KIRP	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.5	7.02	0.41	2.19e-11	Red blood cell count;
KIRP	cis	rs10465746	0.573	rs12121175	chr1:84468961	T/G	cg10977910	chr1:84465055	TTLL7	0.47	5.77	0.35	2.39e-8	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26440361	chr12:122064389	ORAI1	0.5	6.33	0.37	1.15e-9	Parkinson's disease;
KIRP	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06156847	chr2:113672199	IL1F7	0.47	6.46	0.38	5.53e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	8.77	0.49	2.93e-16	Lung cancer in ever smokers;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.79	-11.27	-0.58	4.87e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-8.22	-0.46	1.21e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8067545	0.750	rs1421174	chr17:19950190	G/T	cg13482628	chr17:19912719	NA	0.65	9.32	0.51	7.11e-18	Schizophrenia;
KIRP	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.69	-9.2	-0.51	1.64e-17	Age at first birth;
KIRP	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-8.08	-0.46	2.85e-14	Body mass index;
KIRP	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg03563238	chr19:33554763	RHPN2	-0.33	-6.08	-0.36	4.52e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04366385	chr4:78980382	FRAS1	0.52	7.02	0.41	2.16e-11	Parkinson's disease;
KIRP	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg14505434	chr11:89522851	NA	0.49	5.42	0.33	1.4e-7	White blood cell types;
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg04369109	chr6:150039330	LATS1	-0.65	-8.51	-0.48	1.76e-15	Lung cancer;
KIRP	cis	rs6546324	0.625	rs2902023	chr2:67830279	A/G	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.7e-13	Endometriosis;
KIRP	cis	rs6743068	0.521	rs6705845	chr2:202219039	A/G	cg06431681	chr2:202330990	STRADB	0.37	5.03	0.31	9.41e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg16141378	chr3:129829833	LOC729375	-0.56	-7.73	-0.44	2.83e-13	Mood instability;
KIRP	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	1.12	19.83	0.78	6.15e-53	Bone mineral density;
KIRP	cis	rs4356932	0.656	rs6826085	chr4:76870229	C/T	cg19388996	chr4:76862389	NAAA	-0.42	-5.3	-0.32	2.6e-7	Blood protein levels;
KIRP	cis	rs1355223	1.000	rs11601205	chr11:34768479	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.49	-5.69	-0.34	3.63e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15647029	chr12:104714974	TXNRD1	0.46	6.07	0.36	4.89e-9	Interleukin-4 levels;
KIRP	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.34	5.08	0.31	7.44e-7	Fuchs's corneal dystrophy;
KIRP	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	8.61	0.48	9.08e-16	Joint mobility (Beighton score);
KIRP	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg05347473	chr6:146136440	FBXO30	-0.6	-8.45	-0.47	2.58e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.77	10.7	0.56	3.44e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg03808351	chr9:123631620	PHF19	0.47	6.6	0.39	2.44e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.8	9.11	0.5	2.92e-17	Corneal astigmatism;
KIRP	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.52	5.1	0.31	6.82e-7	Initial pursuit acceleration;
KIRP	cis	rs13315871	0.929	rs9811074	chr3:58421846	A/G	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.5	5.96	0.36	8.75e-9	Menarche (age at onset);
KIRP	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.5	6.8	0.4	7.66e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	0.81	8.76	0.49	3.14e-16	Gut microbiome composition (summer);
KIRP	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.51	7.07	0.41	1.6e-11	Dupuytren's disease;
KIRP	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.68	9.02	0.5	5.41e-17	Colorectal cancer;
KIRP	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg07382826	chr16:28625726	SULT1A1	0.48	5.35	0.32	2.06e-7	Tonsillectomy;Mean corpuscular volume;
KIRP	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg00255919	chr5:131827918	IRF1	-0.3	-6.29	-0.37	1.43e-9	Asthma (sex interaction);
KIRP	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.98	9.97	0.54	7.19e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg25019722	chr6:37503610	NA	-0.78	-10.0	-0.54	5.62e-20	Cognitive performance;
KIRP	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg13180566	chr4:1052158	NA	-0.5	-5.11	-0.31	6.37e-7	Recombination rate (females);
KIRP	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-6.37	-0.38	9.02e-10	Hemoglobin concentration;
KIRP	trans	rs6506900	0.692	rs9947296	chr18:28901124	C/T	cg10906284	chr12:63544430	AVPR1A	0.37	6.04	0.36	5.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg12046867	chr14:103022105	NA	-0.54	-6.99	-0.41	2.6e-11	Platelet count;
KIRP	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.66	-9.43	-0.52	3.23e-18	Colorectal cancer;
KIRP	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg25486957	chr4:152246857	NA	-0.47	-5.31	-0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25902460	chr9:126030596	STRBP	-0.5	-6.79	-0.4	8.3e-11	Metabolic traits;
KIRP	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.7	10.55	0.56	1.08e-21	Dupuytren's disease;
KIRP	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg04896959	chr15:78267971	NA	-0.74	-10.23	-0.55	1.09e-20	Coronary artery disease or large artery stroke;
KIRP	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9972944	0.729	rs10083877	chr17:63773623	T/C	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.28	-0.42	4.48e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg16105309	chr15:79090380	ADAMTS7	0.62	7.54	0.43	8.83e-13	Schizophrenia;
KIRP	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg24110177	chr3:50126178	RBM5	-0.75	-10.23	-0.55	1.08e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg21684588	chr1:67600265	NA	0.44	5.1	0.31	6.82e-7	Psoriasis;
KIRP	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.42	0.65	3.47e-31	Bladder cancer;
KIRP	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.48	6.32	0.37	1.24e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.47	6.52	0.38	4.05e-10	Gout;
KIRP	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.48	0.43	1.32e-12	Neuroticism;
KIRP	cis	rs7818345	1.000	rs11991105	chr8:19290655	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.38	0.38	8.76e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs77861329	1.000	rs352148	chr3:52208898	A/G	cg08692210	chr3:52188851	WDR51A	0.85	6.77	0.4	9.53e-11	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09028132	chr20:37078135	SNORA60;SNHG11	-0.51	-7.01	-0.41	2.22e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.17	-21.11	-0.8	3.83e-57	Ulcerative colitis;
KIRP	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.7	9.24	0.51	1.24e-17	Renal function-related traits (BUN);
KIRP	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26002218	chr14:103986227	CKB	0.29	5.82	0.35	1.86e-8	Body mass index;
KIRP	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg22963979	chr7:1858916	MAD1L1	0.46	6.25	0.37	1.85e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4302748	0.862	rs35940984	chr7:36187333	C/G	cg24442661	chr7:36192818	EEPD1	0.61	6.87	0.4	5.16e-11	Platelet count;
KIRP	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.87	-0.3	1.98e-6	Breast cancer;
KIRP	cis	rs2671245	0.507	rs115562911	chr1:56129966	T/C	cg11523071	chr1:56160889	NA	0.38	5.5	0.33	9.53e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg18882449	chr10:104885122	NT5C2	-0.51	-6.51	-0.38	4.12e-10	Arsenic metabolism;
KIRP	cis	rs7665939	0.932	rs66626876	chr4:190101569	T/G	cg01790032	chr4:190285510	NA	-0.58	-4.89	-0.3	1.79e-6	Amyotrophic lateral sclerosis;
KIRP	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg23166289	chr1:210001082	C1orf107	-0.41	-5.09	-0.31	7.26e-7	Orofacial clefts;
KIRP	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg19077165	chr18:44547161	KATNAL2	0.46	5.74	0.34	2.84e-8	Personality dimensions;
KIRP	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	1.35	10.84	0.57	1.19e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.53	6.79	0.4	8.27e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg00074818	chr8:8560427	CLDN23	0.42	6.36	0.38	9.6e-10	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16637776	chr6:35465342	TEAD3	0.47	6.1	0.36	4.2e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-0.92	-11.3	-0.58	3.93e-24	Vitiligo;
KIRP	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.86	0.35	1.47e-8	Menopause (age at onset);
KIRP	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.68	8.62	0.48	8.08e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg25767906	chr1:53392781	SCP2	-0.35	-4.93	-0.3	1.49e-6	Monocyte count;
KIRP	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.23e-10	Major depressive disorder;
KIRP	trans	rs7160151	0.516	rs2816743	chr14:49811460	C/T	cg24274272	chr17:72278023	DNAI2	0.49	6.04	0.36	5.74e-9	C-reactive protein (red blood cell fatty acid level interaction);
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg23985595	chr17:80112537	CCDC57	-0.37	-5.53	-0.33	8.37e-8	Life satisfaction;
KIRP	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	8.52	0.48	1.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg10018233	chr7:150070692	REPIN1	0.54	7.06	0.41	1.68e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9921338	0.961	rs8043692	chr16:11426957	C/T	cg00044050	chr16:11439710	C16orf75	-0.52	-5.59	-0.34	5.87e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.87	-12.43	-0.62	7.25e-28	Total body bone mineral density;
KIRP	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg02725872	chr8:58115012	NA	-0.36	-4.93	-0.3	1.51e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg07803811	chr1:43423981	SLC2A1	-0.43	-4.93	-0.3	1.53e-6	Red cell distribution width;
KIRP	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.21e-7	Red blood cell count;
KIRP	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.12	-0.31	6.1e-7	Life satisfaction;
KIRP	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg04995300	chr3:66848608	NA	0.71	8.65	0.48	6.56e-16	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs10046574	0.561	rs17403528	chr7:135195531	C/T	cg27474649	chr7:135195673	CNOT4	0.6	5.26	0.32	3.11e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg04025307	chr7:1156635	C7orf50	0.47	5.02	0.3	1e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.67	-0.39	1.65e-10	Alzheimer's disease (late onset);
KIRP	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg04691961	chr3:161091175	C3orf57	-0.45	-6.11	-0.36	3.91e-9	Parkinson's disease;
KIRP	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg10018233	chr7:150070692	REPIN1	0.58	7.31	0.42	3.69e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg10505658	chr17:80084571	CCDC57	-0.26	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.39	-0.51	4.28e-18	Morning vs. evening chronotype;
KIRP	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.63	-7.75	-0.44	2.45e-13	Extraversion;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09148084	chr6:160390131	IGF2R	-0.56	-6.31	-0.37	1.31e-9	Interleukin-4 levels;
KIRP	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg00129232	chr17:37814104	STARD3	-0.45	-5.58	-0.33	6.49e-8	Self-reported allergy;
KIRP	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg10547527	chr2:198650123	BOLL	-0.52	-4.85	-0.3	2.23e-6	Ulcerative colitis;
KIRP	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg12140854	chr5:148520817	ABLIM3	-0.45	-5.16	-0.31	5.08e-7	Breast cancer;
KIRP	cis	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg27487796	chr7:28973253	NA	-0.22	-5.08	-0.31	7.33e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs2644899	0.750	rs2607424	chr19:41275147	C/T	cg24958765	chr19:41283667	RAB4B	-0.59	-6.56	-0.39	3.13e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg21775007	chr8:11205619	TDH	-0.43	-5.12	-0.31	6.27e-7	Neuroticism;
KIRP	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.61	-6.55	-0.39	3.27e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg23991622	chr10:17271303	VIM	-0.58	-6.36	-0.38	9.48e-10	Menopause (age at onset);
KIRP	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.43	0.47	2.92e-15	Personality dimensions;
KIRP	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg07796016	chr1:152779584	LCE1C	0.54	6.63	0.39	2.07e-10	Inflammatory skin disease;
KIRP	cis	rs7116495	0.881	rs673478	chr11:71799104	G/A	cg18441811	chr11:71824068	C11orf51	-0.64	-5.22	-0.32	3.79e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-5.14	-0.31	5.72e-7	Extrinsic epigenetic age acceleration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03518179	chr1:156470915	MEF2D	0.52	6.84	0.4	6.37e-11	Parkinson's disease;
KIRP	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.94e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.71	9.6	0.52	9.83e-19	Red blood cell count;
KIRP	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg00666640	chr1:248458726	OR2T12	0.43	5.28	0.32	2.88e-7	Common traits (Other);
KIRP	cis	rs4664293	0.967	rs10803758	chr2:160548219	T/C	cg08347373	chr2:160653686	CD302	-0.38	-5.79	-0.35	2.15e-8	Monocyte percentage of white cells;
KIRP	trans	rs8001976	0.510	rs9645941	chr13:48331361	G/C	cg23237801	chr1:16476620	EPHA2	0.53	6.54	0.38	3.61e-10	Aging (time to event);
KIRP	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.39	-0.43	2.24e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-1.01	-20.0	-0.79	1.77e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-4.88	-0.3	1.89e-6	Testicular germ cell tumor;
KIRP	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.52	-6.25	-0.37	1.78e-9	Prudent dietary pattern;
KIRP	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg00012203	chr2:219082015	ARPC2	0.63	8.38	0.47	3.98e-15	Colorectal cancer;
KIRP	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg16574807	chr4:6945745	TBC1D14	0.64	5.83	0.35	1.71e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg26874164	chr19:58962979	ZNF324B	0.47	5.58	0.33	6.45e-8	Uric acid clearance;
KIRP	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.69	8.37	0.47	4.43e-15	Blood metabolite levels;
KIRP	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.92	12.02	0.61	1.69e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-7.08	-0.41	1.49e-11	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg10018233	chr7:150070692	REPIN1	0.55	6.46	0.38	5.64e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08251398	chr19:15490696	AKAP8	0.49	6.16	0.37	2.94e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09224134	chr4:187112519	CYP4V2	0.47	6.41	0.38	7.32e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs662064	0.962	rs596537	chr1:10554709	G/T	cg17425144	chr1:10567563	PEX14	0.3	5.13	0.31	5.95e-7	Asthma;
KIRP	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg15557168	chr22:42548783	NA	-0.41	-5.6	-0.34	5.63e-8	Cognitive function;
KIRP	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg05044414	chr3:183734942	ABCC5	0.38	5.81	0.35	1.91e-8	Anterior chamber depth;
KIRP	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs116095464	0.850	rs62330058	chr5:343564	G/A	cg22496380	chr5:211416	CCDC127	-1.11	-6.94	-0.4	3.51e-11	Breast cancer;
KIRP	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Body mass index;
KIRP	cis	rs9815354	1.000	rs9854838	chr3:41805670	C/A	cg03022575	chr3:42003672	ULK4	0.5	5.78	0.35	2.27e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.76	9.89	0.53	1.23e-19	N-glycan levels;
KIRP	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.81	8.01	0.45	4.52e-14	Left atrial antero-posterior diameter;
KIRP	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.81	-8.72	-0.49	4.1e-16	Hair shape;
KIRP	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg17077180	chr1:38461687	NA	0.52	7.47	0.43	1.43e-12	Coronary artery disease;
KIRP	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.32	0.59	3.52e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	6.46	0.38	5.54e-10	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22037077	chr21:19191843	C21orf91	0.59	7.62	0.44	5.33e-13	Parkinson's disease;
KIRP	trans	rs12543645	0.598	rs35338507	chr8:10277982	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	6.69	0.39	1.52e-10	Schizophrenia;
KIRP	cis	rs13315871	1.000	rs13096020	chr3:58367771	G/A	cg12435725	chr3:58293450	RPP14	-0.5	-5.32	-0.32	2.35e-7	Cholesterol, total;
KIRP	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	9.21	0.51	1.52e-17	Lung cancer in ever smokers;
KIRP	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg16141378	chr3:129829833	LOC729375	0.54	7.14	0.41	1.05e-11	Neuroticism;
KIRP	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg06671706	chr8:8559999	CLDN23	0.58	6.52	0.38	4.01e-10	Obesity-related traits;
KIRP	cis	rs9399401	0.961	rs7741741	chr6:142655801	T/A	cg03128060	chr6:142623767	GPR126	0.3	4.91	0.3	1.62e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.84	7.68	0.44	3.75e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg19694781	chr19:47549865	TMEM160	-0.5	-6.07	-0.36	4.69e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg04490037	chr7:50633773	DDC	-0.49	-5.05	-0.31	8.61e-7	Malaria;
KIRP	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.59	-7.62	-0.44	5.34e-13	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.64	-8.55	-0.48	1.36e-15	Motion sickness;
KIRP	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.44	-0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.67	-5.66	-0.34	4.18e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.2	0.37	2.42e-9	Hemoglobin concentration;
KIRP	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg02378861	chr5:212933	CCDC127	-0.71	-5.61	-0.34	5.43e-8	Fat distribution (HIV);
KIRP	cis	rs3026101	0.624	rs1806261	chr17:5317008	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.69	0.39	1.52e-10	Body mass index;
KIRP	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.52	7.08	0.41	1.51e-11	Mean corpuscular volume;
KIRP	cis	rs4262150	0.960	rs7702551	chr5:152280130	A/C	cg12297329	chr5:152029980	NA	0.42	5.87	0.35	1.39e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.56	-7.17	-0.42	8.72e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg27411982	chr8:10470053	RP1L1	-0.51	-6.52	-0.38	3.9e-10	Neuroticism;
KIRP	cis	rs17739167	0.550	rs2665213	chr15:42234265	T/G	cg20935245	chr15:42234343	EHD4	-0.5	-7.88	-0.45	1.03e-13	Monocyte count;
KIRP	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg20302533	chr7:39170763	POU6F2	0.3	6.54	0.38	3.57e-10	IgG glycosylation;
KIRP	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg12315302	chr6:26189340	HIST1H4D	0.73	5.27	0.32	3.01e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg12560992	chr17:57184187	TRIM37	0.59	6.44	0.38	6.14e-10	Testicular germ cell tumor;
KIRP	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.48	5.85	0.35	1.54e-8	Multiple sclerosis;
KIRP	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.91	-0.35	1.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs71636778	0.631	rs77402838	chr1:27197733	T/A	cg12203394	chr1:27248618	NUDC	0.75	5.84	0.35	1.64e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.84	0.49	1.9e-16	Motion sickness;
KIRP	cis	rs2970818	0.831	rs7304949	chr12:4609625	A/G	cg14576962	chr12:4671597	NA	-0.44	-5.32	-0.32	2.33e-7	Phosphorus levels;
KIRP	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-5.58	-0.33	6.46e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.61	8.45	0.47	2.56e-15	Morning vs. evening chronotype;
KIRP	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg02023728	chr11:77925099	USP35	-0.33	-5.13	-0.31	5.75e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.72	11.14	0.58	1.37e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.17	0.31	4.74e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs73198271	1.000	rs11775821	chr8:8609153	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-5.61	-0.34	5.47e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.67	9.01	0.5	5.76e-17	Lymphocyte percentage of white cells;
KIRP	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.45	-5.73	-0.34	2.96e-8	Type 2 diabetes;
KIRP	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg05639522	chr1:247681581	NA	0.59	5.43	0.33	1.37e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05472934	chr7:22766657	IL6	0.75	9.04	0.5	4.72e-17	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
KIRP	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg06223162	chr1:101003688	GPR88	0.48	10.1	0.54	2.73e-20	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09253211	chr11:63438586	ATL3	0.53	7.27	0.42	4.89e-12	Parkinson's disease;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.57	-8.72	-0.49	4.24e-16	Lymphocyte counts;
KIRP	cis	rs2929278	0.617	rs12908467	chr15:44047430	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-6.88	-0.4	4.9e-11	Schizophrenia;
KIRP	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-0.65	-5.96	-0.36	8.66e-9	Alzheimer's disease (late onset);
KIRP	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg03909863	chr11:638404	DRD4	-0.4	-4.96	-0.3	1.32e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6832769	0.961	rs28790098	chr4:56398109	C/T	cg05960024	chr4:56376020	CLOCK	-0.73	-9.31	-0.51	7.38e-18	Personality dimensions;
KIRP	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg00629941	chr15:75287862	SCAMP5	-0.5	-5.25	-0.32	3.27e-7	Blood trace element (Zn levels);
KIRP	trans	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg00806126	chr19:22604979	ZNF98	0.63	6.48	0.38	4.84e-10	Pain;
KIRP	trans	rs6734238	0.966	rs12328368	chr2:113847144	C/G	cg11332951	chr1:2396472	NA	-0.41	-6.01	-0.36	6.48e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.44	-0.47	2.8e-15	Neuroticism;
KIRP	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.63	-5.05	-0.31	8.53e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg01763666	chr17:80159506	CCDC57	-0.36	-5.02	-0.3	9.92e-7	Life satisfaction;
KIRP	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-1.01	-14.67	-0.68	2.03e-35	Blood trace element (Zn levels);
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.87	-12.81	-0.63	4.09e-29	Height;
KIRP	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg08648136	chr8:956695	NA	0.49	7.79	0.44	1.84e-13	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg26174226	chr8:58114915	NA	-0.61	-7.15	-0.41	1e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.94	13.04	0.64	6.58e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7719624	0.870	rs6894815	chr5:135395864	C/G	cg16684184	chr5:135415129	NA	-0.34	-5.15	-0.31	5.25e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs1497828	1.000	rs2815225	chr1:217529336	C/T	cg04411442	chr1:217543379	NA	-0.3	-4.84	-0.3	2.27e-6	Dialysis-related mortality;
KIRP	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg02175503	chr12:58329896	NA	0.61	6.57	0.39	2.9e-10	Multiple sclerosis;
KIRP	cis	rs2882667	0.755	rs55650316	chr5:138467292	C/G	cg04439458	chr5:138467593	SIL1	-0.54	-8.2	-0.46	1.35e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.49	-5.25	-0.32	3.3e-7	Urate levels in overweight individuals;
KIRP	trans	rs3741489	1.000	rs4758889	chr12:133475533	C/T	cg24132527	chr5:140019269	TMCO6	1.0	6.2	0.37	2.34e-9	Cognitive function;
KIRP	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	0.91	11.58	0.59	4.69e-25	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7113874	0.592	rs75600349	chr11:8448092	C/T	cg08015107	chr11:8618950	NA	-0.59	-6.28	-0.37	1.51e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.71e-31	Diabetic retinopathy;
KIRP	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.79	8.32	0.47	6e-15	Resting heart rate;
KIRP	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.47	-0.38	5.14e-10	Height;
KIRP	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg00800569	chr2:239229395	TRAF3IP1	0.45	5.34	0.32	2.16e-7	Multiple system atrophy;
KIRP	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs13067260	0.655	rs6797485	chr3:123747614	T/C	cg19918027	chr3:123987645	KALRN	-0.6	-5.43	-0.33	1.33e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2143950	0.834	rs1048990	chr14:35761675	C/G	cg09327582	chr14:35236912	BAZ1A	-0.56	-5.21	-0.32	4.04e-7	Atopic dermatitis;
KIRP	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	12.12	0.61	7.9e-27	Ileal carcinoids;
KIRP	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg04166393	chr7:2884313	GNA12	0.59	6.94	0.4	3.51e-11	Height;
KIRP	cis	rs4253772	1.000	rs11705483	chr22:46630544	C/A	cg18190219	chr22:46762943	CELSR1	-0.73	-6.13	-0.36	3.39e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg14664628	chr15:75095509	CSK	-0.61	-7.52	-0.43	1.05e-12	Breast cancer;
KIRP	cis	rs2742417	0.967	rs9877499	chr3:45734404	G/A	cg04037228	chr3:45636386	LIMD1	0.36	5.28	0.32	2.89e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.79	-0.35	2.18e-8	Schizophrenia;
KIRP	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.66	8.86	0.49	1.68e-16	Aortic root size;
KIRP	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg04804543	chr8:142233427	SLC45A4	0.72	10.3	0.55	6.36e-21	Immature fraction of reticulocytes;
KIRP	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.72	6.4	0.38	7.58e-10	RR interval (heart rate);
KIRP	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-1.0	-15.22	-0.7	2.69e-37	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.65	7.41	0.43	2.06e-12	Schizophrenia;
KIRP	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.7	-8.55	-0.48	1.32e-15	Aortic root size;
KIRP	cis	rs42648	0.869	rs3810890	chr7:89908833	G/T	cg25739043	chr7:89950458	NA	-0.47	-7.49	-0.43	1.21e-12	Homocysteine levels;
KIRP	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.93	-0.4	3.74e-11	Bladder cancer;
KIRP	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.58	-7.21	-0.42	6.99e-12	Obesity-related traits;
KIRP	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.59	8.02	0.46	4.28e-14	Morning vs. evening chronotype;
KIRP	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg02344993	chr17:57696989	CLTC	0.56	5.41	0.33	1.53e-7	Hemoglobin concentration;
KIRP	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.79	10.54	0.56	1.1e-21	Osteoporosis;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.33	0.62	1.63e-27	Bipolar disorder;
KIRP	cis	rs7760535	0.711	rs455834	chr6:111638105	T/C	cg15721981	chr6:111408429	SLC16A10	-0.45	-5.64	-0.34	4.72e-8	Metabolic traits;
KIRP	cis	rs6032067	1.000	rs2233896	chr20:43850400	C/A	cg10761708	chr20:43804764	PI3	0.51	5.22	0.32	3.78e-7	Blood protein levels;
KIRP	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg21427119	chr20:30132790	HM13	-0.66	-6.91	-0.4	4.22e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14169450	chr9:139327907	INPP5E	0.54	6.26	0.37	1.68e-9	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs6120849	0.754	rs3746446	chr20:33574765	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	6.5	0.38	4.44e-10	Protein C levels;
KIRP	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.77	9.78	0.53	2.66e-19	Corneal astigmatism;
KIRP	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.43	-5.52	-0.33	8.44e-8	IgG glycosylation;
KIRP	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg08885076	chr2:99613938	TSGA10	-0.39	-5.54	-0.33	7.64e-8	Chronic sinus infection;
KIRP	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.67	10.42	0.55	2.74e-21	Neuroticism;
KIRP	cis	rs10814247	0.648	rs10758301	chr9:35263721	G/T	cg15271616	chr9:35490515	RUSC2	-0.34	-4.87	-0.3	1.96e-6	Psoriasis;
KIRP	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg00262122	chr8:11665843	FDFT1	0.41	5.12	0.31	6.15e-7	Neuroticism;
KIRP	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03574289	chr7:149571017	LOC401431;ATP6V0E2	0.48	6.09	0.36	4.35e-9	Myopia (pathological);
KIRP	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg26875233	chr11:93583750	C11orf90	-0.4	-7.55	-0.43	8.25e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.32	0.42	3.47e-12	Prudent dietary pattern;
KIRP	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.74	0.49	3.7e-16	Lung cancer in ever smokers;
KIRP	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.05	0.41	1.81e-11	Arsenic metabolism;
KIRP	cis	rs3820928	1.000	rs3820927	chr2:227779191	C/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-4.89	-0.3	1.83e-6	Pulmonary function;
KIRP	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.91	14.33	0.67	2.75e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg24558204	chr6:135376177	HBS1L	-0.66	-8.43	-0.47	2.9e-15	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7851660	0.809	rs1561957	chr9:100670272	T/C	cg13688889	chr9:100608707	NA	-0.69	-8.69	-0.48	5.34e-16	Strep throat;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05052031	chr3:33138450	TMPPE;GLB1	0.51	6.3	0.37	1.36e-9	Parkinson's disease;
KIRP	cis	rs2279168	1.000	rs79270762	chr15:86074176	G/A	cg17133734	chr15:86042851	AKAP13	0.63	4.93	0.3	1.54e-6	Response to platinum-based chemotherapy (carboplatin);
KIRP	trans	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg15469184	chr8:337539	NA	0.62	6.97	0.41	2.95e-11	Obesity-related traits;
KIRP	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs10073892	0.660	rs7723461	chr5:101944793	A/G	cg19774478	chr5:101632501	SLCO4C1	0.49	5.32	0.32	2.29e-7	Cognitive decline (age-related);
KIRP	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.7	9.69	0.53	4.96e-19	Schizophrenia;
KIRP	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.52	-7.68	-0.44	3.71e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg24315340	chr6:146058215	EPM2A	-0.39	-5.0	-0.3	1.11e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-6.67	-0.39	1.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg08392591	chr16:89556376	ANKRD11	0.42	5.33	0.32	2.26e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg08700190	chr5:6636046	SRD5A1	-0.49	-5.93	-0.35	1.02e-8	Response to amphetamines;
KIRP	cis	rs9436747	0.605	rs2025805	chr1:65949878	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.47	4.92	0.3	1.55e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00151607	chr16:88923507	TRAPPC2L;GALNS	0.5	6.18	0.37	2.71e-9	Parkinson's disease;
KIRP	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.47	-6.09	-0.36	4.32e-9	Bipolar disorder;
KIRP	cis	rs6987853	0.933	rs2974339	chr8:42397529	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.05	0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs883565	0.655	rs4676628	chr3:39095965	G/A	cg01426195	chr3:39028469	NA	-0.74	-12.99	-0.64	1.01e-29	Handedness;
KIRP	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.65	-7.76	-0.44	2.22e-13	Obesity-related traits;
KIRP	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	17.23	0.74	3.71e-44	Height;
KIRP	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg26818010	chr10:134567672	INPP5A	-0.68	-7.56	-0.43	7.73e-13	Migraine;
KIRP	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.73	8.25	0.47	9.6e-15	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	1.11	17.49	0.74	4.57e-45	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.52	-6.63	-0.39	2.13e-10	Schizophrenia;
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.95	17.14	0.74	7.08e-44	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs72634258	0.945	rs12740409	chr1:8027830	A/C	cg00042356	chr1:8021962	PARK7	0.99	7.87	0.45	1.09e-13	Inflammatory bowel disease;
KIRP	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.63	-0.34	4.96e-8	Breast cancer;
KIRP	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs17213078	0.505	rs737101	chr2:106732545	C/T	cg16099169	chr2:106886729	NA	0.36	5.1	0.31	6.68e-7	Facial morphology (factor 23);
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg02996583	chr8:142237188	SLC45A4	-0.5	-6.08	-0.36	4.55e-9	Immature fraction of reticulocytes;
KIRP	cis	rs501120	0.778	rs523297	chr10:44756557	C/T	cg09554077	chr10:44749378	NA	0.51	5.43	0.33	1.36e-7	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.54	6.65	0.39	1.86e-10	Asthma;
KIRP	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg18016565	chr1:150552671	MCL1	-0.34	-5.31	-0.32	2.43e-7	Tonsillectomy;
KIRP	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.74	9.62	0.52	8.37e-19	Pancreatic cancer;
KIRP	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg21475434	chr5:93447410	FAM172A	-0.73	-6.15	-0.37	3.07e-9	Diabetic retinopathy;
KIRP	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg13119609	chr19:45449297	APOC2	0.53	7.72	0.44	2.91e-13	Blood protein levels;
KIRP	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.5	-6.73	-0.39	1.15e-10	Blood metabolite levels;
KIRP	cis	rs17065868	1.000	rs9525971	chr13:45095344	A/G	cg10246903	chr13:45222710	NA	-0.68	-6.68	-0.39	1.55e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	9.04	0.5	4.64e-17	Coffee consumption (cups per day);
KIRP	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.43	0.43	1.83e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-1.04	-14.33	-0.67	2.85e-34	Body mass index;
KIRP	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg00677455	chr12:58241039	CTDSP2	0.6	6.72	0.39	1.24e-10	Multiple sclerosis;
KIRP	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg21064579	chr19:49206444	FUT2	0.59	8.91	0.49	1.15e-16	Dietary macronutrient intake;
KIRP	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.71	8.97	0.5	7.62e-17	Response to antipsychotic treatment;
KIRP	cis	rs13385	0.769	rs4913072	chr5:139608353	T/C	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.41	0.51	3.8e-18	Lung cancer;
KIRP	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.63	0.44	5.03e-13	IgG glycosylation;
KIRP	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.85	12.83	0.63	3.3e-29	Diastolic blood pressure;
KIRP	cis	rs258892	0.895	rs10042574	chr5:72085684	C/G	cg21869765	chr5:72125136	TNPO1	-0.51	-5.61	-0.34	5.35e-8	Small cell lung carcinoma;
KIRP	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.53	6.7	0.39	1.44e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8010715	0.785	rs2877611	chr14:24595430	C/T	cg23112188	chr14:24563095	PCK2	-0.34	-5.02	-0.3	9.9e-7	IgG glycosylation;
KIRP	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.38	0.38	8.71e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19171272	chr22:38449367	NA	-0.57	-8.26	-0.47	9.15e-15	Glioblastoma;Glioma;
KIRP	cis	rs1832871	0.711	rs6906854	chr6:158695000	C/T	cg07215822	chr6:158701037	NA	-0.64	-7.51	-0.43	1.1e-12	Height;
KIRP	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg27490568	chr2:178487706	NA	0.43	5.68	0.34	3.8e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.87	-0.45	1.1e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs4979906	1.000	rs4979910	chr10:79456561	T/C	cg07817648	chr10:79422355	NA	-0.48	-5.06	-0.31	8.07e-7	Mortality in heart failure;
KIRP	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.72	10.31	0.55	6.12e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs216345	1.000	rs216345	chr9:33799370	C/T	cg14607208	chr9:38546089	NA	0.48	6.13	0.36	3.47e-9	Bipolar disorder;
KIRP	trans	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg05802129	chr4:122689817	NA	-0.64	-8.14	-0.46	1.97e-14	Type 2 diabetes;
KIRP	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg12591125	chr7:1885375	MAD1L1	-0.52	-5.33	-0.32	2.22e-7	Bipolar disorder;
KIRP	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.64	0.48	7.08e-16	Bipolar disorder;
KIRP	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.77	-9.21	-0.51	1.52e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07991241	chr10:33269695	NA	0.47	6.59	0.39	2.63e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6504622	0.537	rs1052504	chr17:44993828	C/T	cg16759221	chr17:45003025	GOSR2	-0.39	-5.85	-0.35	1.54e-8	Orofacial clefts;
KIRP	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.89	11.29	0.58	4.27e-24	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.03	-0.31	9.66e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9393813	0.528	rs6911865	chr6:27470778	T/A	cg03332623	chr6:27441972	ZNF184	-0.35	-5.13	-0.31	5.96e-7	Bipolar disorder;
KIRP	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.84	0.57	1.21e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs918629	0.567	rs3777196	chr5:95238160	A/C	cg16656078	chr5:95278638	ELL2	-0.36	-5.51	-0.33	8.85e-8	IgG glycosylation;
KIRP	cis	rs8077577	0.848	rs12600694	chr17:18091019	C/T	cg18869244	chr17:18121946	NA	0.48	5.57	0.33	6.54e-8	Obesity-related traits;
KIRP	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.84	10.17	0.54	1.68e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg06618935	chr21:46677482	NA	-0.41	-5.21	-0.32	4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg15848620	chr12:58087721	OS9	-0.47	-5.43	-0.33	1.38e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.64	9.28	0.51	8.94e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.61	7.58	0.44	6.84e-13	Osteoporosis;
KIRP	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.3	0.32	2.61e-7	Bipolar disorder;
KIRP	cis	rs7546668	1.000	rs1467513	chr1:15894959	T/C	cg21858823	chr1:15850916	CASP9	0.46	5.04	0.31	9.19e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs909341	0.909	rs1048665	chr20:62331989	T/G	cg03999872	chr20:62272968	STMN3	-0.56	-6.58	-0.39	2.79e-10	Atopic dermatitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25198584	chr1:4775233	AJAP1	0.45	6.6	0.39	2.55e-10	Survival in pancreatic cancer;
KIRP	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-8.58	-0.48	1.05e-15	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09148084	chr6:160390131	IGF2R	0.5	6.5	0.38	4.41e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02796278	chr19:885898	MED16	0.5	6.45	0.38	5.97e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6693567	0.516	rs7554686	chr1:150265619	A/T	cg07843065	chr1:150265600	MRPS21	-0.51	-7.38	-0.43	2.5e-12	Migraine;
KIRP	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.43	-4.99	-0.3	1.12e-6	Aortic root size;
KIRP	cis	rs62355272	0.965	rs1494554	chr5:35873872	T/G	cg13894535	chr5:35919491	CAPSL	-0.54	-6.34	-0.37	1.08e-9	Lymphocyte counts;
KIRP	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.48	5.98	0.36	7.73e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg22974920	chr21:40686053	BRWD1	0.47	5.52	0.33	8.48e-8	Cognitive function;
KIRP	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.51	6.94	0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg22256960	chr15:77711686	NA	-0.45	-5.69	-0.34	3.53e-8	Type 2 diabetes;
KIRP	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.47	7.23	0.42	5.9e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs220519	0.783	rs220517	chr20:37282569	G/T	cg24308336	chr20:37270989	C20orf95	0.23	5.13	0.31	5.86e-7	Schizophrenia;
KIRP	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.51	7.22	0.42	6.37e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17125944	0.506	rs7160285	chr14:53311400	A/C	cg00686598	chr14:53173677	PSMC6	-0.7	-6.63	-0.39	2.1e-10	Alzheimer's disease (late onset);
KIRP	cis	rs4700695	0.925	rs1845481	chr5:65397527	A/C	cg21114390	chr5:65439923	SFRS12	-0.48	-5.71	-0.34	3.28e-8	Facial morphology (factor 19);
KIRP	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.75	11.12	0.58	1.54e-23	Ulcerative colitis;
KIRP	cis	rs427941	0.703	rs201447	chr7:101738384	C/A	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.24e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.74	-9.38	-0.51	4.43e-18	Aortic root size;
KIRP	cis	rs2398893	0.924	rs1539282	chr9:96827424	T/C	cg14459158	chr9:96720562	NA	0.29	5.21	0.32	3.96e-7	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.72	6.6	0.39	2.44e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-4.97	-0.3	1.24e-6	Life satisfaction;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10254000	chr22:19748378	TBX1	-0.44	-6.12	-0.36	3.66e-9	Myopia;
KIRP	cis	rs1134634	0.520	rs13121363	chr4:15568992	T/C	cg16509355	chr4:15471240	CC2D2A	0.31	5.38	0.32	1.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg00745463	chr17:30367425	LRRC37B	-0.58	-5.69	-0.34	3.56e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7224685	0.548	rs17710668	chr17:3880546	C/G	cg05562828	chr17:3906858	NA	0.64	7.76	0.44	2.29e-13	Type 2 diabetes;
KIRP	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-1.0	-11.7	-0.6	1.9e-25	White matter hyperintensity burden;
KIRP	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.02	15.08	0.69	7.85e-37	Chronic sinus infection;
KIRP	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.55	4.97	0.3	1.26e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.6	9.17	0.5	1.94e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs1373549	1.000	rs2120736	chr12:46476973	C/T	cg21957191	chr20:1960655	PDYN	0.46	6.15	0.37	3.15e-9	Hippocampal atrophy;
KIRP	cis	rs56079296	0.929	rs4243443	chr5:121274650	A/G	cg05256605	chr5:121412184	LOX	0.47	5.26	0.32	3.15e-7	Coronary artery disease;
KIRP	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.83	0.49	2.05e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg01631408	chr1:248437212	OR2T33	-0.61	-8.39	-0.47	3.72e-15	Common traits (Other);
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg26134248	chr17:3907702	NA	-0.54	-7.88	-0.45	1.05e-13	Type 2 diabetes;
KIRP	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg21573476	chr21:45109991	RRP1B	-0.56	-7.78	-0.44	2.03e-13	Mean corpuscular volume;
KIRP	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg13334819	chr7:99746414	C7orf59	0.52	5.96	0.35	8.89e-9	Coronary artery disease;
KIRP	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-15.85	-0.71	1.85e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2019216	0.542	rs7405615	chr17:21935430	C/G	cg22648282	chr17:21454238	C17orf51	-0.56	-6.96	-0.41	3.03e-11	Pelvic organ prolapse;
KIRP	cis	rs8177876	0.818	rs59177227	chr16:81115129	G/T	cg08591886	chr16:81111003	C16orf46	-0.59	-5.76	-0.34	2.45e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg03563238	chr19:33554763	RHPN2	-0.32	-6.16	-0.37	2.96e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-5.97	-0.36	8.29e-9	Plateletcrit;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04213038	chr11:6704667	MRPL17	0.49	6.3	0.37	1.38e-9	Parkinson's disease;
KIRP	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00585698	chr12:123750864	CDK2AP1	-0.39	-4.87	-0.3	2.04e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs4356932	0.902	rs28548768	chr4:76972755	T/C	cg19388996	chr4:76862389	NAAA	0.39	5.11	0.31	6.37e-7	Blood protein levels;
KIRP	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.05	-0.36	5.37e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02034447	chr16:89574710	SPG7	0.39	4.91	0.3	1.63e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs10465746	0.967	rs12120160	chr1:84342835	T/G	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs4805272	0.853	rs8109100	chr19:29339140	T/G	cg15000279	chr19:29285009	NA	0.38	5.62	0.34	5.24e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs3120667	0.720	rs11581711	chr1:152424479	T/C	cg26876637	chr1:152193138	HRNR	-0.64	-5.94	-0.35	9.63e-9	Eating disorders;
KIRP	cis	rs3737883	1.000	rs3737883	chr1:203034906	C/T	cg03900565	chr1:203031815	PPFIA4	-0.4	-5.86	-0.35	1.45e-8	Early onset atrial fibrillation;
KIRP	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.63	8.56	0.48	1.22e-15	Morning vs. evening chronotype;
KIRP	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg06740227	chr12:86229804	RASSF9	-0.41	-5.16	-0.31	4.98e-7	Major depressive disorder;
KIRP	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg20302533	chr7:39170763	POU6F2	0.25	5.35	0.32	2.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg25487775	chr2:162093969	NA	0.45	6.13	0.36	3.43e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs4664308	0.618	rs6722275	chr2:160893260	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.77	-0.53	2.91e-19	Idiopathic membranous nephropathy;
KIRP	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.63	0.44	5.18e-13	Tonsillectomy;
KIRP	cis	rs2929278	0.617	rs533143	chr15:44188854	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	6.01	0.36	6.53e-9	Schizophrenia;
KIRP	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17507749	chr15:85114479	UBE2QP1	0.77	8.64	0.48	7.44e-16	Schizophrenia;
KIRP	cis	rs9905704	0.633	rs2531731	chr17:56546524	A/C	cg12560992	chr17:57184187	TRIM37	-0.53	-4.92	-0.3	1.57e-6	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.83	-0.35	1.75e-8	IgG glycosylation;
KIRP	cis	rs867371	0.929	rs7176075	chr15:82471339	C/G	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs10242455	0.702	rs17161700	chr7:98977067	A/G	cg18809830	chr7:99032528	PTCD1	-0.85	-5.34	-0.32	2.07e-7	Blood metabolite levels;
KIRP	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17507749	chr15:85114479	UBE2QP1	0.68	7.48	0.43	1.3e-12	Schizophrenia;
KIRP	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg05998816	chr21:47859926	PCNT	0.56	6.22	0.37	2.12e-9	Lymphocyte counts;
KIRP	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.62	-0.39	2.27e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.2	-0.37	2.3e-9	Aortic root size;
KIRP	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	3.99e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07733363	chr4:2248976	NA	-0.5	-6.39	-0.38	8.02e-10	Parkinson's disease;
KIRP	cis	rs4671458	0.894	rs76262922	chr2:63513191	G/A	cg17519650	chr2:63277830	OTX1	-0.56	-5.07	-0.31	7.77e-7	Subjective well-being;
KIRP	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.93	-12.78	-0.63	4.93e-29	Platelet distribution width;
KIRP	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.51	-7.48	-0.43	1.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.74	-10.48	-0.56	1.77e-21	Bipolar disorder and schizophrenia;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.5	8.92	0.49	1.11e-16	Lymphocyte counts;
KIRP	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg20003494	chr4:90757398	SNCA	-0.39	-5.06	-0.31	8.21e-7	Neuroticism;
KIRP	cis	rs7221595	0.778	rs36054194	chr17:3900280	C/T	cg09597638	chr17:3907349	NA	0.53	6.04	0.36	5.6e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg07827796	chr19:33622959	WDR88	-0.42	-4.96	-0.3	1.33e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg06521331	chr12:34319734	NA	-0.53	-6.47	-0.38	5.4e-10	Bladder cancer;
KIRP	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7999699	0.902	rs17337930	chr13:48319392	A/G	cg23237801	chr1:16476620	EPHA2	0.51	6.34	0.37	1.1e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg03526459	chr1:146549940	NA	-0.45	-6.05	-0.36	5.42e-9	HIV-1 control;
KIRP	cis	rs4356975	0.602	rs7674851	chr4:69946831	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg12962167	chr3:53033115	SFMBT1	0.69	5.43	0.33	1.35e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.53	6.32	0.37	1.22e-9	Macular telangiectasia type 2;
KIRP	cis	rs7084402	0.967	rs2842083	chr10:60329230	A/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.41	-0.55	2.88e-21	Refractive error;
KIRP	cis	rs73198271	1.000	rs11775821	chr8:8609153	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.79	-0.35	2.14e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.81	10.46	0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.89	-15.58	-0.7	1.55e-38	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.96	-9.79	-0.53	2.53e-19	Body mass index;
KIRP	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg08533674	chr1:46993347	NA	0.5	6.15	0.36	3.14e-9	Monobrow;
KIRP	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg03714773	chr7:91764589	CYP51A1	0.35	5.17	0.31	4.93e-7	Breast cancer;
KIRP	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg24881330	chr22:46731750	TRMU	0.65	4.93	0.3	1.48e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4805272	1.000	rs7257343	chr19:29323110	C/T	cg15000279	chr19:29285009	NA	-0.37	-5.26	-0.32	3.15e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.95	15.54	0.7	2.14e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.9	-0.3	1.74e-6	Life satisfaction;
KIRP	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.46	-6.29	-0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg14250997	chr9:106856677	SMC2	0.43	5.9	0.35	1.19e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs6681460	1.000	rs6697088	chr1:67044724	C/G	cg13052034	chr1:66999238	SGIP1	-0.41	-5.68	-0.34	3.86e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs13185784	0.667	rs4454029	chr5:179645325	C/T	cg25547937	chr5:178801647	NA	0.35	4.86	0.3	2.05e-6	TRAIL levels;
KIRP	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19717773	chr7:2847554	GNA12	-0.32	-5.59	-0.34	6.14e-8	Height;
KIRP	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg21918786	chr6:109611834	NA	-0.41	-5.64	-0.34	4.64e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15915129	chr11:124933008	SLC37A2	0.49	6.41	0.38	7.49e-10	Smoking initiation;
KIRP	cis	rs6910061	1.000	rs9468416	chr6:11100978	T/C	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1620921	0.505	rs9456588	chr6:161212564	C/G	cg01280913	chr6:161186852	NA	-0.53	-7.0	-0.41	2.48e-11	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.6	8.76	0.49	3.19e-16	Blood metabolite levels;
KIRP	cis	rs4654899	0.802	rs17416732	chr1:21256368	T/C	cg05370193	chr1:21551575	ECE1	0.42	5.46	0.33	1.15e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.58	7.9	0.45	9.09e-14	Mean corpuscular volume;
KIRP	cis	rs2651899	0.867	rs2742675	chr1:3079905	A/G	cg01413848	chr1:3081226	PRDM16	0.4	5.35	0.32	2.06e-7	Migraine;
KIRP	cis	rs11170631	0.504	rs12817180	chr12:54035448	A/G	cg16917193	chr12:54089295	NA	0.82	13.82	0.66	1.53e-32	Height;
KIRP	cis	rs17453880	0.890	rs12515178	chr5:152039638	G/A	cg12297329	chr5:152029980	NA	-0.71	-10.81	-0.57	1.54e-22	Subjective well-being;
KIRP	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	1.35	10.84	0.57	1.19e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg10996143	chr20:1373995	FKBP1A	0.51	6.3	0.37	1.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.642	rs2709842	chr4:152370637	C/T	cg25486957	chr4:152246857	NA	0.41	4.91	0.3	1.65e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6783573	1.000	rs6783573	chr3:46600520	A/G	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.34	-5.55	-0.33	7.43e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1014246	0.807	rs12771069	chr10:118471676	A/G	cg14919929	chr10:118506882	NA	0.67	8.14	0.46	1.99e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg10223061	chr2:219282414	VIL1	0.4	6.23	0.37	2.03e-9	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17562763	chr11:67398026	NUDT8	0.46	6.57	0.39	2.94e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg24253500	chr15:84953950	NA	0.48	5.49	0.33	9.92e-8	Schizophrenia;
KIRP	cis	rs73198271	0.628	rs11780486	chr8:8589494	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	5.14	0.31	5.56e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-15.44	-0.7	4.46e-38	Height;
KIRP	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg08501292	chr6:25962987	TRIM38	1.11	8.45	0.47	2.56e-15	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6601327	0.603	rs10104807	chr8:9669775	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.58	-0.39	2.86e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1519814	1.000	rs7818027	chr8:121158662	G/C	cg22335954	chr8:121166405	COL14A1	-0.64	-6.4	-0.38	7.99e-10	Breast cancer;
KIRP	cis	rs17636747	0.579	rs10202544	chr2:105887549	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.58	-4.92	-0.3	1.57e-6	Preeclampsia;
KIRP	cis	rs959260	0.925	rs9747801	chr17:73396572	C/T	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.09	-0.36	4.32e-9	Systemic lupus erythematosus;
KIRP	trans	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.93	0.4	3.62e-11	Mean corpuscular volume;
KIRP	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg26893134	chr6:116381904	FRK	-0.19	-5.22	-0.32	3.9e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06475006	chr16:89985975	MC1R	-0.67	-4.88	-0.3	1.87e-6	Skin colour saturation;
KIRP	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg25547332	chr5:131281432	NA	-0.46	-5.19	-0.31	4.38e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2223471	0.602	rs2744501	chr6:50749745	T/C	cg03432817	chr6:50765336	NA	-0.34	-5.1	-0.31	6.9e-7	Subcutaneous adipose tissue;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11062677	chr19:13976917	NA	0.6	6.2	0.37	2.43e-9	Lung function (FEV1);
KIRP	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	0.44	6.03	0.36	6.07e-9	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.19	12.88	0.63	2.28e-29	Uric acid levels;
KIRP	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.77	7.64	0.44	4.9e-13	Lung function (FEV1/FVC);
KIRP	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.92	10.7	0.56	3.42e-22	Corneal astigmatism;
KIRP	cis	rs9653442	0.564	rs56054309	chr2:100794940	T/C	cg22139774	chr2:100720529	AFF3	-0.29	-4.95	-0.3	1.38e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9649213	0.593	rs6975156	chr7:97925534	T/C	cg01877450	chr7:97915802	BRI3	-0.55	-7.26	-0.42	5.22e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.62	-0.56	6.31e-22	Gut microbiome composition (summer);
KIRP	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.21	13.48	0.65	2.18e-31	Eosinophil percentage of granulocytes;
KIRP	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg07843065	chr1:150265600	MRPS21	0.42	5.73	0.34	2.98e-8	Migraine;
KIRP	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.1	-19.55	-0.78	5.55e-52	Schizophrenia;
KIRP	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	10.26	0.55	8.55e-21	Exhaled nitric oxide output;
KIRP	cis	rs9638182	0.560	rs66506038	chr7:72995943	T/C	cg07452164	chr7:72993570	TBL2	0.53	6.05	0.36	5.22e-9	Triglycerides;
KIRP	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21643547	chr1:205240462	TMCC2	-0.85	-13.15	-0.64	2.95e-30	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-6.87	-0.4	5.22e-11	Mean platelet volume;
KIRP	cis	rs16957091	0.779	rs6493062	chr15:43017919	G/A	cg24196017	chr15:43021976	CDAN1	-0.44	-5.34	-0.32	2.15e-7	MGMT methylation in smokers;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg21800906	chr11:32914818	QSER1	0.55	6.36	0.38	9.69e-10	Sleep duration;
KIRP	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.54	-6.83	-0.4	6.43e-11	Type 2 diabetes;
KIRP	cis	rs9879311	0.932	rs7427473	chr3:10413197	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.4	5.34	0.32	2.13e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg08885076	chr2:99613938	TSGA10	0.42	6.28	0.37	1.56e-9	Fear of minor pain;
KIRP	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.15	-10.87	-0.57	1e-22	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01628140	chr12:102590990	C12orf48;PMCH	-0.41	-6.16	-0.37	2.94e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.9	15.31	0.7	1.3e-37	Headache;
KIRP	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs2658782	0.901	rs2605611	chr11:93229319	T/G	cg15737290	chr11:93063684	CCDC67	0.77	8.09	0.46	2.77e-14	Pulmonary function decline;
KIRP	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg07511934	chr16:89386912	ANKRD11	0.41	5.37	0.32	1.82e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6009527	0.752	rs7288176	chr22:49568462	A/G	cg12746016	chr22:49560550	NA	-0.43	-6.17	-0.37	2.8e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
KIRP	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg03213289	chr20:61660250	NA	0.72	9.07	0.5	3.85e-17	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-7.19	-0.42	7.91e-12	Neuroticism;
KIRP	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.63	-8.91	-0.49	1.2e-16	Multiple system atrophy;
KIRP	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.53	-6.63	-0.39	2.1e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg10223061	chr2:219282414	VIL1	-0.35	-5.82	-0.35	1.78e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.39	6.74	0.39	1.15e-10	Renal cell carcinoma;
KIRP	cis	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-4.97	-0.3	1.25e-6	Cervical cancer;
KIRP	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2916247	1.000	rs13251018	chr8:93053581	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.64	-8.87	-0.49	1.58e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	9.78	0.53	2.79e-19	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg26174226	chr8:58114915	NA	-0.58	-6.54	-0.38	3.53e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs367943	0.635	rs2222144	chr5:112712208	G/T	cg12552261	chr5:112820674	MCC	0.56	6.61	0.39	2.32e-10	Type 2 diabetes;
KIRP	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.06	-0.46	3.39e-14	Migraine;Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.56	12.27	0.62	2.62e-27	Diabetic kidney disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02095752	chr6:150262961	ULBP2	0.47	7.04	0.41	1.92e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.18e-11	Blood metabolite levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03685910	chr17:39844834	EIF1	0.75	6.39	0.38	8.16e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg16898833	chr6:26189333	HIST1H4D	0.81	5.12	0.31	6.1e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg10756647	chr7:56101905	PSPH	1.08	8.58	0.48	1.08e-15	Diabetic kidney disease;
KIRP	cis	rs7119038	0.774	rs874621	chr11:118655645	G/A	cg19308663	chr11:118741387	NA	0.55	8.47	0.47	2.32e-15	Sjögren's syndrome;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18978324	chr14:24740937	RABGGTA	0.44	6.02	0.36	6.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg15744005	chr10:104629667	AS3MT	-0.28	-5.06	-0.31	8.07e-7	Arsenic metabolism;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15877295	chr7:138915876	UBN2	0.68	6.47	0.38	5.14e-10	Lung function (FEV1);
KIRP	cis	rs4919044	0.688	rs11187221	chr10:94704990	A/G	cg05127821	chr10:94822908	CYP26C1	-0.89	-7.3	-0.42	4.03e-12	Coronary artery disease;
KIRP	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05776053	chr2:74358815	NA	0.5	5.17	0.31	4.9e-7	Gestational age at birth (maternal effect);
KIRP	cis	rs4006360	0.575	rs6416909	chr17:39235389	A/G	cg25341923	chr17:39239918	KRTAP4-7	0.59	8.52	0.48	1.64e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg07636037	chr3:49044803	WDR6	-0.74	-5.59	-0.34	6.11e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.62	-0.44	5.58e-13	Neuroticism;
KIRP	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.6	-7.36	-0.43	2.68e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.56	6.78	0.4	8.61e-11	Coffee consumption (cups per day);
KIRP	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg08648136	chr8:956695	NA	0.49	7.7	0.44	3.35e-13	Schizophrenia;
KIRP	trans	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg06521331	chr12:34319734	NA	-0.51	-6.16	-0.37	2.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.29	-0.32	2.69e-7	Coronary artery disease;
KIRP	cis	rs72829446	0.530	rs11869864	chr17:7407766	C/A	cg02795151	chr17:7402630	POLR2A	0.78	8.07	0.46	3.08e-14	Androgen levels;
KIRP	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs72730918	0.618	rs1378892	chr15:51964865	T/C	cg14296394	chr15:51910925	DMXL2	-0.77	-10.82	-0.57	1.47e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.71	-6.1	-0.36	4.02e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.64	-9.09	-0.5	3.3e-17	Anterior chamber depth;
KIRP	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	9.48	0.52	2.32e-18	Coffee consumption (cups per day);
KIRP	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg12432903	chr7:1882776	MAD1L1	0.52	4.86	0.3	2.13e-6	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg09699651	chr6:150184138	LRP11	0.48	6.35	0.38	1.04e-9	Lung cancer;
KIRP	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg15252951	chr6:33757062	LEMD2	0.46	5.39	0.32	1.69e-7	Crohn's disease;
KIRP	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.62	-0.63	1.68e-28	Breast cancer;
KIRP	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.46	-0.33	1.15e-7	Renal cell carcinoma;
KIRP	cis	rs4356932	0.967	rs6532154	chr4:76974095	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.13	0.31	5.78e-7	Blood protein levels;
KIRP	cis	rs12900413	0.687	rs6496602	chr15:90317797	A/G	cg07116693	chr15:90310901	NA	-0.22	-4.85	-0.3	2.22e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.94	0.4	3.47e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.21	0.37	2.28e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.82	-14.9	-0.69	3.22e-36	Body mass index;
KIRP	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg26338869	chr17:61819248	STRADA	0.45	5.57	0.33	6.66e-8	Prudent dietary pattern;
KIRP	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.03	0.41	2.09e-11	Bipolar disorder;
KIRP	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg15128208	chr22:42549153	NA	0.57	6.15	0.36	3.16e-9	Birth weight;
KIRP	trans	rs12043259	0.892	rs11240293	chr1:204823257	C/T	cg11485465	chr5:54518469	NA	0.41	6.47	0.38	5.16e-10	Addiction;
KIRP	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23422044	chr7:1970798	MAD1L1	0.71	7.21	0.42	6.99e-12	Bipolar disorder;
KIRP	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.43	-5.73	-0.34	2.99e-8	Melanoma;
KIRP	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg06637938	chr14:75390232	RPS6KL1	0.41	5.63	0.34	4.91e-8	Height;
KIRP	trans	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.7	9.49	0.52	2.15e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.62	8.47	0.48	2.2e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12823128	0.839	rs10842783	chr12:26857226	A/T	cg14081884	chr12:26986758	ITPR2	-0.41	-5.61	-0.34	5.44e-8	Birth weight;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg23031518	chr14:88851898	SPATA7	0.47	6.34	0.37	1.11e-9	Coronary artery disease;
KIRP	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg05043794	chr9:111880884	C9orf5	0.24	5.02	0.3	9.92e-7	Menarche (age at onset);
KIRP	cis	rs1867631	0.585	rs9787219	chr1:67080159	G/C	cg13052034	chr1:66999238	SGIP1	0.42	6.13	0.36	3.45e-9	Menopause (age at onset);
KIRP	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.7	9.54	0.52	1.48e-18	Psoriasis;
KIRP	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.61	7.43	0.43	1.77e-12	Corneal astigmatism;
KIRP	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.21	-0.32	4.03e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg06637938	chr14:75390232	RPS6KL1	0.39	5.63	0.34	4.96e-8	Height;
KIRP	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.65	-7.72	-0.44	2.87e-13	Height;
KIRP	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.75	11.04	0.58	2.82e-23	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00330888	chr2:46524148	EPAS1	0.45	6.05	0.36	5.3300000000000004e-09	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg10756647	chr7:56101905	PSPH	0.91	6.41	0.38	7.32e-10	Diabetic kidney disease;
KIRP	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.68	9.21	0.51	1.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.6	-7.52	-0.43	9.93e-13	Vitiligo;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg15233114	chr10:60145133	TFAM	0.5	6.24	0.37	1.94e-9	Colorectal cancer;
KIRP	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.72	-7.8	-0.45	1.82e-13	DNA methylation (variation);
KIRP	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg20243544	chr17:37824526	PNMT	0.37	4.93	0.3	1.52e-6	Self-reported allergy;
KIRP	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg21926883	chr2:100939477	LONRF2	-0.53	-6.83	-0.4	6.78e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.47	-0.33	1.09e-7	Lung cancer;
KIRP	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg01028140	chr2:1542097	TPO	-0.52	-5.77	-0.35	2.42e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.75	6.77	0.4	9.66e-11	Weight;
KIRP	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-6.49	-0.38	4.64e-10	Morning vs. evening chronotype;
KIRP	cis	rs1961637	0.603	rs1550423	chr2:223885812	C/T	cg02552189	chr2:223891284	NA	0.43	6.11	0.36	3.81e-9	Oropharynx cancer;
KIRP	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2412208	0.609	rs10746465	chr1:7107231	C/A	cg20434152	chr1:7120926	CAMTA1	-0.45	-6.3	-0.37	1.33e-9	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13495038	chr10:134582338	INPP5A	-0.44	-6.13	-0.36	3.39e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs6882046	0.513	rs194225	chr5:88001186	A/G	cg24804195	chr5:87968844	LOC645323	-0.49	-6.53	-0.38	3.74e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.25	-6.54	-0.38	3.48e-10	Crohn's disease;
KIRP	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg04398451	chr17:18023971	MYO15A	-0.67	-8.89	-0.49	1.32e-16	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07810114	chr1:12018622	PLOD1	-0.44	-6.33	-0.37	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2219968	0.701	rs34965401	chr8:78991957	C/G	cg00738934	chr8:78996279	NA	0.44	5.85	0.35	1.54e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.46	5.96	0.36	8.85e-9	Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05049096	chr10:5855588	GDI2	0.49	6.29	0.37	1.43e-9	Parkinson's disease;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg11826826	chr5:146258237	PPP2R2B	0.58	7.43	0.43	1.78e-12	Educational attainment;
KIRP	cis	rs16912285	0.688	rs7128680	chr11:24338796	C/T	ch.11.24196551F	chr11:24239977	NA	0.66	5.93	0.35	1.03e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg12560992	chr17:57184187	TRIM37	0.58	5.1	0.31	6.92e-7	Cognitive test performance;
KIRP	cis	rs9398803	0.686	rs3861458	chr6:126912162	G/A	cg19875578	chr6:126661172	C6orf173	0.41	5.37	0.32	1.78e-7	Male-pattern baldness;
KIRP	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg23587288	chr2:27483067	SLC30A3	-0.67	-7.77	-0.44	2.11e-13	Blood metabolite levels;
KIRP	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.66	-0.34	4.31e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17101923	1.000	rs11175967	chr12:66321344	C/G	cg06712651	chr12:66351869	HMGA2	-0.58	-6.59	-0.39	2.64e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg16309518	chr5:176445507	NA	-0.79	-12.36	-0.62	1.31e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg12855166	chr17:30846586	MYO1D	0.39	5.11	0.31	6.62e-7	Schizophrenia;
KIRP	cis	rs2290402	0.536	rs45486093	chr4:875671	T/C	cg14517359	chr4:903473	GAK	-0.53	-5.59	-0.34	6.1e-8	Type 2 diabetes;
KIRP	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.42	4.88	0.3	1.91e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12292205	chr6:26970375	C6orf41	-0.6	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.74	-0.44	2.54e-13	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19977241	chr2:74692637	MOGS	0.5	6.22	0.37	2.16e-9	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.63	9.7	0.53	4.63e-19	Lung cancer;
KIRP	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.52	-5.73	-0.34	2.93e-8	Urate levels in lean individuals;
KIRP	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg23335576	chr14:104009727	NA	0.41	5.91	0.35	1.13e-8	Body mass index;
KIRP	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg10645314	chr2:3704589	ALLC	-0.41	-5.3	-0.32	2.59e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg20387954	chr3:183756860	HTR3D	0.62	9.06	0.5	4.19e-17	Anterior chamber depth;
KIRP	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.39	9.32	0.51	6.93e-18	Asthma (sex interaction);
KIRP	cis	rs72634030	0.536	rs72634020	chr17:5213552	A/G	cg20802942	chr17:5185005	RABEP1	0.52	4.99	0.3	1.17e-6	Rheumatoid arthritis;
KIRP	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.44	6.61	0.39	2.36e-10	Major depressive disorder;
KIRP	cis	rs57024841	0.819	rs11145949	chr9:139857958	A/G	cg00693599	chr9:139836323	FBXW5	-0.45	-5.78	-0.35	2.28e-8	Beta-trace protein levels;
KIRP	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.74	-0.39	1.15e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg03929089	chr4:120376271	NA	0.7	6.75	0.4	1.05e-10	Axial length;
KIRP	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg00204512	chr16:28754710	NA	0.43	5.39	0.33	1.61e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg13565492	chr6:43139072	SRF	-0.94	-8.58	-0.48	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2033732	0.706	rs10103882	chr8:85073033	C/T	cg05716166	chr8:85095498	RALYL	0.54	6.13	0.36	3.39e-9	Body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07557355	chr1:155904306	KIAA0907	0.97	6.63	0.39	2.16e-10	P wave terminal force;
KIRP	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.68	9.57	0.52	1.16e-18	Prostate cancer;
KIRP	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-14.22	-0.67	6.99e-34	Chronic sinus infection;
KIRP	cis	rs6545883	0.794	rs778152	chr2:61608540	C/A	cg15711740	chr2:61764176	XPO1	0.6	7.92	0.45	8.08e-14	Tuberculosis;
KIRP	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg05785598	chr3:49045655	WDR6	0.32	5.72	0.34	3.02e-8	Parkinson's disease;
KIRP	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs8022179	0.566	rs62006258	chr14:103838909	A/C	cg26207909	chr14:103986467	CKB	-0.46	-5.0	-0.3	1.08e-6	Monocyte count;
KIRP	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.56	-6.5	-0.38	4.49e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.89	-14.19	-0.67	8.49e-34	Testicular germ cell tumor;
KIRP	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg10701640	chr17:43249399	NA	0.47	9.73	0.53	3.75e-19	Height;
KIRP	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.6	7.03	0.41	1.98e-11	Response to antipsychotic treatment;
KIRP	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-9.17	-0.5	1.92e-17	Total body bone mineral density;
KIRP	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg15832292	chr6:96025679	MANEA	0.72	5.92	0.35	1.1e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.96	13.06	0.64	5.88e-30	Breast cancer;
KIRP	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg25486957	chr4:152246857	NA	-0.44	-5.24	-0.32	3.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.73	0.49	3.98e-16	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.67	8.7	0.49	4.85e-16	Prudent dietary pattern;
KIRP	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	1.09	9.73	0.53	3.88e-19	Pulse pressure;
KIRP	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg23188684	chr11:67383651	NA	-0.42	-5.54	-0.33	7.78e-8	Mean corpuscular volume;
KIRP	cis	rs3799379	0.550	rs9467736	chr6:26380032	A/G	cg12826209	chr6:26865740	GUSBL1	0.47	5.77	0.35	2.32e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg09311052	chr1:154531418	UBE2Q1	0.58	6.79	0.4	8.39e-11	Sleep duration;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.41	5.44	0.33	1.27e-7	Cardiovascular disease risk factors;
KIRP	cis	rs1010254	0.510	rs72808338	chr5:151755461	C/T	cg12297329	chr5:152029980	NA	-0.66	-6.63	-0.39	2.1e-10	Optic nerve measurement (cup area);
KIRP	cis	rs73198271	0.960	rs73198287	chr8:8612786	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.32	-0.37	1.24e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1864585	0.520	rs73208790	chr8:10680025	T/A	cg26278703	chr11:58910052	FAM111A	0.64	6.41	0.38	7.25e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7870753	0.838	rs10991354	chr9:99249709	T/C	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.74	-8.62	-0.48	8.41e-16	Tonsillectomy;
KIRP	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg02811702	chr13:24901961	NA	0.43	5.51	0.33	9.06e-8	Obesity-related traits;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23068124	chr14:58711505	PSMA3	0.56	6.06	0.36	4.95e-9	Lung cancer in ever smokers;
KIRP	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg22153407	chr1:230290089	GALNT2	0.35	4.92	0.3	1.58e-6	Coronary artery disease;
KIRP	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg05973401	chr12:123451056	ABCB9	0.55	6.26	0.37	1.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	9.37	0.51	4.88e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03647317	chr4:187891568	NA	-0.79	-13.23	-0.64	1.51e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7084402	0.967	rs12261597	chr10:60297662	T/C	cg05938607	chr10:60274200	BICC1	0.38	9.0	0.5	6.31e-17	Refractive error;
KIRP	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-8.04	-0.46	3.88e-14	Platelet count;
KIRP	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg18016565	chr1:150552671	MCL1	-0.47	-7.28	-0.42	4.6e-12	Tonsillectomy;
KIRP	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg10755058	chr3:40428713	ENTPD3	0.49	6.94	0.4	3.53e-11	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25297849	chr2:219922998	IHH	0.48	6.24	0.37	1.89e-9	Parkinson's disease;
KIRP	cis	rs4006360	0.610	rs4986661	chr17:39250448	C/G	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg14972814	chr11:95582409	MTMR2	0.35	5.78	0.35	2.21e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg12623918	chr2:306882	NA	0.47	5.9	0.35	1.21e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg02475777	chr4:1388615	CRIPAK	-0.56	-5.28	-0.32	2.9e-7	Recombination rate (females);
KIRP	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs2030401	0.603	rs1727301	chr12:123664514	G/A	cg05973401	chr12:123451056	ABCB9	0.41	5.21	0.32	3.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg04804543	chr8:142233427	SLC45A4	0.42	5.03	0.31	9.54e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.88	-0.3	1.88e-6	Myopia (pathological);
KIRP	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg03887218	chr1:16534349	ARHGEF19	0.56	7.5	0.43	1.13e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg04492858	chr10:133558786	NA	0.36	5.31	0.32	2.4e-7	Survival in rectal cancer;
KIRP	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.04	-9.62	-0.52	8.47e-19	Lung cancer in ever smokers;
KIRP	trans	rs6828577	0.817	rs298996	chr4:119624745	C/T	cg12830951	chr5:15498033	NA	0.44	6.11	0.36	3.86e-9	Perioperative myocardial infarction in coronary artery bypass surgery;
KIRP	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.31	-0.32	2.42e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg01320579	chr17:75405842	SEPT9	0.47	7.63	0.44	5.18e-13	Airflow obstruction;
KIRP	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.66	7.36	0.42	2.79e-12	Recalcitrant atopic dermatitis;
KIRP	trans	rs73720034	1.000	rs11767202	chr7:125576985	G/A	cg19591595	chr10:133651815	NA	0.66	6.03	0.36	6.08e-9	Response to selective serotonin reuptake inhibitors and depression;
KIRP	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg25019033	chr10:957182	NA	-0.65	-8.54	-0.48	1.38e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg23978390	chr7:1156363	C7orf50	0.45	6.05	0.36	5.5e-9	Longevity;Endometriosis;
KIRP	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg21775007	chr8:11205619	TDH	0.49	6.31	0.37	1.29e-9	Mood instability;
KIRP	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.93	0.49	1.03e-16	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07355392	chr6:108279494	SEC63	0.46	6.18	0.37	2.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.67	8.93	0.49	1.03e-16	Breast cancer;
KIRP	cis	rs2742417	1.000	rs2673051	chr3:45732409	G/T	cg04037228	chr3:45636386	LIMD1	0.36	5.2	0.31	4.14e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.44	-5.64	-0.34	4.57e-8	Ulcerative colitis;
KIRP	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.82e-10	Protein C levels;
KIRP	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg14541582	chr5:601475	NA	-0.58	-6.65	-0.39	1.89e-10	Obesity-related traits;
KIRP	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.62	8.13	0.46	2.07e-14	Height;
KIRP	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg12311346	chr5:56204834	C5orf35	0.35	4.93	0.3	1.49e-6	Coronary artery disease;
KIRP	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg24253500	chr15:84953950	NA	0.53	6.1	0.36	4.19e-9	Schizophrenia;
KIRP	cis	rs6901004	0.772	rs191632	chr6:111544882	C/T	cg15721981	chr6:111408429	SLC16A10	-0.52	-7.1	-0.41	1.36e-11	Blood metabolite levels;
KIRP	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg09408571	chr1:101003634	GPR88	-0.25	-5.75	-0.34	2.63e-8	Monocyte count;
KIRP	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg06121193	chr1:90282411	NA	-0.48	-6.77	-0.4	9.33e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.42	5.32	0.32	2.37e-7	Cystic fibrosis severity;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.49	5.73	0.34	2.93e-8	Longevity;Endometriosis;
KIRP	cis	rs10875746	0.669	rs9634261	chr12:48686871	A/G	cg26205652	chr12:48591994	NA	0.63	8.16	0.46	1.7e-14	Longevity (90 years and older);
KIRP	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.7	-9.34	-0.51	5.82e-18	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2712184	0.687	rs62180470	chr2:217645451	A/G	cg05032264	chr2:217675019	NA	0.41	5.72	0.34	3.01e-8	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.68	-9.83	-0.53	1.83e-19	Waist circumference;Body mass index;
KIRP	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10465746	0.935	rs11580836	chr1:84333310	C/T	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.86	-0.35	1.47e-8	Morning vs. evening chronotype;
KIRP	cis	rs7520050	0.966	rs6677007	chr1:46400590	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.15e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7174755	0.637	rs113002386	chr15:68464713	C/T	cg22576950	chr15:68522787	CLN6	0.36	5.18	0.31	4.71e-7	Major depressive disorder;
KIRP	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	6.14	0.36	3.24e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs981844	0.857	rs56198877	chr4:154718970	A/G	cg14289246	chr4:154710475	SFRP2	0.67	7.83	0.45	1.45e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg13429435	chr10:81271195	EIF5AL1	-0.37	-6.4	-0.38	7.91e-10	Sarcoidosis;
KIRP	cis	rs4356932	1.000	rs6852075	chr4:76952280	T/G	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.62e-9	Blood protein levels;
KIRP	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.68	-5.23	-0.32	3.67e-7	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs2425143	1.000	rs6060572	chr20:34294015	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-5.81	-0.35	1.96e-8	Blood protein levels;
KIRP	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg24826892	chr11:71159390	DHCR7	0.43	5.21	0.32	3.99e-7	Vitamin D levels;
KIRP	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg11635098	chr7:100497156	NA	-0.67	-6.96	-0.41	3.12e-11	Resting heart rate;
KIRP	cis	rs7937682	0.564	rs1944116	chr11:111366792	A/C	cg09085632	chr11:111637200	PPP2R1B	0.5	6.44	0.38	6.16e-10	Primary sclerosing cholangitis;
KIRP	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-8.95	-0.5	9.07e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7779181	1.000	rs7778788	chr7:32346974	A/C	cg13207630	chr7:32358064	NA	0.41	5.47	0.33	1.08e-7	Body mass index;
KIRP	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg02375832	chr11:62437615	C11orf48	-0.49	-5.98	-0.36	7.96e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	0.84	11.02	0.57	3.25e-23	Primary sclerosing cholangitis;
KIRP	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg00094735	chr5:1949198	NA	0.44	5.17	0.31	4.74e-7	Gut microbiome composition (winter);
KIRP	cis	rs2742234	0.910	rs2503866	chr10:43646261	T/A	cg15436174	chr10:43711423	RASGEF1A	-0.54	-6.72	-0.39	1.22e-10	Hirschsprung disease;
KIRP	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.74	-8.86	-0.49	1.62e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs429017	1.000	rs420448	chr5:41265102	G/A	cg06122825	chr1:203488764	NA	0.41	6.06	0.36	5.03e-9	Blood protein levels;
KIRP	cis	rs4789452	1.000	rs35825162	chr17:75373188	G/A	cg05184938	chr17:75369939	SEPT9	-0.38	-5.19	-0.31	4.34e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.57	8.88	0.49	1.45e-16	Lymphocyte counts;
KIRP	trans	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg17822266	chr1:2720087	NA	-0.46	-6.33	-0.37	1.17e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.17	-0.31	4.91e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs258892	0.895	rs10041942	chr5:72049964	T/C	cg21869765	chr5:72125136	TNPO1	-0.48	-5.39	-0.33	1.65e-7	Small cell lung carcinoma;
KIRP	cis	rs829661	0.947	rs829634	chr2:30735763	T/C	cg10949345	chr2:30726833	LCLAT1	0.73	10.49	0.56	1.61e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg26531700	chr6:26746687	NA	0.38	5.16	0.31	5.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7173743	0.525	rs7166723	chr15:79133848	C/T	cg00079375	chr15:79125835	NA	0.39	5.54	0.33	7.88e-8	Coronary artery disease;
KIRP	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.6	6.75	0.4	1.08e-10	DNA methylation (variation);
KIRP	cis	rs1978968	0.751	rs5992139	chr22:18458636	A/G	cg02610425	chr22:18483192	MICAL3	0.38	5.32	0.32	2.38e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.44	2.78e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4363385	0.530	rs11205181	chr1:153045728	C/T	cg13444842	chr1:152974279	SPRR3	-0.45	-6.51	-0.38	4.22e-10	Inflammatory skin disease;
KIRP	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.44	5.3	0.32	2.56e-7	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.53	5.2	0.31	4.25e-7	Alzheimer's disease;
KIRP	cis	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-5.5	-0.33	9.46e-8	Height;
KIRP	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.55	0.33	7.25e-8	Coronary artery disease;
KIRP	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.67	6.73	0.39	1.22e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.55	7.47	0.43	1.4e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs8084125	1.000	rs72981154	chr18:74944135	C/T	cg18461021	chr18:74961002	GALR1	0.62	5.93	0.35	1.02e-8	Obesity-related traits;
KIRP	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg13514129	chr1:39547527	MACF1	0.53	7.8	0.45	1.81e-13	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.68	-0.34	3.72e-8	Colorectal cancer;
KIRP	cis	rs4262150	0.846	rs72797296	chr5:152044445	G/A	cg12297329	chr5:152029980	NA	-0.67	-8.21	-0.46	1.25e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7202877	0.706	rs247436	chr16:75445971	T/G	cg03315344	chr16:75512273	CHST6	-0.58	-5.43	-0.33	1.37e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.01	0.3	1.03e-6	Breast cancer;
KIRP	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs11874712	1.000	rs1800640	chr18:43671400	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.5	-0.33	9.27e-8	Migraine - clinic-based;
KIRP	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.69	-0.39	1.46e-10	Height;
KIRP	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	9.87	0.53	1.43e-19	Cognitive test performance;
KIRP	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.4e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg00631329	chr6:26305371	NA	0.56	7.12	0.41	1.17e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.71	-10.74	-0.57	2.48e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.85	0.35	1.53e-8	Bipolar disorder;
KIRP	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.51	5.02	0.31	9.77e-7	Alzheimer's disease;
KIRP	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg02275930	chr1:2372054	NA	-0.69	-9.27	-0.51	9.83e-18	Non-obstructive azoospermia;
KIRP	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-8.63	-0.48	7.88e-16	Platelet count;
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.72	-10.8	-0.57	1.6400000000000001e-22	Monocyte percentage of white cells;
KIRP	cis	rs7503807	0.701	rs1485329	chr17:78643561	A/G	cg09596252	chr17:78655493	RPTOR	0.45	5.22	0.32	3.8e-7	Obesity;
KIRP	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg24874828	chr4:187887005	NA	-0.47	-7.02	-0.41	2.21e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.65	7.84	0.45	1.34e-13	QRS duration;
KIRP	cis	rs2574975	0.509	rs1203396	chr10:52202119	T/C	cg10034176	chr10:52120283	SGMS1	0.39	5.55	0.33	7.21e-8	Response to amphetamines;
KIRP	cis	rs6589219	0.954	rs3802842	chr11:111171709	C/A	cg25129781	chr11:111156908	C11orf53	-0.49	-6.33	-0.37	1.12e-9	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	1.04	14.23	0.67	6.33e-34	Menopause (age at onset);
KIRP	cis	rs7927370	0.541	rs7932244	chr11:55617173	T/A	cg07850316	chr11:56344833	OR5M10;OR8U8	0.69	5.26	0.32	3.07e-7	Systemic lupus erythematosus;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10502232	chr16:2564005	ATP6V0C	-0.48	-6.2	-0.37	2.39e-9	Morning vs. evening chronotype;
KIRP	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg06795125	chr2:108905320	SULT1C2	-0.45	-7.97	-0.45	6.01e-14	Blood pressure;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg00738919	chr7:1100172	C7orf50	0.43	5.3	0.32	2.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-5.73	-0.34	2.96e-8	Life satisfaction;
KIRP	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.48	7.47	0.43	1.43e-12	Major depressive disorder;
KIRP	cis	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg20542592	chr8:11973495	FAM66D	0.39	4.92	0.3	1.62e-6	Neuroticism;
KIRP	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.52	5.06	0.31	8.23e-7	Initial pursuit acceleration;
KIRP	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg07741184	chr6:167504864	NA	-0.24	-6.4	-0.38	7.85e-10	Crohn's disease;
KIRP	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg19592336	chr6:28129416	ZNF389	0.45	4.95	0.3	1.39e-6	Parkinson's disease;
KIRP	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg12292205	chr6:26970375	C6orf41	-0.4	-4.89	-0.3	1.84e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg27490568	chr2:178487706	NA	0.53	7.22	0.42	6.37e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg00745463	chr17:30367425	LRRC37B	-0.61	-5.98	-0.36	7.66e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs79220007	1.000	rs79220007	chr6:26098474	T/C	cg16482183	chr6:26056742	HIST1H1C	0.93	5.6	0.34	5.58e-8	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1656402	1.000	rs4973544	chr2:233435535	G/A	cg03852847	chr2:233439513	NA	-0.69	-9.12	-0.5	2.67e-17	Non-small cell lung cancer (survival);
KIRP	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg03465714	chr1:152285911	FLG	0.52	5.45	0.33	1.21e-7	Atopic dermatitis;
KIRP	cis	rs6681460	0.932	rs618093	chr1:67178428	T/G	cg13052034	chr1:66999238	SGIP1	0.37	5.26	0.32	3.14e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17077171	chr1:155658509	YY1AP1;DAP3	0.49	6.91	0.4	4.13e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2380205	0.651	rs12357094	chr10:5926303	G/C	cg27141509	chr10:5886111	NA	-0.38	-5.37	-0.32	1.87e-7	Breast cancer;
KIRP	cis	rs13343954	0.518	rs2216594	chr19:33533258	G/A	cg17764715	chr19:33622953	WDR88	0.8	10.91	0.57	7.32e-23	Colorectal cancer;
KIRP	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-0.76	-11.31	-0.58	3.69e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs858239	0.600	rs4321896	chr7:23128056	G/A	cg23682824	chr7:23144976	KLHL7	0.46	5.47	0.33	1.08e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00879163	chr7:66386079	C7orf42	0.52	6.67	0.39	1.71e-10	Parkinson's disease;
KIRP	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.62	-9.09	-0.5	3.5e-17	Monocyte percentage of white cells;
KIRP	trans	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg24644049	chr4:85504048	CDS1	1.01	6.61	0.39	2.41e-10	Skin colour saturation;
KIRP	cis	rs3733418	0.929	rs4691138	chr4:165908641	A/G	cg10852876	chr4:165953100	TRIM60	-0.47	-5.08	-0.31	7.32e-7	Obesity-related traits;
KIRP	cis	rs17539620	0.808	rs57833052	chr6:154877112	C/T	cg20019720	chr6:154832845	CNKSR3	0.35	5.42	0.33	1.41e-7	Lipoprotein (a) levels;
KIRP	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-9.38	-0.51	4.66e-18	Migraine;Coronary artery disease;
KIRP	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.4	5.14	0.31	5.54e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg01689657	chr7:91764605	CYP51A1	-0.37	-5.37	-0.32	1.81e-7	Breast cancer;
KIRP	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.87	-9.95	-0.54	7.92e-20	Gut microbiome composition (summer);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17414372	chr12:32669873	FGD4	0.53	7.55	0.43	8.73e-13	Interleukin-4 levels;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg25533220	chr19:2328480	SPPL2B;LSM7	0.48	6.17	0.37	2.8e-9	Asthma;
KIRP	cis	rs73206853	0.563	rs16940992	chr12:111207515	C/T	cg12870014	chr12:110450643	ANKRD13A	-0.46	-5.58	-0.34	6.31e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs1859156	0.812	rs35306626	chr4:95840485	T/C	cg24204951	chr2:239172084	PER2	0.31	6.94	0.4	3.46e-11	Attention deficit hyperactivity disorder;
KIRP	cis	rs11955398	0.585	rs2100584	chr5:60021487	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg23682824	chr7:23144976	KLHL7	0.45	5.06	0.31	8.36e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4073221	0.789	rs34901970	chr3:18264186	C/G	cg07694806	chr3:18168406	NA	-0.84	-7.13	-0.41	1.11e-11	Parkinson's disease;
KIRP	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg20169779	chr10:135381914	SYCE1	-0.73	-7.7	-0.44	3.23e-13	Gout;
KIRP	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.72	8.02	0.46	4.37e-14	Response to diuretic therapy;
KIRP	cis	rs7084402	0.967	rs1658481	chr10:60289339	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.96	-0.57	4.91e-23	Refractive error;
KIRP	cis	rs595982	0.702	rs623520	chr19:49369943	A/G	cg21252483	chr19:49399788	TULP2	-0.33	-6.04	-0.36	5.56e-9	Red cell distribution width;
KIRP	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.67	7.9	0.45	9.42e-14	Blood protein levels;
KIRP	cis	rs4073416	0.542	rs10143206	chr14:66120675	A/G	cg03016385	chr14:66212404	NA	0.54	6.86	0.4	5.68e-11	N-glycan levels;
KIRP	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs889398	0.802	rs12925700	chr16:69793463	C/A	cg09409435	chr16:70099608	PDXDC2	-0.43	-5.05	-0.31	8.47e-7	Body mass index;
KIRP	trans	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg10756647	chr7:56101905	PSPH	-0.94	-6.9	-0.4	4.35e-11	Diabetic kidney disease;
KIRP	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs4494114	0.967	rs9438978	chr1:39355058	G/T	cg25970120	chr1:39325951	RRAGC	-0.41	-5.08	-0.31	7.43e-7	Blood protein levels;
KIRP	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-6.14	-0.36	3.36e-9	Hemoglobin concentration;
KIRP	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.91	-13.15	-0.64	2.94e-30	Orofacial clefts;
KIRP	cis	rs12431939	1.000	rs55851845	chr14:51645583	A/T	cg23942311	chr14:51606299	NA	-0.61	-5.18	-0.31	4.66e-7	Cancer;
KIRP	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.65	7.03	0.41	2.07e-11	Gut microbiome composition (summer);
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.9	-0.4	4.27e-11	Lymphocyte counts;
KIRP	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg04037228	chr3:45636386	LIMD1	0.35	5.17	0.31	4.92e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.47	-6.66	-0.39	1.8e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg17207736	chr8:142237307	SLC45A4	-0.53	-6.71	-0.39	1.34e-10	Immature fraction of reticulocytes;
KIRP	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.92	12.09	0.61	1.03e-26	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7546094	0.905	rs10776755	chr1:113082974	C/G	cg22162597	chr1:113214053	CAPZA1	-0.46	-6.0	-0.36	7.2e-9	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15541609	chr14:100705844	YY1	0.51	6.39	0.38	8.2e-10	Parkinson's disease;
KIRP	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg04025307	chr7:1156635	C7orf50	0.53	5.47	0.33	1.09e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg00262122	chr8:11665843	FDFT1	0.4	4.9	0.3	1.78e-6	Neuroticism;
KIRP	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs11025559	0.631	rs11025571	chr11:20482801	C/G	cg19653624	chr11:20408972	PRMT3	0.65	6.41	0.38	7.24e-10	Pursuit maintenance gain;
KIRP	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-7.33	-0.42	3.37e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.5	0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.58	7.66	0.44	4.17e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg18164611	chr1:46958628	NA	0.43	5.39	0.32	1.68e-7	Monobrow;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27523423	chr15:75744089	SIN3A	0.52	7.67	0.44	3.95e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17103929	chr8:101225361	SPAG1	0.54	6.32	0.37	1.24e-9	Smoking initiation;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.48	-5.63	-0.34	4.85e-8	Carotid intima media thickness;
KIRP	cis	rs904251	0.504	rs1757188	chr6:37483808	A/G	cg00360474	chr6:37504404	NA	-0.51	-7.46	-0.43	1.52e-12	Cognitive performance;
KIRP	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg18192325	chr2:105854051	NA	0.38	5.25	0.32	3.24e-7	Type 2 diabetes;
KIRP	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	5.38	0.32	1.76e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	trans	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.64	-6.66	-0.39	1.74e-10	Obesity-related traits;
KIRP	trans	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg00405596	chr8:11794950	NA	-0.46	-6.12	-0.36	3.57e-9	Mood instability;
KIRP	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.44	-10.31	-0.55	5.8e-21	Diabetic kidney disease;
KIRP	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.71	8.54	0.48	1.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg07001201	chr5:642380	CEP72	-0.4	-5.09	-0.31	7.07e-7	Obesity-related traits;
KIRP	cis	rs72615157	0.629	rs55839153	chr7:99752566	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.73	7.2	0.42	7.5e-12	Lung function (FEV1/FVC);
KIRP	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-7.82	-0.45	1.5700000000000001e-13	Morning vs. evening chronotype;
KIRP	cis	rs9372498	0.536	rs9489447	chr6:118900846	G/A	cg18833306	chr6:118973337	C6orf204	-0.47	-5.04	-0.31	9.1e-7	Diastolic blood pressure;
KIRP	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg12560992	chr17:57184187	TRIM37	-0.55	-4.88	-0.3	1.93e-6	Cognitive test performance;
KIRP	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-7.19	-0.42	7.72e-12	Vitiligo;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.8	10.9	0.57	7.63e-23	Height;
KIRP	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07691200	chr5:34916224	BRIX1;RAD1	0.51	7.0	0.41	2.41e-11	Parkinson's disease;
KIRP	cis	rs2882667	0.587	rs825674	chr5:138102720	A/G	cg04439458	chr5:138467593	SIL1	0.35	4.92	0.3	1.58e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2274459	1.000	rs34869648	chr6:33724059	G/A	cg06253072	chr6:33679850	C6orf125	0.48	4.86	0.3	2.07e-6	Obesity (extreme);
KIRP	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.11	-0.61	9.02e-27	Alzheimer's disease;
KIRP	cis	rs6142102	0.812	rs6059558	chr20:32516830	G/C	cg24642439	chr20:33292090	TP53INP2	0.52	5.68	0.34	3.77e-8	Skin pigmentation;
KIRP	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg02378861	chr5:212933	CCDC127	-0.79	-6.0	-0.36	7.05e-9	Fat distribution (HIV);
KIRP	cis	rs6540559	0.546	rs7551944	chr1:210029430	G/C	cg22029157	chr1:209979665	IRF6	0.56	4.92	0.3	1.62e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg00360474	chr6:37504404	NA	-0.48	-6.82	-0.4	6.95e-11	Cognitive performance;
KIRP	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.23e-6	Parkinson's disease;
KIRP	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.73e-8	Tonsillectomy;
KIRP	cis	rs3731827	0.511	rs14976	chr2:85818886	C/T	cg23752985	chr2:85803571	VAMP8	0.41	5.18	0.31	4.59e-7	Prostate cancer;
KIRP	cis	rs859767	0.519	rs6707326	chr2:135357705	G/A	cg25422880	chr2:135218333	TMEM163	0.39	5.66	0.34	4.16e-8	Neuroticism;
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.73	-8.64	-0.48	7.44e-16	Longevity;Endometriosis;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg21734707	chr17:3908241	ZZEF1	0.62	9.26	0.51	1.04e-17	Type 2 diabetes;
KIRP	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.66	-10.06	-0.54	3.7799999999999997e-20	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03315247	chr3:122399498	PARP14	0.53	6.91	0.4	4.15e-11	Parkinson's disease;
KIRP	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg08533674	chr1:46993347	NA	0.46	5.72	0.34	3.03e-8	Monobrow;
KIRP	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.51	6.95	0.4	3.33e-11	Coronary artery disease;
KIRP	cis	rs96067	0.805	rs11263860	chr1:36601368	C/G	cg27506609	chr1:36549197	TEKT2	-0.49	-6.0	-0.36	6.92e-9	Corneal structure;
KIRP	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg05861140	chr6:150128134	PCMT1	0.53	7.68	0.44	3.72e-13	Lung cancer;
KIRP	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-4.94	-0.3	1.46e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs2860975	0.875	rs2211272	chr10:96765905	G/A	cg09036531	chr10:96991505	NA	-0.55	-7.08	-0.41	1.52e-11	Immune response to smallpox vaccine (IL-6);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07815385	chr10:70883261	VPS26A	-0.47	-6.62	-0.39	2.24e-10	Migraine with aura;
KIRP	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03713592	chr11:72463424	ARAP1	1.05	9.12	0.5	2.69e-17	Type 2 diabetes;
KIRP	cis	rs9840812	0.623	rs6794351	chr3:136292279	C/T	cg15507776	chr3:136538369	TMEM22	0.4	4.88	0.3	1.94e-6	Fibrinogen levels;
KIRP	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.62	-8.4	-0.47	3.68e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.49	5.78	0.35	2.31e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg02931644	chr1:25747376	RHCE	0.47	8.71	0.49	4.63e-16	Erythrocyte sedimentation rate;
KIRP	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg18306943	chr3:40428807	ENTPD3	-0.47	-6.57	-0.39	3.03e-10	Renal cell carcinoma;
KIRP	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.91	12.17	0.61	5.52e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg24633833	chr3:10029261	TMEM111	-0.51	-4.99	-0.3	1.16e-6	Alzheimer's disease;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13744822	chr11:64902092	SYVN1	0.44	6.19	0.37	2.51e-9	Cancer;
KIRP	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg14250997	chr9:106856677	SMC2	0.44	6.04	0.36	5.64e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.88	13.94	0.66	5.87e-33	Morning vs. evening chronotype;
KIRP	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.61	8.94	0.5	9.75e-17	Dupuytren's disease;
KIRP	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	11.09	0.58	1.91e-23	Total body bone mineral density;
KIRP	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.46	-5.06	-0.31	8.02e-7	Diastolic blood pressure;
KIRP	cis	rs8028182	0.636	rs6495182	chr15:75814388	C/T	cg20655648	chr15:75932815	IMP3	0.51	6.56	0.39	3.17e-10	Sudden cardiac arrest;
KIRP	cis	rs2637030	0.559	rs256083	chr5:52893681	G/A	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg21858823	chr1:15850916	CASP9	-0.53	-5.74	-0.34	2.84e-8	Systolic blood pressure;
KIRP	cis	rs112591243	0.685	rs78443123	chr21:47953331	G/T	cg12379764	chr21:47803548	PCNT	0.73	4.97	0.3	1.28e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs4356975	0.563	rs4454000	chr4:69950571	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs2380205	0.689	rs867053	chr10:5887170	G/A	cg27141509	chr10:5886111	NA	-0.42	-5.76	-0.34	2.52e-8	Breast cancer;
KIRP	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.59	0.34	5.95e-8	Educational attainment;
KIRP	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.7	-6.88	-0.4	5.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.96	0.5	8.26e-17	IgG glycosylation;
KIRP	cis	rs4742903	0.967	rs10820601	chr9:106861281	G/A	cg14250997	chr9:106856677	SMC2	0.38	4.96	0.3	1.32e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg00800038	chr16:89945340	TCF25	-0.62	-5.19	-0.31	4.32e-7	Skin colour saturation;
KIRP	cis	rs9653442	0.564	rs7601892	chr2:100789490	G/A	cg22139774	chr2:100720529	AFF3	-0.29	-4.92	-0.3	1.59e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs6601327	0.586	rs6601340	chr8:9461315	A/T	cg16141378	chr3:129829833	LOC729375	0.45	6.08	0.36	4.6e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9513593	1.000	rs4772181	chr13:99860966	C/G	cg21788972	chr13:99853209	UBAC2	0.51	5.32	0.32	2.28e-7	Psoriasis;
KIRP	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg25547332	chr5:131281432	NA	-0.46	-5.14	-0.31	5.52e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.64	-6.98	-0.41	2.74e-11	DNA methylation (variation);
KIRP	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.52	-6.12	-0.36	3.7e-9	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.46	4.91	0.3	1.68e-6	Type 2 diabetes;
KIRP	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.46	-5.59	-0.34	5.93e-8	Testicular germ cell tumor;
KIRP	cis	rs12210905	0.841	rs12206996	chr6:27066415	A/G	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs860295	0.665	rs12079134	chr1:155466784	C/G	cg02153340	chr1:155202674	NA	-0.52	-7.19	-0.42	7.83e-12	Body mass index;
KIRP	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.53	-0.38	3.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.03	-0.41	2.04e-11	Mean corpuscular volume;
KIRP	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg13264159	chr8:625131	ERICH1	-0.84	-6.95	-0.41	3.22e-11	IgG glycosylation;
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg01798813	chr17:3906674	NA	-0.51	-7.02	-0.41	2.21e-11	Type 2 diabetes;
KIRP	cis	rs8049040	0.586	rs8060176	chr16:71456757	T/C	cg08717414	chr16:71523259	ZNF19	-0.45	-5.02	-0.3	1.01e-6	Blood protein levels;
KIRP	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21640587	chr11:117668038	DSCAML1	0.55	7.09	0.41	1.45e-11	Myopia;
KIRP	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.58	7.61	0.44	5.72e-13	Bladder cancer;
KIRP	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	9.67	0.52	5.88e-19	Total body bone mineral density;
KIRP	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.06	-0.41	1.71e-11	Menopause (age at onset);
KIRP	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg09137382	chr11:130731461	NA	0.5	6.68	0.39	1.56e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.4	6.99	0.41	2.55e-11	Renal cell carcinoma;
KIRP	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.55	6.14	0.36	3.37e-9	Blood metabolite levels;
KIRP	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg16497661	chr14:103986332	CKB	-0.52	-6.87	-0.4	5.14e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2562456	0.793	rs3853838	chr19:21601994	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.92e-6	Pain;
KIRP	cis	rs2273669	0.667	rs12197912	chr6:109338147	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.48	-0.38	4.91e-10	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg26513180	chr16:89883248	FANCA	0.84	5.57	0.33	6.5e-8	Skin colour saturation;
KIRP	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg11555438	chr13:111297484	CARS2	0.32	5.09	0.31	7.13e-7	Coronary artery disease;
KIRP	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg26876637	chr1:152193138	HRNR	0.68	8.07	0.46	3.04e-14	Atopic dermatitis;
KIRP	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.4	6.55	0.39	3.28e-10	Testicular germ cell tumor;
KIRP	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.53	8.1	0.46	2.52e-14	Itch intensity from mosquito bite;
KIRP	cis	rs2522056	1.000	rs2706379	chr5:131805735	C/T	cg07395648	chr5:131743802	NA	0.53	6.38	0.38	8.7e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7621025	0.505	rs13063893	chr3:136387638	C/T	cg15507776	chr3:136538369	TMEM22	-0.67	-5.96	-0.35	8.9e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.78	11.24	0.58	6.37e-24	Blood metabolite ratios;
KIRP	cis	rs4132509	1.000	rs10927040	chr1:243731693	T/C	cg25706552	chr1:244017396	NA	0.5	6.5	0.38	4.38e-10	RR interval (heart rate);
KIRP	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg19554555	chr3:13937349	NA	0.55	8.16	0.46	1.69e-14	Ovarian reserve;
KIRP	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.5	-0.38	4.45e-10	Mood instability;
KIRP	cis	rs876084	0.722	rs1401812	chr8:121042631	G/A	cg06265175	chr8:121136014	COL14A1	0.44	4.96	0.3	1.32e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg24488311	chr11:68621650	NA	0.44	5.12	0.31	6.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg19875535	chr5:140030758	IK	0.65	9.21	0.51	1.53e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs62229266	0.659	rs2026259	chr21:37430627	A/G	cg08632701	chr21:37451849	NA	-0.39	-4.97	-0.3	1.24e-6	Mitral valve prolapse;
KIRP	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.07	-0.31	7.79e-7	Chronic sinus infection;
KIRP	cis	rs9409565	0.762	rs55877910	chr9:97234213	G/C	cg04523069	chr9:97136363	HIATL1	0.47	6.21	0.37	2.23e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg27205649	chr11:78285834	NARS2	0.83	12.11	0.61	8.58e-27	Alzheimer's disease (survival time);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04155756	chr4:6988785	TBC1D14	-0.57	-6.1	-0.36	4.07e-9	Menopause (age at onset);
KIRP	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.82	-12.06	-0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-5.2	-0.31	4.28e-7	Testicular germ cell tumor;
KIRP	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.71	9.87	0.53	1.44e-19	Mean corpuscular volume;
KIRP	cis	rs12580194	0.593	rs12296692	chr12:55756851	A/G	cg19537932	chr12:55886519	OR6C68	-0.47	-6.31	-0.37	1.27e-9	Cancer;
KIRP	cis	rs970548	0.779	rs3891524	chr10:45971689	C/A	cg15590007	chr10:45870220	ALOX5	0.62	6.24	0.37	1.93e-9	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.45	-0.38	5.98e-10	Response to antipsychotic treatment;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg10659575	chr11:102188233	BIRC3	0.76	6.63	0.39	2.1e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg22903657	chr4:1355424	KIAA1530	-0.36	-5.07	-0.31	7.86e-7	Obesity-related traits;
KIRP	cis	rs2997447	0.600	rs1335759	chr1:26471743	G/T	cg12742826	chr1:26365331	SLC30A2	0.37	5.12	0.31	6.06e-7	QRS complex (12-leadsum);
KIRP	cis	rs1978968	1.000	rs2099944	chr22:18438578	G/A	cg02610425	chr22:18483192	MICAL3	0.39	5.88	0.35	1.32e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27663799	chr12:49504641	LMBR1L	0.45	6.07	0.36	4.69e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.83	-12.36	-0.62	1.32e-27	Height;
KIRP	trans	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.75	-0.4	1.03e-10	Obesity-related traits;
KIRP	cis	rs7589728	0.858	rs79992736	chr2:88530575	A/C	cg07952391	chr2:88470173	THNSL2	0.6	5.25	0.32	3.32e-7	Plasma clusterin levels;
KIRP	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	1.22	13.92	0.66	7.04e-33	Atopic dermatitis;
KIRP	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.73	5.86	0.35	1.5e-8	Diabetic retinopathy;
KIRP	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg23307798	chr14:103986281	CKB	0.48	6.73	0.39	1.22e-10	Body mass index;
KIRP	cis	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg07460842	chr6:66804631	NA	0.48	5.76	0.34	2.5e-8	Metabolite levels;
KIRP	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.48e-10	Coronary artery disease;
KIRP	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	0.67	6.3	0.37	1.36e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.65	0.44	4.49e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg27205649	chr11:78285834	NARS2	0.68	9.02	0.5	5.33e-17	Alzheimer's disease (survival time);
KIRP	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.95	12.8	0.63	4.36e-29	Cognitive function;
KIRP	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	0.97	8.19	0.46	1.39e-14	Arsenic metabolism;
KIRP	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg06533319	chr4:3265114	C4orf44	-0.41	-4.91	-0.3	1.65e-6	Parental longevity (mother's age at death);
KIRP	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.57	0.39	3.02e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.82	-7.51	-0.43	1.09e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	0.76	8.34	0.47	5.38e-15	Testicular germ cell tumor;
KIRP	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg02404636	chr22:31891804	SFI1	-0.43	-5.11	-0.31	6.38e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.87	-12.58	-0.63	2.27e-28	Longevity;Endometriosis;
KIRP	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg27205649	chr11:78285834	NARS2	0.66	7.12	0.41	1.19e-11	Alzheimer's disease (survival time);
KIRP	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs6832769	1.000	rs6851838	chr4:56420747	A/C	cg09317128	chr4:56265301	TMEM165	-0.54	-7.25	-0.42	5.29e-12	Personality dimensions;
KIRP	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.58	-6.52	-0.38	3.89e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-1.11	-14.63	-0.68	2.77e-35	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23161317	chr6:28129485	ZNF389	0.42	4.94	0.3	1.44e-6	Depression;
KIRP	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.51	-5.79	-0.35	2.13e-8	Schizophrenia;
KIRP	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.28e-7	Schizophrenia;
KIRP	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2898681	0.581	rs11938140	chr4:53678057	T/A	cg00338735	chr4:53728038	RASL11B	0.43	5.34	0.32	2.09e-7	Optic nerve measurement (cup area);
KIRP	cis	rs745821	0.879	rs3867257	chr18:48146048	T/G	cg18923635	chr18:48083994	NA	0.44	5.06	0.31	8.04e-7	Diastolic blood pressure;
KIRP	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg20991723	chr1:152506922	NA	-0.45	-5.22	-0.32	3.88e-7	Hair morphology;
KIRP	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.64	-9.39	-0.51	4.27e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12976411	0.867	rs8110851	chr19:32828455	C/G	cg18253629	chr19:32836317	ZNF507	0.64	4.99	0.3	1.16e-6	Coronary artery disease;
KIRP	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.19	0.46	1.4e-14	Schizophrenia;
KIRP	cis	rs11264213	0.901	rs811114	chr1:36345758	G/A	cg27506609	chr1:36549197	TEKT2	0.96	10.2	0.55	1.29e-20	Schizophrenia;
KIRP	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.7	7.4	0.43	2.16e-12	Lymphocyte counts;
KIRP	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.75	9.85	0.53	1.69e-19	Huntington's disease progression;
KIRP	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg17941049	chr3:63904683	ATXN7	-0.52	-5.1	-0.31	6.95e-7	Type 2 diabetes;
KIRP	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.75	9.97	0.54	6.75e-20	Resting heart rate;
KIRP	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg27121462	chr16:89883253	FANCA	-0.49	-6.26	-0.37	1.74e-9	Vitiligo;
KIRP	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02359409	chr6:42947317	PEX6	-0.46	-6.14	-0.36	3.28e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-7.48	-0.43	1.33e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8032158	1.000	rs72734373	chr15:56262183	T/G	cg02198044	chr15:56286336	NEDD4	-0.43	-4.94	-0.3	1.46e-6	Keloid;
KIRP	cis	rs13135284	0.509	rs11099924	chr4:154850835	C/T	cg05574313	chr4:155338166	DCHS2	0.37	4.92	0.3	1.61e-6	DNA methylation (parent-of-origin);
KIRP	cis	rs8014252	0.803	rs7158201	chr14:71010546	A/G	cg19730268	chr14:71022823	NA	0.57	5.63	0.34	4.99e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg07884673	chr3:53033167	SFMBT1	0.95	7.39	0.43	2.27e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11622362	chr11:34938112	PDHX;APIP	-0.5	-6.31	-0.37	1.26e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	1.14	7.21	0.42	6.67e-12	LDL cholesterol;
KIRP	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	-0.18	-4.97	-0.3	1.23e-6	Coronary artery disease;
KIRP	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg05127821	chr10:94822908	CYP26C1	-1.1	-11.3	-0.58	3.95e-24	Coronary artery disease;
KIRP	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.43	0.43	1.75e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs17023223	0.537	rs2361269	chr1:119602215	A/G	cg05756136	chr1:119680316	WARS2	-0.54	-7.21	-0.42	6.79e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg06654118	chr4:1303317	MAEA	0.26	5.12	0.31	6.31e-7	Longevity;
KIRP	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg04935436	chr20:30431758	NA	0.49	6.54	0.39	3.46e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg18477163	chr1:228402036	OBSCN	0.37	7.35	0.42	2.86e-12	Diastolic blood pressure;
KIRP	cis	rs667920	0.557	rs35849216	chr3:136327569	C/T	cg15507776	chr3:136538369	TMEM22	-0.67	-5.85	-0.35	1.54e-8	Coronary artery disease;
KIRP	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.65	12.49	0.62	4.79e-28	Bone mineral density;
KIRP	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17183009	chr3:120277827	NA	0.55	6.37	0.38	9.04e-10	Corneal astigmatism;
KIRP	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.69	-10.9	-0.57	8.1e-23	Educational attainment;
KIRP	cis	rs7011507	1.000	rs76073219	chr8:49180444	T/C	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg00814883	chr7:100076585	TSC22D4	-0.57	-6.01	-0.36	6.71e-9	Lung function (FEV1/FVC);
KIRP	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.84	8.39	0.47	3.93e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9653442	0.527	rs4851258	chr2:100780830	T/C	cg17356467	chr2:100759845	AFF3	0.42	5.39	0.33	1.61e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg02106180	chr16:845767	CHTF18	0.38	5.14	0.31	5.58e-7	Mean corpuscular volume;
KIRP	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg07636037	chr3:49044803	WDR6	-0.73	-5.64	-0.34	4.75e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12496230	0.794	rs1867408	chr3:66860026	C/T	cg17646820	chr3:66848679	NA	0.39	6.34	0.37	1.06e-9	Type 2 diabetes;
KIRP	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.5	7.53	0.43	9.33e-13	Schizophrenia;
KIRP	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	cis	rs3741151	0.686	rs7941359	chr11:73158119	A/G	cg17517138	chr11:73019481	ARHGEF17	0.72	6.06	0.36	5.13e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	4.96	0.3	1.3e-6	Resting heart rate;
KIRP	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.73	10.56	0.56	9.77e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-5.11	-0.31	6.38e-7	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27042667	chr1:163295979	NUF2	-0.41	-6.48	-0.38	4.91e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2281603	0.570	rs4632045	chr14:64963126	C/T	cg01860774	chr14:64969374	ZBTB25	0.33	5.37	0.32	1.8e-7	Lymphocyte counts;
KIRP	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.73	8.96	0.5	8.01e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26108683	chr11:67250618	AIP	0.5	6.39	0.38	8.15e-10	Parkinson's disease;
KIRP	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg08076091	chr2:203926405	NBEAL1	0.93	10.0	0.54	5.66e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10267417	0.603	rs116877803	chr7:19925205	C/T	cg05791153	chr7:19748676	TWISTNB	0.51	4.85	0.3	2.22e-6	Night sleep phenotypes;
KIRP	cis	rs17453880	0.929	rs4958570	chr5:152022254	C/G	cg12297329	chr5:152029980	NA	-0.72	-11.2	-0.58	8.35e-24	Subjective well-being;
KIRP	cis	rs427941	0.967	rs6970036	chr7:101841824	A/G	cg06246474	chr7:101738831	CUX1	0.53	6.5	0.38	4.4e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6942756	0.531	rs2896415	chr7:128904523	G/A	cg02491457	chr7:128862824	NA	0.51	6.52	0.38	3.92e-10	White matter hyperintensity burden;
KIRP	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.85	0.45	1.3e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18252515	chr7:66147081	NA	0.47	5.73	0.34	2.87e-8	Aortic root size;
KIRP	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.75	10.47	0.56	1.91e-21	Hemoglobin concentration;
KIRP	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.51	-5.94	-0.35	9.56e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg03060546	chr3:49711283	APEH	0.61	6.0	0.36	6.86e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg19507638	chr5:93509721	C5orf36	-0.55	-5.02	-0.3	1.02e-6	Diabetic retinopathy;
KIRP	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.1	0.46	2.65e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs4302748	0.862	rs11971724	chr7:36184708	T/C	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg23067535	chr8:124195133	FAM83A	0.77	7.56	0.43	7.85e-13	Urinary uromodulin levels;
KIRP	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.44	-5.57	-0.33	6.68e-8	Crohn's disease;
KIRP	cis	rs16857609	0.628	rs874839	chr2:218354087	T/G	cg15335768	chr2:218268053	DIRC3	-0.38	-5.55	-0.33	7.47e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.58	-8.01	-0.46	4.45e-14	Motion sickness;
KIRP	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.71	8.7	0.49	4.85e-16	Multiple sclerosis;
KIRP	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	7.36	0.42	2.82e-12	Myopia (pathological);
KIRP	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg08873628	chr1:175162347	KIAA0040	0.38	5.61	0.34	5.31e-8	Alcohol dependence;
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg02696790	chr15:75250997	RPP25	0.32	5.57	0.33	6.74e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.85	-12.55	-0.62	2.96e-28	Strep throat;
KIRP	cis	rs1593	0.531	rs3822055	chr4:187179678	A/G	cg23442198	chr4:187126114	CYP4V2	0.48	5.01	0.3	1.05e-6	Activated partial thromboplastin time;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16411160	chr2:61645778	SNORA70B;USP34	-0.41	-6.69	-0.39	1.47e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.69	9.4	0.51	4.01e-18	Systemic lupus erythematosus;
KIRP	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	1.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.64	8.8	0.49	2.41e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.08e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10782582	0.609	rs10873797	chr1:76377191	G/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.02	-0.41	2.12e-11	Daytime sleep phenotypes;
KIRP	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg21419209	chr3:44054225	NA	-0.73	-9.07	-0.5	3.77e-17	Coronary artery disease;
KIRP	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-0.97	-15.59	-0.7	1.4e-38	Height;
KIRP	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.61	-6.77	-0.4	9.48e-11	DNA methylation (variation);
KIRP	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.37	0.43	2.66e-12	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23053573	chr1:26662567	AIM1L	0.46	6.22	0.37	2.12e-9	Parkinson's disease;
KIRP	cis	rs77633900	0.772	rs78181637	chr15:76672569	A/C	cg21673338	chr15:77095150	SCAPER	-0.66	-6.25	-0.37	1.76e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6723108	0.616	rs6752634	chr2:135407355	G/A	cg12500956	chr2:135428796	TMEM163	-0.42	-5.68	-0.34	3.78e-8	Type 2 diabetes;
KIRP	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg23102388	chr7:1867652	MAD1L1	-0.49	-6.57	-0.39	3.04e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs6572548	0.504	rs1956082	chr14:49665496	A/C	cg13583085	chr5:133707568	UBE2B	-0.61	-7.05	-0.41	1.75e-11	Subjective well-being;
KIRP	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.58	7.43	0.43	1.81e-12	Platelet distribution width;
KIRP	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.69	8.43	0.47	2.9e-15	Neutrophil percentage of white cells;
KIRP	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg11234688	chr2:1609660	NA	0.58	5.28	0.32	2.79e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-8.92	-0.49	1.12e-16	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg24009623	chr19:33667908	NA	0.49	6.47	0.38	5.38e-10	Bone properties (heel);
KIRP	cis	rs7424096	0.527	rs4670637	chr2:37164857	T/G	cg14987922	chr2:37194071	STRN	0.49	5.79	0.35	2.19e-8	High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	9.13	0.5	2.64e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs73787773	0.867	rs73227501	chr5:111488908	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.55	-4.99	-0.3	1.14e-6	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg07636037	chr3:49044803	WDR6	-0.58	-5.43	-0.33	1.34e-7	Menarche (age at onset);
KIRP	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg12826209	chr6:26865740	GUSBL1	0.66	5.01	0.3	1.03e-6	Breast cancer;
KIRP	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.26	26.34	0.86	1.52e-73	IgG glycosylation;
KIRP	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg16989719	chr2:238392110	NA	-0.56	-5.99	-0.36	7.27e-9	Prostate cancer;
KIRP	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg26338869	chr17:61819248	STRADA	0.48	6.03	0.36	5.96e-9	Prudent dietary pattern;
KIRP	trans	rs615632	0.516	rs13279794	chr8:9684014	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.68	0.39	1.58e-10	Neuroticism;
KIRP	cis	rs6707387	0.686	rs6435783	chr2:214526209	T/C	cg08319019	chr2:214017104	IKZF2	0.42	4.85	0.3	2.15e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.4	-5.89	-0.35	1.28e-8	Coronary artery disease;
KIRP	cis	rs9475752	0.793	rs2817573	chr6:56811124	G/A	cg22880620	chr6:56820808	BEND6;DST	-0.49	-5.11	-0.31	6.45e-7	Menarche (age at onset);
KIRP	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg08000102	chr2:233561755	GIGYF2	-0.51	-6.21	-0.37	2.2e-9	Coronary artery disease;
KIRP	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.81	0.45	1.66e-13	Neuroticism;
KIRP	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg05791153	chr7:19748676	TWISTNB	-0.67	-6.32	-0.37	1.19e-9	Thyroid stimulating hormone;
KIRP	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.65	-8.71	-0.49	4.4e-16	Colorectal cancer;
KIRP	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.2	0.61	4.25e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg26174226	chr8:58114915	NA	-0.58	-6.6	-0.39	2.5e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.65	12.15	0.61	6.45e-27	Blood protein levels;
KIRP	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg04995300	chr3:66848608	NA	-0.76	-9.24	-0.51	1.21e-17	Type 2 diabetes;
KIRP	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg05083358	chr7:2394359	EIF3B	-0.73	-7.08	-0.41	1.46e-11	Multiple sclerosis;
KIRP	trans	rs11671005	0.504	rs7257669	chr19:59064939	T/C	cg22037779	chr5:139682734	PFDN1	-0.52	-6.21	-0.37	2.21e-9	Mean platelet volume;
KIRP	trans	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg15655495	chr12:38532458	NA	0.26	5.05	0.31	8.76e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.46	6.9	0.4	4.35e-11	Tuberculosis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11770404	chr20:60962048	RPS21	-0.51	-6.22	-0.37	2.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.83	-11.68	-0.6	2.35e-25	Autism;
KIRP	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.7	-9.07	-0.5	3.92e-17	Paraoxonase activity;
KIRP	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg12549451	chr6:135224345	NA	0.44	5.2	0.31	4.2e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.2	0.37	2.36e-9	Lung cancer;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs10924309	0.889	rs10924308	chr1:245858131	C/T	cg00036263	chr1:245852353	KIF26B	-0.5	-6.59	-0.39	2.61e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	trans	rs1559473	0.531	rs6729133	chr2:222899169	T/C	cg14426312	chr9:71395063	FAM122A;PIP5K1B	0.49	6.03	0.36	6.09e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.64	5.37	0.32	1.85e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.39	7.29	0.42	4.17e-12	Erythrocyte sedimentation rate;
KIRP	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.38	-7.25	-0.42	5.43e-12	Educational attainment (years of education);
KIRP	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.26	0.42	5.13e-12	Retinal vascular caliber;
KIRP	cis	rs1448094	0.817	rs73176252	chr12:86347649	T/A	cg00310523	chr12:86230176	RASSF9	0.43	6.64	0.39	1.95e-10	Major depressive disorder;
KIRP	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg04906043	chr13:21280425	IL17D	-0.43	-5.06	-0.31	8.11e-7	Dental caries;
KIRP	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg11861562	chr11:117069780	TAGLN	0.4	4.93	0.3	1.5e-6	Blood protein levels;
KIRP	cis	rs9534288	0.700	rs4942466	chr13:46597190	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.38	-0.47	4.2e-15	Blood protein levels;
KIRP	cis	rs3779635	0.844	rs56330356	chr8:27278847	A/G	cg14221460	chr8:27183342	PTK2B	0.44	5.67	0.34	4e-8	Neuroticism;
KIRP	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs3818717	0.507	rs12940675	chr17:17651214	C/T	cg01246520	chr17:17644344	RAI1	-0.36	-5.83	-0.35	1.77e-8	Lymphocyte counts;
KIRP	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.76	11.07	0.58	2.26e-23	Heart rate;
KIRP	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.06	-0.31	8.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg02415014	chr8:143852576	LYNX1	-0.32	-5.07	-0.31	7.99e-7	Urinary tract infection frequency;
KIRP	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg25902810	chr10:99078978	FRAT1	0.59	7.22	0.42	6.43e-12	Monocyte count;
KIRP	cis	rs2274459	0.841	rs2281919	chr6:33663171	A/C	cg06253072	chr6:33679850	C6orf125	0.48	5.16	0.31	5.03e-7	Obesity (extreme);
KIRP	cis	rs76693355	0.512	rs12794618	chr11:120289699	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.07	-0.36	4.91e-9	Intraocular pressure;
KIRP	cis	rs7221595	0.825	rs8081260	chr17:3981937	T/C	cg09597638	chr17:3907349	NA	0.56	5.87	0.35	1.42e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	5.05e-11	Aortic root size;
KIRP	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.59	-7.81	-0.45	1.65e-13	Ulcerative colitis;
KIRP	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.59	-6.73	-0.39	1.17e-10	Hypospadias;
KIRP	cis	rs258892	0.841	rs266427	chr5:72130751	A/G	cg21869765	chr5:72125136	TNPO1	0.57	6.32	0.37	1.22e-9	Small cell lung carcinoma;
KIRP	cis	rs6838801	0.554	rs344122	chr4:77637502	G/T	cg17476223	chr4:77663285	SHROOM3	0.52	6.71	0.39	1.33e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg22974920	chr21:40686053	BRWD1	0.51	6.17	0.37	2.78e-9	Cognitive function;
KIRP	cis	rs12586317	0.576	rs10143690	chr14:35651945	T/A	cg07166546	chr14:35805898	NA	-0.28	-6.69	-0.39	1.48e-10	Psoriasis;
KIRP	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.68	8.22	0.46	1.19e-14	Type 2 diabetes;
KIRP	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg00361562	chr2:198649771	BOLL	-0.53	-5.19	-0.31	4.41e-7	Ulcerative colitis;
KIRP	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21659725	chr3:3221576	CRBN	-0.59	-7.11	-0.41	1.26e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.62	-7.97	-0.45	5.99e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.09	-0.61	9.76e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg03834567	chr2:218808745	TNS1	0.45	5.57	0.33	6.74e-8	Ulcerative colitis;
KIRP	cis	rs6929812	0.576	rs2064219	chr6:27376001	G/A	cg03332623	chr6:27441972	ZNF184	-0.37	-4.98	-0.3	1.18e-6	Neuroticism (multi-trait analysis);
KIRP	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg21573476	chr21:45109991	RRP1B	-0.57	-7.88	-0.45	1.05e-13	Mean corpuscular volume;
KIRP	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.65	7.24	0.42	5.81e-12	Breast cancer;
KIRP	trans	rs9399599	0.866	rs62435630	chr6:147630807	G/C	ch.20.23481851F	chr20:23533851	NA	0.49	6.08	0.36	4.5e-9	Plasma plasminogen activator levels;
KIRP	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.57	-7.7	-0.44	3.33e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs584438	0.780	rs2015561	chr17:38593294	A/G	cg09213124	chr17:38599508	IGFBP4	-0.29	-5.07	-0.31	7.83e-7	Height;
KIRP	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.51	7.12	0.41	1.22e-11	Mean corpuscular volume;
KIRP	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg07004394	chr14:106090750	NA	-0.43	-4.9	-0.3	1.71e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg10223061	chr2:219282414	VIL1	-0.29	-4.93	-0.3	1.52e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg26338869	chr17:61819248	STRADA	0.55	6.4	0.38	7.61e-10	Prudent dietary pattern;
KIRP	cis	rs13424612	1.000	rs10189996	chr2:240908800	G/A	cg01812947	chr2:240904978	NDUFA10	0.48	6.09	0.36	4.34e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs2299587	0.932	rs3780103	chr8:17819572	C/T	cg01800426	chr8:17659068	MTUS1	-0.41	-4.96	-0.3	1.3e-6	Economic and political preferences;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21225450	chr8:98656257	MTDH	0.48	6.28	0.37	1.55e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5.05e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72925845	0.577	rs618329	chr17:76429550	T/C	cg03830375	chr17:76426088	DNAH17	0.48	4.84	0.3	2.24e-6	Triglycerides;
KIRP	cis	rs9303542	0.625	rs4239209	chr17:46574317	T/A	cg04904318	chr17:46607828	HOXB1	0.42	5.09	0.31	7.11e-7	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg11266682	chr4:10021025	SLC2A9	0.4	5.04	0.31	9e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs3789045	0.560	rs3747634	chr1:204411063	C/T	cg17419461	chr1:204415978	PIK3C2B	0.89	8.3	0.47	7.05e-15	Educational attainment (college completion);
KIRP	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.79	7.63	0.44	5.12e-13	Diisocyanate-induced asthma;
KIRP	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.86	-9.27	-0.51	9.55e-18	Body mass index;
KIRP	cis	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg19847130	chr8:10466454	RP1L1	-0.33	-4.85	-0.3	2.15e-6	Neuroticism;
KIRP	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.5	6.25	0.37	1.84e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg23693289	chr8:27183097	PTK2B	0.55	7.02	0.41	2.13e-11	Neuroticism;
KIRP	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.74	0.6	1.41e-25	Alzheimer's disease;
KIRP	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg15934090	chr1:100435551	SLC35A3	0.5	6.31	0.37	1.32e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.59	-8.22	-0.46	1.18e-14	Mean corpuscular volume;
KIRP	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.72	7.0	0.41	2.49e-11	Lung function (FEV1/FVC);
KIRP	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.7	-6.9	-0.4	4.45e-11	Breast cancer;
KIRP	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.96	12.93	0.64	1.57e-29	Breast cancer;
KIRP	cis	rs3736485	0.966	rs10467924	chr15:51787579	A/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.42	-0.33	1.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.51	-0.38	4.24e-10	Morning vs. evening chronotype;
KIRP	cis	rs6973256	0.661	rs2550989	chr7:133500313	A/G	cg10665199	chr7:133106180	EXOC4	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.26	-7.19	-0.42	7.63e-12	Crohn's disease;
KIRP	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.57	-0.39	3.03e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.84	-0.4	6.08e-11	Morning vs. evening chronotype;
KIRP	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg26876637	chr1:152193138	HRNR	-0.77	-9.4	-0.51	3.87e-18	Atopic dermatitis;
KIRP	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg17885191	chr8:135476712	NA	0.53	6.14	0.36	3.31e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs6125597	0.967	rs6067030	chr20:47884403	C/T	cg03212862	chr20:47662828	CSE1L	-0.41	-5.24	-0.32	3.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg07166546	chr14:35805898	NA	0.28	6.45	0.38	5.83e-10	Psoriasis;
KIRP	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28489187	0.730	rs12140103	chr1:85849489	G/A	cg16011679	chr1:85725395	C1orf52	0.52	6.45	0.38	5.92e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg22138327	chr13:27999177	GTF3A	0.81	7.18	0.42	8.17e-12	Weight;
KIRP	cis	rs17453880	0.929	rs4958324	chr5:152022385	T/C	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg11130432	chr3:121712080	ILDR1	-0.47	-5.42	-0.33	1.44e-7	Multiple sclerosis;
KIRP	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg25547332	chr5:131281432	NA	0.46	5.32	0.32	2.32e-7	Life satisfaction;
KIRP	cis	rs2573652	0.723	rs4577068	chr15:100515959	T/A	cg09918751	chr15:100517450	ADAMTS17	-0.79	-12.54	-0.62	3.19e-28	Height;
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg09699651	chr6:150184138	LRP11	0.5	6.53	0.38	3.73e-10	Lung cancer;
KIRP	cis	rs12580194	0.593	rs57050414	chr12:55776926	G/A	cg19537932	chr12:55886519	OR6C68	-0.51	-6.48	-0.38	5e-10	Cancer;
KIRP	cis	rs10045504	0.502	rs72746031	chr5:38743161	G/A	cg15396434	chr5:38725168	NA	-0.96	-9.57	-0.52	1.21e-18	Night sleep phenotypes;
KIRP	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2191566	0.576	rs381888	chr19:44493005	C/T	cg18700516	chr19:44507157	ZNF230	0.42	4.92	0.3	1.58e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.72	-7.29	-0.42	4.21e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.44	-6.84	-0.4	6.11e-11	Major depressive disorder;
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.81	11.89	0.6	4.76e-26	Menarche (age at onset);
KIRP	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg08975724	chr8:8085496	FLJ10661	0.65	8.32	0.47	6.03e-15	Neuroticism;
KIRP	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg16586182	chr3:47516702	SCAP	-0.76	-10.86	-0.57	1.06e-22	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg09699651	chr6:150184138	LRP11	0.45	6.03	0.36	6.13e-9	Lung cancer;
KIRP	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.72	-8.91	-0.49	1.16e-16	Coronary artery disease;
KIRP	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.49	2.6e-16	Bladder cancer;
KIRP	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.4	0.33	1.54e-7	Neuroticism;
KIRP	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.67	-8.16	-0.46	1.77e-14	Neuroticism;
KIRP	trans	rs11199874	0.741	rs1125528	chr10:123019952	A/T	cg03091752	chr19:51221605	SHANK1	0.52	6.14	0.36	3.25e-9	Prostate cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg16211055	chr1:228594250	TRIM11	0.72	6.22	0.37	2.07e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.7e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.43	-7.89	-0.45	9.61e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.36	-5.21	-0.32	3.93e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg26384229	chr12:38710491	ALG10B	-0.5	-7.05	-0.41	1.75e-11	Morning vs. evening chronotype;
KIRP	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg20578329	chr17:80767326	TBCD	0.61	6.94	0.4	3.49e-11	Breast cancer;
KIRP	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.65	5.61	0.34	5.46e-8	Schizophrenia;
KIRP	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg17376030	chr22:41985996	PMM1	0.64	7.1	0.41	1.36e-11	Vitiligo;
KIRP	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg05562828	chr17:3906858	NA	-0.7	-13.78	-0.66	2.09e-32	Type 2 diabetes;
KIRP	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg25486957	chr4:152246857	NA	-0.41	-4.9	-0.3	1.75e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06634786	chr22:41940651	POLR3H	-0.43	-5.06	-0.31	8.32e-7	Vitiligo;
KIRP	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.61	8.92	0.49	1.12e-16	Mean corpuscular volume;
KIRP	cis	rs17057718	0.950	rs76645245	chr3:57140794	A/G	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.37	-4.95	-0.3	1.36e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4886920	0.672	rs11852322	chr15:78121487	C/T	cg10461261	chr15:78109450	NA	0.34	5.68	0.34	3.77e-8	Neuroticism;
KIRP	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg23173402	chr1:227635558	NA	0.88	6.07	0.36	4.89e-9	Major depressive disorder;
KIRP	trans	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg00405596	chr8:11794950	NA	-0.48	-6.54	-0.38	3.49e-10	Joint mobility (Beighton score);
KIRP	cis	rs4262150	0.883	rs12654450	chr5:152238850	T/C	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.46	6.24	0.37	1.92e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.68	7.29	0.42	4.34e-12	Lymphocyte counts;
KIRP	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-0.83	-10.06	-0.54	3.71e-20	Gut microbiome composition (summer);
KIRP	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg14228332	chr4:119757509	SEC24D	0.81	4.89	0.3	1.82e-6	Cannabis dependence symptom count;
KIRP	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.62	-6.73	-0.39	1.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.55	-6.28	-0.37	1.53e-9	Smoking behavior;
KIRP	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.39	-0.55	3.29e-21	Response to antipsychotic treatment;
KIRP	cis	rs6450176	0.633	rs25858	chr5:53339518	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.74	-9.16	-0.5	2.14e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg05347473	chr6:146136440	FBXO30	0.63	8.94	0.5	9.41e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs78320035	1.000	rs7552213	chr1:168137725	G/T	cg17113809	chr1:168148080	TIPRL	-0.66	-4.88	-0.3	1.9e-6	Red cell distribution width;
KIRP	cis	rs255758	0.813	rs406517	chr5:53322229	C/G	cg22592108	chr5:53304441	ARL15	0.45	5.87	0.35	1.44e-8	Rheumatoid arthritis;
KIRP	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg24644049	chr4:85504048	CDS1	0.71	6.09	0.36	4.34e-9	Skin colour saturation;
KIRP	cis	rs7224685	0.569	rs34377654	chr17:3990201	G/A	cg05562828	chr17:3906858	NA	0.56	5.88	0.35	1.35e-8	Type 2 diabetes;
KIRP	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	10.73	0.56	2.8e-22	Total body bone mineral density;
KIRP	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-7.33	-0.42	3.41e-12	Height;
KIRP	cis	rs9900972	0.877	rs8082025	chr17:76876464	C/T	cg00961940	chr17:76876995	TIMP2	0.53	6.76	0.4	9.99e-11	Obesity-related traits;
KIRP	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19623624	chr10:135278901	LOC619207	-0.53	-5.88	-0.35	1.3e-8	Systemic lupus erythematosus;
KIRP	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg00405596	chr8:11794950	NA	0.59	8.3	0.47	6.92e-15	Neuroticism;
KIRP	cis	rs10181042	0.565	rs3108630	chr2:61268160	A/G	cg18625361	chr2:61244694	PEX13;PUS10	0.41	5.32	0.32	2.33e-7	Crohn's disease;
KIRP	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg19016782	chr12:123741754	C12orf65	0.41	5.13	0.31	5.84e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-5.29	-0.32	2.71e-7	Neuroticism;
KIRP	cis	rs714027	0.566	rs4823076	chr22:30519414	G/A	cg27665648	chr22:30112403	NA	-0.45	-6.4	-0.38	7.73e-10	Lymphocyte counts;
KIRP	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs71277158	0.688	rs6762609	chr3:169916919	A/G	cg04067573	chr3:169899625	PHC3	-0.69	-6.52	-0.38	3.94e-10	Prostate cancer;
KIRP	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg19849509	chr2:175204996	NA	-0.53	-6.33	-0.37	1.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.85	0.3	2.19e-6	Bipolar disorder;
KIRP	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-15.09	-0.69	7.45e-37	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24859228	chr10:12391835	CAMK1D	0.54	6.46	0.38	5.46e-10	Smoking initiation;
KIRP	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg13289132	chr10:30722225	MAP3K8	-0.4	-5.04	-0.31	9.02e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs8060686	0.516	rs4640173	chr16:68163602	C/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-7.42	-0.43	1.89e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.73	-9.5	-0.52	1.98e-18	Childhood ear infection;
KIRP	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg13206674	chr6:150067644	NUP43	0.6	8.57	0.48	1.17e-15	Lung cancer;
KIRP	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.67	7.84	0.45	1.36e-13	Height;
KIRP	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-10.52	-0.56	1.27e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs4762326	0.584	rs10859857	chr12:95631556	G/C	cg07737802	chr12:95537812	FGD6	0.38	5.19	0.31	4.34e-7	Endometriosis;
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.71	9.38	0.51	4.4e-18	Longevity;
KIRP	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg03999872	chr20:62272968	STMN3	-0.55	-6.47	-0.38	5.3e-10	Atopic dermatitis;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.51	-8.92	-0.49	1.08e-16	Lymphocyte counts;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.44	6.41	0.38	7.24e-10	Lymphocyte counts;
KIRP	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.75	9.33	0.51	6.45e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.99	0.54	5.99e-20	Lung cancer in ever smokers;
KIRP	cis	rs9653442	0.564	rs13013594	chr2:100784190	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.1	-0.31	6.76e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23903597	chr17:61704154	MAP3K3	-0.59	-6.95	-0.41	3.24e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg01988459	chr11:68622903	NA	-0.38	-5.48	-0.33	1.03e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg08619932	chr19:49200058	FUT2	0.38	5.91	0.35	1.11e-8	Dietary macronutrient intake;
KIRP	cis	rs8018808	0.935	rs11627385	chr14:77936343	T/C	cg18872420	chr14:78023429	SPTLC2	0.37	5.4	0.33	1.54e-7	Myeloid white cell count;
KIRP	cis	rs6681460	0.899	rs1280280	chr1:67173903	G/A	cg13052034	chr1:66999238	SGIP1	0.36	5.1	0.31	6.74e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-0.78	-8.36	-0.47	4.7e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs1408799	0.830	rs13296454	chr9:12677181	G/A	cg05274944	chr9:12693694	TYRP1	0.35	4.98	0.3	1.22e-6	Eye color;Blue vs. green eyes;
KIRP	cis	rs300890	0.664	rs7690761	chr4:144208762	G/A	cg01719995	chr4:144104893	USP38	0.4	4.94	0.3	1.47e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs4901847	0.967	rs7143935	chr14:58558112	C/G	cg15908186	chr14:58618357	C14orf37	0.43	5.43	0.33	1.34e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03442064	chr6:41515050	FOXP4	0.65	6.05	0.36	5.41e-9	Lung function (FEV1);
KIRP	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.62	8.53	0.48	1.48e-15	Lymphocyte counts;
KIRP	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15664640	chr17:80829946	TBCD	0.79	10.08	0.54	3.11e-20	Breast cancer;
KIRP	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.51	0.48	1.68e-15	Motion sickness;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg21186296	chr8:27182909	PTK2B	0.53	6.64	0.39	2.04e-10	Neuroticism;
KIRP	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg16586182	chr3:47516702	SCAP	0.64	8.84	0.49	1.85e-16	Colorectal cancer;
KIRP	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg15556689	chr8:8085844	FLJ10661	0.61	7.97	0.45	5.88e-14	Neuroticism;
KIRP	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	3.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17065868	0.764	rs73190864	chr13:45162227	C/A	cg10246903	chr13:45222710	NA	0.74	6.64	0.39	2.02e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs7939886	0.920	rs11227598	chr11:56000451	G/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs4517514	0.509	rs4385851	chr11:89870750	C/T	cg06174606	chr11:89959870	NA	-0.54	-5.37	-0.32	1.79e-7	Trans fatty acid levels;
KIRP	cis	rs7822232	0.908	rs1127096	chr8:145140472	A/G	cg06495924	chr8:145149574	CYC1	-0.55	-4.87	-0.3	2.01e-6	Blood metabolite levels;
KIRP	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.91	11.37	0.59	2.38e-24	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1476670	0.545	rs2158822	chr1:44519447	C/G	cg09470012	chr1:44509516	NA	-0.33	-5.24	-0.32	3.49e-7	Eotaxin levels;
KIRP	cis	rs35740288	1.000	rs17577449	chr15:86297185	G/A	cg20737812	chr15:86336631	KLHL25	-0.37	-4.98	-0.3	1.2e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg02487422	chr3:49467188	NICN1	0.39	5.53	0.33	8.27e-8	Menarche (age at onset);
KIRP	cis	rs2151522	0.589	rs9388522	chr6:127120271	T/C	cg21431617	chr6:127135037	NA	0.33	5.92	0.35	1.06e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.17	0.31	4.96e-7	Life satisfaction;
KIRP	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.52	7.13	0.41	1.13e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.91	13.61	0.66	8.25e-32	Total body bone mineral density;
KIRP	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg04691961	chr3:161091175	C3orf57	-0.41	-6.28	-0.37	1.55e-9	Morning vs. evening chronotype;
KIRP	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.69	-7.62	-0.44	5.6e-13	Verbal memory performance (residualized delayed recall change);
KIRP	cis	rs9843304	0.529	rs61382471	chr3:149202160	G/A	cg08667024	chr3:149219783	TM4SF4	-0.43	-6.51	-0.38	4.22e-10	Gallstone disease;
KIRP	cis	rs282587	0.569	rs282564	chr13:113373953	G/T	cg04656015	chr13:113407548	ATP11A	-0.62	-7.02	-0.41	2.15e-11	Glycated hemoglobin levels;
KIRP	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.6	-6.81	-0.4	7.4e-11	Response to antineoplastic agents;
KIRP	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.5	7.23	0.42	6.08e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.75	10.7	0.56	3.52e-22	Itch intensity from mosquito bite;
KIRP	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-6.12	-0.36	3.59e-9	Aortic root size;
KIRP	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg07796016	chr1:152779584	LCE1C	-0.45	-5.76	-0.34	2.51e-8	Inflammatory skin disease;
KIRP	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg17652424	chr22:38574118	PLA2G6	-0.24	-4.9	-0.3	1.71e-6	Cutaneous nevi;
KIRP	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.73	8.5	0.48	1.8e-15	Gestational age at birth (maternal effect);
KIRP	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg02297831	chr4:17616191	MED28	-0.49	-6.08	-0.36	4.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15513391	chr7:117003789	ASZ1	-0.44	-7.06	-0.41	1.66e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17554472	chr22:41940697	POLR3H	0.65	6.67	0.39	1.65e-10	Vitiligo;
KIRP	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.59	7.17	0.42	8.83e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-0.76	-10.99	-0.57	3.99e-23	Intelligence (multi-trait analysis);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00170564	chr12:107714106	BTBD11	-0.47	-6.07	-0.36	4.83e-9	Neuroticism;
KIRP	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.63	-6.91	-0.4	4.11e-11	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-5.25	-0.32	3.32e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs7129556	0.690	rs648601	chr11:77586910	A/G	cg12586386	chr11:77299805	AQP11	0.4	5.26	0.32	3.14e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg24579218	chr15:68104479	NA	-0.58	-9.28	-0.51	9.37e-18	Restless legs syndrome;
KIRP	cis	rs6504622	0.537	rs197918	chr17:45003080	A/G	cg16759221	chr17:45003025	GOSR2	-0.41	-5.95	-0.35	9.14e-9	Orofacial clefts;
KIRP	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	cg12689670	chr1:183009347	LAMC1	0.4	4.96	0.3	1.33e-6	Colorectal cancer;
KIRP	trans	rs3128341	0.877	rs12117438	chr1:72822479	A/G	cg16299813	chr17:79632380	C17orf90;CCDC137	-0.34	-6.1	-0.36	4.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.91	10.34	0.55	4.79e-21	Corneal astigmatism;
KIRP	cis	rs6992848	0.719	rs11778452	chr8:141166097	A/G	cg13911501	chr8:141220320	TRAPPC9	0.41	4.85	0.3	2.21e-6	Response to amphetamines;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg02733842	chr7:1102375	C7orf50	0.59	6.02	0.36	6.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	14.56	0.68	4.65e-35	Chronic sinus infection;
KIRP	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.74	8.95	0.5	8.61e-17	Mammographic density (dense area);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04826355	chr4:2272570	ZFYVE28	-0.44	-6.16	-0.37	2.94e-9	Survival in pancreatic cancer;
KIRP	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg06365898	chr1:16533907	ARHGEF19	0.51	7.17	0.42	8.7e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6977660	0.660	rs28663574	chr7:19816905	G/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg00806126	chr19:22604979	ZNF98	-0.57	-6.14	-0.36	3.31e-9	Pain;
KIRP	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.61	8.16	0.46	1.77e-14	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2882667	0.858	rs11242444	chr5:138406379	T/A	cg04439458	chr5:138467593	SIL1	-0.51	-7.79	-0.44	1.85e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg26513180	chr16:89883248	FANCA	0.75	5.28	0.32	2.89e-7	Skin colour saturation;
KIRP	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	7.48	0.43	1.34e-12	Joint mobility (Beighton score);
KIRP	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg27147174	chr7:100797783	AP1S1	-0.73	-9.49	-0.52	2.06e-18	Life satisfaction;
KIRP	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.84	-0.4	6.4e-11	Aortic root size;
KIRP	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg01475377	chr6:109611718	NA	0.42	5.83	0.35	1.69e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg26876637	chr1:152193138	HRNR	0.71	9.66	0.52	6.38e-19	Atopic dermatitis;
KIRP	cis	rs8084125	0.935	rs7238336	chr18:74953540	A/G	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.64	9.17	0.5	1.95e-17	Colorectal cancer;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.77	11.32	0.59	3.32e-24	Menarche (age at onset);
KIRP	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg17764715	chr19:33622953	WDR88	0.67	8.41	0.47	3.39e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.06	-0.41	1.71e-11	Menopause (age at onset);
KIRP	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg26554054	chr8:600488	NA	0.71	5.39	0.33	1.63e-7	IgG glycosylation;
KIRP	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	15.69	0.71	6.23e-39	Ulcerative colitis;
KIRP	cis	rs1434579	0.897	rs8102733	chr19:44944448	A/G	cg15540054	chr19:45004280	ZNF180	0.49	5.26	0.32	3.11e-7	Tuberculosis;
KIRP	trans	rs1620921	0.967	rs783174	chr6:161171919	C/T	cg01090089	chr7:6570974	GRID2IP	0.39	6.09	0.36	4.26e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.73	0.34	2.91e-8	Platelet count;
KIRP	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02519504	chr16:3169384	ZNF205	0.51	6.63	0.39	2.08e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg15976283	chr2:238042351	NA	0.37	4.97	0.3	1.23e-6	Systemic lupus erythematosus;
KIRP	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg21360079	chr12:107162445	NA	-0.67	-9.59	-0.52	1.06e-18	Heart rate;
KIRP	cis	rs1448094	0.791	rs10863110	chr12:86328523	T/C	cg02569458	chr12:86230093	RASSF9	0.35	5.15	0.31	5.44e-7	Major depressive disorder;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg14541582	chr5:601475	NA	-0.58	-6.59	-0.39	2.73e-10	Obesity-related traits;
KIRP	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg08501292	chr6:25962987	TRIM38	0.78	5.32	0.32	2.39e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.8e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg10254082	chr7:997346	NA	0.47	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.75	-10.36	-0.55	4.08e-21	Hypospadias;
KIRP	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.88	8.59	0.48	1.02e-15	Eosinophil percentage of granulocytes;
KIRP	trans	rs1106684	1.000	rs12537441	chr7:131458199	G/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06307176	chr5:131281290	NA	0.57	6.51	0.38	4.14e-10	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.01	0.36	6.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12620999	0.941	rs13005377	chr2:238037759	T/C	cg15976283	chr2:238042351	NA	0.39	5.39	0.32	1.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg09699651	chr6:150184138	LRP11	0.47	6.43	0.38	6.62e-10	Lung cancer;
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg10253484	chr15:75165896	SCAMP2	0.43	4.99	0.3	1.12e-6	Breast cancer;
KIRP	cis	rs2241685	0.850	rs7582679	chr2:1942742	A/G	cg22511877	chr2:1942942	MYT1L	-0.65	-6.12	-0.36	3.74e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs7617773	0.502	rs6804828	chr3:48393556	A/G	cg11946769	chr3:48343235	NME6	0.54	6.57	0.39	2.99e-10	Coronary artery disease;
KIRP	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg04691961	chr3:161091175	C3orf57	-0.5	-7.57	-0.43	7.29e-13	Morning vs. evening chronotype;
KIRP	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.43	-5.11	-0.31	6.55e-7	Red cell distribution width;
KIRP	cis	rs6662572	1.000	rs55951835	chr1:46132442	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.62	0.34	5.09e-8	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.57	-6.31	-0.37	1.27e-9	Menarche (age at onset);
KIRP	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.08	-0.31	7.39e-7	Bipolar disorder;
KIRP	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.7	-0.39	1.39e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04700215	chr12:46320110	SFRS2IP	-0.41	-6.43	-0.38	6.53e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18718343	chr18:268166	THOC1	0.52	6.88	0.4	5.06e-11	Parkinson's disease;
KIRP	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg12718519	chr1:2058417	PRKCZ	-0.2	-5.51	-0.33	8.99e-8	Height;
KIRP	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg08501292	chr6:25962987	TRIM38	1.02	6.0	0.36	7.18e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg02151108	chr14:50098012	C14orf104	-0.44	-5.76	-0.34	2.47e-8	Carotid intima media thickness;
KIRP	cis	rs3105593	0.932	rs2414073	chr15:50850558	A/C	cg05456662	chr15:50716270	USP8	0.37	4.94	0.3	1.46e-6	QT interval;
KIRP	cis	rs3818717	0.539	rs12950737	chr17:17678573	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.44	-5.39	-0.32	1.67e-7	Lymphocyte counts;
KIRP	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.48	-5.96	-0.36	8.78e-9	Testicular germ cell tumor;
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.66	9.76	0.53	3.17e-19	Menarche (age at onset);
KIRP	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg19893067	chr17:80732956	TBCD	-0.36	-4.92	-0.3	1.61e-6	Glycated hemoglobin levels;
KIRP	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg20673091	chr1:2541236	MMEL1	-0.68	-10.63	-0.56	5.94e-22	Ulcerative colitis;
KIRP	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg05938607	chr10:60274200	BICC1	-0.46	-11.34	-0.59	2.91e-24	Refractive error;
KIRP	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-7.42	-0.43	1.9e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.51	-6.67	-0.39	1.69e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10073892	0.664	rs10071721	chr5:101900591	C/T	cg19774478	chr5:101632501	SLCO4C1	0.59	5.8	0.35	2e-8	Cognitive decline (age-related);
KIRP	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.49	-0.43	1.25e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1981331	0.867	rs76188425	chr21:48002207	C/T	cg17243659	chr21:48055224	PRMT2	1.03	6.16	0.37	2.9e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.44	8.41	0.47	3.44e-15	Coronary artery disease;
KIRP	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg06223162	chr1:101003688	GPR88	0.45	9.36	0.51	5.06e-18	Monocyte count;
KIRP	cis	rs35883536	0.708	rs34689792	chr1:101097753	A/G	cg06223162	chr1:101003688	GPR88	0.33	6.62	0.39	2.18e-10	Monocyte count;
KIRP	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.98	16.95	0.73	3.17e-43	Breast cancer;
KIRP	cis	rs3741151	0.686	rs2298469	chr11:73133030	T/C	cg17517138	chr11:73019481	ARHGEF17	0.65	5.64	0.34	4.71e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg12560992	chr17:57184187	TRIM37	0.7	6.76	0.4	9.88e-11	Cognitive test performance;
KIRP	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	6.14	0.36	3.37e-9	Systemic lupus erythematosus;
KIRP	cis	rs10875746	0.551	rs3185921	chr12:48734731	C/T	cg20731937	chr12:48336164	NA	0.42	5.11	0.31	6.36e-7	Longevity (90 years and older);
KIRP	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.62	-7.89	-0.45	9.79e-14	Obesity-related traits;
KIRP	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.68	8.96	0.5	8.21e-17	Motion sickness;
KIRP	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg16898833	chr6:26189333	HIST1H4D	0.7	5.57	0.33	6.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.48	-6.47	-0.38	5.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.59	9.25	0.51	1.1e-17	Mean corpuscular volume;
KIRP	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-7.45	-0.43	1.56e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs3857747	0.537	rs9690724	chr7:40443252	C/T	cg00420559	chr7:40367873	C7orf10	-0.38	-5.42	-0.33	1.43e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg13736514	chr6:26305472	NA	-0.72	-9.04	-0.5	4.86e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg19847130	chr8:10466454	RP1L1	-0.34	-4.89	-0.3	1.78e-6	Neuroticism;
KIRP	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	0.97	11.28	0.58	4.82e-24	Iron status biomarkers;
KIRP	cis	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg07460842	chr6:66804631	NA	-0.49	-6.14	-0.36	3.34e-9	Blood trace element (Cu levels);
KIRP	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg11494091	chr17:61959527	GH2	0.47	5.86	0.35	1.46e-8	Height;
KIRP	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.36	-0.47	4.71e-15	Coronary artery disease;
KIRP	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.95	0.64	1.4e-29	Bladder cancer;
KIRP	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26314531	chr2:26401878	FAM59B	0.48	5.0	0.3	1.08e-6	Gut microbiome composition (summer);
KIRP	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.67	0.71	7.37e-39	Chronic sinus infection;
KIRP	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg00343986	chr7:65444356	GUSB	0.41	4.9	0.3	1.71e-6	Aortic root size;
KIRP	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg00405596	chr8:11794950	NA	0.52	6.38	0.38	8.71e-10	Systolic blood pressure;
KIRP	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg18944383	chr4:111397179	ENPEP	-0.42	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg16141378	chr3:129829833	LOC729375	0.49	6.33	0.37	1.18e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg07005078	chr4:17578674	LAP3	0.42	4.87	0.3	1.98e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg25042112	chr7:64838748	ZNF92	-0.6	-6.42	-0.38	6.88e-10	Pain;
KIRP	cis	rs520865	0.693	rs477016	chr5:80337765	G/A	cg17330048	chr5:80257322	RASGRF2	-0.42	-6.14	-0.36	3.37e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg02297831	chr4:17616191	MED28	0.52	6.58	0.39	2.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	8.03	0.46	4.01e-14	Educational attainment;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg07414643	chr4:187882934	NA	0.39	5.12	0.31	6.16e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg10351095	chr21:47802916	PCNT	-0.44	-5.56	-0.33	7.18e-8	Testicular germ cell tumor;
KIRP	cis	rs4262150	0.883	rs11167597	chr5:152155205	T/A	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.94	-0.35	9.68e-9	Obesity-related traits;
KIRP	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.65	-0.44	4.45e-13	Body mass index;
KIRP	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06850241	chr22:41845214	NA	-0.43	-4.96	-0.3	1.33e-6	Vitiligo;
KIRP	cis	rs4704187	0.649	rs9942407	chr5:74540187	C/T	cg03227963	chr5:74354835	NA	0.42	6.13	0.36	3.54e-9	Response to amphetamines;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22655038	chr22:31477112	SMTN	-0.46	-6.28	-0.37	1.53e-9	Metabolic traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14984162	chr13:114776704	RASA3	0.46	6.46	0.38	5.59e-10	Survival in pancreatic cancer;
KIRP	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg09826364	chr7:158789723	NA	-0.42	-5.41	-0.33	1.47e-7	Facial morphology (factor 20);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04779720	chr1:11919376	NPPB	0.48	6.23	0.37	1.98e-9	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17489451	chr12:28410104	CCDC91	-0.43	-6.65	-0.39	1.9e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs17373728	0.526	rs7017326	chr8:76146574	C/T	cg07016329	chr8:76221503	NA	0.38	4.91	0.3	1.67e-6	Diabetic kidney disease;
KIRP	cis	rs6909279	0.901	rs1832727	chr6:151857713	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-6.22	-0.37	2.08e-9	Bone mineral density;
KIRP	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.41	-0.47	3.35e-15	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.95	16.65	0.73	3.3e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg22284058	chr8:142237359	SLC45A4	0.54	6.87	0.4	5.34e-11	Immature fraction of reticulocytes;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15259947	chr6:151187339	MTHFD1L	-0.62	-6.74	-0.39	1.09e-10	Menopause (age at onset);
KIRP	cis	rs4742903	1.000	rs1026181	chr9:106893334	A/G	cg14250997	chr9:106856677	SMC2	0.39	5.12	0.31	6.3e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs5753037	0.834	rs5763589	chr22:30295561	C/G	cg27665648	chr22:30112403	NA	0.39	5.48	0.33	1.04e-7	Type 1 diabetes;
KIRP	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg04727924	chr7:799746	HEATR2	-0.77	-7.84	-0.45	1.37e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-0.78	-9.18	-0.51	1.86e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.84	0.35	1.68e-8	Total cholesterol levels;
KIRP	cis	rs1440410	0.798	rs11100773	chr4:144054228	A/G	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.26e-10	Ischemic stroke;
KIRP	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.44	-0.38	6.19e-10	Systemic lupus erythematosus;
KIRP	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg05717871	chr11:638507	DRD4	-0.38	-5.53	-0.33	8.23e-8	Systemic lupus erythematosus;
KIRP	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg11031976	chr2:198649780	BOLL	-0.51	-4.95	-0.3	1.35e-6	Ulcerative colitis;
KIRP	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08677398	chr8:58056175	NA	0.61	4.86	0.3	2.05e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.49	-6.63	-0.39	2.15e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-4.97	-0.3	1.24e-6	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.88	14.83	0.69	5.68e-36	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg00852783	chr1:26633632	UBXN11	0.53	7.55	0.43	8.74e-13	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.48	0.38	5.07e-10	Platelet count;
KIRP	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	12.13	0.61	7.65e-27	Blood protein levels;
KIRP	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg18441811	chr11:71824068	C11orf51	-0.82	-5.5	-0.33	9.51e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg00319359	chr11:70116639	PPFIA1	0.66	6.46	0.38	5.58e-10	Coronary artery disease;
KIRP	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg09264619	chr17:80180166	NA	-0.52	-6.0	-0.36	6.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.65	-0.34	4.46e-8	Aortic root size;
KIRP	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.76	-12.79	-0.63	4.75e-29	Calcium levels;
KIRP	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.88	-0.4	5e-11	Neuroticism;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15317837	chr10:1033901	GTPBP4	0.5	6.08	0.36	4.6e-9	DNA methylation (variation);
KIRP	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-18.81	-0.77	1.58e-49	Height;
KIRP	cis	rs9653442	0.564	rs4851253	chr2:100762786	T/G	cg22139774	chr2:100720529	AFF3	-0.3	-5.07	-0.31	7.69e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-7.74	-0.44	2.65e-13	Bipolar disorder;
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.5	-6.45	-0.38	5.76e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs56146971	0.714	rs79810056	chr14:91852929	A/G	cg10511902	chr14:91842949	CCDC88C	0.53	5.91	0.35	1.11e-8	Alzheimer disease and age of onset;
KIRP	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.58	-7.1	-0.41	1.33e-11	Alzheimer's disease (late onset);
KIRP	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg11815991	chr20:30193098	ID1	-0.47	-4.85	-0.3	2.16e-6	Mean corpuscular hemoglobin;
KIRP	trans	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg10756647	chr7:56101905	PSPH	1.09	8.55	0.48	1.29e-15	Diabetic kidney disease;
KIRP	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg10523679	chr1:76189770	ACADM	0.51	7.42	0.43	1.93e-12	Daytime sleep phenotypes;
KIRP	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg05347473	chr6:146136440	FBXO30	-0.63	-9.21	-0.51	1.44e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14077144	chr6:24665159	TTRAP	0.5	6.92	0.4	3.88e-11	Survival in pancreatic cancer;
KIRP	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg24826892	chr11:71159390	DHCR7	0.43	4.92	0.3	1.6e-6	Vitamin D levels;
KIRP	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.64	8.0	0.45	4.88e-14	Cognitive test performance;
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg16590910	chr6:42928470	GNMT	0.46	6.43	0.38	6.56e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg00405596	chr8:11794950	NA	0.54	7.38	0.43	2.36e-12	Mood instability;
KIRP	cis	rs12190007	0.508	rs7452203	chr6:169741858	C/T	cg16388071	chr6:169726476	NA	-0.45	-6.53	-0.38	3.7e-10	Obesity-related traits;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.1	-0.31	6.78e-7	Life satisfaction;
KIRP	cis	rs12936587	0.777	rs12951347	chr17:17534513	C/G	cg01246520	chr17:17644344	RAI1	-0.38	-6.13	-0.36	3.41e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg04998671	chr14:104000505	TRMT61A	-0.48	-5.68	-0.34	3.74e-8	Coronary artery disease;
KIRP	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg06740227	chr12:86229804	RASSF9	-0.43	-5.45	-0.33	1.19e-7	Major depressive disorder;
KIRP	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg23594656	chr7:65796392	TPST1	0.51	7.89	0.45	9.9e-14	Aortic root size;
KIRP	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.53	6.82	0.4	6.85e-11	Coronary heart disease;
KIRP	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg08076091	chr2:203926405	NBEAL1	0.92	9.52	0.52	1.69e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11997175	0.967	rs11993169	chr8:33738004	G/T	ch.8.33884649F	chr8:33765107	NA	0.53	6.57	0.39	2.92e-10	Body mass index;
KIRP	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.64	0.52	7.12e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.59	-6.85	-0.4	5.8e-11	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg10254082	chr7:997346	NA	0.48	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.53	6.62	0.39	2.23e-10	Body mass index;
KIRP	cis	rs66573146	1.000	rs6812391	chr4:6963893	G/A	cg00086871	chr4:6988644	TBC1D14	0.88	5.07	0.31	7.94e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg00277334	chr10:82204260	NA	-0.44	-4.89	-0.3	1.79e-6	Post bronchodilator FEV1;
KIRP	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.7	5.75	0.34	2.61e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg02725872	chr8:58115012	NA	-0.53	-6.07	-0.36	4.86e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.65	9.09	0.5	3.41e-17	Morning vs. evening chronotype;
KIRP	cis	rs42648	0.642	rs11771963	chr7:89887587	G/T	cg25739043	chr7:89950458	NA	-0.41	-6.57	-0.39	2.95e-10	Homocysteine levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg22753607	chr9:37120306	ZCCHC7	0.8	7.14	0.41	1.05e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg11815991	chr20:30193098	ID1	-0.5	-5.1	-0.31	6.75e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs6838801	0.927	rs4422437	chr4:77514866	G/T	cg17476223	chr4:77663285	SHROOM3	-0.54	-7.61	-0.44	5.82e-13	Cleft lip with or without cleft palate;
KIRP	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-4.99	-0.3	1.14e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs4523957	0.583	rs2641438	chr17:2017786	C/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.7	8.73	0.49	3.91e-16	Platelet count;
KIRP	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.88	0.4	4.92e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1270639	0.778	rs1638021	chr7:157438037	A/G	cg13357408	chr7:157437802	PTPRN2	0.59	5.81	0.35	1.93e-8	Colorectal cancer;
KIRP	cis	rs6545883	0.894	rs12615783	chr2:61440947	T/C	cg15711740	chr2:61764176	XPO1	0.57	7.39	0.43	2.36e-12	Tuberculosis;
KIRP	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg08668510	chr10:1095578	IDI1	0.77	5.26	0.32	3.17e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.65	9.66	0.52	6.54e-19	Colorectal cancer;
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18252515	chr7:66147081	NA	-0.46	-5.43	-0.33	1.33e-7	Aortic root size;
KIRP	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg15358701	chr1:161410459	NA	-0.62	-5.78	-0.35	2.2e-8	Rheumatoid arthritis;
KIRP	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.7	10.91	0.57	7.59e-23	Resting heart rate;
KIRP	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg16482183	chr6:26056742	HIST1H1C	0.39	5.17	0.31	4.85e-7	Schizophrenia;
KIRP	cis	rs4332428	1.000	rs4268415	chr10:4983590	C/T	cg19648686	chr10:5044992	AKR1C2	-0.66	-6.32	-0.37	1.23e-9	Height;
KIRP	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg02153584	chr22:29168773	CCDC117	0.57	5.73	0.34	2.92e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.37	0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22496380	chr5:211416	CCDC127	-1.07	-6.67	-0.39	1.63e-10	Breast cancer;
KIRP	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.88	12.81	0.63	4.08e-29	Mean platelet volume;
KIRP	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.46	-5.41	-0.33	1.49e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-4.94	-0.3	1.43e-6	Bipolar disorder and schizophrenia;
KIRP	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-1.06	-10.16	-0.54	1.81e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.45	6.08	0.36	4.6e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2494663	0.610	rs11265049	chr1:154059944	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.34	-4.98	-0.3	1.21e-6	Mean platelet volume;
KIRP	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	1.06	19.62	0.78	3.25e-52	Migraine;
KIRP	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.73	-9.61	-0.52	8.85e-19	Glaucoma (primary open-angle);
KIRP	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.65	12.26	0.62	2.69e-27	Blood protein levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02303361	chr19:47354240	AP2S1	0.57	6.24	0.37	1.95e-9	Lung cancer in ever smokers;
KIRP	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg07870213	chr5:140052090	DND1	0.63	7.65	0.44	4.51e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	1.1	21.52	0.81	1.69e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg05340658	chr4:99064831	C4orf37	0.58	7.08	0.41	1.51e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg18306943	chr3:40428807	ENTPD3	0.45	5.91	0.35	1.12e-8	Renal cell carcinoma;
KIRP	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.61e-11	Bipolar disorder;
KIRP	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.52	7.24	0.42	5.59e-12	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.78	-11.18	-0.58	9.48e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.63	-7.85	-0.45	1.31e-13	Dental caries;
KIRP	cis	rs9815354	0.812	rs73071356	chr3:41829486	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.79	8.7	0.49	4.84e-16	High light scatter reticulocyte count;
KIRP	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs4671458	1.000	rs115634863	chr2:63328774	C/T	cg17519650	chr2:63277830	OTX1	-0.6	-5.78	-0.35	2.23e-8	Subjective well-being;
KIRP	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg07382826	chr16:28625726	SULT1A1	0.47	5.49	0.33	9.99e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4789693	0.938	rs8078595	chr17:80426988	G/T	cg04308225	chr17:80449738	NA	0.53	5.56	0.33	6.95e-8	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs9469913	0.604	rs2814948	chr6:34653413	G/A	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.28	-0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg03245229	chr8:26436527	DPYSL2	0.46	6.06	0.36	5e-9	Inflammatory biomarkers;
KIRP	cis	rs4006360	0.553	rs71383383	chr17:39318172	T/A	cg16985667	chr17:39306289	KRTAP4-5	0.46	6.1	0.36	4.01e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.71	-9.91	-0.53	1.08e-19	Menarche (age at onset);
KIRP	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-6.53	-0.38	3.7e-10	Skin colour saturation;
KIRP	cis	rs2274273	0.773	rs28430823	chr14:55816560	C/G	cg04306507	chr14:55594613	LGALS3	0.43	6.56	0.39	3.14e-10	Protein biomarker;
KIRP	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.4	0.38	7.98e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.73	-8.45	-0.47	2.49e-15	Body mass index;
KIRP	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.49e-8	Blood protein levels;
KIRP	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg00241281	chr14:105779794	PACS2	0.34	5.08	0.31	7.37e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.8	7.61	0.44	5.91e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10267417	0.535	rs6946403	chr7:19861549	C/T	cg05791153	chr7:19748676	TWISTNB	0.51	4.93	0.3	1.49e-6	Night sleep phenotypes;
KIRP	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.37	-0.32	1.86e-7	Neuroticism;
KIRP	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg04306507	chr14:55594613	LGALS3	0.52	8.15	0.46	1.91e-14	Protein biomarker;
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	cis	rs41563	0.593	rs6466034	chr7:104598750	T/C	cg04380332	chr7:105027541	SRPK2	-0.47	-7.13	-0.41	1.1e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8014252	0.614	rs60251828	chr14:71061451	C/G	cg11204974	chr14:71022665	NA	-0.74	-7.31	-0.42	3.65e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg18225595	chr11:63971243	STIP1	0.57	4.93	0.3	1.54e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4664293	0.967	rs4665103	chr2:160532312	G/A	cg08347373	chr2:160653686	CD302	-0.43	-6.12	-0.36	3.7e-9	Monocyte percentage of white cells;
KIRP	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.42e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs73200209	0.744	rs11616043	chr12:116559922	T/C	cg01776926	chr12:116560359	MED13L	-0.54	-6.03	-0.36	5.82e-9	Total body bone mineral density;
KIRP	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg26727032	chr16:67993705	SLC12A4	-0.6	-5.58	-0.34	6.27e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	trans	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	9.18	0.51	1.77e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.44	0.47	2.72e-15	Lung cancer in ever smokers;
KIRP	cis	rs1829883	0.835	rs2963576	chr5:98781722	A/G	cg08333243	chr5:99726346	NA	-0.41	-5.31	-0.32	2.47e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs17221829	0.645	rs4002142	chr11:89374013	G/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-7.29	-0.42	4.24e-12	Hemoglobin concentration;
KIRP	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg12310025	chr6:25882481	NA	0.38	4.97	0.3	1.27e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.43	-5.55	-0.33	7.44e-8	Aortic root size;
KIRP	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.42	5.32	0.32	2.39e-7	Response to temozolomide;
KIRP	trans	rs12517041	1.000	rs6859293	chr5:23312935	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.91	-0.45	8.59e-14	Calcium levels;
KIRP	cis	rs1440410	0.830	rs10519678	chr4:144182073	C/T	cg01719995	chr4:144104893	USP38	0.4	5.2	0.31	4.18e-7	Ischemic stroke;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16248795	chr3:182698009	DCUN1D1	0.55	6.79	0.4	8.47e-11	Parkinson's disease;
KIRP	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg22875332	chr1:76189707	ACADM	-0.35	-5.16	-0.31	5.02e-7	Daytime sleep phenotypes;
KIRP	trans	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg07264238	chr17:33474376	UNC45B	0.49	6.29	0.37	1.45e-9	Breast cancer;
KIRP	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.55	-7.37	-0.43	2.51e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08728297	chr11:72853526	FCHSD2	-0.47	-6.14	-0.36	3.37e-9	Myopia;
KIRP	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.57	8.02	0.46	4.35e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6110278	0.685	rs68026476	chr20:14402541	A/G	cg17696268	chr20:14319035	FLRT3;MACROD2	-0.36	-5.02	-0.3	1e-6	Mean platelet volume;
KIRP	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.58e-33	Intelligence (multi-trait analysis);
KIRP	trans	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg06521331	chr12:34319734	NA	-0.52	-6.48	-0.38	4.86e-10	Heart rate;
KIRP	cis	rs10426930	0.607	rs56251289	chr19:5042732	C/A	cg18473234	chr19:5097819	KDM4B	0.57	6.34	0.37	1.12e-9	Monocyte percentage of white cells;
KIRP	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	1.08	22.9	0.83	6.45e-63	Parkinson's disease;
KIRP	cis	rs600550	0.528	rs17154527	chr11:59828070	A/G	cg02771260	chr11:59836817	MS4A3	0.45	4.99	0.3	1.15e-6	Lipoprotein-associated phospholipase A2 activity and mass;
KIRP	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.7	7.82	0.45	1.59e-13	Cholesterol, total;
KIRP	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-6.29	-0.37	1.42e-9	Bone properties (heel);
KIRP	cis	rs754133	0.964	rs4759318	chr12:54420098	C/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.28	5.76	0.34	2.47e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
KIRP	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg08890418	chr1:21044141	KIF17	0.33	4.97	0.3	1.27e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.79	0.35	2.13e-8	Bipolar disorder;
KIRP	cis	rs13424612	1.000	rs66534347	chr2:240899346	G/A	cg01812947	chr2:240904978	NDUFA10	0.41	5.27	0.32	2.97e-7	Odorant perception (isobutyraldehyde);
KIRP	cis	rs7666738	0.546	rs28444809	chr4:98916934	C/T	cg05340658	chr4:99064831	C4orf37	0.67	7.77	0.44	2.14e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.62	-7.33	-0.42	3.29e-12	Body mass index;
KIRP	cis	rs9596863	0.898	rs6561746	chr13:54358368	T/C	ch.13.53330881F	chr13:54432880	NA	0.53	5.23	0.32	3.66e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9393813	0.509	rs10946915	chr6:27377830	A/G	cg03332623	chr6:27441972	ZNF184	-0.37	-5.19	-0.31	4.31e-7	Bipolar disorder;
KIRP	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.58	7.91	0.45	8.8e-14	Prostate cancer;
KIRP	cis	rs2708977	0.549	rs2678381	chr2:97441266	C/T	cg26665480	chr2:98280029	ACTR1B	-0.46	-5.45	-0.33	1.24e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9309473	0.898	rs10201159	chr2:73858965	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.27	-0.32	2.97e-7	Metabolite levels;
KIRP	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.85	0.49	1.79e-16	Motion sickness;
KIRP	cis	rs17065868	0.803	rs7320306	chr13:45197429	A/G	cg10246903	chr13:45222710	NA	0.55	5.89	0.35	1.25e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	0.64	5.84	0.35	1.69e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg10950524	chr7:2139216	MAD1L1	0.33	5.29	0.32	2.67e-7	Schizophrenia;
KIRP	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.5	6.35	0.38	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.71	9.97	0.54	6.76e-20	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-1.0	-15.49	-0.7	3.08e-38	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.97	0.5	7.55e-17	Bipolar disorder;
KIRP	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg21775007	chr8:11205619	TDH	-0.53	-6.72	-0.39	1.22e-10	Neuroticism;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.56	-7.63	-0.44	5.13e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg27490568	chr2:178487706	NA	0.52	7.07	0.41	1.64e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02006288	chr4:154074145	TRIM2	0.49	6.43	0.38	6.72e-10	Parkinson's disease;
KIRP	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-5.35	-0.32	2.02e-7	Total body bone mineral density;
KIRP	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg02640540	chr1:67518911	SLC35D1	0.51	4.95	0.3	1.35e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.88	-14.0	-0.67	3.75e-33	Urate levels in lean individuals;
KIRP	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.59	7.16	0.42	9.34e-12	Schizophrenia;
KIRP	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.71	7.53	0.43	9.65e-13	Lymphocyte counts;
KIRP	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg21252483	chr19:49399788	TULP2	-0.47	-6.19	-0.37	2.5e-9	Red cell distribution width;
KIRP	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg02820901	chr13:113351484	ATP11A	0.74	6.84	0.4	6.06e-11	Glycated hemoglobin levels;
KIRP	cis	rs11676676	0.593	rs6723609	chr2:109775101	C/T	cg01741688	chr2:109781768	SH3RF3	-0.49	-4.98	-0.3	1.2e-6	Pediatric bone mineral density (spine);
KIRP	cis	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg19847130	chr8:10466454	RP1L1	0.37	5.25	0.32	3.35e-7	Triglycerides;
KIRP	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg26681399	chr22:41777847	TEF	-0.54	-5.46	-0.33	1.17e-7	Vitiligo;
KIRP	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg19847130	chr8:10466454	RP1L1	0.34	5.19	0.31	4.48e-7	Retinal vascular caliber;
KIRP	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.7	10.18	0.54	1.52e-20	Lymphocyte counts;
KIRP	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-13.54	-0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs12043259	0.730	rs57128821	chr1:204813900	G/A	cg11485465	chr5:54518469	NA	0.38	6.58	0.39	2.78e-10	Addiction;
KIRP	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg00225070	chr15:80189496	MTHFS	0.44	5.14	0.31	5.65e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	0.54	6.46	0.38	5.45e-10	Prudent dietary pattern;
KIRP	cis	rs7638995	0.878	rs9844987	chr3:69170012	T/C	cg26574240	chr3:69171822	LMOD3	-0.62	-6.8	-0.4	8.03e-11	Alzheimer's disease (late onset);
KIRP	cis	rs2916247	0.865	rs7834277	chr8:93110255	A/G	cg10183463	chr8:93005414	RUNX1T1	0.47	6.13	0.36	3.45e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.44	0.52	2.91e-18	Bipolar disorder;
KIRP	cis	rs240764	0.658	rs7768210	chr6:101261494	C/T	cg09795085	chr6:101329169	ASCC3	0.49	5.97	0.36	8.37e-9	Neuroticism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10769393	chr19:2819754	ZNF554	0.49	6.05	0.36	5.34e-9	Myopia (pathological);
KIRP	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg03342759	chr3:160939853	NMD3	-0.49	-6.35	-0.38	1.02e-9	Morning vs. evening chronotype;
KIRP	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg18477163	chr1:228402036	OBSCN	0.35	6.62	0.39	2.29e-10	Diastolic blood pressure;
KIRP	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.57	7.18	0.42	8.26e-12	Obesity-related traits;
KIRP	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.67	-0.39	1.7e-10	Neuroticism;
KIRP	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.16	0.58	1.18e-23	Bipolar disorder;
KIRP	cis	rs1999930	0.562	rs13214585	chr6:116235646	C/T	cg15226275	chr6:116381976	FRK	0.25	5.31	0.32	2.43e-7	Age-related macular degeneration;
KIRP	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg12549451	chr6:135224345	NA	0.42	5.38	0.32	1.77e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg20887711	chr4:1340912	KIAA1530	0.79	9.28	0.51	9.31e-18	Longevity;
KIRP	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-7.58	-0.44	6.95e-13	Vitiligo;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09028132	chr20:37078135	SNORA60;SNHG11	0.58	6.93	0.4	3.64e-11	Interleukin-4 levels;
KIRP	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.67	-10.14	-0.54	2.1e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17554472	chr22:41940697	POLR3H	-0.7	-7.05	-0.41	1.79e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.48	-5.99	-0.36	7.49e-9	Longevity;Endometriosis;
KIRP	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.29	7.9	0.45	9.15e-14	Crohn's disease;
KIRP	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg16512390	chr1:228756714	NA	0.39	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-5.59	-0.34	5.98e-8	Metabolite levels;
KIRP	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.44	-0.52	3.05e-18	Chronic sinus infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12402495	chr1:154192844	C1orf43;UBAP2L	0.55	6.66	0.39	1.74e-10	Smoking initiation;
KIRP	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg09238746	chr17:78121135	EIF4A3	-0.44	-5.55	-0.33	7.53e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg11783602	chr8:55087084	NA	-0.57	-7.07	-0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.53	-0.38	3.66e-10	Aortic root size;
KIRP	cis	rs12367572	0.641	rs7964973	chr12:45402893	T/C	cg04608330	chr12:45269318	NELL2	-0.39	-5.19	-0.31	4.43e-7	Gut microbiome composition (summer);
KIRP	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg16898833	chr6:26189333	HIST1H4D	0.73	5.34	0.32	2.09e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg22349387	chr12:9600060	DDX12	-0.35	-5.15	-0.31	5.3e-7	Breast size;
KIRP	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg02376097	chr19:46275166	DMPK	0.48	6.54	0.38	3.59e-10	Coronary artery disease;
KIRP	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-7.61	-0.44	5.67e-13	Morning vs. evening chronotype;
KIRP	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	8.13	0.46	2.15e-14	Educational attainment;
KIRP	cis	rs882732	1.000	rs12586297	chr14:95032394	G/A	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.53	-0.33	8.1e-8	Blood protein levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12593849	chr1:28150710	STX12	0.44	6.45	0.38	6.02e-10	Interleukin-4 levels;
KIRP	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.91	-13.26	-0.65	1.25e-30	Tonsillectomy;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24923219	chr11:94964236	SESN3	-0.42	-6.05	-0.36	5.46e-9	Metabolic traits;
KIRP	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.6	0.44	6.31e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.75	-11.4	-0.59	1.83e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6499755	0.965	rs2042448	chr16:55352063	G/A	cg05099576	chr16:55362342	IRX6	0.28	5.83	0.35	1.78e-8	Hypospadias;
KIRP	cis	rs7033996	1.000	rs7033996	chr9:35927977	T/C	cg00918944	chr9:35908117	LOC158376	0.35	4.98	0.3	1.2e-6	Urate levels (BMI interaction);
KIRP	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.29	7.83	0.45	1.48e-13	Crohn's disease;
KIRP	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.59	7.72	0.44	2.88e-13	Height;
KIRP	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.85	6.73	0.39	1.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs714031	0.934	rs5750870	chr22:40067640	G/A	cg21377881	chr22:40064566	CACNA1I	-0.68	-10.54	-0.56	1.14e-21	Schizophrenia;
KIRP	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg18646521	chr2:111875858	NA	0.37	5.12	0.31	6.06e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs17428704	0.571	rs16903421	chr5:14367568	C/T	cg26595256	chr5:14380529	TRIO	0.88	6.86	0.4	5.57e-11	Electroencephalogram traits;
KIRP	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-10.56	-0.56	9.9e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg16083429	chr3:49237500	CCDC36	0.4	5.29	0.32	2.74e-7	Menarche (age at onset);
KIRP	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.78	7.24	0.42	5.81e-12	Mean platelet volume;
KIRP	cis	rs9898058	0.769	rs12150425	chr17:47913932	C/T	cg06375292	chr17:47786311	SLC35B1	-0.73	-5.67	-0.34	4.06e-8	Milk allergy;
KIRP	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.08	0.31	7.51e-7	Smoking behavior;
KIRP	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.84	-12.49	-0.62	4.66e-28	Strep throat;
KIRP	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg01620082	chr3:125678407	NA	-1.19	-7.53	-0.43	9.43e-13	Depression;
KIRP	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-7.65	-0.44	4.59e-13	Longevity;
KIRP	cis	rs8054556	1.000	rs7204797	chr16:29968015	C/T	cg06326092	chr16:30034487	C16orf92	0.36	5.12	0.31	6.24e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.88e-13	Bipolar disorder;
KIRP	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.88	-14.11	-0.67	1.58e-33	Urate levels in lean individuals;
KIRP	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.5	0.74	4.43e-45	Chronic sinus infection;
KIRP	cis	rs1403694	1.000	rs1648716	chr3:186439529	C/T	cg12454167	chr3:186435060	KNG1	0.49	8.64	0.48	7.01e-16	Blood protein levels;
KIRP	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	6.87	0.4	5.16e-11	Menarche (age at onset);
KIRP	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.47	7.65	0.44	4.61e-13	Lung cancer;
KIRP	cis	rs16958440	0.581	rs56395942	chr18:44672299	G/T	cg17192377	chr18:44677553	HDHD2	0.65	6.32	0.37	1.22e-9	Sitting height ratio;
KIRP	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18932078	chr1:2524107	MMEL1	0.45	6.22	0.37	2.13e-9	Ulcerative colitis;
KIRP	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23281280	chr6:28129359	ZNF389	0.48	5.23	0.32	3.61e-7	Depression;
KIRP	cis	rs7809950	0.822	rs2712228	chr7:107300340	A/C	cg23024343	chr7:107201750	COG5	0.42	6.36	0.38	9.85e-10	Coronary artery disease;
KIRP	cis	rs648044	0.520	rs500629	chr11:114045560	G/T	cg01914181	chr11:114070210	ZBTB16	0.52	6.35	0.38	1e-9	Non-glioblastoma glioma;
KIRP	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg05775895	chr3:12838266	CAND2	0.45	7.44	0.43	1.68e-12	QRS complex (12-leadsum);
KIRP	cis	rs3736594	1.000	rs12477908	chr2:27987046	A/C	cg27432699	chr2:27873401	GPN1	-0.53	-6.93	-0.4	3.58e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.7	-13.13	-0.64	3.37e-30	White blood cell count (basophil);
KIRP	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg10755058	chr3:40428713	ENTPD3	0.44	6.24	0.37	1.95e-9	Renal cell carcinoma;
KIRP	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.72	9.62	0.52	8.28e-19	Crohn's disease;
KIRP	cis	rs8028313	0.504	rs2899730	chr15:68172520	G/T	cg24579218	chr15:68104479	NA	0.5	7.22	0.42	6.62e-12	Obesity;
KIRP	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.73	-10.64	-0.56	5.47e-22	Oral cavity cancer;
KIRP	cis	rs7106204	0.534	rs76997388	chr11:24272878	C/G	ch.11.24196551F	chr11:24239977	NA	0.71	4.93	0.3	1.52e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4700695	0.614	rs2561241	chr5:65206565	C/T	cg21114390	chr5:65439923	SFRS12	0.52	4.97	0.3	1.24e-6	Facial morphology (factor 19);
KIRP	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg17366294	chr4:99064904	C4orf37	-0.37	-5.17	-0.31	4.82e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg08975724	chr8:8085496	FLJ10661	-0.53	-7.38	-0.43	2.47e-12	Myopia (pathological);
KIRP	trans	rs1422110	0.796	rs2909865	chr5:85507394	T/C	cg01787110	chr1:109008453	NBPF6	0.66	7.74	0.44	2.58e-13	Attention function in attention deficit hyperactive disorder;
KIRP	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg18944383	chr4:111397179	ENPEP	0.52	9.1	0.5	3.07e-17	Height;
KIRP	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.35	-4.89	-0.3	1.85e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18252515	chr7:66147081	NA	0.44	5.17	0.31	4.84e-7	Aortic root size;
KIRP	cis	rs7618501	0.699	rs1062633	chr3:49924940	T/C	cg24110177	chr3:50126178	RBM5	-0.67	-9.1	-0.5	3.28e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg07843065	chr1:150265600	MRPS21	0.4	5.45	0.33	1.25e-7	Migraine;
KIRP	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.41	0.59	1.74e-24	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20549688	chr15:59949781	GTF2A2	0.45	6.31	0.37	1.32e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4774899	0.934	rs12912810	chr15:57488378	G/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.39	-0.32	1.65e-7	Urinary tract infection frequency;
KIRP	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg10189774	chr4:17578691	LAP3	-0.47	-5.52	-0.33	8.7e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg03289416	chr15:75166202	SCAMP2	0.41	5.48	0.33	1.06e-7	Breast cancer;
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg21734707	chr17:3908241	ZZEF1	0.59	8.7	0.48	4.99e-16	Type 2 diabetes;
KIRP	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg16506815	chr2:162101123	NA	0.46	5.51	0.33	9.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.31	0.47	6.38e-15	Personality dimensions;
KIRP	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg25019033	chr10:957182	NA	-0.62	-6.84	-0.4	6.18e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.83	0.35	1.74e-8	Lung cancer;
KIRP	cis	rs253959	0.842	rs10079037	chr5:115454221	A/G	cg23108291	chr5:115420582	COMMD10	0.41	4.94	0.3	1.43e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.73	8.94	0.5	9.79e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg22997768	chr12:11092816	TAS2R14;PRR4;PRH1	0.4	6.59	0.39	2.7e-10	C-reactive protein;
KIRP	cis	rs7011507	1.000	rs77765251	chr8:49146031	T/C	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7666738	0.546	rs1456207	chr4:98676911	G/A	cg05340658	chr4:99064831	C4orf37	0.65	7.5	0.43	1.15e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23806609	chr7:66369525	NA	0.47	6.12	0.36	3.58e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.37	-10.46	-0.55	2.08e-21	Diabetic kidney disease;
KIRP	cis	rs3764563	1.000	rs601410	chr19:15693247	C/T	cg20725493	chr19:15740067	CYP4F8	0.89	6.37	0.38	9.25e-10	Inflammatory biomarkers;
KIRP	cis	rs72781680	0.611	rs36052574	chr2:24306587	A/C	cg20701182	chr2:24300061	SF3B14	1.02	10.94	0.57	5.69e-23	Lymphocyte counts;
KIRP	cis	rs10849605	0.737	rs7300039	chr12:1068178	A/T	cg02055889	chr12:1059459	RAD52	0.6	8.02	0.46	4.4e-14	Lung cancer;
KIRP	cis	rs7558233	0.614	rs59454437	chr2:23682476	A/G	cg00747342	chr2:23700632	KLHL29	0.6	5.55	0.33	7.49e-8	Cannabis use (initiation);
KIRP	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg16077055	chr2:106428750	NCK2	0.31	6.24	0.37	1.87e-9	Addiction;
KIRP	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg26138937	chr11:71823887	C11orf51	1.12	7.55	0.43	8.39e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.34	-0.32	2.12e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg07701084	chr6:150067640	NUP43	0.65	8.35	0.47	4.84e-15	Lung cancer;
KIRP	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg20169779	chr10:135381914	SYCE1	0.69	7.29	0.42	4.32e-12	Gout;
KIRP	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg00495681	chr13:53174319	NA	0.4	5.42	0.33	1.4e-7	Lewy body disease;
KIRP	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.86	0.3	2.14e-6	Childhood ear infection;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg19050596	chr2:191879164	STAT1	0.51	6.53	0.38	3.72e-10	Asthma;
KIRP	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.81	10.9	0.57	7.78e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.68	9.11	0.5	2.93e-17	Crohn's disease;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23978390	chr7:1156363	C7orf50	0.46	6.4	0.38	7.74e-10	Longevity;Endometriosis;
KIRP	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg13289132	chr10:30722225	MAP3K8	0.43	5.44	0.33	1.28e-7	Inflammatory bowel disease;
KIRP	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.57	7.45	0.43	1.63e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg11355319	chr5:89825117	LYSMD3	0.46	6.24	0.37	1.9e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs897876	1.000	rs1641480	chr2:65794233	C/G	cg23520757	chr6:24878831	FAM65B	0.43	6.2	0.37	2.32e-9	Pulse pressure in young-onset hypertension;
KIRP	cis	rs17407555	0.657	rs12508233	chr4:10271037	C/T	cg11266682	chr4:10021025	SLC2A9	0.35	5.28	0.32	2.79e-7	Schizophrenia (age at onset);
KIRP	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.64	-8.14	-0.46	1.97e-14	Morning vs. evening chronotype;
KIRP	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.44	-15.64	-0.71	9.48e-39	Schizophrenia;
KIRP	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.64	8.47	0.48	2.26e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.55	8.23	0.46	1.12e-14	Schizophrenia;
KIRP	cis	rs1011018	0.955	rs10262775	chr7:139464375	A/G	cg03224163	chr7:139420300	HIPK2	-0.46	-5.02	-0.3	9.97e-7	Systolic blood pressure;
KIRP	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.6e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	7.94	0.45	7.23e-14	Neuroticism;
KIRP	trans	rs12517041	0.935	rs36035239	chr5:23294107	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg00495681	chr13:53174319	NA	0.43	6.02	0.36	6.27e-9	Lewy body disease;
KIRP	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.83	11.49	0.59	9.86e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.27	0.37	1.58e-9	Axial length;
KIRP	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.49	-0.48	2.03e-15	Osteoarthritis;
KIRP	cis	rs950881	0.932	rs72823646	chr2:102954213	G/A	cg01254707	chr2:102953421	IL1RL1	-0.5	-5.05	-0.31	8.6e-7	Allergy;
KIRP	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg09795085	chr6:101329169	ASCC3	0.51	6.25	0.37	1.79e-9	Neuroticism;
KIRP	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	1.28	15.84	0.71	1.93e-39	Left atrial antero-posterior diameter;
KIRP	cis	rs2997447	0.655	rs2275947	chr1:26383875	A/G	cg19633962	chr1:26362018	EXTL1	-0.69	-7.74	-0.44	2.51e-13	QRS complex (12-leadsum);
KIRP	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg25019033	chr10:957182	NA	-0.58	-5.96	-0.36	8.65e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs4302748	0.862	rs74301277	chr7:36184831	C/G	cg24442661	chr7:36192818	EEPD1	0.62	6.61	0.39	2.33e-10	Platelet count;
KIRP	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg00405596	chr8:11794950	NA	0.59	8.41	0.47	3.31e-15	Neuroticism;
KIRP	cis	rs9309473	0.519	rs13009035	chr2:73845709	T/C	cg20560298	chr2:73613845	ALMS1	0.49	6.03	0.36	6.02e-9	Metabolite levels;
KIRP	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1440410	0.798	rs10026015	chr4:144169639	C/T	cg01719995	chr4:144104893	USP38	0.41	5.61	0.34	5.56e-8	Ischemic stroke;
KIRP	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg26876637	chr1:152193138	HRNR	-0.82	-8.34	-0.47	5.26e-15	Atopic dermatitis;
KIRP	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00938859	chr5:1591904	SDHAP3	0.6	8.12	0.46	2.18e-14	Breast cancer;
KIRP	cis	rs3745672	0.590	rs79343210	chr19:12169723	C/T	cg20127191	chr19:12306497	NA	-0.74	-6.06	-0.36	4.95e-9	Multiple sclerosis;
KIRP	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-4.97	-0.3	1.25e-6	Pulmonary function;
KIRP	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs259842	0.794	rs10153833	chr2:180675114	A/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.42	-6.18	-0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.88	10.14	0.54	2.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	cg12689670	chr1:183009347	LAMC1	0.58	8.06	0.46	3.31e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.43	-5.01	-0.3	1.04e-6	HDL cholesterol;
KIRP	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06544989	chr22:39130855	UNC84B	0.48	7.24	0.42	5.55e-12	Menopause (age at onset);
KIRP	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.66	-7.84	-0.45	1.33e-13	Body mass index;
KIRP	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.43e-12	Obesity-related traits;
KIRP	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.87	-0.6	5.32e-26	Eye color traits;
KIRP	cis	rs963731	0.522	rs1454225	chr2:39228632	T/G	cg04010122	chr2:39346883	SOS1	-0.86	-5.91	-0.35	1.13e-8	Corticobasal degeneration;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12146766	chr12:26347100	SSPN	0.51	6.37	0.38	9.26e-10	Interleukin-4 levels;
KIRP	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.14	-0.41	1.04e-11	Response to antipsychotic treatment;
KIRP	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	8.65	0.48	6.66e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg13180566	chr4:1052158	NA	-0.52	-5.21	-0.32	3.92e-7	Recombination rate (females);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15474272	chr19:1987505	BTBD2	0.54	7.42	0.43	1.87e-12	Interleukin-4 levels;
KIRP	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg01872077	chr2:219646372	CYP27A1	0.41	5.32	0.32	2.31e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg25019033	chr10:957182	NA	-0.59	-6.55	-0.39	3.3e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.11	-0.36	3.78e-9	Lung cancer;
KIRP	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15705062	chr19:5110748	KDM4B	0.51	6.47	0.38	5.11e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg01763666	chr17:80159506	CCDC57	0.34	4.88	0.3	1.89e-6	Life satisfaction;
KIRP	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.64	9.44	0.52	2.97e-18	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.69	-8.58	-0.48	1.05e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07402062	chr16:89894098	SPIRE2	-0.29	-6.17	-0.37	2.75e-9	Vitiligo;
KIRP	cis	rs234043	1.000	rs234043	chr3:172313367	T/C	cg01059398	chr3:172235808	TNFSF10	-0.38	-5.59	-0.34	6.11e-8	Renal cell carcinoma;
KIRP	cis	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.93	13.87	0.66	1.01e-32	Blood protein levels;
KIRP	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.85	-13.93	-0.66	6.77e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.9	-12.01	-0.61	1.92e-26	Platelet distribution width;
KIRP	cis	rs6088813	0.961	rs878639	chr20:33894463	A/G	cg14752227	chr20:34000481	UQCC	0.42	5.28	0.32	2.87e-7	Height;
KIRP	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.62	-0.56	6.23e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg01958934	chr19:45449099	APOC2	0.4	5.17	0.31	4.78e-7	Blood protein levels;
KIRP	cis	rs12143943	1.000	rs12143943	chr1:204572071	G/A	cg20240347	chr1:204465584	NA	-0.36	-6.51	-0.38	4.15e-10	Cognitive performance;
KIRP	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	9.57	0.52	1.19e-18	Schizophrenia;
KIRP	cis	rs7897654	0.571	rs12771681	chr10:104635620	T/C	cg15744005	chr10:104629667	AS3MT	-0.31	-5.08	-0.31	7.51e-7	Schizophrenia;
KIRP	cis	rs2013441	0.670	rs12937327	chr17:19978984	C/T	cg04132472	chr17:19861366	AKAP10	0.44	5.13	0.31	5.9e-7	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01529149	chr8:144815967	FAM83H	-0.45	-6.23	-0.37	2.02e-9	Metabolic traits;
KIRP	cis	rs9788721	0.614	rs951984	chr15:78720915	T/A	cg18825076	chr15:78729989	IREB2	-0.52	-5.91	-0.35	1.16e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs13418717	1.000	rs951817	chr2:127664894	G/T	cg25501666	chr2:127640322	NA	0.89	6.06	0.36	5.18e-9	Heart failure;
KIRP	cis	rs2191566	0.960	rs6509133	chr19:44522913	A/G	cg18700516	chr19:44507157	ZNF230	0.45	5.32	0.32	2.32e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.55	-5.81	-0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.83	9.7	0.53	4.82e-19	Platelet count;
KIRP	cis	rs16976116	0.901	rs28541469	chr15:55500788	G/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg10047753	chr17:41438598	NA	1.15	18.69	0.77	4.17e-49	Menopause (age at onset);
KIRP	cis	rs10875746	0.951	rs10875756	chr12:48562304	C/T	cg26205652	chr12:48591994	NA	0.77	10.46	0.55	2.02e-21	Longevity (90 years and older);
KIRP	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.21e-6	Morning vs. evening chronotype;
KIRP	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.49	-0.48	1.98e-15	Total cholesterol levels;
KIRP	cis	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg12315302	chr6:26189340	HIST1H4D	1.09	6.45	0.38	5.72e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs13034020	0.522	rs12998880	chr2:61240882	G/A	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.29	0.37	1.44e-9	Hodgkin's lymphoma;
KIRP	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.39	-0.32	1.67e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1864729	0.901	rs1348184	chr8:98276912	C/G	cg08679828	chr8:102218111	ZNF706	-0.69	-6.2	-0.37	2.36e-9	Estradiol plasma levels (breast cancer);
KIRP	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg20701182	chr2:24300061	SF3B14	0.48	4.99	0.3	1.13e-6	Asthma;
KIRP	trans	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg10756647	chr7:56101905	PSPH	-0.98	-7.0	-0.41	2.39e-11	Diabetic kidney disease;
KIRP	cis	rs11622475	1.000	rs56060232	chr14:104386165	G/C	cg20488157	chr14:104394430	TDRD9	0.78	11.07	0.58	2.28e-23	Bipolar disorder;
KIRP	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.42	9.33	0.51	6.31e-18	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg10755058	chr3:40428713	ENTPD3	-0.41	-5.92	-0.35	1.08e-8	Renal cell carcinoma;
KIRP	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.45	10.56	0.56	9.72e-22	Cutaneous nevi;
KIRP	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg11344533	chr11:111475393	SIK2	-0.29	-4.97	-0.3	1.28e-6	Primary sclerosing cholangitis;
KIRP	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg09462578	chr12:12878428	APOLD1	-0.7	-7.28	-0.42	4.5e-12	Systemic lupus erythematosus;
KIRP	cis	rs897080	0.552	rs1067392	chr2:44639097	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.93	0.35	1.01e-8	Height;
KIRP	cis	rs1620921	0.563	rs2465850	chr6:161281175	T/C	cg01280913	chr6:161186852	NA	-0.39	-5.17	-0.31	4.85e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs427941	0.655	rs2529095	chr7:101749663	C/T	cg06246474	chr7:101738831	CUX1	0.51	6.27	0.37	1.59e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.47	-6.58	-0.39	2.75e-10	Mean corpuscular volume;
KIRP	cis	rs7712401	0.601	rs35847506	chr5:122327108	G/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	trans	rs1864585	0.505	rs73208792	chr8:10680471	C/T	cg26278703	chr11:58910052	FAM111A	0.64	6.41	0.38	7.25e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg19338460	chr6:170058176	WDR27	-0.66	-7.81	-0.45	1.69e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg20673841	chr7:107026890	COG5	0.41	5.04	0.31	8.82e-7	Coronary artery disease;
KIRP	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.49	6.78	0.4	8.81e-11	Red blood cell count;
KIRP	cis	rs2901460	0.509	rs35056428	chr2:62061943	A/T	cg02183531	chr2:62113199	CCT4	-0.52	-5.32	-0.32	2.38e-7	Mean corpuscular volume;
KIRP	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	1.0	12.81	0.63	4.06e-29	Neutrophil percentage of white cells;
KIRP	cis	rs714027	0.605	rs1989870	chr22:30472254	A/G	cg01021169	chr22:30184971	ASCC2	-0.43	-5.46	-0.33	1.16e-7	Lymphocyte counts;
KIRP	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg03388025	chr16:89894329	SPIRE2	-0.31	-6.04	-0.36	5.63e-9	Vitiligo;
KIRP	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.16	-0.37	2.92e-9	Morning vs. evening chronotype;
KIRP	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg11031976	chr2:198649780	BOLL	-0.56	-5.3	-0.32	2.59e-7	Ulcerative colitis;
KIRP	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.61	-9.88	-0.53	1.32e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs73193808	0.614	rs9976839	chr21:30562710	G/A	cg03476357	chr21:30257390	N6AMT1	0.43	4.9	0.3	1.77e-6	Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-1.0	-16.03	-0.71	4.5e-40	Height;
KIRP	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.14	-0.41	1.05e-11	Migraine;Coronary artery disease;
KIRP	cis	rs394563	0.726	rs6906384	chr6:149664540	G/A	cg03678062	chr6:149772716	ZC3H12D	0.31	5.08	0.31	7.38e-7	Dupuytren's disease;
KIRP	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.54	-7.4	-0.43	2.14e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs4845459	0.967	rs6700290	chr1:152592978	T/A	cg07796016	chr1:152779584	LCE1C	-0.49	-5.95	-0.35	9.1e-9	Psoriasis;
KIRP	cis	rs9469913	0.740	rs2814983	chr6:34591207	A/G	cg17674042	chr6:34482479	PACSIN1	-0.48	-6.39	-0.38	8.36e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg09324608	chr17:30823087	MYO1D	0.45	5.81	0.35	1.88e-8	Schizophrenia;
KIRP	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg12940439	chr1:67600707	NA	0.43	6.41	0.38	7.44e-10	Psoriasis;
KIRP	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.83	8.95	0.5	8.96e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.63	-9.38	-0.51	4.47e-18	Menarche (age at onset);
KIRP	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-7.7	-0.44	3.39e-13	Vitiligo;
KIRP	cis	rs9309473	0.861	rs6546856	chr2:73837751	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.14	-0.31	5.59e-7	Metabolite levels;
KIRP	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.45	-5.51	-0.33	9.17e-8	Red blood cell count;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	5.67	0.34	3.91e-8	Longevity;
KIRP	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.69	-9.75	-0.53	3.31e-19	Retinal vascular caliber;
KIRP	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg12405258	chr13:114927641	NA	-0.44	-6.66	-0.39	1.78e-10	Schizophrenia;
KIRP	cis	rs2071403	0.527	rs2071402	chr2:1417199	A/G	cg07083862	chr2:1417248	TPO	-0.34	-5.34	-0.32	2.14e-7	Thyroid peroxidase antibody positivity;
KIRP	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.34	-4.85	-0.3	2.18e-6	Congenital heart disease (maternal effect);
KIRP	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-7.01	-0.41	2.32e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg14541582	chr5:601475	NA	-0.54	-6.13	-0.36	3.45e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg11693508	chr17:37793320	STARD3	0.78	8.5	0.48	1.9e-15	Bipolar disorder;
KIRP	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-1.2	-10.33	-0.55	5.17e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.43	0.38	6.58e-10	Aortic root size;
KIRP	cis	rs860295	0.580	rs10908483	chr1:155866834	C/T	cg02153340	chr1:155202674	NA	-0.39	-5.08	-0.31	7.48e-7	Body mass index;
KIRP	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs7224685	0.569	rs35586982	chr17:4001993	G/A	cg05562828	chr17:3906858	NA	0.53	5.59	0.34	5.87e-8	Type 2 diabetes;
KIRP	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-13.89	-0.66	8.68e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg11031976	chr2:198649780	BOLL	-0.48	-4.94	-0.3	1.43e-6	Ulcerative colitis;
KIRP	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.67	5.46	0.33	1.17e-7	Putamen volume;
KIRP	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.47	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg05834845	chr3:195489306	MUC4	-0.74	-6.48	-0.38	5.11e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg23594656	chr7:65796392	TPST1	-0.42	-5.92	-0.35	1.08e-8	Aortic root size;
KIRP	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.47	-5.9	-0.35	1.17e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg17376030	chr22:41985996	PMM1	-0.84	-8.91	-0.49	1.15e-16	Vitiligo;
KIRP	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg09571762	chr12:39539558	NA	0.36	5.06	0.31	8.21e-7	Morning vs. evening chronotype;
KIRP	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.03	-0.31	9.6e-7	Fear of minor pain;
KIRP	cis	rs5769707	0.967	rs9616713	chr22:50049109	G/A	cg20744362	chr22:50050164	C22orf34	0.38	6.48	0.38	4.97e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg10818794	chr15:86012489	AKAP13	-0.49	-6.98	-0.41	2.8e-11	Coronary artery disease;
KIRP	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.95	10.41	0.55	3e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-1.14	-13.49	-0.65	2e-31	Breast cancer;
KIRP	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg16558253	chr16:72132732	DHX38	-0.45	-5.6	-0.34	5.85e-8	Blood protein levels;
KIRP	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg07747251	chr5:1868357	NA	0.41	5.2	0.31	4.2e-7	Cardiovascular disease risk factors;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01678790	chr14:102484867	DYNC1H1	0.5	6.54	0.38	3.46e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1021993	0.545	rs4844815	chr1:209529654	G/A	cg24446417	chr1:209558027	NA	-0.44	-5.11	-0.31	6.33e-7	Gut microbiome composition (winter);
KIRP	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg25356066	chr3:128598488	ACAD9	0.41	4.85	0.3	2.14e-6	IgG glycosylation;
KIRP	cis	rs61935443	0.832	rs11107768	chr12:95274182	A/T	cg21533806	chr12:95267307	NA	-0.67	-6.73	-0.39	1.21e-10	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg06417478	chr19:12876846	HOOK2	-0.49	-5.83	-0.35	1.69e-8	Mean corpuscular volume;
KIRP	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg16988262	chr1:15930761	NA	0.4	5.16	0.31	5.18e-7	Systolic blood pressure;
KIRP	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg07701084	chr6:150067640	NUP43	0.58	7.38	0.43	2.44e-12	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24973420	chr4:6711634	MRFAP1L1	0.51	6.69	0.39	1.5e-10	Parkinson's disease;
KIRP	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.41	-6.62	-0.39	2.27e-10	Body mass index;
KIRP	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg21452805	chr1:244014465	NA	0.58	5.69	0.34	3.54e-8	RR interval (heart rate);
KIRP	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg17207736	chr8:142237307	SLC45A4	-0.48	-6.01	-0.36	6.56e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg19592336	chr6:28129416	ZNF389	-0.51	-5.82	-0.35	1.84e-8	Depression;
KIRP	cis	rs4851254	0.961	rs13022707	chr2:100734946	C/A	cg17356467	chr2:100759845	AFF3	0.61	7.33	0.42	3.29e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11874712	1.000	rs9961065	chr18:43653327	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.51	-0.33	9.06e-8	Migraine - clinic-based;
KIRP	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg13880726	chr7:1868755	MAD1L1	0.48	5.79	0.35	2.18e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.63	-0.52	7.91e-19	Neuroticism;
KIRP	cis	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	5.06	0.31	8.21e-7	Cervical cancer;
KIRP	cis	rs4889855	0.505	rs8076974	chr17:78621817	G/A	cg09596252	chr17:78655493	RPTOR	0.53	6.07	0.36	4.87e-9	Fractional excretion of uric acid;
KIRP	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.45	-7.63	-0.44	5.3e-13	Testicular germ cell tumor;
KIRP	cis	rs4478137	0.824	rs4057791	chr4:164225132	A/C	cg06758707	chr4:164254230	NPY1R	0.75	9.99	0.54	6.17e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.49	-6.24	-0.37	1.91e-9	Testicular germ cell tumor;
KIRP	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.32	-0.37	1.24e-9	Arsenic metabolism;
KIRP	trans	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg19694781	chr19:47549865	TMEM160	0.57	7.75	0.44	2.49e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.93	12.16	0.61	5.78e-27	Breast cancer;
KIRP	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-6.67	-0.39	1.72e-10	Daytime sleep phenotypes;
KIRP	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.4	-5.05	-0.31	8.73e-7	Carotid intima media thickness;
KIRP	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.64	11.88	0.6	5.16e-26	Blood protein levels;
KIRP	cis	rs2916247	1.000	rs2976505	chr8:92994972	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.66	-9.23	-0.51	1.32e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-0.89	-12.92	-0.64	1.67e-29	Dupuytren's disease;
KIRP	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg12311346	chr5:56204834	C5orf35	-0.35	-4.87	-0.3	1.96e-6	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs4481887	0.573	rs6689894	chr1:248409579	C/T	cg01631408	chr1:248437212	OR2T33	-0.47	-5.92	-0.35	1.07e-8	Common traits (Other);
KIRP	cis	rs6430538	0.671	rs11884708	chr2:135545282	A/C	cg25422880	chr2:135218333	TMEM163	-0.44	-6.14	-0.36	3.29e-9	Parkinson's disease;
KIRP	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.7	8.07	0.46	3.16e-14	Obesity-related traits;
KIRP	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.58	-7.11	-0.41	1.24e-11	Total body bone mineral density;
KIRP	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.45	-5.08	-0.31	7.39e-7	White matter hyperintensity burden;
KIRP	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg08198773	chr8:1697536	NA	0.51	6.25	0.37	1.76e-9	Systolic blood pressure;
KIRP	cis	rs6952809	1.000	rs12671804	chr7:2449740	C/T	cg23289794	chr7:2394357	EIF3B	-0.41	-4.91	-0.3	1.65e-6	Multiple sclerosis;
KIRP	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	1.0	10.83	0.57	1.35e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-9.09	-0.5	3.37e-17	Coronary artery disease;
KIRP	cis	rs9788721	0.806	rs951985	chr15:78720923	T/G	cg18825076	chr15:78729989	IREB2	-0.54	-6.3	-0.37	1.36e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg05347473	chr6:146136440	FBXO30	0.57	8.14	0.46	1.94e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.82	0.35	1.85e-8	Menopause (age at onset);
KIRP	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.89	0.35	1.27e-8	Depressive symptoms;
KIRP	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg00800038	chr16:89945340	TCF25	-0.76	-5.28	-0.32	2.78e-7	Skin colour saturation;
KIRP	cis	rs7106204	0.514	rs12282611	chr11:24271352	A/C	ch.11.24196551F	chr11:24239977	NA	0.78	6.98	0.41	2.75e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21643547	chr1:205240462	TMCC2	-0.83	-14.06	-0.67	2.42e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs743757	0.878	rs1467914	chr3:50523668	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.52	5.38	0.32	1.74e-7	Diastolic blood pressure;
KIRP	cis	rs9341808	0.590	rs4706841	chr6:81057827	T/A	cg08355045	chr6:80787529	NA	0.36	4.92	0.3	1.59e-6	Sitting height ratio;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg18234130	chr8:27182889	PTK2B	0.55	7.11	0.41	1.28e-11	Neuroticism;
KIRP	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.24	-0.51	1.22e-17	Mood instability;
KIRP	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.7	-9.51	-0.52	1.86e-18	Prudent dietary pattern;
KIRP	cis	rs6542838	0.641	rs6704682	chr2:99499602	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-4.89	-0.3	1.84e-6	Fear of minor pain;
KIRP	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	1.0	17.54	0.75	3.22e-45	Breast cancer;
KIRP	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg26681399	chr22:41777847	TEF	-0.42	-4.92	-0.3	1.6e-6	Neuroticism;
KIRP	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg07511934	chr16:89386912	ANKRD11	0.43	5.53	0.33	8.16e-8	Multiple myeloma (IgH translocation);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03772063	chr4:175440325	HPGD	0.36	6.03	0.36	5.96e-9	C-reactive protein;
KIRP	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.85	12.25	0.62	2.91e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.4	-0.51	3.98e-18	Platelet count;
KIRP	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-7.69	-0.44	3.5e-13	Mean corpuscular volume;
KIRP	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.4	6.21	0.37	2.28e-9	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
KIRP	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.62	-9.2	-0.51	1.56e-17	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs17065868	1.000	rs9533887	chr13:45093359	T/C	cg10246903	chr13:45222710	NA	0.67	6.35	0.38	1.04e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.69	-11.17	-0.58	1.04e-23	Gout;
KIRP	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.8	-11.27	-0.58	4.99e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs1886644	1.000	rs1886644	chr1:85350658	A/C	cg08479277	chr1:85350632	LPAR3	0.75	9.21	0.51	1.52e-17	Glucose homeostasis traits;
KIRP	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.95	-13.45	-0.65	2.77e-31	Coronary artery disease;
KIRP	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.96	0.36	8.73e-9	Putamen volume;
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg13939156	chr17:80058883	NA	-0.46	-7.05	-0.41	1.78e-11	Life satisfaction;
KIRP	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg06307176	chr5:131281290	NA	-0.54	-5.91	-0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	5.01	0.3	1.05e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg11584989	chr19:19387371	SF4	0.41	5.28	0.32	2.81e-7	Tonsillectomy;
KIRP	cis	rs7147624	0.572	rs72714470	chr14:65979173	G/A	cg03016385	chr14:66212404	NA	0.86	5.41	0.33	1.47e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	trans	rs1859156	0.597	rs35992199	chr4:95810628	T/G	cg24204951	chr2:239172084	PER2	0.27	6.23	0.37	1.95e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs13343954	0.778	rs10401503	chr19:33543547	C/T	cg27124370	chr19:33622961	WDR88	0.56	6.09	0.36	4.25e-9	Colorectal cancer;
KIRP	cis	rs2411233	0.811	rs2033544	chr15:39262972	G/T	cg02291532	chr15:39874776	THBS1	-0.48	-6.55	-0.39	3.3e-10	Platelet count;
KIRP	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs4132509	1.000	rs10803158	chr1:243923229	A/G	cg21452805	chr1:244014465	NA	0.48	4.92	0.3	1.61e-6	RR interval (heart rate);
KIRP	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg24851858	chr13:114927579	NA	0.42	5.03	0.31	9.58e-7	Schizophrenia;
KIRP	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.65	-7.11	-0.41	1.27e-11	DNA methylation (variation);
KIRP	cis	rs74181299	0.591	rs2422441	chr2:65370766	A/G	cg05010058	chr2:65284262	CEP68	-0.45	-6.01	-0.36	6.79e-9	Pulse pressure;
KIRP	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs9381107	0.656	rs71561169	chr6:9509017	A/C	cg14735645	chr6:9486422	NA	-0.62	-6.28	-0.37	1.55e-9	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9473924	0.580	rs60100577	chr6:50816134	C/T	cg14470998	chr6:50812995	TFAP2B	0.99	8.92	0.49	1.12e-16	Body mass index;
KIRP	trans	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg10756647	chr7:56101905	PSPH	0.91	6.42	0.38	6.86e-10	Diabetic kidney disease;
KIRP	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg24803719	chr17:45855879	NA	-0.4	-5.31	-0.32	2.45e-7	IgG glycosylation;
KIRP	trans	rs4305714	0.617	rs9379455	chr6:22926459	A/G	cg16403932	chr12:57881247	MARS	0.48	6.06	0.36	5e-9	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer;
KIRP	cis	rs6939532	0.522	rs9358933	chr6:26363688	C/T	cg14345882	chr6:26364793	BTN3A2	0.32	5.0	0.3	1.1e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	9.75	0.53	3.29e-19	Total body bone mineral density;
KIRP	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs40363	1.000	rs250637	chr16:3511007	A/G	cg05754148	chr16:3507555	NAT15	0.5	4.96	0.3	1.34e-6	Tuberculosis;
KIRP	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg22771759	chr13:24902376	NA	0.38	5.03	0.31	9.27e-7	Obesity-related traits;
KIRP	cis	rs1165472	0.755	rs1849681	chr1:56161461	G/A	cg11523071	chr1:56160889	NA	-0.59	-7.61	-0.44	5.8e-13	Paclitaxel-induced neuropathy;
KIRP	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.84	-11.18	-0.58	9.71e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9488822	0.702	rs540981	chr6:116266592	A/G	cg15226275	chr6:116381976	FRK	-0.23	-6.02	-0.36	6.28e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.56	7.41	0.43	2e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs9896933	1.000	rs9896933	chr17:80898088	T/C	cg15664640	chr17:80829946	TBCD	0.68	6.06	0.36	5.04e-9	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg01620082	chr3:125678407	NA	-0.88	-6.43	-0.38	6.75e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.56	8.42	0.47	3.24e-15	Weight;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.37	5.19	0.31	4.36e-7	Lung cancer;
KIRP	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.59	-5.84	-0.35	1.65e-8	DNA methylation (variation);
KIRP	cis	rs796364	0.616	rs2030653	chr2:200677625	C/T	cg23649088	chr2:200775458	C2orf69	0.54	5.22	0.32	3.89e-7	Schizophrenia;
KIRP	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.17	-0.42	8.56e-12	Fear of minor pain;
KIRP	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs2862064	0.932	rs1995378	chr5:156421132	G/A	cg12943317	chr5:156479607	HAVCR1	-0.92	-7.2	-0.42	7.18e-12	Platelet count;
KIRP	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-8.87	-0.49	1.57e-16	Vitiligo;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg01245595	chr21:47648645	LSS;MCM3APAS	0.51	6.18	0.37	2.59e-9	Beard thickness;
KIRP	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.51	-7.61	-0.44	5.88e-13	IgG glycosylation;
KIRP	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.48	6.65	0.39	1.85e-10	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg06636001	chr8:8085503	FLJ10661	0.6	8.04	0.46	3.81e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.71	10.35	0.55	4.33e-21	Morning vs. evening chronotype;
KIRP	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg26248373	chr2:1572462	NA	-0.61	-5.98	-0.36	7.66e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.93	0.61	3.38e-26	Ileal carcinoids;
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.54	0.33	7.67e-8	Lung cancer;
KIRP	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.28	-0.37	1.51e-9	Alcohol dependence;
KIRP	cis	rs7327064	0.666	rs9546846	chr13:36816907	G/T	cg13455704	chr13:36871754	C13orf38	0.55	4.93	0.3	1.55e-6	Economic and political preferences;
KIRP	cis	rs867371	1.000	rs9944197	chr15:82450602	G/A	cg00614314	chr15:82944287	LOC80154	0.54	6.46	0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.88	-10.27	-0.55	8.11e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs742115	0.563	rs2281063	chr6:11298263	T/C	cg25250968	chr6:11318770	NEDD9	-0.42	-5.98	-0.36	7.68e-9	Coronary artery disease;
KIRP	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg17554472	chr22:41940697	POLR3H	0.65	6.61	0.39	2.39e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg23791538	chr6:167370224	RNASET2	0.74	10.49	0.56	1.65e-21	Graves' disease;
KIRP	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	0.95	17.6	0.75	2e-45	Dental caries;
KIRP	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.41	-0.33	1.52e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	6.7	0.39	1.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1937787	0.522	rs12070989	chr1:80841004	G/T	cg24034412	chr19:49122294	RPL18;SPHK2	-0.45	-6.18	-0.37	2.61e-9	Stroke;
KIRP	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg22532475	chr10:104410764	TRIM8	-0.28	-4.89	-0.3	1.84e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-5.63	-0.34	5.02e-8	Blood metabolite levels;
KIRP	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg05343316	chr1:45956843	TESK2	0.72	8.38	0.47	4.23e-15	Platelet count;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00802000	chr16:706648	WDR90	-0.39	-5.02	-0.3	1e-6	Height;
KIRP	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.66	7.94	0.45	7.28e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11954110	chr11:113644656	ZW10	0.46	6.22	0.37	2.13e-9	Parkinson's disease;
KIRP	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.16	-0.37	2.94e-9	Breast cancer;
KIRP	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg01028140	chr2:1542097	TPO	-0.64	-6.39	-0.38	8.32e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.81	0.4	7.47e-11	Mean corpuscular volume;
KIRP	cis	rs12210905	0.920	rs72839468	chr6:27301734	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.55	-0.39	3.29e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9381107	0.932	rs2011335	chr6:9436825	T/A	cg14735645	chr6:9486422	NA	-0.44	-5.45	-0.33	1.19e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs714031	0.934	rs738315	chr22:40069245	T/C	cg21377881	chr22:40064566	CACNA1I	-0.66	-10.33	-0.55	5.22e-21	Schizophrenia;
KIRP	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.61	-8.21	-0.46	1.24e-14	Colorectal cancer;
KIRP	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	0.94	6.67	0.39	1.71e-10	IgG glycosylation;
KIRP	cis	rs9915657	0.595	rs10438697	chr17:70055734	A/G	cg09344028	chr17:70110421	NA	-0.38	-7.96	-0.45	6.46e-14	Thyroid hormone levels;
KIRP	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.36	0.42	2.69e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.93	14.05	0.67	2.64e-33	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03774026	chr6:119399550	FAM184A	0.43	6.05	0.36	5.38e-9	Parkinson's disease;
KIRP	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	7.93	0.45	7.57e-14	Eosinophil percentage of white cells;
KIRP	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg00857998	chr1:205179979	DSTYK	0.48	6.11	0.36	3.87e-9	Red blood cell count;
KIRP	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.54	8.92	0.49	1.12e-16	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg24315340	chr6:146058215	EPM2A	0.39	4.89	0.3	1.82e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.43	5.98	0.36	7.95e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07916071	chr1:151227225	PSMD4	0.44	6.32	0.37	1.25e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg15676125	chr6:33679581	C6orf125	0.39	5.03	0.31	9.43e-7	Height;
KIRP	trans	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg16141378	chr3:129829833	LOC729375	0.56	7.21	0.42	6.96e-12	Neuroticism;
KIRP	trans	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg24644049	chr4:85504048	CDS1	0.93	6.87	0.4	5.17e-11	Skin colour saturation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06819279	chr6:134297853	TBPL1	-0.42	-6.4	-0.38	7.86e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs71636778	0.722	rs71636784	chr1:27169200	T/G	cg12203394	chr1:27248618	NUDC	0.76	5.93	0.35	1.05e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg01689657	chr7:91764605	CYP51A1	-0.38	-5.52	-0.33	8.61e-8	Breast cancer;
KIRP	cis	rs12496230	0.794	rs7642618	chr3:66863002	A/G	cg17646820	chr3:66848679	NA	0.4	6.62	0.39	2.27e-10	Type 2 diabetes;
KIRP	cis	rs7937612	0.931	rs34298380	chr11:120203559	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.85	-0.4	5.96e-11	Intraocular pressure;
KIRP	cis	rs10129255	0.500	rs10143242	chr14:107137831	C/T	cg23076370	chr14:107095027	NA	-0.45	-5.76	-0.34	2.51e-8	Kawasaki disease;
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.42	-5.47	-0.33	1.11e-7	Longevity;
KIRP	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg21960279	chr19:17905606	B3GNT3	0.45	7.91	0.45	8.97e-14	Tumor biomarkers;
KIRP	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.62	-6.94	-0.4	3.52e-11	Neuroticism;
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg07701084	chr6:150067640	NUP43	0.72	10.08	0.54	3.08e-20	Lung cancer;
KIRP	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg09137382	chr11:130731461	NA	0.57	8.21	0.46	1.28e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.04	0.61	1.5e-26	Ileal carcinoids;
KIRP	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.89	0.3	1.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4646404	0.526	rs11867345	chr17:17478390	C/T	cg01246520	chr17:17644344	RAI1	-0.32	-5.59	-0.34	5.97e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24534381	chr11:77348924	CLNS1A	0.53	6.7	0.39	1.43e-10	Parkinson's disease;
KIRP	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.78	-11.33	-0.59	3.21e-24	Parkinson's disease;
KIRP	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg26384229	chr12:38710491	ALG10B	0.66	8.91	0.49	1.14e-16	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17554472	chr22:41940697	POLR3H	0.6	6.52	0.38	3.9e-10	Vitiligo;
KIRP	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.98	-0.3	1.2e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs76793172	1.000	rs60283385	chr19:46329079	T/C	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.12	-0.36	3.65e-9	Eosinophil counts;
KIRP	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01616529	chr11:638424	DRD4	-0.37	-5.13	-0.31	5.84e-7	Systemic lupus erythematosus;
KIRP	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00290607	chr11:67383545	NA	0.35	4.99	0.3	1.13e-6	Mean corpuscular volume;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.82	-13.74	-0.66	2.8e-32	Vitiligo;
KIRP	cis	rs6687430	0.514	rs587916	chr1:10545590	G/A	cg19773385	chr1:10388646	KIF1B	0.41	5.39	0.32	1.68e-7	Hand grip strength;
KIRP	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg21775007	chr8:11205619	TDH	-0.49	-6.45	-0.38	5.81e-10	Triglycerides;
KIRP	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg18132916	chr6:79620363	NA	-0.43	-5.92	-0.35	1.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.75	8.21	0.46	1.29e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	5.97	0.36	8.29e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.59	-7.52	-0.43	1.03e-12	Aortic root size;
KIRP	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.3	-0.32	2.61e-7	Personality dimensions;
KIRP	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.72	0.34	3.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg05085585	chr16:30420623	ZNF771	-0.32	-5.01	-0.3	1.04e-6	Tonsillectomy;
KIRP	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg03465714	chr1:152285911	FLG	-0.44	-6.26	-0.37	1.74e-9	Inflammatory skin disease;
KIRP	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg23422044	chr7:1970798	MAD1L1	-0.7	-7.25	-0.42	5.49e-12	Bipolar disorder;
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg04369109	chr6:150039330	LATS1	-0.56	-6.88	-0.4	4.92e-11	Lung cancer;
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.45	0.33	1.25e-7	Lung cancer;
KIRP	cis	rs687432	0.885	rs35713433	chr11:57708400	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.16	-0.5	2.04e-17	Parkinson's disease;
KIRP	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg26441486	chr22:50317300	CRELD2	0.55	8.6	0.48	9.21e-16	Schizophrenia;
KIRP	cis	rs16957091	0.657	rs34070722	chr15:42938962	G/A	cg24196017	chr15:43021976	CDAN1	-0.44	-5.58	-0.34	6.28e-8	MGMT methylation in smokers;
KIRP	cis	rs1957429	0.614	rs380741	chr14:65322027	C/T	cg23373153	chr14:65346875	NA	-0.58	-4.94	-0.3	1.42e-6	Pediatric areal bone mineral density (radius);
KIRP	cis	rs11997175	0.935	rs3903385	chr8:33687399	T/G	cg04338863	chr8:33670619	NA	0.41	5.21	0.32	3.95e-7	Body mass index;
KIRP	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.68	10.53	0.56	1.24e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs7116495	0.609	rs10736780	chr11:71650241	T/C	cg07596299	chr11:71824057	C11orf51	-0.86	-5.73	-0.34	2.95e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs11877825	0.826	rs1893228	chr18:10578872	C/T	cg07277756	chr18:10589357	NA	0.49	5.96	0.36	8.84e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg21734707	chr17:3908241	ZZEF1	0.6	8.04	0.46	3.71e-14	Type 2 diabetes;
KIRP	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.22	0.32	3.82e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27425700	chr2:227757200	RHBDD1	-0.4	-6.09	-0.36	4.2e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.51	-6.58	-0.39	2.85e-10	Temperament;
KIRP	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.74	-0.44	2.53e-13	Mean platelet volume;
KIRP	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.59	0.34	6.01e-8	Lung cancer;
KIRP	cis	rs7116495	0.881	rs7924516	chr11:71667989	T/C	cg11196788	chr11:71737549	NUMA1	0.56	4.99	0.3	1.14e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.51	7.29	0.42	4.17e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg05370193	chr1:21551575	ECE1	0.49	6.05	0.36	5.26e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg24874828	chr4:187887005	NA	0.57	9.39	0.51	4.28e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25517755	chr10:38738941	LOC399744	-0.52	-7.14	-0.41	1.05e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7246760	0.867	rs61011126	chr19:9814421	A/C	cg02900749	chr2:68251473	NA	-1.19	-10.02	-0.54	4.82e-20	Pursuit maintenance gain;
KIRP	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-11.02	-0.57	3.29e-23	Alzheimer's disease;
KIRP	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.45	5.81	0.35	1.94e-8	Depressive symptoms;
KIRP	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg26876637	chr1:152193138	HRNR	0.71	9.19	0.51	1.71e-17	Atopic dermatitis;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.67	-8.33	-0.47	5.78e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs829661	0.793	rs829684	chr2:30708123	G/C	cg10949345	chr2:30726833	LCLAT1	1.15	14.07	0.67	2.28e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7945718	0.905	rs6486032	chr11:12723693	G/A	cg25843174	chr11:12811716	TEAD1	0.36	6.59	0.39	2.6e-10	Educational attainment (years of education);
KIRP	cis	rs4950322	0.515	rs12060046	chr1:146720934	T/C	cg22381352	chr1:146742008	CHD1L	-0.4	-4.96	-0.3	1.29e-6	Protein quantitative trait loci;
KIRP	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.62	-8.98	-0.5	7.15e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.68	-8.13	-0.46	2.05e-14	Diastolic blood pressure;
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg21186296	chr8:27182909	PTK2B	0.51	6.54	0.38	3.49e-10	Neuroticism;
KIRP	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg25174290	chr11:3078921	CARS	-0.68	-8.83	-0.49	1.98e-16	Calcium levels;
KIRP	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.66	11.69	0.6	2.1e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs138229	0.506	rs9628282	chr22:50534952	G/T	cg16473166	chr22:50639996	SELO	0.47	5.38	0.32	1.71e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg05342945	chr12:48394962	COL2A1	-0.47	-5.34	-0.32	2.13e-7	Lung cancer;
KIRP	cis	rs11016883	1.000	rs11016883	chr10:131500940	C/G	cg14312783	chr10:131504572	MGMT	-0.39	-4.85	-0.3	2.2e-6	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.79	13.03	0.64	7.54e-30	Monocyte percentage of white cells;
KIRP	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.25e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg12046867	chr14:103022105	NA	-0.46	-5.81	-0.35	1.94e-8	Platelet count;
KIRP	cis	rs6450176	1.000	rs60492935	chr5:53306240	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.26	-0.58	5.29e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg09165964	chr15:75287851	SCAMP5	-0.9	-7.34	-0.42	3.04e-12	Lung cancer;
KIRP	cis	rs4953911	1.000	rs4953911	chr2:135068794	A/T	cg18482303	chr2:135041380	MGAT5	-0.27	-5.16	-0.31	5.12e-7	Multiple sclerosis (severity);
KIRP	cis	rs10045504	0.502	rs72746054	chr5:38762351	C/T	cg15396434	chr5:38725168	NA	-0.92	-8.8	-0.49	2.49e-16	Night sleep phenotypes;
KIRP	cis	rs911119	0.866	rs4346460	chr20:23569400	C/T	cg09631192	chr20:23583594	CST9	-0.48	-5.1	-0.31	6.85e-7	Chronic kidney disease;
KIRP	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg00405596	chr8:11794950	NA	-0.53	-6.95	-0.41	3.2e-11	Triglycerides;
KIRP	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.16e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1859156	0.767	rs13122133	chr4:95857273	G/A	cg24204951	chr2:239172084	PER2	0.3	6.15	0.37	3.11e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg22878388	chr2:105853796	NA	-0.44	-7.05	-0.41	1.79e-11	Type 2 diabetes;
KIRP	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.68	10.12	0.54	2.29e-20	Dupuytren's disease;
KIRP	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg09264619	chr17:80180166	NA	0.48	5.59	0.34	5.96e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	6.5	0.38	4.36e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.62	9.22	0.51	1.41e-17	Coronary artery disease;
KIRP	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-7.26	-0.42	4.99e-12	Schizophrenia;
KIRP	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.8	-0.6	9.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg05342945	chr12:48394962	COL2A1	-0.45	-4.97	-0.3	1.27e-6	Lung cancer;
KIRP	cis	rs61990749	0.511	rs724263	chr14:78321874	G/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.78	5.86	0.35	1.52e-8	Fibroblast growth factor basic levels;
KIRP	cis	rs7129556	0.954	rs10899386	chr11:77246426	T/C	cg12586386	chr11:77299805	AQP11	0.41	5.48	0.33	1.04e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs698833	0.886	rs698824	chr2:44723123	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.81	0.35	1.9e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.68	12.33	0.62	1.62e-27	Obesity (extreme);
KIRP	trans	rs1864585	0.520	rs17720365	chr8:10679499	C/G	cg26278703	chr11:58910052	FAM111A	-0.63	-6.56	-0.39	3.22e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	4.94e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg06204229	chr3:52865917	ITIH4	0.59	6.35	0.38	1.01e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6662572	1.000	rs56251392	chr1:46210829	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	4.95	0.3	1.36e-6	Blood protein levels;
KIRP	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.95	-14.9	-0.69	3.21e-36	Height;
KIRP	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.74	7.24	0.42	5.85e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.81	8.97	0.5	7.99e-17	Iron status biomarkers;
KIRP	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-5.94	-0.35	9.77e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs477692	0.637	rs7098619	chr10:131315856	C/T	cg24747557	chr10:131355152	MGMT	-0.42	-5.52	-0.33	8.54e-8	Response to temozolomide;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08432650	chr20:43104474	TTPAL	0.43	6.11	0.36	3.77e-9	Survival in pancreatic cancer;
KIRP	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg04608330	chr12:45269318	NELL2	-0.57	-7.74	-0.44	2.59e-13	Gut microbiome composition (summer);
KIRP	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.72	-0.39	1.26e-10	Response to antipsychotic treatment;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.72	8.67	0.48	5.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9660180	0.967	rs12040325	chr1:1702436	G/A	cg03396347	chr1:1875803	NA	-0.64	-9.53	-0.52	1.59e-18	Body mass index;
KIRP	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg24879335	chr3:133465180	TF	0.47	7.28	0.42	4.45e-12	Iron status biomarkers;
KIRP	cis	rs6707387	0.686	rs12995729	chr2:214508535	G/C	cg08319019	chr2:214017104	IKZF2	0.45	5.24	0.32	3.54e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg12756093	chr1:115239321	AMPD1	0.53	6.93	0.4	3.58e-11	Autism;
KIRP	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.9	-12.62	-0.63	1.72e-28	Coronary artery disease;
KIRP	cis	rs2120243	0.621	rs7634847	chr3:157159145	A/G	cg24825693	chr3:157122686	VEPH1	-0.38	-5.12	-0.31	6.09e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.59	-6.61	-0.39	2.33e-10	Gut microbiome composition (summer);
KIRP	cis	rs806215	0.568	rs806188	chr7:127268806	T/C	cg23081781	chr7:127225937	GCC1	0.4	4.92	0.3	1.59e-6	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs12368653	0.641	rs11172300	chr12:58076515	C/T	cg00677455	chr12:58241039	CTDSP2	-0.59	-6.79	-0.4	8.34e-11	Multiple sclerosis;
KIRP	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs3767633	0.925	rs4656335	chr1:161822078	A/G	cg09175582	chr1:161736000	ATF6	0.74	5.97	0.36	8.39e-9	IgG glycosylation;
KIRP	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.72	-10.13	-0.54	2.25e-20	Plateletcrit;Platelet count;
KIRP	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg03609598	chr5:56110824	MAP3K1	0.68	6.67	0.39	1.69e-10	Initial pursuit acceleration;
KIRP	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17467752	chr17:38218738	THRA	-0.54	-6.81	-0.4	7.44e-11	White blood cell count;
KIRP	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.72	10.33	0.55	5.23e-21	Hip circumference;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03829176	chr3:81810355	GBE1	0.59	7.46	0.43	1.51e-12	Parkinson's disease;
KIRP	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.97	14.01	0.67	3.53e-33	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	15.24	0.7	2.26e-37	Alzheimer's disease;
KIRP	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg05044414	chr3:183734942	ABCC5	0.37	5.67	0.34	3.92e-8	Anterior chamber depth;
KIRP	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.41	5.36	0.32	1.89e-7	Melanoma;
KIRP	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg17425144	chr1:10567563	PEX14	0.48	8.99	0.5	6.78e-17	Breast size;
KIRP	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg04731861	chr2:219085781	ARPC2	0.29	7.36	0.43	2.68e-12	Colorectal cancer;
KIRP	cis	rs815306	1	rs815306	chr1:76168624	A/G	cg10523679	chr1:76189770	ACADM	0.43	6.41	0.38	7.42e-10	Daytime sleep phenotypes;
KIRP	cis	rs5167	0.534	rs56803710	chr19:45481884	C/T	cg13119609	chr19:45449297	APOC2	0.39	4.86	0.3	2.14e-6	Blood protein levels;
KIRP	cis	rs3857747	0.861	rs10238411	chr7:40437450	C/A	cg00420559	chr7:40367873	C7orf10	0.62	8.05	0.46	3.58e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.09e-6	Bladder cancer;
KIRP	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg05072774	chr3:49840536	C3orf54	-0.41	-5.1	-0.31	6.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg16989719	chr2:238392110	NA	-0.56	-5.99	-0.36	7.27e-9	Prostate cancer;
KIRP	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.36	6.35	0.38	1.05e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	cis	rs3105593	0.965	rs12442721	chr15:50910813	C/T	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.51e-7	QT interval;
KIRP	cis	rs986417	1.000	rs1313243	chr14:60876398	C/T	cg27398547	chr14:60952738	C14orf39	-0.66	-5.74	-0.34	2.81e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs1509701	0.663	rs9428812	chr1:239162037	C/T	cg14399018	chr7:126615786	GRM8	0.51	6.1	0.36	4.15e-9	Shingles;
KIRP	cis	rs35740288	0.621	rs12916001	chr15:86245269	G/A	cg20737812	chr15:86336631	KLHL25	-0.34	-4.85	-0.3	2.18e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg01689657	chr7:91764605	CYP51A1	-0.35	-5.08	-0.31	7.33e-7	Breast cancer;
KIRP	cis	rs13178130	0.515	rs2084007	chr5:133891282	A/G	cg06019726	chr5:133897654	PHF15	-0.43	-6.68	-0.39	1.61e-10	Menarche (age at onset);
KIRP	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg17108064	chr15:78857060	CHRNA5	-0.38	-5.4	-0.33	1.55e-7	Sudden cardiac arrest;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.29	5.86	0.35	1.51e-8	Schizophrenia;
KIRP	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs7715811	1.000	rs10039621	chr5:13772457	C/T	cg07548982	chr5:13769939	DNAH5	-0.55	-6.84	-0.4	6.14e-11	Subclinical atherosclerosis traits (other);
KIRP	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.78	-9.99	-0.54	5.96e-20	Coronary artery disease;
KIRP	cis	rs57590327	0.628	rs34439726	chr3:81667241	C/T	cg07356753	chr3:81810745	GBE1	-0.58	-6.23	-0.37	2.06e-9	Extraversion;
KIRP	cis	rs897080	0.515	rs4953088	chr2:44564518	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.52	-5.69	-0.34	3.66e-8	Height;
KIRP	cis	rs1448094	0.872	rs7305869	chr12:86440114	A/G	cg06740227	chr12:86229804	RASSF9	0.4	4.98	0.3	1.21e-6	Major depressive disorder;
KIRP	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21747958	chr19:58740255	ZNF544	0.46	6.16	0.37	2.87e-9	Parkinson's disease;
KIRP	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.76	-10.23	-0.55	1.08e-20	Menarche (age at onset);
KIRP	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg25547332	chr5:131281432	NA	0.47	5.41	0.33	1.52e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs11169552	0.510	rs17124930	chr12:51115935	A/G	cg12884762	chr12:50931848	DIP2B	-0.46	-5.38	-0.32	1.72e-7	Colorectal cancer;
KIRP	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.57	-9.53	-0.52	1.64e-18	Schizophrenia;
KIRP	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.47	6.1	0.36	4e-9	Lung cancer;
KIRP	trans	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.88	-0.4	4.96e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.51	-5.9	-0.35	1.21e-8	Coronary artery disease;
KIRP	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.83	11.8	0.6	9.19e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs17221829	0.733	rs11600011	chr11:89407980	T/C	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.23	-0.32	3.55e-7	Anxiety in major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27611081	chr2:109150596	NA	0.52	6.69	0.39	1.46e-10	Parkinson's disease;
KIRP	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg13798780	chr7:105162888	PUS7	0.66	6.14	0.36	3.37e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.3	0.42	3.86e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.79	-0.53	2.45e-19	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26083396	chr7:128049885	IMPDH1	0.43	6.03	0.36	5.83e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26526719	chr5:1949144	NA	-0.41	-4.96	-0.3	1.34e-6	Gut microbiome composition (winter);
KIRP	cis	rs2223471	0.719	rs9357673	chr6:50779653	C/T	cg03432817	chr6:50765336	NA	-0.43	-6.63	-0.39	2.12e-10	Subcutaneous adipose tissue;
KIRP	cis	rs812925	0.762	rs3213951	chr2:61622251	C/T	cg15711740	chr2:61764176	XPO1	-0.47	-5.27	-0.32	2.93e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.38	-5.29	-0.32	2.76e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15324256	chr3:113775233	QTRTD1;KIAA1407	0.49	6.07	0.36	4.92e-9	Parkinson's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25835160	chr17:80023441	DUS1L	0.52	7.13	0.41	1.1e-11	Survival in pancreatic cancer;
KIRP	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg20636351	chr8:55087400	NA	0.63	7.68	0.44	3.86e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg27661460	chr16:88844969	FAM38A	0.48	6.33	0.37	1.17e-9	Glycated hemoglobin levels;
KIRP	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg04315214	chr1:2043799	PRKCZ	-0.33	-5.5	-0.33	9.59e-8	Height;
KIRP	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg23845249	chr11:68861649	NA	0.54	7.63	0.44	5.22e-13	Blond vs. brown hair color;
KIRP	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-4.86	-0.3	2.06e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg23682824	chr7:23144976	KLHL7	0.49	5.63	0.34	5.03e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.92	9.57	0.52	1.17e-18	Methadone dose in opioid dependence;
KIRP	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg08885076	chr2:99613938	TSGA10	-0.55	-9.67	-0.52	6.06e-19	Chronic sinus infection;
KIRP	cis	rs7923609	0.902	rs10822158	chr10:65094383	A/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.64	-0.34	4.71e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg20503657	chr10:835505	NA	-0.5	-5.92	-0.35	1.05e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs35740288	0.770	rs17570529	chr15:86125607	A/T	cg10818794	chr15:86012489	AKAP13	-0.46	-5.48	-0.33	1.06e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.02	0.3	9.8e-7	Menopause (age at onset);
KIRP	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.41	-5.95	-0.35	9.12e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg08662619	chr6:150070041	PCMT1	-0.35	-5.75	-0.34	2.61e-8	Lung cancer;
KIRP	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.09	0.36	4.29e-9	Height;
KIRP	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.08	-0.41	1.53e-11	Aortic root size;
KIRP	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg17724175	chr1:150552817	MCL1	0.37	5.92	0.35	1.09e-8	Melanoma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13423469	chr10:116856408	ATRNL1	-0.41	-6.16	-0.37	2.96e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg21905437	chr5:178450457	ZNF879	0.57	6.58	0.39	2.8e-10	Pubertal anthropometrics;
KIRP	cis	rs55788414	0.932	rs12103403	chr16:81185904	C/A	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.21	-0.46	1.25e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg04374321	chr14:90722782	PSMC1	-0.61	-7.79	-0.45	1.83e-13	Mortality in heart failure;
KIRP	cis	rs7106204	0.514	rs2099889	chr11:24255971	A/G	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs3007168	1.000	rs2999363	chr14:51605141	A/G	cg23942311	chr14:51606299	NA	0.51	5.47	0.33	1.08e-7	Cancer;
KIRP	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.6	6.83	0.4	6.6e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg16497661	chr14:103986332	CKB	0.43	5.67	0.34	3.94e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.81	14.79	0.69	7.95e-36	Lymphocyte counts;
KIRP	cis	rs7551222	0.752	rs2290854	chr1:204516025	A/G	cg20240347	chr1:204465584	NA	-0.44	-8.42	-0.47	3.07e-15	Schizophrenia;
KIRP	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.66	-11.37	-0.59	2.3e-24	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10448562	chr17:4699384	PSMB6	-0.47	-6.08	-0.36	4.45e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.05	-0.31	8.7e-7	Recombination measurement;
KIRP	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs1472147	0.518	rs1565629	chr7:128445370	G/A	cg00734629	chr7:128471146	FLNC	0.4	4.9	0.3	1.75e-6	Calcium levels;
KIRP	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	0.99	10.71	0.56	3.13e-22	Opioid sensitivity;
KIRP	cis	rs10875746	0.903	rs10875738	chr12:48473739	T/A	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg09238746	chr17:78121135	EIF4A3	-0.65	-7.94	-0.45	7.38e-14	Yeast infection;
KIRP	cis	rs33912345	0.695	rs1254274	chr14:60845309	A/T	cg27398547	chr14:60952738	C14orf39	0.41	5.48	0.33	1.03e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg23533419	chr12:54090519	NA	-0.35	-5.32	-0.32	2.36e-7	Height;
KIRP	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.95	10.29	0.55	6.92e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.92	-12.86	-0.63	2.8e-29	Menopause (age at onset);
KIRP	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg21584983	chr19:11640070	ECSIT	0.56	6.57	0.39	3.03e-10	Sleep duration;
KIRP	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg21360079	chr12:107162445	NA	-0.67	-9.39	-0.51	4.32e-18	Heart rate;
KIRP	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg11189052	chr15:85197271	WDR73	0.48	4.99	0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg13482628	chr17:19912719	NA	0.57	8.08	0.46	3e-14	Schizophrenia;
KIRP	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.45	5.09	0.31	7.08e-7	Height;
KIRP	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg05805236	chr11:65401703	PCNXL3	-0.58	-7.44	-0.43	1.66e-12	Acne (severe);
KIRP	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg20965017	chr5:231967	SDHA	0.59	6.86	0.4	5.48e-11	Breast cancer;
KIRP	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.39	5.09	0.31	7.14e-7	Social autistic-like traits;
KIRP	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg03714773	chr7:91764589	CYP51A1	-0.36	-5.23	-0.32	3.63e-7	Breast cancer;
KIRP	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19717773	chr7:2847554	GNA12	0.36	5.35	0.32	2.04e-7	Height;
KIRP	cis	rs3762637	0.943	rs9289198	chr3:122277160	G/T	cg24169773	chr3:122142474	KPNA1	-0.58	-5.98	-0.36	7.92e-9	LDL cholesterol levels;
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.81	0.49	2.34e-16	Life satisfaction;
KIRP	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg17788362	chr6:86352627	SYNCRIP	0.48	6.39	0.38	8.13e-10	Smooth-surface caries;
KIRP	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.71	-7.11	-0.41	1.24e-11	Migraine;Coronary artery disease;
KIRP	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg02569458	chr12:86230093	RASSF9	0.37	5.36	0.32	1.95e-7	Major depressive disorder;
KIRP	cis	rs25422	0.938	rs62421538	chr6:118729703	A/T	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Renal cell carcinoma;
KIRP	cis	rs6429082	0.875	rs4659524	chr1:235583354	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.52	-6.82	-0.4	6.96e-11	Adiposity;
KIRP	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg27490568	chr2:178487706	NA	0.39	5.2	0.31	4.16e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6546324	0.625	rs2902008	chr2:67802950	T/C	cg15745817	chr2:67799979	NA	-0.65	-7.15	-0.41	9.85e-12	Endometriosis;
KIRP	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.51	6.35	0.38	1.04e-9	Birth weight;
KIRP	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg07701084	chr6:150067640	NUP43	0.61	7.95	0.45	6.8e-14	Lung cancer;
KIRP	cis	rs35883536	0.565	rs2809813	chr1:101032003	A/C	cg06223162	chr1:101003688	GPR88	0.46	9.7	0.53	4.89e-19	Monocyte count;
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.8	9.94	0.54	8.81e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.03	15.9	0.71	1.26e-39	Cognitive function;
KIRP	cis	rs732716	0.785	rs11085073	chr19:4375162	A/G	cg03719555	chr19:4455413	UBXN6	-0.47	-7.03	-0.41	2.07e-11	Mean corpuscular volume;
KIRP	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg26207909	chr14:103986467	CKB	0.5	5.14	0.31	5.49e-7	Coronary artery disease;
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.8	-10.88	-0.57	9.1e-23	Longevity;
KIRP	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.38	0.62	1.11e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg05991184	chr2:219186017	PNKD	0.34	4.9	0.3	1.73e-6	Colorectal cancer;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs72960926	0.744	rs768509	chr6:75005487	G/A	cg03266952	chr6:74778945	NA	-0.76	-5.78	-0.35	2.28e-8	Metabolite levels (MHPG);
KIRP	cis	rs2267137	0.747	rs1963292	chr22:29805867	T/C	cg07256473	chr22:29710276	RASL10A	0.41	6.31	0.37	1.29e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	0.96	12.26	0.62	2.71e-27	Blood protein levels;
KIRP	trans	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17027945	chr15:74284732	STOML1	0.55	6.45	0.38	5.83e-10	Smoking initiation;
KIRP	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11987759	chr7:65425863	GUSB	0.49	6.4	0.38	7.91e-10	Aortic root size;
KIRP	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg09699651	chr6:150184138	LRP11	0.44	5.69	0.34	3.68e-8	Lung cancer;
KIRP	cis	rs2671245	0.934	rs1514146	chr1:56177518	C/A	cg11523071	chr1:56160889	NA	0.41	6.27	0.37	1.63e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.55	-5.09	-0.31	7.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg01656853	chr19:49199172	FUT2	0.34	4.86	0.3	2.09e-6	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.3e-10	Blood metabolite levels;
KIRP	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02725872	chr8:58115012	NA	-0.56	-6.48	-0.38	5.04e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12893428	chr3:195717962	SDHAP1	-0.45	-6.04	-0.36	5.58e-9	Pancreatic cancer;
KIRP	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg01843524	chr15:80216276	C15orf37;ST20	0.54	6.5	0.38	4.51e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	trans	rs7939886	0.920	rs11227850	chr11:56081507	A/G	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	trans	rs4742903	0.509	rs10991160	chr9:106961153	C/G	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.1	-0.36	4.04e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs62229266	0.804	rs11088331	chr21:37421872	T/C	cg08632701	chr21:37451849	NA	-0.43	-5.38	-0.32	1.72e-7	Mitral valve prolapse;
KIRP	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg00262122	chr8:11665843	FDFT1	0.41	5.16	0.31	5.06e-7	Neuroticism;
KIRP	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg02151108	chr14:50098012	C14orf104	-0.58	-8.19	-0.46	1.38e-14	Carotid intima media thickness;
KIRP	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg02002194	chr4:3960332	NA	0.47	7.12	0.41	1.2e-11	Mood instability;
KIRP	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08280861	chr8:58055591	NA	0.7	5.89	0.35	1.27e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.27	-0.42	4.67e-12	Joint mobility (Beighton score);
KIRP	cis	rs2299587	0.554	rs9325823	chr8:17735871	A/G	cg01800426	chr8:17659068	MTUS1	0.42	5.05	0.31	8.74e-7	Economic and political preferences;
KIRP	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.25e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6120849	0.901	rs6060273	chr20:33744323	G/C	cg24642439	chr20:33292090	TP53INP2	0.55	6.12	0.36	3.65e-9	Protein C levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14221825	chr19:46271408	SIX5	0.45	6.31	0.37	1.3e-9	Survival in pancreatic cancer;
KIRP	trans	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.47e-11	Bladder cancer;
KIRP	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.77	-11.05	-0.58	2.5e-23	Height;
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.37	-5.25	-0.32	3.25e-7	Bipolar disorder;
KIRP	cis	rs881375	0.902	rs7021880	chr9:123673890	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.51	-5.85	-0.35	1.56e-8	Rheumatoid arthritis;
KIRP	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.4	-5.21	-0.32	4.03e-7	Crohn's disease;
KIRP	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs35771425	0.626	rs55761812	chr1:211653935	C/T	cg10512769	chr1:211675356	NA	-0.69	-8.17	-0.46	1.67e-14	Educational attainment (years of education);
KIRP	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.75	-10.17	-0.54	1.65e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg00784671	chr22:46762841	CELSR1	-0.88	-8.24	-0.47	1.01e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.47	5.21	0.32	4.06e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Parkinson's disease;
KIRP	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.69	6.5	0.38	4.32e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs17401966	0.898	rs1396	chr1:10247143	C/A	cg19773385	chr1:10388646	KIF1B	-0.6	-7.45	-0.43	1.56e-12	Hepatocellular carcinoma;
KIRP	cis	rs7551222	0.691	rs11240760	chr1:204547268	A/G	cg20240347	chr1:204465584	NA	-0.44	-8.36	-0.47	4.62e-15	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg10755058	chr3:40428713	ENTPD3	-0.42	-6.21	-0.37	2.27e-9	Renal cell carcinoma;
KIRP	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg07645718	chr20:61493192	TCFL5	0.78	6.14	0.36	3.36e-9	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.22	23.66	0.83	2.5e-65	Cognitive function;
KIRP	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.8	10.78	0.57	1.97e-22	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg12560992	chr17:57184187	TRIM37	-0.59	-5.52	-0.33	8.77e-8	Cognitive test performance;
KIRP	cis	rs6707387	0.686	rs7577685	chr2:214458300	C/G	cg08319019	chr2:214017104	IKZF2	0.48	5.47	0.33	1.13e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.56	-6.98	-0.41	2.68e-11	Monocyte count;
KIRP	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.35	-0.78	2.43e-51	Height;
KIRP	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg24253500	chr15:84953950	NA	0.5	5.67	0.34	4.04e-8	Schizophrenia;
KIRP	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.24	-0.32	3.37e-7	Coronary artery disease;
KIRP	cis	rs8060686	0.516	rs7193701	chr16:68185160	A/G	cg26727032	chr16:67993705	SLC12A4	0.59	6.29	0.37	1.44e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg17644776	chr2:200775616	C2orf69	0.62	5.67	0.34	4.01e-8	Schizophrenia;
KIRP	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg02175308	chr1:109941060	SORT1	-0.26	-4.94	-0.3	1.41e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg19094597	chr12:13365769	EMP1	0.52	6.02	0.36	6.15e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg10189774	chr4:17578691	LAP3	0.46	5.7	0.34	3.45e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1014246	0.813	rs1014245	chr10:118466129	G/A	cg14919929	chr10:118506882	NA	0.58	7.2	0.42	7.32e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-6.09	-0.36	4.38e-9	Total cholesterol levels;
KIRP	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg26695010	chr11:65641043	EFEMP2	-0.5	-5.0	-0.3	1.09e-6	Crohn's disease;
KIRP	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13789711	chr9:139743225	PHPT1	0.59	7.01	0.41	2.3e-11	Smoking initiation;
KIRP	cis	rs4654899	0.931	rs6661116	chr1:21337155	C/G	cg05370193	chr1:21551575	ECE1	0.45	6.16	0.37	2.89e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7546094	1.000	rs1001494	chr1:113110619	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg01475377	chr6:109611718	NA	-0.36	-4.92	-0.3	1.6e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16414030	chr3:133502952	NA	-0.51	-5.99	-0.36	7.37e-9	Iron status biomarkers;
KIRP	cis	rs9905704	0.589	rs2680696	chr17:56473013	C/T	cg12560992	chr17:57184187	TRIM37	-0.54	-5.12	-0.31	6.07e-7	Testicular germ cell tumor;
KIRP	cis	rs12496230	0.830	rs6781336	chr3:66858050	A/G	cg17646820	chr3:66848679	NA	0.4	6.66	0.39	1.82e-10	Type 2 diabetes;
KIRP	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg13819577	chr1:248512075	OR14C36	-0.38	-5.16	-0.31	4.99e-7	Common traits (Other);
KIRP	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	1.12	8.19	0.46	1.41e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.73	-0.44	2.68e-13	Type 2 diabetes;
KIRP	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.86	-0.35	1.44e-8	Colorectal cancer;
KIRP	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.95	0.54	8.03e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs787274	1.000	rs787291	chr9:115507904	A/T	cg13803584	chr9:115635662	SNX30	0.72	6.31	0.37	1.29e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.68	-0.39	1.61e-10	Response to antipsychotic treatment;
KIRP	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.56	-9.61	-0.52	9.16e-19	Lung cancer;
KIRP	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3820500	0.543	rs2622363	chr1:118089341	T/C	cg20383390	chr1:117909022	MAN1A2	-0.46	-4.96	-0.3	1.29e-6	Pneumonia;
KIRP	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg18882449	chr10:104885122	NT5C2	-0.39	-5.1	-0.31	6.73e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.49	-0.43	1.24e-12	Pulmonary function;
KIRP	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs2997447	0.802	rs61775415	chr1:26391849	A/C	cg19633962	chr1:26362018	EXTL1	-0.75	-6.27	-0.37	1.58e-9	QRS complex (12-leadsum);
KIRP	cis	rs2084898	0.550	rs550164	chr11:120002727	C/T	cg07435449	chr11:120005650	TRIM29	0.5	6.8	0.4	8.1e-11	Stroke (pediatric);
KIRP	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg09455208	chr3:40491958	NA	0.41	7.02	0.41	2.18e-11	Renal cell carcinoma;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.76	-7.96	-0.45	6.17e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg02696742	chr7:106810147	HBP1	-0.78	-8.95	-0.5	9.04e-17	Coronary artery disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg02221684	chr16:57220272	FAM192A;RSPRY1	0.49	6.34	0.37	1.07e-9	Myopia (pathological);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg27303409	chr5:108746352	PJA2	-0.51	-6.4	-0.38	7.65e-10	Obesity-related traits;
KIRP	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg00343986	chr7:65444356	GUSB	0.43	5.11	0.31	6.5e-7	Aortic root size;
KIRP	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23161317	chr6:28129485	ZNF389	0.42	4.92	0.3	1.57e-6	Depression;
KIRP	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.38	0.38	8.67e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs62388641	0.539	rs56016631	chr6:1542575	T/G	cg01806741	chr6:1527072	NA	-0.38	-5.79	-0.35	2.13e-8	Daytime sleep phenotypes;
KIRP	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.72	10.58	0.56	8.07e-22	High light scatter reticulocyte count;
KIRP	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg16989719	chr2:238392110	NA	-0.54	-6.08	-0.36	4.47e-9	Prostate cancer;
KIRP	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	8.86	0.49	1.6e-16	Resting heart rate;
KIRP	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg05234568	chr11:5960015	NA	-0.6	-6.18	-0.37	2.71e-9	DNA methylation (variation);
KIRP	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.75	10.5	0.56	1.48e-21	Parkinson's disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg19701416	chr10:28592092	NA	0.74	6.42	0.38	6.93e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.55	0.33	7.25e-8	Educational attainment;
KIRP	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg08501292	chr6:25962987	TRIM38	0.96	5.81	0.35	1.97e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs963731	0.649	rs297150	chr2:39326164	C/T	cg04010122	chr2:39346883	SOS1	-0.9	-6.27	-0.37	1.65e-9	Corticobasal degeneration;
KIRP	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.43	5.02	0.3	1e-6	Diastolic blood pressure;
KIRP	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg17366294	chr4:99064904	C4orf37	0.43	5.96	0.36	8.66e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg07936489	chr17:37558343	FBXL20	-0.45	-5.59	-0.34	5.94e-8	Asthma;
KIRP	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	7.34	0.42	3.17e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12292205	chr6:26970375	C6orf41	-0.57	-7.56	-0.43	8.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.66	9.2	0.51	1.63e-17	Longevity;
KIRP	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.66	-0.44	4.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.4e-12	Prudent dietary pattern;
KIRP	cis	rs9914544	0.545	rs8069826	chr17:18765490	G/T	cg26378065	chr17:18585709	ZNF286B	0.39	4.99	0.3	1.15e-6	Educational attainment (years of education);
KIRP	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	11.48	0.59	1.04e-24	Smoking behavior;
KIRP	cis	rs4253772	0.515	rs9615968	chr22:46772695	A/G	cg00784671	chr22:46762841	CELSR1	-0.93	-8.11	-0.46	2.45e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs55962025	0.711	rs3856973	chr4:3080173	A/G	cg06533319	chr4:3265114	C4orf44	-0.39	-5.01	-0.3	1.06e-6	Parental longevity (mother's age at death);
KIRP	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.72	0.34	3.02e-8	Personality dimensions;
KIRP	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-10.02	-0.54	4.95e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs698833	0.548	rs1067350	chr2:44669946	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.83	0.35	1.74e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs10465746	0.967	rs10493744	chr1:84444752	C/T	cg10977910	chr1:84465055	TTLL7	-0.48	-5.91	-0.35	1.12e-8	Obesity-related traits;
KIRP	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg11344533	chr11:111475393	SIK2	-0.3	-5.06	-0.31	8.39e-7	Primary sclerosing cholangitis;
KIRP	cis	rs8060686	0.623	rs7204208	chr16:68069416	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-7.64	-0.44	4.71e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs71277158	0.688	rs3772186	chr3:169889331	A/T	cg04067573	chr3:169899625	PHC3	-0.65	-6.22	-0.37	2.17e-9	Prostate cancer;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.69	10.32	0.55	5.48e-21	Menarche (age at onset);
KIRP	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.23	0.37	1.98e-9	Aortic root size;
KIRP	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.55	-6.23	-0.37	2.02e-9	Menarche (age at onset);
KIRP	cis	rs2033732	0.706	rs10102194	chr8:85075662	T/G	cg05716166	chr8:85095498	RALYL	0.58	6.63	0.39	2.11e-10	Body mass index;
KIRP	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.44	10.98	0.57	4.33e-23	Diastolic blood pressure;
KIRP	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.48	6.42	0.38	7.02e-10	Hemoglobin concentration;
KIRP	cis	rs986417	1.000	rs10143118	chr14:61066043	G/A	cg27398547	chr14:60952738	C14orf39	0.68	5.91	0.35	1.16e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.36	8.16	0.46	1.73e-14	Diastolic blood pressure;
KIRP	cis	rs12474201	0.851	rs4130731	chr2:47022818	T/G	cg06386533	chr2:46925753	SOCS5	1.05	13.95	0.66	5.76e-33	Height;
KIRP	trans	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.7	-7.62	-0.44	5.63e-13	Blood pressure (smoking interaction);
KIRP	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.1e-10	Major depressive disorder;
KIRP	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.73	-0.34	2.93e-8	Bipolar disorder;
KIRP	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.36	5.04	0.31	9.05e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.88e-13	Bipolar disorder;
KIRP	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.47	5.96	0.36	8.66e-9	Height;
KIRP	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg12661370	chr5:149340060	SLC26A2	0.47	5.75	0.34	2.7e-8	HIV-1 control;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06714284	chr1:235812840	GNG4	0.52	7.12	0.41	1.21e-11	Parkinson's disease;
KIRP	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg13010199	chr12:38710504	ALG10B	0.49	6.42	0.38	7.16e-10	Morning vs. evening chronotype;
KIRP	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.68	9.41	0.51	3.65e-18	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.54	0.33	7.95e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg02462569	chr6:150064036	NUP43	-0.38	-5.73	-0.34	2.91e-8	Lung cancer;
KIRP	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.76	-10.47	-0.56	1.82e-21	Blood metabolite levels;
KIRP	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.7	-7.14	-0.41	1.02e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6466055	0.661	rs1468359	chr7:104922022	C/A	cg04380332	chr7:105027541	SRPK2	0.37	5.03	0.31	9.68e-7	Schizophrenia;
KIRP	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg12091567	chr17:66097778	LOC651250	0.68	8.21	0.46	1.29e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.49	-5.12	-0.31	6.07e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs17154702	0.510	rs7831224	chr8:8656647	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-5.53	-0.33	8.24e-8	Neurocognitive impairment in HIV-1 infection (continuous);
KIRP	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.62e-8	Neuroticism;
KIRP	cis	rs11767191	0.846	rs34130920	chr7:48777508	A/G	ch.7.1147807F	chr7:49473528	NA	-0.39	-4.88	-0.3	1.91e-6	Response to amphetamines;
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg04234412	chr22:24373322	LOC391322	-0.68	-7.52	-0.43	1.01e-12	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg00079169	chr19:2811669	THOP1	0.56	6.07	0.36	4.85e-9	Total cholesterol levels;
KIRP	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg10818794	chr15:86012489	AKAP13	-0.65	-9.73	-0.53	3.75e-19	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.81	11.5	0.59	9.08e-25	Morning vs. evening chronotype;
KIRP	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg00204512	chr16:28754710	NA	0.42	5.61	0.34	5.55e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.64	-8.49	-0.48	1.93e-15	Motion sickness;
KIRP	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg10950524	chr7:2139216	MAD1L1	-0.32	-5.03	-0.31	9.3e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2172802	0.659	rs2343251	chr4:62492671	C/A	cg04118610	chr4:62707027	LPHN3	0.57	6.97	0.41	2.85e-11	Partial epilepsies;
KIRP	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	cg21523751	chr1:182988639	NA	-0.45	-6.98	-0.41	2.65e-11	Hypertriglyceridemia;
KIRP	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-9.99	-0.54	5.94e-20	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg11814155	chr7:99998594	ZCWPW1	0.58	5.41	0.33	1.53e-7	Platelet count;
KIRP	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg04317338	chr11:64019027	PLCB3	0.43	5.21	0.32	4.04e-7	Platelet count;
KIRP	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.57	-5.97	-0.36	8.18e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.54	-0.48	1.39e-15	Neuroticism;
KIRP	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19882132	chr14:106167949	NA	-0.41	-5.03	-0.31	9.44e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs73193808	0.614	rs2832251	chr21:30559552	G/C	cg03476357	chr21:30257390	N6AMT1	0.43	5.03	0.31	9.66e-7	Coronary artery disease;
KIRP	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg12549451	chr6:135224345	NA	0.42	5.07	0.31	7.94e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.45	6.88	0.4	4.81e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.5e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2562456	0.833	rs61035285	chr19:21512277	G/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.38e-6	Pain;
KIRP	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05601917	chr6:125855416	NA	-0.36	-5.49	-0.33	1.01e-7	Brugada syndrome;
KIRP	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg02336718	chr17:17403227	NA	0.33	5.21	0.32	4.06e-7	Total body bone mineral density;
KIRP	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.61	6.97	0.41	2.88e-11	Schizophrenia;
KIRP	cis	rs6987853	0.814	rs2167338	chr8:42455079	A/G	cg09913449	chr8:42400586	C8orf40	0.38	4.92	0.3	1.61e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg23594656	chr7:65796392	TPST1	0.35	5.02	0.3	9.85e-7	Aortic root size;
KIRP	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg13072238	chr3:49761600	GMPPB	0.58	5.41	0.33	1.5e-7	Menarche (age at onset);
KIRP	cis	rs76693355	0.512	rs11823264	chr11:120294004	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.39	-5.21	-0.32	4.02e-7	Intraocular pressure;
KIRP	cis	rs11203032	0.831	rs11203009	chr10:90927163	G/A	cg16672925	chr10:90967113	CH25H	0.78	7.68	0.44	3.81e-13	Heart failure;
KIRP	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.93	-0.4	3.67e-11	Eye color traits;
KIRP	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg14082893	chr15:75400931	NA	-0.37	-5.44	-0.33	1.25e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4664293	0.667	rs10169681	chr2:160638576	G/A	cg08347373	chr2:160653686	CD302	0.38	5.97	0.36	8.23e-9	Monocyte percentage of white cells;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09949816	chr15:34503491	C15orf29	0.46	6.24	0.37	1.9e-9	Interleukin-4 levels;
KIRP	trans	rs1973993	0.561	rs3862908	chr1:96987042	G/A	cg10631902	chr5:14652156	NA	-0.52	-6.56	-0.39	3.15e-10	Weight;
KIRP	cis	rs8258	0.501	rs474490	chr11:117287794	T/G	cg15227623	chr11:117232454	CEP164	0.45	5.58	0.34	6.19e-8	Pulse pressure;
KIRP	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.17e-16	Coronary artery disease;
KIRP	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg04865290	chr3:52927548	TMEM110	-0.66	-7.01	-0.41	2.22e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg12718519	chr1:2058417	PRKCZ	-0.19	-5.53	-0.33	8.24e-8	Height;
KIRP	trans	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.17	0.42	8.51e-12	Mean corpuscular volume;
KIRP	cis	rs7551222	0.752	rs12032733	chr1:204481209	G/A	cg20240347	chr1:204465584	NA	-0.46	-8.67	-0.48	5.81e-16	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg10254082	chr7:997346	NA	0.48	5.07	0.31	7.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg21518248	chr2:162101506	NA	0.49	5.84	0.35	1.66e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg04373760	chr16:53404718	NA	0.58	6.12	0.36	3.66e-9	Hypertriglyceridemia;
KIRP	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs1035491	0.715	rs10055308	chr5:63923911	G/A	cg01791865	chr5:63954708	NA	0.33	5.33	0.32	2.2e-7	Body mass index;
KIRP	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.82	12.62	0.63	1.72e-28	Systemic lupus erythematosus;
KIRP	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg16141378	chr3:129829833	LOC729375	-0.53	-6.58	-0.39	2.88e-10	Retinal vascular caliber;
KIRP	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.65	9.44	0.52	2.99e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.82e-7	Life satisfaction;
KIRP	cis	rs4783244	0.862	rs12443878	chr16:82659933	C/A	cg09415485	chr16:82663111	CDH13	-0.28	-5.15	-0.31	5.28e-7	Adiponectin levels;
KIRP	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg20387954	chr3:183756860	HTR3D	0.61	8.96	0.5	8.18e-17	Anterior chamber depth;
KIRP	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg13385521	chr17:29058706	SUZ12P	0.56	5.47	0.33	1.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.64	-0.39	1.99e-10	Total body bone mineral density;
KIRP	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02034447	chr16:89574710	SPG7	0.4	5.04	0.31	8.92e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg06598544	chr20:61472147	COL9A3	-0.83	-6.66	-0.39	1.81e-10	Obesity-related traits;
KIRP	trans	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	9.19	0.51	1.66e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs918629	0.530	rs3777203	chr5:95234377	C/T	cg16656078	chr5:95278638	ELL2	-0.39	-5.89	-0.35	1.3e-8	IgG glycosylation;
KIRP	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.07	11.94	0.61	3.29e-26	Vitiligo;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg04245645	chr14:96343016	NA	-0.45	-6.36	-0.38	9.8e-10	Morning vs. evening chronotype;
KIRP	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs56146971	0.703	rs76533089	chr14:91863973	G/T	cg10511902	chr14:91842949	CCDC88C	0.47	4.89	0.3	1.84e-6	Alzheimer disease and age of onset;
KIRP	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.21	0.58	7.93e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2904967	0.929	rs673147	chr11:65060427	G/A	cg09225861	chr11:65069680	NA	0.42	5.08	0.31	7.54e-7	Mean corpuscular volume;
KIRP	cis	rs77956314	0.606	rs117831534	chr12:117506632	C/T	cg02017074	chr12:117425053	FBXW8	-1.03	-5.93	-0.35	1.02e-8	Subcortical brain region volumes;Hippocampal volume;
KIRP	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-0.74	-7.94	-0.45	7.31e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.57	-7.74	-0.44	2.56e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg24699146	chr1:24152579	HMGCL	-0.47	-6.06	-0.36	5.12e-9	Immature fraction of reticulocytes;
KIRP	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs17592366	0.517	rs11845027	chr14:35315574	A/G	cg09327582	chr14:35236912	BAZ1A	0.57	6.15	0.37	3.09e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	1.17	15.38	0.7	7.58e-38	Left atrial antero-posterior diameter;
KIRP	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.86	-0.4	5.6e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-8.61	-0.48	9.08e-16	Bone mineral density;
KIRP	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.45	-5.81	-0.35	1.95e-8	Body mass index;
KIRP	cis	rs4523957	0.620	rs8070272	chr17:2063117	A/G	cg16513277	chr17:2031491	SMG6	-0.78	-11.0	-0.57	3.82e-23	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05964000	chr1:55564130	USP24	-0.44	-6.19	-0.37	2.51e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.17	-16.12	-0.72	2.23e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg27411982	chr8:10470053	RP1L1	0.43	5.08	0.31	7.46e-7	Neuroticism;
KIRP	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.93	0.49	9.97e-17	Lung cancer in ever smokers;
KIRP	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg10950524	chr7:2139216	MAD1L1	0.32	5.08	0.31	7.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.38	4.97	0.3	1.24e-6	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23089912	chr10:126694147	CTBP2	-0.43	-6.07	-0.36	4.94e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3105593	1.000	rs17645649	chr15:50900370	A/G	cg08437265	chr15:50716283	USP8	0.41	5.1	0.31	6.69e-7	QT interval;
KIRP	cis	rs516946	1.000	rs3802316	chr8:41528228	G/C	cg19441908	chr8:41529140	ANK1	0.49	6.93	0.4	3.75e-11	Type 2 diabetes;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.46	-5.66	-0.34	4.21e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg19847130	chr8:10466454	RP1L1	0.33	4.9	0.3	1.72e-6	Neuroticism;
KIRP	cis	rs9517320	0.934	rs9517319	chr13:99125956	T/G	cg07423050	chr13:99094983	FARP1	0.31	5.07	0.31	7.75e-7	Longevity;
KIRP	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.51	6.57	0.39	2.91e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs654128	0.640	rs1321367	chr6:117238668	A/C	cg12892004	chr6:117198278	RFX6	-0.41	-5.26	-0.32	3.14e-7	Telomere length;
KIRP	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.06	0.46	3.28e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.43	-0.38	6.48e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	0.93	9.85	0.53	1.68e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.55	0.33	7.32e-8	Lung cancer;
KIRP	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6956675	0.915	rs7790432	chr7:62631824	T/C	cg08930214	chr7:62859557	LOC100287834	0.41	4.97	0.3	1.25e-6	Obesity-related traits;
KIRP	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.65	11.01	0.57	3.36e-23	White blood cell count (basophil);
KIRP	trans	rs7158300	1.000	rs11160036	chr14:92481047	A/C	cg22777467	chr5:125826160	GRAMD3	-0.5	-6.02	-0.36	6.24e-9	Height;
KIRP	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg00074818	chr8:8560427	CLDN23	-0.4	-6.31	-0.37	1.26e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-0.9	-10.75	-0.57	2.46e-22	Vitiligo;
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.7	0.53	4.63e-19	Lung cancer;
KIRP	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg18461458	chr19:21324796	ZNF431	-0.47	-4.95	-0.3	1.4e-6	Pain;
KIRP	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-5.54	-0.33	7.76e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs6441961	0.832	rs7374671	chr3:46346036	A/G	cg21077330	chr10:134121709	STK32C	-0.56	-6.22	-0.37	2.11e-9	Celiac disease;
KIRP	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.56	5.38	0.32	1.72e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg18154014	chr19:37997991	ZNF793	-0.61	-6.68	-0.39	1.56e-10	Coronary artery calcification;
KIRP	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-6.96	-0.41	3.14e-11	Schizophrenia;
KIRP	cis	rs11967485	0.609	rs62435828	chr6:157193607	C/T	cg23222435	chr6:157204239	ARID1B	-0.75	-4.9	-0.3	1.72e-6	Calcium levels;
KIRP	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg26338869	chr17:61819248	STRADA	0.4	4.99	0.3	1.13e-6	Prudent dietary pattern;
KIRP	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	11.29	0.58	4.44e-24	Blood protein levels;
KIRP	cis	rs16858210	0.874	rs73177525	chr3:183570286	G/C	cg25686905	chr3:183603175	PARL	-0.42	-4.94	-0.3	1.46e-6	Menopause (age at onset);
KIRP	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.63	9.04	0.5	4.88e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.51	0.38	4.09e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.65	9.91	0.53	1.05e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.66	7.57	0.43	7.44e-13	Platelet count;
KIRP	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.59	-8.31	-0.47	6.47e-15	Calcium levels;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg08132940	chr7:1081526	C7orf50	-0.46	-5.28	-0.32	2.86e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg13753209	chr17:57696993	CLTC	0.57	5.52	0.33	8.44e-8	Hemoglobin concentration;
KIRP	cis	rs258892	0.895	rs34302030	chr5:72059832	T/A	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg17061595	chr4:1245206	C4orf42	0.41	6.74	0.39	1.12e-10	Serum protein levels (sST2);
KIRP	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg24315340	chr6:146058215	EPM2A	0.43	5.48	0.33	1.06e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg07747251	chr5:1868357	NA	0.42	5.57	0.33	6.81e-8	Cardiovascular disease risk factors;
KIRP	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.7	-10.27	-0.55	8.27e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17507749	chr15:85114479	UBE2QP1	0.74	8.23	0.46	1.13e-14	Schizophrenia;
KIRP	cis	rs10411936	0.720	rs7252649	chr19:16582785	G/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	5.14	0.31	5.71e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-8.72	-0.49	4.24e-16	Morning vs. evening chronotype;
KIRP	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.13	0.36	3.53e-9	Height;
KIRP	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg00823993	chr13:113535758	ATP11A	0.47	5.45	0.33	1.25e-7	Interstitial lung disease;
KIRP	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.01	-0.3	1.06e-6	Inflammatory skin disease;
KIRP	cis	rs10924309	0.737	rs1122736	chr1:245852695	A/G	cg00036263	chr1:245852353	KIF26B	-0.54	-7.72	-0.44	2.88e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26841156	chr19:7913922	EVI5L	-0.46	-6.21	-0.37	2.27e-9	Survival in pancreatic cancer;
KIRP	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	7.18	0.42	8.27e-12	Cognitive test performance;
KIRP	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21016266	chr12:122356598	WDR66	-0.62	-8.7	-0.48	4.92e-16	Mean corpuscular volume;
KIRP	cis	rs2067615	0.826	rs2731359	chr12:107255547	T/C	cg21360079	chr12:107162445	NA	-0.42	-5.29	-0.32	2.69e-7	Heart rate;
KIRP	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.3	0.42	3.88e-12	Initial pursuit acceleration;
KIRP	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.52	-0.43	1.05e-12	Systemic lupus erythematosus;
KIRP	cis	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg21775007	chr8:11205619	TDH	0.39	5.33	0.32	2.18e-7	Monocyte count;
KIRP	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg06289844	chr6:126071538	HEY2	0.43	6.38	0.38	8.7e-10	Brugada syndrome;
KIRP	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg23307798	chr14:103986281	CKB	0.74	11.56	0.59	5.47e-25	Body mass index;
KIRP	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.77	9.71	0.53	4.6e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.26	5.1	0.31	6.8e-7	Coronary artery disease;
KIRP	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.5e-10	Bipolar disorder;
KIRP	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.35	6.93	0.4	3.58e-11	Educational attainment (years of education);
KIRP	cis	rs4523957	0.890	rs216222	chr17:2155701	T/A	cg16513277	chr17:2031491	SMG6	0.57	7.76	0.44	2.3e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.8	7.46	0.43	1.51e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.68	-10.52	-0.56	1.33e-21	Hepatocellular carcinoma;
KIRP	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.59	-0.34	5.97e-8	Neuroticism;
KIRP	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs7635838	0.859	rs9869423	chr3:11459156	G/T	cg00170343	chr3:11313890	ATG7	0.45	5.84	0.35	1.63e-8	HDL cholesterol;
KIRP	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg24699146	chr1:24152579	HMGCL	0.5	6.84	0.4	6.09e-11	Immature fraction of reticulocytes;
KIRP	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-8.94	-0.5	9.44e-17	Colorectal cancer;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.21	22.33	0.82	4.35e-61	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg04232466	chr8:21988724	HR	0.45	6.14	0.36	3.37e-9	Asthma;
KIRP	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg14784868	chr12:69753453	YEATS4	0.51	5.25	0.32	3.29e-7	Response to diuretic therapy;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.8	7.71	0.44	3.02e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8028182	0.549	rs10775209	chr15:75634759	G/A	cg20655648	chr15:75932815	IMP3	-0.55	-6.88	-0.4	4.84e-11	Sudden cardiac arrest;
KIRP	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02187348	chr16:89574699	SPG7	0.55	7.11	0.41	1.27e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.55	-7.54	-0.43	8.99e-13	Mean corpuscular volume;
KIRP	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.6	9.28	0.51	8.82e-18	Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg04369109	chr6:150039330	LATS1	-0.48	-6.13	-0.36	3.39e-9	Lung cancer;
KIRP	cis	rs9462794	0.894	rs9471832	chr6:12446863	A/T	cg09853206	chr6:12430810	NA	0.51	6.46	0.38	5.45e-10	Pulse pressure;
KIRP	cis	rs10782582	0.609	rs11588643	chr1:76255613	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-6.32	-0.37	1.25e-9	Daytime sleep phenotypes;
KIRP	cis	rs6969780	0.915	rs12666926	chr7:27189561	A/G	cg11410718	chr7:27170412	HOXA4	-0.42	-5.35	-0.32	2.01e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9815354	0.812	rs73077361	chr3:41850146	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg05370193	chr1:21551575	ECE1	0.44	6.21	0.37	2.23e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.27e-21	Educational attainment;
KIRP	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.15	-0.41	1.01e-11	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs3752645	0.764	rs58386564	chr7:106694274	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-5.19	-0.31	4.35e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.23	-0.64	1.52e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01246405	chr11:3876562	STIM1	0.57	6.85	0.4	5.78e-11	Smoking initiation;
KIRP	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg18132916	chr6:79620363	NA	-0.44	-5.93	-0.35	1.04e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.71	-10.05	-0.54	3.84e-20	Lung cancer;
KIRP	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.68	8.81	0.49	2.36e-16	Breast cancer;
KIRP	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg05785598	chr3:49045655	WDR6	0.3	5.46	0.33	1.19e-7	Parkinson's disease;
KIRP	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.28	-5.58	-0.34	6.37e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.61	7.19	0.42	7.55e-12	Aortic root size;
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg17441377	chr17:3906640	NA	-0.5	-7.27	-0.42	4.84e-12	Type 2 diabetes;
KIRP	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.58	-7.11	-0.41	1.29e-11	Obesity-related traits;
KIRP	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg02980000	chr4:1222292	CTBP1	0.84	8.15	0.46	1.88e-14	Systolic blood pressure;
KIRP	cis	rs3818717	0.538	rs752579	chr17:17660347	C/T	cg04398451	chr17:18023971	MYO15A	0.4	4.97	0.3	1.28e-6	Lymphocyte counts;
KIRP	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.71	-0.39	1.3100000000000001e-10	Systolic blood pressure;
KIRP	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg11906718	chr8:101322791	RNF19A	0.49	6.41	0.38	7.48e-10	Atrioventricular conduction;
KIRP	cis	rs11209185	0.509	rs9326078	chr1:68452388	A/G	cg22082780	chr1:68452167	NA	0.37	5.41	0.33	1.49e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.55	0.39	3.39e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02359409	chr6:42947317	PEX6	-0.5	-6.84	-0.4	6.16e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg22284058	chr8:142237359	SLC45A4	0.53	6.72	0.39	1.24e-10	Immature fraction of reticulocytes;
KIRP	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.78	-9.72	-0.53	4.08e-19	Iron status biomarkers;
KIRP	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-7.24	-0.42	5.78e-12	Morning vs. evening chronotype;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg24562465	chr2:105191709	NA	-0.45	-6.02	-0.36	6.19e-9	Inflammatory biomarkers;
KIRP	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.65	-7.05	-0.41	1.83e-11	Corneal structure;
KIRP	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.87	13.8	0.66	1.76e-32	Blood protein levels;
KIRP	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs4671458	0.570	rs17618390	chr2:63831325	C/G	cg17519650	chr2:63277830	OTX1	-0.53	-5.86	-0.35	1.45e-8	Subjective well-being;
KIRP	cis	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs13033859	0.526	rs12477065	chr2:292753	C/T	cg12623918	chr2:306882	NA	0.51	5.87	0.35	1.39e-8	Mitochondrial DNA levels;
KIRP	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	10.7	0.56	3.58e-22	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15783466	chr12:55846355	OR6C2	0.42	6.13	0.36	3.39e-9	Interleukin-4 levels;
KIRP	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg21395723	chr22:39101663	GTPBP1	-0.44	-5.46	-0.33	1.16e-7	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19173502	chr21:17911688	MIRLET7C;C21orf34	-0.43	-7.04	-0.41	1.91e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22559002	chr17:63898392	CCDC46	0.44	6.14	0.36	3.35e-9	Interleukin-4 levels;
KIRP	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.93	-14.61	-0.68	3.12e-35	Systemic lupus erythematosus;
KIRP	cis	rs4356932	0.817	rs6826406	chr4:76973557	A/C	cg19388996	chr4:76862389	NAAA	0.4	5.15	0.31	5.31e-7	Blood protein levels;
KIRP	cis	rs911119	0.913	rs34792920	chr20:23581876	C/T	cg09631192	chr20:23583594	CST9	-0.64	-6.19	-0.37	2.44e-9	Chronic kidney disease;
KIRP	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.26	17.01	0.74	1.98e-43	Corneal structure;
KIRP	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg15488143	chr7:128924101	AHCYL2	0.63	6.9	0.4	4.47e-11	White matter hyperintensity burden;
KIRP	cis	rs4780401	0.729	rs8045300	chr16:11769266	C/G	cg01061890	chr16:11836724	TXNDC11	-0.4	-4.85	-0.3	2.19e-6	Rheumatoid arthritis;
KIRP	cis	rs1023500	1.000	rs1023498	chr22:42340569	C/T	cg04733989	chr22:42467013	NAGA	-0.49	-5.48	-0.33	1.08e-7	Schizophrenia;
KIRP	cis	rs4713675	0.546	rs2296739	chr6:33656969	G/A	cg14003231	chr6:33640908	ITPR3	0.3	5.31	0.32	2.43e-7	Plateletcrit;
KIRP	cis	rs11696739	0.513	rs34600126	chr20:1597433	G/T	cg11295724	chr20:1538353	SIRPD	-0.5	-4.89	-0.3	1.85e-6	Mean platelet volume;
KIRP	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg15556689	chr8:8085844	FLJ10661	-0.77	-11.03	-0.58	2.97e-23	Triglycerides;
KIRP	cis	rs60311166	1.000	rs72965177	chr3:52635064	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.91	5.6	0.34	5.58e-8	CTACK levels;
KIRP	cis	rs6546886	0.869	rs12995468	chr2:74266778	A/G	cg14702570	chr2:74259524	NA	-0.27	-5.02	-0.3	1.02e-6	Dialysis-related mortality;
KIRP	cis	rs12906542	0.529	rs62008651	chr15:78276417	C/T	cg23683012	chr15:78369302	TBC1D2B	0.37	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg01304814	chr3:48885189	PRKAR2A	0.5	5.0	0.3	1.11e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg10503236	chr1:231470652	EXOC8	-0.52	-7.32	-0.42	3.58e-12	Hemoglobin concentration;
KIRP	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.78	9.88	0.53	1.34e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.86	-0.49	1.62e-16	Response to antipsychotic treatment;
KIRP	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg19077165	chr18:44547161	KATNAL2	0.53	6.85	0.4	5.8200000000000003e-11	Educational attainment;
KIRP	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.16	0.37	2.95e-9	Coronary artery disease;
KIRP	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.4	-0.43	2.12e-12	Blood pressure;
KIRP	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	1.11	16.37	0.72	3.16e-41	Monocyte percentage of white cells;
KIRP	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.29	-0.62	2.21e-27	Eye color traits;
KIRP	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.38	-5.02	-0.3	1.01e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-0.95	-13.26	-0.65	1.23e-30	Blood trace element (Zn levels);
KIRP	cis	rs11877825	0.737	rs6505572	chr18:10579366	T/C	cg07277756	chr18:10589357	NA	0.5	6.1	0.36	4.1e-9	Gut microbiota (bacterial taxa);
KIRP	trans	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg19274270	chr17:78178856	CARD14	0.35	6.35	0.38	1.05e-9	Morning vs. evening chronotype;
KIRP	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-8.69	-0.48	5.26e-16	Platelet count;
KIRP	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg26084005	chr2:241760190	KIF1A	-0.49	-6.99	-0.41	2.57e-11	Urinary metabolites;
KIRP	cis	rs10782582	0.668	rs1250880	chr1:76196602	T/C	cg03433033	chr1:76189801	ACADM	0.37	5.73	0.34	2.9e-8	Daytime sleep phenotypes;
KIRP	cis	rs7615316	0.779	rs9289648	chr3:142036520	A/G	cg20824294	chr3:142316082	PLS1	0.23	5.37	0.32	1.79e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs1973993	1.000	rs1973993	chr1:96943994	A/G	cg10631902	chr5:14652156	NA	0.69	10.62	0.56	6.45e-22	Weight;
KIRP	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.38	-0.38	8.92e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.53	7.17	0.42	8.69e-12	IgG glycosylation;
KIRP	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg06935464	chr4:38784597	TLR10	0.54	5.37	0.32	1.8e-7	Breast cancer;
KIRP	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg01631408	chr1:248437212	OR2T33	-0.44	-5.95	-0.35	9.27e-9	Common traits (Other);
KIRP	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg25706552	chr1:244017396	NA	0.6	7.51	0.43	1.06e-12	RR interval (heart rate);
KIRP	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-5.28	-0.32	2.78e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.48	-6.9	-0.4	4.48e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs422249	0.819	rs174605	chr11:61626921	G/T	cg19610905	chr11:61596333	FADS2	-0.47	-6.06	-0.36	5.19e-9	Trans fatty acid levels;
KIRP	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.06	-0.36	5.13e-9	Response to antipsychotic treatment;
KIRP	cis	rs1978968	1.000	rs1076542	chr22:18446452	A/G	cg02610425	chr22:18483192	MICAL3	-0.38	-5.27	-0.32	3.05e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.69	7.83	0.45	1.48e-13	Monocyte count;
KIRP	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg27205649	chr11:78285834	NARS2	-0.57	-5.1	-0.31	6.67e-7	Testicular germ cell tumor;
KIRP	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs667920	0.557	rs13072691	chr3:136425600	T/C	cg15507776	chr3:136538369	TMEM22	-0.75	-6.28	-0.37	1.49e-9	Coronary artery disease;
KIRP	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg12559939	chr2:27858050	GPN1	-0.39	-5.01	-0.3	1.02e-6	Total body bone mineral density;
KIRP	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	7.48	0.43	1.27e-12	Lung cancer in ever smokers;
KIRP	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.5	-7.31	-0.42	3.77e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg11271282	chr2:238384023	NA	0.56	6.5	0.38	4.33e-10	Prostate cancer;
KIRP	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.53	-5.5	-0.33	9.55e-8	Subjective well-being;
KIRP	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.59	-0.68	3.79e-35	Primary sclerosing cholangitis;
KIRP	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.53	-6.39	-0.38	8.45e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9611198	1.000	rs9611198	chr22:39955873	A/C	cg03390717	chr22:39966585	CACNA1I	0.38	6.77	0.4	9.43e-11	Schizophrenia;
KIRP	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.94	0.4	3.48e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26146184	chr11:124637008	C11orf61	0.47	6.4	0.38	7.67e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.63	-7.43	-0.43	1.77e-12	Menarche (age at onset);
KIRP	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	8.21	0.46	1.29e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23422044	chr7:1970798	MAD1L1	-0.61	-6.32	-0.37	1.23e-9	Bipolar disorder;
KIRP	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15644604	chr19:15443264	NA	0.53	6.76	0.4	9.89e-11	Parkinson's disease;
KIRP	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	6.73	0.39	1.18e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.01	14.55	0.68	5.18e-35	Cognitive ability;
KIRP	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.35	1.11e-8	Total cholesterol levels;
KIRP	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg21433313	chr16:3507492	NAT15	0.67	7.35	0.42	2.98e-12	Tuberculosis;
KIRP	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg13429150	chr8:37710948	NA	0.37	6.19	0.37	2.51e-9	Serum protein levels (sST2);
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.56	5.6	0.34	5.62e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.89	11.21	0.58	8.12e-24	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.63	9.55	0.52	1.41e-18	Lung cancer;
KIRP	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.47	0.33	1.11e-7	Breast cancer;
KIRP	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.85	0.4	5.8e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4742903	0.904	rs28658011	chr9:107006925	G/A	cg14250997	chr9:106856677	SMC2	0.39	5.14	0.31	5.68e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs11997175	0.545	rs7839592	chr8:33666662	T/C	cg04338863	chr8:33670619	NA	0.43	5.47	0.33	1.11e-7	Body mass index;
KIRP	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg05555928	chr11:63887634	MACROD1	0.48	5.72	0.34	3.04e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg26531700	chr6:26746687	NA	-0.42	-5.84	-0.35	1.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs16857609	0.529	rs58933889	chr2:218261933	G/A	cg15335768	chr2:218268053	DIRC3	-0.57	-6.59	-0.39	2.59e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.65	6.09	0.36	4.43e-9	Gut microbiome composition (summer);
KIRP	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	0.85	7.65	0.44	4.68e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg11382394	chr1:2564504	MMEL1	-0.42	-5.54	-0.33	7.89e-8	Multiple sclerosis;
KIRP	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg13444842	chr1:152974279	SPRR3	-0.36	-4.97	-0.3	1.23e-6	Inflammatory skin disease;
KIRP	cis	rs4780355	0.843	rs243325	chr16:11354497	A/G	cg00044050	chr16:11439710	C16orf75	0.44	4.84	0.3	2.26e-6	Crohn's disease and psoriasis;
KIRP	cis	rs7870753	0.578	rs2145985	chr9:99174531	C/T	cg25260653	chr9:99212216	HABP4	0.56	5.72	0.34	3.06e-8	Height;
KIRP	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs2591576	0.816	rs2591567	chr5:165407418	A/G	cg13976338	chr5:165423657	NA	-0.8	-11.96	-0.61	2.74e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.44	0.55	2.31e-21	Body mass index;
KIRP	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.5e-10	Coronary artery disease;
KIRP	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg04013166	chr16:89971882	TCF25	0.68	5.69	0.34	3.58e-8	Skin colour saturation;
KIRP	cis	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg08798685	chr6:27730294	NA	-0.56	-4.86	-0.3	2.06e-6	Lung cancer in ever smokers;
KIRP	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg10932868	chr11:921992	NA	0.65	8.71	0.49	4.42e-16	Alzheimer's disease (late onset);
KIRP	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-5.14	-0.31	5.71e-7	Putamen volume;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs12681366	0.734	rs10102496	chr8:95398181	G/A	cg13257157	chr8:95487014	RAD54B	0.4	4.93	0.3	1.52e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.72	-10.33	-0.55	5.1e-21	Blood metabolite levels;
KIRP	cis	rs654128	1.000	rs654128	chr6:117086378	A/C	cg12892004	chr6:117198278	RFX6	-0.5	-5.82	-0.35	1.85e-8	Telomere length;
KIRP	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.46	-7.18	-0.42	8.03e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg19875535	chr5:140030758	IK	-0.67	-9.49	-0.52	2.16e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs988913	0.581	rs2174115	chr6:54857779	G/A	cg03513858	chr6:54763001	FAM83B	-0.34	-4.9	-0.3	1.76e-6	Menarche (age at onset);
KIRP	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	1.06	11.97	0.61	2.61e-26	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg23978390	chr7:1156363	C7orf50	0.55	5.26	0.32	3.19e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs2554380	0.943	rs2585038	chr15:84337258	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.22	-0.46	1.19e-14	Height;
KIRP	cis	rs3774830	0.679	rs195121	chr4:5436104	C/T	cg26943120	chr4:5472116	STK32B	-0.23	-5.72	-0.34	3e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10373780	chr19:8455179	RAB11B	0.46	6.06	0.36	5.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs7520050	0.966	rs7539932	chr1:46292354	C/T	cg03146154	chr1:46216737	IPP	-0.42	-5.33	-0.32	2.27e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg01017244	chr2:74357527	NA	0.78	9.29	0.51	8.65e-18	Gestational age at birth (maternal effect);
KIRP	cis	rs7612445	0.818	rs2339798	chr3:179173620	A/C	cg01750654	chr3:179170617	GNB4	0.82	8.54	0.48	1.37e-15	Resting heart rate;Heart rate;
KIRP	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-6.66	-0.39	1.75e-10	Urinary tract infection frequency;
KIRP	cis	rs60871478	0.635	rs4725122	chr7:785318	A/G	cg05535760	chr7:792225	HEATR2	0.92	9.53	0.52	1.57e-18	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12120353	0.529	rs1515670	chr1:4626286	A/G	cg11735846	chr1:4770935	AJAP1	-0.69	-5.97	-0.36	8.3e-9	Anxiety disorder;
KIRP	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	7.09	0.41	1.39e-11	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	cis	rs3744061	0.557	rs9889902	chr17:74648034	T/C	cg27546012	chr17:74684504	MXRA7	-0.57	-6.67	-0.39	1.67e-10	Retinal arteriolar caliber;
KIRP	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.42	-0.33	1.44e-7	Schizophrenia;
KIRP	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.89	-14.25	-0.67	5.49e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.42	0.38	6.87e-10	Diabetic retinopathy;
KIRP	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.19	-0.37	2.47e-9	IgG glycosylation;
KIRP	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.35	0.51	5.76e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs494562	1.000	rs1744122	chr6:86115218	T/C	cg27039625	chr6:86159096	NT5E	0.42	5.16	0.31	5.11e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs427941	0.562	rs6950791	chr7:101780458	C/T	cg06246474	chr7:101738831	CUX1	0.52	6.34	0.37	1.08e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16346588	chr10:242978	ZMYND11	0.48	5.91	0.35	1.15e-8	Psychosis in Alzheimer's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15837503	chr17:79669775	MRPL12	0.49	6.22	0.37	2.08e-9	Myopia (pathological);
KIRP	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.09	-0.36	4.35e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14434089	chr14:54911573	NA	0.44	6.04	0.36	5.57e-9	Interleukin-4 levels;
KIRP	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.57	0.56	9.26e-22	Cognitive test performance;
KIRP	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.77	-0.77	2.27e-49	Schizophrenia;
KIRP	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07685180	chr8:600429	NA	0.7	4.9	0.3	1.75e-6	IgG glycosylation;
KIRP	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-7.18	-0.42	8.28e-12	Platelet count;
KIRP	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	cis	rs4638749	0.501	rs1486193	chr2:108756025	G/A	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.14	-0.31	5.57e-7	Blood pressure;
KIRP	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg17691542	chr6:26056736	HIST1H1C	0.49	6.4	0.38	7.64e-10	Height;
KIRP	cis	rs7566780	0.575	rs7605502	chr2:16689951	A/T	cg09580478	chr2:16689509	NA	0.47	5.28	0.32	2.83e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg23442198	chr4:187126114	CYP4V2	0.73	6.37	0.38	9.41e-10	Activated partial thromboplastin time;
KIRP	cis	rs4728302	0.869	rs10231102	chr7:133573310	G/A	cg10665199	chr7:133106180	EXOC4	0.45	5.37	0.32	1.79e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs13385	0.769	rs34675890	chr5:139622272	T/C	cg01860693	chr5:139557145	C5orf32	0.46	5.11	0.31	6.6e-7	Atrial fibrillation;
KIRP	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg00792783	chr2:198669748	PLCL1	0.46	5.41	0.33	1.51e-7	Intracranial aneurysm;
KIRP	cis	rs4262150	0.810	rs17565470	chr5:152063844	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.25	-0.37	1.81e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.64	8.3	0.47	7.01e-15	Colorectal cancer;
KIRP	cis	rs8067287	0.696	rs62065422	chr17:16828570	G/A	cg26910001	chr17:16838321	NA	-0.61	-5.98	-0.36	7.62e-9	Diabetic kidney disease;
KIRP	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	1.99e-8	Lung cancer;
KIRP	cis	rs911119	0.955	rs6048946	chr20:23602307	G/T	cg16589663	chr20:23618590	CST3	0.56	5.6	0.34	5.7e-8	Chronic kidney disease;
KIRP	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	6.08	0.36	4.49e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.38e-7	Ileal carcinoids;
KIRP	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.98	-0.36	7.93e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.791	rs260899	chr4:98707046	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	5.69	0.34	3.68e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg19773385	chr1:10388646	KIF1B	-0.73	-10.14	-0.54	2.07e-20	Hepatocellular carcinoma;
KIRP	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.76	-11.72	-0.6	1.71e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	8.13	0.46	2.15e-14	Rheumatoid arthritis;
KIRP	cis	rs6191	0.901	rs33388	chr5:142697295	A/T	cg08845721	chr5:142780693	NR3C1	0.38	5.16	0.31	4.98e-7	Night sleep phenotypes;
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg26513180	chr16:89883248	FANCA	0.84	13.92	0.66	6.93e-33	Vitiligo;
KIRP	cis	rs258892	0.843	rs16901045	chr5:72033986	A/G	cg21869765	chr5:72125136	TNPO1	-0.55	-6.03	-0.36	5.88e-9	Small cell lung carcinoma;
KIRP	cis	rs6959887	0.890	rs2215614	chr7:35277093	A/C	cg06685737	chr7:35301730	NA	0.44	6.31	0.37	1.26e-9	Birth weight;
KIRP	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.99	-16.06	-0.72	3.63e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg24315340	chr6:146058215	EPM2A	-0.4	-5.03	-0.31	9.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg02807482	chr3:125708958	NA	-0.54	-5.17	-0.31	4.75e-7	Blood pressure (smoking interaction);
KIRP	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg20430773	chr1:16534157	ARHGEF19	0.59	7.32	0.42	3.58e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg20243544	chr17:37824526	PNMT	-0.4	-4.99	-0.3	1.14e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.68	-7.01	-0.41	2.32e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06434353	chr5:114951632	TMED7-TICAM2;TMED7	0.38	6.05	0.36	5.44e-9	C-reactive protein;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg13198984	chr17:80129470	CCDC57	0.54	8.15	0.46	1.84e-14	Life satisfaction;
KIRP	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06544989	chr22:39130855	UNC84B	-0.47	-7.34	-0.42	3.02e-12	Menopause (age at onset);
KIRP	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.66	-0.44	4.38e-13	Systolic blood pressure;
KIRP	cis	rs7113874	0.659	rs12574009	chr11:8519953	G/A	cg08015107	chr11:8618950	NA	-0.49	-6.46	-0.38	5.65e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.71	-7.49	-0.43	1.21e-12	Vitiligo;
KIRP	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.48	-5.55	-0.33	7.55e-8	Fear of minor pain;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23854747	chr20:62612705	PRPF6	0.45	6.09	0.36	4.39e-9	Parkinson's disease;
KIRP	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.26	-0.51	1.07e-17	Personality dimensions;
KIRP	cis	rs787274	1.000	rs2796025	chr9:115549684	A/G	cg13803584	chr9:115635662	SNX30	-0.73	-6.18	-0.37	2.62e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg00361562	chr2:198649771	BOLL	-0.51	-4.91	-0.3	1.69e-6	Ulcerative colitis;
KIRP	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.75	-8.68	-0.48	5.44e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg16586182	chr3:47516702	SCAP	0.82	11.56	0.59	5.48e-25	Colorectal cancer;
KIRP	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.5	-9.32	-0.51	6.7e-18	Cystic fibrosis severity;
KIRP	cis	rs7582180	0.903	rs7562372	chr2:100906331	T/C	cg14675211	chr2:100938903	LONRF2	0.51	6.1	0.36	4.15e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-5.82	-0.35	1.79e-8	Aortic root size;
KIRP	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.76	-10.27	-0.55	7.86e-21	Eye color traits;
KIRP	cis	rs10782582	0.609	rs5745545	chr1:76377356	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.87	-0.4	5.38e-11	Daytime sleep phenotypes;
KIRP	cis	rs2073499	1.000	rs57462170	chr3:50239803	G/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.65	4.86	0.3	2.05e-6	Schizophrenia;
KIRP	cis	rs7119167	0.901	rs7952686	chr11:73128503	C/T	cg17517138	chr11:73019481	ARHGEF17	0.51	5.33	0.32	2.24e-7	Blood protein levels;
KIRP	cis	rs13161895	1.000	rs248320	chr5:179432096	G/A	cg02702477	chr5:179499311	RNF130	0.69	5.38	0.32	1.7e-7	LDL cholesterol;
KIRP	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	16.02	0.71	4.79e-40	Height;
KIRP	cis	rs2594989	0.943	rs2454502	chr3:11499331	T/C	cg01796438	chr3:11312864	ATG7	-0.61	-7.55	-0.43	8.37e-13	Circulating chemerin levels;
KIRP	trans	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg16141378	chr3:129829833	LOC729375	0.52	6.54	0.38	3.57e-10	Mood instability;
KIRP	cis	rs1978968	1.000	rs11705221	chr22:18443287	T/C	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg12623918	chr2:306882	NA	0.4	5.05	0.31	8.71e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg01798813	chr17:3906674	NA	0.42	5.01	0.3	1.02e-6	Type 2 diabetes;
KIRP	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg22604316	chr1:46958801	NA	0.34	4.91	0.3	1.67e-6	Monobrow;
KIRP	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-5.64	-0.34	4.59e-8	Blood metabolite levels;
KIRP	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg20991723	chr1:152506922	NA	-0.46	-5.49	-0.33	1.01e-7	Hair morphology;
KIRP	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg19052272	chr2:3704530	ALLC	-0.37	-4.98	-0.3	1.22e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.49	6.91	0.4	4.15e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07140808	chr4:78978772	FRAS1	0.47	6.14	0.36	3.32e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg21184320	chr1:21044207	KIF17	-0.35	-5.3	-0.32	2.6e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.57	-5.72	-0.34	3.05e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1847505	0.609	rs9317154	chr13:61560533	A/G	cg25164009	chr13:61490935	NA	-0.6	-7.57	-0.43	7.3e-13	Polychlorinated biphenyl levels;
KIRP	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.75	11.19	0.58	8.83e-24	Schizophrenia;
KIRP	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.92	-14.06	-0.67	2.41e-33	Height;
KIRP	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg11518657	chr1:67396239	MIER1	0.48	4.87	0.3	2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg01689657	chr7:91764605	CYP51A1	0.33	5.03	0.31	9.35e-7	Breast cancer;
KIRP	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-6.1	-0.36	4.18e-9	Blood pressure (smoking interaction);
KIRP	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs41264869	0.600	rs12048416	chr1:205134829	T/C	cg21214746	chr1:205091277	RBBP5	0.5	6.4	0.38	7.8e-10	Blood protein levels;
KIRP	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.59	-0.48	1.04e-15	Response to antipsychotic treatment;
KIRP	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.29	7.9	0.45	9.15e-14	Crohn's disease;
KIRP	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.88	9.0	0.5	6.27e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs501120	0.657	rs11238908	chr10:44688080	T/G	cg09554077	chr10:44749378	NA	0.5	5.87	0.35	1.4e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-11.08	-0.58	2.09e-23	Response to antipsychotic treatment;
KIRP	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg02569458	chr12:86230093	RASSF9	0.35	5.04	0.31	8.95e-7	Major depressive disorder;
KIRP	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg05721485	chr17:44071124	MAPT	0.54	7.1	0.41	1.3e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8049040	0.609	rs9940485	chr16:71486105	C/T	cg08717414	chr16:71523259	ZNF19	-0.55	-6.41	-0.38	7.38e-10	Blood protein levels;
KIRP	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg18753928	chr3:113234510	CCDC52	-0.53	-6.83	-0.4	6.68e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	trans	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg01620082	chr3:125678407	NA	-0.97	-7.0	-0.41	2.36e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg07827796	chr19:33622959	WDR88	0.51	6.59	0.39	2.69e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19625377	chr1:11322792	MTOR	0.51	6.12	0.36	3.76e-9	Smoking initiation;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.8	-12.65	-0.63	1.38e-28	Longevity;
KIRP	cis	rs4443100	0.792	rs9612223	chr22:23389142	T/G	cg14186256	chr22:23484241	RTDR1	0.51	4.85	0.3	2.19e-6	Serum parathyroid hormone levels;
KIRP	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	1.07	12.01	0.61	1.87e-26	Uric acid levels;
KIRP	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg06223162	chr1:101003688	GPR88	-0.43	-8.75	-0.49	3.38e-16	Monocyte count;
KIRP	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg18225595	chr11:63971243	STIP1	0.64	5.79	0.35	2.09e-8	Mean platelet volume;
KIRP	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	cis	rs2929282	1	rs2929282	chr15:44245931	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	6.69	0.39	1.5e-10	Triglycerides;Triglyceride levels;
KIRP	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.2	-0.51	1.63e-17	Chronic sinus infection;
KIRP	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg18154014	chr19:37997991	ZNF793	0.7	7.58	0.44	6.91e-13	Coronary artery calcification;
KIRP	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.06	0.41	1.67e-11	Mean platelet volume;
KIRP	trans	rs13170463	0.579	rs11743341	chr5:8039970	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.14	-0.31	5.47e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.47	-6.09	-0.36	4.37e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.42	-6.08	-0.36	4.61e-9	Coronary artery disease;
KIRP	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg07636037	chr3:49044803	WDR6	0.56	5.3	0.32	2.59e-7	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.72	-9.3	-0.51	7.83e-18	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.51	6.28	0.37	1.5e-9	HIV-1 control;
KIRP	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.44	-6.14	-0.36	3.27e-9	Bone mineral density (spine);
KIRP	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6496667	0.779	rs7163560	chr15:91038620	A/T	cg10434728	chr15:90938212	IQGAP1	0.36	4.86	0.3	2.12e-6	Rheumatoid arthritis;
KIRP	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.58	8.07	0.46	3.12e-14	Breast cancer;
KIRP	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg10503236	chr1:231470652	EXOC8	-0.52	-7.5	-0.43	1.14e-12	Hemoglobin concentration;
KIRP	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs1555895	0.521	rs1057303	chr10:853155	T/C	cg10556349	chr10:835070	NA	-0.42	-5.53	-0.33	7.98e-8	Survival in rectal cancer;
KIRP	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.49	-6.31	-0.37	1.28e-9	Body mass index;
KIRP	cis	rs28595532	0.623	rs11932674	chr4:119306807	A/C	cg21605333	chr4:119757512	SEC24D	0.55	5.66	0.34	4.22e-8	Cannabis dependence symptom count;
KIRP	cis	rs311392	0.554	rs2013501	chr8:55104313	A/G	cg20636351	chr8:55087400	NA	-0.54	-6.47	-0.38	5.15e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg26022315	chr17:47021804	SNF8	-0.43	-5.42	-0.33	1.44e-7	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13975730	chr9:139329735	INPP5E	-0.48	-6.77	-0.4	9.58e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs240764	0.817	rs239226	chr6:101107969	G/C	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.49	7.01	0.41	2.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	1.000	rs798416	chr5:130693100	T/C	cg25547332	chr5:131281432	NA	-0.49	-5.44	-0.33	1.26e-7	Life satisfaction;
KIRP	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.37	0.32	1.84e-7	Schizophrenia;
KIRP	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.54	7.24	0.42	5.68e-12	Alzheimer's disease;
KIRP	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.68	-0.39	1.55e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01969662	chr11:1330840	TOLLIP;LOC255512	-0.52	-6.52	-0.38	3.87e-10	Myopia;
KIRP	cis	rs9912468	0.933	rs35183571	chr17:64305015	T/C	cg19474267	chr17:64306194	PRKCA	0.56	7.87	0.45	1.12e-13	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg13334819	chr7:99746414	C7orf59	0.53	6.03	0.36	6.08e-9	Coronary artery disease;
KIRP	cis	rs6690583	0.623	rs61768852	chr1:85454613	T/C	cg22153463	chr1:85462885	MCOLN2	0.59	5.33	0.32	2.19e-7	Serum sulfate level;
KIRP	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-10.66	-0.56	4.67e-22	Height;
KIRP	cis	rs6723108	0.664	rs6741007	chr2:135537119	T/G	cg12500956	chr2:135428796	TMEM163	0.51	6.63	0.39	2.14e-10	Type 2 diabetes;
KIRP	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.49	-6.76	-0.4	1.02e-10	Testicular germ cell tumor;
KIRP	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.88	-0.4	4.99e-11	Systemic lupus erythematosus;
KIRP	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg15895505	chr14:105903354	MTA1	0.51	7.07	0.41	1.62e-11	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14813579	chr19:2328694	SPPL2B;LSM7	0.46	6.3	0.37	1.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6684514	1.000	rs12038203	chr1:156248265	C/T	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg04539111	chr16:67997858	SLC12A4	-0.55	-5.5	-0.33	9.54e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7520050	0.808	rs11211195	chr1:46282295	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.53e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg23100626	chr2:96804247	ASTL	0.42	5.28	0.32	2.91e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs7178909	0.835	rs2174292	chr15:90415581	A/C	cg19708238	chr15:90437601	AP3S2	0.53	7.25	0.42	5.46e-12	Common traits (Other);
KIRP	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg02527881	chr3:46936655	PTH1R	-0.37	-5.26	-0.32	3.15e-7	Colorectal cancer;
KIRP	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg21775007	chr8:11205619	TDH	0.53	6.41	0.38	7.35e-10	Mood instability;
KIRP	cis	rs7084402	0.967	rs1649084	chr10:60292117	T/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg12405258	chr13:114927641	NA	0.5	7.31	0.42	3.8e-12	Schizophrenia;
KIRP	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.66	7.36	0.42	2.79e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs72829446	0.530	rs11869899	chr17:7407915	C/T	cg02795151	chr17:7402630	POLR2A	0.78	8.07	0.46	3.08e-14	Androgen levels;
KIRP	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg07884673	chr3:53033167	SFMBT1	0.81	6.35	0.38	1.06e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg26084005	chr2:241760190	KIF1A	-0.51	-6.87	-0.4	5.36e-11	Urinary metabolites;
KIRP	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.62	-8.08	-0.46	2.98e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.67	-6.99	-0.41	2.55e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.93	-11.13	-0.58	1.44e-23	White matter hyperintensity burden;
KIRP	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.99	15.89	0.71	1.33e-39	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	10.31	0.55	6.03e-21	Hip circumference;
KIRP	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg10755058	chr3:40428713	ENTPD3	0.44	6.24	0.37	1.95e-9	Renal cell carcinoma;
KIRP	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg15247329	chr7:2764246	NA	-0.41	-5.91	-0.35	1.13e-8	Height;
KIRP	cis	rs16976116	0.901	rs28589609	chr15:55503630	C/T	cg11288833	chr15:55489084	RSL24D1	0.63	7.05	0.41	1.84e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg06995285	chr7:2418615	EIF3B	0.8	8.22	0.46	1.15e-14	Multiple sclerosis;
KIRP	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.37	0.38	9.45e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg21573476	chr21:45109991	RRP1B	-0.63	-8.47	-0.48	2.25e-15	Mean corpuscular volume;
KIRP	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg24699146	chr1:24152579	HMGCL	0.44	5.66	0.34	4.3e-8	Immature fraction of reticulocytes;
KIRP	cis	rs929596	0.793	rs2741044	chr2:234579368	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-6.21	-0.37	2.24e-9	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	7.13	0.41	1.14e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.78	9.75	0.53	3.45e-19	Migraine;
KIRP	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.44	-4.93	-0.3	1.55e-6	Type 2 diabetes;
KIRP	cis	rs9612	0.948	rs189408	chr19:44268006	T/C	cg08581076	chr19:44259116	C19orf61	0.55	6.03	0.36	5.89e-9	Exhaled nitric oxide output;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg21734707	chr17:3908241	ZZEF1	0.65	10.01	0.54	5.1e-20	Type 2 diabetes;
KIRP	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.59	6.84	0.4	6.09e-11	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg11693508	chr17:37793320	STARD3	0.49	6.67	0.39	1.68e-10	Neuroticism;
KIRP	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg00149659	chr3:10157352	C3orf10	0.77	6.28	0.37	1.56e-9	Alzheimer's disease;
KIRP	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg01529538	chr14:23388837	RBM23	-0.41	-5.24	-0.32	3.39e-7	Cognitive ability (multi-trait analysis);
KIRP	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.44	-6.56	-0.39	3.07e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg01804193	chr12:63026212	NA	0.59	6.31	0.37	1.27e-9	IgG glycosylation;
KIRP	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	11.52	0.59	7.85e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.16	-0.37	2.98e-9	Morning vs. evening chronotype;
KIRP	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.37	-0.43	2.61e-12	Joint mobility (Beighton score);
KIRP	cis	rs883565	0.655	rs9837975	chr3:39064293	T/C	cg01426195	chr3:39028469	NA	-0.65	-10.57	-0.56	8.85e-22	Handedness;
KIRP	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.32e-9	Obesity-related traits;
KIRP	cis	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.01	-0.3	1.04e-6	Neuroticism;
KIRP	cis	rs939574	0.660	rs6716253	chr2:220127016	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.84	5.63	0.34	5.02e-8	Platelet distribution width;
KIRP	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.38	-5.05	-0.31	8.73e-7	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg06654118	chr4:1303317	MAEA	0.27	5.07	0.31	7.99e-7	Obesity-related traits;
KIRP	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.2	0.42	7.27e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg18944383	chr4:111397179	ENPEP	-0.41	-6.49	-0.38	4.71e-10	Height;
KIRP	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg27205649	chr11:78285834	NARS2	0.67	8.95	0.5	9.11e-17	Alzheimer's disease (survival time);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23670599	chr15:60884729	RORA	-0.47	-6.15	-0.37	3.18e-9	Myopia;
KIRP	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.04	0.36	5.72e-9	Height;
KIRP	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg17554472	chr22:41940697	POLR3H	0.65	6.72	0.39	1.28e-10	Vitiligo;
KIRP	cis	rs742134	0.915	rs4988417	chr22:43520258	A/C	cg26453588	chr22:43506021	BIK	0.39	5.38	0.32	1.75e-7	Prostate cancer;
KIRP	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.44	5.29	0.32	2.65e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg02668984	chr17:48172022	PDK2	0.46	6.21	0.37	2.22e-9	Plasma plasminogen activator levels;
KIRP	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-1.01	-16.56	-0.73	7.07e-42	Height;
KIRP	cis	rs612683	0.896	rs12568038	chr1:100879914	C/T	cg06223162	chr1:101003688	GPR88	0.44	8.02	0.46	4.43e-14	Breast cancer;
KIRP	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.76e-13	Coronary artery calcification;
KIRP	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.54	6.26	0.37	1.74e-9	Schizophrenia;
KIRP	cis	rs1620921	0.967	rs1652482	chr6:161197885	G/A	cg01280913	chr6:161186852	NA	-0.41	-5.77	-0.35	2.42e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg16342193	chr10:102329863	NA	-0.4	-5.14	-0.31	5.56e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7845219	0.544	rs7015841	chr8:95920193	A/C	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.25	-0.37	1.77e-9	Type 2 diabetes;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.45	6.11	0.36	3.8e-9	Mean corpuscular volume;
KIRP	trans	rs2859741	0.565	rs12023397	chr1:37507739	G/A	cg18200741	chr2:33780366	RASGRP3	-0.21	-6.16	-0.37	3e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11594415	chr1:171454668	BAT2L2	0.45	6.05	0.36	5.37e-9	Height;
KIRP	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.93	-13.17	-0.64	2.38e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg17376030	chr22:41985996	PMM1	0.81	8.29	0.47	7.22e-15	Vitiligo;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.68	-0.44	3.69e-13	Aortic root size;
KIRP	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.57	6.13	0.36	3.41e-9	Type 2 diabetes;
KIRP	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.44	7.05	0.41	1.78e-11	Eye color traits;
KIRP	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg07274523	chr3:49395745	GPX1	0.72	8.74	0.49	3.67e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.67	-8.12	-0.46	2.31e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg09699651	chr6:150184138	LRP11	0.59	8.17	0.46	1.6e-14	Testicular germ cell tumor;
KIRP	cis	rs6466055	0.739	rs10953474	chr7:104923005	A/G	cg04380332	chr7:105027541	SRPK2	0.63	9.49	0.52	2.13e-18	Schizophrenia;
KIRP	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg11812906	chr14:75593930	NEK9	0.75	10.64	0.56	5.42e-22	Height;
KIRP	cis	rs2733310	0.895	rs10851612	chr15:57181212	G/T	cg13626582	chr15:57592083	LOC283663	-0.24	-5.57	-0.33	6.72e-8	Mean platelet volume;
KIRP	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.77	0.4	9.27e-11	Axial length;
KIRP	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.65	8.67	0.48	6.02e-16	Obesity-related traits;
KIRP	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.61	-6.5	-0.38	4.45e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg26149184	chr10:133730230	NA	0.44	5.2	0.31	4.23e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs10751667	1.000	rs7927156	chr11:970607	A/G	ch.11.42038R	chr11:967971	AP2A2	0.41	5.45	0.33	1.19e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg16989719	chr2:238392110	NA	-0.54	-7.58	-0.44	7.12e-13	Prostate cancer;
KIRP	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.3	0.37	1.37e-9	Bipolar disorder;
KIRP	cis	rs61160187	0.503	rs152341	chr5:59845963	A/T	cg02684056	chr5:59996105	DEPDC1B	-0.42	-4.93	-0.3	1.49e-6	Educational attainment (years of education);Educational attainment (college completion);
KIRP	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.51	-7.2	-0.42	7.43e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg23594656	chr7:65796392	TPST1	-0.46	-7.31	-0.42	3.81e-12	Aortic root size;
KIRP	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18760194	chr8:35186363	UNC5D	-0.39	-6.11	-0.36	3.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4819052	0.851	rs11558445	chr21:46685175	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	8.56	0.48	1.23e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2742234	1.000	rs1864399	chr10:43610455	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.63	-7.56	-0.43	8.11e-13	Hirschsprung disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25680245	chr18:19284821	ABHD3	0.5	6.5	0.38	4.32e-10	Parkinson's disease;
KIRP	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg01879757	chr17:41196368	BRCA1	-0.76	-10.11	-0.54	2.6e-20	Menopause (age at onset);
KIRP	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.74	8.67	0.48	5.89e-16	Obesity-related traits;
KIRP	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg13264159	chr8:625131	ERICH1	-0.73	-6.37	-0.38	9.28e-10	IgG glycosylation;
KIRP	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.53	-6.61	-0.39	2.32e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02892650	chr16:67380234	LRRC36	-0.38	-6.11	-0.36	3.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.63	8.05	0.46	3.45e-14	Anxiety disorder;
KIRP	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.39	5.98	0.36	7.63e-9	Total body bone mineral density;
KIRP	cis	rs282587	0.542	rs282565	chr13:113373490	C/T	cg04656015	chr13:113407548	ATP11A	-0.59	-6.64	-0.39	2.01e-10	Glycated hemoglobin levels;
KIRP	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	1.02	15.17	0.7	3.8e-37	Alcohol dependence;
KIRP	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg11247378	chr22:39784982	NA	-0.62	-10.02	-0.54	4.81e-20	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18127619	chr14:39511766	SEC23A	-0.44	-6.78	-0.4	8.71e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4523957	0.620	rs9892754	chr17:2084565	G/T	cg16513277	chr17:2031491	SMG6	-0.8	-11.62	-0.6	3.67e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg25042112	chr7:64838748	ZNF92	0.54	6.04	0.36	5.66e-9	Pain;
KIRP	cis	rs988913	0.957	rs960835	chr6:54823422	A/G	cg03513858	chr6:54763001	FAM83B	-0.39	-5.37	-0.32	1.78e-7	Menarche (age at onset);
KIRP	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.59	-7.56	-0.43	7.77e-13	Prostate cancer;
KIRP	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.72	-7.88	-0.45	1.06e-13	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs7939886	0.920	rs11227808	chr11:56070347	A/T	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs72634258	0.842	rs7545745	chr1:8165667	T/A	cg00042356	chr1:8021962	PARK7	-0.48	-4.9	-0.3	1.75e-6	Inflammatory bowel disease;
KIRP	cis	rs758324	0.704	rs31480	chr5:131396332	C/T	cg06307176	chr5:131281290	NA	-0.51	-5.28	-0.32	2.79e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg09582042	chr13:95253676	GPR180	0.29	5.35	0.32	1.98e-7	Triglyceride levels;
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.49	6.38	0.38	8.5e-10	Menarche (age at onset);
KIRP	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg17470723	chr8:74884337	TCEB1	0.66	8.53	0.48	1.54e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg11235152	chr1:67600687	NA	0.68	10.1	0.54	2.79e-20	Psoriasis;
KIRP	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.82	-13.52	-0.65	1.56e-31	Pulse pressure;
KIRP	cis	rs10875746	0.855	rs11168369	chr12:48431168	G/A	cg20731937	chr12:48336164	NA	0.41	5.28	0.32	2.83e-7	Longevity (90 years and older);
KIRP	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.4	-5.0	-0.3	1.1e-6	Aortic root size;
KIRP	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg14664628	chr15:75095509	CSK	-0.44	-5.15	-0.31	5.38e-7	Airflow obstruction;
KIRP	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.61	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.53	-6.3	-0.37	1.4e-9	Longevity;Endometriosis;
KIRP	trans	rs7819412	0.582	rs2409685	chr8:10909193	C/A	cg16141378	chr3:129829833	LOC729375	0.5	6.35	0.38	1.04e-9	Triglycerides;
KIRP	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg03235661	chr20:60525775	NA	-0.37	-5.79	-0.35	2.15e-8	Body mass index;
KIRP	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.12e-6	Atopic dermatitis;
KIRP	cis	rs7919006	0.793	rs12255305	chr10:76794788	C/T	cg01390419	chr10:76803856	DUPD1	0.46	5.67	0.34	3.97e-8	Weight;
KIRP	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.14	0.46	2e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg01420254	chr6:26195488	NA	1.25	9.8	0.53	2.4e-19	Gout;Renal underexcretion gout;
KIRP	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg19507638	chr5:93509721	C5orf36	-0.61	-5.59	-0.34	6.09e-8	Diabetic retinopathy;
KIRP	cis	rs3741151	0.686	rs7125598	chr11:73160589	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.69	-5.86	-0.35	1.52e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.52	7.24	0.42	5.59e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6504950	0.745	rs9915913	chr17:52998168	G/T	cg26251398	chr17:52985966	TOM1L1	0.37	5.0	0.3	1.09e-6	Breast cancer;
KIRP	trans	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.59	-0.44	6.51e-13	Retinal vascular caliber;
KIRP	cis	rs10875746	0.951	rs61918826	chr12:48543978	T/C	cg26205652	chr12:48591994	NA	0.78	10.45	0.55	2.22e-21	Longevity (90 years and older);
KIRP	cis	rs2415984	0.600	rs61993299	chr14:46944880	A/C	cg14871534	chr14:47121158	RPL10L	-0.41	-5.08	-0.31	7.44e-7	Number of children ever born;
KIRP	cis	rs9488822	0.623	rs195516	chr6:116241548	T/A	cg05304507	chr6:116381966	FRK	0.21	5.61	0.34	5.37e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg25828445	chr12:7781288	NA	-0.57	-6.0	-0.36	6.92e-9	HDL cholesterol levels;
KIRP	cis	rs2802372	0.653	rs1250539	chr10:81037229	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.43	-5.69	-0.34	3.61e-8	Granulocyte count;
KIRP	cis	rs644148	0.967	rs2686778	chr19:44972257	G/A	cg15540054	chr19:45004280	ZNF180	-0.65	-7.24	-0.42	5.68e-12	Personality dimensions;
KIRP	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg00360474	chr6:37504404	NA	-0.47	-6.68	-0.39	1.58e-10	Cognitive performance;
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg05941025	chr16:89927596	SPIRE2	0.38	5.73	0.34	2.97e-8	Vitiligo;
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.79	-13.98	-0.67	4.42e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5750854	0.503	rs742159	chr22:40024768	C/A	cg21377881	chr22:40064566	CACNA1I	-0.42	-5.71	-0.34	3.26e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.43	-0.38	6.75e-10	Neuroticism;
KIRP	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.11	0.31	6.58e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.61	-6.97	-0.41	2.94e-11	Bipolar disorder;
KIRP	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg21775007	chr8:11205619	TDH	-0.39	-5.3	-0.32	2.53e-7	Triglycerides;
KIRP	cis	rs3112255	1.000	rs2942904	chr2:101306999	A/G	cg01042948	chr2:101319752	NA	0.43	6.15	0.36	3.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.95	12.86	0.63	2.69e-29	Breast cancer;
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.77	-7.88	-0.45	1.07e-13	Platelet count;
KIRP	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg26384229	chr12:38710491	ALG10B	0.53	7.2	0.42	7.41e-12	Morning vs. evening chronotype;
KIRP	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.05	0.31	8.42e-7	Smoking behavior;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13214474	chr1:215409184	KCNK2	-0.41	-6.39	-0.38	8.16e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg10254082	chr7:997346	NA	0.47	4.9	0.3	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.87	-0.4	5.13e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.42	5.29	0.32	2.71e-7	Cystic fibrosis severity;
KIRP	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg03060546	chr3:49711283	APEH	0.47	5.91	0.35	1.15e-8	Parkinson's disease;
KIRP	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg13271783	chr10:134563150	INPP5A	-0.64	-8.37	-0.47	4.44e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.76	-9.78	-0.53	2.67e-19	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.77e-10	Bipolar disorder;
KIRP	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg15556689	chr8:8085844	FLJ10661	0.47	6.12	0.36	3.59e-9	Neuroticism;
KIRP	cis	rs17023223	0.537	rs2794312	chr1:119591046	C/T	cg18261050	chr1:119551319	NA	0.52	6.98	0.41	2.7e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs12431939	0.598	rs4268678	chr14:51736185	G/T	cg23942311	chr14:51606299	NA	0.42	5.15	0.31	5.29e-7	Cancer;
KIRP	cis	rs2737618	0.674	rs2816973	chr1:200084743	C/G	cg21825944	chr1:200113062	NR5A2	0.54	7.44	0.43	1.72e-12	Uric acid levels;
KIRP	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	1.09	11.84	0.6	7.01e-26	Corneal structure;
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.13	0.46	2.12e-14	Lung cancer;
KIRP	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg09238746	chr17:78121135	EIF4A3	-0.75	-9.4	-0.51	3.89e-18	Yeast infection;
KIRP	trans	rs62056376	0.736	rs758293	chr17:32640523	A/T	cg13554086	chr5:76507100	PDE8B	0.55	6.5	0.38	4.43e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs918629	0.716	rs6897997	chr5:95270241	C/T	cg16656078	chr5:95278638	ELL2	-0.46	-6.6	-0.39	2.57e-10	IgG glycosylation;
KIRP	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.42	-5.25	-0.32	3.29e-7	Aortic root size;
KIRP	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg24375607	chr4:120327624	NA	-0.51	-5.96	-0.36	8.78e-9	Corneal astigmatism;
KIRP	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.81	10.06	0.54	3.61e-20	Corneal astigmatism;
KIRP	cis	rs812925	0.512	rs1729674	chr2:61389737	T/G	cg15711740	chr2:61764176	XPO1	-0.43	-5.14	-0.31	5.73e-7	Immature fraction of reticulocytes;
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.62	-7.34	-0.42	3.15e-12	Menopause (age at onset);
KIRP	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg19760965	chr3:194868843	C3orf21	0.32	5.19	0.31	4.45e-7	Non-small cell lung cancer;
KIRP	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.67	-8.13	-0.46	2.05e-14	Iron status biomarkers;
KIRP	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg08888203	chr3:10149979	C3orf24	0.47	4.98	0.3	1.23e-6	Alzheimer's disease;
KIRP	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg21253087	chr9:139290292	SNAPC4	0.49	6.8	0.4	7.7e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg26614578	chr12:113623930	C12orf52;DDX54	0.68	6.32	0.37	1.23e-9	Lung function (FEV1);
KIRP	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.08	-0.31	7.47e-7	Schizophrenia;
KIRP	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.71	-10.36	-0.55	4.2e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg00360474	chr6:37504404	NA	-0.5	-7.42	-0.43	1.87e-12	Cognitive performance;
KIRP	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg01631408	chr1:248437212	OR2T33	0.58	8.05	0.46	3.63e-14	Common traits (Other);
KIRP	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12908607	chr1:44402522	ARTN	-0.44	-6.48	-0.38	5.03e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7837860	0.588	rs28986511	chr8:89295258	G/A	cg08624180	chr8:89339080	MMP16	-0.61	-5.23	-0.32	3.57e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.77	-8.09	-0.46	2.81e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.65	7.76	0.44	2.2e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg16272484	chr1:17764695	RCC2	0.51	6.21	0.37	2.24e-9	DNA methylation (variation);
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg14338887	chr6:42928500	GNMT	0.49	7.22	0.42	6.4e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.94	-14.8	-0.69	7.09e-36	Primary sclerosing cholangitis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17150246	chr1:161068070	KLHDC9	0.61	7.2	0.42	7.13e-12	Smoking initiation;
KIRP	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg00405596	chr8:11794950	NA	-0.51	-6.72	-0.39	1.22e-10	Neuroticism;
KIRP	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.59	-6.45	-0.38	6.03e-10	Smoking initiation;
KIRP	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.39	9.56	0.52	1.29e-18	Corneal astigmatism;
KIRP	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.45	-5.48	-0.33	1.05e-7	IgG glycosylation;
KIRP	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.41	-7.05	-0.41	1.78e-11	Renal cell carcinoma;
KIRP	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.46	4.91	0.3	1.7e-6	Platelet distribution width;
KIRP	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg23340505	chr13:114927933	NA	0.31	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs10888329	0.665	rs9662722	chr1:248385891	T/G	cg01631408	chr1:248437212	OR2T33	-0.45	-5.17	-0.31	4.85e-7	Autism spectrum disorder;
KIRP	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg17443007	chr1:101659419	NA	0.39	5.53	0.33	8.14e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.69	-0.44	3.55e-13	Platelet count;
KIRP	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.42	-6.05	-0.36	5.47e-9	Height;
KIRP	trans	rs17691453	0.616	rs2119407	chr15:39585428	T/G	cg23282442	chr8:11225832	C8orf12;TDH	0.92	6.19	0.37	2.45e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	13.93	0.66	6.54e-33	Platelet count;
KIRP	cis	rs7572263	0.724	rs6749281	chr2:209050696	C/A	cg23998903	chr2:209048830	C2orf80	-0.36	-5.25	-0.32	3.22e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-11.82	-0.6	7.72e-26	Height;
KIRP	cis	rs1538970	0.884	rs781232	chr1:45890399	C/T	cg05343316	chr1:45956843	TESK2	-0.65	-7.55	-0.43	8.28e-13	Platelet count;
KIRP	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00376283	chr12:123451042	ABCB9	0.67	8.13	0.46	2.05e-14	Neutrophil percentage of white cells;
KIRP	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.63	-8.23	-0.46	1.07e-14	Coronary artery disease;
KIRP	cis	rs4959799	0.557	rs45629235	chr6:3271298	A/G	cg03657281	chr6:3270030	SLC22A23	0.79	6.02	0.36	6.29e-9	Survival in rectal cancer;
KIRP	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs588177	0.522	rs34358026	chr11:64015422	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	6.84	0.4	6.42e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg01631408	chr1:248437212	OR2T33	-0.72	-9.68	-0.53	5.47e-19	Common traits (Other);
KIRP	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg04374321	chr14:90722782	PSMC1	0.64	8.2	0.46	1.31e-14	Mortality in heart failure;
KIRP	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.97	15.61	0.71	1.19e-38	Bone mineral density;
KIRP	cis	rs754423	0.515	rs7143978	chr14:52555201	G/A	cg05884192	chr14:52515736	NID2	0.47	5.21	0.32	4.05e-7	Craniofacial microsomia;
KIRP	cis	rs6939532	0.522	rs4712980	chr6:26355758	G/T	cg12826209	chr6:26865740	GUSBL1	-0.46	-5.51	-0.33	8.98e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg25272121	chr1:152190972	HRNR	-0.4	-5.45	-0.33	1.25e-7	Inflammatory skin disease;
KIRP	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.34e-11	Aortic root size;
KIRP	cis	rs2046867	0.908	rs6771413	chr3:72790308	G/A	cg25664220	chr3:72788482	NA	-0.39	-5.63	-0.34	4.86e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg18944383	chr4:111397179	ENPEP	-0.54	-6.33	-0.37	1.18e-9	Axial length;
KIRP	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.9e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.24	-6.24	-0.37	1.94e-9	Mean corpuscular volume;
KIRP	cis	rs2213920	0.523	rs7857923	chr9:118176789	A/G	cg13918206	chr9:118159781	DEC1	1.0	10.45	0.55	2.2e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7017914	0.967	rs1596566	chr8:71698576	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg13165212	chr22:42675999	NA	0.3	5.26	0.32	3.2e-7	Cognitive function;
KIRP	cis	rs17123764	0.818	rs12311839	chr12:49963405	A/G	cg02054252	chr12:50078554	FMNL3	0.43	5.19	0.31	4.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg27205649	chr11:78285834	NARS2	0.68	9.16	0.5	2.04e-17	Alzheimer's disease (survival time);
KIRP	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg13660082	chr14:53194042	PSMC6	-0.67	-7.3	-0.42	3.88e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg04990556	chr1:26633338	UBXN11	0.65	6.04	0.36	5.71e-9	Obesity-related traits;
KIRP	cis	rs11997175	0.631	rs7826866	chr8:33665090	A/T	cg04338863	chr8:33670619	NA	0.4	5.45	0.33	1.25e-7	Body mass index;
KIRP	cis	rs7180079	0.620	rs567883	chr15:64763174	T/C	cg15337035	chr15:64978493	NA	-0.48	-5.25	-0.32	3.24e-7	Monocyte count;
KIRP	cis	rs7605378	0.567	rs717915	chr2:200714766	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.47	5.79	0.35	2.13e-8	Osteoporosis;
KIRP	cis	rs829661	0.739	rs1869429	chr2:30874777	C/T	cg10949345	chr2:30726833	LCLAT1	1.13	13.59	0.65	9.08e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs4965359	0.737	rs7169099	chr15:101575202	G/T	cg18083008	chr15:101557551	LRRK1	0.34	4.92	0.3	1.6e-6	Central corneal thickness;
KIRP	cis	rs2273669	0.667	rs12201821	chr6:109340291	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.37	-0.38	9.03e-10	Prostate cancer;
KIRP	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.16	-0.42	9.07e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg00689492	chr4:1303491	MAEA	0.29	5.11	0.31	6.42e-7	Longevity;
KIRP	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.27	-22.23	-0.82	8.87e-61	Breast cancer;
KIRP	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18867708	chr6:26865862	GUSBL1	-0.5	-6.28	-0.37	1.51e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs7867456	0.546	rs10757178	chr9:21046674	A/G	cg26803184	chr10:94333922	IDE	0.48	6.05	0.36	5.24e-9	Axial length;
KIRP	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.86	13.26	0.65	1.22e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs10517025	0.673	rs75440143	chr4:42431403	G/T	cg13587180	chr4:42403248	SHISA3	0.44	4.99	0.3	1.13e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25808101	chr3:48282816	ZNF589	0.44	6.04	0.36	5.78e-9	Survival in pancreatic cancer;
KIRP	cis	rs2916247	1.000	rs2920463	chr8:93008292	A/G	cg10183463	chr8:93005414	RUNX1T1	0.69	9.69	0.53	5.06e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg13165212	chr22:42675999	NA	0.4	6.85	0.4	5.84e-11	Cognitive function;
KIRP	cis	rs6693567	0.565	rs834234	chr1:150352494	C/G	cg07843065	chr1:150265600	MRPS21	-0.46	-6.33	-0.37	1.16e-9	Migraine;
KIRP	cis	rs883565	0.569	rs784511	chr3:39165548	A/G	cg01426195	chr3:39028469	NA	0.52	8.31	0.47	6.35e-15	Handedness;
KIRP	cis	rs12210905	1.000	rs72843608	chr6:27122750	G/A	cg11502198	chr6:26597334	ABT1	-0.76	-4.97	-0.3	1.24e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg23250157	chr14:64679961	SYNE2	0.45	5.28	0.32	2.89e-7	Atrial fibrillation;
KIRP	cis	rs13065560	0.534	rs9857724	chr3:38897005	C/T	cg01426195	chr3:39028469	NA	-0.37	-6.06	-0.36	5.02e-9	Interleukin-18 levels;
KIRP	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.64	0.73	3.72e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.93	0.61	3.38e-26	Ileal carcinoids;
KIRP	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.42	5.31	0.32	2.4e-7	Axial length;
KIRP	cis	rs10129255	0.500	rs8006888	chr14:107190456	A/C	cg23076370	chr14:107095027	NA	-0.41	-5.03	-0.31	9.6e-7	Kawasaki disease;
KIRP	cis	rs2415984	0.600	rs72672853	chr14:46932920	T/G	cg14871534	chr14:47121158	RPL10L	-0.45	-5.4	-0.33	1.56e-7	Number of children ever born;
KIRP	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.64	9.54	0.52	1.51e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg25019033	chr10:957182	NA	-0.56	-5.78	-0.35	2.29e-8	Eosinophil percentage of granulocytes;
KIRP	trans	rs6601327	0.665	rs12546411	chr8:9655916	T/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.22	-0.42	6.45e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg10503236	chr1:231470652	EXOC8	-0.5	-7.07	-0.41	1.63e-11	Hemoglobin concentration;
KIRP	trans	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg19955956	chr7:72299837	SBDSP;TYW1B	0.43	6.04	0.36	5.61e-9	Blood metabolite levels;
KIRP	cis	rs7113850	0.541	rs77227176	chr11:24208375	T/C	ch.11.24196551F	chr11:24239977	NA	0.85	7.53	0.43	9.49e-13	Bone fracture in osteoporosis;
KIRP	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.54	6.91	0.4	4.02e-11	Coronary heart disease;
KIRP	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.57	0.39	2.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs11974702	1	rs11974702	chr7:99163951	A/G	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite levels;
KIRP	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg09455208	chr3:40491958	NA	0.35	6.08	0.36	4.55e-9	Renal cell carcinoma;
KIRP	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg00484396	chr16:3507460	NAT15	-0.53	-6.18	-0.37	2.69e-9	Tuberculosis;
KIRP	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg11764359	chr7:65958608	NA	0.79	5.01	0.3	1.02e-6	Diabetic kidney disease;
KIRP	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg22852734	chr6:133119734	C6orf192	0.98	7.14	0.41	1.07e-11	Type 2 diabetes nephropathy;
KIRP	cis	rs34779708	0.733	rs16935948	chr10:35549748	C/G	cg03585969	chr10:35415529	CREM	0.58	6.55	0.39	3.42e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.87	13.91	0.66	7.57e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2299587	0.689	rs6586670	chr8:17772332	A/G	cg01800426	chr8:17659068	MTUS1	-0.53	-6.46	-0.38	5.71e-10	Economic and political preferences;
KIRP	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.42	5.36	0.32	1.91e-7	Aortic root size;
KIRP	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.68	-7.64	-0.44	4.77e-13	Alcohol dependence;
KIRP	cis	rs6959887	0.962	rs988270	chr7:35300561	A/G	cg06685737	chr7:35301730	NA	-0.48	-7.1	-0.41	1.33e-11	Birth weight;
KIRP	cis	rs4765905	0.580	rs75849460	chr12:2312821	G/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.94	-0.4	3.36e-11	Schizophrenia;
KIRP	trans	rs11923600	0.652	rs4544626	chr3:175992530	A/G	cg00728300	chr16:87903283	SLC7A5	-0.49	-6.13	-0.36	3.38e-9	Height;
KIRP	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg04310649	chr10:35416472	CREM	-0.57	-6.96	-0.41	3.13e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg06815112	chr8:27182871	PTK2B	-0.5	-6.22	-0.37	2.07e-9	Alzheimer's disease (late onset);
KIRP	cis	rs259282	0.605	rs35728696	chr19:33108096	C/T	cg02997394	chr19:33096574	ANKRD27	-0.53	-6.25	-0.37	1.84e-9	Schizophrenia;
KIRP	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg18461458	chr19:21324796	ZNF431	-0.48	-4.99	-0.3	1.14e-6	Pain;
KIRP	trans	rs12043259	1.000	rs6688709	chr1:204830071	C/T	cg11485465	chr5:54518469	NA	-0.38	-6.1	-0.36	4.1e-9	Addiction;
KIRP	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg10402321	chr1:26617780	UBXN11	-0.37	-5.04	-0.31	8.99e-7	Obesity-related traits;
KIRP	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.48	-6.37	-0.38	9.41e-10	Multiple sclerosis;
KIRP	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.96	-17.67	-0.75	1.12e-45	Breast cancer;
KIRP	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.41	5.06	0.31	8.03e-7	Psychosis in Alzheimer's disease;
KIRP	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.78	9.4	0.51	3.98e-18	Corneal astigmatism;
KIRP	cis	rs12220238	0.822	rs10824160	chr10:76132267	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	6.56	0.39	3.07e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4728302	0.934	rs2971963	chr7:133641505	A/G	cg10665199	chr7:133106180	EXOC4	-0.41	-4.93	-0.3	1.53e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7119167	0.686	rs61505022	chr11:73054468	C/A	cg17517138	chr11:73019481	ARHGEF17	0.49	5.17	0.31	4.78e-7	Blood protein levels;
KIRP	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg05926928	chr17:57297772	GDPD1	-0.7	-6.84	-0.4	6.37e-11	Opioid sensitivity;
KIRP	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.13	15.34	0.7	9.84e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.64	-6.75	-0.4	1.05e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9810890	1.000	rs73207985	chr3:128578932	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.42e-7	Dental caries;
KIRP	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00889227	chr1:205173544	DSTYK	-0.36	-4.88	-0.3	1.89e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg24879335	chr3:133465180	TF	0.33	4.86	0.3	2.09e-6	Iron status biomarkers;
KIRP	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg21475434	chr5:93447410	FAM172A	-0.44	-5.06	-0.31	8.09e-7	Diabetic retinopathy;
KIRP	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg00405596	chr8:11794950	NA	-0.43	-5.03	-0.31	9.56e-7	Neuroticism;
KIRP	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-7.92	-0.45	8.19e-14	Coronary artery disease;
KIRP	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs4478137	0.824	rs10857353	chr4:164215835	A/G	cg06758707	chr4:164254230	NPY1R	-0.73	-9.87	-0.53	1.4e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs17407555	0.657	rs12505222	chr4:10271136	G/T	cg11266682	chr4:10021025	SLC2A9	0.35	5.44	0.33	1.29e-7	Schizophrenia (age at onset);
KIRP	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.02	-0.36	6.19e-9	IgG glycosylation;
KIRP	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	10.73	0.56	2.71e-22	Menopause (age at onset);
KIRP	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg09998033	chr7:158218633	PTPRN2	-0.42	-5.44	-0.33	1.28e-7	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.83	-7.46	-0.43	1.46e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg22508957	chr16:3507546	NAT15	0.43	6.43	0.38	6.51e-10	Tuberculosis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09887667	chr15:56285261	NEDD4	-0.46	-6.14	-0.36	3.23e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07308232	chr7:1071921	C7orf50	-0.69	-8.64	-0.48	7.09e-16	Longevity;Endometriosis;
KIRP	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10212705	chr1:154297848	ATP8B2	0.4	6.1	0.36	4.16e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.81	8.52	0.48	1.58e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.8	0.45	1.8e-13	Morning vs. evening chronotype;
KIRP	cis	rs1190552	0.739	rs1998421	chr14:102979644	C/T	cg18135206	chr14:102964638	TECPR2	0.47	5.18	0.31	4.68e-7	Blood protein levels;
KIRP	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg14768367	chr16:72042858	DHODH	-0.45	-5.48	-0.33	1.03e-7	Fibrinogen levels;
KIRP	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg19592336	chr6:28129416	ZNF389	-0.51	-5.98	-0.36	7.94e-9	Depression;
KIRP	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg21775007	chr8:11205619	TDH	-0.44	-5.76	-0.34	2.54e-8	Neuroticism;
KIRP	trans	rs972578	0.668	rs5759013	chr22:43289473	A/G	cg15321293	chr3:36422198	STAC	0.48	6.04	0.36	5.52e-9	Mean platelet volume;
KIRP	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg24503407	chr1:205819492	PM20D1	0.5	5.3	0.32	2.57e-7	Parkinson's disease;
KIRP	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.85	-11.28	-0.58	4.58e-24	Type 2 diabetes;
KIRP	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15506890	chr2:3487001	NA	-0.51	-6.26	-0.37	1.73e-9	Neurofibrillary tangles;
KIRP	cis	rs11997175	0.679	rs10954935	chr8:33670379	C/G	cg04338863	chr8:33670619	NA	0.4	5.4	0.33	1.61e-7	Body mass index;
KIRP	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg16586182	chr3:47516702	SCAP	0.82	11.64	0.6	3.07e-25	Colorectal cancer;
KIRP	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg14784868	chr12:69753453	YEATS4	-0.5	-5.26	-0.32	3.2e-7	Response to diuretic therapy;
KIRP	cis	rs8114671	0.647	rs945959	chr20:33734905	G/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.0	0.36	6.87e-9	Height;
KIRP	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg26681399	chr22:41777847	TEF	-0.44	-5.16	-0.31	5.15e-7	Vitiligo;
KIRP	cis	rs7007076	0.609	rs2385505	chr8:124743986	C/T	cg00283535	chr8:124749564	ANXA13	0.64	7.94	0.45	7.05e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7267005	0.661	rs17092937	chr20:34243610	A/G	cg17201900	chr20:34330562	RBM39	-1.11	-6.38	-0.38	8.56e-10	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg26855724	chr1:75198818	TYW3;CRYZ	0.53	6.39	0.38	8.39e-10	Resistin levels;
KIRP	cis	rs10875746	0.551	rs12322348	chr12:48707699	T/A	cg20731937	chr12:48336164	NA	0.45	5.56	0.33	6.88e-8	Longevity (90 years and older);
KIRP	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg05484376	chr2:27715224	FNDC4	0.37	5.95	0.35	9.19e-9	Menopause (age at onset);
KIRP	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.74	-6.79	-0.4	8.48e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.69	-0.34	3.59e-8	Life satisfaction;
KIRP	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.47	-5.92	-0.35	1.08e-8	Coronary artery disease;
KIRP	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.76	8.85	0.49	1.76e-16	Adiposity;
KIRP	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg21419209	chr3:44054225	NA	-0.73	-9.06	-0.5	4.08e-17	Coronary artery disease;
KIRP	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.03e-7	Type 2 diabetes;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.52	-7.16	-0.42	9.43e-12	Renal function-related traits (BUN);
KIRP	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg19847130	chr8:10466454	RP1L1	-0.37	-5.44	-0.33	1.28e-7	Retinal vascular caliber;
KIRP	cis	rs6088813	1.000	rs4911496	chr20:33972053	A/G	cg14752227	chr20:34000481	UQCC	0.51	6.78	0.4	8.62e-11	Height;
KIRP	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.76	7.07	0.41	1.56e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.62	-7.23	-0.42	6e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.58	-6.86	-0.4	5.43e-11	Mosquito bite size;
KIRP	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	8.2	0.46	1.31e-14	Educational attainment;
KIRP	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.94	-8.77	-0.49	3.01e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs10499694	0.735	rs2044859	chr7:50612562	A/G	cg00647317	chr7:50633725	DDC	-0.41	-6.17	-0.37	2.74e-9	Body mass index;
KIRP	cis	rs6752107	0.967	rs11680130	chr2:234157258	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.37	0.51	4.99e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.61	-6.98	-0.41	2.79e-11	Monocyte percentage of white cells;
KIRP	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.3	7.23	0.42	5.95e-12	IgG glycosylation;
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.27	-0.37	1.61e-9	Longevity;Endometriosis;
KIRP	cis	rs8077577	0.708	rs4450455	chr17:18140447	A/G	cg18869244	chr17:18121946	NA	-0.46	-5.27	-0.32	2.92e-7	Obesity-related traits;
KIRP	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs9879311	0.966	rs7619385	chr3:10414909	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.4	5.31	0.32	2.42e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.76	6.49	0.38	4.81e-10	Body mass index;
KIRP	cis	rs17286411	0.836	rs13332113	chr16:71920559	T/C	cg04254540	chr16:71951199	KIAA0174	-0.4	-5.26	-0.32	3.13e-7	Blood protein levels;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg06871246	chr4:1363661	KIAA1530	-0.51	-6.55	-0.39	3.3e-10	Longevity;
KIRP	cis	rs10875746	0.951	rs7485355	chr12:48548342	G/A	cg26205652	chr12:48591994	NA	0.77	10.19	0.54	1.43e-20	Longevity (90 years and older);
KIRP	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.95	-0.5	9.08e-17	Neuroticism;
KIRP	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs6684514	1.000	rs11264467	chr1:156273061	A/G	cg16558208	chr1:156270281	VHLL	0.39	5.33	0.32	2.21e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.56	-7.13	-0.41	1.11e-11	Height;
KIRP	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg22717608	chr11:34937665	PDHX;APIP	-0.41	-5.14	-0.31	5.52e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg26174226	chr8:58114915	NA	-0.59	-6.99	-0.41	2.6e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs394563	0.591	rs805026	chr6:149728254	G/C	cg03678062	chr6:149772716	ZC3H12D	-0.32	-5.12	-0.31	6.1e-7	Dupuytren's disease;
KIRP	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.84	10.31	0.55	6.21e-21	Coronary artery disease;
KIRP	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	1.09	21.78	0.81	2.49e-59	Parkinson's disease;
KIRP	cis	rs1832871	0.643	rs9456282	chr6:158724743	A/G	cg07215822	chr6:158701037	NA	-0.64	-7.12	-0.41	1.15e-11	Height;
KIRP	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.44	-6.58	-0.39	2.79e-10	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13808325	chr4:25915922	C4orf52	0.51	6.39	0.38	8.44e-10	Parkinson's disease;
KIRP	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.66	-0.44	4.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs9473924	0.657	rs9463657	chr6:50882256	T/A	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs4950322	0.570	rs4950409	chr1:146807614	G/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg04455712	chr21:45112962	RRP1B	0.44	5.8	0.35	2.05e-8	Mean corpuscular volume;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.33	5.08	0.31	7.49e-7	Electroencephalogram traits;
KIRP	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg10254082	chr7:997346	NA	0.47	5.02	0.3	9.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01200585	chr1:228362443	C1orf69	0.41	5.14	0.31	5.58e-7	Diastolic blood pressure;
KIRP	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	5.57	0.33	6.74e-8	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	trans	rs587242	1.000	rs12757257	chr1:96898302	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.88	0.4	5e-11	Lung cancer;
KIRP	cis	rs12580194	1.000	rs7308316	chr12:55709162	T/A	cg11794356	chr12:55725991	OR6C3	-0.38	-5.22	-0.32	3.76e-7	Cancer;
KIRP	cis	rs7578199	0.924	rs10469795	chr2:242358416	A/G	cg01632474	chr2:242799312	PDCD1	0.38	4.89	0.3	1.83e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs2733310	0.947	rs1629339	chr15:57171430	A/C	cg13626582	chr15:57592083	LOC283663	-0.23	-5.31	-0.32	2.42e-7	Mean platelet volume;
KIRP	cis	rs4851254	0.920	rs11123808	chr2:100750750	A/C	cg17356467	chr2:100759845	AFF3	0.54	6.87	0.4	5.37e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7709377	0.514	rs11241365	chr5:115466102	C/A	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	12.0	0.61	2.08e-26	Smoking behavior;
KIRP	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.71	10.04	0.54	4.29e-20	Post bronchodilator FEV1;
KIRP	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	8.95	0.5	8.63e-17	Total body bone mineral density;
KIRP	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-0.62	-6.92	-0.4	3.91e-11	Initial pursuit acceleration;
KIRP	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg02297831	chr4:17616191	MED28	0.56	6.62	0.39	2.25e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs630539	0.655	rs1553469	chr17:40842762	C/A	cg10533978	chr17:40842804	CNTNAP1	-0.68	-4.97	-0.3	1.27e-6	Systolic blood pressure change trajectories;
KIRP	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.54	8.69	0.48	5.04e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.34	5.05	0.31	8.53e-7	Eye color traits;
KIRP	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.63	6.57	0.39	2.94e-10	Gut microbiome composition (summer);
KIRP	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	0.75	9.77	0.53	3e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg16574807	chr4:6945745	TBC1D14	0.65	5.62	0.34	5.27e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg03959625	chr15:84868606	LOC388152	0.58	6.59	0.39	2.7e-10	Schizophrenia;
KIRP	trans	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg06521331	chr12:34319734	NA	-0.51	-6.24	-0.37	1.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.38	13.83	0.66	1.49e-32	Schizophrenia;
KIRP	cis	rs7011507	1.000	rs79151006	chr8:49182099	A/G	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.55	7.2	0.42	7.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg17691542	chr6:26056736	HIST1H1C	0.63	7.47	0.43	1.39e-12	Iron status biomarkers;
KIRP	cis	rs6504950	0.830	rs17817847	chr17:53018281	T/A	cg26251398	chr17:52985966	TOM1L1	0.42	5.2	0.31	4.12e-7	Breast cancer;
KIRP	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg15841412	chr13:111365552	ING1	0.5	5.68	0.34	3.78e-8	Coronary artery disease;
KIRP	cis	rs6466055	0.589	rs6980244	chr7:104636940	T/C	cg04380332	chr7:105027541	SRPK2	-0.4	-5.36	-0.32	1.94e-7	Schizophrenia;
KIRP	cis	rs4006360	0.540	rs9915780	chr17:39301074	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.53	-8.05	-0.46	3.65e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	9.13	0.5	2.66e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.67	8.76	0.49	3.33e-16	Mood instability;
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg21253087	chr9:139290292	SNAPC4	0.46	6.49	0.38	4.63e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg16497661	chr14:103986332	CKB	0.42	5.55	0.33	7.38e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	9.28	0.51	9.04e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg14593290	chr7:50529359	DDC	0.42	5.29	0.32	2.74e-7	Malaria;
KIRP	cis	rs12580194	0.593	rs59676560	chr12:55745425	T/C	cg19537932	chr12:55886519	OR6C68	-0.48	-6.36	-0.38	9.58e-10	Cancer;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.28	15.82	0.71	2.27e-39	Platelet count;
KIRP	cis	rs876084	0.505	rs4407921	chr8:121156585	C/T	cg06265175	chr8:121136014	COL14A1	0.41	4.85	0.3	2.16e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.28	-0.55	7.4e-21	Response to antipsychotic treatment;
KIRP	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-7.64	-0.44	4.96e-13	Morning vs. evening chronotype;
KIRP	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs241257	0.643	rs241274	chr1:4627482	A/C	cg08159291	chr1:4715615	AJAP1	0.41	4.85	0.3	2.15e-6	Anxiety disorder;
KIRP	cis	rs12643440	0.538	rs4435747	chr4:17139645	C/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9309473	0.519	rs2421670	chr2:73886661	T/G	cg20560298	chr2:73613845	ALMS1	0.45	5.55	0.33	7.5e-8	Metabolite levels;
KIRP	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg13939156	chr17:80058883	NA	-0.49	-7.42	-0.43	1.84e-12	Life satisfaction;
KIRP	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg11608241	chr8:8085544	FLJ10661	0.55	6.57	0.39	2.99e-10	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03634887	chr16:66730948	CMTM4	0.53	6.24	0.37	1.89e-9	Smoking initiation;
KIRP	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg04539111	chr16:67997858	SLC12A4	-0.55	-5.5	-0.33	9.54e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2562456	0.754	rs11673320	chr19:21507603	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-5.04	-0.31	8.96e-7	Pain;
KIRP	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.74	9.07	0.5	3.78e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs829880	0.558	rs249817	chr12:98896910	T/A	cg25150519	chr12:98850993	NA	0.51	5.51	0.33	8.99e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg13444842	chr1:152974279	SPRR3	-0.38	-5.47	-0.33	1.1e-7	Inflammatory skin disease;
KIRP	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.83	0.49	1.98e-16	Morning vs. evening chronotype;
KIRP	cis	rs2658782	0.901	rs10466368	chr11:93229756	T/C	cg15737290	chr11:93063684	CCDC67	0.77	8.09	0.46	2.77e-14	Pulmonary function decline;
KIRP	cis	rs2483058	0.767	rs61817176	chr1:206621028	A/C	cg19452316	chr1:206680966	RASSF5	0.42	5.6	0.34	5.84e-8	Cholesterol and Triglycerides;
KIRP	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.06	19.08	0.77	2.08e-50	Triglycerides;
KIRP	cis	rs6959887	1.000	rs6963934	chr7:35295503	A/G	cg06685737	chr7:35301730	NA	0.45	6.66	0.39	1.78e-10	Birth weight;
KIRP	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg05043794	chr9:111880884	C9orf5	-0.24	-4.96	-0.3	1.29e-6	Menarche (age at onset);
KIRP	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.54	-7.38	-0.43	2.46e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1978968	1.000	rs1076544	chr22:18446565	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.78	-0.4	8.73e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.58	6.57	0.39	2.94e-10	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7712401	0.601	rs154506	chr5:122202781	A/G	cg19412675	chr5:122181750	SNX24	0.52	5.65	0.34	4.5e-8	Mean platelet volume;
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-0.77	-8.76	-0.49	3.14e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg00857998	chr1:205179979	DSTYK	0.62	7.38	0.43	2.41e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.5	7.58	0.44	6.96e-13	Resting heart rate;
KIRP	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg13482628	chr17:19912719	NA	0.6	8.33	0.47	5.66e-15	Schizophrenia;
KIRP	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	8.75	0.49	3.45e-16	Colorectal cancer;
KIRP	cis	rs5753037	0.653	rs131271	chr22:30151582	A/G	cg01021169	chr22:30184971	ASCC2	-0.44	-6.2	-0.37	2.41e-9	Type 1 diabetes;
KIRP	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg02297831	chr4:17616191	MED28	0.52	6.53	0.38	3.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg05347473	chr6:146136440	FBXO30	0.46	6.75	0.4	1.03e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	7.41	0.43	1.97e-12	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg08662619	chr6:150070041	PCMT1	0.37	6.15	0.37	3.06e-9	Lung cancer;
KIRP	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg01475377	chr6:109611718	NA	-0.36	-4.92	-0.3	1.6e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.54	6.8	0.4	8.06e-11	Longevity;
KIRP	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.58	7.85	0.45	1.29e-13	Mean corpuscular volume;
KIRP	cis	rs944289	0.600	rs2774166	chr14:36638655	C/T	cg21129253	chr14:36638564	NA	0.27	4.91	0.3	1.7e-6	Thyroid cancer;
KIRP	cis	rs6752107	0.512	rs1372097	chr2:234227047	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.51	6.0	0.36	7.13e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.83	-11.8	-0.6	8.9e-26	Systemic sclerosis;
KIRP	cis	rs42648	0.869	rs42617	chr7:89952046	T/A	cg25739043	chr7:89950458	NA	-0.46	-7.17	-0.42	8.77e-12	Homocysteine levels;
KIRP	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.73	-0.49	3.88e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.69	-9.14	-0.5	2.38e-17	Huntington's disease progression;
KIRP	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.35	-4.94	-0.3	1.42e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.66	9.49	0.52	2.16e-18	Vitiligo;
KIRP	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs61332075	0.518	rs892839	chr2:239406446	G/A	cg18131467	chr2:239335373	ASB1	-0.72	-5.37	-0.32	1.83e-7	Lung function (FEV1/FVC);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07254608	chr8:41997973	NA	0.49	6.45	0.38	5.95e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18867708	chr6:26865862	GUSBL1	0.46	5.73	0.34	2.85e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6545883	0.929	rs10193666	chr2:61629408	C/T	cg15711740	chr2:61764176	XPO1	0.61	8.08	0.46	2.96e-14	Tuberculosis;
KIRP	cis	rs8067545	0.532	rs12946508	chr17:19952059	A/T	cg13482628	chr17:19912719	NA	0.46	5.16	0.31	5.01e-7	Schizophrenia;
KIRP	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg07395648	chr5:131743802	NA	-0.35	-5.0	-0.3	1.07e-6	Blood metabolite levels;
KIRP	cis	rs6921919	0.583	rs740621	chr6:28397787	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.01	-0.36	6.59e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-6.92	-0.4	3.8e-11	Total body bone mineral density;
KIRP	cis	rs17286411	0.836	rs2291947	chr16:71890489	C/G	cg04254540	chr16:71951199	KIAA0174	-0.4	-5.25	-0.32	3.35e-7	Blood protein levels;
KIRP	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg13679303	chr9:96623674	NA	-0.51	-7.3	-0.42	3.98e-12	DNA methylation (variation);
KIRP	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg27432699	chr2:27873401	GPN1	-0.44	-5.59	-0.34	5.97e-8	Total body bone mineral density;
KIRP	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-1.0	-16.0	-0.71	5.82e-40	Coronary artery disease;
KIRP	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg19554555	chr3:13937349	NA	-0.44	-5.92	-0.35	1.08e-8	Ovarian reserve;
KIRP	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.61	-8.13	-0.46	2.15e-14	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.06	0.67	2.39e-33	Platelet count;
KIRP	cis	rs11783469	0.524	rs4872139	chr8:23346641	A/G	cg08322043	chr8:23340750	NA	-0.48	-5.18	-0.31	4.56e-7	Reticulocyte count;
KIRP	cis	rs6668534	0.679	rs10753610	chr1:161663823	C/G	cg07385423	chr1:161697574	FCRLB	0.46	5.18	0.31	4.65e-7	Blood protein levels;
KIRP	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.76	9.65	0.52	6.9e-19	Neutrophil percentage of white cells;
KIRP	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Smoking initiation;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg21584983	chr19:11640070	ECSIT	0.5	6.67	0.39	1.67e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-8.65	-0.48	6.75e-16	Lymphocyte counts;
KIRP	cis	rs7508	0.596	rs7824644	chr8:17920807	A/G	cg01800426	chr8:17659068	MTUS1	-0.44	-5.2	-0.31	4.18e-7	Atrial fibrillation;
KIRP	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg15117754	chr3:10150083	C3orf24	-0.48	-4.94	-0.3	1.42e-6	Alzheimer's disease;
KIRP	cis	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg04607699	chr11:48328132	OR4S1	-0.35	-4.94	-0.3	1.46e-6	HDL cholesterol;
KIRP	cis	rs12643440	1.000	rs35915791	chr4:17217890	C/T	cg22650099	chr4:17144496	NA	-0.51	-6.24	-0.37	1.93e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.89	-0.35	1.29e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.24e-6	Menopause (age at onset);
KIRP	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg16482183	chr6:26056742	HIST1H1C	0.8	7.77	0.44	2.19e-13	Iron status biomarkers;
KIRP	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.79	-10.82	-0.57	1.46e-22	Educational attainment;
KIRP	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg02389323	chr16:88786976	FAM38A	1.04	7.03	0.41	2.01e-11	Plateletcrit;
KIRP	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.17	-0.31	4.88e-7	Schizophrenia;
KIRP	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.48	-6.13	-0.36	3.39e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.31	11.91	0.6	4.05e-26	Diabetic retinopathy;
KIRP	cis	rs6450176	0.625	rs56193151	chr5:53287790	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.98	-12.42	-0.62	8.34e-28	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.43	-5.15	-0.31	5.41e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.05	-0.41	1.81e-11	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs2594989	0.943	rs9836824	chr3:11463517	G/A	cg01796438	chr3:11312864	ATG7	-0.71	-8.32	-0.47	6.22e-15	Circulating chemerin levels;
KIRP	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg03959625	chr15:84868606	LOC388152	0.51	5.89	0.35	1.23e-8	Schizophrenia;
KIRP	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.89	-10.1	-0.54	2.81e-20	White matter hyperintensity burden;
KIRP	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg19468946	chr17:37922297	IKZF3	-0.46	-6.54	-0.38	3.6e-10	Asthma;
KIRP	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg02073558	chr3:44770973	ZNF501	0.73	11.72	0.6	1.75e-25	Depressive symptoms;
KIRP	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.45	-6.01	-0.36	6.6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.57	-7.47	-0.43	1.43e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23092527	chr1:8703002	RERE	0.48	6.58	0.39	2.89e-10	Survival in pancreatic cancer;
KIRP	cis	rs78487399	0.808	rs13396401	chr2:43701213	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-4.96	-0.3	1.31e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg00684032	chr4:1343700	KIAA1530	0.52	6.7	0.39	1.37e-10	Longevity;
KIRP	cis	rs6988636	0.710	rs59229243	chr8:124155673	G/A	cg23067535	chr8:124195133	FAM83A	-0.6	-5.34	-0.32	2.11e-7	Urinary uromodulin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14178294	chr17:43109690	DCAKD	-0.45	-6.24	-0.37	1.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg19468946	chr17:37922297	IKZF3	0.55	7.66	0.44	4.39e-13	Self-reported allergy;
KIRP	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg14349672	chr11:133703707	NA	-0.43	-4.98	-0.3	1.22e-6	Childhood ear infection;
KIRP	cis	rs8084125	1.000	rs7230071	chr18:74955482	A/G	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	0.75	6.72	0.39	1.27e-10	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-5.24	-0.32	3.39e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.52	5.68	0.34	3.74e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs258892	0.895	rs2338789	chr5:72038481	A/G	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	0.96	11.99	0.61	2.19e-26	Corneal structure;
KIRP	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg14703610	chr5:56206110	C5orf35	0.52	5.97	0.36	8.05e-9	Initial pursuit acceleration;
KIRP	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg14403583	chr14:105418241	AHNAK2	0.67	9.3	0.51	7.99e-18	Rheumatoid arthritis;
KIRP	cis	rs13385	0.769	rs7737342	chr5:139611011	A/T	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.28	-0.51	8.89e-18	Personality dimensions;
KIRP	cis	rs6910061	1.000	rs6938867	chr6:11095303	A/G	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	cis	rs1408799	0.800	rs13294134	chr9:12673636	A/G	cg05274944	chr9:12693694	TYRP1	0.37	5.33	0.32	2.17e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs2594989	0.887	rs2454498	chr3:11500953	A/G	cg01796438	chr3:11312864	ATG7	-0.67	-8.19	-0.46	1.45e-14	Circulating chemerin levels;
KIRP	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg05340658	chr4:99064831	C4orf37	-0.53	-6.43	-0.38	6.67e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg06050784	chr16:88016603	BANP	0.4	5.09	0.31	7.26e-7	Menopause (age at onset);
KIRP	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.92	-13.88	-0.66	9.37e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7106204	0.702	rs11826172	chr11:24233998	G/A	ch.11.24196551F	chr11:24239977	NA	0.81	9.55	0.52	1.34e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	6.92	0.4	3.96e-11	Eosinophil percentage of white cells;
KIRP	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.89	8.19	0.46	1.45e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.63	7.03	0.41	1.97e-11	Neuroticism;
KIRP	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.92	0.3	1.61e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs62355272	0.965	rs10491435	chr5:35877841	G/A	cg13894535	chr5:35919491	CAPSL	-0.49	-5.81	-0.35	1.93e-8	Lymphocyte counts;
KIRP	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.71	7.21	0.42	6.68e-12	Prostate cancer;
KIRP	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg16797656	chr11:68205561	LRP5	0.4	5.29	0.32	2.71e-7	Total body bone mineral density;
KIRP	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	0.93	11.85	0.6	6.12e-26	Corneal structure;
KIRP	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	cis	rs2976388	0.556	rs2572876	chr8:143830599	C/T	cg06565975	chr8:143823917	SLURP1	-0.55	-7.69	-0.44	3.51e-13	Urinary tract infection frequency;
KIRP	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.64	-8.35	-0.47	5.01e-15	Iron status biomarkers;
KIRP	trans	rs7999699	0.680	rs67503107	chr13:48309103	G/A	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	15.21	0.7	2.72e-37	Platelet count;
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-5.55	-0.33	7.34e-8	Neuroticism;
KIRP	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg18016565	chr1:150552671	MCL1	0.41	6.09	0.36	4.42e-9	Melanoma;
KIRP	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.35	-0.47	4.99e-15	Response to antipsychotic treatment;
KIRP	cis	rs72653721	0.838	rs3798717	chr6:11026471	G/A	cg13562911	chr6:11044106	ELOVL2	0.51	4.96	0.3	1.34e-6	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg21433313	chr16:3507492	NAT15	0.67	6.95	0.4	3.36e-11	Tuberculosis;
KIRP	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	7.86	0.45	1.23e-13	Response to antipsychotic treatment;
KIRP	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg27124370	chr19:33622961	WDR88	0.6	7.48	0.43	1.29e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.67	8.77	0.49	3.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.51	6.88	0.4	5.01e-11	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg17145862	chr1:211918768	LPGAT1	-0.91	-13.27	-0.65	1.11e-30	Leprosy;
KIRP	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	1.08	18.71	0.77	3.43e-49	Bone mineral density;
KIRP	cis	rs10875746	0.669	rs1021313	chr12:48638041	T/A	cg20731937	chr12:48336164	NA	0.42	5.63	0.34	4.9e-8	Longevity (90 years and older);
KIRP	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.5	6.84	0.4	6.25e-11	Type 2 diabetes;
KIRP	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-1.09	-24.19	-0.84	5.47e-67	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg14972814	chr11:95582409	MTMR2	0.35	5.83	0.35	1.74e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.59	0.44	6.6e-13	Major depressive disorder;
KIRP	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.86	-13.62	-0.66	7.52e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.75	0.34	2.7e-8	Birth weight;
KIRP	cis	rs7582180	1.000	rs4851285	chr2:100907598	A/G	cg14675211	chr2:100938903	LONRF2	0.5	5.76	0.34	2.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.96	12.68	0.63	1.12e-28	Homoarginine levels;
KIRP	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.6	7.6	0.44	6.18e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.89	0.45	1.02e-13	Coffee consumption (cups per day);
KIRP	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.9	14.71	0.68	1.42e-35	Breast cancer;
KIRP	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg07827796	chr19:33622959	WDR88	0.5	6.54	0.38	3.62e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.23	0.46	1.09e-14	Personality dimensions;
KIRP	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs885389	0.656	rs12318299	chr12:131617904	C/T	cg00260028	chr12:131606990	GPR133	0.51	4.96	0.3	1.33e-6	RR interval (heart rate);
KIRP	cis	rs1891275	0.509	rs76313529	chr10:93443076	T/C	cg07889827	chr10:93443413	NA	-0.41	-6.84	-0.4	6.36e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.39	6.17	0.37	2.82e-9	Ulcerative colitis;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.75	-9.47	-0.52	2.39e-18	Longevity;Endometriosis;
KIRP	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.77	10.4	0.55	3.12e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.09	-0.36	4.38e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg08076091	chr2:203926405	NBEAL1	0.92	9.52	0.52	1.69e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.81	11.89	0.6	4.73e-26	Heart rate;
KIRP	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-6.11	-0.36	3.77e-9	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.45	-0.33	1.25e-7	Life satisfaction;
KIRP	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.17	10.24	0.55	1e-20	Skin colour saturation;
KIRP	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.71	-0.44	3.1e-13	Morning vs. evening chronotype;
KIRP	cis	rs17095355	1.000	rs11194923	chr10:111695762	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.92	-0.35	1.08e-8	Biliary atresia;
KIRP	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	9.98	0.54	6.37e-20	Hip circumference;
KIRP	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.48	8.46	0.47	2.39e-15	Height;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg14195198	chr19:17322956	MYO9B	0.47	6.06	0.36	5.16e-9	Pancreatic cancer;
KIRP	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.55	-0.43	8.45e-13	Resting heart rate;
KIRP	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg24879335	chr3:133465180	TF	-0.33	-5.27	-0.32	2.99e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.69	-0.39	1.48e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	8.89	0.49	1.31e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-6.7	-0.39	1.41e-10	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.32e-7	Oral cavity cancer;
KIRP	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg02002194	chr4:3960332	NA	-0.48	-7.21	-0.42	6.69e-12	Mood instability;
KIRP	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg20965017	chr5:231967	SDHA	-0.58	-6.73	-0.39	1.17e-10	Breast cancer;
KIRP	cis	rs7481584	0.962	rs2001006	chr11:2974912	A/G	cg25174290	chr11:3078921	CARS	-0.57	-6.35	-0.38	1.01e-9	Calcium levels;
KIRP	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.71	8.69	0.48	5.34e-16	Type 2 diabetes;
KIRP	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	7.17	0.42	9e-12	Renal function-related traits (BUN);
KIRP	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg06521331	chr12:34319734	NA	-0.67	-8.0	-0.45	4.97e-14	Morning vs. evening chronotype;
KIRP	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.72	8.63	0.48	7.51e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2637030	0.515	rs1532163	chr5:52856716	A/G	cg06476337	chr5:52856530	NDUFS4	0.54	5.86	0.35	1.46e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg00405596	chr8:11794950	NA	-0.42	-5.41	-0.33	1.49e-7	Retinal vascular caliber;
KIRP	cis	rs300890	0.689	rs7697838	chr4:144247348	T/C	cg19876092	chr4:144208277	NA	0.3	4.88	0.3	1.88e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.75	9.99	0.54	6.06e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg13736514	chr6:26305472	NA	-0.66	-8.71	-0.49	4.48e-16	Educational attainment;
KIRP	cis	rs17818399	0.817	rs17767994	chr2:46860079	G/T	cg02822958	chr2:46747628	ATP6V1E2	-0.51	-5.59	-0.34	5.9e-8	Height;
KIRP	cis	rs10864907	0.718	rs13032029	chr2:113600415	C/T	cg03712744	chr2:113669835	IL1F7	-0.35	-5.12	-0.31	6.2e-7	Pulmonary function;
KIRP	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg04935436	chr20:30431758	NA	0.38	5.22	0.32	3.83e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg17507749	chr15:85114479	UBE2QP1	0.89	9.86	0.53	1.53e-19	Schizophrenia;
KIRP	trans	rs9784649	0.882	rs72753879	chr5:24947395	C/T	cg08600765	chr20:34638493	LOC647979	-0.67	-6.13	-0.36	3.38e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00933542	chr6:150070202	PCMT1	0.3	5.96	0.36	8.52e-9	Lung cancer;
KIRP	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-0.99	-9.87	-0.53	1.44e-19	Lung cancer;
KIRP	trans	rs6601327	0.635	rs10099122	chr8:9568003	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.08	-0.36	4.45e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg00857998	chr1:205179979	DSTYK	0.62	7.38	0.43	2.51e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg22705602	chr4:152727874	NA	0.56	9.4	0.51	4.07e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.7	-7.75	-0.44	2.35e-13	Body mass index;
KIRP	cis	rs7903847	0.642	rs11814021	chr10:99158386	A/G	cg20016023	chr10:99160130	RRP12	-0.43	-5.7	-0.34	3.37e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg15841412	chr13:111365552	ING1	0.55	6.13	0.36	3.43e-9	Coronary artery disease;
KIRP	cis	rs9311676	0.632	rs62258075	chr3:58359851	G/A	cg06643156	chr3:58380774	PXK	0.36	5.14	0.31	5.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.06	-0.31	8.15e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11987759	chr7:65425863	GUSB	-0.52	-6.91	-0.4	4.06e-11	Aortic root size;
KIRP	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg15997130	chr1:24165203	NA	0.53	7.78	0.44	2.04e-13	Immature fraction of reticulocytes;
KIRP	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.71	10.61	0.56	6.64e-22	Eosinophilic esophagitis;
KIRP	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.8	-10.01	-0.54	5.35e-20	Blood trace element (Zn levels);
KIRP	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.64	8.49	0.48	2.03e-15	Motion sickness;
KIRP	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg25356066	chr3:128598488	ACAD9	-0.46	-5.56	-0.33	6.93e-8	IgG glycosylation;
KIRP	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.9	-11.97	-0.61	2.57e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.43	5.64	0.34	4.75e-8	Blood metabolite levels;
KIRP	cis	rs1829883	0.835	rs2461972	chr5:98776454	G/A	cg08333243	chr5:99726346	NA	-0.41	-5.45	-0.33	1.24e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs9928842	0.823	rs8061356	chr16:75294232	G/A	cg09066997	chr16:75300724	BCAR1	0.66	5.8	0.35	2.04e-8	Alcoholic chronic pancreatitis;
KIRP	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.16	0.54	1.76e-20	Cognitive test performance;
KIRP	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.9	9.51	0.52	1.85e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.85	0.6	6.19e-26	Smoking behavior;
KIRP	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.52	6.76	0.4	1e-10	Birth weight;
KIRP	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.93	13.71	0.66	3.59e-32	Tonsillectomy;
KIRP	cis	rs2278796	0.639	rs6697344	chr1:204971485	G/T	cg17449235	chr1:204966235	NFASC	0.55	7.48	0.43	1.31e-12	Mean platelet volume;
KIRP	cis	rs1185460	0.546	rs474201	chr11:118958229	G/A	cg23280166	chr11:118938394	VPS11	0.61	7.11	0.41	1.27e-11	Coronary artery disease;
KIRP	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg23752985	chr2:85803571	VAMP8	0.46	5.32	0.32	2.34e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.66	-6.83	-0.4	6.46e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.65	-8.24	-0.47	1e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs2554380	0.891	rs1155070	chr15:84303084	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-7.85	-0.45	1.28e-13	Height;
KIRP	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.48	-0.43	1.28e-12	Neuroticism;
KIRP	cis	rs4936894	0.500	rs4331103	chr11:124146921	T/C	cg27160556	chr11:124181099	OR8D1	-0.46	-6.62	-0.39	2.25e-10	Aging (time to death);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12539128	chr2:71222296	TEX261	0.49	6.06	0.36	5.04e-9	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4663866	1.000	rs4663865	chr2:239145960	C/T	cg16914508	chr2:239161102	PER2	-0.73	-5.56	-0.33	6.86e-8	Irritable bowel syndrome;
KIRP	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg04989706	chr14:50066350	PPIL5	-0.49	-5.83	-0.35	1.76e-8	Carotid intima media thickness;
KIRP	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.57	-7.98	-0.45	5.42e-14	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.11	-0.36	3.93e-9	Schizophrenia;
KIRP	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.58	8.5	0.48	1.79e-15	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1440410	0.571	rs4579067	chr4:144041828	T/C	cg01719995	chr4:144104893	USP38	0.45	5.93	0.35	1.04e-8	Ischemic stroke;
KIRP	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23161317	chr6:28129485	ZNF389	-0.46	-5.4	-0.33	1.56e-7	Depression;
KIRP	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.11	0.41	1.23e-11	Resting heart rate;
KIRP	cis	rs644148	0.785	rs118112019	chr19:44965091	T/G	cg15540054	chr19:45004280	ZNF180	0.6	6.12	0.36	3.59e-9	Personality dimensions;
KIRP	cis	rs7923609	0.936	rs10740125	chr10:65209609	T/C	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.8	-8.05	-0.46	3.48e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19171272	chr22:38449367	NA	-0.57	-8.26	-0.47	9.15e-15	Glioblastoma;Glioma;
KIRP	cis	rs72634258	0.503	rs72632055	chr1:7835774	T/G	cg00042356	chr1:8021962	PARK7	0.66	5.18	0.31	4.53e-7	Inflammatory bowel disease;
KIRP	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg26727032	chr16:67993705	SLC12A4	-0.54	-4.96	-0.3	1.29e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-7.99	-0.45	5.32e-14	Monocyte percentage of white cells;
KIRP	cis	rs9400271	0.632	rs34981677	chr6:109590920	T/C	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.21	13.21	0.64	1.79e-30	Uric acid levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27572510	chr17:35474613	ACACA	0.45	6.43	0.38	6.57e-10	Survival in pancreatic cancer;
KIRP	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg01620082	chr3:125678407	NA	-0.84	-6.27	-0.37	1.61e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg10169327	chr19:45448959	APOC2	0.33	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg06636001	chr8:8085503	FLJ10661	0.56	7.5	0.43	1.13e-12	Neuroticism;
KIRP	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.31	5.11	0.31	6.62e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg24315340	chr6:146058215	EPM2A	0.44	5.45	0.33	1.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	12.98	0.64	1.06e-29	Platelet count;
KIRP	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	12.1	0.61	9.1e-27	Menopause (age at onset);
KIRP	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.97	-0.3	1.28e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7582720	1.000	rs72932737	chr2:203654540	G/A	cg08076091	chr2:203926405	NBEAL1	0.84	8.35	0.47	5.01e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.16	-0.54	1.84e-20	Menarche (age at onset);
KIRP	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.03	-0.41	2.05e-11	Mood instability;
KIRP	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg22549504	chr19:17448937	GTPBP3	0.49	5.1	0.31	6.83e-7	Systemic lupus erythematosus;
KIRP	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.0	-0.41	2.42e-11	Joint mobility (Beighton score);
KIRP	cis	rs9914544	0.628	rs4630608	chr17:18678548	C/T	cg26378065	chr17:18585709	ZNF286B	0.4	5.06	0.31	8.11e-7	Educational attainment (years of education);
KIRP	cis	rs7577696	0.524	rs12991444	chr2:32265125	G/T	cg02381751	chr2:32503542	YIPF4	-0.49	-4.89	-0.3	1.81e-6	Inflammatory biomarkers;
KIRP	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.87	-11.77	-0.6	1.17e-25	Cognitive function;
KIRP	cis	rs9517302	0.615	rs3752973	chr13:99097509	G/A	cg22223119	chr13:99095684	FARP1	-0.44	-5.33	-0.32	2.22e-7	Obesity-related traits;
KIRP	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.77	-0.53	2.82e-19	Mood instability;
KIRP	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.69	8.83	0.49	2.04e-16	Age-related hearing impairment;
KIRP	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.72	10.69	0.56	3.65e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg21523564	chr15:75251491	NA	0.41	6.54	0.38	3.55e-10	Breast cancer;
KIRP	cis	rs259842	0.641	rs7603617	chr2:180706502	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.48	-0.33	1.06e-7	Blood protein levels;
KIRP	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.8	0.35	1.98e-8	Educational attainment;
KIRP	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg00204512	chr16:28754710	NA	0.48	6.34	0.37	1.11e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg17366294	chr4:99064904	C4orf37	-0.35	-4.91	-0.3	1.69e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg17294928	chr15:75287854	SCAMP5	0.6	8.02	0.46	4.25e-14	Breast cancer;
KIRP	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.41	5.89	0.35	1.25e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs514024	0.668	rs1573178	chr9:130372487	A/G	cg13643465	chr9:130375613	STXBP1	0.42	5.46	0.33	1.13e-7	Eating disorders (purging via substances);
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.61	10.2	0.55	1.29e-20	Lymphocyte counts;
KIRP	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	0.96	14.81	0.69	6.5e-36	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-9.01	-0.5	5.85e-17	Coffee consumption (cups per day);
KIRP	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.4	0.51	3.94e-18	Prudent dietary pattern;
KIRP	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	10.47	0.56	1.93e-21	Post bronchodilator FEV1;
KIRP	cis	rs1555895	0.656	rs10752020	chr10:840608	G/T	cg10017260	chr10:834428	NA	0.44	6.38	0.38	8.92e-10	Survival in rectal cancer;
KIRP	cis	rs13102973	0.965	rs28769289	chr4:135878230	T/C	cg14419869	chr4:135874104	NA	-0.59	-10.62	-0.56	6.26e-22	Subjective well-being;
KIRP	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg13010199	chr12:38710504	ALG10B	-0.64	-7.98	-0.45	5.41e-14	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26314531	chr2:26401878	FAM59B	-0.5	-5.1	-0.31	6.77e-7	Gut microbiome composition (summer);
KIRP	cis	rs4356932	0.817	rs6826398	chr4:76973546	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.2	0.37	2.42e-9	Blood protein levels;
KIRP	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg04662567	chr6:169592167	NA	0.63	5.39	0.33	1.61e-7	Pulse pressure;
KIRP	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.55	-5.0	-0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-5.84	-0.35	1.64e-8	Mood instability;
KIRP	cis	rs806321	0.641	rs806328	chr13:50849942	T/A	cg10393508	chr13:50950265	NA	-0.44	-6.31	-0.37	1.31e-9	Multiple sclerosis;
KIRP	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.9	-0.4	4.32e-11	Mood instability;
KIRP	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg04990556	chr1:26633338	UBXN11	0.64	6.07	0.36	4.77e-9	Obesity-related traits;
KIRP	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg06026331	chr20:60912101	LAMA5	-0.47	-6.26	-0.37	1.73e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.59	-0.34	6.17e-8	Life satisfaction;
KIRP	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg05938607	chr10:60274200	BICC1	-0.46	-11.34	-0.59	2.91e-24	Refractive error;
KIRP	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg06223162	chr1:101003688	GPR88	-0.41	-8.09	-0.46	2.81e-14	Breast cancer;
KIRP	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.7	10.02	0.54	4.91e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg18016565	chr1:150552671	MCL1	0.4	6.06	0.36	5e-9	Melanoma;
KIRP	cis	rs1953600	0.668	rs11201879	chr10:81908573	A/C	cg13429435	chr10:81271195	EIF5AL1	-0.32	-4.95	-0.3	1.38e-6	Sarcoidosis;
KIRP	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.78	9.95	0.54	8.15e-20	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg24375607	chr4:120327624	NA	0.56	6.33	0.37	1.13e-9	Corneal astigmatism;
KIRP	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.58	7.57	0.43	7.29e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25365794	chr17:8022404	ALOXE3	0.59	7.02	0.41	2.18e-11	Smoking initiation;
KIRP	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.68	-0.6	2.28e-25	Caffeine consumption;
KIRP	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg11189052	chr15:85197271	WDR73	0.52	5.33	0.32	2.26e-7	Schizophrenia;
KIRP	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.81	13.41	0.65	3.77e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg12598211	chr12:123634384	NA	-0.44	-5.37	-0.32	1.8e-7	Neutrophil percentage of white cells;
KIRP	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.22	-20.0	-0.79	1.66e-53	Breast cancer;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.57	6.83	0.4	6.48e-11	Longevity;Endometriosis;
KIRP	cis	rs2797160	0.515	rs9375409	chr6:125972798	A/G	cg05901451	chr6:126070800	HEY2	-0.37	-5.15	-0.31	5.35e-7	Endometrial cancer;
KIRP	cis	rs911119	0.913	rs6048923	chr20:23578206	C/T	cg16589663	chr20:23618590	CST3	0.68	6.35	0.38	1.04e-9	Chronic kidney disease;
KIRP	cis	rs2274459	0.908	rs13207666	chr6:33707227	C/G	cg06253072	chr6:33679850	C6orf125	0.5	5.04	0.31	8.83e-7	Obesity (extreme);
KIRP	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs4908768	0.906	rs2144463	chr1:8583293	C/A	cg03610117	chr1:8450231	RERE	-0.49	-5.29	-0.32	2.66e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg15880211	chr22:50250494	ZBED4	-0.57	-5.16	-0.31	5.02e-7	Schizophrenia;
KIRP	cis	rs9900972	0.918	rs2889530	chr17:76878706	C/T	cg20937029	chr17:76870563	TIMP2	0.43	5.05	0.31	8.64e-7	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02396888	chr1:31191746	MATN1	-0.5	-6.62	-0.39	2.19e-10	Metabolic traits;
KIRP	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg13206674	chr6:150067644	NUP43	0.59	8.63	0.48	7.86e-16	Lung cancer;
KIRP	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12893428	chr3:195717962	SDHAP1	0.47	6.06	0.36	4.98e-9	Pancreatic cancer;
KIRP	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.59	7.64	0.44	4.97e-13	Morning vs. evening chronotype;
KIRP	cis	rs1456297	0.692	rs28555597	chr15:52004560	G/T	cg14296394	chr15:51910925	DMXL2	0.8	10.48	0.56	1.75e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18252515	chr7:66147081	NA	0.42	4.89	0.3	1.86e-6	Aortic root size;
KIRP	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.42	-6.63	-0.39	2.06e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.3	-0.42	3.87e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg20750642	chr13:99100586	FARP1	0.42	5.19	0.31	4.51e-7	Longevity;
KIRP	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.88	9.56	0.52	1.33e-18	Pulmonary function decline;
KIRP	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg24315340	chr6:146058215	EPM2A	0.45	5.67	0.34	4.01e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12195424	0.558	rs75574110	chr6:56299478	A/T	cg20782286	chr6:56298173	NA	-0.66	-5.16	-0.31	5.16e-7	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg12591125	chr7:1885375	MAD1L1	0.59	5.64	0.34	4.57e-8	Bipolar disorder;
KIRP	cis	rs11676348	0.805	rs12694428	chr2:218958820	G/A	cg00012203	chr2:219082015	ARPC2	-0.41	-5.1	-0.31	6.94e-7	Ulcerative colitis;
KIRP	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.62	5.12	0.31	6.15e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg27144592	chr16:783916	NARFL	0.37	5.14	0.31	5.5e-7	Height;
KIRP	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27297192	chr10:134578999	INPP5A	0.63	7.61	0.44	5.77e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg06935464	chr4:38784597	TLR10	0.54	5.38	0.32	1.69e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14226678	chr19:2841332	ZNF555	0.48	6.11	0.36	3.89e-9	Parkinson's disease;
KIRP	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg17507749	chr15:85114479	UBE2QP1	0.42	4.91	0.3	1.62e-6	P wave terminal force;
KIRP	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08439880	chr3:133502540	NA	-0.48	-6.05	-0.36	5.45e-9	Iron status biomarkers;
KIRP	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg05519781	chr21:40033154	ERG	0.6	8.25	0.47	9.7e-15	Coronary artery disease;
KIRP	cis	rs1144	0.537	rs2470944	chr7:104585516	G/C	cg04380332	chr7:105027541	SRPK2	-0.55	-8.06	-0.46	3.28e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs17321999	1.000	rs9558	chr2:30481917	A/G	cg05247661	chr2:30472410	LBH	-0.64	-6.78	-0.4	9.01e-11	Systemic lupus erythematosus;
KIRP	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg03235661	chr20:60525775	NA	-0.31	-5.24	-0.32	3.47e-7	Body mass index;
KIRP	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	0.56	5.9	0.35	1.23e-8	Crohn's disease;
KIRP	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg18882449	chr10:104885122	NT5C2	-0.5	-6.4	-0.38	7.69e-10	Arsenic metabolism;
KIRP	cis	rs883565	0.542	rs6802490	chr3:39033907	T/A	cg01426195	chr3:39028469	NA	-0.68	-11.08	-0.58	2.14e-23	Handedness;
KIRP	cis	rs4683142	0.518	rs6802312	chr3:46025941	T/C	cg18004856	chr3:46029278	FYCO1	0.49	6.62	0.39	2.28e-10	Methadone dose in opioid dependence;
KIRP	trans	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg06521331	chr12:34319734	NA	0.53	6.72	0.39	1.26e-10	Heart rate;
KIRP	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg12317470	chr15:67143691	NA	-0.57	-6.86	-0.4	5.53e-11	Lung cancer (smoking interaction);
KIRP	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.49e-13	IgG glycosylation;
KIRP	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.32	-0.51	6.87e-18	Mean corpuscular volume;
KIRP	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	13.36	0.65	5.76e-31	Personality dimensions;
KIRP	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg10189774	chr4:17578691	LAP3	0.49	5.48	0.33	1.07e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11790388	0.505	rs546493	chr9:129700405	C/G	cg13970942	chr9:129673409	NA	-0.39	-5.17	-0.31	4.78e-7	Schizophrenia;
KIRP	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.64	-7.92	-0.45	8.18e-14	Longevity;
KIRP	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg24881330	chr22:46731750	TRMU	0.76	5.73	0.34	2.97e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.79	0.4	8.41e-11	Electroencephalogram traits;
KIRP	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg16434002	chr17:42200994	HDAC5	-0.48	-6.09	-0.36	4.22e-9	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs10924970	0.967	rs2185020	chr1:235440289	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.55	6.99	0.41	2.51e-11	Coronary heart disease;
KIRP	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.74	-9.85	-0.53	1.69e-19	Childhood ear infection;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.82	-8.98	-0.5	7.08e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg03714773	chr7:91764589	CYP51A1	0.4	5.8	0.35	1.99e-8	Breast cancer;
KIRP	cis	rs79387448	0.655	rs75579337	chr2:102917302	C/A	cg09003973	chr2:102972529	NA	1.18	8.56	0.48	1.24e-15	Gut microbiota (bacterial taxa);
KIRP	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.81	-8.69	-0.48	5.32e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs587242	1.000	rs509770	chr1:96891615	G/A	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.8	-9.68	-0.53	5.36e-19	Blood protein levels;
KIRP	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.39	-5.4	-0.33	1.59e-7	Endometrial cancer;
KIRP	cis	rs3779635	0.742	rs919492	chr8:27254113	T/G	cg23698023	chr8:27181813	PTK2B	0.34	5.03	0.31	9.54e-7	Neuroticism;
KIRP	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7536201	1.000	rs10751776	chr1:25296743	A/C	cg23273869	chr1:25296894	NA	-0.38	-5.29	-0.32	2.64e-7	Psoriasis vulgaris;
KIRP	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg23460707	chr10:133558971	NA	0.36	5.47	0.33	1.08e-7	Survival in rectal cancer;
KIRP	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg04727924	chr7:799746	HEATR2	-0.79	-8.84	-0.49	1.83e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.8	9.65	0.52	6.84e-19	Response to antipsychotic treatment;
KIRP	cis	rs741677	0.963	rs441821	chr17:474394	A/G	cg13332499	chr17:408570	NA	0.38	5.09	0.31	7.19e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.56	5.94	0.35	9.81e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.34	0.32	2.16e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs7737355	1.000	rs9327608	chr5:130650134	G/A	cg06307176	chr5:131281290	NA	0.53	5.71	0.34	3.27e-8	Life satisfaction;
KIRP	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.68	-9.49	-0.52	2.08e-18	Retinal vascular caliber;
KIRP	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg24375607	chr4:120327624	NA	0.54	5.64	0.34	4.73e-8	Corneal astigmatism;
KIRP	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.86	10.8	0.57	1.62e-22	Coronary artery disease;
KIRP	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-0.88	-11.72	-0.6	1.69e-25	Gut microbiota (bacterial taxa);
KIRP	trans	rs2998286	0.862	rs2993990	chr10:28806970	C/T	cg10174683	chr16:85619974	NA	-0.67	-6.08	-0.36	4.67e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs11671005	0.736	rs11668201	chr19:59003632	A/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.52	-5.73	-0.34	2.96e-8	Mean platelet volume;
KIRP	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg10351095	chr21:47802916	PCNT	-0.43	-5.38	-0.32	1.78e-7	Testicular germ cell tumor;
KIRP	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg27147174	chr7:100797783	AP1S1	-0.7	-9.17	-0.5	1.89e-17	Life satisfaction;
KIRP	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg25039879	chr17:56429692	SUPT4H1	0.59	5.14	0.31	5.53e-7	Cognitive test performance;
KIRP	trans	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg10756647	chr7:56101905	PSPH	1.01	7.35	0.42	2.93e-12	Diabetic kidney disease;
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13198984	chr17:80129470	CCDC57	-0.58	-8.78	-0.49	2.83e-16	Life satisfaction;
KIRP	cis	rs2151522	0.603	rs28532376	chr6:127193624	T/C	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.95	13.45	0.65	2.73e-31	Cognitive function;
KIRP	trans	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg24644049	chr4:85504048	CDS1	1.05	7.44	0.43	1.67e-12	Skin colour saturation;
KIRP	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.91	12.18	0.61	4.94e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	1.0	13.32	0.65	7.92e-31	Menopause (age at onset);
KIRP	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.27	0.32	3.04e-7	Lung cancer;
KIRP	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg08890418	chr1:21044141	KIF17	0.66	10.37	0.55	3.88e-21	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.77	8.94	0.5	9.45e-17	Adiposity;
KIRP	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg25482853	chr8:67687455	SGK3	0.8	6.99	0.41	2.52e-11	Obesity-related traits;
KIRP	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg09990169	chr2:241835740	C2orf54	0.46	6.75	0.4	1.07e-10	Urinary metabolites;
KIRP	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg00409905	chr10:38381863	ZNF37A	0.54	6.03	0.36	5.84e-9	Obesity (extreme);
KIRP	cis	rs77861329	1.000	rs352153	chr3:52211184	A/T	cg08692210	chr3:52188851	WDR51A	0.86	6.71	0.39	1.3e-10	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg13444842	chr1:152974279	SPRR3	-0.38	-5.35	-0.32	2.06e-7	Inflammatory skin disease;
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.54	-7.32	-0.42	3.48e-12	Mean corpuscular volume;
KIRP	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	0.83	12.49	0.62	4.86e-28	Body mass index;
KIRP	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.15e-7	Aortic root size;
KIRP	cis	rs8113308	0.810	rs7259622	chr19:52445737	C/T	cg25782003	chr19:52490127	ZNF350	0.53	4.97	0.3	1.23e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.34	3.27e-8	Major depressive disorder;
KIRP	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.47	-6.41	-0.38	7.54e-10	Systolic blood pressure;
KIRP	cis	rs501120	0.564	rs12415866	chr10:44686664	A/G	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.51	-5.39	-0.32	1.67e-7	Body mass index (adult);
KIRP	cis	rs9659323	0.717	rs61806238	chr1:119536378	G/A	cg05756136	chr1:119680316	WARS2	-0.47	-6.43	-0.38	6.68e-10	Body mass index;
KIRP	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg26248373	chr2:1572462	NA	-0.58	-6.91	-0.4	4.05e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.19	13.82	0.66	1.61e-32	Sexual dysfunction (female);
KIRP	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg14673194	chr17:80132900	CCDC57	0.77	8.69	0.48	5.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg16396542	chr1:89473148	GBP3	0.41	5.67	0.34	4.02e-8	Carotid intima media thickness;
KIRP	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg13010199	chr12:38710504	ALG10B	0.36	4.85	0.3	2.18e-6	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14250937	chr9:139723883	C9orf86	0.48	6.27	0.37	1.59e-9	Interleukin-4 levels;
KIRP	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.86e-15	Prudent dietary pattern;
KIRP	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg08501292	chr6:25962987	TRIM38	1.1	8.31	0.47	6.33e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4812048	0.649	rs3761255	chr20:57618802	T/C	cg14073986	chr20:57617431	SLMO2	0.64	5.74	0.34	2.75e-8	Mean platelet volume;
KIRP	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.22	-0.37	2.08e-9	Type 2 diabetes;
KIRP	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg22903471	chr2:27725779	GCKR	-0.48	-6.77	-0.4	9.4e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10641986	chr17:56609534	SEPT4	-0.45	-6.31	-0.37	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.14	16.14	0.72	1.82e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs8113308	1.000	rs8104737	chr19:52441697	T/G	cg24732339	chr19:52471368	ZNF350	-0.45	-5.16	-0.31	5.03e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg04226714	chr8:49833948	SNAI2	-0.49	-6.58	-0.39	2.81e-10	Life satisfaction;
KIRP	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.19	0.7	3.34e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs311392	0.554	rs369839	chr8:55097431	A/C	cg11783602	chr8:55087084	NA	-0.48	-5.82	-0.35	1.8e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs35123781	0.502	rs2336901	chr5:138919078	A/G	cg12205435	chr5:138714322	SLC23A1	-0.39	-5.12	-0.31	6.17e-7	Schizophrenia;
KIRP	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg04310649	chr10:35416472	CREM	-0.52	-5.91	-0.35	1.12e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2617583	0.967	rs2617595	chr5:1448246	C/T	cg07151155	chr5:1473589	LPCAT1	-0.41	-5.49	-0.33	1.02e-7	Breast cancer;
KIRP	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg00981070	chr1:2046702	PRKCZ	-0.31	-5.49	-0.33	9.83e-8	Height;
KIRP	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg22356347	chr1:167427500	CD247	-0.39	-5.58	-0.34	6.37e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.8	0.49	2.39e-16	Motion sickness;
KIRP	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg20673091	chr1:2541236	MMEL1	0.65	9.57	0.52	1.18e-18	Ulcerative colitis;
KIRP	cis	rs4356932	1.000	rs6532163	chr4:76983618	T/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.43	5.52	0.33	8.52e-8	Melanoma;
KIRP	cis	rs10924970	0.967	rs11585350	chr1:235482739	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	4.9	0.3	1.7e-6	Asthma;
KIRP	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-4.86	-0.3	2.12e-6	Blood protein levels;
KIRP	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg25039879	chr17:56429692	SUPT4H1	0.59	5.07	0.31	7.95e-7	Cognitive test performance;
KIRP	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.48	5.14	0.31	5.6e-7	Initial pursuit acceleration;
KIRP	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	0.51	8.94	0.5	9.24e-17	QRS complex (12-leadsum);
KIRP	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.15	-0.46	1.86e-14	Response to antipsychotic treatment;
KIRP	cis	rs793571	0.774	rs10851640	chr15:59137870	T/C	cg05156742	chr15:59063176	FAM63B	-0.53	-6.12	-0.36	3.58e-9	Schizophrenia;
KIRP	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg08501292	chr6:25962987	TRIM38	0.65	4.96	0.3	1.34e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.7	9.6	0.52	9.39e-19	Schizophrenia;
KIRP	cis	rs1978968	1.000	rs1076543	chr22:18446490	T/C	cg02610425	chr22:18483192	MICAL3	0.36	5.07	0.31	7.72e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.16	9.25	0.51	1.12e-17	Skin colour saturation;
KIRP	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg13206674	chr6:150067644	NUP43	0.56	7.79	0.44	1.91e-13	Lung cancer;
KIRP	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.59	-7.01	-0.41	2.28e-11	Mosquito bite size;
KIRP	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.7	-9.27	-0.51	1.01e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.9	14.74	0.68	1.09e-35	Dental caries;
KIRP	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.48	-0.33	1.05e-7	Alcohol dependence;
KIRP	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg05973401	chr12:123451056	ABCB9	0.58	6.73	0.39	1.16e-10	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14022721	chr22:25507536	KIAA1671	0.51	6.36	0.38	9.8e-10	Smoking initiation;
KIRP	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.85	-13.19	-0.64	2.16e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-9.02	-0.5	5.5e-17	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.38	0.32	1.77e-7	Educational attainment;
KIRP	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg21361702	chr7:150065534	REPIN1	0.66	6.71	0.39	1.3e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.47	-5.94	-0.35	9.93e-9	Rheumatoid arthritis;
KIRP	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg21064579	chr19:49206444	FUT2	0.59	8.91	0.49	1.15e-16	Dietary macronutrient intake;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25971741	chr6:15343116	JARID2	0.6	7.58	0.44	6.86e-13	Interleukin-4 levels;
KIRP	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg13409248	chr3:40428643	ENTPD3	0.39	5.25	0.32	3.24e-7	Renal cell carcinoma;
KIRP	cis	rs2290402	0.536	rs4690336	chr4:867242	A/G	cg14517359	chr4:903473	GAK	0.49	5.18	0.31	4.57e-7	Type 2 diabetes;
KIRP	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg06521331	chr12:34319734	NA	-0.64	-7.58	-0.44	6.9e-13	Morning vs. evening chronotype;
KIRP	cis	rs2274273	0.868	rs9919926	chr14:55813890	G/C	cg04306507	chr14:55594613	LGALS3	0.41	6.0	0.36	7.07e-9	Protein biomarker;
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.31	0.32	2.48e-7	Lung cancer;
KIRP	cis	rs17428704	0.571	rs59405120	chr5:14385873	C/A	cg26595256	chr5:14380529	TRIO	-0.85	-6.64	-0.39	1.97e-10	Electroencephalogram traits;
KIRP	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.75	10.44	0.55	2.26e-21	Menarche (age at onset);
KIRP	cis	rs4253772	0.575	rs9615979	chr22:46789021	G/T	cg18190219	chr22:46762943	CELSR1	-0.81	-6.78	-0.4	8.66e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs8103278	0.507	rs4802276	chr19:46260748	T/C	cg11657440	chr19:46296263	DMWD	0.92	14.62	0.68	2.99e-35	Coronary artery disease;
KIRP	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg00977110	chr5:151150581	G3BP1	0.59	5.9	0.35	1.23e-8	Preschool internalizing problems;
KIRP	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.75	10.23	0.55	1.05e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg06671706	chr8:8559999	CLDN23	0.47	5.76	0.34	2.49e-8	Obesity-related traits;
KIRP	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.92	9.44	0.52	2.93e-18	Cerebrospinal P-tau181p levels;
KIRP	cis	rs548987	0.507	rs3757132	chr6:25832691	C/T	cg03264133	chr6:25882463	NA	-0.44	-5.19	-0.31	4.51e-7	Homocysteine levels;
KIRP	cis	rs6800768	0.633	rs59374114	chr3:24112202	G/T	cg10674438	chr3:24145617	LOC152024	-0.36	-5.08	-0.31	7.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13385	0.769	rs36050010	chr5:139569859	C/A	cg01860693	chr5:139557145	C5orf32	0.49	5.09	0.31	6.98e-7	Atrial fibrillation;
KIRP	cis	rs10861342	1.000	rs10778370	chr12:105603139	T/C	cg23923672	chr12:105501055	KIAA1033	0.83	6.34	0.37	1.11e-9	IgG glycosylation;
KIRP	cis	rs6681460	0.866	rs1856318	chr1:67024215	T/C	cg02459107	chr1:67143332	SGIP1	0.42	5.79	0.35	2.12e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg09307838	chr4:120376055	NA	0.63	6.85	0.4	6.04e-11	Educational attainment;
KIRP	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.67	9.36	0.51	5.36e-18	Mood instability;
KIRP	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.51	6.89	0.4	4.58e-11	Schizophrenia;
KIRP	trans	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg06521331	chr12:34319734	NA	-0.49	-6.21	-0.37	2.19e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-6.88	-0.4	4.84e-11	Gut microbiome composition (summer);
KIRP	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.97e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.45	6.09	0.36	4.34e-9	Age-related hearing impairment;
KIRP	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	1.1	20.42	0.79	6.93e-55	Bone mineral density;
KIRP	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg05768032	chr16:30646687	NA	0.5	5.98	0.36	7.66e-9	Multiple myeloma;
KIRP	cis	rs231513	0.954	rs231524	chr17:41953212	G/A	cg26893861	chr17:41843967	DUSP3	-0.48	-4.99	-0.3	1.16e-6	Cognitive function;
KIRP	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs7236492	0.935	rs77865749	chr18:77216756	G/A	cg15644404	chr18:77186268	NFATC1	-0.93	-7.35	-0.42	2.9e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.81	10.46	0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12311346	chr5:56204834	C5orf35	0.37	4.91	0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs2862064	1.000	rs9313400	chr5:156433341	A/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-7.42	-0.43	1.87e-12	Platelet count;
KIRP	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.72	-0.53	4.04e-19	Total body bone mineral density;
KIRP	cis	rs3755132	0.929	rs68147799	chr2:15754346	T/G	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17374677	chr20:2489892	ZNF343	0.46	6.52	0.38	4.01e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8756	0.689	rs1480474	chr12:66326943	A/G	cg06712651	chr12:66351869	HMGA2	-0.68	-9.77	-0.53	2.85e-19	Height;
KIRP	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg15556689	chr8:8085844	FLJ10661	0.82	10.87	0.57	9.63e-23	Mood instability;
KIRP	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg00405596	chr8:11794950	NA	0.52	6.96	0.41	3.08e-11	Mood instability;
KIRP	cis	rs9535307	0.929	rs6561552	chr13:50260905	A/G	cg04663916	chr13:50265991	EBPL	0.7	7.46	0.43	1.53e-12	Obesity-related traits;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg01763666	chr17:80159506	CCDC57	0.36	4.92	0.3	1.56e-6	Life satisfaction;
KIRP	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.88	0.3	1.94e-6	Menopause (age at onset);
KIRP	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg04132472	chr17:19861366	AKAP10	-0.4	-5.15	-0.31	5.42e-7	Schizophrenia;
KIRP	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg02820901	chr13:113351484	ATP11A	0.68	6.29	0.37	1.46e-9	Glycated hemoglobin levels;
KIRP	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.84	9.51	0.52	1.84e-18	Cognitive ability;
KIRP	cis	rs1832871	0.541	rs62438579	chr6:158873858	T/A	cg07215822	chr6:158701037	NA	-0.52	-5.77	-0.35	2.41e-8	Height;
KIRP	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	5.91	0.35	1.15e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg21775007	chr8:11205619	TDH	0.49	6.6	0.39	2.5e-10	Rheumatoid arthritis;
KIRP	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg06521331	chr12:34319734	NA	-0.47	-5.99	-0.36	7.6e-9	Morning vs. evening chronotype;
KIRP	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.93	10.73	0.56	2.7e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.98	-0.36	7.68e-9	Neutrophil percentage of white cells;
KIRP	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg24565620	chr2:194026	NA	0.63	7.39	0.43	2.28e-12	Blood protein levels;
KIRP	cis	rs6681460	0.834	rs2916	chr1:67216697	G/A	cg13052034	chr1:66999238	SGIP1	-0.43	-5.98	-0.36	7.99e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs17095355	1.000	rs12244557	chr10:111746142	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.37	-5.21	-0.32	4.04e-7	Biliary atresia;
KIRP	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg21775007	chr8:11205619	TDH	0.43	5.54	0.33	7.63e-8	Myopia (pathological);
KIRP	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.55	-8.31	-0.47	6.66e-15	Coronary artery disease;
KIRP	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg08807101	chr21:30365312	RNF160	0.57	5.67	0.34	3.97e-8	Cognitive test performance;
KIRP	trans	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg00405596	chr8:11794950	NA	0.48	6.21	0.37	2.28e-9	Joint mobility (Beighton score);
KIRP	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg11150807	chr10:43354902	NA	0.68	7.56	0.43	8.09e-13	Blood protein levels;
KIRP	cis	rs2154427	0.872	rs76446596	chr21:34098391	T/C	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.66	-5.85	-0.35	1.59e-8	Bilirubin levels;
KIRP	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	5.59	0.34	5.94e-8	Red blood cell count;
KIRP	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	9.15	0.5	2.27e-17	Bone mineral density;
KIRP	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg24110177	chr3:50126178	RBM5	-0.66	-7.42	-0.43	1.9e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg22153745	chr1:153894579	GATAD2B	-0.62	-6.63	-0.39	2.13e-10	Total cholesterol levels;
KIRP	cis	rs11997175	0.766	rs56803376	chr8:33687676	T/C	cg04338863	chr8:33670619	NA	0.4	5.3	0.32	2.55e-7	Body mass index;
KIRP	cis	rs6681460	0.834	rs544258	chr1:67219209	T/C	cg13052034	chr1:66999238	SGIP1	-0.42	-5.73	-0.34	2.9e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg09911534	chr15:67153556	NA	-0.46	-5.33	-0.32	2.18e-7	Lung cancer (smoking interaction);
KIRP	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.74	-10.03	-0.54	4.66e-20	Asthma;
KIRP	trans	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg01311341	chr22:25575246	KIAA1671	-0.61	-6.6	-0.39	2.57e-10	Glioblastoma;
KIRP	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.71	-0.6	1.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs600806	0.821	rs3879448	chr1:109891423	C/G	cg07798595	chr1:87379926	SEP15;HS2ST1	0.46	6.37	0.38	9.37e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13059335	chr8:24242109	ADAMDEC1	-0.41	-6.18	-0.37	2.7e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs287982	1.000	rs287979	chr2:9970967	T/C	cg10881225	chr2:9984929	TAF1B	-0.41	-4.95	-0.3	1.4e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs4671458	0.948	rs12471038	chr2:63484639	C/A	cg17519650	chr2:63277830	OTX1	-0.51	-5.21	-0.32	4.08e-7	Subjective well-being;
KIRP	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.21	-0.32	4.03e-7	Pulmonary function;
KIRP	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg00343986	chr7:65444356	GUSB	0.41	4.9	0.3	1.71e-6	Aortic root size;
KIRP	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg17264618	chr3:40429014	ENTPD3	0.33	4.93	0.3	1.49e-6	Renal cell carcinoma;
KIRP	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.49	7.37	0.43	2.63e-12	Sitting height ratio;
KIRP	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05601917	chr6:125855416	NA	-0.35	-5.24	-0.32	3.41e-7	Brugada syndrome;
KIRP	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg03289416	chr15:75166202	SCAMP2	0.52	6.73	0.39	1.21e-10	Caffeine consumption;
KIRP	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.22	-0.37	2.16e-9	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17139369	chr19:8478169	MARCH2	-0.55	-7.53	-0.43	9.91e-13	Myopia;
KIRP	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.64	8.84	0.49	1.87e-16	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.58	10.03	0.54	4.49e-20	White blood cell count (basophil);
KIRP	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-8.56	-0.48	1.24e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg16926213	chr1:1841314	NA	0.32	5.49	0.33	1.01e-7	Body mass index;
KIRP	cis	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.44	-5.52	-0.33	8.42e-8	Leprosy;
KIRP	cis	rs7572644	0.699	rs10209126	chr2:28209283	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-5.24	-0.32	3.39e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg01721255	chr8:58191610	C8orf71	0.52	5.28	0.32	2.83e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg03808351	chr9:123631620	PHF19	0.41	5.53	0.33	8.18e-8	Rheumatoid arthritis;
KIRP	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.68	9.7	0.53	4.7e-19	Prostate cancer;
KIRP	cis	rs17123764	0.710	rs60121503	chr12:50088747	G/C	cg20471783	chr12:50157085	TMBIM6	0.38	5.27	0.32	2.98e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.69	-8.24	-0.47	1.06e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7503807	1.000	rs4890056	chr17:78591211	C/T	cg09596252	chr17:78655493	RPTOR	-0.47	-6.05	-0.36	5.27e-9	Obesity;
KIRP	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.83	8.23	0.46	1.11e-14	Type 2 diabetes;
KIRP	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg10517650	chr3:113235015	CCDC52	-0.41	-5.09	-0.31	7.16e-7	Dental caries;
KIRP	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.46	6.37	0.38	8.99e-10	Red blood cell count;
KIRP	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.56	-7.33	-0.42	3.35e-12	Aortic root size;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg14488081	chr8:73921810	TERF1	0.57	6.25	0.37	1.77e-9	Lung cancer in ever smokers;
KIRP	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.78	7.95	0.45	6.61e-14	Uric acid levels;
KIRP	cis	rs7712401	0.601	rs154501	chr5:122211594	T/C	cg19412675	chr5:122181750	SNX24	0.51	5.55	0.33	7.52e-8	Mean platelet volume;
KIRP	cis	rs6142102	0.602	rs6141435	chr20:32551279	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.45	0.68	1.13e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg08313168	chr12:7315531	NA	0.7	6.26	0.37	1.72e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs78049276	0.688	rs17612693	chr4:148365339	T/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.71	-7.52	-0.43	9.96e-13	Pulse pressure;
KIRP	cis	rs13185784	0.662	rs35759987	chr5:179679980	G/T	cg23248424	chr5:179741104	GFPT2	0.57	5.61	0.34	5.37e-8	TRAIL levels;
KIRP	cis	rs4950322	0.570	rs78681047	chr1:146792732	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs2119480	0.731	rs453757	chr13:111303200	A/G	cg24331049	chr13:111365604	ING1	-0.46	-5.5	-0.33	9.74e-8	Diastolic blood pressure;
KIRP	cis	rs4006360	0.575	rs7501893	chr17:39311411	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.39	-5.25	-0.32	3.27e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.52	6.57	0.39	2.98e-10	Type 2 diabetes;
KIRP	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.46	8.68	0.48	5.67e-16	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs860295	0.812	rs12407800	chr1:155760742	A/C	cg02153340	chr1:155202674	NA	-0.41	-5.48	-0.33	1.07e-7	Body mass index;
KIRP	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg02569458	chr12:86230093	RASSF9	0.54	7.94	0.45	7.21e-14	Major depressive disorder;
KIRP	cis	rs662064	1.000	rs662064	chr1:10557251	T/C	cg07384165	chr1:10488281	NA	-0.42	-5.22	-0.32	3.77e-7	Asthma;
KIRP	cis	rs4332428	1.000	rs66624122	chr10:4981039	C/T	cg19648686	chr10:5044992	AKR1C2	-0.92	-8.01	-0.45	4.6e-14	Height;
KIRP	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.94	13.09	0.64	4.47e-30	Cognitive function;
KIRP	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg16141378	chr3:129829833	LOC729375	-0.59	-7.58	-0.44	7.01e-13	Mood instability;
KIRP	cis	rs78487399	0.710	rs57381820	chr2:43626668	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.01	-0.3	1.06e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg19847130	chr8:10466454	RP1L1	-0.34	-4.88	-0.3	1.91e-6	Neuroticism;
KIRP	cis	rs548987	0.507	rs3757132	chr6:25832691	C/T	cg12310025	chr6:25882481	NA	-0.43	-5.1	-0.31	6.73e-7	Homocysteine levels;
KIRP	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.72	9.09	0.5	3.31e-17	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs9398803	0.687	rs4629706	chr6:126888331	A/T	cg19875578	chr6:126661172	C6orf173	0.43	5.49	0.33	9.98e-8	Male-pattern baldness;
KIRP	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.91	9.18	0.5	1.88e-17	Methadone dose in opioid dependence;
KIRP	cis	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg26585981	chr11:48327164	OR4S1	-0.47	-5.67	-0.34	4.09e-8	HDL cholesterol;
KIRP	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg13319975	chr6:146136371	FBXO30	0.47	6.28	0.37	1.55e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.84	-12.05	-0.61	1.34e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05472934	chr7:22766657	IL6	0.8	10.25	0.55	9.46e-21	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13664345	chr9:4793178	RCL1	0.5	6.28	0.37	1.55e-9	Parkinson's disease;
KIRP	cis	rs9653442	0.545	rs4490209	chr2:100766711	C/G	cg07810366	chr2:100720526	AFF3	-0.33	-5.28	-0.32	2.77e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.64	-7.28	-0.42	4.36e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.66	-0.39	1.78e-10	Aortic root size;
KIRP	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg17366294	chr4:99064904	C4orf37	0.44	6.36	0.38	9.96e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.85	-0.4	6.05e-11	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18141532	chr1:104068301	RNPC3	-0.56	-7.11	-0.41	1.25e-11	Interleukin-4 levels;
KIRP	cis	rs2371030	1.000	rs10167685	chr2:211568055	A/T	cg18417063	chr2:211583084	NA	-0.53	-7.78	-0.44	2.03e-13	Non-small cell lung cancer;
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg20578329	chr17:80767326	TBCD	0.44	5.7	0.34	3.41e-8	Glycated hemoglobin levels;
KIRP	cis	rs1950626	0.750	rs34061904	chr14:101435974	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.82	0.4	7.2e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19346786	chr7:2764209	NA	-0.28	-4.94	-0.3	1.46e-6	Height;
KIRP	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	9.01	0.5	5.92e-17	Exhaled nitric oxide output;
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.78	13.61	0.66	8.21e-32	Height;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.8	7.1	0.41	1.3e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.82	-14.11	-0.67	1.6e-33	Brugada syndrome;
KIRP	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	trans	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg06521331	chr12:34319734	NA	-0.51	-6.3	-0.37	1.36e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3779635	0.711	rs17448278	chr8:27256359	G/A	cg11641102	chr8:27183873	PTK2B	0.45	5.85	0.35	1.59e-8	Neuroticism;
KIRP	cis	rs11264213	0.901	rs72661605	chr1:36326227	A/G	cg27506609	chr1:36549197	TEKT2	1.18	7.12	0.41	1.19e-11	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05655935	chr10:93683722	BTAF1	0.46	6.17	0.37	2.81e-9	Parkinson's disease;
KIRP	cis	rs7289126	1.000	rs7289126	chr22:38628306	A/C	cg25457927	chr22:38595422	NA	0.31	6.82	0.4	7.15e-11	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	1.12	16.71	0.73	2.13e-42	Cognitive function;
KIRP	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg25650185	chr19:21324782	ZNF431	0.49	5.12	0.31	6.3e-7	Pain;
KIRP	cis	rs7429990	0.965	rs34507589	chr3:47874042	C/G	cg11946769	chr3:48343235	NME6	0.53	5.28	0.32	2.87e-7	Educational attainment (years of education);
KIRP	cis	rs9905704	0.836	rs170024	chr17:56831887	T/C	cg12560992	chr17:57184187	TRIM37	0.62	7.15	0.41	9.94e-12	Testicular germ cell tumor;
KIRP	cis	rs4073221	0.520	rs1108439	chr3:18201319	A/G	cg07694806	chr3:18168406	NA	-0.92	-7.34	-0.42	3.19e-12	Parkinson's disease;
KIRP	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19524238	chr7:2802976	GNA12	-0.39	-5.47	-0.33	1.12e-7	Height;
KIRP	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.59	-6.9	-0.4	4.26e-11	Menarche (age at onset);
KIRP	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg18850127	chr7:39170497	POU6F2	0.28	5.15	0.31	5.23e-7	IgG glycosylation;
KIRP	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.58	-6.34	-0.37	1.12e-9	Initial pursuit acceleration;
KIRP	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.67	-9.2	-0.51	1.63e-17	Breast cancer;
KIRP	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.68	-11.12	-0.58	1.52e-23	Facial morphology (factor 23);
KIRP	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.51	-6.67	-0.39	1.7e-10	Schizophrenia;
KIRP	cis	rs13190036	1.000	rs13177748	chr5:176643954	T/G	cg04708888	chr5:176739561	MXD3	0.64	5.02	0.3	1.01e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.53	6.14	0.36	3.24e-9	Aortic root size;
KIRP	cis	rs61884328	0.733	rs61897851	chr11:47201981	G/C	cg23433285	chr11:47201945	PACSIN3	0.62	4.96	0.3	1.31e-6	Total body bone mineral density (age over 60);
KIRP	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.8	-9.87	-0.53	1.46e-19	Corneal astigmatism;
KIRP	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg17885191	chr8:135476712	NA	0.53	6.14	0.36	3.31e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	5.35	0.32	2.05e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs2273669	0.667	rs12215614	chr6:109313629	T/C	cg05315195	chr6:109294784	ARMC2	-0.61	-6.05	-0.36	5.27e-9	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg26513180	chr16:89883248	FANCA	0.83	5.65	0.34	4.31e-8	Skin colour saturation;
KIRP	cis	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg06521331	chr12:34319734	NA	-0.44	-4.96	-0.3	1.3e-6	Resting heart rate;
KIRP	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.43	-5.52	-0.33	8.64e-8	IgG glycosylation;
KIRP	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.49	-7.77	-0.44	2.13e-13	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06384642	chr7:99613517	ZKSCAN1	0.45	6.07	0.36	4.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg02725872	chr8:58115012	NA	-0.46	-5.46	-0.33	1.16e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.91	-12.77	-0.63	5.54e-29	Menopause (age at onset);
KIRP	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.03e-7	Type 2 diabetes;
KIRP	cis	rs3017493	0.786	rs59579317	chr11:70684569	A/G	cg03578926	chr11:70508032	SHANK2	0.29	4.85	0.3	2.23e-6	Renal transplant outcome;
KIRP	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.72	10.5	0.56	1.47e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg26875233	chr11:93583750	C11orf90	-0.41	-7.92	-0.45	8.29e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14769373	chr6:40998127	UNC5CL	0.5	5.75	0.34	2.58e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg07930552	chr6:133119739	C6orf192	0.89	9.4	0.51	3.9e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.65	7.75	0.44	2.38e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg11965913	chr1:205819406	PM20D1	-0.56	-5.06	-0.31	8.38e-7	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.83	-0.35	1.76e-8	Depression;
KIRP	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg19784848	chr5:219127	SDHA;CCDC127	-0.47	-4.95	-0.3	1.36e-6	Breast cancer;
KIRP	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.69	8.56	0.48	1.24e-15	Multiple sclerosis;
KIRP	cis	rs17023223	0.537	rs2361271	chr1:119603405	A/G	cg05756136	chr1:119680316	WARS2	-0.54	-7.17	-0.42	8.73e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18252515	chr7:66147081	NA	0.42	4.86	0.3	2.11e-6	Aortic root size;
KIRP	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg24807547	chr6:37504484	NA	-0.46	-5.76	-0.34	2.53e-8	Cognitive performance;
KIRP	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg16386425	chr10:429943	DIP2C	-0.37	-4.94	-0.3	1.44e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.39	0.32	1.66e-7	Alzheimer's disease;
KIRP	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.97	0.41	2.93e-11	Coffee consumption (cups per day);
KIRP	cis	rs4262150	0.695	rs56117655	chr5:152328969	A/G	cg12297329	chr5:152029980	NA	-0.55	-6.71	-0.39	1.32e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.78	12.06	0.61	1.26e-26	Colorectal cancer;
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg00431236	chr2:264988	ACP1;SH3YL1	-0.47	-6.17	-0.37	2.83e-9	Breast cancer;
KIRP	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg23307798	chr14:103986281	CKB	0.73	11.35	0.59	2.68e-24	Body mass index;
KIRP	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07067904	chr2:74425934	MTHFD2	-0.47	-6.06	-0.36	5.22e-9	Myopia;
KIRP	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.51	6.35	0.38	1.04e-9	Birth weight;
KIRP	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.77	11.87	0.6	5.24e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17401966	0.522	rs10492969	chr1:10286358	T/C	cg17425144	chr1:10567563	PEX14	-0.29	-5.06	-0.31	8.3e-7	Hepatocellular carcinoma;
KIRP	cis	rs17030434	0.953	rs74845915	chr4:154696778	G/T	cg14289246	chr4:154710475	SFRP2	-0.8	-9.6	-0.52	9.6e-19	Electrocardiographic conduction measures;
KIRP	trans	rs78049276	0.568	rs10305839	chr4:148400413	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-7.15	-0.41	9.61e-12	Pulse pressure;
KIRP	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg21385522	chr1:16154831	NA	0.44	5.5	0.33	9.38e-8	Systolic blood pressure;
KIRP	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.49	6.36	0.38	9.69e-10	Menopause (age at onset);
KIRP	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05220968	chr6:146057943	EPM2A	-0.43	-5.37	-0.32	1.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.4	-5.4	-0.33	1.59e-7	Coronary artery disease;
KIRP	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg12131826	chr15:77904385	NA	0.5	6.04	0.36	5.55e-9	Type 2 diabetes;
KIRP	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.32	0.47	6.19e-15	Menopause (age at onset);
KIRP	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg10223061	chr2:219282414	VIL1	0.32	5.36	0.32	1.91e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11613427	chr3:52932208	TMEM110	-0.33	-5.51	-0.33	9.18e-8	Schizophrenia;
KIRP	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.59	0.52	1.03e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs897080	0.515	rs786617	chr2:44593158	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.51	0.38	4.11e-10	Height;
KIRP	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg09658497	chr7:2847517	GNA12	-0.35	-4.89	-0.3	1.86e-6	Height;
KIRP	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg02297831	chr4:17616191	MED28	-0.58	-6.82	-0.4	6.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg25182066	chr10:30743637	MAP3K8	-0.63	-8.6	-0.48	9.53e-16	Inflammatory bowel disease;
KIRP	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.59	9.62	0.52	8.71e-19	Neuroticism;
KIRP	trans	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg21775007	chr8:11205619	TDH	-0.46	-6.11	-0.36	3.84e-9	Joint mobility (Beighton score);
KIRP	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg13271783	chr10:134563150	INPP5A	-0.6	-7.8	-0.45	1.72e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs897080	0.515	rs1067325	chr2:44628997	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.0	0.36	6.85e-9	Height;
KIRP	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.79	10.1	0.54	2.71e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.59	-9.97	-0.54	6.79e-20	Body mass index;
KIRP	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	5.81	0.35	1.9e-8	Birth weight;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.73	6.44	0.38	6.25e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18863486	chr3:185444728	IGF2BP2	0.51	6.78	0.4	8.88e-11	Interleukin-4 levels;
KIRP	trans	rs4905138	0.645	rs4905137	chr14:94466081	C/G	cg14487379	chr9:135481870	DDX31	-0.4	-6.11	-0.36	3.89e-9	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs2708977	0.549	rs6706734	chr2:97429951	T/G	cg01950434	chr2:97203154	ARID5A	-0.47	-5.63	-0.34	5.02e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.58	7.84	0.45	1.39e-13	Mean corpuscular volume;
KIRP	cis	rs7172677	0.737	rs12914536	chr15:75437715	C/T	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.68	-0.44	3.87e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12200782	1.000	rs72843802	chr6:26517515	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-5.98	-0.36	8.01e-9	Small cell lung carcinoma;
KIRP	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg01420254	chr6:26195488	NA	1.24	11.27	0.58	4.85e-24	Gout;Renal underexcretion gout;
KIRP	trans	rs9908158	1	rs9908158	chr17:33890083	T/C	cg19694781	chr19:47549865	TMEM160	0.6	7.91	0.45	8.94e-14	Platelet count;Platelet distribution width;
KIRP	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg14952266	chr13:112191215	NA	0.45	6.71	0.39	1.32e-10	Hepatitis;
KIRP	cis	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.38	4.93	0.3	1.55e-6	Leprosy;
KIRP	cis	rs4638749	0.501	rs2129145	chr2:108758322	C/T	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.14	-0.31	5.57e-7	Blood pressure;
KIRP	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.33	0.42	3.25e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg19923238	chr8:142232952	SLC45A4	0.45	5.22	0.32	3.89e-7	Immature fraction of reticulocytes;
KIRP	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg13334819	chr7:99746414	C7orf59	-0.49	-5.83	-0.35	1.74e-8	Coronary artery disease;
KIRP	cis	rs1757171	0.542	rs3818986	chr6:37484349	C/A	cg08126542	chr6:37504118	NA	-0.77	-10.97	-0.57	4.56e-23	Cognitive performance;
KIRP	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.07	0.5	3.94e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03754165	chr2:60780427	BCL11A	-0.49	-6.94	-0.4	3.56e-11	C-reactive protein;
KIRP	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.57	8.25	0.47	9.64e-15	Fat distribution (HIV);
KIRP	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.55	0.68	5.14e-35	Electrocardiographic conduction measures;
KIRP	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.72	6.42	0.38	6.85e-10	Diabetic retinopathy;
KIRP	cis	rs12580194	0.593	rs12579408	chr12:55764348	G/A	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs7572644	0.582	rs7570730	chr2:28022675	G/A	cg27432699	chr2:27873401	GPN1	0.48	5.51	0.33	9.08e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.0	14.01	0.67	3.57e-33	Cognitive ability;
KIRP	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.76	11.06	0.58	2.33e-23	Hip circumference;
KIRP	cis	rs2708977	1.000	rs13029764	chr2:97328874	C/T	cg01950434	chr2:97203154	ARID5A	-0.54	-6.81	-0.4	7.47e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg10352719	chr14:24769404	DHRS1;C14orf21	0.66	6.1	0.36	4.19e-9	Lung function (FEV1);
KIRP	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.51	-6.39	-0.38	8.34e-10	Monocyte count;
KIRP	cis	rs2223471	0.546	rs1161444	chr6:50576468	C/T	cg03432817	chr6:50765336	NA	-0.35	-5.28	-0.32	2.89e-7	Subcutaneous adipose tissue;
KIRP	cis	rs7674212	0.541	rs2720464	chr4:104073201	G/A	cg16532752	chr4:104119610	CENPE	-0.43	-5.13	-0.31	5.89e-7	Type 2 diabetes;
KIRP	cis	rs253959	0.881	rs1669135	chr5:115611875	C/G	cg23108291	chr5:115420582	COMMD10	0.43	5.26	0.32	3.15e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1832871	0.521	rs62437409	chr6:158820221	G/C	cg07215822	chr6:158701037	NA	-0.54	-6.29	-0.37	1.48e-9	Height;
KIRP	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg08461772	chr7:95026248	PON3	0.41	5.99	0.36	7.38e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg07148914	chr20:33460835	GGT7	-0.52	-6.97	-0.41	2.81e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg22117172	chr7:91764530	CYP51A1	0.46	6.36	0.38	9.65e-10	Breast cancer;
KIRP	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.72	9.06	0.5	4.31e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.75e-7	Red blood cell count;
KIRP	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.7	9.15	0.5	2.18e-17	Alzheimer's disease;
KIRP	cis	rs746627	0.719	rs35337556	chr17:63863661	A/G	cg07283582	chr17:63770753	CCDC46	-0.44	-6.7	-0.39	1.45e-10	Total body bone mineral density;
KIRP	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.42	-6.27	-0.37	1.65e-9	Colorectal cancer;
KIRP	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.56	-7.22	-0.42	6.47e-12	Total body bone mineral density;
KIRP	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.83	-13.83	-0.66	1.4e-32	Brugada syndrome;
KIRP	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.82	-12.26	-0.62	2.78e-27	Body mass index;
KIRP	trans	rs11165623	0.564	rs6673207	chr1:96999259	C/G	cg10631902	chr5:14652156	NA	-0.54	-7.24	-0.42	5.79e-12	Hip circumference;Waist circumference;
KIRP	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.45	-0.59	1.29e-24	Idiopathic membranous nephropathy;
KIRP	cis	rs7127900	0.950	rs7395734	chr11:2231694	C/T	cg25635251	chr11:2234043	NA	0.52	7.82	0.45	1.51e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.05	0.31	8.48e-7	Neuroticism;
KIRP	cis	rs1050631	0.960	rs1789516	chr18:33691688	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.5	6.14	0.36	3.23e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12667521	chr19:29218732	NA	0.93	9.2	0.51	1.59e-17	Methadone dose in opioid dependence;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08677398	chr8:58056175	NA	-0.57	-4.94	-0.3	1.45e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs8523	0.774	rs6920155	chr6:11047956	C/A	cg13562911	chr6:11044106	ELOVL2	0.38	5.0	0.3	1.1e-6	Red blood cell fatty acid levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08577743	chr9:38621011	C9orf122;ANKRD18A	0.54	6.5	0.38	4.56e-10	Smoking initiation;
KIRP	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg07395648	chr5:131743802	NA	-0.36	-5.12	-0.31	6.04e-7	Blood metabolite levels;
KIRP	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.7	8.87	0.49	1.5e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs1106684	1.000	rs12534413	chr7:131453964	C/T	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.92	0.3	1.61e-6	Childhood ear infection;
KIRP	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg08847533	chr14:75593920	NEK9	-0.49	-5.72	-0.34	3.12e-8	IgG glycosylation;
KIRP	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12826209	chr6:26865740	GUSBL1	0.68	6.44	0.38	6.12e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg23920097	chr1:209922102	NA	-0.42	-5.56	-0.33	7.08e-8	Red blood cell count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22774012	chr4:84376821	MRPS18C;HELQ	-0.5	-6.27	-0.37	1.64e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg23978390	chr7:1156363	C7orf50	0.41	5.34	0.32	2.16e-7	Longevity;Endometriosis;
KIRP	cis	rs8179	0.645	rs11764331	chr7:92282624	C/T	cg15732164	chr7:92237376	CDK6	-0.46	-5.98	-0.36	7.78e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg16898833	chr6:26189333	HIST1H4D	0.83	5.89	0.35	1.25e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	0.81	7.14	0.41	1.05e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg23172400	chr8:95962367	TP53INP1	0.35	7.12	0.41	1.17e-11	Type 2 diabetes;
KIRP	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg04310649	chr10:35416472	CREM	-0.54	-6.06	-0.36	5.01e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs2387326	0.717	rs10829342	chr10:129944493	C/T	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.48	-0.33	1.05e-7	Autism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18719814	chr4:47916640	NFXL1	0.53	7.29	0.42	4.21e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13065560	0.659	rs4676476	chr3:38882009	C/T	cg01426195	chr3:39028469	NA	-0.45	-7.19	-0.42	7.78e-12	Interleukin-18 levels;
KIRP	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg10434728	chr15:90938212	IQGAP1	0.39	7.45	0.43	1.62e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.76	-10.2	-0.55	1.33e-20	Coffee consumption (cups per day);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19317265	chr18:12702832	PSMG2;CEP76	0.49	6.12	0.36	3.67e-9	Parkinson's disease;
KIRP	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg01989461	chr14:81687754	GTF2A1	0.8	12.9	0.64	2.02e-29	Schizophrenia;
KIRP	cis	rs575018	0.714	rs1960577	chr5:100594004	T/C	cg03848127	chr5:100126093	NA	-0.46	-5.41	-0.33	1.51e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg09699651	chr6:150184138	LRP11	0.49	6.18	0.37	2.68e-9	Lung cancer;
KIRP	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg07843512	chr7:20992918	NA	0.45	6.09	0.36	4.33e-9	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19508701	chr8:9008170	PPP1R3B	0.5	6.21	0.37	2.19e-9	Parkinson's disease;
KIRP	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08165532	chr3:133293146	CDV3	0.49	6.36	0.38	9.9e-10	Parkinson's disease;
KIRP	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg16751203	chr2:127950803	CYP27C1	0.37	4.99	0.3	1.14e-6	Protein C levels;
KIRP	trans	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg17145862	chr1:211918768	LPGAT1	-0.54	-6.87	-0.4	5.24e-11	Leprosy;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.3	-0.32	2.63e-7	Life satisfaction;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15750611	chr11:68191055	LRP5	0.49	6.42	0.38	6.97e-10	Survival in pancreatic cancer;
KIRP	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.49	10.32	0.55	5.41e-21	Monocyte percentage of white cells;
KIRP	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg22903471	chr2:27725779	GCKR	0.39	5.53	0.33	8.21e-8	Oral cavity cancer;
KIRP	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg17517138	chr11:73019481	ARHGEF17	0.71	5.92	0.35	1.07e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.68	7.02	0.41	2.18e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7172677	1.000	rs4886659	chr15:75414760	A/G	cg10253484	chr15:75165896	SCAMP2	-0.56	-6.15	-0.36	3.14e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.62	-6.61	-0.39	2.34e-10	Aortic root size;
KIRP	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.31	-0.59	3.59e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.49	-10.31	-0.55	5.78e-21	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21511925	chr5:175788234	KIAA1191	0.53	7.1	0.41	1.31e-11	Parkinson's disease;
KIRP	cis	rs7116495	0.609	rs949326	chr11:71730306	A/G	cg10381502	chr11:71823885	C11orf51	1.06	7.11	0.41	1.27e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs7106204	0.686	rs12803800	chr11:24258319	A/G	ch.11.24196551F	chr11:24239977	NA	0.67	5.23	0.32	3.67e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-9.48	-0.52	2.25e-18	Chronic sinus infection;
KIRP	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.87	0.53	1.47e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9488822	0.585	rs7768026	chr6:116274313	A/G	cg15226275	chr6:116381976	FRK	-0.23	-6.0	-0.36	6.98e-9	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16672449	chr3:127842622	RUVBL1	0.51	6.8	0.4	7.88e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-9.55	-0.52	1.43e-18	Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.66	7.94	0.45	7.11e-14	Post bronchodilator FEV1;
KIRP	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg04455712	chr21:45112962	RRP1B	-0.57	-7.05	-0.41	1.79e-11	Mean corpuscular volume;
KIRP	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.03	19.67	0.78	2.19e-52	Birth weight;
KIRP	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.53	7.32	0.42	3.5e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg00310523	chr12:86230176	RASSF9	0.48	7.76	0.44	2.22e-13	Major depressive disorder;
KIRP	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.22	0.61	3.61e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg12751644	chr20:60527061	NA	-0.4	-4.91	-0.3	1.65e-6	Body mass index;
KIRP	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.46	0.43	1.49e-12	Aortic root size;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12196901	chr17:26630081	FLJ40504	0.41	6.43	0.38	6.42e-10	Interleukin-4 levels;
KIRP	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg07827796	chr19:33622959	WDR88	0.53	6.96	0.41	3.07e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1823913	0.637	rs4853578	chr2:192161941	A/G	cg12404831	chr2:192114017	MYO1B	0.46	6.13	0.36	3.42e-9	Obesity-related traits;
KIRP	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg01200585	chr1:228362443	C1orf69	0.47	5.61	0.34	5.51e-8	Diastolic blood pressure;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg08805041	chr16:621841	PIGQ	-0.38	-5.18	-0.31	4.68e-7	Height;
KIRP	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg13877915	chr19:58951672	ZNF132	0.6	5.85	0.35	1.54e-8	Mean platelet volume;
KIRP	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.61	7.59	0.44	6.42e-13	Breast cancer;
KIRP	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg18016565	chr1:150552671	MCL1	-0.5	-7.54	-0.43	9.3e-13	Blood protein levels;
KIRP	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14169450	chr9:139327907	INPP5E	0.34	4.88	0.3	1.91e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg00405596	chr8:11794950	NA	0.38	5.06	0.31	8.28e-7	Triglycerides;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg07869135	chr8:123794843	ZHX2	-0.55	-7.15	-0.41	9.91e-12	Neuroticism;
KIRP	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg21551340	chr2:1609508	NA	0.55	5.04	0.31	9.22e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg19645103	chr12:69753606	YEATS4	-0.45	-4.89	-0.3	1.82e-6	Response to diuretic therapy;
KIRP	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	1.16	11.32	0.59	3.49e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.4	-0.38	7.64e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Corneal astigmatism;
KIRP	cis	rs72772090	0.522	rs73774355	chr5:95994167	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.63	-4.88	-0.3	1.91e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs735539	0.521	rs2251031	chr13:21414326	G/T	cg04906043	chr13:21280425	IL17D	-0.46	-4.88	-0.3	1.9e-6	Dental caries;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15688980	chr3:156975045	NA	0.55	6.11	0.36	3.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	1.000	rs10865039	chr2:100907351	A/G	cg14675211	chr2:100938903	LONRF2	0.49	5.88	0.35	1.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg06565975	chr8:143823917	SLURP1	-0.45	-6.88	-0.4	4.96e-11	Urinary tract infection frequency;
KIRP	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.69	9.34	0.51	6.1e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7646501	0.651	rs4858573	chr3:24051089	A/T	cg21910673	chr3:24143257	LOC152024	0.36	4.89	0.3	1.79e-6	Cognitive ability;Intelligence;
KIRP	cis	rs1448094	0.967	rs6539934	chr12:86343973	G/A	cg00310523	chr12:86230176	RASSF9	0.38	5.93	0.35	1.04e-8	Major depressive disorder;
KIRP	cis	rs253959	0.545	rs712599	chr5:115658765	G/A	cg23108291	chr5:115420582	COMMD10	-0.52	-5.72	-0.34	3.06e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.68	0.44	3.68e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1629083	0.875	rs1793169	chr11:118070264	A/G	cg18857871	chr11:118064634	AMICA1	-0.68	-9.88	-0.53	1.3e-19	Lung cancer;
KIRP	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.01	18.17	0.76	2.31e-47	Testicular germ cell tumor;
KIRP	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.63	0.44	5.16e-13	Obesity-related traits;
KIRP	trans	rs34421088	0.560	rs11780851	chr8:11401116	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.27	-0.47	8.7e-15	Neuroticism;
KIRP	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg21775007	chr8:11205619	TDH	-0.48	-6.14	-0.36	3.37e-9	Joint mobility (Beighton score);
KIRP	cis	rs9937943	0.512	rs13335886	chr16:74577161	C/G	cg01733217	chr16:74700730	RFWD3	-0.57	-6.05	-0.36	5.3300000000000004e-09	Neutrophil percentage of white cells;
KIRP	cis	rs12913538	0.547	rs4573888	chr15:62896704	A/G	cg09983546	chr15:62884068	NA	0.44	5.04	0.31	9.12e-7	Sleep depth;
KIRP	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg02461776	chr11:598696	PHRF1	0.69	7.55	0.43	8.59e-13	Systemic lupus erythematosus;
KIRP	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg17385448	chr1:15911702	AGMAT	0.25	4.94	0.3	1.43e-6	Systolic blood pressure;
KIRP	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg10755058	chr3:40428713	ENTPD3	-0.4	-5.75	-0.34	2.63e-8	Renal cell carcinoma;
KIRP	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.39	4.99	0.3	1.14e-6	Breast cancer;
KIRP	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.07	0.54	3.41e-20	Total body bone mineral density;
KIRP	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs1978968	0.913	rs34272636	chr22:18433603	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.69	-7.7	-0.44	3.42e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg16898833	chr6:26189333	HIST1H4D	0.76	5.38	0.32	1.69e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg10755058	chr3:40428713	ENTPD3	0.41	5.72	0.34	3.03e-8	Renal cell carcinoma;
KIRP	cis	rs1983891	0.954	rs1886816	chr6:41544494	A/G	cg20194872	chr6:41519635	FOXP4	0.56	7.2	0.42	7.16e-12	Prostate cancer;
KIRP	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.6	6.82	0.4	6.97e-11	Height;
KIRP	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.79	10.44	0.55	2.34e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg07884673	chr3:53033167	SFMBT1	0.96	7.1	0.41	1.36e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.44	-0.52	2.97e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.69	-11.51	-0.59	8.43e-25	Urate levels in overweight individuals;
KIRP	cis	rs1971762	0.527	rs7311902	chr12:54015236	A/G	cg16917193	chr12:54089295	NA	0.73	11.77	0.6	1.15e-25	Height;
KIRP	cis	rs4950322	0.542	rs2883434	chr1:146649084	A/C	cg22381352	chr1:146742008	CHD1L	-0.37	-5.18	-0.31	4.6e-7	Protein quantitative trait loci;
KIRP	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.67	0.34	3.94e-8	Lung cancer;
KIRP	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.93	-12.62	-0.63	1.71e-28	Longevity;Endometriosis;
KIRP	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg00409905	chr10:38381863	ZNF37A	0.72	9.12	0.5	2.71e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.36	-0.47	4.6e-15	Total cholesterol levels;
KIRP	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.97	11.68	0.6	2.3e-25	Corneal astigmatism;
KIRP	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.5	7.13	0.41	1.11e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg12454167	chr3:186435060	KNG1	0.53	9.16	0.5	2.15e-17	Adiponectin levels;
KIRP	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg23202291	chr11:1979235	NA	-0.5	-6.62	-0.39	2.22e-10	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.74	-10.44	-0.55	2.25e-21	Hypospadias;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.31	-0.37	1.28e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg13206674	chr6:150067644	NUP43	0.48	5.6	0.34	5.59e-8	Lung cancer;
KIRP	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg23587288	chr2:27483067	SLC30A3	-0.69	-7.38	-0.43	2.38e-12	Blood metabolite levels;
KIRP	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg00677455	chr12:58241039	CTDSP2	-0.46	-5.17	-0.31	4.93e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg23188684	chr11:67383651	NA	-0.43	-5.19	-0.31	4.43e-7	Mean corpuscular volume;
KIRP	cis	rs909341	0.537	rs11696871	chr20:62387417	C/T	cg03999872	chr20:62272968	STMN3	-0.52	-5.46	-0.33	1.14e-7	Atopic dermatitis;
KIRP	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg25664220	chr3:72788482	NA	-0.34	-5.12	-0.31	6.27e-7	Motion sickness;
KIRP	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.85	-0.63	2.87e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg09137382	chr11:130731461	NA	0.56	8.2	0.46	1.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg07068956	chr7:100330872	ZAN	-0.56	-6.09	-0.36	4.23e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.87	-11.46	-0.59	1.16e-24	Type 2 diabetes;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg22907277	chr7:1156413	C7orf50	0.55	7.03	0.41	2e-11	Longevity;Endometriosis;
KIRP	cis	rs4906332	0.754	rs34235720	chr14:104004968	C/T	cg19000871	chr14:103996768	TRMT61A	-0.84	-9.6	-0.52	9.84e-19	Coronary artery disease;
KIRP	cis	rs372883	0.901	rs13048365	chr21:30740394	T/C	cg24692254	chr21:30365293	RNF160	0.41	5.33	0.32	2.21e-7	Pancreatic cancer;
KIRP	cis	rs11650494	0.516	rs13341862	chr17:47494203	A/G	cg08112188	chr17:47440006	ZNF652	-0.86	-6.03	-0.36	5.89e-9	Prostate cancer;
KIRP	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg02931644	chr1:25747376	RHCE	0.4	7.42	0.43	1.9e-12	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg00405596	chr8:11794950	NA	0.51	6.67	0.39	1.66e-10	Retinal vascular caliber;
KIRP	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.76	9.0	0.5	6.24e-17	Corneal astigmatism;
KIRP	cis	rs10875746	0.669	rs11168508	chr12:48683511	G/C	cg26205652	chr12:48591994	NA	0.64	8.23	0.46	1.11e-14	Longevity (90 years and older);
KIRP	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.64	7.67	0.44	4.05e-13	Obesity-related traits;
KIRP	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.14	-0.36	3.35e-9	Bladder cancer;
KIRP	cis	rs740160	0.558	rs17161669	chr7:98908663	G/A	cg12290671	chr7:99195819	NA	-0.51	-4.94	-0.3	1.47e-6	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.63	10.38	0.55	3.72e-21	Anterior chamber depth;
KIRP	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg16497661	chr14:103986332	CKB	-0.45	-5.64	-0.34	4.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg14703610	chr5:56206110	C5orf35	0.49	6.79	0.4	8.18e-11	Coronary artery disease;
KIRP	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg26384229	chr12:38710491	ALG10B	0.67	9.02	0.5	5.43e-17	Morning vs. evening chronotype;
KIRP	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg06521331	chr12:34319734	NA	-0.62	-7.46	-0.43	1.5e-12	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg24315340	chr6:146058215	EPM2A	0.45	5.64	0.34	4.75e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg16744531	chr19:17905626	B3GNT3	0.51	8.19	0.46	1.46e-14	Tumor biomarkers;
KIRP	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-14.22	-0.67	6.55e-34	Coronary artery disease;
KIRP	cis	rs7712401	0.623	rs26372	chr5:122206447	C/T	cg19412675	chr5:122181750	SNX24	-0.51	-5.6	-0.34	5.71e-8	Mean platelet volume;
KIRP	cis	rs812925	0.512	rs7558954	chr2:61384906	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.14	-0.31	5.73e-7	Immature fraction of reticulocytes;
KIRP	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg13482628	chr17:19912719	NA	0.66	9.97	0.54	7.04e-20	Schizophrenia;
KIRP	cis	rs1209950	0.536	rs468057	chr21:40217306	T/G	cg02119577	chr21:40195074	ETS2	-0.37	-5.6	-0.34	5.81e-8	Non-small cell lung cancer (survival);
KIRP	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg00982548	chr2:198649783	BOLL	-0.55	-5.16	-0.31	5.18e-7	Ulcerative colitis;
KIRP	cis	rs2594989	0.831	rs13324245	chr3:11570769	T/G	cg01796438	chr3:11312864	ATG7	0.6	7.43	0.43	1.78e-12	Circulating chemerin levels;
KIRP	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.47	-0.38	5.17e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.11	0.31	6.46e-7	Educational attainment;
KIRP	cis	rs34421088	0.624	rs6986736	chr8:11584503	T/A	cg13293535	chr8:11597251	GATA4	0.39	5.4	0.33	1.58e-7	Neuroticism;
KIRP	cis	rs2598107	0.542	rs10488617	chr7:37937033	C/T	cg25225232	chr7:37962694	EPDR1	0.41	4.92	0.3	1.56e-6	Dupuytren's disease;
KIRP	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.54	-0.38	3.5e-10	Aortic root size;
KIRP	cis	rs6088813	0.677	rs6088831	chr20:34003740	T/C	cg14752227	chr20:34000481	UQCC	0.45	5.12	0.31	6.19e-7	Height;
KIRP	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.79	0.4	8.17e-11	Menarche (age at onset);
KIRP	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.48	6.52	0.38	4.02e-10	Red blood cell count;
KIRP	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.45	0.38	5.91e-10	Electroencephalogram traits;
KIRP	cis	rs2150410	0.915	rs10154057	chr21:40526094	C/G	cg11890956	chr21:40555474	PSMG1	-0.75	-5.38	-0.32	1.75e-7	Temperament (bipolar disorder);
KIRP	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg13334819	chr7:99746414	C7orf59	0.49	5.81	0.35	1.9e-8	Coronary artery disease;
KIRP	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg13072238	chr3:49761600	GMPPB	0.55	5.45	0.33	1.23e-7	Menarche (age at onset);
KIRP	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23281280	chr6:28129359	ZNF389	0.45	4.97	0.3	1.28e-6	Depression;
KIRP	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.84	13.33	0.65	7.34e-31	Schizophrenia;
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg19770292	chr5:1868693	NA	0.4	5.14	0.31	5.61e-7	Cardiovascular disease risk factors;
KIRP	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg26441486	chr22:50317300	CRELD2	-0.49	-5.8	-0.35	2.08e-8	Schizophrenia;
KIRP	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.79	9.08	0.5	3.72e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg05562828	chr17:3906858	NA	-0.77	-16.06	-0.72	3.61e-40	Type 2 diabetes;
KIRP	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg04691961	chr3:161091175	C3orf57	0.66	10.64	0.56	5.47e-22	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg23594656	chr7:65796392	TPST1	-0.44	-6.94	-0.4	3.44e-11	Aortic root size;
KIRP	cis	rs365132	0.967	rs58279426	chr5:176448139	T/C	cg16309518	chr5:176445507	NA	-0.87	-13.23	-0.64	1.55e-30	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg17986701	chr20:44574422	PCIF1	0.5	7.69	0.44	3.54e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.55	7.56	0.43	7.94e-13	Colorectal cancer;
KIRP	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg25356066	chr3:128598488	ACAD9	0.58	6.85	0.4	5.8200000000000003e-11	IgG glycosylation;
KIRP	cis	rs1656402	1.000	rs1190439	chr2:233422390	G/A	cg03852847	chr2:233439513	NA	0.7	11.62	0.6	3.69e-25	Non-small cell lung cancer (survival);
KIRP	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg22974920	chr21:40686053	BRWD1	0.49	5.6	0.34	5.74e-8	Cognitive function;
KIRP	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg01677386	chr11:118938358	VPS11	-0.52	-5.96	-0.36	8.69e-9	Coronary artery disease;
KIRP	cis	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.97	13.13	0.64	3.4e-30	Menopause (age at onset);
KIRP	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.44	5.87	0.35	1.43e-8	Childhood ear infection;
KIRP	cis	rs7665939	1.000	rs7665190	chr4:190123040	A/G	cg14840187	chr4:190284988	NA	-0.79	-6.16	-0.37	2.9e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg05295671	chr13:79234353	RNF219	0.61	5.95	0.35	9.1e-9	Large artery stroke;
KIRP	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg09408571	chr1:101003634	GPR88	0.26	5.83	0.35	1.74e-8	Monocyte count;
KIRP	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.1	10.78	0.57	1.86e-22	Diabetic retinopathy;
KIRP	cis	rs2150410	0.915	rs7275795	chr21:40663670	C/T	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg10701640	chr17:43249399	NA	0.46	9.59	0.52	1.03e-18	Height;
KIRP	cis	rs6974574	1.000	rs1524068	chr7:38110626	T/C	cg10754659	chr7:38110151	NA	-0.37	-5.0	-0.3	1.1e-6	Height;
KIRP	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21643547	chr1:205240462	TMCC2	-0.81	-12.52	-0.62	3.88e-28	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs17539620	0.808	rs62434162	chr6:154874495	A/C	cg20019720	chr6:154832845	CNKSR3	0.34	5.21	0.32	3.97e-7	Lipoprotein (a) levels;
KIRP	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg12598211	chr12:123634384	NA	-0.44	-5.34	-0.32	2.11e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6832769	1.000	rs726967	chr4:56421713	A/T	cg09317128	chr4:56265301	TMEM165	-0.52	-6.54	-0.38	3.61e-10	Personality dimensions;
KIRP	cis	rs3789045	1.000	rs61817485	chr1:204595592	G/A	cg18185008	chr1:204589407	LRRN2	-0.5	-6.62	-0.39	2.28e-10	Educational attainment (college completion);
KIRP	cis	rs57561814	0.826	rs116542785	chr7:22747720	G/A	cg26061582	chr7:22766209	IL6	0.69	5.63	0.34	4.83e-8	Tonsillectomy;
KIRP	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.63	7.57	0.43	7.47e-13	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-4.87	-0.3	1.98e-6	Neuroticism;
KIRP	cis	rs4356975	0.563	rs7375178	chr4:69969679	C/A	cg27372994	chr4:70080453	UGT2B11	0.41	5.44	0.33	1.27e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.24	0.42	5.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.16	0.54	1.73e-20	Cognitive test performance;
KIRP	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.75	0.34	2.7e-8	Birth weight;
KIRP	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.66	-0.39	1.75e-10	Monocyte percentage of white cells;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.26	-5.12	-0.31	6.27e-7	Lymphocyte counts;
KIRP	cis	rs10767971	0.565	rs11032025	chr11:32874926	G/A	cg14042352	chr11:32815968	CCDC73	-0.46	-5.3	-0.32	2.56e-7	Parkinson's disease (age of onset);
KIRP	cis	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.43	-5.37	-0.32	1.86e-7	Leprosy;
KIRP	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.83	12.48	0.62	5.02e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.55	0.59	6.26e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	5.85	0.35	1.56e-8	Schizophrenia;
KIRP	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.28	14.54	0.68	5.29e-35	Uric acid levels;
KIRP	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg12623918	chr2:306882	NA	0.47	6.13	0.36	3.5e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.66	9.71	0.53	4.56e-19	Retinal vascular caliber;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10647644	chr5:118788352	HSD17B4	0.44	6.46	0.38	5.45e-10	Survival in pancreatic cancer;
KIRP	cis	rs10073892	0.660	rs9327869	chr5:101974581	G/A	cg19774478	chr5:101632501	SLCO4C1	0.58	5.73	0.34	2.85e-8	Cognitive decline (age-related);
KIRP	cis	rs981844	0.813	rs72731678	chr4:154671476	T/C	cg14289246	chr4:154710475	SFRP2	0.67	7.54	0.43	9.09e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs2411233	0.967	rs10851377	chr15:39286732	G/T	cg02291532	chr15:39874776	THBS1	0.4	5.31	0.32	2.44e-7	Platelet count;
KIRP	cis	rs4409675	0.913	rs4072744	chr1:28271039	A/T	cg23691781	chr1:28212827	C1orf38	-0.31	-6.18	-0.37	2.66e-9	Corneal astigmatism;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg10150615	chr22:24372951	LOC391322	-0.4	-4.95	-0.3	1.38e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.4	0.33	1.6e-7	Menopause (age at onset);
KIRP	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.6	8.06	0.46	3.23e-14	White matter hyperintensity burden;
KIRP	cis	rs2213920	0.569	rs4979524	chr9:118177617	C/G	cg13918206	chr9:118159781	DEC1	0.67	7.57	0.43	7.32e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs11955398	0.563	rs1117676	chr5:60034824	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3736485	0.966	rs28428679	chr15:51913040	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.21e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.62	0.48	8.08e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.65	-0.68	2.27e-35	Alzheimer's disease;
KIRP	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg23803603	chr1:2058230	PRKCZ	0.4	5.69	0.34	3.64e-8	Height;
KIRP	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.86	9.78	0.53	2.71e-19	High light scatter reticulocyte count;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17507573	chr15:79382998	RASGRF1	-0.48	-6.07	-0.36	4.76e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs14057	0.827	rs61780562	chr1:6758140	C/T	cg16431369	chr1:6694556	THAP3;DNAJC11	-0.42	-5.01	-0.3	1.06e-6	Systolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10998122	chr11:64008466	FKBP2	0.49	6.13	0.36	3.39e-9	Parkinson's disease;
KIRP	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.68	8.33	0.47	5.88e-15	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01779512	chr13:21141325	IFT88	0.5	6.41	0.38	7.44e-10	Parkinson's disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14856220	chr10:123353500	FGFR2	0.57	6.52	0.38	3.88e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg03929089	chr4:120376271	NA	0.89	6.47	0.38	5.16e-10	Axial length;
KIRP	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.78	8.72	0.49	4.11e-16	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09730820	chr16:15736852	NDE1;MIR484;KIAA0430	-0.55	-6.41	-0.38	7.4e-10	Interleukin-4 levels;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg13939156	chr17:80058883	NA	-0.48	-7.19	-0.42	7.62e-12	Life satisfaction;
KIRP	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	10.16	0.54	1.78e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4683702	0.896	rs4683701	chr3:142605146	T/C	cg22826874	chr3:142608218	PCOLCE2	-0.38	-5.62	-0.34	5.07e-8	Blood protein levels;
KIRP	cis	rs698833	0.859	rs1067360	chr2:44661817	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.93	0.3	1.52e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.66	7.94	0.45	7.11e-14	Post bronchodilator FEV1;
KIRP	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg06356454	chr2:241631498	AQP12A	0.39	5.0	0.3	1.11e-6	Response to metformin (IC50);
KIRP	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	cis	rs4389656	0.625	rs274682	chr5:6748518	A/G	cg10857441	chr5:6722123	POLS	-0.45	-6.31	-0.37	1.28e-9	Coronary artery disease;
KIRP	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.54	-0.62	3.12e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg11764359	chr7:65958608	NA	0.77	5.05	0.31	8.42e-7	Gout;
KIRP	cis	rs13006833	0.703	rs291427	chr2:191194059	C/T	cg27211696	chr2:191398769	TMEM194B	0.4	5.67	0.34	4.09e-8	Urinary metabolites;
KIRP	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.79	-10.92	-0.57	6.63e-23	Blood metabolite levels;
KIRP	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-14.38	-0.68	1.98e-34	Alzheimer's disease;
KIRP	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	1.17	7.62	0.44	5.49e-13	Type 2 diabetes nephropathy;
KIRP	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg14664628	chr15:75095509	CSK	0.5	5.92	0.35	1.07e-8	Systemic lupus erythematosus;
KIRP	cis	rs6669919	0.653	rs10863908	chr1:211685097	G/A	cg10512769	chr1:211675356	NA	-0.56	-8.05	-0.46	3.45e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.38	-5.17	-0.31	4.88e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1832871	0.672	rs1342211	chr6:158759496	G/T	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs7562790	0.624	rs68111949	chr2:36655465	A/G	cg09467607	chr2:36825704	FEZ2	0.38	4.91	0.3	1.68e-6	QRS duration;QRS complex (Cornell);
KIRP	cis	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg02972257	chr16:68554789	NA	-0.56	-5.92	-0.35	1.1e-8	Ulcerative colitis;
KIRP	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.65	-9.85	-0.53	1.62e-19	Total body bone mineral density;
KIRP	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg21906852	chr1:75198582	TYW3;CRYZ	0.47	5.56	0.33	7.18e-8	Resistin levels;
KIRP	cis	rs4702718	0.610	rs10078407	chr5:10682208	G/A	cg14521931	chr5:10832172	NA	0.45	5.9	0.35	1.2e-8	Obesity-related traits;
KIRP	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.9	-14.17	-0.67	1e-33	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11723795	chr14:91975931	SMEK1	0.54	7.46	0.43	1.46e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.39	-5.46	-0.33	1.14e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg06637938	chr14:75390232	RPS6KL1	0.44	6.25	0.37	1.78e-9	Height;
KIRP	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	5.77	0.35	2.35e-8	Vitiligo;
KIRP	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg16346588	chr10:242978	ZMYND11	-0.42	-4.95	-0.3	1.38e-6	Psychosis in Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06015521	chr4:128811065	PLK4	-0.46	-7.23	-0.42	6.17e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1355223	0.902	rs7102625	chr11:34739717	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.45	5.28	0.32	2.83e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4594175	0.926	rs11157803	chr14:51627700	C/T	cg23942311	chr14:51606299	NA	0.52	6.99	0.41	2.55e-11	Cancer;
KIRP	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg13385521	chr17:29058706	SUZ12P	0.71	7.04	0.41	1.89e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg04989706	chr14:50066350	PPIL5	-0.48	-5.67	-0.34	4.08e-8	Carotid intima media thickness;
KIRP	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs11209002	0.524	rs2815386	chr1:67541996	A/G	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg00262122	chr8:11665843	FDFT1	0.46	5.77	0.35	2.42e-8	Triglycerides;
KIRP	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.77	7.27	0.42	4.67e-12	Arsenic metabolism;
KIRP	cis	rs34779708	0.702	rs7087150	chr10:35542138	A/T	cg03585969	chr10:35415529	CREM	0.61	6.96	0.41	3.01e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03433313	chr16:819064	MIR662	-0.54	-6.75	-0.4	1.03e-10	Mean corpuscular volume;
KIRP	cis	rs2235544	0.579	rs1537323	chr1:54482523	G/T	cg25741118	chr1:54482237	LDLRAD1	0.32	6.09	0.36	4.23e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg02461776	chr11:598696	PHRF1	0.69	7.55	0.43	8.59e-13	Systemic lupus erythematosus;
KIRP	cis	rs2275565	0.808	rs6660700	chr1:236989608	T/C	cg17297354	chr1:237056641	MTR	-0.38	-5.27	-0.32	2.98e-7	Homocysteine levels;
KIRP	cis	rs9473924	0.505	rs6908879	chr6:50869856	C/T	cg14470998	chr6:50812995	TFAP2B	0.84	7.77	0.44	2.07e-13	Body mass index;
KIRP	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.36	5.06	0.31	8.37e-7	Monocyte count;
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	14.14	0.67	1.26e-33	Platelet count;
KIRP	cis	rs72820985	0.935	rs11150316	chr16:80846399	T/A	cg04448709	chr16:81349954	GAN	-0.49	-5.12	-0.31	6.3e-7	Breast cancer;
KIRP	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.3	-0.32	2.59e-7	Coronary artery disease;
KIRP	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg10189774	chr4:17578691	LAP3	0.54	6.8	0.4	7.8e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.62	8.21	0.46	1.28e-14	Lymphocyte counts;
KIRP	cis	rs4908768	0.906	rs11121182	chr1:8522553	G/T	cg03610117	chr1:8450231	RERE	-0.49	-5.29	-0.32	2.65e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.09	0.46	2.7e-14	Body mass index;
KIRP	cis	rs6832769	0.961	rs1873092	chr4:56444300	T/C	cg09317128	chr4:56265301	TMEM165	-0.49	-6.15	-0.37	3.11e-9	Personality dimensions;
KIRP	cis	rs1823913	0.637	rs1470962	chr2:192134997	C/T	cg12404831	chr2:192114017	MYO1B	-0.45	-6.23	-0.37	1.96e-9	Obesity-related traits;
KIRP	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.72	10.41	0.55	2.97e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.7	-5.97	-0.36	8.2e-9	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.61	8.13	0.46	2.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.86	-10.52	-0.56	1.34e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1823913	0.637	rs7569231	chr2:192167099	G/A	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	0.91	11.58	0.59	4.69e-25	Vitiligo;
KIRP	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.33	0.32	2.26e-7	Coronary artery disease;
KIRP	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	5.52	0.33	8.38e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.9	-0.49	1.24e-16	Total cholesterol levels;
KIRP	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg13160058	chr8:26243215	BNIP3L	-0.53	-7.13	-0.41	1.08e-11	Red cell distribution width;
KIRP	trans	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-8.85	-0.49	1.71e-16	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13676787	chr1:179051132	TOR3A	0.5	6.09	0.36	4.3e-9	Parkinson's disease;
KIRP	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.51	4.93	0.3	1.51e-6	Recombination rate (females);
KIRP	cis	rs6693567	0.586	rs9661040	chr1:150483236	A/C	cg07843065	chr1:150265600	MRPS21	0.42	5.52	0.33	8.52e-8	Migraine;
KIRP	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg13939156	chr17:80058883	NA	-0.49	-7.48	-0.43	1.3e-12	Life satisfaction;
KIRP	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg06154544	chr16:764854	METRN	0.5	6.17	0.37	2.76e-9	Height;
KIRP	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	1.05	13.5	0.65	1.89e-31	Exhaled nitric oxide output;
KIRP	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.97	-9.37	-0.51	4.91e-18	Obesity-related traits;
KIRP	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	1.0	17.72	0.75	7.68e-46	Breast cancer;
KIRP	cis	rs372883	0.901	rs407463	chr21:30722440	G/A	cg24692254	chr21:30365293	RNF160	-0.41	-5.2	-0.31	4.23e-7	Pancreatic cancer;
KIRP	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.7	-8.98	-0.5	7.15e-17	Hypospadias;
KIRP	cis	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs6832769	0.922	rs28665088	chr4:56251080	A/G	cg09317128	chr4:56265301	TMEM165	0.49	6.03	0.36	6.08e-9	Personality dimensions;
KIRP	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.41	-0.38	7.52e-10	Educational attainment (college completion);
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.65	7.35	0.42	2.91e-12	DNA methylation (variation);
KIRP	cis	rs5753618	0.561	rs13054220	chr22:31704492	A/G	cg02404636	chr22:31891804	SFI1	0.47	5.33	0.32	2.2e-7	Colorectal cancer;
KIRP	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.42	5.99	0.36	7.33e-9	Tuberculosis;
KIRP	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.45	-9.18	-0.51	1.79e-17	Longevity;
KIRP	trans	rs7554547	0.667	rs4846072	chr1:11950391	T/C	cg03536846	chr8:120886254	DEPDC6	-0.56	-6.7	-0.39	1.41e-10	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.26	-0.32	3.18e-7	Menarche (age at onset);
KIRP	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.31	12.4	0.62	9.26e-28	Diabetic retinopathy;
KIRP	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.2	0.31	4.1e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.78	-0.4	8.98e-11	Mood instability;
KIRP	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.5	6.89	0.4	4.75e-11	Mean corpuscular volume;
KIRP	cis	rs7527798	0.592	rs12022909	chr1:207859743	T/C	cg09232269	chr1:207846808	CR1L	-0.36	-5.22	-0.32	3.78e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.2	-0.55	1.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.25	-0.37	1.78e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg00405596	chr8:11794950	NA	0.59	8.36	0.47	4.55e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg23894439	chr1:183413866	NA	0.4	5.21	0.32	4e-7	Systemic lupus erythematosus;
KIRP	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg19025524	chr12:109796872	NA	-0.43	-5.66	-0.34	4.19e-8	Neuroticism;
KIRP	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg19875535	chr5:140030758	IK	0.7	10.07	0.54	3.32e-20	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.11	-0.36	3.96e-9	Coronary artery disease;
KIRP	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.47	-6.01	-0.36	6.49e-9	Body mass index;
KIRP	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.87	13.42	0.65	3.6e-31	Metabolic syndrome;
KIRP	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.81e-19	Height;
KIRP	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg18944383	chr4:111397179	ENPEP	0.62	11.42	0.59	1.68e-24	Height;
KIRP	cis	rs329648	0.637	rs34013297	chr11:133774078	C/A	cg03392386	chr11:133800800	IGSF9B	-0.54	-5.81	-0.35	1.98e-8	Parkinson's disease;
KIRP	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.32	5.18	0.31	4.61e-7	Asthma;
KIRP	cis	rs35883536	0.967	rs4908090	chr1:101135177	A/G	cg06223162	chr1:101003688	GPR88	0.31	6.32	0.37	1.22e-9	Monocyte count;
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs4663866	0.901	rs35390666	chr2:239193578	C/T	cg17283117	chr2:239148619	HES6	0.71	5.08	0.31	7.45e-7	Irritable bowel syndrome;
KIRP	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.73	7.07	0.41	1.59e-11	Lung function (FEV1/FVC);
KIRP	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg15704280	chr7:45808275	SEPT13	0.7	6.23	0.37	2.03e-9	Intraocular pressure;
KIRP	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg00579200	chr11:133705235	NA	-0.42	-5.42	-0.33	1.4e-7	Childhood ear infection;
KIRP	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg10223061	chr2:219282414	VIL1	-0.4	-6.48	-0.38	4.93e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7771547	0.692	rs9296192	chr6:36601203	A/G	cg04289385	chr6:36355825	ETV7	0.41	5.76	0.34	2.5e-8	Platelet distribution width;
KIRP	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-4.89	-0.3	1.8e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-6.42	-0.38	7.07e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9644630	0.932	rs6991941	chr8:19352377	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.4	-5.37	-0.32	1.86e-7	Oropharynx cancer;
KIRP	cis	rs4690686	0.538	rs11730551	chr4:177259182	A/G	cg17059388	chr4:177262070	NA	0.81	10.69	0.56	3.71e-22	Essential tremor;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19615174	chr19:4558545	SEMA6B	-0.43	-6.11	-0.36	3.81e-9	Survival in pancreatic cancer;
KIRP	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg11846333	chr4:119757529	SEC24D	1.14	6.8	0.4	7.75e-11	Cannabis dependence symptom count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02667081	chr16:71880439	ATXN1L	0.5	6.14	0.36	3.38e-9	Smoking initiation;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg24168378	chr8:100905427	COX6C	0.5	6.19	0.37	2.55e-9	Educational attainment;
KIRP	cis	rs8033133	0.706	rs12594112	chr15:25350127	A/C	cg14481604	chr15:25334117	SNORD116-22	-0.41	-4.98	-0.3	1.21e-6	Blood osmolality (transformed sodium);
KIRP	cis	rs4638749	0.501	rs1486192	chr2:108751050	A/G	cg25838818	chr2:108905173	SULT1C2	0.33	4.95	0.3	1.35e-6	Blood pressure;
KIRP	cis	rs12230513	0.732	rs4356858	chr12:55867290	A/T	cg11794356	chr12:55725991	OR6C3	-0.53	-6.34	-0.37	1.07e-9	Contrast sensitivity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15814675	chr11:105880605	KIAA1826	-0.38	-6.02	-0.36	6.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-1.06	-13.87	-0.66	1.07e-32	Alopecia areata;
KIRP	cis	rs7937612	0.965	rs7932658	chr11:120211212	A/G	cg24566217	chr11:120254723	ARHGEF12	0.49	7.0	0.41	2.38e-11	Intraocular pressure;
KIRP	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg12591125	chr7:1885375	MAD1L1	0.64	6.09	0.36	4.36e-9	Bipolar disorder;
KIRP	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.33	5.96	0.35	8.9e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24114822	chr1:84542225	NA	0.42	6.13	0.36	3.43e-9	Migraine with aura;
KIRP	trans	rs13170463	0.579	rs11742127	chr5:8037116	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg03098644	chr7:100410630	EPHB4	0.51	5.24	0.32	3.51e-7	Other erythrocyte phenotypes;
KIRP	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-0.86	-7.03	-0.41	2e-11	IgG glycosylation;
KIRP	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg07636037	chr3:49044803	WDR6	-0.74	-5.59	-0.34	6.11e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7937682	0.593	rs1944121	chr11:111347223	T/C	cg09085632	chr11:111637200	PPP2R1B	0.45	5.65	0.34	4.49e-8	Primary sclerosing cholangitis;
KIRP	cis	rs6500395	0.584	rs1345433	chr16:48738222	A/G	cg04672837	chr16:48644449	N4BP1	0.41	5.09	0.31	7.08e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg19507638	chr5:93509721	C5orf36	-0.62	-5.5	-0.33	9.53e-8	Diabetic retinopathy;
KIRP	cis	rs6708331	0.517	rs6743372	chr2:70352640	G/T	cg01613454	chr2:70366299	NA	0.42	5.71	0.34	3.27e-8	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.47	4.97	0.3	1.24e-6	Breast cancer;
KIRP	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg21827317	chr3:136751795	NA	0.36	5.09	0.31	6.95e-7	Neuroticism;
KIRP	cis	rs9393813	0.805	rs2205829	chr6:27480227	A/G	cg11502198	chr6:26597334	ABT1	-0.4	-5.2	-0.31	4.28e-7	Bipolar disorder;
KIRP	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg24829409	chr8:58192753	C8orf71	-0.52	-4.93	-0.3	1.5e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-10.29	-0.55	6.96e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg03714773	chr7:91764589	CYP51A1	0.4	5.75	0.34	2.6e-8	Breast cancer;
KIRP	cis	rs6102059	0.503	rs6029179	chr20:39178679	C/T	cg06665391	chr20:39312290	NA	0.4	5.04	0.31	9.15e-7	LDL cholesterol;
KIRP	cis	rs4776059	1.000	rs4776068	chr15:52947401	G/A	cg22715398	chr15:52968154	KIAA1370	-0.66	-8.0	-0.45	4.8e-14	Schizophrenia;
KIRP	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg04398451	chr17:18023971	MYO15A	0.67	9.26	0.51	1.04e-17	Total body bone mineral density;
KIRP	cis	rs714027	0.585	rs41171	chr22:30422107	C/G	cg27665648	chr22:30112403	NA	-0.41	-5.61	-0.34	5.47e-8	Lymphocyte counts;
KIRP	trans	rs13170463	0.649	rs35402399	chr5:8035630	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs12282928	0.837	rs10742851	chr11:48534771	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-4.96	-0.3	1.29e-6	Migraine - clinic-based;
KIRP	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.96	-14.99	-0.69	1.6e-36	Height;
KIRP	cis	rs10162002	0.935	rs9578603	chr13:24040733	C/G	cg00158254	chr13:24040743	NA	0.5	4.9	0.3	1.76e-6	Hypothyroidism;
KIRP	cis	rs1209950	0.966	rs1209948	chr21:40170078	C/T	cg01359822	chr21:40176597	ETS2	0.37	6.18	0.37	2.69e-9	Non-small cell lung cancer (survival);
KIRP	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg23995753	chr2:160760732	LY75	-0.43	-5.73	-0.34	2.96e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg15556689	chr8:8085844	FLJ10661	-0.69	-8.61	-0.48	8.73e-16	Retinal vascular caliber;
KIRP	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg23202291	chr11:1979235	NA	0.41	5.34	0.32	2.15e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.99	-16.13	-0.72	1.97e-40	Monocyte count;
KIRP	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.42	0.47	3.21e-15	Lung cancer;
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.55	-6.4	-0.38	7.91e-10	Longevity;Endometriosis;
KIRP	cis	rs8084125	1.000	rs62105183	chr18:74951589	C/T	cg26065057	chr18:74961000	GALR1	0.78	7.77	0.44	2.15e-13	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs4889855	0.530	rs9901467	chr17:78574008	G/A	cg09596252	chr17:78655493	RPTOR	0.51	5.87	0.35	1.41e-8	Fractional excretion of uric acid;
KIRP	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg18882449	chr10:104885122	NT5C2	-0.39	-5.07	-0.31	7.69e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12311346	chr5:56204834	C5orf35	-0.49	-6.61	-0.39	2.34e-10	Coronary artery disease;
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.47	-6.62	-0.39	2.21e-10	Paraoxonase activity;
KIRP	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.5	-5.86	-0.35	1.48e-8	Coronary artery disease;
KIRP	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg25182066	chr10:30743637	MAP3K8	-0.63	-7.98	-0.45	5.5e-14	Inflammatory bowel disease;
KIRP	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.68	7.17	0.42	8.58e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.73	9.7	0.53	4.66e-19	Breast cancer;
KIRP	cis	rs2562456	0.833	rs62110426	chr19:21602926	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.92e-6	Pain;
KIRP	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.9	10.54	0.56	1.13e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.82	0.81	1.91e-59	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15224187	chr3:133614804	RAB6B	0.5	6.12	0.36	3.67e-9	Parkinson's disease;
KIRP	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-7.92	-0.45	7.99e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6800768	0.633	rs60635484	chr3:24101328	G/A	cg10674438	chr3:24145617	LOC152024	-0.39	-5.35	-0.32	2.02e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.6	8.37	0.47	4.28e-15	Menarche (age at onset);
KIRP	cis	rs501120	0.657	rs646890	chr10:44741710	C/T	cg09554077	chr10:44749378	NA	0.78	12.08	0.61	1.08e-26	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-10.05	-0.54	4.05e-20	Exhaled nitric oxide output;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.96e-7	Life satisfaction;
KIRP	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.44	-5.46	-0.33	1.15e-7	IgG glycosylation;
KIRP	cis	rs4691139	0.607	rs7684974	chr4:165944299	G/T	cg10852876	chr4:165953100	TRIM60	-0.35	-4.87	-0.3	1.96e-6	Ovarian cancer in BRCA1 mutation carriers;
KIRP	cis	rs10214930	0.625	rs6462037	chr7:27641100	G/A	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg23736307	chr8:27182930	PTK2B	0.54	6.88	0.4	4.99e-11	Neuroticism;
KIRP	cis	rs11671005	0.572	rs11669127	chr19:59003830	A/G	cg04170623	chr19:59071414	UBE2M;LOC100131691	0.52	5.5	0.33	9.4e-8	Mean platelet volume;
KIRP	cis	rs2932538	0.583	rs2279500	chr1:113244433	T/C	cg22162597	chr1:113214053	CAPZA1	-0.88	-8.54	-0.48	1.46e-15	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs520865	0.786	rs516343	chr5:80343748	A/C	cg17330048	chr5:80257322	RASGRF2	-0.5	-7.31	-0.42	3.63e-12	Superior frontal gyrus grey matter volume;
KIRP	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.08	0.41	1.5e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.37	5.11	0.31	6.6e-7	Coronary artery disease;
KIRP	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.79	-9.59	-0.52	1.05e-18	Pancreatic cancer;
KIRP	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.86	14.2	0.67	8.12e-34	Intelligence (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09430954	chr19:46236890	NA	0.51	6.29	0.37	1.43e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs76288851	0.799	rs9847497	chr3:126675566	A/G	cg13821433	chr2:26726535	OTOF	0.58	6.8	0.4	8.01e-11	Alcoholic chronic pancreatitis;
KIRP	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg07621104	chr11:117668040	DSCAML1	0.48	7.18	0.42	8.25e-12	Myopia;
KIRP	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg07169764	chr2:136633963	MCM6	-0.47	-5.45	-0.33	1.21e-7	Mosquito bite size;
KIRP	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8053891	0.756	rs35800852	chr16:72002105	G/T	cg04254540	chr16:71951199	KIAA0174	-0.51	-5.51	-0.33	8.94e-8	Coronary artery disease;
KIRP	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.73	-10.88	-0.57	9.36e-23	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.32	-0.37	1.21e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs71597109	0.639	rs4699259	chr4:102722393	C/A	cg14855874	chr4:102712397	BANK1	0.4	5.06	0.31	8.4e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg08885076	chr2:99613938	TSGA10	-0.42	-6.42	-0.38	7.06e-10	Bipolar disorder;
KIRP	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.59	-0.34	6.17e-8	Life satisfaction;
KIRP	cis	rs4728302	0.871	rs10259686	chr7:133633152	A/G	cg10665199	chr7:133106180	EXOC4	-0.42	-4.88	-0.3	1.88e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9426935	0.816	rs12133492	chr1:153832165	A/T	cg09895920	chr1:153941186	CREB3L4;SLC39A1	0.28	4.98	0.3	1.23e-6	Lentiform nucleus volume;
KIRP	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg04780086	chr2:111875790	ACOXL	0.46	6.31	0.37	1.26e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.79	-0.49	2.64e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs332034	0.546	rs28581487	chr8:8696342	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-4.92	-0.3	1.56e-6	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg15327641	chr2:3715039	ALLC	0.42	5.07	0.31	7.65e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.75	8.82	0.49	2.2e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.95	0.3	1.37e-6	Parkinson's disease;
KIRP	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.2	-0.31	4.19e-7	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08604181	chr7:133040186	EXOC4	-0.45	-6.81	-0.4	7.54e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg19906672	chr4:6918868	TBC1D14	0.57	5.69	0.34	3.6e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11203032	0.831	rs10887925	chr10:90938902	G/T	cg16672925	chr10:90967113	CH25H	0.78	8.15	0.46	1.91e-14	Heart failure;
KIRP	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.7	9.13	0.5	2.57e-17	Schizophrenia;
KIRP	cis	rs860295	0.580	rs66466805	chr1:155888666	A/G	cg02153340	chr1:155202674	NA	-0.39	-4.97	-0.3	1.24e-6	Body mass index;
KIRP	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.59	8.0	0.45	4.95e-14	Mean corpuscular volume;
KIRP	cis	rs807029	0.544	rs55646950	chr10:102760996	C/T	cg04662943	chr10:102668895	NA	0.47	5.07	0.31	7.7e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg02775129	chr4:119771670	NA	-0.79	-4.89	-0.3	1.79e-6	Cannabis dependence symptom count;
KIRP	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg26441486	chr22:50317300	CRELD2	0.36	5.9	0.35	1.18e-8	Schizophrenia;
KIRP	cis	rs838147	0.844	rs8108136	chr19:49247693	C/T	cg13540341	chr19:49222985	MAMSTR	0.35	5.62	0.34	5.06e-8	Dietary macronutrient intake;
KIRP	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg15848620	chr12:58087721	OS9	-0.48	-5.68	-0.34	3.72e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2077654	0.556	rs11024284	chr11:17444590	C/T	cg25308976	chr11:17434268	ABCC8	0.64	6.8	0.4	7.67e-11	Gout;
KIRP	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg03959625	chr15:84868606	LOC388152	0.71	8.44	0.47	2.69e-15	Schizophrenia;
KIRP	cis	rs4234798	0.605	rs4689639	chr4:7213469	C/T	cg18431297	chr4:7219810	SORCS2	-0.56	-6.15	-0.37	3.1e-9	Insulin-like growth factors;
KIRP	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	5.69	0.34	3.68e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg23517279	chr6:96025343	MANEA	-0.6	-5.33	-0.32	2.2e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.8	-10.38	-0.55	3.57e-21	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs34112283	0.592	rs13004149	chr2:144252485	C/T	cg18711535	chr15:64736348	TRIP4	0.36	6.03	0.36	6.07e-9	Neuroticism;
KIRP	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg02524346	chr8:600233	NA	0.88	6.45	0.38	5.84e-10	IgG glycosylation;
KIRP	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg20302533	chr7:39170763	POU6F2	0.25	5.22	0.32	3.9e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04505349	chr6:169050787	SMOC2	0.47	6.03	0.36	5.92e-9	Interleukin-4 levels;
KIRP	cis	rs7542091	0.669	rs11119357	chr1:210042382	C/T	cg05527609	chr1:210001259	C1orf107	-0.37	-4.96	-0.3	1.33e-6	Monobrow;
KIRP	cis	rs7224685	0.569	rs34540447	chr17:3994413	T/C	cg09695851	chr17:3907499	NA	0.54	5.16	0.31	5.11e-7	Type 2 diabetes;
KIRP	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg03733263	chr8:22462867	KIAA1967	-0.96	-13.37	-0.65	5.34e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.75	10.85	0.57	1.12e-22	Blood metabolite levels;
KIRP	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg19196401	chr6:110721138	DDO	-0.46	-7.38	-0.43	2.44e-12	Platelet distribution width;
KIRP	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.51	-5.85	-0.35	1.56e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.46	7.19	0.42	7.88e-12	Major depressive disorder;
KIRP	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.47	-5.03	-0.31	9.6e-7	Fear of minor pain;
KIRP	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.65	-7.19	-0.42	7.68e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg19752551	chr11:57585705	CTNND1	0.68	11.44	0.59	1.4e-24	Schizophrenia;
KIRP	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.8	-7.81	-0.45	1.64e-13	Platelet count;
KIRP	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs17067123	0.614	rs1036767	chr4:180068417	G/A	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.28	27.93	0.87	2.91e-78	IgG glycosylation;
KIRP	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.2e-6	Blood protein levels;
KIRP	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.7	-11.68	-0.6	2.3e-25	Lung function (FVC);
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs3779635	1.000	rs725788	chr8:27265371	T/C	cg21186296	chr8:27182909	PTK2B	0.42	5.4	0.33	1.56e-7	Neuroticism;
KIRP	trans	rs2998286	0.723	rs332177	chr10:28907150	T/C	cg10174683	chr16:85619974	NA	-0.65	-6.06	-0.36	5e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.53	-6.62	-0.39	2.28e-10	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.61	9.38	0.51	4.56e-18	Lung cancer;
KIRP	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.57	-4.95	-0.3	1.35e-6	Body mass index;
KIRP	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg10755058	chr3:40428713	ENTPD3	0.35	5.09	0.31	7.27e-7	Renal cell carcinoma;
KIRP	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-11.89	-0.6	4.73e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg08198773	chr8:1697536	NA	-0.51	-6.12	-0.36	3.69e-9	Systolic blood pressure;
KIRP	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7221595	0.825	rs62072388	chr17:3899567	C/A	cg05562828	chr17:3906858	NA	0.62	6.99	0.41	2.6e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9879311	0.966	rs6442165	chr3:10415108	A/C	cg11030744	chr3:10328490	GHRL;GHRLOS	0.38	5.15	0.31	5.33e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs240764	0.658	rs9498390	chr6:101241438	T/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.34e-7	Neuroticism;
KIRP	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.19	0.46	1.39e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11987759	chr7:65425863	GUSB	0.56	7.34	0.42	3.03e-12	Aortic root size;
KIRP	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.54	6.81	0.4	7.42e-11	Joint mobility (Beighton score);
KIRP	cis	rs911119	0.913	rs6036463	chr20:23578940	A/T	cg16589663	chr20:23618590	CST3	-0.49	-4.91	-0.3	1.64e-6	Chronic kidney disease;
KIRP	cis	rs1497406	0.898	rs36086195	chr1:16510894	C/T	cg06365898	chr1:16533907	ARHGEF19	0.36	4.95	0.3	1.37e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.43	5.27	0.32	3.01e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.49e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6681460	0.966	rs7542924	chr1:67143055	C/T	cg02459107	chr1:67143332	SGIP1	0.5	7.16	0.42	9.08e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.33	-0.32	2.22e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.45	-5.59	-0.34	5.99e-8	Total body bone mineral density;
KIRP	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.43	-5.17	-0.31	4.81e-7	Response to bleomycin (chromatid breaks);
KIRP	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg21573476	chr21:45109991	RRP1B	0.57	7.86	0.45	1.18e-13	Mean corpuscular volume;
KIRP	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.24	11.89	0.6	4.51e-26	Diabetic retinopathy;
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.25	-5.31	-0.32	2.45e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg02297831	chr4:17616191	MED28	0.52	6.44	0.38	6.19e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.32	0.72	4.51e-41	Electrocardiographic conduction measures;
KIRP	cis	rs2882667	0.858	rs11959851	chr5:138421405	C/G	cg04439458	chr5:138467593	SIL1	-0.49	-7.52	-0.43	1.02e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.86	-0.49	1.65e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg14791747	chr16:20752902	THUMPD1	0.62	6.72	0.39	1.28e-10	Cognitive test performance;
KIRP	cis	rs28489187	0.706	rs3768227	chr1:85804087	A/G	cg16011679	chr1:85725395	C1orf52	0.54	6.52	0.38	3.99e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg09455208	chr3:40491958	NA	-0.38	-7.02	-0.41	2.19e-11	Renal cell carcinoma;
KIRP	cis	rs16937956	0.597	rs35022013	chr11:8417503	T/A	cg08015107	chr11:8618950	NA	-0.53	-7.02	-0.41	2.17e-11	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12421388	chr7:73132033	STX1A	0.38	6.16	0.37	2.92e-9	Survival in pancreatic cancer;
KIRP	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-8.55	-0.48	1.28e-15	Chronic sinus infection;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-8.89	-0.49	1.35e-16	Lymphocyte counts;
KIRP	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.16	-0.31	5.1e-7	Bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24574691	chr11:129191447	NA	0.43	6.19	0.37	2.51e-9	Survival in pancreatic cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12093220	chr4:113570694	MIR302D;MIR302B;LARP7;MIR302A;MIR302C	-0.4	-6.35	-0.38	1.03e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg20637307	chr2:213403960	ERBB4	0.56	7.67	0.44	3.95e-13	Symmetrical dimethylarginine levels;
KIRP	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg18367735	chr17:79674897	NA	0.75	7.37	0.43	2.65e-12	Dental caries;
KIRP	cis	rs687432	0.924	rs12421773	chr11:57703164	C/T	cg19752551	chr11:57585705	CTNND1	-0.48	-6.75	-0.4	1.08e-10	Parkinson's disease;
KIRP	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg08885076	chr2:99613938	TSGA10	-0.42	-7.2	-0.42	7.26e-12	Chronic sinus infection;
KIRP	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	15.56	0.7	1.79e-38	Platelet count;
KIRP	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg19773385	chr1:10388646	KIF1B	-0.7	-9.9	-0.53	1.18e-19	Hepatocellular carcinoma;
KIRP	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg17986701	chr20:44574422	PCIF1	-0.34	-5.22	-0.32	3.81e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg21419209	chr3:44054225	NA	-0.75	-9.44	-0.52	3.03e-18	Coronary artery disease;
KIRP	trans	rs12043259	0.730	rs11240292	chr1:204821687	A/G	cg11485465	chr5:54518469	NA	0.38	6.49	0.38	4.65e-10	Addiction;
KIRP	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg12435725	chr3:58293450	RPP14	-0.45	-5.22	-0.32	3.76e-7	Cholesterol, total;
KIRP	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.82	8.65	0.48	6.77e-16	Body mass index;
KIRP	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg15655495	chr12:38532458	NA	-0.25	-4.84	-0.3	2.26e-6	Heart rate;
KIRP	cis	rs74181299	0.571	rs7559813	chr2:65278023	A/G	cg05010058	chr2:65284262	CEP68	-0.43	-5.45	-0.33	1.22e-7	Pulse pressure;
KIRP	cis	rs926392	0.640	rs1007913	chr20:37693592	G/A	cg16355469	chr20:37678765	NA	0.46	5.83	0.35	1.72e-8	Dialysis-related mortality;
KIRP	cis	rs427941	0.595	rs201477	chr7:101746915	G/A	cg06246474	chr7:101738831	CUX1	0.55	6.7	0.39	1.43e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6832769	0.922	rs11133376	chr4:56253033	C/T	cg05960024	chr4:56376020	CLOCK	0.61	7.61	0.44	6.02e-13	Personality dimensions;
KIRP	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17252645	chr8:143867129	LY6D	-0.54	-9.77	-0.53	2.81e-19	Urinary tract infection frequency;
KIRP	cis	rs4494114	1.000	rs6674910	chr1:39357157	C/T	cg25970120	chr1:39325951	RRAGC	0.39	5.0	0.3	1.08e-6	Blood protein levels;
KIRP	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg22563815	chr15:78856949	CHRNA5	0.53	7.91	0.45	8.57e-14	Sudden cardiac arrest;
KIRP	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-6.16	-0.37	2.95e-9	Joint mobility (Beighton score);
KIRP	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs13359291	0.841	rs61627996	chr5:122472015	G/C	cg16368670	chr5:122501738	PRDM6	-0.5	-6.19	-0.37	2.52e-9	Systolic blood pressure;
KIRP	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	5.92	0.35	1.07e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs11627756	0.958	rs2146431	chr14:103071861	A/G	cg01864069	chr14:103024347	NA	0.44	5.19	0.31	4.46e-7	Mean platelet volume;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg01097406	chr16:89675127	NA	0.32	5.23	0.32	3.66e-7	Vitiligo;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg07916058	chr1:180644805	XPR1	0.44	6.69	0.39	1.5e-10	C-reactive protein;
KIRP	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg23565292	chr14:50234668	KLHDC2	-0.44	-5.28	-0.32	2.8e-7	Carotid intima media thickness;
KIRP	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.69	0.48	5.25e-16	Motion sickness;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00437399	chr15:40886176	CASC5	0.45	6.84	0.4	6.27e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7590368	1.000	rs17456225	chr2:10963238	C/G	cg15705551	chr2:10952987	PDIA6	0.45	4.94	0.3	1.46e-6	Educational attainment (years of education);
KIRP	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.47	6.3	0.37	1.39e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.46	5.92	0.35	1.08e-8	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.06	-0.31	8.31e-7	Life satisfaction;
KIRP	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	5.38	0.32	1.72e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7546668	1.000	rs6429746	chr1:15815579	A/G	cg21858823	chr1:15850916	CASP9	-0.45	-5.02	-0.3	1.01e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	13.97	0.67	4.62e-33	Smoking behavior;
KIRP	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-7.42	-0.43	1.95e-12	Obesity-related traits;
KIRP	cis	rs3812049	0.532	rs251216	chr5:127543280	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	8.57	0.48	1.19e-15	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.74	-8.17	-0.46	1.63e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.0	-14.44	-0.68	1.19e-34	Homoarginine levels;
KIRP	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg01444801	chr10:135216882	MTG1	-0.54	-5.63	-0.34	4.78e-8	Systemic lupus erythematosus;
KIRP	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg25686905	chr3:183603175	PARL	-0.44	-5.72	-0.34	3.09e-8	Menopause (age at onset);
KIRP	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.11e-10	Prudent dietary pattern;
KIRP	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg24130564	chr14:104152367	KLC1	-0.43	-5.02	-0.3	1.01e-6	Reticulocyte count;
KIRP	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg00491522	chr10:135256596	NA	0.57	5.82	0.35	1.83e-8	Systemic lupus erythematosus;
KIRP	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs3007168	0.904	rs12884159	chr14:51661855	G/C	cg23942311	chr14:51606299	NA	0.53	5.57	0.33	6.7e-8	Cancer;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00185336	chr7:73153699	ABHD11	-0.47	-6.05	-0.36	5.5e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.44	6.69	0.39	1.5e-10	Neuroticism;
KIRP	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.47	6.29	0.37	1.48e-9	Breast cancer;
KIRP	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.56	6.69	0.39	1.52e-10	Mosquito bite size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01899437	chr4:24914441	CCDC149	0.47	6.09	0.36	4.41e-9	Parkinson's disease;
KIRP	cis	rs7520050	0.966	rs4134386	chr1:46395089	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.85	0.3	2.17e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6125597	0.805	rs6063382	chr20:47889958	C/T	cg03212862	chr20:47662828	CSE1L	-0.41	-5.24	-0.32	3.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4908768	0.906	rs11121213	chr1:8728187	C/A	cg25722041	chr1:8623473	RERE	0.82	9.66	0.52	6.45e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg17554472	chr22:41940697	POLR3H	0.58	6.35	0.38	1.03e-9	Vitiligo;
KIRP	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.5	11.54	0.59	6.64e-25	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-10.43	-0.55	2.48e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1832871	0.541	rs17503148	chr6:158873908	C/T	cg07215822	chr6:158701037	NA	-0.51	-5.58	-0.33	6.48e-8	Height;
KIRP	cis	rs500492	0.542	rs449295	chr16:1074443	G/A	cg03495660	chr16:1074500	NA	0.5	5.59	0.34	6.01e-8	Polycystic ovary syndrome;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg02733842	chr7:1102375	C7orf50	0.52	5.46	0.33	1.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.68	-0.56	3.94e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg09455208	chr3:40491958	NA	0.32	5.77	0.35	2.43e-8	Renal cell carcinoma;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00940313	chr17:1953823	MIR212;MIR132	-0.53	-6.89	-0.4	4.68e-11	Myopia;
KIRP	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg02462569	chr6:150064036	NUP43	-0.38	-5.72	-0.34	3.12e-8	Lung cancer;
KIRP	cis	rs12282928	0.959	rs1503181	chr11:48265379	G/C	cg26585981	chr11:48327164	OR4S1	-0.51	-6.25	-0.37	1.76e-9	Migraine - clinic-based;
KIRP	cis	rs795544	0.580	rs7709692	chr5:13789420	T/C	cg07548982	chr5:13769939	DNAH5	-0.5	-6.11	-0.36	3.84e-9	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-7.69	-0.44	3.61e-13	Initial pursuit acceleration;
KIRP	cis	rs16828019	0.777	rs12047078	chr1:41462986	T/C	cg24596898	chr1:41849189	NA	0.64	4.93	0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.42	8.59	0.48	1.01e-15	Vitiligo;
KIRP	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg08313168	chr12:7315531	NA	0.66	6.07	0.36	4.82e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg24644049	chr4:85504048	CDS1	0.93	6.87	0.4	5.17e-11	Skin colour saturation;
KIRP	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg12046867	chr14:103022105	NA	-0.51	-6.21	-0.37	2.29e-9	Platelet count;
KIRP	cis	rs986417	1.000	rs958504	chr14:60949740	G/A	cg27398547	chr14:60952738	C14orf39	0.73	7.28	0.42	4.38e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs12130219	1.000	rs1552994	chr1:152171461	A/G	cg25272121	chr1:152190972	HRNR	0.42	4.96	0.3	1.3e-6	Inflammatory skin disease;
KIRP	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12292205	chr6:26970375	C6orf41	-0.69	-7.99	-0.45	5.22e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	13.3	0.65	9.17e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg05272587	chr13:111038400	COL4A2	-0.4	-6.24	-0.37	1.95e-9	White matter hyperintensity burden;
KIRP	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg01872077	chr2:219646372	CYP27A1	0.41	5.63	0.34	4.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.51	-0.33	8.98e-8	Lung cancer;
KIRP	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg24375607	chr4:120327624	NA	0.58	6.64	0.39	2e-10	Corneal astigmatism;
KIRP	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg14829155	chr15:31115871	NA	-0.78	-8.66	-0.48	6.13e-16	Huntington's disease progression;
KIRP	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg10381502	chr11:71823885	C11orf51	-1.08	-7.52	-0.43	9.99e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs3844535	1	rs3844535	chr14:81884515	A/G	cg02996355	chr14:81879375	NA	-0.6	-7.64	-0.44	4.85e-13	Plateletcrit;Platelet count;
KIRP	cis	rs9815354	0.680	rs73073242	chr3:42015335	G/A	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs12311304	0.865	rs7132318	chr12:15415874	T/C	cg08258403	chr12:15378311	NA	0.38	5.5	0.33	9.5e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg15691649	chr6:25882328	NA	-0.52	-5.41	-0.33	1.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2411233	0.837	rs12913060	chr15:39250571	T/G	cg19287857	chr15:39890699	NA	0.39	5.17	0.31	4.89e-7	Platelet count;
KIRP	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg08999081	chr20:33150536	PIGU	-0.4	-5.23	-0.32	3.56e-7	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09142144	chr5:35939847	CAPSL	0.37	6.4	0.38	7.82e-10	Survival in pancreatic cancer;
KIRP	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.55e-23	Primary sclerosing cholangitis;
KIRP	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.42	5.29	0.32	2.71e-7	Cystic fibrosis severity;
KIRP	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-16.95	-0.73	3.29e-43	Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg13147721	chr7:65941812	NA	-0.93	-6.63	-0.39	2.14e-10	Diabetic kidney disease;
KIRP	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.76	9.27	0.51	9.7e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4006360	0.579	rs2132841	chr17:39234970	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.55	-7.8	-0.45	1.82e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs12519773	0.905	rs13177386	chr5:92443605	A/C	cg18783429	chr5:92414398	NA	0.28	4.88	0.3	1.89e-6	Migraine;
KIRP	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg03060546	chr3:49711283	APEH	-0.72	-5.1	-0.31	6.73e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.6	8.2	0.46	1.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.63	-6.96	-0.41	3.16e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs10761482	0.638	rs10761507	chr10:62243232	G/T	cg01186212	chr10:62110162	ANK3	0.29	4.99	0.3	1.12e-6	Schizophrenia;
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg02696790	chr15:75250997	RPP25	0.3	5.1	0.31	6.63e-7	Breast cancer;
KIRP	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.65	6.79	0.4	8.16e-11	Bipolar disorder;
KIRP	cis	rs7614311	0.731	rs3774727	chr3:63977875	A/G	cg22134162	chr3:63841271	THOC7	-0.42	-5.1	-0.31	6.87e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs12230513	0.732	rs61547125	chr12:55814082	C/G	cg19537932	chr12:55886519	OR6C68	-0.57	-7.09	-0.41	1.44e-11	Contrast sensitivity;
KIRP	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-5.45	-0.33	1.22e-7	Neuroticism;
KIRP	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg01420254	chr6:26195488	NA	1.18	10.88	0.57	9.42e-23	Gout;Renal underexcretion gout;
KIRP	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13982446	chr9:140512815	C9orf37;EHMT1	-0.51	-6.08	-0.36	4.59e-9	Interleukin-4 levels;
KIRP	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	6.95e-8	Breast cancer;
KIRP	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg21361702	chr7:150065534	REPIN1	0.55	5.92	0.35	1.1e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.92	13.83	0.66	1.47e-32	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.72	10.29	0.55	6.95e-21	Prostate cancer;
KIRP	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg25173405	chr17:45401733	C17orf57	-0.47	-6.48	-0.38	4.97e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs3736485	0.966	rs8042289	chr15:51899884	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.23	-0.32	3.61e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7523050	0.730	rs12726126	chr1:109436128	A/G	cg08274380	chr1:109419600	GPSM2	1.16	10.22	0.55	1.14e-20	Fat distribution (HIV);
KIRP	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs8177876	0.822	rs80315956	chr16:81112859	G/A	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13181291	chr1:151089582	GABPB2	0.47	6.33	0.37	1.18e-9	Interleukin-4 levels;
KIRP	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.96	15.22	0.7	2.59e-37	Testicular germ cell tumor;
KIRP	cis	rs1468333	1.000	rs4835671	chr5:137511801	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	5.07	0.31	7.77e-7	Resting heart rate;
KIRP	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.77	6.08	0.36	4.58e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.62	0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4955124	0.643	rs12636645	chr3:32026343	A/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.7	6.38	0.38	8.49e-10	Schizophrenia;
KIRP	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.48	5.94	0.35	9.7e-9	Aortic root size;
KIRP	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.46	-5.57	-0.33	6.77e-8	Blood protein levels;
KIRP	cis	rs17123764	0.605	rs7954994	chr12:50068089	C/T	cg02054252	chr12:50078554	FMNL3	0.41	4.87	0.3	1.99e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg02569458	chr12:86230093	RASSF9	0.42	6.29	0.37	1.4e-9	Major depressive disorder;
KIRP	cis	rs6838801	0.765	rs3943037	chr4:77600874	A/G	cg17476223	chr4:77663285	SHROOM3	0.53	7.36	0.42	2.79e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg22800045	chr5:56110881	MAP3K1	0.73	7.82	0.45	1.6e-13	Initial pursuit acceleration;
KIRP	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	10.39	0.55	3.37e-21	Menopause (age at onset);
KIRP	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	0.89	6.99	0.41	2.55e-11	Mean corpuscular volume;
KIRP	cis	rs4728302	0.869	rs10808273	chr7:133597691	G/C	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.83	0.49	2.03e-16	Motion sickness;
KIRP	cis	rs4671400	0.571	rs6738482	chr2:61494901	A/G	cg15711740	chr2:61764176	XPO1	0.62	7.03	0.41	2.03e-11	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg01422370	chr2:73384389	NA	0.49	6.63	0.39	2.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg13906792	chr15:75199810	C15orf17	-0.35	-5.04	-0.31	9.14e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg05341848	chr10:17632231	PTPLA	0.38	6.14	0.36	3.31e-9	Migraine with aura;
KIRP	cis	rs10203711	1.000	rs907107	chr2:239565780	T/C	cg14580085	chr2:239553406	NA	0.39	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	ch.11.340609R	chr11:12831013	TEAD1	-0.42	-5.27	-0.32	2.94e-7	Educational attainment (years of education);
KIRP	cis	rs918629	0.567	rs7716691	chr5:95237040	C/T	cg16656078	chr5:95278638	ELL2	-0.35	-5.48	-0.33	1.06e-7	IgG glycosylation;
KIRP	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	7.47	0.43	1.41e-12	Myopia (pathological);
KIRP	cis	rs12144044	0.912	rs3806442	chr1:113249504	C/T	cg22162597	chr1:113214053	CAPZA1	0.44	4.9	0.3	1.73e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg05484376	chr2:27715224	FNDC4	0.38	6.31	0.37	1.28e-9	Total body bone mineral density;
KIRP	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	cis	rs8084125	1.000	rs62105183	chr18:74951589	C/T	cg05528293	chr18:74961138	GALR1	0.56	5.64	0.34	4.71e-8	Obesity-related traits;
KIRP	trans	rs7032317	0.846	rs11243977	chr9:135877904	G/T	cg26256771	chr13:113642784	MCF2L	0.49	6.06	0.36	5.13e-9	Calcium levels;
KIRP	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12963246	chr6:28129442	ZNF389	0.49	6.05	0.36	5.45e-9	Depression;
KIRP	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg06307176	chr5:131281290	NA	-0.54	-5.88	-0.35	1.35e-8	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	5.71	0.34	3.31e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8084125	1.000	rs7229560	chr18:74955538	C/T	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg25706552	chr1:244017396	NA	0.49	6.25	0.37	1.76e-9	RR interval (heart rate);
KIRP	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.69	10.7	0.56	3.37e-22	Blood metabolite ratios;
KIRP	cis	rs963731	0.649	rs78510010	chr2:39348662	T/C	cg04010122	chr2:39346883	SOS1	0.94	6.45	0.38	6.05e-10	Corticobasal degeneration;
KIRP	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.38	-5.28	-0.32	2.8e-7	Breast cancer;
KIRP	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg07148914	chr20:33460835	GGT7	-0.53	-6.99	-0.41	2.53e-11	Height;
KIRP	cis	rs1538970	1.000	rs17395553	chr1:45864761	C/T	cg05343316	chr1:45956843	TESK2	0.66	7.65	0.44	4.68e-13	Platelet count;
KIRP	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg17252645	chr8:143867129	LY6D	-0.44	-7.72	-0.44	2.91e-13	Urinary tract infection frequency;
KIRP	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	6.0	0.36	6.88e-9	Response to antipsychotic treatment;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01118653	chr16:88110441	BANP	0.52	6.63	0.39	2.09e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.64	-9.72	-0.53	4.17e-19	Educational attainment;
KIRP	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.6	-9.27	-0.51	1.01e-17	Menopause (age at onset);
KIRP	trans	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	8.31	0.47	6.71e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg08885076	chr2:99613938	TSGA10	0.55	9.66	0.52	6.16e-19	Chronic sinus infection;
KIRP	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.33	-5.12	-0.31	6.22e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	0.99	8.5	0.48	1.84e-15	Gut microbiota (bacterial taxa);
KIRP	cis	rs12318506	0.826	rs11180452	chr12:75693881	G/T	cg04728562	chr12:75699417	CAPS2	-0.86	-5.9	-0.35	1.22e-8	Coronary artery calcification;
KIRP	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.82	11.91	0.6	3.85e-26	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23974812	chr11:134123664	THYN1;ACAD8	-0.47	-6.07	-0.36	4.88e-9	Myopia;
KIRP	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.71	9.71	0.53	4.55e-19	Schizophrenia;
KIRP	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg06637938	chr14:75390232	RPS6KL1	0.42	5.84	0.35	1.65e-8	Height;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.57	0.52	1.23e-18	Lung cancer;
KIRP	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.65	-10.9	-0.57	8.14e-23	Sense of smell;
KIRP	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-5.26	-0.32	3.06e-7	Schizophrenia;
KIRP	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg18016565	chr1:150552671	MCL1	0.33	5.12	0.31	6.26e-7	Tonsillectomy;
KIRP	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg16797656	chr11:68205561	LRP5	0.39	5.15	0.31	5.29e-7	Total body bone mineral density;
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02161503	chr7:157955692	PTPRN2	0.4	5.19	0.31	4.4e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10849605	0.867	rs10849602	chr12:1062479	A/G	cg22243222	chr12:1059299	RAD52	-0.45	-6.66	-0.39	1.77e-10	Lung cancer;
KIRP	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.43	0.33	1.36e-7	Educational attainment;
KIRP	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg00042356	chr1:8021962	PARK7	0.49	4.95	0.3	1.39e-6	Inflammatory bowel disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20994490	chr1:63988814	ITGB3BP;EFCAB7	-0.49	-6.05	-0.36	5.4e-9	Interleukin-4 levels;
KIRP	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg04374321	chr14:90722782	PSMC1	0.91	14.37	0.68	2.02e-34	Mortality in heart failure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10390473	chr4:164775263	MARCH1	-0.47	-6.98	-0.41	2.7e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg13679303	chr9:96623674	NA	0.44	5.88	0.35	1.35e-8	DNA methylation (variation);
KIRP	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.71	6.96	0.41	3.11e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg09365446	chr1:150670422	GOLPH3L	0.38	4.96	0.3	1.34e-6	Tonsillectomy;
KIRP	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-10.86	-0.57	1.06e-22	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.28	-0.32	2.89e-7	Renal cell carcinoma;
KIRP	cis	rs6662572	0.737	rs2067635	chr1:46537946	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.51	0.33	9.04e-8	Blood protein levels;
KIRP	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg05555928	chr11:63887634	MACROD1	-0.57	-5.33	-0.32	2.23e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.83	11.37	0.59	2.42e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs897080	0.515	rs1085444	chr2:44624155	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.02	0.36	6.29e-9	Height;
KIRP	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.63	7.24	0.42	5.61e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg00784671	chr22:46762841	CELSR1	-0.74	-8.68	-0.48	5.45e-16	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.64	-0.56	5.29e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.83	11.64	0.6	3.19e-25	Mortality in heart failure;
KIRP	cis	rs904251	0.714	rs2776910	chr6:37436284	A/G	cg08126542	chr6:37504118	NA	-0.47	-4.94	-0.3	1.44e-6	Cognitive performance;
KIRP	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg12315302	chr6:26189340	HIST1H4D	0.88	6.08	0.36	4.67e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7149337	1.000	rs4901103	chr14:51746873	C/T	cg23942311	chr14:51606299	NA	0.6	9.27	0.51	9.57e-18	Cancer;
KIRP	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.83	12.34	0.62	1.48e-27	Longevity;
KIRP	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.75	9.41	0.51	3.72e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg01559446	chr3:44596178	ZNF167	-0.36	-5.29	-0.32	2.7e-7	Depressive symptoms;
KIRP	cis	rs2882667	0.867	rs6868085	chr5:138432446	G/A	cg04439458	chr5:138467593	SIL1	-0.41	-6.67	-0.39	1.63e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.31	-6.18	-0.37	2.61e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg21926883	chr2:100939477	LONRF2	-0.56	-7.42	-0.43	1.9e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg01798813	chr17:3906674	NA	0.52	7.24	0.42	5.89e-12	Type 2 diabetes;
KIRP	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.63	8.54	0.48	1.42e-15	Total body bone mineral density;
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.57	7.16	0.42	9.53e-12	Longevity;
KIRP	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.02	-18.68	-0.77	4.36e-49	Myeloid white cell count;
KIRP	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.91	-14.72	-0.68	1.35e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs743757	1.000	rs2236973	chr3:50474284	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	5.62	0.34	5.15e-8	Diastolic blood pressure;
KIRP	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.43	-5.59	-0.34	5.96e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs58649573	0.574	rs10818907	chr9:126770250	C/G	cg14112217	chr9:126806003	NA	-0.37	-5.38	-0.32	1.77e-7	Post-traumatic stress disorder;
KIRP	cis	rs60154123	0.730	rs12040684	chr1:210472053	C/T	cg09074223	chr1:210466472	NA	0.6	6.22	0.37	2.11e-9	Coronary artery disease;
KIRP	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.5	-6.9	-0.4	4.51e-11	Lewy body disease;
KIRP	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.46	4.97	0.3	1.23e-6	Multiple sclerosis;
KIRP	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.72	-10.52	-0.56	1.3e-21	Retinal vascular caliber;
KIRP	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.83	-0.45	1.45e-13	Tonsillectomy;
KIRP	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg04087571	chr11:116723030	SIK3	-0.27	-5.66	-0.34	4.16e-8	Subjective well-being;
KIRP	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs13401104	0.796	rs12466147	chr2:237110404	T/A	cg19324714	chr2:237145437	ASB18	0.47	4.98	0.3	1.22e-6	Educational attainment;
KIRP	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.05	-0.64	6.44e-30	Height;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg21851534	chr17:3907994	ZZEF1	-0.65	-10.56	-0.56	9.75e-22	Type 2 diabetes;
KIRP	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.78	-0.35	2.29e-8	Breast cancer;
KIRP	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.35	0.55	4.42e-21	Monocyte percentage of white cells;
KIRP	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	8.74	0.49	3.71e-16	Lung cancer in ever smokers;
KIRP	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg13902645	chr11:5959945	NA	-0.6	-6.31	-0.37	1.26e-9	DNA methylation (variation);
KIRP	cis	rs9311676	0.632	rs62259779	chr3:58425692	C/G	cg06643156	chr3:58380774	PXK	0.35	4.89	0.3	1.8e-6	Systemic lupus erythematosus;
KIRP	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-5.49	-0.33	1e-7	Parkinson's disease;
KIRP	cis	rs4073416	0.542	rs9323461	chr14:66031405	T/C	cg03016385	chr14:66212404	NA	-0.51	-6.08	-0.36	4.46e-9	N-glycan levels;
KIRP	cis	rs533123	0.818	rs527931	chr1:29167161	T/C	cg08366446	chr1:29138936	OPRD1	0.68	6.4	0.38	7.83e-10	Schizophrenia;
KIRP	cis	rs7688540	0.800	rs12501727	chr4:288074	G/C	cg17891759	chr4:299121	NA	-0.39	-5.03	-0.31	9.4e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg10534938	chr5:1868639	NA	0.36	4.9	0.3	1.74e-6	Cardiovascular disease risk factors;
KIRP	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.83	9.58	0.52	1.1e-18	Neutrophil percentage of white cells;
KIRP	cis	rs732716	0.785	rs9973266	chr19:4392715	G/A	cg03719555	chr19:4455413	UBXN6	0.5	7.53	0.43	9.84e-13	Mean corpuscular volume;
KIRP	cis	rs7224685	0.569	rs8066580	chr17:3996494	T/C	cg09597638	chr17:3907349	NA	0.52	5.24	0.32	3.53e-7	Type 2 diabetes;
KIRP	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg25319279	chr11:5960081	NA	-0.66	-6.8	-0.4	7.89e-11	DNA methylation (variation);
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg23736307	chr8:27182930	PTK2B	-0.52	-6.57	-0.39	3.06e-10	Neuroticism;
KIRP	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg26681399	chr22:41777847	TEF	-0.54	-5.39	-0.33	1.65e-7	Vitiligo;
KIRP	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.95	0.3	1.39e-6	Tonsillectomy;
KIRP	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	5.07	0.31	7.66e-7	Ovarian reserve;
KIRP	cis	rs2425143	1.000	rs28685274	chr20:34358527	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.1	-0.36	4.01e-9	Blood protein levels;
KIRP	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg01689657	chr7:91764605	CYP51A1	0.39	5.78	0.35	2.25e-8	Breast cancer;
KIRP	cis	rs12210905	1.000	rs72843619	chr6:27154830	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.71	-6.11	-0.36	3.92e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg05072774	chr3:49840536	C3orf54	0.41	5.2	0.31	4.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.95	-16.48	-0.72	1.3e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7714584	1.000	rs10051804	chr5:150226424	T/C	cg22134413	chr5:150180641	NA	0.57	5.09	0.31	7.03e-7	Crohn's disease;
KIRP	cis	rs77688320	0.553	rs2540330	chr2:202252856	T/C	cg06431681	chr2:202330990	STRADB	-0.48	-5.65	-0.34	4.4e-8	Breast cancer;
KIRP	cis	rs11864453	0.682	rs10852509	chr16:72026010	G/A	cg01557791	chr16:72042693	DHODH	-0.47	-4.98	-0.3	1.18e-6	Fibrinogen levels;
KIRP	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.88	14.83	0.69	5.49e-36	Alcohol dependence (age at onset);
KIRP	cis	rs6681460	1.000	rs7521111	chr1:67121634	T/C	cg02459107	chr1:67143332	SGIP1	0.49	7.04	0.41	1.94e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.97	11.92	0.61	3.63e-26	Post bronchodilator FEV1;
KIRP	cis	rs9815354	0.767	rs73087378	chr3:41936827	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.9	0.45	9.42e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9815354	0.597	rs60690674	chr3:41997811	G/C	cg03022575	chr3:42003672	ULK4	0.81	8.34	0.47	5.42e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.53	-7.01	-0.41	2.28e-11	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11987759	chr7:65425863	GUSB	0.58	7.63	0.44	5.03e-13	Aortic root size;
KIRP	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.5	-5.14	-0.31	5.54e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg01988459	chr11:68622903	NA	-0.41	-5.57	-0.33	6.69e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.83	-0.4	6.5500000000000006e-11	Heart rate;
KIRP	cis	rs394563	0.591	rs237019	chr6:149727064	G/A	cg03678062	chr6:149772716	ZC3H12D	-0.34	-5.41	-0.33	1.52e-7	Dupuytren's disease;
KIRP	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.3	-0.32	2.57e-7	Bladder cancer;
KIRP	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.46	5.1	0.31	6.64e-7	Diastolic blood pressure;
KIRP	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg13577407	chr3:57994372	FLNB	-0.56	-6.15	-0.37	3.18e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	0.84	7.44	0.43	1.64e-12	Lung disease severity in cystic fibrosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18323984	chr6:45386802	RUNX2	0.49	7.2	0.42	7.22e-12	Interleukin-4 levels;
KIRP	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12963246	chr6:28129442	ZNF389	0.52	6.37	0.38	9.46e-10	Depression;
KIRP	cis	rs7084402	0.967	rs1614258	chr10:60308407	C/T	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg01988459	chr11:68622903	NA	-0.41	-5.77	-0.35	2.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.81	-0.4	7.49e-11	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.41	-11.61	-0.6	3.75e-25	Diabetic kidney disease;
KIRP	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.66	-7.03	-0.41	2.08e-11	Vitiligo;
KIRP	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.48	-6.12	-0.36	3.72e-9	IgG glycosylation;
KIRP	cis	rs10486003	1.000	rs6962416	chr7:97199685	C/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.66	-5.22	-0.32	3.74e-7	Response to platinum-based agents;
KIRP	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.16	-0.31	5.18e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.52	-6.5	-0.38	4.35e-10	Schizophrenia;
KIRP	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.65	-6.7	-0.39	1.41e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9596863	0.898	rs9563177	chr13:54368853	A/G	ch.13.53330881F	chr13:54432880	NA	0.59	5.76	0.34	2.49e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.27	-5.34	-0.32	2.16e-7	Caffeine consumption;
KIRP	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	-0.46	-5.05	-0.31	8.46e-7	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23648919	chr2:156787418	NA	-0.41	-6.08	-0.36	4.51e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.59	-12.45	-0.62	6.65e-28	Diabetic kidney disease;
KIRP	cis	rs4804368	0.535	rs66921136	chr19:7197880	T/C	cg09377704	chr19:7936683	NA	0.44	4.91	0.3	1.62e-6	Renal cell carcinoma;
KIRP	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg12560992	chr17:57184187	TRIM37	0.62	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg08822215	chr16:89438651	ANKRD11	-0.51	-6.56	-0.39	3.2e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	6.16	0.37	2.94e-9	Total cholesterol levels;
KIRP	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.18	0.54	1.5e-20	Coffee consumption (cups per day);
KIRP	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.57	7.09	0.41	1.38e-11	Blood protein levels;
KIRP	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.63	8.96	0.5	8.55e-17	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	15.0	0.69	1.46e-36	Platelet count;
KIRP	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg21858823	chr1:15850916	CASP9	0.52	5.61	0.34	5.38e-8	Systolic blood pressure;
KIRP	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg26335602	chr6:28129616	ZNF389	-0.45	-5.03	-0.31	9.64e-7	Depression;
KIRP	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg07382826	chr16:28625726	SULT1A1	0.52	6.17	0.37	2.8e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs80208956	0.557	rs11827026	chr11:69446913	A/C	cg27021553	chr11:69462783	CCND1	-0.4	-6.05	-0.36	5.29e-9	Major depressive disorder;
KIRP	cis	rs5753037	0.543	rs131268	chr22:30147938	C/G	cg01021169	chr22:30184971	ASCC2	-0.51	-6.97	-0.41	2.98e-11	Type 1 diabetes;
KIRP	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg08807101	chr21:30365312	RNF160	-0.64	-7.38	-0.43	2.46e-12	Cognitive test performance;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	9.11e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17023223	0.537	rs12081585	chr1:119615956	A/C	cg18261050	chr1:119551319	NA	0.54	6.64	0.39	2.01e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg11814155	chr7:99998594	ZCWPW1	0.54	5.41	0.33	1.5e-7	Platelet count;
KIRP	cis	rs4774830	0.744	rs117596592	chr15:56188307	T/G	cg05129572	chr15:56138634	NEDD4	0.75	4.92	0.3	1.61e-6	Delta-5 desaturase activity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04205485	chr20:32399084	CHMP4B	0.47	6.18	0.37	2.58e-9	Parkinson's disease;
KIRP	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.42	5.34	0.32	2.16e-7	Melanoma;
KIRP	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03997321	chr2:33929187	NA	-0.43	-6.31	-0.37	1.28e-9	Select biomarker traits;
KIRP	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.08	-0.41	1.54e-11	Platelet count;
KIRP	cis	rs7712401	0.525	rs246312	chr5:122269455	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.52e-7	Mean platelet volume;
KIRP	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg16497661	chr14:103986332	CKB	0.78	11.35	0.59	2.69e-24	Body mass index;
KIRP	cis	rs7560272	0.538	rs3980695	chr2:73939552	A/G	cg20560298	chr2:73613845	ALMS1	0.49	5.96	0.36	8.72e-9	Schizophrenia;
KIRP	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg00319359	chr11:70116639	PPFIA1	0.64	6.0	0.36	7.02e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg07701084	chr6:150067640	NUP43	0.71	9.65	0.52	6.75e-19	Lung cancer;
KIRP	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.8	7.41	0.43	1.96e-12	Mean platelet volume;
KIRP	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg23594656	chr7:65796392	TPST1	-0.46	-7.18	-0.42	8.45e-12	Aortic root size;
KIRP	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.66	-0.48	6.27e-16	Mean corpuscular volume;
KIRP	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg03641300	chr2:160917029	PLA2R1	-0.53	-8.1	-0.46	2.6e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg06740227	chr12:86229804	RASSF9	0.44	5.57	0.33	6.82e-8	Major depressive disorder;
KIRP	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg07537917	chr2:241836409	C2orf54	-0.33	-6.67	-0.39	1.7e-10	Urinary metabolites;
KIRP	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg23163573	chr2:108905468	SULT1C2	-0.26	-5.02	-0.3	9.97e-7	Blood pressure;
KIRP	cis	rs397969	0.607	rs169413	chr17:19849745	G/A	cg13482628	chr17:19912719	NA	0.47	5.35	0.32	2.02e-7	Platelet count;
KIRP	cis	rs4782151	1.000	rs35283977	chr16:9330103	C/G	ch.16.364290R	chr16:9436357	NA	0.32	4.92	0.3	1.56e-6	Cervical cancer;
KIRP	cis	rs2635047	0.806	rs11659655	chr18:44594220	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	10.32	0.55	5.5e-21	Educational attainment;
KIRP	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.83	12.42	0.62	8.08e-28	Bladder cancer;
KIRP	cis	rs4908768	0.581	rs2784740	chr1:8501057	T/A	cg25722041	chr1:8623473	RERE	0.5	6.08	0.36	4.53e-9	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	12.82	0.63	3.64e-29	Ulcerative colitis;
KIRP	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.18	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs6782228	0.606	rs7613073	chr3:128388503	T/G	cg18648031	chr3:128330563	NA	0.27	5.51	0.33	9.15e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.7	-0.39	1.42e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6445967	0.530	rs12633937	chr3:58333637	C/T	cg02259384	chr3:58523373	ACOX2	-0.35	-4.93	-0.3	1.52e-6	Platelet count;
KIRP	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg10360139	chr7:1886902	MAD1L1	-0.53	-5.91	-0.35	1.13e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg18225595	chr11:63971243	STIP1	0.57	4.93	0.3	1.54e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg01422370	chr2:73384389	NA	0.42	5.67	0.34	4.03e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg24633833	chr3:10029261	TMEM111	0.52	5.33	0.32	2.24e-7	Alzheimer's disease;
KIRP	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg04202892	chr2:111875749	ACOXL	0.5	6.96	0.41	3.13e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.33	-6.31	-0.37	1.28e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.82	9.35	0.51	5.45e-18	Response to diuretic therapy;
KIRP	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg23594656	chr7:65796392	TPST1	0.38	5.61	0.34	5.5e-8	Aortic root size;
KIRP	cis	rs4006360	0.646	rs9902561	chr17:39295384	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.47	-7.18	-0.42	8.21e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs4919044	0.808	rs1238178	chr10:94804043	G/A	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs28595532	0.668	rs58467651	chr4:119349011	T/G	cg21605333	chr4:119757512	SEC24D	0.97	7.49	0.43	1.25e-12	Cannabis dependence symptom count;
KIRP	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.78	-7.33	-0.42	3.3e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4363385	0.530	rs10888529	chr1:153050654	G/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.18	-0.31	4.65e-7	Inflammatory skin disease;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24229963	chr8:82633648	ZFAND1	0.59	6.61	0.39	2.4e-10	Lung cancer in ever smokers;
KIRP	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.6	0.34	5.68e-8	Height;
KIRP	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-5.57	-0.33	6.55e-8	Ulcerative colitis;
KIRP	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.41	-9.72	-0.53	4.29e-19	Cutaneous nevi;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.75	-10.6	-0.56	7.33e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg18964960	chr10:1102726	WDR37	0.52	5.81	0.35	1.97e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs10073892	0.551	rs6892179	chr5:101619815	T/A	cg19774478	chr5:101632501	SLCO4C1	0.56	6.06	0.36	5.06e-9	Cognitive decline (age-related);
KIRP	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg04166393	chr7:2884313	GNA12	0.48	6.54	0.38	3.49e-10	Height;
KIRP	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg08822215	chr16:89438651	ANKRD11	0.45	5.91	0.35	1.14e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.48	-0.33	1.03e-7	Height;
KIRP	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg22916017	chr11:64110731	CCDC88B	0.51	5.63	0.34	4.99e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg08533674	chr1:46993347	NA	-0.37	-4.89	-0.3	1.85e-6	Monobrow;
KIRP	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg01677386	chr11:118938358	VPS11	0.51	6.12	0.36	3.75e-9	Coronary artery disease;
KIRP	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg19913688	chr11:428466	ANO9	-0.74	-5.6	-0.34	5.65e-8	Body mass index;
KIRP	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	0.95	12.19	0.61	4.87e-27	Blood protein levels;
KIRP	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg16255804	chr6:135334527	HBS1L	0.31	4.92	0.3	1.58e-6	Red blood cell count;
KIRP	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.89	0.35	1.29e-8	Schizophrenia;
KIRP	cis	rs11169552	0.510	rs10459233	chr12:50973897	G/C	cg12884762	chr12:50931848	DIP2B	-0.42	-5.02	-0.3	1.02e-6	Colorectal cancer;
KIRP	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.98	0.5	7.16e-17	Motion sickness;
KIRP	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	0.95	11.75	0.6	1.37e-25	Corneal structure;
KIRP	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.99	-0.3	1.14e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.6	0.34	5.83e-8	Personality dimensions;
KIRP	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.47	-5.03	-0.31	9.53e-7	Psoriasis;
KIRP	cis	rs4478858	0.684	rs4949369	chr1:31723845	T/A	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg02464098	chr8:26240309	BNIP3L	0.5	6.15	0.37	3.1e-9	Myopia (pathological);
KIRP	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.62	0.44	5.57e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs737693	1.000	rs737693	chr11:102726142	A/T	cg19620758	chr11:102826565	MMP13	0.71	5.65	0.34	4.42e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6142102	0.923	rs6059586	chr20:32540501	G/A	cg08999081	chr20:33150536	PIGU	0.57	7.24	0.42	5.57e-12	Skin pigmentation;
KIRP	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg00982548	chr2:198649783	BOLL	0.6	5.45	0.33	1.24e-7	Ulcerative colitis;
KIRP	cis	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg27102117	chr16:15229624	NA	0.51	5.91	0.35	1.13e-8	Triglycerides;
KIRP	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.63	-8.37	-0.47	4.46e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs9611198	0.846	rs5757733	chr22:39968173	T/G	cg10455938	chr22:40058150	CACNA1I	0.5	6.89	0.4	4.56e-11	Schizophrenia;
KIRP	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg14346243	chr4:90757452	SNCA	-0.42	-5.22	-0.32	3.74e-7	Neuroticism;
KIRP	trans	rs17046216	0.965	rs6830103	chr4:166260657	A/G	cg23384093	chr5:170745466	NA	-0.45	-6.07	-0.36	4.82e-9	Insulin-related traits;
KIRP	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.16	-0.42	9.23e-12	Gut microbiome composition (summer);
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	15.75	0.71	3.99e-39	Platelet count;
KIRP	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.77	11.17	0.58	1.09e-23	Schizophrenia;
KIRP	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-7.28	-0.42	4.44e-12	Response to antipsychotic treatment;
KIRP	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg01338139	chr15:38987640	C15orf53	-0.53	-5.82	-0.35	1.81e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs7188697	0.922	rs37055	chr16:58560775	C/T	cg21335942	chr16:58549945	SETD6	0.46	5.13	0.31	5.89e-7	QT interval;
KIRP	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.6	-6.28	-0.37	1.5e-9	Chronic sinus infection;
KIRP	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.53	-0.48	1.52e-15	Mean corpuscular volume;
KIRP	cis	rs7011507	1.000	rs76571521	chr8:49118605	A/G	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.09	0.31	7.1e-7	Parkinson's disease;
KIRP	cis	rs1850744	0.702	rs10939428	chr4:9630041	A/G	cg15442990	chr4:9534313	NA	0.77	5.45	0.33	1.24e-7	Economic and political preferences;
KIRP	cis	rs4478037	1.000	rs4074416	chr3:33161729	A/G	cg19404215	chr3:33155277	CRTAP	0.71	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	cis	rs7215564	0.908	rs35253080	chr17:78700167	G/A	cg06153925	chr17:78755379	RPTOR	0.36	5.71	0.34	3.17e-8	Myopia (pathological);
KIRP	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.84	0.45	1.41e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg05361325	chr10:32636312	EPC1	-0.65	-6.14	-0.36	3.26e-9	Sexual dysfunction (female);
KIRP	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.88	-10.72	-0.56	3.04e-22	IgG glycosylation;
KIRP	trans	rs12043259	0.730	rs1358982	chr1:204795915	C/T	cg11485465	chr5:54518469	NA	0.34	6.23	0.37	2.05e-9	Addiction;
KIRP	cis	rs4690686	0.509	rs11730559	chr4:177259257	A/T	cg17059388	chr4:177262070	NA	0.82	11.0	0.57	3.63e-23	Essential tremor;
KIRP	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.52	6.27	0.37	1.6e-9	Initial pursuit acceleration;
KIRP	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg07493874	chr5:1342172	CLPTM1L	0.5	6.56	0.39	3.11e-10	Lung cancer;
KIRP	cis	rs12906542	0.529	rs62008651	chr15:78276417	C/T	cg22832135	chr15:78370102	TBC1D2B	0.59	6.28	0.37	1.52e-9	Breast cancer;
KIRP	cis	rs876084	0.604	rs9297609	chr8:121007998	T/C	cg06265175	chr8:121136014	COL14A1	0.42	4.85	0.3	2.22e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg18764771	chr6:116381957	FRK	0.18	5.24	0.32	3.4e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2151522	0.762	rs62436821	chr6:127175945	G/A	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.36e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7688540	0.771	rs7665727	chr4:277057	A/T	cg17891759	chr4:299121	NA	-0.49	-4.99	-0.3	1.15e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14282440	chr2:27593116	EIF2B4;SNX17	0.53	6.42	0.38	6.88e-10	Parkinson's disease;
KIRP	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.97	-15.49	-0.7	3.05e-38	Prudent dietary pattern;
KIRP	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.18	0.67	9.47e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.74	-0.34	2.83e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg18825076	chr15:78729989	IREB2	-0.45	-5.34	-0.32	2.16e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg05340658	chr4:99064831	C4orf37	-0.44	-5.0	-0.3	1.07e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg00806126	chr19:22604979	ZNF98	0.63	6.48	0.38	4.84e-10	Pain;
KIRP	cis	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.3e-12	Morning vs. evening chronotype;
KIRP	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.67	8.81	0.49	2.32e-16	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg07701084	chr6:150067640	NUP43	0.68	9.32	0.51	6.7e-18	Lung cancer;
KIRP	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.02	-0.3	9.9e-7	Neutrophil percentage of white cells;
KIRP	cis	rs72781680	0.611	rs55788848	chr2:24268721	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	5.8	0.35	2.02e-8	Lymphocyte counts;
KIRP	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg11189052	chr15:85197271	WDR73	0.48	5.03	0.31	9.5e-7	Schizophrenia;
KIRP	cis	rs4974559	0.947	rs28649968	chr4:1362913	G/A	cg02980000	chr4:1222292	CTBP1	0.77	7.44	0.43	1.63e-12	Systolic blood pressure;
KIRP	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.7	-7.66	-0.44	4.2e-13	DNA methylation (variation);
KIRP	cis	rs526231	0.511	rs4421079	chr5:102369076	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.2	-0.31	4.26e-7	Primary biliary cholangitis;
KIRP	cis	rs2219968	0.962	rs6999835	chr8:78948855	T/C	cg00738934	chr8:78996279	NA	0.41	5.28	0.32	2.79e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs11169552	0.510	rs10783382	chr12:51054950	A/G	cg12884762	chr12:50931848	DIP2B	-0.41	-4.93	-0.3	1.49e-6	Colorectal cancer;
KIRP	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.17	0.42	8.49e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg24315340	chr6:146058215	EPM2A	0.4	4.91	0.3	1.67e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.501	rs4790171	chr17:4022899	T/C	cg01798813	chr17:3906674	NA	-0.51	-7.02	-0.41	2.21e-11	Type 2 diabetes;
KIRP	cis	rs3799378	0.579	rs9348715	chr6:26375642	C/G	cg12826209	chr6:26865740	GUSBL1	0.46	5.28	0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	14.94	0.69	2.31e-36	Chronic sinus infection;
KIRP	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg07001201	chr5:642380	CEP72	0.67	6.26	0.37	1.71e-9	Obesity-related traits;
KIRP	cis	rs7538876	0.903	rs1324368	chr1:17752000	A/G	cg01904812	chr1:17746340	RCC2	0.3	5.17	0.31	4.94e-7	Basal cell carcinoma;
KIRP	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg15507776	chr3:136538369	TMEM22	0.4	5.36	0.32	1.94e-7	Neuroticism;
KIRP	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg16497661	chr14:103986332	CKB	0.49	6.61	0.39	2.35e-10	Body mass index;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg15117754	chr3:10150083	C3orf24	0.54	5.15	0.31	5.25e-7	Alzheimer's disease;
KIRP	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18876405	chr7:65276391	NA	-0.42	-5.39	-0.32	1.68e-7	Aortic root size;
KIRP	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.12	-0.41	1.17e-11	Menopause (age at onset);
KIRP	cis	rs9488822	0.651	rs1933738	chr6:116310243	A/G	cg15226275	chr6:116381976	FRK	0.26	5.23	0.32	3.59e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs193541	0.617	rs2045628	chr5:122095154	C/T	cg19412675	chr5:122181750	SNX24	0.52	5.48	0.33	1.04e-7	Glucose homeostasis traits;
KIRP	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.64	6.81	0.4	7.25e-11	Vitiligo;
KIRP	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg23307798	chr14:103986281	CKB	0.52	7.46	0.43	1.51e-12	Body mass index;
KIRP	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg05896524	chr21:47604654	C21orf56	0.41	5.03	0.31	9.28e-7	Testicular germ cell tumor;
KIRP	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg08847533	chr14:75593920	NEK9	0.48	5.65	0.34	4.43e-8	Neuroticism (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00051979	chr10:95462161	C10orf4	0.5	6.03	0.36	6.05e-9	C-reactive protein;
KIRP	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg13289132	chr10:30722225	MAP3K8	-0.38	-4.89	-0.3	1.82e-6	Inflammatory bowel disease;
KIRP	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.21e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.71	-0.34	3.25e-8	Height;
KIRP	cis	rs6450176	0.625	rs3822499	chr5:53289459	C/G	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-12.93	-0.64	1.55e-29	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04417862	chr16:1728242	HN1L	-0.48	-6.1	-0.36	3.99e-9	Myopia;
KIRP	cis	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg19016782	chr12:123741754	C12orf65	0.4	4.99	0.3	1.17e-6	Neutrophil percentage of white cells;
KIRP	cis	rs55871839	0.708	rs4738735	chr8:59816985	T/C	cg07426533	chr8:59803705	TOX	-0.48	-7.94	-0.45	7.38e-14	Pneumonia;
KIRP	cis	rs7221595	0.825	rs12450845	chr17:3972784	G/A	cg09695851	chr17:3907499	NA	0.6	5.85	0.35	1.6e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-6.26	-0.37	1.68e-9	Aortic root size;
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.54	0.33	7.85e-8	Lung cancer;
KIRP	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.89	11.71	0.6	1.86e-25	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16140913	chr4:8430389	ACOX3	0.53	6.1	0.36	4.19e-9	Smoking initiation;
KIRP	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.9	0.6	4.37e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg10755058	chr3:40428713	ENTPD3	0.39	5.23	0.32	3.7e-7	Renal cell carcinoma;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.54	6.34	0.37	1.08e-9	Sleep duration;
KIRP	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg02900749	chr2:68251473	NA	-1.19	-10.02	-0.54	4.82e-20	Pursuit maintenance gain;
KIRP	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg20476274	chr7:133979776	SLC35B4	0.73	9.61	0.52	9.13e-19	Mean platelet volume;
KIRP	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	7.23	0.42	6e-12	Depressive symptoms;
KIRP	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.65	-9.04	-0.5	4.73e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg21360079	chr12:107162445	NA	-0.67	-9.38	-0.51	4.53e-18	Heart rate;
KIRP	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11622362	chr11:34938112	PDHX;APIP	-0.49	-6.07	-0.36	4.71e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg06289844	chr6:126071538	HEY2	-0.39	-5.66	-0.34	4.18e-8	Brugada syndrome;
KIRP	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.67	6.76	0.4	9.82e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs490234	0.841	rs829314	chr9:128415506	A/T	cg14078157	chr9:128172775	NA	0.4	5.06	0.31	8.28e-7	Mean arterial pressure;
KIRP	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.07	11.94	0.61	3.29e-26	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.1	0.36	4.04e-9	Mean corpuscular volume;
KIRP	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg06953865	chr19:18549723	ISYNA1	-0.39	-6.06	-0.36	4.97e-9	Breast cancer;
KIRP	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02725872	chr8:58115012	NA	-0.75	-7.05	-0.41	1.83e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs55675132	0.548	rs6661511	chr1:115437986	G/A	cg12756093	chr1:115239321	AMPD1	0.54	5.35	0.32	1.98e-7	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg04080417	chr5:1859792	NA	-0.56	-6.25	-0.37	1.84e-9	Cardiovascular disease risk factors;
KIRP	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.53	6.39	0.38	8.39e-10	Resistin levels;
KIRP	cis	rs2224391	0.784	rs35048711	chr6:5262235	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.72	-0.39	1.23e-10	Height;
KIRP	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg07777115	chr5:623756	CEP72	-0.52	-5.73	-0.34	2.88e-8	Obesity-related traits;
KIRP	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.73	7.55	0.43	8.42e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.02	-0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.67	9.21	0.51	1.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg01559446	chr3:44596178	ZNF167	-0.37	-5.26	-0.32	3.14e-7	Depressive symptoms;
KIRP	cis	rs12135191	0.741	rs12728000	chr1:236500839	T/C	cg21399712	chr1:236511386	NA	-0.49	-6.21	-0.37	2.2e-9	Urate levels (BMI interaction);
KIRP	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.62	8.42	0.47	3.18e-15	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs76288851	0.668	rs11706899	chr3:126452529	C/G	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	6.78e-10	Alcoholic chronic pancreatitis;
KIRP	trans	rs7999699	0.902	rs36094556	chr13:48308876	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg05340658	chr4:99064831	C4orf37	0.58	7.21	0.42	6.95e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.69	10.3	0.55	6.52e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12210905	1.000	rs116005859	chr6:27155485	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.71	-6.11	-0.36	3.92e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs8177876	0.749	rs12444969	chr16:81083816	A/G	cg08591886	chr16:81111003	C16orf46	-0.67	-5.38	-0.32	1.75e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs16828019	0.777	rs10489521	chr1:41508490	C/T	cg03387723	chr1:41708464	SCMH1	-0.76	-6.23	-0.37	2.05e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4663866	0.901	rs3739066	chr2:239184124	G/T	cg16914508	chr2:239161102	PER2	0.73	5.29	0.32	2.74e-7	Irritable bowel syndrome;
KIRP	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg03959625	chr15:84868606	LOC388152	0.63	6.73	0.39	1.2e-10	Schizophrenia;
KIRP	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg07636037	chr3:49044803	WDR6	-0.57	-5.34	-0.32	2.1e-7	Menarche (age at onset);
KIRP	cis	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg04170623	chr19:59071414	UBE2M;LOC100131691	0.43	5.24	0.32	3.39e-7	Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.62	-7.83	-0.45	1.46e-13	Extraversion;
KIRP	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.49	-6.2	-0.37	2.41e-9	Depressive symptoms;
KIRP	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.37	6.62	0.39	2.23e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg04315214	chr1:2043799	PRKCZ	0.39	5.95	0.35	9.12e-9	Height;
KIRP	cis	rs2916247	1.000	rs4734170	chr8:93051254	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.55	-0.48	1.32e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.05	-0.41	1.8e-11	Body mass index;
KIRP	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.7	0.34	3.47e-8	Educational attainment;
KIRP	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.15	-0.37	3.17e-9	Morning vs. evening chronotype;
KIRP	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg25566285	chr7:158114605	PTPRN2	0.74	9.28	0.51	9.27e-18	Response to amphetamines;
KIRP	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.39	5.91	0.35	1.15e-8	Platelet distribution width;
KIRP	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg06995285	chr7:2418615	EIF3B	0.82	8.54	0.48	1.39e-15	Multiple sclerosis;
KIRP	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg17470449	chr10:769945	NA	0.74	7.79	0.44	1.87e-13	Uric acid levels;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	9.8e-8	Lung cancer;
KIRP	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg11189052	chr15:85197271	WDR73	-0.5	-6.09	-0.36	4.21e-9	P wave terminal force;
KIRP	cis	rs35740288	0.752	rs11635956	chr15:86279928	G/A	cg17133734	chr15:86042851	AKAP13	-0.47	-5.13	-0.31	5.85e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg07862535	chr7:139043722	LUC7L2	0.44	4.96	0.3	1.31e-6	Diisocyanate-induced asthma;
KIRP	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.62	7.91	0.45	8.85e-14	Platelet distribution width;
KIRP	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg08775375	chr8:10454154	NA	0.33	4.93	0.3	1.53e-6	Neuroticism;
KIRP	cis	rs1440410	0.536	rs13137565	chr4:144105698	G/A	cg01719995	chr4:144104893	USP38	0.42	5.46	0.33	1.17e-7	Ischemic stroke;
KIRP	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg17294928	chr15:75287854	SCAMP5	-0.56	-5.53	-0.33	8.37e-8	Blood trace element (Zn levels);
KIRP	cis	rs1165472	1.000	rs1165472	chr1:56108604	A/G	cg11523071	chr1:56160889	NA	-0.41	-5.3	-0.32	2.54e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.71	9.38	0.51	4.4e-18	Longevity;
KIRP	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.19	-0.51	1.69e-17	Platelet count;
KIRP	cis	rs34286592	0.929	rs11863748	chr16:29835588	G/C	cg08218971	chr16:29826754	C16orf53;PRRT2	0.36	5.1	0.31	6.87e-7	Multiple sclerosis;
KIRP	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04004882	chr2:215674386	BARD1	0.83	7.63	0.44	5.03e-13	Neuroblastoma;
KIRP	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.48	-0.43	1.35e-12	Systolic blood pressure;
KIRP	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.39	-5.71	-0.34	3.26e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4728302	0.869	rs6955707	chr7:133612188	G/A	cg10665199	chr7:133106180	EXOC4	0.44	5.45	0.33	1.19e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg26875233	chr11:93583750	C11orf90	-0.37	-7.03	-0.41	2.08e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg01631408	chr1:248437212	OR2T33	-0.67	-8.63	-0.48	7.85e-16	Common traits (Other);
KIRP	cis	rs4761097	0.537	rs1892571	chr12:85173839	C/G	cg00765312	chr12:85674694	ALX1	0.49	5.71	0.34	3.23e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.45	6.28	0.37	1.52e-9	Red blood cell count;
KIRP	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	0.75	10.94	0.57	5.93e-23	Prudent dietary pattern;
KIRP	cis	rs7538876	1.000	rs12129263	chr1:17723870	G/A	cg07394400	chr1:17752023	RCC2	-0.35	-5.02	-0.3	1.01e-6	Basal cell carcinoma;
KIRP	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7084402	0.967	rs1649042	chr10:60328663	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.42e-21	Refractive error;
KIRP	cis	rs77688320	0.535	rs7571761	chr2:202261560	G/T	cg06431681	chr2:202330990	STRADB	0.52	6.97	0.41	2.94e-11	Breast cancer;
KIRP	cis	rs12210905	1.000	rs1062834	chr6:27222539	A/G	cg11502198	chr6:26597334	ABT1	-0.87	-5.32	-0.32	2.33e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15496430	chr1:42664858	FOXJ3	-0.42	-6.07	-0.36	4.92e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg00074818	chr8:8560427	CLDN23	0.42	6.25	0.37	1.76e-9	Obesity-related traits;
KIRP	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg22676075	chr6:135203613	NA	0.47	6.56	0.39	3.19e-10	Red blood cell count;
KIRP	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg12861170	chr19:19639553	YJEFN3	0.47	4.89	0.3	1.82e-6	Bipolar disorder;
KIRP	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18252515	chr7:66147081	NA	0.46	5.51	0.33	9.21e-8	Aortic root size;
KIRP	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.56	-7.23	-0.42	6.14e-12	Menopause (age at onset);
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.82	-9.39	-0.51	4.18e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg26965718	chr17:79658957	HGS	-0.62	-5.11	-0.31	6.43e-7	Dental caries;
KIRP	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg16524733	chr11:117070046	TAGLN	0.41	5.21	0.32	3.96e-7	Blood protein levels;
KIRP	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.92	14.61	0.68	3.1e-35	Breast cancer;
KIRP	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg02569458	chr12:86230093	RASSF9	-0.46	-6.79	-0.4	8.38e-11	Major depressive disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18760729	chr1:93646329	CCDC18;TMED5	0.46	6.66	0.39	1.8e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.1	-0.36	4.07e-9	Arsenic metabolism;
KIRP	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.52	-0.38	4.02e-10	Daytime sleep phenotypes;
KIRP	cis	rs918629	0.530	rs1057963	chr5:95235748	G/C	cg16656078	chr5:95278638	ELL2	-0.38	-5.77	-0.35	2.42e-8	IgG glycosylation;
KIRP	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.7	-9.14	-0.5	2.34e-17	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.63	8.12	0.46	2.25e-14	Mood instability;
KIRP	cis	rs2012796	0.872	rs59397507	chr14:81821334	A/G	cg02996355	chr14:81879375	NA	0.43	5.82	0.35	1.85e-8	Night sleep phenotypes;
KIRP	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.63	-7.24	-0.42	5.82e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg18183042	chr17:80733038	TBCD	-0.41	-5.57	-0.33	6.77e-8	Glycated hemoglobin levels;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg05633190	chr21:35986746	RCAN1	0.5	6.79	0.4	8.58e-11	Educational attainment;
KIRP	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.94	10.29	0.55	7.06e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.34	5.28	0.32	2.85e-7	Asthma (childhood onset);
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.59	5.99	0.36	7.46e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	1.08	14.66	0.68	2.17e-35	Left atrial antero-posterior diameter;
KIRP	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg21452805	chr1:244014465	NA	0.67	5.67	0.34	3.98e-8	RR interval (heart rate);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04936446	chr12:26111348	RASSF8	0.55	7.28	0.42	4.58e-12	Parkinson's disease;
KIRP	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg07001201	chr5:642380	CEP72	0.69	6.47	0.38	5.38e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.61	-7.71	-0.44	3.13e-13	Extraversion;
KIRP	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19171272	chr22:38449367	NA	0.54	7.88	0.45	1.07e-13	Glioblastoma;Glioma;
KIRP	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg24579218	chr15:68104479	NA	0.45	6.42	0.38	7.14e-10	Obesity;
KIRP	cis	rs1359582	0.958	rs2765453	chr10:90302293	T/G	cg15661332	chr10:90342814	RNLS	0.53	5.03	0.31	9.38e-7	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11987759	chr7:65425863	GUSB	0.58	7.96	0.45	6.45e-14	Aortic root size;
KIRP	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg17554472	chr22:41940697	POLR3H	-0.48	-5.45	-0.33	1.25e-7	Neuroticism;
KIRP	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.56	-7.65	-0.44	4.59e-13	Longevity;
KIRP	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg17252645	chr8:143867129	LY6D	0.36	5.7	0.34	3.38e-8	Urinary tract infection frequency;
KIRP	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg03465714	chr1:152285911	FLG	-0.41	-5.02	-0.3	1.02e-6	Atopic dermatitis;
KIRP	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.61	-6.86	-0.4	5.6e-11	Response to antineoplastic agents;
KIRP	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg12405258	chr13:114927641	NA	0.5	7.26	0.42	5.2e-12	Schizophrenia;
KIRP	cis	rs1147199	0.585	rs1332893	chr9:87250808	C/G	cg22402007	chr9:87282823	NTRK2	0.4	5.02	0.3	1.01e-6	Body mass index;
KIRP	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs56161922	0.818	rs111340461	chr1:207870682	A/C	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg07621104	chr11:117668040	DSCAML1	0.47	7.15	0.41	9.66e-12	Myopia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09578018	chr15:60883649	RORA	0.55	6.54	0.38	3.51e-10	Smoking initiation;
KIRP	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.68	-8.3	-0.47	7.11e-15	DNA methylation (variation);
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg01763666	chr17:80159506	CCDC57	-0.38	-5.22	-0.32	3.81e-7	Life satisfaction;
KIRP	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg10326726	chr10:51549505	MSMB	0.58	8.3	0.47	7.07e-15	Prostate-specific antigen levels;
KIRP	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg02725872	chr8:58115012	NA	-0.53	-6.02	-0.36	6.15e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.2	12.8	0.63	4.47e-29	Eosinophil percentage of granulocytes;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg04369109	chr6:150039330	LATS1	-0.52	-6.68	-0.39	1.54e-10	Lung cancer;
KIRP	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.83	-0.4	6.71e-11	Mood instability;
KIRP	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-7.25	-0.42	5.37e-12	Monocyte percentage of white cells;
KIRP	trans	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg16141378	chr3:129829833	LOC729375	0.48	6.17	0.37	2.75e-9	Neuroticism;
KIRP	cis	rs6723226	0.842	rs1901355	chr2:32835664	A/G	cg02381751	chr2:32503542	YIPF4	-0.87	-10.42	-0.55	2.74e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.81	-0.4	7.56e-11	Bladder cancer;
KIRP	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.81	-0.53	2.23e-19	Response to antipsychotic treatment;
KIRP	cis	rs27434	0.583	rs34761	chr5:96153624	C/T	cg16492584	chr5:96139282	ERAP1	-0.43	-5.59	-0.34	5.9e-8	Ankylosing spondylitis;
KIRP	cis	rs4566357	0.964	rs2396443	chr2:227921208	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.02	-0.3	9.85e-7	Coronary artery disease;
KIRP	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.79	-0.35	2.14e-8	IgG glycosylation;
KIRP	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.58	0.34	6.33e-8	Tonsillectomy;
KIRP	trans	rs2859741	0.587	rs510969	chr1:37475061	T/C	cg04172795	chr14:100578523	EVL	-0.47	-6.39	-0.38	8.28e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg13264159	chr8:625131	ERICH1	-0.85	-7.36	-0.43	2.68e-12	IgG glycosylation;
KIRP	cis	rs1593	0.734	rs4253407	chr4:187193308	A/T	cg09526685	chr4:187126073	CYP4V2	0.81	6.99	0.41	2.64e-11	Activated partial thromboplastin time;
KIRP	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.73	-11.42	-0.59	1.63e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.92	10.88	0.57	9.07e-23	Alzheimer's disease;
KIRP	cis	rs9398803	0.687	rs4626447	chr6:126964675	G/A	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.87	0.35	1.42e-8	Tonsillectomy;
KIRP	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.43	-4.89	-0.3	1.8e-6	Schizophrenia;
KIRP	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.2	-0.37	2.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4262150	0.580	rs2964248	chr5:151916767	G/A	cg12297329	chr5:152029980	NA	-0.56	-7.25	-0.42	5.53e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.87	-9.54	-0.52	1.46e-18	Osteoarthritis;
KIRP	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.55	-0.33	7.29e-8	Depression;
KIRP	cis	rs7011507	1.000	rs55723686	chr8:49131081	C/T	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs1859156	0.767	rs13114040	chr4:95816831	T/A	cg24204951	chr2:239172084	PER2	0.29	6.26	0.37	1.68e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs2997447	0.846	rs76713804	chr1:26392437	G/A	cg19633962	chr1:26362018	EXTL1	-0.75	-6.27	-0.37	1.58e-9	QRS complex (12-leadsum);
KIRP	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-5.75	-0.34	2.68e-8	Response to antipsychotic treatment;
KIRP	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-5.3	-0.32	2.52e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.68	-0.39	1.55e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6681460	0.834	rs2916	chr1:67216697	G/A	cg02459107	chr1:67143332	SGIP1	-0.42	-5.9	-0.35	1.22e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.78	6.69	0.39	1.53e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.39	6.77	0.4	9.63e-11	Heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00259882	chr11:70049130	FADD	0.48	7.03	0.41	2.02e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg10760299	chr15:45669010	GATM	0.32	4.87	0.3	1.98e-6	Homoarginine levels;
KIRP	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg17644776	chr2:200775616	C2orf69	0.58	6.11	0.36	3.86e-9	Schizophrenia;
KIRP	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg11941060	chr3:133502564	NA	-0.43	-5.22	-0.32	3.74e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.18	-0.42	8.24e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-8.22	-0.46	1.21e-14	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10500218	chr1:181058063	IER5	0.51	6.91	0.4	4.1e-11	Parkinson's disease;
KIRP	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg10189774	chr4:17578691	LAP3	0.43	5.13	0.31	5.93e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.52	-6.31	-0.37	1.32e-9	Lymphocyte percentage of white cells;
KIRP	trans	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17712092	chr4:129076599	LARP1B	-0.58	-7.18	-0.42	8.45e-12	Eosinophil percentage of white cells;
KIRP	cis	rs10929159	0.928	rs34769167	chr2:236920442	A/G	cg20128773	chr2:236923534	AGAP1	0.3	5.23	0.32	3.57e-7	Parkinson's disease;
KIRP	trans	rs13100616	1.000	rs4396882	chr3:178410614	A/G	cg26530345	chr2:220312410	SPEG	0.49	6.02	0.36	6.17e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs8177876	0.822	rs1563077	chr16:81107556	T/A	cg08591886	chr16:81111003	C16orf46	-0.63	-6.02	-0.36	6.44e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7116495	0.609	rs4477459	chr11:71720616	T/C	cg07596299	chr11:71824057	C11orf51	-0.88	-5.45	-0.33	1.22e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05093860	chr3:132441075	NPHP3;NCRNA00119	0.54	6.21	0.37	2.21e-9	Smoking initiation;
KIRP	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg11150807	chr10:43354902	NA	0.62	6.91	0.4	4.16e-11	Blood protein levels;
KIRP	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.55	0.59	5.92e-25	Menarche (age at onset);
KIRP	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg25650185	chr19:21324782	ZNF431	0.48	4.97	0.3	1.23e-6	Pain;
KIRP	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg26022315	chr17:47021804	SNF8	0.42	5.41	0.33	1.47e-7	Type 2 diabetes;
KIRP	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg20578329	chr17:80767326	TBCD	0.92	8.91	0.49	1.14e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.96	15.76	0.71	3.75e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	8.34	0.47	5.47e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.51	-0.33	9.08e-8	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19373090	chr19:797215	PTBP1	0.52	6.43	0.38	6.58e-10	Parkinson's disease;
KIRP	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.87	13.13	0.64	3.25e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4356932	0.691	rs4859413	chr4:76898250	A/G	cg00809888	chr4:76862425	NAAA	-0.49	-6.86	-0.4	5.65e-11	Blood protein levels;
KIRP	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-1.0	-13.55	-0.65	1.27e-31	Red cell distribution width;
KIRP	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg08499158	chr17:42289980	UBTF	0.76	9.72	0.53	4.21e-19	Total body bone mineral density;
KIRP	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg16898833	chr6:26189333	HIST1H4D	0.97	5.87	0.35	1.38e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg26876637	chr1:152193138	HRNR	0.76	9.9	0.53	1.17e-19	Atopic dermatitis;
KIRP	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.07	-0.46	3.19e-14	Neuroticism;
KIRP	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.16	-0.46	1.75e-14	Personality dimensions;
KIRP	cis	rs4713118	0.866	rs2179094	chr6:27741825	T/C	cg20933634	chr6:27740509	NA	0.39	5.08	0.31	7.58e-7	Parkinson's disease;
KIRP	cis	rs2733201	1.000	rs2733201	chr15:44408401	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-5.1	-0.31	6.81e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs2415984	0.622	rs61993296	chr14:46934216	C/T	cg14871534	chr14:47121158	RPL10L	-0.45	-5.37	-0.32	1.86e-7	Number of children ever born;
KIRP	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg18350739	chr11:68623251	NA	-0.52	-7.73	-0.44	2.82e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs28530674	1.000	rs16862344	chr1:19221842	C/T	cg26407146	chr1:19229049	ALDH4A1	-1.01	-7.55	-0.43	8.68e-13	Eosinophilic esophagitis;
KIRP	cis	rs4716602	0.898	rs10249494	chr7:156159448	G/T	cg04090468	chr7:156181990	NA	0.44	5.28	0.32	2.81e-7	Anti-saccade response;
KIRP	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.77	9.34	0.51	5.93e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.92	0.35	1.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg06740227	chr12:86229804	RASSF9	-0.46	-5.58	-0.34	6.3e-8	Major depressive disorder;
KIRP	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg12549451	chr6:135224345	NA	0.41	5.04	0.31	9.12e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.67	-0.34	3.96e-8	Recombination measurement;
KIRP	cis	rs3767633	0.925	rs2134696	chr1:161781200	A/T	cg09175582	chr1:161736000	ATF6	-0.75	-6.07	-0.36	4.77e-9	IgG glycosylation;
KIRP	cis	rs735860	0.700	rs209524	chr6:53213226	G/C	cg10236188	chr6:53219634	NA	0.4	5.37	0.32	1.83e-7	Glaucoma;
KIRP	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg07741184	chr6:167504864	NA	-0.24	-6.42	-0.38	7.08e-10	Crohn's disease;
KIRP	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.34	-0.51	6.1e-18	Neuroticism;
KIRP	cis	rs4886920	0.855	rs7183989	chr15:78105580	T/C	cg10461261	chr15:78109450	NA	-0.32	-5.3	-0.32	2.55e-7	Neuroticism;
KIRP	cis	rs2929278	0.638	rs2016840	chr15:44211868	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.48	-5.9	-0.35	1.22e-8	Schizophrenia;
KIRP	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.61	8.72	0.49	4.35e-16	Testicular germ cell tumor;
KIRP	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg24110177	chr3:50126178	RBM5	-0.43	-5.53	-0.33	7.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg21775007	chr8:11205619	TDH	0.44	5.97	0.36	8.12e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-9.98	-0.54	6.69e-20	Coronary artery disease;
KIRP	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.59	-0.63	2.15e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2281603	0.570	rs2198347	chr14:64969342	A/C	cg01860774	chr14:64969374	ZBTB25	-0.32	-5.3	-0.32	2.61e-7	Lymphocyte counts;
KIRP	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg19567339	chr10:100142640	NA	0.44	4.95	0.3	1.36e-6	Metabolite levels;
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.46	5.91	0.35	1.17e-8	Longevity;
KIRP	cis	rs1832871	0.599	rs7752547	chr6:158751163	C/T	cg07215822	chr6:158701037	NA	0.6	8.71	0.49	4.53e-16	Height;
KIRP	cis	rs1958560	0.731	rs7142906	chr14:65956456	A/T	cg03016385	chr14:66212404	NA	-0.51	-6.25	-0.37	1.83e-9	Menarche (age at onset);
KIRP	cis	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg12315302	chr6:26189340	HIST1H4D	0.83	5.21	0.32	4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11671005	0.568	rs73068329	chr19:59080325	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.56	-6.47	-0.38	5.35e-10	Mean platelet volume;
KIRP	cis	rs2235573	0.710	rs738443	chr22:38458681	G/A	cg19171272	chr22:38449367	NA	-0.68	-9.65	-0.52	6.83e-19	Glioblastoma;Glioma;
KIRP	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg10503236	chr1:231470652	EXOC8	-0.53	-7.0	-0.41	2.42e-11	Red blood cell count;
KIRP	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs9890032	0.581	rs62070592	chr17:29022549	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.42	-5.35	-0.32	1.99e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.73	8.96	0.5	8.41e-17	Corneal astigmatism;
KIRP	cis	rs42648	0.564	rs6465249	chr7:89824753	A/T	cg25739043	chr7:89950458	NA	-0.37	-5.87	-0.35	1.39e-8	Homocysteine levels;
KIRP	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	9.91	0.53	1.08e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1697938	0.640	rs4957144	chr5:40914326	C/A	cg01087697	chr5:40835557	RPL37	0.48	5.52	0.33	8.58e-8	Multiple system atrophy;
KIRP	cis	rs10901296	0.660	rs2855197	chr9:133764406	A/G	cg03924115	chr9:133768966	QRFP	0.34	4.92	0.3	1.56e-6	Bilirubin levels;
KIRP	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.83	-0.45	1.49e-13	Platelet count;
KIRP	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7224685	0.515	rs7207986	chr17:3979949	G/A	cg11204139	chr17:3907470	NA	0.6	5.77	0.35	2.37e-8	Type 2 diabetes;
KIRP	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.97e-44	Breast cancer;
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg08662619	chr6:150070041	PCMT1	0.37	5.93	0.35	1.02e-8	Lung cancer;
KIRP	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg03959625	chr15:84868606	LOC388152	0.72	8.62	0.48	8.3e-16	Schizophrenia;
KIRP	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg16586182	chr3:47516702	SCAP	-0.77	-11.17	-0.58	1.02e-23	Colorectal cancer;
KIRP	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg25204440	chr1:209979598	IRF6	0.5	5.08	0.31	7.51e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.52	0.38	4.04e-10	Menarche (age at onset);
KIRP	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg06521331	chr12:34319734	NA	-0.65	-7.75	-0.44	2.4e-13	Morning vs. evening chronotype;
KIRP	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	8.16	0.46	1.76e-14	IgG glycosylation;
KIRP	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.0	-0.3	1.07e-6	Iron status biomarkers;
KIRP	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.64	6.68	0.39	1.61e-10	Height;
KIRP	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.07	-11.32	-0.59	3.32e-24	Hip circumference adjusted for BMI;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.13.865492R	chr13:60543691	DIAPH3	0.5	6.93	0.4	3.64e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg20542592	chr8:11973495	FAM66D	0.4	5.02	0.3	9.87e-7	Triglycerides;
KIRP	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg07052231	chr12:7363540	PEX5	0.38	5.08	0.31	7.34e-7	IgG glycosylation;
KIRP	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.24	-0.42	5.69e-12	Life satisfaction;
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg12486944	chr17:80159399	CCDC57	0.4	5.34	0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg03146154	chr1:46216737	IPP	0.46	4.86	0.3	2.07e-6	Platelet distribution width;
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs9463078	0.547	rs2038557	chr6:44740471	G/A	cg25276700	chr6:44698697	NA	0.34	4.94	0.3	1.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	1.06	20.03	0.79	1.42e-53	Heart rate;
KIRP	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.85	0.6	6.19e-26	Smoking behavior;
KIRP	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg22563815	chr15:78856949	CHRNA5	0.5	7.8	0.45	1.8e-13	Sudden cardiac arrest;
KIRP	cis	rs877282	0.945	rs12782447	chr10:771870	C/T	cg17470449	chr10:769945	NA	0.69	6.95	0.4	3.31e-11	Uric acid levels;
KIRP	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg00784671	chr22:46762841	CELSR1	-0.61	-6.15	-0.36	3.14e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs838147	0.537	rs504963	chr19:49208865	G/A	cg08619932	chr19:49200058	FUT2	0.36	5.47	0.33	1.11e-7	Dietary macronutrient intake;
KIRP	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg11952622	chr19:58962976	ZNF324B	0.43	5.03	0.31	9.38e-7	Uric acid clearance;
KIRP	cis	rs6732160	0.809	rs6728959	chr2:73383327	C/T	cg01422370	chr2:73384389	NA	0.44	5.81	0.35	1.94e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12643440	0.538	rs1357233	chr4:17143376	A/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6973256	0.828	rs17167210	chr7:133339343	G/A	cg10665199	chr7:133106180	EXOC4	-0.51	-6.19	-0.37	2.44e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	0.93	12.47	0.62	5.58e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs702634	0.579	rs697109	chr5:53303816	C/G	cg22592108	chr5:53304441	ARL15	0.47	5.88	0.35	1.3e-8	Type 2 diabetes;High light scatter reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.78	-12.9	-0.64	2.02e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.78	-12.25	-0.62	2.97e-27	Schizophrenia;
KIRP	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	4.94	0.3	1.45e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg13160058	chr8:26243215	BNIP3L	-0.4	-6.21	-0.37	2.18e-9	Red cell distribution width;
KIRP	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg13939156	chr17:80058883	NA	-0.49	-5.7	-0.34	3.43e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg24644049	chr4:85504048	CDS1	0.95	6.41	0.38	7.18e-10	Skin colour saturation;
KIRP	cis	rs7709377	0.597	rs11951865	chr5:115492280	G/T	cg23108291	chr5:115420582	COMMD10	0.42	5.06	0.31	8.38e-7	Metabolite levels  (X-11787);
KIRP	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18255839	chr2:239335447	ASB1	0.42	5.01	0.3	1.04e-6	Multiple system atrophy;
KIRP	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.81	11.7	0.6	1.92e-25	Blood metabolite ratios;
KIRP	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg23102388	chr7:1867652	MAD1L1	-0.47	-6.33	-0.37	1.14e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.53	7.03	0.41	2.08e-11	Total body bone mineral density;
KIRP	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.63	-7.93	-0.45	7.58e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.88	9.49	0.52	2.06e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11637445	0.603	rs7183168	chr15:68121483	A/C	cg24579218	chr15:68104479	NA	-0.44	-6.73	-0.39	1.19e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.83	-8.28	-0.47	7.67e-15	Coronary artery calcification;
KIRP	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg24375607	chr4:120327624	NA	0.59	6.42	0.38	6.89e-10	Corneal astigmatism;
KIRP	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.92	-0.53	9.84e-20	Hemoglobin concentration;
KIRP	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg11642891	chr2:3452563	TTC15	-0.56	-7.16	-0.42	9.54e-12	Obesity-related traits;
KIRP	trans	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg10756647	chr7:56101905	PSPH	0.93	6.83	0.4	6.5e-11	Diabetic kidney disease;
KIRP	trans	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg24644049	chr4:85504048	CDS1	1.08	7.09	0.41	1.43e-11	Skin colour saturation;
KIRP	cis	rs601339	1.000	rs525215	chr12:123179771	G/A	cg18578876	chr12:123200353	GPR109B	0.49	4.85	0.3	2.19e-6	Adiponectin levels;
KIRP	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.41	-6.07	-0.36	4.85e-9	Coronary artery disease;
KIRP	cis	rs13067260	0.655	rs7648412	chr3:123746115	A/T	cg19918027	chr3:123987645	KALRN	-0.61	-5.45	-0.33	1.2e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18782564	chr6:158365130	SNX9	-0.43	-6.02	-0.36	6.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg01849466	chr14:104193079	ZFYVE21	0.42	5.1	0.31	6.92e-7	Schizophrenia;
KIRP	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07570687	chr10:102243282	WNT8B	0.52	6.64	0.39	1.94e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg27490568	chr2:178487706	NA	0.56	7.49	0.43	1.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs829661	0.947	rs829630	chr2:30746046	C/T	cg10949345	chr2:30726833	LCLAT1	1.15	13.82	0.66	1.5e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-9.06	-0.5	4.21e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs12976411	0.867	rs12985626	chr19:32828993	A/G	cg02282382	chr19:32836354	ZNF507	-0.66	-5.59	-0.34	5.91e-8	Coronary artery disease;
KIRP	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.55	6.42	0.38	7.07e-10	Height;
KIRP	cis	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg26585981	chr11:48327164	OR4S1	-0.44	-5.37	-0.32	1.79e-7	HDL cholesterol;
KIRP	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg20560298	chr2:73613845	ALMS1	0.45	5.49	0.33	1.02e-7	Metabolite levels;
KIRP	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.73	0.44	2.78e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs427941	0.703	rs201458	chr7:101741439	T/C	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.27e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg10645314	chr2:3704589	ALLC	-0.63	-6.97	-0.41	2.95e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1215050	0.791	rs1215055	chr4:98865454	C/T	cg05340658	chr4:99064831	C4orf37	-0.54	-6.51	-0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	5.16	0.31	5.03e-7	Schizophrenia;
KIRP	cis	rs2241685	0.850	rs7565890	chr2:1942959	G/A	cg22511877	chr2:1942942	MYT1L	-0.65	-6.12	-0.36	3.74e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.78	-10.93	-0.57	6.17e-23	Height;
KIRP	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.46	5.96	0.36	8.51e-9	Calcium levels;
KIRP	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	6.93	0.4	3.69e-11	Systemic lupus erythematosus;
KIRP	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.5	7.14	0.41	1.05e-11	Systemic lupus erythematosus;
KIRP	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg18964960	chr10:1102726	WDR37	-0.59	-6.62	-0.39	2.19e-10	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14145653	chr9:5184772	INSL6	0.51	7.01	0.41	2.32e-11	Survival in pancreatic cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17157516	chr1:35332203	DLGAP3	0.46	6.72	0.39	1.24e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.91	-0.45	8.86e-14	Breast cancer;
KIRP	cis	rs2916247	1.000	rs2976506	chr8:92998874	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.55	-6.99	-0.41	2.65e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.51	8.4	0.47	3.62e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06419771	chr15:42264912	EHD4	0.56	6.54	0.38	3.48e-10	Smoking initiation;
KIRP	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg10760299	chr15:45669010	GATM	0.35	5.12	0.31	6.27e-7	Homoarginine levels;
KIRP	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg08283408	chr3:49949060	MON1A	-0.4	-5.17	-0.31	4.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12996903	chr3:50275575	GNAI2	0.55	6.14	0.36	3.33e-9	Lung cancer in ever smokers;
KIRP	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg24579218	chr15:68104479	NA	-0.54	-8.52	-0.48	1.66e-15	Restless legs syndrome;
KIRP	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.49	6.63	0.39	2.11e-10	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08748207	chr12:46777589	NA	0.58	7.11	0.41	1.26e-11	Smoking initiation;
KIRP	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg23978390	chr7:1156363	C7orf50	0.5	4.92	0.3	1.59e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	6.88	0.4	5.08e-11	Height;
KIRP	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg08999081	chr20:33150536	PIGU	0.45	5.75	0.34	2.68e-8	Height;
KIRP	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.64	5.96	0.36	8.48e-9	Gut microbiome composition (summer);
KIRP	cis	rs12568771	0.505	rs2477134	chr1:17633572	A/C	cg19159961	chr1:17633534	PADI4	0.37	4.93	0.3	1.49e-6	IgA nephropathy;
KIRP	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg06217071	chr17:408420	NA	0.73	11.31	0.58	3.78e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg16497661	chr14:103986332	CKB	0.8	13.13	0.64	3.39e-30	Body mass index;
KIRP	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.67	0.39	1.66e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg13206674	chr6:150067644	NUP43	0.48	5.4	0.33	1.58e-7	Lung cancer;
KIRP	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-1.02	-16.06	-0.72	3.43e-40	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.85	-0.35	1.52e-8	Crohn's disease;
KIRP	cis	rs17209837	0.607	rs2109505	chr7:87079406	T/A	cg00919237	chr7:87102261	ABCB4	-0.68	-7.86	-0.45	1.18e-13	Gallbladder cancer;
KIRP	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.93	11.18	0.58	1e-23	Post bronchodilator FEV1;
KIRP	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.56	-5.92	-0.35	1.05e-8	Ulcerative colitis;
KIRP	trans	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Bladder cancer;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.38	4.91	0.3	1.67e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.28	-0.32	2.82e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10875746	0.903	rs12315625	chr12:48472453	G/A	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04871131	chr7:94954202	PON1	-0.6	-8.5	-0.48	1.85e-15	Paraoxonase activity;
KIRP	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12963246	chr6:28129442	ZNF389	0.49	6.13	0.36	3.43e-9	Depression;
KIRP	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	9.87	0.53	1.42e-19	Caffeine consumption;
KIRP	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg16586182	chr3:47516702	SCAP	0.83	11.97	0.61	2.53e-26	Colorectal cancer;
KIRP	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.79	10.61	0.56	6.54e-22	Menopause (age at onset);
KIRP	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.97	11.53	0.59	7.29e-25	Corneal astigmatism;
KIRP	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	9.82	0.53	2e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.16	-21.36	-0.81	5.66e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.73	-9.29	-0.51	8.8e-18	Pancreatic cancer;
KIRP	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.68	8.09	0.46	2.67e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7084402	0.967	rs7087528	chr10:60301294	A/T	cg05938607	chr10:60274200	BICC1	0.39	9.1	0.5	3.12e-17	Refractive error;
KIRP	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.6	-9.76	-0.53	3.09e-19	Prostate cancer;
KIRP	cis	rs9815354	0.812	rs17215589	chr3:41831203	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10849893	0.557	rs7976840	chr12:121829972	T/C	cg01154721	chr12:121881891	KDM2B	-0.37	-4.88	-0.3	1.89e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7809615	0.901	rs10261661	chr7:99189722	A/T	cg24024660	chr7:99195788	NA	-0.54	-4.92	-0.3	1.58e-6	Blood metabolite ratios;
KIRP	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg11906718	chr8:101322791	RNF19A	-0.63	-8.06	-0.46	3.39e-14	Atrioventricular conduction;
KIRP	cis	rs56079296	0.642	rs2914610	chr5:121314168	A/G	cg05256605	chr5:121412184	LOX	0.5	5.64	0.34	4.67e-8	Coronary artery disease;
KIRP	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.81	8.68	0.48	5.58e-16	Prostate cancer;
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg18209359	chr17:80159595	CCDC57	-0.41	-5.41	-0.33	1.5e-7	Life satisfaction;
KIRP	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg08126542	chr6:37504118	NA	0.56	6.92	0.4	3.89e-11	Cognitive performance;
KIRP	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg14972814	chr11:95582409	MTMR2	0.37	6.1	0.36	3.98e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs2494938	0.535	rs2473588	chr6:40545622	T/C	cg14084896	chr6:40530702	LRFN2	-0.42	-5.28	-0.32	2.83e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs28680850	0.541	rs4876041	chr8:1370441	T/C	cg09050832	chr8:1365175	NA	-0.58	-5.36	-0.32	1.91e-7	Triglycerides;
KIRP	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.62	6.71	0.39	1.3100000000000001e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs28834970	0.571	rs12679874	chr8:27230819	A/G	cg06815112	chr8:27182871	PTK2B	-0.41	-4.84	-0.3	2.26e-6	Alzheimer's disease (late onset);
KIRP	cis	rs986417	0.748	rs10147346	chr14:61083334	G/C	cg27398547	chr14:60952738	C14orf39	0.64	6.03	0.36	6.1e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.37	0.38	9.27e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.78	-0.4	8.73e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg21132104	chr15:45694354	SPATA5L1	0.77	9.78	0.53	2.69e-19	Homoarginine levels;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.73	-10.25	-0.55	9.21e-21	Menarche (age at onset);
KIRP	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.63	9.48	0.52	2.23e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg25664220	chr3:72788482	NA	-0.5	-7.33	-0.42	3.35e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.68	9.66	0.52	6.55e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3762637	0.941	rs75344200	chr3:122073421	C/T	cg24169773	chr3:122142474	KPNA1	-0.58	-5.88	-0.35	1.34e-8	LDL cholesterol levels;
KIRP	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.68	-7.16	-0.42	9.51e-12	Urate levels in lean individuals;
KIRP	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg11161011	chr14:65562177	MAX	-0.6	-7.69	-0.44	3.55e-13	Obesity-related traits;
KIRP	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.6	7.17	0.42	8.71e-12	Platelet count;
KIRP	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.42	-6.08	-0.36	4.56e-9	Reticulocyte fraction of red cells;
KIRP	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg17145862	chr1:211918768	LPGAT1	0.69	6.87	0.4	5.27e-11	Crohn's disease;
KIRP	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.7	8.6	0.48	9.71e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg01629716	chr15:45996671	NA	0.37	6.59	0.39	2.73e-10	Waist circumference;Weight;
KIRP	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.56	-0.43	8.05e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.9	0.49	1.21e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs72925845	0.519	rs589582	chr17:76427732	C/A	cg03830375	chr17:76426088	DNAH17	0.51	5.25	0.32	3.26e-7	Triglycerides;
KIRP	trans	rs6601327	0.586	rs6601340	chr8:9461315	A/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.01	-0.41	2.28e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg11845111	chr2:191398756	TMEM194B	-0.77	-8.37	-0.47	4.31e-15	Diastolic blood pressure;
KIRP	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-9.15	-0.5	2.26e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.64	-5.03	-0.31	9.36e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg12042659	chr19:58951599	ZNF132	0.53	6.47	0.38	5.12e-10	Uric acid clearance;
KIRP	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01994542	chr14:103800472	EIF5	0.54	6.65	0.39	1.88e-10	Parkinson's disease;
KIRP	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg14458575	chr2:238380390	NA	0.55	5.81	0.35	1.97e-8	Prostate cancer;
KIRP	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	8.34	0.47	5.42e-15	Colorectal cancer;
KIRP	cis	rs829661	0.739	rs6759011	chr2:30790818	G/T	cg10949345	chr2:30726833	LCLAT1	1.01	12.91	0.64	1.88e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs16973500	0.711	rs72801789	chr16:71959748	C/T	cg00732059	chr16:71740210	PHLPP2	-0.59	-5.6	-0.34	5.62e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg08600765	chr20:34638493	LOC647979	-0.79	-8.37	-0.47	4.3e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24110177	chr3:50126178	RBM5	0.44	5.6	0.34	5.82e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7615316	0.779	rs6769786	chr3:142097777	A/G	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.15e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.41	5.18	0.31	4.57e-7	Cystic fibrosis severity;
KIRP	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg01879757	chr17:41196368	BRCA1	-0.48	-6.43	-0.38	6.49e-10	Menopause (age at onset);
KIRP	cis	rs9815354	1.000	rs6803560	chr3:41824480	A/G	cg03022575	chr3:42003672	ULK4	0.51	5.94	0.35	9.68e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1656402	1.000	rs1729246	chr2:233426816	T/G	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs7712401	0.569	rs10080185	chr5:122351856	A/G	cg19328475	chr5:122430277	PRDM6	-0.36	-5.04	-0.31	9.2e-7	Mean platelet volume;
KIRP	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.3	-0.42	3.85e-12	Morning vs. evening chronotype;
KIRP	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.83	9.7	0.53	4.76e-19	Neutrophil percentage of white cells;
KIRP	cis	rs6504950	0.830	rs12150038	chr17:53041520	T/G	cg26251398	chr17:52985966	TOM1L1	0.41	5.1	0.31	6.81e-7	Breast cancer;
KIRP	cis	rs1448094	0.717	rs55811543	chr12:86290936	C/T	cg02569458	chr12:86230093	RASSF9	0.37	5.38	0.32	1.76e-7	Major depressive disorder;
KIRP	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg15704280	chr7:45808275	SEPT13	0.7	6.26	0.37	1.69e-9	Intraocular pressure;
KIRP	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg07777115	chr5:623756	CEP72	-0.58	-5.86	-0.35	1.52e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg22705602	chr4:152727874	NA	-0.54	-9.4	-0.51	4.04e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg10397082	chr2:1609832	NA	0.57	5.15	0.31	5.36e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.35	4.87	0.3	2.01e-6	Coronary artery disease;
KIRP	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg09184832	chr6:79620586	NA	-0.44	-6.0	-0.36	7.16e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.36	-0.59	2.62e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7729447	0.804	rs4867471	chr5:32693456	A/T	cg16267343	chr5:32710456	NPR3	0.53	6.0	0.36	6.86e-9	Blood pressure;
KIRP	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.67	-8.43	-0.47	2.88e-15	Sudden cardiac arrest;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18915197	chr5:32017214	PDZD2	0.49	6.31	0.37	1.27e-9	Interleukin-4 levels;
KIRP	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.03	-0.31	9.45e-7	Carotid intima media thickness;
KIRP	cis	rs909341	0.909	rs2257440	chr20:62328267	C/T	cg03999872	chr20:62272968	STMN3	-0.56	-6.52	-0.38	3.89e-10	Atopic dermatitis;
KIRP	cis	rs9309473	1.000	rs10496193	chr2:73773503	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.48	-0.33	1.07e-7	Metabolite levels;
KIRP	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.85	-0.45	1.27e-13	Platelet count;
KIRP	cis	rs2299587	0.637	rs7832527	chr8:17889343	C/A	cg01800426	chr8:17659068	MTUS1	-0.42	-5.05	-0.31	8.73e-7	Economic and political preferences;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09172752	chr15:77197536	NA	0.56	6.96	0.41	3.15e-11	Parkinson's disease;
KIRP	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg18357526	chr6:26021779	HIST1H4A	0.49	6.59	0.39	2.68e-10	Height;
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.7	9.36	0.51	5.26e-18	Obesity-related traits;
KIRP	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg02415014	chr8:143852576	LYNX1	0.33	5.14	0.31	5.49e-7	Urinary tract infection frequency;
KIRP	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.06	-14.23	-0.67	6.25e-34	Body mass index;
KIRP	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.31	0.32	2.43e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg16497661	chr14:103986332	CKB	0.52	7.08	0.41	1.47e-11	Body mass index;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg09263875	chr16:632152	PIGQ	0.74	12.66	0.63	1.27e-28	Height;
KIRP	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	9.24	0.51	1.22e-17	Colorectal cancer;
KIRP	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg24375607	chr4:120327624	NA	0.4	4.87	0.3	2e-6	Diastolic blood pressure;
KIRP	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg24699146	chr1:24152579	HMGCL	-0.41	-5.18	-0.31	4.7e-7	Immature fraction of reticulocytes;
KIRP	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.49	0.65	2.07e-31	Smoking behavior;
KIRP	trans	rs12043259	0.730	rs10458591	chr1:204792210	C/T	cg11485465	chr5:54518469	NA	-0.34	-6.21	-0.37	2.21e-9	Addiction;
KIRP	cis	rs1832871	0.711	rs12527510	chr6:158657299	T/G	cg07215822	chr6:158701037	NA	-0.64	-7.38	-0.43	2.49e-12	Height;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.66	-7.86	-0.45	1.18e-13	Menopause (age at onset);
KIRP	cis	rs3087591	0.683	rs12602834	chr17:29637308	G/A	cg24425628	chr17:29625626	OMG;NF1	0.68	10.34	0.55	4.79e-21	Hip circumference;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg09597638	chr17:3907349	NA	-0.75	-14.16	-0.67	1.09e-33	Type 2 diabetes;
KIRP	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg20488157	chr14:104394430	TDRD9	0.76	10.92	0.57	6.96e-23	Bipolar disorder;
KIRP	cis	rs259282	0.524	rs3760941	chr19:33130866	T/C	cg02997394	chr19:33096574	ANKRD27	-0.49	-4.98	-0.3	1.22e-6	Schizophrenia;
KIRP	cis	rs78545713	1.000	rs16891484	chr6:26242930	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.24	-0.32	3.43e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg18350739	chr11:68623251	NA	-0.53	-7.94	-0.45	7.37e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs2964802	0.505	rs13180011	chr5:10824615	T/C	cg14521931	chr5:10832172	NA	-0.74	-11.38	-0.59	2.12e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.57	5.28	0.32	2.85e-7	Smoking behavior;
KIRP	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs6832769	0.925	rs2899037	chr4:56457347	C/G	cg05960024	chr4:56376020	CLOCK	-0.63	-8.08	-0.46	2.83e-14	Personality dimensions;
KIRP	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg01877450	chr7:97915802	BRI3	-0.53	-6.98	-0.41	2.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6088813	0.961	rs745931	chr20:33956004	A/T	cg14752227	chr20:34000481	UQCC	-0.51	-6.73	-0.39	1.16e-10	Height;
KIRP	cis	rs6102059	0.748	rs6129648	chr20:39231118	A/G	cg06665391	chr20:39312290	NA	0.45	5.82	0.35	1.86e-8	LDL cholesterol;
KIRP	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.27	-0.47	8.32e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.54	5.91	0.35	1.16e-8	Metabolite levels;
KIRP	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.43	5.93	0.35	1.04e-8	Hemoglobin concentration;
KIRP	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06544989	chr22:39130855	UNC84B	-0.47	-7.46	-0.43	1.45e-12	Menopause (age at onset);
KIRP	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.63	7.66	0.44	4.27e-13	Post bronchodilator FEV1;
KIRP	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg01879757	chr17:41196368	BRCA1	-0.75	-10.28	-0.55	7.41e-21	Menopause (age at onset);
KIRP	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.78	-10.73	-0.56	2.78e-22	Body mass index;
KIRP	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg00262122	chr8:11665843	FDFT1	0.44	5.52	0.33	8.67e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg04865290	chr3:52927548	TMEM110	-0.64	-7.57	-0.43	7.53e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6120849	0.707	rs752075	chr20:33591591	C/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.37	0.38	9.09e-10	Protein C levels;
KIRP	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.72	9.51	0.52	1.86e-18	DNA methylation (variation);
KIRP	cis	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg21546286	chr11:48923668	NA	-0.42	-5.0	-0.3	1.1e-6	HDL cholesterol;
KIRP	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12893428	chr3:195717962	SDHAP1	0.45	5.98	0.36	7.72e-9	Pancreatic cancer;
KIRP	cis	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.44	-0.33	1.29e-7	Neuroticism;
KIRP	cis	rs5753037	0.838	rs131293	chr22:30171031	T/G	cg27665648	chr22:30112403	NA	0.45	6.38	0.38	8.72e-10	Type 1 diabetes;
KIRP	cis	rs2172802	0.570	rs2036199	chr4:62540857	A/C	cg04118610	chr4:62707027	LPHN3	0.44	5.54	0.33	7.85e-8	Partial epilepsies;
KIRP	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	1.17	10.23	0.55	1.06e-20	Skin colour saturation;
KIRP	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-4.95	-0.3	1.35e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg11833968	chr6:79620685	NA	0.51	7.67	0.44	3.92e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg02811702	chr13:24901961	NA	0.43	5.67	0.34	3.91e-8	Obesity-related traits;
KIRP	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg17507749	chr15:85114479	UBE2QP1	0.9	10.02	0.54	5e-20	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.62	5.63	0.34	4.92e-8	Alzheimer's disease;
KIRP	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg27205649	chr11:78285834	NARS2	0.83	11.86	0.6	5.93e-26	Alzheimer's disease (survival time);
KIRP	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.96	12.64	0.63	1.47e-28	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.46	0.43	1.45e-12	Systolic blood pressure;
KIRP	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.57	8.12	0.46	2.31e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.14	-0.31	5.48e-7	Autism;
KIRP	cis	rs6959887	0.821	rs17674869	chr7:35275707	A/G	cg06685737	chr7:35301730	NA	0.44	6.31	0.37	1.27e-9	Birth weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08812242	chr19:14606902	GIPC1	0.53	6.63	0.39	2.1e-10	Parkinson's disease;
KIRP	cis	rs9357620	1.000	rs9463511	chr6:13178259	G/A	cg02220008	chr6:13192742	PHACTR1	0.26	5.11	0.31	6.46e-7	Chronotype;Morning vs. evening chronotype;
KIRP	trans	rs12517041	1.000	rs16892388	chr5:23306240	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs4748857	0.947	rs12413144	chr10:23575249	G/C	cg12804278	chr10:23633326	C10orf67	0.43	5.39	0.32	1.68e-7	Systemic lupus erythematosus;
KIRP	cis	rs7624766	0.555	rs2049215	chr3:160512424	C/A	cg22637730	chr3:160473554	PPM1L	0.44	5.53	0.33	8.07e-8	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.47	6.48	0.38	4.94e-10	Testicular germ cell tumor;
KIRP	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.52	5.55	0.33	7.42e-8	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.81	0.63	3.94e-29	Morning vs. evening chronotype;
KIRP	cis	rs7246657	0.765	rs4803262	chr19:38066760	G/A	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg24209194	chr3:40518798	ZNF619	0.42	5.29	0.32	2.73e-7	Renal cell carcinoma;
KIRP	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg02072170	chr3:194406190	FAM43A	0.4	6.07	0.36	4.76e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg01025720	chr13:113346439	ATP11A	0.52	5.02	0.31	9.76e-7	Glycated hemoglobin levels;
KIRP	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg05785598	chr3:49045655	WDR6	0.28	4.91	0.3	1.65e-6	Parkinson's disease;
KIRP	cis	rs2281603	0.570	rs10143839	chr14:64953591	C/T	cg01860774	chr14:64969374	ZBTB25	0.33	5.4	0.33	1.58e-7	Lymphocyte counts;
KIRP	cis	rs2000999	0.691	rs11648003	chr16:72052348	A/G	cg01557791	chr16:72042693	DHODH	-0.57	-5.44	-0.33	1.28e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg01403660	chr11:68851641	TPCN2	0.67	6.4	0.38	7.86e-10	Blond vs. brown hair color;
KIRP	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.57	7.83	0.45	1.47e-13	Night sleep phenotypes;
KIRP	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.62	-7.33	-0.42	3.29e-12	Body mass index;
KIRP	cis	rs10210302	0.502	rs880116	chr2:234246264	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.48	5.99	0.36	7.46e-9	Crohn's disease;
KIRP	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.86	8.72	0.49	4.21e-16	Eosinophil percentage of granulocytes;
KIRP	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.37	-0.78	2.11e-51	Height;
KIRP	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs240764	0.817	rs239245	chr6:101090377	C/A	cg09795085	chr6:101329169	ASCC3	0.47	5.7	0.34	3.51e-8	Neuroticism;
KIRP	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg17133734	chr15:86042851	AKAP13	-0.47	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.83	10.42	0.55	2.79e-21	Lymphocyte percentage of white cells;
KIRP	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-10.57	-0.56	9.29e-22	Alzheimer's disease;
KIRP	trans	rs877282	0.628	rs11253435	chr10:824169	T/C	cg22713356	chr15:30763199	NA	0.86	8.39	0.47	3.9e-15	Uric acid levels;
KIRP	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg22604316	chr1:46958801	NA	0.47	6.7	0.39	1.43e-10	Monobrow;
KIRP	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-6.18	-0.37	2.67e-9	Morning vs. evening chronotype;
KIRP	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.58	7.89	0.45	9.9e-14	Prostate cancer;
KIRP	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.66	6.87	0.4	5.24e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs575018	0.836	rs10062319	chr5:100586946	A/G	cg03848127	chr5:100126093	NA	0.42	5.04	0.31	8.99e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.59	-6.73	-0.39	1.18e-10	Hypospadias;
KIRP	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.96	0.41	3.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1978968	1.000	rs1079576	chr22:18446318	C/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.78	-0.4	8.73e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg00262122	chr8:11665843	FDFT1	-0.43	-5.42	-0.33	1.41e-7	Triglycerides;
KIRP	cis	rs838147	0.844	rs12611201	chr19:49248255	G/A	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.3e-7	Dietary macronutrient intake;
KIRP	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.41	-5.81	-0.35	1.9e-8	Endometrial cancer;
KIRP	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.43	-5.25	-0.32	3.33e-7	Iron status biomarkers;
KIRP	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.57	-7.74	-0.44	2.55e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.55	-5.0	-0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.51	-6.4	-0.38	7.92e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.93	-12.71	-0.63	8.81e-29	Cognitive function;
KIRP	trans	rs9409565	0.826	rs9409556	chr9:97239268	T/C	cg05679027	chr9:99775184	HIATL2	-0.54	-6.39	-0.38	8.15e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs9398803	0.965	rs6919397	chr6:126659043	A/C	cg19875578	chr6:126661172	C6orf173	0.44	5.86	0.35	1.46e-8	Male-pattern baldness;
KIRP	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	8.97	0.5	7.69e-17	Bipolar disorder;
KIRP	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg03060546	chr3:49711283	APEH	-0.64	-6.03	-0.36	5.86e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.58	7.77	0.44	2.1e-13	Blood protein levels;
KIRP	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-4.89	-0.3	1.82e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg04374321	chr14:90722782	PSMC1	-0.55	-6.72	-0.39	1.29e-10	Longevity;
KIRP	cis	rs662064	0.962	rs648399	chr1:10556485	T/C	cg07384165	chr1:10488281	NA	-0.42	-5.22	-0.32	3.79e-7	Asthma;
KIRP	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg02725872	chr8:58115012	NA	-0.52	-5.94	-0.35	9.7e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2820315	1.000	rs2820315	chr1:201872264	A/G	cg11586189	chr1:201857591	SHISA4	0.4	5.35	0.32	1.97e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.42	0.33	1.39e-7	Neutrophil percentage of white cells;
KIRP	trans	rs13413635	0.520	rs62183009	chr2:178594509	T/C	cg00935653	chr7:25897725	NA	-0.6	-6.08	-0.36	4.5e-9	Heart rate;
KIRP	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.91	-0.45	8.48e-14	Neuroticism;
KIRP	cis	rs830383	0.545	rs31765	chr5:165501073	G/A	cg13976338	chr5:165423657	NA	0.49	5.85	0.35	1.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12016809	chr21:47604291	C21orf56	0.4	5.46	0.33	1.14e-7	Testicular germ cell tumor;
KIRP	cis	rs7572644	0.640	rs11901133	chr2:28069713	T/G	cg27432699	chr2:27873401	GPN1	0.48	5.78	0.35	2.26e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg21427119	chr20:30132790	HM13	-0.42	-5.01	-0.3	1.03e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs2219968	1.000	rs59541962	chr8:78964111	G/C	cg00738934	chr8:78996279	NA	0.4	5.09	0.31	7.28e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.71	5.57	0.33	6.77e-8	Body mass index;
KIRP	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg10017260	chr10:834428	NA	-0.49	-5.09	-0.31	7.04e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs2904967	0.866	rs526502	chr11:65026590	T/C	cg09225861	chr11:65069680	NA	-0.43	-5.62	-0.34	5.1e-8	Mean corpuscular volume;
KIRP	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.97	0.3	1.25e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.72	-0.34	3.03e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12615966	0.651	rs72830471	chr2:105407062	A/C	cg16465502	chr2:105461796	NA	0.95	7.92	0.45	8.2e-14	Pancreatic cancer;
KIRP	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.03	-0.31	9.63e-7	Inflammatory skin disease;
KIRP	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	cg21523751	chr1:182988639	NA	0.41	6.47	0.38	5.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.45e-8	Schizophrenia;
KIRP	cis	rs798766	1.000	rs798741	chr4:1712413	A/G	cg07775547	chr4:1625484	NA	-0.43	-5.6	-0.34	5.76e-8	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg24375607	chr4:120327624	NA	0.48	5.37	0.32	1.79e-7	Corneal astigmatism;
KIRP	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg06795125	chr2:108905320	SULT1C2	-0.39	-6.88	-0.4	4.83e-11	Blood pressure;
KIRP	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18357526	chr6:26021779	HIST1H4A	0.9	11.07	0.58	2.26e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg01065977	chr19:18549689	ISYNA1	-0.42	-6.4	-0.38	7.94e-10	Breast cancer;
KIRP	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-0.87	-11.18	-0.58	9.57e-24	Vitiligo;
KIRP	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.88	12.94	0.64	1.52e-29	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs859767	0.501	rs10928507	chr2:135396631	C/T	cg12500956	chr2:135428796	TMEM163	0.41	5.74	0.34	2.82e-8	Neuroticism;
KIRP	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.59	-0.48	1.03e-15	Retinal vascular caliber;
KIRP	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.96	8.3	0.47	6.98e-15	Eosinophilic esophagitis;
KIRP	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg01988459	chr11:68622903	NA	-0.35	-4.84	-0.3	2.26e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg23752985	chr2:85803571	VAMP8	0.62	9.25	0.51	1.13e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg03929089	chr4:120376271	NA	0.67	6.51	0.38	4.18e-10	Axial length;
KIRP	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	9.64	0.52	7.31e-19	Lung cancer in ever smokers;
KIRP	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg05805236	chr11:65401703	PCNXL3	-0.47	-6.14	-0.36	3.21e-9	Acne (severe);
KIRP	cis	rs66561647	0.719	rs3739380	chr8:128944507	G/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.53	6.44	0.38	6.26e-10	Hemoglobin concentration;
KIRP	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.61	-8.91	-0.49	1.13e-16	Testicular germ cell tumor;
KIRP	cis	rs4234798	0.527	rs4689668	chr4:7249378	T/A	cg18431297	chr4:7219810	SORCS2	0.42	4.97	0.3	1.28e-6	Insulin-like growth factors;
KIRP	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg05621596	chr22:47072043	GRAMD4	-0.55	-7.84	-0.45	1.32e-13	Urate levels in obese individuals;
KIRP	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.4	0.33	1.57e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.71	8.98	0.5	7.23e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg01114163	chr5:1856713	NA	-0.44	-5.37	-0.32	1.81e-7	Cardiovascular disease risk factors;
KIRP	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg08999081	chr20:33150536	PIGU	0.44	5.84	0.35	1.63e-8	Height;
KIRP	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg17264618	chr3:40429014	ENTPD3	0.31	4.9	0.3	1.78e-6	Renal cell carcinoma;
KIRP	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg06634786	chr22:41940651	POLR3H	-0.47	-5.15	-0.31	5.26e-7	Neuroticism;
KIRP	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg01631408	chr1:248437212	OR2T33	0.56	7.2	0.42	7.5e-12	Common traits (Other);
KIRP	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.7	9.31	0.51	7.17e-18	Lung cancer;
KIRP	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.68	8.29	0.47	7.57e-15	Type 2 diabetes;
KIRP	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.31	-5.08	-0.31	7.56e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11877825	0.826	rs4121954	chr18:10569713	T/C	cg25239095	chr18:10589360	NA	0.39	4.85	0.3	2.19e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs11169552	0.510	rs11169515	chr12:51053515	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-5.08	-0.31	7.6e-7	Colorectal cancer;
KIRP	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.78	0.49	2.74e-16	Motion sickness;
KIRP	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.84	-10.63	-0.56	5.71e-22	Height;
KIRP	cis	rs2562456	0.793	rs57299552	chr19:21504128	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.98	-10.13	-0.54	2.17e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.85	13.34	0.65	6.39e-31	Breast cancer;
KIRP	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.23	-0.32	3.69e-7	Pulmonary function;
KIRP	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.53	7.2	0.42	7.5e-12	Schizophrenia;
KIRP	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg09915433	chr19:53449742	NA	-0.45	-7.01	-0.41	2.31e-11	Psoriasis;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17027945	chr15:74284732	STOML1	0.46	6.11	0.36	3.89e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs16828019	0.777	rs2300658	chr1:41505022	G/A	cg18742814	chr1:41828276	NA	0.69	5.87	0.35	1.37e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6256	0.932	rs76107484	chr11:13511832	C/T	cg11976911	chr11:13509032	NA	-0.6	-5.02	-0.3	1.01e-6	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.68	5.91	0.35	1.14e-8	Cognitive function;
KIRP	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.45	9.27	0.51	9.61e-18	Ewing sarcoma;
KIRP	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg04117972	chr1:227635322	NA	0.66	5.12	0.31	6.18e-7	Major depressive disorder;
KIRP	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.7	-8.79	-0.49	2.68e-16	Migraine;Coronary artery disease;
KIRP	cis	rs950881	0.667	rs72825916	chr2:103070982	C/T	cg22835712	chr2:102737379	NA	0.42	4.86	0.3	2.07e-6	Allergy;
KIRP	cis	rs877426	0.667	rs9525231	chr13:114829711	G/A	cg25338242	chr13:114786047	RASA3	0.46	4.85	0.3	2.18e-6	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs4660306	0.677	rs1006215	chr1:45909945	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	6.23	0.37	2.02e-9	Homocysteine levels;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg09699651	chr6:150184138	LRP11	0.47	6.33	0.37	1.13e-9	Lung cancer;
KIRP	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Bipolar disorder;
KIRP	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.83	9.0	0.5	6.42e-17	Alzheimer's disease;
KIRP	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.66	9.67	0.52	5.82e-19	Dupuytren's disease;
KIRP	cis	rs1215050	0.743	rs6532692	chr4:98648005	C/A	cg05340658	chr4:99064831	C4orf37	-0.44	-5.11	-0.31	6.37e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg11271282	chr2:238384023	NA	0.5	5.76	0.34	2.48e-8	Prostate cancer;
KIRP	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg11965913	chr1:205819406	PM20D1	-0.61	-6.03	-0.36	6.02e-9	Menarche (age at onset);
KIRP	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.96	15.39	0.7	7.03e-38	Uric acid clearance;
KIRP	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	cg04338863	chr8:33670619	NA	0.41	5.33	0.32	2.22e-7	Body mass index;
KIRP	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg07596299	chr11:71824057	C11orf51	-0.85	-5.75	-0.34	2.66e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs4792901	0.808	rs10853083	chr17:41636340	C/T	cg03184776	chr17:41522069	MIR2117	-0.45	-4.89	-0.3	1.84e-6	Dupuytren's disease;
KIRP	cis	rs4237845	0.591	rs11172389	chr12:58337671	G/A	cg00677455	chr12:58241039	CTDSP2	0.71	7.83	0.45	1.49e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.69	-9.11	-0.5	2.94e-17	Huntington's disease progression;
KIRP	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg00149659	chr3:10157352	C3orf10	0.61	7.17	0.42	8.55e-12	Alzheimer's disease;
KIRP	trans	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg10756647	chr7:56101905	PSPH	0.92	6.91	0.4	4.15e-11	Diabetic kidney disease;
KIRP	cis	rs2371030	1.000	rs12473296	chr2:211583281	A/C	cg18417063	chr2:211583084	NA	-0.51	-7.3	-0.42	3.97e-12	Non-small cell lung cancer;
KIRP	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg08992911	chr2:238395768	MLPH	0.4	5.03	0.31	9.26e-7	Prostate cancer;
KIRP	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.56	0.43	7.84e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.45	-5.14	-0.31	5.47e-7	Neuroticism;
KIRP	cis	rs4851254	0.961	rs13011181	chr2:100732446	T/C	cg17356467	chr2:100759845	AFF3	0.58	6.91	0.4	4.05e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg04490037	chr7:50633773	DDC	-0.4	-4.95	-0.3	1.39e-6	Malaria;
KIRP	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.67	9.17	0.5	1.9e-17	Systemic lupus erythematosus;
KIRP	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	1.0	17.37	0.74	1.24e-44	Breast cancer;
KIRP	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.94	-0.4	3.46e-11	Acne (severe);
KIRP	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21643547	chr1:205240462	TMCC2	0.72	10.91	0.57	7.44e-23	Red blood cell count;
KIRP	cis	rs7551222	0.646	rs4951384	chr1:204452514	A/T	cg20240347	chr1:204465584	NA	-0.41	-7.33	-0.42	3.3e-12	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	6.84	0.4	6.27e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.65	-7.92	-0.45	8.45e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7116495	1.000	rs607446	chr11:71789252	G/A	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs1943345	0.556	rs506503	chr11:82923362	A/T	cg07047830	chr11:82868014	PCF11	0.45	5.18	0.31	4.65e-7	Obesity-related traits;
KIRP	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.15	15.92	0.71	1.07e-39	Lymphocyte percentage of white cells;
KIRP	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	5.64	0.34	4.62e-8	Platelet count;
KIRP	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	6.46	0.38	5.43e-10	Response to antipsychotic treatment;
KIRP	cis	rs2033732	0.954	rs1550215	chr8:85093121	A/C	cg05716166	chr8:85095498	RALYL	0.58	6.18	0.37	2.7e-9	Body mass index;
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.65	9.14	0.5	2.42e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2172802	0.599	rs11131341	chr4:62547726	A/G	cg04118610	chr4:62707027	LPHN3	-0.43	-5.3	-0.32	2.53e-7	Partial epilepsies;
KIRP	cis	rs10875746	0.903	rs61918774	chr12:48448134	C/G	cg26205652	chr12:48591994	NA	0.77	10.29	0.55	6.69e-21	Longevity (90 years and older);
KIRP	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg23920097	chr1:209922102	NA	-0.43	-5.67	-0.34	3.93e-8	Red blood cell count;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20916646	chr4:852691	GAK	0.41	5.05	0.31	8.76e-7	Sjögren's syndrome;
KIRP	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg25828334	chr19:18545568	ISYNA1	-0.32	-4.9	-0.3	1.78e-6	Breast cancer;
KIRP	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg18461458	chr19:21324796	ZNF431	0.47	4.88	0.3	1.94e-6	Pain;
KIRP	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.52	7.07	0.41	1.58e-11	Height;
KIRP	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.81	0.49	2.29e-16	Prudent dietary pattern;
KIRP	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg22800045	chr5:56110881	MAP3K1	0.73	7.84	0.45	1.41e-13	Initial pursuit acceleration;
KIRP	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.47	-0.43	1.35e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.12	-0.54	2.34e-20	Hemoglobin concentration;
KIRP	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg24009623	chr19:33667908	NA	-0.5	-6.21	-0.37	2.21e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09959495	chr2:237029385	AGAP1	1.02	6.12	0.36	3.65e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs13014235	0.532	rs6729982	chr2:202281136	A/G	cg06431681	chr2:202330990	STRADB	0.35	4.87	0.3	2.02e-6	Basal cell carcinoma;
KIRP	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg18944383	chr4:111397179	ENPEP	0.74	14.52	0.68	6.19e-35	Height;
KIRP	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.58	9.38	0.51	4.62e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg07382826	chr16:28625726	SULT1A1	0.48	5.35	0.32	2.06e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2300206	1	rs2300206	chr20:32589808	G/C	cg08999081	chr20:33150536	PIGU	0.48	5.77	0.35	2.4e-8	Cancer;Cancer (pleiotropy);
KIRP	cis	rs10899021	0.512	rs2186955	chr11:74375475	C/T	cg25880958	chr11:74394337	NA	0.52	5.92	0.35	1.08e-8	Response to metformin (IC50);
KIRP	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg16497661	chr14:103986332	CKB	-0.53	-7.04	-0.41	1.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	1.12	8.23	0.46	1.13e-14	Skin colour saturation;
KIRP	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg02660097	chr11:68866761	NA	0.4	4.97	0.3	1.26e-6	Blond vs. brown hair color;
KIRP	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.73	10.29	0.55	6.76e-21	Diastolic blood pressure;
KIRP	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.67	-8.13	-0.46	2.1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.91	15.75	0.71	3.99e-39	Headache;
KIRP	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-6.33	-0.37	1.17e-9	Aortic root size;
KIRP	cis	rs45535039	1.000	rs2155380	chr11:119080037	A/G	cg16724696	chr11:118992527	HINFP	0.4	4.89	0.3	1.84e-6	Plateletcrit;
KIRP	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg10253484	chr15:75165896	SCAMP2	-0.46	-5.6	-0.34	5.64e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.79	11.76	0.6	1.28e-25	Blood metabolite ratios;
KIRP	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.62	7.28	0.42	4.49e-12	Corneal astigmatism;
KIRP	cis	rs7714584	1.000	rs58717741	chr5:150284936	A/G	cg22134413	chr5:150180641	NA	0.79	6.75	0.4	1.08e-10	Crohn's disease;
KIRP	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.81	0.45	1.66e-13	Corneal astigmatism;
KIRP	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg19592336	chr6:28129416	ZNF389	0.51	5.85	0.35	1.53e-8	Depression;
KIRP	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.54	-6.56	-0.39	3.23e-10	Smoking behavior;
KIRP	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00889227	chr1:205173544	DSTYK	-0.39	-5.42	-0.33	1.44e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07234876	chr8:600039	NA	1.02	7.46	0.43	1.5e-12	IgG glycosylation;
KIRP	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg00745463	chr17:30367425	LRRC37B	-0.66	-6.57	-0.39	2.96e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.36	-0.62	1.24e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9506514	0.722	rs11147813	chr13:21258558	T/C	cg04906043	chr13:21280425	IL17D	-0.39	-4.99	-0.3	1.16e-6	Coronary artery calcification;
KIRP	cis	rs12431939	0.762	rs60294020	chr14:51704821	C/A	cg23942311	chr14:51606299	NA	-0.59	-5.77	-0.35	2.37e-8	Cancer;
KIRP	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg00262122	chr8:11665843	FDFT1	0.44	5.37	0.32	1.85e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1823913	0.614	rs7565987	chr2:192166541	G/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.75	11.36	0.59	2.5e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.45	6.51	0.38	4.13e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs3789045	1.000	rs3789045	chr1:204586812	C/T	cg08641003	chr1:204589008	LRRN2	-0.59	-6.15	-0.37	3.1e-9	Educational attainment (college completion);
KIRP	cis	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs4132509	0.895	rs12045787	chr1:244011843	T/A	cg21452805	chr1:244014465	NA	0.57	5.31	0.32	2.43e-7	RR interval (heart rate);
KIRP	cis	rs17221829	0.733	rs1873083	chr11:89396810	G/A	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.44	-0.33	1.31e-7	Anxiety in major depressive disorder;
KIRP	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.62	5.25	0.32	3.22e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15781525	chr6:564561	EXOC2	0.48	6.25	0.37	1.81e-9	Interleukin-4 levels;
KIRP	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.66	-7.46	-0.43	1.52e-12	Blood pressure (smoking interaction);
KIRP	cis	rs7870753	0.578	rs10820378	chr9:99092749	C/T	cg25260653	chr9:99212216	HABP4	-0.53	-5.07	-0.31	7.67e-7	Height;
KIRP	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-7.82	-0.45	1.53e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg10491242	chr19:50366052	PNKP	-0.47	-6.41	-0.38	7.41e-10	Bladder cancer;
KIRP	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.9	0.45	9.11e-14	Coffee consumption (cups per day);
KIRP	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18252515	chr7:66147081	NA	-0.4	-5.11	-0.31	6.41e-7	Aortic root size;
KIRP	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.53	-7.4	-0.43	2.13e-12	Hematocrit;
KIRP	cis	rs311392	0.902	rs423150	chr8:55092804	C/T	cg11783602	chr8:55087084	NA	-0.57	-7.07	-0.41	1.61e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.44	4.04e-13	Bladder cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12738264	chr7:148725795	PDIA4	0.64	7.68	0.44	3.75e-13	Smoking initiation;
KIRP	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16473166	chr22:50639996	SELO	0.68	9.55	0.52	1.36e-18	Obesity-related traits;
KIRP	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	8.07	0.46	3.08e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg02367723	chr1:46378857	MAST2	-0.43	-4.95	-0.3	1.37e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.92	-14.49	-0.68	8.35e-35	Body mass index;
KIRP	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.75	0.6	1.34e-25	Heart rate;
KIRP	cis	rs9311676	0.656	rs4339119	chr3:58389462	A/G	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-6.05	-0.36	5.27e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8062405	0.728	rs11642449	chr16:28896015	C/T	cg07382826	chr16:28625726	SULT1A1	0.45	5.0	0.3	1.09e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7221595	0.825	rs8069643	chr17:3971237	C/T	cg21734707	chr17:3908241	ZZEF1	0.55	5.57	0.33	6.51e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg08992911	chr2:238395768	MLPH	0.56	5.23	0.32	3.66e-7	Prostate cancer;
KIRP	cis	rs3791406	0.500	rs3791414	chr2:240032214	T/C	cg14550559	chr2:240039617	HDAC4	-0.87	-9.3	-0.51	7.93e-18	Skin aging (microtopography measurement);
KIRP	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg01620082	chr3:125678407	NA	-1.18	-7.63	-0.44	5.19e-13	Depression;
KIRP	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.49	-6.71	-0.39	1.34e-10	Dilated cardiomyopathy;
KIRP	cis	rs710987	1.000	rs710988	chr5:3524904	A/C	cg14530963	chr5:3489551	NA	0.41	5.04	0.31	8.92e-7	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.35	0.32	2.03e-7	Rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14866064	chr18:29672736	RNF138	0.48	6.46	0.38	5.42e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs520865	0.843	rs580334	chr5:80332557	G/A	cg17330048	chr5:80257322	RASGRF2	-0.42	-6.21	-0.37	2.24e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9400271	0.632	rs9398191	chr6:109586561	C/T	cg21918786	chr6:109611834	NA	-0.38	-5.6	-0.34	5.6e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg23216685	chr1:86174607	ZNHIT6	-0.6	-8.58	-0.48	1.07e-15	Urate levels in overweight individuals;
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg15117754	chr3:10150083	C3orf24	0.52	5.04	0.31	8.95e-7	Alzheimer's disease;
KIRP	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.24	23.73	0.83	1.51e-65	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03374922	chr13:111267935	CARKD	0.47	6.06	0.36	5.13e-9	Parkinson's disease;
KIRP	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.66	7.64	0.44	4.9e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg00784671	chr22:46762841	CELSR1	-0.67	-8.5	-0.48	1.81e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.21	-0.32	4.08e-7	Colorectal cancer;
KIRP	cis	rs4663866	1.000	rs13033501	chr2:239181860	G/A	cg17283117	chr2:239148619	HES6	0.68	4.96	0.3	1.3e-6	Irritable bowel syndrome;
KIRP	cis	rs986417	0.748	rs12436632	chr14:61034416	T/C	cg27398547	chr14:60952738	C14orf39	0.58	5.85	0.35	1.53e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.51	-0.33	9.23e-8	Pulmonary function;
KIRP	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg00647317	chr7:50633725	DDC	0.42	6.35	0.38	1.04e-9	Body mass index;
KIRP	cis	rs2562456	0.793	rs73537884	chr19:21504710	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-5.04	-0.31	8.96e-7	Pain;
KIRP	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg10253484	chr15:75165896	SCAMP2	0.67	7.28	0.42	4.49e-12	Systemic lupus erythematosus;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02071553	chr2:56229060	MIR216B	-0.39	-6.27	-0.37	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg21605333	chr4:119757512	SEC24D	1.38	10.21	0.55	1.28e-20	Cannabis dependence symptom count;
KIRP	trans	rs9371601	0.780	rs551681	chr6:152718362	G/T	cg05529123	chr2:66910386	NA	-0.46	-6.2	-0.37	2.37e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg08313168	chr12:7315531	NA	0.69	6.29	0.37	1.48e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9875589	0.533	rs12490233	chr3:13977365	G/A	cg19554555	chr3:13937349	NA	-0.46	-6.36	-0.38	9.5e-10	Ovarian reserve;
KIRP	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	9.78	0.53	2.77e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg21064579	chr19:49206444	FUT2	0.59	8.84	0.49	1.86e-16	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs7130144	0.541	rs60284315	chr11:130467096	A/C	cg26307797	chr11:130446613	NA	-0.65	-5.31	-0.32	2.5e-7	Urate levels in lean individuals;
KIRP	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.45	-0.38	5.84e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6594713	0.819	rs10061462	chr5:112726205	A/T	cg12552261	chr5:112820674	MCC	0.51	5.13	0.31	5.99e-7	Brain cytoarchitecture;
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.17	-0.37	2.84e-9	Lung cancer;
KIRP	cis	rs212524	0.807	rs212540	chr1:21593117	A/G	cg21184320	chr1:21044207	KIF17	-0.39	-5.31	-0.32	2.46e-7	Height;
KIRP	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	11.67	0.6	2.51e-25	Smoking behavior;
KIRP	cis	rs11574514	1.000	rs8054034	chr16:67773652	C/A	cg26727032	chr16:67993705	SLC12A4	-0.69	-5.75	-0.34	2.63e-8	Crohn's disease;
KIRP	cis	rs13394619	0.533	rs12615856	chr2:11746177	C/T	cg07314298	chr2:11723111	GREB1	0.49	6.56	0.39	3.06e-10	Endometriosis;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.17	21.71	0.81	4.39e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg25251562	chr2:3704773	ALLC	-0.51	-6.02	-0.36	6.27e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.83	-0.35	1.74e-8	Type 2 diabetes;
KIRP	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.94	13.88	0.66	9.53e-33	Blood protein levels;
KIRP	trans	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.38	-0.38	8.64e-10	Neuroticism;
KIRP	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.56	7.09	0.41	1.39e-11	Eye color traits;
KIRP	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg05340658	chr4:99064831	C4orf37	0.67	8.15	0.46	1.86e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-6.98	-0.41	2.67e-11	Systemic lupus erythematosus;
KIRP	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.96	16.24	0.72	8.53e-41	Breast cancer;
KIRP	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg13264159	chr8:625131	ERICH1	-0.89	-7.31	-0.42	3.73e-12	IgG glycosylation;
KIRP	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.16	-21.62	-0.81	8.21e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.69	8.55	0.48	1.32e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg14458575	chr2:238380390	NA	0.48	5.44	0.33	1.27e-7	Prostate cancer;
KIRP	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3764563	1.000	rs4371280	chr19:15715768	A/C	cg20725493	chr19:15740067	CYP4F8	-0.88	-5.89	-0.35	1.28e-8	Inflammatory biomarkers;
KIRP	cis	rs6484504	0.576	rs58702363	chr11:31246397	C/A	cg26647111	chr11:31128758	NA	-0.43	-5.09	-0.31	7.25e-7	Red blood cell count;
KIRP	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.46	-9.36	-0.51	5.25e-18	Rheumatoid arthritis;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20814179	chr4:940893	TMEM175	0.53	6.14	0.36	3.36e-9	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-1.13	-21.08	-0.8	4.6e-57	Monocyte count;
KIRP	cis	rs754466	0.561	rs11002343	chr10:79705871	G/A	cg17075019	chr10:79541650	NA	-0.73	-5.78	-0.35	2.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg00405596	chr8:11794950	NA	-0.5	-6.55	-0.39	3.41e-10	Triglycerides;
KIRP	cis	rs35123781	1.000	rs34510678	chr5:139064835	C/T	cg10513866	chr5:139070639	NA	0.35	4.93	0.3	1.48e-6	Schizophrenia;
KIRP	cis	rs13385	0.769	rs13175751	chr5:139601097	C/G	cg01860693	chr5:139557145	C5orf32	0.48	5.25	0.32	3.33e-7	Atrial fibrillation;
KIRP	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg04733989	chr22:42467013	NAGA	0.56	7.72	0.44	2.89e-13	Cognitive function;
KIRP	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg16111737	chr12:117408163	FBXW8	-0.53	-5.05	-0.31	8.53e-7	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs6539267	0.885	rs12579099	chr12:106765727	A/G	cg00173435	chr12:106696525	TCP11L2	0.56	5.58	0.34	6.41e-8	Tourette syndrome;
KIRP	cis	rs72949976	0.707	rs62186571	chr2:214038673	C/G	cg08319019	chr2:214017104	IKZF2	-0.52	-5.47	-0.33	1.13e-7	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg20701182	chr2:24300061	SF3B14	0.6	5.19	0.31	4.36e-7	Lymphocyte counts;
KIRP	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.76	-5.47	-0.33	1.09e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.28	-0.32	2.86e-7	Coronary artery disease;
KIRP	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	0.95	12.11	0.61	8.61e-27	Blood protein levels;
KIRP	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg15269541	chr15:43626905	ADAL	0.41	4.96	0.3	1.31e-6	Lung cancer in ever smokers;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02197279	chr6:157955288	ZDHHC14	0.42	6.37	0.38	9.18e-10	Serum protein levels (sST2);
KIRP	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg05709478	chr1:6581295	PLEKHG5	-0.57	-5.31	-0.32	2.47e-7	Body mass index;
KIRP	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.05	-0.36	5.48e-9	Morning vs. evening chronotype;
KIRP	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg13319975	chr6:146136371	FBXO30	-0.37	-4.93	-0.3	1.52e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7178572	0.889	rs869301	chr15:77830633	T/C	cg22256960	chr15:77711686	NA	-0.42	-5.13	-0.31	5.79e-7	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.41	-5.33	-0.32	2.26e-7	Renal cell carcinoma;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.49	5.74	0.34	2.71e-8	Mean platelet volume;
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg16341495	chr8:142228727	SLC45A4	0.4	5.1	0.31	6.9e-7	Immature fraction of reticulocytes;
KIRP	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-1.1	-20.03	-0.79	1.37e-53	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26745394	chr17:42856616	ADAM11	0.62	8.09	0.46	2.79e-14	Parkinson's disease;
KIRP	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-0.97	-15.69	-0.71	6.38e-39	Height;
KIRP	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg09873164	chr1:152488093	CRCT1	0.5	6.4	0.38	7.95e-10	Hair morphology;
KIRP	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.68	10.02	0.54	4.85e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.41	7.02	0.41	2.1e-11	Heart rate;
KIRP	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	5.96	0.36	8.57e-9	Putamen volume;
KIRP	cis	rs8014252	0.803	rs8006487	chr14:71011934	G/A	cg19730268	chr14:71022823	NA	-0.57	-5.48	-0.33	1.04e-7	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg02574844	chr11:5959923	NA	-0.61	-6.61	-0.39	2.37e-10	DNA methylation (variation);
KIRP	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs10463316	0.862	rs1983171	chr5:150778691	A/G	cg03212797	chr5:150827313	SLC36A1	-0.56	-7.4	-0.43	2.15e-12	Metabolite levels (Pyroglutamine);
KIRP	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.91	9.92	0.53	9.89e-20	Corneal astigmatism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24815885	chr19:36486437	SDHAF1	0.58	6.84	0.4	6.11e-11	Myopia (pathological);
KIRP	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06850241	chr22:41845214	NA	0.44	4.97	0.3	1.23e-6	Vitiligo;
KIRP	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	0.98	11.06	0.58	2.42e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs400736	0.729	rs9434949	chr1:8006083	C/G	cg25007680	chr1:8021821	PARK7	-0.56	-7.24	-0.42	5.82e-12	Response to antidepressants and depression;
KIRP	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.31	-6.91	-0.4	4.19e-11	Cutaneous nevi;
KIRP	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.96	13.51	0.65	1.81e-31	Cognitive function;
KIRP	cis	rs9469913	0.740	rs2814973	chr6:34569720	C/T	cg17674042	chr6:34482479	PACSIN1	-0.5	-6.49	-0.38	4.76e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg22903471	chr2:27725779	GCKR	-0.51	-7.31	-0.42	3.84e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs7221595	0.877	rs7219437	chr17:4050138	A/G	cg11204139	chr17:3907470	NA	0.46	5.45	0.33	1.21e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs3736485	0.578	rs4775968	chr15:51980821	A/G	cg14296394	chr15:51910925	DMXL2	0.34	4.88	0.3	1.88e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7209700	0.889	rs11079769	chr17:45349731	A/T	cg25173405	chr17:45401733	C17orf57	0.41	5.25	0.32	3.34e-7	IgG glycosylation;
KIRP	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.94	12.83	0.63	3.38e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs2904967	0.929	rs2904980	chr11:65001679	C/T	cg12562828	chr11:65076843	NA	-0.38	-5.25	-0.32	3.28e-7	Mean corpuscular volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06452464	chr10:67575504	NA	-0.42	-6.81	-0.4	7.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	trans	rs2504916	0.779	rs2457548	chr6:160898641	A/G	cg25840608	chr15:71149242	NA	-0.32	-6.35	-0.38	1.03e-9	Response to hepatitis C treatment;
KIRP	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg02811702	chr13:24901961	NA	0.42	5.51	0.33	9.11e-8	Obesity-related traits;
KIRP	cis	rs62070183	0.752	rs17781005	chr17:31132529	T/C	cg05781649	chr17:31146240	MYO1D	-0.51	-5.13	-0.31	5.78e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.68	-0.44	3.87e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg25486957	chr4:152246857	NA	-0.42	-5.07	-0.31	7.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.7	-0.39	1.4e-10	Blood pressure;
KIRP	cis	rs78579285	0.584	rs9922996	chr16:88800670	G/C	cg09054528	chr16:88821542	FAM38A	-0.65	-5.38	-0.32	1.77e-7	Joint mobility (Beighton score);
KIRP	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26378065	chr17:18585709	ZNF286B	0.5	6.49	0.38	4.61e-10	Educational attainment (years of education);
KIRP	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.5	-6.48	-0.38	5.09e-10	Blood metabolite levels;
KIRP	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.08	-0.46	3e-14	Aortic root size;
KIRP	cis	rs5753037	0.869	rs6006300	chr22:30302153	G/A	cg27665648	chr22:30112403	NA	0.39	5.48	0.33	1.04e-7	Type 1 diabetes;
KIRP	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11987759	chr7:65425863	GUSB	-0.54	-7.16	-0.42	9.46e-12	Aortic root size;
KIRP	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	9.43	0.52	3.27e-18	Hip circumference;
KIRP	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.41	-0.38	7.49e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs61884328	0.777	rs17790336	chr11:47127549	G/T	cg23433285	chr11:47201945	PACSIN3	0.62	5.16	0.31	5e-7	Total body bone mineral density (age over 60);
KIRP	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg08975724	chr8:8085496	FLJ10661	0.52	6.95	0.41	3.31e-11	Retinal vascular caliber;
KIRP	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg13047869	chr3:10149882	C3orf24	0.61	5.18	0.31	4.61e-7	Alzheimer's disease;
KIRP	cis	rs7923609	0.967	rs7909269	chr10:65177766	G/A	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg06815112	chr8:27182871	PTK2B	0.52	6.74	0.39	1.11e-10	Neuroticism;
KIRP	trans	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg21775007	chr8:11205619	TDH	0.48	6.13	0.36	3.5e-9	Mood instability;
KIRP	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	0.83	6.15	0.37	3.11e-9	IgG glycosylation;
KIRP	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg23594656	chr7:65796392	TPST1	-0.45	-7.11	-0.41	1.28e-11	Aortic root size;
KIRP	cis	rs5746492	0.515	rs9604802	chr22:18398018	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.41	-5.66	-0.34	4.3e-8	Eotaxin levels;
KIRP	cis	rs934734	0.563	rs955903	chr2:65575553	A/G	cg08085232	chr2:65598271	SPRED2	-0.56	-7.07	-0.41	1.59e-11	Rheumatoid arthritis;
KIRP	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg22437258	chr11:111473054	SIK2	0.48	5.8	0.35	1.99e-8	Primary sclerosing cholangitis;
KIRP	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21545522	chr1:205238299	TMCC2	0.55	7.31	0.42	3.76e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs909341	0.859	rs2258056	chr20:62328453	T/C	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.42	-0.43	1.91e-12	Atopic dermatitis;
KIRP	cis	rs193541	0.632	rs168913	chr5:122225793	G/A	cg19412675	chr5:122181750	SNX24	0.6	6.33	0.37	1.18e-9	Glucose homeostasis traits;
KIRP	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg25019033	chr10:957182	NA	-0.58	-5.96	-0.36	8.65e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs714027	1.000	rs2412971	chr22:30494371	G/A	cg27665648	chr22:30112403	NA	-0.41	-5.88	-0.35	1.36e-8	Lymphocyte counts;
KIRP	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.93	11.13	0.58	1.44e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.17	-0.37	2.8e-9	Lymphocyte counts;
KIRP	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg24169773	chr3:122142474	KPNA1	-0.57	-6.34	-0.37	1.08e-9	LDL cholesterol levels;
KIRP	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.11	-8.21	-0.46	1.24e-14	Mitochondrial DNA levels;
KIRP	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.56	0.65	1.16e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	1.04	14.44	0.68	1.22e-34	Menopause (age at onset);
KIRP	cis	rs6832769	1.000	rs28670674	chr4:56407103	G/A	cg05960024	chr4:56376020	CLOCK	-0.68	-8.46	-0.47	2.42e-15	Personality dimensions;
KIRP	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg04025307	chr7:1156635	C7orf50	0.86	9.09	0.5	3.39e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs41308713	0.606	rs77984335	chr20:37073286	G/A	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.19	7.69	0.44	3.47e-13	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.43	5.94	0.35	9.54e-9	Red blood cell count;
KIRP	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.6	0.34	5.86e-8	Breast cancer;
KIRP	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg14675211	chr2:100938903	LONRF2	0.48	6.21	0.37	2.19e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4523957	0.928	rs216201	chr17:2198800	C/T	cg16513277	chr17:2031491	SMG6	0.61	8.32	0.47	5.92e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg19645103	chr12:69753606	YEATS4	-0.48	-4.99	-0.3	1.13e-6	Response to diuretic therapy;
KIRP	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg20991723	chr1:152506922	NA	-0.46	-5.54	-0.33	7.68e-8	Hair morphology;
KIRP	cis	rs62413470	1.000	rs3950155	chr6:55936254	T/G	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.25	0.32	3.25e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg25217357	chr12:62997570	C12orf61	0.45	6.28	0.37	1.5e-9	Serum protein levels (sST2);
KIRP	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.42	-5.91	-0.35	1.11e-8	Height;
KIRP	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg07001201	chr5:642380	CEP72	0.64	6.05	0.36	5.4e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9653442	0.545	rs11900482	chr2:100758709	G/C	cg22139774	chr2:100720529	AFF3	-0.33	-5.39	-0.33	1.63e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.82	-12.23	-0.61	3.57e-27	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.59	5.54	0.33	7.59e-8	Eosinophil percentage of granulocytes;
KIRP	trans	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg08499158	chr17:42289980	UBTF	-0.7	-9.35	-0.51	5.61e-18	Total body bone mineral density;
KIRP	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg10326726	chr10:51549505	MSMB	-0.6	-8.9	-0.49	1.25e-16	Prostate-specific antigen levels;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.81	-0.4	7.25e-11	Lymphocyte counts;
KIRP	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.84	12.15	0.61	6.19e-27	Eye color traits;
KIRP	cis	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg18904891	chr8:8559673	CLDN23	0.58	6.57	0.39	3.04e-10	Obesity-related traits;
KIRP	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg16917193	chr12:54089295	NA	-0.89	-16.95	-0.73	3.25e-43	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11731793	chr10:91589234	NA	-0.42	-6.44	-0.38	6.21e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg02527881	chr3:46936655	PTH1R	0.42	6.06	0.36	4.97e-9	Colorectal cancer;
KIRP	cis	rs9815354	0.830	rs1716698	chr3:41957466	T/G	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	6.97	0.41	2.96e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg17264618	chr3:40429014	ENTPD3	-0.35	-5.4	-0.33	1.58e-7	Renal cell carcinoma;
KIRP	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg20243544	chr17:37824526	PNMT	-0.39	-5.03	-0.31	9.39e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.54	-6.51	-0.38	4.17e-10	Longevity;
KIRP	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.97	-11.17	-0.58	1.03e-23	Motion sickness;
KIRP	cis	rs7729447	0.776	rs17540155	chr5:32694033	C/T	cg16267343	chr5:32710456	NPR3	0.51	5.85	0.35	1.55e-8	Blood pressure;
KIRP	cis	rs6088619	1.000	rs6088619	chr20:33411871	A/G	cg06115741	chr20:33292138	TP53INP2	0.67	5.01	0.3	1.02e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.9	14.74	0.68	1.13e-35	Dental caries;
KIRP	cis	rs4663866	0.901	rs34040298	chr2:239191607	T/C	cg17283117	chr2:239148619	HES6	0.71	5.08	0.31	7.33e-7	Irritable bowel syndrome;
KIRP	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg10047753	chr17:41438598	NA	1.06	17.02	0.74	1.84e-43	Menopause (age at onset);
KIRP	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	6.87	0.4	5.31e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg08975724	chr8:8085496	FLJ10661	0.52	6.61	0.39	2.42e-10	Systolic blood pressure;
KIRP	cis	rs10486003	0.881	rs74910195	chr7:97203164	A/G	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.58	-5.19	-0.31	4.43e-7	Response to platinum-based agents;
KIRP	cis	rs2904967	0.810	rs507005	chr11:65045615	T/C	cg12562828	chr11:65076843	NA	0.48	7.21	0.42	6.74e-12	Mean corpuscular volume;
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	15.51	0.7	2.58e-38	Platelet count;
KIRP	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19717773	chr7:2847554	GNA12	-0.3	-4.97	-0.3	1.25e-6	Height;
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13047869	chr3:10149882	C3orf24	0.61	5.64	0.34	4.69e-8	Alzheimer's disease;
KIRP	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg16797656	chr11:68205561	LRP5	0.39	5.31	0.32	2.49e-7	Total body bone mineral density;
KIRP	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	5.44	0.33	1.3e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.43	6.54	0.38	3.57e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.86	11.6	0.59	4.15e-25	Selective IgA deficiency;
KIRP	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg11621586	chr10:70884670	VPS26A	1.17	15.03	0.69	1.17e-36	Left atrial antero-posterior diameter;
KIRP	cis	rs4700695	0.614	rs153374	chr5:65424875	A/G	cg21114390	chr5:65439923	SFRS12	0.75	6.57	0.39	2.99e-10	Facial morphology (factor 19);
KIRP	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg06223162	chr1:101003688	GPR88	0.45	9.36	0.51	5.06e-18	Monocyte count;
KIRP	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.96	10.61	0.56	6.78e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg01283332	chr5:1856932	NA	-0.45	-5.73	-0.34	2.96e-8	Cardiovascular disease risk factors;
KIRP	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.94	-0.4	3.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs151997	0.777	rs6870880	chr5:50256207	G/A	cg06027927	chr5:50259733	NA	0.6	7.89	0.45	1e-13	Callous-unemotional behaviour;
KIRP	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg10047753	chr17:41438598	NA	0.83	11.28	0.58	4.52e-24	Menopause (age at onset);
KIRP	cis	rs7538876	1.000	rs12132237	chr1:17724112	C/T	cg07394400	chr1:17752023	RCC2	-0.34	-4.85	-0.3	2.21e-6	Basal cell carcinoma;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg14430982	chr8:145691629	CYHR1;KIFC2	0.53	6.71	0.39	1.34e-10	Myopia (pathological);
KIRP	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	10.39	0.55	3.27e-21	Triglycerides;
KIRP	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.38	-6.88	-0.4	4.99e-11	Left ventricle wall thickness;
KIRP	cis	rs16828019	0.852	rs3904243	chr1:41574852	T/G	cg03387723	chr1:41708464	SCMH1	-0.8	-6.73	-0.39	1.18e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.48	-7.15	-0.41	1e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg14664628	chr15:75095509	CSK	0.51	6.14	0.36	3.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg03060546	chr3:49711283	APEH	0.47	6.27	0.37	1.61e-9	Parkinson's disease;
KIRP	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg22437258	chr11:111473054	SIK2	0.6	7.05	0.41	1.78e-11	Primary sclerosing cholangitis;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg24822074	chr8:143394317	TSNARE1	-0.51	-6.71	-0.39	1.3e-10	Inflammatory biomarkers;
KIRP	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.53	6.62	0.39	2.23e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4253772	0.637	rs56017104	chr22:46651982	A/G	cg18190219	chr22:46762943	CELSR1	-0.66	-5.74	-0.34	2.71e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs4132509	1.000	rs73124169	chr1:243804939	T/C	cg25706552	chr1:244017396	NA	0.57	7.44	0.43	1.66e-12	RR interval (heart rate);
KIRP	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.89	6.29	0.37	1.42e-9	Inflammatory biomarkers;
KIRP	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.98	-11.95	-0.61	2.86e-26	Colorectal cancer;
KIRP	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.73	-8.77	-0.49	3.08e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-5.15	-0.31	5.29e-7	Total body bone mineral density;
KIRP	cis	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg21775007	chr8:11205619	TDH	-0.45	-5.67	-0.34	4e-8	Triglycerides;
KIRP	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	1.07	14.02	0.67	3.36e-33	Post bronchodilator FEV1;
KIRP	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14598338	chr9:96623480	NA	-0.67	-11.42	-0.59	1.63e-24	DNA methylation (variation);
KIRP	cis	rs3736485	0.966	rs4775960	chr15:51891698	C/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.22	-0.32	3.81e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg13592947	chr5:1111049	SLC12A7	0.31	5.98	0.36	7.79e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.4	7.67	0.44	4.13e-13	Height;
KIRP	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.38	-0.38	8.83e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.82	-0.49	2.09e-16	Resting heart rate;
KIRP	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg09915433	chr19:53449742	NA	-0.45	-7.01	-0.41	2.31e-11	Psoriasis;
KIRP	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.64	7.61	0.44	5.8e-13	Testicular germ cell tumor;
KIRP	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-0.69	-6.01	-0.36	6.54e-9	Obesity-related traits;
KIRP	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.32	-0.32	2.39e-7	Cholesterol, total;
KIRP	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.65	8.4	0.47	3.62e-15	Prudent dietary pattern;
KIRP	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.53	8.3	0.47	6.94e-15	Height;
KIRP	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg03517284	chr6:25882590	NA	0.37	5.04	0.31	8.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg25486957	chr4:152246857	NA	-0.57	-6.01	-0.36	6.8e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.42	-6.37	-0.38	9.21e-10	Obesity-related traits;
KIRP	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.97	-16.58	-0.73	5.7e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.34	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25862684	chr15:101142576	LINS1;ASB7	-0.55	-6.3	-0.37	1.39e-9	Interleukin-4 levels;
KIRP	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs13082711	0.911	rs77685358	chr3:27519158	C/T	cg02860705	chr3:27208620	NA	0.55	7.49	0.43	1.26e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23401436	chr7:26230758	HNRNPA2B1	-0.4	-6.07	-0.36	4.69e-9	Inflammatory biomarkers;
KIRP	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.63	5.12	0.31	6.23e-7	Bipolar disorder;
KIRP	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.49	0.33	9.83e-8	Resistin levels;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	1.03	21.55	0.81	1.36e-58	Multiple myeloma;
KIRP	cis	rs860295	0.702	rs1556488	chr1:155540660	T/G	cg02153340	chr1:155202674	NA	-0.49	-6.8	-0.4	7.87e-11	Body mass index;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg08901578	chr4:187885870	NA	-0.52	-7.94	-0.45	7.07e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5771242	0.845	rs4838859	chr22:50613202	G/A	cg16473166	chr22:50639996	SELO	0.7	7.2	0.42	7.35e-12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11424472	chr17:29036859	NA	-0.53	-6.17	-0.37	2.74e-9	Menopause (age at onset);
KIRP	cis	rs2387326	0.671	rs12256275	chr10:129947139	T/C	cg16087940	chr10:129947807	NA	-0.43	-5.87	-0.35	1.39e-8	Select biomarker traits;
KIRP	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.96	12.27	0.62	2.49e-27	Menopause (age at onset);
KIRP	cis	rs10982256	0.967	rs10982246	chr9:117250393	A/G	cg13636371	chr9:117264095	DFNB31	0.6	8.6	0.48	9.55e-16	Bipolar disorder;
KIRP	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg03929089	chr4:120376271	NA	0.67	6.62	0.39	2.23e-10	Axial length;
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg02462569	chr6:150064036	NUP43	-0.39	-5.89	-0.35	1.25e-8	Lung cancer;
KIRP	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.35	-0.38	1.01e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg27121462	chr16:89883253	FANCA	0.62	8.97	0.5	7.9e-17	Vitiligo;
KIRP	cis	rs11180732	0.851	rs1732754	chr12:76271975	C/T	cg09314702	chr12:76271607	NA	0.47	6.32	0.37	1.19e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.48e-6	Red blood cell count;
KIRP	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.74	-10.82	-0.57	1.47e-22	Prudent dietary pattern;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.77	-9.56	-0.52	1.25e-18	Longevity;Endometriosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04646944	chr16:5008356	SEC14L5	0.49	6.52	0.38	3.87e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14845736	chr1:213189048	ANGEL2	0.45	6.16	0.37	2.99e-9	Parkinson's disease;
KIRP	cis	rs10908458	0.584	rs10908454	chr1:155066416	C/T	cg00103785	chr1:155043322	NA	-0.34	-6.11	-0.36	3.91e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.68	7.07	0.41	1.61e-11	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.64	0.34	4.7e-8	Lung cancer;
KIRP	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-10.02	-0.54	4.79e-20	Triglycerides;
KIRP	cis	rs981844	0.712	rs4696507	chr4:154753702	G/A	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.54	7.59	0.44	6.74e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg00684032	chr4:1343700	KIAA1530	0.46	5.33	0.32	2.23e-7	Longevity;
KIRP	cis	rs7656342	0.665	rs7696971	chr4:9884528	T/A	cg11266682	chr4:10021025	SLC2A9	-0.37	-5.74	-0.34	2.74e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg18357526	chr6:26021779	HIST1H4A	0.4	5.24	0.32	3.39e-7	Height;
KIRP	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.32	-0.32	2.32e-7	Menarche (age at onset);
KIRP	cis	rs12311304	0.965	rs58368403	chr12:15359047	C/A	cg08258403	chr12:15378311	NA	0.35	5.36	0.32	1.87e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.82	-10.85	-0.57	1.16e-22	Lymphocyte percentage of white cells;
KIRP	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg10047753	chr17:41438598	NA	1.15	18.22	0.76	1.51e-47	Menopause (age at onset);
KIRP	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg11995313	chr8:8860691	ERI1	0.38	5.06	0.31	8.02e-7	Joint mobility (Beighton score);
KIRP	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.53	0.33	7.98e-8	Breast cancer;
KIRP	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg17376030	chr22:41985996	PMM1	-0.81	-8.66	-0.48	6.44e-16	Vitiligo;
KIRP	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.67	-7.39	-0.43	2.34e-12	Diabetic retinopathy;
KIRP	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.99	-15.28	-0.7	1.61e-37	Primary sclerosing cholangitis;
KIRP	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg24488311	chr11:68621650	NA	0.42	5.33	0.32	2.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg06637938	chr14:75390232	RPS6KL1	0.45	5.64	0.34	4.62e-8	Non-small cell lung cancer;
KIRP	cis	rs798766	0.909	rs28521716	chr4:1745751	A/G	cg07775547	chr4:1625484	NA	-0.43	-4.98	-0.3	1.19e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.63	9.78	0.53	2.77e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg07701084	chr6:150067640	NUP43	-0.51	-5.82	-0.35	1.79e-8	Lung cancer;
KIRP	cis	rs17401966	0.540	rs1536262	chr1:10438687	C/T	cg19773385	chr1:10388646	KIF1B	-0.42	-5.98	-0.36	7.66e-9	Hepatocellular carcinoma;
KIRP	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.68	-0.39	1.56e-10	Lung cancer;
KIRP	cis	rs41464348	0.515	rs870858	chr2:33501320	G/C	cg16572410	chr2:33467199	LTBP1	-0.49	-5.79	-0.35	2.08e-8	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17691263	chr10:38637466	NA	0.43	6.3	0.37	1.37e-9	Survival in pancreatic cancer;
KIRP	cis	rs2219968	0.923	rs35392911	chr8:78976979	C/A	cg00738934	chr8:78996279	NA	0.39	4.98	0.3	1.19e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1023500	1.000	rs9620001	chr22:42330229	T/C	cg04733989	chr22:42467013	NAGA	-0.51	-5.57	-0.33	6.73e-8	Schizophrenia;
KIRP	cis	rs7187994	0.848	rs12443928	chr16:84780202	G/T	cg07647771	chr16:84786436	USP10	-0.46	-5.64	-0.34	4.74e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg21775007	chr8:11205619	TDH	-0.43	-5.64	-0.34	4.59e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-5.33	-0.32	2.19e-7	Retinal vascular caliber;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23931836	chr19:47615988	ZC3H4	-0.59	-6.77	-0.4	9.64e-11	Interleukin-4 levels;
KIRP	cis	rs501120	0.564	rs2624681	chr10:44677301	G/C	cg09554077	chr10:44749378	NA	0.51	6.78	0.4	8.66e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg24488311	chr11:68621650	NA	0.39	4.86	0.3	2.06e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7534824	0.625	rs2391574	chr1:101373298	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.08	0.41	1.48e-11	Refractive astigmatism;
KIRP	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.36	-6.44	-0.38	6.28e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10518128	1.000	rs10014189	chr4:75710935	G/T	cg20122727	chr4:75719957	BTC	-0.54	-5.31	-0.32	2.4e-7	Electroencephalogram traits;
KIRP	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg25838818	chr2:108905173	SULT1C2	-0.52	-7.45	-0.43	1.59e-12	Blood pressure;
KIRP	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-1.0	-9.15	-0.5	2.26e-17	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.97	-0.3	1.28e-6	Renal cell carcinoma;
KIRP	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	5.2	0.31	4.13e-7	Educational attainment;
KIRP	cis	rs6691722	0.583	rs35671964	chr1:24695749	C/G	cg18323236	chr1:24743029	NIPAL3	0.45	6.28	0.37	1.48e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg02023728	chr11:77925099	USP35	-0.33	-5.38	-0.32	1.77e-7	Alzheimer's disease (survival time);
KIRP	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg13798912	chr7:905769	UNC84A	0.54	5.54	0.33	7.73e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13185784	0.667	rs4700924	chr5:179645870	A/C	cg02891314	chr5:179741120	GFPT2	-0.47	-4.88	-0.3	1.89e-6	TRAIL levels;
KIRP	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg05315796	chr3:52349193	DNAH1	0.38	5.49	0.33	9.87e-8	Bipolar disorder;
KIRP	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg07701084	chr6:150067640	NUP43	0.48	5.93	0.35	9.98e-9	Testicular germ cell tumor;
KIRP	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.7	7.73	0.44	2.73e-13	Corneal astigmatism;
KIRP	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg16141378	chr3:129829833	LOC729375	0.51	6.6	0.39	2.51e-10	Neuroticism;
KIRP	cis	rs10267417	0.603	rs6960607	chr7:19869407	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	5.99	0.36	7.45e-9	Night sleep phenotypes;
KIRP	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.04	0.36	5.72e-9	Height;
KIRP	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg03714773	chr7:91764589	CYP51A1	-0.34	-5.09	-0.31	7.08e-7	Breast cancer;
KIRP	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg17863274	chr19:49399704	TULP2	-0.33	-4.85	-0.3	2.22e-6	Red cell distribution width;
KIRP	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg27147174	chr7:100797783	AP1S1	-0.69	-8.91	-0.49	1.2e-16	Life satisfaction;
KIRP	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.67	-6.14	-0.36	3.29e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.59	7.37	0.43	2.66e-12	Arsenic metabolism;
KIRP	cis	rs10046574	0.561	rs17481974	chr7:135195701	A/G	cg27474649	chr7:135195673	CNOT4	0.55	4.97	0.3	1.24e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg08975724	chr8:8085496	FLJ10661	0.6	7.45	0.43	1.54e-12	Neuroticism;
KIRP	trans	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.83e-26	Heart rate;
KIRP	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.24	0.55	1.01e-20	Cognitive test performance;
KIRP	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	8.18	0.46	1.49e-14	Response to antipsychotic treatment;
KIRP	cis	rs13361707	0.920	rs7730368	chr5:40694966	A/C	cg01087697	chr5:40835557	RPL37	-0.5	-5.74	-0.34	2.84e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg16584676	chr17:46985605	UBE2Z	-0.5	-6.06	-0.36	5.09e-9	Type 2 diabetes;
KIRP	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.54	-7.0	-0.41	2.46e-11	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00154968	chr7:39989544	CDK13	0.48	6.46	0.38	5.58e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg18944383	chr4:111397179	ENPEP	0.46	7.39	0.43	2.31e-12	Coronary artery disease;
KIRP	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs62435770	1.000	rs62433595	chr6:169519081	T/C	cg21011794	chr4:120057110	MYOZ2	-0.63	-6.3	-0.37	1.34e-9	Loneliness;
KIRP	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.57	7.7	0.44	3.39e-13	White matter hyperintensity burden;
KIRP	trans	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.26	-0.37	1.72e-9	Obesity-related traits;
KIRP	cis	rs2292864	0.764	rs35265764	chr17:45363546	G/T	cg18085866	chr17:45331354	ITGB3	-0.73	-5.63	-0.34	4.97e-8	Left atrial antero-posterior diameter;
KIRP	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.65	-9.43	-0.52	3.24e-18	Schizophrenia;
KIRP	cis	rs600550	0.528	rs10897006	chr11:59851874	C/G	cg02771260	chr11:59836817	MS4A3	-0.45	-4.94	-0.3	1.45e-6	Lipoprotein-associated phospholipase A2 activity and mass;
KIRP	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg04310649	chr10:35416472	CREM	-0.53	-6.08	-0.36	4.45e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13095912	1.000	rs2034344	chr3:185337788	T/C	cg11274856	chr3:185301563	NA	0.52	6.69	0.39	1.46e-10	Systolic blood pressure;
KIRP	cis	rs580438	0.792	rs357112	chr3:13326400	C/A	cg10657019	chr3:13328039	NA	0.88	12.32	0.62	1.69e-27	Myringotomy;
KIRP	cis	rs3120667	0.790	rs1923509	chr1:152380128	C/T	cg26876637	chr1:152193138	HRNR	-0.56	-5.5	-0.33	9.68e-8	Eating disorders;
KIRP	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.64	-0.44	4.95e-13	Bone mineral density;
KIRP	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.88	0.3	1.91e-6	Cognitive test performance;
KIRP	cis	rs151997	0.509	rs11744954	chr5:50296729	A/G	cg06027927	chr5:50259733	NA	-0.54	-6.16	-0.37	2.98e-9	Callous-unemotional behaviour;
KIRP	trans	rs2867695	0.651	rs72656549	chr4:81135362	A/G	cg01441113	chr4:186560403	SORBS2	0.53	6.2	0.37	2.35e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg11494091	chr17:61959527	GH2	-0.7	-9.77	-0.53	3e-19	Prudent dietary pattern;
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg23698023	chr8:27181813	PTK2B	0.33	4.93	0.3	1.49e-6	Neuroticism;
KIRP	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.63	-0.44	5.25e-13	Eye color traits;
KIRP	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-8.99	-0.5	6.68e-17	Electroencephalogram traits;
KIRP	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	13.09	0.64	4.43e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.78	12.05	0.61	1.37e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.83	12.35	0.62	1.43e-27	Mean corpuscular volume;
KIRP	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.58	8.37	0.47	4.27e-15	Metabolite levels;
KIRP	cis	rs13130787	0.802	rs17365288	chr4:94904738	A/G	cg11021082	chr4:95130006	SMARCAD1	0.38	4.86	0.3	2.09e-6	Colorectal cancer;
KIRP	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.5	6.99	0.41	2.59e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.29	-0.32	2.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg07148914	chr20:33460835	GGT7	-0.51	-7.02	-0.41	2.09e-11	Glomerular filtration rate (creatinine);
KIRP	trans	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg00938859	chr5:1591904	SDHAP3	0.6	8.0	0.45	5.04e-14	Breast cancer;
KIRP	cis	rs4262150	0.883	rs12153328	chr5:152247221	T/C	cg12297329	chr5:152029980	NA	-0.61	-7.69	-0.44	3.58e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02094989	chr6:169284816	NA	-0.43	-6.11	-0.36	3.92e-9	Survival in pancreatic cancer;
KIRP	cis	rs806321	0.534	rs1319883	chr13:50887164	C/T	cg10393508	chr13:50950265	NA	-0.44	-6.27	-0.37	1.59e-9	Multiple sclerosis;
KIRP	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.06	0.31	8.06e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13266463	0.858	rs13255588	chr8:143384727	C/G	cg16886403	chr8:143471632	TSNARE1	0.49	5.09	0.31	7.06e-7	Schizophrenia;
KIRP	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg03468072	chr12:39539422	NA	0.42	6.05	0.36	5.39e-9	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-10.01	-0.54	5.32e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.66	-7.51	-0.43	1.09e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9311676	0.656	rs56232415	chr3:58394850	C/T	cg06643156	chr3:58380774	PXK	0.35	4.86	0.3	2.13e-6	Systemic lupus erythematosus;
KIRP	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.17	12.42	0.62	8.15e-28	Platelet count;
KIRP	cis	rs7084402	0.523	rs10740730	chr10:60334939	T/C	cg05938607	chr10:60274200	BICC1	-0.37	-8.05	-0.46	3.44e-14	Refractive error;
KIRP	trans	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg26043149	chr18:55253948	FECH	0.53	6.44	0.38	6.16e-10	Bone mineral density;
KIRP	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg18882449	chr10:104885122	NT5C2	-0.51	-6.51	-0.38	4.12e-10	Arsenic metabolism;
KIRP	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.8	-11.4	-0.59	1.93e-24	Blood metabolite levels;
KIRP	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg02951883	chr7:2050386	MAD1L1	-0.47	-5.26	-0.32	3.21e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.88	-0.4	4.95e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2219968	0.962	rs2368508	chr8:78951278	T/C	cg00738934	chr8:78996279	NA	0.41	5.29	0.32	2.74e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.77	0.44	2.17e-13	Morning vs. evening chronotype;
KIRP	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.13	0.5	2.56e-17	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22700091	chr15:48470612	MYEF2	0.45	6.81	0.4	7.61e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg18944383	chr4:111397179	ENPEP	-0.52	-6.12	-0.36	3.58e-9	Intraocular pressure;
KIRP	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg20813462	chr7:2646259	IQCE	0.55	5.44	0.33	1.27e-7	Urate levels in lean individuals;
KIRP	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.16	0.37	2.96e-9	Menopause (age at onset);
KIRP	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Parkinson's disease;
KIRP	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg10755058	chr3:40428713	ENTPD3	0.38	5.74	0.34	2.84e-8	Renal cell carcinoma;
KIRP	cis	rs904251	0.523	rs2797798	chr6:37481437	C/T	cg08126542	chr6:37504118	NA	-0.84	-13.31	-0.65	8.07e-31	Cognitive performance;
KIRP	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.55	-6.76	-0.4	9.92e-11	Platelet distribution width;
KIRP	cis	rs9394841	0.667	rs9357366	chr6:41786976	T/G	cg08135965	chr6:41755394	TOMM6	0.52	5.66	0.34	4.19e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg15488143	chr7:128924101	AHCYL2	0.64	6.83	0.4	6.72e-11	White matter hyperintensity burden;
KIRP	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.7	-0.6	1.96e-25	Diabetic kidney disease;
KIRP	cis	rs1355223	0.902	rs61881050	chr11:34719749	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-5.45	-0.33	1.22e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7590720	0.531	rs6435932	chr2:216906030	T/C	cg12620499	chr2:216877984	MREG	0.66	8.44	0.47	2.74e-15	Alcohol dependence;
KIRP	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.94	-0.35	9.6e-9	IgG glycosylation;
KIRP	cis	rs10821556	1	rs10821556	chr9:136942136	C/A	cg13495838	chr9:136934004	BRD3	0.45	5.33	0.32	2.17e-7	Mean platelet volume;
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.75	10.37	0.55	3.86e-21	Menarche (age at onset);
KIRP	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.13	0.64	3.26e-30	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg16141378	chr3:129829833	LOC729375	0.52	6.74	0.39	1.09e-10	Retinal vascular caliber;
KIRP	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg03060546	chr3:49711283	APEH	0.48	6.17	0.37	2.86e-9	Parkinson's disease;
KIRP	cis	rs7408868	0.572	rs2074616	chr19:15294991	C/T	cg14696996	chr19:15285081	NOTCH3	0.6	6.33	0.37	1.14e-9	Pulse pressure;
KIRP	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.71	10.81	0.57	1.53e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg02023728	chr11:77925099	USP35	0.3	5.07	0.31	7.78e-7	Alzheimer's disease (survival time);
KIRP	trans	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-6.44	-0.38	6.1e-10	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.36	6.29	0.37	1.48e-9	Renal cell carcinoma;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04127825	chr1:167503222	NA	0.54	7.39	0.43	2.36e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg19116668	chr7:99932089	PMS2L1	-0.43	-4.89	-0.3	1.82e-6	Coronary artery disease;
KIRP	cis	rs10214930	0.697	rs1608664	chr7:27623928	C/G	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.6	6.39	0.38	8.21e-10	Hip geometry;
KIRP	cis	rs986417	1.000	rs10144805	chr14:60927652	T/C	cg27398547	chr14:60952738	C14orf39	0.74	7.43	0.43	1.84e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	5.55	0.33	7.2e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2905347	0.726	rs2905321	chr7:22704587	A/G	cg23521230	chr7:22704884	NA	-0.46	-5.93	-0.35	1.01e-8	Major depression and alcohol dependence;
KIRP	cis	rs904251	1.000	rs904251	chr6:37451696	G/T	cg25019722	chr6:37503610	NA	-0.73	-9.6	-0.52	9.52e-19	Cognitive performance;
KIRP	trans	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.23	0.37	2.03e-9	Mean corpuscular volume;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16524936	chr4:1340807	KIAA1530	-0.46	-5.77	-0.35	2.39e-8	Longevity;
KIRP	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.58	-7.66	-0.44	4.35e-13	Primary sclerosing cholangitis;
KIRP	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg12560992	chr17:57184187	TRIM37	0.62	6.54	0.38	3.55e-10	Testicular germ cell tumor;
KIRP	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg03959625	chr15:84868606	LOC388152	0.66	7.97	0.45	6.05e-14	Schizophrenia;
KIRP	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.05	0.31	8.41e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs4262150	0.810	rs35124713	chr5:151951108	G/A	cg12297329	chr5:152029980	NA	-0.65	-7.91	-0.45	8.95e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.7	7.76	0.44	2.28e-13	Corneal astigmatism;
KIRP	cis	rs77956314	0.901	rs7132339	chr12:117335912	C/T	cg02017074	chr12:117425053	FBXW8	-0.54	-4.92	-0.3	1.56e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07308232	chr7:1071921	C7orf50	-0.8	-11.45	-0.59	1.27e-24	Longevity;Endometriosis;
KIRP	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	0.95	7.22	0.42	6.55e-12	Age-related hearing impairment;
KIRP	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.61	-7.02	-0.41	2.1e-11	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25437947	chr8:17941982	ASAH1	0.53	7.72	0.44	2.85e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg00666640	chr1:248458726	OR2T12	0.44	5.89	0.35	1.23e-8	Common traits (Other);
KIRP	cis	rs785830	0.689	rs1536608	chr9:223613	T/G	cg14500300	chr9:211689	NA	0.52	6.96	0.41	3.01e-11	Platelet distribution width;
KIRP	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg02487422	chr3:49467188	NICN1	0.39	5.44	0.33	1.25e-7	Parkinson's disease;
KIRP	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.57	6.41	0.38	7.35e-10	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.5	6.55	0.39	3.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.73	-10.09	-0.54	2.91e-20	Ear protrusion;
KIRP	cis	rs7149242	0.796	rs12588718	chr14:101149605	G/C	cg18089426	chr14:101175970	NA	-0.61	-7.98	-0.45	5.73e-14	Platelet count;
KIRP	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.63	-0.39	2.11e-10	Neuroticism;
KIRP	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-8.93	-0.49	1.05e-16	Morning vs. evening chronotype;
KIRP	cis	rs6969780	1.000	rs6461985	chr7:27150634	T/C	cg26364809	chr7:27145159	NA	-0.59	-5.52	-0.33	8.76e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs11779988	0.545	rs427168	chr8:17784829	G/A	cg01800426	chr8:17659068	MTUS1	-0.61	-6.09	-0.36	4.27e-9	Breast cancer;
KIRP	cis	rs4654899	0.865	rs6673455	chr1:21361048	T/C	cg05370193	chr1:21551575	ECE1	0.47	6.27	0.37	1.57e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs11587400	0.679	rs6537836	chr1:115108923	T/C	cg12756093	chr1:115239321	AMPD1	0.43	5.34	0.32	2.07e-7	Autism;
KIRP	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg05802129	chr4:122689817	NA	-0.47	-6.11	-0.36	3.83e-9	Type 2 diabetes;
KIRP	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg02344993	chr17:57696989	CLTC	-0.61	-6.02	-0.36	6.18e-9	Obesity-related traits;
KIRP	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06481639	chr22:41940642	POLR3H	-0.5	-5.82	-0.35	1.79e-8	Vitiligo;
KIRP	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg18944383	chr4:111397179	ENPEP	0.54	9.58	0.52	1.1e-18	Height;
KIRP	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.74	8.38	0.47	4.08e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.68	8.17	0.46	1.6e-14	Corneal astigmatism;
KIRP	cis	rs9532580	0.620	rs2701859	chr13:41141232	T/C	cg21288729	chr13:41239152	FOXO1	0.7	9.35	0.51	5.54e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs4901847	0.574	rs60055365	chr14:58582693	G/A	cg15908186	chr14:58618357	C14orf37	0.52	6.4	0.38	7.58e-10	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2120243	0.539	rs6801110	chr3:157084731	C/G	cg24825693	chr3:157122686	VEPH1	-0.56	-8.33	-0.47	5.86e-15	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg16497661	chr14:103986332	CKB	-0.49	-4.98	-0.3	1.18e-6	Coronary artery disease;
KIRP	cis	rs6968419	0.747	rs6959237	chr7:115876365	C/T	cg02561103	chr7:115862891	TES	-0.42	-6.03	-0.36	5.89e-9	Intraocular pressure;
KIRP	cis	rs7714584	1.000	rs1896709	chr5:150245032	A/G	cg22134413	chr5:150180641	NA	0.56	5.12	0.31	6.24e-7	Crohn's disease;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.9	-14.74	-0.68	1.17e-35	Longevity;Endometriosis;
KIRP	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg00012203	chr2:219082015	ARPC2	-0.65	-8.26	-0.47	8.77e-15	Colorectal cancer;
KIRP	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.11	-0.31	6.42e-7	Personality dimensions;
KIRP	cis	rs8018808	1.000	rs12101153	chr14:77863091	A/C	cg20045696	chr14:77926864	AHSA1	-0.42	-5.35	-0.32	1.98e-7	Myeloid white cell count;
KIRP	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.34	4.84	0.3	2.27e-6	Coronary artery disease;
KIRP	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-10.78	-0.57	1.94e-22	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg17376030	chr22:41985996	PMM1	-0.77	-8.23	-0.46	1.07e-14	Vitiligo;
KIRP	cis	rs4356932	0.691	rs7436021	chr4:76905472	A/G	cg19388996	chr4:76862389	NAAA	0.43	5.53	0.33	8.36e-8	Blood protein levels;
KIRP	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.57	-6.53	-0.38	3.81e-10	Menarche (age at onset);
KIRP	cis	rs33912345	0.750	rs7155448	chr14:60937851	T/C	cg27398547	chr14:60952738	C14orf39	0.39	5.2	0.31	4.21e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.84	-0.35	1.67e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg15247329	chr7:2764246	NA	-0.34	-5.05	-0.31	8.79e-7	Height;
KIRP	cis	rs42648	0.869	rs2027965	chr7:89912513	C/T	cg25739043	chr7:89950458	NA	-0.45	-7.05	-0.41	1.85e-11	Homocysteine levels;
KIRP	cis	rs1697938	0.557	rs1910016	chr5:40911592	C/T	cg01087697	chr5:40835557	RPL37	-0.45	-5.01	-0.3	1.02e-6	Multiple system atrophy;
KIRP	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-7.26	-0.42	5.13e-12	Schizophrenia;
KIRP	cis	rs9890032	0.520	rs2321926	chr17:29041552	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.48	-6.15	-0.36	3.17e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.08	-0.31	7.46e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg13393036	chr8:95962371	TP53INP1	-0.35	-6.85	-0.4	5.77e-11	Type 2 diabetes;
KIRP	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.52	-6.2	-0.37	2.37e-9	Squamous cell lung carcinoma;
KIRP	cis	rs3026101	0.723	rs1806247	chr17:5310409	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19346786	chr7:2764209	NA	-0.39	-6.63	-0.39	2.12e-10	Height;
KIRP	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.71	-8.12	-0.46	2.25e-14	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.83	-0.45	1.49e-13	Platelet count;
KIRP	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg13180566	chr4:1052158	NA	-0.47	-5.24	-0.32	3.51e-7	Recombination rate (females);
KIRP	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg07384165	chr1:10488281	NA	-0.42	-5.38	-0.32	1.74e-7	Breast size;
KIRP	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg18132916	chr6:79620363	NA	0.4	5.14	0.31	5.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg24375607	chr4:120327624	NA	0.58	6.67	0.39	1.69e-10	Corneal astigmatism;
KIRP	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.37	-5.04	-0.31	9e-7	Neuroticism;
KIRP	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.59	7.92	0.45	8.17e-14	Schizophrenia;
KIRP	cis	rs520865	0.786	rs688662	chr5:80348805	A/G	cg17330048	chr5:80257322	RASGRF2	-0.45	-6.6	-0.39	2.56e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7258465	1.000	rs34171762	chr19:18559410	G/A	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.83	-0.35	1.7e-8	Breast cancer;
KIRP	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg03929089	chr4:120376271	NA	-0.68	-6.97	-0.41	2.88e-11	Axial length;
KIRP	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.61	0.34	5.37e-8	Bipolar disorder;
KIRP	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	6.91	0.4	4.03e-11	Breast cancer;
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg14221460	chr8:27183342	PTK2B	0.51	6.73	0.39	1.22e-10	Neuroticism;
KIRP	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.56	6.79	0.4	8.46e-11	Aortic root size;
KIRP	cis	rs4132509	0.895	rs12138168	chr1:244009113	A/G	cg21452805	chr1:244014465	NA	0.55	5.13	0.31	6e-7	RR interval (heart rate);
KIRP	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.92	-0.4	3.93e-11	Menopause (age at onset);
KIRP	cis	rs405956	0.769	rs9500032	chr6:105566414	C/T	cg22580625	chr6:105627791	POPDC3	-0.49	-5.36	-0.32	1.88e-7	QT interval;
KIRP	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.51	6.59	0.39	2.6200000000000003e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.87	13.3	0.65	8.96e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg04607699	chr11:48328132	OR4S1	-0.39	-5.54	-0.33	7.88e-8	Migraine - clinic-based;
KIRP	cis	rs7224685	0.569	rs67005107	chr17:3991943	A/G	cg05562828	chr17:3906858	NA	0.52	5.63	0.34	4.84e-8	Type 2 diabetes;
KIRP	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.48	5.98	0.36	7.95e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs78487399	0.808	rs13395290	chr2:43706319	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.1	-0.31	6.67e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	cis	rs12973672	1.000	rs10405246	chr19:35768949	A/G	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10425738	0.830	rs3844443	chr19:41431935	C/T	cg09508736	chr19:41385865	CYP2A7	0.47	5.18	0.31	4.58e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg26084005	chr2:241760190	KIF1A	-0.47	-6.17	-0.37	2.76e-9	Urinary metabolites;
KIRP	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg21401794	chr1:90099060	LRRC8C	0.7	9.86	0.53	1.51e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	1.19	8.79	0.49	2.69e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs831571	0.774	rs254858	chr3:64056255	G/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.56	5.6	0.34	5.65e-8	Type 2 diabetes;
KIRP	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs1142	0.507	rs2428161	chr7:104592567	A/G	cg04380332	chr7:105027541	SRPK2	-0.46	-6.82	-0.4	7.08e-11	Advanced age-related macular degeneration;
KIRP	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg22974920	chr21:40686053	BRWD1	-0.43	-4.96	-0.3	1.31e-6	Cognitive function;
KIRP	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg05973401	chr12:123451056	ABCB9	0.54	6.09	0.36	4.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7916697	0.947	rs4745950	chr10:69996455	A/G	cg18338521	chr10:69995036	NA	0.4	5.15	0.31	5.24e-7	Optic disc area;
KIRP	cis	rs1829883	0.701	rs6885820	chr5:98983038	T/A	cg08333243	chr5:99726346	NA	0.41	5.21	0.32	3.93e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7011507	1.000	rs76846479	chr8:49135176	A/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05665937	chr4:1216051	CTBP1	0.51	7.18	0.42	8.2e-12	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.39	-5.42	-0.33	1.43e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.87	-12.61	-0.63	1.83e-28	Total body bone mineral density;
KIRP	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg10523679	chr1:76189770	ACADM	0.72	9.38	0.51	4.55e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.33	5.83	0.35	1.76e-8	Migraine;
KIRP	cis	rs6500395	0.588	rs3826176	chr16:48589062	A/G	cg04672837	chr16:48644449	N4BP1	0.44	6.13	0.36	3.45e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.58	0.59	4.79e-25	Monocyte percentage of white cells;
KIRP	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg00405596	chr8:11794950	NA	0.41	5.44	0.33	1.28e-7	Retinal vascular caliber;
KIRP	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.46	-7.1	-0.41	1.35e-11	Coronary artery disease;
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07402062	chr16:89894098	SPIRE2	0.36	7.29	0.42	4.2e-12	Vitiligo;
KIRP	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-7.34	-0.42	3.08e-12	Bipolar disorder;
KIRP	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.19e-15	Retinal vascular caliber;
KIRP	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-7.76	-0.44	2.29e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs6585424	1.000	rs12769115	chr10:81933501	G/A	cg27417294	chr10:81904244	PLAC9	0.53	5.1	0.31	6.66e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg16590910	chr6:42928470	GNMT	0.43	6.02	0.36	6.39e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg04310649	chr10:35416472	CREM	-0.59	-7.06	-0.41	1.66e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg12560992	chr17:57184187	TRIM37	0.6	5.49	0.33	1.02e-7	Cognitive test performance;
KIRP	cis	rs62413470	1.000	rs12201413	chr6:55933348	C/T	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs6901250	0.655	rs1398404	chr6:117126345	A/C	cg05399210	chr6:117082661	FAM162B	-0.38	-5.14	-0.31	5.72e-7	C-reactive protein levels;
KIRP	cis	rs10814247	0.702	rs7032682	chr9:35209763	G/T	cg15271616	chr9:35490515	RUSC2	0.38	5.39	0.33	1.65e-7	Psoriasis;
KIRP	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg07395648	chr5:131743802	NA	0.56	7.79	0.44	1.86e-13	Breast cancer;Mosquito bite size;
KIRP	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21643547	chr1:205240462	TMCC2	-0.89	-13.87	-0.66	1.01e-32	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3752645	1.000	rs17340577	chr7:106719413	A/G	cg02696742	chr7:106810147	HBP1	0.65	4.98	0.3	1.22e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.67	8.55	0.48	1.32e-15	Prudent dietary pattern;
KIRP	cis	rs6142102	1.000	rs4911414	chr20:32729444	T/G	cg08999081	chr20:33150536	PIGU	0.5	5.88	0.35	1.37e-8	Skin pigmentation;
KIRP	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg00204512	chr16:28754710	NA	0.47	6.14	0.36	3.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.44	-6.58	-0.39	2.86e-10	Major depressive disorder;
KIRP	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	7.63	0.44	5.21e-13	Rheumatoid arthritis;
KIRP	cis	rs4073416	0.542	rs10873191	chr14:66110628	T/C	cg03016385	chr14:66212404	NA	-0.54	-6.67	-0.39	1.68e-10	N-glycan levels;
KIRP	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.75	-0.63	6.19e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg05220968	chr6:146057943	EPM2A	0.45	5.77	0.35	2.37e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06237353	chr15:82554820	EFTUD1;FAM154B	0.51	6.91	0.4	4.11e-11	Parkinson's disease;
KIRP	cis	rs3733418	0.929	rs4690797	chr4:165908505	G/C	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.02	-0.3	9.85e-7	Obesity-related traits;
KIRP	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg23340505	chr13:114927933	NA	0.32	4.95	0.3	1.37e-6	Schizophrenia;
KIRP	cis	rs859767	0.501	rs10210052	chr2:135417350	C/T	cg25422880	chr2:135218333	TMEM163	0.38	5.57	0.33	6.77e-8	Neuroticism;
KIRP	cis	rs9394841	0.692	rs9394834	chr6:41806793	G/A	cg08135965	chr6:41755394	TOMM6	0.52	5.55	0.33	7.51e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.63	-8.22	-0.46	1.2e-14	Colorectal cancer;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg27532560	chr4:187881888	NA	-0.72	-11.79	-0.6	1.02e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg10189774	chr4:17578691	LAP3	-0.47	-5.31	-0.32	2.41e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs748404	0.697	rs498227	chr15:43573052	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.55	0.43	8.31e-13	Lung cancer;
KIRP	cis	rs3126085	0.515	rs10788836	chr1:152350135	A/T	cg26876637	chr1:152193138	HRNR	-0.53	-6.66	-0.39	1.77e-10	Atopic dermatitis;
KIRP	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.94	-13.64	-0.66	6.14e-32	Coronary artery disease;
KIRP	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.58	0.34	6.42e-8	Skin colour saturation;
KIRP	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.43	6.02	0.36	6.16e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg04733989	chr22:42467013	NAGA	0.5	5.96	0.36	8.7e-9	Cognitive function;
KIRP	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.45	-0.52	2.87e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.52	0.48	1.6e-15	Eosinophil percentage of white cells;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.64	-9.07	-0.5	3.82e-17	Total body bone mineral density;
KIRP	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.84	11.64	0.6	3.15e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg00405596	chr8:11794950	NA	-0.47	-6.03	-0.36	6.02e-9	Retinal vascular caliber;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg18209359	chr17:80159595	CCDC57	-0.41	-5.31	-0.32	2.39e-7	Life satisfaction;
KIRP	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg00579200	chr11:133705235	NA	-0.42	-5.62	-0.34	5.04e-8	Childhood ear infection;
KIRP	cis	rs2505998	0.787	rs28502801	chr10:43584039	A/T	cg15436174	chr10:43711423	RASGEF1A	-0.54	-5.69	-0.34	3.57e-8	Hirschsprung disease;
KIRP	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.43	-5.26	-0.32	3.16e-7	Aortic root size;
KIRP	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg03289416	chr15:75166202	SCAMP2	-0.39	-4.91	-0.3	1.64e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg18944383	chr4:111397179	ENPEP	0.51	8.3	0.47	6.79e-15	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.66	8.6	0.48	9.18e-16	Alzheimer's disease;
KIRP	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.62	0.34	5.03e-8	Breast cancer;
KIRP	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg08917208	chr2:24149416	ATAD2B	0.61	5.3	0.32	2.52e-7	Lymphocyte counts;
KIRP	cis	rs829661	0.793	rs2602790	chr2:30869202	T/C	cg10949345	chr2:30726833	LCLAT1	1.08	13.31	0.65	8.61e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg11608241	chr8:8085544	FLJ10661	-0.48	-5.79	-0.35	2.13e-8	Joint mobility (Beighton score);
KIRP	cis	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg07460842	chr6:66804631	NA	-0.48	-5.74	-0.34	2.78e-8	Metabolite levels;
KIRP	cis	rs1010254	0.559	rs991637	chr5:151748808	C/A	cg12297329	chr5:152029980	NA	-0.62	-6.36	-0.38	9.89e-10	Optic nerve measurement (cup area);
KIRP	trans	rs982100	1.000	rs7563820	chr2:118419044	T/C	cg09538006	chr2:3337909	TSSC1	0.68	6.44	0.38	6.12e-10	Alzheimer disease and age of onset;
KIRP	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.56	-8.93	-0.49	1.02e-16	Glomerular filtration rate (creatinine);
KIRP	cis	rs2057178	0.696	rs12278882	chr11:32352400	C/G	cg06489367	chr11:32355509	NA	0.41	5.2	0.31	4.28e-7	Tuberculosis;
KIRP	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg20701182	chr2:24300061	SF3B14	0.47	4.93	0.3	1.51e-6	Asthma;
KIRP	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.38	-7.28	-0.42	4.44e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	trans	rs74233809	0.901	rs1004467	chr10:104594507	A/G	cg26199906	chr8:145106246	OPLAH	-0.43	-6.32	-0.37	1.19e-9	Birth weight;
KIRP	cis	rs6701037	1.000	rs6425323	chr1:175125036	C/T	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.21	-0.32	4e-7	Alcohol dependence;
KIRP	cis	rs62413470	1.000	rs62411452	chr6:55964425	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg07511934	chr16:89386912	ANKRD11	0.44	5.53	0.33	8.14e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs7923609	0.967	rs10509189	chr10:65264126	T/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.88	-0.35	1.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.55	-8.0	-0.45	4.89e-14	Huntington's disease progression;
KIRP	cis	rs1403694	0.966	rs1648715	chr3:186439618	A/G	cg12454167	chr3:186435060	KNG1	0.49	8.64	0.48	7.01e-16	Blood protein levels;
KIRP	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg12549451	chr6:135224345	NA	0.42	5.12	0.31	6.27e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg15655495	chr12:38532458	NA	-0.3	-5.16	-0.31	5.06e-7	Bladder cancer;
KIRP	trans	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg10756647	chr7:56101905	PSPH	1.01	7.6	0.44	6.29e-13	Diabetic kidney disease;
KIRP	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.62	7.64	0.44	4.74e-13	Type 2 diabetes;
KIRP	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg09699651	chr6:150184138	LRP11	0.54	7.28	0.42	4.47e-12	Testicular germ cell tumor;
KIRP	cis	rs11138902	1.000	rs11138902	chr9:72103314	G/A	cg14397918	chr9:72078829	APBA1	0.37	5.99	0.36	7.51e-9	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.77	-10.96	-0.57	5.05e-23	Caffeine consumption;
KIRP	cis	rs11650494	0.710	rs2233666	chr17:47484286	T/C	cg08112188	chr17:47440006	ZNF652	1.43	8.06	0.46	3.27e-14	Prostate cancer;
KIRP	cis	rs1355223	0.902	rs12801509	chr11:34747336	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-5.31	-0.32	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs743757	1.000	rs743757	chr3:50476378	C/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.51	-5.65	-0.34	4.45e-8	Diastolic blood pressure;
KIRP	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.76	-0.73	1.41e-42	Height;
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg16524936	chr4:1340807	KIAA1530	-0.43	-5.05	-0.31	8.56e-7	Obesity-related traits;
KIRP	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.41	-17.53	-0.75	3.48e-45	Uric acid levels;
KIRP	cis	rs2950163	0.898	rs6735726	chr2:6190495	G/T	cg26659079	chr2:5836181	SOX11	0.38	4.96	0.3	1.33e-6	Response to metformin (IC50);
KIRP	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg03260781	chr1:16346299	HSPB7	0.32	5.13	0.31	5.83e-7	Dilated cardiomyopathy;
KIRP	cis	rs4959799	0.655	rs6902992	chr6:3283693	C/G	cg10513992	chr6:3293720	SLC22A23	-0.88	-6.26	-0.37	1.71e-9	Survival in rectal cancer;
KIRP	cis	rs12791968	0.527	rs4755924	chr11:45013328	A/G	cg11846598	chr11:44996168	LOC221122	-0.49	-5.21	-0.31	4.08e-7	Inhibitory control;
KIRP	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.66	0.66	5.36e-32	Cognitive function;
KIRP	cis	rs76533333	0.646	rs7318114	chr13:113420535	A/C	cg04656015	chr13:113407548	ATP11A	0.61	5.54	0.33	7.87e-8	Red cell distribution width;
KIRP	cis	rs300890	0.513	rs4286475	chr4:144046911	T/G	cg01719995	chr4:144104893	USP38	0.44	5.66	0.34	4.31e-8	Nasopharyngeal carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25551918	chr6:7390136	CAGE1;RIOK1	0.54	6.79	0.4	8.38e-11	Parkinson's disease;
KIRP	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg20243544	chr17:37824526	PNMT	0.45	6.16	0.37	3.01e-9	Asthma;
KIRP	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.72	-7.94	-0.45	7.32e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs6690583	1.000	rs10443172	chr1:85485768	T/C	cg22153463	chr1:85462885	MCOLN2	-0.66	-6.53	-0.38	3.78e-10	Serum sulfate level;
KIRP	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	14.54	0.68	5.3e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg26441486	chr22:50317300	CRELD2	0.48	5.52	0.33	8.73e-8	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	6.0	0.36	6.94e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg00405596	chr8:11794950	NA	-0.51	-6.69	-0.39	1.48e-10	Retinal vascular caliber;
KIRP	cis	rs12999616	0.948	rs35958372	chr2:98330858	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	6.21	0.37	2.27e-9	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg01879757	chr17:41196368	BRCA1	-0.74	-10.23	-0.55	1.07e-20	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.36	-0.32	1.93e-7	Breast cancer;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.54	-6.09	-0.36	4.42e-9	Menopause (age at onset);
KIRP	cis	rs4936894	0.500	rs10893202	chr11:124165987	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-6.31	-0.37	1.29e-9	Aging (time to death);
KIRP	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.33	-5.14	-0.31	5.59e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg08745899	chr5:77590760	AP3B1	0.99	6.38	0.38	8.92e-10	P wave terminal force;
KIRP	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.65	0.34	4.43e-8	Skin colour saturation;
KIRP	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg09184832	chr6:79620586	NA	-0.53	-7.41	-0.43	2.04e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2299587	0.560	rs11996792	chr8:17781012	C/G	cg01800426	chr8:17659068	MTUS1	-0.61	-7.38	-0.43	2.49e-12	Economic and political preferences;
KIRP	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.43	-0.38	6.67e-10	QT interval;
KIRP	cis	rs17592366	0.838	rs79459513	chr14:35341167	C/T	cg09327582	chr14:35236912	BAZ1A	0.68	5.16	0.31	5.01e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg17441377	chr17:3906640	NA	0.55	8.34	0.47	5.3e-15	Type 2 diabetes;
KIRP	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.6	-6.26	-0.37	1.72e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04887328	chr17:16945603	MPRIP	-0.45	-6.15	-0.37	3.19e-9	Metabolic traits;
KIRP	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2380205	0.935	rs2380200	chr10:5894939	A/G	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.52e-8	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19503731	chr1:244007303	AKT3	-0.49	-7.74	-0.44	2.51e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7562790	0.597	rs7419733	chr2:36652027	G/C	cg09467607	chr2:36825704	FEZ2	0.43	5.25	0.32	3.33e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg03060546	chr3:49711283	APEH	-0.64	-6.08	-0.36	4.47e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs220519	0.839	rs220521	chr20:37278823	T/C	cg24308336	chr20:37270989	C20orf95	0.23	4.97	0.3	1.23e-6	Schizophrenia;
KIRP	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.22	12.98	0.64	1.1e-29	Uric acid levels;
KIRP	cis	rs911119	0.866	rs6048920	chr20:23576844	A/G	cg16589663	chr20:23618590	CST3	0.48	4.89	0.3	1.79e-6	Chronic kidney disease;
KIRP	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg13902645	chr11:5959945	NA	-0.6	-6.36	-0.38	9.61e-10	DNA methylation (variation);
KIRP	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	16.09	0.72	2.68e-40	Electrocardiographic conduction measures;
KIRP	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg02725872	chr8:58115012	NA	-0.53	-6.0	-0.36	6.98e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7116495	1.000	rs116781589	chr11:71825006	G/T	cg11196788	chr11:71737549	NUMA1	-0.55	-4.86	-0.3	2.07e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg11150807	chr10:43354902	NA	0.6	6.63	0.39	2.15e-10	Blood protein levels;
KIRP	cis	rs2658782	0.724	rs2605626	chr11:93253903	A/G	cg15737290	chr11:93063684	CCDC67	0.66	7.16	0.42	9.27e-12	Pulmonary function decline;
KIRP	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.62	-7.29	-0.42	4.1e-12	Dental caries;
KIRP	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-6.25	-0.37	1.76e-9	HDL cholesterol;
KIRP	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg12140854	chr5:148520817	ABLIM3	-0.56	-5.9	-0.35	1.21e-8	Breast cancer;
KIRP	cis	rs9810890	1.000	rs73198872	chr3:128537683	G/A	cg15033153	chr3:128514015	RAB7A	0.71	5.03	0.31	9.56e-7	Dental caries;
KIRP	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.96	6.69	0.39	1.48e-10	Obesity (early onset extreme);
KIRP	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.75	5.73	0.34	2.89e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1760803	0.754	rs12028554	chr1:154223101	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.5	-0.33	9.44e-8	Nicotine dependence;
KIRP	cis	rs17095355	1.000	rs57440982	chr10:111735772	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.2	-0.31	4.29e-7	Biliary atresia;
KIRP	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-7.98	-0.45	5.67e-14	Neuroticism;
KIRP	cis	rs77956314	0.711	rs4767492	chr12:117436861	C/T	cg02017074	chr12:117425053	FBXW8	0.97	6.88	0.4	4.91e-11	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg16497661	chr14:103986332	CKB	-0.51	-6.48	-0.38	5.05e-10	Coronary artery disease;
KIRP	cis	rs832187	0.813	rs704368	chr3:63868337	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.45	5.23	0.32	3.71e-7	Schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20564913	chr4:1006270	FGFRL1	-0.45	-6.08	-0.36	4.56e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6832769	1.000	rs6851838	chr4:56420747	A/C	cg05960024	chr4:56376020	CLOCK	-0.62	-7.95	-0.45	6.62e-14	Personality dimensions;
KIRP	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.39	-5.17	-0.31	4.79e-7	Renal function-related traits (BUN);
KIRP	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.38	0.38	8.62e-10	Obesity-related traits;
KIRP	cis	rs4141404	0.818	rs5997897	chr22:31570436	G/A	cg02404636	chr22:31891804	SFI1	-0.51	-6.64	-0.39	1.97e-10	Paclitaxel-induced neuropathy;
KIRP	cis	rs8079658	0.868	rs2191967	chr17:63839550	C/T	cg18091269	chr17:63822838	CCDC46	0.48	6.72	0.39	1.25e-10	Post bronchodilator FEV1;
KIRP	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.55	-6.19	-0.37	2.57e-9	Metabolite levels;
KIRP	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg26531700	chr6:26746687	NA	-0.47	-6.72	-0.39	1.25e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12210905	1.000	rs1102557	chr6:27149794	C/A	cg23155468	chr6:27110703	HIST1H2BK	0.76	6.37	0.38	9.47e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg04132472	chr17:19861366	AKAP10	0.43	5.88	0.35	1.35e-8	Schizophrenia;
KIRP	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.66	-0.52	6.18e-19	Schizophrenia;
KIRP	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg15848620	chr12:58087721	OS9	-0.49	-5.75	-0.34	2.65e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9513593	1.000	rs12875982	chr13:99850615	C/T	cg21788972	chr13:99853209	UBAC2	0.53	5.65	0.34	4.51e-8	Psoriasis;
KIRP	cis	rs7601312	0.903	rs2194545	chr2:229283211	A/G	cg02542817	chr2:229291442	NA	-0.56	-8.62	-0.48	8.52e-16	Schizophrenia;
KIRP	cis	rs151997	0.630	rs26064	chr5:50217806	T/C	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg00310523	chr12:86230176	RASSF9	0.37	5.71	0.34	3.27e-8	Major depressive disorder;
KIRP	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-15.75	-0.71	3.92e-39	Primary sclerosing cholangitis;
KIRP	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg18196295	chr10:418757	DIP2C	-0.43	-5.1	-0.31	6.69e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg12591125	chr7:1885375	MAD1L1	0.61	5.98	0.36	7.84e-9	Bipolar disorder;
KIRP	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg02570527	chr1:10970165	NA	-0.41	-5.08	-0.31	7.51e-7	Body mass index;
KIRP	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.42	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg23594656	chr7:65796392	TPST1	-0.44	-6.16	-0.37	2.93e-9	Aortic root size;
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03864326	chr16:67927170	PSKH1	-0.46	-6.15	-0.37	3.17e-9	Electrocardiographic conduction measures;
KIRP	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.56	7.41	0.43	1.99e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg19770292	chr5:1868693	NA	0.42	5.5	0.33	9.71e-8	Cardiovascular disease risk factors;
KIRP	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	5.23	0.32	3.71e-7	Schizophrenia;
KIRP	cis	rs7621025	0.505	rs34613715	chr3:136455007	A/T	cg15507776	chr3:136538369	TMEM22	-0.67	-5.96	-0.35	8.9e-9	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18252515	chr7:66147081	NA	0.47	5.71	0.34	3.3e-8	Aortic root size;
KIRP	cis	rs17453880	0.929	rs7725525	chr5:152041960	C/G	cg12297329	chr5:152029980	NA	0.71	10.57	0.56	9.22e-22	Subjective well-being;
KIRP	cis	rs838147	0.537	rs503279	chr19:49209010	C/T	cg08619932	chr19:49200058	FUT2	-0.35	-5.26	-0.32	3.06e-7	Dietary macronutrient intake;
KIRP	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18357526	chr6:26021779	HIST1H4A	0.5	6.57	0.39	3.01e-10	Height;
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.46	-6.27	-0.37	1.64e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg08890418	chr1:21044141	KIF17	0.34	5.11	0.31	6.41e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7870753	0.838	rs754560	chr9:99212930	T/G	cg25260653	chr9:99212216	HABP4	0.54	6.03	0.36	5.91e-9	Height;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-9.06	-0.5	4.16e-17	Lymphocyte counts;
KIRP	cis	rs5753618	0.504	rs9609296	chr22:31891784	T/G	cg02404636	chr22:31891804	SFI1	0.56	6.42	0.38	7.02e-10	Colorectal cancer;
KIRP	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg04944784	chr2:26401820	FAM59B	-0.66	-7.16	-0.42	9.23e-12	Gut microbiome composition (summer);
KIRP	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.5	-0.38	4.38e-10	Response to antipsychotic treatment;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg24633833	chr3:10029261	TMEM111	0.57	5.33	0.32	2.23e-7	Alzheimer's disease;
KIRP	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.49	-5.09	-0.31	7.14e-7	Alzheimer's disease;
KIRP	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg21775007	chr8:11205619	TDH	0.38	5.13	0.31	5.78e-7	Neuroticism;
KIRP	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-5.02	-0.3	9.97e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg11608241	chr8:8085544	FLJ10661	0.4	4.89	0.3	1.82e-6	Mood instability;
KIRP	cis	rs7005380	0.531	rs10102995	chr8:120961497	A/G	cg21645572	chr8:120931649	DEPDC6	-0.46	-6.34	-0.37	1.07e-9	Interstitial lung disease;
KIRP	cis	rs2131877	0.619	rs6794540	chr3:194867162	C/T	cg16306870	chr3:194868790	C3orf21	0.21	4.94	0.3	1.43e-6	Non-small cell lung cancer;
KIRP	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg22705602	chr4:152727874	NA	-0.4	-6.2	-0.37	2.43e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6568686	0.786	rs3851226	chr6:111826295	A/G	cg15721981	chr6:111408429	SLC16A10	-0.68	-6.04	-0.36	5.72e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27629807	chr5:109812946	TMEM232	-0.45	-7.11	-0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.64	-8.45	-0.47	2.56e-15	Blood metabolite levels;
KIRP	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.66	-0.56	4.51e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg06115741	chr20:33292138	TP53INP2	-0.36	-4.92	-0.3	1.6e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.28	25.03	0.85	1.39e-69	IgG glycosylation;
KIRP	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg20312557	chr2:97357134	FER1L5	-0.73	-5.08	-0.31	7.57e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg02158880	chr13:53174818	NA	-0.37	-4.91	-0.3	1.67e-6	Lewy body disease;
KIRP	cis	rs7809615	0.748	rs9632722	chr7:99115568	A/G	cg12290671	chr7:99195819	NA	-0.46	-4.99	-0.3	1.17e-6	Blood metabolite ratios;
KIRP	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.29	-0.47	7.53e-15	Mean corpuscular volume;
KIRP	cis	rs368755101	1	rs368755101	chr2:100762215	AG/A	cg22139774	chr2:100720529	AFF3	-0.34	-5.49	-0.33	1.02e-7	Plateletcrit;Red blood cell count;
KIRP	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	trans	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg26811252	chr16:29126840	RRN3P2	0.72	9.45	0.52	2.75e-18	Menopause (age at onset);
KIRP	trans	rs9329221	0.585	rs12550717	chr8:10266706	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.48	0.38	5.05e-10	Neuroticism;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg06223162	chr1:101003688	GPR88	-0.43	-8.7	-0.49	4.85e-16	Monocyte count;
KIRP	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg09904177	chr6:26538194	HMGN4	-0.51	-6.59	-0.39	2.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg25547332	chr5:131281432	NA	0.51	6.1	0.36	4.15e-9	Life satisfaction;
KIRP	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.7	9.51	0.52	1.87e-18	Systemic lupus erythematosus;
KIRP	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg19847866	chr10:1019161	NA	-0.62	-5.44	-0.33	1.3e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs11718455	0.767	rs11708363	chr3:43966585	G/A	cg08738300	chr3:44038990	NA	0.65	8.51	0.48	1.73e-15	Coronary artery disease;
KIRP	trans	rs13170463	0.579	rs35639375	chr5:8039275	C/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg17724175	chr1:150552817	MCL1	0.3	5.18	0.31	4.59e-7	Melanoma;
KIRP	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.84	10.12	0.54	2.46e-20	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg08992911	chr2:238395768	MLPH	0.48	5.23	0.32	3.55e-7	Prostate cancer;
KIRP	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.67	6.81	0.4	7.55e-11	Vitiligo;
KIRP	cis	rs6545883	0.894	rs6545845	chr2:61437044	G/C	cg15711740	chr2:61764176	XPO1	0.58	7.63	0.44	5.3e-13	Tuberculosis;
KIRP	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg25457927	chr22:38595422	NA	-0.32	-6.5	-0.38	4.39e-10	Breast cancer;
KIRP	cis	rs6496667	0.779	rs59814752	chr15:91005738	G/A	cg10434728	chr15:90938212	IQGAP1	0.36	4.9	0.3	1.71e-6	Rheumatoid arthritis;
KIRP	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg10818794	chr15:86012489	AKAP13	-0.49	-7.03	-0.41	1.98e-11	Coronary artery disease;
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.7	12.08	0.61	1.09e-26	Cardiovascular disease risk factors;
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-5.76	-0.34	2.44e-8	Lung cancer;
KIRP	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.59	7.37	0.43	2.51e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg22284058	chr8:142237359	SLC45A4	-0.41	-5.03	-0.31	9.58e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.78	-11.73	-0.6	1.53e-25	Height;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg22081084	chr1:89990230	LRRC8B	-0.54	-6.74	-0.39	1.09e-10	Neuroticism;
KIRP	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.59	-0.39	2.66e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.83	11.49	0.59	9.56e-25	Height;
KIRP	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.72	10.74	0.56	2.66e-22	Blood metabolite ratios;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25877054	chr1:95700082	RWDD3	0.45	6.34	0.37	1.06e-9	Survival in pancreatic cancer;
KIRP	cis	rs3789045	0.826	rs12040520	chr1:204564762	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.61	-6.14	-0.36	3.3e-9	Educational attainment (college completion);
KIRP	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.06	-0.31	8.14e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7116495	0.737	rs7101553	chr11:71753903	C/T	cg10381502	chr11:71823885	C11orf51	-1.2	-7.89	-0.45	1.01e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg16558253	chr16:72132732	DHX38	-0.45	-5.21	-0.32	3.95e-7	Blood protein levels;
KIRP	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.8	11.0	0.57	3.64e-23	Aortic root size;
KIRP	trans	rs7160151	0.599	rs2776479	chr14:49836993	A/G	cg24274272	chr17:72278023	DNAI2	0.46	6.14	0.36	3.25e-9	C-reactive protein (red blood cell fatty acid level interaction);
KIRP	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg22676075	chr6:135203613	NA	0.48	6.56	0.39	3.23e-10	Red blood cell count;
KIRP	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg19623624	chr10:135278901	LOC619207	-0.49	-5.49	-0.33	9.9e-8	Systemic lupus erythematosus;
KIRP	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.6	-7.9	-0.45	9.12e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.7	-0.34	3.5e-8	Multiple sclerosis;
KIRP	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08439880	chr3:133502540	NA	-0.5	-6.33	-0.37	1.14e-9	Iron status biomarkers;
KIRP	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.68	-8.53	-0.48	1.54e-15	Body mass index;
KIRP	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg04374321	chr14:90722782	PSMC1	-0.6	-8.08	-0.46	2.92e-14	Mortality in heart failure;
KIRP	cis	rs7116495	0.881	rs1892921	chr11:71702138	G/A	cg26138937	chr11:71823887	C11orf51	-0.72	-5.83	-0.35	1.7e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.66	-0.39	1.76e-10	Morning vs. evening chronotype;
KIRP	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg10932868	chr11:921992	NA	0.62	8.18	0.46	1.56e-14	Alzheimer's disease (late onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03120717	chr11:124670846	C11orf61	-0.44	-6.25	-0.37	1.78e-9	Interleukin-4 levels;
KIRP	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg10189774	chr4:17578691	LAP3	0.52	6.43	0.38	6.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17023223	0.537	rs66715579	chr1:119725432	G/A	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.97	-12.5	-0.62	4.29e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg05791153	chr7:19748676	TWISTNB	0.66	5.98	0.36	8e-9	Thyroid stimulating hormone;
KIRP	trans	rs36715	1.000	rs36705	chr5:127554486	A/G	cg05141384	chr18:14378365	NA	0.5	6.21	0.37	2.25e-9	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14258154	chr1:52718499	ZFYVE9	-0.41	-6.23	-0.37	2.03e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.08e-10	Axial length;
KIRP	cis	rs12447804	0.822	rs9926705	chr16:58081989	C/G	cg03859792	chr16:58121049	NA	0.47	6.37	0.38	9.35e-10	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.25	-0.42	5.36e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg17554472	chr22:41940697	POLR3H	0.42	5.04	0.31	9.13e-7	Vitiligo;
KIRP	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.44	-5.9	-0.35	1.2e-8	Type 2 diabetes;
KIRP	trans	rs2504916	0.911	rs2457577	chr6:160854138	A/C	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	0.62	6.19	0.37	2.45e-9	Response to hepatitis C treatment;
KIRP	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.77	-5.66	-0.34	4.19e-8	IgG glycosylation;
KIRP	cis	rs735539	0.521	rs2762996	chr13:21373908	A/C	cg04906043	chr13:21280425	IL17D	-0.43	-4.99	-0.3	1.16e-6	Dental caries;
KIRP	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.58	-6.44	-0.38	6.36e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.81	11.62	0.6	3.62e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs78487399	0.808	rs7570242	chr2:43706002	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.12	-0.31	6.18e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.85	-0.49	1.78e-16	Triglycerides;
KIRP	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.83	9.81	0.53	2.22e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.57	7.36	0.42	2.83e-12	Colorectal cancer;
KIRP	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.45	5.26	0.32	3.08e-7	Glycated hemoglobin levels;
KIRP	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.78	12.52	0.62	3.66e-28	Menarche (age at onset);
KIRP	cis	rs2790457	0.771	rs2800737	chr10:28943072	T/C	cg04045419	chr10:28823091	WAC	-0.56	-6.23	-0.37	1.97e-9	Multiple myeloma;
KIRP	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg24315340	chr6:146058215	EPM2A	-0.4	-4.94	-0.3	1.46e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg15704280	chr7:45808275	SEPT13	0.7	6.3	0.37	1.39e-9	Axial length;
KIRP	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-9.73	-0.53	3.98e-19	Height;
KIRP	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.9	-10.55	-0.56	1.07e-21	White matter hyperintensity burden;
KIRP	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg18657303	chr4:1051139	NA	0.55	4.99	0.3	1.16e-6	Recombination rate (females);
KIRP	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.84	5.6	0.34	5.61e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.64	9.37	0.51	4.96e-18	Vitiligo;
KIRP	cis	rs922692	0.744	rs2277545	chr15:79083591	T/C	cg04896959	chr15:78267971	NA	0.52	6.83	0.4	6.64e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs796364	0.616	rs2689765	chr2:200696352	T/C	cg23649088	chr2:200775458	C2orf69	0.57	5.56	0.33	6.86e-8	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg10760299	chr15:45669010	GATM	0.35	5.13	0.31	5.79e-7	Homoarginine levels;
KIRP	cis	rs6142102	0.602	rs2268079	chr20:32596750	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	5.74	0.34	2.74e-8	Skin pigmentation;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg21485166	chr2:74757150	HTRA2;AUP1	-0.57	-6.23	-0.37	2.01e-9	Menopause (age at onset);
KIRP	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg22681709	chr2:178499509	PDE11A	0.61	8.19	0.46	1.42e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs8070740	0.898	rs9895440	chr17:5325643	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	7.51	0.43	1.1e-12	Menopause (age at onset);
KIRP	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg06636001	chr8:8085503	FLJ10661	0.6	8.04	0.46	3.81e-14	Myopia (pathological);
KIRP	cis	rs4908768	0.579	rs7520572	chr1:8871690	G/A	cg25722041	chr1:8623473	RERE	0.58	7.55	0.43	8.29e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs504918	0.527	rs78896894	chr3:124013360	T/G	cg05766129	chr3:123988013	KALRN	-0.44	-5.64	-0.34	4.6e-8	Schizophrenia;
KIRP	cis	rs4363385	0.553	rs11580383	chr1:152942192	A/G	cg07796016	chr1:152779584	LCE1C	-0.48	-6.03	-0.36	6.05e-9	Inflammatory skin disease;
KIRP	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg19116668	chr7:99932089	PMS2L1	0.47	5.5	0.33	9.68e-8	Coronary artery disease;
KIRP	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.45	-0.38	5.91e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	12.79	0.63	4.83e-29	Smoking behavior;
KIRP	cis	rs1440410	0.835	rs7665674	chr4:144050334	A/C	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.4	-9.79	-0.53	2.61e-19	Corneal astigmatism;
KIRP	trans	rs1106684	1.000	rs11764235	chr7:131462880	G/A	cg13607082	chr12:122652224	LRRC43	-0.66	-6.77	-0.4	9.51e-11	Body mass index;
KIRP	cis	rs7106204	0.748	rs11827778	chr11:24211321	G/A	ch.11.24196551F	chr11:24239977	NA	0.81	9.6	0.52	9.93e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.14	0.58	1.33e-23	Alzheimer's disease;
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg00684032	chr4:1343700	KIAA1530	0.51	6.74	0.39	1.11e-10	Longevity;
KIRP	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg18357526	chr6:26021779	HIST1H4A	0.4	5.24	0.32	3.39e-7	Height;
KIRP	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.09	0.41	1.46e-11	Lung cancer;
KIRP	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg00405596	chr8:11794950	NA	-0.52	-6.68	-0.39	1.58e-10	Retinal vascular caliber;
KIRP	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.73	10.94	0.57	5.84e-23	Orofacial clefts;
KIRP	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.79	11.58	0.59	4.77e-25	Neuroticism;
KIRP	cis	rs4141404	0.923	rs2413046	chr22:31665909	C/A	cg22777020	chr22:31556080	RNF185	-0.5	-5.29	-0.32	2.74e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.36	-5.53	-0.33	8.19e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2387326	0.767	rs12257487	chr10:129943286	A/G	cg16087940	chr10:129947807	NA	-0.36	-4.85	-0.3	2.24e-6	Select biomarker traits;
KIRP	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	7.58	0.43	7.22e-13	Height;
KIRP	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.86	8.9	0.49	1.21e-16	Prostate cancer;
KIRP	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg00129232	chr17:37814104	STARD3	-0.44	-5.69	-0.34	3.62e-8	Self-reported allergy;
KIRP	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-4.85	-0.3	2.15e-6	Neuroticism;
KIRP	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.76	10.2	0.55	1.3e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.91	14.14	0.67	1.28e-33	Testicular germ cell tumor;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18715318	chr22:19420067	HIRA;MRPL40	0.45	6.46	0.38	5.66e-10	Survival in pancreatic cancer;
KIRP	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg13180566	chr4:1052158	NA	-0.51	-5.25	-0.32	3.33e-7	Recombination rate (females);
KIRP	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.52	-5.48	-0.33	1.05e-7	Corneal structure;
KIRP	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.49	6.36	0.38	9.69e-10	Menopause (age at onset);
KIRP	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg01028140	chr2:1542097	TPO	-0.88	-6.99	-0.41	2.6e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg08662619	chr6:150070041	PCMT1	0.34	5.52	0.33	8.75e-8	Lung cancer;
KIRP	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg13180566	chr4:1052158	NA	-0.5	-5.14	-0.31	5.62e-7	Recombination rate (females);
KIRP	cis	rs73242632	1.000	rs10002090	chr4:57859592	T/C	cg20415529	chr4:57845134	POLR2B;C4orf14	0.7	4.89	0.3	1.8e-6	Congenital heart disease (maternal effect);
KIRP	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.22	0.37	2.07e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.4	-6.94	-0.4	3.38e-11	Heart rate;
KIRP	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.77	9.89	0.53	1.28e-19	Corneal astigmatism;
KIRP	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg07747251	chr5:1868357	NA	0.49	6.56	0.39	3.19e-10	Cardiovascular disease risk factors;
KIRP	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg11845111	chr2:191398756	TMEM194B	-0.96	-10.31	-0.55	6.19e-21	Diastolic blood pressure;
KIRP	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.31	0.51	7.18e-18	Prudent dietary pattern;
KIRP	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.93	9.52	0.52	1.72e-18	Methadone dose in opioid dependence;
KIRP	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11299333	chr21:38379036	DSCR6	-0.42	-6.22	-0.37	2.12e-9	Myopia;
KIRP	cis	rs2274273	0.624	rs7151581	chr14:55788445	A/G	cg04306507	chr14:55594613	LGALS3	-0.37	-5.18	-0.31	4.55e-7	Protein biomarker;
KIRP	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg10503236	chr1:231470652	EXOC8	-0.57	-7.93	-0.45	7.66e-14	Hemoglobin concentration;
KIRP	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg15277658	chr10:73421701	CDH23	0.53	6.16	0.37	2.96e-9	Response to statin therapy;
KIRP	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg09788416	chr12:39539408	NA	0.43	5.25	0.32	3.22e-7	Morning vs. evening chronotype;
KIRP	cis	rs9398803	0.965	rs9388486	chr6:126661154	C/T	cg19875578	chr6:126661172	C6orf173	-0.46	-6.11	-0.36	3.82e-9	Male-pattern baldness;
KIRP	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs11718455	0.767	rs11130019	chr3:43989348	C/A	cg08738300	chr3:44038990	NA	0.65	8.82	0.49	2.17e-16	Coronary artery disease;
KIRP	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	1.01	11.61	0.59	3.87e-25	Vitiligo;
KIRP	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg20469991	chr17:27169893	C17orf63	-0.48	-4.94	-0.3	1.44e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2625529	0.689	rs12161990	chr15:72202440	T/C	cg16672083	chr15:72433130	SENP8	0.47	6.62	0.39	2.27e-10	Red blood cell count;
KIRP	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.5	-5.63	-0.34	4.94e-8	Alzheimer's disease (late onset);
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg11641102	chr8:27183873	PTK2B	0.43	5.51	0.33	9.2e-8	Neuroticism;
KIRP	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.22	-0.46	1.14e-14	Body mass index;
KIRP	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-13.56	-0.65	1.16e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-1.03	-9.52	-0.52	1.74e-18	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.55	7.19	0.42	7.85e-12	Endometrial cancer;
KIRP	cis	rs17384381	0.906	rs2300639	chr1:85823676	T/A	cg16011679	chr1:85725395	C1orf52	0.86	8.54	0.48	1.43e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg27205649	chr11:78285834	NARS2	0.7	7.86	0.45	1.24e-13	Alzheimer's disease (survival time);
KIRP	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg16141378	chr3:129829833	LOC729375	-0.52	-6.97	-0.41	2.94e-11	Mood instability;
KIRP	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.48	-6.48	-0.38	5.06e-10	Hip circumference;Waist circumference;
KIRP	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.18	12.64	0.63	1.53e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.78	8.83	0.49	2.04e-16	Corneal astigmatism;
KIRP	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg03999872	chr20:62272968	STMN3	-0.62	-7.11	-0.41	1.28e-11	Atopic dermatitis;
KIRP	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg12131826	chr15:77904385	NA	0.43	5.66	0.34	4.28e-8	Type 2 diabetes;
KIRP	cis	rs9831754	0.526	rs6548551	chr3:78342292	C/T	cg06138941	chr3:78371609	NA	0.55	7.84	0.45	1.34e-13	Calcium levels;
KIRP	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg17796960	chr10:135278976	LOC619207	-0.48	-5.51	-0.33	8.83e-8	Systemic lupus erythematosus;
KIRP	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg07952391	chr2:88470173	THNSL2	-0.5	-6.53	-0.38	3.8e-10	Response to metformin (IC50);
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00908189	chr16:619842	PIGQ	0.85	11.76	0.6	1.28e-25	Height;
KIRP	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.47	-7.01	-0.41	2.32e-11	Vitamin D levels;
KIRP	cis	rs2249694	0.922	rs4306261	chr10:135410989	A/G	cg20169779	chr10:135381914	SYCE1	-0.42	-4.98	-0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs4006360	0.606	rs11657468	chr17:39233876	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.62	-0.48	8.4e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs4660306	0.961	rs11211138	chr1:46015157	A/G	cg24296786	chr1:45957014	TESK2	0.48	5.35	0.32	2.01e-7	Homocysteine levels;
KIRP	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	23.17	0.83	8.84e-64	Schizophrenia;
KIRP	cis	rs7665939	1.000	rs72709216	chr4:190112484	G/A	cg09826759	chr4:190284978	NA	-0.77	-5.16	-0.31	5.16e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-6.96	-0.41	3.04e-11	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg02160872	chr5:212506	CCDC127	-0.46	-4.98	-0.3	1.18e-6	Breast cancer;
KIRP	trans	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg09872104	chr7:134855509	C7orf49	-0.96	-6.12	-0.36	3.69e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6832769	0.961	rs11735267	chr4:56347287	C/T	cg09317128	chr4:56265301	TMEM165	0.55	7.11	0.41	1.25e-11	Personality dimensions;
KIRP	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg20673091	chr1:2541236	MMEL1	-0.78	-12.67	-0.63	1.21e-28	Ulcerative colitis;
KIRP	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg11608241	chr8:8085544	FLJ10661	-0.49	-6.49	-0.38	4.81e-10	Neuroticism;
KIRP	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg04166393	chr7:2884313	GNA12	0.42	5.4	0.33	1.56e-7	Height;
KIRP	cis	rs4302748	0.862	rs11772280	chr7:36186110	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.57	7.22	0.42	6.4e-12	Menarche (age at onset);
KIRP	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.97	-15.19	-0.7	3.32e-37	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23956068	chr18:33647542	RPRD1A	0.54	7.35	0.42	2.96e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg22284058	chr8:142237359	SLC45A4	-0.52	-6.65	-0.39	1.85e-10	Immature fraction of reticulocytes;
KIRP	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg13160058	chr8:26243215	BNIP3L	-0.53	-7.14	-0.41	1.03e-11	Red cell distribution width;
KIRP	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg24375607	chr4:120327624	NA	0.48	5.6	0.34	5.8e-8	Corneal astigmatism;
KIRP	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg00646381	chr17:77835854	NA	0.54	7.66	0.44	4.38e-13	Glucocorticoid-induced osteonecrosis (age 10 years and older);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08374525	chr5:36876954	NIPBL	-0.5	-6.57	-0.39	3.02e-10	Migraine with aura;
KIRP	cis	rs77956314	0.901	rs7131959	chr12:117335615	G/A	cg02017074	chr12:117425053	FBXW8	-0.56	-4.84	-0.3	2.24e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg10223061	chr2:219282414	VIL1	0.34	5.6	0.34	5.84e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.86	-0.35	1.47e-8	Autism;
KIRP	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	8.35	0.47	4.99e-15	Retinal vascular caliber;
KIRP	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg23625390	chr15:77176239	SCAPER	0.54	7.13	0.41	1.08e-11	Blood metabolite levels;
KIRP	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg08741688	chr4:3415352	RGS12	-0.5	-5.55	-0.33	7.54e-8	Serum sulfate level;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18610958	chr2:71693778	DYSF	-0.48	-6.62	-0.39	2.27e-10	Myopia;
KIRP	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.07	0.58	2.25e-23	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs8049040	0.524	rs12445403	chr16:71428670	G/A	cg08717414	chr16:71523259	ZNF19	-0.59	-6.92	-0.4	3.91e-11	Blood protein levels;
KIRP	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg01765077	chr12:122356316	WDR66	0.64	8.78	0.49	2.79e-16	Mean corpuscular volume;
KIRP	cis	rs17123764	0.892	rs7968302	chr12:50140185	T/C	cg20471783	chr12:50157085	TMBIM6	0.41	5.87	0.35	1.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.12	0.54	2.3e-20	Hip circumference adjusted for BMI;
KIRP	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.3	-0.42	3.91e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg18765712	chr3:179670323	PEX5L	-0.41	-5.5	-0.33	9.36e-8	Blood metabolite levels;
KIRP	cis	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.03e-11	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00585698	chr12:123750864	CDK2AP1	0.49	6.21	0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg05766667	chr16:11350740	SOCS1	-0.48	-6.08	-0.36	4.56e-9	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-0.82	-9.14	-0.5	2.4e-17	Gut microbiome composition (summer);
KIRP	cis	rs2151522	0.762	rs9398822	chr6:127176980	C/A	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.52	-7.26	-0.42	5.12e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs6838801	0.765	rs17002161	chr4:77598673	C/G	cg17476223	chr4:77663285	SHROOM3	0.54	7.38	0.43	2.48e-12	Cleft lip with or without cleft palate;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23521253	chr10:126653589	ZRANB1	-0.38	-6.16	-0.37	3e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg01324507	chr7:1177794	C7orf50	0.5	4.9	0.3	1.78e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.68	8.5	0.48	1.83e-15	Recalcitrant atopic dermatitis;
KIRP	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.56	6.8	0.4	7.94e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg14004847	chr7:1930337	MAD1L1	-0.47	-5.05	-0.31	8.43e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	7.15	0.41	1.01e-11	Aortic root size;
KIRP	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.03	-0.64	7.39e-30	Height;
KIRP	cis	rs72730918	0.564	rs1551657	chr15:51761284	A/C	cg14296394	chr15:51910925	DMXL2	0.78	10.66	0.56	4.67e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.51	-11.59	-0.59	4.46e-25	Diabetic kidney disease;
KIRP	trans	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg18187862	chr3:45730750	SACM1L	-0.57	-6.41	-0.38	7.25e-10	Primary sclerosing cholangitis;
KIRP	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.05	-0.36	5.37e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.66	10.0	0.54	5.51e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.61	-6.51	-0.38	4.25e-10	DNA methylation (variation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00596521	chr2:175260560	CIR1;SCRN3	0.55	7.27	0.42	4.86e-12	Parkinson's disease;
KIRP	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs72792276	0.818	rs3805610	chr5:127487719	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	5.42	0.33	1.44e-7	Red cell distribution width;
KIRP	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg23719950	chr11:63933701	MACROD1	-0.64	-6.16	-0.37	2.88e-9	Mean platelet volume;
KIRP	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.45	-0.43	1.57e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs4523957	0.583	rs4349181	chr17:2040963	A/G	cg16513277	chr17:2031491	SMG6	-0.84	-12.24	-0.62	3.11e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs732716	0.853	rs12459922	chr19:4455862	A/G	cg21720385	chr19:4455239	UBXN6	0.71	8.87	0.49	1.49e-16	Mean corpuscular volume;
KIRP	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.45	6.8	0.4	7.89e-11	Platelet distribution width;
KIRP	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg19761014	chr17:28927070	LRRC37B2	0.66	4.89	0.3	1.86e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.98	0.3	1.2e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs7624766	0.555	rs4525912	chr3:160527149	C/T	cg22637730	chr3:160473554	PPM1L	0.44	5.45	0.33	1.22e-7	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.57	6.79	0.4	8.57e-11	Obesity-related traits;
KIRP	cis	rs3736485	0.934	rs4775955	chr15:51873449	C/T	cg14296394	chr15:51910925	DMXL2	0.34	4.86	0.3	2.1e-6	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6568686	0.627	rs174387	chr6:111915023	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.5	5.1	0.31	6.9e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.62	-7.7	-0.44	3.32e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.73e-10	Diabetic kidney disease;
KIRP	trans	rs73019876	0.869	rs11085505	chr19:22148671	C/G	cg05283091	chr4:19457120	NA	0.47	6.18	0.37	2.67e-9	Testicular germ cell tumor;
KIRP	cis	rs7224685	0.569	rs67815988	chr17:3998312	A/C	cg09695851	chr17:3907499	NA	0.54	5.15	0.31	5.3e-7	Type 2 diabetes;
KIRP	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg13373371	chr19:49828787	SLC6A16	0.41	5.14	0.31	5.57e-7	Multiple sclerosis;
KIRP	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg26531700	chr6:26746687	NA	0.38	4.9	0.3	1.75e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.47	6.42	0.38	7.11e-10	Testicular germ cell tumor;
KIRP	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.5	-0.38	4.42e-10	Aortic root size;
KIRP	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.36	-0.42	2.74e-12	Morning vs. evening chronotype;
KIRP	cis	rs4936894	0.500	rs12362791	chr11:124128232	C/T	cg27160556	chr11:124181099	OR8D1	-0.38	-5.63	-0.34	4.97e-8	Aging (time to death);
KIRP	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg09184832	chr6:79620586	NA	-0.52	-7.11	-0.41	1.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.33	0.62	1.63e-27	Bipolar disorder;
KIRP	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.74	-10.72	-0.56	3.06e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.58e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs7536201	1.000	rs2135755	chr1:25302495	G/A	cg23273869	chr1:25296894	NA	-0.42	-6.05	-0.36	5.23e-9	Psoriasis vulgaris;
KIRP	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.51	-7.74	-0.44	2.53e-13	Bone mineral density;
KIRP	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.39	-5.25	-0.32	3.25e-7	Coronary artery disease;
KIRP	cis	rs7116495	0.609	rs949324	chr11:71714526	G/C	cg07596299	chr11:71824057	C11orf51	-0.83	-5.59	-0.34	6.04e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.59	-7.28	-0.42	4.38e-12	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg13160058	chr8:26243215	BNIP3L	-0.52	-7.41	-0.43	2.01e-12	Red cell distribution width;
KIRP	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.97	0.54	6.75e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7751419	0.651	rs12198923	chr6:39094988	C/G	cg08089693	chr6:39098871	NA	-0.68	-9.77	-0.53	2.82e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs2976388	1.000	rs2976388	chr8:143760256	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-6.46	-0.38	5.68e-10	Urinary tract infection frequency;
KIRP	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.63	-9.15	-0.5	2.23e-17	Total body bone mineral density;
KIRP	cis	rs944802	0.639	rs7022662	chr9:22147715	C/G	cg00491127	chr9:22154101	NA	0.47	5.09	0.31	7.03e-7	White blood cell count;
KIRP	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.47	5.81	0.35	1.88e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00802000	chr16:706648	WDR90	-0.41	-5.21	-0.32	3.98e-7	Height;
KIRP	cis	rs16828019	0.929	rs12029321	chr1:41682530	G/C	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs357618	1.000	rs357625	chr5:150848874	A/G	cg22672639	chr5:150884813	FAT2	0.36	5.4	0.33	1.61e-7	Basophil percentage of white cells;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	1.15	20.42	0.79	6.82e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.36	-0.32	1.88e-7	Bladder cancer;
KIRP	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg09597638	chr17:3907349	NA	-0.53	-7.6	-0.44	6.27e-13	Type 2 diabetes;
KIRP	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.59	-6.05	-0.36	5.29e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg09904177	chr6:26538194	HMGN4	0.4	4.95	0.3	1.4e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1816752	0.755	rs1981277	chr13:24983513	G/A	cg02811702	chr13:24901961	NA	0.39	5.04	0.31	8.88e-7	Obesity-related traits;
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg10360139	chr7:1886902	MAD1L1	-0.5	-5.54	-0.33	7.89e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-7.48	-0.43	1.35e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.47	5.09	0.31	7.05e-7	Smoking behavior;
KIRP	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.8	-12.72	-0.63	7.95e-29	Multiple myeloma (IgH translocation);
KIRP	cis	rs4523957	0.559	rs216174	chr17:2164898	A/G	cg16513277	chr17:2031491	SMG6	0.49	5.44	0.33	1.28e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6430538	0.621	rs4953933	chr2:135543584	T/C	cg12500956	chr2:135428796	TMEM163	0.4	5.1	0.31	6.93e-7	Parkinson's disease;
KIRP	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.2	0.51	1.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg25486957	chr4:152246857	NA	-0.53	-5.77	-0.35	2.32e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg02073558	chr3:44770973	ZNF501	-0.57	-7.98	-0.45	5.39e-14	Depressive symptoms;
KIRP	cis	rs35955747	0.633	rs4541328	chr22:31896172	G/A	cg02404636	chr22:31891804	SFI1	-0.41	-5.53	-0.33	7.96e-8	Neutrophil count;Sum basophil neutrophil counts;
KIRP	trans	rs57996174	0.749	rs73197971	chr21:35020166	C/T	cg02613685	chr15:49174654	SHC4	-0.89	-6.06	-0.36	5.14e-9	Psoriasis;
KIRP	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg07856975	chr6:36356162	ETV7	0.43	5.49	0.33	9.98e-8	Platelet distribution width;
KIRP	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-6.9	-0.4	4.35e-11	Chronic sinus infection;
KIRP	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg27490568	chr2:178487706	NA	0.65	8.97	0.5	7.97e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9815354	0.812	rs57809229	chr3:41840162	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg05802129	chr4:122689817	NA	-0.58	-7.46	-0.43	1.51e-12	Type 2 diabetes;
KIRP	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg08313168	chr12:7315531	NA	0.71	6.4	0.38	7.85e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	6.24	0.37	1.93e-9	Breast cancer;
KIRP	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg05347473	chr6:146136440	FBXO30	0.61	8.51	0.48	1.79e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg13293535	chr8:11597251	GATA4	-0.39	-5.09	-0.31	7.19e-7	Retinal vascular caliber;
KIRP	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.5	6.76	0.4	9.74e-11	Schizophrenia;
KIRP	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.72	-0.34	3.11e-8	Height;
KIRP	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg23625390	chr15:77176239	SCAPER	0.53	6.92	0.4	3.81e-11	Blood metabolite levels;
KIRP	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.97	11.63	0.6	3.41e-25	Exhaled nitric oxide levels;
KIRP	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.85	-11.43	-0.59	1.48e-24	Obesity-related traits;
KIRP	cis	rs4233802	0.737	rs6740399	chr2:151165149	C/A	cg25300694	chr2:151184358	NA	0.71	5.4	0.33	1.54e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg05562828	chr17:3906858	NA	0.82	17.9	0.75	1.84e-46	Type 2 diabetes;
KIRP	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.41	-0.33	1.47e-7	Bipolar disorder;
KIRP	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13185784	0.703	rs6894217	chr5:179667806	G/A	cg23221052	chr5:179740743	GFPT2	0.47	5.16	0.31	5.09e-7	TRAIL levels;
KIRP	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.84	0.35	1.66e-8	Aortic root size;
KIRP	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg20503657	chr10:835505	NA	-0.59	-6.93	-0.4	3.72e-11	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06931446	chr19:7459819	ARHGEF18	0.47	6.16	0.37	2.95e-9	Myopia (pathological);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03213794	chr11:1968318	MRPL23	-0.47	-6.05	-0.36	5.46e-9	Myopia;
KIRP	cis	rs12049351	0.774	rs4925455	chr1:229623665	T/A	cg11742688	chr1:229674241	ABCB10	-0.39	-6.08	-0.36	4.51e-9	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg26965718	chr17:79658957	HGS	-0.61	-5.68	-0.34	3.87e-8	Dental caries;
KIRP	cis	rs10203711	0.966	rs10929288	chr2:239583146	A/G	cg14580085	chr2:239553406	NA	0.4	5.19	0.31	4.36e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg15590007	chr10:45870220	ALOX5	0.55	5.35	0.32	2.04e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.92	15.01	0.69	1.34e-36	Dental caries;
KIRP	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg11987759	chr7:65425863	GUSB	-0.52	-7.15	-0.41	9.75e-12	Calcium levels;
KIRP	cis	rs6578185	0.810	rs3935445	chr8:142452618	C/A	cg07762003	chr8:142452454	FLJ43860	-0.64	-9.6	-0.52	9.4e-19	Endometriosis;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11389618	chr2:144712819	GTDC1	0.45	6.92	0.4	3.86e-11	Migraine with aura;
KIRP	cis	rs11264213	0.591	rs274745	chr1:36538282	G/A	cg27506609	chr1:36549197	TEKT2	-1.18	-8.58	-0.48	1.07e-15	Schizophrenia;
KIRP	cis	rs76533333	0.564	rs17751071	chr13:113392724	G/A	cg04656015	chr13:113407548	ATP11A	0.64	5.63	0.34	4.84e-8	Red cell distribution width;
KIRP	cis	rs10773046	0.740	rs1317312	chr12:124364131	G/C	cg18594669	chr12:124364423	DNAH10	0.39	5.24	0.32	3.4e-7	Osteoarthritis (hip);
KIRP	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.21	0.46	1.23e-14	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.8	-0.35	2.06e-8	Triglycerides;
KIRP	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg12131826	chr15:77904385	NA	0.43	5.71	0.34	3.32e-8	Type 2 diabetes;
KIRP	cis	rs1983891	0.955	rs6917270	chr6:41548755	A/G	cg20194872	chr6:41519635	FOXP4	0.57	7.26	0.42	5.16e-12	Prostate cancer;
KIRP	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.55	7.03	0.41	2.03e-11	Coronary heart disease;
KIRP	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg00579200	chr11:133705235	NA	-0.38	-4.93	-0.3	1.54e-6	Childhood ear infection;
KIRP	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.35	-0.38	1.02e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22187843	chr7:2395126	EIF3B	0.49	6.67	0.39	1.7e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.23	-24.7	-0.84	1.49e-68	Exhaled nitric oxide output;
KIRP	cis	rs3857067	0.736	rs2865333	chr4:95019964	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16863872	chr21:45526972	PWP2	0.44	6.12	0.36	3.75e-9	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.15e-7	Aortic root size;
KIRP	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.68	-0.34	3.78e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg14345882	chr6:26364793	BTN3A2	0.53	4.92	0.3	1.56e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs15676	0.679	rs6478853	chr9:131588813	C/G	cg00228799	chr9:131580591	ENDOG	-0.53	-5.87	-0.35	1.42e-8	Blood metabolite levels;
KIRP	cis	rs17739794	0.517	rs4439155	chr8:781047	C/T	cg01971667	chr8:817044	NA	-0.55	-6.95	-0.41	3.26e-11	Clozapine-induced cytotoxicity;
KIRP	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg04691961	chr3:161091175	C3orf57	-0.54	-8.36	-0.47	4.68e-15	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.68	-0.34	3.74e-8	Total body bone mineral density;
KIRP	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.61	8.48	0.48	2.14e-15	Lymphocyte counts;
KIRP	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.47	-0.52	2.43e-18	Hemoglobin concentration;
KIRP	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg25547332	chr5:131281432	NA	-0.49	-5.98	-0.36	8.02e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.57	7.52	0.43	1.05e-12	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs3931020	0.688	rs277396	chr1:75213648	A/C	cg00121533	chr1:75199117	CRYZ;TYW3	-0.42	-4.99	-0.3	1.14e-6	Resistin levels;
KIRP	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11987759	chr7:65425863	GUSB	0.47	6.04	0.36	5.68e-9	Aortic root size;
KIRP	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.63	7.47	0.43	1.36e-12	Type 2 diabetes;
KIRP	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.79	0.66	2.02e-32	Tonsillectomy;
KIRP	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.61	-5.35	-0.32	1.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7929679	0.602	rs11032870	chr11:34805524	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.34e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs5753037	0.869	rs12710565	chr22:30292724	A/G	cg27665648	chr22:30112403	NA	0.39	5.48	0.33	1.04e-7	Type 1 diabetes;
KIRP	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg19875535	chr5:140030758	IK	-0.72	-10.39	-0.55	3.29e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2073499	0.872	rs58051625	chr3:50278717	G/C	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.65	5.19	0.31	4.49e-7	Schizophrenia;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg27224642	chr2:39665105	MAP4K3	0.59	6.06	0.36	5.11e-9	Response to statin therapy;
KIRP	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg13165212	chr22:42675999	NA	0.29	5.36	0.32	1.94e-7	Cognitive function;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-0.67	-9.04	-0.5	4.93e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.69	7.08	0.41	1.52e-11	Bipolar disorder;
KIRP	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.73	-8.41	-0.47	3.42e-15	Pursuit maintenance gain;
KIRP	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg19592336	chr6:28129416	ZNF389	0.48	5.56	0.33	6.98e-8	Depression;
KIRP	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.44	-4.98	-0.3	1.18e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg20701182	chr2:24300061	SF3B14	0.49	5.08	0.31	7.48e-7	Asthma;
KIRP	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg18527119	chr7:66119851	NA	0.46	5.33	0.32	2.22e-7	Aortic root size;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	7.6	0.44	6.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-10.39	-0.55	3.3e-21	Morning vs. evening chronotype;
KIRP	cis	rs4356932	1.000	rs4859414	chr4:76949997	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16524936	chr4:1340807	KIAA1530	-0.43	-5.61	-0.34	5.38e-8	Longevity;
KIRP	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	0.69	6.77	0.4	9.3e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs8049040	0.547	rs12929335	chr16:71435752	G/A	cg08717414	chr16:71523259	ZNF19	-0.56	-6.65	-0.39	1.86e-10	Blood protein levels;
KIRP	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	0.85	10.54	0.56	1.08e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs1461503	0.934	rs7115651	chr11:122831882	C/T	cg27398637	chr11:122830231	C11orf63	-0.71	-9.68	-0.53	5.36e-19	Menarche (age at onset);
KIRP	cis	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg11266682	chr4:10021025	SLC2A9	0.39	4.89	0.3	1.84e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg24881330	chr22:46731750	TRMU	0.79	5.85	0.35	1.59e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2882667	0.628	rs13154573	chr5:138148064	T/C	cg04439458	chr5:138467593	SIL1	-0.4	-5.21	-0.31	4.09e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	6.09	0.36	4.39e-9	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07603517	chr19:40940074	NA	-0.54	-6.78	-0.4	8.8e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg01420254	chr6:26195488	NA	1.17	8.89	0.49	1.37e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs7225151	0.710	rs16954552	chr17:5252514	C/T	cg24500398	chr17:5266808	RABEP1	0.54	5.65	0.34	4.38e-8	Alzheimer's disease (late onset);
KIRP	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg16309518	chr5:176445507	NA	-0.89	-14.15	-0.67	1.19e-33	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.91	-11.11	-0.58	1.68e-23	Response to antineoplastic agents;
KIRP	cis	rs1832871	1.000	rs705930	chr6:158711855	T/C	cg07215822	chr6:158701037	NA	-0.49	-6.43	-0.38	6.7e-10	Height;
KIRP	cis	rs10044254	0.563	rs16867538	chr5:15680744	A/G	cg07238450	chr5:15720153	FBXL7	-0.29	-5.12	-0.31	6.31e-7	Asthma (corticosteroid response);
KIRP	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg19554555	chr3:13937349	NA	-0.46	-6.25	-0.37	1.82e-9	Ovarian reserve;
KIRP	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.23	-15.93	-0.71	9.6e-40	Type 1 diabetes nephropathy;
KIRP	cis	rs1670533	1.000	rs935971	chr4:1045265	G/A	cg27284194	chr4:1044797	NA	0.52	5.01	0.3	1.05e-6	Recombination rate (females);
KIRP	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.73	9.43	0.52	3.17e-18	Monocyte count;
KIRP	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg04865290	chr3:52927548	TMEM110	-0.46	-5.61	-0.34	5.31e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs367943	0.666	rs6594703	chr5:112691999	A/G	cg12552261	chr5:112820674	MCC	0.52	6.16	0.37	3.02e-9	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25740621	chr2:162164980	PSMD14	0.48	6.16	0.37	2.95e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg24315340	chr6:146058215	EPM2A	-0.47	-5.89	-0.35	1.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-0.96	-9.39	-0.51	4.16e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs7243821	0.705	rs11664828	chr18:52593298	C/G	cg26630735	chr18:52626848	CCDC68	0.53	5.42	0.33	1.39e-7	Chin dimples;
KIRP	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg03957235	chr1:3512243	MEGF6	-0.38	-4.94	-0.3	1.45e-6	Plateletcrit;
KIRP	cis	rs10493773	0.775	rs6667672	chr1:86171072	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.51	-6.7	-0.39	1.44e-10	Urate levels in overweight individuals;
KIRP	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg18833306	chr6:118973337	C6orf204	0.47	4.95	0.3	1.39e-6	Diastolic blood pressure;
KIRP	cis	rs2154427	0.872	rs76474418	chr21:34050113	A/G	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.62	-5.55	-0.33	7.37e-8	Bilirubin levels;
KIRP	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.64	8.99	0.5	6.83e-17	Menarche (age at onset);
KIRP	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17376030	chr22:41985996	PMM1	0.58	6.51	0.38	4.25e-10	Vitiligo;
KIRP	cis	rs6751744	0.513	rs6738215	chr2:160453305	C/T	cg08347373	chr2:160653686	CD302	-0.37	-5.61	-0.34	5.45e-8	Dysphagia;
KIRP	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.43	-5.05	-0.31	8.68e-7	Aortic root size;
KIRP	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.81	-8.81	-0.49	2.31e-16	Coronary artery disease;
KIRP	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg21775007	chr8:11205619	TDH	0.5	6.73	0.39	1.21e-10	Mood instability;
KIRP	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg08975724	chr8:8085496	FLJ10661	-0.72	-9.28	-0.51	9.28e-18	Triglycerides;
KIRP	cis	rs17092148	1.000	rs6058117	chr20:33366905	A/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.6	-0.34	5.78e-8	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16721449	chr2:73052964	EXOC6B	0.52	6.56	0.39	3.15e-10	Parkinson's disease;
KIRP	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg24315340	chr6:146058215	EPM2A	0.45	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2652822	0.525	rs1910094	chr15:63485527	G/C	cg02713581	chr15:63449717	RPS27L	0.47	5.2	0.31	4.21e-7	Metabolic traits;
KIRP	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.97	-15.11	-0.69	6.41e-37	Ulcerative colitis;
KIRP	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.39	0.33	1.61e-7	Coronary artery disease;
KIRP	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg18441811	chr11:71824068	C11orf51	-0.77	-5.21	-0.32	3.96e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	7.85	0.45	1.25e-13	Iron status biomarkers;
KIRP	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.46e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.87	0.3	1.97e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7870753	0.628	rs2406001	chr9:99188970	C/G	cg25260653	chr9:99212216	HABP4	0.57	5.95	0.35	8.95e-9	Height;
KIRP	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.92	0.35	1.08e-8	Lung cancer;
KIRP	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg10503236	chr1:231470652	EXOC8	-0.48	-6.78	-0.4	8.82e-11	Hemoglobin concentration;
KIRP	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs71277158	0.688	rs12493954	chr3:169909941	C/T	cg04067573	chr3:169899625	PHC3	0.72	6.73	0.39	1.16e-10	Prostate cancer;
KIRP	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg19847130	chr8:10466454	RP1L1	-0.36	-5.65	-0.34	4.38e-8	Neuroticism;
KIRP	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.47	6.23	0.37	1.96e-9	Coronary artery disease;
KIRP	cis	rs7523273	0.526	rs2952	chr1:208049077	C/T	cg22525895	chr1:207977042	MIR29B2	0.43	5.39	0.32	1.66e-7	Schizophrenia;
KIRP	cis	rs4740619	0.619	rs1410452	chr9:16042120	G/C	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.45e-22	Chronic sinus infection;
KIRP	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.05	-0.31	8.64e-7	Schizophrenia;
KIRP	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg23202291	chr11:1979235	NA	0.42	5.41	0.33	1.51e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.43	6.54	0.38	3.5e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7011507	1.000	rs76702438	chr8:49189084	T/G	cg15325961	chr8:49183143	NA	0.61	5.21	0.32	3.92e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg21775007	chr8:11205619	TDH	0.5	6.74	0.39	1.11e-10	Mood instability;
KIRP	cis	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg06307176	chr5:131281290	NA	0.55	5.89	0.35	1.28e-8	Life satisfaction;
KIRP	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	1.01	18.24	0.76	1.34e-47	Heart rate;
KIRP	cis	rs7083	1.000	rs7083	chr11:117156552	T/C	cg11523350	chr11:117171073	BACE1	-0.27	-5.25	-0.32	3.27e-7	Blood protein levels;
KIRP	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.4	4.87	0.3	2.04e-6	Renal cell carcinoma;
KIRP	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	6.13	0.36	3.4e-9	Calcium levels;
KIRP	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.94	-0.54	8.62e-20	Hemoglobin concentration;
KIRP	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg17644776	chr2:200775616	C2orf69	-0.57	-5.35	-0.32	2.06e-7	Schizophrenia;
KIRP	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16434002	chr17:42200994	HDAC5	-0.52	-6.38	-0.38	8.9e-10	Total body bone mineral density;
KIRP	cis	rs13343954	0.778	rs10426551	chr19:33541514	A/G	cg17764715	chr19:33622953	WDR88	0.7	7.93	0.45	7.83e-14	Colorectal cancer;
KIRP	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.64	-0.39	1.98e-10	Monocyte percentage of white cells;
KIRP	cis	rs7945071	0.515	rs67249143	chr11:110230648	T/G	cg04157658	chr11:110243994	NA	0.35	4.85	0.3	2.15e-6	Cognitive function;
KIRP	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg03609598	chr5:56110824	MAP3K1	-0.48	-5.57	-0.33	6.64e-8	Initial pursuit acceleration;
KIRP	cis	rs1983891	0.742	rs4711677	chr6:41555862	G/A	cg20194872	chr6:41519635	FOXP4	0.49	6.3	0.37	1.34e-9	Prostate cancer;
KIRP	cis	rs9304742	0.962	rs1044467	chr19:53452769	A/G	cg24044776	chr19:53454761	ZNF816A	-0.41	-6.2	-0.37	2.32e-9	Psoriasis;
KIRP	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg02570527	chr1:10970165	NA	-0.48	-5.18	-0.31	4.58e-7	Body mass index;
KIRP	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.16	-0.37	3.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.62	-8.44	-0.47	2.81e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.95	10.41	0.55	3e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg24375607	chr4:120327624	NA	0.6	6.54	0.39	3.45e-10	Corneal astigmatism;
KIRP	cis	rs1050631	0.592	rs483583	chr18:33759017	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.45	5.35	0.32	2.03e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.57	0.43	7.67e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1863824	0.625	rs12354988	chr10:88155204	G/A	cg07322936	chr10:88137208	NA	-0.56	-5.69	-0.34	3.64e-8	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07023563	chr1:17989633	ARHGEF10L	-0.44	-6.05	-0.36	5.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.75	-0.34	2.59e-8	Colorectal cancer;
KIRP	cis	rs4523957	0.928	rs8074850	chr17:2187931	C/A	cg16513277	chr17:2031491	SMG6	-0.6	-8.2	-0.46	1.34e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg05255149	chr17:80675120	FN3KRP	0.46	5.01	0.3	1.05e-6	Glycated hemoglobin levels;
KIRP	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	1.0	12.24	0.62	3.11e-27	Post bronchodilator FEV1;
KIRP	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg11350586	chr17:70115862	SOX9	0.37	5.35	0.32	1.99e-7	Thyroid hormone levels;
KIRP	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg17279839	chr7:150038598	RARRES2	0.45	5.77	0.35	2.37e-8	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg26597838	chr10:835615	NA	1.28	12.56	0.63	2.7e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.51	5.05	0.31	8.45e-7	Alzheimer's disease;
KIRP	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.09	-0.31	7.19e-7	Bladder cancer;
KIRP	cis	rs10875595	0.836	rs56756237	chr5:140678342	T/C	cg24830062	chr5:140700576	TAF7	-0.56	-5.44	-0.33	1.29e-7	Pulmonary function decline;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27438798	chr4:13546151	NKX3-2	-0.43	-6.01	-0.36	6.49e-9	Metabolic traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10258271	chr2:31361593	GALNT14	0.61	7.75	0.44	2.44e-13	Parkinson's disease;
KIRP	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.4	-4.91	-0.3	1.65e-6	Childhood ear infection;
KIRP	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	8.16	0.46	1.71e-14	Menarche (age at onset);
KIRP	cis	rs11078597	0.767	rs874424	chr17:1640034	G/A	cg17514665	chr17:1657533	SERPINF2	0.45	5.54	0.33	7.84e-8	Serum albumin level;
KIRP	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.88	11.8	0.6	9.08e-26	Coronary artery disease;
KIRP	cis	rs2882667	0.858	rs11951899	chr5:138374310	A/G	cg04439458	chr5:138467593	SIL1	-0.49	-6.99	-0.41	2.55e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.42	-0.33	1.41e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.47	6.14	0.36	3.34e-9	Menopause (age at onset);
KIRP	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.47	-0.38	5.19e-10	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12432903	chr7:1882776	MAD1L1	0.52	5.02	0.3	9.9e-7	Bipolar disorder;
KIRP	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.07e-11	Blood metabolite levels;
KIRP	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg01557791	chr16:72042693	DHODH	-0.49	-6.15	-0.36	3.15e-9	Fibrinogen levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01144148	chr2:24163529	UBXN2A	0.54	6.73	0.39	1.16e-10	Parkinson's disease;
KIRP	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg25486957	chr4:152246857	NA	-0.42	-5.07	-0.31	7.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs654950	0.901	rs607586	chr1:42004379	C/T	cg06885757	chr1:42089581	HIVEP3	-0.66	-9.51	-0.52	1.8e-18	Airway imaging phenotypes;
KIRP	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.98	10.22	0.55	1.14e-20	Alzheimer's disease;
KIRP	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg00990874	chr7:1149470	C7orf50	-0.41	-4.89	-0.3	1.84e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.5	8.78	0.49	2.79e-16	Iron status biomarkers (transferrin levels);
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.6	7.57	0.43	7.67e-13	Menarche (age at onset);
KIRP	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	6.03	0.36	5.86e-9	Schizophrenia;
KIRP	cis	rs4363385	0.510	rs11588463	chr1:152901984	T/C	cg25856811	chr1:152973957	SPRR3	-0.37	-5.13	-0.31	5.88e-7	Inflammatory skin disease;
KIRP	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.34	4.84	0.3	2.25e-6	Menarche (age at onset);
KIRP	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg09631192	chr20:23583594	CST9	-0.52	-5.2	-0.31	4.27e-7	Chronic kidney disease;
KIRP	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07648498	chr16:89883185	FANCA	0.38	4.85	0.3	2.17e-6	Vitiligo;
KIRP	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg27490568	chr2:178487706	NA	0.51	6.7	0.39	1.43e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg11569703	chr11:65557185	OVOL1	0.67	12.07	0.61	1.16e-26	Acne (severe);
KIRP	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.54	6.58	0.39	2.87e-10	Menopause (age at onset);
KIRP	cis	rs77633900	0.772	rs2469554	chr15:76642700	G/C	cg21673338	chr15:77095150	SCAPER	-0.67	-5.7	-0.34	3.48e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00300879	chr1:26503847	CNKSR1	0.46	6.63	0.39	2.15e-10	Height;
KIRP	cis	rs73001065	0.792	rs17216588	chr19:19664077	C/T	cg03709012	chr19:19516395	GATAD2A	1.22	6.99	0.41	2.61e-11	LDL cholesterol;
KIRP	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.45	-5.77	-0.35	2.39e-8	Coronary artery disease;
KIRP	cis	rs3796352	1.000	rs1346719	chr3:53077372	A/G	cg07884673	chr3:53033167	SFMBT1	0.59	5.32	0.32	2.36e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-7.36	-0.42	2.76e-12	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg25039879	chr17:56429692	SUPT4H1	0.58	5.06	0.31	8.07e-7	Cognitive test performance;
KIRP	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg19000871	chr14:103996768	TRMT61A	0.42	5.35	0.32	1.99e-7	Coronary artery disease;
KIRP	cis	rs10203711	1.000	rs4663328	chr2:239574103	A/G	cg14580085	chr2:239553406	NA	-0.39	-5.22	-0.32	3.9e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-5.4	-0.33	1.55e-7	Vitiligo;
KIRP	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.82	-10.55	-0.56	1.03e-21	Cognitive function;
KIRP	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.89	0.49	1.31e-16	Motion sickness;
KIRP	cis	rs7572644	0.656	rs4666016	chr2:28037140	T/A	cg27432699	chr2:27873401	GPN1	0.49	5.58	0.34	6.24e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23524709	chr19:4636345	NA	-0.44	-6.29	-0.37	1.42e-9	Metabolic traits;
KIRP	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.43	0.79	6.53e-55	Prudent dietary pattern;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-1.06	-20.91	-0.8	1.68e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg02336718	chr17:17403227	NA	0.32	4.95	0.3	1.38e-6	Total body bone mineral density;
KIRP	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.79	-0.35	2.17e-8	Colorectal cancer;
KIRP	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.36	-5.26	-0.32	3.12e-7	Eye color traits;
KIRP	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.09	-0.46	2.75e-14	Aortic root size;
KIRP	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.49	-6.16	-0.37	3.01e-9	Neurofibrillary tangles;
KIRP	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.9	12.85	0.63	2.84e-29	Bladder cancer;
KIRP	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.81	-0.4	7.57e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.35	5.19	0.31	4.43e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-6.59	-0.39	2.6e-10	Schizophrenia;
KIRP	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.68	-8.56	-0.48	1.23e-15	Coronary artery disease;
KIRP	cis	rs5770917	1.000	rs8137478	chr22:51017296	G/C	cg00270625	chr22:51017019	CPT1B;CHKB-CPT1B	-0.58	-4.98	-0.3	1.22e-6	Narcolepsy;
KIRP	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg11569703	chr11:65557185	OVOL1	-0.49	-8.79	-0.49	2.55e-16	Acne (severe);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01911352	chr22:38302090	MICALL1	0.51	6.49	0.38	4.81e-10	Parkinson's disease;
KIRP	cis	rs806215	0.723	rs1090682	chr7:127245159	T/C	cg25922125	chr7:127225783	GCC1	0.46	4.95	0.3	1.35e-6	Type 2 diabetes;
KIRP	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.9	-12.33	-0.62	1.63e-27	Platelet distribution width;
KIRP	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.72	10.05	0.54	3.93e-20	Mean corpuscular volume;
KIRP	trans	rs4629203	0.813	rs4952621	chr2:40642423	G/A	cg04572706	chr11:127471623	NA	-0.52	-6.08	-0.36	4.49e-9	Obesity-related traits;
KIRP	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.67	9.49	0.52	2.17e-18	Lymphocyte counts;
KIRP	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.98	13.0	0.64	9.55e-30	Vitamin D levels;
KIRP	cis	rs6662572	1.000	rs28584711	chr1:46212631	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	4.95	0.3	1.36e-6	Blood protein levels;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg17708938	chr17:73937173	FBF1	0.51	6.09	0.36	4.35e-9	DNA methylation (variation);
KIRP	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg14458575	chr2:238380390	NA	0.72	7.48	0.43	1.35e-12	Prostate cancer;
KIRP	cis	rs75064307	0.734	rs13079759	chr3:108088078	G/C	cg14703454	chr3:108065259	HHLA2	0.58	6.63	0.39	2.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02475777	chr4:1388615	CRIPAK	0.65	9.15	0.5	2.29e-17	Longevity;
KIRP	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.91	-10.6	-0.56	7.12e-22	Exhaled nitric oxide output;
KIRP	cis	rs13319406	0.546	rs6801014	chr3:189832834	T/C	cg03343083	chr3:189718843	LEPREL1	-0.58	-5.49	-0.33	9.91e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.4	5.44	0.33	1.27e-7	Blood metabolite levels;
KIRP	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.26	5.29	0.32	2.76e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.78	0.53	2.64e-19	Longevity;
KIRP	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.46	4.86	0.3	2.13e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-9.28	-0.51	9.43e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.8	10.4	0.55	3.12e-21	Platelet count;
KIRP	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.82	10.32	0.55	5.7e-21	Menarche (age at onset);
KIRP	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg11621586	chr10:70884670	VPS26A	1.17	15.03	0.69	1.17e-36	Left atrial antero-posterior diameter;
KIRP	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.69	-9.9	-0.53	1.13e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg05340658	chr4:99064831	C4orf37	-0.54	-6.77	-0.4	9.6e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23598886	chr18:12777645	NA	0.74	6.09	0.36	4.28e-9	Inflammatory skin disease;
KIRP	cis	rs10140922	0.567	rs10149918	chr14:35632487	G/T	cg07166546	chr14:35805898	NA	-0.24	-5.63	-0.34	4.8e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.51	5.71	0.34	3.26e-8	Vitiligo;
KIRP	trans	rs3741489	1.000	rs10161328	chr12:133481884	C/A	cg24132527	chr5:140019269	TMCO6	1.0	6.15	0.37	3.12e-9	Cognitive function;
KIRP	trans	rs35100037	0.803	rs35098027	chr5:128638098	G/A	cg23338408	chr14:31289523	NA	-0.6	-6.12	-0.36	3.58e-9	Ankle injury;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17398066	chr5:93447329	FAM172A	0.49	6.33	0.37	1.13e-9	Parkinson's disease;
KIRP	cis	rs2150410	0.703	rs1984748	chr21:40669898	C/T	cg11890956	chr21:40555474	PSMG1	0.82	5.22	0.32	3.82e-7	Temperament (bipolar disorder);
KIRP	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.43	5.12	0.31	6.04e-7	HDL cholesterol;
KIRP	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	1.08	15.77	0.71	3.3e-39	Cognitive function;
KIRP	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg06289844	chr6:126071538	HEY2	0.45	6.72	0.39	1.25e-10	Brugada syndrome;
KIRP	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.73	-0.44	2.68e-13	Height;
KIRP	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	7.36	0.42	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg07451762	chr16:28383216	NA	0.39	5.02	0.3	9.79e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13102973	0.640	rs34037497	chr4:135833698	C/G	cg14419869	chr4:135874104	NA	0.5	8.3	0.47	7.16e-15	Subjective well-being;
KIRP	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.38	-0.32	1.75e-7	Total body bone mineral density;
KIRP	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	trans	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg24644049	chr4:85504048	CDS1	0.97	6.33	0.37	1.13e-9	Skin colour saturation;
KIRP	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.58	-7.28	-0.42	4.39e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	cg12689670	chr1:183009347	LAMC1	0.52	7.37	0.43	2.61e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-4.86	-0.3	2.07e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg09788416	chr12:39539408	NA	0.42	5.28	0.32	2.86e-7	Morning vs. evening chronotype;
KIRP	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg20701182	chr2:24300061	SF3B14	0.57	5.02	0.3	9.89e-7	Lymphocyte counts;
KIRP	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.45	-0.47	2.55e-15	Height;
KIRP	cis	rs9815354	1.000	rs56776628	chr3:41866856	A/G	cg03022575	chr3:42003672	ULK4	0.6	6.97	0.41	2.98e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-7.47	-0.43	1.42e-12	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.06	0.41	1.68e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs828999	0.688	rs7535267	chr1:108701706	A/T	cg06207961	chr1:108661230	NA	0.36	4.85	0.3	2.2e-6	Monocyte percentage of white cells;
KIRP	trans	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg02900749	chr2:68251473	NA	-1.19	-10.03	-0.54	4.4e-20	Pursuit maintenance gain;
KIRP	trans	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg16934981	chr22:21336404	LZTR1	-0.5	-6.2	-0.37	2.4e-9	Atopic dermatitis;
KIRP	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.9	10.47	0.56	1.88e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.66	10.5	0.56	1.51e-21	Bone mineral density;
KIRP	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	cg21523751	chr1:182988639	NA	0.35	4.95	0.3	1.38e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.48	-5.8	-0.35	1.99e-8	Neutrophil percentage of white cells;
KIRP	cis	rs362272	0.502	rs2857839	chr4:3036630	T/C	cg13731523	chr4:3047190	NA	-0.4	-7.78	-0.44	2.01e-13	Serum sulfate level;
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg08901578	chr4:187885870	NA	-0.48	-7.2	-0.42	7.42e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.2e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg16077055	chr2:106428750	NCK2	-0.25	-4.96	-0.3	1.29e-6	Addiction;
KIRP	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg00579200	chr11:133705235	NA	-0.38	-4.89	-0.3	1.82e-6	Childhood ear infection;
KIRP	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.22	-0.32	3.75e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7084402	0.967	rs1649018	chr10:60288150	T/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.65	-0.39	1.85e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs311392	0.902	rs411839	chr8:55092189	T/C	cg20636351	chr8:55087400	NA	-0.62	-7.35	-0.42	2.91e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9462846	0.652	rs77807794	chr6:42906242	C/T	cg13397359	chr6:42928475	GNMT	0.55	6.05	0.36	5.27e-9	Blood protein levels;
KIRP	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-6.31	-0.37	1.32e-9	Bipolar disorder;
KIRP	trans	rs12030196	0.788	rs10889125	chr1:59417116	A/G	cg05800723	chr4:79103126	FRAS1	0.51	6.11	0.36	3.88e-9	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.46	-6.27	-0.37	1.57e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-1.0	-15.73	-0.71	4.78e-39	Coronary artery disease;
KIRP	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg10932868	chr11:921992	NA	0.68	9.03	0.5	5.07e-17	Alzheimer's disease (late onset);
KIRP	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg17691542	chr6:26056736	HIST1H1C	0.43	5.04	0.31	9.15e-7	Iron status biomarkers;
KIRP	cis	rs28595532	0.720	rs72670231	chr4:119312908	C/T	cg21605333	chr4:119757512	SEC24D	1.03	7.11	0.41	1.27e-11	Cannabis dependence symptom count;
KIRP	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	14.66	0.68	2.16e-35	Chronic sinus infection;
KIRP	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg03999872	chr20:62272968	STMN3	-0.49	-5.04	-0.31	8.97e-7	Glioblastoma;
KIRP	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.48	6.51	0.38	4.09e-10	Testicular germ cell tumor;
KIRP	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.55	-6.04	-0.36	5.77e-9	Lung cancer;
KIRP	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.89	13.44	0.65	2.96e-31	Testicular germ cell tumor;
KIRP	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	16.92	0.73	4.11e-43	Platelet count;
KIRP	cis	rs7520050	0.931	rs11211189	chr1:46261584	A/T	cg03146154	chr1:46216737	IPP	-0.42	-5.29	-0.32	2.7e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg12131826	chr15:77904385	NA	0.41	4.86	0.3	2.14e-6	Type 2 diabetes;
KIRP	cis	rs4664304	0.781	rs6432570	chr2:160808314	A/G	cg03641300	chr2:160917029	PLA2R1	-0.36	-5.22	-0.32	3.8e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	5.97	0.36	8.15e-9	Rheumatoid arthritis;
KIRP	cis	rs73200209	0.744	rs2392968	chr12:116533861	A/C	cg01776926	chr12:116560359	MED13L	-0.57	-6.32	-0.37	1.25e-9	Total body bone mineral density;
KIRP	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	5.17	0.31	4.95e-7	Menarche (age at onset);
KIRP	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-5.88	-0.35	1.33e-8	Educational attainment;
KIRP	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.57	-0.39	2.93e-10	HDL cholesterol;
KIRP	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.64	-6.96	-0.41	3.07e-11	Corneal astigmatism;
KIRP	trans	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-6.96	-0.41	3.12e-11	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.31	-5.49	-0.33	9.84e-8	Renal cell carcinoma;
KIRP	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.97	-0.3	1.27e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.54	0.59	6.69e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07140808	chr4:78978772	FRAS1	-0.47	-6.17	-0.37	2.85e-9	Pancreatic cancer;
KIRP	cis	rs71636778	0.631	rs74465889	chr1:27209439	A/G	cg12203394	chr1:27248618	NUDC	0.78	6.01	0.36	6.61e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg19913688	chr11:428466	ANO9	-0.83	-6.53	-0.38	3.76e-10	Body mass index;
KIRP	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.69	9.16	0.5	2.04e-17	Body mass index;
KIRP	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-7.21	-0.42	7.07e-12	Response to antipsychotic treatment;
KIRP	trans	rs7999699	0.840	rs9534796	chr13:48317867	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.34	0.37	1.1e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs2929278	0.562	rs8033846	chr15:44035363	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.48	-5.79	-0.35	2.14e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20259256	chr3:142443266	TRPC1	0.48	6.15	0.37	3.19e-9	Parkinson's disease;
KIRP	cis	rs7809950	0.530	rs111865019	chr7:106812246	A/G	cg23024343	chr7:107201750	COG5	-0.47	-6.35	-0.38	1.01e-9	Coronary artery disease;
KIRP	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg07274523	chr3:49395745	GPX1	0.69	8.33	0.47	5.8e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg03834567	chr2:218808745	TNS1	0.47	5.7	0.34	3.38e-8	Ulcerative colitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12611296	chr13:76056336	TBC1D4	0.47	6.08	0.36	4.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg11608241	chr8:8085544	FLJ10661	0.39	4.88	0.3	1.88e-6	Mood instability;
KIRP	cis	rs6558530	0.666	rs7845723	chr8:1697086	T/G	cg08198773	chr8:1697536	NA	0.51	6.38	0.38	8.77e-10	Systolic blood pressure;
KIRP	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.52	-0.33	8.51e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.8	10.98	0.57	4.52e-23	Aortic root size;
KIRP	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.7	10.5	0.56	1.51e-21	Lewy body disease;
KIRP	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg01721255	chr8:58191610	C8orf71	0.67	5.81	0.35	1.95e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs7944735	0.567	rs79837139	chr11:48000780	T/C	cg03929089	chr4:120376271	NA	0.82	6.06	0.36	5.12e-9	Intraocular pressure;
KIRP	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.21	5.27	0.32	3.01e-7	Primary biliary cholangitis;
KIRP	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	1.05	10.53	0.56	1.17e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs974417	0.559	rs12662042	chr6:97389090	C/A	cg00261665	chr3:131101138	NUDT16	-0.5	-6.3	-0.37	1.35e-9	Body mass index;
KIRP	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.02	-0.5	5.42e-17	Mean corpuscular volume;
KIRP	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.61	-0.44	5.72e-13	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14751398	chr6:20402153	E2F3	0.45	6.03	0.36	5.83e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg03959625	chr15:84868606	LOC388152	0.71	8.47	0.48	2.22e-15	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11345909	chr1:22270751	NA	0.44	6.07	0.36	4.81e-9	Survival in pancreatic cancer;
KIRP	cis	rs6438504	0.844	rs7610070	chr3:118914814	C/A	cg25372693	chr3:118959985	B4GALT4	0.36	6.06	0.36	5.05e-9	Clozapine-induced cytotoxicity;
KIRP	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.98	10.01	0.54	5.1e-20	Eosinophilic esophagitis;
KIRP	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg17105886	chr17:28927953	LRRC37B2	0.51	5.26	0.32	3.07e-7	Body mass index;
KIRP	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.43	6.01	0.36	6.57e-9	Total body bone mineral density;
KIRP	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.46	10.27	0.55	8.13e-21	Alzheimer's disease (late onset);
KIRP	cis	rs12049351	0.665	rs12035203	chr1:229642517	T/C	cg11742688	chr1:229674241	ABCB10	-0.37	-5.36	-0.32	1.95e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg05785598	chr3:49045655	WDR6	0.31	5.02	0.3	9.81e-7	Menarche (age at onset);
KIRP	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.24e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.6	8.07	0.46	3.22e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18357526	chr6:26021779	HIST1H4A	0.62	6.88	0.4	4.89e-11	Urate levels;
KIRP	cis	rs7923609	0.967	rs3956912	chr10:65205881	C/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg13939156	chr17:80058883	NA	0.51	5.97	0.36	8.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg24009623	chr19:33667908	NA	0.47	5.78	0.35	2.3e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.63	7.94	0.45	7.08e-14	Neuroticism;
KIRP	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.72e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.62	-6.84	-0.4	6.26e-11	Urate levels in lean individuals;
KIRP	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.11	-0.31	6.61e-7	Pulmonary function;
KIRP	cis	rs2280630	0.529	rs784505	chr3:39168757	G/A	cg01426195	chr3:39028469	NA	0.61	9.85	0.53	1.61e-19	Verbal declarative memory;
KIRP	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg02175308	chr1:109941060	SORT1	-0.3	-5.86	-0.35	1.44e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-5.8	-0.35	2.02e-8	HDL cholesterol;
KIRP	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg04691961	chr3:161091175	C3orf57	-0.35	-5.11	-0.31	6.57e-7	Kawasaki disease;
KIRP	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg00977110	chr5:151150581	G3BP1	0.62	6.24	0.37	1.93e-9	Preschool internalizing problems;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22768615	chr10:131567747	NA	0.45	6.23	0.37	1.96e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1978968	0.827	rs5992134	chr22:18433994	G/T	cg02610425	chr22:18483192	MICAL3	0.34	5.01	0.3	1.03e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg13703089	chr14:106090767	NA	-0.35	-4.85	-0.3	2.19e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs9400467	0.528	rs465795	chr6:111676443	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	7.02	0.41	2.17e-11	Menarche (age at onset);
KIRP	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.57	7.06	0.41	1.74e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.54	-0.48	1.42e-15	Common traits (Other);
KIRP	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.73	-10.96	-0.57	5.17e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs983545	0.508	rs9877076	chr3:16898006	C/G	cg23220897	chr3:16924709	NA	-0.3	-5.17	-0.31	4.89e-7	Blood protein levels;
KIRP	cis	rs7951870	0.945	rs79443985	chr11:46710829	T/C	cg19486271	chr11:47235900	DDB2	0.53	4.98	0.3	1.22e-6	Schizophrenia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16739247	chr1:76252438	SNORD45C;SNORD45A;RABGGTB	-0.55	-7.33	-0.42	3.3e-12	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3733418	0.860	rs12647427	chr4:165929209	G/A	cg10852876	chr4:165953100	TRIM60	-0.53	-5.97	-0.36	8.04e-9	Obesity-related traits;
KIRP	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg26554054	chr8:600488	NA	0.73	5.41	0.33	1.47e-7	IgG glycosylation;
KIRP	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.68	6.62	0.39	2.22e-10	Vitiligo;
KIRP	cis	rs1555895	0.543	rs749297	chr10:861837	A/G	cg10556349	chr10:835070	NA	-0.4	-4.97	-0.3	1.28e-6	Survival in rectal cancer;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.48	6.4	0.38	7.61e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.44	6.59	0.39	2.73e-10	Schizophrenia;
KIRP	cis	rs71403859	0.730	rs17355804	chr16:71717214	A/G	cg08717414	chr16:71523259	ZNF19	-1.05	-8.91	-0.49	1.16e-16	Post bronchodilator FEV1;
KIRP	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs10761482	0.500	rs2211220	chr10:62271491	A/G	cg01186212	chr10:62110162	ANK3	-0.3	-5.13	-0.31	5.82e-7	Schizophrenia;
KIRP	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.48	-6.16	-0.37	3.01e-9	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs509477	1.000	rs531558	chr18:32575286	A/T	cg00449728	chr18:32561817	MAPRE2	-0.38	-4.85	-0.3	2.18e-6	Cerebrospinal fluid AB1-42 levels;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg01847620	chr20:60905922	LAMA5	0.49	6.21	0.37	2.25e-9	Pancreatic cancer;
KIRP	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.28	-0.37	1.55e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15750611	chr11:68191055	LRP5	-0.47	-6.43	-0.38	6.5e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-14.22	-0.67	7.01e-34	Headache;
KIRP	cis	rs4959799	0.557	rs9503515	chr6:3272018	G/A	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.25	-0.32	3.34e-7	Survival in rectal cancer;
KIRP	cis	rs7709377	0.546	rs13181756	chr5:115493736	C/T	cg23108291	chr5:115420582	COMMD10	0.42	4.95	0.3	1.37e-6	Metabolite levels  (X-11787);
KIRP	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.82	9.84	0.53	1.72e-19	Post bronchodilator FEV1;
KIRP	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg26811252	chr16:29126840	RRN3P2	0.66	8.88	0.49	1.4e-16	Menopause (age at onset);
KIRP	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.57	14.78	0.69	8.36e-36	Airflow obstruction;
KIRP	cis	rs6546886	0.912	rs4853006	chr2:74263419	A/G	cg14702570	chr2:74259524	NA	-0.29	-5.53	-0.33	7.99e-8	Dialysis-related mortality;
KIRP	cis	rs1562975	0.609	rs12505944	chr4:109411822	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.41	5.12	0.31	6.12e-7	Height;
KIRP	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg17385448	chr1:15911702	AGMAT	0.26	5.16	0.31	5.14e-7	Systolic blood pressure;
KIRP	cis	rs2637030	0.559	rs256087	chr5:52895233	G/A	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg05370193	chr1:21551575	ECE1	0.45	6.19	0.37	2.44e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.13	0.46	2.05e-14	Morning vs. evening chronotype;
KIRP	cis	rs11577318	0.579	rs12131370	chr1:26698430	G/A	cg00852783	chr1:26633632	UBXN11	-0.47	-5.38	-0.32	1.69e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.69	8.34	0.47	5.19e-15	Aortic root size;
KIRP	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg02709834	chr1:75198841	CRYZ;TYW3	0.4	4.94	0.3	1.45e-6	Resistin levels;
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.44	-0.33	1.26e-7	Lung cancer;
KIRP	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg00784671	chr22:46762841	CELSR1	-0.61	-6.15	-0.36	3.14e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.88	-0.35	1.34e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.37	-0.47	4.48e-15	Mood instability;
KIRP	cis	rs4704187	0.663	rs1477935	chr5:74448494	C/T	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.48	-8.22	-0.46	1.15e-14	Pneumonia;
KIRP	cis	rs9687846	1.000	rs9687846	chr5:55861894	G/A	cg15001016	chr5:55860904	NA	-0.31	-5.43	-0.33	1.36e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.69	0.48	5.16e-16	Prudent dietary pattern;
KIRP	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.8	-11.31	-0.59	3.59e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg03714773	chr7:91764589	CYP51A1	0.42	6.28	0.37	1.5e-9	Breast cancer;
KIRP	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg01721255	chr8:58191610	C8orf71	0.47	5.02	0.3	9.82e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	10.91	0.57	7.49e-23	Colorectal cancer;
KIRP	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg06647332	chr5:131281008	NA	-0.45	-5.08	-0.31	7.58e-7	Life satisfaction;
KIRP	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.46	10.09	0.54	3.04e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.58	-7.14	-0.41	1.05e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg02696790	chr15:75250997	RPP25	0.32	5.58	0.33	6.48e-8	Breast cancer;
KIRP	cis	rs172166	0.637	rs1225597	chr6:28162087	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.29	-0.32	2.71e-7	Cardiac Troponin-T levels;
KIRP	cis	rs9381107	0.858	rs6458230	chr6:9465363	G/A	cg14735645	chr6:9486422	NA	-0.45	-5.8	-0.35	2.01e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.23	-0.37	2e-9	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03287527	chr16:10843654	NUBP1	0.53	6.59	0.39	2.66e-10	Interleukin-4 levels;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.54	-4.98	-0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.09	0.31	7.12e-7	Schizophrenia;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.48	-0.52	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12900413	0.603	rs2351494	chr15:90299541	C/T	cg24650279	chr15:90327240	NA	-0.41	-5.13	-0.31	5.91e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.77	-9.48	-0.52	2.2e-18	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs12435908	1.000	rs11851772	chr14:66022047	C/T	cg23373153	chr14:65346875	NA	-0.53	-4.89	-0.3	1.8e-6	Ischemic stroke;
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	1.99e-12	Morning vs. evening chronotype;
KIRP	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg10223061	chr2:219282414	VIL1	0.34	5.6	0.34	5.84e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-7.43	-0.43	1.74e-12	Fear of minor pain;
KIRP	cis	rs4664304	0.754	rs17829052	chr2:160821067	G/A	cg23995753	chr2:160760732	LY75	-0.38	-4.86	-0.3	2.05e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.69	7.54	0.43	8.92e-13	Hip circumference adjusted for BMI;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg13412866	chr18:20715409	CABLES1	0.5	6.53	0.38	3.75e-10	DNA methylation (variation);
KIRP	cis	rs11955398	0.647	rs6449483	chr5:59995393	C/T	cg02684056	chr5:59996105	DEPDC1B	0.46	5.19	0.31	4.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg14580859	chr9:123691850	NA	0.35	5.06	0.31	8.23e-7	Rheumatoid arthritis;
KIRP	cis	rs8060686	0.516	rs255052	chr16:68024995	C/T	cg04539111	chr16:67997858	SLC12A4	-0.45	-5.0	-0.3	1.07e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs12725198	1.000	rs12725694	chr1:16080501	G/A	cg18133145	chr1:16060689	PLEKHM2	-0.58	-6.28	-0.37	1.54e-9	Cardiac Troponin-T levels;
KIRP	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-9.1	-0.5	3.19e-17	Neuroticism;
KIRP	cis	rs2479724	0.625	rs9394835	chr6:41818200	A/T	cg17623882	chr6:41773611	USP49	-0.48	-5.96	-0.36	8.63e-9	Menarche (age at onset);
KIRP	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	1.05	13.34	0.65	6.66e-31	Post bronchodilator FEV1;
KIRP	cis	rs490234	0.841	rs7044663	chr9:128268263	C/T	cg14078157	chr9:128172775	NA	-0.45	-5.74	-0.34	2.83e-8	Mean arterial pressure;
KIRP	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.59	8.33	0.47	5.56e-15	Motion sickness;
KIRP	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg01304814	chr3:48885189	PRKAR2A	0.73	5.61	0.34	5.33e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7267005	1.000	rs77950955	chr20:34514579	A/G	cg17201900	chr20:34330562	RBM39	0.87	4.9	0.3	1.71e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23974812	chr11:134123664	THYN1;ACAD8	-0.52	-7.16	-0.42	9.56e-12	Metabolic traits;
KIRP	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg25110126	chr1:46999211	NA	-0.45	-5.63	-0.34	5.01e-8	Monobrow;
KIRP	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg15103426	chr22:29168792	CCDC117	0.67	9.67	0.52	6.08e-19	Lymphocyte counts;
KIRP	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.35	-0.47	5.06e-15	Common traits (Other);
KIRP	cis	rs3789045	0.774	rs12029692	chr1:204532323	G/A	cg18185008	chr1:204589407	LRRN2	-0.62	-6.7	-0.39	1.4e-10	Educational attainment (college completion);
KIRP	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.28	7.39	0.43	2.22e-12	Primary biliary cholangitis;
KIRP	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg01843034	chr6:37503916	NA	-0.85	-12.05	-0.61	1.4e-26	Cognitive performance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26233408	chr17:78210670	SLC26A11	-0.57	-6.87	-0.4	5.15e-11	Interleukin-4 levels;
KIRP	cis	rs57590327	0.679	rs35628094	chr3:81605371	C/A	cg07356753	chr3:81810745	GBE1	-0.58	-6.31	-0.37	1.26e-9	Extraversion;
KIRP	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.36	5.41	0.33	1.46e-7	Headache;
KIRP	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.71	8.4	0.47	3.53e-15	Corneal astigmatism;
KIRP	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.71	-10.05	-0.54	3.9e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	0.84	10.35	0.55	4.49e-21	Prostate cancer;
KIRP	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-7.25	-0.42	5.33e-12	Gut microbiome composition (summer);
KIRP	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.8	13.64	0.66	6.41e-32	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7590720	0.819	rs12467676	chr2:216895736	T/G	cg12620499	chr2:216877984	MREG	0.9	12.97	0.64	1.19e-29	Alcohol dependence;
KIRP	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.52	-5.44	-0.33	1.26e-7	Corneal structure;
KIRP	cis	rs9398235	1.000	rs9398235	chr6:110732116	A/G	cg00083206	chr6:110721305	DDO	-0.45	-5.08	-0.31	7.63e-7	Systemic lupus erythematosus;
KIRP	cis	rs9462846	1.000	rs56158882	chr6:42860740	T/G	cg05552183	chr6:42928497	GNMT	0.44	5.09	0.31	7.26e-7	Blood protein levels;
KIRP	cis	rs735539	1.000	rs1888001	chr13:21285906	C/G	cg04906043	chr13:21280425	IL17D	-0.63	-8.52	-0.48	1.66e-15	Dental caries;
KIRP	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15644404	chr18:77186268	NFATC1	-0.95	-7.88	-0.45	1.08e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.67	6.73	0.39	1.22e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs78049276	0.736	rs17612742	chr4:148414651	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	0.63	6.76	0.4	9.67e-11	Pulse pressure;
KIRP	cis	rs918629	0.530	rs11738768	chr5:95237780	C/A	cg16656078	chr5:95278638	ELL2	-0.39	-5.87	-0.35	1.38e-8	IgG glycosylation;
KIRP	cis	rs57994353	0.568	rs10870151	chr9:139309584	G/A	cg21253087	chr9:139290292	SNAPC4	0.48	5.34	0.32	2.16e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs7665939	0.932	rs10022377	chr4:190108803	C/T	cg01790032	chr4:190285510	NA	-0.58	-5.03	-0.31	9.48e-7	Amyotrophic lateral sclerosis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04235519	chr10:102505365	PAX2	-0.46	-6.3	-0.37	1.35e-9	Myopia;
KIRP	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg17644776	chr2:200775616	C2orf69	-0.56	-5.67	-0.34	4e-8	Schizophrenia;
KIRP	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg13173536	chr2:3403300	TTC15	-0.36	-4.89	-0.3	1.86e-6	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.28	5.86	0.35	1.46e-8	Schizophrenia;
KIRP	cis	rs1434579	0.572	rs926052	chr19:44952236	A/T	cg15540054	chr19:45004280	ZNF180	0.63	7.46	0.43	1.47e-12	Tuberculosis;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06943149	chr12:77157476	ZDHHC17	0.66	6.38	0.38	8.79e-10	Lung function (FEV1);
KIRP	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	0.85	11.34	0.59	3e-24	Primary sclerosing cholangitis;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg07343612	chr16:622815	PIGQ	-0.87	-13.3	-0.65	9.3e-31	Height;
KIRP	cis	rs7989336	0.625	rs9513122	chr13:97000534	C/T	cg02571835	chr13:96230311	CLDN10	-0.37	-5.1	-0.31	6.71e-7	Obesity;
KIRP	cis	rs4805272	0.889	rs6509071	chr19:29329651	A/G	cg04546413	chr19:29218101	NA	0.45	5.08	0.31	7.4e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4268898	0.552	rs6754391	chr2:24369019	C/T	cg06627628	chr2:24431161	ITSN2	-0.46	-5.61	-0.34	5.52e-8	Asthma;
KIRP	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg04166393	chr7:2884313	GNA12	0.46	6.12	0.36	3.58e-9	Height;
KIRP	trans	rs17801127	0.901	rs35635376	chr2:150564069	G/T	cg05023168	chr6:90351415	NA	0.75	6.4	0.38	7.9e-10	Liver enzyme levels (alanine transaminase);
KIRP	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg23752985	chr2:85803571	VAMP8	-0.55	-7.91	-0.45	8.46e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.37	-0.32	1.87e-7	Leprosy;
KIRP	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg12855166	chr17:30846586	MYO1D	0.36	5.0	0.3	1.1e-6	Schizophrenia;
KIRP	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.38	7.49	0.43	1.25e-12	Educational attainment (years of education);
KIRP	cis	rs7209700	0.963	rs1000232	chr17:45356561	T/C	cg08085267	chr17:45401833	C17orf57	0.45	5.45	0.33	1.2e-7	IgG glycosylation;
KIRP	cis	rs300890	0.760	rs1532981	chr4:144215346	T/C	cg19876092	chr4:144208277	NA	0.41	6.79	0.4	8.21e-11	Nasopharyngeal carcinoma;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02671751	chr10:88281576	WAPAL	-0.59	-6.31	-0.37	1.26e-9	Menopause (age at onset);
KIRP	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	cg12689670	chr1:183009347	LAMC1	0.46	6.73	0.39	1.18e-10	Colorectal cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14297518	chr11:33112779	CSTF3	0.43	6.07	0.36	4.9e-9	C-reactive protein;
KIRP	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	1.09	19.31	0.78	3.45e-51	Schizophrenia;
KIRP	cis	rs883115	0.791	rs10799589	chr1:224819278	C/T	cg01808320	chr1:224927238	CNIH3	0.37	5.34	0.32	2.17e-7	Cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07254066	chr16:54965895	IRX5	0.34	6.09	0.36	4.29e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.04	-0.31	9.07e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.87	-11.92	-0.6	3.84e-26	Obesity-related traits;
KIRP	cis	rs12476592	0.602	rs262487	chr2:63880517	G/T	cg17519650	chr2:63277830	OTX1	0.43	4.85	0.3	2.21e-6	Childhood ear infection;
KIRP	cis	rs9513627	0.915	rs4539436	chr13:100122802	C/G	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	7.04	0.41	1.96e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg17644776	chr2:200775616	C2orf69	0.55	6.34	0.37	1.09e-9	Schizophrenia;
KIRP	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg27446573	chr6:127587934	RNF146	0.57	7.41	0.43	2.05e-12	Breast cancer;
KIRP	cis	rs2400749	0.830	rs4905858	chr14:100032408	A/T	cg19965031	chr14:100038389	CCDC85C	-0.43	-5.3	-0.32	2.6e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg02678768	chr17:74002944	EVPL	0.42	5.54	0.33	7.74e-8	White matter hyperintensity burden;
KIRP	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-7.28	-0.42	4.53e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.03e-7	Coronary artery disease;
KIRP	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	0.64	6.17	0.37	2.76e-9	Skin colour saturation;
KIRP	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.68	-9.42	-0.51	3.49e-18	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9473924	0.542	rs67538952	chr6:50894400	T/C	cg14470998	chr6:50812995	TFAP2B	0.85	7.85	0.45	1.25e-13	Body mass index;
KIRP	trans	rs2048656	0.523	rs6988716	chr8:9670706	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.39	-0.38	8.19e-10	Schizophrenia;
KIRP	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.64	8.3	0.47	7.09e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg08873628	chr1:175162347	KIAA0040	-0.41	-6.04	-0.36	5.63e-9	Alcohol dependence;
KIRP	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.37	5.1	0.31	6.71e-7	Platelet count;
KIRP	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-1.05	-12.8	-0.63	4.33e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg08975724	chr8:8085496	FLJ10661	0.64	8.22	0.46	1.15e-14	Joint mobility (Beighton score);
KIRP	cis	rs4748857	0.947	rs7075197	chr10:23566045	A/T	cg12804278	chr10:23633326	C10orf67	0.41	5.14	0.31	5.67e-7	Systemic lupus erythematosus;
KIRP	trans	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg20993868	chr7:22813445	NA	0.62	9.0	0.5	6.36e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.25	-5.12	-0.31	6.27e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs12580194	0.593	rs61957889	chr12:55724456	C/T	cg19537932	chr12:55886519	OR6C68	-0.54	-5.78	-0.35	2.25e-8	Cancer;
KIRP	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.82	8.1	0.46	2.5e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg13373371	chr19:49828787	SLC6A16	0.42	5.18	0.31	4.73e-7	Multiple sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15051795	chr19:1816298	MIR1909;REXO1	-0.48	-6.42	-0.38	6.99e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7534824	0.625	rs17449022	chr1:101442367	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.03	0.41	2.07e-11	Refractive astigmatism;
KIRP	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg14664628	chr15:75095509	CSK	0.51	6.12	0.36	3.62e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.36	-0.32	1.91e-7	Cholesterol, total;
KIRP	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06544989	chr22:39130855	UNC84B	-0.49	-7.4	-0.43	2.21e-12	Menopause (age at onset);
KIRP	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.8	-0.35	1.99e-8	Cardiac Troponin-T levels;
KIRP	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg21775007	chr8:11205619	TDH	0.51	6.79	0.4	8.24e-11	Mood instability;
KIRP	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.34	-0.37	1.1e-9	Alcohol dependence;
KIRP	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg00106254	chr7:1943704	MAD1L1	0.54	5.81	0.35	1.94e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.59	6.9	0.4	4.48e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.75	12.54	0.62	3.31e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg01444801	chr10:135216882	MTG1	-0.56	-6.21	-0.37	2.2e-9	Systemic lupus erythematosus;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27189623	chr16:705930	WDR90	0.45	6.26	0.37	1.68e-9	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19315081	chr11:10326100	ADM	0.53	6.57	0.39	3.05e-10	Smoking initiation;
KIRP	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	5.29	0.32	2.7e-7	Schizophrenia;
KIRP	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg00792783	chr2:198669748	PLCL1	0.47	5.28	0.32	2.77e-7	Dermatomyositis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23522862	chr17:79829415	ARHGDIA	0.62	7.36	0.42	2.73e-12	Smoking initiation;
KIRP	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.48	-6.45	-0.38	5.78e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-4.94	-0.3	1.42e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs6988636	0.534	rs62521778	chr8:124122794	T/G	cg15893493	chr8:124194847	FAM83A	0.73	5.71	0.34	3.31e-8	Urinary uromodulin levels;
KIRP	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.71	-9.41	-0.51	3.57e-18	Dilated cardiomyopathy;
KIRP	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg21573476	chr21:45109991	RRP1B	0.44	5.7	0.34	3.46e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.63	-8.79	-0.49	2.63e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2997105	1.000	rs2997106	chr13:56380732	C/A	cg08528735	chr3:184428879	MAGEF1	-0.59	-6.09	-0.36	4.37e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs12540874	0.931	rs9791817	chr7:50661187	C/G	cg00647317	chr7:50633725	DDC	0.45	6.64	0.39	1.99e-10	Systemic sclerosis;
KIRP	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.73	9.22	0.51	1.37e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg20302533	chr7:39170763	POU6F2	0.31	6.6	0.39	2.49e-10	IgG glycosylation;
KIRP	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.99	-12.56	-0.63	2.73e-28	Alzheimer's disease;
KIRP	cis	rs76793172	1.000	rs75504740	chr19:46313376	G/A	cg00442267	chr19:46317840	RSPH6A	-0.76	-6.06	-0.36	5.19e-9	Eosinophil counts;
KIRP	cis	rs73206853	0.841	rs16940933	chr12:111102574	C/A	cg12870014	chr12:110450643	ANKRD13A	0.52	4.88	0.3	1.89e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6429082	0.871	rs6675944	chr1:235572669	C/T	cg26050004	chr1:235667680	B3GALNT2	0.52	6.76	0.4	9.69e-11	Adiposity;
KIRP	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00889227	chr1:205173544	DSTYK	-0.39	-5.5	-0.33	9.44e-8	Red blood cell count;
KIRP	cis	rs9815354	0.953	rs1716694	chr3:41986399	G/T	cg03022575	chr3:42003672	ULK4	-0.5	-5.64	-0.34	4.69e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg06521331	chr12:34319734	NA	-0.63	-7.56	-0.43	8.07e-13	Bladder cancer;
KIRP	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg07274523	chr3:49395745	GPX1	0.72	8.48	0.48	2.11e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg13010199	chr12:38710504	ALG10B	-0.47	-5.73	-0.34	2.91e-8	Morning vs. evening chronotype;
KIRP	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	1.11	22.32	0.82	4.45e-61	Gut microbiome composition (winter);
KIRP	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.93	0.35	1e-8	Motion sickness;
KIRP	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg03060546	chr3:49711283	APEH	-0.58	-5.07	-0.31	7.88e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.62	-8.17	-0.46	1.61e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-6.1	-0.36	4.08e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg01320579	chr17:75405842	SEPT9	0.46	7.61	0.44	5.73e-13	Airflow obstruction;
KIRP	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11987759	chr7:65425863	GUSB	0.47	6.04	0.36	5.68e-9	Aortic root size;
KIRP	cis	rs67385638	1.000	rs2855121	chr11:5277291	C/T	cg12559170	chr11:5275217	HBG2	0.48	6.87	0.4	5.31e-11	Hemoglobin levels;
KIRP	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.52	7.53	0.43	9.45e-13	Coronary artery disease;
KIRP	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg24375607	chr4:120327624	NA	0.55	6.08	0.36	4.63e-9	Educational attainment;
KIRP	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.31	0.37	1.3e-9	Bipolar disorder;
KIRP	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.96	13.81	0.66	1.7e-32	Cognitive function;
KIRP	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.08	-0.31	7.45e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.15	0.31	5.36e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2034088	1.000	rs2034088	chr17:423051	T/C	cg01214346	chr17:406501	NA	-0.45	-5.61	-0.34	5.55e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-0.79	-13.98	-0.67	4.41e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.78	11.43	0.59	1.53e-24	Heart rate;
KIRP	cis	rs9290877	0.580	rs1568670	chr3:188467161	T/C	cg17392043	chr3:188495102	LPP	-0.5	-6.33	-0.37	1.17e-9	IgE levels;
KIRP	cis	rs4698790	0.593	rs7356506	chr4:110683454	G/A	cg07850274	chr4:110748770	RRH	0.35	5.19	0.31	4.38e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.52	6.44	0.38	6.35e-10	Mean platelet volume;
KIRP	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg00074818	chr8:8560427	CLDN23	0.29	5.01	0.3	1.05e-6	Mood instability;
KIRP	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.6	7.06	0.41	1.65e-11	Educational attainment;
KIRP	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.83	-13.21	-0.64	1.78e-30	Prostate cancer;
KIRP	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg08076091	chr2:203926405	NBEAL1	-0.83	-9.06	-0.5	4.13e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.59	0.73	5.57e-42	Chronic sinus infection;
KIRP	cis	rs2963155	0.518	rs2918419	chr5:142722353	T/C	cg17617527	chr5:142782415	NR3C1	0.77	8.0	0.45	4.82e-14	Breast cancer;
KIRP	cis	rs7255436	0.894	rs10413136	chr19:8452879	T/C	cg10174797	chr19:8464628	RAB11B	0.51	6.38	0.38	8.56e-10	HDL cholesterol;
KIRP	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.68	-0.34	3.83e-8	Metabolite levels;
KIRP	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg25309564	chr22:51001381	C22orf41	0.74	5.17	0.31	4.9e-7	Narcolepsy;
KIRP	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg13628971	chr7:2884303	GNA12	0.64	7.72	0.44	2.84e-13	Height;
KIRP	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.47	-5.71	-0.34	3.27e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg25486957	chr4:152246857	NA	-0.44	-5.11	-0.31	6.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.02	0.54	4.95e-20	Total body bone mineral density;
KIRP	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg16141378	chr3:129829833	LOC729375	0.58	7.28	0.42	4.46e-12	Neuroticism;
KIRP	cis	rs1468333	1.000	rs3777113	chr5:137493897	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	5.39	0.32	1.68e-7	Resting heart rate;
KIRP	cis	rs12101261	0.890	rs3783947	chr14:81449534	T/C	cg06600135	chr14:81408086	NA	0.42	5.5	0.33	9.56e-8	Graves' disease;
KIRP	cis	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg06585982	chr3:143692056	C3orf58	0.59	7.38	0.43	2.44e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs7584330	0.504	rs11891426	chr2:238434702	T/G	cg14458575	chr2:238380390	NA	0.46	5.83	0.35	1.72e-8	Prostate cancer;
KIRP	cis	rs2292864	1.000	rs2292864	chr17:45367681	C/T	cg18085866	chr17:45331354	ITGB3	-0.73	-5.63	-0.34	4.97e-8	Left atrial antero-posterior diameter;
KIRP	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.72	9.65	0.52	6.79e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.55	6.9	0.4	4.51e-11	Resting heart rate;
KIRP	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.59	7.75	0.44	2.46e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.23	6.45	0.38	5.81e-10	Type 2 diabetes;
KIRP	cis	rs35883536	0.967	rs9434126	chr1:101106981	A/G	cg06223162	chr1:101003688	GPR88	-0.33	-6.81	-0.4	7.37e-11	Monocyte count;
KIRP	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	5.71	0.34	3.31e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.97	17.86	0.75	2.65e-46	Colorectal adenoma (advanced);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25444236	chr13:96329629	DNAJC3	-0.49	-6.48	-0.38	4.95e-10	Myopia;
KIRP	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.9e-8	Glomerular filtration rate;
KIRP	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.2	8.59	0.48	1.04e-15	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs7116495	0.786	rs10736784	chr11:71718911	T/A	cg26138937	chr11:71823887	C11orf51	-0.72	-5.84	-0.35	1.67e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg21475434	chr5:93447410	FAM172A	-0.45	-5.24	-0.32	3.48e-7	Diabetic retinopathy;
KIRP	cis	rs16976116	0.704	rs7183603	chr15:55513718	C/A	cg11288833	chr15:55489084	RSL24D1	0.48	5.55	0.33	7.28e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2019216	0.524	rs1518049	chr17:21922055	C/T	cg22648282	chr17:21454238	C17orf51	-0.5	-6.49	-0.38	4.78e-10	Pelvic organ prolapse;
KIRP	cis	rs72730918	0.818	rs72730927	chr15:51952232	T/C	cg14296394	chr15:51910925	DMXL2	0.84	7.22	0.42	6.51e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.62	8.82	0.49	2.11e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.44	-9.74	-0.53	3.65e-19	Alzheimer's disease (late onset);
KIRP	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.42	-6.02	-0.36	6.15e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg08076091	chr2:203926405	NBEAL1	0.85	9.07	0.5	3.96e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg03929089	chr4:120376271	NA	-0.53	-6.49	-0.38	4.58e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.82e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.55	6.57	0.39	3.04e-10	Longevity;Endometriosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18451035	chr14:31398430	STRN3	-0.4	-6.58	-0.39	2.87e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.81	0.53	2.22e-19	Dupuytren's disease;
KIRP	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg18306943	chr3:40428807	ENTPD3	-0.46	-6.38	-0.38	8.73e-10	Renal cell carcinoma;
KIRP	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	9.51	0.52	1.87e-18	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.59	-5.99	-0.36	7.4e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.64e-11	Lung cancer;
KIRP	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.4	8.28	0.47	7.84e-15	IgG glycosylation;
KIRP	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg21858823	chr1:15850916	CASP9	0.54	5.81	0.35	1.92e-8	Systolic blood pressure;
KIRP	cis	rs12580194	0.593	rs60873827	chr12:55717769	T/C	cg11794356	chr12:55725991	OR6C3	-0.57	-7.41	-0.43	1.96e-12	Cancer;
KIRP	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.83	13.84	0.66	1.29e-32	Longevity;
KIRP	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11987759	chr7:65425863	GUSB	0.5	6.71	0.39	1.35e-10	Aortic root size;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg08862778	chr1:11322643	MTOR	0.48	6.52	0.38	4.07e-10	Ischemic stroke;
KIRP	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg26874164	chr19:58962979	ZNF324B	0.47	5.49	0.33	9.98e-8	Uric acid clearance;
KIRP	cis	rs12220238	0.570	rs11001081	chr10:76368576	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.84	6.12	0.36	3.69e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs255758	0.813	rs373284	chr5:53322694	C/T	cg22592108	chr5:53304441	ARL15	-0.45	-5.85	-0.35	1.58e-8	Rheumatoid arthritis;
KIRP	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.49	-6.01	-0.36	6.77e-9	P wave terminal force;
KIRP	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.7	10.14	0.54	2.02e-20	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	8.85	0.49	1.81e-16	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.43	-0.38	6.53e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2905347	0.965	rs2961272	chr7:22624736	C/G	cg23521230	chr7:22704884	NA	0.39	5.09	0.31	7e-7	Major depression and alcohol dependence;
KIRP	cis	rs6578185	0.810	rs3935445	chr8:142452618	C/A	cg15142913	chr8:142440250	PTP4A3	0.39	5.29	0.32	2.7e-7	Endometriosis;
KIRP	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.4	5.37	0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.64	5.2	0.31	4.21e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg12131826	chr15:77904385	NA	0.45	6.0	0.36	7.06e-9	Type 2 diabetes;
KIRP	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg02725872	chr8:58115012	NA	-0.46	-5.35	-0.32	1.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.73	10.21	0.55	1.21e-20	Joint mobility (Beighton score);
KIRP	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg03834567	chr2:218808745	TNS1	-0.48	-5.77	-0.35	2.35e-8	Ulcerative colitis;
KIRP	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.1e-23	Prudent dietary pattern;
KIRP	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg15436174	chr10:43711423	RASGEF1A	0.78	8.36	0.47	4.83e-15	Hirschsprung disease;
KIRP	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.48	0.43	1.34e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs829661	0.793	rs829581	chr2:30678188	C/T	cg10949345	chr2:30726833	LCLAT1	1.14	14.01	0.67	3.64e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs8028182	0.636	rs4075522	chr15:75864335	G/A	cg20655648	chr15:75932815	IMP3	0.57	7.19	0.42	7.71e-12	Sudden cardiac arrest;
KIRP	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.41	-0.51	3.79e-18	Body mass index;
KIRP	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg02487422	chr3:49467188	NICN1	0.42	5.35	0.32	2.06e-7	Resting heart rate;
KIRP	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.64	8.36	0.47	4.73e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg16989719	chr2:238392110	NA	-0.39	-5.23	-0.32	3.66e-7	Prostate cancer;
KIRP	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11987759	chr7:65425863	GUSB	0.49	6.24	0.37	1.85e-9	Aortic root size;
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg17441377	chr17:3906640	NA	-0.53	-7.98	-0.45	5.58e-14	Type 2 diabetes;
KIRP	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1971762	0.545	rs9788134	chr12:54046067	A/T	cg16917193	chr12:54089295	NA	0.92	16.96	0.73	2.99e-43	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15837832	chr12:132414754	PUS1	0.51	6.33	0.37	1.13e-9	Parkinson's disease;
KIRP	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg13092806	chr2:177043255	NA	0.6	7.99	0.45	5.16e-14	IgG glycosylation;
KIRP	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.93	-0.4	3.63e-11	Morning vs. evening chronotype;
KIRP	cis	rs1322639	0.614	rs9455889	chr6:169566087	A/T	cg04662567	chr6:169592167	NA	-0.58	-5.15	-0.31	5.43e-7	Pulse pressure;
KIRP	cis	rs5753037	0.809	rs997913	chr22:30374621	T/A	cg27665648	chr22:30112403	NA	0.35	5.02	0.3	9.81e-7	Type 1 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16261398	chr11:1410750	BRSK2	0.46	6.47	0.38	5.38e-10	Parkinson's disease;
KIRP	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg12062639	chr20:23401060	NAPB	1.06	7.47	0.43	1.43e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg06565975	chr8:143823917	SLURP1	-0.34	-4.92	-0.3	1.58e-6	Urinary tract infection frequency;
KIRP	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg13385521	chr17:29058706	SUZ12P	0.6	5.95	0.35	9.22e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.39	5.82	0.35	1.84e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.78	8.18	0.46	1.55e-14	Psoriasis;
KIRP	cis	rs6832769	0.922	rs819271	chr4:56238847	G/A	cg05960024	chr4:56376020	CLOCK	0.64	7.89	0.45	9.72e-14	Personality dimensions;
KIRP	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18252515	chr7:66147081	NA	0.44	5.15	0.31	5.36e-7	Aortic root size;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg16255804	chr6:135334527	HBS1L	-0.33	-5.36	-0.32	1.93e-7	Red blood cell count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14250937	chr9:139723883	C9orf86	0.48	7.04	0.41	1.95e-11	Survival in pancreatic cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16578104	chr3:182688462	DCUN1D1	0.39	6.07	0.36	4.91e-9	C-reactive protein;
KIRP	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg09788416	chr12:39539408	NA	0.39	5.26	0.32	3.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs7923609	0.846	rs7896518	chr10:65104500	A/G	cg01631684	chr10:65280961	REEP3	-0.47	-5.42	-0.33	1.45e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9469913	0.740	rs2744937	chr6:34557246	C/T	cg17674042	chr6:34482479	PACSIN1	-0.5	-6.71	-0.39	1.34e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg01097406	chr16:89675127	NA	-0.29	-4.87	-0.3	2.01e-6	Vitiligo;
KIRP	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg07653901	chr22:50250238	ZBED4	0.43	4.98	0.3	1.19e-6	Schizophrenia;
KIRP	trans	rs1973993	0.689	rs17131755	chr1:96886167	G/A	cg10631902	chr5:14652156	NA	-0.57	-7.97	-0.45	6.05e-14	Weight;
KIRP	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.4	9.87	0.53	1.42e-19	Corneal astigmatism;
KIRP	cis	rs6088813	0.744	rs1204656	chr20:33982846	G/A	cg14752227	chr20:34000481	UQCC	-0.47	-5.29	-0.32	2.73e-7	Height;
KIRP	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	cg12689670	chr1:183009347	LAMC1	0.58	8.06	0.46	3.31e-14	Fuchs's corneal dystrophy;
KIRP	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg16141378	chr3:129829833	LOC729375	-0.53	-6.65	-0.39	1.92e-10	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26658471	chr20:25677673	ZNF337	0.49	6.25	0.37	1.81e-9	Parkinson's disease;
KIRP	cis	rs4704187	0.687	rs6889372	chr5:74531150	A/T	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.71e-8	Response to amphetamines;
KIRP	cis	rs8113308	0.810	rs11880193	chr19:52448669	G/C	cg25782003	chr19:52490127	ZNF350	0.53	4.97	0.3	1.23e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24110177	chr3:50126178	RBM5	0.86	12.71	0.63	8.46e-29	Body mass index;
KIRP	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg02158880	chr13:53174818	NA	0.41	5.46	0.33	1.18e-7	Lewy body disease;
KIRP	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.55	-7.44	-0.43	1.66e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03270376	chr2:219536588	RNF25;STK36	0.63	7.68	0.44	3.71e-13	Smoking initiation;
KIRP	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs1476679	0.962	rs34995835	chr7:99990364	T/G	cg19116668	chr7:99932089	PMS2L1	-0.78	-9.63	-0.52	7.64e-19	Alzheimer's disease (late onset);
KIRP	cis	rs7737355	1.000	rs27663	chr5:130741438	T/G	cg06647332	chr5:131281008	NA	-0.45	-4.98	-0.3	1.19e-6	Life satisfaction;
KIRP	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs874426	0.528	rs7928986	chr11:19573108	C/G	cg13922121	chr11:19575262	NAV2	0.46	5.75	0.34	2.65e-8	Attention deficit hyperactivity disorder (time to onset);
KIRP	cis	rs6921919	0.525	rs6929825	chr6:28378959	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg19774624	chr17:42201019	HDAC5	0.76	9.72	0.53	4.17e-19	Total body bone mineral density;
KIRP	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-0.96	-15.44	-0.7	4.46e-38	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15863598	chr10:76708663	MYST4	0.46	6.36	0.38	9.57e-10	Interleukin-4 levels;
KIRP	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.76	-9.38	-0.51	4.49e-18	Height;
KIRP	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg17145862	chr1:211918768	LPGAT1	-0.92	-13.38	-0.65	4.79e-31	Leprosy;
KIRP	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.61	-7.5	-0.43	1.18e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10861661	0.963	rs3782707	chr12:107185187	G/A	cg15890332	chr12:107067104	RFX4	0.37	5.18	0.31	4.59e-7	Triglyceride levels;
KIRP	cis	rs9584850	0.574	rs17471079	chr13:99168721	C/T	cg20750642	chr13:99100586	FARP1	-0.55	-5.79	-0.35	2.11e-8	Neuroticism;
KIRP	cis	rs12679254	0.504	rs12334531	chr8:74263630	A/G	cg00461685	chr8:74198210	NA	-0.47	-6.05	-0.36	5.42e-9	Inattentive symptoms;
KIRP	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg02569458	chr12:86230093	RASSF9	0.54	7.92	0.45	8e-14	Major depressive disorder;
KIRP	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg12315302	chr6:26189340	HIST1H4D	0.71	4.95	0.3	1.36e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6442310	0.534	rs796313	chr3:12449528	G/T	cg02700894	chr3:12045449	SYN2	-0.37	-5.07	-0.31	7.96e-7	Hematocrit;
KIRP	cis	rs11225247	0.649	rs12283885	chr11:102257902	G/T	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs28489187	0.683	rs6671599	chr1:85858857	T/C	cg16011679	chr1:85725395	C1orf52	-0.53	-6.54	-0.39	3.47e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg02696742	chr7:106810147	HBP1	-0.8	-7.99	-0.45	5.19e-14	Coronary artery disease;
KIRP	cis	rs4363506	1.000	rs10830092	chr10:129273898	T/A	cg07804728	chr10:129284050	NA	0.41	5.83	0.35	1.76e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs834603	0.546	rs1704973	chr7:47483705	T/C	cg09696706	chr7:47479511	TNS3	0.43	4.92	0.3	1.55e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg11235152	chr1:67600687	NA	0.65	9.71	0.53	4.33e-19	Psoriasis;
KIRP	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.98	-8.42	-0.47	3.17e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg18404041	chr3:52824283	ITIH1	-0.6	-8.92	-0.49	1.1e-16	Bipolar disorder;
KIRP	cis	rs1497828	0.956	rs2454117	chr1:217552823	T/C	cg04411442	chr1:217543379	NA	0.41	6.17	0.37	2.8e-9	Dialysis-related mortality;
KIRP	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg08738300	chr3:44038990	NA	0.67	9.39	0.51	4.36e-18	Coronary artery disease;
KIRP	cis	rs2048656	0.578	rs10095236	chr8:9684925	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-5.41	-0.33	1.49e-7	Schizophrenia;
KIRP	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Colorectal cancer;
KIRP	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg17764715	chr19:33622953	WDR88	0.82	11.91	0.6	3.95e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.48	-0.43	1.29e-12	Type 2 diabetes;
KIRP	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.39	7.55	0.43	8.7e-13	Multiple system atrophy;
KIRP	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg10818794	chr15:86012489	AKAP13	-0.49	-6.97	-0.41	2.85e-11	Interstitial lung disease;
KIRP	cis	rs806215	1.000	rs698406	chr7:127255285	C/G	cg25922125	chr7:127225783	GCC1	0.46	4.87	0.3	1.96e-6	Type 2 diabetes;
KIRP	cis	rs1524927	0.933	rs12704874	chr7:96340744	A/G	cg00227355	chr7:96336147	SHFM1	-0.32	-4.86	-0.3	2.12e-6	Total body bone mineral density;
KIRP	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg17554472	chr22:41940697	POLR3H	-0.63	-6.42	-0.38	7.15e-10	Vitiligo;
KIRP	cis	rs7837860	0.588	rs71526930	chr8:89281625	T/A	cg08624180	chr8:89339080	MMP16	-0.62	-5.3	-0.32	2.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg21452805	chr1:244014465	NA	0.72	6.56	0.39	3.1e-10	RR interval (heart rate);
KIRP	cis	rs6005807	0.719	rs9625523	chr22:29045745	T/C	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.99	18.52	0.76	1.47e-48	Colorectal adenoma (advanced);
KIRP	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg02454025	chr1:11042201	C1orf127	0.91	14.76	0.69	9.8e-36	Ewing sarcoma;
KIRP	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg26531700	chr6:26746687	NA	-0.42	-5.56	-0.33	6.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.65	10.32	0.55	5.56e-21	Bone mineral density;
KIRP	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-9.36	-0.51	5.25e-18	Morning vs. evening chronotype;
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.96	10.23	0.55	1.06e-20	Alzheimer's disease;
KIRP	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.45	5.46	0.33	1.17e-7	Body mass index;
KIRP	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.69	8.14	0.46	2.01e-14	Smoking initiation;
KIRP	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg01620082	chr3:125678407	NA	-1.24	-7.61	-0.44	5.83e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.13	-0.36	3.42e-9	Response to antipsychotic treatment;
KIRP	cis	rs7923609	0.812	rs10822184	chr10:65337153	C/T	cg08743896	chr10:65200160	JMJD1C	0.35	5.27	0.32	2.93e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24944079	chr11:36510961	TRAF6	0.37	6.1	0.36	4.14e-9	C-reactive protein;
KIRP	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.08	0.54	3.07e-20	Monocyte percentage of white cells;
KIRP	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.49	5.63	0.34	4.84e-8	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.34	12.2	0.61	4.31e-27	Diabetic retinopathy;
KIRP	cis	rs12643440	0.960	rs16894625	chr4:17198247	T/G	cg22650099	chr4:17144496	NA	-0.48	-5.67	-0.34	3.95e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.75	12.1	0.61	9.41e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7897654	0.571	rs12764049	chr10:104634956	A/G	cg15744005	chr10:104629667	AS3MT	-0.31	-5.08	-0.31	7.51e-7	Schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26453592	chr16:2264855	PGP	0.51	6.61	0.39	2.33e-10	Myopia (pathological);
KIRP	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg13906792	chr15:75199810	C15orf17	-0.37	-5.48	-0.33	1.07e-7	Breast cancer;
KIRP	cis	rs829883	0.659	rs11109522	chr12:98930964	C/T	cg25150519	chr12:98850993	NA	-0.75	-9.01	-0.5	5.85e-17	Colorectal adenoma (advanced);
KIRP	cis	rs6753739	0.784	rs1378642	chr2:219950110	G/C	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26207909	chr14:103986467	CKB	0.74	10.41	0.55	2.85e-21	Body mass index;
KIRP	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg01631408	chr1:248437212	OR2T33	-0.5	-5.86	-0.35	1.46e-8	Common traits (Other);
KIRP	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13385	0.769	rs10045140	chr5:139568764	G/A	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg04374321	chr14:90722782	PSMC1	0.48	5.29	0.32	2.7e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-8.72	-0.49	4.22e-16	Coronary artery disease;
KIRP	trans	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg02569458	chr12:86230093	RASSF9	-0.35	-5.02	-0.31	9.76e-7	Major depressive disorder;
KIRP	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg26681399	chr22:41777847	TEF	-0.51	-4.95	-0.3	1.39e-6	Vitiligo;
KIRP	cis	rs2273669	0.667	rs117941557	chr6:109298135	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-6.65	-0.39	1.87e-10	Prostate cancer;
KIRP	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	14.85	0.69	4.8e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.59	-9.73	-0.53	3.8e-19	Total body bone mineral density;
KIRP	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.71	8.79	0.49	2.57e-16	Cognitive function;
KIRP	cis	rs34779708	0.733	rs3936502	chr10:35549218	C/T	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg04166393	chr7:2884313	GNA12	-0.45	-5.91	-0.35	1.14e-8	Height;
KIRP	cis	rs12580194	0.593	rs12580661	chr12:55803129	G/A	cg11794356	chr12:55725991	OR6C3	-0.55	-7.15	-0.42	9.58e-12	Cancer;
KIRP	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.21	-0.37	2.3e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3750965	1.000	rs1466222	chr11:68832848	G/A	cg06818126	chr11:68850279	TPCN2	-0.46	-5.33	-0.32	2.23e-7	Hair color;
KIRP	cis	rs4789452	1.000	rs11658815	chr17:75375881	G/A	cg12985929	chr17:75370611	SEPT9	-0.39	-5.46	-0.33	1.16e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.73	9.31	0.51	7.51e-18	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.04	-0.36	5.68e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1864585	0.520	rs73208782	chr8:10677555	G/A	cg21775007	chr8:11205619	TDH	-0.49	-4.85	-0.3	2.17e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.59	7.28	0.42	4.55e-12	Monocyte percentage of white cells;
KIRP	cis	rs2574975	0.679	rs2574955	chr10:52124527	C/T	cg10034176	chr10:52120283	SGMS1	-0.52	-6.92	-0.4	3.78e-11	Response to amphetamines;
KIRP	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-4.97	-0.3	1.25e-6	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.65	8.36	0.47	4.74e-15	Height;
KIRP	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg10189774	chr4:17578691	LAP3	0.51	6.11	0.36	3.8e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.92	-0.4	3.8e-11	Systemic lupus erythematosus;
KIRP	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg05025164	chr4:1340916	KIAA1530	0.5	6.69	0.39	1.47e-10	Longevity;
KIRP	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.04	-0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg11503966	chr20:62272292	STMN3	-0.41	-5.91	-0.35	1.16e-8	Atopic dermatitis;
KIRP	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.71	9.4	0.51	4.08e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7572644	0.699	rs13416434	chr2:28162274	T/C	cg27432699	chr2:27873401	GPN1	-0.44	-5.29	-0.32	2.72e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9914988	0.576	rs67777803	chr17:27323322	G/T	cg10538030	chr17:27276405	PHF12	-0.56	-4.96	-0.3	1.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.64	9.58	0.52	1.08e-18	Neuroticism;
KIRP	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.52	-6.11	-0.36	3.87e-9	Coronary artery disease;
KIRP	trans	rs13170463	0.579	rs75311637	chr5:8047973	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg09699651	chr6:150184138	LRP11	0.48	6.35	0.38	1.04e-9	Lung cancer;
KIRP	cis	rs2964802	0.505	rs6865234	chr5:10829742	C/A	cg14521931	chr5:10832172	NA	-0.75	-11.34	-0.59	2.95e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg25767906	chr1:53392781	SCP2	-0.39	-5.41	-0.33	1.48e-7	Monocyte count;
KIRP	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg21926883	chr2:100939477	LONRF2	-0.63	-8.73	-0.49	4e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs8084125	1.000	rs62105169	chr18:74945193	A/G	cg26065057	chr18:74961000	GALR1	0.76	7.46	0.43	1.44e-12	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg00933542	chr6:150070202	PCMT1	0.28	5.38	0.32	1.69e-7	Lung cancer;
KIRP	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg05340658	chr4:99064831	C4orf37	0.67	8.14	0.46	2e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs712039	0.652	rs1102920	chr17:35760940	A/G	cg16670864	chr17:35848621	DUSP14	0.43	5.18	0.31	4.68e-7	Tuberculosis;
KIRP	trans	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg00938859	chr5:1591904	SDHAP3	0.59	7.65	0.44	4.46e-13	Breast cancer;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.95e-8	Life satisfaction;
KIRP	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.35	0.32	2.03e-7	Rheumatoid arthritis;
KIRP	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs6701037	1.000	rs11585617	chr1:175123186	C/G	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.23	-0.32	3.67e-7	Alcohol dependence;
KIRP	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.49	-0.43	1.26e-12	Bipolar disorder;
KIRP	cis	rs2275565	0.872	rs10158822	chr1:237050176	G/T	cg17297354	chr1:237056641	MTR	0.4	5.23	0.32	3.7e-7	Homocysteine levels;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.55	5.17	0.31	4.78e-7	Alzheimer's disease;
KIRP	cis	rs10924970	1.000	rs10924870	chr1:235359782	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.41	-5.11	-0.31	6.6e-7	Asthma;
KIRP	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.1	0.61	9.69e-27	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13939156	chr17:80058883	NA	0.48	7.31	0.42	3.81e-12	Life satisfaction;
KIRP	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.63	-6.33	-0.37	1.18e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg09165964	chr15:75287851	SCAMP5	0.44	5.52	0.33	8.6e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs7849270	1.000	rs1571229	chr9:131913711	A/G	cg13538475	chr9:131942899	NA	-0.32	-5.27	-0.32	2.92e-7	Blood metabolite ratios;
KIRP	cis	rs4664293	0.801	rs7590595	chr2:160571709	A/G	cg08347373	chr2:160653686	CD302	-0.36	-5.54	-0.33	7.65e-8	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg04080417	chr5:1859792	NA	-0.63	-8.13	-0.46	2.05e-14	Cardiovascular disease risk factors;
KIRP	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg04310649	chr10:35416472	CREM	-0.61	-7.31	-0.42	3.65e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.51	6.26	0.37	1.67e-9	Asthma (sex interaction);
KIRP	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.94	9.99	0.54	6.14e-20	Alzheimer's disease;
KIRP	cis	rs2230307	0.536	rs6577152	chr1:100434610	A/G	cg24955406	chr1:100503596	HIAT1	0.65	7.22	0.42	6.29e-12	Carotid intima media thickness;
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-13.22	-0.64	1.66e-30	Alzheimer's disease;
KIRP	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-5.62	-0.34	5.03e-8	Recombination measurement;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg19278809	chr4:6785080	KIAA0232	-0.56	-6.15	-0.37	3.16e-9	Menopause (age at onset);
KIRP	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg14768367	chr16:72042858	DHODH	-0.87	-9.65	-0.52	7.05e-19	Blood protein levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23928525	chr17:19266198	B9D1	0.42	6.16	0.37	2.97e-9	Survival in pancreatic cancer;
KIRP	cis	rs963731	0.649	rs297129	chr2:39299271	C/T	cg04010122	chr2:39346883	SOS1	0.87	6.3	0.37	1.33e-9	Corticobasal degeneration;
KIRP	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg16506815	chr2:162101123	NA	0.51	6.13	0.36	3.48e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs362296	0.698	rs3129319	chr4:3265381	A/G	cg06533319	chr4:3265114	C4orf44	0.6	7.84	0.45	1.38e-13	Parental longevity (mother's age at death);
KIRP	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg14768367	chr16:72042858	DHODH	-0.82	-8.62	-0.48	8.12e-16	Blood protein levels;
KIRP	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.22	23.59	0.83	4.36e-65	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.43	5.59	0.34	6.14e-8	Hypertriglyceridemia;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.29	-5.67	-0.34	3.93e-8	Lymphocyte counts;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10795710	chr1:16693622	C1orf144	0.65	7.42	0.43	1.89e-12	Lung cancer in ever smokers;
KIRP	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg08133631	chr1:26527909	CATSPER4	-0.44	-5.05	-0.31	8.71e-7	Obesity-related traits;
KIRP	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.58	-11.9	-0.6	4.31e-26	Gout;
KIRP	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg21918786	chr6:109611834	NA	0.34	5.12	0.31	6.12e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg12661370	chr5:149340060	SLC26A2	-0.49	-5.05	-0.31	8.76e-7	HIV-1 control;
KIRP	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12230513	0.732	rs4130004	chr12:55860773	G/T	cg19537932	chr12:55886519	OR6C68	-0.63	-7.64	-0.44	4.9e-13	Contrast sensitivity;
KIRP	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg12623918	chr2:306882	NA	0.44	5.69	0.34	3.61e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.63	-7.04	-0.41	1.91e-11	Menarche (age at onset);
KIRP	cis	rs7221595	0.825	rs12939802	chr17:3933904	C/T	cg05562828	chr17:3906858	NA	0.51	5.69	0.34	3.59e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4955124	0.643	rs17028716	chr3:32041580	C/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	-0.75	-6.46	-0.38	5.55e-10	Schizophrenia;
KIRP	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.79	-7.64	-0.44	4.96e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg16141378	chr3:129829833	LOC729375	0.62	8.52	0.48	1.64e-15	Triglycerides;
KIRP	cis	rs889398	0.771	rs1500337	chr16:69901884	C/T	cg09409435	chr16:70099608	PDXDC2	-0.41	-4.97	-0.3	1.24e-6	Body mass index;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13060573	chr17:37709314	NA	-0.52	-6.66	-0.39	1.76e-10	Inflammatory biomarkers;
KIRP	cis	rs9469913	0.799	rs2744956	chr6:34618937	T/C	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.15	-0.31	5.38e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs151997	0.962	rs28676922	chr5:50247221	C/T	cg06027927	chr5:50259733	NA	0.57	7.17	0.42	8.68e-12	Callous-unemotional behaviour;
KIRP	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.66	-9.43	-0.52	3.23e-18	Colorectal cancer;
KIRP	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg19847130	chr8:10466454	RP1L1	-0.34	-4.84	-0.3	2.25e-6	Neuroticism;
KIRP	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.51	6.93	0.4	3.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.7	-11.4	-0.59	1.88e-24	Menopause (age at onset);
KIRP	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.39	-5.89	-0.35	1.24e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.46	-0.43	1.52e-12	Bipolar disorder;
KIRP	cis	rs743757	0.938	rs2236981	chr3:50488845	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.53	5.21	0.32	4.06e-7	Diastolic blood pressure;
KIRP	cis	rs8060686	0.920	rs111315946	chr16:67889793	G/C	cg04539111	chr16:67997858	SLC12A4	-0.64	-6.69	-0.39	1.52e-10	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.06e-10	Prudent dietary pattern;
KIRP	cis	rs1413885	0.548	rs6588136	chr1:65837119	C/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.55	5.88	0.35	1.3e-8	Anticoagulant levels;
KIRP	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg01251548	chr11:17372745	DKFZp686O24166	-0.4	-5.26	-0.32	3.08e-7	Type 2 diabetes;
KIRP	cis	rs10940138	0.830	rs6867554	chr5:67207725	A/G	ch.5.1281357F	chr5:67228439	NA	0.78	12.46	0.62	6.16e-28	Menarche (age at onset);
KIRP	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.64	9.4	0.51	3.93e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12481786	chr1:38455876	SF3A3	-0.38	-5.26	-0.32	3.06e-7	Coronary artery disease;
KIRP	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-5.92	-0.35	1.1e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.49	-5.99	-0.36	7.25e-9	Coronary artery disease;
KIRP	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg06027949	chr8:82754900	SNX16	-0.62	-6.74	-0.39	1.13e-10	Diastolic blood pressure;
KIRP	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26306683	chr17:18585705	ZNF286B	0.59	7.49	0.43	1.22e-12	Educational attainment (years of education);
KIRP	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.75	11.39	0.59	2.07e-24	Type 2 diabetes;
KIRP	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg19847130	chr8:10466454	RP1L1	0.34	4.99	0.3	1.12e-6	Retinal vascular caliber;
KIRP	trans	rs4809760	0.737	rs17786148	chr20:48474504	A/G	cg08479635	chr11:45114570	PRDM11	-0.38	-6.11	-0.36	3.87e-9	Gut microbiota (beta diversity);
KIRP	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg24375607	chr4:120327624	NA	0.63	6.56	0.39	3.16e-10	Corneal astigmatism;
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	16.95	0.73	3.29e-43	Platelet count;
KIRP	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg02996583	chr8:142237188	SLC45A4	-0.42	-4.88	-0.3	1.95e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.69	10.4	0.55	3.11e-21	Schizophrenia;
KIRP	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg12315302	chr6:26189340	HIST1H4D	-0.78	-5.35	-0.32	1.97e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17092148	1.000	rs7271289	chr20:33397303	C/T	cg16810054	chr20:33298113	TP53INP2	0.45	5.6	0.34	5.78e-8	Neuroticism;
KIRP	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg04731861	chr2:219085781	ARPC2	-0.23	-5.64	-0.34	4.76e-8	Colorectal cancer;
KIRP	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	12.31	0.62	1.85e-27	Menarche (age at onset);
KIRP	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.79	-9.49	-0.52	2.11e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.07	11.56	0.59	5.82e-25	Lung cancer in ever smokers;
KIRP	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-7.48	-0.43	1.3e-12	Systemic lupus erythematosus;
KIRP	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.74	-0.39	1.1e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.96	-0.41	3.07e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.62	5.42	0.33	1.41e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs228437	0.609	rs7749956	chr6:134961973	C/T	cg24504307	chr6:134963096	NA	0.32	5.37	0.32	1.83e-7	Melanoma;
KIRP	cis	rs17453880	0.571	rs2961759	chr5:151939650	A/G	cg12297329	chr5:152029980	NA	-0.4	-5.78	-0.35	2.29e-8	Subjective well-being;
KIRP	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg13319975	chr6:146136371	FBXO30	0.47	6.27	0.37	1.6e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs564343	0.560	rs2576	chr11:65808467	C/T	cg26701943	chr11:108369231	KDELC2	-0.47	-6.12	-0.36	3.66e-9	Obesity (early onset extreme);
KIRP	cis	rs10129255	0.500	rs6576225	chr14:107186359	G/C	cg23076370	chr14:107095027	NA	-0.4	-4.93	-0.3	1.53e-6	Kawasaki disease;
KIRP	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.19e-13	Corneal astigmatism;
KIRP	cis	rs2671245	0.586	rs2671227	chr1:56150777	T/C	cg11523071	chr1:56160889	NA	0.35	5.0	0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.46	6.49	0.38	4.57e-10	Dupuytren's disease;
KIRP	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg13482628	chr17:19912719	NA	0.53	6.84	0.4	6.26e-11	Schizophrenia;
KIRP	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg06795125	chr2:108905320	SULT1C2	-0.46	-7.92	-0.45	7.94e-14	Blood pressure;
KIRP	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.68	11.31	0.58	3.78e-24	Pulse pressure;
KIRP	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.63	0.44	5e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7523273	0.512	rs2761435	chr1:207918466	C/G	cg22525895	chr1:207977042	MIR29B2	0.5	6.68	0.39	1.61e-10	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26463106	chr3:9404837	THUMPD3	0.51	6.59	0.39	2.71e-10	Parkinson's disease;
KIRP	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.5	5.22	0.32	3.88e-7	Subjective well-being;
KIRP	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg19468946	chr17:37922297	IKZF3	-0.47	-6.63	-0.39	2.12e-10	Asthma;
KIRP	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg06121193	chr1:90282411	NA	-0.48	-6.98	-0.41	2.73e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.6	8.06	0.46	3.27e-14	Myopia (pathological);
KIRP	cis	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg21625330	chr8:9911636	MSRA	0.37	4.86	0.3	2.08e-6	Neuroticism;
KIRP	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.29	6.27	0.37	1.65e-9	Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14039299	chr9:135251409	TTF1	0.58	7.48	0.43	1.28e-12	Interleukin-4 levels;
KIRP	cis	rs1448094	0.773	rs11117100	chr12:86310392	A/G	cg02569458	chr12:86230093	RASSF9	0.37	5.33	0.32	2.25e-7	Major depressive disorder;
KIRP	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.45	0.33	1.22e-7	Menopause (age at onset);
KIRP	cis	rs8062405	0.558	rs231976	chr16:28545587	C/G	cg00931491	chr16:28608288	SULT1A2	-0.23	-5.12	-0.31	6.16e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg17691542	chr6:26056736	HIST1H1C	0.63	7.47	0.43	1.36e-12	Iron status biomarkers;
KIRP	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.17	-0.31	4.86e-7	Bipolar disorder;
KIRP	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg17425144	chr1:10567563	PEX14	-0.41	-7.08	-0.41	1.5e-11	Hand grip strength;
KIRP	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg18016565	chr1:150552671	MCL1	0.4	5.83	0.35	1.74e-8	Melanoma;
KIRP	cis	rs2072732	0.861	rs6679678	chr1:2950594	T/C	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-1.07	-12.78	-0.63	5.21e-29	Exhaled nitric oxide output;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg01763666	chr17:80159506	CCDC57	-0.36	-4.91	-0.3	1.67e-6	Life satisfaction;
KIRP	cis	rs3857067	0.933	rs10023582	chr4:95035811	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.38	-4.99	-0.3	1.15e-6	QT interval;
KIRP	cis	rs7202877	0.656	rs247427	chr16:75439132	T/C	cg03315344	chr16:75512273	CHST6	-0.56	-5.23	-0.32	3.56e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg17279839	chr7:150038598	RARRES2	0.56	7.08	0.41	1.46e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.87	-9.6	-0.52	9.82e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs16857609	0.628	rs2618142	chr2:218336670	A/G	cg15335768	chr2:218268053	DIRC3	-0.36	-5.36	-0.32	1.88e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs6496667	0.779	rs2283442	chr15:90971478	C/G	cg10434728	chr15:90938212	IQGAP1	0.36	4.96	0.3	1.29e-6	Rheumatoid arthritis;
KIRP	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.07	0.31	7.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg13798780	chr7:105162888	PUS7	0.66	6.11	0.36	3.83e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	1.08	16.03	0.71	4.36e-40	Menopause (age at onset);
KIRP	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs17453880	0.929	rs12518097	chr5:152030041	T/C	cg12297329	chr5:152029980	NA	-0.72	-11.2	-0.58	8.35e-24	Subjective well-being;
KIRP	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg02462569	chr6:150064036	NUP43	-0.46	-6.63	-0.39	2.09e-10	Lung cancer;
KIRP	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg21253087	chr9:139290292	SNAPC4	0.46	6.54	0.38	3.5e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.44	-5.31	-0.32	2.42e-7	Tonsillectomy;
KIRP	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	6.86	0.4	5.5e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.27	0.42	4.69e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7737355	0.853	rs26004	chr5:130988955	G/T	cg06307176	chr5:131281290	NA	0.41	4.93	0.3	1.54e-6	Life satisfaction;
KIRP	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg11833968	chr6:79620685	NA	-0.38	-5.23	-0.32	3.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg04691961	chr3:161091175	C3orf57	-0.38	-5.44	-0.33	1.31e-7	Kawasaki disease;
KIRP	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.69	9.63	0.52	8.07e-19	Blood protein levels;
KIRP	cis	rs2219968	1.000	rs13262830	chr8:78957669	C/T	cg00738934	chr8:78996279	NA	0.5	7.0	0.41	2.49e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg07382826	chr16:28625726	SULT1A1	-0.45	-5.25	-0.32	3.24e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.6	7.24	0.42	5.84e-12	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.61	8.5	0.48	1.86e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.8	-0.4	7.73e-11	Monocyte percentage of white cells;
KIRP	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.59	5.57	0.33	6.52e-8	White matter hyperintensity burden;
KIRP	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25214090	chr10:38739885	LOC399744	0.59	7.37	0.43	2.59e-12	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.6	0.34	5.76e-8	Life satisfaction;
KIRP	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg00319359	chr11:70116639	PPFIA1	0.62	6.08	0.36	4.62e-9	Coronary artery disease;
KIRP	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17691542	chr6:26056736	HIST1H1C	0.53	6.67	0.39	1.72e-10	Height;
KIRP	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.77	-11.03	-0.58	3.01e-23	Height;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.59	6.82	0.4	7.21e-11	Height;
KIRP	cis	rs9972944	0.756	rs8072765	chr17:63763508	T/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.79	-0.44	1.86e-13	Total body bone mineral density;
KIRP	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg23594656	chr7:65796392	TPST1	0.4	5.99	0.36	7.32e-9	Aortic root size;
KIRP	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg01849789	chr22:41697279	ZC3H7B	-0.48	-5.35	-0.32	1.97e-7	Neuroticism;
KIRP	cis	rs216026	0.689	rs4765701	chr12:2770891	C/T	cg19945202	chr12:2788847	CACNA1C	0.57	7.11	0.41	1.29e-11	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.98	0.45	5.51e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	1.07	20.46	0.79	5.36e-55	Height;
KIRP	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.39	8.21	0.46	1.23e-14	Body mass index;
KIRP	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-10.28	-0.55	7.24e-21	Vitiligo;
KIRP	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-6.85	-0.4	5.84e-11	Vitiligo;
KIRP	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	4.03e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35771425	1.000	rs35771425	chr1:211609768	T/C	cg10512769	chr1:211675356	NA	-0.56	-5.4	-0.33	1.6e-7	Educational attainment (years of education);
KIRP	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.78	8.67	0.48	5.75e-16	Corneal astigmatism;
KIRP	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.91	-14.78	-0.69	8.3e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs17123764	0.710	rs11169133	chr12:50126058	T/C	cg20471783	chr12:50157085	TMBIM6	0.32	4.98	0.3	1.21e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs34091987	0.582	rs2193053	chr17:70025931	A/C	cg09344028	chr17:70110421	NA	0.29	5.5	0.33	9.32e-8	Nose size;
KIRP	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.76	8.0	0.45	5.03e-14	Uric acid levels;
KIRP	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.79	0.49	2.63e-16	IgG glycosylation;
KIRP	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.73	9.46	0.52	2.55e-18	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs77926410	0.604	rs11053801	chr12:10596117	G/T	cg24004959	chr3:189087191	NA	-0.36	-6.13	-0.36	3.41e-9	Mean corpuscular volume;
KIRP	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.35	6.53	0.38	3.7e-10	Educational attainment (years of education);
KIRP	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.59	7.61	0.44	5.91e-13	Morning vs. evening chronotype;
KIRP	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.47	6.19	0.37	2.53e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.77	-8.07	-0.46	3.09e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs240764	0.711	rs240112	chr6:101059253	C/A	cg09795085	chr6:101329169	ASCC3	0.44	5.12	0.31	6.12e-7	Neuroticism;
KIRP	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg02569458	chr12:86230093	RASSF9	0.54	7.94	0.45	7.21e-14	Major depressive disorder;
KIRP	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.51	6.31	0.37	1.31e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg25486957	chr4:152246857	NA	0.43	5.09	0.31	7.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg11814155	chr7:99998594	ZCWPW1	0.61	5.7	0.34	3.39e-8	Platelet count;
KIRP	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg24296786	chr1:45957014	TESK2	0.63	8.5	0.48	1.91e-15	High light scatter reticulocyte count;
KIRP	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13939156	chr17:80058883	NA	0.54	8.78	0.49	2.75e-16	Life satisfaction;
KIRP	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg09936142	chr19:10668400	KRI1	-0.42	-4.93	-0.3	1.49e-6	Inflammatory skin disease;
KIRP	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.27	-0.37	1.63e-9	Breast cancer;
KIRP	cis	rs2371030	0.965	rs10932351	chr2:211566911	A/G	cg18417063	chr2:211583084	NA	-0.52	-7.54	-0.43	9.15e-13	Non-small cell lung cancer;
KIRP	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg18657303	chr4:1051139	NA	0.54	4.95	0.3	1.39e-6	Recombination rate (females);
KIRP	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg10547527	chr2:198650123	BOLL	-0.51	-4.98	-0.3	1.19e-6	Ulcerative colitis;
KIRP	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg21360079	chr12:107162445	NA	-0.65	-9.15	-0.5	2.29e-17	Heart rate;
KIRP	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg03388025	chr16:89894329	SPIRE2	0.4	8.11	0.46	2.45e-14	Vitiligo;
KIRP	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.27	0.51	9.93e-18	Electroencephalogram traits;
KIRP	cis	rs13424612	1.000	rs4149556	chr2:240915307	C/T	cg01812947	chr2:240904978	NDUFA10	0.48	6.28	0.37	1.54e-9	Odorant perception (isobutyraldehyde);
KIRP	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.87	-10.96	-0.57	5.1e-23	Dupuytren's disease;
KIRP	cis	rs7521681	0.838	rs7523266	chr1:108310224	A/G	cg21202240	chr1:109285050	FNDC7	-0.42	-4.85	-0.3	2.24e-6	Asthma and hay fever;
KIRP	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg04132472	chr17:19861366	AKAP10	0.38	4.88	0.3	1.92e-6	Schizophrenia;
KIRP	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.08	-0.41	1.51e-11	Aortic root size;
KIRP	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs72827839	0.740	rs72823594	chr17:46124276	C/T	cg23391107	chr17:45924227	SP6	0.47	4.98	0.3	1.2e-6	Ease of getting up in the morning;
KIRP	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.22	-0.32	3.75e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.51	5.69	0.34	3.68e-8	Vitiligo;
KIRP	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11987759	chr7:65425863	GUSB	0.5	6.72	0.39	1.23e-10	Aortic root size;
KIRP	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg20651018	chr11:3035856	CARS	-0.38	-5.25	-0.32	3.34e-7	Longevity;
KIRP	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.34	5.28	0.32	2.85e-7	Asthma (childhood onset);
KIRP	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg07930552	chr6:133119739	C6orf192	1.09	9.68	0.53	5.67e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs258892	0.895	rs11953055	chr5:72051503	C/T	cg21869765	chr5:72125136	TNPO1	-0.51	-5.92	-0.35	1.08e-8	Small cell lung carcinoma;
KIRP	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	4.97	0.3	1.24e-6	Cognitive test performance;
KIRP	cis	rs137699	0.652	rs137707	chr22:39751401	T/C	cg11247378	chr22:39784982	NA	-0.47	-5.9	-0.35	1.22e-8	IgG glycosylation;
KIRP	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.47	0.48	2.28e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7116495	0.881	rs6592451	chr11:71674937	G/A	cg26138937	chr11:71823887	C11orf51	-0.72	-5.85	-0.35	1.53e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06512514	chr1:32479141	KHDRBS1	0.45	6.12	0.36	3.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10093031	chr22:50964219	TYMP;SCO2	0.46	6.08	0.36	4.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs745080	0.674	rs4901283	chr14:52997807	A/T	cg23333723	chr14:53022898	GPR137C	-0.41	-5.64	-0.34	4.67e-8	Orofacial clefts;
KIRP	cis	rs1620921	0.524	rs4440440	chr6:161183424	A/C	cg01280913	chr6:161186852	NA	-0.72	-10.56	-0.56	9.67e-22	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.91	15.74	0.71	4.27e-39	Headache;
KIRP	cis	rs1950626	0.671	rs34675695	chr14:101447913	C/T	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.92	0.4	3.93e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4363506	0.625	rs4307637	chr10:129286951	A/G	cg07804728	chr10:129284050	NA	0.44	5.98	0.36	7.85e-9	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.97	12.59	0.63	2.18e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4664293	0.967	rs9646765	chr2:160565648	T/C	cg08347373	chr2:160653686	CD302	-0.4	-6.16	-0.37	2.96e-9	Monocyte percentage of white cells;
KIRP	cis	rs6807915	0.603	rs9823123	chr3:12288569	A/C	cg15873301	chr3:12045459	SYN2	-0.41	-5.44	-0.33	1.29e-7	Leprosy;
KIRP	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.42	5.79	0.35	2.19e-8	Coronary artery disease;
KIRP	cis	rs4523957	0.855	rs1231209	chr17:2124972	G/A	cg16513277	chr17:2031491	SMG6	-0.68	-9.48	-0.52	2.22e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-0.92	-13.4	-0.65	4.2e-31	Dupuytren's disease;
KIRP	trans	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg13565492	chr6:43139072	SRF	-0.94	-8.66	-0.48	6.42e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.48	5.64	0.34	4.73e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg06636001	chr8:8085503	FLJ10661	0.7	9.2	0.51	1.55e-17	Retinal vascular caliber;
KIRP	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10174797	chr19:8464628	RAB11B	0.51	6.41	0.38	7.33e-10	HDL cholesterol;
KIRP	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.11	-0.5	3.06e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs921874	0.553	rs2077594	chr11:86772166	G/A	cg22937172	chr2:240168862	HDAC4	0.51	6.6	0.39	2.46e-10	Total body bone mineral density;
KIRP	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg26373071	chr5:1325741	CLPTM1L	0.45	6.11	0.36	3.97e-9	Lung cancer;
KIRP	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.93	9.91	0.53	1.05e-19	Monocyte percentage of white cells;
KIRP	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.6	7.62	0.44	5.61e-13	Diastolic blood pressure;
KIRP	trans	rs7999699	0.967	rs9534813	chr13:48337965	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.42	0.38	7.01e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.04	-17.68	-0.75	1.08e-45	Multiple system atrophy;
KIRP	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg15488143	chr7:128924101	AHCYL2	0.62	6.63	0.39	2.17e-10	White matter hyperintensity burden;
KIRP	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg10546040	chr5:78280163	ARSB	-0.51	-6.43	-0.38	6.73e-10	Obesity-related traits;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg21395782	chr19:19626814	NDUFA13;TSSK6	0.47	6.21	0.37	2.27e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs56399783	0.614	rs11772508	chr7:2771504	A/C	cg19731401	chr7:2775893	GNA12	-0.79	-7.88	-0.45	1.04e-13	Childhood ear infection;
KIRP	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.01	-0.41	2.35e-11	Systolic blood pressure;
KIRP	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.42	-0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg25019033	chr10:957182	NA	-0.53	-6.58	-0.39	2.84e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.21e-6	Blood protein levels;
KIRP	cis	rs12712073	0.837	rs11692867	chr2:100759477	G/A	cg07810366	chr2:100720526	AFF3	-0.3	-4.88	-0.3	1.89e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03421743	chr4:83932010	LIN54	0.55	7.19	0.42	7.69e-12	Parkinson's disease;
KIRP	cis	rs33912345	0.695	rs932606	chr14:60820471	A/G	cg27398547	chr14:60952738	C14orf39	0.41	5.49	0.33	1e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16386425	chr10:429943	DIP2C	-0.49	-6.72	-0.39	1.24e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	14.88	0.69	3.69e-36	Platelet count;
KIRP	cis	rs35955747	0.934	rs13053245	chr22:31816742	G/C	cg02404636	chr22:31891804	SFI1	-0.39	-5.29	-0.32	2.76e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs4889855	0.556	rs56873925	chr17:78536611	C/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.57	-0.33	6.76e-8	Fractional excretion of uric acid;
KIRP	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-6.14	-0.36	3.33e-9	Skin colour saturation;
KIRP	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.85	-0.35	1.53e-8	Schizophrenia;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg24874828	chr4:187887005	NA	-0.48	-7.2	-0.42	7.39e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.9	0.35	1.2e-8	Schizophrenia;
KIRP	cis	rs7332672	0.620	rs4319612	chr13:100064165	A/G	cg25919922	chr13:100150906	NA	-0.47	-5.26	-0.32	3.09e-7	Eosinophil counts;
KIRP	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.02e-8	Motion sickness;
KIRP	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.92	-0.3	1.55e-6	Pulmonary function;
KIRP	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.42	5.24	0.32	3.39e-7	Lymphocyte counts;
KIRP	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg10932868	chr11:921992	NA	0.67	9.13	0.5	2.59e-17	Alzheimer's disease (late onset);
KIRP	cis	rs12282928	0.917	rs9651621	chr11:48340048	G/C	cg26585981	chr11:48327164	OR4S1	0.5	6.07	0.36	4.7e-9	Migraine - clinic-based;
KIRP	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.38	-5.07	-0.31	7.86e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	6.17	0.37	2.76e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6558174	0.965	rs4072394	chr8:22490800	C/T	cg03733263	chr8:22462867	KIAA1967	0.49	5.81	0.35	1.9e-8	Breast cancer;
KIRP	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg00806126	chr19:22604979	ZNF98	0.56	6.07	0.36	4.87e-9	Pain;
KIRP	cis	rs7225151	0.710	rs76420897	chr17:5196576	C/A	cg24500398	chr17:5266808	RABEP1	-0.58	-5.61	-0.34	5.57e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.27	-0.32	2.95e-7	Calcium levels;
KIRP	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg02073558	chr3:44770973	ZNF501	0.59	8.39	0.47	3.96e-15	Depressive symptoms;
KIRP	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg14003231	chr6:33640908	ITPR3	0.26	4.87	0.3	2.01e-6	Height;
KIRP	cis	rs7072216	0.922	rs4488133	chr10:100159136	A/T	cg26618903	chr10:100175079	PYROXD2	0.34	5.01	0.3	1.02e-6	Metabolite levels;
KIRP	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg27462398	chr1:86174642	ZNHIT6	-0.48	-5.67	-0.34	3.94e-8	Urate levels in overweight individuals;
KIRP	cis	rs16828019	0.852	rs11209531	chr1:41571021	C/T	cg24596898	chr1:41849189	NA	0.63	5.19	0.31	4.39e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05573182	chr20:39318437	MAFB	0.51	6.06	0.36	5.12e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.6	0.56	7.17e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.61	0.6	3.82e-25	Heart rate;
KIRP	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.67	0.39	1.66e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.13	-0.36	3.41e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.81	-11.99	-0.61	2.23e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg06521331	chr12:34319734	NA	-0.56	-6.9	-0.4	4.28e-11	Morning vs. evening chronotype;
KIRP	trans	rs1738074	0.536	rs3127198	chr6:159452532	A/G	cg25738688	chr12:89138236	NA	0.44	6.03	0.36	5.92e-9	Multiple sclerosis;Celiac disease;
KIRP	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.2	-0.46	1.33e-14	Fibrinogen levels;
KIRP	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.99	-16.78	-0.73	1.17e-42	Height;
KIRP	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs7017914	0.840	rs13254851	chr8:71689034	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.71	9.11	0.5	2.94e-17	Bladder cancer;
KIRP	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg18882449	chr10:104885122	NT5C2	-0.5	-6.47	-0.38	5.22e-10	Arsenic metabolism;
KIRP	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.71	-7.92	-0.45	8.15e-14	Coronary artery disease or large artery stroke;
KIRP	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.87	-14.56	-0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.92	9.92	0.53	1.02e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.25e-10	Hypertriglyceridemia;
KIRP	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.44	-0.52	2.97e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.53	-0.33	8.18e-8	Obesity-related traits;
KIRP	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.64	7.85	0.45	1.26e-13	Vitiligo;
KIRP	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg08501292	chr6:25962987	TRIM38	0.78	5.26	0.32	3.1e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg00405596	chr8:11794950	NA	0.41	5.43	0.33	1.35e-7	Retinal vascular caliber;
KIRP	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-7.1	-0.41	1.31e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.67	9.08	0.5	3.71e-17	Crohn's disease;
KIRP	cis	rs6016377	0.689	rs6102039	chr20:39195039	T/G	cg22477343	chr20:39312069	NA	0.52	6.75	0.4	1.06e-10	Birth weight;
KIRP	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.81	7.42	0.43	1.88e-12	Mean platelet volume;
KIRP	cis	rs975210	1.000	rs975210	chr15:70364352	G/A	cg12349571	chr15:70364359	TLE3	-0.59	-6.09	-0.36	4.22e-9	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.59	-7.32	-0.42	3.62e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	1.02	8.66	0.48	6.21e-16	Sitting height ratio;
KIRP	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.61	8.26	0.47	8.86e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.57	-0.48	1.18e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg26876637	chr1:152193138	HRNR	-0.79	-9.88	-0.53	1.29e-19	Atopic dermatitis;
KIRP	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2594989	1.000	rs346077	chr3:11326102	A/C	cg01796438	chr3:11312864	ATG7	-0.63	-7.46	-0.43	1.53e-12	Circulating chemerin levels;
KIRP	cis	rs12580194	0.598	rs12582005	chr12:55772837	A/T	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.84	10.03	0.54	4.52e-20	Multiple sclerosis;
KIRP	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg17595323	chr11:93583763	C11orf90	0.29	5.07	0.31	7.99e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6684428	1.000	rs6684334	chr1:56359726	T/C	cg11651538	chr1:56320950	NA	-0.82	-9.88	-0.53	1.29e-19	Airflow obstruction;
KIRP	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	0.64	5.78	0.35	2.29e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.83	8.98	0.5	7.25e-17	Alzheimer's disease;
KIRP	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.48	-0.33	1.05e-7	IgG glycosylation;
KIRP	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.68	10.53	0.56	1.24e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg05315796	chr3:52349193	DNAH1	0.43	6.27	0.37	1.59e-9	Bipolar disorder;
KIRP	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg26681399	chr22:41777847	TEF	0.55	5.31	0.32	2.46e-7	Vitiligo;
KIRP	cis	rs9372498	0.536	rs9489457	chr6:118920285	C/T	cg21191810	chr6:118973309	C6orf204	-0.42	-4.86	-0.3	2.14e-6	Diastolic blood pressure;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.51	-5.32	-0.32	2.34e-7	Corneal structure;
KIRP	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.79	10.03	0.54	4.67e-20	Longevity;
KIRP	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	9.62	0.52	8.23e-19	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg09695851	chr17:3907499	NA	0.82	15.12	0.69	5.58e-37	Type 2 diabetes;
KIRP	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.8e-11	Hypertriglyceridemia;
KIRP	cis	rs67257959	0.708	rs11671858	chr19:17201520	T/G	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	5.8	0.35	1.98e-8	Selective IgA deficiency;
KIRP	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg16141378	chr3:129829833	LOC729375	0.54	7.32	0.42	3.44e-12	Morning vs. evening chronotype;
KIRP	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.46	6.96	0.41	3.07e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg21699342	chr2:239360505	ASB1	0.43	5.14	0.31	5.72e-7	Multiple system atrophy;
KIRP	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	9.31	0.51	7.5e-18	Neuroticism;
KIRP	cis	rs3806843	0.569	rs753279	chr5:140023818	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.65	0.34	4.46e-8	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-11.04	-0.58	2.84e-23	Total body bone mineral density;
KIRP	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-7.89	-0.45	9.74e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg00806126	chr19:22604979	ZNF98	-0.67	-7.2	-0.42	7.29e-12	Pain;
KIRP	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.63	-9.26	-0.51	1.08e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10463554	0.963	rs72785733	chr5:102374192	T/A	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Parkinson's disease;
KIRP	cis	rs9815354	1.000	rs3774372	chr3:41877414	A/G	cg03022575	chr3:42003672	ULK4	0.63	6.87	0.4	5.19e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg14440974	chr22:39074834	NA	-0.38	-4.94	-0.3	1.44e-6	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs62151617	1.000	rs12619598	chr2:70790987	G/A	cg24334149	chr2:71175539	ATP6V1B1	0.49	4.95	0.3	1.37e-6	Hair shape;
KIRP	cis	rs911119	0.955	rs6048945	chr20:23602228	C/T	cg16589663	chr20:23618590	CST3	0.56	5.6	0.34	5.7e-8	Chronic kidney disease;
KIRP	cis	rs4750440	0.576	rs2447011	chr10:14032199	C/T	cg27542038	chr10:14027202	FRMD4A	-0.38	-5.4	-0.33	1.56e-7	Adiponectin levels;
KIRP	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg24579218	chr15:68104479	NA	-0.58	-9.34	-0.51	6.1e-18	Restless legs syndrome;
KIRP	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.08	0.64	4.81e-30	Exhaled nitric oxide output;
KIRP	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg00852783	chr1:26633632	UBXN11	-0.55	-5.64	-0.34	4.56e-8	Obesity-related traits;
KIRP	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.69	0.56	3.62e-22	Cognitive test performance;
KIRP	cis	rs867371	1.000	rs11855089	chr15:82447265	T/C	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs662064	0.962	rs620405	chr1:10554794	T/C	cg17425144	chr1:10567563	PEX14	0.31	5.29	0.32	2.74e-7	Asthma;
KIRP	cis	rs12982744	0.580	rs4806831	chr19:2136703	C/T	cg09261902	chr19:2140048	AP3D1	0.5	6.91	0.4	4.06e-11	Osteoarthritis;Height;
KIRP	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.43	-0.33	1.38e-7	Schizophrenia;
KIRP	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.49	-5.82	-0.35	1.8e-8	Carotid intima media thickness;
KIRP	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg21724239	chr8:58056113	NA	0.56	5.26	0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	7.14	0.41	1.03e-11	Height;
KIRP	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.67	-8.63	-0.48	7.86e-16	Vitiligo;
KIRP	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg18586891	chr4:952366	TMEM175	0.58	5.05	0.31	8.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12496230	0.794	rs12635628	chr3:66859035	C/A	cg04995300	chr3:66848608	NA	0.45	6.98	0.41	2.81e-11	Type 2 diabetes;
KIRP	cis	rs7215564	0.908	rs59252837	chr17:78717155	A/G	cg06153925	chr17:78755379	RPTOR	0.39	6.26	0.37	1.67e-9	Myopia (pathological);
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.32	-0.32	2.36e-7	Life satisfaction;
KIRP	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.62	-0.34	5.2e-8	Metabolite levels;
KIRP	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg02023728	chr11:77925099	USP35	0.29	5.01	0.3	1.05e-6	Alzheimer's disease (survival time);
KIRP	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.93	11.49	0.59	9.57e-25	Response to antineoplastic agents;
KIRP	cis	rs806321	0.534	rs1269281	chr13:50890538	A/C	cg10393508	chr13:50950265	NA	-0.45	-6.38	-0.38	8.55e-10	Multiple sclerosis;
KIRP	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.3	18.85	0.77	1.15e-49	Corneal structure;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.91	14.45	0.68	1.12e-34	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06310300	chr7:100076089	TSC22D4	0.58	7.09	0.41	1.43e-11	Smoking initiation;
KIRP	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-6.81	-0.4	7.46e-11	Fear of minor pain;
KIRP	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg18171855	chr10:2543474	NA	0.46	6.55	0.39	3.35e-10	Age-related hearing impairment;
KIRP	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.52	-0.38	3.94e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.7	7.81	0.45	1.68e-13	Obesity-related traits;
KIRP	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.96e-9	Breast cancer;
KIRP	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg20651018	chr11:3035856	CARS	-0.36	-5.06	-0.31	8.28e-7	Longevity;
KIRP	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.47	-5.69	-0.34	3.63e-8	Diastolic blood pressure;
KIRP	cis	rs7463659	0.904	rs4075462	chr8:135462617	T/C	cg09855544	chr8:135498122	ZFAT	-0.46	-5.78	-0.35	2.23e-8	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24051350	chr1:77165461	NA	0.45	6.56	0.39	3.21e-10	Interleukin-4 levels;
KIRP	cis	rs73200209	0.912	rs17498648	chr12:116610902	C/G	cg01776926	chr12:116560359	MED13L	-0.45	-5.45	-0.33	1.25e-7	Total body bone mineral density;
KIRP	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-1.21	-14.09	-0.67	1.95e-33	Breast cancer;
KIRP	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg00383909	chr3:49044727	WDR6	-0.51	-4.93	-0.3	1.5e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs754423	0.631	rs904060	chr14:52519254	A/G	cg10149976	chr14:52535953	NID2	-0.35	-5.04	-0.31	9e-7	Craniofacial microsomia;
KIRP	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.48	5.96	0.36	8.71e-9	Iron status biomarkers;
KIRP	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg16797656	chr11:68205561	LRP5	0.39	5.11	0.31	6.46e-7	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15179113	chr7:156433342	C7orf13;RNF32	0.53	7.54	0.43	9.2e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11342046	chr2:242641489	ING5	0.71	8.47	0.48	2.19e-15	Smoking initiation;
KIRP	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.41	-5.46	-0.33	1.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9653442	0.545	rs11123814	chr2:100767082	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.62	8.24	0.47	9.97e-15	Lymphocyte counts;
KIRP	cis	rs830124	0.714	rs658957	chr12:122409664	T/C	cg22618164	chr12:122356400	WDR66	0.49	5.02	0.3	9.85e-7	Urinary metabolites;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg19553056	chr4:142142166	ZNF330	0.53	6.49	0.38	4.78e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04598128	chr22:45016233	NA	0.6	6.05	0.36	5.44e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs2274273	0.522	rs2251366	chr14:55518156	A/G	cg04306507	chr14:55594613	LGALS3	0.42	6.17	0.37	2.75e-9	Protein biomarker;
KIRP	cis	rs12714314	0.535	rs6741568	chr2:1933008	C/A	cg20846728	chr2:1843184	MYT1L	-0.37	-6.18	-0.37	2.59e-9	Type 2 diabetes (age of onset);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17665260	chr19:55814068	BRSK1	-0.54	-6.8	-0.4	8.06e-11	Inflammatory biomarkers;
KIRP	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.9	-8.54	-0.48	1.38e-15	Monocyte percentage of white cells;
KIRP	cis	rs10875746	0.903	rs11168370	chr12:48435280	A/C	cg26205652	chr12:48591994	NA	0.61	8.21	0.46	1.22e-14	Longevity (90 years and older);
KIRP	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg13482628	chr17:19912719	NA	-0.53	-7.0	-0.41	2.49e-11	Schizophrenia;
KIRP	cis	rs10518128	1.000	rs28600316	chr4:75711790	G/A	cg20122727	chr4:75719957	BTC	0.59	5.97	0.36	8.15e-9	Electroencephalogram traits;
KIRP	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg04013166	chr16:89971882	TCF25	0.57	5.86	0.35	1.48e-8	Skin colour saturation;
KIRP	cis	rs496547	0.686	rs477014	chr11:118678986	C/T	cg19308663	chr11:118741387	NA	-0.29	-5.13	-0.31	5.8e-7	Hip minimal joint space width;
KIRP	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11987759	chr7:65425863	GUSB	0.58	7.63	0.44	5.03e-13	Aortic root size;
KIRP	cis	rs7246657	0.722	rs1291	chr19:38229378	G/A	cg18154014	chr19:37997991	ZNF793	-0.51	-5.6	-0.34	5.73e-8	Coronary artery calcification;
KIRP	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.87	9.72	0.53	4.04e-19	Gut microbiome composition (summer);
KIRP	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg20965017	chr5:231967	SDHA	-0.6	-6.82	-0.4	6.84e-11	Breast cancer;
KIRP	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.69	-7.23	-0.42	6.07e-12	Gut microbiome composition (summer);
KIRP	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.17e-6	Pulmonary function;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg03150409	chr4:1892317	WHSC1	0.42	6.2	0.37	2.39e-9	Metabolic traits;
KIRP	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.16	0.54	1.76e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs73157695	0.676	rs2839044	chr21:47323742	G/T	cg12162886	chr21:47318899	PCBP3	-0.35	-5.01	-0.3	1.02e-6	Myopia;
KIRP	cis	rs988913	0.781	rs1963697	chr6:54772814	G/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.46	-0.33	1.18e-7	Menarche (age at onset);
KIRP	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.61	-8.07	-0.46	3.1e-14	Breast cancer;
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-1.0	-11.28	-0.58	4.53e-24	Alzheimer's disease;
KIRP	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.61	8.24	0.47	1.04e-14	Mood instability;
KIRP	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	5.49	0.33	1.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.585	rs569201	chr6:116265861	C/T	cg18764771	chr6:116381957	FRK	-0.2	-5.51	-0.33	8.82e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs501120	0.584	rs61857486	chr10:44719361	A/G	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs5167	0.601	rs892131	chr19:45496996	C/T	cg13119609	chr19:45449297	APOC2	0.39	4.93	0.3	1.49e-6	Blood protein levels;
KIRP	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.18	-0.51	1.81e-17	Bladder cancer;
KIRP	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg04935436	chr20:30431758	NA	0.48	6.42	0.38	6.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs4482537	0.566	rs4494801	chr2:49064811	C/A	cg24885526	chr20:10653480	JAG1	0.49	6.15	0.37	3.1e-9	Laterality in neovascular age-related macular degeneration;
KIRP	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00166722	chr3:10149974	C3orf24	0.48	4.88	0.3	1.92e-6	Alzheimer's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09667134	chr7:98550922	TRRAP	0.53	6.78	0.4	8.97e-11	Interleukin-4 levels;
KIRP	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.65	9.32	0.51	6.68e-18	Lymphocyte counts;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg17127132	chr2:85788382	GGCX	0.51	6.15	0.37	3.17e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.92	10.68	0.56	4.13e-22	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg08132940	chr7:1081526	C7orf50	-0.7	-7.03	-0.41	1.98e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	cis	rs494562	0.892	rs573892	chr6:86118189	A/C	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs8054556	1.000	rs3814880	chr16:30017895	T/C	cg06326092	chr16:30034487	C16orf92	0.37	5.11	0.31	6.5e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-0.62	-5.13	-0.31	5.79e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7870753	0.838	rs10991378	chr9:99260980	A/T	cg25260653	chr9:99212216	HABP4	0.52	4.94	0.3	1.43e-6	Height;
KIRP	cis	rs9948	1.000	rs59244622	chr2:97501632	C/T	cg01990225	chr2:97406019	LMAN2L	-0.95	-6.93	-0.4	3.66e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	1.09	8.89	0.49	1.38e-16	Plasma clusterin levels;
KIRP	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.6	-6.7	-0.39	1.4e-10	Neuroticism;
KIRP	cis	rs1062746	0.520	rs67174101	chr16:87328817	G/A	cg02258303	chr16:87377426	FBXO31	-0.42	-5.05	-0.31	8.63e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs9972944	0.756	rs9894298	chr17:63769225	G/A	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.16e-13	Total body bone mineral density;
KIRP	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg05340658	chr4:99064831	C4orf37	-0.58	-6.99	-0.41	2.64e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg12016809	chr21:47604291	C21orf56	-0.43	-5.64	-0.34	4.57e-8	Testicular germ cell tumor;
KIRP	cis	rs17739167	0.550	rs11634233	chr15:42224563	G/A	cg20935245	chr15:42234343	EHD4	0.49	7.49	0.43	1.21e-12	Monocyte count;
KIRP	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs8084125	1.000	rs8084125	chr18:74952758	T/C	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.63	8.01	0.45	4.66e-14	Prudent dietary pattern;
KIRP	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg04804543	chr8:142233427	SLC45A4	-0.43	-5.31	-0.32	2.46e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg21433121	chr3:58477944	KCTD6	-0.56	-6.14	-0.36	3.3e-9	Menopause (age at onset);
KIRP	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.67	8.46	0.47	2.48e-15	Multiple sclerosis;
KIRP	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg13385521	chr17:29058706	SUZ12P	0.85	6.33	0.37	1.13e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.67	-9.26	-0.51	1.03e-17	Breast cancer;
KIRP	cis	rs13102973	0.932	rs13149380	chr4:135866539	A/C	cg14419869	chr4:135874104	NA	0.55	9.43	0.52	3.2e-18	Subjective well-being;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg06009330	chr2:70485380	PCYOX1	-0.45	-6.09	-0.36	4.37e-9	Blood metabolite levels;
KIRP	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg06637938	chr14:75390232	RPS6KL1	0.53	7.51	0.43	1.06e-12	Height;
KIRP	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.38	-7.29	-0.42	4.29e-12	Height;
KIRP	cis	rs9638182	0.666	rs14415	chr7:72984780	T/C	cg07452164	chr7:72993570	TBL2	0.53	6.04	0.36	5.66e-9	Triglycerides;
KIRP	cis	rs4638749	0.501	rs2129145	chr2:108758322	C/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.94	-0.3	1.43e-6	Blood pressure;
KIRP	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.03	0.31	9.27e-7	Menopause (age at onset);
KIRP	cis	rs2904967	0.929	rs3016001	chr11:65008771	G/A	cg09225861	chr11:65069680	NA	-0.44	-5.71	-0.34	3.32e-8	Mean corpuscular volume;
KIRP	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.62	-6.67	-0.39	1.68e-10	Gut microbiome composition (summer);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02683085	chr20:10655461	JAG1	-0.46	-6.25	-0.37	1.81e-9	Metabolic traits;
KIRP	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25517755	chr10:38738941	LOC399744	-0.39	-5.54	-0.33	7.81e-8	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-1.14	-12.31	-0.62	1.86e-27	Response to hepatitis C treatment;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07308232	chr7:1071921	C7orf50	-0.72	-8.51	-0.48	1.7e-15	Longevity;Endometriosis;
KIRP	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.55	7.28	0.42	4.49e-12	Menarche (age at onset);
KIRP	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg16296679	chr22:42394374	WBP2NL	0.37	4.99	0.3	1.17e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg04455712	chr21:45112962	RRP1B	0.47	6.38	0.38	8.83e-10	Mean corpuscular volume;
KIRP	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg26681399	chr22:41777847	TEF	-0.51	-4.87	-0.3	2.03e-6	Vitiligo;
KIRP	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07570687	chr10:102243282	WNT8B	-0.49	-6.64	-0.39	1.95e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.66	-9.06	-0.5	4.14e-17	Bipolar disorder;
KIRP	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs6467136	0.765	rs10227468	chr7:127161541	T/C	cg08586737	chr7:127225949	GCC1	-0.37	-4.85	-0.3	2.18e-6	Type 2 diabetes;
KIRP	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg00360474	chr6:37504404	NA	-0.47	-6.6	-0.39	2.52e-10	Cognitive performance;
KIRP	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg03959625	chr15:84868606	LOC388152	0.64	7.69	0.44	3.49e-13	Schizophrenia;
KIRP	cis	rs9398803	0.713	rs6921183	chr6:126869029	A/T	cg19875578	chr6:126661172	C6orf173	0.42	5.31	0.32	2.44e-7	Male-pattern baldness;
KIRP	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.27	16.71	0.73	2.06e-42	Atopic dermatitis;
KIRP	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.67	-7.48	-0.43	1.31e-12	Gut microbiome composition (summer);
KIRP	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.49	-6.36	-0.38	9.92e-10	Asthma;
KIRP	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	10.49	0.56	1.66e-21	Hip circumference;
KIRP	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg00074818	chr8:8560427	CLDN23	0.43	6.48	0.38	4.83e-10	Obesity-related traits;
KIRP	cis	rs7577696	0.597	rs11691939	chr2:32339561	A/G	cg02381751	chr2:32503542	YIPF4	0.51	5.15	0.31	5.37e-7	Inflammatory biomarkers;
KIRP	cis	rs258892	0.793	rs10062154	chr5:72021534	C/A	cg21869765	chr5:72125136	TNPO1	-0.52	-5.9	-0.35	1.19e-8	Small cell lung carcinoma;
KIRP	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg20651018	chr11:3035856	CARS	-0.41	-5.95	-0.35	9.22e-9	Longevity;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11339840	chr1:203596058	ATP2B4	0.71	6.2	0.37	2.37e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.62	-8.18	-0.46	1.49e-14	IgG glycosylation;
KIRP	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.66	-10.68	-0.56	4.05e-22	Menopause (age at onset);
KIRP	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Bladder cancer;
KIRP	cis	rs9826463	0.582	rs7633870	chr3:142118914	A/G	cg20824294	chr3:142316082	PLS1	0.39	5.77	0.35	2.34e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-8.58	-0.48	1.11e-15	Mean corpuscular volume;
KIRP	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg02389323	chr16:88786976	FAM38A	0.82	5.1	0.31	6.76e-7	Plateletcrit;
KIRP	cis	rs4262150	0.693	rs4246039	chr5:152302465	G/A	cg12297329	chr5:152029980	NA	0.47	6.66	0.39	1.82e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg11247289	chr1:19991707	HTR6	0.47	6.49	0.38	4.74e-10	Myopia (pathological);
KIRP	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs440932	0.565	rs19334	chr8:9009906	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	5.84	0.35	1.68e-8	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.24	-0.32	3.45e-7	Coronary artery disease;
KIRP	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg03959625	chr15:84868606	LOC388152	0.48	5.68	0.34	3.78e-8	Schizophrenia;
KIRP	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	2.93e-7	Tonsillectomy;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs7572644	0.640	rs4666022	chr2:28057823	T/C	cg27432699	chr2:27873401	GPN1	0.48	5.78	0.35	2.26e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23161317	chr6:28129485	ZNF389	0.42	4.92	0.3	1.57e-6	Depression;
KIRP	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg11972305	chr2:233791962	NGEF	-0.35	-5.03	-0.31	9.61e-7	Schizophrenia;
KIRP	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg09936142	chr19:10668400	KRI1	-0.42	-4.99	-0.3	1.14e-6	Inflammatory skin disease;
KIRP	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.95	15.54	0.7	2.14e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg23752985	chr2:85803571	VAMP8	0.61	9.17	0.5	1.91e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7116495	1.000	rs12293885	chr11:71816092	T/A	cg18441811	chr11:71824068	C11orf51	0.6	4.87	0.3	2.01e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.49	-7.34	-0.42	3.12e-12	Bipolar disorder;
KIRP	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg21918786	chr6:109611834	NA	-0.42	-5.79	-0.35	2.12e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.91	11.58	0.59	4.95e-25	Menopause (age at onset);
KIRP	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg00277334	chr10:82204260	NA	-0.5	-5.76	-0.34	2.53e-8	Post bronchodilator FEV1;
KIRP	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.92	0.3	1.57e-6	Menopause (age at onset);
KIRP	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg11901034	chr3:128598214	ACAD9	-0.46	-5.56	-0.33	7.19e-8	IgG glycosylation;
KIRP	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg05072774	chr3:49840536	C3orf54	-0.41	-5.18	-0.31	4.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-6.9	-0.4	4.49e-11	Gut microbiome composition (summer);
KIRP	cis	rs12780845	0.931	rs11818636	chr10:17244898	C/T	cg01003015	chr10:17271136	VIM	0.47	5.25	0.32	3.23e-7	Homocysteine levels;
KIRP	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.95	-6.58	-0.39	2.86e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.88	-15.01	-0.69	1.41e-36	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-1.05	-9.58	-0.52	1.11e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.56	-7.33	-0.42	3.26e-12	Myopia (pathological);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg19455335	chr8:22457658	C8orf58	0.7	6.06	0.36	5.11e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.6	8.52	0.48	1.63e-15	Multiple system atrophy;
KIRP	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg06647332	chr5:131281008	NA	0.45	4.98	0.3	1.2e-6	Life satisfaction;
KIRP	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg18451016	chr1:38461880	NA	0.39	5.4	0.33	1.6e-7	Coronary artery disease;
KIRP	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.63	-7.85	-0.45	1.31e-13	Body mass index;
KIRP	cis	rs8044995	0.636	rs9888986	chr16:68297228	G/A	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.73	-0.34	2.98e-8	Schizophrenia;
KIRP	cis	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg19847130	chr8:10466454	RP1L1	-0.33	-4.97	-0.3	1.27e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.64	8.05	0.46	3.58e-14	Vitiligo;
KIRP	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg08761264	chr16:28874980	SH2B1	-0.51	-5.9	-0.35	1.21e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.27	0.32	2.97e-7	Asthma;
KIRP	cis	rs7208859	0.778	rs6505219	chr17:29265621	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.47	-5.55	-0.33	7.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13418717	1.000	rs1397340	chr2:127660818	G/T	cg25501666	chr2:127640322	NA	0.94	6.93	0.4	3.6e-11	Heart failure;
KIRP	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.6	-8.3	-0.47	7.01e-15	Diastolic blood pressure;
KIRP	trans	rs921874	0.585	rs2512389	chr11:86790339	C/T	cg22937172	chr2:240168862	HDAC4	0.53	6.15	0.37	3.15e-9	Total body bone mineral density;
KIRP	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg07317062	chr7:27170388	HOXA4	-0.34	-5.0	-0.3	1.11e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg20387954	chr3:183756860	HTR3D	0.59	8.59	0.48	1.03e-15	Anterior chamber depth;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg10505658	chr17:80084571	CCDC57	-0.26	-4.88	-0.3	1.91e-6	Life satisfaction;
KIRP	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.33	-0.32	2.26e-7	Type 2 diabetes;
KIRP	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg16102102	chr5:83017553	HAPLN1	-0.74	-10.43	-0.55	2.54e-21	Prostate cancer;
KIRP	cis	rs7615316	0.751	rs6800695	chr3:142044904	G/A	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.31e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.69	-5.98	-0.36	7.99e-9	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15433604	chr19:18942513	UPF1	0.49	6.83	0.4	6.56e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.49	7.01	0.41	2.3e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6011002	0.504	rs76257944	chr20:62243219	A/G	cg23957118	chr20:62200850	PRIC285	0.91	5.49	0.33	9.85e-8	Dental caries;
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.44	-5.12	-0.31	6.22e-7	Longevity;Endometriosis;
KIRP	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.84	13.99	0.67	3.97e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs2802372	0.620	rs1782646	chr10:81040031	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.43	-5.47	-0.33	1.1e-7	Granulocyte count;
KIRP	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.07	0.46	3.09e-14	Prudent dietary pattern;
KIRP	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.5	-0.33	9.71e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17122278	0.613	rs572126	chr11:118359161	C/T	cg06090739	chr11:118230722	UBE4A	-0.48	-5.15	-0.31	5.45e-7	Total cholesterol levels;
KIRP	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg25866889	chr13:114914595	NA	-0.38	-5.32	-0.32	2.28e-7	Schizophrenia;
KIRP	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.67	9.58	0.52	1.08e-18	Retinal vascular caliber;
KIRP	cis	rs311392	1.000	rs2671804	chr8:55088853	C/T	cg20636351	chr8:55087400	NA	-0.64	-7.88	-0.45	1.04e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.97	-12.64	-0.63	1.53e-28	Platelet distribution width;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg17607973	chr7:100027408	MEPCE;ZCWPW1	0.97	6.38	0.38	8.56e-10	P wave terminal force;
KIRP	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.63	6.56	0.39	3.18e-10	Gastritis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05526376	chr7:97736360	LMTK2	-0.48	-6.35	-0.38	1.03e-9	Myopia;
KIRP	cis	rs7258015	1.000	rs10408916	chr19:10447770	T/G	cg25279553	chr19:10444815	RAVER1;ICAM3	0.49	6.38	0.38	8.58e-10	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg02462569	chr6:150064036	NUP43	-0.34	-4.96	-0.3	1.33e-6	Lung cancer;
KIRP	cis	rs7011507	1.000	rs78242224	chr8:49117765	G/T	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.6	8.42	0.47	3.18e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6545883	0.894	rs2593633	chr2:61571513	T/C	cg15711740	chr2:61764176	XPO1	0.59	7.73	0.44	2.71e-13	Tuberculosis;
KIRP	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.92	10.48	0.56	1.74e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.2	0.31	4.15e-7	Personality dimensions;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.63	-6.47	-0.38	5.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1030268	0.546	rs12707100	chr7:133274376	T/C	cg10665199	chr7:133106180	EXOC4	0.56	5.62	0.34	5.18e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.76	9.44	0.52	2.89e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	13.13	0.64	3.34e-30	Smoking behavior;
KIRP	cis	rs9581857	0.512	rs9581866	chr13:28063176	G/A	cg22138327	chr13:27999177	GTF3A	0.88	6.81	0.4	7.62e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1403694	0.515	rs710448	chr3:186452885	A/G	cg12454167	chr3:186435060	KNG1	0.5	8.49	0.48	2.03e-15	Blood protein levels;
KIRP	cis	rs6466055	0.589	rs12530690	chr7:105005566	C/A	cg04380332	chr7:105027541	SRPK2	0.36	4.95	0.3	1.41e-6	Schizophrenia;
KIRP	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg03714773	chr7:91764589	CYP51A1	0.33	4.92	0.3	1.6e-6	Breast cancer;
KIRP	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.43	5.84	0.35	1.61e-8	Total body bone mineral density;
KIRP	cis	rs6681460	1.000	rs964574	chr1:67062885	T/C	cg13052034	chr1:66999238	SGIP1	0.39	5.37	0.32	1.81e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg21361702	chr7:150065534	REPIN1	0.62	6.52	0.38	3.99e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.64	8.96	0.5	8.32e-17	Blood protein levels;
KIRP	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.49	6.73	0.39	1.18e-10	Red blood cell count;
KIRP	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-7.17	-0.42	8.92e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg26875233	chr11:93583750	C11orf90	-0.4	-7.54	-0.43	8.83e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.92	-16.15	-0.72	1.69e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg24874828	chr4:187887005	NA	-0.47	-7.05	-0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg01475377	chr6:109611718	NA	-0.37	-5.09	-0.31	7.03e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg21231944	chr12:82153410	PPFIA2	-0.42	-5.03	-0.31	9.63e-7	Resting heart rate;
KIRP	cis	rs4889855	0.505	rs4890057	chr17:78591679	A/G	cg09596252	chr17:78655493	RPTOR	0.52	5.99	0.36	7.5e-9	Fractional excretion of uric acid;
KIRP	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg07741184	chr6:167504864	NA	-0.23	-5.71	-0.34	3.24e-8	Crohn's disease;
KIRP	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg02996583	chr8:142237188	SLC45A4	-0.49	-5.98	-0.36	8.01e-9	Immature fraction of reticulocytes;
KIRP	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.78	-0.44	1.99e-13	Height;
KIRP	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg01304814	chr3:48885189	PRKAR2A	0.7	5.43	0.33	1.33e-7	Cognitive function;
KIRP	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg18016565	chr1:150552671	MCL1	0.39	6.0	0.36	7.16e-9	Melanoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22077997	chr3:127399377	ABTB1	-0.5	-7.09	-0.41	1.45e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.01	0.3	1.02e-6	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22698218	chr7:135098264	CNOT4	-0.39	-6.1	-0.36	4.18e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.19e-15	Retinal vascular caliber;
KIRP	cis	rs1971762	0.545	rs10747676	chr12:54049930	T/C	cg16917193	chr12:54089295	NA	0.85	15.06	0.69	9.07e-37	Height;
KIRP	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.76	9.17	0.5	2.01e-17	Type 2 diabetes;
KIRP	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg12560992	chr17:57184187	TRIM37	0.63	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.48	4.98	0.3	1.19e-6	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs6005807	0.719	rs73430118	chr22:28913950	C/T	cg12565055	chr22:29076175	TTC28	0.59	5.12	0.31	6.29e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg15226275	chr6:116381976	FRK	0.21	5.77	0.35	2.39e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3087591	0.708	rs1129506	chr17:29646032	G/A	cg24425628	chr17:29625626	OMG;NF1	0.52	7.02	0.41	2.13e-11	Hip circumference;
KIRP	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg05315796	chr3:52349193	DNAH1	0.44	6.64	0.39	2e-10	Bipolar disorder;
KIRP	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.33	-0.32	2.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg15848620	chr12:58087721	OS9	-0.43	-5.0	-0.3	1.1e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.12	0.54	2.42e-20	Total body bone mineral density;
KIRP	cis	rs2916247	1.000	rs35604666	chr8:93037953	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.7	-0.44	3.32e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00495681	chr13:53174319	NA	0.37	5.02	0.3	9.82e-7	Lewy body disease;
KIRP	trans	rs12517041	1.000	rs995216	chr5:23285541	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.65	-0.48	6.64e-16	Calcium levels;
KIRP	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.84	-0.35	1.66e-8	Multiple sclerosis;
KIRP	cis	rs1318772	0.800	rs67881502	chr5:112924906	T/C	cg12552261	chr5:112820674	MCC	0.87	5.04	0.31	9.12e-7	F-cell distribution;
KIRP	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg23161317	chr6:28129485	ZNF389	0.39	4.87	0.3	1.98e-6	Cardiac Troponin-T levels;
KIRP	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16318349	chr1:154917307	PBXIP1	-0.33	-5.57	-0.33	6.6e-8	Prostate cancer;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg07216194	chr8:27182965	PTK2B	0.44	5.49	0.33	9.85e-8	Neuroticism;
KIRP	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11987759	chr7:65425863	GUSB	0.49	6.52	0.38	4.04e-10	Aortic root size;
KIRP	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.47	6.19	0.37	2.53e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1507153	0.847	rs9341741	chr6:79426838	G/A	cg11833968	chr6:79620685	NA	-0.37	-4.95	-0.3	1.36e-6	Sjögren's syndrome;
KIRP	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.39	0.43	2.33e-12	Prudent dietary pattern;
KIRP	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1843834	0.721	rs6436507	chr2:225598242	T/A	cg22455342	chr2:225449267	CUL3	0.47	5.4	0.33	1.59e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg23032129	chr1:109941072	SORT1	-0.28	-4.86	-0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10904908	0.931	rs7903137	chr10:17259567	C/T	cg01003015	chr10:17271136	VIM	-0.43	-5.32	-0.32	2.38e-7	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-5.4	-0.33	1.57e-7	Chronic sinus infection;
KIRP	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg16898833	chr6:26189333	HIST1H4D	0.85	5.99	0.36	7.4e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg23894439	chr1:183413866	NA	0.39	5.17	0.31	4.74e-7	Systemic lupus erythematosus;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08004919	chr12:56652272	ANKRD52	0.52	6.63	0.39	2.05e-10	Parkinson's disease;
KIRP	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.46	5.29	0.32	2.66e-7	Osteoporosis;
KIRP	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg23587288	chr2:27483067	SLC30A3	0.54	6.89	0.4	4.57e-11	Blood metabolite levels;
KIRP	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg23950597	chr19:37808831	NA	-0.75	-7.59	-0.44	6.43e-13	Coronary artery calcification;
KIRP	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg03563238	chr19:33554763	RHPN2	-0.32	-5.64	-0.34	4.69e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9381107	0.932	rs9349096	chr6:9437004	C/T	cg14735645	chr6:9486422	NA	-0.46	-5.53	-0.33	8.26e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.95	18.19	0.76	2e-47	Dental caries;
KIRP	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg04202892	chr2:111875749	ACOXL	0.49	6.85	0.4	6.03e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg15590007	chr10:45870220	ALOX5	0.55	5.35	0.32	2.04e-7	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg20340149	chr2:122407145	CLASP1	0.58	6.17	0.37	2.75e-9	Response to statin therapy;
KIRP	trans	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg25042112	chr7:64838748	ZNF92	0.6	6.32	0.37	1.22e-9	Pain;
KIRP	cis	rs600806	0.714	rs2781552	chr1:110025881	A/G	cg23032129	chr1:109941072	SORT1	0.29	5.14	0.31	5.56e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.65	-10.0	-0.54	5.81e-20	Hepatocellular carcinoma;
KIRP	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.64	-8.22	-0.46	1.17e-14	Colorectal cancer;
KIRP	cis	rs9309711	0.961	rs6739269	chr2:3470995	C/T	cg10845886	chr2:3471009	TTC15	-0.85	-12.45	-0.62	6.2e-28	Neurofibrillary tangles;
KIRP	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg02297831	chr4:17616191	MED28	0.58	7.44	0.43	1.71e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg19847130	chr8:10466454	RP1L1	0.34	5.0	0.3	1.1e-6	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12576082	chr20:30102058	HM13	0.52	7.2	0.42	7.29e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17092148	1.000	rs6060025	chr20:33326876	A/G	cg16810054	chr20:33298113	TP53INP2	-0.46	-5.72	-0.34	3.03e-8	Neuroticism;
KIRP	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.75	-0.34	2.6e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.48	6.19	0.37	2.56e-9	Post bronchodilator FEV1;
KIRP	trans	rs800082	0.646	rs2717394	chr3:144280612	A/T	cg24215973	chr2:240111563	HDAC4	0.47	6.42	0.38	7.05e-10	Smoking behavior;
KIRP	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-1.02	-10.98	-0.57	4.47e-23	IgG glycosylation;
KIRP	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg11752832	chr7:134001865	SLC35B4	0.43	5.29	0.32	2.7e-7	Mean platelet volume;
KIRP	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.64	7.05	0.41	1.84e-11	Schizophrenia;
KIRP	cis	rs7113850	0.541	rs7129631	chr11:24208560	A/G	ch.11.24196551F	chr11:24239977	NA	0.85	7.53	0.43	9.49e-13	Bone fracture in osteoporosis;
KIRP	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.7	8.05	0.46	3.46e-14	Smoking initiation;
KIRP	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.86e-12	Prudent dietary pattern;
KIRP	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19171272	chr22:38449367	NA	-0.56	-8.27	-0.47	8.26e-15	Glioblastoma;Glioma;
KIRP	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.3	5.56	0.33	7.17e-8	Monocyte percentage of white cells;
KIRP	cis	rs7246657	0.943	rs2279148	chr19:38024683	A/G	cg18154014	chr19:37997991	ZNF793	0.83	8.9	0.49	1.28e-16	Coronary artery calcification;
KIRP	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.63	-8.27	-0.47	8.26e-15	Body mass index;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg08837587	chr8:30601672	UBXN8	0.55	6.06	0.36	4.95e-9	Electroencephalogram traits;
KIRP	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.7	-0.48	4.97e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.76	-0.34	2.46e-8	Parkinson's disease;
KIRP	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg11235152	chr1:67600687	NA	0.65	9.76	0.53	3.12e-19	Psoriasis;
KIRP	cis	rs2219968	1.000	rs6473087	chr8:78974859	A/G	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs12725198	1.000	rs12725694	chr1:16080501	G/A	cg26036626	chr1:16085597	FBLIM1	-0.35	-4.93	-0.3	1.52e-6	Cardiac Troponin-T levels;
KIRP	cis	rs11893307	0.507	rs1465303	chr2:191585440	A/C	cg11845111	chr2:191398756	TMEM194B	-0.44	-4.88	-0.3	1.92e-6	Mean platelet volume;
KIRP	cis	rs17123764	0.892	rs17123970	chr12:50160195	C/G	cg20471783	chr12:50157085	TMBIM6	0.4	5.98	0.36	7.71e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg05805236	chr11:65401703	PCNXL3	-0.48	-6.43	-0.38	6.46e-10	Acne (severe);
KIRP	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02725872	chr8:58115012	NA	-0.74	-7.76	-0.44	2.24e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.8	0.35	2.04e-8	Motion sickness;
KIRP	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg26116260	chr4:7069785	GRPEL1	-0.77	-5.14	-0.31	5.53e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg04369109	chr6:150039330	LATS1	0.4	4.91	0.3	1.63e-6	Lung cancer;
KIRP	cis	rs2278796	0.558	rs35288741	chr1:204928155	A/G	cg17449235	chr1:204966235	NFASC	0.36	4.87	0.3	2.01e-6	Mean platelet volume;
KIRP	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.58	-6.6	-0.39	2.56e-10	Axial length;
KIRP	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs72781680	0.678	rs872169	chr2:24259188	C/G	cg20701182	chr2:24300061	SF3B14	0.93	10.31	0.55	6.03e-21	Lymphocyte counts;
KIRP	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg00079375	chr15:79125835	NA	0.39	5.62	0.34	5.2100000000000003e-08	Coronary artery disease;
KIRP	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.45	-5.48	-0.33	1.05e-7	Response to bleomycin (chromatid breaks);
KIRP	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg10932868	chr11:921992	NA	-0.5	-5.99	-0.36	7.47e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9581857	0.579	rs118061689	chr13:27974499	A/T	cg22138327	chr13:27999177	GTF3A	0.99	7.25	0.42	5.38e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	8.3	0.47	6.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	5.38	0.32	1.73e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs3789045	1.000	rs11588857	chr1:204587047	G/A	cg08641003	chr1:204589008	LRRN2	-0.59	-6.15	-0.37	3.1e-9	Educational attainment (college completion);
KIRP	cis	rs12976411	0.575	rs7252058	chr19:32827391	G/A	cg02282382	chr19:32836354	ZNF507	0.66	5.51	0.33	9.23e-8	Coronary artery disease;
KIRP	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.15	-0.31	5.45e-7	Bipolar disorder;
KIRP	cis	rs9972944	0.756	rs7212901	chr17:63766499	T/C	cg07283582	chr17:63770753	CCDC46	-0.48	-7.92	-0.45	8.31e-14	Total body bone mineral density;
KIRP	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13606994	chr1:44402422	ARTN	-0.3	-5.8	-0.35	1.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21385522	chr1:16154831	NA	0.68	8.37	0.47	4.44e-15	Dilated cardiomyopathy;
KIRP	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.27	-0.32	3.04e-7	Obesity-related traits;
KIRP	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg00977110	chr5:151150581	G3BP1	0.6	6.06	0.36	5.08e-9	Preschool internalizing problems;
KIRP	cis	rs17401966	0.540	rs3748581	chr1:10441664	T/C	cg19773385	chr1:10388646	KIF1B	-0.4	-5.82	-0.35	1.79e-8	Hepatocellular carcinoma;
KIRP	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.34	-0.32	2.08e-7	Breast cancer;
KIRP	cis	rs7640424	0.721	rs326355	chr3:107824663	T/C	cg09227934	chr3:107805635	CD47	0.29	5.1	0.31	6.74e-7	Body mass index;
KIRP	cis	rs73198271	0.628	rs11776981	chr8:8589459	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08446346	chr6:140323987	NA	0.45	6.79	0.4	8.51e-11	Migraine with aura;
KIRP	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.45	5.39	0.32	1.69e-7	Tonsillectomy;
KIRP	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.83	-11.93	-0.61	3.44e-26	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.39	-0.43	2.26e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.99	10.28	0.55	7.37e-21	Eosinophilic esophagitis;
KIRP	cis	rs9296736	1.000	rs4715438	chr6:53901329	G/A	cg04374786	chr6:53939321	C6orf142	-0.38	-4.91	-0.3	1.66e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg18477163	chr1:228402036	OBSCN	0.35	6.63	0.39	2.08e-10	Diastolic blood pressure;
KIRP	cis	rs981844	0.683	rs2405423	chr4:154749823	C/A	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs7615316	0.779	rs2862744	chr3:142105519	C/A	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.37e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.87	-14.79	-0.69	7.95e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg18234130	chr8:27182889	PTK2B	0.56	7.27	0.42	4.8e-12	Neuroticism;
KIRP	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg26384229	chr12:38710491	ALG10B	0.61	7.73	0.44	2.76e-13	Morning vs. evening chronotype;
KIRP	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4722166	0.532	rs1404008	chr7:22756000	A/T	cg05472934	chr7:22766657	IL6	0.51	6.61	0.39	2.31e-10	Lung cancer;
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.56	7.26	0.42	5.09e-12	Longevity;Endometriosis;
KIRP	cis	rs1712517	0.771	rs11191664	chr10:105118476	C/T	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.41e-9	Migraine;
KIRP	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	0.74	6.95	0.41	3.29e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.36	-4.96	-0.3	1.31e-6	IgG glycosylation;
KIRP	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg21132104	chr15:45694354	SPATA5L1	0.75	9.46	0.52	2.64e-18	Homoarginine levels;
KIRP	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg27205649	chr11:78285834	NARS2	-0.67	-7.64	-0.44	4.76e-13	Alzheimer's disease (survival time);
KIRP	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.55	-0.33	7.44e-8	Depression;
KIRP	cis	rs71597109	0.608	rs34499378	chr4:102722182	G/A	cg14855874	chr4:102712397	BANK1	0.4	5.35	0.32	2e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg00405596	chr8:11794950	NA	-0.5	-6.58	-0.39	2.87e-10	Retinal vascular caliber;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15731152	chr12:6781789	ZNF384	-0.46	-6.05	-0.36	5.35e-9	Inflammatory biomarkers;
KIRP	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.51	-0.43	1.11e-12	Response to antipsychotic treatment;
KIRP	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg13482628	chr17:19912719	NA	0.58	8.17	0.46	1.62e-14	Schizophrenia;
KIRP	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg23711669	chr6:146136114	FBXO30	-0.47	-5.82	-0.35	1.79e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.0	-0.36	6.97e-9	Diastolic blood pressure;
KIRP	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg26784012	chr10:32216390	ARHGAP12	0.35	5.41	0.33	1.52e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg13444842	chr1:152974279	SPRR3	-0.38	-5.39	-0.32	1.67e-7	Inflammatory skin disease;
KIRP	cis	rs2594989	0.691	rs347623	chr3:11239748	G/C	cg01796438	chr3:11312864	ATG7	-0.52	-5.31	-0.32	2.44e-7	Circulating chemerin levels;
KIRP	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	1.02	10.39	0.55	3.33e-21	Height;
KIRP	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.84	-0.45	1.39e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg11189052	chr15:85197271	WDR73	0.51	4.89	0.3	1.81e-6	Schizophrenia;
KIRP	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg05639522	chr1:247681581	NA	0.58	5.52	0.33	8.67e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7534824	0.582	rs41312670	chr1:101443431	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.03	0.41	2.07e-11	Refractive astigmatism;
KIRP	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.52	-6.28	-0.37	1.48e-9	Macular telangiectasia type 2;
KIRP	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.48	8.42	0.47	3.12e-15	Iron status biomarkers (transferrin levels);
KIRP	cis	rs240764	0.658	rs9386257	chr6:101252069	A/T	cg09795085	chr6:101329169	ASCC3	0.43	5.15	0.31	5.4e-7	Neuroticism;
KIRP	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg02503808	chr4:7069936	GRPEL1	1.01	10.69	0.56	3.67e-22	Monocyte percentage of white cells;
KIRP	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg03959625	chr15:84868606	LOC388152	0.45	5.37	0.32	1.82e-7	Schizophrenia;
KIRP	cis	rs4594175	0.962	rs7157823	chr14:51633170	C/T	cg23942311	chr14:51606299	NA	0.53	7.12	0.41	1.2e-11	Cancer;
KIRP	cis	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg08501292	chr6:25962987	TRIM38	0.99	5.53	0.33	8.09e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.09	0.41	1.45e-11	Retinal vascular caliber;
KIRP	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	1.01	14.37	0.68	2.15e-34	Platelet distribution width;
KIRP	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21545522	chr1:205238299	TMCC2	0.54	6.97	0.41	2.9100000000000002e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg16586182	chr3:47516702	SCAP	0.83	11.93	0.61	3.43e-26	Colorectal cancer;
KIRP	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03934478	chr11:495069	RNH1	0.86	6.99	0.41	2.55e-11	Body mass index;
KIRP	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg11757124	chr7:157526947	PTPRN2	-0.47	-5.76	-0.34	2.54e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.8	10.78	0.57	1.97e-22	Morning vs. evening chronotype;
KIRP	cis	rs2712184	0.756	rs2712161	chr2:217662384	G/A	cg05032264	chr2:217675019	NA	-0.46	-6.82	-0.4	6.88e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs986417	1.000	rs1033733	chr14:60932438	G/T	cg27398547	chr14:60952738	C14orf39	0.66	5.97	0.36	8.04e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs9309473	0.519	rs2421545	chr2:73639476	T/C	cg20560298	chr2:73613845	ALMS1	0.41	5.05	0.31	8.62e-7	Metabolite levels;
KIRP	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg08805041	chr16:621841	PIGQ	-0.37	-5.08	-0.31	7.53e-7	Height;
KIRP	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg04013166	chr16:89971882	TCF25	0.67	5.63	0.34	4.83e-8	Skin colour saturation;
KIRP	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15557168	chr22:42548783	NA	-0.47	-6.01	-0.36	6.63e-9	Cognitive function;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19775406	chr17:5390252	MIS12;DERL2	0.53	6.39	0.38	8.08e-10	Smoking initiation;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08188073	chr7:39991463	CDK13	0.56	6.09	0.36	4.28e-9	Lung cancer in ever smokers;
KIRP	trans	rs7980799	0.967	rs7971226	chr12:33586881	C/T	cg13010199	chr12:38710504	ALG10B	0.49	6.11	0.36	3.93e-9	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg13147721	chr7:65941812	NA	-0.98	-6.93	-0.4	3.75e-11	Diabetic kidney disease;
KIRP	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	10.48	0.56	1.77e-21	Bone mineral density;
KIRP	cis	rs11997175	0.550	rs7463110	chr8:33837033	A/C	ch.8.33884649F	chr8:33765107	NA	0.48	5.79	0.35	2.08e-8	Body mass index;
KIRP	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.35	-0.42	2.97e-12	Type 2 diabetes;
KIRP	trans	rs7939886	0.844	rs7106504	chr11:55932827	C/T	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.27	-0.32	3.01e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6558530	0.666	rs10113471	chr8:1695827	C/A	cg08198773	chr8:1697536	NA	0.52	6.43	0.38	6.62e-10	Systolic blood pressure;
KIRP	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.51	6.49	0.38	4.71e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs8067545	1.000	rs56142708	chr17:19934963	A/C	cg04132472	chr17:19861366	AKAP10	0.39	5.26	0.32	3.11e-7	Schizophrenia;
KIRP	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg11906718	chr8:101322791	RNF19A	0.47	6.03	0.36	5.81e-9	Atrioventricular conduction;
KIRP	trans	rs9329221	0.636	rs6999466	chr8:10265712	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	6.29	0.37	1.44e-9	Neuroticism;
KIRP	cis	rs7923609	0.812	rs10761753	chr10:65161903	G/A	cg01631684	chr10:65280961	REEP3	-0.52	-6.13	-0.36	3.49e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01799560	chr17:80846075	TBCD	0.43	6.23	0.37	2.06e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.69	10.97	0.57	4.53e-23	Lung cancer;
KIRP	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.34	6.58	0.39	2.77e-10	Urinary metabolites;
KIRP	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22590775	chr19:49891494	CCDC155	0.64	7.75	0.44	2.34e-13	Multiple sclerosis;
KIRP	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.42	-5.65	-0.34	4.48e-8	Total body bone mineral density;
KIRP	trans	rs35100037	0.803	rs10066729	chr5:128574319	T/C	cg23338408	chr14:31289523	NA	-0.62	-6.29	-0.37	1.48e-9	Ankle injury;
KIRP	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.62	8.26	0.47	8.85e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs10861342	1.000	rs73395802	chr12:105588718	T/C	cg23923672	chr12:105501055	KIAA1033	0.81	6.81	0.4	7.55e-11	IgG glycosylation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06720244	chr13:46543102	ZC3H13	-0.45	-6.44	-0.38	6.22e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.47	4.85	0.3	2.15e-6	Obesity (extreme);
KIRP	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.42	5.77	0.35	2.39e-8	Coronary artery disease;
KIRP	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-0.74	-11.03	-0.58	2.94e-23	Prudent dietary pattern;
KIRP	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	6.36	0.38	9.81e-10	Schizophrenia;
KIRP	cis	rs3754214	0.823	rs496203	chr1:150270025	A/G	cg09579323	chr1:150459698	TARS2	-0.4	-5.04	-0.31	9.22e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.61	8.18	0.46	1.52e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg02527881	chr3:46936655	PTH1R	-0.39	-5.56	-0.33	6.9e-8	Colorectal cancer;
KIRP	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.74	11.25	0.58	5.74e-24	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11637445	0.589	rs4776989	chr15:68130684	T/C	cg24579218	chr15:68104479	NA	-0.43	-6.51	-0.38	4.24e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs4780401	0.728	rs7198518	chr16:11771094	C/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.12	-0.31	6.03e-7	Rheumatoid arthritis;
KIRP	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg14820908	chr5:178986412	RUFY1	0.36	5.16	0.31	5.14e-7	Lung cancer;
KIRP	cis	rs72627509	0.680	rs79641006	chr4:57847443	T/G	cg26694713	chr4:57773883	REST	0.62	5.06	0.31	8.18e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg23533926	chr12:111358616	MYL2	-0.52	-6.95	-0.41	3.28e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg09990169	chr2:241835740	C2orf54	-0.41	-5.87	-0.35	1.42e-8	Urinary metabolites;
KIRP	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	9.82	0.53	2.06e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.36	-5.6	-0.34	5.81e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4702718	0.577	rs2918392	chr5:10704797	T/C	cg14521931	chr5:10832172	NA	0.39	5.2	0.31	4.2e-7	Obesity-related traits;
KIRP	cis	rs10510057	0.614	rs9421351	chr10:121324896	T/A	cg06765389	chr10:121379685	NA	-0.48	-7.51	-0.43	1.07e-12	Depressive symptoms (stressful life events interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07392460	chr2:39103068	DHX57;MORN2	0.46	6.1	0.36	4.17e-9	Survival in pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.63	-6.62	-0.39	2.18e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg00310523	chr12:86230176	RASSF9	0.53	8.34	0.47	5.39e-15	Major depressive disorder;
KIRP	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.44	-5.8	-0.35	2.03e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.67	-10.18	-0.54	1.58e-20	Dupuytren's disease;
KIRP	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-5.08	-0.31	7.62e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg16497661	chr14:103986332	CKB	0.76	11.26	0.58	5.58e-24	Body mass index;
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg17133734	chr15:86042851	AKAP13	-0.45	-5.62	-0.34	5.07e-8	Interstitial lung disease;
KIRP	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg21643547	chr1:205240462	TMCC2	-0.53	-7.84	-0.45	1.37e-13	Red blood cell count;
KIRP	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg17401720	chr7:158221031	PTPRN2	-0.33	-5.24	-0.32	3.51e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1850744	0.702	rs6836184	chr4:9633711	A/C	cg15442990	chr4:9534313	NA	0.72	4.86	0.3	2.14e-6	Economic and political preferences;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25445612	chr21:47401277	COL6A1	0.61	7.26	0.42	5.2e-12	Lung cancer in ever smokers;
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.56	-7.66	-0.44	4.17e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.51	7.63	0.44	5.18e-13	Mean corpuscular volume;
KIRP	cis	rs4236601	0.720	rs17516287	chr7:116154186	C/G	cg05166801	chr7:116143459	CAV2	0.49	6.02	0.36	6.44e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg17595323	chr11:93583763	C11orf90	-0.31	-5.23	-0.32	3.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg01988459	chr11:68622903	NA	-0.48	-6.21	-0.37	2.22e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	ch.8.33884649F	chr8:33765107	NA	0.59	7.42	0.43	1.91e-12	Body mass index;
KIRP	cis	rs1823913	0.599	rs55685315	chr2:192171177	A/T	cg12404831	chr2:192114017	MYO1B	0.5	6.96	0.41	3.06e-11	Obesity-related traits;
KIRP	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.5	-6.2	-0.37	2.35e-9	Iron status biomarkers;
KIRP	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.85	11.76	0.6	1.25e-25	Total body bone mineral density;
KIRP	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.94	10.9	0.57	8.02e-23	Monocyte percentage of white cells;
KIRP	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.17	0.31	4.85e-7	Melanoma;
KIRP	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.97	-0.36	8.1e-9	IgG glycosylation;
KIRP	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.82	-12.01	-0.61	1.83e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-11.4	-0.59	1.9e-24	Vitiligo;
KIRP	cis	rs9400467	0.537	rs55643604	chr6:111490648	T/G	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.58	-9.29	-0.51	8.43e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs10861661	0.963	rs11113118	chr12:107199142	G/A	cg21360079	chr12:107162445	NA	-0.61	-7.53	-0.43	9.58e-13	Triglyceride levels;
KIRP	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-1.03	-12.12	-0.61	7.75e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11710088	0.931	rs66482463	chr3:149200080	A/C	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.54	-0.33	7.6e-8	QRS duration;
KIRP	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg06121193	chr1:90282411	NA	-0.48	-6.98	-0.41	2.73e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-5.57	-0.33	6.63e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.85	-12.97	-0.64	1.19e-29	Height;
KIRP	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.62	-9.97	-0.54	7.19e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.57	-8.91	-0.49	1.14e-16	Coronary artery disease;
KIRP	cis	rs882732	1.000	rs10134935	chr14:95037079	T/C	cg05186455	chr14:95027692	SERPINA4	-0.4	-5.77	-0.35	2.37e-8	Blood protein levels;
KIRP	cis	rs12780845	0.540	rs11254406	chr10:17191692	C/T	cg01003015	chr10:17271136	VIM	-0.44	-5.45	-0.33	1.22e-7	Homocysteine levels;
KIRP	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg26531700	chr6:26746687	NA	-0.49	-7.13	-0.41	1.12e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg21300267	chr1:26547059	NA	-0.37	-4.95	-0.3	1.37e-6	Obesity-related traits;
KIRP	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	16.1	0.72	2.57e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.56	7.79	0.44	1.88e-13	Height;
KIRP	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.85	-8.49	-0.48	2.03e-15	Coronary artery calcification;
KIRP	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.86	-0.3	2.05e-6	Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10438487	chr15:99640813	NA	0.49	7.01	0.41	2.24e-11	Survival in pancreatic cancer;
KIRP	cis	rs7534824	0.543	rs61780298	chr1:101402982	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	6.4	0.38	7.72e-10	Refractive astigmatism;
KIRP	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.39	-0.38	8.27e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.34	-0.32	2.14e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22764639	chr12:106532701	NUAK1	0.47	6.85	0.4	5.83e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg14972814	chr11:95582409	MTMR2	0.35	5.76	0.34	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.23	0.32	3.66e-7	Asthma;
KIRP	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.71	-9.76	-0.53	3.19e-19	Plateletcrit;Platelet count;
KIRP	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg12173498	chr6:36355764	ETV7	-0.33	-5.33	-0.32	2.24e-7	Platelet distribution width;
KIRP	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg16396542	chr1:89473148	GBP3	0.42	5.95	0.35	9.3e-9	Carotid intima media thickness;
KIRP	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.58	7.77	0.44	2.1e-13	HDL cholesterol;
KIRP	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.58	7.45	0.43	1.55e-12	Cognitive test performance;
KIRP	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	0.94	11.9	0.6	4.24e-26	Blood protein levels;
KIRP	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg07511934	chr16:89386912	ANKRD11	0.42	5.36	0.32	1.89e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg25801113	chr15:45476975	SHF	0.44	8.1	0.46	2.49e-14	Uric acid levels;
KIRP	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-10.18	-0.54	1.5e-20	Dental caries;
KIRP	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.69	-10.76	-0.57	2.17e-22	Educational attainment;
KIRP	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.89	13.34	0.65	6.66e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6540559	0.673	rs6540560	chr1:209982073	A/G	cg22029157	chr1:209979665	IRF6	-0.47	-5.63	-0.34	4.8e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs7671900	0.516	rs6531968	chr4:88199484	T/G	cg23841344	chr4:88312519	HSD17B11	-0.45	-5.61	-0.34	5.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2802372	0.801	rs1250546	chr10:81032532	A/G	cg18688392	chr10:81059414	ZMIZ1	-0.43	-5.63	-0.34	4.9e-8	Granulocyte count;
KIRP	cis	rs17030434	0.863	rs17030382	chr4:154650887	A/G	cg14289246	chr4:154710475	SFRP2	-0.75	-8.85	-0.49	1.79e-16	Electrocardiographic conduction measures;
KIRP	cis	rs2274459	0.841	rs13204162	chr6:33696131	C/T	cg06253072	chr6:33679850	C6orf125	0.54	5.57	0.33	6.65e-8	Obesity (extreme);
KIRP	cis	rs6832769	0.885	rs6815516	chr4:56399184	A/T	cg05960024	chr4:56376020	CLOCK	-0.62	-8.0	-0.45	4.94e-14	Personality dimensions;
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.71	9.02	0.5	5.53e-17	Longevity;Endometriosis;
KIRP	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg01557791	chr16:72042693	DHODH	-0.59	-7.38	-0.43	2.39e-12	Fibrinogen levels;
KIRP	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg17796960	chr10:135278976	LOC619207	-0.48	-5.51	-0.33	8.83e-8	Systemic lupus erythematosus;
KIRP	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg00631329	chr6:26305371	NA	-0.69	-8.39	-0.47	3.83e-15	Educational attainment;
KIRP	cis	rs9400271	0.632	rs9384704	chr6:109587209	C/T	cg21918786	chr6:109611834	NA	-0.36	-5.21	-0.32	4.05e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	1.15	9.43	0.52	3.3e-18	Plateletcrit;
KIRP	cis	rs2587695	0.789	rs2438980	chr2:120310406	G/T	cg07176264	chr2:120281999	SCTR	0.32	5.02	0.31	9.75e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.12	-0.31	6.29e-7	Post bronchodilator FEV1;
KIRP	cis	rs867371	1.000	rs8041924	chr15:82473661	A/T	cg06066596	chr15:83166174	LOC80154	-0.47	-5.53	-0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.4	5.47	0.33	1.09e-7	Schizophrenia;
KIRP	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.89	-12.12	-0.61	8.15e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.57	-6.96	-0.41	3.16e-11	Tonsillectomy;
KIRP	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.14	16.25	0.72	7.84e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.52	5.74	0.34	2.8e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.57	6.92	0.4	3.87e-11	Aortic root size;
KIRP	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg11906718	chr8:101322791	RNF19A	-0.58	-7.42	-0.43	1.94e-12	Atrioventricular conduction;
KIRP	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.63	-9.25	-0.51	1.1e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.78	-0.6	1.06e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs1973993	0.689	rs17115225	chr1:96884330	C/T	cg10631902	chr5:14652156	NA	-0.57	-7.97	-0.45	6.05e-14	Weight;
KIRP	cis	rs2741335	0.876	rs2741338	chr8:27335734	C/T	cg00421144	chr8:27336675	CHRNA2	0.32	5.02	0.3	1e-6	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs988913	0.723	rs6936015	chr6:54991809	G/A	cg03513858	chr6:54763001	FAM83B	-0.39	-5.55	-0.33	7.49e-8	Menarche (age at onset);
KIRP	cis	rs986417	0.901	rs10782440	chr14:61031648	G/C	cg27398547	chr14:60952738	C14orf39	0.68	6.7	0.39	1.42e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs77688320	0.553	rs2540430	chr2:202368514	A/T	cg06431681	chr2:202330990	STRADB	-0.43	-5.44	-0.33	1.31e-7	Breast cancer;
KIRP	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.59	-7.31	-0.42	3.8e-12	Extraversion;
KIRP	cis	rs10073892	0.917	rs17332107	chr5:101659105	A/G	cg19774478	chr5:101632501	SLCO4C1	0.65	7.14	0.41	1.04e-11	Cognitive decline (age-related);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05102849	chr17:4402132	SPNS2	0.52	6.59	0.39	2.71e-10	Parkinson's disease;
KIRP	cis	rs6449957	0.527	rs11740594	chr5:67459070	T/A	cg13652120	chr5:67430203	NA	0.45	5.6	0.34	5.7e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg05370193	chr1:21551575	ECE1	-0.38	-5.19	-0.31	4.41e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Schizophrenia;
KIRP	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.9	-0.6	4.4e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-9.92	-0.53	1.02e-19	Vitiligo;
KIRP	cis	rs2030401	0.603	rs1727301	chr12:123664514	G/A	cg00376283	chr12:123451042	ABCB9	0.47	6.06	0.36	5.08e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg20965017	chr5:231967	SDHA	-0.58	-6.76	-0.4	9.89e-11	Breast cancer;
KIRP	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs7692976	0.578	rs882405	chr4:110851136	G/A	cg06981781	chr4:110842888	EGF	-0.24	-5.25	-0.32	3.31e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7737355	1.000	rs76753180	chr5:130763701	A/T	cg06647332	chr5:131281008	NA	-0.46	-5.1	-0.31	6.92e-7	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04884102	chr10:17243600	TRDMT1	0.5	6.27	0.37	1.59e-9	Parkinson's disease;
KIRP	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.81	10.41	0.55	2.89e-21	Breast cancer;
KIRP	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg24009623	chr19:33667908	NA	0.47	5.79	0.35	2.13e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6110278	0.685	rs6110288	chr20:14414291	C/A	cg17696268	chr20:14319035	FLRT3;MACROD2	-0.36	-4.98	-0.3	1.19e-6	Mean platelet volume;
KIRP	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.03	-0.46	4.1e-14	Retinal vascular caliber;
KIRP	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.45	5.11	0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.34	-0.37	1.07e-9	Metabolite levels (Pyroglutamine);
KIRP	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.36	-0.51	5.39e-18	Aortic root size;
KIRP	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg02475777	chr4:1388615	CRIPAK	0.53	5.0	0.3	1.09e-6	Recombination rate (females);
KIRP	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7941600	0.643	rs11828205	chr11:9335284	T/A	cg19415743	chr11:9336845	TMEM41B	0.71	6.44	0.38	6.33e-10	Coronary artery disease;
KIRP	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg01244601	chr4:120671846	NA	-0.4	-5.13	-0.31	5.96e-7	Corneal astigmatism;
KIRP	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	1.09	8.1	0.46	2.61e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.56	-7.64	-0.44	4.98e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	5.87	0.35	1.38e-8	Renal cell carcinoma;
KIRP	cis	rs918629	0.599	rs4563648	chr5:95265556	G/A	cg16656078	chr5:95278638	ELL2	-0.37	-5.59	-0.34	6.07e-8	IgG glycosylation;
KIRP	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.34	6.11	0.36	3.91e-9	Renal cell carcinoma;
KIRP	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08280861	chr8:58055591	NA	0.73	5.86	0.35	1.47e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg09873164	chr1:152488093	CRCT1	0.58	7.25	0.42	5.54e-12	Hair morphology;
KIRP	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg05343316	chr1:45956843	TESK2	0.71	6.71	0.39	1.34e-10	Platelet count;
KIRP	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg18132916	chr6:79620363	NA	-0.41	-5.6	-0.34	5.77e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.41	4.98	0.3	1.22e-6	Lung cancer;
KIRP	cis	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg21546286	chr11:48923668	NA	-0.45	-5.79	-0.35	2.19e-8	HDL cholesterol;
KIRP	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg09873164	chr1:152488093	CRCT1	-0.54	-7.07	-0.41	1.61e-11	Hair morphology;
KIRP	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.54	6.3	0.37	1.36e-9	Body mass index (adult);
KIRP	cis	rs9912468	0.933	rs17633437	chr17:64301842	A/G	cg19474267	chr17:64306194	PRKCA	0.57	8.03	0.46	4.09e-14	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs7178909	0.872	rs10852124	chr15:90430464	C/T	cg19708238	chr15:90437601	AP3S2	0.55	7.53	0.43	9.48e-13	Common traits (Other);
KIRP	cis	rs7084783	0.538	rs7067892	chr10:105339698	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.45	5.67	0.34	3.98e-8	Fear of pain;
KIRP	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg13736514	chr6:26305472	NA	-0.72	-9.28	-0.51	9e-18	Educational attainment;
KIRP	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.8	-0.35	2.05e-8	Height;
KIRP	trans	rs7939886	0.920	rs74459856	chr11:56027689	G/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg10223061	chr2:219282414	VIL1	0.32	5.35	0.32	2.01e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs13034020	0.522	rs35976602	chr2:61241582	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.29	0.37	1.44e-9	Hodgkin's lymphoma;
KIRP	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.68	-6.56	-0.39	3.09e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.35	-4.99	-0.3	1.16e-6	Monocyte count;
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg19142026	chr7:27170394	HOXA4	-0.42	-5.98	-0.36	7.87e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.13e-7	Retinal vascular caliber;
KIRP	cis	rs4132509	1.000	rs6429433	chr1:243857994	C/T	cg25706552	chr1:244017396	NA	0.55	6.99	0.41	2.51e-11	RR interval (heart rate);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg09311052	chr1:154531418	UBE2Q1	0.78	6.71	0.39	1.35e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	1.04	8.04	0.46	3.81e-14	Skin colour saturation;
KIRP	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-5.56	-0.33	7.19e-8	Bladder cancer;
KIRP	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.4	0.38	7.84e-10	Diabetic retinopathy;
KIRP	cis	rs714515	0.868	rs9425568	chr1:172316593	G/A	cg01573306	chr1:172330400	DNM3	-0.48	-6.33	-0.37	1.15e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.29	5.85	0.35	1.56e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs77688320	0.535	rs13027669	chr2:202247319	C/G	cg06431681	chr2:202330990	STRADB	0.52	6.93	0.4	3.68e-11	Breast cancer;
KIRP	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.96	-0.5	8.13e-17	Response to antipsychotic treatment;
KIRP	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg15556689	chr8:8085844	FLJ10661	0.66	8.5	0.48	1.81e-15	Neuroticism;
KIRP	cis	rs7202877	0.611	rs7187263	chr16:75308978	C/A	cg03315344	chr16:75512273	CHST6	0.61	5.97	0.36	8.39e-9	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg16497661	chr14:103986332	CKB	-0.49	-6.31	-0.37	1.26e-9	Coronary artery disease;
KIRP	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg16482183	chr6:26056742	HIST1H1C	0.59	6.72	0.39	1.23e-10	Iron status biomarkers;
KIRP	trans	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	7.38	0.43	2.46e-12	Retinal vascular caliber;
KIRP	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06156847	chr2:113672199	IL1F7	0.47	6.35	0.38	1.05e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6882046	0.513	rs681446	chr5:88054292	C/T	cg22951263	chr5:87985283	NA	0.48	6.73	0.39	1.17e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.61	-0.48	8.59e-16	Blood trace element (Zn levels);
KIRP	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15013526	chr3:170588137	RPL22L1	-0.44	-6.16	-0.37	2.99e-9	Metabolic traits;
KIRP	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg23387468	chr7:139079360	LUC7L2	-0.28	-4.89	-0.3	1.81e-6	Diisocyanate-induced asthma;
KIRP	cis	rs9400271	0.632	rs9384706	chr6:109601504	C/T	cg01475377	chr6:109611718	NA	-0.39	-5.68	-0.34	3.76e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06646488	chr20:61569335	C20orf11;DIDO1	0.49	6.85	0.4	5.72e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23535753	chr15:59042242	ADAM10	0.53	7.31	0.42	3.78e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	8.25	0.47	9.56e-15	Systemic lupus erythematosus;
KIRP	cis	rs2625529	0.775	rs2723342	chr15:72107699	G/C	cg16672083	chr15:72433130	SENP8	-0.54	-6.62	-0.39	2.3e-10	Red blood cell count;
KIRP	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs7941030	0.902	rs7127978	chr11:122526501	A/C	cg20555462	chr11:122535518	UBASH3B	-0.45	-5.47	-0.33	1.11e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.46	-0.43	1.52e-12	Bladder cancer;
KIRP	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg05784532	chr1:230284198	GALNT2	0.55	8.19	0.46	1.45e-14	Coronary artery disease;
KIRP	cis	rs1359582	0.836	rs7917696	chr10:90378205	G/A	cg15661332	chr10:90342814	RNLS	0.58	6.1	0.36	4.14e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg21523564	chr15:75251491	NA	0.37	6.39	0.38	8.2e-10	Breast cancer;
KIRP	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.55	0.56	1.06e-21	Cognitive test performance;
KIRP	cis	rs6545883	0.929	rs1209434	chr2:61672958	G/A	cg15711740	chr2:61764176	XPO1	-0.6	-8.09	-0.46	2.69e-14	Tuberculosis;
KIRP	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.67e-20	Gout;Renal underexcretion gout;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.59	-6.71	-0.39	1.34e-10	Menopause (age at onset);
KIRP	cis	rs662064	0.962	rs648399	chr1:10556485	T/C	cg19773385	chr1:10388646	KIF1B	0.37	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-5.32	-0.32	2.33e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg11764359	chr7:65958608	NA	0.74	5.02	0.3	1.01e-6	Diabetic kidney disease;
KIRP	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02187348	chr16:89574699	SPG7	0.53	6.87	0.4	5.26e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.55	7.77	0.44	2.11e-13	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs858239	0.539	rs3950345	chr7:23191114	T/C	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9470361	0.524	rs7740181	chr6:36624111	C/T	cg08179530	chr6:36648295	CDKN1A	0.44	5.72	0.34	3.15e-8	QRS complex (Cornell);QRS duration;Left ventricular fractional shortening;
KIRP	cis	rs9323205	0.817	rs56100232	chr14:51699378	A/G	cg23942311	chr14:51606299	NA	-0.5	-4.89	-0.3	1.78e-6	Cancer;
KIRP	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg12623918	chr2:306882	NA	0.43	5.24	0.32	3.49e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg23894439	chr1:183413866	NA	0.39	5.18	0.31	4.63e-7	Systemic lupus erythematosus;
KIRP	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-0.99	-12.12	-0.61	8.36e-27	Breast cancer;
KIRP	cis	rs4765905	0.610	rs10848635	chr12:2316195	A/T	cg10668781	chr12:2307325	CACNA1C	0.31	6.23	0.37	2.03e-9	Schizophrenia;
KIRP	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg24826892	chr11:71159390	DHCR7	0.43	5.22	0.32	3.81e-7	Vitamin D levels;
KIRP	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.84e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.22	-0.37	2.12e-9	Bladder cancer;
KIRP	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-1.0	-16.82	-0.73	8.87e-43	Height;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05668205	chr19:16738998	MED26	0.47	6.15	0.37	3.16e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs16857609	0.600	rs10084346	chr2:218306736	C/T	cg15335768	chr2:218268053	DIRC3	-0.54	-6.69	-0.39	1.47e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs8028313	0.528	rs338361	chr15:68171116	T/C	cg24579218	chr15:68104479	NA	0.45	6.52	0.38	4.04e-10	Obesity;
KIRP	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.86e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs1800469	1.000	rs1982072	chr19:41864509	T/A	cg09537434	chr19:41945824	ATP5SL	-0.53	-5.85	-0.35	1.56e-8	Colorectal cancer;
KIRP	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.72	10.05	0.54	3.82e-20	Electrocardiographic conduction measures;
KIRP	cis	rs394563	0.589	rs1900300	chr6:149641627	T/C	cg16235748	chr6:149772707	ZC3H12D	0.3	4.93	0.3	1.54e-6	Dupuytren's disease;
KIRP	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.53	-0.43	9.73e-13	Bone mineral density;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.46	6.38	0.38	8.85e-10	Testicular germ cell tumor;
KIRP	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.78	12.54	0.62	3.1e-28	Coronary artery disease;
KIRP	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.17	-0.31	4.83e-7	Colorectal cancer;
KIRP	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg01849789	chr22:41697279	ZC3H7B	-0.5	-5.6	-0.34	5.72e-8	Neuroticism;
KIRP	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.57	7.0	0.41	2.44e-11	Monocyte count;
KIRP	cis	rs5753037	0.702	rs5752961	chr22:30188084	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.72	-0.34	3.11e-8	Type 1 diabetes;
KIRP	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.17	22.51	0.82	1.12e-61	Myeloid white cell count;
KIRP	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg05220968	chr6:146057943	EPM2A	-0.39	-4.97	-0.3	1.24e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	1.01	15.88	0.71	1.47e-39	Sudden cardiac arrest;
KIRP	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.74	-8.84	-0.49	1.83e-16	Coronary artery disease or large artery stroke;
KIRP	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.44	6.07	0.36	4.86e-9	Endometrial cancer;
KIRP	cis	rs9815354	0.953	rs7631914	chr3:41813557	T/C	cg03022575	chr3:42003672	ULK4	0.52	5.91	0.35	1.14e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2979489	0.786	rs2979505	chr8:30387242	T/C	cg26383811	chr8:30366931	RBPMS	-0.48	-5.89	-0.35	1.3e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs55788414	0.932	rs12103358	chr16:81185844	C/G	cg06400318	chr16:81190750	PKD1L2	-0.79	-8.28	-0.47	8.06e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.23	-0.46	1.11e-14	Neuroticism;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg08292112	chr4:39699959	UBE2K	0.53	6.51	0.38	4.23e-10	DNA methylation (variation);
KIRP	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg00784671	chr22:46762841	CELSR1	-0.66	-7.43	-0.43	1.79e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.61e-11	Bipolar disorder;
KIRP	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.46	-5.72	-0.34	3.12e-8	P wave terminal force;
KIRP	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.96	-16.74	-0.73	1.6e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6847149	0.929	rs6839680	chr4:110765496	A/G	cg07850274	chr4:110748770	RRH	-0.44	-5.61	-0.34	5.41e-8	Exercise treadmill test traits;
KIRP	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	0.99	18.16	0.76	2.53e-47	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	0.82	8.66	0.48	6.13e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.0	-0.61	1.97e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.64	-0.52	7.16e-19	Strep throat;
KIRP	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.43	5.56	0.33	7.12e-8	Childhood ear infection;
KIRP	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	1.12	6.9	0.4	4.3e-11	LDL cholesterol;
KIRP	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.73	10.45	0.55	2.23e-21	Diastolic blood pressure;
KIRP	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg02612397	chr6:125855124	NA	-0.33	-4.9	-0.3	1.73e-6	Brugada syndrome;
KIRP	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.19	0.51	1.68e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-7.16	-0.42	9.2e-12	Schizophrenia;
KIRP	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg00262122	chr8:11665843	FDFT1	-0.45	-5.64	-0.34	4.71e-8	Triglycerides;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.28	-0.32	2.83e-7	Obesity-related traits;
KIRP	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-1.09	-7.88	-0.45	1.05e-13	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11977500	chr17:66416767	ARSG	0.53	6.71	0.39	1.33e-10	Interleukin-4 levels;
KIRP	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05220968	chr6:146057943	EPM2A	-0.42	-5.33	-0.32	2.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg17294928	chr15:75287854	SCAMP5	0.63	8.4	0.47	3.62e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.5	5.73	0.34	2.93e-8	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9859260	1.000	rs2300778	chr3:195790737	A/G	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg11641102	chr8:27183873	PTK2B	0.42	5.61	0.34	5.34e-8	Neuroticism;
KIRP	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg06637938	chr14:75390232	RPS6KL1	0.37	5.11	0.31	6.49e-7	Height;
KIRP	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg00656387	chr3:40428638	ENTPD3	-0.36	-4.96	-0.3	1.31e-6	Renal cell carcinoma;
KIRP	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg16141378	chr3:129829833	LOC729375	-0.54	-6.83	-0.4	6.65e-11	Neuroticism;
KIRP	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.89	-0.3	1.83e-6	Pulmonary function;
KIRP	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.51	0.33	8.92e-8	Blood protein levels;
KIRP	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-7.33	-0.42	3.29e-12	Body mass index;
KIRP	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.64	0.48	7.21e-16	Colorectal cancer;
KIRP	cis	rs240764	0.817	rs239216	chr6:101147892	T/G	cg09795085	chr6:101329169	ASCC3	0.46	5.52	0.33	8.75e-8	Neuroticism;
KIRP	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27297192	chr10:134578999	INPP5A	0.67	8.23	0.46	1.11e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	6.56	0.39	3.1e-10	Height;
KIRP	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg14664628	chr15:75095509	CSK	0.55	6.08	0.36	4.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05006947	chr16:58718479	SLC38A7	-0.48	-6.29	-0.37	1.48e-9	Myopia;
KIRP	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.81	0.35	1.88e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.44	6.67	0.39	1.73e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg19770292	chr5:1868693	NA	0.42	5.5	0.33	9.49e-8	Cardiovascular disease risk factors;
KIRP	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg08076091	chr2:203926405	NBEAL1	0.94	9.13	0.5	2.55e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25209633	chr1:207627492	CR2	0.43	6.22	0.37	2.1e-9	Smoking initiation;
KIRP	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.13	0.41	1.12e-11	Lung cancer;
KIRP	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg08890418	chr1:21044141	KIF17	0.34	5.05	0.31	8.58e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8018808	0.935	rs2364156	chr14:77916746	G/A	cg20045696	chr14:77926864	AHSA1	0.46	5.46	0.33	1.17e-7	Myeloid white cell count;
KIRP	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.69	7.05	0.41	1.76e-11	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs11997175	0.766	rs4273817	chr8:33702686	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.84	0.35	1.65e-8	Body mass index;
KIRP	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.25e-11	Diabetic kidney disease;
KIRP	trans	rs12753816	0.886	rs10442644	chr1:169257750	A/C	cg02619135	chr3:51428440	RBM15B	-0.48	-6.24	-0.37	1.91e-9	Coronary artery disease;
KIRP	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg17133734	chr15:86042851	AKAP13	-0.47	-5.93	-0.35	1e-8	Coronary artery disease;
KIRP	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.32	0.59	3.56e-24	Height;
KIRP	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg10935138	chr17:73851978	WBP2	0.47	5.71	0.34	3.3e-8	White matter hyperintensity burden;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26094984	chr2:197457425	HECW2	0.51	6.61	0.39	2.43e-10	Parkinson's disease;
KIRP	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg12940439	chr1:67600707	NA	0.49	7.27	0.42	4.83e-12	Psoriasis;
KIRP	cis	rs6546886	0.869	rs4853007	chr2:74272257	A/C	cg14702570	chr2:74259524	NA	-0.29	-5.69	-0.34	3.68e-8	Dialysis-related mortality;
KIRP	trans	rs1973993	0.561	rs7554152	chr1:96987865	G/C	cg10631902	chr5:14652156	NA	-0.55	-6.72	-0.39	1.26e-10	Weight;
KIRP	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.5	6.14	0.36	3.28e-9	Radiation response;
KIRP	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg01777586	chr17:80163174	CCDC57	0.46	4.97	0.3	1.25e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.88	8.82	0.49	2.19e-16	Monocyte percentage of white cells;
KIRP	cis	rs33912345	0.695	rs941716	chr14:60823044	G/A	cg27398547	chr14:60952738	C14orf39	-0.41	-5.54	-0.33	7.61e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg13198984	chr17:80129470	CCDC57	-0.55	-8.24	-0.47	1.02e-14	Life satisfaction;
KIRP	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18794809	chr3:156480627	NA	0.41	6.81	0.4	7.27e-11	Survival in pancreatic cancer;
KIRP	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	17.09	0.74	1.04e-43	Height;
KIRP	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.63	6.55	0.39	3.26e-10	Response to diuretic therapy;
KIRP	cis	rs6466055	0.565	rs2040915	chr7:104979558	G/A	cg04380332	chr7:105027541	SRPK2	0.36	4.98	0.3	1.2e-6	Schizophrenia;
KIRP	cis	rs2071426	0.501	rs11188128	chr10:96762123	C/T	cg09036531	chr10:96991505	NA	-0.45	-5.25	-0.32	3.21e-7	Blood metabolite levels;
KIRP	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.15	-0.31	5.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.27	0.55	8.12e-21	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20303995	chr10:104159500	NFKB2	0.46	6.06	0.36	5.15e-9	Parkinson's disease;
KIRP	trans	rs1106684	1.000	rs1106683	chr7:131453525	C/T	cg13607082	chr12:122652224	LRRC43	-0.63	-6.81	-0.4	7.27e-11	Body mass index;
KIRP	trans	rs10782582	0.758	rs5745558	chr1:76379497	C/T	cg10283277	chr11:111472630	SIK2	-0.31	-6.21	-0.37	2.23e-9	Daytime sleep phenotypes;
KIRP	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg03959625	chr15:84868606	LOC388152	0.49	5.75	0.34	2.58e-8	Schizophrenia;
KIRP	cis	rs11638511	0.561	rs62007805	chr15:78556571	G/A	cg08594606	chr15:78556512	DNAJA4	-0.37	-4.85	-0.3	2.21e-6	Red blood cell count;
KIRP	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	7.71	0.44	3.06e-13	Triglycerides;
KIRP	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg15117754	chr3:10150083	C3orf24	0.51	5.09	0.31	7.1e-7	Alzheimer's disease;
KIRP	cis	rs2380220	0.872	rs4546494	chr6:95990626	A/C	cg04719120	chr6:96025338	MANEA	0.56	4.94	0.3	1.46e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.8	-8.09	-0.46	2.77e-14	Coronary artery calcification;
KIRP	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.05e-7	Initial pursuit acceleration;
KIRP	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg24315340	chr6:146058215	EPM2A	-0.43	-5.48	-0.33	1.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs1760803	0.754	rs6719	chr1:154179679	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.38	-5.43	-0.33	1.36e-7	Nicotine dependence;
KIRP	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg10189774	chr4:17578691	LAP3	0.52	6.43	0.38	6.63e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg17470449	chr10:769945	NA	0.71	7.13	0.41	1.08e-11	Uric acid levels;
KIRP	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.46	5.39	0.33	1.61e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6496667	0.779	rs113212493	chr15:90960293	T/A	cg10434728	chr15:90938212	IQGAP1	0.4	5.07	0.31	7.99e-7	Rheumatoid arthritis;
KIRP	cis	rs10484885	0.878	rs17506550	chr6:90508896	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.77	-0.44	2.07e-13	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg17724175	chr1:150552817	MCL1	0.36	6.06	0.36	4.96e-9	Blood protein levels;
KIRP	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.32	4.95	0.3	1.41e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.35	-0.38	1.01e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs988913	1.000	rs4715492	chr6:54835178	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.67	-0.34	3.97e-8	Menarche (age at onset);
KIRP	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.77	0.66	2.37e-32	Platelet count;
KIRP	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-6.7	-0.39	1.44e-10	Height;
KIRP	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.63	8.63	0.48	7.65e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24618910	chr2:97523478	ANKRD39	0.48	6.1	0.36	4.12e-9	Parkinson's disease;
KIRP	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.42	-6.31	-0.37	1.3e-9	Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14305943	chr10:120820318	SNORA19;EIF3A	-0.39	-6.03	-0.36	5.86e-9	Inflammatory biomarkers;
KIRP	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.48	0.38	4.91e-10	Retinal vascular caliber;
KIRP	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg06917634	chr15:78832804	PSMA4	-0.55	-5.8	-0.35	2.02e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17712092	chr4:129076599	LARP1B	-0.57	-7.16	-0.42	9.15e-12	Eosinophil percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11952622	chr19:58962976	ZNF324B	0.47	6.3	0.37	1.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	7.01	0.41	2.31e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.47	6.07	0.36	4.91e-9	Parkinson's disease;
KIRP	cis	rs4073221	0.585	rs35441238	chr3:18316117	T/A	cg07694806	chr3:18168406	NA	-0.68	-6.03	-0.36	6.03e-9	Parkinson's disease;
KIRP	cis	rs6570726	0.526	rs9376934	chr6:145738702	A/G	cg23711669	chr6:146136114	FBXO30	0.55	6.91	0.4	4.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.53	-7.46	-0.43	1.44e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg25797454	chr6:150327115	RAET1K	0.37	6.9	0.4	4.49e-11	Alopecia areata;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg01283332	chr5:1856932	NA	-0.45	-5.76	-0.34	2.47e-8	Cardiovascular disease risk factors;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12659933	chr1:113124860	ST7L	-0.46	-7.03	-0.41	1.97e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs988913	0.723	rs4490666	chr6:55000651	C/T	cg03513858	chr6:54763001	FAM83B	0.37	5.37	0.32	1.79e-7	Menarche (age at onset);
KIRP	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.63	-8.5	-0.48	1.83e-15	Colorectal cancer;
KIRP	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.72	-11.56	-0.59	5.49e-25	Idiopathic membranous nephropathy;
KIRP	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.72	-0.49	4.37e-16	Mood instability;
KIRP	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05601917	chr6:125855416	NA	0.33	4.97	0.3	1.28e-6	Brugada syndrome;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00933542	chr6:150070202	PCMT1	0.28	5.62	0.34	5.11e-8	Lung cancer;
KIRP	cis	rs72820985	1.000	rs74030461	chr16:80841121	G/T	cg04448709	chr16:81349954	GAN	-0.5	-4.99	-0.3	1.15e-6	Breast cancer;
KIRP	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg12861170	chr19:19639553	YJEFN3	-0.47	-5.31	-0.32	2.43e-7	Bipolar disorder;
KIRP	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.33	-5.04	-0.31	9.11e-7	Inflammatory bowel disease;
KIRP	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.76	10.51	0.56	1.39e-21	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg26876637	chr1:152193138	HRNR	0.72	9.73	0.53	4e-19	Atopic dermatitis;
KIRP	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg09555818	chr19:45449301	APOC2	0.5	7.26	0.42	4.94e-12	Blood protein levels;
KIRP	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.58	8.02	0.46	4.37e-14	Heart rate;
KIRP	trans	rs1223583	0.743	rs1223580	chr10:95771829	C/G	cg14793753	chr5:64778097	ADAMTS6	-0.41	-6.03	-0.36	5.9e-9	Coronary artery disease;
KIRP	cis	rs7799006	0.723	rs12673108	chr7:2286487	C/A	cg02951883	chr7:2050386	MAD1L1	-0.44	-4.86	-0.3	2.09e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.87	8.31	0.47	6.51e-15	Bronchopulmonary dysplasia;
KIRP	trans	rs10152811	0.716	rs74616635	chr15:86795998	C/A	cg09774649	chr4:8476536	C4orf23	-0.57	-6.41	-0.38	7.28e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs71277158	0.688	rs76146592	chr3:169789234	C/T	cg04067573	chr3:169899625	PHC3	0.62	5.72	0.34	3.09e-8	Prostate cancer;
KIRP	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.36	-4.93	-0.3	1.49e-6	Neuroticism;
KIRP	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	1.03	11.01	0.57	3.39e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs68170813	1.000	rs10953541	chr7:107244545	C/T	cg02696742	chr7:106810147	HBP1	-0.61	-6.14	-0.36	3.3e-9	Coronary artery disease;
KIRP	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	trans	rs7084921	0.608	rs12780514	chr10:101865884	T/C	cg13808641	chr9:96006533	WNK2	-0.41	-6.28	-0.37	1.53e-9	Bone mineral density;
KIRP	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg25486957	chr4:152246857	NA	0.41	4.91	0.3	1.66e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.12	-0.31	6.31e-7	Height;
KIRP	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.93	0.4	3.59e-11	Retinal vascular caliber;
KIRP	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.22	10.7	0.56	3.51e-22	Atopic dermatitis;
KIRP	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.63	9.14	0.5	2.41e-17	Resting heart rate;
KIRP	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg27170947	chr2:26402098	FAM59B	-0.59	-6.53	-0.38	3.64e-10	Gut microbiome composition (summer);
KIRP	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg10117171	chr1:25599238	RHD	0.39	5.39	0.32	1.66e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.23	-0.46	1.08e-14	Bone mineral density;
KIRP	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.68	9.49	0.52	2.1e-18	Post bronchodilator FEV1;
KIRP	trans	rs6479901	0.841	rs10995453	chr10:64934331	T/C	cg15393275	chr2:45165193	NA	-0.47	-6.22	-0.37	2.13e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12050713	chr6:53412803	NA	-0.55	-6.22	-0.37	2.17e-9	Menopause (age at onset);
KIRP	cis	rs580438	0.529	rs7641698	chr3:13435917	G/A	cg10657019	chr3:13328039	NA	-0.49	-6.3	-0.37	1.38e-9	Myringotomy;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.74	6.51	0.38	4.12e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.79	13.32	0.65	7.55e-31	Plasma homocysteine levels (post-methionine load test);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00569953	chr11:66036020	RAB1B	0.5	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03352830	chr11:487213	PTDSS2	0.78	6.53	0.38	3.67e-10	Body mass index;
KIRP	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg13147721	chr7:65941812	NA	-0.93	-6.78	-0.4	8.81e-11	Diabetic kidney disease;
KIRP	trans	rs8002861	0.747	rs12866387	chr13:44391936	A/G	cg17145862	chr1:211918768	LPGAT1	0.8	10.38	0.55	3.53e-21	Leprosy;
KIRP	cis	rs13067260	0.655	rs114726980	chr3:123720669	A/C	cg19918027	chr3:123987645	KALRN	-0.6	-5.26	-0.32	3.21e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs8054556	1.000	rs11901	chr16:29984070	C/G	cg06326092	chr16:30034487	C16orf92	0.34	4.85	0.3	2.2e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs72792276	1.000	rs13357283	chr5:127423114	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	7.64	0.44	4.7e-13	Red cell distribution width;
KIRP	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11987759	chr7:65425863	GUSB	0.57	7.71	0.44	3.1e-13	Aortic root size;
KIRP	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.78	-14.84	-0.69	5.3e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.85	12.99	0.64	9.58e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.54	7.52	0.43	1.04e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg00666640	chr1:248458726	OR2T12	0.48	5.82	0.35	1.84e-8	Common traits (Other);
KIRP	cis	rs35264875	1.000	rs72917389	chr11:68822831	C/T	cg23845249	chr11:68861649	NA	0.6	8.32	0.47	6.1e-15	Blond vs. brown hair color;
KIRP	trans	rs41464545	1.000	rs17085715	chr4:65876011	A/G	cg05059825	chr11:62495950	HNRNPUL2;TTC9C	-0.64	-6.06	-0.36	5.01e-9	Schizophrenia;
KIRP	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.46	6.8	0.4	7.67e-11	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.43	-5.32	-0.32	2.33e-7	Melanoma;
KIRP	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.68	-8.2	-0.46	1.37e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	1.11	7.87	0.45	1.11e-13	Skin colour saturation;
KIRP	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.64	7.2	0.42	7.45e-12	Orofacial clefts;
KIRP	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg09301471	chr16:89349945	ANKRD11	0.45	6.35	0.38	1.02e-9	Warfarin maintenance dose;
KIRP	cis	rs2718058	0.630	rs2722290	chr7:37820403	C/G	cg15028436	chr7:37888078	TXNDC3	0.49	5.24	0.32	3.5e-7	Alzheimer's disease (late onset);
KIRP	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg11965913	chr1:205819406	PM20D1	-0.42	-5.1	-0.31	6.67e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg18154014	chr19:37997991	ZNF793	0.7	7.58	0.44	7.14e-13	Coronary artery calcification;
KIRP	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg18209359	chr17:80159595	CCDC57	0.4	5.36	0.32	1.91e-7	Life satisfaction;
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20887711	chr4:1340912	KIAA1530	0.49	6.33	0.37	1.13e-9	Obesity-related traits;
KIRP	cis	rs4363385	0.647	rs7548977	chr1:152987365	T/G	cg13444842	chr1:152974279	SPRR3	-0.43	-6.17	-0.37	2.79e-9	Inflammatory skin disease;
KIRP	cis	rs2976388	0.669	rs1836633	chr8:143774592	G/A	cg06565975	chr8:143823917	SLURP1	0.44	6.75	0.4	1.03e-10	Urinary tract infection frequency;
KIRP	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg22325292	chr17:80708367	FN3K	0.38	5.06	0.31	8.28e-7	Glycated hemoglobin levels;
KIRP	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.37	7.29	0.42	4.28e-12	Monocyte percentage of white cells;
KIRP	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-8.29	-0.47	7.4e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.69	-8.11	-0.46	2.43e-14	Gut microbiome composition (summer);
KIRP	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.94	11.1	0.58	1.81e-23	Eosinophil percentage of granulocytes;
KIRP	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs1165472	0.755	rs34033335	chr1:56159172	G/A	cg11523071	chr1:56160889	NA	-0.62	-7.77	-0.44	2.13e-13	Paclitaxel-induced neuropathy;
KIRP	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.74	0.49	3.75e-16	Bipolar disorder;
KIRP	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.6	-6.67	-0.39	1.64e-10	Menarche (age at onset);
KIRP	cis	rs7520050	0.807	rs4274104	chr1:46217941	T/C	cg03146154	chr1:46216737	IPP	0.42	5.19	0.31	4.39e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs12549025	0.782	rs11781222	chr8:23389571	A/G	cg08322043	chr8:23340750	NA	-0.56	-5.75	-0.34	2.62e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.62	7.31	0.42	3.62e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.35	5.19	0.31	4.43e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs427941	0.659	rs2529373	chr7:101739618	A/G	cg06246474	chr7:101738831	CUX1	0.56	6.92	0.4	3.91e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs11718455	0.503	rs1404481	chr3:44006666	C/T	cg08738300	chr3:44038990	NA	0.4	6.15	0.37	3.05e-9	Coronary artery disease;
KIRP	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.97	13.93	0.66	6.78e-33	Menopause (age at onset);
KIRP	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17554472	chr22:41940697	POLR3H	-0.64	-6.73	-0.39	1.15e-10	Vitiligo;
KIRP	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg10318148	chr7:1024673	CYP2W1	0.36	5.23	0.32	3.65e-7	Longevity;Endometriosis;
KIRP	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg03959625	chr15:84868606	LOC388152	0.71	8.47	0.48	2.22e-15	Schizophrenia;
KIRP	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-5.02	-0.3	1.01e-6	Major depressive disorder;
KIRP	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg19847130	chr8:10466454	RP1L1	0.34	5.1	0.31	6.7e-7	Neuroticism;
KIRP	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.52e-13	Corneal astigmatism;
KIRP	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg27432699	chr2:27873401	GPN1	-0.6	-7.64	-0.44	4.85e-13	Total body bone mineral density;
KIRP	cis	rs7074356	0.523	rs7087728	chr10:82033470	G/A	cg27171509	chr10:82033454	MAT1A	-0.4	-5.5	-0.33	9.3e-8	Borderline personality disorder;
KIRP	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-11.33	-0.59	3.29e-24	Obesity-related traits;
KIRP	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg21100191	chr22:23484243	RTDR1	0.68	7.42	0.43	1.86e-12	Serum parathyroid hormone levels;
KIRP	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.74	-10.78	-0.57	1.94e-22	Educational attainment;
KIRP	trans	rs9311676	0.693	rs11714515	chr3:58410431	A/G	cg01352688	chr4:6072234	JAKMIP1	-0.31	-6.15	-0.37	3.05e-9	Systemic lupus erythematosus;
KIRP	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg11608241	chr8:8085544	FLJ10661	0.41	4.91	0.3	1.68e-6	Mood instability;
KIRP	cis	rs13067260	0.655	rs9852178	chr3:123750371	G/A	cg19918027	chr3:123987645	KALRN	-0.61	-5.45	-0.33	1.2e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7827545	1.000	rs6578237	chr8:135569358	C/G	cg17885191	chr8:135476712	NA	-0.45	-5.67	-0.34	3.99e-8	Hypertension (SNP x SNP interaction);
KIRP	cis	rs55962025	0.804	rs362268	chr4:3242148	C/G	cg06533319	chr4:3265114	C4orf44	0.5	5.35	0.32	1.98e-7	Parental longevity (mother's age at death);
KIRP	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-10.17	-0.54	1.69e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg11812906	chr14:75593930	NEK9	0.53	5.81	0.35	1.94e-8	Caffeine consumption;
KIRP	cis	rs3109167	0.666	rs2713189	chr7:83114212	C/T	cg14519356	chr7:83097669	SEMA3E	0.46	6.28	0.37	1.52e-9	Blood protein levels;
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	0.8	14.45	0.68	1.13e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg00677455	chr12:58241039	CTDSP2	0.71	8.73	0.49	3.97e-16	Multiple sclerosis;
KIRP	trans	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12081267	chr2:98486185	TMEM131	0.52	6.06	0.36	5.08e-9	Smoking behavior;
KIRP	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.25e-10	Protein C levels;
KIRP	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-5.41	-0.33	1.49e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.44	-5.52	-0.33	8.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.78	11.51	0.59	8.11e-25	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.43	-7.5	-0.43	1.17e-12	Refractive error;
KIRP	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.5	-6.97	-0.41	2.92e-11	Dupuytren's disease;
KIRP	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg24315340	chr6:146058215	EPM2A	-0.4	-5.0	-0.3	1.1e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.95	-0.35	9.32e-9	Diastolic blood pressure;
KIRP	cis	rs860295	0.702	rs12043132	chr1:155562367	T/C	cg02153340	chr1:155202674	NA	-0.49	-6.74	-0.39	1.11e-10	Body mass index;
KIRP	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg13660082	chr14:53194042	PSMC6	0.55	4.93	0.3	1.49e-6	Alzheimer's disease (late onset);
KIRP	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg16497661	chr14:103986332	CKB	-0.49	-6.05	-0.36	5.23e-9	Coronary artery disease;
KIRP	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	5.95	0.35	9.03e-9	Educational attainment;
KIRP	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.12	-0.41	1.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg10047753	chr17:41438598	NA	1.06	17.25	0.74	3.05e-44	Menopause (age at onset);
KIRP	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg10503236	chr1:231470652	EXOC8	-0.48	-6.64	-0.39	2.01e-10	Hemoglobin concentration;
KIRP	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	0.94	8.21	0.46	1.22e-14	Blood protein levels;
KIRP	cis	rs4356932	0.967	rs28642977	chr4:76972731	C/T	cg19388996	chr4:76862389	NAAA	0.39	5.11	0.31	6.37e-7	Blood protein levels;
KIRP	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.64	0.52	7.12e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4262150	0.726	rs4958568	chr5:152016093	G/A	cg12297329	chr5:152029980	NA	-0.63	-8.16	-0.46	1.78e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg26681399	chr22:41777847	TEF	-0.48	-5.24	-0.32	3.49e-7	Vitiligo;
KIRP	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.05	0.41	1.81e-11	Rheumatoid arthritis;
KIRP	cis	rs4908768	0.906	rs12410336	chr1:8623664	A/G	cg25722041	chr1:8623473	RERE	0.81	10.13	0.54	2.17e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	trans	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg10756647	chr7:56101905	PSPH	-0.98	-6.98	-0.41	2.72e-11	Diabetic kidney disease;
KIRP	cis	rs2692947	0.832	rs2579550	chr2:96741944	G/A	cg23100626	chr2:96804247	ASTL	0.47	5.99	0.36	7.46e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.75	12.38	0.62	1.06e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg07451762	chr16:28383216	NA	0.43	5.65	0.34	4.37e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.53	-6.45	-0.38	6.05e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg22906224	chr7:99728672	NA	0.5	6.07	0.36	4.89e-9	Coronary artery disease;
KIRP	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg08885076	chr2:99613938	TSGA10	-0.39	-5.46	-0.33	1.14e-7	Fear of minor pain;
KIRP	cis	rs72653721	0.838	rs3778166	chr6:11033164	A/G	cg13562911	chr6:11044106	ELOVL2	-0.52	-5.11	-0.31	6.42e-7	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.57	-7.72	-0.44	2.87e-13	Menarche (age at onset);
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13198984	chr17:80129470	CCDC57	-0.58	-8.78	-0.49	2.83e-16	Life satisfaction;
KIRP	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.85	-11.26	-0.58	5.56e-24	Type 2 diabetes;
KIRP	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	7.25	0.42	5.35e-12	Systolic blood pressure;
KIRP	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg08999081	chr20:33150536	PIGU	0.48	5.09	0.31	6.99e-7	Protein C levels;
KIRP	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.9	11.62	0.6	3.47e-25	Gestational age at birth (maternal effect);
KIRP	cis	rs1456297	0.840	rs1902590	chr15:51950435	G/T	cg14296394	chr15:51910925	DMXL2	-0.67	-9.41	-0.51	3.81e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.03	-0.46	4.15e-14	Total cholesterol levels;
KIRP	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.37	4.92	0.3	1.57e-6	Axial length;
KIRP	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.51	7.96	0.45	6.21e-14	Testicular germ cell tumor;
KIRP	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg23422044	chr7:1970798	MAD1L1	-0.69	-7.08	-0.41	1.52e-11	Neuroticism;
KIRP	cis	rs597583	0.671	rs2509004	chr11:117410423	G/A	cg27161313	chr11:117392002	DSCAML1	-0.5	-4.98	-0.3	1.19e-6	Putamen volume;
KIRP	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg05805236	chr11:65401703	PCNXL3	-0.56	-7.24	-0.42	5.63e-12	Acne (severe);
KIRP	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg21475434	chr5:93447410	FAM172A	0.76	6.22	0.37	2.11e-9	Diabetic retinopathy;
KIRP	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg13736514	chr6:26305472	NA	-0.66	-7.99	-0.45	5.24e-14	Educational attainment;
KIRP	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg09754948	chr16:28834200	ATXN2L	-0.43	-4.89	-0.3	1.81e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg06766960	chr11:133703094	NA	-0.46	-5.81	-0.35	1.9e-8	Childhood ear infection;
KIRP	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg11031976	chr2:198649780	BOLL	-0.51	-5.03	-0.31	9.51e-7	Ulcerative colitis;
KIRP	cis	rs17023223	0.537	rs10923766	chr1:119726932	G/A	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg25124228	chr12:125621409	AACS	-0.68	-9.38	-0.51	4.4e-18	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4262150	0.883	rs72802874	chr5:152240163	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.81	-8.81	-0.49	2.31e-16	Coronary artery disease;
KIRP	cis	rs6500395	0.708	rs28449353	chr16:48555134	T/A	cg04672837	chr16:48644449	N4BP1	0.41	5.48	0.33	1.07e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7674212	0.541	rs2045746	chr4:104083578	A/C	cg16532752	chr4:104119610	CENPE	0.4	4.85	0.3	2.22e-6	Type 2 diabetes;
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	12.6	0.63	2.03e-28	Platelet count;
KIRP	cis	rs7011507	1.000	rs77535993	chr8:49120463	G/T	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.17	0.7	3.81e-37	Platelet count;
KIRP	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	8.76	0.49	3.2e-16	Resting heart rate;
KIRP	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.58	-6.61	-0.39	2.34e-10	Menarche (age at onset);
KIRP	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.56	-6.63	-0.39	2.1e-10	Aortic root size;
KIRP	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.37	4.95	0.3	1.39e-6	Educational attainment;
KIRP	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.47	6.65	0.39	1.84e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg25463317	chr6:136371535	PDE7B	0.32	4.86	0.3	2.09e-6	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.61	-7.61	-0.44	5.87e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg08501292	chr6:25962987	TRIM38	0.96	5.81	0.35	1.97e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	11.67	0.6	2.51e-25	Smoking behavior;
KIRP	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg22764044	chr5:178986830	RUFY1	0.43	6.26	0.37	1.71e-9	Lung cancer;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13732083	chr21:47605072	C21orf56	-0.5	-6.63	-0.39	2.17e-10	Testicular germ cell tumor;
KIRP	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16386425	chr10:429943	DIP2C	-0.49	-6.76	-0.4	1.01e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg18132916	chr6:79620363	NA	-0.42	-5.67	-0.34	4.05e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg04374321	chr14:90722782	PSMC1	-0.82	-11.56	-0.59	5.79e-25	Mortality in heart failure;
KIRP	cis	rs4750440	0.702	rs7917296	chr10:14029639	G/A	cg27542038	chr10:14027202	FRMD4A	-0.55	-7.54	-0.43	9.19e-13	Adiponectin levels;
KIRP	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg18477163	chr1:228402036	OBSCN	0.34	6.57	0.39	2.99e-10	Diastolic blood pressure;
KIRP	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.37	-0.51	4.78e-18	Personality dimensions;
KIRP	cis	rs2281603	1.000	rs11849530	chr14:64918412	A/G	cg25009451	chr14:65006716	HSPA2	0.49	5.23	0.32	3.59e-7	Lymphocyte counts;
KIRP	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg23166289	chr1:210001082	C1orf107	0.4	5.02	0.3	9.97e-7	Orofacial clefts;
KIRP	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs6959887	0.926	rs2109090	chr7:35270988	G/A	cg06685737	chr7:35301730	NA	0.44	6.38	0.38	8.96e-10	Birth weight;
KIRP	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg21775007	chr8:11205619	TDH	-0.42	-5.3	-0.32	2.52e-7	Triglycerides;
KIRP	cis	rs17384381	0.861	rs35240561	chr1:85775217	C/G	cg16011679	chr1:85725395	C1orf52	0.91	8.7	0.48	4.96e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg26898376	chr11:64110657	CCDC88B	0.47	5.16	0.31	5.16e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs710987	0.933	rs1604439	chr5:3501528	T/A	cg14530963	chr5:3489551	NA	-0.46	-5.82	-0.35	1.87e-8	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis;
KIRP	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.69	7.23	0.42	5.99e-12	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg20261243	chr20:44718728	NCOA5	0.48	6.41	0.38	7.44e-10	Plasma plasminogen activator levels;
KIRP	cis	rs1443512	0.812	rs2044210	chr12:54335533	C/G	cg17410650	chr12:54324560	NA	-0.46	-5.99	-0.36	7.33e-9	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.81	12.03	0.61	1.63e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg04780086	chr2:111875790	ACOXL	0.46	6.33	0.37	1.14e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.47	-0.38	5.12e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg02158880	chr13:53174818	NA	0.38	5.1	0.31	6.65e-7	Lewy body disease;
KIRP	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.58	-7.19	-0.42	7.97e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11967485	0.534	rs62435787	chr6:157141182	T/C	cg23222435	chr6:157204239	ARID1B	-0.75	-5.2	-0.31	4.28e-7	Calcium levels;
KIRP	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg21466736	chr12:48725269	NA	-0.45	-5.78	-0.35	2.23e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs526821	0.553	rs519637	chr11:55295935	A/T	cg15704280	chr7:45808275	SEPT13	-0.53	-6.39	-0.38	8.44e-10	Pediatric bone mineral density (spine);
KIRP	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4132509	1.000	rs2168812	chr1:243777066	G/A	cg25706552	chr1:244017396	NA	0.53	6.83	0.4	6.42e-11	RR interval (heart rate);
KIRP	cis	rs4262150	0.846	rs72799185	chr5:152182070	C/A	cg12297329	chr5:152029980	NA	-0.63	-7.81	-0.45	1.68e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-7.89	-0.45	1.02e-13	Chronic sinus infection;
KIRP	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg06671706	chr8:8559999	CLDN23	0.56	6.33	0.37	1.18e-9	Obesity-related traits;
KIRP	cis	rs9905704	0.596	rs2526367	chr17:56470750	C/T	cg12560992	chr17:57184187	TRIM37	-0.56	-5.44	-0.33	1.26e-7	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17554472	chr22:41940697	POLR3H	0.62	6.78	0.4	9.12e-11	Vitiligo;
KIRP	cis	rs2297441	0.550	rs12053646	chr20:62379748	G/A	cg03999872	chr20:62272968	STMN3	-0.53	-5.44	-0.33	1.27e-7	Ulcerative colitis;
KIRP	cis	rs6542838	0.780	rs981601	chr2:99463882	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-5.38	-0.32	1.75e-7	Fear of minor pain;
KIRP	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.66	-7.48	-0.43	1.29e-12	Type 2 diabetes;
KIRP	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.62	8.08	0.46	3.01e-14	Platelet distribution width;
KIRP	trans	rs225245	0.817	rs225297	chr17:33924587	G/A	cg19694781	chr19:47549865	TMEM160	-0.53	-6.49	-0.38	4.73e-10	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.59	6.26	0.37	1.67e-9	Arsenic metabolism;
KIRP	cis	rs12476592	0.516	rs6546002	chr2:63593829	A/C	cg17519650	chr2:63277830	OTX1	-0.45	-5.13	-0.31	5.94e-7	Childhood ear infection;
KIRP	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg12315302	chr6:26189340	HIST1H4D	-0.94	-6.51	-0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs16936870	0.543	rs1380896	chr8:71235967	C/T	cg14232793	chr8:71155543	NCOA2	0.59	7.28	0.42	4.49e-12	QT interval;
KIRP	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg00677455	chr12:58241039	CTDSP2	-0.46	-5.13	-0.31	5.78e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg13147721	chr7:65941812	NA	-0.97	-7.44	-0.43	1.63e-12	Diabetic kidney disease;
KIRP	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg18306943	chr3:40428807	ENTPD3	0.4	5.67	0.34	4.02e-8	Renal cell carcinoma;
KIRP	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.54	-0.48	1.42e-15	Common traits (Other);
KIRP	cis	rs787274	1.000	rs1539338	chr9:115586187	A/G	cg13803584	chr9:115635662	SNX30	-0.74	-6.66	-0.39	1.82e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg16989719	chr2:238392110	NA	-0.5	-6.51	-0.38	4.16e-10	Prostate cancer;
KIRP	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.18	-0.31	4.63e-7	Autism;
KIRP	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.22e-21	Alzheimer's disease (late onset);
KIRP	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.72	9.95	0.54	8.24e-20	Crohn's disease;
KIRP	trans	rs2797160	0.547	rs9401836	chr6:125956736	T/C	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.16	-0.37	2.9e-9	Endometrial cancer;
KIRP	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg26876637	chr1:152193138	HRNR	0.72	9.67	0.52	5.81e-19	Atopic dermatitis;
KIRP	cis	rs997295	0.713	rs3784695	chr15:68002602	A/G	cg24579218	chr15:68104479	NA	0.36	5.14	0.31	5.63e-7	Motion sickness;
KIRP	cis	rs4356932	0.935	rs6532083	chr4:76929201	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.1	0.31	6.88e-7	Blood protein levels;
KIRP	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg00262122	chr8:11665843	FDFT1	-0.42	-5.08	-0.31	7.29e-7	Triglycerides;
KIRP	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.58	7.97	0.45	5.76e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.872	rs45552534	chr22:46638171	G/A	cg00784671	chr22:46762841	CELSR1	-0.51	-5.71	-0.34	3.19e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg21419209	chr3:44054225	NA	-0.72	-8.88	-0.49	1.4e-16	Coronary artery disease;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.93	15.45	0.7	4.41e-38	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	6.04	0.36	5.75e-9	Schizophrenia;
KIRP	cis	rs832540	0.519	rs10039338	chr5:56260363	C/T	cg12311346	chr5:56204834	C5orf35	0.42	5.64	0.34	4.55e-8	Coronary artery disease;
KIRP	cis	rs12311304	0.965	rs56148413	chr12:15391157	G/A	cg08258403	chr12:15378311	NA	0.39	5.68	0.34	3.77e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs1978968	0.731	rs9605464	chr22:18459922	C/T	cg02610425	chr22:18483192	MICAL3	0.38	5.68	0.34	3.78e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg16179182	chr5:140090404	VTRNA1-1	0.51	6.78	0.4	9e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26002218	chr14:103986227	CKB	-0.33	-6.92	-0.4	3.81e-11	Body mass index;
KIRP	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.74	-9.26	-0.51	1.05e-17	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24380168	chr7:45040141	CCM2	0.5	6.52	0.38	4.06e-10	Parkinson's disease;
KIRP	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.52	0.48	1.66e-15	Motion sickness;
KIRP	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.73	-8.76	-0.49	3.16e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg15934090	chr1:100435551	SLC35A3	0.51	6.42	0.38	6.91e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6893300	0.784	rs62404347	chr5:179145131	T/C	cg14593053	chr5:179126677	CANX	-0.58	-7.09	-0.41	1.4e-11	Resting heart rate;
KIRP	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02501116	chr8:68107083	CSPP1	-0.43	-6.02	-0.36	6.35e-9	Select biomarker traits;
KIRP	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg02491457	chr7:128862824	NA	0.48	6.13	0.36	3.43e-9	White matter hyperintensity burden;
KIRP	cis	rs6746082	0.519	rs503594	chr2:25757803	C/T	cg23192403	chr2:25781496	DTNB	-0.25	-5.02	-0.3	1.01e-6	Multiple myeloma;
KIRP	cis	rs2250402	0.510	rs75578790	chr15:40332440	A/G	cg10636054	chr15:40330586	SRP14	-1.14	-9.45	-0.52	2.7e-18	Corneal curvature;
KIRP	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.8	-10.28	-0.55	7.36e-21	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs6753739	0.745	rs6736620	chr2:219912103	C/T	cg01749213	chr2:219906749	CCDC108	0.44	5.2	0.31	4.24e-7	Height;
KIRP	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-18.82	-0.77	1.5e-49	Ulcerative colitis;
KIRP	trans	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg17822266	chr1:2720087	NA	-0.46	-6.36	-0.38	9.67e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs4073416	0.568	rs1999725	chr14:65904237	C/T	cg03016385	chr14:66212404	NA	-0.5	-6.22	-0.37	2.13e-9	N-glycan levels;
KIRP	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	1.11	13.21	0.64	1.82e-30	Type 2 diabetes nephropathy;
KIRP	trans	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.03	0.36	5.93e-9	Retinal vascular caliber;
KIRP	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg24253500	chr15:84953950	NA	0.51	5.87	0.35	1.42e-8	Schizophrenia;
KIRP	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.53	8.17	0.46	1.6e-14	Anterior chamber depth;
KIRP	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-0.54	-7.61	-0.44	5.86e-13	Coronary artery disease;
KIRP	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.38	4.94	0.3	1.43e-6	Huntington's disease progression;
KIRP	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg01420254	chr6:26195488	NA	1.23	11.05	0.58	2.65e-23	Gout;Renal underexcretion gout;
KIRP	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs950776	0.613	rs12915539	chr15:78940795	T/A	cg06917634	chr15:78832804	PSMA4	0.62	6.72	0.39	1.24e-10	Sudden cardiac arrest;
KIRP	cis	rs4835473	0.932	rs28796049	chr4:144655143	C/G	cg08833778	chr4:144622313	FREM3	0.34	4.91	0.3	1.65e-6	Immature fraction of reticulocytes;
KIRP	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg15128208	chr22:42549153	NA	0.74	8.06	0.46	3.32e-14	Birth weight;
KIRP	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	7.51	0.43	1.11e-12	Rheumatoid arthritis;
KIRP	cis	rs6669919	0.653	rs7522450	chr1:211683424	C/A	cg10512769	chr1:211675356	NA	-0.58	-8.31	-0.47	6.34e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.45	0.33	1.2e-7	Putamen volume;
KIRP	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg16584676	chr17:46985605	UBE2Z	0.47	5.8	0.35	2.06e-8	Type 2 diabetes;
KIRP	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17507749	chr15:85114479	UBE2QP1	0.73	8.16	0.46	1.78e-14	Schizophrenia;
KIRP	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	9.32	0.51	6.98e-18	Cognitive test performance;
KIRP	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg00042356	chr1:8021962	PARK7	0.77	6.27	0.37	1.62e-9	Inflammatory bowel disease;
KIRP	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg12463550	chr7:65579703	CRCP	0.45	5.16	0.31	4.99e-7	Aortic root size;
KIRP	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg03808351	chr9:123631620	PHF19	0.46	6.16	0.37	2.98e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs2223471	0.602	rs9395616	chr6:50700474	A/G	cg03432817	chr6:50765336	NA	-0.37	-5.52	-0.33	8.58e-8	Subcutaneous adipose tissue;
KIRP	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg22800045	chr5:56110881	MAP3K1	-0.58	-6.89	-0.4	4.56e-11	Initial pursuit acceleration;
KIRP	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.49	6.25	0.37	1.79e-9	Testicular germ cell tumor;
KIRP	cis	rs988913	1.000	rs1503136	chr6:54851965	A/C	cg03513858	chr6:54763001	FAM83B	-0.37	-5.43	-0.33	1.32e-7	Menarche (age at onset);
KIRP	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.05	-0.36	5.5e-9	Breast cancer;
KIRP	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.37	-0.51	4.91e-18	Hirschsprung disease;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg26187514	chr1:212458738	PPP2R5A	0.53	6.59	0.39	2.61e-10	Neuroticism;
KIRP	cis	rs1629083	0.967	rs1715449	chr11:118128455	G/A	cg18857871	chr11:118064634	AMICA1	0.69	10.07	0.54	3.38e-20	Lung cancer;
KIRP	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg14593290	chr7:50529359	DDC	-0.57	-8.01	-0.45	4.54e-14	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09241381	chr3:122746131	SEMA5B	-0.49	-6.83	-0.4	6.59e-11	Myopia;
KIRP	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg06781948	chr3:72941472	GXYLT2	0.51	6.52	0.38	4.05e-10	Motion sickness;
KIRP	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg24315340	chr6:146058215	EPM2A	-0.45	-5.78	-0.35	2.2e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.8200000000000003e-11	Bladder cancer;
KIRP	cis	rs7116495	0.609	rs4945378	chr11:71668866	G/A	cg07596299	chr11:71824057	C11orf51	-0.9	-6.08	-0.36	4.49e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12667521	chr19:29218732	NA	0.93	9.2	0.51	1.59e-17	Methadone dose in opioid dependence;
KIRP	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg10223061	chr2:219282414	VIL1	0.4	6.4	0.38	7.66e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.49	0.33	1e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6969780	0.915	rs10085570	chr7:27151188	C/T	cg17457637	chr7:27170717	HOXA4	-0.31	-4.86	-0.3	2.11e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00290607	chr11:67383545	NA	0.35	4.99	0.3	1.13e-6	Mean corpuscular volume;
KIRP	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-5.86	-0.35	1.48e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1190552	0.846	rs3783382	chr14:102965437	A/T	cg18135206	chr14:102964638	TECPR2	0.47	5.32	0.32	2.29e-7	Blood protein levels;
KIRP	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg23387468	chr7:139079360	LUC7L2	0.29	4.9	0.3	1.72e-6	Diisocyanate-induced asthma;
KIRP	cis	rs2901460	0.509	rs6721488	chr2:62071562	A/T	cg02183531	chr2:62113199	CCT4	-0.5	-5.17	-0.31	4.77e-7	Mean corpuscular volume;
KIRP	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.75	11.31	0.58	3.75e-24	Blood metabolite ratios;
KIRP	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg03929089	chr4:120376271	NA	-1.0	-7.28	-0.42	4.42e-12	Myopia (pathological);
KIRP	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg22800045	chr5:56110881	MAP3K1	-0.75	-7.35	-0.42	2.98e-12	Initial pursuit acceleration;
KIRP	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.57	-6.47	-0.38	5.28e-10	Menarche (age at onset);
KIRP	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.73	9.32	0.51	6.81e-18	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.85	-10.57	-0.56	9.14e-22	Vitiligo;
KIRP	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg04226714	chr8:49833948	SNAI2	0.43	6.08	0.36	4.47e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs12360000	0.830	rs11250863	chr10:1912417	T/A	cg26364871	chr10:1889757	NA	-0.58	-7.13	-0.41	1.09e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs3825932	0.961	rs11855406	chr15:79234864	C/T	cg25744700	chr15:79237217	CTSH	-0.42	-5.1	-0.31	6.87e-7	Type 1 diabetes;
KIRP	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.71	-8.85	-0.49	1.71e-16	Total body bone mineral density;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-1.03	-12.12	-0.61	7.75e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.6	-0.44	6.19e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.64	-6.76	-0.4	9.93e-11	Gut microbiome composition (summer);
KIRP	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.91	12.46	0.62	6.09e-28	Cognitive function;
KIRP	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg21475434	chr5:93447410	FAM172A	0.73	5.96	0.36	8.71e-9	Diabetic retinopathy;
KIRP	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.6	-7.61	-0.44	5.8e-13	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.92	0.64	1.65e-29	Exhaled nitric oxide output;
KIRP	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.43	-6.28	-0.37	1.5e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg27490568	chr2:178487706	NA	0.46	6.14	0.36	3.33e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2239815	0.515	rs12170231	chr22:29237824	C/T	cg15103426	chr22:29168792	CCDC117	0.53	5.1	0.31	6.68e-7	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	trans	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs13102973	0.640	rs11099301	chr4:135880662	G/T	cg14419869	chr4:135874104	NA	0.41	6.04	0.36	5.55e-9	Subjective well-being;
KIRP	cis	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg26378065	chr17:18585709	ZNF286B	0.47	6.07	0.36	4.91e-9	Educational attainment (years of education);
KIRP	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg07636037	chr3:49044803	WDR6	-0.74	-5.59	-0.34	6.11e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.5	6.35	0.38	1.04e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.65	7.87	0.45	1.11e-13	Type 2 diabetes;
KIRP	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.46	6.6	0.39	2.47e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7542091	0.704	rs1108628	chr1:210041150	A/G	cg22029157	chr1:209979665	IRF6	0.39	6.0	0.36	6.98e-9	Monobrow;
KIRP	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.02	-0.5	5.33e-17	Mean corpuscular volume;
KIRP	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.89	13.66	0.66	5.47e-32	Coronary artery disease;
KIRP	cis	rs5995756	0.805	rs132580	chr22:39984946	A/G	cg10455938	chr22:40058150	CACNA1I	-0.46	-6.55	-0.39	3.42e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00802000	chr16:706648	WDR90	-0.38	-4.87	-0.3	2e-6	Height;
KIRP	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-1.1	-22.07	-0.82	2.91e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1559088	0.847	rs6510348	chr19:33601946	G/A	cg03563238	chr19:33554763	RHPN2	-0.32	-5.74	-0.34	2.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg23693289	chr8:27183097	PTK2B	-0.5	-5.92	-0.35	1.1e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs6684428	1.000	rs6684428	chr1:56359813	T/A	cg11651538	chr1:56320950	NA	-0.82	-9.9	-0.53	1.19e-19	Airflow obstruction;
KIRP	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.24	-0.32	3.41e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.67	7.42	0.43	1.89e-12	Gut microbiome composition (summer);
KIRP	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.59	6.27	0.37	1.63e-9	Schizophrenia;
KIRP	cis	rs2151522	0.563	rs1539554	chr6:127146182	T/C	cg21431617	chr6:127135037	NA	0.33	5.96	0.36	8.66e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg00585698	chr12:123750864	CDK2AP1	0.5	5.57	0.33	6.77e-8	Neutrophil percentage of white cells;
KIRP	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.63	5.89	0.35	1.29e-8	Schizophrenia;
KIRP	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.81	0.45	1.7e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01504784	chr19:6414019	KHSRP	-0.48	-7.4	-0.43	2.17e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1829883	0.931	rs7720138	chr5:98879849	G/C	cg08333243	chr5:99726346	NA	0.37	5.07	0.31	7.88e-7	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27243409	chr3:57261974	APPL1	0.52	6.5	0.38	4.32e-10	Parkinson's disease;
KIRP	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.44e-8	Schizophrenia;
KIRP	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg18944383	chr4:111397179	ENPEP	0.62	11.31	0.58	3.64e-24	Height;
KIRP	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg27205649	chr11:78285834	NARS2	0.82	11.3	0.58	3.9e-24	Alzheimer's disease (survival time);
KIRP	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-7.56	-0.43	7.98e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs921943	1.000	rs2034900	chr5:78315964	A/G	cg26802063	chr5:78281964	ARSB	-0.49	-6.17	-0.37	2.72e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs12282928	0.657	rs10838826	chr11:48219812	G/T	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.22e-9	Migraine - clinic-based;
KIRP	cis	rs6142102	0.961	rs1319363	chr20:32541876	T/A	cg24642439	chr20:33292090	TP53INP2	0.59	6.63	0.39	2.15e-10	Skin pigmentation;
KIRP	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.86	8.28	0.47	8e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.72	-0.44	2.89e-13	Breast cancer;
KIRP	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs7721647	0.821	rs332518	chr5:90849062	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.4	4.89	0.3	1.78e-6	Breast cancer;
KIRP	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.7	-0.63	9.48e-29	Chronic sinus infection;
KIRP	cis	rs9475752	0.793	rs56381984	chr6:56832708	T/C	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21747090	chr2:27597821	SNX17	-0.5	-6.95	-0.41	3.22e-11	Total body bone mineral density;
KIRP	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg08133631	chr1:26527909	CATSPER4	-0.46	-5.15	-0.31	5.36e-7	Obesity-related traits;
KIRP	trans	rs2048656	0.605	rs7814507	chr8:9646560	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	6.1	0.36	4.16e-9	Schizophrenia;
KIRP	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg10223061	chr2:219282414	VIL1	-0.37	-6.12	-0.36	3.76e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6977660	0.714	rs6976972	chr7:19818315	C/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	cis	rs2708977	1.000	rs2708977	chr2:97230074	G/A	cg01950434	chr2:97203154	ARID5A	-0.55	-6.77	-0.4	9.61e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	1.1	13.74	0.66	2.93e-32	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1923539	1.000	rs1923539	chr10:81694950	G/A	cg12667595	chr10:81743362	NA	0.42	5.2	0.31	4.27e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.6	5.56	0.33	6.93e-8	Schizophrenia;
KIRP	cis	rs7113850	0.541	rs80243979	chr11:24231811	A/C	ch.11.24196551F	chr11:24239977	NA	0.9	8.37	0.47	4.29e-15	Bone fracture in osteoporosis;
KIRP	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg15226275	chr6:116381976	FRK	0.22	5.89	0.35	1.27e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg01214346	chr17:406501	NA	-0.45	-5.89	-0.35	1.26e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.44	-5.78	-0.35	2.23e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg18461458	chr19:21324796	ZNF431	-0.5	-5.04	-0.31	8.87e-7	Pain;
KIRP	cis	rs1408799	0.678	rs2762461	chr9:12696499	G/T	cg05274944	chr9:12693694	TYRP1	0.41	5.82	0.35	1.82e-8	Eye color;Blue vs. green eyes;
KIRP	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.79	6.86	0.4	5.44e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg16482183	chr6:26056742	HIST1H1C	0.43	5.46	0.33	1.17e-7	Schizophrenia;
KIRP	cis	rs10267417	0.603	rs12669215	chr7:19933427	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.11	0.31	6.44e-7	Night sleep phenotypes;
KIRP	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.39	5.26	0.32	3.17e-7	Lewy body disease;
KIRP	cis	rs9914544	1.000	rs1634411	chr17:18833810	C/T	cg26306683	chr17:18585705	ZNF286B	0.66	7.93	0.45	7.8e-14	Educational attainment (years of education);
KIRP	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	12.89	0.63	2.17e-29	Tonsillectomy;
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg11204139	chr17:3907470	NA	-0.81	-14.85	-0.69	4.62e-36	Type 2 diabetes;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22618164	chr12:122356400	WDR66	0.67	9.25	0.51	1.14e-17	Mean corpuscular volume;
KIRP	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg15764593	chr10:829463	NA	-0.83	-8.9	-0.49	1.26e-16	Uric acid levels;
KIRP	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23281280	chr6:28129359	ZNF389	0.44	4.96	0.3	1.33e-6	Depression;
KIRP	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg07148914	chr20:33460835	GGT7	-0.55	-7.19	-0.42	7.98e-12	Height;
KIRP	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.66	-12.44	-0.62	6.87e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-8.81	-0.49	2.28e-16	Menarche (age at onset);
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.25	-0.32	3.36e-7	Electroencephalogram traits;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg14737592	chr12:57914238	DDIT3	-0.51	-6.46	-0.38	5.69e-10	Neuroticism;
KIRP	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.41	-5.08	-0.31	7.42e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.24	0.37	1.93e-9	Depression;
KIRP	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.43	-7.68	-0.44	3.79e-13	Refractive error;
KIRP	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg04310649	chr10:35416472	CREM	-0.5	-5.86	-0.35	1.46e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg08501292	chr6:25962987	TRIM38	1.03	8.19	0.46	1.42e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg27432699	chr2:27873401	GPN1	-0.49	-6.34	-0.37	1.08e-9	Total body bone mineral density;
KIRP	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs1858037	0.867	rs953312	chr2:65567690	C/T	cg08085232	chr2:65598271	SPRED2	-0.52	-6.16	-0.37	2.99e-9	Rheumatoid arthritis;
KIRP	cis	rs9815354	0.812	rs73081321	chr3:41890231	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7709377	0.570	rs4921062	chr5:115445812	T/A	cg23108291	chr5:115420582	COMMD10	0.41	4.94	0.3	1.43e-6	Metabolite levels  (X-11787);
KIRP	cis	rs501120	1.000	rs604674	chr10:44756894	G/T	cg09554077	chr10:44749378	NA	0.72	11.38	0.59	2.26e-24	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg21433313	chr16:3507492	NAT15	0.61	6.99	0.41	2.58e-11	Tuberculosis;
KIRP	cis	rs6973256	0.828	rs2041996	chr7:133390510	G/A	cg10665199	chr7:133106180	EXOC4	-0.52	-6.04	-0.36	5.78e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg03351412	chr1:154909251	PMVK	0.62	8.44	0.47	2.83e-15	Prostate cancer;
KIRP	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg19847130	chr8:10466454	RP1L1	0.36	5.33	0.32	2.21e-7	Retinal vascular caliber;
KIRP	trans	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs7116495	1.000	rs58991229	chr11:71839878	G/A	cg26138937	chr11:71823887	C11orf51	0.71	5.58	0.33	6.47e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs26949	0.511	rs11740327	chr5:59899413	G/A	cg02684056	chr5:59996105	DEPDC1B	0.43	5.17	0.31	4.78e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.94	10.54	0.56	1.14e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs13095912	1.000	rs17523471	chr3:185304018	T/C	cg11274856	chr3:185301563	NA	0.51	6.65	0.39	1.87e-10	Systolic blood pressure;
KIRP	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg07001201	chr5:642380	CEP72	0.45	5.71	0.34	3.21e-8	Obesity-related traits;
KIRP	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.65	7.94	0.45	7.08e-14	Corneal astigmatism;
KIRP	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.62	7.36	0.42	2.73e-12	Iron status biomarkers;
KIRP	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg11833968	chr6:79620685	NA	-0.37	-5.12	-0.31	6.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg06066596	chr15:83166174	LOC80154	0.44	6.02	0.36	6.21e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg01422370	chr2:73384389	NA	0.46	6.24	0.37	1.95e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg05457628	chr5:178986728	RUFY1	0.54	8.2	0.46	1.3e-14	Lung cancer;
KIRP	cis	rs35000415	0.938	rs13239597	chr7:128695983	C/A	cg19972273	chr7:128594194	NA	0.81	6.17	0.37	2.84e-9	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.8	6.31	0.37	1.3e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs6570726	0.811	rs375873	chr6:145812371	G/T	ch.2.129044566R	chr2:129328096	NA	-0.47	-6.06	-0.36	5.06e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2625529	0.557	rs1000281	chr15:72553422	A/G	cg16672083	chr15:72433130	SENP8	0.41	5.77	0.35	2.33e-8	Red blood cell count;
KIRP	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-5.04	-0.31	9.07e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.67	9.21	0.51	1.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	11.32	0.59	3.38e-24	Bone mineral density;
KIRP	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.59	0.52	1.08e-18	Dupuytren's disease;
KIRP	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.03	-0.41	2e-11	Initial pursuit acceleration;
KIRP	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.35	7.19	0.42	7.86e-12	Body mass index;
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.57	-0.33	6.75e-8	Life satisfaction;
KIRP	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.32	0.32	2.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.73e-10	Subjective well-being;
KIRP	cis	rs9905704	0.633	rs2680694	chr17:56469869	T/C	cg12560992	chr17:57184187	TRIM37	-0.56	-5.44	-0.33	1.26e-7	Testicular germ cell tumor;
KIRP	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.57	6.09	0.36	4.34e-9	Bipolar disorder;
KIRP	cis	rs2230307	0.536	rs56215716	chr1:100447486	G/A	cg24955406	chr1:100503596	HIAT1	0.56	6.16	0.37	2.96e-9	Carotid intima media thickness;
KIRP	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-8.39	-0.47	3.81e-15	Coronary artery disease;
KIRP	trans	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg21659725	chr3:3221576	CRBN	0.61	8.25	0.47	9.68e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs4787491	0.679	rs7204852	chr16:30040178	C/G	cg06326092	chr16:30034487	C16orf92	0.5	7.86	0.45	1.23e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs994014	0.727	rs7699396	chr4:82271702	C/A	cg04076444	chr16:85646805	KIAA0182	0.51	6.1	0.36	4.17e-9	Height;
KIRP	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.41	-5.03	-0.31	9.48e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.98	13.89	0.66	9.02e-33	Cognitive function;
KIRP	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.46	6.81	0.4	7.57e-11	Urate levels in lean individuals;
KIRP	cis	rs4689642	0.756	rs4689089	chr4:7225587	C/G	cg21353189	chr4:7228343	SORCS2	0.42	5.65	0.34	4.52e-8	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26207909	chr14:103986467	CKB	0.53	7.19	0.42	7.62e-12	Body mass index;
KIRP	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg24375607	chr4:120327624	NA	0.52	6.17	0.37	2.77e-9	Corneal astigmatism;
KIRP	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.3	-0.32	2.59e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09131844	chr2:27651398	NRBP1	0.51	6.12	0.36	3.6e-9	Parkinson's disease;
KIRP	cis	rs7760535	0.757	rs10456875	chr6:111749725	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.42	-5.44	-0.33	1.29e-7	Metabolic traits;
KIRP	cis	rs7534824	0.625	rs17610202	chr1:101429724	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.16	0.42	9.39e-12	Refractive astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03315484	chr5:137688433	KDM3B	0.5	7.08	0.41	1.54e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.06	-0.46	3.39e-14	Migraine;Coronary artery disease;
KIRP	cis	rs7615316	1.000	rs7646880	chr3:142351930	C/T	cg20824294	chr3:142316082	PLS1	0.22	4.9	0.3	1.72e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs10073892	0.703	rs12332575	chr5:101865789	C/A	cg19774478	chr5:101632501	SLCO4C1	0.63	6.26	0.37	1.66e-9	Cognitive decline (age-related);
KIRP	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg13939156	chr17:80058883	NA	0.47	5.54	0.33	7.83e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs507080	0.733	rs601318	chr11:118519550	C/G	cg04173919	chr11:118528438	PHLDB1	0.37	5.36	0.32	1.96e-7	Serum metabolite levels;
KIRP	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg25039879	chr17:56429692	SUPT4H1	0.59	5.07	0.31	7.95e-7	Cognitive test performance;
KIRP	cis	rs17213078	0.505	rs3795909	chr2:106754734	A/G	cg16099169	chr2:106886729	NA	0.39	5.5	0.33	9.66e-8	Facial morphology (factor 23);
KIRP	cis	rs1215050	0.791	rs165244	chr4:98687889	C/T	cg05340658	chr4:99064831	C4orf37	0.53	6.38	0.38	8.72e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7084402	0.967	rs1649030	chr10:60279830	G/A	cg05938607	chr10:60274200	BICC1	0.46	11.06	0.58	2.41e-23	Refractive error;
KIRP	cis	rs7005380	0.531	rs4871011	chr8:120907771	C/T	cg21645572	chr8:120931649	DEPDC6	0.42	4.91	0.3	1.64e-6	Interstitial lung disease;
KIRP	cis	rs6832769	1.000	rs6811520	chr4:56315178	T/C	cg05960024	chr4:56376020	CLOCK	0.7	8.65	0.48	6.96e-16	Personality dimensions;
KIRP	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1408799	0.523	rs2762463	chr9:12701897	A/T	cg05274944	chr9:12693694	TYRP1	0.46	7.05	0.41	1.82e-11	Eye color;Blue vs. green eyes;
KIRP	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.02	-0.54	4.75e-20	Hemoglobin concentration;
KIRP	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.7	9.85	0.53	1.65e-19	Caffeine consumption;
KIRP	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg00405596	chr8:11794950	NA	0.58	8.03	0.46	4.09e-14	Myopia (pathological);
KIRP	cis	rs11955398	0.625	rs11739209	chr5:59959767	T/C	cg02684056	chr5:59996105	DEPDC1B	0.47	5.31	0.32	2.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.47	-6.02	-0.36	6.25e-9	Post bronchodilator FEV1;
KIRP	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg21433313	chr16:3507492	NAT15	0.65	7.28	0.42	4.49e-12	Tuberculosis;
KIRP	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg04865290	chr3:52927548	TMEM110	-0.65	-7.22	-0.42	6.57e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg24110177	chr3:50126178	RBM5	-0.63	-7.71	-0.44	3.02e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs56346965	0.506	rs929566	chr2:191521441	C/G	cg11845111	chr2:191398756	TMEM194B	-0.51	-5.63	-0.34	4.81e-8	Bone mineral density (Ward's triangle area);
KIRP	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg24579218	chr15:68104479	NA	-0.43	-6.26	-0.37	1.67e-9	Obesity;
KIRP	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.69	-8.71	-0.49	4.54e-16	Systemic lupus erythematosus;
KIRP	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.12	0.41	1.17e-11	Bipolar disorder;
KIRP	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.71	10.28	0.55	7.57e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2275565	0.568	rs12407420	chr1:236960003	G/C	cg17297354	chr1:237056641	MTR	-0.44	-5.68	-0.34	3.72e-8	Homocysteine levels;
KIRP	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.82	-12.23	-0.62	3.4e-27	Asthma;
KIRP	cis	rs3857067	1.000	rs2865330	chr4:95004716	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.89e-7	QT interval;
KIRP	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg21775007	chr8:11205619	TDH	-0.53	-6.77	-0.4	9.2e-11	Joint mobility (Beighton score);
KIRP	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.33	5.97	0.36	8.28e-9	Renal cell carcinoma;
KIRP	cis	rs6841258	0.572	rs16852326	chr4:40553304	A/T	cg25639566	chr4:40539823	RBM47	-0.47	-5.04	-0.31	9.05e-7	Mosquito bite size;
KIRP	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.71	9.79	0.53	2.52e-19	Mean corpuscular volume;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-6.54	-0.38	3.53e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.75	10.93	0.57	6.3e-23	Obesity-related traits;
KIRP	cis	rs918629	0.567	rs4642392	chr5:95255379	A/G	cg16656078	chr5:95278638	ELL2	0.36	5.6	0.34	5.68e-8	IgG glycosylation;
KIRP	cis	rs13185784	0.667	rs4309929	chr5:179650988	A/C	cg23221052	chr5:179740743	GFPT2	-0.47	-4.86	-0.3	2.06e-6	TRAIL levels;
KIRP	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.59	7.16	0.42	9.53e-12	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.18	13.25	0.65	1.31e-30	Platelet count;
KIRP	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.72	-0.44	2.94e-13	Resting heart rate;
KIRP	cis	rs6832769	0.925	rs4371676	chr4:56329008	G/A	cg09317128	chr4:56265301	TMEM165	0.52	6.56	0.39	3.13e-10	Personality dimensions;
KIRP	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg11494091	chr17:61959527	GH2	0.47	5.85	0.35	1.52e-8	Height;
KIRP	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	9.63	0.52	7.69e-19	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.89	-0.45	9.85e-14	Colorectal cancer;
KIRP	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.98	-12.8	-0.63	4.18e-29	Platelet distribution width;
KIRP	cis	rs3735025	0.927	rs13234894	chr7:137068835	G/A	cg13839563	chr7:136910420	NA	-0.43	-4.84	-0.3	2.24e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg15557168	chr22:42548783	NA	-0.37	-5.34	-0.32	2.1e-7	Cognitive function;
KIRP	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.13	-0.31	5.89e-7	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12112058	chr1:224622605	WDR26	0.52	6.18	0.37	2.61e-9	Smoking initiation;
KIRP	cis	rs2400749	0.830	rs11627095	chr14:100033156	C/G	cg19965031	chr14:100038389	CCDC85C	0.45	5.44	0.33	1.32e-7	Alzheimer's disease (survival time);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27393277	chr4:177673704	VEGFC	-0.4	-6.29	-0.37	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.23	24.1	0.84	1.06e-66	Cognitive function;
KIRP	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.58	-6.09	-0.36	4.26e-9	Obesity-related traits;
KIRP	cis	rs11209185	0.509	rs9326077	chr1:68452192	A/G	cg22082780	chr1:68452167	NA	0.36	5.34	0.32	2.14e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs40363	1.000	rs40363	chr16:3509056	G/A	cg00484396	chr16:3507460	NAT15	0.53	5.87	0.35	1.43e-8	Tuberculosis;
KIRP	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-1.15	-14.69	-0.68	1.72e-35	IgG glycosylation;
KIRP	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.95	17.11	0.74	8.82e-44	Intelligence (multi-trait analysis);
KIRP	cis	rs7590368	0.683	rs72779459	chr2:10960650	T/C	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg11271282	chr2:238384023	NA	0.51	5.8	0.35	2.05e-8	Prostate cancer;
KIRP	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg11945507	chr8:142233382	SLC45A4	-0.49	-6.25	-0.37	1.78e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7224685	0.569	rs34377654	chr17:3990201	G/A	cg09597638	chr17:3907349	NA	0.55	5.45	0.33	1.21e-7	Type 2 diabetes;
KIRP	trans	rs73191547	0.617	rs6994636	chr8:10046140	A/C	cg20582800	chr6:43612764	RSPH9	-0.41	-6.06	-0.36	5.15e-9	Schizophrenia;
KIRP	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg09990169	chr2:241835740	C2orf54	-0.45	-6.8	-0.4	7.86e-11	Urinary metabolites;
KIRP	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs494562	0.892	rs619299	chr6:86121482	A/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17912633	chr13:41239612	FOXO1	0.45	6.02	0.36	6.45e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg00319359	chr11:70116639	PPFIA1	0.78	7.17	0.42	8.89e-12	Coronary artery disease;
KIRP	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.6	11.32	0.59	3.38e-24	Bone mineral density;
KIRP	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.13e-12	Uric acid levels;
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg13699009	chr12:122356056	WDR66	0.57	8.57	0.48	1.15e-15	Mean corpuscular volume;
KIRP	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg13010199	chr12:38710504	ALG10B	0.55	6.67	0.39	1.66e-10	Resting heart rate;
KIRP	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.59	6.49	0.38	4.81e-10	DNA methylation (variation);
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.66	9.68	0.53	5.39e-19	Menarche (age at onset);
KIRP	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.77e-10	Protein C levels;
KIRP	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg21605333	chr4:119757512	SEC24D	1.13	8.43	0.47	3.01e-15	Cannabis dependence symptom count;
KIRP	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.54	-6.87	-0.4	5.13e-11	White blood cell count;
KIRP	cis	rs882300	0.967	rs2322864	chr2:136963072	C/T	cg05194412	chr2:137003533	NA	-0.41	-5.51	-0.33	9.25e-8	Multiple sclerosis;Electrocardiographic traits;
KIRP	trans	rs2998286	0.784	rs998362	chr10:28817058	A/G	cg10174683	chr16:85619974	NA	-0.65	-6.04	-0.36	5.52e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs10421328	0.821	rs10423311	chr19:19757262	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	5.37	0.32	1.81e-7	Parental longevity (combined parental age at death);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12229597	chr3:135914755	MSL2	-0.52	-6.47	-0.38	5.28e-10	Myopia;
KIRP	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg05998816	chr21:47859926	PCNT	0.57	6.14	0.36	3.21e-9	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17287725	chr19:12267592	ZNF625	0.52	6.81	0.4	7.45e-11	Parkinson's disease;
KIRP	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.55	0.43	8.28e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.52	0.38	3.97e-10	Breast cancer;
KIRP	cis	rs11645898	0.935	rs11647125	chr16:72243277	T/C	cg14768367	chr16:72042858	DHODH	-0.9	-9.78	-0.53	2.76e-19	Blood protein levels;
KIRP	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8077577	0.945	rs34474249	chr17:18074525	T/C	cg18869244	chr17:18121946	NA	0.49	5.54	0.33	7.58e-8	Obesity-related traits;
KIRP	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.61	8.36	0.47	4.64e-15	Schizophrenia;
KIRP	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg21226059	chr5:178986404	RUFY1	0.42	6.61	0.39	2.39e-10	Lung cancer;
KIRP	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg19468946	chr17:37922297	IKZF3	-0.36	-5.03	-0.31	9.35e-7	Asthma;
KIRP	cis	rs6973256	0.897	rs10231828	chr7:133348337	T/G	cg10665199	chr7:133106180	EXOC4	-0.5	-6.3	-0.37	1.36e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-5.42	-0.33	1.39e-7	Triglycerides;
KIRP	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg13939156	chr17:80058883	NA	0.51	5.97	0.36	8.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg06521331	chr12:34319734	NA	-0.57	-6.99	-0.41	2.52e-11	Heart rate;
KIRP	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg07001201	chr5:642380	CEP72	0.7	6.58	0.39	2.86e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9392653	1.000	rs13340416	chr6:5071438	T/G	cg13207534	chr6:5087447	PPP1R3G	-0.4	-4.97	-0.3	1.26e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg07541023	chr7:19748670	TWISTNB	0.61	5.47	0.33	1.1e-7	Thyroid stimulating hormone;
KIRP	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.81	11.18	0.58	9.58e-24	Breast cancer;
KIRP	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.75	11.86	0.6	5.94e-26	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg23587288	chr2:27483067	SLC30A3	-0.66	-7.5	-0.43	1.19e-12	Blood metabolite levels;
KIRP	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.62	6.31	0.37	1.31e-9	Gut microbiome composition (summer);
KIRP	trans	rs587242	1.000	rs10489740	chr1:96919182	G/A	cg10631902	chr5:14652156	NA	0.53	6.18	0.37	2.66e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-0.94	-12.82	-0.63	3.82e-29	Platelet distribution width;
KIRP	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.72	9.69	0.53	5.15e-19	Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.2	-0.72	1.12e-40	Height;
KIRP	cis	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg06521331	chr12:34319734	NA	-0.5	-6.08	-0.36	4.47e-9	Morning vs. evening chronotype;
KIRP	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg00206168	chr11:65308501	LTBP3	0.85	5.05	0.31	8.49e-7	Height;
KIRP	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	1.05	18.54	0.76	1.3e-48	Bone mineral density;
KIRP	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg22563815	chr15:78856949	CHRNA5	-0.44	-6.99	-0.41	2.56e-11	Sudden cardiac arrest;
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.73e-9	Life satisfaction;
KIRP	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	cis	rs3134353	0.704	rs2386922	chr8:101975479	A/C	cg07585502	chr8:101912084	NA	0.44	5.69	0.34	3.64e-8	Body mass index;
KIRP	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.71	9.07	0.5	3.86e-17	Coronary artery disease;
KIRP	cis	rs6800768	0.633	rs826373	chr3:24163773	C/G	cg10674438	chr3:24145617	LOC152024	-0.47	-6.2	-0.37	2.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.4	-4.96	-0.3	1.32e-6	Blood protein levels;
KIRP	cis	rs17095355	1.000	rs958086	chr10:111752548	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.44	-0.33	1.27e-7	Biliary atresia;
KIRP	cis	rs9596863	0.950	rs7334923	chr13:54394765	G/T	ch.13.53330881F	chr13:54432880	NA	0.62	6.2	0.37	2.43e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg03929089	chr4:120376271	NA	0.91	6.67	0.39	1.69e-10	Intraocular pressure;
KIRP	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	5.4	0.33	1.55e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.34e-13	Neuroticism;
KIRP	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.89	-10.64	-0.56	5.27e-22	White matter hyperintensity burden;
KIRP	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg26207909	chr14:103986467	CKB	-0.44	-5.39	-0.32	1.65e-7	Coronary artery disease;
KIRP	cis	rs5850	0.602	rs1005786	chr7:23145837	G/C	cg23682824	chr7:23144976	KLHL7	0.42	5.07	0.31	7.76e-7	Blood protein levels;
KIRP	cis	rs7127900	1.000	rs11043133	chr11:2232665	G/A	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs4789452	1.000	rs34596832	chr17:75373170	C/T	cg12985929	chr17:75370611	SEPT9	-0.4	-5.58	-0.34	6.4e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.71	8.87	0.49	1.51e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg22676075	chr6:135203613	NA	0.48	6.34	0.37	1.1e-9	Red blood cell count;
KIRP	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg05347473	chr6:146136440	FBXO30	0.46	6.55	0.39	3.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg11846333	chr4:119757529	SEC24D	1.16	7.08	0.41	1.49e-11	Cannabis dependence symptom count;
KIRP	cis	rs4148660	0.727	rs2292772	chr12:22045771	T/C	cg14669847	chr12:22099120	NA	-0.36	-5.91	-0.35	1.12e-8	Gout;
KIRP	cis	rs6499755	0.712	rs31106	chr16:55376359	T/A	cg05099576	chr16:55362342	IRX6	0.27	5.62	0.34	5.11e-8	Hypospadias;
KIRP	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-8.96	-0.5	8.41e-17	Platelet count;
KIRP	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg19468946	chr17:37922297	IKZF3	0.44	6.25	0.37	1.8e-9	Self-reported allergy;
KIRP	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.1	-0.46	2.6e-14	Neuroticism;
KIRP	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg09640425	chr7:158790006	NA	0.4	4.88	0.3	1.9e-6	Facial morphology (factor 20);
KIRP	cis	rs62413470	0.872	rs62404898	chr6:55963825	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.64	6.42	0.38	6.89e-10	Gastritis;
KIRP	cis	rs6993770	0.628	rs6988664	chr8:106513301	C/T	cg12797828	chr8:106520928	ZFPM2	0.33	4.85	0.3	2.21e-6	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
KIRP	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05601917	chr6:125855416	NA	-0.33	-5.07	-0.31	8.01e-7	Brugada syndrome;
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg06871246	chr4:1363661	KIAA1530	0.48	6.04	0.36	5.71e-9	Obesity-related traits;
KIRP	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.65	8.78	0.49	2.89e-16	Multiple sclerosis;
KIRP	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-5.01	-0.3	1.04e-6	Bipolar disorder;
KIRP	cis	rs6516091	0.850	rs75701968	chr20:6049985	C/T	cg25325723	chr20:6104886	FERMT1	-0.64	-6.41	-0.38	7.27e-10	Abdominal aortic aneurysm;
KIRP	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.74e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg10144569	chr3:42726640	KBTBD5	0.5	5.6	0.34	5.8e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6594713	0.605	rs72792189	chr5:112814965	A/G	cg12552261	chr5:112820674	MCC	0.61	5.52	0.33	8.6e-8	Brain cytoarchitecture;
KIRP	cis	rs8067287	0.749	rs62065421	chr17:16827887	T/C	cg26910001	chr17:16838321	NA	-0.61	-5.9	-0.35	1.18e-8	Diabetic kidney disease;
KIRP	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg08717414	chr16:71523259	ZNF19	-0.45	-5.08	-0.31	7.59e-7	Post bronchodilator FEV1;
KIRP	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg20583945	chr8:144636462	GSDMD	0.43	5.09	0.31	7.23e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	trans	rs7939886	0.920	rs57873399	chr11:56059112	T/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.82	8.93	0.49	1.02e-16	Exhaled nitric oxide output;
KIRP	cis	rs9815354	1.000	rs28733681	chr3:41863444	C/A	cg03022575	chr3:42003672	ULK4	0.6	6.9	0.4	4.36e-11	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02267795	chr22:24989065	GGT1;C22orf36	-0.42	-6.07	-0.36	4.81e-9	Metabolic traits;
KIRP	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg23920097	chr1:209922102	NA	0.44	5.3	0.32	2.59e-7	Red blood cell count;
KIRP	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.6	-7.67	-0.44	4.03e-13	Cocaine dependence;
KIRP	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg05347473	chr6:146136440	FBXO30	-0.59	-8.43	-0.47	2.95e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.62	8.09	0.46	2.8e-14	Alcohol dependence;
KIRP	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.85	-0.35	1.56e-8	Pulmonary function;
KIRP	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-4.98	-0.3	1.21e-6	Smoking behavior;
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.83	0.63	3.31e-29	Platelet count;
KIRP	cis	rs4762326	0.584	rs7957257	chr12:95658769	A/T	cg07737802	chr12:95537812	FGD6	0.39	5.21	0.32	3.96e-7	Endometriosis;
KIRP	cis	rs8060686	0.920	rs60769312	chr16:67732186	C/T	cg04539111	chr16:67997858	SLC12A4	-0.59	-5.81	-0.35	1.88e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg26384229	chr12:38710491	ALG10B	0.61	7.97	0.45	5.89e-14	Bladder cancer;
KIRP	cis	rs1629083	0.967	rs12364013	chr11:118119575	C/T	cg18857871	chr11:118064634	AMICA1	0.63	8.52	0.48	1.65e-15	Lung cancer;
KIRP	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-1.07	-17.66	-0.75	1.27e-45	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12559670	chr7:1610220	PSMG3;KIAA1908	0.48	6.24	0.37	1.88e-9	Parkinson's disease;
KIRP	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg11584989	chr19:19387371	SF4	-0.4	-5.16	-0.31	5.07e-7	Tonsillectomy;
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.9	-13.72	-0.66	3.34e-32	Height;
KIRP	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-7.26	-0.42	5.03e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.46	5.2	0.31	4.15e-7	Schizophrenia;
KIRP	cis	rs1318772	1.000	rs182988	chr5:112813566	T/A	cg12552261	chr5:112820674	MCC	-0.81	-6.39	-0.38	8.38e-10	F-cell distribution;
KIRP	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.45	5.68	0.34	3.79e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg21951975	chr1:209979733	IRF6	0.39	4.92	0.3	1.55e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	0.77	10.7	0.56	3.56e-22	Prudent dietary pattern;
KIRP	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg04310649	chr10:35416472	CREM	-0.54	-6.18	-0.37	2.68e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.63	-8.28	-0.47	7.74e-15	Prudent dietary pattern;
KIRP	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg05315796	chr3:52349193	DNAH1	0.39	6.35	0.38	1.02e-9	Bipolar disorder;
KIRP	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	7.64	0.44	4.79e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg07537917	chr2:241836409	C2orf54	-0.32	-6.56	-0.39	3.21e-10	Urinary metabolites;
KIRP	cis	rs55788414	0.932	rs35066366	chr16:81185280	G/A	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.32	-0.47	5.89e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	trans	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg24644049	chr4:85504048	CDS1	0.96	6.32	0.37	1.19e-9	Skin colour saturation;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03407747	chr17:6899364	ALOX12	0.28	5.1	0.31	6.66e-7	Tonsillectomy;
KIRP	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg07884673	chr3:53033167	SFMBT1	0.81	6.38	0.38	8.86e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3818717	0.507	rs12940675	chr17:17651214	C/T	cg04398451	chr17:18023971	MYO15A	0.43	5.45	0.33	1.24e-7	Lymphocyte counts;
KIRP	cis	rs8179	0.645	rs42046	chr7:92252203	C/G	cg15732164	chr7:92237376	CDK6	-0.51	-6.29	-0.37	1.46e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.39	9.44	0.52	2.95e-18	Corneal astigmatism;
KIRP	cis	rs2625529	0.824	rs7183749	chr15:72377278	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.96	-0.36	8.53e-9	Red blood cell count;
KIRP	cis	rs2380220	0.574	rs9400526	chr6:95998441	T/C	cg15832292	chr6:96025679	MANEA	0.71	6.8	0.4	7.88e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs11955398	0.716	rs1870014	chr5:60000470	T/C	cg02684056	chr5:59996105	DEPDC1B	0.4	4.86	0.3	2.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.11	-0.36	3.94e-9	Obesity-related traits;
KIRP	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.42	4.9	0.3	1.71e-6	Refractive astigmatism;
KIRP	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01820584	chr4:52735830	DCUN1D4	0.39	6.35	0.38	1.03e-9	C-reactive protein;
KIRP	cis	rs2223471	0.692	rs9357674	chr6:50779740	A/G	cg03432817	chr6:50765336	NA	-0.43	-6.62	-0.39	2.28e-10	Subcutaneous adipose tissue;
KIRP	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.48	-5.02	-0.3	1.02e-6	Platelet distribution width;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.68	-4.86	-0.3	2.1e-6	Facial emotion recognition (sad faces);
KIRP	cis	rs2464469	0.618	rs8024164	chr15:58205900	A/G	cg12031962	chr15:58353849	ALDH1A2	0.36	5.0	0.3	1.08e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
KIRP	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg01304814	chr3:48885189	PRKAR2A	0.56	5.16	0.31	4.98e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9311676	0.609	rs6770113	chr3:58379297	C/A	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs9913711	1.000	rs9913711	chr17:70098161	C/G	cg09344028	chr17:70110421	NA	0.4	8.12	0.46	2.31e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18252515	chr7:66147081	NA	-0.44	-4.95	-0.3	1.37e-6	Aortic root size;
KIRP	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg12315302	chr6:26189340	HIST1H4D	0.87	5.6	0.34	5.61e-8	Lung cancer in ever smokers;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.77	12.25	0.62	2.97e-27	Menarche (age at onset);
KIRP	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.15	0.69	4.56e-37	Metabolic syndrome;
KIRP	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.58	-7.78	-0.44	1.95e-13	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25618513	chr4:153456716	FBXW7	0.55	7.32	0.42	3.51e-12	Parkinson's disease;
KIRP	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.47	-6.08	-0.36	4.53e-9	Body mass index;
KIRP	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg03808351	chr9:123631620	PHF19	0.38	5.35	0.32	2.04e-7	Rheumatoid arthritis;
KIRP	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg21775007	chr8:11205619	TDH	-0.44	-5.8	-0.35	2.03e-8	Neuroticism;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg01097406	chr16:89675127	NA	-0.32	-5.32	-0.32	2.38e-7	Vitiligo;
KIRP	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg05370193	chr1:21551575	ECE1	-0.36	-4.93	-0.3	1.49e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	5.49	0.33	1.01e-7	Platelet count;
KIRP	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.54	5.96	0.36	8.81e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4663866	1.000	rs6741269	chr2:239179418	A/G	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs4702718	0.549	rs267951	chr5:10743420	C/T	cg14521931	chr5:10832172	NA	-0.45	-5.98	-0.36	7.86e-9	Obesity-related traits;
KIRP	cis	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg06521331	chr12:34319734	NA	-0.56	-6.87	-0.4	5.14e-11	Morning vs. evening chronotype;
KIRP	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.19	-16.17	-0.72	1.46e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs10782582	0.758	rs12087636	chr1:76376846	T/C	cg10523679	chr1:76189770	ACADM	-0.36	-5.12	-0.31	6.27e-7	Daytime sleep phenotypes;
KIRP	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-6.96	-0.41	3.07e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.59	-0.39	2.66e-10	Neuroticism;
KIRP	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg21395723	chr22:39101663	GTPBP1	0.45	5.47	0.33	1.08e-7	Menopause (age at onset);
KIRP	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg26338869	chr17:61819248	STRADA	0.49	5.48	0.33	1.03e-7	Prudent dietary pattern;
KIRP	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.65	-9.87	-0.53	1.39e-19	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg22325292	chr17:80708367	FN3K	0.37	4.97	0.3	1.25e-6	Glycated hemoglobin levels;
KIRP	cis	rs7770227	0.868	rs7767354	chr6:114698877	A/G	cg18406000	chr6:114650610	NA	-0.42	-5.49	-0.33	1.02e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03482339	chr8:38088883	DDHD2	0.43	6.07	0.36	4.78e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.33	8.7	0.49	4.75e-16	Crohn's disease;
KIRP	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.72	7.45	0.43	1.55e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.7	-9.51	-0.52	1.86e-18	Waist circumference;Body mass index;
KIRP	cis	rs4728302	0.607	rs7776858	chr7:133583144	T/C	cg10665199	chr7:133106180	EXOC4	0.42	4.88	0.3	1.87e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg06064525	chr11:970664	AP2A2	-0.38	-7.92	-0.45	8.12e-14	Alzheimer's disease (late onset);
KIRP	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg17470449	chr10:769945	NA	0.7	6.87	0.4	5.09e-11	Uric acid levels;
KIRP	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs12643440	0.538	rs970428	chr4:17136795	C/A	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg06671706	chr8:8559999	CLDN23	0.57	6.85	0.4	5.76e-11	Obesity-related traits;
KIRP	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18252515	chr7:66147081	NA	0.44	5.17	0.31	4.84e-7	Aortic root size;
KIRP	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.8	-11.62	-0.6	3.58e-25	Systemic lupus erythematosus;
KIRP	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.51	7.5	0.43	1.13e-12	Lewy body disease;
KIRP	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg15660573	chr17:549704	VPS53	0.93	15.02	0.69	1.23e-36	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.72	10.42	0.55	2.73e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23161317	chr6:28129485	ZNF389	-0.43	-5.06	-0.31	8.4e-7	Depression;
KIRP	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.55	-6.61	-0.39	2.33e-10	Mosquito bite size;
KIRP	cis	rs7709377	0.595	rs1382344	chr5:115616350	G/A	cg23108291	chr5:115420582	COMMD10	0.43	5.19	0.31	4.3e-7	Metabolite levels  (X-11787);
KIRP	cis	rs4132509	0.553	rs12140414	chr1:243674387	A/G	cg21452805	chr1:244014465	NA	0.57	5.79	0.35	2.12e-8	RR interval (heart rate);
KIRP	cis	rs7624766	0.555	rs972909	chr3:160509506	C/T	cg22637730	chr3:160473554	PPM1L	0.44	5.52	0.33	8.38e-8	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs10789491	0.565	rs2897107	chr1:47206178	A/T	cg15501359	chr1:47185051	KIAA0494	1.1	12.08	0.61	1.13e-26	Response to hepatitis C treatment;
KIRP	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg26784012	chr10:32216390	ARHGAP12	0.32	5.1	0.31	6.74e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg14972814	chr11:95582409	MTMR2	0.34	5.88	0.35	1.33e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.98	13.63	0.66	6.91e-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg12861170	chr19:19639553	YJEFN3	-0.45	-4.87	-0.3	2.02e-6	Bipolar disorder;
KIRP	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg04731861	chr2:219085781	ARPC2	-0.22	-5.3	-0.32	2.6e-7	Colorectal cancer;
KIRP	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12667521	chr19:29218732	NA	0.77	6.92	0.4	3.9e-11	Methadone dose in opioid dependence;
KIRP	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg27205649	chr11:78285834	NARS2	-0.67	-7.7	-0.44	3.25e-13	Alzheimer's disease (survival time);
KIRP	trans	rs4853036	0.903	rs13021969	chr2:70117602	T/C	cg14915290	chr13:42017708	OR7E37P	-0.49	-6.3	-0.37	1.35e-9	Colorectal or endometrial cancer;
KIRP	cis	rs6430538	0.671	rs6716734	chr2:135561141	T/C	cg12500956	chr2:135428796	TMEM163	0.42	5.28	0.32	2.87e-7	Parkinson's disease;
KIRP	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.83	-7.8	-0.45	1.75e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg06871246	chr4:1363661	KIAA1530	-0.51	-6.43	-0.38	6.76e-10	Longevity;
KIRP	cis	rs7916697	0.947	rs4745950	chr10:69996455	A/G	cg06988349	chr10:69991859	ATOH7	-0.42	-5.6	-0.34	5.7e-8	Optic disc area;
KIRP	cis	rs17095355	1.000	rs12570423	chr10:111690942	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.92	-0.35	1.08e-8	Biliary atresia;
KIRP	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	8.13	0.46	2.12e-14	Coronary artery disease;
KIRP	cis	rs11625487	0.645	rs8006951	chr14:77965304	G/A	cg20045696	chr14:77926864	AHSA1	0.55	5.61	0.34	5.56e-8	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	10.46	0.55	2.06e-21	Menopause (age at onset);
KIRP	cis	rs17095355	1.000	rs72828245	chr10:111746596	G/T	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.05	-0.36	5.3e-9	Biliary atresia;
KIRP	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.74e-15	Calcium levels;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg25457927	chr22:38595422	NA	-0.31	-6.18	-0.37	2.59e-9	Breast cancer;
KIRP	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.58	-8.54	-0.48	1.38e-15	Blood metabolite levels;
KIRP	cis	rs754423	0.515	rs8005920	chr14:52560934	C/T	cg10149976	chr14:52535953	NID2	-0.34	-4.87	-0.3	1.99e-6	Craniofacial microsomia;
KIRP	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.1	-0.36	4.15e-9	IgG glycosylation;
KIRP	cis	rs748404	0.697	rs531910	chr15:43560607	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.53	0.38	3.79e-10	Lung cancer;
KIRP	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25701781	chr10:74033558	DDIT4	0.51	6.42	0.38	6.88e-10	Parkinson's disease;
KIRP	cis	rs9394841	0.667	rs9367112	chr6:41769920	T/C	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg19338460	chr6:170058176	WDR27	-0.64	-7.54	-0.43	8.91e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg20744362	chr22:50050164	C22orf34	0.31	4.88	0.3	1.91e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg10755058	chr3:40428713	ENTPD3	0.37	5.12	0.31	6.03e-7	Renal cell carcinoma;
KIRP	cis	rs7572263	0.959	rs6725512	chr2:209050418	A/G	cg23998903	chr2:209048830	C2orf80	-0.31	-5.39	-0.32	1.68e-7	Glioma;Non-glioblastoma glioma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20900203	chr3:65748129	MAGI1	0.49	6.57	0.39	2.96e-10	Interleukin-4 levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03539313	chr3:158541027	MFSD1	-0.4	-6.44	-0.38	6.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.58	-7.07	-0.41	1.6e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.65	6.91	0.4	4.03e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4664304	0.772	rs10183731	chr2:160740989	A/G	cg03641300	chr2:160917029	PLA2R1	0.41	6.21	0.37	2.22e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.41e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.1	0.46	2.5e-14	Lung cancer;
KIRP	cis	rs6088813	0.744	rs1210224	chr20:33980860	T/C	cg14752227	chr20:34000481	UQCC	-0.47	-5.29	-0.32	2.73e-7	Height;
KIRP	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.02	-0.46	4.43e-14	Mean corpuscular volume;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14588259	chr20:50702859	ZFP64	-0.49	-6.52	-0.38	4.03e-10	Inflammatory biomarkers;
KIRP	cis	rs155346	0.947	rs265160	chr5:139390914	A/C	cg01090482	chr5:139365336	NRG2	-0.38	-4.88	-0.3	1.94e-6	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs10832963	0.626	rs4757674	chr11:18619119	T/C	cg20219074	chr11:18656078	SPTY2D1	0.57	7.55	0.43	8.43e-13	Breast cancer;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.52	6.91	0.4	4.13e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.75	-9.63	-0.52	7.74e-19	Aortic root size;
KIRP	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.4	-6.24	-0.37	1.9e-9	Body mass index;
KIRP	trans	rs1106684	1.000	rs58133574	chr7:131461201	A/G	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg04025307	chr7:1156635	C7orf50	0.51	5.35	0.32	2e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg24579218	chr15:68104479	NA	-0.59	-9.61	-0.52	9.34e-19	Restless legs syndrome;
KIRP	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.44	0.38	6.12e-10	Recombination measurement;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20144521	chr1:2237543	SKI	0.47	6.18	0.37	2.6e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.76	10.78	0.57	1.9e-22	Menarche (age at onset);
KIRP	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg21605333	chr4:119757512	SEC24D	1.47	9.89	0.53	1.26e-19	Cannabis dependence symptom count;
KIRP	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	trans	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg26043149	chr18:55253948	FECH	0.49	6.26	0.37	1.69e-9	Bone mineral density;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.77	-7.76	-0.44	2.34e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.54	6.99	0.41	2.65e-11	Calcium levels;
KIRP	cis	rs78487399	0.908	rs57066469	chr2:43843813	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.51	-0.33	9.24e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.87	14.03	0.67	3.05e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7870753	0.838	rs10991379	chr9:99261204	T/C	cg25260653	chr9:99212216	HABP4	0.51	4.86	0.3	2.06e-6	Height;
KIRP	cis	rs7712401	0.601	rs35699701	chr5:122333756	G/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.46	-6.23	-0.37	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6484504	0.652	rs494464	chr11:31386150	C/T	cg26647111	chr11:31128758	NA	0.44	5.09	0.31	7.17e-7	Red blood cell count;
KIRP	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.63	7.87	0.45	1.13e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.68	9.68	0.53	5.62e-19	Heart rate;
KIRP	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-32.13	-0.9	5.1e-90	Myeloid white cell count;
KIRP	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg23950597	chr19:37808831	NA	-0.64	-6.86	-0.4	5.43e-11	Coronary artery calcification;
KIRP	cis	rs6504950	0.760	rs7214573	chr17:53006654	T/C	cg26251398	chr17:52985966	TOM1L1	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.54	8.07	0.46	3.2e-14	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.09	0.5	3.34e-17	Menopause (age at onset);
KIRP	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg15605315	chr1:45957053	TESK2	0.41	5.17	0.31	4.8e-7	High light scatter reticulocyte count;
KIRP	cis	rs2437772	0.521	rs2250070	chr8:97519421	C/A	cg10292139	chr8:97507561	SDC2	-0.42	-5.52	-0.33	8.66e-8	Post-traumatic stress disorder;
KIRP	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21800906	chr11:32914818	QSER1	0.58	6.82	0.4	7.08e-11	Smoking initiation;
KIRP	cis	rs4523957	0.928	rs7406247	chr17:2157925	G/A	cg16513277	chr17:2031491	SMG6	0.58	8.01	0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg25772418	chr12:131519998	GPR133	-0.38	-5.27	-0.32	2.96e-7	Longevity;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg09597638	chr17:3907349	NA	0.74	14.17	0.67	9.7e-34	Type 2 diabetes;
KIRP	cis	rs72820985	1.000	rs34638446	chr16:80844129	C/T	cg04448709	chr16:81349954	GAN	-0.52	-5.26	-0.32	3.12e-7	Breast cancer;
KIRP	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg23594656	chr7:65796392	TPST1	0.39	5.89	0.35	1.26e-8	Aortic root size;
KIRP	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg12591125	chr7:1885375	MAD1L1	-0.61	-5.84	-0.35	1.6e-8	Bipolar disorder;
KIRP	cis	rs6725041	0.627	rs17416799	chr2:213049435	A/G	cg20637307	chr2:213403960	ERBB4	-0.41	-5.37	-0.32	1.81e-7	QT interval (ambient particulate matter interaction);
KIRP	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-8.65	-0.48	6.93e-16	Colorectal cancer;
KIRP	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg07701084	chr6:150067640	NUP43	0.68	8.35	0.47	5.09e-15	Lung cancer;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg21523564	chr15:75251491	NA	0.39	6.34	0.37	1.11e-9	Breast cancer;
KIRP	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.95	14.49	0.68	8.29e-35	Personality dimensions;
KIRP	cis	rs28489187	0.706	rs233119	chr1:85788052	T/C	cg16011679	chr1:85725395	C1orf52	0.5	6.22	0.37	2.1e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.09	-0.41	1.39e-11	Bladder cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04714926	chr4:32135861	NA	-0.4	-6.29	-0.37	1.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg15133208	chr4:90757351	SNCA	0.38	4.96	0.3	1.35e-6	Neuroticism;
KIRP	cis	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg03342759	chr3:160939853	NMD3	0.43	5.15	0.31	5.31e-7	Morning vs. evening chronotype;
KIRP	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg11906718	chr8:101322791	RNF19A	-0.65	-8.25	-0.47	9.48e-15	Atrioventricular conduction;
KIRP	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg04398451	chr17:18023971	MYO15A	-0.65	-8.69	-0.48	5.33e-16	Total body bone mineral density;
KIRP	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg21640587	chr11:117668038	DSCAML1	0.45	6.76	0.4	1.01e-10	Myopia;
KIRP	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21454925	chr18:8784363	KIAA0802	-0.53	-6.58	-0.39	2.76e-10	Parkinson's disease;
KIRP	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg00800038	chr16:89945340	TCF25	-0.79	-5.46	-0.33	1.14e-7	Skin colour saturation;
KIRP	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.44	-5.27	-0.32	2.93e-7	Neurofibrillary tangles;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22253541	chr12:65385603	NA	0.44	6.3	0.37	1.38e-9	Interleukin-4 levels;
KIRP	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	ch.8.33884649F	chr8:33765107	NA	0.56	6.78	0.4	8.81e-11	Body mass index;
KIRP	cis	rs494562	0.667	rs643591	chr6:86103556	A/G	cg21730993	chr6:86159210	NT5E	0.49	5.17	0.31	4.75e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	17.22	0.74	3.75e-44	Platelet count;
KIRP	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.9	-0.49	1.21e-16	Height;
KIRP	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg01119278	chr6:110721349	DDO	-0.46	-7.17	-0.42	8.65e-12	Platelet distribution width;
KIRP	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18364779	chr6:26104403	HIST1H4C	-0.6	-7.91	-0.45	8.68e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1816752	0.819	rs1981276	chr13:24983499	C/A	cg02811702	chr13:24901961	NA	0.38	4.89	0.3	1.79e-6	Obesity-related traits;
KIRP	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg20295408	chr7:1910781	MAD1L1	-0.6	-7.0	-0.41	2.38e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg26207909	chr14:103986467	CKB	-0.48	-6.03	-0.36	5.88e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6939532	0.522	rs6933583	chr6:26355283	A/C	cg14345882	chr6:26364793	BTN3A2	0.32	5.02	0.31	9.76e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.3	-5.75	-0.34	2.7e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg25628740	chr1:11866499	CLCN6;MTHFR	-0.47	-6.29	-0.37	1.47e-9	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.97	-14.99	-0.69	1.54e-36	Height;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg12059226	chr2:152955749	CACNB4	0.47	6.03	0.36	6.05e-9	Colorectal cancer;
KIRP	cis	rs2281558	0.917	rs3787080	chr20:25232604	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	5.19	0.31	4.37e-7	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
KIRP	cis	rs10203711	0.933	rs11883643	chr2:239586885	A/G	cg14580085	chr2:239553406	NA	0.39	5.0	0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21016266	chr12:122356598	WDR66	0.66	9.02	0.5	5.55e-17	Mean corpuscular volume;
KIRP	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.52	-6.71	-0.39	1.33e-10	Body mass index;
KIRP	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg14673194	chr17:80132900	CCDC57	-0.74	-8.02	-0.46	4.22e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg15556689	chr8:8085844	FLJ10661	0.61	7.51	0.43	1.1e-12	Neuroticism;
KIRP	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.84	12.32	0.62	1.78e-27	Colorectal cancer;
KIRP	cis	rs4654899	0.772	rs61778530	chr1:21087363	G/C	cg05370193	chr1:21551575	ECE1	0.45	5.92	0.35	1.05e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.38	-4.89	-0.3	1.83e-6	Leprosy;
KIRP	cis	rs4356932	1.000	rs10856875	chr4:76987167	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs6594713	0.717	rs17331844	chr5:112914426	G/T	cg12552261	chr5:112820674	MCC	0.54	5.3	0.32	2.63e-7	Brain cytoarchitecture;
KIRP	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg05484376	chr2:27715224	FNDC4	0.33	5.37	0.32	1.78e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs7119038	0.509	rs10892260	chr11:118583525	A/C	cg19308663	chr11:118741387	NA	0.44	6.81	0.4	7.6e-11	Sjögren's syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26695837	chr4:37688098	RELL1	0.48	6.14	0.36	3.28e-9	Parkinson's disease;
KIRP	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg12046867	chr14:103022105	NA	0.54	6.22	0.37	2.07e-9	Platelet count;
KIRP	cis	rs9596863	0.898	rs9568905	chr13:54330289	G/A	ch.13.53330881F	chr13:54432880	NA	0.6	5.79	0.35	2.16e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg26752003	chr8:145688521	CYHR1	-0.69	-8.38	-0.47	4.03e-15	Age at first birth;
KIRP	cis	rs7680126	0.596	rs714436	chr4:10314667	A/C	cg20640774	chr4:10143053	NA	0.51	5.18	0.31	4.69e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00777555	chr3:57583074	ARF4	0.62	7.41	0.43	2.06e-12	Smoking initiation;
KIRP	cis	rs1656402	0.906	rs6721592	chr2:233438268	A/C	cg03852847	chr2:233439513	NA	-0.59	-6.68	-0.39	1.61e-10	Non-small cell lung cancer (survival);
KIRP	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.7e-7	Neutrophil percentage of white cells;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.71	9.34	0.51	6.14e-18	Longevity;Endometriosis;
KIRP	cis	rs7116495	0.881	rs1939243	chr11:71742735	A/G	cg11196788	chr11:71737549	NUMA1	-0.62	-5.42	-0.33	1.42e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg19784848	chr5:219127	SDHA;CCDC127	-0.46	-4.88	-0.3	1.9e-6	Breast cancer;
KIRP	cis	rs2223471	0.602	rs9369971	chr6:50711883	A/G	cg03432817	chr6:50765336	NA	-0.35	-5.17	-0.31	4.84e-7	Subcutaneous adipose tissue;
KIRP	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg03060546	chr3:49711283	APEH	-0.67	-6.8	-0.4	7.85e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg12756093	chr1:115239321	AMPD1	0.54	7.05	0.41	1.84e-11	Autism;
KIRP	trans	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	7.23	0.42	5.9e-12	Mean corpuscular volume;
KIRP	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs4302748	0.818	rs61387197	chr7:36184016	T/A	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03200734	chr16:67235732	ELMO3	0.47	6.46	0.38	5.62e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.43	-6.07	-0.36	4.83e-9	Coronary artery disease;
KIRP	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg10645314	chr2:3704589	ALLC	0.49	6.29	0.37	1.45e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	0.95	8.19	0.46	1.46e-14	Arsenic metabolism;
KIRP	cis	rs6662572	0.737	rs4474301	chr1:46255272	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.69	-0.34	3.54e-8	Blood protein levels;
KIRP	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.78	-9.49	-0.52	2.03e-18	Response to antipsychotic treatment;
KIRP	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg07952391	chr2:88470173	THNSL2	0.91	7.51	0.43	1.12e-12	Plasma clusterin levels;
KIRP	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	8.28	0.47	7.71e-15	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.69	-10.92	-0.57	6.59e-23	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.69	7.14	0.41	1.02e-11	Lung function (FEV1/FVC);
KIRP	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.87	13.27	0.65	1.15e-30	Height;
KIRP	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.59	7.71	0.44	3.07e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.1	0.36	4.18e-9	Educational attainment;
KIRP	cis	rs11209002	0.524	rs982131	chr1:67542360	T/C	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.95e-22	Gout;Renal underexcretion gout;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg26429732	chr10:134504836	INPP5A	0.42	6.04	0.36	5.79e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs13102973	0.720	rs13129730	chr4:135888329	G/A	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	trans	rs10507349	0.537	rs478752	chr13:26884262	C/A	cg04413680	chr6:71998398	OGFRL1	0.55	6.12	0.36	3.58e-9	Type 2 diabetes;
KIRP	trans	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg16141378	chr3:129829833	LOC729375	0.51	6.45	0.38	5.91e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg06289844	chr6:126071538	HEY2	0.43	6.22	0.37	2.09e-9	Brugada syndrome;
KIRP	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.39	5.14	0.31	5.59e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7084402	0.967	rs7100474	chr10:60273121	T/C	cg05938607	chr10:60274200	BICC1	0.42	10.2	0.55	1.35e-20	Refractive error;
KIRP	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg01872077	chr2:219646372	CYP27A1	-0.43	-5.96	-0.36	8.54e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.77	11.41	0.59	1.69e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg22832135	chr15:78370102	TBC1D2B	0.58	6.28	0.37	1.5e-9	Breast cancer;
KIRP	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg19539972	chr4:7069911	GRPEL1	0.76	9.13	0.5	2.56e-17	Monocyte percentage of white cells;
KIRP	cis	rs7107174	0.901	rs7937277	chr11:78114977	C/G	cg27205649	chr11:78285834	NARS2	-0.58	-6.06	-0.36	4.99e-9	Testicular germ cell tumor;
KIRP	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.52	6.77	0.4	9.28e-11	Schizophrenia;
KIRP	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.57	-9.43	-0.52	3.16e-18	Prostate cancer;
KIRP	cis	rs1125355	0.589	rs62183012	chr2:159607760	T/C	cg02251393	chr2:159651559	DAPL1	0.42	4.94	0.3	1.43e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06451949	chr17:48942959	NA	0.53	6.21	0.37	2.22e-9	Smoking initiation;
KIRP	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.43	-5.74	-0.34	2.78e-8	Body mass index;
KIRP	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg06026331	chr20:60912101	LAMA5	0.41	5.12	0.31	6.16e-7	Colorectal cancer;
KIRP	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg02487422	chr3:49467188	NICN1	0.42	4.96	0.3	1.32e-6	Menarche (age at onset);
KIRP	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.49	-5.92	-0.35	1.06e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00597055	chr15:41523239	CHP;EXD1	-0.46	-6.37	-0.38	9.21e-10	Survival in pancreatic cancer;
KIRP	cis	rs4654899	0.796	rs77366434	chr1:21520069	C/T	cg05370193	chr1:21551575	ECE1	0.48	6.4	0.38	7.72e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.8	-0.6	9.09e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg17724175	chr1:150552817	MCL1	0.32	5.25	0.32	3.3e-7	Melanoma;
KIRP	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg23307798	chr14:103986281	CKB	0.48	6.73	0.39	1.22e-10	Body mass index;
KIRP	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg19016782	chr12:123741754	C12orf65	0.38	4.88	0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	cis	rs34779708	0.931	rs4934719	chr10:35376769	T/C	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2637030	0.559	rs256108	chr5:52874253	C/T	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-6.98	-0.41	2.67e-11	Response to antipsychotic treatment;
KIRP	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	5.14	0.31	5.66e-7	Body mass index;
KIRP	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.83	9.64	0.52	7.53e-19	Neutrophil percentage of white cells;
KIRP	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg03929089	chr4:120376271	NA	0.76	6.75	0.4	1.05e-10	Intraocular pressure;
KIRP	cis	rs4780401	0.610	rs933574	chr16:11792700	A/C	cg01061890	chr16:11836724	TXNDC11	-0.44	-5.07	-0.31	8.02e-7	Rheumatoid arthritis;
KIRP	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg16141378	chr3:129829833	LOC729375	-0.53	-6.47	-0.38	5.21e-10	Neuroticism;
KIRP	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg03465714	chr1:152285911	FLG	0.53	6.09	0.36	4.29e-9	Atopic dermatitis;
KIRP	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.7	8.12	0.46	2.26e-14	Alcohol dependence;
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.28	15.82	0.71	2.27e-39	Platelet count;
KIRP	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.86	13.64	0.66	6.16e-32	Headache;
KIRP	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.62	-0.34	5.06e-8	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg07701084	chr6:150067640	NUP43	0.69	9.77	0.53	2.86e-19	Lung cancer;
KIRP	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg08222618	chr4:941054	TMEM175	-0.55	-7.19	-0.42	7.81e-12	Parkinson's disease;
KIRP	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.7	10.64	0.56	5.42e-22	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs330048	0.545	rs719409	chr8:9151226	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	8.41	0.47	3.29e-15	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg13206674	chr6:150067644	NUP43	0.6	8.56	0.48	1.2e-15	Lung cancer;
KIRP	cis	rs7737355	0.738	rs7710364	chr5:130842724	T/C	cg06307176	chr5:131281290	NA	0.41	4.9	0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05665937	chr4:1216051	CTBP1	0.46	6.37	0.38	9.32e-10	Obesity-related traits;
KIRP	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.49	-5.79	-0.35	2.13e-8	Systolic blood pressure;
KIRP	cis	rs2904967	0.929	rs2904986	chr11:65031221	A/C	cg09225861	chr11:65069680	NA	0.43	5.62	0.34	5.1e-8	Mean corpuscular volume;
KIRP	cis	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.13e-6	Androgen levels;
KIRP	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.64	-10.41	-0.55	2.88e-21	Morning vs. evening chronotype;
KIRP	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg04132472	chr17:19861366	AKAP10	-0.4	-5.2	-0.31	4.17e-7	Schizophrenia;
KIRP	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.59	0.52	1.02e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27620946	chr8:42011116	AP3M2	-0.44	-6.04	-0.36	5.67e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.42	5.9	0.35	1.21e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg01028140	chr2:1542097	TPO	-0.5	-5.63	-0.34	4.86e-8	IgG glycosylation;
KIRP	cis	rs17221829	0.600	rs3881248	chr11:89362196	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	trans	rs6136813	0.597	rs7272480	chr20:19676301	C/A	cg21580998	chr1:227751410	ZNF678	0.67	6.15	0.37	3.13e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.55	0.56	1.06e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7737355	0.738	rs3776011	chr5:130868840	C/T	cg06307176	chr5:131281290	NA	0.42	5.02	0.3	1.01e-6	Life satisfaction;
KIRP	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg23719950	chr11:63933701	MACROD1	-0.66	-6.35	-0.38	1.04e-9	Mean platelet volume;
KIRP	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg16586182	chr3:47516702	SCAP	0.82	11.55	0.59	6.06e-25	Colorectal cancer;
KIRP	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.46	5.46	0.33	1.19e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.9e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg18306943	chr3:40428807	ENTPD3	0.38	5.12	0.31	6.2e-7	Renal cell carcinoma;
KIRP	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.77	9.19	0.51	1.65e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1823913	0.637	rs4853583	chr2:192169374	A/G	cg12404831	chr2:192114017	MYO1B	-0.45	-6.04	-0.36	5.62e-9	Obesity-related traits;
KIRP	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1018836	0.923	rs6999898	chr8:91650549	G/A	cg16814680	chr8:91681699	NA	-0.79	-10.34	-0.55	4.91e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.24	-0.47	1e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs981844	1.000	rs55792703	chr4:154668278	C/A	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.25	6.69	0.39	1.52e-10	Crohn's disease;
KIRP	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.47	-7.72	-0.44	2.92e-13	Height;
KIRP	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.67	0.71	7.75e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27071312	chr5:5422796	KIAA0947	0.51	6.57	0.39	2.94e-10	Parkinson's disease;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg20973743	chr15:49447782	COPS2;GALK2	-0.43	-6.23	-0.37	2.06e-9	Metabolite levels (MHPG);
KIRP	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.19	-0.42	7.96e-12	Bipolar disorder;
KIRP	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.83	11.42	0.59	1.6e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	1.01	12.68	0.63	1.07e-28	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg14972814	chr11:95582409	MTMR2	0.34	5.88	0.35	1.33e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg02390115	chr1:21767211	NBPF3	0.64	8.85	0.49	1.74e-16	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg10189774	chr4:17578691	LAP3	0.48	5.57	0.33	6.77e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg05665937	chr4:1216051	CTBP1	0.43	5.45	0.33	1.24e-7	Obesity-related traits;
KIRP	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.46	-5.89	-0.35	1.27e-8	Retinal vascular caliber;
KIRP	cis	rs612683	0.560	rs491675	chr1:100902936	A/G	cg09408571	chr1:101003634	GPR88	0.26	5.89	0.35	1.27e-8	Breast cancer;
KIRP	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20135002	chr11:47629003	NA	-0.44	-5.03	-0.31	9.56e-7	Subjective well-being;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12780678	chr2:1746846	PXDN	-0.47	-6.15	-0.37	3.17e-9	Interleukin-4 levels;
KIRP	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg12292205	chr6:26970375	C6orf41	0.48	6.96	0.41	3.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.6	-9.1	-0.5	3.19e-17	Breast cancer;
KIRP	cis	rs2729354	0.729	rs2729353	chr11:57248003	C/T	cg24343310	chr11:57249947	NA	0.29	5.55	0.33	7.31e-8	Blood protein levels;
KIRP	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg01689657	chr7:91764605	CYP51A1	0.35	5.22	0.32	3.81e-7	Breast cancer;
KIRP	cis	rs7692976	0.578	rs12640600	chr4:110840748	C/T	cg06981781	chr4:110842888	EGF	-0.25	-5.4	-0.33	1.54e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs6693567	0.826	rs1260387	chr1:150371448	T/C	cg17724175	chr1:150552817	MCL1	-0.37	-5.22	-0.32	3.8e-7	Migraine;
KIRP	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.7	7.75	0.44	2.4e-13	Exhaled nitric oxide output;
KIRP	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.37	-7.42	-0.43	1.86e-12	Arsenic metabolism;
KIRP	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg06204229	chr3:52865917	ITIH4	0.47	5.4	0.33	1.59e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg02591564	chr12:125578355	AACS	-0.5	-5.13	-0.31	5.83e-7	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1699337	0.502	rs796290	chr3:12449683	C/G	cg22839075	chr3:12045461	SYN2	-0.35	-5.05	-0.31	8.68e-7	Cholesterol, total;
KIRP	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg04731861	chr2:219085781	ARPC2	0.28	7.25	0.42	5.45e-12	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.62	-0.44	5.43e-13	Triglycerides;
KIRP	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.78	-0.35	2.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg08126542	chr6:37504118	NA	-0.72	-10.06	-0.54	3.75e-20	Cognitive performance;
KIRP	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.92	11.99	0.61	2.19e-26	Menopause (age at onset);
KIRP	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg25007680	chr1:8021821	PARK7	0.64	8.9	0.49	1.22e-16	Response to antidepressants and depression;
KIRP	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	1.08	15.79	0.71	2.99e-39	Cognitive function;
KIRP	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg09455208	chr3:40491958	NA	0.31	5.76	0.34	2.55e-8	Renal cell carcinoma;
KIRP	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.44	-6.46	-0.38	5.7e-10	Personality dimensions;
KIRP	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg22777020	chr22:31556080	RNF185	-0.51	-5.39	-0.33	1.62e-7	Colorectal cancer;
KIRP	cis	rs2071426	0.959	rs1934955	chr10:96788561	A/G	cg09036531	chr10:96991505	NA	-0.62	-6.74	-0.39	1.13e-10	Blood metabolite levels;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.43	-5.09	-0.31	7.18e-7	Longevity;Endometriosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22753607	chr9:37120306	ZCCHC7	0.58	7.08	0.41	1.49e-11	Smoking initiation;
KIRP	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.18	0.31	4.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.6	-7.37	-0.43	2.59e-12	Monocyte count;
KIRP	cis	rs9649465	0.704	rs665867	chr7:123432329	A/G	cg03229431	chr7:123269106	ASB15	0.39	4.9	0.3	1.71e-6	Migraine;
KIRP	cis	rs8067287	0.749	rs62065426	chr17:16831506	G/C	cg26910001	chr17:16838321	NA	-0.61	-5.83	-0.35	1.75e-8	Diabetic kidney disease;
KIRP	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg11846333	chr4:119757529	SEC24D	1.14	6.64	0.39	2.01e-10	Cannabis dependence symptom count;
KIRP	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg16898833	chr6:26189333	HIST1H4D	0.74	5.3	0.32	2.52e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs977987	1.000	rs977985	chr16:75506947	C/G	cg03315344	chr16:75512273	CHST6	0.76	12.18	0.61	4.99e-27	Dupuytren's disease;
KIRP	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs6738627	0.965	rs2198550	chr2:165556760	A/C	cg03182029	chr2:165697222	COBLL1	0.44	5.59	0.34	5.94e-8	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.42	-5.09	-0.31	7.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.41	-0.33	1.51e-7	Platelet count;
KIRP	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg15880211	chr22:50250494	ZBED4	0.59	5.15	0.31	5.38e-7	Schizophrenia;
KIRP	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.63	7.69	0.44	3.44e-13	Coronary artery disease;
KIRP	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.73	9.91	0.53	1.07e-19	Colorectal cancer;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg07402062	chr16:89894098	SPIRE2	0.3	6.15	0.37	3.05e-9	Vitiligo;
KIRP	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22770592	chr15:63797403	USP3	0.51	6.72	0.39	1.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.85	-0.35	1.58e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	11.8	0.6	9.08e-26	Monocyte count;
KIRP	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg21253087	chr9:139290292	SNAPC4	0.4	5.21	0.32	3.93e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.38	-6.92	-0.4	3.87e-11	Renal cell carcinoma;
KIRP	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg13010199	chr12:38710504	ALG10B	0.55	6.81	0.4	7.42e-11	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-6.82	-0.4	7.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg20302533	chr7:39170763	POU6F2	0.27	5.53	0.33	8.17e-8	IgG glycosylation;
KIRP	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Parkinson's disease;
KIRP	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg07596299	chr11:71824057	C11orf51	0.93	5.7	0.34	3.49e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg00873937	chr10:69991564	ATOH7	0.49	6.2	0.37	2.38e-9	Sleep duration;
KIRP	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.8	7.32	0.42	3.45e-12	Obesity-related traits;
KIRP	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.88	-12.7	-0.63	9.54e-29	Dupuytren's disease;
KIRP	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg13263691	chr18:77568018	NA	0.48	6.73	0.39	1.2e-10	Schizophrenia;
KIRP	cis	rs6959887	0.609	rs2191883	chr7:35273291	A/G	cg06685737	chr7:35301730	NA	0.61	9.88	0.53	1.35e-19	Birth weight;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg09695851	chr17:3907499	NA	0.81	14.65	0.68	2.3e-35	Type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg08888203	chr3:10149979	C3orf24	0.49	5.14	0.31	5.57e-7	Alzheimer's disease;
KIRP	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	1.1	15.58	0.7	1.59e-38	Breast cancer;
KIRP	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg23958373	chr8:599963	NA	1.02	7.8	0.45	1.75e-13	IgG glycosylation;
KIRP	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.9	0.35	1.2e-8	Motion sickness;
KIRP	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.5	7.56	0.43	8.02e-13	Resting heart rate;
KIRP	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.67	7.65	0.44	4.65e-13	Gut microbiome composition (summer);
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.35	0.47	5.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.62	8.16	0.46	1.74e-14	Motion sickness;
KIRP	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.73	10.28	0.55	7.33e-21	Caffeine consumption;
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg21851534	chr17:3907994	ZZEF1	0.66	10.58	0.56	8.25e-22	Type 2 diabetes;
KIRP	cis	rs7119038	0.818	rs57494551	chr11:118661398	C/T	cg19308663	chr11:118741387	NA	0.56	8.73	0.49	3.91e-16	Sjögren's syndrome;
KIRP	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg13271783	chr10:134563150	INPP5A	-0.55	-7.29	-0.42	4.2e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg04398451	chr17:18023971	MYO15A	0.66	8.89	0.49	1.34e-16	Total body bone mineral density;
KIRP	cis	rs4237845	0.591	rs11172388	chr12:58337132	A/T	cg00677455	chr12:58241039	CTDSP2	0.7	7.83	0.45	1.5e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.48	-4.85	-0.3	2.16e-6	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs939574	0.512	rs2276638	chr2:220145286	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.58	6.22	0.37	2.16e-9	Platelet distribution width;
KIRP	cis	rs17023223	0.537	rs10923759	chr1:119692194	A/G	cg05756136	chr1:119680316	WARS2	0.61	8.4	0.47	3.69e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg20243544	chr17:37824526	PNMT	-0.39	-5.39	-0.33	1.63e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.43	5.7	0.34	3.45e-8	Cardiovascular disease risk factors;
KIRP	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.39	-5.14	-0.31	5.65e-7	Total body bone mineral density;
KIRP	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg21226059	chr5:178986404	RUFY1	0.42	6.61	0.39	2.39e-10	Lung cancer;
KIRP	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4979906	1.000	rs4979786	chr10:79444965	T/C	cg07817648	chr10:79422355	NA	-0.45	-4.94	-0.3	1.45e-6	Mortality in heart failure;
KIRP	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.44	-5.34	-0.32	2.16e-7	Testicular germ cell tumor;
KIRP	cis	rs35955841	0.569	rs12437108	chr14:65309550	G/A	cg23373153	chr14:65346875	NA	0.41	5.8	0.35	2.07e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
KIRP	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg00484396	chr16:3507460	NAT15	0.52	6.77	0.4	9.49e-11	Tuberculosis;
KIRP	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg03929089	chr4:120376271	NA	0.74	6.3	0.37	1.37e-9	Axial length;
KIRP	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.96	8.05	0.46	3.49e-14	Body mass index;
KIRP	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.6	0.39	2.56e-10	Renal cell carcinoma;
KIRP	trans	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.1	0.41	1.32e-11	Retinal vascular caliber;
KIRP	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.85	12.57	0.63	2.65e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.78	6.39	0.38	8.26e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg14458575	chr2:238380390	NA	0.46	5.2	0.31	4.17e-7	Prostate cancer;
KIRP	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg02353165	chr6:42928485	GNMT	-0.44	-5.56	-0.33	7.11e-8	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
KIRP	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.53	-7.18	-0.42	8.1e-12	Lung cancer;
KIRP	cis	rs9653442	0.545	rs11681227	chr2:100754997	A/G	cg07810366	chr2:100720526	AFF3	-0.31	-5.1	-0.31	6.82e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs75920871	0.858	rs17120280	chr11:116942132	G/A	cg23684410	chr11:116897558	SIK3	0.55	5.55	0.33	7.51e-8	Subjective well-being;
KIRP	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg21775007	chr8:11205619	TDH	-0.5	-6.44	-0.38	6.32e-10	Neuroticism;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg11204139	chr17:3907470	NA	0.82	15.22	0.7	2.53e-37	Type 2 diabetes;
KIRP	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.62	8.42	0.47	3.22e-15	Morning vs. evening chronotype;
KIRP	cis	rs4356975	0.563	rs4541594	chr4:69972272	A/G	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg02002194	chr4:3960332	NA	-0.42	-6.08	-0.36	4.57e-9	Mood instability;
KIRP	cis	rs300890	0.513	rs7680365	chr4:144078756	C/T	cg01719995	chr4:144104893	USP38	0.43	5.51	0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.82	-0.4	6.86e-11	Joint mobility (Beighton score);
KIRP	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.75	-10.81	-0.57	1.57e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.17e-6	Atopic dermatitis;
KIRP	cis	rs2281558	1.000	rs2281558	chr20:25240189	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	5.19	0.31	4.37e-7	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
KIRP	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.53	7.0	0.41	2.36e-11	Breast cancer;
KIRP	cis	rs2820315	1.000	rs2820316	chr1:201811761	C/T	cg11586189	chr1:201857591	SHISA4	-0.39	-5.49	-0.33	1.01e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs3026101	0.578	rs11209	chr17:5289580	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.48	-6.19	-0.37	2.48e-9	Body mass index;
KIRP	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.19	16.47	0.72	1.38e-41	Mitochondrial DNA levels;
KIRP	cis	rs501120	0.657	rs494207	chr10:44741256	G/A	cg09554077	chr10:44749378	NA	0.78	12.08	0.61	1.08e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.21	21.33	0.81	7.3e-58	Cognitive function;
KIRP	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg05973401	chr12:123451056	ABCB9	0.54	6.1	0.36	4.12e-9	Neutrophil percentage of white cells;
KIRP	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.81	0.71	2.45e-39	Bipolar disorder;
KIRP	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg05552183	chr6:42928497	GNMT	0.56	6.83	0.4	6.7e-11	Blood protein levels;
KIRP	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.59	-6.64	-0.39	2.01e-10	Coronary artery disease;
KIRP	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.2	-0.31	4.29e-7	Bipolar disorder;
KIRP	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.53	7.06	0.41	1.69e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.49	-5.77	-0.35	2.44e-8	Ulcerative colitis;
KIRP	cis	rs11710088	0.931	rs3890113	chr3:149194041	T/G	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.64	-0.34	4.74e-8	QRS duration;
KIRP	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6580649	0.941	rs72644842	chr12:48448274	A/G	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg14673194	chr17:80132900	CCDC57	0.77	8.26	0.47	9.1e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26585352	chr2:58029565	NA	0.4	6.23	0.37	2.04e-9	Migraine with aura;
KIRP	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	cg12689670	chr1:183009347	LAMC1	0.46	6.66	0.39	1.74e-10	Colorectal cancer;
KIRP	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.76	11.53	0.59	6.98e-25	Metabolite levels;
KIRP	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.36	0.42	2.77e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg00319359	chr11:70116639	PPFIA1	0.66	6.41	0.38	7.27e-10	Coronary artery disease;
KIRP	trans	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.77	-0.4	9.14e-11	Obesity-related traits;
KIRP	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg18709589	chr6:96969512	KIAA0776	-0.42	-5.49	-0.33	9.98e-8	Migraine;Coronary artery disease;
KIRP	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.63	-0.39	2.1e-10	Obesity-related traits;
KIRP	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg24315340	chr6:146058215	EPM2A	-0.39	-4.92	-0.3	1.6e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6973256	0.828	rs12707117	chr7:133429058	G/A	cg10665199	chr7:133106180	EXOC4	0.52	6.61	0.39	2.37e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	5.05	0.31	8.67e-7	Childhood ear infection;
KIRP	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg13902645	chr11:5959945	NA	-0.66	-7.34	-0.42	3.07e-12	DNA methylation (variation);
KIRP	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg07884673	chr3:53033167	SFMBT1	1.04	7.93	0.45	7.73e-14	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.65	8.49	0.48	1.92e-15	Alcohol dependence;
KIRP	cis	rs2273669	0.667	rs78550764	chr6:109312239	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-6.27	-0.37	1.64e-9	Prostate cancer;
KIRP	cis	rs10782582	0.758	rs6687882	chr1:76364825	C/A	cg10523679	chr1:76189770	ACADM	-0.34	-5.02	-0.3	9.98e-7	Daytime sleep phenotypes;
KIRP	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg26116260	chr4:7069785	GRPEL1	-0.8	-5.15	-0.31	5.38e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2905347	0.531	rs2961289	chr7:22677755	C/T	cg23521230	chr7:22704884	NA	0.39	4.89	0.3	1.79e-6	Major depression and alcohol dependence;
KIRP	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg07234876	chr8:600039	NA	-0.74	-5.19	-0.31	4.36e-7	IgG glycosylation;
KIRP	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.7	-0.56	3.54e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.8	9.0	0.5	6.31e-17	Corneal astigmatism;
KIRP	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg14993813	chr1:46806288	NSUN4	-0.6	-6.81	-0.4	7.38e-11	Menopause (age at onset);
KIRP	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.53	-7.56	-0.43	7.92e-13	Coronary artery disease;
KIRP	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg17691542	chr6:26056736	HIST1H1C	0.66	8.0	0.45	4.77e-14	Iron status biomarkers;
KIRP	cis	rs35740288	0.770	rs36044792	chr15:86146551	A/G	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg08501292	chr6:25962987	TRIM38	0.92	6.46	0.38	5.68e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9430161	0.611	rs72644043	chr1:11033051	T/A	cg27631724	chr1:11040367	C1orf127	0.45	9.16	0.5	2.08e-17	Ewing sarcoma;
KIRP	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.44	5.61	0.34	5.48e-8	Iron status biomarkers;
KIRP	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg24009623	chr19:33667908	NA	0.46	5.9	0.35	1.18e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	1.05	22.57	0.82	7.3e-62	Breast cancer;
KIRP	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg19847130	chr8:10466454	RP1L1	0.37	5.63	0.34	4.83e-8	Retinal vascular caliber;
KIRP	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg06115741	chr20:33292138	TP53INP2	0.4	5.31	0.32	2.39e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.19e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs787274	1.000	rs7859381	chr9:115546649	C/T	cg13803584	chr9:115635662	SNX30	-0.72	-7.79	-0.44	1.89e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	1.22	7.13	0.41	1.12e-11	LDL cholesterol;
KIRP	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.59	-0.34	6.16e-8	Platelet count;
KIRP	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-1.08	-21.22	-0.8	1.61e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.84	9.57	0.52	1.16e-18	Gut microbiome composition (summer);
KIRP	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.72	-10.14	-0.54	2.02e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.87	0.4	5.11e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs785830	0.717	rs542669	chr9:224367	G/C	cg14500300	chr9:211689	NA	0.51	6.85	0.4	5.8e-11	Platelet distribution width;
KIRP	cis	rs3931020	0.657	rs10890142	chr1:75179129	G/A	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.42	0.33	1.45e-7	Resistin levels;
KIRP	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg21395723	chr22:39101663	GTPBP1	0.41	5.48	0.33	1.07e-7	Menopause (age at onset);
KIRP	cis	rs7719624	0.811	rs13159365	chr5:135389433	C/T	cg16684184	chr5:135415129	NA	-0.34	-4.92	-0.3	1.56e-6	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.21	21.78	0.81	2.54e-59	Cognitive function;
KIRP	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	13.43	0.65	3.27e-31	Platelet count;
KIRP	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.37	-5.28	-0.32	2.79e-7	Plateletcrit;
KIRP	cis	rs10518128	1.000	rs28575371	chr4:75699537	T/G	cg20122727	chr4:75719957	BTC	0.59	5.95	0.35	9.21e-9	Electroencephalogram traits;
KIRP	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg10096100	chr1:26503862	CNKSR1	0.42	5.95	0.35	9.33e-9	Height;
KIRP	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs2071403	0.933	rs11900674	chr2:1406538	G/A	cg07083862	chr2:1417248	TPO	0.36	5.83	0.35	1.77e-8	Thyroid peroxidase antibody positivity;
KIRP	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.53	6.29	0.37	1.41e-9	Blood metabolite levels;
KIRP	cis	rs1957429	0.614	rs73279833	chr14:65352523	A/G	cg23373153	chr14:65346875	NA	-0.67	-5.53	-0.33	8.22e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg00405596	chr8:11794950	NA	-0.51	-6.74	-0.4	1.09e-10	Retinal vascular caliber;
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg05564831	chr3:52568323	NT5DC2	0.35	5.46	0.33	1.18e-7	Electroencephalogram traits;
KIRP	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.85	-9.72	-0.53	4.14e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs7805747	0.523	rs13239239	chr7:151423196	C/T	cg17611936	chr7:151411526	PRKAG2	-0.43	-5.32	-0.32	2.31e-7	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
KIRP	cis	rs2411233	0.967	rs10851376	chr15:39286628	A/G	cg02291532	chr15:39874776	THBS1	-0.41	-5.71	-0.34	3.31e-8	Platelet count;
KIRP	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.42	-6.0	-0.36	6.89e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg21775007	chr8:11205619	TDH	-0.5	-6.48	-0.38	4.92e-10	Triglycerides;
KIRP	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg17143192	chr8:8559678	CLDN23	0.71	8.21	0.46	1.23e-14	Obesity-related traits;
KIRP	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg23307798	chr14:103986281	CKB	0.74	11.23	0.58	6.92e-24	Body mass index;
KIRP	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.82	10.56	0.56	9.83e-22	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21643547	chr1:205240462	TMCC2	-0.82	-13.45	-0.65	2.77e-31	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.96	0.5	8.26e-17	IgG glycosylation;
KIRP	cis	rs7615316	0.934	rs6440094	chr3:142316443	C/T	cg20824294	chr3:142316082	PLS1	0.22	4.86	0.3	2.07e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.68	-0.39	1.56e-10	Lung cancer;
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg16590910	chr6:42928470	GNMT	0.41	5.61	0.34	5.3e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs73198271	0.710	rs11779561	chr8:8679988	G/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.16	-0.42	9.08e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.53	7.22	0.42	6.32e-12	Mean corpuscular volume;
KIRP	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg04935436	chr20:30431758	NA	0.53	6.41	0.38	7.57e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1978968	1.000	rs1076542	chr22:18446452	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	0.6	7.12	0.41	1.18e-11	Presence of antiphospholipid antibodies;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22627950	chr7:44622302	TMED4	0.55	6.52	0.38	3.9e-10	Smoking initiation;
KIRP	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.66	8.07	0.46	3.11e-14	Blood metabolite levels;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg04234412	chr22:24373322	LOC391322	0.6	7.46	0.43	1.48e-12	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg11608241	chr8:8085544	FLJ10661	-0.39	-4.85	-0.3	2.2e-6	Joint mobility (Beighton score);
KIRP	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.25	-0.32	3.26e-7	Longevity;
KIRP	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg21775007	chr8:11205619	TDH	0.44	5.97	0.36	8.15e-9	Neuroticism;
KIRP	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg04362960	chr10:104952993	NT5C2	-0.52	-6.45	-0.38	5.8e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg07862535	chr7:139043722	LUC7L2	0.49	5.51	0.33	9.17e-8	Diisocyanate-induced asthma;
KIRP	cis	rs4776059	0.958	rs35505902	chr15:52888493	A/G	cg25063058	chr15:52860530	ARPP19	0.61	6.67	0.39	1.67e-10	Schizophrenia;
KIRP	cis	rs745080	0.698	rs7155758	chr14:52921541	G/A	cg23333723	chr14:53022898	GPR137C	-0.39	-5.33	-0.32	2.25e-7	Orofacial clefts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15490694	chr10:50747084	ERCC6	0.46	6.21	0.37	2.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs77633900	0.772	rs75253262	chr15:76657124	G/A	cg21673338	chr15:77095150	SCAPER	-0.6	-5.53	-0.33	7.98e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg12131826	chr15:77904385	NA	0.5	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs11138902	0.673	rs13290847	chr9:72112801	C/T	cg14397918	chr9:72078829	APBA1	0.34	5.42	0.33	1.43e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21643547	chr1:205240462	TMCC2	-0.82	-12.71	-0.63	8.37e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.59	-6.1	-0.36	4.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.01	0.61	1.82e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg14784868	chr12:69753453	YEATS4	0.5	5.18	0.31	4.69e-7	Response to diuretic therapy;
KIRP	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg01689657	chr7:91764605	CYP51A1	-0.34	-4.85	-0.3	2.18e-6	Breast cancer;
KIRP	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	0.77	7.07	0.41	1.55e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4566357	1.000	rs6705783	chr2:227923268	C/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs72781680	0.611	rs4149373	chr2:24300023	C/T	cg20701182	chr2:24300061	SF3B14	1.0	10.98	0.57	4.46e-23	Lymphocyte counts;
KIRP	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.67	-9.34	-0.51	6.05e-18	Lung cancer;
KIRP	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg04226714	chr8:49833948	SNAI2	-0.45	-6.21	-0.37	2.29e-9	Life satisfaction;
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg22903657	chr4:1355424	KIAA1530	-0.38	-5.37	-0.32	1.82e-7	Obesity-related traits;
KIRP	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg10223061	chr2:219282414	VIL1	0.34	5.6	0.34	5.84e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13939156	chr17:80058883	NA	0.54	8.66	0.48	6.4e-16	Life satisfaction;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.89	14.49	0.68	8.18e-35	Menarche (age at onset);
KIRP	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	1.11	17.64	0.75	1.44e-45	Homoarginine levels;
KIRP	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg03999872	chr20:62272968	STMN3	0.43	5.07	0.31	7.72e-7	Prostate cancer;
KIRP	cis	rs7635838	0.819	rs2447607	chr3:11552027	C/T	cg00170343	chr3:11313890	ATG7	0.44	5.44	0.33	1.26e-7	HDL cholesterol;
KIRP	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.73	-0.34	2.94e-8	Myopia (pathological);
KIRP	trans	rs2270927	0.510	rs35930860	chr5:75579946	T/C	cg13563193	chr19:33072644	PDCD5	0.94	6.81	0.4	7.48e-11	Mean corpuscular volume;
KIRP	cis	rs4523957	0.928	rs4790325	chr17:2192085	C/T	cg16513277	chr17:2031491	SMG6	-0.6	-8.31	-0.47	6.62e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg27426351	chr10:43362370	NA	0.45	6.41	0.38	7.26e-10	Blood protein levels;
KIRP	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg01294253	chr9:136912663	BRD3	0.39	5.21	0.31	4.09e-7	Platelet distribution width;
KIRP	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.11e-10	Prudent dietary pattern;
KIRP	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.77	-0.4	9.56e-11	Initial pursuit acceleration;
KIRP	cis	rs258892	0.895	rs155427	chr5:72115763	A/G	cg21869765	chr5:72125136	TNPO1	-0.56	-6.2	-0.37	2.42e-9	Small cell lung carcinoma;
KIRP	cis	rs13102973	0.931	rs13103718	chr4:135843990	C/T	cg14419869	chr4:135874104	NA	0.53	8.85	0.49	1.75e-16	Subjective well-being;
KIRP	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.81	12.31	0.62	1.88e-27	Urate levels in lean individuals;
KIRP	cis	rs7015630	0.648	rs16901016	chr8:90852144	T/G	cg18493113	chr8:90847772	NA	-0.52	-5.96	-0.36	8.65e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6256	0.929	rs10832053	chr11:13550209	T/G	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.48e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg15209934	chr19:52800385	ZNF480	0.42	6.08	0.36	4.6e-9	Coronary artery disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01334186	chr1:151372572	PSMB4	0.63	6.1	0.36	4.08e-9	Lung function (FEV1);
KIRP	cis	rs977987	0.806	rs11644306	chr16:75490053	T/C	cg03315344	chr16:75512273	CHST6	0.69	10.65	0.56	4.93e-22	Dupuytren's disease;
KIRP	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.92e-6	Common traits (Other);
KIRP	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.81	13.28	0.65	1.03e-30	Schizophrenia;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg12502759	chr12:99039019	APAF1;IKBIP	-0.55	-6.35	-0.38	1.01e-9	Brain structure;
KIRP	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs6684514	0.922	rs12128785	chr1:156269389	A/G	cg16558208	chr1:156270281	VHLL	-0.43	-5.76	-0.34	2.45e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.67	-0.6	2.53e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-10.93	-0.57	6.1e-23	Total body bone mineral density;
KIRP	cis	rs514024	0.729	rs4837172	chr9:130384703	A/C	cg13643465	chr9:130375613	STXBP1	0.47	5.8	0.35	2.04e-8	Eating disorders (purging via substances);
KIRP	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.07e-12	Blood protein levels;
KIRP	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16318349	chr1:154917307	PBXIP1	-0.29	-5.09	-0.31	7.25e-7	Prostate cancer;
KIRP	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.88	0.3	1.88e-6	Cognitive test performance;
KIRP	trans	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg14791747	chr16:20752902	THUMPD1	0.63	6.79	0.4	8.35e-11	Cognitive test performance;
KIRP	cis	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg27411982	chr8:10470053	RP1L1	0.41	4.98	0.3	1.21e-6	Neuroticism;
KIRP	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-11.01	-0.57	3.5e-23	Morning vs. evening chronotype;
KIRP	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.09e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4794202	0.534	rs10428	chr17:45915086	G/A	cg10638573	chr17:45915098	SCRN2	0.48	5.68	0.34	3.77e-8	Alzheimer's disease (cognitive decline);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg11255513	chr11:113644528	ZW10	0.53	6.3	0.37	1.39e-9	Lung cancer in ever smokers;
KIRP	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg09795085	chr6:101329169	ASCC3	0.42	5.06	0.31	8.06e-7	Neuroticism;
KIRP	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg11707556	chr5:10655725	ANKRD33B	0.52	6.6	0.39	2.47e-10	Coronary artery disease;
KIRP	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg11502198	chr6:26597334	ABT1	0.52	6.58	0.39	2.82e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6959887	0.962	rs28628585	chr7:35291640	T/A	cg06685737	chr7:35301730	NA	0.44	6.43	0.38	6.76e-10	Birth weight;
KIRP	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs1595825	0.627	rs1435567	chr2:198748726	T/C	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.28e-6	Ulcerative colitis;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg01294297	chr14:35512367	NA	-0.45	-6.26	-0.37	1.72e-9	Select biomarker traits;
KIRP	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.47	-5.68	-0.34	3.72e-8	Testicular germ cell tumor;
KIRP	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg13453750	chr1:205783389	SLC41A1	-0.51	-7.71	-0.44	3.17e-13	Menarche (age at onset);
KIRP	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.56	0.39	3.19e-10	Prudent dietary pattern;
KIRP	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.15	-0.54	1.8899999999999998e-20	Alzheimer's disease (late onset);
KIRP	cis	rs588177	0.522	rs34358026	chr11:64015422	T/C	cg23719950	chr11:63933701	MACROD1	-0.67	-6.18	-0.37	2.62e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs8079658	1.000	rs11651498	chr17:63788615	C/T	cg18091269	chr17:63822838	CCDC46	-0.56	-7.52	-0.43	1.05e-12	Post bronchodilator FEV1;
KIRP	cis	rs6807915	0.603	rs13077979	chr3:12297922	T/G	cg02700894	chr3:12045449	SYN2	-0.36	-5.06	-0.31	8.03e-7	Leprosy;
KIRP	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19717773	chr7:2847554	GNA12	-0.32	-5.0	-0.3	1.08e-6	Height;
KIRP	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.58	7.52	0.43	9.96e-13	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.6e-6	Lung cancer;
KIRP	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.53	7.08	0.41	1.47e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.87	9.58	0.52	1.12e-18	Blood pressure;
KIRP	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.62	8.65	0.48	6.89e-16	Blood protein levels;
KIRP	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.42	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.3	6.39	0.38	8.39e-10	Asthma (sex interaction);
KIRP	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11987759	chr7:65425863	GUSB	-0.46	-5.43	-0.33	1.34e-7	Aortic root size;
KIRP	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.79	-7.06	-0.41	1.64e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg09035930	chr12:129282057	SLC15A4	0.56	7.17	0.42	8.85e-12	Systemic lupus erythematosus;
KIRP	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg07777115	chr5:623756	CEP72	-0.59	-5.93	-0.35	1.05e-8	Obesity-related traits;
KIRP	cis	rs4776059	1.000	rs34431049	chr15:52940538	G/C	cg22715398	chr15:52968154	KIAA1370	-0.58	-6.95	-0.41	3.18e-11	Schizophrenia;
KIRP	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.88	10.02	0.54	4.95e-20	Osteoarthritis;
KIRP	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11987759	chr7:65425863	GUSB	-0.7	-9.8	-0.53	2.38e-19	Calcium levels;
KIRP	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg23387468	chr7:139079360	LUC7L2	0.3	5.23	0.32	3.68e-7	Diisocyanate-induced asthma;
KIRP	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-1.03	-9.41	-0.51	3.6e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs8044995	0.517	rs2863973	chr16:68409435	A/C	cg26727032	chr16:67993705	SLC12A4	-0.49	-5.31	-0.32	2.44e-7	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.46	-6.23	-0.37	2.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg26754761	chr2:177040938	NA	-0.45	-7.69	-0.44	3.64e-13	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg06223162	chr1:101003688	GPR88	0.4	7.83	0.45	1.41e-13	Monocyte count;
KIRP	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.83	0.63	3.5e-29	Smoking behavior;
KIRP	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18867708	chr6:26865862	GUSBL1	0.47	5.93	0.35	1.02e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4845875	0.559	rs4846047	chr1:11843632	C/G	cg24844545	chr1:11908347	NPPA	0.36	4.89	0.3	1.8e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg04306507	chr14:55594613	LGALS3	-0.51	-7.74	-0.44	2.52e-13	Protein biomarker;
KIRP	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.33	5.04	0.31	9.03e-7	QRS complex (12-leadsum);
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg23985595	chr17:80112537	CCDC57	-0.37	-5.51	-0.33	8.98e-8	Life satisfaction;
KIRP	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.58	-9.35	-0.51	5.66e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.28	0.32	2.79e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg26384229	chr12:38710491	ALG10B	0.66	8.95	0.5	9.12e-17	Morning vs. evening chronotype;
KIRP	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.58	-8.16	-0.46	1.75e-14	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.87	0.6	5.24e-26	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21734487	chr8:27695307	PBK	-0.59	-7.1	-0.41	1.32e-11	Interleukin-4 levels;
KIRP	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs10781543	0.845	rs36066734	chr9:139340351	A/G	cg14169450	chr9:139327907	INPP5E	0.52	7.71	0.44	3.05e-13	Monocyte percentage of white cells;
KIRP	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg26695010	chr11:65641043	EFEMP2	0.51	5.1	0.31	6.88e-7	Crohn's disease;
KIRP	cis	rs7923609	0.812	rs10761753	chr10:65161903	G/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.39	-0.33	1.61e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.82	8.24	0.46	1.05e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.62	-6.91	-0.4	4.06e-11	Neuroticism;
KIRP	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.56	4.98	0.3	1.21e-6	Bipolar disorder;
KIRP	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.2	0.31	4.17e-7	Skin colour saturation;
KIRP	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.15	17.71	0.75	8.54e-46	Cognitive function;
KIRP	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg03388025	chr16:89894329	SPIRE2	0.32	5.74	0.34	2.75e-8	Vitiligo;
KIRP	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.4	-5.55	-0.33	7.34e-8	Lung cancer;
KIRP	cis	rs1978968	0.731	rs9617648	chr22:18460059	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.8	-11.35	-0.59	2.7e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg12486944	chr17:80159399	CCDC57	-0.41	-5.43	-0.33	1.33e-7	Life satisfaction;
KIRP	cis	rs2594989	0.943	rs2454492	chr3:11507793	G/A	cg01796438	chr3:11312864	ATG7	-0.63	-7.68	-0.44	3.86e-13	Circulating chemerin levels;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg13453750	chr1:205783389	SLC41A1	-0.46	-7.09	-0.41	1.45e-11	Menarche (age at onset);
KIRP	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.72	9.55	0.52	1.33e-18	Longevity;
KIRP	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg07810366	chr2:100720526	AFF3	-0.33	-6.02	-0.36	6.15e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6732160	0.656	rs2043093	chr2:73407342	G/C	cg01422370	chr2:73384389	NA	0.4	5.1	0.31	6.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.31	-0.51	7.16e-18	Joint mobility (Beighton score);
KIRP	cis	rs6102059	0.503	rs6102032	chr20:39183949	C/T	cg06665391	chr20:39312290	NA	0.4	4.98	0.3	1.22e-6	LDL cholesterol;
KIRP	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.38	0.43	2.5e-12	Aortic root size;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-7.46	-0.43	1.48e-12	Longevity;Endometriosis;
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	5.37	0.32	1.84e-7	Obesity-related traits;
KIRP	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-6.63	-0.39	2.14e-10	Aortic root size;
KIRP	cis	rs9914544	0.583	rs35783872	chr17:18748820	A/C	cg26378065	chr17:18585709	ZNF286B	0.41	5.23	0.32	3.6e-7	Educational attainment (years of education);
KIRP	cis	rs9311676	0.632	rs7624283	chr3:58369897	G/A	cg06643156	chr3:58380774	PXK	0.35	4.92	0.3	1.56e-6	Systemic lupus erythematosus;
KIRP	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.48	-4.92	-0.3	1.62e-6	Schizophrenia;
KIRP	cis	rs12534701	0.904	rs3817518	chr7:154672809	C/T	cg24255201	chr7:154684926	DPP6	0.56	7.88	0.45	1.04e-13	Colorectal cancer (diet interaction);
KIRP	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg06766960	chr11:133703094	NA	-0.6	-7.43	-0.43	1.8e-12	Childhood ear infection;
KIRP	cis	rs7116495	1.000	rs542752	chr11:71810644	T/A	cg26138937	chr11:71823887	C11orf51	0.69	5.51	0.33	9.2e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs2554380	0.628	rs890311	chr15:84440952	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.34	-5.56	-0.33	6.86e-8	Height;
KIRP	cis	rs72820985	1.000	rs34450250	chr16:80841999	C/T	cg04448709	chr16:81349954	GAN	-0.49	-5.03	-0.31	9.3e-7	Breast cancer;
KIRP	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.78	10.58	0.56	8.09e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8084125	0.832	rs62105166	chr18:74944518	A/G	cg26065057	chr18:74961000	GALR1	0.61	6.15	0.37	3.07e-9	Obesity-related traits;
KIRP	cis	rs12282928	1.000	rs7952009	chr11:48286845	A/G	cg26585981	chr11:48327164	OR4S1	-0.52	-6.32	-0.37	1.25e-9	Migraine - clinic-based;
KIRP	cis	rs2224391	0.628	rs2773304	chr6:5242602	G/A	cg13962347	chr6:5174647	LYRM4	-0.75	-10.29	-0.55	7.06e-21	Height;
KIRP	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	4.99	0.3	1.14e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.68	-8.28	-0.47	7.83e-15	Neutrophil percentage of white cells;
KIRP	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-5.19	-0.31	4.34e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.64	-10.01	-0.54	5.35e-20	Airway imaging phenotypes;
KIRP	cis	rs2668423	1.000	rs2668419	chr19:1366994	A/G	cg02639931	chr19:1387894	NDUFS7	-0.76	-9.86	-0.53	1.5e-19	Nonalcoholic fatty liver disease;
KIRP	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-7.33	-0.42	3.37e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.54	7.53	0.43	9.36e-13	Lung cancer;
KIRP	cis	rs7404928	0.589	rs6497687	chr16:23850751	T/C	cg21745164	chr16:23765304	CHP2	0.57	7.33	0.42	3.36e-12	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.92	-12.73	-0.63	7.46e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.12	0.36	3.59e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.54	-5.99	-0.36	7.23e-9	Menarche (age at onset);
KIRP	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg21401794	chr1:90099060	LRRC8C	0.68	9.73	0.53	3.99e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.94	-0.4	3.51e-11	Blood pressure;
KIRP	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg00074818	chr8:8560427	CLDN23	0.41	6.61	0.39	2.42e-10	Obesity-related traits;
KIRP	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-9.7	-0.53	4.75e-19	Coronary artery disease;
KIRP	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.44	5.88	0.35	1.32e-8	Homoarginine levels;
KIRP	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg23307798	chr14:103986281	CKB	0.44	6.19	0.37	2.54e-9	Body mass index;
KIRP	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg19567339	chr10:100142640	NA	0.47	5.17	0.31	4.83e-7	Metabolite levels;
KIRP	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15557168	chr22:42548783	NA	-0.43	-5.48	-0.33	1.08e-7	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15083158	chr17:2615176	KIAA0664	0.49	6.18	0.37	2.62e-9	Parkinson's disease;
KIRP	cis	rs2072732	0.861	rs4576609	chr1:2938265	C/T	cg11731671	chr1:2995604	PRDM16	-0.44	-5.24	-0.32	3.49e-7	Plateletcrit;
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg13906792	chr15:75199810	C15orf17	-0.36	-5.03	-0.31	9.27e-7	Breast cancer;
KIRP	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg01557791	chr16:72042693	DHODH	-0.43	-5.28	-0.32	2.81e-7	Fibrinogen levels;
KIRP	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13939156	chr17:80058883	NA	0.51	7.55	0.43	8.24e-13	Life satisfaction;
KIRP	cis	rs12765878	0.729	rs12573103	chr10:105639241	A/G	cg11005552	chr10:105648138	OBFC1	0.39	5.53	0.33	8e-8	Coronary artery disease;
KIRP	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg04287289	chr16:89883240	FANCA	-0.42	-5.34	-0.32	2.14e-7	Vitiligo;
KIRP	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06757925	chr1:70671216	LRRC40;SFRS11	0.56	6.73	0.39	1.22e-10	Smoking initiation;
KIRP	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg10760299	chr15:45669010	GATM	0.36	5.27	0.32	3.03e-7	Homoarginine levels;
KIRP	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-9.35	-0.51	5.65e-18	Longevity;Endometriosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26394825	chr12:133464689	CHFR	0.51	7.12	0.41	1.19e-11	Survival in pancreatic cancer;
KIRP	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg02367723	chr1:46378857	MAST2	0.42	4.85	0.3	2.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7294478	0.563	rs7962714	chr12:7262797	A/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.38	-5.35	-0.32	1.96e-7	Neuritic plaque;
KIRP	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg10755058	chr3:40428713	ENTPD3	0.34	4.86	0.3	2.1e-6	Renal cell carcinoma;
KIRP	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.58e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.69	9.01	0.5	6.05e-17	Personality dimensions;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.1.194281253F	chr1:196014630	NA	0.49	6.93	0.4	3.56e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs911119	1.000	rs6036478	chr20:23611359	C/A	cg09631192	chr20:23583594	CST9	-0.51	-4.93	-0.3	1.54e-6	Chronic kidney disease;
KIRP	cis	rs66561647	0.895	rs9649959	chr8:128972721	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	-0.52	-7.19	-0.42	7.54e-12	Hemoglobin concentration;
KIRP	cis	rs3026101	0.671	rs3026136	chr17:5310308	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.1e-23	Prudent dietary pattern;
KIRP	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.46	-5.86	-0.35	1.47e-8	Blood protein levels;
KIRP	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg04906043	chr13:21280425	IL17D	0.57	7.36	0.42	2.71e-12	Dental caries;
KIRP	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.92	0.3	1.55e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.89	10.48	0.56	1.72e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg02153340	chr1:155202674	NA	-0.37	-5.15	-0.31	5.44e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-9.53	-0.52	1.58e-18	Platelet count;
KIRP	cis	rs7116495	0.737	rs6592456	chr11:71737663	G/A	cg07596299	chr11:71824057	C11orf51	-0.89	-5.95	-0.35	9.24e-9	Severe influenza A (H1N1) infection;
KIRP	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.53	-6.39	-0.38	8.37e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg02684056	chr5:59996105	DEPDC1B	0.44	5.62	0.34	5.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg22189786	chr22:42395067	WBP2NL	0.44	5.67	0.34	3.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs28489187	0.706	rs233059	chr1:85798936	G/A	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg04289385	chr6:36355825	ETV7	0.43	6.85	0.4	5.85e-11	Mean platelet volume;
KIRP	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.82	12.23	0.61	3.56e-27	Ulcerative colitis;
KIRP	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.83	11.39	0.59	2.04e-24	Total body bone mineral density;
KIRP	cis	rs10411936	0.692	rs62118141	chr19:16602808	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.47	5.18	0.31	4.56e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.05	0.74	1.52e-43	Homoarginine levels;
KIRP	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.72	8.28	0.47	8.18e-15	Gestational age at birth (maternal effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00127505	chr10:131763820	NA	0.42	6.3	0.37	1.39e-9	Parkinson's disease;
KIRP	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.46	-0.43	1.45e-12	Pulmonary function;
KIRP	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg18932078	chr1:2524107	MMEL1	-0.43	-5.94	-0.35	9.91e-9	Ulcerative colitis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26080798	chr6:20402092	E2F3	-0.48	-6.65	-0.39	1.84e-10	Metabolic traits;
KIRP	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg01522456	chr1:115632236	TSPAN2	-0.37	-4.99	-0.3	1.12e-6	Autism;
KIRP	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg04369109	chr6:150039330	LATS1	-0.64	-7.65	-0.44	4.6e-13	Lung cancer;
KIRP	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.45	-0.43	1.57e-12	Bladder cancer;
KIRP	cis	rs55675132	0.548	rs12138998	chr1:115377168	A/G	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs1215050	0.904	rs2903153	chr4:99057457	C/T	cg05340658	chr4:99064831	C4orf37	0.45	5.15	0.31	5.47e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs929596	0.531	rs2741013	chr2:234509911	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.96	-0.36	8.69e-9	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs12580194	0.554	rs12578577	chr12:55716443	C/T	cg19537932	chr12:55886519	OR6C68	-0.47	-6.07	-0.36	4.88e-9	Cancer;
KIRP	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.64	-9.67	-0.52	6.06e-19	Educational attainment;
KIRP	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.58	-9.07	-0.5	3.94e-17	Coronary artery disease;
KIRP	cis	rs2073300	1.000	rs6048813	chr20:23448221	G/A	cg12480562	chr20:23434244	CST11	0.62	6.25	0.37	1.75e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.92	10.67	0.56	4.22e-22	Menarche (age at onset);
KIRP	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	1.02	10.74	0.57	2.51e-22	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20299151	chr14:100758864	SLC25A29	0.55	6.89	0.4	4.76e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-9.34	-0.51	6.05e-18	Coronary artery disease;
KIRP	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.68	-7.49	-0.43	1.22e-12	Obesity-related traits;
KIRP	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg08126542	chr6:37504118	NA	-0.55	-7.06	-0.41	1.74e-11	Cognitive performance;
KIRP	cis	rs13102973	0.931	rs116199858	chr4:135847256	G/C	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.09e-16	Subjective well-being;
KIRP	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg01522456	chr1:115632236	TSPAN2	-0.37	-4.95	-0.3	1.37e-6	Autism;
KIRP	cis	rs9473924	0.505	rs9473938	chr6:50874050	C/T	cg14470998	chr6:50812995	TFAP2B	0.84	7.74	0.44	2.59e-13	Body mass index;
KIRP	cis	rs11593576	0.861	rs10824731	chr10:81009237	C/T	cg18737081	chr10:80999807	ZMIZ1	-0.34	-5.26	-0.32	3.19e-7	Vitiligo;
KIRP	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.72	7.88	0.45	1.04e-13	Corneal astigmatism;
KIRP	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg16141378	chr3:129829833	LOC729375	-0.52	-6.78	-0.4	9.08e-11	Mood instability;
KIRP	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.65	-10.07	-0.54	3.37e-20	Total body bone mineral density;
KIRP	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg20821713	chr7:1055600	C7orf50	-0.32	-4.86	-0.3	2.07e-6	Longevity;Endometriosis;
KIRP	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg21427119	chr20:30132790	HM13	-0.52	-5.84	-0.35	1.61e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.72	8.91	0.49	1.16e-16	Mammographic density (dense area);
KIRP	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00514413	chr19:1238130	C19orf26	0.53	6.74	0.39	1.12e-10	Obesity-related traits;
KIRP	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	cg04338863	chr8:33670619	NA	-0.42	-5.0	-0.3	1.11e-6	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24083067	chr19:48972665	CYTH2	-0.48	-6.43	-0.38	6.73e-10	Metabolic traits;
KIRP	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg03576123	chr11:487126	PTDSS2	0.85	7.59	0.44	6.56e-13	Body mass index;
KIRP	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	10.11	0.54	2.57e-20	Smoking behavior;
KIRP	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.51	-8.01	-0.45	4.51e-14	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.23	-0.32	3.62e-7	Lung cancer;
KIRP	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg00857998	chr1:205179979	DSTYK	0.64	7.59	0.44	6.77e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg19539972	chr4:7069911	GRPEL1	-0.69	-8.02	-0.46	4.2e-14	Monocyte percentage of white cells;
KIRP	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.79	9.45	0.52	2.81e-18	Corneal astigmatism;
KIRP	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.1	13.87	0.66	1.07e-32	IgG glycosylation;
KIRP	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.59	-6.73	-0.39	1.16e-10	Menarche (age at onset);
KIRP	cis	rs10982256	0.789	rs10817629	chr9:117261987	C/T	cg13636371	chr9:117264095	DFNB31	-0.39	-5.03	-0.31	9.59e-7	Bipolar disorder;
KIRP	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg09873164	chr1:152488093	CRCT1	0.6	7.79	0.45	1.82e-13	Hair morphology;
KIRP	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-8.59	-0.48	1.01e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6001982	0.588	rs73167093	chr22:40893789	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg18709589	chr6:96969512	KIAA0776	0.34	5.15	0.31	5.27e-7	Headache;
KIRP	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.56	0.65	1.2e-31	Chronic sinus infection;
KIRP	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.77	6.8	0.4	7.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.9	-12.41	-0.62	9.06e-28	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs76419734	0.614	rs17036097	chr4:106597295	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.67	7.41	0.43	1.97e-12	Post bronchodilator FEV1;
KIRP	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.45	6.04	0.36	5.65e-9	Coronary artery disease;
KIRP	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.65	-7.47	-0.43	1.42e-12	Corneal astigmatism;
KIRP	cis	rs2302729	0.625	rs13328976	chr12:2831151	C/T	cg19945202	chr12:2788847	CACNA1C	0.61	5.57	0.33	6.63e-8	Sleep quality;
KIRP	cis	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg06521331	chr12:34319734	NA	-0.45	-5.17	-0.31	4.94e-7	Resting heart rate;
KIRP	cis	rs12210905	0.688	rs12215353	chr6:27407022	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.74	-0.34	2.75e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg09163369	chr1:210001066	C1orf107	0.49	6.15	0.36	3.16e-9	Orofacial clefts;
KIRP	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg24375607	chr4:120327624	NA	0.55	6.34	0.37	1.11e-9	Corneal astigmatism;
KIRP	cis	rs7737355	0.812	rs42256	chr5:130705906	T/C	cg06307176	chr5:131281290	NA	-0.44	-5.39	-0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	6.86	0.4	5.51e-11	Neuroticism;
KIRP	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.43	5.14	0.31	5.5e-7	Aortic root size;
KIRP	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg17524180	chr13:113633600	MCF2L	-0.29	-5.28	-0.32	2.8e-7	Systolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13784866	chr9:139269562	CARD9	0.56	6.88	0.4	5.06e-11	Interleukin-4 levels;
KIRP	cis	rs1978968	1.000	rs2099942	chr22:18438314	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-8.01	-0.45	4.49e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg20673091	chr1:2541236	MMEL1	-0.78	-12.68	-0.63	1.08e-28	Ulcerative colitis;
KIRP	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.57	-6.73	-0.39	1.16e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7246657	0.722	rs11083432	chr19:38182633	A/G	cg18154014	chr19:37997991	ZNF793	-0.53	-6.08	-0.36	4.64e-9	Coronary artery calcification;
KIRP	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.04	12.81	0.63	3.89e-29	Vitiligo;
KIRP	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg12131826	chr15:77904385	NA	0.42	5.66	0.34	4.16e-8	Type 2 diabetes;
KIRP	cis	rs12519773	0.555	rs2009416	chr5:92415111	C/T	cg18783429	chr5:92414398	NA	0.31	5.16	0.31	4.97e-7	Migraine;
KIRP	cis	rs10875746	0.768	rs10875724	chr12:48420253	C/A	cg20731937	chr12:48336164	NA	0.5	6.34	0.37	1.1e-9	Longevity (90 years and older);
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg09264619	chr17:80180166	NA	0.37	5.36	0.32	1.9e-7	Life satisfaction;
KIRP	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg07382826	chr16:28625726	SULT1A1	0.5	6.07	0.36	4.9e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs78487399	0.908	rs76501189	chr2:43806353	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-4.99	-0.3	1.13e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13064049	chr1:38478702	UTP11L	-0.52	-6.63	-0.39	2.13e-10	Interleukin-4 levels;
KIRP	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.55	8.13	0.46	2.07e-14	Bone mineral density;
KIRP	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg11995313	chr8:8860691	ERI1	0.37	4.91	0.3	1.64e-6	Joint mobility (Beighton score);
KIRP	cis	rs6142102	0.812	rs6059578	chr20:32527706	G/C	cg08999081	chr20:33150536	PIGU	0.51	5.9	0.35	1.18e-8	Skin pigmentation;
KIRP	cis	rs7572644	0.664	rs4313931	chr2:28074701	C/T	cg27432699	chr2:27873401	GPN1	0.45	5.01	0.3	1.06e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.27	-5.52	-0.33	8.72e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs55962025	0.883	rs2298967	chr4:3185747	T/C	cg06533319	chr4:3265114	C4orf44	0.48	5.06	0.31	8.22e-7	Parental longevity (mother's age at death);
KIRP	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.82	12.63	0.63	1.61e-28	IgG glycosylation;
KIRP	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg10167378	chr1:228756711	NA	0.46	5.73	0.34	2.87e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg05347473	chr6:146136440	FBXO30	0.62	8.75	0.49	3.48e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg21734707	chr17:3908241	ZZEF1	0.53	5.0	0.3	1.12e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs9715521	0.718	rs62301190	chr4:59842351	A/G	cg11281224	chr4:60001000	NA	-0.46	-5.53	-0.33	8.11e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs981844	0.775	rs921884	chr4:154753059	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-7.17	-0.42	8.52e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs9826463	1.000	rs28647471	chr3:142333164	A/C	cg20824294	chr3:142316082	PLS1	0.31	5.38	0.32	1.75e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.49	-5.4	-0.33	1.55e-7	Platelet distribution width;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg24874828	chr4:187887005	NA	-0.49	-7.19	-0.42	7.96e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.34	-5.06	-0.31	8.18e-7	Eye color traits;
KIRP	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06616338	chr11:695893	TMEM80;DEAF1	0.48	6.2	0.37	2.4e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg08501292	chr6:25962987	TRIM38	1.09	7.89	0.45	9.64e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.73	-9.74	-0.53	3.71e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.79	-9.58	-0.52	1.09e-18	Blood protein levels;
KIRP	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.45	-5.25	-0.32	3.29e-7	Total body bone mineral density;
KIRP	cis	rs12220238	0.915	rs11000988	chr10:76073723	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.65	0.39	1.92e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg02415014	chr8:143852576	LYNX1	-0.31	-5.0	-0.3	1.1e-6	Urinary tract infection frequency;
KIRP	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg26531700	chr6:26746687	NA	0.46	6.5	0.38	4.31e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6693567	0.545	rs4446975	chr1:150456169	C/T	cg07843065	chr1:150265600	MRPS21	0.48	6.53	0.38	3.78e-10	Migraine;
KIRP	cis	rs11673344	0.796	rs9676450	chr19:37489407	A/G	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.2	-0.31	4.16e-7	Obesity-related traits;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20665205	chr15:49254494	SHC4	-0.49	-6.57	-0.39	2.98e-10	Inflammatory biomarkers;
KIRP	cis	rs2554380	0.628	rs6602990	chr15:84452222	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.33	-4.98	-0.3	1.19e-6	Height;
KIRP	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg06935464	chr4:38784597	TLR10	0.5	5.11	0.31	6.35e-7	Breast cancer;
KIRP	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.62	-8.44	-0.47	2.82e-15	Colorectal cancer;
KIRP	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg16482183	chr6:26056742	HIST1H1C	0.94	9.92	0.53	1.02e-19	Iron status biomarkers;
KIRP	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.65	9.2	0.51	1.58e-17	Coronary artery disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23944480	chr2:120734864	PTPN4	0.39	6.26	0.37	1.73e-9	C-reactive protein;
KIRP	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.29	-0.32	2.76e-7	Bipolar disorder;
KIRP	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg10189774	chr4:17578691	LAP3	0.46	5.6	0.34	5.67e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	12.73	0.63	7.26e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs981844	1.000	rs2118862	chr4:154657782	A/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg06740227	chr12:86229804	RASSF9	0.51	6.7	0.39	1.44e-10	Major depressive disorder;
KIRP	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg07596299	chr11:71824057	C11orf51	-0.84	-5.63	-0.34	5.01e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg02175503	chr12:58329896	NA	0.54	5.88	0.35	1.36e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg25039879	chr17:56429692	SUPT4H1	0.54	4.93	0.3	1.53e-6	Cognitive test performance;
KIRP	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg04362960	chr10:104952993	NT5C2	0.53	6.16	0.37	2.96e-9	Colorectal cancer;
KIRP	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg17554472	chr22:41940697	POLR3H	0.43	5.15	0.31	5.23e-7	Vitiligo;
KIRP	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg04310649	chr10:35416472	CREM	-0.58	-6.86	-0.4	5.69e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg16989719	chr2:238392110	NA	-0.54	-7.58	-0.44	7.12e-13	Prostate cancer;
KIRP	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg11833968	chr6:79620685	NA	-0.36	-4.91	-0.3	1.67e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg01475377	chr6:109611718	NA	-0.36	-4.93	-0.3	1.52e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg27205649	chr11:78285834	NARS2	0.64	8.01	0.45	4.69e-14	Alzheimer's disease (survival time);
KIRP	cis	rs876084	0.505	rs62526984	chr8:121128068	A/G	cg06265175	chr8:121136014	COL14A1	0.52	6.42	0.38	6.84e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.34	0.55	4.87e-21	Coffee consumption (cups per day);
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.82	-9.77	-0.53	2.92e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-0.96	-11.62	-0.6	3.64e-25	Vitiligo;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.75	-12.12	-0.61	8.02e-27	Menarche (age at onset);
KIRP	cis	rs2073300	0.826	rs6137968	chr20:23449550	G/A	cg12062639	chr20:23401060	NAPB	0.91	7.32	0.42	3.61e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.61	-8.88	-0.49	1.39e-16	Electroencephalogram traits;
KIRP	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg02725872	chr8:58115012	NA	-0.78	-6.76	-0.4	9.73e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs3779635	0.742	rs919495	chr8:27250821	T/C	cg11641102	chr8:27183873	PTK2B	0.41	5.49	0.33	1e-7	Neuroticism;
KIRP	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg02175308	chr1:109941060	SORT1	0.31	5.87	0.35	1.43e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12048904	0.533	rs12026932	chr1:101212881	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	7.99	0.45	5.25e-14	Multiple sclerosis;
KIRP	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg06042504	chr8:55087323	NA	-0.6	-7.09	-0.41	1.38e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.51	-6.34	-0.37	1.07e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg00129232	chr17:37814104	STARD3	0.64	7.89	0.45	9.91e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	trans	rs6902257	1.000	rs2496676	chr6:81305670	A/G	cg06063519	chr15:99274532	IGF1R	-0.62	-6.05	-0.36	5.47e-9	Obesity-related traits;
KIRP	cis	rs2273669	0.667	rs2145765	chr6:109296362	C/G	cg05315195	chr6:109294784	ARMC2	-0.67	-6.65	-0.39	1.87e-10	Prostate cancer;
KIRP	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.48	-6.86	-0.4	5.4e-11	Refractive error;
KIRP	cis	rs9487051	0.714	rs6932503	chr6:109607958	G/A	cg12927641	chr6:109611667	NA	-0.38	-4.85	-0.3	2.22e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.13	-21.99	-0.81	5.15e-60	Exhaled nitric oxide output;
KIRP	cis	rs10073892	0.743	rs62372216	chr5:101650882	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs244899	0.967	rs244898	chr5:167918926	T/C	cg13011109	chr5:167955758	FBLL1	0.37	5.18	0.31	4.7e-7	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	6.6	0.39	2.45e-10	Cognitive test performance;
KIRP	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg26681399	chr22:41777847	TEF	0.44	5.1	0.31	6.88e-7	Vitiligo;
KIRP	cis	rs17092148	1.000	rs6060040	chr20:33359054	G/C	cg16810054	chr20:33298113	TP53INP2	-0.46	-5.56	-0.33	7.19e-8	Neuroticism;
KIRP	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg09455208	chr3:40491958	NA	-0.3	-5.16	-0.31	5.18e-7	Renal cell carcinoma;
KIRP	cis	rs4742903	0.904	rs10991167	chr9:106974382	C/T	cg14250997	chr9:106856677	SMC2	-0.37	-4.99	-0.3	1.15e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg05064044	chr6:292385	DUSP22	-0.51	-6.06	-0.36	5e-9	Menopause (age at onset);
KIRP	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.02	0.31	9.75e-7	Breast cancer;
KIRP	cis	rs737693	1.000	rs17361668	chr11:102720344	A/T	cg19620758	chr11:102826565	MMP13	0.68	5.54	0.33	7.86e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs741702	0.928	rs2009222	chr19:13034543	T/C	cg11738485	chr19:12877000	HOOK2	0.44	5.42	0.33	1.4e-7	Red blood cell traits;
KIRP	cis	rs889398	0.741	rs10852461	chr16:69928846	T/C	cg09409435	chr16:70099608	PDXDC2	0.41	5.09	0.31	7.24e-7	Body mass index;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.65e-7	Life satisfaction;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.15	-0.31	5.37e-7	Life satisfaction;
KIRP	cis	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg04607699	chr11:48328132	OR4S1	-0.39	-5.54	-0.33	7.88e-8	Migraine - clinic-based;
KIRP	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.94	0.5	9.23e-17	Resting heart rate;
KIRP	trans	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.48	-0.38	4.93e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.64	7.59	0.44	6.73e-13	Testicular germ cell tumor;
KIRP	cis	rs1440410	0.835	rs10015190	chr4:144081748	A/G	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18252515	chr7:66147081	NA	0.43	5.19	0.31	4.31e-7	Aortic root size;
KIRP	cis	rs13361707	0.920	rs6868517	chr5:40752536	A/G	cg01087697	chr5:40835557	RPL37	-0.51	-5.83	-0.35	1.77e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2882667	0.858	rs11741150	chr5:138431457	C/T	cg04439458	chr5:138467593	SIL1	-0.52	-7.64	-0.44	4.85e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25517755	chr10:38738941	LOC399744	0.37	4.89	0.3	1.83e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.76	12.21	0.61	4.16e-27	Ewing sarcoma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10158598	chr7:47344579	TNS3	0.4	6.3	0.37	1.34e-9	Interleukin-4 levels;
KIRP	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg24699146	chr1:24152579	HMGCL	-0.45	-5.72	-0.34	3.06e-8	Immature fraction of reticulocytes;
KIRP	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.99	-13.88	-0.66	9.5e-33	Response to antipsychotic treatment;
KIRP	cis	rs75920871	1.000	rs7125788	chr11:116883396	T/C	cg23684410	chr11:116897558	SIK3	0.54	5.83	0.35	1.73e-8	Subjective well-being;
KIRP	cis	rs2046867	0.908	rs868336	chr3:72818165	A/C	cg25664220	chr3:72788482	NA	-0.39	-5.98	-0.36	7.91e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.64	-0.44	4.95e-13	Bipolar disorder;
KIRP	cis	rs7923609	0.967	rs10740126	chr10:65210935	A/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg07001201	chr5:642380	CEP72	0.56	5.38	0.32	1.74e-7	Obesity-related traits;
KIRP	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.72	-0.49	4.24e-16	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.29	28.11	0.87	9.15e-79	IgG glycosylation;
KIRP	cis	rs9372498	0.536	rs9489407	chr6:118792337	A/T	cg18833306	chr6:118973337	C6orf204	0.49	5.13	0.31	5.95e-7	Diastolic blood pressure;
KIRP	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.41	8.16	0.46	1.75e-14	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg13939156	chr17:80058883	NA	0.51	5.91	0.35	1.12e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.28	0.37	1.51e-9	Aortic root size;
KIRP	cis	rs258892	0.947	rs266443	chr5:72180377	C/T	cg21869765	chr5:72125136	TNPO1	0.58	6.45	0.38	5.86e-10	Small cell lung carcinoma;
KIRP	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.88	-0.49	1.44e-16	Morning vs. evening chronotype;
KIRP	cis	rs75920871	0.748	rs7106662	chr11:116951385	T/C	cg04087571	chr11:116723030	SIK3	-0.25	-5.33	-0.32	2.26e-7	Subjective well-being;
KIRP	cis	rs4704187	0.640	rs4704188	chr5:74482675	A/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.17	-22.15	-0.82	1.61e-60	Chronic sinus infection;
KIRP	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg10517650	chr3:113235015	CCDC52	-0.44	-5.71	-0.34	3.21e-8	Dental caries;
KIRP	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	cg04338863	chr8:33670619	NA	0.47	6.04	0.36	5.61e-9	Body mass index;
KIRP	cis	rs1408799	0.720	rs2733831	chr9:12703484	A/G	cg05274944	chr9:12693694	TYRP1	0.41	5.97	0.36	8.19e-9	Eye color;Blue vs. green eyes;
KIRP	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.67	8.17	0.46	1.66e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg18461458	chr19:21324796	ZNF431	-0.49	-4.96	-0.3	1.29e-6	Pain;
KIRP	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.77	-10.99	-0.57	4.14e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs10193935	0.748	rs12467253	chr2:42697588	A/C	cg27598129	chr2:42591480	NA	0.71	6.83	0.4	6.71e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg23032965	chr3:12705835	RAF1	0.71	7.85	0.45	1.28e-13	Cholesterol, total;
KIRP	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg12623918	chr2:306882	NA	0.42	5.21	0.32	3.93e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.73	-10.39	-0.55	3.45e-21	Coronary artery disease;
KIRP	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.47	5.36	0.32	1.9e-7	Schizophrenia;
KIRP	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg11235152	chr1:67600687	NA	0.75	11.08	0.58	2.04e-23	Psoriasis;
KIRP	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg15655495	chr12:38532458	NA	0.25	4.89	0.3	1.84e-6	Bladder cancer;
KIRP	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.39	7.07	0.41	1.58e-11	Refractive error;
KIRP	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.78	-0.35	2.21e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.49	7.55	0.43	8.63e-13	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	1.06	18.12	0.76	3.49e-47	Intelligence (multi-trait analysis);
KIRP	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07685180	chr8:600429	NA	0.68	4.85	0.3	2.18e-6	IgG glycosylation;
KIRP	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg00277334	chr10:82204260	NA	-0.45	-4.95	-0.3	1.41e-6	Post bronchodilator FEV1;
KIRP	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-21.7	-0.81	4.73e-59	Height;
KIRP	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg05072774	chr3:49840536	C3orf54	0.43	5.57	0.33	6.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.75	9.62	0.52	8.21e-19	Coronary artery disease;
KIRP	cis	rs4478858	0.647	rs6425720	chr1:31709555	A/G	cg00250761	chr1:31883323	NA	-0.32	-5.51	-0.33	8.89e-8	Alcohol dependence;
KIRP	cis	rs2019216	0.542	rs12450889	chr17:21889379	A/G	cg22648282	chr17:21454238	C17orf51	-0.52	-6.56	-0.39	3.16e-10	Pelvic organ prolapse;
KIRP	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg11707556	chr5:10655725	ANKRD33B	0.56	6.95	0.41	3.21e-11	Coronary artery disease;
KIRP	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.71	-0.49	4.6e-16	Common traits (Other);
KIRP	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.38	6.97	0.41	2.94e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs13190036	1.000	rs13167431	chr5:176621075	G/C	cg04708888	chr5:176739561	MXD3	0.64	5.02	0.3	1.01e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.17	-0.31	4.92e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg19847866	chr10:1019161	NA	-0.6	-5.68	-0.34	3.85e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-5.77	-0.35	2.4e-8	Ulcerative colitis;
KIRP	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.72	-6.59	-0.39	2.6e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.71	7.89	0.45	9.71e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg00621247	chr5:1949277	NA	-0.5	-5.49	-0.33	9.93e-8	Gut microbiome composition (winter);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24533757	chr11:36615953	RAG2;C11orf74	0.53	6.14	0.36	3.25e-9	Lung cancer in ever smokers;
KIRP	cis	rs2151522	0.762	rs13219548	chr6:127165290	C/T	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.54	-7.73	-0.44	2.71e-13	Coronary artery disease;
KIRP	cis	rs7481311	0.956	rs2352802	chr11:27547826	G/A	cg18117895	chr11:27722066	BDNF	0.48	5.21	0.32	4.05e-7	Body mass index;Weight;
KIRP	cis	rs10073892	1.000	rs11749193	chr5:101795556	G/A	cg19774478	chr5:101632501	SLCO4C1	0.61	6.42	0.38	6.89e-10	Cognitive decline (age-related);
KIRP	cis	rs1497828	0.956	rs1497836	chr1:217562407	T/C	cg04411442	chr1:217543379	NA	0.31	4.98	0.3	1.19e-6	Dialysis-related mortality;
KIRP	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg21854759	chr1:92012499	NA	-0.48	-6.11	-0.36	3.88e-9	Breast cancer;
KIRP	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21164727	chr9:95858436	C9orf89	0.49	6.03	0.36	5.85e-9	Parkinson's disease;
KIRP	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.48	7.32	0.42	3.61e-12	Resting heart rate;
KIRP	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg18132916	chr6:79620363	NA	-0.4	-5.62	-0.34	5.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.48	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.75	6.5	0.38	4.54e-10	Diabetic retinopathy;
KIRP	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.43	4.92	0.3	1.56e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.43	-0.43	1.78e-12	Aortic root size;
KIRP	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg24315340	chr6:146058215	EPM2A	-0.43	-5.31	-0.32	2.49e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg11815991	chr20:30193098	ID1	-0.51	-5.16	-0.31	5.16e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.66	8.19	0.46	1.47e-14	Crohn's disease;
KIRP	cis	rs7814319	0.966	rs13276829	chr8:97274990	G/A	cg20787634	chr8:97240163	UQCRB	-0.6	-9.11	-0.5	2.95e-17	Lung function (FVC);
KIRP	cis	rs7520050	0.743	rs61789988	chr1:46085242	G/C	cg15605315	chr1:45957053	TESK2	0.38	4.85	0.3	2.19e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg13289132	chr10:30722225	MAP3K8	-0.41	-5.17	-0.31	4.83e-7	Inflammatory bowel disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg07424155	chr7:116503126	CAPZA2	0.48	6.11	0.36	3.92e-9	DNA methylation (variation);
KIRP	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.9e-26	Heart rate;
KIRP	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.59	-7.13	-0.41	1.09e-11	P wave terminal force;
KIRP	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.89	-11.57	-0.59	5.05e-25	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg23594656	chr7:65796392	TPST1	0.38	5.49	0.33	9.99e-8	Aortic root size;
KIRP	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.16	-0.37	2.9e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg23034840	chr1:205782522	SLC41A1	0.52	6.69	0.39	1.46e-10	Menarche (age at onset);
KIRP	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.71	8.14	0.46	1.94e-14	Vitiligo;
KIRP	cis	rs7224685	0.871	rs9892466	chr17:3969527	A/T	cg17441377	chr17:3906640	NA	-0.44	-5.9	-0.35	1.21e-8	Type 2 diabetes;
KIRP	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.37	0.47	4.42e-15	Response to antipsychotic treatment;
KIRP	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg03929089	chr4:120376271	NA	0.76	6.73	0.39	1.17e-10	Intraocular pressure;
KIRP	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg20169779	chr10:135381914	SYCE1	-0.73	-7.68	-0.44	3.81e-13	Gout;
KIRP	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17554472	chr22:41940697	POLR3H	-0.6	-6.42	-0.38	7.04e-10	Vitiligo;
KIRP	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg10189774	chr4:17578691	LAP3	0.52	6.31	0.37	1.28e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.79	7.61	0.44	5.76e-13	Diisocyanate-induced asthma;
KIRP	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.11	12.04	0.61	1.53e-26	Vitiligo;
KIRP	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-8.74	-0.49	3.59e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	1.03	11.14	0.58	1.31e-23	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.51	7.56	0.43	8.08e-13	Schizophrenia;
KIRP	cis	rs3755132	1.000	rs3755132	chr2:15729820	T/G	cg12888861	chr2:15731646	DDX1	0.4	5.32	0.32	2.36e-7	Wilms tumor;
KIRP	cis	rs12282928	0.959	rs1566737	chr11:48238302	A/C	cg26585981	chr11:48327164	OR4S1	0.53	6.18	0.37	2.67e-9	Migraine - clinic-based;
KIRP	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg21427119	chr20:30132790	HM13	-0.54	-6.19	-0.37	2.53e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs501120	0.543	rs800331	chr10:44806378	C/T	cg09554077	chr10:44749378	NA	0.43	5.62	0.34	5.15e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14033686	chr9:95056052	IARS;SNORA84	-0.46	-6.46	-0.38	5.41e-10	Metabolic traits;
KIRP	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26314531	chr2:26401878	FAM59B	0.48	4.95	0.3	1.35e-6	Gut microbiome composition (summer);
KIRP	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.64	-7.13	-0.41	1.12e-11	Neuroticism;
KIRP	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.95	-13.4	-0.65	4.17e-31	Schizophrenia;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.61	-7.55	-0.43	8.45e-13	Breast cancer;
KIRP	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-4.91	-0.3	1.67e-6	IgG glycosylation;
KIRP	cis	rs55675132	0.590	rs12143421	chr1:115581350	A/T	cg12756093	chr1:115239321	AMPD1	-0.54	-5.21	-0.32	4.05e-7	Schizophrenia;
KIRP	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg01522456	chr1:115632236	TSPAN2	0.37	5.05	0.31	8.73e-7	Autism;
KIRP	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg22705602	chr4:152727874	NA	-0.38	-5.86	-0.35	1.47e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg21856205	chr7:94953877	PON1	-0.45	-5.01	-0.3	1.04e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.53	6.81	0.4	7.49e-11	Coronary heart disease;
KIRP	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.18	-0.31	4.69e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4665630	0.522	rs114880940	chr2:23930352	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	0.98	5.57	0.33	6.55e-8	Hypertension;
KIRP	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.6	8.74	0.49	3.73e-16	Lung cancer;
KIRP	cis	rs7129556	0.737	rs10899404	chr11:77462792	C/T	cg12586386	chr11:77299805	AQP11	0.39	5.28	0.32	2.91e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg00094735	chr5:1949198	NA	-0.43	-5.05	-0.31	8.56e-7	Gut microbiome composition (winter);
KIRP	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg07796016	chr1:152779584	LCE1C	-0.42	-5.42	-0.33	1.43e-7	Inflammatory skin disease;
KIRP	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg22800045	chr5:56110881	MAP3K1	-0.58	-6.91	-0.4	4.06e-11	Initial pursuit acceleration;
KIRP	cis	rs6061231	0.546	rs482220	chr20:60927482	G/A	cg24112000	chr20:60950667	NA	0.59	9.11	0.5	3.04e-17	Colorectal cancer;
KIRP	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.56	-7.27	-0.42	4.7e-12	Aortic root size;
KIRP	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	1.1	9.81	0.53	2.23e-19	Body mass index;
KIRP	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.6	-7.66	-0.44	4.24e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg12856521	chr11:46389249	DGKZ	0.56	7.29	0.42	4.31e-12	Crohn's disease;
KIRP	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.16	9.24	0.51	1.2e-17	Skin colour saturation;
KIRP	trans	rs6601327	0.635	rs10099122	chr8:9568003	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.39	-0.38	8.36e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg03647239	chr10:116582469	FAM160B1	0.52	5.91	0.35	1.15e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg24881330	chr22:46731750	TRMU	0.77	5.29	0.32	2.72e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg04058563	chr4:185651563	MLF1IP	1.0	10.09	0.54	2.98e-20	Systemic lupus erythematosus;
KIRP	cis	rs9649213	0.593	rs34776142	chr7:97899873	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.44	0.33	1.26e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.8	12.43	0.62	7.59e-28	Longevity;
KIRP	cis	rs4073221	0.654	rs35642807	chr3:18275420	T/C	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.4e-9	Parkinson's disease;
KIRP	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg14541582	chr5:601475	NA	-0.57	-6.5	-0.38	4.44e-10	Obesity-related traits;
KIRP	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14169450	chr9:139327907	INPP5E	0.5	7.37	0.43	2.62e-12	Monocyte percentage of white cells;
KIRP	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.33	-0.42	3.21e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.38	-0.47	4.06e-15	Platelet count;
KIRP	cis	rs9634489	0.588	rs1925118	chr13:96944161	A/T	cg02571835	chr13:96230311	CLDN10	-0.34	-4.98	-0.3	1.21e-6	Body mass index;
KIRP	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg23803603	chr1:2058230	PRKCZ	-0.4	-5.79	-0.35	2.18e-8	Height;
KIRP	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.77	9.44	0.52	2.96e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27362222	chr4:124317901	SPRY1	0.47	6.38	0.38	8.64e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11987759	chr7:65425863	GUSB	-0.46	-5.43	-0.33	1.34e-7	Aortic root size;
KIRP	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.33	-0.42	3.25e-12	Morning vs. evening chronotype;
KIRP	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.83	8.87	0.49	1.49e-16	Iron status biomarkers;
KIRP	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg26898376	chr11:64110657	CCDC88B	0.46	5.06	0.31	8.38e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg25019033	chr10:957182	NA	-0.63	-7.56	-0.43	7.96e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.13	0.36	3.56e-9	Platelet count;
KIRP	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21747090	chr2:27597821	SNX17	-0.47	-6.44	-0.38	6.14e-10	Total body bone mineral density;
KIRP	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.2e-23	Prudent dietary pattern;
KIRP	cis	rs2625529	0.824	rs55854204	chr15:72433182	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.27	-0.32	3.02e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17313118	chr5:127157258	NA	0.43	6.08	0.36	4.67e-9	Survival in pancreatic cancer;
KIRP	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.65	-0.66	5.97e-32	Monocyte count;
KIRP	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.08	-0.41	1.47e-11	Response to antipsychotic treatment;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg13906792	chr15:75199810	C15orf17	-0.35	-4.91	-0.3	1.68e-6	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04395431	chr14:45619710	FANCM	-0.41	-6.08	-0.36	4.54e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.58	-7.73	-0.44	2.79e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.51e-15	Mortality in heart failure;
KIRP	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.48	-0.43	1.34e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.81	10.1	0.54	2.73e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.03	-0.31	9.43e-7	Colorectal cancer;
KIRP	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg11845111	chr2:191398756	TMEM194B	-0.95	-9.98	-0.54	6.68e-20	Diastolic blood pressure;
KIRP	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.35	4.95	0.3	1.36e-6	Coronary artery disease;
KIRP	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11987759	chr7:65425863	GUSB	-0.69	-9.79	-0.53	2.49e-19	Calcium levels;
KIRP	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg02980000	chr4:1222292	CTBP1	0.93	8.49	0.48	1.92e-15	Systolic blood pressure;
KIRP	cis	rs1538970	0.924	rs11211117	chr1:45930246	C/T	cg03146154	chr1:46216737	IPP	0.47	5.1	0.31	6.94e-7	Platelet count;
KIRP	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.45	5.08	0.31	7.44e-7	Schizophrenia;
KIRP	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg22974920	chr21:40686053	BRWD1	0.47	5.57	0.33	6.82e-8	Cognitive function;
KIRP	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-10.52	-0.56	1.3e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.63	-6.57	-0.39	2.94e-10	Gut microbiome composition (summer);
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.4	8.43	0.47	2.87e-15	Vitiligo;
KIRP	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.2	22.07	0.82	3.02e-60	Cognitive function;
KIRP	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.9	-14.76	-0.69	9.63e-36	Urate levels in lean individuals;
KIRP	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.65	9.36	0.51	5.25e-18	Lymphocyte counts;
KIRP	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.32	0.37	1.24e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.97	0.66	4.96e-33	Mean platelet volume;
KIRP	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs6866344	0.569	rs56070635	chr5:178150169	A/C	cg10224037	chr5:178157518	ZNF354A	0.9	10.47	0.56	1.9e-21	Neutrophil percentage of white cells;
KIRP	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1864585	0.520	rs73208778	chr8:10670154	A/T	cg26278703	chr11:58910052	FAM111A	0.64	6.45	0.38	5.88e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.3	0.47	7.17e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.31	-5.18	-0.31	4.52e-7	Refractive error;
KIRP	cis	rs2014572	0.967	rs10412975	chr19:57770554	C/A	cg12963866	chr19:57752005	ZNF805	-0.48	-6.06	-0.36	4.98e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs10875746	0.903	rs61918774	chr12:48448134	C/G	cg20731937	chr12:48336164	NA	0.4	5.14	0.31	5.6e-7	Longevity (90 years and older);
KIRP	trans	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg02030672	chr11:45687055	CHST1	0.62	7.88	0.45	1.04e-13	Obesity-related traits;
KIRP	cis	rs7011507	1.000	rs113213719	chr8:49155204	A/G	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-0.85	-12.37	-0.62	1.19e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg17218026	chr1:154582156	ADAR	0.35	5.8	0.35	1.98e-8	Blood protein levels;
KIRP	cis	rs2395528	0.597	rs2670222	chr10:80126266	T/C	cg08356028	chr10:80217969	NA	-0.38	-5.64	-0.34	4.71e-8	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs4591494	0.651	rs73029871	chr3:7924071	C/G	cg06740372	chr3:7957779	NA	-0.36	-4.86	-0.3	2.09e-6	Factor VII;
KIRP	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.71	9.0	0.5	6.1e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg04025307	chr7:1156635	C7orf50	0.81	8.33	0.47	5.63e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62413470	1.000	rs4295483	chr6:55965456	C/A	cg13327911	chr6:55965977	COL21A1	0.55	5.01	0.3	1.04e-6	Joint mobility (Beighton score);
KIRP	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg02792322	chr13:21280448	IL17D	0.31	5.23	0.32	3.64e-7	Dental caries;
KIRP	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs11997175	0.766	rs6983113	chr8:33699513	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.59	0.34	5.87e-8	Body mass index;
KIRP	cis	rs4700695	0.841	rs251610	chr5:65278481	G/T	cg21114390	chr5:65439923	SFRS12	-0.57	-6.17	-0.37	2.84e-9	Facial morphology (factor 19);
KIRP	cis	rs6815814	0.950	rs56357984	chr4:38806462	G/A	cg06935464	chr4:38784597	TLR10	0.52	5.21	0.32	3.94e-7	Breast cancer;
KIRP	cis	rs7681423	1.000	rs2066854	chr4:155535181	T/A	cg20735720	chr4:155535218	FGG	-0.65	-8.56	-0.48	1.23e-15	Fibrinogen;
KIRP	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.83	-12.42	-0.62	8.02e-28	Body mass index;
KIRP	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.53	-0.38	3.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.73	6.88	0.4	4.88e-11	Pulse pressure;
KIRP	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02287279	chr5:89814120	LYSMD3	0.43	6.45	0.38	5.75e-10	Migraine with aura;
KIRP	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg06873352	chr17:61820015	STRADA	-0.49	-5.99	-0.36	7.39e-9	Prudent dietary pattern;
KIRP	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.83	9.94	0.54	8.39e-20	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg00024416	chr22:24240387	NA	-0.35	-5.03	-0.31	9.32e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7116495	1.000	rs7937582	chr11:71744613	C/T	cg07596299	chr11:71824057	C11orf51	-0.62	-4.93	-0.3	1.54e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.62	6.89	0.4	4.79e-11	Menarche (age at onset);
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg17441377	chr17:3906640	NA	-0.55	-8.29	-0.47	7.26e-15	Type 2 diabetes;
KIRP	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.99	13.86	0.66	1.12e-32	Response to antipsychotic treatment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20907517	chr20:47894756	C20orf199;ZNFX1;SNORD12C	0.46	6.17	0.37	2.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.66	-12.19	-0.61	4.87e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg18898632	chr2:242989856	NA	-0.51	-4.98	-0.3	1.2e-6	Obesity-related traits;
KIRP	trans	rs6601327	0.665	rs12543369	chr8:9655915	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.22	-0.42	6.45e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg24747557	chr10:131355152	MGMT	-0.42	-5.68	-0.34	3.7e-8	Response to temozolomide;
KIRP	cis	rs8192282	0.739	rs6662503	chr1:154477069	T/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.33	-4.85	-0.3	2.16e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12379764	chr21:47803548	PCNT	-0.43	-5.2	-0.31	4.16e-7	Testicular germ cell tumor;
KIRP	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg19875535	chr5:140030758	IK	-0.7	-10.11	-0.54	2.64e-20	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg16497661	chr14:103986332	CKB	-0.49	-6.31	-0.37	1.26e-9	Coronary artery disease;
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg26134248	chr17:3907702	NA	-0.54	-7.86	-0.45	1.17e-13	Type 2 diabetes;
KIRP	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.35e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.58	7.63	0.44	5.3e-13	Hip circumference;
KIRP	cis	rs2278796	0.608	rs11240332	chr1:204969317	C/T	cg17449235	chr1:204966235	NFASC	0.55	7.58	0.44	6.92e-13	Mean platelet volume;
KIRP	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.13	14.61	0.68	3.05e-35	Gut microbiome composition (summer);
KIRP	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.43	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs11731606	0.508	rs17021533	chr4:95280587	C/T	cg00507259	chr4:95128692	SMARCAD1	0.6	5.96	0.36	8.75e-9	Mean platelet volume;
KIRP	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg25486957	chr4:152246857	NA	-0.42	-4.86	-0.3	2.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.37	-0.32	1.79e-7	Chronic sinus infection;
KIRP	cis	rs13315871	0.929	rs4560319	chr3:58386274	C/T	cg12435725	chr3:58293450	RPP14	-0.48	-5.12	-0.31	6.19e-7	Cholesterol, total;
KIRP	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.28	5.54	0.33	7.86e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08678925	chr15:85358595	ALPK3	0.55	6.66	0.39	1.75e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg27532560	chr4:187881888	NA	-0.75	-12.83	-0.63	3.53e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg02527881	chr3:46936655	PTH1R	-0.42	-6.06	-0.36	5.21e-9	Colorectal cancer;
KIRP	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg18527119	chr7:66119851	NA	-0.45	-4.88	-0.3	1.87e-6	Aortic root size;
KIRP	trans	rs7980799	0.935	rs10844580	chr12:33553867	G/A	cg26384229	chr12:38710491	ALG10B	-0.54	-6.66	-0.39	1.82e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs796364	0.616	rs6710393	chr2:200697246	G/A	cg23649088	chr2:200775458	C2orf69	0.58	5.6	0.34	5.82e-8	Schizophrenia;
KIRP	cis	rs2574704	0.561	rs2574712	chr3:11667602	G/A	cg07643000	chr3:11666825	VGLL4	-0.51	-6.18	-0.37	2.61e-9	Body mass index;
KIRP	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg03959625	chr15:84868606	LOC388152	0.51	6.09	0.36	4.39e-9	Schizophrenia;
KIRP	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-8.23	-0.46	1.07e-14	Colorectal cancer;
KIRP	cis	rs7116495	0.609	rs4944243	chr11:71674354	T/C	cg10381502	chr11:71823885	C11orf51	-1.04	-7.3	-0.42	4e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.41	5.15	0.31	5.43e-7	Longevity;Endometriosis;
KIRP	trans	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg24644049	chr4:85504048	CDS1	1.04	7.22	0.42	6.41e-12	Skin colour saturation;
KIRP	cis	rs2223471	0.870	rs2744494	chr6:50757690	G/A	cg03432817	chr6:50765336	NA	-0.53	-8.81	-0.49	2.35e-16	Subcutaneous adipose tissue;
KIRP	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg08873628	chr1:175162347	KIAA0040	-0.41	-6.04	-0.36	5.63e-9	Alcohol dependence;
KIRP	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.72	10.45	0.55	2.12e-21	Hip circumference;
KIRP	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	4.92	0.3	1.59e-6	Total cholesterol levels;
KIRP	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.95	-0.35	9.01e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg00106254	chr7:1943704	MAD1L1	-0.51	-5.5	-0.33	9.38e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.3	-0.47	7.1e-15	Fibroblast growth factor basic levels;
KIRP	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-0.99	-13.1	-0.64	4.12e-30	Body mass index;
KIRP	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.72	9.23	0.51	1.26e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg22974920	chr21:40686053	BRWD1	0.47	5.6	0.34	5.67e-8	Cognitive function;
KIRP	cis	rs11264213	0.591	rs399393	chr1:36553673	A/G	cg27506609	chr1:36549197	TEKT2	-0.99	-8.03	-0.46	4.03e-14	Schizophrenia;
KIRP	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.82	-14.56	-0.68	4.55e-35	Post bronchodilator FEV1;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg09264619	chr17:80180166	NA	-0.37	-5.38	-0.32	1.71e-7	Life satisfaction;
KIRP	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.56	-6.97	-0.41	2.85e-11	Uric acid clearance;
KIRP	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.53	6.8	0.4	8.11e-11	Tonsillectomy;
KIRP	cis	rs684232	0.805	rs2360737	chr17:506163	C/T	cg04370829	chr17:406249	NA	0.38	5.01	0.3	1.04e-6	Prostate cancer;
KIRP	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg05315796	chr3:52349193	DNAH1	-0.42	-6.33	-0.37	1.14e-9	Bipolar disorder;
KIRP	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg11168104	chr5:1857477	NA	-0.41	-5.28	-0.32	2.83e-7	Cardiovascular disease risk factors;
KIRP	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg03714773	chr7:91764589	CYP51A1	0.36	5.22	0.32	3.85e-7	Breast cancer;
KIRP	cis	rs7551222	0.752	rs4245737	chr1:204486242	A/G	cg20240347	chr1:204465584	NA	-0.42	-8.0	-0.45	5.02e-14	Schizophrenia;
KIRP	cis	rs9462846	0.652	rs115953673	chr6:42906243	T/A	cg13397359	chr6:42928475	GNMT	0.55	6.05	0.36	5.27e-9	Blood protein levels;
KIRP	cis	rs10203711	0.966	rs4998692	chr2:239564772	T/G	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg18132916	chr6:79620363	NA	-0.42	-5.58	-0.34	6.36e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg02461776	chr11:598696	PHRF1	0.7	7.65	0.44	4.62e-13	Systemic lupus erythematosus;
KIRP	cis	rs1497828	0.956	rs9441482	chr1:217571282	T/A	cg04411442	chr1:217543379	NA	0.44	6.48	0.38	5.04e-10	Dialysis-related mortality;
KIRP	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg24315340	chr6:146058215	EPM2A	-0.4	-4.92	-0.3	1.55e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg23202291	chr11:1979235	NA	0.41	5.28	0.32	2.87e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.91	-9.01	-0.5	5.74e-17	Platelet count;
KIRP	cis	rs643506	1.000	rs612345	chr11:111639122	G/A	cg09085632	chr11:111637200	PPP2R1B	0.52	5.77	0.35	2.36e-8	Breast cancer;
KIRP	cis	rs2274471	0.699	rs12551254	chr9:5043007	C/T	cg03390472	chr9:5043263	JAK2	-0.48	-5.48	-0.33	1.03e-7	Crohn's disease;
KIRP	cis	rs78487399	0.731	rs13395302	chr2:43706350	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.59	-0.34	6e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.54	-6.83	-0.4	6.61e-11	Iron status biomarkers;
KIRP	trans	rs11023787	1.000	rs11023779	chr11:15937067	C/T	cg19973338	chr17:76141249	C17orf99	0.49	6.26	0.37	1.73e-9	Bone mineral density (wrist);
KIRP	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.81	-9.0	-0.5	6.47e-17	Diastolic blood pressure;
KIRP	cis	rs57244997	0.685	rs2226770	chr6:162447251	C/T	cg17173639	chr6:162384350	PARK2	0.53	5.14	0.31	5.7e-7	Mosquito bite size;
KIRP	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg16989719	chr2:238392110	NA	-0.68	-6.16	-0.37	2.94e-9	Prostate cancer;
KIRP	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg10047753	chr17:41438598	NA	0.99	16.39	0.72	2.65e-41	Menopause (age at onset);
KIRP	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.83	13.39	0.65	4.27e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs311392	0.554	rs2666884	chr8:55100906	T/C	cg11783602	chr8:55087084	NA	-0.46	-5.5	-0.33	9.31e-8	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	0.98	11.54	0.59	6.61e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg21775007	chr8:11205619	TDH	0.43	5.83	0.35	1.76e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4561483	0.582	rs35063476	chr16:12044301	A/G	cg08843971	chr16:11963173	GSPT1	-0.49	-5.96	-0.36	8.77e-9	Testicular germ cell tumor;
KIRP	cis	rs1881492	0.554	rs868746	chr2:233457831	A/G	cg03852847	chr2:233439513	NA	-0.66	-8.5	-0.48	1.81e-15	Refractive error;
KIRP	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg06521331	chr12:34319734	NA	0.52	6.73	0.39	1.16e-10	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	3.91e-8	Life satisfaction;
KIRP	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.77	0.35	2.38e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs12043259	0.730	rs7525108	chr1:204793068	C/T	cg11485465	chr5:54518469	NA	0.35	6.28	0.37	1.55e-9	Addiction;
KIRP	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg03929089	chr4:120376271	NA	0.69	6.17	0.37	2.79e-9	Axial length;
KIRP	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg15655495	chr12:38532458	NA	0.26	4.98	0.3	1.2e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	9.24	0.51	1.22e-17	Obesity-related traits;
KIRP	cis	rs6732160	0.706	rs1430348	chr2:73367058	C/T	cg01422370	chr2:73384389	NA	0.4	5.25	0.32	3.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs714027	0.515	rs2412972	chr22:30519825	T/A	cg01021169	chr22:30184971	ASCC2	0.44	5.59	0.34	6.05e-8	Lymphocyte counts;
KIRP	trans	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg06521331	chr12:34319734	NA	-0.51	-6.31	-0.37	1.29e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	7.97	0.45	5.97e-14	Educational attainment;
KIRP	trans	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg06521331	chr12:34319734	NA	-0.53	-6.67	-0.39	1.68e-10	Bladder cancer;
KIRP	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.33	-0.37	1.17e-9	Response to antipsychotic treatment;
KIRP	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg05868516	chr6:26286170	HIST1H4H	0.39	5.01	0.3	1.06e-6	Educational attainment;
KIRP	cis	rs4460629	0.650	rs11264319	chr1:155083942	T/C	cg02153340	chr1:155202674	NA	-0.35	-5.01	-0.3	1.04e-6	Serum magnesium levels;
KIRP	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg08873628	chr1:175162347	KIAA0040	0.43	6.37	0.38	8.99e-10	Alcohol dependence;
KIRP	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg21475434	chr5:93447410	FAM172A	0.77	6.86	0.4	5.64e-11	Diabetic retinopathy;
KIRP	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg17366294	chr4:99064904	C4orf37	-0.35	-4.93	-0.3	1.52e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	trans	rs7210837	0.591	rs11657533	chr17:16804619	A/C	cg11294312	chr17:28900046	NA	-0.67	-6.07	-0.36	4.81e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.46	-5.9	-0.35	1.22e-8	Blood metabolite levels;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.48	5.52	0.33	8.5e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9815354	1.000	rs7646144	chr3:41853125	T/A	cg03022575	chr3:42003672	ULK4	0.51	5.41	0.33	1.51e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs12580194	0.593	rs12099665	chr12:55731191	G/T	cg19537932	chr12:55886519	OR6C68	-0.51	-6.51	-0.38	4.15e-10	Cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11582854	chr19:37569352	ZNF420	-0.56	-6.7	-0.39	1.37e-10	Interleukin-4 levels;
KIRP	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4776059	1.000	rs12915981	chr15:52901433	C/T	cg22715398	chr15:52968154	KIAA1370	-0.66	-7.92	-0.45	8.19e-14	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.93	8.24	0.47	1.02e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg23100626	chr2:96804247	ASTL	0.44	5.36	0.32	1.95e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	8.71	0.49	4.4e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs77861329	1.000	rs9809977	chr3:52166147	T/C	cg08692210	chr3:52188851	WDR51A	0.95	7.61	0.44	5.84e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg00129232	chr17:37814104	STARD3	0.64	8.03	0.46	4.09e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg25486957	chr4:152246857	NA	-0.45	-5.45	-0.33	1.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg26875233	chr11:93583750	C11orf90	0.41	8.01	0.45	4.62e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-9.39	-0.51	4.37e-18	Body mass index;
KIRP	trans	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg26043149	chr18:55253948	FECH	-0.51	-6.64	-0.39	1.98e-10	Bone mineral density;
KIRP	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.41	-5.73	-0.34	2.95e-8	Dementia with Lewy bodies;
KIRP	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.43	-5.73	-0.34	2.92e-8	Height;
KIRP	cis	rs7551222	0.752	rs4951075	chr1:204464446	C/A	cg20240347	chr1:204465584	NA	-0.44	-8.3	-0.47	6.72e-15	Schizophrenia;
KIRP	cis	rs35883536	1.000	rs964906	chr1:101087479	G/A	cg06223162	chr1:101003688	GPR88	0.32	6.46	0.38	5.45e-10	Monocyte count;
KIRP	cis	rs4281086	0.587	rs56225449	chr8:10365181	C/T	cg21775007	chr8:11205619	TDH	0.4	5.14	0.31	5.63e-7	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.92	12.51	0.62	4.12e-28	Menopause (age at onset);
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg11204139	chr17:3907470	NA	0.88	17.07	0.74	1.3e-43	Type 2 diabetes;
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.75	-10.84	-0.57	1.21e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	9.83	0.53	1.89e-19	Total body bone mineral density;
KIRP	cis	rs9372498	0.572	rs62422190	chr6:118909235	A/G	cg18833306	chr6:118973337	C6orf204	-0.48	-4.86	-0.3	2.13e-6	Diastolic blood pressure;
KIRP	cis	rs970821	0.667	rs1985668	chr8:124742952	T/A	cg00283535	chr8:124749564	ANXA13	0.33	5.51	0.33	9.13e-8	Breast cancer;
KIRP	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg04166393	chr7:2884313	GNA12	0.41	5.24	0.32	3.42e-7	Height;
KIRP	trans	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg10756647	chr7:56101905	PSPH	0.9	6.38	0.38	8.82e-10	Diabetic kidney disease;
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13198984	chr17:80129470	CCDC57	-0.58	-8.78	-0.49	2.83e-16	Life satisfaction;
KIRP	trans	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg16141378	chr3:129829833	LOC729375	-0.51	-6.08	-0.36	4.6e-9	Neuroticism;
KIRP	cis	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg21546286	chr11:48923668	NA	0.43	5.18	0.31	4.7e-7	HDL cholesterol;
KIRP	cis	rs9513627	1.000	rs7338335	chr13:100125296	G/C	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs2367563	1.000	rs2367563	chr12:96057184	A/G	cg19013339	chr12:96052514	NTN4	0.35	5.54	0.33	7.74e-8	Allergic dermatitis (nickel);
KIRP	cis	rs1847202	0.826	rs11922892	chr3:72952186	T/G	cg06781948	chr3:72941472	GXYLT2	0.42	5.7	0.34	3.5e-8	Motion sickness;
KIRP	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg02012338	chr4:187126139	CYP4V2	0.93	7.25	0.42	5.55e-12	Blood protein levels;
KIRP	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg23034840	chr1:205782522	SLC41A1	0.58	7.65	0.44	4.66e-13	Menarche (age at onset);
KIRP	cis	rs9826463	0.757	rs77081474	chr3:142294634	T/C	cg20824294	chr3:142316082	PLS1	0.38	6.19	0.37	2.53e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	0.43	6.04	0.36	5.59e-9	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.83	-11.03	-0.58	2.94e-23	Body mass index;
KIRP	cis	rs7951870	1.000	rs7109698	chr11:46673344	A/G	cg16389345	chr11:46697382	NA	0.46	5.0	0.3	1.09e-6	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.48	4.88	0.3	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4332428	1.000	rs7921185	chr10:4976430	G/T	cg19648686	chr10:5044992	AKR1C2	-0.91	-8.03	-0.46	4.11e-14	Height;
KIRP	cis	rs33912345	0.695	rs1254258	chr14:60833202	G/A	cg27398547	chr14:60952738	C14orf39	-0.42	-5.63	-0.34	4.9e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.92	-12.51	-0.62	4.02e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.25	0.32	3.33e-7	Alzheimer's disease;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg27189623	chr16:705930	WDR90	0.45	6.28	0.37	1.55e-9	Height;
KIRP	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.63	8.32	0.47	6.06e-15	Economic and political preferences (feminism/equality);
KIRP	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg26898376	chr11:64110657	CCDC88B	0.57	5.19	0.31	4.46e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs988913	1.000	rs9382407	chr6:54836638	T/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.67	-0.34	3.97e-8	Menarche (age at onset);
KIRP	trans	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg24644049	chr4:85504048	CDS1	0.93	6.88	0.4	4.86e-11	Skin colour saturation;
KIRP	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.45	5.15	0.31	5.27e-7	Schizophrenia;
KIRP	cis	rs7011049	1.000	rs72640852	chr8:53838084	G/A	cg26025543	chr8:53854495	NA	0.75	7.84	0.45	1.33e-13	Systolic blood pressure;
KIRP	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.93	-15.43	-0.7	5.19e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.17	-0.37	2.83e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg09699651	chr6:150184138	LRP11	0.46	5.92	0.35	1.09e-8	Lung cancer;
KIRP	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg26876637	chr1:152193138	HRNR	0.77	10.13	0.54	2.27e-20	Atopic dermatitis;
KIRP	cis	rs11166927	1.000	rs13260415	chr8:140805137	A/C	cg16909799	chr8:140841666	TRAPPC9	0.73	10.71	0.56	3.29e-22	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs6662572	0.641	rs4660891	chr1:46319447	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs6575793	1.000	rs8006176	chr14:101033288	A/G	cg18516195	chr14:101012996	BEGAIN	0.5	7.11	0.41	1.27e-11	Menarche (age at onset);
KIRP	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.29	-0.51	8.7e-18	Response to antipsychotic treatment;
KIRP	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.5	5.95	0.35	8.94e-9	Metabolite levels;
KIRP	cis	rs7215564	0.509	rs61750765	chr17:78519519	T/C	cg06153925	chr17:78755379	RPTOR	0.39	5.13	0.31	5.96e-7	Myopia (pathological);
KIRP	cis	rs6693567	0.545	rs4451552	chr1:150455854	C/G	cg09579323	chr1:150459698	TARS2	0.47	5.69	0.34	3.68e-8	Migraine;
KIRP	cis	rs1359582	0.793	rs7900987	chr10:90399072	G/C	cg15661332	chr10:90342814	RNLS	0.56	5.94	0.35	9.84e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs116095464	0.850	rs10057272	chr5:340188	T/C	cg22857025	chr5:266934	NA	-1.11	-7.21	-0.42	6.72e-12	Breast cancer;
KIRP	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg06634786	chr22:41940651	POLR3H	-0.52	-5.54	-0.33	7.71e-8	Neuroticism;
KIRP	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.2	-0.37	2.38e-9	IgG glycosylation;
KIRP	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs986417	0.901	rs1010052	chr14:61003071	G/A	cg27398547	chr14:60952738	C14orf39	0.67	6.64	0.39	1.97e-10	Gut microbiota (bacterial taxa);
KIRP	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.64	6.39	0.38	8.41e-10	Gastritis;
KIRP	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.47	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.17	-0.31	4.81e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg00922110	chr4:57842668	C4orf14	-0.43	-5.69	-0.34	3.56e-8	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg17133734	chr15:86042851	AKAP13	-0.48	-5.97	-0.36	8.23e-9	Coronary artery disease;
KIRP	cis	rs10858047	0.883	rs72698011	chr1:115093654	T/C	cg12756093	chr1:115239321	AMPD1	0.64	6.11	0.36	3.87e-9	Autism;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03270376	chr2:219536588	RNF25;STK36	0.65	6.04	0.36	5.54e-9	Lung function (FEV1);
KIRP	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.53	-5.28	-0.32	2.88e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg21253087	chr9:139290292	SNAPC4	0.46	6.45	0.38	5.82e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg05347473	chr6:146136440	FBXO30	0.49	7.16	0.42	9.37e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-12.29	-0.62	2.19e-27	Alzheimer's disease;
KIRP	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13047869	chr3:10149882	C3orf24	0.55	5.13	0.31	6.02e-7	Alzheimer's disease;
KIRP	cis	rs11169552	0.510	rs10506295	chr12:51085471	A/G	cg12884762	chr12:50931848	DIP2B	-0.41	-4.94	-0.3	1.45e-6	Colorectal cancer;
KIRP	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.52	6.81	0.4	7.38e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg18154014	chr19:37997991	ZNF793	0.74	7.98	0.45	5.47e-14	Coronary artery calcification;
KIRP	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg10117171	chr1:25599238	RHD	-0.39	-5.37	-0.32	1.86e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.89	13.82	0.66	1.61e-32	Mean corpuscular volume;
KIRP	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.75	-6.91	-0.4	4.19e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg04374321	chr14:90722782	PSMC1	-0.8	-10.86	-0.57	1.07e-22	Mortality in heart failure;
KIRP	cis	rs62413470	0.935	rs62411453	chr6:55964651	A/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs35883536	0.506	rs2809814	chr1:101031829	C/T	cg09408571	chr1:101003634	GPR88	0.23	5.27	0.32	2.96e-7	Monocyte count;
KIRP	cis	rs7213347	0.581	rs4790881	chr17:2068932	C/A	cg16513277	chr17:2031491	SMG6	-0.43	-4.97	-0.3	1.23e-6	Total body bone mineral density;
KIRP	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.82	-8.64	-0.48	7.39e-16	Alzheimer's disease;
KIRP	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.08e-6	Bladder cancer;
KIRP	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg03235661	chr20:60525775	NA	-0.29	-5.06	-0.31	8.2e-7	Body mass index;
KIRP	cis	rs151997	1.000	rs42415	chr5:50207442	T/A	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02100365	chr1:92762956	GLMN	-0.43	-6.12	-0.36	3.69e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2273669	0.667	rs78383792	chr6:109312498	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-6.27	-0.37	1.64e-9	Prostate cancer;
KIRP	cis	rs7845219	0.525	rs3019175	chr8:95949013	G/A	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.71	-0.39	1.29e-10	Type 2 diabetes;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg07254608	chr8:41997973	NA	0.72	6.11	0.36	3.83e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs877282	0.583	rs11253424	chr10:813426	C/T	cg22713356	chr15:30763199	NA	0.92	9.28	0.51	9.26e-18	Uric acid levels;
KIRP	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.58	5.15	0.31	5.46e-7	Alzheimer's disease;
KIRP	cis	rs2033732	0.706	rs10958211	chr8:85074884	G/C	cg05716166	chr8:85095498	RALYL	0.54	6.13	0.36	3.39e-9	Body mass index;
KIRP	cis	rs9653442	0.564	rs10175599	chr2:100787635	C/T	cg22139774	chr2:100720529	AFF3	-0.29	-4.92	-0.3	1.59e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.68	-9.09	-0.5	3.31e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg04662943	chr10:102668895	NA	0.47	5.07	0.31	7.7e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10924970	0.967	rs2152955	chr1:235417773	G/A	cg26050004	chr1:235667680	B3GALNT2	0.4	4.99	0.3	1.12e-6	Asthma;
KIRP	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.95	13.47	0.65	2.44e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.585	rs550480	chr6:116264354	C/A	cg18764771	chr6:116381957	FRK	-0.19	-5.01	-0.3	1.05e-6	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.52	6.53	0.38	3.74e-10	Asthma;
KIRP	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.78	-0.35	2.23e-8	Breast cancer;
KIRP	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-6.15	-0.37	3.03e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.56	10.25	0.55	9.56e-21	Iron status biomarkers (transferrin levels);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23052386	chr13:111553101	ANKRD10	0.5	6.65	0.39	1.89e-10	Interleukin-4 levels;
KIRP	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.39	-0.33	1.64e-7	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg13206674	chr6:150067644	NUP43	0.58	8.52	0.48	1.57e-15	Lung cancer;
KIRP	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg13798912	chr7:905769	UNC84A	0.51	5.23	0.32	3.68e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg20302533	chr7:39170763	POU6F2	0.26	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg22852734	chr6:133119734	C6orf192	1.14	13.89	0.66	8.62e-33	Type 2 diabetes nephropathy;
KIRP	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.6	8.76	0.49	3.24e-16	Immature fraction of reticulocytes;
KIRP	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.58	6.8	0.4	7.67e-11	Corneal astigmatism;
KIRP	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.87	-0.4	5.14e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.31	0.55	6.14e-21	Coffee consumption (cups per day);
KIRP	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.21	27.25	0.87	2.91e-76	Schizophrenia;
KIRP	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.02	0.61	1.76e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg08017634	chr8:144659831	NAPRT1	0.82	5.3	0.32	2.54e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs4783244	0.762	rs62038459	chr16:82646059	G/A	cg09415485	chr16:82663111	CDH13	-0.26	-4.86	-0.3	2.14e-6	Adiponectin levels;
KIRP	cis	rs6942756	0.531	rs4731569	chr7:128930828	C/T	cg02491457	chr7:128862824	NA	0.44	5.71	0.34	3.32e-8	White matter hyperintensity burden;
KIRP	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.77	9.51	0.52	1.84e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg10818794	chr15:86012489	AKAP13	-0.49	-6.97	-0.41	2.85e-11	Interstitial lung disease;
KIRP	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.56	-0.33	6.97e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2380205	0.875	rs4282898	chr10:5899287	T/A	cg27141509	chr10:5886111	NA	-0.36	-5.24	-0.32	3.48e-7	Breast cancer;
KIRP	cis	rs1448094	0.645	rs12301701	chr12:86472798	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-5.02	-0.3	1.01e-6	Major depressive disorder;
KIRP	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg00792783	chr2:198669748	PLCL1	0.47	5.35	0.32	2.04e-7	Dermatomyositis;
KIRP	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.49	5.95	0.35	8.98e-9	Common traits (Other);
KIRP	cis	rs4666002	0.636	rs13023194	chr2:27967260	G/C	cg05484376	chr2:27715224	FNDC4	-0.48	-5.7	-0.34	3.48e-8	Phospholipid levels (plasma);
KIRP	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg26695010	chr11:65641043	EFEMP2	0.51	5.12	0.31	6.29e-7	Crohn's disease;
KIRP	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	5.02e-11	Blood metabolite levels;
KIRP	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg06712362	chr1:7811235	CAMTA1	0.43	5.35	0.32	1.98e-7	Crohn's disease;
KIRP	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.52	6.89	0.4	4.67e-11	Schizophrenia;
KIRP	cis	rs7837860	0.588	rs7011035	chr8:89299708	T/G	cg08624180	chr8:89339080	MMP16	-0.61	-5.19	-0.31	4.42e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg01557791	chr16:72042693	DHODH	-0.65	-7.32	-0.42	3.48e-12	Blood protein levels;
KIRP	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.63	-6.65	-0.39	1.85e-10	Bipolar disorder;
KIRP	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg02996583	chr8:142237188	SLC45A4	0.5	6.2	0.37	2.4e-9	Immature fraction of reticulocytes;
KIRP	cis	rs13082711	0.911	rs57992391	chr3:27511567	A/C	cg02860705	chr3:27208620	NA	0.48	6.69	0.39	1.54e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.37	1.53e-9	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg20965017	chr5:231967	SDHA	-0.58	-6.78	-0.4	8.71e-11	Breast cancer;
KIRP	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg05527609	chr1:210001259	C1orf107	-0.37	-4.95	-0.3	1.41e-6	Monobrow;
KIRP	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.74	-8.61	-0.48	9.15e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg11189052	chr15:85197271	WDR73	0.51	5.33	0.32	2.24e-7	Schizophrenia;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07207957	chr4:41937031	TMEM33	0.93	6.28	0.37	1.49e-9	P wave terminal force;
KIRP	cis	rs73200209	0.789	rs73200220	chr12:116599715	A/T	cg01776926	chr12:116560359	MED13L	-0.4	-5.06	-0.31	8.29e-7	Total body bone mineral density;
KIRP	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg24253500	chr15:84953950	NA	-0.42	-5.26	-0.32	3.08e-7	P wave terminal force;
KIRP	cis	rs9815354	1.000	rs9863915	chr3:41762002	G/A	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.2e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg25356066	chr3:128598488	ACAD9	-0.54	-6.58	-0.39	2.86e-10	IgG glycosylation;
KIRP	cis	rs829883	0.646	rs4762494	chr12:98933834	T/G	cg25150519	chr12:98850993	NA	-0.75	-9.01	-0.5	5.85e-17	Colorectal adenoma (advanced);
KIRP	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.46	6.37	0.38	9.18e-10	Personality dimensions;
KIRP	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.58	8.21	0.46	1.27e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.68	6.33	0.37	1.14e-9	Schizophrenia;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-1.08	-21.66	-0.81	5.98e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs26232	0.521	rs40508	chr5:102443938	A/T	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.23e-7	Rheumatoid arthritis;
KIRP	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg03735888	chr19:58951602	ZNF132	0.78	9.4	0.51	4.03e-18	Mean platelet volume;
KIRP	cis	rs6142102	0.625	rs4911384	chr20:32555807	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.75	0.34	2.67e-8	Skin pigmentation;
KIRP	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg11833968	chr6:79620685	NA	-0.47	-7.04	-0.41	1.92e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.58	7.24	0.42	5.8e-12	Arsenic metabolism;
KIRP	cis	rs4654899	0.931	rs10737454	chr1:21221079	G/C	cg05370193	chr1:21551575	ECE1	-0.36	-4.87	-0.3	1.99e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg05872129	chr22:39784769	NA	-0.65	-9.41	-0.51	3.73e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.99	17.08	0.74	1.15e-43	Menopause (age at onset);
KIRP	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.92e-31	Eye color traits;
KIRP	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg02297831	chr4:17616191	MED28	0.52	5.89	0.35	1.26e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10812641	0.875	rs7032942	chr9:2792552	A/C	cg20069020	chr7:108166782	PNPLA8	0.48	6.03	0.36	6.09e-9	Blood trace element (Se levels);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23134075	chr14:61517513	SLC38A6	-0.43	-6.11	-0.36	3.81e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs909341	0.909	rs67616625	chr20:62363487	A/G	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.95	-0.41	3.29e-11	Atopic dermatitis;
KIRP	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.61	-7.39	-0.43	2.23e-12	Mosquito bite size;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10884052	chr2:135475971	TMEM163	-1.1	-6.59	-0.39	2.67e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs315122	0.588	rs548240	chr12:69756291	A/T	cg14784868	chr12:69753453	YEATS4	0.68	5.44	0.33	1.25e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.29	-0.32	2.68e-7	Retinal vascular caliber;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20033557	chr15:63414489	LACTB	0.49	6.38	0.38	8.85e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12913538	0.890	rs4326998	chr15:62896609	A/G	cg09983546	chr15:62884068	NA	0.49	6.38	0.38	8.71e-10	Sleep depth;
KIRP	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.76	11.11	0.58	1.6e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2242116	0.900	rs1001284	chr3:46933960	C/G	cg16586182	chr3:47516702	SCAP	-0.43	-5.29	-0.32	2.64e-7	Birth weight;
KIRP	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.54	6.33	0.37	1.17e-9	Cognitive test performance;
KIRP	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.81	11.18	0.58	9.55e-24	Total body bone mineral density;
KIRP	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg10326726	chr10:51549505	MSMB	-0.58	-8.35	-0.47	4.85e-15	Prostate-specific antigen levels;
KIRP	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg01988459	chr11:68622903	NA	-0.4	-5.6	-0.34	5.71e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs12517041	1.000	rs7737479	chr5:23288235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.79	-0.49	2.56e-16	Calcium levels;
KIRP	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.76	-0.34	2.54e-8	Height;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.76	-7.87	-0.45	1.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22186263	chr7:137570950	CREB3L2	-0.44	-6.1	-0.36	4.1e-9	Inflammatory biomarkers;
KIRP	cis	rs861020	0.916	rs669694	chr1:209950760	C/G	cg05527609	chr1:210001259	C1orf107	0.86	11.36	0.59	2.64e-24	Orofacial clefts;
KIRP	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg26207909	chr14:103986467	CKB	-0.43	-5.24	-0.32	3.51e-7	Coronary artery disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11881562	chr19:49633902	PPFIA3	0.47	6.04	0.36	5.63e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs3013648	0.777	rs1405076	chr13:85390352	G/A	cg21827674	chr12:133007847	NA	-0.73	-6.55	-0.39	3.36e-10	Huntington's disease progression;
KIRP	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg25036284	chr2:26402008	FAM59B	-0.47	-4.96	-0.3	1.29e-6	Gut microbiome composition (summer);
KIRP	cis	rs12980942	0.591	rs11879429	chr19:41757444	G/A	cg25627403	chr19:41769009	HNRNPUL1	0.66	5.32	0.32	2.29e-7	Coronary artery disease;
KIRP	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-5.32	-0.32	2.39e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg22117172	chr7:91764530	CYP51A1	-0.46	-6.41	-0.38	7.19e-10	Breast cancer;
KIRP	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg21395723	chr22:39101663	GTPBP1	0.48	6.48	0.38	4.99e-10	Menopause (age at onset);
KIRP	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18867708	chr6:26865862	GUSBL1	0.5	6.37	0.38	9.35e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8033133	0.836	rs11634716	chr15:25306646	C/T	cg14481604	chr15:25334117	SNORD116-22	0.43	5.0	0.3	1.07e-6	Blood osmolality (transformed sodium);
KIRP	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg18586891	chr4:952366	TMEM175	0.63	5.11	0.31	6.46e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.81	-12.84	-0.63	3.24e-29	Prostate cancer;
KIRP	cis	rs4356932	1.000	rs11097222	chr4:76987451	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.13	0.31	5.75e-7	Blood protein levels;
KIRP	cis	rs10875746	0.669	rs10431526	chr12:48690143	A/G	cg26205652	chr12:48591994	NA	0.64	8.27	0.47	8.7e-15	Longevity (90 years and older);
KIRP	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.72	10.36	0.55	4.21e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22228783	chr18:74844034	MBP	0.55	7.05	0.41	1.81e-11	Parkinson's disease;
KIRP	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16346588	chr10:242978	ZMYND11	0.48	5.98	0.36	7.67e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg20542592	chr8:11973495	FAM66D	0.4	5.12	0.31	6.29e-7	Retinal vascular caliber;
KIRP	cis	rs7546668	1.000	rs10803390	chr1:15865418	G/A	cg21858823	chr1:15850916	CASP9	0.47	5.14	0.31	5.64e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.54	6.65	0.39	1.91e-10	Colorectal cancer;
KIRP	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg21775007	chr8:11205619	TDH	-0.5	-6.45	-0.38	5.95e-10	Systolic blood pressure;
KIRP	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg14593290	chr7:50529359	DDC	-0.77	-9.68	-0.53	5.49e-19	Malaria;
KIRP	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg04306507	chr14:55594613	LGALS3	0.52	8.02	0.46	4.21e-14	Protein biomarker;
KIRP	cis	rs7937612	0.965	rs12361632	chr11:120215843	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.48	-6.81	-0.4	7.63e-11	Intraocular pressure;
KIRP	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg05347473	chr6:146136440	FBXO30	0.52	7.44	0.43	1.72e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4423214	0.592	rs1790349	chr11:71142350	A/G	cg05163923	chr11:71159392	DHCR7	-0.79	-7.76	-0.44	2.21e-13	Vitamin D levels;
KIRP	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg25664220	chr3:72788482	NA	-0.35	-5.05	-0.31	8.65e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7555523	0.779	rs2790049	chr1:165743523	A/G	cg24409356	chr1:165738333	TMCO1	0.71	5.69	0.34	3.62e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.18	0.31	4.71e-7	Lung cancer;
KIRP	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03352830	chr11:487213	PTDSS2	0.8	6.58	0.39	2.83e-10	Body mass index;
KIRP	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	7.88	0.45	1.07e-13	Lung cancer in ever smokers;
KIRP	cis	rs6684514	1.000	rs12142808	chr1:156230546	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-5.86	-0.35	1.51e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.59	-7.2	-0.42	7.35e-12	Red cell distribution width;
KIRP	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.66	0.39	1.78e-10	Diabetic retinopathy;
KIRP	cis	rs7301016	0.901	rs7975109	chr12:62941643	C/T	cg01804193	chr12:63026212	NA	0.53	5.9	0.35	1.23e-8	IgG glycosylation;
KIRP	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg15128208	chr22:42549153	NA	-0.6	-6.51	-0.38	4.19e-10	Birth weight;
KIRP	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.28	15.6	0.71	1.33e-38	Corneal structure;
KIRP	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.49	-0.33	9.78e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg15047889	chr8:124780837	FAM91A1	-0.5	-5.03	-0.31	9.6e-7	Pancreatic cancer;
KIRP	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.56	-6.62	-0.39	2.2e-10	Corneal astigmatism;
KIRP	cis	rs26949	0.526	rs1960479	chr5:60036215	T/G	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.21	-0.32	4.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg23029597	chr12:123009494	RSRC2	-0.41	-5.05	-0.31	8.48e-7	Body mass index;
KIRP	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.97	0.54	6.75e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.52	-0.33	8.69e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2629046	0.817	rs1823825	chr2:225077832	A/G	cg06102602	chr12:96895446	NA	-0.44	-6.09	-0.36	4.41e-9	Height;
KIRP	cis	rs1249675	0.835	rs2202473	chr1:75682577	C/T	cg11196437	chr1:75593865	LHX8	0.38	5.29	0.32	2.77e-7	Capecitabine sensitivity;
KIRP	cis	rs6142618	0.555	rs242606	chr20:30668633	G/A	cg09796376	chr20:30640595	HCK	0.41	5.6	0.34	5.72e-8	Inflammatory bowel disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg18555811	chr3:193852889	HES1	0.48	6.08	0.36	4.48e-9	Myopia (pathological);
KIRP	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg22764044	chr5:178986830	RUFY1	0.44	6.13	0.36	3.47e-9	Lung cancer;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.7	9.68	0.53	5.64e-19	Menarche (age at onset);
KIRP	cis	rs9488822	0.662	rs495565	chr6:116262976	G/A	cg18764771	chr6:116381957	FRK	-0.19	-5.08	-0.31	7.33e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.76	10.44	0.55	2.32e-21	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	6.13	0.36	3.47e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06850241	chr22:41845214	NA	-0.45	-5.14	-0.31	5.58e-7	Vitiligo;
KIRP	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.65	-9.37	-0.51	4.94e-18	Retinal vascular caliber;
KIRP	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg22676075	chr6:135203613	NA	-0.47	-6.72	-0.39	1.27e-10	Red blood cell count;
KIRP	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.48	7.17	0.42	8.56e-12	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg02023728	chr11:77925099	USP35	0.35	5.38	0.32	1.71e-7	Alzheimer's disease (survival time);
KIRP	cis	rs16828019	0.852	rs16827876	chr1:41539536	T/G	cg18742814	chr1:41828276	NA	0.61	5.55	0.33	7.25e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg10047753	chr17:41438598	NA	1.15	18.37	0.76	5.04e-48	Menopause (age at onset);
KIRP	cis	rs73206853	0.660	rs12313068	chr12:110597304	C/T	cg12870014	chr12:110450643	ANKRD13A	0.48	5.67	0.34	3.92e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg05340658	chr4:99064831	C4orf37	0.53	6.59	0.39	2.61e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-1.0	-10.34	-0.55	4.72e-21	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04362095	chr11:63592001	C11orf84	-0.57	-7.74	-0.44	2.61e-13	Pulse pressure;
KIRP	trans	rs76288851	0.641	rs746139	chr3:126674224	C/A	cg13821433	chr2:26726535	OTOF	-0.54	-6.55	-0.39	3.36e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg01763666	chr17:80159506	CCDC57	-0.38	-5.14	-0.31	5.64e-7	Life satisfaction;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05353415	chr7:42276004	GLI3	0.52	6.35	0.38	1.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs55692468	0.804	rs1579050	chr2:153364527	A/G	cg04681845	chr2:153283485	FMNL2	0.47	5.96	0.36	8.73e-9	Intraocular pressure;
KIRP	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg00933542	chr6:150070202	PCMT1	0.31	5.91	0.35	1.11e-8	Lung cancer;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg02023728	chr11:77925099	USP35	0.31	5.03	0.31	9.27e-7	Testicular germ cell tumor;
KIRP	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.82	0.45	1.55e-13	Height;
KIRP	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg07044859	chr10:101282883	NA	0.3	5.58	0.34	6.26e-8	Dental caries;
KIRP	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg05347473	chr6:146136440	FBXO30	0.49	6.83	0.4	6.73e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12935418	0.733	rs12448615	chr16:80981029	A/G	cg08591886	chr16:81111003	C16orf46	-0.51	-4.89	-0.3	1.81e-6	Mean corpuscular volume;
KIRP	cis	rs3762637	1.000	rs7615930	chr3:122125750	G/T	cg24169773	chr3:122142474	KPNA1	-0.48	-5.25	-0.32	3.33e-7	LDL cholesterol levels;
KIRP	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-12.01	-0.61	1.83e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2882667	0.898	rs10038121	chr5:138389602	A/G	cg04439458	chr5:138467593	SIL1	-0.45	-7.6	-0.44	6.31e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs17023223	0.537	rs2794311	chr1:119595949	A/G	cg18261050	chr1:119551319	NA	-0.5	-6.69	-0.39	1.52e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08450256	chr7:100487572	UFSP1	0.45	6.34	0.37	1.08e-9	Survival in pancreatic cancer;
KIRP	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.8	7.67	0.44	3.97e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs12936587	0.748	rs11871738	chr17:17525243	A/G	cg01246520	chr17:17644344	RAI1	-0.35	-5.47	-0.33	1.11e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.13	-12.88	-0.63	2.32e-29	Sexual dysfunction (female);
KIRP	cis	rs1832871	0.619	rs262823	chr6:158676149	G/C	cg07215822	chr6:158701037	NA	-0.59	-8.8	-0.49	2.47e-16	Height;
KIRP	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	1.01	17.68	0.75	1.03e-45	Breast cancer;
KIRP	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg00343986	chr7:65444356	GUSB	0.44	5.17	0.31	4.93e-7	Aortic root size;
KIRP	cis	rs10875595	0.691	rs1076361	chr5:140674609	C/T	cg24830062	chr5:140700576	TAF7	-0.55	-5.36	-0.32	1.89e-7	Pulmonary function decline;
KIRP	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.78	0.35	2.27e-8	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21395782	chr19:19626814	NDUFA13;TSSK6	0.58	6.87	0.4	5.11e-11	Smoking initiation;
KIRP	cis	rs2519796	0.509	rs648353	chr9:136822827	T/C	cg13751417	chr9:136814406	VAV2	-0.49	-6.52	-0.38	3.92e-10	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs68170813	0.641	rs74451547	chr7:107078435	A/C	cg02696742	chr7:106810147	HBP1	-0.73	-7.28	-0.42	4.45e-12	Coronary artery disease;
KIRP	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.92	-0.3	1.57e-6	Pulmonary function;
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00933542	chr6:150070202	PCMT1	0.29	5.8	0.35	1.99e-8	Lung cancer;
KIRP	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.83	11.26	0.58	5.52e-24	Systemic lupus erythematosus;
KIRP	cis	rs6091737	0.954	rs6097549	chr20:52342899	A/C	cg11837293	chr20:52356911	NA	-0.39	-4.95	-0.3	1.37e-6	Calcium levels;
KIRP	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.21	22.13	0.82	1.89e-60	Cognitive function;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs712039	0.652	rs2680719	chr17:35811453	C/T	cg16670864	chr17:35848621	DUSP14	0.43	5.08	0.31	7.59e-7	Tuberculosis;
KIRP	cis	rs11622475	1.000	rs10136440	chr14:104397367	C/A	cg20488157	chr14:104394430	TDRD9	-0.75	-10.59	-0.56	8.05e-22	Bipolar disorder;
KIRP	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-6.81	-0.4	7.57e-11	Fear of minor pain;
KIRP	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	1.09	9.23	0.51	1.26e-17	Blood protein levels;
KIRP	cis	rs7534824	0.556	rs61780323	chr1:101433407	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.5	0.33	9.37e-8	Refractive astigmatism;
KIRP	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg08313168	chr12:7315531	NA	0.68	6.18	0.37	2.61e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs793571	0.744	rs4775097	chr15:59140801	C/T	cg05156742	chr15:59063176	FAM63B	-0.54	-6.19	-0.37	2.55e-9	Schizophrenia;
KIRP	cis	rs78545713	0.536	rs80202565	chr6:26233882	C/G	cg23601095	chr6:26197514	HIST1H3D	0.88	5.32	0.32	2.38e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg01721255	chr8:58191610	C8orf71	0.53	5.34	0.32	2.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.66	8.62	0.48	8.23e-16	Eye color traits;
KIRP	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	9.81	0.53	2.14e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs1422110	0.879	rs1363268	chr5:85469695	C/T	cg01787110	chr1:109008453	NBPF6	-0.69	-8.19	-0.46	1.47e-14	Attention function in attention deficit hyperactive disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03586029	chr4:128886849	MFSD8;C4orf29	0.48	6.54	0.38	3.56e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg05791153	chr7:19748676	TWISTNB	0.89	7.48	0.43	1.32e-12	Thyroid stimulating hormone;
KIRP	cis	rs859767	0.603	rs842359	chr2:135345568	G/C	cg25422880	chr2:135218333	TMEM163	-0.43	-6.18	-0.37	2.62e-9	Neuroticism;
KIRP	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg16797656	chr11:68205561	LRP5	0.39	5.17	0.31	4.76e-7	Total body bone mineral density;
KIRP	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.93	0.3	1.5e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs8033133	0.958	rs6420956	chr15:25309559	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.49	-5.51	-0.33	9.26e-8	Blood osmolality (transformed sodium);
KIRP	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-6.02	-0.36	6.19e-9	IgG glycosylation;
KIRP	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.87	0.6	5.4e-26	Ileal carcinoids;
KIRP	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.97	13.2	0.64	2.01e-30	Menopause (age at onset);
KIRP	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.71	-10.72	-0.56	2.88e-22	Hepatocellular carcinoma;
KIRP	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg08975724	chr8:8085496	FLJ10661	0.56	7.31	0.42	3.73e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg26384229	chr12:38710491	ALG10B	0.56	7.36	0.42	2.76e-12	Morning vs. evening chronotype;
KIRP	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg15848620	chr12:58087721	OS9	0.46	5.22	0.32	3.87e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs714515	0.934	rs7539464	chr1:172359576	T/A	cg01573306	chr1:172330400	DNM3	0.44	5.79	0.35	2.18e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.08	-0.5	3.71e-17	Mood instability;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02454364	chr1:236156917	NID1	-0.47	-7.0	-0.41	2.48e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs73198271	0.710	rs11779561	chr8:8679988	G/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.88	-0.4	4.92e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3825932	1.000	rs3825932	chr15:79235446	A/G	cg25744700	chr15:79237217	CTSH	0.42	5.19	0.31	4.44e-7	Type 1 diabetes;
KIRP	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	0.84	9.57	0.52	1.18e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg23477460	chr3:66848765	NA	0.71	7.52	0.43	1e-12	Type 2 diabetes;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00673286	chr15:83349613	AP3B2	0.83	6.11	0.36	3.79e-9	P wave terminal force;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03510606	chr2:160303360	BAZ2B	-0.4	-6.08	-0.36	4.49e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.42	-0.38	7e-10	Height;
KIRP	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.83	13.04	0.64	7.01e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	1.11	17.96	0.75	1.22e-46	Migraine;
KIRP	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg23166289	chr1:210001082	C1orf107	0.4	4.99	0.3	1.16e-6	Orofacial clefts;
KIRP	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.82	9.25	0.51	1.12e-17	HIV-1 control;
KIRP	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7127900	1.000	rs6578999	chr11:2231774	G/T	cg25635251	chr11:2234043	NA	0.52	7.72	0.44	2.86e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.23	-0.37	1.97e-9	Dilated cardiomyopathy;
KIRP	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.55	6.44	0.38	6.24e-10	Aortic root size;
KIRP	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-9.87	-0.53	1.39e-19	Response to antipsychotic treatment;
KIRP	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg15128208	chr22:42549153	NA	0.71	7.71	0.44	3.1400000000000003e-13	Birth weight;
KIRP	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.81e-31	Diabetic retinopathy;
KIRP	cis	rs12476592	0.602	rs2305157	chr2:63822785	T/C	cg17519650	chr2:63277830	OTX1	-0.46	-5.06	-0.31	8.15e-7	Childhood ear infection;
KIRP	cis	rs7712401	0.546	rs30021	chr5:122285894	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs714031	1.000	rs5750869	chr22:40065332	T/C	cg21377881	chr22:40064566	CACNA1I	-0.69	-11.08	-0.58	2.03e-23	Schizophrenia;
KIRP	cis	rs7538876	1.000	rs4920603	chr1:17727379	C/G	cg07394400	chr1:17752023	RCC2	0.36	5.14	0.31	5.68e-7	Basal cell carcinoma;
KIRP	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-7.01	-0.41	2.25e-11	Initial pursuit acceleration;
KIRP	cis	rs2865126	0.818	rs2865129	chr18:10763995	C/T	cg21165219	chr18:10698044	FAM38B	-0.56	-5.55	-0.33	7.48e-8	Metabolite levels (5-HIAA/ MHPG Ratio);
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg12705353	chr12:122356852	WDR66	0.54	7.15	0.41	1.01e-11	Mean corpuscular volume;
KIRP	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	6.15	0.37	3.04e-9	Rheumatoid arthritis;
KIRP	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg25319279	chr11:5960081	NA	-0.56	-5.97	-0.36	8.23e-9	DNA methylation (variation);
KIRP	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg22437258	chr11:111473054	SIK2	0.6	7.1	0.41	1.37e-11	Primary sclerosing cholangitis;
KIRP	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.68	-8.92	-0.49	1.09e-16	Longevity;
KIRP	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg15848620	chr12:58087721	OS9	-0.5	-5.86	-0.35	1.44e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs894344	0.650	rs11166599	chr8:135581430	T/C	cg09855544	chr8:135498122	ZFAT	0.4	5.18	0.31	4.73e-7	Systolic blood pressure;
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg02462569	chr6:150064036	NUP43	-0.34	-5.3	-0.32	2.6e-7	Lung cancer;
KIRP	cis	rs9815354	1.000	rs9856088	chr3:41860482	G/T	cg03022575	chr3:42003672	ULK4	0.59	6.86	0.4	5.69e-11	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12074154	chr1:181074635	NA	0.55	7.09	0.41	1.38e-11	Parkinson's disease;
KIRP	cis	rs6681460	1.000	rs6670378	chr1:67126585	C/T	cg02459107	chr1:67143332	SGIP1	0.5	7.25	0.42	5.51e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg01849466	chr14:104193079	ZFYVE21	-0.6	-7.88	-0.45	1.09e-13	Schizophrenia;
KIRP	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.36	0.55	4.28e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs12044355	0.865	rs6691979	chr1:231860682	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	6.12	0.36	3.59e-9	Alzheimer's disease;
KIRP	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.5	5.89	0.35	1.25e-8	Metabolite levels;
KIRP	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.65	8.32	0.47	5.99e-15	Red blood cell count;
KIRP	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg19468946	chr17:37922297	IKZF3	-0.42	-5.86	-0.35	1.45e-8	Self-reported allergy;
KIRP	cis	rs7870753	1.000	rs34304649	chr9:99247301	T/A	cg25260653	chr9:99212216	HABP4	0.54	6.05	0.36	5.3e-9	Height;
KIRP	cis	rs860295	0.812	rs12024257	chr1:155780536	G/A	cg02153340	chr1:155202674	NA	-0.41	-5.5	-0.33	9.54e-8	Body mass index;
KIRP	cis	rs687432	0.812	rs4509781	chr11:57842558	C/T	cg19752551	chr11:57585705	CTNND1	-0.68	-8.67	-0.48	6.04e-16	Parkinson's disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09747230	chr5:43613142	NNT	-0.47	-6.04	-0.36	5.56e-9	Inflammatory biomarkers;
KIRP	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg19847130	chr8:10466454	RP1L1	-0.42	-6.15	-0.37	3.13e-9	Retinal vascular caliber;
KIRP	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.47	-6.55	-0.39	3.32e-10	Symmetrical dimethylarginine levels;
KIRP	cis	rs3733606	0.503	rs11734132	chr4:6891519	C/G	cg05012661	chr4:6891264	NA	-0.51	-6.95	-0.41	3.29e-11	Platelet count;
KIRP	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-1.21	-14.09	-0.67	1.95e-33	Breast cancer;
KIRP	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.08	0.46	2.87e-14	Eosinophil percentage of white cells;
KIRP	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg07451762	chr16:28383216	NA	0.42	5.5	0.33	9.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg11641102	chr8:27183873	PTK2B	-0.42	-5.49	-0.33	9.83e-8	Neuroticism;
KIRP	cis	rs4711336	0.809	rs749338	chr6:33653448	A/G	cg14003231	chr6:33640908	ITPR3	-0.31	-5.27	-0.32	2.95e-7	Height;
KIRP	cis	rs17033621	0.967	rs12471465	chr2:107611137	G/T	cg17818308	chr2:107502146	ST6GAL2	-0.36	-4.86	-0.3	2.11e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.58	-7.95	-0.45	6.69e-14	Lung cancer;
KIRP	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.74	-9.81	-0.53	2.13e-19	Huntington's disease progression;
KIRP	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg21775007	chr8:11205619	TDH	0.44	6.07	0.36	4.85e-9	Neuroticism;
KIRP	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg24633833	chr3:10029261	TMEM111	0.54	5.26	0.32	3.18e-7	Alzheimer's disease;
KIRP	cis	rs6997458	0.902	rs1472360	chr8:86305198	T/C	cg02393479	chr8:86352350	CA3	-0.33	-4.94	-0.3	1.47e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7224685	0.569	rs12452393	chr17:3985427	G/A	cg05562828	chr17:3906858	NA	0.56	6.09	0.36	4.37e-9	Type 2 diabetes;
KIRP	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg06740227	chr12:86229804	RASSF9	0.48	6.1	0.36	4.06e-9	Major depressive disorder;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg15896084	chr13:114927664	NA	0.46	6.18	0.37	2.64e-9	Schizophrenia;
KIRP	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.92	9.94	0.54	8.47e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg07777115	chr5:623756	CEP72	-0.61	-6.14	-0.36	3.34e-9	Obesity-related traits;
KIRP	cis	rs2997447	0.846	rs3008429	chr1:26390833	A/G	cg19633962	chr1:26362018	EXTL1	-0.7	-6.09	-0.36	4.25e-9	QRS complex (12-leadsum);
KIRP	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg12131826	chr15:77904385	NA	0.44	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.71	-0.44	3.04e-13	Type 2 diabetes;
KIRP	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.31	0.37	1.3e-9	Hemoglobin concentration;
KIRP	cis	rs6684428	1.000	rs10888944	chr1:56341409	A/C	cg11651538	chr1:56320950	NA	-0.67	-8.73	-0.49	3.97e-16	Airflow obstruction;
KIRP	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.72	10.46	0.55	2.03e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10893370	chr17:30228961	UTP6	0.56	6.22	0.37	2.17e-9	Lung cancer in ever smokers;
KIRP	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg18306943	chr3:40428807	ENTPD3	0.43	5.57	0.33	6.68e-8	Renal cell carcinoma;
KIRP	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-14.4	-0.68	1.68e-34	Gut microbiome composition (summer);
KIRP	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg17788362	chr6:86352627	SYNCRIP	0.49	6.45	0.38	5.89e-10	Smooth-surface caries;
KIRP	cis	rs9815354	0.812	rs4434125	chr3:42004681	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-8.49	-0.48	1.98e-15	Platelet count;
KIRP	cis	rs11834862	0.663	rs11246993	chr12:132689052	T/A	cg05229598	chr12:132699923	GALNT9	-0.58	-6.37	-0.38	9.38e-10	Anti-saccade response;
KIRP	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.78	8.14	0.46	2e-14	Psoriasis;
KIRP	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-5.69	-0.34	3.69e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7156960	0.540	rs4903393	chr14:76734188	A/C	cg13981132	chr14:76734493	NA	-0.46	-6.04	-0.36	5.51e-9	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02784301	chr16:23194194	SCNN1G	-0.5	-7.08	-0.41	1.49e-11	Metabolic traits;
KIRP	cis	rs3008870	0.628	rs2755257	chr1:67515309	C/T	cg02640540	chr1:67518911	SLC35D1	0.59	7.23	0.42	6e-12	Lymphocyte percentage of white cells;
KIRP	cis	rs67366981	0.778	rs3952319	chr14:77684379	A/T	cg22824376	chr14:77648248	TMEM63C	0.86	8.95	0.5	8.96e-17	Obsessive-compulsive symptoms;
KIRP	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg21926883	chr2:100939477	LONRF2	-0.55	-6.85	-0.4	5.8e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.13	0.31	5.87e-7	Tonsillectomy;
KIRP	cis	rs240764	0.782	rs395521	chr6:101054999	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.57	0.33	6.7e-8	Neuroticism;
KIRP	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.74	-0.39	1.11e-10	Joint mobility (Beighton score);
KIRP	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.08	-0.5	3.68e-17	Mean corpuscular volume;
KIRP	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg21918786	chr6:109611834	NA	0.4	5.62	0.34	5.12e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.55	-5.48	-0.33	1.04e-7	Initial pursuit acceleration;
KIRP	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-7.84	-0.45	1.39e-13	Morning vs. evening chronotype;
KIRP	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg19507638	chr5:93509721	C5orf36	-0.54	-5.13	-0.31	5.8e-7	Diabetic retinopathy;
KIRP	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.85	12.62	0.63	1.69e-28	Coronary artery disease;
KIRP	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-0.42	-5.44	-0.33	1.32e-7	Acne (severe);
KIRP	cis	rs4730250	0.640	rs7783562	chr7:106917438	G/T	cg02696742	chr7:106810147	HBP1	-0.76	-7.25	-0.42	5.48e-12	Osteoarthritis;
KIRP	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg19000871	chr14:103996768	TRMT61A	0.79	9.46	0.52	2.65e-18	Coronary artery disease;
KIRP	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.67	8.75	0.49	3.37e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.61	-5.84	-0.35	1.63e-8	Toenail selenium levels;
KIRP	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg15038512	chr6:170123185	PHF10	0.6	8.79	0.49	2.57e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.58	-6.72	-0.39	1.25e-10	DNA methylation (variation);
KIRP	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg18357526	chr6:26021779	HIST1H4A	0.38	4.85	0.3	2.24e-6	Height;
KIRP	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg19169023	chr15:41853346	TYRO3	-0.69	-7.85	-0.45	1.27e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-6.65	-0.39	1.89e-10	Psoriasis;
KIRP	cis	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.0	-0.3	1.09e-6	Cervical cancer;
KIRP	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg23533926	chr12:111358616	MYL2	0.47	6.2	0.37	2.31e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg05665937	chr4:1216051	CTBP1	0.44	5.61	0.34	5.33e-8	Obesity-related traits;
KIRP	cis	rs13185784	0.667	rs35551113	chr5:179654221	T/C	cg02891314	chr5:179741120	GFPT2	0.54	5.33	0.32	2.18e-7	TRAIL levels;
KIRP	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg26248373	chr2:1572462	NA	-0.69	-7.6	-0.44	6.21e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.1	0.5	3.14e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.5	6.56	0.39	3.19e-10	Schizophrenia;
KIRP	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs6601327	0.665	rs10113155	chr8:9655358	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.83	-0.4	6.54e-11	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.16	13.04	0.64	6.71e-30	Uric acid levels;
KIRP	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg11569703	chr11:65557185	OVOL1	-0.49	-8.79	-0.49	2.55e-16	Acne (severe);
KIRP	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg11859384	chr17:80120422	CCDC57	0.44	5.53	0.33	8.19e-8	Life satisfaction;
KIRP	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg09035930	chr12:129282057	SLC15A4	-0.65	-5.21	-0.32	3.92e-7	Systemic lupus erythematosus;
KIRP	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg07424592	chr7:64974309	NA	0.75	4.92	0.3	1.59e-6	Diabetic kidney disease;
KIRP	cis	rs11153147	0.730	rs2798646	chr6:109310596	C/A	cg05315195	chr6:109294784	ARMC2	0.57	5.48	0.33	1.03e-7	Mean corpuscular volume;
KIRP	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.89	-11.65	-0.6	2.84e-25	Type 2 diabetes;
KIRP	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.86	12.08	0.61	1.11e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs2625529	0.526	rs7183810	chr15:72560458	A/T	cg16672083	chr15:72433130	SENP8	0.46	6.52	0.38	3.95e-10	Red blood cell count;
KIRP	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	1.04	18.37	0.76	4.91e-48	Bone mineral density;
KIRP	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.66	-10.18	-0.54	1.51e-20	Total body bone mineral density;
KIRP	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg19847130	chr8:10466454	RP1L1	0.36	5.41	0.33	1.49e-7	Systolic blood pressure;
KIRP	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.85	12.97	0.64	1.12e-29	Longevity;Endometriosis;
KIRP	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg15128208	chr22:42549153	NA	0.75	8.1	0.46	2.58e-14	Birth weight;
KIRP	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg17802220	chr15:77601643	NA	0.39	5.24	0.32	3.47e-7	Type 2 diabetes;
KIRP	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.6	7.43	0.43	1.77e-12	Arsenic metabolism;
KIRP	cis	rs9443189	0.813	rs2647410	chr6:76433825	A/G	cg01950844	chr6:76311363	SENP6	-0.56	-5.86	-0.35	1.51e-8	Prostate cancer;
KIRP	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg21573476	chr21:45109991	RRP1B	-0.64	-8.56	-0.48	1.27e-15	Mean corpuscular volume;
KIRP	cis	rs9534288	0.577	rs2897029	chr13:46682821	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-7.88	-0.45	1.03e-13	Blood protein levels;
KIRP	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.06	0.46	3.3e-14	Height;
KIRP	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.61	9.74	0.53	3.68e-19	Endometriosis;
KIRP	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg21395723	chr22:39101663	GTPBP1	0.41	5.15	0.31	5.47e-7	Menopause (age at onset);
KIRP	cis	rs4478037	0.558	rs59139633	chr3:33080190	G/T	cg19404215	chr3:33155277	CRTAP	0.92	6.03	0.36	5.9e-9	Major depressive disorder;
KIRP	cis	rs10214930	0.697	rs12672811	chr7:27684883	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.76	9.84	0.53	1.77e-19	Multiple sclerosis;
KIRP	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.41	-0.47	3.44e-15	Mean corpuscular volume;
KIRP	cis	rs4664293	0.867	rs2114626	chr2:160639970	C/T	cg08347373	chr2:160653686	CD302	0.39	6.08	0.36	4.59e-9	Monocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01011910	chr19:13906174	ZSWIM4	0.52	6.54	0.38	3.45e-10	Parkinson's disease;
KIRP	cis	rs4740619	0.619	rs1328298	chr9:16046417	T/C	cg14451791	chr9:16040625	NA	-0.41	-5.43	-0.33	1.37e-7	Body mass index;
KIRP	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.88	11.18	0.58	1.02e-23	Schizophrenia;
KIRP	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg19468946	chr17:37922297	IKZF3	-0.49	-6.73	-0.39	1.18e-10	Self-reported allergy;
KIRP	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.46	-5.56	-0.33	6.92e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs76793172	1.000	rs74450753	chr19:46317709	G/C	cg00442267	chr19:46317840	RSPH6A	-0.82	-6.3	-0.37	1.35e-9	Eosinophil counts;
KIRP	cis	rs7630877	0.962	rs16830940	chr3:179658262	C/T	cg18765712	chr3:179670323	PEX5L	0.48	5.83	0.35	1.77e-8	Type 2 diabetes;
KIRP	cis	rs4794202	0.629	rs7214694	chr17:45895353	C/T	cg02219949	chr17:45927392	SP6	0.56	6.04	0.36	5.61e-9	Alzheimer's disease (cognitive decline);
KIRP	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.53	-6.52	-0.38	3.9e-10	Uric acid levels;
KIRP	cis	rs734999	0.545	rs10910106	chr1:2538886	G/T	cg18932078	chr1:2524107	MMEL1	0.43	5.98	0.36	7.76e-9	Ulcerative colitis;
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.04	-0.36	5.63e-9	Lung cancer;
KIRP	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg17279839	chr7:150038598	RARRES2	0.45	5.77	0.35	2.37e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-5.5	-0.33	9.4e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Bladder cancer;
KIRP	cis	rs6684514	0.961	rs12029695	chr1:156299847	C/T	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.67e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.65	7.85	0.45	1.24e-13	Systemic lupus erythematosus;
KIRP	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	5.84	0.35	1.62e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs785830	0.522	rs600509	chr9:263645	G/A	cg14500300	chr9:211689	NA	0.45	6.3	0.37	1.37e-9	Platelet distribution width;
KIRP	trans	rs6601327	0.571	rs35874762	chr8:9565392	C/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.12	-0.36	3.63e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.03	0.36	6.08e-9	Lung cancer;
KIRP	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.81	10.85	0.57	1.16e-22	Age at first birth;
KIRP	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg19338460	chr6:170058176	WDR27	-1.07	-11.75	-0.6	1.37e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.56	-7.59	-0.44	6.8e-13	High light scatter reticulocyte count;
KIRP	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.27e-20	Alzheimer's disease (late onset);
KIRP	cis	rs6504950	0.705	rs17745123	chr17:52988232	G/T	cg26251398	chr17:52985966	TOM1L1	0.39	5.35	0.32	2.05e-7	Breast cancer;
KIRP	trans	rs656319	0.591	rs17734690	chr8:9713196	T/C	cg16141378	chr3:129829833	LOC729375	0.49	6.22	0.37	2.13e-9	Myopia (pathological);
KIRP	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.72	9.71	0.53	4.4e-19	Mean platelet volume;
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg00684032	chr4:1343700	KIAA1530	-0.43	-4.97	-0.3	1.28e-6	Longevity;
KIRP	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg03644281	chr6:41068752	NFYA;LOC221442	0.48	5.7	0.34	3.33e-8	Alzheimer's disease (late onset);
KIRP	cis	rs12311304	0.965	rs7977262	chr12:15367769	A/G	cg08258403	chr12:15378311	NA	0.34	5.02	0.3	1.01e-6	Behavioural disinhibition (generation interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21707521	chr2:238875814	UBE2F	0.5	6.64	0.39	2.02e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.47	-7.48	-0.43	1.32e-12	Height;
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg15117754	chr3:10150083	C3orf24	0.53	5.12	0.31	6.12e-7	Alzheimer's disease;
KIRP	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.39	-5.21	-0.32	3.96e-7	Blood metabolite levels;
KIRP	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg12119029	chr16:89752879	CDK10	0.28	6.12	0.36	3.71e-9	Vitiligo;
KIRP	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs77633900	0.772	rs157761	chr15:76796078	C/A	cg21673338	chr15:77095150	SCAPER	-0.64	-5.89	-0.35	1.28e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.45	-0.47	2.58e-15	Type 2 diabetes;
KIRP	cis	rs10484761	1.000	rs4612162	chr6:40808654	C/A	cg02680909	chr6:39899321	MOCS1	-0.23	-5.03	-0.31	9.37e-7	Esophageal cancer;
KIRP	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg24315340	chr6:146058215	EPM2A	-0.39	-5.02	-0.3	1.01e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19343871	chr19:48103651	NA	0.5	6.85	0.4	5.78e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg06565975	chr8:143823917	SLURP1	0.47	7.49	0.43	1.24e-12	Urinary tract infection frequency;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17976829	chr10:131934431	GLRX3	0.61	7.26	0.42	5.12e-12	Smoking initiation;
KIRP	cis	rs12580194	0.593	rs66902680	chr12:55724080	A/C	cg11794356	chr12:55725991	OR6C3	-0.55	-7.31	-0.42	3.84e-12	Cancer;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.93	-14.11	-0.67	1.59e-33	Longevity;Endometriosis;
KIRP	cis	rs1978968	1.000	rs7285566	chr22:18445288	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.69	-7.94	-0.45	7.4e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.63	7.24	0.42	5.61e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.36	0.51	5.28e-18	Multiple sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22747848	chr8:38758734	PLEKHA2	0.52	6.55	0.39	3.27e-10	Parkinson's disease;
KIRP	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg06212747	chr3:49208901	KLHDC8B	0.5	5.14	0.31	5.53e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-7.35	-0.42	2.98e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg10792982	chr14:105748885	BRF1	0.9	13.34	0.65	6.77e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg18105134	chr13:113819100	PROZ	-1.03	-11.68	-0.6	2.25e-25	Platelet distribution width;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08257600	chr19:41199188	ADCK4	0.41	6.18	0.37	2.68e-9	Myopia;
KIRP	trans	rs9929218	0.817	rs3114399	chr16:68713385	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.98	-9.72	-0.53	4.03e-19	Colorectal cancer;
KIRP	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.45	9.27	0.51	9.61e-18	Ewing sarcoma;
KIRP	cis	rs1263173	0.566	rs4225	chr11:116703671	G/T	cg15534755	chr11:117069859	TAGLN	0.42	5.16	0.31	5.04e-7	HDL cholesterol;
KIRP	cis	rs9902453	0.817	rs4294865	chr17:28205736	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	5.93	0.35	1e-8	Coffee consumption (cups per day);
KIRP	cis	rs2213920	0.749	rs4637918	chr9:118258247	G/T	cg13918206	chr9:118159781	DEC1	1.02	9.91	0.53	1.08e-19	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.82	8.66	0.48	6.2e-16	Prostate cancer;
KIRP	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg10755058	chr3:40428713	ENTPD3	-0.39	-5.63	-0.34	4.94e-8	Renal cell carcinoma;
KIRP	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg04691961	chr3:161091175	C3orf57	-0.38	-5.8	-0.35	2.08e-8	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07124680	chr13:60587343	DIAPH3	-0.4	-6.34	-0.37	1.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24139898	chr19:35531817	HPN	0.42	6.64	0.39	2.03e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg20243544	chr17:37824526	PNMT	0.45	6.16	0.37	3.01e-9	Asthma;
KIRP	cis	rs986417	0.818	rs10148116	chr14:61101089	C/T	cg27398547	chr14:60952738	C14orf39	0.62	5.64	0.34	4.76e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg23216685	chr1:86174607	ZNHIT6	-0.51	-5.85	-0.35	1.53e-8	Urate levels in overweight individuals;
KIRP	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg23625390	chr15:77176239	SCAPER	0.5	6.59	0.39	2.73e-10	Blood metabolite levels;
KIRP	cis	rs12997796	0.503	rs3020726	chr2:87016506	A/G	cg25203885	chr2:87302643	LOC285074	-0.69	-5.07	-0.31	7.8e-7	Schizophrenia;
KIRP	cis	rs9367716	0.912	rs9382695	chr6:57110054	G/T	cg03371099	chr6:57305889	PRIM2	-0.53	-6.71	-0.39	1.37e-10	Coronary artery disease;
KIRP	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.49	-8.01	-0.45	4.61e-14	Height;
KIRP	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.7	8.24	0.47	1.03e-14	Obesity-related traits;
KIRP	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.28	-0.47	7.88e-15	Blood metabolite levels;
KIRP	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.45	-0.33	1.21e-7	Depression;
KIRP	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.3	-0.32	2.56e-7	Pulmonary function;
KIRP	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.78	-7.44	-0.43	1.68e-12	Alzheimer's disease (late onset);
KIRP	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.84	-0.35	1.61e-8	IgG glycosylation;
KIRP	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg16141378	chr3:129829833	LOC729375	0.48	6.06	0.36	5.13e-9	Neuroticism;
KIRP	cis	rs490234	0.934	rs12553637	chr9:128277258	A/G	cg14078157	chr9:128172775	NA	-0.41	-5.21	-0.32	3.99e-7	Mean arterial pressure;
KIRP	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg08283408	chr3:49949060	MON1A	0.36	4.85	0.3	2.22e-6	Body mass index;
KIRP	cis	rs3849570	0.615	rs6778265	chr3:81985745	C/T	cg07356753	chr3:81810745	GBE1	0.52	6.88	0.4	4.97e-11	Waist circumference;Body mass index;
KIRP	cis	rs11123406	0.762	rs6749625	chr2:111957894	G/A	cg23466623	chr2:111982296	NA	0.52	6.9	0.4	4.29e-11	Type 2 diabetes;
KIRP	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg07636037	chr3:49044803	WDR6	-0.76	-7.78	-0.44	1.97e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7113874	0.625	rs35760680	chr11:8522072	A/G	cg08015107	chr11:8618950	NA	-0.72	-8.72	-0.49	4.22e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19671926	chr4:122722719	EXOSC9	-0.49	-5.65	-0.34	4.51e-8	Type 2 diabetes;
KIRP	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg02175503	chr12:58329896	NA	0.56	6.07	0.36	4.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.48	-4.85	-0.3	2.15e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg00319359	chr11:70116639	PPFIA1	0.56	5.84	0.35	1.67e-8	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.52	-5.86	-0.35	1.47e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs35740288	0.770	rs1157519	chr15:86161658	T/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs894344	0.812	rs894359	chr8:135600805	T/G	cg09855544	chr8:135498122	ZFAT	0.42	5.62	0.34	5.23e-8	Systolic blood pressure;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg02252918	chr12:124458442	ZNF664;CCDC92	-0.51	-6.37	-0.38	9.23e-10	Neuroticism;
KIRP	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-5.97	-0.36	8.43e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11825685	0.836	rs56100135	chr11:134588756	G/T	cg06603561	chr11:134479413	NA	-0.57	-5.11	-0.31	6.47e-7	IgG glycosylation;
KIRP	cis	rs963731	0.737	rs79756054	chr2:39338998	A/G	cg04010122	chr2:39346883	SOS1	0.68	5.21	0.32	3.94e-7	Corticobasal degeneration;
KIRP	cis	rs876084	0.510	rs10096137	chr8:121101910	A/G	cg06265175	chr8:121136014	COL14A1	0.51	6.28	0.37	1.56e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3774830	0.714	rs17464616	chr4:5465004	G/A	cg26943120	chr4:5472116	STK32B	0.24	5.82	0.35	1.87e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.2	0.46	1.3e-14	IgG glycosylation;
KIRP	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.29	-5.73	-0.34	2.9e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.42	6.22	0.37	2.15e-9	Neuroticism;
KIRP	cis	rs687432	0.847	rs12801976	chr11:57738992	T/A	cg19752551	chr11:57585705	CTNND1	-0.69	-9.17	-0.5	2.01e-17	Parkinson's disease;
KIRP	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg02569458	chr12:86230093	RASSF9	0.54	7.94	0.45	7.21e-14	Major depressive disorder;
KIRP	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.99	13.57	0.65	1.06e-31	Height;
KIRP	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3829109	0.564	rs3812578	chr9:139299673	G/C	cg21253087	chr9:139290292	SNAPC4	0.5	5.55	0.33	7.3e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs11997175	0.603	rs4739382	chr8:33807012	C/T	cg04338863	chr8:33670619	NA	0.4	5.09	0.31	7.22e-7	Body mass index;
KIRP	cis	rs11166927	0.967	rs12680346	chr8:140814379	C/T	cg16909799	chr8:140841666	TRAPPC9	0.57	7.71	0.44	3.03e-13	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg16680214	chr1:154839983	KCNN3	-0.39	-5.95	-0.35	9.09e-9	Prostate cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05103132	chr2:73441498	SMYD5	-0.5	-6.15	-0.37	3.04e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs36051354	0.573	rs2581792	chr3:53035044	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.44	-5.15	-0.31	5.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.31	-7.92	-0.45	8.29e-14	Primary biliary cholangitis;
KIRP	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.8	10.56	0.56	9.58e-22	Triglycerides;
KIRP	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg18586891	chr4:952366	TMEM175	0.59	5.02	0.3	1e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg08499158	chr17:42289980	UBTF	-0.84	-11.51	-0.59	8.11e-25	Total body bone mineral density;
KIRP	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.59	7.54	0.43	8.97e-13	Diastolic blood pressure;
KIRP	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.51	5.92	0.35	1.1e-8	Cognitive test performance;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15419852	chr19:39897474	ZFP36	-0.45	-6.33	-0.37	1.13e-9	Metabolic traits;
KIRP	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg08501292	chr6:25962987	TRIM38	1.02	7.99	0.45	5.14e-14	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg11694223	chr8:27473467	CLU	0.5	6.25	0.37	1.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.63	-6.54	-0.38	3.62e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.52	-6.39	-0.38	8.29e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05665937	chr4:1216051	CTBP1	-0.48	-6.61	-0.39	2.4e-10	Obesity-related traits;
KIRP	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	6.29	0.37	1.47e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg10756647	chr7:56101905	PSPH	1.01	7.54	0.43	9.29e-13	Diabetic kidney disease;
KIRP	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.89e-18	Height;
KIRP	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.53	-8.95	-0.5	8.87e-17	Height;
KIRP	cis	rs3735025	0.892	rs12534625	chr7:137067616	T/G	cg13839563	chr7:136910420	NA	-0.43	-4.84	-0.3	2.24e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.65	9.71	0.53	4.38e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7106204	0.513	rs7131144	chr11:24249486	A/G	ch.11.24196551F	chr11:24239977	NA	0.66	6.13	0.36	3.41e-9	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg00666640	chr1:248458726	OR2T12	0.43	5.84	0.35	1.62e-8	Common traits (Other);
KIRP	cis	rs9832740	0.967	rs11128264	chr3:72392310	C/T	cg05607079	chr3:72387937	NA	0.33	5.14	0.31	5.58e-7	Height;
KIRP	trans	rs669484	0.541	rs12337488	chr9:10412586	T/C	cg25509871	chr19:40871557	PLD3	-0.67	-6.51	-0.38	4.24e-10	Gestational age at birth (child effect);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01309726	chr10:99477939	LOC100270710	0.38	6.16	0.37	2.93e-9	Survival in pancreatic cancer;
KIRP	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-1.01	-16.69	-0.73	2.41e-42	Height;
KIRP	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.47	5.62	0.34	5.09e-8	Glycated hemoglobin levels;
KIRP	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg00310523	chr12:86230176	RASSF9	0.57	8.45	0.47	2.51e-15	Major depressive disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18941864	chr2:234851397	TRPM8	-0.44	-6.13	-0.36	3.45e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-10.88	-0.57	8.98e-23	Exhaled nitric oxide output;
KIRP	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg21360079	chr12:107162445	NA	-0.68	-9.44	-0.52	3.01e-18	Heart rate;
KIRP	cis	rs7590368	0.683	rs56344711	chr2:10969688	C/T	cg15705551	chr2:10952987	PDIA6	0.61	5.1	0.31	6.77e-7	Educational attainment (years of education);
KIRP	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.17	-0.54	1.66e-20	Alzheimer's disease (late onset);
KIRP	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg26513180	chr16:89883248	FANCA	-0.4	-4.98	-0.3	1.19e-6	Vitiligo;
KIRP	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.46e-19	Colorectal cancer;
KIRP	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.95	14.86	0.69	4.58e-36	Systemic lupus erythematosus;
KIRP	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.79	12.27	0.62	2.54e-27	Testicular germ cell tumor;
KIRP	cis	rs6433857	0.534	rs1157535	chr2:181361736	T/A	cg23363182	chr2:181467187	NA	-0.36	-4.9	-0.3	1.75e-6	Body mass index;
KIRP	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2057178	1.000	rs11031733	chr11:32367362	G/C	cg05837727	chr11:32355149	NA	0.43	4.86	0.3	2.06e-6	Tuberculosis;
KIRP	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs4132509	0.947	rs320339	chr1:243870910	G/T	cg25706552	chr1:244017396	NA	0.54	7.45	0.43	1.61e-12	RR interval (heart rate);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26624273	chr1:38019894	SNIP1	0.47	6.08	0.36	4.5e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg03289416	chr15:75166202	SCAMP2	0.57	8.01	0.45	4.73e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.83	13.83	0.66	1.44e-32	Longevity;
KIRP	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg14664628	chr15:75095509	CSK	0.51	6.13	0.36	3.46e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.99	0.45	5.09e-14	Height;
KIRP	cis	rs4835473	0.571	rs1992656	chr4:144776439	C/G	cg08833778	chr4:144622313	FREM3	0.35	5.07	0.31	7.8e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg00076555	chr3:49705435	BSN	0.29	4.96	0.3	1.29e-6	Menarche (age at onset);
KIRP	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg19336497	chr11:14380999	RRAS2	-0.52	-7.82	-0.45	1.52e-13	Vitamin D levels;
KIRP	cis	rs290268	0.817	rs291006	chr9:93540244	A/C	cg02608019	chr9:93564028	SYK	0.77	10.58	0.56	8.43e-22	Platelet count;
KIRP	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg08313168	chr12:7315531	NA	0.7	6.28	0.37	1.56e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.53e-10	Aortic root size;
KIRP	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg05347473	chr6:146136440	FBXO30	0.48	7.11	0.41	1.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-8.79	-0.49	2.6e-16	Bipolar disorder;
KIRP	cis	rs6545883	0.931	rs778765	chr2:61786385	A/T	cg15711740	chr2:61764176	XPO1	-0.62	-8.5	-0.48	1.9e-15	Tuberculosis;
KIRP	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.97	-0.5	7.49e-17	Retinal vascular caliber;
KIRP	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02034447	chr16:89574710	SPG7	0.41	5.29	0.32	2.72e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs2667100	0.614	rs77457787	chr4:143001595	A/T	cg06600412	chr4:185655239	MLF1IP	-1.03	-6.2	-0.37	2.31e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-7.62	-0.44	5.43e-13	Migraine;Coronary artery disease;
KIRP	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg15436174	chr10:43711423	RASGEF1A	0.85	9.42	0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg03060546	chr3:49711283	APEH	-0.71	-5.48	-0.33	1.05e-7	Cognitive function;
KIRP	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-11.49	-0.59	9.24e-25	Electrocardiographic conduction measures;
KIRP	cis	rs737693	0.527	rs72983552	chr11:102764093	T/G	cg14995062	chr11:102826570	MMP13	0.59	5.36	0.32	1.92e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg03929089	chr4:120376271	NA	0.7	6.17	0.37	2.75e-9	Axial length;
KIRP	cis	rs75920871	0.764	rs4938326	chr11:116905464	G/C	cg23684410	chr11:116897558	SIK3	0.52	5.32	0.32	2.33e-7	Subjective well-being;
KIRP	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.06	0.31	8.24e-7	Lung cancer;
KIRP	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.33	0.37	1.12e-9	Aortic root size;
KIRP	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg16725984	chr16:89735184	C16orf55	0.2	5.24	0.32	3.47e-7	Vitiligo;
KIRP	cis	rs7737355	0.947	rs11744232	chr5:130911732	A/G	cg06307176	chr5:131281290	NA	0.42	5.02	0.3	9.87e-7	Life satisfaction;
KIRP	cis	rs918629	0.798	rs6898399	chr5:95289398	A/G	cg16656078	chr5:95278638	ELL2	-0.47	-6.78	-0.4	8.68e-11	IgG glycosylation;
KIRP	cis	rs2119480	0.963	rs4773237	chr13:111337777	T/C	cg24331049	chr13:111365604	ING1	0.45	5.4	0.33	1.54e-7	Diastolic blood pressure;
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.58	7.71	0.44	3.1400000000000003e-13	Resistin levels;
KIRP	cis	rs4787491	0.658	rs11647753	chr16:29928115	C/T	cg06326092	chr16:30034487	C16orf92	-0.37	-5.34	-0.32	2.11e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4141404	0.787	rs11913992	chr22:31585220	G/A	cg02404636	chr22:31891804	SFI1	-0.51	-6.56	-0.39	3.1e-10	Paclitaxel-induced neuropathy;
KIRP	cis	rs11874712	1.000	rs8089150	chr18:43674300	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.16e-8	Migraine - clinic-based;
KIRP	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg08992911	chr2:238395768	MLPH	0.42	5.33	0.32	2.27e-7	Prostate cancer;
KIRP	cis	rs4356932	1.000	rs7684889	chr4:76963264	T/A	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22865215	chr19:19260102	LOC729991-MEF2B;MEF2B	0.44	6.1	0.36	3.99e-9	Pancreatic cancer;
KIRP	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.57	-8.18	-0.46	1.54e-14	Testicular germ cell tumor;
KIRP	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg00800038	chr16:89945340	TCF25	-0.83	-6.15	-0.37	3.04e-9	Skin colour saturation;
KIRP	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs904251	0.772	rs10692	chr6:37450914	T/C	cg24807547	chr6:37504484	NA	-0.44	-5.66	-0.34	4.16e-8	Cognitive performance;
KIRP	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-13.34	-0.65	6.6e-31	Gut microbiome composition (summer);
KIRP	cis	rs55675132	0.548	rs3911878	chr1:115378405	A/C	cg12756093	chr1:115239321	AMPD1	0.54	5.23	0.32	3.56e-7	Schizophrenia;
KIRP	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg19875535	chr5:140030758	IK	0.64	8.83	0.49	1.99e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2278796	0.639	rs11240330	chr1:204968258	C/A	cg17449235	chr1:204966235	NFASC	0.58	7.92	0.45	8.06e-14	Mean platelet volume;
KIRP	cis	rs1550532	0.632	rs1441093	chr2:234272484	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.52	-5.19	-0.31	4.48e-7	Calcium levels;Bilirubin levels;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-8.82	-0.49	2.2e-16	Lymphocyte counts;
KIRP	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.62	8.91	0.49	1.19e-16	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.69	-10.78	-0.57	1.86e-22	Educational attainment;
KIRP	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.49	-6.09	-0.36	4.4e-9	Prudent dietary pattern;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03647317	chr4:187891568	NA	-0.74	-11.98	-0.61	2.38e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-8.77	-0.49	3.09e-16	Personality dimensions;
KIRP	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg07843065	chr1:150265600	MRPS21	0.41	5.37	0.32	1.79e-7	Migraine;
KIRP	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-4.88	-0.3	1.91e-6	Ulcerative colitis;
KIRP	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg02487422	chr3:49467188	NICN1	0.35	4.9	0.3	1.72e-6	Parkinson's disease;
KIRP	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg15556689	chr8:8085844	FLJ10661	0.52	7.01	0.41	2.27e-11	Neuroticism;
KIRP	cis	rs4692589	0.965	rs733672	chr4:170950243	C/A	cg19918862	chr4:170955249	NA	0.47	5.69	0.34	3.6e-8	Anxiety disorder;
KIRP	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.63	6.66	0.39	1.82e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg04369109	chr6:150039330	LATS1	-0.44	-5.28	-0.32	2.89e-7	Lung cancer;
KIRP	cis	rs6992848	0.791	rs34121671	chr8:141167664	G/A	cg13911501	chr8:141220320	TRAPPC9	0.41	4.94	0.3	1.41e-6	Response to amphetamines;
KIRP	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00889227	chr1:205173544	DSTYK	-0.38	-5.45	-0.33	1.25e-7	Red blood cell count;
KIRP	cis	rs4664293	0.867	rs10166694	chr2:160594891	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg18016565	chr1:150552671	MCL1	0.37	5.42	0.33	1.4e-7	Tonsillectomy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15525503	chr1:3773166	DFFB;KIAA0562	-0.53	-6.35	-0.38	1.05e-9	Interleukin-4 levels;
KIRP	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.62	-9.67	-0.52	5.83e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg19171272	chr22:38449367	NA	-0.6	-9.05	-0.5	4.36e-17	Glioblastoma;Glioma;
KIRP	cis	rs9309473	0.797	rs6723247	chr2:73846749	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-5.62	-0.34	5.19e-8	Metabolite levels;
KIRP	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-1.01	-16.92	-0.73	3.99e-43	Height;
KIRP	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.77	7.77	0.44	2.15e-13	Hip geometry;
KIRP	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg05973401	chr12:123451056	ABCB9	0.61	5.58	0.34	6.41e-8	Neutrophil percentage of white cells;
KIRP	cis	rs13418717	1.000	rs10203501	chr2:127642143	C/T	cg25501666	chr2:127640322	NA	1.09	7.44	0.43	1.68e-12	Heart failure;
KIRP	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.43	5.94	0.35	9.54e-9	Red blood cell count;
KIRP	cis	rs60154123	0.730	rs12030512	chr1:210466886	A/G	cg09074223	chr1:210466472	NA	0.6	6.3	0.37	1.38e-9	Coronary artery disease;
KIRP	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.81	-0.4	7.61e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7792596	0.861	rs57900160	chr7:93986265	C/G	cg20814616	chr7:94014465	NA	-0.41	-7.08	-0.41	1.46e-11	Intelligence;
KIRP	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg13206674	chr6:150067644	NUP43	0.52	7.21	0.42	6.8e-12	Testicular germ cell tumor;
KIRP	cis	rs9436747	0.605	rs7542824	chr1:65945965	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	-0.47	-4.87	-0.3	2.01e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs501120	1.000	rs559580	chr10:44752078	C/T	cg09554077	chr10:44749378	NA	-0.67	-9.39	-0.51	4.34e-18	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-4.97	-0.3	1.27e-6	Pulmonary function;
KIRP	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.6	6.9	0.4	4.34e-11	HDL cholesterol;
KIRP	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg26384229	chr12:38710491	ALG10B	0.55	7.38	0.43	2.43e-12	Morning vs. evening chronotype;
KIRP	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.37	-0.32	1.86e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs5766691	1.000	rs738665	chr22:47529157	G/A	cg15757745	chr22:47558489	TBC1D22A	-0.42	-5.09	-0.31	7.03e-7	Longevity;
KIRP	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	22.94	0.83	4.76e-63	Schizophrenia;
KIRP	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.67	7.85	0.45	1.28e-13	Pancreatic cancer;
KIRP	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03934478	chr11:495069	RNH1	0.78	6.45	0.38	5.86e-10	Body mass index;
KIRP	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1656402	1.000	rs1729254	chr2:233428809	A/G	cg03852847	chr2:233439513	NA	0.72	12.18	0.61	5.04e-27	Non-small cell lung cancer (survival);
KIRP	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg17376030	chr22:41985996	PMM1	-0.54	-5.73	-0.34	2.93e-8	Vitiligo;
KIRP	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02711726	chr17:80685570	FN3KRP	-0.54	-6.85	-0.4	5.94e-11	Glycated hemoglobin levels;
KIRP	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg15691649	chr6:25882328	NA	-0.42	-5.03	-0.31	9.62e-7	Blood metabolite levels;
KIRP	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg08917208	chr2:24149416	ATAD2B	0.69	6.07	0.36	4.68e-9	Lymphocyte counts;
KIRP	cis	rs4704187	0.687	rs6862740	chr5:74405749	A/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs7072216	0.843	rs4400721	chr10:100147097	C/T	cg19567339	chr10:100142640	NA	0.5	5.51	0.33	9.18e-8	Metabolite levels;
KIRP	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.38	-5.07	-0.31	7.86e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.74	7.69	0.44	3.58e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26306683	chr17:18585705	ZNF286B	0.58	7.55	0.43	8.29e-13	Educational attainment (years of education);
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.49	-5.07	-0.31	7.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg18461021	chr18:74961002	GALR1	0.54	5.69	0.34	3.62e-8	Obesity-related traits;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg08989290	chr16:615782	NHLRC4	0.42	6.33	0.37	1.17e-9	Height;
KIRP	cis	rs9972944	0.729	rs10083872	chr17:63773474	A/G	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg05315796	chr3:52349193	DNAH1	0.42	5.47	0.33	1.08e-7	Schizophrenia;
KIRP	cis	rs17065868	1.000	rs61949807	chr13:45054418	T/G	cg10246903	chr13:45222710	NA	0.58	5.96	0.36	8.8e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg26513180	chr16:89883248	FANCA	0.86	6.04	0.36	5.56e-9	Skin colour saturation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26345444	chr12:16430861	SLC15A5	-0.41	-6.34	-0.37	1.11e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.13	-0.36	3.41e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.77	8.85	0.49	1.71e-16	Corneal astigmatism;
KIRP	cis	rs7246657	0.722	rs35863684	chr19:38109777	C/T	cg23950597	chr19:37808831	NA	-0.59	-6.39	-0.38	8.04e-10	Coronary artery calcification;
KIRP	cis	rs6681460	1.000	rs6659968	chr1:67123459	C/T	cg13052034	chr1:66999238	SGIP1	0.44	6.22	0.37	2.15e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg13770153	chr20:60521292	NA	-0.42	-4.99	-0.3	1.15e-6	Body mass index;
KIRP	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg07541023	chr7:19748670	TWISTNB	0.66	5.82	0.35	1.79e-8	Thyroid stimulating hormone;
KIRP	cis	rs42648	0.869	rs6970376	chr7:89938086	A/G	cg25739043	chr7:89950458	NA	0.46	7.21	0.42	7e-12	Homocysteine levels;
KIRP	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-8.38	-0.47	4.01e-15	Monocyte percentage of white cells;
KIRP	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.65	-7.71	-0.44	3.16e-13	Urate levels;
KIRP	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.51	8.28	0.47	8.16e-15	Major depressive disorder;
KIRP	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.94	-14.84	-0.69	5.14e-36	Body mass index;
KIRP	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg09408571	chr1:101003634	GPR88	0.34	7.81	0.45	1.7e-13	Breast cancer;
KIRP	cis	rs10267417	0.603	rs7791170	chr7:19905411	T/A	cg05791153	chr7:19748676	TWISTNB	0.51	5.27	0.32	3e-7	Night sleep phenotypes;
KIRP	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg23950597	chr19:37808831	NA	-0.67	-5.99	-0.36	7.32e-9	Coronary artery calcification;
KIRP	cis	rs7927370	0.558	rs61896326	chr11:55607057	C/T	cg07850316	chr11:56344833	OR5M10;OR8U8	0.66	5.1	0.31	6.95e-7	Systemic lupus erythematosus;
KIRP	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.29e-7	Red blood cell count;
KIRP	cis	rs963731	0.579	rs6739568	chr2:39287550	G/T	cg04010122	chr2:39346883	SOS1	-0.82	-5.65	-0.34	4.42e-8	Corticobasal degeneration;
KIRP	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-12.75	-0.63	6.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.38	7.18	0.42	8.05e-12	Mean corpuscular volume;
KIRP	cis	rs7523273	1.000	rs12184327	chr1:207978780	A/G	cg22525895	chr1:207977042	MIR29B2	-0.68	-8.67	-0.48	5.77e-16	Schizophrenia;
KIRP	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.87	8.58	0.48	1.07e-15	Fibroblast growth factor basic levels;
KIRP	trans	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.05	0.36	5.41e-9	Mean corpuscular volume;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.44	-5.61	-0.34	5.32e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10056811	0.527	rs55798253	chr5:74380957	A/G	cg19683494	chr5:74908142	NA	0.56	5.0	0.3	1.07e-6	Coronary artery disease;
KIRP	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.33	-7.27	-0.42	4.79e-12	Cutaneous nevi;
KIRP	cis	rs12519773	0.526	rs4469186	chr5:92520266	T/C	cg18783429	chr5:92414398	NA	0.29	5.14	0.31	5.73e-7	Migraine;
KIRP	cis	rs1978968	0.913	rs12158823	chr22:18439420	G/A	cg03078520	chr22:18463400	MICAL3	-0.65	-7.78	-0.44	2e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.61	8.0	0.45	5.02e-14	Coronary artery disease;
KIRP	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg08975724	chr8:8085496	FLJ10661	0.7	10.06	0.54	3.65e-20	Retinal vascular caliber;
KIRP	cis	rs2457480	0.778	rs11238901	chr10:44681012	C/A	cg09554077	chr10:44749378	NA	0.57	5.92	0.35	1.08e-8	Coronary artery disease;
KIRP	cis	rs7011049	0.778	rs113641746	chr8:53870078	T/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.61	-7.98	-0.45	5.67e-14	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	4.92	0.3	1.57e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08449448	chr8:58056501	NA	0.42	4.94	0.3	1.44e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.83	-12.77	-0.63	5.59e-29	Asthma;
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg11814155	chr7:99998594	ZCWPW1	0.62	5.54	0.33	7.79e-8	Platelet count;
KIRP	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs57994353	0.632	rs68142670	chr9:139324573	T/C	cg14169450	chr9:139327907	INPP5E	0.61	7.52	0.43	1.04e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.84	-6.96	-0.41	3.08e-11	Initial pursuit acceleration;
KIRP	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12432903	chr7:1882776	MAD1L1	-0.5	-4.97	-0.3	1.28e-6	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.88	0.3	1.94e-6	Menopause (age at onset);
KIRP	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.02	-0.46	4.34e-14	Neuroticism;
KIRP	trans	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg19274270	chr17:78178856	CARD14	0.35	6.36	0.38	9.49e-10	Morning vs. evening chronotype;
KIRP	cis	rs7941030	1.000	rs10790518	chr11:122520706	C/G	cg20555462	chr11:122535518	UBASH3B	-0.44	-5.45	-0.33	1.21e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6684514	0.845	rs12138564	chr1:156291600	G/T	cg16558208	chr1:156270281	VHLL	-0.43	-5.73	-0.34	2.9e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11671005	0.571	rs56243535	chr19:59006150	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.53	-5.55	-0.33	7.44e-8	Mean platelet volume;
KIRP	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.56	-6.54	-0.38	3.49e-10	Menopause (age at onset);
KIRP	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg00343986	chr7:65444356	GUSB	0.42	4.94	0.3	1.44e-6	Aortic root size;
KIRP	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.7	10.29	0.55	6.89e-21	Dupuytren's disease;
KIRP	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg27432699	chr2:27873401	GPN1	0.53	6.97	0.41	2.98e-11	Total body bone mineral density;
KIRP	trans	rs7982677	0.535	rs1926649	chr13:92991411	A/G	cg16692470	chr16:89184092	ACSF3	-0.51	-6.11	-0.36	3.85e-9	Tetralogy of Fallot;
KIRP	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg16405210	chr4:1374714	KIAA1530	0.48	6.28	0.37	1.54e-9	Obesity-related traits;
KIRP	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg03714773	chr7:91764589	CYP51A1	-0.34	-5.11	-0.31	6.41e-7	Breast cancer;
KIRP	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.72	8.38	0.47	3.99e-15	Gestational age at birth (maternal effect);
KIRP	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.76	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7224685	0.501	rs2727064	chr17:3934101	A/G	cg11204139	chr17:3907470	NA	0.81	14.51	0.68	6.74e-35	Type 2 diabetes;
KIRP	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg10189774	chr4:17578691	LAP3	0.41	4.97	0.3	1.24e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2298632	1.000	rs2298632	chr1:23710475	C/T	cg19743168	chr1:23544995	NA	-0.39	-5.25	-0.32	3.24e-7	QT interval;
KIRP	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.53	-6.22	-0.37	2.12e-9	Iron status biomarkers;
KIRP	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs631288	0.793	rs6593746	chr1:146686649	G/A	cg25205988	chr1:146714368	CHD1L	1.01	5.52	0.33	8.62e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2278796	0.724	rs2794860	chr1:204968392	A/G	cg17947172	chr1:204966197	NFASC	0.6	8.55	0.48	1.33e-15	Mean platelet volume;
KIRP	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs986417	0.818	rs10143831	chr14:61081961	G/T	cg27398547	chr14:60952738	C14orf39	0.64	6.03	0.36	6.1e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs59868192	0.925	rs58818261	chr15:42243098	G/A	cg20935245	chr15:42234343	EHD4	-0.54	-5.3	-0.32	2.56e-7	White blood cell count;
KIRP	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg15247329	chr7:2764246	NA	0.35	5.25	0.32	3.24e-7	Height;
KIRP	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg17986701	chr20:44574422	PCIF1	0.45	7.1	0.41	1.37e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg26338869	chr17:61819248	STRADA	0.52	6.12	0.36	3.66e-9	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19115630	chr4:76439549	RCHY1;THAP6	0.43	6.19	0.37	2.56e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2548003	0.541	rs1812669	chr5:28745835	C/G	cg22863700	chr5:28928346	NA	0.51	5.42	0.33	1.46e-7	Hip geometry;
KIRP	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg02487422	chr3:49467188	NICN1	0.45	6.59	0.39	2.6200000000000003e-10	Menarche (age at onset);
KIRP	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.8	-12.49	-0.62	4.62e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07308232	chr7:1071921	C7orf50	-0.73	-9.79	-0.53	2.44e-19	Longevity;Endometriosis;
KIRP	cis	rs8008758	0.963	rs10132271	chr14:101688874	C/T	cg26224664	chr14:101693935	NA	-0.4	-5.01	-0.3	1.02e-6	Body mass index (alcohol intake interaction);
KIRP	cis	rs10214930	0.813	rs2391447	chr7:27674564	G/A	cg22168087	chr7:27702803	HIBADH	0.51	5.13	0.31	5.91e-7	Hypospadias;
KIRP	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.57	-7.48	-0.43	1.27e-12	Bipolar disorder;
KIRP	cis	rs9547996	0.879	rs9532090	chr13:38203891	A/T	cg13634560	chr13:38173852	POSTN	-0.4	-5.54	-0.33	7.66e-8	Diastolic blood pressure;
KIRP	cis	rs7582720	0.806	rs10932008	chr2:204048840	G/A	cg08076091	chr2:203926405	NBEAL1	-0.42	-5.35	-0.32	2e-7	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.62	8.95	0.5	9.03e-17	Resting heart rate;
KIRP	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.77	7.63	0.44	5.18e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	5.97	0.36	8.41e-9	Breast cancer;
KIRP	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg17724175	chr1:150552817	MCL1	0.29	4.85	0.3	2.22e-6	Melanoma;
KIRP	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.05e-6	Morning vs. evening chronotype;
KIRP	cis	rs6088813	1.000	rs4911492	chr20:33951799	G/A	cg14752227	chr20:34000481	UQCC	-0.51	-6.87	-0.4	5.22e-11	Height;
KIRP	cis	rs1035491	0.715	rs10057925	chr5:63926262	T/G	cg01791865	chr5:63954708	NA	0.33	5.21	0.32	4.07e-7	Body mass index;
KIRP	cis	rs876084	0.505	rs66488706	chr8:121132894	C/T	cg22335954	chr8:121166405	COL14A1	-0.39	-5.19	-0.31	4.44e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg23693289	chr8:27183097	PTK2B	0.54	6.98	0.41	2.72e-11	Neuroticism;
KIRP	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.3	-0.32	2.54e-7	Type 2 diabetes;
KIRP	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.33	-0.37	1.15e-9	Bipolar disorder;
KIRP	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.67	7.39	0.43	2.32e-12	Serum parathyroid hormone levels;
KIRP	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.64	-7.5	-0.43	1.19e-12	Fear of minor pain;
KIRP	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg14673194	chr17:80132900	CCDC57	-0.65	-7.02	-0.41	2.13e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.84	-11.44	-0.59	1.36e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs883565	0.740	rs11925218	chr3:39081171	C/A	cg01426195	chr3:39028469	NA	-0.67	-11.15	-0.58	1.24e-23	Handedness;
KIRP	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg07116693	chr15:90310901	NA	-0.23	-5.03	-0.31	9.63e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	1.15	10.06	0.54	3.77e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs787274	0.718	rs7869100	chr9:115628533	T/C	cg13803584	chr9:115635662	SNX30	-0.71	-5.99	-0.36	7.27e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	6.99	0.41	2.59e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.09	0.31	7.19e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6840360	0.582	rs4696260	chr4:152318924	T/C	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.44e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg23791538	chr6:167370224	RNASET2	-0.42	-5.36	-0.32	1.89e-7	Crohn's disease;
KIRP	cis	rs6728302	0.557	rs73002000	chr2:233254052	C/T	cg06555452	chr2:233241558	NA	0.72	5.41	0.33	1.51e-7	Height;
KIRP	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg02415014	chr8:143852576	LYNX1	-0.31	-4.89	-0.3	1.82e-6	Urinary tract infection frequency;
KIRP	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Hypertriglyceridemia;
KIRP	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.57	-7.79	-0.44	1.87e-13	Endometrial cancer;
KIRP	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg11833968	chr6:79620685	NA	-0.38	-5.22	-0.32	3.85e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25791744	chr6:139695837	CITED2	-0.64	-7.18	-0.42	8.27e-12	Menopause (age at onset);
KIRP	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg26566898	chr11:117069891	TAGLN	0.4	5.31	0.32	2.43e-7	Blood protein levels;
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg02996583	chr8:142237188	SLC45A4	-0.49	-5.98	-0.36	7.81e-9	Immature fraction of reticulocytes;
KIRP	cis	rs17102423	0.589	rs8011585	chr14:65522223	T/A	cg11161011	chr14:65562177	MAX	-0.51	-6.46	-0.38	5.53e-10	Obesity-related traits;
KIRP	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21659725	chr3:3221576	CRBN	-0.5	-6.15	-0.37	3.19e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2766692	1.000	rs34680851	chr14:100723154	A/G	cg14866419	chr14:100704911	YY1	0.66	7.88	0.45	1.05e-13	Electroencephalographic traits in alcoholism;
KIRP	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.76	-11.28	-0.58	4.69e-24	Educational attainment;
KIRP	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg03808351	chr9:123631620	PHF19	0.37	5.09	0.31	7.26e-7	Rheumatoid arthritis;
KIRP	cis	rs16976116	0.803	rs9920136	chr15:55504102	A/G	cg11288833	chr15:55489084	RSL24D1	0.65	7.17	0.42	8.78e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.67	8.24	0.47	1.02e-14	Pulmonary function decline;
KIRP	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1978968	0.717	rs8139578	chr22:18468208	A/G	cg03078520	chr22:18463400	MICAL3	-0.82	-11.88	-0.6	5.12e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs6466055	0.661	rs6942483	chr7:104950161	T/A	cg04380332	chr7:105027541	SRPK2	0.38	5.13	0.31	6.01e-7	Schizophrenia;
KIRP	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-1.04	-12.4	-0.62	9.27e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg21523564	chr15:75251491	NA	0.39	6.26	0.37	1.68e-9	Breast cancer;
KIRP	cis	rs9549260	0.753	rs2297628	chr13:41233905	T/C	cg21288729	chr13:41239152	FOXO1	0.52	5.31	0.32	2.45e-7	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13400516	chr1:2159040	SKI	0.61	8.41	0.47	3.36e-15	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.34	0.74	1.5e-44	Height;
KIRP	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	0.93	11.35	0.59	2.76e-24	Vitiligo;
KIRP	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.84	-10.71	-0.56	3.25e-22	Parkinson's disease;
KIRP	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.83	-0.4	6.8e-11	Aortic root size;
KIRP	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.58	-0.43	7.26e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg06219351	chr7:158114137	PTPRN2	-0.58	-6.59	-0.39	2.73e-10	Response to amphetamines;
KIRP	cis	rs10875746	0.556	rs4760619	chr12:48499931	A/T	cg20731937	chr12:48336164	NA	0.61	6.88	0.4	4.99e-11	Longevity (90 years and older);
KIRP	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg00484396	chr16:3507460	NAT15	0.53	5.37	0.32	1.84e-7	Tuberculosis;
KIRP	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg02903104	chr8:1507517	DLGAP2	0.38	5.84	0.35	1.65e-8	Lung cancer;
KIRP	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg07395648	chr5:131743802	NA	-0.36	-5.29	-0.32	2.65e-7	Blood metabolite levels;
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-5.11	-0.31	6.38e-7	Lung cancer;
KIRP	cis	rs939574	0.656	rs6710315	chr2:220137991	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.62	-4.91	-0.3	1.66e-6	Platelet distribution width;
KIRP	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg03929089	chr4:120376271	NA	-0.79	-10.41	-0.55	2.84e-21	Height;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.43	-0.33	1.36e-7	Lung cancer;
KIRP	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.29	-0.32	2.66e-7	Coronary artery disease;
KIRP	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.63	-9.41	-0.51	3.68e-18	Hip circumference;Waist circumference;
KIRP	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.58	-7.28	-0.42	4.62e-12	Uric acid levels;
KIRP	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg06565975	chr8:143823917	SLURP1	0.47	7.49	0.43	1.24e-12	Urinary tract infection frequency;
KIRP	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-5.5	-0.33	9.31e-8	Height;
KIRP	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	9.88	0.53	1.31e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.22	0.42	6.59e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14510947	chr17:62223546	SNORA76	-0.55	-6.35	-0.38	1.02e-9	Brain structure;
KIRP	cis	rs867371	0.820	rs12443224	chr15:82495610	C/T	cg00614314	chr15:82944287	LOC80154	0.54	6.2	0.37	2.32e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.73	9.11	0.5	2.98e-17	Menopause (age at onset);
KIRP	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.95	15.33	0.7	1.11e-37	Metabolite levels;
KIRP	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg13334819	chr7:99746414	C7orf59	-0.49	-5.76	-0.34	2.53e-8	Coronary artery disease;
KIRP	cis	rs17057718	1.000	rs2035656	chr3:57125101	A/C	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-4.99	-0.3	1.17e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.23	-0.37	1.97e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg01236616	chr12:121019343	POP5	0.46	4.87	0.3	2.04e-6	High light scatter reticulocyte count;
KIRP	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.95	-14.85	-0.69	4.87e-36	Body mass index;
KIRP	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg10818794	chr15:86012489	AKAP13	-0.48	-6.81	-0.4	7.52e-11	Coronary artery disease;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg09699651	chr6:150184138	LRP11	-0.45	-6.01	-0.36	6.67e-9	Lung cancer;
KIRP	cis	rs17407555	0.779	rs57757169	chr4:10115703	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-5.83	-0.35	1.71e-8	Schizophrenia (age at onset);
KIRP	cis	rs959260	1.000	rs4789184	chr17:73383314	A/G	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg24101359	chr6:42928495	GNMT	0.62	9.23	0.51	1.32e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg25650185	chr19:21324782	ZNF431	0.48	4.98	0.3	1.18e-6	Pain;
KIRP	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs4689642	0.718	rs62289707	chr4:7224978	T/C	cg21353189	chr4:7228343	SORCS2	0.43	5.64	0.34	4.65e-8	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs4262150	0.810	rs4557395	chr5:151963272	G/T	cg12297329	chr5:152029980	NA	-0.63	-7.79	-0.44	1.89e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg15832292	chr6:96025679	MANEA	-0.78	-6.91	-0.4	4.18e-11	Behavioural disinhibition (generation interaction);
KIRP	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	6.09	0.36	4.43e-9	Retinal vascular caliber;
KIRP	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg02975922	chr3:195473998	MUC4	-0.53	-6.21	-0.37	2.27e-9	Pancreatic cancer;
KIRP	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-0.79	-10.67	-0.56	4.19e-22	Urate levels;
KIRP	cis	rs7127900	1.000	rs4077456	chr11:2230152	A/G	cg25635251	chr11:2234043	NA	0.53	8.01	0.46	4.45e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs3026101	0.671	rs55662604	chr17:5297457	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.96	0.36	8.81e-9	Body mass index;
KIRP	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg12877253	chr3:19992400	RAB5A	-0.4	-5.64	-0.34	4.62e-8	Post-traumatic stress disorder;
KIRP	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs4656940	0.574	rs540224	chr1:160763370	G/A	cg17331569	chr1:160788135	LY9	0.45	5.3	0.32	2.63e-7	Crohn's disease;
KIRP	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.07	0.46	3.14e-14	Lung cancer;
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.86	14.29	0.67	3.98e-34	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.3	-0.32	2.58e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7700895	0.737	rs11135442	chr5:95222511	T/C	cg16656078	chr5:95278638	ELL2	-0.4	-6.0	-0.36	7.01e-9	IgG glycosylation;
KIRP	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.45	-5.56	-0.33	7.11e-8	Diastolic blood pressure;
KIRP	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg15282417	chr9:129245246	FAM125B	-0.42	-7.06	-0.41	1.69e-11	Intraocular pressure;
KIRP	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.61e-11	Bipolar disorder;
KIRP	cis	rs10875746	0.903	rs12304476	chr12:48482153	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg13319975	chr6:146136371	FBXO30	-0.46	-6.4	-0.38	7.62e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg22903471	chr2:27725779	GCKR	-0.61	-8.93	-0.49	1e-16	Total body bone mineral density;
KIRP	cis	rs72781680	0.593	rs72797817	chr2:24350569	A/G	cg20701182	chr2:24300061	SF3B14	0.91	10.14	0.54	2.08e-20	Lymphocyte counts;
KIRP	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.52	7.34	0.42	3.19e-12	Systemic lupus erythematosus;
KIRP	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.98	-0.36	7.75e-9	Breast cancer;
KIRP	cis	rs4237845	0.591	rs4590915	chr12:58335130	G/A	cg00677455	chr12:58241039	CTDSP2	0.71	7.87	0.45	1.11e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg04607699	chr11:48328132	OR4S1	-0.34	-4.92	-0.3	1.62e-6	Height;
KIRP	cis	rs1011018	0.955	rs6978085	chr7:139454463	C/T	cg03224163	chr7:139420300	HIPK2	-0.46	-4.95	-0.3	1.38e-6	Systolic blood pressure;
KIRP	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.84	9.58	0.52	1.12e-18	Response to diuretic therapy;
KIRP	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg19875535	chr5:140030758	IK	-0.51	-6.45	-0.38	5.84e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.03	0.41	2e-11	Bipolar disorder;
KIRP	trans	rs9409565	0.855	rs7042481	chr9:97064273	C/A	cg05679027	chr9:99775184	HIATL2	0.64	7.64	0.44	4.88e-13	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg17133734	chr15:86042851	AKAP13	-0.41	-5.13	-0.31	5.97e-7	Interstitial lung disease;
KIRP	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.94	16.36	0.72	3.3e-41	Metabolic syndrome;
KIRP	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-6.35	-0.38	1.05e-9	Aortic root size;
KIRP	cis	rs7630877	0.886	rs57376419	chr3:179584385	C/T	cg18765712	chr3:179670323	PEX5L	0.56	6.51	0.38	4.1e-10	Type 2 diabetes;
KIRP	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.64	9.2	0.51	1.6e-17	Colorectal cancer;
KIRP	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs7870753	0.578	rs7851198	chr9:99132375	C/T	cg25260653	chr9:99212216	HABP4	0.53	5.27	0.32	2.96e-7	Height;
KIRP	cis	rs4594175	0.926	rs11851960	chr14:51598610	A/G	cg23942311	chr14:51606299	NA	0.53	6.98	0.41	2.68e-11	Cancer;
KIRP	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00864171	chr11:67383662	NA	-0.4	-5.11	-0.31	6.37e-7	Mean corpuscular volume;
KIRP	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg11234688	chr2:1609660	NA	0.61	5.41	0.33	1.46e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs8179	0.700	rs42040	chr7:92245927	C/T	cg15732164	chr7:92237376	CDK6	-0.57	-7.2	-0.42	7.32e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.44	-5.85	-0.35	1.54e-8	QT interval;
KIRP	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg16110827	chr15:48056943	SEMA6D	-0.36	-4.86	-0.3	2.11e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2688608	0.967	rs1815076	chr10:75659886	C/T	cg23231163	chr10:75533350	FUT11	-0.33	-5.05	-0.31	8.71e-7	Inflammatory bowel disease;
KIRP	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg11783602	chr8:55087084	NA	-0.45	-5.36	-0.32	1.88e-7	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6690583	0.623	rs61768853	chr1:85455707	T/C	cg22153463	chr1:85462885	MCOLN2	0.59	5.45	0.33	1.22e-7	Serum sulfate level;
KIRP	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-5.45	-0.33	1.23e-7	Neuroticism;
KIRP	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	1.99e-8	Lung cancer;
KIRP	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg05785598	chr3:49045655	WDR6	0.33	5.91	0.35	1.14e-8	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.45	5.5	0.33	9.4e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs9508025	0.628	rs7337610	chr13:28962666	T/C	cg11853320	chr13:28493913	PDX1	-0.39	-4.87	-0.3	1.99e-6	Coronary heart disease;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.5	6.78	0.4	8.71e-11	Renal function-related traits (BUN);
KIRP	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.34	-0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs580438	0.529	rs7622028	chr3:13436336	A/C	cg10657019	chr3:13328039	NA	-0.47	-6.07	-0.36	4.84e-9	Myringotomy;
KIRP	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg10755058	chr3:40428713	ENTPD3	0.4	5.87	0.35	1.39e-8	Renal cell carcinoma;
KIRP	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg05082376	chr22:42548792	NA	-0.43	-5.41	-0.33	1.49e-7	Schizophrenia;
KIRP	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.94	-0.54	8.37e-20	Total body bone mineral density;
KIRP	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg15655495	chr12:38532458	NA	-0.27	-4.87	-0.3	2e-6	Bladder cancer;
KIRP	cis	rs11637445	0.677	rs4386088	chr15:68108913	G/A	cg24579218	chr15:68104479	NA	-0.43	-6.53	-0.38	3.65e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs9443189	0.813	rs2748956	chr6:76465003	G/C	cg01950844	chr6:76311363	SENP6	-0.57	-5.91	-0.35	1.12e-8	Prostate cancer;
KIRP	cis	rs7127900	1.000	rs7126857	chr11:2229111	C/T	cg25635251	chr11:2234043	NA	0.53	8.0	0.45	4.9e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg10729496	chr3:10149963	C3orf24	0.55	4.94	0.3	1.41e-6	Alzheimer's disease;
KIRP	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.97	11.63	0.6	3.41e-25	Exhaled nitric oxide levels;
KIRP	cis	rs1497828	0.956	rs2646832	chr1:217544979	A/G	cg04411442	chr1:217543379	NA	0.31	5.02	0.3	1e-6	Dialysis-related mortality;
KIRP	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg17340268	chr14:105411764	AHNAK2	-0.39	-5.03	-0.31	9.34e-7	Rheumatoid arthritis;
KIRP	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.36	-0.38	9.49e-10	Arsenic metabolism;
KIRP	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	1.08	10.26	0.55	8.46e-21	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14846700	chr1:226112165	PYCR2	0.53	6.6	0.39	2.44e-10	Parkinson's disease;
KIRP	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01616529	chr11:638424	DRD4	-0.41	-5.61	-0.34	5.45e-8	Systemic lupus erythematosus;
KIRP	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	8.79	0.49	2.58e-16	Alzheimer's disease;
KIRP	cis	rs12995491	0.731	rs34991383	chr2:88500337	T/G	cg04511125	chr2:88470314	THNSL2	-0.49	-6.09	-0.36	4.32e-9	Response to metformin (IC50);
KIRP	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg25019033	chr10:957182	NA	-0.56	-7.1	-0.41	1.33e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg05754148	chr16:3507555	NAT15	0.49	4.89	0.3	1.78e-6	Tuberculosis;
KIRP	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.11e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg02725872	chr8:58115012	NA	-0.52	-5.86	-0.35	1.51e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.99e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.58	9.48	0.52	2.18e-18	C-reactive protein levels;
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg07701084	chr6:150067640	NUP43	0.62	8.09	0.46	2.75e-14	Lung cancer;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg13957827	chr4:164415471	C4orf43	-0.54	-6.85	-0.4	5.83e-11	Pancreatic cancer;
KIRP	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg02038168	chr22:39784481	NA	-0.45	-5.51	-0.33	8.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	0.87	12.46	0.62	5.92e-28	Homoarginine levels;
KIRP	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.45	5.34	0.32	2.07e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7737355	0.812	rs11750704	chr5:130911578	C/A	cg25547332	chr5:131281432	NA	0.4	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs4742903	0.904	rs1507514	chr9:106986114	T/C	cg14250997	chr9:106856677	SMC2	0.37	4.86	0.3	2.08e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.62	-5.42	-0.33	1.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2299587	0.560	rs7814692	chr8:17780157	G/A	cg01800426	chr8:17659068	MTUS1	-0.62	-7.36	-0.42	2.77e-12	Economic and political preferences;
KIRP	cis	rs2070997	0.702	rs7866565	chr9:133766545	C/T	cg13397898	chr9:133768931	QRFP	0.42	5.45	0.33	1.2e-7	Response to amphetamines;
KIRP	trans	rs12449568	0.816	rs56256630	chr17:54425309	T/C	cg04456437	chr3:119217424	C3orf1	0.48	6.06	0.36	5.07e-9	Height;
KIRP	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.57	0.52	1.18e-18	Dupuytren's disease;
KIRP	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg21905437	chr5:178450457	ZNF879	0.49	5.71	0.34	3.22e-8	Pubertal anthropometrics;
KIRP	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.45	0.38	5.85e-10	Putamen volume;
KIRP	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.18	0.37	2.61e-9	Personality dimensions;
KIRP	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.48	-6.37	-0.38	9.23e-10	Alcohol dependence;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg10892158	chr8:24857894	NA	0.48	6.26	0.37	1.72e-9	Sleep duration;
KIRP	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg09754948	chr16:28834200	ATXN2L	0.5	5.66	0.34	4.28e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12949688	0.967	rs12950062	chr17:55825534	G/A	cg12582317	chr17:55822272	NA	0.59	9.51	0.52	1.77e-18	Schizophrenia;
KIRP	cis	rs2299587	0.662	rs6586671	chr8:17776084	T/C	cg01800426	chr8:17659068	MTUS1	-0.54	-6.45	-0.38	5.97e-10	Economic and political preferences;
KIRP	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.54	7.78	0.44	2.02e-13	Carotid intima media thickness;
KIRP	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.36	-4.99	-0.3	1.12e-6	Neuroticism;
KIRP	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg26681399	chr22:41777847	TEF	0.51	5.19	0.31	4.41e-7	Vitiligo;
KIRP	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg11608241	chr8:8085544	FLJ10661	0.52	6.22	0.37	2.17e-9	Neuroticism;
KIRP	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.82	-12.86	-0.63	2.77e-29	Breast cancer;
KIRP	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.43	5.31	0.32	2.43e-7	P wave terminal force;
KIRP	trans	rs7178375	1.000	rs28693590	chr15:31195021	A/G	cg04373760	chr16:53404718	NA	0.62	6.5	0.38	4.34e-10	Hypertriglyceridemia;
KIRP	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.43	0.74	7.26e-45	Height;
KIRP	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.88	-0.3	1.92e-6	Cervical cancer;
KIRP	cis	rs4363385	0.510	rs17627288	chr1:152923848	C/T	cg13444842	chr1:152974279	SPRR3	-0.47	-6.67	-0.39	1.65e-10	Inflammatory skin disease;
KIRP	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.67	6.72	0.39	1.23e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1030268	0.651	rs12707118	chr7:133474900	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-5.09	-0.31	7.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.42	5.28	0.32	2.82e-7	Aortic root size;
KIRP	cis	rs6584283	0.846	rs11190135	chr10:101286848	A/G	cg07044859	chr10:101282883	NA	-0.27	-4.86	-0.3	2.08e-6	Ulcerative colitis;
KIRP	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.85	-0.3	2.22e-6	Monocyte percentage of white cells;
KIRP	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg24253500	chr15:84953950	NA	0.66	7.11	0.41	1.25e-11	Schizophrenia;
KIRP	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg18404041	chr3:52824283	ITIH1	0.42	5.41	0.33	1.47e-7	Schizophrenia;
KIRP	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.68	-9.28	-0.51	8.85e-18	Colorectal cancer;
KIRP	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.75	0.44	2.46e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs60154123	0.730	rs12403947	chr1:210456524	A/G	cg09074223	chr1:210466472	NA	-0.48	-5.4	-0.33	1.57e-7	Coronary artery disease;
KIRP	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg02569458	chr12:86230093	RASSF9	-0.36	-4.96	-0.3	1.29e-6	Major depressive disorder;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.64	-8.68	-0.48	5.65e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2916247	1.000	rs10100101	chr8:93041761	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.61	-8.03	-0.46	4.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.49e-6	Red blood cell count;
KIRP	cis	rs1823913	0.637	rs4853577	chr2:192161844	C/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.18	-0.37	2.6e-9	Obesity-related traits;
KIRP	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.74	12.93	0.64	1.62e-29	Weight;
KIRP	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg17279839	chr7:150038598	RARRES2	0.44	5.5	0.33	9.41e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs2172802	0.560	rs12510774	chr4:62563504	C/T	cg04118610	chr4:62707027	LPHN3	0.47	5.77	0.35	2.42e-8	Partial epilepsies;
KIRP	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg07884673	chr3:53033167	SFMBT1	0.81	6.35	0.38	1.02e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg20387954	chr3:183756860	HTR3D	-0.81	-9.09	-0.5	3.35e-17	Body mass index;
KIRP	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs580438	0.510	rs4684930	chr3:13403169	T/C	cg10657019	chr3:13328039	NA	-0.59	-7.91	-0.45	8.71e-14	Myringotomy;
KIRP	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.69	-7.69	-0.44	3.54e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.34	0.37	1.11e-9	Monocyte percentage of white cells;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg07216194	chr8:27182965	PTK2B	0.46	5.7	0.34	3.35e-8	Neuroticism;
KIRP	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.58	-6.49	-0.38	4.6e-10	Menarche (age at onset);
KIRP	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.59	-7.24	-0.42	5.74e-12	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.44	-6.9	-0.4	4.48e-11	Coronary artery disease;
KIRP	cis	rs675026	0.926	rs613355	chr6:154449850	A/C	cg07813322	chr6:154414604	OPRM1	0.41	5.36	0.32	1.91e-7	Hypertension;
KIRP	cis	rs8067545	0.603	rs10083830	chr17:19965883	G/A	cg13482628	chr17:19912719	NA	0.56	7.03	0.41	1.98e-11	Schizophrenia;
KIRP	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg26811252	chr16:29126840	RRN3P2	0.66	8.88	0.49	1.4e-16	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.21e-15	Motion sickness;
KIRP	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-12.17	-0.61	5.48e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg24060327	chr5:131705240	SLC22A5	-0.58	-7.8	-0.45	1.71e-13	Acylcarnitine levels;
KIRP	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg13939156	chr17:80058883	NA	0.47	5.54	0.33	7.83e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg13253945	chr7:84569394	NA	0.44	6.82	0.4	6.9e-11	Cancer;
KIRP	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg16141378	chr3:129829833	LOC729375	0.51	6.48	0.38	4.92e-10	Neuroticism;
KIRP	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.17	0.31	4.87e-7	Schizophrenia;
KIRP	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.72	5.61	0.34	5.42e-8	Facial emotion recognition (sad faces);
KIRP	cis	rs2458413	0.522	rs2669449	chr8:105372173	A/C	cg08657449	chr8:105351661	TM7SF4	-0.33	-5.45	-0.33	1.2e-7	Paget's disease;
KIRP	cis	rs735860	0.718	rs209488	chr6:53177540	A/T	cg10236188	chr6:53219634	NA	0.42	5.46	0.33	1.18e-7	Glaucoma;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg25347419	chr2:177043501	NA	0.4	5.54	0.33	7.65e-8	IgG glycosylation;
KIRP	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	14.11	0.67	1.64e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.56	-11.91	-0.6	3.93e-26	Diabetic kidney disease;
KIRP	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.8	-0.35	2.01e-8	Crohn's disease;
KIRP	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg27572855	chr1:25598939	RHD	0.49	8.1	0.46	2.53e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg22223119	chr13:99095684	FARP1	-0.43	-5.09	-0.31	7.2e-7	Obesity-related traits;
KIRP	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg00042356	chr1:8021962	PARK7	-0.53	-5.48	-0.33	1.03e-7	Inflammatory bowel disease;
KIRP	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7737355	0.773	rs192166	chr5:130852525	T/C	cg06307176	chr5:131281290	NA	0.41	4.89	0.3	1.85e-6	Life satisfaction;
KIRP	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.72	-8.67	-0.48	6.04e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6132905	0.590	rs17228085	chr20:2607429	C/T	cg24848351	chr20:2622020	TMC2	0.5	5.62	0.34	5.27e-8	Mumps;
KIRP	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21747090	chr2:27597821	SNX17	-0.48	-6.57	-0.39	2.99e-10	Total body bone mineral density;
KIRP	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg08975724	chr8:8085496	FLJ10661	0.49	6.05	0.36	5.28e-9	Monocyte count;
KIRP	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.75	-10.39	-0.55	3.27e-21	Hypospadias;
KIRP	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.29	-5.65	-0.34	4.47e-8	Lymphocyte counts;
KIRP	cis	rs867371	1.000	rs8042464	chr15:82465536	A/G	cg06066596	chr15:83166174	LOC80154	-0.44	-5.16	-0.31	5.17e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg05555928	chr11:63887634	MACROD1	0.46	6.26	0.37	1.7e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs963731	0.737	rs10194374	chr2:39244914	G/A	cg04010122	chr2:39346883	SOS1	-0.91	-6.14	-0.36	3.23e-9	Corticobasal degeneration;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19990483	chr14:51030485	ATL1	-0.4	-6.15	-0.37	3.11e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.2	8.41	0.47	3.33e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10900048	chr4:73935377	COX18	0.54	7.3	0.42	3.86e-12	Parkinson's disease;
KIRP	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-9.2	-0.51	1.57e-17	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-10.3	-0.55	6.47e-21	Triglycerides;
KIRP	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	10.66	0.56	4.79e-22	Blood protein levels;
KIRP	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg24375607	chr4:120327624	NA	0.59	6.16	0.37	2.9e-9	Corneal astigmatism;
KIRP	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.92	-0.45	8.21e-14	Neuroticism;
KIRP	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg20578329	chr17:80767326	TBCD	-0.67	-7.73	-0.44	2.8e-13	Breast cancer;
KIRP	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg12591125	chr7:1885375	MAD1L1	0.58	5.64	0.34	4.57e-8	Bipolar disorder;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12107699	chr21:46238210	SUMO3	-0.44	-6.13	-0.36	3.47e-9	Myopia;
KIRP	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg11569703	chr11:65557185	OVOL1	-0.51	-8.84	-0.49	1.87e-16	Acne (severe);
KIRP	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg19752551	chr11:57585705	CTNND1	-0.81	-13.55	-0.65	1.25e-31	Schizophrenia;
KIRP	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.55	-7.14	-0.41	1.05e-11	Obesity-related traits;
KIRP	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-6.95	-0.4	3.36e-11	Morning vs. evening chronotype;
KIRP	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg00852783	chr1:26633632	UBXN11	0.54	7.72	0.44	2.91e-13	Obesity-related traits;
KIRP	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.45	0.59	1.28e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13272623	0.690	rs2086538	chr8:71988962	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	0.49	5.4	0.33	1.56e-7	IgG glycosylation;
KIRP	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.42	-5.94	-0.35	9.48e-9	Endometrial cancer;
KIRP	cis	rs8070740	0.503	rs1806246	chr17:5309711	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.42	4.98	0.3	1.2e-6	Menopause (age at onset);
KIRP	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.41	7.01	0.41	2.33e-11	Renal cell carcinoma;
KIRP	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.37	0.32	1.79e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.72	-8.88	-0.49	1.47e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	9.3	0.51	8.1e-18	Mood instability;
KIRP	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.85	12.13	0.61	7.65e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12913538	0.755	rs12915312	chr15:62895475	G/C	cg09983546	chr15:62884068	NA	0.49	6.43	0.38	6.66e-10	Sleep depth;
KIRP	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg03160526	chr17:80928410	B3GNTL1	0.41	5.22	0.32	3.8e-7	Glycated hemoglobin levels;
KIRP	cis	rs4132509	0.948	rs12032342	chr1:243834360	G/A	cg25706552	chr1:244017396	NA	0.6	7.22	0.42	6.64e-12	RR interval (heart rate);
KIRP	cis	rs6546886	1.000	rs12988533	chr2:74243034	A/G	cg14702570	chr2:74259524	NA	-0.32	-6.26	-0.37	1.72e-9	Dialysis-related mortality;
KIRP	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg13147721	chr7:65941812	NA	-1.0	-6.72	-0.39	1.25e-10	Diabetic kidney disease;
KIRP	cis	rs7116495	0.867	rs481300	chr11:71578383	G/A	cg11196788	chr11:71737549	NUMA1	-0.5	-4.95	-0.3	1.36e-6	Severe influenza A (H1N1) infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19922757	chr19:925514	ARID3A	0.54	6.65	0.39	1.9e-10	Parkinson's disease;
KIRP	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg13147721	chr7:65941812	NA	-0.97	-7.1	-0.41	1.32e-11	Gout;
KIRP	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg02696742	chr7:106810147	HBP1	-0.78	-8.72	-0.49	4.12e-16	Coronary artery disease;
KIRP	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg10381502	chr11:71823885	C11orf51	1.15	7.55	0.43	8.26e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg21926883	chr2:100939477	LONRF2	-0.56	-7.6	-0.44	6.27e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.56	-7.9	-0.45	9.28e-14	Schizophrenia;
KIRP	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg16011679	chr1:85725395	C1orf52	-0.63	-6.55	-0.39	3.28e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.4	0.7	6.37e-38	Gut microbiome composition (summer);
KIRP	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.59	-8.53	-0.48	1.52e-15	Testicular germ cell tumor;
KIRP	cis	rs8053891	0.855	rs6499553	chr16:71996715	C/T	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.04	-0.31	8.87e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00940313	chr17:1953823	MIR212;MIR132	0.53	6.64	0.39	2.04e-10	Parkinson's disease;
KIRP	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg02574844	chr11:5959923	NA	-0.56	-5.72	-0.34	3e-8	DNA methylation (variation);
KIRP	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg13409248	chr3:40428643	ENTPD3	-0.38	-5.38	-0.32	1.75e-7	Renal cell carcinoma;
KIRP	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.61	7.75	0.44	2.35e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.68	-8.3	-0.47	7.09e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6701037	1.000	rs1057305	chr1:175126223	T/A	cg08873628	chr1:175162347	KIAA0040	-0.39	-5.54	-0.33	7.63e-8	Alcohol dependence;
KIRP	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg23594656	chr7:65796392	TPST1	0.44	6.22	0.37	2.17e-9	Aortic root size;
KIRP	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.53	5.88	0.35	1.31e-8	Aortic root size;
KIRP	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.55	-6.44	-0.38	6.15e-10	Aortic root size;
KIRP	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg24692254	chr21:30365293	RNF160	-0.51	-5.14	-0.31	5.67e-7	Cognitive test performance;
KIRP	cis	rs2235642	0.621	rs2667665	chr16:1569524	A/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.2	-5.11	-0.31	6.38e-7	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07859478	chr19:808116	PTBP1	-0.5	-6.75	-0.4	1.05e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.98	9.33	0.51	6.48e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7998202	0.614	rs423117	chr13:113346107	C/T	cg02820901	chr13:113351484	ATP11A	-0.6	-5.64	-0.34	4.7e-8	Glycated hemoglobin levels;
KIRP	cis	rs921943	0.957	rs6881725	chr5:78310754	T/C	cg26802063	chr5:78281964	ARSB	0.51	6.34	0.37	1.08e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs12615966	0.872	rs55688943	chr2:105374842	T/A	cg16465502	chr2:105461796	NA	0.65	5.82	0.35	1.83e-8	Pancreatic cancer;
KIRP	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg14675211	chr2:100938903	LONRF2	0.55	7.13	0.41	1.11e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg21064579	chr19:49206444	FUT2	0.51	7.31	0.42	3.73e-12	Dietary macronutrient intake;
KIRP	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.71	-0.44	3.18e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.84	8.97	0.5	7.55e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.81	13.12	0.64	3.62e-30	Longevity;Endometriosis;
KIRP	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg17356467	chr2:100759845	AFF3	0.53	5.41	0.33	1.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.54e-9	Motion sickness;
KIRP	cis	rs9399401	0.961	rs6570509	chr6:142716286	G/T	cg03128060	chr6:142623767	GPR126	0.32	5.12	0.31	6.23e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs6088813	0.961	rs2425062	chr20:33923566	A/G	cg14752227	chr20:34000481	UQCC	0.47	6.03	0.36	6.07e-9	Height;
KIRP	cis	rs12210905	0.614	rs12199685	chr6:27323486	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg08992911	chr2:238395768	MLPH	0.41	4.94	0.3	1.47e-6	Prostate cancer;
KIRP	cis	rs9400467	0.506	rs12195578	chr6:111614786	C/T	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.23	15.1	0.69	6.84e-37	Eosinophil percentage of granulocytes;
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.76	-13.39	-0.65	4.47e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg05484376	chr2:27715224	FNDC4	0.3	4.92	0.3	1.62e-6	Oral cavity cancer;
KIRP	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg04306507	chr14:55594613	LGALS3	0.54	8.34	0.47	5.29e-15	Protein biomarker;
KIRP	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.91	-0.64	1.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg24503407	chr1:205819492	PM20D1	0.48	5.25	0.32	3.25e-7	Parkinson's disease;
KIRP	cis	rs1620921	0.505	rs9458032	chr6:161210205	G/T	cg01280913	chr6:161186852	NA	-0.58	-7.73	-0.44	2.7e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-8.5	-0.48	1.9e-15	Response to antipsychotic treatment;
KIRP	trans	rs982100	0.841	rs2113513	chr2:118424986	G/A	cg09538006	chr2:3337909	TSSC1	0.64	6.14	0.36	3.23e-9	Alzheimer disease and age of onset;
KIRP	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.82	13.93	0.66	6.55e-33	Longevity;
KIRP	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.76	10.3	0.55	6.4e-21	Pancreatic cancer;
KIRP	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.46e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg25811766	chr13:21894605	NA	-0.6	-5.82	-0.35	1.79e-8	White matter hyperintensity burden;
KIRP	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.6	7.08	0.41	1.49e-11	Height;
KIRP	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.76	-0.34	2.56e-8	Height;
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.51e-16	Life satisfaction;
KIRP	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.02	0.5	5.61e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2273156	0.929	rs12050171	chr14:35395451	T/A	cg09327582	chr14:35236912	BAZ1A	-0.53	-5.99	-0.36	7.6e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs10875746	0.669	rs61941006	chr12:48631133	G/A	cg26205652	chr12:48591994	NA	0.66	8.7	0.49	4.86e-16	Longevity (90 years and older);
KIRP	cis	rs10214930	0.647	rs11767188	chr7:27571945	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.84	0.3	2.25e-6	Hypospadias;
KIRP	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.75	7.98	0.45	5.71e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg05555928	chr11:63887634	MACROD1	0.48	5.21	0.32	3.99e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13968233	chr1:197564458	DENND1B	0.51	7.52	0.43	1.02e-12	Interleukin-4 levels;
KIRP	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.47	-0.33	1.11e-7	Height;
KIRP	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg26149184	chr10:133730230	NA	0.43	5.08	0.31	7.62e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.68	-0.34	3.73e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.68e-8	Endometrial cancer;
KIRP	cis	rs77372450	0.636	rs28712355	chr5:157023508	A/G	cg05585991	chr5:157099197	C5orf52	0.43	5.22	0.32	3.75e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg07701084	chr6:150067640	NUP43	0.57	7.23	0.42	6.13e-12	Testicular germ cell tumor;
KIRP	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.53	7.49	0.43	1.27e-12	Body mass index;
KIRP	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg25554036	chr4:6271136	WFS1	0.4	5.67	0.34	3.93e-8	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1823913	0.599	rs13027086	chr2:192158784	A/G	cg12404831	chr2:192114017	MYO1B	0.55	7.7	0.44	3.36e-13	Obesity-related traits;
KIRP	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.36	-5.26	-0.32	3.12e-7	Eye color traits;
KIRP	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg13206674	chr6:150067644	NUP43	0.58	8.34	0.47	5.23e-15	Lung cancer;
KIRP	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg17264618	chr3:40429014	ENTPD3	0.35	5.34	0.32	2.1e-7	Renal cell carcinoma;
KIRP	trans	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	9.11	0.5	2.89e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg15282417	chr9:129245246	FAM125B	0.44	7.48	0.43	1.29e-12	Intraocular pressure;
KIRP	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.92	14.61	0.68	3.15e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.2	22.23	0.82	8.96e-61	Cognitive function;
KIRP	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.73	10.86	0.57	1.05e-22	Calcium levels;
KIRP	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg10189774	chr4:17578691	LAP3	0.49	5.97	0.36	8.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs918629	0.798	rs3777163	chr5:95293316	C/G	cg16656078	chr5:95278638	ELL2	-0.47	-6.75	-0.4	1.09e-10	IgG glycosylation;
KIRP	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.8	-0.35	2e-8	Parkinson's disease;
KIRP	cis	rs4006360	0.600	rs6503595	chr17:39257008	C/G	cg25341923	chr17:39239918	KRTAP4-7	-0.5	-7.02	-0.41	2.14e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg21417399	chr8:145598329	ADCK5	0.54	6.54	0.38	3.51e-10	Obesity-related traits;
KIRP	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg18132916	chr6:79620363	NA	0.53	7.39	0.43	2.24e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg07382826	chr16:28625726	SULT1A1	0.53	6.03	0.36	6.09e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.29	-0.32	2.76e-7	Aortic root size;
KIRP	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg04025307	chr7:1156635	C7orf50	0.7	5.51	0.33	9.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.46	6.19	0.37	2.45e-9	Monocyte count;
KIRP	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg07713946	chr22:31675144	LIMK2	0.32	5.1	0.31	6.68e-7	Colorectal cancer;
KIRP	cis	rs12360000	0.541	rs10903583	chr10:1913891	A/G	cg26364871	chr10:1889757	NA	-0.49	-6.33	-0.37	1.15e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs8070740	1.000	rs8070740	chr17:5331896	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	7.06	0.41	1.72e-11	Menopause (age at onset);
KIRP	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.85	10.94	0.57	5.72e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs12431939	0.598	rs7144511	chr14:51740243	A/G	cg23942311	chr14:51606299	NA	0.42	5.21	0.32	4.03e-7	Cancer;
KIRP	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg03808351	chr9:123631620	PHF19	0.39	5.35	0.32	2.03e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2071403	0.933	rs12329058	chr2:1400608	C/G	cg06500727	chr2:1417164	TPO	-0.46	-7.18	-0.42	8.41e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.64e-16	Life satisfaction;
KIRP	cis	rs13065560	0.505	rs4396821	chr3:38917641	A/C	cg01426195	chr3:39028469	NA	-0.37	-6.04	-0.36	5.61e-9	Interleukin-18 levels;
KIRP	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.44	-6.14	-0.36	3.27e-9	Bone mineral density (spine);
KIRP	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg21184320	chr1:21044207	KIF17	-0.37	-5.48	-0.33	1.06e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg19476082	chr7:2414320	EIF3B	0.56	5.16	0.31	5.07e-7	Multiple sclerosis;
KIRP	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	cg12689670	chr1:183009347	LAMC1	0.49	6.87	0.4	5.12e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9815354	1.000	rs1716651	chr3:41975099	A/T	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs894344	0.650	rs11166592	chr8:135577008	A/C	cg04050898	chr8:135490694	ZFAT	-0.36	-5.04	-0.31	9.13e-7	Systolic blood pressure;
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg06654118	chr4:1303317	MAEA	0.29	5.22	0.32	3.87e-7	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	9.11e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27495617	chr16:89160041	ACSF3	0.45	6.04	0.36	5.52e-9	Parkinson's disease;
KIRP	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg06618935	chr21:46677482	NA	-0.43	-5.15	-0.31	5.46e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9653442	0.545	rs12987209	chr2:100761148	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7520050	0.898	rs34175029	chr1:46483871	C/T	cg03146154	chr1:46216737	IPP	-0.42	-5.36	-0.32	1.95e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs72843166	0.562	rs17687323	chr17:61432866	C/T	cg19683800	chr17:61518354	CYB561	-0.42	-5.23	-0.32	3.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg21573476	chr21:45109991	RRP1B	0.5	6.11	0.36	3.84e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg17554472	chr22:41940697	POLR3H	0.44	5.24	0.32	3.4e-7	Vitiligo;
KIRP	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg21132104	chr15:45694354	SPATA5L1	0.59	7.31	0.42	3.82e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.57	-7.91	-0.45	8.9e-14	Lung cancer;
KIRP	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg12751644	chr20:60527061	NA	-0.44	-4.98	-0.3	1.21e-6	Body mass index;
KIRP	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs33912345	0.643	rs1262172	chr14:60861871	T/G	cg27398547	chr14:60952738	C14orf39	-0.39	-5.12	-0.31	6.21e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-6.18	-0.37	2.68e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg16434002	chr17:42200994	HDAC5	0.62	7.72	0.44	2.89e-13	Total body bone mineral density;
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.48	5.55	0.33	7.37e-8	Glycated hemoglobin levels;
KIRP	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.63	10.4	0.55	3.16e-21	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-6.82	-0.4	7.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11622362	chr11:34938112	PDHX;APIP	-0.44	-5.37	-0.32	1.84e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg12435725	chr3:58293450	RPP14	-0.46	-5.32	-0.32	2.29e-7	Cholesterol, total;
KIRP	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg16576597	chr16:28551801	NUPR1	0.36	5.47	0.33	1.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.61	-0.39	2.42e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg03465714	chr1:152285911	FLG	-0.43	-5.15	-0.31	5.4e-7	Atopic dermatitis;
KIRP	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.62	0.39	2.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-8.93	-0.49	9.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	trans	rs1106684	1.000	rs1592698	chr7:131465135	G/A	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg05234568	chr11:5960015	NA	-0.59	-6.05	-0.36	5.44e-9	DNA methylation (variation);
KIRP	cis	rs3754214	0.823	rs10888579	chr1:150261925	C/T	cg07843065	chr1:150265600	MRPS21	-0.49	-7.0	-0.41	2.4e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.97	13.22	0.64	1.7e-30	Triglycerides;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07156844	chr16:88729753	MGC23284;MVD	0.5	6.23	0.37	2.02e-9	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg14228332	chr4:119757509	SEC24D	0.82	5.09	0.31	6.95e-7	Cannabis dependence symptom count;
KIRP	cis	rs728478	1.000	rs9913367	chr17:57448022	C/G	cg16535752	chr17:57448097	YPEL2	-0.22	-5.18	-0.31	4.61e-7	QT interval;
KIRP	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.61	-6.48	-0.38	4.96e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg12369402	chr1:90227771	NA	0.36	5.17	0.31	4.8e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7179456	0.515	rs602602	chr15:59057023	T/A	cg05156742	chr15:59063176	FAM63B	0.42	4.99	0.3	1.16e-6	Asperger disorder;
KIRP	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02725872	chr8:58115012	NA	-0.78	-7.79	-0.44	1.92e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.47	5.06	0.31	8.24e-7	Smoking behavior;
KIRP	cis	rs4789452	0.967	rs12451315	chr17:75372126	C/G	cg05184938	chr17:75369939	SEPT9	-0.37	-5.24	-0.32	3.41e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2005108	1	rs2005108	chr11:102770353	C/T	cg19620758	chr11:102826565	MMP13	0.64	5.33	0.32	2.18e-7	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.98	15.21	0.7	2.74e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.49	-5.96	-0.36	8.81e-9	Renal function-related traits (BUN);
KIRP	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg26513180	chr16:89883248	FANCA	0.9	14.96	0.69	2.04e-36	Vitiligo;
KIRP	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg04990556	chr1:26633338	UBXN11	0.68	6.69	0.39	1.45e-10	Obesity-related traits;
KIRP	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg07541023	chr7:19748670	TWISTNB	0.63	5.69	0.34	3.55e-8	Thyroid stimulating hormone;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.75	10.45	0.55	2.24e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-1.12	-22.16	-0.82	1.46e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.19	0.31	4.42e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg21775007	chr8:11205619	TDH	0.45	6.33	0.37	1.18e-9	Neuroticism;
KIRP	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.23	-0.42	5.97e-12	Type 2 diabetes;
KIRP	cis	rs7010267	0.668	rs4876876	chr8:119986235	T/C	cg01975934	chr8:119970761	NA	-0.42	-5.45	-0.33	1.21e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg10729496	chr3:10149963	C3orf24	0.54	5.18	0.31	4.62e-7	Alzheimer's disease;
KIRP	cis	rs953387	0.866	rs4954577	chr2:136948711	A/G	cg05194412	chr2:137003533	NA	-0.38	-4.93	-0.3	1.49e-6	Arthritis (juvenile idiopathic);
KIRP	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.91	-12.02	-0.61	1.69e-26	Cognitive function;
KIRP	cis	rs9399401	0.961	rs9403383	chr6:142694049	G/A	cg03128060	chr6:142623767	GPR126	0.32	5.15	0.31	5.29e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg15507776	chr3:136538369	TMEM22	0.53	7.59	0.44	6.52e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06680609	chr16:88894341	GALNS	0.51	6.76	0.4	1.01e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.66	8.92	0.49	1.09e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg05342682	chr7:94953680	PON1	-0.45	-4.97	-0.3	1.28e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7143963	0.666	rs7151954	chr14:103323448	A/G	cg24154132	chr14:103367632	TRAF3	0.34	6.61	0.39	2.43e-10	Body mass index;
KIRP	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-1.07	-14.85	-0.69	4.91e-36	Orofacial clefts;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18931398	chr1:109127959	FAM102B	0.45	6.26	0.37	1.72e-9	Interleukin-4 levels;
KIRP	trans	rs526821	0.595	rs565859	chr11:55297367	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-6.32	-0.37	1.19e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	6.85	0.4	5.98e-11	Lung cancer;
KIRP	cis	rs3105169	0.696	rs60042922	chr8:100193089	G/A	cg00191853	chr8:101177733	SPAG1	0.35	5.02	0.3	1e-6	Smoking initiation;
KIRP	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03264133	chr6:25882463	NA	-0.64	-7.6	-0.44	6.31e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26207909	chr14:103986467	CKB	0.77	11.84	0.6	6.97e-26	Body mass index;
KIRP	cis	rs17023223	0.537	rs2765531	chr1:119585497	A/G	cg05756136	chr1:119680316	WARS2	-0.56	-7.64	-0.44	4.86e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.31	-0.42	3.84e-12	Neuroticism;
KIRP	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg10645314	chr2:3704589	ALLC	-0.63	-6.97	-0.41	2.95e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg00076555	chr3:49705435	BSN	0.29	5.0	0.3	1.07e-6	Body mass index;
KIRP	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.78	9.94	0.54	8.86e-20	Corneal astigmatism;
KIRP	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.64	9.11	0.5	3e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12311304	0.965	rs73055254	chr12:15411547	A/G	cg08258403	chr12:15378311	NA	0.35	4.94	0.3	1.43e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs4594175	0.926	rs12432356	chr14:51631223	T/G	cg23942311	chr14:51606299	NA	0.53	7.0	0.41	2.42e-11	Cancer;
KIRP	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.31	5.96	0.36	8.48e-9	Monocyte percentage of white cells;
KIRP	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg00507259	chr4:95128692	SMARCAD1	0.41	5.25	0.32	3.25e-7	QT interval;
KIRP	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	1.04	10.86	0.57	1.05e-22	Nonalcoholic fatty liver disease;
KIRP	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg06307176	chr5:131281290	NA	0.52	5.65	0.34	4.5e-8	Life satisfaction;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01941219	chr13:98795021	FARP1	-0.42	-6.11	-0.36	3.85e-9	Metabolic traits;
KIRP	cis	rs4716602	0.596	rs10258969	chr7:156157753	A/G	cg16983916	chr7:156159713	NA	-0.42	-5.31	-0.32	2.45e-7	Anti-saccade response;
KIRP	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg20701182	chr2:24300061	SF3B14	0.45	5.29	0.32	2.69e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.86	-11.95	-0.61	2.88e-26	Longevity;Endometriosis;
KIRP	cis	rs2766692	1.000	rs2766690	chr14:100682154	A/G	cg14866419	chr14:100704911	YY1	-0.67	-8.41	-0.47	3.37e-15	Electroencephalographic traits in alcoholism;
KIRP	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg11861562	chr11:117069780	TAGLN	0.39	4.92	0.3	1.62e-6	Blood protein levels;
KIRP	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg26681399	chr22:41777847	TEF	-0.54	-5.26	-0.32	3.1e-7	Vitiligo;
KIRP	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.5	6.6	0.39	2.56e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2150410	0.915	rs7279135	chr21:40523776	G/A	cg11890956	chr21:40555474	PSMG1	-0.75	-5.4	-0.33	1.56e-7	Temperament (bipolar disorder);
KIRP	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-5.98	-0.36	7.89e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg08400319	chr2:242004533	SNED1	0.46	6.46	0.38	5.66e-10	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs9400467	0.506	rs75819068	chr6:111722487	A/C	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.04	0.31	8.82e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg06217071	chr17:408420	NA	0.75	11.66	0.6	2.7e-25	Hip circumference adjusted for BMI;
KIRP	trans	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg06521331	chr12:34319734	NA	-0.54	-6.69	-0.39	1.53e-10	Heart rate;
KIRP	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-13.24	-0.64	1.47e-30	Dental caries;
KIRP	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.61	5.19	0.31	4.3e-7	Putamen volume;
KIRP	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg25036284	chr2:26402008	FAM59B	-0.6	-6.0	-0.36	7.17e-9	Gut microbiome composition (summer);
KIRP	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.41	0.38	7.17e-10	Lung cancer;
KIRP	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21984481	chr17:79567631	NPLOC4	-0.41	-6.41	-0.38	7.29e-10	Eye color traits;
KIRP	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.72	0.49	4.33e-16	Resting heart rate;
KIRP	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg19743168	chr1:23544995	NA	0.48	6.46	0.38	5.5e-10	Height;
KIRP	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg23100626	chr2:96804247	ASTL	0.43	5.39	0.32	1.67e-7	Diastolic blood pressure;
KIRP	cis	rs2299587	0.554	rs2073562	chr8:17742929	A/G	cg01800426	chr8:17659068	MTUS1	-0.45	-5.4	-0.33	1.54e-7	Economic and political preferences;
KIRP	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg16141378	chr3:129829833	LOC729375	-0.56	-6.83	-0.4	6.6e-11	Mood instability;
KIRP	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.05	-0.41	1.81e-11	Morning vs. evening chronotype;
KIRP	cis	rs8028182	1.000	rs8028182	chr15:75718669	G/T	cg09165964	chr15:75287851	SCAMP5	-0.43	-5.02	-0.3	1.01e-6	Sudden cardiac arrest;
KIRP	cis	rs9547692	0.938	rs12020196	chr13:37469191	G/C	cg01493522	chr13:37497338	NA	-0.41	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg00319359	chr11:70116639	PPFIA1	0.78	7.2	0.42	7.45e-12	Coronary artery disease;
KIRP	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg26513180	chr16:89883248	FANCA	0.76	5.35	0.32	2.06e-7	Skin colour saturation;
KIRP	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg16586182	chr3:47516702	SCAP	0.63	8.41	0.47	3.27e-15	Colorectal cancer;
KIRP	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.68	-0.34	3.74e-8	Response to antipsychotic treatment;
KIRP	cis	rs11871801	0.517	rs665268	chr17:40722029	A/G	cg14558262	chr17:40713999	COASY	0.47	5.09	0.31	6.99e-7	Crohn's disease;
KIRP	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.29	28.15	0.87	6.67e-79	IgG glycosylation;
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.71e-7	Life satisfaction;
KIRP	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg15655495	chr12:38532458	NA	0.28	5.37	0.32	1.8e-7	Bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14924899	chr15:62937113	MGC15885	0.48	6.49	0.38	4.71e-10	Survival in pancreatic cancer;
KIRP	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03647317	chr4:187891568	NA	-0.8	-13.43	-0.65	3.16e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2223471	0.546	rs280317	chr6:50629154	A/G	cg03432817	chr6:50765336	NA	-0.36	-5.36	-0.32	1.89e-7	Subcutaneous adipose tissue;
KIRP	cis	rs394563	0.839	rs584916	chr6:149790319	A/C	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.19	-0.37	2.56e-9	Dupuytren's disease;
KIRP	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg15655495	chr12:38532458	NA	-0.28	-5.1	-0.31	6.67e-7	Morning vs. evening chronotype;
KIRP	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg10541313	chr22:46663664	TTC38	0.51	5.16	0.31	5.13e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-7.8	-0.45	1.75e-13	Mean corpuscular volume;
KIRP	cis	rs13067260	0.655	rs13317028	chr3:123745668	C/T	cg19918027	chr3:123987645	KALRN	-0.58	-5.24	-0.32	3.42e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.64	-0.44	4.87e-13	Bipolar disorder;
KIRP	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg08076091	chr2:203926405	NBEAL1	0.78	7.33	0.42	3.22e-12	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-5.02	-0.31	9.7e-7	Fear of minor pain;
KIRP	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg13911629	chr5:110075178	SLC25A46	0.44	6.05	0.36	5.22e-9	Bladder cancer;
KIRP	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-0.72	-7.73	-0.44	2.79e-13	Initial pursuit acceleration;
KIRP	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg22117172	chr7:91764530	CYP51A1	-0.42	-5.68	-0.34	3.82e-8	Breast cancer;
KIRP	cis	rs4656940	0.550	rs7541298	chr1:160767821	C/T	cg17331569	chr1:160788135	LY9	-0.48	-5.76	-0.34	2.51e-8	Crohn's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07336999	chr16:89939803	TCF25	-0.46	-6.34	-0.37	1.12e-9	Metabolic traits;
KIRP	cis	rs494562	0.803	rs727870	chr6:86131156	A/G	cg21730993	chr6:86159210	NT5E	0.48	4.95	0.3	1.39e-6	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	1.06	23.06	0.83	1.99e-63	Breast cancer;
KIRP	cis	rs1215050	0.791	rs11729826	chr4:98657190	G/T	cg05340658	chr4:99064831	C4orf37	-0.49	-6.02	-0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg14972814	chr11:95582409	MTMR2	0.36	6.03	0.36	6.13e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-5.67	-0.34	4.02e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.9	-10.89	-0.57	8.78e-23	Menopause (age at onset);
KIRP	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg27529037	chr20:44575021	PCIF1	0.47	5.7	0.34	3.37e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8177876	0.658	rs12444747	chr16:81074904	C/G	cg08591886	chr16:81111003	C16orf46	-0.67	-5.11	-0.31	6.46e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.45	6.92	0.4	3.97e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.87	11.51	0.59	8.02e-25	Coronary artery disease;
KIRP	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.43	6.3	0.37	1.39e-9	Major depressive disorder;
KIRP	cis	rs754423	0.568	rs1540702	chr14:52521436	A/G	cg05884192	chr14:52515736	NID2	-0.68	-8.09	-0.46	2.73e-14	Craniofacial microsomia;
KIRP	cis	rs7011049	0.673	rs17256515	chr8:53827232	C/T	cg26025543	chr8:53854495	NA	0.49	5.29	0.32	2.67e-7	Systolic blood pressure;
KIRP	cis	rs7809950	1.000	rs2178497	chr7:107278901	T/C	cg23024343	chr7:107201750	COG5	0.51	7.27	0.42	4.67e-12	Coronary artery disease;
KIRP	cis	rs1823913	0.599	rs1378156	chr2:192137192	A/T	cg12404831	chr2:192114017	MYO1B	-0.53	-7.46	-0.43	1.53e-12	Obesity-related traits;
KIRP	cis	rs9361491	0.508	rs7773448	chr6:79417356	C/T	cg09184832	chr6:79620586	NA	-0.39	-5.03	-0.31	9.28e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13065169	chr3:145878979	PLOD2	0.53	7.35	0.42	2.98e-12	Parkinson's disease;
KIRP	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg08603382	chr10:743973	NA	0.54	8.64	0.48	7.29e-16	Psychosis in Alzheimer's disease;
KIRP	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.64	-8.8	-0.49	2.45e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.6	-6.82	-0.4	7.08e-11	Testicular germ cell tumor;
KIRP	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.6	7.85	0.45	1.27e-13	Retinal vascular caliber;
KIRP	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.87	16.54	0.73	8.26e-42	Anterior chamber depth;
KIRP	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.87	13.12	0.64	3.69e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.52	-5.74	-0.34	2.76e-8	Adiposity;
KIRP	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg14346243	chr4:90757452	SNCA	-0.38	-4.86	-0.3	2.1e-6	Neuroticism;
KIRP	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.53	7.35	0.42	2.84e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs80282103	0.618	rs12250141	chr10:1160106	A/T	cg08668510	chr10:1095578	IDI1	0.93	5.82	0.35	1.85e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs3105593	0.933	rs3131595	chr15:50877583	C/T	cg05456662	chr15:50716270	USP8	0.39	5.11	0.31	6.33e-7	QT interval;
KIRP	cis	rs9443189	0.901	rs2038625	chr6:76560968	G/A	cg01950844	chr6:76311363	SENP6	-0.6	-5.72	-0.34	3.03e-8	Prostate cancer;
KIRP	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs9469913	0.867	rs9469895	chr6:34777401	G/T	cg17674042	chr6:34482479	PACSIN1	-0.39	-5.28	-0.32	2.81e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg00031303	chr3:195681400	NA	0.5	6.31	0.37	1.31e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg24375607	chr4:120327624	NA	0.52	6.13	0.36	3.51e-9	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16498533	chr6:74230343	EEF1A1	-0.58	-7.02	-0.41	2.13e-11	Interleukin-4 levels;
KIRP	cis	rs6132905	0.548	rs77557811	chr20:2610648	G/A	cg24848351	chr20:2622020	TMC2	-0.59	-5.19	-0.31	4.32e-7	Mumps;
KIRP	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg18093559	chr17:18951025	GRAP	0.52	6.33	0.37	1.15e-9	Schizophrenia;
KIRP	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-10.5	-0.56	1.48e-21	Gut microbiome composition (summer);
KIRP	cis	rs10949834	0.652	rs2269082	chr7:73519875	A/G	cg07137043	chr7:73588983	EIF4H	-0.53	-5.07	-0.31	7.75e-7	Verbal memory performance (residualized delayed recall change);
KIRP	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg01629716	chr15:45996671	NA	0.36	6.48	0.38	4.85e-10	Waist circumference;Weight;
KIRP	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.67	8.33	0.47	5.65e-15	Dilated cardiomyopathy;
KIRP	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg22974920	chr21:40686053	BRWD1	0.51	6.12	0.36	3.58e-9	Cognitive function;
KIRP	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.92	-13.98	-0.67	4.41e-33	Ulcerative colitis;
KIRP	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.36	0.59	2.6e-24	Alzheimer's disease;
KIRP	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21016266	chr12:122356598	WDR66	0.51	6.72	0.39	1.26e-10	Mean corpuscular volume;
KIRP	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.62e-11	Lung cancer;
KIRP	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.41	0.33	1.48e-7	Breast cancer;
KIRP	cis	rs1448094	0.737	rs10863135	chr12:86382657	C/T	cg00310523	chr12:86230176	RASSF9	0.4	6.17	0.37	2.72e-9	Major depressive disorder;
KIRP	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.32	-0.32	2.28e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.94	-12.4	-0.62	9.52e-28	Coronary artery disease;
KIRP	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.25	-0.32	3.29e-7	Personality dimensions;
KIRP	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg10047753	chr17:41438598	NA	1.13	17.76	0.75	5.67e-46	Menopause (age at onset);
KIRP	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.61	9.44	0.52	2.92e-18	Urate levels in overweight individuals;
KIRP	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7520050	0.966	rs10890352	chr1:46283628	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.53e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg00129232	chr17:37814104	STARD3	-0.51	-6.34	-0.37	1.07e-9	Self-reported allergy;
KIRP	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg17757837	chr7:157058334	UBE3C	0.75	10.15	0.54	1.93e-20	Body mass index;
KIRP	cis	rs9309473	0.847	rs13538	chr2:73868328	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.4	-0.33	1.54e-7	Metabolite levels;
KIRP	cis	rs3751972	0.911	rs4796222	chr17:26216786	A/G	cg18091275	chr17:26120155	NOS2	-0.52	-6.22	-0.37	2.16e-9	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	1.0	15.88	0.71	1.41e-39	Vitamin D levels;
KIRP	cis	rs2929278	0.617	rs2955969	chr15:44114527	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.45	-5.27	-0.32	3.03e-7	Schizophrenia;
KIRP	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.79	9.93	0.53	9.24e-20	Migraine;Coronary artery disease;
KIRP	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.41	6.04	0.36	5.63e-9	Lipoprotein (a) levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07575867	chr3:58223146	ABHD6	-0.52	-6.03	-0.36	5.86e-9	Interleukin-4 levels;
KIRP	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	0.68	7.87	0.45	1.13e-13	Pulmonary function decline;
KIRP	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00889227	chr1:205173544	DSTYK	-0.37	-5.23	-0.32	3.55e-7	Red blood cell count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24767368	chr3:160938424	NMD3	0.43	6.35	0.38	1.04e-9	Interleukin-4 levels;
KIRP	cis	rs400736	0.930	rs225119	chr1:8044361	T/C	cg25007680	chr1:8021821	PARK7	0.64	8.46	0.47	2.37e-15	Response to antidepressants and depression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11048311	chr10:12084973	UPF2	0.46	6.12	0.36	3.68e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.57	-6.02	-0.36	6.31e-9	Smoking behavior;
KIRP	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg05370193	chr1:21551575	ECE1	0.46	6.03	0.36	6.1e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.52	1.73e-18	Colorectal cancer;
KIRP	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.57	-0.39	2.96e-10	Metabolite levels;
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22618164	chr12:122356400	WDR66	-0.61	-8.64	-0.48	7.07e-16	Mean corpuscular volume;
KIRP	cis	rs4262150	0.667	rs10053762	chr5:152276650	A/C	cg12297329	chr5:152029980	NA	0.46	6.41	0.38	7.27e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.95	16.06	0.72	3.57e-40	Breast cancer;
KIRP	cis	rs78487399	0.808	rs12105786	chr2:43676433	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.97	11.37	0.59	2.28e-24	Corneal astigmatism;
KIRP	cis	rs17401966	0.522	rs2027330	chr1:10275592	C/T	cg17425144	chr1:10567563	PEX14	-0.29	-5.05	-0.31	8.44e-7	Hepatocellular carcinoma;
KIRP	cis	rs34779708	0.931	rs72789609	chr10:35306206	C/T	cg04310649	chr10:35416472	CREM	-0.52	-5.95	-0.35	9.41e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.74	-10.67	-0.56	4.25e-22	Height;
KIRP	cis	rs2625529	0.526	rs6494997	chr15:72560642	C/T	cg16672083	chr15:72433130	SENP8	0.4	5.66	0.34	4.18e-8	Red blood cell count;
KIRP	cis	rs8077059	0.885	rs9905339	chr17:55824331	A/G	cg12582317	chr17:55822272	NA	0.43	5.57	0.33	6.75e-8	Sex hormone-binding globulin levels;
KIRP	cis	rs16957091	0.697	rs672054	chr15:42918017	T/C	cg24196017	chr15:43021976	CDAN1	0.41	4.94	0.3	1.48e-6	MGMT methylation in smokers;
KIRP	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.35	0.47	4.88e-15	Lung cancer in ever smokers;
KIRP	cis	rs7623687	0.579	rs78807522	chr3:49056150	C/A	cg19401529	chr3:49056140	DALRD3	1.01	6.17	0.37	2.77e-9	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.46	5.84	0.35	1.64e-8	Coronary artery disease;
KIRP	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.81	8.79	0.49	2.61e-16	Corneal astigmatism;
KIRP	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.94	15.13	0.69	5.14e-37	Menopause (age at onset);
KIRP	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg05304507	chr6:116381966	FRK	0.21	5.43	0.33	1.35e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.51	5.71	0.34	3.26e-8	Vitiligo;
KIRP	trans	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.54	-7.08	-0.41	1.53e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg19373090	chr19:797215	PTBP1	-0.56	-6.02	-0.36	6.21e-9	Menopause (age at onset);
KIRP	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg23950597	chr19:37808831	NA	-0.67	-5.99	-0.36	7.36e-9	Coronary artery calcification;
KIRP	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.19	0.37	2.52e-9	Menopause (age at onset);
KIRP	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg02073558	chr3:44770973	ZNF501	0.72	11.22	0.58	7.54e-24	Depressive symptoms;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg10444037	chr6:42531637	UBR2	0.49	6.34	0.37	1.09e-9	Asthma;
KIRP	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.65	7.71	0.44	3.05e-13	Height;
KIRP	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.66	-8.68	-0.48	5.48e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.88	11.8	0.6	9.08e-26	Coronary artery disease;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.57	7.89	0.45	1.01e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06347499	chr1:9599419	SLC25A33	0.51	6.43	0.38	6.55e-10	Myopia (pathological);
KIRP	cis	rs2882667	0.858	rs11959803	chr5:138451315	G/A	cg04439458	chr5:138467593	SIL1	-0.54	-7.95	-0.45	6.9e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11673344	0.526	rs2291001	chr19:38085332	C/T	cg14683738	chr19:37701593	ZNF585B	-0.43	-5.24	-0.32	3.49e-7	Obesity-related traits;
KIRP	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.67	9.21	0.51	1.5e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg11494091	chr17:61959527	GH2	0.49	5.77	0.35	2.41e-8	Height;
KIRP	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.89	-11.26	-0.58	5.48e-24	Vitamin D levels;
KIRP	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.5e-9	Schizophrenia;
KIRP	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg17644776	chr2:200775616	C2orf69	0.57	6.09	0.36	4.36e-9	Schizophrenia;
KIRP	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg17294928	chr15:75287854	SCAMP5	0.54	5.6	0.34	5.79e-8	Blood trace element (Zn levels);
KIRP	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.77	9.39	0.51	4.34e-18	Response to antipsychotic treatment;
KIRP	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg23387468	chr7:139079360	LUC7L2	0.3	5.13	0.31	5.97e-7	Diisocyanate-induced asthma;
KIRP	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg26898376	chr11:64110657	CCDC88B	0.58	4.9	0.3	1.77e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg04780086	chr2:111875790	ACOXL	0.42	5.82	0.35	1.81e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.02	0.36	6.19e-9	Mean platelet volume;
KIRP	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.6	-7.24	-0.42	5.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs16828019	0.777	rs12047657	chr1:41461513	G/C	cg18742814	chr1:41828276	NA	0.68	5.73	0.34	2.87e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18300819	chr6:88299852	ORC3L;RARS2	-0.88	-6.04	-0.36	5.73e-9	P wave terminal force;
KIRP	cis	rs887797	0.507	rs11658496	chr17:64554545	G/A	cg27019712	chr17:64599478	PRKCA	0.39	4.86	0.3	2.05e-6	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
KIRP	cis	rs6681460	0.932	rs659291	chr1:67180746	A/C	cg02459107	chr1:67143332	SGIP1	0.41	5.92	0.35	1.09e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	1.19	8.43	0.47	3e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.62	-6.52	-0.38	3.94e-10	Initial pursuit acceleration;
KIRP	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	5.18	0.31	4.53e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.99	15.85	0.71	1.76e-39	Uric acid clearance;
KIRP	cis	rs13185784	0.703	rs62406991	chr5:179658323	A/G	cg23221052	chr5:179740743	GFPT2	0.51	4.9	0.3	1.74e-6	TRAIL levels;
KIRP	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-5.6	-0.34	5.82e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.73	-10.97	-0.57	4.85e-23	Oral cavity cancer;
KIRP	trans	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.73	7.7	0.44	3.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-5.92	-0.35	1.1e-8	Lung cancer;
KIRP	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg22563815	chr15:78856949	CHRNA5	0.48	6.52	0.38	3.85e-10	Sudden cardiac arrest;
KIRP	cis	rs9372498	0.536	rs9489399	chr6:118767147	C/A	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	9.79	0.53	2.59e-19	Ileal carcinoids;
KIRP	cis	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg25547332	chr5:131281432	NA	0.48	5.39	0.33	1.63e-7	Life satisfaction;
KIRP	cis	rs9928842	0.882	rs9319481	chr16:75259478	T/C	cg09066997	chr16:75300724	BCAR1	0.62	5.25	0.32	3.36e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-8.67	-0.48	5.87e-16	Coronary artery disease;
KIRP	cis	rs8093481	1.000	rs9954847	chr18:10693188	A/G	cg21165219	chr18:10698044	FAM38B	-0.44	-5.42	-0.33	1.41e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg08885076	chr2:99613938	TSGA10	-0.41	-6.31	-0.37	1.32e-9	Fear of minor pain;
KIRP	cis	rs6504340	0.739	rs4793938	chr17:46665229	T/G	cg05487507	chr17:46671861	LOC404266;HOXB5	0.57	6.54	0.38	3.59e-10	Primary tooth development (number of teeth);
KIRP	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20135002	chr11:47629003	NA	-0.48	-5.78	-0.35	2.23e-8	Subjective well-being;
KIRP	cis	rs6992848	0.791	rs13281578	chr8:141165001	G/A	cg13911501	chr8:141220320	TRAPPC9	0.41	4.85	0.3	2.21e-6	Response to amphetamines;
KIRP	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.72	8.21	0.46	1.23e-14	Itch intensity from mosquito bite;
KIRP	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	9.41	0.51	3.79e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-5.02	-0.3	9.86e-7	IgG glycosylation;
KIRP	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	9.61	0.52	9.13e-19	Personality dimensions;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24607315	chr4:144434338	SMARCA5	0.45	6.03	0.36	6.11e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03427543	chr2:18060490	KCNS3	0.47	6.15	0.37	3.1e-9	Parkinson's disease;
KIRP	cis	rs7714584	1.000	rs7709388	chr5:150246539	C/G	cg22134413	chr5:150180641	NA	0.56	5.12	0.31	6.24e-7	Crohn's disease;
KIRP	cis	rs754423	0.582	rs1390968	chr14:52517629	A/G	cg05884192	chr14:52515736	NID2	-0.59	-6.83	-0.4	6.7e-11	Craniofacial microsomia;
KIRP	cis	rs1355223	0.573	rs7125773	chr11:34723573	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-5.92	-0.35	1.06e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.51	6.65	0.39	1.84e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.55e-13	Life satisfaction;
KIRP	cis	rs758324	0.741	rs10075660	chr5:131240843	C/A	cg06307176	chr5:131281290	NA	-0.49	-5.58	-0.34	6.38e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.73	-7.63	-0.44	5.22e-13	Vitiligo;
KIRP	cis	rs2481665	0.546	rs927531	chr1:62634797	C/G	cg18591186	chr1:62594603	INADL	0.36	5.19	0.31	4.33e-7	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-8.68	-0.48	5.57e-16	Brugada syndrome;
KIRP	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg06521331	chr12:34319734	NA	-0.48	-6.07	-0.36	4.75e-9	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.5	-6.08	-0.36	4.59e-9	Prudent dietary pattern;
KIRP	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.72	-0.44	2.94e-13	Resting heart rate;
KIRP	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg10223061	chr2:219282414	VIL1	0.33	5.53	0.33	8.31e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.94	0.35	9.83e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.51	6.95	0.41	3.18e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2279817	0.735	rs12075624	chr1:17991573	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-8.46	-0.47	2.49e-15	Neuroticism;
KIRP	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06544989	chr22:39130855	UNC84B	0.51	8.37	0.47	4.3e-15	Menopause (age at onset);
KIRP	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.52	8.65	0.48	6.59e-16	Rheumatoid arthritis;
KIRP	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg00792783	chr2:198669748	PLCL1	-0.5	-5.59	-0.34	5.89e-8	Dermatomyositis;
KIRP	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg02336718	chr17:17403227	NA	0.35	5.43	0.33	1.36e-7	Total body bone mineral density;
KIRP	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	1.04	8.04	0.46	3.81e-14	Skin colour saturation;
KIRP	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.88	11.51	0.59	8.29e-25	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.75	-11.2	-0.58	8.2e-24	Total body bone mineral density;
KIRP	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.32	-0.37	1.2e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg12623918	chr2:306882	NA	0.48	5.81	0.35	1.95e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.65	-0.44	4.45e-13	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11861097	chr20:2794877	C20orf141	0.42	6.05	0.36	5.43e-9	Survival in pancreatic cancer;
KIRP	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.57	-6.96	-0.41	3.03e-11	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26706909	chr2:44396058	PPM1B	0.49	6.16	0.37	2.98e-9	Parkinson's disease;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg08662619	chr6:150070041	PCMT1	0.37	6.14	0.36	3.33e-9	Lung cancer;
KIRP	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.93	-15.79	-0.71	3.04e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.43	5.64	0.34	4.7e-8	Motion sickness;
KIRP	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	0.87	12.74	0.63	6.98e-29	Essential tremor;
KIRP	cis	rs4791746	0.948	rs9915929	chr17:8630420	A/G	cg03115937	chr17:8649504	CCDC42	-0.47	-5.91	-0.35	1.11e-8	Heroin dependence;
KIRP	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg06115741	chr20:33292138	TP53INP2	0.38	5.12	0.31	6.17e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.71	9.5	0.52	2e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg01475377	chr6:109611718	NA	-0.36	-4.92	-0.3	1.6e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs62355272	0.965	rs11567751	chr5:35871684	C/T	cg13894535	chr5:35919491	CAPSL	-0.51	-5.75	-0.34	2.57e-8	Lymphocyte counts;
KIRP	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.95	-0.5	8.97e-17	Response to antipsychotic treatment;
KIRP	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.18	0.31	4.7e-7	Bipolar disorder;
KIRP	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg11846333	chr4:119757529	SEC24D	0.99	6.0	0.36	7.02e-9	Cannabis dependence symptom count;
KIRP	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-8.81	-0.49	2.23e-16	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs4889855	0.530	rs75398920	chr17:78544540	C/T	cg09596252	chr17:78655493	RPTOR	-0.49	-5.45	-0.33	1.21e-7	Fractional excretion of uric acid;
KIRP	cis	rs2594989	0.691	rs2596816	chr3:11581200	A/C	cg01796438	chr3:11312864	ATG7	-0.43	-5.56	-0.33	6.98e-8	Circulating chemerin levels;
KIRP	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.63	-8.12	-0.46	2.2e-14	Height;
KIRP	cis	rs1961637	0.960	rs1440066	chr2:223908210	A/C	cg02552189	chr2:223891284	NA	-0.39	-5.24	-0.32	3.48e-7	Oropharynx cancer;
KIRP	cis	rs13067260	0.655	rs9847449	chr3:123719850	C/T	cg19918027	chr3:123987645	KALRN	-0.64	-5.69	-0.34	3.6e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.42	-0.38	7.12e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.71	8.7	0.49	4.86e-16	Cognitive function;
KIRP	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.61	7.22	0.42	6.63e-12	Gestational age at birth (maternal effect);
KIRP	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg08885076	chr2:99613938	TSGA10	-0.38	-5.13	-0.31	5.9e-7	Chronic sinus infection;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg07216194	chr8:27182965	PTK2B	0.46	5.65	0.34	4.32e-8	Neuroticism;
KIRP	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg25767906	chr1:53392781	SCP2	-0.35	-4.91	-0.3	1.66e-6	Monocyte count;
KIRP	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.95	12.55	0.62	2.98e-28	Menopause (age at onset);
KIRP	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg16479474	chr6:28041457	NA	0.44	4.88	0.3	1.94e-6	Depression;
KIRP	cis	rs5752326	0.510	rs5752330	chr22:26859942	C/T	cg20819150	chr22:26891497	TFIP11	0.53	4.98	0.3	1.18e-6	Ischemic stroke;
KIRP	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.68	0.44	3.86e-13	Neuroticism;
KIRP	cis	rs6783573	1.000	rs6783573	chr3:46600520	A/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.52	-7.1	-0.41	1.32e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.69	8.87	0.49	1.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4903604	0.581	rs4903607	chr14:78038462	G/A	cg18872420	chr14:78023429	SPTLC2	0.35	5.47	0.33	1.13e-7	Gut microbiome composition (winter);
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg23102388	chr7:1867652	MAD1L1	-0.44	-5.99	-0.36	7.46e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.08	-0.31	7.59e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.69	8.7	0.49	4.72e-16	Multiple sclerosis;
KIRP	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.96	12.93	0.64	1.57e-29	Breast cancer;
KIRP	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg16497661	chr14:103986332	CKB	0.41	5.31	0.32	2.43e-7	Coronary artery disease;
KIRP	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.61	-6.51	-0.38	4.25e-10	DNA methylation (variation);
KIRP	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.87	16.48	0.72	1.34e-41	Anterior chamber depth;
KIRP	cis	rs6466055	0.661	rs12535043	chr7:104831655	G/C	cg04380332	chr7:105027541	SRPK2	0.37	4.98	0.3	1.23e-6	Schizophrenia;
KIRP	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg27490568	chr2:178487706	NA	-0.54	-7.25	-0.42	5.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg09873164	chr1:152488093	CRCT1	0.5	6.0	0.36	7.01e-9	Hair morphology;
KIRP	cis	rs7084402	1.000	rs6481400	chr10:60268783	T/C	cg05938607	chr10:60274200	BICC1	0.41	9.98	0.54	6.68e-20	Refractive error;
KIRP	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.46	-5.59	-0.34	5.93e-8	Testicular germ cell tumor;
KIRP	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07157834	chr1:205819609	PM20D1	0.44	5.1	0.31	6.95e-7	Parkinson's disease;
KIRP	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17554472	chr22:41940697	POLR3H	-0.68	-7.04	-0.41	1.96e-11	Vitiligo;
KIRP	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg07395648	chr5:131743802	NA	-0.38	-5.16	-0.31	5.15e-7	Blood metabolite levels;
KIRP	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg08313168	chr12:7315531	NA	0.68	6.16	0.37	2.89e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9815354	1.000	rs6801343	chr3:41767234	C/T	cg03022575	chr3:42003672	ULK4	0.48	5.29	0.32	2.67e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg19849509	chr2:175204996	NA	-0.54	-6.4	-0.38	7.67e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs732505	0.717	rs3213651	chr19:5593771	A/G	cg26242866	chr19:5711310	LONP1	0.65	4.93	0.3	1.49e-6	vWF and FVIII levels;
KIRP	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10089	0.552	rs58595196	chr5:127558338	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	8.38	0.47	4.1e-15	Ileal carcinoids;
KIRP	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.75	10.02	0.54	4.97e-20	Multiple sclerosis;
KIRP	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.46	5.79	0.35	2.19e-8	Schizophrenia;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.79	-13.26	-0.65	1.22e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg13319975	chr6:146136371	FBXO30	0.48	6.34	0.37	1.1e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3829109	0.564	rs13297890	chr9:139274643	C/G	cg21253087	chr9:139290292	SNAPC4	0.47	5.32	0.32	2.3e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs7849270	1.000	rs2297112	chr9:131900180	G/A	cg13538475	chr9:131942899	NA	-0.32	-5.14	-0.31	5.72e-7	Blood metabolite ratios;
KIRP	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.38	-0.32	1.76e-7	Red blood cell count;
KIRP	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg10645314	chr2:3704589	ALLC	0.7	8.01	0.45	4.47e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg24375607	chr4:120327624	NA	0.52	6.17	0.37	2.79e-9	Corneal astigmatism;
KIRP	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg08992911	chr2:238395768	MLPH	0.48	5.14	0.31	5.63e-7	Prostate cancer;
KIRP	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.9	9.62	0.52	8.71e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg03511173	chr18:77590860	NA	-0.49	-5.69	-0.34	3.67e-8	Opioid sensitivity;
KIRP	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	7.09	0.41	1.43e-11	Personality dimensions;
KIRP	cis	rs6689305	0.510	rs953019	chr1:100188316	C/T	cg06223162	chr1:101003688	GPR88	0.31	5.1	0.31	6.83e-7	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-8.94	-0.5	9.65e-17	Pancreatic cancer;
KIRP	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg06153925	chr17:78755379	RPTOR	-0.53	-7.41	-0.43	2.07e-12	Myopia (pathological);
KIRP	cis	rs12529514	1.000	rs6932936	chr6:14115090	A/AT	cg11874760	chr6:14118415	CD83	0.56	5.8	0.35	2.01e-8	Rheumatoid arthritis;
KIRP	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.22	0.37	2.08e-9	Educational attainment;
KIRP	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.69	8.48	0.48	2.07e-15	Neutrophil percentage of white cells;
KIRP	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg08847533	chr14:75593920	NEK9	-0.53	-6.35	-0.38	1.04e-9	IgG glycosylation;
KIRP	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.75	-7.62	-0.44	5.4e-13	Gut microbiome composition (summer);
KIRP	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg22138327	chr13:27999177	GTF3A	0.74	6.93	0.4	3.75e-11	Weight;
KIRP	cis	rs17453880	0.929	rs6897983	chr5:151994224	T/C	cg12297329	chr5:152029980	NA	-0.7	-10.53	-0.56	1.23e-21	Subjective well-being;
KIRP	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg11945507	chr8:142233382	SLC45A4	0.62	9.02	0.5	5.65e-17	Immature fraction of reticulocytes;
KIRP	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.69	9.9	0.53	1.19e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg06521331	chr12:34319734	NA	-0.44	-5.18	-0.31	4.67e-7	Resting heart rate;
KIRP	cis	rs4936894	0.500	rs10893206	chr11:124174874	A/G	cg27160556	chr11:124181099	OR8D1	0.46	6.75	0.4	1.05e-10	Aging (time to death);
KIRP	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	9.9	0.53	1.13e-19	Homoarginine levels;
KIRP	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.25	-5.29	-0.32	2.77e-7	Menarche (age at onset);
KIRP	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg27205649	chr11:78285834	NARS2	-0.54	-5.38	-0.32	1.76e-7	Testicular germ cell tumor;
KIRP	cis	rs4845459	0.967	rs1581803	chr1:152592281	A/C	cg07796016	chr1:152779584	LCE1C	0.48	5.93	0.35	1.05e-8	Psoriasis;
KIRP	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg21775007	chr8:11205619	TDH	0.48	6.27	0.37	1.63e-9	Mood instability;
KIRP	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg21775007	chr8:11205619	TDH	-0.5	-6.44	-0.38	6.32e-10	Joint mobility (Beighton score);
KIRP	cis	rs10760158	0.620	rs767769	chr9:124098336	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.41	-5.02	-0.3	9.85e-7	Pulse pressure;
KIRP	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.49	-9.16	-0.5	2.08e-17	Cystic fibrosis severity;
KIRP	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.7	7.7	0.44	3.25e-13	Pediatric autoimmune diseases;
KIRP	cis	rs5771242	0.845	rs7288889	chr22:50625166	T/G	cg16473166	chr22:50639996	SELO	0.71	6.93	0.4	3.62e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
KIRP	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.4	-0.43	2.09e-12	Colorectal cancer;
KIRP	cis	rs10760279	0.584	rs10760280	chr9:126112812	A/G	cg14503395	chr9:126128745	CRB2	0.44	6.16	0.37	3e-9	Body mass index;
KIRP	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg02887458	chr19:19495540	GATAD2A	0.47	5.73	0.34	2.95e-8	Bipolar disorder;
KIRP	cis	rs7246657	0.943	rs2279148	chr19:38024683	A/G	cg23950597	chr19:37808831	NA	-0.76	-7.91	-0.45	8.99e-14	Coronary artery calcification;
KIRP	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.72	-7.66	-0.44	4.33e-13	Asthma;
KIRP	cis	rs2151522	0.603	rs6902861	chr6:127191584	C/G	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs241257	0.643	rs241274	chr1:4627482	A/C	cg11735846	chr1:4770935	AJAP1	-0.38	-5.88	-0.35	1.37e-8	Anxiety disorder;
KIRP	cis	rs11671005	0.568	rs55987239	chr19:59085045	G/A	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.56	-6.46	-0.38	5.48e-10	Mean platelet volume;
KIRP	cis	rs7301016	1.000	rs11174494	chr12:62864877	A/T	cg01804193	chr12:63026212	NA	0.54	5.55	0.33	7.43e-8	IgG glycosylation;
KIRP	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.36	5.44	0.33	1.29e-7	Body mass index;
KIRP	cis	rs775227	0.574	rs55693215	chr3:113064094	T/C	cg18753928	chr3:113234510	CCDC52	-0.6	-5.76	-0.34	2.49e-8	Dental caries;
KIRP	cis	rs10267417	0.589	rs3956536	chr7:19937238	C/T	cg05791153	chr7:19748676	TWISTNB	0.49	4.91	0.3	1.64e-6	Night sleep phenotypes;
KIRP	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.7	8.33	0.47	5.85e-15	Schizophrenia;
KIRP	cis	rs11078597	0.731	rs4989024	chr17:1639719	A/G	cg17514665	chr17:1657533	SERPINF2	0.45	5.57	0.33	6.72e-8	Serum albumin level;
KIRP	cis	rs6973256	0.865	rs62470059	chr7:133334195	T/C	cg10665199	chr7:133106180	EXOC4	-0.5	-6.28	-0.37	1.56e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.63	-0.34	4.85e-8	Coronary artery disease;
KIRP	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23903597	chr17:61704154	MAP3K3	-0.5	-6.06	-0.36	5.07e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs748404	0.697	rs492743	chr15:43560945	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.33	0.42	3.35e-12	Lung cancer;
KIRP	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg00677455	chr12:58241039	CTDSP2	0.98	12.45	0.62	6.25e-28	Multiple sclerosis;
KIRP	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg21518248	chr2:162101506	NA	0.42	4.98	0.3	1.19e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-0.76	-9.01	-0.5	5.76e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.56	6.85	0.4	6.01e-11	Height;
KIRP	cis	rs12496230	0.794	rs7629637	chr3:66863065	G/C	cg04995300	chr3:66848608	NA	0.45	6.96	0.41	3.01e-11	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.4	4.87	0.3	2.04e-6	Renal cell carcinoma;
KIRP	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg18478394	chr8:109455254	TTC35	0.49	5.94	0.35	9.55e-9	Dupuytren's disease;
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.71	-10.85	-0.57	1.12e-22	Monocyte percentage of white cells;
KIRP	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg08822215	chr16:89438651	ANKRD11	-0.59	-7.64	-0.44	4.81e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	8.74	0.49	3.6e-16	Response to antipsychotic treatment;
KIRP	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.39	-0.33	1.63e-7	Bipolar disorder;
KIRP	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.67	-10.03	-0.54	4.43e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.72	9.93	0.54	8.97e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4073221	0.654	rs34712810	chr3:18288343	C/A	cg07694806	chr3:18168406	NA	-0.66	-6.05	-0.36	5.32e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg24315340	chr6:146058215	EPM2A	-0.41	-5.11	-0.31	6.48e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.58	7.67	0.44	3.98e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs12210905	1.000	rs12209456	chr6:27085225	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11987759	chr7:65425863	GUSB	0.48	6.45	0.38	5.99e-10	Aortic root size;
KIRP	cis	rs9581857	0.579	rs9581838	chr13:27966127	G/A	cg22138327	chr13:27999177	GTF3A	1.03	7.41	0.43	2.08e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.7	6.63	0.39	2.09e-10	Body mass index;
KIRP	cis	rs950881	0.932	rs13408661	chr2:102955082	G/A	cg01254707	chr2:102953421	IL1RL1	-0.5	-5.05	-0.31	8.6e-7	Allergy;
KIRP	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.81	-12.43	-0.62	7.44e-28	Breast cancer;
KIRP	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg09904177	chr6:26538194	HMGN4	0.45	6.04	0.36	5.71e-9	Schizophrenia;
KIRP	cis	rs3736594	0.546	rs6719960	chr2:27830067	C/T	cg27432699	chr2:27873401	GPN1	-0.57	-6.67	-0.39	1.73e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg23594656	chr7:65796392	TPST1	0.45	7.12	0.41	1.17e-11	Aortic root size;
KIRP	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg02023728	chr11:77925099	USP35	0.3	5.11	0.31	6.39e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9398803	0.723	rs853981	chr6:127045460	C/T	cg19875578	chr6:126661172	C6orf173	-0.43	-5.56	-0.33	6.93e-8	Male-pattern baldness;
KIRP	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg07395648	chr5:131743802	NA	-0.57	-8.38	-0.47	4.17e-15	Blood metabolite levels;
KIRP	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	10.96	0.57	5.02e-23	Smoking behavior;
KIRP	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.49	-0.48	2.03e-15	Coronary artery disease;
KIRP	cis	rs4702718	0.549	rs267945	chr5:10747689	C/T	cg14521931	chr5:10832172	NA	-0.47	-6.19	-0.37	2.43e-9	Obesity-related traits;
KIRP	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25517755	chr10:38738941	LOC399744	-0.52	-7.18	-0.42	8.46e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14159747	chr11:113255604	NA	0.38	5.83	0.35	1.73e-8	Neuroticism;
KIRP	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.38	-0.51	4.5e-18	Hemoglobin concentration;
KIRP	cis	rs9323205	0.723	rs12147193	chr14:51748063	A/G	cg23942311	chr14:51606299	NA	-0.5	-4.87	-0.3	2.04e-6	Cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12604982	chr17:1394479	MYO1C	0.47	6.08	0.36	4.56e-9	Parkinson's disease;
KIRP	cis	rs7113874	0.512	rs7952429	chr11:8537917	T/C	cg08015107	chr11:8618950	NA	-0.72	-8.73	-0.49	3.86e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2033732	0.706	rs7821182	chr8:85060586	C/T	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs7009516	0.625	rs17799264	chr8:24257137	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.29	6.2	0.37	2.39e-9	Hair greying;
KIRP	cis	rs7737355	0.773	rs4706027	chr5:130932972	T/C	cg25547332	chr5:131281432	NA	0.4	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg16898833	chr6:26189333	HIST1H4D	0.74	5.11	0.31	6.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.45	5.75	0.34	2.62e-8	Leprosy;
KIRP	cis	rs380904	1.000	rs12543128	chr8:144595042	G/A	cg20583945	chr8:144636462	GSDMD	0.41	5.28	0.32	2.84e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.57	-6.68	-0.39	1.6e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg00129232	chr17:37814104	STARD3	-0.54	-6.61	-0.39	2.34e-10	Self-reported allergy;
KIRP	cis	rs6102059	0.503	rs6513673	chr20:39177184	T/C	cg22477343	chr20:39312069	NA	0.41	5.22	0.32	3.88e-7	LDL cholesterol;
KIRP	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg25237894	chr2:233734115	C2orf82	-0.44	-6.19	-0.37	2.56e-9	Coronary artery disease;
KIRP	cis	rs12210905	1.000	rs72843615	chr6:27150569	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.04	-0.31	8.88e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9309473	1.000	rs6707722	chr2:73654363	G/A	cg20560298	chr2:73613845	ALMS1	-0.51	-6.05	-0.36	5.4e-9	Metabolite levels;
KIRP	cis	rs4006360	0.657	rs7225713	chr17:39252092	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg16511985	chr3:153974050	SGEF	-0.37	-5.24	-0.32	3.48e-7	Coronary artery disease;
KIRP	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.86	12.32	0.62	1.71e-27	Coronary artery disease;
KIRP	cis	rs7939886	0.920	rs61887958	chr11:55938234	A/T	cg07850316	chr11:56344833	OR5M10;OR8U8	0.65	5.19	0.31	4.44e-7	Myopia (pathological);
KIRP	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.69	10.09	0.54	2.9e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9308731	0.966	rs4848393	chr2:111877297	T/C	cg23466623	chr2:111982296	NA	-0.46	-5.77	-0.35	2.34e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg04058563	chr4:185651563	MLF1IP	-0.51	-7.24	-0.42	5.77e-12	Kawasaki disease;
KIRP	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-8.47	-0.48	2.27e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.82	11.27	0.58	4.92e-24	Gestational age at birth (maternal effect);
KIRP	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.5	7.32	0.42	3.6e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4363385	0.626	rs11205179	chr1:153021399	A/G	cg13444842	chr1:152974279	SPRR3	-0.4	-5.76	-0.34	2.53e-8	Inflammatory skin disease;
KIRP	cis	rs2625529	0.824	rs12917428	chr15:72221998	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-6.08	-0.36	4.49e-9	Red blood cell count;
KIRP	cis	rs4722166	0.532	rs4719712	chr7:22755807	C/T	cg05472934	chr7:22766657	IL6	0.54	7.0	0.41	2.47e-11	Lung cancer;
KIRP	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg02792322	chr13:21280448	IL17D	0.3	5.07	0.31	7.95e-7	Dental caries;
KIRP	trans	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg16063989	chr7:139929855	NA	0.45	6.19	0.37	2.5e-9	Atopic dermatitis;
KIRP	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.51	-6.15	-0.37	3.12e-9	Response to antidepressants in depression;
KIRP	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	11.56	0.59	5.76e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg16141378	chr3:129829833	LOC729375	0.58	7.91	0.45	8.64e-14	Neuroticism;
KIRP	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg08822215	chr16:89438651	ANKRD11	0.47	6.08	0.36	4.47e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	7.38	0.43	2.37e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.24	0.37	1.93e-9	Colorectal cancer;
KIRP	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg07395648	chr5:131743802	NA	-0.36	-4.94	-0.3	1.41e-6	Blood metabolite levels;
KIRP	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg26597838	chr10:835615	NA	-0.51	-6.26	-0.37	1.66e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs238295	0.881	rs6116869	chr20:5594432	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	0.5	5.29	0.32	2.73e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.36	-0.32	1.92e-7	Aortic root size;
KIRP	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.89	0.49	1.34e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs1440410	0.830	rs6832943	chr4:144181717	G/A	cg01719995	chr4:144104893	USP38	0.39	5.02	0.3	1.01e-6	Ischemic stroke;
KIRP	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-9.67	-0.52	5.88e-19	Response to antipsychotic treatment;
KIRP	cis	rs9400467	0.537	rs17663278	chr6:111504881	A/C	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	0.79	6.95	0.41	3.26e-11	Obesity-related traits;
KIRP	cis	rs9394841	0.692	rs9394837	chr6:41848088	G/A	cg08135965	chr6:41755394	TOMM6	0.51	5.5	0.33	9.51e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg15128208	chr22:42549153	NA	0.74	8.02	0.46	4.33e-14	Birth weight;
KIRP	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.73	0.39	1.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.64	6.4	0.38	7.96e-10	Axial length;
KIRP	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	8.85	0.49	1.7e-16	Cognitive test performance;
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg01763666	chr17:80159506	CCDC57	0.37	5.13	0.31	5.75e-7	Life satisfaction;
KIRP	cis	rs4713675	0.565	rs9394161	chr6:33669793	G/C	cg15676125	chr6:33679581	C6orf125	0.41	5.41	0.33	1.5e-7	Plateletcrit;
KIRP	cis	rs10423674	0.526	rs11085241	chr19:18828546	G/A	cg14292368	chr19:18793705	CRTC1	-0.57	-7.5	-0.43	1.16e-12	Menarche (age at onset);
KIRP	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-7.56	-0.43	7.74e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.7	6.64	0.39	1.95e-10	Lung function (FEV1/FVC);
KIRP	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.45	5.18	0.31	4.72e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs3767633	0.925	rs924777	chr1:161848904	G/A	cg09175582	chr1:161736000	ATF6	0.74	6.03	0.36	5.88e-9	IgG glycosylation;
KIRP	cis	rs11767191	0.811	rs4917168	chr7:48752800	G/C	ch.7.1147807F	chr7:49473528	NA	0.4	5.14	0.31	5.58e-7	Response to amphetamines;
KIRP	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.64	7.93	0.45	7.49e-14	Multiple sclerosis;
KIRP	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.18	-22.61	-0.82	5.21e-62	Ulcerative colitis;
KIRP	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.93	-0.45	7.81e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.72	-11.04	-0.58	2.74e-23	Hepatocellular carcinoma;
KIRP	cis	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg25650185	chr19:21324782	ZNF431	-0.46	-4.96	-0.3	1.3e-6	Pain;
KIRP	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-12.02	-0.61	1.72e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1448094	0.617	rs7297449	chr12:86468442	A/C	cg00310523	chr12:86230176	RASSF9	-0.41	-5.99	-0.36	7.54e-9	Major depressive disorder;
KIRP	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg16553119	chr1:165599451	MGST3	-0.43	-4.99	-0.3	1.15e-6	Total ventricular volume;
KIRP	cis	rs7601312	1.000	rs1989406	chr2:229321657	A/G	cg02542817	chr2:229291442	NA	-0.38	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg05315796	chr3:52349193	DNAH1	0.51	7.88	0.45	1.06e-13	Electroencephalogram traits;
KIRP	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg16339924	chr4:17578868	LAP3	-0.61	-7.88	-0.45	1.04e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20314548	chr15:74426273	ISLR2	-0.46	-6.11	-0.36	3.78e-9	Interleukin-4 levels;
KIRP	cis	rs11735612	0.565	rs12650566	chr4:138530992	A/G	cg12033966	chr4:138453416	PCDH18	0.37	5.13	0.31	5.75e-7	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg01879757	chr17:41196368	BRCA1	-0.53	-7.15	-0.41	9.83e-12	Menopause (age at onset);
KIRP	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg07274523	chr3:49395745	GPX1	0.72	8.75	0.49	3.35e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg06108461	chr20:60628389	TAF4	-0.54	-6.3	-0.37	1.37e-9	Body mass index;
KIRP	cis	rs80130819	0.515	rs6580656	chr12:48570604	C/T	cg26205652	chr12:48591994	NA	0.5	5.97	0.36	8.36e-9	Prostate cancer;
KIRP	cis	rs10128264	0.902	rs1250587	chr10:80978021	A/G	cg18737081	chr10:80999807	ZMIZ1	-0.32	-5.88	-0.35	1.34e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11987759	chr7:65425863	GUSB	0.49	6.23	0.37	1.96e-9	Aortic root size;
KIRP	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.65	-0.34	4.33e-8	Coronary artery disease;
KIRP	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg24807547	chr6:37504484	NA	-0.52	-7.71	-0.44	3.2e-13	Cognitive performance;
KIRP	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.61	-0.34	5.55e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg16558253	chr16:72132732	DHX38	-0.55	-8.08	-0.46	2.84e-14	Fibrinogen levels;
KIRP	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg18806716	chr10:30721971	MAP3K8	-0.31	-5.09	-0.31	7.13e-7	Inflammatory bowel disease;
KIRP	cis	rs11997175	0.624	rs79944133	chr8:33730588	A/G	ch.8.33884649F	chr8:33765107	NA	0.58	6.47	0.38	5.2400000000000005e-10	Body mass index;
KIRP	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.61	-6.52	-0.38	3.96e-10	DNA methylation (variation);
KIRP	cis	rs17209837	1.000	rs17149640	chr7:87086039	A/C	cg00919237	chr7:87102261	ABCB4	-0.78	-8.58	-0.48	1.1e-15	Gallbladder cancer;
KIRP	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.58	-7.83	-0.45	1.48e-13	Obesity-related traits;
KIRP	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22854549	chr19:5904785	VMAC;NDUFA11	0.47	6.04	0.36	5.54e-9	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs876084	0.505	rs11985173	chr8:121107511	G/A	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg05973401	chr12:123451056	ABCB9	0.58	6.64	0.39	2.01e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg04369109	chr6:150039330	LATS1	-0.53	-6.81	-0.4	7.46e-11	Lung cancer;
KIRP	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg14092571	chr14:90743983	NA	0.41	5.24	0.32	3.42e-7	Mortality in heart failure;
KIRP	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.49	8.86	0.49	1.61e-16	Bone mineral density;
KIRP	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.94	11.43	0.59	1.56e-24	Post bronchodilator FEV1;
KIRP	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.37	-0.32	1.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg09264619	chr17:80180166	NA	0.51	6.09	0.36	4.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs77372450	0.636	rs11748443	chr5:157029457	C/T	cg05585991	chr5:157099197	C5orf52	0.44	5.11	0.31	6.56e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.25	-0.42	5.41e-12	Glomerular filtration rate;
KIRP	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.63	-9.69	-0.53	5.03e-19	Prostate cancer;
KIRP	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	5.14	0.31	5.67e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg03213289	chr20:61660250	NA	0.72	9.12	0.5	2.84e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17123764	0.579	rs74089551	chr12:49916373	A/C	cg20471783	chr12:50157085	TMBIM6	0.42	5.07	0.31	7.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg16396542	chr1:89473148	GBP3	0.42	5.97	0.36	8.33e-9	Carotid intima media thickness;
KIRP	cis	rs12900413	0.687	rs7176981	chr15:90315757	A/G	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.66e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-0.39	-4.99	-0.3	1.12e-6	Type 2 diabetes;
KIRP	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg05044414	chr3:183734942	ABCC5	0.37	5.67	0.34	3.92e-8	Anterior chamber depth;
KIRP	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.25	0.37	1.84e-9	Aortic root size;
KIRP	trans	rs933360	0.585	rs6593174	chr7:50836486	A/G	cg20003124	chr12:4557277	NA	0.51	6.17	0.37	2.75e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.46	6.37	0.38	9.15e-10	Dupuytren's disease;
KIRP	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.74	10.4	0.55	3.19e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.88	-12.16	-0.61	6.02e-27	Obesity-related traits;
KIRP	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.3	-0.47	6.97e-15	Retinal vascular caliber;
KIRP	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.86	-12.1	-0.61	9.4e-27	Myeloid white cell count;
KIRP	cis	rs745080	0.674	rs12436846	chr14:53012989	C/T	cg23333723	chr14:53022898	GPR137C	-0.41	-5.61	-0.34	5.34e-8	Orofacial clefts;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00260888	chr20:30865478	KIF3B	-0.5	-6.75	-0.4	1.08e-10	Myopia;
KIRP	cis	rs12912251	0.591	rs3102118	chr15:39003475	A/C	cg10631289	chr15:39006617	NA	-0.79	-8.8	-0.49	2.4e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg06521331	chr12:34319734	NA	-0.62	-7.37	-0.43	2.63e-12	Morning vs. evening chronotype;
KIRP	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.23	-0.37	2.05e-9	Schizophrenia;
KIRP	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05665937	chr4:1216051	CTBP1	0.56	7.84	0.45	1.34e-13	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27340350	chr19:49559583	CGB7	0.55	7.99	0.45	5.32e-14	Parkinson's disease;
KIRP	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-5.56	-0.33	6.85e-8	Crohn's disease;
KIRP	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.49	-0.33	1.02e-7	Metabolite levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg18823784	chr15:79103221	ADAMTS7	0.45	6.93	0.4	3.65e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2179367	0.887	rs2789488	chr6:149725290	A/G	cg03678062	chr6:149772716	ZC3H12D	0.3	4.96	0.3	1.29e-6	Dupuytren's disease;
KIRP	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg11707556	chr5:10655725	ANKRD33B	0.53	6.62	0.39	2.3e-10	Coronary artery disease;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.87	15.17	0.7	3.81e-37	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-7.56	-0.43	8.08e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-7.59	-0.44	6.44e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs10992471	0.528	rs10761158	chr9:95205322	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.0	-0.3	1.08e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4523957	0.651	rs8068642	chr17:2060353	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.35	-0.59	2.84e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.95	-8.67	-0.48	5.85e-16	Rheumatoid arthritis;
KIRP	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg24998770	chr7:37888106	TXNDC3	-0.41	-5.46	-0.33	1.15e-7	Alzheimer's disease (late onset);
KIRP	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg22676075	chr6:135203613	NA	0.5	7.16	0.42	9.16e-12	Red blood cell count;
KIRP	cis	rs12580194	0.593	rs67015069	chr12:55759968	T/A	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.49	-6.21	-0.37	2.18e-9	Height;
KIRP	cis	rs2441986	0.894	rs11604305	chr11:57969053	C/T	cg19752551	chr11:57585705	CTNND1	-0.45	-5.52	-0.33	8.57e-8	Systolic blood pressure;
KIRP	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs28735056	1.000	rs59183289	chr18:77631198	A/G	cg20368463	chr18:77673604	PQLC1	-0.48	-6.38	-0.38	8.94e-10	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23005295	chr11:104780795	NA	0.41	6.4	0.38	7.74e-10	Interleukin-4 levels;
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg22284058	chr8:142237359	SLC45A4	-0.5	-6.39	-0.38	8.3e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.2	0.46	1.38e-14	Lung cancer in ever smokers;
KIRP	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg00656387	chr3:40428638	ENTPD3	0.38	4.87	0.3	1.99e-6	Renal cell carcinoma;
KIRP	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg03315344	chr16:75512273	CHST6	-0.59	-5.69	-0.34	3.52e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs2554380	0.783	rs2554385	chr15:84406587	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.46	-6.45	-0.38	5.89e-10	Height;
KIRP	cis	rs1983891	0.774	rs6935446	chr6:41514372	A/G	cg20194872	chr6:41519635	FOXP4	0.5	6.24	0.37	1.88e-9	Prostate cancer;
KIRP	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.51	-0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs41005	0.967	rs1974696	chr2:8115782	A/G	cg03155496	chr2:8117019	LOC339788	0.63	11.13	0.58	1.42e-23	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	trans	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg16141378	chr3:129829833	LOC729375	-0.55	-7.08	-0.41	1.51e-11	Systolic blood pressure;
KIRP	cis	rs8062405	0.573	rs7140	chr16:28995757	C/A	cg07382826	chr16:28625726	SULT1A1	-0.44	-4.91	-0.3	1.63e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.32	-8.08	-0.46	2.91e-14	Primary biliary cholangitis;
KIRP	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05220968	chr6:146057943	EPM2A	-0.41	-5.3	-0.32	2.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10421328	0.821	rs10405234	chr19:19756662	T/C	cg03709012	chr19:19516395	GATAD2A	0.44	5.03	0.31	9.46e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs7481311	0.956	rs1038660	chr11:27549392	A/C	cg18117895	chr11:27722066	BDNF	0.46	5.09	0.31	7.22e-7	Body mass index;Weight;
KIRP	trans	rs2123959	0.553	rs62311158	chr4:91785994	A/G	cg26127345	chr10:89621940	PTEN;KILLIN	-0.66	-6.32	-0.37	1.22e-9	Gut microbiome composition (summer);
KIRP	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.75	11.31	0.58	3.75e-24	Blood metabolite ratios;
KIRP	cis	rs4728302	0.607	rs7783179	chr7:133588117	C/G	cg10665199	chr7:133106180	EXOC4	0.43	5.04	0.31	9.21e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs16958440	1.000	rs16952848	chr18:44597829	A/G	cg17192377	chr18:44677553	HDHD2	0.75	6.72	0.39	1.24e-10	Sitting height ratio;
KIRP	cis	rs7665939	1.000	rs72709216	chr4:190112484	G/A	cg14840187	chr4:190284988	NA	-0.95	-6.88	-0.4	4.8e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11987759	chr7:65425863	GUSB	0.57	7.71	0.44	3.1e-13	Aortic root size;
KIRP	cis	rs35740288	0.731	rs12898964	chr15:86161277	G/A	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg21858823	chr1:15850916	CASP9	0.55	5.81	0.35	1.96e-8	Systolic blood pressure;
KIRP	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg21573476	chr21:45109991	RRP1B	-0.57	-7.57	-0.43	7.57e-13	Mean corpuscular volume;
KIRP	cis	rs72960926	0.744	rs56405366	chr6:75035257	T/C	cg03266952	chr6:74778945	NA	-0.7	-5.45	-0.33	1.21e-7	Metabolite levels (MHPG);
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg24874828	chr4:187887005	NA	-0.47	-7.02	-0.41	2.21e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.64	-9.58	-0.52	1.15e-18	Total body bone mineral density;
KIRP	cis	rs7951870	1.000	rs61884292	chr11:46684524	A/T	cg19486271	chr11:47235900	DDB2	0.5	4.87	0.3	1.97e-6	Schizophrenia;
KIRP	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg22705602	chr4:152727874	NA	-0.55	-9.67	-0.52	5.88e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg24375607	chr4:120327624	NA	0.66	7.68	0.44	3.67e-13	Corneal astigmatism;
KIRP	cis	rs6142102	0.961	rs2284379	chr20:32594642	T/C	cg08999081	chr20:33150536	PIGU	0.49	5.78	0.35	2.31e-8	Skin pigmentation;
KIRP	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg01721255	chr8:58191610	C8orf71	0.66	5.64	0.34	4.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	8.69	0.48	5.12e-16	Cognitive test performance;
KIRP	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg00908189	chr16:619842	PIGQ	0.83	11.36	0.59	2.61e-24	Height;
KIRP	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	1.08	8.07	0.46	3.05e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08704250	chr15:31115839	NA	0.42	7.25	0.42	5.37e-12	Huntington's disease progression;
KIRP	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	1.02	10.64	0.56	5.45e-22	Eosinophilic esophagitis;
KIRP	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg14458575	chr2:238380390	NA	0.6	6.49	0.38	4.69e-10	Prostate cancer;
KIRP	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7224685	0.569	rs58357241	chr17:3996641	T/C	cg09695851	chr17:3907499	NA	0.54	4.96	0.3	1.31e-6	Type 2 diabetes;
KIRP	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg21926883	chr2:100939477	LONRF2	-0.57	-7.67	-0.44	3.96e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg00629941	chr15:75287862	SCAMP5	-0.48	-5.1	-0.31	6.8e-7	Blood trace element (Zn levels);
KIRP	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg09873164	chr1:152488093	CRCT1	0.51	6.48	0.38	4.9e-10	Hair morphology;
KIRP	cis	rs4356932	0.967	rs13128319	chr4:76975206	A/G	cg19388996	chr4:76862389	NAAA	-0.41	-5.29	-0.32	2.67e-7	Blood protein levels;
KIRP	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg21523564	chr15:75251491	NA	0.47	8.01	0.45	4.53e-14	Breast cancer;
KIRP	cis	rs7621025	0.500	rs71630059	chr3:136581611	G/A	cg15507776	chr3:136538369	TMEM22	-0.8	-9.32	-0.51	7.1e-18	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.82	-11.45	-0.59	1.27e-24	Prostate cancer;
KIRP	cis	rs1200821	0.641	rs11011162	chr10:37674483	G/C	cg00409905	chr10:38381863	ZNF37A	0.48	6.29	0.37	1.47e-9	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.76	0.71	3.8e-39	Chronic sinus infection;
KIRP	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg13679303	chr9:96623674	NA	-0.51	-7.3	-0.42	3.98e-12	DNA methylation (variation);
KIRP	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg07511934	chr16:89386912	ANKRD11	0.45	5.68	0.34	3.82e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs7572644	0.699	rs10170872	chr2:28164553	C/T	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	11.72	0.6	1.72e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1864585	0.520	rs12375394	chr8:10689212	C/T	cg21775007	chr8:11205619	TDH	-0.5	-4.9	-0.3	1.72e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg18833306	chr6:118973337	C6orf204	0.42	5.32	0.32	2.39e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.59	-0.34	5.92e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg07274523	chr3:49395745	GPX1	0.7	8.58	0.48	1.07e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.85	12.79	0.63	4.67e-29	Menarche (age at onset);
KIRP	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	0.93	12.38	0.62	1.14e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg21775007	chr8:11205619	TDH	-0.46	-6.28	-0.37	1.5e-9	Neuroticism;
KIRP	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-10.89	-0.57	8.61e-23	Sense of smell;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg18234130	chr8:27182889	PTK2B	0.54	7.09	0.41	1.4e-11	Neuroticism;
KIRP	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-0.78	-12.22	-0.61	3.78e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs526231	0.543	rs34783	chr5:102457041	C/A	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.35	1.27e-8	Primary biliary cholangitis;
KIRP	cis	rs8033133	0.514	rs2554436	chr15:25292777	G/A	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.46	-5.45	-0.33	1.2e-7	Blood osmolality (transformed sodium);
KIRP	cis	rs7106204	0.514	rs10834307	chr11:24272516	G/A	ch.11.24196551F	chr11:24239977	NA	-0.86	-9.84	-0.53	1.78e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6466055	0.720	rs7357199	chr7:105019355	G/C	cg04380332	chr7:105027541	SRPK2	-0.65	-9.75	-0.53	3.44e-19	Schizophrenia;
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.69	-0.44	3.63e-13	Aortic root size;
KIRP	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.77	-9.9	-0.53	1.12e-19	Aortic root size;
KIRP	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.01	14.55	0.68	5.18e-35	Cognitive ability;
KIRP	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.4	-6.32	-0.37	1.19e-9	Body mass index;
KIRP	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.51	0.59	8.52e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs72820985	1.000	rs8053834	chr16:80844348	A/G	cg04448709	chr16:81349954	GAN	-0.5	-5.07	-0.31	7.99e-7	Breast cancer;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	6.35	0.38	1.01e-9	Lymphocyte counts;
KIRP	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.63	-8.04	-0.46	3.78e-14	Glomerular filtration rate;
KIRP	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg01990225	chr2:97406019	LMAN2L	0.75	5.25	0.32	3.24e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.25	-0.32	3.36e-7	Lung cancer;
KIRP	cis	rs62355272	0.580	rs17376481	chr5:35898876	G/A	cg13894535	chr5:35919491	CAPSL	-0.36	-4.88	-0.3	1.87e-6	Lymphocyte counts;
KIRP	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.29	0.37	1.46e-9	Mean platelet volume;
KIRP	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg15026998	chr2:160761622	LY75	-0.35	-5.05	-0.31	8.76e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs367943	0.712	rs4331889	chr5:112679795	C/T	cg12552261	chr5:112820674	MCC	0.5	5.84	0.35	1.61e-8	Type 2 diabetes;
KIRP	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg05973401	chr12:123451056	ABCB9	-0.5	-5.51	-0.33	8.97e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4356932	1.000	rs6532093	chr4:76948032	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs4690686	1.000	rs2278904	chr4:177248622	C/G	cg17059388	chr4:177262070	NA	-0.51	-6.87	-0.4	5.27e-11	Essential tremor;
KIRP	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.31	0.55	6.14e-21	Coffee consumption (cups per day);
KIRP	cis	rs3925075	0.584	rs12600286	chr16:31360679	G/C	cg02846316	chr16:31340340	ITGAM	0.62	9.46	0.52	2.53e-18	IgA nephropathy;
KIRP	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.43	-5.54	-0.33	7.59e-8	Aortic root size;
KIRP	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg18165381	chr3:44552316	NA	-0.39	-4.95	-0.3	1.36e-6	Depressive symptoms;
KIRP	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.7	-7.66	-0.44	4.2e-13	DNA methylation (variation);
KIRP	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg00129232	chr17:37814104	STARD3	-0.74	-10.05	-0.54	3.96e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg18944383	chr4:111397179	ENPEP	0.58	10.74	0.56	2.56e-22	Height;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15772361	chr18:61328223	SERPINB3	-0.42	-6.34	-0.37	1.08e-9	Myopia (pathological);
KIRP	cis	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg00868766	chr15:40364524	NA	0.36	5.6	0.34	5.57e-8	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg07382826	chr16:28625726	SULT1A1	0.47	5.42	0.33	1.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.27e-10	Hepatitis;
KIRP	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg21775007	chr8:11205619	TDH	-0.49	-6.3	-0.37	1.36e-9	Joint mobility (Beighton score);
KIRP	cis	rs7534824	0.625	rs61782078	chr1:101498212	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.92	7.24	0.42	5.66e-12	Refractive astigmatism;
KIRP	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg04691961	chr3:161091175	C3orf57	-0.37	-5.7	-0.34	3.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.4	-5.48	-0.33	1.05e-7	Endometrial cancer;
KIRP	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.97	0.36	8.41e-9	Breast cancer;
KIRP	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg21643547	chr1:205240462	TMCC2	-0.53	-7.7	-0.44	3.23e-13	Red blood cell count;
KIRP	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg19468946	chr17:37922297	IKZF3	-0.47	-6.45	-0.38	5.97e-10	Self-reported allergy;
KIRP	cis	rs4919687	0.550	rs12259058	chr10:104484799	A/G	cg04362960	chr10:104952993	NT5C2	0.44	5.1	0.31	6.9e-7	Colorectal cancer;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg26165406	chr6:8435716	SLC35B3	-0.53	-6.12	-0.36	3.68e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs3026101	0.671	rs3026109	chr17:5284480	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.46	-5.92	-0.35	1.07e-8	Body mass index;
KIRP	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.49	6.03	0.36	5.94e-9	Body mass index;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg08662619	chr6:150070041	PCMT1	0.39	6.49	0.38	4.58e-10	Lung cancer;
KIRP	cis	rs12949688	0.967	rs2332966	chr17:55819335	T/C	cg12582317	chr17:55822272	NA	0.6	9.67	0.52	6.1e-19	Schizophrenia;
KIRP	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg13319975	chr6:146136371	FBXO30	-0.61	-8.13	-0.46	2.15e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.86	-13.48	-0.65	2.26e-31	Breast cancer;
KIRP	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg11608241	chr8:8085544	FLJ10661	0.4	4.97	0.3	1.23e-6	Mood instability;
KIRP	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	5.97	0.36	8.32e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.99	-14.0	-0.67	3.78e-33	Ulcerative colitis;
KIRP	cis	rs1978968	1.000	rs28434757	chr22:18451554	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.82	-0.4	7.08e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	16.05	0.72	3.92e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9659323	1.000	rs11584380	chr1:119517420	C/T	cg18261050	chr1:119551319	NA	0.38	5.31	0.32	2.49e-7	Body mass index;
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg22764044	chr5:178986830	RUFY1	0.4	5.72	0.34	3.05e-8	Lung cancer;
KIRP	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.68	0.39	1.61e-10	Triglycerides;
KIRP	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.71	11.08	0.58	2.12e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.87	10.36	0.55	4.23e-21	Gestational age at birth (maternal effect);
KIRP	cis	rs7923609	0.875	rs10761741	chr10:65066186	G/T	cg08743896	chr10:65200160	JMJD1C	-0.36	-5.11	-0.31	6.48e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.42	7.24	0.42	5.7e-12	Heart rate;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.62	-0.34	5.13e-8	Crohn's disease;
KIRP	cis	rs2191566	0.600	rs11883068	chr19:44516964	C/T	cg20451226	chr19:44488181	ZNF155	0.6	5.14	0.31	5.71e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs17776563	0.922	rs12148331	chr15:89110081	C/T	cg05013243	chr15:89149849	MIR1179	0.42	5.14	0.31	5.58e-7	Thyroid hormone levels;
KIRP	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	8.99	0.5	6.76e-17	Lymphocyte counts;
KIRP	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.49	0.48	1.92e-15	Motion sickness;
KIRP	cis	rs7172677	0.737	rs4886669	chr15:75448181	C/T	cg14664628	chr15:75095509	CSK	-0.51	-5.75	-0.34	2.63e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.62	7.07	0.41	1.61e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg03474202	chr17:45855739	NA	-0.51	-7.9	-0.45	9.29e-14	IgG glycosylation;
KIRP	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg11764359	chr7:65958608	NA	0.74	5.02	0.3	1.01e-6	Diabetic kidney disease;
KIRP	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	1.2	8.63	0.48	7.72e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.32	-5.7	-0.34	3.39e-8	Alcohol dependence;
KIRP	cis	rs2151522	0.563	rs1077890	chr6:127146152	A/T	cg21431617	chr6:127135037	NA	0.33	5.96	0.36	8.66e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs6838801	1.000	rs7694630	chr4:77556983	C/T	cg17476223	chr4:77663285	SHROOM3	0.51	6.98	0.41	2.78e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19933833	chr11:66247701	DPP3	0.44	6.19	0.37	2.53e-9	Survival in pancreatic cancer;
KIRP	cis	rs7113850	0.551	rs4365050	chr11:24245730	G/A	ch.11.24196551F	chr11:24239977	NA	0.94	7.83	0.45	1.46e-13	Bone fracture in osteoporosis;
KIRP	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.51	-0.48	1.72e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7709377	0.574	rs2416430	chr5:115466392	C/T	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.83e-26	Heart rate;
KIRP	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg04733989	chr22:42467013	NAGA	0.51	6.07	0.36	4.78e-9	Cognitive function;
KIRP	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-4.99	-0.3	1.14e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.7	7.18	0.42	8.32e-12	Protein C levels;
KIRP	cis	rs883565	0.569	rs1274973	chr3:39160441	G/A	cg01426195	chr3:39028469	NA	-0.52	-8.32	-0.47	5.98e-15	Handedness;
KIRP	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06481639	chr22:41940642	POLR3H	0.6	6.36	0.38	9.52e-10	Vitiligo;
KIRP	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.2	-0.31	4.29e-7	Inflammatory bowel disease;
KIRP	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg01990225	chr2:97406019	LMAN2L	-0.97	-7.19	-0.42	7.86e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.58	-9.28	-0.51	8.99e-18	C-reactive protein levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg11458618	chr11:78147532	NARS2	0.39	6.28	0.37	1.52e-9	C-reactive protein;
KIRP	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg21775007	chr8:11205619	TDH	0.41	5.45	0.33	1.21e-7	Retinal vascular caliber;
KIRP	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.6	-8.11	-0.46	2.45e-14	Response to temozolomide;
KIRP	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg15128208	chr22:42549153	NA	0.7	7.79	0.44	1.89e-13	Birth weight;
KIRP	cis	rs4356932	1.000	rs6857372	chr4:76974727	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg01294253	chr9:136912663	BRD3	0.41	5.13	0.31	5.89e-7	Platelet distribution width;
KIRP	cis	rs2267137	0.843	rs570731	chr22:29758817	A/G	cg07256473	chr22:29710276	RASL10A	-0.46	-7.37	-0.43	2.66e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.6	-0.56	7.23e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9488822	0.676	rs12190737	chr6:116328128	C/A	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6032067	0.929	rs6017513	chr20:43835232	A/C	cg10761708	chr20:43804764	PI3	0.52	5.34	0.32	2.08e-7	Blood protein levels;
KIRP	cis	rs2271404	0.506	rs12329287	chr2:111995287	A/T	cg23466623	chr2:111982296	NA	-0.68	-9.19	-0.51	1.74e-17	Atopic dermatitis;
KIRP	trans	rs877282	0.583	rs11253425	chr10:815173	G/A	cg22713356	chr15:30763199	NA	0.88	8.67	0.48	5.94e-16	Uric acid levels;
KIRP	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.26	0.37	1.67e-9	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.83	0.4	6.49e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7119038	0.865	rs11217046	chr11:118698907	G/A	cg19308663	chr11:118741387	NA	0.63	10.31	0.55	5.8e-21	Sjögren's syndrome;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg07701084	chr6:150067640	NUP43	0.71	9.73	0.53	3.78e-19	Lung cancer;
KIRP	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg19116668	chr7:99932089	PMS2L1	-0.51	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	cis	rs5753618	0.561	rs9606830	chr22:31717799	T/G	cg02404636	chr22:31891804	SFI1	0.47	5.31	0.32	2.43e-7	Colorectal cancer;
KIRP	cis	rs3857067	1.000	rs4693364	chr4:95012284	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.85	-0.3	2.16e-6	QT interval;
KIRP	cis	rs16828019	0.852	rs3820090	chr1:41573652	A/G	cg24596898	chr1:41849189	NA	0.63	5.04	0.31	8.88e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-5.89	-0.35	1.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.84	0.49	1.91e-16	Bipolar disorder;
KIRP	cis	rs6088813	0.702	rs6060370	chr20:33909752	A/G	cg14752227	chr20:34000481	UQCC	0.45	5.59	0.34	5.96e-8	Height;
KIRP	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.65	-7.89	-0.45	9.99e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.71	9.6	0.52	9.73e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.97	14.92	0.69	2.81e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14169450	chr9:139327907	INPP5E	0.47	6.62	0.39	2.24e-10	Monocyte percentage of white cells;
KIRP	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.9	-14.7	-0.68	1.54e-35	Breast cancer;
KIRP	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs7180079	0.620	rs620171	chr15:64804862	T/A	cg15337035	chr15:64978493	NA	-0.48	-5.28	-0.32	2.78e-7	Monocyte count;
KIRP	cis	rs57590327	0.679	rs17019030	chr3:81552062	C/T	cg07356753	chr3:81810745	GBE1	-0.59	-6.34	-0.37	1.11e-9	Extraversion;
KIRP	cis	rs241257	0.643	rs241274	chr1:4627482	A/C	cg02837536	chr1:4771682	AJAP1	-0.28	-4.98	-0.3	1.23e-6	Anxiety disorder;
KIRP	cis	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.15e-8	HDL cholesterol;
KIRP	cis	rs7119038	0.509	rs11216961	chr11:118580338	C/G	cg19308663	chr11:118741387	NA	0.41	6.4	0.38	7.8e-10	Sjögren's syndrome;
KIRP	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.68e-11	Hemoglobin concentration;
KIRP	cis	rs4740619	0.619	rs10810526	chr9:16041399	C/T	cg14451791	chr9:16040625	NA	-0.4	-5.11	-0.31	6.54e-7	Body mass index;
KIRP	cis	rs12786942	0.569	rs4271356	chr11:101313984	T/C	cg03942599	chr11:101341554	TRPC6	0.54	7.37	0.43	2.59e-12	Facial depth;
KIRP	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs57590327	0.508	rs4399914	chr3:81965477	C/T	cg07356753	chr3:81810745	GBE1	-0.56	-7.42	-0.43	1.91e-12	Extraversion;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.23	0.37	2.06e-9	Lung cancer;
KIRP	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg21775007	chr8:11205619	TDH	0.53	6.53	0.38	3.73e-10	Mood instability;
KIRP	cis	rs6142618	0.555	rs242604	chr20:30668251	T/C	cg09796376	chr20:30640595	HCK	0.4	5.46	0.33	1.15e-7	Inflammatory bowel disease;
KIRP	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg13165212	chr22:42675999	NA	0.41	7.02	0.41	2.09e-11	Cognitive function;
KIRP	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.52	-0.52	1.72e-18	Gut microbiome composition (summer);
KIRP	cis	rs56775891	0.559	rs11664298	chr18:77578986	G/A	cg02536541	chr18:77568900	NA	-0.64	-7.3	-0.42	4.07e-12	Schizophrenia;
KIRP	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg10523679	chr1:76189770	ACADM	-0.44	-5.95	-0.35	9.05e-9	Daytime sleep phenotypes;
KIRP	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.6	5.21	0.32	3.9e-7	Crohn's disease;
KIRP	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg10760299	chr15:45669010	GATM	-0.37	-5.58	-0.34	6.29e-8	Homoarginine levels;
KIRP	cis	rs7555523	0.830	rs6660601	chr1:165695855	C/T	cg24409356	chr1:165738333	TMCO1	0.71	5.97	0.36	8.25e-9	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.15	-0.5	2.26e-17	Mean corpuscular volume;
KIRP	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg25706552	chr1:244017396	NA	0.61	6.65	0.39	1.83e-10	RR interval (heart rate);
KIRP	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg01721255	chr8:58191610	C8orf71	0.62	5.36	0.32	1.89e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8014252	0.803	rs73282127	chr14:70986413	T/C	cg19730268	chr14:71022823	NA	-0.57	-5.49	-0.33	9.97e-8	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs55962025	0.846	rs363064	chr4:3141410	C/T	cg13731523	chr4:3047190	NA	0.32	4.96	0.3	1.29e-6	Parental longevity (mother's age at death);
KIRP	cis	rs12540874	0.542	rs10238413	chr7:50648184	G/A	cg00647317	chr7:50633725	DDC	0.5	7.21	0.42	7.02e-12	Systemic sclerosis;
KIRP	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs6732160	0.564	rs7605716	chr2:73376250	G/A	cg01422370	chr2:73384389	NA	0.51	6.92	0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg13147721	chr7:65941812	NA	1.04	7.43	0.43	1.73e-12	Diabetic kidney disease;
KIRP	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.85	11.94	0.61	3.24e-26	Total body bone mineral density;
KIRP	cis	rs11997175	0.646	rs7386741	chr8:33769709	A/G	cg04338863	chr8:33670619	NA	0.43	4.91	0.3	1.66e-6	Body mass index;
KIRP	cis	rs67478160	0.643	rs6576005	chr14:104292369	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.59	-7.7	-0.44	3.25e-13	Schizophrenia;
KIRP	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-1.02	-16.72	-0.73	1.99e-42	Height;
KIRP	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg21775007	chr8:11205619	TDH	-0.47	-6.18	-0.37	2.6e-9	Triglycerides;
KIRP	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	1.06	19.96	0.79	2.3e-53	Heart rate;
KIRP	cis	rs16958440	0.737	rs12327081	chr18:44744422	G/A	cg17192377	chr18:44677553	HDHD2	0.89	7.17	0.42	8.93e-12	Sitting height ratio;
KIRP	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.99	17.32	0.74	1.78e-44	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.88	-13.36	-0.65	5.78e-31	Colorectal cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg01089189	chr10:75758046	VCL	0.51	6.39	0.38	8.41e-10	Asthma;
KIRP	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.88	7.91	0.45	8.83e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-5.65	-0.34	4.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg18477163	chr1:228402036	OBSCN	0.34	6.41	0.38	7.43e-10	Diastolic blood pressure;
KIRP	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-7.54	-0.43	8.83e-13	Menopause (age at onset);
KIRP	cis	rs6991838	0.584	rs7823840	chr8:66519001	A/G	cg13398993	chr8:66546079	ARMC1	-0.44	-5.07	-0.31	7.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg00800038	chr16:89945340	TCF25	-0.82	-6.12	-0.36	3.68e-9	Skin colour saturation;
KIRP	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.46	6.79	0.4	8.2e-11	Urate levels in lean individuals;
KIRP	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg06634786	chr22:41940651	POLR3H	-0.46	-5.01	-0.3	1.04e-6	Neuroticism;
KIRP	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.45e-9	Type 2 diabetes;
KIRP	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.96	-0.41	3.13e-11	Initial pursuit acceleration;
KIRP	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-10.94	-0.57	5.73e-23	Sense of smell;
KIRP	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs6992848	0.791	rs11166957	chr8:141177468	G/A	cg13911501	chr8:141220320	TRAPPC9	0.41	4.99	0.3	1.12e-6	Response to amphetamines;
KIRP	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.44	-0.33	1.28e-7	Metabolite levels;
KIRP	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	9.2	0.51	1.54e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02106155	chr7:83860330	NA	-0.4	-6.22	-0.37	2.13e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs858239	0.539	rs7791200	chr7:23182121	A/T	cg23682824	chr7:23144976	KLHL7	0.54	6.37	0.38	9.23e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.81	-11.27	-0.58	4.88e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg16989719	chr2:238392110	NA	-0.42	-5.7	-0.34	3.47e-8	Prostate cancer;
KIRP	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg19875535	chr5:140030758	IK	-0.74	-11.15	-0.58	1.19e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg17724175	chr1:150552817	MCL1	0.3	5.15	0.31	5.42e-7	Melanoma;
KIRP	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg04733989	chr22:42467013	NAGA	0.51	6.05	0.36	5.35e-9	Cognitive function;
KIRP	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg21573476	chr21:45109991	RRP1B	-0.66	-8.77	-0.49	3.06e-16	Mean corpuscular volume;
KIRP	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.45	-5.18	-0.31	4.73e-7	Colorectal cancer;
KIRP	cis	rs5167	0.504	rs3760628	chr19:45457225	G/A	cg20090143	chr19:45452003	APOC2	0.34	5.47	0.33	1.12e-7	Blood protein levels;
KIRP	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13334819	chr7:99746414	C7orf59	0.6	6.59	0.39	2.7e-10	Coronary artery disease;
KIRP	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.91	-0.45	8.48e-14	Neuroticism;
KIRP	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg10047753	chr17:41438598	NA	1.02	12.86	0.63	2.77e-29	Menopause (age at onset);
KIRP	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg23422044	chr7:1970798	MAD1L1	0.58	5.89	0.35	1.29e-8	Bipolar disorder;
KIRP	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7084402	1.000	rs7074778	chr10:60272248	C/T	cg05938607	chr10:60274200	BICC1	0.47	11.34	0.59	3.06e-24	Refractive error;
KIRP	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18647927	chr15:45315307	SORD	0.49	6.18	0.37	2.61e-9	Parkinson's disease;
KIRP	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.45	-0.38	5.85e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs7601312	0.933	rs10183791	chr2:229301491	A/G	cg02542817	chr2:229291442	NA	-0.55	-8.5	-0.48	1.89e-15	Schizophrenia;
KIRP	cis	rs1050631	1.000	rs1050631	chr18:33694120	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.51	-6.26	-0.37	1.66e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.75	8.93	0.49	9.9e-17	Pancreatic cancer;
KIRP	trans	rs10487112	0.625	rs714498	chr7:90167839	A/T	cg06738889	chr1:150208936	ANP32E	0.46	6.17	0.37	2.82e-9	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg21734707	chr17:3908241	ZZEF1	0.5	6.87	0.4	5.34e-11	Type 2 diabetes;
KIRP	cis	rs12096438	1.000	rs11806326	chr1:25899165	G/T	cg21452808	chr1:25900135	NA	-0.38	-6.11	-0.36	3.93e-9	Platelet count;Mean platelet volume;
KIRP	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.55	-15.72	-0.71	5e-39	Hip circumference adjusted for BMI;
KIRP	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg10932868	chr11:921992	NA	0.65	8.77	0.49	3.03e-16	Alzheimer's disease (late onset);
KIRP	cis	rs6783573	0.895	rs1049667	chr3:46623690	C/A	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.36	-5.62	-0.34	5.23e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.21	13.22	0.64	1.65e-30	Alzheimer's disease;
KIRP	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.77	0.4	9.22e-11	Electroencephalogram traits;
KIRP	cis	rs4006360	0.629	rs2132842	chr17:39234214	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.65	-10.01	-0.54	5.3e-20	Bipolar disorder and schizophrenia;
KIRP	cis	rs16854884	1.000	rs13067695	chr3:143781054	C/T	cg06585982	chr3:143692056	C3orf58	0.53	6.1	0.36	4.1e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-7.8	-0.45	1.78e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.45	-6.29	-0.37	1.45e-9	Coronary artery disease;
KIRP	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg00405596	chr8:11794950	NA	0.48	6.52	0.38	3.97e-10	Mood instability;
KIRP	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.6	7.52	0.43	1.04e-12	Personality dimensions;
KIRP	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg02153340	chr1:155202674	NA	-0.37	-5.19	-0.31	4.38e-7	Serum magnesium levels;
KIRP	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.6	9.01	0.5	5.93e-17	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg21698718	chr17:80085957	CCDC57	0.37	5.4	0.33	1.58e-7	Life satisfaction;
KIRP	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.63	7.61	0.44	5.79e-13	Platelet count;
KIRP	cis	rs10924309	0.855	rs7413150	chr1:245858729	G/A	cg00036263	chr1:245852353	KIF26B	-0.5	-6.6	-0.39	2.48e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.93	0.3	1.51e-6	Lung cancer;
KIRP	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.48	7.34	0.42	3.09e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs13132184	0.507	rs35266215	chr4:38048878	C/T	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.19	-0.31	4.45e-7	Verbal declarative memory;
KIRP	cis	rs7845219	0.539	rs13271644	chr8:95853948	A/G	cg09323728	chr8:95962352	TP53INP1	-0.25	-5.03	-0.31	9.5e-7	Type 2 diabetes;
KIRP	cis	rs427941	0.703	rs201455	chr7:101740212	C/T	cg06246474	chr7:101738831	CUX1	0.51	6.31	0.37	1.25e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4702718	0.592	rs364491	chr5:10732008	G/C	cg14521931	chr5:10832172	NA	-0.44	-5.91	-0.35	1.11e-8	Obesity-related traits;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg23378989	chr5:131991993	NA	-0.44	-6.28	-0.37	1.5e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.45	-6.06	-0.36	5.03e-9	Refractive error;
KIRP	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.8	9.8	0.53	2.39e-19	Phospholipid levels (plasma);
KIRP	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08822215	chr16:89438651	ANKRD11	-0.49	-6.45	-0.38	6.05e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs2072732	0.861	rs12408197	chr1:2951511	C/T	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg19913688	chr11:428466	ANO9	-0.77	-6.03	-0.36	6.05e-9	Body mass index;
KIRP	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg10360139	chr7:1886902	MAD1L1	-0.53	-5.91	-0.35	1.13e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10658240	chr2:181925401	UBE2E3	-0.41	-6.47	-0.38	5.14e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg07001201	chr5:642380	CEP72	0.62	5.89	0.35	1.28e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.61	8.31	0.47	6.63e-15	Pulse pressure;
KIRP	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	cg21523751	chr1:182988639	NA	-0.35	-4.92	-0.3	1.55e-6	Fuchs's corneal dystrophy;
KIRP	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-9.91	-0.53	1.11e-19	Neuroticism;
KIRP	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.65	10.34	0.55	4.83e-21	Platelet count;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg09400194	chr10:81107848	PPIF	0.8	6.93	0.4	3.63e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	trans	rs783540	0.500	rs7178459	chr15:83398384	T/C	cg16105309	chr15:79090380	ADAMTS7	-0.63	-7.49	-0.43	1.2e-12	Schizophrenia;
KIRP	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.64	5.55	0.33	7.3e-8	Schizophrenia;
KIRP	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.01	-0.41	2.23e-11	Monocyte count;
KIRP	cis	rs7903847	0.642	rs10786339	chr10:99153076	A/G	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4805272	0.925	rs7260432	chr19:29321477	T/C	cg04546413	chr19:29218101	NA	0.43	4.9	0.3	1.71e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg02725872	chr8:58115012	NA	-0.56	-6.14	-0.36	3.27e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2348418	0.647	rs938081	chr12:28720613	A/G	cg13890972	chr12:28721907	NA	-0.33	-5.16	-0.31	5.04e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs1950626	0.615	rs12893486	chr14:101463800	C/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.41	0.38	7.45e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11245990	chr11:68621969	NA	0.41	5.58	0.34	6.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg04691961	chr3:161091175	C3orf57	-0.39	-5.74	-0.34	2.77e-8	Morning vs. evening chronotype;
KIRP	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.27	-0.37	1.65e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg07636037	chr3:49044803	WDR6	-0.77	-7.37	-0.43	2.65e-12	Cognitive ability (multi-trait analysis);
KIRP	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.82	-0.35	1.79e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17856907	chr10:91353162	MIR107;PANK1	0.49	6.38	0.38	8.78e-10	Interleukin-4 levels;
KIRP	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12560992	chr17:57184187	TRIM37	0.61	7.02	0.41	2.15e-11	Testicular germ cell tumor;
KIRP	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg04539111	chr16:67997858	SLC12A4	-0.66	-6.75	-0.4	1.05e-10	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg01475377	chr6:109611718	NA	0.41	5.8	0.35	2.03e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs1448094	0.872	rs10863146	chr12:86408326	C/G	cg02569458	chr12:86230093	RASSF9	0.34	4.96	0.3	1.3e-6	Major depressive disorder;
KIRP	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.65	-8.76	-0.49	3.18e-16	Morning vs. evening chronotype;
KIRP	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg00319359	chr11:70116639	PPFIA1	0.65	6.37	0.38	9.1e-10	Coronary artery disease;
KIRP	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.52	6.93	0.4	3.77e-11	Mean corpuscular volume;
KIRP	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.95e-8	Type 2 diabetes;
KIRP	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.79	10.91	0.57	7.21e-23	Menarche (age at onset);
KIRP	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg21775007	chr8:11205619	TDH	-0.38	-4.95	-0.3	1.35e-6	Triglycerides;
KIRP	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg06640241	chr16:89574553	SPG7	0.52	6.14	0.36	3.31e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-6.85	-0.4	5.83e-11	Vitiligo;
KIRP	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.52	-6.75	-0.4	1.07e-10	Neutrophil percentage of white cells;
KIRP	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04374321	chr14:90722782	PSMC1	0.96	17.02	0.74	1.91e-43	Mortality in heart failure;
KIRP	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.86	6.42	0.38	6.91e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg10381502	chr11:71823885	C11orf51	-1.11	-7.97	-0.45	5.83e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg02367723	chr1:46378857	MAST2	0.42	4.88	0.3	1.87e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs45544231	0.544	rs9926163	chr16:52565641	G/T	cg09051775	chr16:52580266	TOX3	-0.38	-5.22	-0.32	3.76e-7	Restless legs syndrome;
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg06871246	chr4:1363661	KIAA1530	-0.56	-6.99	-0.41	2.54e-11	Longevity;
KIRP	cis	rs7084402	0.935	rs12264028	chr10:60278140	C/T	cg05938607	chr10:60274200	BICC1	0.45	10.71	0.56	3.22e-22	Refractive error;
KIRP	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.45	-6.97	-0.41	2.96e-11	Coronary artery disease;
KIRP	cis	rs2380220	0.606	rs4559095	chr6:95994154	A/C	cg15832292	chr6:96025679	MANEA	0.73	7.18	0.42	8.35e-12	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.16e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg00343986	chr7:65444356	GUSB	-0.49	-6.0	-0.36	6.91e-9	Aortic root size;
KIRP	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.65	0.39	1.92e-10	Tonsillectomy;
KIRP	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.63	8.21	0.46	1.28e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg11608241	chr8:8085544	FLJ10661	0.44	5.4	0.33	1.58e-7	Systolic blood pressure;
KIRP	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.69	7.91	0.45	8.47e-14	Height;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02708296	chr12:69633319	CPSF6	-0.42	-6.2	-0.37	2.38e-9	Serum protein levels (sST2);
KIRP	cis	rs4700695	0.841	rs152995	chr5:65323172	G/A	cg21114390	chr5:65439923	SFRS12	0.58	5.34	0.32	2.13e-7	Facial morphology (factor 19);
KIRP	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.81	9.62	0.52	8.67e-19	Corneal astigmatism;
KIRP	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.95	-0.5	9.09e-17	Coronary artery disease;
KIRP	cis	rs2223471	0.840	rs2744495	chr6:50756663	T/C	cg03432817	chr6:50765336	NA	-0.53	-8.79	-0.49	2.6e-16	Subcutaneous adipose tissue;
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.59	7.89	0.45	9.91e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg12598211	chr12:123634384	NA	-0.4	-4.97	-0.3	1.25e-6	Platelet count;
KIRP	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02725872	chr8:58115012	NA	-0.58	-6.98	-0.41	2.7e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-7.28	-0.42	4.53e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.62e-8	Motion sickness;
KIRP	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg21890820	chr11:65308645	LTBP3	0.39	5.01	0.3	1.02e-6	Bone mineral density;
KIRP	cis	rs3105593	1.000	rs2292174	chr15:50924956	A/G	cg05456662	chr15:50716270	USP8	0.45	5.43	0.33	1.35e-7	QT interval;
KIRP	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.46	0.68	1.07e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10491083	0.661	rs55748285	chr17:6557329	G/A	cg16536857	chr17:6538525	KIAA0753	0.8	7.5	0.43	1.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4148660	1.000	rs3759236	chr12:22068849	G/T	cg14669847	chr12:22099120	NA	0.32	5.47	0.33	1.11e-7	Gout;
KIRP	cis	rs17608059	0.545	rs9944522	chr17:13918783	C/T	cg11395062	chr17:14139857	CDRT15	0.58	7.55	0.43	8.33e-13	Temperament;
KIRP	cis	rs12210905	0.920	rs9348763	chr6:27302919	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.41	-0.38	7.43e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg00629941	chr15:75287862	SCAMP5	-0.5	-5.26	-0.32	3.09e-7	Blood trace element (Zn levels);
KIRP	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg23649088	chr2:200775458	C2orf69	0.62	7.6	0.44	6.4e-13	Osteoporosis;
KIRP	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.82	11.43	0.59	1.53e-24	Breast cancer;
KIRP	cis	rs6693567	0.565	rs834242	chr1:150379858	G/A	cg09579323	chr1:150459698	TARS2	0.4	5.0	0.3	1.11e-6	Migraine;
KIRP	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.16e-7	Aortic root size;
KIRP	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg17595323	chr11:93583763	C11orf90	-0.37	-6.26	-0.37	1.71e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26976729	chr10:131361502	MGMT	0.48	6.49	0.38	4.82e-10	Migraine with aura;
KIRP	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg23958373	chr8:599963	NA	0.71	5.37	0.32	1.78e-7	IgG glycosylation;
KIRP	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.31	-0.55	5.91e-21	Response to antipsychotic treatment;
KIRP	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-7.68	-0.44	3.86e-13	P wave terminal force;
KIRP	cis	rs2594989	1.000	rs2594994	chr3:11339960	T/A	cg01796438	chr3:11312864	ATG7	-0.7	-8.09	-0.46	2.82e-14	Circulating chemerin levels;
KIRP	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.58	-7.33	-0.42	3.24e-12	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.48	0.33	1.03e-7	Breast cancer;
KIRP	cis	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg12031962	chr15:58353849	ALDH1A2	0.35	4.98	0.3	1.18e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs4262150	0.774	rs72799164	chr5:152132148	C/G	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.19	0.51	1.71e-17	Multiple sclerosis;
KIRP	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.45	-7.29	-0.42	4.25e-12	Testicular germ cell tumor;
KIRP	cis	rs1345301	1.000	rs12470560	chr2:102868840	T/C	cg12451869	chr2:102867685	NA	0.4	5.82	0.35	1.87e-8	Waist circumference;
KIRP	cis	rs10484885	0.592	rs72912554	chr6:90181719	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.5	-5.28	-0.32	2.83e-7	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg17376030	chr22:41985996	PMM1	0.62	6.84	0.4	6.19e-11	Vitiligo;
KIRP	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg11846333	chr4:119757529	SEC24D	1.11	5.88	0.35	1.37e-8	Cannabis dependence symptom count;
KIRP	cis	rs9393777	0.623	rs13211166	chr6:27265940	T/A	cg12292205	chr6:26970375	C6orf41	-0.46	-4.93	-0.3	1.53e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6001982	0.667	rs55864500	chr22:40855293	C/T	cg07138101	chr22:40742427	ADSL	0.73	5.16	0.31	5.09e-7	Breast cancer;
KIRP	trans	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	7.62	0.44	5.6e-13	Blood trace element (Cu levels);
KIRP	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.56	-6.29	-0.37	1.41e-9	Aortic root size;
KIRP	cis	rs911119	0.955	rs6048933	chr20:23595637	T/G	cg09631192	chr20:23583594	CST9	-0.62	-5.83	-0.35	1.69e-8	Chronic kidney disease;
KIRP	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg23422044	chr7:1970798	MAD1L1	-0.41	-5.23	-0.32	3.57e-7	Neuroticism;
KIRP	trans	rs6601327	0.641	rs10111376	chr8:9615470	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.18	0.42	8.09e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4006360	0.604	rs3914090	chr17:39230058	A/T	cg25341923	chr17:39239918	KRTAP4-7	-0.56	-8.78	-0.49	2.9e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs8033133	0.881	rs3803328	chr15:25330550	T/A	cg14481604	chr15:25334117	SNORD116-22	-0.56	-6.73	-0.39	1.17e-10	Blood osmolality (transformed sodium);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16548348	chr22:19842481	GNB1L;C22orf29	0.45	6.4	0.38	7.69e-10	Survival in pancreatic cancer;
KIRP	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg13147721	chr7:65941812	NA	-0.98	-6.9	-0.4	4.48e-11	Diabetic kidney disease;
KIRP	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.61	7.92	0.45	8.4e-14	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg03004497	chr11:58874207	FAM111B	0.49	6.22	0.37	2.18e-9	DNA methylation (variation);
KIRP	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg22974920	chr21:40686053	BRWD1	0.5	5.99	0.36	7.24e-9	Cognitive function;
KIRP	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.46e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2591576	1.000	rs2591577	chr5:165407857	T/A	cg13976338	chr5:165423657	NA	-0.72	-9.97	-0.54	6.77e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.77	0.4	9.42e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg23977821	chr2:24270452	C2orf44	-0.45	-6.28	-0.37	1.51e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg07395648	chr5:131743802	NA	-0.51	-7.4	-0.43	2.09e-12	Breast cancer;
KIRP	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg13010199	chr12:38710504	ALG10B	0.63	7.85	0.45	1.31e-13	Morning vs. evening chronotype;
KIRP	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.32	0.62	1.76e-27	Platelet count;
KIRP	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg25486957	chr4:152246857	NA	-0.43	-5.01	-0.3	1.02e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-15.16	-0.69	4.11e-37	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.39	4.99	0.3	1.16e-6	Birth weight;
KIRP	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.99	-16.45	-0.72	1.59e-41	Chronic sinus infection;
KIRP	cis	rs2030114	0.555	rs34065507	chr16:51595451	G/A	cg03758633	chr16:51611768	NA	0.25	4.94	0.3	1.47e-6	Blood pressure measurement (high sodium and potassium intervention);
KIRP	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg06223162	chr1:101003688	GPR88	-0.4	-7.83	-0.45	1.44e-13	Monocyte count;
KIRP	cis	rs10782582	0.609	rs1498311	chr1:76254726	A/C	cg10523679	chr1:76189770	ACADM	0.45	6.32	0.37	1.21e-9	Daytime sleep phenotypes;
KIRP	cis	rs2191566	0.576	rs381759	chr19:44495145	A/G	cg18700516	chr19:44507157	ZNF230	-0.42	-4.85	-0.3	2.21e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2979489	0.891	rs17626867	chr8:30311177	G/T	cg26383811	chr8:30366931	RBPMS	-0.38	-5.13	-0.31	6e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs4363385	0.510	rs11590835	chr1:153047166	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-6.11	-0.36	3.97e-9	Inflammatory skin disease;
KIRP	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.65	8.6	0.48	9.41e-16	Strep throat;
KIRP	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.16	15.52	0.7	2.44e-38	Lymphocyte percentage of white cells;
KIRP	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg17218026	chr1:154582156	ADAR	0.35	5.85	0.35	1.55e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.64	-7.14	-0.41	1.02e-11	Neuroticism;
KIRP	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.79	-10.54	-0.56	1.1e-21	Osteoporosis;
KIRP	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.5	5.78	0.35	2.29e-8	Parkinson's disease;
KIRP	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.72	9.31	0.51	7.38e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.75	0.34	2.6e-8	Birth weight;
KIRP	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-0.78	-9.26	-0.51	1.08e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	cg21523751	chr1:182988639	NA	0.44	7.09	0.41	1.38e-11	Colorectal cancer;
KIRP	cis	rs1950626	0.750	rs72700530	chr14:101429459	G/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.64	6.86	0.4	5.45e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7851660	0.935	rs4460498	chr9:100620412	T/C	cg13688889	chr9:100608707	NA	-0.83	-12.49	-0.62	4.85e-28	Strep throat;
KIRP	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.77	-8.93	-0.49	1.03e-16	Resting heart rate;
KIRP	cis	rs4478858	0.647	rs11577679	chr1:31726185	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs57590327	0.503	rs9852235	chr3:81508355	A/G	cg07356753	chr3:81810745	GBE1	0.49	6.15	0.37	3.08e-9	Extraversion;
KIRP	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.1	-0.31	6.81e-7	Neuroticism;
KIRP	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04267008	chr7:1944627	MAD1L1	0.48	5.17	0.31	4.8e-7	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.03	0.31	9.65e-7	Renal cell carcinoma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17421021	chr10:114879663	TCF7L2	0.56	7.55	0.43	8.32e-13	Interleukin-4 levels;
KIRP	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.04	-0.41	1.87e-11	Neuroticism;
KIRP	cis	rs17453880	0.700	rs12655008	chr5:151999029	T/C	cg12297329	chr5:152029980	NA	0.5	6.75	0.4	1.03e-10	Subjective well-being;
KIRP	cis	rs3736485	0.868	rs9744054	chr15:51933163	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.14	-0.31	5.56e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg21775007	chr8:11205619	TDH	0.45	6.03	0.36	5.86e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6142102	0.625	rs4243974	chr20:32547868	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg10253484	chr15:75165896	SCAMP2	-0.44	-5.03	-0.31	9.62e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.93	10.95	0.57	5.28e-23	Corneal astigmatism;
KIRP	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.55	7.93	0.45	7.5e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.66	-8.84	-0.49	1.91e-16	Schizophrenia;
KIRP	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18357526	chr6:26021779	HIST1H4A	0.53	6.75	0.4	1.03e-10	Height;
KIRP	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.73	-10.24	-0.55	9.71e-21	Blood metabolite levels;
KIRP	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-0.58	-8.87	-0.49	1.54e-16	LDL cholesterol;
KIRP	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg27490568	chr2:178487706	NA	0.47	6.42	0.38	7.12e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.67	-7.19	-0.42	7.9e-12	Vitiligo;
KIRP	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg02487422	chr3:49467188	NICN1	0.38	5.25	0.32	3.28e-7	Parkinson's disease;
KIRP	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.11	0.61	8.56e-27	Blood protein levels;
KIRP	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.64	-7.18	-0.42	8.38e-12	Neuroticism;
KIRP	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.71	-7.23	-0.42	6.05e-12	Gout;
KIRP	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg13147721	chr7:65941812	NA	-0.97	-6.68	-0.39	1.59e-10	Diabetic kidney disease;
KIRP	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.47e-21	Chronic sinus infection;
KIRP	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.7	7.89	0.45	9.64e-14	Height;
KIRP	cis	rs9328573	0.967	rs2082859	chr15:100509132	C/G	cg09918751	chr15:100517450	ADAMTS17	0.36	4.91	0.3	1.66e-6	Urate levels in lean individuals;
KIRP	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.53	6.85	0.4	5.71e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.55	-4.98	-0.3	1.21e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7191439	0.522	rs4597303	chr16:88763561	T/C	cg27087555	chr16:88793112	FAM38A	-1.32	-7.22	-0.42	6.28e-12	Plateletcrit;
KIRP	cis	rs9314323	0.558	rs7828560	chr8:26188998	G/A	cg11498726	chr8:26250323	BNIP3L	-0.47	-6.79	-0.4	8.38e-11	Red cell distribution width;
KIRP	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.11	-0.46	2.42e-14	Mean corpuscular volume;
KIRP	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg23307798	chr14:103986281	CKB	-0.51	-6.91	-0.4	4.15e-11	Coronary artery disease;
KIRP	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.5	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg04369109	chr6:150039330	LATS1	-0.55	-6.58	-0.39	2.84e-10	Lung cancer;
KIRP	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.82	8.53	0.48	1.56e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg12705353	chr12:122356852	WDR66	0.4	5.42	0.33	1.4e-7	Mean corpuscular volume;
KIRP	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.95	14.83	0.69	5.65e-36	Breast cancer;
KIRP	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.57	8.15	0.46	1.85e-14	Retinal vascular caliber;
KIRP	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs3850699	0.683	rs67481356	chr10:104317811	C/A	cg04362960	chr10:104952993	NT5C2	0.57	6.04	0.36	5.77e-9	Prostate cancer;
KIRP	cis	rs6696239	1.000	rs10799428	chr1:227798565	C/T	cg27395484	chr1:227557617	NA	0.47	5.02	0.3	9.89e-7	Height;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20877313	chr12:56881753	GLS2	0.55	6.1	0.36	4.14e-9	Lung cancer in ever smokers;
KIRP	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.88	11.28	0.58	4.53e-24	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1729407	0.625	rs2727789	chr11:116696887	G/T	cg08985259	chr11:116699649	APOC3	-0.3	-4.91	-0.3	1.69e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg07936489	chr17:37558343	FBXL20	-0.41	-4.89	-0.3	1.85e-6	Asthma;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00982357	chr20:23331308	NXT1	-0.44	-6.04	-0.36	5.51e-9	Metabolic traits;
KIRP	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.87	9.41	0.51	3.7e-18	Cisplatin-induced ototoxicity;
KIRP	trans	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg10756647	chr7:56101905	PSPH	-1.01	-7.56	-0.43	7.77e-13	Diabetic kidney disease;
KIRP	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.77	11.05	0.58	2.68e-23	Menarche (age at onset);
KIRP	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.29	-0.32	2.66e-7	Coronary artery disease;
KIRP	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg19773385	chr1:10388646	KIF1B	-0.68	-8.87	-0.49	1.58e-16	Hepatocellular carcinoma;
KIRP	cis	rs2117029	0.554	rs12306494	chr12:49530781	A/G	cg24176009	chr12:49580217	TUBA1A	-0.37	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-9.9	-0.53	1.14e-19	Coronary artery disease;
KIRP	trans	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.25	-0.42	5.46e-12	Systemic lupus erythematosus;
KIRP	cis	rs7833787	0.929	rs7844317	chr8:18697046	T/A	cg17701159	chr8:18705777	PSD3	-0.33	-5.84	-0.35	1.62e-8	Obesity-related traits;
KIRP	cis	rs12476592	0.636	rs262493	chr2:63845066	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.11	-0.31	6.4e-7	Childhood ear infection;
KIRP	cis	rs12519773	0.662	rs6883741	chr5:92491481	T/A	cg18783429	chr5:92414398	NA	0.28	4.91	0.3	1.64e-6	Migraine;
KIRP	cis	rs7617480	0.756	rs990211	chr3:48721040	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	6.06	0.36	5.18e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg05926928	chr17:57297772	GDPD1	-0.64	-6.33	-0.37	1.13e-9	Opioid sensitivity;
KIRP	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.07	20.06	0.79	1.12e-53	Chronic sinus infection;
KIRP	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.99	-0.64	1.03e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.55	5.76	0.34	2.51e-8	White matter hyperintensity burden;
KIRP	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.63	7.5	0.43	1.14e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.96	12.57	0.63	2.6e-28	Breast cancer;
KIRP	cis	rs12900413	0.687	rs12913572	chr15:90319313	T/C	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.5e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.29	5.86	0.35	1.51e-8	Schizophrenia;
KIRP	cis	rs6102059	0.548	rs6016382	chr20:39181246	T/A	cg22477343	chr20:39312069	NA	0.48	6.21	0.37	2.24e-9	LDL cholesterol;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.44	6.24	0.37	1.91e-9	Testicular germ cell tumor;
KIRP	cis	rs4594175	0.962	rs4254242	chr14:51599184	A/C	cg23942311	chr14:51606299	NA	0.51	6.75	0.4	1.04e-10	Cancer;
KIRP	cis	rs11687659	0.515	rs6725611	chr2:191579025	G/A	cg11845111	chr2:191398756	TMEM194B	-0.47	-5.12	-0.31	6.09e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg05535760	chr7:792225	HEATR2	-0.43	-4.98	-0.3	1.21e-6	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg12549451	chr6:135224345	NA	0.43	5.19	0.31	4.51e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.7e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.71	9.99	0.54	5.88e-20	Caffeine consumption;
KIRP	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.69	-0.34	3.65e-8	Type 2 diabetes;
KIRP	cis	rs7187994	0.848	rs16974515	chr16:84782510	T/G	cg07647771	chr16:84786436	USP10	-0.37	-5.22	-0.32	3.74e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg20243544	chr17:37824526	PNMT	0.56	7.79	0.45	1.83e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.43	5.8	0.35	2.06e-8	Homoarginine levels;
KIRP	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.42	-6.2	-0.37	2.41e-9	Height;
KIRP	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.56	-7.0	-0.41	2.38e-11	Bipolar disorder;
KIRP	cis	rs300890	1.000	rs300891	chr4:144250211	T/C	cg19876092	chr4:144208277	NA	0.44	7.22	0.42	6.59e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.9	-9.6	-0.52	9.48e-19	Corneal astigmatism;
KIRP	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg09455208	chr3:40491958	NA	0.3	4.96	0.3	1.3e-6	Renal cell carcinoma;
KIRP	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg19338460	chr6:170058176	WDR27	-0.6	-7.01	-0.41	2.34e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6701037	1.000	rs6701037	chr1:175120079	G/T	cg17845761	chr1:175162550	KIAA0040	0.33	6.33	0.37	1.13e-9	Alcohol dependence;
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.58	-8.94	-0.5	9.35e-17	Paraoxonase activity;
KIRP	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg24296786	chr1:45957014	TESK2	0.51	5.61	0.34	5.31e-8	Homocysteine levels;
KIRP	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.74	9.6	0.52	9.52e-19	Coronary artery disease;
KIRP	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.47	5.48	0.33	1.03e-7	Schizophrenia;
KIRP	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg04731861	chr2:219085781	ARPC2	0.28	6.82	0.4	7.04e-11	Colorectal cancer;
KIRP	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg18190219	chr22:46762943	CELSR1	-0.83	-7.08	-0.41	1.53e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg23188684	chr11:67383651	NA	-0.42	-5.44	-0.33	1.28e-7	Mean corpuscular volume;
KIRP	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg03128060	chr6:142623767	GPR126	0.36	5.27	0.32	2.96e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02770061	chr7:158046166	PTPRN2	0.36	5.32	0.32	2.38e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.6	7.92	0.45	8.17e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.69	-12.52	-0.62	3.61e-28	White blood cell count (basophil);
KIRP	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.63	-6.39	-0.38	8.11e-10	Blood trace element (Zn levels);
KIRP	cis	rs3736485	0.966	rs11633713	chr15:51908052	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.19e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.8	-9.06	-0.5	4.13e-17	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13530621	chr13:20735337	GJA3	-0.49	-6.46	-0.38	5.5e-10	Interleukin-4 levels;
KIRP	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.48	7.26	0.42	5.2e-12	Resting heart rate;
KIRP	cis	rs6901250	0.589	rs684023	chr6:117092308	T/C	cg12892004	chr6:117198278	RFX6	0.39	6.47	0.38	5.21e-10	C-reactive protein levels;
KIRP	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.04	-0.5	4.73e-17	Colorectal cancer;
KIRP	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.5	6.79	0.4	8.32e-11	Mean corpuscular volume;
KIRP	cis	rs9398803	0.865	rs2130603	chr6:126826819	A/C	cg19875578	chr6:126661172	C6orf173	0.47	6.19	0.37	2.55e-9	Male-pattern baldness;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.19e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg04733989	chr22:42467013	NAGA	-0.4	-5.12	-0.31	6.23e-7	Intelligence;
KIRP	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.78	-0.35	2.25e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11169552	0.510	rs10876060	chr12:50965630	C/T	cg12884762	chr12:50931848	DIP2B	-0.43	-5.0	-0.3	1.08e-6	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04199473	chr14:31464361	STRN3	0.49	6.64	0.39	2.02e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6467136	0.765	rs1557643	chr7:127206134	C/T	cg08586737	chr7:127225949	GCC1	-0.38	-4.87	-0.3	2.03e-6	Type 2 diabetes;
KIRP	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.47	-4.95	-0.3	1.41e-6	Blood metabolite levels;
KIRP	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26314531	chr2:26401878	FAM59B	0.47	5.13	0.31	5.84e-7	Gut microbiome composition (summer);
KIRP	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	IgG glycosylation;
KIRP	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	7.21	0.42	6.98e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-7.09	-0.41	1.41e-11	Daytime sleep phenotypes;
KIRP	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.57	-0.39	3.04e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7923609	1.000	rs10822163	chr10:65124098	C/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.56	-0.33	6.96e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7246657	0.722	rs13744	chr19:38077912	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26637795	chr10:27793165	RAB18	0.47	6.07	0.36	4.73e-9	Parkinson's disease;
KIRP	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg06742321	chr12:123595122	PITPNM2	0.44	5.58	0.34	6.36e-8	Platelet count;
KIRP	cis	rs2275620	0.526	rs1819173	chr10:96680265	C/T	cg09036531	chr10:96991505	NA	-0.46	-5.48	-0.33	1.07e-7	Gout;
KIRP	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg08975724	chr8:8085496	FLJ10661	0.54	7.05	0.41	1.75e-11	Morning vs. evening chronotype;
KIRP	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg07173049	chr1:7289937	CAMTA1	0.64	9.64	0.52	7.08e-19	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	0.72	6.85	0.4	5.87e-11	Breast cancer;
KIRP	cis	rs74181299	0.750	rs1420185	chr2:65315903	A/G	cg05010058	chr2:65284262	CEP68	0.49	7.05	0.41	1.78e-11	Pulse pressure;
KIRP	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.87	12.68	0.63	1.07e-28	Bladder cancer;
KIRP	cis	rs1978968	0.912	rs5992933	chr22:18457043	G/T	cg02610425	chr22:18483192	MICAL3	0.36	4.89	0.3	1.82e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.54	-8.17	-0.46	1.58e-14	Itch intensity from mosquito bite;
KIRP	trans	rs6810798	0.744	rs2163012	chr4:148268027	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	0.52	6.24	0.37	1.9e-9	Coronary artery disease;
KIRP	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.58	-7.51	-0.43	1.11e-12	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs17095355	1.000	rs55717725	chr10:111666629	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.74	-0.34	2.76e-8	Biliary atresia;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg08662619	chr6:150070041	PCMT1	0.37	6.15	0.37	3.06e-9	Lung cancer;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg13331940	chr15:59663987	MYO1E	0.51	6.6	0.39	2.49e-10	Colorectal cancer;
KIRP	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-8.77	-0.49	2.98e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.84	-12.16	-0.61	5.98e-27	Systemic lupus erythematosus;
KIRP	cis	rs73086581	0.945	rs6037715	chr20:3972166	A/T	cg02187196	chr20:3869020	PANK2	0.48	5.03	0.31	9.32e-7	Response to antidepressants in depression;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10070431	chr2:232322438	NCL;SNORD20	-0.44	-6.27	-0.37	1.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	15.28	0.7	1.61e-37	Electrocardiographic conduction measures;
KIRP	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.71	-6.05	-0.36	5.5e-9	Schizophrenia;
KIRP	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-7.18	-0.42	8.02e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.59	0.48	1.05e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	5.73	0.34	2.94e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.17	-0.37	2.79e-9	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18252515	chr7:66147081	NA	0.42	4.91	0.3	1.63e-6	Aortic root size;
KIRP	cis	rs36715	0.953	rs251214	chr5:127544738	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	7.96	0.45	6.19e-14	Breast cancer;
KIRP	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg03808351	chr9:123631620	PHF19	0.44	6.18	0.37	2.69e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7827290	0.863	rs7014099	chr8:142305766	C/T	cg17903548	chr8:142401534	NA	0.49	6.49	0.38	4.79e-10	Bipolar disorder;
KIRP	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg09873164	chr1:152488093	CRCT1	0.61	7.98	0.45	5.71e-14	Hair morphology;
KIRP	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg04865290	chr3:52927548	TMEM110	0.54	6.67	0.39	1.72e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-14.17	-0.67	9.73e-34	Heart rate;
KIRP	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.56	6.62	0.39	2.23e-10	Aortic root size;
KIRP	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.76	-8.03	-0.46	4.14e-14	Asthma;
KIRP	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.67	-8.93	-0.49	1.01e-16	Sudden cardiac arrest;
KIRP	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-9.23	-0.51	1.28e-17	Blood trace element (Cu levels);
KIRP	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.87	-12.05	-0.61	1.36e-26	Platelet distribution width;
KIRP	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg17691542	chr6:26056736	HIST1H1C	0.64	7.43	0.43	1.75e-12	Iron status biomarkers;
KIRP	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.86	0.45	1.2e-13	Coffee consumption (cups per day);
KIRP	cis	rs860295	0.702	rs11264386	chr1:155559170	G/T	cg02153340	chr1:155202674	NA	-0.55	-7.41	-0.43	1.97e-12	Body mass index;
KIRP	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	5.52	0.33	8.62e-8	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg23736307	chr8:27182930	PTK2B	0.53	6.73	0.39	1.15e-10	Neuroticism;
KIRP	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.42	-0.33	1.45e-7	Total body bone mineral density;
KIRP	cis	rs17095355	1.000	rs734163	chr10:111698192	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.96	-0.36	8.65e-9	Biliary atresia;
KIRP	cis	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.85	-0.35	1.55e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.6	-6.26	-0.37	1.72e-9	Body mass index;
KIRP	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg00405596	chr8:11794950	NA	-0.49	-6.45	-0.38	5.86e-10	Retinal vascular caliber;
KIRP	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.64	6.99	0.41	2.51e-11	Gut microbiome composition (summer);
KIRP	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.99	-0.5	6.65e-17	Common traits (Other);
KIRP	cis	rs4073221	0.547	rs13076743	chr3:18235724	C/T	cg07694806	chr3:18168406	NA	-0.63	-5.65	-0.34	4.44e-8	Parkinson's disease;
KIRP	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.62	-0.34	5.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.7	9.17	0.5	2.01e-17	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg24375607	chr4:120327624	NA	0.57	6.49	0.38	4.81e-10	Corneal astigmatism;
KIRP	cis	rs1559088	0.625	rs10411739	chr19:33616327	T/C	cg24009623	chr19:33667908	NA	0.49	6.49	0.38	4.76e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8054556	0.740	rs12716974	chr16:29944832	C/T	cg05445914	chr16:30134068	MAPK3	0.4	5.11	0.31	6.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.4	-0.55	3.19e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs554111	0.574	rs4060971	chr1:21506930	C/T	cg08890418	chr1:21044141	KIF17	0.43	6.48	0.38	4.89e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.54	6.17	0.37	2.8e-9	Sleep duration;
KIRP	cis	rs9815354	0.812	rs73071203	chr3:41977464	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.53	0.48	1.5e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.7	10.01	0.54	5.11e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	6.66	0.39	1.79e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg05562828	chr17:3906858	NA	0.54	6.67	0.39	1.67e-10	Type 2 diabetes;
KIRP	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg13010199	chr12:38710504	ALG10B	0.53	6.95	0.41	3.27e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-5.6	-0.34	5.76e-8	Chronic sinus infection;
KIRP	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-5.45	-0.33	1.25e-7	Life satisfaction;
KIRP	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.62	0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.84	0.45	1.38e-13	Coffee consumption (cups per day);
KIRP	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg09888468	chr15:81410853	NA	-0.43	-5.59	-0.34	6.16e-8	QT interval (drug interaction);
KIRP	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs11638352	1.000	rs4924734	chr15:44328070	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-5.9	-0.35	1.17e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs6684514	1.000	rs3806407	chr1:156251742	T/C	cg16558208	chr1:156270281	VHLL	-0.44	-5.82	-0.35	1.84e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg18404041	chr3:52824283	ITIH1	-0.37	-5.27	-0.32	2.94e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg18016565	chr1:150552671	MCL1	0.38	5.74	0.34	2.79e-8	Melanoma;
KIRP	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg11130432	chr3:121712080	ILDR1	-0.44	-5.1	-0.31	6.65e-7	Multiple sclerosis;
KIRP	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg00405596	chr8:11794950	NA	0.58	8.2	0.46	1.31e-14	Neuroticism;
KIRP	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg08662619	chr6:150070041	PCMT1	0.36	5.79	0.35	2.1e-8	Lung cancer;
KIRP	cis	rs7017914	0.967	rs1838393	chr8:71702591	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.02	-0.3	9.96e-7	Bone mineral density;
KIRP	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg15507776	chr3:136538369	TMEM22	0.51	7.17	0.42	9e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4006360	0.554	rs1848810	chr17:39236025	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	1.03e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg20362242	chr5:692897	TPPP	0.56	4.86	0.3	2.14e-6	Obesity-related traits;
KIRP	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg24633833	chr3:10029261	TMEM111	0.53	5.13	0.31	5.83e-7	Alzheimer's disease;
KIRP	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg01620082	chr3:125678407	NA	-1.13	-7.19	-0.42	7.84e-12	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9644630	1.000	rs6988743	chr8:19369583	C/A	cg01280390	chr8:19363452	CSGALNACT1	-0.38	-4.97	-0.3	1.25e-6	Oropharynx cancer;
KIRP	cis	rs858239	0.899	rs5850	chr7:23314547	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.34	0.32	2.08e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.8	-10.88	-0.57	9.33e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg09904177	chr6:26538194	HMGN4	0.45	6.04	0.36	5.71e-9	Schizophrenia;
KIRP	cis	rs35740288	0.770	rs11636185	chr15:86183118	A/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.76	-0.34	2.55e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17401966	1.000	rs17396382	chr1:10290268	T/C	cg19773385	chr1:10388646	KIF1B	-0.62	-7.45	-0.43	1.61e-12	Hepatocellular carcinoma;
KIRP	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.26	24.08	0.84	1.26e-66	IgG glycosylation;
KIRP	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.93	13.24	0.65	1.44e-30	Height;
KIRP	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	cg12689670	chr1:183009347	LAMC1	0.52	7.55	0.43	8.72e-13	Fuchs's corneal dystrophy;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03811519	chr9:134001305	NUP214	0.51	6.48	0.38	5.07e-10	Asthma;
KIRP	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	8.38	0.47	4.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.36	-0.47	4.67e-15	Neuroticism;
KIRP	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.5	-6.87	-0.4	5.31e-11	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg09699651	chr6:150184138	LRP11	0.6	7.98	0.45	5.43e-14	Lung cancer;
KIRP	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg02807482	chr3:125708958	NA	-0.53	-5.24	-0.32	3.38e-7	Blood pressure (smoking interaction);
KIRP	cis	rs16936870	0.543	rs13276919	chr8:71298775	G/A	cg14232793	chr8:71155543	NCOA2	0.57	7.07	0.41	1.61e-11	QT interval;
KIRP	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.39	0.59	2.01e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1847505	0.520	rs79998091	chr13:61483843	C/G	cg25164009	chr13:61490935	NA	0.57	6.71	0.39	1.3100000000000001e-10	Polychlorinated biphenyl levels;
KIRP	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.96	0.45	6.13e-14	Height;
KIRP	cis	rs858239	0.899	rs7794684	chr7:23310805	A/G	cg23682824	chr7:23144976	KLHL7	0.44	5.03	0.31	9.43e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg02487422	chr3:49467188	NICN1	0.41	5.63	0.34	4.93e-8	Parkinson's disease;
KIRP	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.69	8.26	0.47	9.03e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg13385521	chr17:29058706	SUZ12P	0.54	5.27	0.32	2.94e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9926296	0.581	rs1108064	chr16:89894150	G/C	cg27121462	chr16:89883253	FANCA	0.54	7.11	0.41	1.28e-11	Vitiligo;
KIRP	cis	rs1009170	0.749	rs7143608	chr14:92587733	G/C	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.43	0.33	1.37e-7	Dialysis-related mortality;
KIRP	cis	rs9400271	0.632	rs6930698	chr6:109590304	A/G	cg21918786	chr6:109611834	NA	-0.37	-5.42	-0.33	1.42e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.2	0.37	2.31e-9	Iron status biomarkers;
KIRP	trans	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17809414	chr2:206547231	NRP2	0.46	6.48	0.38	4.9e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs5753618	0.561	rs2078803	chr22:31652852	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.34	-0.32	2.09e-7	Colorectal cancer;
KIRP	cis	rs6701037	0.967	rs1057302	chr1:175126423	A/G	cg08873628	chr1:175162347	KIAA0040	-0.39	-5.53	-0.33	8.37e-8	Alcohol dependence;
KIRP	trans	rs216345	0.966	rs3843935	chr9:33787871	C/T	cg14607208	chr9:38546089	NA	0.5	6.53	0.38	3.66e-10	Bipolar disorder;
KIRP	cis	rs7572644	0.699	rs12465000	chr2:28199424	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-5.3	-0.32	2.57e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	1.05	16.01	0.71	5.37e-40	Menopause (age at onset);
KIRP	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.37	0.32	1.79e-7	Diisocyanate-induced asthma;
KIRP	trans	rs909341	0.909	rs1048665	chr20:62331989	T/G	cg01311341	chr22:25575246	KIAA1671	-0.62	-7.4	-0.43	2.16e-12	Atopic dermatitis;
KIRP	cis	rs11955175	1.000	rs2228058	chr5:40681254	C/T	cg05478818	chr5:40835740	RPL37	0.71	5.29	0.32	2.77e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.23	-0.32	3.58e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg24315340	chr6:146058215	EPM2A	-0.39	-5.0	-0.3	1.11e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.41	-0.51	3.74e-18	Aortic root size;
KIRP	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	1.05	20.21	0.79	3.34e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.42	-5.26	-0.32	3.2e-7	Aortic root size;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg04249460	chr6:41040849	NFYA;C6orf130	-0.61	-6.7	-0.39	1.39e-10	Menopause (age at onset);
KIRP	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.77	8.6	0.48	9.53e-16	Corneal astigmatism;
KIRP	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.32	-6.83	-0.4	6.44e-11	Cutaneous nevi;
KIRP	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg26516362	chr5:178986906	RUFY1	0.41	7.06	0.41	1.74e-11	Lung cancer;
KIRP	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	0.88	8.32	0.47	6.01e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs6088813	1.000	rs6060401	chr20:34005214	C/T	cg14752227	chr20:34000481	UQCC	-0.48	-6.13	-0.36	3.41e-9	Height;
KIRP	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.24e-10	Hypertriglyceridemia;
KIRP	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.37	5.37	0.32	1.81e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg00405596	chr8:11794950	NA	-0.49	-6.45	-0.38	5.85e-10	Retinal vascular caliber;
KIRP	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.96e-7	Body mass index;
KIRP	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg26585981	chr11:48327164	OR4S1	0.5	6.32	0.37	1.24e-9	Migraine - clinic-based;
KIRP	cis	rs56161922	1.000	rs55821028	chr1:207843000	G/A	cg11752769	chr1:207818423	CR1L	-0.77	-5.03	-0.31	9.67e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	8.04	0.46	3.67e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg16141378	chr3:129829833	LOC729375	0.56	6.99	0.41	2.51e-11	Triglycerides;
KIRP	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.09	-11.71	-0.6	1.87e-25	Hip circumference adjusted for BMI;
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg04804543	chr8:142233427	SLC45A4	-1.02	-17.75	-0.75	6.11e-46	Immature fraction of reticulocytes;
KIRP	cis	rs637571	0.546	rs11227311	chr11:65585257	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.4	-4.98	-0.3	1.19e-6	Eosinophil percentage of white cells;
KIRP	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.6	-9.33	-0.51	6.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs516946	1.000	rs3802315	chr8:41528178	G/T	cg19441908	chr8:41529140	ANK1	0.49	6.92	0.4	3.79e-11	Type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21382589	chr2:8785969	NA	0.45	6.32	0.37	1.2e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg06917634	chr15:78832804	PSMA4	-0.55	-5.8	-0.35	2.02e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03771185	chr4:775700	NA	0.49	6.44	0.38	6.1e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2070677	0.736	rs12261564	chr10:135354594	C/T	cg20169779	chr10:135381914	SYCE1	-0.68	-5.91	-0.35	1.14e-8	Gout;
KIRP	cis	rs1134634	0.520	rs28661857	chr4:15591465	C/T	cg16509355	chr4:15471240	CC2D2A	-0.34	-5.86	-0.35	1.49e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	cg12689670	chr1:183009347	LAMC1	-0.45	-6.43	-0.38	6.41e-10	Colorectal cancer;
KIRP	cis	rs290986	0.857	rs290275	chr9:93546691	A/G	cg02608019	chr9:93564028	SYK	-0.6	-5.65	-0.34	4.4e-8	Multiple sclerosis;
KIRP	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg16388071	chr6:169726476	NA	-0.37	-5.03	-0.31	9.37e-7	Obesity-related traits;
KIRP	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-5.03	-0.31	9.42e-7	Schizophrenia;
KIRP	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	9.2	0.51	1.56e-17	Coffee consumption (cups per day);
KIRP	cis	rs6496667	0.779	rs2238320	chr15:90972441	C/T	cg10434728	chr15:90938212	IQGAP1	0.38	5.08	0.31	7.34e-7	Rheumatoid arthritis;
KIRP	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.03	13.83	0.66	1.45e-32	Primary sclerosing cholangitis;
KIRP	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.57	6.98	0.41	2.75e-11	Menopause (age at onset);
KIRP	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	0.77	8.72	0.49	4.22e-16	Testicular germ cell tumor;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14593314	chr6:44191312	SLC29A1	-0.64	-7.09	-0.41	1.45e-11	Menopause (age at onset);
KIRP	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.4	5.44	0.33	1.29e-7	HIV-1 susceptibility;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26146781	chr19:7694475	XAB2;LOC100131801	0.5	6.18	0.37	2.66e-9	Parkinson's disease;
KIRP	cis	rs2067615	0.965	rs2204886	chr12:107128090	T/A	cg21360079	chr12:107162445	NA	-0.47	-5.96	-0.36	8.83e-9	Heart rate;
KIRP	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs501120	0.584	rs11238923	chr10:44701232	A/T	cg09554077	chr10:44749378	NA	0.51	5.54	0.33	7.93e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9815354	0.812	rs73071239	chr3:41992610	C/A	cg03022575	chr3:42003672	ULK4	0.83	8.51	0.48	1.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6500395	0.532	rs4421983	chr16:48723648	G/T	cg04672837	chr16:48644449	N4BP1	-0.38	-5.24	-0.32	3.53e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg15605315	chr1:45957053	TESK2	0.4	5.09	0.31	7.28e-7	High light scatter reticulocyte count;
KIRP	cis	rs34779708	0.966	rs12775548	chr10:35479504	G/T	cg04310649	chr10:35416472	CREM	-0.52	-5.97	-0.36	8.04e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg19847866	chr10:1019161	NA	0.52	5.97	0.36	8.05e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.38	-5.08	-0.31	7.39e-7	Menarche (age at onset);
KIRP	cis	rs10929159	0.928	rs6749436	chr2:236919992	A/G	cg20128773	chr2:236923534	AGAP1	0.31	5.53	0.33	8.17e-8	Parkinson's disease;
KIRP	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg19913688	chr11:428466	ANO9	-0.76	-6.1	-0.36	4.09e-9	Body mass index;
KIRP	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.44	-5.44	-0.33	1.26e-7	Neutrophil percentage of white cells;
KIRP	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg15880211	chr22:50250494	ZBED4	0.47	5.52	0.33	8.72e-8	Schizophrenia;
KIRP	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.91	-0.45	8.86e-14	Sudden cardiac arrest;
KIRP	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.63	5.74	0.34	2.74e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.58	8.48	0.48	2.1e-15	Ovarian reserve;
KIRP	cis	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg26587870	chr6:27730563	NA	-0.67	-5.3	-0.32	2.55e-7	Breast cancer;
KIRP	cis	rs7188697	0.922	rs28479997	chr16:58614877	G/A	cg21335942	chr16:58549945	SETD6	-0.46	-5.12	-0.31	6.31e-7	QT interval;
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.61	0.68	3.15e-35	Platelet count;
KIRP	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg03060546	chr3:49711283	APEH	-0.72	-5.46	-0.33	1.15e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-19.87	-0.78	4.59e-53	Height;
KIRP	cis	rs2151522	0.762	rs9375466	chr6:127167512	A/G	cg21431617	chr6:127135037	NA	0.28	4.87	0.3	2.02e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	1.09	21.33	0.81	7.42e-58	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7939886	0.920	rs11227857	chr11:56082112	A/G	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs787274	1.000	rs4979155	chr9:115560134	G/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.53	-0.38	3.78e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg25706552	chr1:244017396	NA	0.61	6.37	0.38	9.42e-10	RR interval (heart rate);
KIRP	cis	rs3105593	0.933	rs3101850	chr15:50844314	A/G	cg05456662	chr15:50716270	USP8	0.37	4.96	0.3	1.33e-6	QT interval;
KIRP	cis	rs7224685	0.906	rs9915922	chr17:4083242	T/C	cg11204139	chr17:3907470	NA	0.54	6.35	0.38	1.05e-9	Type 2 diabetes;
KIRP	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Bladder cancer;
KIRP	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg10932868	chr11:921992	NA	0.67	9.13	0.5	2.59e-17	Alzheimer's disease (late onset);
KIRP	cis	rs35955747	0.533	rs5998004	chr22:31881829	C/T	cg02404636	chr22:31891804	SFI1	-0.4	-5.18	-0.31	4.64e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	1.19	9.62	0.52	8.2e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs11134338	0.565	rs2925908	chr5:8991487	C/T	cg18330338	chr5:9047211	SEMA5A	0.36	4.85	0.3	2.17e-6	Obesity-related traits;
KIRP	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.5	8.1	0.46	2.5e-14	Total body bone mineral density;
KIRP	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.52	-7.43	-0.43	1.77e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg13293535	chr8:11597251	GATA4	0.54	8.14	0.46	1.93e-14	Neuroticism;
KIRP	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.47	-4.94	-0.3	1.46e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs2425143	0.908	rs58448091	chr20:34325470	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-6.14	-0.36	3.37e-9	Bipolar disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13654993	chr19:5978414	RANBP3	0.5	7.04	0.41	1.95e-11	Survival in pancreatic cancer;
KIRP	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg20636351	chr8:55087400	NA	-0.62	-7.35	-0.42	2.91e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg13319975	chr6:146136371	FBXO30	0.6	7.44	0.43	1.71e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72960926	0.744	rs72959653	chr6:75012112	C/T	cg03266952	chr6:74778945	NA	-0.76	-5.78	-0.35	2.2e-8	Metabolite levels (MHPG);
KIRP	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.73	9.8	0.53	2.42e-19	Childhood ear infection;
KIRP	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg19847130	chr8:10466454	RP1L1	0.39	5.8	0.35	2.03e-8	Retinal vascular caliber;
KIRP	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg12826209	chr6:26865740	GUSBL1	-0.52	-5.66	-0.34	4.18e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs4790559	chr17:4010478	G/T	cg09695851	chr17:3907499	NA	-0.81	-14.69	-0.68	1.7000000000000001e-35	Type 2 diabetes;
KIRP	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.13	-0.61	7.25e-27	Chronic sinus infection;
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.7	-0.39	1.39e-10	Lung cancer;
KIRP	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg19338460	chr6:170058176	WDR27	-0.63	-7.3	-0.42	3.9e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.5e-39	Headache;
KIRP	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-0.73	-6.3	-0.37	1.35e-9	Obesity-related traits;
KIRP	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg02820040	chr2:241836501	C2orf54	-0.24	-5.36	-0.32	1.94e-7	Urinary metabolites;
KIRP	trans	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg21122474	chr19:35606554	FXYD3	-0.42	-6.1	-0.36	4.07e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02376269	chr15:43398346	UBR1	0.49	6.72	0.39	1.22e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg06598544	chr20:61472147	COL9A3	-0.83	-6.86	-0.4	5.66e-11	Obesity-related traits;
KIRP	cis	rs2014572	0.967	rs10411941	chr19:57762886	C/T	cg24459738	chr19:57751996	ZNF805	-0.58	-7.21	-0.42	6.96e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs79387448	0.655	rs77763678	chr2:102916749	G/A	cg20060108	chr2:102954350	IL1RL1	-0.61	-4.88	-0.3	1.94e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg02725872	chr8:58115012	NA	-0.6	-6.94	-0.4	3.55e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs877426	0.609	rs56287057	chr13:114829267	C/A	cg25338242	chr13:114786047	RASA3	0.46	4.85	0.3	2.18e-6	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.57	-7.75	-0.44	2.4e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg21775007	chr8:11205619	TDH	0.35	4.85	0.3	2.2e-6	Neuroticism;
KIRP	cis	rs1062746	0.544	rs8059287	chr16:87332956	G/A	cg02258303	chr16:87377426	FBXO31	-0.43	-5.13	-0.31	5.79e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.7	-0.49	4.93e-16	Neuroticism;
KIRP	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg18882449	chr10:104885122	NT5C2	0.49	6.06	0.36	5.2e-9	Arsenic metabolism;
KIRP	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.8	10.9	0.57	7.63e-23	Mean platelet volume;
KIRP	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg17595323	chr11:93583763	C11orf90	-0.31	-5.23	-0.32	3.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.57	7.26	0.42	5.1e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs787274	0.850	rs7047914	chr9:115620773	A/C	cg13803584	chr9:115635662	SNX30	-0.73	-6.64	-0.39	1.95e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs828999	0.715	rs11185295	chr1:108711074	A/C	cg06207961	chr1:108661230	NA	0.36	4.94	0.3	1.47e-6	Monocyte percentage of white cells;
KIRP	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.63	-9.76	-0.53	3.24e-19	Total body bone mineral density;
KIRP	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05220968	chr6:146057943	EPM2A	0.4	5.12	0.31	6.22e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-6.51	-0.38	4.21e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.97	15.75	0.71	4.02e-39	Uric acid clearance;
KIRP	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.62	-6.59	-0.39	2.6200000000000003e-10	DNA methylation (variation);
KIRP	cis	rs7666738	0.519	rs11732209	chr4:98801643	A/G	cg17366294	chr4:99064904	C4orf37	0.38	4.86	0.3	2.14e-6	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg09579323	chr1:150459698	TARS2	0.4	5.07	0.31	7.86e-7	Migraine;
KIRP	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg24767315	chr2:241525811	CAPN10	0.47	6.03	0.36	6.08e-9	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg10729496	chr3:10149963	C3orf24	0.58	5.25	0.32	3.3e-7	Alzheimer's disease;
KIRP	cis	rs6545883	0.868	rs7574631	chr2:61825142	T/G	cg15711740	chr2:61764176	XPO1	-0.6	-8.16	-0.46	1.68e-14	Tuberculosis;
KIRP	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23281280	chr6:28129359	ZNF389	0.48	5.25	0.32	3.23e-7	Depression;
KIRP	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	1.3	9.0	0.5	6.34e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg24060327	chr5:131705240	SLC22A5	0.42	5.09	0.31	7.13e-7	Blood metabolite levels;
KIRP	cis	rs6662572	0.737	rs10789477	chr1:46306583	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.54	-0.33	7.9e-8	Blood protein levels;
KIRP	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg12315302	chr6:26189340	HIST1H4D	0.98	6.85	0.4	5.92e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg10760299	chr15:45669010	GATM	0.35	5.32	0.32	2.33e-7	Homoarginine levels;
KIRP	cis	rs9876781	0.559	rs1903144	chr3:48406397	T/A	cg11946769	chr3:48343235	NME6	0.41	5.02	0.3	9.84e-7	Longevity;
KIRP	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.86	0.35	1.47e-8	Menopause (age at onset);
KIRP	cis	rs883565	0.569	rs704959	chr3:39180263	G/A	cg01426195	chr3:39028469	NA	0.53	8.42	0.47	3.23e-15	Handedness;
KIRP	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.66	7.55	0.43	8.73e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.54	7.19	0.42	7.87e-12	Mean corpuscular volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg10867947	chr8:95835263	INTS8	1.05	7.04	0.41	1.93e-11	P wave terminal force;
KIRP	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.68	8.02	0.46	4.32e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.66	6.62	0.39	2.25e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg10664184	chr19:17420304	DDA1	0.79	9.03	0.5	5e-17	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs830383	0.515	rs716710	chr5:165512267	G/T	cg13976338	chr5:165423657	NA	0.47	5.44	0.33	1.28e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg05315796	chr3:52349193	DNAH1	0.45	6.67	0.39	1.64e-10	Bipolar disorder;
KIRP	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg12573674	chr2:1569213	NA	-0.65	-7.39	-0.43	2.28e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.65	6.18	0.37	2.64e-9	Lung function (FEV1/FVC);
KIRP	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg11062466	chr8:58055876	NA	0.72	5.12	0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.9	13.11	0.64	3.96e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2273669	0.667	rs12195378	chr6:109284255	A/G	cg05315195	chr6:109294784	ARMC2	-0.59	-5.89	-0.35	1.24e-8	Prostate cancer;
KIRP	cis	rs34746873	0.743	rs657284	chr8:62873803	G/T	cg01509237	chr8:63160509	NKAIN3	-0.43	-5.24	-0.32	3.45e-7	Neurofibrillary tangles;
KIRP	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg08603382	chr10:743973	NA	0.56	8.41	0.47	3.41e-15	Psychosis in Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23088508	chr4:20729211	PACRGL	-0.45	-7.21	-0.42	6.68e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4692589	0.531	rs12650424	chr4:170975204	T/C	cg19918862	chr4:170955249	NA	0.56	6.17	0.37	2.75e-9	Anxiety disorder;
KIRP	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs865483	0.630	rs7215774	chr17:35740855	T/C	cg06716730	chr17:35851459	DUSP14	-0.21	-5.01	-0.3	1.06e-6	Monocyte count;
KIRP	cis	rs4722166	0.532	rs6963866	chr7:22757341	C/T	cg05472934	chr7:22766657	IL6	0.51	6.66	0.39	1.82e-10	Lung cancer;
KIRP	cis	rs981844	0.816	rs56109239	chr4:154726500	A/G	cg14289246	chr4:154710475	SFRP2	0.67	7.86	0.45	1.22e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	1.11	18.31	0.76	7.68e-48	Cognitive function;
KIRP	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.15	-0.5	2.28e-17	Retinal vascular caliber;
KIRP	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	1.05	13.5	0.65	1.89e-31	Exhaled nitric oxide output;
KIRP	cis	rs7692976	0.608	rs2190907	chr4:110885868	T/C	cg06981781	chr4:110842888	EGF	-0.23	-5.15	-0.31	5.35e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs12230513	0.732	rs7294659	chr12:55866519	T/C	cg11794356	chr12:55725991	OR6C3	-0.52	-6.33	-0.37	1.17e-9	Contrast sensitivity;
KIRP	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.94	-0.3	1.43e-6	Schizophrenia;
KIRP	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.9	-10.35	-0.55	4.46e-21	White matter hyperintensity burden;
KIRP	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg21548813	chr6:291882	DUSP22	-0.52	-6.03	-0.36	6.12e-9	Menopause (age at onset);
KIRP	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.2	13.21	0.64	1.84e-30	Nonalcoholic fatty liver disease;
KIRP	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.48	6.67	0.39	1.72e-10	Red blood cell count;
KIRP	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	0.73	6.77	0.4	9.4e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9653442	0.545	rs11681966	chr2:100759457	A/C	cg17356467	chr2:100759845	AFF3	-0.44	-5.85	-0.35	1.52e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.11	-0.46	2.39e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.92	14.02	0.67	3.18e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.8	7.98	0.45	5.57e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg26585981	chr11:48327164	OR4S1	-0.41	-5.17	-0.31	4.85e-7	Coronary artery disease;
KIRP	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.4	0.7	6.37e-38	Gut microbiome composition (summer);
KIRP	cis	rs11955175	1.000	rs79575541	chr5:40672422	C/G	cg04002187	chr5:40835754	RPL37	0.67	5.41	0.33	1.5e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg11641102	chr8:27183873	PTK2B	0.47	6.11	0.36	3.89e-9	Neuroticism;
KIRP	cis	rs2882667	0.931	rs13153618	chr5:138352776	C/A	cg04439458	chr5:138467593	SIL1	-0.43	-7.36	-0.42	2.74e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.46	5.73	0.34	2.91e-8	Multiple sclerosis;
KIRP	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.63	8.06	0.46	3.22e-14	Height;
KIRP	cis	rs12413816	0.824	rs1571008	chr10:13760776	T/C	cg16485048	chr10:13749193	FRMD4A	0.64	9.26	0.51	1.06e-17	Red cell distribution width;
KIRP	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.49	5.78	0.35	2.31e-8	Mean corpuscular hemoglobin;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16656078	chr5:95278638	ELL2	-0.44	-6.41	-0.38	7.43e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	ch.11.42038R	chr11:967971	AP2A2	0.41	5.38	0.32	1.75e-7	Alzheimer's disease (late onset);
KIRP	cis	rs697003	0.520	rs7551341	chr1:211824893	C/T	cg09811860	chr1:211803715	NA	-0.32	-4.94	-0.3	1.41e-6	Red cell distribution width;
KIRP	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.7	-11.45	-0.59	1.28e-24	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.06	-0.31	8.16e-7	Life satisfaction;
KIRP	cis	rs4262150	0.580	rs2964249	chr5:151916766	G/T	cg12297329	chr5:152029980	NA	-0.56	-7.25	-0.42	5.53e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg04865290	chr3:52927548	TMEM110	-0.46	-4.89	-0.3	1.82e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg02138098	chr1:2040968	PRKCZ	-0.45	-6.15	-0.37	3.08e-9	Height;
KIRP	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg16606324	chr3:10149918	C3orf24	0.58	5.37	0.32	1.81e-7	Alzheimer's disease;
KIRP	cis	rs12476592	0.602	rs6724160	chr2:63786423	G/C	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.82	0.63	3.63e-29	Platelet count;
KIRP	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-4.98	-0.3	1.22e-6	Height;
KIRP	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.2	-0.46	1.36e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg04025307	chr7:1156635	C7orf50	0.86	12.74	0.63	6.87e-29	Longevity;Endometriosis;
KIRP	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-4.9	-0.3	1.78e-6	Neutrophil percentage of white cells;
KIRP	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.7	-7.6	-0.44	6.09e-13	Gut microbiome composition (summer);
KIRP	cis	rs2290402	0.536	rs58429160	chr4:875266	G/A	cg14517359	chr4:903473	GAK	-0.55	-6.09	-0.36	4.37e-9	Type 2 diabetes;
KIRP	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-1.06	-12.6	-0.63	2.08e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7565981	1.000	rs59341306	chr2:101428743	C/A	cg02232089	chr2:101440696	NPAS2	-0.57	-5.23	-0.32	3.63e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.91	-0.45	8.52e-14	Homocysteine levels;
KIRP	cis	rs12780845	0.931	rs7095324	chr10:17250900	G/T	cg01003015	chr10:17271136	VIM	0.52	5.74	0.34	2.76e-8	Homocysteine levels;
KIRP	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.25	-0.42	5.48e-12	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg03468072	chr12:39539422	NA	-0.41	-5.98	-0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg13147721	chr7:65941812	NA	-0.93	-6.55	-0.39	3.4e-10	Diabetic kidney disease;
KIRP	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.71	11.2	0.58	8.74e-24	Resting heart rate;
KIRP	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.61	-8.06	-0.46	3.41e-14	Blood protein levels;
KIRP	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg25600027	chr14:23388339	RBM23	-0.51	-6.26	-0.37	1.74e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg04998671	chr14:104000505	TRMT61A	-0.54	-6.38	-0.38	8.83e-10	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg16141378	chr3:129829833	LOC729375	-0.59	-7.8	-0.45	1.73e-13	Mood instability;
KIRP	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05601917	chr6:125855416	NA	0.33	4.9	0.3	1.74e-6	Endometrial cancer;
KIRP	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg09631192	chr20:23583594	CST9	-0.52	-5.17	-0.31	4.9e-7	Chronic kidney disease;
KIRP	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-8.34	-0.47	5.24e-15	Colorectal cancer;
KIRP	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg22906224	chr7:99728672	NA	-0.5	-6.12	-0.36	3.58e-9	Coronary artery disease;
KIRP	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.66	-0.39	1.73e-10	Response to antipsychotic treatment;
KIRP	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-7.31	-0.42	3.69e-12	Myopia (pathological);
KIRP	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg15605315	chr1:45957053	TESK2	-0.43	-5.54	-0.33	7.71e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6088813	1.000	rs6142360	chr20:33960486	T/C	cg14752227	chr20:34000481	UQCC	-0.49	-6.07	-0.36	4.83e-9	Height;
KIRP	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg21204522	chr6:27730016	NA	-0.75	-5.53	-0.33	7.99e-8	Breast cancer;
KIRP	cis	rs11605924	0.819	rs12805422	chr11:45839889	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.51	-6.36	-0.38	9.87e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg02811702	chr13:24901961	NA	0.42	5.53	0.33	8.01e-8	Obesity-related traits;
KIRP	cis	rs11637445	0.640	rs4508380	chr15:68109049	G/A	cg24579218	chr15:68104479	NA	-0.43	-6.53	-0.38	3.65e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.3	-0.37	1.4e-9	IgG glycosylation;
KIRP	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.72	10.45	0.55	2.12e-21	Hip circumference;
KIRP	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.89	10.58	0.56	8.56e-22	Smoking behavior;
KIRP	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.87	8.61	0.48	8.75e-16	Platelet distribution width;
KIRP	cis	rs10875746	0.855	rs10875730	chr12:48427875	A/T	cg20731937	chr12:48336164	NA	0.41	5.28	0.32	2.83e-7	Longevity (90 years and older);
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.72	10.67	0.56	4.36e-22	Menarche (age at onset);
KIRP	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs6594713	0.679	rs66572866	chr5:112761470	G/A	cg12552261	chr5:112820674	MCC	0.6	5.35	0.32	2.04e-7	Brain cytoarchitecture;
KIRP	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15206981	chr4:124323013	SPRY1	0.43	6.08	0.36	4.46e-9	Interleukin-4 levels;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg07582204	chr3:43275279	NA	0.5	6.34	0.37	1.1e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg24804195	chr5:87968844	LOC645323	-0.47	-6.18	-0.37	2.59e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-5.26	-0.32	3.08e-7	Metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01631764	chr19:460135	SHC2	0.49	6.99	0.41	2.5e-11	Parkinson's disease;
KIRP	cis	rs6142102	0.886	rs6059583	chr20:32532114	T/G	cg24642439	chr20:33292090	TP53INP2	0.56	6.0	0.36	6.91e-9	Skin pigmentation;
KIRP	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg13906792	chr15:75199810	C15orf17	-0.37	-5.64	-0.34	4.74e-8	Breast cancer;
KIRP	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	4.85	0.3	2.21e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg21605333	chr4:119757512	SEC24D	1.52	11.71	0.6	1.78e-25	Cannabis dependence symptom count;
KIRP	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.62	7.77	0.44	2.09e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09636849	chr2:96658648	NA	0.56	6.11	0.36	3.88e-9	Lung cancer in ever smokers;
KIRP	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.62	-0.52	8.39e-19	Aortic root size;
KIRP	cis	rs6568686	0.627	rs174374	chr6:111906055	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.52	5.15	0.31	5.24e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs7546668	0.947	rs3737705	chr1:15911349	G/A	cg21858823	chr1:15850916	CASP9	0.46	4.97	0.3	1.26e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.28	-0.32	2.88e-7	Coronary artery disease;
KIRP	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.75	-10.57	-0.56	9.24e-22	Body mass index;
KIRP	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	14.08	0.67	2.09e-33	Alzheimer's disease;
KIRP	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg21858823	chr1:15850916	CASP9	0.54	5.74	0.34	2.81e-8	Systolic blood pressure;
KIRP	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.78	7.64	0.44	4.99e-13	Pediatric areal bone mineral density (radius);
KIRP	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg21184320	chr1:21044207	KIF17	0.46	6.7	0.39	1.41e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs9650657	0.741	rs10100333	chr8:10584288	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.6	-0.39	2.5e-10	Neuroticism;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg22478328	chr22:32340140	C22orf24;YWHAH	0.56	6.57	0.39	2.95e-10	Sleep duration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08438126	chr13:41635362	WBP4	0.48	6.33	0.37	1.14e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.56	6.43	0.38	6.7e-10	Uric acid levels;
KIRP	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.54	-0.48	1.4e-15	Joint mobility (Beighton score);
KIRP	cis	rs259842	0.612	rs1351416	chr2:180708348	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.41	-5.59	-0.34	5.96e-8	Blood protein levels;
KIRP	cis	rs1832871	0.643	rs112195967	chr6:158775695	C/T	cg07215822	chr6:158701037	NA	-0.63	-7.28	-0.42	4.51e-12	Height;
KIRP	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.6	-6.73	-0.39	1.15e-10	Subjective well-being;
KIRP	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-6.6	-0.39	2.48e-10	Aortic root size;
KIRP	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg01566213	chr4:1579287	NA	0.34	4.88	0.3	1.89e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs6969780	0.915	rs12666919	chr7:27189498	A/T	cg17457637	chr7:27170717	HOXA4	-0.37	-4.87	-0.3	1.96e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg20999797	chr1:1681921	NA	-0.53	-8.36	-0.47	4.53e-15	Body mass index;
KIRP	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg00784671	chr22:46762841	CELSR1	-0.84	-8.26	-0.47	8.93e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.52	6.47	0.38	5.2e-10	Longevity;
KIRP	cis	rs2235642	0.551	rs1966171	chr16:1562804	G/A	cg06689990	chr16:1547486	TELO2	-0.41	-5.18	-0.31	4.68e-7	Coronary artery disease;
KIRP	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.32	-6.11	-0.36	3.95e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs6499755	0.897	rs8046197	chr16:55346012	A/C	cg05099576	chr16:55362342	IRX6	0.27	5.64	0.34	4.74e-8	Hypospadias;
KIRP	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg00484396	chr16:3507460	NAT15	0.53	5.3	0.32	2.6e-7	Tuberculosis;
KIRP	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.49	7.42	0.43	1.89e-12	Total body bone mineral density;
KIRP	cis	rs1448094	0.872	rs7311150	chr12:86435989	A/T	cg02569458	chr12:86230093	RASSF9	0.35	5.02	0.31	9.71e-7	Major depressive disorder;
KIRP	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.63	-6.95	-0.41	3.18e-11	Neuroticism;
KIRP	cis	rs829661	0.793	rs895665	chr2:30854803	G/A	cg10949345	chr2:30726833	LCLAT1	1.11	13.46	0.65	2.55e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	11.83	0.6	7.56e-26	Chronic sinus infection;
KIRP	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.76	-10.83	-0.57	1.33e-22	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg03959625	chr15:84868606	LOC388152	0.72	8.6	0.48	9.33e-16	Schizophrenia;
KIRP	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg08885076	chr2:99613938	TSGA10	-0.38	-5.74	-0.34	2.79e-8	Bipolar disorder;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02725872	chr8:58115012	NA	0.72	7.83	0.45	1.41e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19676328	chr12:49525230	TUBA1B	-0.55	-6.04	-0.36	5.75e-9	Total cholesterol levels;
KIRP	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.5	-6.5	-0.38	4.33e-10	Age at first birth;
KIRP	cis	rs71597109	0.639	rs35194352	chr4:102726594	T/C	cg14855874	chr4:102712397	BANK1	0.4	5.2	0.31	4.14e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg19847130	chr8:10466454	RP1L1	0.41	6.1	0.36	4.05e-9	Neuroticism;
KIRP	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg05775895	chr3:12838266	CAND2	0.4	6.98	0.41	2.77e-11	QRS complex (12-leadsum);
KIRP	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	0.84	7.39	0.43	2.33e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg06121193	chr1:90282411	NA	-0.51	-7.36	-0.42	2.77e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-7.73	-0.44	2.77e-13	Self-reported allergy;
KIRP	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.24	0.37	1.92e-9	Menarche (age at onset);
KIRP	cis	rs4363385	0.510	rs56241316	chr1:152901748	A/G	cg25856811	chr1:152973957	SPRR3	-0.4	-5.48	-0.33	1.03e-7	Inflammatory skin disease;
KIRP	cis	rs42648	0.869	rs1015403	chr7:89913702	A/G	cg25739043	chr7:89950458	NA	-0.47	-7.36	-0.42	2.7e-12	Homocysteine levels;
KIRP	cis	rs1519814	1.000	rs6469902	chr8:121171911	A/T	cg22335954	chr8:121166405	COL14A1	-0.66	-6.45	-0.38	5.91e-10	Breast cancer;
KIRP	cis	rs2441986	0.861	rs11605537	chr11:57944616	A/G	cg19752551	chr11:57585705	CTNND1	-0.42	-5.08	-0.31	7.31e-7	Systolic blood pressure;
KIRP	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg01877450	chr7:97915802	BRI3	-0.55	-7.17	-0.42	8.9e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.71	-0.39	1.33e-10	Joint mobility (Beighton score);
KIRP	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg05220968	chr6:146057943	EPM2A	-0.43	-5.55	-0.33	7.48e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.75	0.44	2.39e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg04398451	chr17:18023971	MYO15A	-0.65	-8.7	-0.48	4.94e-16	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15622697	chr1:201924833	TIMM17A	0.48	6.32	0.37	1.19e-9	Parkinson's disease;
KIRP	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	trans	rs7010267	0.503	rs13264172	chr8:120012861	T/A	cg22961513	chr11:14280813	SPON1	0.36	6.15	0.37	3.18e-9	Total body bone mineral density (age 45-60);
KIRP	cis	rs4356932	0.691	rs9307050	chr4:76905649	G/A	cg00809888	chr4:76862425	NAAA	0.5	7.03	0.41	2.03e-11	Blood protein levels;
KIRP	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg01831904	chr17:28903510	LRRC37B2	0.64	5.23	0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11945232	0.624	rs112791869	chr4:88369598	A/G	cg23841344	chr4:88312519	HSD17B11	-0.6	-6.58	-0.39	2.78e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg10050877	chr8:130952333	FAM49B	-0.53	-6.08	-0.36	4.49e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg02570527	chr1:10970165	NA	-0.41	-4.91	-0.3	1.69e-6	Body mass index;
KIRP	cis	rs7809615	0.748	rs35183025	chr7:99030782	A/T	cg24024660	chr7:99195788	NA	-0.56	-4.91	-0.3	1.67e-6	Blood metabolite ratios;
KIRP	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.8	-9.63	-0.52	8.04e-19	Body mass index;
KIRP	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg19592336	chr6:28129416	ZNF389	0.49	5.55	0.33	7.47e-8	Depression;
KIRP	cis	rs3774830	0.811	rs2654501	chr4:5432416	T/C	cg26943120	chr4:5472116	STK32B	-0.24	-5.74	-0.34	2.8e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12431939	1.000	rs34063246	chr14:51663719	G/C	cg23942311	chr14:51606299	NA	-0.57	-4.99	-0.3	1.16e-6	Cancer;
KIRP	cis	rs71636778	1.000	rs71636778	chr1:27104612	T/C	cg12203394	chr1:27248618	NUDC	0.68	5.38	0.32	1.7e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.57	-6.59	-0.39	2.67e-10	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10222474	chr8:103822809	NA	0.45	6.05	0.36	5.36e-9	Parkinson's disease;
KIRP	cis	rs7565981	1.000	rs17024814	chr2:101426316	G/A	cg02232089	chr2:101440696	NPAS2	-0.57	-5.3	-0.32	2.59e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4908768	0.535	rs2708628	chr1:8450448	T/C	cg03610117	chr1:8450231	RERE	-0.71	-8.86	-0.49	1.65e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.86	-11.1	-0.58	1.79e-23	Cognitive function;
KIRP	trans	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg16141378	chr3:129829833	LOC729375	0.48	6.34	0.37	1.1e-9	Mood instability;
KIRP	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.94	9.29	0.51	8.56e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.13e-51	Leprosy;
KIRP	cis	rs16854884	0.770	rs7621093	chr3:143814542	C/G	cg06585982	chr3:143692056	C3orf58	0.39	4.85	0.3	2.16e-6	Economic and political preferences (feminism/equality);
KIRP	cis	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg04608330	chr12:45269318	NELL2	-0.42	-5.94	-0.35	9.46e-9	Gut microbiome composition (summer);
KIRP	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg09264619	chr17:80180166	NA	0.51	6.09	0.36	4.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.37	7.41	0.43	2.07e-12	Diastolic blood pressure;
KIRP	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17376030	chr22:41985996	PMM1	-0.83	-9.02	-0.5	5.41e-17	Vitiligo;
KIRP	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg01620082	chr3:125678407	NA	-0.97	-6.93	-0.4	3.6e-11	Depression;
KIRP	cis	rs2072732	0.861	rs12567620	chr1:2956999	T/G	cg11731671	chr1:2995604	PRDM16	-0.42	-5.23	-0.32	3.59e-7	Plateletcrit;
KIRP	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	5.67	0.34	3.93e-8	Blood metabolite levels;
KIRP	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-1.06	-12.73	-0.63	7.39e-29	Exhaled nitric oxide output;
KIRP	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg12315302	chr6:26189340	HIST1H4D	0.93	6.37	0.38	9.11e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs56176358	1.000	rs56176358	chr17:41920653	C/T	cg26893861	chr17:41843967	DUSP3	0.78	4.91	0.3	1.62e-6	Alzheimer disease and age of onset;
KIRP	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.01	12.76	0.63	5.75e-29	Testicular germ cell tumor;
KIRP	cis	rs11671005	0.656	rs55928441	chr19:59009674	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.6	-5.98	-0.36	7.73e-9	Mean platelet volume;
KIRP	cis	rs1978968	0.640	rs2083882	chr22:18395241	C/T	cg03078520	chr22:18463400	MICAL3	0.64	7.98	0.45	5.57e-14	Presence of antiphospholipid antibodies;
KIRP	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.56	-6.12	-0.36	3.57e-9	DNA methylation (variation);
KIRP	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg07148914	chr20:33460835	GGT7	-0.55	-7.23	-0.42	5.92e-12	Height;
KIRP	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.55	6.99	0.41	2.56e-11	Crohn's disease;
KIRP	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.74	9.23	0.51	1.27e-17	Resting heart rate;
KIRP	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.4	-0.38	7.69e-10	Coronary artery disease;
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.85	11.57	0.59	5.36e-25	Longevity;
KIRP	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.13	-0.69	5.28e-37	Headache;
KIRP	cis	rs6142102	0.961	rs2235596	chr20:32684309	A/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-6.8	-0.4	7.67e-11	Skin pigmentation;
KIRP	cis	rs6005807	0.719	rs9625513	chr22:29022172	C/T	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	trans	rs7939886	0.841	rs1905053	chr11:56011848	C/T	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.31	0.32	2.5e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10267417	0.603	rs10272491	chr7:19946987	T/G	cg05791153	chr7:19748676	TWISTNB	0.5	4.94	0.3	1.47e-6	Night sleep phenotypes;
KIRP	cis	rs7809615	1.000	rs7809615	chr7:99184778	G/T	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite ratios;
KIRP	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg24315340	chr6:146058215	EPM2A	0.39	4.95	0.3	1.4e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.55	7.7	0.44	3.3e-13	Huntington's disease progression;
KIRP	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.71	8.67	0.48	6.12e-16	Neutrophil percentage of white cells;
KIRP	cis	rs7175404	0.793	rs28528354	chr15:94034775	C/A	cg23502883	chr15:93959149	NA	0.44	5.33	0.32	2.22e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00321850	chr1:175162397	KIAA0040	-0.34	-6.08	-0.36	4.68e-9	Alcohol dependence;
KIRP	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.65	-8.3	-0.47	6.87e-15	Iron status biomarkers;
KIRP	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg04398451	chr17:18023971	MYO15A	-0.89	-13.11	-0.64	3.87e-30	Total body bone mineral density;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4690686	0.500	rs12498752	chr4:177265451	T/C	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg04226714	chr8:49833948	SNAI2	-0.5	-6.87	-0.4	5.22e-11	Life satisfaction;
KIRP	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg24315340	chr6:146058215	EPM2A	0.42	5.31	0.32	2.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg06521852	chr22:38141419	TRIOBP	0.38	5.3	0.32	2.57e-7	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.19	-0.31	4.5e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg16482183	chr6:26056742	HIST1H1C	0.44	5.59	0.34	6e-8	Height;
KIRP	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs7656342	0.569	rs4613568	chr4:9862902	T/G	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.16	-0.37	2.89e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7546094	0.846	rs4838959	chr1:113085721	G/T	cg22162597	chr1:113214053	CAPZA1	-0.42	-5.47	-0.33	1.08e-7	Platelet distribution width;
KIRP	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg01872077	chr2:219646372	CYP27A1	0.4	5.21	0.32	3.99e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg12315302	chr6:26189340	HIST1H4D	0.97	6.83	0.4	6.66e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.7e-10	Red blood cell count;
KIRP	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.66	0.34	4.29e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs714027	0.546	rs5763614	chr22:30331290	A/G	cg27665648	chr22:30112403	NA	0.42	5.65	0.34	4.45e-8	Lymphocyte counts;
KIRP	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.87	-7.18	-0.42	8.1e-12	Smoking behavior;
KIRP	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.75	5.75	0.34	2.65e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.87	12.77	0.63	5.59e-29	Eosinophil percentage of white cells;
KIRP	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.33e-13	Morning vs. evening chronotype;
KIRP	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg13679303	chr9:96623674	NA	0.44	5.88	0.35	1.35e-8	DNA methylation (variation);
KIRP	cis	rs2224391	0.590	rs17140068	chr6:5282227	T/G	cg13962347	chr6:5174647	LYRM4	-0.59	-6.06	-0.36	5.11e-9	Height;
KIRP	cis	rs5747327	0.839	rs1470341	chr22:18198109	G/A	cg19898043	chr22:18121309	BCL2L13	-0.44	-5.49	-0.33	9.88e-8	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.91	-0.35	1.15e-8	IgG glycosylation;
KIRP	cis	rs7178572	0.889	rs869301	chr15:77830633	T/C	cg12131826	chr15:77904385	NA	0.45	5.79	0.35	2.11e-8	Type 2 diabetes;
KIRP	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg04310649	chr10:35416472	CREM	0.59	7.15	0.41	9.82e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg04804543	chr8:142233427	SLC45A4	-1.02	-17.71	-0.75	8.42e-46	Immature fraction of reticulocytes;
KIRP	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.9	-10.31	-0.55	6.09e-21	Corneal astigmatism;
KIRP	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg06108461	chr20:60628389	TAF4	-0.55	-6.87	-0.4	5.37e-11	Body mass index;
KIRP	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.11	-0.31	6.59e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7221595	0.778	rs62072386	chr17:3896168	T/C	cg05562828	chr17:3906858	NA	0.57	6.8	0.4	8.03e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs8113308	0.748	rs7251478	chr19:52482511	G/A	cg25782003	chr19:52490127	ZNF350	0.6	5.43	0.33	1.35e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs273218	1.000	rs168861	chr5:53377310	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.63	6.92	0.4	3.96e-11	Migraine;
KIRP	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.87	-0.4	5.28e-11	Aortic root size;
KIRP	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.77	0.4	9.4e-11	Diabetic retinopathy;
KIRP	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.58	-0.34	6.33e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.58	7.91	0.45	8.8e-14	Prostate cancer;
KIRP	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.98	0.54	6.29e-20	Total body bone mineral density;
KIRP	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.17	-0.46	1.64e-14	Triglycerides;
KIRP	cis	rs4776059	1.000	rs11858743	chr15:52936330	G/A	cg25063058	chr15:52860530	ARPP19	0.53	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.82	11.37	0.59	2.42e-24	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg24642439	chr20:33292090	TP53INP2	0.66	10.09	0.54	2.95e-20	Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.84	-0.53	1.76e-19	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24241925	chr17:46125675	NFE2L1	0.46	6.13	0.36	3.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.16	-0.46	1.68e-14	Neuroticism;
KIRP	cis	rs258892	0.895	rs10070210	chr5:72046042	A/G	cg21869765	chr5:72125136	TNPO1	-0.5	-5.64	-0.34	4.56e-8	Small cell lung carcinoma;
KIRP	cis	rs7554547	0.667	rs4846072	chr1:11950391	T/C	cg07603449	chr1:11986842	KIAA2013	-0.43	-5.67	-0.34	4.01e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.95	16.78	0.73	1.26e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs1021993	0.545	rs17014370	chr1:209540091	C/T	cg24446417	chr1:209558027	NA	-0.51	-5.64	-0.34	4.76e-8	Gut microbiome composition (winter);
KIRP	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.46e-11	Hypertriglyceridemia;
KIRP	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.82	7.35	0.42	2.89e-12	Obesity-related traits;
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.7	-10.18	-0.54	1.59e-20	Monocyte percentage of white cells;
KIRP	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg01620082	chr3:125678407	NA	-0.88	-6.44	-0.38	6.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs501120	0.925	rs1632484	chr10:44773984	C/T	cg09554077	chr10:44749378	NA	0.62	8.69	0.48	5.07e-16	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.56	-5.4	-0.33	1.56e-7	Narcolepsy;
KIRP	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-12.61	-0.63	1.81e-28	Vitiligo;
KIRP	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg01879757	chr17:41196368	BRCA1	0.5	7.21	0.42	6.98e-12	Menopause (age at onset);
KIRP	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.54	7.24	0.42	5.87e-12	Mean corpuscular volume;
KIRP	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.35	-0.42	2.88e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6850606	0.577	rs35323328	chr4:42853662	G/A	cg24533989	chr4:42659536	ATP8A1	0.44	4.89	0.3	1.86e-6	Interferon alpha levels in systemic lupus erythematosus;
KIRP	cis	rs35883536	0.967	rs4991930	chr1:101122755	T/C	cg06223162	chr1:101003688	GPR88	0.33	6.68	0.39	1.59e-10	Monocyte count;
KIRP	cis	rs2273156	1.000	rs12880809	chr14:35475656	A/G	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.45	-0.33	1.25e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs7224685	0.569	rs34357603	chr17:4008760	G/A	cg11204139	chr17:3907470	NA	0.53	5.07	0.31	7.95e-7	Type 2 diabetes;
KIRP	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg19507638	chr5:93509721	C5orf36	-0.59	-5.07	-0.31	7.92e-7	Diabetic retinopathy;
KIRP	cis	rs7017914	0.934	rs7015035	chr8:71653601	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.95	15.24	0.7	2.3e-37	Testicular germ cell tumor;
KIRP	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.81e-8	Body mass index;
KIRP	cis	rs6545883	0.894	rs2694634	chr2:61551435	T/C	cg15711740	chr2:61764176	XPO1	0.59	7.75	0.44	2.41e-13	Tuberculosis;
KIRP	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.56	-5.07	-0.31	7.74e-7	Blood pressure (smoking interaction);
KIRP	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg03161606	chr19:29218774	NA	0.76	6.84	0.4	6.15e-11	Methadone dose in opioid dependence;
KIRP	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.88	0.35	1.3e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.5	-7.36	-0.42	2.71e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.38	-5.69	-0.34	3.62e-8	Body mass index;
KIRP	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg05785598	chr3:49045655	WDR6	0.28	4.98	0.3	1.17e-6	Parkinson's disease;
KIRP	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg09699651	chr6:150184138	LRP11	0.46	5.92	0.35	1.09e-8	Lung cancer;
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22168489	chr12:122356033	WDR66	0.57	8.52	0.48	1.61e-15	Mean corpuscular volume;
KIRP	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.93	10.91	0.57	7.49e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.22	0.37	2.08e-9	Lung cancer;
KIRP	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-14.49	-0.68	7.91e-35	Primary sclerosing cholangitis;
KIRP	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg08761264	chr16:28874980	SH2B1	0.45	5.0	0.3	1.09e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9972944	0.729	rs10083875	chr17:63773303	T/C	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs10875746	0.669	rs10875770	chr12:48600520	A/G	cg26205652	chr12:48591994	NA	0.6	8.09	0.46	2.75e-14	Longevity (90 years and older);
KIRP	cis	rs2574975	0.679	rs2842105	chr10:52131167	A/G	cg10034176	chr10:52120283	SGMS1	-0.53	-7.23	-0.42	5.95e-12	Response to amphetamines;
KIRP	cis	rs981844	1.000	rs62325093	chr4:154669733	G/A	cg14289246	chr4:154710475	SFRP2	0.67	7.54	0.43	9.09e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs4356932	1.000	rs4484324	chr4:76984713	G/A	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.62	7.9	0.45	9.25e-14	Coronary artery disease;
KIRP	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg02903104	chr8:1507517	DLGAP2	0.38	5.83	0.35	1.78e-8	Lung cancer;
KIRP	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.68	-8.07	-0.46	3.17e-14	Blood protein levels;
KIRP	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.77	-0.44	2.1e-13	Body mass index;
KIRP	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.68e-7	Life satisfaction;
KIRP	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.58	-7.12	-0.41	1.2e-11	Aortic root size;
KIRP	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.7	10.63	0.56	5.67e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg09344028	chr17:70110421	NA	0.4	8.13	0.46	2.06e-14	Thyroid hormone levels;
KIRP	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg13939156	chr17:80058883	NA	-0.48	-5.65	-0.34	4.5e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-1.08	-10.52	-0.56	1.34e-21	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.69	-9.94	-0.54	8.87e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.72	-10.59	-0.56	7.88e-22	Blood metabolite levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	ch.8.20603847F	chr8:20559567	NA	0.9	6.11	0.36	3.89e-9	P wave terminal force;
KIRP	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg18093559	chr17:18951025	GRAP	0.52	6.33	0.37	1.15e-9	Schizophrenia;
KIRP	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg23601095	chr6:26197514	HIST1H3D	-0.87	-6.95	-0.4	3.36e-11	Gout;Renal underexcretion gout;
KIRP	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.63	-7.82	-0.45	1.52e-13	Metabolite levels;
KIRP	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.44	-5.71	-0.34	3.17e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs963731	0.649	rs74258982	chr2:39344474	T/C	cg04010122	chr2:39346883	SOS1	0.93	6.39	0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs7015630	0.657	rs34525502	chr8:90852580	C/T	cg18493113	chr8:90847772	NA	-0.48	-5.03	-0.31	9.64e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24579424	chr1:214557928	PTPN14	-0.39	-6.08	-0.36	4.55e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg04398451	chr17:18023971	MYO15A	0.67	9.26	0.51	1.04e-17	Total body bone mineral density;
KIRP	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22117172	chr7:91764530	CYP51A1	0.51	7.19	0.42	7.87e-12	Breast cancer;
KIRP	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.52	-6.19	-0.37	2.51e-9	Diastolic blood pressure;
KIRP	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.89	11.77	0.6	1.19e-25	Gestational age at birth (maternal effect);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15973369	chr2:147344230	PABPC1P2	0.42	6.56	0.39	3.14e-10	Survival in pancreatic cancer;
KIRP	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg19142026	chr7:27170394	HOXA4	-0.42	-5.96	-0.35	8.91e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	10.42	0.55	2.74e-21	Chronic sinus infection;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg08132940	chr7:1081526	C7orf50	-0.46	-5.29	-0.32	2.69e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg04154034	chr17:28927549	LRRC37B2	0.53	5.06	0.31	8.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs526231	0.543	rs27698	chr5:102526175	C/T	cg23492399	chr5:102201601	PAM	0.49	5.34	0.32	2.1e-7	Primary biliary cholangitis;
KIRP	cis	rs2299587	0.554	rs2073564	chr8:17743341	G/A	cg01800426	chr8:17659068	MTUS1	-0.45	-5.4	-0.33	1.54e-7	Economic and political preferences;
KIRP	cis	rs9810890	1.000	rs73198869	chr3:128530365	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs1263173	0.566	rs4225	chr11:116703671	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.44	5.17	0.31	4.75e-7	HDL cholesterol;
KIRP	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.67	-0.34	4.03e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.19	0.46	1.39e-14	Menopause (age at onset);
KIRP	cis	rs12190007	0.776	rs2981941	chr6:169786911	G/A	cg15038512	chr6:170123185	PHF10	-0.42	-5.65	-0.34	4.4e-8	Obesity-related traits;
KIRP	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.22	-0.37	2.13e-9	Joint mobility (Beighton score);
KIRP	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.54	6.63	0.39	2.13e-10	Height;
KIRP	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.47	5.68	0.34	3.73e-8	Multiple sclerosis;
KIRP	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.21	0.51	1.46e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07818830	chr12:76953439	OSBPL8	0.51	6.6	0.39	2.5e-10	Parkinson's disease;
KIRP	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.39	-0.32	1.65e-7	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15170644	chr5:80901358	SSBP2	-0.41	-6.24	-0.37	1.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.64	-8.95	-0.5	8.65e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4778581	0.506	rs4778580	chr15:80363161	G/A	cg08257866	chr15:80351198	ZFAND6	0.52	5.45	0.33	1.21e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.35	19.06	0.77	2.43e-50	Corneal structure;
KIRP	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.82	-8.14	-0.46	2e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs526231	0.512	rs28022	chr5:102464367	T/C	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.35	1.27e-8	Primary biliary cholangitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04483163	chr1:147806437	NA	0.42	6.41	0.38	7.55e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg15534755	chr11:117069859	TAGLN	0.46	5.73	0.34	2.93e-8	Blood protein levels;
KIRP	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.58	6.35	0.38	1.02e-9	Alcohol dependence;
KIRP	cis	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg21625330	chr8:9911636	MSRA	0.39	4.94	0.3	1.46e-6	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.54	7.18	0.42	8.47e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19005763	chr3:58225528	ABHD6	0.44	6.16	0.37	3.01e-9	Survival in pancreatic cancer;
KIRP	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	8.95	0.5	8.63e-17	Total body bone mineral density;
KIRP	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg13939156	chr17:80058883	NA	0.47	5.6	0.34	5.86e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4523957	0.583	rs2984940	chr17:2023825	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-0.77	-8.73	-0.49	4.02e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs77633900	0.772	rs157788	chr15:76806011	T/C	cg21673338	chr15:77095150	SCAPER	-0.63	-5.82	-0.35	1.87e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs9596863	0.808	rs9596842	chr13:54280203	C/T	ch.13.53330881F	chr13:54432880	NA	0.54	4.96	0.3	1.29e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg05340658	chr4:99064831	C4orf37	0.61	6.25	0.37	1.83e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg18154014	chr19:37997991	ZNF793	0.75	7.66	0.44	4.38e-13	Coronary artery calcification;
KIRP	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.67	-0.44	4.03e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17543885	chr6:151562429	AKAP12	0.48	6.26	0.37	1.7e-9	Smoking initiation;
KIRP	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.57	-0.48	1.16e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.02	0.36	6.19e-9	Menopause (age at onset);
KIRP	trans	rs199950	0.911	rs199948	chr1:181599033	G/A	cg04237608	chr1:18659049	IGSF21	0.39	6.56	0.39	3.22e-10	Body mass index (change over time);
KIRP	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg22681709	chr2:178499509	PDE11A	-0.62	-8.0	-0.45	4.94e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6466055	0.589	rs888086	chr7:104626690	G/A	cg04380332	chr7:105027541	SRPK2	-0.4	-5.36	-0.32	1.94e-7	Schizophrenia;
KIRP	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg00857998	chr1:205179979	DSTYK	0.51	6.44	0.38	6.14e-10	Red blood cell count;
KIRP	cis	rs12580194	0.556	rs12099811	chr12:55731200	T/A	cg11794356	chr12:55725991	OR6C3	-0.61	-8.75	-0.49	3.44e-16	Cancer;
KIRP	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.65	6.87	0.4	5.2e-11	Mammographic density (dense area);
KIRP	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg11584989	chr19:19387371	SF4	0.41	5.28	0.32	2.81e-7	Tonsillectomy;
KIRP	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.78	-0.35	2.3e-8	Schizophrenia;
KIRP	cis	rs501120	0.929	rs2576355	chr10:44750362	A/G	cg09554077	chr10:44749378	NA	0.74	12.39	0.62	1.01e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10465746	0.775	rs4907186	chr1:84340753	G/T	cg10977910	chr1:84465055	TTLL7	0.57	7.36	0.42	2.78e-12	Obesity-related traits;
KIRP	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.63	-8.46	-0.47	2.34e-15	Colorectal cancer;
KIRP	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	7.65	0.44	4.6e-13	Height;
KIRP	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg20140201	chr2:241835670	C2orf54	-0.35	-4.94	-0.3	1.42e-6	Urinary metabolites;
KIRP	cis	rs11955175	1.000	rs112239156	chr5:40649478	A/C	cg04002187	chr5:40835754	RPL37	0.69	5.55	0.33	7.44e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg26116260	chr4:7069785	GRPEL1	-0.6	-7.61	-0.44	5.76e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.4	6.7	0.39	1.37e-10	Tumor biomarkers;
KIRP	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.84	-0.35	1.67e-8	Bipolar disorder;
KIRP	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg27411982	chr8:10470053	RP1L1	-0.44	-5.67	-0.34	3.92e-8	Neuroticism;
KIRP	cis	rs11657217	0.677	rs8071194	chr17:77698458	A/C	cg06901238	chr17:77706717	ENPP7	0.41	5.49	0.33	9.93e-8	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
KIRP	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg00361562	chr2:198649771	BOLL	-0.53	-5.19	-0.31	4.41e-7	Ulcerative colitis;
KIRP	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-14.64	-0.68	2.5e-35	Primary sclerosing cholangitis;
KIRP	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.37	11.83	0.6	7.07e-26	Alzheimer's disease (late onset);
KIRP	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg16141378	chr3:129829833	LOC729375	-0.59	-7.65	-0.44	4.57e-13	Mood instability;
KIRP	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg03342759	chr3:160939853	NMD3	-0.47	-5.71	-0.34	3.23e-8	Morning vs. evening chronotype;
KIRP	cis	rs2486288	0.656	rs12908581	chr15:45548635	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.56	-6.96	-0.41	3.07e-11	Glomerular filtration rate;
KIRP	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg11783602	chr8:55087084	NA	-0.57	-7.1	-0.41	1.32e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.46	5.83	0.35	1.77e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg03152288	chr2:177042942	NA	0.65	9.24	0.51	1.23e-17	IgG glycosylation;
KIRP	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.67	8.62	0.48	8.38e-16	Height;
KIRP	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.57	5.29	0.32	2.73e-7	Major depressive disorder;
KIRP	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg24579218	chr15:68104479	NA	-0.44	-6.42	-0.38	6.88e-10	Obesity;
KIRP	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.34	-0.32	2.13e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	1.15	9.37	0.51	4.99e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs2504916	0.911	rs2504928	chr6:160853995	T/G	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.62	-6.02	-0.36	6.2e-9	Response to hepatitis C treatment;
KIRP	cis	rs1440410	0.666	rs2165302	chr4:144155897	A/T	cg01719995	chr4:144104893	USP38	0.44	6.02	0.36	6.35e-9	Ischemic stroke;
KIRP	cis	rs1448094	0.802	rs12369634	chr12:86406792	C/G	cg06740227	chr12:86229804	RASSF9	0.41	5.1	0.31	6.9e-7	Major depressive disorder;
KIRP	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg03735888	chr19:58951602	ZNF132	0.46	5.49	0.33	1.02e-7	Uric acid clearance;
KIRP	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg16576597	chr16:28551801	NUPR1	0.36	5.44	0.33	1.29e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-1.01	-17.13	-0.74	7.97e-44	Height;
KIRP	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.5	-6.52	-0.38	3.86e-10	Multiple sclerosis;
KIRP	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.22	-0.46	1.2e-14	Monocyte percentage of white cells;
KIRP	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg16898833	chr6:26189333	HIST1H4D	0.81	5.81	0.35	1.95e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg09873164	chr1:152488093	CRCT1	0.56	6.94	0.4	3.52e-11	Hair morphology;
KIRP	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.97	13.12	0.64	3.54e-30	Menopause (age at onset);
KIRP	cis	rs78487399	0.808	rs78191305	chr2:43673978	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.46	0.47	2.37e-15	Prudent dietary pattern;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.47	-4.91	-0.3	1.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg16989719	chr2:238392110	NA	-0.53	-5.9	-0.35	1.18e-8	Prostate cancer;
KIRP	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg00409905	chr10:38381863	ZNF37A	-0.58	-7.93	-0.45	7.46e-14	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs7939886	0.844	rs7118562	chr11:56050180	A/G	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.13e-8	Common traits (Other);
KIRP	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg15893493	chr8:124194847	FAM83A	0.93	7.94	0.45	7.42e-14	Urinary uromodulin levels;
KIRP	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg24699146	chr1:24152579	HMGCL	-0.44	-5.62	-0.34	5.2e-8	Immature fraction of reticulocytes;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.4	0.43	2.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg24488311	chr11:68621650	NA	0.47	5.55	0.33	7.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.37	-10.31	-0.55	5.82e-21	Diabetic kidney disease;
KIRP	cis	rs2380205	1.000	rs867052	chr10:5887183	A/G	cg27141509	chr10:5886111	NA	-0.39	-5.65	-0.34	4.45e-8	Breast cancer;
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-1.08	-21.58	-0.81	1.11e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11638815	0.520	rs4779032	chr15:83245326	A/G	cg06066596	chr15:83166174	LOC80154	-0.44	-5.62	-0.34	5.07e-8	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy;
KIRP	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.63	7.29	0.42	4.34e-12	Height;
KIRP	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	0.69	9.64	0.52	7.11e-19	Cognitive test performance;
KIRP	cis	rs6142102	0.961	rs4911385	chr20:32558593	C/A	cg08999081	chr20:33150536	PIGU	0.49	5.82	0.35	1.84e-8	Skin pigmentation;
KIRP	cis	rs7258015	1.000	rs3176768	chr19:10449665	A/G	cg25279553	chr19:10444815	RAVER1;ICAM3	-0.49	-6.38	-0.38	8.93e-10	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs2224391	0.822	rs2773321	chr6:5262220	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.72	-0.39	1.23e-10	Height;
KIRP	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.66	-7.97	-0.45	6.12e-14	Late-onset Alzheimer's disease;
KIRP	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg08975724	chr8:8085496	FLJ10661	0.61	7.99	0.45	5.17e-14	Retinal vascular caliber;
KIRP	trans	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg19694781	chr19:47549865	TMEM160	-0.51	-6.07	-0.36	4.92e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.78	10.7	0.56	3.57e-22	Aortic root size;
KIRP	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg02887458	chr19:19495540	GATAD2A	-0.5	-5.8	-0.35	2.05e-8	Bipolar disorder;
KIRP	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	0.78	7.37	0.43	2.57e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-7.53	-0.43	9.61e-13	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7011507	1.000	rs79727929	chr8:49156306	T/G	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.58	-7.22	-0.42	6.55e-12	Obesity-related traits;
KIRP	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg07796016	chr1:152779584	LCE1C	-0.45	-5.91	-0.35	1.13e-8	Inflammatory skin disease;
KIRP	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.7	-0.34	3.41e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg26695010	chr11:65641043	EFEMP2	0.47	5.31	0.32	2.49e-7	Eosinophil percentage of white cells;
KIRP	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.2e-9	Body mass index;
KIRP	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.77	-11.8	-0.6	9.19e-26	Blood metabolite ratios;
KIRP	cis	rs6565681	0.943	rs6565683	chr17:78362300	A/T	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.76	-7.55	-0.43	8.4e-13	Moyamoya disease;
KIRP	cis	rs11638352	1.000	rs4924729	chr15:44291244	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.84	-5.82	-0.35	1.82e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg01864069	chr14:103024347	NA	-0.97	-13.06	-0.64	5.98e-30	Platelet count;
KIRP	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.81	-11.77	-0.6	1.12e-25	Hip circumference adjusted for BMI;
KIRP	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.43	-5.04	-0.31	8.88e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg03161606	chr19:29218774	NA	0.59	5.09	0.31	6.97e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	8.74	0.49	3.74e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg14458575	chr2:238380390	NA	0.6	8.15	0.46	1.91e-14	Prostate cancer;
KIRP	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg22676075	chr6:135203613	NA	0.49	7.17	0.42	8.81e-12	Red blood cell count;
KIRP	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.44	5.91	0.35	1.12e-8	Hemoglobin concentration;
KIRP	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.76	8.97	0.5	7.59e-17	Corneal astigmatism;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg06642177	chr6:134496341	SGK1	0.89	6.07	0.36	4.94e-9	P wave terminal force;
KIRP	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg17145862	chr1:211918768	LPGAT1	-0.92	-12.95	-0.64	1.4e-29	Leprosy;
KIRP	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg14673194	chr17:80132900	CCDC57	-0.74	-8.02	-0.46	4.43e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4478037	0.558	rs60462824	chr3:33085929	T/C	cg19404215	chr3:33155277	CRTAP	0.9	5.68	0.34	3.78e-8	Major depressive disorder;
KIRP	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1010254	0.510	rs72808347	chr5:151760491	G/C	cg12297329	chr5:152029980	NA	-0.71	-6.92	-0.4	3.99e-11	Optic nerve measurement (cup area);
KIRP	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg23752985	chr2:85803571	VAMP8	0.6	8.84	0.49	1.92e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg00432328	chr10:76589109	MYST4	-0.43	-6.11	-0.36	3.97e-9	Select biomarker traits;
KIRP	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.67	5.88	0.35	1.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	cg21523751	chr1:182988639	NA	0.44	7.09	0.41	1.38e-11	Colorectal cancer;
KIRP	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.67	-11.6	-0.59	4.19e-25	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg01872077	chr2:219646372	CYP27A1	-0.38	-5.25	-0.32	3.23e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02303361	chr19:47354240	AP2S1	0.53	6.18	0.37	2.7e-9	Smoking initiation;
KIRP	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.46	-5.6	-0.34	5.57e-8	Diastolic blood pressure;
KIRP	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.73	8.2	0.46	1.31e-14	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17203840	chr5:134209212	TXNDC15	-0.46	-6.34	-0.37	1.09e-9	Inflammatory biomarkers;
KIRP	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.29	6.96	0.41	3.02e-11	Primary biliary cholangitis;
KIRP	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.59	7.91	0.45	8.69e-14	White matter hyperintensity burden;
KIRP	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg00262122	chr8:11665843	FDFT1	-0.41	-4.98	-0.3	1.18e-6	Neuroticism;
KIRP	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.66	-0.39	1.75e-10	Monocyte percentage of white cells;
KIRP	cis	rs911119	0.913	rs6036463	chr20:23578940	A/T	cg09631192	chr20:23583594	CST9	0.47	4.98	0.3	1.22e-6	Chronic kidney disease;
KIRP	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.35	-10.28	-0.55	7.71e-21	Diabetic kidney disease;
KIRP	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.49	-0.43	1.25e-12	Bladder cancer;
KIRP	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg13514129	chr1:39547527	MACF1	0.49	7.14	0.41	1.02e-11	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg07061783	chr6:25882402	NA	-0.5	-5.37	-0.32	1.81e-7	Urate levels;
KIRP	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg18944383	chr4:111397179	ENPEP	0.53	8.79	0.49	2.7e-16	Coronary artery disease;
KIRP	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.59	-6.35	-0.38	1.01e-9	Corneal astigmatism;
KIRP	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.7	8.59	0.48	1.01e-15	Aortic root size;
KIRP	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs78579285	0.583	rs1061238	chr16:88781850	A/G	cg09054528	chr16:88821542	FAM38A	0.53	5.0	0.3	1.07e-6	Joint mobility (Beighton score);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14202946	chr4:169931448	CBR4	0.48	6.39	0.38	8.11e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg13271783	chr10:134563150	INPP5A	-0.54	-6.79	-0.4	8.37e-11	Migraine;
KIRP	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.8	0.49	2.53e-16	IgG glycosylation;
KIRP	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.63	-0.39	2.1e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.79	-12.67	-0.63	1.16e-28	Prostate cancer;
KIRP	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.09	-18.76	-0.77	2.43e-49	Height;
KIRP	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.25	-33.84	-0.91	1.55e-94	Myeloid white cell count;
KIRP	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.54	8.17	0.46	1.61e-14	Huntington's disease progression;
KIRP	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg14784868	chr12:69753453	YEATS4	0.5	5.17	0.31	4.8e-7	Response to diuretic therapy;
KIRP	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.6	-6.56	-0.39	3.21e-10	Gut microbiome composition (summer);
KIRP	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	5.75	0.34	2.69e-8	Schizophrenia;
KIRP	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.88	-10.32	-0.55	5.41e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.63	0.34	5.02e-8	Total cholesterol levels;
KIRP	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.97	14.58	0.68	4.04e-35	Sudden cardiac arrest;
KIRP	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.12	-0.36	3.76e-9	Dupuytren's disease;
KIRP	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.64	8.78	0.49	2.77e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg22117172	chr7:91764530	CYP51A1	0.41	5.67	0.34	4.04e-8	Breast cancer;
KIRP	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg00129232	chr17:37814104	STARD3	-0.53	-6.57	-0.39	2.94e-10	Self-reported allergy;
KIRP	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.84	9.83	0.53	1.88e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11245990	chr11:68621969	NA	0.39	5.34	0.32	2.1e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.63	7.8	0.45	1.79e-13	Multiple sclerosis;
KIRP	cis	rs4523957	0.583	rs2984939	chr17:2023965	T/C	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	8.02	0.46	4.26e-14	Neuroticism;
KIRP	cis	rs876084	0.630	rs2037345	chr8:121021574	A/G	cg22335954	chr8:121166405	COL14A1	-0.4	-4.97	-0.3	1.26e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.35	5.53	0.33	8.24e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg23978390	chr7:1156363	C7orf50	0.54	5.81	0.35	1.94e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs72634258	0.554	rs17374292	chr1:7881234	C/T	cg26816564	chr1:7831052	VAMP3	0.81	8.21	0.46	1.26e-14	Inflammatory bowel disease;
KIRP	cis	rs1816752	0.583	rs6490918	chr13:25002115	G/A	cg22771759	chr13:24902376	NA	-0.39	-4.98	-0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	11.92	0.61	3.77e-26	Smoking behavior;
KIRP	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.49	-6.06	-0.36	5.19e-9	Mean arterial pressure;
KIRP	cis	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg19847130	chr8:10466454	RP1L1	0.39	5.83	0.35	1.71e-8	Neuroticism;
KIRP	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg04166393	chr7:2884313	GNA12	0.42	5.69	0.34	3.62e-8	Height;
KIRP	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg26248373	chr2:1572462	NA	-0.8	-10.9	-0.57	8.14e-23	IgG glycosylation;
KIRP	cis	rs447921	0.861	rs56248611	chr17:74448255	G/A	cg17201438	chr17:74438067	UBE2O	0.46	4.95	0.3	1.41e-6	Mitochondrial DNA levels;
KIRP	cis	rs1440410	0.748	rs4690774	chr4:144085327	A/T	cg01719995	chr4:144104893	USP38	0.45	5.62	0.34	5.24e-8	Ischemic stroke;
KIRP	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg07701084	chr6:150067640	NUP43	0.56	7.26	0.42	4.92e-12	Testicular germ cell tumor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03183257	chr2:101618566	RPL31	0.58	7.45	0.43	1.55e-12	Parkinson's disease;
KIRP	cis	rs77633900	0.772	rs284904	chr15:76744302	A/C	cg21673338	chr15:77095150	SCAPER	0.62	5.27	0.32	3.04e-7	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg18234130	chr8:27182889	PTK2B	0.54	6.92	0.4	3.89e-11	Neuroticism;
KIRP	cis	rs11586313	0.507	rs6658967	chr1:152870372	C/G	cg07796016	chr1:152779584	LCE1C	-0.56	-7.04	-0.41	1.89e-11	Vitamin D levels;
KIRP	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.82	-11.45	-0.59	1.25e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg09579323	chr1:150459698	TARS2	0.39	5.01	0.3	1.03e-6	Migraine;
KIRP	cis	rs35883536	0.967	rs9433740	chr1:101133985	G/A	cg06223162	chr1:101003688	GPR88	-0.33	-6.65	-0.39	1.89e-10	Monocyte count;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02359409	chr6:42947317	PEX6	-0.47	-6.24	-0.37	1.86e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg23594656	chr7:65796392	TPST1	-0.46	-7.28	-0.42	4.55e-12	Aortic root size;
KIRP	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs5756931	0.503	rs5750542	chr22:38534507	T/C	cg25457927	chr22:38595422	NA	-0.25	-4.96	-0.3	1.29e-6	Triglycerides;
KIRP	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg09408571	chr1:101003634	GPR88	0.24	5.33	0.32	2.27e-7	Monocyte count;
KIRP	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.44	6.04	0.36	5.62e-9	Schizophrenia;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.66	-7.83	-0.45	1.48e-13	Menopause (age at onset);
KIRP	cis	rs8054556	0.787	rs12921753	chr16:30018720	C/T	cg06326092	chr16:30034487	C16orf92	0.38	4.93	0.3	1.51e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.68	-9.99	-0.54	5.86e-20	Menopause (age at onset);
KIRP	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg11584989	chr19:19387371	SF4	0.42	5.36	0.32	1.95e-7	Tonsillectomy;
KIRP	cis	rs1147199	0.568	rs10868219	chr9:87246283	C/T	cg22402007	chr9:87282823	NTRK2	-0.29	-5.26	-0.32	3.2e-7	Body mass index;
KIRP	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg07395648	chr5:131743802	NA	-0.58	-8.57	-0.48	1.18e-15	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.7	-6.39	-0.38	8.09e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17123764	1.000	rs113903668	chr12:50001508	A/G	cg02054252	chr12:50078554	FMNL3	0.48	5.06	0.31	8.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs829661	0.947	rs829679	chr2:30709421	A/G	cg10949345	chr2:30726833	LCLAT1	0.69	9.71	0.53	4.45e-19	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.74	-9.45	-0.52	2.76e-18	Facial morphology (factor 19);
KIRP	cis	rs9398803	0.713	rs1387916	chr6:126886731	G/C	cg19875578	chr6:126661172	C6orf173	0.43	5.49	0.33	9.98e-8	Male-pattern baldness;
KIRP	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg04306507	chr14:55594613	LGALS3	0.53	8.11	0.46	2.33e-14	Protein biomarker;
KIRP	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.44	-5.21	-0.32	3.97e-7	P wave terminal force;
KIRP	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.21	14.22	0.67	6.5e-34	Corneal structure;
KIRP	cis	rs10779751	0.655	rs1884429	chr1:11112836	T/C	cg08854313	chr1:11322531	MTOR	0.61	7.14	0.41	1.05e-11	Body mass index;
KIRP	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg26371346	chr8:56986568	SNORD54;RPS20	0.53	4.89	0.3	1.78e-6	Height;
KIRP	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.03	19.67	0.78	2.19e-52	Birth weight;
KIRP	cis	rs7572644	0.665	rs4493211	chr2:28039472	G/T	cg27432699	chr2:27873401	GPN1	0.48	5.49	0.33	1.01e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	9.04	0.5	4.85e-17	Resting heart rate;
KIRP	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.96	14.64	0.68	2.45e-35	Menopause (age at onset);
KIRP	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.4	0.38	7.87e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs9300039	0.803	rs11036600	chr11:41867075	A/G	cg02094273	chr11:86636018	NA	0.5	6.02	0.36	6.25e-9	Type 2 diabetes;
KIRP	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg13266496	chr6:110720918	DDO	-0.34	-5.41	-0.33	1.46e-7	Platelet distribution width;
KIRP	cis	rs3843585	0.836	rs4746013	chr10:71710142	G/A	cg07081753	chr10:71718679	COL13A1	-0.32	-5.06	-0.31	8.28e-7	Middle childhood and early adolescence aggressive behavior;
KIRP	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.1	-0.31	6.77e-7	Cognitive function;
KIRP	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg12173498	chr6:36355764	ETV7	-0.33	-5.28	-0.32	2.82e-7	Platelet distribution width;
KIRP	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg01831904	chr17:28903510	LRRC37B2	0.81	9.3	0.51	8.2e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg14593290	chr7:50529359	DDC	0.8	9.99	0.54	6.24e-20	Malaria;
KIRP	cis	rs6681460	0.966	rs10749763	chr1:67062126	G/A	cg02459107	chr1:67143332	SGIP1	0.48	6.91	0.4	4.22e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.7	-6.9	-0.4	4.45e-11	Breast cancer;
KIRP	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-5.67	-0.34	3.9e-8	Mean corpuscular volume;
KIRP	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03576123	chr11:487126	PTDSS2	-1.15	-10.21	-0.55	1.25e-20	Body mass index;
KIRP	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-9.59	-0.52	1.03e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-7.59	-0.44	6.53e-13	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-0.62	-5.1	-0.31	6.84e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs3857536	0.679	rs7740850	chr6:66981033	G/A	cg07460842	chr6:66804631	NA	-0.45	-5.3	-0.32	2.56e-7	Blood trace element (Cu levels);
KIRP	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05025164	chr4:1340916	KIAA1530	0.4	5.13	0.31	5.81e-7	Obesity-related traits;
KIRP	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.67	7.38	0.43	2.4e-12	Smoking initiation;
KIRP	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.61	-0.34	5.57e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs311392	0.554	rs689591	chr8:55096050	A/G	cg11783602	chr8:55087084	NA	-0.48	-5.83	-0.35	1.69e-8	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.63	-0.56	5.75e-22	Height;
KIRP	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.89	13.82	0.66	1.61e-32	Mean corpuscular volume;
KIRP	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.31	-0.32	2.39e-7	Breast cancer;
KIRP	trans	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.84e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.9	8.64	0.48	7.3e-16	Fibroblast growth factor basic levels;
KIRP	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg21827317	chr3:136751795	NA	0.38	5.42	0.33	1.44e-7	Gestational age at birth (child effect);
KIRP	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.51	0.33	8.99e-8	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.16	0.37	2.9e-9	Platelet count;
KIRP	cis	rs12643440	0.503	rs34795372	chr4:17142116	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs10498514	1.000	rs17101851	chr14:64900854	A/G	cg25134081	chr14:64931936	AKAP5	0.9	4.98	0.3	1.22e-6	Cognitive performance;
KIRP	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.52	-0.33	8.7e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2708977	0.698	rs772160	chr2:97039666	C/A	cg01950434	chr2:97203154	ARID5A	-0.56	-6.14	-0.36	3.37e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7849270	0.842	rs184457	chr9:131940019	G/A	cg13538475	chr9:131942899	NA	0.36	5.02	0.31	9.73e-7	Blood metabolite ratios;
KIRP	cis	rs11264213	0.892	rs67906703	chr1:36178590	C/T	cg27506609	chr1:36549197	TEKT2	0.76	6.7	0.39	1.45e-10	Schizophrenia;
KIRP	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.02	-0.3	9.9e-7	Neutrophil percentage of white cells;
KIRP	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs11074306	0.561	rs9806708	chr15:28073079	G/A	cg26402630	chr15:28053930	OCA2	0.29	4.87	0.3	2.04e-6	Uveal melanoma;
KIRP	cis	rs2487048	0.725	rs2422493	chr9:107690995	G/A	cg14019050	chr9:107690770	ABCA1	-0.31	-5.86	-0.35	1.52e-8	Intraocular pressure;
KIRP	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.58	-6.99	-0.41	2.6e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg23479056	chr15:41276147	INO80	-0.41	-5.96	-0.36	8.76e-9	Menopause (age at onset);
KIRP	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg05251000	chr9:132935664	FREQ	0.53	8.97	0.5	7.99e-17	Alzheimer's disease (cognitive decline);
KIRP	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	cg21523751	chr1:182988639	NA	0.42	6.5	0.38	4.55e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.62	-6.76	-0.4	1.01e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6545883	0.862	rs1880866	chr2:61698972	G/C	cg15711740	chr2:61764176	XPO1	-0.59	-7.87	-0.45	1.12e-13	Tuberculosis;
KIRP	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg16482183	chr6:26056742	HIST1H1C	0.41	5.29	0.32	2.77e-7	Schizophrenia;
KIRP	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg06219351	chr7:158114137	PTPRN2	-0.57	-6.49	-0.38	4.68e-10	Response to amphetamines;
KIRP	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-8.01	-0.45	4.58e-14	Personality dimensions;
KIRP	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11843799	chr3:50297388	NA	0.44	6.03	0.36	5.95e-9	Pancreatic cancer;
KIRP	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg01689657	chr7:91764605	CYP51A1	0.42	5.91	0.35	1.13e-8	Breast cancer;
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.81	-14.68	-0.68	1.77e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	trans	rs12517041	1.000	rs12517041	chr5:23301908	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	0.88	11.65	0.6	2.98e-25	Orofacial clefts;
KIRP	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg00857998	chr1:205179979	DSTYK	-0.53	-6.51	-0.38	4.25e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg13319975	chr6:146136371	FBXO30	-0.36	-4.9	-0.3	1.74e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs865483	0.860	rs853228	chr17:35799889	G/T	cg06716730	chr17:35851459	DUSP14	0.25	5.99	0.36	7.52e-9	Monocyte count;
KIRP	cis	rs255758	0.654	rs255751	chr5:53319517	C/T	cg22592108	chr5:53304441	ARL15	0.4	5.57	0.33	6.76e-8	Rheumatoid arthritis;
KIRP	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.31	0.42	3.69e-12	Aortic root size;
KIRP	cis	rs4728302	0.607	rs6950081	chr7:133588565	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.04	0.31	9.21e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg21926883	chr2:100939477	LONRF2	-0.64	-8.88	-0.49	1.45e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs12780845	0.505	rs10795460	chr10:17244253	A/G	cg01003015	chr10:17271136	VIM	-0.49	-6.27	-0.37	1.63e-9	Homocysteine levels;
KIRP	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.57	-7.02	-0.41	2.17e-11	Metabolite levels;
KIRP	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.54	6.9	0.4	4.35e-11	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17376030	chr22:41985996	PMM1	-0.83	-8.68	-0.48	5.49e-16	Vitiligo;
KIRP	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.11	0.31	6.62e-7	Breast cancer;
KIRP	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-7.85	-0.45	1.29e-13	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04334979	chr4:79732488	BMP2K	-0.39	-6.05	-0.36	5.44e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.61	7.67	0.44	3.99e-13	Alzheimer's disease;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg07216194	chr8:27182965	PTK2B	0.47	5.74	0.34	2.75e-8	Neuroticism;
KIRP	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg08975724	chr8:8085496	FLJ10661	0.5	5.42	0.33	1.41e-7	Obesity-related traits;
KIRP	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.72	-8.06	-0.46	3.39e-14	Neutrophil percentage of white cells;
KIRP	cis	rs4363385	0.510	rs10494282	chr1:152923762	G/C	cg25856811	chr1:152973957	SPRR3	-0.37	-5.03	-0.31	9.38e-7	Inflammatory skin disease;
KIRP	cis	rs6815814	0.851	rs73236644	chr4:38863193	A/G	cg06935464	chr4:38784597	TLR10	0.5	5.12	0.31	6.24e-7	Breast cancer;
KIRP	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-9.37	-0.51	4.85e-18	Prostate cancer;
KIRP	cis	rs7688540	0.771	rs6599318	chr4:243968	C/T	cg17891759	chr4:299121	NA	-0.5	-5.2	-0.31	4.29e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs35955747	0.633	rs1916	chr22:31892121	C/G	cg02404636	chr22:31891804	SFI1	0.41	5.48	0.33	1.04e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg10047753	chr17:41438598	NA	1.15	17.59	0.75	2.17e-45	Menopause (age at onset);
KIRP	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.49	-6.52	-0.38	4.02e-10	Hemoglobin concentration;
KIRP	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg13611997	chr5:233750	SDHA	-0.43	-5.13	-0.31	5.84e-7	Breast cancer;
KIRP	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg05304507	chr6:116381966	FRK	0.21	5.76	0.34	2.51e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6991838	0.584	rs7012856	chr8:66534975	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.73	-9.18	-0.51	1.78e-17	Aortic root size;
KIRP	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg09137382	chr11:130731461	NA	0.55	8.14	0.46	1.98e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14862950	chr11:66112661	BRMS1	0.59	6.93	0.4	3.75e-11	Smoking initiation;
KIRP	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.19	0.46	1.41e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg18261050	chr1:119551319	NA	0.52	6.75	0.4	1.08e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9467773	0.572	rs2076029	chr6:26390830	T/C	cg09904177	chr6:26538194	HMGN4	-0.43	-5.36	-0.32	1.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg17764715	chr19:33622953	WDR88	0.78	11.41	0.59	1.7e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.22	0.61	3.79e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg12140854	chr5:148520817	ABLIM3	0.48	5.61	0.34	5.55e-8	Breast cancer;
KIRP	cis	rs687432	0.737	rs7949119	chr11:57912906	C/T	cg19752551	chr11:57585705	CTNND1	-0.58	-7.62	-0.44	5.57e-13	Parkinson's disease;
KIRP	cis	rs28595532	0.748	rs72670246	chr4:119335061	G/A	cg21605333	chr4:119757512	SEC24D	1.05	7.44	0.43	1.67e-12	Cannabis dependence symptom count;
KIRP	cis	rs11638352	0.661	rs2555384	chr15:44420900	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-4.92	-0.3	1.59e-6	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.8	9.96	0.54	7.48e-20	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg00800038	chr16:89945340	TCF25	-0.83	-6.15	-0.37	3.04e-9	Skin colour saturation;
KIRP	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06544989	chr22:39130855	UNC84B	-0.47	-7.28	-0.42	4.49e-12	Menopause (age at onset);
KIRP	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg17724175	chr1:150552817	MCL1	0.33	5.4	0.33	1.6e-7	Melanoma;
KIRP	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg02073558	chr3:44770973	ZNF501	0.57	8.23	0.46	1.07e-14	Depressive symptoms;
KIRP	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs73200209	0.744	rs7959347	chr12:116479781	A/G	cg01776926	chr12:116560359	MED13L	-0.56	-6.17	-0.37	2.74e-9	Total body bone mineral density;
KIRP	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.58	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg26528668	chr16:1614120	IFT140	0.4	4.99	0.3	1.16e-6	Coronary artery disease;
KIRP	cis	rs12701220	0.895	rs3808348	chr7:1028448	C/T	cg26769984	chr7:1090371	C7orf50	0.76	7.28	0.42	4.58e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg22681709	chr2:178499509	PDE11A	-0.48	-6.87	-0.4	5.29e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	0.93	14.63	0.68	2.62e-35	Heart rate;
KIRP	cis	rs9309473	0.583	rs6718864	chr2:73574591	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.55	-0.39	3.26e-10	Metabolite levels;
KIRP	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg03388025	chr16:89894329	SPIRE2	0.31	5.58	0.34	6.37e-8	Vitiligo;
KIRP	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.18	-0.31	4.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg23387468	chr7:139079360	LUC7L2	0.28	4.85	0.3	2.15e-6	Diisocyanate-induced asthma;
KIRP	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.74	0.53	3.48e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.85	-0.4	5.92e-11	Monocyte percentage of white cells;
KIRP	cis	rs7317038	0.745	rs75590443	chr13:114015421	A/T	cg24344662	chr13:114018021	GRTP1	-0.58	-7.46	-0.43	1.47e-12	Mean platelet volume;
KIRP	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-5.32	-0.32	2.38e-7	IgG glycosylation;
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg02996583	chr8:142237188	SLC45A4	-0.47	-5.72	-0.34	3.09e-8	Immature fraction of reticulocytes;
KIRP	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.72	0.34	3.08e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.95	0.4	3.32e-11	Mean platelet volume;
KIRP	cis	rs3925075	1.000	rs55742763	chr16:31340368	G/A	cg02846316	chr16:31340340	ITGAM	0.61	9.31	0.51	7.63e-18	IgA nephropathy;
KIRP	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg13512537	chr8:22265999	SLC39A14	0.44	6.02	0.36	6.21e-9	Verbal declarative memory;
KIRP	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg16988262	chr1:15930761	NA	0.4	5.17	0.31	4.9e-7	Systolic blood pressure;
KIRP	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.02	-0.36	6.39e-9	Breast cancer;
KIRP	cis	rs7709377	0.570	rs4921063	chr5:115446146	G/T	cg23108291	chr5:115420582	COMMD10	0.41	4.94	0.3	1.43e-6	Metabolite levels  (X-11787);
KIRP	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.71	-0.34	3.23e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg05333889	chr7:157238977	NA	-0.38	-5.28	-0.32	2.9e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.63	5.81	0.35	1.97e-8	Alzheimer's disease;
KIRP	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg16988262	chr1:15930761	NA	0.39	5.12	0.31	6.13e-7	Systolic blood pressure;
KIRP	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.37	-0.38	9.38e-10	Acne (severe);
KIRP	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06230668	chr7:18652971	HDAC9	-0.4	-6.08	-0.36	4.47e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.76	-10.82	-0.57	1.38e-22	Asthma;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg23698023	chr8:27181813	PTK2B	0.32	4.84	0.3	2.26e-6	Neuroticism;
KIRP	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg08885076	chr2:99613938	TSGA10	-0.52	-9.0	-0.5	6.22e-17	Chronic sinus infection;
KIRP	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.89	13.37	0.65	5.38e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg05973401	chr12:123451056	ABCB9	-0.53	-5.87	-0.35	1.39e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9513627	1.000	rs9513627	chr13:100196952	G/A	cg25919922	chr13:100150906	NA	0.7	5.44	0.33	1.28e-7	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.41	-11.61	-0.6	3.75e-25	Diabetic kidney disease;
KIRP	cis	rs7015630	0.648	rs62530862	chr8:90834887	C/G	cg18493113	chr8:90847772	NA	-0.45	-4.9	-0.3	1.73e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.76	-9.78	-0.53	2.67e-19	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg19913688	chr11:428466	ANO9	-0.73	-5.48	-0.33	1.06e-7	Body mass index;
KIRP	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.57	8.9	0.49	1.23e-16	Coronary artery disease;
KIRP	cis	rs3026101	0.671	rs1806256	chr17:5314357	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.82	0.35	1.86e-8	Body mass index;
KIRP	cis	rs35892873	0.501	rs4299436	chr3:126096047	C/T	cg15490784	chr3:126061950	KLF15	-0.39	-5.02	-0.3	1.01e-6	Male-pattern baldness;
KIRP	cis	rs806215	1.000	rs712703	chr7:127257498	C/T	cg25922125	chr7:127225783	GCC1	-0.46	-5.18	-0.31	4.71e-7	Type 2 diabetes;
KIRP	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.81	11.73	0.6	1.55e-25	Eosinophil percentage of white cells;
KIRP	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs10073892	0.660	rs1961737	chr5:101981779	T/C	cg19774478	chr5:101632501	SLCO4C1	0.56	5.57	0.33	6.81e-8	Cognitive decline (age-related);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10771695	chr14:103800476	EIF5	0.51	6.25	0.37	1.75e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25751588	chr7:92077027	GATAD1	0.46	6.27	0.37	1.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg21605333	chr4:119757512	SEC24D	1.54	11.78	0.6	1.07e-25	Cannabis dependence symptom count;
KIRP	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.42	-0.38	6.99e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.82	6.85	0.4	5.77e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-7.89	-0.45	9.67e-14	Common traits (Other);
KIRP	cis	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg26585981	chr11:48327164	OR4S1	-0.47	-5.67	-0.34	4.09e-8	HDL cholesterol;
KIRP	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg07777115	chr5:623756	CEP72	-0.59	-6.02	-0.36	6.46e-9	Obesity-related traits;
KIRP	cis	rs3857067	1.000	rs3846291	chr4:95026735	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.71e-7	QT interval;
KIRP	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg03474202	chr17:45855739	NA	-0.47	-6.46	-0.38	5.71e-10	IgG glycosylation;
KIRP	cis	rs2299587	0.500	rs7815785	chr8:17730338	T/C	cg01800426	chr8:17659068	MTUS1	-0.42	-5.11	-0.31	6.59e-7	Economic and political preferences;
KIRP	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg05315796	chr3:52349193	DNAH1	0.36	5.59	0.34	5.88e-8	Bipolar disorder;
KIRP	cis	rs7078012	0.504	rs17878830	chr10:81690780	C/T	cg24613050	chr10:81743128	NA	-0.53	-4.96	-0.3	1.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.41	5.29	0.32	2.75e-7	Total body bone mineral density;
KIRP	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg05973401	chr12:123451056	ABCB9	0.58	5.24	0.32	3.52e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18357526	chr6:26021779	HIST1H4A	0.55	7.52	0.43	1.01e-12	Height;
KIRP	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg18904891	chr8:8559673	CLDN23	0.56	6.49	0.38	4.58e-10	Obesity-related traits;
KIRP	cis	rs7919006	0.590	rs11813191	chr10:76750091	T/A	cg01390419	chr10:76803856	DUPD1	0.46	4.89	0.3	1.81e-6	Weight;
KIRP	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg12559939	chr2:27858050	GPN1	0.41	5.16	0.31	5.01e-7	Oral cavity cancer;
KIRP	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg10326726	chr10:51549505	MSMB	-0.61	-9.05	-0.5	4.35e-17	Prostate-specific antigen levels;
KIRP	cis	rs7083	0.935	rs529471	chr11:117132809	C/A	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg20140201	chr2:241835670	C2orf54	-0.34	-5.19	-0.31	4.35e-7	Urinary metabolites;
KIRP	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg05393297	chr12:53359155	NA	-0.55	-10.92	-0.57	6.88e-23	Prostate cancer;
KIRP	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg04935436	chr20:30431758	NA	0.38	5.14	0.31	5.7e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.45	6.14	0.36	3.28e-9	Coronary artery disease;
KIRP	trans	rs863345	0.526	rs857676	chr1:158615702	G/A	cg05360176	chr12:48357394	TMEM106C	0.47	6.08	0.36	4.67e-9	Pneumococcal bacteremia;
KIRP	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.71	0.39	1.35e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	11.55	0.59	6.13e-25	Smoking behavior;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg01763666	chr17:80159506	CCDC57	-0.36	-4.88	-0.3	1.9e-6	Life satisfaction;
KIRP	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg14689365	chr7:158441557	NCAPG2	0.4	5.01	0.3	1.04e-6	Height;
KIRP	cis	rs7224685	0.569	rs67533014	chr17:3993910	C/T	cg11204139	chr17:3907470	NA	0.54	5.17	0.31	4.8e-7	Type 2 diabetes;
KIRP	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg26384229	chr12:38710491	ALG10B	0.66	8.34	0.47	5.26e-15	Resting heart rate;
KIRP	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10373256	chr22:32871209	FBXO7	0.47	6.57	0.39	2.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-1.06	-12.94	-0.64	1.45e-29	Exhaled nitric oxide output;
KIRP	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05903289	chr2:130345205	NA	-0.43	-5.56	-0.33	6.85e-8	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs6832769	1.000	rs11931061	chr4:56338793	G/A	cg05960024	chr4:56376020	CLOCK	0.63	8.17	0.46	1.65e-14	Personality dimensions;
KIRP	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg01097406	chr16:89675127	NA	0.32	5.27	0.32	3.02e-7	Hemoglobin concentration;
KIRP	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg24972876	chr7:65420302	NA	-0.41	-5.69	-0.34	3.53e-8	Aortic root size;
KIRP	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.98	12.73	0.63	7.55e-29	Exhaled nitric oxide output;
KIRP	cis	rs7554547	0.667	rs2336377	chr1:11949970	A/G	cg07603449	chr1:11986842	KIAA2013	0.41	5.29	0.32	2.69e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.93	-12.55	-0.62	3.09e-28	Cognitive function;
KIRP	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11779988	0.545	rs409217	chr8:17816597	C/G	cg01800426	chr8:17659068	MTUS1	-0.6	-6.03	-0.36	5.92e-9	Breast cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg14969320	chr1:3731835	KIAA0562	0.48	6.45	0.38	5.74e-10	Educational attainment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04145557	chr15:74907272	CLK3	0.49	6.39	0.38	8.06e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-0.57	-8.19	-0.46	1.4e-14	Coronary artery disease;
KIRP	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.34	6.22	0.37	2.07e-9	Renal cell carcinoma;
KIRP	trans	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg24644049	chr4:85504048	CDS1	1.05	7.45	0.43	1.56e-12	Skin colour saturation;
KIRP	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg06636001	chr8:8085503	FLJ10661	0.7	9.07	0.5	3.79e-17	Retinal vascular caliber;
KIRP	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg03711944	chr11:47377212	SPI1	-0.3	-5.1	-0.31	6.9e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg23594656	chr7:65796392	TPST1	-0.46	-7.31	-0.42	3.81e-12	Aortic root size;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10996143	chr20:1373995	FKBP1A	-0.58	-6.59	-0.39	2.69e-10	Migraine with aura;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg04025307	chr7:1156635	C7orf50	0.8	8.12	0.46	2.22e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg05573767	chr6:167171394	RPS6KA2	-0.22	-4.85	-0.3	2.16e-6	Crohn's disease;
KIRP	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg06818126	chr11:68850279	TPCN2	-0.47	-5.49	-0.33	1.02e-7	Hair color;
KIRP	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg25797454	chr6:150327115	RAET1K	0.32	6.12	0.36	3.6e-9	Alopecia areata;
KIRP	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	6.23	0.37	1.97e-9	Menarche (age at onset);
KIRP	cis	rs6142102	0.847	rs4911413	chr20:32721775	T/A	cg08999081	chr20:33150536	PIGU	0.55	6.9	0.4	4.36e-11	Skin pigmentation;
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.49	-6.37	-0.38	9.34e-10	Testicular germ cell tumor;
KIRP	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg24296786	chr1:45957014	TESK2	-0.65	-8.41	-0.47	3.29e-15	High light scatter reticulocyte count;
KIRP	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.85	0.3	2.19e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.89	0.4	4.74e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg05555928	chr11:63887634	MACROD1	-0.56	-5.07	-0.31	7.7e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2274459	1.000	rs12193658	chr6:33705528	G/T	cg06253072	chr6:33679850	C6orf125	0.49	4.85	0.3	2.2e-6	Obesity (extreme);
KIRP	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg26811252	chr16:29126840	RRN3P2	0.66	8.88	0.49	1.4e-16	Menopause (age at onset);
KIRP	cis	rs4789693	0.872	rs28612648	chr17:80403386	G/A	cg04308225	chr17:80449738	NA	0.6	6.13	0.36	3.53e-9	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.11	0.36	3.8e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.81	0.49	2.36e-16	Bipolar disorder;
KIRP	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.65	-8.99	-0.5	6.61e-17	Brugada syndrome;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg15129777	chr11:8008818	EIF3F	0.7	6.03	0.36	6.03e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.02	-0.36	6.37e-9	Type 2 diabetes;
KIRP	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg16141378	chr3:129829833	LOC729375	-0.46	-6.31	-0.37	1.26e-9	Acne (severe);
KIRP	cis	rs7751419	0.651	rs1864059	chr6:39105177	T/G	cg08089693	chr6:39098871	NA	-0.68	-9.67	-0.52	5.99e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg01631408	chr1:248437212	OR2T33	-0.6	-8.16	-0.46	1.79e-14	Common traits (Other);
KIRP	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-8.95	-0.5	9.15e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs3925075	0.764	rs8044482	chr16:31345752	T/C	cg02846316	chr16:31340340	ITGAM	0.6	9.11	0.5	3.06e-17	IgA nephropathy;
KIRP	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.74	-0.49	3.76e-16	Neuroticism;
KIRP	cis	rs6005807	0.719	rs73430179	chr22:28998821	T/C	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.92	-15.37	-0.7	7.88e-38	Breast cancer;
KIRP	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	1.1	12.3	0.62	2.1e-27	Post bronchodilator FEV1;
KIRP	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.84	-12.63	-0.63	1.64e-28	Height;
KIRP	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.83	0.53	1.94e-19	Parkinson's disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09225295	chr7:95405749	DYNC1I1	0.51	6.31	0.37	1.31e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg00274965	chr21:34405681	NA	0.37	5.7	0.34	3.42e-8	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9815354	0.953	rs1717007	chr3:41942199	T/C	cg03022575	chr3:42003672	ULK4	-0.48	-5.49	-0.33	9.89e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.33	-0.32	2.27e-7	Bipolar disorder;
KIRP	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.34	5.28	0.32	2.85e-7	Asthma;
KIRP	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg17554472	chr22:41940697	POLR3H	0.66	6.78	0.4	8.83e-11	Cannabis dependence symptom count;
KIRP	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	11.2	0.58	8.34e-24	Smoking behavior;
KIRP	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.42	7.27	0.42	4.71e-12	Renal cell carcinoma;
KIRP	cis	rs290268	0.874	rs290995	chr9:93559477	C/A	cg02608019	chr9:93564028	SYK	0.82	11.52	0.59	7.58e-25	Platelet count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04708391	chr4:175177265	FBXO8	-0.4	-6.27	-0.37	1.57e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs904092	0.720	rs1230019	chr4:100172691	A/G	cg12011299	chr4:100065546	ADH4	0.54	5.29	0.32	2.76e-7	Alcohol dependence;
KIRP	cis	rs989128	0.517	rs1809284	chr17:48632310	A/G	cg16068336	chr17:48637367	CACNA1G	-0.41	-5.23	-0.32	3.65e-7	Type 2 diabetes;
KIRP	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.7	-11.68	-0.6	2.3e-25	Lung function (FVC);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27093605	chr15:78560514	DNAJA4	0.46	6.64	0.39	2e-10	Survival in pancreatic cancer;
KIRP	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg14675211	chr2:100938903	LONRF2	0.49	6.38	0.38	8.59e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.38	-5.61	-0.34	5.52e-8	Coronary artery disease;
KIRP	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.95	-0.41	3.2e-11	Response to antipsychotic treatment;
KIRP	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.69	-8.69	-0.48	5.24e-16	Prudent dietary pattern;
KIRP	trans	rs5417	0.610	rs222843	chr17:7145981	T/C	cg15655154	chr3:113604241	GRAMD1C	0.73	10.47	0.56	1.87e-21	Diastolic blood pressure;
KIRP	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.89	0.35	1.25e-8	Menopause (age at onset);
KIRP	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg24296786	chr1:45957014	TESK2	0.39	4.98	0.3	1.19e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg21253087	chr9:139290292	SNAPC4	0.47	6.65	0.39	1.93e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	1.02	14.82	0.69	5.98e-36	Menopause (age at onset);
KIRP	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.46	-5.0	-0.3	1.1e-6	Schizophrenia;
KIRP	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.85	-11.28	-0.58	4.58e-24	Type 2 diabetes;
KIRP	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg10645314	chr2:3704589	ALLC	-0.41	-5.3	-0.32	2.59e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9488822	0.636	rs11153592	chr6:116330574	T/C	cg05304507	chr6:116381966	FRK	0.21	5.86	0.35	1.51e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.86	-9.63	-0.52	8.13e-19	White matter hyperintensity burden;
KIRP	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.49	7.35	0.42	2.94e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs728478	0.935	rs8071771	chr17:57454267	A/G	cg16535752	chr17:57448097	YPEL2	-0.22	-5.25	-0.32	3.35e-7	QT interval;
KIRP	cis	rs7147624	1.000	rs4902408	chr14:66111901	A/T	cg03016385	chr14:66212404	NA	-0.97	-9.88	-0.53	1.3e-19	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg24734643	chr22:39898247	SMCR7L	-0.48	-6.34	-0.37	1.12e-9	Metabolic traits;
KIRP	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.48	7.26	0.42	5.2e-12	Resting heart rate;
KIRP	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14893161	chr1:205819251	PM20D1	-0.44	-4.86	-0.3	2.08e-6	Parkinson's disease;
KIRP	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg24631222	chr15:78858424	CHRNA5	0.76	9.06	0.5	4.17e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg01843034	chr6:37503916	NA	-0.72	-8.42	-0.47	3.06e-15	Cognitive performance;
KIRP	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg27490568	chr2:178487706	NA	0.5	6.55	0.39	3.39e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.71	10.26	0.55	8.63e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.5	0.59	8.73e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs5770917	1.000	rs115743514	chr22:51011933	T/C	cg25309564	chr22:51001381	C22orf41	0.77	5.36	0.32	1.87e-7	Narcolepsy;
KIRP	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06481639	chr22:41940642	POLR3H	0.47	5.55	0.33	7.25e-8	Vitiligo;
KIRP	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.08	-21.68	-0.81	5.22e-59	Myeloid white cell count;
KIRP	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	6.46	0.38	5.48e-10	Educational attainment (years of education);
KIRP	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg12042659	chr19:58951599	ZNF132	0.51	6.41	0.38	7.3e-10	Uric acid clearance;
KIRP	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg17133734	chr15:86042851	AKAP13	-0.45	-5.69	-0.34	3.59e-8	Interstitial lung disease;
KIRP	cis	rs17023223	0.509	rs61806978	chr1:119713215	A/G	cg05756136	chr1:119680316	WARS2	-0.62	-8.36	-0.47	4.76e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7116495	0.867	rs562621	chr11:71579213	C/G	cg11196788	chr11:71737549	NUMA1	-0.49	-4.89	-0.3	1.8e-6	Severe influenza A (H1N1) infection;
KIRP	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.15	12.98	0.64	1.11e-29	Uric acid levels;
KIRP	cis	rs1712517	0.773	rs1063461	chr10:105049105	C/G	cg05636881	chr10:105038444	INA	0.45	6.58	0.39	2.8e-10	Migraine;
KIRP	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.9	16.24	0.72	8.56e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11987759	chr7:65425863	GUSB	-0.69	-9.66	-0.52	6.27e-19	Calcium levels;
KIRP	cis	rs9596863	0.898	rs9316660	chr13:54353562	T/C	ch.13.53330881F	chr13:54432880	NA	0.6	5.84	0.35	1.63e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs1355223	0.573	rs2084970	chr11:34723729	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-6.13	-0.36	3.42e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7520050	0.933	rs4504835	chr1:46455571	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2274273	0.745	rs56262555	chr14:55561962	C/T	cg04306507	chr14:55594613	LGALS3	0.44	6.89	0.4	4.65e-11	Protein biomarker;
KIRP	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.81	-9.31	-0.51	7.58e-18	Parkinson's disease;
KIRP	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg18904891	chr8:8559673	CLDN23	0.48	5.85	0.35	1.54e-8	Obesity-related traits;
KIRP	cis	rs10073892	0.620	rs12655805	chr5:101927366	C/T	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg02951883	chr7:2050386	MAD1L1	-0.56	-6.54	-0.38	3.57e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs5753037	0.809	rs713657	chr22:30211876	A/G	cg27665648	chr22:30112403	NA	0.44	6.12	0.36	3.69e-9	Type 1 diabetes;
KIRP	cis	rs6662572	0.737	rs4660893	chr1:46327532	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6504950	0.830	rs56175787	chr17:53017747	A/G	cg26251398	chr17:52985966	TOM1L1	0.42	5.2	0.31	4.12e-7	Breast cancer;
KIRP	cis	rs7404928	0.794	rs72777936	chr16:23874201	A/T	cg21745164	chr16:23765304	CHP2	-0.54	-6.51	-0.38	4.1e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs9931543	0.504	rs4784650	chr16:56306640	A/G	cg02433656	chr16:56322654	GNAO1	0.44	5.18	0.31	4.68e-7	Subjective well-being;
KIRP	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.57	-7.88	-0.45	1.05e-13	Motion sickness;
KIRP	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg11845111	chr2:191398756	TMEM194B	-0.74	-8.0	-0.45	4.78e-14	Diastolic blood pressure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25313289	chr16:2264884	PGP	-0.52	-7.09	-0.41	1.44e-11	Metabolic traits;
KIRP	cis	rs4460629	0.742	rs6693477	chr1:155081940	A/G	cg23414228	chr1:155043413	NA	-0.3	-4.93	-0.3	1.5e-6	Serum magnesium levels;
KIRP	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg11995313	chr8:8860691	ERI1	0.42	5.75	0.34	2.67e-8	Joint mobility (Beighton score);
KIRP	cis	rs1775715	0.707	rs2808081	chr10:32162342	C/T	cg26784012	chr10:32216390	ARHGAP12	-0.31	-4.9	-0.3	1.75e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg05361325	chr10:32636312	EPC1	-0.67	-6.39	-0.38	8.44e-10	Sexual dysfunction (female);
KIRP	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-6.82	-0.4	7.09e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.58	-9.48	-0.52	2.28e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.28	-0.32	2.88e-7	Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.59	7.71	0.44	3.07e-13	Red blood cell count;
KIRP	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg11833968	chr6:79620685	NA	-0.38	-5.75	-0.34	2.64e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg12560992	chr17:57184187	TRIM37	0.55	5.07	0.31	7.66e-7	Cognitive test performance;
KIRP	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-6.99	-0.41	2.5e-11	Morning vs. evening chronotype;
KIRP	trans	rs3779273	0.776	rs4730110	chr7:77832149	T/C	cg05596911	chr5:118502651	DMXL1	-0.39	-6.13	-0.36	3.54e-9	Body mass index;
KIRP	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	5.29	0.32	2.75e-7	Recombination measurement;
KIRP	cis	rs6662572	0.737	rs72677530	chr1:46529677	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.78	0.35	2.27e-8	Blood protein levels;
KIRP	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-5.82	-0.35	1.85e-8	Aortic root size;
KIRP	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.5	-0.52	1.96e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs4132509	0.779	rs1538773	chr1:243674682	T/G	cg21452805	chr1:244014465	NA	0.5	5.32	0.32	2.34e-7	RR interval (heart rate);
KIRP	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg04166393	chr7:2884313	GNA12	0.44	5.69	0.34	3.65e-8	Height;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg21204356	chr11:3013633	NAP1L4	0.54	6.45	0.38	6e-10	Educational attainment;
KIRP	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	trans	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.11	-0.41	1.27e-11	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.22	-0.46	1.19e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg16141378	chr3:129829833	LOC729375	0.6	8.41	0.47	3.34e-15	Triglycerides;
KIRP	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.77	13.08	0.64	5.07e-30	Cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18687753	chr17:65850416	BPTF	-0.38	-6.27	-0.37	1.62e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg26876637	chr1:152193138	HRNR	-0.78	-8.95	-0.5	8.65e-17	Atopic dermatitis;
KIRP	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	9.86	0.53	1.55e-19	Ileal carcinoids;
KIRP	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	7.15	0.41	1.02e-11	Retinal vascular caliber;
KIRP	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.75	-7.77	-0.44	2.07e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.79	9.62	0.52	8.68e-19	Corneal astigmatism;
KIRP	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg03563238	chr19:33554763	RHPN2	0.33	5.75	0.34	2.65e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs12517041	1.000	rs10074124	chr5:23318235	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.55	-0.43	8.27e-13	Calcium levels;
KIRP	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.76	9.9	0.53	1.13e-19	N-glycan levels;
KIRP	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg16141378	chr3:129829833	LOC729375	0.54	6.86	0.4	5.43e-11	Neuroticism;
KIRP	cis	rs1847505	0.562	rs1554022	chr13:61429211	G/A	cg25164009	chr13:61490935	NA	0.48	5.13	0.31	5.8e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.07	-0.41	1.6e-11	Blood pressure;
KIRP	trans	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg18998321	chr18:7038943	LAMA1	0.3	6.31	0.37	1.3e-9	Schizophrenia;
KIRP	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.14	0.31	5.68e-7	Menopause (age at onset);
KIRP	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.42	-5.19	-0.31	4.48e-7	Obesity-related traits;
KIRP	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg05315796	chr3:52349193	DNAH1	0.46	7.0	0.41	2.41e-11	Bipolar disorder;
KIRP	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg03585969	chr10:35415529	CREM	0.79	9.74	0.53	3.61e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	trans	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-6.87	-0.4	5.24e-11	Neuroticism;
KIRP	cis	rs943466	0.537	rs2296329	chr6:33650743	A/G	cg14003231	chr6:33640908	ITPR3	0.42	5.51	0.33	8.91e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
KIRP	cis	rs1694068	1.000	rs1694068	chr5:53283630	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.47	-5.26	-0.32	3.2e-7	Reticulocyte count;
KIRP	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.65	-7.0	-0.41	2.45e-11	DNA methylation (variation);
KIRP	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg08975724	chr8:8085496	FLJ10661	-0.72	-10.08	-0.54	3.2e-20	Triglycerides;
KIRP	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.71	-10.62	-0.56	6.07e-22	Retinal vascular caliber;
KIRP	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg24169773	chr3:122142474	KPNA1	-0.53	-5.41	-0.33	1.47e-7	LDL cholesterol levels;
KIRP	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.7	9.5	0.52	1.97e-18	Systemic lupus erythematosus;
KIRP	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06307176	chr5:131281290	NA	0.54	5.89	0.35	1.29e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.96	-0.41	3.04e-11	Eye color traits;
KIRP	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.64	-8.1	-0.46	2.64e-14	Schizophrenia;
KIRP	cis	rs988913	1.000	rs9382408	chr6:54836984	A/G	cg03513858	chr6:54763001	FAM83B	-0.37	-5.37	-0.32	1.8e-7	Menarche (age at onset);
KIRP	cis	rs9323205	0.634	rs61987266	chr14:51734909	C/T	cg23942311	chr14:51606299	NA	-0.51	-5.06	-0.31	8.02e-7	Cancer;
KIRP	cis	rs9859260	1.000	rs2284890	chr3:195788147	T/C	cg12923728	chr3:195709715	SDHAP1	-0.42	-4.92	-0.3	1.57e-6	Mean corpuscular volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18749629	chr8:144566769	ZC3H3	0.47	6.37	0.38	9.27e-10	Survival in pancreatic cancer;
KIRP	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg24110177	chr3:50126178	RBM5	-0.44	-5.62	-0.34	5.05e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg00990874	chr7:1149470	C7orf50	-0.42	-5.3	-0.32	2.61e-7	Longevity;Endometriosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04964845	chr14:60761524	PPM1A	-0.42	-6.43	-0.38	6.57e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg14703610	chr5:56206110	C5orf35	0.48	6.8	0.4	7.78e-11	Coronary artery disease;
KIRP	cis	rs9400467	0.537	rs12211045	chr6:111498116	C/T	cg15721981	chr6:111408429	SLC16A10	0.82	6.54	0.38	3.49e-10	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs155346	1.000	rs265156	chr5:139386659	C/T	cg01090482	chr5:139365336	NRG2	-0.42	-5.31	-0.32	2.4e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs9400467	0.506	rs12198556	chr6:111662338	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6568686	0.786	rs7776286	chr6:111810216	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.57	-5.26	-0.32	3.09e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	4.94	0.3	1.43e-6	Longevity;
KIRP	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2048656	0.578	rs925610	chr8:9681836	G/C	cg16141378	chr3:129829833	LOC729375	0.5	6.57	0.39	2.98e-10	Schizophrenia;
KIRP	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.24	-0.37	1.88e-9	Mood instability;
KIRP	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg12549451	chr6:135224345	NA	-0.43	-5.33	-0.32	2.17e-7	Red blood cell count;
KIRP	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg26875233	chr11:93583750	C11orf90	-0.34	-6.49	-0.38	4.64e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg14061069	chr19:46274453	DMPK	-0.57	-8.58	-0.48	1.12e-15	Coronary artery disease;
KIRP	trans	rs2685295	0.509	rs10925504	chr1:237904870	C/T	cg01300546	chr3:3841853	LRRN1	0.49	6.15	0.37	3.17e-9	Bipolar disorder and eating disorder;
KIRP	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07234876	chr8:600039	NA	0.78	5.83	0.35	1.72e-8	IgG glycosylation;
KIRP	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Colorectal cancer;
KIRP	cis	rs6430538	0.621	rs12465725	chr2:135550086	C/T	cg12500956	chr2:135428796	TMEM163	0.41	5.2	0.31	4.29e-7	Parkinson's disease;
KIRP	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.83	-0.45	1.46e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs17428704	0.571	rs12110161	chr5:14397728	A/G	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02251172	chr10:135192226	PAOX	0.49	6.09	0.36	4.4e-9	Parkinson's disease;
KIRP	cis	rs735539	0.598	rs2290144	chr13:21265658	C/G	cg04906043	chr13:21280425	IL17D	-0.44	-5.18	-0.31	4.56e-7	Dental caries;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.73	7.54	0.43	8.93e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03973866	chr1:16270229	ZBTB17	0.51	6.49	0.38	4.57e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg02975922	chr3:195473998	MUC4	-0.44	-5.26	-0.32	3.14e-7	Pancreatic cancer;
KIRP	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.75	9.31	0.51	7.22e-18	Prostate cancer;
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg05627522	chr15:75251581	NA	0.33	4.91	0.3	1.66e-6	Caffeine consumption;
KIRP	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	0.79	6.96	0.41	3.05e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs2281558	1.000	rs2281558	chr20:25240189	G/T	cg08601574	chr20:25228251	PYGB	0.47	4.91	0.3	1.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
KIRP	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6978712	0.591	rs60908730	chr7:127077673	G/A	cg24655706	chr7:127078268	NA	0.68	5.36	0.32	1.88e-7	Medication adherence in chronic diseases;
KIRP	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg04374321	chr14:90722782	PSMC1	0.99	17.36	0.74	1.32e-44	Mortality in heart failure;
KIRP	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.9	-10.07	-0.54	3.48e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.52	0.38	3.91e-10	Neuroticism;
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg08901578	chr4:187885870	NA	0.5	7.83	0.45	1.49e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.52	-7.07	-0.41	1.58e-11	Blood metabolite levels;
KIRP	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.72	0.34	3.1e-8	Homoarginine levels;
KIRP	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.71	6.8	0.4	8e-11	Chronic kidney disease;
KIRP	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.84	-7.16	-0.42	9.29e-12	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg24315340	chr6:146058215	EPM2A	0.45	5.64	0.34	4.78e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg27490568	chr2:178487706	NA	0.45	5.84	0.35	1.62e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-14.05	-0.67	2.59e-33	Gut microbiome composition (summer);
KIRP	trans	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg16141378	chr3:129829833	LOC729375	0.51	6.83	0.4	6.72e-11	Mood instability;
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg07648498	chr16:89883185	FANCA	0.41	5.18	0.31	4.6e-7	Vitiligo;
KIRP	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05665937	chr4:1216051	CTBP1	0.56	7.84	0.45	1.34e-13	Obesity-related traits;
KIRP	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.14	9.07	0.5	3.85e-17	Skin colour saturation;
KIRP	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-11.29	-0.58	4.29e-24	Morning vs. evening chronotype;
KIRP	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.87	-7.79	-0.45	1.82e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg14458575	chr2:238380390	NA	0.62	8.31	0.47	6.33e-15	Prostate cancer;
KIRP	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg19847130	chr8:10466454	RP1L1	-0.34	-5.02	-0.3	1e-6	Retinal vascular caliber;
KIRP	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.83	12.79	0.63	4.61e-29	Testicular germ cell tumor;
KIRP	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg22903471	chr2:27725779	GCKR	-0.47	-6.65	-0.39	1.89e-10	Oral cavity cancer;
KIRP	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.75	-7.64	-0.44	4.98e-13	Uric acid levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04416895	chr22:42949810	SERHL2	0.44	6.1	0.36	4.03e-9	Parkinson's disease;
KIRP	cis	rs4478858	0.735	rs4949389	chr1:31824023	A/G	cg00250761	chr1:31883323	NA	0.29	4.87	0.3	2.03e-6	Alcohol dependence;
KIRP	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg22117172	chr7:91764530	CYP51A1	0.49	6.71	0.39	1.35e-10	Breast cancer;
KIRP	cis	rs9506514	0.722	rs4769124	chr13:21226845	C/T	cg04906043	chr13:21280425	IL17D	-0.4	-5.16	-0.31	5.14e-7	Coronary artery calcification;
KIRP	cis	rs472402	0.623	rs7727273	chr5:6635933	A/C	cg08700190	chr5:6636046	SRD5A1	-0.48	-6.06	-0.36	5e-9	Response to amphetamines;
KIRP	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg12623918	chr2:306882	NA	0.46	5.74	0.34	2.85e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg12315302	chr6:26189340	HIST1H4D	1.05	6.41	0.38	7.21e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12180372	chr14:94547582	DDX24;IFI27L1	-0.53	-6.26	-0.37	1.7e-9	Interleukin-4 levels;
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg11859384	chr17:80120422	CCDC57	-0.41	-5.19	-0.31	4.3e-7	Life satisfaction;
KIRP	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg05938607	chr10:60274200	BICC1	-0.46	-11.34	-0.59	2.91e-24	Refractive error;
KIRP	cis	rs1359582	0.556	rs701825	chr10:90417547	G/A	cg15661332	chr10:90342814	RNLS	0.57	5.8	0.35	2.03e-8	Depressive and manic episodes in bipolar disorder;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01506766	chr13:46626746	ZC3H13	-0.48	-6.87	-0.4	5.17e-11	Metabolic traits;
KIRP	cis	rs4742903	0.509	rs12379563	chr9:106956786	G/A	cg14250997	chr9:106856677	SMC2	0.37	4.87	0.3	2.04e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9896933	0.895	rs6416854	chr17:80899811	T/A	cg15664640	chr17:80829946	TBCD	0.57	5.29	0.32	2.71e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05491852	chr1:3663832	KIAA0495	0.54	7.07	0.41	1.61e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2562456	0.833	rs62109229	chr19:21537182	C/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.52	6.68	0.39	1.59e-10	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs35100037	0.803	rs35665310	chr5:128578737	T/C	cg23338408	chr14:31289523	NA	-0.59	-6.04	-0.36	5.51e-9	Ankle injury;
KIRP	trans	rs9329221	0.636	rs6999466	chr8:10265712	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.38	0.43	2.44e-12	Neuroticism;
KIRP	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg15848620	chr12:58087721	OS9	-0.47	-5.39	-0.32	1.67e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg21546286	chr11:48923668	NA	-0.46	-5.92	-0.35	1.08e-8	HDL cholesterol;
KIRP	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg18132916	chr6:79620363	NA	-0.42	-5.72	-0.34	3.15e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2904967	0.631	rs650056	chr11:65025106	G/A	cg12562828	chr11:65076843	NA	-0.84	-11.46	-0.59	1.22e-24	Mean corpuscular volume;
KIRP	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.13	-0.36	3.47e-9	Neuroticism;
KIRP	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-5.99	-0.36	7.4e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.31	7.82	0.45	1.59e-13	Primary biliary cholangitis;
KIRP	trans	rs242364	0.531	rs242368	chr21:28868212	T/C	cg01278232	chr17:17606846	RAI1	0.57	6.02	0.36	6.16e-9	Daytime sleep phenotypes;
KIRP	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg26875233	chr11:93583750	C11orf90	-0.34	-6.9	-0.4	4.31e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Bipolar disorder;
KIRP	cis	rs5753037	0.653	rs140107	chr22:30130516	C/A	cg27665648	chr22:30112403	NA	0.35	5.08	0.31	7.3e-7	Type 1 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14498074	chr13:45992574	SLC25A30	0.46	6.29	0.37	1.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.32	5.6	0.34	5.84e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg14675211	chr2:100938903	LONRF2	0.48	6.32	0.37	1.25e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9826463	1.000	rs2140434	chr3:142343791	T/G	cg20824294	chr3:142316082	PLS1	0.31	5.41	0.33	1.52e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.44	-6.24	-0.37	1.88e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs77362122	0.614	rs1187322	chr9:87283317	C/G	cg22402007	chr9:87282823	NTRK2	-0.4	-4.92	-0.3	1.62e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9596863	0.898	rs9568917	chr13:54351040	G/A	ch.13.53330881F	chr13:54432880	NA	0.6	5.84	0.35	1.63e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs6859018	1.000	rs7730390	chr5:158730792	T/C	cg26646896	chr5:158686746	NA	-0.37	-5.44	-0.33	1.27e-7	Serum sulfate level;
KIRP	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-7.29	-0.42	4.27e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg17644776	chr2:200775616	C2orf69	-0.56	-5.29	-0.32	2.66e-7	Schizophrenia;
KIRP	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.81e-15	Atrioventricular conduction;
KIRP	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.48	-6.19	-0.37	2.55e-9	Asthma;
KIRP	cis	rs2274273	1.000	rs10149435	chr14:55627489	C/T	cg04306507	chr14:55594613	LGALS3	0.46	7.04	0.41	1.92e-11	Protein biomarker;
KIRP	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs160189	0.788	rs7234119	chr18:77231787	A/G	cg16308790	chr18:77225973	NFATC1	-0.43	-5.58	-0.33	6.47e-8	Mean platelet volume;
KIRP	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg16586182	chr3:47516702	SCAP	0.62	8.61	0.48	8.87e-16	Colorectal cancer;
KIRP	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	9.33	0.51	6.55e-18	Cognitive test performance;
KIRP	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.56	-8.94	-0.5	9.8e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-10.04	-0.54	4.15e-20	Morning vs. evening chronotype;
KIRP	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.48	-0.38	4.99e-10	Height;
KIRP	cis	rs6893300	0.785	rs3797762	chr5:179202688	A/G	cg14593053	chr5:179126677	CANX	-0.58	-7.23	-0.42	6.14e-12	Resting heart rate;
KIRP	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg13444842	chr1:152974279	SPRR3	-0.37	-5.27	-0.32	2.92e-7	Inflammatory skin disease;
KIRP	cis	rs2692947	0.800	rs2692948	chr2:96673565	T/A	cg23100626	chr2:96804247	ASTL	0.46	5.77	0.35	2.34e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.55	7.02	0.41	2.13e-11	Longevity;Endometriosis;
KIRP	trans	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg13565492	chr6:43139072	SRF	-0.93	-8.53	-0.48	1.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg08017634	chr8:144659831	NAPRT1	0.84	5.45	0.33	1.2e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.59e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.38	-5.28	-0.32	2.86e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.48	-6.1	-0.36	4.03e-9	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg02331583	chr17:40021711	KLHL11	0.52	6.32	0.37	1.22e-9	Educational attainment;
KIRP	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.62	8.16	0.46	1.73e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg21698718	chr17:80085957	CCDC57	0.36	5.14	0.31	5.65e-7	Life satisfaction;
KIRP	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg10617943	chr7:1981403	MAD1L1	-0.4	-5.44	-0.33	1.27e-7	Neuroticism;
KIRP	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.2	-0.31	4.29e-7	Bipolar disorder;
KIRP	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.28	-5.19	-0.31	4.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg17133734	chr15:86042851	AKAP13	-0.47	-5.75	-0.34	2.68e-8	Coronary artery disease;
KIRP	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.55	-7.56	-0.43	8.1e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg05756136	chr1:119680316	WARS2	-0.6	-8.1	-0.46	2.57e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.48	6.37	0.38	9.12e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs6561151	1.000	rs6561151	chr13:44484706	G/A	cg17145862	chr1:211918768	LPGAT1	0.67	8.18	0.46	1.53e-14	Crohn's disease;
KIRP	cis	rs7127900	0.950	rs7121039	chr11:2232911	C/G	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-9.11	-0.5	2.95e-17	Coronary artery disease;
KIRP	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.52	8.67	0.48	6.04e-16	Rheumatoid arthritis;
KIRP	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-5.3	-0.32	2.6e-7	Alzheimer's disease (late onset);
KIRP	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.33	-0.47	5.59e-15	Retinal vascular caliber;
KIRP	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.71	-11.05	-0.58	2.59e-23	Educational attainment;
KIRP	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.54	7.27	0.42	4.64e-12	Primary sclerosing cholangitis;
KIRP	trans	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.2	-0.37	2.38e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.7	9.5	0.52	1.91e-18	Schizophrenia;
KIRP	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.62	7.51	0.43	1.06e-12	Blood protein levels;
KIRP	cis	rs17123764	0.818	rs74089573	chr12:49976074	C/T	cg20471783	chr12:50157085	TMBIM6	0.42	5.54	0.33	7.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg00074818	chr8:8560427	CLDN23	0.39	6.34	0.37	1.11e-9	Obesity-related traits;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.64	7.98	0.45	5.56e-14	Menarche (age at onset);
KIRP	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg04374321	chr14:90722782	PSMC1	0.99	18.3	0.76	8.23e-48	Mortality in heart failure;
KIRP	cis	rs7551222	0.752	rs10900594	chr1:204470129	C/G	cg20240347	chr1:204465584	NA	-0.45	-8.31	-0.47	6.35e-15	Schizophrenia;
KIRP	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.73	11.07	0.58	2.23e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs9612	0.950	rs60649310	chr19:44269241	A/G	cg08581076	chr19:44259116	C19orf61	0.52	5.65	0.34	4.53e-8	Exhaled nitric oxide output;
KIRP	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	1.0	19.34	0.78	2.64e-51	Parkinson's disease;
KIRP	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg04317338	chr11:64019027	PLCB3	-0.43	-5.13	-0.31	5.75e-7	Platelet count;
KIRP	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg18657303	chr4:1051139	NA	0.57	5.13	0.31	5.75e-7	Recombination rate (females);
KIRP	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.7	10.17	0.54	1.61e-20	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10654737	chr15:25655057	UBE3A	0.52	7.85	0.45	1.3e-13	Survival in pancreatic cancer;
KIRP	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg19847130	chr8:10466454	RP1L1	0.33	4.91	0.3	1.65e-6	Retinal vascular caliber;
KIRP	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg21858823	chr1:15850916	CASP9	0.54	5.68	0.34	3.78e-8	Systolic blood pressure;
KIRP	cis	rs6772849	0.805	rs13325747	chr3:128336023	G/A	cg08795948	chr3:128337044	NA	0.38	4.97	0.3	1.25e-6	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg10117171	chr1:25599238	RHD	-0.4	-5.25	-0.32	3.27e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs1010254	0.559	rs114626875	chr5:151740939	G/A	cg12297329	chr5:152029980	NA	-0.62	-6.29	-0.37	1.44e-9	Optic nerve measurement (cup area);
KIRP	cis	rs6466055	0.661	rs2299328	chr7:104905588	A/T	cg04380332	chr7:105027541	SRPK2	0.37	5.05	0.31	8.71e-7	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05782811	chr16:675980	RAB40C	0.49	6.51	0.38	4.18e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17384381	0.953	rs2076699	chr1:85817295	G/A	cg16011679	chr1:85725395	C1orf52	0.78	7.94	0.45	7.14e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4654899	0.727	rs11805169	chr1:21156862	A/T	cg05370193	chr1:21551575	ECE1	-0.39	-5.23	-0.32	3.66e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08508325	chr11:3079039	CARS	0.34	6.41	0.38	7.24e-10	Calcium levels;
KIRP	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg17507749	chr15:85114479	UBE2QP1	0.74	7.13	0.41	1.1e-11	Schizophrenia;
KIRP	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg16479474	chr6:28041457	NA	-0.45	-5.09	-0.31	7.26e-7	Depression;
KIRP	cis	rs17030434	0.911	rs115948674	chr4:154742052	G/T	cg14289246	chr4:154710475	SFRP2	-0.76	-9.42	-0.51	3.44e-18	Electrocardiographic conduction measures;
KIRP	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg11941060	chr3:133502564	NA	-0.48	-5.95	-0.35	8.95e-9	Iron status biomarkers;
KIRP	cis	rs838721	0.574	rs13014016	chr2:234257454	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	4.93	0.3	1.49e-6	Total body bone mineral density;
KIRP	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg03647239	chr10:116582469	FAM160B1	-0.5	-5.77	-0.35	2.36e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg26875233	chr11:93583750	C11orf90	0.35	6.82	0.4	6.82e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg15691649	chr6:25882328	NA	0.55	6.09	0.36	4.37e-9	Blood metabolite levels;
KIRP	cis	rs829661	0.739	rs1252640	chr2:30739298	G/A	cg10949345	chr2:30726833	LCLAT1	1.14	13.67	0.66	4.84e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg12692727	chr7:1102344	C7orf50	0.47	5.09	0.31	6.96e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg02156862	chr17:685377	RNMTL1;GLOD4	0.58	6.81	0.4	7.23e-11	Plasma plasminogen activator levels;
KIRP	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg24803719	chr17:45855879	NA	-0.43	-5.59	-0.34	6.14e-8	IgG glycosylation;
KIRP	cis	rs8018808	0.870	rs11159264	chr14:77937017	T/C	cg18872420	chr14:78023429	SPTLC2	0.37	5.49	0.33	1.01e-7	Myeloid white cell count;
KIRP	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg21466736	chr12:48725269	NA	-0.5	-6.21	-0.37	2.25e-9	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.76e-11	Aortic root size;
KIRP	cis	rs9912468	0.933	rs35135345	chr17:64325539	G/A	cg19474267	chr17:64306194	PRKCA	0.62	8.49	0.48	2.04e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg11859384	chr17:80120422	CCDC57	-0.4	-5.05	-0.31	8.5e-7	Life satisfaction;
KIRP	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg23533926	chr12:111358616	MYL2	-0.48	-6.35	-0.38	1.01e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg18132916	chr6:79620363	NA	-0.42	-5.68	-0.34	3.78e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg04369109	chr6:150039330	LATS1	-0.67	-8.88	-0.49	1.43e-16	Lung cancer;
KIRP	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg04733989	chr22:42467013	NAGA	0.53	6.45	0.38	5.89e-10	Cognitive function;
KIRP	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.03e-13	Obesity-related traits;
KIRP	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.34	-0.51	6.04e-18	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.52	-5.9	-0.35	1.2e-8	Chronic sinus infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15044954	chr7:89874365	C7orf63	0.55	6.47	0.38	5.13e-10	Smoking initiation;
KIRP	cis	rs7096127	1.000	rs2366908	chr10:24499940	A/G	cg04122385	chr10:24535410	KIAA1217;PRINS	0.41	5.05	0.31	8.72e-7	Lobe attachment (rater scored);
KIRP	trans	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg13565492	chr6:43139072	SRF	-0.69	-6.45	-0.38	5.92e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1859156	0.556	rs13133713	chr4:95840995	G/A	cg24204951	chr2:239172084	PER2	0.3	6.54	0.38	3.55e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs7714584	1.000	rs7709650	chr5:150246685	C/T	cg22134413	chr5:150180641	NA	0.74	6.6	0.39	2.49e-10	Crohn's disease;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.6e-9	Lung cancer;
KIRP	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.6	-7.27	-0.42	4.85e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10207060	0.500	rs1316923	chr2:240719792	A/G	cg20333904	chr2:240724165	NA	0.42	5.46	0.33	1.14e-7	Obesity-related traits;
KIRP	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	8.17	0.46	1.68e-14	Educational attainment;
KIRP	cis	rs4523957	0.788	rs7217687	chr17:2098272	G/C	cg16513277	chr17:2031491	SMG6	-0.62	-8.79	-0.49	2.71e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg03808351	chr9:123631620	PHF19	-0.39	-5.17	-0.31	4.83e-7	Rheumatoid arthritis;
KIRP	cis	rs4774899	0.934	rs11632069	chr15:57474756	C/A	cg13626582	chr15:57592083	LOC283663	-0.21	-4.93	-0.3	1.55e-6	Urinary tract infection frequency;
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05195085	chr7:157951403	PTPRN2	0.5	7.57	0.43	7.31e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6959887	1.000	rs6959846	chr7:35295234	C/G	cg06685737	chr7:35301730	NA	0.45	6.66	0.39	1.78e-10	Birth weight;
KIRP	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	0.99	12.66	0.63	1.3e-28	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.5e-39	Headache;
KIRP	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.54	-5.53	-0.33	8.26e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg11584989	chr19:19387371	SF4	0.42	5.36	0.32	1.94e-7	Tonsillectomy;
KIRP	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg15880211	chr22:50250494	ZBED4	0.44	5.18	0.31	4.65e-7	Schizophrenia;
KIRP	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.37	-5.12	-0.31	6.11e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-1.06	-21.18	-0.8	2.33e-57	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	4.95	0.3	1.37e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg13699009	chr12:122356056	WDR66	0.68	10.81	0.57	1.49e-22	Mean corpuscular volume;
KIRP	cis	rs9311676	0.632	rs62259780	chr3:58428078	T/G	cg06643156	chr3:58380774	PXK	0.35	4.89	0.3	1.8e-6	Systemic lupus erythematosus;
KIRP	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg18190219	chr22:46762943	CELSR1	-0.61	-6.39	-0.38	8.3e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg22800045	chr5:56110881	MAP3K1	0.6	6.93	0.4	3.63e-11	Initial pursuit acceleration;
KIRP	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg21775007	chr8:11205619	TDH	0.66	9.63	0.52	7.66e-19	Retinal vascular caliber;
KIRP	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.34	-7.04	-0.41	1.91e-11	Urinary metabolites;
KIRP	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.8	-10.26	-0.55	8.87e-21	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs61935443	0.832	rs10859778	chr12:95268010	C/G	cg21533806	chr12:95267307	NA	0.67	6.61	0.39	2.3e-10	Schizophrenia;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17562763	chr11:67398026	NUDT8	0.53	7.12	0.41	1.15e-11	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24128593	chr6:151712759	ZBTB2	0.52	6.25	0.37	1.84e-9	Parkinson's disease;
KIRP	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.99	-0.3	1.14e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs76917914	0.820	rs7869762	chr9:100814573	G/T	cg03040243	chr9:100819229	NANS	0.61	6.35	0.38	1.04e-9	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.8	-0.4	7.83e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13331940	chr15:59663987	MYO1E	0.56	7.22	0.42	6.61e-12	Parkinson's disease;
KIRP	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.67	10.82	0.57	1.42e-22	Pulse pressure;
KIRP	cis	rs7700895	0.691	rs3777183	chr5:95263735	G/A	cg16656078	chr5:95278638	ELL2	-0.38	-5.61	-0.34	5.38e-8	IgG glycosylation;
KIRP	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg26876637	chr1:152193138	HRNR	-0.78	-8.95	-0.5	8.65e-17	Atopic dermatitis;
KIRP	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg04369109	chr6:150039330	LATS1	-0.45	-5.54	-0.33	7.6e-8	Lung cancer;
KIRP	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-0.9	-9.89	-0.53	1.22e-19	Gut microbiome composition (summer);
KIRP	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg21361702	chr7:150065534	REPIN1	0.5	5.43	0.33	1.32e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	trans	rs2859741	0.587	rs580029	chr1:37471609	C/A	cg04172795	chr14:100578523	EVL	-0.47	-6.38	-0.38	8.49e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs2150410	0.915	rs2236437	chr21:40556595	C/T	cg11890956	chr21:40555474	PSMG1	0.76	5.61	0.34	5.32e-8	Temperament (bipolar disorder);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15617883	chr1:200371248	NA	0.41	6.31	0.37	1.29e-9	C-reactive protein;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15780484	chr4:26862189	STIM2	0.5	7.0	0.41	2.49e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17125944	0.686	rs11621275	chr14:53363316	C/G	cg00686598	chr14:53173677	PSMC6	-0.7	-6.23	-0.37	2.02e-9	Alzheimer's disease (late onset);
KIRP	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg05361325	chr10:32636312	EPC1	-0.67	-6.38	-0.38	8.52e-10	Sexual dysfunction (female);
KIRP	cis	rs9912468	0.966	rs9910577	chr17:64314548	T/C	cg19474267	chr17:64306194	PRKCA	-0.66	-9.46	-0.52	2.58e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs2820315	1.000	rs8024	chr1:201845575	C/A	cg11586189	chr1:201857591	SHISA4	-0.4	-5.61	-0.34	5.33e-8	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs4523957	0.854	rs404392	chr17:2191000	G/A	cg16513277	chr17:2031491	SMG6	0.6	8.29	0.47	7.58e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21230317	chr9:116240607	RGS3	-0.45	-6.54	-0.38	3.48e-10	Inflammatory biomarkers;
KIRP	cis	rs526231	0.543	rs26820	chr5:102528092	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.5	-0.33	9.37e-8	Primary biliary cholangitis;
KIRP	cis	rs2224391	0.628	rs9405260	chr6:5249612	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-5.79	-0.35	2.16e-8	Height;
KIRP	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg13010199	chr12:38710504	ALG10B	0.53	6.6	0.39	2.57e-10	Resting heart rate;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.61	9.45	0.52	2.78e-18	Lung cancer;
KIRP	cis	rs74181299	0.684	rs6736728	chr2:65305499	A/G	cg05010058	chr2:65284262	CEP68	0.42	5.74	0.34	2.79e-8	Pulse pressure;
KIRP	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.85	12.93	0.64	1.58e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	0.92	12.36	0.62	1.33e-27	Blood trace element (Zn levels);
KIRP	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg15534755	chr11:117069859	TAGLN	0.46	5.79	0.35	2.15e-8	Blood protein levels;
KIRP	cis	rs11264213	0.686	rs12041193	chr1:36412760	C/T	cg27506609	chr1:36549197	TEKT2	0.95	9.99	0.54	5.88e-20	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg09699651	chr6:150184138	LRP11	0.45	6.15	0.37	3.06e-9	Lung cancer;
KIRP	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-7.0	-0.41	2.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7091068	0.550	rs7901909	chr10:95492508	C/T	cg20715218	chr10:95462985	C10orf4	0.57	6.35	0.38	1.01e-9	Urinary tract infection frequency;
KIRP	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.43	6.15	0.37	3.1e-9	Testicular germ cell tumor;
KIRP	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg12591125	chr7:1885375	MAD1L1	0.61	5.98	0.36	7.84e-9	Bipolar disorder;
KIRP	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.48	-0.48	2.08e-15	Triglycerides;
KIRP	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.87	13.57	0.65	1.07e-31	Dental caries;
KIRP	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.8	10.78	0.57	1.97e-22	Morning vs. evening chronotype;
KIRP	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg19899395	chr1:46959349	NA	0.39	4.9	0.3	1.76e-6	Monobrow;
KIRP	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.86	11.84	0.6	6.77e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg05785598	chr3:49045655	WDR6	0.29	5.25	0.32	3.3e-7	Parkinson's disease;
KIRP	cis	rs4148660	1.000	rs870135	chr12:22079263	T/C	cg14669847	chr12:22099120	NA	-0.34	-5.8	-0.35	2.07e-8	Gout;
KIRP	cis	rs73058052	0.597	rs56873913	chr19:50091199	T/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.48	5.62	0.34	5.14e-8	Fibrinogen levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg01458961	chr4:102269425	PPP3CA	1.11	7.64	0.44	4.91e-13	P wave terminal force;
KIRP	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg03468072	chr12:39539422	NA	0.45	6.11	0.36	3.87e-9	Morning vs. evening chronotype;
KIRP	cis	rs8033133	0.957	rs7162559	chr15:25352341	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.49	5.66	0.34	4.26e-8	Blood osmolality (transformed sodium);
KIRP	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.44	-7.01	-0.41	2.22e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg01631408	chr1:248437212	OR2T33	-0.43	-6.05	-0.36	5.34e-9	Common traits (Other);
KIRP	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg01721255	chr8:58191610	C8orf71	0.55	5.69	0.34	3.69e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.45	6.47	0.38	5.32e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3105593	1.000	rs28494067	chr15:50908272	A/G	cg08437265	chr15:50716283	USP8	0.39	4.93	0.3	1.48e-6	QT interval;
KIRP	trans	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.44	-0.38	6.22e-10	Heart rate;
KIRP	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.54	-0.33	7.7e-8	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06015645	chr18:42260134	SETBP1	0.58	7.29	0.42	4.19e-12	Parkinson's disease;
KIRP	cis	rs9653442	0.527	rs2164712	chr2:100745404	C/G	cg17356467	chr2:100759845	AFF3	0.42	5.94	0.35	9.44e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs28489187	0.706	rs233127	chr1:85793801	A/G	cg16011679	chr1:85725395	C1orf52	0.5	6.1	0.36	4.01e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.52	0.48	1.64e-15	Bipolar disorder;
KIRP	cis	rs13095912	0.752	rs7613002	chr3:185353235	T/C	cg11274856	chr3:185301563	NA	0.64	7.91	0.45	8.54e-14	Systolic blood pressure;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.9	-0.3	1.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9810259	0.966	rs13066322	chr3:12269266	C/T	cg15873301	chr3:12045459	SYN2	-0.37	-5.04	-0.31	8.86e-7	Platelet count;
KIRP	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.42	5.27	0.32	2.96e-7	Common traits (Other);
KIRP	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.75	-9.54	-0.52	1.45e-18	Height;
KIRP	cis	rs73411413	0.661	rs11599981	chr11:1520063	C/T	cg04803994	chr11:1592587	HCCA2;LOC338651;DUSP8	-0.55	-6.75	-0.4	1.03e-10	Myringotomy;
KIRP	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17067123	0.614	rs55983301	chr4:180070495	A/G	cg26610307	chr4:180072759	NA	-0.47	-5.21	-0.32	3.92e-7	Response to hepatitis C treatment;
KIRP	cis	rs6546324	0.694	rs1023692	chr2:67868756	T/C	cg15745817	chr2:67799979	NA	-0.51	-6.33	-0.37	1.17e-9	Endometriosis;
KIRP	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02887679	chr6:36410977	PXT1;KCTD20	0.49	6.57	0.39	2.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17065868	1.000	rs56296224	chr13:45107081	G/A	cg10246903	chr13:45222710	NA	0.72	6.9	0.4	4.37e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg02811702	chr13:24901961	NA	0.43	5.69	0.34	3.67e-8	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05954147	chr7:126417956	GRM8	-0.42	-6.12	-0.36	3.66e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11809208	chr10:27529791	ACBD5	0.49	6.2	0.37	2.39e-9	Parkinson's disease;
KIRP	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.23	-0.32	3.65e-7	Tonsillectomy;
KIRP	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.78	-9.19	-0.51	1.72e-17	Vitiligo;
KIRP	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg26876637	chr1:152193138	HRNR	-0.72	-9.79	-0.53	2.49e-19	Atopic dermatitis;
KIRP	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.57	-0.68	4.3e-35	Primary sclerosing cholangitis;
KIRP	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.56	9.29	0.51	8.77e-18	Schizophrenia;
KIRP	cis	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	5.13	0.31	5.74e-7	Leprosy;
KIRP	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs4671458	0.948	rs10496101	chr2:63454114	T/C	cg17519650	chr2:63277830	OTX1	-0.52	-5.52	-0.33	8.61e-8	Subjective well-being;
KIRP	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-5.67	-0.34	4.06e-8	Endometrial cancer;
KIRP	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg08975724	chr8:8085496	FLJ10661	-0.65	-9.02	-0.5	5.56e-17	Mood instability;
KIRP	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg03289416	chr15:75166202	SCAMP2	-0.4	-5.29	-0.32	2.72e-7	Systemic lupus erythematosus;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12050497	chr2:14773274	FAM84A	0.44	6.11	0.36	3.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	6.2	0.37	2.43e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.01	-0.5	5.76e-17	Schizophrenia;
KIRP	cis	rs6545883	0.965	rs3771258	chr2:61764140	C/T	cg15711740	chr2:61764176	XPO1	-0.63	-8.58	-0.48	1.06e-15	Tuberculosis;
KIRP	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Bipolar disorder;
KIRP	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	1.1	18.17	0.76	2.26e-47	Cognitive function;
KIRP	cis	rs2920503	0.659	rs17029006	chr3:12329452	C/T	cg23514324	chr3:12329213	PPARG	0.64	6.73	0.39	1.18e-10	LDL cholesterol;
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.89	-9.23	-0.51	1.26e-17	Platelet count;
KIRP	cis	rs31771	0.775	rs41012	chr5:165487589	C/A	cg13976338	chr5:165423657	NA	0.57	5.52	0.33	8.48e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-0.81	-8.68	-0.48	5.37e-16	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs9547996	0.879	rs4432141	chr13:38172236	A/G	cg13634560	chr13:38173852	POSTN	-0.4	-5.54	-0.33	7.8e-8	Diastolic blood pressure;
KIRP	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg14458575	chr2:238380390	NA	0.56	6.03	0.36	5.91e-9	Prostate cancer;
KIRP	cis	rs9303542	0.559	rs2229302	chr17:46620402	G/A	cg05487507	chr17:46671861	LOC404266;HOXB5	0.43	4.93	0.3	1.51e-6	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg13147721	chr7:65941812	NA	-0.96	-6.91	-0.4	4.25e-11	Diabetic kidney disease;
KIRP	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.46	-6.63	-0.39	2.14e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg00738919	chr7:1100172	C7orf50	0.42	5.08	0.31	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-0.9	-11.33	-0.59	3.23e-24	Vitiligo;
KIRP	cis	rs6466055	0.661	rs67620169	chr7:104895639	C/T	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	7.01e-7	Schizophrenia;
KIRP	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.15e-51	Height;
KIRP	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.43	-7.01	-0.41	2.31e-11	Eye color traits;
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.69	9.55	0.52	1.4e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.91	0.35	1.16e-8	Total cholesterol levels;
KIRP	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg00990874	chr7:1149470	C7orf50	-0.84	-8.39	-0.47	3.9e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.64	8.78	0.49	2.87e-16	High light scatter reticulocyte count;
KIRP	cis	rs6546324	1.000	rs4141819	chr2:67864675	C/T	cg15745817	chr2:67799979	NA	-0.43	-5.75	-0.34	2.67e-8	Endometriosis;
KIRP	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg08873628	chr1:175162347	KIAA0040	0.44	6.53	0.38	3.78e-10	Alcohol dependence;
KIRP	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg21427119	chr20:30132790	HM13	-0.42	-5.04	-0.31	8.89e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.63	8.5	0.48	1.88e-15	Total body bone mineral density;
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.35	5.86	0.35	1.51e-8	Lung cancer;
KIRP	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-7.63	-0.44	5.16e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.75	10.8	0.57	1.65e-22	Lung cancer;
KIRP	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.55	-6.85	-0.4	5.77e-11	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.65	-8.0	-0.45	4.95e-14	Iron status biomarkers;
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg22533281	chr1:70509936	LRRC7	-0.34	-6.17	-0.37	2.79e-9	Suicide attempts in major depressive disorder;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg19789848	chr17:30454741	NA	0.91	6.03	0.36	5.89e-9	P wave terminal force;
KIRP	cis	rs12762955	0.519	rs7094331	chr10:1022816	T/C	cg26597838	chr10:835615	NA	-0.52	-6.78	-0.4	9.12e-11	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs2591576	0.648	rs248547	chr5:165390351	A/T	cg13976338	chr5:165423657	NA	-0.69	-9.79	-0.53	2.58e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg08603382	chr10:743973	NA	-0.63	-9.5	-0.52	1.93e-18	Psychosis in Alzheimer's disease;
KIRP	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7692976	0.608	rs6533483	chr4:110887989	G/A	cg06981781	chr4:110842888	EGF	-0.22	-4.88	-0.3	1.95e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4774899	0.934	rs12912392	chr15:57489503	C/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.39	-0.32	1.65e-7	Urinary tract infection frequency;
KIRP	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg05072774	chr3:49840536	C3orf54	0.43	5.57	0.33	6.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	1.000	rs6814012	chr4:76950778	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26880963	chr1:65209468	RAVER2	-0.47	-7.35	-0.42	2.91e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.8	-0.4	7.75e-11	Bladder cancer;
KIRP	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.49	5.19	0.31	4.34e-7	Smoking behavior;
KIRP	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg10935138	chr17:73851978	WBP2	0.59	7.52	0.43	9.96e-13	Psoriasis;
KIRP	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg23625390	chr15:77176239	SCAPER	0.49	6.55	0.39	3.42e-10	Blood metabolite levels;
KIRP	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs888194	0.898	rs10850379	chr12:110002777	A/G	cg05360138	chr12:110035743	NA	-0.4	-5.02	-0.3	9.83e-7	Neuroticism;
KIRP	cis	rs2299587	0.585	rs379167	chr8:17778924	C/G	cg01800426	chr8:17659068	MTUS1	-0.51	-5.28	-0.32	2.9e-7	Economic and political preferences;
KIRP	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.52	-6.65	-0.39	1.85e-10	Coronary heart disease;
KIRP	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg18461458	chr19:21324796	ZNF431	0.45	4.85	0.3	2.24e-6	Pain;
KIRP	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.67	-7.85	-0.45	1.29e-13	Systemic lupus erythematosus;
KIRP	cis	rs8054556	0.787	rs11150581	chr16:30030699	T/C	cg06326092	chr16:30034487	C16orf92	0.44	5.94	0.35	9.78e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg22117172	chr7:91764530	CYP51A1	-0.38	-5.42	-0.33	1.43e-7	Breast cancer;
KIRP	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	0.56	5.44	0.33	1.31e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg22974920	chr21:40686053	BRWD1	0.51	5.88	0.35	1.33e-8	Cognitive function;
KIRP	cis	rs28834970	0.925	rs6987305	chr8:27208126	G/A	cg14221460	chr8:27183342	PTK2B	-0.47	-6.1	-0.36	4.08e-9	Alzheimer's disease (late onset);
KIRP	cis	rs72781680	0.611	rs72797819	chr2:24351141	T/G	cg20701182	chr2:24300061	SF3B14	0.97	10.56	0.56	9.8e-22	Lymphocyte counts;
KIRP	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg07402062	chr16:89894098	SPIRE2	-0.34	-6.98	-0.41	2.75e-11	Vitiligo;
KIRP	trans	rs6601327	0.601	rs11249939	chr8:9556500	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.44	-0.38	6.14e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.86	-17.02	-0.74	1.82e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.34	-0.32	2.09e-7	Life satisfaction;
KIRP	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	5.05	0.31	8.58e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.55	-8.5	-0.48	1.85e-15	Longevity;
KIRP	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.56	-0.48	1.25e-15	Neuroticism;
KIRP	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg25650185	chr19:21324782	ZNF431	-0.49	-5.16	-0.31	4.97e-7	Pain;
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg02297831	chr4:17616191	MED28	0.59	7.61	0.44	5.7e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg09408571	chr1:101003634	GPR88	-0.36	-8.14	-0.46	2.03e-14	Breast cancer;
KIRP	cis	rs4690686	0.554	rs13141274	chr4:177285027	C/T	cg17059388	chr4:177262070	NA	0.56	7.37	0.43	2.56e-12	Essential tremor;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg26770187	chr3:14693171	C3orf19	0.49	6.72	0.39	1.22e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.67	-0.44	4.03e-13	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16687034	chr1:12483556	VPS13D	0.55	7.38	0.43	2.39e-12	Interleukin-4 levels;
KIRP	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.87	11.4	0.59	1.93e-24	Monocyte count;
KIRP	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.77	-11.99	-0.61	2.1e-26	Hepatocellular carcinoma;
KIRP	cis	rs7804356	1.000	rs3823934	chr7:26853934	T/C	cg03456212	chr7:26904342	SKAP2	-0.52	-4.88	-0.3	1.9e-6	Type 1 diabetes;
KIRP	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg25486957	chr4:152246857	NA	-0.5	-5.32	-0.32	2.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.842	rs7966352	chr12:86438705	A/C	cg02569458	chr12:86230093	RASSF9	0.35	4.98	0.3	1.21e-6	Major depressive disorder;
KIRP	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg23533419	chr12:54090519	NA	-0.33	-5.16	-0.31	5.07e-7	Height;
KIRP	cis	rs526231	0.644	rs35797	chr5:102614327	A/G	cg18986329	chr5:102455989	GIN1	0.37	4.9	0.3	1.77e-6	Primary biliary cholangitis;
KIRP	cis	rs10988449	0.891	rs62586368	chr9:132387882	C/T	cg18327994	chr9:132372705	NA	-0.52	-5.11	-0.31	6.61e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.41	5.32	0.32	2.3e-7	Childhood ear infection;
KIRP	cis	rs7546094	0.935	rs10776757	chr1:113121673	G/C	cg22162597	chr1:113214053	CAPZA1	0.39	5.23	0.32	3.54e-7	Platelet distribution width;
KIRP	cis	rs2070997	0.702	rs7457	chr9:133762826	C/T	cg13397898	chr9:133768931	QRFP	0.37	5.02	0.3	9.92e-7	Response to amphetamines;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13030132	chr2:20189828	WDR35	-0.53	-6.1	-0.36	4.03e-9	Interleukin-4 levels;
KIRP	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23161317	chr6:28129485	ZNF389	0.43	5.06	0.31	8.25e-7	Depression;
KIRP	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06544989	chr22:39130855	UNC84B	0.49	8.2	0.46	1.35e-14	Menopause (age at onset);
KIRP	cis	rs909341	0.868	rs2315009	chr20:62344140	C/G	cg03999872	chr20:62272968	STMN3	-0.56	-6.57	-0.39	2.93e-10	Atopic dermatitis;
KIRP	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.93	14.28	0.67	4.17e-34	Menopause (age at onset);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg04242559	chr16:1435541	NA	0.47	6.08	0.36	4.5e-9	Pancreatic cancer;
KIRP	cis	rs9886651	0.935	rs36157705	chr8:128797938	A/G	cg24514600	chr8:128805414	PVT1	-0.73	-12.48	-0.62	5.25e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs9398803	0.865	rs9401882	chr6:126755055	A/G	cg19875578	chr6:126661172	C6orf173	0.5	6.42	0.38	6.87e-10	Male-pattern baldness;
KIRP	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	cis	rs117492019	1.000	rs117492019	chr19:58681861	G/T	cg07378217	chr19:58662286	ZNF329	-0.58	-5.5	-0.33	9.64e-8	LDL cholesterol;
KIRP	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.7	10.23	0.55	1.03e-20	Oral cavity cancer;
KIRP	cis	rs494003	1.000	rs494003	chr11:65542298	G/A	cg11569703	chr11:65557185	OVOL1	-0.37	-4.96	-0.3	1.34e-6	Systemic lupus erythematosus;
KIRP	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg08742575	chr21:47604166	C21orf56	0.38	4.89	0.3	1.82e-6	Testicular germ cell tumor;
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.4	5.31	0.32	2.4e-7	Cardiovascular disease risk factors;
KIRP	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.72	7.88	0.45	1.08e-13	Corneal astigmatism;
KIRP	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg09914555	chr8:142094789	NA	-0.45	-5.76	-0.34	2.53e-8	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	cis	rs6504622	0.905	rs9898981	chr17:45026715	T/G	cg24703533	chr17:45055318	NA	0.4	5.59	0.34	6.16e-8	Orofacial clefts;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg06371346	chr10:52283680	SGMS1	-0.42	-6.11	-0.36	3.95e-9	Select biomarker traits;
KIRP	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg13978929	chr19:21580086	ZNF493	0.52	5.06	0.31	8.17e-7	Pain;
KIRP	cis	rs1983891	0.954	rs4714481	chr6:41521110	T/C	cg20194872	chr6:41519635	FOXP4	0.55	6.96	0.41	3.07e-11	Prostate cancer;
KIRP	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7404928	0.681	rs16972959	chr16:23901376	G/A	cg05497750	chr16:23765381	CHP2	-0.45	-4.93	-0.3	1.54e-6	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27297192	chr10:134578999	INPP5A	0.57	7.09	0.41	1.43e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg02795151	chr17:7402630	POLR2A	0.79	7.97	0.45	5.83e-14	Androgen levels;
KIRP	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.71	9.51	0.52	1.89e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.05	-0.36	5.37e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs533123	0.816	rs569356	chr1:29136686	A/G	cg08366446	chr1:29138936	OPRD1	-1.06	-8.59	-0.48	1.01e-15	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	7.97e-43	Homoarginine levels;
KIRP	cis	rs7589728	1.000	rs6722069	chr2:88533151	C/T	cg04511125	chr2:88470314	THNSL2	0.68	5.29	0.32	2.67e-7	Plasma clusterin levels;
KIRP	cis	rs4783244	0.864	rs8062260	chr16:82658090	G/A	cg09415485	chr16:82663111	CDH13	-0.28	-5.3	-0.32	2.61e-7	Adiponectin levels;
KIRP	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.61	-0.34	5.54e-8	Metabolite levels;
KIRP	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.09	-0.54	2.9e-20	Hemoglobin concentration;
KIRP	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg20387954	chr3:183756860	HTR3D	0.61	8.98	0.5	7.18e-17	Anterior chamber depth;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05349356	chr20:3451609	ATRN	0.45	6.03	0.36	5.93e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21591848	chr15:42500463	VPS39	0.48	6.64	0.39	2.03e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg16141378	chr3:129829833	LOC729375	0.57	7.86	0.45	1.21e-13	Mood instability;
KIRP	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.69	8.48	0.48	2.17e-15	Corneal astigmatism;
KIRP	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg15556689	chr8:8085844	FLJ10661	0.54	6.59	0.39	2.68e-10	Neuroticism;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15819808	chr12:122631519	NA	0.47	6.52	0.38	4.06e-10	Pancreatic cancer;
KIRP	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.9	11.98	0.61	2.36e-26	Vitamin D levels;
KIRP	cis	rs6466055	0.661	rs3801279	chr7:104904868	C/T	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05665937	chr4:1216051	CTBP1	0.51	7.27	0.42	4.88e-12	Obesity-related traits;
KIRP	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.18	0.37	2.61e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.69	-7.6	-0.44	6.07e-13	Gut microbiome composition (summer);
KIRP	cis	rs6578185	0.568	rs13248753	chr8:142464967	C/T	cg15142913	chr8:142440250	PTP4A3	-0.4	-5.27	-0.32	2.95e-7	Endometriosis;
KIRP	cis	rs80282103	0.618	rs11816485	chr10:1147974	T/C	cg08668510	chr10:1095578	IDI1	0.97	6.51	0.38	4.29e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs6882046	0.513	rs42850	chr5:88019474	G/A	cg22951263	chr5:87985283	NA	-0.46	-6.49	-0.38	4.75e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.72	-0.53	4.08e-19	Height;
KIRP	cis	rs754423	0.532	rs941625	chr14:52547735	A/G	cg05884192	chr14:52515736	NID2	-0.52	-6.78	-0.4	8.71e-11	Craniofacial microsomia;
KIRP	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.67	-10.42	-0.55	2.66e-21	Hepatocellular carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24360513	chr1:249120106	SH3BP5L	0.46	6.59	0.39	2.6200000000000003e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg23594656	chr7:65796392	TPST1	0.51	7.85	0.45	1.32e-13	Aortic root size;
KIRP	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.83	9.12	0.5	2.71e-17	Alzheimer's disease;
KIRP	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.63	-7.17	-0.42	8.53e-12	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg03342759	chr3:160939853	NMD3	0.41	4.88	0.3	1.87e-6	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10207510	chr8:87243979	SLC7A13	0.46	6.91	0.4	4.23e-11	Survival in pancreatic cancer;
KIRP	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg13180566	chr4:1052158	NA	-0.49	-5.28	-0.32	2.84e-7	Recombination rate (females);
KIRP	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.45	5.63	0.34	4.91e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18384926	chr15:45722598	C15orf48	0.48	6.99	0.41	2.6e-11	Parkinson's disease;
KIRP	cis	rs6585424	1.000	rs6585424	chr10:81933748	A/G	cg27417294	chr10:81904244	PLAC9	0.52	5.13	0.31	5.93e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg20060108	chr2:102954350	IL1RL1	-0.61	-5.52	-0.33	8.54e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg08662619	chr6:150070041	PCMT1	0.38	6.2	0.37	2.32e-9	Lung cancer;
KIRP	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.39	0.38	8.1e-10	Neuroticism;
KIRP	cis	rs7845219	0.544	rs4735332	chr8:95923660	C/T	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.44	-0.38	6.24e-10	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg13409248	chr3:40428643	ENTPD3	0.37	5.11	0.31	6.43e-7	Renal cell carcinoma;
KIRP	cis	rs933688	0.509	rs7731341	chr5:90524105	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-5.61	-0.34	5.33e-8	Smoking behavior;
KIRP	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.29	0.32	2.77e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg26248373	chr2:1572462	NA	-0.8	-10.82	-0.57	1.43e-22	IgG glycosylation;
KIRP	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	cis	rs1978968	0.956	rs12159837	chr22:18447491	G/A	cg03078520	chr22:18463400	MICAL3	-0.64	-7.61	-0.44	5.68e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg22974920	chr21:40686053	BRWD1	0.5	5.93	0.35	1.02e-8	Cognitive function;
KIRP	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.79	7.17	0.42	8.77e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.74	-0.49	3.68e-16	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.34	-0.42	3.07e-12	Aortic root size;
KIRP	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.98	-11.82	-0.6	7.76e-26	Dilated cardiomyopathy;
KIRP	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	1.26	26.57	0.86	2.99e-74	IgG glycosylation;
KIRP	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	cg21523751	chr1:182988639	NA	0.34	4.86	0.3	2.06e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg24503407	chr1:205819492	PM20D1	0.45	4.91	0.3	1.69e-6	Prostate-specific antigen levels;
KIRP	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg05791153	chr7:19748676	TWISTNB	0.66	6.05	0.36	5.43e-9	Thyroid stimulating hormone;
KIRP	trans	rs12517041	1.000	rs6889624	chr5:23304501	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.21e-13	Calcium levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08862778	chr1:11322643	MTOR	0.59	7.07	0.41	1.64e-11	Smoking initiation;
KIRP	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.52	6.28	0.37	1.55e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg23067535	chr8:124195133	FAM83A	-0.78	-7.63	-0.44	5.05e-13	Urinary uromodulin levels;
KIRP	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.63	-8.73	-0.49	3.92e-16	Menarche (age at onset);
KIRP	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.47	6.16	0.37	2.93e-9	Lung cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg10243787	chr22:19419481	HIRA;MRPL40	0.48	6.03	0.36	6e-9	Asthma;
KIRP	cis	rs9937943	0.721	rs8059315	chr16:74506447	C/G	cg01733217	chr16:74700730	RFWD3	0.59	5.66	0.34	4.18e-8	Neutrophil percentage of white cells;
KIRP	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.71	-10.57	-0.56	8.81e-22	Colorectal cancer;
KIRP	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.48	5.45	0.33	1.25e-7	Coronary artery disease;
KIRP	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.3	-6.01	-0.36	6.71e-9	Schizophrenia;
KIRP	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22590775	chr19:49891494	CCDC155	0.59	7.29	0.42	4.33e-12	Multiple sclerosis;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg05573182	chr20:39318437	MAFB	0.48	6.03	0.36	5.84e-9	Asthma;
KIRP	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg18833306	chr6:118973337	C6orf204	0.4	5.21	0.32	4e-7	Electrocardiographic conduction measures;
KIRP	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.67	7.66	0.44	4.38e-13	Corneal astigmatism;
KIRP	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs7215564	0.908	rs2315922	chr17:78695127	C/T	cg08454507	chr17:78755406	RPTOR	0.32	4.92	0.3	1.57e-6	Myopia (pathological);
KIRP	cis	rs11628318	0.805	rs749543	chr14:103057250	C/A	cg12046867	chr14:103022105	NA	-0.43	-5.91	-0.35	1.14e-8	Platelet count;
KIRP	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.46	-6.78	-0.4	8.65e-11	Daytime sleep phenotypes;
KIRP	cis	rs867371	0.929	rs1501371	chr15:82460440	A/C	cg00614314	chr15:82944287	LOC80154	0.5	5.94	0.35	9.74e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.72	10.28	0.55	7.72e-21	Red blood cell count;
KIRP	cis	rs6504340	0.739	rs4793943	chr17:46666937	C/G	cg04904318	chr17:46607828	HOXB1	-0.55	-5.68	-0.34	3.77e-8	Primary tooth development (number of teeth);
KIRP	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg06637938	chr14:75390232	RPS6KL1	0.44	6.25	0.37	1.75e-9	Height;
KIRP	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.2	0.51	1.55e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-9.95	-0.54	8.19e-20	Exhaled nitric oxide output;
KIRP	cis	rs2278796	1.000	rs2278796	chr1:204951209	C/T	cg17947172	chr1:204966197	NFASC	0.67	9.06	0.5	4.23e-17	Mean platelet volume;
KIRP	cis	rs4704187	0.687	rs10462354	chr5:74453027	T/G	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-17.79	-0.75	4.62e-46	Height;
KIRP	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg03714773	chr7:91764589	CYP51A1	0.33	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.06	-0.41	1.69e-11	Myopia (pathological);
KIRP	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.44	0.43	1.65e-12	Aortic root size;
KIRP	cis	rs2522056	1.000	rs2522054	chr5:131799526	G/T	cg07395648	chr5:131743802	NA	0.55	6.64	0.39	2.05e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg23100626	chr2:96804247	ASTL	0.5	6.89	0.4	4.65e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.72	-10.59	-0.56	7.6e-22	Total body bone mineral density;
KIRP	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.58	8.7	0.49	4.89e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4927850	0.794	rs13070153	chr3:195741185	A/T	cg01181863	chr3:195395398	SDHAP2	-0.83	-9.51	-0.52	1.88e-18	Pancreatic cancer;
KIRP	cis	rs1448094	0.845	rs17354637	chr12:86347752	A/G	cg00310523	chr12:86230176	RASSF9	0.41	6.32	0.37	1.24e-9	Major depressive disorder;
KIRP	cis	rs4849845	0.889	rs4091515	chr2:121043403	G/A	cg24070213	chr2:121070622	NA	0.39	5.4	0.33	1.6e-7	Mean platelet volume;
KIRP	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.57	7.17	0.42	8.64e-12	Mosquito bite size;
KIRP	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18364779	chr6:26104403	HIST1H4C	-0.37	-4.89	-0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.59	-7.65	-0.44	4.45e-13	Aortic root size;
KIRP	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.92	-0.57	6.63e-23	Acylcarnitine levels;
KIRP	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.46	-6.24	-0.37	1.89e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.37	-0.32	1.8e-7	Reticulocyte count;
KIRP	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.63e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.45	-5.9	-0.35	1.22e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11225247	0.772	rs11601671	chr11:102250065	C/T	cg06323957	chr11:102217781	BIRC2	0.92	5.66	0.34	4.25e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Visceral adipose tissue adjusted for BMI;
KIRP	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.63	9.97	0.54	6.97e-20	Bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20127207	chr2:160625571	CD302	-0.39	-6.31	-0.37	1.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.45	-5.5	-0.33	9.71e-8	Testicular germ cell tumor;
KIRP	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.43	-5.0	-0.3	1.08e-6	Metabolite levels;
KIRP	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg04546413	chr19:29218101	NA	0.64	5.94	0.35	9.74e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs3813948	0.505	rs17020993	chr1:207288392	A/G	cg26044340	chr1:207277291	C4BPA	-0.48	-5.72	-0.34	3.02e-8	C4b binding protein levels;
KIRP	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.56	6.95	0.4	3.31e-11	Immature fraction of reticulocytes;Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09060784	chr1:220324033	RAB3GAP2	0.45	6.52	0.38	4.03e-10	Interleukin-4 levels;
KIRP	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11987759	chr7:65425863	GUSB	-0.56	-7.22	-0.42	6.65e-12	Aortic root size;
KIRP	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.57	8.27	0.47	8.62e-15	Reticulocyte fraction of red cells;
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.46	-5.38	-0.32	1.72e-7	Lung cancer;
KIRP	cis	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg19680485	chr15:31195859	MTMR15	-0.52	-4.91	-0.3	1.66e-6	Hypertriglyceridemia;
KIRP	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg10932868	chr11:921992	NA	0.58	7.33	0.42	3.21e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.72	9.5	0.52	1.92e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4356975	0.583	rs4632729	chr4:69946004	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.0	0.3	1.09e-6	Obesity-related traits;
KIRP	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.85	-0.49	1.7e-16	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7187994	0.848	rs12933228	chr16:84770691	G/A	cg07647771	chr16:84786436	USP10	-0.5	-6.04	-0.36	5.54e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4253772	0.872	rs45576140	chr22:46638216	C/G	cg18190219	chr22:46762943	CELSR1	-0.61	-5.78	-0.35	2.3e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.91	11.92	0.61	3.73e-26	Homoarginine levels;
KIRP	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.92	14.65	0.68	2.32e-35	Blood protein levels;
KIRP	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs2172802	0.570	rs1542834	chr4:62540430	A/G	cg04118610	chr4:62707027	LPHN3	-0.43	-5.38	-0.32	1.71e-7	Partial epilepsies;
KIRP	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.54	7.01	0.41	2.25e-11	Monobrow;
KIRP	cis	rs9815354	1.000	rs7648578	chr3:41858731	C/T	cg03022575	chr3:42003672	ULK4	0.5	5.84	0.35	1.63e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg17145862	chr1:211918768	LPGAT1	0.77	10.4	0.55	3.06e-21	Leprosy;
KIRP	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.26	7.5	0.43	1.18e-12	Type 2 diabetes;
KIRP	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.54	-5.77	-0.35	2.33e-8	Subjective well-being;
KIRP	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg07596299	chr11:71824057	C11orf51	0.93	5.89	0.35	1.29e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.66	-8.62	-0.48	8.23e-16	Motion sickness;
KIRP	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg19592336	chr6:28129416	ZNF389	0.48	5.52	0.33	8.75e-8	Depression;
KIRP	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg26408565	chr15:76604113	ETFA	-0.44	-6.09	-0.36	4.38e-9	Blood metabolite levels;
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	0.85	14.53	0.68	6.04e-35	Vitiligo;
KIRP	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.39	5.26	0.32	3.12e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.73	-8.86	-0.49	1.59e-16	Cognitive function;
KIRP	cis	rs79881201	0.895	rs10455025	chr5:110404999	A/C	cg04022379	chr5:110408740	TSLP	-0.47	-5.91	-0.35	1.13e-8	Sum eosinophil basophil counts;
KIRP	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg24955955	chr5:415729	AHRR	0.77	6.34	0.37	1.12e-9	Fat distribution (HIV);
KIRP	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.89	-12.97	-0.64	1.13e-29	Dupuytren's disease;
KIRP	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg18944383	chr4:111397179	ENPEP	0.44	7.24	0.42	5.59e-12	Height;
KIRP	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3026101	0.723	rs1544400	chr17:5305924	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.65	0.39	1.84e-10	Body mass index;
KIRP	cis	rs1832871	0.711	rs9457264	chr6:158689367	G/A	cg07215822	chr6:158701037	NA	-0.64	-7.51	-0.43	1.1e-12	Height;
KIRP	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg12591125	chr7:1885375	MAD1L1	-0.55	-5.44	-0.33	1.28e-7	Bipolar disorder;
KIRP	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg22437258	chr11:111473054	SIK2	0.59	7.35	0.42	3.01e-12	Primary sclerosing cholangitis;
KIRP	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg15117754	chr3:10150083	C3orf24	0.56	5.35	0.32	2.02e-7	Alzheimer's disease;
KIRP	cis	rs2151522	0.603	rs62439171	chr6:127203281	A/C	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.82	13.41	0.65	3.93e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06481639	chr22:41940642	POLR3H	-0.48	-5.83	-0.35	1.69e-8	Vitiligo;
KIRP	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1832871	0.683	rs9457224	chr6:158666139	C/T	cg07215822	chr6:158701037	NA	-0.64	-7.41	-0.43	2.03e-12	Height;
KIRP	cis	rs2635047	0.519	rs2668771	chr18:44775897	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	4.99	0.3	1.17e-6	Educational attainment;
KIRP	cis	rs3007729	0.509	rs6665151	chr1:18800247	A/G	cg04846421	chr1:18800208	NA	-0.57	-7.94	-0.45	7.27e-14	Diabetic retinopathy;
KIRP	cis	rs754423	0.703	rs753436	chr14:52519839	G/A	cg10149976	chr14:52535953	NID2	-0.39	-5.33	-0.32	2.23e-7	Craniofacial microsomia;
KIRP	cis	rs933360	0.535	rs10248029	chr7:50845703	T/C	cg14997413	chr7:51384937	COBL	0.31	4.87	0.3	1.95e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg26513180	chr16:89883248	FANCA	0.84	5.61	0.34	5.45e-8	Skin colour saturation;
KIRP	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg02367723	chr1:46378857	MAST2	0.44	5.17	0.31	4.93e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	1.11	16.36	0.72	3.42e-41	Breast cancer;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00636124	chr16:27215281	JMJD5	0.93	6.36	0.38	9.52e-10	P wave terminal force;
KIRP	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.62	8.12	0.46	2.23e-14	Motion sickness;
KIRP	cis	rs4148660	0.963	rs1283804	chr12:22050206	T/C	cg14669847	chr12:22099120	NA	0.34	5.88	0.35	1.3e-8	Gout;
KIRP	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs5167	0.566	rs2075618	chr19:45495668	G/C	cg13119609	chr19:45449297	APOC2	0.39	4.86	0.3	2.14e-6	Blood protein levels;
KIRP	cis	rs876084	0.505	rs11985197	chr8:121107553	G/A	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs13315871	1.000	rs4075403	chr3:58411445	G/C	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg09455208	chr3:40491958	NA	0.32	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	cis	rs7849270	0.959	rs10739742	chr9:131921668	A/G	cg13538475	chr9:131942899	NA	-0.36	-5.79	-0.35	2.16e-8	Blood metabolite ratios;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03022926	chr14:92248966	TC2N	-0.41	-6.16	-0.37	2.98e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg10503236	chr1:231470652	EXOC8	-0.49	-6.67	-0.39	1.64e-10	Hemoglobin concentration;
KIRP	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg18016565	chr1:150552671	MCL1	0.39	5.9	0.35	1.19e-8	Melanoma;
KIRP	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.66	9.09	0.5	3.5e-17	Obesity-related traits;
KIRP	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg05022225	chr19:49866942	DKKL1;TEAD2	0.46	5.89	0.35	1.24e-8	Multiple sclerosis;
KIRP	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.36	0.32	1.93e-7	Initial pursuit acceleration;
KIRP	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.71	9.57	0.52	1.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3026101	0.671	rs3026129	chr17:5295371	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg02254774	chr11:50257496	LOC441601	-0.39	-5.0	-0.3	1.09e-6	Height;
KIRP	cis	rs364477	0.721	rs279876	chr9:996439	G/T	cg13952963	chr9:998547	NA	-0.65	-5.37	-0.32	1.85e-7	Major depressive disorder;
KIRP	cis	rs10824796	1.000	rs10824796	chr10:54534613	A/G	cg27418851	chr10:54531653	MBL2	0.45	5.48	0.33	1.04e-7	Blood protein levels;
KIRP	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.68	9.95	0.54	8.26e-20	Dupuytren's disease;
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.25	5.24	0.32	3.5e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11169552	0.510	rs34867510	chr12:50974541	G/C	cg12884762	chr12:50931848	DIP2B	-0.42	-5.02	-0.3	1.02e-6	Colorectal cancer;
KIRP	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.57	7.86	0.45	1.22e-13	Heart rate;
KIRP	cis	rs12496230	0.794	rs7638818	chr3:66860600	T/A	cg04995300	chr3:66848608	NA	0.44	6.85	0.4	5.99e-11	Type 2 diabetes;
KIRP	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.77	0.35	2.37e-8	Blood protein levels;
KIRP	cis	rs447921	0.861	rs17596582	chr17:74438120	A/T	cg16776035	chr17:74542680	NA	0.6	4.89	0.3	1.84e-6	Mitochondrial DNA levels;
KIRP	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.98	-16.64	-0.73	3.7e-42	Prudent dietary pattern;
KIRP	cis	rs12580194	0.593	rs7976828	chr12:55726450	A/T	cg11794356	chr12:55725991	OR6C3	-0.54	-7.13	-0.41	1.11e-11	Cancer;
KIRP	cis	rs73198271	0.562	rs35432123	chr8:8671018	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.05	-0.31	8.81e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12949688	0.967	rs8081251	chr17:55824033	A/G	cg12582317	chr17:55822272	NA	0.62	10.39	0.55	3.27e-21	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	trans	rs2048656	0.570	rs7814635	chr8:9646620	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	6.57	0.39	2.97e-10	Schizophrenia;
KIRP	cis	rs6725041	0.792	rs11676942	chr2:213091716	A/T	cg20637307	chr2:213403960	ERBB4	-0.39	-5.12	-0.31	6.15e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs6601327	0.602	rs12678014	chr8:9649165	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	7.4	0.43	2.18e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10267417	0.673	rs12668698	chr7:19932986	C/T	cg05791153	chr7:19748676	TWISTNB	0.46	4.87	0.3	1.98e-6	Night sleep phenotypes;
KIRP	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-7.14	-0.41	1.08e-11	Educational attainment;
KIRP	cis	rs16937	0.557	rs11240386	chr1:205175401	G/T	cg21643547	chr1:205240462	TMCC2	-0.43	-5.78	-0.35	2.24e-8	Schizophrenia;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg01763666	chr17:80159506	CCDC57	-0.38	-5.12	-0.31	6.04e-7	Life satisfaction;
KIRP	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.4	-5.2	-0.31	4.17e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg02336718	chr17:17403227	NA	0.36	5.49	0.33	1.01e-7	Total body bone mineral density;
KIRP	cis	rs710216	0.763	rs12029931	chr1:43456880	C/T	cg03128534	chr1:43423976	SLC2A1	0.5	5.23	0.32	3.61e-7	Red cell distribution width;
KIRP	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.8	10.79	0.57	1.84e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg06740227	chr12:86229804	RASSF9	0.48	6.14	0.36	3.2e-9	Major depressive disorder;
KIRP	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-12.65	-0.63	1.37e-28	Vitiligo;
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg11204139	chr17:3907470	NA	0.68	10.73	0.56	2.83e-22	Type 2 diabetes;
KIRP	cis	rs2241685	0.850	rs58404476	chr2:1936998	C/T	cg22511877	chr2:1942942	MYT1L	-0.65	-6.14	-0.36	3.37e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs858239	0.508	rs2390754	chr7:23190494	A/G	cg23682824	chr7:23144976	KLHL7	0.49	5.64	0.34	4.74e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	cg04338863	chr8:33670619	NA	0.48	6.22	0.37	2.11e-9	Body mass index;
KIRP	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	15.52	0.7	2.43e-38	Menopause (age at onset);
KIRP	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.63	-7.67	-0.44	4.02e-13	Non-response to antidepressants and depression;
KIRP	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg23387468	chr7:139079360	LUC7L2	-0.31	-5.29	-0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg08131204	chr22:41487073	MIR1281	-0.44	-5.17	-0.31	4.94e-7	Neuroticism;
KIRP	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.67	-9.01	-0.5	6.02e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7538876	0.903	rs7528427	chr1:17746273	C/T	cg01904812	chr1:17746340	RCC2	0.29	5.04	0.31	8.86e-7	Basal cell carcinoma;
KIRP	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.59	0.34	5.99e-8	Lung cancer;
KIRP	trans	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg10756647	chr7:56101905	PSPH	-0.97	-7.04	-0.41	1.89e-11	Diabetic kidney disease;
KIRP	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.29	-6.03	-0.36	5.91e-9	Diastolic blood pressure;
KIRP	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.61	-7.89	-0.45	9.82e-14	Smoking behavior;
KIRP	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.68	7.81	0.45	1.66e-13	Carotid intima media thickness;
KIRP	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.6	-9.33	-0.51	6.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.73	8.98	0.5	7.44e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.46	6.38	0.38	8.55e-10	Red blood cell count;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg12857488	chr7:149195092	ZNF746	-0.94	-6.2	-0.37	2.39e-9	P wave terminal force;
KIRP	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg25356066	chr3:128598488	ACAD9	0.5	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs6662572	0.737	rs6659064	chr1:46346724	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.56	-7.09	-0.41	1.4e-11	Coronary artery disease;
KIRP	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.92	-15.13	-0.69	5.23e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg23387468	chr7:139079360	LUC7L2	0.3	5.32	0.32	2.37e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg26134248	chr17:3907702	NA	0.58	8.65	0.48	6.95e-16	Type 2 diabetes;
KIRP	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.62	7.98	0.45	5.69e-14	Vitiligo;
KIRP	trans	rs7550636	0.808	rs3900531	chr1:192814574	A/C	cg24249403	chr15:101189058	ASB7	0.47	6.42	0.38	6.98e-10	Coronary artery calcification;
KIRP	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg15128208	chr22:42549153	NA	0.75	8.06	0.46	3.36e-14	Birth weight;
KIRP	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.87	-14.79	-0.69	7.95e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.43	5.61	0.34	5.35e-8	Homoarginine levels;
KIRP	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg06671706	chr8:8559999	CLDN23	0.56	6.33	0.37	1.18e-9	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs2223471	0.602	rs9395617	chr6:50703325	G/A	cg03432817	chr6:50765336	NA	-0.37	-5.43	-0.33	1.32e-7	Subcutaneous adipose tissue;
KIRP	cis	rs72781680	0.611	rs72797810	chr2:24336469	G/A	cg20701182	chr2:24300061	SF3B14	0.94	10.33	0.55	5.11e-21	Lymphocyte counts;
KIRP	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.52	6.81	0.4	7.37e-11	Bladder cancer;
KIRP	cis	rs1476670	0.710	rs4660763	chr1:44503576	T/C	cg09470012	chr1:44509516	NA	0.34	5.46	0.33	1.14e-7	Eotaxin levels;
KIRP	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.04	16.59	0.73	5.49e-42	Subjective well-being;
KIRP	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.65	-8.71	-0.49	4.62e-16	Educational attainment;
KIRP	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.87e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.88	0.63	2.3e-29	Morning vs. evening chronotype;
KIRP	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.23	0.32	3.63e-7	Coronary artery disease;
KIRP	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg11161011	chr14:65562177	MAX	-0.55	-6.97	-0.41	2.92e-11	Obesity-related traits;
KIRP	cis	rs4789452	1.000	rs11659109	chr17:75375859	C/T	cg05184938	chr17:75369939	SEPT9	-0.36	-4.94	-0.3	1.42e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6684428	0.505	rs6588581	chr1:56393537	C/T	cg11651538	chr1:56320950	NA	-0.56	-7.86	-0.45	1.21e-13	Airflow obstruction;
KIRP	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.36	4.96	0.3	1.32e-6	Menarche (age at onset);
KIRP	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg13385521	chr17:29058706	SUZ12P	0.98	7.65	0.44	4.6e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.48	-6.48	-0.38	5.06e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg03959625	chr15:84868606	LOC388152	0.61	6.23	0.37	2.02e-9	Schizophrenia;
KIRP	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.49	-6.29	-0.37	1.48e-9	Coronary heart disease;
KIRP	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.98	14.12	0.67	1.47e-33	Cognitive function;
KIRP	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.81	7.77	0.44	2.16e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.83	-12.58	-0.63	2.37e-28	Height;
KIRP	cis	rs6001982	0.748	rs6001946	chr22:40903421	A/G	cg07138101	chr22:40742427	ADSL	0.66	5.22	0.32	3.88e-7	Breast cancer;
KIRP	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.46	6.61	0.39	2.32e-10	Sitting height ratio;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg04865290	chr3:52927548	TMEM110	-0.4	-5.02	-0.3	9.82e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.69	8.23	0.46	1.07e-14	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25732045	chr19:1241620	ATP5D	0.61	7.9	0.45	9.26e-14	Parkinson's disease;
KIRP	cis	rs7810240	1.000	rs7799903	chr7:150091453	C/T	cg21361702	chr7:150065534	REPIN1	-0.41	-5.02	-0.3	1e-6	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.42	-0.55	2.65e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	1.11	18.1	0.76	4.1e-47	Cognitive function;
KIRP	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg00405596	chr8:11794950	NA	0.47	5.71	0.34	3.21e-8	Retinal vascular caliber;
KIRP	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.56	-5.47	-0.33	1.1e-7	Hip geometry;
KIRP	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg10223061	chr2:219282414	VIL1	0.4	6.45	0.38	5.85e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg03392386	chr11:133800800	IGSF9B	0.53	5.67	0.34	3.92e-8	Parkinson's disease;
KIRP	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.84e-6	Menopause (age at onset);
KIRP	cis	rs12282928	1.000	rs7481393	chr11:48302735	C/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.9e-9	Migraine - clinic-based;
KIRP	cis	rs3120667	0.790	rs726863	chr1:152400361	A/G	cg26876637	chr1:152193138	HRNR	0.54	5.78	0.35	2.28e-8	Eating disorders;
KIRP	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.81	6.96	0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.66	-12.05	-0.61	1.36e-26	White blood cell count (basophil);
KIRP	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.66	-0.39	1.76e-10	Neuroticism;
KIRP	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg13293535	chr8:11597251	GATA4	-0.42	-5.45	-0.33	1.25e-7	Retinal vascular caliber;
KIRP	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.89	0.45	9.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs6693295	0.877	rs10924515	chr1:246306225	C/T	cg11798871	chr1:246315928	SMYD3	0.53	5.74	0.34	2.74e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg00666640	chr1:248458726	OR2T12	0.45	5.53	0.33	8.01e-8	Common traits (Other);
KIRP	cis	rs4776059	0.550	rs8032394	chr15:52868032	G/A	cg25063058	chr15:52860530	ARPP19	0.64	6.63	0.39	2.11e-10	Schizophrenia;
KIRP	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	0.66	7.54	0.43	9.06e-13	Dental caries;
KIRP	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg07068956	chr7:100330872	ZAN	0.4	5.46	0.33	1.14e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg06521331	chr12:34319734	NA	-0.59	-7.25	-0.42	5.45e-12	Morning vs. evening chronotype;
KIRP	cis	rs311392	0.902	rs413667	chr8:55091908	C/A	cg06042504	chr8:55087323	NA	-0.58	-6.86	-0.4	5.54e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.42	5.42	0.33	1.44e-7	Height;
KIRP	cis	rs35740288	0.770	rs75039806	chr15:86105044	C/T	cg17133734	chr15:86042851	AKAP13	-0.53	-5.76	-0.34	2.55e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17169635	0.579	rs1563047	chr7:134573443	C/G	cg02516134	chr7:134575187	CALD1	0.4	4.89	0.3	1.8e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs7224685	0.506	rs12452569	chr17:4023667	T/A	cg09597638	chr17:3907349	NA	0.52	5.21	0.32	3.92e-7	Type 2 diabetes;
KIRP	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg20542592	chr8:11973495	FAM66D	0.39	4.93	0.3	1.55e-6	Neuroticism;
KIRP	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg17507749	chr15:85114479	UBE2QP1	0.83	8.5	0.48	1.79e-15	Schizophrenia;
KIRP	cis	rs33912345	0.695	rs1254316	chr14:60900113	C/T	cg27398547	chr14:60952738	C14orf39	-0.4	-5.42	-0.33	1.41e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.63	-0.39	2.14e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg03959625	chr15:84868606	LOC388152	0.63	7.03	0.41	2.02e-11	Schizophrenia;
KIRP	cis	rs6662572	0.737	rs75490316	chr1:46553785	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.18	0.31	4.57e-7	Blood protein levels;
KIRP	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-9.63	-0.52	7.98e-19	Morning vs. evening chronotype;
KIRP	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.18	-23.13	-0.83	1.23e-63	Exhaled nitric oxide output;
KIRP	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg05625103	chr10:2543513	NA	0.37	4.91	0.3	1.64e-6	Age-related hearing impairment;
KIRP	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.8	10.87	0.57	9.64e-23	Aortic root size;
KIRP	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26526719	chr5:1949144	NA	-0.43	-5.07	-0.31	7.87e-7	Gut microbiome composition (winter);
KIRP	cis	rs2278796	1.000	rs3892249	chr1:204947489	C/G	cg17947172	chr1:204966197	NFASC	0.68	8.94	0.5	9.81e-17	Mean platelet volume;
KIRP	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg14458575	chr2:238380390	NA	0.55	7.64	0.44	4.95e-13	Prostate cancer;
KIRP	cis	rs10773046	0.740	rs11057381	chr12:124357857	C/G	cg18594669	chr12:124364423	DNAH10	0.39	5.23	0.32	3.7e-7	Osteoarthritis (hip);
KIRP	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14159672	chr1:205819179	PM20D1	0.49	5.51	0.33	8.9e-8	Prostate-specific antigen levels;
KIRP	cis	rs7119167	0.901	rs10793060	chr11:73120653	A/G	cg17517138	chr11:73019481	ARHGEF17	0.47	4.94	0.3	1.42e-6	Blood protein levels;
KIRP	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg01677386	chr11:118938358	VPS11	-0.55	-6.64	-0.39	2.02e-10	Coronary artery disease;
KIRP	cis	rs3857067	1.000	rs1397025	chr4:95018987	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs1448094	0.845	rs11117129	chr12:86349390	A/G	cg00310523	chr12:86230176	RASSF9	0.43	6.64	0.39	1.95e-10	Major depressive disorder;
KIRP	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg08975724	chr8:8085496	FLJ10661	0.61	7.55	0.43	8.37e-13	Neuroticism;
KIRP	cis	rs6969780	1.000	rs6969780	chr7:27159136	G/C	cg26364809	chr7:27145159	NA	-0.59	-5.6	-0.34	5.84e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg02640540	chr1:67518911	SLC35D1	0.4	4.98	0.3	1.2e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg23992470	chr4:843637	GAK	0.63	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.76	10.35	0.55	4.48e-21	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.73	10.82	0.57	1.43e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs7849270	0.959	rs7032712	chr9:131893087	C/T	cg13538475	chr9:131942899	NA	-0.32	-5.04	-0.31	8.84e-7	Blood metabolite ratios;
KIRP	cis	rs4478858	0.735	rs6670067	chr1:31842947	C/T	cg00250761	chr1:31883323	NA	-0.3	-5.23	-0.32	3.6e-7	Alcohol dependence;
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.11	0.36	3.95e-9	Platelet count;
KIRP	cis	rs7692976	0.549	rs10017564	chr4:110858474	C/G	cg06981781	chr4:110842888	EGF	-0.23	-5.28	-0.32	2.9e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.58	7.45	0.43	1.6e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg02023728	chr11:77925099	USP35	-0.28	-4.87	-0.3	2.04e-6	Alzheimer's disease (survival time);
KIRP	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.87	13.78	0.66	2.08e-32	Height;
KIRP	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.62	-10.1	-0.54	2.76e-20	Morning vs. evening chronotype;
KIRP	trans	rs12043259	0.730	rs16854428	chr1:204788314	C/T	cg11485465	chr5:54518469	NA	-0.34	-6.23	-0.37	2.05e-9	Addiction;
KIRP	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.4	5.37	0.32	1.82e-7	Oropharynx cancer;
KIRP	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-8.18	-0.46	1.54e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg03959625	chr15:84868606	LOC388152	0.66	7.94	0.45	7.28e-14	Schizophrenia;
KIRP	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00982548	chr2:198649783	BOLL	0.57	5.68	0.34	3.84e-8	Ulcerative colitis;
KIRP	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-6.92	-0.4	3.87e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.75	9.86	0.53	1.5e-19	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs7010267	0.902	rs4242592	chr8:119968975	T/G	cg01975934	chr8:119970761	NA	-0.42	-5.32	-0.32	2.34e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs6499255	0.951	rs7200935	chr16:69564497	T/C	cg15192750	chr16:69999425	NA	0.45	4.85	0.3	2.18e-6	IgE levels;
KIRP	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg25036284	chr2:26402008	FAM59B	-0.47	-4.94	-0.3	1.42e-6	Gut microbiome composition (summer);
KIRP	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.81	8.03	0.46	3.93e-14	Neuroblastoma;
KIRP	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg27205649	chr11:78285834	NARS2	0.62	7.38	0.43	2.44e-12	Alzheimer's disease (survival time);
KIRP	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19717773	chr7:2847554	GNA12	-0.36	-5.63	-0.34	5.01e-8	Height;
KIRP	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	0.82	11.28	0.58	4.57e-24	Primary sclerosing cholangitis;
KIRP	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg23950597	chr19:37808831	NA	0.62	6.66	0.39	1.81e-10	Coronary artery calcification;
KIRP	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.65	-9.41	-0.51	3.67e-18	Schizophrenia;
KIRP	cis	rs2411233	1.000	rs11635288	chr15:39270328	G/C	cg02291532	chr15:39874776	THBS1	0.4	5.44	0.33	1.28e-7	Platelet count;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18813170	chr20:25677664	ZNF337	-0.47	-6.07	-0.36	4.87e-9	Myopia;
KIRP	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.55	0.33	7.23e-8	Blood protein levels;
KIRP	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.47	10.86	0.57	1.03e-22	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.73	11.63	0.6	3.42e-25	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.6	8.2	0.46	1.31e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7712401	0.601	rs13164134	chr5:122337941	T/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs1448094	0.809	rs11117103	chr12:86314431	C/T	cg02569458	chr12:86230093	RASSF9	0.39	5.75	0.34	2.68e-8	Major depressive disorder;
KIRP	cis	rs909341	0.710	rs3848669	chr20:62300811	G/T	cg03999872	chr20:62272968	STMN3	0.61	7.0	0.41	2.42e-11	Atopic dermatitis;
KIRP	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.73	10.67	0.56	4.46e-22	Schizophrenia;
KIRP	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.03	-0.64	7.39e-30	Height;
KIRP	cis	rs1413885	1.000	rs1334880	chr1:65818481	C/T	cg19924025	chr1:65720054	NA	-0.47	-5.18	-0.31	4.58e-7	Anticoagulant levels;
KIRP	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg09263875	chr16:632152	PIGQ	0.75	12.62	0.63	1.68e-28	Height;
KIRP	cis	rs72653721	0.730	rs9468303	chr6:11042029	A/T	cg13562911	chr6:11044106	ELOVL2	0.56	5.67	0.34	4.09e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	10.84	0.57	1.2e-22	Platelet count;
KIRP	trans	rs1864585	0.520	rs60167323	chr8:10590715	G/A	cg26278703	chr11:58910052	FAM111A	0.58	6.06	0.36	5.11e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.46	-0.38	5.45e-10	Height;
KIRP	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.59	6.3	0.37	1.4e-9	Alcohol dependence;
KIRP	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.83	8.81	0.49	2.35e-16	Exhaled nitric oxide output;
KIRP	cis	rs7116495	1.000	rs7949480	chr11:71697588	T/C	cg18441811	chr11:71824068	C11orf51	-0.61	-4.9	-0.3	1.74e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7808935	0.633	rs12668668	chr7:27936709	T/G	cg22168087	chr7:27702803	HIBADH	0.75	7.17	0.42	8.68e-12	Prostate cancer;
KIRP	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.16	21.52	0.81	1.8e-58	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs28489187	0.706	rs233067	chr1:85804978	C/G	cg16011679	chr1:85725395	C1orf52	0.51	6.29	0.37	1.41e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg13444842	chr1:152974279	SPRR3	-0.35	-5.01	-0.3	1.06e-6	Inflammatory skin disease;
KIRP	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg00800569	chr2:239229395	TRAF3IP1	0.45	5.19	0.31	4.42e-7	Multiple system atrophy;
KIRP	cis	rs10506328	0.509	rs4759073	chr12:54653258	G/A	cg27478242	chr12:54611928	NA	-0.27	-4.99	-0.3	1.16e-6	Mean platelet volume;
KIRP	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg00405596	chr8:11794950	NA	-0.44	-5.72	-0.34	3.08e-8	Retinal vascular caliber;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg03541381	chr16:790595	NARFL	0.63	8.09	0.46	2.73e-14	Myopia (pathological);
KIRP	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.57	-7.09	-0.41	1.4e-11	Arsenic metabolism;
KIRP	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg23534315	chr17:78082725	GAA	0.39	5.21	0.32	4.02e-7	Yeast infection;
KIRP	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.29	-0.37	1.48e-9	Height;
KIRP	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.64	5.38	0.32	1.69e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg06345736	chr22:50966936	TYMP	0.65	9.87	0.53	1.43e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.58	7.96	0.45	6.47e-14	Blood protein levels;
KIRP	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.73	-8.15	-0.46	1.85e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21643547	chr1:205240462	TMCC2	0.87	13.81	0.66	1.69e-32	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.8	11.03	0.58	3.05e-23	Coronary artery disease;
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg12705353	chr12:122356852	WDR66	-0.49	-6.59	-0.39	2.69e-10	Mean corpuscular volume;
KIRP	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg26727032	chr16:67993705	SLC12A4	-0.68	-5.86	-0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg02600515	chr11:62521696	ZBTB3	0.5	5.15	0.31	5.32e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs960902	0.935	rs2373110	chr2:37717832	A/G	cg25341268	chr2:37734390	NA	-0.5	-6.77	-0.4	9.64e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs4750440	0.702	rs4748066	chr10:14029313	A/T	cg27542038	chr10:14027202	FRMD4A	0.48	6.7	0.39	1.41e-10	Adiponectin levels;
KIRP	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg22800045	chr5:56110881	MAP3K1	-0.67	-6.55	-0.39	3.37e-10	Initial pursuit acceleration;
KIRP	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg19847866	chr10:1019161	NA	-0.63	-5.78	-0.35	2.28e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg00405596	chr8:11794950	NA	0.56	7.63	0.44	5.11e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.3	7.29	0.42	4.22e-12	IgG glycosylation;
KIRP	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	ch.8.33884649F	chr8:33765107	NA	0.54	6.79	0.4	8.34e-11	Body mass index;
KIRP	cis	rs7084402	0.967	rs1346302	chr10:60267137	G/A	cg05938607	chr10:60274200	BICC1	0.41	10.01	0.54	5.22e-20	Refractive error;
KIRP	cis	rs1978968	1.000	rs11704733	chr22:18446212	T/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.82	-0.4	6.92e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.61	-7.87	-0.45	1.16e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg15270235	chr3:195682595	NA	0.32	4.88	0.3	1.87e-6	Mean corpuscular volume;
KIRP	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg08501292	chr6:25962987	TRIM38	0.81	5.5	0.33	9.56e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1144	0.537	rs916705	chr7:104589690	C/A	cg04380332	chr7:105027541	SRPK2	-0.54	-7.89	-0.45	1e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18252515	chr7:66147081	NA	0.45	5.3	0.32	2.59e-7	Aortic root size;
KIRP	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.97	-0.64	1.18e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.02	-0.36	6.18e-9	Response to antipsychotic treatment;
KIRP	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg10169327	chr19:45448959	APOC2	0.33	4.99	0.3	1.16e-6	Blood protein levels;
KIRP	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg11987759	chr7:65425863	GUSB	-0.53	-7.21	-0.42	6.92e-12	Calcium levels;
KIRP	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	0.58	7.71	0.44	3.08e-13	Prostate cancer;
KIRP	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.72e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs78487399	0.831	rs12469373	chr2:43829191	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-5.06	-0.31	8.11e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.88	-12.55	-0.62	3e-28	Longevity;Endometriosis;
KIRP	cis	rs7923609	0.846	rs10761739	chr10:65062008	C/G	cg08743896	chr10:65200160	JMJD1C	0.35	5.02	0.31	9.76e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06438815	chr21:46292710	PTTG1IP	0.61	7.6	0.44	6.3e-13	Smoking initiation;
KIRP	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.18	12.71	0.63	8.91e-29	Eosinophil percentage of granulocytes;
KIRP	cis	rs6959887	0.962	rs714956	chr7:35290201	C/T	cg06685737	chr7:35301730	NA	0.43	6.31	0.37	1.26e-9	Birth weight;
KIRP	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.6	6.05	0.36	5.25e-9	Axial length;
KIRP	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.85	11.93	0.61	3.36e-26	Breast cancer;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.53	8.42	0.47	3.24e-15	Lymphocyte counts;
KIRP	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg12042659	chr19:58951599	ZNF132	0.5	6.09	0.36	4.35e-9	Uric acid clearance;
KIRP	trans	rs7999699	0.840	rs73185674	chr13:48301872	A/G	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs755109	1.000	rs113315674	chr9:100720053	G/A	cg13688889	chr9:100608707	NA	-0.45	-5.28	-0.32	2.86e-7	Quantitative traits;
KIRP	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg10189774	chr4:17578691	LAP3	0.46	5.32	0.32	2.28e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg16497661	chr14:103986332	CKB	0.5	6.92	0.4	3.86e-11	Body mass index;
KIRP	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg06223162	chr1:101003688	GPR88	0.42	8.43	0.47	2.89e-15	Monocyte count;
KIRP	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg19324714	chr2:237145437	ASB18	0.51	5.77	0.35	2.33e-8	Educational attainment;
KIRP	cis	rs241257	0.643	rs241270	chr1:4625189	A/T	cg11735846	chr1:4770935	AJAP1	0.36	5.74	0.34	2.84e-8	Anxiety disorder;
KIRP	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg04490037	chr7:50633773	DDC	0.39	5.04	0.31	8.84e-7	Systemic sclerosis;
KIRP	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.47	-7.14	-0.41	1.06e-11	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25404930	chr17:58212864	NA	0.55	6.6	0.39	2.46e-10	Smoking initiation;
KIRP	cis	rs7737355	0.945	rs245801	chr5:130666955	T/C	cg06307176	chr5:131281290	NA	-0.51	-5.5	-0.33	9.7e-8	Life satisfaction;
KIRP	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg18478394	chr8:109455254	TTC35	0.48	5.95	0.35	8.93e-9	Dupuytren's disease;
KIRP	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.64	-8.57	-0.48	1.19e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2617583	0.935	rs1354139	chr5:1451782	T/C	cg07151155	chr5:1473589	LPCAT1	-0.44	-6.12	-0.36	3.63e-9	Breast cancer;
KIRP	cis	rs1843834	0.688	rs2396149	chr2:225601985	G/A	cg22455342	chr2:225449267	CUL3	0.48	5.44	0.33	1.26e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.58	7.84	0.45	1.39e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2795502	0.872	rs2744062	chr10:43254789	T/A	cg20628663	chr10:43360327	NA	-0.55	-5.1	-0.31	6.8e-7	Blood protein levels;
KIRP	cis	rs6120849	0.754	rs6088682	chr20:33615702	A/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.77e-10	Protein C levels;
KIRP	cis	rs12976411	0.575	rs35555788	chr19:32820544	C/T	cg02282382	chr19:32836354	ZNF507	0.62	5.17	0.31	4.93e-7	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg13680184	chr4:122791314	BBS7	-0.46	-6.06	-0.36	5.2e-9	Migraine with aura;
KIRP	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.93	-0.4	3.58e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6686643	1.000	rs957644	chr1:165616157	C/T	cg19407955	chr1:165599744	MGST3	-0.47	-5.41	-0.33	1.49e-7	Total ventricular volume;
KIRP	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.29	0.42	4.23e-12	Height;
KIRP	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	0.94	14.58	0.68	4e-35	Triglycerides;
KIRP	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.38	6.22	0.37	2.09e-9	Heart rate;
KIRP	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.44	-5.49	-0.33	9.89e-8	Mean platelet volume;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg12692727	chr7:1102344	C7orf50	0.47	5.08	0.31	7.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9469913	0.674	rs2744965	chr6:34589632	C/T	cg14254433	chr6:34482411	PACSIN1	-0.44	-5.33	-0.32	2.17e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.45	-0.33	1.2e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg23307798	chr14:103986281	CKB	0.42	6.05	0.36	5.48e-9	Body mass index;
KIRP	cis	rs9652601	0.748	rs35294447	chr16:11240854	A/T	cg04616529	chr16:11181986	CLEC16A	0.38	4.86	0.3	2.09e-6	Systemic lupus erythematosus;
KIRP	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg08499158	chr17:42289980	UBTF	0.72	9.63	0.52	7.64e-19	Total body bone mineral density;
KIRP	cis	rs4950928	0.700	rs946263	chr1:203165381	A/G	cg17014757	chr1:203156097	CHI3L1	0.61	6.57	0.39	3.04e-10	YKL-40 levels;
KIRP	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06481639	chr22:41940642	POLR3H	0.48	5.54	0.33	7.71e-8	Vitiligo;
KIRP	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.34	5.37	0.32	1.85e-7	Asthma;
KIRP	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg06121193	chr1:90282411	NA	-0.53	-7.52	-0.43	1e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05347473	chr6:146136440	FBXO30	0.5	7.15	0.41	9.65e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4774899	1.000	rs62025331	chr15:57231034	T/C	cg13626582	chr15:57592083	LOC283663	-0.21	-5.05	-0.31	8.8e-7	Urinary tract infection frequency;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg19729279	chr5:133861951	PHF15	0.49	6.04	0.36	5.73e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.66	-9.05	-0.5	4.34e-17	Rheumatoid arthritis;
KIRP	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-5.16	-0.31	5.17e-7	Height;
KIRP	cis	rs6959887	0.962	rs10263165	chr7:35285857	G/A	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.41	-0.38	7.46e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.46	5.74	0.34	2.79e-8	Total body bone mineral density;
KIRP	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.48	-6.75	-0.4	1.04e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.5	-0.43	1.15e-12	Type 2 diabetes;
KIRP	cis	rs11638352	0.661	rs2733209	chr15:44450496	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.73	-5.39	-0.33	1.61e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7520050	0.966	rs4545281	chr1:46360054	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.48	-0.33	1.06e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1318772	0.932	rs58479323	chr5:112877691	C/T	cg12552261	chr5:112820674	MCC	0.77	5.36	0.32	1.89e-7	F-cell distribution;
KIRP	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.46	-10.5	-0.56	1.52e-21	Alzheimer's disease (late onset);
KIRP	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.73e-10	Subjective well-being;
KIRP	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg13147721	chr7:65941812	NA	-0.97	-6.86	-0.4	5.62e-11	Diabetic kidney disease;
KIRP	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg05347473	chr6:146136440	FBXO30	-0.58	-8.14	-0.46	2e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.97	-0.45	6.12e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.51	7.79	0.44	1.91e-13	Testicular germ cell tumor;
KIRP	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.64	9.4	0.51	3.93e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-1.05	-12.64	-0.63	1.47e-28	Exhaled nitric oxide output;
KIRP	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs42648	0.738	rs10248104	chr7:89895262	C/T	cg25739043	chr7:89950458	NA	-0.38	-4.98	-0.3	1.22e-6	Homocysteine levels;
KIRP	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg00677455	chr12:58241039	CTDSP2	0.8	10.6	0.56	7.01e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	6.87	0.4	5.19e-11	Breast cancer;
KIRP	cis	rs11593576	0.550	rs7909463	chr10:80993918	A/G	cg18737081	chr10:80999807	ZMIZ1	-0.29	-5.18	-0.31	4.53e-7	Vitiligo;
KIRP	cis	rs904251	0.714	rs2776910	chr6:37436284	A/G	cg25019722	chr6:37503610	NA	-0.59	-5.99	-0.36	7.36e-9	Cognitive performance;
KIRP	cis	rs832540	0.519	rs10940518	chr5:56270794	C/T	cg12311346	chr5:56204834	C5orf35	-0.38	-5.05	-0.31	8.69e-7	Coronary artery disease;
KIRP	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg06521331	chr12:34319734	NA	-0.48	-5.99	-0.36	7.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.28	-0.37	1.49e-9	Neutrophil percentage of white cells;
KIRP	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg08632701	chr21:37451849	NA	-0.43	-5.45	-0.33	1.2e-7	Mitral valve prolapse;
KIRP	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.5	6.56	0.39	3.1e-10	Schizophrenia;
KIRP	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.88	10.49	0.56	1.64e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-10.52	-0.56	1.34e-21	Bladder cancer;
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.13	0.36	3.56e-9	Platelet count;
KIRP	cis	rs6681460	0.932	rs524114	chr1:67188335	C/T	cg02459107	chr1:67143332	SGIP1	-0.37	-5.34	-0.32	2.09e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg04731861	chr2:219085781	ARPC2	0.28	7.35	0.42	2.94e-12	Colorectal cancer;
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02359409	chr6:42947317	PEX6	-0.39	-5.05	-0.31	8.73e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-12.37	-0.62	1.22e-27	Gut microbiome composition (summer);
KIRP	cis	rs3748682	0.731	rs9729719	chr1:38298207	G/A	cg12658694	chr1:38397304	INPP5B	0.46	5.1	0.31	6.73e-7	Hypothyroidism;
KIRP	trans	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.1	0.41	1.32e-11	Retinal vascular caliber;
KIRP	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg05805236	chr11:65401703	PCNXL3	0.43	5.41	0.33	1.48e-7	Urate levels;
KIRP	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.51	6.76	0.4	9.69e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.66	7.76	0.44	2.24e-13	Alcohol dependence;
KIRP	trans	rs459571	1.000	rs467387	chr9:136907005	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.8	-9.11	-0.5	2.93e-17	Platelet distribution width;
KIRP	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.09	-0.36	4.32e-9	Neuroticism;
KIRP	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg04519387	chr11:65556438	OVOL1	0.35	5.41	0.33	1.52e-7	Acne (severe);
KIRP	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.51	-6.21	-0.37	2.23e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg26084005	chr2:241760190	KIF1A	-0.49	-6.32	-0.37	1.21e-9	Urinary metabolites;
KIRP	cis	rs7113874	0.625	rs16938253	chr11:8500380	A/G	cg08015107	chr11:8618950	NA	-0.65	-7.92	-0.45	8.07e-14	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg24826892	chr11:71159390	DHCR7	-0.46	-5.21	-0.32	4.03e-7	Vitamin D levels;
KIRP	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	8.3	0.47	6.88e-15	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs2278796	0.639	rs4950977	chr1:204970777	T/A	cg04862289	chr1:204966208	NFASC	0.66	9.37	0.51	4.95e-18	Mean platelet volume;
KIRP	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.91	-0.45	8.71e-14	Eye color traits;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg07701084	chr6:150067640	NUP43	0.69	9.76	0.53	3.13e-19	Lung cancer;
KIRP	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.17	-0.42	8.51e-12	Retinal vascular caliber;
KIRP	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg11062466	chr8:58055876	NA	0.57	5.4	0.33	1.6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.83	11.43	0.59	1.55e-24	Height;
KIRP	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.67	9.37	0.51	4.85e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg16141378	chr3:129829833	LOC729375	-0.51	-6.27	-0.37	1.65e-9	Neuroticism;
KIRP	cis	rs7542091	0.635	rs7550733	chr1:210044968	G/A	cg05527609	chr1:210001259	C1orf107	-0.37	-4.94	-0.3	1.47e-6	Monobrow;
KIRP	cis	rs597583	0.671	rs525110	chr11:117411392	A/G	cg27161313	chr11:117392002	DSCAML1	-0.56	-5.13	-0.31	5.85e-7	Putamen volume;
KIRP	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	6.68	0.39	1.62e-10	Rheumatoid arthritis;
KIRP	cis	rs755109	1.000	rs3758253	chr9:100700654	C/T	cg13688889	chr9:100608707	NA	-0.43	-5.0	-0.3	1.1e-6	Quantitative traits;
KIRP	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg02151108	chr14:50098012	C14orf104	-0.48	-6.22	-0.37	2.11e-9	Carotid intima media thickness;
KIRP	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg25319279	chr11:5960081	NA	-0.52	-5.02	-0.3	1.01e-6	DNA methylation (variation);
KIRP	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.6	0.39	2.54e-10	Educational attainment;
KIRP	cis	rs7011049	1.000	rs11997774	chr8:53833370	T/A	cg26025543	chr8:53854495	NA	0.71	7.56	0.43	7.93e-13	Systolic blood pressure;
KIRP	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.34	-6.06	-0.36	4.97e-9	Height;
KIRP	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	0.83	7.47	0.43	1.39e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg19913688	chr11:428466	ANO9	-0.75	-5.53	-0.33	7.98e-8	Body mass index;
KIRP	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.41	5.21	0.32	3.96e-7	Alzheimer's disease (late onset);
KIRP	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg15556689	chr8:8085844	FLJ10661	0.74	10.99	0.57	4.03e-23	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06292898	chr11:33060817	TCP11L1	0.56	6.97	0.41	2.95e-11	Parkinson's disease;
KIRP	cis	rs13082711	0.911	rs3736312	chr3:27442336	G/A	cg02860705	chr3:27208620	NA	0.58	8.2	0.46	1.32e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg24315340	chr6:146058215	EPM2A	-0.48	-6.26	-0.37	1.74e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.84	-14.04	-0.67	2.8e-33	Brugada syndrome;
KIRP	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs180358	0.588	rs2542062	chr11:116680449	G/A	cg08985259	chr11:116699649	APOC3	0.48	5.77	0.35	2.41e-8	Multiple sclerosis (severity);
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	8.9e-8	Life satisfaction;
KIRP	cis	rs12210905	1.000	rs12205921	chr6:27113540	G/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.09	-0.31	6.97e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.45	5.52	0.33	8.57e-8	Common traits (Other);
KIRP	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg01877450	chr7:97915802	BRI3	-0.58	-7.5	-0.43	1.13e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg22676075	chr6:135203613	NA	0.45	6.29	0.37	1.44e-9	Red blood cell count;
KIRP	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00149659	chr3:10157352	C3orf10	-0.58	-7.17	-0.42	8.64e-12	Alzheimer's disease;
KIRP	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg06027949	chr8:82754900	SNX16	0.46	5.64	0.34	4.61e-8	Diastolic blood pressure;
KIRP	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.72	-6.58	-0.39	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22138219	chr8:117355748	NA	-0.41	-6.29	-0.37	1.42e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2230307	0.572	rs512999	chr1:100563330	A/G	cg24955406	chr1:100503596	HIAT1	0.66	7.52	0.43	1.01e-12	Carotid intima media thickness;
KIRP	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.37	6.36	0.38	9.64e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg05370193	chr1:21551575	ECE1	0.45	6.24	0.37	1.87e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs74576663	0.810	rs7331473	chr13:107181265	G/A	cg06534061	chr13:107220663	ARGLU1	0.5	5.67	0.34	4e-8	Ankle injury;
KIRP	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.79	9.68	0.53	5.56e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.43	-6.24	-0.37	1.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7011049	1.000	rs72643586	chr8:53847859	A/T	cg26025543	chr8:53854495	NA	0.75	7.77	0.44	2.17e-13	Systolic blood pressure;
KIRP	cis	rs35740288	0.770	rs4843082	chr15:86153390	A/G	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17376030	chr22:41985996	PMM1	0.7	7.55	0.43	8.54e-13	Vitiligo;
KIRP	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.45	6.47	0.38	5.2400000000000005e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.4	-0.43	2.12e-12	Type 2 diabetes;
KIRP	cis	rs520865	0.786	rs565408	chr5:80342824	A/G	cg17330048	chr5:80257322	RASGRF2	-0.46	-6.77	-0.4	9.24e-11	Superior frontal gyrus grey matter volume;
KIRP	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19717773	chr7:2847554	GNA12	-0.35	-5.16	-0.31	5.06e-7	Height;
KIRP	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.55	7.59	0.44	6.53e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg16558253	chr16:72132732	DHX38	-0.54	-7.92	-0.45	8.35e-14	Fibrinogen levels;
KIRP	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.17	14.96	0.69	2.09e-36	Platelet count;
KIRP	cis	rs17092148	1.000	rs2425004	chr20:33405956	G/T	cg16810054	chr20:33298113	TP53INP2	0.45	5.6	0.34	5.78e-8	Neuroticism;
KIRP	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.58	-6.12	-0.36	3.68e-9	Obesity-related traits;
KIRP	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg24881330	chr22:46731750	TRMU	0.76	5.75	0.34	2.61e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.73	-8.23	-0.46	1.09e-14	Diastolic blood pressure;
KIRP	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg13206674	chr6:150067644	NUP43	0.69	10.52	0.56	1.31e-21	Lung cancer;
KIRP	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.04	14.87	0.69	4.14e-36	Cognitive ability;
KIRP	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg23166289	chr1:210001082	C1orf107	0.54	5.99	0.36	7.44e-9	Orofacial clefts;
KIRP	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg25547332	chr5:131281432	NA	0.47	5.31	0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg03959625	chr15:84868606	LOC388152	0.47	5.5	0.33	9.44e-8	Schizophrenia;
KIRP	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg16989719	chr2:238392110	NA	-0.53	-6.05	-0.36	5.3e-9	Prostate cancer;
KIRP	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.86	12.08	0.61	1.12e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2387326	0.767	rs11016094	chr10:129942423	G/A	cg16087940	chr10:129947807	NA	-0.36	-4.93	-0.3	1.49e-6	Select biomarker traits;
KIRP	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg15655495	chr12:38532458	NA	-0.28	-5.07	-0.31	7.74e-7	Bladder cancer;
KIRP	cis	rs2591576	0.651	rs10051355	chr5:165434036	C/T	cg13976338	chr5:165423657	NA	-0.78	-11.27	-0.58	4.87e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg20368463	chr18:77673604	PQLC1	-0.57	-6.24	-0.37	1.89e-9	Opioid sensitivity;
KIRP	cis	rs15676	0.947	rs2977994	chr9:131585216	G/T	cg00228799	chr9:131580591	ENDOG	0.58	6.58	0.39	2.89e-10	Blood metabolite levels;
KIRP	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg10556349	chr10:835070	NA	0.56	4.85	0.3	2.2e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.7	0.34	3.5e-8	Homoarginine levels;
KIRP	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.44	-0.33	1.28e-7	Type 2 diabetes;
KIRP	cis	rs77861329	1.000	rs9847073	chr3:52144947	C/T	cg08692210	chr3:52188851	WDR51A	-0.96	-7.69	-0.44	3.42e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg13206674	chr6:150067644	NUP43	0.57	7.98	0.45	5.49e-14	Lung cancer;
KIRP	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.6	-9.67	-0.52	5.84e-19	Itch intensity from mosquito bite;
KIRP	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02725872	chr8:58115012	NA	-0.65	-6.29	-0.37	1.47e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.3	6.04	0.36	5.75e-9	Schizophrenia;
KIRP	cis	rs6840360	0.607	rs2724565	chr4:152350305	A/G	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs17020663	0.713	rs73943418	chr2:101640637	T/C	cg15506514	chr2:101638852	TBC1D8	-0.54	-5.27	-0.32	2.93e-7	Pulse pressure;
KIRP	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg11031976	chr2:198649780	BOLL	-0.47	-4.89	-0.3	1.82e-6	Ulcerative colitis;
KIRP	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-7.75	-0.44	2.48e-13	Morning vs. evening chronotype;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07256732	chr16:621771	PIGQ	-0.47	-6.53	-0.38	3.68e-10	Height;
KIRP	cis	rs35955747	0.869	rs131219	chr22:31760250	T/C	cg02404636	chr22:31891804	SFI1	0.38	5.01	0.3	1.04e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-6.4	-0.38	7.91e-10	Longevity;Endometriosis;
KIRP	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg00147788	chr6:125855365	NA	-0.33	-5.11	-0.31	6.5e-7	Brugada syndrome;
KIRP	cis	rs8084125	1.000	rs7237781	chr18:74953527	C/T	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.38	6.33	0.37	1.15e-9	Dupuytren's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26561986	chr12:95939442	USP44	0.54	7.12	0.41	1.2e-11	Interleukin-4 levels;
KIRP	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg20991723	chr1:152506922	NA	-0.45	-5.37	-0.32	1.81e-7	Hair morphology;
KIRP	cis	rs6058796	1.000	rs6141781	chr20:31263342	C/T	cg13636640	chr20:31349939	DNMT3B	0.59	5.25	0.32	3.36e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.69	-0.39	1.53e-10	Morning vs. evening chronotype;
KIRP	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg20991723	chr1:152506922	NA	0.45	5.48	0.33	1.04e-7	Hair morphology;
KIRP	cis	rs13385	0.769	rs4913078	chr5:139626680	A/T	cg01860693	chr5:139557145	C5orf32	0.46	5.09	0.31	7.01e-7	Atrial fibrillation;
KIRP	trans	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00950418	chr7:105029125	SRPK2	-0.53	-6.58	-0.39	2.86e-10	Height;
KIRP	cis	rs11989744	0.843	rs10481331	chr8:23559257	T/C	cg03324961	chr8:23605601	NA	0.43	5.05	0.31	8.52e-7	Waist-hip ratio;
KIRP	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.11	-23.5	-0.83	8.1e-65	Myeloid white cell count;
KIRP	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg11812906	chr14:75593930	NEK9	-0.52	-5.71	-0.34	3.18e-8	Caffeine consumption;
KIRP	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	1.04	19.91	0.79	3.46e-53	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1190596	0.525	rs7153005	chr14:102698599	G/T	cg23904247	chr14:102554826	HSP90AA1	-0.25	-5.22	-0.32	3.82e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg15896084	chr13:114927664	NA	0.48	6.5	0.38	4.42e-10	Schizophrenia;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg20940661	chr2:18060086	KCNS3	0.56	6.73	0.39	1.2e-10	Sleep duration;
KIRP	cis	rs12711979	0.513	rs1454241	chr2:3851675	A/G	cg17052675	chr2:3827356	NA	0.34	4.99	0.3	1.17e-6	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.33	-12.76	-0.63	5.88e-29	Hip circumference adjusted for BMI;
KIRP	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg20999797	chr1:1681921	NA	-0.34	-4.99	-0.3	1.14e-6	Body mass index;
KIRP	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	cg12689670	chr1:183009347	LAMC1	0.44	6.46	0.38	5.63e-10	Colorectal cancer;
KIRP	cis	rs4835473	0.932	rs17018238	chr4:144703890	A/T	cg08833778	chr4:144622313	FREM3	-0.33	-4.86	-0.3	2.09e-6	Immature fraction of reticulocytes;
KIRP	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg05315796	chr3:52349193	DNAH1	0.45	6.94	0.4	3.42e-11	Electroencephalogram traits;
KIRP	cis	rs2882667	0.858	rs35812969	chr5:138377550	G/C	cg04439458	chr5:138467593	SIL1	-0.51	-7.63	-0.44	5.01e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-5.35	-0.32	1.99e-7	Aortic root size;
KIRP	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg08975724	chr8:8085496	FLJ10661	0.61	7.54	0.43	8.87e-13	Retinal vascular caliber;
KIRP	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.62	-0.56	6.31e-22	Gut microbiome composition (summer);
KIRP	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.49	6.99	0.41	2.56e-11	Schizophrenia;
KIRP	cis	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg03342759	chr3:160939853	NMD3	-0.45	-5.47	-0.33	1.09e-7	Morning vs. evening chronotype;
KIRP	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.56	-6.55	-0.39	3.39e-10	Diabetic retinopathy;
KIRP	cis	rs981844	0.922	rs75543972	chr4:154664792	G/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.38	0.59	2.23e-24	Height;
KIRP	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.64	-9.66	-0.52	6.39e-19	Fibrinogen levels;
KIRP	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg09699651	chr6:150184138	LRP11	0.49	6.31	0.37	1.3e-9	Lung cancer;
KIRP	cis	rs4332037	0.576	rs62434668	chr7:1866901	G/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-5.65	-0.34	4.32e-8	Bipolar disorder;
KIRP	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg25019033	chr10:957182	NA	0.56	5.97	0.36	8.08e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.71	10.27	0.55	8.29e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg02336718	chr17:17403227	NA	-0.4	-6.14	-0.36	3.28e-9	Schizophrenia;
KIRP	cis	rs6988636	0.818	rs59428574	chr8:124166061	G/A	cg23067535	chr8:124195133	FAM83A	-0.81	-6.63	-0.39	2.16e-10	Urinary uromodulin levels;
KIRP	cis	rs7808935	0.914	rs67746093	chr7:27985524	C/G	cg22168087	chr7:27702803	HIBADH	0.77	7.92	0.45	8.26e-14	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11952604	chr15:69113456	ANP32A	0.53	7.23	0.42	6.25e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.76	11.56	0.59	5.7e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.62	-9.67	-0.52	5.83e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.02	0.31	9.74e-7	Diisocyanate-induced asthma;
KIRP	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg19025524	chr12:109796872	NA	-0.56	-8.0	-0.45	4.86e-14	Neuroticism;
KIRP	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.74	-0.44	2.61e-13	IgG glycosylation;
KIRP	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.2e-15	Motion sickness;
KIRP	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.74	-9.13	-0.5	2.67e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2073499	1.000	rs45536634	chr3:50400081	G/A	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.68	4.91	0.3	1.64e-6	Schizophrenia;
KIRP	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.11	12.65	0.63	1.37e-28	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.53	-0.38	3.65e-10	Educational attainment;
KIRP	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg21361702	chr7:150065534	REPIN1	0.64	6.14	0.36	3.21e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.31	0.51	7.42e-18	Lung cancer;
KIRP	cis	rs2671245	0.586	rs9436526	chr1:56141532	T/C	cg11523071	chr1:56160889	NA	0.41	5.98	0.36	7.94e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.64	0.34	4.7e-8	Lung cancer;
KIRP	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-6.78	-0.4	8.96e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7572644	0.640	rs12464988	chr2:28058226	C/T	cg27432699	chr2:27873401	GPN1	0.46	5.66	0.34	4.29e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06481639	chr22:41940642	POLR3H	-0.65	-6.84	-0.4	6.39e-11	Vitiligo;
KIRP	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.68	7.82	0.45	1.5700000000000001e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4908768	0.581	rs2784739	chr1:8497558	T/G	cg03610117	chr1:8450231	RERE	-0.69	-8.64	-0.48	7.02e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg10117171	chr1:25599238	RHD	-0.4	-5.3	-0.32	2.63e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19524238	chr7:2802976	GNA12	0.36	4.99	0.3	1.16e-6	Height;
KIRP	cis	rs4262150	0.883	rs56269251	chr5:152194094	A/G	cg12297329	chr5:152029980	NA	-0.63	-8.1	-0.46	2.54e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7538876	0.967	rs72637463	chr1:17719089	G/A	cg07965774	chr1:17746286	RCC2	0.28	4.9	0.3	1.75e-6	Basal cell carcinoma;
KIRP	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.79	9.35	0.51	5.42e-18	Smoking behavior;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07753891	chr4:141445266	ELMOD2	0.54	6.7	0.39	1.39e-10	Parkinson's disease;
KIRP	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg16512390	chr1:228756714	NA	0.74	6.07	0.36	4.92e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg23594656	chr7:65796392	TPST1	0.43	6.02	0.36	6.47e-9	Aortic root size;
KIRP	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.23	-21.13	-0.8	3.28e-57	Breast cancer;
KIRP	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg05709478	chr1:6581295	PLEKHG5	-0.62	-5.09	-0.31	7.26e-7	Body mass index;
KIRP	cis	rs4262150	0.803	rs72799145	chr5:152102663	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.34	-0.47	5.43e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-5.65	-0.34	4.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6137287	1.000	rs6137287	chr20:21180259	C/T	cg04219410	chr20:21106687	PLK1S1	-0.45	-5.02	-0.3	9.85e-7	Height;
KIRP	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.55	-0.43	8.52e-13	Bipolar disorder;
KIRP	cis	rs6466055	0.636	rs7796945	chr7:104838050	G/A	cg04380332	chr7:105027541	SRPK2	0.37	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg00806126	chr19:22604979	ZNF98	-0.69	-6.33	-0.37	1.13e-9	Pain;
KIRP	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.43	6.72	0.39	1.23e-10	Inflammatory bowel disease;
KIRP	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.51	6.54	0.38	3.61e-10	Schizophrenia;
KIRP	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	1.05	9.16	0.5	2.13e-17	Fat distribution (HIV);
KIRP	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg22974920	chr21:40686053	BRWD1	0.51	6.21	0.37	2.29e-9	Cognitive function;
KIRP	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg24296786	chr1:45957014	TESK2	0.51	5.65	0.34	4.39e-8	Homocysteine levels;
KIRP	cis	rs259842	0.764	rs165380	chr2:180693147	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.36	-5.38	-0.32	1.77e-7	Blood protein levels;
KIRP	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05665937	chr4:1216051	CTBP1	0.52	7.23	0.42	6.12e-12	Obesity-related traits;
KIRP	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg02574844	chr11:5959923	NA	0.54	5.8	0.35	2e-8	DNA methylation (variation);
KIRP	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05025164	chr4:1340916	KIAA1530	0.65	9.06	0.5	4.27e-17	Longevity;
KIRP	cis	rs2281603	0.570	rs11158542	chr14:64929658	C/T	cg01860774	chr14:64969374	ZBTB25	-0.32	-5.08	-0.31	7.53e-7	Lymphocyte counts;
KIRP	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.9	-0.49	1.24e-16	Total cholesterol levels;
KIRP	cis	rs829661	0.793	rs2123753	chr2:30764808	T/G	cg10949345	chr2:30726833	LCLAT1	1.13	14.14	0.67	1.28e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.05e-8	Motion sickness;
KIRP	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.85	14.12	0.67	1.53e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-7.64	-0.44	4.75e-13	Parkinson's disease;
KIRP	cis	rs7011507	1.000	rs74793980	chr8:49152885	A/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs16973500	0.808	rs57807129	chr16:71948043	T/C	cg00732059	chr16:71740210	PHLPP2	-0.59	-5.61	-0.34	5.5e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18932078	chr1:2524107	MMEL1	-0.45	-6.34	-0.37	1.07e-9	Ulcerative colitis;
KIRP	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-13.93	-0.66	6.65e-33	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09634481	chr6:45345446	RUNX2;SUPT3H	0.48	6.44	0.38	6.29e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.55	-5.13	-0.31	5.74e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.91	-12.5	-0.62	4.25e-28	Gut microbiota (bacterial taxa);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18005222	chr5:55008112	SLC38A9	0.48	6.22	0.37	2.13e-9	Parkinson's disease;
KIRP	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.71	0.39	1.36e-10	Colorectal cancer;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.83	-11.9	-0.6	4.45e-26	Longevity;Endometriosis;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg17215449	chr22:50968516	TYMP	0.46	6.22	0.37	2.07e-9	DNA methylation (variation);
KIRP	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg23791538	chr6:167370224	RNASET2	-0.48	-5.78	-0.35	2.31e-8	Primary biliary cholangitis;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17162682	chr2:135960123	ZRANB3	0.52	6.35	0.38	1.04e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.4	5.39	0.33	1.63e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.74	-8.04	-0.46	3.83e-14	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.83	-11.56	-0.59	5.87e-25	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.51	-0.52	1.84e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg13271783	chr10:134563150	INPP5A	-0.55	-6.85	-0.4	5.85e-11	Migraine;
KIRP	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09675484	chr2:483917	NA	0.48	6.73	0.39	1.17e-10	Interleukin-4 levels;
KIRP	cis	rs9815354	1.000	rs1716661	chr3:41962818	C/T	cg03022575	chr3:42003672	ULK4	-0.51	-5.87	-0.35	1.42e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.77	8.66	0.48	6.24e-16	Corneal astigmatism;
KIRP	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg21605333	chr4:119757512	SEC24D	1.47	9.91	0.53	1.09e-19	Cannabis dependence symptom count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10409449	chr15:86283707	AKAP13	0.48	6.41	0.38	7.44e-10	Interleukin-4 levels;
KIRP	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg11952622	chr19:58962976	ZNF324B	0.42	4.92	0.3	1.58e-6	Uric acid clearance;
KIRP	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg00343986	chr7:65444356	GUSB	-0.43	-4.99	-0.3	1.15e-6	Aortic root size;
KIRP	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg15247329	chr7:2764246	NA	-0.35	-4.91	-0.3	1.65e-6	Height;
KIRP	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1971762	0.527	rs2365343	chr12:54038149	C/T	cg23533419	chr12:54090519	NA	0.37	5.78	0.35	2.29e-8	Height;
KIRP	cis	rs6783573	0.894	rs939408	chr3:46599079	C/A	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.36	-5.61	-0.34	5.49e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6684514	1.000	rs2273833	chr1:156233189	C/T	cg16558208	chr1:156270281	VHLL	-0.45	-5.86	-0.35	1.51e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.61	7.42	0.43	1.87e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17453880	0.929	rs11948856	chr5:151983819	G/T	cg12297329	chr5:152029980	NA	0.62	8.99	0.5	6.82e-17	Subjective well-being;
KIRP	cis	rs7224685	0.569	rs67815988	chr17:3998312	A/C	cg05562828	chr17:3906858	NA	0.54	5.68	0.34	3.72e-8	Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.13e-6	Aortic root size;
KIRP	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.55	7.66	0.44	4.33e-13	Retinal vascular caliber;
KIRP	cis	rs710216	0.917	rs3754223	chr1:43419091	A/T	cg22176566	chr1:43424700	SLC2A1	0.51	4.95	0.3	1.37e-6	Red cell distribution width;
KIRP	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-6.35	-0.38	1.01e-9	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.589	rs9790132	chr3:160627289	A/T	cg04691961	chr3:161091175	C3orf57	0.44	6.3	0.37	1.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs79478560	0.504	rs1317386	chr12:124373678	C/T	cg18594669	chr12:124364423	DNAH10	-0.37	-5.22	-0.32	3.85e-7	Lymphocyte counts;
KIRP	cis	rs244899	0.967	rs184957	chr5:167919623	T/A	cg13011109	chr5:167955758	FBLL1	0.37	5.16	0.31	5.12e-7	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.87	-14.68	-0.68	1.76e-35	Intelligence (multi-trait analysis);
KIRP	cis	rs867371	0.519	rs1566560	chr15:82524457	C/T	cg00614314	chr15:82944287	LOC80154	0.42	5.49	0.33	9.85e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03399598	chr4:174091002	GALNT7	0.67	6.16	0.37	2.88e-9	Lung function (FEV1);
KIRP	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg24253500	chr15:84953950	NA	-0.42	-5.23	-0.32	3.62e-7	P wave terminal force;
KIRP	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg00204512	chr16:28754710	NA	0.4	5.17	0.31	4.94e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg25019033	chr10:957182	NA	-0.6	-6.44	-0.38	6.32e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs7923609	0.905	rs10740129	chr10:65250808	G/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.88	-0.35	1.35e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.61	-8.26	-0.47	9.02e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6568686	0.786	rs3851226	chr6:111826295	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.56	-5.21	-0.32	3.99e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs582384	0.599	rs582213	chr2:45876026	C/G	cg05208381	chr2:45870771	NA	-0.34	-5.05	-0.31	8.45e-7	Coronary artery disease;
KIRP	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.13	-0.46	2.06e-14	Neuroticism;
KIRP	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.23	0.42	5.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.58	15.48	0.7	3.39e-38	Airflow obstruction;
KIRP	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-7.15	-0.41	9.65e-12	Hemoglobin concentration;
KIRP	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.49	-0.48	2.03e-15	Neuroticism;
KIRP	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg21919602	chr1:242011447	EXO1	-0.47	-6.14	-0.36	3.21e-9	Menopause (age at onset);
KIRP	cis	rs7172677	0.960	rs8026273	chr15:75413766	T/A	cg14664628	chr15:75095509	CSK	-0.56	-6.17	-0.37	2.75e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg00031303	chr3:195681400	NA	-0.43	-5.6	-0.34	5.62e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs1961637	0.642	rs10206046	chr2:223887697	G/A	cg02552189	chr2:223891284	NA	-0.47	-6.88	-0.4	5.07e-11	Oropharynx cancer;
KIRP	cis	rs4262150	0.810	rs12188715	chr5:151973884	T/A	cg12297329	chr5:152029980	NA	-0.67	-8.15	-0.46	1.9e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg01721255	chr8:58191610	C8orf71	0.53	5.26	0.32	3.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs282587	0.569	rs399569	chr13:113398464	A/T	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.64e-12	Glycated hemoglobin levels;
KIRP	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg00310523	chr12:86230176	RASSF9	-0.56	-8.64	-0.48	7.24e-16	Major depressive disorder;
KIRP	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.61	8.22	0.46	1.2e-14	Mood instability;
KIRP	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-12.1	-0.61	9.52e-27	Vitiligo;
KIRP	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg19442545	chr10:75533431	FUT11	0.44	5.63	0.34	5e-8	Inflammatory bowel disease;
KIRP	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.47	-6.93	-0.4	3.7e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg21905437	chr5:178450457	ZNF879	0.48	5.39	0.32	1.67e-7	Pubertal anthropometrics;
KIRP	cis	rs10114408	0.921	rs7020529	chr9:96640224	G/A	cg14598338	chr9:96623480	NA	-0.33	-4.89	-0.3	1.8e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg24747557	chr10:131355152	MGMT	-0.38	-5.16	-0.31	4.97e-7	Response to temozolomide;
KIRP	cis	rs1020064	0.609	rs2576748	chr2:105911258	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.39	-5.17	-0.31	4.95e-7	AIDS;
KIRP	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-6.24	-0.37	1.86e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12780845	1.000	rs7100163	chr10:17181177	C/T	cg01003015	chr10:17271136	VIM	0.46	4.95	0.3	1.4e-6	Homocysteine levels;
KIRP	trans	rs3932549	1	rs3932549	chr9:97073588	A/C	cg05679027	chr9:99775184	HIATL2	0.55	6.76	0.4	1.02e-10	Body mass index;
KIRP	cis	rs71403859	0.730	rs35390364	chr16:71740049	A/G	cg08717414	chr16:71523259	ZNF19	-1.05	-8.43	-0.47	2.91e-15	Post bronchodilator FEV1;
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg08132940	chr7:1081526	C7orf50	-0.54	-6.22	-0.37	2.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.7	-11.04	-0.58	2.7e-23	Lung cancer;
KIRP	cis	rs2281603	0.808	rs10132424	chr14:64993875	T/A	cg25009451	chr14:65006716	HSPA2	0.5	5.39	0.33	1.61e-7	Lymphocyte counts;
KIRP	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg11693508	chr17:37793320	STARD3	0.68	7.16	0.42	9.24e-12	Bipolar disorder;
KIRP	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.71	-0.34	3.23e-8	Breast cancer;
KIRP	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.44	-6.11	-0.36	3.96e-9	Testicular germ cell tumor;
KIRP	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg04101203	chr11:20408940	PRMT3	-0.48	-4.89	-0.3	1.8e-6	Pursuit maintenance gain;
KIRP	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs2820315	0.867	rs2819348	chr1:201884952	T/C	cg11586189	chr1:201857591	SHISA4	-0.42	-6.11	-0.36	3.95e-9	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7572644	0.640	rs4632296	chr2:28024984	T/C	cg27432699	chr2:27873401	GPN1	0.49	5.6	0.34	5.78e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.0	-0.3	1.09e-6	Coronary artery disease;
KIRP	cis	rs73200209	0.744	rs61939700	chr12:116570921	T/C	cg01776926	chr12:116560359	MED13L	-0.55	-5.65	-0.34	4.4e-8	Total body bone mineral density;
KIRP	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg04374321	chr14:90722782	PSMC1	-0.82	-12.02	-0.61	1.66e-26	Mortality in heart failure;
KIRP	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-5.04	-0.31	9e-7	Neuroticism;
KIRP	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-14.23	-0.67	6.18e-34	Headache;
KIRP	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.77	-9.05	-0.5	4.5e-17	Pancreatic cancer;
KIRP	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22618164	chr12:122356400	WDR66	0.65	8.75	0.49	3.44e-16	Mean corpuscular volume;
KIRP	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs3736485	0.966	rs10467923	chr15:51767265	A/C	cg14296394	chr15:51910925	DMXL2	-0.37	-5.66	-0.34	4.23e-8	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs5753037	0.547	rs140134	chr22:30163332	G/A	cg01021169	chr22:30184971	ASCC2	-0.51	-7.25	-0.42	5.49e-12	Type 1 diabetes;
KIRP	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.22	0.42	6.63e-12	Height;
KIRP	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-9.51	-0.52	1.8e-18	Waist circumference;Body mass index;
KIRP	cis	rs3756766	0.500	rs12514117	chr5:137656477	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.41	4.94	0.3	1.44e-6	Schizophrenia;
KIRP	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.99	-17.33	-0.74	1.58e-44	Bone mineral density;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23063740	chr3:55182246	NA	-0.41	-6.14	-0.36	3.27e-9	Inflammatory biomarkers;
KIRP	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.25	-0.7	2.03e-37	Alzheimer's disease;
KIRP	cis	rs9469913	0.733	rs2814986	chr6:34602685	T/C	cg17674042	chr6:34482479	PACSIN1	-0.49	-6.47	-0.38	5.13e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.54	6.93	0.4	3.74e-11	Total body bone mineral density;
KIRP	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg03808351	chr9:123631620	PHF19	0.44	5.95	0.35	9.3e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.08	-0.36	4.52e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	1.13	8.75	0.49	3.56e-16	Plasma clusterin levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15877295	chr7:138915876	UBN2	0.53	6.61	0.39	2.33e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7577696	0.568	rs462878	chr2:32438655	A/G	cg02381751	chr2:32503542	YIPF4	0.62	6.05	0.36	5.4e-9	Inflammatory biomarkers;
KIRP	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg04995300	chr3:66848608	NA	0.76	8.31	0.47	6.58e-15	Type 2 diabetes;
KIRP	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.36	0.42	2.77e-12	Bipolar disorder;
KIRP	cis	rs4650994	0.593	rs2761459	chr1:178551576	G/A	cg12486710	chr1:178512616	C1orf220	-0.23	-4.98	-0.3	1.18e-6	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs12643440	0.736	rs35072602	chr4:17224721	A/G	cg22650099	chr4:17144496	NA	-0.54	-6.8	-0.4	7.72e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg03959625	chr15:84868606	LOC388152	0.62	6.29	0.37	1.41e-9	Schizophrenia;
KIRP	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.44	-6.53	-0.38	3.82e-10	Major depressive disorder;
KIRP	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.11	0.61	8.89e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg21401794	chr1:90099060	LRRC8C	0.55	6.85	0.4	5.86e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	8.05	0.46	3.65e-14	Tonsillectomy;
KIRP	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	0.7	6.37	0.38	9.39e-10	Severe influenza A (H1N1) infection;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06836181	chr2:64995545	NA	0.5	6.03	0.36	6.11e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.44	-6.0	-0.36	7.04e-9	Monocyte count;
KIRP	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg09795085	chr6:101329169	ASCC3	-0.49	-5.87	-0.35	1.4e-8	Neuroticism;
KIRP	cis	rs4742903	0.904	rs10121829	chr9:106993996	A/G	cg14250997	chr9:106856677	SMC2	0.39	5.18	0.31	4.51e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01554304	chr11:74105865	PGM2L1	-0.39	-6.27	-0.37	1.57e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg18154014	chr19:37997991	ZNF793	-0.62	-6.7	-0.39	1.44e-10	Coronary artery calcification;
KIRP	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg26727032	chr16:67993705	SLC12A4	-0.79	-9.19	-0.51	1.71e-17	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg10065182	chr12:49182837	ADCY6	-0.56	-6.03	-0.36	6.09e-9	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12662555	chr3:57742520	SLMAP	0.58	7.26	0.42	5.07e-12	Parkinson's disease;
KIRP	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.79	13.49	0.65	2e-31	Anterior chamber depth;
KIRP	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.21	-0.32	4.01e-7	Bipolar disorder;
KIRP	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.78	-12.2	-0.61	4.26e-27	Longevity;Endometriosis;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg02493798	chr17:6899577	ALOX12	0.34	6.66	0.39	1.8e-10	Tonsillectomy;
KIRP	cis	rs13401104	0.796	rs1530955	chr2:237111003	C/T	cg19324714	chr2:237145437	ASB18	0.47	5.09	0.31	7.06e-7	Educational attainment;
KIRP	cis	rs3857747	0.578	rs17171680	chr7:40364448	A/G	cg00420559	chr7:40367873	C7orf10	-0.46	-6.71	-0.39	1.3100000000000001e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs17057718	0.948	rs1872942	chr3:57154878	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-5.09	-0.31	7.19e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2729354	0.768	rs2848635	chr11:57253931	T/C	cg24343310	chr11:57249947	NA	0.29	5.44	0.33	1.3e-7	Blood protein levels;
KIRP	cis	rs9687846	0.877	rs11743303	chr5:55859952	A/G	cg15001016	chr5:55860904	NA	-0.29	-5.31	-0.32	2.4e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10751667	0.600	rs10902264	chr11:1003523	G/A	cg06064525	chr11:970664	AP2A2	-0.3	-5.68	-0.34	3.84e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg00086871	chr4:6988644	TBC1D14	0.73	6.22	0.37	2.09e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	9.21	0.51	1.48e-17	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11203032	0.831	rs10430718	chr10:90937951	A/T	cg16672925	chr10:90967113	CH25H	0.78	8.15	0.46	1.91e-14	Heart failure;
KIRP	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.73	-9.69	-0.53	5.23e-19	Age at first birth;
KIRP	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.7	8.28	0.47	8.03e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg26876637	chr1:152193138	HRNR	0.73	9.87	0.53	1.45e-19	Atopic dermatitis;
KIRP	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.75	6.14	0.36	3.25e-9	Diabetic retinopathy;
KIRP	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.59	-7.21	-0.42	6.92e-12	Aortic root size;
KIRP	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.14	9.52	0.52	1.74e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7709377	0.553	rs6889212	chr5:115461123	G/A	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Metabolite levels  (X-11787);
KIRP	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.69	-8.41	-0.47	3.37e-15	Cognitive function;
KIRP	cis	rs3784262	0.839	rs1579744	chr15:58229523	G/A	cg12031962	chr15:58353849	ALDH1A2	0.44	6.19	0.37	2.5e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs829661	0.793	rs2602782	chr2:30873358	G/A	cg10949345	chr2:30726833	LCLAT1	1.09	13.4	0.65	3.99e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg01559446	chr3:44596178	ZNF167	-0.38	-5.53	-0.33	8.32e-8	Depressive symptoms;
KIRP	cis	rs10214930	0.697	rs9639560	chr7:27605772	G/A	cg22168087	chr7:27702803	HIBADH	0.47	4.91	0.3	1.66e-6	Hypospadias;
KIRP	cis	rs35740288	0.770	rs56092539	chr15:86182512	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-5.29	-0.32	2.73e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.85	-10.91	-0.57	7.23e-23	Breast cancer;
KIRP	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26879891	chr1:152191343	HRNR	-0.46	-6.43	-0.38	6.48e-10	Inflammatory skin disease;
KIRP	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg08999081	chr20:33150536	PIGU	-0.4	-5.09	-0.31	7.14e-7	Height;
KIRP	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg05791153	chr7:19748676	TWISTNB	0.61	5.33	0.32	2.27e-7	Thyroid stimulating hormone;
KIRP	trans	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.19	0.37	2.51e-9	Mean corpuscular volume;
KIRP	cis	rs4727443	0.866	rs2897075	chr7:99630342	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.41	5.24	0.32	3.42e-7	Interstitial lung disease;
KIRP	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg07389463	chr12:132296394	NA	0.37	5.26	0.32	3.08e-7	Migraine;
KIRP	cis	rs9372498	0.536	rs9481821	chr6:118846022	A/C	cg18833306	chr6:118973337	C6orf204	-0.45	-4.85	-0.3	2.23e-6	Diastolic blood pressure;
KIRP	cis	rs9948	0.521	rs62156207	chr2:97359236	C/A	cg01990225	chr2:97406019	LMAN2L	-0.84	-6.16	-0.37	2.92e-9	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.73	-9.95	-0.54	8.05e-20	Schizophrenia;
KIRP	cis	rs9914544	0.564	rs9907723	chr17:18758853	T/C	cg26378065	chr17:18585709	ZNF286B	0.4	5.12	0.31	6.09e-7	Educational attainment (years of education);
KIRP	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-5.46	-0.33	1.16e-7	Morning vs. evening chronotype;
KIRP	cis	rs62413470	1.000	rs12210468	chr6:55934393	T/C	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.85	-0.3	2.17e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg07537917	chr2:241836409	C2orf54	-0.26	-5.54	-0.33	7.69e-8	Urinary metabolites;
KIRP	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	0.97	8.48	0.48	2.06e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.34	0.37	1.09e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.3	-0.32	2.53e-7	Iron status biomarkers;
KIRP	cis	rs4711350	0.765	rs1318691	chr6:33761884	G/A	cg25922239	chr6:33757077	LEMD2	0.59	6.28	0.37	1.5e-9	Schizophrenia;
KIRP	trans	rs61884328	0.733	rs61897843	chr11:47187549	G/A	cg06181697	chr3:50294603	GNAI2	0.8	6.07	0.36	4.76e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs7129556	0.701	rs4322421	chr11:77459394	C/T	cg12586386	chr11:77299805	AQP11	0.41	5.45	0.33	1.22e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg06417478	chr19:12876846	HOOK2	-0.49	-5.82	-0.35	1.82e-8	Mean corpuscular volume;
KIRP	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg25019033	chr10:957182	NA	-0.58	-7.19	-0.42	7.94e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.63	-6.95	-0.41	3.23e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7374004	0.655	rs7374826	chr3:38635589	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.44	5.18	0.31	4.69e-7	PR interval;
KIRP	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg00599163	chr2:162100495	NA	0.43	4.99	0.3	1.16e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg06027949	chr8:82754900	SNX16	-0.61	-6.6	-0.39	2.53e-10	Diastolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01033360	chr19:3381432	NFIC	-0.42	-6.17	-0.37	2.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg04607699	chr11:48328132	OR4S1	-0.35	-4.94	-0.3	1.46e-6	HDL cholesterol;
KIRP	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.61	7.9	0.45	9.08e-14	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12427896	chr2:111880694	BCL2L11	0.62	7.33	0.42	3.29e-12	Smoking initiation;
KIRP	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.41	5.13	0.31	5.83e-7	Aortic root size;
KIRP	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg22771759	chr13:24902376	NA	0.39	5.02	0.3	9.94e-7	Obesity-related traits;
KIRP	cis	rs7116495	0.609	rs577435	chr11:71794681	C/T	cg07596299	chr11:71824057	C11orf51	-0.95	-6.08	-0.36	4.44e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs9715521	0.775	rs62301195	chr4:59846934	G/T	cg11281224	chr4:60001000	NA	-0.46	-5.53	-0.33	8.11e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.21	-0.46	1.29e-14	Coronary artery disease;
KIRP	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg19906672	chr4:6918868	TBC1D14	0.66	6.33	0.37	1.15e-9	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24881765	chr18:51751092	MBD2	0.48	6.07	0.36	4.75e-9	Parkinson's disease;
KIRP	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.86	-0.35	1.47e-8	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.71	10.78	0.57	1.85e-22	Anterior chamber depth;
KIRP	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.32	-0.32	2.34e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg17279839	chr7:150038598	RARRES2	0.42	5.92	0.35	1.06e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs997295	1.000	rs11637027	chr15:67937755	G/T	cg14210607	chr15:68128175	NA	-0.3	-4.92	-0.3	1.62e-6	Motion sickness;
KIRP	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.99	8.13	0.46	2.1e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.28	-0.55	7.29e-21	Triglycerides;
KIRP	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg10755058	chr3:40428713	ENTPD3	-0.36	-5.03	-0.31	9.53e-7	Renal cell carcinoma;
KIRP	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.61	5.24	0.32	3.45e-7	Bipolar disorder;
KIRP	cis	rs12986413	1.000	rs12986413	chr19:2170954	A/T	cg09261902	chr19:2140048	AP3D1	-0.63	-9.87	-0.53	1.43e-19	Height;
KIRP	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	1.0	15.69	0.71	6.34e-39	Personality dimensions;
KIRP	cis	rs7011049	1.000	rs72643585	chr8:53847651	A/G	cg26025543	chr8:53854495	NA	0.75	7.77	0.44	2.17e-13	Systolic blood pressure;
KIRP	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs7721647	0.810	rs10038508	chr5:90797244	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.45	5.08	0.31	7.5e-7	Breast cancer;
KIRP	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02359409	chr6:42947317	PEX6	-0.52	-7.15	-0.41	1.02e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	cg04338863	chr8:33670619	NA	0.41	5.28	0.32	2.88e-7	Body mass index;
KIRP	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03605463	chr16:89740564	NA	0.41	4.87	0.3	2.03e-6	Vitiligo;
KIRP	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.64	8.24	0.46	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00338735	chr4:53728038	RASL11B	0.5	5.83	0.35	1.71e-8	Optic nerve measurement (cup area);
KIRP	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.4e-21	Alzheimer's disease (late onset);
KIRP	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	1.06	15.45	0.7	4.25e-38	Cognitive function;
KIRP	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.56	7.11	0.41	1.23e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs838147	0.844	rs12611211	chr19:49248331	G/A	cg13540341	chr19:49222985	MAMSTR	0.36	5.75	0.34	2.58e-8	Dietary macronutrient intake;
KIRP	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg22437258	chr11:111473054	SIK2	0.54	6.11	0.36	3.92e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg03465714	chr1:152285911	FLG	-0.42	-4.99	-0.3	1.12e-6	Atopic dermatitis;
KIRP	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.62	8.24	0.47	1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	10.98	0.57	4.2e-23	Coffee consumption (cups per day);
KIRP	cis	rs6782228	0.606	rs4857919	chr3:128407495	C/T	cg18648031	chr3:128330563	NA	0.26	5.2	0.31	4.28e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs10073892	0.703	rs62372213	chr5:101639236	T/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs6546886	0.912	rs7560668	chr2:74300717	A/G	cg14702570	chr2:74259524	NA	-0.31	-6.0	-0.36	6.94e-9	Dialysis-related mortality;
KIRP	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg19743168	chr1:23544995	NA	-0.61	-8.77	-0.49	2.94e-16	Height;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.43	-5.92	-0.35	1.08e-8	Lymphocyte counts;
KIRP	cis	rs732505	1.000	rs8109716	chr19:5585245	G/A	cg26242866	chr19:5711310	LONP1	0.66	5.01	0.3	1.06e-6	vWF and FVIII levels;
KIRP	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.98	18.98	0.77	4.33e-50	Electrocardiographic conduction measures;
KIRP	cis	rs7612445	0.818	rs73172225	chr3:179173969	A/T	cg01750654	chr3:179170617	GNB4	-0.84	-8.56	-0.48	1.24e-15	Resting heart rate;Heart rate;
KIRP	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg18944383	chr4:111397179	ENPEP	0.49	7.96	0.45	6.3e-14	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg11130432	chr3:121712080	ILDR1	-0.49	-5.79	-0.35	2.13e-8	Multiple sclerosis;
KIRP	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg08992911	chr2:238395768	MLPH	0.48	4.99	0.3	1.12e-6	Prostate cancer;
KIRP	cis	rs909341	0.868	rs1291206	chr20:62329169	G/A	cg11503966	chr20:62272292	STMN3	-0.41	-5.91	-0.35	1.16e-8	Atopic dermatitis;
KIRP	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	7.49	0.43	1.25e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14317554	chr3:184870948	C3orf70	0.53	7.42	0.43	1.87e-12	Parkinson's disease;
KIRP	cis	rs2671245	1.000	rs2767515	chr1:56165742	C/G	cg11523071	chr1:56160889	NA	-0.39	-5.93	-0.35	1.02e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg19875535	chr5:140030758	IK	0.57	7.25	0.42	5.53e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7404928	0.526	rs2575384	chr16:23837694	C/T	cg21745164	chr16:23765304	CHP2	-0.77	-8.95	-0.5	9.13e-17	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.71	-8.53	-0.48	1.48e-15	Plateletcrit;Platelet count;
KIRP	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.7	-7.62	-0.44	5.63e-13	Blood pressure (smoking interaction);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.8	14.78	0.69	8.55e-36	Lymphocyte counts;
KIRP	trans	rs6076960	0.711	rs6085426	chr20:6165768	A/G	cg21095983	chr6:86352623	SYNCRIP	0.56	7.48	0.43	1.29e-12	Smooth-surface caries;
KIRP	cis	rs41278232	1.000	rs67080992	chr20:62676243	A/G	cg03065311	chr20:62601662	ZNF512B	0.33	4.97	0.3	1.25e-6	Tonsillectomy;
KIRP	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg00405596	chr8:11794950	NA	0.49	6.35	0.38	1.01e-9	Retinal vascular caliber;
KIRP	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12764182	0.851	rs12764787	chr10:77916490	C/T	cg06487870	chr10:77542354	C10orf11	-0.29	-5.21	-0.32	3.92e-7	QRS complex (Cornell);
KIRP	cis	rs8054556	0.647	rs8048433	chr16:29931593	T/C	cg06326092	chr16:30034487	C16orf92	0.36	4.98	0.3	1.19e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.5	-6.48	-0.38	4.93e-10	Rheumatoid arthritis;
KIRP	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg24253500	chr15:84953950	NA	0.41	4.9	0.3	1.72e-6	Schizophrenia;
KIRP	cis	rs6540556	0.608	rs2064148	chr1:209909385	C/T	cg23920097	chr1:209922102	NA	0.4	5.4	0.33	1.6e-7	Red blood cell count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27467803	chr13:58203618	NA	0.45	6.04	0.36	5.53e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.9	13.28	0.65	1.01e-30	Triglycerides;
KIRP	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	1.11	16.31	0.72	4.73e-41	Breast cancer;
KIRP	cis	rs4704187	0.687	rs1582504	chr5:74479545	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	6.05e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	trans	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg21775007	chr8:11205619	TDH	0.47	6.25	0.37	1.79e-9	Neuroticism;
KIRP	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.67	10.28	0.55	7.7e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg18209359	chr17:80159595	CCDC57	0.42	5.51	0.33	9.25e-8	Life satisfaction;
KIRP	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.98	-0.36	7.72e-9	Breast cancer;
KIRP	cis	rs10465746	0.780	rs7550413	chr1:84423891	T/A	cg10977910	chr1:84465055	TTLL7	0.55	7.13	0.41	1.1e-11	Obesity-related traits;
KIRP	cis	rs72934535	0.778	rs78999781	chr2:204290037	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.94	6.6	0.39	2.45e-10	Coronary artery disease;
KIRP	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.59	-0.34	6.08e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg00990874	chr7:1149470	C7orf50	-0.79	-7.88	-0.45	1.07e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg18132916	chr6:79620363	NA	-0.43	-5.89	-0.35	1.27e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.96	15.76	0.71	3.75e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.52	6.0	0.36	7.18e-9	Pubertal anthropometrics;
KIRP	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg08738300	chr3:44038990	NA	0.65	8.81	0.49	2.29e-16	Coronary artery disease;
KIRP	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg15128208	chr22:42549153	NA	0.74	8.05	0.46	3.49e-14	Birth weight;
KIRP	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.6	9.66	0.52	6.33e-19	Neuroticism;
KIRP	cis	rs6142102	0.625	rs6141431	chr20:32540314	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	5.76	0.34	2.51e-8	Skin pigmentation;
KIRP	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.52	5.89	0.35	1.29e-8	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg15655495	chr12:38532458	NA	-0.31	-5.33	-0.32	2.21e-7	Bladder cancer;
KIRP	cis	rs6442310	0.534	rs1875796	chr3:12443657	C/T	cg22839075	chr3:12045461	SYN2	0.4	5.59	0.34	6.05e-8	Hematocrit;
KIRP	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg08603382	chr10:743973	NA	0.48	7.19	0.42	7.81e-12	Psychosis in Alzheimer's disease;
KIRP	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg27205649	chr11:78285834	NARS2	-0.53	-5.06	-0.31	8.08e-7	Testicular germ cell tumor;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg27425459	chr2:105697589	MRPS9	0.56	6.63	0.39	2.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg05754148	chr16:3507555	NAT15	0.51	5.06	0.31	8.17e-7	Tuberculosis;
KIRP	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg08603382	chr10:743973	NA	0.52	7.95	0.45	6.83e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs714031	1.000	rs5757765	chr22:40067840	T/C	cg21377881	chr22:40064566	CACNA1I	-0.66	-10.2	-0.55	1.36e-20	Schizophrenia;
KIRP	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg11995313	chr8:8860691	ERI1	0.42	5.46	0.33	1.16e-7	Joint mobility (Beighton score);
KIRP	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.55	7.53	0.43	9.86e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7751419	0.651	rs10947780	chr6:39093663	T/C	cg25014318	chr6:39016776	GLP1R	0.35	4.98	0.3	1.18e-6	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.45	0.38	5.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.64	7.5	0.43	1.19e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.38	-4.85	-0.3	2.23e-6	Mean platelet volume;
KIRP	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.64	7.6	0.44	6.32e-13	Obesity-related traits;
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg21851534	chr17:3907994	ZZEF1	-0.62	-9.6	-0.52	9.83e-19	Type 2 diabetes;
KIRP	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.78	5.51	0.33	8.82e-8	Body mass index;
KIRP	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.66	0.73	3.06e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg05370193	chr1:21551575	ECE1	0.42	5.99	0.36	7.31e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4148660	0.656	rs704215	chr12:22046058	G/A	cg14669847	chr12:22099120	NA	0.38	6.19	0.37	2.49e-9	Gout;
KIRP	cis	rs8060686	0.668	rs8046355	chr16:68205214	T/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-7.5	-0.43	1.15e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.59	-7.79	-0.45	1.83e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg27205649	chr11:78285834	NARS2	0.84	12.14	0.61	7e-27	Alzheimer's disease (survival time);
KIRP	cis	rs3784262	0.692	rs4646581	chr15:58307898	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.93	-0.3	1.5e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.75	11.18	0.58	9.9e-24	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs838147	0.844	rs8104897	chr19:49249814	C/A	cg13540341	chr19:49222985	MAMSTR	0.31	5.03	0.31	9.29e-7	Dietary macronutrient intake;
KIRP	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.67	0.34	3.9e-8	Lung cancer;
KIRP	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.6	-7.68	-0.44	3.74e-13	Gut microbiota (bacterial taxa);
KIRP	cis	rs8177876	0.822	rs10514514	chr16:81115273	A/G	cg08591886	chr16:81111003	C16orf46	-0.58	-5.87	-0.35	1.44e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg09873164	chr1:152488093	CRCT1	-0.57	-7.21	-0.42	6.81e-12	Hair morphology;
KIRP	cis	rs1595825	0.891	rs16825181	chr2:198740276	G/T	cg00982548	chr2:198649783	BOLL	-0.55	-4.94	-0.3	1.43e-6	Ulcerative colitis;
KIRP	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg21132104	chr15:45694354	SPATA5L1	0.47	5.65	0.34	4.38e-8	Glomerular filtration rate;
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg17294928	chr15:75287854	SCAMP5	0.57	7.68	0.44	3.72e-13	Breast cancer;
KIRP	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg10617943	chr7:1981403	MAD1L1	-0.4	-5.47	-0.33	1.12e-7	Neuroticism;
KIRP	cis	rs1185460	0.565	rs538478	chr11:118925341	C/T	cg23280166	chr11:118938394	VPS11	-0.54	-6.55	-0.39	3.41e-10	Coronary artery disease;
KIRP	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.61	-7.99	-0.45	5.07e-14	Coronary artery disease;
KIRP	cis	rs4787491	0.729	rs4788215	chr16:30047930	G/A	cg06326092	chr16:30034487	C16orf92	0.5	7.82	0.45	1.54e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11874712	0.527	rs12955201	chr18:43643435	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.48	-7.04	-0.41	1.97e-11	Migraine - clinic-based;
KIRP	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00149659	chr3:10157352	C3orf10	0.83	8.92	0.49	1.08e-16	Alzheimer's disease;
KIRP	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.79	11.63	0.6	3.26e-25	Heart rate;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.89	14.45	0.68	1.09e-34	Menarche (age at onset);
KIRP	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.21	-0.32	4.05e-7	Schizophrenia;
KIRP	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.96	10.26	0.55	8.64e-21	Body mass index;
KIRP	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.77	-10.09	-0.54	2.95e-20	Iron status biomarkers;
KIRP	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.65	-0.52	6.81e-19	Mean corpuscular volume;
KIRP	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.39	-5.29	-0.32	2.76e-7	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18803535	chr1:92015933	NA	0.51	6.29	0.37	1.43e-9	Interleukin-4 levels;
KIRP	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.99	-13.42	-0.65	3.55e-31	Response to antipsychotic treatment;
KIRP	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.49	6.37	0.38	9.25e-10	Iron status biomarkers;
KIRP	cis	rs42648	0.564	rs12154563	chr7:89828226	G/T	cg25739043	chr7:89950458	NA	-0.38	-5.95	-0.35	9.35e-9	Homocysteine levels;
KIRP	trans	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	6.71	0.39	1.35e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3218477	1.000	rs74531889	chr7:152365123	A/C	cg06618968	chr7:152373420	XRCC2	-0.83	-5.38	-0.32	1.69e-7	Mean platelet volume;
KIRP	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	1.22	11.35	0.59	2.68e-24	Lymphocyte counts;
KIRP	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.67	-7.96	-0.45	6.27e-14	Menarche (age at onset);
KIRP	cis	rs1816752	0.905	rs2000153	chr13:24979890	G/A	cg02811702	chr13:24901961	NA	0.4	5.14	0.31	5.53e-7	Obesity-related traits;
KIRP	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs7187994	0.848	rs16974535	chr16:84783473	G/A	cg07647771	chr16:84786436	USP10	-0.43	-5.51	-0.33	8.85e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1144	0.537	rs2470938	chr7:104581402	C/A	cg04380332	chr7:105027541	SRPK2	-0.53	-7.78	-0.44	2.01e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs2033732	0.559	rs6981432	chr8:85049009	C/T	cg05716166	chr8:85095498	RALYL	0.54	5.04	0.31	8.92e-7	Body mass index;
KIRP	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	cg12689670	chr1:183009347	LAMC1	-0.46	-6.65	-0.39	1.91e-10	Colorectal cancer;
KIRP	trans	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.51	-0.38	4.18e-10	Neuroticism;
KIRP	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00889227	chr1:205173544	DSTYK	-0.4	-5.7	-0.34	3.41e-8	Red blood cell count;
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.24	-26.31	-0.86	1.85e-73	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.45	4.92	0.3	1.59e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg09408571	chr1:101003634	GPR88	-0.24	-5.54	-0.33	7.85e-8	Monocyte count;
KIRP	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg01304814	chr3:48885189	PRKAR2A	0.71	5.14	0.31	5.68e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-6.87	-0.4	5.27e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg07741184	chr6:167504864	NA	-0.24	-6.42	-0.38	7.08e-10	Crohn's disease;
KIRP	cis	rs2274273	0.840	rs10150760	chr14:55821548	C/T	cg04306507	chr14:55594613	LGALS3	-0.48	-7.22	-0.42	6.37e-12	Protein biomarker;
KIRP	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.5	6.27	0.37	1.59e-9	Mean platelet volume;
KIRP	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11987759	chr7:65425863	GUSB	0.56	6.66	0.39	1.81e-10	Aortic root size;
KIRP	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg24009623	chr19:33667908	NA	0.5	6.24	0.37	1.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.45	6.37	0.38	9.38e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-7.7	-0.44	3.4e-13	Vitiligo;
KIRP	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	cg12689670	chr1:183009347	LAMC1	0.42	6.0	0.36	6.97e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.45	0.33	1.23e-7	Lung cancer;
KIRP	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.8	13.14	0.64	3.22e-30	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20047447	chr15:44084326	SERF2	0.48	6.11	0.36	3.88e-9	Parkinson's disease;
KIRP	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.63	0.44	5.31e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.77	-0.35	2.34e-8	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-0.78	-9.26	-0.51	1.08e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1847505	0.563	rs3127052	chr13:61410840	G/C	cg25164009	chr13:61490935	NA	-0.45	-5.19	-0.31	4.39e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs9535307	0.584	rs61961500	chr13:50392624	G/C	cg04663916	chr13:50265991	EBPL	-0.57	-5.56	-0.33	7e-8	Obesity-related traits;
KIRP	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.49	6.44	0.38	6.3e-10	Coronary artery disease;
KIRP	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.81	-12.33	-0.62	1.6e-27	Body mass index;
KIRP	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07570687	chr10:102243282	WNT8B	-0.52	-7.11	-0.41	1.27e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-0.64	-5.89	-0.35	1.28e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-7.29	-0.42	4.1e-12	Lung cancer;
KIRP	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.37	-5.28	-0.32	2.79e-7	Plateletcrit;
KIRP	cis	rs3829109	0.564	rs11145910	chr9:139300494	A/G	cg14169450	chr9:139327907	INPP5E	0.48	5.64	0.34	4.75e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.75e-8	Neuroticism;
KIRP	cis	rs7084402	0.967	rs11006171	chr10:60278487	C/T	cg05938607	chr10:60274200	BICC1	0.39	9.36	0.51	5.14e-18	Refractive error;
KIRP	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.56	12.27	0.62	2.62e-27	Diabetic kidney disease;
KIRP	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.61	-6.78	-0.4	9.02e-11	Coronary artery disease;
KIRP	cis	rs17095355	1.000	rs12265204	chr10:111752163	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.4	-5.44	-0.33	1.27e-7	Biliary atresia;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.79	14.7	0.68	1.59e-35	Lymphocyte counts;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.8	7.18	0.42	8.36e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21819024	chr1:52344978	NRD1	-0.49	-6.4	-0.38	7.96e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.02	0.36	6.17e-9	Diabetic retinopathy;
KIRP	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg21285383	chr16:89894308	SPIRE2	0.34	6.52	0.38	3.95e-10	Vitiligo;
KIRP	cis	rs4972806	0.849	rs2071581	chr2:177026148	G/T	cg14324370	chr2:177042789	NA	0.75	10.52	0.56	1.33e-21	IgG glycosylation;
KIRP	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg13147721	chr7:65941812	NA	-1.08	-7.52	-0.43	9.98e-13	Diabetic kidney disease;
KIRP	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.48	8.25	0.47	9.73e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-8.26	-0.47	9.31e-15	Personality dimensions;
KIRP	cis	rs3751972	0.911	rs11657613	chr17:26252856	T/C	cg05765580	chr17:26120370	NOS2	-0.48	-5.02	-0.3	9.93e-7	Fractional exhaled nitric oxide (childhood);
KIRP	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.92	-15.06	-0.69	8.97e-37	IgG glycosylation;
KIRP	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg08992911	chr2:238395768	MLPH	0.38	4.93	0.3	1.5e-6	Prostate cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24192786	chr5:122917781	CSNK1G3	0.4	6.21	0.37	2.26e-9	Migraine with aura;
KIRP	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg24829409	chr8:58192753	C8orf71	-0.64	-5.65	-0.34	4.51e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.86	8.93	0.49	1.03e-16	Gut microbiome composition (summer);
KIRP	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs6466055	0.666	rs12671047	chr7:104999535	C/A	cg04380332	chr7:105027541	SRPK2	-0.63	-9.28	-0.51	8.99e-18	Schizophrenia;
KIRP	cis	rs4774899	1.000	rs12916237	chr15:57249294	T/C	cg13626582	chr15:57592083	LOC283663	-0.21	-5.08	-0.31	7.64e-7	Urinary tract infection frequency;
KIRP	cis	rs42648	0.869	rs42613	chr7:89950303	C/T	cg25739043	chr7:89950458	NA	-0.46	-7.16	-0.42	9.55e-12	Homocysteine levels;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.61	-7.91	-0.45	8.9e-14	Longevity;Endometriosis;
KIRP	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.57	0.43	7.72e-13	Lung cancer;
KIRP	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.44	5.16	0.31	5.01e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9488822	0.651	rs521985	chr6:116264940	G/A	cg26893134	chr6:116381904	FRK	-0.21	-5.66	-0.34	4.27e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.88	-0.35	1.3e-8	Educational attainment;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg16428631	chr12:110338164	TCHP	-1.21	-6.96	-0.41	3.16e-11	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs7923609	0.902	rs10822182	chr10:65325478	G/A	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.19	-0.31	4.47e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg16926213	chr1:1841314	NA	0.31	5.28	0.32	2.79e-7	Body mass index;
KIRP	cis	rs7614311	0.636	rs17344090	chr3:64004101	T/C	cg09006292	chr3:64049408	NA	-0.52	-5.16	-0.31	5.16e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg18016565	chr1:150552671	MCL1	0.38	5.99	0.36	7.34e-9	Melanoma;
KIRP	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.7	-8.46	-0.47	2.35e-15	Cognitive function;
KIRP	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22541963	chr20:60982533	CABLES2	-0.46	-5.49	-0.33	1.02e-7	Colorectal cancer;
KIRP	cis	rs1629083	0.790	rs647099	chr11:118067009	A/G	cg18857871	chr11:118064634	AMICA1	0.74	10.65	0.56	4.88e-22	Lung cancer;
KIRP	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-8.91	-0.49	1.19e-16	Parkinson's disease;
KIRP	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg12940439	chr1:67600707	NA	0.37	5.42	0.33	1.4e-7	Psoriasis;
KIRP	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.03e-7	Type 2 diabetes;
KIRP	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg05393297	chr12:53359155	NA	-0.26	-4.96	-0.3	1.33e-6	Cancer (pleiotropy);
KIRP	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19777998	chr3:11762192	VGLL4	0.66	6.05	0.36	5.44e-9	Lung function (FEV1);
KIRP	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.42	5.05	0.31	8.57e-7	Glycated hemoglobin levels;
KIRP	cis	rs7007076	0.901	rs1529620	chr8:124724690	C/T	cg00283535	chr8:124749564	ANXA13	0.7	7.67	0.44	4.08e-13	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs4742903	0.509	rs4451366	chr9:106959666	G/A	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.09	-0.36	4.22e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs1440410	0.795	rs34282097	chr4:144191970	C/A	cg01719995	chr4:144104893	USP38	0.4	5.13	0.31	5.89e-7	Ischemic stroke;
KIRP	cis	rs7582180	0.932	rs6542923	chr2:100892516	C/T	cg14675211	chr2:100938903	LONRF2	0.44	4.99	0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-6.6	-0.39	2.53e-10	Response to antipsychotic treatment;
KIRP	cis	rs2562456	0.793	rs62110424	chr19:21599637	A/C	cg18461458	chr19:21324796	ZNF431	-0.54	-5.05	-0.31	8.79e-7	Pain;
KIRP	cis	rs1298062	0.563	rs2445828	chr19:50941807	A/G	cg11430371	chr19:50961752	MYBPC2	0.42	5.92	0.35	1.06e-8	Age of smoking initiation;
KIRP	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg00647317	chr7:50633725	DDC	-0.42	-5.54	-0.33	7.82e-8	Malaria;
KIRP	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.52	0.33	8.79e-8	Homoarginine levels;
KIRP	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg01304814	chr3:48885189	PRKAR2A	0.5	5.1	0.31	6.74e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10875746	0.855	rs73102067	chr12:48494426	A/C	cg26205652	chr12:48591994	NA	0.78	10.5	0.56	1.49e-21	Longevity (90 years and older);
KIRP	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg24060327	chr5:131705240	SLC22A5	-0.47	-5.71	-0.34	3.21e-8	Blood metabolite levels;
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.44	6.81	0.4	7.49e-11	Lung cancer;
KIRP	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg16586182	chr3:47516702	SCAP	0.67	9.01	0.5	6.06e-17	Colorectal cancer;
KIRP	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.83	11.98	0.61	2.41e-26	Heart rate;
KIRP	cis	rs12791968	0.527	rs12285862	chr11:45014326	T/G	cg11846598	chr11:44996168	LOC221122	-0.5	-5.37	-0.32	1.83e-7	Inhibitory control;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03666205	chr15:67812280	C15orf61	-0.43	-6.09	-0.36	4.34e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.79	-0.44	1.92e-13	Myopia (pathological);
KIRP	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg18132916	chr6:79620363	NA	-0.4	-5.62	-0.34	5.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg02931644	chr1:25747376	RHCE	0.37	6.53	0.38	3.69e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg24253500	chr15:84953950	NA	0.52	5.84	0.35	1.61e-8	Schizophrenia;
KIRP	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.39	-5.58	-0.34	6.25e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Life satisfaction;
KIRP	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17554472	chr22:41940697	POLR3H	0.65	6.7	0.39	1.44e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2882667	0.858	rs11948429	chr5:138458584	G/A	cg04439458	chr5:138467593	SIL1	-0.49	-7.45	-0.43	1.62e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.63	-8.25	-0.47	9.92e-15	Iron status biomarkers;
KIRP	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg00800038	chr16:89945340	TCF25	-0.78	-5.27	-0.32	3.04e-7	Skin colour saturation;
KIRP	cis	rs1351164	0.557	rs111945704	chr2:218369566	C/T	cg15335768	chr2:218268053	DIRC3	-0.54	-6.09	-0.36	4.23e-9	Height;
KIRP	cis	rs7010876	0.568	rs6469298	chr8:89222426	T/C	cg08624180	chr8:89339080	MMP16	0.52	4.91	0.3	1.66e-6	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12044355	0.892	rs12048349	chr1:231850323	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.44	5.31	0.32	2.41e-7	Alzheimer's disease;
KIRP	cis	rs3767633	0.612	rs2490427	chr1:161943070	T/C	cg09175582	chr1:161736000	ATF6	0.78	4.85	0.3	2.16e-6	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00032419	chr17:27895566	TP53I13	0.5	6.09	0.36	4.26e-9	Parkinson's disease;
KIRP	cis	rs9434723	1.000	rs9434723	chr1:9292282	C/T	cg04199779	chr1:9294473	H6PD	0.62	7.24	0.42	5.73e-12	Height;
KIRP	cis	rs8084125	1.000	rs62105170	chr18:74945570	A/G	cg05528293	chr18:74961138	GALR1	0.49	4.86	0.3	2.05e-6	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.78	0.35	2.2e-8	Menopause (age at onset);
KIRP	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg08999081	chr20:33150536	PIGU	0.47	6.29	0.37	1.48e-9	Height;
KIRP	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.33e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg21475434	chr5:93447410	FAM172A	-0.44	-5.03	-0.31	9.3e-7	Diabetic retinopathy;
KIRP	trans	rs11786541	0.521	rs2409619	chr8:9817420	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.27	-0.37	1.6e-9	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.65	-8.5	-0.48	1.89e-15	Body mass index;
KIRP	cis	rs4692589	0.772	rs34642369	chr4:170973469	G/A	cg19918862	chr4:170955249	NA	0.56	6.96	0.41	3.06e-11	Anxiety disorder;
KIRP	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.53	6.68	0.39	1.56e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg16989719	chr2:238392110	NA	-0.57	-5.74	-0.34	2.81e-8	Prostate cancer;
KIRP	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg24009623	chr19:33667908	NA	0.47	5.78	0.35	2.3e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg03808351	chr9:123631620	PHF19	0.38	5.2	0.31	4.29e-7	Rheumatoid arthritis;
KIRP	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg09873164	chr1:152488093	CRCT1	0.56	6.7	0.39	1.44e-10	Hair morphology;
KIRP	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	8.58	0.48	1.11e-15	Platelet count;
KIRP	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.7	0.39	1.42e-10	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4523957	0.963	rs216178	chr17:2168840	T/C	cg16513277	chr17:2031491	SMG6	0.61	8.37	0.47	4.51e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	0.9	7.85	0.45	1.29e-13	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01356948	chr8:116652764	TRPS1	-0.38	-6.1	-0.36	4.15e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg16434002	chr17:42200994	HDAC5	0.51	6.08	0.36	4.58e-9	Total body bone mineral density;
KIRP	cis	rs8014252	0.803	rs74712571	chr14:70986751	C/G	cg11204974	chr14:71022665	NA	-0.74	-7.39	-0.43	2.35e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg18850127	chr7:39170497	POU6F2	-0.26	-5.12	-0.31	6.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs735539	0.645	rs9552253	chr13:21202350	T/C	cg27499820	chr13:21296301	IL17D	0.36	5.16	0.31	4.97e-7	Dental caries;
KIRP	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg08822215	chr16:89438651	ANKRD11	-0.46	-6.06	-0.36	5.15e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19717773	chr7:2847554	GNA12	-0.41	-6.15	-0.37	3.05e-9	Height;
KIRP	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.58	-7.97	-0.45	5.97e-14	Migraine;
KIRP	cis	rs4692589	0.581	rs6821641	chr4:170960193	C/T	cg19918862	chr4:170955249	NA	0.56	6.05	0.36	5.27e-9	Anxiety disorder;
KIRP	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.85	9.61	0.52	8.97e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	9.73	0.53	3.81e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.43	-0.33	1.37e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.6	-0.48	9.23e-16	Retinal vascular caliber;
KIRP	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	8.51	0.48	1.7e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6684514	1.000	rs10908499	chr1:156279176	G/C	cg16558208	chr1:156270281	VHLL	-0.43	-5.79	-0.35	2.13e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.94	10.15	0.54	1.91e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.49	-5.47	-0.33	1.11e-7	Neuroticism;
KIRP	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.76	7.94	0.45	7.29e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.45	6.29	0.37	1.41e-9	Sitting height ratio;
KIRP	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs3087591	0.600	rs2952975	chr17:29490992	A/G	cg24425628	chr17:29625626	OMG;NF1	0.61	5.25	0.32	3.36e-7	Hip circumference;
KIRP	cis	rs6732160	0.613	rs57208378	chr2:73389999	G/A	cg01422370	chr2:73384389	NA	0.51	6.75	0.4	1.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.33	-6.74	-0.39	1.1e-10	Diastolic blood pressure;
KIRP	cis	rs7771547	0.642	rs9470309	chr6:36509751	A/G	cg04289385	chr6:36355825	ETV7	0.42	6.56	0.39	3.09e-10	Platelet distribution width;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22903657	chr4:1355424	KIAA1530	-0.5	-7.1	-0.41	1.33e-11	Obesity-related traits;
KIRP	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	7.01	0.41	2.32e-11	Body mass index;
KIRP	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg08076091	chr2:203926405	NBEAL1	0.86	8.64	0.48	7.17e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.74	0.49	3.7e-16	Lung cancer in ever smokers;
KIRP	cis	rs9815354	0.537	rs73073272	chr3:42022446	G/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7017914	0.934	rs35109143	chr8:71577900	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24991452	chr6:35996059	MAPK14	0.57	6.52	0.38	4.06e-10	Smoking initiation;
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.82	-13.6	-0.66	8.7e-32	Vitiligo;
KIRP	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00585698	chr12:123750864	CDK2AP1	0.49	6.21	0.37	2.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.6	-7.71	-0.44	3.11e-13	Total body bone mineral density;
KIRP	cis	rs2411233	0.868	rs12899419	chr15:39261036	A/C	cg19287857	chr15:39890699	NA	0.39	5.28	0.32	2.77e-7	Platelet count;
KIRP	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.43	5.47	0.33	1.11e-7	High light scatter reticulocyte count;
KIRP	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.38	-7.84	-0.45	1.36e-13	Arsenic metabolism;
KIRP	cis	rs4356932	1.000	rs6846814	chr4:76952288	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.16	0.37	2.98e-9	Blood protein levels;
KIRP	cis	rs17209837	0.831	rs56223611	chr7:87083157	C/A	cg00919237	chr7:87102261	ABCB4	-0.71	-7.21	-0.42	7.03e-12	Gallbladder cancer;
KIRP	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg00800038	chr16:89945340	TCF25	-0.67	-5.59	-0.34	6.02e-8	Skin colour saturation;
KIRP	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg23565292	chr14:50234668	KLHDC2	-0.44	-5.31	-0.32	2.4e-7	Carotid intima media thickness;
KIRP	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg03060546	chr3:49711283	APEH	0.43	5.48	0.33	1.06e-7	Parkinson's disease;
KIRP	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg04995300	chr3:66848608	NA	0.67	8.9	0.49	1.24e-16	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg05861140	chr6:150128134	PCMT1	-0.55	-7.81	-0.45	1.63e-13	Lung cancer;
KIRP	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.75	-9.17	-0.5	1.91e-17	Coronary artery disease;
KIRP	cis	rs9603616	0.719	rs6563739	chr13:40239785	G/T	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.64	-0.34	4.68e-8	Type 2 diabetes;
KIRP	cis	rs240764	0.631	rs12195369	chr6:101204106	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-5.62	-0.34	5.08e-8	Neuroticism;
KIRP	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.39	-0.38	8.3e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.96	12.16	0.61	5.77e-27	Response to antineoplastic agents;
KIRP	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	1.09	17.57	0.75	2.51e-45	Homoarginine levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26187166	chr20:56884786	RAB22A;PPP4R1L	-0.44	-6.02	-0.36	6.26e-9	Metabolic traits;
KIRP	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.09	-0.31	7.14e-7	Pulmonary function;
KIRP	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.87	16.37	0.72	2.98e-41	Anterior chamber depth;
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg23594656	chr7:65796392	TPST1	-0.45	-6.96	-0.41	3.03e-11	Aortic root size;
KIRP	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg20060108	chr2:102954350	IL1RL1	-0.59	-5.01	-0.3	1.06e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg10792982	chr14:105748885	BRF1	0.86	12.8	0.63	4.26e-29	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9513627	1.000	rs7327068	chr13:100126965	A/G	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg10792982	chr14:105748885	BRF1	0.86	13.23	0.64	1.51e-30	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg18016565	chr1:150552671	MCL1	0.4	6.02	0.36	6.44e-9	Melanoma;
KIRP	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.72	-5.06	-0.31	8.13e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.52	-6.31	-0.37	1.28e-9	Ulcerative colitis;
KIRP	cis	rs3105593	0.965	rs3109891	chr15:50874964	T/C	cg08437265	chr15:50716283	USP8	0.39	5.06	0.31	8.36e-7	QT interval;
KIRP	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.62	9.21	0.51	1.46e-17	Carotid intima media thickness;
KIRP	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg12560992	chr17:57184187	TRIM37	0.62	5.79	0.35	2.14e-8	Cognitive test performance;
KIRP	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.44	5.14	0.31	5.53e-7	Aortic root size;
KIRP	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.48	6.03	0.36	5.93e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11326717	chr8:87354814	WWP1	0.48	6.25	0.37	1.8e-9	Parkinson's disease;
KIRP	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.7	6.95	0.41	3.21e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg05692746	chr2:100937584	LONRF2	-0.39	-5.03	-0.31	9.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.48	-6.2	-0.37	2.33e-9	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.69	-0.44	3.43e-13	Type 2 diabetes;
KIRP	cis	rs35955747	0.934	rs926928	chr22:31821719	G/A	cg02404636	chr22:31891804	SFI1	-0.39	-5.29	-0.32	2.76e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg19731401	chr7:2775893	GNA12	0.56	6.1	0.36	4.11e-9	Childhood ear infection;
KIRP	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.55	6.83	0.4	6.79e-11	HDL cholesterol;
KIRP	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs250677	0.524	rs417413	chr5:148452726	T/C	cg12140854	chr5:148520817	ABLIM3	-0.41	-5.31	-0.32	2.48e-7	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18983090	chr13:37575004	EXOSC8	0.45	6.74	0.39	1.12e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.93	-0.3	1.49e-6	Pulmonary function;
KIRP	trans	rs7594645	1.000	rs73985728	chr2:207668245	G/A	cg04135372	chr2:99061383	INPP4A	0.84	6.11	0.36	3.8e-9	Episodic memory;
KIRP	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.08	-0.5	3.71e-17	Rheumatoid arthritis;
KIRP	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg24375607	chr4:120327624	NA	0.58	6.73	0.39	1.15e-10	Corneal astigmatism;
KIRP	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg24253500	chr15:84953950	NA	0.64	7.08	0.41	1.55e-11	Schizophrenia;
KIRP	cis	rs1045714	0.779	rs3735113	chr7:2651563	G/A	cg20813462	chr7:2646259	IQCE	0.66	6.29	0.37	1.46e-9	Urate levels in lean individuals;
KIRP	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7536201	0.934	rs10903119	chr1:25294902	A/G	cg23273869	chr1:25296894	NA	-0.36	-5.02	-0.3	9.92e-7	Psoriasis vulgaris;
KIRP	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg23845249	chr11:68861649	NA	0.57	8.22	0.46	1.18e-14	Blond vs. brown hair color;
KIRP	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg04398451	chr17:18023971	MYO15A	-0.89	-13.81	-0.66	1.64e-32	Total body bone mineral density;
KIRP	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.98	11.78	0.6	1.05e-25	Platelet count;
KIRP	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.1	-0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg16342193	chr10:102329863	NA	-0.38	-4.99	-0.3	1.14e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.69	8.62	0.48	8.16e-16	Coronary artery disease;
KIRP	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.6	7.58	0.44	7.03e-13	Menarche (age at onset);
KIRP	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.49	-5.02	-0.3	1.01e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg12504415	chr17:74722752	JMJD6;C17orf95	-0.45	-6.08	-0.36	4.46e-9	Blood metabolite levels;
KIRP	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.76	12.21	0.61	4.16e-27	Ewing sarcoma;
KIRP	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg11234688	chr2:1609660	NA	0.53	5.01	0.3	1.05e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.55	-7.34	-0.42	3.06e-12	Urate levels in overweight individuals;
KIRP	cis	rs938554	0.570	rs7696983	chr4:9995829	A/C	cg11266682	chr4:10021025	SLC2A9	0.36	4.98	0.3	1.2e-6	Blood metabolite levels;
KIRP	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.81	-10.97	-0.57	4.74e-23	Coronary artery disease;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs6580649	0.941	rs17122611	chr12:48458149	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.58	7.83	0.45	1.45e-13	Height;
KIRP	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg27211696	chr2:191398769	TMEM194B	-0.75	-9.19	-0.51	1.71e-17	Diastolic blood pressure;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25551661	chr18:11851326	GNAL;CHMP1B	0.54	8.1	0.46	2.58e-14	Survival in pancreatic cancer;
KIRP	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.03	-0.36	6.05e-9	Height;
KIRP	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg04317338	chr11:64019027	PLCB3	0.56	6.57	0.39	2.94e-10	Platelet count;
KIRP	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.61	-8.88	-0.49	1.43e-16	Testicular germ cell tumor;
KIRP	cis	rs860295	0.629	rs12026638	chr1:155401260	T/C	cg02153340	chr1:155202674	NA	-0.56	-7.62	-0.44	5.37e-13	Body mass index;
KIRP	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.57	-5.13	-0.31	5.83e-7	Cognitive test performance;
KIRP	cis	rs1832871	1.000	rs1832871	chr6:158722034	C/T	cg07215822	chr6:158701037	NA	-0.49	-6.08	-0.36	4.56e-9	Height;
KIRP	cis	rs4851254	0.660	rs9784000	chr2:100697201	G/C	cg17356467	chr2:100759845	AFF3	0.5	5.27	0.32	3.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg22705602	chr4:152727874	NA	-0.54	-9.41	-0.51	3.59e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.91	12.93	0.64	1.54e-29	Tonsillectomy;
KIRP	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.4	-6.27	-0.37	1.63e-9	Body mass index;
KIRP	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.97	14.73	0.68	1.27e-35	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg00204512	chr16:28754710	NA	0.46	5.96	0.36	8.63e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.51	-6.05	-0.36	5.36e-9	Response to antipsychotic treatment;
KIRP	cis	rs714027	0.605	rs41176	chr22:30432403	G/T	cg01021169	chr22:30184971	ASCC2	0.43	5.37	0.32	1.79e-7	Lymphocyte counts;
KIRP	cis	rs34779708	0.931	rs7923172	chr10:35309367	G/A	cg03585969	chr10:35415529	CREM	0.77	9.5	0.52	2.02e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.55	5.17	0.31	4.78e-7	Alzheimer's disease;
KIRP	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	5.33	0.32	2.23e-7	Renal cell carcinoma;
KIRP	trans	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg26043149	chr18:55253948	FECH	0.53	6.39	0.38	8.14e-10	Bone mineral density;
KIRP	cis	rs7105934	1.000	rs7943577	chr11:69231876	A/G	cg24478926	chr11:69237550	NA	-0.56	-5.48	-0.33	1.07e-7	Renal cell carcinoma;
KIRP	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-7.92	-0.45	8.22e-14	Osteoarthritis;
KIRP	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.82	0.45	1.55e-13	Joint mobility (Beighton score);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15708219	chr10:22621481	NA	0.5	7.51	0.43	1.12e-12	Interleukin-4 levels;
KIRP	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg19592336	chr6:28129416	ZNF389	-0.51	-5.73	-0.34	2.97e-8	Depression;
KIRP	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg13072238	chr3:49761600	GMPPB	0.56	5.05	0.31	8.61e-7	Menarche (age at onset);
KIRP	cis	rs7129556	0.775	rs17752006	chr11:77393993	G/C	cg12586386	chr11:77299805	AQP11	0.43	5.67	0.34	4.01e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg08847533	chr14:75593920	NEK9	0.95	12.98	0.64	1.06e-29	Height;
KIRP	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.72	-0.34	3.13e-8	Bipolar disorder;
KIRP	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17430032	chr12:64317120	SRGAP1	-0.47	-6.69	-0.39	1.47e-10	Inflammatory biomarkers;
KIRP	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg25174290	chr11:3078921	CARS	0.69	9.31	0.51	7.25e-18	Longevity;
KIRP	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.6	9.25	0.51	1.14e-17	Lung cancer;
KIRP	cis	rs9815354	1.000	rs1717031	chr3:41905791	G/T	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.91	-7.28	-0.42	4.38e-12	Breast cancer;
KIRP	cis	rs4356975	0.563	rs6600883	chr4:69960671	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.49e-7	Obesity-related traits;
KIRP	trans	rs9650657	0.525	rs7819602	chr8:10726842	C/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.84	-0.4	6.19e-11	Neuroticism;
KIRP	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.5	6.67	0.39	1.72e-10	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08952407	chr5:42756860	CCDC152	0.46	6.02	0.36	6.36e-9	Interleukin-4 levels;
KIRP	cis	rs367943	0.712	rs26966	chr5:112740434	T/C	cg12552261	chr5:112820674	MCC	0.56	6.69	0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs1829883	0.614	rs10042540	chr5:99017159	T/G	cg08333243	chr5:99726346	NA	0.39	5.0	0.3	1.08e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg03188948	chr7:1209495	NA	0.8	5.49	0.33	1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.54	-0.33	7.58e-8	Pulmonary function;
KIRP	cis	rs11605275	1.000	rs76399107	chr11:20029148	C/T	cg14835545	chr11:20032148	NAV2	-0.79	-6.0	-0.36	6.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6009824	1.000	rs6009824	chr22:50086373	C/T	cg22070880	chr22:50098194	NA	0.69	7.94	0.45	7.16e-14	Natriuretic peptide levels;
KIRP	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	5.62	0.34	5.19e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.86	-8.95	-0.5	8.67e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.74	7.45	0.43	1.53e-12	Uric acid levels;
KIRP	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.56	7.34	0.42	3.06e-12	Blood metabolite levels;
KIRP	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.61	5.11	0.31	6.46e-7	Putamen volume;
KIRP	cis	rs12780845	1.000	rs7096692	chr10:17180828	G/A	cg01003015	chr10:17271136	VIM	0.46	4.91	0.3	1.63e-6	Homocysteine levels;
KIRP	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.69	10.27	0.55	8.1e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg19292749	chr17:79650816	ARL16;HGS	0.54	5.04	0.31	9.18e-7	Dental caries;
KIRP	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.83	11.33	0.59	3.15e-24	Gestational age at birth (maternal effect);
KIRP	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg24315340	chr6:146058215	EPM2A	0.43	5.42	0.33	1.42e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg02725872	chr8:58115012	NA	-0.52	-5.92	-0.35	1.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.53	6.25	0.37	1.77e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs239198	0.578	rs11155708	chr6:101292189	G/A	cg09795085	chr6:101329169	ASCC3	0.49	5.64	0.34	4.6e-8	Menarche (age at onset);
KIRP	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.34e-18	Alzheimer's disease;
KIRP	cis	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg26585981	chr11:48327164	OR4S1	-0.51	-6.3	-0.37	1.39e-9	Migraine - clinic-based;
KIRP	cis	rs72772090	0.539	rs11748795	chr5:96168056	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.7	-5.98	-0.36	7.85e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11997175	0.766	rs56803376	chr8:33687676	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.77	0.35	2.36e-8	Body mass index;
KIRP	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg26566898	chr11:117069891	TAGLN	0.39	5.07	0.31	7.65e-7	Blood protein levels;
KIRP	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg14541582	chr5:601475	NA	-0.58	-6.61	-0.39	2.42e-10	Obesity-related traits;
KIRP	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.77	-10.33	-0.55	5.28e-21	Aortic root size;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.7	10.63	0.56	5.89e-22	Menarche (age at onset);
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.85	14.52	0.68	6.21e-35	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04047827	chr16:24740859	TNRC6A	0.53	6.23	0.37	2.01e-9	Smoking initiation;
KIRP	cis	rs12956009	0.583	rs4452038	chr18:44856529	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.33	4.84	0.3	2.27e-6	Educational attainment (years of education);
KIRP	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.64	-8.34	-0.47	5.49e-15	Inflammatory bowel disease;
KIRP	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	7.07	0.41	1.61e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18516317	chr2:54950679	EML6	0.48	6.05	0.36	5.42e-9	Parkinson's disease;
KIRP	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02949481	chr16:131562	MPG	0.57	5.54	0.33	7.93e-8	Glioblastoma;
KIRP	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg14593290	chr7:50529359	DDC	-0.65	-7.58	-0.43	7.21e-13	Malaria;
KIRP	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs71597109	0.681	rs4496585	chr4:102718286	A/G	cg14855874	chr4:102712397	BANK1	0.36	4.84	0.3	2.26e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg20573242	chr4:122745356	CCNA2	0.41	5.11	0.31	6.54e-7	Type 2 diabetes;
KIRP	cis	rs7666738	0.546	rs10440329	chr4:98903735	C/T	cg05340658	chr4:99064831	C4orf37	0.65	7.82	0.45	1.5700000000000001e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10214930	0.813	rs1404282	chr7:27585451	A/C	cg22168087	chr7:27702803	HIBADH	0.52	5.11	0.31	6.55e-7	Hypospadias;
KIRP	cis	rs10875746	0.855	rs10875728	chr12:48426392	T/G	cg26205652	chr12:48591994	NA	0.65	8.89	0.49	1.38e-16	Longevity (90 years and older);
KIRP	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.76	10.72	0.56	2.93e-22	Body mass index;
KIRP	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg21497246	chr14:78225524	SNW1;C14orf178	-0.53	-5.03	-0.31	9.68e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs10121009	0.587	rs723877	chr9:35407431	A/G	cg15271616	chr9:35490515	RUSC2	0.38	5.19	0.31	4.34e-7	Parkinson's disease;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21995377	chr11:77921677	USP35	0.42	6.03	0.36	6.07e-9	Cancer;
KIRP	cis	rs3818285	0.505	rs71479284	chr10:111746437	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.44	-6.1	-0.36	4.04e-9	Superior crus of antihelix expression;
KIRP	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.43	0.43	1.83e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.61	-7.76	-0.44	2.26e-13	Mean platelet volume;
KIRP	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs2979489	0.838	rs2979513	chr8:30397925	G/C	cg26383811	chr8:30366931	RBPMS	-0.46	-6.25	-0.37	1.76e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs1629083	0.967	rs61900655	chr11:118120802	G/C	cg18857871	chr11:118064634	AMICA1	0.63	8.52	0.48	1.65e-15	Lung cancer;
KIRP	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg12131826	chr15:77904385	NA	-0.48	-5.84	-0.35	1.64e-8	Type 2 diabetes;
KIRP	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.54	-8.57	-0.48	1.17e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg16482183	chr6:26056742	HIST1H1C	0.44	5.5	0.33	9.62e-8	Height;
KIRP	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.57	-7.64	-0.44	4.85e-13	Ulcerative colitis;
KIRP	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg01631408	chr1:248437212	OR2T33	-0.61	-8.06	-0.46	3.39e-14	Common traits (Other);
KIRP	cis	rs7615316	0.872	rs6414350	chr3:142316660	C/G	cg20824294	chr3:142316082	PLS1	0.26	5.82	0.35	1.82e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-6.96	-0.41	2.99e-11	Vitiligo;
KIRP	cis	rs11587400	0.593	rs2336365	chr1:115175415	G/T	cg12756093	chr1:115239321	AMPD1	-0.38	-4.85	-0.3	2.16e-6	Autism;
KIRP	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.65	-8.79	-0.49	2.67e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.84	9.82	0.53	2.1e-19	Neutrophil percentage of white cells;
KIRP	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg01620082	chr3:125678407	NA	-0.93	-6.7	-0.39	1.45e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13198984	chr17:80129470	CCDC57	0.57	8.58	0.48	1.06e-15	Life satisfaction;
KIRP	cis	rs981844	0.740	rs6858578	chr4:154682058	G/T	cg14289246	chr4:154710475	SFRP2	-0.5	-6.59	-0.39	2.69e-10	Response to statins (LDL cholesterol change);
KIRP	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26314531	chr2:26401878	FAM59B	0.48	5.16	0.31	5.17e-7	Gut microbiome composition (summer);
KIRP	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.85	11.42	0.59	1.63e-24	Response to antipsychotic treatment;
KIRP	cis	rs9962915	1.000	rs1719944	chr18:5596603	A/G	cg22335490	chr18:5544237	EPB41L3	-0.41	-4.97	-0.3	1.26e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9354308	0.764	rs9345711	chr6:66591447	C/T	cg07460842	chr6:66804631	NA	0.38	4.84	0.3	2.26e-6	Metabolite levels;
KIRP	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6691722	0.503	rs1142057	chr1:24706292	C/T	cg18323236	chr1:24743029	NIPAL3	-0.49	-7.2	-0.42	7.5e-12	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs9810890	1.000	rs73198840	chr3:128502194	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs12580194	0.593	rs7311751	chr12:55748847	A/G	cg11794356	chr12:55725991	OR6C3	-0.55	-7.71	-0.44	3.06e-13	Cancer;
KIRP	cis	rs2904967	0.866	rs676573	chr11:65026462	T/G	cg12562828	chr11:65076843	NA	-0.6	-8.91	-0.49	1.19e-16	Mean corpuscular volume;
KIRP	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.35	-0.38	1.02e-9	Neuroticism;
KIRP	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.03	0.41	2.05e-11	Caffeine consumption;
KIRP	cis	rs72627123	0.867	rs8018226	chr14:74471377	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.8	4.97	0.3	1.24e-6	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.948	rs10410778	chr19:33592301	C/A	cg07827796	chr19:33622959	WDR88	0.41	4.91	0.3	1.65e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg01677386	chr11:118938358	VPS11	-0.54	-6.57	-0.39	3.02e-10	Coronary artery disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22115305	chr5:14004436	NA	0.42	6.19	0.37	2.55e-9	Survival in pancreatic cancer;
KIRP	cis	rs2278796	0.608	rs6700069	chr1:204968945	A/G	cg17449235	chr1:204966235	NFASC	0.58	7.94	0.45	7.18e-14	Mean platelet volume;
KIRP	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	cis	rs6125597	0.967	rs6067048	chr20:47926561	A/T	cg03212862	chr20:47662828	CSE1L	-0.39	-5.09	-0.31	7.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.57	0.59	5.26e-25	Alzheimer's disease;
KIRP	cis	rs10207628	0.698	rs10182292	chr2:127869462	G/A	cg06223080	chr2:127868745	NA	-0.68	-9.09	-0.5	3.35e-17	Psychosis and Alzheimer's disease;
KIRP	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.69	-0.39	1.54e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7904368	0.760	rs56936588	chr10:16876486	A/C	cg14835575	chr10:16859367	RSU1	0.89	9.12	0.5	2.78e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg12131826	chr15:77904385	NA	0.4	5.34	0.32	2.11e-7	Type 2 diabetes;
KIRP	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.48	-5.77	-0.35	2.34e-8	Iron status biomarkers;
KIRP	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.44	-5.41	-0.33	1.49e-7	Aortic root size;
KIRP	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-5.6	-0.34	5.79e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.52	-0.43	1e-12	Neuroticism;
KIRP	cis	rs10924970	1.000	rs10924501	chr1:235351447	G/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.14	0.31	5.69e-7	Asthma;
KIRP	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.71	7.71	0.44	3.09e-13	Corneal astigmatism;
KIRP	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg00405596	chr8:11794950	NA	0.52	6.86	0.4	5.52e-11	Joint mobility (Beighton score);
KIRP	cis	rs12986413	0.934	rs6510645	chr19:2158398	T/C	cg09261902	chr19:2140048	AP3D1	0.65	10.15	0.54	1.85e-20	Height;
KIRP	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Melanoma;
KIRP	cis	rs273218	0.694	rs274369	chr5:53379987	G/C	ch.5.1024479R	chr5:53302184	ARL15	0.53	6.07	0.36	4.88e-9	Migraine;
KIRP	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.62	0.39	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.62	-10.01	-0.54	5.42e-20	Prostate cancer;
KIRP	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg18882449	chr10:104885122	NT5C2	-0.5	-6.41	-0.38	7.5e-10	Arsenic metabolism;
KIRP	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg14346243	chr4:90757452	SNCA	-0.38	-4.85	-0.3	2.14e-6	Neuroticism;
KIRP	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4132509	1.000	rs9782958	chr1:243892972	C/G	cg25706552	chr1:244017396	NA	0.5	6.4	0.38	7.86e-10	RR interval (heart rate);
KIRP	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.84	-6.81	-0.4	7.24e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05903289	chr2:130345205	NA	-0.38	-4.86	-0.3	2.08e-6	Response to cytidine analogues (gemcitabine);
KIRP	trans	rs7690819	0.601	rs1601657	chr4:112096427	C/T	cg26129310	chr6:37664451	MDGA1	0.45	6.04	0.36	5.62e-9	Medication adherence in chronic diseases;
KIRP	cis	rs865483	0.929	rs853194	chr17:35848045	A/C	cg06716730	chr17:35851459	DUSP14	0.23	5.59	0.34	5.92e-8	Monocyte count;
KIRP	cis	rs5997397	1.000	rs5997397	chr22:29154455	A/G	cg02153584	chr22:29168773	CCDC117	0.45	5.78	0.35	2.29e-8	Red cell distribution width;
KIRP	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	15.71	0.71	5.44e-39	Chronic sinus infection;
KIRP	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13030908	chr1:11741533	MAD2L2	0.56	6.54	0.38	3.6e-10	Smoking initiation;
KIRP	cis	rs4791746	0.948	rs4413002	chr17:8619809	A/G	cg03115937	chr17:8649504	CCDC42	-0.53	-6.37	-0.38	9.46e-10	Heroin dependence;
KIRP	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg07541023	chr7:19748670	TWISTNB	0.63	5.61	0.34	5.34e-8	Thyroid stimulating hormone;
KIRP	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.79	0.49	2.71e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg01631408	chr1:248437212	OR2T33	-0.68	-8.74	-0.49	3.75e-16	Common traits (Other);
KIRP	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs35955747	0.934	rs4820045	chr22:31785969	G/A	cg02404636	chr22:31891804	SFI1	-0.37	-5.04	-0.31	8.83e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10116904	chr1:190068092	FAM5C	-0.42	-6.21	-0.37	2.27e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23903597	chr17:61704154	MAP3K3	-0.61	-7.97	-0.45	5.99e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.58	7.33	0.42	3.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.53	7.2	0.42	7.19e-12	Testicular germ cell tumor;
KIRP	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg08975724	chr8:8085496	FLJ10661	0.61	7.99	0.45	5.19e-14	Joint mobility (Beighton score);
KIRP	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.53	-7.28	-0.42	4.53e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.85	-11.12	-0.58	1.58e-23	Type 2 diabetes;
KIRP	cis	rs7009516	0.625	rs1907754	chr8:24259027	A/C	cg01759110	chr8:24241694	ADAMDEC1	-0.27	-6.0	-0.36	6.9e-9	Hair greying;
KIRP	cis	rs10267417	0.657	rs4721842	chr7:19913237	T/C	cg05791153	chr7:19748676	TWISTNB	0.52	4.91	0.3	1.7e-6	Night sleep phenotypes;
KIRP	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg24955955	chr5:415729	AHRR	0.74	6.12	0.36	3.59e-9	Fat distribution (HIV);
KIRP	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-7.13	-0.41	1.08e-11	Menarche (age at onset);
KIRP	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg07541023	chr7:19748670	TWISTNB	0.46	5.07	0.31	7.95e-7	Thyroid stimulating hormone;
KIRP	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg10790698	chr19:18539756	SSBP4	-0.33	-7.1	-0.41	1.35e-11	Breast cancer;
KIRP	trans	rs8112211	0.637	rs2270093	chr19:38839859	T/C	cg09817427	chr6:85474313	TBX18	0.54	6.08	0.36	4.64e-9	Blood protein levels;
KIRP	cis	rs72848980	0.706	rs11191732	chr10:105331761	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.65	6.85	0.4	5.76e-11	White matter hyperintensity burden;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00844078	chr2:26098817	ASXL2	-0.41	-6.24	-0.37	1.91e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.28	0.51	9.06e-18	Morning vs. evening chronotype;
KIRP	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.77	9.02	0.5	5.4e-17	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.5	-7.13	-0.41	1.09e-11	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21861644	chr18:13726504	C18orf19;RNMT	0.52	6.45	0.38	6.03e-10	Parkinson's disease;
KIRP	cis	rs77972916	0.518	rs55877805	chr2:43557597	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-6.4	-0.38	7.72e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg16511985	chr3:153974050	SGEF	0.38	5.36	0.32	1.95e-7	Coronary artery disease;
KIRP	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.56	7.0	0.41	2.37e-11	Height;
KIRP	cis	rs4638749	0.680	rs12612935	chr2:108818409	A/G	cg25838818	chr2:108905173	SULT1C2	-0.6	-7.15	-0.41	9.74e-12	Blood pressure;
KIRP	cis	rs12976411	0.575	rs73927590	chr19:32821559	G/C	cg02282382	chr19:32836354	ZNF507	0.62	5.17	0.31	4.93e-7	Coronary artery disease;
KIRP	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg19468946	chr17:37922297	IKZF3	-0.46	-6.48	-0.38	4.88e-10	Asthma;
KIRP	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg25036284	chr2:26402008	FAM59B	-0.67	-6.98	-0.41	2.76e-11	Gut microbiome composition (summer);
KIRP	cis	rs7601312	0.967	rs55790701	chr2:229310157	C/T	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.12	-19.09	-0.77	1.85e-50	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.77	-6.9	-0.4	4.43e-11	Diabetic retinopathy;
KIRP	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.44	5.81	0.35	1.91e-8	Homoarginine levels;
KIRP	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg11833968	chr6:79620685	NA	-0.46	-6.87	-0.4	5.23e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.84	9.73	0.53	3.99e-19	Iron status biomarkers;
KIRP	cis	rs151997	0.962	rs27271	chr5:50183369	A/G	cg06027927	chr5:50259733	NA	0.6	7.56	0.43	8.2e-13	Callous-unemotional behaviour;
KIRP	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	1.1	8.05	0.46	3.62e-14	Skin colour saturation;
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg07701084	chr6:150067640	NUP43	0.72	9.53	0.52	1.62e-18	Lung cancer;
KIRP	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.48	-0.43	1.32e-12	Neuroticism;
KIRP	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.97	-15.04	-0.69	1.12e-36	Height;
KIRP	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg13147721	chr7:65941812	NA	-1.01	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-5.01	-0.3	1.02e-6	Reticulocyte count;
KIRP	cis	rs2329775	0.534	rs16880229	chr7:40442741	A/T	cg00420559	chr7:40367873	C7orf10	-0.39	-5.4	-0.33	1.55e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.43	5.04	0.31	8.83e-7	Lung cancer;
KIRP	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.01	16.22	0.72	1e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03399598	chr4:174091002	GALNT7	0.75	6.35	0.38	1.04e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4870684	0.509	rs11763804	chr7:57702125	G/C	cg01314568	chr7:57830625	NA	-0.63	-6.73	-0.39	1.21e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg20307385	chr11:47447363	PSMC3	-0.56	-5.51	-0.33	9.07e-8	Subjective well-being;
KIRP	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg14779329	chr11:130786720	SNX19	-0.37	-4.97	-0.3	1.28e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9308731	0.563	rs11899831	chr2:111932694	G/A	cg03171003	chr2:111875934	NA	0.42	5.74	0.34	2.78e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs4704187	0.663	rs56012051	chr5:74551828	A/G	cg03227963	chr5:74354835	NA	0.41	5.96	0.35	8.9e-9	Response to amphetamines;
KIRP	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.75	-7.77	-0.44	2.13e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg00405596	chr8:11794950	NA	-0.39	-4.97	-0.3	1.24e-6	Retinal vascular caliber;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04902049	chr1:36622448	MAP7D1	0.48	6.34	0.37	1.08e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg12011299	chr4:100065546	ADH4	-0.48	-6.57	-0.39	2.95e-10	Alcohol dependence;
KIRP	cis	rs9905704	0.633	rs2632511	chr17:56490989	G/A	cg12560992	chr17:57184187	TRIM37	0.54	5.13	0.31	5.79e-7	Testicular germ cell tumor;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13047869	chr3:10149882	C3orf24	0.61	5.64	0.34	4.69e-8	Alzheimer's disease;
KIRP	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.81	11.7	0.6	1.9e-25	Height;
KIRP	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg02980000	chr4:1222292	CTBP1	0.75	8.57	0.48	1.16e-15	Systolic blood pressure;
KIRP	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.77	11.15	0.58	1.19e-23	Morning vs. evening chronotype;
KIRP	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg19847130	chr8:10466454	RP1L1	0.35	5.36	0.32	1.96e-7	Triglycerides;
KIRP	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	1.01	16.73	0.73	1.84e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs1355223	0.573	rs947501	chr11:34753375	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.29	-0.37	1.46e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs4349753	0.904	rs423327	chr5:144192139	G/A	cg16033277	chr17:80885358	TBCD	0.41	6.28	0.37	1.49e-9	Photic sneeze reflex;
KIRP	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.72	9.5	0.52	2.01e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.5	5.95	0.35	8.94e-9	Metabolite levels;
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg16898833	chr6:26189333	HIST1H4D	0.76	5.33	0.32	2.19e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.86	-9.51	-0.52	1.82e-18	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14102272	chr2:201729414	CLK1	0.55	6.62	0.39	2.26e-10	Parkinson's disease;
KIRP	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg02569458	chr12:86230093	RASSF9	0.35	5.01	0.3	1.02e-6	Major depressive disorder;
KIRP	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.45	-0.38	5.76e-10	Aortic root size;
KIRP	trans	rs6601327	0.775	rs12156017	chr8:9406837	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.23	-0.37	2.04e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.68	9.24	0.51	1.17e-17	Hemoglobin concentration;
KIRP	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.84	-0.3	2.27e-6	Crohn's disease;
KIRP	cis	rs72925845	0.577	rs72907463	chr17:76428660	G/A	cg03830375	chr17:76426088	DNAH17	0.49	5.09	0.31	7.21e-7	Triglycerides;
KIRP	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg11569703	chr11:65557185	OVOL1	-0.31	-4.96	-0.3	1.29e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.67	-6.14	-0.36	3.28e-9	Schizophrenia;
KIRP	cis	rs6991838	0.584	rs4737221	chr8:66481310	G/A	cg13398993	chr8:66546079	ARMC1	-0.45	-5.04	-0.31	8.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3847687	0.869	rs11061300	chr12:131523261	G/A	cg25772418	chr12:131519998	GPR133	-0.38	-5.24	-0.32	3.44e-7	Longevity;
KIRP	cis	rs4908760	0.757	rs301807	chr1:8484823	A/G	cg03610117	chr1:8450231	RERE	0.36	5.17	0.31	4.79e-7	Vitiligo;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.59	7.94	0.45	7.01e-14	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12769566	chr4:47487497	ATP10D	0.44	6.05	0.36	5.47e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg22857025	chr5:266934	NA	-1.21	-8.24	-0.47	9.98e-15	Breast cancer;
KIRP	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.44	-0.52	2.99e-18	Aortic root size;
KIRP	trans	rs921874	0.553	rs2512357	chr11:86775119	A/G	cg22937172	chr2:240168862	HDAC4	0.5	6.46	0.38	5.62e-10	Total body bone mineral density;
KIRP	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg04058563	chr4:185651563	MLF1IP	-0.38	-4.86	-0.3	2.05e-6	Kawasaki disease;
KIRP	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg12560992	chr17:57184187	TRIM37	0.6	5.53	0.33	8.18e-8	Cognitive test performance;
KIRP	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg03465714	chr1:152285911	FLG	-0.42	-5.13	-0.31	5.97e-7	Atopic dermatitis;
KIRP	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.78	0.35	2.2e-8	Educational attainment;
KIRP	cis	rs7225151	0.710	rs75754694	chr17:5259765	C/G	cg24500398	chr17:5266808	RABEP1	-0.54	-5.13	-0.31	5.89e-7	Alzheimer's disease (late onset);
KIRP	cis	rs9378796	0.518	rs13216490	chr6:3436467	A/G	cg00476032	chr6:3446245	SLC22A23	-0.52	-5.21	-0.31	4.09e-7	Mean platelet volume;
KIRP	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16434002	chr17:42200994	HDAC5	-0.58	-7.22	-0.42	6.31e-12	Total body bone mineral density;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg08901578	chr4:187885870	NA	-0.45	-6.79	-0.4	8.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.55	-0.33	7.36e-8	Colorectal cancer;
KIRP	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs1867631	0.958	rs7536188	chr1:67087926	A/T	cg13052034	chr1:66999238	SGIP1	-0.49	-7.13	-0.41	1.12e-11	Menopause (age at onset);
KIRP	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg16141378	chr3:129829833	LOC729375	0.61	8.25	0.47	9.36e-15	Neuroticism;
KIRP	cis	rs4566357	1.000	rs3820926	chr2:227926621	G/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-12.71	-0.63	8.85e-29	Height;
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg03289416	chr15:75166202	SCAMP2	-0.5	-6.74	-0.39	1.15e-10	Breast cancer;
KIRP	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg20362242	chr5:692897	TPPP	0.62	5.32	0.32	2.35e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg18350739	chr11:68623251	NA	0.52	8.09	0.46	2.73e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12663357	chr1:78353198	NEXN	-0.42	-6.42	-0.38	7.13e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.43e-33	Primary sclerosing cholangitis;
KIRP	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg00901687	chr17:48585270	MYCBPAP	-0.48	-6.55	-0.39	3.25e-10	Visceral fat;
KIRP	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg02375832	chr11:62437615	C11orf48	-0.52	-6.26	-0.37	1.68e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.75	-11.09	-0.58	1.92e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.88	-14.05	-0.67	2.5e-33	Ulcerative colitis;
KIRP	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs6547631	0.844	rs1436968	chr2:85903470	C/G	cg07313956	chr2:85895360	SFTPB	0.34	4.92	0.3	1.56e-6	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00850501	chr19:14530371	DDX39	0.47	6.19	0.37	2.44e-9	Parkinson's disease;
KIRP	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.46	-7.03	-0.41	1.99e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.98	-0.3	1.17e-6	Pulmonary function;
KIRP	cis	rs4908768	1.000	rs12134896	chr1:8656227	G/A	cg25722041	chr1:8623473	RERE	0.85	10.49	0.56	1.56e-21	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs1978968	0.830	rs11089210	chr22:18445692	A/T	cg02610425	chr22:18483192	MICAL3	0.36	4.97	0.3	1.24e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	6.78	0.4	8.93e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs62413470	1.000	rs12208615	chr6:55933489	T/C	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-7.69	-0.44	3.57e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg19274270	chr17:78178856	CARD14	0.35	6.29	0.37	1.44e-9	Morning vs. evening chronotype;
KIRP	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.59	8.36	0.47	4.6e-15	Urate levels in overweight individuals;
KIRP	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.28	14.61	0.68	3.17e-35	Uric acid levels;
KIRP	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg22800045	chr5:56110881	MAP3K1	0.8	7.66	0.44	4.28e-13	Type 2 diabetes;
KIRP	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg12856521	chr11:46389249	DGKZ	0.56	7.35	0.42	3e-12	Crohn's disease;
KIRP	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	8.33	0.47	5.86e-15	Myopia (pathological);
KIRP	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg20312557	chr2:97357134	FER1L5	-0.79	-5.43	-0.33	1.34e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.95	14.98	0.69	1.67e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg20243544	chr17:37824526	PNMT	-0.45	-5.42	-0.33	1.43e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.69	10.65	0.56	5.14e-22	Anterior chamber depth;
KIRP	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.4	5.55	0.33	7.32e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11260421	chr19:35645680	FXYD5	0.42	6.26	0.37	1.66e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg11608241	chr8:8085544	FLJ10661	0.52	6.15	0.37	3.09e-9	Mood instability;
KIRP	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.78	10.61	0.56	6.54e-22	Resting heart rate;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg08662619	chr6:150070041	PCMT1	0.39	6.37	0.38	9.1e-10	Lung cancer;
KIRP	cis	rs9843304	0.529	rs4681511	chr3:149201579	C/T	cg08667024	chr3:149219783	TM4SF4	-0.42	-6.44	-0.38	6.21e-10	Gallstone disease;
KIRP	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg05342682	chr7:94953680	PON1	-0.45	-5.05	-0.31	8.74e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg18932078	chr1:2524107	MMEL1	0.43	5.98	0.36	7.76e-9	Ulcerative colitis;
KIRP	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg25251562	chr2:3704773	ALLC	-0.4	-5.42	-0.33	1.44e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.92	0.4	3.99e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6438504	0.922	rs4234657	chr3:118948288	C/T	cg25372693	chr3:118959985	B4GALT4	-0.31	-5.29	-0.32	2.74e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.57	-5.2	-0.31	4.17e-7	Yeast infection;
KIRP	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.98	7.75	0.44	2.35e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13095912	0.638	rs6791369	chr3:185289989	C/A	cg11274856	chr3:185301563	NA	0.6	7.41	0.43	2.08e-12	Systolic blood pressure;
KIRP	cis	rs7481584	0.564	rs432585	chr11:3084903	G/A	cg08508325	chr11:3079039	CARS	0.33	6.06	0.36	5.14e-9	Calcium levels;
KIRP	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.68	9.37	0.51	4.74e-18	Schizophrenia;
KIRP	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.35	5.15	0.31	5.29e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06649899	chr16:67261154	TMEM208;LRRC29	0.56	6.22	0.37	2.1e-9	Lung cancer in ever smokers;
KIRP	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.53	7.51	0.43	1.11e-12	Colorectal cancer;
KIRP	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-6.96	-0.41	2.99e-11	Hemoglobin concentration;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg27144592	chr16:783916	NARFL	0.35	4.86	0.3	2.08e-6	Height;
KIRP	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.77	-8.53	-0.48	1.48e-15	Platelet count;
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.38	5.25	0.32	3.23e-7	Lung cancer;
KIRP	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.49	-6.55	-0.39	3.43e-10	Lung cancer;
KIRP	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg02820040	chr2:241836501	C2orf54	-0.25	-5.89	-0.35	1.25e-8	Urinary metabolites;
KIRP	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.84	11.65	0.6	2.86e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	1.08	21.17	0.8	2.41e-57	Height;
KIRP	cis	rs2929278	0.617	rs575082	chr15:44110142	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.45	-5.27	-0.32	3.03e-7	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg04865290	chr3:52927548	TMEM110	-0.62	-7.01	-0.41	2.27e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	cg21523751	chr1:182988639	NA	0.42	6.39	0.38	8.3e-10	Colorectal cancer;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg09597638	chr17:3907349	NA	0.8	15.88	0.71	1.39e-39	Type 2 diabetes;
KIRP	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.72	-9.58	-0.52	1.1e-18	Coronary artery disease;
KIRP	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.14	-0.41	1.04e-11	Response to antipsychotic treatment;
KIRP	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg15979348	chr13:112237479	NA	0.4	5.19	0.31	4.38e-7	Menarche (age at onset);
KIRP	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	0.91	10.63	0.56	5.96e-22	White matter hyperintensity burden;
KIRP	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.62	9.98	0.54	6.49e-20	Bone mineral density;
KIRP	cis	rs925255	0.901	rs906805	chr2:28604879	A/G	cg01273330	chr2:28605224	NA	-0.54	-11.11	-0.58	1.6e-23	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs10416265	0.527	rs7508599	chr19:33546512	A/T	cg17764715	chr19:33622953	WDR88	0.8	11.18	0.58	9.77e-24	Bone properties (heel);
KIRP	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.48	5.99	0.36	7.3e-9	Eosinophil percentage of white cells;
KIRP	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.62	8.64	0.48	7.16e-16	Plateletcrit;Platelet count;
KIRP	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg06027949	chr8:82754900	SNX16	-0.45	-5.59	-0.34	6.1e-8	Diastolic blood pressure;
KIRP	cis	rs7172677	0.960	rs1602360	chr15:75420761	G/A	cg03289416	chr15:75166202	SCAMP2	0.39	4.86	0.3	2.11e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7737355	0.773	rs9327616	chr5:130902196	C/T	cg25547332	chr5:131281432	NA	0.39	4.91	0.3	1.63e-6	Life satisfaction;
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.52	-8.67	-0.48	6.04e-16	Lung cancer;
KIRP	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg21174375	chr14:64681225	SYNE2	0.57	6.75	0.4	1.08e-10	Atrial fibrillation;
KIRP	cis	rs6832769	1.000	rs1522108	chr4:56380733	T/C	cg09317128	chr4:56265301	TMEM165	0.52	6.34	0.37	1.09e-9	Personality dimensions;
KIRP	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.26	6.53	0.38	3.84e-10	Breast cancer;Mosquito bite size;
KIRP	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.82	11.3	0.58	3.86e-24	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg25288420	chr1:78511713	GIPC2	0.5	6.54	0.38	3.59e-10	Obesity-related traits;
KIRP	cis	rs876084	0.505	rs7834024	chr8:121103053	T/C	cg06265175	chr8:121136014	COL14A1	0.5	6.28	0.37	1.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.78	6.83	0.4	6.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.35	-5.46	-0.33	1.18e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg14791747	chr16:20752902	THUMPD1	0.63	6.91	0.4	4.22e-11	Cognitive test performance;
KIRP	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.72	6.98	0.41	2.71e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg10932868	chr11:921992	NA	0.67	9.12	0.5	2.82e-17	Alzheimer's disease (late onset);
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg18612461	chr15:75251733	NA	0.33	5.12	0.31	6.14e-7	Breast cancer;
KIRP	cis	rs4955124	0.558	rs62244393	chr3:32020533	T/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.8	7.41	0.43	1.98e-12	Schizophrenia;
KIRP	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.68	-9.47	-0.52	2.34e-18	QRS duration;
KIRP	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.61	-7.62	-0.44	5.46e-13	Dental caries;
KIRP	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-5.39	-0.33	1.64e-7	Skin colour saturation;
KIRP	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.92	0.3	1.55e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.63	-7.25	-0.42	5.47e-12	Obesity-related traits;
KIRP	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.39	-0.32	1.69e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17877485	chr5:162871794	CCNG1	-0.43	-6.78	-0.4	8.98e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg00405596	chr8:11794950	NA	0.47	5.94	0.35	9.86e-9	Systemic lupus erythematosus;
KIRP	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.46e-19	Colorectal cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15351736	chr11:111808104	DIXDC1	0.56	7.12	0.41	1.19e-11	Smoking initiation;
KIRP	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.91	15.32	0.7	1.17e-37	Breast cancer;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg07747251	chr5:1868357	NA	0.42	5.55	0.33	7.3900000000000007e-08	Cardiovascular disease risk factors;
KIRP	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg07827796	chr19:33622959	WDR88	0.46	5.68	0.34	3.88e-8	Colorectal cancer;
KIRP	cis	rs4566357	0.930	rs1917128	chr2:227927936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.0	-0.3	1.08e-6	Coronary artery disease;
KIRP	cis	rs6939532	0.522	rs9379870	chr6:26374410	A/G	cg14345882	chr6:26364793	BTN3A2	0.33	5.16	0.31	5.18e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4132509	0.793	rs9428579	chr1:243690034	C/T	cg21452805	chr1:244014465	NA	0.54	5.11	0.31	6.59e-7	RR interval (heart rate);
KIRP	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.57	-0.52	1.21e-18	Coronary artery disease;
KIRP	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.99	-14.76	-0.69	9.56e-36	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg05973401	chr12:123451056	ABCB9	0.41	5.02	0.3	9.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.36	-0.42	2.74e-12	Bipolar disorder;
KIRP	cis	rs4006360	0.524	rs6503601	chr17:39280487	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.62	-8.09	-0.46	2.68e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	5.39	0.32	1.66e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg08975724	chr8:8085496	FLJ10661	0.51	6.61	0.39	2.31e-10	Retinal vascular caliber;
KIRP	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg02319466	chr17:76381040	PGS1	0.46	6.35	0.38	1e-9	HDL cholesterol levels;
KIRP	cis	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs2019216	0.542	rs2221893	chr17:21930012	A/G	cg22648282	chr17:21454238	C17orf51	-0.58	-7.37	-0.43	2.52e-12	Pelvic organ prolapse;
KIRP	cis	rs7224685	0.501	rs6502765	chr17:3901814	A/G	cg21851534	chr17:3907994	ZZEF1	0.72	12.14	0.61	6.85e-27	Type 2 diabetes;
KIRP	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	9.63	0.52	8.07e-19	Alzheimer's disease;
KIRP	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg02353165	chr6:42928485	GNMT	0.44	4.96	0.3	1.35e-6	Blood protein levels;
KIRP	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.3	0.32	2.6e-7	Tonsillectomy;
KIRP	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg21573476	chr21:45109991	RRP1B	0.57	7.66	0.44	4.22e-13	Mean corpuscular volume;
KIRP	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.8	11.79	0.6	9.92e-26	Heart rate;
KIRP	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg22676075	chr6:135203613	NA	0.5	7.21	0.42	7.07e-12	Red blood cell count;
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg07341007	chr3:195489909	MUC4	0.64	6.21	0.37	2.28e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1434579	0.798	rs12460231	chr19:44954688	A/T	cg15540054	chr19:45004280	ZNF180	0.54	5.82	0.35	1.79e-8	Tuberculosis;
KIRP	cis	rs6578185	0.684	rs9987318	chr8:142437352	A/G	cg07762003	chr8:142452454	FLJ43860	0.53	7.46	0.43	1.46e-12	Endometriosis;
KIRP	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	6.81	0.4	7.4e-11	Retinal vascular caliber;
KIRP	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.85	13.49	0.65	2e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg10047753	chr17:41438598	NA	0.82	11.46	0.59	1.16e-24	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00933542	chr6:150070202	PCMT1	0.3	6.03	0.36	6.08e-9	Lung cancer;
KIRP	cis	rs259842	0.759	rs6752731	chr2:180684007	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.42	-0.33	1.39e-7	Blood protein levels;
KIRP	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg00074818	chr8:8560427	CLDN23	0.4	6.11	0.36	3.87e-9	Obesity-related traits;
KIRP	cis	rs13082711	0.911	rs6776318	chr3:27523457	T/C	cg02860705	chr3:27208620	NA	0.53	7.16	0.42	9.16e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs72730918	0.590	rs1840707	chr15:51979674	G/A	cg14296394	chr15:51910925	DMXL2	-0.68	-9.63	-0.52	7.85e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.53	6.81	0.4	7.4e-11	Breast cancer;
KIRP	cis	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.43	-5.37	-0.32	1.86e-7	Leprosy;
KIRP	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg09201719	chr10:104596890	CYP17A1	0.35	5.0	0.3	1.11e-6	Arsenic metabolism;
KIRP	cis	rs73198271	0.595	rs11780672	chr8:8584153	A/C	cg15556689	chr8:8085844	FLJ10661	-0.58	-5.1	-0.31	6.63e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg27124370	chr19:33622961	WDR88	0.72	10.19	0.54	1.43e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.45	5.87	0.35	1.43e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2120243	0.572	rs2305620	chr3:157127586	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-8.9	-0.49	1.26e-16	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg13206674	chr6:150067644	NUP43	0.55	7.8	0.45	1.74e-13	Lung cancer;
KIRP	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg14086364	chr5:150678334	SLC36A3	0.35	5.87	0.35	1.43e-8	Skin aging (microtopography measurement);
KIRP	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg21427119	chr20:30132790	HM13	-0.47	-5.33	-0.32	2.23e-7	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11987759	chr7:65425863	GUSB	-0.46	-5.47	-0.33	1.09e-7	Aortic root size;
KIRP	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11528984	chr1:228353883	C1orf69	0.55	7.0	0.41	2.41e-11	Parkinson's disease;
KIRP	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.2	-23.34	-0.83	2.64e-64	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.87	6.56	0.39	3.22e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7520050	0.807	rs28844317	chr1:46209207	T/C	cg15605315	chr1:45957053	TESK2	-0.39	-4.98	-0.3	1.18e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs5753618	0.561	rs4820963	chr22:31698166	C/T	cg02404636	chr22:31891804	SFI1	-0.49	-5.42	-0.33	1.4e-7	Colorectal cancer;
KIRP	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.62	7.84	0.45	1.37e-13	Neuroticism;
KIRP	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg14851346	chr12:38532713	NA	-0.39	-4.97	-0.3	1.26e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.69	-0.39	1.46e-10	Bipolar disorder;
KIRP	cis	rs6800768	0.604	rs75990679	chr3:24155774	G/C	cg10674438	chr3:24145617	LOC152024	-0.52	-6.86	-0.4	5.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.68	10.04	0.54	4.23e-20	Dupuytren's disease;
KIRP	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-1.06	-12.94	-0.64	1.47e-29	Vitiligo;
KIRP	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs7084402	0.934	rs1593673	chr10:60294170	C/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs6504950	0.800	rs9907961	chr17:53012927	C/G	cg26251398	chr17:52985966	TOM1L1	0.45	6.06	0.36	5.02e-9	Breast cancer;
KIRP	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg13819577	chr1:248512075	OR14C36	-0.36	-5.11	-0.31	6.55e-7	Common traits (Other);
KIRP	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.63	7.41	0.43	2.05e-12	Alzheimer's disease (late onset);
KIRP	cis	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg08798685	chr6:27730294	NA	-0.57	-4.95	-0.3	1.38e-6	Lung cancer in ever smokers;
KIRP	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg08992911	chr2:238395768	MLPH	0.67	6.42	0.38	6.98e-10	Prostate cancer;
KIRP	cis	rs8177253	0.514	rs6790668	chr3:133442481	T/A	cg24879335	chr3:133465180	TF	0.51	8.51	0.48	1.71e-15	Iron status biomarkers;
KIRP	cis	rs77688320	0.553	rs2908763	chr2:202368583	T/C	cg06431681	chr2:202330990	STRADB	-0.44	-5.17	-0.31	4.84e-7	Breast cancer;
KIRP	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.54	8.22	0.46	1.18e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9916302	0.665	rs4795369	chr17:37609120	G/A	cg15445000	chr17:37608096	MED1	0.51	5.57	0.33	6.66e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03605463	chr16:89740564	NA	-0.44	-5.32	-0.32	2.36e-7	Hemoglobin concentration;
KIRP	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.52	0.43	1e-12	Neuroticism;
KIRP	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.39	0.43	2.28e-12	Mean corpuscular volume;
KIRP	cis	rs7582180	0.868	rs6542924	chr2:100893113	A/C	cg14675211	chr2:100938903	LONRF2	-0.46	-4.89	-0.3	1.86e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs12517041	1.000	rs35380017	chr5:23310237	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.83	-7.48	-0.43	1.31e-12	Calcium levels;
KIRP	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.54	5.16	0.31	5.15e-7	Skin colour saturation;
KIRP	cis	rs2591576	0.655	rs1348692	chr5:165354855	C/T	cg13976338	chr5:165423657	NA	-0.71	-9.8	-0.53	2.31e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.74	11.41	0.59	1.71e-24	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.17	0.54	1.63e-20	Cognitive test performance;
KIRP	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.14	-0.41	1.04e-11	Response to antipsychotic treatment;
KIRP	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg25418670	chr11:30344373	C11orf46	0.6	5.11	0.31	6.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07395648	chr5:131743802	NA	-0.57	-7.95	-0.45	6.58e-14	Breast cancer;Mosquito bite size;
KIRP	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.43	5.16	0.31	5.08e-7	Neurofibrillary tangles;
KIRP	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	0.83	6.92	0.4	3.96e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.1	0.36	4.01e-9	Neuroticism;
KIRP	cis	rs8084125	1.000	rs72978668	chr18:74953748	A/C	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg21851534	chr17:3907994	ZZEF1	0.74	12.4	0.62	9.44e-28	Type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	6.8e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.62	8.14	0.46	1.95e-14	Pancreatic cancer;
KIRP	cis	rs3105593	1.000	rs3105593	chr15:50845018	C/T	cg05456662	chr15:50716270	USP8	0.37	4.96	0.3	1.33e-6	QT interval;
KIRP	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Life satisfaction;
KIRP	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18252515	chr7:66147081	NA	-0.47	-5.58	-0.34	6.31e-8	Aortic root size;
KIRP	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.72	8.58	0.48	1.07e-15	Corneal astigmatism;
KIRP	cis	rs2249694	0.960	rs4133041	chr10:135408387	G/A	cg20169779	chr10:135381914	SYCE1	-0.42	-4.98	-0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.87	13.58	0.65	9.89e-32	Menarche (age at onset);
KIRP	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.52	6.45	0.38	5.86e-10	Longevity;Endometriosis;
KIRP	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.75	-0.44	2.39e-13	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs7572263	0.959	rs12995271	chr2:209048136	T/C	cg23998903	chr2:209048830	C2orf80	-0.32	-5.44	-0.33	1.29e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.83e-7	Red blood cell count;
KIRP	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg06360820	chr2:242988706	NA	-0.74	-6.54	-0.38	3.6e-10	Obesity-related traits;
KIRP	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	1.12	10.2	0.55	1.3e-20	Lymphocyte counts;
KIRP	trans	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.38	0.38	8.92e-10	Mean corpuscular volume;
KIRP	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.16	-0.31	5.14e-7	Schizophrenia;
KIRP	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg10047753	chr17:41438598	NA	0.89	12.9	0.64	2e-29	Menopause (age at onset);
KIRP	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.26	17.69	0.75	9.67e-46	Atopic dermatitis;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.88	8.7	0.48	4.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	5.26	0.32	3.15e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg02175503	chr12:58329896	NA	0.62	6.74	0.39	1.13e-10	Multiple sclerosis;
KIRP	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-5.1	-0.31	6.81e-7	Neuroticism;
KIRP	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg00656387	chr3:40428638	ENTPD3	0.38	4.86	0.3	2.08e-6	Renal cell carcinoma;
KIRP	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.69	-0.39	1.52e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs62109865	0.655	rs62111795	chr19:12597903	T/G	cg19721055	chr19:12753329	NA	-0.84	-4.94	-0.3	1.48e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg16988262	chr1:15930761	NA	0.36	4.9	0.3	1.77e-6	Systolic blood pressure;
KIRP	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.61	-9.02	-0.5	5.39e-17	Body mass index;
KIRP	cis	rs7130144	0.541	rs60642492	chr11:130465155	G/A	cg26307797	chr11:130446613	NA	-0.63	-5.21	-0.32	4.02e-7	Urate levels in lean individuals;
KIRP	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.48	0.33	1.06e-7	Intracranial aneurysm;
KIRP	cis	rs56399783	0.901	rs17132594	chr7:2775102	G/A	cg19731401	chr7:2775893	GNA12	0.78	7.42	0.43	1.93e-12	Childhood ear infection;
KIRP	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg14789911	chr21:47582049	C21orf56	-0.46	-5.63	-0.34	4.82e-8	Testicular germ cell tumor;
KIRP	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.84	-0.45	1.4e-13	Mean corpuscular volume;
KIRP	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.22	-0.51	1.37e-17	Bladder cancer;
KIRP	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.68	-10.04	-0.54	4.16e-20	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9488822	0.662	rs195534	chr6:116254834	T/C	cg26893134	chr6:116381904	FRK	0.19	5.01	0.3	1.05e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg25039879	chr17:56429692	SUPT4H1	0.58	5.13	0.31	5.85e-7	Cognitive test performance;
KIRP	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg06121193	chr1:90282411	NA	-0.52	-7.53	-0.43	9.68e-13	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.11	-0.36	3.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg08662619	chr6:150070041	PCMT1	0.36	5.92	0.35	1.1e-8	Lung cancer;
KIRP	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs9323205	0.677	rs4264315	chr14:51728356	G/A	cg23942311	chr14:51606299	NA	-0.53	-5.21	-0.32	4.07e-7	Cancer;
KIRP	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	21.71	0.81	4.2e-59	Chronic sinus infection;
KIRP	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07570687	chr10:102243282	WNT8B	0.51	6.69	0.39	1.5e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.75	0.34	2.59e-8	Menopause (age at onset);
KIRP	cis	rs16958440	1.000	rs12326600	chr18:44596497	C/T	cg17192377	chr18:44677553	HDHD2	0.75	6.72	0.39	1.24e-10	Sitting height ratio;
KIRP	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.65	5.51	0.33	9.18e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02463440	chr8:22132932	PIWIL2	0.39	5.19	0.31	4.5e-7	Hypertriglyceridemia;
KIRP	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.95	13.81	0.66	1.63e-32	Primary sclerosing cholangitis;
KIRP	trans	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg06636001	chr8:8085503	FLJ10661	0.48	6.21	0.37	2.25e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.01	0.45	4.74e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.42	-5.04	-0.31	9.2e-7	Educational attainment;
KIRP	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg00745463	chr17:30367425	LRRC37B	-0.78	-7.44	-0.43	1.67e-12	Hip circumference adjusted for BMI;
KIRP	trans	rs11593840	0.717	rs11001779	chr10:78191036	T/G	cg18555199	chr3:180630509	FXR1	0.48	6.12	0.36	3.75e-9	Male-pattern baldness;
KIRP	cis	rs11239930	0.517	rs942689	chr1:146550780	T/C	cg16700924	chr1:146552102	NA	-0.44	-4.86	-0.3	2.06e-6	AIDS progression;
KIRP	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.76	-9.8	-0.53	2.28e-19	Aortic root size;
KIRP	trans	rs909341	0.868	rs2738758	chr20:62349625	C/G	cg01311341	chr22:25575246	KIAA1671	0.6	7.3	0.42	3.98e-12	Atopic dermatitis;
KIRP	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00908189	chr16:619842	PIGQ	0.86	11.85	0.6	6.4e-26	Height;
KIRP	trans	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg01311341	chr22:25575246	KIAA1671	0.53	6.55	0.39	3.42e-10	Prostate cancer;
KIRP	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg11663144	chr21:46675770	NA	-0.67	-10.03	-0.54	4.52e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg17279839	chr7:150038598	RARRES2	0.55	7.09	0.41	1.42e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg24579218	chr15:68104479	NA	-0.42	-5.78	-0.35	2.28e-8	Obesity;
KIRP	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	cg12689670	chr1:183009347	LAMC1	0.51	7.24	0.42	5.72e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs33912345	0.695	rs1262173	chr14:60874311	T/C	cg27398547	chr14:60952738	C14orf39	-0.4	-5.44	-0.33	1.3e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs6681460	0.898	rs1032634	chr1:67195192	C/G	cg02459107	chr1:67143332	SGIP1	-0.4	-5.67	-0.34	3.95e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg05973401	chr12:123451056	ABCB9	0.59	5.34	0.32	2.16e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.69	6.69	0.39	1.51e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg25753631	chr6:25732923	NA	0.27	5.33	0.32	2.19e-7	Iron status biomarkers;
KIRP	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg01990225	chr2:97406019	LMAN2L	-1.01	-7.07	-0.41	1.57e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.2	8.43	0.47	2.94e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs490234	0.702	rs12553882	chr9:128195044	G/A	cg14078157	chr9:128172775	NA	-0.63	-7.14	-0.41	1.07e-11	Mean arterial pressure;
KIRP	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.19e-15	Retinal vascular caliber;
KIRP	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.52	8.21	0.46	1.26e-14	Schizophrenia;
KIRP	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.41	-0.47	3.32e-15	Mean corpuscular volume;
KIRP	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg14458575	chr2:238380390	NA	0.55	5.76	0.34	2.45e-8	Prostate cancer;
KIRP	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg23127183	chr11:57508653	C11orf31	-0.55	-7.08	-0.41	1.47e-11	Schizophrenia;
KIRP	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg22676075	chr6:135203613	NA	0.52	7.71	0.44	3.17e-13	Red blood cell count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05013783	chr12:56652058	ANKRD52	0.65	7.58	0.44	7.24e-13	Smoking initiation;
KIRP	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-1.01	-16.92	-0.73	3.99e-43	Height;
KIRP	cis	rs7084402	0.967	rs1649076	chr10:60294061	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-5.74	-0.34	2.71e-8	Morning vs. evening chronotype;
KIRP	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg06671706	chr8:8559999	CLDN23	0.57	6.45	0.38	5.94e-10	Obesity-related traits;
KIRP	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg10434728	chr15:90938212	IQGAP1	0.43	8.33	0.47	5.81e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs72730918	0.564	rs11070861	chr15:51894270	A/T	cg14296394	chr15:51910925	DMXL2	-0.76	-10.68	-0.56	4.03e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg15269541	chr15:43626905	ADAL	-0.4	-4.9	-0.3	1.76e-6	Lung cancer in ever smokers;
KIRP	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg25801113	chr15:45476975	SHF	-0.44	-8.11	-0.46	2.41e-14	Uric acid levels;
KIRP	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg26384229	chr12:38710491	ALG10B	0.54	7.25	0.42	5.44e-12	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14177620	chr4:56719854	EXOC1	0.43	6.26	0.37	1.71e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.12	-0.41	1.16e-11	Response to antipsychotic treatment;
KIRP	cis	rs11169552	0.510	rs10783372	chr12:50952524	C/A	cg12884762	chr12:50931848	DIP2B	-0.42	-4.9	-0.3	1.72e-6	Colorectal cancer;
KIRP	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg03351412	chr1:154909251	PMVK	0.63	8.61	0.48	9.1e-16	Prostate cancer;
KIRP	trans	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17996757	chr7:131013207	MKLN1	-0.44	-6.09	-0.36	4.22e-9	Breast cancer;
KIRP	cis	rs732505	0.618	rs1337057	chr19:5676950	G/A	cg26242866	chr19:5711310	LONP1	0.69	5.38	0.32	1.71e-7	vWF and FVIII levels;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg11641102	chr8:27183873	PTK2B	0.42	5.53	0.33	8.31e-8	Neuroticism;
KIRP	cis	rs8054556	0.760	rs11642740	chr16:30060655	C/T	cg06326092	chr16:30034487	C16orf92	-0.39	-5.08	-0.31	7.55e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg27147174	chr7:100797783	AP1S1	-0.72	-9.4	-0.51	3.83e-18	Life satisfaction;
KIRP	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.52	-6.74	-0.39	1.12e-10	Aortic root size;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.79	12.08	0.61	1.09e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4764487	0.626	rs758730	chr12:6314243	T/C	cg08284733	chr12:6341482	CD9	0.34	5.42	0.33	1.41e-7	Mean platelet volume;
KIRP	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg26412358	chr1:26503933	CNKSR1	0.4	5.64	0.34	4.7e-8	Height;
KIRP	cis	rs1760803	0.754	rs9803857	chr1:154191791	A/G	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.37	5.44	0.33	1.25e-7	Nicotine dependence;
KIRP	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg09163369	chr1:210001066	C1orf107	0.5	6.4	0.38	8e-10	Orofacial clefts;
KIRP	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg00310523	chr12:86230176	RASSF9	0.56	8.84	0.49	1.89e-16	Major depressive disorder;
KIRP	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.53	-8.05	-0.46	3.46e-14	Itch intensity from mosquito bite;
KIRP	cis	rs16828019	0.777	rs12047657	chr1:41461513	G/C	cg24596898	chr1:41849189	NA	0.64	4.93	0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.85	-12.29	-0.62	2.21e-27	Height;
KIRP	cis	rs4356975	0.527	rs62296943	chr4:69959183	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.46	0.33	1.17e-7	Obesity-related traits;
KIRP	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg18932078	chr1:2524107	MMEL1	0.49	6.76	0.4	1.01e-10	Ulcerative colitis;
KIRP	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.54	7.31	0.42	3.8e-12	Mean corpuscular volume;
KIRP	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.38	-5.72	-0.34	3.02e-8	Body mass index;
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.03	0.41	2.03e-11	Electroencephalogram traits;
KIRP	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-14.22	-0.67	6.86e-34	Gut microbiome composition (summer);
KIRP	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.62	-6.78	-0.4	8.85e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.57	-6.36	-0.38	9.52e-10	Menarche (age at onset);
KIRP	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg12559939	chr2:27858050	GPN1	0.42	5.37	0.32	1.83e-7	Oral cavity cancer;
KIRP	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg10047753	chr17:41438598	NA	1.13	18.02	0.75	7.6e-47	Menopause (age at onset);
KIRP	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.37	-0.47	4.29e-15	Total cholesterol levels;
KIRP	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg03929089	chr4:120376271	NA	0.61	6.07	0.36	4.94e-9	Axial length;
KIRP	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.43	-5.27	-0.32	2.94e-7	Aortic root size;
KIRP	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg21360079	chr12:107162445	NA	0.69	9.92	0.53	1.01e-19	Heart rate;
KIRP	cis	rs7106204	1.000	rs4244512	chr11:24217355	A/G	ch.11.24196551F	chr11:24239977	NA	-0.85	-9.12	-0.5	2.84e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.69	-8.04	-0.46	3.8e-14	Pancreatic cancer;
KIRP	cis	rs17221829	0.673	rs10830334	chr11:89403921	A/G	cg02982614	chr11:89391479	FOLH1B	-0.32	-5.24	-0.32	3.42e-7	Anxiety in major depressive disorder;
KIRP	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg10523679	chr1:76189770	ACADM	0.44	6.18	0.37	2.57e-9	Daytime sleep phenotypes;
KIRP	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.62	7.26	0.42	4.92e-12	Type 2 diabetes;
KIRP	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs12096438	0.903	rs3924486	chr1:25892880	G/T	cg21452808	chr1:25900135	NA	-0.39	-6.13	-0.36	3.52e-9	Platelet count;Mean platelet volume;
KIRP	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.93	13.55	0.65	1.29e-31	Response to bleomycin (chromatid breaks);
KIRP	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg25019722	chr6:37503610	NA	-0.78	-10.59	-0.56	7.84e-22	Cognitive performance;
KIRP	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg18944383	chr4:111397179	ENPEP	0.46	7.38	0.43	2.43e-12	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17323739	chr6:119043982	NA	0.56	7.17	0.42	8.54e-12	Interleukin-4 levels;
KIRP	cis	rs28595532	0.545	rs17594782	chr4:119250877	G/T	cg21605333	chr4:119757512	SEC24D	0.69	5.84	0.35	1.67e-8	Cannabis dependence symptom count;
KIRP	cis	rs6142102	0.602	rs11696338	chr20:32687611	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	5.74	0.34	2.74e-8	Skin pigmentation;
KIRP	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg24579218	chr15:68104479	NA	-0.55	-8.08	-0.46	3e-14	Restless legs syndrome;
KIRP	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg06050784	chr16:88016603	BANP	0.44	5.25	0.32	3.22e-7	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.52	5.15	0.31	5.25e-7	Alzheimer's disease;
KIRP	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg18944383	chr4:111397179	ENPEP	0.54	9.49	0.52	2.08e-18	Height;
KIRP	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg08975724	chr8:8085496	FLJ10661	0.61	8.03	0.46	4.15e-14	Retinal vascular caliber;
KIRP	cis	rs6959887	0.962	rs2270223	chr7:35281211	A/G	cg06685737	chr7:35301730	NA	0.42	6.25	0.37	1.82e-9	Birth weight;
KIRP	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-7.45	-0.43	1.53e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg16141378	chr3:129829833	LOC729375	0.61	8.29	0.47	7.49e-15	Triglycerides;
KIRP	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	1.21	20.37	0.79	1.02e-54	Total cholesterol levels;
KIRP	cis	rs904251	0.523	rs2797796	chr6:37480886	T/C	cg24807547	chr6:37504484	NA	-0.62	-10.0	-0.54	5.65e-20	Cognitive performance;
KIRP	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg23950597	chr19:37808831	NA	-0.63	-6.77	-0.4	9.43e-11	Coronary artery calcification;
KIRP	cis	rs6142102	0.581	rs4911148	chr20:32668244	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.76	0.34	2.46e-8	Skin pigmentation;
KIRP	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg12046867	chr14:103022105	NA	-0.5	-6.09	-0.36	4.36e-9	Platelet count;
KIRP	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg19196401	chr6:110721138	DDO	-0.46	-7.38	-0.43	2.44e-12	Platelet distribution width;
KIRP	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	1.02	10.86	0.57	1.06e-22	Alzheimer's disease;
KIRP	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.82	-0.45	1.55e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg18196295	chr10:418757	DIP2C	-0.42	-4.93	-0.3	1.5e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7011507	1.000	rs77556531	chr8:49120142	G/A	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg00204512	chr16:28754710	NA	0.48	6.34	0.37	1.11e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.67	-6.56	-0.39	3.23e-10	Bipolar disorder;
KIRP	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.89	14.04	0.67	2.85e-33	Coronary artery disease;
KIRP	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.42	-0.33	1.4e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.35	-10.28	-0.55	7.71e-21	Diabetic kidney disease;
KIRP	cis	rs362272	0.505	rs2857854	chr4:3043184	G/T	cg14003022	chr4:3043019	NA	-0.36	-4.9	-0.3	1.7e-6	Serum sulfate level;
KIRP	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg00360474	chr6:37504404	NA	-0.47	-6.93	-0.4	3.69e-11	Cognitive performance;
KIRP	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.52	0.38	4.04e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg02153584	chr22:29168773	CCDC117	0.58	5.91	0.35	1.15e-8	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
KIRP	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg17554472	chr22:41940697	POLR3H	-0.48	-5.45	-0.33	1.25e-7	Neuroticism;
KIRP	cis	rs2281603	0.951	rs61615397	chr14:64981064	C/T	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs7870753	0.838	rs7030316	chr9:99250463	C/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg08501292	chr6:25962987	TRIM38	1.03	8.22	0.46	1.18e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	4.89	0.3	1.86e-6	Rheumatoid arthritis;
KIRP	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg23587288	chr2:27483067	SLC30A3	0.55	6.86	0.4	5.4e-11	Blood metabolite levels;
KIRP	cis	rs2281603	0.762	rs10130241	chr14:65044120	C/T	cg25009451	chr14:65006716	HSPA2	0.45	4.85	0.3	2.22e-6	Lymphocyte counts;
KIRP	cis	rs2235642	0.507	rs2235643	chr16:1585115	A/G	cg03034668	chr16:1723424	CRAMP1L	0.47	5.15	0.31	5.44e-7	Coronary artery disease;
KIRP	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.76	-11.09	-0.58	1.89e-23	Waist circumference;Body mass index;
KIRP	cis	rs62005083	0.541	rs61059815	chr14:74536465	A/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.53	5.18	0.31	4.59e-7	Mean corpuscular volume;
KIRP	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg14847009	chr1:175162515	KIAA0040	0.25	5.13	0.31	5.75e-7	Alcohol dependence;
KIRP	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.56	-7.84	-0.45	1.39e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg03571507	chr19:53239146	ZNF611	-0.23	-5.76	-0.34	2.45e-8	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg24505687	chr6:33548425	BAK1	0.28	5.65	0.34	4.39e-8	Platelet count;
KIRP	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	9.8	0.53	2.27e-19	Cognitive test performance;
KIRP	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg11833968	chr6:79620685	NA	-0.39	-5.8	-0.35	2.03e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg03188948	chr7:1209495	NA	0.79	6.89	0.4	4.65e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg09003973	chr2:102972529	NA	0.49	5.04	0.31	9.06e-7	Blood protein levels;
KIRP	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-11.22	-0.58	7.24e-24	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.77	6.94	0.4	3.5e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs926392	0.589	rs6093115	chr20:37693817	T/C	cg16355469	chr20:37678765	NA	0.49	6.2	0.37	2.41e-9	Dialysis-related mortality;
KIRP	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.6	-9.8	-0.53	2.31e-19	Total body bone mineral density;
KIRP	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.69	-8.59	-0.48	1.03e-15	Vitiligo;
KIRP	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg20387954	chr3:183756860	HTR3D	0.52	7.42	0.43	1.95e-12	Anterior chamber depth;
KIRP	cis	rs2652822	0.554	rs11635698	chr15:63478573	G/A	cg02713581	chr15:63449717	RPS27L	0.47	5.25	0.32	3.31e-7	Metabolic traits;
KIRP	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg06289844	chr6:126071538	HEY2	0.36	5.09	0.31	6.97e-7	Brugada syndrome;
KIRP	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg00149659	chr3:10157352	C3orf10	0.6	6.85	0.4	5.8200000000000003e-11	Alzheimer's disease;
KIRP	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.74	6.81	0.4	7.33e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.7	8.12	0.46	2.24e-14	Itch intensity from mosquito bite;
KIRP	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.58	7.42	0.43	1.84e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13758310	chr4:1834493	LETM1	-0.46	-6.77	-0.4	9.18e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg10021447	chr6:2766774	WRNIP1	0.5	6.05	0.36	5.25e-9	Educational attainment;
KIRP	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.75	-10.21	-0.55	1.28e-20	Dental caries;
KIRP	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.02	-0.31	9.73e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-0.76	-9.01	-0.5	5.76e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs28655083	1.000	rs11864710	chr16:77075284	A/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.55	-6.19	-0.37	2.48e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4268898	0.516	rs7597149	chr2:24371962	C/T	cg06627628	chr2:24431161	ITSN2	0.46	5.61	0.34	5.38e-8	Asthma;
KIRP	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg18192325	chr2:105854051	NA	-0.38	-5.37	-0.32	1.8e-7	Type 2 diabetes;
KIRP	cis	rs7180079	0.563	rs2733381	chr15:64857043	T/C	cg15337035	chr15:64978493	NA	-0.48	-5.24	-0.32	3.44e-7	Monocyte count;
KIRP	cis	rs2273669	0.667	rs10457185	chr6:109322477	G/C	cg05315195	chr6:109294784	ARMC2	-0.63	-5.99	-0.36	7.6e-9	Prostate cancer;
KIRP	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21545522	chr1:205238299	TMCC2	-0.42	-5.63	-0.34	4.92e-8	Red blood cell count;
KIRP	cis	rs77633900	0.772	rs387321	chr15:76743565	A/G	cg21673338	chr15:77095150	SCAPER	-0.63	-6.2	-0.37	2.3e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4664293	0.764	rs1425044	chr2:160474937	C/T	cg08347373	chr2:160653686	CD302	-0.35	-5.39	-0.32	1.67e-7	Monocyte percentage of white cells;
KIRP	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.82	10.72	0.56	3.05e-22	Response to diuretic therapy;
KIRP	cis	rs6959887	1.000	rs6959887	chr7:35295365	A/G	cg06685737	chr7:35301730	NA	0.46	6.77	0.4	9.63e-11	Birth weight;
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13198984	chr17:80129470	CCDC57	-0.53	-8.12	-0.46	2.29e-14	Life satisfaction;
KIRP	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.58	-0.34	6.23e-8	Type 2 diabetes;
KIRP	cis	rs7172677	0.737	rs7178005	chr15:75437420	T/C	cg03289416	chr15:75166202	SCAMP2	0.39	4.89	0.3	1.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.49	6.6	0.39	2.57e-10	Migraine;
KIRP	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg03060546	chr3:49711283	APEH	-0.73	-5.54	-0.33	7.62e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg04607699	chr11:48328132	OR4S1	-0.39	-5.57	-0.33	6.55e-8	Migraine - clinic-based;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg04921814	chr1:145575587	PIAS3	0.93	6.45	0.38	5.78e-10	P wave terminal force;
KIRP	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.88	14.26	0.67	5.01e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg05315796	chr3:52349193	DNAH1	0.45	6.78	0.4	8.74e-11	Bipolar disorder;
KIRP	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg04935436	chr20:30431758	NA	0.49	6.57	0.39	3.06e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-0.94	-16.93	-0.73	3.68e-43	Dental caries;
KIRP	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05601917	chr6:125855416	NA	-0.34	-5.2	-0.31	4.17e-7	Brugada syndrome;
KIRP	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs10214930	0.560	rs42088	chr7:27701861	C/T	cg22168087	chr7:27702803	HIBADH	-0.58	-6.4	-0.38	7.91e-10	Hypospadias;
KIRP	cis	rs62027291	0.654	rs56402836	chr15:77081967	A/C	cg23625390	chr15:77176239	SCAPER	-0.76	-5.48	-0.33	1.07e-7	Plateletcrit;
KIRP	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.45	4.92	0.3	1.59e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.64	-10.31	-0.55	6.19e-21	Pulse pressure;
KIRP	cis	rs6466055	0.661	rs68004394	chr7:104788261	G/C	cg04380332	chr7:105027541	SRPK2	0.39	5.2	0.31	4.24e-7	Schizophrenia;
KIRP	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00669777	chr8:95565739	KIAA1429	0.52	6.25	0.37	1.78e-9	Smoking initiation;
KIRP	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg05370193	chr1:21551575	ECE1	0.43	6.12	0.36	3.59e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg16736954	chr20:23401023	NAPB	0.63	4.97	0.3	1.26e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.59	0.34	5.89e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4595586	0.655	rs7953715	chr12:39325539	T/C	cg26384229	chr12:38710491	ALG10B	0.49	6.31	0.37	1.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.86	9.95	0.54	8.29e-20	Cognitive ability;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05697697	chr10:111683345	XPNPEP1	-0.64	-7.06	-0.41	1.66e-11	Menopause (age at onset);
KIRP	cis	rs12282928	0.959	rs4980426	chr11:48296019	A/G	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.81	-11.15	-0.58	1.27e-23	Chronic sinus infection;
KIRP	cis	rs12135191	0.544	rs10802528	chr1:236506815	T/G	cg21399712	chr1:236511386	NA	-0.39	-5.24	-0.32	3.49e-7	Urate levels (BMI interaction);
KIRP	trans	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg25214090	chr10:38739885	LOC399744	0.48	6.17	0.37	2.81e-9	Diastolic blood pressure;
KIRP	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg16141378	chr3:129829833	LOC729375	-0.54	-7.09	-0.41	1.43e-11	Retinal vascular caliber;
KIRP	cis	rs1448094	0.872	rs7313373	chr12:86398370	C/G	cg02569458	chr12:86230093	RASSF9	0.34	4.88	0.3	1.9e-6	Major depressive disorder;
KIRP	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	0.95	8.19	0.46	1.46e-14	Arsenic metabolism;
KIRP	cis	rs7106204	0.609	rs11825384	chr11:24285137	G/T	ch.11.24196551F	chr11:24239977	NA	0.71	5.6	0.34	5.81e-8	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2574975	0.679	rs2255849	chr10:52131993	C/T	cg10034176	chr10:52120283	SGMS1	-0.53	-7.1	-0.41	1.35e-11	Response to amphetamines;
KIRP	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.45	4.98	0.3	1.19e-6	Schizophrenia;
KIRP	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.65	-9.02	-0.5	5.67e-17	Prostate cancer;
KIRP	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-7.95	-0.45	6.66e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	19.14	0.77	1.25e-50	Exhaled nitric oxide output;
KIRP	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.64	9.21	0.51	1.53e-17	Resting heart rate;
KIRP	trans	rs12545912	0.770	rs4313162	chr8:9548592	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.23	-0.37	2.04e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.48	6.07	0.36	4.93e-9	Testicular germ cell tumor;
KIRP	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.56	7.61	0.44	6e-13	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg10755058	chr3:40428713	ENTPD3	0.43	6.17	0.37	2.79e-9	Renal cell carcinoma;
KIRP	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11987759	chr7:65425863	GUSB	-0.49	-6.36	-0.38	9.64e-10	Aortic root size;
KIRP	cis	rs7534824	0.625	rs6699653	chr1:101499162	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.25	0.42	5.33e-12	Refractive astigmatism;
KIRP	cis	rs12044355	0.929	rs6693517	chr1:231852444	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.41	4.96	0.3	1.33e-6	Alzheimer's disease;
KIRP	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17554472	chr22:41940697	POLR3H	0.62	6.59	0.39	2.64e-10	Vitiligo;
KIRP	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.72	-9.89	-0.53	1.22e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs2785946	0.526	rs17607240	chr13:55000405	G/A	cg16797300	chr15:89942816	NA	0.52	6.23	0.37	1.99e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.47	-6.14	-0.36	3.33e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.83	8.58	0.48	1.05e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6500395	0.775	rs13331298	chr16:48661489	G/A	cg04672837	chr16:48644449	N4BP1	0.45	6.31	0.37	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09247534	chr1:172502038	C1orf9	0.45	6.1	0.36	3.99e-9	Parkinson's disease;
KIRP	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg12317470	chr15:67143691	NA	0.65	9.27	0.51	9.87e-18	Lung cancer (smoking interaction);
KIRP	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.59	0.39	2.67e-10	Educational attainment;
KIRP	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-6.4	-0.38	7.74e-10	Dilated cardiomyopathy;
KIRP	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.41	-5.17	-0.31	4.84e-7	Schizophrenia;
KIRP	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg20701182	chr2:24300061	SF3B14	0.58	5.24	0.32	3.46e-7	Lymphocyte counts;
KIRP	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.75	-8.52	-0.48	1.59e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	0.62	6.17	0.37	2.78e-9	Skin colour saturation;
KIRP	cis	rs62355272	0.965	rs3194051	chr5:35876274	A/G	cg13894535	chr5:35919491	CAPSL	-0.52	-6.08	-0.36	4.63e-9	Lymphocyte counts;
KIRP	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.55	7.28	0.42	4.5e-12	Menarche (age at onset);
KIRP	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg03834567	chr2:218808745	TNS1	0.39	4.95	0.3	1.38e-6	Ulcerative colitis;
KIRP	trans	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs734999	0.572	rs3748816	chr1:2526746	A/G	cg18932078	chr1:2524107	MMEL1	0.41	5.64	0.34	4.57e-8	Ulcerative colitis;
KIRP	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.55	-6.78	-0.4	8.98e-11	Multiple sclerosis;
KIRP	cis	rs16828019	0.704	rs34486565	chr1:41522510	C/T	cg03387723	chr1:41708464	SCMH1	-0.78	-6.48	-0.38	5.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg00629941	chr15:75287862	SCAMP5	0.52	5.68	0.34	3.77e-8	Blood trace element (Zn levels);
KIRP	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg27205649	chr11:78285834	NARS2	-0.66	-7.57	-0.43	7.66e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg17554472	chr22:41940697	POLR3H	-0.48	-5.36	-0.32	1.88e-7	Neuroticism;
KIRP	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg26769984	chr7:1090371	C7orf50	0.51	5.52	0.33	8.38e-8	Bronchopulmonary dysplasia;
KIRP	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg27411982	chr8:10470053	RP1L1	0.4	5.29	0.32	2.67e-7	Retinal vascular caliber;
KIRP	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg11886554	chr3:170076028	SKIL	-0.45	-4.97	-0.3	1.25e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.69	8.82	0.49	2.21e-16	Bladder cancer;
KIRP	cis	rs282587	0.502	rs446186	chr13:113420087	A/G	cg04656015	chr13:113407548	ATP11A	0.62	6.86	0.4	5.63e-11	Glycated hemoglobin levels;
KIRP	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.73e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.6	0.44	6.29e-13	Diabetic kidney disease;
KIRP	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	trans	rs7830939	1.000	rs7830939	chr8:9380132	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.92	-0.4	3.86e-11	Neuroticism;
KIRP	cis	rs7507204	0.723	rs12610998	chr19:3413653	T/C	cg08380311	chr19:3435252	NFIC	0.64	5.75	0.34	2.63e-8	Height;
KIRP	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.64	7.55	0.43	8.72e-13	Dental caries;
KIRP	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.69	-9.99	-0.54	5.84e-20	Educational attainment;
KIRP	cis	rs2070615	0.833	rs6580695	chr12:49201207	C/G	cg26266429	chr12:49174651	ADCY6	-0.37	-5.21	-0.32	4.07e-7	Bipolar disorder;
KIRP	cis	rs4589502	1.000	rs12440279	chr15:67133339	G/A	cg09911534	chr15:67153556	NA	-0.49	-4.98	-0.3	1.2e-6	Lung cancer (smoking interaction);
KIRP	cis	rs7010267	0.602	rs1485307	chr8:120007395	T/C	cg01975934	chr8:119970761	NA	-0.39	-5.04	-0.31	9.14e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg10189774	chr4:17578691	LAP3	0.47	5.74	0.34	2.81e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.93	12.46	0.62	6.15e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.5	-5.16	-0.31	5.06e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	11.98	0.61	2.29e-26	Platelet count;
KIRP	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.85	7.98	0.45	5.48e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg10932868	chr11:921992	NA	-0.63	-8.59	-0.48	1.01e-15	Alzheimer's disease (late onset);
KIRP	cis	rs13385	0.769	rs34994530	chr5:139558669	C/T	cg01860693	chr5:139557145	C5orf32	0.49	5.1	0.31	6.86e-7	Atrial fibrillation;
KIRP	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg10523679	chr1:76189770	ACADM	-0.44	-6.06	-0.36	5.05e-9	Daytime sleep phenotypes;
KIRP	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.89	0.45	9.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.58	-6.74	-0.39	1.11e-10	Monocyte count;
KIRP	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.57	-11.84	-0.6	6.91e-26	Diabetic kidney disease;
KIRP	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg03060546	chr3:49711283	APEH	0.49	6.38	0.38	8.91e-10	Parkinson's disease;
KIRP	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg00405596	chr8:11794950	NA	0.48	6.24	0.37	1.93e-9	Retinal vascular caliber;
KIRP	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg18944383	chr4:111397179	ENPEP	0.62	11.32	0.59	3.56e-24	Height;
KIRP	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.87	8.86	0.49	1.61e-16	Prostate cancer;
KIRP	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg10360139	chr7:1886902	MAD1L1	-0.53	-5.93	-0.35	1.02e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7116495	0.609	rs7115513	chr11:71664495	T/A	cg10381502	chr11:71823885	C11orf51	-1.08	-7.52	-0.43	9.99e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11987759	chr7:65425863	GUSB	0.49	6.66	0.39	1.79e-10	Aortic root size;
KIRP	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.36	-4.99	-0.3	1.12e-6	Neuroticism;
KIRP	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg16482183	chr6:26056742	HIST1H1C	0.64	7.33	0.42	3.36e-12	Iron status biomarkers;
KIRP	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg14092571	chr14:90743983	NA	0.41	5.52	0.33	8.72e-8	Mortality in heart failure;
KIRP	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg07636037	chr3:49044803	WDR6	-0.77	-7.38	-0.43	2.48e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.38	-15.16	-0.7	4.02e-37	Schizophrenia;
KIRP	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.81	10.98	0.57	4.33e-23	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3126085	0.515	rs7534951	chr1:152362972	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-6.66	-0.39	1.83e-10	Atopic dermatitis;
KIRP	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg05775895	chr3:12838266	CAND2	0.5	8.79	0.49	2.72e-16	QRS complex (12-leadsum);
KIRP	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.24	-11.21	-0.58	7.95e-24	Diabetic kidney disease;
KIRP	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg11663144	chr21:46675770	NA	0.68	9.2	0.51	1.59e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.51	-6.08	-0.36	4.45e-9	Coronary artery disease;
KIRP	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg09184832	chr6:79620586	NA	-0.43	-6.03	-0.36	6.07e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg16434002	chr17:42200994	HDAC5	0.6	7.42	0.43	1.89e-12	Total body bone mineral density;
KIRP	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg23740940	chr11:68924746	NA	0.3	5.09	0.31	7.09e-7	Blond vs. brown hair color;
KIRP	cis	rs1465370	0.682	rs7811409	chr7:130024701	G/C	cg03229158	chr7:130009420	NA	0.34	5.1	0.31	6.91e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg07256473	chr22:29710276	RASL10A	0.48	7.74	0.44	2.53e-13	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg02696790	chr15:75250997	RPP25	0.35	5.85	0.35	1.57e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg15620404	chr13:113666762	MCF2L	-0.49	-4.99	-0.3	1.15e-6	Systolic blood pressure;
KIRP	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00290607	chr11:67383545	NA	-0.41	-5.29	-0.32	2.75e-7	Mean corpuscular volume;
KIRP	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	6.2	0.37	2.41e-9	Putamen volume;
KIRP	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg06271696	chr7:157225062	NA	-0.58	-7.58	-0.44	7.04e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs8756	0.967	rs10784502	chr12:66343810	C/T	cg06712651	chr12:66351869	HMGA2	-0.69	-11.73	-0.6	1.6e-25	Height;
KIRP	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.88	11.71	0.6	1.77e-25	Response to diuretic therapy;
KIRP	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg02023728	chr11:77925099	USP35	0.3	4.91	0.3	1.65e-6	Alzheimer's disease (survival time);
KIRP	cis	rs6838801	1.000	rs6818060	chr4:77553691	C/T	cg17476223	chr4:77663285	SHROOM3	0.49	6.66	0.39	1.79e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg22771759	chr13:24902376	NA	0.44	5.54	0.33	7.92e-8	Obesity-related traits;
KIRP	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg13409248	chr3:40428643	ENTPD3	0.39	5.23	0.32	3.59e-7	Renal cell carcinoma;
KIRP	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg09455208	chr3:40491958	NA	0.34	6.14	0.36	3.24e-9	Renal cell carcinoma;
KIRP	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg20701182	chr2:24300061	SF3B14	0.49	4.96	0.3	1.31e-6	Lymphocyte counts;
KIRP	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg03734594	chr13:111297400	CARS2	0.38	5.86	0.35	1.51e-8	Coronary artery disease;
KIRP	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg06223162	chr1:101003688	GPR88	-0.42	-8.67	-0.48	5.77e-16	Monocyte count;
KIRP	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.89	13.27	0.65	1.15e-30	Mean platelet volume;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs12153243	0.686	rs17342813	chr5:142909383	T/C	cg13907255	chr5:142895549	NA	-0.38	-4.89	-0.3	1.82e-6	Migraine;
KIRP	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg07741184	chr6:167504864	NA	0.24	6.43	0.38	6.51e-10	Crohn's disease;
KIRP	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg10326726	chr10:51549505	MSMB	0.54	7.78	0.44	1.97e-13	Prostate-specific antigen levels;
KIRP	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg23791538	chr6:167370224	RNASET2	-0.44	-5.35	-0.32	2.01e-7	Primary biliary cholangitis;
KIRP	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.72	0.34	3.1e-8	Homoarginine levels;
KIRP	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg18944383	chr4:111397179	ENPEP	0.53	9.27	0.51	1e-17	Height;
KIRP	cis	rs6959887	0.962	rs73099148	chr7:35281619	T/G	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs12049351	0.774	rs12079612	chr1:229649372	T/C	cg11742688	chr1:229674241	ABCB10	-0.37	-5.52	-0.33	8.52e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg05754148	chr16:3507555	NAT15	0.43	4.96	0.3	1.31e-6	Body mass index (adult);
KIRP	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-11.09	-0.58	1.9e-23	Chronic sinus infection;
KIRP	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.5	0.48	1.8e-15	Bipolar disorder;
KIRP	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg12173498	chr6:36355764	ETV7	0.3	5.0	0.3	1.08e-6	Platelet distribution width;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13047869	chr3:10149882	C3orf24	0.6	5.82	0.35	1.79e-8	Alzheimer's disease;
KIRP	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.55	7.01	0.41	2.22e-11	Platelet count;
KIRP	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05220968	chr6:146057943	EPM2A	0.41	5.28	0.32	2.88e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg15893493	chr8:124194847	FAM83A	0.93	8.13	0.46	2.14e-14	Urinary uromodulin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12057946	chr11:120195905	TMEM136	0.53	7.62	0.44	5.44e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg05775895	chr3:12838266	CAND2	0.4	6.53	0.38	3.81e-10	QRS complex (12-leadsum);
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.57	-8.29	-0.47	7.62e-15	Renal function-related traits (BUN);
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-7.63	-0.44	5.14e-13	Lymphocyte counts;
KIRP	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg11941060	chr3:133502564	NA	0.43	5.37	0.32	1.87e-7	Iron status biomarkers;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.44	-5.02	-0.3	9.86e-7	Longevity;Endometriosis;
KIRP	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	cg04338863	chr8:33670619	NA	-0.49	-6.49	-0.38	4.76e-10	Body mass index;
KIRP	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg22633769	chr20:60982531	CABLES2	-0.43	-5.28	-0.32	2.9e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.61	8.18	0.46	1.53e-14	Hip circumference adjusted for BMI;
KIRP	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg16141378	chr3:129829833	LOC729375	-0.51	-6.71	-0.39	1.33e-10	Retinal vascular caliber;
KIRP	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.63	-0.44	5.19e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg14593290	chr7:50529359	DDC	-0.49	-6.69	-0.39	1.48e-10	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21574574	chr3:132400646	NPHP3	0.4	6.22	0.37	2.07e-9	C-reactive protein;
KIRP	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.85	-0.35	1.56e-8	Pulmonary function;
KIRP	cis	rs2273669	0.667	rs9688496	chr6:109364825	G/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.41	-0.38	7.27e-10	Prostate cancer;
KIRP	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.5	0.38	4.42e-10	Rheumatoid arthritis;
KIRP	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.78	6.55	0.39	3.3e-10	Fat distribution (HIV);
KIRP	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25214090	chr10:38739885	LOC399744	0.64	8.22	0.46	1.18e-14	Corneal astigmatism;
KIRP	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.29	-0.37	1.44e-9	Breast cancer;
KIRP	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-5.19	-0.31	4.38e-7	Total cholesterol levels;
KIRP	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg04662567	chr6:169592167	NA	-0.7	-8.5	-0.48	1.84e-15	Pulse pressure;
KIRP	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg03060546	chr3:49711283	APEH	-0.72	-5.46	-0.33	1.15e-7	Cognitive function;
KIRP	cis	rs12900413	0.603	rs4448912	chr15:90299690	G/A	cg24650279	chr15:90327240	NA	-0.41	-5.08	-0.31	7.51e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.89	-0.35	1.24e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs11809524	0.759	rs12064766	chr1:103517530	T/C	cg15143788	chr5:92909434	FLJ42709	-0.51	-6.11	-0.36	3.9e-9	Bone mineral density;
KIRP	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs1420098	0.505	rs1921622	chr2:102966067	G/A	cg01254707	chr2:102953421	IL1RL1	0.44	5.54	0.33	7.62e-8	Inflammatory bowel disease;
KIRP	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21545522	chr1:205238299	TMCC2	0.44	5.91	0.35	1.14e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg00204512	chr16:28754710	NA	-0.49	-6.44	-0.38	6.09e-10	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg00504896	chr12:9437009	LOC642846	-0.54	-7.31	-0.42	3.72e-12	Breast size;
KIRP	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.93	12.01	0.61	1.9e-26	Menopause (age at onset);
KIRP	cis	rs2380220	0.720	rs9374178	chr6:95979974	G/T	cg15832292	chr6:96025679	MANEA	0.65	6.24	0.37	1.85e-9	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.78	10.19	0.54	1.48e-20	Systemic lupus erythematosus;
KIRP	cis	rs12022452	0.544	rs11208423	chr1:41029614	T/C	cg25568243	chr1:40974465	DEM1	0.54	5.74	0.34	2.74e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	12.5	0.62	4.3e-28	Menopause (age at onset);
KIRP	cis	rs3849570	0.643	rs10779987	chr3:81970856	C/T	cg07356753	chr3:81810745	GBE1	-0.55	-7.38	-0.43	2.45e-12	Waist circumference;Body mass index;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14870673	chr2:97481843	CNNM3	-0.55	-6.02	-0.36	6.46e-9	Menopause (age at onset);
KIRP	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg00310523	chr12:86230176	RASSF9	0.42	6.45	0.38	5.83e-10	Major depressive disorder;
KIRP	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.6	0.39	2.44e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7221595	0.756	rs9900661	chr17:3962450	A/G	cg21734707	chr17:3908241	ZZEF1	0.58	5.76	0.34	2.47e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.83	-12.01	-0.61	1.91e-26	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25531249	chr21:30671681	BACH1	0.49	6.3	0.37	1.35e-9	Parkinson's disease;
KIRP	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg27411982	chr8:10470053	RP1L1	0.38	5.29	0.32	2.68e-7	Neuroticism;
KIRP	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg13010199	chr12:38710504	ALG10B	0.56	6.78	0.4	9.04e-11	Morning vs. evening chronotype;
KIRP	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg24579218	chr15:68104479	NA	-0.44	-7.15	-0.41	1.01e-11	Restless legs syndrome;
KIRP	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs9581857	0.685	rs79699519	chr13:28023241	C/T	cg22138327	chr13:27999177	GTF3A	0.68	5.63	0.34	4.86e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.45	6.51	0.38	4.23e-10	Obesity-related traits;
KIRP	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	0.8	8.77	0.49	3.04e-16	Gut microbiome composition (summer);
KIRP	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg23100626	chr2:96804247	ASTL	0.45	5.69	0.34	3.6e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.73	-9.48	-0.52	2.27e-18	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs3736485	0.934	rs8036821	chr15:51861646	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	7.81	0.45	1.61e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.59	-6.69	-0.39	1.5e-10	Lung cancer;
KIRP	cis	rs12311304	1.000	rs12309172	chr12:15403226	C/T	cg08258403	chr12:15378311	NA	0.39	5.7	0.34	3.5e-8	Behavioural disinhibition (generation interaction);
KIRP	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	7.74	0.44	2.55e-13	Systemic lupus erythematosus;
KIRP	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg01200585	chr1:228362443	C1orf69	0.44	5.4	0.33	1.61e-7	Diastolic blood pressure;
KIRP	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg14458575	chr2:238380390	NA	0.59	5.77	0.35	2.35e-8	Prostate cancer;
KIRP	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg05044414	chr3:183734942	ABCC5	-0.37	-5.59	-0.34	5.89e-8	Anterior chamber depth;
KIRP	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg14541582	chr5:601475	NA	-0.52	-5.89	-0.35	1.27e-8	Lung disease severity in cystic fibrosis;
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg08462117	chr11:62432583	SNORA57;C11orf48;METTL12	-0.41	-6.1	-0.36	4.03e-9	Type 1 diabetes;
KIRP	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.02	0.36	6.18e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2274273	0.624	rs68138420	chr14:55777967	G/T	cg04306507	chr14:55594613	LGALS3	0.38	5.31	0.32	2.4e-7	Protein biomarker;
KIRP	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.61	6.03	0.36	5.94e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs6681460	0.932	rs536410	chr1:67191084	C/T	cg02459107	chr1:67143332	SGIP1	0.43	6.13	0.36	3.51e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.27	0.42	4.69e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.49	-6.62	-0.39	2.22e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs55728055	0.661	rs62239169	chr22:32042514	G/A	cg02791973	chr19:1132256	SBNO2	-0.61	-6.64	-0.39	1.96e-10	Age-related hearing impairment;
KIRP	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg08125733	chr17:73851984	WBP2	0.48	6.02	0.36	6.16e-9	White matter hyperintensity burden;
KIRP	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg18477163	chr1:228402036	OBSCN	0.37	7.35	0.42	2.95e-12	Diastolic blood pressure;
KIRP	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.41	-6.13	-0.36	3.44e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg08501292	chr6:25962987	TRIM38	0.7	4.92	0.3	1.58e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.07	-0.41	1.59e-11	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg03744954	chr7:23637556	CCDC126	0.49	6.28	0.37	1.53e-9	DNA methylation (variation);
KIRP	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg16586182	chr3:47516702	SCAP	0.63	7.71	0.44	3.08e-13	Colorectal cancer;
KIRP	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.08	-0.54	3.24e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.24	0.55	9.91e-21	Dupuytren's disease;
KIRP	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.62	-7.38	-0.43	2.38e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.52	-0.48	1.62e-15	Blood trace element (Zn levels);
KIRP	cis	rs16828019	0.640	rs1140227	chr1:41493811	C/T	cg18742814	chr1:41828276	NA	0.69	5.85	0.35	1.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	cis	rs2273669	0.915	rs6904998	chr6:109311560	G/T	cg05315195	chr6:109294784	ARMC2	0.47	5.3	0.32	2.62e-7	Prostate cancer;
KIRP	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg00361562	chr2:198649771	BOLL	-0.48	-4.92	-0.3	1.6e-6	Ulcerative colitis;
KIRP	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg17691542	chr6:26056736	HIST1H1C	0.53	6.73	0.39	1.16e-10	Height;
KIRP	trans	rs1859156	0.723	rs17428994	chr4:95793041	G/A	cg24204951	chr2:239172084	PER2	0.29	6.36	0.38	9.63e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs4950322	0.518	rs72692965	chr1:146803815	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg08992911	chr2:238395768	MLPH	0.4	5.04	0.31	8.96e-7	Prostate cancer;
KIRP	cis	rs889312	0.923	rs12697152	chr5:56025716	A/G	cg14703610	chr5:56206110	C5orf35	-0.41	-5.23	-0.32	3.58e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06481639	chr22:41940642	POLR3H	0.66	6.72	0.39	1.24e-10	Vitiligo;
KIRP	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-7.82	-0.45	1.5700000000000001e-13	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg21995068	chr20:25989032	LOC100134868	-0.46	-6.67	-0.39	1.68e-10	Colorectal or endometrial cancer;
KIRP	cis	rs2273156	1.000	rs12895051	chr14:35444070	G/A	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.44	-0.33	1.29e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg05964544	chr11:70165517	PPFIA1	-0.53	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs3857067	1.000	rs3846292	chr4:95027717	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.85e-7	QT interval;
KIRP	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg05973401	chr12:123451056	ABCB9	-0.58	-5.08	-0.31	7.43e-7	Neutrophil percentage of white cells;
KIRP	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.62	-6.55	-0.39	3.35e-10	Body mass index;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.35	-5.16	-0.31	4.97e-7	Lymphocyte counts;
KIRP	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	6.98	0.41	2.71e-11	Height;
KIRP	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg04733989	chr22:42467013	NAGA	-0.46	-6.06	-0.36	4.99e-9	Cognitive function;
KIRP	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg21360079	chr12:107162445	NA	-0.68	-9.43	-0.52	3.23e-18	Heart rate;
KIRP	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.83	12.48	0.62	5.02e-28	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2898857	0.504	rs7214496	chr17:47384611	C/G	cg11430096	chr6:110968061	CDK19	0.54	6.59	0.39	2.68e-10	Cancer;
KIRP	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.36	-0.38	9.64e-10	Aortic root size;
KIRP	cis	rs10924309	0.765	rs1122735	chr1:245853299	G/A	cg00036263	chr1:245852353	KIF26B	-0.52	-7.38	-0.43	2.47e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.84	-11.91	-0.6	3.91e-26	Total body bone mineral density;
KIRP	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.42	-5.42	-0.33	1.4e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.65	9.66	0.52	6.14e-19	Blood metabolite levels;
KIRP	cis	rs7546668	1.000	rs6685648	chr1:15825195	T/C	cg21858823	chr1:15850916	CASP9	0.46	5.1	0.31	6.64e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7523273	0.565	rs4081159	chr1:207885479	G/A	cg22525895	chr1:207977042	MIR29B2	0.46	5.81	0.35	1.95e-8	Schizophrenia;
KIRP	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	1.12	18.9	0.77	7.77e-50	Cognitive function;
KIRP	cis	rs953387	1.000	rs2102896	chr2:136906640	T/C	cg05194412	chr2:137003533	NA	-0.4	-5.23	-0.32	3.58e-7	Arthritis (juvenile idiopathic);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg01758588	chr16:5257240	NA	0.4	6.09	0.36	4.27e-9	Cancer;
KIRP	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.5	6.8	0.4	7.96e-11	Mean corpuscular volume;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01092528	chr4:76861103	NAAA	0.68	6.87	0.4	5.18e-11	Lung function (FEV1);
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.34	-6.62	-0.39	2.3e-10	Lymphocyte counts;
KIRP	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.62	-7.69	-0.44	3.56e-13	Breast cancer;
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg14221460	chr8:27183342	PTK2B	0.52	6.74	0.39	1.11e-10	Neuroticism;
KIRP	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-1.13	-18.97	-0.77	4.7e-50	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs1459104	0.866	rs35456973	chr11:54838812	C/A	cg26562691	chr16:23850404	PRKCB	0.61	6.04	0.36	5.55e-9	Body mass index;
KIRP	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg19847130	chr8:10466454	RP1L1	0.43	6.42	0.38	7e-10	Neuroticism;
KIRP	cis	rs477692	0.637	rs2388331	chr10:131314173	G/A	cg24747557	chr10:131355152	MGMT	-0.4	-5.25	-0.32	3.21e-7	Response to temozolomide;
KIRP	cis	rs912057	0.671	rs1294434	chr6:6745377	G/A	cg06612196	chr6:6737390	NA	0.51	8.59	0.48	1.02e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.05	-0.5	4.33e-17	Urate levels in overweight individuals;
KIRP	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg09177884	chr7:1199841	ZFAND2A	0.57	6.69	0.39	1.45e-10	Longevity;Endometriosis;
KIRP	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.7	10.69	0.56	3.64e-22	Noise-induced hearing loss;
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.52	0.65	1.64e-31	Platelet count;
KIRP	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.48	6.0	0.36	6.94e-9	Mean platelet volume;
KIRP	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	1.04	20.17	0.79	4.8e-54	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.97	-9.72	-0.53	4.14e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg14768367	chr16:72042858	DHODH	-0.72	-8.51	-0.48	1.67e-15	Blood protein levels;
KIRP	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.88	8.12	0.46	2.26e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.96	13.14	0.64	3.21e-30	Primary sclerosing cholangitis;
KIRP	cis	rs73058052	0.935	rs3745473	chr19:50086626	T/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.59	6.71	0.39	1.35e-10	Fibrinogen levels;
KIRP	cis	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg21775007	chr8:11205619	TDH	-0.36	-4.86	-0.3	2.05e-6	Monocyte count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04598128	chr22:45016233	NA	0.45	6.18	0.37	2.62e-9	Smoking initiation;
KIRP	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.41	-0.47	3.36e-15	Inflammatory bowel disease;
KIRP	cis	rs6540559	1.000	rs2073485	chr1:209962794	G/A	cg21951975	chr1:209979733	IRF6	0.39	4.92	0.3	1.55e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg15556689	chr8:8085844	FLJ10661	-0.66	-8.4	-0.47	3.52e-15	Joint mobility (Beighton score);
KIRP	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg23422044	chr7:1970798	MAD1L1	-0.61	-6.56	-0.39	3.16e-10	Neuroticism;
KIRP	cis	rs79976124	0.797	rs2226266	chr6:66617302	C/T	cg07460842	chr6:66804631	NA	0.76	8.76	0.49	3.21e-16	Type 2 diabetes;
KIRP	cis	rs12049351	0.774	rs36021190	chr1:229697863	T/C	cg11742688	chr1:229674241	ABCB10	-0.39	-5.88	-0.35	1.31e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg17133734	chr15:86042851	AKAP13	-0.47	-5.92	-0.35	1.1e-8	Coronary artery disease;
KIRP	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg09264619	chr17:80180166	NA	-0.39	-5.6	-0.34	5.67e-8	Life satisfaction;
KIRP	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12591125	chr7:1885375	MAD1L1	0.5	4.85	0.3	2.19e-6	Bipolar disorder;
KIRP	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	16.08	0.72	2.98e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1413885	0.525	rs1334878	chr1:65846124	A/G	cg13202122	chr1:65886182	LEPROT;LEPR	0.47	5.48	0.33	1.06e-7	Anticoagulant levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19997236	chr12:121790271	ANAPC5	0.47	6.09	0.36	4.32e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19671926	chr4:122722719	EXOSC9	0.51	6.12	0.36	3.76e-9	Type 2 diabetes;
KIRP	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.81	-0.4	7.61e-11	Mood instability;
KIRP	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.51	6.76	0.4	9.97e-11	Schizophrenia;
KIRP	cis	rs6662572	0.737	rs4557909	chr1:46316949	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs7017914	0.967	rs13256250	chr8:71596193	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg17554472	chr22:41940697	POLR3H	-0.7	-6.98	-0.41	2.79e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.79	10.79	0.57	1.84e-22	Menopause (age at onset);
KIRP	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.39	-5.01	-0.3	1.04e-6	Menarche (age at onset);
KIRP	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.61	-8.93	-0.49	1e-16	Total body bone mineral density;
KIRP	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	14.79	0.69	7.91e-36	Electrocardiographic conduction measures;
KIRP	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg07395648	chr5:131743802	NA	0.52	7.36	0.42	2.72e-12	Breast cancer;
KIRP	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.73	-9.42	-0.51	3.52e-18	Morning vs. evening chronotype;
KIRP	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-6.02	-0.36	6.46e-9	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.84	9.1	0.5	3.2e-17	Alzheimer's disease;
KIRP	cis	rs12208915	0.767	rs12208017	chr6:79823371	G/T	cg18132916	chr6:79620363	NA	-0.48	-5.15	-0.31	5.41e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	6.03	0.36	6.1e-9	Type 2 diabetes;
KIRP	cis	rs4253772	0.938	rs77378083	chr22:46639386	G/A	cg18190219	chr22:46762943	CELSR1	-0.7	-5.95	-0.35	9.02e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg05399210	chr6:117082661	FAM162B	0.4	5.56	0.33	6.96e-8	C-reactive protein levels;
KIRP	cis	rs10988449	0.891	rs7020510	chr9:132392356	C/T	cg18327994	chr9:132372705	NA	-0.5	-4.86	-0.3	2.05e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg07423050	chr13:99094983	FARP1	-0.31	-5.19	-0.31	4.35e-7	Longevity;
KIRP	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg08885076	chr2:99613938	TSGA10	-0.42	-6.36	-0.38	9.85e-10	Fear of minor pain;
KIRP	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.99	-11.01	-0.57	3.38e-23	Alzheimer's disease;
KIRP	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.07	0.36	4.83e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg10645314	chr2:3704589	ALLC	-0.41	-5.16	-0.31	5.03e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.07	0.31	8.01e-7	Lung cancer;
KIRP	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg26893134	chr6:116381904	FRK	0.19	5.16	0.31	5.14e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg22681709	chr2:178499509	PDE11A	-0.62	-9.04	-0.5	4.84e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.55	-0.56	1.07e-21	Height;
KIRP	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.43	5.02	0.3	9.9e-7	Resistin levels;
KIRP	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	13.89	0.66	8.89e-33	Monocyte percentage of white cells;
KIRP	cis	rs17123764	0.818	rs7975599	chr12:49944926	A/G	cg20471783	chr12:50157085	TMBIM6	0.32	4.96	0.3	1.31e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06481639	chr22:41940642	POLR3H	0.68	6.9	0.4	4.29e-11	Vitiligo;
KIRP	cis	rs7258465	1.000	rs10164323	chr19:18569492	C/T	cg10790698	chr19:18539756	SSBP4	-0.35	-7.5	-0.43	1.15e-12	Breast cancer;
KIRP	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.61e-11	Bipolar disorder;
KIRP	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg25173405	chr17:45401733	C17orf57	-0.47	-6.28	-0.37	1.56e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.71	9.35	0.51	5.48e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs1712790	0.613	rs2213072	chr11:114640554	G/C	cg19465033	chr11:114479364	NA	0.39	5.14	0.31	5.63e-7	Urinary albumin excretion;
KIRP	cis	rs8062405	0.964	rs12448902	chr16:28871191	C/G	cg09754948	chr16:28834200	ATXN2L	0.51	5.47	0.33	1.1e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg00405596	chr8:11794950	NA	0.38	4.9	0.3	1.72e-6	Retinal vascular caliber;
KIRP	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.79	12.27	0.62	2.52e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.85	-12.42	-0.62	8.23e-28	Body mass index (adult);
KIRP	cis	rs7523273	0.606	rs1962149	chr1:207956559	G/A	cg22525895	chr1:207977042	MIR29B2	-0.72	-10.08	-0.54	3.08e-20	Schizophrenia;
KIRP	cis	rs34779708	0.733	rs4934740	chr10:35547141	C/T	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3829109	0.564	rs13297890	chr9:139274643	C/G	cg14169450	chr9:139327907	INPP5E	0.47	5.7	0.34	3.44e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg17747265	chr1:1875780	NA	-0.72	-13.18	-0.64	2.31e-30	Body mass index;
KIRP	cis	rs12580194	0.593	rs74844018	chr12:55766871	G/A	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg01495344	chr13:39260543	FREM2	-0.51	-6.28	-0.37	1.56e-9	Bladder cancer;
KIRP	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs7961894	1.000	rs7961894	chr12:122365583	A/G	cg22168489	chr12:122356033	WDR66	-0.68	-5.25	-0.32	3.33e-7	Platelet count;Mean platelet volume;
KIRP	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.41	0.38	7.33e-10	Educational attainment;
KIRP	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.37	-5.88	-0.35	1.31e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.34	0.55	4.87e-21	Coffee consumption (cups per day);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15985196	chr1:39325463	RRAGC	-0.47	-6.06	-0.36	4.99e-9	Myopia;
KIRP	cis	rs6545883	0.965	rs2305156	chr2:61729268	T/C	cg15711740	chr2:61764176	XPO1	-0.6	-8.21	-0.46	1.25e-14	Tuberculosis;
KIRP	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.55	7.59	0.44	6.53e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs732765	0.734	rs12897105	chr14:75188122	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.86	-0.3	2.08e-6	Non-small cell lung cancer;
KIRP	cis	rs4262150	0.810	rs17565505	chr5:152064433	A/G	cg12297329	chr5:152029980	NA	0.69	8.54	0.48	1.45e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg01522456	chr1:115632236	TSPAN2	-0.37	-5.05	-0.31	8.73e-7	Autism;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07308232	chr7:1071921	C7orf50	-0.59	-7.47	-0.43	1.44e-12	Longevity;Endometriosis;
KIRP	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg25753631	chr6:25732923	NA	-0.26	-4.89	-0.3	1.82e-6	Iron status biomarkers;
KIRP	cis	rs9596863	1.000	rs9536557	chr13:54433190	A/G	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.64	-0.34	4.68e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-0.8	-9.06	-0.5	4.04e-17	Gut microbiome composition (summer);
KIRP	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.14	-0.36	3.28e-9	Bladder cancer;
KIRP	cis	rs714027	1.000	rs4823074	chr22:30512478	G/A	cg27665648	chr22:30112403	NA	-0.41	-5.96	-0.35	8.91e-9	Lymphocyte counts;
KIRP	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg05768032	chr16:30646687	NA	0.44	5.07	0.31	7.68e-7	Multiple myeloma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24868830	chr4:140374821	RAB33B	0.47	6.04	0.36	5.6e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7714584	1.000	rs10065172	chr5:150227998	C/T	cg22134413	chr5:150180641	NA	0.58	5.21	0.32	3.98e-7	Crohn's disease;
KIRP	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.47	-6.93	-0.4	3.72e-11	Daytime sleep phenotypes;
KIRP	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg23387468	chr7:139079360	LUC7L2	-0.29	-5.05	-0.31	8.48e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg11833968	chr6:79620685	NA	-0.38	-5.74	-0.34	2.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.57	6.59	0.39	2.72e-10	Initial pursuit acceleration;
KIRP	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg17376030	chr22:41985996	PMM1	0.58	6.6	0.39	2.44e-10	Vitiligo;
KIRP	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17221829	0.626	rs10830305	chr11:89366794	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7601312	0.935	rs10490601	chr2:229326626	A/G	cg02542817	chr2:229291442	NA	-0.41	-6.05	-0.36	5.22e-9	Schizophrenia;
KIRP	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.57	6.98	0.41	2.78e-11	Total body bone mineral density;
KIRP	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.73	-9.28	-0.51	9.35e-18	Gestational age at birth (maternal effect);
KIRP	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9398803	0.687	rs7740134	chr6:127009669	T/A	cg19875578	chr6:126661172	C6orf173	-0.42	-5.44	-0.33	1.3e-7	Male-pattern baldness;
KIRP	cis	rs72627509	1.000	rs72627509	chr4:57839051	C/G	cg26694713	chr4:57773883	REST	0.54	5.07	0.31	7.97e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.88	13.04	0.64	6.84e-30	Monocyte count;
KIRP	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.67	-8.41	-0.47	3.32e-15	Aortic root size;
KIRP	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg23682824	chr7:23144976	KLHL7	0.54	6.5	0.38	4.48e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7766436	0.885	rs12524244	chr6:22585287	T/C	cg13666174	chr6:22585274	NA	-0.44	-6.14	-0.36	3.36e-9	Coronary artery disease;
KIRP	trans	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17183009	chr3:120277827	NA	0.52	6.06	0.36	5.2e-9	Corneal astigmatism;
KIRP	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg09184832	chr6:79620586	NA	-0.38	-4.93	-0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg24110177	chr3:50126178	RBM5	-0.82	-11.95	-0.61	2.99e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg12435725	chr3:58293450	RPP14	-0.51	-5.14	-0.31	5.65e-7	Cholesterol, total;
KIRP	cis	rs4671458	0.948	rs72815377	chr2:63599530	C/T	cg17519650	chr2:63277830	OTX1	-0.52	-5.13	-0.31	5.93e-7	Subjective well-being;
KIRP	cis	rs9915657	0.660	rs982534	chr17:70081366	T/G	cg09344028	chr17:70110421	NA	0.39	8.09	0.46	2.67e-14	Thyroid hormone levels;
KIRP	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.53	-5.14	-0.31	5.63e-7	Hip geometry;
KIRP	cis	rs4664293	0.867	rs3863924	chr2:160614758	A/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs7044106	0.655	rs1359329	chr9:123370985	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	5.1	0.31	6.66e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.81	-12.07	-0.61	1.15e-26	Headache;
KIRP	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.62	9.03	0.5	5.19e-17	Vitiligo;
KIRP	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22541963	chr20:60982533	CABLES2	0.47	5.82	0.35	1.82e-8	Colorectal cancer;
KIRP	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg09795085	chr6:101329169	ASCC3	-0.49	-5.87	-0.35	1.4e-8	Neuroticism;
KIRP	cis	rs7178909	0.835	rs17241302	chr15:90406537	C/G	cg19708238	chr15:90437601	AP3S2	0.55	7.28	0.42	4.54e-12	Common traits (Other);
KIRP	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg06742321	chr12:123595122	PITPNM2	0.42	5.03	0.31	9.5e-7	Platelet count;
KIRP	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg06115741	chr20:33292138	TP53INP2	0.39	5.25	0.32	3.32e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.59	6.62	0.39	2.18e-10	Aortic root size;
KIRP	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg13978929	chr19:21580086	ZNF493	-0.52	-5.1	-0.31	6.94e-7	Pain;
KIRP	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs9596863	0.851	rs9568894	chr13:54309601	C/T	ch.13.53330881F	chr13:54432880	NA	0.56	5.33	0.32	2.27e-7	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg21775007	chr8:11205619	TDH	0.43	5.33	0.32	2.23e-7	Triglycerides;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14473030	chr9:119336987	ASTN2	-0.49	-6.34	-0.37	1.1e-9	Inflammatory biomarkers;
KIRP	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.2	14.28	0.67	4.16e-34	Uric acid levels;
KIRP	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg24633833	chr3:10029261	TMEM111	0.58	5.61	0.34	5.53e-8	Alzheimer's disease;
KIRP	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.51	-6.65	-0.39	1.86e-10	Schizophrenia;
KIRP	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg19592336	chr6:28129416	ZNF389	0.54	5.73	0.34	2.9e-8	Depression;
KIRP	cis	rs9308433	0.505	rs867446	chr1:214502322	G/T	cg06198575	chr1:214491504	SMYD2	0.47	5.85	0.35	1.59e-8	IgG glycosylation;
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg00599163	chr2:162100495	NA	0.63	8.23	0.46	1.13e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7572644	0.679	rs12986980	chr2:28030437	A/G	cg27432699	chr2:27873401	GPN1	0.5	6.05	0.36	5.48e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg24747557	chr10:131355152	MGMT	-0.42	-5.59	-0.34	6.05e-8	Response to temozolomide;
KIRP	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg23649088	chr2:200775458	C2orf69	-0.59	-5.06	-0.31	8.36e-7	Schizophrenia;
KIRP	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.51	0.33	9.14e-8	Blood protein levels;
KIRP	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg27205649	chr11:78285834	NARS2	-0.56	-5.48	-0.33	1.03e-7	Testicular germ cell tumor;
KIRP	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.46	6.45	0.38	5.73e-10	Red blood cell count;
KIRP	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.47	5.32	0.32	2.3e-7	Schizophrenia;
KIRP	cis	rs9513627	1.000	rs7985908	chr13:100186218	T/C	cg25919922	chr13:100150906	NA	0.72	5.38	0.32	1.69e-7	Obesity-related traits;
KIRP	cis	rs6691722	0.503	rs12135404	chr1:24704263	C/T	cg18323236	chr1:24743029	NIPAL3	-0.46	-6.29	-0.37	1.45e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs6681460	1.000	rs1329978	chr1:67116231	C/T	cg13052034	chr1:66999238	SGIP1	0.41	5.62	0.34	5.24e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.64	9.69	0.53	5.04e-19	Lung cancer;
KIRP	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-0.85	-9.24	-0.51	1.24e-17	Blood pressure (smoking interaction);
KIRP	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg19539972	chr4:7069911	GRPEL1	-0.82	-5.16	-0.31	4.99e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1620921	0.901	rs783165	chr6:161177842	A/C	cg01280913	chr6:161186852	NA	-0.43	-6.17	-0.37	2.77e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg00792783	chr2:198669748	PLCL1	0.46	5.4	0.33	1.55e-7	Dermatomyositis;
KIRP	cis	rs9672608	1.000	rs9672608	chr15:78797463	T/A	cg24631222	chr15:78858424	CHRNA5	0.82	9.37	0.51	4.96e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg13165212	chr22:42675999	NA	0.38	6.5	0.38	4.43e-10	Cognitive function;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20775307	chr11:77850646	ALG8	-0.58	-6.38	-0.38	8.95e-10	Menopause (age at onset);
KIRP	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.22	-0.32	3.89e-7	Red blood cell count;
KIRP	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-8.13	-0.46	2.1e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg22974920	chr21:40686053	BRWD1	-0.43	-5.1	-0.31	6.77e-7	Cognitive function;
KIRP	cis	rs6466055	0.720	rs1204058	chr7:104958129	T/G	cg04380332	chr7:105027541	SRPK2	0.63	9.44	0.52	3e-18	Schizophrenia;
KIRP	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg20991723	chr1:152506922	NA	0.46	5.43	0.33	1.32e-7	Hair morphology;
KIRP	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg05639522	chr1:247681581	NA	0.57	5.22	0.32	3.72e-7	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg08921397	chr10:115991467	TDRD1	-0.44	-6.58	-0.39	2.81e-10	Inflammatory biomarkers;
KIRP	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg23682824	chr7:23144976	KLHL7	0.55	6.57	0.39	3.03e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7106204	0.800	rs7120940	chr11:24236485	C/A	ch.11.24196551F	chr11:24239977	NA	0.79	9.55	0.52	1.34e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7011507	1.000	rs76461611	chr8:49113318	C/T	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.68	-9.08	-0.5	3.75e-17	Height;
KIRP	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg03526459	chr1:146549940	NA	0.46	6.1	0.36	4.07e-9	HIV-1 control;
KIRP	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.54	-6.58	-0.39	2.87e-10	Coronary artery disease;
KIRP	cis	rs372883	0.600	rs2832291	chr21:30734388	C/T	cg08807101	chr21:30365312	RNF160	0.53	6.28	0.37	1.53e-9	Pancreatic cancer;
KIRP	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.16	16.3	0.72	5.1e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27209110	chr19:53662353	ZNF347	0.45	6.3	0.37	1.35e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-5.33	-0.32	2.22e-7	Height;
KIRP	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg10223061	chr2:219282414	VIL1	-0.36	-5.99	-0.36	7.5e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.93	-14.33	-0.67	2.83e-34	Sudden cardiac arrest;
KIRP	cis	rs1006703	0.544	rs8067516	chr17:3838248	T/C	cg06463185	chr17:3833770	ATP2A3	-0.65	-5.98	-0.36	7.77e-9	Glucose homeostasis traits;
KIRP	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.5	7.01	0.41	2.29e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12580194	0.593	rs12578879	chr12:55797773	C/T	cg11794356	chr12:55725991	OR6C3	-0.53	-6.97	-0.41	2.9e-11	Cancer;
KIRP	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.94	-14.67	-0.68	2.02e-35	Intelligence (multi-trait analysis);
KIRP	cis	rs6545883	0.894	rs778157	chr2:61554289	C/G	cg15711740	chr2:61764176	XPO1	-0.59	-7.79	-0.44	1.91e-13	Tuberculosis;
KIRP	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.57	-5.72	-0.34	3.07e-8	Pubertal anthropometrics;
KIRP	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg07631383	chr7:131012765	MKLN1	0.52	6.66	0.39	1.79e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg04607699	chr11:48328132	OR4S1	-0.33	-4.99	-0.3	1.15e-6	Height;
KIRP	cis	rs17065868	1.000	rs17278115	chr13:45128221	C/T	cg10246903	chr13:45222710	NA	0.72	6.4	0.38	7.86e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg20243544	chr17:37824526	PNMT	0.45	6.39	0.38	8.3e-10	Asthma;
KIRP	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.97	-0.3	1.27e-6	Metabolite levels;
KIRP	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01110552	chr10:103578627	MGEA5	0.57	6.42	0.38	7.08e-10	Lung cancer in ever smokers;
KIRP	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg26513180	chr16:89883248	FANCA	-0.59	-5.48	-0.33	1.05e-7	Skin colour saturation;
KIRP	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.6	7.14	0.41	1.08e-11	Mosquito bite size;
KIRP	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-0.74	-7.99	-0.45	5.21e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg09029085	chr17:47094198	IGF2BP1	0.25	5.74	0.34	2.72e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs988913	0.706	rs4521592	chr6:54955279	A/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.68	-0.34	3.83e-8	Menarche (age at onset);
KIRP	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.57	0.43	7.38e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg27102117	chr16:15229624	NA	0.48	5.58	0.34	6.24e-8	Triglycerides;
KIRP	cis	rs4740619	0.619	rs4741560	chr9:16043170	C/T	cg14451791	chr9:16040625	NA	0.4	5.26	0.32	3.1e-7	Body mass index;
KIRP	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17554472	chr22:41940697	POLR3H	0.67	7.16	0.42	9.31e-12	Vitiligo;
KIRP	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.65e-30	Eye color traits;
KIRP	cis	rs997295	0.737	rs11631474	chr15:67934167	C/T	cg24579218	chr15:68104479	NA	-0.35	-5.0	-0.3	1.07e-6	Motion sickness;
KIRP	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.68	4.89	0.3	1.79e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4654899	1.000	rs10916921	chr1:21334542	C/T	cg05370193	chr1:21551575	ECE1	0.45	6.22	0.37	2.14e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.91	13.33	0.65	7.05e-31	Personality dimensions;
KIRP	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	trans	rs62056376	0.646	rs7210639	chr17:32588628	C/T	cg17635953	chr13:28535085	NA	0.59	6.05	0.36	5.24e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg08501292	chr6:25962987	TRIM38	0.7	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.67	-11.09	-0.58	1.92e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs12360000	0.897	rs7921481	chr10:1898756	A/C	cg26364871	chr10:1889757	NA	0.5	6.22	0.37	2.16e-9	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06124975	chr6:107810578	SOBP	0.54	7.19	0.42	7.91e-12	Smoking initiation;
KIRP	cis	rs1559088	0.847	rs10416218	chr19:33599127	T/C	cg24009623	chr19:33667908	NA	0.48	6.1	0.36	3.98e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02247463	chr10:134145482	LRRC27	0.49	6.06	0.36	4.98e-9	Parkinson's disease;
KIRP	cis	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg07460842	chr6:66804631	NA	-0.49	-6.0	-0.36	6.94e-9	Blood trace element (Cu levels);
KIRP	cis	rs7168353	0.948	rs10520720	chr15:93634724	A/G	cg12595281	chr15:93633172	RGMA	-0.48	-5.66	-0.34	4.18e-8	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
KIRP	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	cis	rs10751667	0.600	rs7395387	chr11:1008664	G/C	cg06064525	chr11:970664	AP2A2	-0.29	-5.28	-0.32	2.79e-7	Alzheimer's disease (late onset);
KIRP	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.38	-0.32	1.7e-7	Joint mobility (Beighton score);
KIRP	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg01631408	chr1:248437212	OR2T33	-0.43	-5.75	-0.34	2.64e-8	Common traits (Other);
KIRP	cis	rs79387448	0.655	rs77763678	chr2:102916749	G/A	cg09003973	chr2:102972529	NA	1.18	8.56	0.48	1.24e-15	Gut microbiota (bacterial taxa);
KIRP	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg11784071	chr10:104629166	AS3MT	-0.35	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.58	-9.1	-0.5	3.11e-17	Longevity;
KIRP	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.77	-0.44	2.15e-13	Height;
KIRP	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg13206674	chr6:150067644	NUP43	0.48	6.8	0.4	8.11e-11	Lung cancer;
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	14.73	0.68	1.28e-35	Smoking behavior;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04783966	chr14:21152735	RNASE4;ANG	-0.49	-6.62	-0.39	2.25e-10	Survival in pancreatic cancer;
KIRP	trans	rs2504916	1.000	rs2457572	chr6:160836406	C/T	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	0.57	6.03	0.36	5.99e-9	Response to hepatitis C treatment;
KIRP	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg03289416	chr15:75166202	SCAMP2	-0.42	-5.44	-0.33	1.31e-7	Systemic lupus erythematosus;
KIRP	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.73	-0.34	2.99e-8	Bipolar disorder;
KIRP	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg08213375	chr14:104286397	PPP1R13B	0.3	6.03	0.36	6.08e-9	Schizophrenia;
KIRP	cis	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14604386	chr6:119670882	MAN1A1	-0.44	-5.94	-0.35	9.47e-9	Electrocardiographic conduction measures;
KIRP	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.45	-5.19	-0.31	4.41e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4073221	0.615	rs13068577	chr3:18230439	T/C	cg07694806	chr3:18168406	NA	-0.64	-5.71	-0.34	3.32e-8	Parkinson's disease;
KIRP	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg04731861	chr2:219085781	ARPC2	-0.21	-5.22	-0.32	3.86e-7	Colorectal cancer;
KIRP	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.87e-10	Fibrinogen levels;
KIRP	cis	rs6960043	1.000	rs6962498	chr7:15050305	C/G	cg19272540	chr7:15055459	NA	-0.22	-5.86	-0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs3818717	0.541	rs55767800	chr17:17674967	T/C	cg01246520	chr17:17644344	RAI1	-0.33	-5.31	-0.32	2.49e-7	Lymphocyte counts;
KIRP	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.67	-0.39	1.63e-10	Electroencephalogram traits;
KIRP	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg03929089	chr4:120376271	NA	0.7	6.23	0.37	2.02e-9	Axial length;
KIRP	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.62	-9.76	-0.53	3.09e-19	Total body bone mineral density;
KIRP	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.15	0.41	9.81e-12	Prudent dietary pattern;
KIRP	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg01879757	chr17:41196368	BRCA1	0.53	6.98	0.41	2.67e-11	Menopause (age at onset);
KIRP	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-16.8	-0.73	1.03e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.63	-0.52	8.06e-19	Hemoglobin concentration;
KIRP	cis	rs6960043	1.000	rs6972516	chr7:15051789	G/T	cg19272540	chr7:15055459	NA	-0.21	-5.54	-0.33	7.86e-8	Type 2 diabetes;
KIRP	cis	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.41	5.27	0.32	2.98e-7	Leprosy;
KIRP	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg14851346	chr12:38532713	NA	-0.4	-4.96	-0.3	1.3e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	0.96	16.16	0.72	1.6e-40	Ulcerative colitis;
KIRP	cis	rs7818345	0.967	rs6990357	chr8:19276681	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.45	6.44	0.38	6.1e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.86	-0.53	1.56e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.67	0.63	1.17e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.66	-0.39	1.74e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.47	6.03	0.36	5.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17818399	0.815	rs62136873	chr2:46861237	G/A	cg06386533	chr2:46925753	SOCS5	0.49	4.94	0.3	1.43e-6	Height;
KIRP	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg05914723	chr15:78953907	NA	0.58	5.3	0.32	2.55e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.87	9.04	0.5	4.85e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.53	-0.38	3.79e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg12205435	chr5:138714322	SLC23A1	-0.38	-5.1	-0.31	6.77e-7	Esophageal squamous cell carcinoma;
KIRP	cis	rs6542838	0.641	rs12478574	chr2:99476369	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.49	-5.38	-0.32	1.75e-7	Fear of minor pain;
KIRP	cis	rs2425143	1.000	rs2425143	chr20:34350666	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.06	-0.36	5.04e-9	Blood protein levels;
KIRP	cis	rs60154123	0.730	rs10863818	chr1:210458007	C/T	cg09074223	chr1:210466472	NA	0.56	5.94	0.35	9.67e-9	Coronary artery disease;
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg24642844	chr7:1081250	C7orf50	-0.78	-8.19	-0.46	1.46e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg01721255	chr8:58191610	C8orf71	0.54	5.51	0.33	9.08e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.7	-7.83	-0.45	1.46e-13	Blood pressure (smoking interaction);
KIRP	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg09184832	chr6:79620586	NA	-0.48	-5.37	-0.32	1.79e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg25801113	chr15:45476975	SHF	0.42	7.71	0.44	3.21e-13	Uric acid levels;
KIRP	cis	rs7534824	0.556	rs61780323	chr1:101433407	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.12	0.41	1.2e-11	Refractive astigmatism;
KIRP	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg18306943	chr3:40428807	ENTPD3	0.42	5.89	0.35	1.28e-8	Renal cell carcinoma;
KIRP	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-5.72	-0.34	3.02e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.91	11.85	0.6	6.2e-26	Homoarginine levels;
KIRP	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.21	14.04	0.67	2.88e-33	Sexual dysfunction (female);
KIRP	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg10351095	chr21:47802916	PCNT	0.4	4.99	0.3	1.12e-6	Testicular germ cell tumor;
KIRP	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.56	-7.71	-0.44	3.19e-13	IgG glycosylation;
KIRP	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg05564831	chr3:52568323	NT5DC2	0.44	7.1	0.41	1.35e-11	Electroencephalogram traits;
KIRP	cis	rs4345220	0.585	rs28459824	chr4:41643508	A/G	cg15232654	chr4:41643107	LIMCH1	0.47	6.25	0.37	1.84e-9	Migraine with aura;
KIRP	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.6	5.81	0.35	1.97e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23281280	chr6:28129359	ZNF389	0.44	4.87	0.3	2.01e-6	Parkinson's disease;
KIRP	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs40363	0.645	rs37838	chr16:3509754	G/A	cg22508957	chr16:3507546	NAT15	0.44	6.57	0.39	2.91e-10	Tuberculosis;
KIRP	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg17376030	chr22:41985996	PMM1	-0.76	-8.19	-0.46	1.46e-14	Vitiligo;
KIRP	cis	rs7224685	0.569	rs7212168	chr17:4024640	G/A	cg05562828	chr17:3906858	NA	0.53	5.52	0.33	8.62e-8	Type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09132121	chr2:178981007	RBM45	-0.44	-6.75	-0.4	1.08e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg13332499	chr17:408570	NA	0.59	8.1	0.46	2.59e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.98	-15.95	-0.71	8.26e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg12140854	chr5:148520817	ABLIM3	-0.57	-5.72	-0.34	3.01e-8	Breast cancer;
KIRP	cis	rs9346649	0.967	rs6907103	chr6:168490016	C/T	cg09211372	chr6:168490623	NA	0.31	5.58	0.34	6.26e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs4887140	0.867	rs12899897	chr15:74055191	A/C	cg11789681	chr15:74046708	NA	0.53	5.29	0.32	2.71e-7	Glucose homeostasis traits;
KIRP	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg05220968	chr6:146057943	EPM2A	0.39	5.09	0.31	7.06e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.19	-0.42	7.55e-12	Joint mobility (Beighton score);
KIRP	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-6.96	-0.41	3.07e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7923609	0.936	rs10761779	chr10:65274927	A/G	cg08743896	chr10:65200160	JMJD1C	-0.41	-6.18	-0.37	2.68e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.91	14.54	0.68	5.51e-35	Dental caries;
KIRP	cis	rs258892	0.841	rs34665	chr5:72158396	T/C	cg21869765	chr5:72125136	TNPO1	0.57	6.31	0.37	1.27e-9	Small cell lung carcinoma;
KIRP	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg07382826	chr16:28625726	SULT1A1	0.48	5.6	0.34	5.6e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.79	-10.51	-0.56	1.39e-21	Body mass index;
KIRP	cis	rs12049351	0.722	rs4148763	chr1:229654960	A/T	cg11742688	chr1:229674241	ABCB10	-0.37	-5.57	-0.33	6.67e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-5.52	-0.33	8.59e-8	Bipolar disorder;
KIRP	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.59	5.56	0.33	6.85e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg27205649	chr11:78285834	NARS2	-0.5	-5.56	-0.33	7.19e-8	Testicular germ cell tumor;
KIRP	cis	rs9581857	0.519	rs9581880	chr13:28105850	C/A	cg22138327	chr13:27999177	GTF3A	0.72	5.8	0.35	2.02e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.72	-8.55	-0.48	1.31e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg02475777	chr4:1388615	CRIPAK	0.52	4.87	0.3	2.01e-6	Recombination rate (females);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg24126187	chr3:46923546	PTH1R	-0.5	-6.03	-0.36	6.03e-9	Menopause (age at onset);
KIRP	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.9	-13.44	-0.65	3.01e-31	Height;
KIRP	cis	rs8177876	0.749	rs10459872	chr16:81094951	C/T	cg08591886	chr16:81111003	C16orf46	0.65	5.63	0.34	4.88e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs75920871	1.000	rs11820814	chr11:116765700	T/C	cg23684410	chr11:116897558	SIK3	0.53	5.78	0.35	2.25e-8	Subjective well-being;
KIRP	cis	rs2219968	1.000	rs13248763	chr8:78975616	G/A	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	0.9	7.28	0.42	4.39e-12	Alzheimer's disease (late onset);
KIRP	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.15	0.69	4.67e-37	Chronic sinus infection;
KIRP	cis	rs12595433	1.000	rs12595433	chr15:63290645	C/T	cg03196360	chr15:63270641	NA	-0.26	-4.94	-0.3	1.43e-6	Obesity-related traits;
KIRP	cis	rs3789045	0.774	rs12041243	chr1:204490470	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.29	-0.37	1.42e-9	Educational attainment (college completion);
KIRP	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg25272121	chr1:152190972	HRNR	-0.42	-5.83	-0.35	1.77e-8	Inflammatory skin disease;
KIRP	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.85	-11.35	-0.59	2.84e-24	Longevity;
KIRP	cis	rs11166927	0.901	rs7827091	chr8:140812044	G/C	cg16909799	chr8:140841666	TRAPPC9	0.56	7.73	0.44	2.7e-13	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs1440410	0.835	rs11737209	chr4:144132672	T/C	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.31	12.44	0.62	7.1e-28	Diabetic retinopathy;
KIRP	cis	rs6722613	0.900	rs749131	chr2:25529624	A/C	cg10614445	chr2:25526696	DNMT3A	-0.31	-5.37	-0.32	1.85e-7	Ossification of the posterior longitudinal ligament of the spine;
KIRP	cis	rs6484504	0.576	rs2447671	chr11:31334323	A/G	cg26647111	chr11:31128758	NA	-0.43	-5.08	-0.31	7.64e-7	Red blood cell count;
KIRP	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.74	-10.32	-0.55	5.78e-21	Childhood ear infection;
KIRP	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.72	7.63	0.44	5.23e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg15691649	chr6:25882328	NA	0.44	5.41	0.33	1.51e-7	Blood metabolite levels;
KIRP	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.43	6.11	0.36	3.8e-9	Monocyte percentage of white cells;
KIRP	cis	rs6670533	0.571	rs72884449	chr1:24869837	C/T	cg07475527	chr1:24864545	NA	-0.92	-6.37	-0.38	9.28e-10	Fasting blood insulin (BMI interaction);
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.64	7.91	0.45	8.65e-14	Menarche (age at onset);
KIRP	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.17	0.7	3.81e-37	Platelet count;
KIRP	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-16.85	-0.73	7.13e-43	Height;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	7.33	0.42	3.32e-12	Lymphocyte counts;
KIRP	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15541040	chr2:3486749	NA	-0.44	-5.14	-0.31	5.48e-7	Neurofibrillary tangles;
KIRP	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.8	9.64	0.52	7.19e-19	Corneal astigmatism;
KIRP	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.75	-9.94	-0.54	8.61e-20	Ulcerative colitis;
KIRP	cis	rs6137287	0.920	rs6075769	chr20:21111710	A/G	cg04219410	chr20:21106687	PLK1S1	0.46	5.14	0.31	5.68e-7	Height;
KIRP	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg14517863	chr17:44321492	NA	0.49	5.63	0.34	5.02e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs981844	0.775	rs17299246	chr4:154743504	C/T	cg14289246	chr4:154710475	SFRP2	0.65	7.44	0.43	1.68e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.59	-0.59	4.36e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg05973401	chr12:123451056	ABCB9	0.55	6.39	0.38	8.11e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4132509	1.000	rs28869008	chr1:243986344	C/A	cg25706552	chr1:244017396	NA	0.61	7.38	0.43	2.45e-12	RR interval (heart rate);
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg21851534	chr17:3907994	ZZEF1	-0.7	-11.62	-0.6	3.52e-25	Type 2 diabetes;
KIRP	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	0.74	6.95	0.41	3.29e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	5.7	0.34	3.37e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1971762	0.545	rs11170632	chr12:54047935	C/T	cg23533419	chr12:54090519	NA	0.33	5.1	0.31	6.94e-7	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00692763	chr18:47088373	LIPG	0.51	6.39	0.38	8.11e-10	Smoking initiation;
KIRP	cis	rs1050631	0.960	rs4799848	chr18:33686292	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.48	5.93	0.35	1e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-7.08	-0.41	1.49e-11	Coronary artery disease;
KIRP	cis	rs9488822	0.596	rs6568921	chr6:116373616	C/T	cg05304507	chr6:116381966	FRK	0.2	5.1	0.31	6.8e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs687432	0.885	rs67305834	chr11:57831450	A/C	cg19752551	chr11:57585705	CTNND1	-0.69	-9.04	-0.5	4.73e-17	Parkinson's disease;
KIRP	cis	rs4849845	0.886	rs934722	chr2:121010443	A/T	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	7.4	0.43	2.12e-12	Coronary artery disease;
KIRP	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.84	-0.35	1.63e-8	Height;
KIRP	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg07645718	chr20:61493192	TCFL5	0.74	6.01	0.36	6.52e-9	Obesity-related traits;
KIRP	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg15839431	chr19:19639596	YJEFN3	0.47	5.1	0.31	6.76e-7	Bipolar disorder;
KIRP	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs17020663	0.723	rs12474501	chr2:101642843	A/C	cg17494863	chr2:101638916	TBC1D8	0.54	5.81	0.35	1.93e-8	Pulse pressure;
KIRP	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.58	7.91	0.45	8.8e-14	Prostate cancer;
KIRP	cis	rs7534824	0.625	rs3087816	chr1:101441775	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	5.49	0.33	9.76e-8	Refractive astigmatism;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-6.47	-0.38	5.15e-10	Height;
KIRP	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-5.06	-0.31	8.12e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3540	0.960	rs11857092	chr15:90960115	T/C	cg10434728	chr15:90938212	IQGAP1	0.29	4.91	0.3	1.64e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs526231	0.543	rs246909	chr5:102563677	A/G	cg23492399	chr5:102201601	PAM	-0.48	-5.1	-0.31	6.8e-7	Primary biliary cholangitis;
KIRP	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.64	7.59	0.44	6.43e-13	Obesity-related traits;
KIRP	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.03	0.31	9.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg19500275	chr17:80737654	TBCD	-0.52	-7.13	-0.41	1.11e-11	Glycated hemoglobin levels;
KIRP	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.63	-0.63	1.57e-28	Breast cancer;
KIRP	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg10755058	chr3:40428713	ENTPD3	0.47	6.58	0.39	2.78e-10	Renal cell carcinoma;
KIRP	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs7116495	0.609	rs73543643	chr11:71835596	C/T	cg26138937	chr11:71823887	C11orf51	1.16	8.02	0.46	4.37e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.48	5.65	0.34	4.51e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.76	0.4	1.02e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg16306078	chr6:126000798	NA	0.26	4.91	0.3	1.66e-6	Endometrial cancer;
KIRP	cis	rs4790333	0.813	rs2926992	chr17:2256026	C/A	cg02569219	chr17:2266849	SGSM2	0.51	6.24	0.37	1.87e-9	Proinsulin levels;
KIRP	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18252515	chr7:66147081	NA	-0.43	-5.2	-0.31	4.28e-7	Aortic root size;
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.83	-0.45	1.42e-13	Platelet count;
KIRP	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.13e-15	Menarche (age at onset);
KIRP	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.73	-0.44	2.73e-13	Resting heart rate;
KIRP	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg14675211	chr2:100938903	LONRF2	0.55	7.45	0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg23594656	chr7:65796392	TPST1	0.45	7.12	0.41	1.18e-11	Aortic root size;
KIRP	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	0.95	10.68	0.56	3.88e-22	Triglycerides;
KIRP	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs6893807	0.778	rs1501673	chr5:87963600	G/A	cg24804195	chr5:87968844	LOC645323	0.52	5.24	0.32	3.5e-7	Body mass index;
KIRP	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg05025164	chr4:1340916	KIAA1530	0.42	5.22	0.32	3.82e-7	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.88	10.21	0.55	1.26e-20	Corneal astigmatism;
KIRP	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.54	7.25	0.42	5.46e-12	Menarche (age at onset);
KIRP	cis	rs59197085	0.636	rs2307037	chr7:128449405	G/A	cg00734629	chr7:128471146	FLNC	0.43	4.85	0.3	2.18e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg14343924	chr8:8086146	FLJ10661	0.44	5.21	0.32	3.92e-7	Neuroticism;
KIRP	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.51	6.9	0.4	4.48e-11	Coronary artery disease;
KIRP	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	0.99	12.64	0.63	1.52e-28	Blood protein levels;
KIRP	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.7	0.44	3.24e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.44	5.04	0.31	9.12e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6545883	0.894	rs2694632	chr2:61558682	T/C	cg15711740	chr2:61764176	XPO1	0.61	7.95	0.45	6.81e-14	Tuberculosis;
KIRP	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.74	8.83	0.49	1.99e-16	Type 2 diabetes;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.72	10.11	0.54	2.5e-20	Renal function-related traits (BUN);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14938029	chr20:23421747	CSTL1	0.48	6.91	0.4	4.11e-11	Interleukin-4 levels;
KIRP	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.48	-7.08	-0.41	1.51e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg13010199	chr12:38710504	ALG10B	0.48	6.35	0.38	1.02e-9	Morning vs. evening chronotype;
KIRP	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg22117172	chr7:91764530	CYP51A1	0.47	6.65	0.39	1.88e-10	Breast cancer;
KIRP	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg25486957	chr4:152246857	NA	-0.5	-5.48	-0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg14675211	chr2:100938903	LONRF2	0.49	6.41	0.38	7.29e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.82	-0.45	1.56e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2150410	0.915	rs2183576	chr21:40599225	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs258892	0.895	rs34811011	chr5:72030243	G/A	cg21869765	chr5:72125136	TNPO1	-0.53	-6.05	-0.36	5.23e-9	Small cell lung carcinoma;
KIRP	cis	rs780094	0.500	rs74175068	chr2:27833502	T/C	cg05484376	chr2:27715224	FNDC4	-0.36	-5.4	-0.33	1.54e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.72	6.54	0.38	3.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.61	7.83	0.45	1.47e-13	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg00631329	chr6:26305371	NA	-0.64	-8.3	-0.47	7.17e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg16898833	chr6:26189333	HIST1H4D	0.83	5.9	0.35	1.19e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg14972814	chr11:95582409	MTMR2	0.37	6.03	0.36	5.89e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.24	12.74	0.63	7.08e-29	Diabetic retinopathy;
KIRP	cis	rs1215050	0.791	rs1648546	chr4:98899294	T/C	cg17366294	chr4:99064904	C4orf37	-0.38	-5.26	-0.32	3.2e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9419702	0.614	rs7907614	chr10:133532208	T/C	cg04492858	chr10:133558786	NA	0.37	5.45	0.33	1.19e-7	Survival in rectal cancer;
KIRP	cis	rs2346160	0.899	rs206977	chr6:167690746	G/C	cg04673565	chr6:167680447	NA	-0.38	-4.94	-0.3	1.48e-6	Parental extreme longevity (95 years and older);
KIRP	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg02353165	chr6:42928485	GNMT	0.57	6.87	0.4	5.31e-11	Blood protein levels;
KIRP	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.57	5.02	0.3	9.89e-7	Skin colour saturation;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13516655	chr8:67526293	MYBL1	0.42	6.26	0.37	1.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2411233	0.875	rs1991886	chr15:39291996	G/T	cg19287857	chr15:39890699	NA	0.35	4.89	0.3	1.86e-6	Platelet count;
KIRP	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs4938330	0.608	rs2239011	chr11:117088994	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26378065	chr17:18585709	ZNF286B	0.53	6.75	0.4	1.07e-10	Educational attainment (years of education);
KIRP	cis	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.0	-0.36	7.19e-9	Neuroticism;
KIRP	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg08668510	chr10:1095578	IDI1	0.89	6.1	0.36	4.05e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-6.34	-0.37	1.07e-9	Total body bone mineral density;
KIRP	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.11	0.31	6.56e-7	Menopause (age at onset);
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg06675538	chr2:114033490	PAX8;LOC440839	-0.45	-7.57	-0.43	7.55e-13	Lymphocyte counts;
KIRP	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.58	7.52	0.43	1.02e-12	Aortic root size;
KIRP	cis	rs748404	0.646	rs2253268	chr15:43800968	A/C	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.34	0.32	2.15e-7	Lung cancer;
KIRP	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg02993010	chr8:124780839	FAM91A1	-0.59	-6.11	-0.36	3.8e-9	Pancreatic cancer;
KIRP	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19671926	chr4:122722719	EXOSC9	0.5	6.01	0.36	6.5e-9	Type 2 diabetes;
KIRP	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.91	-6.4	-0.38	7.83e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.42	0.43	1.96e-12	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24058025	chr1:44412156	IPO13	0.52	6.65	0.39	1.87e-10	Parkinson's disease;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg22748630	chr12:122241475	LOC338799;SETD1B	-1.13	-6.39	-0.38	8.32e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg00647317	chr7:50633725	DDC	0.39	5.76	0.34	2.52e-8	Systemic sclerosis;
KIRP	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg27494647	chr7:150038898	RARRES2	0.43	5.94	0.35	9.63e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6728642	1.000	rs73959416	chr2:97604518	A/T	cg26665480	chr2:98280029	ACTR1B	-0.5	-4.99	-0.3	1.12e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs2290402	0.536	rs2061846	chr4:852484	A/G	cg14517359	chr4:903473	GAK	-0.53	-5.9	-0.35	1.22e-8	Type 2 diabetes;
KIRP	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg17470723	chr8:74884337	TCEB1	0.63	8.0	0.45	4.96e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17401966	0.540	rs6541084	chr1:10285447	A/G	cg19773385	chr1:10388646	KIF1B	-0.43	-6.2	-0.37	2.41e-9	Hepatocellular carcinoma;
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.43	5.53	0.33	8e-8	Longevity;
KIRP	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-6.92	-0.4	3.94e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.97	0.36	8.09e-9	Platelet count;
KIRP	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.48	5.62	0.34	5.12e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs7937612	0.965	rs10750172	chr11:120270253	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.49	-7.36	-0.42	2.75e-12	Intraocular pressure;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11987759	chr7:65425863	GUSB	0.58	7.73	0.44	2.69e-13	Aortic root size;
KIRP	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg05347473	chr6:146136440	FBXO30	0.49	6.91	0.4	4.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg25019033	chr10:957182	NA	-0.59	-6.17	-0.37	2.81e-9	Eosinophil percentage of granulocytes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18317022	chr19:48017995	NAPA	0.47	6.31	0.37	1.26e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12888358	chr2:86668281	KDM3A	-0.45	-6.18	-0.37	2.7e-9	Survival in pancreatic cancer;
KIRP	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg19773385	chr1:10388646	KIF1B	-0.62	-9.6	-0.52	9.58e-19	Hepatocellular carcinoma;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.9	-14.41	-0.68	1.53e-34	Height;
KIRP	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.57	9.9	0.53	1.18e-19	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
KIRP	cis	rs12220238	0.915	rs11000987	chr10:76073265	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.65	0.39	1.92e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg24826892	chr11:71159390	DHCR7	0.42	4.99	0.3	1.13e-6	Vitamin D levels;
KIRP	cis	rs754423	0.515	rs12587906	chr14:52553959	T/G	cg10149976	chr14:52535953	NID2	0.38	5.34	0.32	2.09e-7	Craniofacial microsomia;
KIRP	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14169450	chr9:139327907	INPP5E	0.56	6.73	0.39	1.18e-10	White blood cell count;
KIRP	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.62	8.05	0.46	3.51e-14	Platelet distribution width;
KIRP	cis	rs17065868	1.000	rs17278318	chr13:45139146	A/G	cg10246903	chr13:45222710	NA	0.6	5.13	0.31	5.82e-7	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg15282417	chr9:129245246	FAM125B	0.43	7.2	0.42	7.41e-12	Intraocular pressure;
KIRP	cis	rs7178909	0.902	rs10459674	chr15:90438295	G/C	cg19708238	chr15:90437601	AP3S2	0.59	8.2	0.46	1.35e-14	Common traits (Other);
KIRP	cis	rs10214930	0.697	rs12535844	chr7:27689824	G/T	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	trans	rs34117943	1	rs34117943	chr16:68819642	C/CT	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-7.28	-0.42	4.6e-12	Mean corpuscular volume;
KIRP	cis	rs11634397	0.513	rs4778754	chr15:80421200	T/C	cg08257866	chr15:80351198	ZFAND6	0.53	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs7819412	0.502	rs4840548	chr8:10992883	C/T	cg21775007	chr8:11205619	TDH	-0.43	-5.23	-0.32	3.65e-7	Triglycerides;
KIRP	trans	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.9e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11605275	1.000	rs78687006	chr11:20032176	G/A	cg14835545	chr11:20032148	NAV2	-0.8	-6.14	-0.36	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs918629	0.761	rs3777173	chr5:95281353	C/T	cg16656078	chr5:95278638	ELL2	-0.5	-7.1	-0.41	1.34e-11	IgG glycosylation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11392389	chr12:13153689	HTR7P;HEBP1	0.47	6.07	0.36	4.78e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.91	0.4	4.15e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9372498	0.505	rs9481789	chr6:118734320	A/C	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.45	-5.77	-0.35	2.36e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.56	-8.32	-0.47	6e-15	Itch intensity from mosquito bite;
KIRP	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg25547332	chr5:131281432	NA	-0.48	-5.43	-0.33	1.34e-7	Life satisfaction;
KIRP	cis	rs8060686	0.920	rs73594581	chr16:67955554	G/A	cg27539214	chr16:67997921	SLC12A4	-0.56	-5.16	-0.31	5.16e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg19610905	chr11:61596333	FADS2	-0.73	-7.01	-0.41	2.22e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10756170	chr10:75900050	AP3M1	-0.43	-6.14	-0.36	3.31e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg17182837	chr8:41585554	ANK1	-0.5	-7.04	-0.41	1.91e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	1.99e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg00800569	chr2:239229395	TRAF3IP1	0.44	5.09	0.31	7.08e-7	Multiple system atrophy;
KIRP	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.41	-0.43	1.97e-12	Gut microbiome composition (summer);
KIRP	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.82	-0.35	1.83e-8	Type 2 diabetes;
KIRP	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg03474202	chr17:45855739	NA	-0.52	-8.27	-0.47	8.65e-15	IgG glycosylation;
KIRP	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.1	-0.36	4.01e-9	Ulcerative colitis;
KIRP	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg16505056	chr13:95253998	GPR180	-0.5	-6.16	-0.37	2.89e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg26513180	chr16:89883248	FANCA	0.55	6.86	0.4	5.56e-11	Vitiligo;
KIRP	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg02187348	chr16:89574699	SPG7	0.49	6.31	0.37	1.3e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.62	-6.92	-0.4	3.8e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg11502198	chr6:26597334	ABT1	-0.8	-5.43	-0.33	1.38e-7	Small cell lung carcinoma;
KIRP	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg02536541	chr18:77568900	NA	0.71	10.0	0.54	5.73e-20	Schizophrenia;
KIRP	cis	rs9443189	0.762	rs2748955	chr6:76464302	C/G	cg01950844	chr6:76311363	SENP6	-0.6	-6.38	-0.38	8.7e-10	Prostate cancer;
KIRP	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.56	-6.79	-0.4	8.56e-11	Obesity-related traits;
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg18209359	chr17:80159595	CCDC57	0.41	5.43	0.33	1.38e-7	Life satisfaction;
KIRP	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg23479056	chr15:41276147	INO80	-0.38	-5.09	-0.31	7.05e-7	Menopause (age at onset);
KIRP	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-8.03	-0.46	3.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11264213	0.901	rs7542179	chr1:36461122	A/G	cg27506609	chr1:36549197	TEKT2	-0.94	-9.97	-0.54	7.22e-20	Schizophrenia;
KIRP	cis	rs8060686	0.516	rs10852439	chr16:68288331	T/C	cg26727032	chr16:67993705	SLC12A4	-0.75	-8.57	-0.48	1.14e-15	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2651899	0.872	rs207199	chr1:3076857	T/G	cg01413848	chr1:3081226	PRDM16	0.38	5.1	0.31	6.95e-7	Migraine;
KIRP	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.65	7.83	0.45	1.45e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg11764359	chr7:65958608	NA	0.74	5.02	0.3	1.01e-6	Diabetic kidney disease;
KIRP	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.95	0.5	8.79e-17	Colorectal cancer;
KIRP	cis	rs17065868	0.803	rs9533891	chr13:45099224	C/T	cg10246903	chr13:45222710	NA	0.54	5.9	0.35	1.2e-8	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg18755752	chr8:142205143	DENND3	-0.37	-4.93	-0.3	1.5e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg23920097	chr1:209922102	NA	-0.4	-5.36	-0.32	1.92e-7	Red blood cell count;
KIRP	cis	rs17095355	1.000	rs12259261	chr10:111725145	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.28	-0.32	2.9e-7	Biliary atresia;
KIRP	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-5.51	-0.33	9.15e-8	Lung cancer;
KIRP	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	8.68	0.48	5.68e-16	Bipolar disorder;
KIRP	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg11995313	chr8:8860691	ERI1	0.39	5.16	0.31	5.02e-7	Joint mobility (Beighton score);
KIRP	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.46	6.47	0.38	5.31e-10	Red blood cell count;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.61e-8	Life satisfaction;
KIRP	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-9.45	-0.52	2.87e-18	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg09626299	chr10:82213104	TSPAN14	-0.33	-5.03	-0.31	9.3e-7	Post bronchodilator FEV1;
KIRP	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg08975724	chr8:8085496	FLJ10661	0.62	7.89	0.45	9.94e-14	Retinal vascular caliber;
KIRP	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs933360	0.585	rs6593174	chr7:50836486	A/G	cg14240098	chr7:50518052	FIGNL1	0.43	4.98	0.3	1.18e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs6496667	0.908	rs8039446	chr15:90853061	A/G	cg10434728	chr15:90938212	IQGAP1	-0.35	-5.01	-0.3	1.06e-6	Rheumatoid arthritis;
KIRP	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.84	-13.81	-0.66	1.73e-32	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	11.12	0.58	1.58e-23	Primary sclerosing cholangitis;
KIRP	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg08738300	chr3:44038990	NA	0.69	9.64	0.52	7.45e-19	Coronary artery disease;
KIRP	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.6	0.34	5.85e-8	Putamen volume;
KIRP	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg21573476	chr21:45109991	RRP1B	-0.51	-6.71	-0.39	1.34e-10	Mean corpuscular volume;
KIRP	cis	rs4774899	1.000	rs34262415	chr15:57253829	C/T	cg13626582	chr15:57592083	LOC283663	0.21	5.12	0.31	6.28e-7	Urinary tract infection frequency;
KIRP	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.81	0.35	1.92e-8	Personality dimensions;
KIRP	cis	rs1134634	0.520	rs10022610	chr4:15637487	G/T	cg16509355	chr4:15471240	CC2D2A	-0.35	-5.97	-0.36	8.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7560272	0.501	rs13003035	chr2:73957227	T/A	cg20560298	chr2:73613845	ALMS1	0.44	5.22	0.32	3.81e-7	Schizophrenia;
KIRP	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.74	0.49	3.69e-16	Motion sickness;
KIRP	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg07884673	chr3:53033167	SFMBT1	-0.74	-6.38	-0.38	8.88e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.64	8.46	0.47	2.44e-15	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12712270	chr4:3519929	LRPAP1	-0.52	-6.6	-0.39	2.45e-10	Parkinson's disease;
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg27121462	chr16:89883253	FANCA	0.63	9.44	0.52	2.93e-18	Vitiligo;
KIRP	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg24579218	chr15:68104479	NA	-0.51	-7.49	-0.43	1.24e-12	Restless legs syndrome;
KIRP	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.18	0.5	1.88e-17	Bladder cancer;
KIRP	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.54	0.38	3.54e-10	Prudent dietary pattern;
KIRP	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	1.12	17.0	0.73	2.24e-43	Monocyte percentage of white cells;
KIRP	cis	rs580438	0.529	rs6807014	chr3:13438319	G/A	cg10657019	chr3:13328039	NA	-0.49	-6.21	-0.37	2.22e-9	Myringotomy;
KIRP	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	cg12689670	chr1:183009347	LAMC1	0.46	6.55	0.39	3.3e-10	Hypertriglyceridemia;
KIRP	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.63e-9	Dilated cardiomyopathy;
KIRP	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.64	8.3	0.47	7.09e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg12315302	chr6:26189340	HIST1H4D	0.87	5.62	0.34	5.23e-8	Lung cancer;Intelligence (multi-trait analysis);
KIRP	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg16797656	chr11:68205561	LRP5	0.55	6.69	0.39	1.49e-10	Total body bone mineral density (age 45-60);
KIRP	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-13.0	-0.64	9.06e-30	Alzheimer's disease;
KIRP	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.59	-6.44	-0.38	6.16e-10	Menopause (age at onset);
KIRP	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05665937	chr4:1216051	CTBP1	-0.47	-6.37	-0.38	9.43e-10	Obesity-related traits;
KIRP	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs6032067	1.000	rs6017526	chr20:43871555	A/T	cg10761708	chr20:43804764	PI3	0.53	5.42	0.33	1.45e-7	Blood protein levels;
KIRP	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.82	-10.57	-0.56	8.86e-22	Cognitive function;
KIRP	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.72	9.2	0.51	1.61e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2411233	0.837	rs1897738	chr15:39261480	G/A	cg19287857	chr15:39890699	NA	0.45	6.19	0.37	2.55e-9	Platelet count;
KIRP	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.22	-0.37	2.15e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.0	-0.41	2.36e-11	Morning vs. evening chronotype;
KIRP	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg25019033	chr10:957182	NA	-0.59	-7.34	-0.42	3.02e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg27564123	chr1:46958475	NA	0.38	4.88	0.3	1.93e-6	Monobrow;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09952002	chr17:46640774	HOXB3	0.48	6.32	0.37	1.23e-9	Interleukin-4 levels;
KIRP	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Parkinson's disease;
KIRP	cis	rs7561149	0.580	rs36051007	chr2:179545859	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.51	5.04	0.31	9.16e-7	QT interval;
KIRP	cis	rs3947	0.951	rs1692813	chr8:11704296	G/T	cg21775007	chr8:11205619	TDH	-0.47	-5.03	-0.31	9.65e-7	Blood protein levels;
KIRP	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg17724175	chr1:150552817	MCL1	0.37	5.97	0.36	8.19e-9	Melanoma;
KIRP	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.82	12.23	0.61	3.46e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs72730918	0.564	rs34448759	chr15:51807924	C/G	cg14296394	chr15:51910925	DMXL2	0.81	11.22	0.58	7.46e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.75	9.52	0.52	1.65e-18	Alzheimer's disease;
KIRP	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg07451762	chr16:28383216	NA	0.42	5.48	0.33	1.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10788264	0.569	rs7089468	chr10:124019052	T/C	cg09507567	chr10:124027408	NA	0.36	6.94	0.4	3.38e-11	Total body bone mineral density;
KIRP	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg19468946	chr17:37922297	IKZF3	-0.49	-6.71	-0.39	1.32e-10	Self-reported allergy;
KIRP	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg18032289	chr17:61959525	GH2	-0.38	-4.94	-0.3	1.45e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg04132472	chr17:19861366	AKAP10	0.64	9.65	0.52	6.97e-19	Schizophrenia;
KIRP	cis	rs9815354	0.904	rs73073235	chr3:42012693	C/A	cg03022575	chr3:42003672	ULK4	0.8	8.07	0.46	3.15e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.31	0.37	1.29e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.65	9.32	0.51	6.68e-18	Lymphocyte counts;
KIRP	cis	rs7945718	0.621	rs6485977	chr11:12678387	C/T	cg25843174	chr11:12811716	TEAD1	0.31	5.58	0.34	6.41e-8	Educational attainment (years of education);
KIRP	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	9.59	0.52	1.05e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10465746	0.725	rs12070578	chr1:84349607	A/G	cg10977910	chr1:84465055	TTLL7	0.57	7.36	0.42	2.78e-12	Obesity-related traits;
KIRP	cis	rs11203032	0.634	rs2154255	chr10:90942967	A/T	cg16672925	chr10:90967113	CH25H	-0.68	-6.97	-0.41	2.87e-11	Heart failure;
KIRP	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg05887092	chr17:76393375	PGS1	0.54	7.55	0.43	8.26e-13	HDL cholesterol levels;
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.57	8.3	0.47	7.15e-15	Obesity-related traits;
KIRP	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	7.43	0.43	1.76e-12	Personality dimensions;
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.75	10.8	0.57	1.65e-22	Lung cancer;
KIRP	cis	rs68170813	0.652	rs763386	chr7:107196723	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-7.02	-0.41	2.21e-11	Coronary artery disease;
KIRP	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.57	7.48	0.43	1.3e-12	Hip circumference;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15537567	chr4:23017280	NA	-0.43	-7.02	-0.41	2.21e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg02569458	chr12:86230093	RASSF9	-0.52	-7.64	-0.44	4.79e-13	Major depressive disorder;
KIRP	cis	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.03	-0.41	1.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg12741994	chr3:170137321	CLDN11	-0.48	-4.9	-0.3	1.71e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.5	0.52	2.02e-18	Coffee consumption (cups per day);
KIRP	cis	rs7084402	0.967	rs7091440	chr10:60271372	T/A	cg05938607	chr10:60274200	BICC1	0.42	10.11	0.54	2.53e-20	Refractive error;
KIRP	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg16988262	chr1:15930761	NA	0.37	5.09	0.31	7.16e-7	Systolic blood pressure;
KIRP	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg16141378	chr3:129829833	LOC729375	0.58	7.5	0.43	1.16e-12	Joint mobility (Beighton score);
KIRP	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.77	0.66	2.37e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.68	-9.41	-0.51	3.61e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg08847533	chr14:75593920	NEK9	-0.48	-5.75	-0.34	2.57e-8	IgG glycosylation;
KIRP	cis	rs2916247	1.000	rs6992515	chr8:93042269	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.65	-0.44	4.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.8	0.4	7.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3736485	0.966	rs4775959	chr15:51891636	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.19	-0.31	4.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.77	-12.18	-0.61	5.13e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs4742903	0.509	rs1004358	chr9:106966367	C/T	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.21	-0.37	2.21e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg17372223	chr3:52568218	NT5DC2	0.32	4.92	0.3	1.55e-6	Electroencephalogram traits;
KIRP	cis	rs9815354	0.904	rs7647561	chr3:41848627	T/A	cg03022575	chr3:42003672	ULK4	0.52	5.92	0.35	1.08e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-1.18	-9.81	-0.53	2.15e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg10189774	chr4:17578691	LAP3	0.55	6.99	0.41	2.57e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs4700695	0.925	rs414001	chr5:65383259	C/G	cg21114390	chr5:65439923	SFRS12	-0.55	-5.38	-0.32	1.71e-7	Facial morphology (factor 19);
KIRP	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.95	-16.7	-0.73	2.25e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg03609598	chr5:56110824	MAP3K1	-0.48	-5.55	-0.33	7.3e-8	Initial pursuit acceleration;
KIRP	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08462924	chr1:41848221	NA	0.42	6.01	0.36	6.5e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12560992	chr17:57184187	TRIM37	0.6	6.98	0.41	2.66e-11	Testicular germ cell tumor;
KIRP	cis	rs889398	0.802	rs12919094	chr16:69843357	A/G	cg09409435	chr16:70099608	PDXDC2	-0.44	-5.23	-0.32	3.66e-7	Body mass index;
KIRP	cis	rs11673344	0.566	rs11666708	chr19:37887110	G/C	cg14683738	chr19:37701593	ZNF585B	0.45	5.18	0.31	4.55e-7	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.57	8.17	0.46	1.66e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-0.93	-7.1	-0.41	1.31e-11	Mitochondrial DNA levels;
KIRP	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2901656	0.677	rs2269615	chr1:172415451	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.42	5.54	0.33	7.82e-8	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs2860975	1.000	rs12781471	chr10:96765362	T/C	cg09036531	chr10:96991505	NA	-0.55	-7.08	-0.41	1.52e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-12.07	-0.61	1.15e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07648498	chr16:89883185	FANCA	0.38	4.91	0.3	1.69e-6	Vitiligo;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07308232	chr7:1071921	C7orf50	-0.7	-8.98	-0.5	7.37e-17	Longevity;Endometriosis;
KIRP	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.61	-6.76	-0.4	1.02e-10	Urate levels in lean individuals;
KIRP	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.7	7.22	0.42	6.41e-12	Protein C levels;
KIRP	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.05	0.41	1.81e-11	Height;
KIRP	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg00806126	chr19:22604979	ZNF98	0.6	6.54	0.38	3.62e-10	Pain;
KIRP	cis	rs743757	1.000	rs2236984	chr3:50495487	A/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.52	5.16	0.31	4.99e-7	Diastolic blood pressure;
KIRP	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg00745463	chr17:30367425	LRRC37B	-0.86	-8.1	-0.46	2.59e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs72829446	0.530	rs72827503	chr17:7371268	G/T	cg02795151	chr17:7402630	POLR2A	0.78	7.18	0.42	8.19e-12	Androgen levels;
KIRP	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg17182837	chr8:41585554	ANK1	-0.5	-5.33	-0.32	2.23e-7	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg16255804	chr6:135334527	HBS1L	-0.38	-5.93	-0.35	1.01e-8	Red blood cell count;
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.79	-0.44	1.92e-13	Platelet count;
KIRP	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26002218	chr14:103986227	CKB	0.28	5.75	0.34	2.64e-8	Body mass index;
KIRP	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.45	6.35	0.38	1e-9	Endometrial cancer;
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg00857998	chr1:205179979	DSTYK	0.62	7.5	0.43	1.13e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs12643302	0.774	rs13106722	chr4:172358164	A/G	cg01158574	chr2:11809997	NTSR2	-0.44	-6.09	-0.36	4.4e-9	Facial morphology (factor 3, length of philtrum);
KIRP	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg22974920	chr21:40686053	BRWD1	-0.45	-5.17	-0.31	4.73e-7	Cognitive function;
KIRP	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg05347473	chr6:146136440	FBXO30	0.63	8.94	0.5	9.41e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.25	-0.47	9.64e-15	Total cholesterol levels;
KIRP	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-0.52	-7.57	-0.43	7.44e-13	Coronary artery disease;
KIRP	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.91	15.29	0.7	1.52e-37	Coronary artery disease;
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.59	-6.06	-0.36	5.11e-9	Platelet count;
KIRP	cis	rs7849270	1.000	rs10988224	chr9:131903334	A/T	cg13538475	chr9:131942899	NA	-0.32	-5.27	-0.32	3.02e-7	Blood metabolite ratios;
KIRP	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg00784671	chr22:46762841	CELSR1	-0.8	-7.81	-0.45	1.65e-13	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs76288851	0.799	rs73203680	chr3:126568666	A/G	cg13821433	chr2:26726535	OTOF	0.57	6.44	0.38	6.25e-10	Alcoholic chronic pancreatitis;
KIRP	trans	rs10874322	1.000	rs72711838	chr1:83021138	T/G	cg12753787	chr1:3239712	PRDM16	0.64	6.51	0.38	4.29e-10	Response to taxane treatment (docetaxel);
KIRP	cis	rs10073892	0.664	rs12653423	chr5:101908121	T/C	cg19774478	chr5:101632501	SLCO4C1	0.59	5.8	0.35	2e-8	Cognitive decline (age-related);
KIRP	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.87e-32	Mean platelet volume;
KIRP	cis	rs6450176	0.564	rs31227	chr5:53326467	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-8.64	-0.48	7.09e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.58	-7.88	-0.45	1.03e-13	Height;
KIRP	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg14541582	chr5:601475	NA	-0.56	-6.26	-0.37	1.74e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.51	6.18	0.37	2.6e-9	Ulcerative colitis;
KIRP	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg16482183	chr6:26056742	HIST1H1C	0.6	6.83	0.4	6.5e-11	Iron status biomarkers;
KIRP	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.66	7.91	0.45	8.9e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.46	-0.43	1.52e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.42	7.06	0.41	1.71e-11	Heart rate;
KIRP	cis	rs8133932	0.654	rs2839050	chr21:47326666	G/A	cg11214348	chr21:47283868	PCBP3	0.45	5.15	0.31	5.34e-7	Schizophrenia;
KIRP	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.47	6.54	0.38	3.59e-10	Red blood cell count;
KIRP	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-6.81	-0.4	7.65e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg26875233	chr11:93583750	C11orf90	0.34	6.49	0.38	4.69e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1448094	0.836	rs7313442	chr12:86405642	C/T	cg06740227	chr12:86229804	RASSF9	0.4	5.09	0.31	6.95e-7	Major depressive disorder;
KIRP	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.59	7.94	0.45	7.14e-14	Retinal vascular caliber;
KIRP	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.97	13.94	0.66	6.19e-33	Platelet distribution width;
KIRP	cis	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg11271282	chr2:238384023	NA	0.44	5.09	0.31	7e-7	Prostate cancer;
KIRP	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg18306943	chr3:40428807	ENTPD3	-0.41	-5.54	-0.33	7.91e-8	Renal cell carcinoma;
KIRP	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.47	0.48	2.24e-15	Eosinophil percentage of white cells;
KIRP	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23702897	chr4:2263850	MXD4	0.53	6.68	0.39	1.54e-10	Parkinson's disease;
KIRP	cis	rs4888378	0.600	rs729109	chr16:75316074	A/G	cg07303275	chr16:75499416	TMEM170A	-0.47	-5.77	-0.35	2.37e-8	Coronary artery disease;
KIRP	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	9.94	0.54	8.56e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10465746	0.935	rs12133778	chr1:84367626	A/G	cg10977910	chr1:84465055	TTLL7	0.47	5.59	0.34	6.05e-8	Obesity-related traits;
KIRP	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	11.31	0.58	3.72e-24	Menopause (age at onset);
KIRP	cis	rs963731	0.649	rs10439459	chr2:39236983	G/T	cg04010122	chr2:39346883	SOS1	-0.88	-6.15	-0.37	3.11e-9	Corticobasal degeneration;
KIRP	cis	rs3743162	0.553	rs12900463	chr15:85415386	T/C	cg17507749	chr15:85114479	UBE2QP1	0.58	5.87	0.35	1.4e-8	Alzheimer's disease (age of onset);
KIRP	cis	rs7113850	0.541	rs56679749	chr11:24235649	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	8.41	0.47	3.28e-15	Bone fracture in osteoporosis;
KIRP	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg24642439	chr20:33292090	TP53INP2	0.7	10.92	0.57	7.04e-23	Glomerular filtration rate (creatinine);
KIRP	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg02996583	chr8:142237188	SLC45A4	-0.42	-5.11	-0.31	6.34e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs71277158	0.688	rs12492606	chr3:169808354	A/G	cg04067573	chr3:169899625	PHC3	-0.6	-5.87	-0.35	1.41e-8	Prostate cancer;
KIRP	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.48	-6.59	-0.39	2.6e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg07274523	chr3:49395745	GPX1	0.69	5.01	0.3	1.03e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs10128264	0.902	rs1250583	chr10:80975004	A/G	cg18737081	chr10:80999807	ZMIZ1	0.29	5.34	0.32	2.06e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.23	-0.46	1.12e-14	Mean corpuscular volume;
KIRP	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.69	-9.04	-0.5	4.66e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg22654517	chr2:96458247	NA	0.35	5.41	0.33	1.51e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs78487399	0.808	rs111783562	chr2:43759381	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.93	-0.3	1.48e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13047869	chr3:10149882	C3orf24	0.51	4.86	0.3	2.05e-6	Alzheimer's disease;
KIRP	cis	rs654384	0.933	rs588123	chr7:4164277	G/A	cg21882563	chr7:4172065	SDK1	-0.39	-5.05	-0.31	8.48e-7	Positive affect;
KIRP	trans	rs17834760	0.909	rs62426164	chr6:62056951	G/T	cg08476511	chr6:168435923	KIF25	0.52	6.09	0.36	4.37e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11987759	chr7:65425863	GUSB	-0.69	-9.79	-0.53	2.49e-19	Aortic root size;
KIRP	cis	rs9488822	0.662	rs195521	chr6:116244114	T/C	cg15226275	chr6:116381976	FRK	0.2	5.25	0.32	3.35e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	7.42	0.43	1.95e-12	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-6.15	-0.36	3.16e-9	Aortic root size;
KIRP	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.51	-7.73	-0.44	2.82e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20685352	chr3:47823121	SMARCC1	0.53	6.57	0.39	2.99e-10	Parkinson's disease;
KIRP	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.31	5.59	0.34	6.07e-8	Calcium levels;
KIRP	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg00321850	chr1:175162397	KIAA0040	0.33	5.77	0.35	2.36e-8	Alcohol dependence;
KIRP	cis	rs3789045	0.729	rs16853822	chr1:204450341	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.59	-6.07	-0.36	4.78e-9	Educational attainment (college completion);
KIRP	cis	rs78487399	0.808	rs6752964	chr2:43754655	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-5.12	-0.31	6.04e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2820315	1.000	rs2644107	chr1:201818629	T/C	cg11586189	chr1:201857591	SHISA4	-0.39	-5.49	-0.33	1e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.63	-0.39	2.16e-10	Body mass index;
KIRP	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.88	-0.4	5.04e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg18478394	chr8:109455254	TTC35	0.44	5.19	0.31	4.31e-7	Dupuytren's disease;
KIRP	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.47	6.48	0.38	4.94e-10	Gut microbiome composition (summer);
KIRP	cis	rs282587	0.569	rs1756076	chr13:113395819	T/C	cg04656015	chr13:113407548	ATP11A	0.63	7.31	0.42	3.82e-12	Glycated hemoglobin levels;
KIRP	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.29	-0.55	7.09e-21	Hypospadias;
KIRP	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.53	7.28	0.42	4.52e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12496230	0.794	rs12633969	chr3:66859170	A/C	cg17646820	chr3:66848679	NA	-0.39	-6.3	-0.37	1.38e-9	Type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26385013	chr3:98249859	GPR15	0.48	6.65	0.39	1.92e-10	Interleukin-4 levels;
KIRP	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg05802129	chr4:122689817	NA	-0.48	-6.92	-0.4	3.99e-11	Type 2 diabetes;
KIRP	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.18	25.78	0.85	7.02e-72	Schizophrenia;
KIRP	cis	rs10788264	0.716	rs7091348	chr10:124016160	C/T	cg09507567	chr10:124027408	NA	0.29	5.33	0.32	2.26e-7	Total body bone mineral density;
KIRP	cis	rs6681460	0.674	rs2121051	chr1:67017177	G/A	cg02459107	chr1:67143332	SGIP1	0.39	5.28	0.32	2.83e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg26248373	chr2:1572462	NA	-0.72	-9.56	-0.52	1.26e-18	IgG glycosylation;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg25365034	chr2:23785230	KLHL29	0.46	6.6	0.39	2.5e-10	Serum protein levels (sST2);
KIRP	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.79	-0.4	8.53e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.73	10.02	0.54	4.82e-20	Red blood cell count;
KIRP	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	1.08	16.83	0.73	8.02e-43	Cognitive function;
KIRP	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg23587288	chr2:27483067	SLC30A3	-0.66	-7.46	-0.43	1.46e-12	Blood metabolite levels;
KIRP	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.66	7.57	0.43	7.58e-13	Corneal astigmatism;
KIRP	cis	rs4356932	1.000	rs10003382	chr4:76955473	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18252515	chr7:66147081	NA	-0.46	-5.68	-0.34	3.76e-8	Aortic root size;
KIRP	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	0.81	6.98	0.41	2.66e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06850241	chr22:41845214	NA	-0.43	-5.26	-0.32	3.09e-7	Vitiligo;
KIRP	cis	rs7335046	0.614	rs61176003	chr13:100088711	G/A	cg25919922	chr13:100150906	NA	-0.55	-5.06	-0.31	8.15e-7	Basal cell carcinoma;
KIRP	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-0.76	-9.01	-0.5	5.76e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-5.45	-0.33	1.24e-7	Testicular germ cell tumor;
KIRP	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.25e-10	Protein C levels;
KIRP	cis	rs4006360	0.543	rs937403	chr17:39296016	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.52	-6.82	-0.4	6.84e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-5.42	-0.33	1.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.06	0.64	5.78e-30	Exhaled nitric oxide output;
KIRP	cis	rs17209837	1.000	rs6465116	chr7:87113001	G/A	cg00919237	chr7:87102261	ABCB4	-0.68	-6.74	-0.4	1.09e-10	Gallbladder cancer;
KIRP	cis	rs9653442	0.527	rs10185059	chr2:100790172	C/T	cg17356467	chr2:100759845	AFF3	0.44	5.63	0.34	4.78e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.96	-0.41	3.13e-11	Initial pursuit acceleration;
KIRP	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.25	-0.32	3.27e-7	Skin colour saturation;
KIRP	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.69	-6.88	-0.4	5.01e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.73	11.42	0.59	1.6e-24	Menarche (age at onset);
KIRP	cis	rs11168351	0.927	rs10875716	chr12:48389023	C/T	cg21466736	chr12:48725269	NA	-0.44	-5.38	-0.32	1.73e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg21605333	chr4:119757512	SEC24D	1.56	10.58	0.56	8.15e-22	Cannabis dependence symptom count;
KIRP	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.47	-6.4	-0.38	8.01e-10	Schizophrenia;
KIRP	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg14289246	chr4:154710475	SFRP2	-0.52	-6.83	-0.4	6.5e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.3	0.37	1.35e-9	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4950322	0.543	rs2883323	chr1:146788708	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	1.04	8.04	0.46	3.81e-14	Skin colour saturation;
KIRP	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg05585630	chr7:157510462	PTPRN2	-0.5	-6.7	-0.39	1.39e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs12517041	0.935	rs10062553	chr5:23294800	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs4716602	0.596	rs10267031	chr7:156159649	A/G	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.5	0.48	1.83e-15	Bipolar disorder;
KIRP	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25517755	chr10:38738941	LOC399744	-0.52	-7.3	-0.42	3.85e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.46	6.76	0.4	9.91e-11	Urate levels in lean individuals;
KIRP	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg00042356	chr1:8021962	PARK7	0.75	6.37	0.38	9.39e-10	Inflammatory bowel disease;
KIRP	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	12.11	0.61	8.88e-27	Smoking behavior;
KIRP	cis	rs9217	0.841	rs11078685	chr17:7411447	C/T	cg02795151	chr17:7402630	POLR2A	-0.58	-7.11	-0.41	1.22e-11	Height;
KIRP	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-1.24	-12.61	-0.63	1.89e-28	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14593314	chr6:44191312	SLC29A1	0.46	6.08	0.36	4.57e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg21775007	chr8:11205619	TDH	-0.53	-6.8	-0.4	7.81e-11	Neuroticism;
KIRP	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg17796960	chr10:135278976	LOC619207	-0.48	-5.53	-0.33	8.27e-8	Systemic lupus erythematosus;
KIRP	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.75	7.56	0.43	8.2e-13	Bipolar disorder;
KIRP	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.95	-11.09	-0.58	1.95e-23	Colorectal cancer;
KIRP	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg18196295	chr10:418757	DIP2C	0.43	5.39	0.32	1.67e-7	Psychosis in Alzheimer's disease;
KIRP	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.63	-0.44	5.25e-13	Type 2 diabetes;
KIRP	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	0.98	15.59	0.7	1.45e-38	Multiple system atrophy;
KIRP	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.13	10.95	0.57	5.37e-23	Alzheimer's disease (late onset);
KIRP	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.45	-6.54	-0.38	3.57e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs7221595	0.825	rs9905748	chr17:3968639	C/T	cg21851534	chr17:3907994	ZZEF1	0.6	6.33	0.37	1.17e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.81	10.46	0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.55	-0.39	3.36e-10	Response to antipsychotic treatment;
KIRP	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.53	-6.21	-0.37	2.3e-9	Aortic root size;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg12692727	chr7:1102344	C7orf50	0.47	5.04	0.31	9.21e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.61	9.11	0.5	2.99e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10267417	0.603	rs36077006	chr7:19933853	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	5.14	0.31	5.7e-7	Night sleep phenotypes;
KIRP	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11245990	chr11:68621969	NA	-0.37	-5.07	-0.31	7.81e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg10351095	chr21:47802916	PCNT	-0.43	-5.52	-0.33	8.42e-8	Testicular germ cell tumor;
KIRP	cis	rs4664293	0.805	rs7593273	chr2:160605860	T/G	cg08347373	chr2:160653686	CD302	-0.42	-6.48	-0.38	4.95e-10	Monocyte percentage of white cells;
KIRP	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg00800038	chr16:89945340	TCF25	-0.89	-7.28	-0.42	4.62e-12	Skin colour saturation;
KIRP	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.12	0.31	6.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	1.23	11.13	0.58	1.44e-23	Birth weight;
KIRP	cis	rs13034020	0.522	rs35217978	chr2:61246548	A/G	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.29	0.37	1.44e-9	Hodgkin's lymphoma;
KIRP	cis	rs42648	0.935	rs42668	chr7:89986525	A/C	cg25739043	chr7:89950458	NA	-0.44	-6.79	-0.4	8.54e-11	Homocysteine levels;
KIRP	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.6	7.28	0.42	4.36e-12	Platelet count;
KIRP	cis	rs4787491	0.729	rs11544328	chr16:30037128	A/C	cg06326092	chr16:30034487	C16orf92	0.5	7.86	0.45	1.23e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.66	-9.1	-0.5	3.16e-17	Hypospadias;
KIRP	cis	rs17799476	0.938	rs56033319	chr2:46358886	G/C	cg12428440	chr2:46370979	PRKCE	0.53	4.93	0.3	1.52e-6	Hemoglobin concentration;Hematocrit;
KIRP	trans	rs1021487	1.000	rs1021487	chr4:59457085	C/T	cg17294928	chr15:75287854	SCAMP5	0.6	6.06	0.36	5.1e-9	Schizophrenia;
KIRP	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg16497661	chr14:103986332	CKB	0.43	5.59	0.34	5.93e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.2	-0.31	4.21e-7	Bladder cancer;
KIRP	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg19338460	chr6:170058176	WDR27	-0.73	-8.0	-0.45	4.97e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.67	-7.82	-0.45	1.51e-13	IgG glycosylation;
KIRP	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg04568710	chr12:38710424	ALG10B	-0.38	-4.89	-0.3	1.8e-6	Morning vs. evening chronotype;
KIRP	cis	rs17767294	0.541	rs72845051	chr6:27610545	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.72	-5.39	-0.32	1.66e-7	Parkinson's disease;
KIRP	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.42	0.43	1.92e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.7	9.63	0.52	8.06e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg11584989	chr19:19387371	SF4	0.42	5.32	0.32	2.37e-7	Tonsillectomy;
KIRP	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.17	-15.29	-0.7	1.48e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg05220968	chr6:146057943	EPM2A	-0.38	-4.95	-0.3	1.37e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7712401	0.601	rs30069	chr5:122293026	A/G	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07520141	chr5:10564205	ANKRD33B	0.64	7.62	0.44	5.56e-13	Smoking initiation;
KIRP	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.05	0.41	1.79e-11	Lung cancer;
KIRP	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg09754948	chr16:28834200	ATXN2L	0.5	5.87	0.35	1.41e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8133932	0.654	rs2839041	chr21:47322616	T/C	cg11214348	chr21:47283868	PCBP3	0.46	5.26	0.32	3.09e-7	Schizophrenia;
KIRP	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.48	6.37	0.38	9.09e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg07862535	chr7:139043722	LUC7L2	-0.47	-5.31	-0.32	2.47e-7	Diisocyanate-induced asthma;
KIRP	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.63	-8.65	-0.48	6.64e-16	Menarche (age at onset);
KIRP	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.58	7.91	0.45	8.52e-14	Ulcerative colitis;
KIRP	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg14972814	chr11:95582409	MTMR2	0.36	6.08	0.36	4.56e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs300890	0.513	rs6812522	chr4:144098071	G/A	cg01719995	chr4:144104893	USP38	0.43	5.52	0.33	8.64e-8	Nasopharyngeal carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15209945	chr19:13261065	IER2;STX10	0.57	7.22	0.42	6.63e-12	Parkinson's disease;
KIRP	cis	rs829661	0.532	rs829626	chr2:30756528	C/G	cg10949345	chr2:30726833	LCLAT1	0.48	7.08	0.41	1.54e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.46	5.92	0.35	1.07e-8	IgG glycosylation;
KIRP	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg26576206	chr19:1064938	ABCA7	0.37	5.14	0.31	5.59e-7	Alzheimer's disease (late onset);
KIRP	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg15660573	chr17:549704	VPS53	-0.96	-15.05	-0.69	9.84e-37	Prostate cancer;
KIRP	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg23127183	chr11:57508653	C11orf31	-0.46	-6.25	-0.37	1.78e-9	Schizophrenia;
KIRP	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg02475777	chr4:1388615	CRIPAK	0.36	4.93	0.3	1.49e-6	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05929645	chr1:52456024	RAB3B	-0.52	-6.79	-0.4	8.12e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	7.19	0.42	7.81e-12	Bipolar disorder;
KIRP	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.92	15.96	0.71	7.66e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs35740288	0.770	rs11638379	chr15:86111290	G/T	cg10818794	chr15:86012489	AKAP13	-0.47	-5.67	-0.34	4.03e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg06618935	chr21:46677482	NA	-0.44	-5.54	-0.33	7.6e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-1.03	-11.14	-0.58	1.31e-23	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	7.24	0.42	5.74e-12	Bipolar disorder;
KIRP	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.86	-7.74	-0.44	2.64e-13	Coronary artery disease;
KIRP	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.89	15.35	0.7	9.09e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs2130392	0.562	rs876838	chr4:185655487	G/T	cg04058563	chr4:185651563	MLF1IP	-0.43	-5.76	-0.34	2.47e-8	Kawasaki disease;
KIRP	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg00129232	chr17:37814104	STARD3	-0.67	-7.25	-0.42	5.53e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.65	10.05	0.54	4.02e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg04289385	chr6:36355825	ETV7	-0.48	-7.54	-0.43	9.23e-13	Platelet distribution width;
KIRP	cis	rs4908768	1.000	rs7523186	chr1:8655495	C/T	cg25722041	chr1:8623473	RERE	-0.61	-7.37	-0.43	2.6e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.8	9.01	0.5	5.79e-17	Corneal astigmatism;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg14820908	chr5:178986412	RUFY1	0.55	8.43	0.47	2.97e-15	Lung cancer;
KIRP	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg16524733	chr11:117070046	TAGLN	0.4	5.01	0.3	1.03e-6	Blood protein levels;
KIRP	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg05347473	chr6:146136440	FBXO30	0.46	6.76	0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21436751	chr20:18118344	PET117	0.56	6.59	0.39	2.64e-10	Lung cancer in ever smokers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26916470	chr14:32546448	ARHGAP5;C14orf128	0.46	6.38	0.38	8.94e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.45e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.1	0.36	4.16e-9	Lung cancer;
KIRP	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.07	12.87	0.63	2.44e-29	Vitiligo;
KIRP	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-8.3	-0.47	7.13e-15	Coronary artery disease;
KIRP	cis	rs8192282	0.739	rs12118074	chr1:154477585	G/A	cg07911225	chr1:154474108	TDRD10;SHE	-0.34	-5.0	-0.3	1.08e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg06935464	chr4:38784597	TLR10	0.56	5.78	0.35	2.25e-8	Breast cancer;
KIRP	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg25182066	chr10:30743637	MAP3K8	-0.64	-8.7	-0.48	5e-16	Inflammatory bowel disease;
KIRP	cis	rs7712401	0.601	rs246268	chr5:122256342	C/T	cg19412675	chr5:122181750	SNX24	0.45	4.98	0.3	1.21e-6	Mean platelet volume;
KIRP	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01256522	chr21:15755449	HSPA13	-0.43	-6.14	-0.36	3.32e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00149659	chr3:10157352	C3orf10	0.56	6.61	0.39	2.37e-10	Alzheimer's disease;
KIRP	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg13010199	chr12:38710504	ALG10B	-0.5	-6.5	-0.38	4.37e-10	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg24315340	chr6:146058215	EPM2A	0.45	5.65	0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg00684032	chr4:1343700	KIAA1530	0.45	5.39	0.32	1.68e-7	Longevity;
KIRP	cis	rs7601312	0.904	rs6729779	chr2:229308856	A/G	cg02542817	chr2:229291442	NA	-0.38	-5.49	-0.33	1.02e-7	Schizophrenia;
KIRP	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg02836325	chr17:76403955	PGS1	0.4	6.64	0.39	2.04e-10	HDL cholesterol levels;
KIRP	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05220968	chr6:146057943	EPM2A	0.41	5.24	0.32	3.53e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19354750	chr17:61554413	ACE	-0.4	-6.04	-0.36	5.6e-9	Metabolic traits;
KIRP	cis	rs2411233	0.935	rs2898672	chr15:39292434	C/T	cg05886626	chr15:39873553	THBS1	0.32	4.87	0.3	2.02e-6	Platelet count;
KIRP	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03934478	chr11:495069	RNH1	0.94	7.54	0.43	8.85e-13	Body mass index;
KIRP	trans	rs17801127	0.818	rs17744655	chr2:150566319	T/G	cg05023168	chr6:90351415	NA	0.75	6.1	0.36	4.1e-9	Liver enzyme levels (alanine transaminase);
KIRP	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.62	-9.42	-0.51	3.44e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.54	-0.43	8.94e-13	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25748391	chr11:1330779	TOLLIP;LOC255512	0.51	7.17	0.42	8.53e-12	Survival in pancreatic cancer;
KIRP	trans	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg06521331	chr12:34319734	NA	-0.51	-6.24	-0.37	1.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.69	8.82	0.49	2.21e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs35740288	0.857	rs3803506	chr15:86290940	A/C	cg10818794	chr15:86012489	AKAP13	-0.41	-4.87	-0.3	2.02e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg23166289	chr1:210001082	C1orf107	0.51	5.58	0.33	6.5e-8	Orofacial clefts;
KIRP	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg20701182	chr2:24300061	SF3B14	0.51	5.27	0.32	3.02e-7	Asthma;
KIRP	cis	rs76917914	0.561	rs2224773	chr9:100824223	C/A	cg03040243	chr9:100819229	NANS	0.5	5.44	0.33	1.27e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9914544	0.628	rs4630608	chr17:18678548	C/T	cg26306683	chr17:18585705	ZNF286B	0.4	4.96	0.3	1.34e-6	Educational attainment (years of education);
KIRP	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.44	-0.33	1.27e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg00405596	chr8:11794950	NA	-0.47	-6.12	-0.36	3.64e-9	Retinal vascular caliber;
KIRP	trans	rs1973993	0.745	rs6593606	chr1:96968005	C/T	cg10631902	chr5:14652156	NA	-0.59	-8.32	-0.47	6.18e-15	Weight;
KIRP	cis	rs4523957	0.819	rs12450354	chr17:2159982	C/T	cg16513277	chr17:2031491	SMG6	0.58	8.01	0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs838147	0.733	rs8106205	chr19:49250197	T/C	cg13540341	chr19:49222985	MAMSTR	0.33	5.21	0.32	4e-7	Dietary macronutrient intake;
KIRP	cis	rs6956675	0.831	rs10268923	chr7:62652624	C/G	cg08930214	chr7:62859557	LOC100287834	0.42	5.17	0.31	4.84e-7	Obesity-related traits;
KIRP	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs10465746	0.967	rs12757632	chr1:84416408	T/C	cg10977910	chr1:84465055	TTLL7	0.47	5.77	0.35	2.37e-8	Obesity-related traits;
KIRP	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg16482183	chr6:26056742	HIST1H1C	0.63	7.38	0.43	2.4e-12	Iron status biomarkers;
KIRP	cis	rs7523273	1.000	rs34385765	chr1:207993637	A/G	cg22525895	chr1:207977042	MIR29B2	-0.66	-8.2	-0.46	1.36e-14	Schizophrenia;
KIRP	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg24315340	chr6:146058215	EPM2A	0.4	4.94	0.3	1.47e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60871478	0.853	rs62432222	chr7:787194	T/C	cg05535760	chr7:792225	HEATR2	0.87	8.55	0.48	1.32e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg23752985	chr2:85803571	VAMP8	0.46	5.3	0.32	2.51e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.82	10.2	0.55	1.36e-20	Corneal astigmatism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17031898	chr4:145563731	NA	0.38	6.44	0.38	6.19e-10	C-reactive protein;
KIRP	cis	rs2494938	0.819	rs10947898	chr6:40532893	C/G	cg14084896	chr6:40530702	LRFN2	0.38	4.98	0.3	1.19e-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg06675538	chr2:114033490	PAX8;LOC440839	-0.44	-7.55	-0.43	8.61e-13	Lymphocyte counts;
KIRP	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg13147721	chr7:65941812	NA	-1.0	-6.94	-0.4	3.42e-11	Diabetic kidney disease;
KIRP	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.84	-12.37	-0.62	1.17e-27	Total body bone mineral density;
KIRP	cis	rs55788414	0.932	rs12102728	chr16:81181436	C/T	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.17	-0.46	1.58e-14	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.89	-15.41	-0.7	5.92e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg05991184	chr2:219186017	PNKD	0.34	4.9	0.3	1.73e-6	Colorectal cancer;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg24201716	chr10:115933917	C10orf118;MIR2110	-0.46	-6.04	-0.36	5.53e-9	Morning vs. evening chronotype;
KIRP	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.09	-0.31	7.03e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-5.97	-0.36	8.4e-9	Parkinson's disease;
KIRP	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.06	-0.31	8.05e-7	Schizophrenia;
KIRP	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.83	0.45	1.42e-13	Corneal astigmatism;
KIRP	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg24296786	chr1:45957014	TESK2	0.65	8.77	0.49	3.1e-16	High light scatter reticulocyte count;
KIRP	cis	rs3736594	0.513	rs60854669	chr2:27786929	T/C	cg27432699	chr2:27873401	GPN1	0.56	6.2	0.37	2.37e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.52	-5.62	-0.34	5.26e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20905760	chr15:43478003	CCNDBP1	0.45	4.96	0.3	1.32e-6	Lung cancer in ever smokers;
KIRP	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.79	10.57	0.56	9.25e-22	Resting heart rate;
KIRP	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg03289416	chr15:75166202	SCAMP2	0.58	7.61	0.44	5.9e-13	Caffeine consumption;
KIRP	cis	rs1413885	0.516	rs11208637	chr1:65836553	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.61	0.34	5.54e-8	Anticoagulant levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07196858	chr1:2085232	PRKCZ	0.42	6.3	0.37	1.39e-9	Interleukin-4 levels;
KIRP	cis	rs96067	0.652	rs274132	chr1:36581978	C/T	cg27506609	chr1:36549197	TEKT2	0.78	6.91	0.4	4.05e-11	Corneal structure;
KIRP	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg00647317	chr7:50633725	DDC	0.45	6.94	0.4	3.53e-11	Body mass index;
KIRP	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg05973401	chr12:123451056	ABCB9	0.58	6.71	0.39	1.37e-10	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.77	-9.46	-0.52	2.67e-18	Breast cancer;
KIRP	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.17	12.83	0.63	3.51e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs1034435	0.547	rs743846	chr22:48900819	C/T	cg05992904	chr22:48892994	FAM19A5	-0.66	-7.98	-0.45	5.47e-14	Late-onset Alzheimer's disease;
KIRP	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg24747557	chr10:131355152	MGMT	-0.38	-5.16	-0.31	4.99e-7	Response to temozolomide;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12461364	chr10:12084985	UPF2	0.48	6.13	0.36	3.5e-9	Parkinson's disease;
KIRP	cis	rs3126085	0.560	rs941935	chr1:152339488	A/G	cg26876637	chr1:152193138	HRNR	-0.57	-6.22	-0.37	2.11e-9	Atopic dermatitis;
KIRP	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.31	5.87	0.35	1.37e-8	Asthma (sex interaction);
KIRP	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.78	-9.48	-0.52	2.18e-18	Parkinson's disease;
KIRP	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg09699651	chr6:150184138	LRP11	0.44	5.61	0.34	5.49e-8	Lung cancer;
KIRP	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg23594656	chr7:65796392	TPST1	0.35	5.03	0.31	9.67e-7	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25483749	chr7:16696735	BZW2	-0.45	-6.86	-0.4	5.7e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.71	-8.29	-0.47	7.51e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	1.26	9.27	0.51	9.57e-18	LDL cholesterol;
KIRP	cis	rs7084402	0.935	rs1658456	chr10:60304326	C/T	cg05938607	chr10:60274200	BICC1	-0.42	-9.8	-0.53	2.4e-19	Refractive error;
KIRP	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg26727032	chr16:67993705	SLC12A4	-0.77	-8.75	-0.49	3.45e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2671245	0.898	rs2671232	chr1:56162109	C/G	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg00277334	chr10:82204260	NA	-0.62	-6.33	-0.37	1.18e-9	Post bronchodilator FEV1;
KIRP	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg00864860	chr1:7907996	UTS2	0.45	5.37	0.32	1.8e-7	Crohn's disease;
KIRP	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg00255919	chr5:131827918	IRF1	-0.3	-6.45	-0.38	5.99e-10	Asthma (sex interaction);
KIRP	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.56	7.81	0.45	1.63e-13	Night sleep phenotypes;
KIRP	cis	rs8012145	0.543	rs1951440	chr14:55186813	C/T	cg19913537	chr14:55186044	SAMD4A	0.32	4.93	0.3	1.51e-6	Plateletcrit;
KIRP	cis	rs9400467	0.528	rs56827	chr6:111623203	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.41	-5.36	-0.32	1.87e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.84	-0.4	6.34e-11	Diastolic blood pressure;
KIRP	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.56	7.05	0.41	1.76e-11	Breast cancer;
KIRP	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.79	-10.28	-0.55	7.51e-21	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg23625390	chr15:77176239	SCAPER	0.47	6.19	0.37	2.55e-9	Blood metabolite levels;
KIRP	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	6.32	0.37	1.21e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6545883	0.825	rs7578139	chr2:61564121	G/A	cg15711740	chr2:61764176	XPO1	0.61	7.95	0.45	6.81e-14	Tuberculosis;
KIRP	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg21775007	chr8:11205619	TDH	-0.42	-5.35	-0.32	2.06e-7	Neuroticism;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg21803754	chr20:60718392	PSMA7;SS18L1	0.52	6.49	0.38	4.61e-10	Myopia (pathological);
KIRP	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg00800038	chr16:89945340	TCF25	0.56	6.25	0.37	1.77e-9	Skin colour saturation;
KIRP	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.06	0.31	8.17e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9653442	0.510	rs12712068	chr2:100764439	A/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg03734594	chr13:111297400	CARS2	0.37	5.59	0.34	6.17e-8	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.76e-8	Life satisfaction;
KIRP	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	8.32	0.47	5.94e-15	Total body bone mineral density;
KIRP	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.93	-12.24	-0.62	3.17e-27	Platelet distribution width;
KIRP	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg18357526	chr6:26021779	HIST1H4A	0.4	5.17	0.31	4.76e-7	Height;
KIRP	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg22800045	chr5:56110881	MAP3K1	0.79	8.52	0.48	1.6e-15	Initial pursuit acceleration;
KIRP	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg13444842	chr1:152974279	SPRR3	-0.35	-4.97	-0.3	1.28e-6	Inflammatory skin disease;
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg23533926	chr12:111358616	MYL2	-0.48	-6.26	-0.37	1.67e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg23324259	chr8:82754387	SNX16	0.45	4.96	0.3	1.32e-6	Diastolic blood pressure;
KIRP	cis	rs17123764	0.710	rs7296281	chr12:49964558	A/G	cg02054252	chr12:50078554	FMNL3	0.42	4.87	0.3	2.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg20295408	chr7:1910781	MAD1L1	-0.55	-6.09	-0.36	4.4e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs16958440	1.000	rs2289131	chr18:44602864	G/A	cg17192377	chr18:44677553	HDHD2	0.75	6.98	0.41	2.8e-11	Sitting height ratio;
KIRP	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg23100626	chr2:96804247	ASTL	0.54	8.22	0.46	1.21e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9309473	0.948	rs6719753	chr2:73749054	T/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.41	-0.33	1.52e-7	Metabolite levels;
KIRP	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.81	12.03	0.61	1.63e-26	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08073142	chr16:24740747	TNRC6A	0.5	6.15	0.37	3.09e-9	Parkinson's disease;
KIRP	cis	rs6132905	0.590	rs78781119	chr20:2612417	T/C	cg24848351	chr20:2622020	TMC2	-0.59	-5.19	-0.31	4.32e-7	Mumps;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg06815112	chr8:27182871	PTK2B	0.5	6.41	0.38	7.35e-10	Neuroticism;
KIRP	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.53	0.48	1.52e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs258892	0.793	rs6452682	chr5:72082390	T/G	cg21869765	chr5:72125136	TNPO1	-0.55	-5.94	-0.35	9.53e-9	Small cell lung carcinoma;
KIRP	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.47	5.23	0.32	3.67e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg08890418	chr1:21044141	KIF17	0.43	6.59	0.39	2.69e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.2	21.98	0.81	5.85e-60	Cognitive function;
KIRP	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.07	0.64	5.42e-30	Tonsillectomy;
KIRP	cis	rs67079557	1	rs67079557	chr15:75930300	ATAATAAG/A	cg20655648	chr15:75932815	IMP3	0.6	7.54	0.43	8.91e-13	Breast cancer;
KIRP	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.81	13.25	0.65	1.28e-30	Schizophrenia;
KIRP	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.76	9.97	0.54	6.77e-20	Menopause (age at onset);
KIRP	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg25547332	chr5:131281432	NA	0.5	5.94	0.35	9.55e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7106204	0.609	rs16912369	chr11:24297601	C/T	ch.11.24196551F	chr11:24239977	NA	0.68	5.11	0.31	6.58e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1538970	0.961	rs7553318	chr1:45843086	A/G	cg05343316	chr1:45956843	TESK2	0.66	7.7	0.44	3.38e-13	Platelet count;
KIRP	cis	rs9815354	0.761	rs12186109	chr3:41836920	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	15.12	0.69	5.79e-37	Alzheimer's disease;
KIRP	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg00277334	chr10:82204260	NA	-0.49	-5.6	-0.34	5.76e-8	Post bronchodilator FEV1;
KIRP	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg17810781	chr1:201082982	CACNA1S	0.43	6.71	0.39	1.3100000000000001e-10	Permanent tooth development;
KIRP	cis	rs75920871	0.748	rs7946219	chr11:116962759	C/T	cg04087571	chr11:116723030	SIK3	-0.28	-5.55	-0.33	7.48e-8	Subjective well-being;
KIRP	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.71	8.36	0.47	4.58e-15	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12371681	chr3:125239117	SNX4	0.5	6.25	0.37	1.84e-9	Parkinson's disease;
KIRP	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg23958373	chr8:599963	NA	-1.03	-6.2	-0.37	2.34e-9	IgG glycosylation;
KIRP	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg01872077	chr2:219646372	CYP27A1	0.42	5.45	0.33	1.2e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg03474202	chr17:45855739	NA	-0.42	-5.91	-0.35	1.14e-8	IgG glycosylation;
KIRP	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.82	-11.64	-0.6	3.17e-25	Total body bone mineral density;
KIRP	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	0.54	6.42	0.38	7.02e-10	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27095527	chr3:12329080	PPARG	0.49	6.38	0.38	8.94e-10	Parkinson's disease;
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg01721255	chr8:58191610	C8orf71	0.63	5.58	0.34	6.27e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.66	-7.98	-0.45	5.68e-14	Blood protein levels;
KIRP	cis	rs501120	0.657	rs649192	chr10:44741179	G/C	cg09554077	chr10:44749378	NA	0.77	11.99	0.61	2.1e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.7	8.31	0.47	6.48e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-9.25	-0.51	1.15e-17	Hemoglobin concentration;
KIRP	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	0.97	10.77	0.57	2.11e-22	Type 2 diabetes nephropathy;
KIRP	cis	rs2275620	0.501	rs1853208	chr10:96663819	A/G	cg09036531	chr10:96991505	NA	-0.48	-5.69	-0.34	3.64e-8	Gout;
KIRP	cis	rs7213347	0.707	rs216215	chr17:2140668	C/T	cg15816464	chr17:2026533	SMG6	0.34	5.11	0.31	6.42e-7	Total body bone mineral density;
KIRP	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs9308433	0.553	rs2047445	chr1:214469962	G/A	cg06198575	chr1:214491504	SMYD2	0.53	6.62	0.39	2.21e-10	IgG glycosylation;
KIRP	cis	rs911119	0.908	rs12624424	chr20:23601878	C/T	cg16589663	chr20:23618590	CST3	0.68	6.28	0.37	1.49e-9	Chronic kidney disease;
KIRP	trans	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg11693508	chr17:37793320	STARD3	0.84	8.41	0.47	3.32e-15	Neuroticism;
KIRP	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.75	-0.4	1.03e-10	Capecitabine sensitivity;
KIRP	cis	rs7116495	1.000	rs3018302	chr11:71790942	A/C	cg26138937	chr11:71823887	C11orf51	-0.71	-5.64	-0.34	4.59e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.86	-10.88	-0.57	9.25e-23	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs4762326	0.584	rs12371088	chr12:95678387	A/G	cg07737802	chr12:95537812	FGD6	0.39	5.2	0.31	4.2e-7	Endometriosis;
KIRP	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg00204512	chr16:28754710	NA	0.45	6.01	0.36	6.7e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.24	-5.31	-0.32	2.51e-7	Type 2 diabetes;
KIRP	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg00990874	chr7:1149470	C7orf50	-0.8	-8.22	-0.46	1.2e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg15893493	chr8:124194847	FAM83A	0.93	8.13	0.46	2.14e-14	Urinary uromodulin levels;
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg01763666	chr17:80159506	CCDC57	0.36	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg00204512	chr16:28754710	NA	0.41	5.34	0.32	2.16e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11673344	0.764	rs13345491	chr19:37473099	G/T	cg14683738	chr19:37701593	ZNF585B	-0.43	-5.02	-0.3	9.93e-7	Obesity-related traits;
KIRP	cis	rs865483	0.895	rs853234	chr17:35843050	A/G	cg06716730	chr17:35851459	DUSP14	-0.25	-6.0	-0.36	7.18e-9	Monocyte count;
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.52	-6.28	-0.37	1.55e-9	Longevity;Endometriosis;
KIRP	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg11005552	chr10:105648138	OBFC1	0.41	5.73	0.34	2.9e-8	Coronary artery disease;
KIRP	cis	rs865483	0.895	rs2107104	chr17:35835031	G/A	cg06716730	chr17:35851459	DUSP14	0.25	6.04	0.36	5.61e-9	Monocyte count;
KIRP	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.63	8.05	0.46	3.63e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs10875746	0.903	rs989144	chr12:48483973	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.5	-6.45	-0.38	5.82e-10	Systolic blood pressure;
KIRP	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00908189	chr16:619842	PIGQ	0.85	11.76	0.6	1.28e-25	Height;
KIRP	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.69	9.31	0.51	7.27e-18	Prostate cancer;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg01238044	chr22:24384105	GSTT1	-0.55	-7.36	-0.42	2.75e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs13359291	0.658	rs2287696	chr5:122460332	G/A	cg16368670	chr5:122501738	PRDM6	-0.48	-5.45	-0.33	1.23e-7	Systolic blood pressure;
KIRP	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg03808351	chr9:123631620	PHF19	0.43	5.75	0.34	2.6e-8	Birth weight;
KIRP	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.41	-0.38	7.53e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.54	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs2414059	0.518	rs11070776	chr15:50735488	G/A	cg05456662	chr15:50716270	USP8	0.4	5.55	0.33	7.53e-8	QT interval;
KIRP	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.62	8.53	0.48	1.56e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2117029	0.619	rs2753	chr12:49521672	C/T	cg24176009	chr12:49580217	TUBA1A	-0.39	-5.33	-0.32	2.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs244293	0.730	rs12945579	chr17:53022714	A/T	cg07707039	chr17:53042137	COX11	-0.4	-5.07	-0.31	7.85e-7	Menarche (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06616338	chr11:695893	TMEM80;DEAF1	-0.47	-6.59	-0.39	2.63e-10	Metabolic traits;
KIRP	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg00383909	chr3:49044727	WDR6	-0.58	-5.61	-0.34	5.49e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg06289844	chr6:126071538	HEY2	0.43	6.22	0.37	2.09e-9	Brugada syndrome;
KIRP	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg21854759	chr1:92012499	NA	-0.48	-5.79	-0.35	2.11e-8	Breast cancer;
KIRP	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg26441486	chr22:50317300	CRELD2	0.55	9.05	0.5	4.39e-17	Schizophrenia;
KIRP	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.67	6.67	0.39	1.67e-10	Axial length;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg23693289	chr8:27183097	PTK2B	0.58	7.41	0.43	1.98e-12	Neuroticism;
KIRP	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.56	-6.23	-0.37	2.05e-9	Menarche (age at onset);
KIRP	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.92	12.8	0.63	4.3e-29	Menopause (age at onset);
KIRP	trans	rs13170463	0.579	rs116069632	chr5:8048216	T/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs4809219	1	rs4809219	chr20:62303115	C/A	cg11503966	chr20:62272292	STMN3	0.44	6.13	0.36	3.54e-9	Atopic dermatitis;
KIRP	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.93	12.15	0.61	6.51e-27	Menopause (age at onset);
KIRP	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg00677455	chr12:58241039	CTDSP2	0.98	12.65	0.63	1.36e-28	Multiple sclerosis;
KIRP	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg04662567	chr6:169592167	NA	-0.74	-6.66	-0.39	1.76e-10	Pulse pressure;
KIRP	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg03714773	chr7:91764589	CYP51A1	0.35	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-0.71	-8.38	-0.47	4.08e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.68	-12.44	-0.62	6.84e-28	White blood cell count (basophil);
KIRP	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.86	13.67	0.66	4.93e-32	Prostate cancer;
KIRP	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg11995313	chr8:8860691	ERI1	0.4	5.39	0.32	1.68e-7	Joint mobility (Beighton score);
KIRP	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg00982548	chr2:198649783	BOLL	-0.54	-5.07	-0.31	7.65e-7	Ulcerative colitis;
KIRP	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	0.99	7.51	0.43	1.08e-12	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	0.98	11.14	0.58	1.33e-23	Iron status biomarkers;
KIRP	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.57	7.47	0.43	1.38e-12	Vitiligo;
KIRP	cis	rs8077577	0.945	rs8069094	chr17:18096528	C/T	cg18869244	chr17:18121946	NA	0.45	5.12	0.31	6.26e-7	Obesity-related traits;
KIRP	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.54	-6.61	-0.39	2.35e-10	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.64	9.01	0.5	5.7e-17	Schizophrenia;
KIRP	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg16989719	chr2:238392110	NA	-0.63	-6.11	-0.36	3.88e-9	Prostate cancer;
KIRP	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23978390	chr7:1156363	C7orf50	0.55	7.03	0.41	1.97e-11	Longevity;Endometriosis;
KIRP	cis	rs11225247	1.000	rs12275185	chr11:102272277	G/T	cg06323957	chr11:102217781	BIRC2	0.98	6.08	0.36	4.57e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg27068330	chr11:65405492	SIPA1	0.38	5.15	0.31	5.33e-7	Acne (severe);
KIRP	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg00981070	chr1:2046702	PRKCZ	-0.35	-5.28	-0.32	2.87e-7	Height;
KIRP	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.29	-0.32	2.75e-7	Breast cancer;
KIRP	cis	rs2274273	0.806	rs7146752	chr14:55738907	A/G	cg04306507	chr14:55594613	LGALS3	0.53	8.22	0.46	1.2e-14	Protein biomarker;
KIRP	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg22963979	chr7:1858916	MAD1L1	-0.54	-6.9	-0.4	4.28e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs929596	0.564	rs2741030	chr2:234536152	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.59	-0.34	6.16e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg23693289	chr8:27183097	PTK2B	0.54	6.93	0.4	3.77e-11	Neuroticism;
KIRP	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.71	8.05	0.46	3.47e-14	Obesity-related traits;
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	13.45	0.65	2.8e-31	Platelet count;
KIRP	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.85	12.55	0.62	3.01e-28	Coronary artery disease;
KIRP	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	7.24	0.42	5.56e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-1.02	-13.49	-0.65	2.05e-31	Orofacial clefts;
KIRP	cis	rs11628318	0.805	rs4906229	chr14:103057511	A/C	cg01864069	chr14:103024347	NA	-0.65	-7.98	-0.45	5.45e-14	Platelet count;
KIRP	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg08501292	chr6:25962987	TRIM38	1.13	8.21	0.46	1.24e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Melanoma;
KIRP	cis	rs397969	0.646	rs6813	chr17:19808445	C/T	cg04132472	chr17:19861366	AKAP10	-0.56	-7.82	-0.45	1.55e-13	Platelet count;
KIRP	cis	rs4704187	0.640	rs1600073	chr5:74436737	C/T	cg03227963	chr5:74354835	NA	0.4	6.01	0.36	6.52e-9	Response to amphetamines;
KIRP	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-10.67	-0.56	4.25e-22	Gut microbiome composition (summer);
KIRP	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg08648136	chr8:956695	NA	0.42	6.17	0.37	2.8e-9	Schizophrenia;
KIRP	cis	rs9469913	0.542	rs3800461	chr6:34616322	G/C	cg14254433	chr6:34482411	PACSIN1	-0.61	-6.16	-0.37	2.97e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04132851	chr1:85155548	SSX2IP	0.54	6.56	0.39	3.14e-10	Interleukin-4 levels;
KIRP	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.95	9.44	0.52	2.96e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs14057	0.965	rs2294528	chr1:6729749	G/A	cg27299712	chr1:6550532	PLEKHG5	0.39	4.91	0.3	1.7e-6	Systolic blood pressure;
KIRP	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.11	-0.69	6.44e-37	Headache;
KIRP	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.35	-0.38	1.02e-9	Systolic blood pressure;
KIRP	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.3	-6.99	-0.41	2.59e-11	Mean corpuscular volume;
KIRP	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.97	17.09	0.74	1.05e-43	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26105702	chr2:209120195	IDH1	0.5	6.56	0.39	3.2e-10	Parkinson's disease;
KIRP	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-6.63	-0.39	2.15e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.07	-0.36	4.87e-9	Mood instability;
KIRP	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg14092571	chr14:90743983	NA	0.42	5.5	0.33	9.51e-8	Mortality in heart failure;
KIRP	cis	rs10859871	1.000	rs10777683	chr12:95699929	G/T	cg07737802	chr12:95537812	FGD6	0.38	4.86	0.3	2.12e-6	Endometriosis;
KIRP	cis	rs56079296	0.929	rs4345341	chr5:121278751	A/T	cg05256605	chr5:121412184	LOX	0.51	5.51	0.33	9.2e-8	Coronary artery disease;
KIRP	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-12.16	-0.61	5.73e-27	Eye color traits;
KIRP	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	9.23	0.51	1.27e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.96	0.54	7.42e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.68	10.01	0.54	5.41e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.77	-9.02	-0.5	5.45e-17	Resting heart rate;
KIRP	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg10523679	chr1:76189770	ACADM	-0.47	-6.57	-0.39	3.05e-10	Daytime sleep phenotypes;
KIRP	cis	rs970548	0.730	rs61854092	chr10:45934795	G/A	cg15590007	chr10:45870220	ALOX5	0.52	5.66	0.34	4.2e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	0.74	10.12	0.54	2.45e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg05234568	chr11:5960015	NA	-0.57	-5.91	-0.35	1.14e-8	DNA methylation (variation);
KIRP	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.44	-6.47	-0.38	5.2e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.99	-15.44	-0.7	4.79e-38	Bipolar disorder;
KIRP	trans	rs8042543	0.511	rs6493623	chr15:31657248	C/A	cg14477745	chr5:137577632	NA	-0.54	-6.12	-0.36	3.7e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg22117172	chr7:91764530	CYP51A1	0.46	6.49	0.38	4.61e-10	Breast cancer;
KIRP	cis	rs240764	0.817	rs239242	chr6:101092776	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.58	0.34	6.38e-8	Neuroticism;
KIRP	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.86	14.41	0.68	1.51e-34	Mortality in heart failure;
KIRP	cis	rs6888304	0.851	rs10052382	chr5:31024586	C/T	cg10919204	chr5:31193340	CDH6	-0.35	-4.97	-0.3	1.24e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	0.66	5.93	0.35	1.01e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6142102	0.961	rs2284387	chr20:32644588	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	6.33	0.37	1.16e-9	Skin pigmentation;
KIRP	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13047869	chr3:10149882	C3orf24	-0.54	-5.17	-0.31	4.87e-7	Alzheimer's disease;
KIRP	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg12573674	chr2:1569213	NA	-0.59	-5.78	-0.35	2.21e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10875746	0.587	rs9788082	chr12:48752056	C/A	cg20731937	chr12:48336164	NA	0.43	5.05	0.31	8.68e-7	Longevity (90 years and older);
KIRP	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.58	-7.82	-0.45	1.55e-13	Pulse pressure;
KIRP	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01616529	chr11:638424	DRD4	-0.37	-5.04	-0.31	9.04e-7	Systemic lupus erythematosus;
KIRP	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.81	-0.4	7.36e-11	Monocyte percentage of white cells;
KIRP	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg15655495	chr12:38532458	NA	-0.27	-4.93	-0.3	1.53e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs68170813	0.652	rs17404067	chr7:107168119	G/T	cg02696742	chr7:106810147	HBP1	-0.78	-7.62	-0.44	5.46e-13	Coronary artery disease;
KIRP	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	15.33	0.7	1.07e-37	Platelet count;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg22907277	chr7:1156413	C7orf50	0.86	8.16	0.46	1.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg20302533	chr7:39170763	POU6F2	0.31	6.37	0.38	9.05e-10	IgG glycosylation;
KIRP	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.9	13.61	0.66	7.77e-32	Systemic lupus erythematosus;
KIRP	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg16482183	chr6:26056742	HIST1H1C	0.38	5.02	0.31	9.72e-7	Schizophrenia;
KIRP	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg17554472	chr22:41940697	POLR3H	0.68	7.19	0.42	7.98e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg19849509	chr2:175204996	NA	-0.53	-6.34	-0.37	1.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.64	9.65	0.52	6.91e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-8.58	-0.48	1.05e-15	Morning vs. evening chronotype;
KIRP	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs11874712	0.965	rs8083998	chr18:43673144	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.16e-8	Migraine - clinic-based;
KIRP	cis	rs883565	0.568	rs4616582	chr3:39028854	G/T	cg01426195	chr3:39028469	NA	0.78	14.36	0.68	2.27e-34	Handedness;
KIRP	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06544989	chr22:39130855	UNC84B	0.47	7.21	0.42	6.79e-12	Menopause (age at onset);
KIRP	trans	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg25042112	chr7:64838748	ZNF92	0.59	6.14	0.36	3.37e-9	Pain;
KIRP	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.43	5.52	0.33	8.62e-8	Aortic root size;
KIRP	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs17123764	0.710	rs58278271	chr12:50017975	G/A	cg20471783	chr12:50157085	TMBIM6	0.37	5.29	0.32	2.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg13332499	chr17:408570	NA	0.61	8.98	0.5	7.01e-17	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.1	0.36	4.18e-9	Menopause (age at onset);
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg07402062	chr16:89894098	SPIRE2	0.31	6.62	0.39	2.26e-10	Vitiligo;
KIRP	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs193541	0.632	rs30023	chr5:122285299	T/G	cg19412675	chr5:122181750	SNX24	0.6	6.38	0.38	8.51e-10	Glucose homeostasis traits;
KIRP	cis	rs3736485	0.966	rs2414110	chr15:51901302	T/C	cg14296394	chr15:51910925	DMXL2	-0.35	-5.19	-0.31	4.47e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs7201408	0.908	rs6497436	chr16:20123515	T/C	cg16249711	chr14:55907501	TBPL2	0.55	6.11	0.36	3.9e-9	Attention deficit hyperactivity disorder (inattention symptoms);
KIRP	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.53	6.5	0.38	4.39e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg05526886	chr2:227700861	RHBDD1	-0.41	-5.01	-0.3	1.06e-6	Pulmonary function;
KIRP	cis	rs988913	0.957	rs2064432	chr6:54782652	A/G	cg03513858	chr6:54763001	FAM83B	-0.39	-5.41	-0.33	1.5e-7	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13338022	chr15:43029438	CDAN1	0.54	6.34	0.37	1.11e-9	Smoking initiation;
KIRP	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg00405596	chr8:11794950	NA	-0.4	-5.11	-0.31	6.57e-7	Triglycerides;
KIRP	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.95	-14.31	-0.67	3.27e-34	Body mass index;
KIRP	cis	rs62355272	0.541	rs3734107	chr5:35921266	G/A	cg13894535	chr5:35919491	CAPSL	-0.39	-5.25	-0.32	3.23e-7	Lymphocyte counts;
KIRP	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	-0.61	-7.89	-0.45	9.96e-14	Inflammatory bowel disease;
KIRP	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-7.89	-0.45	9.9e-14	Homocysteine levels;
KIRP	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.61	-11.52	-0.59	7.63e-25	Blood protein levels;
KIRP	trans	rs6601327	0.613	rs7835002	chr8:9455045	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.11	0.41	1.26e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.6	8.14	0.46	1.95e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.69	10.97	0.57	4.53e-23	Lung cancer;
KIRP	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-7.04	-0.41	1.86e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-8.69	-0.48	5.18e-16	Height;
KIRP	cis	rs4742903	0.509	rs10991160	chr9:106961153	C/G	cg14250997	chr9:106856677	SMC2	0.37	4.88	0.3	1.87e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg03388025	chr16:89894329	SPIRE2	0.41	8.29	0.47	7.56e-15	Vitiligo;
KIRP	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg24565620	chr2:194026	NA	-0.69	-6.16	-0.37	2.9e-9	Blood protein levels;
KIRP	cis	rs920590	1.000	rs6995371	chr8:19650268	A/G	cg03894339	chr8:19674705	INTS10	0.46	5.77	0.35	2.37e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2371030	1.000	rs2371030	chr2:211569722	A/G	cg18417063	chr2:211583084	NA	0.5	7.2	0.42	7.13e-12	Non-small cell lung cancer;
KIRP	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.36	5.26	0.32	3.12e-7	Eye color traits;
KIRP	cis	rs10540	0.541	rs7482356	chr11:437088	T/C	cg03576123	chr11:487126	PTDSS2	0.85	7.57	0.43	7.36e-13	Body mass index;
KIRP	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18713687	chr3:195489789	MUC4	0.71	6.32	0.37	1.25e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14360444	chr9:129643082	ZBTB34	0.56	6.86	0.4	5.54e-11	Interleukin-4 levels;
KIRP	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23281280	chr6:28129359	ZNF389	0.44	4.87	0.3	2.01e-6	Depression;
KIRP	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg10017260	chr10:834428	NA	-0.55	-5.2	-0.31	4.17e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg21813546	chr1:182808991	DHX9	0.53	6.35	0.38	1.03e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.59	0.73	5.57e-42	Chronic sinus infection;
KIRP	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-15.73	-0.71	4.78e-39	Coronary artery disease;
KIRP	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg00334542	chr7:100209784	MOSPD3	0.53	5.04	0.31	9.12e-7	Other erythrocyte phenotypes;
KIRP	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.81	11.76	0.6	1.26e-25	Itch intensity from mosquito bite;
KIRP	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.14	-0.5	2.39e-17	Retinal vascular caliber;
KIRP	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.89	-0.35	1.26e-8	Breast cancer;
KIRP	cis	rs883565	0.502	rs7427462	chr3:38963275	G/A	cg01426195	chr3:39028469	NA	0.55	8.84	0.49	1.92e-16	Handedness;
KIRP	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.05	12.98	0.64	1.06e-29	Platelet count;
KIRP	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.33	6.37	0.38	9.36e-10	Diastolic blood pressure;
KIRP	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg08885076	chr2:99613938	TSGA10	-0.43	-6.59	-0.39	2.67e-10	Bipolar disorder;
KIRP	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg11693508	chr17:37793320	STARD3	0.74	8.14	0.46	1.98e-14	Bipolar disorder;
KIRP	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg03060546	chr3:49711283	APEH	-0.45	-5.79	-0.35	2.17e-8	Parkinson's disease;
KIRP	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg08198773	chr8:1697536	NA	0.51	6.25	0.37	1.76e-9	Systolic blood pressure;
KIRP	cis	rs6838801	0.760	rs13148163	chr4:77504400	C/T	cg17476223	chr4:77663285	SHROOM3	0.37	5.32	0.32	2.37e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	1.16	8.82	0.49	2.13e-16	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.56	-6.36	-0.38	9.99e-10	Initial pursuit acceleration;
KIRP	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03783058	chr20:3451627	ATRN	0.51	6.36	0.38	9.5e-10	Parkinson's disease;
KIRP	trans	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg10756647	chr7:56101905	PSPH	-0.98	-7.0	-0.41	2.4e-11	Diabetic kidney disease;
KIRP	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg06637938	chr14:75390232	RPS6KL1	0.49	6.78	0.4	8.96e-11	Height;
KIRP	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.87	0.45	1.11e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1050631	0.563	rs685042	chr18:33743998	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.89	0.35	1.28e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs735539	0.645	rs6490600	chr13:21208189	G/T	cg27499820	chr13:21296301	IL17D	0.35	5.09	0.31	7.01e-7	Dental caries;
KIRP	cis	rs4959799	0.655	rs6902992	chr6:3283693	C/G	cg03657281	chr6:3270030	SLC22A23	0.72	5.14	0.31	5.68e-7	Survival in rectal cancer;
KIRP	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.2	-0.37	2.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg26441486	chr22:50317300	CRELD2	0.51	8.28	0.47	7.77e-15	Schizophrenia;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.64	-8.74	-0.49	3.72e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2290402	0.536	rs7684266	chr4:856609	T/C	cg14517359	chr4:903473	GAK	-0.56	-6.0	-0.36	6.94e-9	Type 2 diabetes;
KIRP	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.39	-5.51	-0.33	9.26e-8	Bipolar disorder;
KIRP	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.13	-0.36	3.5e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-0.6	-5.74	-0.34	2.82e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14851460	chr1:20235923	OTUD3	0.52	6.43	0.38	6.41e-10	Interleukin-4 levels;
KIRP	cis	rs9398803	0.706	rs9388502	chr6:126909389	G/A	cg19875578	chr6:126661172	C6orf173	0.38	4.96	0.3	1.34e-6	Male-pattern baldness;
KIRP	cis	rs9534288	0.730	rs2148412	chr13:46595849	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.38	-0.47	4.2e-15	Blood protein levels;
KIRP	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg24315340	chr6:146058215	EPM2A	0.4	5.1	0.31	6.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4750440	0.735	rs2447014	chr10:14010122	C/T	cg27542038	chr10:14027202	FRMD4A	0.43	5.23	0.32	3.71e-7	Adiponectin levels;
KIRP	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg08125733	chr17:73851984	WBP2	0.54	6.8	0.4	7.86e-11	White matter hyperintensity burden;
KIRP	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.69	7.93	0.45	7.87e-14	Alcohol dependence;
KIRP	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg12573674	chr2:1569213	NA	-0.53	-5.21	-0.32	3.93e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	4.98	0.3	1.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs17123764	0.892	rs57342147	chr12:50129422	A/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.9	0.3	1.74e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.79	6.4	0.38	7.75e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.43	0.62	7.37e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg01765077	chr12:122356316	WDR66	-0.56	-7.58	-0.44	6.87e-13	Mean corpuscular volume;
KIRP	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.45	-6.37	-0.38	9.08e-10	Coronary artery disease;
KIRP	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.39	-8.62	-0.48	8.09e-16	Body mass index;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.59	-9.75	-0.53	3.46e-19	Lymphocyte counts;
KIRP	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.69	8.48	0.48	2.07e-15	Neutrophil percentage of white cells;
KIRP	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.46	-5.56	-0.33	7.03e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg14458575	chr2:238380390	NA	0.62	8.25	0.47	9.35e-15	Prostate cancer;
KIRP	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg19847130	chr8:10466454	RP1L1	-0.37	-5.14	-0.31	5.55e-7	Neuroticism;
KIRP	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	1.01	17.52	0.75	3.77e-45	Systemic lupus erythematosus;
KIRP	cis	rs8077059	1.000	rs9303396	chr17:55825118	A/G	cg12582317	chr17:55822272	NA	0.4	5.68	0.34	3.74e-8	Sex hormone-binding globulin levels;
KIRP	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.62	-6.59	-0.39	2.63e-10	Initial pursuit acceleration;
KIRP	cis	rs7973719	0.966	rs1450962	chr12:7320545	A/G	cg07052231	chr12:7363540	PEX5	0.39	4.97	0.3	1.23e-6	IgG glycosylation;
KIRP	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg16141378	chr3:129829833	LOC729375	0.63	8.55	0.48	1.36e-15	Triglycerides;
KIRP	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.02	-0.36	6.22e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6960043	0.818	rs1974620	chr7:15065467	A/G	cg19272540	chr7:15055459	NA	0.22	6.43	0.38	6.55e-10	Type 2 diabetes;
KIRP	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.45	6.24	0.37	1.89e-9	Sitting height ratio;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17422427	chr2:241507521	RNPEPL1	0.72	6.16	0.37	3.02e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.42	0.33	1.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs667920	0.512	rs13071085	chr3:136014923	G/A	cg15507776	chr3:136538369	TMEM22	-0.68	-5.78	-0.35	2.24e-8	Coronary artery disease;
KIRP	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.73	-8.76	-0.49	3.13e-16	Breast size;
KIRP	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.56	-6.79	-0.4	8.33e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.54	-7.07	-0.41	1.63e-11	Menopause (age at onset);
KIRP	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.84	13.41	0.65	3.93e-31	Menarche (age at onset);
KIRP	trans	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg06521331	chr12:34319734	NA	-0.49	-6.21	-0.37	2.19e-9	Bladder cancer;
KIRP	cis	rs7635838	0.892	rs12163566	chr3:11483096	T/A	cg00170343	chr3:11313890	ATG7	0.48	6.14	0.36	3.26e-9	HDL cholesterol;
KIRP	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.43	-5.14	-0.31	5.5e-7	Aortic root size;
KIRP	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.6	7.24	0.42	5.64e-12	Monocyte count;
KIRP	cis	rs66569888	0.581	rs17271098	chr2:106692818	A/G	cg16099169	chr2:106886729	NA	0.56	7.1	0.41	1.37e-11	Facial morphology (factor 23);
KIRP	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	8.81	0.49	2.33e-16	Ileal carcinoids;
KIRP	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg05775895	chr3:12838266	CAND2	0.32	4.87	0.3	2.01e-6	QRS complex (12-leadsum);
KIRP	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.71	10.04	0.54	4.2e-20	Height;
KIRP	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04374321	chr14:90722782	PSMC1	0.9	14.55	0.68	5.12e-35	Mortality in heart failure;
KIRP	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-5.01	-0.3	1.04e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs380904	0.517	rs11775744	chr8:144649192	A/G	cg21643262	chr8:144646939	NA	-0.55	-5.78	-0.35	2.23e-8	Venous thromboembolism (SNP x SNP interaction);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg13496098	chr10:97666894	C10orf131	-0.43	-6.18	-0.37	2.57e-9	Migraine with aura;
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-7.7	-0.44	3.29e-13	Lung cancer;
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.57	-0.39	2.9e-10	Response to antipsychotic treatment;
KIRP	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.46	-5.84	-0.35	1.66e-8	Blood metabolite levels;
KIRP	cis	rs7534824	0.625	rs61780321	chr1:101428304	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.7	5.45	0.33	1.25e-7	Refractive astigmatism;
KIRP	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.23	-0.37	2.03e-9	Monocyte count;
KIRP	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	9.01	0.5	5.69e-17	Personality dimensions;
KIRP	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.97	11.35	0.59	2.71e-24	Corneal astigmatism;
KIRP	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg10223061	chr2:219282414	VIL1	0.28	4.85	0.3	2.17e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg13324568	chr11:61197484	CPSF7;SDHAF2	-0.5	-6.36	-0.38	9.89e-10	Myopia;
KIRP	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.48	7.23	0.42	6.03e-12	Total body bone mineral density;
KIRP	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-4.86	-0.3	2.13e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27526149	chr1:33430462	RNF19B	0.52	6.51	0.38	4.15e-10	Parkinson's disease;
KIRP	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02534363	chr3:47050950	NBEAL2	0.29	5.08	0.31	7.48e-7	Colorectal cancer;
KIRP	cis	rs2562456	0.833	rs2928211	chr19:21541297	A/G	cg25650185	chr19:21324782	ZNF431	0.51	5.4	0.33	1.56e-7	Pain;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg12692727	chr7:1102344	C7orf50	0.49	5.16	0.31	5.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3741798	1.000	rs61922047	chr12:12496471	C/A	cg08615371	chr12:12503544	MANSC1	0.96	8.46	0.47	2.42e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg08738300	chr3:44038990	NA	0.67	9.41	0.51	3.72e-18	Coronary artery disease;
KIRP	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.56	0.33	7.15e-8	Putamen volume;
KIRP	cis	rs4704187	0.687	rs6862754	chr5:74427193	T/C	cg03227963	chr5:74354835	NA	0.41	5.93	0.35	9.96e-9	Response to amphetamines;
KIRP	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.45	-5.64	-0.34	4.76e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg14593290	chr7:50529359	DDC	0.44	5.63	0.34	4.79e-8	Malaria;
KIRP	trans	rs2048656	0.578	rs2090061	chr8:9680978	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.4	-0.38	7.78e-10	Schizophrenia;
KIRP	cis	rs860295	0.702	rs2175391	chr1:155625602	G/T	cg02153340	chr1:155202674	NA	0.44	6.01	0.36	6.48e-9	Body mass index;
KIRP	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.46	-0.33	1.14e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17558214	chr7:11101436	PHF14	-0.47	-6.62	-0.39	2.2e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7709377	0.595	rs10056823	chr5:115609454	C/G	cg23108291	chr5:115420582	COMMD10	0.44	5.22	0.32	3.72e-7	Metabolite levels  (X-11787);
KIRP	cis	rs80282103	0.618	rs74117831	chr10:1145707	A/C	cg08668510	chr10:1095578	IDI1	0.96	6.43	0.38	6.45e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs35883536	0.528	rs1577511	chr1:101030859	G/A	cg06223162	chr1:101003688	GPR88	0.47	9.71	0.53	4.36e-19	Monocyte count;
KIRP	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.23	13.53	0.65	1.52e-31	Uric acid levels;
KIRP	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg02367723	chr1:46378857	MAST2	0.44	5.11	0.31	6.36e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	12.76	0.63	6.11e-29	Electrocardiographic conduction measures;
KIRP	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg01879757	chr17:41196368	BRCA1	-0.54	-6.99	-0.41	2.61e-11	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.77	11.19	0.58	9.08e-24	Lung cancer;
KIRP	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg06204229	chr3:52865917	ITIH4	0.44	5.11	0.31	6.41e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs311392	0.554	rs395449	chr8:55100391	A/G	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.51e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-5.09	-0.31	7.06e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9815354	0.638	rs113712591	chr3:42050624	C/T	cg03022575	chr3:42003672	ULK4	0.77	7.14	0.41	1.02e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00933542	chr6:150070202	PCMT1	0.28	5.36	0.32	1.95e-7	Lung cancer;
KIRP	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.28	14.54	0.68	5.29e-35	Uric acid levels;
KIRP	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.91	15.5	0.7	2.9e-38	Metabolic syndrome;
KIRP	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-5.57	-0.33	6.58e-8	Bipolar disorder;
KIRP	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.58	-6.4	-0.38	8.01e-10	Primary sclerosing cholangitis;
KIRP	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg08999081	chr20:33150536	PIGU	0.46	4.9	0.3	1.77e-6	Protein C levels;
KIRP	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg02461776	chr11:598696	PHRF1	0.72	8.24	0.47	1.02e-14	Systemic lupus erythematosus;
KIRP	cis	rs7808935	0.672	rs38504	chr7:28016334	T/C	cg22168087	chr7:27702803	HIBADH	-0.69	-6.48	-0.38	4.87e-10	Prostate cancer;
KIRP	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg11845111	chr2:191398756	TMEM194B	-0.74	-8.0	-0.45	4.78e-14	Diastolic blood pressure;
KIRP	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	9.25	0.51	1.11e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6684514	0.922	rs2075166	chr1:156215562	G/A	cg16558208	chr1:156270281	VHLL	-0.41	-5.22	-0.32	3.82e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg11833968	chr6:79620685	NA	-0.47	-6.93	-0.4	3.66e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.6.1361432F	chr6:62787138	KHDRBS2	0.48	6.39	0.38	8.17e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg07148914	chr20:33460835	GGT7	-0.54	-7.13	-0.41	1.15e-11	Height;
KIRP	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-10.46	-0.55	1.99e-21	Joint mobility (Beighton score);
KIRP	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.09	-0.5	3.42e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg24879335	chr3:133465180	TF	0.46	6.97	0.41	2.94e-11	Iron status biomarkers;
KIRP	trans	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg08975724	chr8:8085496	FLJ10661	0.48	6.06	0.36	5.03e-9	Myopia (pathological);
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13198984	chr17:80129470	CCDC57	-0.54	-8.16	-0.46	1.76e-14	Life satisfaction;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07256732	chr16:621771	PIGQ	-0.43	-6.07	-0.36	4.9e-9	Height;
KIRP	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	0.900	rs3756334	chr5:140213796	G/A	cg21161173	chr5:140098174	VTRNA1-2	-0.38	-4.95	-0.3	1.4e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11593576	0.550	rs7895110	chr10:80994117	T/A	cg20744163	chr10:80999841	ZMIZ1	-0.3	-4.89	-0.3	1.83e-6	Vitiligo;
KIRP	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.85	-0.35	1.59e-8	Electroencephalogram traits;
KIRP	cis	rs984222	0.967	rs10802069	chr1:119517357	T/C	cg18261050	chr1:119551319	NA	0.36	4.99	0.3	1.12e-6	Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;
KIRP	cis	rs1823913	0.637	rs6741454	chr2:192134246	T/G	cg12404831	chr2:192114017	MYO1B	-0.47	-6.31	-0.37	1.28e-9	Obesity-related traits;
KIRP	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.59e-11	Tonsillectomy;
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-9.69	-0.53	5.1e-19	Chronic sinus infection;
KIRP	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg07689907	chr11:61582574	FADS1	0.49	6.09	0.36	4.24e-9	Trans fatty acid levels;
KIRP	trans	rs4262150	0.658	rs2964223	chr5:151940822	C/T	cg01176028	chr21:43653234	ABCG1	-0.23	-6.09	-0.36	4.35e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.5	-6.56	-0.39	3.07e-10	Testicular germ cell tumor;
KIRP	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs7849270	1.000	rs7869804	chr9:131913144	C/T	cg13538475	chr9:131942899	NA	-0.32	-5.27	-0.32	2.92e-7	Blood metabolite ratios;
KIRP	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg09597638	chr17:3907349	NA	0.49	6.26	0.37	1.74e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg08499158	chr17:42289980	UBTF	-0.65	-8.56	-0.48	1.21e-15	Total body bone mineral density;
KIRP	cis	rs3755132	0.929	rs3770467	chr2:15762935	G/A	cg12888861	chr2:15731646	DDX1	0.41	5.34	0.32	2.1e-7	Wilms tumor;
KIRP	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-1.28	-12.57	-0.63	2.53e-28	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4132509	0.779	rs3006940	chr1:243683001	A/G	cg25706552	chr1:244017396	NA	0.48	6.92	0.4	3.98e-11	RR interval (heart rate);
KIRP	cis	rs6142102	0.961	rs2268089	chr20:32667298	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	6.99	0.41	2.57e-11	Skin pigmentation;
KIRP	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg25039879	chr17:56429692	SUPT4H1	0.57	5.41	0.33	1.47e-7	Cognitive test performance;
KIRP	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg21926883	chr2:100939477	LONRF2	0.52	6.91	0.4	4.16e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg21775007	chr8:11205619	TDH	-0.41	-5.19	-0.31	4.48e-7	Neuroticism;
KIRP	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg06647332	chr5:131281008	NA	0.44	4.88	0.3	1.9e-6	Life satisfaction;
KIRP	trans	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg00938859	chr5:1591904	SDHAP3	0.58	7.82	0.45	1.51e-13	Breast cancer;
KIRP	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg06766960	chr11:133703094	NA	-0.45	-5.89	-0.35	1.23e-8	Childhood ear infection;
KIRP	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.89	10.57	0.56	9.14e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs255758	0.627	rs255749	chr5:53318596	G/A	cg22592108	chr5:53304441	ARL15	0.41	5.69	0.34	3.55e-8	Rheumatoid arthritis;
KIRP	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg22138327	chr13:27999177	GTF3A	0.89	6.55	0.39	3.28e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs2494663	0.610	rs7514662	chr1:154044715	G/C	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.33	-4.85	-0.3	2.19e-6	Mean platelet volume;
KIRP	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg15117754	chr3:10150083	C3orf24	0.55	5.13	0.31	5.89e-7	Alzheimer's disease;
KIRP	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg07884673	chr3:53033167	SFMBT1	-0.79	-6.42	-0.38	6.85e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg04865290	chr3:52927548	TMEM110	-0.6	-6.02	-0.36	6.28e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs865483	0.860	rs12603185	chr17:35868304	T/C	cg06716730	chr17:35851459	DUSP14	0.21	4.89	0.3	1.85e-6	Monocyte count;
KIRP	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg00277334	chr10:82204260	NA	-0.46	-5.38	-0.32	1.76e-7	Post bronchodilator FEV1;
KIRP	cis	rs7665939	1.000	rs72727639	chr4:190107992	G/C	cg14840187	chr4:190284988	NA	-0.93	-6.77	-0.4	9.53e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.62	-7.74	-0.44	2.53e-13	Breast cancer;
KIRP	cis	rs10267417	0.603	rs10273376	chr7:19911647	T/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.6	5.97	0.36	8.34e-9	Total cholesterol levels;
KIRP	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.41	-5.88	-0.35	1.34e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	5.16	0.31	5.12e-7	Schizophrenia;
KIRP	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	0.63	8.15	0.46	1.88e-14	Red blood cell count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14118424	chr5:110445104	WDR36	-0.45	-6.94	-0.4	3.54e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg18806716	chr10:30721971	MAP3K8	-0.46	-7.19	-0.42	7.61e-12	Inflammatory bowel disease;
KIRP	trans	rs11220082	0.644	rs34435097	chr11:125338971	G/A	cg12585429	chr16:49889252	NA	0.5	6.14	0.36	3.38e-9	Schizophrenia;
KIRP	cis	rs6120849	0.901	rs6088735	chr20:33745676	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.12	0.36	3.65e-9	Protein C levels;
KIRP	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg14768367	chr16:72042858	DHODH	-0.89	-9.73	-0.53	3.96e-19	Blood protein levels;
KIRP	cis	rs7097610	1	rs7097610	chr10:82304162	C/T	cg01528321	chr10:82214614	TSPAN14	-1.06	-9.76	-0.53	3.05e-19	Post bronchodilator FEV1;
KIRP	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg21573476	chr21:45109991	RRP1B	-0.59	-8.14	-0.46	2.04e-14	Mean corpuscular volume;
KIRP	cis	rs7246657	0.722	rs2291002	chr19:38033926	G/A	cg18154014	chr19:37997991	ZNF793	0.61	6.66	0.39	1.79e-10	Coronary artery calcification;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20821899	chr2:196642630	DNAH7	-0.42	-6.6	-0.39	2.54e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg14440974	chr22:39074834	NA	-0.38	-4.94	-0.3	1.44e-6	Menopause (age at onset);
KIRP	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.05	-0.31	8.69e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg24747557	chr10:131355152	MGMT	-0.38	-5.23	-0.32	3.66e-7	Response to temozolomide;
KIRP	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.67	-7.26	-0.42	4.96e-12	DNA methylation (variation);
KIRP	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.74	-9.29	-0.51	8.43e-18	Coronary artery disease;
KIRP	cis	rs448720	0.840	rs399755	chr15:68161587	T/A	cg24579218	chr15:68104479	NA	0.4	6.02	0.36	6.35e-9	Cognitive performance;
KIRP	cis	rs2964802	0.505	rs4410623	chr5:10832271	A/C	cg14521931	chr5:10832172	NA	0.75	12.07	0.61	1.16e-26	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.55	-0.48	1.36e-15	Lymphocyte counts;
KIRP	cis	rs3849570	0.555	rs6548783	chr3:81993621	G/A	cg07356753	chr3:81810745	GBE1	-0.54	-6.62	-0.39	2.25e-10	Waist circumference;Body mass index;
KIRP	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg08133631	chr1:26527909	CATSPER4	-0.44	-4.9	-0.3	1.78e-6	Obesity-related traits;
KIRP	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.57	-5.3	-0.32	2.58e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs11603020	0.950	rs78624400	chr11:57375463	G/C	cg23127183	chr11:57508653	C11orf31	-0.46	-5.37	-0.32	1.85e-7	Blood protein levels;
KIRP	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11645453	chr3:52864694	ITIH4	0.33	4.87	0.3	2.02e-6	Bipolar disorder;
KIRP	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.68	10.22	0.55	1.18e-20	Neuroticism;
KIRP	cis	rs75920871	0.623	rs625145	chr11:116727936	A/T	cg04087571	chr11:116723030	SIK3	-0.29	-6.05	-0.36	5.43e-9	Subjective well-being;
KIRP	cis	rs643506	1.000	rs1788955	chr11:111630998	C/G	cg09085632	chr11:111637200	PPP2R1B	0.52	5.86	0.35	1.46e-8	Breast cancer;
KIRP	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.46	-5.97	-0.36	8.39e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.39	-7.51	-0.43	1.12e-12	Monocyte percentage of white cells;
KIRP	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg12384639	chr17:618140	VPS53	0.49	6.22	0.37	2.12e-9	Prostate cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15077376	chr3:159943308	LOC401097	-0.46	-6.27	-0.37	1.57e-9	Myopia;
KIRP	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg26441486	chr22:50317300	CRELD2	0.45	7.25	0.42	5.52e-12	Schizophrenia;
KIRP	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg06781948	chr3:72941472	GXYLT2	0.48	6.37	0.38	8.99e-10	Motion sickness;
KIRP	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.79	10.58	0.56	8.49e-22	Monocyte count;
KIRP	trans	rs1106684	1.000	rs67655809	chr7:131463711	G/A	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	cis	rs2072732	1.000	rs72630911	chr1:2974064	A/G	cg11731671	chr1:2995604	PRDM16	-0.59	-6.6	-0.39	2.54e-10	Plateletcrit;
KIRP	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.94	12.52	0.62	3.71e-28	Orofacial clefts;
KIRP	cis	rs7116495	0.609	rs7121080	chr11:71703935	G/A	cg26138937	chr11:71823887	C11orf51	-1.01	-6.94	-0.4	3.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.85	13.66	0.66	5.35e-32	Prostate cancer;
KIRP	cis	rs9473924	0.505	rs7753025	chr6:50858352	A/C	cg14470998	chr6:50812995	TFAP2B	0.84	7.77	0.44	2.07e-13	Body mass index;
KIRP	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg22906224	chr7:99728672	NA	-0.64	-7.8	-0.45	1.81e-13	Coronary artery disease;
KIRP	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg07005078	chr4:17578674	LAP3	0.42	4.85	0.3	2.23e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.45	6.4e-14	Aortic root size;
KIRP	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-0.87	-13.03	-0.64	7.21e-30	Total body bone mineral density;
KIRP	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg13615516	chr5:77269221	NA	0.53	8.25	0.47	9.75e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.67	7.7	0.44	3.35e-13	Corneal astigmatism;
KIRP	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.62	-0.66	7.24e-32	Height;
KIRP	cis	rs960902	0.805	rs12995330	chr2:37710569	C/T	cg25341268	chr2:37734390	NA	0.51	6.72	0.39	1.28e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg13482628	chr17:19912719	NA	0.56	8.01	0.45	4.65e-14	Schizophrenia;
KIRP	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg02187348	chr16:89574699	SPG7	0.52	6.64	0.39	1.99e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.8	0.35	2.04e-8	Motion sickness;
KIRP	trans	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg04702396	chr17:15466718	FAM18B2	0.53	6.84	0.4	6.29e-11	Educational attainment (years of education);
KIRP	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11955398	0.563	rs1816864	chr5:60011273	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06157539	chr18:32621265	MAPRE2	0.48	6.09	0.36	4.29e-9	Parkinson's disease;
KIRP	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg12349571	chr15:70364359	TLE3	-0.57	-5.04	-0.31	8.84e-7	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs12282928	0.959	rs10769331	chr11:48249779	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.06	-0.36	5.11e-9	Migraine - clinic-based;
KIRP	cis	rs2862064	1.000	rs6867207	chr5:156450106	G/A	cg12943317	chr5:156479607	HAVCR1	-0.89	-7.96	-0.45	6.21e-14	Platelet count;
KIRP	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg03585969	chr10:35415529	CREM	0.79	9.51	0.52	1.78e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6589219	0.954	rs10789823	chr11:111172403	T/C	cg25129781	chr11:111156908	C11orf53	-0.5	-6.5	-0.38	4.46e-10	Colorectal cancer;
KIRP	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg12705353	chr12:122356852	WDR66	-0.5	-6.85	-0.4	5.9e-11	Mean corpuscular volume;
KIRP	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg09990169	chr2:241835740	C2orf54	-0.45	-6.78	-0.4	8.6e-11	Urinary metabolites;
KIRP	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.9	-14.88	-0.69	3.73e-36	Prostate cancer;
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg04369109	chr6:150039330	LATS1	-0.53	-6.73	-0.39	1.17e-10	Lung cancer;
KIRP	cis	rs357618	0.531	rs7723079	chr5:150886616	G/A	cg22672639	chr5:150884813	FAT2	-0.42	-5.16	-0.31	5.18e-7	Basophil percentage of white cells;
KIRP	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.86	8.31	0.47	6.38e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.06	0.36	5.19e-9	Total cholesterol levels;
KIRP	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.45	5.32	0.32	2.33e-7	Neuroticism;
KIRP	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	10.44	0.55	2.25e-21	Hip circumference;
KIRP	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg06565975	chr8:143823917	SLURP1	-0.5	-7.27	-0.42	4.86e-12	Urinary tract infection frequency;
KIRP	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg11846333	chr4:119757529	SEC24D	1.05	5.8	0.35	2e-8	Cannabis dependence symptom count;
KIRP	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg00745463	chr17:30367425	LRRC37B	-1.08	-7.85	-0.45	1.28e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.31	-5.98	-0.36	7.79e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg15880211	chr22:50250494	ZBED4	0.47	5.67	0.34	4.04e-8	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16054451	chr17:47755353	SPOP	0.45	6.48	0.38	5.02e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.7	-7.75	-0.44	2.37e-13	Multiple sclerosis;
KIRP	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.15	-0.37	3.1e-9	Neuroticism;
KIRP	cis	rs1823913	0.637	rs6434461	chr2:192167387	G/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs35740288	0.742	rs2061818	chr15:86136244	G/A	cg06993955	chr15:86301167	NA	-0.4	-5.09	-0.31	7.26e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.61	6.12	0.36	3.61e-9	Eotaxin levels;
KIRP	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg20312557	chr2:97357134	FER1L5	-0.71	-5.16	-0.31	5.07e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-5.31	-0.32	2.4e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg16482183	chr6:26056742	HIST1H1C	0.39	4.94	0.3	1.48e-6	Height;
KIRP	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-1.16	-11.4	-0.59	1.83e-24	Post bronchodilator FEV1;
KIRP	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.55	5.28	0.32	2.89e-7	Height;
KIRP	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.51e-10	Aortic root size;
KIRP	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.0	-0.36	6.86e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs72730918	0.564	rs6493507	chr15:51874119	C/T	cg14296394	chr15:51910925	DMXL2	-0.76	-10.53	-0.56	1.21e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs9625935	0.748	rs2412974	chr22:30539821	C/T	cg27665648	chr22:30112403	NA	-0.39	-5.46	-0.33	1.19e-7	Tonsillectomy;
KIRP	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg14317384	chr8:216788	NA	0.5	5.25	0.32	3.36e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.57	7.55	0.43	8.69e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18364779	chr6:26104403	HIST1H4C	-0.49	-5.49	-0.33	1.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.56	-6.93	-0.4	3.56e-11	Total body bone mineral density;
KIRP	cis	rs6693295	0.887	rs7514524	chr1:246261526	A/G	cg11798871	chr1:246315928	SMYD3	-0.41	-5.23	-0.32	3.63e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg02070118	chr4:952128	TMEM175	0.57	4.87	0.3	2.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7106204	0.800	rs6484026	chr11:24214633	G/A	ch.11.24196551F	chr11:24239977	NA	0.81	9.58	0.52	1.13e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs981844	0.848	rs72731652	chr4:154641123	A/T	cg14289246	chr4:154710475	SFRP2	0.66	7.17	0.42	8.9e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.78	0.4	8.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.96	13.82	0.66	1.54e-32	Cognitive function;
KIRP	cis	rs4692589	1.000	rs7666219	chr4:170932739	T/C	cg19918862	chr4:170955249	NA	0.48	5.84	0.35	1.64e-8	Anxiety disorder;
KIRP	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	11.87	0.6	5.57e-26	Bipolar disorder;
KIRP	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg16083429	chr3:49237500	CCDC36	0.39	5.17	0.31	4.78e-7	Menarche (age at onset);
KIRP	trans	rs1864585	0.520	rs73208762	chr8:10659987	T/C	cg26278703	chr11:58910052	FAM111A	0.64	6.41	0.38	7.39e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs684232	1.000	rs684232	chr17:618965	T/C	cg15660573	chr17:549704	VPS53	0.46	5.84	0.35	1.62e-8	Prostate cancer;
KIRP	cis	rs7709377	0.595	rs1382343	chr5:115616345	A/G	cg23108291	chr5:115420582	COMMD10	-0.44	-5.43	-0.33	1.34e-7	Metabolite levels  (X-11787);
KIRP	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.48	-5.6	-0.34	5.7e-8	Body mass index;
KIRP	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19882132	chr14:106167949	NA	-0.42	-5.2	-0.31	4.19e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.58	8.66	0.48	6.42e-16	Anterior chamber depth;
KIRP	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.89	-14.98	-0.69	1.71e-36	Height;
KIRP	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.66	-0.34	4.1e-8	Yeast infection;
KIRP	cis	rs7589342	0.801	rs13411829	chr2:106466101	G/C	cg16077055	chr2:106428750	NCK2	0.26	5.33	0.32	2.25e-7	Addiction;
KIRP	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.49	-6.2	-0.37	2.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	9.13	0.5	2.5e-17	Prudent dietary pattern;
KIRP	cis	rs2594989	0.778	rs6764721	chr3:11470639	A/T	cg01796438	chr3:11312864	ATG7	-0.55	-7.0	-0.41	2.39e-11	Circulating chemerin levels;
KIRP	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg18154014	chr19:37997991	ZNF793	0.7	7.62	0.44	5.36e-13	Coronary artery calcification;
KIRP	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg01988459	chr11:68622903	NA	-0.43	-5.9	-0.35	1.19e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.77	6.8	0.4	7.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg15234197	chr11:68924956	NA	0.34	4.92	0.3	1.59e-6	Blond vs. brown hair color;
KIRP	trans	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg06521331	chr12:34319734	NA	-0.57	-7.03	-0.41	2.02e-11	Morning vs. evening chronotype;
KIRP	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg06636001	chr8:8085503	FLJ10661	0.7	8.54	0.48	1.43e-15	Systemic lupus erythematosus;
KIRP	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.35	0.42	3e-12	Aortic root size;
KIRP	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg07382826	chr16:28625726	SULT1A1	0.5	6.02	0.36	6.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg01721255	chr8:58191610	C8orf71	0.6	5.42	0.33	1.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.91	13.39	0.65	4.32e-31	Menopause (age at onset);
KIRP	cis	rs137699	1.000	rs2049986	chr22:39756854	C/G	cg05872129	chr22:39784769	NA	0.39	5.31	0.32	2.43e-7	IgG glycosylation;
KIRP	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	0.73	10.77	0.57	2.01e-22	Prudent dietary pattern;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20716571	chr10:1102456	WDR37	0.46	6.24	0.37	1.9e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	1.07	23.14	0.83	1.12e-63	Parkinson's disease;
KIRP	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.65	9.08	0.5	3.63e-17	Mean platelet volume;
KIRP	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	0.88	13.74	0.66	2.93e-32	Breast cancer;
KIRP	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg00405596	chr8:11794950	NA	-0.48	-6.19	-0.37	2.47e-9	Retinal vascular caliber;
KIRP	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.9	-13.38	-0.65	4.67e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.74	10.37	0.55	3.83e-21	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg06521331	chr12:34319734	NA	-0.47	-5.99	-0.36	7.49e-9	Morning vs. evening chronotype;
KIRP	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs2070433	1.000	rs11701310	chr21:47962836	G/C	cg12379764	chr21:47803548	PCNT	0.46	4.86	0.3	2.07e-6	Lymphocyte counts;
KIRP	cis	rs4908768	0.906	rs74324642	chr1:8620172	A/C	cg03610117	chr1:8450231	RERE	-0.5	-5.24	-0.32	3.54e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.3	6.15	0.37	3.09e-9	Body mass index;
KIRP	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.47	-0.33	1.12e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs12230513	0.732	rs61956331	chr12:55840856	G/A	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.5	-6.45	-0.38	5.82e-10	Systolic blood pressure;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg22903657	chr4:1355424	KIAA1530	-0.53	-7.54	-0.43	9.25e-13	Obesity-related traits;
KIRP	cis	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.07	-0.36	4.89e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg04310649	chr10:35416472	CREM	-0.58	-7.11	-0.41	1.28e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg15252951	chr6:33757062	LEMD2	0.43	5.15	0.31	5.3e-7	Crohn's disease;
KIRP	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg00800038	chr16:89945340	TCF25	0.62	6.1	0.36	4.17e-9	Skin colour saturation;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.61	7.58	0.44	6.93e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.84	0.4	6.41e-11	Tonsillectomy;
KIRP	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.56	6.87	0.4	5.18e-11	Diastolic blood pressure;
KIRP	cis	rs6545883	0.868	rs2518932	chr2:61801277	T/A	cg15711740	chr2:61764176	XPO1	-0.61	-8.3	-0.47	7.02e-15	Tuberculosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11318576	chr5:130599431	CDC42SE2	0.44	6.41	0.38	7.38e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.61	-7.67	-0.44	4.1e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.14	-0.31	5.7e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg00376283	chr12:123451042	ABCB9	0.46	5.9	0.35	1.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1629083	0.875	rs11216819	chr11:118084980	G/A	cg18857871	chr11:118064634	AMICA1	0.62	8.12	0.46	2.25e-14	Lung cancer;
KIRP	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg03653399	chr8:142233436	SLC45A4	0.94	14.69	0.68	1.64e-35	Immature fraction of reticulocytes;
KIRP	cis	rs61935443	0.832	rs7308359	chr12:95272904	G/T	cg21533806	chr12:95267307	NA	0.67	6.73	0.39	1.19e-10	Schizophrenia;
KIRP	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs11608355	0.521	rs11066503	chr12:109842434	A/G	cg19025524	chr12:109796872	NA	-0.49	-6.6	-0.39	2.55e-10	Neuroticism;
KIRP	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	0.89	12.12	0.61	8.22e-27	Monocyte percentage of white cells;
KIRP	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg17279839	chr7:150038598	RARRES2	0.46	6.08	0.36	4.62e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4356932	1.000	rs12502834	chr4:76980499	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-5.7	-0.34	3.48e-8	Life satisfaction;
KIRP	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs4972806	0.849	rs2857541	chr2:177029086	C/T	cg13092806	chr2:177043255	NA	0.62	8.55	0.48	1.29e-15	IgG glycosylation;
KIRP	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	9.65	0.52	6.86e-19	Schizophrenia;
KIRP	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.77	-12.98	-0.64	1.08e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7180079	0.620	rs686634	chr15:64854511	A/G	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.58e-7	Monocyte count;
KIRP	cis	rs2625529	0.938	rs2742323	chr15:72116778	A/T	cg16672083	chr15:72433130	SENP8	0.51	6.16	0.37	2.93e-9	Red blood cell count;
KIRP	cis	rs1010254	0.510	rs72808305	chr5:151719521	C/G	cg12297329	chr5:152029980	NA	-0.66	-6.75	-0.4	1.04e-10	Optic nerve measurement (cup area);
KIRP	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg04935436	chr20:30431758	NA	0.56	6.86	0.4	5.47e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg27413430	chr6:13925136	RNF182	0.54	6.39	0.38	8.13e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.62	6.71	0.39	1.36e-10	Post bronchodilator FEV1;
KIRP	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.68	9.63	0.52	8.06e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77861329	0.800	rs6777340	chr3:52188308	T/C	cg08692210	chr3:52188851	WDR51A	0.61	6.16	0.37	3.02e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.24	0.32	3.48e-7	Alzheimer's disease;
KIRP	cis	rs6974574	0.890	rs1717719	chr7:38112622	G/A	cg10754659	chr7:38110151	NA	-0.37	-5.0	-0.3	1.1e-6	Height;
KIRP	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.42	5.85	0.35	1.57e-8	Sense of smell;
KIRP	cis	rs6091737	1.000	rs6091737	chr20:52349892	A/G	cg20178976	chr20:52357117	NA	-0.43	-5.3	-0.32	2.63e-7	Calcium levels;
KIRP	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.78	-11.56	-0.59	5.52e-25	Neurofibrillary tangles;
KIRP	cis	rs952623	0.611	rs10435033	chr7:39054837	G/A	cg18850127	chr7:39170497	POU6F2	0.26	5.05	0.31	8.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	0.84	12.62	0.63	1.72e-28	Body mass index;
KIRP	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.8	-8.07	-0.46	3.19e-14	Prostate cancer;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg02073427	chr10:15252052	NA	0.51	6.38	0.38	8.7e-10	Sleep duration;
KIRP	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.98	13.42	0.65	3.46e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11718455	0.503	rs6441813	chr3:44041323	C/T	cg08738300	chr3:44038990	NA	0.38	5.85	0.35	1.58e-8	Coronary artery disease;
KIRP	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-6.44	-0.38	6.3e-10	Primary sclerosing cholangitis;
KIRP	cis	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	trans	rs2998286	0.643	rs332181	chr10:28910116	C/T	cg10174683	chr16:85619974	NA	-0.65	-6.06	-0.36	5e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.36	-5.3	-0.32	2.61e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78579285	0.544	rs4782321	chr16:88780175	G/A	cg09054528	chr16:88821542	FAM38A	-0.59	-5.02	-0.3	9.88e-7	Joint mobility (Beighton score);
KIRP	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.78	11.38	0.59	2.26e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg07541023	chr7:19748670	TWISTNB	0.95	7.65	0.44	4.52e-13	Thyroid stimulating hormone;
KIRP	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09459146	chr3:195595813	TNK2	0.58	6.24	0.37	1.87e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg18498241	chr11:69286352	NA	0.55	6.9	0.4	4.4e-11	Breast cancer (early onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05877768	chr10:34427076	PARD3	-0.38	-6.25	-0.37	1.76e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs714031	0.872	rs3788576	chr22:40071894	G/A	cg21377881	chr22:40064566	CACNA1I	-0.7	-10.71	-0.56	3.25e-22	Schizophrenia;
KIRP	cis	rs16857609	1.000	rs16857611	chr2:218296732	C/T	cg15335768	chr2:218268053	DIRC3	-0.47	-6.88	-0.4	4.8e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.6	-6.2	-0.37	2.3e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg04098458	chr2:149402448	EPC2	-0.47	-6.06	-0.36	4.99e-9	Myopia;
KIRP	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.65	7.06	0.41	1.74e-11	Alcohol dependence;
KIRP	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.09e-8	Motion sickness;
KIRP	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.51	-6.63	-0.39	2.15e-10	Pulse pressure;
KIRP	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	1.09	15.85	0.71	1.82e-39	Multiple sclerosis;
KIRP	cis	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.38	-0.32	1.74e-7	Leprosy;
KIRP	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.61	-8.81	-0.49	2.28e-16	Schizophrenia;
KIRP	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg13206674	chr6:150067644	NUP43	0.48	5.6	0.34	5.59e-8	Lung cancer;
KIRP	cis	rs12360000	0.864	rs11250842	chr10:1904284	A/C	cg26364871	chr10:1889757	NA	-0.58	-7.11	-0.41	1.29e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg18944383	chr4:111397179	ENPEP	0.48	8.19	0.46	1.46e-14	Height;
KIRP	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs300890	0.562	rs28589653	chr4:144207790	G/A	cg19876092	chr4:144208277	NA	0.41	6.48	0.38	5.05e-10	Nasopharyngeal carcinoma;
KIRP	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg23682824	chr7:23144976	KLHL7	-0.48	-6.08	-0.36	4.54e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10982256	0.567	rs10817620	chr9:117238405	C/T	cg13636371	chr9:117264095	DFNB31	0.53	7.25	0.42	5.42e-12	Bipolar disorder;
KIRP	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.53	7.39	0.43	2.3e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg21395723	chr22:39101663	GTPBP1	0.44	5.39	0.33	1.63e-7	Menopause (age at onset);
KIRP	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.81	-12.19	-0.61	4.73e-27	Morning vs. evening chronotype;
KIRP	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00585698	chr12:123750864	CDK2AP1	-0.44	-5.62	-0.34	5.25e-8	Platelet count;
KIRP	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.82	9.79	0.53	2.52e-19	Corneal astigmatism;
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.25	0.37	1.83e-9	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07464605	chr10:18940606	NSUN6	0.47	6.41	0.38	7.44e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.98	-0.57	4.33e-23	Height;
KIRP	cis	rs3736485	0.934	rs114641722	chr15:51863572	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07570687	chr10:102243282	WNT8B	0.54	7.11	0.41	1.25e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg04780086	chr2:111875790	ACOXL	0.47	6.53	0.38	3.81e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.8	11.81	0.6	8.43e-26	Heart rate;
KIRP	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.64	-7.62	-0.44	5.57e-13	Iron status biomarkers;
KIRP	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.46	7.01	0.41	2.28e-11	Lymphocyte counts;
KIRP	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg17372223	chr3:52568218	NT5DC2	-0.3	-4.86	-0.3	2.07e-6	Bipolar disorder;
KIRP	trans	rs56336142	0.619	rs10456468	chr6:39151425	A/C	cg17445213	chr7:47408746	TNS3	-0.47	-6.35	-0.38	1.01e-9	Coronary artery disease;
KIRP	cis	rs9984896	0.541	rs12626484	chr21:37911678	G/A	cg16719517	chr21:37442385	CBR1	-0.43	-4.89	-0.3	1.85e-6	QT interval;
KIRP	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.44	-5.4	-0.33	1.6e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9972944	0.692	rs8071561	chr17:63763434	C/T	cg07283582	chr17:63770753	CCDC46	-0.47	-7.83	-0.45	1.44e-13	Total body bone mineral density;
KIRP	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg10223061	chr2:219282414	VIL1	-0.37	-5.88	-0.35	1.32e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	9.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg13409248	chr3:40428643	ENTPD3	-0.37	-5.25	-0.32	3.26e-7	Renal cell carcinoma;
KIRP	cis	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg21775007	chr8:11205619	TDH	0.44	5.63	0.34	5.02e-8	Neuroticism;
KIRP	trans	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg26043149	chr18:55253948	FECH	0.51	6.19	0.37	2.5e-9	Bone mineral density;
KIRP	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.63	-8.75	-0.49	3.49e-16	Morning vs. evening chronotype;
KIRP	cis	rs981844	0.775	rs17299211	chr4:154738284	G/A	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.47	6.05	0.36	5.31e-9	Menopause (age at onset);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07781988	chr4:87927978	AFF1	0.53	6.54	0.38	3.56e-10	Myopia (pathological);
KIRP	cis	rs9948	0.867	rs17119598	chr2:97486315	A/G	cg20312557	chr2:97357134	FER1L5	0.73	5.31	0.32	2.46e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.7	-0.63	9.44e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.62	6.98	0.41	2.69e-11	HDL cholesterol;
KIRP	cis	rs8033133	0.602	rs1549477	chr15:25332118	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.5	-6.07	-0.36	4.72e-9	Blood osmolality (transformed sodium);
KIRP	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.39	4.88	0.3	1.9e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs16828019	0.704	rs12024115	chr1:41534357	C/T	cg03387723	chr1:41708464	SCMH1	-0.82	-7.22	-0.42	6.63e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs714027	0.546	rs5763614	chr22:30331290	A/G	cg01021169	chr22:30184971	ASCC2	-0.41	-5.03	-0.31	9.62e-7	Lymphocyte counts;
KIRP	cis	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.91	13.98	0.67	4.32e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg15691649	chr6:25882328	NA	-0.39	-4.91	-0.3	1.64e-6	Blood metabolite levels;
KIRP	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg04166393	chr7:2884313	GNA12	0.62	7.28	0.42	4.55e-12	Height;
KIRP	cis	rs2916247	1.000	rs2028652	chr8:92990029	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.55	-6.99	-0.41	2.65e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs9309473	0.861	rs6546857	chr2:73837955	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.1	-0.31	6.93e-7	Metabolite levels;
KIRP	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	1.19	10.39	0.55	3.28e-21	Skin colour saturation;
KIRP	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg07395648	chr5:131743802	NA	-0.39	-5.29	-0.32	2.71e-7	Blood metabolite levels;
KIRP	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26850624	chr5:429559	AHRR	0.32	5.84	0.35	1.65e-8	Cystic fibrosis severity;
KIRP	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg13906792	chr15:75199810	C15orf17	-0.38	-5.54	-0.33	7.85e-8	Breast cancer;
KIRP	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.51	5.63	0.34	5.01e-8	Lung cancer;
KIRP	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.72	10.45	0.55	2.12e-21	Hip circumference;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03041700	chr1:1407645	ATAD3B	0.6	7.2	0.42	7.26e-12	Smoking initiation;
KIRP	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.74	-8.6	-0.48	9.19e-16	Tonsillectomy;
KIRP	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg09507567	chr10:124027408	NA	0.31	5.65	0.34	4.36e-8	Total body bone mineral density;
KIRP	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	2.04e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10518128	1.000	rs1377032	chr4:75712104	T/C	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg04202892	chr2:111875749	ACOXL	0.49	6.89	0.4	4.75e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08280861	chr8:58055591	NA	0.72	5.92	0.35	1.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.55	-0.33	7.38e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs925228	0.504	rs6755030	chr2:24318343	C/T	cg01493198	chr2:24299560	SF3B14	0.78	6.4	0.38	7.66e-10	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.43	-5.79	-0.35	2.19e-8	Refractive error;
KIRP	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg18888403	chr1:24152774	HMGCL	0.36	5.16	0.31	5.21e-7	Immature fraction of reticulocytes;
KIRP	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg10818794	chr15:86012489	AKAP13	-0.5	-7.15	-0.41	9.9e-12	Coronary artery disease;
KIRP	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	trans	rs6601327	0.600	rs4841219	chr8:9654185	A/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.04	-0.41	1.91e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.92	-11.11	-0.58	1.64e-23	Diastolic blood pressure;
KIRP	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg03788504	chr6:150331562	NA	-0.36	-6.82	-0.4	6.88e-11	Alopecia areata;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg20187250	chr17:41277381	BRCA1;NBR2	-0.47	-6.05	-0.36	5.23e-9	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00014806	chr19:2475658	GADD45B	0.49	6.11	0.36	3.88e-9	Parkinson's disease;
KIRP	cis	rs10924309	0.737	rs4658797	chr1:245854862	G/A	cg00036263	chr1:245852353	KIF26B	-0.54	-7.78	-0.44	2.03e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg24851858	chr13:114927579	NA	-0.41	-4.96	-0.3	1.31e-6	Schizophrenia;
KIRP	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25517755	chr10:38738941	LOC399744	-0.51	-7.0	-0.41	2.5e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg10381502	chr11:71823885	C11orf51	-1.1	-7.75	-0.44	2.39e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.45	6.1	0.36	4.06e-9	Dupuytren's disease;
KIRP	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg12573674	chr2:1569213	NA	-0.51	-5.58	-0.34	6.34e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.65	-0.34	4.51e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg26412358	chr1:26503933	CNKSR1	0.39	5.53	0.33	8.14e-8	Height;
KIRP	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.53	6.86	0.4	5.51e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.78	-10.48	-0.56	1.7e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11800820	0.647	rs67365918	chr1:246673387	C/A	cg16700716	chr1:246684329	NA	0.61	5.9	0.35	1.19e-8	Obesity-related traits;
KIRP	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg15485101	chr11:133734466	NA	0.43	5.76	0.34	2.45e-8	Childhood ear infection;
KIRP	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.42	-5.54	-0.33	7.84e-8	Body mass index;
KIRP	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.37	-5.05	-0.31	8.64e-7	Coronary artery disease;
KIRP	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.67	-7.55	-0.43	8.59e-13	Vitiligo;
KIRP	cis	rs4654899	1.000	rs3767248	chr1:21276854	A/G	cg05370193	chr1:21551575	ECE1	0.46	6.41	0.38	7.52e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs5753618	0.539	rs2228619	chr22:31663842	C/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.29	-0.32	2.74e-7	Colorectal cancer;
KIRP	trans	rs41464545	1.000	rs17085713	chr4:65875586	A/G	cg05059825	chr11:62495950	HNRNPUL2;TTC9C	-0.64	-6.06	-0.36	5.01e-9	Schizophrenia;
KIRP	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg10223061	chr2:219282414	VIL1	0.33	5.46	0.33	1.15e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg13198984	chr17:80129470	CCDC57	0.56	8.39	0.47	3.82e-15	Life satisfaction;
KIRP	cis	rs4363385	0.530	rs6663448	chr1:152894627	C/T	cg13444842	chr1:152974279	SPRR3	-0.46	-6.66	-0.39	1.8e-10	Inflammatory skin disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08496016	chr9:99181722	ZNF367	0.47	6.27	0.37	1.65e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.48	5.23	0.32	3.63e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6467136	0.754	rs10258162	chr7:127158623	C/T	cg08586737	chr7:127225949	GCC1	-0.37	-4.84	-0.3	2.25e-6	Type 2 diabetes;
KIRP	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg18350739	chr11:68623251	NA	-0.52	-7.96	-0.45	6.38e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg15880211	chr22:50250494	ZBED4	-0.65	-7.3	-0.42	3.86e-12	Schizophrenia;
KIRP	trans	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.38	-0.43	2.39e-12	Blood trace element (Cu levels);
KIRP	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.74	9.44	0.52	3.03e-18	Coronary artery disease;
KIRP	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg02297831	chr4:17616191	MED28	0.59	7.55	0.43	8.45e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.75	9.38	0.51	4.64e-18	Coronary artery disease;
KIRP	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.36	-8.12	-0.46	2.29e-14	Cutaneous nevi;
KIRP	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg02375832	chr11:62437615	C11orf48	-0.42	-5.24	-0.32	3.42e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.79	-11.73	-0.6	1.56e-25	Height;
KIRP	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg11234688	chr2:1609660	NA	0.51	4.95	0.3	1.38e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	5.67	0.34	4.02e-8	Renal cell carcinoma;
KIRP	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.41	-0.38	7.53e-10	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02146453	chr8:37620111	PROSC	0.55	7.58	0.44	7.11e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs16912285	0.636	rs7114960	chr11:24310828	G/A	ch.11.24196551F	chr11:24239977	NA	0.76	7.89	0.45	9.97e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg14343924	chr8:8086146	FLJ10661	0.46	5.18	0.31	4.66e-7	Mood instability;
KIRP	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg15226275	chr6:116381976	FRK	0.21	5.98	0.36	7.75e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9513627	1.000	rs7317330	chr13:100119876	T/G	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	5.98	0.36	7.72e-9	Breast cancer;
KIRP	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25517755	chr10:38738941	LOC399744	-0.49	-6.71	-0.39	1.35e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg15117754	chr3:10150083	C3orf24	0.51	5.19	0.31	4.38e-7	Alzheimer's disease;
KIRP	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.91	10.33	0.55	5e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	0.93	7.41	0.43	2.08e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26314531	chr2:26401878	FAM59B	-0.48	-5.2	-0.31	4.17e-7	Gut microbiome composition (summer);
KIRP	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg06307176	chr5:131281290	NA	-0.54	-5.88	-0.35	1.35e-8	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.63	-0.39	2.14e-10	Renal cell carcinoma;
KIRP	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14159672	chr1:205819179	PM20D1	0.46	5.3	0.32	2.54e-7	Parkinson's disease;
KIRP	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-9.83	-0.53	1.89e-19	Joint mobility (Beighton score);
KIRP	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.7	-0.48	4.9e-16	Life satisfaction;
KIRP	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-9.15	-0.5	2.31e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg25482853	chr8:67687455	SGK3	0.8	7.05	0.41	1.76e-11	Obesity-related traits;
KIRP	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.02	-0.41	2.15e-11	Initial pursuit acceleration;
KIRP	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg27432699	chr2:27873401	GPN1	-0.52	-6.92	-0.4	3.8e-11	Total body bone mineral density;
KIRP	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg23307798	chr14:103986281	CKB	-0.51	-6.82	-0.4	7.21e-11	Coronary artery disease;
KIRP	cis	rs12643440	0.538	rs10489117	chr4:17145568	G/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.17	-0.42	8.56e-12	Fear of minor pain;
KIRP	trans	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg06521331	chr12:34319734	NA	-0.52	-6.33	-0.37	1.12e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.7	-0.44	3.35e-13	Platelet count;
KIRP	cis	rs1978968	0.956	rs35598889	chr22:18450794	T/C	cg03078520	chr22:18463400	MICAL3	-0.67	-8.26	-0.47	9.09e-15	Presence of antiphospholipid antibodies;
KIRP	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.49	-5.83	-0.35	1.75e-8	Body mass index;
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg17441377	chr17:3906640	NA	-0.49	-7.1	-0.41	1.36e-11	Type 2 diabetes;
KIRP	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg13010199	chr12:38710504	ALG10B	0.49	6.46	0.38	5.42e-10	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg08975724	chr8:8085496	FLJ10661	0.67	8.88	0.49	1.48e-16	Mood instability;
KIRP	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.97	17.08	0.74	1.19e-43	Mortality in heart failure;
KIRP	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg16586182	chr3:47516702	SCAP	-0.7	-9.85	-0.53	1.68e-19	Colorectal cancer;
KIRP	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg25036284	chr2:26402008	FAM59B	-0.52	-5.41	-0.33	1.51e-7	Gut microbiome composition (summer);
KIRP	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg08400316	chr16:204221	HBZ	-0.39	-5.13	-0.31	5.81e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.59	-6.66	-0.39	1.77e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.65	0.48	6.69e-16	Prudent dietary pattern;
KIRP	cis	rs2242420	0.920	rs10917028	chr1:21963854	C/T	cg00421585	chr1:21930189	RAP1GAP	0.52	4.89	0.3	1.79e-6	Hematological and biochemical traits;
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.5	6.06	0.36	4.96e-9	Glycated hemoglobin levels;
KIRP	cis	rs6545883	0.868	rs2427885	chr2:61816777	A/G	cg15711740	chr2:61764176	XPO1	-0.62	-8.33	-0.47	5.78e-15	Tuberculosis;
KIRP	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	5.78	0.35	2.29e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.93	12.46	0.62	6.15e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.54	6.95	0.41	3.26e-11	Crohn's disease;
KIRP	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg21858823	chr1:15850916	CASP9	0.54	5.71	0.34	3.25e-8	Systolic blood pressure;
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg06028808	chr11:68637592	NA	0.71	8.38	0.47	4.2e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6684428	1.000	rs10789010	chr1:56353295	C/G	cg11651538	chr1:56320950	NA	-0.82	-10.06	-0.54	3.58e-20	Airflow obstruction;
KIRP	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg23842812	chr7:76127459	DTX2	0.53	5.04	0.31	8.88e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs12476592	0.602	rs10469944	chr2:63816672	C/G	cg17519650	chr2:63277830	OTX1	-0.45	-5.04	-0.31	9.19e-7	Childhood ear infection;
KIRP	cis	rs72634258	0.519	rs4908713	chr1:7946831	G/A	cg26816564	chr1:7831052	VAMP3	0.6	5.18	0.31	4.64e-7	Inflammatory bowel disease;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.26	-5.47	-0.33	1.12e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.06	-0.5	4.21e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.02	0.46	4.19e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.35	5.29	0.32	2.7e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	0.53	6.76	0.4	9.68e-11	Acne (severe);
KIRP	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.69	-10.24	-0.55	9.77e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs787274	0.867	rs1711744	chr9:115453484	A/T	cg13803584	chr9:115635662	SNX30	-0.57	-6.96	-0.41	3.03e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-7.48	-0.43	1.32e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs72792276	1.000	rs10519971	chr5:127379216	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.81	-6.89	-0.4	4.6e-11	Red cell distribution width;
KIRP	cis	rs798766	0.779	rs55895920	chr4:1735930	C/T	cg01566213	chr4:1579287	NA	-0.36	-4.94	-0.3	1.42e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg05231480	chr19:49170277	SEC1;NTN5	-0.32	-4.88	-0.3	1.94e-6	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs35000415	0.938	rs12531054	chr7:128644251	A/C	cg19972273	chr7:128594194	NA	-0.81	-5.77	-0.35	2.43e-8	Systemic lupus erythematosus;
KIRP	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg01631408	chr1:248437212	OR2T33	-0.68	-9.16	-0.5	2.15e-17	Common traits (Other);
KIRP	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	6.92	0.4	3.84e-11	Platelet count;
KIRP	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs4148087	0.505	rs10084554	chr21:43623281	G/T	cg08841829	chr21:43638893	ABCG1	-0.43	-5.19	-0.31	4.5e-7	Eating disorder in bipolar disorder;
KIRP	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg07653901	chr22:50250238	ZBED4	-0.62	-6.77	-0.4	9.21e-11	Schizophrenia;
KIRP	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	1.17	10.23	0.55	1.06e-20	Skin colour saturation;
KIRP	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.6	-5.31	-0.32	2.41e-7	Schizophrenia;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05165339	chr4:1420672	NA	-0.33	-4.93	-0.3	1.51e-6	Longevity;
KIRP	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg08501292	chr6:25962987	TRIM38	1.01	8.08	0.46	2.89e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.58	-7.0	-0.41	2.43e-11	Arsenic metabolism;
KIRP	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.13	0.41	1.1e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.67	-9.51	-0.52	1.82e-18	Brugada syndrome;
KIRP	cis	rs10872587	0.500	rs362832	chr6:146660624	G/A	cg23711669	chr6:146136114	FBXO30	0.69	6.06	0.36	5.16e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.83	-10.05	-0.54	4.04e-20	Menarche (age at onset);
KIRP	cis	rs8014252	0.803	rs1959477	chr14:71034216	A/G	cg11204974	chr14:71022665	NA	-0.56	-6.04	-0.36	5.61e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4638749	0.501	rs2171181	chr2:108750391	G/C	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.07	-0.31	7.95e-7	Blood pressure;
KIRP	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg00981070	chr1:2046702	PRKCZ	0.4	5.63	0.34	4.85e-8	Height;
KIRP	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.46	9.29	0.51	8.37e-18	Multiple system atrophy;
KIRP	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg05998816	chr21:47859926	PCNT	0.53	5.76	0.34	2.48e-8	Lymphocyte counts;
KIRP	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg09658497	chr7:2847517	GNA12	-0.36	-5.04	-0.31	8.93e-7	Height;
KIRP	cis	rs7538876	1.000	rs56384645	chr1:17722952	T/C	cg07394400	chr1:17752023	RCC2	-0.36	-5.08	-0.31	7.38e-7	Basal cell carcinoma;
KIRP	cis	rs883565	0.792	rs813669	chr3:39181723	C/T	cg01426195	chr3:39028469	NA	0.53	6.97	0.41	2.9100000000000002e-11	Handedness;
KIRP	cis	rs853679	0.550	rs1225598	chr6:28160799	T/G	cg23281280	chr6:28129359	ZNF389	0.5	5.48	0.33	1.05e-7	Depression;
KIRP	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.83	9.93	0.54	9.08e-20	Pulmonary function decline;
KIRP	cis	rs4728302	0.869	rs11770927	chr7:133593126	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	6.01	0.36	6.75e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.64	9.58	0.52	1.09e-18	Vitiligo;
KIRP	trans	rs921874	0.586	rs2512332	chr11:86770257	A/T	cg22937172	chr2:240168862	HDAC4	0.55	6.17	0.37	2.78e-9	Total body bone mineral density;
KIRP	cis	rs7404928	0.957	rs56098067	chr16:23881203	C/T	cg21745164	chr16:23765304	CHP2	-0.42	-5.72	-0.34	3.09e-8	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.46	-5.41	-0.33	1.51e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg10047753	chr17:41438598	NA	1.12	18.2	0.76	1.84e-47	Menopause (age at onset);
KIRP	cis	rs4363385	0.510	rs55959888	chr1:152913490	A/G	cg07796016	chr1:152779584	LCE1C	-0.46	-5.7	-0.34	3.39e-8	Inflammatory skin disease;
KIRP	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg02297831	chr4:17616191	MED28	-0.64	-8.1	-0.46	2.56e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs151997	0.925	rs28077	chr5:50191946	T/A	cg06027927	chr5:50259733	NA	0.59	7.37	0.43	2.57e-12	Callous-unemotional behaviour;
KIRP	cis	rs7481584	0.924	rs16925010	chr11:3013996	C/T	cg25174290	chr11:3078921	CARS	-0.61	-6.42	-0.38	7.04e-10	Calcium levels;
KIRP	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	7.64	0.44	4.71e-13	Joint mobility (Beighton score);
KIRP	cis	rs9311676	0.656	rs11718352	chr3:58401480	G/A	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.2e-16	Motion sickness;
KIRP	cis	rs2976388	0.566	rs4736301	chr8:143829499	T/G	cg06565975	chr8:143823917	SLURP1	-0.53	-7.8	-0.45	1.74e-13	Urinary tract infection frequency;
KIRP	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	0.85	12.71	0.63	8.95e-29	Homoarginine levels;
KIRP	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	1.1	17.86	0.75	2.61e-46	Cognitive function;
KIRP	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.34	0.37	1.11e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11926764	chr11:92930916	SLC36A4	0.44	6.08	0.36	4.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg23933602	chr10:16859644	RSU1	0.56	6.17	0.37	2.84e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7630877	0.924	rs73060760	chr3:179658851	C/T	cg18765712	chr3:179670323	PEX5L	0.58	7.15	0.41	9.91e-12	Type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.47	6.71	0.39	1.3e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Visceral adipose tissue adjusted for BMI;
KIRP	cis	rs1971762	0.563	rs4759285	chr12:54079513	G/T	cg23533419	chr12:54090519	NA	-0.35	-5.23	-0.32	3.7e-7	Height;
KIRP	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.53	-8.14	-0.46	1.98e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg26441486	chr22:50317300	CRELD2	0.47	7.63	0.44	5.1e-13	Schizophrenia;
KIRP	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.71	-9.36	-0.51	5.08e-18	Pancreatic cancer;
KIRP	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.53	-0.43	9.32e-13	Initial pursuit acceleration;
KIRP	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg22676075	chr6:135203613	NA	0.49	6.95	0.41	3.3e-11	Red blood cell count;
KIRP	cis	rs1978968	0.763	rs9605473	chr22:18463266	C/T	cg02610425	chr22:18483192	MICAL3	-0.35	-5.28	-0.32	2.82e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs11997175	0.609	rs4733459	chr8:33663793	T/C	cg04338863	chr8:33670619	NA	0.4	5.4	0.33	1.57e-7	Body mass index;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg24568646	chr21:30446238	CCT8	0.92	6.11	0.36	3.83e-9	P wave terminal force;
KIRP	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	9.54	0.52	1.45e-18	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs10849893	0.557	rs7962143	chr12:121830033	G/T	cg01154721	chr12:121881891	KDM2B	-0.37	-4.89	-0.3	1.85e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs35300120	0.757	rs12097489	chr1:233653532	T/A	cg23054119	chr1:233659267	NA	-0.42	-5.93	-0.35	1.04e-8	Cognitive function;
KIRP	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.75	-11.93	-0.61	3.38e-26	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10267417	0.673	rs34499705	chr7:19956737	G/C	cg05791153	chr7:19748676	TWISTNB	0.47	4.96	0.3	1.31e-6	Night sleep phenotypes;
KIRP	cis	rs4006360	0.575	rs7503162	chr17:39233899	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.62	-0.48	8.4e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.68	7.03	0.41	2.03e-11	Corneal astigmatism;
KIRP	cis	rs362296	0.698	rs362282	chr4:3259671	G/A	cg06533319	chr4:3265114	C4orf44	0.53	6.11	0.36	3.93e-9	Parental longevity (mother's age at death);
KIRP	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg11271282	chr2:238384023	NA	0.46	5.35	0.32	2.01e-7	Prostate cancer;
KIRP	cis	rs6504340	0.790	rs35825473	chr17:46645394	G/A	cg05487507	chr17:46671861	LOC404266;HOXB5	0.47	5.4	0.33	1.57e-7	Primary tooth development (number of teeth);
KIRP	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg05579598	chr16:88989069	CBFA2T3	-0.29	-6.06	-0.36	4.95e-9	Social autistic-like traits;
KIRP	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg24804195	chr5:87968844	LOC645323	-0.47	-6.1	-0.36	4.2e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg19610905	chr11:61596333	FADS2	0.54	8.68	0.48	5.46e-16	Trans fatty acid levels;
KIRP	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg04455712	chr21:45112962	RRP1B	0.5	6.85	0.4	6.04e-11	Mean corpuscular volume;
KIRP	cis	rs501120	0.657	rs11238909	chr10:44688088	C/T	cg09554077	chr10:44749378	NA	0.43	5.15	0.31	5.33e-7	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.76	9.01	0.5	5.98e-17	Coronary artery disease;
KIRP	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.65	9.47	0.52	2.36e-18	Schizophrenia;
KIRP	cis	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg21546286	chr11:48923668	NA	0.47	6.13	0.36	3.49e-9	HDL cholesterol;
KIRP	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg05861140	chr6:150128134	PCMT1	-0.4	-5.28	-0.32	2.78e-7	Lung cancer;
KIRP	trans	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg25288420	chr1:78511713	GIPC2	-0.48	-6.25	-0.37	1.81e-9	Obesity-related traits;
KIRP	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.78	10.2	0.55	1.28e-20	Aortic root size;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg23693289	chr8:27183097	PTK2B	0.56	7.21	0.42	6.79e-12	Neuroticism;
KIRP	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs12496230	0.794	rs4856826	chr3:66858576	C/T	cg04995300	chr3:66848608	NA	0.45	7.09	0.41	1.44e-11	Type 2 diabetes;
KIRP	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.78e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9649213	0.593	rs6948540	chr7:97960066	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	8.28	0.47	7.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6102059	0.667	rs6129649	chr20:39234223	C/T	cg06665391	chr20:39312290	NA	-0.44	-5.39	-0.32	1.67e-7	LDL cholesterol;
KIRP	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs920590	0.643	rs13280085	chr8:19669959	G/T	cg03894339	chr8:19674705	INTS10	-0.41	-4.9	-0.3	1.75e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg17764715	chr19:33622953	WDR88	0.68	8.36	0.47	4.57e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg23067535	chr8:124195133	FAM83A	-0.8	-7.37	-0.43	2.62e-12	Urinary uromodulin levels;
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9810890	1.000	rs73198823	chr3:128484405	G/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs6969780	0.915	rs4722659	chr7:27166750	C/T	cg04317399	chr7:27170313	HOXA4	-0.35	-5.15	-0.31	5.34e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg09597638	chr17:3907349	NA	0.81	16.24	0.72	8.35e-41	Type 2 diabetes;
KIRP	cis	rs2219968	1.000	rs11783780	chr8:78971571	A/T	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	9.12	0.5	2.84e-17	Bone mineral density;
KIRP	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg01721255	chr8:58191610	C8orf71	0.56	5.35	0.32	2.01e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg09264619	chr17:80180166	NA	-0.51	-6.08	-0.36	4.63e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17554472	chr22:41940697	POLR3H	-0.66	-6.77	-0.4	9.15e-11	Vitiligo;
KIRP	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-8.5	-0.48	1.82e-15	Blood metabolite levels;
KIRP	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg06212747	chr3:49208901	KLHDC8B	0.47	4.91	0.3	1.64e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21733011	chr17:28257040	EFCAB5;SSH2	0.48	6.09	0.36	4.27e-9	Parkinson's disease;
KIRP	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-5.39	-0.32	1.68e-7	Aortic root size;
KIRP	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13174850	chr14:93673699	C14orf142;UBR7	0.5	6.05	0.36	5.23e-9	Parkinson's disease;
KIRP	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg24253500	chr15:84953950	NA	0.65	7.46	0.43	1.46e-12	Schizophrenia;
KIRP	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg06212747	chr3:49208901	KLHDC8B	0.65	5.61	0.34	5.4e-8	Menarche (age at onset);
KIRP	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg24375607	chr4:120327624	NA	0.39	4.9	0.3	1.76e-6	Diastolic blood pressure;
KIRP	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22338127	chr1:209979572	IRF6	0.4	5.31	0.32	2.48e-7	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
KIRP	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	1.06	17.87	0.75	2.49e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.74	11.11	0.58	1.69e-23	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	5.81	0.35	1.95e-8	Longevity;
KIRP	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg17724175	chr1:150552817	MCL1	0.37	6.3	0.37	1.34e-9	Melanoma;
KIRP	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg19997662	chr15:101784653	CHSY1	-0.7	-10.73	-0.56	2.8e-22	Corneal structure;
KIRP	cis	rs742071	0.527	rs17352100	chr1:18952112	A/G	cg22389438	chr1:18926496	NA	0.39	5.85	0.35	1.53e-8	Nonsyndromic cleft lip with cleft palate;Orofacial clefts;
KIRP	cis	rs7224685	0.501	rs2603025	chr17:3996964	C/A	cg26134248	chr17:3907702	NA	-0.55	-8.1	-0.46	2.63e-14	Type 2 diabetes;
KIRP	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg07796016	chr1:152779584	LCE1C	-0.43	-5.52	-0.33	8.7e-8	Inflammatory skin disease;
KIRP	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg14092571	chr14:90743983	NA	-0.43	-4.95	-0.3	1.4e-6	Mortality in heart failure;
KIRP	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.81	0.45	1.66e-13	Neuroticism;
KIRP	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg19507638	chr5:93509721	C5orf36	-0.54	-5.08	-0.31	7.32e-7	Diabetic retinopathy;
KIRP	cis	rs2067663	0.786	rs627450	chr5:88060311	G/T	cg18498987	chr5:88179539	MEF2C	-0.38	-4.91	-0.3	1.7e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg07775547	chr4:1625484	NA	0.45	5.4	0.33	1.55e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.72	-0.34	3.12e-8	Morning vs. evening chronotype;
KIRP	cis	rs7224314	1.000	rs7224314	chr17:65386214	A/C	cg01507342	chr17:65387096	PITPNC1	-0.49	-7.0	-0.41	2.42e-11	Diisocyanate-induced asthma;
KIRP	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	trans	rs7404928	0.718	rs12447916	chr16:23858915	G/A	cg06734812	chr19:3223915	BRUNOL5	0.61	6.15	0.37	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.68	9.66	0.52	6.45e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs883565	0.569	rs7638329	chr3:39020408	T/C	cg01426195	chr3:39028469	NA	-0.57	-9.02	-0.5	5.31e-17	Handedness;
KIRP	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.57	-0.39	2.95e-10	Depression;
KIRP	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	15.58	0.7	1.5e-38	Platelet count;
KIRP	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.41	0.62	8.85e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7520050	0.966	rs4076006	chr1:46438076	C/T	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.32	0.47	6.01e-15	Neutrophil percentage of white cells;
KIRP	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg23163573	chr2:108905468	SULT1C2	0.27	5.21	0.32	3.96e-7	Blood pressure;
KIRP	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg17788227	chr17:7347145	FGF11;CHRNB1	-0.49	-5.37	-0.32	1.81e-7	Androgen levels;
KIRP	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.12	-0.36	3.71e-9	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs860295	0.702	rs11264380	chr1:155520144	T/C	cg02153340	chr1:155202674	NA	-0.51	-7.1	-0.41	1.32e-11	Body mass index;
KIRP	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18252515	chr7:66147081	NA	-0.46	-5.33	-0.32	2.21e-7	Aortic root size;
KIRP	cis	rs4805272	0.962	rs2870546	chr19:29324815	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9217	0.813	rs8081271	chr17:7384628	A/G	cg02795151	chr17:7402630	POLR2A	-0.56	-6.88	-0.4	5.08e-11	Height;
KIRP	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg09408571	chr1:101003634	GPR88	-0.24	-5.39	-0.32	1.67e-7	Monocyte count;
KIRP	cis	rs860295	0.702	rs11264383	chr1:155545346	C/T	cg02153340	chr1:155202674	NA	-0.55	-7.41	-0.43	1.97e-12	Body mass index;
KIRP	cis	rs580438	0.510	rs877511	chr3:13402150	C/T	cg10657019	chr3:13328039	NA	-0.61	-8.04	-0.46	3.9e-14	Myringotomy;
KIRP	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.87	-0.35	1.43e-8	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs8018808	0.936	rs4903576	chr14:77844869	A/G	cg20045696	chr14:77926864	AHSA1	-0.42	-5.19	-0.31	4.43e-7	Myeloid white cell count;
KIRP	cis	rs9475752	0.739	rs2613119	chr6:56809322	A/G	cg22880620	chr6:56820808	BEND6;DST	-0.49	-5.11	-0.31	6.45e-7	Menarche (age at onset);
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg04025307	chr7:1156635	C7orf50	0.81	8.38	0.47	4.15e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg06565975	chr8:143823917	SLURP1	-0.34	-5.08	-0.31	7.33e-7	Urinary tract infection frequency;
KIRP	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg00405596	chr8:11794950	NA	0.53	6.36	0.38	9.69e-10	Mood instability;
KIRP	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.7e-10	Red blood cell count;
KIRP	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg06521331	chr12:34319734	NA	-0.62	-7.42	-0.43	1.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.9	-15.81	-0.71	2.41e-39	Electrocardiographic conduction measures;
KIRP	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg09788416	chr12:39539408	NA	-0.39	-5.31	-0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.77	5.59	0.34	5.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9399135	0.715	rs7743042	chr6:135419834	A/G	cg24558204	chr6:135376177	HBS1L	0.44	5.57	0.33	6.67e-8	Red blood cell count;
KIRP	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.32	-0.32	2.37e-7	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10563352	chr2:228028774	COL4A3;COL4A4	0.48	6.41	0.38	7.24e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg19197139	chr17:4613644	ARRB2	0.74	7.6	0.44	6.27e-13	Lymphocyte counts;
KIRP	cis	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg15623398	chr1:160312544	COPA;NCSTN	-0.35	-4.92	-0.3	1.6e-6	C-reactive protein;
KIRP	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg00647317	chr7:50633725	DDC	0.46	7.0	0.41	2.36e-11	Body mass index;
KIRP	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.83	0.49	2.05e-16	Bladder cancer;
KIRP	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.45	0.59	1.29e-24	Heart rate;
KIRP	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	9.16	0.5	2.12e-17	Neuroticism;
KIRP	cis	rs860295	0.557	rs10796944	chr1:155416328	G/A	cg02153340	chr1:155202674	NA	-0.56	-6.87	-0.4	5.08e-11	Body mass index;
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.34	-0.51	5.94e-18	Platelet count;
KIRP	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.9	-13.66	-0.66	5.48e-32	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs1973993	0.745	rs56119386	chr1:96962215	C/T	cg10631902	chr5:14652156	NA	-0.59	-8.37	-0.47	4.24e-15	Weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25887236	chr18:74844781	MBP	0.48	6.24	0.37	1.91e-9	Parkinson's disease;
KIRP	cis	rs10875746	0.669	rs11168487	chr12:48640709	G/A	cg20731937	chr12:48336164	NA	0.49	5.94	0.35	9.58e-9	Longevity (90 years and older);
KIRP	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.61	8.42	0.47	3.06e-15	Brugada syndrome;
KIRP	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-6.92	-0.4	3.79e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs7773004	0.526	rs806973	chr6:26148326	A/G	cg00631329	chr6:26305371	NA	-0.4	-4.91	-0.3	1.7e-6	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.47	6.43	0.38	6.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2839627	0.638	rs9974287	chr21:44317003	T/G	cg03543861	chr21:44258195	NA	0.57	6.06	0.36	5.21e-9	Information processing speed;
KIRP	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-14.01	-0.67	3.5e-33	Blood trace element (Zn levels);
KIRP	cis	rs882300	0.934	rs1519523	chr2:136934449	A/C	cg05194412	chr2:137003533	NA	-0.4	-5.39	-0.33	1.62e-7	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg03959625	chr15:84868606	LOC388152	0.49	5.82	0.35	1.82e-8	Schizophrenia;
KIRP	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	10.37	0.55	3.77e-21	Blood protein levels;
KIRP	cis	rs752010	0.902	rs28635337	chr1:42101391	G/A	cg06885757	chr1:42089581	HIVEP3	0.59	8.96	0.5	8.3e-17	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	1.06	15.31	0.7	1.32e-37	Cognitive function;
KIRP	trans	rs9420	0.528	rs34052104	chr11:57384519	A/C	cg16592121	chr10:133794558	BNIP3	-0.32	-6.05	-0.36	5.5e-9	Schizophrenia;
KIRP	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs11671005	0.779	rs35631681	chr19:58999840	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.51	-5.04	-0.31	9.19e-7	Mean platelet volume;
KIRP	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg03526459	chr1:146549940	NA	-0.45	-5.98	-0.36	7.95e-9	HIV-1 control;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15171982	chr2:183903302	NCKAP1	0.53	7.01	0.41	2.28e-11	Parkinson's disease;
KIRP	cis	rs10024216	0.559	rs115820155	chr4:38772730	G/T	cg06935464	chr4:38784597	TLR10	0.39	4.89	0.3	1.82e-6	Systemic sclerosis (anti-topoisomerase-positive);
KIRP	cis	rs4363385	0.510	rs11205182	chr1:153045748	C/T	cg07796016	chr1:152779584	LCE1C	-0.41	-5.21	-0.32	3.92e-7	Inflammatory skin disease;
KIRP	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12463550	chr7:65579703	CRCP	0.75	4.85	0.3	2.17e-6	Diabetic kidney disease;
KIRP	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.61	8.09	0.46	2.78e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
KIRP	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg00405596	chr8:11794950	NA	0.58	8.2	0.46	1.31e-14	Neuroticism;
KIRP	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg10326726	chr10:51549505	MSMB	-0.6	-8.94	-0.5	9.54e-17	Prostate-specific antigen levels;
KIRP	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.25	-0.55	9.4e-21	Neuroticism;
KIRP	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg19507638	chr5:93509721	C5orf36	-0.63	-5.69	-0.34	3.62e-8	Diabetic retinopathy;
KIRP	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg26585981	chr11:48327164	OR4S1	-0.5	-6.29	-0.37	1.41e-9	Migraine - clinic-based;
KIRP	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-7.35	-0.42	2.92e-12	Glomerular filtration rate;
KIRP	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.43	5.56	0.33	6.85e-8	Blood metabolite levels;
KIRP	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-1.21	-14.19	-0.67	8.31e-34	Breast cancer;
KIRP	trans	rs6832769	0.621	rs10033028	chr4:56519876	C/G	ch.5.1339988F	chr5:71435042	MAP1B	0.54	6.11	0.36	3.87e-9	Personality dimensions;
KIRP	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-0.78	-8.43	-0.47	2.95e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg00576331	chr11:65640516	EFEMP2	0.5	5.56	0.33	6.98e-8	Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15676015	chr11:67272636	PITPNM1	0.56	7.15	0.41	9.97e-12	Parkinson's disease;
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.52	-6.43	-0.38	6.72e-10	Testicular germ cell tumor;
KIRP	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-4.98	-0.3	1.22e-6	IgG glycosylation;
KIRP	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.48	-5.91	-0.35	1.11e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs918629	0.679	rs12055287	chr5:95272428	G/C	cg16656078	chr5:95278638	ELL2	-0.5	-7.24	-0.42	5.65e-12	IgG glycosylation;
KIRP	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.29e-7	Red blood cell count;
KIRP	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg21551340	chr2:1609508	NA	0.52	5.04	0.31	8.99e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg10189774	chr4:17578691	LAP3	0.52	6.53	0.38	3.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg23682824	chr7:23144976	KLHL7	0.47	5.69	0.34	3.58e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-6.18	-0.37	2.58e-9	Schizophrenia;
KIRP	cis	rs761772	0.810	rs429216	chr17:76126204	G/T	cg06146665	chr17:76799964	USP36	-0.38	-5.14	-0.31	5.62e-7	Glycated hemoglobin levels;
KIRP	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.64	8.16	0.46	1.75e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg13699009	chr12:122356056	WDR66	0.66	10.3	0.55	6.6e-21	Mean corpuscular volume;
KIRP	cis	rs7172677	1.000	rs55662404	chr15:75432341	G/A	cg14082893	chr15:75400931	NA	-0.35	-4.91	-0.3	1.65e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02034447	chr16:89574710	SPG7	0.4	4.97	0.3	1.28e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg09165964	chr15:75287851	SCAMP5	-0.9	-8.36	-0.47	4.7e-15	Lung cancer;
KIRP	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg22117172	chr7:91764530	CYP51A1	-0.38	-5.45	-0.33	1.21e-7	Breast cancer;
KIRP	trans	rs76288851	0.799	rs73193177	chr3:126681111	A/G	cg13821433	chr2:26726535	OTOF	0.57	6.2	0.37	2.38e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-1.08	-10.52	-0.56	1.34e-21	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs2998286	0.862	rs2790448	chr10:28801757	G/A	cg10174683	chr16:85619974	NA	-0.67	-6.08	-0.36	4.54e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs7546668	0.948	rs12736181	chr1:15869284	G/A	cg21858823	chr1:15850916	CASP9	0.45	5.01	0.3	1.03e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.67	-8.12	-0.46	2.3e-14	Iron status biomarkers;
KIRP	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg23743428	chr13:21893420	NA	-0.36	-5.17	-0.31	4.78e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.64	-6.99	-0.41	2.51e-11	Gut microbiome composition (summer);
KIRP	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.75	10.88	0.57	9.17e-23	Body mass index;
KIRP	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg24642844	chr7:1081250	C7orf50	-0.86	-7.43	-0.43	1.8e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7017697	1.000	rs6980875	chr8:19685948	C/T	cg03894339	chr8:19674705	INTS10	-0.51	-6.41	-0.38	7.37e-10	Breast cancer;
KIRP	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg27165867	chr14:105738592	BRF1	-0.41	-4.87	-0.3	2.01e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.44	-0.38	6.31e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs9815354	1.000	rs61744385	chr3:41756986	A/T	cg03022575	chr3:42003672	ULK4	0.55	6.1	0.36	4.02e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.48	5.75	0.34	2.58e-8	Diastolic blood pressure;
KIRP	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.15	-0.41	1.01e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9810890	1.000	rs73198874	chr3:128538514	A/T	cg15033153	chr3:128514015	RAB7A	0.72	5.04	0.31	8.98e-7	Dental caries;
KIRP	cis	rs34779708	0.931	rs35317849	chr10:35285721	C/A	cg03585969	chr10:35415529	CREM	0.84	10.09	0.54	2.9e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1106684	1.000	rs4535659	chr7:131454056	A/G	cg13607082	chr12:122652224	LRRC43	0.6	6.76	0.4	9.71e-11	Body mass index;
KIRP	cis	rs11997175	0.766	rs60855034	chr8:33684732	G/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.77	0.35	2.36e-8	Body mass index;
KIRP	cis	rs34421088	0.532	rs2736258	chr8:11170449	C/T	cg00405596	chr8:11794950	NA	0.45	5.47	0.33	1.11e-7	Neuroticism;
KIRP	cis	rs4523957	0.583	rs2984942	chr17:2030155	A/G	cg16513277	chr17:2031491	SMG6	-0.86	-12.6	-0.63	2e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.82	-12.02	-0.61	1.76e-26	Prudent dietary pattern;
KIRP	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.96	-16.78	-0.73	1.23e-42	Height;
KIRP	cis	rs959260	1.000	rs9902966	chr17:73362147	C/T	cg20590849	chr17:73267439	MIF4GD	-0.61	-6.56	-0.39	3.19e-10	Systemic lupus erythematosus;
KIRP	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18252515	chr7:66147081	NA	-0.42	-4.86	-0.3	2.12e-6	Aortic root size;
KIRP	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.72	9.88	0.53	1.36e-19	Prostate cancer;
KIRP	cis	rs6832769	1.000	rs2177129	chr4:56365414	C/T	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	1.02	18.97	0.77	4.63e-50	Heart rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15675420	chr19:12273866	ZNF136	0.51	6.37	0.38	9.04e-10	Parkinson's disease;
KIRP	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs12712073	0.845	rs1370353	chr2:100764824	G/C	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.36	-0.42	2.69e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs14403	1.000	rs14403	chr1:243663893	A/G	cg21452805	chr1:244014465	NA	-0.57	-5.78	-0.35	2.26e-8	Schizophrenia;
KIRP	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.46	-7.04	-0.41	1.89e-11	Coronary artery disease;
KIRP	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.67	-8.78	-0.49	2.9e-16	Blood metabolite levels;
KIRP	cis	rs7017914	0.934	rs62530826	chr8:71641643	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg19575753	chr5:1948995	NA	-0.43	-5.07	-0.31	7.99e-7	Gut microbiome composition (winter);
KIRP	cis	rs7017914	0.934	rs35214141	chr8:71574564	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs66561647	0.719	rs7812386	chr8:128937609	C/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.49	6.01	0.36	6.64e-9	Hemoglobin concentration;
KIRP	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06544989	chr22:39130855	UNC84B	0.44	6.58	0.39	2.75e-10	Menopause (age at onset);
KIRP	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.65	8.85	0.49	1.81e-16	Alcohol dependence;
KIRP	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg21573476	chr21:45109991	RRP1B	-0.61	-8.75	-0.49	3.51e-16	Mean corpuscular volume;
KIRP	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg10189774	chr4:17578691	LAP3	0.43	5.06	0.31	8.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.71	-9.95	-0.54	8.16e-20	Primary sclerosing cholangitis;
KIRP	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.18	-0.37	2.67e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1440410	0.571	rs4690768	chr4:144039278	G/T	cg01719995	chr4:144104893	USP38	-0.46	-5.79	-0.35	2.11e-8	Ischemic stroke;
KIRP	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg13147721	chr7:65941812	NA	-0.57	-4.97	-0.3	1.27e-6	Diabetic kidney disease;
KIRP	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg22549504	chr19:17448937	GTPBP3	0.46	5.05	0.31	8.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.6	-6.95	-0.41	3.26e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs1322639	0.614	rs6925201	chr6:169563357	C/T	cg04662567	chr6:169592167	NA	0.62	5.41	0.33	1.51e-7	Pulse pressure;
KIRP	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.54	6.33	0.37	1.12e-9	Aortic root size;
KIRP	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg04132472	chr17:19861366	AKAP10	0.42	5.84	0.35	1.62e-8	Schizophrenia;
KIRP	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg25356066	chr3:128598488	ACAD9	0.48	5.53	0.33	8.16e-8	IgG glycosylation;
KIRP	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg25174290	chr11:3078921	CARS	-0.67	-8.69	-0.48	5.05e-16	Calcium levels;
KIRP	cis	rs73200209	0.744	rs7974638	chr12:116462700	C/G	cg01776926	chr12:116560359	MED13L	-0.5	-5.61	-0.34	5.41e-8	Total body bone mineral density;
KIRP	cis	rs16973500	0.808	rs72801786	chr16:71955085	C/T	cg09427745	chr16:71932006	KIAA0174	-0.59	-5.1	-0.31	6.74e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg26531700	chr6:26746687	NA	0.41	5.58	0.34	6.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.93	-0.45	7.51e-14	Mean corpuscular volume;
KIRP	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg23625390	chr15:77176239	SCAPER	0.54	7.01	0.41	2.29e-11	Blood metabolite levels;
KIRP	cis	rs4664293	0.867	rs2303550	chr2:160637621	G/A	cg08347373	chr2:160653686	CD302	-0.42	-6.43	-0.38	6.58e-10	Monocyte percentage of white cells;
KIRP	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg06533319	chr4:3265114	C4orf44	0.59	7.69	0.44	3.49e-13	Parental longevity (mother's age at death);
KIRP	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	0.88	7.06	0.41	1.69e-11	Mitochondrial DNA levels;
KIRP	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs2230307	0.536	rs581097	chr1:100515920	C/T	cg24955406	chr1:100503596	HIAT1	0.69	7.87	0.45	1.1e-13	Carotid intima media thickness;
KIRP	cis	rs6859018	0.950	rs3212220	chr5:158754195	C/A	cg26646896	chr5:158686746	NA	-0.34	-4.95	-0.3	1.39e-6	Serum sulfate level;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23206325	chr1:78353422	NEXN	0.4	6.25	0.37	1.79e-9	Migraine with aura;
KIRP	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.44	6.64	0.39	2.04e-10	Major depressive disorder;
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.37	5.92	0.35	1.08e-8	Electroencephalogram traits;
KIRP	cis	rs2637030	0.515	rs2130744	chr5:52896723	C/T	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08822215	chr16:89438651	ANKRD11	-0.44	-6.04	-0.36	5.71e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg02336718	chr17:17403227	NA	-0.35	-5.49	-0.33	1.01e-7	Total body bone mineral density;
KIRP	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg13906792	chr15:75199810	C15orf17	-0.37	-5.62	-0.34	5.07e-8	Breast cancer;
KIRP	cis	rs12681366	0.663	rs2921389	chr8:95466366	G/A	cg13257157	chr8:95487014	RAD54B	0.41	5.05	0.31	8.78e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg00857998	chr1:205179979	DSTYK	0.49	6.26	0.37	1.67e-9	Red blood cell count;
KIRP	cis	rs6722613	0.900	rs6546070	chr2:25531779	A/G	cg10614445	chr2:25526696	DNMT3A	-0.32	-5.26	-0.32	3.12e-7	Ossification of the posterior longitudinal ligament of the spine;
KIRP	cis	rs3096299	0.646	rs918722	chr16:89415081	C/G	cg07511934	chr16:89386912	ANKRD11	0.49	6.32	0.37	1.2e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	7.99	0.45	5.16e-14	Eosinophil percentage of white cells;
KIRP	cis	rs7680126	0.536	rs3796841	chr4:10007904	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	4.87	0.3	2.01e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg05527609	chr1:210001259	C1orf107	-0.43	-5.28	-0.32	2.79e-7	Red blood cell count;
KIRP	cis	rs1062746	0.694	rs62053080	chr16:87378214	T/G	cg02258303	chr16:87377426	FBXO31	-0.54	-6.68	-0.39	1.59e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg12369402	chr1:90227771	NA	-0.36	-5.29	-0.32	2.69e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18252515	chr7:66147081	NA	-0.44	-5.42	-0.33	1.41e-7	Aortic root size;
KIRP	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.87e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-7.54	-0.43	9.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs61884328	0.789	rs3751097	chr11:46916693	C/T	cg10758369	chr1:48459236	NA	0.44	6.18	0.37	2.63e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg21361702	chr7:150065534	REPIN1	0.5	4.97	0.3	1.24e-6	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.27e-12	Bladder cancer;
KIRP	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.65	9.17	0.5	1.9e-17	Alcohol dependence;
KIRP	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.84	0.57	1.27e-22	Cognitive test performance;
KIRP	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.66	8.68	0.48	5.48e-16	Menarche (age at onset);
KIRP	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06634786	chr22:41940651	POLR3H	-0.41	-4.85	-0.3	2.21e-6	Vitiligo;
KIRP	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.77	-11.07	-0.58	2.16e-23	Blood metabolite levels;
KIRP	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.71	7.7	0.44	3.32e-13	Corneal astigmatism;
KIRP	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg13147721	chr7:65941812	NA	-0.97	-6.86	-0.4	5.62e-11	Diabetic kidney disease;
KIRP	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg08283408	chr3:49949060	MON1A	-0.41	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs2275565	0.808	rs12138911	chr1:236977143	T/C	cg17297354	chr1:237056641	MTR	-0.43	-5.63	-0.34	4.87e-8	Homocysteine levels;
KIRP	cis	rs311392	0.867	rs434952	chr8:55091998	C/T	cg20636351	chr8:55087400	NA	-0.62	-7.63	-0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg04989706	chr14:50066350	PPIL5	-0.43	-5.02	-0.3	1.01e-6	Carotid intima media thickness;
KIRP	cis	rs6988985	0.560	rs4736343	chr8:143933200	G/A	cg10324643	chr8:143916377	GML	0.42	4.94	0.3	1.41e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg22117172	chr7:91764530	CYP51A1	-0.44	-6.15	-0.36	3.13e-9	Breast cancer;
KIRP	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg16296679	chr22:42394374	WBP2NL	0.36	4.94	0.3	1.45e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg09264619	chr17:80180166	NA	0.41	6.11	0.36	3.89e-9	Life satisfaction;
KIRP	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.91	14.33	0.67	2.95e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.68	0.39	1.6e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2273669	0.504	rs11966104	chr6:109459287	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-5.12	-0.31	6.11e-7	Prostate cancer;
KIRP	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.65	6.83	0.4	6.7e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs752010	0.523	rs10890159	chr1:42118282	A/G	cg06885757	chr1:42089581	HIVEP3	0.56	8.53	0.48	1.55e-15	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg00631329	chr6:26305371	NA	-0.55	-6.7	-0.39	1.44e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2213920	0.749	rs10121366	chr9:118244022	T/C	cg13918206	chr9:118159781	DEC1	0.94	9.81	0.53	2.17e-19	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs2073300	1.000	rs2207989	chr20:23446014	T/G	cg12062639	chr20:23401060	NAPB	0.8	6.97	0.41	2.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.75	-10.37	-0.55	3.87e-21	Plateletcrit;Platelet count;
KIRP	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-8.45	-0.47	2.58e-15	Response to antipsychotic treatment;
KIRP	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.63	-9.22	-0.51	1.4e-17	Body mass index;
KIRP	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.55	6.46	0.38	5.48e-10	Mean corpuscular volume;
KIRP	cis	rs10761482	0.813	rs7087726	chr10:62162582	G/C	cg01186212	chr10:62110162	ANK3	-0.29	-4.87	-0.3	2.04e-6	Schizophrenia;
KIRP	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.58	-6.12	-0.36	3.68e-9	Obesity-related traits;
KIRP	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg22138327	chr13:27999177	GTF3A	1.0	7.55	0.43	8.64e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.28	11.72	0.6	1.71e-25	Diabetic retinopathy;
KIRP	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.93	13.5	0.65	1.94e-31	Bladder cancer;
KIRP	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg05335186	chr13:53173507	NA	0.32	5.09	0.31	7e-7	Lewy body disease;
KIRP	cis	rs965513	0.524	rs1443432	chr9:100583195	C/T	cg13688889	chr9:100608707	NA	-0.59	-7.16	-0.42	9.45e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11987759	chr7:65425863	GUSB	0.59	7.84	0.45	1.4e-13	Aortic root size;
KIRP	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg05304507	chr6:116381966	FRK	0.19	5.22	0.32	3.84e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4959799	0.557	rs6901135	chr6:3273694	T/C	cg03657281	chr6:3270030	SLC22A23	0.79	6.06	0.36	5.14e-9	Survival in rectal cancer;
KIRP	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.63	-8.15	-0.46	1.81e-14	Colorectal cancer;
KIRP	cis	rs2367563	0.927	rs2367562	chr12:96057213	G/A	cg19013339	chr12:96052514	NTN4	0.35	5.53	0.33	8.28e-8	Allergic dermatitis (nickel);
KIRP	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.81	-11.05	-0.58	2.69e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs72634258	0.520	rs12078018	chr1:7857309	G/A	cg26816564	chr1:7831052	VAMP3	0.85	8.27	0.47	8.6e-15	Inflammatory bowel disease;
KIRP	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg06640241	chr16:89574553	SPG7	0.58	7.35	0.42	2.92e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.83	-10.26	-0.55	8.59e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.62	-0.52	8.25e-19	Gut microbiome composition (summer);
KIRP	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.4	5.76	0.34	2.56e-8	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.73	-9.39	-0.51	4.21e-18	Squamous cell carcinoma;
KIRP	cis	rs12786942	0.569	rs10082588	chr11:101315000	A/G	cg03942599	chr11:101341554	TRPC6	0.56	7.71	0.44	3.1e-13	Facial depth;
KIRP	cis	rs7737355	0.947	rs17167760	chr5:130782699	A/G	cg25547332	chr5:131281432	NA	-0.46	-5.17	-0.31	4.89e-7	Life satisfaction;
KIRP	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.42	6.15	0.37	3.05e-9	Lipoprotein (a) levels;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.78	0.49	2.81e-16	Life satisfaction;
KIRP	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs3825932	0.961	rs2870085	chr15:79234268	T/C	cg25744700	chr15:79237217	CTSH	0.43	5.25	0.32	3.32e-7	Type 1 diabetes;
KIRP	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.69	-10.59	-0.56	7.54e-22	Educational attainment;
KIRP	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.58	-5.02	-0.3	1e-6	Schizophrenia;
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.19e-7	Life satisfaction;
KIRP	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	trans	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg17822266	chr1:2720087	NA	-0.45	-6.24	-0.37	1.94e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg11608241	chr8:8085544	FLJ10661	0.45	5.46	0.33	1.17e-7	Neuroticism;
KIRP	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.68	8.74	0.49	3.74e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.65	-8.28	-0.47	7.76e-15	Iron status biomarkers;
KIRP	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.74	9.7	0.53	4.63e-19	Schizophrenia;
KIRP	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-10.3	-0.55	6.66e-21	Morning vs. evening chronotype;
KIRP	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.49	-5.81	-0.35	1.96e-8	Carotid intima media thickness;
KIRP	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg14440974	chr22:39074834	NA	-0.39	-4.91	-0.3	1.64e-6	Menopause (age at onset);
KIRP	cis	rs8014252	0.803	rs2018131	chr14:71062432	T/C	cg11204974	chr14:71022665	NA	-0.57	-6.2	-0.37	2.34e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.82	0.35	1.81e-8	Height;
KIRP	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg01843524	chr15:80216276	C15orf37;ST20	0.42	5.31	0.32	2.39e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs4400599	0.568	rs11265251	chr1:154157090	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.39	-5.81	-0.35	1.92e-8	Platelet distribution width;
KIRP	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg09137382	chr11:130731461	NA	0.6	8.72	0.49	4.22e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg23307798	chr14:103986281	CKB	0.46	6.56	0.39	3.22e-10	Body mass index;
KIRP	cis	rs12580194	0.593	rs7959124	chr12:55726957	A/G	cg19537932	chr12:55886519	OR6C68	-0.51	-6.55	-0.39	3.35e-10	Cancer;
KIRP	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	0.75	6.61	0.39	2.31e-10	Blood pressure (smoking interaction);
KIRP	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs2594989	0.779	rs13353407	chr3:11585299	C/T	cg01796438	chr3:11312864	ATG7	0.44	5.6	0.34	5.62e-8	Circulating chemerin levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26433140	chr1:55181354	TTC4	0.49	6.11	0.36	3.97e-9	Parkinson's disease;
KIRP	cis	rs4144743	1.000	rs67615769	chr17:45325478	A/G	cg18085866	chr17:45331354	ITGB3	-0.81	-8.86	-0.49	1.59e-16	Body mass index;
KIRP	cis	rs2151522	0.724	rs2022479	chr6:127117724	A/G	cg21431617	chr6:127135037	NA	-0.31	-5.67	-0.34	4e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.16	0.31	5.08e-7	Smoking behavior;
KIRP	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg04731861	chr2:219085781	ARPC2	0.29	7.44	0.43	1.67e-12	Colorectal cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26314566	chr7:44153406	AEBP1	0.49	6.29	0.37	1.46e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.6	7.77	0.44	2.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg04727924	chr7:799746	HEATR2	-0.79	-8.95	-0.5	8.95e-17	Cerebrospinal P-tau181p levels;
KIRP	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.41	5.06	0.31	8.03e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg17133734	chr15:86042851	AKAP13	-0.46	-5.77	-0.35	2.35e-8	Coronary artery disease;
KIRP	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg05044414	chr3:183734942	ABCC5	0.39	5.79	0.35	2.14e-8	Anterior chamber depth;
KIRP	cis	rs259842	0.824	rs2367797	chr2:180724510	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.41	-5.93	-0.35	1.02e-8	Blood protein levels;
KIRP	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg11502198	chr6:26597334	ABT1	-0.79	-5.38	-0.32	1.71e-7	Small cell lung carcinoma;
KIRP	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.47	-6.73	-0.39	1.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.83	0.35	1.74e-8	Motion sickness;
KIRP	cis	rs57590327	0.679	rs13061830	chr3:81525696	A/G	cg07356753	chr3:81810745	GBE1	-0.53	-5.66	-0.34	4.1e-8	Extraversion;
KIRP	cis	rs735860	0.726	rs209507	chr6:53194768	T/A	cg10236188	chr6:53219634	NA	0.41	5.46	0.33	1.18e-7	Glaucoma;
KIRP	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.52	9.45	0.52	2.74e-18	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7808935	0.914	rs10807843	chr7:27992390	T/C	cg05786569	chr7:27702416	HIBADH	0.52	5.03	0.31	9.67e-7	Prostate cancer;
KIRP	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	1.08	6.22	0.37	2.1e-9	Height;
KIRP	cis	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg21775007	chr8:11205619	TDH	-0.48	-6.33	-0.37	1.13e-9	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10335543	chr14:102829157	TECPR2;CINP	0.49	6.03	0.36	6.02e-9	Parkinson's disease;
KIRP	cis	rs1461503	1.000	rs1461503	chr11:122845075	A/C	cg27398637	chr11:122830231	C11orf63	-0.65	-8.52	-0.48	1.63e-15	Menarche (age at onset);
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.64	10.51	0.56	1.37e-21	Lymphocyte counts;
KIRP	cis	rs13401104	0.796	rs11894483	chr2:237114619	T/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg09695851	chr17:3907499	NA	-0.82	-14.63	-0.68	2.76e-35	Type 2 diabetes;
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.39	-5.43	-0.33	1.32e-7	Lung cancer;
KIRP	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg01028140	chr2:1542097	TPO	-0.69	-6.98	-0.41	2.72e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg01320579	chr17:75405842	SEPT9	0.45	7.22	0.42	6.36e-12	Airflow obstruction;
KIRP	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg23625390	chr15:77176239	SCAPER	0.48	6.42	0.38	7.01e-10	Blood metabolite levels;
KIRP	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg25902810	chr10:99078978	FRAT1	0.59	7.22	0.42	6.43e-12	Monocyte count;
KIRP	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.68	-9.39	-0.51	4.26e-18	Myeloid white cell count;
KIRP	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.55	9.36	0.51	5.24e-18	Height;
KIRP	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.65	-8.49	-0.48	1.99e-15	Blood trace element (Cu levels);
KIRP	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.88	-0.4	4.95e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg23100626	chr2:96804247	ASTL	0.45	5.66	0.34	4.26e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg16077055	chr2:106428750	NCK2	0.31	6.19	0.37	2.53e-9	Addiction;
KIRP	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.77	9.15	0.5	2.26e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs405956	0.769	rs4946657	chr6:105582076	C/T	cg22580625	chr6:105627791	POPDC3	-0.45	-5.03	-0.31	9.58e-7	QT interval;
KIRP	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg19077165	chr18:44547161	KATNAL2	-0.39	-4.95	-0.3	1.39e-6	Educational attainment;
KIRP	cis	rs4765905	0.610	rs2239023	chr12:2310616	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.92	-0.4	3.94e-11	Schizophrenia;
KIRP	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg11608241	chr8:8085544	FLJ10661	0.38	4.88	0.3	1.9e-6	Mood instability;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg11050527	chr8:54755511	ATP6V1H	0.56	6.52	0.38	4.05e-10	Sleep duration;
KIRP	cis	rs6191	0.874	rs852976	chr5:142685438	T/C	cg08845721	chr5:142780693	NR3C1	-0.39	-5.28	-0.32	2.86e-7	Night sleep phenotypes;
KIRP	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.71	8.55	0.48	1.31e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09959495	chr2:237029385	AGAP1	0.45	6.08	0.36	4.63e-9	Survival in pancreatic cancer;
KIRP	cis	rs7005380	0.531	rs6469860	chr8:120909348	G/A	cg21645572	chr8:120931649	DEPDC6	0.42	4.86	0.3	2.11e-6	Interstitial lung disease;
KIRP	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg06307176	chr5:131281290	NA	0.57	6.41	0.38	7.48e-10	Life satisfaction;
KIRP	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21545522	chr1:205238299	TMCC2	0.49	6.47	0.38	5.39e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.88	-0.49	1.4e-16	Resting heart rate;
KIRP	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg00631329	chr6:26305371	NA	0.55	7.15	0.41	9.78e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.26e-12	Prudent dietary pattern;
KIRP	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg06204229	chr3:52865917	ITIH4	0.46	5.32	0.32	2.28e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg05347473	chr6:146136440	FBXO30	-0.55	-7.68	-0.44	3.87e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12210905	0.688	rs72841376	chr6:27456321	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.16	-0.37	2.94e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg23307798	chr14:103986281	CKB	0.41	5.02	0.3	1e-6	Monocyte count;
KIRP	cis	rs8070740	0.841	rs4790771	chr17:5324966	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	7.43	0.43	1.84e-12	Menopause (age at onset);
KIRP	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.18	-0.46	1.53e-14	Response to antipsychotic treatment;
KIRP	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	trans	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg09904177	chr6:26538194	HMGN4	0.46	6.2	0.37	2.41e-9	Schizophrenia;
KIRP	cis	rs3857067	0.967	rs1841925	chr4:95035175	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.38	-4.89	-0.3	1.8e-6	QT interval;
KIRP	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg23102388	chr7:1867652	MAD1L1	-0.44	-5.35	-0.32	1.99e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.73	0.44	2.69e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.96	11.28	0.58	4.81e-24	Corneal astigmatism;
KIRP	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg16141378	chr3:129829833	LOC729375	0.62	8.49	0.48	2e-15	Neuroticism;
KIRP	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg16497661	chr14:103986332	CKB	0.48	6.53	0.38	3.68e-10	Body mass index;
KIRP	cis	rs494562	0.892	rs7767800	chr6:86124526	G/A	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20983617	chr3:133614790	RAB6B	0.5	6.29	0.37	1.43e-9	Parkinson's disease;
KIRP	cis	rs10214930	0.671	rs6948460	chr7:27690238	T/A	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.6	8.91	0.49	1.13e-16	Educational attainment;
KIRP	cis	rs1440410	0.835	rs6854861	chr4:144053091	A/C	cg01719995	chr4:144104893	USP38	0.47	6.5	0.38	4.42e-10	Ischemic stroke;
KIRP	trans	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg17712092	chr4:129076599	LARP1B	-0.63	-8.04	-0.46	3.69e-14	Eosinophil percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03421743	chr4:83932010	LIN54	0.52	7.37	0.43	2.54e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg14092571	chr14:90743983	NA	0.41	4.87	0.3	1.98e-6	Mortality in heart failure;
KIRP	cis	rs904092	0.720	rs1618572	chr4:100195121	C/G	cg12011299	chr4:100065546	ADH4	0.52	5.08	0.31	7.33e-7	Alcohol dependence;
KIRP	cis	rs10227331	0.692	rs34036749	chr7:157298870	T/C	cg04156418	chr7:157293606	NA	0.44	6.12	0.36	3.57e-9	Inattentive symptoms;
KIRP	cis	rs7078219	0.505	rs7893840	chr10:101293341	T/C	cg07044859	chr10:101282883	NA	-0.31	-5.57	-0.33	6.57e-8	Dental caries;
KIRP	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.73	11.66	0.6	2.7e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg13731523	chr4:3047190	NA	-0.34	-6.02	-0.36	6.45e-9	Serum sulfate level;
KIRP	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg00262122	chr8:11665843	FDFT1	-0.42	-4.97	-0.3	1.25e-6	Retinal vascular caliber;
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13939156	chr17:80058883	NA	-0.49	-7.36	-0.42	2.8e-12	Life satisfaction;
KIRP	cis	rs9815354	0.680	rs79211428	chr3:41921810	C/T	cg03022575	chr3:42003672	ULK4	0.62	6.43	0.38	6.49e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg25019033	chr10:957182	NA	-0.6	-6.09	-0.36	4.36e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.99	10.55	0.56	1.02e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.6	7.38	0.43	2.4e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7017914	0.967	rs6998786	chr8:71694630	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.94	-0.45	6.98e-14	Neuroticism;
KIRP	cis	rs714515	0.586	rs4916267	chr1:172450888	A/G	cg01573306	chr1:172330400	DNM3	0.4	4.92	0.3	1.56e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg11266682	chr4:10021025	SLC2A9	0.39	4.89	0.3	1.84e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs4664308	0.618	rs4665139	chr2:160890692	G/T	cg03641300	chr2:160917029	PLA2R1	-0.64	-9.96	-0.54	7.26e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg15507776	chr3:136538369	TMEM22	0.4	5.42	0.33	1.39e-7	Neuroticism;
KIRP	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.68	-9.04	-0.5	4.71e-17	Blood metabolite levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11203551	chr1:52610547	ZFYVE9	0.47	6.36	0.38	9.56e-10	Interleukin-4 levels;
KIRP	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.76	-11.26	-0.58	5.3e-24	Obesity-related traits;
KIRP	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.68	7.22	0.42	6.48e-12	Lymphocyte counts;
KIRP	cis	rs741702	0.758	rs2967893	chr19:13033062	T/G	cg11738485	chr19:12877000	HOOK2	0.4	4.86	0.3	2.12e-6	Red blood cell traits;
KIRP	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg08603382	chr10:743973	NA	0.51	7.68	0.44	3.78e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg20368463	chr18:77673604	PQLC1	0.6	8.4	0.47	3.56e-15	Schizophrenia;
KIRP	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.75	-11.07	-0.58	2.3e-23	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs6601327	0.602	rs35431433	chr8:9660621	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.16	-0.42	9.25e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4704187	0.687	rs9293642	chr5:74365026	C/T	cg03227963	chr5:74354835	NA	0.41	6.01	0.36	6.8e-9	Response to amphetamines;
KIRP	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Intracranial aneurysm;
KIRP	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.6	0.48	9.47e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.57	-7.27	-0.42	4.67e-12	Bipolar disorder;
KIRP	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg23100626	chr2:96804247	ASTL	0.45	6.21	0.37	2.28e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg15501526	chr10:2543763	NA	-0.53	-6.38	-0.38	8.9e-10	Age-related hearing impairment;
KIRP	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.43	0.33	1.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg07701084	chr6:150067640	NUP43	0.7	8.71	0.49	4.41e-16	Lung cancer;
KIRP	cis	rs6466055	0.589	rs1029596	chr7:104698848	C/G	cg04380332	chr7:105027541	SRPK2	-0.4	-5.39	-0.32	1.66e-7	Schizophrenia;
KIRP	cis	rs7523050	0.730	rs41279678	chr1:109440215	G/A	cg08274380	chr1:109419600	GPSM2	1.16	10.2	0.55	1.34e-20	Fat distribution (HIV);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26375147	chr11:60674132	PRPF19	0.5	6.29	0.37	1.43e-9	Parkinson's disease;
KIRP	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg20936604	chr3:58311152	NA	-0.69	-5.92	-0.35	1.05e-8	Cholesterol, total;
KIRP	cis	rs4851254	0.695	rs12712069	chr2:100766354	C/G	cg17356467	chr2:100759845	AFF3	0.62	8.0	0.45	4.88e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.69	-9.9	-0.53	1.15e-19	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14867121	chr4:146297077	NA	-0.42	-6.12	-0.36	3.74e-9	Inflammatory biomarkers;
KIRP	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg00922110	chr4:57842668	C4orf14	-0.4	-5.24	-0.32	3.49e-7	Response to bleomycin (chromatid breaks);
KIRP	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg02733842	chr7:1102375	C7orf50	-0.48	-5.93	-0.35	1.01e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.57	-6.48	-0.38	4.97e-10	Hypospadias;
KIRP	cis	rs2522056	0.808	rs2706373	chr5:131804256	C/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.11	0.36	3.77e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.5	-0.33	9.54e-8	Lung cancer;
KIRP	cis	rs10488172	0.761	rs3757406	chr7:133502387	A/C	cg10665199	chr7:133106180	EXOC4	-0.47	-5.14	-0.31	5.68e-7	Tonometry;
KIRP	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.95	15.24	0.7	2.25e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs12643440	0.538	rs1522081	chr4:17135357	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg08805041	chr16:621841	PIGQ	-0.39	-5.26	-0.32	3.09e-7	Height;
KIRP	cis	rs1003719	0.667	rs2298682	chr21:38444890	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.77	10.6	0.56	7.31e-22	Eye color traits;
KIRP	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.14	10.96	0.57	4.89e-23	Alzheimer's disease (late onset);
KIRP	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.05	0.5	4.53e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.76	9.38	0.51	4.71e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4474465	0.920	rs12222907	chr11:78219726	C/T	cg27205649	chr11:78285834	NARS2	0.62	7.85	0.45	1.24e-13	Alzheimer's disease (survival time);
KIRP	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04213235	chr1:145826932	GPR89A	0.48	6.28	0.37	1.49e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg00579200	chr11:133705235	NA	-0.38	-5.0	-0.3	1.12e-6	Childhood ear infection;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg15066777	chr18:66382427	CCDC102B;TMX3	0.53	6.25	0.37	1.81e-9	Plasma plasminogen activator levels;
KIRP	cis	rs9649213	0.531	rs35216698	chr7:97896175	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.37	0.32	1.82e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg19500275	chr17:80737654	TBCD	0.43	5.23	0.32	3.62e-7	Glycated hemoglobin levels;
KIRP	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.54	5.71	0.34	3.22e-8	Response to diuretic therapy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03789575	chr3:33842675	PDCD6IP	-0.43	-6.31	-0.37	1.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs7770227	0.901	rs1337332	chr6:114696790	A/C	cg18406000	chr6:114650610	NA	-0.42	-5.49	-0.33	1.01e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.61	-6.76	-0.4	1.02e-10	Obesity-related traits;
KIRP	cis	rs11644362	1.000	rs72782620	chr16:12987416	T/A	cg06890432	chr16:12997467	SHISA9	-0.39	-6.02	-0.36	6.16e-9	Positive affect;Subjective well-being;
KIRP	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg25173405	chr17:45401733	C17orf57	-0.47	-6.1	-0.36	4.07e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg05347473	chr6:146136440	FBXO30	0.62	8.75	0.49	3.48e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.63	8.87	0.49	1.54e-16	Lymphocyte counts;
KIRP	cis	rs17030434	1.000	rs6853522	chr4:154706220	A/C	cg14289246	chr4:154710475	SFRP2	0.81	9.53	0.52	1.58e-18	Electrocardiographic conduction measures;
KIRP	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg15557168	chr22:42548783	NA	-0.37	-5.29	-0.32	2.69e-7	Cognitive function;
KIRP	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg14458575	chr2:238380390	NA	0.48	5.44	0.33	1.27e-7	Prostate cancer;
KIRP	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.75	9.22	0.51	1.38e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.71	-6.55	-0.39	3.32e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7582720	1.000	rs72932763	chr2:203678658	A/T	cg08076091	chr2:203926405	NBEAL1	0.83	8.63	0.48	7.67e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg02800362	chr5:177631904	HNRNPAB	0.64	6.02	0.36	6.41e-9	Obesity-related traits;
KIRP	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.48	-0.48	2.08e-15	Retinal vascular caliber;
KIRP	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.39	0.59	2.07e-24	Alzheimer's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07312556	chr10:61666263	CCDC6	-0.46	-6.33	-0.37	1.16e-9	Metabolic traits;
KIRP	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg26531700	chr6:26746687	NA	0.4	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.68	8.14	0.46	1.91e-14	Iron status biomarkers;
KIRP	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.45	5.81	0.35	1.97e-8	Testicular germ cell tumor;
KIRP	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4356932	1.000	rs6819597	chr4:76957171	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.75	6.9	0.4	4.26e-11	Bipolar disorder;
KIRP	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg25797454	chr6:150327115	RAET1K	0.36	6.66	0.39	1.75e-10	Alopecia areata;
KIRP	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg00990874	chr7:1149470	C7orf50	-0.65	-7.05	-0.41	1.83e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg06953865	chr19:18549723	ISYNA1	-0.4	-5.98	-0.36	7.75e-9	Breast cancer;
KIRP	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26314531	chr2:26401878	FAM59B	0.47	5.03	0.31	9.57e-7	Gut microbiome composition (summer);
KIRP	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg25650185	chr19:21324782	ZNF431	0.48	4.97	0.3	1.28e-6	Pain;
KIRP	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg13010199	chr12:38710504	ALG10B	0.56	6.94	0.4	3.49e-11	Morning vs. evening chronotype;
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg14221460	chr8:27183342	PTK2B	0.5	6.6	0.39	2.5e-10	Neuroticism;
KIRP	cis	rs698833	0.892	rs1067322	chr2:44630107	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.68	0.39	1.59e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg09491104	chr22:46646882	C22orf40	0.65	8.53	0.48	1.52e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.76	-8.17	-0.46	1.6e-14	Gut microbiome composition (summer);
KIRP	cis	rs6991838	0.557	rs57419568	chr8:66510868	G/A	cg13398993	chr8:66546079	ARMC1	-0.44	-5.05	-0.31	8.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg04731861	chr2:219085781	ARPC2	-0.28	-7.32	-0.42	3.53e-12	Colorectal cancer;
KIRP	trans	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg13010199	chr12:38710504	ALG10B	0.57	7.16	0.42	9.13e-12	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06622737	chr1:171750501	METTL13	0.48	6.5	0.38	4.4e-10	Survival in pancreatic cancer;
KIRP	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.44	-6.0	-0.36	6.97e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.44	5.17	0.31	4.74e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg21546286	chr11:48923668	NA	-0.44	-5.22	-0.32	3.85e-7	HDL cholesterol;
KIRP	cis	rs4740619	0.619	rs1410454	chr9:16042193	C/A	cg14451791	chr9:16040625	NA	-0.43	-5.67	-0.34	3.92e-8	Body mass index;
KIRP	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.46	-6.06	-0.36	5.02e-9	Blood protein levels;
KIRP	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg21573476	chr21:45109991	RRP1B	-0.7	-10.5	-0.56	1.46e-21	Mean corpuscular volume;
KIRP	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Parkinson's disease;
KIRP	cis	rs2213920	0.522	rs4978639	chr9:118241443	G/A	cg13918206	chr9:118159781	DEC1	0.56	7.1	0.41	1.31e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.95	-0.5	9.06e-17	Mood instability;
KIRP	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.09	11.98	0.61	2.39e-26	Corneal structure;
KIRP	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg04132472	chr17:19861366	AKAP10	-0.39	-5.09	-0.31	7.11e-7	Schizophrenia;
KIRP	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg12573674	chr2:1569213	NA	-0.51	-4.88	-0.3	1.87e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.41e-59	Prudent dietary pattern;
KIRP	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg17133734	chr15:86042851	AKAP13	0.44	5.41	0.33	1.47e-7	Coronary artery disease;
KIRP	trans	rs4349753	0.870	rs389997	chr5:144182045	T/C	cg16033277	chr17:80885358	TBCD	0.4	6.25	0.37	1.8e-9	Photic sneeze reflex;
KIRP	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.08	-0.41	1.47e-11	Response to antipsychotic treatment;
KIRP	cis	rs9596863	0.808	rs9596837	chr13:54258063	T/C	ch.13.53330881F	chr13:54432880	NA	0.54	4.91	0.3	1.69e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs34929064	0.536	rs2961279	chr7:22638154	T/C	cg23521230	chr7:22704884	NA	0.39	4.93	0.3	1.53e-6	Major depression and alcohol dependence;
KIRP	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg08501292	chr6:25962987	TRIM38	0.85	5.87	0.35	1.37e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.4	-0.33	1.54e-7	Personality dimensions;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11564339	chr21:36261702	RUNX1	-0.46	-6.24	-0.37	1.86e-9	Myopia;
KIRP	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	9.57	0.52	1.21e-18	Lung cancer in ever smokers;
KIRP	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg21775007	chr8:11205619	TDH	-0.48	-6.6	-0.39	2.56e-10	Mood instability;
KIRP	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	1.03	13.23	0.64	1.54e-30	Post bronchodilator FEV1;
KIRP	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.03	-0.36	6.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg11584989	chr19:19387371	SF4	0.62	6.65	0.39	1.85e-10	Bipolar disorder;
KIRP	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.62	6.83	0.4	6.6e-11	Multiple sclerosis;
KIRP	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg14132834	chr19:41945861	ATP5SL	-0.62	-8.45	-0.47	2.6e-15	Height;
KIRP	cis	rs13418717	0.793	rs3795874	chr2:127656383	A/G	cg25501666	chr2:127640322	NA	0.97	8.51	0.48	1.77e-15	Heart failure;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs10267417	0.603	rs13307910	chr7:19858392	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.17	0.31	4.87e-7	Night sleep phenotypes;
KIRP	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.58	7.46	0.43	1.45e-12	Asthma (sex interaction);
KIRP	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.8	-11.62	-0.6	3.5e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg15605315	chr1:45957053	TESK2	0.39	5.16	0.31	5e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11955398	0.585	rs1117675	chr5:60034886	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.45	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.91	-0.45	8.91e-14	Neuroticism;
KIRP	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs42648	0.869	rs6973816	chr7:89921072	C/T	cg25739043	chr7:89950458	NA	-0.44	-6.81	-0.4	7.49e-11	Homocysteine levels;
KIRP	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.52	-6.76	-0.4	1.01e-10	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-13.35	-0.65	6.21e-31	Alzheimer's disease;
KIRP	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.71	8.98	0.5	7.45e-17	Bladder cancer;
KIRP	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.75	9.52	0.52	1.74e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg11382394	chr1:2564504	MMEL1	0.4	5.1	0.31	6.77e-7	Ulcerative colitis;
KIRP	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg18944383	chr4:111397179	ENPEP	-0.69	-12.34	-0.62	1.51e-27	Coronary artery disease;
KIRP	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.55	-0.39	3.3e-10	Neuroticism;
KIRP	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.89	-12.89	-0.64	2.1e-29	Blood protein levels;
KIRP	cis	rs73200209	0.912	rs11067904	chr12:116529835	C/G	cg01776926	chr12:116560359	MED13L	0.44	5.16	0.31	5.18e-7	Total body bone mineral density;
KIRP	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	5.84	0.35	1.65e-8	Aortic root size;
KIRP	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg00405596	chr8:11794950	NA	0.48	6.02	0.36	6.19e-9	Retinal vascular caliber;
KIRP	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.87	-11.62	-0.6	3.5e-25	Blood protein levels;
KIRP	cis	rs9815354	0.812	rs73073233	chr3:42010550	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.71	10.54	0.56	1.1e-21	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs7246760	0.867	rs66880218	chr19:9774155	A/G	cg02900749	chr2:68251473	NA	-1.15	-9.35	-0.51	5.5e-18	Pursuit maintenance gain;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00116463	chr17:19266443	B9D1	0.49	6.41	0.38	7.56e-10	Parkinson's disease;
KIRP	cis	rs6959887	0.926	rs4723407	chr7:35287673	T/G	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs7116495	0.786	rs4479013	chr11:71673732	C/G	cg11196788	chr11:71737549	NUMA1	0.55	4.94	0.3	1.45e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.46	-5.74	-0.34	2.78e-8	IgG glycosylation;
KIRP	cis	rs5753037	0.653	rs131272	chr22:30153655	A/G	cg01021169	chr22:30184971	ASCC2	-0.43	-5.93	-0.35	1.02e-8	Type 1 diabetes;
KIRP	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs4654899	0.733	rs10799677	chr1:21318456	A/C	cg05370193	chr1:21551575	ECE1	0.41	5.48	0.33	1.05e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.63	-6.98	-0.41	2.66e-11	Neuroticism;
KIRP	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.56	6.35	0.38	1.05e-9	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.19e-7	Life satisfaction;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg27305525	chr1:154955752	FLAD1	0.54	6.13	0.36	3.49e-9	Sleep duration;
KIRP	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.82	7.41	0.43	1.97e-12	Coronary artery disease;
KIRP	cis	rs2708977	0.966	rs749027	chr2:97203137	A/C	cg01950434	chr2:97203154	ARID5A	-0.57	-7.16	-0.42	9.11e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs838147	0.760	rs12979144	chr19:49237547	G/A	cg13540341	chr19:49222985	MAMSTR	0.35	5.63	0.34	4.97e-8	Dietary macronutrient intake;
KIRP	cis	rs4704187	0.617	rs2035192	chr5:74407231	T/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.56	7.15	0.41	9.64e-12	Asthma (sex interaction);
KIRP	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.39	6.73	0.39	1.16e-10	QRS complex (12-leadsum);
KIRP	cis	rs34779708	0.931	rs35997236	chr10:35376690	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs4349753	0.904	rs4913000	chr5:144168172	T/G	cg16033277	chr17:80885358	TBCD	0.4	6.25	0.37	1.83e-9	Photic sneeze reflex;
KIRP	cis	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg24110177	chr3:50126178	RBM5	-0.43	-5.1	-0.31	6.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg00361562	chr2:198649771	BOLL	-0.52	-5.03	-0.31	9.35e-7	Ulcerative colitis;
KIRP	cis	rs9921338	0.961	rs9936093	chr16:11437316	C/G	cg00044050	chr16:11439710	C16orf75	-0.54	-5.77	-0.35	2.35e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.63	-6.57	-0.39	3.02e-10	Gut microbiome composition (summer);
KIRP	cis	rs6466055	0.661	rs12538590	chr7:104896470	C/A	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs7010267	0.805	rs2062375	chr8:119977792	G/C	cg01975934	chr8:119970761	NA	-0.4	-5.04	-0.31	9.04e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06481639	chr22:41940642	POLR3H	0.7	7.2	0.42	7.33e-12	Vitiligo;
KIRP	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg02297831	chr4:17616191	MED28	-0.45	-5.17	-0.31	4.83e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.81	-11.6	-0.59	4.29e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg13010199	chr12:38710504	ALG10B	-0.48	-5.87	-0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs11605275	1.000	rs11605275	chr11:20031865	C/T	cg14835545	chr11:20032148	NAV2	-0.8	-6.14	-0.36	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.65	-7.32	-0.42	3.46e-12	Menarche (age at onset);
KIRP	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21747090	chr2:27597821	SNX17	-0.46	-6.4	-0.38	7.62e-10	Total body bone mineral density;
KIRP	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg16482183	chr6:26056742	HIST1H1C	0.44	5.5	0.33	9.62e-8	Height;
KIRP	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg05315796	chr3:52349193	DNAH1	0.44	6.85	0.4	6e-11	Electroencephalogram traits;
KIRP	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	1.16	13.69	0.66	4.38e-32	Red blood cell traits;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg02733842	chr7:1102375	C7orf50	0.43	5.06	0.31	8.32e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.39	5.44	0.33	1.27e-7	Night sleep phenotypes;
KIRP	cis	rs1559088	0.947	rs7259879	chr19:33549462	T/C	cg03563238	chr19:33554763	RHPN2	-0.35	-6.07	-0.36	4.84e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg23594656	chr7:65796392	TPST1	-0.42	-5.85	-0.35	1.58e-8	Aortic root size;
KIRP	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.54	-6.61	-0.39	2.32e-10	Prudent dietary pattern;
KIRP	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg05526886	chr2:227700861	RHBDD1	0.48	5.79	0.35	2.16e-8	Pulmonary function;
KIRP	cis	rs6594713	0.684	rs1816062	chr5:112856023	A/C	cg12552261	chr5:112820674	MCC	0.55	4.96	0.3	1.34e-6	Brain cytoarchitecture;
KIRP	cis	rs501764	0.731	rs263423	chr10:8089033	C/T	cg16952963	chr10:8089182	NA	-0.39	-4.9	-0.3	1.73e-6	Hodgkin's lymphoma;
KIRP	cis	rs258892	0.842	rs11951999	chr5:72020144	C/G	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.67	8.35	0.47	5.05e-15	Aortic root size;
KIRP	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.77	-10.17	-0.54	1.68e-20	Systemic lupus erythematosus;
KIRP	cis	rs7856656	1.000	rs59967810	chr9:37420311	C/T	cg09233161	chr9:37079712	NA	0.43	4.9	0.3	1.73e-6	Cancer;
KIRP	cis	rs9462846	0.959	rs57514728	chr6:42860748	C/T	cg05552183	chr6:42928497	GNMT	0.44	5.09	0.31	7.26e-7	Blood protein levels;
KIRP	cis	rs9549260	0.564	rs4943808	chr13:41293950	C/T	cg21288729	chr13:41239152	FOXO1	0.56	7.35	0.42	2.85e-12	Red blood cell count;
KIRP	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg00647317	chr7:50633725	DDC	0.45	6.94	0.4	3.55e-11	Body mass index;
KIRP	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg15226275	chr6:116381976	FRK	0.22	5.73	0.34	2.94e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7572263	0.724	rs67989853	chr2:209055164	T/C	cg23998903	chr2:209048830	C2orf80	-0.37	-5.2	-0.31	4.14e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg07775547	chr4:1625484	NA	-0.44	-5.44	-0.33	1.27e-7	Bladder cancer;Urinary bladder cancer;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg27556566	chr18:29671984	RNF138	0.52	6.27	0.37	1.58e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.64	8.94	0.5	9.29e-17	Dental caries;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02591871	chr19:14228565	PRKACA	0.52	6.47	0.38	5.31e-10	Parkinson's disease;
KIRP	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg15556689	chr8:8085844	FLJ10661	0.6	7.62	0.44	5.44e-13	Mood instability;
KIRP	cis	rs6901004	0.803	rs405948	chr6:111540372	C/T	cg15721981	chr6:111408429	SLC16A10	-0.53	-7.38	-0.43	2.49e-12	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18844304	chr19:55851052	SUV420H2	0.47	6.02	0.36	6.46e-9	Parkinson's disease;
KIRP	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.45e-21	Diabetic kidney disease;
KIRP	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-1.02	-17.28	-0.74	2.33e-44	Height;
KIRP	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.42	-6.04	-0.36	5.69e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg21546286	chr11:48923668	NA	-0.49	-6.32	-0.37	1.19e-9	HDL cholesterol;
KIRP	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.44e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17832277	chr13:103249000	TPP2	0.49	6.43	0.38	6.57e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.86	9.88	0.53	1.37e-19	Lung function (FEV1/FVC);
KIRP	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.25	25.57	0.85	3.13e-71	IgG glycosylation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14569576	chr9:102585669	NR4A3	0.43	6.99	0.41	2.62e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11605275	1.000	rs11605704	chr11:20032096	A/G	cg14835545	chr11:20032148	NAV2	0.77	6.06	0.36	5.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg24060327	chr5:131705240	SLC22A5	-0.51	-6.63	-0.39	2.06e-10	Blood metabolite levels;
KIRP	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	8.95	0.5	8.67e-17	IgG glycosylation;
KIRP	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg13289132	chr10:30722225	MAP3K8	-0.41	-5.08	-0.31	7.46e-7	Inflammatory bowel disease;
KIRP	cis	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg21605333	chr4:119757512	SEC24D	0.79	6.41	0.38	7.31e-10	Cannabis dependence symptom count;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.13e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09938634	chr8:22987034	NA	-0.46	-6.41	-0.38	7.34e-10	Parkinson's disease;
KIRP	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg06307176	chr5:131281290	NA	-0.55	-5.97	-0.36	8.34e-9	Life satisfaction;
KIRP	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.63	-0.39	2.09e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs17321999	1.000	rs10171305	chr2:30481343	A/T	cg05247661	chr2:30472410	LBH	0.67	6.87	0.4	5.31e-11	Systemic lupus erythematosus;
KIRP	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.7	10.63	0.56	5.67e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg09165964	chr15:75287851	SCAMP5	-0.37	-4.99	-0.3	1.13e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs860295	0.676	rs11264374	chr1:155421512	A/C	cg02153340	chr1:155202674	NA	-0.57	-7.83	-0.45	1.43e-13	Body mass index;
KIRP	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.55	-0.33	7.51e-8	Coronary artery disease;
KIRP	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg15691649	chr6:25882328	NA	-0.46	-5.59	-0.34	5.9e-8	Blood metabolite levels;
KIRP	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.66	-7.64	-0.44	4.73e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg20415053	chr1:26527928	CATSPER4	-0.43	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs17065868	1.000	rs9645991	chr13:45165813	C/A	cg10246903	chr13:45222710	NA	0.71	6.6	0.39	2.56e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4950322	0.542	rs17159914	chr1:146654805	C/T	cg22381352	chr1:146742008	CHD1L	0.37	5.17	0.31	4.95e-7	Protein quantitative trait loci;
KIRP	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.69e-59	Prudent dietary pattern;
KIRP	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.94	9.77	0.53	2.81e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27431247	chr11:67888603	CHKA	0.47	6.8	0.4	7.89e-11	Survival in pancreatic cancer;
KIRP	cis	rs526231	0.578	rs1898672	chr5:102293853	A/T	cg23492399	chr5:102201601	PAM	0.47	5.3	0.32	2.57e-7	Primary biliary cholangitis;
KIRP	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg11906718	chr8:101322791	RNF19A	0.47	6.13	0.36	3.44e-9	Atrioventricular conduction;
KIRP	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.56	7.54	0.43	8.82e-13	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs42648	0.564	rs17863031	chr7:89805813	A/G	cg25739043	chr7:89950458	NA	-0.39	-6.04	-0.36	5.57e-9	Homocysteine levels;
KIRP	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg00262122	chr8:11665843	FDFT1	0.44	5.38	0.32	1.76e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11605924	0.692	rs877412	chr11:45897651	A/C	ch.11.939596F	chr11:45881766	CRY2	0.66	8.59	0.48	1.02e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	8.66	0.48	6.23e-16	Breast cancer;
KIRP	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.45	9.81	0.53	2.19e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg22676075	chr6:135203613	NA	0.51	7.28	0.42	4.47e-12	Red blood cell count;
KIRP	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg24296786	chr1:45957014	TESK2	0.51	5.68	0.34	3.83e-8	Homocysteine levels;
KIRP	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.69	-6.93	-0.4	3.59e-11	Blood trace element (Zn levels);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00771170	chr19:3971184	DAPK3	0.49	6.21	0.37	2.28e-9	Parkinson's disease;
KIRP	cis	rs12208915	0.945	rs116984077	chr6:79583325	A/G	cg18132916	chr6:79620363	NA	0.56	5.0	0.3	1.09e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.65	8.37	0.47	4.31e-15	Height;
KIRP	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.71	-0.39	1.34e-10	Triglycerides;
KIRP	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg21926883	chr2:100939477	LONRF2	-0.55	-7.57	-0.43	7.49e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg18306943	chr3:40428807	ENTPD3	0.4	5.65	0.34	4.34e-8	Renal cell carcinoma;
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg13206674	chr6:150067644	NUP43	0.59	8.6	0.48	9.21e-16	Lung cancer;
KIRP	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.46	6.34	0.37	1.09e-9	Coronary artery disease;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	7.27	0.42	4.69e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.81	11.47	0.59	1.09e-24	Mean platelet volume;
KIRP	cis	rs42648	0.748	rs10227385	chr7:89890368	C/A	cg25739043	chr7:89950458	NA	-0.42	-6.67	-0.39	1.67e-10	Homocysteine levels;
KIRP	cis	rs7017914	0.935	rs7826483	chr8:71702893	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.02	-0.3	9.96e-7	Bone mineral density;
KIRP	cis	rs2916247	1.000	rs4735044	chr8:93057478	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.7	-0.44	3.24e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg19554555	chr3:13937349	NA	-0.46	-6.23	-0.37	2e-9	Ovarian reserve;
KIRP	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs526231	0.543	rs34767	chr5:102489511	A/C	cg23492399	chr5:102201601	PAM	-0.52	-5.71	-0.34	3.18e-8	Primary biliary cholangitis;
KIRP	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.15	-17.39	-0.74	1.04e-44	Ulcerative colitis;
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.77	12.32	0.62	1.71e-27	Menarche (age at onset);
KIRP	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg15556689	chr8:8085844	FLJ10661	0.55	7.31	0.42	3.66e-12	Joint mobility (Beighton score);
KIRP	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg25019722	chr6:37503610	NA	0.71	9.96	0.54	7.57e-20	Cognitive performance;
KIRP	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg19761014	chr17:28927070	LRRC37B2	0.53	5.1	0.31	6.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	9.03	0.5	5.06e-17	Smoking behavior;
KIRP	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.68e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	13.79	0.66	1.92e-32	Alzheimer's disease;
KIRP	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.1	0.31	6.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6450176	0.625	rs11747281	chr5:53289047	G/A	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-12.99	-0.64	9.68e-30	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs2985684	0.948	rs7143010	chr14:50081803	T/C	cg02151108	chr14:50098012	C14orf104	-0.54	-6.88	-0.4	4.97e-11	Carotid intima media thickness;
KIRP	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.62	-10.03	-0.54	4.45e-20	Morning vs. evening chronotype;
KIRP	cis	rs698833	0.886	rs4953086	chr2:44561532	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	6.13	0.36	3.45e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.61	8.16	0.46	1.76e-14	Prostate cancer;
KIRP	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.44	5.04	0.31	9.15e-7	Schizophrenia;
KIRP	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg08662619	chr6:150070041	PCMT1	0.33	5.15	0.31	5.3e-7	Lung cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg14258675	chr14:75348443	DLST	0.52	6.69	0.39	1.51e-10	Asthma;
KIRP	cis	rs2282032	1.000	rs76139392	chr14:90746462	G/T	cg04374321	chr14:90722782	PSMC1	0.5	4.92	0.3	1.56e-6	Longevity;
KIRP	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.71	-0.44	3.06e-13	Resting heart rate;
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg05861140	chr6:150128134	PCMT1	-0.46	-6.54	-0.38	3.56e-10	Lung cancer;
KIRP	cis	rs1461503	0.900	rs7102462	chr11:122828767	C/G	cg27398637	chr11:122830231	C11orf63	-0.81	-11.51	-0.59	8.27e-25	Menarche (age at onset);
KIRP	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.75	5.14	0.31	5.58e-7	Childhood ear infection;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg10230466	chr17:7145863	GABARAP	0.52	6.4	0.38	7.99e-10	Educational attainment;
KIRP	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06850241	chr22:41845214	NA	-0.47	-5.34	-0.32	2.16e-7	Vitiligo;
KIRP	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	1.11	7.89	0.45	9.87e-14	Skin colour saturation;
KIRP	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-5.79	-0.35	2.1e-8	Subjective well-being;
KIRP	cis	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19171272	chr22:38449367	NA	-0.58	-8.81	-0.49	2.37e-16	Glioblastoma;Glioma;
KIRP	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg05333889	chr7:157238977	NA	-0.35	-4.96	-0.3	1.3e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg12435725	chr3:58293450	RPP14	-0.45	-5.11	-0.31	6.35e-7	Cholesterol, total;
KIRP	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19853194	chr18:9913725	VAPA	0.58	6.89	0.4	4.52e-11	Smoking initiation;
KIRP	cis	rs490234	0.902	rs10739662	chr9:128278687	T/C	cg14078157	chr9:128172775	NA	-0.41	-5.21	-0.32	3.99e-7	Mean arterial pressure;
KIRP	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.52	0.38	3.91e-10	Neuroticism;
KIRP	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg08076091	chr2:203926405	NBEAL1	0.92	9.89	0.53	1.2e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg20003494	chr4:90757398	SNCA	-0.37	-4.87	-0.3	2.01e-6	Neuroticism;
KIRP	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.8	12.13	0.61	7.66e-27	Bladder cancer;
KIRP	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.63	-8.14	-0.46	1.99e-14	Multiple myeloma (IgH translocation);
KIRP	cis	rs687432	0.812	rs7113760	chr11:57846682	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-8.77	-0.49	3e-16	Parkinson's disease;
KIRP	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.46	10.03	0.54	4.44e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg06521331	chr12:34319734	NA	-0.54	-6.73	-0.39	1.18e-10	Heart rate;
KIRP	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.7	8.84	0.49	1.84e-16	Height;
KIRP	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.47	0.38	5.12e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.44	5.46	0.33	1.15e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg18944383	chr4:111397179	ENPEP	0.45	7.33	0.42	3.23e-12	Height;
KIRP	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.68	-7.85	-0.45	1.26e-13	Alcohol dependence;
KIRP	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.89	-12.16	-0.61	5.84e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21747090	chr2:27597821	SNX17	-0.49	-6.7	-0.39	1.38e-10	Menopause (age at onset);
KIRP	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-9.38	-0.51	4.62e-18	Coffee consumption (cups per day);
KIRP	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.2	-18.06	-0.75	5.54e-47	Ulcerative colitis;
KIRP	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg25809561	chr17:30822961	MYO1D	0.51	6.51	0.38	4.11e-10	Schizophrenia;
KIRP	cis	rs9581857	0.547	rs9581877	chr13:28104321	T/A	cg22138327	chr13:27999177	GTF3A	0.72	5.8	0.35	2.02e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.96	15.29	0.7	1.53e-37	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.31	-0.32	2.51e-7	Bladder cancer;
KIRP	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.11	23.09	0.83	1.64e-63	Testicular germ cell tumor;
KIRP	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07570687	chr10:102243282	WNT8B	0.52	6.7	0.39	1.41e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.59	6.95	0.41	3.29e-11	Corneal astigmatism;
KIRP	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.59	-8.23	-0.46	1.1e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg10659575	chr11:102188233	BIRC3	0.49	6.77	0.4	9.49e-11	Ischemic stroke;
KIRP	cis	rs6732160	0.809	rs13416592	chr2:73365056	C/T	cg01422370	chr2:73384389	NA	0.39	5.17	0.31	4.93e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3026101	0.671	rs1989946	chr17:5313152	T/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.6	0.39	2.47e-10	Body mass index;
KIRP	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.54	7.52	0.43	1.04e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.77	7.78	0.44	1.97e-13	Migraine;Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.65	7.19	0.42	7.97e-12	Personality dimensions;
KIRP	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.97	-15.04	-0.69	1.12e-36	Height;
KIRP	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.43	-8.2	-0.46	1.35e-14	Educational attainment (years of education);
KIRP	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.55e-20	Dupuytren's disease;
KIRP	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.64	8.66	0.48	6.17e-16	High light scatter reticulocyte count;
KIRP	trans	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.34	0.37	1.1e-9	Retinal vascular caliber;
KIRP	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg24881330	chr22:46731750	TRMU	0.64	5.49	0.33	9.92e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.74	7.17	0.42	8.77e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.84	11.85	0.6	6.4e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.45	-5.91	-0.35	1.15e-8	Calcium levels;
KIRP	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05903289	chr2:130345205	NA	-0.41	-5.41	-0.33	1.47e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg04865290	chr3:52927548	TMEM110	-0.66	-7.01	-0.41	2.22e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg00792783	chr2:198669748	PLCL1	0.45	5.01	0.3	1.04e-6	Intracranial aneurysm;
KIRP	cis	rs738322	0.839	rs2413505	chr22:38592967	G/A	cg25457927	chr22:38595422	NA	0.44	10.49	0.56	1.6e-21	Cutaneous nevi;
KIRP	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.34	-6.95	-0.4	3.33e-11	Arsenic metabolism;
KIRP	cis	rs34779708	0.897	rs4934527	chr10:35281118	T/A	cg04310649	chr10:35416472	CREM	-0.58	-6.87	-0.4	5.3e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07403728	chr16:21361628	NA	0.47	6.7	0.39	1.38e-10	Survival in pancreatic cancer;
KIRP	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg13010199	chr12:38710504	ALG10B	0.62	7.75	0.44	2.48e-13	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg02487422	chr3:49467188	NICN1	0.4	5.53	0.33	8.23e-8	Menarche (age at onset);
KIRP	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.88	-11.27	-0.58	4.99e-24	Breast cancer;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.41	-5.26	-0.32	3.14e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg06671706	chr8:8559999	CLDN23	0.56	6.37	0.38	9.01e-10	Obesity-related traits;
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.73	-11.04	-0.58	2.83e-23	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.78	10.2	0.55	1.28e-20	Aortic root size;
KIRP	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.87	-0.57	9.92e-23	Height;
KIRP	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg17279839	chr7:150038598	RARRES2	0.58	7.26	0.42	5.19e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	8.71	0.49	4.67e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.67	-9.69	-0.53	5.01e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.75	8.86	0.49	1.67e-16	Corneal astigmatism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13887016	chr20:61443577	OGFR	0.51	6.61	0.39	2.3e-10	Survival in pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14884256	chr3:50374861	RASSF1	0.53	6.62	0.39	2.26e-10	Parkinson's disease;
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg08901578	chr4:187885870	NA	-0.5	-7.68	-0.44	3.79e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	0.738	rs10051609	chr5:130877080	G/C	cg25547332	chr5:131281432	NA	0.4	4.92	0.3	1.62e-6	Life satisfaction;
KIRP	cis	rs73198271	0.960	rs73198287	chr8:8612786	C/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-5.98	-0.36	7.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.71	9.4	0.51	4.03e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26850624	chr5:429559	AHRR	0.32	5.84	0.35	1.6e-8	Cystic fibrosis severity;
KIRP	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.68	-8.15	-0.46	1.86e-14	Height;
KIRP	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	5.84	0.35	1.65e-8	Bipolar disorder;
KIRP	trans	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg26043149	chr18:55253948	FECH	0.53	6.19	0.37	2.53e-9	Bone mineral density;
KIRP	cis	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg00405596	chr8:11794950	NA	-0.5	-6.51	-0.38	4.12e-10	Monocyte count;
KIRP	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.62	-10.22	-0.55	1.11e-20	Sense of smell;
KIRP	cis	rs1823913	0.538	rs11892998	chr2:192204885	A/G	cg12404831	chr2:192114017	MYO1B	0.48	6.35	0.38	1.04e-9	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1505368	0.533	rs4369808	chr2:213261279	G/C	cg20637307	chr2:213403960	ERBB4	0.51	6.94	0.4	3.38e-11	Symmetrical dimethylarginine levels;
KIRP	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.92	-12.3	-0.62	1.97e-27	Platelet distribution width;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25978090	chr4:2011084	WHSC2	0.44	6.11	0.36	3.83e-9	Survival in pancreatic cancer;
KIRP	cis	rs13102973	0.899	rs13126625	chr4:135900322	C/T	cg14419869	chr4:135874104	NA	0.48	7.46	0.43	1.48e-12	Subjective well-being;
KIRP	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg09323728	chr8:95962352	TP53INP1	0.25	5.4	0.33	1.57e-7	Type 2 diabetes;
KIRP	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-5.75	-0.34	2.63e-8	Blood metabolite levels;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.83	11.65	0.6	2.96e-25	Height;
KIRP	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg27141850	chr2:20869434	GDF7	-0.39	-6.15	-0.37	3.1e-9	Abdominal aortic aneurysm;
KIRP	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg11130432	chr3:121712080	ILDR1	-0.43	-4.96	-0.3	1.31e-6	Multiple sclerosis;
KIRP	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg10578777	chr12:7781093	NA	0.6	6.05	0.36	5.4e-9	HDL cholesterol levels;
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11245990	chr11:68621969	NA	0.38	5.09	0.31	6.97e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17665859	0.844	rs6980614	chr8:447844	G/A	cg17960703	chr8:356704	FBXO25	0.76	5.52	0.33	8.52e-8	Bilirubin levels;
KIRP	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.46	5.91	0.35	1.11e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg15733309	chr7:157513707	PTPRN2	0.44	6.64	0.39	2e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	14.62	0.68	3e-35	Chronic sinus infection;
KIRP	cis	rs2625529	0.762	rs1384007	chr15:72229534	T/C	cg16672083	chr15:72433130	SENP8	-0.49	-6.0	-0.36	7.16e-9	Red blood cell count;
KIRP	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.62	-6.92	-0.4	3.8e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7656342	0.724	rs35512765	chr4:9883233	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.91	0.3	1.7e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs3857067	1.000	rs3857067	chr4:95026434	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-5.24	-0.32	3.47e-7	QT interval;
KIRP	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.72	8.82	0.49	2.1e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	1.0	18.01	0.75	7.98e-47	Leprosy;
KIRP	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	0.81	8.77	0.49	3.06e-16	Gut microbiome composition (summer);
KIRP	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.9	13.1	0.64	4.09e-30	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.7	-8.34	-0.47	5.34e-15	Obesity-related traits;
KIRP	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.64	-0.39	2.04e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg00631329	chr6:26305371	NA	-0.69	-8.39	-0.47	3.82e-15	Educational attainment;
KIRP	cis	rs7760949	0.888	rs9296853	chr6:13893945	T/A	cg27413430	chr6:13925136	RNF182	0.4	5.03	0.31	9.38e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.88	9.03	0.5	5.15e-17	Hip geometry;
KIRP	cis	rs4561483	0.549	rs33657	chr16:11969724	G/C	cg08843971	chr16:11963173	GSPT1	-0.56	-7.92	-0.45	8.16e-14	Testicular germ cell tumor;
KIRP	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg09658497	chr7:2847517	GNA12	-0.36	-5.12	-0.31	6.18e-7	Height;
KIRP	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.64	-0.56	5.29e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg16989719	chr2:238392110	NA	-0.56	-7.7	-0.44	3.27e-13	Prostate cancer;
KIRP	trans	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg13565492	chr6:43139072	SRF	-0.71	-6.72	-0.39	1.24e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.42	-5.21	-0.32	4.04e-7	Diastolic blood pressure;
KIRP	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.53	-7.43	-0.43	1.82e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg20387954	chr3:183756860	HTR3D	0.6	8.57	0.48	1.17e-15	Anterior chamber depth;
KIRP	cis	rs4561483	0.603	rs11544193	chr16:12009304	C/A	cg08843971	chr16:11963173	GSPT1	0.53	7.52	0.43	1.04e-12	Testicular germ cell tumor;
KIRP	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.69	-9.24	-0.51	1.17e-17	Huntington's disease progression;
KIRP	cis	rs755109	1.000	rs1475695	chr9:100691168	G/A	cg13688889	chr9:100608707	NA	-0.42	-4.92	-0.3	1.62e-6	Quantitative traits;
KIRP	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg06742321	chr12:123595122	PITPNM2	0.44	5.44	0.33	1.29e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.22	-0.42	6.51e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.45	-6.04	-0.36	5.59e-9	Mean corpuscular volume;
KIRP	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-7.44	-0.43	1.7e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg01879757	chr17:41196368	BRCA1	-0.78	-10.85	-0.57	1.18e-22	Menopause (age at onset);
KIRP	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.5	5.55	0.33	7.52e-8	Vitiligo;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11905131	chr22:24372483	LOC391322	0.54	6.53	0.38	3.74e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.71	-0.53	4.34e-19	Morning vs. evening chronotype;
KIRP	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	-0.48	-5.7	-0.34	3.44e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg07148914	chr20:33460835	GGT7	-0.55	-7.27	-0.42	4.84e-12	Height;
KIRP	cis	rs151997	0.962	rs27268	chr5:50184778	T/C	cg06027927	chr5:50259733	NA	0.59	7.54	0.43	9.27e-13	Callous-unemotional behaviour;
KIRP	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.68	9.84	0.53	1.82e-19	Dupuytren's disease;
KIRP	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg09596252	chr17:78655493	RPTOR	0.5	6.24	0.37	1.94e-9	Obesity;
KIRP	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	5.63	0.34	4.91e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	5.22	0.32	3.79e-7	Educational attainment (years of education);
KIRP	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.24	-0.37	1.88e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg05692746	chr2:100937584	LONRF2	0.46	5.44	0.33	1.29e-7	Educational attainment;
KIRP	cis	rs11955398	0.716	rs3857236	chr5:59909529	G/A	cg02684056	chr5:59996105	DEPDC1B	0.43	5.17	0.31	4.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4851254	0.961	rs11680586	chr2:100746207	G/T	cg17356467	chr2:100759845	AFF3	0.61	7.53	0.43	9.53e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.69	8.33	0.47	5.53e-15	Aortic root size;
KIRP	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg14703610	chr5:56206110	C5orf35	0.51	5.89	0.35	1.27e-8	Initial pursuit acceleration;
KIRP	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.8	12.23	0.62	3.3699999999999996e-27	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	0.85	7.63	0.44	5.13e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2594989	0.887	rs9985349	chr3:11591200	T/G	cg01796438	chr3:11312864	ATG7	0.49	6.14	0.36	3.23e-9	Circulating chemerin levels;
KIRP	cis	rs4262150	0.810	rs17565365	chr5:152056234	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7937612	1.000	rs7117063	chr11:120238824	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.07	-0.41	1.61e-11	Intraocular pressure;
KIRP	cis	rs35740288	0.787	rs727379	chr15:86229890	A/G	cg17133734	chr15:86042851	AKAP13	-0.48	-5.23	-0.32	3.58e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs12519773	0.846	rs1496332	chr5:92439320	A/G	cg18783429	chr5:92414398	NA	0.28	4.98	0.3	1.19e-6	Migraine;
KIRP	cis	rs2712184	0.756	rs2712181	chr2:217654869	C/T	cg05032264	chr2:217675019	NA	0.42	6.06	0.36	5.13e-9	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	trans	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.36	0.38	9.61e-10	Systolic blood pressure;
KIRP	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg06740227	chr12:86229804	RASSF9	0.49	6.34	0.37	1.1e-9	Major depressive disorder;
KIRP	cis	rs1863824	0.625	rs10887600	chr10:88169072	C/T	cg07322936	chr10:88137208	NA	-0.52	-5.13	-0.31	5.83e-7	Schizophrenia;
KIRP	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg22437258	chr11:111473054	SIK2	0.57	7.09	0.41	1.45e-11	Primary sclerosing cholangitis;
KIRP	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.7	-9.18	-0.5	1.87e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.47	6.32	0.37	1.24e-9	Coronary artery disease;
KIRP	cis	rs2275565	0.809	rs4659727	chr1:237006914	A/G	cg17297354	chr1:237056641	MTR	-0.41	-5.22	-0.32	3.88e-7	Homocysteine levels;
KIRP	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.52	5.61	0.34	5.33e-8	Lung cancer;
KIRP	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg20673091	chr1:2541236	MMEL1	-0.78	-12.67	-0.63	1.21e-28	Ulcerative colitis;
KIRP	cis	rs362296	0.698	rs362289	chr4:3256378	G/A	cg06533319	chr4:3265114	C4orf44	0.58	6.46	0.38	5.49e-10	Parental longevity (mother's age at death);
KIRP	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg10556349	chr10:835070	NA	0.6	5.62	0.34	5.23e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.49	-6.41	-0.38	7.36e-10	Schizophrenia;
KIRP	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.6	0.34	5.74e-8	Coronary artery disease;
KIRP	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.45	-5.86	-0.35	1.51e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg04691961	chr3:161091175	C3orf57	0.46	6.78	0.4	8.93e-11	Morning vs. evening chronotype;
KIRP	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.98	10.01	0.54	5.1e-20	Eosinophilic esophagitis;
KIRP	cis	rs1018697	1.000	rs1018696	chr10:104549066	A/G	cg04362960	chr10:104952993	NT5C2	0.48	5.81	0.35	1.91e-8	Colorectal adenoma (advanced);
KIRP	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.11	-8.88	-0.49	1.45e-16	Mitochondrial DNA levels;
KIRP	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	1.08	18.72	0.77	3.17e-49	Schizophrenia;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg20296188	chr17:77397067	HRNBP3	0.99	6.77	0.4	9.64e-11	P wave terminal force;
KIRP	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg13147721	chr7:65941812	NA	0.79	6.23	0.37	1.97e-9	Diabetic kidney disease;
KIRP	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08280861	chr8:58055591	NA	0.62	5.17	0.31	4.83e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6028335	0.674	rs8120715	chr20:37598781	G/A	cg16355469	chr20:37678765	NA	0.53	5.26	0.32	3.2e-7	Alcohol and nicotine co-dependence;
KIRP	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.84	13.94	0.66	6.06e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg01872077	chr2:219646372	CYP27A1	0.38	4.85	0.3	2.17e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg22681709	chr2:178499509	PDE11A	-0.46	-4.99	-0.3	1.13e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.15	0.31	5.25e-7	Menopause (age at onset);
KIRP	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.74	-9.67	-0.52	5.86e-19	Longevity;Endometriosis;
KIRP	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg07884673	chr3:53033167	SFMBT1	0.81	6.35	0.38	1.02e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg05887092	chr17:76393375	PGS1	0.53	7.48	0.43	1.34e-12	HDL cholesterol levels;
KIRP	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg02696742	chr7:106810147	HBP1	-0.76	-7.02	-0.41	2.21e-11	Coronary artery disease;
KIRP	cis	rs10751667	0.600	rs1128413	chr11:1010694	C/T	cg10932868	chr11:921992	NA	0.5	5.76	0.34	2.44e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.55	0.48	1.33e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2554380	0.891	rs2244838	chr15:84298598	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-8.86	-0.49	1.59e-16	Height;
KIRP	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.6	0.44	6.25e-13	Colorectal cancer;
KIRP	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	0.95	14.84	0.69	5.01e-36	Breast cancer;
KIRP	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg16606324	chr3:10149918	C3orf24	0.6	5.58	0.34	6.23e-8	Alzheimer's disease;
KIRP	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg06212747	chr3:49208901	KLHDC8B	0.66	6.16	0.37	2.89e-9	Menarche (age at onset);
KIRP	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.47	9.08	0.5	3.7e-17	Educational attainment (years of education);
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.46	-5.77	-0.35	2.43e-8	Longevity;Endometriosis;
KIRP	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg24101359	chr6:42928495	GNMT	0.59	8.47	0.48	2.24e-15	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.83	-11.92	-0.6	3.83e-26	Neuroticism;
KIRP	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg03609598	chr5:56110824	MAP3K1	0.48	5.51	0.33	9.24e-8	Initial pursuit acceleration;
KIRP	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg00343986	chr7:65444356	GUSB	0.48	5.66	0.34	4.16e-8	Aortic root size;
KIRP	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.48	6.1	0.36	4.1e-9	Menopause (age at onset);
KIRP	cis	rs8067354	0.645	rs2645491	chr17:57877049	C/T	cg13753209	chr17:57696993	CLTC	0.56	5.48	0.33	1.04e-7	Hemoglobin concentration;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg07145255	chr5:59995354	DEPDC1B	0.71	6.08	0.36	4.63e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg21132104	chr15:45694354	SPATA5L1	0.58	7.13	0.41	1.09e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg04132472	chr17:19861366	AKAP10	-0.39	-5.08	-0.31	7.43e-7	Schizophrenia;
KIRP	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.92	14.65	0.68	2.36e-35	Testicular germ cell tumor;
KIRP	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.62	8.26	0.47	8.85e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	0.99	10.65	0.56	5.09e-22	Opioid sensitivity;
KIRP	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.94	0.4	3.51e-11	Platelet count;
KIRP	trans	rs6738485	0.601	rs13011900	chr2:106845059	G/C	cg14715136	chr2:108537789	NA	0.38	6.12	0.36	3.77e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.22	0.58	7.06e-24	Morning vs. evening chronotype;
KIRP	cis	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.85e-9	Leprosy;
KIRP	cis	rs2151522	0.612	rs13215613	chr6:127185508	T/C	cg21431617	chr6:127135037	NA	0.29	5.25	0.32	3.24e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.71	-7.43	-0.43	1.84e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	Myopia (pathological);
KIRP	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg19257562	chr1:2043853	PRKCZ	-0.35	-5.21	-0.32	3.91e-7	Height;
KIRP	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.54e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12913538	0.862	rs7162434	chr15:62888070	A/G	cg09983546	chr15:62884068	NA	0.61	8.92	0.49	1.1e-16	Sleep depth;
KIRP	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	6.66	0.39	1.79e-10	Lymphocyte counts;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22618164	chr12:122356400	WDR66	0.68	9.07	0.5	3.99e-17	Mean corpuscular volume;
KIRP	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.62	-8.92	-0.49	1.07e-16	Total body bone mineral density;
KIRP	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-11.3	-0.58	3.89e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.53	7.07	0.41	1.59e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.69	-8.97	-0.5	7.65e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35883536	1.000	rs6663612	chr1:101085835	A/G	cg06223162	chr1:101003688	GPR88	0.28	5.52	0.33	8.53e-8	Monocyte count;
KIRP	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.63	0.34	4.91e-8	Menopause (age at onset);
KIRP	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.43	7.09	0.41	1.39e-11	Electroencephalogram traits;
KIRP	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg13628971	chr7:2884303	GNA12	0.61	7.03	0.41	2.01e-11	Height;
KIRP	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg18016565	chr1:150552671	MCL1	-0.34	-5.12	-0.31	6.19e-7	Tonsillectomy;
KIRP	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.31	-4.86	-0.3	2.13e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg25706552	chr1:244017396	NA	0.58	6.36	0.38	9.76e-10	RR interval (heart rate);
KIRP	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-5.19	-0.31	4.42e-7	Height;
KIRP	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-36.41	-0.92	4.61e-101	Myeloid white cell count;
KIRP	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg26248373	chr2:1572462	NA	-0.63	-5.73	-0.34	2.88e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg22718636	chr4:961658	DGKQ	0.39	7.63	0.44	5.15e-13	Sjögren's syndrome;
KIRP	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg07117364	chr1:16154769	NA	-0.4	-4.85	-0.3	2.18e-6	Dilated cardiomyopathy;
KIRP	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg02811702	chr13:24901961	NA	0.4	5.36	0.32	1.89e-7	Obesity-related traits;
KIRP	cis	rs9309473	0.519	rs7606947	chr2:73909818	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.15	-0.37	3.13e-9	Metabolite levels;
KIRP	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.67	9.86	0.53	1.56e-19	Dupuytren's disease;
KIRP	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg05564831	chr3:52568323	NT5DC2	0.34	5.54	0.33	7.67e-8	Cognitive function;
KIRP	cis	rs3112255	0.901	rs2942890	chr2:101293283	A/G	cg01042948	chr2:101319752	NA	0.43	6.23	0.37	2e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg01620082	chr3:125678407	NA	-1.01	-6.67	-0.39	1.66e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.3	0.37	1.39e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg10326726	chr10:51549505	MSMB	-0.63	-9.31	-0.51	7.4e-18	Prostate-specific antigen levels;
KIRP	cis	rs6725041	0.631	rs4673657	chr2:213151230	C/T	cg16329650	chr2:213403929	ERBB4	-0.37	-4.88	-0.3	1.94e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg23533419	chr12:54090519	NA	0.32	4.97	0.3	1.25e-6	Height;
KIRP	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg26727032	chr16:67993705	SLC12A4	-0.61	-6.04	-0.36	5.55e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.24	-26.31	-0.86	1.85e-73	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.36	-0.32	1.93e-7	Breast cancer;
KIRP	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg15655495	chr12:38532458	NA	0.27	5.4	0.33	1.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	8.55	0.48	1.28e-15	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.71	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs4073221	0.615	rs35098540	chr3:18207406	A/G	cg07694806	chr3:18168406	NA	-0.64	-5.95	-0.35	9.38e-9	Parkinson's disease;
KIRP	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.72	-7.66	-0.44	4.21e-13	Gut microbiome composition (summer);
KIRP	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg02915290	chr3:183675533	ABCC5	0.73	6.33	0.37	1.13e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.57	8.16	0.46	1.78e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23475109	chr2:97530683	SEMA4C	0.47	6.01	0.36	6.47e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.68	7.97	0.45	5.81e-14	Height;
KIRP	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg08975724	chr8:8085496	FLJ10661	-0.73	-10.62	-0.56	6.17e-22	Neuroticism;
KIRP	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.36e-8	Platelet count;
KIRP	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.03	19.66	0.78	2.31e-52	Birth weight;
KIRP	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg08847533	chr14:75593920	NEK9	0.95	12.84	0.63	3.15e-29	Height;
KIRP	cis	rs1359582	1.000	rs2576162	chr10:90319445	G/A	cg15661332	chr10:90342814	RNLS	0.55	5.19	0.31	4.3e-7	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs11874712	0.931	rs8095031	chr18:43666861	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs16933812	0.510	rs4880048	chr9:36989054	A/G	cg13738729	chr9:36989127	PAX5	-0.36	-4.99	-0.3	1.13e-6	Obesity-related traits;
KIRP	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg05887092	chr17:76393375	PGS1	0.61	9.34	0.51	6.12e-18	HDL cholesterol levels;
KIRP	cis	rs258892	0.895	rs13159570	chr5:72045109	A/T	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs6545883	0.894	rs2121661	chr2:61561658	A/G	cg15711740	chr2:61764176	XPO1	0.59	7.71	0.44	3.19e-13	Tuberculosis;
KIRP	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	1.12	8.1	0.46	2.53e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg15212821	chr22:44395017	PARVB	1.04	6.46	0.38	5.66e-10	Thrombomodulin levels in ischemic stroke;
KIRP	trans	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg26043149	chr18:55253948	FECH	0.48	6.09	0.36	4.3e-9	Bone mineral density;
KIRP	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.8	11.13	0.58	1.44e-23	Menarche (age at onset);
KIRP	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.64	7.92	0.45	8.11e-14	Vitiligo;
KIRP	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18252515	chr7:66147081	NA	-0.45	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.45	-5.45	-0.33	1.23e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg25233709	chr10:116636983	FAM160B1	0.34	5.22	0.32	3.76e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11690256	1.000	rs11690256	chr2:129542767	A/G	cg16353174	chr2:129543148	NA	0.45	6.6	0.39	2.53e-10	Symmetrical dimethylarginine levels;
KIRP	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg23107878	chr1:152161397	NA	-0.48	-5.26	-0.32	3.11e-7	Inflammatory skin disease;
KIRP	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.79	-11.15	-0.58	1.24e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.84	11.95	0.61	2.9e-26	Monocyte count;
KIRP	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.28	-0.32	2.83e-7	Obesity-related traits;
KIRP	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.17	-0.46	1.6e-14	Migraine;Coronary artery disease;
KIRP	cis	rs4750440	0.642	rs7921741	chr10:14030776	G/A	cg27542038	chr10:14027202	FRMD4A	-0.47	-6.44	-0.38	6.38e-10	Adiponectin levels;
KIRP	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.75	8.07	0.46	3.14e-14	Corneal astigmatism;
KIRP	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.55	-6.92	-0.4	3.93e-11	Coronary artery disease;
KIRP	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg15655495	chr12:38532458	NA	-0.27	-5.03	-0.31	9.59e-7	Heart rate;
KIRP	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.05	-0.31	8.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.52	-6.76	-0.4	9.94e-11	Body mass index;
KIRP	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.81	8.76	0.49	3.34e-16	Exhaled nitric oxide output;
KIRP	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg08975724	chr8:8085496	FLJ10661	0.53	7.17	0.42	8.98e-12	Myopia (pathological);
KIRP	trans	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg08400319	chr2:242004533	SNED1	0.46	6.43	0.38	6.69e-10	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs6445967	1.000	rs11712758	chr3:58306579	T/C	cg16569813	chr3:58235849	ABHD6	-0.33	-4.95	-0.3	1.38e-6	Platelet count;
KIRP	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.66	-0.34	4.21e-8	Bipolar disorder;
KIRP	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.86	-0.45	1.2e-13	Neuroticism;
KIRP	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg09184832	chr6:79620586	NA	-0.44	-6.06	-0.36	5.06e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg06521331	chr12:34319734	NA	-0.5	-6.23	-0.37	2.05e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg11784071	chr10:104629166	AS3MT	-0.37	-5.1	-0.31	6.79e-7	Arsenic metabolism;
KIRP	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.45	-5.97	-0.36	8.4e-9	Asthma;
KIRP	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg18657303	chr4:1051139	NA	-0.54	-4.95	-0.3	1.35e-6	Recombination rate (females);
KIRP	cis	rs12282928	0.959	rs11500496	chr11:48304436	A/G	cg26585981	chr11:48327164	OR4S1	0.5	6.05	0.36	5.29e-9	Migraine - clinic-based;
KIRP	cis	rs3931020	0.688	rs1051122	chr1:75190452	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	0.42	4.98	0.3	1.17e-6	Resistin levels;
KIRP	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg00800038	chr16:89945340	TCF25	-0.76	-5.28	-0.32	2.78e-7	Skin colour saturation;
KIRP	cis	rs71277158	0.688	rs73030653	chr3:169841926	G/A	cg04067573	chr3:169899625	PHC3	0.59	5.7	0.34	3.36e-8	Prostate cancer;
KIRP	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg22974920	chr21:40686053	BRWD1	-0.44	-5.26	-0.32	3.12e-7	Cognitive function;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg16176301	chr11:8933372	ST5;C11orf17	0.52	6.53	0.38	3.73e-10	Asthma;
KIRP	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06544989	chr22:39130855	UNC84B	-0.47	-7.87	-0.45	1.11e-13	Menopause (age at onset);
KIRP	cis	rs4716602	0.542	rs10249935	chr7:156159781	G/A	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.37	-6.19	-0.37	2.47e-9	Menarche (age at onset);
KIRP	trans	rs264162	0.687	rs264187	chr18:10957727	A/C	cg19813362	chr1:956108	AGRN	0.48	6.11	0.36	3.83e-9	Stem cell growth factor beta levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16771474	chr7:7776115	NA	-0.46	-6.6	-0.39	2.57e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs73200209	0.744	rs61354255	chr12:116444609	A/T	cg01776926	chr12:116560359	MED13L	-0.52	-5.72	-0.34	3.06e-8	Total body bone mineral density;
KIRP	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.77	9.11	0.5	2.87e-17	Migraine;Coronary artery disease;
KIRP	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.59	-7.39	-0.43	2.34e-12	Fibrinogen levels;
KIRP	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg22138327	chr13:27999177	GTF3A	-0.91	-6.96	-0.41	3.11e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10532362	chr17:39992352	NT5C3L	0.58	7.38	0.43	2.36e-12	Parkinson's disease;
KIRP	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg24631222	chr15:78858424	CHRNA5	0.43	5.27	0.32	2.93e-7	Sudden cardiac arrest;
KIRP	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg10326726	chr10:51549505	MSMB	0.51	7.01	0.41	2.28e-11	Prostate-specific antigen levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09041337	chr13:96640017	UGGT2	0.35	6.35	0.38	1.02e-9	Survival in pancreatic cancer;
KIRP	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg01843034	chr6:37503916	NA	-0.82	-11.5	-0.59	9.23e-25	Cognitive performance;
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27189623	chr16:705930	WDR90	0.43	6.02	0.36	6.44e-9	Height;
KIRP	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg26531700	chr6:26746687	NA	0.4	5.42	0.33	1.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs6568686	0.786	rs2146459	chr6:111815963	T/C	cg15721981	chr6:111408429	SLC16A10	-0.69	-5.96	-0.36	8.63e-9	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.51	7.19	0.42	7.53e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.2	13.21	0.64	1.84e-30	Nonalcoholic fatty liver disease;
KIRP	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	0.9	14.06	0.67	2.36e-33	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.11	-0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.55	7.11	0.41	1.24e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg01798813	chr17:3906674	NA	-0.53	-7.39	-0.43	2.27e-12	Type 2 diabetes;
KIRP	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg17443007	chr1:101659419	NA	0.39	5.53	0.33	8.14e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg03468072	chr12:39539422	NA	0.43	5.8	0.35	2.07e-8	Morning vs. evening chronotype;
KIRP	cis	rs6690583	1.000	rs6690464	chr1:85466369	A/G	cg22153463	chr1:85462885	MCOLN2	-0.72	-8.14	-0.46	2.04e-14	Serum sulfate level;
KIRP	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.93	0.53	9.3e-20	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.78	-10.58	-0.56	8.56e-22	Aortic root size;
KIRP	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg21775007	chr8:11205619	TDH	0.66	9.67	0.52	5.95e-19	Retinal vascular caliber;
KIRP	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.78e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs8014252	0.803	rs1959477	chr14:71034216	A/G	cg19730268	chr14:71022823	NA	-0.5	-4.87	-0.3	2.04e-6	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg18132916	chr6:79620363	NA	-0.37	-4.91	-0.3	1.69e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	0.96	18.11	0.76	3.79e-47	Dental caries;
KIRP	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	0.99	16.48	0.72	1.33e-41	Multiple system atrophy;
KIRP	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.7	10.62	0.56	6.1e-22	Dupuytren's disease;
KIRP	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.64	8.68	0.48	5.4e-16	Height;
KIRP	trans	rs2504916	0.955	rs2457014	chr6:160824145	C/T	cg18189607	chr15:42119864	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.57	-6.03	-0.36	5.98e-9	Response to hepatitis C treatment;
KIRP	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg15676125	chr6:33679581	C6orf125	0.39	5.06	0.31	8.23e-7	Plateletcrit;
KIRP	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.58	8.54	0.48	1.38e-15	Blood metabolite levels;
KIRP	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg01843034	chr6:37503916	NA	-0.94	-14.92	-0.69	2.7e-36	Cognitive performance;
KIRP	cis	rs10875746	0.551	rs10875799	chr12:48740879	C/A	cg20731937	chr12:48336164	NA	0.46	5.71	0.34	3.29e-8	Longevity (90 years and older);
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg14338887	chr6:42928500	GNMT	0.47	6.8	0.4	8.05e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-7.16	-0.42	9.06e-12	Monocyte percentage of white cells;
KIRP	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	9.18	0.51	1.77e-17	Mood instability;
KIRP	cis	rs2017305	0.764	rs2805918	chr10:70782514	T/C	cg01024728	chr10:70782572	NA	0.6	4.87	0.3	2.02e-6	Depression (quantitative trait);
KIRP	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.65	5.87	0.35	1.38e-8	Diabetic retinopathy;
KIRP	trans	rs17079247	0.841	rs9602700	chr13:85810147	T/C	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg20701182	chr2:24300061	SF3B14	0.5	4.97	0.3	1.24e-6	Lymphocyte counts;
KIRP	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.69	-8.55	-0.48	1.34e-15	Cognitive function;
KIRP	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.16	-14.67	-0.68	2.05e-35	Gut microbiome composition (summer);
KIRP	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg17385448	chr1:15911702	AGMAT	0.27	5.72	0.34	3.08e-8	Systolic blood pressure;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg04127825	chr1:167503222	NA	0.69	6.52	0.38	3.93e-10	Lung function (FEV1);
KIRP	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	6.1	0.36	4.11e-9	Breast cancer;
KIRP	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.96	12.91	0.64	1.81e-29	Breast cancer;
KIRP	cis	rs2916247	1.000	rs4415366	chr8:93052634	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.65	-0.44	4.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg14906510	chr12:7781169	NA	-0.49	-5.24	-0.32	3.41e-7	HDL cholesterol levels;
KIRP	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08048268	chr3:133502702	NA	-0.44	-5.26	-0.32	3.09e-7	Iron status biomarkers;
KIRP	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	1.08	14.23	0.67	6.25e-34	Breast cancer;
KIRP	cis	rs1497828	0.956	rs2646861	chr1:217521978	G/A	cg04411442	chr1:217543379	NA	-0.43	-6.49	-0.38	4.76e-10	Dialysis-related mortality;
KIRP	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg05304507	chr6:116381966	FRK	0.2	5.32	0.32	2.36e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9487051	1.000	rs6568571	chr6:109613252	A/T	cg21918786	chr6:109611834	NA	-0.37	-5.18	-0.31	4.66e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.71	7.46	0.43	1.52e-12	Diastolic blood pressure;
KIRP	cis	rs4356932	0.967	rs6532159	chr4:76978124	A/G	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	8.89	0.49	1.36e-16	Colorectal cancer;
KIRP	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg07636037	chr3:49044803	WDR6	0.56	5.27	0.32	3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs151997	1.000	rs152817	chr5:50230879	T/A	cg06027927	chr5:50259733	NA	-0.57	-7.18	-0.42	8.25e-12	Callous-unemotional behaviour;
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg12463550	chr7:65579703	CRCP	0.43	4.88	0.3	1.95e-6	Aortic root size;
KIRP	cis	rs6832769	0.922	rs501679	chr4:56237327	C/T	cg05960024	chr4:56376020	CLOCK	0.57	7.29	0.42	4.32e-12	Personality dimensions;
KIRP	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.47	-6.65	-0.39	1.85e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg24644049	chr4:85504048	CDS1	0.99	6.64	0.39	2.03e-10	Skin colour saturation;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.36	-5.15	-0.31	5.33e-7	Bipolar disorder;
KIRP	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.87	8.47	0.48	2.3e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs1448094	0.933	rs10779218	chr12:86320053	A/G	cg00310523	chr12:86230176	RASSF9	0.38	5.85	0.35	1.52e-8	Major depressive disorder;
KIRP	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-7.44	-0.43	1.68e-12	Height;
KIRP	cis	rs7100689	1.000	rs7100689	chr10:82222178	C/A	cg01528321	chr10:82214614	TSPAN14	1.31	14.33	0.67	2.94e-34	Post bronchodilator FEV1;
KIRP	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.41	5.24	0.32	3.44e-7	Aortic root size;
KIRP	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs2067663	1.000	rs2067663	chr5:88191635	C/T	cg18498987	chr5:88179539	MEF2C	0.42	5.36	0.32	1.95e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs4363385	0.510	rs11812015	chr1:153045584	G/T	cg07796016	chr1:152779584	LCE1C	-0.46	-5.89	-0.35	1.3e-8	Inflammatory skin disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15558982	chr1:115632262	TSPAN2	-0.55	-7.03	-0.41	2e-11	Menopause (age at onset);
KIRP	cis	rs6909279	0.678	rs6557143	chr6:151848611	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.53	-6.42	-0.38	7.04e-10	Bone mineral density;
KIRP	cis	rs9815354	1.000	rs79548696	chr3:41803385	C/T	cg03022575	chr3:42003672	ULK4	0.54	6.1	0.36	4.06e-9	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs6993813	0.678	rs7824837	chr8:120008736	A/C	cg22961513	chr11:14280813	SPON1	0.36	6.08	0.36	4.45e-9	Bone mineral density (hip);
KIRP	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	12.47	0.62	5.56e-28	Monocyte percentage of white cells;
KIRP	cis	rs2862064	0.649	rs1995377	chr5:156436679	T/A	cg12943317	chr5:156479607	HAVCR1	-0.88	-7.71	-0.44	3.16e-13	Platelet count;
KIRP	trans	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.17	-0.37	2.82e-9	Neuroticism;
KIRP	cis	rs2120243	0.539	rs1568609	chr3:157066839	G/A	cg24825693	chr3:157122686	VEPH1	-0.43	-6.65	-0.39	1.92e-10	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg17279839	chr7:150038598	RARRES2	0.42	5.82	0.35	1.85e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	0.83	12.64	0.63	1.54e-28	Breast cancer;
KIRP	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.77	10.17	0.54	1.71e-20	Resting heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20495179	chr2:96689067	GPAT2	-0.44	-6.32	-0.37	1.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4704187	0.687	rs7720620	chr5:74366023	A/G	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.63	8.45	0.47	2.55e-15	Motion sickness;
KIRP	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.84	-12.06	-0.61	1.3e-26	Dental caries;
KIRP	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.72	8.38	0.47	3.99e-15	Gestational age at birth (maternal effect);
KIRP	cis	rs8177876	0.658	rs77874075	chr16:81066339	T/G	cg08591886	chr16:81111003	C16orf46	-0.71	-5.55	-0.33	7.35e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg10434728	chr15:90938212	IQGAP1	0.38	6.55	0.39	3.26e-10	Rheumatoid arthritis;
KIRP	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	14.95	0.69	2.25e-36	Lymphocyte percentage of white cells;
KIRP	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.22	0.37	2.09e-9	Aortic root size;
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg18806716	chr10:30721971	MAP3K8	-0.36	-5.62	-0.34	5.11e-8	Inflammatory bowel disease;
KIRP	cis	rs1635	0.655	rs16893917	chr6:28269407	G/A	cg15743358	chr6:28303923	ZNF323	-0.76	-5.47	-0.33	1.13e-7	Schizophrenia;
KIRP	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.49	7.16	0.42	9.1e-12	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg08126542	chr6:37504118	NA	-0.69	-9.03	-0.5	5.31e-17	Cognitive performance;
KIRP	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg00677455	chr12:58241039	CTDSP2	0.97	12.61	0.63	1.88e-28	Multiple sclerosis;
KIRP	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg05347473	chr6:146136440	FBXO30	0.5	7.05	0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.7	0.39	1.39e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6545883	0.501	rs935860	chr2:61406561	G/C	cg15711740	chr2:61764176	XPO1	-0.47	-5.8	-0.35	2.03e-8	Tuberculosis;
KIRP	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.7	-0.34	3.44e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs6593803	0.732	rs1043806	chr1:147229299	G/A	cg27546670	chr1:147246839	GJA5	0.67	7.9	0.45	9.38e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg06637938	chr14:75390232	RPS6KL1	0.45	6.34	0.37	1.08e-9	Height;
KIRP	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg16255804	chr6:135334527	HBS1L	-0.37	-5.75	-0.34	2.58e-8	Red blood cell count;
KIRP	cis	rs6988636	0.534	rs62521775	chr8:124109949	A/G	cg15893493	chr8:124194847	FAM83A	0.59	4.85	0.3	2.24e-6	Urinary uromodulin levels;
KIRP	cis	rs2273156	1.000	rs35090385	chr14:35444435	T/G	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.44	-0.33	1.29e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.4	-5.79	-0.35	2.12e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23861078	chr2:27435638	SLC5A6;C2orf28	0.53	6.19	0.37	2.55e-9	Smoking initiation;
KIRP	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs41563	0.593	rs7807853	chr7:104597669	A/T	cg04380332	chr7:105027541	SRPK2	-0.47	-7.13	-0.41	1.12e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.92	10.5	0.56	1.46e-21	Triglycerides;
KIRP	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.47e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg22939043	chr6:170059563	WDR27	0.52	6.83	0.4	6.63e-11	Pancreatic cancer;
KIRP	cis	rs2411233	0.837	rs12906667	chr15:39249829	C/A	cg19287857	chr15:39890699	NA	0.38	5.15	0.31	5.43e-7	Platelet count;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg24572153	chr13:21047387	CRYL1	-0.47	-6.11	-0.36	3.82e-9	Inflammatory biomarkers;
KIRP	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg09455208	chr3:40491958	NA	0.32	5.79	0.35	2.13e-8	Renal cell carcinoma;
KIRP	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.63	7.28	0.42	4.42e-12	Subjective well-being;
KIRP	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.69	-10.76	-0.57	2.17e-22	Educational attainment;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.8	-0.4	7.89e-11	Aortic root size;
KIRP	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.54	8.7	0.49	4.84e-16	Total body bone mineral density;
KIRP	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg12598211	chr12:123634384	NA	-0.45	-5.19	-0.31	4.34e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7011507	1.000	rs7008568	chr8:49119132	A/G	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs76917914	0.820	rs58427887	chr9:100820671	C/T	cg03040243	chr9:100819229	NANS	0.66	7.11	0.41	1.25e-11	Immature fraction of reticulocytes;
KIRP	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs9653442	0.564	rs11123809	chr2:100758137	C/T	cg22139774	chr2:100720529	AFF3	-0.31	-5.22	-0.32	3.8e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.69	-10.33	-0.55	5.22e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18656765	chr4:159644664	PPID	0.55	6.42	0.38	6.8e-10	Smoking initiation;
KIRP	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.87	-15.74	-0.71	4.42e-39	Body mass index;
KIRP	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg25019033	chr10:957182	NA	-0.51	-5.46	-0.33	1.17e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	5.67	0.34	4.02e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.57	5.38e-23	Orofacial clefts;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02856606	chr1:19282682	IFFO2	0.47	6.14	0.36	3.24e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2249694	0.520	rs10776685	chr10:135327317	T/C	cg20169779	chr10:135381914	SYCE1	-0.57	-6.28	-0.37	1.54e-9	Obesity-related traits;
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	5.97	0.36	8.09e-9	Platelet count;
KIRP	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.76	10.16	0.54	1.78e-20	Mood instability;
KIRP	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.0	-0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17604090	0.887	rs850013	chr7:29666530	T/C	cg19413766	chr7:29689036	LOC646762	-0.67	-6.83	-0.4	6.56e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
KIRP	cis	rs754423	0.558	rs10498441	chr14:52544224	C/T	cg05884192	chr14:52515736	NID2	-0.48	-6.17	-0.37	2.85e-9	Craniofacial microsomia;
KIRP	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	12.17	0.61	5.55e-27	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00933542	chr6:150070202	PCMT1	0.28	5.31	0.32	2.48e-7	Lung cancer;
KIRP	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.51	7.3	0.42	4.08e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.38	-5.03	-0.31	9.57e-7	Renal function-related traits (BUN);
KIRP	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.96	13.28	0.65	1.07e-30	Ulcerative colitis;
KIRP	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg12598211	chr12:123634384	NA	-0.41	-4.97	-0.3	1.24e-6	Neutrophil percentage of white cells;
KIRP	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.8	10.84	0.57	1.19e-22	Systemic lupus erythematosus;
KIRP	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg17218026	chr1:154582156	ADAR	0.34	5.15	0.31	5.36e-7	Blood protein levels;
KIRP	cis	rs687432	0.774	rs12805812	chr11:57910378	G/A	cg19752551	chr11:57585705	CTNND1	-0.67	-8.54	-0.48	1.38e-15	Parkinson's disease;
KIRP	cis	rs2562456	0.641	rs62107468	chr19:21489979	A/C	cg18461458	chr19:21324796	ZNF431	-0.54	-5.2	-0.31	4.28e-7	Pain;
KIRP	cis	rs7601312	1.000	rs7601312	chr2:229320093	A/G	cg02542817	chr2:229291442	NA	-0.38	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.67	9.4	0.51	3.82e-18	Morning vs. evening chronotype;
KIRP	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-8.42	-0.47	3.17e-15	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg03929089	chr4:120376271	NA	0.71	6.33	0.37	1.16e-9	Axial length;
KIRP	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08439880	chr3:133502540	NA	-0.5	-6.2	-0.37	2.3e-9	Iron status biomarkers;
KIRP	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.84	-14.4	-0.68	1.66e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.94	13.29	0.65	9.61e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs11638352	1.000	rs2899103	chr15:44340555	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.78	-5.44	-0.33	1.31e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg27205649	chr11:78285834	NARS2	0.62	7.87	0.45	1.16e-13	Alzheimer's disease (survival time);
KIRP	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg17470449	chr10:769945	NA	0.7	7.08	0.41	1.54e-11	Uric acid levels;
KIRP	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.44	0.38	6.07e-10	Major depressive disorder;
KIRP	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.67	7.64	0.44	4.84e-13	Height;
KIRP	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.83	-10.89	-0.57	8.51e-23	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg10636054	chr15:40330586	SRP14	0.62	5.98	0.36	7.99e-9	Response to haloperidol in psychosis;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.74	-10.18	-0.54	1.54e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.7e-6	Coronary artery disease;
KIRP	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.77	-0.35	2.43e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.8	6.99	0.41	2.64e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.55	0.43	8.57e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4077515	0.839	rs1132005	chr9:139296927	T/C	cg21253087	chr9:139290292	SNAPC4	0.48	6.73	0.39	1.21e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.75	-7.57	-0.43	7.59e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.71	-12.85	-0.63	2.95e-29	Body mass index;
KIRP	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.53	-6.96	-0.41	3.15e-11	Migraine;
KIRP	cis	rs4237845	0.591	rs10877041	chr12:58328500	G/A	cg02175503	chr12:58329896	NA	0.88	10.79	0.57	1.72e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs13190036	0.748	rs28395268	chr5:176710547	C/G	cg04708888	chr5:176739561	MXD3	-0.54	-5.31	-0.32	2.47e-7	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg06521331	chr12:34319734	NA	-0.5	-6.18	-0.37	2.62e-9	Bladder cancer;
KIRP	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg24747557	chr10:131355152	MGMT	-0.47	-6.39	-0.38	8.06e-10	Response to temozolomide;
KIRP	cis	rs56161922	1.000	rs11118363	chr1:207859251	G/A	cg09557387	chr1:207818395	CR1L	-1.07	-6.31	-0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.45	6.41	0.38	7.43e-10	Endometrial cancer;
KIRP	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.45	-5.0	-0.3	1.09e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg06212747	chr3:49208901	KLHDC8B	0.64	5.96	0.36	8.85e-9	Menarche (age at onset);
KIRP	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg14456004	chr13:21872349	NA	-1.11	-13.86	-0.66	1.12e-32	White matter hyperintensity burden;
KIRP	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg07169764	chr2:136633963	MCM6	0.53	6.15	0.36	3.18e-9	Mosquito bite size;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs9888739	0.668	rs9933520	chr16:31343386	A/G	cg15817542	chr16:31343056	ITGAM	-0.49	-5.11	-0.31	6.36e-7	Systemic lupus erythematosus;
KIRP	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.65	-8.25	-0.47	9.61e-15	Body mass index;
KIRP	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.17	0.58	1.04e-23	Smoking behavior;
KIRP	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.58	8.47	0.48	2.22e-15	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.03e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg12181417	chr19:49337499	HSD17B14	-0.46	-4.98	-0.3	1.21e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9682041	0.877	rs12489967	chr3:170073339	A/C	cg11886554	chr3:170076028	SKIL	0.5	5.17	0.31	4.78e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.43	-5.9	-0.35	1.18e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs62413470	1.000	rs62411457	chr6:55968487	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs11574514	1.000	rs7200950	chr16:67689752	C/T	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.86	-0.35	1.49e-8	Crohn's disease;
KIRP	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21659725	chr3:3221576	CRBN	-0.58	-7.15	-0.41	9.79e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.42	-0.51	3.38e-18	Joint mobility (Beighton score);
KIRP	cis	rs838147	0.844	rs8111399	chr19:49247963	G/T	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.27e-7	Dietary macronutrient intake;
KIRP	cis	rs4356932	0.967	rs6816898	chr4:76969057	C/A	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs7113874	0.802	rs4291677	chr11:8680891	T/C	cg08015107	chr11:8618950	NA	-0.42	-5.89	-0.35	1.3e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.2	-0.31	4.21e-7	Bladder cancer;
KIRP	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg15556689	chr8:8085844	FLJ10661	0.49	5.56	0.33	7.14e-8	Myopia (pathological);
KIRP	cis	rs427941	0.703	rs1734879	chr7:101740610	C/A	cg06246474	chr7:101738831	CUX1	0.56	6.93	0.4	3.65e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.92	-16.16	-0.72	1.62e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg12615879	chr12:58013172	SLC26A10	0.37	5.66	0.34	4.2e-8	Multiple sclerosis;
KIRP	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.56	7.01	0.41	2.28e-11	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg13319975	chr6:146136371	FBXO30	-0.39	-5.2	-0.31	4.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17739167	0.532	rs11638953	chr15:42245652	G/A	cg20935245	chr15:42234343	EHD4	0.48	7.58	0.44	7.09e-13	Monocyte count;
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.46	0.74	5.75e-45	Platelet count;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg02733842	chr7:1102375	C7orf50	0.46	4.97	0.3	1.23e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs12143943	0.738	rs11240750	chr1:204459786	T/C	cg20240347	chr1:204465584	NA	-0.38	-6.95	-0.4	3.33e-11	Cognitive performance;
KIRP	cis	rs17321999	0.904	rs2089657	chr2:30470178	C/T	cg05247661	chr2:30472410	LBH	0.74	7.83	0.45	1.44e-13	Systemic lupus erythematosus;
KIRP	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg03474202	chr17:45855739	NA	-0.42	-5.96	-0.36	8.53e-9	IgG glycosylation;
KIRP	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-5.86	-0.35	1.48e-8	Morning vs. evening chronotype;
KIRP	cis	rs10782582	0.609	rs1689270	chr1:76390937	A/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.98	-0.36	8.02e-9	Daytime sleep phenotypes;
KIRP	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.1	-0.41	1.35e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg12384639	chr17:618140	VPS53	0.49	5.98	0.36	7.86e-9	Prostate cancer;
KIRP	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.88	10.02	0.54	4.95e-20	Osteoarthritis;
KIRP	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-7.29	-0.42	4.1e-12	Dental caries;
KIRP	cis	rs4740619	0.619	rs10810520	chr9:16029467	G/T	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.04e-7	Body mass index;
KIRP	trans	rs848490	0.963	rs848494	chr7:77537964	G/A	cg05483252	chr3:19988132	RAB5A	-0.59	-6.13	-0.36	3.52e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.68	-7.66	-0.44	4.34e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03264133	chr6:25882463	NA	-0.38	-5.34	-0.32	2.15e-7	Height;
KIRP	cis	rs4908768	0.657	rs4908778	chr1:8804888	C/G	cg25722041	chr1:8623473	RERE	0.55	7.36	0.43	2.67e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg07511934	chr16:89386912	ANKRD11	0.41	5.36	0.32	1.9e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.54	5.7	0.34	3.46e-8	Coronary artery disease;
KIRP	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg04362960	chr10:104952993	NT5C2	-0.44	-4.84	-0.3	2.25e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-5.68	-0.34	3.87e-8	Parkinson's disease;
KIRP	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.44	-0.38	6.36e-10	Total body bone mineral density;
KIRP	cis	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.44	-5.5	-0.33	9.45e-8	Leprosy;
KIRP	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg13010199	chr12:38710504	ALG10B	0.63	7.83	0.45	1.46e-13	Morning vs. evening chronotype;
KIRP	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.49	6.0	0.36	6.87e-9	Initial pursuit acceleration;
KIRP	cis	rs7558233	0.568	rs4665212	chr2:23678544	A/G	cg00747342	chr2:23700632	KLHL29	0.6	5.54	0.33	7.79e-8	Cannabis use (initiation);
KIRP	cis	rs1009181	0.965	rs1059490	chr6:26171250	T/C	cg00631329	chr6:26305371	NA	-0.5	-5.87	-0.35	1.37e-8	Childhood ear infection;
KIRP	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.65	11.42	0.59	1.57e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.84	-0.45	1.39e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg26513180	chr16:89883248	FANCA	0.62	5.34	0.32	2.12e-7	Skin colour saturation;
KIRP	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.07	-0.46	3.18e-14	Body mass index;
KIRP	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.9	-0.49	1.25e-16	Blood trace element (Zn levels);
KIRP	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.39e-9	Neuroticism;
KIRP	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg23102388	chr7:1867652	MAD1L1	-0.47	-6.42	-0.38	7.06e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-7.6	-0.44	6.25e-13	Platelet count;
KIRP	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.47	-5.0	-0.3	1.1e-6	Initial pursuit acceleration;
KIRP	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.59	-8.46	-0.47	2.44e-15	Diastolic blood pressure;
KIRP	trans	rs3935996	0.767	rs12058859	chr1:56302126	C/T	cg18696692	chr7:140771827	NA	0.41	6.32	0.37	1.25e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
KIRP	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg03060546	chr3:49711283	APEH	0.48	6.17	0.37	2.86e-9	Parkinson's disease;
KIRP	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.71	9.41	0.51	3.62e-18	Morning vs. evening chronotype;
KIRP	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.92	-10.01	-0.54	5.41e-20	Type 2 diabetes;
KIRP	cis	rs16828019	0.852	rs34286980	chr1:41608389	A/G	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.86	8.72	0.49	4.24e-16	Methadone dose in opioid dependence;
KIRP	cis	rs4664293	1.000	rs6753181	chr2:160492438	C/A	cg08347373	chr2:160653686	CD302	-0.4	-6.1	-0.36	3.99e-9	Monocyte percentage of white cells;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10743145	chr19:45927001	ERCC1	0.48	6.09	0.36	4.38e-9	Myopia (pathological);
KIRP	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-5.99	-0.36	7.6e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg13271783	chr10:134563150	INPP5A	-0.54	-7.14	-0.41	1.07e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	6.0	0.36	6.98e-9	Depressive symptoms;
KIRP	cis	rs6921919	0.609	rs9468365	chr6:28357966	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.25	-5.29	-0.32	2.77e-7	Menarche (age at onset);
KIRP	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg21827317	chr3:136751795	NA	0.36	5.09	0.31	6.95e-7	Neuroticism;
KIRP	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.38	5.1	0.31	6.94e-7	Dupuytren's disease;
KIRP	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.74	0.44	2.5e-13	Coffee consumption (cups per day);
KIRP	cis	rs4658101	0.653	rs11165002	chr1:92048966	G/T	cg09075522	chr1:92031145	NA	-0.45	-5.56	-0.33	6.89e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	trans	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg06521331	chr12:34319734	NA	-0.59	-7.08	-0.41	1.5e-11	Bladder cancer;
KIRP	trans	rs2055729	0.645	rs12543685	chr8:9747056	T/C	cg06636001	chr8:8085503	FLJ10661	0.56	6.29	0.37	1.48e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg14082893	chr15:75400931	NA	-0.36	-5.27	-0.32	3.01e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2282032	1.000	rs3742671	chr14:90756760	A/T	cg04374321	chr14:90722782	PSMC1	0.56	5.25	0.32	3.27e-7	Longevity;
KIRP	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg16497661	chr14:103986332	CKB	0.81	13.7	0.66	3.82e-32	Body mass index;
KIRP	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.02	-0.36	6.3e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.88	14.07	0.67	2.19e-33	Mean corpuscular volume;
KIRP	cis	rs6540559	0.543	rs672819	chr1:210436404	T/A	cg09074223	chr1:210466472	NA	0.56	5.37	0.32	1.79e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs7582180	0.903	rs2309825	chr2:100905101	A/C	cg14675211	chr2:100938903	LONRF2	0.56	7.18	0.42	8.41e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg00343986	chr7:65444356	GUSB	0.42	4.94	0.3	1.42e-6	Aortic root size;
KIRP	cis	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg00405596	chr8:11794950	NA	-0.52	-6.46	-0.38	5.59e-10	Triglycerides;
KIRP	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-7.67	-0.44	3.93e-13	Neuroticism;
KIRP	cis	rs365132	0.875	rs353491	chr5:176432947	C/G	cg16309518	chr5:176445507	NA	-0.81	-12.21	-0.61	4.13e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.74	-0.39	1.12e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	16.04	0.71	4.15e-40	Electrocardiographic conduction measures;
KIRP	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.42	11.13	0.58	1.42e-23	Prostate cancer;
KIRP	cis	rs10875746	0.551	rs3185921	chr12:48734731	C/T	cg26205652	chr12:48591994	NA	0.78	9.81	0.53	2.25e-19	Longevity (90 years and older);
KIRP	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	7.58	0.43	7.22e-13	Height;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.61	-7.38	-0.43	2.44e-12	Longevity;Endometriosis;
KIRP	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9308433	0.643	rs7412913	chr1:214463228	G/A	cg06198575	chr1:214491504	SMYD2	0.5	6.36	0.38	9.98e-10	IgG glycosylation;
KIRP	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg18350739	chr11:68623251	NA	-0.52	-7.67	-0.44	3.88e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.89	-12.2	-0.61	4.42e-27	Gut microbiota (bacterial taxa);
KIRP	cis	rs904092	0.720	rs1230028	chr4:100182886	C/G	cg12011299	chr4:100065546	ADH4	0.49	4.94	0.3	1.42e-6	Alcohol dependence;
KIRP	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.59	-5.56	-0.33	7.17e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs981844	0.583	rs2289318	chr4:154633734	G/C	cg14289246	chr4:154710475	SFRP2	0.5	5.23	0.32	3.67e-7	Response to statins (LDL cholesterol change);
KIRP	cis	rs8028182	0.549	rs7402844	chr15:75637396	C/G	cg20655648	chr15:75932815	IMP3	-0.55	-6.88	-0.4	4.98e-11	Sudden cardiac arrest;
KIRP	cis	rs7539542	0.529	rs7542125	chr1:202871238	T/C	cg19681188	chr1:202830198	LOC148709	-0.48	-5.15	-0.31	5.33e-7	Mean platelet volume;
KIRP	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.73	9.42	0.52	3.33e-18	Eye color traits;
KIRP	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.72	8.05	0.46	3.61e-14	Corneal astigmatism;
KIRP	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.68	-0.34	3.82e-8	Depression;
KIRP	cis	rs4664308	0.618	rs66667042	chr2:160886703	A/C	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.03	-0.54	4.66e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	6.27	0.37	1.57e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg26043149	chr18:55253948	FECH	0.51	6.2	0.37	2.32e-9	Bone mineral density;
KIRP	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg07636037	chr3:49044803	WDR6	0.43	4.99	0.3	1.14e-6	Resting heart rate;
KIRP	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg00277334	chr10:82204260	NA	-0.5	-5.76	-0.34	2.53e-8	Post bronchodilator FEV1;
KIRP	cis	rs7577696	0.597	rs17011801	chr2:32298072	A/T	cg02381751	chr2:32503542	YIPF4	-0.52	-5.26	-0.32	3.08e-7	Inflammatory biomarkers;
KIRP	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.45	-4.84	-0.3	2.26e-6	Urate levels in overweight individuals;
KIRP	cis	rs6969780	0.915	rs12666919	chr7:27189498	A/T	cg19142026	chr7:27170394	HOXA4	-0.43	-5.53	-0.33	8.08e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1485395	0.945	rs10876470	chr12:54023491	G/A	cg16917193	chr12:54089295	NA	0.63	5.85	0.35	1.54e-8	Migraine without aura;
KIRP	cis	rs61884328	0.713	rs76716952	chr11:46990462	A/T	cg23433285	chr11:47201945	PACSIN3	0.69	5.55	0.33	7.35e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.86	11.31	0.59	3.58e-24	Monocyte count;
KIRP	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg14952266	chr13:112191215	NA	0.45	6.6	0.39	2.52e-10	Hepatitis;
KIRP	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.42	-4.98	-0.3	1.2e-6	Blood metabolite levels;
KIRP	cis	rs9826463	1.000	rs9857567	chr3:142340201	G/A	cg20824294	chr3:142316082	PLS1	0.34	5.8	0.35	2.02e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	7.57	0.43	7.35e-13	Bone mineral density;
KIRP	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Colorectal cancer;
KIRP	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.59	-8.14	-0.46	1.92e-14	Breast cancer;
KIRP	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.74	10.68	0.56	3.87e-22	Hip circumference;
KIRP	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg13939156	chr17:80058883	NA	-0.48	-5.45	-0.33	1.25e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.68	-9.15	-0.5	2.29e-17	Eye color traits;
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.07	-13.44	-0.65	2.92e-31	Alzheimer's disease;
KIRP	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12826209	chr6:26865740	GUSBL1	0.67	6.41	0.38	7.44e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg08923054	chr8:41654455	ANK1	-0.69	-7.51	-0.43	1.08e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.89	-0.45	9.74e-14	Retinal vascular caliber;
KIRP	cis	rs7224685	0.569	rs8066378	chr17:3996334	T/C	cg09597638	chr17:3907349	NA	0.52	5.24	0.32	3.53e-7	Type 2 diabetes;
KIRP	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg01529538	chr14:23388837	RBM23	0.42	5.33	0.32	2.25e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7665939	1.000	rs72727637	chr4:190106678	G/T	cg14840187	chr4:190284988	NA	-0.93	-6.77	-0.4	9.53e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-13.56	-0.65	1.18e-31	Monocyte count;
KIRP	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.02	0.3	9.8e-7	Menopause (age at onset);
KIRP	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07570687	chr10:102243282	WNT8B	0.51	6.26	0.37	1.74e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg24579218	chr15:68104479	NA	0.38	6.14	0.36	3.23e-9	Restless legs syndrome;
KIRP	trans	rs62056376	0.736	rs758293	chr17:32640523	A/T	cg17635953	chr13:28535085	NA	0.65	6.65	0.39	1.91e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22027860	chr2:113033717	ZC3H6	0.45	6.25	0.37	1.82e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs75920871	1.000	rs61905680	chr11:116836031	G/A	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	8.65	0.48	6.58e-16	Mood instability;
KIRP	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.6	9.32	0.51	6.75e-18	IgA nephropathy;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09592463	chr17:40995321	PSME3;AOC2	0.43	6.14	0.36	3.25e-9	Survival in pancreatic cancer;
KIRP	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg05791153	chr7:19748676	TWISTNB	0.63	5.74	0.34	2.75e-8	Thyroid stimulating hormone;
KIRP	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg18441811	chr11:71824068	C11orf51	-0.78	-5.29	-0.32	2.67e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05904283	chr16:716021	WDR90	0.47	6.22	0.37	2.14e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.75	7.7	0.44	3.33e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02042904	chr12:40645170	LRRK2	-0.41	-6.78	-0.4	9.03e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7106204	0.514	rs12805363	chr11:24258357	T/G	ch.11.24196551F	chr11:24239977	NA	0.67	5.23	0.32	3.67e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg07541023	chr7:19748670	TWISTNB	0.66	5.83	0.35	1.71e-8	Thyroid stimulating hormone;
KIRP	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-9.31	-0.51	7.54e-18	Gut microbiome composition (summer);
KIRP	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.41	4.97	0.3	1.24e-6	Body mass index;
KIRP	cis	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.18	0.31	4.64e-7	Leprosy;
KIRP	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.33	6.28	0.37	1.51e-9	Educational attainment (years of education);
KIRP	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg05347473	chr6:146136440	FBXO30	-0.5	-6.97	-0.41	2.95e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs73320584	0.518	rs1936614	chr10:92434957	C/T	cg14313238	chr10:92632228	RPP30	0.61	5.43	0.33	1.37e-7	Alzheimer disease and age of onset;
KIRP	cis	rs10495907	0.591	rs4953004	chr2:43961752	A/G	cg11659317	chr2:43863985	PLEKHH2	-0.42	-4.96	-0.3	1.32e-6	Coronary artery disease;
KIRP	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg07402062	chr16:89894098	SPIRE2	0.31	6.31	0.37	1.29e-9	Vitiligo;
KIRP	cis	rs6484504	0.600	rs2761593	chr11:31326752	G/T	cg26647111	chr11:31128758	NA	0.44	5.2	0.31	4.25e-7	Red blood cell count;
KIRP	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.98	9.74	0.53	3.49e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4742903	0.967	rs10991120	chr9:106909051	C/T	cg14250997	chr9:106856677	SMC2	0.37	4.89	0.3	1.8e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.95	-0.35	9.34e-9	Metabolite levels;
KIRP	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.67	-0.34	4.08e-8	Breast cancer;
KIRP	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg09137382	chr11:130731461	NA	0.49	6.56	0.39	3.14e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.64	7.86	0.45	1.21e-13	Cannabis dependence symptom count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21450318	chr19:6280351	MLLT1	0.49	6.18	0.37	2.7e-9	Parkinson's disease;
KIRP	cis	rs12130219	1.000	rs12733173	chr1:152173972	C/T	cg23107878	chr1:152161397	NA	-0.47	-5.19	-0.31	4.5e-7	Inflammatory skin disease;
KIRP	trans	rs2548003	0.518	rs13157411	chr5:28751609	C/T	cg23224356	chr2:98206733	ANKRD36B	-0.63	-6.27	-0.37	1.6e-9	Hip geometry;
KIRP	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg00343986	chr7:65444356	GUSB	0.44	5.18	0.31	4.69e-7	Aortic root size;
KIRP	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.54	7.44	0.43	1.68e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg08975724	chr8:8085496	FLJ10661	0.69	9.6	0.52	9.82e-19	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15229323	chr19:2820209	ZNF554	0.49	6.1	0.36	4.08e-9	Parkinson's disease;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg01322290	chr4:40818120	APBB2	-0.43	-6.31	-0.37	1.29e-9	Select biomarker traits;
KIRP	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.37	5.0	0.3	1.11e-6	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg04310649	chr10:35416472	CREM	-0.57	-6.51	-0.38	4.29e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.44	6.84e-13	Vitiligo;
KIRP	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13131263	chr1:9324393	H6PD	0.46	6.04	0.36	5.8e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs735539	0.521	rs2585902	chr13:21417636	A/C	cg04906043	chr13:21280425	IL17D	-0.43	-5.06	-0.31	8.11e-7	Dental caries;
KIRP	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg10189774	chr4:17578691	LAP3	0.49	5.99	0.36	7.36e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-0.92	-12.62	-0.63	1.76e-28	Blood trace element (Zn levels);
KIRP	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-9.01	-0.5	6e-17	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg16141378	chr3:129829833	LOC729375	0.47	6.15	0.37	3.19e-9	Triglycerides;
KIRP	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg05673287	chr15:77411982	SGK269	-0.38	-4.88	-0.3	1.94e-6	Type 2 diabetes;
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg09264619	chr17:80180166	NA	0.34	4.89	0.3	1.83e-6	Life satisfaction;
KIRP	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.62	10.86	0.57	1.04e-22	Total body bone mineral density;
KIRP	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg09201719	chr10:104596890	CYP17A1	0.39	5.67	0.34	3.91e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.29	-0.42	4.33e-12	Diisocyanate-induced asthma;
KIRP	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-8.12	-0.46	2.24e-14	Personality dimensions;
KIRP	cis	rs34779708	0.931	rs7099036	chr10:35349574	C/T	cg03585969	chr10:35415529	CREM	0.77	9.46	0.52	2.63e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08048268	chr3:133502702	NA	-0.4	-4.97	-0.3	1.25e-6	Iron status biomarkers;
KIRP	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	6.39	0.38	8.1e-10	Neuroticism;
KIRP	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg10434728	chr15:90938212	IQGAP1	-0.39	-7.49	-0.43	1.27e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.71	9.4	0.51	4.03e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg07856975	chr6:36356162	ETV7	0.4	5.72	0.34	3.13e-8	Platelet distribution width;
KIRP	cis	rs5995756	0.666	rs926231	chr22:40006986	C/G	cg21377881	chr22:40064566	CACNA1I	-0.39	-5.14	-0.31	5.56e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg19171272	chr22:38449367	NA	0.4	4.91	0.3	1.63e-6	Breast cancer;
KIRP	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg01097406	chr16:89675127	NA	-0.33	-5.4	-0.33	1.57e-7	Vitiligo;
KIRP	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.37	0.51	4.98e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15904821	chr3:141206028	RASA2	-0.47	-6.41	-0.38	7.54e-10	Metabolic traits;
KIRP	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.6	7.68	0.44	3.76e-13	Homocysteine levels;
KIRP	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	0.99	10.76	0.57	2.17e-22	Blood protein levels;
KIRP	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg00585698	chr12:123750864	CDK2AP1	0.49	5.42	0.33	1.43e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.55	-0.39	3.35e-10	Educational attainment;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05519436	chr8:133858872	PHF20L1	0.39	6.14	0.36	3.27e-9	C-reactive protein;
KIRP	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.59	5.8	0.35	2.04e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs41005	0.597	rs34452414	chr2:8101593	C/T	cg03155496	chr2:8117019	LOC339788	-0.44	-5.75	-0.34	2.64e-8	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg20243544	chr17:37824526	PNMT	0.54	7.66	0.44	4.36e-13	Asthma;
KIRP	cis	rs6956675	1.000	rs6956675	chr7:62577770	A/G	cg08930214	chr7:62859557	LOC100287834	0.49	5.79	0.35	2.14e-8	Obesity-related traits;
KIRP	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg23166289	chr1:210001082	C1orf107	0.4	4.97	0.3	1.24e-6	Orofacial clefts;
KIRP	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.62	8.01	0.45	4.65e-14	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	cg12689670	chr1:183009347	LAMC1	0.49	6.96	0.41	2.98e-11	Hypertriglyceridemia;
KIRP	cis	rs838721	0.574	rs11681192	chr2:234258064	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.46	5.02	0.31	9.74e-7	Total body bone mineral density;
KIRP	cis	rs2249694	0.960	rs4351776	chr10:135415572	G/T	cg20169779	chr10:135381914	SYCE1	-0.41	-4.89	-0.3	1.82e-6	Obesity-related traits;
KIRP	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.65	9.5	0.52	1.89e-18	Lymphocyte counts;
KIRP	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg11972305	chr2:233791962	NGEF	0.39	5.34	0.32	2.12e-7	Schizophrenia;
KIRP	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg15128208	chr22:42549153	NA	0.52	6.28	0.37	1.49e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.84	8.39	0.47	3.93e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg05938607	chr10:60274200	BICC1	-0.44	-10.26	-0.55	8.33e-21	Refractive error;
KIRP	cis	rs9840812	0.577	rs503973	chr3:136059537	C/G	cg15507776	chr3:136538369	TMEM22	-0.47	-5.66	-0.34	4.19e-8	Fibrinogen levels;
KIRP	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.47	-7.0	-0.41	2.38e-11	Daytime sleep phenotypes;
KIRP	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.34	5.38	0.32	1.72e-7	QRS complex (12-leadsum);
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.32	-0.32	2.3e-7	Breast cancer;
KIRP	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-5.9	-0.35	1.19e-8	Airflow obstruction;
KIRP	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.76	11.36	0.59	2.5300000000000002e-24	Heart rate;
KIRP	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg14580859	chr9:123691850	NA	0.36	5.14	0.31	5.58e-7	Rheumatoid arthritis;
KIRP	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.49	-7.22	-0.42	6.59e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs35883536	1.000	rs2282253	chr1:101094383	C/G	cg06223162	chr1:101003688	GPR88	0.32	6.54	0.38	3.63e-10	Monocyte count;
KIRP	cis	rs73200209	0.912	rs61935844	chr12:116617887	A/G	cg01776926	chr12:116560359	MED13L	-0.45	-5.48	-0.33	1.07e-7	Total body bone mineral density;
KIRP	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-10.17	-0.54	1.65e-20	Body mass index;
KIRP	cis	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.83	-11.41	-0.59	1.78e-24	Schizophrenia;
KIRP	trans	rs61884328	0.561	rs3809047	chr11:46367702	T/C	cg10758369	chr1:48459236	NA	0.53	6.85	0.4	5.8e-11	Total body bone mineral density (age over 60);
KIRP	cis	rs9354308	0.802	rs2814102	chr6:66523230	A/G	cg07460842	chr6:66804631	NA	0.48	5.5	0.33	9.73e-8	Metabolite levels;
KIRP	cis	rs77688320	0.517	rs11691865	chr2:202272032	T/A	cg06431681	chr2:202330990	STRADB	0.52	6.92	0.4	3.96e-11	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11542543	chr13:108017565	FAM155A	0.42	6.07	0.36	4.75e-9	Interleukin-4 levels;
KIRP	cis	rs13082711	0.911	rs13086867	chr3:27529937	G/A	cg02860705	chr3:27208620	NA	0.53	6.93	0.4	3.58e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg11015251	chr7:27170554	HOXA4	-0.39	-5.25	-0.32	3.26e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs7116495	1.000	rs58991229	chr11:71839878	G/A	cg18441811	chr11:71824068	C11orf51	0.62	4.95	0.3	1.4e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg23985595	chr17:80112537	CCDC57	-0.34	-4.99	-0.3	1.15e-6	Life satisfaction;
KIRP	cis	rs9303401	0.564	rs4968396	chr17:57247805	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.0	0.3	1.07e-6	Cognitive test performance;
KIRP	cis	rs10073892	0.660	rs1113814	chr5:101982039	A/G	cg19774478	chr5:101632501	SLCO4C1	0.58	5.7	0.34	3.46e-8	Cognitive decline (age-related);
KIRP	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg21680719	chr1:38466677	FHL3	-0.23	-5.06	-0.31	8.11e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg22117172	chr7:91764530	CYP51A1	0.44	5.98	0.36	7.69e-9	Breast cancer;
KIRP	cis	rs9783347	1.000	rs4353250	chr11:18323517	T/C	cg15585147	chr11:18324498	HPS5	0.47	6.35	0.38	1.02e-9	Pancreatic cancer;
KIRP	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.38	-7.09	-0.41	1.44e-11	Refractive error;
KIRP	trans	rs330071	0.515	rs12545193	chr8:9251880	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	7.23	0.42	6.18e-12	Acne (severe);
KIRP	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg15128208	chr22:42549153	NA	-0.44	-5.43	-0.33	1.37e-7	Cognitive function;
KIRP	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs2562456	0.754	rs76688173	chr19:21504658	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs311392	1.000	rs2666870	chr8:55086427	T/C	cg20636351	chr8:55087400	NA	-0.63	-7.53	-0.43	9.71e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg00701064	chr4:6280414	WFS1	0.36	7.2	0.42	7.36e-12	Cisplatin-induced ototoxicity;
KIRP	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg24747557	chr10:131355152	MGMT	0.46	6.31	0.37	1.28e-9	Response to temozolomide;
KIRP	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.5	0.33	9.28e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.67	9.31	0.51	7.5e-18	Body mass index;
KIRP	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.19	-0.37	2.44e-9	Bladder cancer;
KIRP	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.8	10.77	0.57	2.03e-22	Systemic lupus erythematosus;
KIRP	cis	rs4363385	0.510	rs11590369	chr1:152903603	G/C	cg13444842	chr1:152974279	SPRR3	-0.44	-6.31	-0.37	1.3e-9	Inflammatory skin disease;
KIRP	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg07148914	chr20:33460835	GGT7	0.57	7.5	0.43	1.13e-12	Height;
KIRP	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg20701182	chr2:24300061	SF3B14	0.58	5.16	0.31	5.13e-7	Lymphocyte counts;
KIRP	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg06618935	chr21:46677482	NA	-0.45	-5.55	-0.33	7.22e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.71	-11.0	-0.57	3.79e-23	Prostate cancer;
KIRP	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.99	15.75	0.71	4.17e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs7903847	0.642	rs7078004	chr10:99140511	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.86	0.4	5.41e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.89	-8.82	-0.49	2.09e-16	Lung cancer in ever smokers;
KIRP	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.52	-7.3	-0.42	3.92e-12	Glycated hemoglobin levels;
KIRP	cis	rs253959	0.662	rs13190269	chr5:115465523	A/G	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.33e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg04691961	chr3:161091175	C3orf57	-0.38	-5.71	-0.34	3.18e-8	Morning vs. evening chronotype;
KIRP	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg05370193	chr1:21551575	ECE1	0.42	5.91	0.35	1.13e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.63	-8.69	-0.48	5.31e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1345301	0.905	rs2310243	chr2:102877560	A/G	cg12451869	chr2:102867685	NA	0.4	5.89	0.35	1.24e-8	Waist circumference;
KIRP	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg27205649	chr11:78285834	NARS2	0.44	4.93	0.3	1.54e-6	Testicular germ cell tumor;
KIRP	trans	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg06521331	chr12:34319734	NA	-0.5	-6.22	-0.37	2.17e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.9	10.23	0.55	1.09e-20	Menopause (age at onset);
KIRP	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.61	8.46	0.47	2.34e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs2573652	0.722	rs11858932	chr15:100542763	G/A	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.54	-0.43	8.96e-13	Height;
KIRP	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.46	-5.36	-0.32	1.92e-7	Total body bone mineral density;
KIRP	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg20295408	chr7:1910781	MAD1L1	-0.52	-5.46	-0.33	1.14e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4356932	1.000	rs4359936	chr4:76971976	G/A	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.64e-9	Blood protein levels;
KIRP	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg14458575	chr2:238380390	NA	0.7	6.96	0.41	3.11e-11	Prostate cancer;
KIRP	cis	rs35740288	0.770	rs34048547	chr15:86181067	A/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.76	-0.34	2.55e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg10433463	chr1:1889099	KIAA1751	0.32	4.86	0.3	2.13e-6	Body mass index;
KIRP	cis	rs787274	1.000	rs4979154	chr9:115555031	A/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.3	-0.37	1.38e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2273669	0.667	rs7761290	chr6:109326621	T/G	cg05315195	chr6:109294784	ARMC2	-0.65	-6.32	-0.37	1.19e-9	Prostate cancer;
KIRP	cis	rs981844	0.775	rs62323977	chr4:154746141	G/A	cg14289246	chr4:154710475	SFRP2	0.66	7.68	0.44	3.66e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg15655495	chr12:38532458	NA	-0.3	-5.2	-0.31	4.15e-7	Bladder cancer;
KIRP	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.11e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	4.87	0.3	2.03e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	13.79	0.66	2.03e-32	Platelet count;
KIRP	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg19077165	chr18:44547161	KATNAL2	-0.43	-5.03	-0.31	9.26e-7	Educational attainment (years of education);
KIRP	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg25554036	chr4:6271136	WFS1	0.44	6.53	0.38	3.79e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.4	-0.51	3.98e-18	Platelet count;
KIRP	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg24315340	chr6:146058215	EPM2A	0.45	5.65	0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22182451	chr15:72486158	GRAMD2	0.44	6.07	0.36	4.85e-9	Survival in pancreatic cancer;
KIRP	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	6.85	0.4	5.9e-11	Height;
KIRP	cis	rs193541	0.632	rs7735618	chr5:122176245	C/G	cg19412675	chr5:122181750	SNX24	0.57	5.96	0.36	8.61e-9	Glucose homeostasis traits;
KIRP	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg06740227	chr12:86229804	RASSF9	0.43	5.45	0.33	1.21e-7	Major depressive disorder;
KIRP	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg21905437	chr5:178450457	ZNF879	0.57	6.67	0.39	1.64e-10	Pubertal anthropometrics;
KIRP	cis	rs883565	0.569	rs7637036	chr3:38997778	C/T	cg01426195	chr3:39028469	NA	-0.56	-8.95	-0.5	8.69e-17	Handedness;
KIRP	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.34	-5.36	-0.32	1.95e-7	Asthma;
KIRP	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.84	12.07	0.61	1.21e-26	Mean corpuscular hemoglobin;
KIRP	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg12140854	chr5:148520817	ABLIM3	-0.51	-6.15	-0.36	3.13e-9	Breast cancer;
KIRP	cis	rs7714584	1.000	rs73282255	chr5:150223647	A/T	cg22134413	chr5:150180641	NA	0.57	5.08	0.31	7.4e-7	Crohn's disease;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg24537038	chr9:99213506	HABP4	0.46	6.07	0.36	4.7e-9	Ischemic stroke;
KIRP	cis	rs10979	0.571	rs6909701	chr6:143922918	C/G	cg25407410	chr6:143891975	LOC285740	-0.53	-5.58	-0.34	6.39e-8	Hypospadias;
KIRP	cis	rs7793239	0.550	rs10246191	chr7:130029811	G/A	cg03229158	chr7:130009420	NA	0.35	5.22	0.32	3.86e-7	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg13319975	chr6:146136371	FBXO30	0.48	6.82	0.4	6.9e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg25753631	chr6:25732923	NA	0.27	5.11	0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.78	-10.02	-0.54	4.96e-20	Macular telangiectasia type 2;
KIRP	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.66e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.81	9.93	0.53	9.32e-20	Corneal astigmatism;
KIRP	cis	rs6725041	0.532	rs12623803	chr2:213201642	G/C	cg16329650	chr2:213403929	ERBB4	-0.38	-4.94	-0.3	1.41e-6	QT interval (ambient particulate matter interaction);
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.46	-4.95	-0.3	1.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06544989	chr22:39130855	UNC84B	0.5	9.02	0.5	5.63e-17	Menopause (age at onset);
KIRP	cis	rs96067	0.772	rs2231318	chr1:36602943	C/T	cg24686825	chr1:36642396	MAP7D1	-0.54	-5.91	-0.35	1.11e-8	Corneal structure;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.86	-0.6	5.86e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	0.68	7.53	0.43	9.54e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs2274273	0.901	rs10140801	chr14:55730404	C/T	cg04306507	chr14:55594613	LGALS3	0.54	8.39	0.47	3.92e-15	Protein biomarker;
KIRP	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg03929089	chr4:120376271	NA	0.71	6.33	0.37	1.16e-9	Axial length;
KIRP	cis	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg06521331	chr12:34319734	NA	-0.43	-4.96	-0.3	1.34e-6	Resting heart rate;
KIRP	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	13.27	0.65	1.1e-30	Alzheimer's disease;
KIRP	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg15655495	chr12:38532458	NA	0.25	4.87	0.3	2.01e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.14	0.36	3.28e-9	Depression;
KIRP	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg10259518	chr2:233765616	NGEF	0.34	4.94	0.3	1.43e-6	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg08662619	chr6:150070041	PCMT1	0.39	6.43	0.38	6.64e-10	Lung cancer;
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg09699651	chr6:150184138	LRP11	0.45	6.02	0.36	6.28e-9	Lung cancer;
KIRP	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.73	-9.28	-0.51	8.96e-18	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-0.99	-12.12	-0.61	8.36e-27	Breast cancer;
KIRP	cis	rs7017914	0.870	rs34282253	chr8:71582366	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.85	14.14	0.67	1.3e-33	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg03585969	chr10:35415529	CREM	0.78	9.51	0.52	1.88e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.52	-6.88	-0.4	4.87e-11	Immature fraction of reticulocytes;
KIRP	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg06223162	chr1:101003688	GPR88	0.41	7.64	0.44	4.97e-13	Breast cancer;
KIRP	cis	rs17092148	1.000	rs3787223	chr20:33331385	C/T	cg16810054	chr20:33298113	TP53INP2	0.46	5.69	0.34	3.53e-8	Neuroticism;
KIRP	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.77	11.16	0.58	1.13e-23	Hip circumference;
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg07701084	chr6:150067640	NUP43	0.71	9.96	0.54	7.75e-20	Lung cancer;
KIRP	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.6	7.04	0.41	1.92e-11	Pancreatic cancer;
KIRP	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg01990225	chr2:97406019	LMAN2L	-1.0	-6.97	-0.41	2.81e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs4646404	0.509	rs4646365	chr17:17467783	C/T	cg01246520	chr17:17644344	RAI1	-0.32	-5.49	-0.33	9.98e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14787287	chr1:94587589	ABCA4	0.58	6.96	0.41	3.08e-11	Interleukin-4 levels;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.78	6.86	0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6832769	1.000	rs10016506	chr4:56396674	G/T	cg09317128	chr4:56265301	TMEM165	-0.55	-6.96	-0.41	3.03e-11	Personality dimensions;
KIRP	cis	rs13034020	0.641	rs35852308	chr2:61225563	A/C	cg18625361	chr2:61244694	PEX13;PUS10	0.56	5.0	0.3	1.11e-6	Hodgkin's lymphoma;
KIRP	cis	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg19171272	chr22:38449367	NA	-0.66	-10.19	-0.54	1.39e-20	Glioblastoma;Glioma;
KIRP	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg04289385	chr6:36355825	ETV7	0.43	6.85	0.4	5.85e-11	Platelet distribution width;
KIRP	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.32	0.59	3.56e-24	Height;
KIRP	cis	rs11718455	0.585	rs11710802	chr3:43930155	T/G	cg08738300	chr3:44038990	NA	0.58	7.51	0.43	1.08e-12	Coronary artery disease;
KIRP	cis	rs1569175	0.655	rs10175678	chr2:200901481	T/C	cg17644776	chr2:200775616	C2orf69	-0.69	-4.92	-0.3	1.61e-6	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs3849570	0.615	rs1851918	chr3:81980557	C/T	cg07356753	chr3:81810745	GBE1	-0.53	-7.23	-0.42	6.01e-12	Waist circumference;Body mass index;
KIRP	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.54	7.58	0.44	6.9e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4423214	0.592	rs7114252	chr11:71237606	G/A	cg05163923	chr11:71159392	DHCR7	-0.71	-7.0	-0.41	2.41e-11	Vitamin D levels;
KIRP	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg00255919	chr5:131827918	IRF1	0.27	5.04	0.31	9.19e-7	Asthma (sex interaction);
KIRP	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.74	-7.58	-0.44	6.97e-13	Tourette syndrome;
KIRP	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-6.21	-0.37	2.22e-9	Rheumatoid arthritis;
KIRP	cis	rs7760535	0.811	rs455732	chr6:111695268	C/T	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.92e-8	Metabolic traits;
KIRP	cis	rs501120	1.000	rs504799	chr10:44753456	C/T	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg14324370	chr2:177042789	NA	-0.69	-8.45	-0.47	2.62e-15	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.48	5.71	0.34	3.24e-8	Uric acid levels;
KIRP	cis	rs1018836	0.923	rs12545726	chr8:91532087	T/A	cg16814680	chr8:91681699	NA	-0.72	-8.77	-0.49	2.92e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-0.86	-9.63	-0.52	7.6e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-0.67	-7.81	-0.45	1.67e-13	Initial pursuit acceleration;
KIRP	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg19748678	chr4:122722346	EXOSC9	0.52	5.3	0.32	2.59e-7	Type 2 diabetes;
KIRP	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg04731861	chr2:219085781	ARPC2	0.27	6.73	0.39	1.2e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	trans	rs9329221	0.505	rs7840347	chr8:10072350	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.92	-0.4	3.86e-11	Neuroticism;
KIRP	cis	rs4006360	0.504	rs7502045	chr17:39252972	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.64	-0.52	7.21e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13424612	0.839	rs6437355	chr2:240905550	G/C	cg19172429	chr2:240878313	NA	0.29	4.94	0.3	1.48e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs7951870	0.945	rs79175663	chr11:46730043	C/T	cg19486271	chr11:47235900	DDB2	0.53	5.0	0.3	1.09e-6	Schizophrenia;
KIRP	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02018176	chr4:1364513	KIAA1530	-0.47	-5.8	-0.35	2.04e-8	Longevity;
KIRP	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg12501888	chr15:85177176	SCAND2	-0.41	-5.18	-0.31	4.68e-7	P wave terminal force;
KIRP	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg19847130	chr8:10466454	RP1L1	-0.38	-5.39	-0.33	1.63e-7	Retinal vascular caliber;
KIRP	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.92	13.84	0.66	1.28e-32	Mean platelet volume;
KIRP	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	cg21523751	chr1:182988639	NA	0.41	6.31	0.37	1.31e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs10924970	0.934	rs4288584	chr1:235436631	C/T	cg26050004	chr1:235667680	B3GALNT2	0.42	5.16	0.31	5.11e-7	Asthma;
KIRP	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.68	8.96	0.5	8.35e-17	Morning vs. evening chronotype;
KIRP	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.71	0.34	3.22e-8	Birth weight;
KIRP	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs77972916	0.609	rs13414381	chr2:43567218	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-6.87	-0.4	5.13e-11	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg15704280	chr7:45808275	SEPT13	-0.54	-6.09	-0.36	4.33e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs539514	0.587	rs7320216	chr13:76332689	A/G	cg04757411	chr13:76259545	LMO7	-0.47	-6.79	-0.4	8.15e-11	Type 1 diabetes;
KIRP	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	5.95e-24	Aortic root size;
KIRP	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.74	-0.39	1.14e-10	Morning vs. evening chronotype;
KIRP	cis	rs3815148	0.569	rs12705406	chr7:106792554	A/G	cg02696742	chr7:106810147	HBP1	0.85	7.23	0.42	6.25e-12	Osteoarthritis;
KIRP	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg05802129	chr4:122689817	NA	-0.46	-6.7	-0.39	1.39e-10	Type 2 diabetes;
KIRP	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg07511934	chr16:89386912	ANKRD11	0.48	5.89	0.35	1.25e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.85	11.99	0.61	2.24e-26	Longevity;
KIRP	cis	rs2901460	0.509	rs11125898	chr2:62079895	T/C	cg02183531	chr2:62113199	CCT4	-0.49	-5.07	-0.31	7.69e-7	Mean corpuscular volume;
KIRP	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-5.75	-0.34	2.65e-8	Blood metabolite levels;
KIRP	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27297192	chr10:134578999	INPP5A	0.57	7.12	0.41	1.15e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs13315871	0.585	rs12107189	chr3:58349022	C/T	cg12435725	chr3:58293450	RPP14	-0.37	-5.32	-0.32	2.29e-7	Cholesterol, total;
KIRP	cis	rs41005	1.000	rs193932	chr2:8107383	C/T	cg03155496	chr2:8117019	LOC339788	-0.56	-9.01	-0.5	5.75e-17	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.92	11.0	0.57	3.76e-23	Diastolic blood pressure;
KIRP	cis	rs507080	0.697	rs653008	chr11:118520480	G/T	cg04173919	chr11:118528438	PHLDB1	0.37	5.29	0.32	2.73e-7	Serum metabolite levels;
KIRP	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg10047753	chr17:41438598	NA	1.14	17.86	0.75	2.59e-46	Menopause (age at onset);
KIRP	cis	rs394563	0.726	rs6922130	chr6:149672375	C/G	cg16235748	chr6:149772707	ZC3H12D	0.32	5.31	0.32	2.47e-7	Dupuytren's disease;
KIRP	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg01677386	chr11:118938358	VPS11	-0.45	-5.18	-0.31	4.55e-7	Coronary artery disease;
KIRP	cis	rs2963155	0.518	rs258748	chr5:142656454	C/G	cg17617527	chr5:142782415	NR3C1	0.77	7.93	0.45	7.65e-14	Breast cancer;
KIRP	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.57	7.56	0.43	8.05e-13	Aortic root size;
KIRP	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.69	10.05	0.54	3.86e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.95	-13.3	-0.65	9.2e-31	Cognitive function;
KIRP	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00376283	chr12:123451042	ABCB9	-0.69	-6.42	-0.38	6.96e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg04691961	chr3:161091175	C3orf57	-0.57	-8.93	-0.49	1.04e-16	Morning vs. evening chronotype;
KIRP	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.08	0.46	2.92e-14	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09712216	chr3:49977428	RBM6	0.46	6.48	0.38	4.99e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg18230493	chr5:56204884	C5orf35	0.41	4.85	0.3	2.23e-6	Coronary artery disease;
KIRP	cis	rs258892	0.895	rs394274	chr5:72135955	C/T	cg21869765	chr5:72125136	TNPO1	0.57	6.33	0.37	1.15e-9	Small cell lung carcinoma;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.44	4.9	0.3	1.73e-6	Renal function-related traits (BUN);
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.73	-10.87	-0.57	9.99e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6580649	0.882	rs59766465	chr12:48470169	G/A	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs10940138	0.887	rs58669650	chr5:67194598	C/A	ch.5.1281357F	chr5:67228439	NA	0.68	10.03	0.54	4.45e-20	Menarche (age at onset);
KIRP	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7e-8	Schizophrenia;
KIRP	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	9.1	0.5	3.22e-17	Lung cancer in ever smokers;
KIRP	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg01378222	chr16:28622494	SULT1A1	-0.67	-6.34	-0.37	1.09e-9	Platelet distribution width;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg04369109	chr6:150039330	LATS1	-0.48	-5.92	-0.35	1.09e-8	Lung cancer;
KIRP	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg15880211	chr22:50250494	ZBED4	0.58	5.08	0.31	7.59e-7	Schizophrenia;
KIRP	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg17941049	chr3:63904683	ATXN7	-0.47	-5.06	-0.31	8.23e-7	Type 2 diabetes;
KIRP	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.61	-11.98	-0.61	2.38e-26	Gout;
KIRP	cis	rs2151522	0.762	rs62426329	chr6:127162070	A/T	cg21431617	chr6:127135037	NA	0.29	5.16	0.31	4.99e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg10503236	chr1:231470652	EXOC8	-0.52	-7.14	-0.41	1.06e-11	Hemoglobin concentration;
KIRP	cis	rs73206853	0.764	rs67715513	chr12:110562910	G/A	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.62	0.39	2.27e-10	Rheumatoid arthritis;
KIRP	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.55	-6.71	-0.39	1.3100000000000001e-10	Uric acid clearance;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17742459	chr8:38710358	TACC1	0.52	7.05	0.41	1.8e-11	Interleukin-4 levels;
KIRP	cis	rs6132905	0.520	rs2422824	chr20:2647370	C/T	cg19137662	chr20:2633362	NOP56;MIR1292;SNORD110	-0.43	-5.1	-0.31	6.88e-7	Mumps;
KIRP	cis	rs2267137	0.868	rs174770	chr22:29766895	C/T	cg07256473	chr22:29710276	RASL10A	0.46	7.5	0.43	1.15e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02250241	chr15:75648987	MAN2C1	0.5	6.25	0.37	1.84e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.52	-6.62	-0.39	2.27e-10	Longevity;
KIRP	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg04935436	chr20:30431758	NA	0.51	4.86	0.3	2.13e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.44	-6.11	-0.36	3.8e-9	Systolic blood pressure;
KIRP	cis	rs4775041	0.920	rs80123226	chr15:58676032	A/T	cg02971627	chr15:59042282	ADAM10	0.45	4.86	0.3	2.08e-6	Metabolite levels;Triglycerides;HDL cholesterol;
KIRP	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.61	8.16	0.46	1.77e-14	Bladder cancer;
KIRP	cis	rs367943	0.712	rs9326886	chr5:112728458	A/C	cg12552261	chr5:112820674	MCC	0.58	6.88	0.4	4.98e-11	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg13939156	chr17:80058883	NA	-0.49	-7.4	-0.43	2.2e-12	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14693961	chr19:42388097	ARHGEF1	0.5	6.07	0.36	4.74e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17376030	chr22:41985996	PMM1	0.83	8.85	0.49	1.78e-16	Vitiligo;
KIRP	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.85	-0.35	1.56e-8	Educational attainment;
KIRP	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	5.88	0.35	1.32e-8	Response to antipsychotic treatment;
KIRP	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg00409905	chr10:38381863	ZNF37A	0.54	5.98	0.36	8.02e-9	Obesity (extreme);
KIRP	cis	rs12049351	0.774	rs1053513	chr1:229652587	T/C	cg11742688	chr1:229674241	ABCB10	-0.37	-5.57	-0.33	6.67e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.69	-0.34	3.59e-8	Life satisfaction;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.78	6.83	0.4	6.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs787274	0.867	rs4978507	chr9:115609376	G/A	cg13803584	chr9:115635662	SNX30	-0.74	-6.46	-0.38	5.61e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg26207909	chr14:103986467	CKB	-0.48	-6.03	-0.36	5.88e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-5.61	-0.34	5.48e-8	Bipolar disorder;
KIRP	cis	rs7714584	0.826	rs12655654	chr5:150174295	A/C	cg22134413	chr5:150180641	NA	1.06	7.46	0.43	1.48e-12	Crohn's disease;
KIRP	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-19.28	-0.78	4.35e-51	Ulcerative colitis;
KIRP	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg03289416	chr15:75166202	SCAMP2	-0.43	-6.11	-0.36	3.82e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.5	0.52	1.99e-18	Cognitive test performance;
KIRP	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.43	5.41	0.33	1.51e-7	Crohn's disease;
KIRP	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	11.85	0.6	6.19e-26	Smoking behavior;
KIRP	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg08133631	chr1:26527909	CATSPER4	0.42	4.95	0.3	1.37e-6	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.82	8.77	0.49	3.08e-16	Alzheimer's disease;
KIRP	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17554472	chr22:41940697	POLR3H	0.53	5.94	0.35	9.78e-9	Vitiligo;
KIRP	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg10932868	chr11:921992	NA	0.49	5.8	0.35	1.98e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1318772	1.000	rs67344014	chr5:112687127	A/C	cg12552261	chr5:112820674	MCC	0.69	5.07	0.31	7.77e-7	F-cell distribution;
KIRP	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.65	-7.15	-0.41	1.01e-11	Initial pursuit acceleration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05744073	chr17:1953268	MIR132	0.54	6.38	0.38	8.58e-10	Smoking initiation;
KIRP	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg02975922	chr3:195473998	MUC4	-0.56	-6.33	-0.37	1.13e-9	Pancreatic cancer;
KIRP	cis	rs7833787	0.965	rs6586777	chr8:18702471	A/C	cg17701159	chr8:18705777	PSD3	0.38	7.25	0.42	5.42e-12	Obesity-related traits;
KIRP	cis	rs10761482	0.564	rs10733765	chr10:62237399	T/C	cg01186212	chr10:62110162	ANK3	-0.29	-5.0	-0.3	1.08e-6	Schizophrenia;
KIRP	cis	rs67366981	0.925	rs41438045	chr14:77692781	A/T	cg22824376	chr14:77648248	TMEM63C	0.79	6.17	0.37	2.77e-9	Obsessive-compulsive symptoms;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg04362027	chr10:70883301	VPS26A	-0.44	-6.05	-0.36	5.43e-9	Migraine with aura;
KIRP	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg01689657	chr7:91764605	CYP51A1	-0.38	-5.52	-0.33	8.61e-8	Breast cancer;
KIRP	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg22705602	chr4:152727874	NA	-0.5	-8.7	-0.49	4.8e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg26139080	chr11:47293733	MADD	-0.42	-5.27	-0.32	2.98e-7	HDL cholesterol;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00632861	chr13:46626485	ZC3H13	0.42	6.38	0.38	8.68e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg07936489	chr17:37558343	FBXL20	-0.41	-5.01	-0.3	1.05e-6	Asthma;
KIRP	cis	rs17253792	0.545	rs17745459	chr14:56008549	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.11	0.31	6.5e-7	Putamen volume;
KIRP	cis	rs4363385	0.588	rs6661059	chr1:153027257	A/T	cg07796016	chr1:152779584	LCE1C	-0.46	-6.01	-0.36	6.65e-9	Inflammatory skin disease;
KIRP	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.67	8.81	0.49	2.28e-16	Aortic root size;
KIRP	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.44	6.6	0.39	2.57e-10	Schizophrenia;
KIRP	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.15	-0.46	1.87e-14	Total cholesterol levels;
KIRP	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg10755058	chr3:40428713	ENTPD3	-0.43	-6.24	-0.37	1.86e-9	Renal cell carcinoma;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.58	-9.52	-0.52	1.69e-18	Lymphocyte counts;
KIRP	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg14593290	chr7:50529359	DDC	0.41	5.15	0.31	5.37e-7	Malaria;
KIRP	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.35	20.62	0.8	1.59e-55	Corneal structure;
KIRP	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.71	8.05	0.46	3.5e-14	Bipolar disorder;
KIRP	cis	rs6088813	1.000	rs1406947	chr20:33969530	C/T	cg14752227	chr20:34000481	UQCC	-0.52	-6.89	-0.4	4.75e-11	Height;
KIRP	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	0.95	12.24	0.62	3.27e-27	Blood protein levels;
KIRP	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg11317459	chr13:21872234	NA	-1.02	-11.88	-0.6	5.1e-26	White matter hyperintensity burden;
KIRP	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg25174290	chr11:3078921	CARS	-0.69	-8.98	-0.5	7.09e-17	Calcium levels;
KIRP	cis	rs2882667	0.861	rs10043676	chr5:138389561	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-7.6	-0.44	6.31e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.5	6.48	0.38	4.95e-10	Testicular germ cell tumor;
KIRP	cis	rs15676	0.947	rs2759009	chr9:131599008	C/T	cg00228799	chr9:131580591	ENDOG	0.58	6.61	0.39	2.39e-10	Blood metabolite levels;
KIRP	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.73	8.32	0.47	5.91e-15	Corneal astigmatism;
KIRP	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.92	8.04	0.46	3.67e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07570687	chr10:102243282	WNT8B	0.42	4.95	0.3	1.41e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg19473369	chr15:99190447	NA	0.92	6.18	0.37	2.59e-9	P wave terminal force;
KIRP	trans	rs13061878	0.925	rs4488823	chr3:61581008	G/T	cg06220521	chr13:95254216	GPR180	0.96	6.04	0.36	5.57e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg07777115	chr5:623756	CEP72	-0.58	-5.68	-0.34	3.85e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.86	0.3	2.14e-6	Menopause (age at onset);
KIRP	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.62	8.38	0.47	4.02e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6952809	1.000	rs2023968	chr7:2451461	A/G	cg23289794	chr7:2394357	EIF3B	0.39	4.9	0.3	1.71e-6	Multiple sclerosis;
KIRP	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg15557168	chr22:42548783	NA	-0.38	-5.34	-0.32	2.15e-7	Cognitive function;
KIRP	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.49	7.03	0.41	2.08e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg11584989	chr19:19387371	SF4	0.4	5.18	0.31	4.57e-7	Tonsillectomy;
KIRP	cis	rs8077577	0.945	rs62073649	chr17:18080522	T/C	cg18869244	chr17:18121946	NA	0.46	5.17	0.31	4.87e-7	Obesity-related traits;
KIRP	cis	rs7116495	1.000	rs7127865	chr11:71747781	G/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.92	-15.92	-0.71	1.09e-39	Breast cancer;
KIRP	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-19.85	-0.78	5.53e-53	Height;
KIRP	cis	rs9378796	1.000	rs9378796	chr6:3448645	G/T	cg00476032	chr6:3446245	SLC22A23	-0.47	-5.42	-0.33	1.44e-7	Mean platelet volume;
KIRP	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.32	0.37	1.22e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.44	-0.52	3e-18	Coronary artery disease;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg16140913	chr4:8430389	ACOX3	-0.47	-6.03	-0.36	5.89e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.72	10.37	0.55	3.92e-21	Retinal vascular caliber;
KIRP	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.58	7.75	0.44	2.39e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg16898833	chr6:26189333	HIST1H4D	0.85	5.91	0.35	1.13e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10267417	0.603	rs1159874	chr7:19916619	T/C	cg05791153	chr7:19748676	TWISTNB	0.54	5.17	0.31	4.82e-7	Night sleep phenotypes;
KIRP	cis	rs4474465	0.850	rs4945287	chr11:78226521	C/T	cg02023728	chr11:77925099	USP35	-0.32	-5.39	-0.32	1.67e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg22681709	chr2:178499509	PDE11A	-0.56	-6.27	-0.37	1.58e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg10503236	chr1:231470652	EXOC8	-0.49	-7.04	-0.41	1.92e-11	Hemoglobin concentration;
KIRP	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg20295408	chr7:1910781	MAD1L1	0.48	5.53	0.33	8.3e-8	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13409248	chr3:40428643	ENTPD3	0.38	4.94	0.3	1.42e-6	Renal cell carcinoma;
KIRP	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.85	-8.35	-0.47	4.99e-15	Coronary artery calcification;
KIRP	cis	rs501120	0.584	rs11238892	chr10:44671194	A/G	cg09554077	chr10:44749378	NA	-0.61	-6.68	-0.39	1.57e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7561273	0.609	rs10189243	chr2:24293756	C/T	cg20701182	chr2:24300061	SF3B14	0.44	5.42	0.33	1.4e-7	Quantitative traits;
KIRP	cis	rs62380364	0.565	rs617944	chr5:88057915	T/C	cg24804195	chr5:87968844	LOC645323	-0.43	-5.56	-0.33	6.85e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12579753	0.619	rs11115089	chr12:82311132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.46	-5.49	-0.33	9.85e-8	Resting heart rate;
KIRP	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.97	11.53	0.59	7.35e-25	Exhaled nitric oxide levels;
KIRP	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Recalcitrant atopic dermatitis;
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.53	11.69	0.6	2.05e-25	Diabetic kidney disease;
KIRP	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg17279839	chr7:150038598	RARRES2	0.47	6.45	0.38	5.97e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13101948	chr6:4056654	PRPF4B	0.43	6.07	0.36	4.73e-9	Survival in pancreatic cancer;
KIRP	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.81	12.86	0.63	2.75e-29	Dental caries;
KIRP	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03264133	chr6:25882463	NA	-0.38	-5.37	-0.32	1.85e-7	Height;
KIRP	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg04374321	chr14:90722782	PSMC1	-0.61	-8.23	-0.46	1.13e-14	Mortality in heart failure;
KIRP	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.98e-14	Body mass index;
KIRP	cis	rs5746492	0.568	rs5747408	chr22:18397120	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.43	-5.76	-0.34	2.51e-8	Eotaxin levels;
KIRP	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg00334542	chr7:100209784	MOSPD3	-0.54	-5.1	-0.31	6.7e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7792596	0.539	rs34907227	chr7:94010535	C/T	cg20814616	chr7:94014465	NA	-0.45	-5.13	-0.31	5.93e-7	Intelligence;
KIRP	cis	rs1165472	1.000	rs1392140	chr1:56101822	C/T	cg11523071	chr1:56160889	NA	0.42	5.19	0.31	4.44e-7	Paclitaxel-induced neuropathy;
KIRP	trans	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.76	0.34	2.47e-8	Lung cancer;
KIRP	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.3	25.75	0.85	8.84e-72	IgG glycosylation;
KIRP	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.27	0.37	1.62e-9	Ovarian reserve;
KIRP	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.07	-0.41	1.56e-11	Chronic sinus infection;
KIRP	cis	rs1050631	0.592	rs1789546	chr18:33725874	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.82	0.35	1.78e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg12861170	chr19:19639553	YJEFN3	-0.49	-5.07	-0.31	8e-7	Bipolar disorder;
KIRP	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.54	6.37	0.38	9.41e-10	Aortic root size;
KIRP	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.68	9.7	0.53	4.79e-19	Retinal vascular caliber;
KIRP	trans	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg00405596	chr8:11794950	NA	-0.48	-6.5	-0.38	4.41e-10	Mood instability;
KIRP	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	8.62	0.48	8.29e-16	Neuroticism;
KIRP	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg25356066	chr3:128598488	ACAD9	0.58	6.85	0.4	5.8200000000000003e-11	IgG glycosylation;
KIRP	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg14541582	chr5:601475	NA	-0.53	-5.67	-0.34	3.94e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9653442	0.564	rs11687586	chr2:100789346	A/G	cg22139774	chr2:100720529	AFF3	-0.29	-4.92	-0.3	1.59e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.4	5.11	0.31	6.37e-7	Mean platelet volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15190354	chr11:125494874	CHEK1	0.6	7.46	0.43	1.49e-12	Interleukin-4 levels;
KIRP	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg06289844	chr6:126071538	HEY2	0.35	4.92	0.3	1.55e-6	Endometrial cancer;
KIRP	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.89	14.75	0.68	1.08e-35	Prostate cancer;
KIRP	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.39	5.32	0.32	2.34e-7	Lewy body disease;
KIRP	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.59	6.93	0.4	3.69e-11	Cocaine dependence;
KIRP	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.78	10.08	0.54	3.09e-20	Mean platelet volume;
KIRP	cis	rs12050794	0.671	rs8192362	chr15:72519858	G/A	cg16672083	chr15:72433130	SENP8	0.4	5.65	0.34	4.4e-8	Metabolite levels (HVA/MHPG ratio);
KIRP	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.95	0.54	8.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-4.99	-0.3	1.13e-6	Schizophrenia;
KIRP	trans	rs225245	0.541	rs321613	chr17:33881718	G/A	cg19694781	chr19:47549865	TMEM160	-0.55	-6.84	-0.4	6.38e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg09904177	chr6:26538194	HMGN4	0.46	6.32	0.37	1.21e-9	Schizophrenia;
KIRP	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25517755	chr10:38738941	LOC399744	0.34	4.86	0.3	2.12e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2011503	0.597	rs8103992	chr19:19665643	A/C	cg11584989	chr19:19387371	SF4	-0.53	-5.88	-0.35	1.35e-8	Bipolar disorder;
KIRP	cis	rs9828933	0.832	rs3774723	chr3:63962339	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.8	-8.18	-0.46	1.48e-14	Type 2 diabetes;
KIRP	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-9.66	-0.52	6.36e-19	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg10223061	chr2:219282414	VIL1	-0.33	-5.4	-0.33	1.57e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.55	-0.43	8.4e-13	Response to antipsychotic treatment;
KIRP	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-7.35	-0.42	2.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs7113874	0.802	rs7118611	chr11:8685685	A/C	cg08015107	chr11:8618950	NA	-0.44	-5.78	-0.35	2.25e-8	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.26	-0.32	3.07e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg10167378	chr1:228756711	NA	0.89	7.32	0.42	3.47e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-7.56	-0.43	7.81e-13	Body mass index;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg01798813	chr17:3906674	NA	0.61	8.62	0.48	8.44e-16	Type 2 diabetes;
KIRP	cis	rs6142102	0.923	rs6059586	chr20:32540501	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.98	0.41	2.65e-11	Skin pigmentation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03758392	chr3:184870408	C3orf70	0.48	6.22	0.37	2.14e-9	Smoking initiation;
KIRP	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.77	8.22	0.46	1.2e-14	Corneal astigmatism;
KIRP	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.16	0.31	5.09e-7	Menopause (age at onset);
KIRP	cis	rs981844	0.683	rs1037647	chr4:154737991	A/G	cg14289246	chr4:154710475	SFRP2	-0.54	-7.06	-0.41	1.74e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2522056	1.000	rs2706383	chr5:131792402	G/A	cg07395648	chr5:131743802	NA	0.56	6.77	0.4	9.64e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg00103785	chr1:155043322	NA	-0.29	-5.26	-0.32	3.15e-7	Serum magnesium levels;
KIRP	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg07856975	chr6:36356162	ETV7	-0.4	-5.78	-0.35	2.3e-8	Platelet distribution width;
KIRP	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg22903657	chr4:1355424	KIAA1530	-0.42	-5.95	-0.35	8.94e-9	Obesity-related traits;
KIRP	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	1.23	12.74	0.63	6.73e-29	Red blood cell traits;
KIRP	cis	rs9596863	1.000	rs9591538	chr13:54407573	A/C	ch.13.53330881F	chr13:54432880	NA	0.65	6.58	0.39	2.79e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12963246	chr6:28129442	ZNF389	-0.48	-5.96	-0.36	8.83e-9	Depression;
KIRP	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.39	-0.38	8.02e-10	Morning vs. evening chronotype;
KIRP	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.71	-7.31	-0.42	3.8e-12	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17627617	chr3:142682682	PAQR9	0.47	6.2	0.37	2.39e-9	Parkinson's disease;
KIRP	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.42	0.68	1.43e-34	Alzheimer's disease;
KIRP	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19671926	chr4:122722719	EXOSC9	0.44	5.13	0.31	5.98e-7	Type 2 diabetes;
KIRP	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.58	-7.98	-0.45	5.59e-14	Homocysteine levels;
KIRP	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg14952266	chr13:112191215	NA	0.46	6.77	0.4	9.5e-11	Hepatitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07234880	chr4:185570559	CASP3;CCDC111	0.46	6.32	0.37	1.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs16936870	0.543	rs1473409	chr8:71185827	C/T	cg14232793	chr8:71155543	NCOA2	0.57	6.42	0.38	6.83e-10	QT interval;
KIRP	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.54	-15.6	-0.71	1.3e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.28	-11.27	-0.58	5.17e-24	Diabetic retinopathy;
KIRP	cis	rs7119167	0.805	rs11235729	chr11:73098326	G/A	cg17517138	chr11:73019481	ARHGEF17	0.51	5.46	0.33	1.18e-7	Blood protein levels;
KIRP	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.77	11.22	0.58	7.44e-24	Multiple myeloma (IgH translocation);
KIRP	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-11.12	-0.58	1.56e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7688540	0.771	rs11722521	chr4:276765	A/T	cg17891759	chr4:299121	NA	-0.49	-5.13	-0.31	5.79e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg25486957	chr4:152246857	NA	-0.51	-5.45	-0.33	1.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg12560992	chr17:57184187	TRIM37	0.61	5.62	0.34	5.09e-8	Cognitive test performance;
KIRP	cis	rs62380364	0.565	rs40504	chr5:88011139	G/C	cg24804195	chr5:87968844	LOC645323	-0.46	-6.1	-0.36	4.12e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg14673194	chr17:80132900	CCDC57	0.76	8.48	0.48	2.06e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4765905	0.610	rs10774033	chr12:2314426	C/T	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs3736485	0.966	rs7182977	chr15:51854130	C/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7106204	0.748	rs7947388	chr11:24224903	A/G	ch.11.24196551F	chr11:24239977	NA	0.85	10.87	0.57	1.01e-22	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9372498	0.536	rs9489450	chr6:118904385	G/A	cg18833306	chr6:118973337	C6orf204	-0.47	-5.04	-0.31	9.1e-7	Diastolic blood pressure;
KIRP	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.63	7.39	0.43	2.24e-12	Metabolic traits;
KIRP	cis	rs11764561	0.632	rs1922087	chr7:156016756	C/T	cg26118637	chr7:155353417	NA	-0.32	-5.03	-0.31	9.38e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.66	-6.91	-0.4	4.18e-11	Vitiligo;
KIRP	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.17e-13	Corneal astigmatism;
KIRP	cis	rs78487399	0.710	rs6544665	chr2:43729212	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.02	-0.3	9.81e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg18490616	chr2:88469792	THNSL2	0.67	5.4	0.33	1.56e-7	Plasma clusterin levels;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg12486944	chr17:80159399	CCDC57	-0.41	-5.49	-0.33	1e-7	Life satisfaction;
KIRP	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.81	-8.81	-0.49	2.23e-16	Alzheimer's disease;
KIRP	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	5.78	0.35	2.22e-8	HIV-1 control;
KIRP	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.26	0.47	8.87e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-0.97	-15.57	-0.7	1.66e-38	Height;
KIRP	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.56	7.45	0.43	1.63e-12	Colorectal cancer;
KIRP	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.68	0.44	3.66e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.03	-0.67	3.08e-33	Primary sclerosing cholangitis;
KIRP	cis	rs16976116	0.643	rs7183255	chr15:55513601	A/T	cg11288833	chr15:55489084	RSL24D1	-0.46	-5.22	-0.32	3.85e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6500395	0.588	rs3785138	chr16:48588614	T/C	cg04672837	chr16:48644449	N4BP1	0.43	6.07	0.36	4.72e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-6.6	-0.39	2.49e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg21214613	chr1:16344536	HSPB7	0.34	5.24	0.32	3.43e-7	Dilated cardiomyopathy;
KIRP	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg16917193	chr12:54089295	NA	-0.54	-6.65	-0.39	1.93e-10	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4805834	0.719	rs11673502	chr19:33293607	C/T	cg07201929	chr19:33182834	NUDT19	-0.62	-5.24	-0.32	3.4e-7	Creatinine levels;
KIRP	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.78	-0.35	2.29e-8	Breast cancer;
KIRP	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg19743168	chr1:23544995	NA	0.47	6.26	0.37	1.66e-9	Height;
KIRP	cis	rs6968419	0.609	rs73716708	chr7:115905743	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.01	-0.36	6.7e-9	Intraocular pressure;
KIRP	trans	rs79976124	0.837	rs10498840	chr6:66658513	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.74	8.77	0.49	3.11e-16	Type 2 diabetes;
KIRP	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg12435725	chr3:58293450	RPP14	-0.46	-5.16	-0.31	5.16e-7	Cholesterol, total;
KIRP	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.52	-6.75	-0.4	1.03e-10	Blood metabolite levels;
KIRP	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.87	-12.61	-0.63	1.83e-28	Total body bone mineral density;
KIRP	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.76	7.84	0.45	1.41e-13	Resting heart rate;
KIRP	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.91	13.59	0.65	9.66e-32	Personality dimensions;
KIRP	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg11784071	chr10:104629166	AS3MT	-0.38	-5.28	-0.32	2.83e-7	Arsenic metabolism;
KIRP	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg17724175	chr1:150552817	MCL1	0.36	6.07	0.36	4.94e-9	Melanoma;
KIRP	cis	rs17123764	0.818	rs52824916	chr12:49993678	C/T	cg20471783	chr12:50157085	TMBIM6	0.4	5.69	0.34	3.64e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.48	6.09	0.36	4.37e-9	Height;
KIRP	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.77e-10	Protein C levels;
KIRP	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg22676075	chr6:135203613	NA	0.5	7.34	0.42	3.14e-12	Red blood cell count;
KIRP	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg07827796	chr19:33622959	WDR88	0.54	7.15	0.42	9.6e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.54	-5.33	-0.32	2.21e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg23920097	chr1:209922102	NA	-0.46	-6.26	-0.37	1.67e-9	Red blood cell count;
KIRP	trans	rs7521492	0.647	rs2760215	chr1:163675883	C/T	cg21988461	chr4:88008667	AFF1	-0.39	-6.18	-0.37	2.64e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.7	-7.75	-0.44	2.35e-13	Body mass index;
KIRP	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.73	-8.62	-0.48	8.16e-16	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8060686	0.920	rs73597578	chr16:67679348	C/T	cg26727032	chr16:67993705	SLC12A4	-0.55	-5.04	-0.31	8.83e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.54	7.5	0.43	1.13e-12	Schizophrenia;
KIRP	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.45	-0.33	1.23e-7	Longevity;Endometriosis;
KIRP	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.66	9.07	0.5	3.93e-17	Mean platelet volume;
KIRP	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	trans	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg16141378	chr3:129829833	LOC729375	0.55	6.8	0.4	8.11e-11	Neuroticism;
KIRP	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.59	-7.26	-0.42	5.21e-12	Neuroticism;
KIRP	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.79	-11.11	-0.58	1.69e-23	Menarche (age at onset);
KIRP	cis	rs755109	1.000	rs10984361	chr9:100681490	C/T	cg13688889	chr9:100608707	NA	-0.42	-4.89	-0.3	1.81e-6	Quantitative traits;
KIRP	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg02951883	chr7:2050386	MAD1L1	-0.44	-4.91	-0.3	1.68e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.74	9.16	0.5	2.05e-17	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.72	-11.04	-0.58	2.74e-23	Hepatocellular carcinoma;
KIRP	cis	rs4356932	1.000	rs10017484	chr4:76984936	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg03563238	chr19:33554763	RHPN2	-0.29	-4.85	-0.3	2.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.82	-14.01	-0.67	3.51e-33	Brugada syndrome;
KIRP	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg04370829	chr17:406249	NA	0.39	4.86	0.3	2.11e-6	Prostate cancer;
KIRP	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg15327641	chr2:3715039	ALLC	0.44	5.36	0.32	1.87e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs7246760	0.867	rs2336090	chr19:9879584	A/G	cg02900749	chr2:68251473	NA	-1.05	-8.87	-0.49	1.51e-16	Pursuit maintenance gain;
KIRP	cis	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.66	0.34	4.24e-8	Primary sclerosing cholangitis;
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26002218	chr14:103986227	CKB	0.28	5.75	0.34	2.63e-8	Body mass index;
KIRP	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-0.89	-10.77	-0.57	2.09e-22	Vitiligo;
KIRP	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.53	7.35	0.42	2.84e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.29	-7.8	-0.45	1.73e-13	Rheumatoid arthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22160911	chr5:79775282	ZFYVE16	-0.4	-6.25	-0.37	1.77e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs62344088	1.000	rs7715867	chr5:129059	C/T	cg22857025	chr5:266934	NA	-0.73	-4.9	-0.3	1.71e-6	Asthma (childhood onset);
KIRP	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.65	0.34	4.39e-8	Aortic root size;
KIRP	cis	rs11874712	1.000	rs9944637	chr18:43655239	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.43	-6.06	-0.36	5.18e-9	Migraine - clinic-based;
KIRP	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg01097406	chr16:89675127	NA	-0.29	-4.86	-0.3	2.08e-6	Vitiligo;
KIRP	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.58	8.87	0.49	1.54e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs2562456	0.754	rs11666213	chr19:21605645	G/A	cg00806126	chr19:22604979	ZNF98	-0.58	-5.32	-0.32	2.38e-7	Pain;
KIRP	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg18657303	chr4:1051139	NA	0.55	5.16	0.31	4.99e-7	Recombination rate (females);
KIRP	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	1.2	8.59	0.48	1.04e-15	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs889512	0.642	rs73605136	chr16:75299967	C/T	cg03315344	chr16:75512273	CHST6	-0.67	-5.16	-0.31	5.07e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8084125	1.000	rs7229560	chr18:74955538	C/T	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg24049888	chr11:111250129	POU2AF1	0.4	7.01	0.41	2.24e-11	Primary biliary cholangitis;
KIRP	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg23594656	chr7:65796392	TPST1	-0.52	-8.18	-0.46	1.54e-14	Aortic root size;
KIRP	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg07541023	chr7:19748670	TWISTNB	0.83	6.82	0.4	7.19e-11	Thyroid stimulating hormone;
KIRP	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg22705602	chr4:152727874	NA	-0.54	-9.64	-0.52	7.09e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.59	-6.87	-0.4	5.38e-11	Corneal astigmatism;
KIRP	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs4601821	1.000	rs3897584	chr11:113249725	C/G	cg14159747	chr11:113255604	NA	-0.37	-5.24	-0.32	3.47e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs6693567	0.565	rs11205373	chr1:150404708	A/G	cg07843065	chr1:150265600	MRPS21	0.47	6.63	0.39	2.1e-10	Migraine;
KIRP	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.5	5.48	0.33	1.08e-7	Menopause (age at onset);
KIRP	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs73086581	1.000	rs56069856	chr20:3965709	A/C	cg02187196	chr20:3869020	PANK2	0.5	5.02	0.3	9.9e-7	Response to antidepressants in depression;
KIRP	cis	rs889398	0.771	rs8048550	chr16:69891759	T/G	cg09409435	chr16:70099608	PDXDC2	0.44	5.23	0.32	3.7e-7	Body mass index;
KIRP	cis	rs17221829	0.702	rs2075536	chr11:89407391	G/T	cg02982614	chr11:89391479	FOLH1B	0.32	5.29	0.32	2.71e-7	Anxiety in major depressive disorder;
KIRP	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.6	7.3	0.42	3.86e-12	Coronary artery disease;
KIRP	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg05362011	chr13:21860987	NA	-0.48	-5.31	-0.32	2.43e-7	White matter hyperintensity burden;
KIRP	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg07936489	chr17:37558343	FBXL20	-0.5	-6.26	-0.37	1.68e-9	Asthma;
KIRP	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.09	-0.41	1.42e-11	Hemoglobin concentration;
KIRP	cis	rs2637030	0.559	rs256107	chr5:52873776	C/T	cg06476337	chr5:52856530	NDUFS4	0.55	6.18	0.37	2.68e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs4950322	0.570	rs4950402	chr1:146791402	T/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27297192	chr10:134578999	INPP5A	0.64	7.97	0.45	5.96e-14	Migraine;
KIRP	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg27411982	chr8:10470053	RP1L1	0.43	5.25	0.32	3.3e-7	Retinal vascular caliber;
KIRP	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg07511934	chr16:89386912	ANKRD11	0.4	5.2	0.31	4.26e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg13010199	chr12:38710504	ALG10B	0.64	7.93	0.45	7.79e-14	Morning vs. evening chronotype;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg22718636	chr4:961658	DGKQ	0.35	6.21	0.37	2.29e-9	Sjögren's syndrome;
KIRP	cis	rs35771425	0.642	rs3767380	chr1:211452845	A/G	cg11089029	chr1:211432536	RCOR3	0.44	5.09	0.31	7.22e-7	Educational attainment (years of education);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01809819	chr1:31192165	MATN1	0.55	6.16	0.37	2.95e-9	Lung cancer in ever smokers;
KIRP	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.73	8.48	0.48	2.16e-15	Type 2 diabetes;
KIRP	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.03	-18.01	-0.75	8.33e-47	Testicular germ cell tumor;
KIRP	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16346588	chr10:242978	ZMYND11	0.48	5.92	0.35	1.08e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs9596863	0.898	rs9316658	chr13:54333620	C/T	ch.13.53330881F	chr13:54432880	NA	-0.59	-5.69	-0.34	3.69e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03339469	chr19:44259181	C19orf61	0.45	6.19	0.37	2.52e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.62	-0.44	5.61e-13	Life satisfaction;
KIRP	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.69	-8.8	-0.49	2.41e-16	Systemic lupus erythematosus;
KIRP	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.64	0.6	3.11e-25	Menarche (age at onset);
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13939156	chr17:80058883	NA	0.47	7.04	0.41	1.93e-11	Life satisfaction;
KIRP	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg06671706	chr8:8559999	CLDN23	0.47	5.33	0.32	2.17e-7	Obesity-related traits;
KIRP	cis	rs1190552	0.846	rs3783381	chr14:102965435	A/G	cg10241871	chr14:102965420	TECPR2	-0.58	-6.83	-0.4	6.61e-11	Blood protein levels;
KIRP	cis	rs13323323	1.000	rs13323323	chr3:44333324	G/T	cg02073558	chr3:44770973	ZNF501	0.47	5.6	0.34	5.66e-8	IgG glycosylation;
KIRP	cis	rs42648	0.819	rs2285399	chr7:89969878	A/G	cg25739043	chr7:89950458	NA	-0.44	-6.84	-0.4	6.06e-11	Homocysteine levels;
KIRP	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.58	4.9	0.3	1.71e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg13206674	chr6:150067644	NUP43	0.52	7.41	0.43	1.96e-12	Testicular germ cell tumor;
KIRP	cis	rs501120	0.564	rs7917089	chr10:44688587	G/A	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs77956314	0.505	rs118025365	chr12:117477082	G/A	cg02017074	chr12:117425053	FBXW8	-1.0	-5.76	-0.34	2.45e-8	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg04317338	chr11:64019027	PLCB3	0.53	6.16	0.37	2.88e-9	Platelet count;
KIRP	cis	rs7236492	0.572	rs7242868	chr18:77179564	G/A	cg15644404	chr18:77186268	NFATC1	-1.02	-6.63	-0.39	2.08e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.5	-6.22	-0.37	2.16e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	6.53	0.38	3.63e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	0.89	10.53	0.56	1.25e-21	Mosquito bite size;
KIRP	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.44	5.09	0.31	6.96e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg12560992	chr17:57184187	TRIM37	-0.62	-6.48	-0.38	4.94e-10	Testicular germ cell tumor;
KIRP	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.01	-0.41	2.26e-11	Triglycerides;
KIRP	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.58	-7.82	-0.45	1.52e-13	Asthma;
KIRP	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.75	9.63	0.52	7.9e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.81	-12.85	-0.63	2.87e-29	Blood metabolite levels;
KIRP	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg12315302	chr6:26189340	HIST1H4D	0.71	5.24	0.32	3.44e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg06212747	chr3:49208901	KLHDC8B	0.72	8.6	0.48	9.36e-16	Menarche (age at onset);
KIRP	cis	rs1823913	1.000	rs1823913	chr2:192118047	C/T	cg12404831	chr2:192114017	MYO1B	0.5	6.81	0.4	7.29e-11	Obesity-related traits;
KIRP	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg20607798	chr8:58055168	NA	0.6	4.9	0.3	1.76e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6545883	1.000	rs778763	chr2:61785639	C/G	cg15711740	chr2:61764176	XPO1	-0.62	-8.5	-0.48	1.82e-15	Tuberculosis;
KIRP	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.7	-13.15	-0.64	2.79e-30	White blood cell count (basophil);
KIRP	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg22138327	chr13:27999177	GTF3A	0.81	7.18	0.42	8.17e-12	Weight;
KIRP	cis	rs11155671	0.530	rs9371505	chr6:150184148	A/C	cg07701084	chr6:150067640	NUP43	0.59	7.64	0.44	4.93e-13	Testicular germ cell tumor;
KIRP	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg21161173	chr5:140098174	VTRNA1-2	-0.39	-5.13	-0.31	5.84e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg20411813	chr1:160162766	CASQ1	-0.4	-5.45	-0.33	1.25e-7	Breast size;
KIRP	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg08668510	chr10:1095578	IDI1	0.94	6.91	0.4	4.13e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07308232	chr7:1071921	C7orf50	-0.82	-10.4	-0.55	3.11e-21	Longevity;Endometriosis;
KIRP	trans	rs2123959	0.553	rs34377081	chr4:91781009	T/C	cg26127345	chr10:89621940	PTEN;KILLIN	-0.65	-6.27	-0.37	1.59e-9	Gut microbiome composition (summer);
KIRP	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.4	-4.91	-0.3	1.68e-6	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg07741184	chr6:167504864	NA	-0.24	-6.4	-0.38	7.85e-10	Crohn's disease;
KIRP	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00166722	chr3:10149974	C3orf24	0.48	4.93	0.3	1.53e-6	Alzheimer's disease;
KIRP	trans	rs2302464	1.000	rs28396343	chr4:15556045	G/A	cg24908198	chr11:128812992	TP53AIP1	0.43	6.08	0.36	4.61e-9	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg24703018	chr4:75859815	PARM1	-0.37	-6.22	-0.37	2.14e-9	Warfarin maintenance dose;
KIRP	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.5	7.56	0.43	8.02e-13	Resting heart rate;
KIRP	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg22681709	chr2:178499509	PDE11A	-0.5	-5.77	-0.35	2.37e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12311346	chr5:56204834	C5orf35	-0.42	-5.6	-0.34	5.65e-8	Coronary artery disease;
KIRP	cis	rs575018	0.714	rs1960576	chr5:100593998	A/G	cg03848127	chr5:100126093	NA	-0.45	-5.38	-0.32	1.74e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs6939532	0.522	rs9366652	chr6:26354219	C/G	cg14345882	chr6:26364793	BTN3A2	0.32	5.11	0.31	6.5e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg00129232	chr17:37814104	STARD3	-0.54	-6.64	-0.39	2.01e-10	Self-reported allergy;
KIRP	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg13293535	chr8:11597251	GATA4	-0.38	-4.85	-0.3	2.15e-6	Retinal vascular caliber;
KIRP	cis	rs10465746	0.935	rs6692233	chr1:84327214	A/G	cg10977910	chr1:84465055	TTLL7	-0.49	-5.8	-0.35	2e-8	Obesity-related traits;
KIRP	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.17	-0.37	2.78e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.82	11.54	0.59	6.63e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22826071	chr19:344165	MIER2	0.53	6.34	0.37	1.12e-9	Parkinson's disease;
KIRP	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.29	0.37	1.46e-9	Educational attainment;
KIRP	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg22117172	chr7:91764530	CYP51A1	0.46	6.36	0.38	9.56e-10	Breast cancer;
KIRP	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg05234568	chr11:5960015	NA	-0.57	-5.59	-0.34	6e-8	DNA methylation (variation);
KIRP	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.81	6.28	0.37	1.54e-9	Arsenic metabolism;
KIRP	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg23594656	chr7:65796392	TPST1	0.51	7.93	0.45	7.68e-14	Aortic root size;
KIRP	cis	rs10465746	0.780	rs6703493	chr1:84435812	G/A	cg10977910	chr1:84465055	TTLL7	0.58	7.46	0.43	1.45e-12	Obesity-related traits;
KIRP	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg12692727	chr7:1102344	C7orf50	0.48	5.16	0.31	5.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs13185784	0.667	rs62406986	chr5:179644055	G/A	cg23221052	chr5:179740743	GFPT2	0.5	4.88	0.3	1.95e-6	TRAIL levels;
KIRP	cis	rs3026101	0.671	rs8077471	chr17:5299356	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg21775007	chr8:11205619	TDH	-0.44	-5.74	-0.34	2.71e-8	Triglycerides;
KIRP	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg12661370	chr5:149340060	SLC26A2	0.45	5.53	0.33	8.28e-8	HIV-1 control;
KIRP	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg03060546	chr3:49711283	APEH	0.47	6.18	0.37	2.63e-9	Parkinson's disease;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02340915	chr12:121904480	KDM2B	-0.44	-6.74	-0.39	1.09e-10	Serum protein levels (sST2);
KIRP	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-6.68	-0.39	1.6e-10	Joint mobility (Beighton score);
KIRP	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.4	8.28	0.47	7.84e-15	IgG glycosylation;
KIRP	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.14	-0.36	3.27e-9	Obesity-related traits;
KIRP	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.57	7.57	0.43	7.58e-13	Blood protein levels;
KIRP	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.43	5.49	0.33	9.75e-8	Melanoma;
KIRP	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg15655495	chr12:38532458	NA	0.27	5.4	0.33	1.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs4262150	0.883	rs72802868	chr5:152235215	G/T	cg12297329	chr5:152029980	NA	-0.61	-7.71	-0.44	3.11e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.42	5.13	0.31	5.97e-7	Asthma;
KIRP	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg15488143	chr7:128924101	AHCYL2	0.62	6.7	0.39	1.37e-10	White matter hyperintensity burden;
KIRP	cis	rs4073221	0.789	rs67917716	chr3:18228007	C/A	cg07694806	chr3:18168406	NA	-0.77	-6.79	-0.4	8.13e-11	Parkinson's disease;
KIRP	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg22001208	chr19:18782374	NA	-0.46	-6.07	-0.36	4.85e-9	Obesity-related traits;
KIRP	cis	rs12615966	0.790	rs72830459	chr2:105387628	T/G	cg16465502	chr2:105461796	NA	0.54	5.15	0.31	5.41e-7	Pancreatic cancer;
KIRP	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg01620082	chr3:125678407	NA	-0.85	-6.3	-0.37	1.33e-9	Urinary tract infection frequency;
KIRP	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.46	6.67	0.39	1.68e-10	Urate levels in lean individuals;
KIRP	cis	rs9549260	0.683	rs35594717	chr13:41240783	G/A	cg21288729	chr13:41239152	FOXO1	0.51	5.14	0.31	5.71e-7	Red blood cell count;
KIRP	trans	rs8042680	0.554	rs8026781	chr15:91530675	G/A	cg15616111	chr1:154955537	FLAD1	-0.53	-6.04	-0.36	5.56e-9	Type 2 diabetes;
KIRP	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.54	-5.98	-0.36	7.81e-9	Monocyte percentage of white cells;
KIRP	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.95	-0.41	3.26e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg23505145	chr19:12996616	KLF1	0.57	8.4	0.47	3.61e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg22139774	chr2:100720529	AFF3	-0.31	-5.25	-0.32	3.36e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2671245	0.933	rs2767503	chr1:56152725	T/G	cg11523071	chr1:56160889	NA	0.41	6.7	0.39	1.41e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.55	6.0	0.36	6.83e-9	Type 2 diabetes;
KIRP	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg10434728	chr15:90938212	IQGAP1	0.3	5.03	0.31	9.53e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.68	5.51	0.33	8.82e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.96	12.48	0.62	4.98e-28	Homoarginine levels;
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.53	-0.33	8.27e-8	Lung cancer;
KIRP	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg13147721	chr7:65941812	NA	-0.99	-6.89	-0.4	4.57e-11	Diabetic kidney disease;
KIRP	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.14	-0.36	3.27e-9	Daytime sleep phenotypes;
KIRP	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg01448562	chr3:133502909	NA	0.37	4.87	0.3	2.04e-6	Iron status biomarkers;
KIRP	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg08847533	chr14:75593920	NEK9	0.54	6.49	0.38	4.69e-10	IgG glycosylation;
KIRP	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg04287289	chr16:89883240	FANCA	-0.42	-5.34	-0.32	2.15e-7	Vitiligo;
KIRP	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg17143192	chr8:8559678	CLDN23	0.57	6.81	0.4	7.29e-11	Obesity-related traits;
KIRP	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.85	10.46	0.55	1.95e-21	Multiple sclerosis;
KIRP	cis	rs1215050	0.818	rs6532703	chr4:98777486	A/T	cg05340658	chr4:99064831	C4orf37	0.46	5.15	0.31	5.44e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs860295	0.580	rs7528441	chr1:155843256	T/G	cg02153340	chr1:155202674	NA	-0.42	-5.54	-0.33	7.74e-8	Body mass index;
KIRP	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.52	5.02	0.3	9.94e-7	Recombination rate (females);
KIRP	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg01028140	chr2:1542097	TPO	-0.64	-6.46	-0.38	5.66e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.71	0.39	1.29e-10	Hypertriglyceridemia;
KIRP	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.55	-0.39	3.27e-10	Myopia;Myopia (pathological);
KIRP	cis	rs7656342	0.653	rs1107912	chr4:9820179	A/G	cg11266682	chr4:10021025	SLC2A9	0.32	4.96	0.3	1.3e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg25110126	chr1:46999211	NA	0.43	5.44	0.33	1.31e-7	Monobrow;
KIRP	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-10.87	-0.57	9.97e-23	Acylcarnitine levels;
KIRP	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg06521331	chr12:34319734	NA	0.48	6.12	0.36	3.67e-9	Morning vs. evening chronotype;
KIRP	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg03788504	chr6:150331562	NA	-0.26	-4.88	-0.3	1.94e-6	Alopecia areata;
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg16141378	chr3:129829833	LOC729375	0.54	7.07	0.41	1.62e-11	Retinal vascular caliber;
KIRP	cis	rs904251	0.600	rs9380673	chr6:37415125	T/C	cg11522683	chr6:37501428	NA	-0.37	-4.86	-0.3	2.14e-6	Cognitive performance;
KIRP	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.33	-0.32	2.23e-7	Height;
KIRP	cis	rs357618	1.000	rs357622	chr5:150848405	A/G	cg22672639	chr5:150884813	FAT2	0.35	5.34	0.32	2.15e-7	Basophil percentage of white cells;
KIRP	cis	rs3931020	0.688	rs525487	chr1:75217420	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.47	-5.52	-0.33	8.8e-8	Resistin levels;
KIRP	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg08888203	chr3:10149979	C3orf24	0.47	4.98	0.3	1.23e-6	Alzheimer's disease;
KIRP	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.74	-8.01	-0.45	4.64e-14	Asthma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18166862	chr1:166136262	FAM78B	0.58	7.6	0.44	6.07e-13	Parkinson's disease;
KIRP	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.64	-0.44	4.95e-13	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg13206674	chr6:150067644	NUP43	0.62	8.29	0.47	7.2e-15	Lung cancer;
KIRP	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.42	-5.31	-0.32	2.45e-7	Type 2 diabetes;
KIRP	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg24399712	chr22:39784796	NA	-0.76	-12.18	-0.61	5.19e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12016809	chr21:47604291	C21orf56	0.36	4.88	0.3	1.95e-6	Testicular germ cell tumor;
KIRP	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.59	-0.39	2.66e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.37	-0.47	4.51e-15	Coronary artery disease;
KIRP	cis	rs17094448	0.557	rs117276277	chr14:74497463	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.87	5.59	0.34	6.15e-8	Blood protein levels;
KIRP	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs2415984	0.622	rs55833034	chr14:46825055	C/A	cg14871534	chr14:47121158	RPL10L	-0.45	-5.32	-0.32	2.35e-7	Number of children ever born;
KIRP	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.05	19.07	0.77	2.15e-50	Testicular germ cell tumor;
KIRP	cis	rs4262150	0.810	rs72797233	chr5:151992765	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.11	-0.46	2.42e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1816752	0.712	rs9507335	chr13:24983904	G/A	cg22771759	chr13:24902376	NA	0.38	4.92	0.3	1.62e-6	Obesity-related traits;
KIRP	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg07810366	chr2:100720526	AFF3	-0.34	-6.42	-0.38	7.11e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.05	0.46	3.51e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg23202291	chr11:1979235	NA	0.39	5.25	0.32	3.34e-7	DNA methylation (variation);
KIRP	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.23	-0.55	1.04e-20	Hemoglobin concentration;
KIRP	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25517755	chr10:38738941	LOC399744	-0.37	-5.25	-0.32	3.23e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	12.23	0.62	3.38e-27	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4253772	0.872	rs11704508	chr22:46638540	A/G	cg18190219	chr22:46762943	CELSR1	-0.7	-5.95	-0.35	9.02e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.48	0.48	2.11e-15	Joint mobility (Beighton score);
KIRP	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06634786	chr22:41940651	POLR3H	-0.47	-5.21	-0.32	4.03e-7	Vitiligo;
KIRP	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg02151108	chr14:50098012	C14orf104	-0.46	-6.02	-0.36	6.4e-9	Carotid intima media thickness;
KIRP	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs4268898	0.552	rs11125454	chr2:24373669	T/C	cg06627628	chr2:24431161	ITSN2	0.48	5.77	0.35	2.4e-8	Asthma;
KIRP	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12963246	chr6:28129442	ZNF389	0.42	5.0	0.3	1.07e-6	Parkinson's disease;
KIRP	cis	rs72781680	0.611	rs72783636	chr2:24328706	C/T	cg20701182	chr2:24300061	SF3B14	0.94	10.33	0.55	5.11e-21	Lymphocyte counts;
KIRP	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg07828024	chr6:149772892	ZC3H12D	-0.32	-5.49	-0.33	9.84e-8	Dupuytren's disease;
KIRP	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.95	13.45	0.65	2.73e-31	Cognitive function;
KIRP	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11584989	chr19:19387371	SF4	0.6	6.63	0.39	2.16e-10	Bipolar disorder;
KIRP	cis	rs9815354	0.597	rs73073281	chr3:42026366	C/T	cg03022575	chr3:42003672	ULK4	0.77	7.07	0.41	1.61e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	0.97	10.58	0.56	8.13e-22	Blood protein levels;
KIRP	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg02297831	chr4:17616191	MED28	0.6	7.53	0.43	9.62e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06481639	chr22:41940642	POLR3H	0.47	5.55	0.33	7.25e-8	Vitiligo;
KIRP	cis	rs1014246	0.813	rs11197805	chr10:118479677	G/A	cg14919929	chr10:118506882	NA	0.68	8.2	0.46	1.35e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg13736514	chr6:26305472	NA	-0.49	-5.12	-0.31	6.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.17	-0.31	4.89e-7	Life satisfaction;
KIRP	trans	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg13134607	chr9:20684551	KIAA1797	-0.64	-6.2	-0.37	2.42e-9	Orofacial clefts;
KIRP	cis	rs8084125	0.832	rs62105172	chr18:74946703	C/T	cg26065057	chr18:74961000	GALR1	0.62	6.5	0.38	4.39e-10	Obesity-related traits;
KIRP	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg12573674	chr2:1569213	NA	-0.54	-5.2	-0.31	4.19e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg09165964	chr15:75287851	SCAMP5	-0.94	-8.43	-0.47	2.9e-15	Lung cancer;
KIRP	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg12405258	chr13:114927641	NA	0.47	6.52	0.38	4.07e-10	Schizophrenia;
KIRP	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg23950597	chr19:37808831	NA	-0.72	-6.72	-0.39	1.23e-10	Coronary artery calcification;
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.75	-10.78	-0.57	1.86e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.51	7.06	0.41	1.71e-11	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06544989	chr22:39130855	UNC84B	0.46	7.92	0.45	8.45e-14	Menopause (age at onset);
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.86	-0.53	1.56e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.93	11.13	0.58	1.46e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7714584	1.000	rs59321715	chr5:150313480	C/A	cg22134413	chr5:150180641	NA	1.0	6.76	0.4	9.72e-11	Crohn's disease;
KIRP	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg04132472	chr17:19861366	AKAP10	-0.4	-5.25	-0.32	3.29e-7	Schizophrenia;
KIRP	cis	rs11718455	0.618	rs35351588	chr3:43926386	C/G	cg08738300	chr3:44038990	NA	0.62	7.49	0.43	1.25e-12	Coronary artery disease;
KIRP	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.49e-13	IgG glycosylation;
KIRP	trans	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.36	3.81e-9	Mean corpuscular volume;
KIRP	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg18694418	chr7:2742484	AMZ1	0.45	5.06	0.31	8.41e-7	Height;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18367020	chr2:73461259	CCT7;C2orf7	-0.45	-6.13	-0.36	3.54e-9	Myopia;
KIRP	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.58	-7.01	-0.41	2.25e-11	Cholesterol, total;
KIRP	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	8.88	0.49	1.45e-16	Cognitive ability;
KIRP	cis	rs10214930	0.697	rs986706	chr7:27612752	T/C	cg22168087	chr7:27702803	HIBADH	0.46	4.92	0.3	1.61e-6	Hypospadias;
KIRP	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.1	0.61	9.4e-27	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.83	-12.85	-0.63	2.87e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg13271783	chr10:134563150	INPP5A	-0.62	-8.0	-0.45	4.8e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.74	-11.1	-0.58	1.81e-23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs1978968	0.731	rs9605467	chr22:18461166	A/G	cg03078520	chr22:18463400	MICAL3	-0.84	-12.08	-0.61	1.07e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg15691649	chr6:25882328	NA	0.44	5.38	0.32	1.76e-7	Blood metabolite levels;
KIRP	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg14593290	chr7:50529359	DDC	-0.77	-9.51	-0.52	1.82e-18	Malaria;
KIRP	cis	rs72829446	0.530	rs56078345	chr17:7394341	T/C	cg17788227	chr17:7347145	FGF11;CHRNB1	0.47	5.03	0.31	9.42e-7	Androgen levels;
KIRP	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18932078	chr1:2524107	MMEL1	-0.48	-6.76	-0.4	1.02e-10	Ulcerative colitis;
KIRP	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg07870213	chr5:140052090	DND1	0.63	7.68	0.44	3.77e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg10756647	chr7:56101905	PSPH	1.07	8.32	0.47	6.01e-15	Diabetic kidney disease;
KIRP	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.79	-11.49	-0.59	9.7e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg07148914	chr20:33460835	GGT7	-0.4	-5.02	-0.31	9.76e-7	Height;
KIRP	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.87	14.14	0.67	1.26e-33	Metabolic syndrome;
KIRP	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.63	8.41	0.47	3.4e-15	Eosinophil percentage of white cells;
KIRP	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	1.0	9.55	0.52	1.4e-18	Lymphocyte counts;
KIRP	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.56	7.13	0.41	1.11e-11	Menopause (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07494646	chr22:37415349	MPST;TST	-0.47	-6.43	-0.38	6.73e-10	Metabolic traits;
KIRP	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.77	8.58	0.48	1.1e-15	Corneal astigmatism;
KIRP	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs885389	0.924	rs7957882	chr12:131617417	G/T	cg00260028	chr12:131606990	GPR133	-0.42	-5.1	-0.31	6.85e-7	RR interval (heart rate);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09269103	chr10:104155497	NFKB2	0.47	6.49	0.38	4.65e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2746347	0.722	rs72666495	chr1:57138082	G/A	cg09935045	chr1:57111199	PRKAA2	0.53	5.5	0.33	9.32e-8	Lymphocyte counts;
KIRP	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg01475377	chr6:109611718	NA	-0.4	-5.58	-0.34	6.18e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs507080	0.769	rs2077173	chr11:118492591	G/A	cg04173919	chr11:118528438	PHLDB1	0.34	4.98	0.3	1.2e-6	Serum metabolite levels;
KIRP	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs8018808	0.935	rs760257	chr14:77935145	G/A	cg18872420	chr14:78023429	SPTLC2	0.38	5.46	0.33	1.17e-7	Myeloid white cell count;
KIRP	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg14851346	chr12:38532713	NA	-0.4	-4.97	-0.3	1.23e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.88	14.18	0.67	9.43e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.71	6.9	0.4	4.51e-11	Prostate cancer;
KIRP	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg18016565	chr1:150552671	MCL1	-0.46	-7.19	-0.42	7.56e-12	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.66	5.61	0.34	5.49e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg05991184	chr2:219186017	PNKD	0.34	4.99	0.3	1.14e-6	Colorectal cancer;
KIRP	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg19000871	chr14:103996768	TRMT61A	0.4	5.13	0.31	6.02e-7	Coronary artery disease;
KIRP	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.24	-0.65	1.45e-30	Height;
KIRP	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg22654517	chr2:96458247	NA	0.34	5.02	0.3	9.8e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6753739	0.871	rs6436109	chr2:219980481	A/T	cg01749213	chr2:219906749	CCDC108	0.44	5.46	0.33	1.14e-7	Height;
KIRP	cis	rs7976059	0.824	rs12230839	chr12:52249405	A/G	cg09126859	chr12:52244063	NA	0.47	8.13	0.46	2.07e-14	Urate levels;
KIRP	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17507749	chr15:85114479	UBE2QP1	0.74	8.19	0.46	1.4e-14	Schizophrenia;
KIRP	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg16482183	chr6:26056742	HIST1H1C	-0.43	-5.02	-0.31	9.71e-7	Iron status biomarkers;
KIRP	cis	rs7614311	0.689	rs73122704	chr3:63841228	C/T	cg14183384	chr3:63264335	SYNPR	-0.59	-5.03	-0.31	9.27e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs4776059	1.000	rs17614559	chr15:52878719	G/A	cg25063058	chr15:52860530	ARPP19	0.56	6.27	0.37	1.62e-9	Schizophrenia;
KIRP	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-8.09	-0.46	2.69e-14	Vitiligo;
KIRP	cis	rs7116495	1.000	rs12283462	chr11:71835406	T/G	cg11196788	chr11:71737549	NUMA1	-0.55	-4.93	-0.3	1.54e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2017305	0.834	rs2246952	chr10:70782592	A/G	cg01024728	chr10:70782572	NA	0.6	4.87	0.3	2.02e-6	Depression (quantitative trait);
KIRP	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.75	-9.2	-0.51	1.61e-17	Personality dimensions;
KIRP	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.35	-5.33	-0.32	2.19e-7	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs6681460	0.966	rs10749765	chr1:67150280	C/T	cg02459107	chr1:67143332	SGIP1	0.53	7.58	0.44	6.88e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.55	8.22	0.46	1.15e-14	Itch intensity from mosquito bite;
KIRP	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.66	9.17	0.5	2.01e-17	Schizophrenia;
KIRP	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg20936604	chr3:58311152	NA	-0.66	-5.01	-0.3	1.03e-6	Cholesterol, total;
KIRP	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg16141378	chr3:129829833	LOC729375	-0.54	-7.08	-0.41	1.52e-11	Retinal vascular caliber;
KIRP	trans	rs76288851	0.799	rs17750671	chr3:126585852	G/A	cg13821433	chr2:26726535	OTOF	0.58	6.49	0.38	4.61e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.76	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.78	8.33	0.47	5.66e-15	Bipolar disorder;
KIRP	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg01721255	chr8:58191610	C8orf71	0.56	5.19	0.31	4.35e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs711830	0.965	rs2857532	chr2:177033283	A/G	cg13092806	chr2:177043255	NA	0.65	6.9	0.4	4.35e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg12315302	chr6:26189340	HIST1H4D	1.07	6.38	0.38	8.79e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg02151108	chr14:50098012	C14orf104	-0.51	-7.03	-0.41	2.07e-11	Carotid intima media thickness;
KIRP	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	4.97	0.3	1.24e-6	Height;
KIRP	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.21	0.42	6.88e-12	Caffeine consumption;
KIRP	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg11189052	chr15:85197271	WDR73	0.48	4.99	0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.62	-9.39	-0.51	4.28e-18	Obesity-related traits;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.62	-9.06	-0.5	4.27e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.67	-9.77	-0.53	2.84e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg27207500	chr12:133317906	ANKLE2	-0.59	-6.15	-0.37	3.11e-9	Plasma thyroid-stimulating hormone levels;
KIRP	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.53	5.06	0.31	8.27e-7	Height;
KIRP	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs71277158	0.688	rs76146702	chr3:169868720	G/T	cg04067573	chr3:169899625	PHC3	0.66	6.25	0.37	1.81e-9	Prostate cancer;
KIRP	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.47	0.43	1.43e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs4972806	0.814	rs1446575	chr2:177047801	A/C	cg26754761	chr2:177040938	NA	0.32	5.6	0.34	5.68e-8	IgG glycosylation;
KIRP	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg15848620	chr12:58087721	OS9	-0.51	-5.95	-0.35	9.17e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9815354	0.812	rs73069209	chr3:41939781	G/A	cg03022575	chr3:42003672	ULK4	0.78	8.02	0.46	4.26e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg10223061	chr2:219282414	VIL1	-0.39	-6.16	-0.37	2.87e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg16926213	chr1:1841314	NA	0.33	5.74	0.34	2.82e-8	Body mass index;
KIRP	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.05e-8	Skin colour saturation;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.44	5.66	0.34	4.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.28	0.62	2.4200000000000002e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1983891	0.738	rs3747745	chr6:41568064	G/A	cg20194872	chr6:41519635	FOXP4	0.51	5.44	0.33	1.3e-7	Prostate cancer;
KIRP	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	1.03	13.07	0.64	5.34e-30	Exhaled nitric oxide output;
KIRP	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12963246	chr6:28129442	ZNF389	0.51	6.3	0.37	1.38e-9	Depression;
KIRP	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.07	-0.77	2.17e-50	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01150270	chr15:95869918	NA	-0.39	-6.52	-0.38	4e-10	Survival in pancreatic cancer;
KIRP	cis	rs282587	0.569	rs4907750	chr13:113391348	C/A	cg04656015	chr13:113407548	ATP11A	0.6	7.0	0.41	2.48e-11	Glycated hemoglobin levels;
KIRP	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg24807547	chr6:37504484	NA	0.39	5.22	0.32	3.88e-7	Cognitive performance;
KIRP	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.68	-4.89	-0.3	1.81e-6	Facial emotion recognition (sad faces);
KIRP	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.63	-8.53	-0.48	1.48e-15	Aortic root size;
KIRP	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.86	9.81	0.53	2.25e-19	Gut microbiome composition (summer);
KIRP	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.2e-24	Cognitive test performance;
KIRP	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	12.8	0.63	4.4e-29	Smoking behavior;
KIRP	trans	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.78	0.4	8.69e-11	Neuroticism;
KIRP	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.92	10.5	0.56	1.46e-21	Triglycerides;
KIRP	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg15327641	chr2:3715039	ALLC	0.47	6.09	0.36	4.23e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs9381107	1.000	rs11759603	chr6:9443977	T/C	cg14735645	chr6:9486422	NA	-0.45	-5.36	-0.32	1.88e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg09455208	chr3:40491958	NA	-0.33	-5.86	-0.35	1.45e-8	Renal cell carcinoma;
KIRP	cis	rs73200209	0.744	rs11614867	chr12:116658916	A/C	cg01776926	chr12:116560359	MED13L	-0.57	-6.29	-0.37	1.4e-9	Total body bone mineral density;
KIRP	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg08975724	chr8:8085496	FLJ10661	0.62	8.7	0.49	4.72e-16	Neuroticism;
KIRP	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg14851346	chr12:38532713	NA	-0.4	-4.95	-0.3	1.36e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg15660573	chr17:549704	VPS53	-0.95	-14.92	-0.69	2.71e-36	Prostate cancer;
KIRP	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.12	-0.5	2.76e-17	Platelet count;
KIRP	cis	rs2275620	0.508	rs7912502	chr10:96646803	C/A	cg09036531	chr10:96991505	NA	-0.49	-5.85	-0.35	1.55e-8	Gout;
KIRP	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.12e-6	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15048078	chr4:38665599	KLF3;FLJ13197	0.47	6.14	0.36	3.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.59	6.8	0.4	7.68e-11	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18718189	chr14:20902347	KLHL33	0.5	6.52	0.38	3.86e-10	Interleukin-4 levels;
KIRP	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs2151522	0.762	rs9388532	chr6:127165475	C/T	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-9.37	-0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg23594656	chr7:65796392	TPST1	0.5	7.75	0.44	2.38e-13	Aortic root size;
KIRP	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg11815991	chr20:30193098	ID1	-0.5	-5.07	-0.31	7.7e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-7.09	-0.41	1.45e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.63	7.61	0.44	6.02e-13	Post bronchodilator FEV1;
KIRP	cis	rs4713675	0.505	rs2395450	chr6:33654588	C/T	cg14003231	chr6:33640908	ITPR3	0.3	5.14	0.31	5.59e-7	Plateletcrit;
KIRP	cis	rs7116495	0.609	rs79889241	chr11:71815585	T/C	cg10381502	chr11:71823885	C11orf51	1.18	7.21	0.42	6.73e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-1.11	-9.64	-0.52	7.26e-19	Body mass index;
KIRP	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.88e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg08163220	chr3:31574309	STT3B	0.54	6.78	0.4	8.77e-11	Myopia (pathological);
KIRP	cis	rs7737355	0.738	rs55955246	chr5:131078498	C/G	cg25547332	chr5:131281432	NA	0.42	5.19	0.31	4.37e-7	Life satisfaction;
KIRP	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.64	6.76	0.4	9.82e-11	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6005807	0.719	rs7289625	chr22:28896546	G/A	cg12565055	chr22:29076175	TTC28	0.59	5.14	0.31	5.48e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.55	-0.48	1.3e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg07701084	chr6:150067640	NUP43	0.54	6.9	0.4	4.35e-11	Lung cancer;
KIRP	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.8	11.79	0.6	9.69e-26	Heart rate;
KIRP	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg25019033	chr10:957182	NA	-0.56	-6.73	-0.39	1.2e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg26207909	chr14:103986467	CKB	-0.44	-5.64	-0.34	4.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.74	-10.29	-0.55	6.84e-21	Childhood ear infection;
KIRP	cis	rs7116495	1.000	rs585228	chr11:71773289	G/C	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	1.24	17.5	0.74	4.45e-45	Night sleep phenotypes;
KIRP	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	7.27	0.42	4.72e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.26	0.51	1.03e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22117172	chr7:91764530	CYP51A1	0.48	6.89	0.4	4.55e-11	Breast cancer;
KIRP	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.43	7.02	0.41	2.11e-11	Testicular germ cell tumor;
KIRP	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs3779635	0.713	rs4733063	chr8:27302885	A/G	cg14221460	chr8:27183342	PTK2B	0.4	5.1	0.31	6.77e-7	Neuroticism;
KIRP	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.09	-0.54	2.86e-20	Hemoglobin concentration;
KIRP	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg23280166	chr11:118938394	VPS11	0.62	7.58	0.43	7.19e-13	Coronary artery disease;
KIRP	cis	rs12220238	0.915	rs11001021	chr10:76139657	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.73	0.39	1.22e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.59	-4.99	-0.3	1.16e-6	Putamen volume;
KIRP	cis	rs882732	1.000	rs10139629	chr14:95035277	C/T	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.4	-0.33	1.61e-7	Blood protein levels;
KIRP	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.82	8.49	0.48	1.93e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs9394169	0.514	rs1886355	chr6:33776877	C/T	cg25922239	chr6:33757077	LEMD2	0.5	5.87	0.35	1.44e-8	Essential tremor;
KIRP	cis	rs78487399	0.908	rs7576643	chr2:43841269	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-4.93	-0.3	1.52e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.91	-14.64	-0.68	2.42e-35	Height;
KIRP	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg23995753	chr2:160760732	LY75	-0.41	-5.54	-0.33	7.64e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg05791153	chr7:19748676	TWISTNB	-0.73	-6.46	-0.38	5.42e-10	Thyroid stimulating hormone;
KIRP	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.6	-5.08	-0.31	7.62e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.55	-0.7	1.9e-38	Gut microbiome composition (summer);
KIRP	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg16309518	chr5:176445507	NA	-0.89	-13.82	-0.66	1.57e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01729401	chr1:1750560	GNB1	0.37	6.04	0.36	5.74e-9	Warfarin maintenance dose;
KIRP	trans	rs1106684	0.850	rs55848281	chr7:131461887	G/T	cg13607082	chr12:122652224	LRRC43	-0.66	-6.72	-0.39	1.25e-10	Body mass index;
KIRP	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.74	11.62	0.6	3.52e-25	Resting heart rate;
KIRP	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs8113308	0.688	rs7259507	chr19:52445728	A/G	cg25782003	chr19:52490127	ZNF350	0.53	4.97	0.3	1.23e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.6	0.39	2.45e-10	Educational attainment;
KIRP	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.53	7.48	0.43	1.33e-12	Metabolite levels;
KIRP	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg01831904	chr17:28903510	LRRC37B2	0.83	9.62	0.52	8.21e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6707387	0.641	rs7602331	chr2:214530228	C/A	cg08319019	chr2:214017104	IKZF2	0.42	4.87	0.3	1.96e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg23461126	chr4:151513084	LRBA	-0.5	-6.08	-0.36	4.57e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9400467	0.568	rs12204075	chr6:111489059	G/T	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg24315340	chr6:146058215	EPM2A	-0.4	-4.99	-0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg15832292	chr6:96025679	MANEA	0.77	6.98	0.41	2.71e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg24324837	chr19:49891574	CCDC155	0.63	8.75	0.49	3.35e-16	Multiple sclerosis;
KIRP	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg04166393	chr7:2884313	GNA12	0.63	7.59	0.44	6.58e-13	Height;
KIRP	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.76	-10.53	-0.56	1.18e-21	Schizophrenia;
KIRP	cis	rs2916247	1.000	rs6987284	chr8:93018479	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.66	-9.18	-0.51	1.86e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8135828	1.000	rs2531848	chr22:30032484	A/C	cg23204276	chr22:29729285	AP1B1;SNORD125	0.44	4.92	0.3	1.55e-6	Lipid traits;
KIRP	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	1.14	9.51	0.52	1.78e-18	Cognitive function;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14021564	chr10:104169126	PSD	-0.52	-6.4	-0.38	7.96e-10	Menopause (age at onset);
KIRP	cis	rs6142102	0.625	rs6142061	chr20:32548335	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	0.93	10.34	0.55	4.76e-21	Triglycerides;
KIRP	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.44	-4.99	-0.3	1.12e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	1.05	15.06	0.69	9.04e-37	Menopause (age at onset);
KIRP	cis	rs1829883	0.651	rs3018493	chr5:98843240	G/A	cg08333243	chr5:99726346	NA	-0.42	-5.33	-0.32	2.21e-7	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg23533926	chr12:111358616	MYL2	0.48	6.07	0.36	4.8e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.57	5.73	0.34	2.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1440410	0.835	rs11100782	chr4:144152897	A/T	cg01719995	chr4:144104893	USP38	0.39	5.09	0.31	7.12e-7	Ischemic stroke;
KIRP	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15206621	chr1:180123983	QSOX1	0.5	6.13	0.36	3.5e-9	DNA methylation (variation);
KIRP	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-11.38	-0.59	2.27e-24	Menopause (age at onset);
KIRP	cis	rs7246657	0.663	rs10408619	chr19:38070474	C/T	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg09873164	chr1:152488093	CRCT1	0.52	6.54	0.38	3.5e-10	Hair morphology;
KIRP	cis	rs6893807	0.778	rs35991856	chr5:87968347	C/A	cg24804195	chr5:87968844	LOC645323	0.53	5.27	0.32	2.96e-7	Body mass index;
KIRP	cis	rs7359257	0.967	rs6494654	chr15:67681907	C/T	cg24579218	chr15:68104479	NA	-0.36	-5.32	-0.32	2.31e-7	Menarche (age at onset);
KIRP	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.67	8.53	0.48	1.5e-15	Prudent dietary pattern;
KIRP	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.58	-6.44	-0.38	6.38e-10	Menarche (age at onset);
KIRP	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.7	10.58	0.56	8.22e-22	Dupuytren's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16821385	chr11:46467232	AMBRA1	0.52	7.1	0.41	1.31e-11	Interleukin-4 levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05796909	chr17:7465070	SENP3	0.45	6.19	0.37	2.55e-9	Survival in pancreatic cancer;
KIRP	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg19731401	chr7:2775893	GNA12	0.77	7.13	0.41	1.11e-11	Childhood ear infection;
KIRP	cis	rs7614311	0.731	rs3774721	chr3:63954649	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.77	-0.35	2.37e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg23806715	chr17:73775811	H3F3B	0.79	6.61	0.39	2.41e-10	Psoriasis;
KIRP	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-9.25	-0.51	1.16e-17	Morning vs. evening chronotype;
KIRP	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.42	7.43	0.43	1.76e-12	Renal cell carcinoma;
KIRP	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.47	-0.52	2.49e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-6.61	-0.39	2.35e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-7.11	-0.41	1.28e-11	Myopia (pathological);
KIRP	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.32	0.37	1.22e-9	Putamen volume;
KIRP	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.53	6.65	0.39	1.84e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.56	-7.18	-0.42	8.2e-12	Life satisfaction;
KIRP	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.27	0.32	3.04e-7	Lung cancer;
KIRP	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg11845111	chr2:191398756	TMEM194B	-0.8	-8.6	-0.48	9.48e-16	Diastolic blood pressure;
KIRP	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg16179182	chr5:140090404	VTRNA1-1	-0.53	-7.18	-0.42	8.2e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg00360474	chr6:37504404	NA	0.46	6.89	0.4	4.55e-11	Cognitive performance;
KIRP	cis	rs4494114	1.000	rs4494114	chr1:39339682	C/T	cg25970120	chr1:39325951	RRAGC	0.4	5.05	0.31	8.62e-7	Blood protein levels;
KIRP	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.18	21.46	0.81	2.71e-58	Cognitive function;
KIRP	trans	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	8.51	0.48	1.71e-15	Type 2 diabetes;
KIRP	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.57	7.4	0.43	2.12e-12	Coronary artery disease;
KIRP	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23903597	chr17:61704154	MAP3K3	-0.5	-5.95	-0.35	9.23e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6783573	0.895	rs1049667	chr3:46623690	C/A	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.53	-6.38	-0.38	8.82e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg24315340	chr6:146058215	EPM2A	0.46	5.91	0.35	1.15e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.97	0.36	8.46e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.7	-0.44	3.35e-13	Platelet count;
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg04080417	chr5:1859792	NA	-0.64	-8.03	-0.46	4.06e-14	Cardiovascular disease risk factors;
KIRP	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.96	15.14	0.69	4.97e-37	Systemic lupus erythematosus;
KIRP	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg04374321	chr14:90722782	PSMC1	-0.84	-12.22	-0.61	3.88e-27	Mortality in heart failure;
KIRP	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg08807101	chr21:30365312	RNF160	-0.55	-5.38	-0.32	1.72e-7	Cognitive test performance;
KIRP	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	8.74	0.49	3.71e-16	Lung cancer in ever smokers;
KIRP	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.79	-0.4	8.31e-11	Joint mobility (Beighton score);
KIRP	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Visceral adipose tissue adjusted for BMI;
KIRP	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.79	-9.05	-0.5	4.41e-17	Diastolic blood pressure;
KIRP	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.58	-6.87	-0.4	5.12e-11	Monobrow;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09434832	chr19:52642515	ZNF616	-0.9	-6.17	-0.37	2.8e-9	P wave terminal force;
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-5.63	-0.34	4.98e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg16988262	chr1:15930761	NA	0.38	5.03	0.31	9.66e-7	Systolic blood pressure;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg25333258	chr7:44365029	CAMK2B	-0.61	-7.29	-0.42	4.13e-12	Menopause (age at onset);
KIRP	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.2	0.46	1.36e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-8.39	-0.47	3.76e-15	Parkinson's disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14115324	chr17:80023822	DUS1L	-0.47	-6.34	-0.37	1.1e-9	Metabolic traits;
KIRP	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-13.59	-0.65	9.16e-32	Ulcerative colitis;
KIRP	cis	rs11203032	1.000	rs17117124	chr10:90963997	C/G	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.26	-0.32	3.17e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.83	11.71	0.6	1.8e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.14	12.97	0.64	1.15e-29	Platelet count;
KIRP	cis	rs711830	1.000	rs1562315	chr2:177045482	T/A	cg13092806	chr2:177043255	NA	0.67	7.13	0.41	1.13e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg20999797	chr1:1681921	NA	0.52	8.12	0.46	2.29e-14	Body mass index;
KIRP	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.91	14.33	0.67	2.95e-34	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06089463	chr4:121988066	C4orf31	-0.41	-6.6	-0.39	2.57e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg10431340	chr1:161279108	MPZ	-0.46	-4.97	-0.3	1.27e-6	Rheumatoid arthritis;
KIRP	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.8	12.96	0.64	1.24e-29	Schizophrenia;
KIRP	cis	rs5753037	0.653	rs131270	chr22:30149896	C/T	cg01021169	chr22:30184971	ASCC2	-0.44	-6.2	-0.37	2.41e-9	Type 1 diabetes;
KIRP	cis	rs4728302	0.869	rs6955279	chr7:133612113	C/T	cg10665199	chr7:133106180	EXOC4	0.46	5.72	0.34	3.04e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg15443732	chr18:74961078	GALR1	0.55	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs4073054	0.564	rs4564157	chr1:161178155	G/A	cg04436964	chr1:161167745	NDUFS2;ADAMTS4	-0.33	-5.28	-0.32	2.88e-7	Blood metabolite levels;
KIRP	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1448094	0.802	rs11513957	chr12:86435551	C/T	cg06740227	chr12:86229804	RASSF9	0.47	5.74	0.34	2.72e-8	Major depressive disorder;
KIRP	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg07382826	chr16:28625726	SULT1A1	0.47	5.49	0.33	9.99e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg06995285	chr7:2418615	EIF3B	0.61	7.36	0.42	2.82e-12	Multiple sclerosis;
KIRP	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.3	0.67	3.7e-34	Platelet count;
KIRP	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg20578329	chr17:80767326	TBCD	-0.88	-9.33	-0.51	6.25e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.64	3.14e-30	Bladder cancer;
KIRP	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.57	-7.48	-0.43	1.3e-12	Bladder cancer;
KIRP	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15320075	chr8:145703422	NA	-0.59	-7.74	-0.44	2.52e-13	Age at first birth;
KIRP	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-0.89	-12.53	-0.62	3.36e-28	Dupuytren's disease;
KIRP	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.77	-0.35	2.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.65	7.4	0.43	2.11e-12	Body mass index;
KIRP	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.48	0.48	2.16e-15	Bipolar disorder;
KIRP	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2346160	0.899	rs206974	chr6:167690300	G/A	cg27333441	chr6:167680455	NA	-0.44	-5.8	-0.35	2.07e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.06	-7.76	-0.44	2.27e-13	Mitochondrial DNA levels;
KIRP	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.04	0.36	5.53e-9	Colorectal cancer;
KIRP	cis	rs7666738	0.546	rs10025064	chr4:98914060	A/G	cg05340658	chr4:99064831	C4orf37	0.67	7.99	0.45	5.36e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	cis	rs7221595	0.825	rs4790552	chr17:3923366	G/A	cg11204139	chr17:3907470	NA	0.61	6.54	0.39	3.45e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg06064525	chr11:970664	AP2A2	-0.37	-7.59	-0.44	6.45e-13	Alzheimer's disease (late onset);
KIRP	cis	rs4950322	0.543	rs4950319	chr1:146787963	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg16898833	chr6:26189333	HIST1H4D	0.71	5.1	0.31	6.69e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs829661	0.894	rs1252625	chr2:30747398	C/A	cg10949345	chr2:30726833	LCLAT1	0.73	10.43	0.55	2.48e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs9949291	0.565	rs1581426	chr18:61375519	C/T	cg25057269	chr12:54378826	HOXC10	-0.45	-6.15	-0.37	3.11e-9	Eosinophil percentage of white cells;
KIRP	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg03235661	chr20:60525775	NA	-0.32	-5.39	-0.33	1.62e-7	Body mass index;
KIRP	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg10818794	chr15:86012489	AKAP13	-0.49	-6.97	-0.41	2.85e-11	Interstitial lung disease;
KIRP	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs7173389	0.530	rs6495062	chr15:73682691	T/C	cg01796676	chr15:73680284	NA	0.51	5.64	0.34	4.66e-8	Resting heart rate;
KIRP	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg02996583	chr8:142237188	SLC45A4	-0.43	-5.17	-0.31	4.95e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.54	6.77	0.4	9.32e-11	Morning vs. evening chronotype;
KIRP	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg02023728	chr11:77925099	USP35	-0.3	-5.2	-0.31	4.17e-7	Alzheimer's disease (survival time);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03609826	chr1:185126156	C1orf25;C1orf26	0.44	6.05	0.36	5.49e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.18	0.31	4.56e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.7	7.71	0.44	3.17e-13	Lung function (FEV1/FVC);
KIRP	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.41	9.17	0.5	1.97e-17	Cutaneous nevi;
KIRP	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg09788416	chr12:39539408	NA	0.43	5.25	0.32	3.22e-7	Morning vs. evening chronotype;
KIRP	cis	rs981844	0.712	rs4302444	chr4:154745663	A/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg13160058	chr8:26243215	BNIP3L	-0.49	-7.1	-0.41	1.32e-11	Red cell distribution width;
KIRP	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-0.97	-10.21	-0.55	1.22e-20	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14311630	chr11:57363669	SERPING1	0.41	6.39	0.38	8.3e-10	Survival in pancreatic cancer;
KIRP	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg13906792	chr15:75199810	C15orf17	-0.37	-5.19	-0.31	4.43e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22022881	chr2:105853494	NA	-0.37	-5.42	-0.33	1.39e-7	Type 2 diabetes;
KIRP	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02891801	chr12:6472782	SCNN1A	0.52	7.02	0.41	2.16e-11	Smoking initiation;
KIRP	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.44	5.79	0.35	2.19e-8	Hypertriglyceridemia;
KIRP	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.37	-7.53	-0.43	9.84e-13	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23954953	chr1:97187154	PTBP2	0.49	6.15	0.37	3.15e-9	Parkinson's disease;
KIRP	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg24972876	chr7:65420302	NA	-0.4	-5.48	-0.33	1.04e-7	Aortic root size;
KIRP	trans	rs9329221	0.597	rs11776973	chr8:10117411	C/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-7.03	-0.41	1.98e-11	Neuroticism;
KIRP	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.81	-8.46	-0.47	2.41e-15	Gut microbiome composition (summer);
KIRP	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg23625390	chr15:77176239	SCAPER	0.48	6.42	0.38	7.01e-10	Blood metabolite levels;
KIRP	cis	rs2625529	0.652	rs2034879	chr15:72429989	A/G	cg16672083	chr15:72433130	SENP8	-0.4	-5.62	-0.34	5.29e-8	Red blood cell count;
KIRP	cis	rs7258465	0.931	rs271626	chr19:18627067	C/T	cg10790698	chr19:18539756	SSBP4	0.34	7.22	0.42	6.45e-12	Breast cancer;
KIRP	trans	rs9409565	0.821	rs7858082	chr9:97063929	T/A	cg05679027	chr9:99775184	HIATL2	0.64	7.71	0.44	3.21e-13	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.97	-15.05	-0.69	1.02e-36	Height;
KIRP	cis	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-5.12	-0.31	6.07e-7	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6732160	0.613	rs62151837	chr2:73390396	G/T	cg01422370	chr2:73384389	NA	0.51	6.81	0.4	7.61e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg19743168	chr1:23544995	NA	0.56	7.76	0.44	2.32e-13	Height;
KIRP	cis	rs9826463	0.582	rs11720762	chr3:142140511	T/G	cg20824294	chr3:142316082	PLS1	0.41	5.98	0.36	7.98e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7852872	0.704	rs12353303	chr9:119255634	C/T	cg13792444	chr9:119245443	ASTN2	0.39	5.66	0.34	4.19e-8	Hippocampal volume;
KIRP	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	13.14	0.64	2.99e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.33	-0.51	6.31e-18	Personality dimensions;
KIRP	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	6.63	0.39	2.05e-10	Myopia (pathological);
KIRP	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.47	6.36	0.38	9.79e-10	Age-related hearing impairment;
KIRP	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg06671706	chr8:8559999	CLDN23	-0.47	-5.31	-0.32	2.48e-7	Obesity-related traits;
KIRP	cis	rs55788414	0.932	rs35852981	chr16:81180897	G/A	cg06400318	chr16:81190750	PKD1L2	-1.19	-7.65	-0.44	4.58e-13	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.79	-10.63	-0.56	5.79e-22	Longevity;Endometriosis;
KIRP	cis	rs732716	0.785	rs62130979	chr19:4432444	T/C	cg21720385	chr19:4455239	UBXN6	0.73	8.8	0.49	2.4e-16	Mean corpuscular volume;
KIRP	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.43	5.13	0.31	5.94e-7	Melanoma;
KIRP	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.81	-11.99	-0.61	2.23e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs698833	0.886	rs2053455	chr2:44550233	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	6.36	0.38	9.63e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg06307176	chr5:131281290	NA	0.55	6.11	0.36	3.97e-9	Life satisfaction;
KIRP	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg20169779	chr10:135381914	SYCE1	0.69	7.27	0.42	4.81e-12	Gout;
KIRP	cis	rs11605275	0.681	rs74841319	chr11:20027707	A/T	cg14835545	chr11:20032148	NAV2	-0.74	-5.65	-0.34	4.4e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.64	-7.86	-0.45	1.22e-13	Aortic root size;
KIRP	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.84	8.54	0.48	1.45e-15	Methadone dose in opioid dependence;
KIRP	cis	rs6840360	0.935	rs3919716	chr4:152456387	A/G	cg22705602	chr4:152727874	NA	-0.5	-8.26	-0.47	9.06e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs55882075	0.730	rs10794700	chr5:179148335	C/G	cg14593053	chr5:179126677	CANX	0.74	11.07	0.58	2.26e-23	Monocyte percentage of white cells;
KIRP	trans	rs9409565	0.658	rs2809768	chr9:97128369	G/A	cg05679027	chr9:99775184	HIATL2	0.56	6.89	0.4	4.71e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.74	-9.73	-0.53	3.97e-19	Type 2 diabetes;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.89	0.53	1.28e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs5762813	0.561	rs59224170	chr22:29293162	G/C	cg02153584	chr22:29168773	CCDC117	0.59	5.09	0.31	7.15e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs6088813	0.677	rs1570003	chr20:33958127	C/G	cg14752227	chr20:34000481	UQCC	-0.47	-5.31	-0.32	2.48e-7	Height;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg10295955	chr4:187884368	NA	-1.09	-17.45	-0.74	6.17e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1983891	0.553	rs3800283	chr6:41558358	A/G	cg20194872	chr6:41519635	FOXP4	0.46	6.06	0.36	5.16e-9	Prostate cancer;
KIRP	trans	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg16141378	chr3:129829833	LOC729375	-0.51	-6.6	-0.39	2.56e-10	Joint mobility (Beighton score);
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.59	-8.93	-0.49	1.03e-16	Paraoxonase activity;
KIRP	cis	rs8070740	0.617	rs9908179	chr17:5323631	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.61	8.18	0.46	1.5e-14	Menopause (age at onset);
KIRP	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg20744362	chr22:50050164	C22orf34	0.37	6.08	0.36	4.66e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-1.0	-12.55	-0.62	3.05e-28	Breast cancer;
KIRP	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.95	-14.39	-0.68	1.75e-34	Coronary artery disease;
KIRP	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg16558253	chr16:72132732	DHX38	-0.37	-4.97	-0.3	1.24e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.73	-0.44	2.73e-13	Resting heart rate;
KIRP	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.76	9.38	0.51	4.71e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg05998816	chr21:47859926	PCNT	-0.5	-6.07	-0.36	4.75e-9	Lymphocyte counts;
KIRP	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg08662619	chr6:150070041	PCMT1	0.36	5.78	0.35	2.26e-8	Lung cancer;
KIRP	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg24315340	chr6:146058215	EPM2A	0.39	4.92	0.3	1.61e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.62	-8.27	-0.47	8.45e-15	Obesity-related traits;
KIRP	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.32	0.32	2.32e-7	Educational attainment;
KIRP	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg08917208	chr2:24149416	ATAD2B	0.58	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg14580859	chr9:123691850	NA	0.37	5.18	0.31	4.52e-7	Rheumatoid arthritis;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.58	-7.37	-0.43	2.6e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg16849860	chr7:48352531	ABCA13	0.57	6.43	0.38	6.77e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg16141378	chr3:129829833	LOC729375	-0.52	-6.78	-0.4	9e-11	Mood instability;
KIRP	cis	rs72829446	0.530	rs4796420	chr17:7379617	A/T	cg02795151	chr17:7402630	POLR2A	0.8	7.96	0.45	6.42e-14	Androgen levels;
KIRP	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.46	6.43	0.38	6.76e-10	Testicular germ cell tumor;
KIRP	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg13736514	chr6:26305472	NA	0.45	5.04	0.31	9.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg10223061	chr2:219282414	VIL1	-0.35	-5.59	-0.34	6.02e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.65	-7.02	-0.41	2.17e-11	Corneal astigmatism;
KIRP	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg07777115	chr5:623756	CEP72	-0.59	-6.04	-0.36	5.7e-9	Obesity-related traits;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08121760	chr12:111126960	HVCN1	0.53	7.58	0.44	7.02e-13	Parkinson's disease;
KIRP	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg23894439	chr1:183413866	NA	0.39	5.21	0.32	4.08e-7	Systemic lupus erythematosus;
KIRP	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg02733842	chr7:1102375	C7orf50	0.58	5.92	0.35	1.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22117172	chr7:91764530	CYP51A1	0.46	6.22	0.37	2.16e-9	Breast cancer;
KIRP	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg03289416	chr15:75166202	SCAMP2	0.53	6.8	0.4	8.01e-11	Caffeine consumption;
KIRP	cis	rs787274	1.000	rs2796035	chr9:115515597	C/T	cg13803584	chr9:115635662	SNX30	-0.74	-6.68	-0.39	1.56e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.53	5.2	0.31	4.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.69	7.04	0.41	1.95e-11	Protein C levels;
KIRP	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Breast cancer;
KIRP	cis	rs6546886	0.912	rs13006407	chr2:74280275	G/A	cg14702570	chr2:74259524	NA	-0.34	-6.92	-0.4	3.89e-11	Dialysis-related mortality;
KIRP	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.58	6.23	0.37	2.02e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-0.86	-8.48	-0.48	2.18e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg16434002	chr17:42200994	HDAC5	0.55	6.87	0.4	5.32e-11	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23931836	chr19:47615988	ZC3H4	0.57	7.73	0.44	2.77e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg02297831	chr4:17616191	MED28	0.53	6.5	0.38	4.34e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.62	8.07	0.46	3.14e-14	Height;
KIRP	cis	rs7116495	1.000	rs659513	chr11:71812411	C/T	cg26138937	chr11:71823887	C11orf51	0.67	5.24	0.32	3.48e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.27	0.37	1.59e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs13102973	0.829	rs13126756	chr4:135900185	G/A	cg14419869	chr4:135874104	NA	0.48	7.46	0.43	1.48e-12	Subjective well-being;
KIRP	cis	rs2384207	0.584	rs6489897	chr12:113765204	A/T	cg13296563	chr12:112847257	RPL6	-0.6	-4.92	-0.3	1.61e-6	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.62	-6.88	-0.4	4.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.66	-7.33	-0.42	3.32e-12	Vitiligo;
KIRP	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.44	5.33	0.32	2.21e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.08e-11	Blood metabolite levels;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg09838262	chr17:37921981	IKZF3	0.98	6.13	0.36	3.47e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs600231	0.613	rs12803915	chr11:65211979	G/A	cg17120908	chr11:65337727	SSSCA1	-0.58	-5.38	-0.32	1.74e-7	Bone mineral density;
KIRP	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.48	5.92	0.35	1.09e-8	Height;
KIRP	cis	rs357618	1.000	rs193299	chr5:150847655	G/C	cg22672639	chr5:150884813	FAT2	0.35	5.34	0.32	2.15e-7	Basophil percentage of white cells;
KIRP	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.66	9.95	0.54	7.8e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7923609	0.967	rs7085621	chr10:65208926	T/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.58	-0.33	6.46e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.03	0.31	9.27e-7	Menopause (age at onset);
KIRP	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.54	0.56	1.12e-21	Birth weight;
KIRP	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.59	0.39	2.59e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.54	-0.43	8.98e-13	Systolic blood pressure;
KIRP	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg05784532	chr1:230284198	GALNT2	0.41	6.32	0.37	1.21e-9	Coronary artery disease;
KIRP	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg18586891	chr4:952366	TMEM175	0.59	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19386169	chr12:133296477	PGAM5	0.51	6.35	0.38	1.05e-9	Interleukin-4 levels;
KIRP	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.41	-0.33	1.52e-7	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06952534	chr1:196946228	CFHR5	-0.45	-6.73	-0.39	1.16e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.57	8.36	0.47	4.61e-15	Carotid intima media thickness;
KIRP	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.48	6.86	0.4	5.7e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10267417	0.657	rs28833898	chr7:19861022	G/A	cg05791153	chr7:19748676	TWISTNB	0.54	5.15	0.31	5.33e-7	Night sleep phenotypes;
KIRP	cis	rs367943	0.665	rs4705560	chr5:112977073	T/G	cg12552261	chr5:112820674	MCC	0.45	5.02	0.3	1.01e-6	Type 2 diabetes;
KIRP	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-8.62	-0.48	8.07e-16	Triglycerides;
KIRP	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.34	-5.39	-0.33	1.63e-7	Asthma;
KIRP	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14769373	chr6:40998127	UNC5CL	0.59	6.01	0.36	6.75e-9	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.3	-0.47	7.02e-15	Neuroticism;
KIRP	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg16141378	chr3:129829833	LOC729375	0.55	6.97	0.41	2.89e-11	Retinal vascular caliber;
KIRP	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg17691542	chr6:26056736	HIST1H1C	0.63	7.52	0.43	1.02e-12	Iron status biomarkers;
KIRP	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.93	-10.78	-0.57	1.88e-22	Corneal astigmatism;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg12685995	chr10:126849062	CTBP2	-0.47	-6.13	-0.36	3.41e-9	Hippocampal sclerosis of aging;
KIRP	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-6.36	-0.38	9.96e-10	Alzheimer's disease (late onset);
KIRP	cis	rs7534824	0.625	rs61780286	chr1:101359898	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	5.63	0.34	4.83e-8	Refractive astigmatism;
KIRP	cis	rs2041895	0.509	rs1035236	chr12:107310797	C/T	cg15890332	chr12:107067104	RFX4	0.35	4.92	0.3	1.6e-6	Glaucoma (low intraocular pressure);
KIRP	cis	rs9815354	0.812	rs17283929	chr3:41941898	C/G	cg03022575	chr3:42003672	ULK4	-0.75	-7.66	-0.44	4.38e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.86	11.22	0.58	7.43e-24	Gestational age at birth (maternal effect);
KIRP	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg26876637	chr1:152193138	HRNR	0.75	9.63	0.52	7.62e-19	Atopic dermatitis;
KIRP	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.65	-10.04	-0.54	4.09e-20	Menopause (age at onset);
KIRP	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-0.96	-9.39	-0.51	4.16e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg15327641	chr2:3715039	ALLC	0.43	5.45	0.33	1.23e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg16325326	chr1:53192061	ZYG11B	-0.72	-8.0	-0.45	4.86e-14	Monocyte count;
KIRP	cis	rs7091068	0.518	rs4919436	chr10:95461475	C/T	cg20715218	chr10:95462985	C10orf4	0.5	6.06	0.36	5.07e-9	Urinary tract infection frequency;
KIRP	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg23127183	chr11:57508653	C11orf31	-0.54	-7.01	-0.41	2.24e-11	Schizophrenia;
KIRP	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.67	-6.14	-0.36	3.28e-9	Schizophrenia;
KIRP	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.87	7.41	0.43	2.03e-12	Fat distribution (HIV);
KIRP	cis	rs6977660	0.714	rs6945533	chr7:19813913	G/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.28	0.32	2.86e-7	Thyroid stimulating hormone;
KIRP	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.65	-0.44	4.54e-13	Neuroticism;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg15181151	chr6:150070149	PCMT1	0.31	5.18	0.31	4.71e-7	Lung cancer;
KIRP	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg22117172	chr7:91764530	CYP51A1	0.39	5.37	0.32	1.83e-7	Breast cancer;
KIRP	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-7.12	-0.41	1.22e-11	Alzheimer's disease (late onset);
KIRP	cis	rs8113308	0.515	rs55866828	chr19:52441585	T/C	cg25782003	chr19:52490127	ZNF350	0.79	5.76	0.34	2.45e-8	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.66	-9.78	-0.53	2.64e-19	Triglycerides;
KIRP	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg23594656	chr7:65796392	TPST1	0.5	7.69	0.44	3.45e-13	Aortic root size;
KIRP	cis	rs12718244	0.816	rs11765672	chr7:50187504	G/A	cg02697348	chr7:50199187	C7orf72	-0.4	-5.17	-0.31	4.9e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg16497661	chr14:103986332	CKB	-0.5	-6.37	-0.38	9.4e-10	Coronary artery disease;
KIRP	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg12131826	chr15:77904385	NA	-0.42	-5.03	-0.31	9.51e-7	Type 2 diabetes;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg02733842	chr7:1102375	C7orf50	0.5	5.24	0.32	3.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg12315302	chr6:26189340	HIST1H4D	-0.93	-6.54	-0.38	3.54e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17065868	0.881	rs17068853	chr13:45050742	G/A	cg10246903	chr13:45222710	NA	0.58	5.96	0.36	8.8e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1408799	0.549	rs2209277	chr9:12706236	A/G	cg05274944	chr9:12693694	TYRP1	0.45	7.01	0.41	2.31e-11	Eye color;Blue vs. green eyes;
KIRP	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.44	-5.82	-0.35	1.87e-8	Bladder cancer;
KIRP	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.72	-0.39	1.26e-10	Menopause (age at onset);
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.83	0.35	1.7e-8	Platelet count;
KIRP	cis	rs1867631	0.585	rs5008753	chr1:67092248	A/G	cg13052034	chr1:66999238	SGIP1	0.42	6.17	0.37	2.8e-9	Menopause (age at onset);
KIRP	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg18200150	chr17:30822561	MYO1D	0.48	5.93	0.35	9.98e-9	Schizophrenia;
KIRP	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg24169773	chr3:122142474	KPNA1	-0.57	-5.94	-0.35	9.53e-9	LDL cholesterol levels;
KIRP	trans	rs78049276	0.736	rs72957606	chr4:148400011	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.75	-9.08	-0.5	3.52e-17	Pulse pressure;
KIRP	trans	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.56	0.43	7.82e-13	Corneal astigmatism;
KIRP	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg10318148	chr7:1024673	CYP2W1	0.34	4.91	0.3	1.67e-6	Longevity;Endometriosis;
KIRP	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.83	-0.45	1.49e-13	Retinal vascular caliber;
KIRP	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.7	5.0	0.3	1.11e-6	Childhood ear infection;
KIRP	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.44	-5.57	-0.33	6.5e-8	Personality dimensions;
KIRP	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.89	-10.07	-0.54	3.36e-20	Gut microbiome composition (summer);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20038169	chr19:19754386	GMIP	0.48	6.23	0.37	2.02e-9	Myopia (pathological);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23138817	chr14:105864896	NA	0.57	7.46	0.43	1.48e-12	Parkinson's disease;
KIRP	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.88	-9.09	-0.5	3.45e-17	Vitamin D levels;
KIRP	cis	rs10423674	0.526	rs11668545	chr19:18829529	C/T	cg14292368	chr19:18793705	CRTC1	-0.53	-6.52	-0.38	3.93e-10	Menarche (age at onset);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18108111	chr6:122753562	HSF2	0.42	6.23	0.37	2e-9	Migraine with aura;
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg07609200	chr11:93583253	C11orf90	0.49	6.07	0.36	4.93e-9	QT interval;
KIRP	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg13482628	chr17:19912719	NA	0.53	6.85	0.4	5.99e-11	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16717690	chr1:1208709	UBE2J2	0.5	6.16	0.37	3.03e-9	Parkinson's disease;
KIRP	trans	rs1941687	0.764	rs1493918	chr18:31381845	C/G	cg04226714	chr8:49833948	SNAI2	-0.49	-6.71	-0.39	1.33e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs3105593	0.933	rs3105598	chr15:50825266	A/G	cg08437265	chr15:50716283	USP8	0.38	5.16	0.31	5.04e-7	QT interval;
KIRP	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.41	-0.33	1.53e-7	Autism;
KIRP	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.84	9.65	0.52	6.67e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg03060546	chr3:49711283	APEH	0.54	7.34	0.42	3.11e-12	Menarche (age at onset);
KIRP	cis	rs1707322	1.000	rs1707303	chr1:46598273	A/C	cg03146154	chr1:46216737	IPP	-0.61	-7.6	-0.44	6.17e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2880765	0.525	rs35899940	chr15:86053697	A/G	cg10818794	chr15:86012489	AKAP13	-0.51	-6.92	-0.4	3.78e-11	Coronary artery disease;
KIRP	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24397884	chr7:158709396	WDR60	0.73	9.78	0.53	2.8e-19	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03399598	chr4:174091002	GALNT7	0.66	7.82	0.45	1.53e-13	Smoking initiation;
KIRP	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg17507749	chr15:85114479	UBE2QP1	0.8	8.4	0.47	3.58e-15	Schizophrenia;
KIRP	cis	rs2625529	0.775	rs4777466	chr15:72136872	C/T	cg16672083	chr15:72433130	SENP8	-0.46	-6.49	-0.38	4.8e-10	Red blood cell count;
KIRP	cis	rs9634489	0.511	rs7999958	chr13:97005532	A/G	cg02571835	chr13:96230311	CLDN10	0.37	4.91	0.3	1.69e-6	Body mass index;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg05889321	chr10:97416837	ALDH18A1	0.65	6.12	0.36	3.74e-9	Lung function (FEV1);
KIRP	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.09	0.41	1.41e-11	Morning vs. evening chronotype;
KIRP	trans	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg01311341	chr22:25575246	KIAA1671	-0.61	-6.68	-0.39	1.59e-10	Glioblastoma;
KIRP	cis	rs9303542	0.559	rs1042818	chr17:46620111	T/C	cg05487507	chr17:46671861	LOC404266;HOXB5	0.42	4.84	0.3	2.25e-6	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs8033133	0.581	rs8042796	chr15:25327396	A/C	cg14481604	chr15:25334117	SNORD116-22	-0.4	-4.98	-0.3	1.21e-6	Blood osmolality (transformed sodium);
KIRP	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	1.0	15.87	0.71	1.58e-39	Vitamin D levels;
KIRP	cis	rs1009170	0.794	rs112924085	chr14:92581713	C/T	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.55	5.46	0.33	1.18e-7	Dialysis-related mortality;
KIRP	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg04369109	chr6:150039330	LATS1	-0.48	-5.72	-0.34	3.16e-8	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17499294	chr4:99955894	METAP1	-0.48	-7.72	-0.44	2.95e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13521891	chr12:95466445	NR2C1	0.5	6.03	0.36	6.08e-9	Smoking initiation;
KIRP	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.57	-8.03	-0.46	3.94e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg12861170	chr19:19639553	YJEFN3	-0.47	-4.85	-0.3	2.21e-6	Bipolar disorder;
KIRP	cis	rs6601327	0.540	rs4841225	chr8:9669164	T/A	cg27411982	chr8:10470053	RP1L1	-0.4	-5.14	-0.31	5.55e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg23067535	chr8:124195133	FAM83A	0.71	7.0	0.41	2.46e-11	Urinary uromodulin levels;
KIRP	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg08989290	chr16:615782	NHLRC4	0.38	5.68	0.34	3.86e-8	Height;
KIRP	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg04025307	chr7:1156635	C7orf50	0.58	4.96	0.3	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg11641102	chr8:27183873	PTK2B	0.45	5.9	0.35	1.2e-8	Neuroticism;
KIRP	trans	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.8	0.4	8.04e-11	Mean corpuscular volume;
KIRP	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg07777115	chr5:623756	CEP72	-0.6	-6.02	-0.36	6.19e-9	Obesity-related traits;
KIRP	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.81	12.15	0.61	6.5e-27	Bladder cancer;
KIRP	cis	rs9972944	0.651	rs7222415	chr17:63765137	T/C	cg07283582	chr17:63770753	CCDC46	-0.49	-8.06	-0.46	3.38e-14	Total body bone mineral density;
KIRP	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg25019033	chr10:957182	NA	-0.68	-8.23	-0.46	1.13e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg05082376	chr22:42548792	NA	-0.44	-5.29	-0.32	2.66e-7	Schizophrenia;
KIRP	cis	rs984222	0.527	rs2645291	chr1:119572541	C/T	cg18261050	chr1:119551319	NA	0.34	4.91	0.3	1.64e-6	Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;
KIRP	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg05127821	chr10:94822908	CYP26C1	-1.1	-11.26	-0.58	5.51e-24	Coronary artery disease;
KIRP	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg06585982	chr3:143692056	C3orf58	0.61	7.73	0.44	2.67e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.63	8.35	0.47	5.13e-15	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01459777	chr11:47664264	MTCH2	0.51	6.29	0.37	1.46e-9	Parkinson's disease;
KIRP	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.89	8.16	0.46	1.76e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.69	-7.26	-0.42	5.14e-12	Vitiligo;
KIRP	cis	rs4908768	0.911	rs6693127	chr1:8774973	G/A	cg25722041	chr1:8623473	RERE	0.54	7.1	0.41	1.3e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg11204139	chr17:3907470	NA	0.85	16.32	0.72	4.47e-41	Type 2 diabetes;
KIRP	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-8.82	-0.49	2.21e-16	Neuroticism;
KIRP	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg22974920	chr21:40686053	BRWD1	0.49	5.85	0.35	1.57e-8	Cognitive function;
KIRP	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg13264159	chr8:625131	ERICH1	-0.85	-6.72	-0.39	1.25e-10	IgG glycosylation;
KIRP	cis	rs11673344	0.555	rs502546	chr19:37852690	A/G	cg14683738	chr19:37701593	ZNF585B	0.43	5.02	0.31	9.71e-7	Obesity-related traits;
KIRP	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.32	5.08	0.31	7.51e-7	Testicular germ cell tumor;
KIRP	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.62	7.17	0.42	8.76e-12	Menarche (age at onset);
KIRP	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg06289844	chr6:126071538	HEY2	-0.45	-6.63	-0.39	2.14e-10	Brugada syndrome;
KIRP	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg05347473	chr6:146136440	FBXO30	-0.59	-8.45	-0.47	2.57e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg22117172	chr7:91764530	CYP51A1	-0.43	-5.8	-0.35	1.98e-8	Breast cancer;
KIRP	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.89	12.61	0.63	1.88e-28	Morning vs. evening chronotype;
KIRP	cis	rs17221829	0.733	rs11018725	chr11:89413251	C/T	cg02982614	chr11:89391479	FOLH1B	-0.34	-5.53	-0.33	8.3e-8	Anxiety in major depressive disorder;
KIRP	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.37	-0.32	1.85e-7	Educational attainment (years of education);
KIRP	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	trans	rs2048656	0.578	rs7817784	chr8:9682553	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.4	-0.38	7.86e-10	Schizophrenia;
KIRP	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.68	8.61	0.48	8.79e-16	Renal function-related traits (BUN);
KIRP	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.74	-9.78	-0.53	2.64e-19	Endometriosis;
KIRP	cis	rs7224685	0.569	rs12940782	chr17:3992712	T/C	cg05562828	chr17:3906858	NA	0.56	5.81	0.35	1.91e-8	Type 2 diabetes;
KIRP	cis	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.44	5.83	0.35	1.71e-8	Leprosy;
KIRP	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.63	-6.98	-0.41	2.66e-11	Neuroticism;
KIRP	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.94	13.54	0.65	1.38e-31	Height;
KIRP	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.67	-7.57	-0.43	7.64e-13	Bone mineral density;
KIRP	cis	rs2120243	0.501	rs1456107	chr3:157119520	A/C	cg24825693	chr3:157122686	VEPH1	-0.56	-9.23	-0.51	1.26e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03647317	chr4:187891568	NA	-0.77	-12.86	-0.63	2.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21925296	chr8:22102597	POLR3D;MIR320A	-0.45	-6.04	-0.36	5.69e-9	Metabolic traits;
KIRP	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg06289844	chr6:126071538	HEY2	-0.45	-6.7	-0.39	1.38e-10	Brugada syndrome;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.76	10.34	0.55	4.89e-21	Longevity;
KIRP	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.11	-0.46	2.45e-14	Neuroticism;
KIRP	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg19773385	chr1:10388646	KIF1B	-0.68	-9.01	-0.5	5.74e-17	Hepatocellular carcinoma;
KIRP	cis	rs2275620	1.000	rs7910936	chr10:96804451	C/T	cg09036531	chr10:96991505	NA	-0.51	-6.53	-0.38	3.64e-10	Gout;
KIRP	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.45	0.33	1.2e-7	Bipolar disorder;
KIRP	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.66	-9.95	-0.54	8.09e-20	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.95	-16.48	-0.72	1.3e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs412050	0.547	rs78907487	chr22:22151939	A/C	cg17089214	chr22:22089827	YPEL1	0.64	5.85	0.35	1.55e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.02	16.9	0.73	4.65e-43	Multiple system atrophy;
KIRP	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.67	-11.6	-0.59	4.19e-25	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg03684893	chr10:554711	DIP2C	-0.42	-6.08	-0.36	4.59e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs7017914	0.967	rs34905858	chr8:71659450	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg24060327	chr5:131705240	SLC22A5	-0.42	-5.3	-0.32	2.59e-7	Breast cancer;
KIRP	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.73	8.51	0.48	1.69e-15	Corneal astigmatism;
KIRP	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.73	6.99	0.41	2.52e-11	Arsenic metabolism;
KIRP	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.9	-0.4	4.48e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.82	13.56	0.65	1.17e-31	Longevity;
KIRP	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg07382826	chr16:28625726	SULT1A1	0.46	5.06	0.31	8.39e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg18944383	chr4:111397179	ENPEP	0.51	8.5	0.48	1.87e-15	Height;
KIRP	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg01304814	chr3:48885189	PRKAR2A	0.68	5.2	0.31	4.29e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.4	-9.16	-0.5	2.07e-17	Diastolic blood pressure;
KIRP	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg16898833	chr6:26189333	HIST1H4D	0.85	6.0	0.36	6.94e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-6.28	-0.37	1.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7657257	1.000	rs7657257	chr4:15646941	G/A	cg19145858	chr7:129781681	NA	-0.66	-6.44	-0.38	6.35e-10	Blood protein levels;
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.79	-7.97	-0.45	6.09e-14	Platelet count;
KIRP	cis	rs812925	0.559	rs2600667	chr2:61404931	A/T	cg15711740	chr2:61764176	XPO1	-0.48	-5.19	-0.31	4.39e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg00409905	chr10:38381863	ZNF37A	-0.54	-6.05	-0.36	5.28e-9	Obesity (extreme);
KIRP	cis	rs17270561	0.609	rs9467572	chr6:25704126	T/G	cg17691542	chr6:26056736	HIST1H1C	-0.65	-7.74	-0.44	2.64e-13	Iron status biomarkers;
KIRP	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg18944383	chr4:111397179	ENPEP	0.48	8.19	0.46	1.46e-14	Height;
KIRP	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg15556689	chr8:8085844	FLJ10661	-0.68	-9.31	-0.51	7.38e-18	Triglycerides;
KIRP	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.25	-0.37	1.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.45	6.29	0.37	1.42e-9	Dupuytren's disease;
KIRP	cis	rs17121403	0.661	rs12127181	chr1:100627774	T/C	cg24955406	chr1:100503596	HIAT1	0.78	5.11	0.31	6.5e-7	Pulmonary function decline;
KIRP	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg24498760	chr8:49746867	NA	0.41	5.16	0.31	5.17e-7	Blood metabolite ratios;
KIRP	cis	rs258892	0.895	rs114748070	chr5:72024794	C/A	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.75	11.11	0.58	1.64e-23	Prudent dietary pattern;
KIRP	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.95	14.52	0.68	6.41e-35	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	1.12	17.38	0.74	1.11e-44	Monocyte percentage of white cells;
KIRP	cis	rs6690583	0.623	rs12047435	chr1:85452927	T/G	cg22153463	chr1:85462885	MCOLN2	0.6	5.13	0.31	5.91e-7	Serum sulfate level;
KIRP	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.7	7.06	0.41	1.67e-11	Menarche (age at onset);
KIRP	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg26116260	chr4:7069785	GRPEL1	-0.8	-6.63	-0.39	2.16e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.91e-10	Hypertriglyceridemia;
KIRP	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.57	-6.39	-0.38	8.28e-10	LDL cholesterol levels;
KIRP	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.2800000000000005e-19	Morning vs. evening chronotype;
KIRP	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg26531700	chr6:26746687	NA	-0.38	-5.04	-0.31	8.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.52	-11.24	-0.58	6.18e-24	Refractive error;
KIRP	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg11031976	chr2:198649780	BOLL	0.52	5.01	0.3	1.05e-6	Ulcerative colitis;
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	8.72	0.49	4.32e-16	Lymphocyte counts;
KIRP	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-7.03	-0.41	2.05e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25214090	chr10:38739885	LOC399744	0.59	7.37	0.43	2.59e-12	Corneal astigmatism;
KIRP	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-7.05	-0.41	1.81e-11	Platelet count;
KIRP	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg01620082	chr3:125678407	NA	-1.15	-7.44	-0.43	1.65e-12	Depression;
KIRP	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg12131826	chr15:77904385	NA	0.48	5.63	0.34	4.99e-8	Type 2 diabetes;
KIRP	cis	rs6545883	0.894	rs6545867	chr2:61651027	C/T	cg15711740	chr2:61764176	XPO1	0.61	8.12	0.46	2.24e-14	Tuberculosis;
KIRP	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	7.93	0.45	7.8500000000000006e-14	Mood instability;
KIRP	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg07052231	chr12:7363540	PEX5	0.41	5.39	0.33	1.65e-7	IgG glycosylation;
KIRP	cis	rs9308731	0.591	rs879623	chr2:111946824	G/A	cg04202892	chr2:111875749	ACOXL	0.39	5.13	0.31	5.94e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg07167872	chr1:205819463	PM20D1	-0.53	-5.11	-0.31	6.46e-7	Menarche (age at onset);
KIRP	cis	rs2594989	0.733	rs9876898	chr3:11567961	T/C	cg01796438	chr3:11312864	ATG7	0.41	5.48	0.33	1.05e-7	Circulating chemerin levels;
KIRP	cis	rs2236918	0.932	rs2526697	chr1:242040129	A/G	cg17736920	chr1:242011382	EXO1	-0.65	-8.52	-0.48	1.63e-15	Menopause (age at onset);
KIRP	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10121009	0.565	rs4498642	chr9:35436662	C/G	cg15271616	chr9:35490515	RUSC2	0.38	5.2	0.31	4.21e-7	Parkinson's disease;
KIRP	cis	rs11024102	0.830	rs11024110	chr11:17028390	T/A	cg15378786	chr11:17036137	PLEKHA7	0.51	5.42	0.33	1.43e-7	Glaucoma (primary angle closure);
KIRP	cis	rs9400467	0.537	rs12213248	chr6:111499394	G/C	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2274273	0.805	rs28660594	chr14:55846174	T/C	cg04306507	chr14:55594613	LGALS3	0.44	6.91	0.4	4.14e-11	Protein biomarker;
KIRP	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.61	-0.34	5.44e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-9.07	-0.5	3.8e-17	Menarche (age at onset);
KIRP	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg09904177	chr6:26538194	HMGN4	0.43	5.8	0.35	2e-8	Schizophrenia;
KIRP	cis	rs2151522	0.762	rs9401912	chr6:127152724	G/A	cg21431617	chr6:127135037	NA	0.3	5.41	0.33	1.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.61	-0.34	5.3e-8	Renal cell carcinoma;
KIRP	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.56	8.21	0.46	1.23e-14	Huntington's disease progression;
KIRP	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.46	5.82	0.35	1.82e-8	Response to temozolomide;
KIRP	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg18944383	chr4:111397179	ENPEP	0.49	8.03	0.46	4.01e-14	Coronary artery disease;
KIRP	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.76	11.59	0.59	4.56e-25	Oral cavity cancer;
KIRP	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg00553149	chr7:99775558	STAG3;GPC2	0.48	6.03	0.36	5.83e-9	Coronary artery disease;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg06942814	chr7:27170819	HOXA4	-0.37	-5.23	-0.32	3.54e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs526231	0.543	rs27361	chr5:102548967	G/A	cg23492399	chr5:102201601	PAM	-0.52	-5.65	-0.34	4.53e-8	Primary biliary cholangitis;
KIRP	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg26022315	chr17:47021804	SNF8	0.42	5.48	0.33	1.05e-7	Type 2 diabetes;
KIRP	cis	rs4664304	0.531	rs11691616	chr2:160758680	G/C	cg06856378	chr2:160759118	LY75	0.37	4.99	0.3	1.16e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6960043	1.000	rs12666046	chr7:15050381	A/G	cg19272540	chr7:15055459	NA	-0.22	-5.86	-0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs12579753	0.667	rs73359938	chr12:82308613	T/A	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.68	-0.34	3.74e-8	Resting heart rate;
KIRP	cis	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg08930214	chr7:62859557	LOC100287834	-0.56	-6.71	-0.39	1.33e-10	Obesity-related traits;
KIRP	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.36	5.69	0.34	3.61e-8	Multiple sclerosis;
KIRP	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg02820040	chr2:241836501	C2orf54	-0.24	-5.52	-0.33	8.7e-8	Urinary metabolites;
KIRP	cis	rs9324022	0.790	rs56011271	chr14:101167732	C/T	cg18089426	chr14:101175970	NA	0.69	6.17	0.37	2.8e-9	Plateletcrit;
KIRP	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg11693508	chr17:37793320	STARD3	0.67	7.25	0.42	5.54e-12	Bipolar disorder;
KIRP	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.6	6.84	0.4	6.26e-11	Aortic root size;
KIRP	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.79	-9.18	-0.51	1.81e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.79	-10.8	-0.57	1.66e-22	Coffee consumption (cups per day);
KIRP	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	1.02	7.85	0.45	1.26e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	5.03	0.31	9.48e-7	Parkinson's disease;
KIRP	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.79	-10.76	-0.57	2.28e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs75920871	1.000	rs61905681	chr11:116836209	A/C	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs7326068	0.510	rs4432108	chr13:21342151	G/A	cg04906043	chr13:21280425	IL17D	-0.43	-4.97	-0.3	1.26e-6	Schizophrenia, bipolar disorder and depression (combined);
KIRP	cis	rs2904967	1.000	rs509303	chr11:65093190	A/C	cg12562828	chr11:65076843	NA	-0.46	-6.94	-0.4	3.51e-11	Mean corpuscular volume;
KIRP	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg08501292	chr6:25962987	TRIM38	1.06	8.25	0.47	9.54e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg15556689	chr8:8085844	FLJ10661	0.56	7.32	0.42	3.48e-12	Mood instability;
KIRP	cis	rs9603616	1.000	rs9943	chr13:40326282	A/G	cg26701198	chr13:40229707	COG6	-0.44	-4.96	-0.3	1.35e-6	Rheumatoid arthritis;
KIRP	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-8.03	-0.46	4.14e-14	Asthma;
KIRP	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.63	0.52	8.08e-19	Bladder cancer;
KIRP	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg25486957	chr4:152246857	NA	-0.42	-5.09	-0.31	7.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2072732	0.821	rs12039548	chr1:2947909	C/T	cg11731671	chr1:2995604	PRDM16	0.42	5.4	0.33	1.54e-7	Plateletcrit;
KIRP	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21014159	chr11:117668035	DSCAML1	0.4	5.03	0.31	9.53e-7	Myopia;
KIRP	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg04490037	chr7:50633773	DDC	0.36	4.92	0.3	1.62e-6	Body mass index;
KIRP	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg20578329	chr17:80767326	TBCD	-0.52	-7.36	-0.42	2.69e-12	Breast cancer;
KIRP	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg16497661	chr14:103986332	CKB	0.85	14.76	0.69	1.01e-35	Body mass index;
KIRP	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06544989	chr22:39130855	UNC84B	0.52	9.45	0.52	2.74e-18	Menopause (age at onset);
KIRP	cis	rs12022452	0.506	rs12569328	chr1:41019221	G/C	cg25568243	chr1:40974465	DEM1	0.59	6.27	0.37	1.6e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs72772090	1.000	rs72772095	chr5:96053853	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.54	-5.02	-0.3	1.01e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13198984	chr17:80129470	CCDC57	-0.59	-9.14	-0.5	2.34e-17	Life satisfaction;
KIRP	cis	rs11644362	1.000	rs976243	chr16:12991679	A/T	cg06890432	chr16:12997467	SHISA9	-0.39	-6.08	-0.36	4.6e-9	Positive affect;Subjective well-being;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22168489	chr12:122356033	WDR66	0.63	9.35	0.51	5.66e-18	Mean corpuscular volume;
KIRP	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg04374321	chr14:90722782	PSMC1	0.59	8.12	0.46	2.22e-14	Mortality in heart failure;
KIRP	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.98	18.58	0.76	9.26e-49	Electrocardiographic conduction measures;
KIRP	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-0.68	-7.68	-0.44	3.69e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.38	-0.38	8.8e-10	Lung cancer;
KIRP	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.63	-5.57	-0.33	6.68e-8	Menarche (age at onset);
KIRP	cis	rs9398803	0.865	rs9398805	chr6:126726295	C/T	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.35e-10	Male-pattern baldness;
KIRP	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26526719	chr5:1949144	NA	0.44	5.25	0.32	3.29e-7	Gut microbiome composition (winter);
KIRP	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2820315	1.000	rs2459761	chr1:201808469	C/G	cg11586189	chr1:201857591	SHISA4	-0.39	-5.45	-0.33	1.24e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs7584330	0.554	rs57140815	chr2:238428330	A/G	cg08992911	chr2:238395768	MLPH	0.46	5.25	0.32	3.36e-7	Prostate cancer;
KIRP	cis	rs2235544	0.579	rs11804837	chr1:54482915	G/A	cg25741118	chr1:54482237	LDLRAD1	-0.32	-6.16	-0.37	2.98e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.67	-6.47	-0.38	5.19e-10	Opioid sensitivity;
KIRP	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg00405596	chr8:11794950	NA	0.58	8.21	0.46	1.26e-14	Neuroticism;
KIRP	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs9863706	0.520	rs4676872	chr3:72399570	C/G	cg05607079	chr3:72387937	NA	-0.44	-5.7	-0.34	3.38e-8	Height;
KIRP	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs2562456	0.833	rs8102783	chr19:21538553	T/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma (childhood onset);
KIRP	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg14851346	chr12:38532713	NA	-0.4	-4.97	-0.3	1.24e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2882667	0.858	rs66839813	chr5:138442322	A/T	cg04439458	chr5:138467593	SIL1	-0.51	-7.51	-0.43	1.12e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg13010199	chr12:38710504	ALG10B	0.43	5.51	0.33	9.25e-8	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.77	6.63	0.39	2.08e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs2270927	0.510	rs6891108	chr5:75579152	C/A	cg13563193	chr19:33072644	PDCD5	0.91	6.65	0.39	1.91e-10	Mean corpuscular volume;
KIRP	cis	rs220519	0.693	rs220532	chr20:37270964	A/T	cg24308336	chr20:37270989	C20orf95	0.24	5.35	0.32	1.97e-7	Schizophrenia;
KIRP	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.07	0.41	1.55e-11	Rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00587304	chr3:172468157	NA	0.63	7.84	0.45	1.36e-13	Smoking initiation;
KIRP	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.66	-0.34	4.23e-8	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15066556	chr1:169336845	BLZF1;NME7	0.44	6.41	0.38	7.19e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.96	-11.54	-0.59	6.75e-25	Bipolar disorder and schizophrenia;
KIRP	cis	rs11895698	1	rs11895698	chr2:239338495	C/T	cg18131467	chr2:239335373	ASB1	-0.69	-5.59	-0.34	5.87e-8	Chronotype;
KIRP	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg24375607	chr4:120327624	NA	0.53	6.08	0.36	4.52e-9	Corneal astigmatism;
KIRP	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg04132472	chr17:19861366	AKAP10	0.45	6.2	0.37	2.35e-9	Schizophrenia;
KIRP	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.52	-5.84	-0.35	1.66e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-15.36	-0.7	8.34e-38	Height;
KIRP	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg00262122	chr8:11665843	FDFT1	0.43	5.26	0.32	3.08e-7	Retinal vascular caliber;
KIRP	cis	rs6772849	0.930	rs12487604	chr3:128337075	T/A	cg08795948	chr3:128337044	NA	0.58	6.84	0.4	6.28e-11	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-9.22	-0.51	1.39e-17	Morning vs. evening chronotype;
KIRP	cis	rs77861329	0.748	rs749995	chr3:52176701	C/T	cg08692210	chr3:52188851	WDR51A	0.61	6.19	0.37	2.48e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.46	-5.85	-0.35	1.57e-8	Body mass index;
KIRP	trans	rs12570744	0.810	rs17141724	chr10:6797972	A/G	cg15089864	chr11:75946986	NA	0.67	6.08	0.36	4.51e-9	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg12131826	chr15:77904385	NA	0.44	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs7779181	1.000	rs10951331	chr7:32354374	A/G	cg13207630	chr7:32358064	NA	0.42	5.11	0.31	6.52e-7	Body mass index;
KIRP	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18596952	chr19:50354230	PTOV1	0.5	6.26	0.37	1.69e-9	Parkinson's disease;
KIRP	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg23307798	chr14:103986281	CKB	0.73	12.03	0.61	1.65e-26	Body mass index;
KIRP	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.95e-8	Type 2 diabetes;
KIRP	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.57	-8.03	-0.46	3.98e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg00792783	chr2:198669748	PLCL1	0.45	5.05	0.31	8.78e-7	Dermatomyositis;
KIRP	cis	rs4658101	0.774	rs11165008	chr1:92050615	T/C	cg09075522	chr1:92031145	NA	0.45	5.57	0.33	6.83e-8	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	5.5	0.33	9.59e-8	Myopia (pathological);
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.75	0.34	2.7e-8	Lung cancer;
KIRP	cis	rs4006360	0.547	rs9892487	chr17:39252969	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.64	-0.52	7.21e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg07741184	chr6:167504864	NA	-0.24	-6.45	-0.38	5.8e-10	Crohn's disease;
KIRP	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.89	-9.46	-0.52	2.56e-18	Systolic blood pressure;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.65	6.19	0.37	2.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.99	14.0	0.67	3.7e-33	Cognitive function;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg05562828	chr17:3906858	NA	0.8	17.25	0.74	3.12e-44	Type 2 diabetes;
KIRP	cis	rs2479106	0.791	rs4838083	chr9:126714308	A/C	cg16191174	chr9:126692580	DENND1A	-0.39	-4.9	-0.3	1.77e-6	Polycystic ovary syndrome;
KIRP	cis	rs1881396	0.945	rs62141291	chr2:27784034	C/T	cg27432699	chr2:27873401	GPN1	0.55	6.14	0.36	3.26e-9	Nonalcoholic fatty liver disease;
KIRP	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg18357526	chr6:26021779	HIST1H4A	0.39	4.95	0.3	1.38e-6	Height;
KIRP	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.41	-5.01	-0.3	1.06e-6	Neurofibrillary tangles;
KIRP	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg10223061	chr2:219282414	VIL1	0.31	5.01	0.3	1.06e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.44	5.04	0.31	8.99e-7	Schizophrenia;
KIRP	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	cg04338863	chr8:33670619	NA	0.5	6.74	0.39	1.15e-10	Body mass index;
KIRP	cis	rs7202877	0.610	rs1010631	chr16:75328590	C/G	cg03315344	chr16:75512273	CHST6	0.57	5.44	0.33	1.27e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.61	-9.03	-0.5	5.29e-17	Caffeine consumption;
KIRP	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg27147174	chr7:100797783	AP1S1	-0.54	-6.86	-0.4	5.57e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21576300	chr4:124107741	SPATA5	-0.47	-7.63	-0.44	5.05e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07167872	chr1:205819463	PM20D1	-0.48	-5.56	-0.33	7.13e-8	Parkinson's disease;
KIRP	cis	rs7011507	1.000	rs11995012	chr8:49117497	G/A	cg15325961	chr8:49183143	NA	0.61	5.15	0.31	5.27e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.6	-9.54	-0.52	1.49e-18	Prostate cancer;
KIRP	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg07777115	chr5:623756	CEP72	-0.53	-5.73	-0.34	2.91e-8	Obesity-related traits;
KIRP	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.55	7.89	0.45	9.8e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.65	7.5	0.43	1.13e-12	Corneal astigmatism;
KIRP	cis	rs2014572	0.870	rs10426580	chr19:57756221	G/A	cg24459738	chr19:57751996	ZNF805	-0.56	-7.03	-0.41	2.08e-11	Hyperactive-impulsive symptoms;
KIRP	cis	rs6723108	0.515	rs4954179	chr2:135557737	A/G	cg12500956	chr2:135428796	TMEM163	0.42	5.28	0.32	2.86e-7	Type 2 diabetes;
KIRP	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg20469991	chr17:27169893	C17orf63	-0.51	-5.28	-0.32	2.82e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs9534288	0.659	rs2146882	chr13:46668111	A/G	cg15192986	chr13:46630673	CPB2	-0.64	-7.85	-0.45	1.31e-13	Blood protein levels;
KIRP	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-6.93	-0.4	3.59e-11	Bone mineral density;
KIRP	cis	rs675026	0.963	rs581439	chr6:154447392	T/C	cg07813322	chr6:154414604	OPRM1	-0.55	-6.82	-0.4	7.1e-11	Hypertension;
KIRP	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg16586182	chr3:47516702	SCAP	0.81	11.58	0.59	4.94e-25	Colorectal cancer;
KIRP	cis	rs3733418	0.858	rs11100583	chr4:165877645	C/G	cg10852876	chr4:165953100	TRIM60	-0.51	-5.46	-0.33	1.16e-7	Obesity-related traits;
KIRP	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg11608241	chr8:8085544	FLJ10661	0.48	6.53	0.38	3.72e-10	Acne (severe);
KIRP	cis	rs7851660	0.809	rs12006522	chr9:100652711	G/C	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-7.93	-0.45	7.62e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.66	7.94	0.45	7.16e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg00204512	chr16:28754710	NA	-0.41	-5.22	-0.32	3.74e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7546094	1.000	rs12728001	chr1:113076756	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.55	0.39	3.34e-10	Platelet distribution width;
KIRP	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.56	8.02	0.46	4.22e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg25142954	chr15:41245554	CHAC1	0.91	6.23	0.37	1.97e-9	P wave terminal force;
KIRP	cis	rs2278796	0.639	rs11240331	chr1:204968339	C/T	cg17449235	chr1:204966235	NFASC	0.57	7.83	0.45	1.46e-13	Mean platelet volume;
KIRP	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.79	-10.05	-0.54	4.01e-20	Blood trace element (Zn levels);
KIRP	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg01710450	chr16:89662404	CPNE7	-0.63	-8.75	-0.49	3.39e-16	Tanning;
KIRP	cis	rs68170813	0.652	rs6947674	chr7:107193504	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-7.4	-0.43	2.18e-12	Coronary artery disease;
KIRP	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.6e-10	Morning vs. evening chronotype;
KIRP	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.65	8.36	0.47	4.53e-15	Alcohol dependence;
KIRP	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg22974920	chr21:40686053	BRWD1	-0.44	-5.15	-0.31	5.23e-7	Cognitive function;
KIRP	cis	rs10982256	0.777	rs7865843	chr9:117245960	A/G	cg13636371	chr9:117264095	DFNB31	-0.52	-7.24	-0.42	5.89e-12	Bipolar disorder;
KIRP	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.63	7.42	0.43	1.93e-12	Neutrophil percentage of white cells;
KIRP	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	cg12689670	chr1:183009347	LAMC1	0.45	6.31	0.37	1.31e-9	Hypertriglyceridemia;
KIRP	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.02	11.5	0.59	8.7e-25	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4849845	1.000	rs4849845	chr2:121013169	G/A	cg24070213	chr2:121070622	NA	0.39	5.28	0.32	2.81e-7	Mean platelet volume;
KIRP	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg04944784	chr2:26401820	FAM59B	-0.7	-7.6	-0.44	6.16e-13	Gut microbiome composition (summer);
KIRP	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.62	0.48	8.18e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.21	-23.6	-0.83	3.98e-65	Exhaled nitric oxide output;
KIRP	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.7	6.45	0.38	5.95e-10	Methadone dose in opioid dependence;
KIRP	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.95	10.38	0.55	3.49e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3737883	1.000	rs4950913	chr1:203032153	A/G	cg03900565	chr1:203031815	PPFIA4	0.4	5.76	0.34	2.52e-8	Early onset atrial fibrillation;
KIRP	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.4	-5.35	-0.32	2.01e-7	Menarche (age at onset);
KIRP	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.81e-7	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06334471	chr10:96305598	HELLS	0.49	6.07	0.36	4.7e-9	Parkinson's disease;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg23179321	chr10:15138793	C10orf111;RPP38	0.92	6.19	0.37	2.53e-9	P wave terminal force;
KIRP	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg15252951	chr6:33757062	LEMD2	0.46	5.54	0.33	7.57e-8	Crohn's disease;
KIRP	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg21734707	chr17:3908241	ZZEF1	0.44	5.02	0.3	1.01e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.57	-7.15	-0.41	9.95e-12	Height;
KIRP	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.79	7.7	0.44	3.33e-13	Menopause (age at onset);
KIRP	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.71	-0.34	3.26e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.61	8.84	0.49	1.83e-16	Immature fraction of reticulocytes;
KIRP	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg16586182	chr3:47516702	SCAP	-0.75	-10.62	-0.56	6.44e-22	Colorectal cancer;
KIRP	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.45	8.73	0.49	3.97e-16	Educational attainment (years of education);
KIRP	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.41	5.63	0.34	4.83e-8	Blood metabolite levels;
KIRP	cis	rs4148660	0.697	rs7308718	chr12:22039254	T/C	cg14669847	chr12:22099120	NA	-0.36	-5.93	-0.35	1.01e-8	Gout;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09273779	chr9:35605990	TESK1	0.6	7.22	0.42	6.54e-12	Smoking initiation;
KIRP	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg24253500	chr15:84953950	NA	0.54	6.17	0.37	2.75e-9	Schizophrenia;
KIRP	cis	rs253959	0.545	rs712592	chr5:115657381	G/C	cg23108291	chr5:115420582	COMMD10	-0.51	-5.69	-0.34	3.66e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9430161	0.611	rs12081181	chr1:11034165	T/G	cg02454025	chr1:11042201	C1orf127	0.91	14.97	0.69	1.92e-36	Ewing sarcoma;
KIRP	cis	rs3924048	0.574	rs11121931	chr1:12617009	G/A	cg00291366	chr1:12616550	NA	0.45	6.37	0.38	9.43e-10	Optic cup area;
KIRP	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	6.77	0.4	9.17e-11	Educational attainment;
KIRP	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.85	-11.55	-0.59	6.15e-25	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.95	0.66	5.8e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.32	4.93	0.3	1.54e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.83	10.42	0.55	2.79e-21	Lymphocyte percentage of white cells;
KIRP	cis	rs1062177	0.855	rs919262	chr5:151266084	C/T	cg00977110	chr5:151150581	G3BP1	-0.56	-5.86	-0.35	1.49e-8	Preschool internalizing problems;
KIRP	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.85	-12.27	-0.62	2.47e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7818345	0.935	rs6990217	chr8:19276661	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.29	0.37	1.41e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22168489	chr12:122356033	WDR66	0.61	9.24	0.51	1.22e-17	Mean corpuscular volume;
KIRP	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	10.48	0.56	1.74e-21	Personality dimensions;
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg02811702	chr13:24901961	NA	0.43	5.69	0.34	3.67e-8	Obesity-related traits;
KIRP	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs4262150	0.960	rs7713322	chr5:152278906	T/C	cg12297329	chr5:152029980	NA	0.45	6.16	0.37	2.97e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs5995756	0.736	rs5995755	chr22:39999013	A/G	cg03390717	chr22:39966585	CACNA1I	-0.29	-5.19	-0.31	4.36e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17554472	chr22:41940697	POLR3H	0.74	7.34	0.42	3.13e-12	Vitiligo;
KIRP	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg07843065	chr1:150265600	MRPS21	0.43	5.89	0.35	1.28e-8	Migraine;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg01834010	chr13:111365570	ING1	-0.56	-6.04	-0.36	5.67e-9	Response to statin therapy;
KIRP	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.41	-4.99	-0.3	1.13e-6	Schizophrenia;
KIRP	cis	rs7941030	0.934	rs7128198	chr11:122526601	C/T	cg20555462	chr11:122535518	UBASH3B	-0.45	-5.46	-0.33	1.19e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.49	-5.12	-0.31	6.29e-7	Obesity (extreme);
KIRP	cis	rs2387326	0.717	rs10829335	chr10:129943515	A/G	cg16087940	chr10:129947807	NA	-0.36	-5.01	-0.3	1.05e-6	Select biomarker traits;
KIRP	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg18944383	chr4:111397179	ENPEP	0.52	9.14	0.5	2.35e-17	Height;
KIRP	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.54	8.29	0.47	7.64e-15	Huntington's disease progression;
KIRP	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08280861	chr8:58055591	NA	0.72	5.96	0.36	8.8e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.54	-0.33	7.82e-8	Bladder cancer;
KIRP	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.63	0.56	5.95e-22	Lung cancer in ever smokers;
KIRP	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg19507638	chr5:93509721	C5orf36	-0.55	-5.02	-0.31	9.73e-7	Diabetic retinopathy;
KIRP	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.93	-10.8	-0.57	1.6e-22	Post bronchodilator FEV1;
KIRP	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg22705602	chr4:152727874	NA	-0.54	-9.39	-0.51	4.29e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.6	-9.77	-0.53	2.82e-19	Itch intensity from mosquito bite;
KIRP	cis	rs34779708	0.733	rs61449529	chr10:35543914	T/C	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.59	-0.52	1.04e-18	Neuroticism;
KIRP	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg12315302	chr6:26189340	HIST1H4D	0.74	5.18	0.31	4.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7707921	0.705	rs226194	chr5:81585026	G/T	cg07807695	chr5:81608485	ATP6AP1L	-0.45	-5.85	-0.35	1.53e-8	Breast cancer;
KIRP	cis	rs2346177	0.816	rs74179078	chr2:46654651	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-5.59	-0.34	5.98e-8	HDL cholesterol;
KIRP	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg17376030	chr22:41985996	PMM1	0.61	7.28	0.42	4.35e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	1.11	8.26	0.47	9.1e-15	Skin colour saturation;
KIRP	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.5	-0.33	9.43e-8	Parkinson's disease;
KIRP	cis	rs1355223	0.902	rs1361645	chr11:34746385	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.04	-0.31	9.15e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	7.52	0.43	1.02e-12	Eosinophil percentage of white cells;
KIRP	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg03929089	chr4:120376271	NA	0.69	6.11	0.36	3.84e-9	Axial length;
KIRP	trans	rs7246760	0.867	rs61580479	chr19:9782940	G/A	cg02900749	chr2:68251473	NA	-1.16	-9.53	-0.52	1.56e-18	Pursuit maintenance gain;
KIRP	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.58	8.86	0.49	1.62e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.89	-11.91	-0.6	4.03e-26	Cognitive function;
KIRP	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.48	-6.23	-0.37	1.98e-9	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg17554472	chr22:41940697	POLR3H	-0.6	-6.49	-0.38	4.57e-10	Vitiligo;
KIRP	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06544989	chr22:39130855	UNC84B	0.48	7.58	0.44	6.86e-13	Menopause (age at onset);
KIRP	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.61	-8.66	-0.48	6.49e-16	Menarche (age at onset);
KIRP	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.5	5.93	0.35	1.01e-8	Neurofibrillary tangles;
KIRP	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.02	0.46	4.21e-14	Coffee consumption (cups per day);
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg24874828	chr4:187887005	NA	-0.53	-8.28	-0.47	8.12e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.96	-12.37	-0.62	1.22e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.5	6.5	0.38	4.51e-10	HDL cholesterol levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04100724	chr12:92539208	BTG1	0.47	6.24	0.37	1.89e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs714027	1.000	rs5763767	chr22:30493882	G/A	cg27665648	chr22:30112403	NA	-0.41	-5.88	-0.35	1.36e-8	Lymphocyte counts;
KIRP	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg16584676	chr17:46985605	UBE2Z	0.47	5.76	0.34	2.51e-8	Type 2 diabetes;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.38	-0.55	3.54e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.24	-0.55	9.68e-21	Hypospadias;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08974500	chr6:170863287	PSMB1;TBP	0.55	6.34	0.37	1.1e-9	Smoking initiation;
KIRP	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.24	23.97	0.84	2.62e-66	Cognitive function;
KIRP	trans	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg02030672	chr11:45687055	CHST1	0.72	9.33	0.51	6.52e-18	Obesity-related traits;
KIRP	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20135002	chr11:47629003	NA	-0.48	-5.5	-0.33	9.73e-8	Subjective well-being;
KIRP	cis	rs6681460	0.834	rs1280310	chr1:67216823	T/A	cg13052034	chr1:66999238	SGIP1	-0.43	-5.98	-0.36	7.99e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.65	-0.48	6.81e-16	Mean corpuscular volume;
KIRP	cis	rs787274	1.000	rs4979148	chr9:115553399	C/T	cg13803584	chr9:115635662	SNX30	-0.74	-8.38	-0.47	4e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg01620082	chr3:125678407	NA	-1.03	-6.65	-0.39	1.84e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg23752985	chr2:85803571	VAMP8	0.63	9.57	0.52	1.23e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2120243	1.000	rs2120243	chr3:157147568	A/C	cg24825693	chr3:157122686	VEPH1	-0.33	-4.99	-0.3	1.12e-6	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs6504950	0.566	rs7226272	chr17:53046447	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.53	6.22	0.37	2.1e-9	Breast cancer;
KIRP	cis	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg08501292	chr6:25962987	TRIM38	0.91	6.45	0.38	5.82e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03487200	chr16:24580235	RBBP6	-0.45	-6.41	-0.38	7.2e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4889855	0.556	rs3923514	chr17:78515210	A/G	cg09596252	chr17:78655493	RPTOR	-0.44	-5.2	-0.31	4.15e-7	Fractional excretion of uric acid;
KIRP	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg01422370	chr2:73384389	NA	0.46	6.14	0.36	3.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	trans	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg16356956	chr22:37317934	CSF2RB	-0.45	-5.88	-0.35	1.32e-8	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
KIRP	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18252515	chr7:66147081	NA	-0.47	-5.57	-0.33	6.77e-8	Aortic root size;
KIRP	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.64	-7.81	-0.45	1.61e-13	Systemic lupus erythematosus;
KIRP	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs748404	0.697	rs493177	chr15:43543258	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.52	6.77	0.4	9.16e-11	Lung cancer;
KIRP	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.38	5.72	0.34	3.11e-8	Neuroticism;
KIRP	cis	rs6466055	0.661	rs6963661	chr7:104932821	G/A	cg04380332	chr7:105027541	SRPK2	0.36	4.89	0.3	1.8e-6	Schizophrenia;
KIRP	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg23422044	chr7:1970798	MAD1L1	-0.72	-6.74	-0.39	1.1e-10	Neuroticism;
KIRP	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.84	-10.71	-0.56	3.25e-22	Parkinson's disease;
KIRP	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg17554472	chr22:41940697	POLR3H	-0.7	-6.98	-0.41	2.79e-11	Vitiligo;
KIRP	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	7.09	0.41	1.38e-11	Mean platelet volume;
KIRP	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-5.69	-0.34	3.54e-8	Height;
KIRP	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.76	-11.04	-0.58	2.78e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.58	7.61	0.44	5.88e-13	Colorectal cancer;
KIRP	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg08603382	chr10:743973	NA	0.55	8.67	0.48	6.12e-16	Psychosis in Alzheimer's disease;
KIRP	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg13319975	chr6:146136371	FBXO30	0.38	5.12	0.31	6.13e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.73	-9.48	-0.52	2.24e-18	Coronary artery disease;
KIRP	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.96	0.61	2.65e-26	Monocyte percentage of white cells;
KIRP	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.95	-11.85	-0.6	6.28e-26	Diastolic blood pressure;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.67	9.27	0.51	9.85e-18	Mean corpuscular volume;
KIRP	cis	rs8070740	0.898	rs4578712	chr17:5324431	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.36	0.43	2.68e-12	Menopause (age at onset);
KIRP	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg19016782	chr12:123741754	C12orf65	0.4	4.99	0.3	1.17e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9815354	0.855	rs73071261	chr3:42003369	C/A	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg22800045	chr5:56110881	MAP3K1	0.68	7.37	0.43	2.58e-12	Initial pursuit acceleration;
KIRP	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	cg04338863	chr8:33670619	NA	0.38	4.99	0.3	1.16e-6	Body mass index;
KIRP	cis	rs2072732	0.808	rs74048148	chr1:2954031	A/G	cg11731671	chr1:2995604	PRDM16	-0.44	-5.63	-0.34	4.89e-8	Plateletcrit;
KIRP	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg23307798	chr14:103986281	CKB	0.51	6.76	0.4	9.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	8.31	0.47	6.64e-15	Bone mineral density;
KIRP	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.52	-5.9	-0.35	1.17e-8	Schizophrenia;
KIRP	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.44	-6.99	-0.41	2.62e-11	Testicular germ cell tumor;
KIRP	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.83	10.23	0.55	1.1e-20	Neutrophil percentage of white cells;
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.78	12.63	0.63	1.63e-28	Vitiligo;
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.43	-5.65	-0.34	4.51e-8	Testicular germ cell tumor;
KIRP	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.24	-0.32	3.45e-7	Calcium levels;
KIRP	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.67	-8.74	-0.49	3.59e-16	Calcium levels;
KIRP	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.71	10.81	0.57	1.53e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg25019033	chr10:957182	NA	0.53	5.62	0.34	5.03e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs6960043	0.818	rs10258074	chr7:15064216	A/T	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.66e-11	Type 2 diabetes;
KIRP	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.41	5.5	0.33	9.67e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg14784868	chr12:69753453	YEATS4	0.5	5.09	0.31	6.98e-7	Response to diuretic therapy;
KIRP	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.74	-0.34	2.83e-8	IgG glycosylation;
KIRP	cis	rs3120667	0.720	rs72698999	chr1:152452246	A/G	cg26876637	chr1:152193138	HRNR	-0.61	-5.34	-0.32	2.08e-7	Eating disorders;
KIRP	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg08662619	chr6:150070041	PCMT1	0.36	5.96	0.36	8.57e-9	Lung cancer;
KIRP	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	12.31	0.62	1.88e-27	Menarche (age at onset);
KIRP	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-10.77	-0.57	2.11e-22	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19863459	chr19:4639366	TNFAIP8L1	0.43	6.11	0.36	3.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg00631329	chr6:26305371	NA	-0.67	-8.32	-0.47	6.27e-15	Educational attainment;
KIRP	cis	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg00405596	chr8:11794950	NA	-0.49	-5.48	-0.33	1.04e-7	Sjögren's syndrome;Systemic lupus erythematosus;
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-1.07	-23.13	-0.83	1.18e-63	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.41	-5.13	-0.31	5.77e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4886920	0.855	rs4886526	chr15:78113421	C/T	cg10461261	chr15:78109450	NA	-0.33	-5.36	-0.32	1.91e-7	Neuroticism;
KIRP	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.46	-5.59	-0.34	5.93e-8	Testicular germ cell tumor;
KIRP	cis	rs228437	1.000	rs985122	chr6:134931300	A/G	cg24504307	chr6:134963096	NA	-0.53	-7.75	-0.44	2.49e-13	Melanoma;
KIRP	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.84	10.18	0.54	1.54e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07570687	chr10:102243282	WNT8B	0.5	6.0	0.36	7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.57	-7.31	-0.42	3.64e-12	Aortic root size;
KIRP	cis	rs735539	0.521	rs7984503	chr13:21448486	T/C	cg04906043	chr13:21280425	IL17D	-0.42	-4.92	-0.3	1.57e-6	Dental caries;
KIRP	cis	rs6732160	0.593	rs2288630	chr2:73457552	C/T	cg01422370	chr2:73384389	NA	0.43	5.67	0.34	4.09e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1978968	0.717	rs34263881	chr22:18401597	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-5.88	-0.35	1.34e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs4690686	0.538	rs4690428	chr4:177263665	C/T	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs1971762	0.545	rs10783586	chr12:53980821	C/T	cg23533419	chr12:54090519	NA	-0.33	-5.29	-0.32	2.66e-7	Height;
KIRP	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.9	0.3	1.77e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg08992911	chr2:238395768	MLPH	0.41	5.14	0.31	5.65e-7	Prostate cancer;
KIRP	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.45	-0.47	2.65e-15	Total cholesterol levels;
KIRP	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	7.5	0.43	1.17e-12	Caffeine consumption;
KIRP	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg19338460	chr6:170058176	WDR27	-0.71	-8.26	-0.47	9.1e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg26513180	chr16:89883248	FANCA	-0.75	-5.35	-0.32	1.97e-7	Skin colour saturation;
KIRP	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.54	7.28	0.42	4.45e-12	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	1.0	17.32	0.74	1.8e-44	Breast cancer;
KIRP	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06544989	chr22:39130855	UNC84B	0.47	7.89	0.45	9.79e-14	Menopause (age at onset);
KIRP	cis	rs12230513	0.732	rs4318592	chr12:55837124	C/A	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.84	-0.49	1.83e-16	Mean corpuscular volume;
KIRP	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.58	7.1	0.41	1.33e-11	Obesity-related traits;
KIRP	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg24531977	chr5:56204891	C5orf35	-0.41	-5.1	-0.31	6.82e-7	Coronary artery disease;
KIRP	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.37	4.9	0.3	1.77e-6	Dupuytren's disease;
KIRP	cis	rs9938149	0.767	rs58577366	chr16:88323323	T/C	cg05435882	chr16:88311214	NA	0.45	5.16	0.31	5.1e-7	Corneal structure;Central corneal thickness;
KIRP	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.66	-5.6	-0.34	5.82e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs796825	0.530	rs1492272	chr3:119962322	G/C	cg21790991	chr3:120137480	FSTL1	-0.29	-4.99	-0.3	1.15e-6	HIV-1 susceptibility;
KIRP	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.82	-0.4	6.86e-11	Triglycerides;
KIRP	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg16584676	chr17:46985605	UBE2Z	0.47	5.86	0.35	1.48e-8	Type 2 diabetes;
KIRP	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg17507749	chr15:85114479	UBE2QP1	0.86	9.88	0.53	1.33e-19	Schizophrenia;
KIRP	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs12534701	1.000	rs13232266	chr7:154681363	A/T	cg24255201	chr7:154684926	DPP6	0.61	8.77	0.49	2.97e-16	Colorectal cancer (diet interaction);
KIRP	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg19442545	chr10:75533431	FUT11	-0.38	-5.04	-0.31	9.04e-7	Inflammatory bowel disease;
KIRP	cis	rs6016377	0.689	rs6029183	chr20:39181070	C/G	cg22477343	chr20:39312069	NA	0.49	6.29	0.37	1.48e-9	Birth weight;
KIRP	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17554472	chr22:41940697	POLR3H	0.71	7.15	0.41	9.81e-12	Vitiligo;
KIRP	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.49	-0.48	2e-15	Coronary artery disease;
KIRP	cis	rs4561483	0.583	rs12149833	chr16:12003723	C/T	cg08843971	chr16:11963173	GSPT1	0.53	7.54	0.43	9.09e-13	Testicular germ cell tumor;
KIRP	cis	rs2279817	0.775	rs35493100	chr1:17993120	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.69	-8.4	-0.47	3.49e-15	Neuroticism;
KIRP	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.63	7.82	0.45	1.5700000000000001e-13	Multiple sclerosis;
KIRP	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg22437258	chr11:111473054	SIK2	0.62	7.53	0.43	9.74e-13	Primary sclerosing cholangitis;
KIRP	cis	rs365132	1.000	rs35977534	chr5:176335231	T/C	cg16309518	chr5:176445507	NA	-0.89	-14.15	-0.67	1.19e-33	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg03788504	chr6:150331562	NA	-0.36	-6.63	-0.39	2.14e-10	Alopecia areata;
KIRP	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.56	7.28	0.42	4.59e-12	Obesity-related traits;
KIRP	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.31	5.04	0.31	9.04e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.44	-5.53	-0.33	8.01e-8	Testicular germ cell tumor;
KIRP	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	6.75	0.4	1.07e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-12.76	-0.63	6.02e-29	Exhaled nitric oxide output;
KIRP	cis	rs712039	0.652	rs34711199	chr17:35858039	C/T	cg16670864	chr17:35848621	DUSP14	0.43	5.41	0.33	1.5e-7	Tuberculosis;
KIRP	cis	rs12220238	0.841	rs12098284	chr10:76047464	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	6.07	0.36	4.84e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg13482628	chr17:19912719	NA	-0.51	-6.79	-0.4	8.42e-11	Schizophrenia;
KIRP	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-1.09	-14.46	-0.68	9.91e-35	Alopecia areata;
KIRP	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	1.1	14.41	0.68	1.55e-34	Post bronchodilator FEV1;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg06074448	chr4:187884817	NA	-0.8	-14.3	-0.67	3.65e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg15896084	chr13:114927664	NA	0.45	6.42	0.38	7.13e-10	Schizophrenia;
KIRP	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-9.1	-0.5	3.07e-17	Neuroticism;
KIRP	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg13615516	chr5:77269221	NA	0.5	7.69	0.44	3.47e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	1.01	10.02	0.54	4.84e-20	Psoriasis;
KIRP	cis	rs1978968	1.000	rs5992135	chr22:18447114	C/T	cg03078520	chr22:18463400	MICAL3	-0.64	-7.61	-0.44	5.68e-13	Presence of antiphospholipid antibodies;
KIRP	trans	rs6601327	0.775	rs12156017	chr8:9406837	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.8	-0.4	7.97e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4908768	0.911	rs12121933	chr1:8777081	A/T	cg25722041	chr1:8623473	RERE	0.53	7.03	0.41	2e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.76	-12.5	-0.62	4.31e-28	Calcium levels;
KIRP	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs220324	0.954	rs467479	chr21:43592910	G/C	cg08841829	chr21:43638893	ABCG1	0.45	4.99	0.3	1.13e-6	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs3736485	0.966	rs28376817	chr15:51889280	A/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.03	-0.31	9.33e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.65	-10.03	-0.54	4.57e-20	Total body bone mineral density;
KIRP	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.62	0.34	5.12e-8	Coronary artery disease;
KIRP	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg21926883	chr2:100939477	LONRF2	-0.56	-7.9	-0.45	9.14e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.56	-4.87	-0.3	1.97e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs16912285	0.688	rs11827298	chr11:24324000	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	8.67	0.48	5.77e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.48	6.81	0.4	7.49e-11	Schizophrenia;
KIRP	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.68	8.23	0.46	1.11e-14	Post bronchodilator FEV1;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14335767	chr8:124286570	ZHX1	-0.6	-7.18	-0.42	8.37e-12	Interleukin-4 levels;
KIRP	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.58	6.87	0.4	5.38e-11	Aortic root size;
KIRP	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.52	-6.19	-0.37	2.51e-9	Diastolic blood pressure;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg17294928	chr15:75287854	SCAMP5	0.57	7.68	0.44	3.86e-13	Breast cancer;
KIRP	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg17554472	chr22:41940697	POLR3H	0.64	6.21	0.37	2.25e-9	Vitiligo;
KIRP	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.38	0.55	3.66e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-5.28	-0.32	2.86e-7	Cardiac Troponin-T levels;
KIRP	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg00864860	chr1:7907996	UTS2	-0.51	-6.03	-0.36	6.12e-9	Crohn's disease;
KIRP	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.9	14.25	0.67	5.4e-34	Coronary artery disease;
KIRP	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.66	9.91	0.53	1.04e-19	Prostate cancer;
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-7.11	-0.41	1.26e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg16068336	chr17:48637367	CACNA1G	-0.41	-5.36	-0.32	1.88e-7	Type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-9.72	-0.53	4.25e-19	Hemoglobin concentration;
KIRP	trans	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg24644049	chr4:85504048	CDS1	0.98	6.32	0.37	1.19e-9	Skin colour saturation;
KIRP	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.97	-0.3	1.25e-6	Blood metabolite levels;
KIRP	cis	rs2073499	1.000	rs79499880	chr3:50259551	A/G	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.61	4.95	0.3	1.37e-6	Schizophrenia;
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.46	6.17	0.37	2.81e-9	Vitiligo;
KIRP	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.33	-0.51	6.45e-18	Neuroticism;
KIRP	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg26338869	chr17:61819248	STRADA	0.54	6.31	0.37	1.32e-9	Prudent dietary pattern;
KIRP	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.38	-5.63	-0.34	4.95e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2790457	0.792	rs1265841	chr10:28920701	A/T	cg04045419	chr10:28823091	WAC	-0.44	-5.01	-0.3	1.04e-6	Multiple myeloma;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg23522862	chr17:79829415	ARHGDIA	0.83	7.14	0.41	1.08e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.54	-6.59	-0.39	2.65e-10	Colorectal cancer;
KIRP	cis	rs9826463	1.000	rs6440096	chr3:142331360	A/G	cg20824294	chr3:142316082	PLS1	0.33	5.78	0.35	2.28e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg05347473	chr6:146136440	FBXO30	0.56	7.76	0.44	2.25e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg04370829	chr17:406249	NA	-0.39	-5.05	-0.31	8.44e-7	Prostate cancer;
KIRP	cis	rs2033732	0.706	rs6473527	chr8:85070610	C/T	cg05716166	chr8:85095498	RALYL	0.52	5.96	0.36	8.53e-9	Body mass index;
KIRP	cis	rs7011049	0.778	rs72648430	chr8:53872396	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs1978968	1.000	rs11704733	chr22:18446212	T/G	cg03078520	chr22:18463400	MICAL3	-0.65	-7.68	-0.44	3.81e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs2457480	0.778	rs11238933	chr10:44714250	C/G	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;
KIRP	cis	rs4656940	0.550	rs6427544	chr1:160760201	G/A	cg17331569	chr1:160788135	LY9	-0.51	-6.12	-0.36	3.76e-9	Crohn's disease;
KIRP	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.63	6.61	0.39	2.3e-10	Gut microbiome composition (summer);
KIRP	trans	rs688034	0.583	rs137206	chr22:26690561	A/G	cg04699474	chr19:9945708	PIN1	0.43	6.02	0.36	6.47e-9	Coronary heart disease;
KIRP	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-0.83	-9.79	-0.53	2.5e-19	Gut microbiome composition (summer);
KIRP	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg19847866	chr10:1019161	NA	-0.61	-5.59	-0.34	6.17e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg21573476	chr21:45109991	RRP1B	-0.62	-8.51	-0.48	1.71e-15	Mean corpuscular volume;
KIRP	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg08499158	chr17:42289980	UBTF	-0.63	-8.1	-0.46	2.58e-14	Total body bone mineral density;
KIRP	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg00360474	chr6:37504404	NA	-0.47	-6.68	-0.39	1.58e-10	Cognitive performance;
KIRP	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.52	5.78	0.35	2.23e-8	Glomerular filtration rate (creatinine);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14509581	chr15:68522181	CLN6	0.46	6.37	0.38	9.44e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.76	11.3	0.58	4.02e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs490234	0.702	rs3814129	chr9:128365953	A/G	cg14078157	chr9:128172775	NA	-0.52	-6.26	-0.37	1.66e-9	Mean arterial pressure;
KIRP	cis	rs4953911	0.573	rs935474	chr2:135079978	A/C	cg18482303	chr2:135041380	MGAT5	-0.26	-4.87	-0.3	2.02e-6	Multiple sclerosis (severity);
KIRP	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.03e-8	Motion sickness;
KIRP	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg09231725	chr11:64357281	SLC22A12	-0.52	-5.91	-0.35	1.13e-8	Body mass index;Urate levels;
KIRP	cis	rs7520050	0.966	rs4073846	chr1:46462881	C/T	cg03146154	chr1:46216737	IPP	0.43	5.46	0.33	1.17e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7113874	1.000	rs11042018	chr11:8649707	A/C	cg08015107	chr11:8618950	NA	0.35	4.96	0.3	1.31e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg16989719	chr2:238392110	NA	-0.56	-7.7	-0.44	3.36e-13	Prostate cancer;
KIRP	cis	rs4888378	0.535	rs9319483	chr16:75345791	T/C	cg03315344	chr16:75512273	CHST6	-0.4	-5.02	-0.3	9.9e-7	Coronary artery disease;
KIRP	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg12560992	chr17:57184187	TRIM37	0.63	5.66	0.34	4.22e-8	Cognitive test performance;
KIRP	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg26174226	chr8:58114915	NA	-0.63	-7.43	-0.43	1.79e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs526231	0.543	rs62362884	chr5:102567455	G/A	cg23492399	chr5:102201601	PAM	-0.48	-5.1	-0.31	6.8e-7	Primary biliary cholangitis;
KIRP	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	0.97	12.77	0.63	5.65e-29	Breast cancer;
KIRP	cis	rs4430311	1.000	rs3008659	chr1:244023962	G/C	cg25706552	chr1:244017396	NA	-0.58	-9.27	-0.51	9.58e-18	Post-traumatic stress disorder (asjusted for relatedness);
KIRP	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg00094735	chr5:1949198	NA	-0.48	-5.78	-0.35	2.24e-8	Gut microbiome composition (winter);
KIRP	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.44	-6.89	-0.4	4.62e-11	Fractional excretion of uric acid;
KIRP	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg07274523	chr3:49395745	GPX1	0.69	8.55	0.48	1.28e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs748404	0.650	rs518261	chr15:43573429	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.33	0.42	3.35e-12	Lung cancer;
KIRP	cis	rs6973256	0.568	rs7783019	chr7:133347347	A/G	cg10665199	chr7:133106180	EXOC4	-0.49	-6.25	-0.37	1.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs17453880	0.929	rs12517065	chr5:152054583	A/T	cg12297329	chr5:152029980	NA	0.68	9.99	0.54	6.19e-20	Subjective well-being;
KIRP	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.8	-11.47	-0.59	1.09e-24	Body mass index (adult);
KIRP	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg06781948	chr3:72941472	GXYLT2	0.47	6.18	0.37	2.64e-9	Motion sickness;
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg12692727	chr7:1102344	C7orf50	0.45	5.0	0.3	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg08992911	chr2:238395768	MLPH	0.55	5.23	0.32	3.54e-7	Prostate cancer;
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.82	0.35	1.81e-8	Lung cancer;
KIRP	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.98	-16.36	-0.72	3.24e-41	Bone mineral density;
KIRP	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg10189774	chr4:17578691	LAP3	0.45	5.31	0.32	2.48e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg02297831	chr4:17616191	MED28	0.58	7.36	0.43	2.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg18882449	chr10:104885122	NT5C2	-0.51	-6.61	-0.39	2.43e-10	Arsenic metabolism;
KIRP	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg03563238	chr19:33554763	RHPN2	0.32	5.67	0.34	4.08e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10128264	0.902	rs1250588	chr10:80980169	T/C	cg20744163	chr10:80999841	ZMIZ1	-0.33	-5.57	-0.33	6.53e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg07395648	chr5:131743802	NA	0.55	7.7	0.44	3.33e-13	Breast cancer;
KIRP	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23161317	chr6:28129485	ZNF389	0.46	5.34	0.32	2.15e-7	Depression;
KIRP	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.2	0.37	2.42e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14893161	chr1:205819251	PM20D1	0.46	5.13	0.31	5.84e-7	Parkinson's disease;
KIRP	trans	rs193541	0.530	rs2125857	chr5:122083156	G/A	cg05232207	chr8:969542	NA	-0.55	-6.11	-0.36	3.97e-9	Glucose homeostasis traits;
KIRP	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.86	11.6	0.59	4.12e-25	Menarche (age at onset);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg17522907	chr19:571416	BSG	-0.41	-6.29	-0.37	1.47e-9	Warfarin maintenance dose;
KIRP	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg19197139	chr17:4613644	ARRB2	0.72	7.52	0.43	1.02e-12	Lymphocyte counts;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13150344	chr11:67889062	CHKA	0.5	6.33	0.37	1.14e-9	Myopia (pathological);
KIRP	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.67	9.19	0.51	1.74e-17	Lymphocyte counts;
KIRP	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-1.03	-11.87	-0.6	5.52e-26	Vitiligo;
KIRP	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg07274523	chr3:49395745	GPX1	0.69	8.62	0.48	8.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.92	9.28	0.51	9.06e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg24579218	chr15:68104479	NA	-0.52	-7.62	-0.44	5.62e-13	Restless legs syndrome;
KIRP	trans	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg25214090	chr10:38739885	LOC399744	0.63	7.44	0.43	1.67e-12	Educational attainment;
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.47	5.78	0.35	2.29e-8	Longevity;
KIRP	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg14673194	chr17:80132900	CCDC57	0.76	8.48	0.48	2.06e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.75	-12.17	-0.61	5.36e-27	Vitiligo;
KIRP	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg19575753	chr5:1948995	NA	-0.55	-6.39	-0.38	8.47e-10	Gut microbiome composition (winter);
KIRP	cis	rs5753037	0.585	rs249396	chr22:30213972	T/G	cg01021169	chr22:30184971	ASCC2	-0.49	-6.83	-0.4	6.67e-11	Type 1 diabetes;
KIRP	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg26207909	chr14:103986467	CKB	-0.48	-6.16	-0.37	2.93e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg13319975	chr6:146136371	FBXO30	-0.41	-5.7	-0.34	3.42e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.79	10.9	0.57	7.97e-23	Aortic root size;
KIRP	cis	rs9534288	0.912	rs9534297	chr13:46624630	T/C	cg15192986	chr13:46630673	CPB2	-0.83	-10.14	-0.54	2.09e-20	Blood protein levels;
KIRP	cis	rs7635838	0.892	rs9814907	chr3:11438645	G/A	cg00170343	chr3:11313890	ATG7	0.45	5.68	0.34	3.73e-8	HDL cholesterol;
KIRP	cis	rs4888378	0.576	rs8050367	chr16:75313258	A/G	cg03315344	chr16:75512273	CHST6	-0.42	-4.93	-0.3	1.5e-6	Coronary artery disease;
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.59	7.42	0.43	1.87e-12	Longevity;Endometriosis;
KIRP	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.68	0.39	1.59e-10	Educational attainment;
KIRP	cis	rs9831754	0.756	rs1512476	chr3:78434219	G/A	cg06138941	chr3:78371609	NA	-0.8	-11.33	-0.59	3.14e-24	Calcium levels;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg22907277	chr7:1156413	C7orf50	0.54	6.78	0.4	8.61e-11	Longevity;Endometriosis;
KIRP	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.98	12.89	0.63	2.16e-29	Homoarginine levels;
KIRP	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	8.0	0.45	4.78e-14	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg15507776	chr3:136538369	TMEM22	0.39	5.29	0.32	2.69e-7	Neuroticism;
KIRP	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.45	5.01	0.3	1.03e-6	Parkinson's disease;
KIRP	trans	rs7479949	0.731	rs12283611	chr11:83487277	C/A	cg05583831	chr3:27772705	NA	-0.41	-6.14	-0.36	3.36e-9	Parkinson's disease;
KIRP	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.74	11.7	0.6	1.95e-25	Resting heart rate;
KIRP	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.67	6.67	0.39	1.66e-10	Bronchopulmonary dysplasia;
KIRP	trans	rs1859156	0.767	rs13120952	chr4:95856752	G/A	cg24204951	chr2:239172084	PER2	0.3	6.15	0.37	3.11e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.73	-8.1	-0.46	2.49e-14	Menarche (age at onset);
KIRP	cis	rs4356932	1.000	rs6844097	chr4:76950757	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs1847505	0.663	rs8002365	chr13:61589772	A/G	cg25164009	chr13:61490935	NA	0.57	6.82	0.4	7.06e-11	Polychlorinated biphenyl levels;
KIRP	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	6.36	0.38	9.76e-10	Educational attainment;
KIRP	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.77	-11.4	-0.59	1.94e-24	Heart rate;
KIRP	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	8.94	0.5	9.34e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.71	-0.49	4.52e-16	Total cholesterol levels;
KIRP	cis	rs10073892	1.000	rs10055353	chr5:101699526	G/T	cg19774478	chr5:101632501	SLCO4C1	0.65	7.14	0.41	1.04e-11	Cognitive decline (age-related);
KIRP	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.87	13.68	0.66	4.48e-32	Ulcerative colitis;
KIRP	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg10047753	chr17:41438598	NA	1.12	17.92	0.75	1.57e-46	Menopause (age at onset);
KIRP	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg13010199	chr12:38710504	ALG10B	0.62	7.75	0.44	2.48e-13	Morning vs. evening chronotype;
KIRP	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.59	8.06	0.46	3.39e-14	Longevity;Endometriosis;
KIRP	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.49	-6.96	-0.41	2.99e-11	Blood metabolite levels;
KIRP	cis	rs9473924	0.632	rs9473937	chr6:50870306	C/T	cg03432817	chr6:50765336	NA	0.34	5.37	0.32	1.81e-7	Body mass index;
KIRP	cis	rs981844	1.000	rs2606325	chr4:154652681	C/T	cg14289246	chr4:154710475	SFRP2	0.65	7.04	0.41	1.89e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.53	9.26	0.51	1.08e-17	Vitiligo;
KIRP	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.69	9.19	0.51	1.67e-17	Personality dimensions;
KIRP	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11987759	chr7:65425863	GUSB	0.47	6.02	0.36	6.33e-9	Aortic root size;
KIRP	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.25	-0.55	9.11e-21	Hypospadias;
KIRP	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.84	11.08	0.58	2.09e-23	Coronary artery disease or large artery stroke;
KIRP	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.99e-31	Eye color traits;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10323490	chr2:88469007	THNSL2	-0.44	-6.1	-0.36	4.09e-9	Inflammatory biomarkers;
KIRP	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg00792783	chr2:198669748	PLCL1	0.47	5.28	0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.86e-15	Prudent dietary pattern;
KIRP	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.51	-6.69	-0.39	1.51e-10	Multiple sclerosis;
KIRP	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.52	-5.41	-0.33	1.52e-7	Corneal structure;
KIRP	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.47	5.83	0.35	1.75e-8	Height;
KIRP	cis	rs9815354	0.953	rs1717034	chr3:41955913	A/G	cg03022575	chr3:42003672	ULK4	-0.5	-5.81	-0.35	1.93e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg22563815	chr15:78856949	CHRNA5	0.47	7.44	0.43	1.71e-12	Sudden cardiac arrest;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.33e-13	Life satisfaction;
KIRP	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.95	-0.4	3.35e-11	Type 2 diabetes;
KIRP	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.6	-6.57	-0.39	2.92e-10	Aortic root size;
KIRP	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.35	-5.12	-0.31	6.24e-7	Educational attainment;
KIRP	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg02390115	chr1:21767211	NBPF3	0.51	6.77	0.4	9.22e-11	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg08738300	chr3:44038990	NA	0.68	9.63	0.52	7.95e-19	Coronary artery disease;
KIRP	cis	rs2594989	0.943	rs9877694	chr3:11418873	A/C	cg01796438	chr3:11312864	ATG7	-0.56	-7.27	-0.42	4.63e-12	Circulating chemerin levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06665941	chr21:34602869	IFNAR2	0.52	6.25	0.37	1.82e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.97	12.58	0.63	2.39e-28	Homoarginine levels;
KIRP	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.4	-5.61	-0.34	5.56e-8	Blood metabolite levels;
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.5	-0.33	9.66e-8	Lung cancer;
KIRP	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.58	4.91	0.3	1.67e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.63	-7.34	-0.42	3.17e-12	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-7.72	-0.44	2.89e-13	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7274811	0.652	rs291672	chr20:31951168	G/A	cg14921437	chr20:32255988	NECAB3;C20orf134	0.42	4.96	0.3	1.3e-6	Height;
KIRP	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17376030	chr22:41985996	PMM1	-0.83	-8.85	-0.49	1.78e-16	Vitiligo;
KIRP	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg02012338	chr4:187126139	CYP4V2	0.6	5.45	0.33	1.24e-7	Blood protein levels;
KIRP	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg22089800	chr15:90895588	ZNF774	0.42	4.95	0.3	1.38e-6	Rheumatoid arthritis;
KIRP	cis	rs7721647	0.853	rs6863217	chr5:90867259	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.41	5.04	0.31	8.88e-7	Breast cancer;
KIRP	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.38	6.53	0.38	3.81e-10	Heart rate;
KIRP	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-6.44	-0.38	6.15e-10	Aortic root size;
KIRP	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg21573476	chr21:45109991	RRP1B	-0.67	-10.02	-0.54	4.74e-20	Mean corpuscular volume;
KIRP	cis	rs11203032	0.901	rs7098394	chr10:90960906	T/A	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs73200209	0.744	rs61937389	chr12:116723951	G/T	cg01776926	chr12:116560359	MED13L	-0.54	-5.78	-0.35	2.25e-8	Total body bone mineral density;
KIRP	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg19507638	chr5:93509721	C5orf36	-0.59	-5.07	-0.31	7.92e-7	Diabetic retinopathy;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs7258465	1.000	rs4808136	chr19:18618867	A/G	cg10790698	chr19:18539756	SSBP4	0.33	6.98	0.41	2.68e-11	Breast cancer;
KIRP	cis	rs7520050	0.966	rs785481	chr1:46554518	G/A	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.51	6.29	0.37	1.43e-9	Radiation response;
KIRP	trans	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg17401890	chr11:36426482	PRR5L	0.42	6.39	0.38	8.42e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg13798780	chr7:105162888	PUS7	0.65	5.99	0.36	7.22e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.07	0.72	3.3e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.74	10.84	0.57	1.2e-22	Gut microbiome composition (winter);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17790605	chr4:44451526	KCTD8	0.41	6.03	0.36	6.05e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.68	-9.14	-0.5	2.48e-17	Huntington's disease progression;
KIRP	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.92	12.31	0.62	1.9e-27	Coronary artery disease;
KIRP	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Parkinson's disease;
KIRP	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg19025524	chr12:109796872	NA	-0.57	-8.13	-0.46	2.1e-14	Neuroticism;
KIRP	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-7.41	-0.43	1.98e-12	Bipolar disorder;
KIRP	cis	rs7572644	0.640	rs6744348	chr2:28018025	A/C	cg27432699	chr2:27873401	GPN1	0.5	5.63	0.34	5.02e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.65e-9	Neuroticism;
KIRP	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.44	-6.14	-0.36	3.27e-9	Bone mineral density (spine);
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg08662619	chr6:150070041	PCMT1	0.38	6.39	0.38	8.22e-10	Lung cancer;
KIRP	cis	rs2404602	0.669	rs12911987	chr15:76953256	C/T	cg23625390	chr15:77176239	SCAPER	0.49	6.08	0.36	4.64e-9	Blood metabolite levels;
KIRP	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.53	0.52	1.59e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4006360	0.574	rs35944108	chr17:39238561	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	1.03e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs73195822	0.773	rs10849903	chr12:111112319	T/C	cg12870014	chr12:110450643	ANKRD13A	0.51	6.29	0.37	1.41e-9	Itch intensity from mosquito bite;
KIRP	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg27490568	chr2:178487706	NA	0.57	8.09	0.46	2.71e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg20999797	chr1:1681921	NA	0.53	8.29	0.47	7.44e-15	Body mass index;
KIRP	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.1e-9	Morning vs. evening chronotype;
KIRP	cis	rs1978968	1.000	rs5992926	chr22:18449876	A/G	cg02610425	chr22:18483192	MICAL3	0.37	5.09	0.31	7.21e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg23985595	chr17:80112537	CCDC57	0.36	5.39	0.33	1.63e-7	Life satisfaction;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg06235973	chr19:14183619	LOC113230	0.51	6.08	0.36	4.45e-9	Sleep duration;
KIRP	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.38	-4.89	-0.3	1.8e-6	Pancreatic cancer;
KIRP	trans	rs6572548	0.885	rs7156421	chr14:49622975	C/A	cg27110129	chr4:15683224	LOC285550	0.47	6.02	0.36	6.21e-9	Subjective well-being;
KIRP	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04374321	chr14:90722782	PSMC1	-0.88	-14.26	-0.67	4.94e-34	Mortality in heart failure;
KIRP	trans	rs13170463	0.579	rs11739022	chr5:8038624	C/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs12995491	0.698	rs34352413	chr2:88498754	T/G	cg04511125	chr2:88470314	THNSL2	-0.49	-6.09	-0.36	4.31e-9	Response to metformin (IC50);
KIRP	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg11895451	chr1:16533891	ARHGEF19	-0.5	-6.81	-0.4	7.22e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg02158880	chr13:53174818	NA	0.37	4.95	0.3	1.38e-6	Lewy body disease;
KIRP	trans	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg24644049	chr4:85504048	CDS1	0.95	6.29	0.37	1.44e-9	Skin colour saturation;
KIRP	cis	rs6256	1.000	rs10832063	chr11:13574634	T/C	cg11976911	chr11:13509032	NA	-0.6	-5.05	-0.31	8.46e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.7	10.44	0.55	2.33e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.87	-11.46	-0.59	1.16e-24	Type 2 diabetes;
KIRP	cis	rs35883536	0.868	rs2484535	chr1:101107748	C/T	cg06223162	chr1:101003688	GPR88	-0.32	-6.58	-0.39	2.79e-10	Monocyte count;
KIRP	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg08501292	chr6:25962987	TRIM38	1.01	7.73	0.44	2.69e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.25	0.37	1.75e-9	Mean platelet volume;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19732469	chr14:96968481	PAPOLA	0.47	6.06	0.36	5.05e-9	Myopia (pathological);
KIRP	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.77	-9.08	-0.5	3.52e-17	Blood metabolite levels;
KIRP	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.48	-5.7	-0.34	3.41e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg05973401	chr12:123451056	ABCB9	0.55	6.26	0.37	1.69e-9	Neutrophil percentage of white cells;
KIRP	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.28	0.55	7.46e-21	Total body bone mineral density;
KIRP	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg17420585	chr12:42539391	GXYLT1	-0.4	-5.47	-0.33	1.09e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg20673091	chr1:2541236	MMEL1	-0.74	-11.48	-0.59	1.02e-24	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06221861	chr7:100425075	EPHB4	0.47	6.63	0.39	2.17e-10	Parkinson's disease;
KIRP	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	14.58	0.68	3.99e-35	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2274273	0.662	rs2094436	chr14:55661495	C/G	cg04306507	chr14:55594613	LGALS3	0.42	5.58	0.34	6.18e-8	Protein biomarker;
KIRP	cis	rs17739167	0.550	rs11070354	chr15:42233211	C/T	cg20935245	chr15:42234343	EHD4	0.49	7.69	0.44	3.58e-13	Monocyte count;
KIRP	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg21926883	chr2:100939477	LONRF2	-0.56	-7.6	-0.44	6.23e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg00376283	chr12:123451042	ABCB9	-0.65	-7.06	-0.41	1.7e-11	Neutrophil percentage of white cells;
KIRP	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-8.44	-0.47	2.71e-15	Coronary artery disease;
KIRP	cis	rs7267005	0.661	rs74763238	chr20:34386034	T/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.36	0.38	1e-9	Mean platelet volume;
KIRP	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-4.87	-0.3	1.96e-6	Personality dimensions;
KIRP	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.65	-4.86	-0.3	2.13e-6	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs4356932	0.691	rs4859413	chr4:76898250	A/G	cg19388996	chr4:76862389	NAAA	-0.42	-5.27	-0.32	3.01e-7	Blood protein levels;
KIRP	cis	rs12367572	0.580	rs1495034	chr12:45414203	C/T	cg04608330	chr12:45269318	NELL2	-0.38	-5.22	-0.32	3.77e-7	Gut microbiome composition (summer);
KIRP	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg03992096	chr13:114928177	NA	-0.39	-4.88	-0.3	1.93e-6	Schizophrenia;
KIRP	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.51	6.14	0.36	3.2e-9	Lymphocyte counts;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-0.67	-5.11	-0.31	6.58e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.791	rs13107606	chr4:98823187	C/A	cg05340658	chr4:99064831	C4orf37	0.58	7.08	0.41	1.51e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	cis	rs12220238	0.722	rs10740441	chr10:76410225	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.55	-5.92	-0.35	1.1e-8	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	9.66	0.52	6.22e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs4700695	1.000	rs4700695	chr5:65411710	G/T	cg21114390	chr5:65439923	SFRS12	-0.6	-5.71	-0.34	3.23e-8	Facial morphology (factor 19);
KIRP	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.72	8.44	0.47	2.77e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.47	7.24	0.42	5.74e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg26513180	chr16:89883248	FANCA	0.61	5.56	0.33	7.13e-8	Skin colour saturation;
KIRP	cis	rs4237845	0.591	rs3751326	chr12:58335330	C/G	cg02175503	chr12:58329896	NA	0.88	10.79	0.57	1.72e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs17095355	1.000	rs55728195	chr10:111715599	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.36	-0.32	1.92e-7	Biliary atresia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02145411	chr1:110528025	AHCYL1	0.54	6.35	0.38	1.04e-9	Smoking initiation;
KIRP	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05220968	chr6:146057943	EPM2A	0.39	4.9	0.3	1.78e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11969893	0.737	rs1358758	chr6:101411891	T/C	cg12253828	chr6:101329408	ASCC3	0.98	7.66	0.44	4.14e-13	Economic and political preferences (immigration/crime);
KIRP	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.03	11.7	0.6	1.96e-25	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07824265	chr4:96469029	UNC5C	0.44	6.33	0.37	1.14e-9	Parkinson's disease;
KIRP	cis	rs3857536	0.904	rs9363544	chr6:66898799	C/T	cg07460842	chr6:66804631	NA	-0.38	-5.05	-0.31	8.44e-7	Blood trace element (Cu levels);
KIRP	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg27205649	chr11:78285834	NARS2	0.83	12.16	0.61	6.12e-27	Alzheimer's disease (survival time);
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg09695851	chr17:3907499	NA	0.83	15.25	0.7	2.09e-37	Type 2 diabetes;
KIRP	cis	rs9309473	0.847	rs4547554	chr2:73867862	G/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.4	-0.33	1.54e-7	Metabolite levels;
KIRP	trans	rs12517041	1.000	rs6898560	chr5:23312968	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.61e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg02105002	chr10:106028928	GSTO2	-0.58	-6.61	-0.39	2.42e-10	Menopause (age at onset);
KIRP	cis	rs829883	0.659	rs12366275	chr12:98920276	G/C	cg25150519	chr12:98850993	NA	-0.75	-9.04	-0.5	4.9e-17	Colorectal adenoma (advanced);
KIRP	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.68	-8.15	-0.46	1.86e-14	Height;
KIRP	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg16898833	chr6:26189333	HIST1H4D	0.68	4.9	0.3	1.73e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23544223	chr18:12777786	NA	0.78	6.5	0.38	4.39e-10	Inflammatory skin disease;
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14443515	chr22:38598875	MAFF	-0.46	-4.97	-0.3	1.23e-6	Menopause (age at onset);
KIRP	cis	rs3936840	0.539	rs11850701	chr14:102983857	G/A	cg18135206	chr14:102964638	TECPR2	0.48	5.59	0.34	6.15e-8	Plateletcrit;
KIRP	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.75	10.47	0.56	1.91e-21	Hemoglobin concentration;
KIRP	cis	rs897080	0.515	rs1067336	chr2:44625876	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.92	0.35	1.06e-8	Height;
KIRP	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.82	9.9	0.53	1.11e-19	Corneal astigmatism;
KIRP	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.75	0.44	2.47e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.4	5.35	0.32	2.06e-7	Homoarginine levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01241576	chr4:57973922	IGFBP7	-0.44	-6.25	-0.37	1.76e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	0.89	7.44	0.43	1.71e-12	Obesity-related traits;
KIRP	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg22676075	chr6:135203613	NA	0.49	6.95	0.41	3.3e-11	Red blood cell count;
KIRP	cis	rs1185460	1.000	rs15818	chr11:118952173	A/G	cg23280166	chr11:118938394	VPS11	0.57	6.73	0.39	1.17e-10	Coronary artery disease;
KIRP	cis	rs11628318	0.591	rs8010679	chr14:103155637	T/G	cg01864069	chr14:103024347	NA	0.44	5.41	0.33	1.46e-7	Platelet count;
KIRP	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.96	-13.0	-0.64	9.32e-30	Ulcerative colitis;
KIRP	cis	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg17788227	chr17:7347145	FGF11;CHRNB1	0.48	4.99	0.3	1.15e-6	Androgen levels;
KIRP	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg04691961	chr3:161091175	C3orf57	-0.58	-8.93	-0.49	1.05e-16	Morning vs. evening chronotype;
KIRP	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.54	-0.62	3.22e-28	Primary sclerosing cholangitis;
KIRP	cis	rs10861661	1.000	rs10861661	chr12:107174646	A/C	cg21360079	chr12:107162445	NA	-0.61	-7.38	-0.43	2.4e-12	Triglyceride levels;
KIRP	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg08795948	chr3:128337044	NA	0.49	6.12	0.36	3.68e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg08992911	chr2:238395768	MLPH	0.42	5.35	0.32	2e-7	Prostate cancer;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-7.96	-0.45	6.33e-14	Obesity-related traits;
KIRP	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.68	9.37	0.51	4.81e-18	Red blood cell count;
KIRP	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg00656387	chr3:40428638	ENTPD3	0.38	4.87	0.3	1.96e-6	Renal cell carcinoma;
KIRP	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg21545522	chr1:205238299	TMCC2	0.42	5.62	0.34	5.06e-8	Red blood cell count;
KIRP	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg23758822	chr17:41437982	NA	0.88	9.88	0.53	1.29e-19	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.69	9.12	0.5	2.77e-17	Motion sickness;
KIRP	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27415969	chr3:186500848	EIF4A2	0.53	6.07	0.36	4.72e-9	Smoking initiation;
KIRP	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-18.42	-0.76	3.25e-48	Height;
KIRP	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18252515	chr7:66147081	NA	0.43	5.05	0.31	8.64e-7	Aortic root size;
KIRP	cis	rs12476592	0.543	rs1446569	chr2:63818314	C/G	cg17519650	chr2:63277830	OTX1	-0.45	-5.04	-0.31	9.19e-7	Childhood ear infection;
KIRP	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg22974920	chr21:40686053	BRWD1	0.52	6.17	0.37	2.73e-9	Cognitive function;
KIRP	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.51	-7.13	-0.41	1.09e-11	Height;
KIRP	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.74	9.42	0.52	3.33e-18	Response to antipsychotic treatment;
KIRP	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.6	-6.11	-0.36	3.77e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg03060546	chr3:49711283	APEH	0.48	6.31	0.37	1.27e-9	Parkinson's disease;
KIRP	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg05791153	chr7:19748676	TWISTNB	0.69	6.16	0.37	2.87e-9	Thyroid stimulating hormone;
KIRP	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg11859384	chr17:80120422	CCDC57	-0.42	-5.4	-0.33	1.57e-7	Life satisfaction;
KIRP	cis	rs9634489	0.559	rs7998759	chr13:96940284	T/A	cg02571835	chr13:96230311	CLDN10	-0.34	-4.93	-0.3	1.52e-6	Body mass index;
KIRP	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg12173498	chr6:36355764	ETV7	0.32	5.2	0.31	4.19e-7	Platelet distribution width;
KIRP	cis	rs77861329	0.748	rs12629791	chr3:52175783	C/T	cg08692210	chr3:52188851	WDR51A	0.61	6.19	0.37	2.48e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs5498	0.933	rs12972990	chr19:10406431	T/G	cg10604476	chr19:10403908	ICAM5	0.36	5.62	0.34	5.2e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	Neuroticism;
KIRP	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22455342	chr2:225449267	CUL3	0.52	6.12	0.36	3.64e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg23479056	chr15:41276147	INO80	-0.43	-6.33	-0.37	1.16e-9	Menopause (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12092561	chr1:11538840	PTCHD2	-0.5	-6.12	-0.36	3.72e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.56	-7.61	-0.44	6e-13	Systolic blood pressure;
KIRP	cis	rs365132	0.517	rs3762974	chr5:176328336	G/A	cg16309518	chr5:176445507	NA	0.69	8.35	0.47	4.96e-15	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1620921	0.505	rs12214254	chr6:161195932	C/A	cg01280913	chr6:161186852	NA	-0.68	-9.51	-0.52	1.8e-18	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg14003231	chr6:33640908	ITPR3	0.3	5.4	0.33	1.6e-7	Plateletcrit;
KIRP	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6840360	0.692	rs4479686	chr4:152399324	C/T	cg22705602	chr4:152727874	NA	-0.36	-5.54	-0.33	7.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27297192	chr10:134578999	INPP5A	0.66	8.08	0.46	2.83e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.38	6.22	0.37	2.1e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg12826209	chr6:26865740	GUSBL1	0.73	4.95	0.3	1.35e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.5	7.16	0.42	9.33e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.12	-0.31	6.27e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs42648	0.596	rs194518	chr7:89853149	G/A	cg25739043	chr7:89950458	NA	-0.43	-6.91	-0.4	4.22e-11	Homocysteine levels;
KIRP	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.92	7.57	0.43	7.5e-13	Major depressive disorder;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02749984	chr4:141418478	NA	-0.42	-6.21	-0.37	2.28e-9	Select biomarker traits;
KIRP	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg04374321	chr14:90722782	PSMC1	-0.59	-8.08	-0.46	2.86e-14	Mortality in heart failure;
KIRP	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.92	-0.49	1.1e-16	Retinal vascular caliber;
KIRP	cis	rs12580194	0.593	rs56677471	chr12:55749967	T/A	cg11794356	chr12:55725991	OR6C3	-0.55	-7.73	-0.44	2.69e-13	Cancer;
KIRP	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.83	9.81	0.53	2.22e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg08742575	chr21:47604166	C21orf56	0.41	5.31	0.32	2.45e-7	Testicular germ cell tumor;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.76	6.24	0.37	1.86e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-6.93	-0.4	3.62e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg08648136	chr8:956695	NA	0.47	7.27	0.42	4.76e-12	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02358172	chr15:81616486	STARD5	0.47	6.08	0.36	4.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs41264869	0.657	rs7530217	chr1:205109019	T/A	cg21214746	chr1:205091277	RBBP5	0.52	6.63	0.39	2.07e-10	Blood protein levels;
KIRP	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.15	-16.73	-0.73	1.74e-42	Lymphocyte percentage of white cells;
KIRP	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.06	-0.36	4.97e-9	Neuroticism;
KIRP	cis	rs7766436	0.885	rs13202434	chr6:22583694	G/C	cg13666174	chr6:22585274	NA	-0.44	-6.1	-0.36	4.02e-9	Coronary artery disease;
KIRP	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.67	-8.71	-0.49	4.61e-16	Calcium levels;
KIRP	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg02660097	chr11:68866761	NA	0.4	5.16	0.31	5.17e-7	Blond vs. brown hair color;
KIRP	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.53	-7.18	-0.42	7.99e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.41	-5.44	-0.33	1.29e-7	Red blood cell count;
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13198984	chr17:80129470	CCDC57	0.57	8.65	0.48	6.71e-16	Life satisfaction;
KIRP	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg20469991	chr17:27169893	C17orf63	0.54	5.66	0.34	4.19e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs1021993	0.545	rs76438740	chr1:209539726	G/A	cg24446417	chr1:209558027	NA	-0.51	-5.49	-0.33	1.02e-7	Gut microbiome composition (winter);
KIRP	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg20493526	chr2:3714936	ALLC	0.44	5.59	0.34	6.11e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.56e-13	Corneal astigmatism;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.48	6.4	0.38	7.61e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1823913	1.000	rs4853461	chr2:192119298	C/T	cg12404831	chr2:192114017	MYO1B	-0.5	-6.7	-0.39	1.39e-10	Obesity-related traits;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.22	-22.7	-0.82	2.81e-62	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12900413	0.687	rs13343254	chr15:90311283	G/A	cg24650279	chr15:90327240	NA	-0.41	-5.23	-0.32	3.7e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.48	7.07	0.41	1.58e-11	Bipolar disorder;
KIRP	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.55	5.56	0.33	7.14e-8	Gut microbiome composition (summer);
KIRP	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg13679303	chr9:96623674	NA	0.49	6.97	0.41	2.88e-11	DNA methylation (variation);
KIRP	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	0.85	7.65	0.44	4.68e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.4	-0.33	1.61e-7	Platelet count;
KIRP	cis	rs11138902	0.649	rs13283450	chr9:72164094	C/G	cg14123607	chr9:72164709	APBA1	-0.42	-5.29	-0.32	2.74e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.71	5.98	0.36	7.64e-9	Diabetic retinopathy;
KIRP	cis	rs11593576	0.550	rs1749845	chr10:80991900	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.3	-4.85	-0.3	2.15e-6	Vitiligo;
KIRP	trans	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg06521331	chr12:34319734	NA	-0.51	-6.16	-0.37	2.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.19	0.58	9.07e-24	Alzheimer's disease;
KIRP	cis	rs7897654	0.571	rs12765002	chr10:104635348	C/T	cg15744005	chr10:104629667	AS3MT	-0.31	-5.12	-0.31	6.2e-7	Schizophrenia;
KIRP	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.85e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9880211	1.000	rs6768743	chr3:136205007	C/T	cg15507776	chr3:136538369	TMEM22	-0.43	-4.85	-0.3	2.15e-6	Body mass index;Height;
KIRP	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg11189052	chr15:85197271	WDR73	-0.53	-4.99	-0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs11209002	0.567	rs983111	chr1:67539356	T/C	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs3768617	0.811	rs12144261	chr1:183014148	A/G	cg21523751	chr1:182988639	NA	0.37	5.09	0.31	7.19e-7	Fuchs's corneal dystrophy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00371891	chr19:4723959	DPP9	0.61	7.2	0.42	7.28e-12	Smoking initiation;
KIRP	cis	rs2904967	0.929	rs2904980	chr11:65001679	C/T	cg09225861	chr11:65069680	NA	-0.44	-5.49	-0.33	1.01e-7	Mean corpuscular volume;
KIRP	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.58	6.89	0.4	4.75e-11	Menarche (age at onset);
KIRP	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg03684893	chr10:554711	DIP2C	-0.43	-6.4	-0.38	7.78e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg23752985	chr2:85803571	VAMP8	0.49	6.04	0.36	5.61e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg18132916	chr6:79620363	NA	-0.4	-5.57	-0.33	6.78e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg23601095	chr6:26197514	HIST1H3D	0.97	8.23	0.46	1.08e-14	Gout;Renal underexcretion gout;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.65	-0.39	1.91e-10	Lung cancer;
KIRP	cis	rs524023	0.914	rs7932437	chr11:64373504	T/C	cg09231725	chr11:64357281	SLC22A12	0.61	8.03	0.46	4.02e-14	Urate levels in obese individuals;
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.7	9.55	0.52	1.33e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.16	-0.46	1.77e-14	Neuroticism;
KIRP	trans	rs507506	0.771	rs929229	chr17:7105399	C/T	cg15655154	chr3:113604241	GRAMD1C	0.68	9.89	0.53	1.25e-19	Adiponectin levels;
KIRP	cis	rs11997175	0.569	rs36034014	chr8:33814219	G/A	ch.8.33884649F	chr8:33765107	NA	-0.43	-5.11	-0.31	6.49e-7	Body mass index;
KIRP	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.88	11.53	0.59	6.92e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg16558253	chr16:72132732	DHX38	-0.43	-6.29	-0.37	1.42e-9	Prostate cancer;
KIRP	cis	rs2411233	0.817	rs1841439	chr15:39285085	A/C	cg19287857	chr15:39890699	NA	-0.4	-5.41	-0.33	1.51e-7	Platelet count;
KIRP	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.37e-7	Lymphocyte percentage of white cells;
KIRP	trans	rs7246760	0.867	rs2336089	chr19:9849972	C/T	cg02900749	chr2:68251473	NA	-1.2	-10.05	-0.54	3.86e-20	Pursuit maintenance gain;
KIRP	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg06766960	chr11:133703094	NA	-0.45	-5.62	-0.34	5.12e-8	Childhood ear infection;
KIRP	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.3	1.44e-6	Cognitive test performance;
KIRP	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg03959625	chr15:84868606	LOC388152	0.47	5.45	0.33	1.23e-7	Schizophrenia;
KIRP	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.92	14.88	0.69	3.93e-36	Blood protein levels;
KIRP	cis	rs11603020	0.950	rs78364821	chr11:57370742	C/T	cg19752551	chr11:57585705	CTNND1	-0.66	-9.14	-0.5	2.44e-17	Blood protein levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15690853	chr13:97928270	MBNL2	0.58	7.61	0.44	5.88e-13	Interleukin-4 levels;
KIRP	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.6	-9.33	-0.51	6.46e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.44e-8	Motion sickness;
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02725872	chr8:58115012	NA	-0.74	-7.44	-0.43	1.7e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg08975724	chr8:8085496	FLJ10661	0.67	8.27	0.47	8.28e-15	Neuroticism;
KIRP	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.96e-9	Breast cancer;
KIRP	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.54	0.48	1.41e-15	Motion sickness;
KIRP	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg16497661	chr14:103986332	CKB	0.49	6.38	0.38	8.57e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.12	-0.36	3.73e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.99	-7.82	-0.45	1.6e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg08885076	chr2:99613938	TSGA10	-0.38	-5.05	-0.31	8.53e-7	Chronic sinus infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25021339	chr5:92917125	FLJ42709	0.4	6.04	0.36	5.74e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.88	-10.9	-0.57	7.86e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs34381861	0.520	rs74382390	chr16:71458526	C/G	cg08717414	chr16:71523259	ZNF19	-0.92	-8.83	-0.49	2.06e-16	Post bronchodilator FEV1;
KIRP	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.52	6.5	0.38	4.46e-10	Plateletcrit;
KIRP	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.46	-6.86	-0.4	5.61e-11	Bipolar disorder;
KIRP	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs7688540	0.771	rs77234191	chr4:258294	G/A	cg17891759	chr4:299121	NA	-0.49	-4.97	-0.3	1.23e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg03161606	chr19:29218774	NA	0.76	6.84	0.4	6.15e-11	Methadone dose in opioid dependence;
KIRP	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.6	7.74	0.44	2.57e-13	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.37	-0.38	9.21e-10	Height;
KIRP	cis	rs9653442	0.510	rs12712068	chr2:100764439	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.27e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-4.86	-0.3	2.08e-6	Educational attainment (years of education);
KIRP	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg25418670	chr11:30344373	C11orf46	0.6	5.07	0.31	7.92e-7	Morning vs. evening chronotype;
KIRP	cis	rs10267417	0.603	rs2214318	chr7:19899150	G/A	cg05791153	chr7:19748676	TWISTNB	0.49	4.87	0.3	2.04e-6	Night sleep phenotypes;
KIRP	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.41	-6.97	-0.41	2.83e-11	Heart rate;
KIRP	trans	rs6762644	0.504	rs9682063	chr3:4737842	A/G	cg06150299	chr16:30993485	SETD1A	0.45	6.02	0.36	6.19e-9	Breast cancer;
KIRP	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg26754761	chr2:177040938	NA	-0.45	-7.69	-0.44	3.64e-13	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg21858823	chr1:15850916	CASP9	0.54	5.69	0.34	3.52e-8	Systolic blood pressure;
KIRP	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12311346	chr5:56204834	C5orf35	0.45	5.96	0.36	8.69e-9	Initial pursuit acceleration;
KIRP	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.5	-5.63	-0.34	4.93e-8	Neuroticism;
KIRP	cis	rs10267417	0.603	rs6960607	chr7:19869407	A/G	cg07541023	chr7:19748670	TWISTNB	0.49	5.04	0.31	8.91e-7	Night sleep phenotypes;
KIRP	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.38	-0.32	1.7e-7	Life satisfaction;
KIRP	cis	rs1420338	0.933	rs731844	chr7:34150264	C/T	cg01275685	chr7:34179230	BMPER	-0.61	-9.2	-0.51	1.57e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs62070183	0.938	rs9898762	chr17:31038659	G/A	cg05781649	chr17:31146240	MYO1D	-0.55	-5.54	-0.33	7.64e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24615749	chr5:102611933	C5orf30	-0.42	-6.69	-0.39	1.49e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.91	14.19	0.67	8.38e-34	Blood protein levels;
KIRP	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.69	-8.85	-0.49	1.75e-16	Prudent dietary pattern;
KIRP	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg25650185	chr19:21324782	ZNF431	-0.48	-5.04	-0.31	8.93e-7	Pain;
KIRP	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.42	-5.72	-0.34	3.01e-8	Renal function-related traits (BUN);
KIRP	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg08742575	chr21:47604166	C21orf56	-0.4	-5.03	-0.31	9.53e-7	Testicular germ cell tumor;
KIRP	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.91	-13.05	-0.64	6.34e-30	Blood protein levels;
KIRP	cis	rs5743618	0.537	rs6832466	chr4:38770543	A/G	cg06935464	chr4:38784597	TLR10	0.39	4.86	0.3	2.05e-6	Asthma;Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	1.2	12.46	0.62	5.9e-28	Alzheimer's disease;
KIRP	cis	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg21775007	chr8:11205619	TDH	-0.4	-5.22	-0.32	3.8e-7	Morning vs. evening chronotype;
KIRP	cis	rs838721	0.574	rs11679046	chr2:234258101	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	4.98	0.3	1.22e-6	Total body bone mineral density;
KIRP	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg25281562	chr12:121454272	C12orf43	0.5	5.48	0.33	1.03e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.63	7.28	0.42	4.52e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs925255	0.810	rs7574996	chr2:28643523	G/C	cg01273330	chr2:28605224	NA	-0.39	-6.78	-0.4	9.09e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9914544	0.545	rs3764445	chr17:18767923	C/T	cg26306683	chr17:18585705	ZNF286B	0.38	4.94	0.3	1.47e-6	Educational attainment (years of education);
KIRP	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg26874164	chr19:58962979	ZNF324B	0.47	5.58	0.33	6.45e-8	Uric acid clearance;
KIRP	cis	rs7078219	0.505	rs10883372	chr10:101292483	T/A	cg07044859	chr10:101282883	NA	-0.3	-5.35	-0.32	2.05e-7	Dental caries;
KIRP	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.13	-0.5	2.52e-17	Response to antipsychotic treatment;
KIRP	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg11945507	chr8:142233382	SLC45A4	-0.9	-15.46	-0.7	3.9e-38	Immature fraction of reticulocytes;
KIRP	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.9	-0.3	1.71e-6	Pulmonary function;
KIRP	cis	rs1018836	0.700	rs7824376	chr8:91521498	T/C	cg16814680	chr8:91681699	NA	-0.62	-7.13	-0.41	1.14e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.63	0.44	5.21e-13	Neuroticism;
KIRP	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg19575753	chr5:1948995	NA	-0.54	-6.25	-0.37	1.76e-9	Gut microbiome composition (winter);
KIRP	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.73	-9.8	-0.53	2.31e-19	Childhood ear infection;
KIRP	cis	rs7615316	0.751	rs2862746	chr3:142042815	C/G	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.07e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-15.38	-0.7	7.22e-38	Ulcerative colitis;
KIRP	cis	rs15300	1.000	rs15300	chr6:8413412	A/G	cg23788917	chr6:8435910	SLC35B3	0.91	4.88	0.3	1.9e-6	Pursuit maintenance gain;
KIRP	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	6.26	0.37	1.68e-9	Menarche (age at onset);
KIRP	cis	rs1982963	0.587	rs2516593	chr14:52503369	T/C	cg10843707	chr14:52510701	NID2	-0.32	-5.58	-0.33	6.45e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg26205026	chr15:66080704	DENND4A	-0.42	-6.22	-0.37	2.15e-9	Inflammatory biomarkers;
KIRP	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-10.84	-0.57	1.2e-22	Colorectal cancer;
KIRP	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs9581857	0.579	rs79653667	chr13:27961109	G/A	cg22138327	chr13:27999177	GTF3A	1.05	7.47	0.43	1.36e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs10207628	0.698	rs13410629	chr2:127868733	C/T	cg06223080	chr2:127868745	NA	-0.71	-9.38	-0.51	4.52e-18	Psychosis and Alzheimer's disease;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg08662619	chr6:150070041	PCMT1	0.39	6.5	0.38	4.42e-10	Lung cancer;
KIRP	cis	rs282587	0.569	rs447717	chr13:113415038	A/G	cg04656015	chr13:113407548	ATP11A	0.67	7.86	0.45	1.16e-13	Glycated hemoglobin levels;
KIRP	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.21	-0.51	1.46e-17	Triglycerides;
KIRP	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04374321	chr14:90722782	PSMC1	0.9	14.55	0.68	5.12e-35	Mortality in heart failure;
KIRP	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg16434002	chr17:42200994	HDAC5	-0.46	-5.49	-0.33	9.94e-8	Total body bone mineral density;
KIRP	cis	rs2120243	0.539	rs4640512	chr3:157120066	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-9.12	-0.5	2.7e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03776034	chr3:154042375	DHX36	0.53	6.89	0.4	4.58e-11	Parkinson's disease;
KIRP	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg00852783	chr1:26633632	UBXN11	-0.57	-5.82	-0.35	1.86e-8	Obesity-related traits;
KIRP	cis	rs17221829	0.733	rs12277139	chr11:89389606	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7937612	1.000	rs10892567	chr11:120244192	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.49	-7.43	-0.43	1.81e-12	Intraocular pressure;
KIRP	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg08603382	chr10:743973	NA	0.52	7.64	0.44	4.71e-13	Psychosis in Alzheimer's disease;
KIRP	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.43	5.67	0.34	3.99e-8	Homoarginine levels;
KIRP	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.61	0.44	5.72e-13	Bladder cancer;
KIRP	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.94	-0.35	9.68e-9	Obesity-related traits;
KIRP	cis	rs2880765	0.527	rs1483578	chr15:86075417	A/G	cg10818794	chr15:86012489	AKAP13	-0.52	-7.0	-0.41	2.48e-11	Coronary artery disease;
KIRP	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.88	13.95	0.66	5.66e-33	Height;
KIRP	cis	rs17641971	0.684	rs4873100	chr8:50025772	G/A	cg00325661	chr8:49890786	NA	0.44	5.69	0.34	3.54e-8	Blood metabolite levels;
KIRP	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.89	-11.48	-0.59	1.07e-24	Cognitive function;
KIRP	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs17453880	0.890	rs28749810	chr5:152048630	C/A	cg12297329	chr5:152029980	NA	-0.71	-10.5	-0.56	1.47e-21	Subjective well-being;
KIRP	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg27102117	chr16:15229624	NA	0.51	6.68	0.39	1.58e-10	Triglycerides;
KIRP	cis	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg23939001	chr4:940644	TMEM175	-0.46	-7.36	-0.43	2.67e-12	Systemic sclerosis;
KIRP	trans	rs6775745	0.652	rs1920007	chr3:131796170	C/T	cg08905652	chr6:74161099	C6orf150	-0.49	-6.39	-0.38	8.13e-10	Neutrophil count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26785250	chr3:13461660	NUP210	0.53	6.46	0.38	5.44e-10	Parkinson's disease;
KIRP	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg09631939	chr20:60582478	TAF4	-0.41	-4.91	-0.3	1.66e-6	Body mass index;
KIRP	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg16388071	chr6:169726476	NA	-0.41	-5.67	-0.34	3.92e-8	Obesity-related traits;
KIRP	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg02023728	chr11:77925099	USP35	-0.33	-4.88	-0.3	1.87e-6	Alzheimer's disease (survival time);
KIRP	cis	rs1448094	0.817	rs10863111	chr12:86330615	T/C	cg00310523	chr12:86230176	RASSF9	0.41	6.43	0.38	6.75e-10	Major depressive disorder;
KIRP	cis	rs7551222	0.752	rs12138846	chr1:204556478	T/A	cg20240347	chr1:204465584	NA	-0.43	-8.47	-0.48	2.21e-15	Schizophrenia;
KIRP	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg13266496	chr6:110720918	DDO	-0.35	-5.62	-0.34	5.07e-8	Platelet distribution width;
KIRP	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg19077165	chr18:44547161	KATNAL2	0.51	6.39	0.38	8.39e-10	Personality dimensions;
KIRP	cis	rs4566357	1.000	rs7567796	chr2:227922109	T/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.85	-0.3	2.24e-6	Coronary artery disease;
KIRP	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	cg21523751	chr1:182988639	NA	0.44	6.88	0.4	4.99e-11	Colorectal cancer;
KIRP	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs12282928	0.959	rs2870509	chr11:48284109	T/C	cg26585981	chr11:48327164	OR4S1	-0.52	-6.32	-0.37	1.25e-9	Migraine - clinic-based;
KIRP	cis	rs7721647	0.853	rs1120946	chr5:90859257	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.4	4.98	0.3	1.21e-6	Breast cancer;
KIRP	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.56	6.83	0.4	6.5e-11	Aortic root size;
KIRP	cis	rs977987	0.836	rs11646044	chr16:75312548	G/T	cg03315344	chr16:75512273	CHST6	0.66	9.96	0.54	7.23e-20	Dupuytren's disease;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg02733842	chr7:1102375	C7orf50	0.51	5.26	0.32	3.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	ch.11.42038R	chr11:967971	AP2A2	0.41	5.28	0.32	2.9e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.57	-0.39	2.9e-10	Coronary artery calcification;
KIRP	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.49	0.48	1.96e-15	Motion sickness;
KIRP	cis	rs4654899	0.965	rs7525620	chr1:21458392	G/A	cg05370193	chr1:21551575	ECE1	0.43	5.94	0.35	9.84e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2790457	0.958	rs1265829	chr10:28911303	T/C	cg05705492	chr10:28955341	NA	-0.55	-8.43	-0.47	2.86e-15	Multiple myeloma;
KIRP	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg00129232	chr17:37814104	STARD3	0.7	7.64	0.44	4.78e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg03735888	chr19:58951602	ZNF132	0.46	5.51	0.33	8.84e-8	Uric acid clearance;
KIRP	cis	rs6545883	0.929	rs12612982	chr2:61747355	G/A	cg15711740	chr2:61764176	XPO1	-0.57	-7.74	-0.44	2.59e-13	Tuberculosis;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	7.85	0.45	1.25e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs7312774	0.881	rs7297923	chr12:107305573	T/C	cg16260113	chr12:107380972	MTERFD3	0.71	6.44	0.38	6.26e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs240764	0.782	rs239222	chr6:101112817	T/A	cg09795085	chr6:101329169	ASCC3	0.47	5.57	0.33	6.63e-8	Neuroticism;
KIRP	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs13102973	0.932	rs4130841	chr4:135869673	T/C	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.54	6.02	0.36	6.15e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-0.97	-11.38	-0.59	2.15e-24	Vitiligo;
KIRP	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg10932868	chr11:921992	NA	0.46	5.34	0.32	2.12e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2281603	0.951	rs1453004	chr14:64996955	A/G	cg25009451	chr14:65006716	HSPA2	0.49	5.35	0.32	2.06e-7	Lymphocyte counts;
KIRP	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.79	8.29	0.47	7.6e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.52	-5.98	-0.36	7.76e-9	Urate levels in overweight individuals;
KIRP	cis	rs9325144	0.957	rs61937729	chr12:39025682	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-5.49	-0.33	9.81e-8	Morning vs. evening chronotype;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg02685945	chr6:22570146	HDGFL1	0.4	6.19	0.37	2.54e-9	Serum protein levels (sST2);
KIRP	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg06818126	chr11:68850279	TPCN2	-0.47	-5.45	-0.33	1.2e-7	Hair color;
KIRP	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg09165964	chr15:75287851	SCAMP5	0.55	7.29	0.42	4.13e-12	Breast cancer;
KIRP	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.68	-7.51	-0.43	1.08e-12	Schizophrenia;
KIRP	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-7.03	-0.41	2.08e-11	Axial length;
KIRP	cis	rs9379832	1	rs9379832	chr6:26186200	A/G	cg00631329	chr6:26305371	NA	-0.7	-8.71	-0.49	4.39e-16	Birth weight;
KIRP	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg23335576	chr14:104009727	NA	-0.35	-4.92	-0.3	1.61e-6	Body mass index;
KIRP	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg06026331	chr20:60912101	LAMA5	0.5	5.53	0.33	8.09e-8	Colorectal cancer;
KIRP	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.72	8.08	0.46	2.96e-14	Corneal astigmatism;
KIRP	cis	rs2637030	0.559	rs2607501	chr5:52989545	A/T	cg06476337	chr5:52856530	NDUFS4	0.56	6.3	0.37	1.34e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.37	-10.44	-0.55	2.37e-21	Diabetic kidney disease;
KIRP	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.83	-10.42	-0.55	2.68e-21	Longevity;Endometriosis;
KIRP	cis	rs7919006	0.590	rs4589232	chr10:76785448	T/C	cg01390419	chr10:76803856	DUPD1	0.5	6.04	0.36	5.64e-9	Weight;
KIRP	cis	rs4356932	1.000	rs4859600	chr4:76959967	C/G	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.28	0.37	1.51e-9	Aortic root size;
KIRP	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg18132916	chr6:79620363	NA	-0.4	-5.61	-0.34	5.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg25174290	chr11:3078921	CARS	-0.68	-8.82	-0.49	2.15e-16	Calcium levels;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg20948262	chr1:100231977	FRRS1	0.98	6.03	0.36	5.82e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	1.13	14.82	0.69	6.06e-36	Platelet distribution width;
KIRP	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs7578199	0.924	rs13426326	chr2:242340674	C/T	cg01632474	chr2:242799312	PDCD1	0.38	4.86	0.3	2.1e-6	Chronic lymphocytic leukemia;
KIRP	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg03929089	chr4:120376271	NA	0.69	6.76	0.4	1.02e-10	Axial length;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg01843034	chr6:37503916	NA	-0.86	-12.34	-0.62	1.46e-27	Cognitive performance;
KIRP	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-9.31	-0.51	7.4e-18	Bladder cancer;
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.88	-13.05	-0.64	6.44e-30	Longevity;
KIRP	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.66	-12.44	-0.62	6.87e-28	Intelligence (multi-trait analysis);
KIRP	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.87	-10.96	-0.57	4.92e-23	Dupuytren's disease;
KIRP	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.52	7.32	0.42	3.43e-12	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs2839627	0.513	rs67571721	chr21:44306446	A/T	cg03543861	chr21:44258195	NA	0.57	6.06	0.36	5.21e-9	Information processing speed;
KIRP	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg26384229	chr12:38710491	ALG10B	0.63	7.98	0.45	5.42e-14	Resting heart rate;
KIRP	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-1.04	-13.87	-0.66	1.05e-32	Body mass index;
KIRP	cis	rs2072732	0.904	rs9661525	chr1:2952840	A/C	cg11731671	chr1:2995604	PRDM16	-0.46	-6.0	-0.36	7e-9	Plateletcrit;
KIRP	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.49	6.45	0.38	5.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.82	-11.52	-0.59	7.46e-25	Educational attainment;
KIRP	cis	rs1011018	0.955	rs12703062	chr7:139419104	T/C	cg03224163	chr7:139420300	HIPK2	-0.48	-4.99	-0.3	1.13e-6	Systolic blood pressure;
KIRP	cis	rs4478037	0.822	rs9883177	chr3:33123354	T/C	cg19404215	chr3:33155277	CRTAP	0.57	5.51	0.33	9.17e-8	Major depressive disorder;
KIRP	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg10241871	chr14:102965420	TECPR2	-0.54	-6.08	-0.36	4.44e-9	Plateletcrit;
KIRP	cis	rs7301016	0.707	rs11174588	chr12:63052601	G/T	cg01804193	chr12:63026212	NA	0.53	5.74	0.34	2.83e-8	IgG glycosylation;
KIRP	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs4363385	0.567	rs7551791	chr1:153024267	A/T	cg07796016	chr1:152779584	LCE1C	-0.49	-6.35	-0.38	1.02e-9	Inflammatory skin disease;
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg04234412	chr22:24373322	LOC391322	-0.6	-7.91	-0.45	8.72e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg16497661	chr14:103986332	CKB	0.52	7.08	0.41	1.47e-11	Body mass index;
KIRP	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.29	0.58	4.2e-24	Cognitive test performance;
KIRP	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg22077389	chr15:40226273	EIF2AK4	0.56	5.47	0.33	1.09e-7	Response to haloperidol in psychosis;
KIRP	cis	rs17057718	1.000	rs12486855	chr3:57125864	A/G	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-4.91	-0.3	1.7e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg03609598	chr5:56110824	MAP3K1	0.46	5.38	0.32	1.76e-7	Initial pursuit acceleration;
KIRP	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.55	6.74	0.39	1.11e-10	Cognitive test performance;
KIRP	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	1.1	22.2	0.82	1.1e-60	Parkinson's disease;
KIRP	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg17105886	chr17:28927953	LRRC37B2	0.52	5.32	0.32	2.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.83	-13.42	-0.65	3.65e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.501	rs1486194	chr2:108755891	C/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.94	-0.3	1.43e-6	Blood pressure;
KIRP	cis	rs4919687	0.544	rs12764219	chr10:104398895	G/T	cg04362960	chr10:104952993	NT5C2	0.57	5.91	0.35	1.14e-8	Colorectal cancer;
KIRP	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg22138327	chr13:27999177	GTF3A	1.0	7.63	0.44	5.31e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg04865290	chr3:52927548	TMEM110	-0.66	-7.16	-0.42	9.46e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg06521331	chr12:34319734	NA	-0.59	-7.02	-0.41	2.16e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs75920871	1.000	rs79974099	chr11:116802581	T/A	cg23684410	chr11:116897558	SIK3	0.54	5.99	0.36	7.57e-9	Subjective well-being;
KIRP	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg21573476	chr21:45109991	RRP1B	-0.6	-8.54	-0.48	1.38e-15	Mean corpuscular volume;
KIRP	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07570687	chr10:102243282	WNT8B	0.39	5.01	0.3	1.05e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.41	0.51	3.66e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-14.02	-0.67	3.17e-33	Alzheimer's disease;
KIRP	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.45	-9.22	-0.51	1.37e-17	Longevity;
KIRP	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.49	-4.96	-0.3	1.31e-6	Initial pursuit acceleration;
KIRP	cis	rs9896052	0.649	rs6501797	chr17:73444312	G/A	cg25649188	chr17:73499917	CASKIN2	0.49	6.21	0.37	2.22e-9	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg25600027	chr14:23388339	RBM23	-0.51	-6.26	-0.37	1.74e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs71597109	0.681	rs10446708	chr4:102723740	T/C	cg14855874	chr4:102712397	BANK1	0.4	5.35	0.32	2e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg24579218	chr15:68104479	NA	-0.6	-9.98	-0.54	6.57e-20	Restless legs syndrome;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg09137423	chr10:51827642	FAM21A	0.71	6.19	0.37	2.48e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-1.0	-16.62	-0.73	4.35e-42	Height;
KIRP	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.5	-5.74	-0.34	2.73e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	5.4	0.33	1.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16386425	chr10:429943	DIP2C	-0.48	-6.57	-0.39	2.91e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.43	-5.17	-0.31	4.78e-7	Longevity;Endometriosis;
KIRP	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.63	7.85	0.45	1.24e-13	Type 2 diabetes;
KIRP	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-6.53	-0.38	3.77e-10	Morning vs. evening chronotype;
KIRP	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg24253500	chr15:84953950	NA	-0.42	-5.23	-0.32	3.62e-7	P wave terminal force;
KIRP	cis	rs6976053	0.518	rs314353	chr7:100406144	A/G	cg03098644	chr7:100410630	EPHB4	-0.59	-8.18	-0.46	1.56e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
KIRP	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg11833968	chr6:79620685	NA	-0.46	-7.02	-0.41	2.21e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6504340	0.741	rs34822124	chr17:46648679	G/T	cg05487507	chr17:46671861	LOC404266;HOXB5	0.49	5.59	0.34	6.09e-8	Primary tooth development (number of teeth);
KIRP	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	1.01	17.75	0.75	6.16e-46	Leprosy;
KIRP	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg12311346	chr5:56204834	C5orf35	-0.36	-5.03	-0.31	9.34e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23161317	chr6:28129485	ZNF389	0.46	5.11	0.31	6.47e-7	Depression;
KIRP	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.56	9.27	0.51	9.89e-18	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23209098	chr14:100149367	CYP46A1	0.5	6.65	0.39	1.91e-10	Parkinson's disease;
KIRP	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg04226714	chr8:49833948	SNAI2	-0.5	-6.79	-0.4	8.22e-11	Life satisfaction;
KIRP	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.58	-7.62	-0.44	5.32e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg15485101	chr11:133734466	NA	0.48	6.15	0.36	3.13e-9	Childhood ear infection;
KIRP	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg06121193	chr1:90282411	NA	-0.46	-6.4	-0.38	7.74e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs67385638	1.000	rs2855039	chr11:5271671	C/T	cg12559170	chr11:5275217	HBG2	0.46	6.64	0.39	2.02e-10	Hemoglobin levels;
KIRP	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg18225595	chr11:63971243	STIP1	0.64	5.83	0.35	1.74e-8	Mean platelet volume;
KIRP	cis	rs963731	0.649	rs4670905	chr2:39266134	A/T	cg04010122	chr2:39346883	SOS1	-1.02	-7.17	-0.42	8.61e-12	Corticobasal degeneration;
KIRP	cis	rs2150410	1.000	rs2150410	chr21:40569779	C/T	cg17971929	chr21:40555470	PSMG1	0.72	5.05	0.31	8.79e-7	Temperament (bipolar disorder);
KIRP	trans	rs1925953	1.000	rs1925953	chr1:68848681	A/T	cg11714801	chr19:41859555	TGFB1	-0.48	-6.03	-0.36	5.91e-9	Vertical cup-disc ratio;
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg03653399	chr8:142233436	SLC45A4	0.93	14.04	0.67	2.78e-33	Immature fraction of reticulocytes;
KIRP	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	7.92e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg10018233	chr7:150070692	REPIN1	0.54	6.9	0.4	4.34e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg15893493	chr8:124194847	FAM83A	0.87	6.8	0.4	8.01e-11	Urinary uromodulin levels;
KIRP	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21643547	chr1:205240462	TMCC2	-0.77	-12.83	-0.63	3.34e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	10.06	0.54	3.66e-20	Calcium levels;
KIRP	cis	rs7834588	0.678	rs58909118	chr8:63920362	A/T	cg04220482	chr8:63952370	GGH	0.51	5.46	0.33	1.17e-7	Response to Vitamin E supplementation;
KIRP	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg20578329	chr17:80767326	TBCD	0.57	5.97	0.36	8.21e-9	Breast cancer;
KIRP	cis	rs6909279	0.678	rs11753987	chr6:151851428	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.55	-6.75	-0.4	1.03e-10	Bone mineral density;
KIRP	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	5.24	0.32	3.51e-7	Rheumatoid arthritis;
KIRP	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg27494647	chr7:150038898	RARRES2	0.4	5.95	0.35	9.05e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.8	-11.32	-0.59	3.52e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4683702	0.965	rs11708647	chr3:142617353	G/A	cg22826874	chr3:142608218	PCOLCE2	-0.38	-5.64	-0.34	4.74e-8	Blood protein levels;
KIRP	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-7.77	-0.44	2.17e-13	Schizophrenia;
KIRP	cis	rs1978968	0.869	rs35035092	chr22:18463274	G/T	cg03078520	chr22:18463400	MICAL3	-0.8	-9.1	-0.5	3.25e-17	Presence of antiphospholipid antibodies;
KIRP	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg18190219	chr22:46762943	CELSR1	-0.61	-5.78	-0.35	2.3e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg16179182	chr5:140090404	VTRNA1-1	0.49	6.36	0.38	9.79e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg00409905	chr10:38381863	ZNF37A	0.59	6.63	0.39	2.11e-10	Obesity (extreme);
KIRP	cis	rs4835473	0.900	rs7698963	chr4:144654343	T/C	cg08833778	chr4:144622313	FREM3	0.35	4.91	0.3	1.67e-6	Immature fraction of reticulocytes;
KIRP	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.56	-6.96	-0.41	3.07e-11	Iron status biomarkers;
KIRP	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.57	-7.78	-0.44	1.97e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg12756093	chr1:115239321	AMPD1	0.55	7.35	0.42	2.91e-12	Autism;
KIRP	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.93	-0.3	1.54e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.5	6.5	0.38	4.34e-10	Pancreatic cancer;
KIRP	cis	rs6714788	0.523	rs6542905	chr2:100654707	C/G	cg17356467	chr2:100759845	AFF3	0.37	5.01	0.3	1.05e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9790314	0.638	rs6441339	chr3:160619683	T/G	cg04691961	chr3:161091175	C3orf57	0.43	6.29	0.37	1.46e-9	Morning vs. evening chronotype;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08930741	chr1:59369549	NA	-0.47	-6.96	-0.41	3.12e-11	Myopia;
KIRP	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.46	-5.71	-0.34	3.32e-8	HIV-1 control;
KIRP	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.53	-7.64	-0.44	4.98e-13	Bipolar disorder;
KIRP	cis	rs78487399	0.908	rs61754256	chr2:43805739	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.78	-0.35	2.28e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15813266	chr4:188045689	NA	-0.38	-6.1	-0.36	4.16e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.11	-0.54	2.48e-20	Height;
KIRP	cis	rs2415984	0.622	rs7156444	chr14:46933296	C/G	cg14871534	chr14:47121158	RPL10L	-0.45	-5.4	-0.33	1.56e-7	Number of children ever born;
KIRP	trans	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg17830980	chr10:43048298	ZNF37B	0.52	6.08	0.36	4.62e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.66	0.34	4.15e-8	Motion sickness;
KIRP	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.82	8.19	0.46	1.44e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs8028182	0.636	rs8028277	chr15:75684085	A/G	cg20655648	chr15:75932815	IMP3	0.53	6.73	0.39	1.22e-10	Sudden cardiac arrest;
KIRP	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg21573476	chr21:45109991	RRP1B	0.57	7.77	0.44	2.12e-13	Mean corpuscular volume;
KIRP	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	0.83	5.86	0.35	1.49e-8	IgG glycosylation;
KIRP	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.81	0.49	2.32e-16	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg01689657	chr7:91764605	CYP51A1	0.35	4.96	0.3	1.33e-6	Breast cancer;
KIRP	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg02475777	chr4:1388615	CRIPAK	0.51	4.86	0.3	2.14e-6	Recombination rate (females);
KIRP	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.43	0.38	6.66e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.85	-8.98	-0.5	7.16e-17	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg22262055	chr6:25984395	TRIM38	0.42	6.46	0.38	5.45e-10	Migraine with aura;
KIRP	cis	rs6516091	0.714	rs2232081	chr20:6060395	C/T	cg25325723	chr20:6104886	FERMT1	-0.64	-5.9	-0.35	1.22e-8	Abdominal aortic aneurysm;
KIRP	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg20935368	chr5:178288625	ZNF354B	0.41	5.52	0.33	8.79e-8	Sleep duration;
KIRP	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg14952266	chr13:112191215	NA	0.46	6.77	0.4	9.5e-11	Hepatitis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24894158	chr6:145069599	UTRN	0.41	6.24	0.37	1.86e-9	Interleukin-4 levels;
KIRP	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.25	0.32	3.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72792276	1.000	rs72794370	chr5:127444907	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	7.21	0.42	6.83e-12	Red cell distribution width;
KIRP	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.43	5.11	0.31	6.44e-7	Aortic root size;
KIRP	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg17554472	chr22:41940697	POLR3H	0.58	6.58	0.39	2.79e-10	Vitiligo;
KIRP	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.73	-5.23	-0.32	3.59e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10463554	0.526	rs114525197	chr5:102443045	T/C	cg23492399	chr5:102201601	PAM	-0.51	-5.53	-0.33	8.01e-8	Parkinson's disease;
KIRP	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg05692746	chr2:100937584	LONRF2	-0.4	-5.09	-0.31	7.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.93	-14.58	-0.68	3.92e-35	Systemic lupus erythematosus;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg06654118	chr4:1303317	MAEA	0.27	5.13	0.31	5.9e-7	Longevity;
KIRP	cis	rs6956675	0.915	rs4285375	chr7:62650353	C/T	cg08930214	chr7:62859557	LOC100287834	0.43	5.21	0.32	3.95e-7	Obesity-related traits;
KIRP	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg01557791	chr16:72042693	DHODH	-0.54	-5.09	-0.31	7.29e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg11608241	chr8:8085544	FLJ10661	0.38	4.89	0.3	1.82e-6	Mood instability;
KIRP	cis	rs4849845	0.849	rs3889224	chr2:121024419	A/G	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	0.84	10.27	0.55	7.87e-21	Prostate cancer;
KIRP	cis	rs7680126	0.632	rs78030862	chr4:10150412	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.16	-0.31	5.17e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs3820881	0.516	rs842824	chr2:201254277	C/T	cg23516759	chr2:201153734	NA	-0.6	-6.01	-0.36	6.64e-9	Chickenpox;
KIRP	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg12131826	chr15:77904385	NA	-0.44	-5.25	-0.32	3.24e-7	Type 2 diabetes;
KIRP	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg08662619	chr6:150070041	PCMT1	0.37	6.2	0.37	2.4e-9	Lung cancer;
KIRP	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg11764359	chr7:65958608	NA	0.79	5.17	0.31	4.76e-7	Diabetic kidney disease;
KIRP	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.49	-6.42	-0.38	6.78e-10	Platelet count;
KIRP	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg24747557	chr10:131355152	MGMT	-0.4	-5.3	-0.32	2.55e-7	Response to temozolomide;
KIRP	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg22676075	chr6:135203613	NA	0.49	7.06	0.41	1.72e-11	Red blood cell count;
KIRP	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.59	0.39	2.61e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs16912285	0.748	rs12786638	chr11:24346006	A/G	ch.11.24196551F	chr11:24239977	NA	0.72	6.79	0.4	8.3e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.6e-10	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.66	-6.96	-0.41	3.15e-11	Vitiligo;
KIRP	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg12560992	chr17:57184187	TRIM37	0.61	5.4	0.33	1.6e-7	Cognitive test performance;
KIRP	cis	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.93	0.3	1.49e-6	Leprosy;
KIRP	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg09184832	chr6:79620586	NA	-0.39	-5.0	-0.3	1.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg27189623	chr16:705930	WDR90	0.46	6.08	0.36	4.46e-9	Height;
KIRP	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-8.18	-0.46	1.57e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg13409248	chr3:40428643	ENTPD3	0.4	5.2	0.31	4.1e-7	Renal cell carcinoma;
KIRP	cis	rs7011049	0.778	rs6994265	chr8:53866234	G/A	cg26025543	chr8:53854495	NA	0.59	6.54	0.38	3.57e-10	Systolic blood pressure;
KIRP	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	1.09	22.12	0.82	2.03e-60	Parkinson's disease;
KIRP	cis	rs7017914	0.967	rs6999739	chr8:71637212	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg06223162	chr1:101003688	GPR88	0.41	8.19	0.46	1.46e-14	Monocyte count;
KIRP	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg09888468	chr15:81410853	NA	-0.59	-6.58	-0.39	2.88e-10	QT interval (drug interaction);
KIRP	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.77	11.49	0.59	9.75e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.25	-6.49	-0.38	4.67e-10	Mean corpuscular volume;
KIRP	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-6.68	-0.39	1.61e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs524023	0.957	rs893006	chr11:64365796	C/A	cg09231725	chr11:64357281	SLC22A12	0.57	7.57	0.43	7.5e-13	Urate levels in obese individuals;
KIRP	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg13010199	chr12:38710504	ALG10B	-0.5	-6.6	-0.39	2.47e-10	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-7.31	-0.42	3.8e-12	Morning vs. evening chronotype;
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01283332	chr5:1856932	NA	-0.52	-6.69	-0.39	1.54e-10	Cardiovascular disease risk factors;
KIRP	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-7.66	-0.44	4.33e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.66	-9.63	-0.52	7.98e-19	Waist circumference;Body mass index;
KIRP	cis	rs4790333	0.715	rs2447110	chr17:2261677	A/G	cg02569219	chr17:2266849	SGSM2	0.44	5.67	0.34	3.95e-8	Proinsulin levels;
KIRP	cis	rs4862307	0.623	rs11730046	chr4:184988245	C/G	cg06737308	chr4:185021514	ENPP6	0.42	5.47	0.33	1.08e-7	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.73	9.55	0.52	1.4e-18	Renal function-related traits (BUN);
KIRP	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg06742321	chr12:123595122	PITPNM2	0.45	5.16	0.31	5.17e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	1.1	17.86	0.75	2.62e-46	Migraine;
KIRP	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg03711944	chr11:47377212	SPI1	-0.32	-5.21	-0.32	3.94e-7	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs4356932	1.000	rs10014837	chr4:76941818	G/A	cg19388996	chr4:76862389	NAAA	0.39	5.02	0.3	9.95e-7	Blood protein levels;
KIRP	cis	rs35740288	0.822	rs11638720	chr15:86229273	C/T	cg17133734	chr15:86042851	AKAP13	-0.48	-5.23	-0.32	3.58e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.99	0.5	6.59e-17	Motion sickness;
KIRP	cis	rs9616064	0.889	rs7284276	chr22:46996137	G/C	cg25730555	chr22:47059586	GRAMD4	0.46	5.18	0.31	4.6e-7	Urate levels in obese individuals;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.63	7.57	0.43	7.59e-13	Smoking initiation;
KIRP	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg26513180	chr16:89883248	FANCA	0.59	5.51	0.33	9e-8	Skin colour saturation;
KIRP	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.4	-0.38	7.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.67	8.12	0.46	2.3e-14	Aortic root size;
KIRP	cis	rs2832270	0.562	rs73192155	chr21:30455919	A/G	cg24692254	chr21:30365293	RNF160	-0.62	-4.9	-0.3	1.74e-6	Response to mTOR inhibitor (everolimus);
KIRP	cis	rs7771547	0.607	rs632943	chr6:36469121	A/G	cg07856975	chr6:36356162	ETV7	0.36	5.19	0.31	4.36e-7	Platelet distribution width;
KIRP	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs365132	0.902	rs353489	chr5:176461974	T/C	cg16309518	chr5:176445507	NA	-0.88	-13.52	-0.65	1.67e-31	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg20936604	chr3:58311152	NA	-0.65	-5.05	-0.31	8.6e-7	Cholesterol, total;
KIRP	trans	rs1424233	1.000	rs10514465	chr16:79680852	G/T	cg11120865	chr14:21853037	SUPT16H	0.39	6.45	0.38	5.79e-10	Obesity;
KIRP	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.46	5.19	0.31	4.46e-7	Schizophrenia;
KIRP	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg16898833	chr6:26189333	HIST1H4D	0.67	4.89	0.3	1.79e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.45	-8.99	-0.5	6.89e-17	Longevity;
KIRP	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.3	-0.37	1.4e-9	IgG glycosylation;
KIRP	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.51	6.43	0.38	6.42e-10	Resistin levels;
KIRP	cis	rs9815354	0.672	rs12107296	chr3:41892503	C/G	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg15556689	chr8:8085844	FLJ10661	0.54	6.55	0.39	3.29e-10	Neuroticism;
KIRP	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	0.9	14.42	0.68	1.39e-34	Ewing sarcoma;
KIRP	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	trans	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.75	9.33	0.51	6.6e-18	Menarche (age at onset);
KIRP	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	8.65	0.48	6.74e-16	Platelet distribution width;
KIRP	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg22903657	chr4:1355424	KIAA1530	-0.4	-5.84	-0.35	1.63e-8	Obesity-related traits;
KIRP	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11583043	0.546	rs35363849	chr1:101591293	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	5.01	0.3	1.02e-6	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg01268866	chr2:3683757	COLEC11	0.5	4.91	0.3	1.68e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg24375607	chr4:120327624	NA	0.42	5.3	0.32	2.62e-7	Corneal astigmatism;
KIRP	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.49	-6.49	-0.38	4.72e-10	Schizophrenia;
KIRP	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg05835009	chr4:710272	PCGF3	0.57	7.02	0.41	2.17e-11	White blood cell count;
KIRP	trans	rs7246760	0.867	rs56307296	chr19:9744099	G/T	cg02900749	chr2:68251473	NA	-1.13	-8.93	-0.49	1.03e-16	Pursuit maintenance gain;
KIRP	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg22916017	chr11:64110731	CCDC88B	0.56	6.46	0.38	5.7e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg15888849	chr15:76094525	NA	0.56	7.18	0.42	8.3e-12	Myopia (pathological);
KIRP	cis	rs4423214	0.592	rs7130829	chr11:71237702	A/T	cg05163923	chr11:71159392	DHCR7	-0.69	-6.71	-0.39	1.33e-10	Vitamin D levels;
KIRP	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg06742321	chr12:123595122	PITPNM2	0.41	4.94	0.3	1.42e-6	Schizophrenia;
KIRP	cis	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg21625330	chr8:9911636	MSRA	0.37	4.87	0.3	2.01e-6	Neuroticism;
KIRP	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg08179530	chr6:36648295	CDKN1A	-0.56	-7.13	-0.41	1.1e-11	QRS duration;
KIRP	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23281280	chr6:28129359	ZNF389	0.45	4.91	0.3	1.68e-6	Depression;
KIRP	cis	rs7224685	0.569	rs28481302	chr17:4011527	T/G	cg09695851	chr17:3907499	NA	0.53	4.87	0.3	1.99e-6	Type 2 diabetes;
KIRP	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg17691542	chr6:26056736	HIST1H1C	0.66	8.1	0.46	2.62e-14	Iron status biomarkers;
KIRP	cis	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg15212455	chr7:39170539	POU6F2	-0.23	-5.04	-0.31	8.93e-7	IgG glycosylation;
KIRP	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg18882449	chr10:104885122	NT5C2	-0.47	-6.04	-0.36	5.53e-9	Arsenic metabolism;
KIRP	cis	rs72480748	0.509	rs3865457	chr19:41398969	C/T	cg09508736	chr19:41385865	CYP2A7	-0.62	-8.37	-0.47	4.46e-15	Post bronchodilator FEV1;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs397969	0.596	rs12453720	chr17:19895202	A/G	cg04132472	chr17:19861366	AKAP10	-0.41	-5.05	-0.31	8.69e-7	Platelet count;
KIRP	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg17554472	chr22:41940697	POLR3H	0.43	5.2	0.31	4.17e-7	Vitiligo;
KIRP	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.55	-0.43	8.29e-13	Retinal vascular caliber;
KIRP	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.49	-0.43	1.24e-12	Platelet count;
KIRP	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.43	5.94	0.35	9.53e-9	Coronary artery disease;
KIRP	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg14338887	chr6:42928500	GNMT	0.47	6.83	0.4	6.59e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.69	-7.8	-0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg15655495	chr12:38532458	NA	-0.28	-5.05	-0.31	8.72e-7	Heart rate;
KIRP	cis	rs4356975	0.583	rs4351080	chr4:69972319	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07368265	chr1:219375142	LYPLAL1	-0.46	-7.13	-0.41	1.11e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg01557791	chr16:72042693	DHODH	-0.42	-5.14	-0.31	5.62e-7	Fibrinogen levels;
KIRP	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs7119038	0.629	rs11216995	chr11:118603526	G/A	cg19308663	chr11:118741387	NA	0.48	7.79	0.44	1.86e-13	Sjögren's syndrome;
KIRP	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg14664628	chr15:75095509	CSK	0.52	5.63	0.34	4.78e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1635	0.655	rs73742539	chr6:28305471	C/T	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.41	-5.15	-0.31	5.28e-7	Response to temozolomide;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg17543885	chr6:151562429	AKAP12	0.42	6.13	0.36	3.53e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4646404	0.582	rs4646343	chr17:17492077	G/T	cg01246520	chr17:17644344	RAI1	-0.32	-5.31	-0.32	2.47e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23104823	chr14:45553408	PRPF39	0.66	8.02	0.46	4.25e-14	Smoking initiation;
KIRP	cis	rs16828019	0.704	rs35071528	chr1:41612657	C/G	cg03387723	chr1:41708464	SCMH1	-0.92	-6.39	-0.38	8.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9419702	0.614	rs7907614	chr10:133532208	T/C	cg20568497	chr10:133558893	NA	0.33	5.11	0.31	6.48e-7	Survival in rectal cancer;
KIRP	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.53	5.89	0.35	1.27e-8	Fear of minor pain;
KIRP	cis	rs6967385	0.560	rs10248602	chr7:12347113	G/C	cg06484146	chr7:12443880	VWDE	0.4	5.06	0.31	8.19e-7	Response to taxane treatment (placlitaxel);
KIRP	cis	rs865483	0.929	rs853195	chr17:35848255	G/T	cg06716730	chr17:35851459	DUSP14	0.23	5.48	0.33	1.06e-7	Monocyte count;
KIRP	cis	rs1010254	0.559	rs72808322	chr5:151742736	G/A	cg12297329	chr5:152029980	NA	-0.61	-6.25	-0.37	1.81e-9	Optic nerve measurement (cup area);
KIRP	cis	rs5995756	0.627	rs3788568	chr22:40011273	G/T	cg10455938	chr22:40058150	CACNA1I	0.4	5.58	0.34	6.38e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg06637938	chr14:75390232	RPS6KL1	0.52	7.45	0.43	1.57e-12	Height;
KIRP	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg17595323	chr11:93583763	C11orf90	-0.31	-5.23	-0.32	3.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.71	7.11	0.41	1.22e-11	Chronic kidney disease;
KIRP	cis	rs2274273	0.774	rs9323278	chr14:55541574	C/G	cg04306507	chr14:55594613	LGALS3	0.44	6.7	0.39	1.41e-10	Protein biomarker;
KIRP	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.46	-7.42	-0.43	1.96e-12	Height;
KIRP	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg00800038	chr16:89945340	TCF25	-0.78	-5.25	-0.32	3.26e-7	Skin colour saturation;
KIRP	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg26384229	chr12:38710491	ALG10B	0.67	8.42	0.47	3.12e-15	Morning vs. evening chronotype;
KIRP	cis	rs6707387	0.530	rs7561615	chr2:214371649	A/G	cg08319019	chr2:214017104	IKZF2	0.43	4.93	0.3	1.54e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs10486003	1.000	rs6963652	chr7:97217206	G/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.59	-4.92	-0.3	1.62e-6	Response to platinum-based agents;
KIRP	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.86	-13.29	-0.65	9.77e-31	Breast cancer;
KIRP	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.63	6.57	0.39	2.94e-10	Gut microbiome composition (summer);
KIRP	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.69e-10	Diabetic kidney disease;
KIRP	cis	rs830383	0.512	rs62383309	chr5:165465469	C/T	cg13976338	chr5:165423657	NA	-0.62	-6.02	-0.36	6.13e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.38e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs61935443	0.720	rs11107776	chr12:95294283	T/G	cg21533806	chr12:95267307	NA	0.64	6.23	0.37	2.06e-9	Schizophrenia;
KIRP	cis	rs193541	0.632	rs7729834	chr5:122122159	A/G	cg19412675	chr5:122181750	SNX24	0.56	5.97	0.36	8.44e-9	Glucose homeostasis traits;
KIRP	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.71	-10.76	-0.57	2.21e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4886920	0.672	rs4886933	chr15:78131240	G/A	cg10461261	chr15:78109450	NA	0.33	5.49	0.33	9.8e-8	Neuroticism;
KIRP	cis	rs860295	0.702	rs10908479	chr1:155643403	C/T	cg02153340	chr1:155202674	NA	-0.44	-6.01	-0.36	6.48e-9	Body mass index;
KIRP	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg25486957	chr4:152246857	NA	-0.48	-5.39	-0.33	1.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.17	0.31	4.85e-7	Melanoma;
KIRP	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07691761	chr5:131892711	RAD50	0.47	6.12	0.36	3.72e-9	Parkinson's disease;
KIRP	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg17385448	chr1:15911702	AGMAT	0.24	4.94	0.3	1.44e-6	Systolic blood pressure;
KIRP	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05347473	chr6:146136440	FBXO30	-0.48	-6.8	-0.4	8.08e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg02023728	chr11:77925099	USP35	-0.33	-5.33	-0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7527798	0.501	rs12125256	chr1:207851361	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-5.52	-0.33	8.78e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.4	0.7	6.37e-38	Gut microbiome composition (summer);
KIRP	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.65	-0.56	4.99e-22	Chronic sinus infection;
KIRP	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.78	8.99	0.5	6.55e-17	Post bronchodilator FEV1;
KIRP	cis	rs9372498	0.536	rs13437605	chr6:118899014	C/T	cg18833306	chr6:118973337	C6orf204	-0.47	-5.04	-0.31	9.1e-7	Diastolic blood pressure;
KIRP	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg17524265	chr8:144659883	NAPRT1	0.8	5.2	0.31	4.1e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg09184832	chr6:79620586	NA	-0.38	-4.9	-0.3	1.76e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.19	0.46	1.41e-14	Motion sickness;
KIRP	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg07701084	chr6:150067640	NUP43	0.72	10.14	0.54	2e-20	Lung cancer;
KIRP	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.4	-5.06	-0.31	8.38e-7	Coronary artery disease;
KIRP	cis	rs3008706	1.000	rs3008706	chr9:16034538	A/C	cg14451791	chr9:16040625	NA	-0.53	-5.56	-0.33	6.93e-8	Bilirubin levels;
KIRP	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13198984	chr17:80129470	CCDC57	-0.5	-7.23	-0.42	6.25e-12	Life satisfaction;
KIRP	cis	rs2223471	0.546	rs661524	chr6:50596139	T/C	cg03432817	chr6:50765336	NA	-0.36	-5.3	-0.32	2.62e-7	Subcutaneous adipose tissue;
KIRP	cis	rs1823913	0.637	rs1973068	chr2:192166953	T/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.508	rs4916115	chr1:248383316	T/G	cg01631408	chr1:248437212	OR2T33	-0.41	-5.16	-0.31	5.18e-7	Common traits (Other);
KIRP	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	5.38	0.32	1.76e-7	Menarche (age at onset);
KIRP	cis	rs2904967	1.000	rs626555	chr11:65063553	A/T	cg12562828	chr11:65076843	NA	0.49	7.33	0.42	3.3e-12	Mean corpuscular volume;
KIRP	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg26752003	chr8:145688521	CYHR1	-0.54	-6.38	-0.38	8.73e-10	Age at first birth;
KIRP	cis	rs6142102	0.602	rs6142069	chr20:32560542	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.96e-8	Skin pigmentation;
KIRP	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.43	-0.33	1.38e-7	Aortic root size;
KIRP	cis	rs2071403	1.000	rs2071399	chr2:1416528	A/G	cg06500727	chr2:1417164	TPO	0.44	6.94	0.4	3.5e-11	Thyroid peroxidase antibody positivity;
KIRP	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg19000871	chr14:103996768	TRMT61A	-0.49	-5.56	-0.33	6.95e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs282587	0.502	rs282603	chr13:113393984	G/A	cg04656015	chr13:113407548	ATP11A	0.6	7.0	0.41	2.48e-11	Glycated hemoglobin levels;
KIRP	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.67	0.34	4e-8	Menopause (age at onset);
KIRP	cis	rs7520050	0.898	rs4660885	chr1:46243756	C/T	cg03146154	chr1:46216737	IPP	-0.44	-5.7	-0.34	3.37e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.52	5.47	0.33	1.09e-7	Obesity (extreme);
KIRP	cis	rs5766691	1.000	rs4823469	chr22:47532014	T/C	cg15757745	chr22:47558489	TBC1D22A	-0.43	-5.17	-0.31	4.74e-7	Longevity;
KIRP	cis	rs7923609	0.838	rs7909960	chr10:65239177	T/A	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.86	-0.35	1.46e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.61	-0.48	8.87e-16	Response to antipsychotic treatment;
KIRP	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06998765	chr14:75389618	RPS6KL1	-0.27	-5.19	-0.31	4.39e-7	Caffeine consumption;
KIRP	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg24874828	chr4:187887005	NA	-0.5	-7.46	-0.43	1.46e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg26338869	chr17:61819248	STRADA	0.47	5.66	0.34	4.12e-8	Prudent dietary pattern;
KIRP	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	7.63	0.44	5.01e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg22717608	chr11:34937665	PDHX;APIP	-0.41	-5.11	-0.31	6.6e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	7.33	0.42	3.36e-12	Iron status biomarkers;
KIRP	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-6.75	-0.4	1.06e-10	Chronic sinus infection;
KIRP	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.47	-7.96	-0.45	6.52e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.71	9.45	0.52	2.85e-18	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17779336	chr2:24299434	SF3B14	0.54	6.68	0.39	1.55e-10	Parkinson's disease;
KIRP	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-9.85	-0.53	1.6e-19	Coronary artery disease;
KIRP	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg13010199	chr12:38710504	ALG10B	-0.39	-5.05	-0.31	8.47e-7	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10116456	chr1:231838098	TSNAX-DISC1;DISC1	0.49	6.52	0.38	3.94e-10	Interleukin-4 levels;
KIRP	cis	rs6973256	0.897	rs10954422	chr7:133327587	G/A	cg10665199	chr7:133106180	EXOC4	-0.51	-6.5	-0.38	4.43e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs8523	0.804	rs9295763	chr6:11045192	G/C	cg13562911	chr6:11044106	ELOVL2	0.43	5.64	0.34	4.67e-8	Red blood cell fatty acid levels;
KIRP	cis	rs10489525	0.560	rs10858062	chr1:115602563	A/G	cg01522456	chr1:115632236	TSPAN2	0.51	6.7	0.39	1.42e-10	Autism;
KIRP	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg18904891	chr8:8559673	CLDN23	0.59	6.73	0.39	1.16e-10	Obesity-related traits;
KIRP	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg15655495	chr12:38532458	NA	-0.28	-5.16	-0.31	5.04e-7	Bladder cancer;
KIRP	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.63	-0.34	4.95e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4849845	0.889	rs7578369	chr2:121052451	T/C	cg24070213	chr2:121070622	NA	0.4	5.38	0.32	1.77e-7	Mean platelet volume;
KIRP	cis	rs2274273	0.529	rs10131562	chr14:55847015	G/A	cg04306507	chr14:55594613	LGALS3	0.41	6.07	0.36	4.85e-9	Protein biomarker;
KIRP	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-6.64	-0.39	2e-10	Mean platelet volume;
KIRP	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.53	6.91	0.4	4.15e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13082711	0.953	rs35124294	chr3:27539526	A/G	cg02860705	chr3:27208620	NA	0.59	7.53	0.43	9.63e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg14851346	chr12:38532713	NA	-0.4	-4.93	-0.3	1.54e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	ch.8.33884649F	chr8:33765107	NA	0.6	7.55	0.43	8.37e-13	Body mass index;
KIRP	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.52	-6.65	-0.39	1.83e-10	Blood metabolite levels;
KIRP	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.01	-0.3	1.03e-6	Pulmonary function;
KIRP	cis	rs860295	0.702	rs11264366	chr1:155335411	A/T	cg02153340	chr1:155202674	NA	-0.52	-6.98	-0.41	2.7e-11	Body mass index;
KIRP	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg19847130	chr8:10466454	RP1L1	-0.35	-4.93	-0.3	1.52e-6	Retinal vascular caliber;
KIRP	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.55	-7.12	-0.41	1.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg03342759	chr3:160939853	NMD3	-0.55	-6.97	-0.41	2.83e-11	Morning vs. evening chronotype;
KIRP	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg20243544	chr17:37824526	PNMT	0.4	4.98	0.3	1.22e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg07827796	chr19:33622959	WDR88	0.42	5.0	0.3	1.09e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg06654118	chr4:1303317	MAEA	0.28	5.22	0.32	3.83e-7	Obesity-related traits;
KIRP	cis	rs3087591	1.000	rs4795577	chr17:29456879	T/G	cg24425628	chr17:29625626	OMG;NF1	0.72	10.21	0.55	1.23e-20	Hip circumference;
KIRP	trans	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg18998321	chr18:7038943	LAMA1	0.32	6.74	0.39	1.15e-10	Schizophrenia;
KIRP	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg03128060	chr6:142623767	GPR126	0.36	5.2	0.31	4.21e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg06386533	chr2:46925753	SOCS5	0.91	12.84	0.63	3.1e-29	Height;
KIRP	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.05e-8	Motion sickness;
KIRP	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg17724175	chr1:150552817	MCL1	0.39	6.46	0.38	5.43e-10	Tonsillectomy;
KIRP	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs5995756	0.736	rs8140185	chr22:40010806	A/G	cg10455938	chr22:40058150	CACNA1I	0.57	8.63	0.48	7.6e-16	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg08890418	chr1:21044141	KIF17	-0.38	-5.93	-0.35	1.02e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	cis	rs7520050	0.933	rs6666743	chr1:46311275	C/T	cg03146154	chr1:46216737	IPP	-0.4	-5.05	-0.31	8.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10073892	0.619	rs1901515	chr5:101711249	T/C	cg19774478	chr5:101632501	SLCO4C1	0.48	5.62	0.34	5.28e-8	Cognitive decline (age-related);
KIRP	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg10932868	chr11:921992	NA	0.66	9.06	0.5	4.1e-17	Alzheimer's disease (late onset);
KIRP	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg04691961	chr3:161091175	C3orf57	-0.58	-9.2	-0.51	1.55e-17	Morning vs. evening chronotype;
KIRP	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg02023728	chr11:77925099	USP35	0.29	5.04	0.31	8.82e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.62	6.2	0.37	2.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6753739	0.871	rs2030450	chr2:219996879	C/A	cg01749213	chr2:219906749	CCDC108	0.41	5.04	0.31	8.97e-7	Height;
KIRP	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg05370193	chr1:21551575	ECE1	0.44	6.27	0.37	1.61e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs78487399	0.808	rs6752448	chr2:43682596	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	7.26	0.42	4.95e-12	Neuroticism;
KIRP	cis	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.43	5.59	0.34	5.95e-8	Leprosy;
KIRP	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg26512142	chr11:2554198	KCNQ1	0.5	6.16	0.37	2.91e-9	Asthma;
KIRP	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.75	-10.63	-0.56	5.76e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg17366294	chr4:99064904	C4orf37	-0.35	-4.91	-0.3	1.69e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg17644776	chr2:200775616	C2orf69	0.63	5.78	0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.13	0.64	3.26e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.43	0.55	2.48e-21	Body mass index;
KIRP	cis	rs6546886	0.956	rs10168249	chr2:74243453	A/G	cg14702570	chr2:74259524	NA	-0.26	-4.95	-0.3	1.38e-6	Dialysis-related mortality;
KIRP	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11987759	chr7:65425863	GUSB	0.53	6.74	0.39	1.13e-10	Aortic root size;
KIRP	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg25233709	chr10:116636983	FAM160B1	0.36	5.51	0.33	9.17e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1678542	0.679	rs10783834	chr12:57975953	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	5.27	0.32	3.03e-7	Rheumatoid arthritis;
KIRP	cis	rs228437	1.000	rs9376050	chr6:134910136	A/G	cg24504307	chr6:134963096	NA	-0.51	-7.46	-0.43	1.48e-12	Melanoma;
KIRP	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.9	10.18	0.54	1.58e-20	Corneal astigmatism;
KIRP	cis	rs71403859	0.685	rs12444890	chr16:71636026	G/A	cg08717414	chr16:71523259	ZNF19	-1.08	-9.99	-0.54	6.03e-20	Post bronchodilator FEV1;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00933542	chr6:150070202	PCMT1	0.29	5.81	0.35	1.88e-8	Lung cancer;
KIRP	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.63	-10.24	-0.55	1.01e-20	Morning vs. evening chronotype;
KIRP	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.6	-8.86	-0.49	1.67e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs228437	1.000	rs1474828	chr6:134926962	A/C	cg24504307	chr6:134963096	NA	-0.53	-7.67	-0.44	4.02e-13	Melanoma;
KIRP	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.94	-0.45	7.26e-14	Coffee consumption (cups per day);
KIRP	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg11987759	chr7:65425863	GUSB	-0.58	-7.97	-0.45	5.83e-14	Calcium levels;
KIRP	cis	rs4356932	0.656	rs11931349	chr4:76860040	G/A	cg19388996	chr4:76862389	NAAA	-0.42	-5.3	-0.32	2.62e-7	Blood protein levels;
KIRP	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg06102403	chr20:30458708	TTLL9;DUSP15	0.56	6.48	0.38	5.02e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.64	10.71	0.56	3.1e-22	Coronary artery disease;
KIRP	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.76	-7.01	-0.41	2.24e-11	Cerebrospinal P-tau181p levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21972176	chr19:38270453	ZNF573	-0.52	-6.95	-0.41	3.27e-11	Interleukin-4 levels;
KIRP	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg04166393	chr7:2884313	GNA12	0.66	8.02	0.46	4.22e-14	Height;
KIRP	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg12046867	chr14:103022105	NA	-0.51	-5.97	-0.36	8.04e-9	Platelet count;
KIRP	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.49	0.65	2.07e-31	Smoking behavior;
KIRP	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.64	7.9	0.45	9.54e-14	Corneal astigmatism;
KIRP	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.43	-5.57	-0.33	6.65e-8	Parkinson's disease;
KIRP	cis	rs71403859	0.570	rs77809998	chr16:71430687	C/T	cg08717414	chr16:71523259	ZNF19	-1.0	-7.74	-0.44	2.59e-13	Post bronchodilator FEV1;
KIRP	cis	rs33912345	0.695	rs1313245	chr14:60878544	A/T	cg27398547	chr14:60952738	C14orf39	-0.4	-5.44	-0.33	1.3e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs17209837	0.915	rs12538707	chr7:87124268	T/C	cg00919237	chr7:87102261	ABCB4	-0.69	-6.68	-0.39	1.63e-10	Gallbladder cancer;
KIRP	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg05333889	chr7:157238977	NA	-0.4	-5.53	-0.33	8.02e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.55	5.52	0.33	8.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9831754	0.704	rs1512492	chr3:78471190	A/C	cg06138941	chr3:78371609	NA	-0.65	-9.07	-0.5	3.84e-17	Calcium levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17383421	chr3:151599085	SUCNR1	0.5	6.17	0.37	2.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07991241	chr10:33269695	NA	0.53	6.54	0.38	3.62e-10	Smoking initiation;
KIRP	cis	rs1978968	0.763	rs34364976	chr22:18462027	C/T	cg02610425	chr22:18483192	MICAL3	0.37	5.59	0.34	6.06e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-6.2	-0.37	2.38e-9	Bone mineral density;
KIRP	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg01872077	chr2:219646372	CYP27A1	-0.38	-4.85	-0.3	2.22e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14077144	chr6:24665159	TTRAP	-0.44	-6.24	-0.37	1.89e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.15e-6	Morning vs. evening chronotype;
KIRP	trans	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.18	-0.37	2.7e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-5.89	-0.35	1.29e-8	Schizophrenia;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg18454973	chr6:136411615	PDE7B	-0.46	-6.45	-0.38	5.76e-10	Select biomarker traits;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg27532560	chr4:187881888	NA	0.77	12.98	0.64	1.03e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829883	0.573	rs73136486	chr12:98913727	T/A	cg25150519	chr12:98850993	NA	-0.76	-9.3	-0.51	8.12e-18	Colorectal adenoma (advanced);
KIRP	cis	rs920590	0.549	rs11204077	chr8:19653739	C/G	cg03894339	chr8:19674705	INTS10	0.4	4.87	0.3	2e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg21226059	chr5:178986404	RUFY1	0.48	7.58	0.43	7.26e-13	Lung cancer;
KIRP	cis	rs1635	0.655	rs723476	chr6:28305104	C/T	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs7011049	1.000	rs72640849	chr8:53836430	A/T	cg26025543	chr8:53854495	NA	0.75	7.87	0.45	1.11e-13	Systolic blood pressure;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg09086987	chr3:18470432	SATB1	0.53	6.71	0.39	1.33e-10	Myopia (pathological);
KIRP	cis	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg21775007	chr8:11205619	TDH	0.39	5.33	0.32	2.24e-7	Monocyte count;
KIRP	trans	rs7939886	0.920	rs10896157	chr11:56037621	T/G	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.38	-5.08	-0.31	7.5e-7	Axial length;
KIRP	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg13319975	chr6:146136371	FBXO30	-0.43	-5.75	-0.34	2.7e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13293650	chr15:28341193	OCA2	0.52	6.84	0.4	6.12e-11	Smoking initiation;
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-6.24	-0.37	1.9e-9	Lung cancer;
KIRP	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg23166289	chr1:210001082	C1orf107	0.4	4.99	0.3	1.16e-6	Orofacial clefts;
KIRP	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-8.75	-0.49	3.44e-16	Retinal vascular caliber;
KIRP	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.59	8.12	0.46	2.28e-14	Menarche (age at onset);
KIRP	cis	rs9625935	0.700	rs9625921	chr22:30508275	C/G	cg27665648	chr22:30112403	NA	-0.39	-5.51	-0.33	9.21e-8	Tonsillectomy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15491540	chr20:13145549	SPTLC3	0.52	6.79	0.4	8.19e-11	Interleukin-4 levels;
KIRP	cis	rs240764	0.604	rs4840153	chr6:101213723	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-5.0	-0.3	1.07e-6	Neuroticism;
KIRP	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.83e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.54	8.15	0.46	1.8e-14	Lung cancer;
KIRP	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.58	-7.27	-0.42	4.64e-12	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.84	-12.68	-0.63	1.1e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.77	-10.5	-0.56	1.5e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1816752	0.819	rs4770665	chr13:24988948	G/A	cg02811702	chr13:24901961	NA	0.41	5.47	0.33	1.08e-7	Obesity-related traits;
KIRP	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.55	-0.39	3.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.56	5.59	0.34	6.09e-8	Initial pursuit acceleration;
KIRP	cis	rs78545713	0.649	rs79662647	chr6:26217845	G/A	cg01420254	chr6:26195488	NA	1.21	7.59	0.44	6.71e-13	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs55962025	0.883	rs61792530	chr4:3145866	T/C	cg06533319	chr4:3265114	C4orf44	0.47	5.05	0.31	8.48e-7	Parental longevity (mother's age at death);
KIRP	cis	rs12765878	0.812	rs10786776	chr10:105662994	A/G	cg11005552	chr10:105648138	OBFC1	-0.42	-5.76	-0.34	2.54e-8	Coronary artery disease;
KIRP	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.64	-7.12	-0.41	1.19e-11	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg13072238	chr3:49761600	GMPPB	-0.56	-5.31	-0.32	2.5e-7	Menarche (age at onset);
KIRP	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg23391107	chr17:45924227	SP6	0.5	6.53	0.38	3.64e-10	Ease of getting up in the morning;
KIRP	cis	rs1050631	0.592	rs1785933	chr18:33719191	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.46	5.74	0.34	2.71e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.91	-10.31	-0.55	6.07e-21	Lung cancer in ever smokers;
KIRP	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.18	-21.93	-0.81	8.12e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9815354	0.951	rs9837273	chr3:41813104	T/C	cg03022575	chr3:42003672	ULK4	0.57	6.65	0.39	1.92e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2723242	0.657	rs13006699	chr2:171867152	A/G	cg12801329	chr2:171670795	NA	0.46	5.02	0.3	9.82e-7	Platelet distribution width;
KIRP	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg20573242	chr4:122745356	CCNA2	-0.42	-5.19	-0.31	4.42e-7	Type 2 diabetes;
KIRP	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg18402987	chr7:1209562	NA	0.69	4.95	0.3	1.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.35	6.56	0.39	3.19e-10	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs259282	0.605	rs8101007	chr19:33109557	G/A	cg02997394	chr19:33096574	ANKRD27	-0.52	-6.15	-0.37	3.09e-9	Schizophrenia;
KIRP	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg16989719	chr2:238392110	NA	-0.55	-7.32	-0.42	3.54e-12	Prostate cancer;
KIRP	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg17470723	chr8:74884337	TCEB1	0.62	7.92	0.45	8.29e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs55788414	0.932	rs57461213	chr16:81185419	G/C	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.32	-0.47	5.89e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.12	-0.36	3.63e-9	Hemoglobin concentration;
KIRP	trans	rs17079247	0.841	rs9594004	chr13:85807276	C/G	cg07750655	chr16:5121855	ALG1	-0.58	-6.11	-0.36	3.83e-9	Bipolar disorder (mania);
KIRP	cis	rs17739167	0.550	rs11631075	chr15:42235173	G/A	cg20935245	chr15:42234343	EHD4	0.51	8.11	0.46	2.38e-14	Monocyte count;
KIRP	cis	rs1891498	0.560	rs35594137	chr1:147245497	C/T	cg27546670	chr1:147246839	GJA5	-0.8	-11.22	-0.58	7.14e-24	Cognitive performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04627496	chr15:88799973	NTRK3	0.51	6.75	0.4	1.07e-10	Parkinson's disease;
KIRP	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2862064	1.000	rs1501910	chr5:156418790	A/G	cg12943317	chr5:156479607	HAVCR1	-0.92	-7.34	-0.42	3.14e-12	Platelet count;
KIRP	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs11735612	0.624	rs11933939	chr4:138523412	T/A	cg12033966	chr4:138453416	PCDH18	0.39	5.47	0.33	1.12e-7	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18424115	chr14:24768909	DHRS1;C14orf21	0.51	6.89	0.4	4.59e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs7607369	0.526	rs10498060	chr2:219431291	G/A	cg02176678	chr2:219576539	TTLL4	-0.31	-5.08	-0.31	7.48e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg02462569	chr6:150064036	NUP43	-0.39	-6.07	-0.36	4.93e-9	Lung cancer;
KIRP	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg00405596	chr8:11794950	NA	0.39	4.92	0.3	1.55e-6	Retinal vascular caliber;
KIRP	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg12738264	chr7:148725795	PDIA4	0.73	6.23	0.37	2.04e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg11130432	chr3:121712080	ILDR1	-0.45	-4.99	-0.3	1.13e-6	Multiple sclerosis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg19233923	chr11:63753598	OTUB1	1.07	7.34	0.42	3.2e-12	P wave terminal force;
KIRP	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05903289	chr2:130345205	NA	-0.43	-5.61	-0.34	5.44e-8	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25517755	chr10:38738941	LOC399744	-0.51	-7.1	-0.41	1.31e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3766606	0.505	rs67002863	chr1:7923478	G/A	cg26816564	chr1:7831052	VAMP3	0.64	5.72	0.34	3.12e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2671245	0.565	rs1955316	chr1:56133988	G/T	cg11523071	chr1:56160889	NA	0.42	6.29	0.37	1.44e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24948079	chr17:1888850	RTN4RL1	0.5	6.55	0.39	3.39e-10	Interleukin-4 levels;
KIRP	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg06307176	chr5:131281290	NA	0.56	6.37	0.38	9.09e-10	Life satisfaction;
KIRP	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg04576672	chr12:54422239	HOXC4;HOXC5;HOXC6	-0.22	-5.29	-0.32	2.71e-7	Waist circumference adjusted for body mass index;
KIRP	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg12723191	chr1:186429967	PDC;MIR548F1	0.38	6.32	0.37	1.2e-9	C-reactive protein;
KIRP	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg15226275	chr6:116381976	FRK	0.22	5.89	0.35	1.27e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs960902	0.592	rs4450582	chr2:37734141	T/C	cg25341268	chr2:37734390	NA	-0.64	-9.1	-0.5	3.2e-17	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg05665937	chr4:1216051	CTBP1	0.42	5.37	0.32	1.8e-7	Obesity-related traits;
KIRP	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-5.5	-0.33	9.39e-8	Neuroticism;
KIRP	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.94	-13.71	-0.66	3.59e-32	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg27087555	chr16:88793112	FAM38A	-1.23	-10.13	-0.54	2.2e-20	Plateletcrit;
KIRP	cis	rs17173637	0.681	rs16884656	chr7:150512307	A/G	cg22812874	chr7:150872892	ASB10	-0.52	-4.96	-0.3	1.33e-6	HDL cholesterol;HDL cholesterol levels;
KIRP	trans	rs488628	0.524	rs34289148	chr3:118196006	C/T	cg08165971	chr2:233792394	NGEF	0.64	6.1	0.36	4.06e-9	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg20578329	chr17:80767326	TBCD	-0.66	-7.68	-0.44	3.84e-13	Breast cancer;
KIRP	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.55	0.43	8.56e-13	Lung cancer;
KIRP	cis	rs748404	0.697	rs564946	chr15:43556272	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.57	0.39	2.99e-10	Lung cancer;
KIRP	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg24631222	chr15:78858424	CHRNA5	-0.88	-10.62	-0.56	6.25e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg20818283	chr2:191399100	TMEM194B	-0.52	-6.54	-0.38	3.58e-10	Pulse pressure;
KIRP	cis	rs10499694	0.697	rs3779074	chr7:50612202	A/G	cg14593290	chr7:50529359	DDC	-0.4	-5.57	-0.33	6.79e-8	Body mass index;
KIRP	cis	rs7106204	0.748	rs11820336	chr11:24219701	G/A	ch.11.24196551F	chr11:24239977	NA	0.81	9.61	0.52	9.01e-19	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10423674	0.526	rs757317	chr19:18819984	C/T	cg14292368	chr19:18793705	CRTC1	-0.57	-7.51	-0.43	1.1e-12	Menarche (age at onset);
KIRP	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg08890418	chr1:21044141	KIF17	0.35	5.25	0.32	3.32e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6681460	0.625	rs6696812	chr1:67100309	T/C	cg13052034	chr1:66999238	SGIP1	0.35	5.08	0.31	7.59e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.37	-14.92	-0.69	2.87e-36	Schizophrenia;
KIRP	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs17123764	1.000	rs7131915	chr12:49967660	C/G	cg02054252	chr12:50078554	FMNL3	0.42	5.1	0.31	6.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.94	10.54	0.56	1.14e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs7809615	0.892	rs58964157	chr7:99034055	G/A	cg12290671	chr7:99195819	NA	-0.69	-6.59	-0.39	2.63e-10	Blood metabolite ratios;
KIRP	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.85	0.4	5.8200000000000003e-11	Mean platelet volume;
KIRP	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.85	-12.99	-0.64	9.83e-30	Height;
KIRP	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.81	9.6	0.52	9.51e-19	Corneal astigmatism;
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.46	0.7	4.07e-38	Platelet count;
KIRP	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.54	-6.71	-0.39	1.3100000000000001e-10	Type 2 diabetes;
KIRP	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.63	-0.34	4.85e-8	Coronary artery disease;
KIRP	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.66	-8.1	-0.46	2.53e-14	Aortic root size;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.92	9.2	0.51	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.57	-6.74	-0.39	1.13e-10	Mosquito bite size;
KIRP	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.49	6.15	0.37	3.07e-9	Height;
KIRP	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.81	9.63	0.52	7.68e-19	Body mass index;
KIRP	cis	rs2274273	0.870	rs7153612	chr14:55788762	T/C	cg04306507	chr14:55594613	LGALS3	0.43	6.62	0.39	2.24e-10	Protein biomarker;
KIRP	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg15556689	chr8:8085844	FLJ10661	0.53	6.63	0.39	2.08e-10	Retinal vascular caliber;
KIRP	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg17986701	chr20:44574422	PCIF1	0.45	7.04	0.41	1.9e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.69	7.96	0.45	6.53e-14	Corneal astigmatism;
KIRP	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	trans	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg19274270	chr17:78178856	CARD14	0.37	6.73	0.39	1.19e-10	Morning vs. evening chronotype;
KIRP	cis	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.95	15.31	0.7	1.33e-37	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.26	7.09	0.41	1.43e-11	Crohn's disease;
KIRP	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-8.32	-0.47	6.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20135002	chr11:47629003	NA	-0.47	-5.47	-0.33	1.1e-7	Subjective well-being;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg13101088	chr2:64320678	PELI1	-0.42	-6.03	-0.36	6.02e-9	Select biomarker traits;
KIRP	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg27147174	chr7:100797783	AP1S1	-0.55	-7.03	-0.41	2.08e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.4	-0.51	3.85e-18	Triglycerides;
KIRP	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg24315340	chr6:146058215	EPM2A	0.46	6.12	0.36	3.72e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg06204229	chr3:52865917	ITIH4	0.61	6.74	0.39	1.12e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs11700980	1.000	rs11702477	chr21:30086177	G/A	cg08807101	chr21:30365312	RNF160	-0.63	-4.85	-0.3	2.22e-6	QRS complex (12-leadsum);
KIRP	cis	rs55962025	0.846	rs16843804	chr4:3104390	C/T	cg06533319	chr4:3265114	C4orf44	0.46	4.99	0.3	1.12e-6	Parental longevity (mother's age at death);
KIRP	cis	rs3779635	0.806	rs17376255	chr8:27257046	A/G	cg11641102	chr8:27183873	PTK2B	0.45	5.9	0.35	1.2e-8	Neuroticism;
KIRP	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg06612196	chr6:6737390	NA	0.51	8.4	0.47	3.58e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.84	13.74	0.66	2.97e-32	Monocyte percentage of white cells;
KIRP	cis	rs10073892	0.743	rs9327834	chr5:101658000	A/G	cg19774478	chr5:101632501	SLCO4C1	0.65	6.74	0.39	1.14e-10	Cognitive decline (age-related);
KIRP	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg18404041	chr3:52824283	ITIH1	-0.4	-4.94	-0.3	1.47e-6	Schizophrenia;
KIRP	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.56	0.39	3.08e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06221695	chr2:27546071	MPV17	-0.5	-7.24	-0.42	5.56e-12	Metabolic traits;
KIRP	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.62	7.27	0.42	4.69e-12	Pancreatic cancer;
KIRP	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.8	8.04	0.46	3.77e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26207909	chr14:103986467	CKB	0.77	12.12	0.61	7.92e-27	Body mass index;
KIRP	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	cis	rs1030877	0.924	rs2250658	chr2:105889683	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.67	10.54	0.56	1.13e-21	Obesity-related traits;
KIRP	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-6.17	-0.37	2.78e-9	Bone mineral density;
KIRP	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2235573	0.805	rs4821738	chr22:38500480	G/T	cg19171272	chr22:38449367	NA	0.58	7.94	0.45	7.42e-14	Glioblastoma;Glioma;
KIRP	trans	rs2531992	0.858	rs2230742	chr16:4016676	C/T	cg09155362	chr15:33487289	NA	0.55	6.82	0.4	6.97e-11	Waist circumference;
KIRP	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.88	8.65	0.48	6.74e-16	Platelet distribution width;
KIRP	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12893428	chr3:195717962	SDHAP1	0.48	6.32	0.37	1.22e-9	Pancreatic cancer;
KIRP	cis	rs7015630	0.648	rs35183880	chr8:90853071	A/C	cg18493113	chr8:90847772	NA	-0.51	-6.01	-0.36	6.81e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg19770292	chr5:1868693	NA	0.43	5.65	0.34	4.44e-8	Cardiovascular disease risk factors;
KIRP	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg09060608	chr5:178986726	RUFY1	-0.64	-10.74	-0.57	2.54e-22	Lung cancer;
KIRP	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg06565975	chr8:143823917	SLURP1	-0.34	-4.97	-0.3	1.27e-6	Urinary tract infection frequency;
KIRP	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-1.01	-13.68	-0.66	4.76e-32	Dilated cardiomyopathy;
KIRP	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg19680485	chr15:31195859	MTMR15	-0.56	-5.14	-0.31	5.48e-7	Hypertriglyceridemia;
KIRP	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg19847866	chr10:1019161	NA	-0.64	-5.77	-0.35	2.41e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg19052272	chr2:3704530	ALLC	0.72	9.53	0.52	1.64e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2882877	0.648	rs13027987	chr2:190389720	C/G	cg10752008	chr2:190445175	SLC40A1	-0.45	-5.02	-0.3	1.01e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.4	-0.33	1.6e-7	Bladder cancer;
KIRP	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.86	12.12	0.61	8.19e-27	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg20673091	chr1:2541236	MMEL1	0.37	5.09	0.31	7.09e-7	Ulcerative colitis;
KIRP	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg01420254	chr6:26195488	NA	1.13	9.92	0.53	9.66e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.74	6.5	0.38	4.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22601496	chr3:45004671	ZDHHC3	0.5	6.26	0.37	1.66e-9	Interleukin-4 levels;
KIRP	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05776053	chr2:74358815	NA	0.64	6.51	0.38	4.23e-10	Gestational age at birth (maternal effect);
KIRP	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg21856205	chr7:94953877	PON1	-0.43	-5.0	-0.3	1.1e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.74	8.99	0.5	6.66e-17	Mammographic density (dense area);
KIRP	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.63	-7.83	-0.45	1.43e-13	Longevity;
KIRP	cis	rs687432	0.774	rs55763633	chr11:57897152	A/G	cg19752551	chr11:57585705	CTNND1	-0.66	-8.52	-0.48	1.6e-15	Parkinson's disease;
KIRP	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg03959625	chr15:84868606	LOC388152	0.63	7.39	0.43	2.33e-12	Schizophrenia;
KIRP	cis	rs10207060	0.500	rs4380264	chr2:240699378	G/T	cg20333904	chr2:240724165	NA	-0.47	-5.26	-0.32	3.09e-7	Obesity-related traits;
KIRP	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg03808351	chr9:123631620	PHF19	-0.44	-6.15	-0.37	3.08e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.24	6.3	0.37	1.33e-9	Crohn's disease;
KIRP	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	9.3	0.51	7.73e-18	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.61	-0.34	5.55e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg02297831	chr4:17616191	MED28	0.54	6.73	0.39	1.21e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7808935	0.628	rs12666447	chr7:27937267	C/T	cg22168087	chr7:27702803	HIBADH	0.75	7.21	0.42	7.03e-12	Prostate cancer;
KIRP	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs963731	0.579	rs7594644	chr2:39206456	A/C	cg04010122	chr2:39346883	SOS1	-0.71	-5.04	-0.31	8.89e-7	Corticobasal degeneration;
KIRP	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg16898833	chr6:26189333	HIST1H4D	0.73	5.34	0.32	2.09e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09126467	chr6:42796794	KIAA0240	0.59	7.45	0.43	1.58e-12	Interleukin-4 levels;
KIRP	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg00792783	chr2:198669748	PLCL1	-0.44	-4.87	-0.3	2.03e-6	Intracranial aneurysm;
KIRP	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg12560992	chr17:57184187	TRIM37	0.61	5.62	0.34	5.09e-8	Cognitive test performance;
KIRP	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.85	0.49	1.73e-16	Morning vs. evening chronotype;
KIRP	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg14458575	chr2:238380390	NA	0.46	5.23	0.32	3.55e-7	Prostate cancer;
KIRP	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.2	12.76	0.63	5.97e-29	Uric acid levels;
KIRP	cis	rs60154123	0.554	rs1338290	chr1:210465467	G/A	cg09074223	chr1:210466472	NA	0.56	6.1	0.36	4.13e-9	Coronary artery disease;
KIRP	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg08603382	chr10:743973	NA	0.44	6.35	0.38	1.03e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg12311346	chr5:56204834	C5orf35	-0.37	-5.04	-0.31	8.96e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-9.22	-0.51	1.37e-17	Bladder cancer;
KIRP	cis	rs2033732	0.706	rs1437512	chr8:85064763	T/G	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.73	-6.45	-0.38	5.86e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.46	6.6	0.39	2.57e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7569084	0.522	rs906577	chr2:65596657	A/G	cg08085232	chr2:65598271	SPRED2	-0.56	-7.21	-0.42	6.93e-12	Sum eosinophil basophil counts;
KIRP	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg27205649	chr11:78285834	NARS2	0.68	8.25	0.47	9.59e-15	Alzheimer's disease (survival time);
KIRP	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.55	-7.14	-0.41	1.06e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.83	-0.35	1.7e-8	Type 2 diabetes;
KIRP	cis	rs6430538	0.582	rs11903701	chr2:135565250	G/T	cg12500956	chr2:135428796	TMEM163	0.4	5.14	0.31	5.69e-7	Parkinson's disease;
KIRP	cis	rs7834588	0.539	rs6472071	chr8:63999990	T/A	cg04220482	chr8:63952370	GGH	0.44	5.59	0.34	6.04e-8	Response to Vitamin E supplementation;
KIRP	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9488822	0.662	rs195520	chr6:116242740	A/G	cg18764771	chr6:116381957	FRK	0.18	4.98	0.3	1.17e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.99	-0.36	7.47e-9	Response to antipsychotic treatment;
KIRP	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs7116495	0.609	rs4387373	chr11:71774908	A/G	cg10381502	chr11:71823885	C11orf51	-1.17	-8.23	-0.46	1.08e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg23985595	chr17:80112537	CCDC57	0.36	5.39	0.33	1.63e-7	Life satisfaction;
KIRP	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg05639522	chr1:247681581	NA	0.59	5.65	0.34	4.4e-8	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs17125944	0.615	rs11629431	chr14:53320528	C/G	cg19583211	chr2:162273185	TBR1	0.55	6.16	0.37	2.91e-9	Alzheimer's disease (late onset);
KIRP	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg23166289	chr1:210001082	C1orf107	0.4	4.98	0.3	1.2e-6	Orofacial clefts;
KIRP	cis	rs4654899	0.571	rs1888759	chr1:21065167	G/A	cg05370193	chr1:21551575	ECE1	0.35	4.86	0.3	2.05e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg08975724	chr8:8085496	FLJ10661	0.51	6.57	0.39	3.03e-10	Joint mobility (Beighton score);
KIRP	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg15556689	chr8:8085844	FLJ10661	0.78	10.18	0.54	1.58e-20	Mood instability;
KIRP	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	6.86	0.4	5.5e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs17101923	0.803	rs1871674	chr12:66348134	T/A	cg06712651	chr12:66351869	HMGA2	-0.56	-5.75	-0.34	2.59e-8	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg18877969	chr2:232395326	NMUR1	-0.37	-5.43	-0.33	1.36e-7	Height;
KIRP	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg07810366	chr2:100720526	AFF3	-0.29	-4.84	-0.3	2.25e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7929679	0.551	rs10836302	chr11:34791897	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.46	5.65	0.34	4.45e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.2e-8	Life satisfaction;
KIRP	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg16141378	chr3:129829833	LOC729375	0.58	7.91	0.45	8.98e-14	Neuroticism;
KIRP	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.37	-5.29	-0.32	2.77e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02237855	chr2:74329332	TET3	0.45	6.03	0.36	6.04e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10875746	0.669	rs11168496	chr12:48650855	G/A	cg26205652	chr12:48591994	NA	0.62	8.09	0.46	2.76e-14	Longevity (90 years and older);
KIRP	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.59	-0.34	5.92e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg16396542	chr1:89473148	GBP3	0.36	5.05	0.31	8.72e-7	Carotid intima media thickness;
KIRP	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs15300	0.661	rs9505461	chr6:8495128	C/G	cg07606381	chr6:8435919	SLC35B3	0.99	5.64	0.34	4.74e-8	Pursuit maintenance gain;
KIRP	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.55	6.91	0.4	4.12e-11	Eye color traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20438451	chr8:146052944	ZNF7	0.56	7.4	0.43	2.15e-12	Parkinson's disease;
KIRP	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg16141378	chr3:129829833	LOC729375	0.6	8.16	0.46	1.7e-14	Triglycerides;
KIRP	cis	rs7116495	0.609	rs1894004	chr11:71759817	G/A	cg18441811	chr11:71824068	C11orf51	-0.77	-5.12	-0.31	6.29e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.76	8.7	0.49	4.69e-16	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs1873147	1.000	rs4775601	chr15:63311980	C/T	cg12160578	chr15:63334699	TPM1	0.47	5.77	0.35	2.39e-8	Orofacial clefts;
KIRP	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs16976116	0.901	rs8030981	chr15:55499442	A/G	cg11288833	chr15:55489084	RSL24D1	0.6	6.67	0.39	1.72e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13006833	0.668	rs2582736	chr2:191144892	A/T	cg27211696	chr2:191398769	TMEM194B	0.4	5.56	0.33	6.92e-8	Urinary metabolites;
KIRP	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg18764771	chr6:116381957	FRK	0.2	5.48	0.33	1.07e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7225151	0.803	rs16954560	chr17:5252811	C/G	cg24500398	chr17:5266808	RABEP1	-0.48	-5.06	-0.31	8.36e-7	Alzheimer's disease (late onset);
KIRP	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg11833968	chr6:79620685	NA	-0.4	-5.66	-0.34	4.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs55962025	0.686	rs362314	chr4:3235241	A/G	cg06533319	chr4:3265114	C4orf44	0.42	5.23	0.32	3.68e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.63	5.93	0.35	1.02e-8	Platelet count;
KIRP	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg13264159	chr8:625131	ERICH1	-0.83	-7.19	-0.42	7.97e-12	IgG glycosylation;
KIRP	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg23594656	chr7:65796392	TPST1	-0.52	-8.09	-0.46	2.75e-14	Aortic root size;
KIRP	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.1	0.67	1.79e-33	Platelet count;
KIRP	cis	rs9393813	0.529	rs2064093	chr6:27442247	C/T	cg18711553	chr6:27366782	ZNF391	0.38	5.06	0.31	8.06e-7	Bipolar disorder;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg14331148	chr19:47551893	TMEM160	-0.47	-6.42	-0.38	7.16e-10	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.41	-0.33	1.51e-7	Platelet count;
KIRP	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg02297831	chr4:17616191	MED28	0.46	5.42	0.33	1.42e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.87	10.62	0.56	6.34e-22	Schizophrenia;
KIRP	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs892085	0.654	rs8106691	chr19:10889469	C/A	cg17710535	chr19:10819994	QTRT1	0.49	6.26	0.37	1.68e-9	Psoriasis vulgaris;Psoriasis;
KIRP	cis	rs4664293	0.967	rs12999124	chr2:160531328	A/G	cg08347373	chr2:160653686	CD302	-0.39	-6.09	-0.36	4.39e-9	Monocyte percentage of white cells;
KIRP	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.55	-4.96	-0.3	1.32e-6	Bipolar disorder;
KIRP	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg12560992	chr17:57184187	TRIM37	0.63	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	cis	rs6723108	0.619	rs1942041	chr2:135515492	T/C	cg12500956	chr2:135428796	TMEM163	0.47	6.09	0.36	4.34e-9	Type 2 diabetes;
KIRP	cis	rs5753037	0.543	rs131267	chr22:30147861	A/G	cg01021169	chr22:30184971	ASCC2	-0.51	-6.97	-0.41	2.98e-11	Type 1 diabetes;
KIRP	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.46	5.91	0.35	1.15e-8	Neutrophil percentage of white cells;
KIRP	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.55	-0.33	7.48e-8	Triglycerides;
KIRP	cis	rs3931020	0.548	rs17618340	chr1:75247617	G/A	cg17719053	chr1:75198211	TYW3;CRYZ	0.46	6.58	0.39	2.87e-10	Resistin levels;
KIRP	cis	rs12930096	1.000	rs35592815	chr16:11677236	T/C	cg07439791	chr16:11680400	LITAF	0.74	6.16	0.37	3.03e-9	QT interval;
KIRP	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.05	-0.31	8.72e-7	Tonsillectomy;
KIRP	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg19913688	chr11:428466	ANO9	-0.84	-6.47	-0.38	5.33e-10	Body mass index;
KIRP	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg20568497	chr10:133558893	NA	0.33	5.1	0.31	6.74e-7	Survival in rectal cancer;
KIRP	cis	rs7715811	0.913	rs73749951	chr5:13762514	G/A	cg07548982	chr5:13769939	DNAH5	-0.54	-6.59	-0.39	2.6200000000000003e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs2882667	0.858	rs10900856	chr5:138417746	C/T	cg04439458	chr5:138467593	SIL1	0.5	7.58	0.44	7.15e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11638352	0.661	rs2706490	chr15:44422238	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.08	-0.36	4.49e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg10134651	chr19:15539926	WIZ	1.06	6.16	0.37	2.91e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg04317399	chr7:27170313	HOXA4	-0.4	-5.63	-0.34	4.86e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.9	-14.19	-0.67	8.6e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.57	0.59	5.09e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4646404	0.509	rs897450	chr17:17475350	T/G	cg01246520	chr17:17644344	RAI1	-0.33	-5.56	-0.33	7.07e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.56	7.02	0.41	2.19e-11	Arsenic metabolism;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.53	0.33	8.26e-8	Life satisfaction;
KIRP	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg02775129	chr4:119771670	NA	-0.87	-4.91	-0.3	1.62e-6	Cannabis dependence symptom count;
KIRP	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-7.17	-0.42	8.94e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.63	-0.34	4.87e-8	Bipolar disorder;
KIRP	cis	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg00405596	chr8:11794950	NA	0.39	5.04	0.31	8.99e-7	Neuroticism;
KIRP	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.37	6.14	0.36	3.35e-9	Heart rate;
KIRP	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg14345882	chr6:26364793	BTN3A2	0.33	5.57	0.33	6.81e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	5.93	0.35	1.04e-8	Type 2 diabetes;
KIRP	cis	rs508618	0.731	rs576462	chr1:231544607	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.5	-5.84	-0.35	1.64e-8	Red blood cell count;
KIRP	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	14.54	0.68	5.38e-35	Platelet count;
KIRP	cis	rs3751972	0.911	rs11657613	chr17:26252856	T/C	cg18091275	chr17:26120155	NOS2	-0.55	-6.42	-0.38	6.88e-10	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15557168	chr22:42548783	NA	-0.42	-5.73	-0.34	2.98e-8	Cognitive function;
KIRP	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg26441486	chr22:50317300	CRELD2	0.54	7.8	0.45	1.79e-13	Schizophrenia;
KIRP	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg13962347	chr6:5174647	LYRM4	-0.71	-10.05	-0.54	4e-20	Height;
KIRP	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg05791153	chr7:19748676	TWISTNB	0.52	5.93	0.35	1.05e-8	Thyroid stimulating hormone;
KIRP	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg05754148	chr16:3507555	NAT15	0.47	4.9	0.3	1.72e-6	Tuberculosis;
KIRP	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs258892	0.895	rs16901131	chr5:72054836	C/T	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.68	-10.02	-0.54	4.77e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.57	-7.03	-0.41	2.08e-11	Uric acid clearance;
KIRP	cis	rs112591243	1.000	rs112591243	chr21:47718796	G/A	cg12379764	chr21:47803548	PCNT	0.72	5.32	0.32	2.37e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26306683	chr17:18585705	ZNF286B	0.58	7.38	0.43	2.46e-12	Educational attainment (years of education);
KIRP	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-0.73	-6.41	-0.38	7.56e-10	Obesity-related traits;
KIRP	cis	rs2034650	0.544	rs2289330	chr15:40705105	A/G	cg08996748	chr15:40651036	DISP2	-0.37	-5.11	-0.31	6.47e-7	Interstitial lung disease;
KIRP	cis	rs8067287	0.688	rs11651187	chr17:16845402	T/A	cg26910001	chr17:16838321	NA	-0.46	-5.54	-0.33	7.81e-8	Diabetic kidney disease;
KIRP	cis	rs17092148	0.945	rs6087622	chr20:33310471	A/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.6	-0.34	5.78e-8	Neuroticism;
KIRP	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg26681399	chr22:41777847	TEF	-0.5	-4.94	-0.3	1.47e-6	Vitiligo;
KIRP	cis	rs10861342	1.000	rs11112368	chr12:105494218	T/C	cg23923672	chr12:105501055	KIAA1033	0.91	9.19	0.51	1.66e-17	IgG glycosylation;
KIRP	cis	rs775227	0.574	rs36108475	chr3:113038406	C/T	cg10517650	chr3:113235015	CCDC52	-0.41	-5.08	-0.31	7.45e-7	Dental caries;
KIRP	cis	rs829661	0.793	rs2609955	chr2:30872022	C/T	cg10949345	chr2:30726833	LCLAT1	-1.09	-13.88	-0.66	9.93e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg07001201	chr5:642380	CEP72	0.69	6.46	0.38	5.61e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3731827	0.511	rs2289976	chr2:85818797	G/A	cg23752985	chr2:85803571	VAMP8	0.39	4.88	0.3	1.91e-6	Prostate cancer;
KIRP	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.8	-9.03	-0.5	5.01e-17	Hirschsprung disease;
KIRP	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.95	10.29	0.55	6.92e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.52	-7.24	-0.42	5.87e-12	Menarche (age at onset);
KIRP	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg25797454	chr6:150327115	RAET1K	0.32	5.89	0.35	1.25e-8	Alopecia areata;
KIRP	cis	rs11628318	0.539	rs57749886	chr14:103095652	C/T	cg01864069	chr14:103024347	NA	-0.41	-4.99	-0.3	1.15e-6	Platelet count;
KIRP	cis	rs699	0.583	rs2493150	chr1:230868427	C/T	cg07502417	chr1:230849801	AGT	0.24	4.9	0.3	1.72e-6	Coronary artery disease;
KIRP	cis	rs8067545	1.000	rs8067545	chr17:19912710	T/C	cg13482628	chr17:19912719	NA	0.69	10.5	0.56	1.49e-21	Schizophrenia;
KIRP	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg17077180	chr1:38461687	NA	-0.39	-4.86	-0.3	2.06e-6	Coronary artery disease;
KIRP	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-5.19	-0.31	4.36e-7	Metabolite levels;
KIRP	cis	rs2839619	0.521	rs2839625	chr21:44447347	C/T	cg20154816	chr21:44412511	PKNOX1	0.34	5.33	0.32	2.2e-7	Biochemical measures;
KIRP	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.57	-7.24	-0.42	5.73e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06505273	chr16:24850292	NA	0.37	5.15	0.31	5.3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg17385448	chr1:15911702	AGMAT	0.26	5.3	0.32	2.61e-7	Systolic blood pressure;
KIRP	trans	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17183009	chr3:120277827	NA	0.54	6.44	0.38	6.37e-10	Corneal astigmatism;
KIRP	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs754423	0.631	rs1497085	chr14:52521243	G/C	cg05884192	chr14:52515736	NID2	-0.57	-7.14	-0.41	1.02e-11	Craniofacial microsomia;
KIRP	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.46	-0.43	1.52e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.48	-6.83	-0.4	6.52e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.16	-11.09	-0.58	1.88e-23	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.76	-11.93	-0.61	3.54e-26	Rheumatoid arthritis;
KIRP	cis	rs17818399	0.815	rs17768018	chr2:46862011	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.65	0.34	4.43e-8	Height;
KIRP	cis	rs7601312	1.000	rs6752389	chr2:229325525	A/G	cg02542817	chr2:229291442	NA	-0.38	-5.53	-0.33	8.32e-8	Schizophrenia;
KIRP	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg18478394	chr8:109455254	TTC35	0.55	6.65	0.39	1.85e-10	Dupuytren's disease;
KIRP	cis	rs35740288	0.770	rs11638278	chr15:86211404	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.48	-0.33	1.04e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs193541	0.564	rs62377434	chr5:122340569	C/A	cg19412675	chr5:122181750	SNX24	-0.64	-6.87	-0.4	5.32e-11	Glucose homeostasis traits;
KIRP	cis	rs13161895	1.000	rs12654148	chr5:179438920	T/A	cg02702477	chr5:179499311	RNF130	-0.69	-5.36	-0.32	1.95e-7	LDL cholesterol;
KIRP	cis	rs62384625	0.888	rs28372841	chr5:141487979	T/C	cg08523384	chr5:141488047	NDFIP1	-0.36	-4.9	-0.3	1.74e-6	White blood cell count (basophil);
KIRP	cis	rs76917914	0.820	rs4743158	chr9:100821275	T/C	cg03040243	chr9:100819229	NANS	0.66	7.11	0.41	1.25e-11	Immature fraction of reticulocytes;
KIRP	cis	rs11264213	0.901	rs72661616	chr1:36370512	G/A	cg27506609	chr1:36549197	TEKT2	1.21	7.18	0.42	8.17e-12	Schizophrenia;
KIRP	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.98	0.3	1.2e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.17	-0.37	2.79e-9	Response to antipsychotic treatment;
KIRP	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.48	0.38	5.08e-10	Neuroticism;
KIRP	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg11635098	chr7:100497156	NA	-0.67	-7.23	-0.42	6.1e-12	Resting heart rate;
KIRP	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg08888203	chr3:10149979	C3orf24	0.5	5.25	0.32	3.3e-7	Alzheimer's disease;
KIRP	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	cg12689670	chr1:183009347	LAMC1	0.55	7.67	0.44	4.09e-13	Fuchs's corneal dystrophy;
KIRP	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.82	9.77	0.53	2.96e-19	Corneal astigmatism;
KIRP	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg21191810	chr6:118973309	C6orf204	0.39	5.53	0.33	8.2e-8	Electrocardiographic conduction measures;
KIRP	cis	rs72781680	0.611	rs72781692	chr2:24263319	T/G	cg20701182	chr2:24300061	SF3B14	0.94	10.22	0.55	1.16e-20	Lymphocyte counts;
KIRP	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg27556566	chr18:29671984	RNF138	0.53	6.96	0.41	3.1e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	0.93	14.63	0.68	2.62e-35	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12282928	0.700	rs10838817	chr11:48200265	G/A	cg04607699	chr11:48328132	OR4S1	-0.38	-5.24	-0.32	3.52e-7	Migraine - clinic-based;
KIRP	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg10331922	chr1:1916718	KIAA1751	0.41	6.35	0.38	1e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs10073892	0.789	rs10054879	chr5:101741420	C/T	cg19774478	chr5:101632501	SLCO4C1	0.67	6.47	0.38	5.2e-10	Cognitive decline (age-related);
KIRP	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.61	-6.97	-0.41	2.94e-11	Bipolar disorder;
KIRP	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-8.89	-0.49	1.37e-16	Colorectal cancer;
KIRP	cis	rs10276381	0.901	rs73300638	chr7:28187344	A/C	cg23620719	chr7:28220237	JAZF1	0.6	6.2	0.37	2.41e-9	Crohn's disease;
KIRP	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.61	0.39	2.43e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18252515	chr7:66147081	NA	0.47	5.71	0.34	3.3e-8	Aortic root size;
KIRP	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.52	6.46	0.38	5.51e-10	Body mass index;
KIRP	trans	rs1106684	1.000	rs12535127	chr7:131465283	G/A	cg13607082	chr12:122652224	LRRC43	-0.62	-6.21	-0.37	2.28e-9	Body mass index;
KIRP	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg27432699	chr2:27873401	GPN1	-0.44	-5.57	-0.33	6.58e-8	Total body bone mineral density;
KIRP	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	0.9	7.92	0.45	8.11e-14	Skin colour saturation;
KIRP	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.54	-6.33	-0.37	1.15e-9	HDL cholesterol;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.66	-9.52	-0.52	1.65e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	0.64	6.06	0.36	5.14e-9	Skin colour saturation;
KIRP	cis	rs7221595	0.756	rs35852805	chr17:3892563	C/T	cg05562828	chr17:3906858	NA	0.62	6.99	0.41	2.6e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2964802	0.505	rs7728436	chr5:10814464	T/A	cg14521931	chr5:10832172	NA	-0.74	-11.28	-0.58	4.64e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.89	11.17	0.58	1.03e-23	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg17524180	chr13:113633600	MCF2L	-0.32	-6.27	-0.37	1.57e-9	Systolic blood pressure;
KIRP	cis	rs34779708	0.931	rs4934700	chr10:35310842	A/G	cg03585969	chr10:35415529	CREM	0.83	9.96	0.54	7.76e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg24375607	chr4:120327624	NA	0.49	5.78	0.35	2.24e-8	Corneal astigmatism;
KIRP	cis	rs909341	0.909	rs2872881	chr20:62342801	G/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.83	-0.4	6.8e-11	Atopic dermatitis;
KIRP	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg16141378	chr3:129829833	LOC729375	-0.48	-6.26	-0.37	1.66e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.85	-12.92	-0.64	1.72e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs57994353	0.600	rs1130640	chr9:139317979	C/T	cg21253087	chr9:139290292	SNAPC4	0.48	5.0	0.3	1.09e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs743757	0.938	rs2282753	chr3:50436716	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.31	0.32	2.47e-7	Diastolic blood pressure;
KIRP	trans	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00950418	chr7:105029125	SRPK2	-0.52	-6.46	-0.38	5.7e-10	Height;
KIRP	cis	rs7771547	0.642	rs668499	chr6:36496379	A/G	cg04289385	chr6:36355825	ETV7	0.44	6.81	0.4	7.6e-11	Platelet distribution width;
KIRP	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.84	-9.8	-0.53	2.36e-19	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg24851858	chr13:114927579	NA	0.4	4.94	0.3	1.46e-6	Schizophrenia;
KIRP	cis	rs35661897	0.920	rs4490174	chr2:227325171	G/A	cg03426602	chr2:227312417	NA	-0.58	-7.03	-0.41	2.05e-11	Urinary tract infection frequency;
KIRP	cis	rs7714584	1.000	rs1896707	chr5:150245129	C/T	cg22134413	chr5:150180641	NA	0.56	5.07	0.31	7.65e-7	Crohn's disease;
KIRP	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.27	-0.32	3.04e-7	Schizophrenia;
KIRP	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg16141378	chr3:129829833	LOC729375	0.53	6.96	0.41	3.12e-11	Retinal vascular caliber;
KIRP	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.86	0.35	1.52e-8	Morning vs. evening chronotype;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg19246076	chr11:128329809	ETS1	0.37	6.06	0.36	5.17e-9	Serum protein levels (sST2);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26082856	chr14:23503928	PSMB5	0.62	7.06	0.41	1.68e-11	Lung cancer in ever smokers;
KIRP	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg10047753	chr17:41438598	NA	1.14	17.84	0.75	2.96e-46	Menopause (age at onset);
KIRP	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg26331595	chr3:39149181	GORASP1;TTC21A	-0.46	-4.94	-0.3	1.47e-6	Handedness;
KIRP	cis	rs55962025	0.883	rs59613878	chr4:3139152	C/T	cg06533319	chr4:3265114	C4orf44	0.47	5.04	0.31	8.99e-7	Parental longevity (mother's age at death);
KIRP	cis	rs1983891	0.955	rs7753653	chr6:41548430	C/T	cg20194872	chr6:41519635	FOXP4	-0.57	-7.25	-0.42	5.22e-12	Prostate cancer;
KIRP	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-7.9	-0.45	9.13e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23182539	chr10:121355708	TIAL1	0.58	6.89	0.4	4.62e-11	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23308293	chr11:74660156	XRRA1;SPCS2	0.48	6.03	0.36	5.96e-9	Parkinson's disease;
KIRP	cis	rs71277158	0.688	rs73879180	chr3:169874968	T/C	cg04067573	chr3:169899625	PHC3	0.65	5.86	0.35	1.45e-8	Prostate cancer;
KIRP	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.99	-16.1	-0.72	2.62e-40	Height;
KIRP	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.55	-7.48	-0.43	1.3e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.85	12.83	0.63	3.53e-29	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.62	-8.52	-0.48	1.57e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg11859384	chr17:80120422	CCDC57	-0.4	-5.3	-0.32	2.6e-7	Life satisfaction;
KIRP	cis	rs9434723	0.765	rs2268171	chr1:9302315	C/T	cg04199779	chr1:9294473	H6PD	0.43	5.08	0.31	7.54e-7	Height;
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg12463550	chr7:65579703	CRCP	-0.44	-4.95	-0.3	1.39e-6	Aortic root size;
KIRP	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg12573791	chr2:3828286	NA	0.42	5.78	0.35	2.2e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.51	-6.74	-0.4	1.09e-10	Blood metabolite levels;
KIRP	cis	rs13401104	0.796	rs1466204	chr2:237121154	C/A	cg19324714	chr2:237145437	ASB18	0.48	4.99	0.3	1.13e-6	Educational attainment;
KIRP	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.72	0.49	4.16e-16	Motion sickness;
KIRP	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.87	10.85	0.57	1.17e-22	Coronary artery disease;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00802000	chr16:706648	WDR90	-0.42	-5.26	-0.32	3.07e-7	Height;
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.66	0.68	2.07e-35	Platelet count;
KIRP	cis	rs9581857	0.579	rs9581836	chr13:27963824	T/G	cg22138327	chr13:27999177	GTF3A	1.03	7.44	0.43	1.72e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9649213	0.574	rs7802560	chr7:97903806	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.38	-4.9	-0.3	1.73e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg22906224	chr7:99728672	NA	-0.65	-7.82	-0.45	1.58e-13	Coronary artery disease;
KIRP	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-0.78	-9.84	-0.53	1.77e-19	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	13.5	0.65	1.83e-31	Platelet count;
KIRP	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.44	5.81	0.35	1.91e-8	Homoarginine levels;
KIRP	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg06483076	chr3:194406458	FAM43A	0.46	6.9	0.4	4.32e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18252515	chr7:66147081	NA	0.43	5.09	0.31	6.97e-7	Aortic root size;
KIRP	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.44	4.93	0.3	1.53e-6	Schizophrenia;
KIRP	cis	rs4728302	0.585	rs7798673	chr7:133584077	C/T	cg10665199	chr7:133106180	EXOC4	0.43	5.0	0.3	1.1e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg05941025	chr16:89927596	SPIRE2	0.34	5.33	0.32	2.27e-7	Vitiligo;
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.91	-0.35	1.14e-8	Life satisfaction;
KIRP	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.43	-5.14	-0.31	5.66e-7	Facial morphology (factor 20);
KIRP	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg22283653	chr8:49824208	NA	0.45	6.1	0.36	4.17e-9	Sudden cardiac arrest;
KIRP	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18252515	chr7:66147081	NA	-0.45	-5.48	-0.33	1.04e-7	Aortic root size;
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg00933542	chr6:150070202	PCMT1	0.31	5.91	0.35	1.14e-8	Lung cancer;
KIRP	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.57	-7.71	-0.44	3.15e-13	Vitiligo;
KIRP	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	9.9	0.53	1.17e-19	Systolic blood pressure;
KIRP	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg26875233	chr11:93583750	C11orf90	-0.39	-7.21	-0.42	6.93e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg05340658	chr4:99064831	C4orf37	-0.56	-7.0	-0.41	2.48e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg10254082	chr7:997346	NA	0.47	4.96	0.3	1.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.93	-9.28	-0.51	9.29e-18	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-6.2	-0.37	2.4e-9	Bipolar disorder;
KIRP	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.65	-7.79	-0.44	1.88e-13	Iron status biomarkers;
KIRP	cis	rs7116495	1.000	rs73539529	chr11:71815596	T/C	cg18441811	chr11:71824068	C11orf51	0.63	5.06	0.31	8.02e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.58	-7.28	-0.42	4.62e-12	Uric acid levels;
KIRP	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg08648136	chr8:956695	NA	0.49	7.68	0.44	3.77e-13	Schizophrenia;
KIRP	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.06	-0.36	5.18e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg05791153	chr7:19748676	TWISTNB	0.68	6.16	0.37	2.99e-9	Thyroid stimulating hormone;
KIRP	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.75	8.11	0.46	2.4e-14	Uric acid levels;
KIRP	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg08847533	chr14:75593920	NEK9	-0.53	-6.14	-0.36	3.35e-9	IgG glycosylation;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg26200001	chr6:56955042	ZNF451	-0.48	-6.35	-0.38	1.01e-9	Myopia;
KIRP	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.5	-5.51	-0.33	8.97e-8	Total body bone mineral density;
KIRP	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	6.87	0.4	5.34e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62380364	0.542	rs2457979	chr5:88039660	T/A	cg24804195	chr5:87968844	LOC645323	-0.47	-6.18	-0.37	2.7e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs75920871	0.528	rs10892071	chr11:116954565	C/T	cg04087571	chr11:116723030	SIK3	-0.25	-5.36	-0.32	1.9e-7	Subjective well-being;
KIRP	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg04490037	chr7:50633773	DDC	0.41	5.01	0.3	1.04e-6	Malaria;
KIRP	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.73	-10.22	-0.55	1.17e-20	Menopause (age at onset);
KIRP	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.65	9.44	0.52	3.04e-18	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11995069	chr11:47600522	KBTBD4;NDUFS3	0.49	6.08	0.36	4.57e-9	Parkinson's disease;
KIRP	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21545522	chr1:205238299	TMCC2	0.47	6.25	0.37	1.83e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2061333	0.557	rs28539456	chr19:44607547	G/T	cg21636353	chr19:44617292	ZNF225	-0.49	-5.14	-0.31	5.62e-7	Alzheimer's disease;
KIRP	cis	rs4742903	1.000	rs4742906	chr9:106857078	A/G	cg14250997	chr9:106856677	SMC2	0.4	5.18	0.31	4.7e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs2290402	0.505	rs17165087	chr4:845841	C/T	cg00846425	chr4:957561	DGKQ	-0.51	-5.61	-0.34	5.48e-8	Type 2 diabetes;
KIRP	cis	rs9912468	1.000	rs9910355	chr17:64315205	A/C	cg19474267	chr17:64306194	PRKCA	-0.66	-9.46	-0.52	2.58e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.29	5.85	0.35	1.6e-8	Schizophrenia;
KIRP	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg13660082	chr14:53194042	PSMC6	-0.78	-7.44	-0.43	1.68e-12	Alzheimer's disease (late onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20001609	chr4:106629840	INTS12;GSTCD	0.45	6.06	0.36	4.99e-9	Parkinson's disease;
KIRP	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.98	6.64	0.39	1.96e-10	LDL cholesterol;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.73	11.15	0.58	1.25e-23	Menarche (age at onset);
KIRP	cis	rs9399401	0.667	rs6912639	chr6:142770548	T/C	cg03128060	chr6:142623767	GPR126	0.35	5.19	0.31	4.39e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg00405596	chr8:11794950	NA	-0.44	-4.97	-0.3	1.28e-6	Rheumatoid arthritis;
KIRP	cis	rs4765905	0.610	rs11062156	chr12:2317523	C/T	cg10668781	chr12:2307325	CACNA1C	-0.29	-5.77	-0.35	2.32e-8	Schizophrenia;
KIRP	trans	rs1106684	0.929	rs888540	chr7:131454224	G/A	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.9	-0.57	7.71e-23	Neuroticism;
KIRP	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg22437258	chr11:111473054	SIK2	0.6	7.15	0.41	9.85e-12	Primary sclerosing cholangitis;
KIRP	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.3	-0.32	2.6e-7	Crohn's disease;
KIRP	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.84	8.87	0.49	1.52e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.97	-13.98	-0.67	4.45e-33	Chronic sinus infection;
KIRP	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg20991723	chr1:152506922	NA	-0.46	-5.5	-0.33	9.59e-8	Hair morphology;
KIRP	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-4.9	-0.3	1.71e-6	Pulmonary function;
KIRP	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.8	8.74	0.49	3.62e-16	Coronary artery disease;
KIRP	cis	rs7927370	0.558	rs61897473	chr11:55611511	C/A	cg07850316	chr11:56344833	OR5M10;OR8U8	0.68	5.25	0.32	3.25e-7	Systemic lupus erythematosus;
KIRP	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg05072774	chr3:49840536	C3orf54	0.43	5.47	0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4660306	0.961	rs2152077	chr1:45986670	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.6	-8.17	-0.46	1.59e-14	Homocysteine levels;
KIRP	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.53	-6.8	-0.4	7.8e-11	Type 2 diabetes;
KIRP	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg08501292	chr6:25962987	TRIM38	0.7	4.92	0.3	1.6e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg08885076	chr2:99613938	TSGA10	0.53	9.0	0.5	6.34e-17	Chronic sinus infection;
KIRP	cis	rs35883536	0.875	rs1970227	chr1:101140723	G/A	cg06223162	chr1:101003688	GPR88	-0.33	-6.65	-0.39	1.89e-10	Monocyte count;
KIRP	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.67	9.43	0.52	3.12e-18	Cancer;
KIRP	cis	rs1011018	0.955	rs7782128	chr7:139441661	C/T	cg03224163	chr7:139420300	HIPK2	0.47	5.06	0.31	8.33e-7	Systolic blood pressure;
KIRP	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-7.86	-0.45	1.21e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2120019	0.507	rs4886642	chr15:75228846	T/C	cg17294928	chr15:75287854	SCAMP5	-0.6	-5.84	-0.35	1.61e-8	Blood trace element (Zn levels);
KIRP	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg02367723	chr1:46378857	MAST2	0.45	5.24	0.32	3.47e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg16672083	chr15:72433130	SENP8	0.45	6.28	0.37	1.56e-9	Red blood cell count;
KIRP	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	5.52	0.33	8.45e-8	Bipolar disorder;
KIRP	cis	rs16937956	0.657	rs3751096	chr11:8435078	A/C	cg08015107	chr11:8618950	NA	-0.56	-7.33	-0.42	3.28e-12	Body mass index;
KIRP	cis	rs394563	0.967	rs438852	chr6:149794533	C/T	cg03678062	chr6:149772716	ZC3H12D	0.35	5.4	0.33	1.6e-7	Dupuytren's disease;
KIRP	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.22	-0.51	1.34e-17	Response to antipsychotic treatment;
KIRP	cis	rs4930776	0.838	rs368436	chr12:5754618	T/C	cg02086166	chr12:5775618	ANO2	0.39	4.85	0.3	2.19e-6	Plasma clusterin levels;
KIRP	cis	rs6681460	0.649	rs967325	chr1:67003722	C/T	cg13052034	chr1:66999238	SGIP1	0.4	5.35	0.32	1.97e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg07636037	chr3:49044803	WDR6	-0.56	-5.12	-0.31	6.08e-7	Menarche (age at onset);
KIRP	cis	rs6541297	0.699	rs4846916	chr1:230296492	G/A	cg20703242	chr1:230279135	GALNT2	0.33	4.9	0.3	1.76e-6	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1982963	1.000	rs3818187	chr14:52509788	A/G	cg10843707	chr14:52510701	NID2	0.34	4.93	0.3	1.54e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg27624424	chr6:160112604	SOD2	0.55	6.52	0.38	3.94e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg15880211	chr22:50250494	ZBED4	-0.68	-7.66	-0.44	4.2e-13	Schizophrenia;
KIRP	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.51	6.57	0.39	2.92e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.5	6.78	0.4	9e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs10924970	0.967	rs12739707	chr1:235466564	C/G	cg26050004	chr1:235667680	B3GALNT2	0.4	5.05	0.31	8.58e-7	Asthma;
KIRP	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	trans	rs13170463	0.579	rs11740013	chr5:8039797	C/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7224685	0.569	rs965515	chr17:4038149	G/A	cg09597638	chr17:3907349	NA	0.52	5.2	0.31	4.19e-7	Type 2 diabetes;
KIRP	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-1.05	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	6.7	0.39	1.38e-10	Electroencephalogram traits;
KIRP	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	9.96	0.54	7.42e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19567168	chr12:6438502	TNFRSF1A	0.51	6.81	0.4	7.4e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg04317338	chr11:64019027	PLCB3	0.39	4.91	0.3	1.63e-6	Platelet count;
KIRP	cis	rs7615316	1.000	rs9824893	chr3:142341152	A/T	cg20824294	chr3:142316082	PLS1	0.22	4.93	0.3	1.55e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	5.92	0.35	1.1e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.59	7.07	0.41	1.56e-11	Aortic root size;
KIRP	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg16586182	chr3:47516702	SCAP	-0.84	-11.97	-0.61	2.56e-26	Colorectal cancer;
KIRP	cis	rs6693295	0.877	rs10924535	chr1:246351720	A/T	cg11798871	chr1:246315928	SMYD3	-0.6	-6.58	-0.39	2.84e-10	Migraine - clinic-based;Migraine with aura;
KIRP	trans	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.34	-0.37	1.09e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2273156	0.706	rs12881698	chr14:35503505	G/A	cg09327582	chr14:35236912	BAZ1A	-0.49	-4.97	-0.3	1.26e-6	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs10073892	0.625	rs9327814	chr5:101617905	T/C	cg19774478	chr5:101632501	SLCO4C1	0.61	6.11	0.36	3.82e-9	Cognitive decline (age-related);
KIRP	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.72	-12.73	-0.63	7.52e-29	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs9473924	0.542	rs2245173	chr6:50810540	T/C	cg14470998	chr6:50812995	TFAP2B	1.01	9.07	0.5	3.83e-17	Body mass index;
KIRP	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.51	-7.24	-0.42	5.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.59	8.93	0.49	9.95e-17	Personality dimensions;
KIRP	cis	rs735860	0.712	rs6909592	chr6:53163090	C/G	cg10236188	chr6:53219634	NA	0.4	5.42	0.33	1.42e-7	Glaucoma;
KIRP	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-0.85	-10.0	-0.54	5.73e-20	Gut microbiome composition (summer);
KIRP	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.7	-8.39	-0.47	3.94e-15	Obesity-related traits;
KIRP	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg10547527	chr2:198650123	BOLL	-0.55	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg25650185	chr19:21324782	ZNF431	-0.48	-5.08	-0.31	7.5e-7	Pain;
KIRP	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.69	-9.26	-0.51	1.03e-17	Total body bone mineral density;
KIRP	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.59	-7.07	-0.41	1.64e-11	Monocyte count;
KIRP	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.21	0.61	4.01e-27	Platelet count;
KIRP	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.84	12.35	0.62	1.41e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.9	-14.39	-0.68	1.8e-34	Height;
KIRP	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg11234688	chr2:1609660	NA	0.53	4.97	0.3	1.24e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4356932	1.000	rs4616778	chr4:76981206	C/T	cg00809888	chr4:76862425	NAAA	-0.45	-6.3	-0.37	1.38e-9	Blood protein levels;
KIRP	cis	rs9393813	1.000	rs6913166	chr6:27355460	C/T	cg18711553	chr6:27366782	ZNF391	-0.37	-5.43	-0.33	1.38e-7	Bipolar disorder;
KIRP	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg11846333	chr4:119757529	SEC24D	0.96	5.76	0.34	2.47e-8	Cannabis dependence symptom count;
KIRP	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.08	-0.31	7.59e-7	Breast cancer;
KIRP	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.58	7.24	0.42	5.58e-12	Fibrinogen levels;
KIRP	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg08501292	chr6:25962987	TRIM38	0.93	7.61	0.44	5.83e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg04369109	chr6:150039330	LATS1	-0.65	-8.51	-0.48	1.76e-15	Lung cancer;
KIRP	cis	rs3754214	0.857	rs488271	chr1:150284534	A/G	cg07843065	chr1:150265600	MRPS21	-0.51	-7.34	-0.42	3.15e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.46	-6.38	-0.38	8.6e-10	Personality dimensions;
KIRP	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg14132834	chr19:41945861	ATP5SL	0.57	7.37	0.43	2.64e-12	Height;
KIRP	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	4.92	0.3	1.55e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2916247	1.000	rs2916248	chr8:93013260	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.61	-7.94	-0.45	7.15e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.4	-5.57	-0.33	6.51e-8	Blood metabolite levels;
KIRP	cis	rs2000999	0.514	rs17604676	chr16:72221984	C/T	cg04254540	chr16:71951199	KIAA0174	-0.8	-5.91	-0.35	1.14e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
KIRP	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.41	4.93	0.3	1.5e-6	Diastolic blood pressure;
KIRP	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg26752888	chr8:11627280	NEIL2	-0.43	-5.21	-0.32	3.92e-7	Myopia (pathological);
KIRP	cis	rs918629	0.798	rs3777168	chr5:95285771	G/A	cg16656078	chr5:95278638	ELL2	-0.51	-7.25	-0.42	5.26e-12	IgG glycosylation;
KIRP	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-8.9	-0.49	1.21e-16	Urate levels in overweight individuals;
KIRP	cis	rs12210905	0.920	rs9366690	chr6:27291079	T/C	cg11502198	chr6:26597334	ABT1	-0.8	-4.94	-0.3	1.43e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.28	-0.32	2.78e-7	Bladder cancer;
KIRP	cis	rs4356932	0.967	rs6837830	chr4:76980179	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	10.63	0.56	5.97e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.84	10.2	0.55	1.3e-20	Migraine;
KIRP	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg08885076	chr2:99613938	TSGA10	0.43	6.55	0.39	3.38e-10	Bipolar disorder;
KIRP	cis	rs6568686	0.576	rs12201640	chr6:111618318	G/A	cg15721981	chr6:111408429	SLC16A10	0.76	7.04	0.41	1.93e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	trans	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.49	6.75	0.4	1.07e-10	Endometrial cancer;
KIRP	cis	rs2742234	0.955	rs2435385	chr10:43665750	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.62	-7.41	-0.43	2.01e-12	Hirschsprung disease;
KIRP	cis	rs7640424	0.649	rs62262420	chr3:107909940	C/T	cg09227934	chr3:107805635	CD47	-0.36	-6.07	-0.36	4.71e-9	Body mass index;
KIRP	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg23791538	chr6:167370224	RNASET2	-0.42	-5.36	-0.32	1.89e-7	Crohn's disease;
KIRP	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.56	6.9	0.4	4.26e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg02026896	chr6:158589113	GTF2H5;SERAC1	0.49	6.02	0.36	6.24e-9	DNA methylation (variation);
KIRP	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg21775007	chr8:11205619	TDH	0.5	6.75	0.4	1.03e-10	Mood instability;
KIRP	cis	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg21546286	chr11:48923668	NA	0.4	4.87	0.3	2e-6	HDL cholesterol;
KIRP	cis	rs992157	0.932	rs10203039	chr2:219187367	T/C	cg00012203	chr2:219082015	ARPC2	0.78	10.77	0.57	2.04e-22	Colorectal cancer;
KIRP	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg14517863	chr17:44321492	NA	0.5	5.84	0.35	1.68e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.5	7.59	0.44	6.67e-13	Bone mineral density;
KIRP	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg11235152	chr1:67600687	NA	-0.7	-10.56	-0.56	9.96e-22	Psoriasis;
KIRP	cis	rs2131877	0.645	rs903310	chr3:194875944	C/T	cg16306870	chr3:194868790	C3orf21	0.21	5.13	0.31	5.85e-7	Non-small cell lung cancer;
KIRP	cis	rs6256	1.000	rs6256	chr11:13514053	G/T	cg11976911	chr11:13509032	NA	-0.61	-5.07	-0.31	7.93e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18867708	chr6:26865862	GUSBL1	0.47	5.9	0.35	1.21e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg00531865	chr16:30841666	NA	-0.38	-4.96	-0.3	1.35e-6	Multiple myeloma;
KIRP	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg23601095	chr6:26197514	HIST1H3D	0.98	8.28	0.47	8.02e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.16	0.67	1.06e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg18306943	chr3:40428807	ENTPD3	-0.38	-5.03	-0.31	9.36e-7	Renal cell carcinoma;
KIRP	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg13010199	chr12:38710504	ALG10B	-0.48	-6.02	-0.36	6.14e-9	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-6.92	-0.4	3.8e-11	Total body bone mineral density;
KIRP	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg01721255	chr8:58191610	C8orf71	0.48	5.18	0.31	4.69e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.21	0.37	2.18e-9	Hemoglobin concentration;
KIRP	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	9.49	0.52	2.13e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg09035930	chr12:129282057	SLC15A4	1.07	19.45	0.78	1.16e-51	Systemic lupus erythematosus;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06158944	chr4:99182422	RAP1GDS1	-0.5	-6.76	-0.4	1e-10	Metabolic traits;
KIRP	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg03060546	chr3:49711283	APEH	-0.59	-5.19	-0.31	4.43e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg10018233	chr7:150070692	REPIN1	0.73	9.42	0.51	3.37e-18	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.27	-0.32	2.91e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg23479056	chr15:41276147	INO80	-0.36	-4.93	-0.3	1.5e-6	Menopause (age at onset);
KIRP	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.73	-8.34	-0.47	5.24e-15	Corneal astigmatism;
KIRP	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.33	-0.32	2.18e-7	Personality dimensions;
KIRP	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.3	-6.04	-0.36	5.56e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg19507638	chr5:93509721	C5orf36	-0.57	-5.51	-0.33	8.85e-8	Diabetic retinopathy;
KIRP	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg20891283	chr12:69753455	YEATS4	0.65	6.79	0.4	8.54e-11	Response to diuretic therapy;
KIRP	cis	rs28834970	0.571	rs12679874	chr8:27230819	A/G	cg23693289	chr8:27183097	PTK2B	-0.42	-4.86	-0.3	2.08e-6	Alzheimer's disease (late onset);
KIRP	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08997352	chr12:9597637	DDX12	-0.45	-4.93	-0.3	1.53e-6	IgG glycosylation;
KIRP	cis	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg20368463	chr18:77673604	PQLC1	-0.47	-5.11	-0.31	6.34e-7	Opioid sensitivity;
KIRP	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg11642891	chr2:3452563	TTC15	-0.55	-7.02	-0.41	2.16e-11	Obesity-related traits;
KIRP	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg08603382	chr10:743973	NA	-0.52	-8.14	-0.46	1.97e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg24253500	chr15:84953950	NA	0.67	7.78	0.44	2.01e-13	Schizophrenia;
KIRP	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg01620082	chr3:125678407	NA	-1.08	-6.73	-0.39	1.18e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.64	6.74	0.39	1.14e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.92	10.72	0.56	2.94e-22	Corneal astigmatism;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.68	-10.2	-0.55	1.37e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7106204	0.534	rs77761450	chr11:24338593	G/A	ch.11.24196551F	chr11:24239977	NA	0.7	4.87	0.3	2.02e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35955841	0.569	rs1570295	chr14:65310367	C/T	cg23373153	chr14:65346875	NA	0.41	5.78	0.35	2.2e-8	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.67	-6.84	-0.4	6.21e-11	Bronchopulmonary dysplasia;
KIRP	cis	rs12318506	0.826	rs11180453	chr12:75694006	T/C	cg04728562	chr12:75699417	CAPS2	-0.87	-5.9	-0.35	1.18e-8	Coronary artery calcification;
KIRP	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg12560992	chr17:57184187	TRIM37	0.6	5.64	0.34	4.62e-8	Cognitive test performance;
KIRP	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.62	-6.92	-0.4	3.82e-11	Gut microbiome composition (summer);
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.59	8.0	0.45	4.94e-14	Mean corpuscular volume;
KIRP	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.65	9.06	0.5	4.27e-17	Lymphocyte counts;
KIRP	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg02725872	chr8:58115012	NA	-0.59	-7.35	-0.42	2.92e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg16329650	chr2:213403929	ERBB4	0.44	6.08	0.36	4.58e-9	Symmetrical dimethylarginine levels;
KIRP	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg26248373	chr2:1572462	NA	-0.63	-5.73	-0.34	2.88e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02784301	chr16:23194194	SCNN1G	0.52	6.92	0.4	3.87e-11	Parkinson's disease;
KIRP	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.63	8.3	0.47	7.11e-15	Body mass index;
KIRP	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.35	-4.88	-0.3	1.95e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg17372223	chr3:52568218	NT5DC2	-0.36	-5.85	-0.35	1.55e-8	Electroencephalogram traits;
KIRP	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.82	-0.53	1.98e-19	Triglycerides;
KIRP	cis	rs9462846	1.000	rs2395941	chr6:42867821	G/A	cg13397359	chr6:42928475	GNMT	0.44	4.92	0.3	1.55e-6	Blood protein levels;
KIRP	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg00277334	chr10:82204260	NA	-0.5	-5.76	-0.34	2.53e-8	Post bronchodilator FEV1;
KIRP	cis	rs597583	0.502	rs3016797	chr11:117409884	G/C	cg27161313	chr11:117392002	DSCAML1	-0.77	-6.23	-0.37	2.06e-9	Putamen volume;
KIRP	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.93	10.67	0.56	4.17e-22	Corneal astigmatism;
KIRP	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg17243659	chr21:48055224	PRMT2	1.05	6.22	0.37	2.15e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.51	0.52	1.83e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.47	-5.2	-0.31	4.24e-7	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg12131826	chr15:77904385	NA	0.44	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.97	-0.36	8.1e-9	IgG glycosylation;
KIRP	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	16.01	0.71	5.24e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9473924	0.632	rs6933099	chr6:50896577	G/A	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.72	-8.07	-0.46	3.17e-14	Menarche (age at onset);
KIRP	cis	rs6921919	0.525	rs11760133	chr6:28386739	A/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.32	-0.37	1.23e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs3825932	0.961	rs28655102	chr15:79232700	C/T	cg25744700	chr15:79237217	CTSH	0.42	5.08	0.31	7.38e-7	Type 1 diabetes;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg18789337	chr6:114180353	MARCKS	0.42	6.19	0.37	2.44e-9	Ischemic stroke;
KIRP	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.92	14.65	0.68	2.32e-35	Blood protein levels;
KIRP	cis	rs68092024	0.731	rs793480	chr3:99488364	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.41	-4.94	-0.3	1.42e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs7215564	0.908	rs35844609	chr17:78664850	T/C	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.7	-9.49	-0.52	2.13e-18	Metabolic syndrome;
KIRP	cis	rs12282928	0.959	rs12790767	chr11:48332171	G/A	cg26585981	chr11:48327164	OR4S1	0.52	6.33	0.37	1.15e-9	Migraine - clinic-based;
KIRP	cis	rs1620921	0.870	rs62436729	chr6:161210806	T/A	cg01280913	chr6:161186852	NA	-0.4	-5.49	-0.33	9.89e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1555895	0.543	rs1555898	chr10:853783	T/C	cg10017260	chr10:834428	NA	-0.47	-6.99	-0.41	2.52e-11	Survival in rectal cancer;
KIRP	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.6	7.76	0.44	2.2e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.24	-0.55	1.01e-20	Response to antipsychotic treatment;
KIRP	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-5.24	-0.32	3.51e-7	Triglycerides;
KIRP	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03576123	chr11:487126	PTDSS2	-1.06	-7.22	-0.42	6.53e-12	Body mass index;
KIRP	cis	rs7694379	0.508	rs58073039	chr4:88287363	A/G	cg23841344	chr4:88312519	HSD17B11	0.43	5.03	0.31	9.44e-7	Platelet count;
KIRP	cis	rs4664293	0.967	rs6432548	chr2:160545537	T/C	cg08347373	chr2:160653686	CD302	-0.39	-5.94	-0.35	9.93e-9	Monocyte percentage of white cells;
KIRP	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.69	-11.0	-0.57	3.75e-23	Calcium levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg05863116	chr5:133562407	PPP2CA	0.55	7.18	0.42	8.36e-12	Myopia (pathological);
KIRP	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg16898833	chr6:26189333	HIST1H4D	0.73	5.25	0.32	3.31e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg03929089	chr4:120376271	NA	-0.77	-6.91	-0.4	4.16e-11	Intraocular pressure;
KIRP	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.97	-14.58	-0.68	3.97e-35	Coronary artery disease;
KIRP	cis	rs10210302	0.504	rs1000141	chr2:234242347	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	6.67	0.39	1.69e-10	Crohn's disease;
KIRP	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg01346077	chr3:125931526	NA	-0.29	-4.91	-0.3	1.69e-6	Metabolite levels;
KIRP	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.37	-4.87	-0.3	1.97e-6	Menarche (age at onset);
KIRP	cis	rs7729447	0.813	rs4867470	chr5:32692536	C/A	cg16267343	chr5:32710456	NPR3	0.52	6.04	0.36	5.8e-9	Blood pressure;
KIRP	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg16141378	chr3:129829833	LOC729375	0.53	6.97	0.41	2.89e-11	Morning vs. evening chronotype;
KIRP	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.54	7.2	0.42	7.21e-12	Mean corpuscular volume;
KIRP	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	0.91	13.58	0.65	1.03e-31	Primary sclerosing cholangitis;
KIRP	trans	rs62056376	0.736	rs62054939	chr17:32645165	T/C	cg09712683	chr2:95692352	MAL	-0.46	-6.23	-0.37	2.01e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs6466055	0.576	rs2106500	chr7:104616744	G/A	cg04380332	chr7:105027541	SRPK2	-0.39	-5.29	-0.32	2.74e-7	Schizophrenia;
KIRP	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.58	0.34	6.27e-8	Resting heart rate;
KIRP	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg05805236	chr11:65401703	PCNXL3	-0.52	-6.9	-0.4	4.34e-11	Acne (severe);
KIRP	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.42	-5.3	-0.32	2.55e-7	Crohn's disease;
KIRP	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.62	7.95	0.45	6.88e-14	Alcohol dependence;
KIRP	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.84	11.75	0.6	1.31e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2224391	0.628	rs2773307	chr6:5244290	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.48	-0.38	5.09e-10	Height;
KIRP	cis	rs918629	0.567	rs1057964	chr5:95235627	T/C	cg16656078	chr5:95278638	ELL2	-0.36	-5.49	-0.33	9.75e-8	IgG glycosylation;
KIRP	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.29	-6.02	-0.36	6.29e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs17401966	0.522	rs12133617	chr1:10288463	C/T	cg17425144	chr1:10567563	PEX14	-0.29	-5.06	-0.31	8.3e-7	Hepatocellular carcinoma;
KIRP	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg12131826	chr15:77904385	NA	0.43	5.62	0.34	5.12e-8	Type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg25846339	chr11:85359022	TMEM126A	0.52	6.05	0.36	5.32e-9	Sleep duration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17688733	chr19:14201991	SAMD1	0.57	7.51	0.43	1.12e-12	Parkinson's disease;
KIRP	cis	rs7551222	0.721	rs4252717	chr1:204512100	T/C	cg20240347	chr1:204465584	NA	-0.45	-8.73	-0.49	3.91e-16	Schizophrenia;
KIRP	cis	rs7945718	0.591	rs12797960	chr11:12841771	T/C	ch.11.340609R	chr11:12831013	TEAD1	0.4	4.99	0.3	1.17e-6	Educational attainment (years of education);
KIRP	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg04733989	chr22:42467013	NAGA	0.57	7.64	0.44	4.9e-13	Cognitive function;
KIRP	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.33	5.05	0.31	8.76e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7565981	1.000	rs13398996	chr2:101426869	G/T	cg02232089	chr2:101440696	NPAS2	-0.57	-5.3	-0.32	2.59e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.58	-6.54	-0.38	3.51e-10	Hypospadias;
KIRP	cis	rs10128264	0.902	rs1250588	chr10:80980169	T/C	cg18737081	chr10:80999807	ZMIZ1	-0.32	-5.87	-0.35	1.41e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.49	7.44	0.43	1.67e-12	Testicular germ cell tumor;
KIRP	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.45	-5.45	-0.33	1.21e-7	P wave terminal force;
KIRP	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs9354308	0.702	rs2814132	chr6:66561267	A/G	cg07460842	chr6:66804631	NA	0.4	4.94	0.3	1.44e-6	Metabolite levels;
KIRP	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.7	8.65	0.48	6.56e-16	Neutrophil percentage of white cells;
KIRP	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.62	-11.78	-0.6	1.09e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs876084	0.722	rs1401812	chr8:121042631	G/A	cg22335954	chr8:121166405	COL14A1	-0.4	-5.02	-0.3	9.95e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.66	9.7	0.53	4.85e-19	Metabolite levels;
KIRP	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.44	5.88	0.35	1.32e-8	Homoarginine levels;
KIRP	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02804564	chr10:112679224	NCRNA00081;SHOC2	0.46	6.14	0.36	3.22e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.76	9.62	0.52	8.5e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs737693	1.000	rs72981680	chr11:102721859	C/A	cg19620758	chr11:102826565	MMP13	0.71	5.65	0.34	4.42e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg10756647	chr7:56101905	PSPH	-0.84	-6.74	-0.39	1.12e-10	Diabetic kidney disease;
KIRP	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg21395723	chr22:39101663	GTPBP1	0.44	5.39	0.33	1.63e-7	Menopause (age at onset);
KIRP	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg04691961	chr3:161091175	C3orf57	-0.39	-5.89	-0.35	1.27e-8	Morning vs. evening chronotype;
KIRP	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg01765077	chr12:122356316	WDR66	0.58	8.04	0.46	3.89e-14	Mean corpuscular volume;
KIRP	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.13e-20	Dupuytren's disease;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.78	-12.08	-0.61	1.08e-26	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10861661	0.856	rs4964190	chr12:107216359	C/T	cg21360079	chr12:107162445	NA	-0.49	-6.27	-0.37	1.62e-9	Triglyceride levels;
KIRP	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg12435725	chr3:58293450	RPP14	-0.47	-5.47	-0.33	1.09e-7	Cholesterol, total;
KIRP	cis	rs9914578	1.000	rs4061660	chr17:2004377	C/T	cg16513277	chr17:2031491	SMG6	-0.74	-8.88	-0.49	1.43e-16	Body mass index;
KIRP	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	8.83	0.49	1.96e-16	Eye color traits;
KIRP	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.52	-0.33	8.77e-8	Fractional excretion of uric acid;
KIRP	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.62	-7.34	-0.42	3.16e-12	Bipolar disorder;
KIRP	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.66	8.26	0.47	9.27e-15	Red blood cell count;
KIRP	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.77	-10.36	-0.55	4.28e-21	Huntington's disease progression;
KIRP	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.76	10.8	0.57	1.63e-22	Height;
KIRP	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.93	13.79	0.66	2.02e-32	Tonsillectomy;
KIRP	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg00241281	chr14:105779794	PACS2	-0.35	-5.02	-0.3	9.81e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03934478	chr11:495069	RNH1	0.87	7.08	0.41	1.46e-11	Body mass index;
KIRP	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg24807547	chr6:37504484	NA	-0.55	-8.23	-0.46	1.13e-14	Cognitive performance;
KIRP	cis	rs4704187	0.687	rs4704179	chr5:74457273	C/T	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs9653442	0.527	rs11123812	chr2:100761548	T/C	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg10932868	chr11:921992	NA	0.65	8.77	0.49	3.03e-16	Alzheimer's disease (late onset);
KIRP	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg26876637	chr1:152193138	HRNR	0.74	9.76	0.53	3.1e-19	Atopic dermatitis;
KIRP	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.19	0.42	7.66e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7814319	0.700	rs3808385	chr8:97273513	C/T	cg20787634	chr8:97240163	UQCRB	-0.58	-7.65	-0.44	4.62e-13	Lung function (FVC);
KIRP	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.77	-10.96	-0.57	4.94e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.7	-0.44	3.38e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg16988262	chr1:15930761	NA	0.37	4.86	0.3	2.06e-6	Systolic blood pressure;
KIRP	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.72	8.29	0.47	7.66e-15	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg00732059	chr16:71740210	PHLPP2	-0.57	-5.46	-0.33	1.16e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.52	-6.62	-0.39	2.26e-10	Schizophrenia;
KIRP	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.84	-0.4	6.4e-11	Aortic root size;
KIRP	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.71	-10.51	-0.56	1.41e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.88	-14.22	-0.67	6.85e-34	Headache;
KIRP	cis	rs13424612	0.868	rs6738667	chr2:240902570	A/G	cg19172429	chr2:240878313	NA	0.29	4.97	0.3	1.27e-6	Odorant perception (isobutyraldehyde);
KIRP	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.67	9.59	0.52	1.05e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.3	0.37	1.4e-9	Height;
KIRP	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.95	-13.09	-0.64	4.73e-30	Menopause (age at onset);
KIRP	cis	rs12930096	0.878	rs12917676	chr16:11680268	A/G	cg07439791	chr16:11680400	LITAF	0.67	5.47	0.33	1.09e-7	QT interval;
KIRP	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg13334819	chr7:99746414	C7orf59	0.53	6.0	0.36	6.85e-9	Coronary artery disease;
KIRP	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.67	-7.29	-0.42	4.22e-12	DNA methylation (variation);
KIRP	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	trans	rs34773007	0.610	rs11595537	chr10:94843688	C/T	cg10869376	chr13:41345315	MRPS31	0.71	6.21	0.37	2.25e-9	Type 2 diabetes;
KIRP	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	0.93	5.32	0.32	2.36e-7	Height;
KIRP	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-1.0	-16.84	-0.73	7.85e-43	Height;
KIRP	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg18825076	chr15:78729989	IREB2	-0.41	-4.92	-0.3	1.62e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg08499158	chr17:42289980	UBTF	-0.49	-6.21	-0.37	2.2e-9	Total body bone mineral density;
KIRP	cis	rs1978968	0.912	rs5992932	chr22:18456254	C/T	cg02610425	chr22:18483192	MICAL3	0.36	4.86	0.3	2.07e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.61	-9.45	-0.52	2.72e-18	Sense of smell;
KIRP	cis	rs687432	0.718	rs2441952	chr11:57792001	C/T	cg19752551	chr11:57585705	CTNND1	0.44	5.97	0.36	8.21e-9	Parkinson's disease;
KIRP	cis	rs59868192	0.925	rs1868831	chr15:42257929	C/T	cg20935245	chr15:42234343	EHD4	0.48	5.02	0.3	9.82e-7	White blood cell count;
KIRP	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.68	-0.53	5.51e-19	Coronary artery disease;
KIRP	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.71	11.14	0.58	1.34e-23	Glomerular filtration rate (creatinine);
KIRP	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg19336497	chr11:14380999	RRAS2	-0.36	-5.44	-0.33	1.27e-7	Mitochondrial DNA levels;
KIRP	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.73	-9.43	-0.52	3.24e-18	Multiple sclerosis;
KIRP	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.97e-44	Breast cancer;
KIRP	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.72	-9.54	-0.52	1.48e-18	Prudent dietary pattern;
KIRP	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg07827796	chr19:33622959	WDR88	-0.42	-5.04	-0.31	8.93e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.89	8.89	0.49	1.38e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7180079	1.000	rs2062249	chr15:64672159	C/A	cg15337035	chr15:64978493	NA	-0.47	-4.86	-0.3	2.12e-6	Monocyte count;
KIRP	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg13939156	chr17:80058883	NA	-0.48	-5.5	-0.33	9.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7998202	0.720	rs2274773	chr13:113343171	A/G	cg04656015	chr13:113407548	ATP11A	0.52	5.51	0.33	9.03e-8	Glycated hemoglobin levels;
KIRP	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-0.64	-6.29	-0.37	1.45e-9	Skin colour saturation;
KIRP	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.59	7.26	0.42	5.2e-12	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs1847202	0.793	rs13088835	chr3:72949861	A/T	cg06781948	chr3:72941472	GXYLT2	0.49	6.27	0.37	1.6e-9	Motion sickness;
KIRP	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg17143192	chr8:8559678	CLDN23	0.73	8.44	0.47	2.7e-15	Obesity-related traits;
KIRP	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.92	9.96	0.54	7.29e-20	Alzheimer's disease;
KIRP	cis	rs858239	0.539	rs6956828	chr7:23187347	A/G	cg23682824	chr7:23144976	KLHL7	0.53	6.21	0.37	2.22e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10875746	0.768	rs4760609	chr12:48415757	A/C	cg26205652	chr12:48591994	NA	-0.71	-9.64	-0.52	7.21e-19	Longevity (90 years and older);
KIRP	cis	rs7851660	0.805	rs4255258	chr9:100647545	A/G	cg13688889	chr9:100608707	NA	-0.68	-8.5	-0.48	1.83e-15	Strep throat;
KIRP	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.35	-4.94	-0.3	1.45e-6	Congenital heart disease (maternal effect);
KIRP	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.49	7.39	0.43	2.3e-12	Resting heart rate;
KIRP	cis	rs4788196	1	rs4788196	chr16:29967434	A/G	cg06326092	chr16:30034487	C16orf92	0.38	5.56	0.33	6.88e-8	Pubertal anthropometrics;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10521094	chr7:107262441	BCAP29	0.61	6.92	0.4	3.96e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.68	-0.53	5.51e-19	Coronary artery disease;
KIRP	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.78	-11.18	-0.58	9.85e-24	Recombination rate (males);
KIRP	cis	rs3741151	0.686	rs12291233	chr11:73272946	T/G	cg17517138	chr11:73019481	ARHGEF17	0.6	5.34	0.32	2.07e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.49	5.98	0.36	7.76e-9	Height;
KIRP	cis	rs7243821	0.672	rs11661650	chr18:52587751	A/G	cg26630735	chr18:52626848	CCDC68	0.49	5.02	0.3	9.94e-7	Chin dimples;
KIRP	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg18882449	chr10:104885122	NT5C2	-0.51	-6.56	-0.39	3.07e-10	Arsenic metabolism;
KIRP	cis	rs17023223	0.537	rs12065809	chr1:119724535	A/T	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg19694781	chr19:47549865	TMEM160	-0.5	-6.07	-0.36	4.69e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg23594656	chr7:65796392	TPST1	0.52	8.08	0.46	2.96e-14	Aortic root size;
KIRP	cis	rs7083	1.000	rs512188	chr11:117126710	C/T	cg11523350	chr11:117171073	BACE1	0.27	5.37	0.32	1.82e-7	Blood protein levels;
KIRP	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.79	10.03	0.54	4.67e-20	Longevity;
KIRP	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg17252645	chr8:143867129	LY6D	-0.31	-4.91	-0.3	1.69e-6	Urinary tract infection frequency;
KIRP	cis	rs3779635	0.874	rs881188	chr8:27276209	T/C	cg18234130	chr8:27182889	PTK2B	0.47	6.02	0.36	6.35e-9	Neuroticism;
KIRP	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.63	8.36	0.47	4.75e-15	Total body bone mineral density;
KIRP	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.6	-6.91	-0.4	4.24e-11	Menarche (age at onset);
KIRP	cis	rs77972916	0.536	rs11694173	chr2:43590899	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.52	5.6	0.34	5.8e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7611694	0.609	rs10934228	chr3:113099461	C/G	cg11138929	chr3:113251189	SIDT1	0.36	4.87	0.3	2.02e-6	Prostate cancer;
KIRP	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	8.98	0.5	7.38e-17	Migraine;Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.67	0.48	5.77e-16	Motion sickness;
KIRP	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg22532475	chr10:104410764	TRIM8	-0.32	-5.12	-0.31	6.13e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg05220968	chr6:146057943	EPM2A	0.39	5.0	0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.59	-7.39	-0.43	2.34e-12	Fibrinogen levels;
KIRP	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-0.61	-7.85	-0.45	1.25e-13	Red blood cell count;
KIRP	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.87	-14.06	-0.67	2.3e-33	Headache;
KIRP	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg25547332	chr5:131281432	NA	0.47	5.41	0.33	1.52e-7	Life satisfaction;
KIRP	cis	rs6132905	0.590	rs76972451	chr20:2599723	C/A	cg24848351	chr20:2622020	TMC2	-0.56	-5.02	-0.3	9.91e-7	Mumps;
KIRP	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.72	0.34	3.1e-8	Educational attainment;
KIRP	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-5.96	-0.36	8.8e-9	Lung cancer;
KIRP	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-7.58	-0.44	6.89e-13	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24500358	chr17:48450523	EME1;MRPL27	0.48	6.15	0.37	3.06e-9	Parkinson's disease;
KIRP	cis	rs2625529	0.586	rs59975112	chr15:72423710	G/T	cg16672083	chr15:72433130	SENP8	0.41	5.93	0.35	1.04e-8	Red blood cell count;
KIRP	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg09462578	chr12:12878428	APOLD1	-0.7	-7.28	-0.42	4.5e-12	Systemic lupus erythematosus;
KIRP	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.74	-9.57	-0.52	1.21e-18	Coronary artery disease;
KIRP	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.91	-0.64	1.9e-29	Exhaled nitric oxide output;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg11845111	chr2:191398756	TMEM194B	-0.96	-10.14	-0.54	2.04e-20	Diastolic blood pressure;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.43	-6.04	-0.36	5.73e-9	Longevity;
KIRP	cis	rs11969893	0.850	rs9390713	chr6:101424262	G/A	cg12253828	chr6:101329408	ASCC3	1.29	7.37	0.43	2.61e-12	Economic and political preferences (immigration/crime);
KIRP	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg05756136	chr1:119680316	WARS2	-0.62	-8.36	-0.47	4.76e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.59	-6.45	-0.38	5.81e-10	Aortic root size;
KIRP	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs3755605	0.520	rs1082975	chr3:169939512	T/C	cg02973263	chr3:169940162	PRKCI	0.43	4.91	0.3	1.67e-6	Testicular germ cell tumor;
KIRP	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.65	-7.2	-0.42	7.34e-12	Mean corpuscular hemoglobin;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg23693289	chr8:27183097	PTK2B	0.54	6.98	0.41	2.72e-11	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14103574	chr5:162932455	MAT2B	0.63	7.65	0.44	4.61e-13	Smoking initiation;
KIRP	cis	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg21775007	chr8:11205619	TDH	0.57	7.07	0.41	1.56e-11	Neuroticism;
KIRP	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.18	0.31	4.58e-7	Breast cancer;
KIRP	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.32e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2718058	0.769	rs12155159	chr7:37800529	G/A	cg15028436	chr7:37888078	TXNDC3	-0.44	-5.66	-0.34	4.24e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg03351412	chr1:154909251	PMVK	0.58	6.94	0.4	3.49e-11	Prostate cancer;
KIRP	cis	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg00405596	chr8:11794950	NA	-0.53	-6.63	-0.39	2.08e-10	Triglycerides;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg21186296	chr8:27182909	PTK2B	0.51	6.51	0.38	4.25e-10	Neuroticism;
KIRP	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg06521331	chr12:34319734	NA	-0.56	-6.81	-0.4	7.51e-11	Morning vs. evening chronotype;
KIRP	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.61	-7.44	-0.43	1.64e-12	Blood metabolite levels;
KIRP	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.32	8.58	0.48	1.08e-15	Crohn's disease;
KIRP	cis	rs7243821	0.639	rs11664604	chr18:52665457	T/C	cg26630735	chr18:52626848	CCDC68	0.54	5.72	0.34	3.11e-8	Chin dimples;
KIRP	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.95	10.3	0.55	6.53e-21	Cognitive test performance;
KIRP	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/C	cg09695851	chr17:3907499	NA	0.53	4.98	0.3	1.18e-6	Type 2 diabetes;
KIRP	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg15038512	chr6:170123185	PHF10	-0.56	-8.39	-0.47	3.91e-15	Obesity-related traits;
KIRP	cis	rs16958440	1.000	rs75800624	chr18:44633605	G/C	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs7224685	0.817	rs9901620	chr17:4165741	G/C	cg09597638	chr17:3907349	NA	0.54	6.19	0.37	2.57e-9	Type 2 diabetes;
KIRP	cis	rs4006360	0.629	rs7214220	chr17:39236627	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.6	-8.4	-0.47	3.69e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs6882716	0.636	rs1470023	chr5:10800150	A/G	cg14521931	chr5:10832172	NA	-0.76	-8.98	-0.5	7.12e-17	Alcohol consumption (maxi-drinks);
KIRP	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg17863274	chr19:49399704	TULP2	-0.41	-5.85	-0.35	1.57e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9962915	0.967	rs1719938	chr18:5590045	A/C	cg12967001	chr18:5544089	EPB41L3	-0.39	-4.85	-0.3	2.21e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs72730918	0.564	rs55725532	chr15:51800919	C/G	cg14296394	chr15:51910925	DMXL2	0.82	11.15	0.58	1.23e-23	Intelligence (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20295353	chr14:64989846	ZBTB1	-0.48	-6.66	-0.39	1.76e-10	Inflammatory biomarkers;
KIRP	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.42	0.33	1.44e-7	Melanoma;
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg22903657	chr4:1355424	KIAA1530	-0.41	-6.0	-0.36	6.93e-9	Obesity-related traits;
KIRP	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.56	-7.71	-0.44	3.07e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.58	7.0	0.41	2.39e-11	Mosquito bite size;
KIRP	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg10818794	chr15:86012489	AKAP13	-0.5	-7.15	-0.41	9.9e-12	Coronary artery disease;
KIRP	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.57	-5.3	-0.32	2.58e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2916247	0.954	rs35983766	chr8:93056882	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.7	-0.44	3.24e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1215050	0.782	rs6853916	chr4:98653387	C/T	cg05340658	chr4:99064831	C4orf37	-0.49	-6.02	-0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg00002236	chr18:67873061	RTTN	0.49	6.24	0.37	1.88e-9	Asthma;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg14830952	chr8:86089500	E2F5	0.5	6.24	0.37	1.94e-9	Educational attainment;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg14932796	chr17:55038330	COIL	0.77	6.55	0.39	3.32e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.53	6.97	0.41	2.94e-11	Longevity;
KIRP	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.67	9.03	0.5	5.12e-17	High light scatter reticulocyte count;
KIRP	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg24253500	chr15:84953950	NA	0.51	5.83	0.35	1.72e-8	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-7.61	-0.44	5.98e-13	Morning vs. evening chronotype;
KIRP	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.41	6.95	0.4	3.31e-11	Tumor biomarkers;
KIRP	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.66	7.97	0.45	6.03e-14	Vitiligo;
KIRP	cis	rs55788414	0.932	rs11649028	chr16:81185326	G/A	cg06400318	chr16:81190750	PKD1L2	0.82	8.45	0.47	2.54e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg17595323	chr11:93583763	C11orf90	-0.38	-6.36	-0.38	9.61e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg21401794	chr1:90099060	LRRC8C	-0.66	-9.21	-0.51	1.47e-17	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.61	0.52	9.17e-19	Dupuytren's disease;
KIRP	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-5.4	-0.33	1.55e-7	Vitiligo;
KIRP	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.8	-0.4	7.84e-11	Aortic root size;
KIRP	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.43	-5.3	-0.32	2.55e-7	Acne (severe);
KIRP	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.3	-0.42	3.92e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg16898833	chr6:26189333	HIST1H4D	0.81	5.71	0.34	3.27e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.21	-0.37	2.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06544989	chr22:39130855	UNC84B	0.51	9.09	0.5	3.34e-17	Menopause (age at onset);
KIRP	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg23565292	chr14:50234668	KLHDC2	-0.45	-5.39	-0.33	1.64e-7	Carotid intima media thickness;
KIRP	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-0.96	-15.37	-0.7	7.72e-38	Height;
KIRP	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs9400467	0.506	rs12205046	chr6:111619620	G/A	cg15721981	chr6:111408429	SLC16A10	0.76	7.02	0.41	2.1e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.93	-16.14	-0.72	1.83e-40	Electrocardiographic conduction measures;
KIRP	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.43	-5.16	-0.31	4.99e-7	IgG glycosylation;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23397434	chr2:38070667	NA	-0.43	-6.18	-0.37	2.64e-9	Inflammatory biomarkers;
KIRP	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21643547	chr1:205240462	TMCC2	-0.72	-11.02	-0.57	3.28e-23	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7929679	0.602	rs1396885	chr11:34805210	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.32	0.32	2.34e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs35771425	0.642	rs11586974	chr1:211464115	A/G	cg11089029	chr1:211432536	RCOR3	-0.47	-5.34	-0.32	2.11e-7	Educational attainment (years of education);
KIRP	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg05669848	chr5:237993	SDHA	0.48	5.01	0.3	1.04e-6	Breast cancer;
KIRP	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.53	6.51	0.38	4.09e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2219968	0.962	rs13266874	chr8:78946400	T/C	cg00738934	chr8:78996279	NA	0.39	5.04	0.31	9.24e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg00990874	chr7:1149470	C7orf50	-0.61	-6.29	-0.37	1.44e-9	Bronchopulmonary dysplasia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07118243	chr12:94853994	CCDC41;LOC144486	0.51	6.99	0.41	2.51e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.1	16.48	0.72	1.26e-41	Cognitive ability;
KIRP	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg06636001	chr8:8085503	FLJ10661	-0.76	-10.27	-0.55	7.86e-21	Retinal vascular caliber;
KIRP	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.7	8.94	0.5	9.29e-17	Coronary artery disease;
KIRP	cis	rs9914578	1.000	rs8082647	chr17:2010597	C/T	cg16513277	chr17:2031491	SMG6	0.64	7.91	0.45	8.59e-14	Body mass index;
KIRP	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.26	0.32	3.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.93	0.3	1.5e-6	Coronary artery disease;
KIRP	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg06565975	chr8:143823917	SLURP1	-0.44	-6.65	-0.39	1.92e-10	Urinary tract infection frequency;
KIRP	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg19567339	chr10:100142640	NA	0.47	5.42	0.33	1.43e-7	Metabolite levels;
KIRP	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg17376030	chr22:41985996	PMM1	-0.58	-6.6	-0.39	2.51e-10	Vitiligo;
KIRP	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg13165212	chr22:42675999	NA	0.38	6.68	0.39	1.59e-10	Cognitive function;
KIRP	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.35	0.38	1.03e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg22903471	chr2:27725779	GCKR	0.4	5.5	0.33	9.59e-8	Oral cavity cancer;
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg08805041	chr16:621841	PIGQ	-0.38	-5.23	-0.32	3.62e-7	Height;
KIRP	cis	rs867371	1.000	rs1501372	chr15:82468455	C/T	cg06066596	chr15:83166174	LOC80154	-0.47	-5.53	-0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.8	11.4	0.59	1.83e-24	Obesity-related traits;
KIRP	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.37	5.34	0.32	2.08e-7	Temperament;
KIRP	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06481639	chr22:41940642	POLR3H	0.46	5.4	0.33	1.61e-7	Vitiligo;
KIRP	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.69	0.81	4.83e-59	Prudent dietary pattern;
KIRP	cis	rs6662572	0.737	rs72692603	chr1:46378838	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.52	0.33	8.53e-8	Blood protein levels;
KIRP	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.65	7.75	0.44	2.38e-13	Testicular germ cell tumor;
KIRP	trans	rs587242	1.000	rs60507779	chr1:96914875	C/A	cg10631902	chr5:14652156	NA	0.53	6.16	0.37	2.9e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg26875137	chr12:53738046	NA	-0.41	-5.54	-0.33	7.61e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-1.03	-7.4	-0.43	2.17e-12	Lung cancer in ever smokers;
KIRP	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.15	0.54	1.85e-20	Cognitive test performance;
KIRP	cis	rs6495367	0.898	rs1443657	chr15:79386946	C/A	cg17916960	chr15:79447300	NA	0.33	5.64	0.34	4.73e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	0.9	13.86	0.66	1.17e-32	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs7005380	0.581	rs9649949	chr8:120913575	G/A	cg21645572	chr8:120931649	DEPDC6	0.48	6.76	0.4	9.7e-11	Interstitial lung disease;
KIRP	cis	rs73157695	0.676	rs2839049	chr21:47326021	A/G	cg12162886	chr21:47318899	PCBP3	-0.35	-4.98	-0.3	1.17e-6	Myopia;
KIRP	cis	rs6001982	0.748	rs12159787	chr22:40870699	A/G	cg07138101	chr22:40742427	ADSL	0.82	7.26	0.42	5.18e-12	Breast cancer;
KIRP	cis	rs501120	1.000	rs670056	chr10:44753375	C/T	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.52	6.44	0.38	6.35e-10	Mean platelet volume;
KIRP	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.11	12.04	0.61	1.53e-26	Vitiligo;
KIRP	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs13385	0.773	rs10067578	chr5:139558496	G/T	cg01860693	chr5:139557145	C5orf32	0.49	5.46	0.33	1.17e-7	Atrial fibrillation;
KIRP	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.67	-7.04	-0.41	1.92e-11	Vitiligo;
KIRP	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs9398803	0.605	rs112166936	chr6:126733140	A/C	cg19875578	chr6:126661172	C6orf173	0.51	6.6	0.39	2.5e-10	Male-pattern baldness;
KIRP	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.32	-10.22	-0.55	1.15e-20	Diabetic kidney disease;
KIRP	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg16141378	chr3:129829833	LOC729375	-0.54	-6.96	-0.41	3.13e-11	Neuroticism;
KIRP	cis	rs17023223	0.537	rs3936018	chr1:119682370	T/C	cg18261050	chr1:119551319	NA	0.5	5.9	0.35	1.17e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg16141378	chr3:129829833	LOC729375	0.48	6.32	0.37	1.19e-9	Mood instability;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15874270	chr4:123161078	KIAA1109	0.52	7.15	0.41	9.98e-12	Interleukin-4 levels;
KIRP	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.29	28.11	0.87	9.15e-79	IgG glycosylation;
KIRP	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.3	0.42	3.94e-12	Vitiligo;
KIRP	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	1.08	20.52	0.79	3.18e-55	Height;
KIRP	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg13010199	chr12:38710504	ALG10B	0.7	9.04	0.5	4.84e-17	Morning vs. evening chronotype;
KIRP	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg26850624	chr5:429559	AHRR	-0.38	-6.3	-0.37	1.4e-9	Cystic fibrosis severity;
KIRP	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.62	7.93	0.45	7.47e-14	Coronary artery disease;
KIRP	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg06223162	chr1:101003688	GPR88	-0.42	-8.51	-0.48	1.78e-15	Monocyte count;
KIRP	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.72	-8.58	-0.48	1.11e-15	Breast size;
KIRP	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	4.07e-15	Protein biomarker;
KIRP	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.5	8.66	0.48	6.33e-16	Erythrocyte sedimentation rate;
KIRP	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.64	-0.34	4.75e-8	Menarche (age at onset);
KIRP	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.6	6.5	0.38	4.4e-10	Alcohol dependence;
KIRP	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg16989719	chr2:238392110	NA	-0.47	-5.75	-0.34	2.69e-8	Prostate cancer;
KIRP	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.11	-0.36	3.77e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.03	0.36	5.85e-9	Leprosy;
KIRP	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	2.93e-7	Tonsillectomy;
KIRP	cis	rs10073892	0.701	rs62372220	chr5:101651411	C/A	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.69	-10.69	-0.56	3.82e-22	Airway imaging phenotypes;
KIRP	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.79	-10.61	-0.56	6.57e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg07068956	chr7:100330872	ZAN	-0.6	-6.64	-0.39	1.97e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg09571762	chr12:39539558	NA	-0.35	-5.14	-0.31	5.65e-7	Morning vs. evening chronotype;
KIRP	cis	rs16854884	0.770	rs1530477	chr3:143819506	A/G	cg06585982	chr3:143692056	C3orf58	-0.5	-6.29	-0.37	1.48e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs734999	0.545	rs4648565	chr1:2570023	A/G	cg18932078	chr1:2524107	MMEL1	-0.43	-5.92	-0.35	1.1e-8	Ulcerative colitis;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.63	-8.7	-0.49	4.81e-16	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.03	-0.41	2.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg04935436	chr20:30431758	NA	0.36	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-6.13	-0.36	3.52e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg24579218	chr15:68104479	NA	-0.44	-7.16	-0.42	9.33e-12	Restless legs syndrome;
KIRP	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs13185784	0.703	rs6894217	chr5:179667806	G/A	cg13944838	chr5:179740914	GFPT2	0.46	5.02	0.31	9.78e-7	TRAIL levels;
KIRP	cis	rs7646881	0.767	rs73015669	chr3:158456318	C/A	cg19483011	chr3:158453295	NA	-0.56	-5.94	-0.35	9.55e-9	Tetralogy of Fallot;
KIRP	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.47	-5.76	-0.34	2.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	0.609	rs60054591	chr11:71825687	G/A	cg26138937	chr11:71823887	C11orf51	1.16	7.55	0.43	8.52e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg09455208	chr3:40491958	NA	0.37	6.64	0.39	1.98e-10	Renal cell carcinoma;
KIRP	cis	rs4704187	0.687	rs1592948	chr5:74504152	G/A	cg03227963	chr5:74354835	NA	0.4	5.81	0.35	1.88e-8	Response to amphetamines;
KIRP	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03576123	chr11:487126	PTDSS2	-1.15	-10.21	-0.55	1.25e-20	Body mass index;
KIRP	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.69	-9.31	-0.51	7.57e-18	Breast cancer;
KIRP	trans	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.4	-0.43	2.12e-12	Systemic lupus erythematosus;
KIRP	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.73	10.3	0.55	6.53e-21	High light scatter reticulocyte count;
KIRP	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-11.1	-0.58	1.72e-23	Exhaled nitric oxide levels;
KIRP	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.42	6.32	0.37	1.25e-9	Neuroticism;
KIRP	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.72	-7.08	-0.41	1.47e-11	Psoriasis vulgaris;
KIRP	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg22705602	chr4:152727874	NA	-0.55	-8.8	-0.49	2.55e-16	Intelligence (multi-trait analysis);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg17031493	chr1:186343755	C1orf27;TPR;MIR548F1	-0.43	-6.26	-0.37	1.68e-9	Migraine with aura;
KIRP	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg06742321	chr12:123595122	PITPNM2	0.47	5.46	0.33	1.14e-7	Neutrophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10722938	chr19:14317606	LPHN1	0.51	6.35	0.38	1.04e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12315302	chr6:26189340	HIST1H4D	-0.73	-5.78	-0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.65	8.47	0.47	2.32e-15	Age at first birth;
KIRP	cis	rs12049351	0.774	rs4148755	chr1:229694866	G/A	cg11742688	chr1:229674241	ABCB10	-0.39	-5.7	-0.34	3.4e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6450176	0.556	rs111423662	chr5:53288661	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.2	-14.02	-0.67	3.36e-33	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.61	9.49	0.52	2.04e-18	Bone mineral density;
KIRP	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg07862535	chr7:139043722	LUC7L2	-0.5	-5.66	-0.34	4.26e-8	Diisocyanate-induced asthma;
KIRP	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg02151108	chr14:50098012	C14orf104	-0.51	-7.03	-0.41	2.07e-11	Carotid intima media thickness;
KIRP	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.34	0.32	2.1e-7	Breast cancer;
KIRP	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs3820928	1.000	rs4675115	chr2:227769123	C/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.0	-0.3	1.1e-6	Pulmonary function;
KIRP	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg18850127	chr7:39170497	POU6F2	0.28	5.15	0.31	5.23e-7	IgG glycosylation;
KIRP	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.94	-0.61	3.15e-26	Eye color traits;
KIRP	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.55	7.25	0.42	5.26e-12	Mean corpuscular volume;
KIRP	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg18944383	chr4:111397179	ENPEP	0.46	7.39	0.43	2.28e-12	Coronary artery disease;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg10254082	chr7:997346	NA	0.46	4.88	0.3	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11191270	1.000	rs11191270	chr10:104124605	C/T	cg15320455	chr10:103880129	LDB1	0.59	5.36	0.32	1.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	0.817	rs6826398	chr4:76973546	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.15	0.31	5.31e-7	Blood protein levels;
KIRP	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg25730555	chr22:47059586	GRAMD4	0.51	6.13	0.36	3.53e-9	Urate levels in obese individuals;
KIRP	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08109568	chr15:31115862	NA	-0.77	-9.44	-0.52	2.91e-18	Huntington's disease progression;
KIRP	trans	rs12517041	1.000	rs34694473	chr5:23311661	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.47	-6.42	-0.38	7.13e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.55	7.44	0.43	1.64e-12	Blood metabolite levels;
KIRP	cis	rs9513627	1.000	rs7996624	chr13:100127541	G/T	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.48	-0.33	1.05e-7	Lung cancer;
KIRP	cis	rs2224391	0.590	rs72813700	chr6:5275531	T/C	cg24031505	chr6:4779396	CDYL	-0.61	-5.03	-0.31	9.67e-7	Height;
KIRP	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.53	4.86	0.3	2.08e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs73198271	0.562	rs2048420	chr8:8667603	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.17	-0.31	4.8e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.69	9.37	0.51	4.88e-18	Schizophrenia;
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg05941025	chr16:89927596	SPIRE2	0.37	5.63	0.34	4.88e-8	Vitiligo;
KIRP	cis	rs17065868	0.881	rs61948029	chr13:45186684	C/T	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7129556	0.701	rs72947668	chr11:77428933	C/T	cg12586386	chr11:77299805	AQP11	0.48	5.55	0.33	7.56e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs4950322	0.570	rs76236344	chr1:146769674	G/A	cg22381352	chr1:146742008	CHD1L	-0.44	-5.27	-0.32	2.96e-7	Protein quantitative trait loci;
KIRP	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg12741994	chr3:170137321	CLDN11	-0.49	-4.98	-0.3	1.17e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7395581	0.918	rs1055510	chr11:47292237	A/G	cg25783544	chr11:47291846	MADD	0.43	4.93	0.3	1.48e-6	HDL cholesterol;
KIRP	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.18	0.37	2.67e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg07972983	chr1:205091412	RBBP5	-0.44	-5.28	-0.32	2.79e-7	Red blood cell count;
KIRP	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.37	6.93	0.4	3.59e-11	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.49	-6.4	-0.38	7.77e-10	Lung cancer;
KIRP	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg00800038	chr16:89945340	TCF25	-0.89	-7.26	-0.42	4.94e-12	Skin colour saturation;
KIRP	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.69	-9.86	-0.53	1.55e-19	Retinal vascular caliber;
KIRP	cis	rs8077577	0.945	rs62073609	chr17:18071843	T/C	cg09161412	chr17:18057145	MYO15A	-0.39	-5.17	-0.31	4.75e-7	Obesity-related traits;
KIRP	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg25866889	chr13:114914595	NA	0.4	5.55	0.33	7.34e-8	Schizophrenia;
KIRP	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg25173405	chr17:45401733	C17orf57	-0.5	-6.38	-0.38	8.83e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7614311	0.636	rs73117057	chr3:63915689	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-5.08	-0.31	7.55e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.68	-9.39	-0.51	4.21e-18	Breast cancer;
KIRP	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg08917208	chr2:24149416	ATAD2B	1.15	9.51	0.52	1.85e-18	Lymphocyte counts;
KIRP	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-6.88	-0.4	5.07e-11	Testicular germ cell tumor;
KIRP	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.63	9.6	0.52	9.81e-19	Prudent dietary pattern;
KIRP	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.78	8.89	0.49	1.37e-16	Corneal astigmatism;
KIRP	cis	rs2150410	0.915	rs7282947	chr21:40616568	G/C	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs7737355	0.812	rs2158294	chr5:130878215	A/G	cg25547332	chr5:131281432	NA	0.39	4.91	0.3	1.63e-6	Life satisfaction;
KIRP	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.75	11.26	0.58	5.47e-24	Blood metabolite ratios;
KIRP	cis	rs12282928	0.917	rs7942804	chr11:48297076	C/A	cg26585981	chr11:48327164	OR4S1	-0.52	-6.31	-0.37	1.27e-9	Migraine - clinic-based;
KIRP	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg06937882	chr20:24974362	C20orf3	-0.43	-4.89	-0.3	1.86e-6	Blood protein levels;
KIRP	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.97	0.41	2.93e-11	Coffee consumption (cups per day);
KIRP	cis	rs1701930	0.814	rs1701932	chr19:51419694	C/T	cg20971220	chr19:50554067	FLJ26850	-0.39	-5.22	-0.32	3.88e-7	Obesity-related traits;
KIRP	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg05315796	chr3:52349193	DNAH1	0.41	6.47	0.38	5.32e-10	Electroencephalogram traits;
KIRP	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.64	8.0	0.45	4.88e-14	Cognitive test performance;
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg02733842	chr7:1102375	C7orf50	-0.52	-5.89	-0.35	1.23e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.7	-8.68	-0.48	5.65e-16	Triglycerides;
KIRP	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg27432699	chr2:27873401	GPN1	-0.47	-6.19	-0.37	2.47e-9	Total body bone mineral density;
KIRP	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg10645314	chr2:3704589	ALLC	-0.63	-6.91	-0.4	4.11e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.92e-31	Eye color traits;
KIRP	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg09473613	chr1:24152604	HMGCL	-0.45	-6.31	-0.37	1.31e-9	Immature fraction of reticulocytes;
KIRP	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.01	0.36	6.65e-9	Iron status biomarkers;
KIRP	cis	rs9921338	0.961	rs11074958	chr16:11397079	C/T	cg00044050	chr16:11439710	C16orf75	-0.56	-5.87	-0.35	1.42e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs10073892	0.660	rs10515327	chr5:101963516	T/C	cg19774478	chr5:101632501	SLCO4C1	0.52	5.2	0.31	4.15e-7	Cognitive decline (age-related);
KIRP	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.56	10.36	0.55	4.21e-21	Iron status biomarkers;
KIRP	cis	rs6840360	0.726	rs6816292	chr4:152730543	C/T	cg22705602	chr4:152727874	NA	0.54	8.93	0.49	9.88e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.84	11.84	0.6	6.71e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05477027	chr19:46295590	DMWD	0.59	6.97	0.41	2.97e-11	Smoking initiation;
KIRP	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.5	-0.52	2e-18	Colorectal cancer;
KIRP	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.71	9.47	0.52	2.45e-18	Coronary artery disease;
KIRP	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg21184320	chr1:21044207	KIF17	0.51	6.87	0.4	5.1e-11	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs17209837	1.000	rs7802783	chr7:87130397	A/G	cg00919237	chr7:87102261	ABCB4	0.63	6.51	0.38	4.1e-10	Gallbladder cancer;
KIRP	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg22875332	chr1:76189707	ACADM	-0.34	-4.85	-0.3	2.16e-6	Daytime sleep phenotypes;
KIRP	cis	rs7246865	0.871	rs10421727	chr19:17225128	G/A	cg18440316	chr19:18077727	KCNN1	-0.41	-5.69	-0.34	3.53e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.26	-16.91	-0.73	4.36e-43	Breast cancer;
KIRP	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.66	10.06	0.54	3.76e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.55	7.39	0.43	2.34e-12	Colorectal cancer;
KIRP	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg06417478	chr19:12876846	HOOK2	0.42	5.18	0.31	4.53e-7	Bipolar disorder;
KIRP	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg23422044	chr7:1970798	MAD1L1	-0.69	-8.57	-0.48	1.16e-15	Bipolar disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26395828	chr5:14665166	FAM105B	0.45	6.24	0.37	1.86e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.66	-8.51	-0.48	1.68e-15	Personality dimensions;
KIRP	cis	rs1832871	0.630	rs11754501	chr6:158710451	A/G	cg07215822	chr6:158701037	NA	-0.65	-7.64	-0.44	4.7e-13	Height;
KIRP	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.7	-0.34	3.41e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7688540	0.771	rs11729365	chr4:272524	G/A	cg17891759	chr4:299121	NA	-0.49	-5.08	-0.31	7.58e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs787274	0.718	rs4979178	chr9:115644335	G/C	cg13803584	chr9:115635662	SNX30	-0.74	-8.83	-0.49	1.98e-16	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg03315344	chr16:75512273	CHST6	0.54	5.11	0.31	6.5e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.81	11.39	0.59	2.05e-24	Breast cancer;
KIRP	trans	rs7819412	0.502	rs34440473	chr8:10906841	A/T	cg15556689	chr8:8085844	FLJ10661	0.6	7.59	0.44	6.52e-13	Triglycerides;
KIRP	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs8014252	0.803	rs57339942	chr14:71083307	T/A	cg19730268	chr14:71022823	NA	-0.75	-6.61	-0.39	2.39e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs988913	1.000	rs1393776	chr6:54763018	A/C	cg03513858	chr6:54763001	FAM83B	0.39	5.55	0.33	7.5e-8	Menarche (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07267515	chr16:48644020	N4BP1	0.47	6.08	0.36	4.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.66	0.52	6.33e-19	Prudent dietary pattern;
KIRP	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.75	8.11	0.46	2.4e-14	Uric acid levels;
KIRP	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	7.26	0.42	5.19e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.48	-5.65	-0.34	4.38e-8	Multiple sclerosis;
KIRP	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg18016565	chr1:150552671	MCL1	0.39	5.97	0.36	8.23e-9	Melanoma;
KIRP	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.24	16.41	0.72	2.14e-41	Corneal structure;
KIRP	cis	rs986417	1.000	rs4901985	chr14:60948318	A/C	cg27398547	chr14:60952738	C14orf39	0.68	6.84	0.4	6.35e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs4148660	1.000	rs11046230	chr12:22060023	A/G	cg14669847	chr12:22099120	NA	0.32	5.49	0.33	1.02e-7	Gout;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06665941	chr21:34602869	IFNAR2	-0.5	-6.33	-0.37	1.17e-9	Neuroticism;
KIRP	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.44	-7.07	-0.41	1.61e-11	Superior crus of antihelix expression;
KIRP	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.43	4.95	0.3	1.38e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs11955398	0.501	rs10067618	chr5:60010995	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.43	-4.96	-0.3	1.32e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.75	10.53	0.56	1.24e-21	Schizophrenia;
KIRP	cis	rs4664308	0.618	rs3749117	chr2:160885442	T/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-10.38	-0.55	3.6e-21	Idiopathic membranous nephropathy;
KIRP	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg16988262	chr1:15930761	NA	0.38	4.87	0.3	1.97e-6	Systolic blood pressure;
KIRP	trans	rs4684585	1.000	rs12637032	chr3:908745	C/T	cg23077498	chr10:76801843	DUPD1	0.51	6.09	0.36	4.4e-9	Response to statin therapy;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.32	12.47	0.62	5.32e-28	Diabetic retinopathy;
KIRP	cis	rs4073221	0.789	rs4688901	chr3:18219037	G/A	cg07694806	chr3:18168406	NA	-0.72	-6.31	-0.37	1.32e-9	Parkinson's disease;
KIRP	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg23387468	chr7:139079360	LUC7L2	0.3	5.23	0.32	3.68e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-1.01	-13.18	-0.64	2.35e-30	Platelet distribution width;
KIRP	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.08	12.86	0.63	2.74e-29	Vitiligo;
KIRP	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.23	6.45	0.38	5.81e-10	Type 2 diabetes;
KIRP	cis	rs2380205	0.967	rs11255577	chr10:5898170	T/C	cg27141509	chr10:5886111	NA	-0.39	-5.61	-0.34	5.31e-8	Breast cancer;
KIRP	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.46	6.51	0.38	4.15e-10	Sitting height ratio;
KIRP	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg02975922	chr3:195473998	MUC4	-0.53	-6.22	-0.37	2.13e-9	Pancreatic cancer;
KIRP	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	1.17	10.09	0.54	2.93e-20	Skin colour saturation;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg21698718	chr17:80085957	CCDC57	0.37	5.27	0.32	2.91e-7	Life satisfaction;
KIRP	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.69	-10.33	-0.55	5.02e-21	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15703322	chr3:14239644	LSM3	0.48	6.38	0.38	8.93e-10	Interleukin-4 levels;
KIRP	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.46	5.82	0.35	1.82e-8	Testicular germ cell tumor;
KIRP	cis	rs4654899	1.000	rs6426656	chr1:21343245	G/C	cg05370193	chr1:21551575	ECE1	0.45	6.18	0.37	2.64e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.66	-11.61	-0.59	3.94e-25	White blood cell count (basophil);
KIRP	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.43	5.57	0.33	6.72e-8	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.82	-10.88	-0.57	9.08e-23	Eosinophil percentage of white cells;
KIRP	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.59	7.99	0.45	5.36e-14	Height;
KIRP	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg08917208	chr2:24149416	ATAD2B	0.58	5.04	0.31	8.97e-7	Lymphocyte counts;
KIRP	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.73	-9.18	-0.51	1.78e-17	Aortic root size;
KIRP	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg23791538	chr6:167370224	RNASET2	-0.49	-6.07	-0.36	4.89e-9	Primary biliary cholangitis;
KIRP	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.5	8.35	0.47	4.88e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg22705602	chr4:152727874	NA	0.52	8.34	0.47	5.46e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg25482853	chr8:67687455	SGK3	0.84	7.48	0.43	1.34e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs860295	0.841	rs7556102	chr1:155368203	C/A	cg02153340	chr1:155202674	NA	0.37	4.87	0.3	2.01e-6	Body mass index;
KIRP	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg23422044	chr7:1970798	MAD1L1	-0.51	-6.86	-0.4	5.39e-11	Neuroticism;
KIRP	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18364779	chr6:26104403	HIST1H4C	0.62	8.03	0.46	3.91e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.39	2.66e-10	Bipolar disorder;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.66	8.13	0.46	2.09e-14	Longevity;Endometriosis;
KIRP	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.79	10.35	0.55	4.37e-21	Mood instability;
KIRP	cis	rs4654899	1.000	rs7537072	chr1:21434533	T/C	cg05370193	chr1:21551575	ECE1	0.37	5.01	0.3	1.03e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.21e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.62	7.35	0.42	2.89e-12	Osteoporosis;
KIRP	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg13175981	chr1:150552382	MCL1	0.42	5.22	0.32	3.84e-7	Tonsillectomy;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02480602	chr6:137518909	IFNGR1	0.4	6.15	0.37	3.13e-9	Migraine with aura;
KIRP	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	0.76	6.93	0.4	3.66e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7700895	0.737	rs17085231	chr5:95222156	C/T	cg16656078	chr5:95278638	ELL2	-0.39	-5.89	-0.35	1.26e-8	IgG glycosylation;
KIRP	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg21926883	chr2:100939477	LONRF2	-0.55	-7.42	-0.43	1.95e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9409565	0.826	rs2139189	chr9:97238538	A/G	cg04523069	chr9:97136363	HIATL1	0.49	6.39	0.38	8.44e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs2970992	0.764	rs2137667	chr2:101332618	C/T	cg01042948	chr2:101319752	NA	0.39	5.77	0.35	2.33e-8	Educational attainment;
KIRP	cis	rs4805272	0.512	rs17772319	chr19:29343064	T/A	cg04546413	chr19:29218101	NA	0.64	5.94	0.35	9.74e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2301573	1.000	rs2301573	chr3:129305919	A/G	cg15504747	chr3:129312979	PLXND1	-0.45	-5.92	-0.35	1.08e-8	Hip circumference;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25732522	chr19:10514404	MIR1181;CDC37	-0.57	-7.58	-0.44	7.18e-13	Myopia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09059670	chr5:79552137	SERINC5	-0.49	-6.47	-0.38	5.19e-10	Myopia;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-8.87	-0.49	1.58e-16	Platelet count;
KIRP	cis	rs34779708	0.931	rs4934693	chr10:35271844	G/A	cg04310649	chr10:35416472	CREM	-0.55	-6.11	-0.36	3.97e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.76	8.76	0.49	3.19e-16	Corneal astigmatism;
KIRP	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.46	5.9	0.35	1.19e-8	IgG glycosylation;
KIRP	cis	rs8067354	0.645	rs2645486	chr17:57885901	T/A	cg02344993	chr17:57696989	CLTC	0.61	5.86	0.35	1.46e-8	Hemoglobin concentration;
KIRP	cis	rs12995849	0.905	rs7565757	chr2:106452408	T/A	cg16077055	chr2:106428750	NCK2	0.24	5.11	0.31	6.6e-7	Addiction;
KIRP	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg27205649	chr11:78285834	NARS2	-0.52	-4.9	-0.3	1.76e-6	Testicular germ cell tumor;
KIRP	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg21366198	chr4:185655624	MLF1IP	-0.41	-5.59	-0.34	5.92e-8	Kawasaki disease;
KIRP	cis	rs16828019	0.852	rs12408956	chr1:41651952	G/A	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg22863700	chr5:28928346	NA	0.6	6.21	0.37	2.23e-9	Hip geometry;
KIRP	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.56	8.23	0.46	1.1e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg04013166	chr16:89971882	TCF25	0.67	5.64	0.34	4.54e-8	Skin colour saturation;
KIRP	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg06636001	chr8:8085503	FLJ10661	0.64	8.79	0.49	2.6e-16	Retinal vascular caliber;
KIRP	cis	rs311392	0.902	rs448238	chr8:55093655	C/T	cg11783602	chr8:55087084	NA	0.58	7.08	0.41	1.48e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.26	24.21	0.84	4.93e-67	IgG glycosylation;
KIRP	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg04727924	chr7:799746	HEATR2	-0.81	-8.15	-0.46	1.84e-14	Cerebrospinal P-tau181p levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21635948	chr2:53994617	LOC100302652;ASB3;CHAC2	-0.4	-6.11	-0.36	3.8e-9	C-reactive protein;
KIRP	trans	rs12517041	0.935	rs1428628	chr5:23311925	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.91	-0.45	8.59e-14	Calcium levels;
KIRP	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg23477460	chr3:66848765	NA	0.67	7.7	0.44	3.31e-13	Type 2 diabetes;
KIRP	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.71	-6.49	-0.38	4.61e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.7	9.23	0.51	1.32e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.43	5.65	0.34	4.48e-8	Birth weight;
KIRP	cis	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg00405596	chr8:11794950	NA	-0.52	-7.17	-0.42	8.62e-12	Monocyte count;
KIRP	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg05998816	chr21:47859926	PCNT	0.54	5.97	0.36	8.08e-9	Lymphocyte counts;
KIRP	cis	rs12541635	0.677	rs10808408	chr8:107005034	C/T	cg10147462	chr8:107024639	NA	0.34	5.11	0.31	6.34e-7	Age of smoking initiation;
KIRP	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.59	-8.2	-0.46	1.32e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.69	0.48	5.03e-16	Electroencephalogram traits;
KIRP	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4400599	0.618	rs4393149	chr1:154195753	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.41	-5.98	-0.36	7.67e-9	Platelet distribution width;
KIRP	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.37	-5.24	-0.32	3.4e-7	Coronary artery disease;
KIRP	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg23894439	chr1:183413866	NA	0.39	5.17	0.31	4.76e-7	Systemic lupus erythematosus;
KIRP	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.56	5.84	0.35	1.65e-8	Platelet distribution width;
KIRP	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.3	-6.04	-0.36	5.79e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.61	0.39	2.35e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.73	-0.39	1.19e-10	Capecitabine sensitivity;
KIRP	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.88	-11.75	-0.6	1.36e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg08461772	chr7:95026248	PON3	0.43	5.98	0.36	7.61e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	10.08	0.54	3.12e-20	Alzheimer's disease;
KIRP	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg18709589	chr6:96969512	KIAA0776	-0.34	-5.11	-0.31	6.52e-7	Headache;
KIRP	cis	rs12496230	0.794	rs2083928	chr3:66860014	T/C	cg17646820	chr3:66848679	NA	0.39	6.34	0.37	1.06e-9	Type 2 diabetes;
KIRP	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg19847130	chr8:10466454	RP1L1	0.34	4.99	0.3	1.12e-6	Triglycerides;
KIRP	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.21	-0.55	1.19e-20	Alzheimer's disease (late onset);
KIRP	cis	rs258892	0.895	rs34782328	chr5:72060974	T/C	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg05627522	chr15:75251581	NA	0.34	5.12	0.31	6.09e-7	Caffeine consumption;
KIRP	cis	rs9513627	0.510	rs4365162	chr13:100212614	G/C	cg25919922	chr13:100150906	NA	0.73	5.43	0.33	1.33e-7	Obesity-related traits;
KIRP	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.82	-8.89	-0.49	1.3e-16	Asthma;
KIRP	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	10.87	0.57	1e-22	Lung cancer in ever smokers;
KIRP	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg00310523	chr12:86230176	RASSF9	-0.57	-8.93	-0.49	9.94e-17	Major depressive disorder;
KIRP	cis	rs4332037	0.508	rs56758848	chr7:1868727	A/G	cg23422044	chr7:1970798	MAD1L1	-0.62	-5.65	-0.34	4.32e-8	Bipolar disorder;
KIRP	cis	rs829661	0.793	rs10865520	chr2:30785395	G/A	cg10949345	chr2:30726833	LCLAT1	1.01	12.95	0.64	1.37e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	5.79	0.35	2.13e-8	Mean platelet volume;
KIRP	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.45	-6.35	-0.38	1.02e-9	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19306474	chr10:6243561	PFKFB3	0.53	7.18	0.42	8.26e-12	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg26876637	chr1:152193138	HRNR	-0.77	-9.14	-0.5	2.37e-17	Atopic dermatitis;
KIRP	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg19761014	chr17:28927070	LRRC37B2	0.68	5.04	0.31	9.02e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	7.91	0.45	8.84e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.98	15.83	0.71	2.13e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.68	8.14	0.46	1.95e-14	Neutrophil percentage of white cells;
KIRP	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.46	6.73	0.39	1.2e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs714515	0.609	rs4916262	chr1:172450528	A/C	cg01573306	chr1:172330400	DNM3	0.39	4.92	0.3	1.58e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs17101923	0.853	rs17179670	chr12:66349812	A/G	cg06712651	chr12:66351869	HMGA2	-0.57	-5.89	-0.35	1.28e-8	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs6991838	0.551	rs7007505	chr8:66533954	C/G	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-6.05	-0.36	5.34e-9	Depression;
KIRP	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.73	-9.14	-0.5	2.48e-17	Facial morphology (factor 19);
KIRP	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg22508957	chr16:3507546	NAT15	0.57	5.65	0.34	4.43e-8	Tuberculosis;
KIRP	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-7.55	-0.43	8.35e-13	Prudent dietary pattern;
KIRP	cis	rs743757	0.938	rs2236959	chr3:50441627	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.48	5.28	0.32	2.81e-7	Diastolic blood pressure;
KIRP	cis	rs6969780	0.915	rs12666926	chr7:27189561	A/G	cg19142026	chr7:27170394	HOXA4	-0.43	-5.53	-0.33	8.08e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1215050	0.755	rs1238462	chr4:98850603	A/G	cg17366294	chr4:99064904	C4orf37	-0.37	-5.03	-0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.88	0.49	1.43e-16	Colorectal cancer;
KIRP	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg04289385	chr6:36355825	ETV7	0.43	6.85	0.4	5.85e-11	Platelet distribution width;
KIRP	cis	rs10875746	0.903	rs11168414	chr12:48512331	C/T	cg20731937	chr12:48336164	NA	0.41	5.29	0.32	2.74e-7	Longevity (90 years and older);
KIRP	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg11846333	chr4:119757529	SEC24D	1.1	6.27	0.37	1.63e-9	Cannabis dependence symptom count;
KIRP	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg05347473	chr6:146136440	FBXO30	0.45	6.39	0.38	8.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.75	8.62	0.48	8.09e-16	High light scatter reticulocyte count;
KIRP	cis	rs9311676	0.656	rs56097407	chr3:58378079	G/A	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05665937	chr4:1216051	CTBP1	0.6	8.4	0.47	3.48e-15	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17716463	chr6:70506983	LMBRD1	0.47	6.02	0.36	6.18e-9	Parkinson's disease;
KIRP	cis	rs7523273	0.565	rs11118453	chr1:207887996	A/C	cg22525895	chr1:207977042	MIR29B2	0.45	5.79	0.35	2.14e-8	Schizophrenia;
KIRP	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg21551340	chr2:1609508	NA	0.52	5.04	0.31	8.99e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg05639522	chr1:247681581	NA	0.55	5.25	0.32	3.34e-7	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs6601327	0.571	rs35874762	chr8:9565392	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.95	-0.41	3.26e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.82	-13.24	-0.64	1.47e-30	Dental caries;
KIRP	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg05072774	chr3:49840536	C3orf54	-0.39	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.84	12.15	0.61	6.19e-27	Eye color traits;
KIRP	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg01631684	chr10:65280961	REEP3	-0.51	-6.02	-0.36	6.42e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	0.99	11.43	0.59	1.46e-24	Eosinophil percentage of granulocytes;
KIRP	trans	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg07817883	chr1:32538562	TMEM39B	1.26	8.05	0.46	3.62e-14	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg04628465	chr16:85015467	ZDHHC7	0.45	6.3	0.37	1.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	9.12	0.5	2.82e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.96e-7	Body mass index;
KIRP	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.61	-0.34	5.55e-8	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03337784	chr13:41768818	KBTBD7	0.67	6.51	0.38	4.08e-10	Lung function (FEV1);
KIRP	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg25237894	chr2:233734115	C2orf82	-0.38	-5.1	-0.31	6.92e-7	Schizophrenia;
KIRP	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg25037394	chr1:24152592	HMGCL	0.38	5.07	0.31	7.91e-7	Immature fraction of reticulocytes;
KIRP	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs860295	0.665	rs11264367	chr1:155337338	T/C	cg02153340	chr1:155202674	NA	-0.54	-7.25	-0.42	5.26e-12	Body mass index;
KIRP	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-11.22	-0.58	7.24e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.44	0.65	3.04e-31	Platelet count;
KIRP	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	cis	rs6832769	0.961	rs1011095	chr4:56264941	C/G	cg09317128	chr4:56265301	TMEM165	0.53	7.16	0.42	9.35e-12	Personality dimensions;
KIRP	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.35	-7.78	-0.44	1.94e-13	Breast cancer;
KIRP	trans	rs1422110	0.572	rs6884343	chr5:85444051	G/T	cg01787110	chr1:109008453	NBPF6	0.73	8.75	0.49	3.41e-16	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.43	6.11	0.36	3.89e-9	Testicular germ cell tumor;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg05135397	chr12:108956758	ISCU	0.5	6.2	0.37	2.34e-9	Asthma;
KIRP	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg04691961	chr3:161091175	C3orf57	-0.39	-5.83	-0.35	1.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg20735989	chr4:730612	PCGF3	-0.48	-6.04	-0.36	5.68e-9	White blood cell count;
KIRP	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg19847130	chr8:10466454	RP1L1	-0.42	-6.15	-0.37	3.13e-9	Retinal vascular caliber;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg19586645	chr17:73266642	MIF4GD	-0.47	-6.08	-0.36	4.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2635047	0.638	rs2668777	chr18:44748683	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.45	6.87	0.4	5.13e-11	Educational attainment;
KIRP	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.48	1.43e-15	Motion sickness;
KIRP	cis	rs2387326	0.717	rs12261194	chr10:129944464	T/C	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs4789452	0.967	rs12451315	chr17:75372126	C/G	cg12985929	chr17:75370611	SEPT9	-0.38	-5.58	-0.34	6.23e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs26232	0.521	rs3776855	chr5:102358815	A/C	cg23492399	chr5:102201601	PAM	-0.52	-5.74	-0.34	2.79e-8	Rheumatoid arthritis;
KIRP	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.79	-11.27	-0.58	5e-24	Height;
KIRP	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.3	-0.37	1.33e-9	Total cholesterol levels;
KIRP	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.46	6.33	0.37	1.17e-9	Blood protein levels;
KIRP	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.48	5.64	0.34	4.76e-8	Ulcerative colitis;
KIRP	cis	rs965513	1.000	rs10983701	chr9:100537577	G/A	cg13688889	chr9:100608707	NA	-0.59	-7.56	-0.43	7.73e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs2273156	0.706	rs7153331	chr14:35501670	A/G	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.19	-0.31	4.35e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg27532560	chr4:187881888	NA	-0.73	-12.12	-0.61	7.87e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg25600027	chr14:23388339	RBM23	-0.52	-6.37	-0.38	9.15e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs12823128	0.766	rs11611531	chr12:26927565	T/C	cg14081884	chr12:26986758	ITPR2	0.39	4.9	0.3	1.76e-6	Birth weight;
KIRP	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.75	10.81	0.57	1.52e-22	Prostate cancer;
KIRP	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg25019033	chr10:957182	NA	-0.5	-5.31	-0.32	2.48e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg09754948	chr16:28834200	ATXN2L	0.47	5.44	0.33	1.32e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.18	-0.46	1.49e-14	Bone mineral density;
KIRP	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.71	9.1	0.5	3.11e-17	Coronary artery disease;
KIRP	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg17724175	chr1:150552817	MCL1	0.36	6.24	0.37	1.87e-9	Tonsillectomy;
KIRP	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg09231725	chr11:64357281	SLC22A12	-0.64	-8.62	-0.48	8.08e-16	Urate levels in obese individuals;
KIRP	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.22	0.37	2.13e-9	Mean corpuscular volume;
KIRP	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg17366294	chr4:99064904	C4orf37	-0.37	-5.16	-0.31	5.05e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg00405596	chr8:11794950	NA	-0.49	-6.27	-0.37	1.6e-9	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20793623	chr3:41236272	NA	0.42	6.18	0.37	2.6e-9	Interleukin-4 levels;
KIRP	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg18154014	chr19:37997991	ZNF793	0.6	5.11	0.31	6.52e-7	Coronary artery calcification;
KIRP	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.59	-6.45	-0.38	5.81e-10	Aortic root size;
KIRP	cis	rs4262150	0.767	rs72795389	chr5:151944518	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.13	-0.46	2.09e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs12900413	0.687	rs35562959	chr15:90310537	C/T	cg24650279	chr15:90327240	NA	-0.41	-5.23	-0.32	3.7e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg18105134	chr13:113819100	PROZ	1.02	13.38	0.65	4.88e-31	Platelet distribution width;
KIRP	cis	rs3779635	0.742	rs28482046	chr8:27248164	T/A	cg23693289	chr8:27183097	PTK2B	0.56	7.2	0.42	7.19e-12	Neuroticism;
KIRP	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg13319975	chr6:146136371	FBXO30	0.43	5.83	0.35	1.74e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.31	6.11	0.36	3.92e-9	Lung cancer;
KIRP	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg00504896	chr12:9437009	LOC642846	-0.56	-7.54	-0.43	8.76e-13	Breast size;
KIRP	cis	rs61863818	0.521	rs7923907	chr10:99143499	C/T	cg20016023	chr10:99160130	RRP12	0.35	4.91	0.3	1.65e-6	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.75	5.75	0.34	2.65e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.69	-7.24	-0.42	5.67e-12	Urate levels in lean individuals;
KIRP	cis	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	5.19	0.31	4.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4132509	1.000	rs9782958	chr1:243892972	C/G	cg21452805	chr1:244014465	NA	0.57	5.79	0.35	2.15e-8	RR interval (heart rate);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09828310	chr1:2452844	PANK4	0.48	6.41	0.38	7.3e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg23594656	chr7:65796392	TPST1	-0.48	-7.39	-0.43	2.32e-12	Aortic root size;
KIRP	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg03609598	chr5:56110824	MAP3K1	-0.44	-4.96	-0.3	1.35e-6	Coronary artery disease;
KIRP	trans	rs9650657	0.601	rs10903330	chr8:10673104	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.08	0.36	4.65e-9	Neuroticism;
KIRP	cis	rs7688540	0.771	rs2353605	chr4:219538	C/T	cg17891759	chr4:299121	NA	-0.46	-5.21	-0.32	4e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs838147	0.760	rs12979144	chr19:49237547	G/A	cg08619932	chr19:49200058	FUT2	-0.37	-5.5	-0.33	9.5e-8	Dietary macronutrient intake;
KIRP	cis	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg00405596	chr8:11794950	NA	-0.49	-6.08	-0.36	4.53e-9	Triglycerides;
KIRP	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg14250997	chr9:106856677	SMC2	0.43	5.9	0.35	1.19e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs259842	0.790	rs2170240	chr2:180725310	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.42	-6.0	-0.36	7.1e-9	Blood protein levels;
KIRP	cis	rs3741489	1.000	rs2062162	chr12:133432744	C/T	cg15275758	chr12:133412815	NA	0.5	5.02	0.3	1.01e-6	Cognitive function;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-1.01	-11.87	-0.6	5.24e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	5.32	0.32	2.3e-7	Height;
KIRP	cis	rs7520050	0.966	rs6675726	chr1:46560643	A/G	cg03146154	chr1:46216737	IPP	-0.41	-5.38	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.57	-8.9	-0.49	1.22e-16	Coronary artery disease;
KIRP	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg02038168	chr22:39784481	NA	-0.46	-5.25	-0.32	3.22e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.77	-0.44	2.19e-13	Neuroticism;
KIRP	cis	rs7923609	0.967	rs7915779	chr10:65244244	G/C	cg01631684	chr10:65280961	REEP3	-0.51	-6.0	-0.36	7.17e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.5	6.38	0.38	8.88e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7766436	0.848	rs2294828	chr6:22598018	G/A	cg13666174	chr6:22585274	NA	-0.46	-6.52	-0.38	3.86e-10	Coronary artery disease;
KIRP	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-6.91	-0.4	4.1e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg01629716	chr15:45996671	NA	0.35	6.34	0.37	1.1e-9	Waist circumference;Weight;
KIRP	cis	rs4765905	0.610	rs4765669	chr12:2313111	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg13615516	chr5:77269221	NA	0.52	8.09	0.46	2.75e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg05721485	chr17:44071124	MAPT	-0.52	-7.58	-0.44	6.97e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.58	-6.87	-0.4	5.23e-11	Mosquito bite size;
KIRP	cis	rs7580658	0.545	rs13001179	chr2:127952193	A/C	cg16751203	chr2:127950803	CYP27C1	0.4	5.62	0.34	5.24e-8	Protein C levels;
KIRP	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg26566898	chr11:117069891	TAGLN	0.41	5.36	0.32	1.94e-7	Blood protein levels;
KIRP	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.75	-6.68	-0.39	1.55e-10	Diabetic retinopathy;
KIRP	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg13256891	chr4:100009986	ADH5	0.51	6.28	0.37	1.49e-9	Alcohol dependence;
KIRP	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.02	7.81	0.45	1.66e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1371867	0.810	rs2919470	chr8:101233301	C/A	cg11906718	chr8:101322791	RNF19A	-0.67	-8.38	-0.47	4.05e-15	Atrioventricular conduction;
KIRP	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg04374321	chr14:90722782	PSMC1	0.55	6.63	0.39	2.13e-10	Longevity;
KIRP	cis	rs2562456	0.678	rs7260140	chr19:21523525	T/C	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.57	7.79	0.44	1.87e-13	Obesity-related traits;
KIRP	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg18357526	chr6:26021779	HIST1H4A	0.48	5.61	0.34	5.41e-8	Blood metabolite levels;
KIRP	cis	rs74181299	0.684	rs17040050	chr2:65327042	G/A	cg05010058	chr2:65284262	CEP68	-0.43	-5.89	-0.35	1.26e-8	Pulse pressure;
KIRP	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.88	-12.29	-0.62	2.18e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.65	-7.37	-0.43	2.53e-12	Hair shape;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12990844	chr2:170655321	SSB	0.55	6.84	0.4	6.28e-11	Parkinson's disease;
KIRP	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.71	10.18	0.54	1.59e-20	Bladder cancer;
KIRP	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	ch.1.3259774R	chr1:166827647	TADA1	0.42	5.11	0.31	6.58e-7	Refractive astigmatism;
KIRP	cis	rs7666738	0.518	rs13133925	chr4:98706398	G/T	cg05340658	chr4:99064831	C4orf37	0.66	7.67	0.44	4.04e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6988636	0.710	rs17316158	chr8:124157607	A/C	cg23067535	chr8:124195133	FAM83A	-0.61	-5.53	-0.33	8.08e-8	Urinary uromodulin levels;
KIRP	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.51	7.84	0.45	1.36e-13	Monocyte count;
KIRP	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.74	9.94	0.54	8.75e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg09795085	chr6:101329169	ASCC3	-0.5	-6.01	-0.36	6.74e-9	Neuroticism;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.73	9.81	0.53	2.14e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs467650	0.509	rs183628	chr5:97979491	C/G	cg12450016	chr5:98112437	RGMB	0.38	4.93	0.3	1.5e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs4356932	1.000	rs7670789	chr4:76940381	G/A	cg19388996	chr4:76862389	NAAA	0.39	5.02	0.3	9.95e-7	Blood protein levels;
KIRP	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.41	-5.15	-0.31	5.26e-7	Aortic root size;
KIRP	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg12856521	chr11:46389249	DGKZ	0.5	6.88	0.4	5.05e-11	Crohn's disease;
KIRP	cis	rs698833	0.886	rs17580226	chr2:44570776	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.46	0.33	1.18e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg24972876	chr7:65420302	NA	-0.4	-5.48	-0.33	1.06e-7	Aortic root size;
KIRP	cis	rs4566357	1.000	rs6721237	chr2:227923357	T/A	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.07	-0.31	7.96e-7	Coronary artery disease;
KIRP	cis	rs6991838	0.584	rs1533285	chr8:66549364	T/C	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.93	-13.81	-0.66	1.62e-32	Tonsillectomy;
KIRP	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg09788416	chr12:39539408	NA	0.39	5.26	0.32	3.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	9.52	0.52	1.74e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7215564	0.908	rs7501674	chr17:78662177	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg16989719	chr2:238392110	NA	-0.55	-5.78	-0.35	2.3e-8	Prostate cancer;
KIRP	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14829155	chr15:31115871	NA	-0.77	-9.53	-0.52	1.62e-18	Huntington's disease progression;
KIRP	cis	rs394563	0.967	rs447025	chr6:149799128	A/C	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.35	-0.32	1.98e-7	Dupuytren's disease;
KIRP	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	9.99	0.54	6.1e-20	Cognitive test performance;
KIRP	trans	rs9790314	0.613	rs34297047	chr3:160631478	A/G	cg19274270	chr17:78178856	CARD14	0.34	6.14	0.36	3.25e-9	Morning vs. evening chronotype;
KIRP	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.52	-6.72	-0.39	1.22e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.97	17.25	0.74	2.99e-44	Breast cancer;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08449448	chr8:58056501	NA	0.42	4.88	0.3	1.9e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs12220238	0.915	rs11001027	chr10:76152655	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.29	0.37	1.48e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg26597838	chr10:835615	NA	0.53	6.63	0.39	2.06e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs4253772	0.938	rs41355347	chr22:46637511	G/A	cg24881330	chr22:46731750	TRMU	0.66	4.98	0.3	1.19e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10083777	0.551	rs111889995	chr16:81033771	A/C	cg08591886	chr16:81111003	C16orf46	-0.72	-5.22	-0.32	3.8e-7	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg25182066	chr10:30743637	MAP3K8	-0.63	-8.1	-0.46	2.49e-14	Inflammatory bowel disease;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg04025307	chr7:1156635	C7orf50	0.78	8.06	0.46	3.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs4006360	0.588	rs2001523	chr17:39262814	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.53	-7.73	-0.44	2.67e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg13565492	chr6:43139072	SRF	-0.94	-8.64	-0.48	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg17366294	chr4:99064904	C4orf37	-0.37	-5.17	-0.31	4.82e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg21427119	chr20:30132790	HM13	0.52	5.89	0.35	1.27e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs1883415	0.534	rs760905	chr6:24479782	T/C	cg20631270	chr6:24437470	GPLD1	0.39	4.99	0.3	1.13e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.55	7.32	0.42	3.54e-12	Longevity;Endometriosis;
KIRP	cis	rs2270968	0.542	rs7611381	chr3:182649203	T/A	cg17054674	chr3:182697310	DCUN1D1	0.37	5.31	0.32	2.43e-7	Blood metabolite levels;Parkinson's disease;
KIRP	cis	rs7894051	1.000	rs7894051	chr10:135184421	C/G	cg24905316	chr10:135186343	ECHS1	-0.47	-5.23	-0.32	3.64e-7	Lifespan;
KIRP	cis	rs6110278	0.698	rs6105269	chr20:14400165	G/A	cg17696268	chr20:14319035	FLRT3;MACROD2	-0.36	-5.01	-0.3	1.03e-6	Mean platelet volume;
KIRP	cis	rs921916	1.000	rs921916	chr7:50228698	C/T	cg02697348	chr7:50199187	C7orf72	-0.52	-4.98	-0.3	1.22e-6	Systemic lupus erythematosus;
KIRP	cis	rs4638749	0.501	rs12624041	chr2:108763547	C/A	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.87	-0.3	2.04e-6	Blood pressure;
KIRP	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg08603382	chr10:743973	NA	-0.55	-8.08	-0.46	2.86e-14	Psychosis in Alzheimer's disease;
KIRP	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg21573476	chr21:45109991	RRP1B	-0.79	-10.23	-0.55	1.07e-20	Mean corpuscular volume;
KIRP	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.1e-9	Cognitive function;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg14799209	chr7:106809543	HBP1	0.42	6.65	0.39	1.9e-10	Bladder cancer;
KIRP	cis	rs3790645	0.831	rs873151	chr1:26880989	T/C	cg23229016	chr1:26872525	RPS6KA1	0.24	6.12	0.36	3.74e-9	Glucose homeostasis traits;
KIRP	cis	rs311392	0.903	rs6993362	chr8:55089220	A/G	cg11783602	chr8:55087084	NA	-0.58	-7.19	-0.42	7.8e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg00857998	chr1:205179979	DSTYK	0.52	6.57	0.39	3.01e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg02725872	chr8:58115012	NA	-0.48	-5.55	-0.33	7.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3736485	0.903	rs11630842	chr15:51750652	G/A	cg14296394	chr15:51910925	DMXL2	-0.36	-5.34	-0.32	2.15e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.73	-11.02	-0.57	3.21e-23	Idiopathic membranous nephropathy;
KIRP	cis	rs2882667	0.628	rs13171173	chr5:138042464	A/C	cg04439458	chr5:138467593	SIL1	0.37	4.89	0.3	1.83e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.21	14.22	0.67	6.91e-34	Corneal structure;
KIRP	cis	rs6662572	0.855	rs7517418	chr1:46252418	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.54	-0.33	7.71e-8	Blood protein levels;
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg18538332	chr22:24372958	LOC391322	-0.58	-6.11	-0.36	3.87e-9	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.77	12.22	0.61	3.8e-27	Menarche (age at onset);
KIRP	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.92	-0.3	1.58e-6	Breast cancer;Mosquito bite size;
KIRP	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs8038465	0.967	rs55868793	chr15:73956856	T/G	cg15420318	chr15:73925796	NPTN	0.55	6.9	0.4	4.46e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.47	-5.61	-0.34	5.55e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-5.68	-0.34	3.87e-8	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg03959625	chr15:84868606	LOC388152	0.52	6.24	0.37	1.95e-9	Schizophrenia;
KIRP	cis	rs6142102	0.812	rs725478	chr20:32518354	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-5.64	-0.34	4.76e-8	Skin pigmentation;
KIRP	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg19875535	chr5:140030758	IK	0.5	6.28	0.37	1.52e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs73200209	0.744	rs59619030	chr12:116475001	T/C	cg01776926	chr12:116560359	MED13L	-0.54	-6.04	-0.36	5.52e-9	Total body bone mineral density;
KIRP	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.34	-0.72	4e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-0.41	-5.11	-0.31	6.43e-7	Type 2 diabetes;
KIRP	cis	rs4619890	0.641	rs13132025	chr4:7812038	C/T	cg18538662	chr4:7941764	AFAP1	-0.44	-5.01	-0.3	1.05e-6	Glaucoma (primary open-angle);
KIRP	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg00977110	chr5:151150581	G3BP1	-0.58	-6.0	-0.36	7.07e-9	Preschool internalizing problems;
KIRP	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-6.87	-0.4	5.2e-11	Vitiligo;
KIRP	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg04568710	chr12:38710424	ALG10B	-0.38	-5.13	-0.31	5.91e-7	Morning vs. evening chronotype;
KIRP	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg11608241	chr8:8085544	FLJ10661	-0.43	-5.18	-0.31	4.54e-7	Recombination measurement;
KIRP	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.55	6.7	0.39	1.41e-10	Arsenic metabolism;
KIRP	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.67	6.2	0.37	2.38e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.35	-6.05	-0.36	5.23e-9	Height;
KIRP	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-6.88	-0.4	5.03e-11	Urate levels in overweight individuals;
KIRP	cis	rs4474465	0.920	rs7941889	chr11:78154401	T/G	cg02023728	chr11:77925099	USP35	0.3	4.92	0.3	1.56e-6	Alzheimer's disease (survival time);
KIRP	cis	rs2839627	0.608	rs2001521	chr21:44232180	T/A	cg03543861	chr21:44258195	NA	0.59	6.34	0.37	1.11e-9	Information processing speed;
KIRP	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.5	-5.96	-0.36	8.77e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.83	-13.53	-0.65	1.51e-31	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.84	-12.49	-0.62	4.66e-28	Strep throat;
KIRP	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg14664628	chr15:75095509	CSK	0.5	5.59	0.34	6e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.85	-0.35	1.56e-8	Pulmonary function;
KIRP	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.83	-11.39	-0.59	2.06e-24	Acylcarnitine levels;
KIRP	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg15664640	chr17:80829946	TBCD	-0.72	-6.73	-0.39	1.2e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg20859525	chr6:80714300	TTK	0.7	6.08	0.36	4.65e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs62413470	1.000	rs62406157	chr6:55941999	C/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs7779181	0.680	rs4723146	chr7:32397448	A/G	cg13207630	chr7:32358064	NA	0.48	5.02	0.31	9.77e-7	Body mass index;
KIRP	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	1.09	20.03	0.79	1.36e-53	Gut microbiome composition (winter);
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg12486944	chr17:80159399	CCDC57	-0.41	-5.49	-0.33	1.02e-7	Life satisfaction;
KIRP	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.69	8.04	0.46	3.89e-14	Height;
KIRP	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs877282	0.583	rs10904564	chr10:819459	C/G	cg22713356	chr15:30763199	NA	0.88	8.71	0.49	4.57e-16	Uric acid levels;
KIRP	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg02415014	chr8:143852576	LYNX1	0.32	4.92	0.3	1.56e-6	Urinary tract infection frequency;
KIRP	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg02570527	chr1:10970165	NA	-0.4	-4.9	-0.3	1.74e-6	Body mass index;
KIRP	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg01411142	chr8:19674711	INTS10	0.47	5.14	0.31	5.71e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg16049864	chr8:95962084	TP53INP1	-0.39	-6.18	-0.37	2.66e-9	Type 2 diabetes;
KIRP	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg03563238	chr19:33554763	RHPN2	-0.33	-5.79	-0.35	2.19e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg07382826	chr16:28625726	SULT1A1	0.51	5.86	0.35	1.48e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg14517863	chr17:44321492	NA	0.47	5.44	0.33	1.29e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg09264619	chr17:80180166	NA	-0.52	-5.98	-0.36	7.81e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg04865290	chr3:52927548	TMEM110	-0.66	-7.01	-0.41	2.22e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg17691542	chr6:26056736	HIST1H1C	0.69	8.22	0.46	1.17e-14	Iron status biomarkers;
KIRP	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.54	7.34	0.42	3.19e-12	Bladder cancer;
KIRP	cis	rs28680850	0.541	rs1024549	chr8:1377191	C/T	cg06035437	chr8:1398411	NA	0.87	9.06	0.5	4.22e-17	Triglycerides;
KIRP	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.69	-11.28	-0.58	4.65e-24	Urate levels in overweight individuals;
KIRP	cis	rs2970818	0.831	rs1029769	chr12:4645448	T/C	cg14576962	chr12:4671597	NA	-0.43	-5.2	-0.31	4.22e-7	Phosphorus levels;
KIRP	cis	rs595982	0.702	rs626974	chr19:49375900	T/C	cg21252483	chr19:49399788	TULP2	-0.31	-5.59	-0.34	5.93e-8	Red cell distribution width;
KIRP	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg00101154	chr16:420108	MRPL28	-0.45	-5.32	-0.32	2.35e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg05768032	chr16:30646687	NA	0.53	6.61	0.39	2.35e-10	Multiple myeloma;
KIRP	cis	rs7923609	0.902	rs10733793	chr10:65323809	T/G	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.19	-0.31	4.47e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.68	8.43	0.47	2.96e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2591576	0.673	rs248548	chr5:165390453	G/T	cg13976338	chr5:165423657	NA	-0.68	-9.41	-0.51	3.65e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg04731861	chr2:219085781	ARPC2	-0.24	-6.03	-0.36	6.09e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1514687	0.534	rs2138020	chr2:1482093	T/A	cg13703866	chr2:1479523	TPO	-0.63	-5.04	-0.31	9.2e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg05791153	chr7:19748676	TWISTNB	0.69	6.39	0.38	8.22e-10	Thyroid stimulating hormone;
KIRP	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.65	8.96	0.5	8.46e-17	Coronary artery disease;
KIRP	cis	rs1190545	0.588	rs4906213	chr14:102991021	C/T	cg18135206	chr14:102964638	TECPR2	0.46	5.67	0.34	4.07e-8	Platelet count;
KIRP	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.52	7.01	0.41	2.23e-11	HDL cholesterol;
KIRP	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg01879757	chr17:41196368	BRCA1	-0.78	-10.87	-0.57	9.59e-23	Menopause (age at onset);
KIRP	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.64	-0.52	7.2e-19	Total body bone mineral density;
KIRP	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-9.55	-0.52	1.42e-18	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.95e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.92	-10.95	-0.57	5.59e-23	White matter hyperintensity burden;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg00915609	chr2:97174045	NEURL3	0.46	6.08	0.36	4.51e-9	Beard thickness;
KIRP	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg00012203	chr2:219082015	ARPC2	-0.41	-5.1	-0.31	6.87e-7	Ulcerative colitis;
KIRP	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg10223061	chr2:219282414	VIL1	-0.32	-5.34	-0.32	2.08e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1351164	1.000	rs10183694	chr2:218279923	T/A	cg15335768	chr2:218268053	DIRC3	-0.48	-6.41	-0.38	7.37e-10	Height;
KIRP	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg00129232	chr17:37814104	STARD3	-0.53	-6.57	-0.39	2.94e-10	Self-reported allergy;
KIRP	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.71	-0.39	1.32e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.83	-0.45	1.49e-13	Platelet count;
KIRP	cis	rs6466055	0.661	rs4406343	chr7:104918313	A/G	cg04380332	chr7:105027541	SRPK2	-0.36	-5.14	-0.31	5.65e-7	Schizophrenia;
KIRP	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg05834625	chr6:170176447	C6orf70	0.47	4.85	0.3	2.24e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2387326	0.671	rs12268728	chr10:129945897	G/A	cg16087940	chr10:129947807	NA	-0.43	-5.86	-0.35	1.5e-8	Select biomarker traits;
KIRP	cis	rs687432	0.924	rs7109912	chr11:57706108	A/G	cg19752551	chr11:57585705	CTNND1	-0.47	-6.49	-0.38	4.57e-10	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13917712	chr19:38714681	DPF1	0.44	6.61	0.39	2.39e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.33	0.42	3.31e-12	IgG glycosylation;
KIRP	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.94	11.43	0.59	1.54e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg27280279	chr2:33820674	FAM98A	0.41	6.87	0.4	5.08e-11	C-reactive protein;
KIRP	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg23958373	chr8:599963	NA	-1.02	-6.25	-0.37	1.8e-9	IgG glycosylation;
KIRP	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02725872	chr8:58115012	NA	-0.67	-6.56	-0.39	3.1e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg01798813	chr17:3906674	NA	-0.55	-7.44	-0.43	1.66e-12	Type 2 diabetes;
KIRP	cis	rs9783347	0.857	rs4150561	chr11:18354877	T/C	cg15585147	chr11:18324498	HPS5	0.44	5.95	0.35	9.4e-9	Pancreatic cancer;
KIRP	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.61	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1143633	0.537	rs4447608	chr2:113605957	C/T	cg03712744	chr2:113669835	IL1F7	-0.41	-5.96	-0.36	8.75e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2791713	0.531	rs2791701	chr1:207178263	T/A	cg24040043	chr1:207224982	YOD1	0.3	5.16	0.31	5.01e-7	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	cis	rs55692468	0.804	rs6742066	chr2:153329163	A/G	cg04681845	chr2:153283485	FMNL2	-0.47	-5.85	-0.35	1.57e-8	Intraocular pressure;
KIRP	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.55	7.47	0.43	1.4e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg22633769	chr20:60982531	CABLES2	0.66	8.49	0.48	1.92e-15	Colorectal cancer;
KIRP	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg15839431	chr19:19639596	YJEFN3	-0.46	-5.01	-0.3	1.04e-6	Bipolar disorder;
KIRP	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27297192	chr10:134578999	INPP5A	0.67	8.2	0.46	1.3e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4006360	0.535	rs2173202	chr17:39235235	C/T	cg15015397	chr17:39261100	KRTAP4-9	0.51	7.69	0.44	3.45e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg01522456	chr1:115632236	TSPAN2	-0.4	-5.5	-0.33	9.66e-8	Autism;
KIRP	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.69	-6.22	-0.37	2.11e-9	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs13401104	0.587	rs7581196	chr2:237151098	A/C	cg19324714	chr2:237145437	ASB18	-0.48	-5.42	-0.33	1.43e-7	Educational attainment;
KIRP	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10861342	0.892	rs2044307	chr12:105531171	G/T	cg23923672	chr12:105501055	KIAA1033	0.87	7.05	0.41	1.82e-11	IgG glycosylation;
KIRP	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg07636037	chr3:49044803	WDR6	0.59	5.72	0.34	3.13e-8	Menarche (age at onset);
KIRP	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg17554472	chr22:41940697	POLR3H	0.5	5.45	0.33	1.23e-7	Vitiligo;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09667589	chr1:151400745	POGZ	0.5	6.04	0.36	5.65e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10491083	0.661	rs2072150	chr17:6564627	C/A	cg13067509	chr17:6538498	KIAA0753	0.69	6.98	0.41	2.76e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20949959	chr2:43453251	ZFP36L2;LOC100129726	0.5	6.27	0.37	1.59e-9	Parkinson's disease;
KIRP	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg14972814	chr11:95582409	MTMR2	0.35	5.75	0.34	2.61e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.1	-0.5	3.14e-17	Mean corpuscular volume;
KIRP	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg07116693	chr15:90310901	NA	-0.23	-4.86	-0.3	2.11e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1595825	0.891	rs16824631	chr2:198708695	T/G	cg00361562	chr2:198649771	BOLL	-0.5	-5.18	-0.31	4.69e-7	Ulcerative colitis;
KIRP	cis	rs6132905	0.590	rs77686753	chr20:2602757	G/A	cg24848351	chr20:2622020	TMC2	-0.57	-5.19	-0.31	4.32e-7	Mumps;
KIRP	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg14456004	chr13:21872349	NA	-1.14	-14.21	-0.67	7.06e-34	White matter hyperintensity burden;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg02733842	chr7:1102375	C7orf50	0.56	5.76	0.34	2.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs7572644	0.679	rs4419196	chr2:28075298	A/G	cg27432699	chr2:27873401	GPN1	0.46	5.66	0.34	4.29e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.51	-0.48	1.75e-15	Life satisfaction;
KIRP	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.75	-8.79	-0.49	2.69e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12615966	0.872	rs11898434	chr2:105376704	G/A	cg16465502	chr2:105461796	NA	0.64	5.68	0.34	3.76e-8	Pancreatic cancer;
KIRP	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.87	-0.6	5.24e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg10755058	chr3:40428713	ENTPD3	0.34	4.97	0.3	1.25e-6	Renal cell carcinoma;
KIRP	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.53	-6.61	-0.39	2.43e-10	Asthma (sex interaction);
KIRP	cis	rs4704187	0.687	rs1477937	chr5:74524837	A/G	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.73e-8	Response to amphetamines;
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg11814155	chr7:99998594	ZCWPW1	0.62	5.57	0.33	6.69e-8	Platelet count;
KIRP	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg02462569	chr6:150064036	NUP43	-0.36	-5.55	-0.33	7.3e-8	Lung cancer;
KIRP	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.86	9.91	0.53	1.09e-19	Neutrophil percentage of white cells;
KIRP	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.47	-5.66	-0.34	4.11e-8	Testicular germ cell tumor;
KIRP	cis	rs7246657	0.722	rs10409605	chr19:38123137	T/G	cg23950597	chr19:37808831	NA	-0.61	-6.63	-0.39	2.17e-10	Coronary artery calcification;
KIRP	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.58	-7.53	-0.43	9.72e-13	White matter hyperintensity burden;
KIRP	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.47	0.65	2.36e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg01864069	chr14:103024347	NA	-0.81	-8.82	-0.49	2.17e-16	Platelet count;
KIRP	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.75	0.49	3.44e-16	Motion sickness;
KIRP	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.76	-8.98	-0.5	7.26e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.73	7.47	0.43	1.43e-12	Prostate cancer;
KIRP	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.5	-5.98	-0.36	7.99e-9	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.45	9.24	0.51	1.23e-17	Vitiligo;
KIRP	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg23000734	chr10:126850823	CTBP2	0.35	5.55	0.33	7.21e-8	Menarche (age at onset);
KIRP	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.48	5.79	0.35	2.11e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs240764	0.782	rs239231	chr6:101105022	G/A	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.6	-7.32	-0.42	3.44e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.61	-7.37	-0.43	2.54e-12	Post bronchodilator FEV1;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg09672890	chr17:70536484	NA	0.57	6.28	0.37	1.56e-9	Lung cancer in ever smokers;
KIRP	cis	rs4363385	0.574	rs4845503	chr1:152959939	A/G	cg13444842	chr1:152974279	SPRR3	-0.48	-6.95	-0.41	3.25e-11	Inflammatory skin disease;
KIRP	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg04725166	chr1:7887271	PER3	-0.36	-5.79	-0.35	2.09e-8	Crohn's disease;
KIRP	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg02807482	chr3:125708958	NA	-0.56	-5.21	-0.32	3.99e-7	Blood pressure (smoking interaction);
KIRP	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.67	10.16	0.54	1.72e-20	Lung cancer;
KIRP	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.51	6.95	0.41	3.21e-11	Coronary artery disease;
KIRP	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.9	12.81	0.63	3.97e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg17309464	chr19:36705192	ZNF565;ZNF146	1.09	8.01	0.45	4.49e-14	P wave terminal force;
KIRP	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg23920097	chr1:209922102	NA	-0.4	-5.36	-0.32	1.92e-7	Red blood cell count;
KIRP	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.79	-0.4	8.25e-11	Diabetic kidney disease;
KIRP	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.52	4.87	0.3	1.95e-6	Height;
KIRP	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.7	8.43	0.47	3.04e-15	Post bronchodilator FEV1;
KIRP	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06505273	chr16:24850292	NA	-0.37	-5.04	-0.31	9.18e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg04369109	chr6:150039330	LATS1	-0.6	-7.71	-0.44	3.15e-13	Lung cancer;
KIRP	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	1.02	11.15	0.58	1.2e-23	Height;
KIRP	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg17105886	chr17:28927953	LRRC37B2	-0.53	-5.51	-0.33	9.2e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.47	-5.7	-0.34	3.46e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4268898	0.552	rs7560342	chr2:24371691	T/C	cg06627628	chr2:24431161	ITSN2	0.46	5.61	0.34	5.31e-8	Asthma;
KIRP	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	11.9	0.6	4.28e-26	Ileal carcinoids;
KIRP	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.66	8.29	0.47	7.19e-15	Aortic root size;
KIRP	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.78	-0.35	2.27e-8	Chronic sinus infection;
KIRP	cis	rs7709377	0.595	rs11241359	chr5:115448150	G/T	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.64e-7	Metabolite levels  (X-11787);
KIRP	cis	rs9611198	0.792	rs5757727	chr22:39963173	G/A	cg10455938	chr22:40058150	CACNA1I	0.49	6.76	0.4	9.93e-11	Schizophrenia;
KIRP	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.42	-5.2	-0.31	4.15e-7	Height;
KIRP	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.77	8.22	0.46	1.18e-14	Vitiligo;
KIRP	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg09163369	chr1:210001066	C1orf107	0.51	5.48	0.33	1.05e-7	Orofacial clefts;
KIRP	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19930420	chr8:74888567	TMEM70	0.48	6.04	0.36	5.59e-9	Parkinson's disease;
KIRP	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg11569703	chr11:65557185	OVOL1	0.5	7.56	0.43	7.9e-13	Breast cancer;
KIRP	cis	rs9308731	0.583	rs4848406	chr2:111933758	G/A	cg03171003	chr2:111875934	NA	0.4	5.59	0.34	6.02e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg23307798	chr14:103986281	CKB	-0.51	-6.8	-0.4	7.92e-11	Coronary artery disease;
KIRP	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.69	8.89	0.49	1.35e-16	Morning vs. evening chronotype;
KIRP	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-7.78	-0.44	1.96e-13	Platelet distribution width;
KIRP	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.91	10.59	0.56	7.67e-22	Corneal astigmatism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15459342	chr1:228296991	MRPL55	0.57	6.85	0.4	5.8200000000000003e-11	Smoking initiation;
KIRP	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.15	-0.41	1.01e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9488822	0.662	rs195531	chr6:116252551	A/T	cg05304507	chr6:116381966	FRK	0.2	5.46	0.33	1.14e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.12	0.46	2.23e-14	Motion sickness;
KIRP	cis	rs77633900	0.772	rs284905	chr15:76743345	C/T	cg21673338	chr15:77095150	SCAPER	-0.61	-5.87	-0.35	1.44e-8	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg06636001	chr8:8085503	FLJ10661	0.66	9.18	0.51	1.82e-17	Retinal vascular caliber;
KIRP	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.57	-0.33	6.54e-8	Aortic root size;
KIRP	cis	rs897080	0.515	rs698813	chr2:44705615	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.31	0.32	2.49e-7	Height;
KIRP	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg11846333	chr4:119757529	SEC24D	1.11	5.88	0.35	1.37e-8	Cannabis dependence symptom count;
KIRP	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.71	-0.39	1.33e-10	Dilated cardiomyopathy;
KIRP	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-8.52	-0.48	1.6e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15484899	chr15:73977283	CD276	0.51	6.83	0.4	6.43e-11	Parkinson's disease;
KIRP	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg08501292	chr6:25962987	TRIM38	1.01	7.86	0.45	1.22e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2625529	0.668	rs8192386	chr15:72513148	A/C	cg16672083	chr15:72433130	SENP8	0.46	5.51	0.33	8.83e-8	Red blood cell count;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg08293367	chr22:22089752	YPEL1	1.02	6.88	0.4	5.04e-11	P wave terminal force;
KIRP	cis	rs2281603	0.570	rs2123460	chr14:64952225	C/A	cg01860774	chr14:64969374	ZBTB25	0.33	5.4	0.33	1.58e-7	Lymphocyte counts;
KIRP	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.5	-6.02	-0.36	6.41e-9	Lung function (FVC);Lung function (FEV1);
KIRP	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg01620082	chr3:125678407	NA	-1.07	-6.54	-0.38	3.61e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.65	-9.41	-0.51	3.63e-18	Retinal vascular caliber;
KIRP	cis	rs10751667	0.557	rs4077531	chr11:1013167	G/A	cg06064525	chr11:970664	AP2A2	-0.32	-5.9	-0.35	1.17e-8	Alzheimer's disease (late onset);
KIRP	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.4	-5.1	-0.31	6.9e-7	Multiple myeloma;
KIRP	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg16141378	chr3:129829833	LOC729375	0.55	7.33	0.42	3.38e-12	Neuroticism;
KIRP	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	8.22	0.46	1.19e-14	Lymphocyte percentage of white cells;
KIRP	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg00405596	chr8:11794950	NA	-0.48	-6.32	-0.37	1.22e-9	Retinal vascular caliber;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg27252587	chr3:197477231	FYTTD1;KIAA0226	-0.48	-6.11	-0.36	3.9e-9	Myopia;
KIRP	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.59e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.85	-14.08	-0.67	1.97e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	0.62	5.98	0.36	7.88e-9	Gut microbiome composition (summer);
KIRP	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg13978929	chr19:21580086	ZNF493	-0.52	-5.1	-0.31	6.94e-7	Pain;
KIRP	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg17757837	chr7:157058334	UBE3C	0.82	11.08	0.58	2.14e-23	Body mass index;
KIRP	cis	rs12208915	0.848	rs9352654	chr6:79500281	A/G	cg18132916	chr6:79620363	NA	0.56	4.99	0.3	1.17e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.87	-0.35	1.41e-8	Crohn's disease;
KIRP	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21747090	chr2:27597821	SNX17	-0.5	-6.95	-0.41	3.29e-11	Total body bone mineral density;
KIRP	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg11608241	chr8:8085544	FLJ10661	0.51	6.16	0.37	2.91e-9	Systolic blood pressure;
KIRP	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg16576597	chr16:28551801	NUPR1	0.36	5.47	0.33	1.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs250677	0.524	rs250665	chr5:148454394	A/C	cg12140854	chr5:148520817	ABLIM3	-0.42	-5.4	-0.33	1.59e-7	Breast cancer;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.84	13.04	0.64	6.9e-30	Monocyte percentage of white cells;
KIRP	cis	rs714027	0.605	rs193476	chr22:30450521	G/A	cg01021169	chr22:30184971	ASCC2	0.43	5.41	0.33	1.49e-7	Lymphocyte counts;
KIRP	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg05669848	chr5:237993	SDHA	-0.47	-4.96	-0.3	1.31e-6	Breast cancer;
KIRP	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs6815814	0.808	rs3860069	chr4:38862121	A/C	cg06935464	chr4:38784597	TLR10	0.45	5.42	0.33	1.41e-7	Breast cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13935310	chr11:107461639	ELMOD1;LOC643923	0.48	6.74	0.39	1.11e-10	Smoking initiation;
KIRP	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.24	-0.55	9.69e-21	Heart rate;
KIRP	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.21e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs72781680	0.611	rs6720131	chr2:24364736	C/T	cg06627628	chr2:24431161	ITSN2	-0.6	-5.43	-0.33	1.34e-7	Lymphocyte counts;
KIRP	cis	rs258892	0.947	rs9885319	chr5:72179404	T/G	cg21869765	chr5:72125136	TNPO1	0.58	6.44	0.38	6.16e-10	Small cell lung carcinoma;
KIRP	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg18944383	chr4:111397179	ENPEP	0.47	8.0	0.45	4.93e-14	Height;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24232053	chr12:121177221	ACADS	0.47	6.4	0.38	7.93e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.96	12.93	0.64	1.62e-29	Vitamin D levels;
KIRP	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg16497661	chr14:103986332	CKB	0.75	11.17	0.58	1.06e-23	Body mass index;
KIRP	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.82	11.32	0.59	3.52e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-5.89	-0.35	1.23e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-5.77	-0.35	2.33e-8	Calcium levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg13038030	chr17:73267041	MIF4GD	0.87	7.46	0.43	1.47e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.72	-6.94	-0.4	3.49e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-9.5	-0.52	1.95e-18	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs7225151	0.710	rs55947703	chr17:5231618	A/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.71	-0.34	3.23e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg21191810	chr6:118973309	C6orf204	-0.45	-5.05	-0.31	8.64e-7	Diastolic blood pressure;
KIRP	cis	rs12210905	0.610	rs72845033	chr6:27546262	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.71	-5.66	-0.34	4.19e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.98	17.35	0.74	1.38e-44	Breast cancer;
KIRP	cis	rs737693	0.607	rs644885	chr11:102728612	G/A	cg19620758	chr11:102826565	MMP13	0.52	5.56	0.33	7.03e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22618164	chr12:122356400	WDR66	0.6	8.2	0.46	1.34e-14	Mean corpuscular volume;
KIRP	cis	rs6088813	0.677	rs224322	chr20:34011048	G/A	cg14752227	chr20:34000481	UQCC	-0.5	-5.94	-0.35	9.83e-9	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16189954	chr22:29138267	HSCB;CHEK2	0.53	6.27	0.37	1.63e-9	Smoking initiation;
KIRP	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs3736485	0.966	rs12440990	chr15:51902259	G/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.49e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.6	7.42	0.43	1.88e-12	Mosquito bite size;
KIRP	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13939156	chr17:80058883	NA	0.5	7.51	0.43	1.07e-12	Life satisfaction;
KIRP	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.31	4.95	0.3	1.37e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-11.24	-0.58	6.35e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.58	7.24	0.42	5.79e-12	Arsenic metabolism;
KIRP	cis	rs853679	0.546	rs200995	chr6:27813694	C/T	cg21204522	chr6:27730016	NA	0.75	5.63	0.34	4.85e-8	Depression;
KIRP	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg02896835	chr1:92012615	NA	-0.43	-5.65	-0.34	4.35e-8	Breast cancer;
KIRP	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.19	19.07	0.77	2.12e-50	Cognitive function;
KIRP	cis	rs7404928	0.915	rs7203367	chr16:23902344	A/G	cg21745164	chr16:23765304	CHP2	-0.36	-5.15	-0.31	5.44e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.41	5.13	0.31	5.77e-7	Recombination rate (males);
KIRP	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.39	-5.08	-0.31	7.29e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg09695851	chr17:3907499	NA	0.52	5.63	0.34	4.93e-8	Type 2 diabetes;
KIRP	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg26831259	chr4:1366826	KIAA1530	0.37	4.88	0.3	1.92e-6	Obesity-related traits;
KIRP	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg13731523	chr4:3047190	NA	-0.29	-5.16	-0.31	5e-7	Parental longevity (mother's age at death);
KIRP	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg24375607	chr4:120327624	NA	0.57	5.81	0.35	1.89e-8	Corneal astigmatism;
KIRP	cis	rs4950322	0.515	rs76327075	chr1:146717973	C/T	cg22381352	chr1:146742008	CHD1L	-0.4	-4.96	-0.3	1.29e-6	Protein quantitative trait loci;
KIRP	cis	rs4253772	0.530	rs9615989	chr22:46803774	A/T	cg00784671	chr22:46762841	CELSR1	-0.76	-6.91	-0.4	4.16e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.68	9.33	0.51	6.56e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.13	-0.31	5.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg22189786	chr22:42395067	WBP2NL	0.45	5.72	0.34	3.07e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04698434	chr2:25265145	EFR3B	0.46	6.23	0.37	2.05e-9	Parkinson's disease;
KIRP	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg11757124	chr7:157526947	PTPRN2	-0.5	-5.88	-0.35	1.31e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg20965017	chr5:231967	SDHA	-0.6	-6.99	-0.41	2.59e-11	Breast cancer;
KIRP	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.89	14.08	0.67	2.08e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.81	0.53	2.22e-19	Dupuytren's disease;
KIRP	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg15226275	chr6:116381976	FRK	0.22	5.92	0.35	1.1e-8	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22337605	chr1:12227417	TNFRSF1B	-0.45	-6.19	-0.37	2.47e-9	Interleukin-4 levels;
KIRP	cis	rs11583043	0.958	rs12730160	chr1:101438791	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.97	0.45	6.06e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.95e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.4	-5.11	-0.31	6.62e-7	Longevity;Endometriosis;
KIRP	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg13660082	chr14:53194042	PSMC6	-0.67	-7.31	-0.42	3.8e-12	Alzheimer's disease (late onset);
KIRP	cis	rs7119038	0.731	rs10892283	chr11:118636980	A/G	cg19308663	chr11:118741387	NA	0.55	8.69	0.48	5.22e-16	Sjögren's syndrome;
KIRP	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.45	-5.94	-0.35	9.58e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg21724239	chr8:58056113	NA	0.57	4.94	0.3	1.48e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.77	-11.46	-0.59	1.22e-24	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg15655495	chr12:38532458	NA	0.26	5.03	0.31	9.37e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg05564831	chr3:52568323	NT5DC2	0.41	6.47	0.38	5.23e-10	Electroencephalogram traits;
KIRP	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-14.98	-0.69	1.69e-36	Gut microbiome composition (summer);
KIRP	cis	rs35000415	0.873	rs13246321	chr7:128701331	T/C	cg19972273	chr7:128594194	NA	0.8	6.14	0.36	3.35e-9	Systemic lupus erythematosus;
KIRP	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	cis	rs9308433	0.529	rs867445	chr1:214502230	C/G	cg06198575	chr1:214491504	SMYD2	0.45	5.71	0.34	3.3e-8	IgG glycosylation;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04272560	chr4:925854	TMEM175;GAK	-0.46	-6.02	-0.36	6.26e-9	Metabolic traits;
KIRP	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.93	12.44	0.62	6.83e-28	Breast cancer;
KIRP	cis	rs55728055	0.661	rs9621295	chr22:32007153	G/A	cg27454842	chr22:32027588	PISD	-0.81	-4.93	-0.3	1.54e-6	Age-related hearing impairment;
KIRP	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.17	-20.5	-0.79	3.9e-55	Cognitive function;
KIRP	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.78	-12.05	-0.61	1.37e-26	Asthma;
KIRP	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.33	-4.86	-0.3	2.14e-6	Monocyte count;
KIRP	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.45	-0.38	5.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.35	-0.32	2.05e-7	Morning vs. evening chronotype;
KIRP	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-0.58	-8.9	-0.49	1.22e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg26681399	chr22:41777847	TEF	0.56	5.49	0.33	9.93e-8	Vitiligo;
KIRP	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.82	-0.53	2.09e-19	Lung cancer;
KIRP	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg11814155	chr7:99998594	ZCWPW1	0.54	5.4	0.33	1.57e-7	Platelet count;
KIRP	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg09035930	chr12:129282057	SLC15A4	0.66	6.1	0.36	4e-9	Systemic lupus erythematosus;
KIRP	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg16917193	chr12:54089295	NA	0.38	4.98	0.3	1.2e-6	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs9863706	1.000	rs59193875	chr3:72437681	G/A	cg05607079	chr3:72387937	NA	0.45	5.26	0.32	3.11e-7	Height;
KIRP	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg06636001	chr8:8085503	FLJ10661	0.62	7.62	0.44	5.42e-13	Neuroticism;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg11173422	chr1:41832478	NA	0.45	6.53	0.38	3.81e-10	Educational attainment;
KIRP	cis	rs17221829	0.692	rs55823055	chr11:89388744	G/A	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.35	-0.32	2.03e-7	Anxiety in major depressive disorder;
KIRP	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26002218	chr14:103986227	CKB	0.28	5.79	0.35	2.1e-8	Bone mineral density;
KIRP	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg06223162	chr1:101003688	GPR88	-0.43	-8.7	-0.49	4.85e-16	Monocyte count;
KIRP	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.82	13.26	0.65	1.22e-30	Morning vs. evening chronotype;
KIRP	cis	rs3784262	0.669	rs2197092	chr15:58247781	C/T	cg12031962	chr15:58353849	ALDH1A2	0.36	5.11	0.31	6.39e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7709377	0.595	rs254173	chr5:115622018	A/T	cg23108291	chr5:115420582	COMMD10	-0.44	-5.4	-0.33	1.58e-7	Metabolite levels  (X-11787);
KIRP	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.46	-0.38	5.46e-10	Menopause (age at onset);
KIRP	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg16141378	chr3:129829833	LOC729375	0.54	7.0	0.41	2.47e-11	Retinal vascular caliber;
KIRP	cis	rs7503807	0.688	rs901061	chr17:78595328	G/C	cg09596252	chr17:78655493	RPTOR	0.53	5.93	0.35	9.96e-9	Obesity;
KIRP	cis	rs7851660	0.839	rs10113884	chr9:100624622	C/T	cg13688889	chr9:100608707	NA	-0.69	-8.86	-0.49	1.61e-16	Strep throat;
KIRP	cis	rs4006360	0.579	rs6416910	chr17:39235562	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.62	-8.76	-0.49	3.14e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg26043149	chr18:55253948	FECH	-0.52	-6.06	-0.36	5.09e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16117910	chr2:109745648	SH3RF3;LOC100287216	0.54	7.39	0.43	2.27e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.43	0.33	1.37e-7	Total cholesterol levels;
KIRP	cis	rs9614461	0.702	rs2294202	chr22:45738327	A/T	cg23503501	chr22:45809793	SMC1B;RIBC2	0.56	5.23	0.32	3.6e-7	Tonsillectomy;
KIRP	cis	rs4903604	0.581	rs12879719	chr14:78035253	C/A	cg18872420	chr14:78023429	SPTLC2	0.36	5.62	0.34	5.2e-8	Gut microbiome composition (winter);
KIRP	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.87	11.61	0.6	3.75e-25	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.67	-8.28	-0.47	7.7e-15	Blood metabolite levels;
KIRP	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg19567339	chr10:100142640	NA	0.47	5.17	0.31	4.83e-7	Metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22824647	chr19:17830645	MAP1S	0.57	7.11	0.41	1.24e-11	Parkinson's disease;
KIRP	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg15848620	chr12:58087721	OS9	-0.45	-5.17	-0.31	4.9e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs8032158	0.963	rs1912398	chr15:56159103	T/G	cg02198044	chr15:56286336	NEDD4	-0.41	-4.89	-0.3	1.84e-6	Keloid;
KIRP	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.63	-7.0	-0.41	2.39e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs12823128	0.766	rs12581907	chr12:26934416	A/G	cg14081884	chr12:26986758	ITPR2	0.4	5.01	0.3	1.02e-6	Birth weight;
KIRP	cis	rs3849570	0.514	rs4389498	chr3:82015395	G/A	cg07356753	chr3:81810745	GBE1	-0.55	-6.75	-0.4	1.07e-10	Waist circumference;Body mass index;
KIRP	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.69	-6.42	-0.38	6.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg08435603	chr19:21933459	LOC641367;ZNF100	0.47	6.52	0.38	3.87e-10	Pancreatic cancer;
KIRP	cis	rs4453791	1.000	rs13094414	chr3:38930568	A/G	cg23654821	chr3:39188656	CSRNP1	0.48	4.89	0.3	1.84e-6	Social communication problems;
KIRP	cis	rs6442310	0.534	rs1151997	chr3:12446004	A/G	cg15873301	chr3:12045459	SYN2	0.4	5.35	0.32	2.03e-7	Hematocrit;
KIRP	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-10.8	-0.57	1.71e-22	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.68	8.78	0.49	2.88e-16	Plateletcrit;Platelet count;
KIRP	cis	rs7929679	0.551	rs10466455	chr11:34780936	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.46	-5.57	-0.33	6.83e-8	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.04	14.87	0.69	4.14e-36	Cognitive ability;
KIRP	cis	rs231513	0.906	rs179586	chr17:41999094	T/C	cg26893861	chr17:41843967	DUSP3	-0.6	-5.04	-0.31	8.9e-7	Cognitive function;
KIRP	trans	rs6601327	0.600	rs4841219	chr8:9654185	A/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.36	-0.38	9.99e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	1.06	15.34	0.7	1.05e-37	Height;
KIRP	cis	rs10114408	0.801	rs6479519	chr9:96663421	A/G	cg14598338	chr9:96623480	NA	-0.32	-4.91	-0.3	1.67e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.7	-7.59	-0.44	6.72e-13	Gut microbiome composition (summer);
KIRP	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-1.02	-17.35	-0.74	1.44e-44	Height;
KIRP	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	6.48	0.38	5.05e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg23693289	chr8:27183097	PTK2B	0.59	7.41	0.43	1.96e-12	Neuroticism;
KIRP	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg08461772	chr7:95026248	PON3	0.41	6.04	0.36	5.53e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg14580859	chr9:123691850	NA	0.36	5.12	0.31	6.31e-7	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.77	-10.35	-0.55	4.58e-21	Platelet count;
KIRP	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-6.16	-0.37	3.02e-9	Breast cancer;
KIRP	cis	rs7224685	0.569	rs12950310	chr17:4001980	T/C	cg09695851	chr17:3907499	NA	0.54	5.14	0.31	5.72e-7	Type 2 diabetes;
KIRP	cis	rs6681460	0.671	rs628655	chr1:67213573	T/G	cg02459107	chr1:67143332	SGIP1	-0.42	-5.94	-0.35	9.77e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	5.32	0.32	2.39e-7	Renal cell carcinoma;
KIRP	trans	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2290402	0.536	rs60492656	chr4:875008	C/T	cg00846425	chr4:957561	DGKQ	-0.48	-5.23	-0.32	3.56e-7	Type 2 diabetes;
KIRP	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg07701084	chr6:150067640	NUP43	0.67	9.09	0.5	3.31e-17	Lung cancer;
KIRP	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.91	10.29	0.55	7.02e-21	Corneal astigmatism;
KIRP	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.72	0.53	4.12e-19	Pulse pressure;
KIRP	cis	rs3136516	0.696	rs10838611	chr11:46697199	G/C	cg16389345	chr11:46697382	NA	0.51	7.24	0.42	5.76e-12	Venous thromboembolism;
KIRP	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg18527119	chr7:66119851	NA	0.47	5.04	0.31	8.94e-7	Aortic root size;
KIRP	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.6	7.54	0.43	9.29e-13	Red cell distribution width;
KIRP	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.65	8.75	0.49	3.46e-16	Age at first birth;
KIRP	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	0.91	11.63	0.6	3.31e-25	Vitiligo;
KIRP	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg11584989	chr19:19387371	SF4	0.43	5.46	0.33	1.18e-7	Tonsillectomy;
KIRP	cis	rs4728302	0.869	rs10954434	chr7:133597864	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.66	0.34	4.25e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.41	-0.47	3.36e-15	Inflammatory bowel disease;
KIRP	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	6.16	0.37	3.03e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	cg04338863	chr8:33670619	NA	0.48	6.22	0.37	2.11e-9	Body mass index;
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.58	10.0	0.54	5.53e-20	Lung cancer;
KIRP	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.62	6.75	0.4	1.05e-10	Ulcerative colitis;
KIRP	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25214090	chr10:38739885	LOC399744	0.59	7.37	0.43	2.59e-12	Educational attainment;
KIRP	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.65	-9.65	-0.52	6.59e-19	Airway imaging phenotypes;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.31e-13	Life satisfaction;
KIRP	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.91	-13.53	-0.65	1.47e-31	Height;
KIRP	trans	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg12210378	chr14:105685021	BRF1	-0.4	-6.13	-0.36	3.47e-9	Coronary artery disease;
KIRP	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs5753037	0.653	rs140133	chr22:30152522	G/C	cg01021169	chr22:30184971	ASCC2	-0.44	-6.2	-0.37	2.41e-9	Type 1 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19446589	chr2:63268631	EHBP1	-0.46	-6.41	-0.38	7.26e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.57	-6.61	-0.39	2.36e-10	Corneal astigmatism;
KIRP	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.79	10.91	0.57	7.56e-23	Aortic root size;
KIRP	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg18132916	chr6:79620363	NA	-0.41	-5.62	-0.34	5.27e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16386425	chr10:429943	DIP2C	-0.39	-5.09	-0.31	6.98e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.64	11.8	0.6	9.15e-26	Blood protein levels;
KIRP	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.54	0.38	3.5e-10	Electroencephalogram traits;
KIRP	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-5.89	-0.35	1.29e-8	Triglycerides;
KIRP	cis	rs787274	0.850	rs7862183	chr9:115529696	C/T	cg13803584	chr9:115635662	SNX30	-0.74	-8.38	-0.47	4.15e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs3935996	0.767	rs12058859	chr1:56302126	C/T	cg03356760	chr6:37665051	MDGA1	0.46	6.21	0.37	2.18e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
KIRP	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.53	7.55	0.43	8.41e-13	Lewy body disease;
KIRP	cis	rs2625529	0.526	rs55763892	chr15:72540180	C/T	cg16672083	chr15:72433130	SENP8	0.46	6.33	0.37	1.17e-9	Red blood cell count;
KIRP	cis	rs6088813	0.677	rs6087706	chr20:34006315	C/T	cg14752227	chr20:34000481	UQCC	0.46	5.15	0.31	5.34e-7	Height;
KIRP	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-0.73	-7.7	-0.44	3.23e-13	Gout;
KIRP	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06850241	chr22:41845214	NA	-0.49	-5.51	-0.33	9.07e-8	Vitiligo;
KIRP	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg27211696	chr2:191398769	TMEM194B	-0.68	-8.52	-0.48	1.67e-15	Diastolic blood pressure;
KIRP	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17376030	chr22:41985996	PMM1	0.72	7.68	0.44	3.66e-13	Vitiligo;
KIRP	cis	rs6496667	0.908	rs8040697	chr15:90853427	A/C	cg10434728	chr15:90938212	IQGAP1	0.35	5.01	0.3	1.06e-6	Rheumatoid arthritis;
KIRP	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.46	6.6	0.39	2.51e-10	Lewy body disease;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.49	-0.33	9.9e-8	Lung cancer;
KIRP	cis	rs2274273	0.662	rs4525413	chr14:55661138	A/T	cg04306507	chr14:55594613	LGALS3	0.41	5.75	0.34	2.67e-8	Protein biomarker;
KIRP	cis	rs7224685	0.569	rs34859684	chr17:3982628	G/C	cg21851534	chr17:3907994	ZZEF1	0.5	4.9	0.3	1.72e-6	Type 2 diabetes;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg09597638	chr17:3907349	NA	-0.74	-14.32	-0.67	3.16e-34	Type 2 diabetes;
KIRP	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.87	0.75	2.38e-46	Height;
KIRP	cis	rs12282928	1.000	rs10838851	chr11:48286231	T/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs72634258	0.503	rs707457	chr1:7831064	C/A	cg00042356	chr1:8021962	PARK7	0.64	4.95	0.3	1.37e-6	Inflammatory bowel disease;
KIRP	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-5.24	-0.32	3.45e-7	Neuroticism;
KIRP	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg03563238	chr19:33554763	RHPN2	-0.32	-5.94	-0.35	9.9e-9	Bone properties (heel);
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.46	6.88	0.4	5.05e-11	Lymphocyte counts;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14964934	chr19:4723942	DPP9	0.44	6.03	0.36	5.88e-9	Survival in pancreatic cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg19828298	chr1:3713105	LRRC47	0.71	6.03	0.36	6.07e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg26043149	chr18:55253948	FECH	0.51	6.15	0.37	3.17e-9	Bone mineral density;
KIRP	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.34	-0.37	1.1e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.74	-10.87	-0.57	1e-22	Morning vs. evening chronotype;
KIRP	cis	rs4262150	0.705	rs72804800	chr5:152330518	C/T	cg12297329	chr5:152029980	NA	-0.49	-5.37	-0.32	1.84e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1355223	0.837	rs11600402	chr11:34691751	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-4.96	-0.3	1.29e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg08462924	chr1:41848221	NA	0.5	7.41	0.43	2.03e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.16	-21.61	-0.81	9.02e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.51	7.77	0.44	2.18e-13	Lupus nephritis in systemic lupus erythematosus;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22373415	chr15:66996361	SMAD6	0.52	6.28	0.37	1.51e-9	Parkinson's disease;
KIRP	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg22951263	chr5:87985283	NA	-0.48	-6.83	-0.4	6.71e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.56	5.7	0.34	3.49e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3857067	0.967	rs5019896	chr4:95035751	C/T	cg11021082	chr4:95130006	SMARCAD1	0.38	5.04	0.31	9e-7	QT interval;
KIRP	cis	rs897080	0.552	rs1067377	chr2:44648239	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.77	0.35	2.4e-8	Height;
KIRP	trans	rs783540	0.500	rs7178459	chr15:83398384	T/C	cg18393722	chr15:85113863	UBE2QP1	0.52	6.24	0.37	1.86e-9	Schizophrenia;
KIRP	cis	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg07460842	chr6:66804631	NA	-0.5	-6.18	-0.37	2.64e-9	Blood trace element (Cu levels);
KIRP	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	11.75	0.6	1.31e-25	Blood protein levels;
KIRP	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg02375832	chr11:62437615	C11orf48	-0.4	-4.88	-0.3	1.95e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11138902	0.673	rs11139245	chr9:72157882	A/G	cg14397918	chr9:72078829	APBA1	0.33	5.31	0.32	2.47e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg09788416	chr12:39539408	NA	-0.44	-5.7	-0.34	3.42e-8	Heart rate;
KIRP	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.51	-6.18	-0.37	2.67e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4638749	0.501	rs750523	chr2:108746221	T/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.91	-0.3	1.64e-6	Blood pressure;
KIRP	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg26850624	chr5:429559	AHRR	-0.45	-7.16	-0.42	9.53e-12	Cystic fibrosis severity;
KIRP	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.76	11.18	0.58	9.81e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9361491	0.534	rs10943568	chr6:79404207	G/T	cg11833968	chr6:79620685	NA	-0.36	-4.93	-0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.33	-0.37	1.16e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02360337	chr11:65627185	MUS81;CFL1	0.5	6.16	0.37	2.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs78487399	0.908	rs6717791	chr2:43822006	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-4.88	-0.3	1.9e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7246657	0.678	rs4802024	chr19:38052193	T/C	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-13.43	-0.65	3.37e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg05861140	chr6:150128134	PCMT1	-0.51	-7.2	-0.42	7.21e-12	Lung cancer;
KIRP	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.15	0.61	6.59e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg07936489	chr17:37558343	FBXL20	-0.53	-6.63	-0.39	2.07e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs12760731	0.720	rs71628282	chr1:178449993	C/G	cg00404053	chr1:178313656	RASAL2	0.65	5.0	0.3	1.09e-6	Obesity-related traits;
KIRP	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.44	-0.33	1.29e-7	P wave terminal force;
KIRP	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	11.03	0.58	3e-23	Total body bone mineral density;
KIRP	cis	rs231513	0.954	rs231516	chr17:41963205	G/A	cg26893861	chr17:41843967	DUSP3	-0.49	-5.09	-0.31	7.06e-7	Cognitive function;
KIRP	cis	rs13401104	0.587	rs62190972	chr2:237145164	T/C	cg26422059	chr2:237146110	ASB18	0.46	5.27	0.32	3.03e-7	Educational attainment;
KIRP	cis	rs3779635	0.742	rs28496151	chr8:27255003	G/A	cg18234130	chr8:27182889	PTK2B	0.54	6.96	0.41	3e-11	Neuroticism;
KIRP	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.45	5.69	0.34	3.61e-8	White matter hyperintensity burden;
KIRP	cis	rs5753037	0.869	rs5763645	chr22:30357801	A/G	cg27665648	chr22:30112403	NA	0.38	5.29	0.32	2.66e-7	Type 1 diabetes;
KIRP	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.43	7.22	0.42	6.33e-12	Renal cell carcinoma;
KIRP	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-0.94	-11.17	-0.58	1.09e-23	Blood protein levels;
KIRP	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg09699651	chr6:150184138	LRP11	0.59	8.17	0.46	1.6e-14	Testicular germ cell tumor;
KIRP	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06544989	chr22:39130855	UNC84B	0.48	7.21	0.42	7.06e-12	Menopause (age at onset);
KIRP	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg13165212	chr22:42675999	NA	0.31	5.48	0.33	1.08e-7	Cognitive function;
KIRP	trans	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.28	0.37	1.49e-9	Mean corpuscular volume;
KIRP	trans	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg17712092	chr4:129076599	LARP1B	-0.63	-7.61	-0.44	5.67e-13	Eosinophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7737355	1.000	rs257390	chr5:130740617	C/T	cg25547332	chr5:131281432	NA	-0.47	-5.26	-0.32	3.14e-7	Life satisfaction;
KIRP	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.41	0.51	3.62e-18	Morning vs. evening chronotype;
KIRP	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.56	-5.92	-0.35	1.06e-8	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.51	-0.38	4.29e-10	Lung cancer;
KIRP	cis	rs16828019	0.929	rs1032728	chr1:41679566	A/T	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.65	-7.11	-0.41	1.27e-11	DNA methylation (variation);
KIRP	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.58	-6.54	-0.38	3.51e-10	Hypospadias;
KIRP	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg04398451	chr17:18023971	MYO15A	0.4	4.89	0.3	1.8e-6	Body mass index;
KIRP	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg01338084	chr22:32026380	PISD	1.06	7.16	0.42	9.25e-12	Age-related hearing impairment;
KIRP	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg01304814	chr3:48885189	PRKAR2A	0.67	5.13	0.31	5.76e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9972944	0.651	rs1819910	chr17:63814576	C/A	cg07283582	chr17:63770753	CCDC46	-0.5	-7.97	-0.45	6.03e-14	Total body bone mineral density;
KIRP	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg15327641	chr2:3715039	ALLC	0.46	5.95	0.35	9.14e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.74	9.86	0.53	1.55e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7224685	0.501	rs1878332	chr17:3904446	G/A	cg21851534	chr17:3907994	ZZEF1	0.72	12.14	0.61	6.85e-27	Type 2 diabetes;
KIRP	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.43	-0.38	6.46e-10	Response to antipsychotic treatment;
KIRP	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.96	-12.01	-0.61	1.85e-26	Alzheimer's disease;
KIRP	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.83	-12.4	-0.62	9.24e-28	Strep throat;
KIRP	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg19468946	chr17:37922297	IKZF3	-0.52	-6.95	-0.4	3.34e-11	Lymphocyte counts;
KIRP	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg11234688	chr2:1609660	NA	0.58	5.21	0.32	4e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9905704	0.589	rs2632509	chr17:56487887	C/T	cg12560992	chr17:57184187	TRIM37	-0.54	-5.04	-0.31	9.14e-7	Testicular germ cell tumor;
KIRP	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.28	0.37	1.52e-9	Putamen volume;
KIRP	trans	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg06521331	chr12:34319734	NA	-0.54	-6.63	-0.39	2.08e-10	Heart rate;
KIRP	cis	rs4132509	0.947	rs10927041	chr1:243731890	T/C	cg25706552	chr1:244017396	NA	0.51	6.64	0.39	1.96e-10	RR interval (heart rate);
KIRP	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.68	10.02	0.54	4.85e-20	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2189812	1.000	rs2189812	chr7:86348999	C/G	cg11080430	chr17:16557885	ZNF624	0.6	6.43	0.38	6.54e-10	IgG glycosylation;
KIRP	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg11738485	chr19:12877000	HOOK2	-0.48	-5.62	-0.34	5.27e-8	Mean corpuscular volume;
KIRP	cis	rs13132184	0.507	rs2303422	chr4:38091800	C/T	cg19090437	chr4:38080799	TBC1D1	0.53	5.09	0.31	7.12e-7	Verbal declarative memory;
KIRP	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.77	11.11	0.58	1.67e-23	Bladder cancer;
KIRP	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.25	0.51	1.15e-17	Morning vs. evening chronotype;
KIRP	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.53	8.04	0.46	3.84e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg06565975	chr8:143823917	SLURP1	0.48	7.61	0.44	5.74e-13	Urinary tract infection frequency;
KIRP	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.4e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg00074818	chr8:8560427	CLDN23	0.37	5.81	0.35	1.97e-8	Obesity-related traits;
KIRP	cis	rs11718455	0.960	rs3843373	chr3:44011053	C/T	cg08738300	chr3:44038990	NA	-0.66	-9.06	-0.5	4.25e-17	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02689667	chr17:8066184	VAMP2	0.46	6.07	0.36	4.75e-9	Parkinson's disease;
KIRP	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.78	-0.35	2.3e-8	Schizophrenia;
KIRP	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.93	-15.29	-0.7	1.49e-37	Dental caries;
KIRP	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.5	6.26	0.37	1.7e-9	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24491895	chr11:6889596	OR10A2	-0.41	-6.36	-0.38	9.65e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14060402	chr9:37141146	ZCCHC7	0.41	6.02	0.36	6.29e-9	Migraine with aura;
KIRP	cis	rs7267005	0.661	rs78449143	chr20:34365830	A/G	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg26412358	chr1:26503933	CNKSR1	0.42	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs9309473	0.500	rs2421582	chr2:73898420	A/G	cg20560298	chr2:73613845	ALMS1	0.45	5.61	0.34	5.47e-8	Metabolite levels;
KIRP	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.61	-7.75	-0.44	2.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.69	-7.72	-0.44	2.93e-13	Vitiligo;
KIRP	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.55	7.32	0.42	3.56e-12	Colorectal cancer;
KIRP	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg18595228	chr15:67193261	NA	0.44	5.69	0.34	3.59e-8	Lung cancer (smoking interaction);
KIRP	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg05791153	chr7:19748676	TWISTNB	0.74	6.7	0.39	1.43e-10	Thyroid stimulating hormone;
KIRP	cis	rs7113850	0.541	rs77868378	chr11:24233684	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	7.72	0.44	2.99e-13	Bone fracture in osteoporosis;
KIRP	cis	rs8067545	0.532	rs3862151	chr17:19957289	A/G	cg04132472	chr17:19861366	AKAP10	0.42	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08066407	chr11:81789082	NA	0.41	6.42	0.38	6.9e-10	C-reactive protein;
KIRP	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.87	-0.6	5.58e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.37	7.41	0.43	2.07e-12	Diastolic blood pressure;
KIRP	cis	rs28834970	0.675	rs6557994	chr8:27232018	A/G	cg14221460	chr8:27183342	PTK2B	-0.45	-5.5	-0.33	9.27e-8	Alzheimer's disease (late onset);
KIRP	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.75	-10.21	-0.55	1.24e-20	Mortality in heart failure;
KIRP	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.67	-6.97	-0.41	2.9e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4671458	0.802	rs12463603	chr2:63798198	C/A	cg17519650	chr2:63277830	OTX1	-0.52	-5.21	-0.32	3.93e-7	Subjective well-being;
KIRP	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	cg21523751	chr1:182988639	NA	0.46	7.02	0.41	2.09e-11	Hypertriglyceridemia;
KIRP	cis	rs7635838	0.892	rs6792718	chr3:11434380	A/G	cg00170343	chr3:11313890	ATG7	0.45	5.69	0.34	3.64e-8	HDL cholesterol;
KIRP	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs62355272	0.760	rs2361395	chr5:35824922	T/C	cg13894535	chr5:35919491	CAPSL	-0.46	-5.27	-0.32	2.98e-7	Lymphocyte counts;
KIRP	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.41	-6.57	-0.39	2.95e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs1021993	0.545	rs17014375	chr1:209543560	T/G	cg24446417	chr1:209558027	NA	-0.52	-5.66	-0.34	4.19e-8	Gut microbiome composition (winter);
KIRP	cis	rs4919044	0.808	rs835275	chr10:94796683	T/C	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.73	-8.0	-0.45	4.75e-14	DNA methylation (variation);
KIRP	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.56	-7.63	-0.44	5.24e-13	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	4.91	0.3	1.65e-6	Mean platelet volume;
KIRP	cis	rs1538970	0.962	rs4660849	chr1:45819872	A/G	cg05343316	chr1:45956843	TESK2	-0.62	-7.26	-0.42	4.96e-12	Platelet count;
KIRP	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg06115741	chr20:33292138	TP53INP2	0.47	6.44	0.38	6.36e-10	Coronary artery disease;
KIRP	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.58	-7.33	-0.42	3.26e-12	Uric acid levels;
KIRP	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg06365898	chr1:16533907	ARHGEF19	-0.52	-7.17	-0.42	9.01e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.06	-0.41	1.65e-11	Bladder cancer;
KIRP	cis	rs12532214	0.543	rs76502292	chr7:3135736	G/T	cg19214707	chr7:3157722	NA	-0.81	-6.34	-0.37	1.07e-9	Itch intensity from mosquito bite;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg22826071	chr19:344165	MIER2	-0.59	-6.23	-0.37	2.01e-9	Menopause (age at onset);
KIRP	trans	rs1859156	0.812	rs3755872	chr4:95815616	C/G	cg24204951	chr2:239172084	PER2	0.29	6.75	0.4	1.05e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.53	8.1	0.46	2.52e-14	Itch intensity from mosquito bite;
KIRP	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg20965017	chr5:231967	SDHA	-0.58	-6.78	-0.4	8.71e-11	Breast cancer;
KIRP	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg25801113	chr15:45476975	SHF	0.43	7.92	0.45	8.44e-14	Uric acid levels;
KIRP	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg22987457	chr7:157211561	NA	0.44	5.76	0.34	2.46e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg27490568	chr2:178487706	NA	0.57	7.65	0.44	4.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.74	-12.56	-0.63	2.81e-28	Itch intensity from mosquito bite;
KIRP	cis	rs7903847	0.642	rs2297667	chr10:99145492	A/T	cg20016023	chr10:99160130	RRP12	-0.39	-5.39	-0.33	1.64e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.84	-0.35	1.66e-8	Crohn's disease;
KIRP	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.68	-10.53	-0.56	1.21e-21	Extrinsic epigenetic age acceleration;
KIRP	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg21573476	chr21:45109991	RRP1B	0.77	10.71	0.56	3.29e-22	Mean corpuscular volume;
KIRP	cis	rs684232	0.897	rs1237094	chr17:619842	C/T	cg15660573	chr17:549704	VPS53	0.41	5.26	0.32	3.08e-7	Prostate cancer;
KIRP	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	16.99	0.73	2.26e-43	Platelet count;
KIRP	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg11502198	chr6:26597334	ABT1	0.46	4.88	0.3	1.94e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg19539972	chr4:7069911	GRPEL1	-0.91	-9.35	-0.51	5.65e-18	Monocyte percentage of white cells;
KIRP	cis	rs9372498	0.536	rs72969531	chr6:118729974	C/A	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs4748857	0.947	rs10764395	chr10:23511697	G/A	cg12804278	chr10:23633326	C10orf67	0.43	5.34	0.32	2.1e-7	Systemic lupus erythematosus;
KIRP	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.56	-0.56	9.71e-22	Menopause (age at onset);
KIRP	cis	rs6850606	0.577	rs1993060	chr4:42857175	A/G	cg24533989	chr4:42659536	ATP8A1	-0.43	-4.91	-0.3	1.69e-6	Interferon alpha levels in systemic lupus erythematosus;
KIRP	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	11.22	0.58	7.55e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.52	5.57	0.33	6.73e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs3026101	0.671	rs58832024	chr17:5306536	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.61	-6.97	-0.41	2.94e-11	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg12486944	chr17:80159399	CCDC57	-0.41	-5.54	-0.33	7.74e-8	Life satisfaction;
KIRP	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg13482628	chr17:19912719	NA	-0.53	-7.02	-0.41	2.17e-11	Schizophrenia;
KIRP	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.82	10.5	0.56	1.45e-21	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg01119278	chr6:110721349	DDO	-0.46	-7.08	-0.41	1.48e-11	Platelet distribution width;
KIRP	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.14	16.41	0.72	2.18e-41	Breast cancer;
KIRP	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg01631408	chr1:248437212	OR2T33	0.65	8.53	0.48	1.53e-15	Common traits (Other);
KIRP	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg22705602	chr4:152727874	NA	0.53	9.32	0.51	6.74e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	0.92	7.71	0.44	3.11e-13	Thyroid stimulating hormone;
KIRP	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg08923054	chr8:41654455	ANK1	0.71	7.77	0.44	2.07e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-8.72	-0.49	4.12e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg06675538	chr2:114033490	PAX8;LOC440839	0.35	5.29	0.32	2.72e-7	Renal function-related traits (BUN);
KIRP	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg06606381	chr12:133084897	FBRSL1	-1.04	-6.29	-0.37	1.44e-9	Depression;
KIRP	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.55	0.39	3.31e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg11995313	chr8:8860691	ERI1	0.41	5.41	0.33	1.48e-7	Joint mobility (Beighton score);
KIRP	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.73	11.46	0.59	1.18e-24	Resting heart rate;
KIRP	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	24.1	0.84	1.03e-66	Chronic sinus infection;
KIRP	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.59	0.44	6.6e-13	Major depressive disorder;
KIRP	cis	rs17453880	0.929	rs10071370	chr5:152048813	T/G	cg12297329	chr5:152029980	NA	-0.71	-10.54	-0.56	1.11e-21	Subjective well-being;
KIRP	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.82	11.05	0.58	2.63e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg17554472	chr22:41940697	POLR3H	-0.62	-7.0	-0.41	2.42e-11	Vitiligo;
KIRP	cis	rs7011507	1.000	rs75413798	chr8:49186797	G/A	cg15325961	chr8:49183143	NA	0.59	5.0	0.3	1.08e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7572644	0.680	rs12465012	chr2:28028191	C/T	cg27432699	chr2:27873401	GPN1	0.5	6.05	0.36	5.48e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg04978709	chr7:75101039	POM121C	0.46	6.11	0.36	3.82e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13102973	0.720	rs7668824	chr4:135884707	A/T	cg14419869	chr4:135874104	NA	0.38	6.02	0.36	6.18e-9	Subjective well-being;
KIRP	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.84	13.5	0.65	1.92e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.56	0.33	6.88e-8	Ovarian reserve;
KIRP	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.84	10.64	0.56	5.31e-22	Gestational age at birth (maternal effect);
KIRP	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg00310523	chr12:86230176	RASSF9	0.56	8.69	0.48	5.29e-16	Major depressive disorder;
KIRP	cis	rs7903847	0.642	rs11189179	chr10:99143320	T/C	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.23	-0.32	3.55e-7	Electroencephalogram traits;
KIRP	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg10790698	chr19:18539756	SSBP4	-0.33	-6.71	-0.39	1.3e-10	Breast cancer;
KIRP	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg21395723	chr22:39101663	GTPBP1	0.37	4.89	0.3	1.78e-6	Menopause (age at onset);
KIRP	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg18350739	chr11:68623251	NA	-0.48	-7.49	-0.43	1.22e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.1	-0.36	4.01e-9	Ulcerative colitis;
KIRP	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.54	-5.92	-0.35	1.09e-8	Uric acid levels;
KIRP	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	9.33	0.51	6.46e-18	Body mass index (adult);
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg25622155	chr1:158173687	NA	-0.43	-6.12	-0.36	3.6e-9	Obesity-related traits;
KIRP	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05665937	chr4:1216051	CTBP1	0.45	6.24	0.37	1.91e-9	Obesity-related traits;
KIRP	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.92	15.05	0.69	1.02e-36	Metabolic syndrome;
KIRP	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00864171	chr11:67383662	NA	-0.41	-5.21	-0.32	3.99e-7	Mean corpuscular volume;
KIRP	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.61	8.75	0.49	3.57e-16	Resting heart rate;
KIRP	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.71	9.38	0.51	4.57e-18	Height;
KIRP	cis	rs7005380	0.581	rs4871795	chr8:120941665	C/T	cg21645572	chr8:120931649	DEPDC6	-0.49	-6.41	-0.38	7.22e-10	Interstitial lung disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg24996433	chr7:150777871	FASTK	-0.57	-6.4	-0.38	7.65e-10	Menopause (age at onset);
KIRP	trans	rs9841504	1.000	rs9841454	chr3:114362596	C/G	cg24348448	chr19:55493930	NLRP2	-0.85	-6.99	-0.41	2.61e-11	Gastric cancer;
KIRP	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs7301016	0.846	rs12369751	chr12:63031133	G/C	cg01804193	chr12:63026212	NA	0.59	6.28	0.37	1.49e-9	IgG glycosylation;
KIRP	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15369054	chr17:80825471	TBCD	-0.63	-7.58	-0.44	6.83e-13	Breast cancer;
KIRP	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.59	-7.13	-0.41	1.14e-11	Red cell distribution width;
KIRP	cis	rs9534288	0.671	rs4942465	chr13:46562687	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-8.32	-0.47	6.17e-15	Blood protein levels;
KIRP	cis	rs8038465	0.967	rs3935942	chr15:73971361	C/A	cg15420318	chr15:73925796	NPTN	0.58	7.5	0.43	1.17e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg25019033	chr10:957182	NA	-0.69	-9.13	-0.5	2.54e-17	Eosinophil percentage of granulocytes;
KIRP	cis	rs2223471	0.870	rs2817422	chr6:50750240	G/C	cg03432817	chr6:50765336	NA	-0.51	-8.62	-0.48	8.54e-16	Subcutaneous adipose tissue;
KIRP	cis	rs7520050	0.966	rs10789475	chr1:46304177	C/G	cg03146154	chr1:46216737	IPP	-0.4	-5.05	-0.31	8.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs981844	0.712	rs3925717	chr4:154750917	C/G	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.99	10.64	0.56	5.48e-22	Cognitive test performance;
KIRP	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg25356066	chr3:128598488	ACAD9	0.48	5.52	0.33	8.42e-8	IgG glycosylation;
KIRP	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1448094	0.802	rs11117146	chr12:86382870	C/T	cg00310523	chr12:86230176	RASSF9	-0.39	-6.06	-0.36	5.19e-9	Major depressive disorder;
KIRP	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg19875535	chr5:140030758	IK	0.64	9.0	0.5	6.12e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7937682	0.593	rs1944118	chr11:111352032	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.42	-5.53	-0.33	8.3e-8	Primary sclerosing cholangitis;
KIRP	cis	rs2425143	1.000	rs56052651	chr20:34344084	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.14	-0.31	5.48e-7	Blood protein levels;
KIRP	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg26248373	chr2:1572462	NA	-0.8	-10.95	-0.57	5.37e-23	IgG glycosylation;
KIRP	cis	rs1981331	0.609	rs8127722	chr21:48077293	A/C	cg17243659	chr21:48055224	PRMT2	1.35	8.3	0.47	7.13e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.27e-10	Hepatitis;
KIRP	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg02336718	chr17:17403227	NA	0.39	5.92	0.35	1.07e-8	Total body bone mineral density;
KIRP	cis	rs259842	0.764	rs2630539	chr2:180707298	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.41	-0.33	1.47e-7	Blood protein levels;
KIRP	cis	rs7112043	0.868	rs10768093	chr11:34777559	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.48	5.75	0.34	2.6e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg23307798	chr14:103986281	CKB	0.78	13.45	0.65	2.7e-31	Body mass index;
KIRP	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.86	-11.77	-0.6	1.14e-25	Breast cancer;
KIRP	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23598886	chr18:12777645	NA	0.75	6.14	0.36	3.35e-9	Inflammatory skin disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27228276	chr1:151119210	SEMA6C	0.48	6.06	0.36	5.09e-9	Parkinson's disease;
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg16341495	chr8:142228727	SLC45A4	-0.4	-4.93	-0.3	1.51e-6	Immature fraction of reticulocytes;
KIRP	cis	rs6838801	0.538	rs17322488	chr4:77560635	G/A	cg17476223	chr4:77663285	SHROOM3	-0.45	-6.62	-0.39	2.22e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg24375607	chr4:120327624	NA	-0.47	-5.62	-0.34	5.28e-8	Corneal astigmatism;
KIRP	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg11645453	chr3:52864694	ITIH4	-0.34	-5.25	-0.32	3.33e-7	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03187894	chr7:36429470	ANLN;KIAA0895	0.46	6.22	0.37	2.12e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9888739	0.800	rs11859300	chr16:31355895	G/T	cg15817542	chr16:31343056	ITGAM	-0.48	-5.08	-0.31	7.34e-7	Systemic lupus erythematosus;
KIRP	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	11.08	0.58	2.03e-23	Colorectal cancer;
KIRP	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.79	-8.59	-0.48	1.02e-15	Hair shape;
KIRP	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19524238	chr7:2802976	GNA12	-0.4	-5.74	-0.34	2.85e-8	Height;
KIRP	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.84	9.53	0.52	1.59e-18	Iron status biomarkers;
KIRP	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.29	10.41	0.55	2.91e-21	Prostate cancer;
KIRP	cis	rs4794202	0.629	rs2010952	chr17:45892859	G/T	cg02219949	chr17:45927392	SP6	-0.53	-4.97	-0.3	1.26e-6	Alzheimer's disease (cognitive decline);
KIRP	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg00103785	chr1:155043322	NA	-0.3	-5.34	-0.32	2.14e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg21858823	chr1:15850916	CASP9	0.51	5.5	0.33	9.5e-8	Systolic blood pressure;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10166090	chr14:68162924	RDH11	0.44	6.47	0.38	5.31e-10	Survival in pancreatic cancer;
KIRP	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.67	-6.01	-0.36	6.65e-9	Schizophrenia;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.7	0.44	3.3e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.52	6.55	0.39	3.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9398803	0.796	rs1361107	chr6:126767511	A/C	cg19875578	chr6:126661172	C6orf173	0.49	6.37	0.38	9.02e-10	Male-pattern baldness;
KIRP	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg24154853	chr7:158122151	PTPRN2	0.38	5.44	0.33	1.29e-7	Calcium levels;
KIRP	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg11189052	chr15:85197271	WDR73	0.48	5.03	0.31	9.5e-7	Schizophrenia;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.53	13.23	0.64	1.58e-30	Airflow obstruction;
KIRP	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg07148914	chr20:33460835	GGT7	-0.52	-6.97	-0.41	2.81e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.59	-6.75	-0.4	1.07e-10	Metabolite levels;
KIRP	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg06289844	chr6:126071538	HEY2	0.34	4.91	0.3	1.69e-6	Brugada syndrome;
KIRP	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg19468946	chr17:37922297	IKZF3	-0.47	-6.95	-0.4	3.35e-11	Asthma;
KIRP	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-7.0	-0.41	2.49e-11	Alzheimer's disease;
KIRP	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.84	-13.97	-0.67	4.76e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	cis	rs16828019	0.852	rs11209576	chr1:41586029	T/C	cg18742814	chr1:41828276	NA	0.67	5.89	0.35	1.24e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg10790698	chr19:18539756	SSBP4	-0.34	-7.34	-0.42	3.16e-12	Breast cancer;
KIRP	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-7.84	-0.45	1.39e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7116495	1.000	rs675185	chr11:71775572	T/G	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg05998816	chr21:47859926	PCNT	0.54	5.82	0.35	1.87e-8	Lymphocyte counts;
KIRP	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.72	9.83	0.53	1.86e-19	Heart rate;
KIRP	cis	rs6594713	0.717	rs13174075	chr5:112795352	A/T	cg12552261	chr5:112820674	MCC	0.62	5.95	0.35	9.26e-9	Brain cytoarchitecture;
KIRP	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	13.83	0.66	1.44e-32	Platelet count;
KIRP	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg24315340	chr6:146058215	EPM2A	-0.42	-5.34	-0.32	2.12e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs68170813	1.000	rs35061190	chr7:107249844	C/T	cg02696742	chr7:106810147	HBP1	-0.62	-6.14	-0.36	3.31e-9	Coronary artery disease;
KIRP	cis	rs2930047	0.535	rs267948	chr5:10744197	C/G	cg14521931	chr5:10832172	NA	-0.51	-6.74	-0.39	1.15e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11677416	1.000	rs3783514	chr2:113547425	A/G	cg23974023	chr2:113544294	IL1A	-0.33	-5.13	-0.31	5.87e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.82	-0.4	7e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4523957	0.552	rs923862	chr17:2031382	A/C	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg20673091	chr1:2541236	MMEL1	-0.66	-9.84	-0.53	1.77e-19	Ulcerative colitis;
KIRP	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg08131204	chr22:41487073	MIR1281	-0.41	-4.85	-0.3	2.19e-6	Neuroticism;
KIRP	cis	rs4765905	0.610	rs2238053	chr12:2317096	C/T	cg10668781	chr12:2307325	CACNA1C	0.28	5.51	0.33	8.82e-8	Schizophrenia;
KIRP	cis	rs10203711	1.000	rs907112	chr2:239566603	C/G	cg14580085	chr2:239553406	NA	0.39	5.21	0.32	3.91e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs829661	0.739	rs829635	chr2:30736811	G/A	cg10949345	chr2:30726833	LCLAT1	1.0	12.07	0.61	1.17e-26	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.13e-20	Dupuytren's disease;
KIRP	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	0.77	7.47	0.43	1.37e-12	Pediatric areal bone mineral density (radius);
KIRP	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.57	7.62	0.44	5.64e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs9549328	0.800	rs1317507	chr13:113631780	G/T	cg20742385	chr13:113633654	MCF2L	-0.34	-5.63	-0.34	4.81e-8	Systolic blood pressure;
KIRP	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19524238	chr7:2802976	GNA12	-0.39	-5.33	-0.32	2.21e-7	Height;
KIRP	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.86	8.26	0.47	8.78e-15	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs6835098	0.692	rs1316411	chr4:174075143	A/G	cg08422745	chr4:174089978	GALNT7	-0.69	-9.3	-0.51	8e-18	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-7.56	-0.43	8.08e-13	Tonsillectomy;
KIRP	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.09	0.54	3.04e-20	Total body bone mineral density;
KIRP	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg08000102	chr2:233561755	GIGYF2	-0.58	-6.37	-0.38	9.15e-10	Schizophrenia;
KIRP	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.26	0.42	5e-12	Bladder cancer;
KIRP	cis	rs2282032	0.527	rs55664487	chr14:90765880	C/T	cg04374321	chr14:90722782	PSMC1	0.57	6.89	0.4	4.71e-11	Longevity;
KIRP	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.54	-7.58	-0.44	6.86e-13	Bladder cancer;
KIRP	cis	rs1894292	0.715	rs2010987	chr4:74472876	A/G	cg12566645	chr4:74483141	RASSF6	0.37	5.1	0.31	6.75e-7	Prostate cancer;
KIRP	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg16989719	chr2:238392110	NA	-0.41	-5.49	-0.33	1.02e-7	Prostate cancer;
KIRP	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-9.49	-0.52	2.1e-18	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25202845	chr15:74753513	UBL7	0.47	6.09	0.36	4.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs16858210	0.874	rs7618182	chr3:183607003	T/A	cg01324343	chr3:183735012	ABCC5	0.4	5.34	0.32	2.13e-7	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08642814	chr1:3734907	KIAA0562	0.44	6.09	0.36	4.31e-9	Survival in pancreatic cancer;
KIRP	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg14835575	chr10:16859367	RSU1	0.59	7.64	0.44	4.73e-13	Platelet distribution width;
KIRP	trans	rs8001976	0.507	rs12586070	chr13:48317389	T/G	cg23237801	chr1:16476620	EPHA2	0.5	6.3	0.37	1.33e-9	Aging (time to event);
KIRP	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.61	-6.5	-0.38	4.45e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.56	-7.46	-0.43	1.46e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs8014252	0.803	rs2877672	chr14:71036259	T/C	cg11204974	chr14:71022665	NA	-0.56	-6.04	-0.36	5.61e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16139199	chr18:19180362	ESCO1	0.51	6.86	0.4	5.67e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs1937787	0.522	rs12070989	chr1:80841004	G/T	cg02315508	chr14:77787366	POMT2;GSTZ1	-0.51	-6.62	-0.39	2.2e-10	Stroke;
KIRP	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg12858261	chr2:113808755	IL1F8	0.46	5.34	0.32	2.16e-7	Protein quantitative trait loci;
KIRP	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg16309518	chr5:176445507	NA	-0.89	-13.8	-0.66	1.77e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.75	-7.65	-0.44	4.51e-13	Hair shape;
KIRP	cis	rs2177596	0.525	rs2229814	chr2:227954599	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.96	-0.3	1.31e-6	Body mass index;
KIRP	cis	rs12431939	0.947	rs55974960	chr14:51633742	T/C	cg23942311	chr14:51606299	NA	-0.62	-5.34	-0.32	2.13e-7	Cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg22975147	chr17:8021903	ALOXE3	0.53	6.65	0.39	1.93e-10	Asthma;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25141894	chr1:115164619	DENND2C	0.43	6.39	0.38	8.31e-10	Interleukin-4 levels;
KIRP	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg24879335	chr3:133465180	TF	0.33	4.85	0.3	2.15e-6	Iron status biomarkers;
KIRP	cis	rs2845885	1.000	rs11231698	chr11:63877163	C/T	cg05555928	chr11:63887634	MACROD1	-0.75	-5.22	-0.32	3.9e-7	Body mass index;
KIRP	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg19743168	chr1:23544995	NA	-0.48	-6.35	-0.38	1.01e-9	Height;
KIRP	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	8.58	0.48	1.08e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg14517863	chr17:44321492	NA	0.48	5.61	0.34	5.38e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.47	6.58	0.39	2.78e-10	Sitting height ratio;
KIRP	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.54	-6.58	-0.39	2.79e-10	Total body bone mineral density;
KIRP	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.67	-6.68	-0.39	1.6e-10	Menarche (age at onset);
KIRP	trans	rs899435	0.765	rs1531591	chr12:13451225	T/C	cg12827708	chr18:32172486	DTNA	0.42	6.21	0.37	2.27e-9	Coronary artery calcification;
KIRP	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.76	11.3	0.58	4.15e-24	Height;
KIRP	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg18154014	chr19:37997991	ZNF793	0.68	7.31	0.42	3.73e-12	Coronary artery calcification;
KIRP	cis	rs7589728	1.000	rs7425670	chr2:88522028	C/T	cg04511125	chr2:88470314	THNSL2	0.69	5.48	0.33	1.06e-7	Plasma clusterin levels;
KIRP	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.716	rs356549	chr4:98699344	A/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.88	13.81	0.66	1.71e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.5	6.17	0.37	2.77e-9	Urinary tract infection frequency;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23914026	chr8:59506823	NSMAF	-0.41	-6.36	-0.38	9.54e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs7640424	0.835	rs1561029	chr3:107822245	A/C	cg09227934	chr3:107805635	CD47	0.3	5.16	0.31	5.08e-7	Body mass index;
KIRP	trans	rs12659622	0.850	rs77611788	chr5:15639700	C/T	cg25746134	chr1:202129865	PTPN7	-0.48	-6.04	-0.36	5.71e-9	Obesity-related traits;
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg06815112	chr8:27182871	PTK2B	0.51	6.43	0.38	6.49e-10	Neuroticism;
KIRP	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.48	-7.24	-0.42	5.76e-12	Vitamin D levels;
KIRP	trans	rs2472591	0.852	rs3116591	chr13:50570774	G/T	cg04548715	chr7:99598775	NA	0.54	6.1	0.36	4.02e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.96	16.06	0.72	3.41e-40	Height;
KIRP	cis	rs1298062	0.825	rs1673020	chr19:50987847	C/G	cg11430371	chr19:50961752	MYBPC2	0.35	4.93	0.3	1.51e-6	Age of smoking initiation;
KIRP	cis	rs1975974	0.935	rs11870387	chr17:21730236	G/C	cg18423549	chr17:21743878	NA	-0.46	-4.85	-0.3	2.23e-6	Psoriasis;
KIRP	cis	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg21775007	chr8:11205619	TDH	0.45	5.85	0.35	1.53e-8	Systemic lupus erythematosus;
KIRP	cis	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg21546286	chr11:48923668	NA	-0.47	-5.99	-0.36	7.59e-9	HDL cholesterol;
KIRP	cis	rs4073221	0.789	rs35709168	chr3:18236105	G/A	cg07694806	chr3:18168406	NA	-0.77	-6.64	-0.39	1.95e-10	Parkinson's disease;
KIRP	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	1.0	17.54	0.75	3.22e-45	Breast cancer;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg24864683	chr1:180199274	LHX4	-0.49	-6.18	-0.37	2.72e-9	Blood metabolite levels;
KIRP	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	0.92	5.3	0.32	2.58e-7	Height;
KIRP	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	8.43	0.47	2.9e-15	Lung cancer in ever smokers;
KIRP	cis	rs960902	0.747	rs7593333	chr2:37725712	A/G	cg25341268	chr2:37734390	NA	0.6	7.92	0.45	8.3e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg27490568	chr2:178487706	NA	0.75	10.16	0.54	1.79e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	8.2	0.46	1.38e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.94	15.63	0.71	1.02e-38	Breast cancer;
KIRP	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.48	6.0	0.36	7.04e-9	Depressive symptoms;
KIRP	cis	rs6695223	0.571	rs4907133	chr1:85538947	A/G	cg22153463	chr1:85462885	MCOLN2	-0.54	-5.22	-0.32	3.79e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9488822	0.651	rs521985	chr6:116264940	G/A	cg15226275	chr6:116381976	FRK	-0.23	-6.13	-0.36	3.46e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg17366294	chr4:99064904	C4orf37	0.37	5.26	0.32	3.14e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg08662619	chr6:150070041	PCMT1	0.36	5.73	0.34	2.96e-8	Lung cancer;
KIRP	cis	rs2591576	0.780	rs830238	chr5:165405702	C/T	cg13976338	chr5:165423657	NA	-0.72	-10.73	-0.56	2.78e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.44	-15.77	-0.71	3.53e-39	Schizophrenia;
KIRP	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg20415053	chr1:26527928	CATSPER4	-0.42	-4.88	-0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.77	9.78	0.53	2.66e-19	Corneal astigmatism;
KIRP	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg04166393	chr7:2884313	GNA12	-0.62	-7.78	-0.44	1.99e-13	Height;
KIRP	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg18306943	chr3:40428807	ENTPD3	0.46	5.96	0.36	8.83e-9	Renal cell carcinoma;
KIRP	cis	rs4523957	0.583	rs2760739	chr17:2024217	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3109167	0.524	rs2713182	chr7:83097221	T/A	cg14519356	chr7:83097669	SEMA3E	0.61	9.58	0.52	1.12e-18	Blood protein levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00745731	chr19:929724	ARID3A	0.5	6.43	0.38	6.57e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg17366294	chr4:99064904	C4orf37	0.45	6.44	0.38	6.24e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.54	-14.69	-0.68	1.62e-35	Airflow obstruction;
KIRP	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.2	0.42	7.27e-12	Aortic root size;
KIRP	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.59	0.34	6.11e-8	Educational attainment;
KIRP	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.24	0.42	5.79e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.58	9.72	0.53	4.13e-19	Schizophrenia;
KIRP	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg25338242	chr13:114786047	RASA3	0.41	4.92	0.3	1.59e-6	Schizophrenia;
KIRP	cis	rs17453880	0.890	rs6860811	chr5:152049653	G/T	cg12297329	chr5:152029980	NA	-0.71	-10.56	-0.56	9.55e-22	Subjective well-being;
KIRP	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.23	0.37	2.05e-9	Mean platelet volume;
KIRP	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.82	-0.4	6.93e-11	Total cholesterol levels;
KIRP	cis	rs9653442	0.545	rs12712067	chr2:100763900	A/C	cg22139774	chr2:100720529	AFF3	0.36	5.65	0.34	4.35e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1440410	0.798	rs7693817	chr4:144051525	T/C	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.53	9.26	0.51	1.08e-17	Vitiligo;
KIRP	cis	rs7225151	0.710	rs12602528	chr17:5245437	T/A	cg24500398	chr17:5266808	RABEP1	-0.54	-5.46	-0.33	1.17e-7	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.64	-5.87	-0.35	1.37e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-6.04	-0.36	5.74e-9	Multiple sclerosis;
KIRP	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg01200585	chr1:228362443	C1orf69	0.47	5.6	0.34	5.65e-8	Diastolic blood pressure;
KIRP	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.84	12.07	0.61	1.21e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-5.05	-0.31	8.79e-7	Neuroticism;
KIRP	cis	rs11169552	0.510	rs10876061	chr12:50968685	G/A	cg12884762	chr12:50931848	DIP2B	-0.42	-4.91	-0.3	1.68e-6	Colorectal cancer;
KIRP	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg25233709	chr10:116636983	FAM160B1	0.33	4.91	0.3	1.68e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg22356347	chr1:167427500	CD247	-0.41	-5.86	-0.35	1.49e-8	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg09006292	chr3:64049408	NA	-0.53	-4.9	-0.3	1.76e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.07	-0.64	5.21e-30	Chronic sinus infection;
KIRP	cis	rs55962025	0.686	rs362331	chr4:3215835	T/C	cg06533319	chr4:3265114	C4orf44	0.41	5.17	0.31	4.86e-7	Parental longevity (mother's age at death);
KIRP	cis	rs1215050	0.791	rs2658477	chr4:98850993	G/A	cg17366294	chr4:99064904	C4orf37	-0.37	-5.1	-0.31	6.71e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.01	-0.36	6.51e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16724481	chr1:63464679	NA	0.42	6.31	0.37	1.26e-9	Interleukin-4 levels;
KIRP	cis	rs9398803	0.931	rs2045258	chr6:126674354	A/G	cg19875578	chr6:126661172	C6orf173	0.49	6.49	0.38	4.73e-10	Male-pattern baldness;
KIRP	cis	rs7319311	0.565	rs7991436	chr13:111026440	G/A	cg06243866	chr13:111019493	COL4A2	0.59	6.25	0.37	1.82e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-1.06	-12.94	-0.64	1.47e-29	Vitiligo;
KIRP	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-7.0	-0.41	2.38e-11	Bladder cancer;
KIRP	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.81	-8.46	-0.47	2.41e-15	Gut microbiome composition (summer);
KIRP	cis	rs1443512	0.812	rs1975472	chr12:54337083	A/G	cg17410650	chr12:54324560	NA	-0.46	-5.92	-0.35	1.05e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.56	-6.55	-0.39	3.26e-10	Initial pursuit acceleration;
KIRP	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg00656387	chr3:40428638	ENTPD3	0.41	5.15	0.31	5.24e-7	Renal cell carcinoma;
KIRP	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.29	-0.51	8.41e-18	Retinal vascular caliber;
KIRP	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg00405596	chr8:11794950	NA	-0.51	-6.64	-0.39	2.02e-10	Neuroticism;
KIRP	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-11.97	-0.61	2.55e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.82	6.41	0.38	7.39e-10	Parkinson's disease;
KIRP	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.62	-0.34	5.17e-8	Metabolite levels;
KIRP	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg24315340	chr6:146058215	EPM2A	-0.43	-5.54	-0.33	7.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg15896084	chr13:114927664	NA	0.47	6.29	0.37	1.46e-9	Schizophrenia;
KIRP	cis	rs1105228	0.501	rs4709075	chr6:165665299	A/G	cg12582777	chr6:165658423	NA	-0.49	-5.96	-0.36	8.81e-9	Number of pregnancies;Number of children;
KIRP	cis	rs3857536	0.707	rs9345793	chr6:66929807	G/C	cg07460842	chr6:66804631	NA	-0.46	-5.84	-0.35	1.63e-8	Blood trace element (Cu levels);
KIRP	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	4.93e-23	Prudent dietary pattern;
KIRP	cis	rs780094	0.500	rs12473139	chr2:27765587	T/C	cg05484376	chr2:27715224	FNDC4	-0.36	-5.25	-0.32	3.3e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg22800045	chr5:56110881	MAP3K1	0.82	8.73	0.49	3.89e-16	Initial pursuit acceleration;
KIRP	cis	rs8084125	0.765	rs72981157	chr18:74944238	A/G	cg18461021	chr18:74961002	GALR1	0.52	5.3	0.32	2.59e-7	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10346758	chr22:47097389	CERK	0.51	6.5	0.38	4.5e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg12598211	chr12:123634384	NA	-0.39	-4.95	-0.3	1.35e-6	Platelet count;
KIRP	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26002218	chr14:103986227	CKB	0.26	4.96	0.3	1.33e-6	Body mass index;
KIRP	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.48	-0.38	4.92e-10	Metabolite levels;
KIRP	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	1.23	7.29	0.42	4.18e-12	LDL cholesterol;
KIRP	cis	rs31771	0.818	rs31767	chr5:165498874	C/T	cg13976338	chr5:165423657	NA	0.59	5.87	0.35	1.41e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.73	-9.34	-0.51	6.15e-18	Breast size;
KIRP	cis	rs6921919	0.525	rs16894095	chr6:28390230	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.48	-6.7	-0.39	1.39e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.2	-0.37	2.39e-9	QT interval;
KIRP	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg19554555	chr3:13937349	NA	-0.45	-6.07	-0.36	4.69e-9	Ovarian reserve;
KIRP	cis	rs1519814	0.956	rs6995843	chr8:121159867	C/T	cg22335954	chr8:121166405	COL14A1	-0.64	-6.4	-0.38	7.99e-10	Breast cancer;
KIRP	cis	rs9652601	0.959	rs12925642	chr16:11171602	A/G	cg04616529	chr16:11181986	CLEC16A	0.37	4.97	0.3	1.26e-6	Systemic lupus erythematosus;
KIRP	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.66	-8.43	-0.47	2.87e-15	Sudden cardiac arrest;
KIRP	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02725872	chr8:58115012	NA	-0.75	-7.74	-0.44	2.65e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4073416	0.518	rs7151561	chr14:65890603	T/C	cg03016385	chr14:66212404	NA	-0.54	-6.74	-0.39	1.1e-10	N-glycan levels;
KIRP	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.28	5.55	0.33	7.5e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.59	8.44	0.47	2.84e-15	Carotid intima media thickness;
KIRP	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg12173498	chr6:36355764	ETV7	0.31	4.96	0.3	1.33e-6	Platelet distribution width;
KIRP	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg02297831	chr4:17616191	MED28	0.57	6.69	0.39	1.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg21366198	chr4:185655624	MLF1IP	0.39	5.19	0.31	4.39e-7	Kawasaki disease;
KIRP	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg10167378	chr1:228756711	NA	0.44	5.69	0.34	3.68e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.66	-9.27	-0.51	9.68e-18	Temperament;
KIRP	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	cg21523751	chr1:182988639	NA	0.41	6.32	0.37	1.22e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs427941	0.632	rs201492	chr7:101754138	C/T	cg06246474	chr7:101738831	CUX1	0.52	6.34	0.37	1.09e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg01391022	chr12:122360665	WDR66	0.34	5.14	0.31	5.73e-7	Mean corpuscular volume;
KIRP	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.48	0.43	1.29e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.73	6.15	0.37	3.05e-9	Body mass index;
KIRP	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.43	-5.33	-0.32	2.22e-7	Aortic root size;
KIRP	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg15832292	chr6:96025679	MANEA	0.77	7.05	0.41	1.79e-11	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg00319359	chr11:70116639	PPFIA1	0.56	5.84	0.35	1.67e-8	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	6.95e-7	Life satisfaction;
KIRP	cis	rs6987853	0.666	rs2923403	chr8:42447748	G/T	cg09913449	chr8:42400586	C8orf40	0.4	5.27	0.32	2.99e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.24	0.32	3.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.45	-5.75	-0.34	2.61e-8	Initial pursuit acceleration;
KIRP	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg10144569	chr3:42726640	KBTBD5	-0.48	-5.0	-0.3	1.11e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7546094	1.000	rs6669096	chr1:113132361	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg16306078	chr6:126000798	NA	-0.26	-4.87	-0.3	1.97e-6	Endometrial cancer;
KIRP	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg14675211	chr2:100938903	LONRF2	0.47	6.02	0.36	6.29e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.768	rs11168750	chr12:38992710	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.7	-0.44	3.21e-13	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	1.01	17.45	0.74	6.38e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg07862535	chr7:139043722	LUC7L2	0.46	5.16	0.31	4.99e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-4.88	-0.3	1.9e-6	Testicular germ cell tumor;
KIRP	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg25039879	chr17:56429692	SUPT4H1	0.61	5.35	0.32	1.98e-7	Cognitive test performance;
KIRP	cis	rs7937682	0.593	rs1944117	chr11:111351184	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	5.65	0.34	4.34e-8	Primary sclerosing cholangitis;
KIRP	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.74	-0.63	6.71e-29	Exhaled nitric oxide output;
KIRP	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg05418105	chr22:50981406	NA	-0.58	-7.24	-0.42	5.88e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.04	-0.31	8.86e-7	Heart rate;
KIRP	cis	rs6546886	0.957	rs35609589	chr2:74256015	A/G	cg14702570	chr2:74259524	NA	-0.27	-5.09	-0.31	7.15e-7	Dialysis-related mortality;
KIRP	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-0.98	-11.4	-0.59	1.9e-24	Vitiligo;
KIRP	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-1.05	-14.64	-0.68	2.43e-35	Orofacial clefts;
KIRP	cis	rs4262150	0.544	rs17549307	chr5:151914462	T/C	cg12297329	chr5:152029980	NA	-0.71	-8.85	-0.49	1.73e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg15880211	chr22:50250494	ZBED4	-0.42	-4.98	-0.3	1.22e-6	Schizophrenia;
KIRP	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.67	-6.43	-0.38	6.45e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.7	8.21	0.46	1.26e-14	Corneal astigmatism;
KIRP	cis	rs2839627	0.638	rs8133179	chr21:44272327	G/A	cg03543861	chr21:44258195	NA	0.6	6.29	0.37	1.48e-9	Information processing speed;
KIRP	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg11895451	chr1:16533891	ARHGEF19	0.42	5.83	0.35	1.75e-8	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9400271	0.632	rs9374069	chr6:109586334	A/G	cg21918786	chr6:109611834	NA	-0.38	-5.65	-0.34	4.5e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	trans	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg06521331	chr12:34319734	NA	-0.53	-6.73	-0.39	1.16e-10	Bladder cancer;
KIRP	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.97	-15.2	-0.7	3.14e-37	Height;
KIRP	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg23601095	chr6:26197514	HIST1H3D	0.98	8.28	0.47	8.02e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.75	9.02	0.5	5.67e-17	Blood trace element (Zn levels);
KIRP	trans	rs453301	0.686	rs6748	chr8:8890802	C/T	cg00405596	chr8:11794950	NA	-0.45	-6.05	-0.36	5.32e-9	Joint mobility (Beighton score);
KIRP	cis	rs365132	0.934	rs251844	chr5:176476605	T/A	cg16309518	chr5:176445507	NA	-0.88	-13.48	-0.65	2.14e-31	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg11130432	chr3:121712080	ILDR1	-0.47	-5.82	-0.35	1.79e-8	Multiple sclerosis;
KIRP	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.83	-0.63	3.46e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	27.17	0.87	5.11e-76	Chronic sinus infection;
KIRP	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg24851858	chr13:114927579	NA	0.4	4.88	0.3	1.95e-6	Schizophrenia;
KIRP	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg12315302	chr6:26189340	HIST1H4D	1.06	6.0	0.36	7.15e-9	Breast cancer;
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.55	-0.43	8.31e-13	Life satisfaction;
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.07	-0.31	7.65e-7	Lung cancer;
KIRP	cis	rs28595532	0.623	rs71608363	chr4:119227259	T/C	cg21605333	chr4:119757512	SEC24D	0.76	5.9	0.35	1.17e-8	Cannabis dependence symptom count;
KIRP	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg06115741	chr20:33292138	TP53INP2	-0.38	-5.18	-0.31	4.61e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg21965820	chr15:72978371	HIGD2B;BBS4	-0.48	-6.19	-0.37	2.46e-9	Morning vs. evening chronotype;
KIRP	cis	rs9479482	0.686	rs2010259	chr6:150385475	C/T	cg25797454	chr6:150327115	RAET1K	0.31	5.51	0.33	8.92e-8	Alopecia areata;
KIRP	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg03929089	chr4:120376271	NA	0.96	7.1	0.41	1.31e-11	Myopia (pathological);
KIRP	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.61	7.33	0.42	3.27e-12	Monocyte count;
KIRP	cis	rs6546886	0.912	rs60279245	chr2:74312743	T/G	cg14702570	chr2:74259524	NA	-0.3	-6.0	-0.36	7.04e-9	Dialysis-related mortality;
KIRP	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.63	7.17	0.42	8.67e-12	Initial pursuit acceleration;
KIRP	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.01	0.67	3.42e-33	Chronic sinus infection;
KIRP	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.87	0.4	5.11e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg11211951	chr8:145729740	GPT	-0.32	-5.23	-0.32	3.6e-7	Age at first birth;
KIRP	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-5.03	-0.31	9.27e-7	Extrinsic epigenetic age acceleration;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25084332	chr12:62997409	MIRLET7I;C12orf61	0.44	6.16	0.37	2.9e-9	Survival in pancreatic cancer;
KIRP	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	6.34	0.37	1.11e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1472147	1.000	rs4323418	chr7:128506970	C/T	cg17511168	chr7:128516960	KCP	-0.36	-5.13	-0.31	5.91e-7	Calcium levels;
KIRP	cis	rs4588572	0.774	rs4072853	chr5:77656402	G/C	cg11547950	chr5:77652471	NA	0.51	5.29	0.32	2.64e-7	Triglycerides;
KIRP	cis	rs7084402	0.967	rs1427224	chr10:60290620	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg19592336	chr6:28129416	ZNF389	0.51	5.85	0.35	1.56e-8	Depression;
KIRP	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.1	-0.46	2.52e-14	Retinal vascular caliber;
KIRP	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg26022315	chr17:47021804	SNF8	0.42	5.4	0.33	1.54e-7	Type 2 diabetes;
KIRP	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.42	-0.33	1.42e-7	Colorectal cancer;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09795127	chr1:238417847	NA	0.38	6.02	0.36	6.36e-9	C-reactive protein;
KIRP	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg24009623	chr19:33667908	NA	-0.45	-5.64	-0.34	4.65e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11209002	0.522	rs2224502	chr1:67539439	A/G	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs7224685	0.774	rs8081417	chr17:3902650	T/A	cg21851534	chr17:3907994	ZZEF1	0.68	9.8	0.53	2.36e-19	Type 2 diabetes;
KIRP	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.52	7.26	0.42	4.96e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg22437258	chr11:111473054	SIK2	0.58	6.77	0.4	9.39e-11	Primary sclerosing cholangitis;
KIRP	cis	rs57590327	0.679	rs17019088	chr3:81611535	A/T	cg07356753	chr3:81810745	GBE1	-0.58	-6.43	-0.38	6.75e-10	Extraversion;
KIRP	cis	rs7202877	0.656	rs6564245	chr16:75308899	A/G	cg03315344	chr16:75512273	CHST6	-0.56	-5.15	-0.31	5.33e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg01214346	chr17:406501	NA	-0.39	-4.85	-0.3	2.22e-6	Prostate cancer;
KIRP	cis	rs12210905	0.688	rs72845031	chr6:27535404	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-5.83	-0.35	1.72e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg01324507	chr7:1177794	C7orf50	0.55	5.02	0.3	9.96e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg22947322	chr17:47091978	IGF2BP1	0.4	5.32	0.32	2.39e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs3736485	0.966	rs11070862	chr15:51902227	G/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.22	-0.32	3.83e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22565399	chr5:176890677	DBN1	0.51	6.19	0.37	2.46e-9	Interleukin-4 levels;
KIRP	cis	rs5167	0.536	rs1882752	chr19:45461342	G/C	cg13119609	chr19:45449297	APOC2	0.39	4.92	0.3	1.62e-6	Blood protein levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg17143303	chr17:33734764	NA	0.4	6.07	0.36	4.89e-9	Cancer;
KIRP	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-7.41	-0.43	2.02e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg10556349	chr10:835070	NA	0.56	4.85	0.3	2.24e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.61	-7.27	-0.42	4.77e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	cg07049167	chr1:166818506	POGK	0.62	7.07	0.41	1.61e-11	Refractive astigmatism;
KIRP	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14396892	chr9:96623032	NA	-0.38	-5.26	-0.32	3.17e-7	DNA methylation (variation);
KIRP	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.15	0.41	9.81e-12	Prudent dietary pattern;
KIRP	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg06671706	chr8:8559999	CLDN23	0.56	6.34	0.37	1.09e-9	Obesity-related traits;
KIRP	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg01879757	chr17:41196368	BRCA1	-0.79	-11.23	-0.58	6.68e-24	Menopause (age at onset);
KIRP	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	1.04	20.17	0.79	4.8e-54	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg18154014	chr19:37997991	ZNF793	0.93	9.4	0.51	4.07e-18	Coronary artery calcification;
KIRP	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.66	-0.56	4.68e-22	Height;
KIRP	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg04731861	chr2:219085781	ARPC2	0.3	7.5	0.43	1.16e-12	Colorectal cancer;
KIRP	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.49e-9	Myopia (pathological);
KIRP	cis	rs2573652	0.723	rs2727201	chr15:100515311	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.78	-12.39	-0.62	9.88e-28	Height;
KIRP	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	5.99	0.36	7.42e-9	Total body bone mineral density;
KIRP	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.87	12.58	0.63	2.45e-28	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	9.31	0.51	7.54e-18	Cognitive test performance;
KIRP	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg23307798	chr14:103986281	CKB	0.72	11.22	0.58	7.27e-24	Body mass index;
KIRP	cis	rs752010	0.571	rs10890135	chr1:42054084	G/A	cg06885757	chr1:42089581	HIVEP3	0.37	5.25	0.32	3.33e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.34	-4.95	-0.3	1.41e-6	Monocyte count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.61	7.37	0.43	2.53e-12	Smoking initiation;
KIRP	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg00784671	chr22:46762841	CELSR1	-0.82	-8.14	-0.46	2.02e-14	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.68	9.8	0.53	2.42e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.37	-0.47	4.51e-15	Coronary artery disease;
KIRP	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg00204512	chr16:28754710	NA	0.38	4.9	0.3	1.75e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.52	-6.62	-0.39	2.21e-10	Testicular germ cell tumor;
KIRP	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg15147215	chr3:52552868	STAB1	0.27	4.9	0.3	1.77e-6	Bipolar disorder;
KIRP	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg04226714	chr8:49833948	SNAI2	0.5	6.98	0.41	2.8e-11	Life satisfaction;
KIRP	cis	rs832540	0.519	rs1445998	chr5:56268205	A/G	cg14703610	chr5:56206110	C5orf35	0.48	6.43	0.38	6.74e-10	Coronary artery disease;
KIRP	cis	rs981844	1.000	rs2606335	chr4:154656536	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.77	-10.76	-0.57	2.17e-22	Pulse pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04409420	chr1:78282478	FAM73A	-0.41	-6.4	-0.38	7.65e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.65	-7.58	-0.44	7.16e-13	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.54	-0.43	8.95e-13	Bipolar disorder;
KIRP	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.85	12.19	0.61	4.72e-27	Morning vs. evening chronotype;
KIRP	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.02	-0.31	9.7e-7	IgG glycosylation;
KIRP	cis	rs11866815	0.739	rs35050910	chr16:394483	T/G	cg26913058	chr16:419975	MRPL28	-0.5	-5.47	-0.33	1.1e-7	Body mass index;
KIRP	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-6.27	-0.37	1.59e-9	Cardiac Troponin-T levels;
KIRP	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.55	5.6	0.34	5.79e-8	Height;
KIRP	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg24315340	chr6:146058215	EPM2A	0.42	5.19	0.31	4.37e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22541963	chr20:60982533	CABLES2	-0.41	-5.14	-0.31	5.56e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg27170947	chr2:26402098	FAM59B	-0.59	-6.58	-0.39	2.78e-10	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.4	-4.98	-0.3	1.17e-6	Aortic root size;
KIRP	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.6	-0.44	6.31e-13	Alcohol dependence;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.7	10.62	0.56	6.11e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9652601	0.959	rs12927355	chr16:11194771	C/T	cg04616529	chr16:11181986	CLEC16A	0.4	5.18	0.31	4.67e-7	Systemic lupus erythematosus;
KIRP	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg01849466	chr14:104193079	ZFYVE21	0.41	5.12	0.31	6.03e-7	Schizophrenia;
KIRP	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.18	-0.31	4.61e-7	Metabolite levels;
KIRP	cis	rs7113874	0.612	rs11517715	chr11:8511888	G/C	cg08015107	chr11:8618950	NA	-0.51	-6.78	-0.4	8.79e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17401966	0.558	rs12128374	chr1:10426417	G/A	cg19773385	chr1:10388646	KIF1B	-0.4	-5.83	-0.35	1.77e-8	Hepatocellular carcinoma;
KIRP	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.63	0.39	2.14e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg07741184	chr6:167504864	NA	0.24	6.41	0.38	7.23e-10	Crohn's disease;
KIRP	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.85	-0.35	1.55e-8	Educational attainment;
KIRP	cis	rs55675132	0.548	rs76034359	chr1:115375048	C/G	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs9398803	0.624	rs1455738	chr6:126636820	A/G	cg19875578	chr6:126661172	C6orf173	0.4	5.05	0.31	8.49e-7	Male-pattern baldness;
KIRP	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.61	7.75	0.44	2.44e-13	Prostate cancer;
KIRP	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.64	7.55	0.43	8.72e-13	Dental caries;
KIRP	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.78	7.59	0.44	6.54e-13	Neuroblastoma;
KIRP	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs1891275	0.515	rs1592051	chr10:93542186	A/G	cg07889827	chr10:93443413	NA	0.44	7.45	0.43	1.6e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg09455208	chr3:40491958	NA	0.3	5.25	0.32	3.26e-7	Renal cell carcinoma;
KIRP	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.45	-5.86	-0.35	1.5e-8	Crohn's disease;
KIRP	cis	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg13370280	chr6:137539688	IFNGR1	-0.47	-6.23	-0.37	2.02e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg12623918	chr2:306882	NA	0.45	5.59	0.34	5.97e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	5.74	0.34	2.83e-8	Birth weight;
KIRP	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.6	-7.8	-0.45	1.77e-13	Smoking behavior;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07592830	chr1:198259669	NEK7	-0.43	-6.92	-0.4	3.82e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs12475964	0.740	rs10201149	chr2:37387587	A/G	cg26124318	chr8:38965122	ADAM32	-0.43	-6.13	-0.36	3.52e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.77	-9.61	-0.52	9.14e-19	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg10180764	chr2:128284465	IWS1	0.55	6.6	0.39	2.47e-10	Educational attainment;
KIRP	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg26811252	chr16:29126840	RRN3P2	0.63	8.31	0.47	6.41e-15	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08414021	chr3:184607877	VPS8	-0.45	-6.96	-0.41	3.08e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	11.96	0.61	2.65e-26	Monocyte percentage of white cells;
KIRP	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg12962167	chr3:53033115	SFMBT1	0.81	5.92	0.35	1.07e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6959887	1.000	rs6959920	chr7:35295094	G/T	cg06685737	chr7:35301730	NA	0.45	6.66	0.39	1.78e-10	Birth weight;
KIRP	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg08198773	chr8:1697536	NA	0.4	5.26	0.32	3.13e-7	Systolic blood pressure;
KIRP	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg02996583	chr8:142237188	SLC45A4	-0.41	-4.98	-0.3	1.2e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.66	-8.17	-0.46	1.68e-14	Height;
KIRP	trans	rs330071	0.515	rs12545193	chr8:9251880	G/A	cg15556689	chr8:8085844	FLJ10661	0.56	7.44	0.43	1.65e-12	Acne (severe);
KIRP	cis	rs5753037	0.869	rs5763671	chr22:30384572	G/A	cg27665648	chr22:30112403	NA	0.38	5.25	0.32	3.22e-7	Type 1 diabetes;
KIRP	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.77	9.0	0.5	6.17e-17	Vitiligo;
KIRP	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.69	8.37	0.47	4.43e-15	Blood metabolite levels;
KIRP	cis	rs593254	0.774	rs942009	chr6:164392814	G/A	cg00040411	chr6:164393165	NA	-0.46	-5.39	-0.33	1.63e-7	Gestational age at birth in labor-initiated deliveries (maternal effect);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg10633746	chr17:18164442	SMCR7	0.75	6.35	0.38	1.06e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	4.85	0.3	2.17e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg07870213	chr5:140052090	DND1	0.63	7.68	0.44	3.77e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.04	-0.46	3.68e-14	Coronary artery disease;
KIRP	cis	rs7870753	0.628	rs10820597	chr9:99188347	C/A	cg25260653	chr9:99212216	HABP4	0.56	5.72	0.34	3.06e-8	Height;
KIRP	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.64	9.21	0.51	1.53e-17	Resting heart rate;
KIRP	cis	rs12311304	0.965	rs767201	chr12:15370878	A/G	cg08258403	chr12:15378311	NA	-0.35	-5.24	-0.32	3.5e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7319311	0.589	rs952358	chr13:111026738	T/A	cg06243866	chr13:111019493	COL4A2	0.59	6.25	0.37	1.82e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.48	8.25	0.47	9.4e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg21644426	chr2:191273491	MFSD6	-0.52	-4.93	-0.3	1.53e-6	Diastolic blood pressure;
KIRP	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg24879335	chr3:133465180	TF	0.5	8.13	0.46	2.15e-14	Iron status biomarkers;
KIRP	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg13010199	chr12:38710504	ALG10B	-0.38	-4.86	-0.3	2.08e-6	Bladder cancer;
KIRP	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.79	-0.35	2.17e-8	Colorectal cancer;
KIRP	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.65	8.74	0.49	3.58e-16	Bladder cancer;
KIRP	cis	rs1981331	0.609	rs8127722	chr21:48077293	A/C	cg23283320	chr21:48055893	PRMT2	1.42	8.84	0.49	1.93e-16	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.73	-9.9	-0.53	1.19e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.64	8.83	0.49	2.01e-16	Gut microbiome composition (summer);
KIRP	trans	rs11250097	0.501	rs2409665	chr8:10736233	G/C	cg16141378	chr3:129829833	LOC729375	0.47	6.22	0.37	2.1e-9	Neuroticism;
KIRP	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg24642439	chr20:33292090	TP53INP2	-0.43	-5.14	-0.31	5.61e-7	Height;
KIRP	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.84	-12.83	-0.63	3.34e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs397969	0.570	rs2108981	chr17:19878666	G/A	cg04132472	chr17:19861366	AKAP10	0.47	5.35	0.32	2.02e-7	Platelet count;
KIRP	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg25251562	chr2:3704773	ALLC	-0.51	-6.02	-0.36	6.27e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs3924048	0.559	rs6541038	chr1:12626210	G/T	cg00291366	chr1:12616550	NA	0.42	5.89	0.35	1.29e-8	Optic cup area;
KIRP	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg15226275	chr6:116381976	FRK	0.23	6.09	0.36	4.21e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg03060546	chr3:49711283	APEH	-0.63	-7.5	-0.43	1.19e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	10.11	0.54	2.54e-20	Coffee consumption (cups per day);
KIRP	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	0.58	7.82	0.45	1.58e-13	Prostate cancer;
KIRP	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	0.98	8.33	0.47	5.56e-15	Arsenic metabolism;
KIRP	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.58	0.73	6e-42	Electrocardiographic conduction measures;
KIRP	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg21747090	chr2:27597821	SNX17	-0.39	-5.25	-0.32	3.34e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.15	15.43	0.7	4.85e-38	Gut microbiome composition (summer);
KIRP	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02725872	chr8:58115012	NA	-0.75	-7.74	-0.44	2.65e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01391346	chr6:99873300	SFRS18	0.56	6.7	0.39	1.38e-10	Lung cancer in ever smokers;
KIRP	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg08873628	chr1:175162347	KIAA0040	0.44	6.39	0.38	8.04e-10	Alcohol dependence;
KIRP	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.3	-7.07	-0.41	1.58e-11	Mean corpuscular volume;
KIRP	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04238871	chr10:126431886	FAM53B	0.61	8.14	0.46	2e-14	Smoking initiation;
KIRP	cis	rs2737618	0.722	rs1986405	chr1:200095935	C/G	cg21825944	chr1:200113062	NR5A2	-0.53	-7.5	-0.43	1.14e-12	Uric acid levels;
KIRP	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-6.99	-0.41	2.59e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg00409905	chr10:38381863	ZNF37A	0.49	6.36	0.38	9.82e-10	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs737693	0.915	rs17368582	chr11:102738075	T/C	cg19620758	chr11:102826565	MMP13	0.73	5.8	0.35	2.05e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg08648136	chr8:956695	NA	0.36	4.97	0.3	1.27e-6	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.98	17.35	0.74	1.38e-44	Breast cancer;
KIRP	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.48	-5.08	-0.31	7.32e-7	Psoriasis;
KIRP	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-6.51	-0.38	4.22e-10	Response to antipsychotic treatment;
KIRP	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg06060754	chr5:176797920	RGS14	-0.46	-7.05	-0.41	1.84e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-0.66	-7.74	-0.44	2.65e-13	Initial pursuit acceleration;
KIRP	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.34	-10.3	-0.55	6.61e-21	Diabetic kidney disease;
KIRP	cis	rs17373728	0.507	rs13248105	chr8:76166869	G/A	cg07016329	chr8:76221503	NA	0.43	5.69	0.34	3.56e-8	Diabetic kidney disease;
KIRP	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.98	-0.45	5.61e-14	Mean corpuscular volume;
KIRP	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg25039879	chr17:56429692	SUPT4H1	0.55	5.03	0.31	9.56e-7	Cognitive test performance;
KIRP	cis	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg21775007	chr8:11205619	TDH	-0.36	-4.9	-0.3	1.75e-6	Triglycerides;
KIRP	cis	rs1978968	1.000	rs7286607	chr22:18444657	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	trans	rs17079247	0.841	rs9566051	chr13:85807798	A/G	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs7404928	0.794	rs56046165	chr16:23874366	T/G	cg05497750	chr16:23765381	CHP2	-0.45	-5.33	-0.32	2.24e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg22903657	chr4:1355424	KIAA1530	-0.42	-6.08	-0.36	4.5e-9	Obesity-related traits;
KIRP	cis	rs11138902	0.666	rs11139274	chr9:72161136	C/T	cg14397918	chr9:72078829	APBA1	0.35	5.61	0.34	5.42e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	0.95	12.16	0.61	6e-27	Blood protein levels;
KIRP	cis	rs10128264	1.000	rs2802364	chr10:80960486	G/C	cg18737081	chr10:80999807	ZMIZ1	-0.3	-5.59	-0.34	6.12e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg10645314	chr2:3704589	ALLC	0.56	6.49	0.38	4.77e-10	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.41	4.93	0.3	1.5e-6	Diastolic blood pressure;
KIRP	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.4	-0.33	1.55e-7	Bronchopulmonary dysplasia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08808811	chr3:184079573	CLCN2	0.42	6.07	0.36	4.88e-9	Survival in pancreatic cancer;
KIRP	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.52	5.39	0.33	1.62e-7	Obesity (extreme);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19425100	chr11:111749553	FDXACB1;C11orf1	0.47	6.37	0.38	9.11e-10	Parkinson's disease;
KIRP	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.49	7.23	0.42	5.94e-12	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs4594175	0.926	rs11157800	chr14:51615502	A/T	cg23942311	chr14:51606299	NA	0.51	6.68	0.39	1.58e-10	Cancer;
KIRP	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg25719798	chr6:13487668	GFOD1;C6orf114	0.51	6.33	0.37	1.17e-9	DNA methylation (variation);
KIRP	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.33	18.62	0.76	6.97e-49	Corneal structure;
KIRP	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20814179	chr4:940893	TMEM175	0.58	9.49	0.52	2.09e-18	Sjögren's syndrome;
KIRP	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg17133734	chr15:86042851	AKAP13	-0.47	-5.93	-0.35	1.02e-8	Coronary artery disease;
KIRP	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.32	-0.32	2.33e-7	Neuroticism;
KIRP	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg02353165	chr6:42928485	GNMT	0.56	6.61	0.39	2.39e-10	Blood protein levels;
KIRP	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.91	14.71	0.68	1.46e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1318772	0.577	rs9326899	chr5:112972120	C/A	cg12552261	chr5:112820674	MCC	0.72	4.94	0.3	1.47e-6	F-cell distribution;
KIRP	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg02160872	chr5:212506	CCDC127	-0.46	-5.01	-0.3	1.04e-6	Breast cancer;
KIRP	trans	rs9409565	0.826	rs2139189	chr9:97238538	A/G	cg05679027	chr9:99775184	HIATL2	-0.55	-6.5	-0.38	4.46e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs9303542	0.571	rs2202895	chr17:46584657	T/C	cg04904318	chr17:46607828	HOXB1	0.45	5.7	0.34	3.36e-8	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.74	-11.31	-0.58	3.66e-24	Hip circumference;
KIRP	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg02002194	chr4:3960332	NA	-0.47	-6.57	-0.39	2.97e-10	Neuroticism;
KIRP	cis	rs11731606	0.508	rs9307140	chr4:95288670	G/C	cg20625393	chr4:95128694	SMARCAD1	0.56	5.32	0.32	2.32e-7	Mean platelet volume;
KIRP	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg16329650	chr2:213403929	ERBB4	-0.42	-5.91	-0.35	1.14e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg04935436	chr20:30431758	NA	0.48	5.86	0.35	1.48e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg05507819	chr15:63340323	TPM1	0.5	6.02	0.36	6.31e-9	Platelet count;
KIRP	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.68	0.53	5.37e-19	Monocyte percentage of white cells;
KIRP	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs112591243	0.570	rs77436553	chr21:47759343	G/A	cg26904215	chr21:47823096	PCNT	-0.86	-6.24	-0.37	1.87e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.65	-7.61	-0.44	5.74e-13	Bone mineral density;
KIRP	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg13264159	chr8:625131	ERICH1	-0.8	-6.32	-0.37	1.21e-9	IgG glycosylation;
KIRP	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.73	11.67	0.6	2.52e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg18154014	chr19:37997991	ZNF793	0.93	10.04	0.54	4.26e-20	Coronary artery calcification;
KIRP	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg00094735	chr5:1949198	NA	-0.52	-5.99	-0.36	7.5e-9	Gut microbiome composition (winter);
KIRP	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg00074818	chr8:8560427	CLDN23	0.41	6.61	0.39	2.42e-10	Obesity-related traits;
KIRP	cis	rs10992471	0.533	rs331377	chr9:95243549	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.4	-4.96	-0.3	1.3e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg26335602	chr6:28129616	ZNF389	0.43	4.86	0.3	2.08e-6	Depression;
KIRP	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.55	6.0	0.36	6.83e-9	Type 2 diabetes;
KIRP	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg15880211	chr22:50250494	ZBED4	0.54	5.66	0.34	4.12e-8	Schizophrenia;
KIRP	cis	rs2979489	0.786	rs2979514	chr8:30399461	A/C	cg26383811	chr8:30366931	RBPMS	-0.43	-6.0	-0.36	7.05e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.43	-5.68	-0.34	3.85e-8	Monocyte count;
KIRP	cis	rs6032067	0.929	rs2233883	chr20:43835822	T/C	cg10761708	chr20:43804764	PI3	0.52	5.34	0.32	2.08e-7	Blood protein levels;
KIRP	cis	rs258892	0.895	rs115204336	chr5:72024800	A/G	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg27189623	chr16:705930	WDR90	0.45	6.17	0.37	2.73e-9	Height;
KIRP	cis	rs8014252	0.803	rs12588723	chr14:70984951	C/T	cg19730268	chr14:71022823	NA	0.76	6.46	0.38	5.46e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	8.9	0.49	1.23e-16	Personality dimensions;
KIRP	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg21187068	chr8:144659627	NAPRT1	0.72	4.95	0.3	1.38e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.53e-45	Cognitive function;
KIRP	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg17724175	chr1:150552817	MCL1	0.36	6.16	0.37	2.94e-9	Tonsillectomy;
KIRP	cis	rs8038465	0.874	rs11574497	chr15:74004557	A/T	cg15420318	chr15:73925796	NPTN	0.48	5.91	0.35	1.13e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.53	7.08	0.41	1.51e-11	Schizophrenia;
KIRP	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg25753631	chr6:25732923	NA	-0.29	-5.33	-0.32	2.24e-7	Iron status biomarkers;
KIRP	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg15117754	chr3:10150083	C3orf24	0.57	5.37	0.32	1.83e-7	Alzheimer's disease;
KIRP	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.7	-11.43	-0.59	1.53e-24	Menopause (age at onset);
KIRP	cis	rs12541635	0.677	rs1006480	chr8:106975524	T/C	cg10147462	chr8:107024639	NA	0.34	5.08	0.31	7.46e-7	Age of smoking initiation;
KIRP	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg20636351	chr8:55087400	NA	-0.64	-7.57	-0.43	7.35e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg10381502	chr11:71823885	C11orf51	-1.03	-7.17	-0.42	8.64e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.12	-0.31	6.17e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-5.64	-0.34	4.56e-8	Schizophrenia;
KIRP	cis	rs4356932	1.000	rs12640367	chr4:76989870	G/C	cg00809888	chr4:76862425	NAAA	0.45	6.34	0.37	1.08e-9	Blood protein levels;
KIRP	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	5.36	0.32	1.96e-7	Personality dimensions;
KIRP	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.42	11.13	0.58	1.42e-23	Prostate cancer;
KIRP	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06056004	chr5:44809616	MRPS30	0.52	6.2	0.37	2.42e-9	Smoking initiation;
KIRP	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	6.34	0.37	1.07e-9	Bipolar disorder;
KIRP	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	1.1	11.83	0.6	7.12e-26	Corneal structure;
KIRP	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.93	-0.35	1e-8	Educational attainment;
KIRP	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg06618935	chr21:46677482	NA	0.41	5.04	0.31	8.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs10992471	0.729	rs13284038	chr9:95555488	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.26	-0.32	3.07e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg11901034	chr3:128598214	ACAD9	-0.46	-5.68	-0.34	3.88e-8	IgG glycosylation;
KIRP	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg14092571	chr14:90743983	NA	0.43	5.33	0.32	2.18e-7	Mortality in heart failure;
KIRP	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	0.85	6.62	0.39	2.2e-10	Mitochondrial DNA levels;
KIRP	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg07395648	chr5:131743802	NA	-0.38	-5.3	-0.32	2.6e-7	Blood metabolite levels;
KIRP	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.55	7.36	0.42	2.69e-12	Bladder cancer;
KIRP	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.77	8.98	0.5	7.3e-17	Gut microbiome composition (summer);
KIRP	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.64	8.18	0.46	1.51e-14	Tonsillectomy;
KIRP	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-11.04	-0.58	2.8e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg25650185	chr19:21324782	ZNF431	-0.49	-4.93	-0.3	1.55e-6	Pain;
KIRP	cis	rs8054556	0.692	rs4788199	chr16:29970857	C/G	cg06326092	chr16:30034487	C16orf92	0.47	6.97	0.41	2.92e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-14.28	-0.67	4.38e-34	Gut microbiome composition (summer);
KIRP	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg20387954	chr3:183756860	HTR3D	-0.82	-12.9	-0.64	2.06e-29	Anterior chamber depth;
KIRP	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.39	-9.56	-0.52	1.3e-18	Asthma (sex interaction);
KIRP	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	cg12689670	chr1:183009347	LAMC1	-0.43	-6.24	-0.37	1.86e-9	Colorectal cancer;
KIRP	cis	rs6558530	0.666	rs28376731	chr8:1696252	C/A	cg08198773	chr8:1697536	NA	0.49	6.08	0.36	4.59e-9	Systolic blood pressure;
KIRP	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.67	6.74	0.4	1.09e-10	Vitiligo;
KIRP	cis	rs2412208	0.795	rs4074964	chr1:7105079	A/G	cg20434152	chr1:7120926	CAMTA1	-0.37	-4.98	-0.3	1.22e-6	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg22496380	chr5:211416	CCDC127	-0.86	-6.2	-0.37	2.42e-9	Breast cancer;
KIRP	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	12.76	0.63	5.78e-29	Platelet count;
KIRP	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.98	-0.3	1.18e-6	Life satisfaction;
KIRP	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-16.01	-0.71	5.08e-40	Coronary artery disease;
KIRP	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg06417478	chr19:12876846	HOOK2	-0.48	-5.73	-0.34	2.88e-8	Mean corpuscular volume;
KIRP	trans	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg21659725	chr3:3221576	CRBN	-0.71	-8.41	-0.47	3.31e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.52	-5.41	-0.33	1.46e-7	Subjective well-being;
KIRP	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.48	-0.33	1.03e-7	Height;
KIRP	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg17347335	chr11:93583973	C11orf90	-0.31	-5.12	-0.31	6.17e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.71	9.19	0.51	1.69e-17	Iron status biomarkers;
KIRP	cis	rs6832769	1.000	rs6834676	chr4:56298414	C/G	cg05960024	chr4:56376020	CLOCK	0.73	9.32	0.51	6.77e-18	Personality dimensions;
KIRP	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg12311346	chr5:56204834	C5orf35	-0.39	-5.33	-0.32	2.27e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-4.94	-0.3	1.46e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.44	5.17	0.31	4.74e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg23958373	chr8:599963	NA	0.84	6.79	0.4	8.42e-11	IgG glycosylation;
KIRP	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18357526	chr6:26021779	HIST1H4A	0.84	10.39	0.55	3.43e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs888194	0.651	rs10850443	chr12:110040622	A/G	cg05360138	chr12:110035743	NA	0.47	5.76	0.34	2.44e-8	Neuroticism;
KIRP	cis	rs8179	0.514	rs2282978	chr7:92264410	A/G	cg15732164	chr7:92237376	CDK6	-0.42	-5.96	-0.36	8.52e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg18944383	chr4:111397179	ENPEP	0.69	12.55	0.62	2.89e-28	Coronary artery disease;
KIRP	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.58	-11.74	-0.6	1.41e-25	Diabetic kidney disease;
KIRP	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11987759	chr7:65425863	GUSB	0.49	6.37	0.38	9.01e-10	Aortic root size;
KIRP	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg13482628	chr17:19912719	NA	0.53	6.94	0.4	3.45e-11	Schizophrenia;
KIRP	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	9.16	0.5	2.1e-17	Lymphocyte counts;
KIRP	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.67	-9.43	-0.52	3.17e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.81	-13.3	-0.65	8.85e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.37	0.38	9.01e-10	Aortic root size;
KIRP	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.69	9.06	0.5	4.15e-17	Macular telangiectasia type 2;
KIRP	cis	rs702634	0.579	rs255758	chr5:53311502	C/A	cg22592108	chr5:53304441	ARL15	0.46	5.79	0.35	2.09e-8	Type 2 diabetes;High light scatter reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26806016	chr1:21307656	EIF4G3	-0.43	-6.08	-0.36	4.58e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.73	-0.34	2.92e-8	Subjective well-being;
KIRP	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs7539542	0.577	rs6662398	chr1:202888456	T/G	cg08940984	chr1:202857613	RABIF	0.46	5.78	0.35	2.26e-8	Mean platelet volume;
KIRP	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs11605924	0.967	rs6485646	chr11:45865764	G/A	cg23097878	chr11:45879730	CRY2	0.32	6.54	0.38	3.55e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	23.3	0.83	3.44e-64	Schizophrenia;
KIRP	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14228332	chr4:119757509	SEC24D	0.48	7.07	0.41	1.61e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	cg21523751	chr1:182988639	NA	0.44	6.96	0.41	3.01e-11	Colorectal cancer;
KIRP	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg01877450	chr7:97915802	BRI3	-0.57	-7.43	-0.43	1.79e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.08	0.36	4.56e-9	Mean platelet volume;
KIRP	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.9	12.37	0.62	1.23e-27	Response to diuretic therapy;
KIRP	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg19767477	chr5:127420684	SLC12A2	-0.34	-4.91	-0.3	1.64e-6	Ileal carcinoids;
KIRP	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.39	5.36	0.32	1.96e-7	Endometrial cancer;
KIRP	cis	rs10073892	0.703	rs9327824	chr5:101638168	G/T	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs13033859	0.691	rs10460597	chr2:165976	T/C	cg10118717	chr2:203439	NA	-0.42	-6.57	-0.39	2.93e-10	Mitochondrial DNA levels;
KIRP	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.4	-0.38	7.85e-10	Alcohol dependence;
KIRP	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg26354017	chr1:205819088	PM20D1	0.49	5.41	0.33	1.52e-7	Parkinson's disease;
KIRP	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg16558253	chr16:72132732	DHX38	-0.6	-9.05	-0.5	4.52e-17	Fibrinogen levels;
KIRP	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07570687	chr10:102243282	WNT8B	0.48	5.77	0.35	2.42e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6753739	0.627	rs2293070	chr2:220023604	A/T	cg01749213	chr2:219906749	CCDC108	0.41	5.11	0.31	6.46e-7	Height;
KIRP	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg12315302	chr6:26189340	HIST1H4D	0.91	5.99	0.36	7.53e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.56	6.37	0.38	9.2e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.91	6.17	0.37	2.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.62	-0.39	2.2e-10	Morning vs. evening chronotype;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18883852	chr13:45965548	LOC100190939	0.59	7.72	0.44	2.89e-13	Interleukin-4 levels;
KIRP	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg20243544	chr17:37824526	PNMT	0.39	4.85	0.3	2.23e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg05791153	chr7:19748676	TWISTNB	0.79	6.87	0.4	5.14e-11	Thyroid stimulating hormone;
KIRP	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg19610905	chr11:61596333	FADS2	-0.58	-8.27	-0.47	8.61e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.57	-0.33	6.52e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.69	7.98	0.45	5.57e-14	Obesity-related traits;
KIRP	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg24565620	chr2:194026	NA	-0.67	-7.53	-0.43	9.66e-13	Blood protein levels;
KIRP	cis	rs6142102	1.000	rs6142102	chr20:32704627	C/G	cg08999081	chr20:33150536	PIGU	0.52	6.62	0.39	2.27e-10	Skin pigmentation;
KIRP	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg03834567	chr2:218808745	TNS1	0.45	5.33	0.32	2.2e-7	Ulcerative colitis;
KIRP	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11987759	chr7:65425863	GUSB	0.49	6.28	0.37	1.51e-9	Aortic root size;
KIRP	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg11657440	chr19:46296263	DMWD	-0.7	-8.91	-0.49	1.17e-16	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05475091	chr4:48644525	FRYL	-0.41	-6.17	-0.37	2.78e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11628318	0.515	rs4906248	chr14:103126570	A/T	cg01864069	chr14:103024347	NA	0.4	4.84	0.3	2.26e-6	Platelet count;
KIRP	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg09184832	chr6:79620586	NA	0.48	5.32	0.32	2.37e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.71	-8.65	-0.48	6.86e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9826463	0.582	rs114066728	chr3:142022265	T/C	cg20824294	chr3:142316082	PLS1	0.44	6.38	0.38	8.91e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg19468946	chr17:37922297	IKZF3	-0.51	-7.11	-0.41	1.23e-11	Self-reported allergy;
KIRP	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	trans	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.29e-11	Bladder cancer;
KIRP	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg14593290	chr7:50529359	DDC	0.8	10.01	0.54	5.36e-20	Malaria;
KIRP	cis	rs3105593	0.965	rs11070801	chr15:50943685	A/T	cg05456662	chr15:50716270	USP8	0.41	4.9	0.3	1.75e-6	QT interval;
KIRP	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13409248	chr3:40428643	ENTPD3	0.37	5.08	0.31	7.43e-7	Renal cell carcinoma;
KIRP	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg26827852	chr1:89887630	LOC400759	0.36	4.89	0.3	1.78e-6	Carotid intima media thickness;
KIRP	cis	rs4762326	0.584	rs10777677	chr12:95617829	A/G	cg07737802	chr12:95537812	FGD6	0.36	4.88	0.3	1.93e-6	Endometriosis;
KIRP	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-7.35	-0.42	2.88e-12	Response to antipsychotic treatment;
KIRP	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg00579200	chr11:133705235	NA	0.41	5.48	0.33	1.03e-7	Childhood ear infection;
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.4	-5.0	-0.3	1.1e-6	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18705916	chr5:1800069	MRPL36;NDUFS6	0.47	6.15	0.37	3.04e-9	Parkinson's disease;
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	14.62	0.68	2.94e-35	Platelet count;
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg17441377	chr17:3906640	NA	0.57	8.42	0.47	3.12e-15	Type 2 diabetes;
KIRP	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	1.05	18.46	0.76	2.4e-48	Height;
KIRP	cis	rs6832769	1.000	rs28514423	chr4:56429239	C/T	cg09317128	chr4:56265301	TMEM165	-0.54	-7.24	-0.42	5.62e-12	Personality dimensions;
KIRP	cis	rs897080	0.515	rs1145519	chr2:44708709	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.95	0.35	8.94e-9	Height;
KIRP	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg09873164	chr1:152488093	CRCT1	0.56	7.31	0.42	3.78e-12	Hair morphology;
KIRP	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.53	7.03	0.41	2.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1757171	0.534	rs2797793	chr6:37477262	C/T	cg24807547	chr6:37504484	NA	0.45	6.81	0.4	7.43e-11	Cognitive performance;
KIRP	trans	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg06521331	chr12:34319734	NA	0.47	6.06	0.36	5.05e-9	Morning vs. evening chronotype;
KIRP	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.77	10.64	0.56	5.37e-22	Menarche (age at onset);
KIRP	cis	rs56399783	0.614	rs73047355	chr7:2758145	G/A	cg19731401	chr7:2775893	GNA12	0.76	6.87	0.4	5.37e-11	Childhood ear infection;
KIRP	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-8.24	-0.46	1.06e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.05e-7	Initial pursuit acceleration;
KIRP	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.57	-6.07	-0.36	4.69e-9	DNA methylation (variation);
KIRP	cis	rs4237845	0.591	rs10877040	chr12:58326448	T/C	cg00677455	chr12:58241039	CTDSP2	0.71	7.87	0.45	1.11e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.41	-5.17	-0.31	4.84e-7	IgG glycosylation;
KIRP	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02725872	chr8:58115012	NA	-0.77	-7.55	-0.43	8.73e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs80264589	1	rs80264589	chr6:26927602	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.27	0.32	3.02e-7	Lung cancer;Intelligence (multi-trait analysis);
KIRP	cis	rs9649213	0.593	rs6465675	chr7:97982103	C/T	cg01877450	chr7:97915802	BRI3	0.57	7.46	0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00934597	chr7:893267	UNC84A	-0.49	-6.17	-0.37	2.79e-9	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg07689907	chr11:61582574	FADS1	0.42	5.28	0.32	2.85e-7	Trans fatty acid levels;
KIRP	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg01528321	chr10:82214614	TSPAN14	1.27	18.67	0.77	4.78e-49	Post bronchodilator FEV1;
KIRP	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.09	0.54	3.04e-20	Total body bone mineral density;
KIRP	cis	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg26983326	chr7:143893948	ARHGEF5L	-0.29	-5.59	-0.34	6.1e-8	Obesity-related traits;
KIRP	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.72	-5.13	-0.31	5.76e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	0.76	5.44	0.33	1.26e-7	Alzheimer's disease or small vessel stroke;
KIRP	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.0	-0.45	4.94e-14	Personality dimensions;
KIRP	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.73	10.83	0.57	1.35e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg08648136	chr8:956695	NA	0.53	8.23	0.46	1.12e-14	Schizophrenia;
KIRP	trans	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg10756647	chr7:56101905	PSPH	1.01	7.54	0.43	9.29e-13	Diabetic kidney disease;
KIRP	cis	rs3124314	1.000	rs10788821	chr1:152141381	A/T	cg13071333	chr1:152595882	LCE3A	0.36	5.08	0.31	7.52e-7	Hair morphology;
KIRP	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	0.77	10.2	0.55	1.34e-20	Menopause (age at onset);
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg18404041	chr3:52824283	ITIH1	0.36	4.96	0.3	1.34e-6	Electroencephalogram traits;
KIRP	cis	rs12044355	0.892	rs1538974	chr1:231828596	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-6.44	-0.38	6.2e-10	Alzheimer's disease;
KIRP	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg06050784	chr16:88016603	BANP	0.42	5.19	0.31	4.49e-7	Menopause (age at onset);
KIRP	cis	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.44	-5.4	-0.33	1.58e-7	Mean platelet volume;
KIRP	cis	rs734999	0.967	rs10797433	chr1:2502010	T/C	cg18854424	chr1:2615690	NA	0.34	5.3	0.32	2.56e-7	Ulcerative colitis;
KIRP	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg24631222	chr15:78858424	CHRNA5	0.99	13.41	0.65	3.71e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs883565	0.655	rs6599002	chr3:39076073	T/C	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.33e-29	Handedness;
KIRP	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg07271561	chr3:50359363	HYAL2	-0.49	-6.17	-0.37	2.73e-9	Schizophrenia;
KIRP	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg20302533	chr7:39170763	POU6F2	0.23	5.02	0.31	9.72e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.4	12.99	0.64	9.87e-30	Opioid sensitivity;
KIRP	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg01280390	chr8:19363452	CSGALNACT1	0.4	5.39	0.32	1.67e-7	Oropharynx cancer;
KIRP	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg26248373	chr2:1572462	NA	-0.8	-10.9	-0.57	8.14e-23	IgG glycosylation;
KIRP	cis	rs12049351	0.943	rs6687883	chr1:229717856	A/G	cg11742688	chr1:229674241	ABCB10	0.35	4.98	0.3	1.2e-6	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs10484761	0.956	rs6932398	chr6:40809464	T/C	cg02680909	chr6:39899321	MOCS1	-0.24	-5.06	-0.31	8.07e-7	Esophageal cancer;
KIRP	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.88	-11.15	-0.58	1.26e-23	Vitamin D levels;
KIRP	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg23216685	chr1:86174607	ZNHIT6	-0.53	-6.15	-0.36	3.15e-9	Urate levels in overweight individuals;
KIRP	cis	rs6684514	1.000	rs12141236	chr1:156302575	A/C	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.67e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.43	5.97	0.36	8.42e-9	Schizophrenia;
KIRP	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	5.55	0.33	7.56e-8	Schizophrenia;
KIRP	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.96	10.92	0.57	6.86e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg00738919	chr7:1100172	C7orf50	0.44	5.16	0.31	4.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.44	5.47	0.33	1.11e-7	Resistin levels;
KIRP	cis	rs9311676	0.656	rs6799077	chr3:58404096	C/T	cg06643156	chr3:58380774	PXK	0.35	4.87	0.3	1.99e-6	Systemic lupus erythematosus;
KIRP	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.68	-9.07	-0.5	3.8e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs60594510	1	rs60594510	chr12:110594503	C/T	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-0.91	-13.23	-0.64	1.51e-30	Dupuytren's disease;
KIRP	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.98	10.21	0.55	1.26e-20	Alzheimer's disease;
KIRP	cis	rs59197085	0.534	rs2307038	chr7:128449356	A/C	cg00734629	chr7:128471146	FLNC	0.43	4.85	0.3	2.18e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg18478394	chr8:109455254	TTC35	0.51	6.26	0.37	1.71e-9	Dupuytren's disease;
KIRP	cis	rs6545883	0.894	rs2694642	chr2:61596180	A/G	cg15711740	chr2:61764176	XPO1	0.58	7.38	0.43	2.47e-12	Tuberculosis;
KIRP	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg04306507	chr14:55594613	LGALS3	0.48	7.41	0.43	1.99e-12	Protein biomarker;
KIRP	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg26875137	chr12:53738046	NA	-0.38	-5.29	-0.32	2.7e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs2458413	0.564	rs2669452	chr8:105370385	C/A	cg08657449	chr8:105351661	TM7SF4	-0.33	-5.37	-0.32	1.83e-7	Paget's disease;
KIRP	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-8.12	-0.46	2.27e-14	Pancreatic cancer;
KIRP	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2151522	0.603	rs3926855	chr6:127199312	T/G	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg25907053	chr2:70369816	NA	-0.48	-6.49	-0.38	4.71e-10	Morning vs. evening chronotype;
KIRP	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg04691961	chr3:161091175	C3orf57	-0.39	-5.12	-0.31	6.1e-7	Parkinson's disease;
KIRP	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.09	-0.36	4.3e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs1538970	0.748	rs11211137	chr1:46013892	T/A	cg05343316	chr1:45956843	TESK2	0.83	9.15	0.5	2.18e-17	Platelet count;
KIRP	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg13319975	chr6:146136371	FBXO30	0.48	6.25	0.37	1.79e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.96	9.1	0.5	3.11e-17	Type 2 diabetes;
KIRP	cis	rs7246865	0.510	rs8103578	chr19:17171227	C/T	cg16202187	chr19:17186497	HAUS8;MYO9B	0.5	6.3	0.37	1.37e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.58	6.08	0.36	4.52e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03934478	chr11:495069	RNH1	0.87	6.89	0.4	4.6e-11	Body mass index;
KIRP	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-4.95	-0.3	1.38e-6	Large artery stroke;
KIRP	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.88	13.39	0.65	4.55e-31	Ulcerative colitis;
KIRP	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg21479132	chr6:26055353	NA	0.81	5.67	0.34	4.09e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg02900749	chr2:68251473	NA	-1.06	-9.08	-0.5	3.73e-17	Pursuit maintenance gain;
KIRP	cis	rs2737618	0.630	rs2821324	chr1:200078006	G/A	cg21825944	chr1:200113062	NR5A2	-0.5	-6.97	-0.41	2.94e-11	Uric acid levels;
KIRP	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.5	7.81	0.45	1.69e-13	Bone mineral density;
KIRP	cis	rs11874712	1.000	rs7244950	chr18:43676523	G/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.16e-8	Migraine - clinic-based;
KIRP	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg10223061	chr2:219282414	VIL1	0.36	5.9	0.35	1.22e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.71	-8.84	-0.49	1.83e-16	Height;
KIRP	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.11	0.31	6.41e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2483058	0.739	rs963893	chr1:206625695	C/T	cg19452316	chr1:206680966	RASSF5	0.4	5.4	0.33	1.58e-7	Cholesterol and Triglycerides;
KIRP	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.79	-10.57	-0.56	8.78e-22	Triglycerides;
KIRP	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.04	0.31	8.89e-7	Parkinson's disease;
KIRP	cis	rs9815354	0.812	rs73071344	chr3:41827062	C/T	cg03022575	chr3:42003672	ULK4	0.79	8.24	0.47	1.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-7.96	-0.45	6.54e-14	Neuroticism;
KIRP	cis	rs17818399	0.781	rs4952837	chr2:46865734	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.5	5.44	0.33	1.28e-7	Height;
KIRP	cis	rs67385638	0.962	rs10128556	chr11:5263683	C/T	cg12559170	chr11:5275217	HBG2	0.45	6.47	0.38	5.28e-10	Hemoglobin levels;
KIRP	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg17724175	chr1:150552817	MCL1	0.35	5.87	0.35	1.37e-8	Melanoma;
KIRP	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17507749	chr15:85114479	UBE2QP1	0.68	7.46	0.43	1.44e-12	Schizophrenia;
KIRP	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg09655341	chr17:79618100	PDE6G	0.31	4.9	0.3	1.78e-6	Eye color traits;
KIRP	cis	rs1559088	0.948	rs12610266	chr19:33581237	C/G	cg24009623	chr19:33667908	NA	-0.5	-6.2	-0.37	2.35e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.03	0.36	5.86e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.58	-7.76	-0.44	2.25e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.569	rs34859684	chr17:3982628	G/C	cg09695851	chr17:3907499	NA	0.57	5.58	0.34	6.23e-8	Type 2 diabetes;
KIRP	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg07741184	chr6:167504864	NA	0.24	6.2	0.37	2.37e-9	Crohn's disease;
KIRP	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.02	-0.36	6.16e-9	Height;
KIRP	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7520050	0.751	rs2991975	chr1:46024526	A/G	cg15605315	chr1:45957053	TESK2	0.43	5.54	0.33	7.75e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg26138937	chr11:71823887	C11orf51	-1.12	-6.64	-0.39	1.94e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.95	0.3	1.4e-6	Tonsillectomy;
KIRP	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.41	7.78	0.44	2e-13	Height;
KIRP	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.67	0.44	4.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg15841412	chr13:111365552	ING1	0.5	5.78	0.35	2.23e-8	Coronary artery disease;
KIRP	cis	rs12620999	0.878	rs7593514	chr2:237980691	A/G	cg23555395	chr2:238036564	NA	0.42	4.88	0.3	1.95e-6	Systemic lupus erythematosus;
KIRP	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg13147721	chr7:65941812	NA	1.02	7.05	0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg20312557	chr2:97357134	FER1L5	-0.73	-5.34	-0.32	2.06e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.57	-6.69	-0.39	1.47e-10	Aortic root size;
KIRP	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	1.12	8.73	0.49	3.86e-16	LDL cholesterol;
KIRP	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg00255919	chr5:131827918	IRF1	0.28	5.88	0.35	1.36e-8	Asthma (sex interaction);
KIRP	trans	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg14791747	chr16:20752902	THUMPD1	0.58	6.29	0.37	1.42e-9	Cognitive test performance;
KIRP	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.55	6.75	0.4	1.04e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7221595	0.825	rs9905748	chr17:3968639	C/T	cg09597638	chr17:3907349	NA	0.59	6.52	0.38	4.05e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs7011507	1.000	rs55777725	chr8:49114477	T/G	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg24315340	chr6:146058215	EPM2A	0.4	4.97	0.3	1.24e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg21851534	chr17:3907994	ZZEF1	0.65	10.56	0.56	9.75e-22	Type 2 diabetes;
KIRP	cis	rs2441986	0.857	rs61902828	chr11:57982053	G/A	cg19752551	chr11:57585705	CTNND1	-0.45	-5.52	-0.33	8.42e-8	Systolic blood pressure;
KIRP	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg02527881	chr3:46936655	PTH1R	-0.41	-6.0	-0.36	7.05e-9	Colorectal cancer;
KIRP	cis	rs7804356	0.906	rs73069541	chr7:26904928	A/G	cg03456212	chr7:26904342	SKAP2	-0.57	-5.18	-0.31	4.55e-7	Type 1 diabetes;
KIRP	cis	rs6545883	0.929	rs2600663	chr2:61540687	A/G	cg15711740	chr2:61764176	XPO1	0.58	7.79	0.44	1.84e-13	Tuberculosis;
KIRP	cis	rs4805272	0.962	rs2042191	chr19:29321080	C/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs11967485	0.609	rs11969332	chr6:157143703	A/C	cg23222435	chr6:157204239	ARID1B	-0.68	-5.02	-0.3	1e-6	Calcium levels;
KIRP	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.14	16.25	0.72	7.84e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	15.17	0.7	3.81e-37	Platelet count;
KIRP	cis	rs11264213	0.892	rs7530222	chr1:36200778	T/C	cg27506609	chr1:36549197	TEKT2	0.75	6.88	0.4	4.83e-11	Schizophrenia;
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	4.94	0.3	1.46e-6	Longevity;
KIRP	trans	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg13565492	chr6:43139072	SRF	-0.94	-8.66	-0.48	6.42e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.81	-10.45	-0.55	2.15e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs6120849	0.901	rs6060266	chr20:33733078	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	6.77	0.4	9.46e-11	Protein C levels;
KIRP	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.66	7.46	0.43	1.5e-12	Body mass index;
KIRP	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.38	-4.86	-0.3	2.08e-6	Longevity;Endometriosis;
KIRP	cis	rs80207740	1.000	rs17296501	chr8:21849566	C/T	cg17168535	chr8:21777572	XPO7	0.68	6.64	0.39	1.96e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.22	0.42	6.28e-12	Aortic root size;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27506178	chr19:17186356	HAUS8;MYO9B	-0.59	-6.51	-0.38	4.09e-10	Menopause (age at onset);
KIRP	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg21890820	chr11:65308645	LTBP3	0.59	5.58	0.34	6.18e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg21926883	chr2:100939477	LONRF2	-0.53	-6.96	-0.41	3.1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.39	-0.38	8.31e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.59	5.33	0.32	2.22e-7	Alzheimer's disease;
KIRP	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14396892	chr9:96623032	NA	0.35	4.86	0.3	2.07e-6	DNA methylation (variation);
KIRP	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg22437258	chr11:111473054	SIK2	-0.57	-6.55	-0.39	3.28e-10	Primary sclerosing cholangitis;
KIRP	cis	rs12135191	0.544	rs6664395	chr1:236510822	G/T	cg21399712	chr1:236511386	NA	-0.38	-5.01	-0.3	1.02e-6	Urate levels (BMI interaction);
KIRP	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.98	14.87	0.69	4.18e-36	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.23	-0.42	5.9e-12	Type 2 diabetes;
KIRP	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.5	7.23	0.42	6.08e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.65	10.21	0.55	1.27e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs11955175	1.000	rs11954632	chr5:40674929	C/G	cg04002187	chr5:40835754	RPL37	0.67	5.41	0.33	1.5e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.87	10.13	0.54	2.16e-20	Osteoarthritis;
KIRP	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg07343612	chr16:622815	PIGQ	-0.9	-13.04	-0.64	6.52e-30	Height;
KIRP	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg11764359	chr7:65958608	NA	0.77	5.07	0.31	7.84e-7	Diabetic kidney disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02326534	chr10:30722736	MAP3K8	0.46	6.46	0.38	5.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs911119	1.000	rs6036476	chr20:23610308	C/G	cg16589663	chr20:23618590	CST3	0.62	5.94	0.35	9.5e-9	Chronic kidney disease;
KIRP	cis	rs4950322	0.570	rs4950403	chr1:146791441	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs17592366	0.540	rs3818801	chr14:35242700	C/T	cg09327582	chr14:35236912	BAZ1A	0.51	5.25	0.32	3.25e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs7903847	0.620	rs10882904	chr10:99115683	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.75	-0.34	2.61e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2594989	0.831	rs7651790	chr3:11572610	C/T	cg01796438	chr3:11312864	ATG7	0.6	7.25	0.42	5.31e-12	Circulating chemerin levels;
KIRP	trans	rs1916521	1.000	rs1916521	chr10:57416961	A/G	cg10367743	chr4:15003669	NA	0.49	6.24	0.37	1.93e-9	Cardiac hypertrophy;
KIRP	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg19875535	chr5:140030758	IK	-0.69	-9.64	-0.52	7.26e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	6.34	0.37	1.1e-9	Height;
KIRP	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.48	0.43	1.34e-12	Lung cancer;
KIRP	cis	rs986417	1.000	rs11845369	chr14:60944959	A/G	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg02733842	chr7:1102375	C7orf50	0.46	4.87	0.3	2.02e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg06558623	chr16:89946397	TCF25	1.11	8.08	0.46	2.97e-14	Skin colour saturation;
KIRP	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	1.08	23.14	0.83	1.1e-63	Parkinson's disease;
KIRP	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg22617819	chr1:44378782	ST3GAL3	0.39	6.24	0.37	1.89e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-0.62	-6.92	-0.4	3.91e-11	Initial pursuit acceleration;
KIRP	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.35	6.69	0.39	1.52e-10	Educational attainment (years of education);
KIRP	trans	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg00938859	chr5:1591904	SDHAP3	0.56	6.82	0.4	6.96e-11	Breast cancer;
KIRP	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg17376030	chr22:41985996	PMM1	-0.54	-5.73	-0.34	2.93e-8	Vitiligo;
KIRP	cis	rs12826942	0.605	rs17801478	chr12:42481545	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	4.87	0.3	2.03e-6	Coronary artery disease;
KIRP	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg08992911	chr2:238395768	MLPH	0.4	5.0	0.3	1.08e-6	Prostate cancer;
KIRP	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.58	7.27	0.42	4.75e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg17554472	chr22:41940697	POLR3H	-0.49	-5.56	-0.33	6.96e-8	Neuroticism;
KIRP	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.69	-9.51	-0.52	1.86e-18	Systemic lupus erythematosus;
KIRP	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	9.07	0.5	3.88e-17	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4236601	0.745	rs11983865	chr7:116142462	A/G	cg12739419	chr7:116140593	CAV2	0.48	5.97	0.36	8.03e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg22676075	chr6:135203613	NA	0.49	7.06	0.41	1.72e-11	Red blood cell count;
KIRP	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.76	-9.69	-0.53	5.28e-19	Pancreatic cancer;
KIRP	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.48e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7017914	0.967	rs6472543	chr8:71664408	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13198984	chr17:80129470	CCDC57	-0.55	-8.25	-0.47	9.88e-15	Life satisfaction;
KIRP	cis	rs909341	0.859	rs2297441	chr20:62327582	A/G	cg11503966	chr20:62272292	STMN3	-0.41	-5.8	-0.35	2.01e-8	Atopic dermatitis;
KIRP	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.75	-0.34	2.65e-8	Lung cancer;
KIRP	trans	rs9329221	0.508	rs6601455	chr8:10273426	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	6.64	0.39	2.04e-10	Neuroticism;
KIRP	cis	rs4523957	0.651	rs9906968	chr17:2077493	G/C	cg16513277	chr17:2031491	SMG6	-0.79	-11.52	-0.59	7.56e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.73	10.16	0.54	1.83e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg26876637	chr1:152193138	HRNR	0.73	10.07	0.54	3.34e-20	Atopic dermatitis;
KIRP	cis	rs7520050	0.902	rs7514192	chr1:46248977	A/G	cg03146154	chr1:46216737	IPP	-0.41	-5.17	-0.31	4.93e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs78761021	0.688	rs55811931	chr17:9796537	G/A	cg26853458	chr17:9805074	RCVRN	0.52	5.05	0.31	8.81e-7	Type 2 diabetes;
KIRP	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.49	-0.38	4.64e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg03894339	chr8:19674705	INTS10	0.59	6.9	0.4	4.48e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.65	-7.85	-0.45	1.29e-13	Gut microbiome composition (summer);
KIRP	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.56	8.0	0.45	4.83e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2274273	0.870	rs59629906	chr14:55781189	T/C	cg04306507	chr14:55594613	LGALS3	0.43	6.62	0.39	2.24e-10	Protein biomarker;
KIRP	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Hypertriglyceridemia;
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.56	7.26	0.42	5.09e-12	Longevity;Endometriosis;
KIRP	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	8.31	0.47	6.32e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg20195367	chr6:144976500	UTRN	0.43	6.07	0.36	4.84e-9	Migraine with aura;
KIRP	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg21285383	chr16:89894308	SPIRE2	0.32	6.19	0.37	2.5e-9	Vitiligo;
KIRP	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg00800038	chr16:89945340	TCF25	-0.67	-6.64	-0.39	1.97e-10	Skin colour saturation;
KIRP	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.57	7.03	0.41	1.98e-11	Total body bone mineral density;
KIRP	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.39e-10	Diabetic retinopathy;
KIRP	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg17788362	chr6:86352627	SYNCRIP	0.47	6.04	0.36	5.58e-9	Smooth-surface caries;
KIRP	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg05072774	chr3:49840536	C3orf54	0.41	5.37	0.32	1.85e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg10254082	chr7:997346	NA	0.49	5.25	0.32	3.3e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.72	-7.49	-0.43	1.2e-12	Verbal memory performance (residualized delayed recall change);
KIRP	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.39	5.06	0.31	8.1e-7	Body mass index;
KIRP	cis	rs8049040	0.524	rs12445377	chr16:71428601	G/A	cg08717414	chr16:71523259	ZNF19	-0.59	-6.92	-0.4	3.91e-11	Blood protein levels;
KIRP	cis	rs3752645	1.000	rs113841792	chr7:106728584	G/C	cg02696742	chr7:106810147	HBP1	-0.66	-5.02	-0.3	1.01e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs4849845	0.889	rs6746250	chr2:121058254	A/G	cg24070213	chr2:121070622	NA	0.41	5.53	0.33	8.02e-8	Mean platelet volume;
KIRP	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg09491104	chr22:46646882	C22orf40	-0.6	-6.74	-0.39	1.13e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg20368463	chr18:77673604	PQLC1	-0.46	-5.77	-0.35	2.33e-8	Schizophrenia;
KIRP	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.85	11.09	0.58	1.92e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1208285	0.564	rs6934010	chr6:134203010	C/T	cg06643013	chr6:134217242	NA	-0.41	-4.93	-0.3	1.54e-6	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg27490568	chr2:178487706	NA	0.5	6.55	0.39	3.37e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4849845	0.637	rs2028147	chr2:121058412	C/T	cg24070213	chr2:121070622	NA	-0.4	-6.01	-0.36	6.61e-9	Mean platelet volume;
KIRP	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg00405596	chr8:11794950	NA	0.59	8.23	0.46	1.08e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1983891	0.874	rs2395779	chr6:41511950	C/T	cg20194872	chr6:41519635	FOXP4	0.45	5.52	0.33	8.38e-8	Prostate cancer;
KIRP	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.39	5.34	0.32	2.12e-7	Lewy body disease;
KIRP	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg05791153	chr7:19748676	TWISTNB	0.49	5.17	0.31	4.95e-7	Thyroid stimulating hormone;
KIRP	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg18306943	chr3:40428807	ENTPD3	0.46	6.17	0.37	2.86e-9	Renal cell carcinoma;
KIRP	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.9	-0.49	1.24e-16	Mean corpuscular volume;
KIRP	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.79	-0.4	8.55e-11	Neuroticism;
KIRP	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg00517849	chr4:183373496	ODZ3	0.36	6.05	0.36	5.35e-9	Myopia (pathological);
KIRP	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.97	13.14	0.64	3.05e-30	Multiple sclerosis;
KIRP	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg23505145	chr19:12996616	KLF1	0.55	7.96	0.45	6.2e-14	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27525037	chr1:182361500	GLUL	0.43	6.22	0.37	2.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.82	-0.35	1.78e-8	Bipolar disorder;
KIRP	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.76	-10.93	-0.57	6.29e-23	Caffeine consumption;
KIRP	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg08885076	chr2:99613938	TSGA10	0.51	8.61	0.48	9.07e-16	Chronic sinus infection;
KIRP	cis	rs13185784	0.667	rs62406986	chr5:179644055	G/A	cg13944838	chr5:179740914	GFPT2	0.51	5.04	0.31	8.89e-7	TRAIL levels;
KIRP	cis	rs236907	0.859	rs35930163	chr1:171768184	G/A	cg01410279	chr1:171621941	MYOC	-0.47	-5.35	-0.32	2.01e-7	Mean platelet volume;
KIRP	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg11859384	chr17:80120422	CCDC57	-0.47	-5.94	-0.35	9.59e-9	Life satisfaction;
KIRP	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17376030	chr22:41985996	PMM1	0.71	8.07	0.46	3.12e-14	Vitiligo;
KIRP	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg19906672	chr4:6918868	TBC1D14	0.5	5.12	0.31	6.08e-7	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs10007810	0.760	rs7687668	chr4:41556746	T/C	cg25639531	chr10:128148004	C10orf90	-0.6	-6.29	-0.37	1.47e-9	Longevity (90 years and older);
KIRP	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg01631408	chr1:248437212	OR2T33	-0.65	-8.35	-0.47	5.06e-15	Common traits (Other);
KIRP	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg08992911	chr2:238395768	MLPH	0.45	5.61	0.34	5.42e-8	Prostate cancer;
KIRP	cis	rs986417	0.901	rs1955690	chr14:61000492	A/G	cg27398547	chr14:60952738	C14orf39	-0.68	-6.78	-0.4	8.76e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs9400467	0.506	rs12192617	chr6:111490275	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.17	0.31	4.91e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg19847866	chr10:1019161	NA	0.5	5.9	0.35	1.17e-8	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.42	-0.33	1.4e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs12517041	1.000	rs7734279	chr5:23300161	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.87	-7.96	-0.45	6.4e-14	Calcium levels;
KIRP	cis	rs7106204	0.609	rs34237482	chr11:24295932	G/A	ch.11.24196551F	chr11:24239977	NA	0.71	5.26	0.32	3.16e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.53	6.71	0.39	1.3e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg19507638	chr5:93509721	C5orf36	0.6	5.49	0.33	1.01e-7	Diabetic retinopathy;
KIRP	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.87	11.48	0.59	1.04e-24	Primary sclerosing cholangitis;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg08901578	chr4:187885870	NA	-0.51	-7.98	-0.45	5.5e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg01843034	chr6:37503916	NA	-0.97	-14.54	-0.68	5.61e-35	Cognitive performance;
KIRP	cis	rs6738627	0.931	rs7592412	chr2:165526338	T/C	cg03182029	chr2:165697222	COBLL1	0.4	5.3	0.32	2.59e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg07689907	chr11:61582574	FADS1	-0.39	-5.11	-0.31	6.54e-7	Trans fatty acid levels;
KIRP	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg20140201	chr2:241835670	C2orf54	-0.34	-5.23	-0.32	3.57e-7	Urinary metabolites;
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg23594656	chr7:65796392	TPST1	-0.38	-5.65	-0.34	4.51e-8	Aortic root size;
KIRP	cis	rs526231	0.543	rs158244	chr5:102410766	G/C	cg23492399	chr5:102201601	PAM	-0.54	-5.96	-0.36	8.85e-9	Primary biliary cholangitis;
KIRP	cis	rs59197085	0.636	rs4728138	chr7:128468105	A/G	cg00734629	chr7:128471146	FLNC	0.43	4.89	0.3	1.79e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	trans	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	6.53	0.38	3.77e-10	Neuroticism;
KIRP	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23903597	chr17:61704154	MAP3K3	-0.45	-5.66	-0.34	4.24e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.42	-5.5	-0.33	9.66e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7712401	0.601	rs62377424	chr5:122332322	G/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-5.18	-0.31	4.73e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg07424592	chr7:64974309	NA	0.75	4.93	0.3	1.51e-6	Diabetic kidney disease;
KIRP	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.54	6.29	0.37	1.42e-9	Aortic root size;
KIRP	cis	rs8102732	1.000	rs8102732	chr19:1023867	C/G	cg13770691	chr19:1021866	C19orf6	0.38	5.48	0.33	1.07e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs4794202	0.629	rs916798	chr17:45895571	T/A	cg02219949	chr17:45927392	SP6	0.5	4.87	0.3	2.02e-6	Alzheimer's disease (cognitive decline);
KIRP	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17691542	chr6:26056736	HIST1H1C	0.51	6.42	0.38	7.01e-10	Height;
KIRP	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg06289844	chr6:126071538	HEY2	0.44	6.42	0.38	6.98e-10	Brugada syndrome;
KIRP	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg25173405	chr17:45401733	C17orf57	0.42	5.37	0.32	1.79e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.48	-6.07	-0.36	4.69e-9	Mean platelet volume;
KIRP	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg07653901	chr22:50250238	ZBED4	-0.62	-6.77	-0.4	9.21e-11	Schizophrenia;
KIRP	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.93	12.07	0.61	1.14e-26	Cognitive function;
KIRP	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg08975724	chr8:8085496	FLJ10661	-0.56	-6.66	-0.39	1.76e-10	Retinal vascular caliber;
KIRP	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg21366198	chr4:185655624	MLF1IP	0.42	5.88	0.35	1.34e-8	Kawasaki disease;
KIRP	cis	rs11945232	0.624	rs9654160	chr4:88377324	G/C	cg23841344	chr4:88312519	HSD17B11	-0.59	-6.51	-0.38	4.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.61	8.06	0.46	3.32e-14	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.02	0.41	2.16e-11	Bipolar disorder;
KIRP	cis	rs559928	0.553	rs1320628	chr11:64175986	C/T	cg05555928	chr11:63887634	MACROD1	-0.44	-5.43	-0.33	1.33e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7113874	0.659	rs1867810	chr11:8505528	A/T	cg08015107	chr11:8618950	NA	-0.48	-6.27	-0.37	1.64e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg25753631	chr6:25732923	NA	-0.28	-5.34	-0.32	2.09e-7	Iron status biomarkers;
KIRP	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11987759	chr7:65425863	GUSB	0.54	6.6	0.39	2.55e-10	Aortic root size;
KIRP	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.7	9.21	0.51	1.48e-17	Response to diuretic therapy;
KIRP	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25517755	chr10:38738941	LOC399744	-0.51	-7.0	-0.41	2.5e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1823913	0.599	rs35150635	chr2:192152029	G/A	cg12404831	chr2:192114017	MYO1B	0.52	7.27	0.42	4.69e-12	Obesity-related traits;
KIRP	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.75	6.69	0.39	1.5e-10	Diabetic retinopathy;
KIRP	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.82	-0.4	7.19e-11	Mood instability;
KIRP	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.72	9.24	0.51	1.21e-17	Bladder cancer;
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs7224685	0.569	rs67533014	chr17:3993910	C/T	cg09695851	chr17:3907499	NA	0.54	5.16	0.31	5.11e-7	Type 2 diabetes;
KIRP	cis	rs918629	0.716	rs6861531	chr5:95274702	A/G	cg16656078	chr5:95278638	ELL2	-0.46	-6.7	-0.39	1.38e-10	IgG glycosylation;
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.36	-5.18	-0.31	4.64e-7	Lymphocyte counts;
KIRP	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.75	0.34	2.7e-8	Lung cancer;
KIRP	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.07	7.95	0.45	6.84e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1832871	0.672	rs6899322	chr6:158753669	G/T	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs11696739	0.866	rs1535882	chr20:1600524	T/C	cg02198625	chr20:1600641	SIRPB1	0.38	5.05	0.31	8.55e-7	Mean platelet volume;
KIRP	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg14517359	chr4:903473	GAK	-0.59	-5.99	-0.36	7.34e-9	Type 2 diabetes;
KIRP	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs6499755	0.901	rs2042447	chr16:55352022	A/C	cg05099576	chr16:55362342	IRX6	-0.25	-5.27	-0.32	3.04e-7	Hypospadias;
KIRP	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg22117172	chr7:91764530	CYP51A1	0.43	6.18	0.37	2.64e-9	Breast cancer;
KIRP	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg26248373	chr2:1572462	NA	-0.82	-10.99	-0.57	4.15e-23	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.25e-17	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16739247	chr1:76252438	SNORD45C;SNORD45A;RABGGTB	0.57	6.75	0.4	1.08e-10	Smoking initiation;
KIRP	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	5.82	0.35	1.78e-8	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.16e-51	Leprosy;
KIRP	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.2e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.67	9.65	0.52	7.01e-19	Schizophrenia;
KIRP	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg19507638	chr5:93509721	C5orf36	-0.6	-5.14	-0.31	5.55e-7	Diabetic retinopathy;
KIRP	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.82	9.75	0.53	3.37e-19	Corneal astigmatism;
KIRP	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.82	12.13	0.61	7.59e-27	Blood metabolite ratios;
KIRP	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg04374321	chr14:90722782	PSMC1	0.44	5.17	0.31	4.95e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg13429435	chr10:81271195	EIF5AL1	0.35	5.67	0.34	4.05e-8	Sarcoidosis;
KIRP	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	1.06	18.97	0.77	4.74e-50	Bone mineral density;
KIRP	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.21	-0.32	3.94e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.14	10.96	0.57	4.89e-23	Alzheimer's disease (late onset);
KIRP	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.52	6.55	0.39	3.25e-10	Coronary heart disease;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-10.13	-0.54	2.23e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.35	-5.01	-0.3	1.06e-6	Motion sickness;
KIRP	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs1983891	0.673	rs9381083	chr6:41570250	T/A	cg20194872	chr6:41519635	FOXP4	0.48	6.32	0.37	1.2e-9	Prostate cancer;
KIRP	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg05805236	chr11:65401703	PCNXL3	-0.53	-6.94	-0.4	3.46e-11	Acne (severe);
KIRP	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs1981331	0.609	rs7279368	chr21:48065999	A/G	cg17243659	chr21:48055224	PRMT2	1.37	8.45	0.47	2.6e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg14541582	chr5:601475	NA	-0.57	-6.47	-0.38	5.19e-10	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.96	0.36	8.57e-9	Lung cancer;
KIRP	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg13180566	chr4:1052158	NA	-0.53	-5.37	-0.32	1.82e-7	Recombination rate (females);
KIRP	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg00981070	chr1:2046702	PRKCZ	0.41	5.87	0.35	1.39e-8	Height;
KIRP	cis	rs7635838	0.892	rs9310381	chr3:11458466	A/G	cg00170343	chr3:11313890	ATG7	0.47	5.92	0.35	1.09e-8	HDL cholesterol;
KIRP	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.59	-0.63	2.15e-28	Extrinsic epigenetic age acceleration;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg05360402	chr5:110848191	STARD4	0.53	6.31	0.37	1.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.47	6.45	0.38	5.75e-10	Testicular germ cell tumor;
KIRP	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.64	0.39	1.99e-10	Putamen volume;
KIRP	cis	rs1417569	0.517	rs3006596	chr10:31181876	C/T	cg00428179	chr10:31322131	ZNF438	-0.37	-5.54	-0.33	7.83e-8	Tuberculosis;
KIRP	cis	rs1832871	0.672	rs9456289	chr6:158740347	G/A	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.85e-8	Life satisfaction;
KIRP	cis	rs10266483	0.656	rs670966	chr7:63762899	A/T	cg04636841	chr7:63768139	NA	-0.39	-5.27	-0.32	2.98e-7	Response to statin therapy;
KIRP	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.46	6.55	0.39	3.26e-10	Schizophrenia;
KIRP	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.27	5.03	0.31	9.27e-7	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
KIRP	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg08975724	chr8:8085496	FLJ10661	0.82	10.85	0.57	1.16e-22	Neuroticism;
KIRP	trans	rs360932	0.550	rs360925	chr4:152905397	T/C	cg13462599	chr1:151484211	CGN	0.46	6.11	0.36	3.98e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.66	-7.25	-0.42	5.49e-12	Gut microbiome composition (summer);
KIRP	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-0.66	-7.75	-0.44	2.45e-13	Initial pursuit acceleration;
KIRP	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	cg04338863	chr8:33670619	NA	0.46	5.68	0.34	3.77e-8	Body mass index;
KIRP	cis	rs17193922	0.876	rs17194040	chr16:53550898	C/T	cg09728985	chr16:53543985	NA	-0.48	-5.52	-0.33	8.42e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	0.97	10.18	0.54	1.56e-20	White matter hyperintensity burden;
KIRP	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.39	-7.03	-0.41	2.03e-11	Refractive error;
KIRP	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg04490037	chr7:50633773	DDC	0.4	5.18	0.31	4.51e-7	Systemic sclerosis;
KIRP	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.48	-6.03	-0.36	6.06e-9	Red blood cell count;
KIRP	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg20362242	chr5:692897	TPPP	-0.56	-4.86	-0.3	2.11e-6	Obesity-related traits;
KIRP	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg10761708	chr20:43804764	PI3	0.5	5.19	0.31	4.45e-7	Blood protein levels;
KIRP	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg03929089	chr4:120376271	NA	0.88	6.53	0.38	3.8e-10	Myopia (pathological);
KIRP	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs1448094	1.000	rs4919776	chr12:86353763	T/C	cg06740227	chr12:86229804	RASSF9	0.41	5.19	0.31	4.46e-7	Major depressive disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21379008	chr1:154297555	ATP8B2;AQP10	0.49	6.25	0.37	1.78e-9	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14242528	chr9:33166541	B4GALT1	0.49	6.09	0.36	4.32e-9	Parkinson's disease;
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg14338887	chr6:42928500	GNMT	0.46	6.82	0.4	6.87e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.63	-0.34	4.94e-8	Multiple sclerosis;
KIRP	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.64	-6.98	-0.41	2.76e-11	Vitiligo;
KIRP	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06544989	chr22:39130855	UNC84B	0.48	8.23	0.46	1.07e-14	Menopause (age at onset);
KIRP	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg07972983	chr1:205091412	RBBP5	0.43	5.1	0.31	6.71e-7	Red blood cell count;
KIRP	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg05991184	chr2:219186017	PNKD	0.36	5.06	0.31	8.39e-7	Colorectal cancer;
KIRP	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.95	-16.56	-0.73	7.11e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs6800768	0.663	rs7428009	chr3:24094151	A/C	cg10674438	chr3:24145617	LOC152024	-0.43	-5.88	-0.35	1.3e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.48	7.42	0.43	1.89e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22277996	chr4:57888331	POLR2B	0.42	6.16	0.37	2.91e-9	Interleukin-4 levels;
KIRP	cis	rs9653442	0.545	rs11900482	chr2:100758709	G/C	cg07810366	chr2:100720526	AFF3	-0.31	-5.13	-0.31	5.87e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs8756	0.905	rs1351394	chr12:66351826	T/C	cg06712651	chr12:66351869	HMGA2	-0.78	-13.29	-0.65	9.32e-31	Height;
KIRP	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg12315302	chr6:26189340	HIST1H4D	1.1	6.09	0.36	4.27e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5753618	0.561	rs2073857	chr22:31658281	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.36	-0.32	1.96e-7	Colorectal cancer;
KIRP	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.29	0.37	1.4e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.79	11.19	0.58	8.82e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg14768256	chr3:44754587	ZNF502	-0.39	-4.9	-0.3	1.76e-6	Depressive symptoms;
KIRP	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.7	-0.39	1.42e-10	Obesity-related traits;
KIRP	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.76	-0.66	2.39e-32	Ulcerative colitis;
KIRP	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg24315340	chr6:146058215	EPM2A	-0.43	-5.46	-0.33	1.16e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.85	0.4	5.95e-11	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg24633833	chr3:10029261	TMEM111	-0.57	-5.55	-0.33	7.5e-8	Alzheimer's disease;
KIRP	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.43	-5.9	-0.35	1.18e-8	Total body bone mineral density;
KIRP	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg23587288	chr2:27483067	SLC30A3	-0.57	-7.23	-0.42	6.04e-12	Blood metabolite levels;
KIRP	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	9.7	0.53	4.92e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg06606381	chr12:133084897	FBRSL1	-1.02	-6.16	-0.37	2.89e-9	Depression;
KIRP	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.48	-6.84	-0.4	6.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.52	-7.26	-0.42	5.18e-12	Menarche (age at onset);
KIRP	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg11645453	chr3:52864694	ITIH4	-0.49	-6.75	-0.4	1.03e-10	Schizophrenia;
KIRP	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg06521331	chr12:34319734	NA	-0.64	-7.58	-0.44	6.9e-13	Morning vs. evening chronotype;
KIRP	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.58	-6.77	-0.4	9.56e-11	Aortic root size;
KIRP	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.5	6.23	0.37	2.06e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs10843647	0.935	rs2351219	chr12:30319380	C/T	cg14585054	chr17:37351173	CACNB1	0.58	6.07	0.36	4.91e-9	Glucose homeostasis traits;
KIRP	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.56	-7.77	-0.44	2.09e-13	Bladder cancer;
KIRP	trans	rs10838634	1.000	rs7120113	chr11:46934369	C/T	cg09441501	chr11:798350	NA	-0.69	-6.05	-0.36	5.32e-9	Schizophrenia;
KIRP	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-9.01	-0.5	5.75e-17	Morning vs. evening chronotype;
KIRP	cis	rs11673344	0.526	rs55909413	chr19:38069565	C/T	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.52	-0.33	8.41e-8	Obesity-related traits;
KIRP	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	5.53	0.33	8.33e-8	Birth weight;
KIRP	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	5.0	0.3	1.09e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg00361562	chr2:198649771	BOLL	-0.52	-5.03	-0.31	9.35e-7	Ulcerative colitis;
KIRP	cis	rs11644601	1	rs11644601	chr16:15172118	T/C	cg27102117	chr16:15229624	NA	0.51	6.05	0.36	5.36e-9	Metabolite levels (lipid measures);
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.98	-11.77	-0.6	1.19e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs73200209	1.000	rs73200209	chr12:116555786	A/T	cg01776926	chr12:116560359	MED13L	-0.45	-5.46	-0.33	1.18e-7	Total body bone mineral density;
KIRP	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg14952266	chr13:112191215	NA	0.45	6.72	0.39	1.27e-10	Hepatitis;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg25635251	chr11:2234043	NA	-0.47	-5.72	-0.34	3.04e-8	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs13185784	0.703	rs6894217	chr5:179667806	G/A	cg02891314	chr5:179741120	GFPT2	0.48	5.24	0.32	3.37e-7	TRAIL levels;
KIRP	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg27205649	chr11:78285834	NARS2	0.64	8.01	0.46	4.45e-14	Alzheimer's disease (survival time);
KIRP	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.78	6.5	0.38	4.47e-10	Body mass index;
KIRP	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	trans	rs3741489	1.000	rs2062162	chr12:133432744	C/T	cg24132527	chr5:140019269	TMCO6	1.16	9.06	0.5	4.27e-17	Cognitive function;
KIRP	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.69	-0.66	4.32e-32	Primary sclerosing cholangitis;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.86	-0.3	2.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.96	-11.9	-0.6	4.32e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg05347473	chr6:146136440	FBXO30	-0.49	-6.86	-0.4	5.49e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg06917634	chr15:78832804	PSMA4	0.59	6.66	0.39	1.79e-10	Sudden cardiac arrest;
KIRP	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg19257562	chr1:2043853	PRKCZ	0.48	7.25	0.42	5.33e-12	Height;
KIRP	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.3	-0.47	7.05e-15	Coronary artery disease;
KIRP	cis	rs9400467	0.528	rs10872067	chr6:111788391	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.56	-0.33	7.03e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs3008706	0.850	rs3124458	chr9:16022186	C/T	cg14451791	chr9:16040625	NA	0.53	5.65	0.34	4.34e-8	Bilirubin levels;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.73	11.63	0.6	3.42e-25	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.53	7.24	0.42	5.58e-12	Schizophrenia;
KIRP	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.49	5.39	0.33	1.64e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs9303542	0.559	rs2229302	chr17:46620402	G/A	cg04904318	chr17:46607828	HOXB1	-0.63	-6.85	-0.4	5.89e-11	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.55e-13	Life satisfaction;
KIRP	cis	rs939574	0.512	rs908197	chr2:220144410	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.55	5.86	0.35	1.48e-8	Platelet distribution width;
KIRP	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.44	5.17	0.31	4.74e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs829661	0.793	rs7605994	chr2:30790161	G/T	cg10949345	chr2:30726833	LCLAT1	1.01	12.91	0.64	1.88e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.58	-7.94	-0.45	7.17e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs336284	0.529	rs336283	chr7:35293193	A/G	cg06685737	chr7:35301730	NA	0.49	5.1	0.31	6.87e-7	Suicide;Suicide behavior;
KIRP	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	0.92	11.0	0.57	3.81e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.57	-5.3	-0.32	2.58e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.0	0.3	1.09e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7175404	0.938	rs117530692	chr15:94052278	C/T	cg23502883	chr15:93959149	NA	0.51	5.14	0.31	5.68e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg00982548	chr2:198649783	BOLL	-0.55	-5.04	-0.31	9.05e-7	Ulcerative colitis;
KIRP	cis	rs9488822	0.636	rs7745074	chr6:116347432	G/A	cg26893134	chr6:116381904	FRK	0.2	5.75	0.34	2.67e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6032067	0.925	rs35875037	chr20:43859921	A/G	cg10761708	chr20:43804764	PI3	0.51	5.25	0.32	3.26e-7	Blood protein levels;
KIRP	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.95	-0.41	3.18e-11	Hemoglobin concentration;
KIRP	cis	rs2274273	0.934	rs10139337	chr14:55742113	C/T	cg04306507	chr14:55594613	LGALS3	0.44	6.34	0.37	1.11e-9	Protein biomarker;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10354764	chr16:3285464	ZNF200	-0.46	-6.03	-0.36	6.09e-9	Pancreatic cancer;
KIRP	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.94	-16.19	-0.72	1.25e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	0.812	rs28610	chr5:130832382	T/C	cg06307176	chr5:131281290	NA	0.42	5.01	0.3	1.04e-6	Life satisfaction;
KIRP	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.6	-6.56	-0.39	3.21e-10	Gut microbiome composition (summer);
KIRP	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg17652424	chr22:38574118	PLA2G6	-0.24	-4.9	-0.3	1.71e-6	Cutaneous nevi;
KIRP	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg01566213	chr4:1579287	NA	-0.38	-5.3	-0.32	2.63e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg23958373	chr8:599963	NA	0.73	5.82	0.35	1.8e-8	IgG glycosylation;
KIRP	cis	rs714027	0.546	rs5997549	chr22:30265344	C/T	cg27665648	chr22:30112403	NA	0.41	5.51	0.33	8.93e-8	Lymphocyte counts;
KIRP	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.47	-5.61	-0.34	5.39e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs7267005	0.661	rs2425110	chr20:34318815	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	5.04	0.31	8.89e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17528648	chr5:38846100	OSMR	-0.52	-7.48	-0.43	1.29e-12	Myopia;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg02733842	chr7:1102375	C7orf50	0.58	5.98	0.36	7.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.74	11.25	0.58	6.01e-24	Lewy body disease;
KIRP	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg18132916	chr6:79620363	NA	0.41	5.75	0.34	2.57e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12826209	chr6:26865740	GUSBL1	0.66	5.26	0.32	3.13e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	0.97	11.48	0.59	1.04e-24	Iron status biomarkers;
KIRP	cis	rs745080	0.634	rs8015267	chr14:52954436	T/C	cg23333723	chr14:53022898	GPR137C	-0.39	-5.48	-0.33	1.04e-7	Orofacial clefts;
KIRP	cis	rs35955747	0.869	rs8142988	chr22:31587158	T/C	cg02404636	chr22:31891804	SFI1	-0.39	-5.24	-0.32	3.52e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.63	-7.92	-0.45	8.23e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs71636778	0.631	rs71636788	chr1:27186485	T/C	cg12203394	chr1:27248618	NUDC	0.7	5.57	0.33	6.52e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg05721485	chr17:44071124	MAPT	-0.53	-7.54	-0.43	9.21e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12230513	0.732	rs55797706	chr12:55836585	G/A	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	13.69	0.66	4.36e-32	Platelet count;
KIRP	cis	rs7607980	0.585	rs12692738	chr2:165558252	A/G	cg03182029	chr2:165697222	COBLL1	0.4	4.99	0.3	1.13e-6	Fasting blood insulin (BMI interaction);Fasting blood insulin;Type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg22676075	chr6:135203613	NA	-0.46	-6.61	-0.39	2.35e-10	Red blood cell count;
KIRP	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	5.29	0.32	2.75e-7	Homoarginine levels;
KIRP	cis	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg03714773	chr7:91764589	CYP51A1	-0.35	-5.0	-0.3	1.07e-6	Breast cancer;
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-7.77	-0.44	2.07e-13	Glycated hemoglobin levels;
KIRP	cis	rs6732160	0.588	rs72841902	chr2:73372212	T/A	cg01422370	chr2:73384389	NA	0.51	6.92	0.4	3.86e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12615966	1.000	rs17030309	chr2:105391328	G/A	cg16465502	chr2:105461796	NA	0.56	5.46	0.33	1.17e-7	Pancreatic cancer;
KIRP	cis	rs7127900	1.000	rs11043134	chr11:2232682	T/C	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs10267417	0.603	rs13228500	chr7:19939331	T/C	cg05791153	chr7:19748676	TWISTNB	0.51	5.05	0.31	8.64e-7	Night sleep phenotypes;
KIRP	cis	rs3204270	0.673	rs62077190	chr17:79676109	C/A	cg18367735	chr17:79674897	NA	0.74	6.84	0.4	6.12e-11	Dental caries;
KIRP	cis	rs4716602	0.596	rs12386682	chr7:156158265	C/T	cg16983916	chr7:156159713	NA	-0.43	-5.44	-0.33	1.26e-7	Anti-saccade response;
KIRP	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg03641300	chr2:160917029	PLA2R1	-0.53	-8.1	-0.46	2.6e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.43	5.95	0.35	9.18e-9	Sitting height ratio;
KIRP	cis	rs78487399	0.808	rs76171330	chr2:43677440	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.89	-0.3	1.85e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg02461776	chr11:598696	PHRF1	0.49	5.3	0.32	2.53e-7	Systemic lupus erythematosus;
KIRP	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-33.21	-0.9	6.92e-93	Myeloid white cell count;
KIRP	trans	rs6601327	0.665	rs10107992	chr8:9653287	G/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.16	-0.42	9.57e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg12559939	chr2:27858050	GPN1	0.42	5.33	0.32	2.25e-7	Oral cavity cancer;
KIRP	cis	rs6546324	0.625	rs4260227	chr2:67843537	G/A	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.84e-13	Endometriosis;
KIRP	trans	rs593982	0.858	rs537385	chr11:65504900	G/A	cg16063989	chr7:139929855	NA	0.45	6.19	0.37	2.5e-9	Atopic dermatitis;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07009125	chr16:2321791	MIR940	-0.47	-6.93	-0.4	3.62e-11	Bladder cancer;
KIRP	cis	rs823156	0.687	rs708729	chr1:205773461	C/T	cg14159672	chr1:205819179	PM20D1	0.53	5.72	0.34	3.05e-8	Parkinson's disease;
KIRP	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.47	9.76	0.53	3.04e-19	Longevity;
KIRP	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg02461776	chr11:598696	PHRF1	0.51	5.46	0.33	1.17e-7	Systemic lupus erythematosus;
KIRP	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs2980439	0.729	rs2955585	chr8:8093511	A/G	cg15556689	chr8:8085844	FLJ10661	0.85	12.15	0.61	6.51e-27	Neuroticism;
KIRP	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg22764044	chr5:178986830	RUFY1	0.45	6.6	0.39	2.46e-10	Lung cancer;
KIRP	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19717773	chr7:2847554	GNA12	-0.36	-5.69	-0.34	3.58e-8	Height;
KIRP	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.43	-5.09	-0.31	7.18e-7	Aortic root size;
KIRP	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.41	-0.47	3.34e-15	Neuroticism;
KIRP	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg05709478	chr1:6581295	PLEKHG5	0.58	5.31	0.32	2.44e-7	Body mass index;
KIRP	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg18461021	chr18:74961002	GALR1	0.5	5.45	0.33	1.21e-7	Obesity-related traits;
KIRP	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg12405258	chr13:114927641	NA	0.48	6.96	0.41	3.03e-11	Schizophrenia;
KIRP	cis	rs7011049	0.778	rs111990543	chr8:53867626	T/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.8	-10.94	-0.57	5.92e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-5.81	-0.35	1.91e-8	Blood metabolite levels;
KIRP	cis	rs12580194	0.593	rs12581060	chr12:55797484	A/C	cg19537932	chr12:55886519	OR6C68	-0.52	-6.68	-0.39	1.62e-10	Cancer;
KIRP	cis	rs2411233	0.868	rs11853815	chr15:39257395	A/C	cg02291532	chr15:39874776	THBS1	0.47	6.12	0.36	3.62e-9	Platelet count;
KIRP	cis	rs9308731	0.644	rs1821968	chr2:111880623	C/T	cg04202892	chr2:111875749	ACOXL	0.5	6.95	0.41	3.22e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs6969780	0.778	rs79619106	chr7:27146328	A/C	cg26364809	chr7:27145159	NA	-0.62	-5.71	-0.34	3.22e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs35995292	1.000	rs35995292	chr7:38913017	T/G	cg19327137	chr7:38886074	VPS41	0.52	6.14	0.36	3.32e-9	Subjective well-being (multi-trait analysis);
KIRP	cis	rs8070740	0.559	rs16954604	chr17:5294450	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.43	5.1	0.31	6.79e-7	Menopause (age at onset);
KIRP	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg06671706	chr8:8559999	CLDN23	0.52	6.24	0.37	1.91e-9	Obesity-related traits;
KIRP	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg03834567	chr2:218808745	TNS1	0.45	5.54	0.33	7.77e-8	Ulcerative colitis;
KIRP	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg21226059	chr5:178986404	RUFY1	0.33	4.92	0.3	1.59e-6	Lung cancer;
KIRP	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.62	7.67	0.44	4.01e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.7	10.18	0.54	1.58e-20	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13065577	chr13:90014513	NA	0.46	7.07	0.41	1.59e-11	Survival in pancreatic cancer;
KIRP	cis	rs7173743	1.000	rs4567668	chr15:79140692	T/C	cg00079375	chr15:79125835	NA	-0.37	-5.18	-0.31	4.71e-7	Coronary artery disease;
KIRP	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg18755752	chr8:142205143	DENND3	-0.47	-6.47	-0.38	5.14e-10	Immature fraction of reticulocytes;
KIRP	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg02896835	chr1:92012615	NA	0.52	5.24	0.32	3.44e-7	Eosinophil percentage of white cells;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16758348	chr14:58335480	NA	-0.41	-6.28	-0.37	1.54e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs734999	0.545	rs41300092	chr1:2537838	C/T	cg20673091	chr1:2541236	MMEL1	0.67	10.05	0.54	3.8e-20	Ulcerative colitis;
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-9.68	-0.53	5.7e-19	Lymphocyte counts;
KIRP	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg16586182	chr3:47516702	SCAP	0.76	10.72	0.56	3e-22	Colorectal cancer;
KIRP	cis	rs17416285	0.559	rs56198059	chr1:56974534	A/G	cg12180551	chr1:56975583	PPAP2B	0.43	4.87	0.3	1.96e-6	Coronary artery disease;
KIRP	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg16736954	chr20:23401023	NAPB	0.64	5.09	0.31	7.18e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.9	-10.55	-0.56	1.03e-21	White matter hyperintensity burden;
KIRP	cis	rs9912468	0.933	rs8081834	chr17:64331037	C/T	cg19474267	chr17:64306194	PRKCA	0.6	8.45	0.47	2.61e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg02972257	chr16:68554789	NA	0.62	6.23	0.37	2.05e-9	Plateletcrit;
KIRP	cis	rs3767633	0.925	rs6427639	chr1:161866372	C/A	cg09175582	chr1:161736000	ATF6	0.74	5.98	0.36	7.87e-9	IgG glycosylation;
KIRP	cis	rs2273156	0.570	rs7144423	chr14:35572547	C/T	cg09327582	chr14:35236912	BAZ1A	-0.52	-5.16	-0.31	5.06e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg05941025	chr16:89927596	SPIRE2	0.33	5.22	0.32	3.75e-7	Vitiligo;
KIRP	cis	rs10875746	0.807	rs12313300	chr12:48470717	G/A	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.92e-34	Menopause (age at onset);
KIRP	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.34	-0.47	5.37e-15	Total cholesterol levels;
KIRP	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg06495924	chr8:145149574	CYC1	-0.54	-5.04	-0.31	9.19e-7	Blood metabolite levels;
KIRP	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.55	5.56	0.33	7.02e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1620921	0.505	rs34797199	chr6:161203769	C/T	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg27494647	chr7:150038898	RARRES2	0.43	5.97	0.36	8.36e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs17221829	0.627	rs10830315	chr11:89375574	G/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs4236601	0.778	rs10256914	chr7:116175711	C/T	cg05166801	chr7:116143459	CAV2	-0.43	-5.15	-0.31	5.45e-7	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	8.2	0.46	1.29e-14	Response to antipsychotic treatment;
KIRP	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg11189052	chr15:85197271	WDR73	0.48	4.87	0.3	2.02e-6	Schizophrenia;
KIRP	cis	rs9653442	0.545	rs1821826	chr2:100764711	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.54	-0.33	7.92e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs13102973	0.640	rs10434071	chr4:135842080	C/G	cg14419869	chr4:135874104	NA	0.49	8.15	0.46	1.8e-14	Subjective well-being;
KIRP	cis	rs6547631	0.622	rs10206121	chr2:85930169	T/A	cg24620635	chr2:85921963	GNLY	0.31	4.93	0.3	1.53e-6	Blood protein levels;
KIRP	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg02175503	chr12:58329896	NA	-0.44	-4.89	-0.3	1.79e-6	Multiple sclerosis;
KIRP	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg06121193	chr1:90282411	NA	-0.53	-7.52	-0.43	1e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.51	-0.38	4.1e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.33	-0.32	2.26e-7	Pulmonary function;
KIRP	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg25706552	chr1:244017396	NA	0.58	7.23	0.42	5.9e-12	RR interval (heart rate);
KIRP	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.11	-0.31	6.49e-7	Pulmonary function;
KIRP	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.19	11.28	0.58	4.7e-24	Alzheimer's disease (late onset);
KIRP	cis	rs6746896	0.683	rs6730773	chr2:97441643	A/G	cg01990225	chr2:97406019	LMAN2L	-0.58	-7.46	-0.43	1.45e-12	Bipolar disorder;
KIRP	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.68	5.21	0.32	3.99e-7	Major depressive disorder;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.81	-11.03	-0.58	3.03e-23	Longevity;
KIRP	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16386425	chr10:429943	DIP2C	-0.48	-6.62	-0.39	2.23e-10	Psychosis in Alzheimer's disease;
KIRP	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.98	-13.77	-0.66	2.21e-32	Response to antipsychotic treatment;
KIRP	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.19	-0.51	1.69e-17	Platelet count;
KIRP	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg25838818	chr2:108905173	SULT1C2	-0.59	-7.79	-0.44	1.92e-13	Blood pressure;
KIRP	cis	rs4849845	0.678	rs3896632	chr2:121023496	C/T	cg24070213	chr2:121070622	NA	0.38	5.67	0.34	3.97e-8	Mean platelet volume;
KIRP	cis	rs2230307	0.656	rs531174	chr1:100485988	G/T	cg24955406	chr1:100503596	HIAT1	0.56	5.6	0.34	5.65e-8	Carotid intima media thickness;
KIRP	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9596863	0.898	rs35732706	chr13:54343886	T/G	ch.13.53330881F	chr13:54432880	NA	0.59	5.72	0.34	3.13e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2011503	0.509	rs11668721	chr19:19760916	G/A	cg11584989	chr19:19387371	SF4	0.51	5.05	0.31	8.63e-7	Bipolar disorder;
KIRP	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg23594656	chr7:65796392	TPST1	-0.41	-6.33	-0.37	1.15e-9	Aortic root size;
KIRP	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg00383909	chr3:49044727	WDR6	0.55	5.49	0.33	1e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg12315302	chr6:26189340	HIST1H4D	0.79	5.18	0.31	4.66e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.57	0.52	1.22e-18	Body mass index;
KIRP	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	1.06	19.85	0.78	5.22e-53	Heart rate;
KIRP	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	0.79	7.14	0.41	1.02e-11	Gut microbiota (bacterial taxa);
KIRP	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.81	-11.81	-0.6	8.5e-26	Itch intensity from mosquito bite;
KIRP	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	19.64	0.78	2.63e-52	Exhaled nitric oxide output;
KIRP	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.63	7.78	0.44	2.03e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.77	-0.4	9.34e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg05315796	chr3:52349193	DNAH1	0.44	6.78	0.4	9.07e-11	Bipolar disorder;
KIRP	cis	rs787274	0.681	rs4978506	chr9:115600162	C/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.53	-0.38	3.8e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg14768367	chr16:72042858	DHODH	0.44	5.35	0.32	2.05e-7	Fibrinogen levels;
KIRP	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg03808351	chr9:123631620	PHF19	0.37	5.09	0.31	7.26e-7	Rheumatoid arthritis;
KIRP	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg05555928	chr11:63887634	MACROD1	-0.58	-5.29	-0.32	2.69e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.39	7.47	0.43	1.39e-12	Height;
KIRP	trans	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg10756647	chr7:56101905	PSPH	1.01	7.56	0.43	8e-13	Diabetic kidney disease;
KIRP	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg00277334	chr10:82204260	NA	-0.48	-5.53	-0.33	8.3e-8	Post bronchodilator FEV1;
KIRP	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.63	-8.14	-0.46	1.92e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg23602478	chr1:26503979	CNKSR1	0.45	6.35	0.38	1.05e-9	Height;
KIRP	cis	rs42648	0.720	rs9655741	chr7:89933874	C/G	cg25739043	chr7:89950458	NA	-0.43	-6.79	-0.4	8.48e-11	Homocysteine levels;
KIRP	cis	rs933360	0.557	rs1978208	chr7:50785448	A/G	cg14240098	chr7:50518052	FIGNL1	-0.48	-5.22	-0.32	3.77e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs4073416	0.518	rs2210805	chr14:65892724	C/G	cg03016385	chr14:66212404	NA	-0.54	-6.7	-0.39	1.37e-10	N-glycan levels;
KIRP	trans	rs7980799	0.935	rs2892701	chr12:33547395	C/T	cg26384229	chr12:38710491	ALG10B	0.49	6.03	0.36	6.05e-9	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg05347473	chr6:146136440	FBXO30	0.57	7.83	0.45	1.43e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.55	-6.26	-0.37	1.66e-9	Breast cancer;
KIRP	cis	rs2016266	0.787	rs56358776	chr12:53682457	G/A	cg16917193	chr12:54089295	NA	-0.41	-5.26	-0.32	3.15e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.68	8.29	0.47	7.48e-15	Aortic root size;
KIRP	cis	rs732716	0.740	rs62129356	chr19:4400314	C/T	cg19820705	chr19:4455316	UBXN6	0.66	7.98	0.45	5.42e-14	Mean corpuscular volume;
KIRP	cis	rs282587	0.569	rs282593	chr13:113378882	T/C	cg04656015	chr13:113407548	ATP11A	0.67	8.05	0.46	3.59e-14	Glycated hemoglobin levels;
KIRP	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs981844	0.807	rs10517577	chr4:154644537	T/C	cg14289246	chr4:154710475	SFRP2	0.68	7.19	0.42	7.94e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs9309473	0.950	rs1918863	chr2:73644481	A/G	cg20560298	chr2:73613845	ALMS1	-0.54	-6.52	-0.38	3.85e-10	Metabolite levels;
KIRP	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.47	5.11	0.31	6.36e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.57	-6.01	-0.36	6.52e-9	Ulcerative colitis;
KIRP	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg21643547	chr1:205240462	TMCC2	-0.61	-8.88	-0.49	1.47e-16	Red blood cell count;
KIRP	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg21775007	chr8:11205619	TDH	-0.49	-6.8	-0.4	7.8e-11	Neuroticism;
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg08132940	chr7:1081526	C7orf50	-0.51	-4.94	-0.3	1.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.72	11.01	0.57	3.53e-23	Height;
KIRP	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg10503236	chr1:231470652	EXOC8	-0.54	-7.44	-0.43	1.66e-12	Hemoglobin concentration;
KIRP	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.63	-0.34	5.02e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.72	-11.29	-0.58	4.38e-24	Menarche (age at onset);
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.48	-5.43	-0.33	1.33e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg16898833	chr6:26189333	HIST1H4D	0.67	5.12	0.31	6.11e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg07701084	chr6:150067640	NUP43	0.65	8.39	0.47	3.94e-15	Lung cancer;
KIRP	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.8	-11.47	-0.59	1.13e-24	Multiple sclerosis;
KIRP	trans	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg06521331	chr12:34319734	NA	-0.5	-6.24	-0.37	1.93e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.88	13.81	0.66	1.71e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.76	-10.25	-0.55	9.25e-21	Longevity;Endometriosis;
KIRP	cis	rs7221595	0.825	rs62072392	chr17:3910125	A/G	cg05562828	chr17:3906858	NA	0.63	6.83	0.4	6.62e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.67	9.41	0.51	3.68e-18	Body mass index;
KIRP	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg00262122	chr8:11665843	FDFT1	0.5	6.2	0.37	2.4e-9	Morning vs. evening chronotype;
KIRP	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.15	16.3	0.72	5.14e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.07	0.72	3.3e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg04398451	chr17:18023971	MYO15A	-0.65	-8.78	-0.49	2.8e-16	Total body bone mineral density;
KIRP	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.61	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg21184320	chr1:21044207	KIF17	-0.37	-5.56	-0.33	7e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.11	0.36	3.92e-9	Platelet count;
KIRP	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.69	10.0	0.54	5.52e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg15655495	chr12:38532458	NA	0.26	5.0	0.3	1.08e-6	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg27309920	chr12:6798957	ZNF384	0.47	6.4	0.38	7.61e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs16937956	0.657	rs35976355	chr11:8428657	T/C	cg08015107	chr11:8618950	NA	-0.58	-7.44	-0.43	1.64e-12	Body mass index;
KIRP	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.42	5.83	0.35	1.7e-8	Testicular germ cell tumor;
KIRP	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg00405596	chr8:11794950	NA	0.47	5.85	0.35	1.57e-8	Retinal vascular caliber;
KIRP	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.12	0.41	1.17e-11	Bipolar disorder;
KIRP	cis	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.01	-0.3	1.06e-6	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16046740	chr11:95522512	CEP57;FAM76B	0.47	6.44	0.38	6.31e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg13880726	chr7:1868755	MAD1L1	0.49	5.49	0.33	1.01e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg18882449	chr10:104885122	NT5C2	-0.42	-5.36	-0.32	1.9e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs62229266	0.771	rs7277791	chr21:37383227	C/A	cg08632701	chr21:37451849	NA	-0.41	-5.07	-0.31	7.68e-7	Mitral valve prolapse;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg24874828	chr4:187887005	NA	-0.48	-7.15	-0.41	1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9649213	0.593	rs6465665	chr7:97934150	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.65	0.34	4.51e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs807669	0.900	rs712964	chr22:19156117	T/C	cg02655711	chr22:19163373	SLC25A1	0.81	13.31	0.65	8.01e-31	Metabolite levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23260255	chr3:187871479	LPP	0.51	6.04	0.36	5.79e-9	Smoking initiation;
KIRP	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.55	7.88	0.45	1.07e-13	Schizophrenia;
KIRP	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg23719950	chr11:63933701	MACROD1	-0.68	-6.55	-0.39	3.26e-10	Mean platelet volume;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg10207240	chr12:122356781	WDR66	0.47	6.39	0.38	8.14e-10	Mean corpuscular volume;
KIRP	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg26898376	chr11:64110657	CCDC88B	0.49	5.67	0.34	4.09e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg09597638	chr17:3907349	NA	0.42	5.01	0.3	1.04e-6	Type 2 diabetes;
KIRP	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Body mass index;
KIRP	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.66	7.33	0.42	3.33e-12	Initial pursuit acceleration;
KIRP	cis	rs96067	0.805	rs4653162	chr1:36613704	G/T	cg24686825	chr1:36642396	MAP7D1	0.45	5.24	0.32	3.44e-7	Corneal structure;
KIRP	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.6	6.36	0.38	1e-9	Diisocyanate-induced asthma;
KIRP	cis	rs9290877	0.667	rs9877870	chr3:188456755	A/C	cg17392043	chr3:188495102	LPP	-0.49	-6.45	-0.38	5.99e-10	IgE levels;
KIRP	cis	rs4132509	0.948	rs12136624	chr1:243981611	C/A	cg25706552	chr1:244017396	NA	0.55	6.65	0.39	1.89e-10	RR interval (heart rate);
KIRP	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.54	7.17	0.42	8.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.67	-8.66	-0.48	6.54e-16	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05564831	chr3:52568323	NT5DC2	0.43	7.04	0.41	1.94e-11	Electroencephalogram traits;
KIRP	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs75920871	1.000	rs61905706	chr11:116883777	G/T	cg23684410	chr11:116897558	SIK3	0.57	6.15	0.37	3.05e-9	Subjective well-being;
KIRP	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	4.92	0.3	1.59e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg07843065	chr1:150265600	MRPS21	0.42	5.66	0.34	4.3e-8	Migraine;
KIRP	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.69	8.22	0.46	1.18e-14	Blood protein levels;
KIRP	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg07884673	chr3:53033167	SFMBT1	0.98	7.6	0.44	6.35e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.74	0.49	3.73e-16	Bladder cancer;
KIRP	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg04306507	chr14:55594613	LGALS3	0.53	8.45	0.47	2.62e-15	Protein biomarker;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-0.91	-14.36	-0.68	2.24e-34	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs62380364	0.602	rs448809	chr5:88005828	G/T	cg24804195	chr5:87968844	LOC645323	-0.45	-5.99	-0.36	7.42e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.93	0.35	1.05e-8	Melanoma;
KIRP	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	7.65	0.44	4.51e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6707387	0.686	rs1515913	chr2:214489466	G/A	cg08319019	chr2:214017104	IKZF2	0.47	5.38	0.32	1.72e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg17724175	chr1:150552817	MCL1	0.32	4.97	0.3	1.24e-6	Melanoma;
KIRP	cis	rs7539542	0.538	rs2363772	chr1:202899361	C/A	cg19681188	chr1:202830198	LOC148709	-0.48	-4.85	-0.3	2.22e-6	Mean platelet volume;
KIRP	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	12.01	0.61	1.8e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6546886	0.869	rs3902790	chr2:74303203	A/T	cg14702570	chr2:74259524	NA	-0.29	-5.62	-0.34	5.23e-8	Dialysis-related mortality;
KIRP	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.64	0.39	1.94e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.83	11.2	0.58	8.63e-24	Morning vs. evening chronotype;
KIRP	cis	rs496547	0.557	rs516719	chr11:118679445	C/T	cg19308663	chr11:118741387	NA	-0.28	-5.1	-0.31	6.91e-7	Hip minimal joint space width;
KIRP	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.57	0.43	7.52e-13	Mean corpuscular volume;
KIRP	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg01411142	chr8:19674711	INTS10	0.41	4.85	0.3	2.24e-6	Breast cancer;
KIRP	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.56	-0.39	3.12e-10	Obesity-related traits;
KIRP	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg20936604	chr3:58311152	NA	-0.7	-6.1	-0.36	4.15e-9	Cholesterol, total;
KIRP	cis	rs10861661	0.963	rs7977765	chr12:107205390	A/G	cg15890332	chr12:107067104	RFX4	0.35	4.91	0.3	1.69e-6	Triglyceride levels;
KIRP	cis	rs501120	0.584	rs11238915	chr10:44696665	C/A	cg09554077	chr10:44749378	NA	0.51	5.54	0.33	7.93e-8	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs12431410	0.536	rs11622268	chr14:60151508	T/C	cg20601314	chr10:104179541	FBXL15;PSD	-0.56	-6.22	-0.37	2.08e-9	Schizophrenia;
KIRP	cis	rs6570726	0.559	rs11754523	chr6:145727951	A/G	cg23711669	chr6:146136114	FBXO30	-0.46	-5.45	-0.33	1.22e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6832769	0.767	rs11133394	chr4:56383238	C/T	cg05960024	chr4:56376020	CLOCK	0.57	7.29	0.42	4.25e-12	Personality dimensions;
KIRP	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg23166289	chr1:210001082	C1orf107	0.5	5.3	0.32	2.59e-7	Orofacial clefts;
KIRP	cis	rs1448094	0.817	rs7973694	chr12:86335589	A/G	cg00310523	chr12:86230176	RASSF9	0.41	6.31	0.37	1.28e-9	Major depressive disorder;
KIRP	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg13319975	chr6:146136371	FBXO30	0.43	5.7	0.34	3.46e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.64	8.1	0.46	2.61e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg18646521	chr2:111875858	NA	0.4	5.74	0.34	2.85e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs17023223	0.537	rs12086549	chr1:119614337	A/T	cg05756136	chr1:119680316	WARS2	0.56	7.47	0.43	1.37e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.19e-9	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06481639	chr22:41940642	POLR3H	0.68	6.89	0.4	4.73e-11	Vitiligo;
KIRP	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg26681399	chr22:41777847	TEF	-0.44	-4.87	-0.3	2e-6	Neuroticism;
KIRP	cis	rs6540559	0.611	rs76766079	chr1:209997731	C/T	cg22029157	chr1:209979665	IRF6	0.51	5.16	0.31	5.04e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.56	-7.52	-0.43	1.03e-12	Total body bone mineral density;
KIRP	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-6.19	-0.37	2.46e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.68	9.62	0.52	8.27e-19	Retinal vascular caliber;
KIRP	cis	rs2084898	0.550	rs470725	chr11:119997599	T/C	cg07435449	chr11:120005650	TRIM29	0.48	6.35	0.38	1.05e-9	Stroke (pediatric);
KIRP	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	8.24	0.47	1.02e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg08999081	chr20:33150536	PIGU	0.42	5.27	0.32	2.98e-7	Height;
KIRP	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.77	9.45	0.52	2.84e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.69	10.51	0.56	1.42e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.59	7.97	0.45	5.8e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg05043794	chr9:111880884	C9orf5	0.24	4.87	0.3	2.03e-6	Menarche (age at onset);
KIRP	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.61	8.9	0.49	1.29e-16	Immature fraction of reticulocytes;
KIRP	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg10503236	chr1:231470652	EXOC8	-0.54	-7.75	-0.44	2.44e-13	Hemoglobin concentration;
KIRP	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-10.64	-0.56	5.21e-22	Height;
KIRP	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg06417478	chr19:12876846	HOOK2	-0.45	-5.06	-0.31	8.14e-7	Mean corpuscular volume;
KIRP	cis	rs7520050	0.931	rs6686134	chr1:46378268	A/G	cg03146154	chr1:46216737	IPP	-0.42	-5.29	-0.32	2.65e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg10047753	chr17:41438598	NA	1.12	18.2	0.76	1.84e-47	Menopause (age at onset);
KIRP	cis	rs16828019	0.777	rs13376450	chr1:41469043	A/G	cg24596898	chr1:41849189	NA	0.62	4.85	0.3	2.16e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.667	rs4266275	chr4:152348064	A/G	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg17376030	chr22:41985996	PMM1	0.8	8.21	0.46	1.24e-14	Vitiligo;
KIRP	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.6	8.27	0.47	8.52e-15	Economic and political preferences (feminism/equality);
KIRP	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.56	6.93	0.4	3.58e-11	Eosinophil percentage of white cells;
KIRP	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.69	8.46	0.47	2.47e-15	Neutrophil percentage of white cells;
KIRP	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.36	-4.89	-0.3	1.86e-6	Coronary artery disease;
KIRP	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg11189052	chr15:85197271	WDR73	0.53	5.47	0.33	1.12e-7	Schizophrenia;
KIRP	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.9	-15.65	-0.71	8.73e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg11859384	chr17:80120422	CCDC57	-0.47	-5.96	-0.36	8.75e-9	Life satisfaction;
KIRP	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.61	-7.76	-0.44	2.28e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg04824913	chr4:887549	GAK	0.62	5.2	0.31	4.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg06671706	chr8:8559999	CLDN23	0.52	6.24	0.37	1.91e-9	Obesity-related traits;
KIRP	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	-0.8	-7.86	-0.45	1.23e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3736485	0.966	rs2124877	chr15:51906275	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.16e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.51	-6.46	-0.38	5.63e-10	Schizophrenia;
KIRP	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.88	11.8	0.6	9.08e-26	Coronary artery disease;
KIRP	cis	rs6893300	0.961	rs55827522	chr5:179177116	C/T	cg14593053	chr5:179126677	CANX	-0.57	-6.33	-0.37	1.15e-9	Resting heart rate;
KIRP	cis	rs9473924	0.542	rs9473925	chr6:50834565	T/C	cg14470998	chr6:50812995	TFAP2B	0.83	7.63	0.44	5.19e-13	Body mass index;
KIRP	cis	rs10114408	0.959	rs7874271	chr9:96638818	C/A	cg14598338	chr9:96623480	NA	-0.34	-5.17	-0.31	4.92e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg24009623	chr19:33667908	NA	0.47	5.68	0.34	3.72e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2294369	0.635	rs136829	chr22:40046176	T/C	cg21377881	chr22:40064566	CACNA1I	0.46	4.95	0.3	1.4e-6	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg07382826	chr16:28625726	SULT1A1	0.53	6.31	0.37	1.28e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13065560	0.534	rs4481097	chr3:38909570	C/T	cg01426195	chr3:39028469	NA	0.37	6.04	0.36	5.52e-9	Interleukin-18 levels;
KIRP	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.42	5.41	0.33	1.47e-7	Aortic root size;
KIRP	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg16989719	chr2:238392110	NA	-0.59	-5.9	-0.35	1.17e-8	Prostate cancer;
KIRP	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.64	-9.05	-0.5	4.47e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.74	-10.21	-0.55	1.22e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.37	-0.32	1.79e-7	Lung cancer;
KIRP	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.72	9.37	0.51	5.03e-18	Morning vs. evening chronotype;
KIRP	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg11189052	chr15:85197271	WDR73	-0.49	-5.16	-0.31	5.11e-7	Schizophrenia;
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg07701084	chr6:150067640	NUP43	0.7	9.33	0.51	6.38e-18	Lung cancer;
KIRP	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg15247329	chr7:2764246	NA	0.37	5.37	0.32	1.86e-7	Height;
KIRP	cis	rs6579956	0.517	rs2961750	chr5:152020985	T/C	cg12297329	chr5:152029980	NA	-0.39	-5.16	-0.31	5.12e-7	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs2048656	0.540	rs55868514	chr8:9680400	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.48	-0.38	5.09e-10	Schizophrenia;
KIRP	cis	rs1538970	1.000	rs4520450	chr1:45834773	A/G	cg05343316	chr1:45956843	TESK2	0.64	7.35	0.42	2.92e-12	Platelet count;
KIRP	trans	rs12709013	0.591	rs2086206	chr16:58835998	T/C	cg12115882	chr11:133449267	NA	-0.44	-6.04	-0.36	5.59e-9	Blood metabolite ratios;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg06815112	chr8:27182871	PTK2B	0.54	6.94	0.4	3.49e-11	Neuroticism;
KIRP	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.28	-0.37	1.55e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.52	6.62	0.39	2.24e-10	Coronary heart disease;
KIRP	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.59	7.14	0.41	1.03e-11	Menopause (age at onset);
KIRP	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg20243544	chr17:37824526	PNMT	0.53	7.55	0.43	8.32e-13	Asthma;
KIRP	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg21366198	chr4:185655624	MLF1IP	-0.4	-5.4	-0.33	1.6e-7	Kawasaki disease;
KIRP	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.85	-9.26	-0.51	1.06e-17	Osteoarthritis;
KIRP	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs7615316	1.000	rs2049325	chr3:142337430	A/G	cg20824294	chr3:142316082	PLS1	0.23	5.11	0.31	6.47e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg11494091	chr17:61959527	GH2	0.7	9.98	0.54	6.3e-20	Prudent dietary pattern;
KIRP	cis	rs7523273	0.597	rs2796265	chr1:207920788	A/G	cg22525895	chr1:207977042	MIR29B2	-0.56	-5.65	-0.34	4.5e-8	Schizophrenia;
KIRP	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg22532475	chr10:104410764	TRIM8	-0.29	-5.02	-0.3	1e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.64	-8.34	-0.47	5.49e-15	Inflammatory bowel disease;
KIRP	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg02725872	chr8:58115012	NA	-0.52	-5.94	-0.35	9.7e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4704187	0.640	rs74719230	chr5:74431888	G/C	cg03227963	chr5:74354835	NA	0.41	5.93	0.35	9.96e-9	Response to amphetamines;
KIRP	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg21231944	chr12:82153410	PPFIA2	-0.39	-4.92	-0.3	1.6e-6	Resting heart rate;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14504697	chr2:177190235	MTX2	-0.44	-6.6	-0.39	2.45e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs348196	0.672	rs670876	chr1:155671678	T/G	cg02153340	chr1:155202674	NA	-0.46	-6.04	-0.36	5.57e-9	Breast cancer;
KIRP	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg23950597	chr19:37808831	NA	0.59	6.39	0.38	8.04e-10	Coronary artery calcification;
KIRP	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.48	0.43	1.3e-12	Neuroticism;
KIRP	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.14	0.5	2.41e-17	Colorectal cancer;
KIRP	cis	rs3779635	1.000	rs3779635	chr8:27284692	C/T	cg06815112	chr8:27182871	PTK2B	0.45	5.84	0.35	1.61e-8	Neuroticism;
KIRP	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg05315796	chr3:52349193	DNAH1	0.44	6.66	0.39	1.79e-10	Bipolar disorder;
KIRP	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.43	-6.05	-0.36	5.49e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	cg21523751	chr1:182988639	NA	0.45	6.79	0.4	8.22e-11	Hypertriglyceridemia;
KIRP	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg16145915	chr7:1198662	ZFAND2A	0.63	6.36	0.38	9.51e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.73	11.07	0.58	2.18e-23	Longevity;Endometriosis;
KIRP	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg08999081	chr20:33150536	PIGU	-0.47	-6.29	-0.37	1.48e-9	Height;
KIRP	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.74	8.93	0.49	1.02e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.67	8.26	0.47	8.94e-15	Dilated cardiomyopathy;
KIRP	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24110177	chr3:50126178	RBM5	-0.65	-8.93	-0.49	1.04e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg15660573	chr17:549704	VPS53	-0.85	-12.79	-0.63	4.66e-29	Prostate cancer;
KIRP	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.31	13.02	0.64	7.66e-30	Diabetic retinopathy;
KIRP	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.34	4.9	0.3	1.73e-6	Abdominal aortic aneurysm;
KIRP	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg22437258	chr11:111473054	SIK2	0.63	7.48	0.43	1.29e-12	Primary sclerosing cholangitis;
KIRP	cis	rs17789174	0.951	rs12596553	chr16:85104752	G/T	cg01715842	chr16:85045600	ZDHHC7	-0.42	-5.45	-0.33	1.2e-7	Dysphagia;
KIRP	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg23127183	chr11:57508653	C11orf31	-0.55	-6.9	-0.4	4.26e-11	Schizophrenia;
KIRP	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.11	-0.36	3.84e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17882959	chr1:160231874	DCAF8	0.49	6.08	0.36	4.57e-9	Parkinson's disease;
KIRP	cis	rs9320282	0.587	rs1546721	chr6:109625796	T/C	cg21918786	chr6:109611834	NA	-0.35	-5.02	-0.3	9.97e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs11673344	0.864	rs8110696	chr19:37500351	G/T	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.19	-0.31	4.42e-7	Obesity-related traits;
KIRP	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg18016565	chr1:150552671	MCL1	0.35	5.4	0.33	1.6e-7	Tonsillectomy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08876899	chr1:35545196	ZMYM1	-0.47	-6.15	-0.37	3.03e-9	Interleukin-4 levels;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17157516	chr1:35332203	DLGAP3	0.69	6.44	0.38	6.3e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs238295	0.805	rs6053525	chr20:5577000	C/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.51	-5.12	-0.31	6.2e-7	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs6960043	0.743	rs1002061	chr7:15039499	A/T	cg19272540	chr7:15055459	NA	-0.2	-5.52	-0.33	8.66e-8	Type 2 diabetes;
KIRP	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg04226714	chr8:49833948	SNAI2	0.45	6.29	0.37	1.46e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg25036284	chr2:26402008	FAM59B	-0.54	-5.55	-0.33	7.45e-8	Gut microbiome composition (summer);
KIRP	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.91	0.4	4.19e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs3126085	0.515	rs9633410	chr1:152363922	G/T	cg26876637	chr1:152193138	HRNR	-0.71	-7.11	-0.41	1.26e-11	Atopic dermatitis;
KIRP	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.85	12.68	0.63	1.13e-28	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	7.74	0.44	2.51e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.87	13.73	0.66	3.21e-32	Ulcerative colitis;
KIRP	cis	rs830383	0.597	rs10077308	chr5:165456486	C/T	cg13976338	chr5:165423657	NA	-0.44	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs2148482	chr10:35348910	A/G	cg03585969	chr10:35415529	CREM	0.78	9.55	0.52	1.41e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg18306516	chr10:81103258	NA	-0.3	-4.85	-0.3	2.2e-6	Height;
KIRP	cis	rs4363506	1.000	rs10741273	chr10:129271508	A/G	cg07804728	chr10:129284050	NA	0.39	5.49	0.33	9.81e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.54	-0.52	1.46e-18	Chronic sinus infection;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg02609781	chr13:50656090	DLEU1;DLEU2	-0.45	-6.2	-0.37	2.34e-9	Cancer;
KIRP	cis	rs2718812	0.766	rs11924101	chr3:133394478	T/G	cg01448562	chr3:133502909	NA	-0.38	-4.99	-0.3	1.12e-6	Iron status biomarkers;
KIRP	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.03	0.36	5.98e-9	Breast cancer;
KIRP	cis	rs4765905	0.520	rs10848637	chr12:2316554	C/A	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.85	-0.4	6.04e-11	Schizophrenia;
KIRP	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.9	10.61	0.56	6.57e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6516091	0.706	rs62199230	chr20:6050124	G/C	cg25325723	chr20:6104886	FERMT1	-0.64	-6.41	-0.38	7.27e-10	Abdominal aortic aneurysm;
KIRP	cis	rs3762637	0.943	rs78429050	chr3:122252428	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-6.17	-0.37	2.8e-9	LDL cholesterol levels;
KIRP	cis	rs9308731	0.692	rs604126	chr2:111943200	A/G	cg23466623	chr2:111982296	NA	-0.47	-5.81	-0.35	1.94e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg07741184	chr6:167504864	NA	0.24	6.39	0.38	8.45e-10	Crohn's disease;
KIRP	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.71	8.86	0.49	1.65e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.4	5.37	0.32	1.81e-7	Homoarginine levels;
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.63	-10.63	-0.56	5.82e-22	Lung cancer;
KIRP	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.6	6.56	0.39	3.21e-10	Gut microbiome composition (summer);
KIRP	cis	rs10802346	0.685	rs10924614	chr1:246409434	C/T	cg15962031	chr1:246363574	SMYD3	0.76	5.57	0.33	6.66e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.95	0.45	6.56e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13102973	0.617	rs11734991	chr4:135885411	T/G	cg14419869	chr4:135874104	NA	0.38	6.01	0.36	6.59e-9	Subjective well-being;
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.71	-0.44	3.16e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg23280166	chr11:118938394	VPS11	0.59	7.4	0.43	2.18e-12	Coronary artery disease;
KIRP	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.43	-5.56	-0.33	7.05e-8	Iron status biomarkers;
KIRP	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg19197139	chr17:4613644	ARRB2	0.74	7.52	0.43	1.05e-12	Lymphocyte counts;
KIRP	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	0.79	6.98	0.41	2.79e-11	Obesity-related traits;
KIRP	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg01629716	chr15:45996671	NA	0.36	6.48	0.38	4.85e-10	Waist circumference;Weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00529946	chr2:26568848	SELI;GPR113	0.48	6.22	0.37	2.13e-9	Parkinson's disease;
KIRP	cis	rs1448094	0.817	rs10779220	chr12:86323543	T/A	cg02569458	chr12:86230093	RASSF9	0.35	5.15	0.31	5.44e-7	Major depressive disorder;
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg07747251	chr5:1868357	NA	0.44	5.71	0.34	3.26e-8	Cardiovascular disease risk factors;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg00838250	chr3:186287958	TBCCD1;DNAJB11	-0.47	-6.2	-0.37	2.37e-9	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.6e-6	Lung cancer;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg08648136	chr8:956695	NA	0.46	7.08	0.41	1.49e-11	Schizophrenia;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg23698023	chr8:27181813	PTK2B	0.33	4.93	0.3	1.49e-6	Neuroticism;
KIRP	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.55	-7.59	-0.44	6.78e-13	Lung cancer;
KIRP	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.55	7.56	0.43	7.85e-13	IgG glycosylation;
KIRP	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00538642	chr19:2096903	C19orf36;MOBKL2A	0.51	6.26	0.37	1.68e-9	Parkinson's disease;
KIRP	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-11.33	-0.59	3.15e-24	Neuroticism;
KIRP	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.81	-8.94	-0.5	9.65e-17	Neuroblastoma;
KIRP	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.0	0.5	6.4e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10214930	0.767	rs56282178	chr7:27698592	C/A	cg22168087	chr7:27702803	HIBADH	-0.52	-5.26	-0.32	3.06e-7	Hypospadias;
KIRP	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg25547332	chr5:131281432	NA	0.49	5.38	0.32	1.71e-7	Life satisfaction;
KIRP	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.67	9.76	0.53	3.22e-19	Dupuytren's disease;
KIRP	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.51	-11.28	-0.58	4.73e-24	Diabetic kidney disease;
KIRP	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg02319466	chr17:76381040	PGS1	0.48	6.6	0.39	2.48e-10	HDL cholesterol levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20448717	chr6:7542126	DSP	0.49	6.06	0.36	5.06e-9	Parkinson's disease;
KIRP	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg23422044	chr7:1970798	MAD1L1	-0.59	-5.92	-0.35	1.06e-8	Bipolar disorder;
KIRP	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.97	-16.58	-0.73	5.97e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1010254	0.559	rs114309942	chr5:151743915	G/A	cg12297329	chr5:152029980	NA	-0.66	-6.75	-0.4	1.09e-10	Optic nerve measurement (cup area);
KIRP	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.44	-5.07	-0.31	7.81e-7	Pubertal anthropometrics;
KIRP	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.29	-0.32	2.7e-7	Primary biliary cholangitis;
KIRP	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.49e-13	Life satisfaction;
KIRP	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg26084005	chr2:241760190	KIF1A	-0.51	-6.81	-0.4	7.36e-11	Urinary metabolites;
KIRP	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg00071950	chr4:10020882	SLC2A9	0.47	6.6	0.39	2.46e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg03235661	chr20:60525775	NA	-0.31	-5.26	-0.32	3.21e-7	Body mass index;
KIRP	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.77	10.33	0.55	5.31e-21	Huntington's disease progression;
KIRP	cis	rs6693295	0.941	rs2361364	chr1:246259375	G/A	cg11798871	chr1:246315928	SMYD3	-0.43	-5.41	-0.33	1.52e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	0.77	7.56	0.43	8.01e-13	Prostate cancer;
KIRP	cis	rs7937612	1.000	rs1373270	chr11:120324080	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.45	-6.51	-0.38	4.28e-10	Intraocular pressure;
KIRP	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg22284058	chr8:142237359	SLC45A4	-0.49	-6.11	-0.36	3.94e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg26068271	chr17:76253126	NA	-0.57	-7.72	-0.44	3e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4979906	1.000	rs4979907	chr10:79451969	C/A	cg07817648	chr10:79422355	NA	-0.5	-5.37	-0.32	1.85e-7	Mortality in heart failure;
KIRP	cis	rs4702718	0.651	rs2930048	chr5:10698569	C/G	cg14521931	chr5:10832172	NA	0.37	5.04	0.31	9.22e-7	Obesity-related traits;
KIRP	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.86	0.35	1.5e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.06	-0.36	5.09e-9	Personality dimensions;
KIRP	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.61	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2694528	0.686	rs7729652	chr5:59872414	A/G	cg11474532	chr5:59995715	DEPDC1B	0.85	6.38	0.38	8.86e-10	Parkinson's disease;
KIRP	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.67	0.34	3.96e-8	Lung cancer;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg25444344	chr7:55639586	VOPP1	0.52	6.56	0.39	3.06e-10	Myopia (pathological);
KIRP	cis	rs6696239	1.000	rs6669236	chr1:227813909	C/T	cg27395484	chr1:227557617	NA	0.44	5.0	0.3	1.09e-6	Height;
KIRP	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg04691961	chr3:161091175	C3orf57	-0.37	-5.35	-0.32	2.05e-7	Kawasaki disease;
KIRP	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.52	-4.85	-0.3	2.16e-6	Narcolepsy;
KIRP	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.88	12.69	0.63	1.01e-28	Coronary artery disease;
KIRP	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.42	8.89	0.49	1.33e-16	Longevity;
KIRP	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg18404041	chr3:52824283	ITIH1	0.37	5.34	0.32	2.13e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13375462	chr13:98795555	FARP1	0.5	6.29	0.37	1.47e-9	Parkinson's disease;
KIRP	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg08847533	chr14:75593920	NEK9	-0.54	-6.4	-0.38	7.88e-10	IgG glycosylation;
KIRP	cis	rs9328573	1.000	rs9920482	chr15:100510477	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.45	-6.39	-0.38	8.29e-10	Urate levels in lean individuals;
KIRP	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg23594656	chr7:65796392	TPST1	0.44	6.04	0.36	5.76e-9	Aortic root size;
KIRP	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.72	-8.53	-0.48	1.49e-15	Diastolic blood pressure;
KIRP	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13047869	chr3:10149882	C3orf24	-0.52	-5.13	-0.31	5.92e-7	Alzheimer's disease;
KIRP	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.47	-6.41	-0.38	7.25e-10	Triglycerides;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15478081	chr4:186103979	KIAA1430	-0.39	-6.26	-0.37	1.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.95	-16.19	-0.72	1.29e-40	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7974425	1.000	rs1472737	chr12:60730415	A/T	cg13532505	chr9:100398470	NCBP1	-0.83	-6.52	-0.38	3.99e-10	Obesity-related traits;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg21422770	chr21:38362632	HLCS	0.48	6.2	0.37	2.42e-9	DNA methylation (variation);
KIRP	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.81	-10.68	-0.56	4.01e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.16	0.61	5.86e-27	Platelet count;
KIRP	trans	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg06521331	chr12:34319734	NA	-0.6	-7.13	-0.41	1.08e-11	Bladder cancer;
KIRP	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.42	-0.33	1.39e-7	Aortic root size;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17014914	chr15:35798749	ATPBD4	0.46	6.51	0.38	4.23e-10	C-reactive protein;
KIRP	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.4	-4.91	-0.3	1.69e-6	Personality dimensions;
KIRP	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.83	10.86	0.57	1.03e-22	Menarche (age at onset);
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg09699651	chr6:150184138	LRP11	0.46	6.03	0.36	5.88e-9	Lung cancer;
KIRP	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	9.77	0.53	2.86e-19	Cognitive test performance;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg08650016	chr11:62359048	TUT1	-0.42	-6.11	-0.36	3.82e-9	Warfarin maintenance dose;
KIRP	cis	rs12249377	0.519	rs10881838	chr10:92590233	A/G	cg14313238	chr10:92632228	RPP30	0.45	5.54	0.33	7.86e-8	White matter microstructure (global fractional anisotropy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25750404	chr12:6579648	VAMP1	0.52	6.12	0.36	3.7e-9	Smoking initiation;
KIRP	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg22117172	chr7:91764530	CYP51A1	0.42	5.94	0.35	9.56e-9	Breast cancer;
KIRP	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg05347473	chr6:146136440	FBXO30	0.6	8.77	0.49	3.12e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.67	-7.56	-0.43	7.9e-13	Adiposity;
KIRP	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.6	7.62	0.44	5.61e-13	Diastolic blood pressure;
KIRP	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.9	-13.19	-0.64	2.18e-30	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07132125	chr11:121323558	SORL1	0.5	6.31	0.37	1.26e-9	Parkinson's disease;
KIRP	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.9	-0.71	1.23e-39	Chronic sinus infection;
KIRP	cis	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.47	6.14	0.36	3.36e-9	Leprosy;
KIRP	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg05802129	chr4:122689817	NA	-0.52	-6.92	-0.4	3.97e-11	Type 2 diabetes;
KIRP	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.08	19.88	0.79	4.46e-53	Testicular germ cell tumor;
KIRP	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg05484376	chr2:27715224	FNDC4	0.38	6.34	0.37	1.08e-9	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14897419	chr10:134121413	STK32C	0.46	6.13	0.36	3.43e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19343871	chr19:48103651	NA	0.53	6.28	0.37	1.54e-9	Smoking initiation;
KIRP	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg01721255	chr8:58191610	C8orf71	0.56	5.87	0.35	1.43e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.75	10.83	0.57	1.35e-22	Bladder cancer;
KIRP	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.76	-0.49	3.24e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.46	6.37	0.38	9.08e-10	Dupuytren's disease;
KIRP	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.54	5.25	0.32	3.24e-7	Alzheimer's disease;
KIRP	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.41	-4.98	-0.3	1.21e-6	Crohn's disease;
KIRP	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.07e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg23750338	chr8:142222470	SLC45A4	0.36	4.93	0.3	1.49e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg20750642	chr13:99100586	FARP1	-0.54	-6.48	-0.38	4.96e-10	Neuroticism;
KIRP	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.71	6.5	0.38	4.42e-10	Methadone dose in opioid dependence;
KIRP	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg14851346	chr12:38532713	NA	-0.4	-4.92	-0.3	1.61e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.49	7.71	0.44	3.05e-13	Schizophrenia;
KIRP	cis	rs55962025	0.686	rs2237007	chr4:3235450	T/C	cg06533319	chr4:3265114	C4orf44	0.41	5.16	0.31	5.09e-7	Parental longevity (mother's age at death);
KIRP	cis	rs629922	0.855	rs542273	chr11:114050631	A/T	cg25009965	chr11:114031120	ZBTB16	0.42	5.74	0.34	2.85e-8	Paneth cell defects in Crohn's disease;
KIRP	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.75	8.72	0.49	4.34e-16	High light scatter reticulocyte count;
KIRP	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs6256	0.932	rs75849294	chr11:13501392	G/A	cg11976911	chr11:13509032	NA	-0.61	-5.17	-0.31	4.79e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.57	-7.61	-0.44	5.66e-13	Total body bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18430465	chr8:116422845	TRPS1	-0.38	-6.03	-0.36	5.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg14673194	chr17:80132900	CCDC57	-0.77	-8.69	-0.48	5.19e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13805052	chr1:2283063	LOC100129534;MORN1	0.55	6.8	0.4	7.8e-11	Interleukin-4 levels;
KIRP	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7566780	0.630	rs6705856	chr2:16698235	C/T	cg09580478	chr2:16689509	NA	0.47	5.28	0.32	2.84e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg21775007	chr8:11205619	TDH	-0.39	-4.85	-0.3	2.19e-6	Triglycerides;
KIRP	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg17108064	chr15:78857060	CHRNA5	0.37	5.41	0.33	1.53e-7	Sudden cardiac arrest;
KIRP	cis	rs244899	0.901	rs173435	chr5:167907217	A/G	cg06604206	chr5:167912465	RARS	-0.55	-7.88	-0.45	1.07e-13	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.57	-9.31	-0.51	7.51e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.73	-8.42	-0.47	3.25e-15	Longevity;Endometriosis;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.44	5.58	0.34	6.39e-8	Longevity;
KIRP	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.98	-13.6	-0.66	8.37e-32	Response to antipsychotic treatment;
KIRP	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.68	-7.58	-0.44	6.87e-13	Body mass index;
KIRP	cis	rs259282	0.538	rs6510270	chr19:33114514	A/G	cg02997394	chr19:33096574	ANKRD27	-0.5	-5.05	-0.31	8.62e-7	Schizophrenia;
KIRP	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.92	-12.49	-0.62	4.65e-28	Cognitive function;
KIRP	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08439880	chr3:133502540	NA	-0.56	-6.89	-0.4	4.7e-11	Iron status biomarkers;
KIRP	cis	rs2075064	0.900	rs7035028	chr9:126789000	C/T	cg14112217	chr9:126806003	NA	0.37	5.29	0.32	2.68e-7	Waist circumference;
KIRP	cis	rs749052	0.520	rs56808819	chr2:233263697	C/T	cg02061626	chr2:233274167	ALPPL2	0.86	4.88	0.3	1.88e-6	Height;
KIRP	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg21747090	chr2:27597821	SNX17	-0.49	-6.68	-0.39	1.59e-10	Total body bone mineral density;
KIRP	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg00079375	chr15:79125835	NA	0.38	5.52	0.33	8.78e-8	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.26e-23	Prudent dietary pattern;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.38	0.47	4.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11203032	0.901	rs4073283	chr10:90958000	G/C	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-0.83	-14.28	-0.67	4.36e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg19507638	chr5:93509721	C5orf36	-0.61	-5.59	-0.34	6.09e-8	Diabetic retinopathy;
KIRP	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg03128534	chr1:43423976	SLC2A1	0.54	4.93	0.3	1.51e-6	Monocyte count;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08917092	chr7:16566261	NA	0.48	6.09	0.36	4.34e-9	Interleukin-4 levels;
KIRP	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg00852783	chr1:26633632	UBXN11	-0.54	-5.38	-0.32	1.77e-7	Obesity-related traits;
KIRP	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.18	-16.24	-0.72	8.32e-41	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs10803016	1.000	rs6663013	chr1:242276117	A/G	cg23840812	chr1:242252992	PLD5	0.39	5.0	0.3	1.1e-6	Coronary artery calcification;
KIRP	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.51	-6.68	-0.39	1.59e-10	Total body bone mineral density;
KIRP	trans	rs12517041	0.938	rs16892305	chr5:23267355	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.58	-6.17	-0.37	2.81e-9	Calcium levels;
KIRP	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.63	9.29	0.51	8.52e-18	Hip circumference;
KIRP	cis	rs9649213	0.555	rs6948346	chr7:97959956	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.67	0.34	4.06e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.42	5.64	0.34	4.65e-8	Childhood ear infection;
KIRP	trans	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg20506550	chr10:7452815	SFMBT2	0.46	6.59	0.39	2.59e-10	Caffeine consumption;
KIRP	cis	rs55962025	0.883	rs82334	chr4:3225371	A/C	cg06533319	chr4:3265114	C4orf44	0.45	5.14	0.31	5.47e-7	Parental longevity (mother's age at death);
KIRP	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs472402	0.623	rs8192133	chr5:6636645	A/G	cg08700190	chr5:6636046	SRD5A1	-0.48	-6.08	-0.36	4.56e-9	Response to amphetamines;
KIRP	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	15.18	0.7	3.63e-37	Platelet count;
KIRP	cis	rs8177876	0.822	rs9923732	chr16:81110903	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs28834970	0.675	rs6557994	chr8:27232018	A/G	cg18234130	chr8:27182889	PTK2B	-0.47	-5.63	-0.34	4.78e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs4409675	1.000	rs6676158	chr1:28257209	A/G	cg23691781	chr1:28212827	C1orf38	-0.34	-7.3	-0.42	3.98e-12	Corneal astigmatism;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg14054467	chr9:37511793	FBXO10	1.13	6.44	0.38	6.31e-10	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs10266483	0.921	rs624257	chr7:63745226	A/G	cg04636841	chr7:63768139	NA	0.38	5.03	0.31	9.29e-7	Response to statin therapy;
KIRP	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg21138405	chr5:131827807	IRF1	-0.25	-5.61	-0.34	5.42e-8	Asthma;
KIRP	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.58	-5.61	-0.34	5.31e-8	Narcolepsy;
KIRP	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg02975922	chr3:195473998	MUC4	-0.57	-6.45	-0.38	5.99e-10	Pancreatic cancer;
KIRP	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.43	0.47	2.92e-15	Personality dimensions;
KIRP	cis	rs1364705	1.000	rs61600037	chr8:120225613	T/C	cg09273054	chr8:120220131	MAL2	0.5	5.97	0.36	8.08e-9	Hippocampal atrophy;
KIRP	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.2	-0.31	4.12e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	6.19	0.37	2.53e-9	Neuroticism;
KIRP	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.6	0.34	5.85e-8	Putamen volume;
KIRP	cis	rs6662572	0.737	rs6700322	chr1:46409176	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.68	-0.34	3.82e-8	Blood protein levels;
KIRP	cis	rs860295	0.812	rs12081192	chr1:155738044	A/G	cg02153340	chr1:155202674	NA	-0.41	-5.59	-0.34	6.13e-8	Body mass index;
KIRP	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg27205649	chr11:78285834	NARS2	-0.63	-7.47	-0.43	1.42e-12	Alzheimer's disease (survival time);
KIRP	cis	rs16857609	0.628	rs12475467	chr2:218357382	A/G	cg15335768	chr2:218268053	DIRC3	-0.34	-4.97	-0.3	1.24e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.95	-0.4	3.35e-11	Morning vs. evening chronotype;
KIRP	cis	rs2063714	1.000	rs2063714	chr6:157195980	C/G	cg23222435	chr6:157204239	ARID1B	-0.47	-6.99	-0.41	2.6e-11	Sitting height ratio;
KIRP	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.62	0.44	5.57e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.82	12.21	0.61	4.2e-27	IgG glycosylation;
KIRP	cis	rs6466055	0.661	rs7780006	chr7:104936469	C/T	cg04380332	chr7:105027541	SRPK2	0.35	4.91	0.3	1.65e-6	Schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg13701083	chr2:48338530	NA	-0.44	-6.06	-0.36	4.95e-9	Metabolic traits;
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.51	-0.38	4.2e-10	Lung cancer;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs259842	0.612	rs13407401	chr2:180715706	T/A	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.01	-0.3	1.03e-6	Blood protein levels;
KIRP	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.64	8.43	0.47	3.02e-15	Prudent dietary pattern;
KIRP	cis	rs8067287	0.708	rs55635506	chr17:16838685	G/A	cg26910001	chr17:16838321	NA	-0.62	-5.94	-0.35	9.68e-9	Diabetic kidney disease;
KIRP	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.62	-5.73	-0.34	2.88e-8	Schizophrenia;
KIRP	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg17333051	chr19:2783644	SGTA	0.41	5.31	0.32	2.43e-7	Total cholesterol levels;
KIRP	cis	rs2384207	0.584	rs16942754	chr12:113766291	T/C	cg13296563	chr12:112847257	RPL6	-0.6	-4.92	-0.3	1.61e-6	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg26174226	chr8:58114915	NA	-0.54	-6.47	-0.38	5.31e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs2288912	0.838	rs7251503	chr19:45455715	C/G	cg20090143	chr19:45452003	APOC2	0.34	5.47	0.33	1.12e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg13318129	chr22:45737514	FAM118A	0.53	6.57	0.39	3.03e-10	Tonsillectomy;
KIRP	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.3	-0.32	2.53e-7	Iron status biomarkers;
KIRP	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg09699651	chr6:150184138	LRP11	-0.44	-5.77	-0.35	2.42e-8	Lung cancer;
KIRP	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.9	-14.5	-0.68	7.34e-35	Dental caries;
KIRP	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg26752003	chr8:145688521	CYHR1	-0.56	-6.64	-0.39	2.03e-10	Age at first birth;
KIRP	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.47	5.93	0.35	9.99e-9	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs9938149	0.736	rs7501109	chr16:88320862	C/G	cg05435882	chr16:88311214	NA	0.49	5.95	0.35	9.26e-9	Corneal structure;Central corneal thickness;
KIRP	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg21775007	chr8:11205619	TDH	-0.46	-5.97	-0.36	8.13e-9	Systemic lupus erythematosus;
KIRP	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg12560992	chr17:57184187	TRIM37	0.61	5.47	0.33	1.11e-7	Cognitive test performance;
KIRP	cis	rs4262150	0.883	rs12659802	chr5:152274478	A/G	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.93e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.11	-0.31	6.61e-7	Pulmonary function;
KIRP	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-5.13	-0.31	5.75e-7	Joint mobility (Beighton score);
KIRP	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.52	6.93	0.4	3.64e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs6840360	0.642	rs1470280	chr4:152431770	C/T	cg25486957	chr4:152246857	NA	-0.41	-4.85	-0.3	2.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-9.34	-0.51	6.05e-18	Coronary artery disease;
KIRP	cis	rs1656402	0.906	rs1190436	chr2:233424096	G/A	cg03852847	chr2:233439513	NA	0.7	11.53	0.59	6.86e-25	Non-small cell lung cancer (survival);
KIRP	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.63e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs147766666	1	rs147766666	chr16:67829763	TAAAC/T	cg04539111	chr16:67997858	SLC12A4	-0.63	-5.64	-0.34	4.72e-8	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg06565975	chr8:143823917	SLURP1	0.47	7.39	0.43	2.23e-12	Urinary tract infection frequency;
KIRP	trans	rs8102137	0.550	rs34331990	chr19:30321561	A/C	cg21937244	chr14:103406412	CDC42BPB	-0.42	-6.29	-0.37	1.42e-9	Bladder cancer;
KIRP	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg23127183	chr11:57508653	C11orf31	0.51	6.61	0.39	2.36e-10	Schizophrenia;
KIRP	cis	rs3736485	0.934	rs12442803	chr15:51898754	C/G	cg14296394	chr15:51910925	DMXL2	-0.36	-5.41	-0.33	1.47e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.45	5.45	0.33	1.23e-7	Longevity;
KIRP	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.54	6.09	0.36	4.21e-9	Blood metabolite levels;
KIRP	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-7.54	-0.43	8.85e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg14458575	chr2:238380390	NA	0.5	5.64	0.34	4.6e-8	Prostate cancer;
KIRP	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg03970086	chr16:88974840	CBFA2T3	0.45	5.9	0.35	1.22e-8	Social autistic-like traits;
KIRP	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg12181417	chr19:49337499	HSD17B14	-0.47	-5.06	-0.31	8.06e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4594175	0.926	rs7160948	chr14:51612537	T/A	cg23942311	chr14:51606299	NA	0.51	6.75	0.4	1.04e-10	Cancer;
KIRP	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.75	9.09	0.5	3.32e-17	Smoking behavior;
KIRP	cis	rs258892	0.895	rs465388	chr5:72135899	C/T	cg21869765	chr5:72125136	TNPO1	0.6	6.53	0.38	3.76e-10	Small cell lung carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03357260	chr4:40631775	RBM47	0.5	6.27	0.37	1.57e-9	Parkinson's disease;
KIRP	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.18	-15.92	-0.71	1.08e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg09455208	chr3:40491958	NA	-0.31	-5.23	-0.32	3.57e-7	Renal cell carcinoma;
KIRP	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg23594656	chr7:65796392	TPST1	0.39	5.69	0.34	3.6e-8	Aortic root size;
KIRP	cis	rs988913	0.813	rs1566723	chr6:54777833	G/A	cg03513858	chr6:54763001	FAM83B	-0.36	-5.27	-0.32	3.04e-7	Menarche (age at onset);
KIRP	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg06558623	chr16:89946397	TCF25	1.11	7.86	0.45	1.19e-13	Skin colour saturation;
KIRP	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg02023728	chr11:77925099	USP35	-0.31	-5.05	-0.31	8.68e-7	Alzheimer's disease (survival time);
KIRP	cis	rs16828019	0.852	rs3820090	chr1:41573652	A/G	cg03387723	chr1:41708464	SCMH1	-0.78	-6.68	-0.39	1.55e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	1.14	20.33	0.79	1.36e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.74	-9.38	-0.51	4.43e-18	Aortic root size;
KIRP	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.86	0.45	1.2e-13	Neuroticism;
KIRP	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.89	14.2	0.67	7.98e-34	Height;
KIRP	cis	rs2929278	0.562	rs8033846	chr15:44035363	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.51	-6.27	-0.37	1.58e-9	Schizophrenia;
KIRP	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg21427119	chr20:30132790	HM13	-0.5	-5.51	-0.33	8.99e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs76917914	0.820	rs55978131	chr9:100813404	G/A	cg03040243	chr9:100819229	NANS	0.62	6.42	0.38	7.16e-10	Immature fraction of reticulocytes;
KIRP	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg21605333	chr4:119757512	SEC24D	1.63	12.03	0.61	1.62e-26	Cannabis dependence symptom count;
KIRP	cis	rs933360	0.585	rs7785914	chr7:50833576	T/C	cg14240098	chr7:50518052	FIGNL1	0.43	4.92	0.3	1.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs55871839	0.598	rs4737525	chr8:59799781	G/A	cg07426533	chr8:59803705	TOX	-0.51	-8.78	-0.49	2.9e-16	Pneumonia;
KIRP	cis	rs2224391	0.554	rs928170	chr6:5255154	C/T	cg13962347	chr6:5174647	LYRM4	-0.73	-10.27	-0.55	8e-21	Height;
KIRP	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg05621596	chr22:47072043	GRAMD4	-0.73	-9.13	-0.5	2.6e-17	Urate levels in obese individuals;
KIRP	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg23719950	chr11:63933701	MACROD1	-0.68	-6.58	-0.39	2.79e-10	Mean platelet volume;
KIRP	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg00990874	chr7:1149470	C7orf50	-0.48	-5.23	-0.32	3.69e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.56	-6.3	-0.37	1.34e-9	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	1.07	15.87	0.71	1.52e-39	Menopause (age at onset);
KIRP	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg15320075	chr8:145703422	NA	0.69	9.19	0.51	1.66e-17	Age at first birth;
KIRP	cis	rs6977940	0.512	rs11765726	chr7:2850878	A/G	cg19731401	chr7:2775893	GNA12	0.64	5.92	0.35	1.07e-8	White matter integrity;
KIRP	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg24315340	chr6:146058215	EPM2A	0.45	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg11764359	chr7:65958608	NA	-0.75	-4.86	-0.3	2.11e-6	Gout;
KIRP	cis	rs1497828	1.000	rs2810767	chr1:217564937	T/C	cg04411442	chr1:217543379	NA	0.42	6.43	0.38	6.41e-10	Dialysis-related mortality;
KIRP	cis	rs4851254	0.961	rs13019618	chr2:100753963	G/T	cg17356467	chr2:100759845	AFF3	0.55	6.84	0.4	6.28e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3736485	0.932	rs8037167	chr15:51918126	G/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.29e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.32	5.03	0.31	9.64e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.53	-5.64	-0.34	4.65e-8	Total cholesterol levels;
KIRP	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.98	12.84	0.63	3.27e-29	Homoarginine levels;
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg04369109	chr6:150039330	LATS1	-0.46	-5.67	-0.34	4.09e-8	Lung cancer;
KIRP	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08989290	chr16:615782	NHLRC4	0.43	6.45	0.38	5.96e-10	Height;
KIRP	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.3	-0.37	1.34e-9	Breast cancer;
KIRP	cis	rs6834538	0.597	rs9991830	chr4:113485372	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.45	5.58	0.33	6.45e-8	Free thyroxine concentration;
KIRP	cis	rs7924005	0.543	rs71479758	chr10:6177894	A/G	cg17191567	chr10:6178319	NA	-0.52	-6.57	-0.39	2.98e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.74	0.39	1.1e-10	Bipolar disorder;
KIRP	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg01666796	chr15:70364327	TLE3	-0.54	-4.87	-0.3	1.97e-6	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs7546668	1.000	rs4646100	chr1:15820041	C/T	cg21858823	chr1:15850916	CASP9	0.46	5.1	0.31	6.64e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09417640	chr7:99723162	MBLAC1	0.53	6.47	0.38	5.17e-10	Menopause (age at onset);
KIRP	trans	rs994014	0.691	rs7698086	chr4:82271775	G/A	cg04076444	chr16:85646805	KIAA0182	0.53	6.36	0.38	9.88e-10	Height;
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg11062466	chr8:58055876	NA	0.57	4.99	0.3	1.14e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg24060327	chr5:131705240	SLC22A5	0.47	5.24	0.32	3.43e-7	Breast cancer;Mosquito bite size;
KIRP	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.82	8.19	0.46	1.44e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg23649088	chr2:200775458	C2orf69	0.68	5.95	0.35	9.33e-9	Schizophrenia;
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.71	8.92	0.49	1.09e-16	Longevity;
KIRP	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.71	9.7	0.53	4.84e-19	Bladder cancer;
KIRP	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg03468072	chr12:39539422	NA	0.33	4.86	0.3	2.13e-6	Morning vs. evening chronotype;
KIRP	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg21475434	chr5:93447410	FAM172A	0.43	4.93	0.3	1.53e-6	Diabetic retinopathy;
KIRP	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs78487399	0.614	rs77061610	chr2:43659970	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-5.07	-0.31	7.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.72	7.95	0.45	6.85e-14	Corneal astigmatism;
KIRP	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-5.86	-0.35	1.52e-8	Chronic sinus infection;
KIRP	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg06307176	chr5:131281290	NA	0.56	6.37	0.38	9.09e-10	Life satisfaction;
KIRP	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.48	6.63	0.39	2.1e-10	Mean corpuscular volume;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11824764	chr17:78812487	RPTOR	0.45	6.05	0.36	5.37e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.85	0.81	1.53e-59	Prudent dietary pattern;
KIRP	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	trans	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.72	9.11	0.5	2.89e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11874712	1.000	rs11872985	chr18:43686578	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.39	-5.28	-0.32	2.89e-7	Migraine - clinic-based;
KIRP	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.77e-14	Coffee consumption (cups per day);
KIRP	cis	rs7116495	0.748	rs481355	chr11:71578356	G/A	cg11196788	chr11:71737549	NUMA1	-0.5	-4.95	-0.3	1.36e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.5	6.05	0.36	5.22e-9	Glycated hemoglobin levels;
KIRP	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.27	-0.51	9.88e-18	Chronic sinus infection;
KIRP	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg16606324	chr3:10149918	C3orf24	0.68	5.77	0.35	2.4e-8	Alzheimer's disease;
KIRP	cis	rs45544231	0.569	rs9923558	chr16:52548183	A/T	cg09051775	chr16:52580266	TOX3	-0.36	-5.01	-0.3	1.02e-6	Restless legs syndrome;
KIRP	cis	rs10411936	0.692	rs3810196	chr19:16601154	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.46	5.11	0.31	6.32e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg05484376	chr2:27715224	FNDC4	0.37	6.18	0.37	2.69e-9	Total body bone mineral density;
KIRP	cis	rs3105593	0.547	rs3131559	chr15:50780214	C/A	cg08437265	chr15:50716283	USP8	0.42	5.63	0.34	4.88e-8	QT interval;
KIRP	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-7.22	-0.42	6.54e-12	Common traits (Other);
KIRP	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg23307798	chr14:103986281	CKB	-0.43	-5.9	-0.35	1.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg10253484	chr15:75165896	SCAMP2	0.6	7.25	0.42	5.36e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.73	9.67	0.52	5.75e-19	Coronary artery disease;
KIRP	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg17595323	chr11:93583763	C11orf90	-0.39	-6.49	-0.38	4.67e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg22437258	chr11:111473054	SIK2	0.63	7.68	0.44	3.81e-13	Primary sclerosing cholangitis;
KIRP	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.61	-8.63	-0.48	8e-16	Colorectal cancer;
KIRP	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg05784532	chr1:230284198	GALNT2	0.47	7.32	0.42	3.51e-12	Coronary artery disease;
KIRP	cis	rs71277158	0.688	rs16854875	chr3:169899667	T/G	cg04067573	chr3:169899625	PHC3	0.7	6.56	0.39	3.11e-10	Prostate cancer;
KIRP	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg05484376	chr2:27715224	FNDC4	0.41	6.76	0.4	1.01e-10	Total body bone mineral density;
KIRP	cis	rs9840812	0.535	rs695983	chr3:136064547	C/T	cg15507776	chr3:136538369	TMEM22	0.46	6.01	0.36	6.54e-9	Fibrinogen levels;
KIRP	cis	rs2273669	0.915	rs2145766	chr6:109296261	G/C	cg05315195	chr6:109294784	ARMC2	-0.49	-5.59	-0.34	6.1e-8	Prostate cancer;
KIRP	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg15605315	chr1:45957053	TESK2	-0.49	-6.02	-0.36	6.47e-9	High light scatter reticulocyte count;
KIRP	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg05887092	chr17:76393375	PGS1	0.53	7.42	0.43	1.92e-12	HDL cholesterol levels;
KIRP	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.73	-9.37	-0.51	4.92e-18	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.82	8.83	0.49	2.03e-16	Prostate cancer;
KIRP	cis	rs9644630	0.901	rs13276417	chr8:19350199	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.39	-5.28	-0.32	2.91e-7	Oropharynx cancer;
KIRP	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.74	-8.55	-0.48	1.34e-15	High light scatter reticulocyte count;
KIRP	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg27205649	chr11:78285834	NARS2	-0.68	-7.81	-0.45	1.68e-13	Alzheimer's disease (survival time);
KIRP	cis	rs1014246	0.848	rs2420330	chr10:118457481	C/T	cg14919929	chr10:118506882	NA	0.7	9.48	0.52	2.31e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs1364705	1.000	rs12682591	chr8:120282455	T/C	cg09273054	chr8:120220131	MAL2	0.52	6.1	0.36	4.09e-9	Hippocampal atrophy;
KIRP	cis	rs2882667	0.658	rs311592	chr5:138070195	T/C	cg04439458	chr5:138467593	SIL1	-0.33	-4.85	-0.3	2.2e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.51	-7.48	-0.43	1.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1468333	1.000	rs62381795	chr5:137577870	G/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	5.13	0.31	5.81e-7	Resting heart rate;
KIRP	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg16989719	chr2:238392110	NA	-0.55	-7.32	-0.42	3.54e-12	Prostate cancer;
KIRP	cis	rs9815354	0.812	rs17284313	chr3:41986787	G/T	cg03022575	chr3:42003672	ULK4	-0.81	-8.41	-0.47	3.27e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg05347473	chr6:146136440	FBXO30	0.47	6.79	0.4	8.31e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg08992911	chr2:238395768	MLPH	0.46	5.74	0.34	2.83e-8	Prostate cancer;
KIRP	cis	rs8018808	0.935	rs2364156	chr14:77916746	G/A	cg18872420	chr14:78023429	SPTLC2	0.37	5.41	0.33	1.49e-7	Myeloid white cell count;
KIRP	cis	rs7173389	0.867	rs74022964	chr15:73677264	C/T	cg01796676	chr15:73680284	NA	0.52	5.22	0.32	3.75e-7	Resting heart rate;
KIRP	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg01270228	chr10:1369114	ADARB2	0.44	5.57	0.33	6.53e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg10207240	chr12:122356781	WDR66	0.61	8.06	0.46	3.36e-14	Mean corpuscular volume;
KIRP	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg18404041	chr3:52824283	ITIH1	-0.44	-5.3	-0.32	2.55e-7	Schizophrenia;
KIRP	cis	rs3784262	0.669	rs12914455	chr15:58312096	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-5.07	-0.31	7.88e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs741951	0.635	rs235323	chr21:46278047	G/C	cg08823554	chr21:46269191	NA	-0.62	-5.34	-0.32	2.09e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg19680485	chr15:31195859	MTMR15	-0.39	-4.96	-0.3	1.3e-6	Huntington's disease progression;
KIRP	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	0.93	10.93	0.57	6.22e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.75	11.03	0.58	3.04e-23	Schizophrenia;
KIRP	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.4	5.15	0.31	5.24e-7	Birth weight;
KIRP	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	1.03	14.19	0.67	8.7e-34	Neutrophil percentage of white cells;
KIRP	cis	rs7011049	1.000	rs72643600	chr8:53854530	T/G	cg26025543	chr8:53854495	NA	0.75	7.78	0.44	2.06e-13	Systolic blood pressure;
KIRP	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	1.05	19.0	0.77	3.6e-50	Monocyte count;
KIRP	cis	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	5.29	0.32	2.71e-7	Recombination measurement;
KIRP	trans	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17183009	chr3:120277827	NA	0.52	6.06	0.36	5.2e-9	Corneal astigmatism;
KIRP	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg13256891	chr4:100009986	ADH5	0.5	6.13	0.36	3.5e-9	Alcohol dependence;
KIRP	cis	rs9488822	0.651	rs36061333	chr6:116311763	C/G	cg15226275	chr6:116381976	FRK	0.27	5.34	0.32	2.09e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg07884673	chr3:53033167	SFMBT1	0.81	6.35	0.38	1.02e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.75	9.86	0.53	1.5e-19	Menarche (age at onset);
KIRP	cis	rs6484504	0.576	rs158146	chr11:31210433	G/A	cg26647111	chr11:31128758	NA	-0.43	-5.13	-0.31	5.81e-7	Red blood cell count;
KIRP	cis	rs8141529	0.529	rs5762767	chr22:29141241	C/T	cg02153584	chr22:29168773	CCDC117	0.54	4.86	0.3	2.12e-6	Lymphocyte counts;
KIRP	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg15660573	chr17:549704	VPS53	-0.94	-15.18	-0.7	3.62e-37	Prostate cancer;
KIRP	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.65	-7.86	-0.45	1.22e-13	Bipolar disorder;
KIRP	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg17328964	chr8:145687451	CYHR1	-0.55	-7.07	-0.41	1.64e-11	Age at first birth;
KIRP	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.07	-7.81	-0.45	1.62e-13	Mitochondrial DNA levels;
KIRP	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg05340658	chr4:99064831	C4orf37	0.66	8.58	0.48	1.09e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.46	-5.49	-0.33	1e-7	Schizophrenia;
KIRP	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.14	-16.15	-0.72	1.68e-40	Lymphocyte percentage of white cells;
KIRP	trans	rs1973993	0.708	rs6593605	chr1:96956775	A/G	cg10631902	chr5:14652156	NA	-0.57	-8.18	-0.46	1.52e-14	Weight;
KIRP	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg13409248	chr3:40428643	ENTPD3	-0.39	-5.48	-0.33	1.06e-7	Renal cell carcinoma;
KIRP	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg00852783	chr1:26633632	UBXN11	-0.52	-5.57	-0.33	6.55e-8	Obesity-related traits;
KIRP	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.43	-0.38	6.64e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10982256	0.567	rs1000709	chr9:117237754	C/T	cg13636371	chr9:117264095	DFNB31	0.53	7.28	0.42	4.55e-12	Bipolar disorder;
KIRP	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs9603616	1.000	rs12872801	chr13:40354200	C/T	cg26701198	chr13:40229707	COG6	-0.46	-5.08	-0.31	7.36e-7	Rheumatoid arthritis;
KIRP	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.56	-11.93	-0.61	3.47e-26	Diabetic kidney disease;
KIRP	cis	rs2997447	0.706	rs2783713	chr1:26429351	C/A	cg19633962	chr1:26362018	EXTL1	-0.56	-5.6	-0.34	5.63e-8	QRS complex (12-leadsum);
KIRP	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg03060546	chr3:49711283	APEH	0.44	5.8	0.35	2.04e-8	Parkinson's disease;
KIRP	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg27490568	chr2:178487706	NA	0.76	10.16	0.54	1.82e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg03115019	chr17:80708279	FN3K	0.42	5.03	0.31	9.3e-7	Glycated hemoglobin levels;
KIRP	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.51	7.15	0.41	9.79e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs554111	0.660	rs667687	chr1:21072577	A/G	cg21184320	chr1:21044207	KIF17	0.37	5.48	0.33	1.06e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2377585	0.653	rs34187657	chr12:8844413	G/C	cg03761649	chr12:8850719	RIMKLB	0.51	5.05	0.31	8.52e-7	Reticulocyte fraction of red cells;
KIRP	trans	rs28595532	0.702	rs55981733	chr4:119306600	G/A	cg26518628	chr1:97050305	NA	-0.81	-6.13	-0.36	3.52e-9	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.52	-4.86	-0.3	2.06e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4345220	0.585	rs4861123	chr4:41642833	A/G	cg15232654	chr4:41643107	LIMCH1	0.42	5.35	0.32	2.04e-7	Migraine with aura;
KIRP	cis	rs16828019	0.789	rs36084778	chr1:41479538	A/G	cg18742814	chr1:41828276	NA	0.62	5.51	0.33	9.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.84	11.91	0.6	3.96e-26	Mean platelet volume;
KIRP	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-5.76	-0.34	2.55e-8	Lung cancer;
KIRP	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.81	11.77	0.6	1.15e-25	Blood metabolite ratios;
KIRP	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.19	23.7	0.83	1.85e-65	Schizophrenia;
KIRP	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg13092806	chr2:177043255	NA	0.68	7.14	0.41	1.03e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs2120243	0.508	rs1965246	chr3:157111586	G/A	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.88	-0.3	1.89e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg24169773	chr3:122142474	KPNA1	-0.58	-6.43	-0.38	6.7e-10	LDL cholesterol levels;
KIRP	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg17554472	chr22:41940697	POLR3H	-0.42	-5.16	-0.31	5.08e-7	Vitiligo;
KIRP	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.6	8.0	0.45	4.82e-14	Lung cancer;
KIRP	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.61	-7.7	-0.44	3.27e-13	Homocysteine levels;
KIRP	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs17384381	1.000	rs12118950	chr1:85864519	T/C	cg16011679	chr1:85725395	C1orf52	0.84	8.39	0.47	3.93e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs76917914	0.589	rs12552242	chr9:100866201	A/C	cg03040243	chr9:100819229	NANS	0.46	4.85	0.3	2.15e-6	Immature fraction of reticulocytes;
KIRP	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05025164	chr4:1340916	KIAA1530	0.4	5.12	0.31	6.15e-7	Obesity-related traits;
KIRP	cis	rs1971762	0.527	rs7300936	chr12:54030586	C/T	cg16917193	chr12:54089295	NA	0.86	14.98	0.69	1.69e-36	Height;
KIRP	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.46	-6.87	-0.4	5.37e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.64	8.29	0.47	7.35e-15	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.88	-0.3	1.87e-6	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08977639	chr16:1047820	NA	0.47	6.62	0.39	2.26e-10	Smoking initiation;
KIRP	cis	rs3755132	0.929	rs41264163	chr2:15763788	C/T	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg23024343	chr7:107201750	COG5	0.4	4.9	0.3	1.74e-6	Coronary artery disease;
KIRP	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.82	9.82	0.53	2.06e-19	Gestational age at birth (maternal effect);
KIRP	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.66	9.15	0.5	2.17e-17	Lymphocyte counts;
KIRP	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg11906718	chr8:101322791	RNF19A	-0.49	-6.5	-0.38	4.48e-10	Atrioventricular conduction;
KIRP	cis	rs9815354	1.000	rs3934103	chr3:41977214	C/T	cg03022575	chr3:42003672	ULK4	-0.57	-6.68	-0.39	1.6e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg15247329	chr7:2764246	NA	-0.36	-5.1	-0.31	6.86e-7	Height;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.84	-14.93	-0.69	2.46e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.38	0.38	8.76e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4713675	0.546	rs9348925	chr6:33710696	C/T	cg15676125	chr6:33679581	C6orf125	0.42	5.28	0.32	2.87e-7	Plateletcrit;
KIRP	cis	rs57590327	0.503	rs9880844	chr3:81507217	C/T	cg07356753	chr3:81810745	GBE1	0.49	6.19	0.37	2.46e-9	Extraversion;
KIRP	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg13731523	chr4:3047190	NA	-0.39	-6.29	-0.37	1.42e-9	Serum sulfate level;
KIRP	cis	rs7945718	0.905	rs4454698	chr11:12720560	A/G	cg25843174	chr11:12811716	TEAD1	-0.35	-6.54	-0.38	3.48e-10	Educational attainment (years of education);
KIRP	cis	rs6690583	1.000	rs6690583	chr1:85466337	A/G	cg22153463	chr1:85462885	MCOLN2	-0.68	-7.73	-0.44	2.75e-13	Serum sulfate level;
KIRP	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg01320130	chr1:67600311	NA	0.43	5.45	0.33	1.22e-7	Psoriasis;
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.51	5.22	0.32	3.72e-7	Alzheimer's disease;
KIRP	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg23594656	chr7:65796392	TPST1	-0.47	-7.45	-0.43	1.57e-12	Aortic root size;
KIRP	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.74	-9.09	-0.5	3.45e-17	Urate levels in obese individuals;
KIRP	trans	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.86	0.49	1.63e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.7	7.65	0.44	4.65e-13	Corneal astigmatism;
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.84	0.35	1.67e-8	Aortic root size;
KIRP	cis	rs2777491	0.957	rs1757454	chr15:41777934	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-13.39	-0.65	4.43e-31	Ulcerative colitis;
KIRP	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg12658694	chr1:38397304	INPP5B	-0.65	-7.68	-0.44	3.74e-13	Coronary artery disease;
KIRP	cis	rs10073892	0.701	rs28421510	chr5:101652252	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg00204512	chr16:28754710	NA	0.42	5.23	0.32	3.67e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17221829	0.733	rs1962259	chr11:89380637	G/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.87	-0.3	1.98e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg21466736	chr12:48725269	NA	-0.45	-5.73	-0.34	2.98e-8	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.55	-8.55	-0.48	1.36e-15	Personality dimensions;
KIRP	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9318086	0.935	rs9652080	chr13:24435426	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-7.86	-0.45	1.22e-13	Myopia (pathological);
KIRP	cis	rs4141404	0.582	rs5753630	chr22:31861950	A/G	cg02404636	chr22:31891804	SFI1	0.45	5.83	0.35	1.74e-8	Paclitaxel-induced neuropathy;
KIRP	cis	rs1134634	0.520	rs16892140	chr4:15548550	T/C	cg16509355	chr4:15471240	CC2D2A	-0.3	-5.05	-0.31	8.74e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg03128060	chr6:142623767	GPR126	0.35	5.01	0.3	1.06e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12292205	chr6:26970375	C6orf41	-0.69	-7.3	-0.42	3.89e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs258892	0.947	rs266446	chr5:72182030	T/G	cg21869765	chr5:72125136	TNPO1	0.58	6.41	0.38	7.55e-10	Small cell lung carcinoma;
KIRP	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg17554472	chr22:41940697	POLR3H	-0.7	-6.98	-0.41	2.79e-11	Vitiligo;
KIRP	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.44	5.88	0.35	1.35e-8	Blood metabolite levels;
KIRP	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	0.97	11.16	0.58	1.16e-23	Vitiligo;
KIRP	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg02023728	chr11:77925099	USP35	-0.31	-5.18	-0.31	4.51e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.54	-5.06	-0.31	8.18e-7	Other erythrocyte phenotypes;
KIRP	cis	rs17123764	0.710	rs2278068	chr12:49944588	T/C	cg02054252	chr12:50078554	FMNL3	0.43	5.19	0.31	4.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs743757	0.878	rs12494849	chr3:50524558	C/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.51	5.31	0.32	2.5e-7	Diastolic blood pressure;
KIRP	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.63	-6.77	-0.4	9.22e-11	Initial pursuit acceleration;
KIRP	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.74	10.75	0.57	2.32e-22	Hip circumference;
KIRP	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg21475434	chr5:93447410	FAM172A	0.77	6.9	0.4	4.46e-11	Diabetic retinopathy;
KIRP	cis	rs72634258	0.786	rs12563704	chr1:8033837	G/A	cg00042356	chr1:8021962	PARK7	0.53	5.0	0.3	1.07e-6	Inflammatory bowel disease;
KIRP	cis	rs7180079	0.620	rs1976112	chr15:65059220	T/A	cg15337035	chr15:64978493	NA	-0.51	-5.46	-0.33	1.16e-7	Monocyte count;
KIRP	cis	rs1448094	0.717	rs7305873	chr12:86290831	G/C	cg00310523	chr12:86230176	RASSF9	0.41	6.25	0.37	1.75e-9	Major depressive disorder;
KIRP	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.87	-13.51	-0.65	1.77e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11209185	0.563	rs10889735	chr1:68435400	T/C	cg22082780	chr1:68452167	NA	-0.34	-5.22	-0.32	3.76e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg01097406	chr16:89675127	NA	-0.35	-5.56	-0.33	6.87e-8	Hemoglobin concentration;
KIRP	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-8.88	-0.49	1.4e-16	Platelet count;
KIRP	trans	rs17046216	0.965	rs11726415	chr4:166260729	C/T	cg23384093	chr5:170745466	NA	-0.5	-6.18	-0.37	2.67e-9	Insulin-related traits;
KIRP	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24120357	chr5:118691415	TNFAIP8	0.54	6.66	0.39	1.82e-10	Smoking initiation;
KIRP	cis	rs7116495	0.609	rs2276396	chr11:71823905	G/C	cg10381502	chr11:71823885	C11orf51	1.14	7.46	0.43	1.49e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg15691649	chr6:25882328	NA	-0.46	-5.58	-0.34	6.33e-8	Blood metabolite levels;
KIRP	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg00806126	chr19:22604979	ZNF98	0.68	7.14	0.41	1.04e-11	Pain;
KIRP	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	1.01	15.57	0.7	1.68e-38	Chronic sinus infection;
KIRP	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg04657146	chr19:12876947	HOOK2	-0.48	-5.74	-0.34	2.78e-8	Mean corpuscular volume;
KIRP	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg27068330	chr11:65405492	SIPA1	0.42	5.66	0.34	4.29e-8	Acne (severe);
KIRP	cis	rs1215050	0.791	rs1506438	chr4:98789542	C/T	cg05340658	chr4:99064831	C4orf37	0.57	6.87	0.4	5.34e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08106487	chr16:67980202	SLC12A4	0.52	6.29	0.37	1.44e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.68	8.69	0.48	5.13e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.8	-0.49	2.48e-16	Mean corpuscular volume;
KIRP	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg26354017	chr1:205819088	PM20D1	-0.61	-6.08	-0.36	4.51e-9	Menarche (age at onset);
KIRP	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.74	7.7	0.44	3.35e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg05555928	chr11:63887634	MACROD1	0.45	5.21	0.32	4.05e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19668278	chr17:19281621	MAPK7	0.5	6.23	0.37	1.96e-9	Parkinson's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14095283	chr1:230513277	PGBD5	0.44	6.12	0.36	3.74e-9	Survival in pancreatic cancer;
KIRP	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.53e-20	Morning vs. evening chronotype;
KIRP	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg18357526	chr6:26021779	HIST1H4A	0.44	5.34	0.32	2.12e-7	Blood metabolite levels;
KIRP	trans	rs1478898	0.569	rs2249260	chr8:11388714	T/C	cg08975724	chr8:8085496	FLJ10661	-0.57	-6.27	-0.37	1.64e-9	Morning vs. evening chronotype;
KIRP	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.81	0.35	1.88e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7937612	0.965	rs4938801	chr11:120223399	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.61	-0.39	2.31e-10	Intraocular pressure;
KIRP	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg20240347	chr1:204465584	NA	-0.41	-7.82	-0.45	1.58e-13	Schizophrenia;
KIRP	cis	rs904251	0.523	rs1776455	chr6:37482923	A/T	cg08126542	chr6:37504118	NA	-0.82	-12.76	-0.63	6.1e-29	Cognitive performance;
KIRP	trans	rs6851508	0.573	rs309705	chr4:177427340	G/T	cg07610776	chr16:1832675	SPSB3;NUBP2	0.54	6.14	0.36	3.2e-9	Left ventricle wall thickness;
KIRP	cis	rs9430161	0.611	rs12081197	chr1:11034239	T/C	cg02454025	chr1:11042201	C1orf127	0.9	14.42	0.68	1.39e-34	Ewing sarcoma;
KIRP	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg16865965	chr2:85811662	VAMP5	0.34	5.06	0.31	8.05e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00294898	chr3:160939446	NMD3	0.51	6.09	0.36	4.29e-9	Parkinson's disease;
KIRP	cis	rs2072732	0.821	rs10909864	chr1:2948178	T/C	cg11731671	chr1:2995604	PRDM16	-0.4	-5.24	-0.32	3.5e-7	Plateletcrit;
KIRP	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.49	0.48	1.92e-15	Motion sickness;
KIRP	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.53	6.28	0.37	1.55e-9	Coronary artery disease;
KIRP	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.72	9.83	0.53	1.86e-19	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.47	-9.76	-0.53	3.16e-19	Monocyte percentage of white cells;
KIRP	cis	rs427941	0.632	rs201471	chr7:101744145	T/G	cg06246474	chr7:101738831	CUX1	0.53	6.49	0.38	4.6e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs2191566	0.922	rs7245749	chr19:44513932	G/A	cg18700516	chr19:44507157	ZNF230	-0.47	-5.48	-0.33	1.07e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg06935464	chr4:38784597	TLR10	0.57	5.85	0.35	1.59e-8	Breast cancer;
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01114163	chr5:1856713	NA	-0.44	-5.42	-0.33	1.44e-7	Cardiovascular disease risk factors;
KIRP	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg18016565	chr1:150552671	MCL1	-0.35	-5.43	-0.33	1.35e-7	Melanoma;
KIRP	cis	rs56079296	1.000	rs3792801	chr5:121403410	A/G	cg05256605	chr5:121412184	LOX	0.48	5.65	0.34	4.35e-8	Coronary artery disease;
KIRP	cis	rs3779635	0.742	rs11777664	chr8:27244722	A/G	cg07216194	chr8:27182965	PTK2B	0.43	5.27	0.32	2.93e-7	Neuroticism;
KIRP	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-12.33	-0.62	1.66e-27	Cognitive function;
KIRP	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.77	8.85	0.49	1.72e-16	Corneal astigmatism;
KIRP	cis	rs760762	0.506	rs6129760	chr20:39746403	A/G	cg06424997	chr20:39929561	ZHX3	0.38	4.85	0.3	2.14e-6	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
KIRP	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg21184320	chr1:21044207	KIF17	-0.36	-5.41	-0.33	1.53e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg15744005	chr10:104629667	AS3MT	-0.32	-6.32	-0.37	1.19e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.77	11.45	0.59	1.28e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.2	-0.31	4.14e-7	Chronic sinus infection;
KIRP	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.94	-0.4	3.45e-11	Height;
KIRP	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.92	14.05	0.67	2.64e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs79976124	1.000	rs79976124	chr6:66618657	G/A	cg07460842	chr6:66804631	NA	0.76	8.79	0.49	2.63e-16	Type 2 diabetes;
KIRP	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.63	0.39	2.1e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	1.0	17.43	0.74	7.3e-45	Breast cancer;
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	13.9	0.66	7.99e-33	Platelet count;
KIRP	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.76	6.24	0.37	1.87e-9	Inflammatory bowel disease;
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg10254082	chr7:997346	NA	0.48	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7224685	0.569	rs58357241	chr17:3996641	T/C	cg05562828	chr17:3906858	NA	0.52	5.37	0.32	1.83e-7	Type 2 diabetes;
KIRP	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	0.95	17.61	0.75	1.87e-45	Dental caries;
KIRP	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.42	-5.12	-0.31	6.07e-7	Leprosy;
KIRP	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg26513180	chr16:89883248	FANCA	0.79	5.6	0.34	5.64e-8	Skin colour saturation;
KIRP	cis	rs73198271	0.960	rs73198286	chr8:8612022	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-6.37	-0.38	9.07e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg27211696	chr2:191398769	TMEM194B	-0.6	-7.2	-0.42	7.38e-12	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13775310	chr9:114937099	SUSD1	0.47	6.21	0.37	2.26e-9	Parkinson's disease;
KIRP	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg13482628	chr17:19912719	NA	-0.59	-8.41	-0.47	3.3e-15	Schizophrenia;
KIRP	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.9	15.37	0.7	8.32e-38	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs2077654	0.822	rs12280242	chr11:17433737	C/T	cg25308976	chr11:17434268	ABCC8	1.07	10.92	0.57	6.92e-23	Gout;
KIRP	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg13147721	chr7:65941812	NA	1.02	7.1	0.41	1.34e-11	Diabetic kidney disease;
KIRP	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.48	-5.86	-0.35	1.48e-8	Systemic lupus erythematosus;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg07051718	chr19:1438596	RPS15	0.5	6.06	0.36	5.12e-9	Educational attainment;
KIRP	cis	rs7191700	0.836	rs12708722	chr16:11428905	T/A	cg00044050	chr16:11439710	C16orf75	0.47	4.93	0.3	1.49e-6	Multiple sclerosis;
KIRP	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.4	-5.44	-0.33	1.28e-7	IgG glycosylation;
KIRP	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.51	7.18	0.42	8.19e-12	Systemic lupus erythematosus;
KIRP	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg09264619	chr17:80180166	NA	0.36	5.36	0.32	1.94e-7	Life satisfaction;
KIRP	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg13206674	chr6:150067644	NUP43	0.53	7.48	0.43	1.3e-12	Testicular germ cell tumor;
KIRP	cis	rs17209837	1.000	rs4148808	chr7:87105795	T/C	cg00919237	chr7:87102261	ABCB4	-0.68	-7.36	-0.42	2.77e-12	Gallbladder cancer;
KIRP	cis	rs4517514	0.509	rs11018875	chr11:89876356	T/C	cg06174606	chr11:89959870	NA	-0.51	-5.2	-0.31	4.16e-7	Trans fatty acid levels;
KIRP	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs12615966	1.000	rs6543268	chr2:105370105	G/C	cg16465502	chr2:105461796	NA	0.67	6.55	0.39	3.27e-10	Pancreatic cancer;
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.48	6.6	0.39	2.51e-10	Testicular germ cell tumor;
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg05255149	chr17:80675120	FN3KRP	-0.45	-4.86	-0.3	2.08e-6	Glycated hemoglobin levels;
KIRP	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.19	-0.46	1.39e-14	Retinal vascular caliber;
KIRP	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.82	-9.74	-0.53	3.52e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs6191	1.000	rs6191	chr5:142658156	C/A	cg08845721	chr5:142780693	NR3C1	0.37	4.98	0.3	1.21e-6	Night sleep phenotypes;
KIRP	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.44	5.44	0.33	1.3e-7	Common traits (Other);
KIRP	cis	rs55728055	0.661	rs62237773	chr22:31965054	A/G	cg01338084	chr22:32026380	PISD	0.89	5.41	0.33	1.49e-7	Age-related hearing impairment;
KIRP	cis	rs838147	0.844	rs8111288	chr19:49247900	G/A	cg08619932	chr19:49200058	FUT2	-0.36	-5.44	-0.33	1.27e-7	Dietary macronutrient intake;
KIRP	cis	rs921943	1.000	rs7705658	chr5:78315305	A/G	cg26802063	chr5:78281964	ARSB	0.5	6.21	0.37	2.22e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs6684428	0.536	rs6684599	chr1:56392558	G/T	cg11651538	chr1:56320950	NA	-0.56	-7.91	-0.45	8.46e-14	Airflow obstruction;
KIRP	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg26371346	chr8:56986568	SNORD54;RPS20	0.58	5.55	0.33	7.46e-8	Height;
KIRP	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.53	7.14	0.41	1.07e-11	Coronary artery disease;
KIRP	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.7	8.02	0.46	4.38e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17376030	chr22:41985996	PMM1	-0.82	-9.16	-0.5	2.03e-17	Vitiligo;
KIRP	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg04896959	chr15:78267971	NA	0.51	6.68	0.39	1.56e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.27e-15	Motion sickness;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03384915	chr19:16986822	SIN3B	0.5	6.29	0.37	1.41e-9	Interleukin-4 levels;
KIRP	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.66	9.29	0.51	8.66e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.62	-9.54	-0.52	1.45e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg16584676	chr17:46985605	UBE2Z	0.49	6.03	0.36	5.82e-9	Type 2 diabetes;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.79	12.77	0.63	5.37e-29	Menarche (age at onset);
KIRP	cis	rs7937612	1.000	rs10892574	chr11:120288944	G/C	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.14	-0.41	1.05e-11	Intraocular pressure;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13551228	chr9:140727297	EHMT1	-0.45	-6.6	-0.39	2.47e-10	Pancreatic cancer;
KIRP	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg16989719	chr2:238392110	NA	-0.49	-5.95	-0.35	9.04e-9	Prostate cancer;
KIRP	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.07	0.36	4.74e-9	Menopause (age at onset);
KIRP	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.52	-7.96	-0.45	6.54e-14	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24169248	chr11:66247869	DPP3	0.48	6.11	0.36	3.81e-9	Myopia (pathological);
KIRP	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg02887458	chr19:19495540	GATAD2A	0.48	5.8	0.35	1.99e-8	Bipolar disorder;
KIRP	cis	rs1823913	0.637	rs4853582	chr2:192168209	A/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs9549260	0.564	rs6563845	chr13:41318907	A/G	cg21288729	chr13:41239152	FOXO1	0.55	7.18	0.42	8e-12	Red blood cell count;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.88e-7	Life satisfaction;
KIRP	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.56	-7.61	-0.44	6e-13	Systolic blood pressure;
KIRP	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.4	8.19	0.46	1.4e-14	Longevity;
KIRP	cis	rs2046867	0.908	rs62251655	chr3:72821708	T/C	cg25664220	chr3:72788482	NA	-0.49	-7.2	-0.42	7.1e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg03894339	chr8:19674705	INTS10	0.53	6.41	0.38	7.56e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2562456	0.833	rs62110416	chr19:21584726	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.89	-0.3	1.81e-6	Pain;
KIRP	trans	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg06521331	chr12:34319734	NA	-0.52	-6.33	-0.37	1.12e-9	Bladder cancer;
KIRP	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg19847130	chr8:10466454	RP1L1	0.35	5.07	0.31	7.77e-7	Systolic blood pressure;
KIRP	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg05714579	chr10:131428358	MGMT	0.48	6.22	0.37	2.1e-9	Response to temozolomide;
KIRP	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-5.86	-0.35	1.45e-8	Educational attainment;
KIRP	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg00094735	chr5:1949198	NA	-0.46	-5.3	-0.32	2.58e-7	Gut microbiome composition (winter);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07051257	chr19:39897430	ZFP36	0.53	6.53	0.38	3.8e-10	Parkinson's disease;
KIRP	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.52	-6.66	-0.39	1.74e-10	Mortality in heart failure;
KIRP	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.81	10.24	0.55	9.79e-21	Ileal carcinoids;
KIRP	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg02487422	chr3:49467188	NICN1	0.37	5.08	0.31	7.32e-7	Parkinson's disease;
KIRP	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Renal cell carcinoma;
KIRP	cis	rs4728302	0.869	rs7779370	chr7:133595702	T/C	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.53	-7.47	-0.43	1.38e-12	Airway imaging phenotypes;
KIRP	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg10326726	chr10:51549505	MSMB	-0.59	-8.41	-0.47	3.33e-15	Prostate-specific antigen levels;
KIRP	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18252515	chr7:66147081	NA	0.46	5.23	0.32	3.55e-7	Aortic root size;
KIRP	cis	rs42648	0.837	rs3761804	chr7:89915338	C/T	cg25739043	chr7:89950458	NA	-0.39	-5.94	-0.35	9.88e-9	Homocysteine levels;
KIRP	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.42	6.7	0.39	1.4e-10	Type 2 diabetes;
KIRP	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.87	12.11	0.61	8.55e-27	Total body bone mineral density;
KIRP	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg00852783	chr1:26633632	UBXN11	-0.53	-5.41	-0.33	1.5e-7	Obesity-related traits;
KIRP	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.62	-8.0	-0.45	4.91e-14	Prudent dietary pattern;
KIRP	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg20469991	chr17:27169893	C17orf63	-0.5	-5.08	-0.31	7.33e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.87	9.04	0.5	4.85e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.3	-0.72	5.51e-41	Height;
KIRP	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg16141378	chr3:129829833	LOC729375	0.52	6.71	0.39	1.34e-10	Retinal vascular caliber;
KIRP	cis	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.4	5.18	0.31	4.58e-7	Leprosy;
KIRP	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.74	-10.24	-0.55	9.8e-21	Caffeine consumption;
KIRP	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	0.6	9.06	0.5	4.08e-17	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs16958440	0.521	rs16950323	chr18:44577327	G/A	cg17192377	chr18:44677553	HDHD2	0.52	5.23	0.32	3.7e-7	Sitting height ratio;
KIRP	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg05802129	chr4:122689817	NA	-0.58	-7.42	-0.43	1.96e-12	Type 2 diabetes;
KIRP	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	1.03	13.24	0.65	1.42e-30	Exhaled nitric oxide output;
KIRP	cis	rs988913	0.634	rs9464182	chr6:54921938	A/G	cg03513858	chr6:54763001	FAM83B	-0.35	-4.87	-0.3	2.03e-6	Menarche (age at onset);
KIRP	cis	rs4073416	0.569	rs11158605	chr14:66107920	T/A	cg03016385	chr14:66212404	NA	-0.43	-5.6	-0.34	5.84e-8	N-glycan levels;
KIRP	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg00277334	chr10:82204260	NA	-0.58	-6.75	-0.4	1.04e-10	Post bronchodilator FEV1;
KIRP	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.9	-0.6	4.45e-26	Eye color traits;
KIRP	cis	rs4006360	0.551	rs11868548	chr17:39237132	C/G	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.64	-0.48	7.14e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg16512390	chr1:228756714	NA	0.45	5.02	0.3	9.87e-7	Diastolic blood pressure;
KIRP	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.73	9.47	0.52	2.41e-18	Platelet count;
KIRP	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20135002	chr11:47629003	NA	-0.49	-5.84	-0.35	1.64e-8	Subjective well-being;
KIRP	cis	rs8103278	0.507	rs7260651	chr19:46260245	G/A	cg02376097	chr19:46275166	DMPK	0.48	6.54	0.38	3.58e-10	Coronary artery disease;
KIRP	cis	rs7845219	0.544	rs4570121	chr8:95917088	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-5.99	-0.36	7.31e-9	Type 2 diabetes;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27557143	chr19:19754301	GMIP	-0.46	-6.29	-0.37	1.45e-9	Metabolic traits;
KIRP	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg18478394	chr8:109455254	TTC35	0.52	6.43	0.38	6.47e-10	Dupuytren's disease;
KIRP	cis	rs9912468	1.000	rs9892651	chr17:64303793	C/T	cg19474267	chr17:64306194	PRKCA	-0.66	-9.37	-0.51	5.02e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.08	-0.31	7.31e-7	Bipolar disorder;
KIRP	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.33	5.23	0.32	3.65e-7	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg07701084	chr6:150067640	NUP43	0.71	9.84	0.53	1.74e-19	Lung cancer;
KIRP	cis	rs300774	0.841	rs453447	chr2:205446	G/T	cg10118717	chr2:203439	NA	0.38	4.94	0.3	1.44e-6	Suicide attempts in bipolar disorder;
KIRP	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.84	-10.68	-0.56	4e-22	Post bronchodilator FEV1;
KIRP	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.52	0.48	1.65e-15	Prudent dietary pattern;
KIRP	cis	rs9584850	0.794	rs17574433	chr13:99138057	A/G	cg20750642	chr13:99100586	FARP1	0.56	6.6	0.39	2.55e-10	Neuroticism;
KIRP	cis	rs13315871	0.929	rs35007301	chr3:58230352	G/A	cg20936604	chr3:58311152	NA	-0.69	-5.88	-0.35	1.32e-8	Cholesterol, total;
KIRP	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.61	6.94	0.4	3.5e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1403694	1.000	rs2651640	chr3:186438393	G/A	cg12454167	chr3:186435060	KNG1	0.5	8.9	0.49	1.28e-16	Blood protein levels;
KIRP	cis	rs6959887	0.962	rs17606844	chr7:35288213	T/C	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.66	7.46	0.43	1.5e-12	Body mass index;
KIRP	cis	rs7119167	0.722	rs12282282	chr11:73057013	A/G	cg17517138	chr11:73019481	ARHGEF17	0.48	5.04	0.31	9.13e-7	Blood protein levels;
KIRP	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.62	5.44	0.33	1.28e-7	Bipolar disorder;
KIRP	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs28595532	0.668	rs56410164	chr4:119331625	A/G	cg21605333	chr4:119757512	SEC24D	1.1	8.23	0.46	1.06e-14	Cannabis dependence symptom count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26513850	chr22:51038720	MAPK8IP2	-0.45	-6.36	-0.38	1e-9	Metabolic traits;
KIRP	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-7.85	-0.45	1.31e-13	Dental caries;
KIRP	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg16497661	chr14:103986332	CKB	0.51	7.06	0.41	1.65e-11	Body mass index;
KIRP	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.6	7.37	0.43	2.51e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.4	-7.21	-0.42	7.01e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8453	0.708	rs10858054	chr1:115338190	G/T	cg12756093	chr1:115239321	AMPD1	-0.52	-5.43	-0.33	1.37e-7	Autism;
KIRP	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg04310649	chr10:35416472	CREM	-0.58	-6.82	-0.4	7.16e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.84	12.0	0.61	1.99e-26	Itch intensity from mosquito bite;
KIRP	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs6141600	0.540	rs761312	chr20:34687809	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-5.07	-0.31	8.02e-7	Height;Hip circumference;
KIRP	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg04691961	chr3:161091175	C3orf57	-0.66	-11.15	-0.58	1.2e-23	Morning vs. evening chronotype;
KIRP	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.57	6.98	0.41	2.75e-11	Blood metabolite levels;
KIRP	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.77	-10.35	-0.55	4.64e-21	Hemoglobin concentration;
KIRP	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg18357526	chr6:26021779	HIST1H4A	0.42	4.86	0.3	2.13e-6	Blood metabolite levels;
KIRP	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	0.95	8.07	0.46	3.03e-14	Gut microbiota (bacterial taxa);
KIRP	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.48	5.62	0.34	5.06e-8	Glycated hemoglobin levels;
KIRP	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg21523564	chr15:75251491	NA	-0.35	-5.9	-0.35	1.17e-8	Caffeine consumption;
KIRP	cis	rs11628318	0.588	rs12892602	chr14:103114091	T/C	cg01864069	chr14:103024347	NA	0.41	5.12	0.31	6.3e-7	Platelet count;
KIRP	cis	rs4073416	0.542	rs8007497	chr14:66044476	T/C	cg03016385	chr14:66212404	NA	-0.52	-6.42	-0.38	6.89e-10	N-glycan levels;
KIRP	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.58	-8.29	-0.47	7.49e-15	Gut microbiome composition (summer);
KIRP	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg03714773	chr7:91764589	CYP51A1	-0.36	-5.26	-0.32	3.15e-7	Breast cancer;
KIRP	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg21775007	chr8:11205619	TDH	0.49	6.59	0.39	2.68e-10	Mood instability;
KIRP	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.67	5.86	0.35	1.48e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs16828019	0.929	rs2363805	chr1:41719434	G/T	cg18742814	chr1:41828276	NA	0.62	5.62	0.34	5.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.96	13.27	0.65	1.1e-30	Multiple sclerosis;
KIRP	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg00889227	chr1:205173544	DSTYK	-0.39	-5.63	-0.34	4.81e-8	Red blood cell count;
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg23736307	chr8:27182930	PTK2B	0.55	6.96	0.41	3.16e-11	Neuroticism;
KIRP	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.37	-0.43	2.52e-12	Bipolar disorder;
KIRP	cis	rs7837860	0.541	rs13248408	chr8:89285609	C/T	cg08624180	chr8:89339080	MMP16	-0.62	-5.3	-0.32	2.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg09491104	chr22:46646882	C22orf40	-0.53	-6.47	-0.38	5.25e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.76	9.0	0.5	6.17e-17	Smoking behavior;
KIRP	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.6	-6.67	-0.39	1.7e-10	Menarche (age at onset);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23171203	chr5:128796099	ADAMTS19	0.43	6.37	0.38	9.22e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg09699651	chr6:150184138	LRP11	0.54	7.36	0.42	2.74e-12	Testicular germ cell tumor;
KIRP	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg15605315	chr1:45957053	TESK2	0.47	5.78	0.35	2.29e-8	High light scatter reticulocyte count;
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg10729496	chr3:10149963	C3orf24	0.54	5.18	0.31	4.62e-7	Alzheimer's disease;
KIRP	cis	rs1215050	0.765	rs1530905	chr4:98805705	A/G	cg05340658	chr4:99064831	C4orf37	0.53	6.4	0.38	7.89e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs714515	0.868	rs2001128	chr1:172361179	G/C	cg01573306	chr1:172330400	DNM3	0.38	4.88	0.3	1.92e-6	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	trans	rs13170463	0.579	rs13166405	chr5:8034955	C/A	cg03862380	chr20:43029895	HNF4A	0.39	6.03	0.36	6.1e-9	Colorectal cancer;
KIRP	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.53	-6.38	-0.38	8.61e-10	Metabolite levels;
KIRP	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.39	-5.74	-0.34	2.8e-8	Body mass index;
KIRP	cis	rs7221595	0.825	rs9905748	chr17:3968639	C/T	cg21734707	chr17:3908241	ZZEF1	0.58	5.83	0.35	1.73e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs9398803	0.865	rs9372840	chr6:126822635	A/C	cg19875578	chr6:126661172	C6orf173	0.47	6.19	0.37	2.55e-9	Male-pattern baldness;
KIRP	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.53	-6.6	-0.39	2.46e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	15.15	0.69	4.42e-37	Primary sclerosing cholangitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05221544	chr6:150185369	LRP11	0.49	6.4	0.38	7.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg12046867	chr14:103022105	NA	-0.53	-6.78	-0.4	8.91e-11	Platelet count;
KIRP	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.69	10.05	0.54	3.86e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11676348	0.741	rs12694425	chr2:218942313	A/G	cg00012203	chr2:219082015	ARPC2	0.41	5.08	0.31	7.46e-7	Ulcerative colitis;
KIRP	cis	rs737008	0.922	rs1559394	chr16:11369205	A/G	cg00044050	chr16:11439710	C16orf75	-0.59	-7.05	-0.41	1.78e-11	Obesity-related traits;
KIRP	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg15655495	chr12:38532458	NA	-0.25	-4.9	-0.3	1.7e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg22563815	chr15:78856949	CHRNA5	0.51	7.8	0.45	1.74e-13	Sudden cardiac arrest;
KIRP	cis	rs2223471	0.905	rs2817414	chr6:50748813	G/A	cg03432817	chr6:50765336	NA	-0.53	-9.01	-0.5	5.83e-17	Subcutaneous adipose tissue;
KIRP	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg16482183	chr6:26056742	HIST1H1C	0.38	5.02	0.31	9.72e-7	Schizophrenia;
KIRP	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg09163369	chr1:210001066	C1orf107	-0.45	-5.77	-0.35	2.35e-8	Monobrow;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27641141	chr10:43892910	HNRNPF	0.56	7.55	0.43	8.74e-13	Parkinson's disease;
KIRP	cis	rs8014252	0.803	rs74062746	chr14:71024944	A/G	cg19730268	chr14:71022823	NA	-0.69	-6.16	-0.37	2.95e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg16103275	chr6:290800	DUSP22	0.47	6.12	0.36	3.61e-9	Menopause (age at onset);
KIRP	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.87	10.62	0.56	6.2e-22	Platelet distribution width;
KIRP	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.43	-6.38	-0.38	8.62e-10	Coronary artery disease;
KIRP	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg16736954	chr20:23401023	NAPB	0.63	4.96	0.3	1.3e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs831571	0.915	rs6797912	chr3:64058240	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.54	5.07	0.31	7.9e-7	Type 2 diabetes;
KIRP	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs4845875	0.600	rs6699881	chr1:11836628	T/C	cg24844545	chr1:11908347	NPPA	0.37	4.9	0.3	1.73e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.76	11.04	0.58	2.81e-23	Parkinson's disease;
KIRP	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	1.12	12.12	0.61	7.76e-27	Psoriasis;
KIRP	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg03115019	chr17:80708279	FN3K	0.42	4.9	0.3	1.76e-6	Glycated hemoglobin levels;
KIRP	cis	rs807029	0.758	rs807025	chr10:102764821	C/T	cg04662943	chr10:102668895	NA	0.53	6.05	0.36	5.49e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg12334488	chr2:20871173	GDF7	-0.41	-5.25	-0.32	3.34e-7	Abdominal aortic aneurysm;
KIRP	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.61	9.33	0.51	6.55e-18	Lung cancer;
KIRP	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg09788416	chr12:39539408	NA	0.4	5.33	0.32	2.19e-7	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.501	rs2727060	chr17:3989968	C/T	cg21851534	chr17:3907994	ZZEF1	-0.64	-10.23	-0.55	1.07e-20	Type 2 diabetes;
KIRP	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg00571178	chr13:114841904	RASA3	-0.47	-5.07	-0.31	7.78e-7	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs131805	1.000	rs131805	chr22:50964153	T/C	cg05418105	chr22:50981406	NA	-0.73	-7.5	-0.43	1.18e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.68	9.15	0.5	2.29e-17	Eye color traits;
KIRP	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.22	0.32	3.89e-7	Personality dimensions;
KIRP	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.4	-0.38	8e-10	Hemoglobin concentration;
KIRP	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-6.19	-0.37	2.46e-9	Morning vs. evening chronotype;
KIRP	cis	rs2637030	0.559	rs256110	chr5:52879803	A/G	cg06476337	chr5:52856530	NDUFS4	0.54	5.86	0.35	1.46e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs7011507	1.000	rs77687743	chr8:49117673	G/A	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg02336718	chr17:17403227	NA	0.34	5.39	0.32	1.65e-7	Total body bone mineral density;
KIRP	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg25036284	chr2:26402008	FAM59B	0.54	5.63	0.34	4.79e-8	Gut microbiome composition (summer);
KIRP	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg21775007	chr8:11205619	TDH	-0.44	-5.83	-0.35	1.77e-8	Neuroticism;
KIRP	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.23	-0.32	3.69e-7	Pulmonary function;
KIRP	cis	rs490234	0.812	rs4838285	chr9:128446888	C/T	cg14078157	chr9:128172775	NA	-0.46	-5.59	-0.34	6.15e-8	Mean arterial pressure;
KIRP	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	10.43	0.55	2.54e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7646501	1.000	rs7646501	chr3:24079291	A/G	cg21910673	chr3:24143257	LOC152024	0.47	6.18	0.37	2.6e-9	Cognitive ability;Intelligence;
KIRP	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.73	-9.01	-0.5	5.71e-17	Pancreatic cancer;
KIRP	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg17279839	chr7:150038598	RARRES2	0.47	6.28	0.37	1.52e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-1.01	-15.44	-0.7	4.7e-38	Sudden cardiac arrest;
KIRP	cis	rs920590	0.573	rs4392917	chr8:19680635	G/C	cg03894339	chr8:19674705	INTS10	-0.52	-6.2	-0.37	2.38e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs934734	0.967	rs17534670	chr2:65615428	A/G	cg08085232	chr2:65598271	SPRED2	0.46	5.93	0.35	1.03e-8	Rheumatoid arthritis;
KIRP	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.91	12.33	0.62	1.61e-27	Cognitive function;
KIRP	trans	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.22	-0.42	6.47e-12	Schizophrenia;
KIRP	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg17595323	chr11:93583763	C11orf90	-0.3	-5.15	-0.31	5.31e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg16574807	chr4:6945745	TBC1D14	0.67	5.98	0.36	7.91e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs311392	0.554	rs2666883	chr8:55100897	A/G	cg20636351	chr8:55087400	NA	-0.53	-6.48	-0.38	4.96e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs860295	0.702	rs12039893	chr1:155614815	A/C	cg02153340	chr1:155202674	NA	-0.51	-6.83	-0.4	6.58e-11	Body mass index;
KIRP	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs745821	0.783	rs4599004	chr18:48140238	A/G	cg18923635	chr18:48083994	NA	-0.47	-5.36	-0.32	1.91e-7	Diastolic blood pressure;
KIRP	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.98	15.84	0.71	1.92e-39	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07210466	chr3:33444388	UBP1	0.45	6.68	0.39	1.63e-10	Interleukin-4 levels;
KIRP	cis	rs7584330	0.704	rs60079197	chr2:238358584	A/T	cg16989719	chr2:238392110	NA	-0.55	-6.03	-0.36	5.84e-9	Prostate cancer;
KIRP	cis	rs1021993	0.545	rs79950910	chr1:209517898	G/A	cg24446417	chr1:209558027	NA	-0.48	-4.94	-0.3	1.43e-6	Gut microbiome composition (winter);
KIRP	cis	rs7833787	0.896	rs6586779	chr8:18711139	C/T	cg17701159	chr8:18705777	PSD3	0.33	5.68	0.34	3.74e-8	Obesity-related traits;
KIRP	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg26513180	chr16:89883248	FANCA	0.79	5.63	0.34	4.9e-8	Skin colour saturation;
KIRP	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.83	-0.35	1.75e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg06917634	chr15:78832804	PSMA4	-0.5	-5.4	-0.33	1.57e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.48	6.99	0.41	2.56e-11	Lewy body disease;
KIRP	cis	rs2348418	0.681	rs10843207	chr12:28722862	A/G	cg13890972	chr12:28721907	NA	-0.33	-5.13	-0.31	5.88e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg13880726	chr7:1868755	MAD1L1	0.47	5.64	0.34	4.58e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg23791538	chr6:167370224	RNASET2	-0.42	-5.36	-0.32	1.89e-7	Crohn's disease;
KIRP	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg25811766	chr13:21894605	NA	-0.62	-6.14	-0.36	3.21e-9	White matter hyperintensity burden;
KIRP	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.88	10.36	0.55	4.1e-21	Gut microbiome composition (summer);
KIRP	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-8.02	-0.46	4.41e-14	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs10073892	0.660	rs10043147	chr5:101956225	T/C	cg19774478	chr5:101632501	SLCO4C1	0.53	5.43	0.33	1.38e-7	Cognitive decline (age-related);
KIRP	cis	rs6991838	0.584	rs73236948	chr8:66521411	T/G	cg13398993	chr8:66546079	ARMC1	-0.44	-5.08	-0.31	7.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4727443	0.866	rs13238380	chr7:99629061	C/T	cg22004693	chr7:99632812	ZKSCAN1	0.41	5.24	0.32	3.42e-7	Interstitial lung disease;
KIRP	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-8.91	-0.49	1.15e-16	Multiple sclerosis;
KIRP	trans	rs17834760	0.909	rs62424072	chr6:62080711	A/T	cg08476511	chr6:168435923	KIF25	0.52	6.05	0.36	5.31e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg03808351	chr9:123631620	PHF19	0.41	5.51	0.33	8.99e-8	Rheumatoid arthritis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg24845296	chr3:142775293	SR140	0.41	6.37	0.38	9.34e-10	C-reactive protein;
KIRP	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.89	0.45	1.02e-13	Coffee consumption (cups per day);
KIRP	cis	rs12049351	0.665	rs10799534	chr1:229657213	A/C	cg11742688	chr1:229674241	ABCB10	-0.37	-5.57	-0.33	6.67e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.83e-26	Heart rate;
KIRP	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.37	-5.36	-0.32	1.94e-7	Headache;
KIRP	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.37	-14.92	-0.69	2.87e-36	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26053073	chr8:131455383	NA	0.46	6.19	0.37	2.53e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10242455	0.557	rs57830676	chr7:99281363	C/T	cg18809830	chr7:99032528	PTCD1	-0.82	-4.92	-0.3	1.59e-6	Blood metabolite levels;
KIRP	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.76	-10.67	-0.56	4.4e-22	Blood protein levels;
KIRP	cis	rs1448094	0.842	rs12318815	chr12:86452281	T/C	cg02569458	chr12:86230093	RASSF9	-0.36	-5.16	-0.31	5.09e-7	Major depressive disorder;
KIRP	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg13939156	chr17:80058883	NA	-0.49	-7.42	-0.43	1.84e-12	Life satisfaction;
KIRP	cis	rs4765905	0.675	rs10744559	chr12:2298298	C/T	cg10668781	chr12:2307325	CACNA1C	-0.32	-6.55	-0.39	3.36e-10	Schizophrenia;
KIRP	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg04398451	chr17:18023971	MYO15A	0.68	9.5	0.52	1.92e-18	Total body bone mineral density;
KIRP	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg18764771	chr6:116381957	FRK	0.19	5.13	0.31	5.76e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7760535	0.831	rs62420437	chr6:111748780	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.42	-5.44	-0.33	1.29e-7	Metabolic traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg14688129	chr8:86160306	CA13	-0.41	-6.46	-0.38	5.67e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.34	0.42	3.03e-12	Bipolar disorder;
KIRP	cis	rs11024102	0.962	rs12575487	chr11:17019317	C/T	cg15378786	chr11:17036137	PLEKHA7	0.49	4.94	0.3	1.41e-6	Glaucoma (primary angle closure);
KIRP	trans	rs8073060	0.654	rs11650473	chr17:33864632	A/G	cg19694781	chr19:47549865	TMEM160	0.88	10.76	0.57	2.22e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg06636001	chr8:8085503	FLJ10661	0.74	9.26	0.51	1.03e-17	Systemic lupus erythematosus;
KIRP	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.28	-0.32	2.77e-7	Total body bone mineral density;
KIRP	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.66	-8.23	-0.46	1.11e-14	Type 1 diabetes;
KIRP	cis	rs4561483	0.551	rs1126889	chr16:12061910	C/G	cg08843971	chr16:11963173	GSPT1	-0.47	-6.22	-0.37	2.13e-9	Testicular germ cell tumor;
KIRP	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.9	10.84	0.57	1.23e-22	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6450176	1.000	rs6876198	chr5:53303595	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.47	-0.59	1.14e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.11	12.29	0.62	2.27e-27	Corneal structure;
KIRP	cis	rs6545883	0.894	rs1186703	chr2:61672965	A/C	cg15711740	chr2:61764176	XPO1	-0.6	-7.97	-0.45	5.92e-14	Tuberculosis;
KIRP	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg16797656	chr11:68205561	LRP5	0.37	4.87	0.3	2.01e-6	Total body bone mineral density;
KIRP	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.85	13.22	0.64	1.66e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.81	9.89	0.53	1.22e-19	Corneal astigmatism;
KIRP	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.49	7.67	0.44	3.94e-13	Testicular germ cell tumor;
KIRP	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg08603382	chr10:743973	NA	-0.66	-10.65	-0.56	4.98e-22	Psychosis in Alzheimer's disease;
KIRP	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.55	6.19	0.37	2.44e-9	Pubertal anthropometrics;
KIRP	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-7.54	-0.43	9e-13	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	9.21	0.51	1.51e-17	Cognitive test performance;
KIRP	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.54	0.73	7.92e-42	Chronic sinus infection;
KIRP	trans	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg25042112	chr7:64838748	ZNF92	0.59	6.33	0.37	1.17e-9	Pain;
KIRP	cis	rs13385	0.813	rs67432087	chr5:139689454	T/C	cg01860693	chr5:139557145	C5orf32	0.47	4.87	0.3	2.02e-6	Atrial fibrillation;
KIRP	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18252515	chr7:66147081	NA	0.45	5.3	0.32	2.58e-7	Aortic root size;
KIRP	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg25039879	chr17:56429692	SUPT4H1	0.72	6.43	0.38	6.47e-10	Cognitive test performance;
KIRP	cis	rs7520050	1.000	rs12410070	chr1:46358882	T/C	cg03146154	chr1:46216737	IPP	-0.43	-5.34	-0.32	2.13e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs11997175	0.624	rs7388511	chr8:33735582	C/G	cg04338863	chr8:33670619	NA	0.42	4.89	0.3	1.82e-6	Body mass index;
KIRP	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg12559939	chr2:27858050	GPN1	-0.41	-4.86	-0.3	2.07e-6	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13009711	chr14:69446137	ACTN1	0.52	6.26	0.37	1.7e-9	Parkinson's disease;
KIRP	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.34	-7.09	-0.41	1.39e-11	Body mass index;
KIRP	cis	rs1546924	0.570	rs197415	chr1:112311593	C/T	cg23955903	chr1:112298873	DDX20;C1orf183	0.47	5.88	0.35	1.34e-8	Body mass index;
KIRP	cis	rs7520050	0.931	rs785472	chr1:46518288	T/A	cg03146154	chr1:46216737	IPP	-0.42	-5.48	-0.33	1.05e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.36	0.32	1.91e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.47	-6.17	-0.37	2.72e-9	Bladder cancer;
KIRP	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06156847	chr2:113672199	IL1F7	0.45	5.99	0.36	7.43e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg04398451	chr17:18023971	MYO15A	0.62	8.51	0.48	1.71e-15	Total body bone mineral density;
KIRP	cis	rs7560272	0.723	rs4346412	chr2:73843571	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.62	-0.34	5.17e-8	Schizophrenia;
KIRP	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg09184832	chr6:79620586	NA	-0.53	-7.49	-0.43	1.25e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.75	9.4	0.51	3.96e-18	Response to antipsychotic treatment;
KIRP	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.54	-0.48	1.43e-15	Morning vs. evening chronotype;
KIRP	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.26	-0.37	1.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg00666640	chr1:248458726	OR2T12	-0.4	-4.9	-0.3	1.72e-6	Common traits (Other);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21433121	chr3:58477944	KCTD6	0.51	6.22	0.37	2.1e-9	Parkinson's disease;
KIRP	cis	rs7555523	0.943	rs4537525	chr1:165711089	T/G	cg24409356	chr1:165738333	TMCO1	0.7	5.75	0.34	2.65e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg05775895	chr3:12838266	CAND2	0.4	6.85	0.4	5.95e-11	QRS complex (12-leadsum);
KIRP	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-0.7	-9.31	-0.51	7.32e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs16973500	0.808	rs72801786	chr16:71955085	C/T	cg00732059	chr16:71740210	PHLPP2	-0.59	-5.61	-0.34	5.5e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs76533333	1.000	rs34011672	chr13:113360938	A/G	cg21786786	chr13:113365464	ATP11A	-0.59	-5.04	-0.31	9e-7	Red cell distribution width;
KIRP	cis	rs9372498	0.536	rs9320660	chr6:118956827	A/T	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg16141378	chr3:129829833	LOC729375	0.52	6.63	0.39	2.09e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.43	5.9	0.35	1.18e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg16898833	chr6:26189333	HIST1H4D	0.95	5.77	0.35	2.35e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7939886	0.920	rs80232778	chr11:55970655	G/A	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg08392591	chr16:89556376	ANKRD11	0.43	5.2	0.31	4.28e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs747782	0.536	rs10838873	chr11:48337765	T/C	cg03929089	chr4:120376271	NA	0.69	6.29	0.37	1.44e-9	Intraocular pressure;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.27	5.12	0.31	6.27e-7	Lymphocyte counts;
KIRP	cis	rs2274273	0.662	rs67958555	chr14:55670866	G/A	cg04306507	chr14:55594613	LGALS3	0.41	5.41	0.33	1.51e-7	Protein biomarker;
KIRP	cis	rs7221595	0.825	rs8081260	chr17:3981937	T/C	cg21851534	chr17:3907994	ZZEF1	0.55	5.46	0.33	1.18e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg01879757	chr17:41196368	BRCA1	-0.8	-11.22	-0.58	7.23e-24	Menopause (age at onset);
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg01645753	chr15:83316734	CPEB1	0.46	6.24	0.37	1.92e-9	Colorectal cancer;
KIRP	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.09	-0.31	7.19e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs1973993	0.561	rs1475173	chr1:96993374	C/A	cg10631902	chr5:14652156	NA	-0.55	-6.79	-0.4	8.16e-11	Weight;
KIRP	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.31	-6.11	-0.36	3.81e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-7.38	-0.43	2.49e-12	Monocyte percentage of white cells;
KIRP	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg24579218	chr15:68104479	NA	0.38	6.25	0.37	1.82e-9	Restless legs syndrome;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09112717	chr4:100009950	ADH5	-0.47	-6.46	-0.38	5.52e-10	Metabolic traits;
KIRP	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.71	8.99	0.5	6.71e-17	Morning vs. evening chronotype;
KIRP	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg26384229	chr12:38710491	ALG10B	0.74	9.84	0.53	1.76e-19	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg17145862	chr1:211918768	LPGAT1	-0.54	-6.79	-0.4	8.35e-11	Leprosy;
KIRP	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.7e-6	Coronary artery disease;
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.62	-7.68	-0.44	3.81e-13	Breast cancer;
KIRP	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.99	-10.86	-0.57	1.06e-22	Body mass index;
KIRP	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.78	-10.85	-0.57	1.11e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs13190036	1.000	rs35535623	chr5:176629296	A/G	cg04708888	chr5:176739561	MXD3	0.64	5.02	0.3	1.01e-6	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01669482	chr16:25043131	NA	0.52	6.1	0.36	3.99e-9	Smoking initiation;
KIRP	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg23594656	chr7:65796392	TPST1	0.39	5.9	0.35	1.2e-8	Aortic root size;
KIRP	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.4	-5.05	-0.31	8.73e-7	Carotid intima media thickness;
KIRP	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.16	15.26	0.7	1.88e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg01849789	chr22:41697279	ZC3H7B	-0.5	-5.76	-0.34	2.54e-8	Neuroticism;
KIRP	cis	rs78487399	0.808	rs75126888	chr2:43664007	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	5.32	0.32	2.36e-7	Renal cell carcinoma;
KIRP	cis	rs3857067	0.967	rs899135	chr4:95019816	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.91	-0.3	1.7e-6	QT interval;
KIRP	cis	rs1144	0.537	rs2470948	chr7:104588533	A/G	cg04380332	chr7:105027541	SRPK2	-0.54	-7.94	-0.45	7.34e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-6.18	-0.37	2.7e-9	Obesity-related traits;
KIRP	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	6.8	0.4	7.8e-11	LDL cholesterol;
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.58	-7.95	-0.45	6.69e-14	Obesity-related traits;
KIRP	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.72	6.95	0.4	3.32e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.96	12.99	0.64	9.57e-30	Menopause (age at onset);
KIRP	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg19539972	chr4:7069911	GRPEL1	-0.41	-5.07	-0.31	7.93e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs9469913	0.675	rs6907508	chr6:34592090	A/G	cg17674042	chr6:34482479	PACSIN1	-0.6	-6.39	-0.38	8.24e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.93	-9.28	-0.51	9.29e-18	Obesity-related traits;
KIRP	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg22437258	chr11:111473054	SIK2	-0.56	-6.51	-0.38	4.23e-10	Primary sclerosing cholangitis;
KIRP	cis	rs4849845	0.925	rs6723584	chr2:121011162	T/C	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg12962167	chr3:53033115	SFMBT1	0.64	4.94	0.3	1.42e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.64	7.46	0.43	1.48e-12	Platelet distribution width;
KIRP	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg01689657	chr7:91764605	CYP51A1	0.41	6.07	0.36	4.68e-9	Breast cancer;
KIRP	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg08076091	chr2:203926405	NBEAL1	0.85	8.61	0.48	8.8e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.72	-9.89	-0.53	1.22e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.9	-11.37	-0.59	2.41e-24	IgG glycosylation;
KIRP	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	16.08	0.72	2.98e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.13	-0.5	2.65e-17	Colorectal cancer;
KIRP	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg11569703	chr11:65557185	OVOL1	-0.37	-5.23	-0.32	3.55e-7	Urate levels;
KIRP	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg05340658	chr4:99064831	C4orf37	-0.59	-7.3	-0.42	3.86e-12	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg11130432	chr3:121712080	ILDR1	-0.45	-4.85	-0.3	2.21e-6	Multiple sclerosis;
KIRP	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4073221	0.789	rs35630651	chr3:18224286	G/C	cg07694806	chr3:18168406	NA	-0.79	-6.99	-0.41	2.56e-11	Parkinson's disease;
KIRP	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.8	9.71	0.53	4.52e-19	Corneal astigmatism;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.55	-7.52	-0.43	1.03e-12	Longevity;Endometriosis;
KIRP	trans	rs638882	1.000	rs651667	chr11:115760678	G/A	cg27346806	chr10:135050758	VENTX	-0.43	-6.23	-0.37	2.05e-9	Hip geometry;
KIRP	cis	rs758324	0.704	rs587759	chr5:131392480	G/A	cg06307176	chr5:131281290	NA	-0.53	-5.32	-0.32	2.3e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg04727924	chr7:799746	HEATR2	-0.68	-6.46	-0.38	5.41e-10	Cerebrospinal P-tau181p levels;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23273935	chr6:10412486	TFAP2A	0.58	6.32	0.37	1.21e-9	Lung cancer in ever smokers;
KIRP	cis	rs11603020	0.950	rs11229067	chr11:57374946	A/C	cg23127183	chr11:57508653	C11orf31	0.46	5.36	0.32	1.88e-7	Blood protein levels;
KIRP	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg00106254	chr7:1943704	MAD1L1	-0.58	-6.38	-0.38	8.49e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	13.8	0.66	1.88e-32	Electrocardiographic conduction measures;
KIRP	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg20628663	chr10:43360327	NA	0.55	6.56	0.39	3.15e-10	Blood protein levels;
KIRP	cis	rs13361707	0.920	rs4509070	chr5:40699684	A/T	cg01087697	chr5:40835557	RPL37	-0.48	-5.44	-0.33	1.29e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg16898833	chr6:26189333	HIST1H4D	0.62	5.03	0.31	9.48e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs963731	0.649	rs297139	chr2:39318310	A/G	cg04010122	chr2:39346883	SOS1	-0.89	-6.28	-0.37	1.53e-9	Corticobasal degeneration;
KIRP	cis	rs11120822	0.814	rs6656691	chr1:7122453	C/G	cg20434152	chr1:7120926	CAMTA1	-0.4	-5.71	-0.34	3.33e-8	Stearic acid (18:0) levels;
KIRP	trans	rs9371601	0.859	rs549981	chr6:152718505	C/T	cg05529123	chr2:66910386	NA	-0.46	-6.2	-0.37	2.37e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.41	-5.71	-0.34	3.17e-8	Blood metabolite levels;
KIRP	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-4.88	-0.3	1.91e-6	Chronic sinus infection;
KIRP	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-7.04	-0.41	1.88e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.24	-6.55	-0.39	3.37e-10	Mean corpuscular volume;
KIRP	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg18269503	chr6:26104560	HIST1H4C	-0.4	-6.09	-0.36	4.22e-9	Parkinson's disease (motor and cognition);
KIRP	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.7	9.21	0.51	1.53e-17	Response to diuretic therapy;
KIRP	cis	rs3105593	1.000	rs3131573	chr15:50869601	G/A	cg08437265	chr15:50716283	USP8	0.39	4.97	0.3	1.24e-6	QT interval;
KIRP	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg25281562	chr12:121454272	C12orf43	0.55	6.17	0.37	2.77e-9	N-glycan levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03343262	chr16:2255396	MLST8	-0.49	-6.2	-0.37	2.4e-9	Myopia;
KIRP	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.45	-6.06	-0.36	5.12e-9	Coronary artery disease;
KIRP	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.08	-0.41	1.55e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg06871246	chr4:1363661	KIAA1530	-0.49	-6.13	-0.36	3.4e-9	Longevity;
KIRP	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg07862535	chr7:139043722	LUC7L2	0.48	5.41	0.33	1.46e-7	Diisocyanate-induced asthma;
KIRP	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.62	-7.8	-0.45	1.79e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg25866889	chr13:114914595	NA	-0.38	-5.43	-0.33	1.38e-7	Schizophrenia;
KIRP	cis	rs3748682	1.000	rs3748682	chr1:38279987	C/T	cg12658694	chr1:38397304	INPP5B	-0.54	-5.92	-0.35	1.09e-8	Hypothyroidism;
KIRP	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg25019033	chr10:957182	NA	-0.6	-6.44	-0.38	6.38e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs300890	0.609	rs2119270	chr4:144309721	A/C	cg01719995	chr4:144104893	USP38	-0.41	-5.13	-0.31	5.93e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg08975724	chr8:8085496	FLJ10661	0.48	5.01	0.3	1.06e-6	Obesity-related traits;
KIRP	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.19	0.31	4.37e-7	Height;
KIRP	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	0.9	13.2	0.64	1.93e-30	Dupuytren's disease;
KIRP	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg17279839	chr7:150038598	RARRES2	0.46	6.08	0.36	4.62e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs60311166	1.000	rs57869735	chr3:52662850	A/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.95	5.8	0.35	1.98e-8	CTACK levels;
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg18402987	chr7:1209562	NA	0.8	7.15	0.41	9.82e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.57	-7.02	-0.41	2.14e-11	Aortic root size;
KIRP	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.53	-6.66	-0.39	1.8e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg18872420	chr14:78023429	SPTLC2	0.34	4.98	0.3	1.18e-6	Myeloid white cell count;
KIRP	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.46	5.71	0.34	3.28e-8	Age at first birth;
KIRP	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg18305652	chr10:134549665	INPP5A	0.48	7.2	0.42	7.43e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg12181417	chr19:49337499	HSD17B14	-0.42	-4.89	-0.3	1.79e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.48	-8.44	-0.47	2.75e-15	Type 2 diabetes;
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg11814155	chr7:99998594	ZCWPW1	0.55	5.42	0.33	1.44e-7	Platelet count;
KIRP	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.52	-6.8	-0.4	7.87e-11	Longevity;
KIRP	cis	rs5753618	0.539	rs1034588	chr22:31616301	A/G	cg02404636	chr22:31891804	SFI1	-0.47	-5.28	-0.32	2.89e-7	Colorectal cancer;
KIRP	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg00106254	chr7:1943704	MAD1L1	-0.59	-6.31	-0.37	1.32e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.9	-10.55	-0.56	1.03e-21	White matter hyperintensity burden;
KIRP	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg07166546	chr14:35805898	NA	0.26	6.36	0.38	9.83e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7870753	0.838	rs10820666	chr9:99234997	G/T	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.28	-0.37	1.5e-9	Arsenic metabolism;
KIRP	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg11833968	chr6:79620685	NA	-0.4	-5.66	-0.34	4.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs501120	0.584	rs673778	chr10:44733739	G/T	cg09554077	chr10:44749378	NA	0.72	8.03	0.46	3.93e-14	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06124975	chr6:107810578	SOBP	0.6	6.2	0.37	2.31e-9	Lung function (FEV1);
KIRP	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.84	10.17	0.54	1.68e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg10242476	chr3:46619364	LRRC2;TDGF1	-0.44	-5.32	-0.32	2.28e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7011049	0.818	rs112140190	chr8:53866713	C/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.29e-10	Systolic blood pressure;
KIRP	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg02461776	chr11:598696	PHRF1	0.49	5.23	0.32	3.65e-7	Systemic lupus erythematosus;
KIRP	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.25	-0.47	9.36e-15	Extrinsic epigenetic age acceleration;
KIRP	trans	rs2945733	1.000	rs2922445	chr8:134608745	T/G	cg03126616	chr5:179003843	RUFY1	-0.75	-6.05	-0.36	5.35e-9	Intraocular pressure;
KIRP	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg17294928	chr15:75287854	SCAMP5	-0.59	-4.96	-0.3	1.31e-6	Lung cancer;
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg13699009	chr12:122356056	WDR66	0.72	11.28	0.58	4.66e-24	Mean corpuscular volume;
KIRP	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.7	-9.72	-0.53	4.07e-19	Migraine;Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18342900	chr16:46865048	C16orf87	0.64	7.72	0.44	2.86e-13	Smoking initiation;
KIRP	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	10.55	0.56	1.02e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.74	-8.32	-0.47	6.2e-15	Platelet distribution width;
KIRP	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs236907	0.859	rs6674364	chr1:171728781	C/T	cg01410279	chr1:171621941	MYOC	-0.52	-5.31	-0.32	2.43e-7	Mean platelet volume;
KIRP	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg19899395	chr1:46959349	NA	-0.45	-5.5	-0.33	9.46e-8	Monobrow;
KIRP	cis	rs2574975	0.531	rs1203385	chr10:52208709	T/C	cg10034176	chr10:52120283	SGMS1	0.4	5.63	0.34	4.81e-8	Response to amphetamines;
KIRP	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-0.77	-9.84	-0.53	1.75e-19	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg22824376	chr14:77648248	TMEM63C	0.87	8.21	0.46	1.29e-14	Obsessive-compulsive symptoms;
KIRP	cis	rs11264213	0.711	rs489534	chr1:36155418	C/T	cg27506609	chr1:36549197	TEKT2	-0.64	-5.88	-0.35	1.31e-8	Schizophrenia;
KIRP	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.69	8.61	0.48	8.77e-16	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg19847866	chr10:1019161	NA	-0.62	-5.77	-0.35	2.35e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs2997447	0.846	rs61775430	chr1:26411109	G/A	cg19633962	chr1:26362018	EXTL1	-0.69	-5.76	-0.34	2.48e-8	QRS complex (12-leadsum);
KIRP	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg03808351	chr9:123631620	PHF19	0.46	6.25	0.37	1.78e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.63	7.47	0.43	1.38e-12	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12215853	chr19:45927018	ERCC1	-0.49	-6.55	-0.39	3.3e-10	Myopia;
KIRP	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg23601095	chr6:26197514	HIST1H3D	1.02	8.6	0.48	9.47e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.09	0.31	6.99e-7	Parkinson's disease;
KIRP	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.84	11.88	0.6	4.9e-26	Total body bone mineral density;
KIRP	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg02297831	chr4:17616191	MED28	0.59	7.37	0.43	2.56e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-8.32	-0.47	6.14e-15	Colorectal cancer;
KIRP	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.66	6.96	0.41	3.12e-11	Eotaxin levels;
KIRP	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.48	8.02	0.46	4.22e-14	Height;
KIRP	cis	rs12210905	0.688	rs12194842	chr6:27367978	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.61	-0.39	2.42e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs13100616	1.000	rs4293681	chr3:178411796	C/T	cg26530345	chr2:220312410	SPEG	0.49	6.02	0.36	6.17e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg27490568	chr2:178487706	NA	0.97	12.21	0.61	4.14e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10782582	0.609	rs5745410	chr1:76314356	C/A	cg10523679	chr1:76189770	ACADM	-0.44	-6.13	-0.36	3.46e-9	Daytime sleep phenotypes;
KIRP	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.72	-8.4	-0.47	3.56e-15	Diabetic retinopathy;
KIRP	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.88	14.18	0.67	9.43e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26314531	chr2:26401878	FAM59B	0.47	4.9	0.3	1.75e-6	Gut microbiome composition (summer);
KIRP	cis	rs72387598	1	rs72387598	chr1:45922977	CAT/C	cg05343316	chr1:45956843	TESK2	0.77	8.88	0.49	1.48e-16	Platelet distribution width;
KIRP	cis	rs7084402	0.967	rs1649081	chr10:60292444	G/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.92	-0.57	6.8e-23	Refractive error;
KIRP	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.65	8.79	0.49	2.56e-16	Prudent dietary pattern;
KIRP	cis	rs11673344	0.526	rs17303902	chr19:38042814	T/C	cg14683738	chr19:37701593	ZNF585B	-0.44	-5.31	-0.32	2.4e-7	Obesity-related traits;
KIRP	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg01770232	chr7:22766155	IL6	0.92	7.02	0.41	2.14e-11	Tonsillectomy;
KIRP	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.33	0.37	1.13e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg06121193	chr1:90282411	NA	-0.55	-7.62	-0.44	5.48e-13	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	1.09	17.58	0.75	2.33e-45	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg00767560	chr19:19887256	LOC284440	0.51	6.37	0.38	9.43e-10	Body mass index in non-asthmatics;
KIRP	cis	rs7584330	0.628	rs7591065	chr2:238390739	G/T	cg16989719	chr2:238392110	NA	-0.61	-7.67	-0.44	4.01e-13	Prostate cancer;
KIRP	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.43	6.63	0.39	2.11e-10	Schizophrenia;
KIRP	cis	rs9815354	0.680	rs73071354	chr3:41829186	C/A	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.2	0.42	7.23e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg16497661	chr14:103986332	CKB	0.46	6.16	0.37	2.91e-9	Body mass index;
KIRP	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.46	6.94	0.4	3.4e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.67	9.05	0.5	4.61e-17	Eye color traits;
KIRP	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9549260	0.592	rs9532588	chr13:41302913	G/A	cg21288729	chr13:41239152	FOXO1	0.54	7.19	0.42	7.87e-12	Red blood cell count;
KIRP	cis	rs12900413	0.687	rs10152954	chr15:90307442	T/C	cg24650279	chr15:90327240	NA	-0.43	-5.47	-0.33	1.09e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs35883536	1.000	rs9803842	chr1:101134877	G/T	cg06223162	chr1:101003688	GPR88	0.34	6.97	0.41	2.96e-11	Monocyte count;
KIRP	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg00814883	chr7:100076585	TSC22D4	-0.56	-6.2	-0.37	2.42e-9	Lung function (FEV1/FVC);
KIRP	cis	rs258892	0.895	rs4254881	chr5:72031360	T/C	cg21869765	chr5:72125136	TNPO1	-0.52	-5.83	-0.35	1.71e-8	Small cell lung carcinoma;
KIRP	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg03684893	chr10:554711	DIP2C	0.37	5.08	0.31	7.32e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg09873164	chr1:152488093	CRCT1	0.51	6.01	0.36	6.6e-9	Hair morphology;
KIRP	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-7.23	-0.42	5.97e-12	Type 2 diabetes;
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg14338887	chr6:42928500	GNMT	0.47	6.94	0.4	3.44e-11	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs1215050	0.755	rs2952911	chr4:98850666	T/C	cg05340658	chr4:99064831	C4orf37	-0.54	-6.51	-0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7712401	0.715	rs451195	chr5:122359640	T/C	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg00784671	chr22:46762841	CELSR1	-0.77	-7.89	-0.45	9.67e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs10046574	0.519	rs7799873	chr7:135214030	C/T	cg27474649	chr7:135195673	CNOT4	0.54	5.15	0.31	5.31e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg12559939	chr2:27858050	GPN1	-0.42	-5.31	-0.32	2.43e-7	Oral cavity cancer;
KIRP	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs11625487	0.645	rs8006951	chr14:77965304	G/A	cg16049707	chr14:77965284	ISM2	0.43	4.92	0.3	1.6e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06666157	chr19:4791552	FEM1A	0.55	6.51	0.38	4.1e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg03959625	chr15:84868606	LOC388152	-0.46	-5.14	-0.31	5.49e-7	Schizophrenia;
KIRP	cis	rs4742903	0.875	rs1857980	chr9:106992265	G/T	cg14250997	chr9:106856677	SMC2	0.38	4.98	0.3	1.18e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg20465933	chr4:152376761	FAM160A1	-0.42	-6.37	-0.38	9.36e-10	Inflammatory biomarkers;
KIRP	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg04691961	chr3:161091175	C3orf57	-0.39	-5.74	-0.34	2.73e-8	Morning vs. evening chronotype;
KIRP	cis	rs17125944	0.686	rs7158555	chr14:53362006	G/A	cg00686598	chr14:53173677	PSMC6	-0.73	-6.9	-0.4	4.43e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.48	-6.56	-0.39	3.07e-10	Asthma;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.79	-11.63	-0.6	3.44e-25	Heart rate;
KIRP	cis	rs3774830	0.714	rs55816120	chr4:5463350	C/T	cg26943120	chr4:5472116	STK32B	0.24	5.84	0.35	1.61e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11627756	0.957	rs7144340	chr14:103128777	G/T	cg01864069	chr14:103024347	NA	0.4	4.84	0.3	2.26e-6	Mean platelet volume;
KIRP	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg18944383	chr4:111397179	ENPEP	0.54	9.48	0.52	2.33e-18	Height;
KIRP	cis	rs12780845	0.540	rs3780961	chr10:17195132	G/A	cg01003015	chr10:17271136	VIM	-0.4	-4.91	-0.3	1.65e-6	Homocysteine levels;
KIRP	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.75	7.52	0.43	1.03e-12	Uric acid levels;
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.4	5.88	0.35	1.35e-8	Lipoprotein (a) levels;
KIRP	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.88	-12.04	-0.61	1.5e-26	Cognitive function;
KIRP	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg15556689	chr8:8085844	FLJ10661	0.52	6.59	0.39	2.61e-10	Retinal vascular caliber;
KIRP	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg15556689	chr8:8085844	FLJ10661	0.46	5.56	0.33	7.08e-8	Joint mobility (Beighton score);
KIRP	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.16	0.67	1.06e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.24	-0.37	1.9e-9	Lung cancer;
KIRP	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg00800038	chr16:89945340	TCF25	-0.89	-7.26	-0.42	4.94e-12	Skin colour saturation;
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.89	-9.33	-0.51	6.25e-18	Vitamin D levels;
KIRP	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg00677455	chr12:58241039	CTDSP2	-0.59	-7.04	-0.41	1.9e-11	Multiple sclerosis;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02359409	chr6:42947317	PEX6	0.38	5.03	0.31	9.48e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs290268	1.000	rs290274	chr9:93546913	C/T	cg02608019	chr9:93564028	SYK	0.77	10.67	0.56	4.3e-22	Platelet count;
KIRP	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.42	-4.91	-0.3	1.65e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs4523957	0.583	rs9889861	chr17:2041369	A/G	cg16513277	chr17:2031491	SMG6	-0.86	-12.82	-0.63	3.79e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.76	9.99	0.54	6.25e-20	Breast cancer;
KIRP	trans	rs2048656	0.550	rs7001484	chr8:9667203	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.32	-0.37	1.21e-9	Schizophrenia;
KIRP	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg12559939	chr2:27858050	GPN1	0.47	5.9	0.35	1.22e-8	Oral cavity cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg05090725	chr11:107799287	RAB39	0.72	6.35	0.38	1.05e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.34	-7.06	-0.41	1.73e-11	Urinary metabolites;
KIRP	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.69	7.66	0.44	4.29e-13	Corneal astigmatism;
KIRP	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.38	5.37	0.32	1.8e-7	Ovarian reserve;
KIRP	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.56	-0.48	1.24e-15	Joint mobility (Beighton score);
KIRP	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg21361702	chr7:150065534	REPIN1	0.62	6.02	0.36	6.36e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg18132916	chr6:79620363	NA	-0.4	-5.47	-0.33	1.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.56	-7.71	-0.44	3.06e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs806215	0.906	rs806195	chr7:127249178	A/G	cg25922125	chr7:127225783	GCC1	0.47	5.05	0.31	8.61e-7	Type 2 diabetes;
KIRP	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg02931644	chr1:25747376	RHCE	0.39	7.3	0.42	3.92e-12	Erythrocyte sedimentation rate;
KIRP	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg10223061	chr2:219282414	VIL1	-0.45	-7.26	-0.42	5.1e-12	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs10751667	0.557	rs12281858	chr11:1022187	C/T	cg10932868	chr11:921992	NA	0.52	6.01	0.36	6.51e-9	Alzheimer's disease (late onset);
KIRP	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.91	-14.57	-0.68	4.46e-35	Systemic lupus erythematosus;
KIRP	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.65	-12.43	-0.62	7.44e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.05	0.41	1.78e-11	Bipolar disorder;
KIRP	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.28	5.74	0.34	2.83e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.16	0.31	5.09e-7	Menopause (age at onset);
KIRP	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg13819577	chr1:248512075	OR14C36	0.35	4.92	0.3	1.6e-6	Common traits (Other);
KIRP	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg23307798	chr14:103986281	CKB	0.67	7.68	0.44	3.68e-13	Body mass index;
KIRP	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg02002194	chr4:3960332	NA	-0.43	-6.16	-0.37	2.88e-9	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg08999081	chr20:33150536	PIGU	0.41	5.24	0.32	3.46e-7	Height;
KIRP	cis	rs13102973	0.640	rs13113331	chr4:135838729	C/T	cg14419869	chr4:135874104	NA	0.49	8.11	0.46	2.41e-14	Subjective well-being;
KIRP	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.08	-0.41	1.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg00405596	chr8:11794950	NA	-0.47	-6.05	-0.36	5.3e-9	Joint mobility (Beighton score);
KIRP	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg06640241	chr16:89574553	SPG7	0.9	15.27	0.7	1.75e-37	Multiple myeloma (IgH translocation);
KIRP	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.6	-6.4	-0.38	7.87e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.46	-6.0	-0.36	6.9e-9	Bladder cancer;
KIRP	cis	rs548987	0.507	rs35875210	chr6:25827484	A/G	cg12310025	chr6:25882481	NA	-0.43	-5.04	-0.31	8.84e-7	Homocysteine levels;
KIRP	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.69	8.4	0.47	3.52e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9654415	0.560	rs6893178	chr5:72541096	G/A	cg14879418	chr5:72571312	NA	-0.47	-5.8	-0.35	1.99e-8	Eyebrow thickness;
KIRP	cis	rs41308713	0.786	rs8116471	chr20:37034694	A/C	cg09132763	chr20:37064059	LOC388796;SNORA71D	1.33	8.08	0.46	3.01e-14	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg27124370	chr19:33622961	WDR88	0.61	7.43	0.43	1.75e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.75	6.44	0.38	6.11e-10	Body mass index;
KIRP	cis	rs539514	0.587	rs9530466	chr13:76323774	T/C	cg04757411	chr13:76259545	LMO7	-0.46	-6.76	-0.4	9.8e-11	Type 1 diabetes;
KIRP	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg16586182	chr3:47516702	SCAP	0.81	11.74	0.6	1.44e-25	Colorectal cancer;
KIRP	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.51	-7.05	-0.41	1.77e-11	Type 2 diabetes;
KIRP	cis	rs6005807	0.719	rs9625520	chr22:29037864	C/A	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs8077577	0.895	rs11654741	chr17:18124470	C/A	cg18869244	chr17:18121946	NA	0.48	5.48	0.33	1.03e-7	Obesity-related traits;
KIRP	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.66	6.87	0.4	5.18e-11	Vitiligo;
KIRP	trans	rs1820616	1.000	rs7633762	chr3:54793362	A/G	cg21775463	chr8:25538546	NA	0.68	6.29	0.37	1.46e-9	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-6.17	-0.37	2.82e-9	Obesity (extreme);
KIRP	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.51	5.92	0.35	1.09e-8	Parkinson's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17168428	chr7:35844045	SEPT7	0.44	6.17	0.37	2.84e-9	Survival in pancreatic cancer;
KIRP	cis	rs2120243	0.539	rs10936086	chr3:157099859	A/C	cg24825693	chr3:157122686	VEPH1	-0.56	-9.03	-0.5	5.22e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2273156	1.000	rs2383688	chr14:35403451	C/T	cg09327582	chr14:35236912	BAZ1A	-0.55	-6.02	-0.36	6.4e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs7621025	0.630	rs1681818	chr3:136473673	A/G	cg15507776	chr3:136538369	TMEM22	-0.43	-5.32	-0.32	2.32e-7	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.7	-9.7	-0.53	4.71e-19	Rheumatoid arthritis;
KIRP	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-8.71	-0.49	4.61e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs27434	0.607	rs695965	chr5:96148366	C/T	cg16492584	chr5:96139282	ERAP1	-0.42	-5.74	-0.34	2.77e-8	Ankylosing spondylitis;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg13678283	chr1:153919171	DENND4B	0.55	6.89	0.4	4.74e-11	DNA methylation (variation);
KIRP	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg22467129	chr15:76604101	ETFA	-0.44	-6.13	-0.36	3.53e-9	Blood metabolite levels;
KIRP	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg03563238	chr19:33554763	RHPN2	-0.33	-5.63	-0.34	4.87e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6693295	0.877	rs2787970	chr1:246231670	T/C	cg11798871	chr1:246315928	SMYD3	-0.47	-5.75	-0.34	2.63e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.96	15.53	0.7	2.25e-38	Systemic lupus erythematosus;
KIRP	cis	rs6832769	1.000	rs28448438	chr4:56416665	C/T	cg09317128	chr4:56265301	TMEM165	-0.54	-6.89	-0.4	4.74e-11	Personality dimensions;
KIRP	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.59	7.37	0.43	2.51e-12	Arsenic metabolism;
KIRP	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.93e-10	Hypertriglyceridemia;
KIRP	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg03929089	chr4:120376271	NA	-0.55	-6.56	-0.39	3.11e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg04990556	chr1:26633338	UBXN11	-0.62	-6.26	-0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs6499755	0.768	rs31097	chr16:55368635	A/G	cg05099576	chr16:55362342	IRX6	-0.32	-6.69	-0.39	1.48e-10	Hypospadias;
KIRP	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg13072238	chr3:49761600	GMPPB	0.39	4.87	0.3	1.99e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg02336718	chr17:17403227	NA	-0.33	-5.1	-0.31	6.68e-7	Total body bone mineral density;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.58	-6.08	-0.36	4.49e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.44	-5.81	-0.35	1.95e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.36	16.68	0.73	2.63e-42	Uric acid levels;
KIRP	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.91	0.45	8.56e-14	Obesity-related traits;
KIRP	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.11	0.58	1.6e-23	Smoking behavior;
KIRP	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17344932	chr17:38183730	MED24;SNORD124	0.46	7.35	0.42	2.96e-12	White blood cell count;
KIRP	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg11833968	chr6:79620685	NA	-0.48	-7.22	-0.42	6.43e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.96	-0.45	6.18e-14	Mean corpuscular volume;
KIRP	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.61	-8.64	-0.48	7.26e-16	Menarche (age at onset);
KIRP	cis	rs3857747	0.520	rs12701817	chr7:40364841	A/T	cg00420559	chr7:40367873	C7orf10	-0.6	-8.46	-0.47	2.37e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9843304	0.568	rs71304473	chr3:149217190	G/A	cg08667024	chr3:149219783	TM4SF4	-0.45	-6.08	-0.36	4.63e-9	Gallstone disease;
KIRP	cis	rs427941	0.655	rs2734782	chr7:101749667	T/C	cg06246474	chr7:101738831	CUX1	0.51	6.27	0.37	1.59e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9420	0.796	rs685149	chr11:57657413	A/G	cg19752551	chr11:57585705	CTNND1	0.65	10.17	0.54	1.67e-20	Schizophrenia;
KIRP	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg00079169	chr19:2811669	THOP1	0.54	5.66	0.34	4.31e-8	Total cholesterol levels;
KIRP	cis	rs698813	0.763	rs786615	chr2:44590608	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.59	6.45	0.38	5.78e-10	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs858239	0.509	rs6975524	chr7:23186452	T/C	cg23682824	chr7:23144976	KLHL7	0.53	6.21	0.37	2.22e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4006360	0.600	rs1828327	chr17:39249464	T/C	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.78	-0.53	2.78e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg07148914	chr20:33460835	GGT7	-0.54	-7.15	-0.41	9.81e-12	Height;
KIRP	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.5	-9.19	-0.51	1.68e-17	Cystic fibrosis severity;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg25622855	chr1:228395347	OBSCN	-0.51	-6.42	-0.38	6.87e-10	Bladder cancer;
KIRP	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.85	11.26	0.58	5.56e-24	Type 2 diabetes;
KIRP	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.38	0.38	8.66e-10	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6496667	0.779	rs2238324	chr15:91006989	T/C	cg10434728	chr15:90938212	IQGAP1	0.36	4.9	0.3	1.71e-6	Rheumatoid arthritis;
KIRP	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg03465714	chr1:152285911	FLG	-0.44	-5.35	-0.32	2.03e-7	Atopic dermatitis;
KIRP	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.21	0.37	2.19e-9	Retinal vascular caliber;
KIRP	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg11707556	chr5:10655725	ANKRD33B	0.57	7.13	0.41	1.1e-11	Coronary artery disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23349227	chr19:18255298	MAST3	0.42	6.19	0.37	2.46e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6545883	0.965	rs6718887	chr2:61727215	G/A	cg15711740	chr2:61764176	XPO1	-0.59	-8.19	-0.46	1.44e-14	Tuberculosis;
KIRP	trans	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg24644049	chr4:85504048	CDS1	1.01	6.58	0.39	2.79e-10	Skin colour saturation;
KIRP	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg00933542	chr6:150070202	PCMT1	0.26	4.86	0.3	2.08e-6	Testicular germ cell tumor;
KIRP	cis	rs12360000	0.800	rs34963788	chr10:1926436	A/C	cg26364871	chr10:1889757	NA	-0.56	-6.64	-0.39	2e-10	Metabolite levels (Dihydroxy docosatrienoic acid);
KIRP	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	1.03	13.25	0.65	1.28e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00933542	chr6:150070202	PCMT1	0.3	5.79	0.35	2.14e-8	Lung cancer;
KIRP	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.81	9.65	0.52	6.73e-19	Corneal astigmatism;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14329045	chr2:106694419	C2orf40	-0.46	-6.34	-0.37	1.06e-9	Inflammatory biomarkers;
KIRP	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.44	-5.65	-0.34	4.34e-8	Type 2 diabetes;
KIRP	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.69	-7.8	-0.45	1.8e-13	Adiposity;
KIRP	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02711726	chr17:80685570	FN3KRP	-0.7	-10.26	-0.55	8.73e-21	Glycated hemoglobin levels;
KIRP	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg05347473	chr6:146136440	FBXO30	0.62	8.8	0.49	2.54e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2652822	0.935	rs12594313	chr15:63436662	A/G	cg02713581	chr15:63449717	RPS27L	0.63	7.39	0.43	2.25e-12	Metabolic traits;
KIRP	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.12	0.41	1.17e-11	Lung cancer;
KIRP	cis	rs71277158	0.688	rs16854836	chr3:169804730	T/C	cg04067573	chr3:169899625	PHC3	0.59	5.7	0.34	3.36e-8	Prostate cancer;
KIRP	cis	rs1864400	0.690	rs2565200	chr10:43622933	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.84	-9.27	-0.51	9.89e-18	Hirschsprung disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26962342	chr5:153418526	MFAP3;FAM114A2	0.53	6.38	0.38	8.56e-10	Parkinson's disease;
KIRP	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.76	10.05	0.54	3.92e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08212772	chr14:21549755	FLJ10357	0.46	6.19	0.37	2.56e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.77	12.07	0.61	1.17e-26	Schizophrenia;
KIRP	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.16e-10	Axial length;
KIRP	cis	rs4716602	0.898	rs10275754	chr7:156161763	A/G	cg04090468	chr7:156181990	NA	0.45	5.4	0.33	1.6e-7	Anti-saccade response;
KIRP	cis	rs9535307	0.522	rs55732704	chr13:50414205	G/A	cg04663916	chr13:50265991	EBPL	-0.59	-5.86	-0.35	1.46e-8	Obesity-related traits;
KIRP	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.75	12.08	0.61	1.11e-26	Monocyte percentage of white cells;
KIRP	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.62	8.4	0.47	3.66e-15	Schizophrenia;
KIRP	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.67	-0.44	4.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9400467	0.506	rs11153281	chr6:111594594	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg04310649	chr10:35416472	CREM	-0.57	-6.94	-0.4	3.45e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg17757837	chr7:157058334	UBE3C	-0.81	-11.24	-0.58	6.13e-24	Body mass index;
KIRP	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.32	7.99	0.45	5.37e-14	Primary biliary cholangitis;
KIRP	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs911119	0.913	rs6036465	chr20:23588003	G/T	cg16589663	chr20:23618590	CST3	0.5	5.08	0.31	7.38e-7	Chronic kidney disease;
KIRP	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg00919237	chr7:87102261	ABCB4	-0.73	-9.14	-0.5	2.44e-17	Gallbladder cancer;
KIRP	cis	rs2901656	0.629	rs10752946	chr1:172376632	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.4	5.2	0.31	4.17e-7	Red cell distribution width;Platelet distribution width;
KIRP	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.8	10.78	0.57	1.97e-22	Morning vs. evening chronotype;
KIRP	cis	rs77956314	0.901	rs118117321	chr12:117414790	C/G	cg02017074	chr12:117425053	FBXW8	-0.95	-5.73	-0.34	2.95e-8	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg25418670	chr11:30344373	C11orf46	-0.61	-5.14	-0.31	5.64e-7	Morning vs. evening chronotype;
KIRP	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg17279839	chr7:150038598	RARRES2	0.46	6.08	0.36	4.62e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.83	11.14	0.58	1.32e-23	Platelet count;
KIRP	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg19257562	chr1:2043853	PRKCZ	-0.38	-5.48	-0.33	1.04e-7	Height;
KIRP	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg19554555	chr3:13937349	NA	-0.45	-6.16	-0.37	2.98e-9	Ovarian reserve;
KIRP	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-5.78	-0.35	2.25e-8	Schizophrenia;
KIRP	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.1	0.69	6.47e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.18e-8	Skin colour saturation;
KIRP	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg23625390	chr15:77176239	SCAPER	0.53	6.97	0.41	2.82e-11	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19275779	chr10:70166985	RUFY2	0.51	6.41	0.38	7.53e-10	Parkinson's disease;
KIRP	cis	rs1958560	0.863	rs1958559	chr14:66052055	C/T	cg03016385	chr14:66212404	NA	-0.39	-5.09	-0.31	7.04e-7	Menarche (age at onset);
KIRP	cis	rs7106204	0.668	rs7951530	chr11:24246904	T/C	ch.11.24196551F	chr11:24239977	NA	0.81	10.17	0.54	1.65e-20	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg00080972	chr5:178986291	RUFY1	0.37	5.43	0.33	1.35e-7	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22252469	chr13:33702794	STARD13	-0.44	-6.55	-0.39	3.27e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg24642439	chr20:33292090	TP53INP2	0.5	5.72	0.34	3.05e-8	Height;
KIRP	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs73108077	0.736	rs73105954	chr20:29943706	C/T	cg19241311	chr20:30028893	DEFB123	0.63	4.89	0.3	1.81e-6	Red blood cell density in sickle cell anemia;
KIRP	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg15691649	chr6:25882328	NA	0.42	5.11	0.31	6.32e-7	Blood metabolite levels;
KIRP	cis	rs629922	0.507	rs606942	chr11:114061889	A/T	cg01914181	chr11:114070210	ZBTB16	-0.51	-5.29	-0.32	2.65e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs7560272	0.723	rs62153184	chr2:73773869	G/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.42	-0.33	1.42e-7	Schizophrenia;
KIRP	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg06647332	chr5:131281008	NA	0.47	5.12	0.31	6.16e-7	Life satisfaction;
KIRP	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg16141378	chr3:129829833	LOC729375	-0.57	-7.57	-0.43	7.29e-13	Joint mobility (Beighton score);
KIRP	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.53	-6.69	-0.39	1.49e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs372883	0.509	rs28462110	chr21:30544318	C/T	cg24692254	chr21:30365293	RNF160	-0.42	-4.93	-0.3	1.48e-6	Pancreatic cancer;
KIRP	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.46	-6.28	-0.37	1.52e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs17539620	0.506	rs77962262	chr6:154845814	T/A	cg20019720	chr6:154832845	CNKSR3	0.45	5.76	0.34	2.49e-8	Lipoprotein (a) levels;
KIRP	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.47	6.08	0.36	4.53e-9	Menopause (age at onset);
KIRP	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-6.38	-0.38	8.61e-10	Response to antipsychotic treatment;
KIRP	cis	rs11264213	0.901	rs72661640	chr1:36447232	T/G	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg13962347	chr6:5174647	LYRM4	-0.75	-10.86	-0.57	1.05e-22	Height;
KIRP	cis	rs7537052	0.669	rs6686192	chr1:36642991	C/T	cg24686825	chr1:36642396	MAP7D1	-0.72	-9.59	-0.52	1.06e-18	Schizophrenia;
KIRP	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.89	10.42	0.55	2.69e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-0.73	-10.59	-0.56	7.64e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.59	-8.1	-0.46	2.64e-14	Diastolic blood pressure;
KIRP	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.73	-8.94	-0.5	9.33e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	trans	rs7857709	0.542	rs10813563	chr9:31369884	G/A	cg07287508	chr17:59471566	NA	0.39	6.08	0.36	4.58e-9	Lobe size;
KIRP	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg10223061	chr2:219282414	VIL1	-0.32	-5.52	-0.33	8.6e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.52	-5.52	-0.33	8.68e-8	Subjective well-being;
KIRP	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg15369054	chr17:80825471	TBCD	-0.62	-5.23	-0.32	3.59e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	ch.11.42038R	chr11:967971	AP2A2	0.39	4.93	0.3	1.53e-6	Alzheimer's disease (late onset);
KIRP	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg11569703	chr11:65557185	OVOL1	0.73	14.09	0.67	1.89e-33	Acne (severe);
KIRP	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg04731861	chr2:219085781	ARPC2	0.3	7.65	0.44	4.53e-13	Colorectal cancer;
KIRP	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22466217	chr16:89788880	C16orf7;ZNF276	0.5	6.36	0.38	9.54e-10	Smoking initiation;
KIRP	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-1.0	-13.26	-0.65	1.23e-30	Height;
KIRP	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4776059	1.000	rs1863512	chr15:52959687	C/T	cg25063058	chr15:52860530	ARPP19	0.58	6.38	0.38	8.82e-10	Schizophrenia;
KIRP	trans	rs2048656	0.578	rs4841235	chr8:9683358	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.11	-0.36	3.77e-9	Schizophrenia;
KIRP	cis	rs1116547	0.714	rs10063334	chr5:112760874	T/C	cg12552261	chr5:112820674	MCC	-0.48	-5.2	-0.31	4.11e-7	Cerebral amyloid angiopathy;
KIRP	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.66	0.34	4.29e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.55	-6.74	-0.39	1.12e-10	Type 2 diabetes;
KIRP	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg08280861	chr8:58055591	NA	0.67	6.15	0.37	3.06e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.45	6.82	0.4	6.99e-11	Coronary artery disease;
KIRP	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	10.4	0.55	3.06e-21	Smoking behavior;
KIRP	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.58	-7.39	-0.43	2.35e-12	Aortic root size;
KIRP	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.38	-7.92	-0.45	8.03e-14	Body mass index;
KIRP	cis	rs4727443	1.000	rs6974373	chr7:99590893	C/G	cg22004693	chr7:99632812	ZKSCAN1	0.41	5.5	0.33	9.63e-8	Interstitial lung disease;
KIRP	cis	rs7903847	0.642	rs7088410	chr10:99135539	G/T	cg20016023	chr10:99160130	RRP12	-0.42	-5.86	-0.35	1.46e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.72	-6.94	-0.4	3.49e-11	Menarche (age at onset);
KIRP	cis	rs8113308	0.810	rs8104626	chr19:52480617	G/A	cg25782003	chr19:52490127	ZNF350	0.55	5.0	0.3	1.1e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-1.09	-13.79	-0.66	1.97e-32	Obesity-related traits;
KIRP	cis	rs10924970	0.967	rs7518225	chr1:235394541	A/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.74	-0.34	2.81e-8	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.84	11.94	0.61	3.11e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs362296	0.590	rs4690081	chr4:3262105	T/G	cg06533319	chr4:3265114	C4orf44	0.59	7.68	0.44	3.66e-13	Parental longevity (mother's age at death);
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg08662619	chr6:150070041	PCMT1	0.37	6.1	0.36	4.05e-9	Lung cancer;
KIRP	cis	rs860295	0.776	rs11264362	chr1:155315615	C/T	cg02153340	chr1:155202674	NA	0.39	5.03	0.31	9.4e-7	Body mass index;
KIRP	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-1.01	-16.75	-0.73	1.53e-42	Height;
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08280861	chr8:58055591	NA	-0.68	-5.77	-0.35	2.42e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg27532560	chr4:187881888	NA	-0.73	-12.39	-0.62	9.92e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg06742321	chr12:123595122	PITPNM2	0.44	5.44	0.33	1.29e-7	Platelet count;
KIRP	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg17554472	chr22:41940697	POLR3H	-0.61	-6.53	-0.38	3.74e-10	Vitiligo;
KIRP	cis	rs7646881	1.000	rs73015654	chr3:158451654	G/A	cg19483011	chr3:158453295	NA	-0.58	-6.35	-0.38	1.03e-9	Tetralogy of Fallot;
KIRP	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg00074818	chr8:8560427	CLDN23	0.43	6.45	0.38	6.04e-10	Obesity-related traits;
KIRP	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg10503236	chr1:231470652	EXOC8	-0.5	-7.05	-0.41	1.76e-11	Hemoglobin concentration;
KIRP	cis	rs8067287	0.708	rs56369903	chr17:16838594	C/T	cg26910001	chr17:16838321	NA	-0.62	-5.88	-0.35	1.32e-8	Diabetic kidney disease;
KIRP	cis	rs12986413	1.000	rs4807208	chr19:2170205	A/C	cg09261902	chr19:2140048	AP3D1	0.64	10.0	0.54	5.7e-20	Height;
KIRP	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.51	-0.38	4.29e-10	Testicular germ cell tumor;
KIRP	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	1.09	20.16	0.79	5.05e-54	Height;
KIRP	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg22604316	chr1:46958801	NA	-0.35	-5.08	-0.31	7.42e-7	Monobrow;
KIRP	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	7.07	0.41	1.58e-11	Height;
KIRP	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg23594656	chr7:65796392	TPST1	0.52	8.08	0.46	2.96e-14	Aortic root size;
KIRP	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.21	-16.37	-0.72	3.04e-41	Type 1 diabetes nephropathy;
KIRP	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.97	15.22	0.7	2.68e-37	Menopause (age at onset);
KIRP	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.45	-5.84	-0.35	1.66e-8	Crohn's disease;
KIRP	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.17	11.53	0.59	7.16e-25	Alzheimer's disease (late onset);
KIRP	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg12623918	chr2:306882	NA	0.46	5.74	0.34	2.85e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.74	-8.34	-0.47	5.47e-15	Parkinson's disease;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg10744928	chr11:122889248	LOC341056	0.35	6.43	0.38	6.42e-10	Warfarin maintenance dose;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26943708	chr13:35516454	NBEA	0.48	6.86	0.4	5.64e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.65	9.31	0.51	7.54e-18	Menarche (age at onset);
KIRP	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg15436174	chr10:43711423	RASGEF1A	-0.53	-6.66	-0.39	1.78e-10	Hirschsprung disease;
KIRP	cis	rs4690686	0.500	rs72623907	chr4:177261965	C/G	cg17059388	chr4:177262070	NA	0.86	12.45	0.62	6.18e-28	Essential tremor;
KIRP	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg07451762	chr16:28383216	NA	0.38	4.99	0.3	1.14e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.9	9.1	0.5	3.06e-17	Methadone dose in opioid dependence;
KIRP	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg18944383	chr4:111397179	ENPEP	0.53	9.4	0.51	3.88e-18	Height;
KIRP	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg08992911	chr2:238395768	MLPH	0.41	5.1	0.31	6.86e-7	Prostate cancer;
KIRP	cis	rs7615316	0.751	rs57177110	chr3:142139172	T/C	cg20824294	chr3:142316082	PLS1	0.24	5.54	0.33	7.63e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg11569703	chr11:65557185	OVOL1	0.57	9.91	0.53	1.04e-19	Acne (severe);
KIRP	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg21017887	chr14:105400489	NA	-0.48	-7.66	-0.44	4.14e-13	Rheumatoid arthritis;
KIRP	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg01475377	chr6:109611718	NA	-0.39	-5.41	-0.33	1.47e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg20673091	chr1:2541236	MMEL1	0.69	10.59	0.56	7.91e-22	Multiple sclerosis;
KIRP	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.74	9.96	0.54	7.27e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs72949976	0.584	rs12471432	chr2:214022893	A/T	cg08319019	chr2:214017104	IKZF2	0.52	6.45	0.38	6.04e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.73	-8.54	-0.48	1.4e-15	Longevity;Endometriosis;
KIRP	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	1.06	23.28	0.83	3.94e-64	Breast cancer;
KIRP	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg08662619	chr6:150070041	PCMT1	0.33	5.34	0.32	2.08e-7	Testicular germ cell tumor;
KIRP	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.49	6.67	0.39	1.68e-10	Systemic lupus erythematosus;
KIRP	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg19507638	chr5:93509721	C5orf36	-0.6	-5.26	-0.32	3.06e-7	Diabetic retinopathy;
KIRP	cis	rs3857067	0.772	rs10018905	chr4:95076767	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-5.82	-0.35	1.82e-8	QT interval;
KIRP	cis	rs259842	0.670	rs1352110	chr2:180708518	C/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.3	-0.32	2.52e-7	Blood protein levels;
KIRP	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.72	8.85	0.49	1.76e-16	Cognitive function;
KIRP	cis	rs311392	0.525	rs311422	chr8:55105483	T/C	cg20636351	chr8:55087400	NA	-0.52	-6.17	-0.37	2.79e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg27147174	chr7:100797783	AP1S1	-0.71	-9.11	-0.5	2.98e-17	Life satisfaction;
KIRP	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg07936489	chr17:37558343	FBXL20	-0.5	-6.44	-0.38	6.2e-10	Asthma;
KIRP	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg18154014	chr19:37997991	ZNF793	0.7	7.65	0.44	4.57e-13	Coronary artery calcification;
KIRP	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg13628971	chr7:2884303	GNA12	0.46	6.05	0.36	5.22e-9	Height;
KIRP	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.96	-12.78	-0.63	5.04e-29	Exhaled nitric oxide output;
KIRP	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.8	10.27	0.55	7.81e-21	Mean platelet volume;
KIRP	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.82	11.06	0.58	2.38e-23	Height;
KIRP	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.08	-0.41	1.49e-11	Response to antipsychotic treatment;
KIRP	cis	rs17023223	0.537	rs3936018	chr1:119682370	T/C	cg05756136	chr1:119680316	WARS2	-0.51	-6.05	-0.36	5.3300000000000004e-09	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.99	15.49	0.7	3.09e-38	Diastolic blood pressure;
KIRP	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.89	10.56	0.56	9.6e-22	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-5.65	-0.34	4.33e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.55	-7.16	-0.42	9.24e-12	Aortic root size;
KIRP	trans	rs72683786	0.623	rs4596627	chr8:141708394	T/C	cg15577373	chr2:48642414	NA	0.45	6.08	0.36	4.46e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.44	-6.04	-0.36	5.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.8	11.0	0.57	3.64e-23	Aortic root size;
KIRP	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12667521	chr19:29218732	NA	0.6	5.24	0.32	3.4e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg02151108	chr14:50098012	C14orf104	-0.57	-7.99	-0.45	5.24e-14	Carotid intima media thickness;
KIRP	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs12765878	0.967	rs7920217	chr10:105668172	C/T	cg11005552	chr10:105648138	OBFC1	0.41	5.9	0.35	1.2e-8	Coronary artery disease;
KIRP	cis	rs3105593	0.901	rs3098200	chr15:50821945	G/A	cg08437265	chr15:50716283	USP8	0.38	5.16	0.31	5.17e-7	QT interval;
KIRP	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-9.26	-0.51	1.05e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.66	11.9	0.6	4.2e-26	Educational attainment (years of education);
KIRP	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19524238	chr7:2802976	GNA12	0.38	5.37	0.32	1.8e-7	Height;
KIRP	cis	rs4523957	0.928	rs170045	chr17:2196905	A/G	cg16513277	chr17:2031491	SMG6	0.6	8.31	0.47	6.62e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4740619	0.711	rs4740629	chr9:15981633	T/G	cg14451791	chr9:16040625	NA	-0.39	-4.92	-0.3	1.57e-6	Body mass index;
KIRP	cis	rs10214930	0.813	rs961724	chr7:27658035	A/C	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs4363385	0.574	rs4845505	chr1:152960943	T/A	cg25856811	chr1:152973957	SPRR3	-0.37	-5.17	-0.31	4.74e-7	Inflammatory skin disease;
KIRP	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.49	5.9	0.35	1.17e-8	Glycated hemoglobin levels;
KIRP	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00338735	chr4:53728038	RASL11B	0.43	5.32	0.32	2.29e-7	Optic nerve measurement (cup area);
KIRP	cis	rs4666002	0.789	rs4616435	chr2:27933642	C/T	cg27432699	chr2:27873401	GPN1	0.55	5.27	0.32	2.96e-7	Phospholipid levels (plasma);
KIRP	cis	rs4762326	0.584	rs10859858	chr12:95639676	T/C	cg07737802	chr12:95537812	FGD6	0.38	5.18	0.31	4.69e-7	Endometriosis;
KIRP	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.46	-5.78	-0.35	2.24e-8	Non-small cell lung cancer;
KIRP	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg05861140	chr6:150128134	PCMT1	-0.54	-7.68	-0.44	3.66e-13	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00684757	chr18:77711999	PQLC1	0.5	6.1	0.36	4.19e-9	Parkinson's disease;
KIRP	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg23100626	chr2:96804247	ASTL	-0.44	-5.49	-0.33	9.94e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	14.13	0.67	1.33e-33	Tonsillectomy;
KIRP	cis	rs4786125	0.588	rs1473516	chr16:6923077	C/T	cg03623568	chr16:6915990	A2BP1	-0.43	-5.27	-0.32	3.04e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.72	-0.63	7.93e-29	Alzheimer's disease;
KIRP	cis	rs9828933	0.882	rs3816156	chr3:63999712	A/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.84	-9.09	-0.5	3.31e-17	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg20261243	chr20:44718728	NCOA5	-0.49	-6.19	-0.37	2.45e-9	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20091128	chr12:104234963	NT5DC3	0.51	6.34	0.37	1.11e-9	Parkinson's disease;
KIRP	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05776053	chr2:74358815	NA	0.48	5.16	0.31	5e-7	Gestational age at birth (maternal effect);
KIRP	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.61	-7.99	-0.45	5.36e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2219968	1.000	rs7465474	chr8:78959166	C/T	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2044029	0.617	rs11852640	chr15:71645663	C/G	cg19634315	chr15:71679485	THSD4	-0.39	-5.09	-0.31	7.08e-7	Airflow obstruction;
KIRP	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg00310523	chr12:86230176	RASSF9	0.47	7.47	0.43	1.36e-12	Major depressive disorder;
KIRP	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.27	-7.05	-0.41	1.8e-11	Rheumatoid arthritis;
KIRP	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg27170947	chr2:26402098	FAM59B	0.53	5.99	0.36	7.53e-9	Gut microbiome composition (summer);
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.43	-5.0	-0.3	1.07e-6	Longevity;Endometriosis;
KIRP	cis	rs2403221	0.547	rs11042503	chr11:9847641	A/G	cg07197493	chr11:9884649	SBF2	-0.35	-4.88	-0.3	1.9e-6	Smoking initiation;
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg03188948	chr7:1209495	NA	0.76	5.09	0.31	7.14e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17885091	chr1:68299057	GNG12	-0.55	-6.93	-0.4	3.59e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg11764359	chr7:65958608	NA	0.78	5.12	0.31	6.21e-7	Diabetic kidney disease;
KIRP	cis	rs4006360	0.606	rs11657468	chr17:39233876	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-9.91	-0.53	1.05e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs6466055	0.589	rs17270450	chr7:105013788	G/A	cg04380332	chr7:105027541	SRPK2	0.36	4.91	0.3	1.66e-6	Schizophrenia;
KIRP	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.76	0.4	1.01e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.87	-0.66	1.06e-32	Ulcerative colitis;
KIRP	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.82	-9.53	-0.52	1.64e-18	Osteoarthritis;
KIRP	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg23791538	chr6:167370224	RNASET2	-0.42	-5.31	-0.32	2.46e-7	Crohn's disease;
KIRP	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg18032289	chr17:61959525	GH2	-0.39	-4.97	-0.3	1.25e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11987759	chr7:65425863	GUSB	-0.53	-7.01	-0.41	2.23e-11	Aortic root size;
KIRP	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.84	11.27	0.58	4.99e-24	Age at first birth;
KIRP	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.44	-5.12	-0.31	6.03e-7	Obesity-related traits;
KIRP	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.54	-6.61	-0.39	2.35e-10	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9488822	0.623	rs195518	chr6:116241693	A/G	cg26893134	chr6:116381904	FRK	0.2	5.43	0.33	1.32e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.59	-6.52	-0.38	4.04e-10	Corneal structure;
KIRP	cis	rs7116495	0.881	rs673478	chr11:71799104	G/A	cg26138937	chr11:71823887	C11orf51	-0.71	-5.64	-0.34	4.59e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2288327	0.643	rs16866334	chr2:179336672	A/G	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	0.62	6.07	0.36	4.71e-9	Atrial fibrillation;
KIRP	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.4e-12	Bipolar disorder;
KIRP	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg03289416	chr15:75166202	SCAMP2	0.52	7.05	0.41	1.76e-11	Breast cancer;
KIRP	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.95	13.0	0.64	9.51e-30	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24902075	chr3:127309853	TPRA1	0.49	6.08	0.36	4.67e-9	Parkinson's disease;
KIRP	cis	rs7851660	0.844	rs6478445	chr9:100624299	A/G	cg13688889	chr9:100608707	NA	-0.69	-8.99	-0.5	6.83e-17	Strep throat;
KIRP	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.74	8.17	0.46	1.61e-14	Corneal astigmatism;
KIRP	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg07541023	chr7:19748670	TWISTNB	0.64	5.71	0.34	3.24e-8	Thyroid stimulating hormone;
KIRP	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.57	-6.74	-0.39	1.13e-10	Type 2 diabetes;
KIRP	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-0.97	-10.4	-0.55	3.15e-21	Blood pressure (smoking interaction);
KIRP	cis	rs13418717	0.793	rs13403026	chr2:127618436	A/G	cg25501666	chr2:127640322	NA	-1.17	-7.52	-0.43	1e-12	Heart failure;
KIRP	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.05	0.31	8.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg23594656	chr7:65796392	TPST1	-0.49	-7.57	-0.43	7.38e-13	Aortic root size;
KIRP	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg23803603	chr1:2058230	PRKCZ	-0.4	-6.28	-0.37	1.5e-9	Height;
KIRP	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg17105886	chr17:28927953	LRRC37B2	0.54	5.54	0.33	7.69e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.29	-0.42	4.3e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4638749	0.501	rs750523	chr2:108746221	T/C	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.04	-0.31	8.97e-7	Blood pressure;
KIRP	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	6.5	0.38	4.36e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.63	7.68	0.44	3.72e-13	Corneal astigmatism;
KIRP	cis	rs7246657	0.551	rs10407224	chr19:37651470	G/T	cg23950597	chr19:37808831	NA	-0.74	-6.62	-0.39	2.25e-10	Coronary artery calcification;
KIRP	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.37	-0.32	1.81e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.57	7.43	0.43	1.83e-12	Red blood cell count;
KIRP	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.56	6.89	0.4	4.75e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg05666200	chr11:89790683	NA	-0.52	-5.53	-0.33	8.21e-8	White blood cell types;
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg19500275	chr17:80737654	TBCD	0.45	5.36	0.32	1.91e-7	Glycated hemoglobin levels;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg16405210	chr4:1374714	KIAA1530	-0.45	-5.56	-0.33	7.1e-8	Obesity-related traits;
KIRP	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.95	-16.34	-0.72	4e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg08761264	chr16:28874980	SH2B1	-0.46	-5.03	-0.31	9.31e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	0.79	10.39	0.55	3.26e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg10189774	chr4:17578691	LAP3	0.46	5.51	0.33	9.06e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	16.93	0.73	3.86e-43	Height;
KIRP	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.54	7.24	0.42	5.84e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs9362426	0.895	rs242292	chr6:88078074	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	5.66	0.34	4.18e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg22906224	chr7:99728672	NA	-0.52	-6.28	-0.37	1.52e-9	Coronary artery disease;
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg05025164	chr4:1340916	KIAA1530	0.45	5.43	0.33	1.35e-7	Obesity-related traits;
KIRP	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.62	-8.11	-0.46	2.38e-14	Inhibitory control;
KIRP	cis	rs1270639	0.778	rs2906928	chr7:157444976	T/G	cg13357408	chr7:157437802	PTPRN2	0.62	5.99	0.36	7.5e-9	Colorectal cancer;
KIRP	cis	rs8018808	1.000	rs35881785	chr14:77873571	C/T	cg20045696	chr14:77926864	AHSA1	0.43	5.19	0.31	4.35e-7	Myeloid white cell count;
KIRP	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.74	-8.17	-0.46	1.63e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.51	8.28	0.47	7.68e-15	Rheumatoid arthritis;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.3	5.74	0.34	2.8e-8	Lymphocyte counts;
KIRP	cis	rs1009181	0.585	rs2066295	chr6:26168903	A/G	cg00631329	chr6:26305371	NA	-0.59	-6.68	-0.39	1.56e-10	Childhood ear infection;
KIRP	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.7	-0.39	1.42e-10	Response to antipsychotic treatment;
KIRP	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.81	-0.35	1.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg00405596	chr8:11794950	NA	0.44	5.51	0.33	9.27e-8	Retinal vascular caliber;
KIRP	cis	rs4671458	1.000	rs72813411	chr2:63364225	G/C	cg17519650	chr2:63277830	OTX1	-0.56	-5.64	-0.34	4.57e-8	Subjective well-being;
KIRP	cis	rs7923609	1.000	rs4379723	chr10:64963449	T/C	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.61	-0.34	5.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg25309564	chr22:51001381	C22orf41	0.53	5.08	0.31	7.31e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4561483	0.583	rs10852344	chr16:12016919	C/T	cg08843971	chr16:11963173	GSPT1	0.54	7.56	0.43	7.82e-13	Testicular germ cell tumor;
KIRP	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg12861170	chr19:19639553	YJEFN3	-0.47	-5.31	-0.32	2.43e-7	Bipolar disorder;
KIRP	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg11965913	chr1:205819406	PM20D1	-0.61	-6.03	-0.36	6.02e-9	Menarche (age at onset);
KIRP	cis	rs11608355	0.508	rs11066394	chr12:109799212	C/A	cg19025524	chr12:109796872	NA	-0.43	-5.38	-0.32	1.75e-7	Neuroticism;
KIRP	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	7.12	0.41	1.19e-11	Aortic root size;
KIRP	cis	rs2415984	0.622	rs2415998	chr14:46930712	A/G	cg14871534	chr14:47121158	RPL10L	-0.43	-5.15	-0.31	5.35e-7	Number of children ever born;
KIRP	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-1.07	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.63	-6.66	-0.39	1.82e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06544989	chr22:39130855	UNC84B	0.48	8.29	0.47	7.3e-15	Menopause (age at onset);
KIRP	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg04080417	chr5:1859792	NA	-0.57	-6.37	-0.38	9.28e-10	Cardiovascular disease risk factors;
KIRP	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.49	7.75	0.44	2.39e-13	Major depressive disorder;
KIRP	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.18	23.98	0.84	2.56e-66	Chronic sinus infection;
KIRP	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.95	-0.3	1.39e-6	Metabolite levels;
KIRP	cis	rs7737355	0.812	rs32107	chr5:131039633	C/A	cg25547332	chr5:131281432	NA	0.39	4.85	0.3	2.23e-6	Life satisfaction;
KIRP	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.21	21.86	0.81	1.41e-59	Cognitive function;
KIRP	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg14675211	chr2:100938903	LONRF2	0.46	5.38	0.32	1.72e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35995292	0.500	rs2392606	chr7:38926955	C/A	cg19327137	chr7:38886074	VPS41	0.79	12.13	0.61	7.34e-27	Subjective well-being (multi-trait analysis);
KIRP	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg23815491	chr16:72088622	HP	0.43	5.98	0.36	7.92e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.14	16.52	0.73	9.43e-42	Breast cancer;
KIRP	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.21	22.12	0.82	1.97e-60	Cognitive function;
KIRP	cis	rs926938	0.618	rs360587	chr1:115467553	A/G	cg12756093	chr1:115239321	AMPD1	0.57	7.95	0.45	6.97e-14	Autism;
KIRP	cis	rs56399783	0.901	rs73051444	chr7:2866529	G/A	cg19731401	chr7:2775893	GNA12	0.71	6.45	0.38	6.01e-10	Childhood ear infection;
KIRP	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	5.58	0.34	6.43e-8	Renal cell carcinoma;
KIRP	cis	rs9469913	0.799	rs2814996	chr6:34621314	T/C	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.13	-0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.75	8.99	0.5	6.73e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg08761264	chr16:28874980	SH2B1	-0.45	-4.93	-0.3	1.54e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.9	-13.52	-0.65	1.59e-31	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg10189774	chr4:17578691	LAP3	0.48	5.73	0.34	2.93e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg21191810	chr6:118973309	C6orf204	0.39	5.49	0.33	9.78e-8	Electrocardiographic conduction measures;
KIRP	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.46	-10.25	-0.55	9.22e-21	Alzheimer's disease (late onset);
KIRP	cis	rs4523957	0.553	rs2131702	chr17:2025458	T/C	cg16513277	chr17:2031491	SMG6	-0.84	-12.62	-0.63	1.8e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg01620082	chr3:125678407	NA	-0.93	-6.24	-0.37	1.93e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg25019033	chr10:957182	NA	-0.64	-7.82	-0.45	1.6e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs3850699	0.926	rs7094325	chr10:104429746	G/C	cg04362960	chr10:104952993	NT5C2	0.52	6.03	0.36	6e-9	Prostate cancer;
KIRP	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.47	5.93	0.35	1.01e-8	Height;
KIRP	cis	rs258892	1.000	rs187731	chr5:72289671	G/T	cg21869765	chr5:72125136	TNPO1	0.54	6.55	0.39	3.25e-10	Small cell lung carcinoma;
KIRP	cis	rs9815354	1.000	rs2272006	chr3:41997059	C/T	cg03022575	chr3:42003672	ULK4	-0.5	-5.65	-0.34	4.46e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.94	-14.36	-0.68	2.3e-34	Body mass index;
KIRP	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	1.0	7.17	0.42	8.91e-12	IgG glycosylation;
KIRP	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19346786	chr7:2764209	NA	-0.29	-4.92	-0.3	1.57e-6	Height;
KIRP	cis	rs12249377	0.519	rs4520504	chr10:92602373	T/C	cg14313238	chr10:92632228	RPP30	0.47	5.71	0.34	3.26e-8	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.65	0.44	4.49e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.68	-9.44	-0.52	2.88e-18	Brugada syndrome;
KIRP	cis	rs3737883	1.000	rs11579558	chr1:203032038	G/T	cg03900565	chr1:203031815	PPFIA4	0.4	5.75	0.34	2.59e-8	Early onset atrial fibrillation;
KIRP	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.47	5.05	0.31	8.8e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg05914723	chr15:78953907	NA	0.44	5.2	0.31	4.25e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg19894588	chr14:64061835	NA	-0.64	-7.56	-0.43	7.81e-13	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs946836	0.537	rs7529370	chr1:48402367	G/A	cg08121652	chr1:48381824	NA	0.21	4.84	0.3	2.25e-6	White matter integrity;
KIRP	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg14768367	chr16:72042858	DHODH	0.44	5.35	0.32	2.05e-7	Fibrinogen levels;
KIRP	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.32	-0.42	3.49e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8133932	0.520	rs380120	chr21:47364511	C/A	cg11214348	chr21:47283868	PCBP3	-0.44	-5.16	-0.31	5.2e-7	Schizophrenia;
KIRP	trans	rs8001976	0.510	rs17422793	chr13:48321136	T/A	cg23237801	chr1:16476620	EPHA2	0.52	6.48	0.38	5.07e-10	Aging (time to event);
KIRP	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.77	8.8	0.49	2.4e-16	Corneal astigmatism;
KIRP	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.51	-5.8	-0.35	2.03e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.8	11.12	0.58	1.54e-23	Menarche (age at onset);
KIRP	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.69	10.35	0.55	4.54e-21	Dupuytren's disease;
KIRP	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	7.89	0.45	1.02e-13	Eosinophil percentage of white cells;
KIRP	cis	rs929596	0.531	rs2741021	chr2:234511883	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.47	5.22	0.32	3.81e-7	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs28680850	0.541	rs1024549	chr8:1377191	C/T	cg09050832	chr8:1365175	NA	0.56	4.89	0.3	1.85e-6	Triglycerides;
KIRP	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.56	7.2	0.42	7.41e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7187994	0.848	rs16974560	chr16:84788425	A/G	cg07647771	chr16:84786436	USP10	-0.42	-5.37	-0.32	1.8e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg19500275	chr17:80737654	TBCD	0.46	5.47	0.33	1.11e-7	Glycated hemoglobin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10691848	chr3:184032283	EIF4G1	0.46	6.21	0.37	2.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.38	4.96	0.3	1.33e-6	Melanoma;
KIRP	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.66	6.42	0.38	7.05e-10	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20225246	chr19:2200020	DOT1L	0.46	6.55	0.39	3.3e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03452623	chr4:187889614	NA	-1.03	-18.64	-0.77	6.04e-49	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.44	-5.35	-0.32	1.99e-7	Testicular germ cell tumor;
KIRP	cis	rs2790457	0.760	rs1265834	chr10:28941861	A/G	cg04045419	chr10:28823091	WAC	0.46	5.09	0.31	7.19e-7	Multiple myeloma;
KIRP	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.7	13.72	0.66	3.37e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg01988459	chr11:68622903	NA	-0.39	-5.53	-0.33	8.14e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.44	6.05	0.36	5.42e-9	Schizophrenia;
KIRP	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg10223061	chr2:219282414	VIL1	-0.37	-6.13	-0.36	3.39e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.52	-6.58	-0.39	2.79e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25595541	chr3:73109909	FLJ10213;PPP4R2	0.42	6.27	0.37	1.64e-9	Interleukin-4 levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04760117	chr10:75900017	AP3M1	0.43	6.11	0.36	3.89e-9	Cancer;
KIRP	cis	rs9549260	0.564	rs4943804	chr13:41269994	A/G	cg21288729	chr13:41239152	FOXO1	0.52	6.69	0.39	1.49e-10	Red blood cell count;
KIRP	trans	rs62056376	0.736	rs1233651	chr17:32639361	C/T	cg13554086	chr5:76507100	PDE8B	0.54	6.43	0.38	6.71e-10	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs4953911	0.963	rs4144833	chr2:135064596	C/T	cg18482303	chr2:135041380	MGAT5	-0.27	-5.0	-0.3	1.07e-6	Multiple sclerosis (severity);
KIRP	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.33	0.79	1.39e-54	Chronic sinus infection;
KIRP	cis	rs9914544	0.545	rs4393623	chr17:18775900	A/G	cg26378065	chr17:18585709	ZNF286B	0.4	5.3	0.32	2.51e-7	Educational attainment (years of education);
KIRP	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2296225	0.556	rs7552264	chr1:21087927	G/A	cg14666476	chr1:21112556	HP1BP3	0.56	5.76	0.34	2.46e-8	Eosinophilic esophagitis;
KIRP	cis	rs7937612	1.000	rs12417256	chr11:120337519	A/C	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.01	-0.41	2.28e-11	Intraocular pressure;
KIRP	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg18016565	chr1:150552671	MCL1	0.39	5.92	0.35	1.07e-8	Melanoma;
KIRP	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg06115741	chr20:33292138	TP53INP2	-0.47	-6.13	-0.36	3.53e-9	Coronary artery disease;
KIRP	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08903422	chr17:7328532	C17orf74	0.43	6.8	0.4	7.77e-11	Survival in pancreatic cancer;
KIRP	trans	rs12517041	1.000	rs7737671	chr5:23288400	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.92	-0.49	1.11e-16	Calcium levels;
KIRP	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.61	-7.7	-0.44	3.26e-13	Personality dimensions;
KIRP	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.82	0.53	2.02e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-9.08	-0.5	3.61e-17	Resting heart rate;
KIRP	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg19847130	chr8:10466454	RP1L1	-0.35	-5.13	-0.31	5.82e-7	Retinal vascular caliber;
KIRP	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.72	0.71	5.08e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.83	-0.45	1.49e-13	Platelet count;
KIRP	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.19	0.51	1.69e-17	Electroencephalogram traits;
KIRP	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-8.66	-0.48	6.27e-16	Alzheimer's disease;
KIRP	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg09699651	chr6:150184138	LRP11	0.47	6.05	0.36	5.44e-9	Lung cancer;
KIRP	cis	rs28489187	0.667	rs233114	chr1:85786957	T/G	cg16011679	chr1:85725395	C1orf52	0.5	6.11	0.36	3.9e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg00319359	chr11:70116639	PPFIA1	0.77	6.64	0.39	2.03e-10	Coronary artery disease;
KIRP	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.64	7.38	0.43	2.45e-12	Alcohol dependence;
KIRP	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.84	14.0	0.67	3.82e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	0.75	6.97	0.41	2.89e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs778371	0.749	rs2592120	chr2:233793664	C/T	cg11972305	chr2:233791962	NGEF	-0.42	-5.43	-0.33	1.34e-7	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02738049	chr15:43663357	ZSCAN29;TUBGCP4	0.56	7.01	0.41	2.24e-11	Parkinson's disease;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01765077	chr12:122356316	WDR66	0.43	5.9	0.35	1.18e-8	Mean corpuscular volume;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17328631	chr3:124609514	NA	-0.45	-6.01	-0.36	6.48e-9	Inflammatory biomarkers;
KIRP	cis	rs6987853	0.933	rs2974353	chr8:42409165	A/C	cg09913449	chr8:42400586	C8orf40	0.39	5.08	0.31	7.35e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg23121777	chr7:75115714	POM121C	0.54	7.02	0.41	2.16e-11	Educational attainment;
KIRP	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg10189774	chr4:17578691	LAP3	0.51	6.12	0.36	3.7e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.42	5.47	0.33	1.11e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs740495	0.615	rs2075710	chr19:1106845	C/T	cg01235197	chr19:1119986	SBNO2	0.46	5.38	0.32	1.71e-7	Crohn's disease;
KIRP	cis	rs3736594	0.918	rs9677663	chr2:27972445	G/A	cg27432699	chr2:27873401	GPN1	-0.59	-7.64	-0.44	4.87e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg10503236	chr1:231470652	EXOC8	-0.48	-6.55	-0.39	3.43e-10	Hemoglobin concentration;
KIRP	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	cg12689670	chr1:183009347	LAMC1	0.58	8.06	0.46	3.31e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs7534824	0.625	rs61780332	chr1:101484733	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.68	5.38	0.32	1.71e-7	Refractive astigmatism;
KIRP	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.56	-5.41	-0.33	1.5e-7	Hip geometry;
KIRP	cis	rs7246657	0.722	rs2909102	chr19:38167364	C/T	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg13857086	chr12:6580257	VAMP1	0.87	8.53	0.48	1.48e-15	Hip geometry;
KIRP	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	-0.42	-5.15	-0.31	5.32e-7	Lung cancer;
KIRP	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	14.43	0.68	1.31e-34	Gut microbiome composition (summer);
KIRP	cis	rs62380364	0.602	rs606393	chr5:88058163	T/C	cg24804195	chr5:87968844	LOC645323	-0.43	-5.56	-0.33	6.85e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.73	0.34	2.94e-8	Motion sickness;
KIRP	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.92	15.59	0.7	1.43e-38	Metabolic syndrome;
KIRP	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.65	-0.44	4.61e-13	Aortic root size;
KIRP	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.51	-6.64	-0.39	1.99e-10	Type 2 diabetes;
KIRP	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04013166	chr16:89971882	TCF25	0.64	5.6	0.34	5.75e-8	Skin colour saturation;
KIRP	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg13395646	chr4:1353034	KIAA1530	0.37	4.88	0.3	1.87e-6	Obesity-related traits;
KIRP	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.72	-8.72	-0.49	4.18e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.86	10.37	0.55	3.75e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs580438	0.510	rs6442376	chr3:13411823	T/C	cg10657019	chr3:13328039	NA	-0.52	-6.79	-0.4	8.22e-11	Myringotomy;
KIRP	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.5	-7.09	-0.41	1.39e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12643440	1.000	rs567404	chr4:17201248	G/T	cg22650099	chr4:17144496	NA	0.42	5.3	0.32	2.53e-7	Metabolite levels (Pyroglutamine);
KIRP	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg02297831	chr4:17616191	MED28	0.56	6.66	0.39	1.81e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs494562	0.892	rs617483	chr6:86124008	C/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13866795	chr9:135283313	TTF1	0.56	7.2	0.42	7.27e-12	Interleukin-4 levels;
KIRP	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06307176	chr5:131281290	NA	0.54	5.91	0.35	1.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.37	5.42	0.33	1.45e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs405956	0.769	rs4945716	chr6:105573741	C/T	cg22580625	chr6:105627791	POPDC3	-0.48	-5.33	-0.32	2.24e-7	QT interval;
KIRP	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg01879757	chr17:41196368	BRCA1	-0.76	-10.58	-0.56	8.56e-22	Menopause (age at onset);
KIRP	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.97	-16.64	-0.73	3.52e-42	Breast cancer;
KIRP	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg09904177	chr6:26538194	HMGN4	-0.4	-4.93	-0.3	1.51e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.66	7.62	0.44	5.53e-13	Gut microbiome composition (summer);
KIRP	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg20312557	chr2:97357134	FER1L5	-0.7	-4.91	-0.3	1.66e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.47	6.62	0.39	2.29e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs67145503	0.769	rs913987	chr9:130629139	G/T	cg13483413	chr9:130628573	NA	-0.37	-4.86	-0.3	2.08e-6	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs9513593	0.892	rs7320298	chr13:99875666	G/T	cg21788972	chr13:99853209	UBAC2	0.65	6.41	0.38	7.2e-10	Psoriasis;
KIRP	cis	rs2446066	0.605	rs8938	chr12:53936878	G/T	cg16917193	chr12:54089295	NA	0.64	5.68	0.34	3.83e-8	Red blood cell count;
KIRP	cis	rs77688320	0.535	rs7579853	chr2:202248979	T/A	cg06431681	chr2:202330990	STRADB	0.51	6.78	0.4	9.02e-11	Breast cancer;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22168489	chr12:122356033	WDR66	0.66	9.74	0.53	3.49e-19	Mean corpuscular volume;
KIRP	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg08499158	chr17:42289980	UBTF	-0.73	-9.8	-0.53	2.36e-19	Total body bone mineral density;
KIRP	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg23719950	chr11:63933701	MACROD1	-0.66	-6.49	-0.38	4.77e-10	Mean platelet volume;
KIRP	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.65	-8.3	-0.47	6.78e-15	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.05	0.36	5.5e-9	Hypertriglyceridemia;
KIRP	cis	rs6693295	0.838	rs1416086	chr1:246237560	A/G	cg11798871	chr1:246315928	SMYD3	-0.39	-4.94	-0.3	1.46e-6	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.5	6.86	0.4	5.49e-11	Mean corpuscular volume;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg19768357	chr5:77072009	TBCA	0.48	6.08	0.36	4.66e-9	Myopia (pathological);
KIRP	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg00125455	chr20:44574271	PCIF1	-0.31	-5.03	-0.31	9.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1116547	0.714	rs57530930	chr5:112765075	T/C	cg12552261	chr5:112820674	MCC	-0.48	-5.2	-0.31	4.11e-7	Cerebral amyloid angiopathy;
KIRP	cis	rs12780845	0.540	rs2273736	chr10:17195428	G/C	cg01003015	chr10:17271136	VIM	-0.43	-5.15	-0.31	5.31e-7	Homocysteine levels;
KIRP	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.66	-9.08	-0.5	3.76e-17	QRS duration;
KIRP	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.56	8.0	0.45	4.92e-14	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4936891	0.599	rs729775	chr11:123910401	C/A	cg22125253	chr11:123886957	OR10G4	-0.41	-5.18	-0.31	4.63e-7	Male fertility;
KIRP	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs8014252	0.803	rs73282127	chr14:70986413	T/C	cg11204974	chr14:71022665	NA	-0.62	-6.59	-0.39	2.66e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg23216685	chr1:86174607	ZNHIT6	-0.55	-7.34	-0.42	3.06e-12	Urate levels in overweight individuals;
KIRP	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.54	6.58	0.39	2.75e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs4765905	0.671	rs11062166	chr12:2334260	G/A	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.69	-0.34	3.56e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16405026	chr2:145281942	NA	0.44	6.64	0.39	1.97e-10	Parkinson's disease;
KIRP	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.6	7.67	0.44	3.98e-13	Body mass index;
KIRP	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-1.03	-12.18	-0.61	5.14e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.79	-7.64	-0.44	4.96e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.99	11.89	0.6	4.52e-26	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg02600515	chr11:62521696	ZBTB3	0.49	5.1	0.31	6.64e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.26	5.02	0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg21926883	chr2:100939477	LONRF2	-0.52	-6.95	-0.41	3.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-0.69	-7.05	-0.41	1.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25519033	chr11:695585	TMEM80;DEAF1	0.51	6.57	0.39	3.05e-10	Parkinson's disease;
KIRP	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg25036284	chr2:26402008	FAM59B	-0.59	-5.94	-0.35	9.91e-9	Gut microbiome composition (summer);
KIRP	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.34	-0.32	2.14e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	10.26	0.55	8.33e-21	Coronary artery disease;
KIRP	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.87	12.47	0.62	5.6e-28	Coronary artery disease;
KIRP	cis	rs17030434	0.784	rs11099896	chr4:154664697	T/G	cg14289246	chr4:154710475	SFRP2	-0.52	-6.88	-0.4	5.06e-11	Electrocardiographic conduction measures;
KIRP	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.73	5.29	0.32	2.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg11814155	chr7:99998594	ZCWPW1	0.58	5.41	0.33	1.53e-7	Platelet count;
KIRP	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19821804	chr19:49401915	TULP2	0.44	6.04	0.36	5.56e-9	Survival in pancreatic cancer;
KIRP	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.15	12.4	0.62	9.58e-28	Mitochondrial DNA levels;
KIRP	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg07309820	chr7:148901717	ZNF282	-0.4	-5.21	-0.32	3.92e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg24304309	chr1:154577895	ADAR	0.37	5.53	0.33	8.36e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7221595	0.673	rs115725560	chr17:3980493	T/A	cg09695851	chr17:3907499	NA	0.59	5.72	0.34	3.03e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs4664293	1.000	rs6745766	chr2:160454795	G/A	cg08347373	chr2:160653686	CD302	-0.39	-5.97	-0.36	8.08e-9	Monocyte percentage of white cells;
KIRP	cis	rs7523050	0.749	rs193139	chr1:109483975	T/C	cg08274380	chr1:109419600	GPSM2	0.57	5.52	0.33	8.81e-8	Fat distribution (HIV);
KIRP	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.67	10.1	0.54	2.65e-20	Age-related hearing impairment;
KIRP	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.44	7.57	0.43	7.29e-13	Testicular germ cell tumor;
KIRP	cis	rs17102423	0.559	rs7160037	chr14:65490948	T/C	cg11161011	chr14:65562177	MAX	-0.64	-7.29	-0.42	4.31e-12	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg22105103	chr4:187893119	NA	0.73	10.6	0.56	7.24e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.58	8.8	0.49	2.39e-16	Personality dimensions;
KIRP	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg12292205	chr6:26970375	C6orf41	-0.34	-5.07	-0.31	7.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.55	-7.28	-0.42	4.56e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs16857609	1.000	rs3821098	chr2:218292141	T/C	cg15335768	chr2:218268053	DIRC3	0.35	5.14	0.31	5.6e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.46	5.15	0.31	5.4e-7	Schizophrenia;
KIRP	cis	rs2548724	0.513	rs1452058	chr5:101642903	G/C	cg19774478	chr5:101632501	SLCO4C1	0.62	6.34	0.37	1.1e-9	Type 2 diabetes;
KIRP	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.82	10.05	0.54	4.02e-20	Corneal astigmatism;
KIRP	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.71	11.01	0.57	3.41e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs806215	0.950	rs989099	chr7:127220827	A/G	cg25922125	chr7:127225783	GCC1	-0.52	-5.36	-0.32	1.92e-7	Type 2 diabetes;
KIRP	cis	rs12282928	0.729	rs7932309	chr11:48345179	T/C	cg26585981	chr11:48327164	OR4S1	0.52	6.26	0.37	1.7e-9	Migraine - clinic-based;
KIRP	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01200585	chr1:228362443	C1orf69	-0.46	-5.92	-0.35	1.05e-8	Diastolic blood pressure;
KIRP	cis	rs7175404	1.000	rs56697175	chr15:94038296	T/C	cg23502883	chr15:93959149	NA	0.54	5.67	0.34	3.92e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.54	5.47	0.33	1.1e-7	Height;
KIRP	cis	rs3736594	0.513	rs62138968	chr2:27824485	C/G	cg27432699	chr2:27873401	GPN1	0.55	6.14	0.36	3.34e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06873606	chr13:20625618	ZMYM2	-0.45	-6.76	-0.4	9.73e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg09264619	chr17:80180166	NA	-0.37	-5.33	-0.32	2.22e-7	Life satisfaction;
KIRP	cis	rs4740619	0.557	rs997410	chr9:16040430	A/G	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.67	9.62	0.52	8.7e-19	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.12	-0.41	1.18e-11	Glomerular filtration rate;
KIRP	cis	rs1620921	0.967	rs1247555	chr6:161189018	A/C	cg01280913	chr6:161186852	NA	-0.41	-5.61	-0.34	5.57e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg08847533	chr14:75593920	NEK9	-1.05	-19.65	-0.78	2.44e-52	Height;
KIRP	cis	rs7546094	1.000	rs2932532	chr1:113234456	G/A	cg22162597	chr1:113214053	CAPZA1	-0.51	-7.42	-0.43	1.95e-12	Platelet distribution width;
KIRP	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.6e-25	Morning vs. evening chronotype;
KIRP	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	1.12	10.55	0.56	1.03e-21	Left atrial antero-posterior diameter;
KIRP	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg11738485	chr19:12877000	HOOK2	-0.47	-5.48	-0.33	1.04e-7	Mean corpuscular volume;
KIRP	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg26335602	chr6:28129616	ZNF389	0.44	4.84	0.3	2.27e-6	Parkinson's disease;
KIRP	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg03465714	chr1:152285911	FLG	-0.41	-4.92	-0.3	1.57e-6	Atopic dermatitis;
KIRP	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg23032965	chr3:12705835	RAF1	0.73	8.05	0.46	3.49e-14	Cholesterol, total;
KIRP	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg24807547	chr6:37504484	NA	-0.44	-6.2	-0.37	2.39e-9	Cognitive performance;
KIRP	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg13319975	chr6:146136371	FBXO30	0.37	5.1	0.31	6.91e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.53	-6.18	-0.37	2.69e-9	Urate levels in overweight individuals;
KIRP	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.92	7.57	0.43	7.69e-13	IgG glycosylation;
KIRP	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg05564831	chr3:52568323	NT5DC2	0.45	7.29	0.42	4.16e-12	Electroencephalogram traits;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg06212747	chr3:49208901	KLHDC8B	0.63	8.86	0.49	1.6e-16	Resting heart rate;
KIRP	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg20430773	chr1:16534157	ARHGEF19	-0.56	-6.7	-0.39	1.4e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.58	7.0	0.41	2.49e-11	Osteoporosis;
KIRP	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg22903471	chr2:27725779	GCKR	0.39	5.37	0.32	1.86e-7	Oral cavity cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26939377	chr19:41869719	B9D2;TMEM91	0.42	6.09	0.36	4.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg00800038	chr16:89945340	TCF25	-0.62	-6.08	-0.36	4.48e-9	Skin colour saturation;
KIRP	cis	rs9826463	1.000	rs6800573	chr3:142345817	C/T	cg20824294	chr3:142316082	PLS1	0.34	5.59	0.34	5.95e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6545883	0.929	rs1838978	chr2:61540923	T/C	cg15711740	chr2:61764176	XPO1	0.56	7.35	0.42	2.89e-12	Tuberculosis;
KIRP	cis	rs78487399	0.808	rs10200815	chr2:43673273	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-5.66	-0.34	4.11e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.81	-12.3	-0.62	2.04e-27	Coronary artery disease;
KIRP	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27297192	chr10:134578999	INPP5A	0.63	7.82	0.45	1.59e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	5.97	0.36	8.3e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs17023223	0.537	rs2765530	chr1:119584396	G/A	cg18261050	chr1:119551319	NA	0.52	6.97	0.41	2.84e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs10849893	0.557	rs10774593	chr12:121828763	T/C	cg01154721	chr12:121881891	KDM2B	-0.37	-4.88	-0.3	1.89e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg24253500	chr15:84953950	NA	0.67	7.81	0.45	1.69e-13	Schizophrenia;
KIRP	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg04166393	chr7:2884313	GNA12	0.63	7.6	0.44	6.36e-13	Height;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg06770877	chr13:31897247	B3GALTL	0.6	6.86	0.4	5.42e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17660384	chr11:101918145	C11orf70	-0.41	-6.46	-0.38	5.59e-10	Metabolic traits;
KIRP	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-8.69	-0.48	5.31e-16	Retinal vascular caliber;
KIRP	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg00800038	chr16:89945340	TCF25	-0.83	-6.23	-0.37	2.06e-9	Skin colour saturation;
KIRP	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.15	-0.61	6.62e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg21775007	chr8:11205619	TDH	-0.46	-6.06	-0.36	5.2e-9	Mood instability;
KIRP	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg21918786	chr6:109611834	NA	-0.42	-5.94	-0.35	9.89e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs4908768	0.871	rs4908508	chr1:8800780	T/C	cg03610117	chr1:8450231	RERE	-0.42	-4.89	-0.3	1.8e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.03	-0.31	9.57e-7	Schizophrenia;
KIRP	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg06742321	chr12:123595122	PITPNM2	0.46	5.77	0.35	2.34e-8	Platelet count;
KIRP	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg04374321	chr14:90722782	PSMC1	0.5	5.51	0.33	9.23e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.8	-11.74	-0.6	1.45e-25	Heart rate;
KIRP	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg23533926	chr12:111358616	MYL2	0.52	6.96	0.41	3.11e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11997175	0.562	rs72630962	chr8:33761447	C/T	ch.8.33884649F	chr8:33765107	NA	0.57	6.29	0.37	1.45e-9	Body mass index;
KIRP	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg16434002	chr17:42200994	HDAC5	0.42	4.94	0.3	1.46e-6	Total body bone mineral density;
KIRP	cis	rs10128251	0.847	rs12777965	chr10:5724297	T/C	cg11519256	chr10:5708881	ASB13	-0.54	-6.72	-0.39	1.25e-10	Childhood ear infection;
KIRP	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs12049351	0.774	rs3738187	chr1:229683264	G/A	cg11742688	chr1:229674241	ABCB10	-0.42	-6.84	-0.4	6.34e-11	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg16898833	chr6:26189333	HIST1H4D	0.65	4.92	0.3	1.61e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.77	9.39	0.51	4.1e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg22800045	chr5:56110881	MAP3K1	0.76	6.45	0.38	5.84e-10	Type 2 diabetes;
KIRP	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05265988	chr5:180688748	TRIM52	-0.51	-6.84	-0.4	6.38e-11	Myopia;
KIRP	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.37	-0.43	2.57e-12	Morning vs. evening chronotype;
KIRP	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.3	0.37	1.36e-9	Lipoprotein (a) levels;
KIRP	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg00262122	chr8:11665843	FDFT1	-0.41	-5.23	-0.32	3.56e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg07159286	chr12:133779169	ZNF268	0.44	6.67	0.39	1.65e-10	Serum protein levels (sST2);
KIRP	cis	rs7209700	0.547	rs11649785	chr17:45355720	G/A	cg25173405	chr17:45401733	C17orf57	0.53	5.23	0.32	3.71e-7	IgG glycosylation;
KIRP	cis	rs6722613	0.775	rs934612	chr2:25530687	G/A	cg10614445	chr2:25526696	DNMT3A	-0.4	-6.92	-0.4	3.87e-11	Ossification of the posterior longitudinal ligament of the spine;
KIRP	cis	rs501120	0.657	rs617542	chr10:44743636	G/A	cg09554077	chr10:44749378	NA	0.78	12.08	0.61	1.08e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.67	6.73	0.39	1.21e-10	Cannabis dependence symptom count;
KIRP	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.59	0.34	5.89e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-8.36	-0.47	4.62e-15	Monocyte percentage of white cells;
KIRP	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07570687	chr10:102243282	WNT8B	0.51	6.26	0.37	1.74e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-6.04	-0.36	5.53e-9	Pulmonary function;
KIRP	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17023223	0.509	rs6668960	chr1:119600812	C/T	cg05756136	chr1:119680316	WARS2	-0.54	-7.16	-0.42	9.53e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16362014	chr5:118321556	DTWD2	0.39	6.38	0.38	8.93e-10	C-reactive protein;
KIRP	cis	rs6988985	0.791	rs13257680	chr8:143997309	C/T	cg10324643	chr8:143916377	GML	-0.43	-4.98	-0.3	1.2e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.52	5.97	0.36	8.2e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs920590	0.641	rs2035889	chr8:19634087	T/A	cg03894339	chr8:19674705	INTS10	0.53	6.06	0.36	4.98e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg10223061	chr2:219282414	VIL1	0.33	5.39	0.33	1.63e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.14	-0.5	2.42e-17	Personality dimensions;
KIRP	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg04166393	chr7:2884313	GNA12	0.38	5.06	0.31	8.22e-7	Height;
KIRP	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg02138098	chr1:2040968	PRKCZ	-0.43	-5.95	-0.35	9.01e-9	Height;
KIRP	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.76	0.49	3.16e-16	Prudent dietary pattern;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24713789	chr21:45285448	AGPAT3	0.51	6.63	0.39	2.07e-10	Myopia (pathological);
KIRP	cis	rs7712401	0.601	rs30022	chr5:122285716	T/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07387570	chr22:46663686	TTC38	0.62	7.45	0.43	1.54e-12	Smoking initiation;
KIRP	trans	rs12543645	0.609	rs35112858	chr8:10277269	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.16	0.37	2.94e-9	Schizophrenia;
KIRP	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.57	7.15	0.41	9.91e-12	Coronary artery disease;
KIRP	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg16141378	chr3:129829833	LOC729375	-0.61	-8.35	-0.47	4.88e-15	Retinal vascular caliber;
KIRP	cis	rs9912468	0.933	rs12944131	chr17:64307611	C/A	cg19474267	chr17:64306194	PRKCA	0.58	8.26	0.47	8.85e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs6867032	1.000	rs4074914	chr5:2020274	C/T	cg00094735	chr5:1949198	NA	0.48	5.56	0.33	7.08e-8	Gut microbiome composition (winter);
KIRP	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg21452805	chr1:244014465	NA	0.7	6.03	0.36	5.81e-9	RR interval (heart rate);
KIRP	cis	rs4700695	0.841	rs433773	chr5:65309609	G/C	cg21114390	chr5:65439923	SFRS12	0.59	5.51	0.33	8.87e-8	Facial morphology (factor 19);
KIRP	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg23594656	chr7:65796392	TPST1	0.46	7.27	0.42	4.84e-12	Aortic root size;
KIRP	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.91	-12.46	-0.62	6.09e-28	Cognitive function;
KIRP	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.81	10.98	0.57	4.33e-23	Morning vs. evening chronotype;
KIRP	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.28	24.61	0.84	2.84e-68	IgG glycosylation;
KIRP	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.52	-7.09	-0.41	1.45e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg15655495	chr12:38532458	NA	0.25	4.89	0.3	1.84e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg05938607	chr10:60274200	BICC1	0.41	10.01	0.54	5.21e-20	Refractive error;
KIRP	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs12900413	0.687	rs12903462	chr15:90304075	C/T	cg24650279	chr15:90327240	NA	-0.41	-5.17	-0.31	4.79e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1971762	0.545	rs9788134	chr12:54046067	A/T	cg23533419	chr12:54090519	NA	-0.35	-5.31	-0.32	2.46e-7	Height;
KIRP	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg22349387	chr12:9600060	DDX12	-0.36	-5.18	-0.31	4.61e-7	Breast size;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.6	8.38	0.47	4.05e-15	Mean corpuscular volume;
KIRP	cis	rs10875746	0.903	rs989144	chr12:48483973	T/C	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs1468333	1.000	rs17171772	chr5:137514853	A/G	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	5.18	0.31	4.57e-7	Resting heart rate;
KIRP	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-16.83	-0.73	8.37e-43	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2949837	0.581	rs1543270	chr7:46006323	C/T	cg04796162	chr7:45961102	IGFBP3	0.31	4.86	0.3	2.13e-6	Sitting height ratio;
KIRP	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.49	-0.33	1e-7	Neutrophil percentage of white cells;
KIRP	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.62	8.03	0.46	3.91e-14	Neuroticism;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14294629	chr14:103989315	CKB	-0.44	-6.08	-0.36	4.66e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6988985	0.728	rs3753121	chr8:143926380	C/T	cg10324643	chr8:143916377	GML	-0.42	-4.94	-0.3	1.41e-6	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	cis	rs7760535	0.711	rs240972	chr6:111638335	C/T	cg15721981	chr6:111408429	SLC16A10	-0.45	-5.64	-0.34	4.72e-8	Metabolic traits;
KIRP	cis	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg21546286	chr11:48923668	NA	-0.45	-5.73	-0.34	2.86e-8	HDL cholesterol;
KIRP	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-8.49	-0.48	2.03e-15	Coronary artery disease;
KIRP	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg03060546	chr3:49711283	APEH	0.44	5.7	0.34	3.44e-8	Parkinson's disease;
KIRP	cis	rs9443189	0.950	rs6453845	chr6:76576527	G/T	cg01950844	chr6:76311363	SENP6	-0.6	-5.68	-0.34	3.84e-8	Prostate cancer;
KIRP	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.25	13.53	0.65	1.46e-31	Uric acid levels;
KIRP	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.59	-6.66	-0.39	1.77e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.21	-0.51	1.52e-17	Personality dimensions;
KIRP	trans	rs1864585	0.520	rs77559025	chr8:10692761	C/A	cg26278703	chr11:58910052	FAM111A	0.63	6.27	0.37	1.59e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.71	8.9	0.49	1.26e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7546094	0.935	rs9429486	chr1:113157372	T/C	cg22162597	chr1:113214053	CAPZA1	0.41	5.53	0.33	8.13e-8	Platelet distribution width;
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.8	7.64	0.44	4.75e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs9603616	0.719	rs4943688	chr13:40236390	A/G	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs28374715	0.662	rs28554139	chr15:41531084	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-14.26	-0.67	5e-34	Ulcerative colitis;
KIRP	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg02527881	chr3:46936655	PTH1R	-0.56	-8.51	-0.48	1.78e-15	Birth weight;
KIRP	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.47	5.49	0.33	1.02e-7	Parkinson's disease;
KIRP	cis	rs17253792	0.545	rs35536987	chr14:56024021	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.88	0.4	5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg03735888	chr19:58951602	ZNF132	0.46	5.52	0.33	8.52e-8	Uric acid clearance;
KIRP	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.08	-14.14	-0.67	1.26e-33	Corneal structure;
KIRP	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg08992911	chr2:238395768	MLPH	0.7	6.71	0.39	1.36e-10	Prostate cancer;
KIRP	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.85	-11.94	-0.61	3.22e-26	Total body bone mineral density;
KIRP	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.67	-11.02	-0.57	3.35e-23	Urate levels in overweight individuals;
KIRP	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.62	0.39	2.2e-10	Height;
KIRP	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg03627880	chr6:151815985	C6orf97	-0.43	-5.16	-0.31	5.06e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-6.3	-0.37	1.37e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg23985595	chr17:80112537	CCDC57	-0.33	-4.86	-0.3	2.09e-6	Life satisfaction;
KIRP	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.7	0.34	3.5e-8	Homoarginine levels;
KIRP	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.61	-5.21	-0.32	3.94e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg21643547	chr1:205240462	TMCC2	-0.53	-7.73	-0.44	2.8e-13	Red blood cell count;
KIRP	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.91	12.31	0.62	1.9e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-14.51	-0.68	7.01e-35	Height;
KIRP	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg03511173	chr18:77590860	NA	-0.45	-5.48	-0.33	1.07e-7	Opioid sensitivity;
KIRP	cis	rs8133932	0.654	rs375254	chr21:47337151	T/A	cg11214348	chr21:47283868	PCBP3	-0.44	-5.12	-0.31	6.18e-7	Schizophrenia;
KIRP	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-18.98	-0.77	4.38e-50	Height;
KIRP	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs858239	0.539	rs6949363	chr7:23192394	A/G	cg23682824	chr7:23144976	KLHL7	0.55	6.55	0.39	3.42e-10	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg05133900	chr22:19166543	SLC25A1	-0.5	-6.32	-0.37	1.23e-9	Neuroticism;
KIRP	cis	rs34779708	0.931	rs7084196	chr10:35367161	T/C	cg04310649	chr10:35416472	CREM	-0.58	-6.87	-0.4	5.33e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2071403	0.901	rs12471910	chr2:1412802	A/G	cg07083862	chr2:1417248	TPO	0.33	5.27	0.32	2.93e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.48	0.48	2.08e-15	Personality dimensions;
KIRP	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.71	-0.44	3.03e-13	Neuroticism;
KIRP	cis	rs2172802	0.598	rs1391320	chr4:62544596	C/T	cg04118610	chr4:62707027	LPHN3	-0.43	-5.25	-0.32	3.26e-7	Partial epilepsies;
KIRP	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg16447950	chr5:562315	NA	-0.45	-5.42	-0.33	1.42e-7	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.28	0.67	4.17e-34	Platelet count;
KIRP	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg26531700	chr6:26746687	NA	0.41	5.63	0.34	4.99e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6959887	1.000	rs6946632	chr7:35295820	T/C	cg06685737	chr7:35301730	NA	0.47	6.87	0.4	5.15e-11	Birth weight;
KIRP	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg23102388	chr7:1867652	MAD1L1	-0.46	-6.04	-0.36	5.58e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.82	-0.45	1.58e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4664293	0.867	rs13432	chr2:160625727	C/G	cg08347373	chr2:160653686	CD302	-0.45	-6.69	-0.39	1.53e-10	Monocyte percentage of white cells;
KIRP	cis	rs16976116	0.901	rs1061870	chr15:55496769	G/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg14893161	chr1:205819251	PM20D1	-0.58	-5.69	-0.34	3.64e-8	Menarche (age at onset);
KIRP	cis	rs11718455	0.585	rs6789465	chr3:43932045	G/A	cg21419209	chr3:44054225	NA	-0.62	-7.12	-0.41	1.18e-11	Coronary artery disease;
KIRP	cis	rs1550582	0.548	rs11538239	chr8:135490539	A/G	cg17885191	chr8:135476712	NA	-0.99	-11.4	-0.59	1.84e-24	Educational attainment;
KIRP	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.82	9.87	0.53	1.39e-19	Corneal astigmatism;
KIRP	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-10.0	-0.54	5.75e-20	Gut microbiome composition (summer);
KIRP	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00321850	chr1:175162397	KIAA0040	-0.34	-6.17	-0.37	2.77e-9	Alcohol dependence;
KIRP	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs787274	0.867	rs787269	chr9:115548676	T/C	cg13803584	chr9:115635662	SNX30	-0.73	-7.9	-0.45	9.56e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.62	7.45	0.43	1.6e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07269724	chr19:12904655	NA	0.55	7.44	0.43	1.66e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.98	-0.36	8.01e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg02297831	chr4:17616191	MED28	-0.6	-7.77	-0.44	2.14e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg23335576	chr14:104009727	NA	0.35	5.06	0.31	8.16e-7	Body mass index;
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.89	-0.45	1.01e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.88	8.59	0.48	1.02e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.57	7.56	0.43	7.73e-13	Prostate cancer;
KIRP	cis	rs1497406	0.590	rs6676143	chr1:16528218	G/T	cg03887218	chr1:16534349	ARHGEF19	0.38	5.24	0.32	3.53e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.44	-10.1	-0.54	2.83e-20	Alzheimer's disease (late onset);
KIRP	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.82	11.12	0.58	1.52e-23	Morning vs. evening chronotype;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.59	-6.75	-0.4	1.06e-10	Menopause (age at onset);
KIRP	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.66	7.76	0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs6987853	0.901	rs2923429	chr8:42389743	A/G	cg09913449	chr8:42400586	C8orf40	0.39	5.01	0.3	1.04e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.42	5.66	0.34	4.27e-8	Testicular germ cell tumor;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21445527	chr4:737453	PCGF3	-0.41	-6.1	-0.36	4.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg04166393	chr7:2884313	GNA12	0.47	6.03	0.36	5.83e-9	Height;
KIRP	cis	rs2802372	0.620	rs1250540	chr10:81036007	A/G	cg18688392	chr10:81059414	ZMIZ1	-0.41	-5.31	-0.32	2.46e-7	Granulocyte count;
KIRP	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.34	-0.37	1.1e-9	Mean corpuscular volume;
KIRP	cis	rs977987	0.864	rs37594	chr16:75496943	T/C	cg03315344	chr16:75512273	CHST6	-0.69	-10.39	-0.55	3.44e-21	Dupuytren's disease;
KIRP	cis	rs5997397	0.720	rs132549	chr22:29318724	C/T	cg02153584	chr22:29168773	CCDC117	-0.46	-5.67	-0.34	4.03e-8	Red cell distribution width;
KIRP	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.84	-0.4	6.42e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs737693	0.920	rs2276109	chr11:102745791	T/C	cg19620758	chr11:102826565	MMP13	0.69	5.53	0.33	8.08e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	12.15	0.61	6.22e-27	Bipolar disorder;
KIRP	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.63	-0.34	4.92e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-7.8	-0.45	1.77e-13	Osteoarthritis;
KIRP	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs7712401	0.562	rs2927639	chr5:122279666	G/C	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.75	5.75	0.34	2.65e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2997105	1.000	rs1472407	chr13:56408211	C/T	cg08528735	chr3:184428879	MAGEF1	-0.61	-6.19	-0.37	2.48e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs7659604	0.517	rs55989500	chr4:122682155	C/T	cg06713675	chr4:122721982	EXOSC9	-0.64	-6.46	-0.38	5.71e-10	Type 2 diabetes;
KIRP	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg21360079	chr12:107162445	NA	-0.69	-9.88	-0.53	1.37e-19	Heart rate;
KIRP	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.53	8.51	0.48	1.71e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4356932	1.000	rs6532158	chr4:76977964	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	trans	rs9300039	0.634	rs9783289	chr11:41859393	A/G	cg18072871	chr22:50919961	ADM2	-0.87	-6.18	-0.37	2.7e-9	Type 2 diabetes;
KIRP	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg06212747	chr3:49208901	KLHDC8B	0.48	4.98	0.3	1.2e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.61	8.75	0.49	3.57e-16	Resting heart rate;
KIRP	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg05802129	chr4:122689817	NA	-0.58	-7.33	-0.42	3.27e-12	Type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4789452	0.509	rs2627208	chr17:75353102	A/G	cg05865280	chr17:75406074	SEPT9	-0.26	-5.68	-0.34	3.82e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.78	10.62	0.56	6.3e-22	Resting heart rate;
KIRP	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg13703089	chr14:106090767	NA	-0.35	-4.88	-0.3	1.89e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs10858047	0.883	rs6537839	chr1:115188908	G/T	cg12756093	chr1:115239321	AMPD1	0.67	6.45	0.38	5.97e-10	Autism;
KIRP	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg00405596	chr8:11794950	NA	-0.46	-5.92	-0.35	1.08e-8	Triglycerides;
KIRP	cis	rs9469913	0.668	rs112563428	chr6:34800435	C/T	cg17674042	chr6:34482479	PACSIN1	-0.5	-5.41	-0.33	1.48e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg17366294	chr4:99064904	C4orf37	0.37	5.1	0.31	6.68e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	0.75	8.25	0.47	9.47e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.84	0.3	2.25e-6	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08219991	chr14:100054932	CCDC85C	0.49	6.48	0.38	4.86e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	0.33	5.42	0.33	1.45e-7	Lymphocyte counts;
KIRP	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg15660573	chr17:549704	VPS53	-0.95	-14.9	-0.69	3.25e-36	Prostate cancer;
KIRP	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.97	0.88	2.9e-81	Chronic sinus infection;
KIRP	cis	rs702634	0.579	rs697108	chr5:53304351	C/T	cg22592108	chr5:53304441	ARL15	0.47	6.02	0.36	6.39e-9	Type 2 diabetes;High light scatter reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg23602478	chr1:26503979	CNKSR1	0.45	6.5	0.38	4.48e-10	Height;
KIRP	cis	rs3124314	1.000	rs4845419	chr1:152141074	A/G	cg13071333	chr1:152595882	LCE3A	-0.35	-4.98	-0.3	1.22e-6	Hair morphology;
KIRP	cis	rs236907	0.859	rs56377810	chr1:171757657	A/C	cg01410279	chr1:171621941	MYOC	-0.52	-5.13	-0.31	5.96e-7	Mean platelet volume;
KIRP	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.75	-0.44	2.38e-13	Height;
KIRP	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg06598544	chr20:61472147	COL9A3	-0.79	-6.62	-0.39	2.29e-10	Obesity-related traits;
KIRP	cis	rs7119038	0.818	rs2077579	chr11:118619047	T/G	cg19308663	chr11:118741387	NA	0.55	8.69	0.48	5.22e-16	Sjögren's syndrome;
KIRP	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.44	6.5	0.38	4.49e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg01295188	chr5:476791	SLC9A3	0.51	4.85	0.3	2.2e-6	Obesity-related traits;
KIRP	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg11196788	chr11:71737549	NUMA1	0.54	4.85	0.3	2.16e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.55	6.34	0.37	1.09e-9	Bone mineral density (spine);
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg09754948	chr16:28834200	ATXN2L	-0.48	-5.0	-0.3	1.09e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.26	11.81	0.6	8.44e-26	Alzheimer's disease (late onset);
KIRP	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	cis	rs4936894	0.500	rs10790667	chr11:124179450	A/G	cg27160556	chr11:124181099	OR8D1	-0.44	-6.22	-0.37	2.1e-9	Aging (time to death);
KIRP	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.86	-11.83	-0.6	7.15e-26	Total body bone mineral density;
KIRP	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg25650185	chr19:21324782	ZNF431	0.48	5.19	0.31	4.46e-7	Pain;
KIRP	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05220968	chr6:146057943	EPM2A	0.39	4.97	0.3	1.26e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg17366294	chr4:99064904	C4orf37	-0.36	-5.11	-0.31	6.58e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.25	-0.32	3.26e-7	Pulmonary function;
KIRP	cis	rs57994353	0.861	rs13301660	chr9:139340802	C/T	cg14169450	chr9:139327907	INPP5E	0.57	6.59	0.39	2.65e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.8	-10.42	-0.55	2.6e-21	Longevity;Endometriosis;
KIRP	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-14.4	-0.68	1.68e-34	Gut microbiome composition (summer);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19670317	chr17:8093380	C17orf59	0.58	7.08	0.41	1.49e-11	Smoking initiation;
KIRP	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg26681399	chr22:41777847	TEF	-0.5	-4.94	-0.3	1.41e-6	Vitiligo;
KIRP	cis	rs6504950	0.720	rs28564882	chr17:52989598	C/T	cg26251398	chr17:52985966	TOM1L1	0.41	5.54	0.33	7.61e-8	Breast cancer;
KIRP	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg20750642	chr13:99100586	FARP1	0.41	4.96	0.3	1.29e-6	Neuroticism;
KIRP	cis	rs78487399	0.808	rs17030818	chr2:43680318	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.28	-0.32	2.9e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs9815354	0.767	rs12185934	chr3:41836558	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06481639	chr22:41940642	POLR3H	0.74	7.97	0.45	6.1e-14	Vitiligo;
KIRP	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.59	0.39	2.66e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg27490568	chr2:178487706	NA	0.46	5.91	0.35	1.12e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1620921	0.505	rs13216458	chr6:161204262	T/C	cg01280913	chr6:161186852	NA	-0.58	-7.84	-0.45	1.35e-13	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs580438	0.510	rs9847393	chr3:13407147	C/G	cg10657019	chr3:13328039	NA	-0.58	-7.76	-0.44	2.21e-13	Myringotomy;
KIRP	cis	rs9583531	0.891	rs9515270	chr13:111352073	C/T	cg24331049	chr13:111365604	ING1	-0.76	-6.47	-0.38	5.28e-10	Coronary artery disease;
KIRP	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.41	-5.28	-0.32	2.81e-7	Parkinson's disease;
KIRP	cis	rs1018697	1.000	rs7088711	chr10:104559266	A/G	cg04362960	chr10:104952993	NT5C2	-0.48	-5.75	-0.34	2.69e-8	Colorectal adenoma (advanced);
KIRP	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.7	-7.66	-0.44	4.33e-13	Gut microbiome composition (summer);
KIRP	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.29	-12.51	-0.62	4.05e-28	Atopic dermatitis;
KIRP	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg05340658	chr4:99064831	C4orf37	-0.64	-7.69	-0.44	3.55e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg05347473	chr6:146136440	FBXO30	0.41	5.58	0.33	6.46e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.46	-0.43	1.51e-12	Morning vs. evening chronotype;
KIRP	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg01689657	chr7:91764605	CYP51A1	0.46	6.98	0.41	2.7e-11	Breast cancer;
KIRP	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2150410	0.665	rs6517525	chr21:40573104	A/G	cg11890956	chr21:40555474	PSMG1	0.76	5.52	0.33	8.68e-8	Temperament (bipolar disorder);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18535011	chr5:31194448	CDH6	0.56	7.16	0.42	9.55e-12	Smoking initiation;
KIRP	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg10253484	chr15:75165896	SCAMP2	-0.46	-5.38	-0.32	1.78e-7	Breast cancer;
KIRP	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	10.41	0.55	2.94e-21	Exhaled nitric oxide levels;
KIRP	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs4805272	1.000	rs7256685	chr19:29323357	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.36	-0.32	1.89e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7621025	0.500	rs1965107	chr3:136648643	T/A	cg15507776	chr3:136538369	TMEM22	0.78	10.81	0.57	1.58e-22	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	trans	rs73198271	0.586	rs3789850	chr8:8686845	G/T	cg00405596	chr8:11794950	NA	-0.5	-6.1	-0.36	4.07e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6691722	0.503	rs12086212	chr1:24708740	C/T	cg18323236	chr1:24743029	NIPAL3	0.45	6.33	0.37	1.15e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs10782582	0.609	rs76260657	chr1:76338017	C/T	cg10523679	chr1:76189770	ACADM	-0.45	-6.1	-0.36	4.01e-9	Daytime sleep phenotypes;
KIRP	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg11569703	chr11:65557185	OVOL1	-0.48	-8.45	-0.47	2.5e-15	Acne (severe);
KIRP	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17467752	chr17:38218738	THRA	-0.54	-7.0	-0.41	2.37e-11	White blood cell count;
KIRP	cis	rs7851660	0.874	rs1443436	chr9:100631298	T/A	cg13688889	chr9:100608707	NA	-0.67	-8.93	-0.49	1.04e-16	Strep throat;
KIRP	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.75	-9.02	-0.5	5.58e-17	Iron status biomarkers;
KIRP	cis	rs2302729	0.578	rs11062299	chr12:2771738	T/C	cg19945202	chr12:2788847	CACNA1C	-0.75	-10.8	-0.57	1.59e-22	Sleep quality;
KIRP	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.66	-9.83	-0.53	1.88e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.49	7.64	0.44	4.95e-13	Testicular germ cell tumor;
KIRP	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.01	10.69	0.56	3.84e-22	Cognitive test performance;
KIRP	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.71	-9.67	-0.52	6.05e-19	Hypospadias;
KIRP	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.52	-6.27	-0.37	1.63e-9	Response to antipsychotic treatment;
KIRP	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.93	0.35	1.04e-8	Type 2 diabetes;
KIRP	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg05315796	chr3:52349193	DNAH1	-0.36	-5.47	-0.33	1.12e-7	Bipolar disorder;
KIRP	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg04804543	chr8:142233427	SLC45A4	-0.45	-5.5	-0.33	9.52e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg06742321	chr12:123595122	PITPNM2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.56	-0.39	3.07e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.76	10.31	0.55	6.13e-21	Red blood cell count;
KIRP	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17554472	chr22:41940697	POLR3H	0.45	5.43	0.33	1.32e-7	Vitiligo;
KIRP	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg06565975	chr8:143823917	SLURP1	0.48	7.6	0.44	6.33e-13	Urinary tract infection frequency;
KIRP	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg05552183	chr6:42928497	GNMT	0.65	10.01	0.54	5.38e-20	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs244293	0.701	rs4793783	chr17:53025480	T/C	cg07707039	chr17:53042137	COX11	-0.4	-5.07	-0.31	7.85e-7	Menarche (age at onset);
KIRP	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.51	6.81	0.4	7.22e-11	Coronary artery disease;
KIRP	cis	rs7215564	0.908	rs756077	chr17:78663071	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.13	0.31	6.01e-7	Myopia (pathological);
KIRP	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	1.04	20.37	0.79	9.98e-55	Breast cancer;
KIRP	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg01872077	chr2:219646372	CYP27A1	-0.37	-5.1	-0.31	6.78e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg06204229	chr3:52865917	ITIH4	0.54	5.93	0.35	1.05e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg14851346	chr12:38532713	NA	-0.39	-4.89	-0.3	1.82e-6	Bladder cancer;
KIRP	trans	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg21775007	chr8:11205619	TDH	-0.49	-6.45	-0.38	5.73e-10	Mood instability;
KIRP	cis	rs12643440	0.538	rs60281935	chr4:17143251	G/A	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs697003	0.520	rs7553718	chr1:211824797	T/C	cg09811860	chr1:211803715	NA	0.32	4.94	0.3	1.41e-6	Red cell distribution width;
KIRP	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	0.98	7.07	0.41	1.55e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9535307	0.584	rs7996307	chr13:50408023	C/T	cg04663916	chr13:50265991	EBPL	-0.55	-5.34	-0.32	2.16e-7	Obesity-related traits;
KIRP	cis	rs651907	0.554	rs10470501	chr3:101630497	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	4.99	0.3	1.12e-6	Colorectal cancer;
KIRP	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1448094	0.933	rs11836175	chr12:86311644	A/T	cg00310523	chr12:86230176	RASSF9	0.38	5.87	0.35	1.38e-8	Major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17960347	chr12:2457373	CACNA1C	-0.44	-6.12	-0.36	3.59e-9	Parkinson's disease;
KIRP	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.67	-10.19	-0.54	1.4e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.75	-10.41	-0.55	2.96e-21	Hypospadias;
KIRP	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.43	-5.17	-0.31	4.88e-7	Crohn's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00997172	chr20:32399000	CHMP4B	0.48	6.42	0.38	6.96e-10	Survival in pancreatic cancer;
KIRP	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19524238	chr7:2802976	GNA12	-0.38	-5.2	-0.31	4.2e-7	Height;
KIRP	trans	rs4843747	0.803	rs72818526	chr16:88068524	T/C	cg26811252	chr16:29126840	RRN3P2	0.72	9.2	0.51	1.54e-17	Menopause (age at onset);
KIRP	trans	rs1555543	0.517	rs2391766	chr1:96909240	T/C	cg10631902	chr5:14652156	NA	-0.49	-6.15	-0.37	3.12e-9	Body mass index;
KIRP	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg13206674	chr6:150067644	NUP43	0.58	8.3	0.47	6.79e-15	Lung cancer;
KIRP	cis	rs6466055	0.720	rs2030776	chr7:105008458	C/G	cg04380332	chr7:105027541	SRPK2	-0.61	-9.09	-0.5	3.48e-17	Schizophrenia;
KIRP	cis	rs72781680	0.611	rs72781696	chr2:24267014	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	5.8	0.35	2.02e-8	Lymphocyte counts;
KIRP	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	0.44	6.13	0.36	3.45e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg10326726	chr10:51549505	MSMB	0.58	8.48	0.48	2.12e-15	Prostate-specific antigen levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07335397	chr17:40265767	KAT2A;DHX58	0.46	6.46	0.38	5.45e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7404095	0.505	rs3852779	chr16:23831962	C/T	cg21745164	chr16:23765304	CHP2	0.36	5.09	0.31	6.96e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg01238044	chr22:24384105	GSTT1	0.52	5.37	0.32	1.84e-7	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs7590368	1.000	rs7576898	chr2:10958956	A/G	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.65	8.17	0.46	1.68e-14	Corneal astigmatism;
KIRP	cis	rs3105593	0.575	rs4318151	chr15:50729274	A/G	cg08437265	chr15:50716283	USP8	0.41	5.59	0.34	6.12e-8	QT interval;
KIRP	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.45	-9.21	-0.51	1.44e-17	Longevity;
KIRP	cis	rs4006360	0.646	rs8080447	chr17:39301276	T/A	cg15015397	chr17:39261100	KRTAP4-9	-0.47	-7.18	-0.42	8.21e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.37	0.47	4.5e-15	Response to antipsychotic treatment;
KIRP	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg06521331	chr12:34319734	NA	-0.61	-7.33	-0.42	3.25e-12	Morning vs. evening chronotype;
KIRP	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg02073558	chr3:44770973	ZNF501	0.6	8.48	0.48	2.09e-15	Depressive symptoms;
KIRP	cis	rs17453880	0.929	rs10041396	chr5:152041300	T/C	cg12297329	chr5:152029980	NA	-0.71	-10.74	-0.56	2.59e-22	Subjective well-being;
KIRP	cis	rs1978968	1.000	rs4410378	chr22:18451391	G/A	cg03078520	chr22:18463400	MICAL3	-0.61	-7.19	-0.42	7.84e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-5.94	-0.35	9.76e-9	Bladder cancer;
KIRP	cis	rs78487399	0.710	rs79625619	chr2:43594483	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.33	-0.32	2.26e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs17539620	0.565	rs61225515	chr6:154841625	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	5.98	0.36	7.62e-9	Lipoprotein (a) levels;
KIRP	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg05973401	chr12:123451056	ABCB9	0.57	6.57	0.39	2.94e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg01631408	chr1:248437212	OR2T33	-0.64	-8.2	-0.46	1.3e-14	Common traits (Other);
KIRP	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19671926	chr4:122722719	EXOSC9	0.49	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.5	-10.3	-0.55	6.48e-21	Rheumatoid arthritis;
KIRP	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.02	0.36	6.16e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7903847	0.642	rs9888117	chr10:99159963	C/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.82	-0.35	1.78e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11710088	0.740	rs73152638	chr3:149201086	A/G	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.54	-0.33	7.62e-8	QRS duration;
KIRP	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg26398791	chr1:38455867	SF3A3	-0.38	-4.99	-0.3	1.16e-6	Coronary artery disease;
KIRP	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg13010199	chr12:38710504	ALG10B	0.45	5.58	0.34	6.23e-8	Morning vs. evening chronotype;
KIRP	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs75920871	0.925	rs61905716	chr11:116919067	C/T	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg17279839	chr7:150038598	RARRES2	0.46	6.0	0.36	6.97e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12780845	0.931	rs34709865	chr10:17245329	T/C	cg01003015	chr10:17271136	VIM	0.47	5.17	0.31	4.77e-7	Homocysteine levels;
KIRP	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.78	-0.4	8.65e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.74	-7.87	-0.45	1.16e-13	Blood pressure (smoking interaction);
KIRP	cis	rs11191270	0.554	rs11191274	chr10:104140350	G/A	cg15320455	chr10:103880129	LDB1	1.0	7.84	0.45	1.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs78761021	0.685	rs62064483	chr17:9796862	C/T	cg26853458	chr17:9805074	RCVRN	0.52	5.05	0.31	8.81e-7	Type 2 diabetes;
KIRP	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.84	7.9	0.45	9.24e-14	Methadone dose in opioid dependence;
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.63	-0.48	7.59e-16	Lymphocyte counts;
KIRP	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.68	10.45	0.55	2.14e-21	Intelligence (multi-trait analysis);
KIRP	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg13010199	chr12:38710504	ALG10B	0.55	6.69	0.39	1.47e-10	Resting heart rate;
KIRP	cis	rs12230513	0.732	rs6581047	chr12:55832001	C/G	cg19537932	chr12:55886519	OR6C68	-0.61	-7.57	-0.43	7.7e-13	Contrast sensitivity;
KIRP	cis	rs1971762	0.545	rs11170632	chr12:54047935	C/T	cg16917193	chr12:54089295	NA	-0.89	-16.77	-0.73	1.3e-42	Height;
KIRP	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg13409248	chr3:40428643	ENTPD3	0.41	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.37	-6.35	-0.38	1.06e-9	Height;
KIRP	cis	rs80226907	1.000	rs58737648	chr14:55648115	C/T	cg13517138	chr14:55658249	DLGAP5	0.58	5.44	0.33	1.29e-7	Mean platelet volume;
KIRP	cis	rs12786942	0.569	rs12273188	chr11:101313615	A/C	cg03942599	chr11:101341554	TRPC6	0.54	7.37	0.43	2.59e-12	Facial depth;
KIRP	cis	rs2979489	0.773	rs10954993	chr8:30303388	C/T	cg26383811	chr8:30366931	RBPMS	0.39	5.3	0.32	2.61e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg00495681	chr13:53174319	NA	0.45	6.11	0.36	3.79e-9	Lewy body disease;
KIRP	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg26681399	chr22:41777847	TEF	0.5	5.02	0.3	1.01e-6	Vitiligo;
KIRP	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.48	-0.33	1.07e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.29	-7.81	-0.45	1.62e-13	Primary biliary cholangitis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22976360	chr2:70528671	FAM136A	-0.46	-6.23	-0.37	2.05e-9	Metabolic traits;
KIRP	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-7.49	-0.43	1.25e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00938859	chr5:1591904	SDHAP3	0.59	7.95	0.45	6.54e-14	Breast cancer;
KIRP	cis	rs501120	0.810	rs510785	chr10:44749990	C/A	cg09554077	chr10:44749378	NA	0.75	12.45	0.62	6.35e-28	Coronary artery disease;Coronary heart disease;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg08488058	chr3:143318826	SLC9A9	0.41	6.13	0.36	3.55e-9	Educational attainment;
KIRP	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.82	9.84	0.53	1.73e-19	Corneal astigmatism;
KIRP	cis	rs889398	0.651	rs1566455	chr16:69900164	G/T	cg09409435	chr16:70099608	PDXDC2	0.44	5.31	0.32	2.4e-7	Body mass index;
KIRP	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.36	-6.31	-0.37	1.31e-9	Refractive error;
KIRP	cis	rs6142102	0.961	rs4911146	chr20:32640047	C/G	cg08999081	chr20:33150536	PIGU	0.53	6.26	0.37	1.67e-9	Skin pigmentation;
KIRP	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	1.14	9.67	0.52	6.12e-19	Corneal curvature;
KIRP	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	1.06	19.47	0.78	9.79e-52	Height;
KIRP	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.46	6.02	0.36	6.4e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-5.82	-0.35	1.86e-8	Bipolar disorder;
KIRP	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.78	13.42	0.65	3.52e-31	Calcium levels;
KIRP	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.07	-0.36	4.75e-9	Morning vs. evening chronotype;
KIRP	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg08975724	chr8:8085496	FLJ10661	0.69	8.94	0.5	9.2e-17	Neuroticism;
KIRP	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.71	-0.39	1.36e-10	Renal cell carcinoma;
KIRP	cis	rs10465746	0.967	rs11163861	chr1:84354282	T/C	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.19e-8	Obesity-related traits;
KIRP	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg25019033	chr10:957182	NA	-0.6	-6.44	-0.38	6.32e-10	Eosinophil percentage of granulocytes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24669694	chr12:1800136	ADIPOR2	0.47	6.2	0.37	2.4e-9	Parkinson's disease;
KIRP	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.11	-0.31	6.38e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.13	0.61	7.56e-27	Blood protein levels;
KIRP	cis	rs858239	0.539	rs4294098	chr7:23185995	G/A	cg23682824	chr7:23144976	KLHL7	0.53	6.21	0.37	2.22e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg16590910	chr6:42928470	GNMT	0.41	5.61	0.34	5.3e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2150410	0.915	rs7275773	chr21:40646090	C/T	cg11890956	chr21:40555474	PSMG1	-0.78	-5.54	-0.33	7.87e-8	Temperament (bipolar disorder);
KIRP	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg15247329	chr7:2764246	NA	-0.37	-5.31	-0.32	2.39e-7	Height;
KIRP	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.47	-0.33	1.09e-7	Schizophrenia;
KIRP	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-0.98	-11.66	-0.6	2.61e-25	White matter hyperintensity burden;
KIRP	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.38e-8	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.16	0.31	5.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs55962025	0.842	rs73193303	chr4:3192200	A/G	cg06533319	chr4:3265114	C4orf44	0.47	4.99	0.3	1.16e-6	Parental longevity (mother's age at death);
KIRP	cis	rs11638352	1.000	rs2706471	chr15:44414370	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-5.11	-0.31	6.36e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.99	-13.88	-0.66	9.5e-33	Response to antipsychotic treatment;
KIRP	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.64	-0.39	1.97e-10	Bipolar disorder;
KIRP	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.71	7.79	0.44	1.85e-13	Corneal astigmatism;
KIRP	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg18252515	chr7:66147081	NA	-0.62	-6.5	-0.38	4.54e-10	Corneal structure;
KIRP	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg23307798	chr14:103986281	CKB	-0.51	-6.91	-0.4	4.21e-11	Coronary artery disease;
KIRP	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.59	7.3	0.42	4.08e-12	Eosinophil percentage of white cells;
KIRP	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.9	-14.81	-0.69	6.45e-36	Urate levels in lean individuals;
KIRP	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.58	-7.22	-0.42	6.46e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6960043	0.875	rs17168594	chr7:15048776	T/C	cg19272540	chr7:15055459	NA	-0.21	-5.55	-0.33	7.54e-8	Type 2 diabetes;
KIRP	trans	rs979961	0.568	rs115034638	chr4:117924433	G/A	cg02574033	chr7:141398961	KIAA1147	0.94	6.28	0.37	1.53e-9	Ulcerative colitis;
KIRP	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.22	0.61	3.65e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg00666640	chr1:248458726	OR2T12	0.57	6.09	0.36	4.33e-9	Common traits (Other);
KIRP	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg12046867	chr14:103022105	NA	-0.51	-6.15	-0.37	3.09e-9	Platelet count;
KIRP	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg19847130	chr8:10466454	RP1L1	0.42	6.11	0.36	3.79e-9	Joint mobility (Beighton score);
KIRP	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.62	-7.75	-0.44	2.37e-13	Vitiligo;
KIRP	cis	rs2554380	0.800	rs1544876	chr15:84375801	T/A	cg14598478	chr15:84363061	ADAMTSL3	-0.54	-7.45	-0.43	1.54e-12	Height;
KIRP	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.93	14.04	0.67	2.8e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.6	-8.34	-0.47	5.19e-15	Colorectal cancer;
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.74	-8.18	-0.46	1.49e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs412658	0.812	rs17554725	chr19:22317759	A/G	cg17074339	chr11:11642133	GALNTL4	-0.54	-6.29	-0.37	1.41e-9	Telomere length;
KIRP	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.86	12.52	0.62	3.82e-28	Eosinophil percentage of white cells;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.74	6.26	0.37	1.73e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg22081084	chr1:89990230	LRRC8B	0.49	6.02	0.36	6.2e-9	Asthma;
KIRP	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg13180566	chr4:1052158	NA	-0.51	-5.25	-0.32	3.33e-7	Recombination rate (females);
KIRP	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.88	12.81	0.63	3.88e-29	Monocyte count;
KIRP	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg05692746	chr2:100937584	LONRF2	-0.46	-5.41	-0.33	1.51e-7	Educational attainment;
KIRP	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.07	-0.36	4.94e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.7	-8.95	-0.5	9.12e-17	Eosinophil percentage of white cells;
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.64	7.84	0.45	1.35e-13	Longevity;Endometriosis;
KIRP	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.33	0.32	2.25e-7	Menopause (age at onset);
KIRP	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg24209194	chr3:40518798	ZNF619	-0.38	-4.92	-0.3	1.55e-6	Renal cell carcinoma;
KIRP	cis	rs1978968	0.731	rs9605469	chr22:18461231	T/C	cg02610425	chr22:18483192	MICAL3	0.37	5.59	0.34	6.06e-8	Presence of antiphospholipid antibodies;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg14796908	chr4:159078866	FAM198B	-0.47	-6.18	-0.37	2.64e-9	Select biomarker traits;
KIRP	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg19847130	chr8:10466454	RP1L1	0.42	6.32	0.37	1.24e-9	Joint mobility (Beighton score);
KIRP	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.14	-0.41	1.06e-11	Platelet count;
KIRP	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.65	0.71	8.71e-39	Metabolic syndrome;
KIRP	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg05340658	chr4:99064831	C4orf37	0.63	6.62	0.39	2.25e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.65	6.77	0.4	9.16e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg23752985	chr2:85803571	VAMP8	0.59	8.82	0.49	2.11e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.7	9.92	0.53	1e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.67	8.85	0.49	1.71e-16	Breast cancer;
KIRP	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.61	9.32	0.51	7.11e-18	Height;
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	7.53	0.43	9.65e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06481639	chr22:41940642	POLR3H	0.74	7.18	0.42	8.26e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.47	-5.62	-0.34	5.09e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.89	0.45	9.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.9	-0.49	1.24e-16	Total cholesterol levels;
KIRP	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.18	0.42	8.07e-12	Aortic root size;
KIRP	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-8.14	-0.46	2e-14	Neuroticism;
KIRP	cis	rs12580194	0.593	rs58709231	chr12:55719090	T/C	cg11794356	chr12:55725991	OR6C3	-0.6	-8.56	-0.48	1.23e-15	Cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27580026	chr2:27717965	FNDC4	-0.55	-6.87	-0.4	5.15e-11	Menopause (age at onset);
KIRP	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg02570527	chr1:10970165	NA	-0.45	-5.1	-0.31	6.85e-7	Body mass index;
KIRP	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.8	-11.96	-0.61	2.72e-26	Height;
KIRP	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg01721255	chr8:58191610	C8orf71	0.6	5.42	0.33	1.4e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7615316	0.779	rs3816805	chr3:142076059	A/G	cg20824294	chr3:142316082	PLS1	0.24	5.53	0.33	8.12e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs4924590	0.513	rs4244586	chr15:42238759	T/G	cg20935245	chr15:42234343	EHD4	0.42	6.49	0.38	4.59e-10	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
KIRP	cis	rs731174	0.802	rs6426030	chr1:38188195	A/G	cg14170840	chr1:38155120	C1orf109	-0.39	-4.97	-0.3	1.27e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg17691542	chr6:26056736	HIST1H1C	0.65	7.69	0.44	3.54e-13	Iron status biomarkers;
KIRP	cis	rs2458413	0.500	rs2514665	chr8:105351531	C/T	cg08657449	chr8:105351661	TM7SF4	-0.39	-6.16	-0.37	2.96e-9	Paget's disease;
KIRP	cis	rs6466055	0.720	rs12668097	chr7:104996472	A/G	cg04380332	chr7:105027541	SRPK2	0.54	8.06	0.46	3.23e-14	Schizophrenia;
KIRP	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg08975724	chr8:8085496	FLJ10661	0.52	6.45	0.38	5.82e-10	Retinal vascular caliber;
KIRP	cis	rs62070183	0.639	rs111360490	chr17:31251148	C/T	cg05781649	chr17:31146240	MYO1D	-0.49	-4.86	-0.3	2.11e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6738627	0.895	rs10930133	chr2:165506724	T/A	cg03182029	chr2:165697222	COBLL1	0.39	5.04	0.31	8.93e-7	Body fat percentage;circulating leptin levels adjusted for BMI;circulating leptin levels;
KIRP	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.72	10.11	0.54	2.57e-20	Blood metabolite levels;
KIRP	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.61	9.64	0.52	7.24e-19	Sense of smell;
KIRP	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.97	-0.36	8.05e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs587242	1.000	rs35729443	chr1:96897468	C/T	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.66	9.01	0.5	6.08e-17	Coronary artery disease;
KIRP	cis	rs12210905	1.000	rs72843611	chr6:27131382	C/T	cg11502198	chr6:26597334	ABT1	-0.78	-5.15	-0.31	5.31e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7919006	0.793	rs72803465	chr10:76795410	C/T	cg01390419	chr10:76803856	DUPD1	0.51	5.97	0.36	8.16e-9	Weight;
KIRP	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg21132104	chr15:45694354	SPATA5L1	-0.5	-5.94	-0.35	9.78e-9	Glomerular filtration rate;
KIRP	cis	rs1816854	1.000	rs10880570	chr12:44202465	A/T	cg20956634	chr12:44200518	TWF1	-0.49	-5.33	-0.32	2.27e-7	Inflammatory bowel disease;
KIRP	cis	rs758324	0.783	rs253941	chr5:131320293	C/T	cg06647332	chr5:131281008	NA	-0.43	-4.85	-0.3	2.18e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.52	7.31	0.42	3.71e-12	Coronary artery disease;
KIRP	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	6.23	0.37	1.96e-9	Menarche (age at onset);
KIRP	cis	rs2274273	0.967	rs11622740	chr14:55617844	G/A	cg04306507	chr14:55594613	LGALS3	0.47	7.22	0.42	6.4e-12	Protein biomarker;
KIRP	cis	rs2072732	0.950	rs55775305	chr1:2975119	C/G	cg11731671	chr1:2995604	PRDM16	-0.6	-6.64	-0.39	2.01e-10	Plateletcrit;
KIRP	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.75	0.34	2.67e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	14.85	0.69	4.63e-36	Platelet count;
KIRP	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.56	5.08	0.31	7.42e-7	Major depressive disorder;
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg03152288	chr2:177042942	NA	0.67	9.35	0.51	5.48e-18	IgG glycosylation;
KIRP	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.58	-7.36	-0.42	2.73e-12	Breast size;
KIRP	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.46	-0.56	1.94e-21	Morning vs. evening chronotype;
KIRP	cis	rs3736485	0.932	rs4774598	chr15:51919667	G/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.11	-0.31	6.5e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.6	9.06	0.5	4.06e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.82	-9.08	-0.5	3.57e-17	Menarche (age at onset);
KIRP	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-5.79	-0.35	2.13e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.09	-0.41	1.45e-11	Retinal vascular caliber;
KIRP	cis	rs10266483	0.739	rs2692104	chr7:63760955	G/C	cg04636841	chr7:63768139	NA	-0.38	-5.2	-0.31	4.19e-7	Response to statin therapy;
KIRP	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.67	8.04	0.46	3.87e-14	Longevity;Endometriosis;
KIRP	cis	rs2235642	0.582	rs8051374	chr16:1566284	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.2	-5.04	-0.31	9.09e-7	Coronary artery disease;
KIRP	cis	rs4073416	0.542	rs2300864	chr14:66119800	A/G	cg03016385	chr14:66212404	NA	-0.55	-6.85	-0.4	5.79e-11	N-glycan levels;
KIRP	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg11833968	chr6:79620685	NA	-0.46	-6.91	-0.4	4.19e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.58	-6.46	-0.38	5.44e-10	LDL cholesterol levels;
KIRP	cis	rs4953911	0.893	rs10207197	chr2:135048531	A/T	cg18482303	chr2:135041380	MGAT5	0.29	5.46	0.33	1.15e-7	Multiple sclerosis (severity);
KIRP	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.91	-0.64	1.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs4791746	1.000	rs9303230	chr17:8630396	G/A	cg03115937	chr17:8649504	CCDC42	-0.47	-5.89	-0.35	1.26e-8	Heroin dependence;
KIRP	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg11764359	chr7:65958608	NA	0.8	5.22	0.32	3.74e-7	Diabetic kidney disease;
KIRP	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00321850	chr1:175162397	KIAA0040	-0.33	-6.05	-0.36	5.25e-9	Alcohol dependence;
KIRP	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-5.83	-0.35	1.69e-8	Height;
KIRP	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg27205649	chr11:78285834	NARS2	0.7	7.63	0.44	5.03e-13	Alzheimer's disease (survival time);
KIRP	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.77	11.45	0.59	1.27e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.63	-6.91	-0.4	4.1e-11	Personality dimensions;
KIRP	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg22732515	chr19:44031385	ETHE1	0.64	9.43	0.52	3.25e-18	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.43	1.36e-12	Body mass index;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	14.77	0.69	8.93e-36	Lymphocyte counts;
KIRP	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs7666738	0.512	rs6532704	chr4:98777562	C/T	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg02002194	chr4:3960332	NA	0.44	6.58	0.39	2.76e-10	Mood instability;
KIRP	trans	rs1422110	1.000	rs1422110	chr5:85466140	C/T	cg01787110	chr1:109008453	NBPF6	-0.65	-7.49	-0.43	1.23e-12	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg04310649	chr10:35416472	CREM	0.59	6.97	0.41	2.95e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9513627	0.915	rs73556174	chr13:100121797	T/C	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16414030	chr3:133502952	NA	-0.49	-5.57	-0.33	6.62e-8	Iron status biomarkers;
KIRP	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg02367723	chr1:46378857	MAST2	0.42	4.86	0.3	2.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02923393	chr16:1543003	TELO2	0.53	6.15	0.37	3.15e-9	Smoking initiation;
KIRP	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.54	-6.24	-0.37	1.95e-9	Menopause (age at onset);
KIRP	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg06307176	chr5:131281290	NA	0.53	5.8	0.35	2.01e-8	Life satisfaction;
KIRP	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg21926883	chr2:100939477	LONRF2	-0.54	-7.22	-0.42	6.54e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.791	rs7300340	chr12:86329867	G/T	cg02569458	chr12:86230093	RASSF9	0.35	5.15	0.31	5.44e-7	Major depressive disorder;
KIRP	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.48	7.59	0.44	6.76e-13	Major depressive disorder;
KIRP	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-0.9	-7.35	-0.42	2.89e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.67	9.69	0.53	5.04e-19	Dupuytren's disease;
KIRP	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs6594499	0.872	rs10060003	chr5:110449357	A/G	cg04022379	chr5:110408740	TSLP	0.49	7.37	0.43	2.52e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.82	-14.03	-0.67	3.09e-33	Brugada syndrome;
KIRP	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg03929089	chr4:120376271	NA	-0.69	-6.94	-0.4	3.54e-11	Axial length;
KIRP	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.53	-0.33	8.22e-8	Hip geometry;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01585784	chr2:120517537	PTPN4	0.49	6.34	0.37	1.06e-9	Parkinson's disease;
KIRP	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	5.71	0.34	3.31e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs73200209	0.626	rs56159711	chr12:116578050	T/C	cg01776926	chr12:116560359	MED13L	-0.54	-6.03	-0.36	5.82e-9	Total body bone mineral density;
KIRP	cis	rs7712401	0.715	rs385996	chr5:122355228	T/G	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	cis	rs2411233	1.000	rs11856921	chr15:39278107	A/C	cg02291532	chr15:39874776	THBS1	-0.41	-5.46	-0.33	1.15e-7	Platelet count;
KIRP	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.78	10.57	0.56	9.03e-22	Iron status biomarkers;
KIRP	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg21926883	chr2:100939477	LONRF2	-0.54	-7.09	-0.41	1.38e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7572644	0.699	rs1506537	chr2:28181901	G/C	cg27432699	chr2:27873401	GPN1	-0.44	-5.3	-0.32	2.57e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	ch.8.33884649F	chr8:33765107	NA	0.59	7.42	0.43	1.91e-12	Body mass index;
KIRP	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg06217071	chr17:408420	NA	0.4	5.12	0.31	6.03e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9324022	0.929	rs72698721	chr14:101181189	G/A	cg18089426	chr14:101175970	NA	0.6	5.39	0.33	1.64e-7	Plateletcrit;
KIRP	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg02175503	chr12:58329896	NA	0.55	5.92	0.35	1.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs743757	0.878	rs6786523	chr3:50524221	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.5	-4.97	-0.3	1.26e-6	Diastolic blood pressure;
KIRP	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.82	10.11	0.54	2.47e-20	Menarche (age at onset);
KIRP	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.81	10.06	0.54	3.61e-20	Corneal astigmatism;
KIRP	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg25600027	chr14:23388339	RBM23	-0.52	-6.37	-0.38	9.15e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg20673841	chr7:107026890	COG5	0.4	5.0	0.3	1.08e-6	Coronary artery disease;
KIRP	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.34	6.43	0.38	6.65e-10	Height;
KIRP	cis	rs3849570	0.643	rs6548779	chr3:81968512	A/G	cg07356753	chr3:81810745	GBE1	-0.54	-7.3	-0.42	3.91e-12	Waist circumference;Body mass index;
KIRP	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg13010199	chr12:38710504	ALG10B	0.48	6.35	0.38	1.02e-9	Morning vs. evening chronotype;
KIRP	cis	rs752010	0.543	rs1570355	chr1:42042317	C/T	cg06885757	chr1:42089581	HIVEP3	0.4	5.76	0.34	2.48e-8	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7845219	0.544	rs10956930	chr8:95919786	C/G	cg16049864	chr8:95962084	TP53INP1	-0.37	-5.82	-0.35	1.87e-8	Type 2 diabetes;
KIRP	trans	rs1864585	0.552	rs9650658	chr8:10625241	A/G	cg26278703	chr11:58910052	FAM111A	0.64	6.06	0.36	5.02e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs364477	0.547	rs438294	chr9:979611	A/T	cg13952963	chr9:998547	NA	0.57	5.22	0.32	3.78e-7	Major depressive disorder;
KIRP	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.56	-7.93	-0.45	7.71e-14	Testicular germ cell tumor;
KIRP	cis	rs4356932	1.000	rs4241579	chr4:76947284	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs960902	0.869	rs6735123	chr2:37735864	C/G	cg25341268	chr2:37734390	NA	-0.55	-7.49	-0.43	1.24e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17739026	chr1:27114420	PIGV	0.52	7.27	0.42	4.84e-12	Survival in pancreatic cancer;
KIRP	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg03929089	chr4:120376271	NA	0.7	6.28	0.37	1.5e-9	Axial length;
KIRP	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	1.08	10.78	0.57	1.85e-22	Red blood cell traits;
KIRP	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.57	0.73	6.1e-42	Electrocardiographic conduction measures;
KIRP	cis	rs10861342	0.786	rs1078420	chr12:105595563	C/T	cg23923672	chr12:105501055	KIAA1033	0.8	5.35	0.32	2.02e-7	IgG glycosylation;
KIRP	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.53	6.73	0.39	1.19e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	14.5	0.68	7.51e-35	Platelet count;
KIRP	cis	rs3750965	0.920	rs10896420	chr11:68863047	G/A	cg06818126	chr11:68850279	TPCN2	-0.53	-6.31	-0.37	1.28e-9	Hair color;
KIRP	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.61	7.18	0.42	8.07e-12	Blood metabolite levels;
KIRP	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-10.05	-0.54	3.84e-20	Coffee consumption (cups per day);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg07051718	chr19:1438596	RPS15	0.52	6.23	0.37	2.05e-9	Myopia (pathological);
KIRP	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg00852783	chr1:26633632	UBXN11	-0.52	-5.12	-0.31	6.03e-7	Obesity-related traits;
KIRP	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg02151108	chr14:50098012	C14orf104	-0.55	-7.46	-0.43	1.48e-12	Carotid intima media thickness;
KIRP	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-8.69	-0.48	5.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg23796481	chr11:64053134	BAD;GPR137	-0.63	-7.47	-0.43	1.39e-12	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs6681460	0.625	rs2312154	chr1:67072976	C/T	cg13052034	chr1:66999238	SGIP1	-0.38	-5.44	-0.33	1.26e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.36	4.89	0.3	1.83e-6	Vitiligo;
KIRP	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.15	-0.54	1.96e-20	Hypospadias;
KIRP	cis	rs2073499	1.000	rs3806708	chr3:50306249	T/C	cg24954670	chr3:50337092	HYAL3;NAT6	-0.66	-5.01	-0.3	1.03e-6	Schizophrenia;
KIRP	cis	rs4936894	0.500	rs10790650	chr11:124080388	A/C	cg27160556	chr11:124181099	OR8D1	-0.47	-6.83	-0.4	6.44e-11	Aging (time to death);
KIRP	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.47	-7.11	-0.41	1.22e-11	Bone mineral density;
KIRP	cis	rs1861628	0.512	rs1548943	chr2:217618897	C/G	cg06569117	chr2:217657537	NA	0.43	5.07	0.31	7.94e-7	Serum thyroid-stimulating hormone levels;Hypothyroidism;
KIRP	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.43	-0.38	6.64e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399401	0.589	rs2294775	chr6:142766347	C/G	cg03128060	chr6:142623767	GPR126	0.35	5.17	0.31	4.89e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs2448490	0.642	rs535111	chr11:65485337	A/G	cg11569703	chr11:65557185	OVOL1	-0.35	-5.59	-0.34	6.13e-8	Platelet count;
KIRP	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.84	12.13	0.61	7.25e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14613607	chr9:139333683	INPP5E	-0.59	-6.34	-0.37	1.09e-9	Menopause (age at onset);
KIRP	cis	rs731174	0.765	rs599891	chr1:38176505	A/T	cg14170840	chr1:38155120	C1orf109	-0.4	-5.08	-0.31	7.36e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.96	8.08	0.46	2.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.81	7.83	0.45	1.43e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06481639	chr22:41940642	POLR3H	0.66	7.07	0.41	1.56e-11	Vitiligo;
KIRP	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg10932868	chr11:921992	NA	0.59	7.51	0.43	1.1e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6466055	0.661	rs17707878	chr7:104913228	G/A	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.48	-0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.57e-6	Tonsillectomy;
KIRP	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.49	-6.96	-0.41	3.05e-11	Daytime sleep phenotypes;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.05	-11.15	-0.58	1.19e-23	Alzheimer's disease;
KIRP	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.45	-5.89	-0.35	1.26e-8	Renal cell carcinoma;
KIRP	cis	rs12143943	0.866	rs3789052	chr1:204494283	A/G	cg20240347	chr1:204465584	NA	0.35	6.41	0.38	7.44e-10	Cognitive performance;
KIRP	cis	rs9488822	0.585	rs195525	chr6:116248273	C/T	cg26893134	chr6:116381904	FRK	0.19	4.98	0.3	1.22e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg17376030	chr22:41985996	PMM1	-0.83	-9.0	-0.5	6.35e-17	Vitiligo;
KIRP	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg11518657	chr1:67396239	MIER1	0.49	4.96	0.3	1.3e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs684232	0.649	rs838369	chr17:578180	T/C	cg12384639	chr17:618140	VPS53	0.47	6.03	0.36	5.98e-9	Prostate cancer;
KIRP	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg16691251	chr5:66510806	NA	0.54	7.61	0.44	5.89e-13	Breast cancer;
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg09699651	chr6:150184138	LRP11	0.45	5.73	0.34	2.98e-8	Lung cancer;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg23459997	chr3:9932426	JAGN1	-0.47	-6.35	-0.38	1.04e-9	Myopia;
KIRP	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.52	6.72	0.39	1.25e-10	Colorectal cancer;
KIRP	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.87	-10.97	-0.57	4.85e-23	Blood protein levels;
KIRP	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.46	9.47	0.52	2.44e-18	Ewing sarcoma;
KIRP	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.88	-0.35	1.33e-8	Blood metabolite levels;
KIRP	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.27	5.45	0.33	1.2e-7	Height;
KIRP	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg20965017	chr5:231967	SDHA	-0.54	-6.23	-0.37	1.96e-9	Breast cancer;
KIRP	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg17279839	chr7:150038598	RARRES2	0.46	6.29	0.37	1.47e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11987759	chr7:65425863	GUSB	-0.69	-9.72	-0.53	4.02e-19	Aortic root size;
KIRP	cis	rs745080	0.634	rs8016583	chr14:53067681	G/A	cg23333723	chr14:53022898	GPR137C	-0.43	-5.77	-0.35	2.4e-8	Orofacial clefts;
KIRP	trans	rs12517041	1.000	rs6887969	chr5:23304261	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.45	6.35	0.38	1e-9	Endometrial cancer;
KIRP	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.7	7.66	0.44	4.36e-13	Corneal astigmatism;
KIRP	cis	rs33912345	0.695	rs1266416	chr14:60822662	C/T	cg27398547	chr14:60952738	C14orf39	-0.42	-5.63	-0.34	4.84e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-1.09	-24.92	-0.85	3.12e-69	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs240764	0.782	rs151637	chr6:101104191	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.69	0.34	3.62e-8	Neuroticism;
KIRP	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg04310649	chr10:35416472	CREM	-0.55	-6.24	-0.37	1.93e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs7084402	0.902	rs1593670	chr10:60300766	C/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.87	-0.57	1.02e-22	Refractive error;
KIRP	cis	rs9488822	0.676	rs12202641	chr6:116314634	A/G	cg05304507	chr6:116381966	FRK	-0.21	-5.5	-0.33	9.7e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.68	9.19	0.51	1.67e-17	Crohn's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15154797	chr10:91174526	IFIT5	-0.48	-6.07	-0.36	4.9e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	3.99e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg21427119	chr20:30132790	HM13	-0.52	-5.83	-0.35	1.77e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg09184832	chr6:79620586	NA	-0.58	-8.21	-0.46	1.29e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg07817648	chr10:79422355	NA	-0.56	-6.72	-0.39	1.25e-10	Bone mineral density;
KIRP	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg18154014	chr19:37997991	ZNF793	0.91	9.36	0.51	5.12e-18	Coronary artery calcification;
KIRP	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg05347473	chr6:146136440	FBXO30	0.5	6.9	0.4	4.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg17372223	chr3:52568218	NT5DC2	0.32	5.28	0.32	2.79e-7	Bipolar disorder;
KIRP	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.44	5.77	0.35	2.42e-8	Initial pursuit acceleration;
KIRP	cis	rs258892	0.793	rs34655	chr5:72147269	A/G	cg21869765	chr5:72125136	TNPO1	0.57	6.31	0.37	1.27e-9	Small cell lung carcinoma;
KIRP	cis	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg27411982	chr8:10470053	RP1L1	0.42	5.15	0.31	5.44e-7	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21074911	chr14:60040732	C14orf38	0.38	6.25	0.37	1.77e-9	C-reactive protein;
KIRP	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg06636001	chr8:8085503	FLJ10661	0.68	8.95	0.5	8.77e-17	Retinal vascular caliber;
KIRP	cis	rs12311304	1.000	rs11056404	chr12:15378291	C/T	cg08258403	chr12:15378311	NA	0.37	5.55	0.33	7.33e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.4	0.33	1.6e-7	Blood protein levels;
KIRP	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12560992	chr17:57184187	TRIM37	0.61	7.13	0.41	1.09e-11	Testicular germ cell tumor;
KIRP	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-6.12	-0.36	3.68e-9	Aortic root size;
KIRP	cis	rs7084402	0.967	rs1649077	chr10:60293906	A/G	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	trans	rs1422110	0.616	rs1862230	chr5:85444868	C/T	cg01787110	chr1:109008453	NBPF6	-0.74	-9.32	-0.51	6.88e-18	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.5	-7.63	-0.44	5.18e-13	Resting heart rate;
KIRP	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.91	11.55	0.59	5.98e-25	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19615174	chr19:4558545	SEMA6B	0.41	6.08	0.36	4.53e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.66	-8.83	-0.49	1.95e-16	Ear protrusion;
KIRP	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.57	8.59	0.48	1.04e-15	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-7.99	-0.45	5.31e-14	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.53	7.09	0.41	1.44e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg08133631	chr1:26527909	CATSPER4	-0.47	-5.18	-0.31	4.53e-7	Obesity-related traits;
KIRP	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.73	0.39	1.15e-10	Height;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.71	8.6	0.48	9.28e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg00147788	chr6:125855365	NA	-0.31	-4.98	-0.3	1.19e-6	Brugada syndrome;
KIRP	cis	rs9653442	0.527	rs4851258	chr2:100780830	T/C	cg07810366	chr2:100720526	AFF3	-0.31	-4.96	-0.3	1.32e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.768	rs4990735	chr1:209943592	C/T	cg05527609	chr1:210001259	C1orf107	-0.61	-5.51	-0.33	8.86e-8	Red blood cell count;
KIRP	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.63	8.41	0.47	3.35e-15	Mood instability;
KIRP	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg08975724	chr8:8085496	FLJ10661	-0.73	-10.83	-0.57	1.33e-22	Neuroticism;
KIRP	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.55	8.15	0.46	1.79e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	1.05	7.48	0.43	1.32e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs17023223	0.537	rs17023185	chr1:119610787	C/T	cg18261050	chr1:119551319	NA	0.55	7.26	0.42	5.12e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.81	10.0	0.54	5.57e-20	Menarche (age at onset);
KIRP	cis	rs7083	0.716	rs574603	chr11:117177741	C/T	cg11523350	chr11:117171073	BACE1	-0.31	-5.72	-0.34	3.03e-8	Blood protein levels;
KIRP	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-0.74	-7.99	-0.45	5.21e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.35	-0.38	1.05e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11878675	chr2:74211845	NA	-0.5	-7.05	-0.41	1.84e-11	Metabolic traits;
KIRP	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg03808351	chr9:123631620	PHF19	0.41	5.58	0.34	6.33e-8	Rheumatoid arthritis;
KIRP	cis	rs10982256	0.766	rs1535959	chr9:117248479	G/A	cg13636371	chr9:117264095	DFNB31	0.58	7.58	0.43	7.21e-13	Bipolar disorder;
KIRP	cis	rs4523957	0.583	rs2760738	chr17:2024600	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.59	-0.59	4.65e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14122300	chr14:69446504	ACTN1	-0.47	-6.08	-0.36	4.68e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.92	-14.99	-0.69	1.61e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.58	7.17	0.42	8.54e-12	Systemic lupus erythematosus;
KIRP	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.62	8.82	0.49	2.11e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7481584	0.962	rs2071110	chr11:2991219	C/G	cg25174290	chr11:3078921	CARS	-0.56	-6.24	-0.37	1.86e-9	Calcium levels;
KIRP	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg23250157	chr14:64679961	SYNE2	0.56	6.3	0.37	1.39e-9	Atrial fibrillation;
KIRP	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.66	-8.51	-0.48	1.73e-15	Extraversion;
KIRP	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.72	0.49	4.22e-16	Bipolar disorder;
KIRP	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg14440974	chr22:39074834	NA	-0.38	-4.95	-0.3	1.4e-6	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16734451	chr8:32430022	NRG1	-0.44	-6.91	-0.4	4.2e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6499755	0.768	rs31103	chr16:55373850	C/T	cg05099576	chr16:55362342	IRX6	0.33	6.63	0.39	2.05e-10	Hypospadias;
KIRP	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg08999081	chr20:33150536	PIGU	0.45	5.66	0.34	4.3e-8	Height;
KIRP	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg03714773	chr7:91764589	CYP51A1	0.41	6.06	0.36	5.05e-9	Breast cancer;
KIRP	cis	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg21546286	chr11:48923668	NA	-0.45	-5.4	-0.33	1.59e-7	HDL cholesterol;
KIRP	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.62	-6.51	-0.38	4.31e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg17470449	chr10:769945	NA	0.7	6.99	0.41	2.61e-11	Uric acid levels;
KIRP	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.61	-5.18	-0.31	4.69e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7560272	0.538	rs12053242	chr2:73937168	G/A	cg20560298	chr2:73613845	ALMS1	0.47	5.61	0.34	5.53e-8	Schizophrenia;
KIRP	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	trans	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.39	-0.38	8.16e-10	Triglycerides;
KIRP	cis	rs7172677	0.737	rs58201389	chr15:75446835	G/A	cg10253484	chr15:75165896	SCAMP2	-0.47	-4.97	-0.3	1.25e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	7.22	0.42	6.57e-12	Height;
KIRP	cis	rs1190552	0.846	rs12883789	chr14:102954621	G/A	cg10241871	chr14:102965420	TECPR2	-0.59	-6.95	-0.4	3.35e-11	Blood protein levels;
KIRP	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg27205649	chr11:78285834	NARS2	0.69	7.61	0.44	5.73e-13	Alzheimer's disease (survival time);
KIRP	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.72	9.13	0.5	2.57e-17	Platelet count;
KIRP	cis	rs806215	0.951	rs327510	chr7:127257894	G/A	cg25922125	chr7:127225783	GCC1	0.44	4.91	0.3	1.66e-6	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.9e-15	Lung cancer;
KIRP	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg20701182	chr2:24300061	SF3B14	0.62	5.28	0.32	2.86e-7	Lymphocyte counts;
KIRP	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.46	5.77	0.35	2.36e-8	Platelet count;
KIRP	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg23920097	chr1:209922102	NA	-0.48	-5.78	-0.35	2.28e-8	Red blood cell count;
KIRP	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.93	-11.45	-0.59	1.28e-24	Diastolic blood pressure;
KIRP	cis	rs273573	0.643	rs7117695	chr11:30891382	C/G	cg14844989	chr11:31128820	NA	0.34	4.98	0.3	1.18e-6	Total body bone mineral density;
KIRP	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg14458575	chr2:238380390	NA	-0.45	-5.16	-0.31	4.97e-7	Prostate cancer;
KIRP	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg10818794	chr15:86012489	AKAP13	0.5	7.05	0.41	1.85e-11	Coronary artery disease;
KIRP	cis	rs4901847	0.967	rs7143063	chr14:58549178	A/G	cg15908186	chr14:58618357	C14orf37	-0.38	-5.0	-0.3	1.1e-6	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.46	-6.07	-0.36	4.89e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg00262122	chr8:11665843	FDFT1	-0.44	-5.4	-0.33	1.6e-7	Retinal vascular caliber;
KIRP	cis	rs1425132	0.654	rs1549424	chr7:37581254	A/G	cg15028436	chr7:37888078	TXNDC3	-0.38	-4.85	-0.3	2.14e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
KIRP	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	9.66	0.52	6.21e-19	Smoking behavior;
KIRP	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.66	-6.05	-0.36	5.48e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.46	0.33	1.15e-7	Breast cancer;
KIRP	cis	rs4664293	0.867	rs2081723	chr2:160594160	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs13185784	0.667	rs35551113	chr5:179654221	T/C	cg23248424	chr5:179741104	GFPT2	0.57	5.63	0.34	4.89e-8	TRAIL levels;
KIRP	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg00631329	chr6:26305371	NA	-0.6	-7.75	-0.44	2.35e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.63	9.74	0.53	3.56e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.4	6.11	0.36	3.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.33	6.12	0.36	3.67e-9	Educational attainment (years of education);
KIRP	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg06121193	chr1:90282411	NA	-0.51	-7.04	-0.41	1.89e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.45	6.4e-14	Aortic root size;
KIRP	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg07972983	chr1:205091412	RBBP5	0.43	5.1	0.31	6.71e-7	Red blood cell count;
KIRP	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg03929089	chr4:120376271	NA	0.73	6.66	0.39	1.83e-10	Intraocular pressure;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04025307	chr7:1156635	C7orf50	0.57	5.72	0.34	3.13e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg02153340	chr1:155202674	NA	-0.36	-5.04	-0.31	9.15e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4523957	0.552	rs2760742	chr17:2019037	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.25	0.37	1.79e-9	Mean corpuscular volume;
KIRP	cis	rs17123764	1.000	rs74089566	chr12:49956575	T/C	cg02054252	chr12:50078554	FMNL3	0.49	4.89	0.3	1.8e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11874712	0.932	rs8092674	chr18:43665982	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs113084984	0.816	rs4669749	chr2:11692664	A/C	cg07314298	chr2:11723111	GREB1	-0.45	-5.85	-0.35	1.6e-8	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09845184	chr4:187510183	FAT1	0.53	7.37	0.43	2.57e-12	Interleukin-4 levels;
KIRP	cis	rs55962025	0.846	rs16843836	chr4:3113337	G/A	cg06533319	chr4:3265114	C4orf44	0.46	5.02	0.3	9.96e-7	Parental longevity (mother's age at death);
KIRP	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.61	6.04	0.36	5.65e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs714027	0.605	rs5753037	chr22:30581722	C/T	cg27665648	chr22:30112403	NA	0.47	6.63	0.39	2.07e-10	Lymphocyte counts;
KIRP	cis	rs13226913	0.875	rs6463656	chr7:7244181	C/T	cg04827551	chr7:7268805	C1GALT1	-0.36	-5.13	-0.31	5.94e-7	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.43	4.87	0.3	1.97e-6	Schizophrenia;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg27297123	chr10:103330038	NA	-0.43	-6.04	-0.36	5.64e-9	Hippocampal sclerosis of aging;
KIRP	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.35	-0.47	5.15e-15	Neuroticism;
KIRP	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.4	-0.43	2.19e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg01879757	chr17:41196368	BRCA1	-0.5	-6.73	-0.39	1.18e-10	Menopause (age at onset);
KIRP	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.78	8.5	0.48	1.83e-15	Cholesterol, total;
KIRP	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.46	6.01	0.36	6.7e-9	Response to temozolomide;
KIRP	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.87	-0.35	1.38e-8	Parkinson's disease;
KIRP	cis	rs76793172	0.841	rs111386720	chr19:46302145	G/A	cg00442267	chr19:46317840	RSPH6A	-0.76	-6.05	-0.36	5.22e-9	Eosinophil counts;
KIRP	cis	rs6558530	0.666	rs6558520	chr8:1697573	T/C	cg08198773	chr8:1697536	NA	0.49	6.08	0.36	4.59e-9	Systolic blood pressure;
KIRP	trans	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg07393940	chr7:158741817	NA	0.46	6.29	0.37	1.48e-9	Life satisfaction;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.84	-8.77	-0.49	2.95e-16	Bronchopulmonary dysplasia;
KIRP	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.51	-5.93	-0.35	1.03e-8	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4423214	0.592	rs11233977	chr11:71221605	C/T	cg05163923	chr11:71159392	DHCR7	-0.68	-6.89	-0.4	4.77e-11	Vitamin D levels;
KIRP	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-9.93	-0.53	9.61e-20	Colorectal cancer;
KIRP	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.54	-6.09	-0.36	4.23e-9	Adiposity;
KIRP	cis	rs8079658	1.000	rs62065084	chr17:63822357	T/C	cg18091269	chr17:63822838	CCDC46	-0.56	-7.8	-0.45	1.76e-13	Post bronchodilator FEV1;
KIRP	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.48	-6.41	-0.38	7.28e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg04662567	chr6:169592167	NA	0.64	8.64	0.48	7.28e-16	Pulse pressure;
KIRP	trans	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.13	-0.41	1.08e-11	Bladder cancer;
KIRP	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg24253500	chr15:84953950	NA	-0.63	-6.58	-0.39	2.76e-10	Schizophrenia;
KIRP	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg00977110	chr5:151150581	G3BP1	0.62	6.21	0.37	2.24e-9	Preschool internalizing problems;
KIRP	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg06223162	chr1:101003688	GPR88	-0.43	-8.75	-0.49	3.38e-16	Monocyte count;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg08001895	chr6:94129582	EPHA7	-0.42	-6.17	-0.37	2.84e-9	Migraine with aura;
KIRP	trans	rs9409565	0.762	rs55877910	chr9:97234213	G/C	cg05679027	chr9:99775184	HIATL2	-0.55	-6.57	-0.39	2.94e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.74	11.57	0.59	5.37e-25	Eosinophilic esophagitis;
KIRP	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.79	-10.06	-0.54	3.74e-20	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.68	-8.37	-0.47	4.42e-15	Blood metabolite levels;
KIRP	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs9309711	0.736	rs13412581	chr2:3497187	G/A	cg10845886	chr2:3471009	TTC15	-0.72	-9.04	-0.5	4.68e-17	Neurofibrillary tangles;
KIRP	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg16988262	chr1:15930761	NA	0.38	4.85	0.3	2.16e-6	Systolic blood pressure;
KIRP	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21545522	chr1:205238299	TMCC2	0.55	7.11	0.41	1.22e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg17849569	chr6:28058911	ZSCAN12L1	0.39	4.86	0.3	2.05e-6	Parkinson's disease;
KIRP	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg09408571	chr1:101003634	GPR88	-0.24	-5.24	-0.32	3.46e-7	Monocyte count;
KIRP	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg00647317	chr7:50633725	DDC	-0.43	-5.83	-0.35	1.71e-8	Malaria;
KIRP	cis	rs9886651	0.935	rs4427135	chr8:128802021	A/C	cg24514600	chr8:128805414	PVT1	-0.73	-12.52	-0.62	3.65e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
KIRP	cis	rs10102274	1.000	rs73311066	chr8:91788932	G/C	cg16814680	chr8:91681699	NA	-0.8	-4.9	-0.3	1.73e-6	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs614226	0.515	rs77755019	chr12:120921346	A/T	cg01236616	chr12:121019343	POP5	-1.19	-6.98	-0.41	2.7e-11	Type 1 diabetes nephropathy;
KIRP	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.44	5.66	0.34	4.23e-8	Motion sickness;
KIRP	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.8	11.0	0.57	3.64e-23	Aortic root size;
KIRP	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg07395648	chr5:131743802	NA	-0.57	-7.88	-0.45	1.05e-13	Breast cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00399650	chr7:141402322	KIAA1147	0.48	6.35	0.38	1.01e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-7.98	-0.45	5.53e-14	Glomerular filtration rate;
KIRP	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.77	9.42	0.51	3.55e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	1.02	18.91	0.77	7.65e-50	Parkinson's disease;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg27121462	chr16:89883253	FANCA	-0.39	-5.02	-0.3	9.92e-7	Vitiligo;
KIRP	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg05721485	chr17:44071124	MAPT	0.6	7.77	0.44	2.08e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg07395648	chr5:131743802	NA	-0.35	-4.86	-0.3	2.11e-6	Blood metabolite levels;
KIRP	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg07936489	chr17:37558343	FBXL20	-0.41	-4.95	-0.3	1.35e-6	Asthma;
KIRP	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.3	1.44e-6	Cognitive test performance;
KIRP	cis	rs12580194	0.556	rs58780687	chr12:55736498	A/C	cg19537932	chr12:55886519	OR6C68	-0.51	-6.53	-0.38	3.76e-10	Cancer;
KIRP	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.44	-6.05	-0.36	5.39e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.61	6.26	0.37	1.71e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	7.31	0.42	3.82e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg13072238	chr3:49761600	GMPPB	-0.57	-5.34	-0.32	2.1e-7	Menarche (age at onset);
KIRP	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg11130432	chr3:121712080	ILDR1	-0.46	-5.42	-0.33	1.43e-7	Multiple sclerosis;
KIRP	cis	rs7096127	1.000	rs7096127	chr10:24506439	C/T	cg04122385	chr10:24535410	KIAA1217;PRINS	0.39	4.9	0.3	1.75e-6	Lobe attachment (rater scored);
KIRP	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.66	9.2	0.51	1.58e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9296736	0.922	rs625899	chr6:53957588	C/T	cg04374786	chr6:53939321	C6orf142	-0.36	-4.86	-0.3	2.14e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4791746	1.000	rs34336857	chr17:8616815	T/C	cg03115937	chr17:8649504	CCDC42	-0.53	-6.35	-0.38	1.03e-9	Heroin dependence;
KIRP	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg18833306	chr6:118973337	C6orf204	0.4	5.12	0.31	6.1e-7	Electrocardiographic conduction measures;
KIRP	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.32	-0.32	2.3e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	7.08	0.41	1.46e-11	Iron status biomarkers;
KIRP	cis	rs9381107	0.932	rs9380624	chr6:9418725	A/C	cg14735645	chr6:9486422	NA	-0.46	-5.44	-0.33	1.3e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	trans	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg06521331	chr12:34319734	NA	-0.55	-6.78	-0.4	8.76e-11	Heart rate;
KIRP	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg16917193	chr12:54089295	NA	0.86	16.52	0.73	9.67e-42	Height;
KIRP	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.44	5.64	0.34	4.65e-8	Crohn's disease;
KIRP	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.4	-5.19	-0.31	4.35e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg17294928	chr15:75287854	SCAMP5	-0.68	-6.14	-0.36	3.3e-9	Lung cancer;
KIRP	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg04733989	chr22:42467013	NAGA	0.52	6.24	0.37	1.93e-9	Cognitive function;
KIRP	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.44	5.01	0.3	1.02e-6	Fear of minor pain;
KIRP	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.33	-0.37	1.18e-9	Axial length;
KIRP	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.29	-0.62	2.2e-27	Blood trace element (Zn levels);
KIRP	cis	rs6732160	0.774	rs7606271	chr2:73367698	T/G	cg01422370	chr2:73384389	NA	0.4	5.25	0.32	3.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	6.09	0.36	4.41e-9	Longevity;
KIRP	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg02569458	chr12:86230093	RASSF9	-0.47	-6.98	-0.41	2.77e-11	Major depressive disorder;
KIRP	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg00277334	chr10:82204260	NA	-0.47	-5.41	-0.33	1.51e-7	Post bronchodilator FEV1;
KIRP	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg17554472	chr22:41940697	POLR3H	0.58	6.42	0.38	6.97e-10	Vitiligo;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.78	12.24	0.62	3.13e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.58	-6.47	-0.38	5.11e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12200782	1.000	rs12208390	chr6:26437106	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.72	-6.27	-0.37	1.63e-9	Small cell lung carcinoma;
KIRP	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.99	-0.45	5.06e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs4908768	1.000	rs4908768	chr1:8654764	G/A	cg03610117	chr1:8450231	RERE	-0.49	-4.97	-0.3	1.27e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg27490568	chr2:178487706	NA	0.49	6.39	0.38	8.21e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2862064	0.872	rs6555822	chr5:156473185	A/G	cg12943317	chr5:156479607	HAVCR1	-0.91	-8.14	-0.46	2.04e-14	Platelet count;
KIRP	cis	rs684232	0.835	rs1833459	chr17:562244	C/T	cg15660573	chr17:549704	VPS53	-0.53	-7.24	-0.42	5.82e-12	Prostate cancer;
KIRP	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.8	10.6	0.56	7.02e-22	Aortic root size;
KIRP	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg04025307	chr7:1156635	C7orf50	0.53	6.72	0.39	1.27e-10	Bronchopulmonary dysplasia;
KIRP	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4664304	0.789	rs7595388	chr2:160756345	G/A	cg03641300	chr2:160917029	PLA2R1	-0.34	-4.84	-0.3	2.25e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.99	10.23	0.55	1.1e-20	Alzheimer's disease;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.6	8.15	0.46	1.83e-14	Mean corpuscular volume;
KIRP	cis	rs75216060	0.906	rs9657226	chr8:13817785	G/T	cg12665059	chr8:13787749	NA	0.31	4.89	0.3	1.85e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.63	10.38	0.55	3.61e-21	Coronary artery disease;
KIRP	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg22604316	chr1:46958801	NA	0.34	4.99	0.3	1.13e-6	Monobrow;
KIRP	cis	rs4073416	0.518	rs2184601	chr14:65897368	T/A	cg03016385	chr14:66212404	NA	-0.54	-6.7	-0.39	1.37e-10	N-glycan levels;
KIRP	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg08501292	chr6:25962987	TRIM38	0.9	7.1	0.41	1.33e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg00677455	chr12:58241039	CTDSP2	-0.48	-5.37	-0.32	1.82e-7	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs800082	0.501	rs9873732	chr3:144191665	C/T	cg24215973	chr2:240111563	HDAC4	0.49	6.2	0.37	2.43e-9	Smoking behavior;
KIRP	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.99	11.9	0.6	4.39e-26	Migraine;
KIRP	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg15117754	chr3:10150083	C3orf24	0.5	5.04	0.31	9.21e-7	Alzheimer's disease;
KIRP	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.71	10.45	0.55	2.17e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08439880	chr3:133502540	NA	-0.5	-6.22	-0.37	2.09e-9	Iron status biomarkers;
KIRP	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19882132	chr14:106167949	NA	-0.42	-5.26	-0.32	3.19e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.29	0.62	2.24e-27	Blood protein levels;
KIRP	cis	rs10982256	0.774	rs7036125	chr9:117253973	T/C	cg13636371	chr9:117264095	DFNB31	-0.51	-7.19	-0.42	7.73e-12	Bipolar disorder;
KIRP	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg04013166	chr16:89971882	TCF25	0.67	5.64	0.34	4.54e-8	Skin colour saturation;
KIRP	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg20607798	chr8:58055168	NA	0.59	5.4	0.33	1.59e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg25356066	chr3:128598488	ACAD9	-0.56	-6.55	-0.39	3.36e-10	IgG glycosylation;
KIRP	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05220968	chr6:146057943	EPM2A	0.38	4.94	0.3	1.44e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12282928	0.959	rs713325	chr11:48285301	A/G	cg26585981	chr11:48327164	OR4S1	-0.52	-6.32	-0.37	1.25e-9	Migraine - clinic-based;
KIRP	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg24633833	chr3:10029261	TMEM111	0.53	5.12	0.31	6.12e-7	Alzheimer's disease;
KIRP	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.51	-5.59	-0.34	5.95e-8	Lung cancer;
KIRP	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg00204512	chr16:28754710	NA	0.43	5.39	0.33	1.61e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00031443	chr19:7599076	PNPLA6	0.48	6.17	0.37	2.82e-9	Parkinson's disease;
KIRP	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.58	5.33	0.32	2.25e-7	Bipolar disorder;
KIRP	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg00277334	chr10:82204260	NA	-0.48	-5.62	-0.34	5.06e-8	Post bronchodilator FEV1;
KIRP	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.81	-7.31	-0.42	3.75e-12	Coronary artery disease;
KIRP	cis	rs2279817	0.818	rs34421778	chr1:17984859	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-8.06	-0.46	3.31e-14	Neuroticism;
KIRP	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20887711	chr4:1340912	KIAA1530	-0.42	-5.12	-0.31	6.1e-7	Obesity-related traits;
KIRP	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.62	8.06	0.46	3.3e-14	Height;
KIRP	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-0.76	-6.66	-0.39	1.81e-10	Obesity-related traits;
KIRP	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg22974920	chr21:40686053	BRWD1	-0.44	-5.15	-0.31	5.23e-7	Cognitive function;
KIRP	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.32e-9	Obesity-related traits;
KIRP	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.54	-6.63	-0.39	2.09e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15719572	chr1:40506319	CAP1	-0.5	-6.14	-0.36	3.31e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10858047	0.883	rs11102827	chr1:115181843	C/T	cg12756093	chr1:115239321	AMPD1	-0.67	-6.46	-0.38	5.42e-10	Autism;
KIRP	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg05315796	chr3:52349193	DNAH1	0.39	5.02	0.3	9.79e-7	Schizophrenia;
KIRP	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.16	15.4	0.7	6.37e-38	Gut microbiome composition (summer);
KIRP	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg01320130	chr1:67600311	NA	0.54	6.46	0.38	5.48e-10	Psoriasis;
KIRP	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg07423050	chr13:99094983	FARP1	0.32	5.29	0.32	2.73e-7	Longevity;
KIRP	cis	rs8028182	0.636	rs7495610	chr15:75784441	T/C	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg14250997	chr9:106856677	SMC2	0.43	5.88	0.35	1.3e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.13	-0.41	1.08e-11	Neuroticism;
KIRP	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.51	-7.2	-0.42	7.39e-12	Sense of smell;
KIRP	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.22	0.32	3.9e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.74	-5.66	-0.34	4.23e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	9.96	0.54	7.58e-20	Cognitive test performance;
KIRP	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg25039879	chr17:56429692	SUPT4H1	0.58	5.07	0.31	7.96e-7	Cognitive test performance;
KIRP	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg23985595	chr17:80112537	CCDC57	-0.38	-5.64	-0.34	4.72e-8	Life satisfaction;
KIRP	cis	rs311392	0.902	rs411371	chr8:55092609	G/A	cg06042504	chr8:55087323	NA	-0.59	-7.26	-0.42	4.97e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.01	14.01	0.67	3.51e-33	Cognitive ability;
KIRP	trans	rs7819412	0.593	rs11778398	chr8:10974243	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.37	-0.38	9.34e-10	Triglycerides;
KIRP	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.64	-5.57	-0.33	6.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7715811	0.913	rs73749952	chr5:13762518	T/C	cg07548982	chr5:13769939	DNAH5	-0.54	-6.59	-0.39	2.66e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.82	7.35	0.42	2.89e-12	Obesity-related traits;
KIRP	cis	rs7209700	0.547	rs884696	chr17:45341244	C/A	cg08085267	chr17:45401833	C17orf57	0.55	5.73	0.34	2.88e-8	IgG glycosylation;
KIRP	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg22356347	chr1:167427500	CD247	-0.45	-6.2	-0.37	2.38e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs4704187	0.506	rs3935470	chr5:74352180	A/G	cg03227963	chr5:74354835	NA	0.38	5.72	0.34	3.04e-8	Response to amphetamines;
KIRP	cis	rs7577696	0.597	rs56322034	chr2:32353013	T/C	cg02381751	chr2:32503542	YIPF4	-0.52	-5.33	-0.32	2.27e-7	Inflammatory biomarkers;
KIRP	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.83	8.93	0.49	1.05e-16	Alzheimer's disease;
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.74	-11.81	-0.6	8.44e-26	Vitiligo;
KIRP	cis	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg06521331	chr12:34319734	NA	-0.42	-5.29	-0.32	2.66e-7	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25023717	chr11:8077914	TUB	0.42	6.33	0.37	1.16e-9	Survival in pancreatic cancer;
KIRP	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	1.09	8.9	0.49	1.26e-16	Plasma clusterin levels;
KIRP	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	0.74	8.21	0.46	1.27e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-8.47	-0.48	2.28e-15	Neuroticism;
KIRP	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.74	11.5	0.59	9.13e-25	Neuroticism;
KIRP	cis	rs1215050	0.791	rs165254	chr4:98763564	C/T	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.94e-7	Red blood cell count;
KIRP	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.46	6.63	0.39	2.14e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs2688419	0.509	rs115374	chr3:23048377	A/G	cg00327796	chr3:23032191	NA	-0.48	-6.48	-0.38	5.01e-10	Type 2 diabetes;
KIRP	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg04414720	chr1:150670196	GOLPH3L	0.36	4.87	0.3	1.99e-6	Melanoma;
KIRP	cis	rs10211205	1.000	rs13389509	chr2:236614630	T/C	cg02339850	chr2:236586191	AGAP1	-0.53	-5.43	-0.33	1.33e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	13.85	0.66	1.22e-32	Platelet count;
KIRP	cis	rs6732160	0.564	rs2043096	chr2:73375723	T/C	cg01422370	chr2:73384389	NA	0.52	7.0	0.41	2.38e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.64	7.59	0.44	6.43e-13	Obesity-related traits;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg08222618	chr4:941054	TMEM175	0.68	7.35	0.42	2.92e-12	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.59	6.9	0.4	4.48e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg03609598	chr5:56110824	MAP3K1	0.59	5.85	0.35	1.53e-8	Initial pursuit acceleration;
KIRP	cis	rs6088813	1.000	rs6087704	chr20:34001058	C/T	cg14752227	chr20:34000481	UQCC	-0.52	-6.72	-0.39	1.23e-10	Height;
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg04369109	chr6:150039330	LATS1	-0.63	-8.25	-0.47	9.48e-15	Lung cancer;
KIRP	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg05834625	chr6:170176447	C6orf70	0.45	5.84	0.35	1.62e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7534824	0.543	rs61780299	chr1:101403471	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.25	0.42	5.24e-12	Refractive astigmatism;
KIRP	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.34	5.35	0.32	2.06e-7	Asthma;
KIRP	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.53	-6.6	-0.39	2.56e-10	Body mass index;
KIRP	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg22563815	chr15:78856949	CHRNA5	-0.47	-7.14	-0.41	1.03e-11	Sudden cardiac arrest;
KIRP	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20743544	chr7:32982957	RP9P	0.62	7.31	0.42	3.82e-12	Smoking initiation;
KIRP	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.68	9.24	0.51	1.19e-17	Coronary artery disease;
KIRP	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs4132509	0.744	rs320305	chr1:243859909	G/T	cg25706552	chr1:244017396	NA	0.52	6.73	0.39	1.16e-10	RR interval (heart rate);
KIRP	cis	rs28493229	0.786	rs3745213	chr19:41248009	C/T	cg21869046	chr19:41225005	ITPKC	0.52	6.16	0.37	2.93e-9	Kawasaki disease;
KIRP	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-1.06	-14.82	-0.69	5.92e-36	Alopecia areata;
KIRP	cis	rs6504950	0.720	rs9914596	chr17:52996551	C/T	cg26251398	chr17:52985966	TOM1L1	0.4	5.47	0.33	1.12e-7	Breast cancer;
KIRP	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.31	5.68	0.34	3.7e-8	Calcium levels;
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg13293535	chr8:11597251	GATA4	-0.41	-5.32	-0.32	2.35e-7	Retinal vascular caliber;
KIRP	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.6	-7.08	-0.41	1.5e-11	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.57	-8.15	-0.46	1.88e-14	Testicular germ cell tumor;
KIRP	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-1.02	-16.59	-0.73	5.6e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12826209	chr6:26865740	GUSBL1	0.47	5.9	0.35	1.18e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs73206853	0.640	rs3825390	chr12:110976409	A/C	cg12870014	chr12:110450643	ANKRD13A	0.54	6.33	0.37	1.13e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.7	6.56	0.39	3.15e-10	Schizophrenia;
KIRP	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg19875535	chr5:140030758	IK	0.51	6.43	0.38	6.46e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg23024343	chr7:107201750	COG5	0.41	4.91	0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.49	7.13	0.41	1.13e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg00977110	chr5:151150581	G3BP1	0.59	5.9	0.35	1.21e-8	Preschool internalizing problems;
KIRP	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-8.7	-0.49	4.81e-16	Response to antipsychotic treatment;
KIRP	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.79	-11.42	-0.59	1.63e-24	Testicular germ cell tumor;
KIRP	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.05	0.54	3.9e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23281280	chr6:28129359	ZNF389	0.44	4.87	0.3	2.01e-6	Depression;
KIRP	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg05484376	chr2:27715224	FNDC4	-0.38	-6.55	-0.39	3.3e-10	Total body bone mineral density;
KIRP	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.44	0.38	6.06e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7562790	0.571	rs4670146	chr2:36651561	G/C	cg09467607	chr2:36825704	FEZ2	0.42	5.16	0.31	4.98e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg26681399	chr22:41777847	TEF	-0.54	-5.39	-0.33	1.65e-7	Vitiligo;
KIRP	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg18404041	chr3:52824283	ITIH1	-0.47	-5.64	-0.34	4.66e-8	Schizophrenia;
KIRP	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.49	-5.23	-0.32	3.67e-7	Smoking behavior;
KIRP	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg21734707	chr17:3908241	ZZEF1	-0.46	-5.71	-0.34	3.17e-8	Type 2 diabetes;
KIRP	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-5.82	-0.35	1.79e-8	Joint mobility (Beighton score);
KIRP	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg08126542	chr6:37504118	NA	-0.87	-13.48	-0.65	2.17e-31	Cognitive performance;
KIRP	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg04691961	chr3:161091175	C3orf57	-0.42	-6.27	-0.37	1.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.45	-5.41	-0.33	1.46e-7	Neutrophil percentage of white cells;
KIRP	cis	rs501120	0.584	rs556434	chr10:44732519	T/A	cg09554077	chr10:44749378	NA	0.71	7.76	0.44	2.32e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs72781680	0.611	rs56326157	chr2:24312407	T/C	cg06627628	chr2:24431161	ITSN2	-0.58	-5.08	-0.31	7.36e-7	Lymphocyte counts;
KIRP	cis	rs997295	0.675	rs17242605	chr15:67963436	A/G	cg24579218	chr15:68104479	NA	0.35	4.97	0.3	1.25e-6	Motion sickness;
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	5.29	0.32	2.71e-7	Platelet count;
KIRP	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.77	-10.04	-0.54	4.3e-20	Body mass index;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg00576014	chr1:161284450	SDHC;LOC642502	0.46	6.12	0.36	3.71e-9	DNA methylation (variation);
KIRP	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg11642891	chr2:3452563	TTC15	-0.54	-6.92	-0.4	3.84e-11	Obesity-related traits;
KIRP	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19159602	chr1:29557611	MECR	0.49	6.05	0.36	5.47e-9	Parkinson's disease;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.73	10.65	0.56	4.86e-22	Menarche (age at onset);
KIRP	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.8	-11.74	-0.6	1.46e-25	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg23352942	chr3:46931381	PTH1R	-0.41	-5.25	-0.32	3.29e-7	Birth weight;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07851808	chr3:14988835	NR2C2	0.51	6.17	0.37	2.82e-9	Parkinson's disease;
KIRP	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg21147944	chr13:114264438	TFDP1	0.5	6.22	0.37	2.09e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2278796	0.918	rs11240324	chr1:204955319	G/A	cg17947172	chr1:204966197	NFASC	0.57	7.66	0.44	4.2e-13	Mean platelet volume;
KIRP	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	0.71	7.09	0.41	1.38e-11	Gut microbiome composition (summer);
KIRP	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.8	10.47	0.56	1.92e-21	Platelet count;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.77	12.46	0.62	5.89e-28	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9473924	0.542	rs9296645	chr6:50831194	A/G	cg14470998	chr6:50812995	TFAP2B	0.82	7.49	0.43	1.23e-12	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09361219	chr2:61293079	KIAA1841	0.51	6.2	0.37	2.41e-9	Parkinson's disease;
KIRP	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.85	10.12	0.54	2.35e-20	Body mass index;
KIRP	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg25930673	chr12:123319894	HIP1R	-0.93	-6.65	-0.39	1.84e-10	Adiponectin levels;
KIRP	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13198984	chr17:80129470	CCDC57	0.56	8.41	0.47	3.34e-15	Life satisfaction;
KIRP	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg00981070	chr1:2046702	PRKCZ	-0.41	-6.53	-0.38	3.75e-10	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10463451	chr21:37432625	SETD4	0.5	6.96	0.41	3.17e-11	Parkinson's disease;
KIRP	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.95	-0.45	6.89e-14	Retinal vascular caliber;
KIRP	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	1.06	19.32	0.78	3.16e-51	Leprosy;
KIRP	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg10755058	chr3:40428713	ENTPD3	0.39	5.5	0.33	9.38e-8	Renal cell carcinoma;
KIRP	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg22437258	chr11:111473054	SIK2	0.62	7.46	0.43	1.46e-12	Primary sclerosing cholangitis;
KIRP	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.53	8.51	0.48	1.78e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.49	6.14	0.36	3.32e-9	Glycated hemoglobin levels;
KIRP	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg20243544	chr17:37824526	PNMT	-0.4	-4.93	-0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09517757	chr8:58174422	NA	0.54	6.61	0.39	2.35e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-8.98	-0.5	7.38e-17	Total cholesterol levels;
KIRP	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg24209194	chr3:40518798	ZNF619	0.39	4.96	0.3	1.29e-6	Renal cell carcinoma;
KIRP	cis	rs7572644	0.656	rs4666018	chr2:28042059	C/T	cg27432699	chr2:27873401	GPN1	0.51	5.78	0.35	2.29e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.82	9.9	0.53	1.11e-19	Corneal astigmatism;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg02733842	chr7:1102375	C7orf50	0.57	5.91	0.35	1.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs13385	0.769	rs13359060	chr5:139605202	C/T	cg01860693	chr5:139557145	C5orf32	0.46	4.96	0.3	1.32e-6	Atrial fibrillation;
KIRP	trans	rs12449568	0.874	rs34788074	chr17:54407506	T/C	cg04456437	chr3:119217424	C3orf1	0.48	6.13	0.36	3.49e-9	Height;
KIRP	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.67	-6.81	-0.4	7.45e-11	Ulcerative colitis;
KIRP	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg16586182	chr3:47516702	SCAP	-0.63	-8.96	-0.5	8.32e-17	Colorectal cancer;
KIRP	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg22907277	chr7:1156413	C7orf50	0.56	6.87	0.4	5.19e-11	Longevity;Endometriosis;
KIRP	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-10.54	-0.56	1.13e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg16898833	chr6:26189333	HIST1H4D	0.98	5.91	0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.67	8.33	0.47	5.65e-15	Dilated cardiomyopathy;
KIRP	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg08885076	chr2:99613938	TSGA10	0.61	10.84	0.57	1.19e-22	Chronic sinus infection;
KIRP	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05220968	chr6:146057943	EPM2A	-0.38	-5.04	-0.31	9.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7614311	1.000	rs2087704	chr3:63820493	A/C	cg22134162	chr3:63841271	THOC7	0.33	5.3	0.32	2.6e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg27068330	chr11:65405492	SIPA1	-0.41	-4.97	-0.3	1.26e-6	Acne (severe);
KIRP	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg26876637	chr1:152193138	HRNR	-0.72	-9.79	-0.53	2.49e-19	Atopic dermatitis;
KIRP	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg22541963	chr20:60982533	CABLES2	-0.41	-5.14	-0.31	5.56e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7714584	0.793	rs2161363	chr5:150182079	G/C	cg22134413	chr5:150180641	NA	1.06	8.79	0.49	2.67e-16	Crohn's disease;
KIRP	cis	rs9316337	0.557	rs9509659	chr13:21924162	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.44	-4.97	-0.3	1.27e-6	Schizophrenia;
KIRP	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.24	-26.09	-0.86	8.62e-73	IgG glycosylation;
KIRP	cis	rs15676	0.783	rs10819442	chr9:131564750	C/G	cg00228799	chr9:131580591	ENDOG	-0.49	-4.99	-0.3	1.14e-6	Blood metabolite levels;
KIRP	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	16.35	0.72	3.49e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7246657	0.508	rs1644702	chr19:37491907	C/T	cg23950597	chr19:37808831	NA	-0.62	-5.06	-0.31	8.26e-7	Coronary artery calcification;
KIRP	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg25486957	chr4:152246857	NA	-0.5	-5.47	-0.33	1.11e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs12936587	0.748	rs12939297	chr17:17524247	G/A	cg01246520	chr17:17644344	RAI1	-0.35	-5.42	-0.33	1.45e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.5	5.92	0.35	1.07e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6426558	0.681	rs10495274	chr1:227175253	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.77	-11.11	-0.58	1.64e-23	Neutrophil percentage of white cells;
KIRP	cis	rs16828019	0.777	rs11209363	chr1:41485077	T/C	cg18742814	chr1:41828276	NA	0.62	5.51	0.33	9.22e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.46	0.38	5.47e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.49	6.54	0.38	3.54e-10	Testicular germ cell tumor;
KIRP	cis	rs3099143	0.901	rs76036665	chr15:77232720	A/G	cg21673338	chr15:77095150	SCAPER	-0.59	-5.74	-0.34	2.71e-8	Recalcitrant atopic dermatitis;
KIRP	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.42	5.48	0.33	1.05e-7	Menarche (age at onset);
KIRP	cis	rs7665939	1.000	rs72709206	chr4:190109171	T/C	cg14840187	chr4:190284988	NA	-0.93	-6.77	-0.4	9.53e-11	Amyotrophic lateral sclerosis;
KIRP	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.5	7.56	0.43	8.02e-13	Resting heart rate;
KIRP	cis	rs4589502	1.000	rs80263963	chr15:67127228	C/T	cg12317470	chr15:67143691	NA	0.65	5.3	0.32	2.63e-7	Lung cancer (smoking interaction);
KIRP	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.67	6.74	0.4	1.09e-10	Vitiligo;
KIRP	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg11031976	chr2:198649780	BOLL	-0.49	-4.88	-0.3	1.88e-6	Ulcerative colitis;
KIRP	cis	rs4955124	0.558	rs62244399	chr3:32025595	C/T	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.76	6.81	0.4	7.49e-11	Schizophrenia;
KIRP	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.7	-9.47	-0.52	2.42e-18	Adiposity;
KIRP	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg17031739	chr1:67600172	NA	0.52	5.52	0.33	8.77e-8	Psoriasis;
KIRP	cis	rs9815354	1.000	rs6790732	chr3:41864872	C/T	cg03022575	chr3:42003672	ULK4	0.51	5.96	0.36	8.8e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2219968	1.000	rs12679679	chr8:78974231	T/C	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10266483	0.739	rs679966	chr7:63767066	C/T	cg04636841	chr7:63768139	NA	-0.39	-5.24	-0.32	3.5e-7	Response to statin therapy;
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg11641102	chr8:27183873	PTK2B	0.45	5.88	0.35	1.31e-8	Neuroticism;
KIRP	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.75e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.64	8.01	0.45	4.48e-14	Iron status biomarkers;
KIRP	cis	rs2274273	0.837	rs6573010	chr14:55721592	T/C	cg04306507	chr14:55594613	LGALS3	0.53	8.11	0.46	2.33e-14	Protein biomarker;
KIRP	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00791764	chr4:53727839	RASL11B	0.37	5.34	0.32	2.1e-7	Optic nerve measurement (cup area);
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-1.08	-21.37	-0.81	5.42e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.46	6.35	0.38	1.05e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg11952622	chr19:58962976	ZNF324B	0.43	5.02	0.31	9.69e-7	Uric acid clearance;
KIRP	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.72	9.73	0.53	3.82e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg01879757	chr17:41196368	BRCA1	0.77	10.71	0.56	3.31e-22	Menopause (age at onset);
KIRP	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg22676075	chr6:135203613	NA	0.51	7.41	0.43	1.97e-12	Red blood cell count;
KIRP	cis	rs7301016	1.000	rs11174504	chr12:62877036	A/G	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg23594656	chr7:65796392	TPST1	0.45	7.12	0.41	1.17e-11	Aortic root size;
KIRP	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg24375607	chr4:120327624	NA	0.48	5.95	0.35	9.3e-9	Diastolic blood pressure;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg06282189	chr18:67735875	RTTN	0.43	6.16	0.37	2.94e-9	Migraine with aura;
KIRP	cis	rs11779988	0.528	rs208029	chr8:17840987	A/C	cg01800426	chr8:17659068	MTUS1	-0.63	-6.38	-0.38	8.89e-10	Breast cancer;
KIRP	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.44	-5.41	-0.33	1.5e-7	White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27142229	chr19:4246911	CCDC94	0.5	6.47	0.38	5.37e-10	Parkinson's disease;
KIRP	cis	rs7941600	0.581	rs11042273	chr11:9322132	T/G	cg19415743	chr11:9336845	TMEM41B	0.71	6.49	0.38	4.67e-10	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.6	0.52	9.84e-19	Prudent dietary pattern;
KIRP	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg09658497	chr7:2847517	GNA12	-0.36	-5.07	-0.31	7.68e-7	Height;
KIRP	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.55	-5.89	-0.35	1.29e-8	Body mass index;
KIRP	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.69	-9.03	-0.5	5.08e-17	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7209700	0.962	rs56327427	chr17:45354746	C/T	cg25173405	chr17:45401733	C17orf57	0.41	5.11	0.31	6.48e-7	IgG glycosylation;
KIRP	cis	rs6973256	0.897	rs9656422	chr7:133324665	C/T	cg10665199	chr7:133106180	EXOC4	-0.52	-6.56	-0.39	3.13e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.09	-0.31	7.24e-7	Obesity-related traits;
KIRP	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19346786	chr7:2764209	NA	-0.54	-9.02	-0.5	5.45e-17	Height;
KIRP	cis	rs2119480	0.928	rs7998328	chr13:111321551	A/C	cg24331049	chr13:111365604	ING1	0.45	5.4	0.33	1.54e-7	Diastolic blood pressure;
KIRP	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	8.11	0.46	2.4e-14	Joint mobility (Beighton score);
KIRP	cis	rs4908768	0.555	rs55939938	chr1:8863664	A/T	cg25722041	chr1:8623473	RERE	0.55	7.17	0.42	9.01e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.77	8.68	0.48	5.52e-16	Corneal astigmatism;
KIRP	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg00147788	chr6:125855365	NA	-0.32	-4.98	-0.3	1.18e-6	Brugada syndrome;
KIRP	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.53	-6.29	-0.37	1.43e-9	Bone mineral density;
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.07	0.36	4.92e-9	Height;
KIRP	cis	rs1555895	0.576	rs12413228	chr10:849230	G/T	cg10017260	chr10:834428	NA	-0.42	-6.37	-0.38	9.2e-10	Survival in rectal cancer;
KIRP	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.94	16.15	0.72	1.72e-40	Breast cancer;
KIRP	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg17960426	chr8:142067321	NA	-0.58	-6.61	-0.39	2.35e-10	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	trans	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg10756647	chr7:56101905	PSPH	1.02	7.5	0.43	1.18e-12	Diabetic kidney disease;
KIRP	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.58	-7.44	-0.43	1.67e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.28	14.58	0.68	4e-35	Eosinophil percentage of granulocytes;
KIRP	trans	rs1859156	0.812	rs6849640	chr4:95823682	T/C	cg24204951	chr2:239172084	PER2	0.28	6.58	0.39	2.74e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs3779635	0.742	rs1429940	chr8:27242622	A/T	cg23698023	chr8:27181813	PTK2B	-0.33	-4.94	-0.3	1.47e-6	Neuroticism;
KIRP	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.61	-0.44	5.88e-13	Mean platelet volume;
KIRP	cis	rs7091068	0.536	rs503758	chr10:95406935	C/A	cg20715218	chr10:95462985	C10orf4	-0.57	-6.05	-0.36	5.34e-9	Urinary tract infection frequency;
KIRP	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20930514	chr14:77499758	NA	0.6	7.16	0.42	9.12e-12	Smoking initiation;
KIRP	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.83	12.99	0.64	9.93e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.16	18.19	0.76	2.05e-47	Height;
KIRP	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.61	7.74	0.44	2.61e-13	Coronary artery disease;
KIRP	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg04727924	chr7:799746	HEATR2	-0.78	-8.86	-0.49	1.63e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6001982	0.584	rs6001912	chr22:40828361	T/C	cg07138101	chr22:40742427	ADSL	0.64	4.99	0.3	1.14e-6	Breast cancer;
KIRP	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.92	-15.3	-0.7	1.35e-37	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.45	-6.9	-0.4	4.44e-11	Coronary artery disease;
KIRP	cis	rs10214930	0.723	rs6948814	chr7:27633401	C/G	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg08999081	chr20:33150536	PIGU	-0.38	-4.92	-0.3	1.55e-6	Height;
KIRP	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg04287289	chr16:89883240	FANCA	0.39	5.11	0.31	6.55e-7	Vitiligo;
KIRP	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-6.9	-0.4	4.49e-11	Gut microbiome composition (summer);
KIRP	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	11.05	0.58	2.68e-23	Personality dimensions;
KIRP	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.53	7.14	0.41	1.03e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	6.48	0.38	5.09e-10	Lymphocyte counts;
KIRP	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.35	-0.79	1.17e-54	Height;
KIRP	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.72	9.78	0.53	2.7e-19	Mood instability;
KIRP	cis	rs400736	0.671	rs863171	chr1:7992615	A/G	cg25007680	chr1:8021821	PARK7	0.48	6.69	0.39	1.48e-10	Response to antidepressants and depression;
KIRP	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg23815491	chr16:72088622	HP	0.45	7.39	0.43	2.33e-12	Fibrinogen levels;
KIRP	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	10.1	0.54	2.8e-20	Hip circumference;
KIRP	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-6.78	-0.4	8.9e-11	Schizophrenia;
KIRP	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg04025307	chr7:1156635	C7orf50	0.55	7.89	0.45	9.61e-14	Longevity;Endometriosis;
KIRP	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.77	11.33	0.59	3.08e-24	Ulcerative colitis;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.87	8.38	0.47	4.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	9.17	0.5	2.02e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg15556689	chr8:8085844	FLJ10661	0.59	7.17	0.42	8.77e-12	Neuroticism;
KIRP	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg04896959	chr15:78267971	NA	-0.39	-5.02	-0.3	1.02e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg14086599	chr2:241536098	CAPN10	-0.42	-4.86	-0.3	2.1e-6	Bipolar disorder;
KIRP	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.58	7.37	0.43	2.65e-12	Corneal astigmatism;
KIRP	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.81	0.35	1.88e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg04132472	chr17:19861366	AKAP10	0.41	5.35	0.32	2e-7	Schizophrenia;
KIRP	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.61	-6.36	-0.38	9.52e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.71	9.15	0.5	2.24e-17	Pancreatic cancer;
KIRP	cis	rs4728302	0.869	rs12707129	chr7:133593177	A/G	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.62	11.88	0.6	4.88e-26	Bone mineral density;
KIRP	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.45	-6.06	-0.36	5.09e-9	Red blood cell count;
KIRP	cis	rs4971059	0.617	rs10908458	chr1:155126948	T/C	cg02153340	chr1:155202674	NA	-0.43	-6.15	-0.36	3.15e-9	Breast cancer;
KIRP	cis	rs8060686	0.516	rs1975802	chr16:68285847	A/G	cg26727032	chr16:67993705	SLC12A4	-0.75	-8.61	-0.48	8.82e-16	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.23	13.96	0.66	5.01e-33	Platelet count;
KIRP	cis	rs4765905	0.609	rs2238047	chr12:2300008	A/G	cg10668781	chr12:2307325	CACNA1C	-0.35	-7.01	-0.41	2.31e-11	Schizophrenia;
KIRP	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	1.01	15.83	0.71	2.06e-39	Vitamin D levels;
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.69	9.35	0.51	5.76e-18	Menarche (age at onset);
KIRP	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.61	-6.58	-0.39	2.8e-10	DNA methylation (variation);
KIRP	cis	rs9596863	1.000	rs7328595	chr13:54424070	G/A	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.64	-0.34	4.68e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg26876637	chr1:152193138	HRNR	0.72	9.72	0.53	4.25e-19	Atopic dermatitis;
KIRP	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg20965017	chr5:231967	SDHA	-0.59	-6.88	-0.4	5.01e-11	Breast cancer;
KIRP	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.58	8.11	0.46	2.36e-14	Economic and political preferences (feminism/equality);
KIRP	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.44	0.38	6.35e-10	Mean platelet volume;
KIRP	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.53	6.51	0.38	4.22e-10	Asthma;
KIRP	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.14	-0.36	3.23e-9	Morning vs. evening chronotype;
KIRP	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg06640241	chr16:89574553	SPG7	0.67	8.91	0.49	1.19e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.41	0.33	1.47e-7	Lung cancer;
KIRP	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.62	5.7	0.34	3.39e-8	Smoking behavior;
KIRP	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.31	-0.47	6.51e-15	Response to antipsychotic treatment;
KIRP	cis	rs367943	0.712	rs13188946	chr5:112722855	C/T	cg12552261	chr5:112820674	MCC	0.57	6.76	0.4	1.02e-10	Type 2 diabetes;
KIRP	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg24315340	chr6:146058215	EPM2A	0.4	4.95	0.3	1.35e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7808935	0.768	rs757138	chr7:27989403	T/G	cg22168087	chr7:27702803	HIBADH	0.59	7.09	0.41	1.45e-11	Prostate cancer;
KIRP	cis	rs2562456	0.876	rs2650844	chr19:21602090	A/T	cg18461458	chr19:21324796	ZNF431	-0.52	-5.03	-0.31	9.6e-7	Pain;
KIRP	cis	rs4900069	0.764	rs12433069	chr14:91594186	A/G	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.44	-5.43	-0.33	1.33e-7	Resting heart rate;
KIRP	cis	rs6701037	1.000	rs11580331	chr1:175123288	T/C	cg17845761	chr1:175162550	KIAA0040	-0.32	-6.1	-0.36	4.1e-9	Alcohol dependence;
KIRP	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	9.11	0.5	2.94e-17	Coronary artery disease;
KIRP	cis	rs4356932	1.000	rs10003382	chr4:76955473	C/T	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs10486003	0.881	rs6976323	chr7:97198233	T/C	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.57	-5.07	-0.31	7.71e-7	Response to platinum-based agents;
KIRP	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.58	5.48	0.33	1.05e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20617344	chr13:113537534	ATP11A	-0.44	-6.24	-0.37	1.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2070997	0.816	rs1800609	chr9:133731184	A/G	cg13397898	chr9:133768931	QRFP	0.32	4.93	0.3	1.53e-6	Response to amphetamines;
KIRP	cis	rs7834588	0.736	rs111620542	chr8:63884089	G/A	cg04220482	chr8:63952370	GGH	0.49	5.37	0.32	1.82e-7	Response to Vitamin E supplementation;
KIRP	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg12549451	chr6:135224345	NA	0.42	5.12	0.31	6.11e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg11859384	chr17:80120422	CCDC57	0.44	5.53	0.33	8.19e-8	Life satisfaction;
KIRP	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08195029	chr19:9695212	ZNF121	0.48	6.09	0.36	4.31e-9	Parkinson's disease;
KIRP	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg24826892	chr11:71159390	DHCR7	-0.46	-5.12	-0.31	6.23e-7	Vitamin D levels;
KIRP	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.25e-10	Protein C levels;
KIRP	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg02534363	chr3:47050950	NBEAL2	0.28	4.85	0.3	2.17e-6	Colorectal cancer;
KIRP	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg18461458	chr19:21324796	ZNF431	-0.46	-4.9	-0.3	1.76e-6	Pain;
KIRP	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.42	5.34	0.32	2.16e-7	Melanoma;
KIRP	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.84	11.97	0.61	2.51e-26	Morning vs. evening chronotype;
KIRP	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg11395062	chr17:14139857	CDRT15	0.58	7.75	0.44	2.41e-13	Temperament;
KIRP	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.16	12.93	0.64	1.59e-29	Platelet count;
KIRP	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	10.27	0.55	8.05e-21	Bone mineral density;
KIRP	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg05802129	chr4:122689817	NA	-0.59	-7.48	-0.43	1.31e-12	Type 2 diabetes;
KIRP	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.96	-0.54	7.44e-20	Mood instability;
KIRP	cis	rs13385	0.769	rs28450136	chr5:139598090	A/G	cg01860693	chr5:139557145	C5orf32	0.48	5.25	0.32	3.33e-7	Atrial fibrillation;
KIRP	cis	rs838147	0.507	rs692854	chr19:49209464	C/A	cg16867584	chr19:49200180	FUT2	0.33	5.21	0.32	3.94e-7	Dietary macronutrient intake;
KIRP	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg15832292	chr6:96025679	MANEA	0.82	8.19	0.46	1.46e-14	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10982256	0.782	rs10982244	chr9:117250278	A/G	cg13636371	chr9:117264095	DFNB31	-0.44	-5.77	-0.35	2.36e-8	Bipolar disorder;
KIRP	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-0.58	-8.87	-0.49	1.54e-16	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg08975724	chr8:8085496	FLJ10661	0.63	7.69	0.44	3.54e-13	Systemic lupus erythematosus;
KIRP	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg12560992	chr17:57184187	TRIM37	0.59	5.58	0.34	6.29e-8	Cognitive test performance;
KIRP	cis	rs7224685	0.569	rs34356467	chr17:3978531	G/T	cg21851534	chr17:3907994	ZZEF1	0.53	5.18	0.31	4.61e-7	Type 2 diabetes;
KIRP	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg14972814	chr11:95582409	MTMR2	0.35	5.72	0.34	3.09e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg13010199	chr12:38710504	ALG10B	-0.48	-6.19	-0.37	2.56e-9	Bladder cancer;
KIRP	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18867708	chr6:26865862	GUSBL1	-0.53	-6.47	-0.38	5.31e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg09264619	chr17:80180166	NA	0.39	5.53	0.33	8.11e-8	Life satisfaction;
KIRP	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg00784671	chr22:46762841	CELSR1	-0.59	-7.43	-0.43	1.79e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.85	11.64	0.6	3.14e-25	Longevity;
KIRP	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.56	-6.39	-0.38	8.03e-10	Vitiligo;
KIRP	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.42	6.43	0.38	6.61e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.44	-0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.68	9.42	0.52	3.35e-18	Obesity-related traits;
KIRP	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.02	-0.41	2.15e-11	Retinal vascular caliber;
KIRP	cis	rs7119167	0.686	rs7342249	chr11:73046299	T/C	cg17517138	chr11:73019481	ARHGEF17	0.46	4.96	0.3	1.32e-6	Blood protein levels;
KIRP	trans	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg16141378	chr3:129829833	LOC729375	0.54	7.09	0.41	1.45e-11	Mood instability;
KIRP	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.88	-0.4	5.04e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs16854884	0.770	rs6784938	chr3:143817528	C/T	cg06585982	chr3:143692056	C3orf58	0.44	5.43	0.33	1.32e-7	Economic and political preferences (feminism/equality);
KIRP	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.91	11.9	0.6	4.28e-26	Homoarginine levels;
KIRP	cis	rs6125597	0.904	rs2273146	chr20:47839653	C/T	cg03212862	chr20:47662828	CSE1L	-0.4	-5.06	-0.31	8.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8523	0.901	rs3798711	chr6:11002810	C/T	cg13562911	chr6:11044106	ELOVL2	-0.37	-4.86	-0.3	2.09e-6	Red blood cell fatty acid levels;
KIRP	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg25486957	chr4:152246857	NA	-0.42	-5.02	-0.31	9.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg06558623	chr16:89946397	TCF25	1.03	7.71	0.44	3.02e-13	Skin colour saturation;
KIRP	cis	rs9815354	0.812	rs17283243	chr3:41914792	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg17279839	chr7:150038598	RARRES2	-0.44	-5.96	-0.36	8.78e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg07653901	chr22:50250238	ZBED4	-0.61	-6.63	-0.39	2.15e-10	Schizophrenia;
KIRP	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg24253500	chr15:84953950	NA	0.52	5.87	0.35	1.39e-8	Schizophrenia;
KIRP	cis	rs12496230	0.830	rs6781336	chr3:66858050	A/G	cg04995300	chr3:66848608	NA	0.44	6.81	0.4	7.64e-11	Type 2 diabetes;
KIRP	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.69	6.87	0.4	5.24e-11	Cannabis dependence symptom count;
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07402062	chr16:89894098	SPIRE2	0.34	7.24	0.42	5.57e-12	Vitiligo;
KIRP	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg07395648	chr5:131743802	NA	-0.36	-4.94	-0.3	1.48e-6	Blood metabolite levels;
KIRP	cis	rs240764	0.507	rs9390695	chr6:101266770	A/G	cg09795085	chr6:101329169	ASCC3	0.43	4.84	0.3	2.25e-6	Neuroticism;
KIRP	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.82	11.86	0.6	5.71e-26	Mean platelet volume;
KIRP	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs55788414	0.872	rs12102958	chr16:81186207	T/A	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.63	-0.48	7.88e-16	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7794364	0.658	rs2193255	chr7:117520009	A/C	cg21880328	chr7:117514017	CTTNBP2	-0.37	-5.58	-0.34	6.32e-8	Idiopathic osteonecrosis of the femoral head;
KIRP	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.44	6.31	0.37	1.25e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4356932	1.000	rs4484329	chr4:76978692	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.54	-0.33	7.78e-8	Bipolar disorder;
KIRP	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.63e-17	Coronary artery calcification;
KIRP	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.35	-0.47	4.83e-15	Mood instability;
KIRP	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg08126542	chr6:37504118	NA	-0.72	-10.05	-0.54	3.89e-20	Cognitive performance;
KIRP	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg06521331	chr12:34319734	NA	-0.62	-7.42	-0.43	1.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs35995292	1.000	rs9638944	chr7:38947417	T/C	cg19327137	chr7:38886074	VPS41	0.49	5.87	0.35	1.4e-8	Subjective well-being (multi-trait analysis);
KIRP	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg23100626	chr2:96804247	ASTL	-0.49	-6.65	-0.39	1.93e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9914544	0.545	rs2305064	chr17:18770733	G/A	cg26378065	chr17:18585709	ZNF286B	0.38	4.98	0.3	1.19e-6	Educational attainment (years of education);
KIRP	trans	rs117483095	0.579	rs4836687	chr9:132822845	C/T	cg25623768	chr2:45241008	NA	-0.81	-6.07	-0.36	4.87e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.41	5.23	0.32	3.63e-7	Height;
KIRP	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.76e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7221595	0.756	rs35102999	chr17:3892700	G/A	cg09695851	chr17:3907499	NA	0.59	5.88	0.35	1.35e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.87	9.64	0.52	7.51e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg05484376	chr2:27715224	FNDC4	0.41	6.84	0.4	6.21e-11	Total body bone mineral density;
KIRP	cis	rs4356975	0.563	rs11940316	chr4:69961127	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.35	6.36	0.38	9.68e-10	Erythrocyte sedimentation rate;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02767470	chr2:152663031	ARL5A	0.49	6.3	0.37	1.33e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg19847130	chr8:10466454	RP1L1	0.38	5.32	0.32	2.28e-7	Systolic blood pressure;
KIRP	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-12.62	-0.63	1.74e-28	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03960681	chr15:60769981	NARG2	0.48	6.85	0.4	5.77e-11	Interleukin-4 levels;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg01798813	chr17:3906674	NA	0.51	7.13	0.41	1.13e-11	Type 2 diabetes;
KIRP	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.75	9.62	0.52	8.32e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs714515	0.900	rs4916252	chr1:172354017	T/C	cg01573306	chr1:172330400	DNM3	0.45	5.83	0.35	1.69e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.46	-6.05	-0.36	5.28e-9	Ulcerative colitis;
KIRP	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.75	-10.48	-0.56	1.77e-21	Parkinson's disease;
KIRP	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.36	-0.32	1.94e-7	Aortic root size;
KIRP	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg26597838	chr10:835615	NA	-0.5	-6.08	-0.36	4.57e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs12643440	0.922	rs13142734	chr4:17200948	A/G	cg22650099	chr4:17144496	NA	-0.47	-5.67	-0.34	3.96e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg00495681	chr13:53174319	NA	0.44	6.08	0.36	4.58e-9	Lewy body disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg12107626	chr17:39992626	KLHL10;NT5C3L	0.74	6.2	0.37	2.32e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs12476592	0.602	rs262505	chr2:63861786	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.95	-0.3	1.37e-6	Childhood ear infection;
KIRP	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg21573476	chr21:45109991	RRP1B	0.55	7.21	0.42	6.95e-12	Mean corpuscular volume;
KIRP	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.87	0.4	5.21e-11	Educational attainment;
KIRP	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.34e-15	Bone mineral density;
KIRP	cis	rs735539	0.574	rs10870743	chr13:21258756	C/A	cg27499820	chr13:21296301	IL17D	0.35	5.11	0.31	6.5e-7	Dental caries;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.73	-6.66	-0.39	1.73e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg15848620	chr12:58087721	OS9	-0.49	-5.75	-0.34	2.65e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg01988459	chr11:68622903	NA	-0.43	-5.88	-0.35	1.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg24644049	chr4:85504048	CDS1	0.93	6.87	0.4	5.17e-11	Skin colour saturation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18173908	chr7:129710284	KLHDC10	0.44	6.26	0.37	1.71e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.96	0.57	4.96e-23	Cognitive test performance;
KIRP	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.19	0.31	4.47e-7	Educational attainment;
KIRP	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg27462398	chr1:86174642	ZNHIT6	-0.45	-5.19	-0.31	4.32e-7	Urate levels in overweight individuals;
KIRP	trans	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg10756647	chr7:56101905	PSPH	0.92	6.89	0.4	4.61e-11	Diabetic kidney disease;
KIRP	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.85	8.58	0.48	1.1e-15	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs662064	0.962	rs607941	chr1:10539543	C/T	cg19773385	chr1:10388646	KIF1B	0.4	5.36	0.32	1.94e-7	Asthma;
KIRP	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.84	-10.03	-0.54	4.39e-20	IgG glycosylation;
KIRP	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.47	6.4	0.38	7.99e-10	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs7635838	0.819	rs2454478	chr3:11541885	A/G	cg00170343	chr3:11313890	ATG7	0.48	6.03	0.36	5.91e-9	HDL cholesterol;
KIRP	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.42	-6.48	-0.38	5.07e-10	Body mass index;
KIRP	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg06204229	chr3:52865917	ITIH4	-0.48	-5.51	-0.33	9.07e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.95	0.3	1.4e-6	Tonsillectomy;
KIRP	cis	rs6466055	0.720	rs1204077	chr7:104984019	T/C	cg04380332	chr7:105027541	SRPK2	0.63	9.41	0.51	3.58e-18	Schizophrenia;
KIRP	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.84	-10.89	-0.57	8.81e-23	Cognitive function;
KIRP	cis	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg20368463	chr18:77673604	PQLC1	-0.45	-5.67	-0.34	4e-8	Schizophrenia;
KIRP	cis	rs57994353	0.796	rs13283788	chr9:139384521	T/G	cg14169450	chr9:139327907	INPP5E	0.59	6.39	0.38	8.3e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-9.6	-0.52	9.52e-19	Morning vs. evening chronotype;
KIRP	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.0	0.57	3.65e-23	Exhaled nitric oxide levels;
KIRP	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.74	11.02	0.57	3.18e-23	Blood metabolite ratios;
KIRP	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.52	5.77	0.35	2.39e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-0.93	-9.26	-0.51	1.06e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg06618935	chr21:46677482	NA	-0.43	-5.17	-0.31	4.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06544989	chr22:39130855	UNC84B	0.49	8.04	0.46	3.72e-14	Menopause (age at onset);
KIRP	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.6	8.21	0.46	1.23e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs300890	0.513	rs7684017	chr4:144045365	A/G	cg01719995	chr4:144104893	USP38	0.42	5.45	0.33	1.21e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg16797656	chr11:68205561	LRP5	0.37	4.88	0.3	1.93e-6	Total body bone mineral density;
KIRP	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.61	8.81	0.49	2.34e-16	Colorectal cancer;
KIRP	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.92	15.64	0.71	9.43e-39	Menarche (age at onset);
KIRP	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.43	-0.47	2.87e-15	Common traits (Other);
KIRP	cis	rs16828019	0.777	rs3738369	chr1:41486408	G/A	cg03387723	chr1:41708464	SCMH1	-0.72	-6.19	-0.37	2.44e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9625935	0.518	rs9625870	chr22:30261219	C/T	cg01021169	chr22:30184971	ASCC2	-0.43	-6.04	-0.36	5.61e-9	Tonsillectomy;
KIRP	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.93	-11.02	-0.57	3.31e-23	Gut microbiome composition (summer);
KIRP	cis	rs2274273	0.682	rs8008134	chr14:55507520	T/C	cg04306507	chr14:55594613	LGALS3	0.42	6.36	0.38	9.98e-10	Protein biomarker;
KIRP	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.77	10.16	0.54	1.73e-20	Aortic root size;
KIRP	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg15655495	chr12:38532458	NA	-0.29	-5.14	-0.31	5.54e-7	Bladder cancer;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg21166781	chr9:124262344	GGTA1	0.41	6.22	0.37	2.13e-9	Cancer;
KIRP	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg14689365	chr7:158441557	NCAPG2	-0.41	-5.03	-0.31	9.31e-7	Height;
KIRP	cis	rs4006360	0.575	rs436266	chr17:39313798	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.44	-5.84	-0.35	1.66e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg06212747	chr3:49208901	KLHDC8B	0.62	5.34	0.32	2.09e-7	Menarche (age at onset);
KIRP	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg22284058	chr8:142237359	SLC45A4	-0.41	-4.98	-0.3	1.19e-6	Immature fraction of reticulocytes;
KIRP	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17507749	chr15:85114479	UBE2QP1	0.73	8.15	0.46	1.89e-14	Schizophrenia;
KIRP	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg17724175	chr1:150552817	MCL1	-0.34	-5.87	-0.35	1.41e-8	Tonsillectomy;
KIRP	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16346588	chr10:242978	ZMYND11	0.49	6.06	0.36	5.04e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg04833713	chr10:74871078	NUDT13	0.49	5.71	0.34	3.27e-8	Incident atrial fibrillation;
KIRP	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Hypertriglyceridemia;
KIRP	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.98	-0.3	1.22e-6	Bipolar disorder;
KIRP	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg15162869	chr22:32027605	PISD	-0.66	-4.84	-0.3	2.27e-6	Age-related hearing impairment;
KIRP	cis	rs662064	0.962	rs620405	chr1:10554794	T/C	cg07384165	chr1:10488281	NA	-0.43	-5.42	-0.33	1.43e-7	Asthma;
KIRP	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.77	-0.35	2.34e-8	Type 2 diabetes;
KIRP	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.61	8.3	0.47	7.03e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg13334819	chr7:99746414	C7orf59	-0.49	-5.76	-0.34	2.53e-8	Coronary artery disease;
KIRP	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	7.09	0.41	1.41e-11	Retinal vascular caliber;
KIRP	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	0.89	6.73	0.39	1.18e-10	IgG glycosylation;
KIRP	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	1.16	14.34	0.67	2.67e-34	Type 2 diabetes nephropathy;
KIRP	cis	rs12643440	0.718	rs629542	chr4:17137284	C/A	cg22650099	chr4:17144496	NA	0.51	7.07	0.41	1.63e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	7.84	0.45	1.33e-13	Chronic sinus infection;
KIRP	cis	rs6882076	0.925	rs4704826	chr5:156392082	C/A	cg12943317	chr5:156479607	HAVCR1	-0.63	-7.59	-0.44	6.49e-13	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02860732	chr16:12995292	SHISA9	0.47	6.13	0.36	3.45e-9	Parkinson's disease;
KIRP	cis	rs11650494	0.710	rs8065814	chr17:47470720	T/C	cg08112188	chr17:47440006	ZNF652	1.17	6.85	0.4	5.78e-11	Prostate cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26108683	chr11:67250618	AIP	-0.46	-6.17	-0.37	2.73e-9	Metabolic traits;
KIRP	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg03788504	chr6:150331562	NA	-0.32	-5.91	-0.35	1.12e-8	Alopecia areata;
KIRP	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.85	0.53	1.6e-19	Ileal carcinoids;
KIRP	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.76	10.63	0.56	5.73e-22	Coronary artery disease;
KIRP	cis	rs2723242	0.558	rs3821090	chr2:171786088	C/T	cg12801329	chr2:171670795	NA	0.43	4.93	0.3	1.48e-6	Platelet distribution width;
KIRP	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg07701084	chr6:150067640	NUP43	0.69	8.75	0.49	3.49e-16	Lung cancer;
KIRP	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11987759	chr7:65425863	GUSB	-0.44	-5.32	-0.32	2.34e-7	Aortic root size;
KIRP	cis	rs9400271	0.609	rs9386783	chr6:109588644	G/T	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg14703610	chr5:56206110	C5orf35	0.51	6.77	0.4	9.65e-11	Coronary artery disease;
KIRP	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg05555928	chr11:63887634	MACROD1	-0.58	-5.29	-0.32	2.69e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9816226	0.591	rs4234589	chr3:185818882	A/G	cg00760338	chr3:185826511	ETV5	-0.78	-6.71	-0.39	1.36e-10	Obesity;Body mass index;
KIRP	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	1.1	20.25	0.79	2.5e-54	Bone mineral density;
KIRP	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.41	6.14	0.36	3.2e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.61	-7.02	-0.41	2.13e-11	Menarche (age at onset);
KIRP	cis	rs11169552	0.580	rs4768913	chr12:51135956	G/A	cg12884762	chr12:50931848	DIP2B	-0.44	-4.98	-0.3	1.22e-6	Colorectal cancer;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.23e-9	Breast cancer;
KIRP	cis	rs11690462	0.528	rs6710942	chr2:26636390	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.44	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.56	-5.27	-0.32	2.93e-7	Mosquito bite size;
KIRP	cis	rs2279817	0.818	rs883379	chr1:17983789	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-9.21	-0.51	1.49e-17	Neuroticism;
KIRP	cis	rs2574975	0.531	rs1203397	chr10:52201752	G/T	cg10034176	chr10:52120283	SGMS1	0.4	5.7	0.34	3.5e-8	Response to amphetamines;
KIRP	cis	rs580438	0.529	rs6804328	chr3:13437883	G/T	cg10657019	chr3:13328039	NA	-0.49	-6.27	-0.37	1.65e-9	Myringotomy;
KIRP	cis	rs4728302	0.607	rs10241782	chr7:133588380	A/G	cg10665199	chr7:133106180	EXOC4	0.43	4.93	0.3	1.49e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.79	-7.5	-0.43	1.15e-12	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.71	-10.68	-0.56	4.1e-22	Prudent dietary pattern;
KIRP	cis	rs3736594	0.607	rs7584462	chr2:28176056	A/T	cg27432699	chr2:27873401	GPN1	-0.45	-5.37	-0.32	1.82e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7591446	0.517	rs13427985	chr2:45838840	C/A	cg15146906	chr2:45838581	SRBD1	0.52	5.34	0.32	2.09e-7	Squamous cell lung carcinoma;
KIRP	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg05347473	chr6:146136440	FBXO30	0.46	6.54	0.38	3.48e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1642645	0.793	rs642579	chr1:42431397	C/T	cg26038582	chr1:42384390	HIVEP3	0.27	4.88	0.3	1.87e-6	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg21132104	chr15:45694354	SPATA5L1	0.75	9.46	0.52	2.64e-18	Homoarginine levels;
KIRP	cis	rs1359582	0.836	rs1409136	chr10:90356598	C/T	cg15661332	chr10:90342814	RNLS	-0.6	-6.03	-0.36	5.88e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs2150410	0.915	rs67212994	chr21:40551138	C/T	cg11890956	chr21:40555474	PSMG1	-0.76	-5.5	-0.33	9.59e-8	Temperament (bipolar disorder);
KIRP	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.55	-6.49	-0.38	4.77e-10	Metabolite levels;
KIRP	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.05	15.76	0.71	3.68e-39	Primary sclerosing cholangitis;
KIRP	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26002218	chr14:103986227	CKB	0.29	5.55	0.33	7.48e-8	Body mass index;
KIRP	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg16586182	chr3:47516702	SCAP	-0.78	-11.06	-0.58	2.42e-23	Colorectal cancer;
KIRP	cis	rs10114408	0.921	rs1890376	chr9:96661535	A/C	cg14598338	chr9:96623480	NA	-0.32	-4.88	-0.3	1.95e-6	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs7980799	0.772	rs6488162	chr12:33593127	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-6.29	-0.37	1.45e-9	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.55	-5.41	-0.33	1.52e-7	Pubertal anthropometrics;
KIRP	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10174797	chr19:8464628	RAB11B	0.51	6.4	0.38	7.87e-10	HDL cholesterol;
KIRP	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.4	-5.38	-0.32	1.76e-7	Schizophrenia;
KIRP	cis	rs34779708	0.966	rs35079558	chr10:35479886	A/G	cg03585969	chr10:35415529	CREM	0.8	9.68	0.53	5.57e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg13010199	chr12:38710504	ALG10B	0.54	6.52	0.38	4.04e-10	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg01798813	chr17:3906674	NA	0.56	7.94	0.45	7e-14	Type 2 diabetes;
KIRP	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.67	7.71	0.44	3.05e-13	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg21827317	chr3:136751795	NA	0.35	4.87	0.3	1.96e-6	Neuroticism;
KIRP	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg27205649	chr11:78285834	NARS2	0.84	11.39	0.59	1.97e-24	Alzheimer's disease (survival time);
KIRP	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.16	0.42	9.21e-12	Bipolar disorder;
KIRP	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg05315796	chr3:52349193	DNAH1	0.41	6.58	0.39	2.89e-10	Bipolar disorder;
KIRP	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg01879757	chr17:41196368	BRCA1	0.77	10.66	0.56	4.77e-22	Menopause (age at onset);
KIRP	cis	rs2151522	0.762	rs11754682	chr6:127177719	T/C	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.74	0.71	4.26e-39	Bipolar disorder;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg18212924	chr14:105608474	JAG2	0.59	6.7	0.39	1.4e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.67	8.91	0.49	1.17e-16	Multiple sclerosis;
KIRP	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.27	-0.37	1.6e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.41	-6.4	-0.38	7.99e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.61	8.33	0.47	5.89e-15	Obesity-related traits;
KIRP	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg26554054	chr8:600488	NA	0.71	5.39	0.33	1.63e-7	IgG glycosylation;
KIRP	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.03e-13	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.97e-44	Breast cancer;
KIRP	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-6.82	-0.4	7.05e-11	Total body bone mineral density;
KIRP	trans	rs1422110	0.515	rs1155791	chr5:85417582	A/C	cg01787110	chr1:109008453	NBPF6	0.61	7.59	0.44	6.67e-13	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-0.93	-11.06	-0.58	2.48e-23	Lymphocyte counts;
KIRP	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg08847533	chr14:75593920	NEK9	0.52	6.0	0.36	6.85e-9	IgG glycosylation;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21995682	chr6:116989978	ZUFSP	0.58	6.41	0.38	7.39e-10	Lung cancer in ever smokers;
KIRP	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg24699146	chr1:24152579	HMGCL	0.44	5.94	0.35	9.59e-9	Immature fraction of reticulocytes;
KIRP	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.3	0.62	2.03e-27	Bipolar disorder;
KIRP	cis	rs7937612	0.861	rs4245213	chr11:120273597	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.51	-7.79	-0.44	1.9e-13	Intraocular pressure;
KIRP	cis	rs10186029	0.509	rs13425936	chr2:213940346	C/T	cg08319019	chr2:214017104	IKZF2	-0.42	-4.99	-0.3	1.15e-6	Systemic sclerosis;
KIRP	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.83	-8.3	-0.47	7.1e-15	Fibroblast growth factor basic levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21575078	chr14:105956409	C14orf80	-0.52	-6.3	-0.37	1.34e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00338735	chr4:53728038	RASL11B	0.5	5.83	0.35	1.71e-8	Optic nerve measurement (cup area);
KIRP	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg00599163	chr2:162100495	NA	0.46	5.28	0.32	2.81e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4285028	0.699	rs6771068	chr3:121478745	A/T	cg11130432	chr3:121712080	ILDR1	0.44	5.19	0.31	4.47e-7	Multiple sclerosis;
KIRP	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.63	7.45	0.43	1.59e-12	Obesity-related traits;
KIRP	cis	rs2279817	0.735	rs75044419	chr1:18008241	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.39	-0.47	3.76e-15	Neuroticism;
KIRP	cis	rs3779635	0.742	rs17375610	chr8:27249328	G/C	cg18234130	chr8:27182889	PTK2B	0.56	7.3	0.42	3.92e-12	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12187049	chr5:70882888	MCCC2	0.54	6.7	0.39	1.45e-10	Smoking initiation;
KIRP	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.45	-5.32	-0.32	2.32e-7	Response to antidepressants in depression;
KIRP	cis	rs4356975	0.563	rs7438244	chr4:69964209	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs7113850	0.541	rs79932281	chr11:24231839	T/G	ch.11.24196551F	chr11:24239977	NA	0.9	8.34	0.47	5.17e-15	Bone fracture in osteoporosis;
KIRP	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.61	6.46	0.38	5.52e-10	Diisocyanate-induced asthma;
KIRP	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.74	-8.94	-0.5	9.25e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7714670	1.000	rs34929759	chr5:73073075	T/C	cg04480106	chr5:72934606	RGNEF	-0.37	-4.84	-0.3	2.25e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.49	11.76	0.6	1.28e-25	Ewing sarcoma;
KIRP	cis	rs7577696	0.524	rs212696	chr2:32441685	A/G	cg02381751	chr2:32503542	YIPF4	0.61	5.9	0.35	1.19e-8	Inflammatory biomarkers;
KIRP	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.17	0.42	8.63e-12	Bipolar disorder;
KIRP	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.57	-6.39	-0.38	8.28e-10	LDL cholesterol levels;
KIRP	cis	rs3748682	0.821	rs12022363	chr1:38252609	A/G	cg12658694	chr1:38397304	INPP5B	0.57	6.11	0.36	3.77e-9	Hypothyroidism;
KIRP	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.58	8.44	0.47	2.72e-15	Immature fraction of reticulocytes;
KIRP	cis	rs8010715	0.636	rs3825584	chr14:24587639	C/T	cg23112188	chr14:24563095	PCK2	-0.34	-4.96	-0.3	1.32e-6	IgG glycosylation;
KIRP	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg26441486	chr22:50317300	CRELD2	-0.39	-5.45	-0.33	1.23e-7	Schizophrenia;
KIRP	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg22138327	chr13:27999177	GTF3A	0.93	7.11	0.41	1.24e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg18154014	chr19:37997991	ZNF793	0.67	6.03	0.36	6e-9	Coronary artery calcification;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg08911638	chr6:167708827	UNC93A	0.36	6.02	0.36	6.23e-9	Serum protein levels (sST2);
KIRP	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg03315344	chr16:75512273	CHST6	0.54	5.11	0.31	6.5e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	trans	rs1928295	0.786	rs10759926	chr9:120366225	T/C	cg04204072	chr16:20752857	THUMPD1	-0.51	-6.27	-0.37	1.58e-9	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.83	10.17	0.54	1.62e-20	Sudden cardiac arrest;
KIRP	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.95	-14.08	-0.67	2.08e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg13482628	chr17:19912719	NA	0.53	6.91	0.4	4.08e-11	Schizophrenia;
KIRP	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	0.95	8.09	0.46	2.79e-14	Arsenic metabolism;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	9.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.03	-0.31	9.45e-7	Carotid intima media thickness;
KIRP	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.41	-6.13	-0.36	3.47e-9	Platelet distribution width;
KIRP	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.32	-5.81	-0.35	1.93e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.94e-11	Alzheimer's disease (late onset);
KIRP	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.59	-8.57	-0.48	1.18e-15	Renal function-related traits (BUN);
KIRP	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-5.13	-0.31	5.98e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.73	-10.18	-0.54	1.59e-20	Obesity-related traits;
KIRP	cis	rs7937612	1.000	rs2305010	chr11:120330149	C/G	cg24566217	chr11:120254723	ARHGEF12	0.46	6.68	0.39	1.55e-10	Intraocular pressure;
KIRP	cis	rs2562456	0.833	rs77576302	chr19:21518187	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs2267137	0.868	rs5763178	chr22:29773869	A/G	cg07256473	chr22:29710276	RASL10A	0.46	7.29	0.42	4.15e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg14338887	chr6:42928500	GNMT	0.47	6.87	0.4	5.32e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg05555928	chr11:63887634	MACROD1	-0.54	-5.13	-0.31	5.91e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.55	9.77	0.53	2.89e-19	Bone mineral density;
KIRP	cis	rs16958440	0.521	rs62095426	chr18:44585481	C/T	cg17192377	chr18:44677553	HDHD2	0.61	5.47	0.33	1.08e-7	Sitting height ratio;
KIRP	cis	rs3105593	0.543	rs28582911	chr15:50729629	G/A	cg08437265	chr15:50716283	USP8	0.36	5.0	0.3	1.07e-6	QT interval;
KIRP	cis	rs1484642	0.618	rs546901	chr8:9859936	C/A	cg15537082	chr8:9762300	MIR124-1;LOC157627	0.62	5.4	0.33	1.59e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.5	6.12	0.36	3.58e-9	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.82	-6.9	-0.4	4.3e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	1.08	19.52	0.78	6.89e-52	Systemic lupus erythematosus;
KIRP	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-0.64	-5.34	-0.32	2.13e-7	Blood pressure (smoking interaction);
KIRP	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg12623918	chr2:306882	NA	0.48	5.82	0.35	1.87e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs16828019	0.852	rs12742379	chr1:41526381	A/G	cg03387723	chr1:41708464	SCMH1	-0.75	-6.45	-0.38	5.81e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.85	-0.3	2.17e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg20636351	chr8:55087400	NA	-0.65	-8.0	-0.45	5.03e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg15744005	chr10:104629667	AS3MT	-0.38	-7.93	-0.45	7.91e-14	Arsenic metabolism;
KIRP	cis	rs883565	0.655	rs6777651	chr3:39143599	G/C	cg01426195	chr3:39028469	NA	-0.72	-12.3	-0.62	2.1e-27	Handedness;
KIRP	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.44	5.94	0.35	9.87e-9	Coronary artery disease;
KIRP	cis	rs9473924	0.632	rs9369984	chr6:50866676	T/G	cg03432817	chr6:50765336	NA	0.35	5.41	0.33	1.52e-7	Body mass index;
KIRP	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	5.58	0.34	6.38e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9302635	0.816	rs7202323	chr16:72217113	T/G	cg01557791	chr16:72042693	DHODH	-0.46	-4.9	-0.3	1.75e-6	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21059382	chr19:15236615	ILVBL	0.51	6.27	0.37	1.62e-9	Parkinson's disease;
KIRP	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg12599982	chr1:44399894	ARTN	0.43	5.19	0.31	4.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.85	12.92	0.64	1.65e-29	Ulcerative colitis;
KIRP	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.86	-9.64	-0.52	7.25e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs3947	0.951	rs1692817	chr8:11704719	C/A	cg21775007	chr8:11205619	TDH	-0.46	-5.0	-0.3	1.1e-6	Blood protein levels;
KIRP	cis	rs539514	0.501	rs8000656	chr13:76400640	A/G	cg04757411	chr13:76259545	LMO7	0.45	6.53	0.38	3.65e-10	Type 1 diabetes;
KIRP	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg07856975	chr6:36356162	ETV7	0.45	5.86	0.35	1.49e-8	Platelet distribution width;
KIRP	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs17123764	1.000	rs2241418	chr12:49951232	T/C	cg02054252	chr12:50078554	FMNL3	0.43	5.25	0.32	3.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7551222	0.646	rs6594015	chr1:204461622	C/T	cg20240347	chr1:204465584	NA	-0.43	-7.81	-0.45	1.68e-13	Schizophrenia;
KIRP	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.57	-7.81	-0.45	1.62e-13	Schizophrenia;
KIRP	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.49	-5.56	-0.33	7.01e-8	Schizophrenia;
KIRP	cis	rs4974559	0.895	rs10004411	chr4:1354306	T/G	cg02980000	chr4:1222292	CTBP1	0.75	7.23	0.42	5.94e-12	Systolic blood pressure;
KIRP	cis	rs7903847	0.620	rs11189165	chr10:99123457	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.67	-0.34	3.98e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.06	-0.5	4.27e-17	Rheumatoid arthritis;
KIRP	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.58	8.12	0.46	2.23e-14	Multiple system atrophy;
KIRP	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg18657303	chr4:1051139	NA	0.55	4.99	0.3	1.16e-6	Recombination rate (females);
KIRP	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg03959625	chr15:84868606	LOC388152	0.72	8.6	0.48	9.33e-16	Schizophrenia;
KIRP	cis	rs13361707	0.920	rs116825503	chr5:40705419	A/T	cg01087697	chr5:40835557	RPL37	-0.48	-5.46	-0.33	1.16e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.74	9.45	0.52	2.75e-18	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.4	0.62	9.37e-28	Monocyte percentage of white cells;
KIRP	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg15664640	chr17:80829946	TBCD	-0.7	-6.79	-0.4	8.49e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg14673194	chr17:80132900	CCDC57	-0.74	-8.36	-0.47	4.72e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16346588	chr10:242978	ZMYND11	0.48	5.94	0.35	9.51e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.54	-0.43	9.17e-13	Migraine;Coronary artery disease;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	7.71	0.44	3.11e-13	Lymphocyte counts;
KIRP	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg06647332	chr5:131281008	NA	0.45	5.02	0.3	9.95e-7	Life satisfaction;
KIRP	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg21573476	chr21:45109991	RRP1B	-0.66	-9.4	-0.51	4.04e-18	Mean corpuscular volume;
KIRP	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs8060686	0.516	rs2290700	chr16:68288983	T/G	cg26727032	chr16:67993705	SLC12A4	-0.71	-7.8	-0.45	1.77e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10214930	0.767	rs1980330	chr7:27630323	G/T	cg22168087	chr7:27702803	HIBADH	0.53	5.13	0.31	5.86e-7	Hypospadias;
KIRP	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.87	-14.77	-0.69	8.95e-36	Breast cancer;
KIRP	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.76	-9.69	-0.53	5.01e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2790457	0.792	rs1265841	chr10:28920701	A/T	cg05705492	chr10:28955341	NA	-0.51	-7.62	-0.44	5.58e-13	Multiple myeloma;
KIRP	cis	rs2665103	0.632	rs3902959	chr15:82544927	C/T	cg00614314	chr15:82944287	LOC80154	0.42	5.39	0.33	1.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1440410	0.795	rs724517	chr4:144196536	T/C	cg01719995	chr4:144104893	USP38	0.4	5.19	0.31	4.4e-7	Ischemic stroke;
KIRP	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.91	0.4	4.1e-11	Platelet count;
KIRP	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.46	-16.83	-0.73	8.37e-43	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg06521331	chr12:34319734	NA	-0.53	-6.47	-0.38	5.36e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.51	-7.17	-0.42	8.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7084402	0.967	rs1658496	chr10:60279909	G/A	cg05938607	chr10:60274200	BICC1	0.46	11.06	0.58	2.41e-23	Refractive error;
KIRP	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.7	7.5	0.43	1.14e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.26e-9	Schizophrenia;
KIRP	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg22903471	chr2:27725779	GCKR	0.4	5.65	0.34	4.36e-8	Oral cavity cancer;
KIRP	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.51	6.19	0.37	2.47e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.34	0.62	1.46e-27	Bipolar disorder;
KIRP	cis	rs9400467	0.506	rs12200610	chr6:111663567	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs6684428	0.611	rs6657176	chr1:56328238	G/T	cg11651538	chr1:56320950	NA	-0.8	-11.12	-0.58	1.58e-23	Airflow obstruction;
KIRP	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.97	15.98	0.71	6.8100000000000004e-40	Systemic lupus erythematosus;
KIRP	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Bladder cancer;
KIRP	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.96	15.21	0.7	2.82e-37	Uric acid clearance;
KIRP	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg03465714	chr1:152285911	FLG	0.44	5.33	0.32	2.19e-7	Atopic dermatitis;
KIRP	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.87	-14.78	-0.69	8.11e-36	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg05370193	chr1:21551575	ECE1	-0.37	-5.26	-0.32	3.11e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6708331	0.540	rs6546576	chr2:70401488	G/A	cg05298696	chr2:70188691	ASPRV1	-0.46	-6.12	-0.36	3.73e-9	Obesity-related traits;
KIRP	cis	rs4690686	0.509	rs61482060	chr4:177264465	A/G	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg05347473	chr6:146136440	FBXO30	0.58	8.31	0.47	6.67e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.69	-8.34	-0.47	5.38e-15	Aortic root size;
KIRP	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg23093090	chr10:104574429	C10orf26	0.38	6.18	0.37	2.7e-9	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg20701182	chr2:24300061	SF3B14	0.48	5.11	0.31	6.54e-7	Asthma;
KIRP	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.79	0.49	2.58e-16	Bladder cancer;
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg12486944	chr17:80159399	CCDC57	0.38	5.11	0.31	6.56e-7	Life satisfaction;
KIRP	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg06026331	chr20:60912101	LAMA5	0.51	5.59	0.34	6.02e-8	Colorectal cancer;
KIRP	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.53	7.01	0.41	2.32e-11	Menarche (age at onset);
KIRP	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.24	-0.47	1.03e-14	Retinal vascular caliber;
KIRP	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6725041	0.631	rs4673657	chr2:213151230	C/T	cg20637307	chr2:213403960	ERBB4	-0.41	-5.25	-0.32	3.25e-7	QT interval (ambient particulate matter interaction);
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg06333435	chr8:22102724	POLR3D;MIR320A	0.54	6.37	0.38	9.24e-10	Electroencephalogram traits;
KIRP	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg24955955	chr5:415729	AHRR	0.65	5.66	0.34	4.25e-8	Fat distribution (HIV);
KIRP	cis	rs357618	0.897	rs165362	chr5:150863087	T/G	cg22672639	chr5:150884813	FAT2	0.33	4.97	0.3	1.26e-6	Basophil percentage of white cells;
KIRP	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6028335	0.674	rs68173814	chr20:37621180	A/G	cg16355469	chr20:37678765	NA	0.51	4.98	0.3	1.21e-6	Alcohol and nicotine co-dependence;
KIRP	cis	rs6662572	0.737	rs10789476	chr1:46305362	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-6.85	-0.4	5.72e-11	Vitiligo;
KIRP	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.44	7.48	0.43	1.3e-12	Heart rate;
KIRP	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.96	-0.3	1.33e-6	Life satisfaction;
KIRP	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-1.05	-16.74	-0.73	1.63e-42	Cognitive function;
KIRP	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.9	13.22	0.64	1.7e-30	Selective IgA deficiency;
KIRP	cis	rs12580194	0.593	rs13377995	chr12:55757380	C/G	cg19537932	chr12:55886519	OR6C68	-0.47	-6.22	-0.37	2.12e-9	Cancer;
KIRP	cis	rs2250402	0.655	rs2307101	chr15:40322460	C/T	cg10636054	chr15:40330586	SRP14	-1.19	-8.55	-0.48	1.3e-15	Corneal curvature;
KIRP	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.63	0.48	7.65e-16	Motion sickness;
KIRP	cis	rs6545883	0.894	rs12997538	chr2:61564249	A/C	cg15711740	chr2:61764176	XPO1	0.56	7.28	0.42	4.48e-12	Tuberculosis;
KIRP	cis	rs2920503	1.000	rs2920503	chr3:12324230	C/T	cg04748988	chr3:12329223	PPARG	0.62	6.59	0.39	2.58e-10	LDL cholesterol;
KIRP	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg20631270	chr6:24437470	GPLD1	0.47	5.7	0.34	3.37e-8	Liver enzyme levels;
KIRP	cis	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg21204522	chr6:27730016	NA	-0.75	-5.53	-0.33	7.99e-8	Breast cancer;
KIRP	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.65	7.23	0.42	6e-12	Aortic root size;
KIRP	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-5.98	-0.36	7.74e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs7215564	0.730	rs2316066	chr17:78659785	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs7760535	0.763	rs9487666	chr6:111869024	A/C	cg22127309	chr6:111907043	TRAF3IP2	-0.48	-6.4	-0.38	7.63e-10	Metabolic traits;
KIRP	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg11271282	chr2:238384023	NA	0.48	5.66	0.34	4.22e-8	Prostate cancer;
KIRP	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.56	7.21	0.42	6.87e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg03437748	chr15:99193247	IGF1R	0.74	9.05	0.5	4.38e-17	Birth weight;
KIRP	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	0.93	8.9	0.49	1.22e-16	Type 2 diabetes;
KIRP	cis	rs60311166	1.000	rs34173244	chr3:52668776	A/G	cg13174197	chr3:52720522	GNL3;PBRM1	0.95	5.8	0.35	1.98e-8	CTACK levels;
KIRP	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.62	8.47	0.48	2.2e-15	Morning vs. evening chronotype;
KIRP	trans	rs9650657	0.711	rs10100209	chr8:10584212	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.33	-0.37	1.14e-9	Neuroticism;
KIRP	trans	rs17767392	0.670	rs11627918	chr14:71724408	T/C	cg26589485	chr17:1838439	RTN4RL1	0.47	6.07	0.36	4.73e-9	Mitral valve prolapse;
KIRP	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg18944383	chr4:111397179	ENPEP	0.71	13.3	0.65	9.3e-31	Coronary artery disease;
KIRP	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg16306078	chr6:126000798	NA	-0.26	-4.92	-0.3	1.59e-6	Endometrial cancer;
KIRP	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg23188430	chr6:125850052	NA	-0.33	-5.21	-0.32	4.05e-7	Brugada syndrome;
KIRP	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg11608241	chr8:8085544	FLJ10661	-0.5	-6.47	-0.38	5.22e-10	Triglycerides;
KIRP	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.4	-5.34	-0.32	2.09e-7	Type 2 diabetes;
KIRP	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg23067535	chr8:124195133	FAM83A	-0.72	-7.1	-0.41	1.31e-11	Urinary uromodulin levels;
KIRP	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	5.32	0.32	2.36e-7	Menopause (age at onset);
KIRP	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg18944383	chr4:111397179	ENPEP	-0.53	-6.26	-0.37	1.73e-9	Axial length;
KIRP	cis	rs6545883	0.895	rs2177961	chr2:61560264	T/C	cg15711740	chr2:61764176	XPO1	0.56	7.49	0.43	1.19e-12	Tuberculosis;
KIRP	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.73	-8.25	-0.47	9.59e-15	Diabetic retinopathy;
KIRP	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.39	-6.19	-0.37	2.49e-9	Body mass index;
KIRP	cis	rs926392	0.666	rs35166252	chr20:37695601	C/T	cg16355469	chr20:37678765	NA	0.56	6.77	0.4	9.6e-11	Dialysis-related mortality;
KIRP	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.48	6.82	0.4	6.97e-11	Height;
KIRP	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17554472	chr22:41940697	POLR3H	-0.51	-5.92	-0.35	1.1e-8	Vitiligo;
KIRP	cis	rs986417	0.901	rs12436953	chr14:61001546	C/T	cg27398547	chr14:60952738	C14orf39	0.67	6.68	0.39	1.6e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs1894292	0.645	rs13131954	chr4:74476924	A/G	cg12566645	chr4:74483141	RASSF6	0.36	4.87	0.3	1.98e-6	Prostate cancer;
KIRP	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg13679303	chr9:96623674	NA	-0.47	-6.52	-0.38	3.9e-10	DNA methylation (variation);
KIRP	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.57	-7.63	-0.44	5.02e-13	Response to temozolomide;
KIRP	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg26784012	chr10:32216390	ARHGAP12	0.32	5.18	0.31	4.57e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.82	12.75	0.63	6.32e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg17764715	chr19:33622953	WDR88	0.68	8.25	0.47	9.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.54	-8.27	-0.47	8.33e-15	Huntington's disease progression;
KIRP	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.84	-11.89	-0.6	4.77e-26	Colorectal cancer;
KIRP	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.47	-0.48	2.22e-15	Joint mobility (Beighton score);
KIRP	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.5	-7.45	-0.43	1.61e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13441753	chr9:139127333	QSOX2	0.5	6.54	0.38	3.55e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs10802346	0.636	rs12045300	chr1:246398484	T/C	cg15962031	chr1:246363574	SMYD3	0.79	5.89	0.35	1.24e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg09699651	chr6:150184138	LRP11	0.46	5.83	0.35	1.74e-8	Lung cancer;
KIRP	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.89	0.35	1.29e-8	Total cholesterol levels;
KIRP	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg01864069	chr14:103024347	NA	-0.86	-10.12	-0.54	2.36e-20	Platelet count;
KIRP	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	cg07049167	chr1:166818506	POGK	0.45	4.86	0.3	2.05e-6	Refractive astigmatism;
KIRP	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.48e-6	Red blood cell count;
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg16931447	chr4:875861	GAK	-0.5	-5.74	-0.34	2.71e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg00677455	chr12:58241039	CTDSP2	-0.46	-5.18	-0.31	4.66e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg04369109	chr6:150039330	LATS1	-0.59	-7.69	-0.44	3.47e-13	Lung cancer;
KIRP	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-7.03	-0.41	2.03e-11	Bipolar disorder;
KIRP	cis	rs155346	0.625	rs264342	chr5:139355056	A/G	cg24724630	chr5:139362307	NRG2	-0.4	-5.25	-0.32	3.23e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23055707	chr2:1681153	PXDN	0.49	6.26	0.37	1.68e-9	Interleukin-4 levels;
KIRP	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19717773	chr7:2847554	GNA12	-0.37	-5.42	-0.33	1.41e-7	Height;
KIRP	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	cg21523751	chr1:182988639	NA	0.35	5.27	0.32	2.92e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.43	0.38	6.53e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.75	-0.63	6.19e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.69	9.12	0.5	2.8e-17	Bladder cancer;
KIRP	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.71	7.89	0.45	9.71e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs889398	0.802	rs12598642	chr16:69848772	A/G	cg09409435	chr16:70099608	PDXDC2	-0.46	-5.6	-0.34	5.75e-8	Body mass index;
KIRP	cis	rs397969	0.646	rs403021	chr17:19806829	C/T	cg04132472	chr17:19861366	AKAP10	0.6	7.96	0.45	6.28e-14	Platelet count;
KIRP	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	9.98	0.54	6.55e-20	Schizophrenia;
KIRP	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg26384229	chr12:38710491	ALG10B	0.62	7.86	0.45	1.19e-13	Resting heart rate;
KIRP	cis	rs34997829	0.619	rs6597834	chr10:126231401	C/T	cg25260426	chr10:126222996	LHPP	0.26	5.04	0.31	9.08e-7	Risky sexual behaviors (alcohol dependence interaction);
KIRP	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-1.24	-10.94	-0.57	5.94e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12210905	0.920	rs9368500	chr6:27290981	A/C	cg11502198	chr6:26597334	ABT1	-0.8	-4.94	-0.3	1.43e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg19116668	chr7:99932089	PMS2L1	0.43	4.89	0.3	1.81e-6	Coronary artery disease;
KIRP	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg08992911	chr2:238395768	MLPH	0.46	5.74	0.34	2.83e-8	Prostate cancer;
KIRP	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08109568	chr15:31115862	NA	0.76	10.89	0.57	8.51e-23	Huntington's disease progression;
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20456258	chr4:962124	DGKQ	0.37	5.78	0.35	2.21e-8	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.77	-0.44	2.19e-13	Total cholesterol levels;
KIRP	cis	rs11038871	1.000	rs10838601	chr11:46392825	C/G	cg16389345	chr11:46697382	NA	-0.48	-6.52	-0.38	3.95e-10	Immunoglobulin A;
KIRP	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.63	-7.54	-0.43	8.97e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.68	-8.41	-0.47	3.44e-15	Multiple sclerosis;
KIRP	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.26	7.73	0.44	2.76e-13	Type 2 diabetes;
KIRP	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.88	7.52	0.43	1.04e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg24268161	chr22:39747459	SYNGR1	-0.25	-5.23	-0.32	3.68e-7	Rheumatoid arthritis;
KIRP	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.8	-11.88	-0.6	5.16e-26	Hip circumference;
KIRP	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.76	11.06	0.58	2.44e-23	Bladder cancer;
KIRP	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg04780086	chr2:111875790	ACOXL	0.42	5.89	0.35	1.29e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	1.06	17.73	0.75	7.43e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	1.09	20.03	0.79	1.36e-53	Gut microbiome composition (winter);
KIRP	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.34	5.08	0.31	7.53e-7	Body mass index;
KIRP	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.19	13.83	0.66	1.44e-32	Sexual dysfunction (female);
KIRP	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Colorectal cancer;
KIRP	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.53	11.26	0.58	5.28e-24	Monocyte percentage of white cells;
KIRP	cis	rs2273156	0.570	rs79436302	chr14:35578797	C/T	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.05	-0.31	8.58e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.77	11.11	0.58	1.67e-23	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg21161173	chr5:140098174	VTRNA1-2	-0.37	-4.89	-0.3	1.86e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg18154014	chr19:37997991	ZNF793	0.71	7.99	0.45	5.15e-14	Coronary artery calcification;
KIRP	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.68	-7.58	-0.44	6.93e-13	Menarche (age at onset);
KIRP	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs10875746	0.951	rs4760689	chr12:48563644	G/A	cg26205652	chr12:48591994	NA	0.78	10.57	0.56	8.92e-22	Longevity (90 years and older);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13739116	chr9:139622701	SNORA17;SNHG7	0.48	6.07	0.36	4.92e-9	Parkinson's disease;
KIRP	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.81	7.25	0.42	5.51e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg09667013	chr22:42394590	WBP2NL	-0.37	-4.95	-0.3	1.4e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.97e-23	Chronic sinus infection;
KIRP	trans	rs7545126	1.000	rs7545126	chr1:207938236	C/T	cg12264626	chr8:86350381	CA3	-0.4	-6.04	-0.36	5.62e-9	Obesity-related traits;
KIRP	cis	rs7584330	0.554	rs3751106	chr2:238428418	G/A	cg08992911	chr2:238395768	MLPH	0.46	5.24	0.32	3.48e-7	Prostate cancer;
KIRP	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.87	-8.55	-0.48	1.32e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23281280	chr6:28129359	ZNF389	-0.46	-5.04	-0.31	9.07e-7	Depression;
KIRP	cis	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08605855	chr7:86825549	C7orf23;DMTF1	0.38	5.42	0.33	1.39e-7	Interleukin-4 levels;
KIRP	cis	rs4664293	0.867	rs3821299	chr2:160585740	C/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs231513	0.911	rs231521	chr17:41955158	A/G	cg26893861	chr17:41843967	DUSP3	-0.59	-5.17	-0.31	4.93e-7	Cognitive function;
KIRP	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.18	21.46	0.81	2.71e-58	Cognitive function;
KIRP	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.65	7.83	0.45	1.48e-13	Mean platelet volume;
KIRP	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.92	11.26	0.58	5.57e-24	Bipolar disorder;
KIRP	trans	rs13172324	0.536	rs13170722	chr5:7405831	G/A	cg18545596	chr22:40322629	GRAP2	-0.72	-6.41	-0.38	7.58e-10	Myopia (pathological);
KIRP	cis	rs494562	0.730	rs9450270	chr6:86114766	A/G	cg21730993	chr6:86159210	NT5E	0.49	5.31	0.32	2.49e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg09231725	chr11:64357281	SLC22A12	-0.64	-8.58	-0.48	1.08e-15	Urate levels in obese individuals;
KIRP	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg00800038	chr16:89945340	TCF25	-0.89	-7.28	-0.42	4.62e-12	Skin colour saturation;
KIRP	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.79	7.67	0.44	4.01e-13	Diisocyanate-induced asthma;
KIRP	cis	rs66561647	0.517	rs7819924	chr8:128914008	A/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.47	5.15	0.31	5.32e-7	Hemoglobin concentration;
KIRP	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.76	9.89	0.53	1.23e-19	N-glycan levels;
KIRP	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg16141378	chr3:129829833	LOC729375	0.57	7.9	0.45	9.27e-14	Triglycerides;
KIRP	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.57	-7.11	-0.41	1.23e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9646944	0.636	rs72998585	chr2:102858490	A/T	cg22835712	chr2:102737379	NA	0.39	5.06	0.31	8.32e-7	Blood protein levels;
KIRP	cis	rs3931020	0.688	rs277374	chr1:75200486	G/A	cg00121533	chr1:75199117	CRYZ;TYW3	-0.46	-5.2	-0.31	4.18e-7	Resistin levels;
KIRP	cis	rs9372498	0.536	rs9489460	chr6:118925754	C/T	cg18833306	chr6:118973337	C6orf204	-0.47	-4.93	-0.3	1.52e-6	Diastolic blood pressure;
KIRP	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg03609598	chr5:56110824	MAP3K1	-0.48	-5.55	-0.33	7.3e-8	Initial pursuit acceleration;
KIRP	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs4481887	0.604	rs10888330	chr1:248410506	A/T	cg01631408	chr1:248437212	OR2T33	-0.48	-5.78	-0.35	2.25e-8	Common traits (Other);
KIRP	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.43	-7.88	-0.45	1.08e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.52	-6.41	-0.38	7.21e-10	Monocyte percentage of white cells;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg00600029	chr5:1088442	SLC12A7	0.46	6.12	0.36	3.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs17030434	0.784	rs11099900	chr4:154669471	C/T	cg14289246	chr4:154710475	SFRP2	-0.56	-6.91	-0.4	4.18e-11	Electrocardiographic conduction measures;
KIRP	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12667521	chr19:29218732	NA	0.57	4.91	0.3	1.65e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.5	-5.97	-0.36	8.1e-9	Colorectal cancer;
KIRP	cis	rs4664293	0.967	rs12611922	chr2:160462749	T/G	cg08347373	chr2:160653686	CD302	-0.4	-6.18	-0.37	2.62e-9	Monocyte percentage of white cells;
KIRP	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.41	5.05	0.31	8.8e-7	Lung cancer;Squamous cell lung carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27453492	chr16:50059188	TMEM188	0.49	6.34	0.37	1.07e-9	Parkinson's disease;
KIRP	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.49	5.66	0.34	4.19e-8	Glycated hemoglobin levels;
KIRP	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.75	-0.34	2.58e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg03342759	chr3:160939853	NMD3	0.45	5.38	0.32	1.74e-7	Morning vs. evening chronotype;
KIRP	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.68	-7.88	-0.45	1.09e-13	Pancreatic cancer;
KIRP	cis	rs2712184	0.756	rs2541388	chr2:217664284	A/G	cg05032264	chr2:217675019	NA	0.44	6.36	0.38	9.65e-10	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs6991838	0.584	rs7841652	chr8:66518627	T/G	cg13398993	chr8:66546079	ARMC1	-0.45	-5.23	-0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7010267	0.740	rs6993910	chr8:119950781	C/T	cg13268132	chr8:119964037	TNFRSF11B	-0.39	-4.93	-0.3	1.55e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs228769	0.653	rs2523162	chr17:42179281	A/G	cg19774624	chr17:42201019	HDAC5	0.5	5.35	0.32	2.03e-7	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg08198773	chr8:1697536	NA	0.51	6.25	0.37	1.76e-9	Systolic blood pressure;
KIRP	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.78	12.17	0.61	5.41e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4704187	0.687	rs9654429	chr5:74466925	C/G	cg03227963	chr5:74354835	NA	0.4	5.92	0.35	1.08e-8	Response to amphetamines;
KIRP	cis	rs7712401	0.601	rs1990890	chr5:122182970	C/T	cg19412675	chr5:122181750	SNX24	0.51	5.52	0.33	8.41e-8	Mean platelet volume;
KIRP	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.61	-0.44	6e-13	Resting heart rate;
KIRP	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg08076091	chr2:203926405	NBEAL1	0.83	8.85	0.49	1.78e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.37	-0.38	9.05e-10	Response to antipsychotic treatment;
KIRP	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	1.12	18.66	0.77	4.99e-49	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14022434	chr10:123687714	ATE1	0.6	7.48	0.43	1.32e-12	Parkinson's disease;
KIRP	cis	rs9400271	0.632	rs9374072	chr6:109591586	A/G	cg21918786	chr6:109611834	NA	-0.37	-5.39	-0.33	1.63e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg17885191	chr8:135476712	NA	0.52	6.15	0.37	3.1e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.31	-0.32	2.51e-7	Bladder cancer;
KIRP	cis	rs4073416	0.542	rs10142283	chr14:66044129	G/A	cg03016385	chr14:66212404	NA	-0.51	-6.24	-0.37	1.92e-9	N-glycan levels;
KIRP	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-6.74	-0.4	1.09e-10	Obesity-related traits;
KIRP	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.34	-0.32	2.07e-7	Bipolar disorder;
KIRP	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.38e-13	Mean corpuscular hemoglobin;
KIRP	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg25124228	chr12:125621409	AACS	-0.55	-6.28	-0.37	1.54e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12826209	chr6:26865740	GUSBL1	0.77	5.37	0.32	1.82e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs11250097	0.506	rs34365278	chr8:11309780	G/A	cg16141378	chr3:129829833	LOC729375	0.56	6.56	0.39	3.12e-10	Neuroticism;
KIRP	cis	rs4699052	0.963	rs11097801	chr4:104150323	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-5.19	-0.31	4.3e-7	Testicular germ cell tumor;
KIRP	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.0	-0.36	7.18e-9	Parkinson's disease;
KIRP	cis	rs644148	0.785	rs117048220	chr19:44965555	G/A	cg15540054	chr19:45004280	ZNF180	0.57	6.2	0.37	2.33e-9	Personality dimensions;
KIRP	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.97	-0.5	7.99e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs220519	0.745	rs414387	chr20:37274320	C/G	cg24308336	chr20:37270989	C20orf95	0.24	5.35	0.32	2.03e-7	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10323490	chr2:88469007	THNSL2	0.5	6.76	0.4	9.75e-11	Interleukin-4 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17647431	chr5:174905402	SFXN1	0.48	6.22	0.37	2.14e-9	Parkinson's disease;
KIRP	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	1.07	15.02	0.69	1.23e-36	Menopause (age at onset);
KIRP	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.65	8.04	0.46	3.7e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21972741	chr5:435613	AHRR	0.53	6.94	0.4	3.49e-11	Cystic fibrosis severity;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.58	8.34	0.47	5.46e-15	Monocyte percentage of white cells;
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.71	-12.39	-0.62	1.02e-27	Lung cancer;
KIRP	cis	rs259842	0.505	rs13418648	chr2:180684202	T/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.43	-5.84	-0.35	1.63e-8	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24017470	chr18:12947925	SEH1L	0.56	7.0	0.41	2.47e-11	Parkinson's disease;
KIRP	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg21360079	chr12:107162445	NA	0.67	9.76	0.53	3.15e-19	Heart rate;
KIRP	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-1.08	-20.12	-0.79	6.82e-54	Gut microbiome composition (winter);
KIRP	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.66	7.33	0.42	3.33e-12	Initial pursuit acceleration;
KIRP	cis	rs3779635	0.681	rs17447286	chr8:27244919	C/T	cg14221460	chr8:27183342	PTK2B	0.53	6.92	0.4	4e-11	Neuroticism;
KIRP	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg14673194	chr17:80132900	CCDC57	0.73	8.16	0.46	1.76e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.84	11.84	0.6	6.71e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4523957	0.579	rs903161	chr17:2092006	A/T	cg16513277	chr17:2031491	SMG6	-0.72	-10.41	-0.55	2.81e-21	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.78	-9.99	-0.54	5.96e-20	Coronary artery disease;
KIRP	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg02804510	chr19:49199965	FUT2	0.36	5.17	0.31	4.8e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.81	11.6	0.59	4.16e-25	Morning vs. evening chronotype;
KIRP	cis	rs4077515	0.967	rs4078099	chr9:139267533	G/A	cg21253087	chr9:139290292	SNAPC4	0.42	5.85	0.35	1.56e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8008758	1.000	rs915379	chr14:101689392	T/C	cg26224664	chr14:101693935	NA	-0.41	-5.1	-0.31	6.9e-7	Body mass index (alcohol intake interaction);
KIRP	cis	rs2279817	0.780	rs11585339	chr1:18000120	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-9.79	-0.53	2.48e-19	Neuroticism;
KIRP	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg09890400	chr1:26503858	CNKSR1	0.42	5.63	0.34	4.79e-8	Height;
KIRP	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg21858823	chr1:15850916	CASP9	0.45	4.9	0.3	1.76e-6	Systolic blood pressure;
KIRP	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.39	-0.33	1.61e-7	Height;
KIRP	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg07741184	chr6:167504864	NA	-0.25	-6.48	-0.38	4.88e-10	Crohn's disease;
KIRP	cis	rs7274811	0.634	rs4911356	chr20:32255034	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	-0.4	-5.05	-0.31	8.72e-7	Height;
KIRP	cis	rs4751006	0.543	rs61875501	chr10:128769951	G/C	cg05702161	chr10:128779687	DOCK1	-1.17	-9.14	-0.5	2.38e-17	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25781121	chr3:48282641	ZNF589	0.53	6.43	0.38	6.66e-10	Parkinson's disease;
KIRP	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.84	12.92	0.64	1.7e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg26585981	chr11:48327164	OR4S1	-0.43	-5.36	-0.32	1.88e-7	HDL cholesterol;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg25930748	chr6:82957449	IBTK	0.46	6.15	0.37	3.17e-9	Coronary artery disease;
KIRP	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg07117364	chr1:16154769	NA	-0.46	-5.71	-0.34	3.29e-8	Dilated cardiomyopathy;
KIRP	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg12486944	chr17:80159399	CCDC57	-0.38	-5.09	-0.31	6.98e-7	Life satisfaction;
KIRP	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.91e-10	Colorectal cancer;
KIRP	cis	rs1215050	0.791	rs155019	chr4:98759126	G/A	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.62	9.0	0.5	6.2e-17	Colorectal cancer;
KIRP	cis	rs259842	0.728	rs165381	chr2:180693343	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.38	-5.53	-0.33	8.08e-8	Blood protein levels;
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg09165964	chr15:75287851	SCAMP5	0.5	6.42	0.38	6.79e-10	Breast cancer;
KIRP	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.77	10.14	0.54	2.1e-20	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17073432	chr10:104221224	TMEM180	0.51	6.31	0.37	1.28e-9	Parkinson's disease;
KIRP	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg27572855	chr1:25598939	RHD	0.59	10.35	0.55	4.6e-21	Erythrocyte sedimentation rate;
KIRP	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.56	8.07	0.46	3.2e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.72	-10.44	-0.55	2.28e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg20701182	chr2:24300061	SF3B14	0.52	5.05	0.31	8.77e-7	Lymphocyte counts;
KIRP	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	cis	rs6589219	0.754	rs7105857	chr11:111170744	C/T	cg25129781	chr11:111156908	C11orf53	-0.44	-5.78	-0.35	2.26e-8	Colorectal cancer;
KIRP	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg00405596	chr8:11794950	NA	-0.45	-5.96	-0.36	8.89e-9	Triglycerides;
KIRP	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.67	0.39	1.72e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg23594656	chr7:65796392	TPST1	0.47	7.48	0.43	1.35e-12	Aortic root size;
KIRP	cis	rs4363385	0.720	rs1984197	chr1:152962915	C/G	cg13444842	chr1:152974279	SPRR3	-0.35	-4.99	-0.3	1.16e-6	Inflammatory skin disease;
KIRP	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.44	5.82	0.35	1.81e-8	Ulcerative colitis;
KIRP	cis	rs10214930	0.752	rs7782422	chr7:27663503	A/G	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.66	-9.83	-0.53	1.97e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1448094	0.842	rs7301280	chr12:86455752	G/T	cg06740227	chr12:86229804	RASSF9	-0.41	-5.25	-0.32	3.34e-7	Major depressive disorder;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20805961	chr1:91361641	NA	0.35	6.03	0.36	6.07e-9	Warfarin maintenance dose;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10782065	chr14:60823282	NA	0.4	6.85	0.4	5.93e-11	C-reactive protein;
KIRP	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg05347473	chr6:146136440	FBXO30	0.59	8.25	0.47	9.68e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg18944383	chr4:111397179	ENPEP	0.52	9.13	0.5	2.54e-17	Height;
KIRP	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.82	0.45	1.56e-13	Neuroticism;
KIRP	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.7	11.26	0.58	5.5e-24	Lung cancer;
KIRP	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.8	-12.7	-0.63	9.23e-29	Electrocardiographic conduction measures;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01919060	chr13:21872515	NA	0.47	6.09	0.36	4.36e-9	Parkinson's disease;
KIRP	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg04166393	chr7:2884313	GNA12	0.41	5.3	0.32	2.64e-7	Height;
KIRP	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11987759	chr7:65425863	GUSB	0.61	7.99	0.45	5.31e-14	Aortic root size;
KIRP	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg01631408	chr1:248437212	OR2T33	-0.62	-8.14	-0.46	1.93e-14	Common traits (Other);
KIRP	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg08888203	chr3:10149979	C3orf24	0.49	4.96	0.3	1.3e-6	Alzheimer's disease;
KIRP	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.65	7.48	0.43	1.31e-12	Schizophrenia;
KIRP	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg11621586	chr10:70884670	VPS26A	1.16	14.81	0.69	6.81e-36	Left atrial antero-posterior diameter;
KIRP	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.94	-12.32	-0.62	1.8e-27	Platelet distribution width;
KIRP	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.97	-14.59	-0.68	3.63e-35	Coronary artery disease;
KIRP	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.59	-7.39	-0.43	2.22e-12	Extraversion;
KIRP	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.92	-13.69	-0.66	4.33e-32	Ulcerative colitis;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg22266764	chr19:2740123	SLC39A3	-1.09	-6.09	-0.36	4.38e-9	Thrombomodulin levels in ischemic stroke;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07934068	chr4:80883595	ANTXR2	-0.46	-7.25	-0.42	5.31e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs5743890	1.000	rs5743890	chr11:1325829	A/G	cg06066251	chr11:1309984	TOLLIP	0.63	5.54	0.33	7.9e-8	Idiopathic pulmonary fibrosis;
KIRP	cis	rs4751006	0.543	rs61875506	chr10:128778438	A/G	cg05702161	chr10:128779687	DOCK1	-1.14	-8.26	-0.47	9.13e-15	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg00405596	chr8:11794950	NA	-0.54	-7.57	-0.43	7.54e-13	Mood instability;
KIRP	cis	rs4073221	0.654	rs34059277	chr3:18293934	A/C	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.4e-9	Parkinson's disease;
KIRP	cis	rs7989336	0.625	rs1925108	chr13:97006998	A/T	cg02571835	chr13:96230311	CLDN10	0.37	5.08	0.31	7.46e-7	Obesity;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg15731816	chr14:75230414	YLPM1	0.72	6.08	0.36	4.46e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs77948430	0.867	rs55818733	chr8:13148924	G/A	cg04284319	chr17:77351040	HRNBP3	1.0	6.34	0.37	1.1e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg01338139	chr15:38987640	C15orf53	-0.56	-6.24	-0.37	1.93e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg08283408	chr3:49949060	MON1A	-0.43	-5.74	-0.34	2.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg17764715	chr19:33622953	WDR88	0.68	8.25	0.47	9.74e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.87	8.92	0.49	1.07e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg08284733	chr12:6341482	CD9	0.61	10.67	0.56	4.34e-22	Mean platelet volume;
KIRP	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.89	-0.35	1.23e-8	Fear of minor pain;
KIRP	trans	rs12517041	1.000	rs6894688	chr5:23312285	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.91	-0.45	8.59e-14	Calcium levels;
KIRP	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg15605315	chr1:45957053	TESK2	0.4	5.11	0.31	6.5e-7	High light scatter reticulocyte count;
KIRP	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.46	-6.33	-0.37	1.17e-9	Blood protein levels;
KIRP	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4409675	0.956	rs4072743	chr1:28270934	T/C	cg23691781	chr1:28212827	C1orf38	-0.31	-6.13	-0.36	3.52e-9	Corneal astigmatism;
KIRP	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.63	8.25	0.47	9.9e-15	Pulse pressure;
KIRP	cis	rs7656342	0.599	rs9684729	chr4:9862036	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.16	-0.37	2.89e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.77	9.89	0.53	1.28e-19	Corneal astigmatism;
KIRP	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg27205649	chr11:78285834	NARS2	-0.78	-11.02	-0.58	3.15e-23	Alzheimer's disease (survival time);
KIRP	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.87	-13.73	-0.66	3.17e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16867335	0.625	rs7573877	chr2:181478111	A/G	cg23363182	chr2:181467187	NA	-0.48	-6.32	-0.37	1.23e-9	Survival in rectal cancer;
KIRP	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.67	0.66	4.91e-32	Smoking behavior;
KIRP	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg04539111	chr16:67997858	SLC12A4	-0.55	-5.5	-0.33	9.54e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.56	-7.35	-0.42	2.86e-12	Height;
KIRP	cis	rs13102973	0.899	rs10212820	chr4:135899842	G/T	cg14419869	chr4:135874104	NA	-0.49	-7.71	-0.44	3.04e-13	Subjective well-being;
KIRP	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.31	0.37	1.3e-9	Bipolar disorder;
KIRP	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg13444842	chr1:152974279	SPRR3	-0.36	-5.01	-0.3	1.06e-6	Inflammatory skin disease;
KIRP	cis	rs8084125	1.000	rs62105185	chr18:74954808	G/A	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs6575793	0.512	rs6575791	chr14:101029203	A/G	cg18516195	chr14:101012996	BEGAIN	-0.42	-5.58	-0.34	6.31e-8	Menarche (age at onset);
KIRP	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.13	0.41	1.12e-11	Lung cancer;
KIRP	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-6.88	-0.4	4.96e-11	Monocyte count;
KIRP	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg26875233	chr11:93583750	C11orf90	-0.36	-6.66	-0.39	1.75e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg13798912	chr7:905769	UNC84A	0.67	6.51	0.38	4.27e-10	Cerebrospinal P-tau181p levels;
KIRP	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.58	-6.93	-0.4	3.6e-11	P wave terminal force;
KIRP	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg26513180	chr16:89883248	FANCA	0.56	7.32	0.42	3.42e-12	Vitiligo;
KIRP	cis	rs10875746	0.903	rs4760681	chr12:48505230	C/T	cg20731937	chr12:48336164	NA	0.41	5.34	0.32	2.16e-7	Longevity (90 years and older);
KIRP	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg14338887	chr6:42928500	GNMT	0.45	6.61	0.39	2.4e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.63	10.57	0.56	9.29e-22	Coronary artery disease;
KIRP	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg06521331	chr12:34319734	NA	-0.63	-7.56	-0.43	8.15e-13	Morning vs. evening chronotype;
KIRP	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.47	-7.56	-0.43	7.76e-13	Eye color traits;
KIRP	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg08501292	chr6:25962987	TRIM38	-0.8	-5.5	-0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.52	-0.33	8.69e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18932078	chr1:2524107	MMEL1	-0.45	-6.11	-0.36	3.8e-9	Ulcerative colitis;
KIRP	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.35	6.31	0.37	1.27e-9	Refractive error;
KIRP	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg22437258	chr11:111473054	SIK2	-0.51	-5.93	-0.35	1.04e-8	Primary sclerosing cholangitis;
KIRP	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg03929089	chr4:120376271	NA	0.69	6.17	0.37	2.84e-9	Intraocular pressure;
KIRP	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg16068336	chr17:48637367	CACNA1G	-0.42	-5.41	-0.33	1.51e-7	Type 2 diabetes;
KIRP	trans	rs13170463	0.579	rs13160818	chr5:8051429	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10381076	chr19:42829639	MEGF8	0.48	6.19	0.37	2.44e-9	Parkinson's disease;
KIRP	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.65	-0.34	4.46e-8	Height;
KIRP	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg19773385	chr1:10388646	KIF1B	-0.67	-8.71	-0.49	4.54e-16	Hepatocellular carcinoma;
KIRP	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg12454167	chr3:186435060	KNG1	0.53	9.16	0.5	2.15e-17	Blood protein levels;
KIRP	cis	rs2908197	0.737	rs10230188	chr7:75980872	A/G	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.29	-4.85	-0.3	2.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17376030	chr22:41985996	PMM1	-0.79	-7.89	-0.45	9.98e-14	Vitiligo;
KIRP	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.8	10.26	0.55	8.34e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.51	7.25	0.42	5.29e-12	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs7172677	1.000	rs2029519	chr15:75415962	A/G	cg14664628	chr15:75095509	CSK	-0.56	-6.12	-0.36	3.59e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.66	8.97	0.5	7.87e-17	Longevity;
KIRP	cis	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.45	-5.29	-0.32	2.66e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17985166	chr4:139937034	CCRN4L	0.46	6.02	0.36	6.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.54	-6.99	-0.41	2.58e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1318772	0.932	rs11747062	chr5:112901836	A/T	cg12552261	chr5:112820674	MCC	0.78	5.46	0.33	1.14e-7	F-cell distribution;
KIRP	cis	rs329674	0.556	rs61910564	chr11:133726647	T/A	cg06766960	chr11:133703094	NA	-0.67	-4.92	-0.3	1.55e-6	Bipolar disorder;
KIRP	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.37	-5.8	-0.35	2e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3931020	0.616	rs277381	chr1:75266815	T/A	cg26855724	chr1:75198818	TYW3;CRYZ	-0.42	-4.89	-0.3	1.82e-6	Resistin levels;
KIRP	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg17554472	chr22:41940697	POLR3H	-0.67	-7.22	-0.42	6.46e-12	Vitiligo;
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.97	-14.1	-0.67	1.79e-33	Longevity;Endometriosis;
KIRP	cis	rs116726256	0.744	rs77163073	chr2:1847851	G/A	cg07855242	chr2:1841068	MYT1L	0.67	6.19	0.37	2.54e-9	Interleukin-8 levels;
KIRP	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.63	-7.22	-0.42	6.44e-12	Gut microbiome composition (summer);
KIRP	cis	rs897080	0.515	rs1067400	chr2:44677647	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.8	0.35	1.98e-8	Height;
KIRP	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg18478394	chr8:109455254	TTC35	0.49	6.36	0.38	9.65e-10	Dupuytren's disease;
KIRP	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg02023728	chr11:77925099	USP35	0.31	5.49	0.33	1.01e-7	Alzheimer's disease (survival time);
KIRP	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg06766960	chr11:133703094	NA	-0.75	-9.92	-0.53	9.97e-20	Childhood ear infection;
KIRP	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.13	-0.31	5.92e-7	Pulmonary function;
KIRP	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.71	8.47	0.48	2.18e-15	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16592149	chr4:95409312	PDLIM5	-0.38	-6.1	-0.36	4.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg23335576	chr14:104009727	NA	0.36	5.24	0.32	3.39e-7	Body mass index;
KIRP	cis	rs40363	1.000	rs17554547	chr16:3507802	G/A	cg21433313	chr16:3507492	NAT15	0.66	7.3	0.42	4.04e-12	Tuberculosis;
KIRP	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.64	-10.5	-0.56	1.49e-21	Morning vs. evening chronotype;
KIRP	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg00981070	chr1:2046702	PRKCZ	0.41	5.86	0.35	1.5e-8	Height;
KIRP	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	6.26	0.37	1.66e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg05785598	chr3:49045655	WDR6	0.29	5.27	0.32	2.92e-7	Parkinson's disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23134169	chr19:16682794	SLC35E1	0.45	6.06	0.36	4.97e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg08591472	chr7:1030197	NA	-0.39	-4.9	-0.3	1.75e-6	Longevity;Endometriosis;
KIRP	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg17554472	chr22:41940697	POLR3H	0.59	6.41	0.38	7.48e-10	Vitiligo;
KIRP	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg00405596	chr8:11794950	NA	0.47	5.92	0.35	1.05e-8	Retinal vascular caliber;
KIRP	cis	rs34779708	0.931	rs4934524	chr10:35270921	G/C	cg04310649	chr10:35416472	CREM	-0.55	-6.11	-0.36	3.97e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs72634258	0.945	rs397349	chr1:8074872	A/C	cg00042356	chr1:8021962	PARK7	0.52	5.41	0.33	1.51e-7	Inflammatory bowel disease;
KIRP	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.07	-0.36	4.92e-9	Lung cancer;
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg17441377	chr17:3906640	NA	0.51	7.68	0.44	3.67e-13	Type 2 diabetes;
KIRP	cis	rs4698036	0.586	rs7672759	chr4:10285015	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	5.48	0.33	1.03e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg23791538	chr6:167370224	RNASET2	-0.47	-5.72	-0.34	3.09e-8	Crohn's disease;
KIRP	cis	rs2151522	0.724	rs9388520	chr6:127116475	C/T	cg21431617	chr6:127135037	NA	0.31	5.71	0.34	3.24e-8	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.56	-8.16	-0.46	1.7e-14	Caffeine consumption;
KIRP	cis	rs1816752	0.905	rs9511242	chr13:24993399	G/A	cg02811702	chr13:24901961	NA	0.44	5.76	0.34	2.49e-8	Obesity-related traits;
KIRP	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs2250402	0.655	rs2307101	chr15:40322460	C/T	cg01081584	chr15:40268610	EIF2AK4	0.51	5.37	0.32	1.82e-7	Corneal curvature;
KIRP	cis	rs4930561	0.765	rs4930564	chr11:67983281	C/T	cg16338278	chr11:67432957	ALDH3B2	-0.39	-5.07	-0.31	7.69e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg23974023	chr2:113544294	IL1A	-0.32	-4.84	-0.3	2.27e-6	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.03	0.41	2e-11	Arsenic metabolism;
KIRP	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.9e-8	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03531984	chr17:3500374	TRPV1	0.45	6.53	0.38	3.74e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg20991723	chr1:152506922	NA	-0.45	-5.43	-0.33	1.34e-7	Hair morphology;
KIRP	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.66	6.8	0.4	8.09e-11	Gut microbiome composition (summer);
KIRP	cis	rs10465746	0.725	rs4907188	chr1:84361608	C/T	cg10977910	chr1:84465055	TTLL7	0.54	6.76	0.4	1e-10	Obesity-related traits;
KIRP	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.32	-0.32	2.3e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg21724239	chr8:58056113	NA	0.54	5.08	0.31	7.48e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.56	-0.33	6.92e-8	Response to bleomycin (chromatid breaks);
KIRP	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.56	5.92	0.35	1.07e-8	NT-proBNP levels in acute coronary syndrome;
KIRP	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.47	-5.78	-0.35	2.22e-8	Diastolic blood pressure;
KIRP	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.19	-0.51	1.66e-17	Platelet count;
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg24633833	chr3:10029261	TMEM111	0.54	5.28	0.32	2.78e-7	Alzheimer's disease;
KIRP	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	1.12	18.48	0.76	2.06e-48	Cognitive function;
KIRP	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.75	-0.4	1.06e-10	Hemoglobin concentration;
KIRP	cis	rs258892	0.895	rs13174766	chr5:72057135	C/T	cg21869765	chr5:72125136	TNPO1	-0.55	-6.09	-0.36	4.41e-9	Small cell lung carcinoma;
KIRP	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.5	6.34	0.37	1.09e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.85	-13.36	-0.65	5.75e-31	Breast cancer;
KIRP	cis	rs6968419	0.747	rs3807975	chr7:115880277	G/A	cg02561103	chr7:115862891	TES	-0.43	-6.15	-0.36	3.16e-9	Intraocular pressure;
KIRP	cis	rs9596863	0.898	rs115170157	chr13:54399898	T/A	ch.13.53330881F	chr13:54432880	NA	0.62	6.24	0.37	1.9e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10890291	chr6:44214802	HSP90AB1	0.5	6.11	0.36	3.97e-9	Parkinson's disease;
KIRP	cis	rs7221595	0.778	rs57625058	chr17:3914513	T/G	cg11204139	chr17:3907470	NA	0.6	5.78	0.35	2.23e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg25512537	chr17:76250053	NA	0.43	6.89	0.4	4.54e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.67	-0.39	1.7e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.79	-13.37	-0.65	5.14e-31	Corneal structure;
KIRP	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	1.03	8.09	0.46	2.79e-14	Skin colour saturation;
KIRP	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg05941025	chr16:89927596	SPIRE2	0.34	5.27	0.32	2.95e-7	Vitiligo;
KIRP	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg11569703	chr11:65557185	OVOL1	0.81	15.54	0.7	2.11e-38	Acne (severe);
KIRP	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.67	-6.81	-0.4	7.45e-11	Ulcerative colitis;
KIRP	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs34779708	0.931	rs7079205	chr10:35324619	C/T	cg04310649	chr10:35416472	CREM	-0.58	-6.86	-0.4	5.52e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg13565492	chr6:43139072	SRF	-0.92	-8.66	-0.48	6.31e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7572644	0.699	rs10194283	chr2:28159079	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-5.36	-0.32	1.93e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs2625529	0.652	rs2957735	chr15:72265173	T/C	cg16672083	chr15:72433130	SENP8	0.44	6.29	0.37	1.47e-9	Red blood cell count;
KIRP	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg17133734	chr15:86042851	AKAP13	-0.47	-5.91	-0.35	1.15e-8	Coronary artery disease;
KIRP	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	6.54	0.38	3.58e-10	Height;
KIRP	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg05527609	chr1:210001259	C1orf107	-0.53	-6.0	-0.36	7.16e-9	Red blood cell count;
KIRP	cis	rs7833787	1.000	rs17383616	chr8:18704800	A/C	cg17701159	chr8:18705777	PSD3	-0.34	-5.96	-0.36	8.56e-9	Obesity-related traits;
KIRP	cis	rs9399401	0.961	rs1418201	chr6:142648056	A/T	cg03128060	chr6:142623767	GPR126	0.3	4.9	0.3	1.71e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs6901250	0.632	rs1853080	chr6:117196157	T/C	cg05399210	chr6:117082661	FAM162B	0.4	5.57	0.33	6.61e-8	C-reactive protein levels;
KIRP	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.57	7.39	0.43	2.28e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg19592336	chr6:28129416	ZNF389	-0.49	-5.53	-0.33	8.17e-8	Depression;
KIRP	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.59	5.45	0.33	1.23e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg04166393	chr7:2884313	GNA12	0.63	7.6	0.44	6.31e-13	Height;
KIRP	cis	rs4751006	0.543	rs17692028	chr10:128783983	C/T	cg05702161	chr10:128779687	DOCK1	-1.18	-9.54	-0.52	1.53e-18	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.48	7.13	0.41	1.1e-11	Lewy body disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19361615	chr7:80372286	SEMA3C	-0.42	-6.11	-0.36	3.79e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg00147788	chr6:125855365	NA	-0.31	-4.93	-0.3	1.51e-6	Brugada syndrome;
KIRP	cis	rs9810890	1.000	rs78460081	chr3:128446113	A/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.57	-7.34	-0.42	3.15e-12	Aortic root size;
KIRP	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.61	7.84	0.45	1.37e-13	Vitiligo;
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.5	6.5	0.38	4.37e-10	Testicular germ cell tumor;
KIRP	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg24060327	chr5:131705240	SLC22A5	-0.6	-7.56	-0.43	7.89e-13	Acylcarnitine levels;
KIRP	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg05340658	chr4:99064831	C4orf37	0.66	7.29	0.42	4.18e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.28	6.57	0.39	2.97e-10	IgG glycosylation;
KIRP	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.47	-0.52	2.43e-18	Hemoglobin concentration;
KIRP	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.95	17.55	0.75	2.85e-45	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs10267417	0.603	rs10248506	chr7:19905674	T/A	cg05791153	chr7:19748676	TWISTNB	0.51	5.27	0.32	3e-7	Night sleep phenotypes;
KIRP	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg08648136	chr8:956695	NA	0.44	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg27211696	chr2:191398769	TMEM194B	-0.52	-6.32	-0.37	1.24e-9	Diastolic blood pressure;
KIRP	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.93	-9.7	-0.53	4.69e-19	Schizophrenia;
KIRP	cis	rs6968419	0.747	rs2030978	chr7:115874560	C/T	cg02561103	chr7:115862891	TES	-0.42	-6.03	-0.36	6.12e-9	Intraocular pressure;
KIRP	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg03060546	chr3:49711283	APEH	-0.65	-5.89	-0.35	1.23e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-19.64	-0.78	2.71e-52	Height;
KIRP	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.67	9.32	0.51	6.68e-18	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs4765905	0.610	rs2238052	chr12:2307296	G/A	cg10668781	chr12:2307325	CACNA1C	-0.35	-6.98	-0.41	2.7e-11	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg01721255	chr8:58191610	C8orf71	0.7	5.68	0.34	3.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg13798780	chr7:105162888	PUS7	0.65	5.89	0.35	1.26e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.48	5.73	0.34	2.98e-8	Metabolite levels;
KIRP	cis	rs7312774	0.529	rs12314792	chr12:107333672	T/C	cg16260113	chr12:107380972	MTERFD3	0.77	6.81	0.4	7.58e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.37	-5.84	-0.35	1.67e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.47	0.43	1.4e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg07001201	chr5:642380	CEP72	-0.66	-6.18	-0.37	2.68e-9	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs240764	0.755	rs12206564	chr6:100987009	A/G	cg09795085	chr6:101329169	ASCC3	-0.4	-4.85	-0.3	2.19e-6	Neuroticism;
KIRP	cis	rs2929278	0.561	rs2927071	chr15:43919081	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	6.32	0.37	1.21e-9	Schizophrenia;
KIRP	cis	rs930036	0.655	rs35047553	chr2:171952109	C/T	cg12801329	chr2:171670795	NA	0.43	4.89	0.3	1.78e-6	Menopause (age at onset);
KIRP	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs239198	0.578	rs13193416	chr6:101299602	A/T	cg09795085	chr6:101329169	ASCC3	0.49	5.7	0.34	3.45e-8	Menarche (age at onset);
KIRP	cis	rs3748682	0.821	rs71642605	chr1:38256427	T/C	cg12658694	chr1:38397304	INPP5B	0.57	6.15	0.36	3.18e-9	Hypothyroidism;
KIRP	cis	rs16975963	0.644	rs12462505	chr19:38138125	C/G	cg18030218	chr19:38865513	PSMD8	0.53	4.86	0.3	2.06e-6	Longevity;
KIRP	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.89	-0.3	1.86e-6	Pulmonary function;
KIRP	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg17554472	chr22:41940697	POLR3H	0.44	5.12	0.31	6.27e-7	Vitiligo;
KIRP	cis	rs9547996	0.879	rs17197908	chr13:38175744	G/T	cg13634560	chr13:38173852	POSTN	-0.41	-5.6	-0.34	5.73e-8	Diastolic blood pressure;
KIRP	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg03235661	chr20:60525775	NA	-0.35	-5.35	-0.32	2.03e-7	Body mass index;
KIRP	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.04e-6	Lung cancer;
KIRP	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.93	-12.96	-0.64	1.27e-29	Cognitive function;
KIRP	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	1.09	12.1	0.61	9.74e-27	Psoriasis;
KIRP	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.55	-7.58	-0.44	6.89e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21747090	chr2:27597821	SNX17	-0.5	-6.95	-0.41	3.29e-11	Total body bone mineral density;
KIRP	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.44	-5.9	-0.35	1.2e-8	Type 2 diabetes;
KIRP	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg06453172	chr10:134556979	INPP5A	-0.52	-5.77	-0.35	2.41e-8	Migraine;
KIRP	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.5	-0.38	4.38e-10	Response to antipsychotic treatment;
KIRP	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.57	-7.3	-0.42	3.88e-12	Iron status biomarkers;
KIRP	cis	rs7923609	0.902	rs10822182	chr10:65325478	G/A	cg01631684	chr10:65280961	REEP3	-0.46	-5.45	-0.33	1.23e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg01721255	chr8:58191610	C8orf71	0.56	5.58	0.34	6.29e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.59	5.52	0.33	8.69e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.86	-12.19	-0.61	4.61e-27	Breast cancer;
KIRP	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.46	0.43	1.47e-12	Rheumatoid arthritis;
KIRP	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.57	-8.3	-0.47	6.91e-15	Blood metabolite levels;
KIRP	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.61	8.33	0.47	5.57e-15	Total body bone mineral density;
KIRP	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg26513180	chr16:89883248	FANCA	0.79	5.63	0.34	4.9e-8	Skin colour saturation;
KIRP	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg23920097	chr1:209922102	NA	0.46	5.37	0.32	1.87e-7	Red blood cell count;
KIRP	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	6.84	0.4	6.23e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg23533926	chr12:111358616	MYL2	-0.47	-6.21	-0.37	2.19e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1021993	0.545	rs77070927	chr1:209530305	C/T	cg24446417	chr1:209558027	NA	-0.51	-5.15	-0.31	5.35e-7	Gut microbiome composition (winter);
KIRP	cis	rs6545883	0.895	rs2421192	chr2:61643631	T/C	cg15711740	chr2:61764176	XPO1	0.61	8.18	0.46	1.55e-14	Tuberculosis;
KIRP	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.44	-5.77	-0.35	2.39e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18266620	chr1:110882148	RBM15	0.5	6.18	0.37	2.61e-9	Parkinson's disease;
KIRP	cis	rs981844	0.826	rs4585278	chr4:154684145	A/G	cg14289246	chr4:154710475	SFRP2	0.58	7.11	0.41	1.26e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg02570527	chr1:10970165	NA	-0.4	-4.98	-0.3	1.18e-6	Body mass index;
KIRP	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg10096100	chr1:26503862	CNKSR1	-0.42	-6.02	-0.36	6.45e-9	Height;
KIRP	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.02	11.42	0.59	1.68e-24	Vitiligo;
KIRP	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg23719950	chr11:63933701	MACROD1	-0.68	-6.55	-0.39	3.26e-10	Mean platelet volume;
KIRP	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg23517279	chr6:96025343	MANEA	0.6	5.38	0.32	1.77e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs4664293	0.867	rs35196716	chr2:160589777	T/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15320075	chr8:145703422	NA	-0.57	-7.43	-0.43	1.78e-12	Age at first birth;
KIRP	cis	rs258892	0.843	rs11954478	chr5:72019275	A/T	cg21869765	chr5:72125136	TNPO1	-0.48	-5.37	-0.32	1.78e-7	Small cell lung carcinoma;
KIRP	cis	rs300774	0.841	rs2926788	chr2:199410	G/A	cg10118717	chr2:203439	NA	0.4	4.9	0.3	1.77e-6	Suicide attempts in bipolar disorder;
KIRP	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg16329650	chr2:213403929	ERBB4	0.43	5.84	0.35	1.66e-8	Symmetrical dimethylarginine levels;
KIRP	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	1.0	18.13	0.76	3.17e-47	Leprosy;
KIRP	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg13939156	chr17:80058883	NA	-0.47	-5.52	-0.33	8.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25833597	chr17:30823145	MYO1D	0.42	5.34	0.32	2.09e-7	Schizophrenia;
KIRP	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.36	0.38	1e-9	Retinal vascular caliber;
KIRP	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg10790698	chr19:18539756	SSBP4	-0.33	-7.16	-0.42	9.2e-12	Breast cancer;
KIRP	cis	rs2219968	0.962	rs9643733	chr8:78950551	G/T	cg00738934	chr8:78996279	NA	0.4	5.15	0.31	5.25e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg21999071	chr5:14313270	TRIO	0.41	6.29	0.37	1.43e-9	Migraine with aura;
KIRP	cis	rs17023223	0.553	rs11484962	chr1:119725186	G/A	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs7792596	0.539	rs13221576	chr7:94006994	C/T	cg20814616	chr7:94014465	NA	-0.45	-5.21	-0.32	3.91e-7	Intelligence;
KIRP	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	5.52	0.33	8.48e-8	Total cholesterol levels;
KIRP	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg24169773	chr3:122142474	KPNA1	-0.57	-5.91	-0.35	1.12e-8	LDL cholesterol levels;
KIRP	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.31	-0.37	1.27e-9	Obesity-related traits;
KIRP	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.5	6.93	0.4	3.76e-11	Multiple myeloma (IgH translocation);
KIRP	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.01	-0.45	4.53e-14	Neuroticism;
KIRP	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg26207909	chr14:103986467	CKB	-0.43	-5.4	-0.33	1.57e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg10434728	chr15:90938212	IQGAP1	0.38	7.08	0.41	1.53e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.86	-0.4	5.41e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg21395723	chr22:39101663	GTPBP1	0.47	6.29	0.37	1.47e-9	Menopause (age at onset);
KIRP	cis	rs1076160	1.000	rs4367688	chr9:135791103	G/A	cg04648087	chr9:135819397	TSC1	-0.4	-5.17	-0.31	4.93e-7	Psoriasis;
KIRP	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.57	-6.36	-0.38	9.57e-10	Aortic root size;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg13846473	chr9:131709761	DOLK;NUP188	0.53	6.05	0.36	5.41e-9	Electroencephalogram traits;
KIRP	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.69	-9.86	-0.53	1.58e-19	Longevity;
KIRP	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg10755058	chr3:40428713	ENTPD3	0.49	6.74	0.39	1.12e-10	Renal cell carcinoma;
KIRP	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs7536201	1.000	rs7547501	chr1:25301653	T/C	cg23273869	chr1:25296894	NA	-0.4	-5.75	-0.34	2.59e-8	Psoriasis vulgaris;
KIRP	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.85	0.3	2.21e-6	Menopause (age at onset);
KIRP	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.68	-10.21	-0.55	1.2e-20	Heart rate;
KIRP	cis	rs3779635	0.742	rs10089637	chr8:27241832	A/C	cg23693289	chr8:27183097	PTK2B	0.57	7.37	0.43	2.59e-12	Neuroticism;
KIRP	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.62	8.1	0.46	2.62e-14	Coronary artery disease;
KIRP	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg12454167	chr3:186435060	KNG1	0.64	12.11	0.61	8.55e-27	Blood protein levels;
KIRP	cis	rs4073416	0.542	rs7143318	chr14:65940689	G/A	cg03016385	chr14:66212404	NA	-0.53	-6.61	-0.39	2.33e-10	N-glycan levels;
KIRP	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg13072238	chr3:49761600	GMPPB	0.57	5.13	0.31	5.8e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg24009623	chr19:33667908	NA	0.5	6.35	0.38	1.03e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11888559	0.511	rs1351826	chr2:203850508	G/A	cg24605529	chr2:203879461	NBEAL1	0.76	4.98	0.3	1.2e-6	Height;
KIRP	cis	rs933360	0.585	rs11238315	chr7:50835549	A/G	cg14240098	chr7:50518052	FIGNL1	0.43	4.92	0.3	1.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-5.6	-0.34	5.61e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg23594656	chr7:65796392	TPST1	-0.38	-5.54	-0.33	7.8e-8	Aortic root size;
KIRP	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg24315340	chr6:146058215	EPM2A	-0.42	-5.34	-0.32	2.14e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3784262	0.565	rs12595410	chr15:58293040	A/G	cg12031962	chr15:58353849	ALDH1A2	0.36	4.91	0.3	1.64e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.52	-8.76	-0.49	3.15e-16	Height;
KIRP	trans	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19894588	chr14:64061835	NA	0.5	6.88	0.4	4.81e-11	Glioblastoma;Glioma;
KIRP	cis	rs687432	0.924	rs7121139	chr11:57782820	C/T	cg19752551	chr11:57585705	CTNND1	-0.68	-8.88	-0.49	1.44e-16	Parkinson's disease;
KIRP	cis	rs10203711	0.932	rs4353597	chr2:239597772	C/G	cg14580085	chr2:239553406	NA	0.39	5.18	0.31	4.62e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg09314708	chr11:132812991	OPCML	0.48	6.9	0.4	4.44e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.08	-0.31	7.48e-7	Pulmonary function;
KIRP	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.91	0.35	1.11e-8	Lung cancer;
KIRP	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg20469991	chr17:27169893	C17orf63	0.54	5.64	0.34	4.55e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.74e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg11972305	chr2:233791962	NGEF	-0.39	-5.32	-0.32	2.37e-7	Schizophrenia;
KIRP	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05347473	chr6:146136440	FBXO30	-0.63	-9.21	-0.51	1.48e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs687432	0.924	rs34594669	chr11:57703516	C/T	cg19752551	chr11:57585705	CTNND1	-0.54	-7.47	-0.43	1.4e-12	Parkinson's disease;
KIRP	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg12560992	chr17:57184187	TRIM37	0.62	5.82	0.35	1.84e-8	Cognitive test performance;
KIRP	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg13147721	chr7:65941812	NA	-0.74	-6.6	-0.39	2.57e-10	Diabetic kidney disease;
KIRP	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.94	12.28	0.62	2.32e-27	Menopause (age at onset);
KIRP	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.37	-10.36	-0.55	4.23e-21	Diabetic kidney disease;
KIRP	cis	rs6832769	0.767	rs6850524	chr4:56381997	C/G	cg09317128	chr4:56265301	TMEM165	0.48	6.29	0.37	1.47e-9	Personality dimensions;
KIRP	cis	rs193541	0.632	rs62377425	chr5:122332625	C/G	cg19412675	chr5:122181750	SNX24	-0.6	-6.45	-0.38	6.03e-10	Glucose homeostasis traits;
KIRP	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	10.62	0.56	6.09e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	8.49	0.48	1.92e-15	Colorectal cancer;
KIRP	cis	rs61884328	0.789	rs61897788	chr11:47181051	A/T	cg23433285	chr11:47201945	PACSIN3	0.68	5.27	0.32	2.99e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs4805272	1.000	rs7256812	chr19:29323430	G/A	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7523273	0.526	rs12132968	chr1:207884292	T/C	cg22525895	chr1:207977042	MIR29B2	0.49	5.94	0.35	9.69e-9	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12840245	chr4:30855141	PCDH7	-0.39	-6.27	-0.37	1.6e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-8.45	-0.47	2.51e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg16060761	chr17:80687452	NA	0.45	5.43	0.33	1.37e-7	Breast cancer;
KIRP	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg02297831	chr4:17616191	MED28	0.59	7.54	0.43	8.98e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg24881330	chr22:46731750	TRMU	0.78	5.59	0.34	5.9e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2273156	0.570	rs941653	chr14:35592538	C/G	cg09327582	chr14:35236912	BAZ1A	-0.48	-4.91	-0.3	1.69e-6	Immunoglobulin light chain (AL) amyloidosis;
KIRP	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.81e-19	Height;
KIRP	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.83	0.4	6.56e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.62	-8.97	-0.5	7.88e-17	Renal function-related traits (BUN);
KIRP	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.82	10.7	0.56	3.56e-22	Orofacial clefts;
KIRP	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.3	0.42	4.03e-12	Myopia (pathological);
KIRP	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg04022379	chr5:110408740	TSLP	0.71	10.54	0.56	1.13e-21	Eosinophilic esophagitis;
KIRP	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg11382394	chr1:2564504	MMEL1	0.38	4.88	0.3	1.89e-6	Ulcerative colitis;
KIRP	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.28	-0.78	4.15e-51	Height;
KIRP	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.5	0.43	1.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6504950	0.720	rs9913784	chr17:52989071	A/T	cg26251398	chr17:52985966	TOM1L1	0.48	6.66	0.39	1.82e-10	Breast cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21027713	chr11:66115023	B3GNT1	-0.47	-6.4	-0.38	7.95e-10	Metabolic traits;
KIRP	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg21427119	chr20:30132790	HM13	-0.52	-5.89	-0.35	1.27e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.03	-0.31	9.52e-7	Bladder cancer;
KIRP	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg10932868	chr11:921992	NA	0.64	8.46	0.47	2.35e-15	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.66	-10.46	-0.55	2.07e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.91	-12.36	-0.62	1.31e-27	Menopause (age at onset);
KIRP	trans	rs58106596	0.660	rs62197212	chr2:232562727	G/A	cg01370599	chr3:116745421	NA	0.7	6.5	0.38	4.38e-10	White blood cell count;Lymphocyte counts;
KIRP	cis	rs11264213	0.892	rs11264194	chr1:36195372	C/T	cg27506609	chr1:36549197	TEKT2	0.74	6.9	0.4	4.26e-11	Schizophrenia;
KIRP	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.65	-0.34	4.33e-8	Coronary artery disease;
KIRP	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg13010199	chr12:38710504	ALG10B	-0.39	-5.06	-0.31	8.28e-7	Heart rate;
KIRP	cis	rs6737205	0.579	rs937813	chr2:28301540	T/C	cg05484376	chr2:27715224	FNDC4	-0.59	-5.67	-0.34	3.94e-8	RR interval (tricyclic/tetracyclic antidepressant use interaction);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg09133192	chr4:89205337	PPM1K	0.71	6.83	0.4	6.75e-11	Lung function (FEV1);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg27351449	chr6:135606436	AHI1	0.49	6.01	0.36	6.5e-9	Myopia (pathological);
KIRP	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg15282417	chr9:129245246	FAM125B	0.42	7.19	0.42	7.89e-12	Intraocular pressure;
KIRP	cis	rs6967385	0.560	rs4554369	chr7:12356511	C/T	cg20607287	chr7:12443886	VWDE	0.38	5.01	0.3	1.02e-6	Response to taxane treatment (placlitaxel);
KIRP	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg08885076	chr2:99613938	TSGA10	-0.38	-5.56	-0.33	7.1e-8	Fear of minor pain;
KIRP	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-8.58	-0.48	1.08e-15	Coronary artery disease;
KIRP	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.95	-14.03	-0.67	3.08e-33	Primary sclerosing cholangitis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22430734	chr17:35849794	DUSP14	0.54	6.39	0.38	8.19e-10	Smoking initiation;
KIRP	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg02297831	chr4:17616191	MED28	0.57	7.43	0.43	1.74e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06498398	chr8:11627480	NEIL2	0.54	6.57	0.39	2.92e-10	Smoking initiation;
KIRP	cis	rs2594989	0.831	rs66488222	chr3:11576289	C/T	cg01796438	chr3:11312864	ATG7	0.53	6.45	0.38	5.85e-10	Circulating chemerin levels;
KIRP	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg01843524	chr15:80216276	C15orf37;ST20	0.42	5.15	0.31	5.46e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14680556	chr19:44144305	CADM4	0.46	6.53	0.38	3.76e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs66530629	0.797	rs12758422	chr1:25078061	T/C	cg22509179	chr1:25234806	RUNX3	-0.39	-5.11	-0.31	6.45e-7	Plateletcrit;
KIRP	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12153243	0.714	rs17341992	chr5:142893637	T/C	cg13907255	chr5:142895549	NA	-0.39	-5.12	-0.31	6.12e-7	Migraine;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg03289416	chr15:75166202	SCAMP2	0.48	6.5	0.38	4.41e-10	Breast cancer;
KIRP	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.1	-0.31	6.69e-7	Metabolite levels;
KIRP	cis	rs11191270	0.784	rs11191264	chr10:104096732	A/T	cg15320455	chr10:103880129	LDB1	0.55	4.96	0.3	1.3e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.01	17.38	0.74	1.12e-44	Multiple system atrophy;
KIRP	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.32	4.91	0.3	1.67e-6	Neuroticism;
KIRP	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg02175503	chr12:58329896	NA	0.63	7.61	0.44	5.78e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg13482628	chr17:19912719	NA	0.6	8.38	0.47	4.08e-15	Schizophrenia;
KIRP	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.53	7.05	0.41	1.83e-11	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs7923609	0.846	rs7098181	chr10:65027143	G/T	cg01631684	chr10:65280961	REEP3	-0.47	-5.4	-0.33	1.56e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.33	-5.96	-0.36	8.84e-9	Pursuit maintenance gain;
KIRP	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	5.38	0.32	1.73e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.35	-0.32	2.02e-7	Schizophrenia;
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.64	8.52	0.48	1.67e-15	Aortic root size;
KIRP	cis	rs12049351	0.774	rs12033713	chr1:229638440	G/C	cg11742688	chr1:229674241	ABCB10	-0.4	-5.66	-0.34	4.3e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14893161	chr1:205819251	PM20D1	0.51	5.9	0.35	1.17e-8	Prostate-specific antigen levels;
KIRP	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg14593290	chr7:50529359	DDC	-0.77	-9.45	-0.52	2.77e-18	Malaria;
KIRP	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.52	-5.92	-0.35	1.08e-8	Schizophrenia;
KIRP	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.72	-10.6	-0.56	7.15e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09698166	chr20:21106763	PLK1S1	-0.52	-6.41	-0.38	7.4e-10	Neuroticism;
KIRP	cis	rs9815354	1.000	rs6803652	chr3:41824556	A/G	cg03022575	chr3:42003672	ULK4	0.51	5.94	0.35	9.68e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg15485101	chr11:133734466	NA	0.42	5.73	0.34	2.98e-8	Childhood ear infection;
KIRP	cis	rs311392	0.966	rs425548	chr8:55087468	C/T	cg11783602	chr8:55087084	NA	-0.59	-7.34	-0.42	3.11e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg01200585	chr1:228362443	C1orf69	0.45	5.45	0.33	1.23e-7	Diastolic blood pressure;
KIRP	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.99	-0.3	1.13e-6	Bipolar disorder;
KIRP	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg02297831	chr4:17616191	MED28	0.52	6.58	0.39	2.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs10465746	0.967	rs11576870	chr1:84333301	G/A	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.85	12.56	0.63	2.72e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10128264	0.902	rs1250584	chr10:80976442	G/T	cg20744163	chr10:80999841	ZMIZ1	-0.33	-5.57	-0.33	6.75e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.26	0.32	3.2e-7	Asthma (childhood onset);
KIRP	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05220968	chr6:146057943	EPM2A	-0.4	-4.95	-0.3	1.41e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08439880	chr3:133502540	NA	-0.5	-6.21	-0.37	2.28e-9	Iron status biomarkers;
KIRP	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg22961513	chr11:14280813	SPON1	0.32	5.28	0.32	2.83e-7	Mitochondrial DNA levels;
KIRP	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.81	8.1	0.46	2.53e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.04	15.25	0.7	2.07e-37	Primary sclerosing cholangitis;
KIRP	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.48	-5.38	-0.32	1.75e-7	Coronary artery disease;
KIRP	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.56	-8.96	-0.5	8.06e-17	Prostate cancer;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg26207909	chr14:103986467	CKB	-0.51	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23386594	chr11:6866523	OR10A5	-0.4	-6.22	-0.37	2.15e-9	Inflammatory biomarkers;
KIRP	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs959260	0.610	rs9906825	chr17:73350580	C/T	cg20590849	chr17:73267439	MIF4GD	-0.51	-5.14	-0.31	5.69e-7	Systemic lupus erythematosus;
KIRP	cis	rs12476592	0.602	rs10865339	chr2:63811884	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.02	-0.31	9.72e-7	Childhood ear infection;
KIRP	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13198984	chr17:80129470	CCDC57	-0.5	-7.62	-0.44	5.47e-13	Life satisfaction;
KIRP	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.56	8.23	0.46	1.12e-14	Body mass index;
KIRP	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg21452805	chr1:244014465	NA	0.72	6.78	0.4	9.01e-11	RR interval (heart rate);
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg02668984	chr17:48172022	PDK2	0.52	6.09	0.36	4.29e-9	Sleep duration;
KIRP	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.28	-0.32	2.82e-7	Primary biliary cholangitis;
KIRP	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.4	4.97	0.3	1.28e-6	Aortic root size;
KIRP	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg10017260	chr10:834428	NA	-0.55	-5.53	-0.33	8.08e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs4236601	0.720	rs11980719	chr7:116142808	T/A	cg05166801	chr7:116143459	CAV2	0.49	5.97	0.36	8.28e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.27	-0.32	2.96e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs77688320	0.535	rs10931944	chr2:202263598	C/T	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	cis	rs72792276	1.000	rs72792279	chr5:127374404	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	5.91	0.35	1.14e-8	Red cell distribution width;
KIRP	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.5	-5.78	-0.35	2.27e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg04519387	chr11:65556438	OVOL1	0.34	5.0	0.3	1.1e-6	Acne (severe);
KIRP	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.46	5.0	0.3	1.08e-6	Lung function (FEV1/FVC);
KIRP	cis	rs2531992	0.686	rs933392	chr16:4032716	T/G	cg05927578	chr16:4029543	ADCY9	0.48	5.1	0.31	6.64e-7	Waist circumference;
KIRP	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs2882667	0.898	rs2116789	chr5:138394262	G/T	cg04439458	chr5:138467593	SIL1	-0.44	-7.45	-0.43	1.55e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6504340	0.739	rs1123630	chr17:46671816	C/T	cg04904318	chr17:46607828	HOXB1	-0.54	-5.74	-0.34	2.72e-8	Primary tooth development (number of teeth);
KIRP	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	6.13	0.36	3.5e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg21360079	chr12:107162445	NA	-0.67	-9.7	-0.53	4.79e-19	Heart rate;
KIRP	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg01420254	chr6:26195488	NA	1.24	11.27	0.58	4.85e-24	Gout;Renal underexcretion gout;
KIRP	cis	rs2625529	0.617	rs7175373	chr15:72203517	G/T	cg16672083	chr15:72433130	SENP8	0.43	6.24	0.37	1.93e-9	Red blood cell count;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg08901578	chr4:187885870	NA	0.5	7.73	0.44	2.78e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg12292205	chr6:26970375	C6orf41	0.33	4.92	0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.6	-9.43	-0.52	3.31e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.509	rs10426093	chr19:37615629	G/A	cg18154014	chr19:37997991	ZNF793	0.6	5.11	0.31	6.52e-7	Coronary artery calcification;
KIRP	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06915872	chr16:87998081	BANP	-0.6	-6.43	-0.38	6.44e-10	Menopause (age at onset);
KIRP	cis	rs9815354	0.812	rs113528686	chr3:41951547	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.7	0.39	1.37e-10	Colorectal cancer;
KIRP	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.45	0.74	6.14e-45	Height;
KIRP	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-5.98	-0.36	7.68e-9	Chronic sinus infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26804004	chr15:77155428	SCAPER	-0.44	-6.79	-0.4	8.47e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-5.68	-0.34	3.73e-8	Schizophrenia;
KIRP	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs6662572	0.737	rs4660333	chr1:46462059	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.35e-8	Blood protein levels;
KIRP	cis	rs2742417	1.000	rs2245705	chr3:45749722	A/G	cg04837898	chr3:45731254	SACM1L	-0.35	-4.96	-0.3	1.31e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.24	0.47	1.01e-14	IgG glycosylation;
KIRP	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg07843065	chr1:150265600	MRPS21	0.45	6.25	0.37	1.75e-9	Migraine;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03136512	chr1:16767024	NECAP2	-0.48	-6.07	-0.36	4.94e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg24631222	chr15:78858424	CHRNA5	-0.8	-9.64	-0.52	7.57e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg19913688	chr11:428466	ANO9	-0.75	-5.53	-0.33	7.98e-8	Body mass index;
KIRP	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.88	-11.13	-0.58	1.45e-23	Blood protein levels;
KIRP	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg06223162	chr1:101003688	GPR88	-0.43	-8.9	-0.49	1.25e-16	Monocyte count;
KIRP	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg04607235	chr12:12878440	APOLD1	-0.8	-8.45	-0.47	2.51e-15	Systemic lupus erythematosus;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08981514	chr11:129486010	NA	0.4	6.14	0.36	3.26e-9	Survival in pancreatic cancer;
KIRP	cis	rs11605924	0.934	rs7945565	chr11:45878992	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.56	-6.93	-0.4	3.68e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.58	6.87	0.4	5.38e-11	Aortic root size;
KIRP	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg24296786	chr1:45957014	TESK2	-0.62	-7.8	-0.45	1.73e-13	High light scatter reticulocyte count;
KIRP	cis	rs16828019	0.929	rs35813191	chr1:41742800	T/C	cg03387723	chr1:41708464	SCMH1	-0.77	-6.8	-0.4	7.68e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs10491083	0.661	rs2072150	chr17:6564627	C/A	cg16536857	chr17:6538525	KIAA0753	0.74	7.52	0.43	1.05e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7714584	1.000	rs11167526	chr5:150332481	G/A	cg22134413	chr5:150180641	NA	0.72	5.32	0.32	2.3e-7	Crohn's disease;
KIRP	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.57	-5.2	-0.31	4.21e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg03115019	chr17:80708279	FN3K	0.43	5.13	0.31	5.78e-7	Glycated hemoglobin levels;
KIRP	trans	rs12517041	1.000	rs35753092	chr5:23277623	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.87	-7.97	-0.45	5.75e-14	Calcium levels;
KIRP	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.58	0.34	6.27e-8	Resting heart rate;
KIRP	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Parkinson's disease;
KIRP	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg01988459	chr11:68622903	NA	-0.37	-5.4	-0.33	1.57e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7560272	0.723	rs6743576	chr2:73814333	G/A	cg20560298	chr2:73613845	ALMS1	-0.41	-5.02	-0.3	9.93e-7	Schizophrenia;
KIRP	cis	rs997154	0.655	rs8015121	chr14:23375251	A/G	cg25600027	chr14:23388339	RBM23	-0.45	-4.97	-0.3	1.28e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg25019033	chr10:957182	NA	-0.58	-5.98	-0.36	7.64e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.56	5.62	0.34	5.2e-8	Tuberculosis;
KIRP	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	7.61	0.44	5.9e-13	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.13	0.31	5.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17376030	chr22:41985996	PMM1	-0.81	-8.72	-0.49	4.11e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26378065	chr17:18585709	ZNF286B	0.54	6.77	0.4	9.51e-11	Educational attainment (years of education);
KIRP	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.3	6.17	0.37	2.85e-9	Body mass index;
KIRP	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg13264159	chr8:625131	ERICH1	-0.86	-6.65	-0.39	1.88e-10	IgG glycosylation;
KIRP	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg00106254	chr7:1943704	MAD1L1	-0.51	-5.15	-0.31	5.43e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg00684032	chr4:1343700	KIAA1530	-0.55	-7.3	-0.42	3.93e-12	Obesity-related traits;
KIRP	cis	rs7712401	0.601	rs4555798	chr5:122332114	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26250228	chr2:166700068	NA	-0.39	-6.09	-0.36	4.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.42	-5.21	-0.32	4.04e-7	Aortic root size;
KIRP	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg00405596	chr8:11794950	NA	-0.51	-6.74	-0.39	1.1e-10	Retinal vascular caliber;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg26770187	chr3:14693171	C3orf19	0.64	6.12	0.36	3.66e-9	Lung function (FEV1);
KIRP	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg04306507	chr14:55594613	LGALS3	0.52	8.14	0.46	2.04e-14	Protein biomarker;
KIRP	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.45	-5.7	-0.34	3.45e-8	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg00405596	chr8:11794950	NA	0.53	6.95	0.41	3.23e-11	Mood instability;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-6.27	-0.37	1.64e-9	Lung cancer;
KIRP	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs11264213	0.901	rs716926	chr1:36424476	A/G	cg27506609	chr1:36549197	TEKT2	0.96	10.13	0.54	2.27e-20	Schizophrenia;
KIRP	cis	rs471756	0.523	rs575307	chr9:219774	G/A	cg14500300	chr9:211689	NA	0.4	5.55	0.33	7.3900000000000007e-08	Mean platelet volume;
KIRP	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.87	-0.6	5.26e-26	Eye color traits;
KIRP	cis	rs6723108	0.616	rs6752634	chr2:135407355	G/A	cg25422880	chr2:135218333	TMEM163	0.34	5.04	0.31	8.92e-7	Type 2 diabetes;
KIRP	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg07843065	chr1:150265600	MRPS21	0.44	6.21	0.37	2.28e-9	Migraine;
KIRP	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg21774377	chr6:34760070	UHRF1BP1	0.48	6.26	0.37	1.73e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.63	8.13	0.46	2.13e-14	Prudent dietary pattern;
KIRP	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.57	-0.43	7.64e-13	Bone mineral density;
KIRP	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.66	-11.2	-0.58	8.44e-24	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg09264619	chr17:80180166	NA	-0.38	-5.55	-0.33	7.38e-8	Life satisfaction;
KIRP	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg17507749	chr15:85114479	UBE2QP1	-0.81	-8.33	-0.47	5.59e-15	Schizophrenia;
KIRP	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15369054	chr17:80825471	TBCD	0.66	5.77	0.35	2.32e-8	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.07e-12	Blood protein levels;
KIRP	cis	rs7551222	0.752	rs11240754	chr1:204477977	A/G	cg20240347	chr1:204465584	NA	-0.46	-8.75	-0.49	3.42e-16	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.66	8.79	0.49	2.68e-16	Motion sickness;
KIRP	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg00361562	chr2:198649771	BOLL	0.5	4.9	0.3	1.71e-6	Ulcerative colitis;
KIRP	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg24296786	chr1:45957014	TESK2	-0.43	-5.5	-0.33	9.41e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	8.53	0.48	1.47e-15	Motion sickness;
KIRP	trans	rs8141529	0.507	rs5762936	chr22:29381377	A/G	cg10359940	chr2:183580906	DNAJC10	0.83	6.35	0.38	1.06e-9	Lymphocyte counts;
KIRP	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg02297831	chr4:17616191	MED28	0.6	7.69	0.44	3.61e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7116495	0.867	rs4378421	chr11:71761996	T/C	cg26138937	chr11:71823887	C11orf51	-1.15	-8.03	-0.46	3.95e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03647317	chr4:187891568	NA	-0.76	-12.2	-0.61	4.33e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.51	6.57	0.39	3.05e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg12855166	chr17:30846586	MYO1D	0.39	4.97	0.3	1.27e-6	Schizophrenia;
KIRP	cis	rs9682041	0.561	rs9856511	chr3:170140165	C/G	cg11886554	chr3:170076028	SKIL	0.46	4.85	0.3	2.23e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-1.02	-18.69	-0.77	4.02e-49	Height;
KIRP	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.69	-0.44	3.56e-13	Resting heart rate;
KIRP	cis	rs2281603	0.951	rs28626711	chr14:64988279	A/G	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	10.15	0.54	1.85e-20	Lymphocyte counts;
KIRP	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.44	-5.1	-0.31	6.66e-7	Lung cancer;
KIRP	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.56	-0.33	6.96e-8	Triglycerides;
KIRP	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.98	13.7	0.66	3.84e-32	Menopause (age at onset);
KIRP	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg19847130	chr8:10466454	RP1L1	-0.34	-5.41	-0.33	1.48e-7	Neuroticism;
KIRP	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg05802129	chr4:122689817	NA	-0.46	-6.63	-0.39	2.06e-10	Type 2 diabetes;
KIRP	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.85	-9.97	-0.54	6.78e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	0.7	5.35	0.32	1.97e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.87	-13.51	-0.65	1.77e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.19	-0.31	4.47e-7	Bipolar disorder;
KIRP	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg27494647	chr7:150038898	RARRES2	0.44	6.16	0.37	2.96e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg09256448	chr16:638327	NA	0.36	5.08	0.31	7.53e-7	Height;
KIRP	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg07952391	chr2:88470173	THNSL2	0.91	7.51	0.43	1.12e-12	Plasma clusterin levels;
KIRP	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.07	-0.36	4.75e-9	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.63	-10.24	-0.55	1.01e-20	Morning vs. evening chronotype;
KIRP	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg06565975	chr8:143823917	SLURP1	0.47	7.42	0.43	1.88e-12	Urinary tract infection frequency;
KIRP	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg27205649	chr11:78285834	NARS2	-0.66	-8.19	-0.46	1.46e-14	Alzheimer's disease (survival time);
KIRP	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.45	5.11	0.31	6.43e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg05315796	chr3:52349193	DNAH1	0.39	6.35	0.38	1.02e-9	Bipolar disorder;
KIRP	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg02378861	chr5:212933	CCDC127	-0.71	-5.6	-0.34	5.82e-8	Fat distribution (HIV);
KIRP	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.9	-13.71	-0.66	3.62e-32	Ulcerative colitis;
KIRP	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs35883536	0.967	rs4908085	chr1:101087901	C/G	cg06223162	chr1:101003688	GPR88	0.32	6.42	0.38	6.77e-10	Monocyte count;
KIRP	cis	rs13161895	0.818	rs78282770	chr5:179483686	T/A	cg02702477	chr5:179499311	RNF130	1.03	7.13	0.41	1.12e-11	LDL cholesterol;
KIRP	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg16586182	chr3:47516702	SCAP	-0.73	-10.39	-0.55	3.34e-21	Colorectal cancer;
KIRP	cis	rs13095912	0.962	rs1568664	chr3:185312231	T/C	cg11274856	chr3:185301563	NA	0.53	6.83	0.4	6.44e-11	Systolic blood pressure;
KIRP	cis	rs7688540	0.713	rs12511388	chr4:297547	T/C	cg17891759	chr4:299121	NA	-0.43	-4.97	-0.3	1.24e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg18350739	chr11:68623251	NA	-0.46	-7.33	-0.42	3.3e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1413885	0.549	rs1334879	chr1:65846051	A/G	cg13202122	chr1:65886182	LEPROT;LEPR	0.42	4.85	0.3	2.15e-6	Anticoagulant levels;
KIRP	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	0.92	7.33	0.42	3.21e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.64	-9.41	-0.51	3.66e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.71	9.03	0.5	5.23e-17	Coronary artery disease;
KIRP	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg01557791	chr16:72042693	DHODH	-0.74	-9.78	-0.53	2.79e-19	Fibrinogen levels;
KIRP	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.52	6.59	0.39	2.68e-10	Birth weight;
KIRP	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg09699651	chr6:150184138	LRP11	0.54	7.21	0.42	6.98e-12	Testicular germ cell tumor;
KIRP	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05665937	chr4:1216051	CTBP1	0.57	7.84	0.45	1.32e-13	Obesity-related traits;
KIRP	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.4	9.99	0.54	6.15e-20	Corneal astigmatism;
KIRP	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.12	-0.31	6.31e-7	Bipolar disorder;
KIRP	cis	rs7534824	0.625	rs7521668	chr1:101491108	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.72	-6.01	-0.36	6.66e-9	Refractive astigmatism;
KIRP	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.52	-6.63	-0.39	2.11e-10	Birth weight;
KIRP	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	5.56	0.33	7.18e-8	Resting heart rate;
KIRP	cis	rs963731	0.649	rs75712619	chr2:39357262	G/C	cg04010122	chr2:39346883	SOS1	0.88	5.57	0.33	6.61e-8	Corticobasal degeneration;
KIRP	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg21926883	chr2:100939477	LONRF2	-0.57	-7.66	-0.44	4.15e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg11859384	chr17:80120422	CCDC57	-0.41	-5.19	-0.31	4.3e-7	Life satisfaction;
KIRP	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg19257562	chr1:2043853	PRKCZ	-0.38	-5.46	-0.33	1.14e-7	Height;
KIRP	cis	rs2282032	1.000	rs75816060	chr14:90759470	C/T	cg04374321	chr14:90722782	PSMC1	0.56	5.28	0.32	2.89e-7	Longevity;
KIRP	cis	rs244731	0.881	rs62397242	chr5:176738538	C/A	cg06060754	chr5:176797920	RGS14	0.6	6.88	0.4	4.92e-11	Urate levels in lean individuals;
KIRP	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.89	12.2	0.61	4.36e-27	Breast cancer;
KIRP	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg08603382	chr10:743973	NA	-0.48	-7.12	-0.41	1.16e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg10534938	chr5:1868639	NA	0.36	4.86	0.3	2.06e-6	Cardiovascular disease risk factors;
KIRP	cis	rs6499755	0.712	rs31104	chr16:55374309	A/G	cg05099576	chr16:55362342	IRX6	0.25	5.11	0.31	6.36e-7	Hypospadias;
KIRP	cis	rs6539288	0.933	rs10746070	chr12:107304459	C/T	cg16260113	chr12:107380972	MTERFD3	0.4	5.02	0.3	9.78e-7	Total body bone mineral density;
KIRP	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs8018808	0.935	rs4899654	chr14:77867314	A/C	cg20045696	chr14:77926864	AHSA1	0.44	5.41	0.33	1.48e-7	Myeloid white cell count;
KIRP	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.82	-0.35	1.8e-8	Morning vs. evening chronotype;
KIRP	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.75	6.52	0.38	3.98e-10	Diabetic retinopathy;
KIRP	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg06307176	chr5:131281290	NA	0.55	5.94	0.35	9.87e-9	Life satisfaction;
KIRP	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.43	-5.35	-0.32	1.99e-7	Testicular germ cell tumor;
KIRP	cis	rs1440410	0.830	rs4290853	chr4:144183169	G/C	cg01719995	chr4:144104893	USP38	0.42	5.6	0.34	5.73e-8	Ischemic stroke;
KIRP	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.94	16.03	0.71	4.34e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg18306943	chr3:40428807	ENTPD3	0.49	6.23	0.37	2.03e-9	Renal cell carcinoma;
KIRP	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg00405596	chr8:11794950	NA	0.55	7.4	0.43	2.21e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.7	-8.34	-0.47	5.24e-15	Resting heart rate;
KIRP	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.7	12.03	0.61	1.65e-26	Cardiovascular disease risk factors;
KIRP	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs2177596	0.525	rs2229814	chr2:227954599	G/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-6.21	-0.37	2.24e-9	Body mass index;
KIRP	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12560992	chr17:57184187	TRIM37	0.61	6.98	0.41	2.75e-11	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg05220968	chr6:146057943	EPM2A	0.41	5.19	0.31	4.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6504622	0.875	rs2316330	chr17:45040032	G/T	cg24703533	chr17:45055318	NA	0.39	5.53	0.33	8.33e-8	Orofacial clefts;
KIRP	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs4671458	0.656	rs12470478	chr2:63769308	G/A	cg17519650	chr2:63277830	OTX1	-0.5	-5.04	-0.31	9e-7	Subjective well-being;
KIRP	cis	rs9653442	0.545	rs2009095	chr2:100765081	C/T	cg22139774	chr2:100720529	AFF3	-0.33	-5.29	-0.32	2.71e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg26831259	chr4:1366826	KIAA1530	-0.38	-5.08	-0.31	7.35e-7	Obesity-related traits;
KIRP	trans	rs7306455	0.558	rs12371643	chr12:95325382	A/G	cg02647998	chr3:12201096	TIMP4;SYN2	-0.85	-6.1	-0.36	4.09e-9	Coronary artery disease;
KIRP	cis	rs4474465	0.831	rs12287010	chr11:78161452	A/T	cg27205649	chr11:78285834	NARS2	0.66	7.5	0.43	1.14e-12	Alzheimer's disease (survival time);
KIRP	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13939156	chr17:80058883	NA	-0.5	-7.57	-0.43	7.32e-13	Life satisfaction;
KIRP	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.4	0.38	7.88e-10	Bipolar disorder;
KIRP	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg24304309	chr1:154577895	ADAR	-0.36	-5.52	-0.33	8.55e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.6	-7.31	-0.42	3.7e-12	Sum neutrophil eosinophil counts;
KIRP	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.61	5.52	0.33	8.79e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs66696671	0.542	rs3847488	chr10:121388960	A/T	cg06765389	chr10:121379685	NA	-0.43	-6.54	-0.38	3.49e-10	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01349190	chr15:67835140	MAP2K5	0.5	6.75	0.4	1.05e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.53	-6.3	-0.37	1.34e-9	Glomerular filtration rate;
KIRP	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.25	-0.32	3.36e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9318086	0.904	rs9580769	chr13:24439724	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.6	-8.0	-0.45	4.81e-14	Myopia (pathological);
KIRP	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.83	10.79	0.57	1.83e-22	Breast cancer;
KIRP	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.04	0.54	4.36e-20	Total body bone mineral density;
KIRP	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs4742903	1.000	rs3739736	chr9:106857908	G/A	cg14250997	chr9:106856677	SMC2	0.4	5.18	0.31	4.7e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.6	-6.43	-0.38	6.59e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	10.37	0.55	3.81e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.72	-6.81	-0.4	7.26e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.42	-5.55	-0.33	7.42e-8	Menarche (age at onset);
KIRP	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.81	-14.68	-0.68	1.77e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28834970	1.000	rs28834970	chr8:27195121	T/C	cg18234130	chr8:27182889	PTK2B	-0.53	-6.51	-0.38	4.15e-10	Alzheimer's disease (late onset);
KIRP	cis	rs75064307	0.626	rs11720532	chr3:108066516	C/T	cg14703454	chr3:108065259	HHLA2	0.53	6.39	0.38	8.41e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg06079966	chr6:26237621	NA	-0.34	-6.04	-0.36	5.69e-9	Height;
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg00405596	chr8:11794950	NA	0.42	5.35	0.32	2.04e-7	Retinal vascular caliber;
KIRP	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg21184320	chr1:21044207	KIF17	-0.36	-5.38	-0.32	1.7e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6838801	0.892	rs10029193	chr4:77576894	G/A	cg17476223	chr4:77663285	SHROOM3	0.55	7.97	0.45	6.06e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg06740227	chr12:86229804	RASSF9	-0.42	-5.4	-0.33	1.54e-7	Major depressive disorder;
KIRP	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.69	8.07	0.46	3.18e-14	Smoking initiation;
KIRP	trans	rs593982	1.000	rs470360	chr11:65500530	T/C	cg16063989	chr7:139929855	NA	0.45	6.19	0.37	2.5e-9	Atopic dermatitis;
KIRP	cis	rs4761097	0.516	rs7966805	chr12:85228865	T/G	cg00765312	chr12:85674694	ALX1	0.51	6.0	0.36	7.11e-9	Behavioural disinhibition (generation interaction);
KIRP	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg02336718	chr17:17403227	NA	-0.32	-4.89	-0.3	1.83e-6	Total body bone mineral density;
KIRP	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.72	10.75	0.57	2.44e-22	Orofacial clefts;
KIRP	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	8.68	0.48	5.41e-16	Personality dimensions;
KIRP	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.81	-7.47	-0.43	1.37e-12	Alzheimer's disease;
KIRP	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.59	7.79	0.44	1.91e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6580649	0.941	rs11612578	chr12:48414798	T/C	cg26205652	chr12:48591994	NA	-0.45	-5.04	-0.31	9.07e-7	Lung cancer;
KIRP	cis	rs559928	0.524	rs4963222	chr11:64184735	T/C	cg05555928	chr11:63887634	MACROD1	-0.42	-4.98	-0.3	1.22e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2625529	0.730	rs3759900	chr15:72451827	A/C	cg16672083	chr15:72433130	SENP8	0.45	6.26	0.37	1.68e-9	Red blood cell count;
KIRP	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg08847533	chr14:75593920	NEK9	0.49	5.91	0.35	1.11e-8	IgG glycosylation;
KIRP	cis	rs11583043	1.000	rs17100939	chr1:101443701	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.99	0.41	2.52e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.87	13.54	0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1062746	0.528	rs12149622	chr16:87340235	A/G	cg02258303	chr16:87377426	FBXO31	-0.41	-5.09	-0.31	7.28e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2290402	0.536	rs4690339	chr4:854712	T/C	cg21249729	chr9:138392748	C9orf116;MRPS2	0.62	6.24	0.37	1.89e-9	Type 2 diabetes;
KIRP	cis	rs7215564	0.908	rs8076854	chr17:78663962	A/G	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg01579765	chr21:45077557	HSF2BP	0.41	8.36	0.47	4.65e-15	Mean corpuscular volume;
KIRP	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.56	-8.18	-0.46	1.48e-14	Blood metabolite levels;
KIRP	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.55	-8.97	-0.5	7.59e-17	Prostate cancer;
KIRP	cis	rs7712401	0.601	rs36180885	chr5:122356403	C/A	cg19412675	chr5:122181750	SNX24	-0.55	-5.93	-0.35	1.02e-8	Mean platelet volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13520373	chr11:108463818	EXPH5	0.45	6.32	0.37	1.21e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.66	-0.34	4.26e-8	Colorectal cancer;
KIRP	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.7	9.49	0.52	2.13e-18	Systemic lupus erythematosus;
KIRP	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg05784532	chr1:230284198	GALNT2	0.52	7.17	0.42	8.56e-12	Coronary artery disease;
KIRP	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.66	-0.73	3.11e-42	Height;
KIRP	cis	rs904251	0.561	rs1757189	chr6:37483727	G/C	cg25019722	chr6:37503610	NA	-0.98	-14.91	-0.69	2.9e-36	Cognitive performance;
KIRP	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg00129232	chr17:37814104	STARD3	0.68	7.32	0.42	3.58e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg16586182	chr3:47516702	SCAP	0.71	9.5	0.52	1.99e-18	Colorectal cancer;
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg14004847	chr7:1930337	MAD1L1	-0.45	-4.9	-0.3	1.76e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs10782582	0.586	rs5745383	chr1:76288590	G/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.44	-0.38	6.21e-10	Daytime sleep phenotypes;
KIRP	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.24	4.92	0.3	1.56e-6	Coronary artery disease;
KIRP	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.46	-5.44	-0.33	1.31e-7	Obesity-related traits;
KIRP	cis	rs870825	0.655	rs6844929	chr4:185653809	C/G	cg04058563	chr4:185651563	MLF1IP	-0.92	-11.55	-0.59	6.18e-25	Blood protein levels;
KIRP	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.43	-0.33	1.32e-7	Multiple sclerosis;
KIRP	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg10189261	chr14:101176105	NA	-0.49	-4.94	-0.3	1.42e-6	Plateletcrit;
KIRP	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg01304814	chr3:48885189	PRKAR2A	0.68	5.49	0.33	1.01e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg13147721	chr7:65941812	NA	-0.94	-7.11	-0.41	1.27e-11	Diabetic kidney disease;
KIRP	cis	rs883565	0.740	rs2037655	chr3:39072754	T/C	cg01426195	chr3:39028469	NA	-0.67	-11.15	-0.58	1.24e-23	Handedness;
KIRP	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.74	11.44	0.59	1.36e-24	Type 2 diabetes;
KIRP	cis	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-4.9	-0.3	1.78e-6	Systolic blood pressure;
KIRP	cis	rs8038465	0.789	rs57909886	chr15:73973662	T/C	cg15420318	chr15:73925796	NPTN	0.57	7.6	0.44	6.29e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs59197085	0.636	rs61012549	chr7:128442897	G/A	cg00734629	chr7:128471146	FLNC	0.43	4.87	0.3	2.02e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs13185784	0.667	rs4700728	chr5:179647551	T/G	cg23248424	chr5:179741104	GFPT2	-0.5	-5.27	-0.32	3e-7	TRAIL levels;
KIRP	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	1.03	14.21	0.67	7.47e-34	Menopause (age at onset);
KIRP	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.67	7.81	0.45	1.64e-13	Blood protein levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg27261837	chr1:146714163	CHD1L	0.47	6.19	0.37	2.49e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2671245	0.586	rs9436524	chr1:56139681	A/G	cg11523071	chr1:56160889	NA	0.42	6.46	0.38	5.67e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg05220968	chr6:146057943	EPM2A	0.4	5.14	0.31	5.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.8.2087691R	chr8:103313232	UBR5	0.43	6.26	0.37	1.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg08847533	chr14:75593920	NEK9	-0.53	-6.35	-0.38	1.04e-9	IgG glycosylation;
KIRP	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.45	-5.05	-0.31	8.63e-7	Parkinson's disease;
KIRP	cis	rs2599510	1.000	rs2599510	chr2:32826002	A/G	cg02381751	chr2:32503542	YIPF4	0.5	5.57	0.33	6.74e-8	Interleukin-18 levels;
KIRP	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.85	-11.26	-0.58	5.56e-24	Type 2 diabetes;
KIRP	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	1.03	22.67	0.82	3.5e-62	Multiple myeloma;
KIRP	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.71	10.88	0.57	8.89e-23	Height;
KIRP	cis	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg26585981	chr11:48327164	OR4S1	-0.45	-5.54	-0.33	7.93e-8	HDL cholesterol;
KIRP	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.42	-5.1	-0.31	6.85e-7	Neuroticism;
KIRP	cis	rs7833787	0.965	rs7833694	chr8:18700346	T/C	cg17701159	chr8:18705777	PSD3	-0.34	-6.05	-0.36	5.24e-9	Obesity-related traits;
KIRP	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	8.7	0.48	4.94e-16	Platelet count;
KIRP	cis	rs838147	0.873	rs11667321	chr19:49250538	A/G	cg13540341	chr19:49222985	MAMSTR	0.33	5.23	0.32	3.56e-7	Dietary macronutrient intake;
KIRP	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.19	-0.31	4.32e-7	Red blood cell count;
KIRP	cis	rs4148660	0.963	rs10743426	chr12:22051089	C/T	cg14669847	chr12:22099120	NA	0.34	5.8	0.35	2.02e-8	Gout;
KIRP	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Educational attainment (college completion);
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.3	-0.37	1.34e-9	Lung cancer;
KIRP	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.56	8.33	0.47	5.72e-15	Itch intensity from mosquito bite;
KIRP	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg18132916	chr6:79620363	NA	-0.41	-5.66	-0.34	4.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.58	8.37	0.47	4.39e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.68	9.0	0.5	6.19e-17	Hemoglobin concentration;
KIRP	cis	rs7737355	0.773	rs32112	chr5:131048122	G/A	cg06307176	chr5:131281290	NA	0.41	4.92	0.3	1.59e-6	Life satisfaction;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg04590956	chr2:70057467	GMCL1	0.7	6.55	0.39	3.3e-10	Lung function (FEV1);
KIRP	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg00792783	chr2:198669748	PLCL1	-0.47	-5.28	-0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.63	0.52	8.08e-19	Bipolar disorder;
KIRP	cis	rs10892173	0.846	rs2298647	chr11:117671641	A/T	cg07621104	chr11:117668040	DSCAML1	0.48	7.19	0.42	7.55e-12	Myopia;
KIRP	cis	rs1656402	1.000	rs2573217	chr2:233427015	G/A	cg03852847	chr2:233439513	NA	0.7	11.48	0.59	1.03e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.82	-12.02	-0.61	1.76e-26	Prudent dietary pattern;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg13546538	chr9:111754815	CTNNAL1	0.38	6.63	0.39	2.15e-10	Serum protein levels (sST2);
KIRP	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.84	9.9	0.53	1.19e-19	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14598338	chr9:96623480	NA	-0.67	-11.49	-0.59	9.68e-25	DNA methylation (variation);
KIRP	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg00343986	chr7:65444356	GUSB	0.43	5.12	0.31	6.05e-7	Aortic root size;
KIRP	cis	rs758970	0.523	rs12351417	chr9:129192677	T/C	cg15282417	chr9:129245246	FAM125B	-0.33	-5.18	-0.31	4.61e-7	Obesity-related traits;
KIRP	cis	rs11166927	0.967	rs56343024	chr8:140803580	G/A	cg16909799	chr8:140841666	TRAPPC9	0.7	10.11	0.54	2.58e-20	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08439880	chr3:133502540	NA	0.55	6.76	0.4	1e-10	Iron status biomarkers;
KIRP	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.64	5.02	0.3	9.83e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg25801113	chr15:45476975	SHF	0.48	9.27	0.51	1.01e-17	Uric acid levels;
KIRP	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-0.77	-7.07	-0.41	1.58e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg14696996	chr19:15285081	NOTCH3	0.67	7.28	0.42	4.52e-12	Pulse pressure;
KIRP	cis	rs918629	0.601	rs889302	chr5:95264652	A/C	cg16656078	chr5:95278638	ELL2	-0.36	-5.43	-0.33	1.36e-7	IgG glycosylation;
KIRP	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg12140854	chr5:148520817	ABLIM3	-0.52	-6.33	-0.37	1.12e-9	Breast cancer;
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02398342	chr17:80708632	TBCD;FN3K	-0.43	-5.16	-0.31	5.11e-7	Glycated hemoglobin levels;
KIRP	cis	rs151997	0.925	rs26089	chr5:50172251	A/G	cg06027927	chr5:50259733	NA	-0.61	-7.55	-0.43	8.57e-13	Callous-unemotional behaviour;
KIRP	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.94	0.4	3.51e-11	Platelet count;
KIRP	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg14289246	chr4:154710475	SFRP2	-0.55	-7.12	-0.41	1.18e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg06915872	chr16:87998081	BANP	0.5	5.06	0.31	8.3e-7	Menopause (age at onset);
KIRP	cis	rs6032067	1.000	rs6032069	chr20:43867388	C/T	cg10761708	chr20:43804764	PI3	-0.54	-5.55	-0.33	7.56e-8	Blood protein levels;
KIRP	cis	rs3779635	0.711	rs11777854	chr8:27247662	G/C	cg18234130	chr8:27182889	PTK2B	0.57	7.43	0.43	1.84e-12	Neuroticism;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg03289416	chr15:75166202	SCAMP2	0.56	7.61	0.44	5.83e-13	Breast cancer;
KIRP	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg01557791	chr16:72042693	DHODH	-0.42	-5.14	-0.31	5.62e-7	Fibrinogen levels;
KIRP	cis	rs9393813	0.506	rs13201985	chr6:27433633	G/A	cg03332623	chr6:27441972	ZNF184	-0.35	-5.15	-0.31	5.23e-7	Bipolar disorder;
KIRP	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.4	-5.66	-0.34	4.11e-8	Coronary artery disease;
KIRP	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg20368463	chr18:77673604	PQLC1	-0.55	-5.6	-0.34	5.7e-8	Opioid sensitivity;
KIRP	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg17376030	chr22:41985996	PMM1	-0.71	-7.58	-0.43	7.21e-13	Vitiligo;
KIRP	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.58	7.16	0.42	9.04e-12	Monobrow;
KIRP	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-9.73	-0.53	3.88e-19	Coronary artery disease;
KIRP	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg27532560	chr4:187881888	NA	-0.75	-12.83	-0.63	3.43e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.51	7.27	0.42	4.63e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg17885191	chr8:135476712	NA	0.54	6.46	0.38	5.67e-10	Hypertension (SNP x SNP interaction);
KIRP	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg14250997	chr9:106856677	SMC2	0.44	6.17	0.37	2.76e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.5	5.98	0.36	7.86e-9	Longevity;Endometriosis;
KIRP	cis	rs10861342	0.786	rs11112386	chr12:105538758	A/G	cg23923672	chr12:105501055	KIAA1033	0.87	7.25	0.42	5.33e-12	IgG glycosylation;
KIRP	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.89	10.57	0.56	9.14e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.75	8.63	0.48	8e-16	Coronary artery disease;
KIRP	cis	rs2483058	0.767	rs2336939	chr1:206620173	A/T	cg19452316	chr1:206680966	RASSF5	0.41	5.55	0.33	7.45e-8	Cholesterol and Triglycerides;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg14295958	chr14:24025576	THTPA	-0.46	-6.28	-0.37	1.56e-9	Blood metabolite levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02860732	chr16:12995292	SHISA9	-0.43	-6.03	-0.36	6.13e-9	Metabolic traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17736116	chr15:56923479	ZNF280D	-0.43	-6.66	-0.39	1.8e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.21	0.32	4.04e-7	Asthma;
KIRP	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.83	9.07	0.5	3.83e-17	Alzheimer's disease;
KIRP	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg00204512	chr16:28754710	NA	0.47	6.14	0.36	3.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg07585502	chr8:101912084	NA	-0.66	-8.32	-0.47	6.16e-15	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.2	16.14	0.72	1.85e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg06212747	chr3:49208901	KLHDC8B	-0.57	-5.49	-0.33	9.98e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg04672837	chr16:48644449	N4BP1	0.51	7.1	0.41	1.3e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.43	5.56	0.33	7.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7520050	0.966	rs11211230	chr1:46406767	G/T	cg03146154	chr1:46216737	IPP	-0.42	-5.39	-0.33	1.61e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg15764593	chr10:829463	NA	-0.81	-8.75	-0.49	3.41e-16	Uric acid levels;
KIRP	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.69	-7.27	-0.42	4.73e-12	Urate levels in lean individuals;
KIRP	cis	rs367943	0.712	rs13359330	chr5:112708529	T/C	cg12552261	chr5:112820674	MCC	0.56	6.64	0.39	1.98e-10	Type 2 diabetes;
KIRP	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.44	-5.85	-0.35	1.53e-8	IgG glycosylation;
KIRP	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg02336718	chr17:17403227	NA	0.33	5.31	0.32	2.49e-7	Total body bone mineral density;
KIRP	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg15880211	chr22:50250494	ZBED4	-0.68	-7.66	-0.44	4.2e-13	Schizophrenia;
KIRP	cis	rs12282928	0.959	rs1827502	chr11:48265966	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.25	-0.37	1.76e-9	Migraine - clinic-based;
KIRP	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.49	5.66	0.34	4.28e-8	Testicular germ cell tumor;
KIRP	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.04	-0.46	3.71e-14	Retinal vascular caliber;
KIRP	cis	rs10518128	0.850	rs1452310	chr4:75715125	A/G	cg20122727	chr4:75719957	BTC	0.59	5.93	0.35	1.01e-8	Electroencephalogram traits;
KIRP	cis	rs7172677	0.737	rs7169545	chr15:75436123	A/G	cg14082893	chr15:75400931	NA	0.33	4.9	0.3	1.72e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9715521	0.746	rs62301192	chr4:59843340	T/C	cg11281224	chr4:60001000	NA	-0.4	-4.96	-0.3	1.33e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs13385	0.769	rs17118759	chr5:139617407	A/G	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs8018808	0.935	rs1061629	chr14:77926011	A/G	cg20045696	chr14:77926864	AHSA1	-0.47	-5.43	-0.33	1.37e-7	Myeloid white cell count;
KIRP	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.06	0.31	8.14e-7	Diabetic retinopathy;
KIRP	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg04990556	chr1:26633338	UBXN11	-0.6	-7.49	-0.43	1.26e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-7.94	-0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg21427119	chr20:30132790	HM13	-0.55	-6.5	-0.38	4.52e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.73	-9.15	-0.5	2.21e-17	Height;
KIRP	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg07511668	chr11:68622177	NA	0.38	4.97	0.3	1.24e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.09	-0.31	6.97e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.73	-0.53	3.8e-19	Triglycerides;
KIRP	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.89	6.56	0.39	3.18e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.91	13.21	0.64	1.82e-30	Diastolic blood pressure;Systolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06068991	chr11:20140241	NAV2	-0.43	-6.26	-0.37	1.7e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.52	-7.93	-0.45	7.87e-14	Huntington's disease progression;
KIRP	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00495681	chr13:53174319	NA	-0.36	-4.93	-0.3	1.49e-6	Lewy body disease;
KIRP	cis	rs4664304	0.652	rs2221808	chr2:160870944	T/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-5.61	-0.34	5.54e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs631288	0.557	rs894470	chr1:146671947	A/G	cg25205988	chr1:146714368	CHD1L	0.91	5.99	0.36	7.51e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs61884328	0.777	rs17197619	chr11:47132760	A/C	cg23433285	chr11:47201945	PACSIN3	0.59	5.17	0.31	4.94e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs244731	0.920	rs67008484	chr5:176735383	T/C	cg17509989	chr5:176798049	RGS14	0.75	7.78	0.44	2.02e-13	Urate levels in lean individuals;
KIRP	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	1.04	6.62	0.39	2.29e-10	Type 2 diabetes nephropathy;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg09695851	chr17:3907499	NA	-0.82	-15.36	-0.7	8.33e-38	Type 2 diabetes;
KIRP	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg04733989	chr22:42467013	NAGA	0.55	7.49	0.43	1.25e-12	Cognitive function;
KIRP	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.3	-0.32	2.6e-7	Neuroticism;
KIRP	cis	rs9420	0.528	rs7117896	chr11:57388551	G/A	cg19752551	chr11:57585705	CTNND1	-0.6	-8.52	-0.48	1.59e-15	Schizophrenia;
KIRP	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.55	-0.43	8.62e-13	Type 2 diabetes;
KIRP	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg01620082	chr3:125678407	NA	-1.2	-7.68	-0.44	3.82e-13	Depression;
KIRP	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg19554555	chr3:13937349	NA	-0.46	-6.2	-0.37	2.42e-9	Ovarian reserve;
KIRP	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.42	-0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs7113850	0.541	rs11820983	chr11:24211705	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	8.41	0.47	3.37e-15	Bone fracture in osteoporosis;
KIRP	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.53	7.01	0.41	2.25e-11	HDL cholesterol;
KIRP	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg20573242	chr4:122745356	CCNA2	0.41	4.97	0.3	1.26e-6	Type 2 diabetes;
KIRP	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.47	-6.64	-0.39	1.95e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.55	-7.8	-0.45	1.76e-13	Coronary artery disease;
KIRP	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg13047869	chr3:10149882	C3orf24	0.62	5.13	0.31	5.79e-7	Alzheimer's disease;
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.62	7.68	0.44	3.69e-13	Breast cancer;
KIRP	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg16141378	chr3:129829833	LOC729375	0.54	7.06	0.41	1.71e-11	Retinal vascular caliber;
KIRP	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.82	-8.97	-0.5	7.99e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs1215050	0.791	rs783960	chr4:98893437	A/G	cg17366294	chr4:99064904	C4orf37	-0.4	-5.43	-0.33	1.34e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.56	8.09	0.46	2.69e-14	Schizophrenia;
KIRP	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg06740227	chr12:86229804	RASSF9	0.47	5.79	0.35	2.13e-8	Major depressive disorder;
KIRP	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.85	14.28	0.67	4.37e-34	Height;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.71	-10.78	-0.57	1.87e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg01028140	chr2:1542097	TPO	-0.55	-5.79	-0.35	2.16e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	trans	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17183009	chr3:120277827	NA	0.52	6.06	0.36	5.11e-9	Corneal astigmatism;
KIRP	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.11	0.36	3.78e-9	Menopause (age at onset);
KIRP	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	1.05	11.28	0.58	4.68e-24	Height;
KIRP	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg20430773	chr1:16534157	ARHGEF19	0.61	7.55	0.43	8.57e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg05941025	chr16:89927596	SPIRE2	0.32	5.08	0.31	7.34e-7	Vitiligo;
KIRP	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.95	-0.57	5.39e-23	Chronic sinus infection;
KIRP	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg00807237	chr7:934156	C7orf20	0.43	5.12	0.31	6.31e-7	Subjective well-being;
KIRP	cis	rs2294693	0.581	rs9462670	chr6:41014309	G/C	cg14769373	chr6:40998127	UNC5CL	-0.46	-5.09	-0.31	7.14e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	5.39	0.33	1.62e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.94	12.34	0.62	1.45e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg20592017	chr15:40364740	NA	0.35	5.17	0.31	4.75e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18252515	chr7:66147081	NA	0.47	5.57	0.33	6.7e-8	Aortic root size;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	trans	rs2859741	0.565	rs11263962	chr1:37509239	C/T	cg18200741	chr2:33780366	RASGRP3	-0.21	-6.15	-0.37	3.06e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.79	9.37	0.51	4.9e-18	Corneal astigmatism;
KIRP	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg13736514	chr6:26305472	NA	-0.61	-7.87	-0.45	1.11e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg24565620	chr2:194026	NA	0.64	7.52	0.43	1.01e-12	Blood protein levels;
KIRP	cis	rs12144044	1.000	rs12144044	chr1:113248791	G/T	cg22162597	chr1:113214053	CAPZA1	0.44	4.88	0.3	1.94e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05601917	chr6:125855416	NA	-0.38	-5.85	-0.35	1.57e-8	Brugada syndrome;
KIRP	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-9.22	-0.51	1.39e-17	Morning vs. evening chronotype;
KIRP	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.42	-5.95	-0.35	9.39e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.08	-0.31	7.51e-7	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg26875233	chr11:93583750	C11orf90	-0.41	-7.65	-0.44	4.57e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.87	-12.74	-0.63	6.88e-29	Ulcerative colitis;
KIRP	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.44	-0.52	2.98e-18	Joint mobility (Beighton score);
KIRP	cis	rs2522056	1.000	rs2522056	chr5:131801726	C/T	cg24060327	chr5:131705240	SLC22A5	0.6	6.19	0.37	2.47e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg04804543	chr8:142233427	SLC45A4	-0.56	-7.02	-0.41	2.14e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18252515	chr7:66147081	NA	-0.45	-5.51	-0.33	9.22e-8	Aortic root size;
KIRP	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg08885076	chr2:99613938	TSGA10	-0.6	-10.62	-0.56	6.05e-22	Chronic sinus infection;
KIRP	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg17356467	chr2:100759845	AFF3	0.55	5.63	0.34	4.79e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg26513180	chr16:89883248	FANCA	-0.52	-6.65	-0.39	1.89e-10	Vitiligo;
KIRP	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg02297831	chr4:17616191	MED28	0.53	6.61	0.39	2.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.73	7.58	0.44	6.85e-13	Carotid intima media thickness;
KIRP	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.81	0.66	1.7e-32	Cognitive function;
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg09695851	chr17:3907499	NA	-0.82	-14.77	-0.69	8.75e-36	Type 2 diabetes;
KIRP	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.78	12.11	0.61	8.52e-27	Multiple myeloma (IgH translocation);
KIRP	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg13047869	chr3:10149882	C3orf24	0.61	5.18	0.31	4.61e-7	Alzheimer's disease;
KIRP	cis	rs1010254	0.559	rs991635	chr5:151748921	A/G	cg12297329	chr5:152029980	NA	-0.62	-6.36	-0.38	9.89e-10	Optic nerve measurement (cup area);
KIRP	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.69	9.16	0.5	2.08e-17	Eye color traits;
KIRP	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg00631329	chr6:26305371	NA	-0.7	-8.56	-0.48	1.22e-15	Educational attainment;
KIRP	cis	rs6921919	0.583	rs13437294	chr6:28341535	C/A	cg18815343	chr6:28367644	ZSCAN12	-0.42	-6.03	-0.36	5.83e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.52	5.16	0.31	5.18e-7	Alzheimer's disease;
KIRP	trans	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg12929700	chr20:62947519	NA	-0.6	-6.11	-0.36	3.79e-9	Refractive error;
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.81	11.05	0.58	2.66e-23	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22833147	chr4:178230858	NEIL3	-0.48	-6.3	-0.37	1.33e-9	Interleukin-4 levels;
KIRP	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.14	0.36	3.34e-9	Putamen volume;
KIRP	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg10223061	chr2:219282414	VIL1	0.28	4.85	0.3	2.17e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2302729	0.545	rs1894979	chr12:2766999	G/A	cg19945202	chr12:2788847	CACNA1C	-0.79	-11.54	-0.59	6.64e-25	Sleep quality;
KIRP	cis	rs6120849	0.851	rs13040631	chr20:33747714	T/C	cg24642439	chr20:33292090	TP53INP2	0.55	6.09	0.36	4.39e-9	Protein C levels;
KIRP	cis	rs753955	0.593	rs7982516	chr13:24410278	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.44	5.7	0.34	3.39e-8	Lung cancer;
KIRP	cis	rs2916247	1.000	rs2920471	chr8:92981874	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.56	-7.23	-0.42	6.14e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.51e-7	Retinal vascular caliber;
KIRP	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg04166393	chr7:2884313	GNA12	0.63	8.15	0.46	1.85e-14	Height;
KIRP	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.38	-0.32	1.74e-7	Coronary artery disease;
KIRP	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.92	-0.57	6.66e-23	Menopause (age at onset);
KIRP	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.63	-7.58	-0.44	7.13e-13	Educational attainment;
KIRP	cis	rs582384	0.568	rs546639	chr2:45876655	A/G	cg05208381	chr2:45870771	NA	-0.34	-4.93	-0.3	1.5e-6	Coronary artery disease;
KIRP	cis	rs1832871	0.672	rs9457345	chr6:158743098	A/G	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg18209359	chr17:80159595	CCDC57	0.43	5.58	0.34	6.4e-8	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19333194	chr2:188093537	NA	-0.39	-6.09	-0.36	4.32e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.4	0.33	1.56e-7	Coronary artery disease;
KIRP	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-6.26	-0.37	1.7e-9	Neuroticism;
KIRP	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg04691961	chr3:161091175	C3orf57	0.45	6.73	0.39	1.15e-10	Morning vs. evening chronotype;
KIRP	cis	rs6142102	0.625	rs4012234	chr20:32553047	T/G	cg24642439	chr20:33292090	TP53INP2	0.49	5.75	0.34	2.67e-8	Skin pigmentation;
KIRP	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs2860975	0.620	rs7087256	chr10:96795524	T/C	cg09036531	chr10:96991505	NA	-0.48	-5.83	-0.35	1.7e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs10940138	0.501	rs11950162	chr5:67243415	C/T	ch.5.1281357F	chr5:67228439	NA	-0.53	-8.01	-0.45	4.5e-14	Menarche (age at onset);
KIRP	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg00074818	chr8:8560427	CLDN23	0.43	6.48	0.38	4.83e-10	Obesity-related traits;
KIRP	cis	rs6545883	0.929	rs12617911	chr2:61740825	A/G	cg15711740	chr2:61764176	XPO1	-0.59	-8.05	-0.46	3.5e-14	Tuberculosis;
KIRP	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg13660082	chr14:53194042	PSMC6	-0.67	-7.3	-0.42	4.02e-12	Alzheimer's disease (late onset);
KIRP	cis	rs6701037	1.000	rs12747817	chr1:175118895	C/T	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.2	-0.31	4.26e-7	Alcohol dependence;
KIRP	cis	rs7700895	0.737	rs10035477	chr5:95227507	C/T	cg16656078	chr5:95278638	ELL2	0.37	5.46	0.33	1.18e-7	IgG glycosylation;
KIRP	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.68	-8.96	-0.5	8.04e-17	Alzheimer's disease;
KIRP	cis	rs7529073	0.815	rs1431982	chr1:214149061	T/G	cg24083324	chr1:214162604	PROX1	-0.39	-5.71	-0.34	3.23e-8	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07267515	chr16:48644020	N4BP1	0.52	6.2	0.37	2.43e-9	Parkinson's disease;
KIRP	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg25173405	chr17:45401733	C17orf57	0.46	6.11	0.36	3.82e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	8.55	0.48	1.31e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg22508957	chr16:3507546	NAT15	0.57	7.07	0.41	1.61e-11	Tuberculosis;
KIRP	cis	rs4742903	0.904	rs1605448	chr9:106976405	T/G	cg14250997	chr9:106856677	SMC2	0.38	5.04	0.31	9.12e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs785830	0.749	rs578216	chr9:250935	G/C	cg14500300	chr9:211689	NA	0.56	7.57	0.43	7.54e-13	Platelet distribution width;
KIRP	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.88	13.43	0.65	3.23e-31	Mean corpuscular volume;
KIRP	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg05692746	chr2:100937584	LONRF2	-0.42	-5.58	-0.34	6.44e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.24	-0.32	3.52e-7	Total body bone mineral density;
KIRP	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg09473613	chr1:24152604	HMGCL	-0.42	-5.16	-0.31	5.13e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg04369109	chr6:150039330	LATS1	-0.63	-8.12	-0.46	2.21e-14	Lung cancer;
KIRP	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg13010199	chr12:38710504	ALG10B	-0.39	-5.08	-0.31	7.31e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2414059	0.518	rs3098176	chr15:50781963	T/A	cg05456662	chr15:50716270	USP8	0.39	5.29	0.32	2.7e-7	QT interval;
KIRP	cis	rs981844	0.890	rs62325115	chr4:154694847	A/G	cg14289246	chr4:154710475	SFRP2	0.69	7.85	0.45	1.27e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-5.66	-0.34	4.23e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.23	0.67	6.32e-34	Electrocardiographic conduction measures;
KIRP	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.38	5.16	0.31	5.07e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg03571507	chr19:53239146	ZNF611	-0.21	-5.15	-0.31	5.28e-7	Response to paliperidone in schizophrenia (PANSS score);
KIRP	cis	rs10463316	0.779	rs6871318	chr5:150801545	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-6.77	-0.4	9.62e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.13e-20	Dupuytren's disease;
KIRP	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.47	-5.03	-0.31	9.61e-7	Schizophrenia;
KIRP	trans	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg06521331	chr12:34319734	NA	-0.51	-6.32	-0.37	1.23e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4926611	0.795	rs12563871	chr1:54071610	A/G	cg08927728	chr1:54059983	GLIS1	-0.24	-5.07	-0.31	7.99e-7	Hand grip strength;
KIRP	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg26531700	chr6:26746687	NA	0.46	6.17	0.37	2.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.32	-0.42	3.45e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg18867708	chr6:26865862	GUSBL1	-0.52	-6.43	-0.38	6.62e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17482927	chr17:63133259	RGS9	-0.46	-6.43	-0.38	6.65e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg08975724	chr8:8085496	FLJ10661	0.53	7.09	0.41	1.39e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs755109	1.000	rs755109	chr9:100696203	C/T	cg13688889	chr9:100608707	NA	0.43	4.97	0.3	1.25e-6	Quantitative traits;
KIRP	cis	rs6584283	0.875	rs10748783	chr10:101285872	C/A	cg07044859	chr10:101282883	NA	-0.28	-4.9	-0.3	1.73e-6	Ulcerative colitis;
KIRP	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg17863274	chr19:49399704	TULP2	-0.41	-5.79	-0.35	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-0.95	-13.95	-0.66	5.69e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg05709478	chr1:6581295	PLEKHG5	0.58	5.51	0.33	8.94e-8	Body mass index;
KIRP	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.76	0.4	1.02e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2224391	0.628	rs2753238	chr6:5252795	A/C	cg13962347	chr6:5174647	LYRM4	-0.72	-10.03	-0.54	4.69e-20	Height;
KIRP	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.19e-9	Body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16248795	chr3:182698009	DCUN1D1	0.47	6.1	0.36	3.99e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9896052	0.533	rs7406173	chr17:73454563	G/A	cg25649188	chr17:73499917	CASKIN2	0.5	6.46	0.38	5.43e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg23442198	chr4:187126114	CYP4V2	0.58	5.6	0.34	5.74e-8	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.93	-9.28	-0.51	9.29e-18	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.69	-10.06	-0.54	3.67e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg08712631	chr7:1960676	MAD1L1	-0.44	-5.61	-0.34	5.44e-8	Neuroticism;
KIRP	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.65	-6.2	-0.37	2.35e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs787274	0.867	rs1711747	chr9:115452286	T/C	cg13803584	chr9:115635662	SNX30	0.59	5.93	0.35	1.04e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs6546324	0.625	rs6730286	chr2:67848054	C/T	cg15745817	chr2:67799979	NA	-0.7	-7.52	-0.43	1.01e-12	Endometriosis;
KIRP	cis	rs4663866	0.803	rs71426511	chr2:239180200	G/A	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg14541582	chr5:601475	NA	-0.58	-6.59	-0.39	2.73e-10	Obesity-related traits;
KIRP	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.47	0.47	2.32e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg11814155	chr7:99998594	ZCWPW1	0.55	5.42	0.33	1.42e-7	Platelet count;
KIRP	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg16127683	chr15:40268777	EIF2AK4	-0.57	-8.0	-0.45	4.98e-14	Response to haloperidol in psychosis;
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.79	0.35	2.1e-8	Life satisfaction;
KIRP	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12667521	chr19:29218732	NA	0.77	6.92	0.4	3.9e-11	Methadone dose in opioid dependence;
KIRP	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg02524346	chr8:600233	NA	0.63	4.99	0.3	1.13e-6	IgG glycosylation;
KIRP	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg07451762	chr16:28383216	NA	0.38	5.07	0.31	8.01e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.3	-7.76	-0.44	2.25e-13	Crohn's disease;
KIRP	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.48	10.95	0.57	5.39e-23	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06009330	chr2:70485380	PCYOX1	0.49	7.3	0.42	3.91e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02895278	chr8:26195897	PPP2R2A	-0.43	-6.5	-0.38	4.46e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6504950	0.745	rs35079296	chr17:52994210	T/G	cg26251398	chr17:52985966	TOM1L1	0.4	5.47	0.33	1.12e-7	Breast cancer;
KIRP	cis	rs2729354	0.768	rs2729384	chr11:57258617	T/C	cg24343310	chr11:57249947	NA	0.28	5.38	0.32	1.72e-7	Blood protein levels;
KIRP	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg02336718	chr17:17403227	NA	-0.32	-5.1	-0.31	6.85e-7	Total body bone mineral density;
KIRP	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05025164	chr4:1340916	KIAA1530	0.57	7.69	0.44	3.45e-13	Obesity-related traits;
KIRP	trans	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg06521331	chr12:34319734	NA	-0.53	-6.53	-0.38	3.81e-10	Heart rate;
KIRP	trans	rs56238310	0.570	rs80184502	chr3:111167381	A/C	cg05829482	chr2:210288514	MAP2	-0.86	-6.24	-0.37	1.9e-9	Current cigarettes per day in chronic obstructive pulmonary disease;
KIRP	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.6	5.82	0.35	1.84e-8	Plateletcrit;
KIRP	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.32	-0.51	6.78e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg15655495	chr12:38532458	NA	0.26	4.93	0.3	1.49e-6	Bladder cancer;
KIRP	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg07741184	chr6:167504864	NA	-0.24	-6.4	-0.38	7.85e-10	Crohn's disease;
KIRP	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.18	-0.46	1.53e-14	Response to antipsychotic treatment;
KIRP	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.58	7.39	0.43	2.3e-12	Breast cancer;
KIRP	cis	rs77972916	0.609	rs72790907	chr2:43575195	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.73	-6.58	-0.39	2.74e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg07451762	chr16:28383216	NA	0.42	5.48	0.33	1.04e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6681460	0.932	rs523132	chr1:67174440	A/G	cg02459107	chr1:67143332	SGIP1	-0.43	-6.08	-0.36	4.63e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14409850	chr12:27091377	C12orf11;FGFR1OP2	-0.47	-6.27	-0.37	1.59e-9	Survival in pancreatic cancer;
KIRP	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	5.97	0.36	8.28e-9	Iron status biomarkers;
KIRP	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg01426195	chr3:39028469	NA	-0.58	-8.53	-0.48	1.52e-15	Handedness;
KIRP	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.27	-5.57	-0.33	6.58e-8	Menarche (age at onset);
KIRP	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.25	7.01	0.41	2.33e-11	Type 2 diabetes;
KIRP	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.13	0.41	1.12e-11	Lung cancer;
KIRP	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.43	0.38	6.42e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.54	6.58	0.39	2.87e-10	Asthma;
KIRP	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg04087571	chr11:116723030	SIK3	-0.23	-4.99	-0.3	1.16e-6	Subjective well-being;
KIRP	cis	rs4851254	0.618	rs13001130	chr2:100668699	G/A	cg17356467	chr2:100759845	AFF3	0.53	5.52	0.33	8.63e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1562975	0.722	rs56011514	chr4:109456614	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.39	4.97	0.3	1.26e-6	Height;
KIRP	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.07	0.41	1.55e-11	Rheumatoid arthritis;
KIRP	cis	rs11718455	0.767	rs13076333	chr3:43955070	G/A	cg21419209	chr3:44054225	NA	-0.71	-8.1	-0.46	2.5e-14	Coronary artery disease;
KIRP	cis	rs62413470	1.000	rs62411456	chr6:55968420	G/A	cg13327911	chr6:55965977	COL21A1	0.55	5.01	0.3	1.04e-6	Joint mobility (Beighton score);
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg16822855	chr3:40428330	ENTPD3	-0.31	-4.86	-0.3	2.09e-6	Renal cell carcinoma;
KIRP	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg10223061	chr2:219282414	VIL1	-0.32	-5.34	-0.32	2.15e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg22705602	chr4:152727874	NA	0.56	9.39	0.51	4.37e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2425143	1.000	rs6058325	chr20:34388806	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.56	-5.08	-0.31	7.38e-7	Blood protein levels;
KIRP	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-7.08	-0.41	1.53e-11	Morning vs. evening chronotype;
KIRP	cis	rs1345301	1.000	rs12475055	chr2:102878891	G/T	cg12451869	chr2:102867685	NA	-0.39	-5.87	-0.35	1.38e-8	Waist circumference;
KIRP	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.51	7.27	0.42	4.7e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.08	-0.67	1.99e-33	Alzheimer's disease;
KIRP	trans	rs57502260	0.764	rs7105218	chr11:68222461	C/A	cg12549906	chr5:6846268	NA	0.57	6.07	0.36	4.7e-9	Total body bone mineral density (age 45-60);
KIRP	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.23	-0.32	3.67e-7	Alcohol dependence;
KIRP	cis	rs6662572	0.806	rs11211133	chr1:45991079	G/A	cg24296786	chr1:45957014	TESK2	-0.52	-5.19	-0.31	4.46e-7	Blood protein levels;
KIRP	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg10047753	chr17:41438598	NA	1.17	19.34	0.78	2.71e-51	Menopause (age at onset);
KIRP	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.33	-0.37	1.14e-9	Monocyte count;
KIRP	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.64	-8.63	-0.48	7.83e-16	Pancreatic cancer;
KIRP	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.83	-9.5	-0.52	2e-18	Body mass index;
KIRP	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg05709478	chr1:6581295	PLEKHG5	0.6	5.07	0.31	7.89e-7	Body mass index;
KIRP	cis	rs7560272	0.501	rs2006997	chr2:73947846	G/A	cg20560298	chr2:73613845	ALMS1	0.44	5.11	0.31	6.37e-7	Schizophrenia;
KIRP	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg06742321	chr12:123595122	PITPNM2	0.48	5.59	0.34	6.11e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg04369109	chr6:150039330	LATS1	-0.64	-8.05	-0.46	3.52e-14	Lung cancer;
KIRP	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	9.12	0.5	2.84e-17	Bone mineral density;
KIRP	cis	rs2522056	1.000	rs2706339	chr5:131800105	G/T	cg24060327	chr5:131705240	SLC22A5	0.59	6.06	0.36	4.98e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.54	6.31	0.37	1.32e-9	Aortic root size;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15891644	chr15:40751006	BAHD1	0.47	6.11	0.36	3.98e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19524810	chr5:1112228	SLC12A7	0.57	7.6	0.44	6.16e-13	Parkinson's disease;
KIRP	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg21663122	chr6:26250936	HIST1H2BH;HIST1H3F	-0.61	-4.86	-0.3	2.07e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	10.81	0.57	1.54e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg02297831	chr4:17616191	MED28	-0.57	-7.13	-0.41	1.11e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-0.67	-5.53	-0.33	8.22e-8	Pediatric areal bone mineral density (radius);
KIRP	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg23903597	chr17:61704154	MAP3K3	-0.44	-5.45	-0.33	1.22e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.62e-11	Lung cancer;
KIRP	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg14689365	chr7:158441557	NCAPG2	0.39	4.95	0.3	1.38e-6	Height;
KIRP	cis	rs914615	0.529	rs11264338	chr1:155138557	A/G	cg02153340	chr1:155202674	NA	-0.48	-7.29	-0.42	4.18e-12	Urinary albumin-to-creatinine ratio;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg11665564	chr2:20850802	HS1BP3	-0.57	-6.15	-0.37	3.17e-9	Menopause (age at onset);
KIRP	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.04	-14.26	-0.67	5.01e-34	Blood pressure (smoking interaction);
KIRP	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.68e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg26513180	chr16:89883248	FANCA	0.84	5.51	0.33	9.12e-8	Skin colour saturation;
KIRP	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.67	-7.3	-0.42	3.92e-12	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg07701084	chr6:150067640	NUP43	0.61	7.92	0.45	8.18e-14	Lung cancer;
KIRP	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.31	5.42	0.33	1.42e-7	Dupuytren's disease;
KIRP	cis	rs6540556	0.723	rs11487867	chr1:209892070	G/T	cg05527609	chr1:210001259	C1orf107	-0.59	-5.65	-0.34	4.39e-8	Red blood cell count;
KIRP	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7923609	0.934	rs10761756	chr10:65172328	C/T	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	1.0	17.53	0.75	3.51e-45	Breast cancer;
KIRP	cis	rs10443215	0.659	rs61776382	chr1:56095944	C/T	cg11523071	chr1:56160889	NA	0.34	5.09	0.31	7.08e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg24375607	chr4:120327624	NA	0.52	5.74	0.34	2.84e-8	Corneal astigmatism;
KIRP	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg06121193	chr1:90282411	NA	0.52	7.41	0.43	2.07e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.89	14.03	0.67	2.92e-33	Mean corpuscular volume;
KIRP	cis	rs8523	0.901	rs953413	chr6:11012859	G/A	cg13562911	chr6:11044106	ELOVL2	0.39	5.09	0.31	7.27e-7	Red blood cell fatty acid levels;
KIRP	trans	rs933360	0.585	rs2074722	chr7:50834782	G/T	cg20003124	chr12:4557277	NA	0.53	6.46	0.38	5.69e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.3	-6.97	-0.41	2.84e-11	Mean corpuscular volume;
KIRP	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg10818794	chr15:86012489	AKAP13	-0.49	-6.98	-0.41	2.67e-11	Coronary artery disease;
KIRP	cis	rs1420338	0.967	rs2192874	chr7:34144916	G/A	cg01275685	chr7:34179230	BMPER	-0.59	-8.54	-0.48	1.43e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs832187	0.776	rs854622	chr3:63862842	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.5	-5.82	-0.35	1.85e-8	Schizophrenia;
KIRP	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.53	7.39	0.43	2.31e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.41	-5.27	-0.32	3.01e-7	IgG glycosylation;
KIRP	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg19257562	chr1:2043853	PRKCZ	0.5	7.45	0.43	1.59e-12	Height;
KIRP	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.01	0.3	1.03e-6	Breast cancer;
KIRP	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.87	12.12	0.61	8.36e-27	Breast cancer;
KIRP	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg01988459	chr11:68622903	NA	0.37	5.4	0.33	1.57e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg19847130	chr8:10466454	RP1L1	0.37	5.63	0.34	4.83e-8	Retinal vascular caliber;
KIRP	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	15.21	0.7	2.88e-37	Platelet count;
KIRP	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-10.07	-0.54	3.29e-20	Triglycerides;
KIRP	cis	rs9308731	0.583	rs7596789	chr2:111932616	G/A	cg18646521	chr2:111875858	NA	0.38	5.32	0.32	2.38e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.73	-11.26	-0.58	5.21e-24	Prostate cancer;
KIRP	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs10865541	0.934	rs6738333	chr2:3403404	T/C	cg11642891	chr2:3452563	TTC15	-0.51	-6.35	-0.38	1.03e-9	Obesity-related traits;
KIRP	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.86	-8.53	-0.48	1.51e-15	Developmental language disorder (linguistic errors);
KIRP	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2224391	0.628	rs2773313	chr6:5252213	C/G	cg13962347	chr6:5174647	LYRM4	-0.72	-10.23	-0.55	1.07e-20	Height;
KIRP	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.72	-9.52	-0.52	1.75e-18	Aortic root size;
KIRP	cis	rs10465746	0.846	rs12146038	chr1:84405065	A/T	cg10977910	chr1:84465055	TTLL7	0.47	5.77	0.35	2.37e-8	Obesity-related traits;
KIRP	cis	rs7084402	0.967	rs1649072	chr10:60298112	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.76	8.02	0.46	4.22e-14	Gastritis;
KIRP	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg01304814	chr3:48885189	PRKAR2A	0.61	5.44	0.33	1.27e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg05973401	chr12:123451056	ABCB9	-0.58	-6.76	-0.4	9.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.73	0.53	3.92e-19	Lung cancer in ever smokers;
KIRP	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.62	9.92	0.53	9.9e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Parkinson's disease;
KIRP	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.57	-7.77	-0.44	2.1e-13	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-7.53	-0.43	9.59e-13	Glycated hemoglobin levels;
KIRP	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-6.24	-0.37	1.92e-9	Fear of minor pain;
KIRP	cis	rs35740288	0.770	rs745191	chr15:86123170	G/T	cg17133734	chr15:86042851	AKAP13	-0.5	-5.57	-0.33	6.54e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg00938859	chr5:1591904	SDHAP3	0.53	6.13	0.36	3.44e-9	Breast cancer;
KIRP	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.91	-13.33	-0.65	7.29e-31	Primary sclerosing cholangitis;
KIRP	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.41	-0.33	1.47e-7	Aortic root size;
KIRP	cis	rs787274	1.000	rs2796027	chr9:115529404	A/T	cg13803584	chr9:115635662	SNX30	-0.74	-6.76	-0.4	9.71e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.52	-7.67	-0.44	4.12e-13	Daytime sleep phenotypes;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10720867	chr6:155537595	TIAM2	-0.47	-6.36	-0.38	9.82e-10	Inflammatory biomarkers;
KIRP	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06850241	chr22:41845214	NA	0.47	5.12	0.31	6.11e-7	Vitiligo;
KIRP	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg00666640	chr1:248458726	OR2T12	0.44	5.95	0.35	9.09e-9	Common traits (Other);
KIRP	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.98	0.45	5.51e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs4845875	0.626	rs12735869	chr1:11834163	C/T	cg24844545	chr1:11908347	NPPA	0.35	4.89	0.3	1.8e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs17381785	0.715	rs1494954	chr4:14911682	A/T	cg12377275	chr4:15005593	CPEB2	0.46	5.61	0.34	5.44e-8	Urate levels in overweight individuals;
KIRP	cis	rs7119038	0.774	rs10892290	chr11:118653503	G/T	cg19308663	chr11:118741387	NA	0.55	8.47	0.47	2.32e-15	Sjögren's syndrome;
KIRP	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.53	6.59	0.39	2.69e-10	Body mass index;
KIRP	cis	rs7084402	0.967	rs12569559	chr10:60312711	T/G	cg05938607	chr10:60274200	BICC1	0.39	9.15	0.5	2.23e-17	Refractive error;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21134252	chr6:131383887	EPB41L2	0.61	7.93	0.45	7.45e-14	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.47	-7.0	-0.41	2.49e-11	Daytime sleep phenotypes;
KIRP	cis	rs9398803	0.678	rs9401892	chr6:126895368	G/A	cg19875578	chr6:126661172	C6orf173	0.38	4.89	0.3	1.81e-6	Male-pattern baldness;
KIRP	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.66	-7.07	-0.41	1.58e-11	Vitiligo;
KIRP	cis	rs7572644	0.509	rs13001060	chr2:28025061	T/C	cg27432699	chr2:27873401	GPN1	0.49	5.5	0.33	9.58e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg02462569	chr6:150064036	NUP43	0.36	5.35	0.32	1.98e-7	Lung cancer;
KIRP	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg21231944	chr12:82153410	PPFIA2	-0.42	-5.11	-0.31	6.45e-7	Resting heart rate;
KIRP	cis	rs12230513	0.793	rs10783756	chr12:55920314	A/G	cg11794356	chr12:55725991	OR6C3	-0.38	-5.43	-0.33	1.38e-7	Contrast sensitivity;
KIRP	cis	rs311392	0.902	rs1511147	chr8:55091227	C/T	cg20636351	chr8:55087400	NA	-0.62	-7.63	-0.44	5.05e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs35883536	1.000	rs1932351	chr1:101142049	C/T	cg06223162	chr1:101003688	GPR88	0.34	6.97	0.41	2.96e-11	Monocyte count;
KIRP	trans	rs6601327	0.600	rs10103925	chr8:9652211	G/A	cg16141378	chr3:129829833	LOC729375	0.46	6.09	0.36	4.32e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4959799	0.655	rs9503518	chr6:3273457	A/G	cg03657281	chr6:3270030	SLC22A23	0.78	6.03	0.36	6.04e-9	Survival in rectal cancer;
KIRP	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg25251562	chr2:3704773	ALLC	-0.49	-5.95	-0.35	9.37e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.62	-6.6	-0.39	2.54e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.8	12.12	0.61	7.85e-27	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.63	0.48	7.71e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.71	-8.58	-0.48	1.1e-15	Post bronchodilator FEV1;
KIRP	cis	rs57561814	0.655	rs75443424	chr7:22742519	T/C	cg01770232	chr7:22766155	IL6	0.55	4.98	0.3	1.17e-6	Tonsillectomy;
KIRP	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg09184832	chr6:79620586	NA	-0.53	-7.38	-0.43	2.37e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.19e-15	Retinal vascular caliber;
KIRP	cis	rs3736485	0.966	rs11070854	chr15:51808365	A/G	cg14296394	chr15:51910925	DMXL2	-0.34	-5.12	-0.31	6.12e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.56	8.58	0.48	1.06e-15	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7009516	0.625	rs13262293	chr8:24263618	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.32	-6.74	-0.39	1.14e-10	Hair greying;
KIRP	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.86	12.43	0.62	7.51e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	6.94	0.4	3.44e-11	Schizophrenia;
KIRP	trans	rs12043259	1.000	rs59021437	chr1:204830320	A/G	cg11485465	chr5:54518469	NA	0.37	6.06	0.36	4.96e-9	Addiction;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg04025307	chr7:1156635	C7orf50	0.81	8.32	0.47	6.21e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	1.33	10.85	0.57	1.11e-22	Diabetic retinopathy;
KIRP	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.98	13.28	0.65	1.03e-30	Menopause (age at onset);
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.65	-8.24	-0.47	1e-14	Breast cancer;
KIRP	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg05347473	chr6:146136440	FBXO30	-0.55	-7.67	-0.44	3.92e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4006360	0.579	rs1817965	chr17:39244724	A/T	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.71	-0.49	4.38e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.41	-5.5	-0.33	9.49e-8	Dupuytren's disease;
KIRP	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	0.95	17.16	0.74	6.35e-44	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.91	-14.2	-0.67	7.72e-34	Dental caries;
KIRP	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-6.8	-0.4	7.8e-11	Menarche (age at onset);
KIRP	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg18016565	chr1:150552671	MCL1	0.39	5.38	0.32	1.77e-7	Melanoma;
KIRP	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg00931491	chr16:28608288	SULT1A2	0.23	5.05	0.31	8.67e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.12	0.36	3.65e-9	Height;
KIRP	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg16497661	chr14:103986332	CKB	0.52	6.57	0.39	2.99e-10	Coronary artery disease;
KIRP	cis	rs4742903	0.967	rs2122577	chr9:106866703	C/T	cg14250997	chr9:106856677	SMC2	0.38	4.98	0.3	1.22e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.67	10.19	0.54	1.38e-20	Schizophrenia;
KIRP	cis	rs72792276	1.000	rs3805608	chr5:127480998	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.68	6.07	0.36	4.78e-9	Red cell distribution width;
KIRP	cis	rs7224685	0.548	rs17710668	chr17:3880546	C/G	cg11204139	chr17:3907470	NA	0.58	6.16	0.37	2.92e-9	Type 2 diabetes;
KIRP	cis	rs62229266	0.605	rs11701331	chr21:37458392	T/C	cg08632701	chr21:37451849	NA	-0.58	-8.23	-0.46	1.08e-14	Mitral valve prolapse;
KIRP	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg00262122	chr8:11665843	FDFT1	0.39	4.93	0.3	1.48e-6	Neuroticism;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	7.06	0.41	1.68e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Bipolar disorder;
KIRP	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23978390	chr7:1156363	C7orf50	-0.56	-7.6	-0.44	6.15e-13	Longevity;Endometriosis;
KIRP	cis	rs4764487	0.760	rs10849421	chr12:6327008	A/G	cg08284733	chr12:6341482	CD9	0.55	9.06	0.5	4.2e-17	Mean platelet volume;
KIRP	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.67	-9.68	-0.53	5.54e-19	Brugada syndrome;
KIRP	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg27147174	chr7:100797783	AP1S1	0.51	6.51	0.38	4.08e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07343612	chr16:622815	PIGQ	-0.89	-13.45	-0.65	2.68e-31	Height;
KIRP	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg04034577	chr2:241836375	C2orf54	0.29	5.38	0.32	1.75e-7	Urinary metabolites;
KIRP	cis	rs7116495	0.737	rs670802	chr11:71799668	A/C	cg26138937	chr11:71823887	C11orf51	-0.72	-5.79	-0.35	2.08e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1443512	0.796	rs1822437	chr12:54340077	A/G	cg17410650	chr12:54324560	NA	0.43	5.33	0.32	2.21e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg14091149	chr1:16273971	ZBTB17	0.4	6.11	0.36	3.94e-9	Dilated cardiomyopathy;
KIRP	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1106684	0.925	rs59651443	chr7:131456486	C/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.71	-0.39	1.32e-10	Body mass index;
KIRP	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg19468946	chr17:37922297	IKZF3	-0.46	-6.54	-0.38	3.6e-10	Asthma;
KIRP	cis	rs9469913	0.675	rs6907508	chr6:34592090	A/G	cg14254433	chr6:34482411	PACSIN1	-0.6	-6.02	-0.36	6.37e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg01950434	chr2:97203154	ARID5A	0.57	7.0	0.41	2.43e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.77	-0.35	2.34e-8	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.56	7.56	0.43	8.17e-13	Blood metabolite levels;
KIRP	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs1050631	0.592	rs9958282	chr18:33710440	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.42	-5.5	-0.33	9.58e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.44	-0.47	2.79e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.53	6.12	0.36	3.73e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26314531	chr2:26401878	FAM59B	-0.47	-4.85	-0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg08198773	chr8:1697536	NA	0.4	5.18	0.31	4.6e-7	Systolic blood pressure;
KIRP	cis	rs681343	1.000	rs516246	chr19:49206172	C/T	cg04660111	chr19:49199234	FUT2	0.36	5.47	0.33	1.13e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs151997	0.671	rs27281	chr5:50200764	C/T	cg06027927	chr5:50259733	NA	0.54	7.37	0.43	2.56e-12	Callous-unemotional behaviour;
KIRP	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	0.64	8.13	0.46	2.15e-14	Red blood cell count;
KIRP	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.08	0.46	2.87e-14	Eosinophil percentage of white cells;
KIRP	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg16386425	chr10:429943	DIP2C	0.39	4.9	0.3	1.75e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.26	-0.37	1.71e-9	Monocyte percentage of white cells;
KIRP	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.6	6.98	0.41	2.78e-11	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.6	0.52	9.51e-19	Corneal astigmatism;
KIRP	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.51	5.91	0.35	1.16e-8	Parkinson's disease;
KIRP	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg12940923	chr8:10282607	MSRA	-0.4	-5.06	-0.31	8.21e-7	Neuroticism;
KIRP	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.29	0.47	7.23e-15	Personality dimensions;
KIRP	cis	rs6832769	1.000	rs6837710	chr4:56374455	C/T	cg05960024	chr4:56376020	CLOCK	0.7	8.76	0.49	3.22e-16	Personality dimensions;
KIRP	cis	rs2204008	0.526	rs2320448	chr12:38224180	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-5.89	-0.35	1.24e-8	Bladder cancer;
KIRP	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg12560992	chr17:57184187	TRIM37	0.61	5.52	0.33	8.6e-8	Cognitive test performance;
KIRP	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.7	6.9	0.4	4.31e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg06766960	chr11:133703094	NA	-0.56	-7.22	-0.42	6.28e-12	Childhood ear infection;
KIRP	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg06115741	chr20:33292138	TP53INP2	0.4	4.86	0.3	2.13e-6	Height;
KIRP	trans	rs76288851	0.799	rs73205613	chr3:126588176	G/A	cg13821433	chr2:26726535	OTOF	0.58	6.49	0.38	4.61e-10	Alcoholic chronic pancreatitis;
KIRP	trans	rs1106684	1.000	rs66792142	chr7:131457274	C/T	cg13607082	chr12:122652224	LRRC43	-0.64	-6.71	-0.39	1.32e-10	Body mass index;
KIRP	cis	rs13102973	0.931	rs13128765	chr4:135888141	A/G	cg14419869	chr4:135874104	NA	0.52	8.63	0.48	7.62e-16	Subjective well-being;
KIRP	trans	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg06521331	chr12:34319734	NA	-0.51	-6.16	-0.37	2.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg04321618	chr7:27170880	HOXA4	-0.35	-5.09	-0.31	7.05e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg13047869	chr3:10149882	C3orf24	0.52	4.91	0.3	1.63e-6	Alzheimer's disease;
KIRP	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg13798780	chr7:105162888	PUS7	0.64	5.76	0.34	2.55e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg09344028	chr17:70110421	NA	0.38	7.91	0.45	8.97e-14	Thyroid hormone levels;
KIRP	cis	rs6882046	0.513	rs254779	chr5:88019629	T/C	cg24804195	chr5:87968844	LOC645323	-0.48	-6.27	-0.37	1.63e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.49	-0.48	2e-15	Coronary artery disease;
KIRP	cis	rs7662987	0.793	rs4699700	chr4:99998335	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-5.58	-0.33	6.49e-8	Smoking initiation;
KIRP	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-10.02	-0.54	4.77e-20	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg12369402	chr1:90227771	NA	-0.46	-6.87	-0.4	5.27e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs16828019	0.929	rs111309254	chr1:41736000	A/G	cg03387723	chr1:41708464	SCMH1	-0.77	-6.8	-0.4	7.68e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	14.28	0.67	4.17e-34	Platelet count;
KIRP	cis	rs9400467	0.506	rs3204953	chr6:111628626	C/T	cg15721981	chr6:111408429	SLC16A10	0.77	7.11	0.41	1.29e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg00484396	chr16:3507460	NAT15	0.56	7.39	0.43	2.29e-12	Tuberculosis;
KIRP	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg04691961	chr3:161091175	C3orf57	-0.66	-10.97	-0.57	4.54e-23	Morning vs. evening chronotype;
KIRP	cis	rs9394841	0.692	rs9381094	chr6:41800629	T/C	cg08135965	chr6:41755394	TOMM6	0.52	5.55	0.33	7.51e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg18944383	chr4:111397179	ENPEP	0.39	6.33	0.37	1.12e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.37	-5.15	-0.31	5.32e-7	Blood metabolite levels;
KIRP	cis	rs1978968	0.763	rs13055106	chr22:18465208	G/A	cg03078520	chr22:18463400	MICAL3	-0.8	-10.08	-0.54	3.15e-20	Presence of antiphospholipid antibodies;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg04629194	chr10:97050357	PDLIM1	0.45	6.09	0.36	4.28e-9	Myopia (pathological);
KIRP	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	9.8	0.53	2.27e-19	Cognitive test performance;
KIRP	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg14456004	chr13:21872349	NA	-1.08	-13.59	-0.65	9.35e-32	White matter hyperintensity burden;
KIRP	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-0.73	-10.92	-0.57	6.84e-23	Prudent dietary pattern;
KIRP	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.45	5.76	0.34	2.45e-8	Recombination rate (males);
KIRP	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg27170947	chr2:26402098	FAM59B	-0.58	-6.5	-0.38	4.37e-10	Gut microbiome composition (summer);
KIRP	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg10518543	chr12:38710700	ALG10B	-0.4	-4.86	-0.3	2.13e-6	Morning vs. evening chronotype;
KIRP	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.62	7.1	0.41	1.31e-11	Height;
KIRP	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg00277334	chr10:82204260	NA	-0.46	-5.26	-0.32	3.11e-7	Post bronchodilator FEV1;
KIRP	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	cg12689670	chr1:183009347	LAMC1	0.42	5.89	0.35	1.28e-8	Colorectal cancer;
KIRP	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.05	11.84	0.6	6.77e-26	Vitiligo;
KIRP	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.89	6.64	0.39	2.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg00376283	chr12:123451042	ABCB9	-0.64	-7.38	-0.43	2.49e-12	Neutrophil percentage of white cells;
KIRP	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	5.11	0.31	6.56e-7	Neuroticism;
KIRP	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg23533419	chr12:54090519	NA	0.32	5.11	0.31	6.37e-7	Height;
KIRP	cis	rs17065868	1.000	rs17210766	chr13:45049002	C/G	cg10246903	chr13:45222710	NA	0.66	6.28	0.37	1.55e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.75	-10.53	-0.56	1.18e-21	Caffeine consumption;
KIRP	cis	rs1408799	0.549	rs2733830	chr9:12703359	A/T	cg05274944	chr9:12693694	TYRP1	0.46	7.0	0.41	2.45e-11	Eye color;Blue vs. green eyes;
KIRP	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg05676341	chr10:135206831	MTG1	0.8	4.88	0.3	1.93e-6	Lifespan;
KIRP	cis	rs3126085	0.515	rs1923503	chr1:152360820	G/A	cg26876637	chr1:152193138	HRNR	-0.54	-6.93	-0.4	3.6e-11	Atopic dermatitis;
KIRP	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.62	-0.44	5.5e-13	Height;
KIRP	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.69	9.55	0.52	1.4e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.67	10.17	0.54	1.61e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg19673125	chr6:150240577	RAET1G	0.21	4.87	0.3	2.02e-6	Testicular germ cell tumor;
KIRP	cis	rs9940149	1.000	rs9934398	chr16:300696	T/A	cg26484247	chr16:313425	ITFG3	0.44	5.02	0.3	1.01e-6	Type 2 diabetes;
KIRP	cis	rs2224391	0.590	rs2773312	chr6:5251798	C/T	cg13962347	chr6:5174647	LYRM4	-0.72	-10.18	-0.54	1.49e-20	Height;
KIRP	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg19901468	chr14:105411992	AHNAK2	0.71	10.88	0.57	9.43e-23	Rheumatoid arthritis;
KIRP	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-8.37	-0.47	4.36e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.65	-0.48	6.61e-16	Coronary artery disease;
KIRP	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.78	10.75	0.57	2.48e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg23791538	chr6:167370224	RNASET2	-0.48	-5.66	-0.34	4.3e-8	Crohn's disease;
KIRP	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.73	-11.67	-0.6	2.46e-25	Monocyte percentage of white cells;
KIRP	cis	rs6693567	0.565	rs1260398	chr1:150279876	T/C	cg09579323	chr1:150459698	TARS2	-0.4	-5.11	-0.31	6.54e-7	Migraine;
KIRP	cis	rs12718244	0.788	rs7811661	chr7:50188834	C/T	cg02697348	chr7:50199187	C7orf72	-0.39	-5.0	-0.3	1.07e-6	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg14664628	chr15:75095509	CSK	-0.65	-8.32	-0.47	6.02e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1850744	0.826	rs9291607	chr4:9708798	C/G	cg15442990	chr4:9534313	NA	-0.86	-7.01	-0.41	2.29e-11	Economic and political preferences;
KIRP	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg10047753	chr17:41438598	NA	1.12	17.22	0.74	4.01e-44	Menopause (age at onset);
KIRP	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg03959625	chr15:84868606	LOC388152	0.59	6.16	0.37	2.94e-9	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg04369109	chr6:150039330	LATS1	-0.58	-7.37	-0.43	2.6e-12	Lung cancer;
KIRP	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.72	8.6	0.48	9.7e-16	Mammographic density (dense area);
KIRP	cis	rs2279817	0.780	rs12737453	chr1:18006107	A/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.54	-0.48	1.38e-15	Neuroticism;
KIRP	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.71	0.53	4.35e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.71	-9.77	-0.53	2.88e-19	Bladder cancer;
KIRP	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.7	-7.44	-0.43	1.73e-12	Initial pursuit acceleration;
KIRP	cis	rs12282928	1.000	rs7949513	chr11:48329713	T/C	cg26585981	chr11:48327164	OR4S1	0.48	5.66	0.34	4.29e-8	Migraine - clinic-based;
KIRP	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg27462398	chr1:86174642	ZNHIT6	-0.53	-6.99	-0.41	2.58e-11	Urate levels in overweight individuals;
KIRP	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg05527609	chr1:210001259	C1orf107	-0.44	-5.37	-0.32	1.8e-7	Red blood cell count;
KIRP	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg06289844	chr6:126071538	HEY2	-0.35	-4.91	-0.3	1.66e-6	Endometrial cancer;
KIRP	cis	rs1874124	0.504	rs2491257	chr1:221029242	C/T	cg22888665	chr1:221052729	HLX	-0.51	-5.06	-0.31	8.35e-7	Cholesterol, total;
KIRP	cis	rs141670911	1	rs141670911	chr6:26581258	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	cis	rs1440410	0.798	rs1039763	chr4:144168013	C/A	cg01719995	chr4:144104893	USP38	0.41	5.54	0.33	7.88e-8	Ischemic stroke;
KIRP	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg24253500	chr15:84953950	NA	0.51	5.84	0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.81	-7.33	-0.42	3.38e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.41e-28	Breast cancer;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs1635	0.655	rs73742535	chr6:28302925	G/A	cg15743358	chr6:28303923	ZNF323	-0.9	-6.67	-0.39	1.65e-10	Schizophrenia;
KIRP	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.53	6.31	0.37	1.27e-9	Menarche (age at onset);
KIRP	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.71	-8.3	-0.47	6.96e-15	Body mass index;
KIRP	cis	rs4523957	0.855	rs12602764	chr17:2123200	A/T	cg16513277	chr17:2031491	SMG6	-0.68	-9.49	-0.52	2.13e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg02811702	chr13:24901961	NA	0.43	5.76	0.34	2.52e-8	Obesity-related traits;
KIRP	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	0.85	7.43	0.43	1.74e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg12311346	chr5:56204834	C5orf35	0.36	4.96	0.3	1.33e-6	Breast cancer;Breast cancer (early onset);
KIRP	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.55	7.39	0.43	2.25e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.41	-7.26	-0.42	5.01e-12	Refractive error;
KIRP	cis	rs3806843	0.569	rs753279	chr5:140023818	A/G	cg19875535	chr5:140030758	IK	-0.61	-8.77	-0.49	3.01e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2904967	0.778	rs689288	chr11:65118997	A/G	cg12562828	chr11:65076843	NA	-0.83	-10.73	-0.56	2.77e-22	Mean corpuscular volume;
KIRP	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.19	10.39	0.55	3.44e-21	Skin colour saturation;
KIRP	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg05775895	chr3:12838266	CAND2	0.46	7.59	0.44	6.73e-13	QRS complex (12-leadsum);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24513433	chr18:47088234	LIPG	0.46	6.48	0.38	4.85e-10	Parkinson's disease;
KIRP	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs4234798	0.500	rs7661077	chr4:7219889	C/T	cg18431297	chr4:7219810	SORCS2	0.67	8.99	0.5	6.98e-17	Insulin-like growth factors;
KIRP	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg11189052	chr15:85197271	WDR73	-0.49	-5.91	-0.35	1.15e-8	P wave terminal force;
KIRP	cis	rs17123764	0.818	rs7973389	chr12:49980745	T/C	cg02054252	chr12:50078554	FMNL3	0.43	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.07	-0.31	7.98e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs883565	0.606	rs6763607	chr3:39091596	C/G	cg01426195	chr3:39028469	NA	-0.65	-10.59	-0.56	7.78e-22	Handedness;
KIRP	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.38	6.52	0.38	3.93e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	7.92	0.45	8.36e-14	Schizophrenia;
KIRP	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg27490568	chr2:178487706	NA	0.46	6.08	0.36	4.45e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.37	5.92	0.35	1.07e-8	Electroencephalogram traits;
KIRP	cis	rs4363385	0.574	rs4041402	chr1:152947397	T/C	cg13444842	chr1:152974279	SPRR3	-0.49	-7.03	-0.41	1.97e-11	Inflammatory skin disease;
KIRP	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg21475434	chr5:93447410	FAM172A	0.69	5.17	0.31	4.89e-7	Diabetic retinopathy;
KIRP	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	trans	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs35110281	0.600	rs11089092	chr21:45120994	A/C	cg04455712	chr21:45112962	RRP1B	0.56	7.73	0.44	2.67e-13	Mean corpuscular volume;
KIRP	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.27	-0.37	1.64e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg06640241	chr16:89574553	SPG7	0.63	7.63	0.44	5.22e-13	Multiple myeloma (IgH translocation);
KIRP	cis	rs72634258	0.740	rs4489581	chr1:8174495	A/C	cg00042356	chr1:8021962	PARK7	-0.51	-5.05	-0.31	8.53e-7	Inflammatory bowel disease;
KIRP	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg02733842	chr7:1102375	C7orf50	-0.51	-5.58	-0.34	6.3e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	0.97	10.58	0.56	8.13e-22	Blood protein levels;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.8	14.13	0.67	1.41e-33	Height;
KIRP	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.43	-5.86	-0.35	1.5e-8	Monocyte count;
KIRP	cis	rs17221829	0.610	rs1844195	chr11:89389332	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs514024	0.729	rs3824523	chr9:130426944	T/G	cg13643465	chr9:130375613	STXBP1	0.44	5.48	0.33	1.08e-7	Eating disorders (purging via substances);
KIRP	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg01557791	chr16:72042693	DHODH	-0.4	-4.97	-0.3	1.23e-6	Fibrinogen levels;
KIRP	cis	rs1215050	0.791	rs968854	chr4:98837863	T/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg14820908	chr5:178986412	RUFY1	-0.48	-7.16	-0.42	9.03e-12	Lung cancer;
KIRP	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.44	6.16	0.37	2.87e-9	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06879219	chr14:70346082	SMOC1	-0.54	-6.72	-0.39	1.27e-10	Interleukin-4 levels;
KIRP	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-1.03	-7.55	-0.43	8.27e-13	Mitochondrial DNA levels;
KIRP	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.57	7.1	0.41	1.34e-11	Breast cancer;
KIRP	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27297192	chr10:134578999	INPP5A	0.61	7.64	0.44	4.88e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6681460	1.000	rs6588207	chr1:67066555	A/G	cg13052034	chr1:66999238	SGIP1	0.37	5.03	0.31	9.34e-7	Presence of antiphospholipid antibodies;
KIRP	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.26	0.42	5.06e-12	Morning vs. evening chronotype;
KIRP	cis	rs7998202	0.561	rs442098	chr13:113353032	C/A	cg02820901	chr13:113351484	ATP11A	0.59	5.54	0.33	7.58e-8	Glycated hemoglobin levels;
KIRP	cis	rs7187994	0.836	rs16974519	chr16:84782750	A/C	cg11201751	chr16:85158047	NA	0.47	4.86	0.3	2.1e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2296225	0.722	rs74840517	chr1:21049848	G/A	cg14666476	chr1:21112556	HP1BP3	0.7	6.51	0.38	4.16e-10	Eosinophilic esophagitis;
KIRP	cis	rs3026101	0.671	rs11868032	chr17:5283617	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.54	0.39	3.45e-10	Body mass index;
KIRP	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg06795125	chr2:108905320	SULT1C2	-0.46	-7.9	-0.45	9.38e-14	Blood pressure;
KIRP	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.15	15.16	0.69	4.11e-37	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.8	0.49	2.39e-16	Motion sickness;
KIRP	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.32	5.24	0.32	3.49e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4908768	0.535	rs2661868	chr1:8469789	C/T	cg03610117	chr1:8450231	RERE	-0.72	-8.99	-0.5	6.8e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg21573476	chr21:45109991	RRP1B	-0.65	-9.04	-0.5	4.71e-17	Mean corpuscular volume;
KIRP	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs259842	0.800	rs259833	chr2:180706328	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.37	-5.41	-0.33	1.5e-7	Blood protein levels;
KIRP	cis	rs7175404	0.938	rs8039312	chr15:94037596	G/A	cg23502883	chr15:93959149	NA	0.53	5.69	0.34	3.61e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs10486003	1.000	rs6967796	chr7:97221769	T/A	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.69	-5.27	-0.32	3.05e-7	Response to platinum-based agents;
KIRP	cis	rs526231	0.543	rs34784	chr5:102457330	G/C	cg23492399	chr5:102201601	PAM	-0.5	-5.52	-0.33	8.78e-8	Primary biliary cholangitis;
KIRP	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.8	-0.35	2e-8	Parkinson's disease;
KIRP	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12379764	chr21:47803548	PCNT	-0.46	-5.47	-0.33	1.12e-7	Testicular germ cell tumor;
KIRP	cis	rs7536700	0.642	rs35240348	chr1:153662340	G/A	cg08477332	chr1:153590243	S100A14	-0.78	-4.93	-0.3	1.5e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg00491522	chr10:135256596	NA	0.56	5.95	0.35	9.39e-9	Systemic lupus erythematosus;
KIRP	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg00784671	chr22:46762841	CELSR1	-0.88	-8.29	-0.47	7.24e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg07622451	chr1:3079886	PRDM16	0.37	5.31	0.32	2.45e-7	Migraine;
KIRP	cis	rs4664293	0.867	rs3771719	chr2:160630964	C/T	cg08347373	chr2:160653686	CD302	0.39	6.42	0.38	6.91e-10	Monocyte percentage of white cells;
KIRP	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg25174290	chr11:3078921	CARS	-0.57	-6.11	-0.36	3.92e-9	Calcium levels;
KIRP	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	ch.11.42038R	chr11:967971	AP2A2	0.46	6.04	0.36	5.72e-9	Alzheimer's disease (late onset);
KIRP	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.94	14.12	0.67	1.48e-33	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg10756647	chr7:56101905	PSPH	0.99	7.03	0.41	2.07e-11	Diabetic kidney disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07964097	chr12:131708081	NA	-0.44	-6.43	-0.38	6.53e-10	Survival in pancreatic cancer;
KIRP	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	0.69	9.64	0.52	7.11e-19	Cognitive test performance;
KIRP	cis	rs9972944	0.783	rs9972942	chr17:63771007	A/G	cg07283582	chr17:63770753	CCDC46	0.47	7.76	0.44	2.25e-13	Total body bone mineral density;
KIRP	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.64	8.16	0.46	1.78e-14	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg16736954	chr20:23401023	NAPB	0.63	4.96	0.3	1.3e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs981844	0.712	rs11099915	chr4:154743624	A/G	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.63	-6.64	-0.39	2.01e-10	DNA methylation (variation);
KIRP	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-5.48	-0.33	1.07e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg24375607	chr4:120327624	NA	0.49	5.77	0.35	2.4e-8	Corneal astigmatism;
KIRP	cis	rs34779708	0.931	rs4007289	chr10:35269790	G/A	cg03585969	chr10:35415529	CREM	0.78	9.56	0.52	1.24e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.83	12.27	0.62	2.56e-27	Eye color traits;
KIRP	trans	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17712092	chr4:129076599	LARP1B	-0.57	-6.45	-0.38	6.04e-10	Breast cancer;
KIRP	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.75	11.04	0.58	2.87e-23	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs13170463	0.649	rs13183531	chr5:8039213	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-4.92	-0.3	1.57e-6	Cognitive function;
KIRP	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2594989	0.943	rs4684070	chr3:11437551	A/G	cg01796438	chr3:11312864	ATG7	-0.65	-8.05	-0.46	3.6e-14	Circulating chemerin levels;
KIRP	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.47	6.89	0.4	4.75e-11	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	7.05e-13	Life satisfaction;
KIRP	cis	rs9652601	0.920	rs12923098	chr16:11177053	T/C	cg04616529	chr16:11181986	CLEC16A	0.37	4.85	0.3	2.15e-6	Systemic lupus erythematosus;
KIRP	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.51	6.57	0.39	2.91e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs2522056	1.000	rs2522062	chr5:131805416	A/G	cg07395648	chr5:131743802	NA	0.53	6.38	0.38	8.7e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs1010254	0.510	rs2881985	chr5:151700329	C/G	cg12297329	chr5:152029980	NA	0.64	6.56	0.39	3.14e-10	Optic nerve measurement (cup area);
KIRP	cis	rs3857067	1.000	rs6532463	chr4:95027048	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.1	-0.31	6.86e-7	QT interval;
KIRP	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.51	5.27	0.32	2.93e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs5753618	0.539	rs737888	chr22:31611549	A/G	cg02404636	chr22:31891804	SFI1	-0.47	-5.2	-0.31	4.22e-7	Colorectal cancer;
KIRP	cis	rs732716	0.853	rs62129349	chr19:4385659	A/G	cg03719555	chr19:4455413	UBXN6	0.51	7.71	0.44	3.06e-13	Mean corpuscular volume;
KIRP	cis	rs2250402	0.510	rs75578790	chr15:40332440	A/G	cg16127683	chr15:40268777	EIF2AK4	0.44	5.02	0.3	9.78e-7	Corneal curvature;
KIRP	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.63	8.69	0.48	5.1e-16	Mood instability;
KIRP	cis	rs4400599	1.000	rs4540651	chr1:154128672	G/A	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.36	-5.16	-0.31	5.09e-7	Platelet distribution width;
KIRP	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg23950597	chr19:37808831	NA	-0.86	-8.65	-0.48	6.98e-16	Coronary artery calcification;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.37	-5.42	-0.33	1.39e-7	Lymphocyte counts;
KIRP	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg13047869	chr3:10149882	C3orf24	0.56	5.24	0.32	3.46e-7	Alzheimer's disease;
KIRP	cis	rs27434	0.583	rs34762	chr5:96153966	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.15e-8	Ankylosing spondylitis;
KIRP	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg18709589	chr6:96969512	KIAA0776	0.34	5.05	0.31	8.41e-7	Headache;
KIRP	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg18306943	chr3:40428807	ENTPD3	0.41	5.62	0.34	5.1e-8	Renal cell carcinoma;
KIRP	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg19847130	chr8:10466454	RP1L1	-0.32	-4.89	-0.3	1.83e-6	Retinal vascular caliber;
KIRP	cis	rs1200921	0.642	rs1200821	chr10:37559580	A/G	cg00409905	chr10:38381863	ZNF37A	0.39	5.06	0.31	8.32e-7	Breast cancer;
KIRP	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.58	7.33	0.42	3.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.51	5.12	0.31	6.16e-7	Alzheimer's disease;
KIRP	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.05	0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg04656015	chr13:113407548	ATP11A	-0.49	-4.84	-0.3	2.25e-6	Glycated hemoglobin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06109664	chr4:99850540	EIF4E	0.44	6.63	0.39	2.13e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-5.03	-0.31	9.26e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25214090	chr10:38739885	LOC399744	0.59	7.51	0.43	1.06e-12	Corneal astigmatism;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg26649251	chr19:44598564	ZNF224	1.03	7.18	0.42	8.25e-12	P wave terminal force;
KIRP	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg06636001	chr8:8085503	FLJ10661	0.65	8.74	0.49	3.67e-16	Retinal vascular caliber;
KIRP	trans	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg06521331	chr12:34319734	NA	-0.53	-6.53	-0.38	3.81e-10	Heart rate;
KIRP	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg21775007	chr8:11205619	TDH	-0.4	-5.15	-0.31	5.47e-7	Neuroticism;
KIRP	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.56	-0.52	1.33e-18	Neuroticism;
KIRP	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg23894439	chr1:183413866	NA	-0.4	-5.21	-0.32	4.03e-7	Systemic lupus erythematosus;
KIRP	cis	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg00868766	chr15:40364524	NA	0.36	5.68	0.34	3.79e-8	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.95	-11.55	-0.59	6.08e-25	Alzheimer's disease;
KIRP	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg21926883	chr2:100939477	LONRF2	-0.64	-8.68	-0.48	5.55e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2562456	0.754	rs62107469	chr19:21495501	T/C	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs2411233	1.000	rs9920185	chr15:39273575	C/A	cg02291532	chr15:39874776	THBS1	0.41	5.46	0.33	1.13e-7	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20809997	chr1:19282380	IFFO2	0.49	6.06	0.36	5.18e-9	Parkinson's disease;
KIRP	cis	rs2718058	0.630	rs2718051	chr7:37824790	G/A	cg15028436	chr7:37888078	TXNDC3	0.46	4.92	0.3	1.62e-6	Alzheimer's disease (late onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg21603133	chr17:47022237	SNF8	-0.47	-6.38	-0.38	8.48e-10	Metabolic traits;
KIRP	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg19899395	chr1:46959349	NA	-0.48	-5.77	-0.35	2.42e-8	Monobrow;
KIRP	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.19	13.78	0.66	2.2e-32	Sexual dysfunction (female);
KIRP	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.72	-8.72	-0.49	4.18e-16	Breast cancer;
KIRP	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.98	-0.41	2.72e-11	Neuroticism;
KIRP	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg25019033	chr10:957182	NA	-0.6	-7.14	-0.41	1.03e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	trans	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg06521331	chr12:34319734	NA	-0.59	-7.25	-0.42	5.53e-12	Bladder cancer;
KIRP	cis	rs1190552	0.761	rs4900536	chr14:102862994	A/G	cg10241871	chr14:102965420	TECPR2	0.44	5.22	0.32	3.74e-7	Blood protein levels;
KIRP	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg16524936	chr4:1340807	KIAA1530	-0.45	-5.28	-0.32	2.83e-7	Obesity-related traits;
KIRP	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg14851346	chr12:38532713	NA	-0.42	-5.25	-0.32	3.21e-7	Bladder cancer;
KIRP	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg21573476	chr21:45109991	RRP1B	-0.64	-8.72	-0.49	4.2e-16	Mean corpuscular volume;
KIRP	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg00784671	chr22:46762841	CELSR1	-0.53	-6.33	-0.37	1.15e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7551222	0.789	rs2290855	chr1:204515863	C/T	cg20240347	chr1:204465584	NA	-0.44	-8.58	-0.48	1.09e-15	Schizophrenia;
KIRP	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-11.67	-0.6	2.53e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg06742321	chr12:123595122	PITPNM2	0.47	5.81	0.35	1.91e-8	Platelet count;
KIRP	cis	rs4566357	0.695	rs11892058	chr2:227951063	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-5.93	-0.35	1.04e-8	Coronary artery disease;
KIRP	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg23594656	chr7:65796392	TPST1	-0.52	-8.09	-0.46	2.75e-14	Aortic root size;
KIRP	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg25173405	chr17:45401733	C17orf57	0.42	5.37	0.32	1.79e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4936894	0.500	rs12283067	chr11:124070087	G/A	cg27160556	chr11:124181099	OR8D1	-0.39	-5.81	-0.35	1.89e-8	Aging (time to death);
KIRP	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg26754761	chr2:177040938	NA	-0.45	-7.69	-0.44	3.64e-13	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs4262150	0.804	rs4958316	chr5:151942251	C/A	cg12297329	chr5:152029980	NA	-0.59	-7.29	-0.42	4.17e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs11600901	1.000	rs611960	chr11:118034228	T/G	cg05416223	chr11:117947997	TMPRSS4	-0.45	-4.93	-0.3	1.48e-6	Preeclampsia;
KIRP	cis	rs8060686	0.920	rs2292316	chr16:67861134	C/G	cg04539111	chr16:67997858	SLC12A4	0.54	5.96	0.36	8.62e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs35771425	1.000	rs72743233	chr1:211556996	C/T	cg10512769	chr1:211675356	NA	-0.54	-5.24	-0.32	3.5e-7	Educational attainment (years of education);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23677990	chr8:74207183	RPL7;RDH10	0.57	7.07	0.41	1.59e-11	Parkinson's disease;
KIRP	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg20312557	chr2:97357134	FER1L5	-0.75	-5.14	-0.31	5.59e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs17065868	1.000	rs61948032	chr13:45199422	C/T	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs3218477	1.000	rs3218446	chr7:152362211	A/G	cg06618968	chr7:152373420	XRCC2	0.77	5.04	0.31	9.09e-7	Mean platelet volume;
KIRP	cis	rs4262150	0.810	rs72799113	chr5:152055862	G/T	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg12131826	chr15:77904385	NA	0.41	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs7870753	0.578	rs16910750	chr9:99084471	C/G	cg25260653	chr9:99212216	HABP4	0.54	4.97	0.3	1.24e-6	Height;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12006733	chr15:90177014	KIF7	0.44	6.05	0.36	5.31e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24729481	chr1:43833600	ELOVL1	0.5	6.32	0.37	1.2e-9	Parkinson's disease;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg18803535	chr1:92015933	NA	0.43	6.13	0.36	3.56e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-18.78	-0.77	2.02e-49	Ulcerative colitis;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	15.44	0.7	4.72e-38	Alzheimer's disease;
KIRP	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.71	8.83	0.49	2.05e-16	Resting heart rate;
KIRP	cis	rs4972806	0.739	rs10834	chr2:177042087	A/G	cg10304824	chr2:177028804	HOXD3	0.26	5.12	0.31	6.13e-7	IgG glycosylation;
KIRP	cis	rs9488822	0.623	rs195516	chr6:116241548	T/A	cg18764771	chr6:116381957	FRK	0.19	5.1	0.31	6.91e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	0.9	7.92	0.45	8.11e-14	Major depression and alcohol dependence;
KIRP	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.45	-4.89	-0.3	1.82e-6	Atrial fibrillation;
KIRP	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg17724175	chr1:150552817	MCL1	0.29	4.87	0.3	2.03e-6	Melanoma;
KIRP	cis	rs4728302	0.869	rs10224683	chr7:133590937	A/G	cg10665199	chr7:133106180	EXOC4	-0.43	-5.32	-0.32	2.31e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.69	9.69	0.53	5.08e-19	Retinal vascular caliber;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.68	-6.35	-0.38	1.01e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs959260	0.688	rs1369299	chr17:73347325	T/C	cg20590849	chr17:73267439	MIF4GD	-0.52	-5.23	-0.32	3.55e-7	Systemic lupus erythematosus;
KIRP	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg06289844	chr6:126071538	HEY2	0.45	6.81	0.4	7.52e-11	Brugada syndrome;
KIRP	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg00310523	chr12:86230176	RASSF9	0.42	6.45	0.38	5.83e-10	Major depressive disorder;
KIRP	cis	rs9324022	0.790	rs7156824	chr14:101171480	C/A	cg18089426	chr14:101175970	NA	0.62	5.61	0.34	5.4e-8	Plateletcrit;
KIRP	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.42	4.9	0.3	1.74e-6	Aortic root size;
KIRP	cis	rs867371	0.502	rs2047679	chr15:82531881	T/C	cg00614314	chr15:82944287	LOC80154	0.42	5.41	0.33	1.53e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2898290	0.512	rs899366	chr8:11430485	G/A	cg00405596	chr8:11794950	NA	0.44	5.61	0.34	5.33e-8	Systolic blood pressure;
KIRP	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	8.52	0.48	1.61e-15	Lung cancer in ever smokers;
KIRP	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Bipolar disorder;
KIRP	cis	rs7116495	0.609	rs17161751	chr11:71688347	G/A	cg18441811	chr11:71824068	C11orf51	0.76	5.01	0.3	1.05e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	6.4	0.38	7.88e-10	Bipolar disorder;
KIRP	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.52	6.82	0.4	7.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.87	0.49	1.55e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs2594989	1.000	rs388407	chr3:11320709	C/T	cg01796438	chr3:11312864	ATG7	-0.7	-8.03	-0.46	4.02e-14	Circulating chemerin levels;
KIRP	cis	rs5753618	0.509	rs5997912	chr22:31593861	A/G	cg02404636	chr22:31891804	SFI1	-0.48	-5.3	-0.32	2.54e-7	Colorectal cancer;
KIRP	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.82	11.58	0.59	4.91e-25	Breast cancer;
KIRP	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg26769984	chr7:1090371	C7orf50	0.66	6.32	0.37	1.21e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs675026	0.963	rs671531	chr6:154440742	A/G	cg07813322	chr6:154414604	OPRM1	-0.51	-6.71	-0.39	1.37e-10	Hypertension;
KIRP	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.93e-9	Breast cancer;
KIRP	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg20749741	chr2:264178	ACP1;SH3YL1	0.44	4.89	0.3	1.79e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg24579218	chr15:68104479	NA	-0.57	-9.2	-0.51	1.62e-17	Restless legs syndrome;
KIRP	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg23899408	chr19:12877188	HOOK2	-0.43	-5.17	-0.31	4.8e-7	Mean corpuscular volume;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.83	-15.42	-0.7	5.33e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3105593	0.933	rs3131588	chr15:50842052	G/T	cg05456662	chr15:50716270	USP8	0.38	5.06	0.31	8.37e-7	QT interval;
KIRP	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg03060546	chr3:49711283	APEH	-0.57	-4.85	-0.3	2.14e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	1.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg10434728	chr15:90938212	IQGAP1	-0.41	-7.63	-0.44	5.02e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.14	-0.41	1.06e-11	Aortic root size;
KIRP	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.78	-11.79	-0.6	9.89e-26	Educational attainment;
KIRP	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.46	-0.59	1.25e-24	Breast cancer;
KIRP	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg12861170	chr19:19639553	YJEFN3	-0.49	-5.07	-0.31	8e-7	Bipolar disorder;
KIRP	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.49	-6.95	-0.41	3.18e-11	Height;
KIRP	cis	rs1829883	0.835	rs2845982	chr5:98879638	C/A	cg08333243	chr5:99726346	NA	0.39	5.44	0.33	1.28e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.66	8.15	0.46	1.8e-14	Crohn's disease;
KIRP	cis	rs12949688	0.934	rs12449409	chr17:55822467	G/A	cg12582317	chr17:55822272	NA	0.63	10.56	0.56	9.6e-22	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17837792	chr4:83273357	NA	0.5	7.64	0.44	4.98e-13	Interleukin-4 levels;
KIRP	cis	rs7258465	0.965	rs2561043	chr19:18622683	A/T	cg06953865	chr19:18549723	ISYNA1	-0.36	-5.4	-0.33	1.59e-7	Breast cancer;
KIRP	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.42	5.35	0.32	2.06e-7	Aortic root size;
KIRP	cis	rs712039	0.652	rs17137970	chr17:35771826	C/T	cg16670864	chr17:35848621	DUSP14	0.43	5.32	0.32	2.33e-7	Tuberculosis;
KIRP	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.17	0.31	4.96e-7	Asthma (childhood onset);
KIRP	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	10.17	0.54	1.63e-20	Birth weight;
KIRP	cis	rs4713118	0.662	rs149901	chr6:27965503	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.45	-5.01	-0.3	1.04e-6	Parkinson's disease;
KIRP	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.76	-9.48	-0.52	2.3e-18	Coronary artery disease;
KIRP	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	8.1	0.46	2.64e-14	Coffee consumption (cups per day);
KIRP	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg13409248	chr3:40428643	ENTPD3	0.41	5.56	0.33	7.04e-8	Renal cell carcinoma;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06713199	chr3:28390809	AZI2	0.56	6.1	0.36	4.09e-9	Lung cancer in ever smokers;
KIRP	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg18904891	chr8:8559673	CLDN23	0.7	7.89	0.45	9.86e-14	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs2859741	0.608	rs480411	chr1:37476077	T/C	cg04172795	chr14:100578523	EVL	-0.47	-6.39	-0.38	8.28e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs73198271	0.694	rs115037021	chr8:8647080	A/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.63	8.29	0.47	7.63e-15	Obesity-related traits;
KIRP	cis	rs8060686	0.591	rs255054	chr16:68017356	A/G	cg04539111	chr16:67997858	SLC12A4	-0.49	-5.15	-0.31	5.27e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.51	-6.69	-0.39	1.46e-10	Childhood ear infection;
KIRP	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.7	-8.87	-0.49	1.56e-16	Response to temozolomide;
KIRP	cis	rs7662987	0.793	rs12106	chr4:99993350	A/G	cg13256891	chr4:100009986	ADH5	-0.65	-5.59	-0.34	5.93e-8	Smoking initiation;
KIRP	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg02404636	chr22:31891804	SFI1	-0.49	-5.42	-0.33	1.4e-7	Colorectal cancer;
KIRP	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg24289452	chr6:170231220	NA	-0.52	-6.85	-0.4	5.88e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs311392	0.966	rs404354	chr8:55087196	A/G	cg11783602	chr8:55087084	NA	-0.59	-7.34	-0.42	3.11e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs793571	0.566	rs610877	chr15:59103328	C/A	cg05156742	chr15:59063176	FAM63B	0.58	7.32	0.42	3.52e-12	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20773729	chr13:50265533	EBPL	0.47	6.04	0.36	5.8e-9	Parkinson's disease;
KIRP	trans	rs12043259	0.803	rs16854533	chr1:204821164	G/A	cg11485465	chr5:54518469	NA	0.38	6.15	0.37	3.09e-9	Addiction;
KIRP	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs10489202	0.908	rs6692861	chr1:168079553	G/C	cg24449463	chr1:168025552	DCAF6	-0.43	-5.01	-0.3	1.06e-6	Schizophrenia;
KIRP	cis	rs10849605	0.737	rs6489769	chr12:1072965	C/T	cg02055889	chr12:1059459	RAD52	0.59	8.2	0.46	1.3e-14	Lung cancer;
KIRP	trans	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg16141378	chr3:129829833	LOC729375	0.53	6.56	0.39	3.12e-10	Mood instability;
KIRP	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.71	-7.53	-0.43	9.68e-13	Blood pressure (smoking interaction);
KIRP	cis	rs501120	0.925	rs1746049	chr10:44776310	C/T	cg09554077	chr10:44749378	NA	0.67	9.81	0.53	2.16e-19	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2929278	0.617	rs11070410	chr15:44057045	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.52	-6.29	-0.37	1.46e-9	Schizophrenia;
KIRP	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08439880	chr3:133502540	NA	-0.46	-5.42	-0.33	1.41e-7	Iron status biomarkers;
KIRP	cis	rs8060686	0.858	rs2271294	chr16:67902326	A/T	cg04539111	chr16:67997858	SLC12A4	-0.45	-5.2	-0.31	4.26e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.75	9.4	0.51	4.04e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg05784532	chr1:230284198	GALNT2	0.42	6.35	0.38	1.05e-9	Coronary artery disease;
KIRP	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	9.76	0.53	3.03e-19	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	0.35	4.97	0.3	1.23e-6	Lymphocyte counts;
KIRP	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-10.69	-0.56	3.64e-22	Triglycerides;
KIRP	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.48	6.91	0.4	4.06e-11	Testicular germ cell tumor;
KIRP	cis	rs11967485	0.534	rs62435817	chr6:157154688	A/G	cg23222435	chr6:157204239	ARID1B	-0.68	-4.91	-0.3	1.67e-6	Calcium levels;
KIRP	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.97	9.52	0.52	1.73e-18	Eosinophilic esophagitis;
KIRP	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-1.05	-20.17	-0.79	4.72e-54	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6429082	0.509	rs2789362	chr1:235521235	A/G	cg26050004	chr1:235667680	B3GALNT2	0.39	4.88	0.3	1.93e-6	Adiposity;
KIRP	cis	rs3120667	0.790	rs3753444	chr1:152387867	C/G	cg26876637	chr1:152193138	HRNR	-0.5	-5.25	-0.32	3.3e-7	Eating disorders;
KIRP	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs1440410	0.535	rs10015279	chr4:144041025	A/G	cg01719995	chr4:144104893	USP38	0.45	5.96	0.36	8.79e-9	Ischemic stroke;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03255942	chr1:24979088	SRRM1	-0.45	-6.41	-0.38	7.32e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs400736	0.655	rs55634431	chr1:8149549	G/A	cg25007680	chr1:8021821	PARK7	-0.53	-6.93	-0.4	3.65e-11	Response to antidepressants and depression;
KIRP	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-5.37	-0.32	1.86e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg07884673	chr3:53033167	SFMBT1	0.92	6.93	0.4	3.64e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.58	-6.7	-0.39	1.38e-10	Menopause (age at onset);
KIRP	cis	rs300890	0.513	rs10005340	chr4:144043631	A/T	cg01719995	chr4:144104893	USP38	0.44	5.71	0.34	3.26e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.79	-0.49	2.67e-16	Mean corpuscular volume;
KIRP	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.56	8.94	0.5	9.69e-17	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg07701084	chr6:150067640	NUP43	0.74	10.22	0.55	1.12e-20	Lung cancer;
KIRP	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-5.68	-0.34	3.73e-8	Schizophrenia;
KIRP	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.84	-0.35	1.66e-8	Crohn's disease;
KIRP	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.68	10.14	0.54	2.1e-20	Retinal vascular caliber;
KIRP	cis	rs7916697	0.540	rs4551651	chr10:70024529	A/G	cg06988349	chr10:69991859	ATOH7	0.38	4.9	0.3	1.74e-6	Optic disc area;
KIRP	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg16486109	chr11:613632	IRF7	0.43	5.34	0.32	2.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.8	11.3	0.58	3.99e-24	Mean platelet volume;
KIRP	cis	rs12476592	0.543	rs12105140	chr2:63797218	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.93	-0.3	1.52e-6	Childhood ear infection;
KIRP	cis	rs78487399	0.808	rs6751161	chr2:43752548	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-5.12	-0.31	6.19e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.26	-4.96	-0.3	1.3e-6	Oropharynx cancer;
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg00684032	chr4:1343700	KIAA1530	0.53	6.67	0.39	1.64e-10	Longevity;
KIRP	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg04935436	chr20:30431758	NA	0.48	5.86	0.35	1.48e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-0.98	-11.4	-0.59	1.9e-24	Vitiligo;
KIRP	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs2591576	0.789	rs830231	chr5:165403406	A/T	cg13976338	chr5:165423657	NA	-0.7	-10.43	-0.55	2.58e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg04731861	chr2:219085781	ARPC2	0.28	7.2	0.42	7.5e-12	Colorectal cancer;
KIRP	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.82	7.08	0.41	1.54e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs17030434	0.822	rs28367474	chr4:154718642	A/G	cg14289246	chr4:154710475	SFRP2	-0.64	-8.01	-0.45	4.64e-14	Electrocardiographic conduction measures;
KIRP	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.36	5.09	0.31	7.25e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs10814247	0.730	rs2381302	chr9:35235820	A/C	cg15271616	chr9:35490515	RUSC2	-0.4	-5.63	-0.34	5.02e-8	Psoriasis;
KIRP	cis	rs1971256	0.500	rs3912290	chr6:151818297	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-6.4	-0.38	7.9e-10	Endometriosis;
KIRP	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.06	0.5	4.31e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1345301	0.518	rs1558623	chr2:102862402	T/A	cg12451869	chr2:102867685	NA	0.46	6.7	0.39	1.42e-10	Waist circumference;
KIRP	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg02073558	chr3:44770973	ZNF501	0.61	8.65	0.48	6.86e-16	Depressive symptoms;
KIRP	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	cg07049167	chr1:166818506	POGK	0.57	6.5	0.38	4.55e-10	Refractive astigmatism;
KIRP	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.05	-0.31	8.42e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg08461772	chr7:95026248	PON3	0.43	5.9	0.35	1.2e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs73200209	0.744	rs11615595	chr12:116470876	T/C	cg01776926	chr12:116560359	MED13L	-0.56	-6.21	-0.37	2.29e-9	Total body bone mineral density;
KIRP	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg03713592	chr11:72463424	ARAP1	1.05	9.12	0.5	2.69e-17	Type 2 diabetes;
KIRP	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.69	6.47	0.38	5.14e-10	Platelet count;
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg23985595	chr17:80112537	CCDC57	0.37	5.54	0.33	7.67e-8	Life satisfaction;
KIRP	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.51	8.28	0.47	8.11e-15	Monocyte count;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg13837097	chr14:55034666	SAMD4A	0.45	6.05	0.36	5.34e-9	Coronary artery disease;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg15563952	chr10:12110679	DHTKD1	0.51	6.08	0.36	4.46e-9	Beard thickness;
KIRP	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.87	11.48	0.59	1.06e-24	Monocyte count;
KIRP	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-13.28	-0.65	1.06e-30	Vitiligo;
KIRP	cis	rs7792596	0.894	rs6948901	chr7:93977748	T/C	cg20814616	chr7:94014465	NA	-0.3	-5.01	-0.3	1.02e-6	Intelligence;
KIRP	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.49	5.5	0.33	9.72e-8	Diisocyanate-induced asthma;
KIRP	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg05991184	chr2:219186017	PNKD	0.36	4.98	0.3	1.22e-6	Colorectal cancer;
KIRP	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg07274523	chr3:49395745	GPX1	0.7	8.26	0.47	8.75e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25517755	chr10:38738941	LOC399744	-0.5	-6.85	-0.4	5.95e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs4409675	0.913	rs61789696	chr1:28258905	G/A	cg23691781	chr1:28212827	C1orf38	0.34	5.93	0.35	1.04e-8	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16654851	chr7:148725968	PDIA4	0.49	6.33	0.37	1.18e-9	Parkinson's disease;
KIRP	trans	rs6601327	0.665	rs4841218	chr8:9653902	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.55	-0.43	8.54e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.53	6.55	0.39	3.4e-10	Body mass index;
KIRP	cis	rs2281603	0.951	rs10138256	chr14:64995212	T/C	cg25009451	chr14:65006716	HSPA2	0.48	5.2	0.31	4.12e-7	Lymphocyte counts;
KIRP	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.66	-9.29	-0.51	8.3e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs11650494	0.516	rs117384420	chr17:47505383	G/C	cg08112188	chr17:47440006	ZNF652	0.91	6.01	0.36	6.81e-9	Prostate cancer;
KIRP	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.83	-11.77	-0.6	1.12e-25	Headache;
KIRP	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs11955175	0.717	rs41271053	chr5:40835393	A/C	cg04002187	chr5:40835754	RPL37	0.74	5.5	0.33	9.7e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg07859478	chr19:808116	PTBP1	-0.71	-6.03	-0.36	5.89e-9	Hirschsprung disease;
KIRP	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-4.95	-0.3	1.35e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs35000415	0.688	rs13232316	chr7:128715299	A/T	cg19972273	chr7:128594194	NA	0.59	5.0	0.3	1.09e-6	Systemic lupus erythematosus;
KIRP	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.49	7.21	0.42	6.89e-12	Urate levels in lean individuals;
KIRP	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	15.19	0.7	3.32e-37	Platelet count;
KIRP	cis	rs9473924	0.542	rs2857506	chr6:50800308	C/T	cg14470998	chr6:50812995	TFAP2B	0.95	8.76	0.49	3.31e-16	Body mass index;
KIRP	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.76	-8.21	-0.46	1.25e-14	Obesity-related traits;
KIRP	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.74	11.11	0.58	1.68e-23	Blood metabolite levels;
KIRP	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg21775007	chr8:11205619	TDH	-0.45	-6.02	-0.36	6.34e-9	Triglycerides;
KIRP	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs2329775	0.534	rs2329772	chr7:40476625	C/T	cg00420559	chr7:40367873	C7orf10	-0.37	-5.11	-0.31	6.63e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2071426	0.622	rs7909806	chr10:96762439	G/A	cg09036531	chr10:96991505	NA	-0.46	-5.39	-0.33	1.63e-7	Blood metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23568334	chr11:129079485	NA	-0.45	-7.53	-0.43	9.75e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.81	12.83	0.63	3.41e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg19731401	chr7:2775893	GNA12	0.66	6.31	0.37	1.27e-9	Childhood ear infection;
KIRP	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg11344533	chr11:111475393	SIK2	0.29	4.97	0.3	1.24e-6	Primary sclerosing cholangitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03503802	chr22:46933237	CELSR1	0.44	6.03	0.36	5.85e-9	Parkinson's disease;
KIRP	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.09	0.31	6.99e-7	Parkinson's disease;
KIRP	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg20731937	chr12:48336164	NA	-0.35	-4.9	-0.3	1.78e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2274273	0.967	rs10137409	chr14:55611441	A/C	cg04306507	chr14:55594613	LGALS3	0.47	7.26	0.42	5.04e-12	Protein biomarker;
KIRP	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.47	5.85	0.35	1.54e-8	Common traits (Other);
KIRP	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.62	-0.39	2.22e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg27129171	chr3:47204927	SETD2	0.63	8.12	0.46	2.19e-14	Granulocyte count;Sum neutrophil eosinophil counts;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg26134248	chr17:3907702	NA	0.55	8.16	0.46	1.69e-14	Type 2 diabetes;
KIRP	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs10266483	0.843	rs10272639	chr7:63739322	T/C	cg04636841	chr7:63768139	NA	-0.41	-5.38	-0.32	1.77e-7	Response to statin therapy;
KIRP	cis	rs240110	0.525	rs6917195	chr6:101277926	C/T	cg09795085	chr6:101329169	ASCC3	0.46	5.3	0.32	2.56e-7	Neuroticism;
KIRP	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.36	5.57	0.33	6.83e-8	Multiple sclerosis;
KIRP	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.73	9.58	0.52	1.11e-18	Eye color traits;
KIRP	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-1.18	-9.85	-0.53	1.64e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg03653399	chr8:142233436	SLC45A4	-0.94	-14.76	-0.69	9.47e-36	Immature fraction of reticulocytes;
KIRP	cis	rs1076160	0.846	rs4962220	chr9:135713036	G/A	cg04648087	chr9:135819397	TSC1	-0.39	-4.86	-0.3	2.13e-6	Psoriasis;
KIRP	cis	rs1021993	0.545	rs6681466	chr1:209529258	G/T	cg24446417	chr1:209558027	NA	-0.46	-5.43	-0.33	1.34e-7	Gut microbiome composition (winter);
KIRP	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.34	-0.47	5.37e-15	Total cholesterol levels;
KIRP	cis	rs2299587	0.762	rs62500086	chr8:17787808	T/A	cg01800426	chr8:17659068	MTUS1	-0.4	-4.93	-0.3	1.53e-6	Economic and political preferences;
KIRP	cis	rs9400467	0.537	rs9647629	chr6:111501484	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs6601327	0.613	rs12677507	chr8:9481687	G/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.13	-0.36	3.43e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg02991063	chr10:120938274	PRDX3	-0.48	-6.18	-0.37	2.59e-9	Blood metabolite levels;
KIRP	cis	rs981844	0.712	rs6535956	chr4:154746001	G/A	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.47	0.38	5.31e-10	Birth weight;
KIRP	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg23307798	chr14:103986281	CKB	-0.51	-6.91	-0.4	4.21e-11	Coronary artery disease;
KIRP	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.55	7.3	0.42	4.04e-12	Red blood cell count;
KIRP	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg05973401	chr12:123451056	ABCB9	-0.5	-5.51	-0.33	8.97e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg02023728	chr11:77925099	USP35	-0.34	-5.12	-0.31	6.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg15676125	chr6:33679581	C6orf125	0.42	5.71	0.34	3.17e-8	Height;
KIRP	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.66	6.91	0.4	4.14e-11	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	cis	rs240764	0.658	rs9322183	chr6:101225121	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-4.87	-0.3	2.03e-6	Neuroticism;
KIRP	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg04310649	chr10:35416472	CREM	0.57	6.8	0.4	8.09e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.54	-6.34	-0.37	1.07e-9	Aortic root size;
KIRP	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs981844	0.712	rs1037650	chr4:154737657	G/A	cg14289246	chr4:154710475	SFRP2	-0.54	-7.06	-0.41	1.74e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg11569703	chr11:65557185	OVOL1	0.5	7.56	0.43	7.9e-13	Breast cancer;
KIRP	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.81	-11.7	-0.6	1.96e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg17574911	chr8:145726688	PPP1R16A	-0.26	-4.91	-0.3	1.67e-6	Age at first birth;
KIRP	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg24253500	chr15:84953950	NA	0.7	8.14	0.46	2e-14	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.91	-0.35	1.14e-8	Breast cancer;
KIRP	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg05347473	chr6:146136440	FBXO30	-0.59	-8.46	-0.47	2.34e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg09256556	chr8:142187200	DENND3	-0.41	-6.05	-0.36	5.31e-9	Bladder cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06009330	chr2:70485380	PCYOX1	0.5	6.78	0.4	8.68e-11	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.41e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs977987	0.864	rs37595	chr16:75496963	G/C	cg03315344	chr16:75512273	CHST6	-0.69	-10.39	-0.55	3.43e-21	Dupuytren's disease;
KIRP	cis	rs7267005	0.661	rs17093086	chr20:34373661	T/C	cg17201900	chr20:34330562	RBM39	0.9	5.02	0.3	1e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12850832	chr2:27309063	KHK;EMILIN1	0.47	6.47	0.38	5.38e-10	Parkinson's disease;
KIRP	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg17764715	chr19:33622953	WDR88	-0.67	-8.39	-0.47	3.82e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1030268	0.577	rs13244007	chr7:133260825	A/G	cg10665199	chr7:133106180	EXOC4	0.58	5.73	0.34	2.89e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg06307176	chr5:131281290	NA	0.57	6.41	0.38	7.48e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.75	11.31	0.58	3.75e-24	Blood metabolite ratios;
KIRP	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.91	-0.64	1.86e-29	Exhaled nitric oxide output;
KIRP	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-6.79	-0.4	8.2e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.53	6.08	0.36	4.47e-9	Mean arterial pressure;
KIRP	cis	rs1355223	0.867	rs1869360	chr11:34698590	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-5.4	-0.33	1.58e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs6601327	0.600	rs10103925	chr8:9652211	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.56	-0.43	7.82e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs753955	0.567	rs11617286	chr13:24409348	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.44	-5.73	-0.34	2.92e-8	Lung cancer;
KIRP	cis	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.59	-0.34	5.9e-8	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09373875	chr4:159182779	NA	0.39	6.27	0.37	1.61e-9	C-reactive protein;
KIRP	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.43	5.1	0.31	6.77e-7	Airway imaging phenotypes;
KIRP	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.58	-7.09	-0.41	1.42e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1823913	0.599	rs1454754	chr2:192168288	G/C	cg12404831	chr2:192114017	MYO1B	0.54	7.55	0.43	8.62e-13	Obesity-related traits;
KIRP	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.83	14.93	0.69	2.63e-36	Body mass index;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg10254082	chr7:997346	NA	0.47	4.99	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23386594	chr11:6866523	OR10A5	0.44	6.54	0.38	3.56e-10	Interleukin-4 levels;
KIRP	cis	rs926938	0.606	rs6537844	chr1:115289295	G/A	cg12756093	chr1:115239321	AMPD1	-0.63	-8.41	-0.47	3.35e-15	Autism;
KIRP	cis	rs2820315	1.000	rs1400875	chr1:201821443	T/C	cg11586189	chr1:201857591	SHISA4	-0.39	-5.46	-0.33	1.14e-7	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.57	0.52	1.21e-18	Coffee consumption (cups per day);
KIRP	cis	rs832540	0.519	rs6895442	chr5:56260998	T/C	cg12311346	chr5:56204834	C5orf35	-0.41	-5.43	-0.33	1.32e-7	Coronary artery disease;
KIRP	cis	rs4236601	0.720	rs7811851	chr7:116156731	A/T	cg12739419	chr7:116140593	CAV2	0.44	5.47	0.33	1.11e-7	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21747090	chr2:27597821	SNX17	-0.47	-6.44	-0.38	6.14e-10	Total body bone mineral density;
KIRP	cis	rs2034650	0.544	rs2289331	chr15:40699940	T/C	cg08996748	chr15:40651036	DISP2	-0.36	-5.21	-0.32	3.91e-7	Interstitial lung disease;
KIRP	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.97e-7	Bladder cancer;
KIRP	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg10047753	chr17:41438598	NA	1.11	17.42	0.74	7.78e-45	Menopause (age at onset);
KIRP	cis	rs4660306	0.614	rs12032658	chr1:45923851	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	6.23	0.37	2.06e-9	Homocysteine levels;
KIRP	cis	rs10073892	0.957	rs10479209	chr5:101701640	A/T	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.96e-11	Cognitive decline (age-related);
KIRP	cis	rs10924309	0.889	rs884987	chr1:245860076	G/C	cg00036263	chr1:245852353	KIF26B	-0.5	-6.53	-0.38	3.79e-10	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg23625390	chr15:77176239	SCAPER	0.54	6.94	0.4	3.48e-11	Blood metabolite levels;
KIRP	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.66	8.99	0.5	6.57e-17	Obesity-related traits;
KIRP	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg15247329	chr7:2764246	NA	-0.35	-5.01	-0.3	1.05e-6	Height;
KIRP	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6142102	0.961	rs1055857	chr20:32613873	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	6.81	0.4	7.31e-11	Skin pigmentation;
KIRP	cis	rs12620999	0.941	rs10929213	chr2:238020637	A/G	cg23555395	chr2:238036564	NA	-0.5	-5.75	-0.34	2.62e-8	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.72	-11.82	-0.6	8.19e-26	Itch intensity from mosquito bite;
KIRP	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.58	6.72	0.39	1.25e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.22	0.61	3.66e-27	Bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg26743569	chr2:25194997	DNAJC27	0.58	6.7	0.39	1.4e-10	Smoking initiation;
KIRP	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.77	-9.11	-0.5	3.01e-17	Pancreatic cancer;
KIRP	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.64	5.74	0.34	2.71e-8	Diabetic retinopathy;
KIRP	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg21132104	chr15:45694354	SPATA5L1	0.76	9.54	0.52	1.52e-18	Homoarginine levels;
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg14338887	chr6:42928500	GNMT	0.49	7.31	0.42	3.71e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg18825076	chr15:78729989	IREB2	0.41	4.94	0.3	1.42e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.33	6.06	0.36	5.21e-9	Renal cell carcinoma;
KIRP	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg16141378	chr3:129829833	LOC729375	0.51	6.63	0.39	2.14e-10	Neuroticism;
KIRP	cis	rs2916247	0.909	rs13259499	chr8:93057823	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.54	-6.83	-0.4	6.69e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.67	6.73	0.39	1.18e-10	Bronchopulmonary dysplasia;
KIRP	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.66	8.04	0.46	3.86e-14	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg02570527	chr1:10970165	NA	-0.42	-5.2	-0.31	4.1e-7	Body mass index;
KIRP	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04232466	chr8:21988724	HR	-0.43	-6.07	-0.36	4.87e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08418172	chr19:55791495	HSPBP1	0.46	6.16	0.37	3e-9	Parkinson's disease;
KIRP	cis	rs11673344	0.832	rs8104296	chr19:37516536	G/A	cg14683738	chr19:37701593	ZNF585B	-0.43	-4.92	-0.3	1.59e-6	Obesity-related traits;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-9.86	-0.53	1.56e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg26513180	chr16:89883248	FANCA	0.86	5.77	0.35	2.37e-8	Skin colour saturation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16315668	chr3:123676816	CCDC14	-0.42	-6.47	-0.38	5.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7010267	0.562	rs3134058	chr8:119954108	C/T	cg13459393	chr19:53326091	ZNF28	0.5	6.06	0.36	5.03e-9	Total body bone mineral density (age 45-60);
KIRP	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12826209	chr6:26865740	GUSBL1	0.67	6.41	0.38	7.44e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs741677	0.826	rs12938729	chr17:475780	T/C	cg06217071	chr17:408420	NA	0.52	7.46	0.43	1.52e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg12369402	chr1:90227771	NA	0.36	5.22	0.32	3.83e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg23283320	chr21:48055893	PRMT2	1.36	8.49	0.48	1.98e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs1712517	0.835	rs2506961	chr10:105007926	G/T	cg05636881	chr10:105038444	INA	-0.4	-5.93	-0.35	1.03e-8	Migraine;
KIRP	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.81	11.38	0.59	2.2e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg22800045	chr5:56110881	MAP3K1	0.76	7.39	0.43	2.28e-12	Initial pursuit acceleration;
KIRP	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	0.84	14.15	0.67	1.13e-33	Vitiligo;
KIRP	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg19875535	chr5:140030758	IK	0.64	8.78	0.49	2.77e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg00262122	chr8:11665843	FDFT1	0.44	5.52	0.33	8.67e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05976516	chr16:53269100	CHD9	-0.41	-6.13	-0.36	3.4e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg19894588	chr14:64061835	NA	-0.48	-6.48	-0.38	4.98e-10	Fat distribution (HIV);
KIRP	cis	rs34779708	0.733	rs7914560	chr10:35548099	G/A	cg03585969	chr10:35415529	CREM	0.56	6.56	0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	7.29	0.42	4.1e-12	Eosinophil percentage of white cells;
KIRP	cis	rs3733418	0.929	rs12512234	chr4:165908865	C/T	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.02	-0.3	9.85e-7	Obesity-related traits;
KIRP	cis	rs7180079	0.563	rs10468032	chr15:64702168	G/A	cg15337035	chr15:64978493	NA	-0.47	-5.1	-0.31	6.87e-7	Monocyte count;
KIRP	cis	rs7833986	1.000	rs35883156	chr8:57078933	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	5.11	0.31	6.51e-7	Height;
KIRP	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg14664628	chr15:75095509	CSK	0.57	6.14	0.36	3.3e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs6142102	0.602	rs4911396	chr20:32579945	C/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.76	0.34	2.55e-8	Skin pigmentation;
KIRP	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	4.99	0.3	1.14e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs55962025	0.686	rs110501	chr4:3225478	A/G	cg06533319	chr4:3265114	C4orf44	0.43	5.53	0.33	8.19e-8	Parental longevity (mother's age at death);
KIRP	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg21890820	chr11:65308645	LTBP3	-0.57	-5.6	-0.34	5.83e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs7572644	0.713	rs35841453	chr2:28072702	T/C	cg27432699	chr2:27873401	GPN1	0.45	5.01	0.3	1.06e-6	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg14768367	chr16:72042858	DHODH	0.45	5.5	0.33	9.51e-8	Fibrinogen levels;
KIRP	cis	rs77372450	0.636	rs6877434	chr5:157028947	A/C	cg23851860	chr5:157002805	ADAM19	-0.46	-5.06	-0.31	8.13e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs236907	0.859	rs12565176	chr1:171736641	A/G	cg01410279	chr1:171621941	MYOC	-0.53	-5.33	-0.32	2.28e-7	Mean platelet volume;
KIRP	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.23	-16.96	-0.73	2.94e-43	Type 1 diabetes nephropathy;
KIRP	cis	rs490234	0.783	rs2416967	chr9:128440014	T/C	cg14078157	chr9:128172775	NA	-0.56	-6.64	-0.39	2.04e-10	Mean arterial pressure;
KIRP	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg23594656	chr7:65796392	TPST1	-0.44	-6.96	-0.41	3.16e-11	Aortic root size;
KIRP	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg21698718	chr17:80085957	CCDC57	0.36	5.37	0.32	1.81e-7	Life satisfaction;
KIRP	cis	rs6102059	0.525	rs4810296	chr20:39192317	A/G	cg06665391	chr20:39312290	NA	-0.46	-5.77	-0.35	2.35e-8	LDL cholesterol;
KIRP	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.99	-0.36	7.21e-9	Obesity-related traits;
KIRP	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12446151	chr22:50846837	SAPS2	0.44	6.24	0.37	1.86e-9	Survival in pancreatic cancer;
KIRP	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.72	-8.7	-0.49	4.8e-16	Cognitive test performance;
KIRP	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg26384229	chr12:38710491	ALG10B	-0.68	-9.27	-0.51	9.67e-18	Morning vs. evening chronotype;
KIRP	cis	rs6088813	0.677	rs6088833	chr20:34007663	T/A	cg14752227	chr20:34000481	UQCC	0.46	5.15	0.31	5.34e-7	Height;
KIRP	trans	rs11875537	0.867	rs622943	chr18:2299472	A/T	cg16108132	chr10:75174197	ANXA7	-0.45	-6.09	-0.36	4.24e-9	Brain volume in infants (cerebrospinal fluid);
KIRP	cis	rs9296736	0.885	rs9349693	chr6:53939724	A/G	cg04374786	chr6:53939321	C6orf142	0.42	5.59	0.34	6e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.86	13.22	0.64	1.71e-30	Blood protein levels;
KIRP	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg10755058	chr3:40428713	ENTPD3	-0.4	-5.7	-0.34	3.42e-8	Renal cell carcinoma;
KIRP	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.65	9.66	0.52	6.41e-19	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg01879757	chr17:41196368	BRCA1	-0.78	-10.79	-0.57	1.84e-22	Menopause (age at onset);
KIRP	cis	rs55728055	0.661	rs62237845	chr22:32027892	G/A	cg01338084	chr22:32026380	PISD	1.02	6.35	0.38	1.01e-9	Age-related hearing impairment;
KIRP	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.74	9.89	0.53	1.24e-19	Crohn's disease;
KIRP	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg12384639	chr17:618140	VPS53	0.47	5.92	0.35	1.05e-8	Prostate cancer;
KIRP	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg00806126	chr19:22604979	ZNF98	0.68	7.14	0.41	1.07e-11	Pain;
KIRP	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.95	12.86	0.63	2.69e-29	Breast cancer;
KIRP	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg10547527	chr2:198650123	BOLL	-0.57	-5.21	-0.32	3.93e-7	Ulcerative colitis;
KIRP	cis	rs61990749	0.511	rs10130790	chr14:78324192	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.78	5.86	0.35	1.52e-8	Fibroblast growth factor basic levels;
KIRP	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.47	5.54	0.33	7.78e-8	Diastolic blood pressure;
KIRP	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg15556689	chr8:8085844	FLJ10661	0.68	9.39	0.51	4.29e-18	Neuroticism;
KIRP	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg13736514	chr6:26305472	NA	-0.54	-6.94	-0.4	3.5e-11	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
KIRP	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17816390	chr8:37553296	ZNF703	0.51	6.89	0.4	4.51e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8014252	0.803	rs7145530	chr14:71036510	T/C	cg11204974	chr14:71022665	NA	-0.61	-6.38	-0.38	8.6e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs72730918	0.590	rs2622770	chr15:51971322	C/T	cg14296394	chr15:51910925	DMXL2	0.6	7.95	0.45	6.63e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.81	10.39	0.55	3.36e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg21184320	chr1:21044207	KIF17	-0.37	-5.55	-0.33	7.47e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1484642	0.656	rs9329213	chr8:9949856	T/A	cg15537082	chr8:9762300	MIR124-1;LOC157627	0.5	4.93	0.3	1.53e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.68	7.77	0.44	2.13e-13	IgG glycosylation;
KIRP	cis	rs4666002	0.636	rs2272406	chr2:27892023	A/T	cg27432699	chr2:27873401	GPN1	0.57	5.56	0.33	7.08e-8	Phospholipid levels (plasma);
KIRP	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg08975724	chr8:8085496	FLJ10661	0.64	8.21	0.46	1.24e-14	Mood instability;
KIRP	cis	rs17301259	0.548	rs2246562	chr7:88401837	C/T	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.3	-4.89	-0.3	1.82e-6	Heschl's gyrus morphology;
KIRP	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.95	-12.83	-0.63	3.38e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.92	14.72	0.68	1.36e-35	Blood protein levels;
KIRP	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg08807101	chr21:30365312	RNF160	0.67	7.85	0.45	1.28e-13	Pancreatic cancer;
KIRP	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg05785598	chr3:49045655	WDR6	0.3	5.53	0.33	8.27e-8	Parkinson's disease;
KIRP	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs999943	0.774	rs12212284	chr6:33640874	T/A	cg14003231	chr6:33640908	ITPR3	0.78	12.76	0.63	5.77e-29	Obesity (extreme);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16929187	chr11:71791555	LRTOMT;NUMA1	0.51	6.57	0.39	2.9e-10	Parkinson's disease;
KIRP	cis	rs259282	0.669	rs731673	chr19:33132295	A/C	cg02997394	chr19:33096574	ANKRD27	-0.44	-5.18	-0.31	4.6e-7	Schizophrenia;
KIRP	cis	rs17023223	0.537	rs2765542	chr1:119560326	T/A	cg18261050	chr1:119551319	NA	0.52	7.0	0.41	2.42e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg16141378	chr3:129829833	LOC729375	0.54	7.04	0.41	1.9e-11	Retinal vascular caliber;
KIRP	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg02524346	chr8:600233	NA	0.7	5.61	0.34	5.53e-8	IgG glycosylation;
KIRP	cis	rs9896933	1.000	rs9896933	chr17:80898088	T/C	cg15369054	chr17:80825471	TBCD	-0.57	-5.05	-0.31	8.71e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs13427251	0.692	rs10206082	chr2:100160024	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-5.98	-0.36	7.71e-9	Chronic sinus infection;
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05315796	chr3:52349193	DNAH1	0.39	6.15	0.37	3.08e-9	Bipolar disorder;
KIRP	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg02023728	chr11:77925099	USP35	-0.32	-5.17	-0.31	4.81e-7	Alzheimer's disease (survival time);
KIRP	cis	rs17020663	0.771	rs10451616	chr2:101613603	G/A	cg12594615	chr2:101643137	TBC1D8	-0.38	-5.53	-0.33	8.09e-8	Pulse pressure;
KIRP	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg23565292	chr14:50234668	KLHDC2	-0.42	-4.87	-0.3	2.02e-6	Carotid intima media thickness;
KIRP	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg18154014	chr19:37997991	ZNF793	0.62	6.77	0.4	9.23e-11	Coronary artery calcification;
KIRP	cis	rs35883536	0.935	rs1106347	chr1:101149059	A/T	cg06223162	chr1:101003688	GPR88	0.34	7.05	0.41	1.8e-11	Monocyte count;
KIRP	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg05991184	chr2:219186017	PNKD	0.34	4.99	0.3	1.14e-6	Colorectal cancer;
KIRP	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.54	-6.9	-0.4	4.47e-11	Prostate cancer;
KIRP	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-9.65	-0.52	6.98e-19	Chronic sinus infection;
KIRP	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg24296786	chr1:45957014	TESK2	0.62	8.33	0.47	5.84e-15	High light scatter reticulocyte count;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06992027	chr1:159895302	TAGLN2	0.71	6.03	0.36	5.93e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg23985595	chr17:80112537	CCDC57	0.33	5.19	0.31	4.5e-7	Life satisfaction;
KIRP	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg11995313	chr8:8860691	ERI1	0.38	5.03	0.31	9.36e-7	Joint mobility (Beighton score);
KIRP	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	1.15	11.83	0.6	7.49e-26	Red blood cell traits;
KIRP	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.77	9.7	0.53	4.91e-19	White matter hyperintensity burden;
KIRP	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-7.21	-0.42	7.07e-12	Response to antipsychotic treatment;
KIRP	cis	rs72843506	1.000	rs7223910	chr17:19982768	G/A	cg13482628	chr17:19912719	NA	0.52	5.36	0.32	1.93e-7	Schizophrenia;
KIRP	cis	rs3849570	0.643	rs10779986	chr3:81970818	C/G	cg07356753	chr3:81810745	GBE1	0.61	7.82	0.45	1.55e-13	Waist circumference;Body mass index;
KIRP	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	1.22	11.23	0.58	6.82e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7546668	1.000	rs6695562	chr1:15842842	C/T	cg21858823	chr1:15850916	CASP9	0.47	5.19	0.31	4.35e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs17057051	0.614	rs13260543	chr8:27251325	A/G	cg23693289	chr8:27183097	PTK2B	-0.4	-4.89	-0.3	1.83e-6	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1134634	0.520	rs741180	chr4:15563410	T/A	cg16509355	chr4:15471240	CC2D2A	-0.3	-5.18	-0.31	4.72e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.47	-5.58	-0.34	6.37e-8	Body mass index;
KIRP	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg05347473	chr6:146136440	FBXO30	0.46	6.69	0.39	1.47e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.02	-0.5	5.55e-17	Total body bone mineral density;
KIRP	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-8.3	-0.47	6.78e-15	Neuroticism;
KIRP	cis	rs8014252	0.803	rs73282153	chr14:71002310	C/T	cg11204974	chr14:71022665	NA	-0.63	-6.66	-0.39	1.78e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg23594656	chr7:65796392	TPST1	0.47	7.5	0.43	1.16e-12	Aortic root size;
KIRP	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11645453	chr3:52864694	ITIH4	0.33	4.87	0.3	2.02e-6	Bipolar disorder;
KIRP	cis	rs988913	1.000	rs6922438	chr6:54841383	A/C	cg03513858	chr6:54763001	FAM83B	-0.37	-5.41	-0.33	1.47e-7	Menarche (age at onset);
KIRP	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg07741184	chr6:167504864	NA	0.22	5.86	0.35	1.46e-8	Crohn's disease;
KIRP	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.7	10.78	0.57	1.93e-22	Blood metabolite ratios;
KIRP	cis	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg21546286	chr11:48923668	NA	-0.48	-6.05	-0.36	5.39e-9	HDL cholesterol;
KIRP	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.818	rs165238	chr4:98712138	G/T	cg05340658	chr4:99064831	C4orf37	0.53	6.32	0.37	1.24e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08280861	chr8:58055591	NA	0.7	6.4	0.38	7.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6800768	0.604	rs76298099	chr3:24155775	G/T	cg10674438	chr3:24145617	LOC152024	-0.52	-6.86	-0.4	5.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.1	13.09	0.64	4.48e-30	Vitiligo;
KIRP	cis	rs1497828	0.956	rs2815242	chr1:217552998	C/T	cg04411442	chr1:217543379	NA	0.41	6.17	0.37	2.75e-9	Dialysis-related mortality;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-0.78	-7.74	-0.44	2.65e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg05315796	chr3:52349193	DNAH1	0.39	6.35	0.38	1.02e-9	Bipolar disorder;
KIRP	cis	rs9815354	1.000	rs13087719	chr3:41951576	C/T	cg03022575	chr3:42003672	ULK4	-0.48	-5.49	-0.33	9.89e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg07460842	chr6:66804631	NA	0.48	5.76	0.34	2.5e-8	Metabolite levels;
KIRP	trans	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg26043149	chr18:55253948	FECH	0.5	6.11	0.36	3.89e-9	Bone mineral density;
KIRP	cis	rs7635838	0.819	rs7637414	chr3:11522228	C/G	cg00170343	chr3:11313890	ATG7	0.48	6.19	0.37	2.51e-9	HDL cholesterol;
KIRP	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.12	0.54	2.42e-20	Total body bone mineral density;
KIRP	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg14952266	chr13:112191215	NA	0.43	6.24	0.37	1.9e-9	Hepatitis;
KIRP	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.88	0.4	4.84e-11	Electroencephalogram traits;
KIRP	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.42	5.6	0.34	5.78e-8	Childhood ear infection;
KIRP	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.92e-18	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.07e-10	Height;
KIRP	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.51	-6.01	-0.36	6.66e-9	White matter hyperintensity burden;
KIRP	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.47	-5.49	-0.33	1e-7	Colorectal cancer;
KIRP	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg04310649	chr10:35416472	CREM	-0.59	-6.96	-0.41	3.15e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.61	0.39	2.35e-10	Mean platelet volume;
KIRP	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg08313168	chr12:7315531	NA	0.7	6.26	0.37	1.72e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-5.12	-0.31	6.3e-7	Bipolar disorder;
KIRP	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.11	0.46	2.36e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	9.08	0.5	3.69e-17	Colorectal cancer;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4704187	0.687	rs2335134	chr5:74478843	A/C	cg03227963	chr5:74354835	NA	0.42	6.01	0.36	6.75e-9	Response to amphetamines;
KIRP	cis	rs7116495	1.000	rs520025	chr11:71562832	C/G	cg11196788	chr11:71737549	NUMA1	-0.5	-5.04	-0.31	8.88e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs4789452	0.967	rs7217986	chr17:75369578	T/C	cg05184938	chr17:75369939	SEPT9	-0.37	-5.02	-0.3	9.93e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6681460	1.000	rs6680876	chr1:67129482	G/A	cg02459107	chr1:67143332	SGIP1	0.5	7.25	0.42	5.51e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg04691961	chr3:161091175	C3orf57	-0.66	-11.01	-0.57	3.51e-23	Morning vs. evening chronotype;
KIRP	cis	rs11792861	0.566	rs1003346	chr9:111815340	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.48	6.19	0.37	2.47e-9	Menarche (age at onset);
KIRP	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.91	-16.4	-0.72	2.33e-41	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.5	-5.91	-0.35	1.12e-8	Lung cancer;
KIRP	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.32	11.73	0.6	1.53e-25	Diabetic retinopathy;
KIRP	cis	rs8077577	0.945	rs8065026	chr17:18046290	A/G	cg18869244	chr17:18121946	NA	0.42	5.02	0.3	1e-6	Obesity-related traits;
KIRP	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	4.93	0.3	1.55e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.0	0.69	1.45e-36	Platelet count;
KIRP	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg25866889	chr13:114914595	NA	-0.39	-5.37	-0.32	1.84e-7	Schizophrenia;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg25932496	chr4:165118868	MARCH1;ANP32C	0.36	6.13	0.36	3.46e-9	Serum protein levels (sST2);
KIRP	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.01	-0.3	1.06e-6	Pulmonary function;
KIRP	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs1699337	0.832	rs1175540	chr3:12465243	C/A	cg02700894	chr3:12045449	SYN2	-0.38	-5.11	-0.31	6.57e-7	Cholesterol, total;
KIRP	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.56	-7.0	-0.41	2.42e-11	Coronary artery disease;
KIRP	cis	rs1318772	1.000	rs34361144	chr5:112734005	C/T	cg12552261	chr5:112820674	MCC	0.77	4.97	0.3	1.24e-6	F-cell distribution;
KIRP	cis	rs4253772	0.872	rs78864133	chr22:46638486	C/T	cg18190219	chr22:46762943	CELSR1	-0.61	-5.79	-0.35	2.19e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4650994	0.593	rs2811302	chr1:178552875	C/T	cg12486710	chr1:178512616	C1orf220	-0.26	-5.56	-0.33	7.07e-8	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9608946	1.000	rs9606739	chr22:30891294	G/C	cg23383138	chr22:30885012	SEC14L4	0.4	4.9	0.3	1.76e-6	Red cell distribution width;
KIRP	cis	rs2905347	0.560	rs2961293	chr7:22684084	G/A	cg23521230	chr7:22704884	NA	0.39	4.86	0.3	2.05e-6	Major depression and alcohol dependence;
KIRP	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	cis	rs2712184	0.729	rs2541390	chr2:217664020	A/G	cg05032264	chr2:217675019	NA	-0.49	-6.81	-0.4	7.24e-11	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.39	-0.38	8.43e-10	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg14580859	chr9:123691850	NA	0.35	4.86	0.3	2.13e-6	Rheumatoid arthritis;
KIRP	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg25650185	chr19:21324782	ZNF431	0.46	4.85	0.3	2.15e-6	Pain;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26227975	chr3:9773404	BRPF1	0.42	6.03	0.36	5.82e-9	Survival in pancreatic cancer;
KIRP	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg09323728	chr8:95962352	TP53INP1	-0.24	-5.11	-0.31	6.6e-7	Type 2 diabetes;
KIRP	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.58	-6.66	-0.39	1.8e-10	Vitiligo;
KIRP	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg23594656	chr7:65796392	TPST1	-0.45	-7.0	-0.41	2.38e-11	Aortic root size;
KIRP	cis	rs13343954	0.825	rs7254716	chr19:33532128	T/C	cg17764715	chr19:33622953	WDR88	0.73	8.09	0.46	2.69e-14	Colorectal cancer;
KIRP	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.83	-10.74	-0.56	2.6e-22	Cognitive function;
KIRP	cis	rs5753037	0.809	rs17711377	chr22:30212986	C/T	cg27665648	chr22:30112403	NA	0.46	6.38	0.38	8.48e-10	Type 1 diabetes;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.51	-5.55	-0.33	7.47e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.49	-6.33	-0.37	1.13e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs9400467	0.568	rs12204075	chr6:111489059	G/T	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4787491	0.729	rs8043883	chr16:30044581	G/A	cg06326092	chr16:30034487	C16orf92	0.5	7.82	0.45	1.5700000000000001e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.69	9.65	0.52	6.65e-19	Post bronchodilator FEV1;
KIRP	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.36	-4.98	-0.3	1.2e-6	Motion sickness;
KIRP	cis	rs1468333	1.000	rs2057831	chr5:137535133	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	5.29	0.32	2.71e-7	Resting heart rate;
KIRP	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.71	-11.0	-0.57	3.79e-23	Prostate cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02668984	chr17:48172022	PDK2	0.69	8.62	0.48	8.19e-16	Smoking initiation;
KIRP	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.07	-22.74	-0.82	2.12e-62	Myeloid white cell count;
KIRP	cis	rs7429990	0.965	rs11709289	chr3:47806649	G/A	cg11946769	chr3:48343235	NME6	0.54	5.42	0.33	1.43e-7	Educational attainment (years of education);
KIRP	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.7	0.39	1.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg22777020	chr22:31556080	RNF185	-0.48	-5.1	-0.31	6.92e-7	Colorectal cancer;
KIRP	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.55	-6.53	-0.38	3.82e-10	Schizophrenia;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.36	5.12	0.31	6.04e-7	Ovarian reserve;
KIRP	cis	rs7945718	0.781	rs11022505	chr11:12822366	A/G	cg25843174	chr11:12811716	TEAD1	-0.3	-5.39	-0.33	1.61e-7	Educational attainment (years of education);
KIRP	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.8	-0.45	1.71e-13	Gut microbiome composition (summer);
KIRP	trans	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg16141378	chr3:129829833	LOC729375	-0.53	-7.18	-0.42	8.36e-12	Joint mobility (Beighton score);
KIRP	cis	rs10214930	0.697	rs7806605	chr7:27613585	A/G	cg22168087	chr7:27702803	HIBADH	0.46	4.92	0.3	1.61e-6	Hypospadias;
KIRP	cis	rs9815354	0.680	rs79239400	chr3:42030249	C/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9381107	0.932	rs9349172	chr6:9458941	C/G	cg14735645	chr6:9486422	NA	-0.44	-5.42	-0.33	1.39e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg13206674	chr6:150067644	NUP43	0.62	9.02	0.5	5.61e-17	Testicular germ cell tumor;
KIRP	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.69	9.69	0.53	5.08e-19	Blood protein levels;
KIRP	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-4.89	-0.3	1.8e-6	Aortic root size;
KIRP	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.16	-0.37	3.01e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg04989706	chr14:50066350	PPIL5	-0.46	-5.5	-0.33	9.64e-8	Carotid intima media thickness;
KIRP	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.39	8.22	0.46	1.18e-14	Body mass index;
KIRP	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24375607	chr4:120327624	NA	0.61	6.58	0.39	2.76e-10	Corneal astigmatism;
KIRP	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.26	0.74	2.82e-44	Height;
KIRP	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg01864069	chr14:103024347	NA	0.87	10.16	0.54	1.81e-20	Platelet count;
KIRP	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.69	5.49	0.33	1.01e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10214930	0.671	rs2391449	chr7:27685146	C/T	cg22168087	chr7:27702803	HIBADH	0.46	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg05552183	chr6:42928497	GNMT	0.54	6.74	0.39	1.15e-10	Blood protein levels;
KIRP	cis	rs59698941	0.550	rs60042615	chr5:132193220	A/G	cg14825688	chr5:132208181	LEAP2	-0.37	-4.98	-0.3	1.19e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08354309	chr15:59063586	FAM63B	-0.49	-6.41	-0.38	7.38e-10	Myopia;
KIRP	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.49	6.38	0.38	8.56e-10	Blood metabolite levels;
KIRP	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg16524733	chr11:117070046	TAGLN	0.44	5.73	0.34	2.99e-8	Blood protein levels;
KIRP	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.02	-0.3	9.99e-7	Colorectal cancer;
KIRP	cis	rs10208940	0.920	rs35002937	chr2:68753240	T/A	cg12452813	chr2:68675892	NA	0.47	5.06	0.31	8.07e-7	Urate levels in lean individuals;
KIRP	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg05370193	chr1:21551575	ECE1	0.43	6.03	0.36	6.07e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg15038512	chr6:170123185	PHF10	-0.56	-8.58	-0.48	1.08e-15	Obesity-related traits;
KIRP	cis	rs4356932	0.967	rs4859608	chr4:76991807	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.14	0.36	3.33e-9	Blood protein levels;
KIRP	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.92	-0.4	3.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.62	-6.9	-0.4	4.39e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.77	-14.18	-0.67	9.48e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg11833968	chr6:79620685	NA	-0.47	-7.03	-0.41	1.97e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg03074872	chr20:45035404	ELMO2	-0.45	-6.29	-0.37	1.43e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg23933602	chr10:16859644	RSU1	0.6	7.08	0.41	1.46e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01829450	chr3:135914745	MSL2	0.47	6.62	0.39	2.25e-10	Survival in pancreatic cancer;
KIRP	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.18e-7	Red blood cell count;
KIRP	trans	rs399593	0.636	rs452843	chr10:30899929	C/T	cg02831383	chr1:3329820	PRDM16	0.59	6.09	0.36	4.24e-9	Dental caries;
KIRP	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.64	-5.91	-0.35	1.16e-8	Tuberculosis;
KIRP	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg18646521	chr2:111875858	NA	0.42	5.98	0.36	7.66e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs1969253	0.805	rs6775140	chr3:183870960	C/T	cg23202575	chr3:183888295	DVL3	-0.36	-4.86	-0.3	2.11e-6	Major depressive disorder;
KIRP	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	1.17	9.79	0.53	2.45e-19	Prostate cancer;
KIRP	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.86	-11.66	-0.6	2.56e-25	Cognitive function;
KIRP	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg20749741	chr2:264178	ACP1;SH3YL1	0.47	5.11	0.31	6.59e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg13798912	chr7:905769	UNC84A	0.54	5.47	0.33	1.09e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7236492	0.505	rs11663549	chr18:77181989	A/G	cg15644404	chr18:77186268	NFATC1	0.8	5.83	0.35	1.76e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	0.84	11.94	0.61	3.06e-26	Homoarginine levels;
KIRP	cis	rs10463316	0.832	rs246484	chr5:150730938	T/C	cg03212797	chr5:150827313	SLC36A1	-0.46	-6.08	-0.36	4.57e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg00071950	chr4:10020882	SLC2A9	0.41	5.13	0.31	6e-7	Blood metabolite levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18377446	chr1:100335651	AGL	0.41	6.14	0.36	3.22e-9	Migraine with aura;
KIRP	cis	rs4594175	0.926	rs10138345	chr14:51624651	A/G	cg23942311	chr14:51606299	NA	0.45	5.45	0.33	1.24e-7	Cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08146442	chr12:19668616	AEBP2	-0.39	-6.02	-0.36	6.3e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.63	6.13	0.36	3.44e-9	Tuberculosis;
KIRP	cis	rs9913711	1.000	rs9913711	chr17:70098161	C/G	cg04438997	chr17:70115868	SOX9	0.37	4.99	0.3	1.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg01689657	chr7:91764605	CYP51A1	0.43	6.2	0.37	2.36e-9	Breast cancer;
KIRP	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg27490568	chr2:178487706	NA	0.46	5.98	0.36	7.64e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-9.28	-0.51	9.1e-18	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg11569703	chr11:65557185	OVOL1	0.53	9.13	0.5	2.57e-17	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	trans	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs7590368	1.000	rs2884289	chr2:10959724	G/A	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs7258465	1.000	rs10403249	chr19:18604942	T/C	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.0	-0.36	7.17e-9	Breast cancer;
KIRP	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg00405596	chr8:11794950	NA	-0.48	-6.35	-0.38	1.01e-9	Retinal vascular caliber;
KIRP	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.4e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05143398	chr2:175713189	CHN1	0.38	6.57	0.39	2.92e-10	C-reactive protein;
KIRP	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	12.42	0.62	8.27e-28	Menopause (age at onset);
KIRP	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.67e-7	Life satisfaction;
KIRP	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.68	8.3	0.47	6.97e-15	Neutrophil percentage of white cells;
KIRP	trans	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.89	-0.4	4.72e-11	Morning vs. evening chronotype;
KIRP	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.57	-6.07	-0.36	4.9e-9	Obesity-related traits;
KIRP	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg08648136	chr8:956695	NA	0.49	7.68	0.44	3.86e-13	Schizophrenia;
KIRP	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.52	0.65	1.65e-31	Platelet count;
KIRP	cis	rs4356975	0.522	rs11940220	chr4:69960940	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.72	8.13	0.46	2.11e-14	Obesity-related traits;
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs412050	0.501	rs2876980	chr22:22106535	C/T	cg17089214	chr22:22089827	YPEL1	-0.63	-5.95	-0.35	8.94e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg18129178	chr5:148520854	ABLIM3	0.49	5.21	0.32	4.04e-7	Breast cancer;
KIRP	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.75	9.33	0.51	6.45e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg23594656	chr7:65796392	TPST1	-0.52	-8.18	-0.46	1.54e-14	Aortic root size;
KIRP	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02359409	chr6:42947317	PEX6	-0.52	-7.21	-0.42	6.79e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg17652424	chr22:38574118	PLA2G6	-0.26	-5.55	-0.33	7.33e-8	Cutaneous nevi;
KIRP	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-5.46	-0.33	1.17e-7	Personality dimensions;
KIRP	cis	rs7792596	0.565	rs10487252	chr7:93981089	C/T	cg20814616	chr7:94014465	NA	0.39	6.29	0.37	1.43e-9	Intelligence;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15618428	chr6:146919983	C6orf103	0.86	6.08	0.36	4.5e-9	P wave terminal force;
KIRP	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.42	-5.31	-0.32	2.44e-7	Blood metabolite levels;
KIRP	cis	rs981844	1.000	rs72731670	chr4:154662471	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs3741151	0.892	rs11821094	chr11:73061905	C/G	cg17517138	chr11:73019481	ARHGEF17	0.65	5.94	0.35	9.85e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.66	7.54	0.43	8.93e-13	Corneal astigmatism;
KIRP	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	12.22	0.61	3.86e-27	Menopause (age at onset);
KIRP	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.45	-5.87	-0.35	1.42e-8	Body mass index;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg26496372	chr5:37379396	WDR70	0.48	6.39	0.38	8.29e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2219968	0.884	rs9643433	chr8:78952371	T/A	cg00738934	chr8:78996279	NA	0.41	5.28	0.32	2.79e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.39	-5.12	-0.31	6.23e-7	Parkinson's disease;
KIRP	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.43	1.36e-12	Body mass index;
KIRP	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg21427119	chr20:30132790	HM13	-0.54	-6.19	-0.37	2.53e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs7074356	0.569	rs17102596	chr10:82035173	T/C	cg27171509	chr10:82033454	MAT1A	-0.4	-5.52	-0.33	8.67e-8	Borderline personality disorder;
KIRP	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg24253500	chr15:84953950	NA	0.51	5.84	0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg03171003	chr2:111875934	NA	0.44	6.15	0.37	3.1e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg02297831	chr4:17616191	MED28	0.52	6.57	0.39	2.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs2230307	0.572	rs6677080	chr1:100633469	A/T	cg24955406	chr1:100503596	HIAT1	0.59	6.08	0.36	4.58e-9	Carotid intima media thickness;
KIRP	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20274746	chr5:65221372	ERBB2IP	0.52	6.06	0.36	5e-9	Smoking initiation;
KIRP	cis	rs11955175	1.000	rs2228058	chr5:40681254	C/T	cg17351974	chr5:40835760	RPL37	0.63	5.5	0.33	9.62e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg18833306	chr6:118973337	C6orf204	0.4	5.04	0.31	8.85e-7	Electrocardiographic conduction measures;
KIRP	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.73	8.79	0.49	2.67e-16	Developmental language disorder (linguistic errors);
KIRP	trans	rs9975691	1	rs9975691	chr21:14928355	G/T	cg09173587	chr20:4666747	PRNP	0.51	6.21	0.37	2.26e-9	Neurofibrillary tangles;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.56	-5.71	-0.34	3.18e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg10360139	chr7:1886902	MAD1L1	-0.43	-4.96	-0.3	1.29e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-0.7	-9.34	-0.51	5.96e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.24	0.42	5.63e-12	Neuroticism;
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg13906792	chr15:75199810	C15orf17	-0.38	-5.38	-0.32	1.73e-7	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00179663	chr4:92189705	FAM190A	-0.39	-6.01	-0.36	6.49e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05152925	chr14:45603667	FKBP3;FANCM	0.49	6.21	0.37	2.28e-9	Parkinson's disease;
KIRP	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg21851534	chr17:3907994	ZZEF1	-0.45	-5.25	-0.32	3.24e-7	Type 2 diabetes;
KIRP	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.49	-0.33	1.01e-7	Testicular germ cell tumor;
KIRP	cis	rs3109167	0.598	rs7798156	chr7:83105842	T/G	cg14519356	chr7:83097669	SEMA3E	-0.38	-5.13	-0.31	5.76e-7	Blood protein levels;
KIRP	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.5	6.63	0.39	2.09e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.43	7.12	0.41	1.17e-11	Testicular germ cell tumor;
KIRP	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-10.75	-0.57	2.36e-22	Educational attainment;
KIRP	cis	rs6667605	0.527	rs4422947	chr1:2539590	C/T	cg20673091	chr1:2541236	MMEL1	0.78	12.69	0.63	9.81e-29	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs9513627	1.000	rs7321269	chr13:100126271	C/T	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg02696790	chr15:75250997	RPP25	0.29	5.3	0.32	2.53e-7	Breast cancer;
KIRP	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg01631408	chr1:248437212	OR2T33	-0.66	-8.99	-0.5	6.69e-17	Common traits (Other);
KIRP	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	11.01	0.57	3.42e-23	Smoking behavior;
KIRP	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg20673091	chr1:2541236	MMEL1	0.7	10.32	0.55	5.61e-21	Ulcerative colitis;
KIRP	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg00491522	chr10:135256596	NA	0.5	5.36	0.32	1.91e-7	Systemic lupus erythematosus;
KIRP	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg19645103	chr12:69753606	YEATS4	-0.48	-4.99	-0.3	1.13e-6	Response to diuretic therapy;
KIRP	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg17764715	chr19:33622953	WDR88	-0.65	-8.14	-0.46	1.96e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg04310649	chr10:35416472	CREM	-0.58	-6.8	-0.4	8e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg07382826	chr16:28625726	SULT1A1	0.47	5.42	0.33	1.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg00405596	chr8:11794950	NA	0.58	8.03	0.46	4.09e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg12486944	chr17:80159399	CCDC57	0.38	5.11	0.31	6.4e-7	Life satisfaction;
KIRP	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg07511934	chr16:89386912	ANKRD11	0.43	5.4	0.33	1.57e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs2594989	0.943	rs2594995	chr3:11369117	A/G	cg01796438	chr3:11312864	ATG7	0.66	7.89	0.45	9.9e-14	Circulating chemerin levels;
KIRP	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.84	10.18	0.54	1.54e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2708977	0.730	rs596069	chr2:97076642	C/T	cg01950434	chr2:97203154	ARID5A	0.42	5.39	0.33	1.65e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	1.11	21.9	0.81	1.03e-59	Height;
KIRP	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg02415014	chr8:143852576	LYNX1	-0.31	-5.07	-0.31	7.74e-7	Urinary tract infection frequency;
KIRP	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg17376030	chr22:41985996	PMM1	-0.64	-6.74	-0.39	1.1e-10	Vitiligo;
KIRP	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg02527881	chr3:46936655	PTH1R	-0.42	-6.06	-0.36	5.21e-9	Colorectal cancer;
KIRP	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs78487399	0.808	rs10180005	chr2:43737465	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-4.97	-0.3	1.28e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs12210905	1.000	rs72843641	chr6:27203335	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.4	-0.38	7.77e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg12560992	chr17:57184187	TRIM37	0.59	5.61	0.34	5.32e-8	Cognitive test performance;
KIRP	cis	rs12541635	0.639	rs10955408	chr8:107020789	G/A	cg10147462	chr8:107024639	NA	0.35	5.2	0.31	4.1e-7	Age of smoking initiation;
KIRP	cis	rs7187994	1.000	rs7187994	chr16:84753453	A/G	cg07647771	chr16:84786436	USP10	-0.39	-5.15	-0.31	5.25e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg10547527	chr2:198650123	BOLL	-0.56	-5.06	-0.31	8.05e-7	Ulcerative colitis;
KIRP	cis	rs12210905	0.688	rs72845025	chr6:27524443	G/C	cg08851530	chr6:28072375	NA	0.95	5.42	0.33	1.4e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg21427119	chr20:30132790	HM13	-0.55	-6.53	-0.38	3.69e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs1478898	0.569	rs2264866	chr8:11388653	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.19	-0.37	2.46e-9	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13148126	chr17:8924759	NTN1	0.5	6.59	0.39	2.7e-10	Parkinson's disease;
KIRP	cis	rs7106204	0.514	rs1443043	chr11:24251991	A/G	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	9.52	0.52	1.73e-18	Cognitive test performance;
KIRP	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.52	-7.68	-0.44	3.65e-13	IgG glycosylation;
KIRP	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg00982548	chr2:198649783	BOLL	-0.55	-5.52	-0.33	8.69e-8	Ulcerative colitis;
KIRP	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg17420585	chr12:42539391	GXYLT1	-0.39	-5.35	-0.32	1.99e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	6.03	0.36	6.05e-9	Bipolar disorder;
KIRP	cis	rs1950626	0.623	rs61991083	chr14:101436435	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.54	6.1	0.36	4.03e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6968419	0.714	rs12666168	chr7:115856681	T/C	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.59	7.16	0.42	9.16e-12	Colorectal cancer;
KIRP	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-9.2	-0.51	1.6e-17	Heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10813644	chr19:2271093	OAZ1	0.55	7.5	0.43	1.16e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg16586182	chr3:47516702	SCAP	0.83	11.93	0.61	3.38e-26	Colorectal cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg11699593	chr8:22102731	POLR3D;MIR320A	-0.45	-6.04	-0.36	5.51e-9	Metabolic traits;
KIRP	cis	rs10486003	0.881	rs73402251	chr7:97202582	A/G	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.58	-5.16	-0.31	5.12e-7	Response to platinum-based agents;
KIRP	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26207909	chr14:103986467	CKB	0.75	11.43	0.59	1.52e-24	Body mass index;
KIRP	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.86	-12.44	-0.62	6.71e-28	Headache;
KIRP	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.54	-6.87	-0.4	5.38e-11	Type 2 diabetes;
KIRP	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.87	-10.96	-0.57	4.92e-23	Dupuytren's disease;
KIRP	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.39	-5.36	-0.32	1.9e-7	HIV-1 susceptibility;
KIRP	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg07212818	chr11:638076	DRD4	-0.43	-5.24	-0.32	3.5e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg23950597	chr19:37808831	NA	0.61	6.64	0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg05717871	chr11:638507	DRD4	-0.4	-5.38	-0.32	1.76e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4006360	0.531	rs7502102	chr17:39307041	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.44	-5.83	-0.35	1.75e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg03171003	chr2:111875934	NA	0.41	5.83	0.35	1.74e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg18192325	chr2:105854051	NA	-0.38	-5.33	-0.32	2.19e-7	Type 2 diabetes;
KIRP	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg05535760	chr7:792225	HEATR2	-0.95	-8.39	-0.47	3.9e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6453429	0.720	rs626105	chr5:78369901	A/G	cg08328513	chr5:78365691	BHMT2;DMGDH	-0.29	-5.22	-0.32	3.84e-7	Urinary metabolites;
KIRP	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg11833968	chr6:79620685	NA	-0.46	-7.02	-0.41	2.1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04447216	chr19:53290205	ZNF600	0.49	6.05	0.36	5.47e-9	Smoking initiation;
KIRP	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg23307798	chr14:103986281	CKB	0.76	12.47	0.62	5.31e-28	Body mass index;
KIRP	cis	rs10782582	0.758	rs5745558	chr1:76379497	C/T	cg10523679	chr1:76189770	ACADM	-0.36	-5.12	-0.31	6.27e-7	Daytime sleep phenotypes;
KIRP	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg18132916	chr6:79620363	NA	-0.37	-4.99	-0.3	1.13e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.08	0.31	7.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs365132	0.875	rs691141	chr5:176323298	A/G	cg16309518	chr5:176445507	NA	0.75	11.53	0.59	7.11e-25	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	1.08	19.91	0.79	3.31e-53	Gut microbiome composition (winter);
KIRP	cis	rs8177876	0.642	rs8052490	chr16:81111856	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06481639	chr22:41940642	POLR3H	0.73	7.63	0.44	4.99e-13	Vitiligo;
KIRP	cis	rs9840812	0.559	rs6439640	chr3:136185680	A/G	cg15507776	chr3:136538369	TMEM22	0.48	5.07	0.31	8.01e-7	Fibrinogen levels;
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg05564831	chr3:52568323	NT5DC2	-0.41	-6.62	-0.39	2.24e-10	Electroencephalogram traits;
KIRP	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.47	6.42	0.38	7.11e-10	Testicular germ cell tumor;
KIRP	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg17376030	chr22:41985996	PMM1	0.79	8.79	0.49	2.67e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6466055	0.932	rs7811681	chr7:104928869	A/G	cg04380332	chr7:105027541	SRPK2	0.51	7.77	0.44	2.07e-13	Schizophrenia;
KIRP	cis	rs8002861	0.515	rs9525846	chr13:44390857	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.4	-5.08	-0.31	7.5e-7	Leprosy;
KIRP	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg02336718	chr17:17403227	NA	0.33	5.2	0.31	4.14e-7	Total body bone mineral density;
KIRP	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg25486957	chr4:152246857	NA	-0.43	-5.04	-0.31	9.14e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.92	-12.75	-0.63	6.29e-29	Cognitive function;
KIRP	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.59	7.69	0.44	3.52e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-0.51	-7.16	-0.42	9.27e-12	Coronary artery disease;
KIRP	trans	rs10152811	0.675	rs56121718	chr15:86817215	A/G	cg09774649	chr4:8476536	C4orf23	-0.54	-6.09	-0.36	4.3e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs11673344	0.544	rs6508721	chr19:37910021	G/T	cg14683738	chr19:37701593	ZNF585B	0.44	5.18	0.31	4.53e-7	Obesity-related traits;
KIRP	cis	rs2274273	0.588	rs58296156	chr14:55828327	C/T	cg04306507	chr14:55594613	LGALS3	0.38	5.2	0.31	4.28e-7	Protein biomarker;
KIRP	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-0.97	-11.52	-0.59	7.9e-25	Blood pressure (smoking interaction);
KIRP	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	4.96	0.3	1.34e-6	Tonsillectomy;
KIRP	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	6.6	0.39	2.48e-10	Colorectal cancer;
KIRP	cis	rs16828019	0.852	rs34386859	chr1:41564024	C/T	cg03387723	chr1:41708464	SCMH1	-0.76	-6.71	-0.39	1.33e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.59	6.2	0.37	2.34e-9	Crohn's disease;
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs9815354	1.000	rs9874975	chr3:41764300	G/A	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.33	8.71e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.97	-0.3	1.26e-6	Life satisfaction;
KIRP	cis	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-4.91	-0.3	1.66e-6	Neuroticism;
KIRP	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg24296786	chr1:45957014	TESK2	0.43	5.39	0.32	1.66e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01375172	chr16:23464338	COG7	0.54	7.05	0.41	1.75e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs17453880	0.929	rs12517092	chr5:152054744	A/C	cg12297329	chr5:152029980	NA	-0.68	-10.06	-0.54	3.75e-20	Subjective well-being;
KIRP	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg27205649	chr11:78285834	NARS2	-0.64	-8.29	-0.47	7.63e-15	Alzheimer's disease (survival time);
KIRP	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg23216685	chr1:86174607	ZNHIT6	-0.67	-10.24	-0.55	1.02e-20	Urate levels in overweight individuals;
KIRP	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.68	10.73	0.56	2.83e-22	Anterior chamber depth;
KIRP	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg25039879	chr17:56429692	SUPT4H1	0.7	6.43	0.38	6.66e-10	Cognitive test performance;
KIRP	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	15.66	0.71	8.4e-39	Electrocardiographic conduction measures;
KIRP	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.87	10.17	0.54	1.63e-20	Gut microbiome composition (summer);
KIRP	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg07843065	chr1:150265600	MRPS21	0.43	5.62	0.34	5.17e-8	Migraine;
KIRP	trans	rs12517041	1.000	rs1428621	chr5:23283431	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.45	-0.47	2.58e-15	Calcium levels;
KIRP	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.47	5.93	0.35	1.02e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13553906	chr4:157713147	PDGFC	-0.4	-6.24	-0.37	1.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs988913	1.000	rs1503142	chr6:54818948	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.6	-0.34	5.69e-8	Menarche (age at onset);
KIRP	cis	rs6674970	0.777	rs11204782	chr1:151118035	C/G	cg03258749	chr1:151040405	MLLT11	0.56	6.45	0.38	5.94e-10	Childhood ear infection;
KIRP	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.79	-8.83	-0.49	2.03e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.12	0.54	2.42e-20	Total body bone mineral density;
KIRP	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg02725872	chr8:58115012	NA	-0.44	-5.16	-0.31	5.09e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18252515	chr7:66147081	NA	0.44	5.17	0.31	4.84e-7	Aortic root size;
KIRP	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.99	15.47	0.7	3.69e-38	Bipolar disorder;
KIRP	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.4	-6.35	-0.38	1.06e-9	Bone mineral density;
KIRP	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	trans	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg10756647	chr7:56101905	PSPH	-0.94	-6.9	-0.4	4.35e-11	Diabetic kidney disease;
KIRP	cis	rs4356932	1.000	rs4456983	chr4:76958688	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.38	-5.12	-0.31	6.31e-7	Height;
KIRP	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg12549451	chr6:135224345	NA	0.41	4.98	0.3	1.21e-6	Red blood cell count;
KIRP	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.13	-0.46	2.16e-14	Response to antipsychotic treatment;
KIRP	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg11843606	chr2:227700838	RHBDD1	0.4	5.16	0.31	5.13e-7	Pulmonary function;
KIRP	cis	rs714027	0.605	rs2899147	chr22:30533065	A/G	cg27665648	chr22:30112403	NA	-0.45	-6.4	-0.38	7.73e-10	Lymphocyte counts;
KIRP	cis	rs2067663	0.591	rs665674	chr5:88055481	T/C	cg18498987	chr5:88179539	MEF2C	-0.38	-4.91	-0.3	1.7e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
KIRP	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18252515	chr7:66147081	NA	0.44	5.1	0.31	6.9e-7	Aortic root size;
KIRP	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg19683494	chr5:74908142	NA	-0.52	-5.16	-0.31	5.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg25173405	chr17:45401733	C17orf57	-0.48	-6.33	-0.37	1.13e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04374321	chr14:90722782	PSMC1	0.93	15.79	0.71	2.82e-39	Mortality in heart failure;
KIRP	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.92	-10.68	-0.56	3.97e-22	Diastolic blood pressure;
KIRP	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.61	-8.37	-0.47	4.28e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs13385	0.769	rs6872766	chr5:139595614	A/C	cg01860693	chr5:139557145	C5orf32	0.49	5.38	0.32	1.75e-7	Atrial fibrillation;
KIRP	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	12.31	0.62	1.88e-27	Menarche (age at onset);
KIRP	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg15128208	chr22:42549153	NA	0.5	5.41	0.33	1.47e-7	Birth weight;
KIRP	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg13206674	chr6:150067644	NUP43	0.63	8.45	0.47	2.61e-15	Lung cancer;
KIRP	cis	rs7919006	0.590	rs7914131	chr10:76807320	G/A	cg01390419	chr10:76803856	DUPD1	0.5	5.85	0.35	1.53e-8	Weight;
KIRP	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg04398451	chr17:18023971	MYO15A	0.69	9.58	0.52	1.15e-18	Total body bone mineral density;
KIRP	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.63	8.54	0.48	1.42e-15	Total body bone mineral density;
KIRP	cis	rs8014252	0.803	rs58092588	chr14:71028678	T/C	cg19730268	chr14:71022823	NA	-0.69	-6.16	-0.37	2.95e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs35883536	1.000	rs3904672	chr1:101136651	C/T	cg06223162	chr1:101003688	GPR88	0.34	6.97	0.41	2.96e-11	Monocyte count;
KIRP	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.77	9.93	0.53	9.26e-20	Aortic root size;
KIRP	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.91	0.3	1.67e-6	Lymphocyte counts;
KIRP	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg23594656	chr7:65796392	TPST1	-0.4	-5.85	-0.35	1.53e-8	Aortic root size;
KIRP	cis	rs526231	0.578	rs2112886	chr5:102251382	C/T	cg23492399	chr5:102201601	PAM	0.49	5.47	0.33	1.12e-7	Primary biliary cholangitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16652790	chr16:776895	HAGHL;CCDC78	0.39	6.05	0.36	5.41e-9	Survival in pancreatic cancer;
KIRP	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.51	6.57	0.39	3.05e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs6466055	0.589	rs66638610	chr7:104977023	G/C	cg04380332	chr7:105027541	SRPK2	0.36	4.93	0.3	1.52e-6	Schizophrenia;
KIRP	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.75	-0.57	2.38e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2274273	1.000	rs2147972	chr14:55598030	T/C	cg04306507	chr14:55594613	LGALS3	0.46	7.08	0.41	1.53e-11	Protein biomarker;
KIRP	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.72	-11.04	-0.58	2.89e-23	Resting heart rate;
KIRP	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg05938607	chr10:60274200	BICC1	0.41	10.01	0.54	5.22e-20	Refractive error;
KIRP	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg18306943	chr3:40428807	ENTPD3	0.41	5.51	0.33	8.83e-8	Renal cell carcinoma;
KIRP	cis	rs2669010	1.000	rs4432068	chr12:76982825	A/C	cg14998926	chr12:77026162	NA	-0.41	-5.31	-0.32	2.4e-7	Systemic lupus erythematosus;
KIRP	cis	rs1448094	0.872	rs7314272	chr12:86401005	T/C	cg02569458	chr12:86230093	RASSF9	0.35	5.01	0.3	1.02e-6	Major depressive disorder;
KIRP	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg16586182	chr3:47516702	SCAP	-0.72	-10.22	-0.55	1.16e-20	Colorectal cancer;
KIRP	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg23594656	chr7:65796392	TPST1	-0.47	-7.41	-0.43	2.07e-12	Aortic root size;
KIRP	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.19	-0.37	2.55e-9	Myopia (pathological);
KIRP	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg00677455	chr12:58241039	CTDSP2	-0.49	-5.61	-0.34	5.41e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg25036284	chr2:26402008	FAM59B	-0.53	-5.47	-0.33	1.12e-7	Gut microbiome composition (summer);
KIRP	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.8	-10.88	-0.57	9.33e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg01420254	chr6:26195488	NA	1.12	10.65	0.56	4.9e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.3	-4.95	-0.3	1.39e-6	Height;
KIRP	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	cg04338863	chr8:33670619	NA	0.48	6.64	0.39	2e-10	Body mass index;
KIRP	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg21360079	chr12:107162445	NA	-0.65	-9.03	-0.5	5.07e-17	Heart rate;
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg02462569	chr6:150064036	NUP43	-0.34	-5.07	-0.31	7.69e-7	Lung cancer;
KIRP	cis	rs290268	0.669	rs10993693	chr9:93557698	C/T	cg02608019	chr9:93564028	SYK	0.68	8.62	0.48	8.18e-16	Platelet count;
KIRP	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg26248373	chr2:1572462	NA	-0.63	-6.41	-0.38	7.28e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06850241	chr22:41845214	NA	-0.43	-4.96	-0.3	1.33e-6	Vitiligo;
KIRP	cis	rs11638352	0.661	rs1426657	chr15:44434529	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.06	-0.36	5.1e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.68	5.73	0.34	2.95e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg17376030	chr22:41985996	PMM1	0.81	8.29	0.47	7.22e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05080328	chr22:19132130	DGCR14	-0.52	-6.31	-0.37	1.29e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg26876637	chr1:152193138	HRNR	0.74	9.95	0.54	8.14e-20	Atopic dermatitis;
KIRP	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.8	-8.98	-0.5	7.37e-17	Hirschsprung disease;
KIRP	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.84	0.35	1.67e-8	Coronary artery disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10097105	chr1:200586761	KIF14	0.49	6.97	0.41	2.93e-11	Interleukin-4 levels;
KIRP	cis	rs6539288	0.630	rs10778520	chr12:107364873	A/G	cg15890332	chr12:107067104	RFX4	-0.33	-5.4	-0.33	1.6e-7	Total body bone mineral density;
KIRP	cis	rs7715811	1.000	rs6860236	chr5:13762013	C/T	cg07548982	chr5:13769939	DNAH5	-0.52	-6.45	-0.38	5.83e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs6663390	0.831	rs3754172	chr1:208086878	G/T	cg00387621	chr1:208086895	NA	0.65	6.07	0.36	4.81e-9	Facial morphology (factor 18);
KIRP	cis	rs8067545	1.000	rs9891739	chr17:19942177	C/T	cg13482628	chr17:19912719	NA	0.69	10.7	0.56	3.57e-22	Schizophrenia;
KIRP	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg11569703	chr11:65557185	OVOL1	0.77	14.52	0.68	6.43e-35	Acne (severe);
KIRP	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.22	0.42	6.29e-12	Bipolar disorder;
KIRP	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.06	9.12	0.5	2.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg03152288	chr2:177042942	NA	0.66	9.4	0.51	3.97e-18	IgG glycosylation;
KIRP	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg22974920	chr21:40686053	BRWD1	0.45	5.3	0.32	2.56e-7	Cognitive function;
KIRP	cis	rs12282928	0.670	rs12576395	chr11:48355132	A/G	cg26585981	chr11:48327164	OR4S1	-0.52	-6.32	-0.37	1.25e-9	Migraine - clinic-based;
KIRP	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg26898376	chr11:64110657	CCDC88B	0.61	5.13	0.31	5.89e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.64	-0.34	4.68e-8	Vitiligo;
KIRP	cis	rs7582720	1.000	rs79633844	chr2:203683990	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	8.93	0.49	1.04e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19048426	chr11:1594312	HCCA2;DUSP8;LOC338651	0.48	6.34	0.37	1.08e-9	Parkinson's disease;
KIRP	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.56	7.36	0.42	2.83e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs4805272	0.962	rs4805277	chr19:29330943	C/G	cg15000279	chr19:29285009	NA	-0.38	-5.77	-0.35	2.39e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.83	0.35	1.7e-8	Platelet count;
KIRP	cis	rs2071403	1.000	rs2298876	chr2:1416037	G/A	cg06500727	chr2:1417164	TPO	0.43	6.67	0.39	1.72e-10	Thyroid peroxidase antibody positivity;
KIRP	cis	rs9900972	0.721	rs11656224	chr17:76867996	A/G	cg20937029	chr17:76870563	TIMP2	0.44	4.87	0.3	2e-6	Obesity-related traits;
KIRP	cis	rs6800768	0.633	rs62255804	chr3:24149034	G/A	cg10674438	chr3:24145617	LOC152024	-0.52	-6.88	-0.4	4.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.49	6.57	0.39	3.03e-10	Testicular germ cell tumor;
KIRP	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.47	6.78	0.4	8.85e-11	Lewy body disease;
KIRP	cis	rs1190552	0.846	rs3742437	chr14:102965047	G/A	cg10241871	chr14:102965420	TECPR2	-0.58	-6.84	-0.4	6.25e-11	Blood protein levels;
KIRP	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.61	11.32	0.59	3.51e-24	Bone mineral density;
KIRP	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.36	-0.47	4.63e-15	Retinal vascular caliber;
KIRP	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.58	-0.39	2.81e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.58	-6.99	-0.41	2.54e-11	P wave terminal force;
KIRP	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg00806126	chr19:22604979	ZNF98	-0.67	-7.11	-0.41	1.29e-11	Pain;
KIRP	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg08501292	chr6:25962987	TRIM38	1.05	7.99	0.45	5.26e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3789045	0.866	rs11584700	chr1:204576983	C/T	cg18185008	chr1:204589407	LRRN2	0.63	7.19	0.42	7.93e-12	Educational attainment (college completion);
KIRP	trans	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg25214090	chr10:38739885	LOC399744	0.48	6.15	0.37	3.18e-9	Diastolic blood pressure;
KIRP	cis	rs13385	0.769	rs6878006	chr5:139595751	T/C	cg01860693	chr5:139557145	C5orf32	0.49	5.38	0.32	1.75e-7	Atrial fibrillation;
KIRP	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg05973401	chr12:123451056	ABCB9	-0.52	-5.19	-0.31	4.5e-7	Neutrophil percentage of white cells;
KIRP	cis	rs9469913	0.799	rs2815005	chr6:34638847	G/A	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.31	-0.37	1.26e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	0.74	6.91	0.4	4.02e-11	Arsenic metabolism;
KIRP	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.15	-11.21	-0.58	7.68e-24	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs4740619	0.647	rs9792412	chr9:16025889	C/T	cg14451791	chr9:16040625	NA	-0.41	-5.24	-0.32	3.42e-7	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07089235	chr4:141294546	SCOC	-0.5	-6.03	-0.36	6.07e-9	Interleukin-4 levels;
KIRP	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg18016565	chr1:150552671	MCL1	-0.36	-5.61	-0.34	5.48e-8	Melanoma;
KIRP	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.65	9.03	0.5	5.25e-17	Total body bone mineral density;
KIRP	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21747090	chr2:27597821	SNX17	-0.46	-6.28	-0.37	1.49e-9	Total body bone mineral density;
KIRP	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg14346243	chr4:90757452	SNCA	-0.42	-5.29	-0.32	2.73e-7	Neuroticism;
KIRP	cis	rs4774899	0.966	rs7161965	chr15:57485620	G/A	cg13626582	chr15:57592083	LOC283663	-0.21	-5.02	-0.3	9.96e-7	Urinary tract infection frequency;
KIRP	cis	rs72634258	0.740	rs6665452	chr1:8172492	A/T	cg00042356	chr1:8021962	PARK7	-0.49	-4.95	-0.3	1.4e-6	Inflammatory bowel disease;
KIRP	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg13628971	chr7:2884303	GNA12	0.61	7.06	0.41	1.71e-11	Height;
KIRP	cis	rs7007076	0.808	rs1529619	chr8:124723780	A/T	cg00283535	chr8:124749564	ANXA13	-0.58	-6.57	-0.39	2.92e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg00074818	chr8:8560427	CLDN23	0.43	6.39	0.38	8.42e-10	Obesity-related traits;
KIRP	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.92	-8.6	-0.48	9.34e-16	Rheumatoid arthritis;
KIRP	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.15	-0.37	3.03e-9	Systolic blood pressure;
KIRP	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg02931644	chr1:25747376	RHCE	0.47	8.95	0.5	8.66e-17	Plateletcrit;Mean corpuscular volume;
KIRP	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.8	7.36	0.42	2.7e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11645453	chr3:52864694	ITIH4	-0.36	-5.49	-0.33	9.95e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg00405596	chr8:11794950	NA	0.44	5.29	0.32	2.77e-7	Monocyte count;
KIRP	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.6	9.75	0.53	3.41e-19	Total body bone mineral density;
KIRP	cis	rs7709377	0.597	rs6594952	chr5:115488032	A/C	cg23108291	chr5:115420582	COMMD10	0.43	5.24	0.32	3.53e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.86	-0.49	1.69e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4006360	0.646	rs4890158	chr17:39295805	A/T	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.78	-0.44	1.99e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs2224391	0.554	rs114825667	chr6:5242618	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-6.04	-0.36	5.65e-9	Height;
KIRP	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.5	0.48	1.81e-15	IgG glycosylation;
KIRP	cis	rs2213920	1.000	rs9299227	chr9:118263508	A/G	cg13918206	chr9:118159781	DEC1	0.87	8.53	0.48	1.52e-15	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.82	11.32	0.59	3.52e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.8	0.49	2.45e-16	Motion sickness;
KIRP	cis	rs78487399	0.808	rs17030946	chr2:43733509	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-5.06	-0.31	8.25e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg17145862	chr1:211918768	LPGAT1	-0.9	-13.12	-0.64	3.65e-30	Leprosy;
KIRP	cis	rs7005380	0.581	rs2017310	chr8:120933341	A/G	cg21645572	chr8:120931649	DEPDC6	-0.51	-7.12	-0.41	1.21e-11	Interstitial lung disease;
KIRP	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg12435725	chr3:58293450	RPP14	-0.48	-5.1	-0.31	6.77e-7	Cholesterol, total;
KIRP	cis	rs4979906	1.000	rs11002246	chr10:79446777	T/A	cg07817648	chr10:79422355	NA	-0.48	-5.14	-0.31	5.5e-7	Mortality in heart failure;
KIRP	cis	rs7258465	1.000	rs4808133	chr19:18608518	C/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.08	-0.36	4.64e-9	Breast cancer;
KIRP	trans	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg13565492	chr6:43139072	SRF	-0.87	-8.04	-0.46	3.8e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg13962347	chr6:5174647	LYRM4	-0.63	-8.65	-0.48	6.93e-16	Height;
KIRP	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.71	-8.45	-0.47	2.6e-15	Homoarginine levels;
KIRP	cis	rs55962025	0.804	rs3775061	chr4:3238754	A/G	cg13731523	chr4:3047190	NA	0.32	5.03	0.31	9.51e-7	Parental longevity (mother's age at death);
KIRP	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.49	7.35	0.42	2.94e-12	Resting heart rate;
KIRP	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg20368463	chr18:77673604	PQLC1	0.65	5.39	0.32	1.66e-7	Opioid sensitivity;
KIRP	cis	rs4742903	0.904	rs10123189	chr9:107000640	A/G	cg14250997	chr9:106856677	SMC2	0.39	5.26	0.32	3.11e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.81	0.35	1.92e-8	Melanoma;
KIRP	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04025307	chr7:1156635	C7orf50	0.52	6.16	0.37	2.89e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg27490568	chr2:178487706	NA	0.39	5.26	0.32	3.14e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg11846333	chr4:119757529	SEC24D	1.1	6.27	0.37	1.63e-9	Cannabis dependence symptom count;
KIRP	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.45	-0.38	5.88e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	6.66	0.39	1.75e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs7424096	0.613	rs72873859	chr2:37246738	T/G	cg14987922	chr2:37194071	STRN	0.49	5.03	0.31	9.28e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.97	0.36	8.07e-9	Type 2 diabetes;
KIRP	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg23594656	chr7:65796392	TPST1	0.38	5.26	0.32	3.15e-7	Aortic root size;
KIRP	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg01721255	chr8:58191610	C8orf71	0.56	4.89	0.3	1.83e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs10077591	0.549	rs2112352	chr5:165329713	T/C	cg13976338	chr5:165423657	NA	-0.55	-7.2	-0.42	7.27e-12	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.46	6.53	0.38	3.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg02023728	chr11:77925099	USP35	0.35	5.51	0.33	8.95e-8	Alzheimer's disease (survival time);
KIRP	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	5.48	0.33	1.04e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.44	6.14	0.36	3.31e-9	Coronary artery disease;
KIRP	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.54	-7.2	-0.42	7.21e-12	Vitiligo;
KIRP	cis	rs6952809	1.000	rs28712717	chr7:2449590	T/C	cg06995285	chr7:2418615	EIF3B	0.37	4.94	0.3	1.46e-6	Multiple sclerosis;
KIRP	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg17207736	chr8:142237307	SLC45A4	0.53	6.71	0.39	1.35e-10	Immature fraction of reticulocytes;
KIRP	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.68	-8.6	-0.48	9.25e-16	Blood trace element (Zn levels);
KIRP	cis	rs829883	0.934	rs1641642	chr12:98898726	A/G	cg25150519	chr12:98850993	NA	0.85	12.51	0.62	3.95e-28	Colorectal adenoma (advanced);
KIRP	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg01422370	chr2:73384389	NA	0.45	6.08	0.36	4.45e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2220004	0.642	rs11227155	chr11:55842512	C/G	cg01505312	chr11:56258856	OR5M8;OR8U8	0.51	5.72	0.34	3.05e-8	Odorant perception (&beta-damascenone);
KIRP	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.2	-0.42	7.13e-12	Type 2 diabetes;
KIRP	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	1.08	16.23	0.72	9.3e-41	Menopause (age at onset);
KIRP	cis	rs6686643	0.868	rs9333461	chr1:165618320	G/T	cg19407955	chr1:165599744	MGST3	-0.42	-5.08	-0.31	7.34e-7	Total ventricular volume;
KIRP	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.29	-0.42	4.13e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.56	5.06	0.31	8.14e-7	Diabetic retinopathy;
KIRP	cis	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg19847130	chr8:10466454	RP1L1	0.38	5.67	0.34	3.96e-8	Neuroticism;
KIRP	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17376030	chr22:41985996	PMM1	0.81	8.31	0.47	6.37e-15	Vitiligo;
KIRP	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.84	13.55	0.65	1.24e-31	Multiple myeloma (IgH translocation);
KIRP	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.59	-6.56	-0.39	3.18e-10	Menarche (age at onset);
KIRP	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.49	-5.66	-0.34	4.15e-8	Neuroticism;
KIRP	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.96	15.95	0.71	8.53e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg22437258	chr11:111473054	SIK2	0.58	6.79	0.4	8.51e-11	Primary sclerosing cholangitis;
KIRP	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg09571762	chr12:39539558	NA	0.34	4.99	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.78	14.85	0.69	4.8e-36	Lymphocyte counts;
KIRP	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg00204512	chr16:28754710	NA	0.41	5.2	0.31	4.2e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg07701084	chr6:150067640	NUP43	0.71	9.72	0.53	4.18e-19	Lung cancer;
KIRP	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-6.97	-0.41	2.84e-11	Personality dimensions;
KIRP	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg00129232	chr17:37814104	STARD3	0.66	7.04	0.41	1.87e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26002218	chr14:103986227	CKB	0.28	5.79	0.35	2.1e-8	Body mass index;
KIRP	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.71	-8.86	-0.49	1.6e-16	Pancreatic cancer;
KIRP	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.62	-8.9	-0.49	1.25e-16	Schizophrenia;
KIRP	cis	rs16973500	0.711	rs72801789	chr16:71959748	C/T	cg09427745	chr16:71932006	KIAA0174	-0.59	-5.13	-0.31	5.79e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.74	9.25	0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg06307176	chr5:131281290	NA	0.57	6.51	0.38	4.07e-10	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.5	-6.16	-0.37	2.88e-9	Longevity;Endometriosis;
KIRP	cis	rs6909279	0.648	rs6919923	chr6:151849670	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	-0.57	-7.05	-0.41	1.77e-11	Bone mineral density;
KIRP	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-6.66	-0.39	1.78e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.63	6.02	0.36	6.22e-9	Lung function (FEV1);
KIRP	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.87	-9.45	-0.52	2.8e-18	Pulmonary function decline;
KIRP	cis	rs9879311	0.522	rs7627223	chr3:10422406	C/G	cg11030744	chr3:10328490	GHRL;GHRLOS	0.44	5.24	0.32	3.41e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs13170463	0.579	rs80105893	chr5:8037630	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.69	10.2	0.55	1.29e-20	Prostate cancer;
KIRP	cis	rs8050500	0.567	rs11150621	chr16:31406756	C/T	cg08509907	chr16:31477327	ARMC5	-0.53	-5.95	-0.35	9.38e-9	Red cell distribution width;
KIRP	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.93	-0.45	7.63e-14	Tonsillectomy;
KIRP	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.68	8.83	0.49	2.01e-16	Bladder cancer;
KIRP	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.33	-0.32	2.26e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12976411	0.575	rs59290294	chr19:32827336	T/C	cg18253629	chr19:32836317	ZNF507	0.66	5.1	0.31	6.75e-7	Coronary artery disease;
KIRP	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg26769984	chr7:1090371	C7orf50	0.84	6.95	0.4	3.34e-11	Bronchopulmonary dysplasia;
KIRP	trans	rs61884328	0.866	rs17790156	chr11:46905318	A/T	cg10758369	chr1:48459236	NA	0.44	6.19	0.37	2.51e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg00129232	chr17:37814104	STARD3	0.52	6.56	0.39	3.07e-10	Self-reported allergy;
KIRP	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.95	-0.3	1.4e-6	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19372731	chr12:1800405	ADIPOR2	0.5	6.42	0.38	6.83e-10	Parkinson's disease;
KIRP	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg02023728	chr11:77925099	USP35	0.3	5.17	0.31	4.78e-7	Alzheimer's disease (survival time);
KIRP	cis	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.27	-0.37	1.6e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.63	8.69	0.48	5.17e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	0.94	11.19	0.58	9.06e-24	Vitiligo;
KIRP	cis	rs7260538	0.509	rs10420194	chr19:41529781	A/T	cg27089200	chr19:41531976	NA	0.38	4.9	0.3	1.76e-6	DDT metabolite (p,p'-DDE levels);
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.69	0.34	3.6e-8	Lung cancer;
KIRP	cis	rs77688320	0.535	rs60148247	chr2:202378493	C/T	cg06431681	chr2:202330990	STRADB	-0.44	-5.23	-0.32	3.65e-7	Breast cancer;
KIRP	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg16586182	chr3:47516702	SCAP	0.56	6.72	0.39	1.23e-10	Birth weight;
KIRP	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.83	-8.03	-0.46	4.07e-14	Obesity;Body mass index;
KIRP	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg21427119	chr20:30132790	HM13	-0.55	-6.2	-0.37	2.34e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs7630877	0.886	rs7637613	chr3:179620717	A/G	cg18765712	chr3:179670323	PEX5L	0.56	6.75	0.4	1.04e-10	Type 2 diabetes;
KIRP	cis	rs9467160	0.644	rs3846833	chr6:24462367	C/T	cg20631270	chr6:24437470	GPLD1	0.5	4.91	0.3	1.63e-6	Liver enzyme levels;
KIRP	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.07	-0.36	4.72e-9	Mean corpuscular volume;
KIRP	cis	rs12200782	1.000	rs12200782	chr6:26403036	C/G	cg11502198	chr6:26597334	ABT1	-0.79	-5.51	-0.33	8.89e-8	Small cell lung carcinoma;
KIRP	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.62	8.76	0.49	3.2e-16	Schizophrenia;
KIRP	cis	rs2273669	0.667	rs7766248	chr6:109347262	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.48	6.78	0.4	8.94e-11	Red blood cell count;
KIRP	cis	rs4356932	0.967	rs4241581	chr4:76962055	G/A	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-5.34	-0.32	2.09e-7	Eosinophil percentage of white cells;
KIRP	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg18882449	chr10:104885122	NT5C2	-0.49	-6.33	-0.37	1.16e-9	Arsenic metabolism;
KIRP	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.2e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg25730555	chr22:47059586	GRAMD4	0.5	6.02	0.36	6.23e-9	Urate levels in obese individuals;
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.65	-0.39	1.85e-10	Lung cancer;
KIRP	cis	rs963731	0.649	rs1377860	chr2:39290425	C/G	cg04010122	chr2:39346883	SOS1	0.87	5.73	0.34	2.93e-8	Corticobasal degeneration;
KIRP	cis	rs6684428	1.000	rs61774842	chr1:56366173	A/G	cg11651538	chr1:56320950	NA	-0.79	-9.49	-0.52	2.11e-18	Airflow obstruction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12518626	chr4:121079963	NA	-0.41	-6.78	-0.4	8.72e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.81	-10.94	-0.57	5.85e-23	Longevity;Endometriosis;
KIRP	cis	rs375066	0.620	rs10401170	chr19:44299623	C/T	cg11993925	chr19:44307056	LYPD5	-0.36	-5.02	-0.3	9.88e-7	Breast cancer;
KIRP	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	0.99	7.36	0.43	2.68e-12	IgG glycosylation;
KIRP	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.79	0.4	8.59e-11	Electroencephalogram traits;
KIRP	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	1.02	10.88	0.57	9.33e-23	HIV-1 control;
KIRP	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.67	9.94	0.54	8.71e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.62	5.05	0.31	8.71e-7	Putamen volume;
KIRP	trans	rs7656342	0.755	rs1320054	chr4:9870125	C/T	cg26043149	chr18:55253948	FECH	0.51	6.13	0.36	3.46e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.9	12.41	0.62	9.06e-28	Schizophrenia;
KIRP	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg17366294	chr4:99064904	C4orf37	0.43	6.22	0.37	2.1e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs357618	1.000	rs165352	chr5:150856107	T/G	cg22672639	chr5:150884813	FAT2	0.35	5.33	0.32	2.21e-7	Basophil percentage of white cells;
KIRP	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.73	8.96	0.5	8.52e-17	Mammographic density (dense area);
KIRP	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg19000871	chr14:103996768	TRMT61A	-0.54	-5.86	-0.35	1.51e-8	Reticulocyte count;
KIRP	cis	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs6669919	0.653	rs6674367	chr1:211685413	C/T	cg10512769	chr1:211675356	NA	-0.56	-8.03	-0.46	4.09e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11955175	1.000	rs11954639	chr5:40674979	A/G	cg05478818	chr5:40835740	RPL37	-0.62	-5.04	-0.31	8.86e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg01138653	chr3:52720323	GNL3;PBRM1	-0.44	-6.38	-0.38	8.95e-10	Warfarin maintenance dose;
KIRP	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg12560992	chr17:57184187	TRIM37	0.64	6.73	0.39	1.21e-10	Testicular germ cell tumor;
KIRP	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg11707556	chr5:10655725	ANKRD33B	0.67	8.48	0.48	2.11e-15	Coronary artery disease;
KIRP	cis	rs500492	0.508	rs449566	chr16:1074581	C/T	cg09791621	chr16:1078722	NA	0.44	4.99	0.3	1.12e-6	Polycystic ovary syndrome;
KIRP	cis	rs2733201	1.000	rs1426658	chr15:44338919	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.67	-5.24	-0.32	3.5e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.77	12.03	0.61	1.59e-26	Colorectal cancer;
KIRP	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg23307798	chr14:103986281	CKB	-0.44	-5.95	-0.35	9.13e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6815814	0.861	rs6843043	chr4:38843136	A/G	cg06935464	chr4:38784597	TLR10	0.42	5.17	0.31	4.95e-7	Breast cancer;
KIRP	cis	rs10782582	0.586	rs1856791	chr1:76308942	C/T	cg10523679	chr1:76189770	ACADM	-0.47	-6.53	-0.38	3.74e-10	Daytime sleep phenotypes;
KIRP	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.64	12.23	0.61	3.57e-27	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24310785	chr6:163985223	QKI	-0.43	-6.45	-0.38	5.75e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs2073300	1.000	rs6137967	chr20:23447108	A/T	cg12062639	chr20:23401060	NAPB	-0.8	-6.95	-0.41	3.23e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	10.06	0.54	3.6e-20	Total body bone mineral density;
KIRP	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg07395648	chr5:131743802	NA	0.36	4.99	0.3	1.16e-6	Blood metabolite levels;
KIRP	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg23978390	chr7:1156363	C7orf50	-0.56	-6.12	-0.36	3.65e-9	Bronchopulmonary dysplasia;
KIRP	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.78	9.17	0.5	1.98e-17	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg04226714	chr8:49833948	SNAI2	-0.49	-6.74	-0.39	1.09e-10	Life satisfaction;
KIRP	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11264213	0.591	rs274728	chr1:36493420	T/C	cg27506609	chr1:36549197	TEKT2	-1.19	-7.55	-0.43	8.47e-13	Schizophrenia;
KIRP	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.11	-0.54	2.56e-20	Hemoglobin concentration;
KIRP	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.51	6.65	0.39	1.84e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg09137382	chr11:130731461	NA	0.59	8.53	0.48	1.49e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.61	-7.5	-0.43	1.18e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg05025164	chr4:1340916	KIAA1530	0.55	7.26	0.42	5.18e-12	Longevity;
KIRP	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.76	11.47	0.59	1.16e-24	Oral cavity cancer;
KIRP	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11613427	chr3:52932208	TMEM110	-0.31	-5.07	-0.31	7.71e-7	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17358127	chr4:118005533	TRAM1L1	0.54	7.35	0.42	2.95e-12	Interleukin-4 levels;
KIRP	cis	rs2635047	0.542	rs2668764	chr18:44790218	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.45	-6.85	-0.4	5.84e-11	Educational attainment;
KIRP	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg27490568	chr2:178487706	NA	0.55	7.56	0.43	7.84e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12681366	0.734	rs16916796	chr8:95402229	A/G	cg13257157	chr8:95487014	RAD54B	0.4	4.93	0.3	1.52e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs9398803	0.723	rs1262546	chr6:127075491	T/C	cg19875578	chr6:126661172	C6orf173	-0.42	-5.5	-0.33	9.37e-8	Male-pattern baldness;
KIRP	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg11608241	chr8:8085544	FLJ10661	0.45	5.51	0.33	9.15e-8	Mood instability;
KIRP	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-8.02	-0.46	4.28e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg23978390	chr7:1156363	C7orf50	0.56	5.97	0.36	8.06e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.34	-0.32	2.16e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg08975724	chr8:8085496	FLJ10661	-0.64	-7.96	-0.45	6.23e-14	Retinal vascular caliber;
KIRP	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	17.44	0.74	6.65e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2072732	0.756	rs12041634	chr1:2951034	A/T	cg11731671	chr1:2995604	PRDM16	-0.45	-5.83	-0.35	1.74e-8	Plateletcrit;
KIRP	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs11735612	0.624	rs58336339	chr4:138527674	A/G	cg12033966	chr4:138453416	PCDH18	0.36	4.97	0.3	1.28e-6	Obsessive-compulsive disorder or autism spectrum disorder;
KIRP	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.44	5.02	0.31	9.75e-7	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg07148914	chr20:33460835	GGT7	-0.53	-7.04	-0.41	1.89e-11	Height;
KIRP	cis	rs62413470	1.000	rs78996483	chr6:55934556	C/T	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg08600765	chr20:34638493	LOC647979	-0.84	-8.83	-0.49	2.06e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg14768367	chr16:72042858	DHODH	-1.06	-11.56	-0.59	5.6e-25	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17253835	chr13:72248378	DACH1	-0.4	-6.11	-0.36	3.8e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg22906224	chr7:99728672	NA	0.62	6.96	0.41	3e-11	Coronary artery disease;
KIRP	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9815354	1.000	rs28755797	chr3:41774446	C/T	cg03022575	chr3:42003672	ULK4	0.64	6.52	0.38	4.01e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.06	0.67	2.32e-33	Platelet count;
KIRP	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.28	7.47	0.43	1.42e-12	Primary biliary cholangitis;
KIRP	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	13.88	0.66	9.97e-33	Ulcerative colitis;
KIRP	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.84	9.38	0.51	4.53e-18	Gut microbiome composition (summer);
KIRP	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg22532475	chr10:104410764	TRIM8	0.29	5.21	0.32	4.03e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10814247	0.675	rs1930361	chr9:35266881	T/A	cg15271616	chr9:35490515	RUSC2	0.4	5.53	0.33	8.3e-8	Psoriasis;
KIRP	cis	rs2281727	0.500	rs2169356	chr17:2138016	A/T	cg16513277	chr17:2031491	SMG6	-0.67	-9.31	-0.51	7.53e-18	Coronary artery disease;Body mass index;
KIRP	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.46	6.58	0.39	2.75e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs8103278	0.507	rs4802275	chr19:46260375	C/T	cg02376097	chr19:46275166	DMPK	0.48	6.54	0.38	3.58e-10	Coronary artery disease;
KIRP	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.66	8.25	0.47	9.4e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs787274	1.000	rs787302	chr9:115543839	G/A	cg13803584	chr9:115635662	SNX30	-0.72	-6.54	-0.39	3.45e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg25838818	chr2:108905173	SULT1C2	-0.43	-6.5	-0.38	4.51e-10	Blood pressure;
KIRP	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg22437258	chr11:111473054	SIK2	0.58	6.79	0.4	8.51e-11	Primary sclerosing cholangitis;
KIRP	trans	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs193541	0.593	rs154517	chr5:122189825	A/T	cg19412675	chr5:122181750	SNX24	0.6	6.4	0.38	7.67e-10	Glucose homeostasis traits;
KIRP	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.84	-0.4	6.2e-11	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.46	6.08	0.36	4.44e-9	Parkinson's disease;
KIRP	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.58	-0.39	2.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13858975	chr15:52016644	LYSMD2	0.4	6.18	0.37	2.64e-9	C-reactive protein;
KIRP	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg06521331	chr12:34319734	NA	-0.63	-7.56	-0.43	8.15e-13	Morning vs. evening chronotype;
KIRP	cis	rs4908768	0.906	rs55830087	chr1:8681550	C/T	cg25722041	chr1:8623473	RERE	0.82	9.58	0.52	1.15e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.6	8.17	0.46	1.62e-14	Multiple myeloma (IgH translocation);
KIRP	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg12623918	chr2:306882	NA	0.46	5.83	0.35	1.72e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg02336718	chr17:17403227	NA	0.37	5.6	0.34	5.81e-8	Total body bone mineral density;
KIRP	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg13256891	chr4:100009986	ADH5	0.52	6.64	0.39	1.98e-10	Alcohol dependence;
KIRP	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.94	10.54	0.56	1.14e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg18306943	chr3:40428807	ENTPD3	0.47	6.34	0.37	1.1e-9	Renal cell carcinoma;
KIRP	cis	rs9463078	0.547	rs4714822	chr6:44742290	T/C	cg25276700	chr6:44698697	NA	0.34	4.94	0.3	1.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg12841684	chr4:149251768	NR3C2	-0.41	-6.09	-0.36	4.38e-9	Select biomarker traits;
KIRP	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg10503236	chr1:231470652	EXOC8	-0.49	-7.07	-0.41	1.57e-11	Hemoglobin concentration;
KIRP	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.91	14.88	0.69	3.83e-36	Breast cancer;
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.51	6.86	0.4	5.61e-11	Testicular germ cell tumor;
KIRP	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.62	-5.56	-0.33	7.04e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	1.01	12.42	0.62	8.22e-28	Platelet distribution width;
KIRP	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.68	-8.0	-0.45	4.97e-14	Serum sulfate level;
KIRP	cis	rs10518128	1.000	rs6847968	chr4:75715519	G/A	cg20122727	chr4:75719957	BTC	0.56	5.66	0.34	4.25e-8	Electroencephalogram traits;
KIRP	cis	rs6909279	0.933	rs9479072	chr6:151890789	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.52	-6.75	-0.4	1.07e-10	Bone mineral density;
KIRP	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg02696742	chr7:106810147	HBP1	-0.78	-8.13	-0.46	2.16e-14	Coronary artery disease;
KIRP	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18657643	chr3:195545456	NA	0.52	4.91	0.3	1.64e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.93	-10.32	-0.55	5.67e-21	Blood protein levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06588466	chr13:30338633	UBL3	-0.42	-6.41	-0.38	7.21e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.54	6.04	0.36	5.78e-9	Cystic fibrosis severity;
KIRP	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg22117172	chr7:91764530	CYP51A1	0.48	6.88	0.4	4.9e-11	Breast cancer;
KIRP	cis	rs7083	0.935	rs492151	chr11:117145815	G/A	cg11523350	chr11:117171073	BACE1	-0.27	-5.32	-0.32	2.34e-7	Blood protein levels;
KIRP	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg03128945	chr5:622914	CEP72	-0.49	-6.77	-0.4	9.13e-11	Obesity-related traits;
KIRP	cis	rs9584850	0.609	rs7983408	chr13:99155593	G/C	cg20750642	chr13:99100586	FARP1	-0.53	-5.62	-0.34	5.11e-8	Neuroticism;
KIRP	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg00543991	chr22:32367038	NA	0.53	4.88	0.3	1.94e-6	Childhood ear infection;
KIRP	cis	rs6142102	0.961	rs4911408	chr20:32700566	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	6.53	0.38	3.81e-10	Skin pigmentation;
KIRP	cis	rs1448094	0.717	rs7298614	chr12:86296513	C/T	cg02569458	chr12:86230093	RASSF9	0.37	5.39	0.32	1.69e-7	Major depressive disorder;
KIRP	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg23682824	chr7:23144976	KLHL7	0.42	5.45	0.33	1.23e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs72634258	0.554	rs35307738	chr1:7919839	C/G	cg26816564	chr1:7831052	VAMP3	0.66	5.9	0.35	1.22e-8	Inflammatory bowel disease;
KIRP	cis	rs1045714	0.943	rs1045711	chr7:2653571	C/T	cg20813462	chr7:2646259	IQCE	0.69	6.15	0.37	3.11e-9	Urate levels in lean individuals;
KIRP	cis	rs6782228	0.628	rs7641584	chr3:128392630	G/C	cg18648031	chr3:128330563	NA	0.26	5.37	0.32	1.78e-7	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	trans	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg19694781	chr19:47549865	TMEM160	0.58	7.7	0.44	3.26e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg23683012	chr15:78369302	TBC1D2B	0.36	5.13	0.31	5.92e-7	Breast cancer;
KIRP	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18252515	chr7:66147081	NA	0.47	5.71	0.34	3.3e-8	Aortic root size;
KIRP	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.95	6.71	0.39	1.36e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.63	-7.98	-0.45	5.64e-14	Obesity-related traits;
KIRP	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.77	9.05	0.5	4.6e-17	Corneal astigmatism;
KIRP	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-7.98	-0.45	5.69e-14	Alzheimer's disease;
KIRP	cis	rs7084783	0.519	rs10883885	chr10:105333852	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.43	5.45	0.33	1.23e-7	Fear of pain;
KIRP	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg27205649	chr11:78285834	NARS2	-0.51	-5.12	-0.31	6.17e-7	Testicular germ cell tumor;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03460032	chr13:48936995	RB1	-0.48	-7.39	-0.43	2.32e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg01872077	chr2:219646372	CYP27A1	0.38	4.98	0.3	1.19e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.81	-0.45	1.69e-13	Tonsillectomy;
KIRP	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg06074448	chr4:187884817	NA	-0.78	-13.19	-0.64	2.07e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.35	-0.42	2.92e-12	Neuroticism;
KIRP	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.39	5.57	0.33	6.56e-8	Optic cup area;
KIRP	cis	rs516946	1.000	rs750625	chr8:41525914	C/T	cg19441908	chr8:41529140	ANK1	0.49	6.93	0.4	3.75e-11	Type 2 diabetes;
KIRP	cis	rs10465746	0.967	rs12407641	chr1:84368115	T/C	cg10977910	chr1:84465055	TTLL7	0.45	5.43	0.33	1.34e-7	Obesity-related traits;
KIRP	cis	rs2055729	0.591	rs17150950	chr8:9881009	T/C	cg21625330	chr8:9911636	MSRA	-0.48	-5.96	-0.36	8.6e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7116495	0.609	rs7126394	chr11:71685429	A/G	cg10381502	chr11:71823885	C11orf51	-1.03	-7.17	-0.42	8.64e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg13409248	chr3:40428643	ENTPD3	0.39	5.25	0.32	3.24e-7	Renal cell carcinoma;
KIRP	cis	rs5753618	0.561	rs2040533	chr22:31679110	G/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.37	-0.32	1.8e-7	Colorectal cancer;
KIRP	cis	rs2150410	0.915	rs68086041	chr21:40524875	T/G	cg11890956	chr21:40555474	PSMG1	-0.75	-5.38	-0.32	1.75e-7	Temperament (bipolar disorder);
KIRP	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.56	7.29	0.42	4.27e-12	Height;
KIRP	cis	rs4356932	1.000	rs17288671	chr4:76932001	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.25	0.37	1.75e-9	Blood protein levels;
KIRP	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.44	7.11	0.41	1.27e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.85	0.3	2.2e-6	Menopause (age at onset);
KIRP	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	1.04	9.52	0.52	1.65e-18	Type 2 diabetes;
KIRP	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg16141378	chr3:129829833	LOC729375	0.61	8.29	0.47	7.49e-15	Triglycerides;
KIRP	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg27124370	chr19:33622961	WDR88	0.58	7.15	0.41	9.82e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.71	10.92	0.57	6.8e-23	Coronary artery disease;
KIRP	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	1.22	7.13	0.41	1.09e-11	LDL cholesterol;
KIRP	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.05	-13.26	-0.65	1.24e-30	Exhaled nitric oxide output;
KIRP	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.82	11.35	0.59	2.71e-24	Morning vs. evening chronotype;
KIRP	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.49	7.52	0.43	1.02e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04409048	chr6:146203625	NA	-0.43	-6.57	-0.39	3e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg14650228	chr8:144573510	ZC3H3	-0.69	-4.89	-0.3	1.82e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs6088765	0.606	rs2425024	chr20:33844938	G/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-6.31	-0.37	1.31e-9	Ulcerative colitis;
KIRP	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg16926213	chr1:1841314	NA	0.32	5.51	0.33	9.11e-8	Body mass index;
KIRP	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg05340658	chr4:99064831	C4orf37	0.84	11.34	0.59	3.06e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg12131826	chr15:77904385	NA	-0.42	-4.9	-0.3	1.74e-6	Type 2 diabetes;
KIRP	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg12623918	chr2:306882	NA	0.46	5.78	0.35	2.2e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg12646754	chr1:2574751	NA	0.99	6.76	0.4	9.73e-11	P wave terminal force;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg10254082	chr7:997346	NA	0.48	5.07	0.31	7.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg23594656	chr7:65796392	TPST1	-0.34	-4.95	-0.3	1.37e-6	Aortic root size;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg09699651	chr6:150184138	LRP11	0.48	6.34	0.37	1.07e-9	Lung cancer;
KIRP	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.32	15.09	0.69	7.48e-37	Uric acid levels;
KIRP	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20939322	chr14:53342622	FERMT2	0.54	6.8	0.4	7.87e-11	Myopia (pathological);
KIRP	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg01528321	chr10:82214614	TSPAN14	0.83	9.78	0.53	2.8e-19	Post bronchodilator FEV1;
KIRP	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.35	-4.94	-0.3	1.41e-6	Monocyte count;
KIRP	cis	rs2274273	0.905	rs8007620	chr14:55586587	T/C	cg04306507	chr14:55594613	LGALS3	0.44	6.91	0.4	4.08e-11	Protein biomarker;
KIRP	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.61	-7.59	-0.44	6.69e-13	Mosquito bite size;
KIRP	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs2273156	1.000	rs36008567	chr14:35421076	G/C	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.69	-0.34	3.54e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.91	-0.45	8.77e-14	Height;
KIRP	cis	rs2273669	0.667	rs11153150	chr6:109316652	C/G	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.2	-0.37	2.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-6.44	-0.38	6.23e-10	Bipolar disorder;
KIRP	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.68	10.25	0.55	9.22e-21	Lung cancer;
KIRP	cis	rs7590368	0.673	rs2306922	chr2:10942520	C/T	cg15705551	chr2:10952987	PDIA6	0.65	6.28	0.37	1.54e-9	Educational attainment (years of education);
KIRP	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.93	-0.49	1.03e-16	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.7	0.53	4.62e-19	Corneal astigmatism;
KIRP	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg13731523	chr4:3047190	NA	-0.36	-6.06	-0.36	5.09e-9	Serum sulfate level;
KIRP	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.81	7.96	0.45	6.33e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs950776	0.678	rs12910237	chr15:78956338	C/T	cg06917634	chr15:78832804	PSMA4	0.61	6.84	0.4	6.42e-11	Sudden cardiac arrest;
KIRP	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.6	-8.47	-0.48	2.22e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.55	-7.19	-0.42	7.62e-12	Monobrow;
KIRP	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg08742575	chr21:47604166	C21orf56	-0.48	-5.13	-0.31	5.8e-7	Lymphocyte counts;
KIRP	cis	rs1215050	0.791	rs260890	chr4:98741698	A/G	cg05340658	chr4:99064831	C4orf37	0.55	6.63	0.39	2.08e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.51	-0.78	7.36e-52	Height;
KIRP	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.62	-9.56	-0.52	1.3e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg06917634	chr15:78832804	PSMA4	0.47	4.9	0.3	1.78e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4356975	0.563	rs11932131	chr4:69949547	G/T	cg27372994	chr4:70080453	UGT2B11	0.37	4.94	0.3	1.44e-6	Obesity-related traits;
KIRP	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg03511173	chr18:77590860	NA	-0.44	-4.88	-0.3	1.89e-6	Opioid sensitivity;
KIRP	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg03929089	chr4:120376271	NA	0.75	6.77	0.4	9.44e-11	Intraocular pressure;
KIRP	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.97e-8	Motion sickness;
KIRP	cis	rs6546886	0.912	rs7589915	chr2:74282130	G/C	cg14702570	chr2:74259524	NA	-0.31	-6.15	-0.37	3.06e-9	Dialysis-related mortality;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.78	-13.08	-0.64	5.02e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2219968	1.000	rs1073445	chr8:78959745	T/C	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.08e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.9	12.43	0.62	7.47e-28	Intelligence (multi-trait analysis);
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg18139020	chr1:33938191	ZSCAN20	-0.62	-6.4	-0.38	7.79e-10	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.63	-0.44	5.19e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.8	-7.81	-0.45	1.61e-13	Systemic lupus erythematosus;
KIRP	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.73	9.98	0.54	6.64e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20481151	chr12:117457813	FBXW8	0.51	6.22	0.37	2.07e-9	Interleukin-4 levels;
KIRP	cis	rs72634030	0.536	rs72634014	chr17:5177150	A/G	cg20802942	chr17:5185005	RABEP1	0.55	5.46	0.33	1.16e-7	Rheumatoid arthritis;
KIRP	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg08992911	chr2:238395768	MLPH	0.56	5.43	0.33	1.38e-7	Prostate cancer;
KIRP	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg05914723	chr15:78953907	NA	0.6	5.49	0.33	1.01e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg24642439	chr20:33292090	TP53INP2	-0.59	-7.68	-0.44	3.78e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.81	8.18	0.46	1.52e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs2456568	0.571	rs1105113	chr11:93693323	G/A	cg26875233	chr11:93583750	C11orf90	0.29	5.32	0.32	2.32e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg14993813	chr1:46806288	NSUN4	0.61	7.09	0.41	1.39e-11	Menopause (age at onset);
KIRP	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.06	0.36	5.13e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.97	-0.3	1.26e-6	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg18209359	chr17:80159595	CCDC57	-0.42	-5.48	-0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs7011507	1.000	rs56005426	chr8:49174998	T/C	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs741677	0.963	rs7214033	chr17:472173	C/T	cg13332499	chr17:408570	NA	0.41	5.34	0.32	2.16e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg23173402	chr1:227635558	NA	0.68	5.13	0.31	5.92e-7	Major depressive disorder;
KIRP	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg00919237	chr7:87102261	ABCB4	-0.75	-9.44	-0.52	3.05e-18	Gallbladder cancer;
KIRP	cis	rs10992471	0.528	rs10992347	chr9:95220633	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.42	-5.02	-0.3	9.83e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	0.55	6.47	0.38	5.14e-10	Prudent dietary pattern;
KIRP	cis	rs4356932	1.000	rs10000130	chr4:76939335	T/C	cg00809888	chr4:76862425	NAAA	0.45	6.23	0.37	2.03e-9	Blood protein levels;
KIRP	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.58	-6.99	-0.41	2.59e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2692947	0.562	rs11693248	chr2:96884553	G/A	cg23100626	chr2:96804247	ASTL	0.49	6.45	0.38	5.85e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	0.38	4.87	0.3	2.02e-6	Type 2 diabetes;
KIRP	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg04317338	chr11:64019027	PLCB3	0.83	6.38	0.38	8.79e-10	Mean platelet volume;
KIRP	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12756686	chr19:29218302	NA	0.87	8.56	0.48	1.25e-15	Methadone dose in opioid dependence;
KIRP	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.65	8.99	0.5	6.69e-17	Blood protein levels;
KIRP	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.64	-0.34	4.73e-8	Educational attainment;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14857851	chr3:15115139	ZFYVE20	0.44	6.3	0.37	1.33e-9	Survival in pancreatic cancer;
KIRP	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.9	13.63	0.66	6.64e-32	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.27	-22.18	-0.82	1.27e-60	Breast cancer;
KIRP	cis	rs4849845	0.886	rs10180682	chr2:121012033	A/G	cg24070213	chr2:121070622	NA	0.39	5.24	0.32	3.41e-7	Mean platelet volume;
KIRP	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.61	-5.27	-0.32	3e-7	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg23124695	chr7:108211104	THAP5;DNAJB9	-0.45	-6.13	-0.36	3.47e-9	Cancer;
KIRP	cis	rs2371030	1.000	rs1019392	chr2:211593082	A/C	cg18417063	chr2:211583084	NA	-0.51	-7.24	-0.42	5.63e-12	Non-small cell lung cancer;
KIRP	cis	rs4460629	0.710	rs11264318	chr1:155083717	A/T	cg02153340	chr1:155202674	NA	-0.39	-5.6	-0.34	5.8e-8	Serum magnesium levels;
KIRP	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg05361325	chr10:32636312	EPC1	-0.67	-6.34	-0.37	1.08e-9	Sexual dysfunction (female);
KIRP	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	1.05	14.72	0.68	1.29e-35	Menopause (age at onset);
KIRP	cis	rs4601821	0.895	rs2155464	chr11:113242448	T/C	cg14159747	chr11:113255604	NA	0.36	5.26	0.32	3.08e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.65	8.43	0.47	2.95e-15	Prudent dietary pattern;
KIRP	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	1.02	22.11	0.82	2.18e-60	Multiple myeloma;
KIRP	cis	rs8177876	0.642	rs56032321	chr16:81117906	A/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.64	-5.88	-0.35	1.36e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6001982	0.667	rs73167096	chr22:40894463	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg14673194	chr17:80132900	CCDC57	0.76	8.55	0.48	1.29e-15	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.97	-0.41	2.96e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg21401794	chr1:90099060	LRRC8C	0.7	9.8	0.53	2.4e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg06740227	chr12:86229804	RASSF9	0.41	5.17	0.31	4.93e-7	Major depressive disorder;
KIRP	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.39	-5.47	-0.33	1.08e-7	Coronary artery disease;
KIRP	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg05973401	chr12:123451056	ABCB9	0.63	7.53	0.43	9.88e-13	Platelet count;
KIRP	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg18016565	chr1:150552671	MCL1	0.4	6.04	0.36	5.66e-9	Melanoma;
KIRP	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.69	7.81	0.45	1.7e-13	Corneal astigmatism;
KIRP	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	6.92	0.4	3.87e-11	Neuroticism;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02359409	chr6:42947317	PEX6	-0.38	-5.18	-0.31	4.71e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.86	13.61	0.66	8.25e-32	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs526231	0.543	rs7714539	chr5:102328878	G/A	cg23492399	chr5:102201601	PAM	-0.48	-5.54	-0.33	7.81e-8	Primary biliary cholangitis;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg09597638	chr17:3907349	NA	0.81	16.43	0.72	1.87e-41	Type 2 diabetes;
KIRP	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.97	0.36	8.12e-9	Birth weight;
KIRP	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg16482183	chr6:26056742	HIST1H1C	0.64	7.28	0.42	4.54e-12	Iron status biomarkers;
KIRP	cis	rs11605924	0.901	rs11038672	chr11:45846498	C/G	ch.11.939596F	chr11:45881766	CRY2	-0.48	-5.77	-0.35	2.43e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs3790645	1.000	rs383913	chr1:26893306	A/G	cg23229016	chr1:26872525	RPS6KA1	0.23	6.15	0.36	3.14e-9	Glucose homeostasis traits;
KIRP	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg25319279	chr11:5960081	NA	-0.57	-5.8	-0.35	1.99e-8	DNA methylation (variation);
KIRP	trans	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg06521331	chr12:34319734	NA	0.53	6.56	0.39	3.18e-10	Bladder cancer;
KIRP	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg00684032	chr4:1343700	KIAA1530	0.48	6.14	0.36	3.25e-9	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.49	-0.33	1.02e-7	Life satisfaction;
KIRP	cis	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg07541023	chr7:19748670	TWISTNB	0.71	6.43	0.38	6.43e-10	Thyroid stimulating hormone;
KIRP	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.83	-11.41	-0.59	1.73e-24	Primary sclerosing cholangitis;
KIRP	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg17757837	chr7:157058334	UBE3C	-0.82	-11.3	-0.58	4.04e-24	Body mass index;
KIRP	cis	rs3779635	0.742	rs5000732	chr8:27253951	G/A	cg21186296	chr8:27182909	PTK2B	0.51	6.45	0.38	6.01e-10	Neuroticism;
KIRP	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.82	8.97	0.5	7.62e-17	Phospholipid levels (plasma);
KIRP	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg01879757	chr17:41196368	BRCA1	-0.73	-10.47	-0.56	1.91e-21	Menopause (age at onset);
KIRP	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg26681399	chr22:41777847	TEF	0.43	4.9	0.3	1.73e-6	Vitiligo;
KIRP	cis	rs17401966	0.558	rs17402762	chr1:10414470	T/C	cg17425144	chr1:10567563	PEX14	-0.29	-5.1	-0.31	6.88e-7	Hepatocellular carcinoma;
KIRP	cis	rs2380205	0.967	rs12784539	chr10:5898121	A/G	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.49e-8	Breast cancer;
KIRP	cis	rs6496044	0.963	rs6496050	chr15:86069250	A/G	cg17133734	chr15:86042851	AKAP13	-0.44	-5.24	-0.32	3.52e-7	Interstitial lung disease;
KIRP	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg03060546	chr3:49711283	APEH	-0.72	-5.46	-0.33	1.15e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7116495	1.000	rs2845857	chr11:71715215	C/G	cg11196788	chr11:71737549	NUMA1	0.57	5.16	0.31	5.09e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10405333	chr21:28516138	NA	0.38	6.04	0.36	5.54e-9	Cancer;
KIRP	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg26384229	chr12:38710491	ALG10B	0.66	9.13	0.5	2.49e-17	Morning vs. evening chronotype;
KIRP	cis	rs73086581	1.000	rs73086535	chr20:3944150	T/C	cg02187196	chr20:3869020	PANK2	0.5	5.02	0.3	9.9e-7	Response to antidepressants in depression;
KIRP	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg06481639	chr22:41940642	POLR3H	-0.42	-5.04	-0.31	8.98e-7	Neuroticism;
KIRP	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.58	-7.07	-0.41	1.61e-11	Osteoporosis;
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg11859384	chr17:80120422	CCDC57	0.46	5.91	0.35	1.11e-8	Life satisfaction;
KIRP	cis	rs7923609	1.000	rs10822149	chr10:64987412	G/A	cg01631684	chr10:65280961	REEP3	-0.48	-5.67	-0.34	4.07e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05347473	chr6:146136440	FBXO30	0.42	5.73	0.34	2.93e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-1.04	-8.46	-0.47	2.38e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg14580859	chr9:123691850	NA	0.36	5.05	0.31	8.62e-7	Rheumatoid arthritis;
KIRP	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg19637330	chr1:19110922	NA	-0.49	-5.22	-0.32	3.74e-7	Drug-induced liver injury (nitrofurantoin);
KIRP	cis	rs1448094	0.617	rs952851	chr12:86477341	C/T	cg00310523	chr12:86230176	RASSF9	-0.42	-6.17	-0.37	2.72e-9	Major depressive disorder;
KIRP	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.99	-0.3	1.15e-6	Bipolar disorder;
KIRP	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.22	0.42	6.6e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg12131826	chr15:77904385	NA	0.45	5.37	0.32	1.8e-7	Type 2 diabetes;
KIRP	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	0.84	11.75	0.6	1.3e-25	Primary sclerosing cholangitis;
KIRP	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg13147721	chr7:65941812	NA	-0.89	-6.36	-0.38	9.86e-10	Diabetic kidney disease;
KIRP	cis	rs953387	1.000	rs6715785	chr2:136910273	C/T	cg05194412	chr2:137003533	NA	-0.39	-5.03	-0.31	9.52e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.92	5.03	0.31	9.67e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4646312	0.555	rs9606190	chr22:19926004	T/C	cg07194846	chr22:19930177	COMT;TXNRD2	0.46	4.89	0.3	1.8e-6	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg15655495	chr12:38532458	NA	-0.29	-5.12	-0.31	6.13e-7	Bladder cancer;
KIRP	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg16524733	chr11:117070046	TAGLN	-0.4	-5.13	-0.31	5.85e-7	Blood protein levels;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	1.03	11.05	0.58	2.63e-23	Alzheimer's disease;
KIRP	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.55	-6.12	-0.36	3.57e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04374321	chr14:90722782	PSMC1	0.91	15.84	0.71	1.98e-39	Mortality in heart failure;
KIRP	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg22117172	chr7:91764530	CYP51A1	-0.39	-5.45	-0.33	1.2e-7	Breast cancer;
KIRP	cis	rs7359257	1.000	rs11071951	chr15:67694766	C/T	cg24579218	chr15:68104479	NA	0.36	5.36	0.32	1.91e-7	Menarche (age at onset);
KIRP	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg06521331	chr12:34319734	NA	-0.62	-7.42	-0.43	1.88e-12	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.57	-6.24	-0.37	1.9e-9	DNA methylation (variation);
KIRP	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg14829360	chr17:73884958	NA	-0.62	-8.92	-0.49	1.11e-16	Psoriasis;
KIRP	trans	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg19274270	chr17:78178856	CARD14	-0.36	-6.5	-0.38	4.33e-10	Educational attainment (years of education);
KIRP	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.71	9.33	0.51	6.33e-18	Cognitive function;
KIRP	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-8.39	-0.47	3.95e-15	Chronic sinus infection;
KIRP	cis	rs12620999	0.838	rs13007071	chr2:238038755	A/G	cg23555395	chr2:238036564	NA	-0.57	-6.72	-0.39	1.27e-10	Systemic lupus erythematosus;
KIRP	cis	rs2071403	0.933	rs10180405	chr2:1404850	A/G	cg06500727	chr2:1417164	TPO	0.49	7.79	0.44	1.86e-13	Thyroid peroxidase antibody positivity;
KIRP	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg11031976	chr2:198649780	BOLL	-0.57	-5.38	-0.32	1.7e-7	Ulcerative colitis;
KIRP	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.69	-0.39	1.51e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6910061	1.000	rs9468452	chr6:11121993	A/G	cg27233058	chr6:11094804	LOC221710	0.56	5.66	0.34	4.22e-8	Diabetic kidney disease;
KIRP	trans	rs9409565	0.826	rs9409564	chr9:97248166	C/T	cg05679027	chr9:99775184	HIATL2	-0.55	-6.45	-0.38	5.75e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.5	6.43	0.38	6.48e-10	Response to temozolomide;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg01879757	chr17:41196368	BRCA1	-0.78	-10.79	-0.57	1.82e-22	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07147063	chr16:67260764	TMEM208;LRRC29	0.54	6.93	0.4	3.6e-11	Parkinson's disease;
KIRP	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg23533926	chr12:111358616	MYL2	-0.53	-7.09	-0.41	1.38e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.51	-6.0	-0.36	7.03e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs1010254	0.510	rs888877	chr5:151760425	C/T	cg12297329	chr5:152029980	NA	-0.7	-6.76	-0.4	9.99e-11	Optic nerve measurement (cup area);
KIRP	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg01324507	chr7:1177794	C7orf50	0.4	4.98	0.3	1.18e-6	Longevity;Endometriosis;
KIRP	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg12131826	chr15:77904385	NA	0.48	6.46	0.38	5.62e-10	Type 2 diabetes;
KIRP	cis	rs11203032	0.831	rs4617498	chr10:90943713	G/A	cg16672925	chr10:90967113	CH25H	0.76	8.01	0.45	4.68e-14	Heart failure;
KIRP	cis	rs10129255	0.536	rs8004835	chr14:107142378	A/C	cg23076370	chr14:107095027	NA	-0.42	-5.42	-0.33	1.45e-7	Kawasaki disease;
KIRP	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg22778903	chr21:42741698	MX2	0.6	7.95	0.45	6.95e-14	Melanoma;
KIRP	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.42	6.61	0.39	2.38e-10	Multiple sclerosis;
KIRP	cis	rs4700695	0.697	rs2561240	chr5:65235310	T/C	cg21114390	chr5:65439923	SFRS12	0.58	5.18	0.31	4.58e-7	Facial morphology (factor 19);
KIRP	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.77	7.87	0.45	1.13e-13	Body mass index;
KIRP	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg13482628	chr17:19912719	NA	0.61	8.69	0.48	5.18e-16	Schizophrenia;
KIRP	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-6.17	-0.37	2.74e-9	Obesity-related traits;
KIRP	cis	rs785830	0.749	rs2479325	chr9:253282	C/G	cg14500300	chr9:211689	NA	-0.53	-7.33	-0.42	3.37e-12	Platelet distribution width;
KIRP	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.38	5.1	0.31	6.94e-7	Dupuytren's disease;
KIRP	cis	rs11734570	0.581	rs75356782	chr4:38600053	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	6.02	0.36	6.23e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs4862750	0.872	rs10027252	chr4:187873462	T/G	cg03452623	chr4:187889614	NA	-1.06	-18.94	-0.77	5.77e-50	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg10664184	chr19:17420304	DDA1	0.79	9.03	0.5	5e-17	Systemic lupus erythematosus;
KIRP	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg19025524	chr12:109796872	NA	-0.43	-5.64	-0.34	4.62e-8	Neuroticism;
KIRP	cis	rs7635838	0.892	rs9870881	chr3:11447082	A/G	cg00170343	chr3:11313890	ATG7	0.47	5.94	0.35	9.5e-9	HDL cholesterol;
KIRP	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.65	0.44	4.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2635047	0.542	rs2137289	chr18:44752125	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.76	0.4	1.01e-10	Educational attainment;
KIRP	cis	rs273573	0.643	rs921880	chr11:30899309	C/T	cg14844989	chr11:31128820	NA	0.34	4.84	0.3	2.27e-6	Total body bone mineral density;
KIRP	cis	rs7084402	0.967	rs1649091	chr10:60289440	T/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.34	0.51	6.18e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg23601095	chr6:26197514	HIST1H3D	1.02	8.78	0.49	2.85e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.59	0.34	5.96e-8	Homoarginine levels;
KIRP	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-9.62	-0.52	8.36e-19	Total body bone mineral density;
KIRP	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00933542	chr6:150070202	PCMT1	0.31	5.98	0.36	7.61e-9	Lung cancer;
KIRP	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.51	0.33	9.14e-8	Blood protein levels;
KIRP	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.55	-6.93	-0.4	3.77e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg08822215	chr16:89438651	ANKRD11	0.54	6.84	0.4	6.19e-11	Multiple myeloma (IgH translocation);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg26164735	chr4:71768712	MOBKL1A	0.47	6.07	0.36	4.71e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs8063160	0.688	rs35415928	chr16:89724268	C/T	cg07984980	chr16:89898383	SPIRE2	0.95	5.32	0.32	2.39e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
KIRP	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.77	0.44	2.07e-13	Aortic root size;
KIRP	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.48	-0.33	1.04e-7	Ileal carcinoids;
KIRP	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.64	7.65	0.44	4.54e-13	Height;
KIRP	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg03315344	chr16:75512273	CHST6	0.67	9.72	0.53	4.29e-19	Dupuytren's disease;
KIRP	cis	rs3136516	0.537	rs752848	chr11:47175176	G/A	cg16389345	chr11:46697382	NA	0.5	6.21	0.37	2.29e-9	Venous thromboembolism;
KIRP	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg23788917	chr6:8435910	SLC35B3	-0.62	-8.01	-0.45	4.48e-14	Motion sickness;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-10.24	-0.55	1.03e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg22907277	chr7:1156413	C7orf50	0.58	7.45	0.43	1.58e-12	Longevity;Endometriosis;
KIRP	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-1.0	-16.62	-0.73	4.21e-42	Height;
KIRP	cis	rs6032067	0.852	rs6032053	chr20:43829935	G/T	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg06204229	chr3:52865917	ITIH4	0.46	5.32	0.32	2.28e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.45	5.36	0.32	1.95e-7	HDL cholesterol;
KIRP	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.6	8.09	0.46	2.7e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7577696	0.597	rs212690	chr2:32437631	C/G	cg02381751	chr2:32503542	YIPF4	0.62	6.0	0.36	6.93e-9	Inflammatory biomarkers;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg01014287	chr1:78445169	FUBP1	0.47	6.55	0.39	3.3e-10	Inflammatory biomarkers;
KIRP	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.82	9.99	0.54	5.94e-20	Menarche (age at onset);
KIRP	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg15737290	chr11:93063684	CCDC67	0.59	7.03	0.41	2.08e-11	Pulmonary function decline;
KIRP	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	cis	rs9362426	1.000	rs9362426	chr6:88089874	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.43	5.2	0.31	4.25e-7	Depressive episodes in bipolar disorder;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg24095088	chr6:160210874	MRPL18;TCP1	0.93	6.28	0.37	1.48e-9	P wave terminal force;
KIRP	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg15556689	chr8:8085844	FLJ10661	0.55	7.51	0.43	1.08e-12	Mood instability;
KIRP	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.52	0.38	4.01e-10	Atrioventricular conduction;
KIRP	cis	rs35883536	1.000	rs12409831	chr1:101107670	A/T	cg06223162	chr1:101003688	GPR88	0.32	6.58	0.39	2.73e-10	Monocyte count;
KIRP	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg04317399	chr7:27170313	HOXA4	-0.35	-5.09	-0.31	7.26e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs42648	0.564	rs7777651	chr7:89822344	G/A	cg25739043	chr7:89950458	NA	-0.38	-5.98	-0.36	7.74e-9	Homocysteine levels;
KIRP	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.57	-0.59	5.33e-25	Caffeine consumption;
KIRP	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg07701084	chr6:150067640	NUP43	0.54	6.97	0.41	2.87e-11	Lung cancer;
KIRP	cis	rs1062746	0.558	rs889608	chr16:87337543	A/G	cg02258303	chr16:87377426	FBXO31	-0.44	-6.0	-0.36	6.9e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.85	-9.91	-0.53	1.04e-19	Corneal astigmatism;
KIRP	cis	rs2280630	0.529	rs4342048	chr3:39012943	A/G	cg01426195	chr3:39028469	NA	-0.67	-10.77	-0.57	2.04e-22	Verbal declarative memory;
KIRP	cis	rs357618	1.000	rs357629	chr5:150850946	C/T	cg22672639	chr5:150884813	FAT2	-0.35	-5.21	-0.32	4.04e-7	Basophil percentage of white cells;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03115081	chr17:74722049	C17orf95;JMJD6	0.49	6.69	0.39	1.52e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg18944383	chr4:111397179	ENPEP	-0.71	-13.29	-0.65	9.53e-31	Coronary artery disease;
KIRP	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.81	-8.9	-0.49	1.26e-16	Alzheimer's disease;
KIRP	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	1.29	8.99	0.5	6.91e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg12623918	chr2:306882	NA	0.41	5.26	0.32	3.2e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.68	10.12	0.54	2.29e-20	Dupuytren's disease;
KIRP	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.61	-0.34	5.55e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg18490616	chr2:88469792	THNSL2	0.67	5.4	0.33	1.56e-7	Plasma clusterin levels;
KIRP	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg07212818	chr11:638076	DRD4	-0.4	-5.11	-0.31	6.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.65	-0.44	4.44e-13	Life satisfaction;
KIRP	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.03	-0.36	5.87e-9	Type 2 diabetes;
KIRP	cis	rs7113850	0.541	rs7948382	chr11:24246608	T/C	ch.11.24196551F	chr11:24239977	NA	0.91	8.55	0.48	1.3e-15	Bone fracture in osteoporosis;
KIRP	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg19468946	chr17:37922297	IKZF3	-0.45	-6.35	-0.38	1.01e-9	Asthma;
KIRP	cis	rs17321999	1.000	rs906867	chr2:30478628	A/G	cg05247661	chr2:30472410	LBH	0.63	7.13	0.41	1.08e-11	Systemic lupus erythematosus;
KIRP	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.54	0.38	3.57e-10	Major depressive disorder;
KIRP	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg05484376	chr2:27715224	FNDC4	0.36	5.64	0.34	4.62e-8	Total body bone mineral density;
KIRP	cis	rs580438	0.707	rs357121	chr3:13340010	C/T	cg10657019	chr3:13328039	NA	0.48	6.32	0.37	1.25e-9	Myringotomy;
KIRP	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.66	8.53	0.48	1.55e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06544989	chr22:39130855	UNC84B	0.49	7.49	0.43	1.26e-12	Menopause (age at onset);
KIRP	cis	rs13424612	0.965	rs58652766	chr2:240904884	G/A	cg01812947	chr2:240904978	NDUFA10	0.48	6.09	0.36	4.34e-9	Odorant perception (isobutyraldehyde);
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.12	-0.31	6.26e-7	Longevity;
KIRP	cis	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg00262122	chr8:11665843	FDFT1	-0.42	-5.28	-0.32	2.8e-7	Retinal vascular caliber;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.83	-8.95	-0.5	9.15e-17	Asthma;
KIRP	cis	rs7481584	0.926	rs12806061	chr11:3008404	G/A	cg25174290	chr11:3078921	CARS	-0.55	-6.13	-0.36	3.39e-9	Calcium levels;
KIRP	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.16	0.61	5.86e-27	Platelet count;
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.42	5.55	0.33	7.2e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg18016565	chr1:150552671	MCL1	0.37	5.73	0.34	2.91e-8	Melanoma;
KIRP	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.87	0.45	1.13e-13	Iron status biomarkers;
KIRP	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-5.88	-0.35	1.31e-8	Neuroticism;
KIRP	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7709377	0.951	rs2112570	chr5:115547594	C/G	cg06112779	chr12:54982626	PPP1R1A	0.42	6.25	0.37	1.8e-9	Metabolite levels  (X-11787);
KIRP	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.03	-0.61	1.58e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.98	13.75	0.66	2.64e-32	Triglycerides;
KIRP	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg08885076	chr2:99613938	TSGA10	-0.42	-6.22	-0.37	2.14e-9	Fear of minor pain;
KIRP	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.8	-10.52	-0.56	1.31e-21	Coronary artery disease or large artery stroke;
KIRP	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg08499158	chr17:42289980	UBTF	-0.65	-8.36	-0.47	4.58e-15	Total body bone mineral density;
KIRP	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.07	-0.41	1.6e-11	Migraine;Coronary artery disease;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15676677	chr5:112573320	MCC	0.49	6.18	0.37	2.61e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.52	-6.17	-0.37	2.76e-9	Prudent dietary pattern;
KIRP	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.66	8.85	0.49	1.71e-16	Height;
KIRP	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg19336497	chr11:14380999	RRAS2	-0.34	-5.06	-0.31	8.39e-7	Mitochondrial DNA levels;
KIRP	cis	rs40363	1.000	rs250636	chr16:3510416	T/C	cg00484396	chr16:3507460	NAT15	0.52	5.23	0.32	3.68e-7	Tuberculosis;
KIRP	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg08501292	chr6:25962987	TRIM38	0.71	4.85	0.3	2.22e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.72	9.77	0.53	2.84e-19	Red blood cell count;
KIRP	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg13319975	chr6:146136371	FBXO30	-0.48	-6.45	-0.38	5.78e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.79	0.4	8.49e-11	Coffee consumption (cups per day);
KIRP	cis	rs8133932	0.654	rs369245	chr21:47337821	G/A	cg11214348	chr21:47283868	PCBP3	-0.44	-5.04	-0.31	8.88e-7	Schizophrenia;
KIRP	cis	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg19875578	chr6:126661172	C6orf173	0.46	6.09	0.36	4.25e-9	Male-pattern baldness;
KIRP	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg21361702	chr7:150065534	REPIN1	0.62	6.51	0.38	4.15e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg02297831	chr4:17616191	MED28	0.59	7.52	0.43	9.99e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg05370193	chr1:21551575	ECE1	0.48	6.44	0.38	6.31e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg18306943	chr3:40428807	ENTPD3	0.41	5.34	0.32	2.1e-7	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16064518	chr18:72920985	ZADH2	0.57	7.46	0.43	1.45e-12	Parkinson's disease;
KIRP	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg19197139	chr17:4613644	ARRB2	0.74	7.76	0.44	2.34e-13	Lymphocyte counts;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26652666	chr19:3121109	GNA11	0.48	6.15	0.37	3.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.94	-0.45	7.13e-14	Coronary artery disease;
KIRP	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg02487422	chr3:49467188	NICN1	0.41	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs1894292	0.715	rs6446944	chr4:74466132	T/C	cg12566645	chr4:74483141	RASSF6	0.36	4.99	0.3	1.12e-6	Prostate cancer;
KIRP	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.81	-11.96	-0.61	2.66e-26	Dental caries;
KIRP	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs8084125	0.832	rs62105168	chr18:74944848	T/C	cg05528293	chr18:74961138	GALR1	0.5	5.35	0.32	2.03e-7	Obesity-related traits;
KIRP	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.77e-10	Protein C levels;
KIRP	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.65	0.52	7.02e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg02795151	chr17:7402630	POLR2A	0.78	8.03	0.46	4.11e-14	Androgen levels;
KIRP	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.67	-7.44	-0.43	1.64e-12	Type 2 diabetes;
KIRP	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.69	-9.1	-0.5	3.08e-17	Huntington's disease progression;
KIRP	cis	rs7113874	0.625	rs10743073	chr11:8504619	C/T	cg08015107	chr11:8618950	NA	0.47	6.1	0.36	4.02e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.28e-6	Menopause (age at onset);
KIRP	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg02725872	chr8:58115012	NA	-0.5	-6.17	-0.37	2.8e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.32	-5.06	-0.31	8.02e-7	QRS complex (12-leadsum);
KIRP	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.73	11.07	0.58	2.23e-23	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.31	4.93	0.3	1.48e-6	Testicular germ cell tumor;
KIRP	cis	rs1448094	0.933	rs11117102	chr12:86312720	A/C	cg00310523	chr12:86230176	RASSF9	0.38	5.87	0.35	1.38e-8	Major depressive disorder;
KIRP	cis	rs6563210	0.711	rs9545707	chr13:36486554	C/G	cg19801062	chr13:36872135	C13orf38	-0.48	-5.19	-0.31	4.5e-7	Height;
KIRP	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg22903471	chr2:27725779	GCKR	-0.37	-5.0	-0.3	1.08e-6	Oral cavity cancer;
KIRP	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.43	-5.35	-0.32	1.99e-7	Acne (severe);
KIRP	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22857025	chr5:266934	NA	-1.21	-8.57	-0.48	1.19e-15	Asthma (childhood onset);
KIRP	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg02725872	chr8:58115012	NA	-0.36	-4.93	-0.3	1.51e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-1.1	-22.36	-0.82	3.43e-61	Height;
KIRP	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs2275620	1.000	rs1891071	chr10:96805371	C/T	cg09036531	chr10:96991505	NA	-0.51	-6.53	-0.38	3.64e-10	Gout;
KIRP	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	11.32	0.59	3.46e-24	Platelet count;
KIRP	cis	rs17761864	0.718	rs8064885	chr17:2047564	G/A	cg16513277	chr17:2031491	SMG6	0.43	5.1	0.31	6.68e-7	Esophageal cancer (squamous cell);
KIRP	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.06	0.46	3.23e-14	Hip circumference adjusted for BMI;
KIRP	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	7.63	0.44	5.26e-13	Neuroticism;
KIRP	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-8.37	-0.47	4.44e-15	Cognitive function;
KIRP	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.92	-0.61	3.66e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.87	13.84	0.66	1.31e-32	Blood protein levels;
KIRP	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg09455208	chr3:40491958	NA	-0.35	-6.24	-0.37	1.91e-9	Renal cell carcinoma;
KIRP	trans	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg11693508	chr17:37793320	STARD3	0.81	8.73	0.49	3.86e-16	Bipolar disorder;
KIRP	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.01	11.42	0.59	1.63e-24	Body mass index;
KIRP	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.72	-0.34	3.14e-8	Life satisfaction;
KIRP	cis	rs897080	0.515	rs1065783	chr2:44660741	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.42	0.33	1.43e-7	Height;
KIRP	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.18	10.57	0.56	8.72e-22	Atopic dermatitis;
KIRP	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.5	5.8	0.35	2.07e-8	Platelet distribution width;
KIRP	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.82	8.74	0.49	3.58e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4805834	0.777	rs11671229	chr19:33307117	A/G	cg07201929	chr19:33182834	NUDT19	-0.58	-4.9	-0.3	1.74e-6	Creatinine levels;
KIRP	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.11	-0.5	2.94e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.52	-6.28	-0.37	1.56e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg11031976	chr2:198649780	BOLL	-0.52	-4.99	-0.3	1.15e-6	Ulcerative colitis;
KIRP	cis	rs16857609	0.529	rs74723351	chr2:218288217	G/A	cg15335768	chr2:218268053	DIRC3	-0.52	-6.7	-0.39	1.42e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.29	0.37	1.45e-9	Mean platelet volume;
KIRP	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.6	-8.28	-0.47	8.07e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7572263	0.724	rs6710543	chr2:209050447	G/A	cg23998903	chr2:209048830	C2orf80	-0.36	-5.25	-0.32	3.22e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg18306943	chr3:40428807	ENTPD3	-0.43	-5.97	-0.36	8.23e-9	Renal cell carcinoma;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg01786151	chr1:41347977	NA	0.55	6.31	0.37	1.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.78	-10.47	-0.56	1.82e-21	Menarche (age at onset);
KIRP	cis	rs57590327	0.528	rs4856346	chr3:81502655	T/G	cg07356753	chr3:81810745	GBE1	0.47	5.96	0.36	8.54e-9	Extraversion;
KIRP	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.75	-0.34	2.58e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.62	9.76	0.53	3.19e-19	Airway imaging phenotypes;
KIRP	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.43	-0.33	1.33e-7	Aortic root size;
KIRP	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.15e-7	Retinal vascular caliber;
KIRP	cis	rs1823913	0.526	rs36028476	chr2:192165321	G/A	cg12404831	chr2:192114017	MYO1B	0.54	7.53	0.43	9.36e-13	Obesity-related traits;
KIRP	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg17376030	chr22:41985996	PMM1	-0.45	-5.43	-0.33	1.36e-7	Vitiligo;
KIRP	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg04733989	chr22:42467013	NAGA	0.53	6.46	0.38	5.51e-10	Cognitive function;
KIRP	cis	rs787274	0.850	rs10739376	chr9:115616775	A/T	cg13803584	chr9:115635662	SNX30	-0.72	-6.69	-0.39	1.53e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs15676	0.561	rs10739736	chr9:131577981	A/T	cg00228799	chr9:131580591	ENDOG	0.58	6.7	0.39	1.45e-10	Blood metabolite levels;
KIRP	cis	rs6684428	0.614	rs11206680	chr1:56364414	A/G	cg11651538	chr1:56320950	NA	-0.86	-10.11	-0.54	2.52e-20	Airflow obstruction;
KIRP	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.62	8.58	0.48	1.1e-15	Total body bone mineral density;
KIRP	cis	rs7601312	1.000	rs35496184	chr2:229313547	G/A	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.89	12.07	0.61	1.21e-26	Menopause (age at onset);
KIRP	trans	rs909341	0.909	rs914559	chr20:62369300	C/G	cg01311341	chr22:25575246	KIAA1671	0.61	6.91	0.4	4.08e-11	Atopic dermatitis;
KIRP	cis	rs7560272	0.512	rs4530394	chr2:73929650	T/C	cg20560298	chr2:73613845	ALMS1	0.51	6.1	0.36	4.13e-9	Schizophrenia;
KIRP	cis	rs11955175	1.000	rs11954639	chr5:40674979	A/G	cg04002187	chr5:40835754	RPL37	-0.64	-5.41	-0.33	1.52e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	4.85	0.3	2.21e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.37	-0.38	9.42e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.25	11.52	0.59	7.56e-25	Diabetic retinopathy;
KIRP	cis	rs9611519	0.531	rs1967708	chr22:41444444	G/C	cg03806693	chr22:41940476	POLR3H	-0.43	-5.18	-0.31	4.59e-7	Neuroticism;
KIRP	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg19847866	chr10:1019161	NA	0.62	5.55	0.33	7.51e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs1318772	1.000	rs67894881	chr5:112613778	C/G	cg12552261	chr5:112820674	MCC	0.82	5.09	0.31	6.97e-7	F-cell distribution;
KIRP	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.49	-7.43	-0.43	1.78e-12	Coronary artery disease;
KIRP	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	10.04	0.54	4.37e-20	Total body bone mineral density;
KIRP	cis	rs1505368	0.505	rs6760554	chr2:213255417	C/T	cg16329650	chr2:213403929	ERBB4	0.4	5.51	0.33	8.88e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.38	-0.32	1.75e-7	Life satisfaction;
KIRP	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg14061069	chr19:46274453	DMPK	-0.52	-8.04	-0.46	3.9e-14	Coronary artery disease;
KIRP	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.72	0.34	3.04e-8	Birth weight;
KIRP	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.94	10.07	0.54	3.47e-20	Systolic blood pressure;
KIRP	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg04166393	chr7:2884313	GNA12	0.63	7.62	0.44	5.49e-13	Height;
KIRP	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.17	15.67	0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs240764	0.697	rs9485411	chr6:101261352	A/C	cg09795085	chr6:101329169	ASCC3	0.44	5.19	0.31	4.36e-7	Neuroticism;
KIRP	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg27494647	chr7:150038898	RARRES2	0.38	5.67	0.34	3.95e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.2	-0.37	2.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-10.18	-0.54	1.51e-20	Response to antipsychotic treatment;
KIRP	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-6.2	-0.37	2.43e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs16976116	0.803	rs28530662	chr15:55498836	A/G	cg11288833	chr15:55489084	RSL24D1	0.6	6.67	0.39	1.72e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg05861140	chr6:150128134	PCMT1	-0.5	-7.13	-0.41	1.09e-11	Lung cancer;
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.59	9.3	0.51	8.21e-18	Mean corpuscular volume;
KIRP	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.82	11.58	0.59	5.02e-25	Breast cancer;
KIRP	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg17554472	chr22:41940697	POLR3H	-0.7	-7.48	-0.43	1.31e-12	Vitiligo;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10355997	chr15:50647554	GABPB1;FLJ10038;LOC100129387	0.62	7.04	0.41	1.93e-11	Lung cancer in ever smokers;
KIRP	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs1950626	0.751	rs12883799	chr14:101396850	A/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.83	0.4	6.72e-11	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs656319	0.729	rs671370	chr8:9813317	T/C	cg16141378	chr3:129829833	LOC729375	0.48	6.08	0.36	4.64e-9	Myopia (pathological);
KIRP	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg22705602	chr4:152727874	NA	0.53	9.19	0.51	1.66e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9630089	0.746	rs10882873	chr10:98966485	A/G	cg25902810	chr10:99078978	FRAT1	-0.42	-4.89	-0.3	1.86e-6	Neutrophil percentage of white cells;
KIRP	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.51	7.23	0.42	5.97e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1448094	0.817	rs12370270	chr12:86343303	T/G	cg02569458	chr12:86230093	RASSF9	0.37	5.36	0.32	1.95e-7	Major depressive disorder;
KIRP	cis	rs9308731	0.863	rs17558117	chr2:111940996	A/T	cg23466623	chr2:111982296	NA	-0.52	-6.8	-0.4	8.02e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg20673091	chr1:2541236	MMEL1	-0.66	-9.81	-0.53	2.22e-19	Ulcerative colitis;
KIRP	cis	rs73086581	0.947	rs11906612	chr20:3903634	C/T	cg02187196	chr20:3869020	PANK2	0.51	4.89	0.3	1.83e-6	Response to antidepressants in depression;
KIRP	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.52	-6.3	-0.37	1.38e-9	Corneal curvature;
KIRP	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs17321999	0.516	rs7587320	chr2:30496783	C/T	cg05247661	chr2:30472410	LBH	0.59	4.99	0.3	1.17e-6	Systemic lupus erythematosus;
KIRP	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.92e-18	Morning vs. evening chronotype;
KIRP	cis	rs2671245	0.933	rs2767504	chr1:56154317	A/G	cg11523071	chr1:56160889	NA	0.41	6.74	0.39	1.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7520050	0.966	rs6680380	chr1:46300189	T/G	cg03146154	chr1:46216737	IPP	-0.43	-5.39	-0.32	1.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.7	0.49	4.88e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs71277158	0.565	rs16854778	chr3:169748111	G/A	cg04067573	chr3:169899625	PHC3	0.63	5.75	0.34	2.7e-8	Prostate cancer;
KIRP	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg26022315	chr17:47021804	SNF8	0.42	5.42	0.33	1.43e-7	Type 2 diabetes;
KIRP	cis	rs9815354	0.951	rs6768438	chr3:41865355	G/A	cg03022575	chr3:42003672	ULK4	0.45	4.97	0.3	1.24e-6	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg26585981	chr11:48327164	OR4S1	-0.41	-4.98	-0.3	1.21e-6	Coronary artery disease;
KIRP	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-0.88	-9.38	-0.51	4.67e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.13	0.41	1.09e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.53	-0.48	1.5e-15	Calcium levels;
KIRP	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.06e-10	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs710913	0.738	rs755247	chr1:39994545	A/T	cg27567593	chr1:39956653	BMP8A	0.33	4.93	0.3	1.51e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg19913688	chr11:428466	ANO9	-0.74	-5.71	-0.34	3.2e-8	Body mass index;
KIRP	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.12	0.46	2.23e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg04906043	chr13:21280425	IL17D	-0.42	-4.99	-0.3	1.13e-6	Dental caries;
KIRP	cis	rs9815354	0.638	rs17218866	chr3:42017634	T/C	cg03022575	chr3:42003672	ULK4	0.78	7.58	0.43	7.26e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.3	0.51	7.85e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.61	-5.15	-0.31	5.34e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg00857998	chr1:205179979	DSTYK	0.49	6.1	0.36	4.15e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.64	-7.18	-0.42	8.17e-12	Obesity-related traits;
KIRP	cis	rs1185460	0.546	rs592190	chr11:118955314	G/A	cg23280166	chr11:118938394	VPS11	-0.61	-7.12	-0.41	1.19e-11	Coronary artery disease;
KIRP	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg23163573	chr2:108905468	SULT1C2	-0.27	-5.28	-0.32	2.8e-7	Blood pressure;
KIRP	cis	rs2494938	0.730	rs410066	chr6:40516220	A/G	cg14084896	chr6:40530702	LRFN2	-0.43	-5.4	-0.33	1.54e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.75e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	21.18	0.8	2.24e-57	Prudent dietary pattern;
KIRP	cis	rs4704187	0.687	rs10066946	chr5:74508021	T/A	cg03227963	chr5:74354835	NA	0.4	5.86	0.35	1.46e-8	Response to amphetamines;
KIRP	cis	rs12282928	0.743	rs2202249	chr11:48200586	C/T	cg26585981	chr11:48327164	OR4S1	-0.5	-6.11	-0.36	3.85e-9	Migraine - clinic-based;
KIRP	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg03929089	chr4:120376271	NA	-0.53	-6.46	-0.38	5.57e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1943345	0.556	rs606381	chr11:82907249	G/A	cg07047830	chr11:82868014	PCF11	0.42	4.85	0.3	2.2e-6	Obesity-related traits;
KIRP	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.93	-0.53	9.11e-20	Triglycerides;
KIRP	cis	rs9372498	0.536	rs9481833	chr6:118919631	G/A	cg18833306	chr6:118973337	C6orf204	-0.47	-4.97	-0.3	1.23e-6	Diastolic blood pressure;
KIRP	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.23	-0.32	3.58e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.33	-0.32	2.18e-7	Personality dimensions;
KIRP	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.49	7.08	0.41	1.55e-11	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs2063714	0.967	rs1012534	chr6:157209663	A/G	cg23222435	chr6:157204239	ARID1B	-0.44	-6.25	-0.37	1.79e-9	Sitting height ratio;
KIRP	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.76	12.07	0.61	1.15e-26	Coronary artery disease;
KIRP	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.55	6.16	0.37	2.97e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs11673344	0.566	rs10419281	chr19:37950253	C/T	cg14683738	chr19:37701593	ZNF585B	0.44	5.18	0.31	4.53e-7	Obesity-related traits;
KIRP	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.74	8.01	0.45	4.57e-14	Body mass index;
KIRP	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.58	-0.34	6.27e-8	Coronary artery disease;
KIRP	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg23594656	chr7:65796392	TPST1	-0.47	-7.21	-0.42	6.98e-12	Aortic root size;
KIRP	cis	rs7927771	0.756	rs2856661	chr11:47374998	A/G	cg20307385	chr11:47447363	PSMC3	0.53	5.42	0.33	1.41e-7	Subjective well-being;
KIRP	cis	rs754133	1.000	rs754133	chr12:54418920	C/T	cg10005224	chr12:54424964	HOXC4;HOXC5	0.28	5.77	0.35	2.37e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
KIRP	trans	rs6499100	0.695	rs4784258	chr16:52837310	C/T	cg17160590	chr1:222886778	C1orf58;AIDA	0.47	6.12	0.36	3.66e-9	Tetralogy of Fallot;
KIRP	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17554472	chr22:41940697	POLR3H	0.74	7.54	0.43	9.26e-13	Cannabis dependence symptom count;
KIRP	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.67	6.95	0.41	3.2e-11	Corneal astigmatism;
KIRP	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.73	-8.49	-0.48	1.93e-15	Monocyte count;
KIRP	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg05973401	chr12:123451056	ABCB9	0.56	6.52	0.38	3.99e-10	Neutrophil percentage of white cells;
KIRP	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg27165867	chr14:105738592	BRF1	-0.42	-4.95	-0.3	1.39e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20135002	chr11:47629003	NA	-0.49	-5.84	-0.35	1.64e-8	Subjective well-being;
KIRP	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.65	8.91	0.49	1.18e-16	Bipolar disorder;
KIRP	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg23958373	chr8:599963	NA	0.89	6.24	0.37	1.93e-9	IgG glycosylation;
KIRP	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.9	-14.0	-0.67	3.81e-33	Primary sclerosing cholangitis;
KIRP	cis	rs240764	0.658	rs1336251	chr6:101247698	C/T	cg09795085	chr6:101329169	ASCC3	-0.42	-5.09	-0.31	7.14e-7	Neuroticism;
KIRP	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.38	-6.99	-0.41	2.55e-11	Renal cell carcinoma;
KIRP	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg08822215	chr16:89438651	ANKRD11	-0.52	-6.92	-0.4	3.86e-11	Multiple myeloma (IgH translocation);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20247102	chr3:141206102	RASA2	0.47	6.08	0.36	4.64e-9	Myopia (pathological);
KIRP	cis	rs2554380	0.843	rs2554386	chr15:84403522	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.47	-6.53	-0.38	3.77e-10	Height;
KIRP	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.78	-10.71	-0.56	3.22e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.5	6.04	0.36	5.56e-9	Subjective well-being;
KIRP	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg08992911	chr2:238395768	MLPH	0.38	5.05	0.31	8.7e-7	Prostate cancer;
KIRP	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.42	6.2	0.37	2.35e-9	Lymphocyte counts;
KIRP	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-0.96	-15.85	-0.71	1.8e-39	Height;
KIRP	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-9.47	-0.52	2.47e-18	Response to antipsychotic treatment;
KIRP	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.8	-0.4	8.07e-11	Obesity-related traits;
KIRP	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg01620082	chr3:125678407	NA	-0.84	-6.27	-0.37	1.61e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg14703610	chr5:56206110	C5orf35	0.48	6.34	0.37	1.09e-9	Coronary artery disease;
KIRP	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg10932868	chr11:921992	NA	0.7	9.58	0.52	1.15e-18	Alzheimer's disease (late onset);
KIRP	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.75	-9.63	-0.52	7.74e-19	Aortic root size;
KIRP	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg25251562	chr2:3704773	ALLC	-0.41	-5.4	-0.33	1.54e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	9.42	0.51	3.5e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs9815354	0.638	rs111465678	chr3:41864405	C/A	cg03022575	chr3:42003672	ULK4	0.6	7.01	0.41	2.28e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.54	7.58	0.44	7.1e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.09	-0.36	4.36e-9	Metabolite levels;
KIRP	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg24699146	chr1:24152579	HMGCL	0.48	6.63	0.39	2.06e-10	Immature fraction of reticulocytes;
KIRP	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.54	-6.76	-0.4	1.01e-10	Morning vs. evening chronotype;
KIRP	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.46	-5.51	-0.33	9.2e-8	Response to bleomycin (chromatid breaks);
KIRP	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-7.75	-0.44	2.43e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg24972876	chr7:65420302	NA	0.41	5.53	0.33	8.27e-8	Calcium levels;
KIRP	cis	rs7937612	0.931	rs7121779	chr11:120213360	A/T	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.56	-0.39	3.17e-10	Intraocular pressure;
KIRP	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.6	-7.3	-0.42	4.08e-12	P wave terminal force;
KIRP	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg04691961	chr3:161091175	C3orf57	-0.34	-4.88	-0.3	1.92e-6	Educational attainment (years of education);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27402766	chr3:100468242	ABI3BP	0.42	6.19	0.37	2.44e-9	Migraine with aura;
KIRP	cis	rs17321999	0.904	rs72787716	chr2:30472355	C/T	cg05247661	chr2:30472410	LBH	0.75	8.15	0.46	1.84e-14	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg17145862	chr1:211918768	LPGAT1	0.67	8.25	0.47	9.49e-15	Leprosy;
KIRP	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	ch.11.42038R	chr11:967971	AP2A2	0.39	4.93	0.3	1.53e-6	Alzheimer's disease (late onset);
KIRP	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	5.45	0.33	1.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.82	-10.01	-0.54	5.16e-20	Schizophrenia;
KIRP	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg13395646	chr4:1353034	KIAA1530	-0.38	-4.99	-0.3	1.14e-6	Obesity-related traits;
KIRP	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	10.81	0.57	1.54e-22	Exhaled nitric oxide levels;
KIRP	cis	rs3744061	0.557	rs4261577	chr17:74648566	T/C	cg27546012	chr17:74684504	MXRA7	-0.44	-5.38	-0.32	1.71e-7	Retinal arteriolar caliber;
KIRP	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.58	-6.95	-0.41	3.28e-11	Alzheimer's disease (late onset);
KIRP	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg19445457	chr11:5799446	OR52N5	0.43	5.14	0.31	5.59e-7	DNA methylation (variation);
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.86	-10.78	-0.57	1.93e-22	Longevity;Endometriosis;
KIRP	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.8	10.78	0.57	1.97e-22	Morning vs. evening chronotype;
KIRP	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg18478394	chr8:109455254	TTC35	0.52	6.54	0.38	3.52e-10	Dupuytren's disease;
KIRP	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.62	-0.52	8.53e-19	Gut microbiome composition (summer);
KIRP	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.58	7.77	0.44	2.1e-13	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11087358	chr12:57940980	DCTN2	0.6	7.2	0.42	7.51e-12	Smoking initiation;
KIRP	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg25173405	chr17:45401733	C17orf57	-0.58	-7.42	-0.43	1.85e-12	Coronary artery disease;
KIRP	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg13319975	chr6:146136371	FBXO30	-0.39	-5.2	-0.31	4.24e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.51	-6.8	-0.4	7.95e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg11972305	chr2:233791962	NGEF	-0.42	-5.2	-0.31	4.1e-7	Schizophrenia;
KIRP	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg22681709	chr2:178499509	PDE11A	-0.46	-5.52	-0.33	8.42e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12220238	0.915	rs11001020	chr10:76139217	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.21	0.37	2.24e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-6.44	-0.38	6.13e-10	Longevity;Endometriosis;
KIRP	trans	rs7594645	1.000	rs73985728	chr2:207668245	G/A	cg13400176	chr6:135501811	MYB	-0.9	-6.54	-0.38	3.47e-10	Episodic memory;
KIRP	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.96	-11.78	-0.6	1.04e-25	Corneal astigmatism;
KIRP	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.29	-0.37	1.47e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg15212455	chr7:39170539	POU6F2	0.23	4.94	0.3	1.45e-6	IgG glycosylation;
KIRP	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.27	0.42	4.77e-12	Prudent dietary pattern;
KIRP	cis	rs4006360	0.541	rs6503606	chr17:39309901	A/T	cg15015397	chr17:39261100	KRTAP4-9	-0.39	-5.25	-0.32	3.27e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg04374321	chr14:90722782	PSMC1	0.59	7.24	0.42	5.88e-12	Longevity;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05641884	chr4:76735041	USO1	0.42	6.43	0.38	6.57e-10	C-reactive protein;
KIRP	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs654128	0.640	rs339342	chr6:117216125	G/A	cg12892004	chr6:117198278	RFX6	-0.39	-5.15	-0.31	5.27e-7	Telomere length;
KIRP	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg19875535	chr5:140030758	IK	-0.56	-7.01	-0.41	2.33e-11	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg17822266	chr1:2720087	NA	-0.47	-6.43	-0.38	6.6e-10	Economic and political preferences (feminism/equality);
KIRP	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg03714773	chr7:91764589	CYP51A1	0.44	6.57	0.39	3.04e-10	Breast cancer;
KIRP	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05665937	chr4:1216051	CTBP1	-0.51	-7.06	-0.41	1.72e-11	Obesity-related traits;
KIRP	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.57	0.39	2.98e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	10.52	0.56	1.28e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.44	5.1	0.31	6.63e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg19468946	chr17:37922297	IKZF3	-0.55	-7.61	-0.44	5.86e-13	Self-reported allergy;
KIRP	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg01522456	chr1:115632236	TSPAN2	-0.43	-5.53	-0.33	8.36e-8	Autism;
KIRP	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.44	-0.43	1.71e-12	Retinal vascular caliber;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09254361	chr3:52008107	ABHD14B;ABHD14A	0.55	7.13	0.41	1.09e-11	Parkinson's disease;
KIRP	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.81	9.96	0.54	7.53e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.79	6.89	0.4	4.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.64	6.67	0.39	1.64e-10	Iron status biomarkers;
KIRP	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-0.94	-7.26	-0.42	5.17e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg20673091	chr1:2541236	MMEL1	0.79	12.8	0.63	4.42e-29	Ulcerative colitis;
KIRP	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.48	-6.54	-0.38	3.6e-10	Blood metabolite levels;
KIRP	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg12549451	chr6:135224345	NA	-0.4	-5.13	-0.31	6e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg05555928	chr11:63887634	MACROD1	0.45	6.37	0.38	9.08e-10	Platelet count;
KIRP	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.61	-9.02	-0.5	5.69e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2411233	0.935	rs11855986	chr15:39269840	C/G	cg02291532	chr15:39874776	THBS1	-0.37	-5.11	-0.31	6.6e-7	Platelet count;
KIRP	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.22	-0.42	6.45e-12	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg09165964	chr15:75287851	SCAMP5	0.4	5.1	0.31	6.82e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs2151522	0.713	rs9385407	chr6:127161066	A/G	cg21431617	chr6:127135037	NA	0.29	5.12	0.31	6.3e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.64	8.15	0.46	1.91e-14	Prudent dietary pattern;
KIRP	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.72	-0.34	3.15e-8	Parkinson's disease;
KIRP	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg00677455	chr12:58241039	CTDSP2	-0.51	-5.73	-0.34	2.96e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7929679	0.602	rs10501135	chr11:34811180	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.29	0.32	2.76e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg05362011	chr13:21860987	NA	-0.48	-5.17	-0.31	4.83e-7	White matter hyperintensity burden;
KIRP	cis	rs9311676	0.632	rs6777066	chr3:58361603	T/C	cg06643156	chr3:58380774	PXK	0.36	5.14	0.31	5.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.45	-6.4	-0.38	7.98e-10	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
KIRP	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.57	0.52	1.23e-18	Prudent dietary pattern;
KIRP	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg11569703	chr11:65557185	OVOL1	0.62	11.08	0.58	2.15e-23	Acne (severe);
KIRP	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.57	0.39	2.91e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg25650185	chr19:21324782	ZNF431	0.49	5.13	0.31	5.77e-7	Pain;
KIRP	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs9463078	0.527	rs2040032	chr6:44743009	C/T	cg25276700	chr6:44698697	NA	0.34	4.94	0.3	1.42e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs687432	0.924	rs1113335	chr11:57743449	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.03	-0.5	4.97e-17	Parkinson's disease;
KIRP	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs1413885	0.516	rs716592	chr1:65843982	C/T	cg14976592	chr1:65886160	LEPROT;LEPR	-0.59	-6.59	-0.39	2.65e-10	Anticoagulant levels;
KIRP	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.73	5.87	0.35	1.41e-8	Diabetic retinopathy;
KIRP	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg05527609	chr1:210001259	C1orf107	-0.42	-5.0	-0.3	1.07e-6	Red blood cell count;
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.48	6.63	0.39	2.1e-10	Testicular germ cell tumor;
KIRP	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg00666640	chr1:248458726	OR2T12	0.45	5.41	0.33	1.47e-7	Common traits (Other);
KIRP	cis	rs12976411	0.867	rs8110851	chr19:32828455	C/G	cg02282382	chr19:32836354	ZNF507	0.66	5.6	0.34	5.81e-8	Coronary artery disease;
KIRP	cis	rs2661868	0.918	rs2636314	chr1:8440643	G/A	cg03610117	chr1:8450231	RERE	-0.71	-8.93	-0.49	1.04e-16	Life satisfaction;
KIRP	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.42	-5.48	-0.33	1.08e-7	Body mass index;
KIRP	cis	rs2671245	0.586	rs9326036	chr1:56140358	G/A	cg11523071	chr1:56160889	NA	0.43	6.6	0.39	2.53e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14522873	chr20:21283801	XRN2	0.51	6.41	0.38	7.32e-10	Parkinson's disease;
KIRP	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg07862535	chr7:139043722	LUC7L2	0.49	5.53	0.33	8.14e-8	Diisocyanate-induced asthma;
KIRP	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.16	16.0	0.71	5.83e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-6.29	-0.37	1.46e-9	Blood metabolite levels;
KIRP	cis	rs6450176	1.000	rs6450175	chr5:53297824	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.33	-0.59	3.2e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs16937956	0.597	rs12793685	chr11:8402130	G/C	cg08015107	chr11:8618950	NA	-0.57	-7.42	-0.43	1.96e-12	Body mass index;
KIRP	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.84	5.6	0.34	5.85e-8	Putamen volume;
KIRP	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.94	0.45	7.07e-14	Lung cancer in ever smokers;
KIRP	cis	rs2637030	0.559	rs370594	chr5:52955554	C/T	cg06476337	chr5:52856530	NDUFS4	0.54	5.86	0.35	1.46e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.53	0.33	8.26e-8	Life satisfaction;
KIRP	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.49	-6.58	-0.39	2.79e-10	Multiple sclerosis;
KIRP	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg15181151	chr6:150070149	PCMT1	0.32	5.39	0.33	1.64e-7	Lung cancer;
KIRP	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-8.57	-0.48	1.15e-15	Lung cancer;
KIRP	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs16976116	0.855	rs28649719	chr15:55500211	C/T	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs748404	0.518	rs480108	chr15:43817406	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.46	0.38	5.6e-10	Lung cancer;
KIRP	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	10.88	0.57	9.37e-23	Total body bone mineral density;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25878830	chr10:86260687	FAM190B	-0.43	-6.78	-0.4	8.78e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-14.95	-0.69	2.19e-36	Electrocardiographic conduction measures;
KIRP	trans	rs11165623	0.564	rs7555035	chr1:96996026	T/C	cg10631902	chr5:14652156	NA	-0.51	-6.77	-0.4	9.14e-11	Hip circumference;Waist circumference;
KIRP	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00585698	chr12:123750864	CDK2AP1	0.5	5.08	0.31	7.61e-7	Neutrophil percentage of white cells;
KIRP	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg06636001	chr8:8085503	FLJ10661	0.59	7.52	0.43	1.04e-12	Neuroticism;
KIRP	cis	rs57590327	0.679	rs13094809	chr3:81666806	G/A	cg07356753	chr3:81810745	GBE1	-0.58	-6.23	-0.37	2.06e-9	Extraversion;
KIRP	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.54	-7.9	-0.45	9.31e-14	Immature fraction of reticulocytes;
KIRP	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7221595	0.825	rs71366590	chr17:4006685	T/A	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.61e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2839627	0.561	rs4148970	chr21:44313293	A/G	cg03543861	chr21:44258195	NA	0.52	5.75	0.34	2.63e-8	Information processing speed;
KIRP	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg02297831	chr4:17616191	MED28	0.55	6.78	0.4	8.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9815354	0.767	rs115702638	chr3:42058594	C/T	cg03022575	chr3:42003672	ULK4	0.72	7.59	0.44	6.56e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg17764715	chr19:33622953	WDR88	0.81	11.65	0.6	2.96e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.56	7.53	0.43	9.89e-13	Red blood cell count;
KIRP	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg17279839	chr7:150038598	RARRES2	0.48	6.27	0.37	1.59e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-6.12	-0.36	3.6e-9	Lung cancer;
KIRP	cis	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg16898833	chr6:26189333	HIST1H4D	0.98	5.91	0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.79	-8.0	-0.45	4.83e-14	Coronary artery calcification;
KIRP	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.5	-7.4	-0.43	2.19e-12	Bipolar disorder;
KIRP	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.7	8.78	0.49	2.89e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10501293	0.529	rs2902301	chr11:43093159	A/T	cg03447554	chr11:43094025	NA	-0.34	-5.45	-0.33	1.2e-7	Cognitive performance;
KIRP	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26207909	chr14:103986467	CKB	0.74	10.59	0.56	7.51e-22	Body mass index;
KIRP	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.63	9.78	0.53	2.77e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg05347473	chr6:146136440	FBXO30	0.5	7.01	0.41	2.31e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg09717352	chr4:89740889	FAM13A	0.44	7.2	0.42	7.46e-12	C-reactive protein;
KIRP	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.88	-11.32	-0.59	3.53e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.57	0.39	2.99e-10	Lung cancer;
KIRP	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg11707556	chr5:10655725	ANKRD33B	0.54	6.83	0.4	6.56e-11	Coronary artery disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25325159	chr1:19812210	CAPZB	-0.47	-6.58	-0.39	2.88e-10	Metabolic traits;
KIRP	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg01980928	chr19:1952821	C19orf34;CSNK1G2	-0.47	-5.42	-0.33	1.44e-7	Coronary artery disease;
KIRP	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg04226714	chr8:49833948	SNAI2	-0.51	-6.87	-0.4	5.28e-11	Life satisfaction;
KIRP	cis	rs365132	1.000	rs353468	chr5:176445494	A/T	cg16309518	chr5:176445507	NA	-0.88	-13.64	-0.66	6.2e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.67	8.85	0.49	1.79e-16	Motion sickness;
KIRP	cis	rs1021993	0.545	rs17014337	chr1:209527465	T/C	cg24446417	chr1:209558027	NA	-0.47	-4.91	-0.3	1.69e-6	Gut microbiome composition (winter);
KIRP	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs6546324	0.539	rs4671192	chr2:67841855	A/G	cg15745817	chr2:67799979	NA	-0.69	-7.44	-0.43	1.72e-12	Endometriosis;
KIRP	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg27170947	chr2:26402098	FAM59B	0.55	5.45	0.33	1.2e-7	Gut microbiome composition (summer);
KIRP	cis	rs2274273	0.661	rs2147964	chr14:55564395	T/G	cg04306507	chr14:55594613	LGALS3	0.48	7.53	0.43	9.81e-13	Protein biomarker;
KIRP	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-5.31	-0.32	2.47e-7	Skin colour saturation;
KIRP	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	16.94	0.73	3.36e-43	Platelet count;
KIRP	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg21858823	chr1:15850916	CASP9	0.55	5.91	0.35	1.15e-8	Systolic blood pressure;
KIRP	cis	rs911119	0.908	rs8114619	chr20:23601813	G/T	cg16589663	chr20:23618590	CST3	0.55	5.52	0.33	8.58e-8	Chronic kidney disease;
KIRP	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg21643547	chr1:205240462	TMCC2	-0.7	-10.33	-0.55	5.3e-21	Red blood cell count;
KIRP	cis	rs4561483	0.583	rs33636	chr16:11990323	C/G	cg08843971	chr16:11963173	GSPT1	-0.53	-7.55	-0.43	8.42e-13	Testicular germ cell tumor;
KIRP	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg05802129	chr4:122689817	NA	-0.47	-6.82	-0.4	6.84e-11	Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	8.78	0.49	2.82e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.43	-5.16	-0.31	5.18e-7	Aortic root size;
KIRP	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg24747557	chr10:131355152	MGMT	-0.42	-5.82	-0.35	1.84e-8	Response to temozolomide;
KIRP	cis	rs7084402	0.935	rs7474570	chr10:60343085	C/G	cg05938607	chr10:60274200	BICC1	-0.46	-11.41	-0.59	1.78e-24	Refractive error;
KIRP	trans	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg02002194	chr4:3960332	NA	0.42	6.3	0.37	1.33e-9	Mood instability;
KIRP	cis	rs7258465	1.000	rs4595905	chr19:18547305	T/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.64	-0.44	4.97e-13	Breast cancer;
KIRP	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg14132834	chr19:41945861	ATP5SL	-0.57	-7.31	-0.42	3.75e-12	Height;
KIRP	cis	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg08773314	chr2:239334832	ASB1	-0.56	-5.76	-0.34	2.48e-8	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.58	8.43	0.47	3.03e-15	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2964802	0.505	rs7717266	chr5:10832134	C/G	cg14521931	chr5:10832172	NA	-0.74	-11.39	-0.59	2.06e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs300890	0.760	rs10028909	chr4:144200592	C/T	cg19876092	chr4:144208277	NA	0.43	7.08	0.41	1.47e-11	Nasopharyngeal carcinoma;
KIRP	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.77	11.28	0.58	4.75e-24	Height;
KIRP	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	1.05	7.8	0.45	1.74e-13	Skin colour saturation;
KIRP	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.12	0.46	2.2e-14	Response to antipsychotic treatment;
KIRP	cis	rs2737618	0.889	rs2737617	chr1:200097130	A/G	cg21825944	chr1:200113062	NR5A2	-0.6	-7.63	-0.44	5.02e-13	Uric acid levels;
KIRP	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg16141378	chr3:129829833	LOC729375	0.62	8.37	0.47	4.35e-15	Neuroticism;
KIRP	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg23188430	chr6:125850052	NA	-0.35	-5.61	-0.34	5.37e-8	Brugada syndrome;
KIRP	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.05	-0.31	8.61e-7	Metabolite levels;
KIRP	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg03929089	chr4:120376271	NA	-0.75	-9.77	-0.53	2.98e-19	Coronary artery disease;
KIRP	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg01528321	chr10:82214614	TSPAN14	0.61	7.87	0.45	1.11e-13	Post bronchodilator FEV1;
KIRP	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.37	4.87	0.3	1.98e-6	Birth weight;
KIRP	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg22089800	chr15:90895588	ZNF774	0.43	5.26	0.32	3.15e-7	Rheumatoid arthritis;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg06680609	chr16:88894341	GALNS	0.48	6.17	0.37	2.86e-9	Pancreatic cancer;
KIRP	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.86	-0.35	1.47e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.76	8.92	0.49	1.05e-16	Adiposity;
KIRP	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	7.46	0.43	1.46e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg04691961	chr3:161091175	C3orf57	-0.38	-5.75	-0.34	2.68e-8	Morning vs. evening chronotype;
KIRP	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.89	-13.44	-0.65	3.12e-31	Height;
KIRP	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg10755058	chr3:40428713	ENTPD3	0.38	5.32	0.32	2.39e-7	Renal cell carcinoma;
KIRP	trans	rs6601327	0.663	rs12543346	chr8:9655823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.26	-0.42	5.17e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs867371	1.000	rs881308	chr15:82475797	A/G	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg09264619	chr17:80180166	NA	-0.46	-5.36	-0.32	1.9e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs931812	0.691	rs884488	chr8:101898523	C/G	cg07585502	chr8:101912084	NA	-0.61	-8.12	-0.46	2.24e-14	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.87	13.54	0.65	1.43e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg22138327	chr13:27999177	GTF3A	0.9	6.91	0.4	4.08e-11	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-0.7	-7.13	-0.41	1.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg27205649	chr11:78285834	NARS2	0.83	11.59	0.59	4.47e-25	Alzheimer's disease (survival time);
KIRP	trans	rs61904987	0.561	rs61907874	chr11:113741208	C/A	cg02842869	chr17:79921131	NA	0.37	6.35	0.38	1.05e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg08890418	chr1:21044141	KIF17	-0.38	-5.72	-0.34	3.07e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.74	7.25	0.42	5.49e-12	Obesity-related traits;
KIRP	cis	rs10858047	0.883	rs6701882	chr1:115181249	C/T	cg12756093	chr1:115239321	AMPD1	-0.67	-6.46	-0.38	5.42e-10	Autism;
KIRP	cis	rs2281603	0.951	rs10143170	chr14:64993763	C/T	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg22366001	chr1:2066006	PRKCZ	-0.36	-4.91	-0.3	1.67e-6	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18864914	chr18:43678438	ATP5A1	0.51	6.23	0.37	2.04e-9	Parkinson's disease;
KIRP	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg18753928	chr3:113234510	CCDC52	-0.53	-6.71	-0.39	1.32e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.6	-0.44	6.34e-13	Mood instability;
KIRP	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	0.82	9.7	0.53	4.95e-19	Post bronchodilator FEV1;
KIRP	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.56	7.07	0.41	1.64e-11	Longevity;Endometriosis;
KIRP	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg05729581	chr11:3078854	CARS	-0.52	-6.64	-0.39	2.04e-10	Longevity;
KIRP	cis	rs7172677	1.000	rs8032261	chr15:75424012	A/T	cg14664628	chr15:75095509	CSK	-0.48	-5.39	-0.32	1.66e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg21395723	chr22:39101663	GTPBP1	0.47	6.38	0.38	8.73e-10	Menopause (age at onset);
KIRP	cis	rs3754214	0.769	rs509345	chr1:150276022	A/G	cg07843065	chr1:150265600	MRPS21	-0.47	-6.37	-0.38	9.23e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	trans	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg00938859	chr5:1591904	SDHAP3	0.54	6.28	0.37	1.53e-9	Breast cancer;
KIRP	cis	rs3755132	0.852	rs2302937	chr2:15770061	G/A	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg23307798	chr14:103986281	CKB	0.72	11.24	0.58	6.34e-24	Body mass index;
KIRP	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	1.0	7.8	0.45	1.73e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg21523564	chr15:75251491	NA	0.37	6.06	0.36	4.98e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.86	-0.4	5.63e-11	Aortic root size;
KIRP	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.62	5.94	0.35	9.76e-9	Breast cancer;
KIRP	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.48e-20	Dupuytren's disease;
KIRP	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg14675211	chr2:100938903	LONRF2	0.55	7.07	0.41	1.58e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.36	-0.68	2.23e-34	Primary sclerosing cholangitis;
KIRP	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.43	6.04	0.36	5.51e-9	Coronary artery disease;
KIRP	cis	rs3733606	0.832	rs34411702	chr4:6835635	G/A	cg05012661	chr4:6891264	NA	0.5	6.2	0.37	2.42e-9	Platelet count;
KIRP	cis	rs12580194	0.593	rs7487895	chr12:55796720	T/C	cg11794356	chr12:55725991	OR6C3	-0.53	-6.97	-0.41	2.9e-11	Cancer;
KIRP	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.7	-7.71	-0.44	3.06e-13	Gut microbiome composition (summer);
KIRP	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.44	-5.89	-0.35	1.27e-8	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.68	-0.39	1.56e-10	Lung cancer;
KIRP	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg00684032	chr4:1343700	KIAA1530	0.44	5.67	0.34	4.09e-8	Obesity-related traits;
KIRP	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg04398451	chr17:18023971	MYO15A	-0.87	-13.53	-0.65	1.52e-31	Total body bone mineral density;
KIRP	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.44	5.4	0.33	1.61e-7	Height;
KIRP	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.38	-4.85	-0.3	2.2e-6	Mean platelet volume;
KIRP	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.36	-0.42	2.73e-12	Vitiligo;
KIRP	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.56	0.39	3.19e-10	Educational attainment;
KIRP	cis	rs2559856	1.000	rs2559856	chr12:102089561	A/G	cg15068132	chr12:102092402	CHPT1	-0.39	-4.97	-0.3	1.27e-6	Blood protein levels;
KIRP	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.38	-8.04	-0.46	3.76e-14	Body mass index;
KIRP	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg19875535	chr5:140030758	IK	0.69	9.64	0.52	7.26e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.33	-10.11	-0.54	2.53e-20	Diabetic kidney disease;
KIRP	cis	rs7113850	0.541	rs7118538	chr11:24223615	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.35	0.47	5.02e-15	Bone fracture in osteoporosis;
KIRP	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg07382826	chr16:28625726	SULT1A1	0.54	5.97	0.36	8.29e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.93	-11.28	-0.58	4.71e-24	Diastolic blood pressure;
KIRP	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg15691649	chr6:25882328	NA	-0.44	-5.45	-0.33	1.25e-7	Blood metabolite levels;
KIRP	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg25019033	chr10:957182	NA	-0.5	-5.42	-0.33	1.41e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg02487422	chr3:49467188	NICN1	-0.39	-5.54	-0.33	7.81e-8	Menarche (age at onset);
KIRP	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.53	-6.05	-0.36	5.36e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg25251562	chr2:3704773	ALLC	0.57	6.83	0.4	6.45e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs526231	0.511	rs56235607	chr5:102372606	G/A	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	9.53	0.52	1.58e-18	Bone mineral density;
KIRP	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.9	-0.4	4.49e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.85	12.16	0.61	6.12e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs11718455	0.503	rs2302351	chr3:44039889	G/A	cg08738300	chr3:44038990	NA	0.38	5.85	0.35	1.58e-8	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01417339	chr8:135813202	MIR30B	-0.47	-6.84	-0.4	6.21e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3744061	0.530	rs8182300	chr17:74650608	T/C	cg27546012	chr17:74684504	MXRA7	-0.45	-5.47	-0.33	1.1e-7	Retinal arteriolar caliber;
KIRP	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	1.2	11.38	0.59	2.16e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg18132916	chr6:79620363	NA	-0.41	-5.6	-0.34	5.6e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg21095983	chr6:86352623	SYNCRIP	0.53	6.98	0.41	2.69e-11	Smooth-surface caries;
KIRP	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg09263875	chr16:632152	PIGQ	0.7	10.93	0.57	6.11e-23	Height;
KIRP	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.74	-9.17	-0.5	1.97e-17	Pancreatic cancer;
KIRP	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	8.45	0.47	2.55e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3935685	0.874	rs11072662	chr15:77999436	A/G	cg25212270	chr15:78015279	NA	0.58	7.56	0.43	8.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs1050631	0.960	rs1789503	chr18:33696865	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.48	5.97	0.36	8.25e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs960902	0.620	rs11693033	chr2:37737206	C/T	cg25341268	chr2:37734390	NA	-0.57	-7.34	-0.42	3.08e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs7274811	0.681	rs291707	chr20:31964256	G/A	cg03904042	chr20:32255491	NECAB3;C20orf134	0.4	4.89	0.3	1.78e-6	Height;
KIRP	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.71	0.39	1.35e-10	Tonsillectomy;
KIRP	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.9	-14.02	-0.67	3.27e-33	Lung cancer;
KIRP	cis	rs6921919	0.559	rs13210866	chr6:28383842	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.38	-0.38	8.49e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.71	8.13	0.46	2.15e-14	Height;
KIRP	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg03647239	chr10:116582469	FAM160B1	0.51	5.75	0.34	2.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7582720	0.945	rs72932720	chr2:203646934	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	9.63	0.52	8.09e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg27205649	chr11:78285834	NARS2	0.68	9.05	0.5	4.56e-17	Alzheimer's disease (survival time);
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22168489	chr12:122356033	WDR66	0.67	9.71	0.53	4.51e-19	Mean corpuscular volume;
KIRP	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.44	-5.81	-0.35	1.96e-8	Blood metabolite levels;
KIRP	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-5.55	-0.33	7.34e-8	Neuroticism;
KIRP	cis	rs832187	0.665	rs7627690	chr3:63900477	C/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.46	-5.34	-0.32	2.12e-7	Schizophrenia;
KIRP	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg23920097	chr1:209922102	NA	-0.49	-5.65	-0.34	4.45e-8	Red blood cell count;
KIRP	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.82	8.82	0.49	2.16e-16	Prostate cancer;
KIRP	cis	rs10875746	0.669	rs2279464	chr12:48690409	C/T	cg24011408	chr12:48396354	COL2A1	-0.45	-5.09	-0.31	7e-7	Longevity (90 years and older);
KIRP	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg00684032	chr4:1343700	KIAA1530	0.5	6.71	0.39	1.36e-10	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22295628	chr17:1733433	RPA1;SMYD4	0.49	6.33	0.37	1.18e-9	Parkinson's disease;
KIRP	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.4	5.36	0.32	1.94e-7	Educational attainment;
KIRP	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg11995313	chr8:8860691	ERI1	0.39	5.16	0.31	5.18e-7	Joint mobility (Beighton score);
KIRP	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg08603382	chr10:743973	NA	-0.66	-10.54	-0.56	1.09e-21	Psychosis in Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25572812	chr11:31391649	DCDC1;DNAJC24	0.46	6.25	0.37	1.76e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg20243544	chr17:37824526	PNMT	0.38	4.93	0.3	1.5e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs3829109	0.564	rs10781506	chr9:139271461	C/T	cg21253087	chr9:139290292	SNAPC4	0.47	5.42	0.33	1.43e-7	Peak insulin response;Acute insulin response;
KIRP	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.71	9.08	0.5	3.62e-17	Corneal structure;
KIRP	cis	rs2970992	0.764	rs13024200	chr2:101329338	T/G	cg01042948	chr2:101319752	NA	0.42	5.91	0.35	1.15e-8	Educational attainment;
KIRP	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.25	0.55	8.96e-21	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg25036284	chr2:26402008	FAM59B	-0.48	-5.06	-0.31	8.09e-7	Gut microbiome composition (summer);
KIRP	cis	rs7078219	1.000	rs61872688	chr10:101273546	G/A	cg07044859	chr10:101282883	NA	-0.34	-5.78	-0.35	2.22e-8	Dental caries;
KIRP	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.51	6.31	0.37	1.26e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10073892	0.660	rs9327868	chr5:101955726	T/C	cg19774478	chr5:101632501	SLCO4C1	0.53	5.43	0.33	1.38e-7	Cognitive decline (age-related);
KIRP	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.48	-5.49	-0.33	9.77e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Body mass index;
KIRP	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg17554472	chr22:41940697	POLR3H	0.64	6.59	0.39	2.58e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg18501202	chr6:125855421	NA	-0.35	-5.42	-0.33	1.44e-7	Brugada syndrome;
KIRP	cis	rs7998202	0.667	rs2104789	chr13:113365398	G/A	cg04656015	chr13:113407548	ATP11A	-0.57	-6.23	-0.37	1.97e-9	Glycated hemoglobin levels;
KIRP	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.29	-0.55	6.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg03128060	chr6:142623767	GPR126	0.35	5.0	0.3	1.11e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg02012338	chr4:187126139	CYP4V2	0.85	7.05	0.41	1.8e-11	Activated partial thromboplastin time;
KIRP	cis	rs35661897	0.790	rs62190940	chr2:227349175	G/A	cg03426602	chr2:227312417	NA	-0.54	-5.73	-0.34	2.89e-8	Urinary tract infection frequency;
KIRP	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.46	-5.85	-0.35	1.59e-8	Motion sickness;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.8	10.85	0.57	1.12e-22	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06878840	chr8:38854115	TM2D2;ADAM9	0.46	6.59	0.39	2.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.47	-7.01	-0.41	2.32e-11	Vitamin D levels;
KIRP	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.3	-6.87	-0.4	5.11e-11	Mean corpuscular volume;
KIRP	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.73	-0.34	2.93e-8	Bipolar disorder;
KIRP	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.76	-10.56	-0.56	9.54e-22	Metabolic syndrome;
KIRP	cis	rs6466055	0.720	rs4730080	chr7:105001133	T/C	cg04380332	chr7:105027541	SRPK2	-0.63	-9.35	-0.51	5.66e-18	Schizophrenia;
KIRP	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg00074818	chr8:8560427	CLDN23	0.41	6.34	0.37	1.1e-9	Obesity-related traits;
KIRP	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg13206674	chr6:150067644	NUP43	0.57	8.09	0.46	2.68e-14	Lung cancer;
KIRP	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12480562	chr20:23434244	CST11	0.65	5.25	0.32	3.34e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6024905	0.722	rs2275954	chr20:36962667	C/T	cg07053727	chr20:36965646	BPI	-0.4	-6.39	-0.38	8.32e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-13.49	-0.65	2.06e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg21926883	chr2:100939477	LONRF2	-0.58	-7.69	-0.44	3.5e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7078219	0.686	rs12412214	chr10:101276256	G/A	cg07044859	chr10:101282883	NA	-0.38	-5.97	-0.36	8.43e-9	Dental caries;
KIRP	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.86	10.85	0.57	1.15e-22	Platelet distribution width;
KIRP	cis	rs60154123	0.730	rs652256	chr1:210465017	T/C	cg09074223	chr1:210466472	NA	0.53	5.59	0.34	6.07e-8	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-1.01	-11.87	-0.6	5.24e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs963731	0.649	rs61405040	chr2:39350372	T/C	cg04010122	chr2:39346883	SOS1	0.9	6.15	0.36	3.2e-9	Corticobasal degeneration;
KIRP	cis	rs1555895	0.576	rs752375	chr10:863329	C/T	cg10017260	chr10:834428	NA	-0.43	-6.14	-0.36	3.31e-9	Survival in rectal cancer;
KIRP	cis	rs1958560	0.932	rs4587890	chr14:65863784	A/T	cg03016385	chr14:66212404	NA	0.43	5.59	0.34	5.97e-8	Menarche (age at onset);
KIRP	cis	rs6968419	0.747	rs1000966	chr7:115862902	A/G	cg02561103	chr7:115862891	TES	-0.42	-6.12	-0.36	3.63e-9	Intraocular pressure;
KIRP	cis	rs4663866	1.000	rs4663866	chr2:239150815	A/C	cg16914508	chr2:239161102	PER2	0.7	5.06	0.31	8.08e-7	Irritable bowel syndrome;
KIRP	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg25182066	chr10:30743637	MAP3K8	-0.62	-8.37	-0.47	4.49e-15	Inflammatory bowel disease;
KIRP	cis	rs4704187	0.663	rs28539749	chr5:74533902	G/A	cg03227963	chr5:74354835	NA	0.4	5.84	0.35	1.65e-8	Response to amphetamines;
KIRP	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.47	-0.48	2.31e-15	Retinal vascular caliber;
KIRP	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg17294928	chr15:75287854	SCAMP5	-0.65	-5.56	-0.33	7e-8	Lung cancer;
KIRP	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.48	6.27	0.37	1.63e-9	High light scatter reticulocyte count;
KIRP	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.78e-7	Aortic root size;
KIRP	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg02336718	chr17:17403227	NA	-0.34	-5.53	-0.33	8.35e-8	Total body bone mineral density;
KIRP	cis	rs8054556	0.669	rs4787491	chr16:30015337	A/G	cg06326092	chr16:30034487	C16orf92	0.4	5.82	0.35	1.79e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg15691649	chr6:25882328	NA	-0.51	-5.39	-0.33	1.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.63	9.62	0.52	8.47e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg25547332	chr5:131281432	NA	-0.5	-5.7	-0.34	3.42e-8	Life satisfaction;
KIRP	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.75	-11.03	-0.58	3.06e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.62	-8.43	-0.47	2.96e-15	Colorectal cancer;
KIRP	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg20749741	chr2:264178	ACP1;SH3YL1	0.45	5.02	0.3	9.89e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs960902	1.000	rs10204024	chr2:37732029	A/G	cg25341268	chr2:37734390	NA	-0.49	-6.67	-0.39	1.69e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.62	0.39	2.29e-10	Height;
KIRP	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19623624	chr10:135278901	LOC619207	-0.53	-5.88	-0.35	1.3e-8	Systemic lupus erythematosus;
KIRP	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	8.24	0.47	1.06e-14	Lewy body disease;
KIRP	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg16255804	chr6:135334527	HBS1L	-0.32	-5.2	-0.31	4.18e-7	Red blood cell count;
KIRP	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.21	-0.31	4.09e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs1941687	0.797	rs8096533	chr18:31383889	A/C	cg27147174	chr7:100797783	AP1S1	-0.57	-7.11	-0.41	1.22e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	0.92	10.07	0.54	3.43e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.22	0.72	1.01e-40	Electrocardiographic conduction measures;
KIRP	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	1.11	8.3	0.47	6.82e-15	Skin colour saturation;
KIRP	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs930036	0.602	rs731692	chr2:171797189	G/A	cg12801329	chr2:171670795	NA	0.43	4.91	0.3	1.67e-6	Menopause (age at onset);
KIRP	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg01028140	chr2:1542097	TPO	-0.58	-6.55	-0.39	3.27e-10	IgG glycosylation;
KIRP	cis	rs4664304	0.620	rs12692568	chr2:160718440	T/C	cg03641300	chr2:160917029	PLA2R1	0.35	5.35	0.32	1.98e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg12560992	chr17:57184187	TRIM37	0.65	5.83	0.35	1.76e-8	Cognitive test performance;
KIRP	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	0.64	5.78	0.35	2.29e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11987759	chr7:65425863	GUSB	0.5	6.71	0.39	1.32e-10	Aortic root size;
KIRP	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg12315302	chr6:26189340	HIST1H4D	0.89	6.2	0.37	2.39e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6504663	0.558	rs7627	chr17:48552154	G/C	cg00901687	chr17:48585270	MYCBPAP	0.44	5.65	0.34	4.46e-8	Visceral fat;
KIRP	cis	rs6840360	0.642	rs11099815	chr4:152343888	G/T	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.59	7.38	0.43	2.41e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.68	-9.1	-0.5	3.13e-17	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs6504622	0.818	rs758391	chr17:45017241	G/A	cg24703533	chr17:45055318	NA	0.39	5.18	0.31	4.68e-7	Orofacial clefts;
KIRP	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.92	12.16	0.61	6.14e-27	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.72e-7	Life satisfaction;
KIRP	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	1.04	9.74	0.53	3.63e-19	Thyroid stimulating hormone;
KIRP	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg20651018	chr11:3035856	CARS	-0.38	-5.26	-0.32	3.09e-7	Longevity;
KIRP	cis	rs3857067	1.000	rs1588381	chr4:95017558	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.02	-0.3	9.95e-7	QT interval;
KIRP	cis	rs4742903	0.875	rs2122581	chr9:107008811	G/A	cg14250997	chr9:106856677	SMC2	0.36	4.91	0.3	1.63e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs10875746	0.859	rs11168371	chr12:48437686	C/T	cg20731937	chr12:48336164	NA	0.42	5.17	0.31	4.88e-7	Longevity (90 years and older);
KIRP	cis	rs9325144	0.768	rs11168750	chr12:38992710	C/A	cg13010199	chr12:38710504	ALG10B	-0.45	-5.44	-0.33	1.32e-7	Morning vs. evening chronotype;
KIRP	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.68	-12.44	-0.62	6.84e-28	White blood cell count (basophil);
KIRP	cis	rs7945718	0.621	rs7931934	chr11:12679245	T/G	cg25843174	chr11:12811716	TEAD1	0.32	5.91	0.35	1.15e-8	Educational attainment (years of education);
KIRP	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg25856811	chr1:152973957	SPRR3	-0.36	-4.88	-0.3	1.87e-6	Inflammatory skin disease;
KIRP	cis	rs10958369	0.613	rs1477957	chr8:54435433	T/C	cg12485204	chr8:54507357	NA	0.42	5.4	0.33	1.61e-7	Response to antineoplastic agents;
KIRP	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.06	0.41	1.73e-11	Rheumatoid arthritis;
KIRP	cis	rs909341	0.909	rs67616625	chr20:62363487	A/G	cg11503966	chr20:62272292	STMN3	-0.42	-5.84	-0.35	1.66e-8	Atopic dermatitis;
KIRP	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.63	9.14	0.5	2.45e-17	Resting heart rate;
KIRP	cis	rs4783244	0.862	rs7198176	chr16:82647971	C/T	cg09415485	chr16:82663111	CDH13	-0.27	-4.99	-0.3	1.13e-6	Adiponectin levels;
KIRP	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.49	6.66	0.39	1.74e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg08975724	chr8:8085496	FLJ10661	0.68	8.97	0.5	7.76e-17	Mood instability;
KIRP	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.59	7.85	0.45	1.3e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.69	-7.23	-0.42	5.96e-12	Blood pressure (smoking interaction);
KIRP	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.4	-0.43	2.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg17724175	chr1:150552817	MCL1	-0.35	-6.01	-0.36	6.57e-9	Tonsillectomy;
KIRP	cis	rs9398803	0.865	rs4418209	chr6:126819699	T/G	cg19875578	chr6:126661172	C6orf173	0.5	6.47	0.38	5.15e-10	Male-pattern baldness;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13939156	chr17:80058883	NA	0.5	7.51	0.43	1.07e-12	Life satisfaction;
KIRP	cis	rs113084984	0.718	rs12994182	chr2:11683898	C/A	cg07314298	chr2:11723111	GREB1	0.39	5.09	0.31	7.15e-7	Breast cancer;
KIRP	cis	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg04607699	chr11:48328132	OR4S1	0.39	5.55	0.33	7.47e-8	Migraine - clinic-based;
KIRP	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg13010199	chr12:38710504	ALG10B	0.62	7.75	0.44	2.36e-13	Morning vs. evening chronotype;
KIRP	trans	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.58	0.39	2.79e-10	Skin colour saturation;
KIRP	cis	rs600806	0.778	rs10494040	chr1:110015732	C/T	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg20368463	chr18:77673604	PQLC1	0.52	6.08	0.36	4.6e-9	Schizophrenia;
KIRP	cis	rs9611565	0.592	rs56021266	chr22:41756571	C/T	cg03806693	chr22:41940476	POLR3H	-0.97	-8.66	-0.48	6.33e-16	Vitiligo;
KIRP	cis	rs427941	0.632	rs201509	chr7:101765002	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.61	0.39	2.4e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.09	-0.64	4.71e-30	Alzheimer's disease;
KIRP	cis	rs397969	0.596	rs35925051	chr17:19877369	G/A	cg13482628	chr17:19912719	NA	0.45	4.94	0.3	1.45e-6	Platelet count;
KIRP	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.58	-0.34	6.31e-8	Height;
KIRP	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg22903657	chr4:1355424	KIAA1530	-0.42	-5.92	-0.35	1.05e-8	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10884052	chr2:135475971	TMEM163	0.45	6.25	0.37	1.81e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs754133	0.963	rs12319419	chr12:54420776	G/C	cg10005224	chr12:54424964	HOXC4;HOXC5	0.26	5.41	0.33	1.51e-7	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23377693	chr6:43597122	MAD2L1BP;GTPBP2	0.52	6.9	0.4	4.26e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg24009623	chr19:33667908	NA	0.5	6.24	0.37	1.91e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16682257	chr1:245411712	KIF26B	0.43	6.23	0.37	2.04e-9	Interleukin-4 levels;
KIRP	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-6.29	-0.37	1.43e-9	Fear of minor pain;
KIRP	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg08890418	chr1:21044141	KIF17	-0.42	-6.37	-0.38	9.06e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7577696	0.568	rs410469	chr2:32476992	G/T	cg02381751	chr2:32503542	YIPF4	-0.51	-5.13	-0.31	5.81e-7	Inflammatory biomarkers;
KIRP	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.53	-7.16	-0.42	9.45e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs1570884	0.857	rs9535263	chr13:50137363	T/A	cg03651054	chr13:50194643	NA	0.59	7.83	0.45	1.41e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7692976	0.578	rs12510173	chr4:110843260	A/G	cg06981781	chr4:110842888	EGF	-0.25	-5.4	-0.33	1.54e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.21	0.51	1.44e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-4.89	-0.3	1.8e-6	Aortic root size;
KIRP	cis	rs9469913	0.799	rs2744954	chr6:34621470	A/G	cg17674042	chr6:34482479	PACSIN1	-0.47	-6.28	-0.37	1.48e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs6500395	0.962	rs17826468	chr16:48568271	A/G	cg04672837	chr16:48644449	N4BP1	0.49	6.49	0.38	4.61e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs7737355	0.812	rs10078640	chr5:131071246	C/G	cg06307176	chr5:131281290	NA	0.46	5.57	0.33	6.6e-8	Life satisfaction;
KIRP	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.53	-9.21	-0.51	1.45e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.28	-4.85	-0.3	2.16e-6	Monocyte count;
KIRP	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.21	27.25	0.87	2.91e-76	Schizophrenia;
KIRP	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg10017260	chr10:834428	NA	-0.58	-5.56	-0.33	7e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00933542	chr6:150070202	PCMT1	0.3	5.91	0.35	1.16e-8	Lung cancer;
KIRP	cis	rs3105593	1.000	rs17645649	chr15:50900370	A/G	cg05456662	chr15:50716270	USP8	0.44	5.32	0.32	2.36e-7	QT interval;
KIRP	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.46	0.43	1.44e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.29	5.72	0.34	3.01e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	0.99	11.59	0.59	4.58e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg00677901	chr16:88017247	BANP	-0.41	-5.01	-0.3	1.06e-6	Menopause (age at onset);
KIRP	cis	rs8113308	1.000	rs7246064	chr19:52442262	C/T	cg25782003	chr19:52490127	ZNF350	0.51	4.99	0.3	1.15e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg23024343	chr7:107201750	COG5	0.44	5.07	0.31	7.95e-7	Coronary artery disease;
KIRP	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.38	-0.38	8.58e-10	Height;
KIRP	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.11	0.74	9.41e-44	Chronic sinus infection;
KIRP	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.92	13.86	0.66	1.13e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-6.01	-0.36	6.58e-9	Vitiligo;
KIRP	cis	rs9488822	0.676	rs12524249	chr6:116368813	G/A	cg26893134	chr6:116381904	FRK	0.2	5.45	0.33	1.2e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.61	-9.11	-0.5	2.9e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg04989706	chr14:50066350	PPIL5	-0.48	-5.65	-0.34	4.35e-8	Carotid intima media thickness;
KIRP	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg02725872	chr8:58115012	NA	-0.36	-4.93	-0.3	1.51e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-5.27	-0.32	2.94e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg01677386	chr11:118938358	VPS11	-0.48	-5.67	-0.34	4.04e-8	Coronary artery disease;
KIRP	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs4765905	0.546	rs11062161	chr12:2329970	A/G	cg10668781	chr12:2307325	CACNA1C	-0.28	-5.38	-0.32	1.7e-7	Schizophrenia;
KIRP	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.58	-0.59	4.79e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4389656	0.740	rs412643	chr5:6720715	A/G	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs427941	0.703	rs1637257	chr7:101740606	T/G	cg06246474	chr7:101738831	CUX1	0.56	6.93	0.4	3.65e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06505273	chr16:24850292	NA	-0.37	-5.01	-0.3	1.04e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.47	-0.33	1.1e-7	Bipolar disorder;
KIRP	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.52	7.25	0.42	5.5e-12	Schizophrenia;
KIRP	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.6	8.38	0.47	4.15e-15	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg10950524	chr7:2139216	MAD1L1	-0.3	-4.96	-0.3	1.33e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg20891283	chr12:69753455	YEATS4	0.64	6.63	0.39	2.09e-10	Response to diuretic therapy;
KIRP	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.67	9.27	0.51	1e-17	Morning vs. evening chronotype;
KIRP	cis	rs3779635	0.742	rs11776858	chr8:27244300	A/G	cg21186296	chr8:27182909	PTK2B	0.48	6.11	0.36	3.83e-9	Neuroticism;
KIRP	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.81	9.83	0.53	1.87e-19	Corneal astigmatism;
KIRP	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.56	7.54	0.43	8.96e-13	Endometrial cancer;
KIRP	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.69	-8.72	-0.49	4.17e-16	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9469913	0.799	rs2814994	chr6:34620153	T/A	cg14254433	chr6:34482411	PACSIN1	-0.43	-5.33	-0.32	2.17e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg10189774	chr4:17578691	LAP3	0.44	5.3	0.32	2.54e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg06917634	chr15:78832804	PSMA4	0.56	6.11	0.36	3.94e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1215050	0.791	rs10856931	chr4:98819306	C/T	cg17366294	chr4:99064904	C4orf37	0.39	5.28	0.32	2.8e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.13	-0.36	3.55e-9	Neuroticism;
KIRP	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	8.54	0.48	1.37e-15	Myopia (pathological);
KIRP	cis	rs35343117	1	rs35343117	chr15:86079115	C/G	cg17133734	chr15:86042851	AKAP13	-0.58	-7.01	-0.41	2.32e-11	Psoriasis;
KIRP	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs6496667	1.000	rs6496668	chr15:90893704	A/T	cg10434728	chr15:90938212	IQGAP1	0.38	4.96	0.3	1.3e-6	Rheumatoid arthritis;
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg26990660	chr17:40913221	LOC100190938;RAMP2	-0.39	-6.1	-0.36	4.18e-9	Suicide attempts in major depressive disorder;
KIRP	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg06223162	chr1:101003688	GPR88	0.42	8.25	0.47	9.59e-15	Breast cancer;
KIRP	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.25	6.75	0.4	1.07e-10	Crohn's disease;
KIRP	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.77	11.94	0.61	3.25e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.54	6.98	0.41	2.67e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10761482	0.531	rs10740029	chr10:62238902	G/A	cg01186212	chr10:62110162	ANK3	-0.29	-5.0	-0.3	1.08e-6	Schizophrenia;
KIRP	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.56	-0.43	7.82e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	0.71	6.87	0.4	5.19e-11	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11197481	0.614	rs10490988	chr10:117702645	A/T	cg18864804	chr10:117642441	ATRNL1	0.39	4.89	0.3	1.81e-6	Huntington's disease progression;
KIRP	cis	rs11676676	0.593	rs6723487	chr2:109774977	G/C	cg01741688	chr2:109781768	SH3RF3	-0.49	-4.98	-0.3	1.2e-6	Pediatric bone mineral density (spine);
KIRP	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg10760299	chr15:45669010	GATM	0.34	5.12	0.31	6.12e-7	Homoarginine levels;
KIRP	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06544989	chr22:39130855	UNC84B	0.43	6.74	0.4	1.09e-10	Menopause (age at onset);
KIRP	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg22256960	chr15:77711686	NA	-0.43	-5.55	-0.33	7.37e-8	Type 2 diabetes;
KIRP	cis	rs4950322	0.570	rs72691098	chr1:146771840	G/A	cg22381352	chr1:146742008	CHD1L	-0.44	-5.27	-0.32	2.96e-7	Protein quantitative trait loci;
KIRP	cis	rs72730918	0.590	rs1378894	chr15:51937462	G/A	cg14296394	chr15:51910925	DMXL2	-0.78	-10.94	-0.57	6.04e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.69	-9.74	-0.53	3.63e-19	Prudent dietary pattern;
KIRP	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.46	-6.25	-0.37	1.83e-9	Glomerular filtration rate (creatinine);
KIRP	cis	rs13067260	0.655	rs9867225	chr3:123719717	T/A	cg19918027	chr3:123987645	KALRN	-0.62	-5.51	-0.33	9.2e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg18882449	chr10:104885122	NT5C2	-0.49	-6.28	-0.37	1.5e-9	Arsenic metabolism;
KIRP	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.89	12.42	0.62	8.18e-28	Gestational age at birth (maternal effect);
KIRP	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg23682824	chr7:23144976	KLHL7	-0.44	-5.08	-0.31	7.43e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2151522	0.603	rs13207064	chr6:127176369	T/C	cg21431617	chr6:127135037	NA	0.31	5.44	0.33	1.29e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7662987	0.793	rs28730602	chr4:100001682	G/T	cg13256891	chr4:100009986	ADH5	-0.64	-5.47	-0.33	1.1e-7	Smoking initiation;
KIRP	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg22117172	chr7:91764530	CYP51A1	0.4	5.55	0.33	7.36e-8	Breast cancer;
KIRP	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg23594656	chr7:65796392	TPST1	0.39	5.73	0.34	2.92e-8	Aortic root size;
KIRP	cis	rs2011503	0.739	rs4808973	chr19:19725456	A/G	cg11584989	chr19:19387371	SF4	-0.51	-5.47	-0.33	1.11e-7	Bipolar disorder;
KIRP	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.5	-5.4	-0.33	1.56e-7	Coronary artery disease;
KIRP	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.75	-12.34	-0.62	1.45e-27	Prostate cancer;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg14150280	chr10:70660547	DDX50	-0.49	-6.03	-0.36	5.99e-9	Blood metabolite levels;
KIRP	cis	rs7172677	1.000	rs7177528	chr15:75409594	T/C	cg10253484	chr15:75165896	SCAMP2	-0.56	-6.12	-0.36	3.66e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7129556	0.815	rs11607715	chr11:77238859	T/C	cg12586386	chr11:77299805	AQP11	0.45	5.3	0.32	2.58e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.88	10.67	0.56	4.39e-22	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.63	7.75	0.44	2.36e-13	Alcohol dependence;
KIRP	cis	rs11078597	0.731	rs62090051	chr17:1640640	C/G	cg17514665	chr17:1657533	SERPINF2	0.45	5.59	0.34	6.03e-8	Serum albumin level;
KIRP	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.34	-5.06	-0.31	8.34e-7	Headache;
KIRP	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.67	5.52	0.33	8.53e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.5	6.97	0.41	2.92e-11	Dupuytren's disease;
KIRP	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg08501292	chr6:25962987	TRIM38	0.82	5.32	0.32	2.34e-7	Lung cancer in ever smokers;
KIRP	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg09904177	chr6:26538194	HMGN4	-0.52	-6.63	-0.39	2.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.676	rs10456902	chr6:116333742	C/G	cg05304507	chr6:116381966	FRK	-0.21	-5.85	-0.35	1.53e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.52	-7.93	-0.45	7.87e-14	Huntington's disease progression;
KIRP	cis	rs9928842	0.770	rs4888364	chr16:75279510	A/G	cg09066997	chr16:75300724	BCAR1	0.57	4.95	0.3	1.37e-6	Alcoholic chronic pancreatitis;
KIRP	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg06565975	chr8:143823917	SLURP1	-0.55	-7.55	-0.43	8.69e-13	Urinary tract infection frequency;
KIRP	cis	rs4774899	1.000	rs4774902	chr15:57240760	A/C	cg13626582	chr15:57592083	LOC283663	-0.2	-4.85	-0.3	2.15e-6	Urinary tract infection frequency;
KIRP	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	10.26	0.55	8.56e-21	Parkinson's disease;
KIRP	cis	rs2143950	0.749	rs57275892	chr14:35747271	G/A	cg09327582	chr14:35236912	BAZ1A	-0.6	-5.72	-0.34	3.06e-8	Atopic dermatitis;
KIRP	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg18709589	chr6:96969512	KIAA0776	0.34	5.15	0.31	5.36e-7	Headache;
KIRP	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.6	7.35	0.42	2.86e-12	Tuberculosis;
KIRP	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs10242455	0.571	rs11734	chr7:99229768	C/G	cg18809830	chr7:99032528	PTCD1	0.82	5.31	0.32	2.48e-7	Blood metabolite levels;
KIRP	cis	rs981844	0.775	rs17371261	chr4:154738479	G/T	cg14289246	chr4:154710475	SFRP2	-0.67	-7.8	-0.45	1.73e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg11204139	chr17:3907470	NA	0.67	10.71	0.56	3.2800000000000002e-22	Type 2 diabetes;
KIRP	trans	rs2244497	0.966	rs9908953	chr17:64518433	A/C	cg01045337	chr16:374988	AXIN1	-0.38	-6.04	-0.36	5.69e-9	Neuroticism;
KIRP	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg13180566	chr4:1052158	NA	-0.52	-5.22	-0.32	3.88e-7	Recombination rate (females);
KIRP	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.7	-0.49	4.91e-16	Retinal vascular caliber;
KIRP	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg25182066	chr10:30743637	MAP3K8	-0.63	-8.63	-0.48	7.81e-16	Inflammatory bowel disease;
KIRP	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	5.18	0.31	4.54e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-5.9	-0.35	1.22e-8	Aortic root size;
KIRP	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.75	-11.0	-0.57	3.62e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3755132	0.929	rs2302930	chr2:15737343	A/G	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	trans	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg06521331	chr12:34319734	NA	-0.56	-6.87	-0.4	5.29e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs897080	0.515	rs1067349	chr2:44670369	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.83	0.35	1.71e-8	Height;
KIRP	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg09631192	chr20:23583594	CST9	-0.54	-5.2	-0.31	4.14e-7	Chronic kidney disease;
KIRP	cis	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg06521331	chr12:34319734	NA	-0.44	-5.04	-0.31	9.1e-7	Resting heart rate;
KIRP	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg01391022	chr12:122360665	WDR66	-0.4	-6.12	-0.36	3.57e-9	Mean corpuscular volume;
KIRP	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg25486957	chr4:152246857	NA	-0.5	-5.47	-0.33	1.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg07080220	chr10:102295463	HIF1AN	1.02	10.21	0.55	1.26e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg03342759	chr3:160939853	NMD3	0.56	7.13	0.41	1.1e-11	Morning vs. evening chronotype;
KIRP	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.69	-9.04	-0.5	4.82e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg20255370	chr15:40268687	EIF2AK4	0.3	4.87	0.3	1.99e-6	Response to haloperidol in psychosis;
KIRP	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg04398451	chr17:18023971	MYO15A	-0.66	-9.19	-0.51	1.71e-17	Total body bone mineral density;
KIRP	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg06611532	chr13:114900021	NA	0.22	5.2	0.31	4.24e-7	Schizophrenia;
KIRP	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.65	0.34	4.53e-8	Total cholesterol levels;
KIRP	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg10223061	chr2:219282414	VIL1	-0.33	-5.29	-0.32	2.68e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg24315340	chr6:146058215	EPM2A	-0.47	-6.15	-0.36	3.17e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg10761708	chr20:43804764	PI3	0.52	5.23	0.32	3.62e-7	Blood protein levels;
KIRP	cis	rs13082711	0.871	rs34209332	chr3:27434061	A/T	cg02860705	chr3:27208620	NA	0.58	8.2	0.46	1.32e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1620921	0.967	rs783162	chr6:161182954	A/G	cg01280913	chr6:161186852	NA	-0.45	-6.52	-0.38	3.88e-10	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs13401104	0.716	rs57014724	chr2:237127936	G/A	cg19324714	chr2:237145437	ASB18	0.52	5.44	0.33	1.3e-7	Educational attainment;
KIRP	cis	rs9608946	1.000	rs9606738	chr22:30891250	T/C	cg23383138	chr22:30885012	SEC14L4	0.4	4.94	0.3	1.44e-6	Red cell distribution width;
KIRP	cis	rs7565981	1.000	rs6706203	chr2:101425719	A/G	cg02232089	chr2:101440696	NPAS2	-0.57	-5.3	-0.32	2.59e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.76	12.66	0.63	1.3e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg25251562	chr2:3704773	ALLC	0.57	6.82	0.4	7.1e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.96	-7.9	-0.45	9.32e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.43	-0.33	1.37e-7	Colorectal cancer;
KIRP	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg19468946	chr17:37922297	IKZF3	-0.42	-6.0	-0.36	7.15e-9	Asthma;
KIRP	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7590368	1.000	rs72779469	chr2:10963764	C/G	cg15705551	chr2:10952987	PDIA6	0.45	4.94	0.3	1.46e-6	Educational attainment (years of education);
KIRP	cis	rs1978968	1.000	rs1110662	chr22:18444908	G/A	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg02931644	chr1:25747376	RHCE	-0.37	-6.69	-0.39	1.49e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17967973	chr11:126139042	FOXRED1;SRPR	-0.47	-6.09	-0.36	4.27e-9	Myopia;
KIRP	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg03808351	chr9:123631620	PHF19	0.43	5.96	0.35	8.9e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.44	6.08	0.36	4.59e-9	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15066777	chr18:66382427	CCDC102B;TMX3	0.45	6.2	0.37	2.39e-9	Survival in pancreatic cancer;
KIRP	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.33	6.36	0.38	9.49e-10	Monocyte percentage of white cells;
KIRP	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg18357526	chr6:26021779	HIST1H4A	0.4	5.01	0.3	1.03e-6	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15910486	chr5:142783621	NR3C1	0.44	6.54	0.38	3.59e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	7.25	0.42	5.28e-12	Menarche (age at onset);
KIRP	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.49	-0.33	1e-7	Pulmonary function;
KIRP	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg17554472	chr22:41940697	POLR3H	0.68	7.12	0.41	1.15e-11	Vitiligo;
KIRP	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06481639	chr22:41940642	POLR3H	0.49	5.89	0.35	1.26e-8	Vitiligo;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg16587006	chr16:1726892	HN1L;CRAMP1L	0.43	6.46	0.38	5.65e-10	Warfarin maintenance dose;
KIRP	cis	rs11638352	0.661	rs2555382	chr15:44424316	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	6.06	0.36	5.19e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg02336718	chr17:17403227	NA	0.33	5.21	0.32	3.92e-7	Total body bone mineral density;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg14275779	chr17:40830236	PLEKHH3	0.53	6.15	0.37	3.1e-9	Sleep duration;
KIRP	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg10402321	chr1:26617780	UBXN11	-0.43	-5.61	-0.34	5.3e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg18225595	chr11:63971243	STIP1	0.65	5.98	0.36	7.85e-9	Mean platelet volume;
KIRP	cis	rs963731	0.649	rs7577088	chr2:39233500	G/A	cg04010122	chr2:39346883	SOS1	-0.88	-5.81	-0.35	1.88e-8	Corticobasal degeneration;
KIRP	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.83	-8.81	-0.49	2.27e-16	Hair shape;
KIRP	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg07395648	chr5:131743802	NA	-0.52	-7.47	-0.43	1.42e-12	Acylcarnitine levels;
KIRP	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.53	7.07	0.41	1.55e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.59	-7.15	-0.41	9.72e-12	Mosquito bite size;
KIRP	cis	rs4849845	0.962	rs11898472	chr2:121019244	G/T	cg24070213	chr2:121070622	NA	0.38	5.21	0.32	3.92e-7	Mean platelet volume;
KIRP	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg22676075	chr6:135203613	NA	0.49	7.06	0.41	1.72e-11	Red blood cell count;
KIRP	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg14517863	chr17:44321492	NA	0.51	5.81	0.35	1.97e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs17750015	0.733	rs12454365	chr18:54396215	G/A	cg18434998	chr18:54306185	TXNL1	-0.44	-5.58	-0.34	6.42e-8	Depression and alcohol dependence;
KIRP	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.93	13.45	0.65	2.79e-31	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs494562	0.892	rs1322403	chr6:86127162	A/G	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs72829446	0.530	rs8071847	chr17:7407327	A/G	cg02795151	chr17:7402630	POLR2A	0.78	8.07	0.46	3.08e-14	Androgen levels;
KIRP	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg10755058	chr3:40428713	ENTPD3	0.48	6.57	0.39	3e-10	Renal cell carcinoma;
KIRP	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg14458575	chr2:238380390	NA	0.47	5.3	0.32	2.61e-7	Prostate cancer;
KIRP	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg01294253	chr9:136912663	BRD3	-0.39	-5.17	-0.31	4.87e-7	Platelet distribution width;
KIRP	cis	rs7536201	1.000	rs7523412	chr1:25294264	G/A	cg23273869	chr1:25296894	NA	-0.36	-4.93	-0.3	1.48e-6	Psoriasis vulgaris;
KIRP	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.88	-11.19	-0.58	9.35e-24	Vitamin D levels;
KIRP	cis	rs7951870	0.617	rs12361673	chr11:46723937	G/A	cg16389345	chr11:46697382	NA	0.43	5.24	0.32	3.52e-7	Schizophrenia;
KIRP	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.51	7.04	0.41	1.86e-11	Childhood ear infection;
KIRP	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.66	-9.95	-0.54	7.94e-20	Educational attainment;
KIRP	trans	rs1912785	1.000	rs4681123	chr3:146405343	C/T	cg27583690	chr10:134599823	NKX6-2	0.39	6.06	0.36	4.98e-9	Barrett's esophagus;
KIRP	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.88	-0.4	4.99e-11	Gut microbiome composition (summer);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17314160	chr12:110399253	GIT2	-0.42	-6.11	-0.36	3.84e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.98	10.44	0.55	2.31e-21	Blood protein levels;
KIRP	cis	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08380311	chr19:3435252	NFIC	0.71	6.68	0.39	1.57e-10	Height;
KIRP	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-0.94	-12.06	-0.61	1.29e-26	Blood protein levels;
KIRP	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg15556689	chr8:8085844	FLJ10661	0.59	7.44	0.43	1.67e-12	Retinal vascular caliber;
KIRP	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg23815491	chr16:72088622	HP	0.39	6.29	0.37	1.41e-9	Fibrinogen levels;
KIRP	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.58	-6.12	-0.36	3.68e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg14930904	chr10:32216787	ARHGAP12	0.36	4.91	0.3	1.68e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.04	0.36	5.56e-9	Menopause (age at onset);
KIRP	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	1.04	13.27	0.65	1.13e-30	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs2163503	1.000	rs72674923	chr1:71754982	A/G	cg27386431	chr1:200990482	KIF21B	-0.67	-6.47	-0.38	5.38e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.57	7.53	0.43	9.37e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6732160	0.845	rs6718690	chr2:73387162	C/T	cg01422370	chr2:73384389	NA	-0.43	-5.8	-0.35	2.01e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08280861	chr8:58055591	NA	0.73	5.74	0.34	2.74e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg06204229	chr3:52865917	ITIH4	0.53	5.94	0.35	9.49e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.25	13.55	0.65	1.26e-31	Uric acid levels;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04155289	chr7:94953770	PON1	0.48	6.43	0.38	6.56e-10	Paraoxonase activity;
KIRP	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.72	9.59	0.52	1.03e-18	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1823913	0.599	rs58106487	chr2:192157130	A/G	cg12404831	chr2:192114017	MYO1B	0.54	7.47	0.43	1.43e-12	Obesity-related traits;
KIRP	cis	rs62229266	0.804	rs2255858	chr21:37412752	T/C	cg12218747	chr21:37451666	NA	-0.44	-5.52	-0.33	8.41e-8	Mitral valve prolapse;
KIRP	cis	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg19180546	chr13:44453867	C13orf31;CCDC122	0.44	5.91	0.35	1.14e-8	Leprosy;
KIRP	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.54	7.07	0.41	1.58e-11	Age at first birth;
KIRP	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg23985595	chr17:80112537	CCDC57	0.33	4.99	0.3	1.15e-6	Life satisfaction;
KIRP	cis	rs11671005	0.735	rs12981649	chr19:58930043	G/C	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg14019158	chr19:45754992	MARK4	-0.55	-6.08	-0.36	4.44e-9	Menopause (age at onset);
KIRP	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.65	-7.44	-0.43	1.64e-12	Testicular germ cell tumor;
KIRP	cis	rs3857747	0.931	rs17171685	chr7:40368882	C/T	cg00420559	chr7:40367873	C7orf10	0.61	8.6	0.48	9.74e-16	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs5753618	0.504	rs5753671	chr22:31910734	T/C	cg02404636	chr22:31891804	SFI1	0.56	6.55	0.39	3.35e-10	Colorectal cancer;
KIRP	cis	rs921943	1.000	rs7731142	chr5:78325519	A/C	cg26802063	chr5:78281964	ARSB	0.48	6.09	0.36	4.4e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.93	14.95	0.69	2.23e-36	Total body bone mineral density;
KIRP	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.55	-0.39	3.25e-10	Acne (severe);
KIRP	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg10047753	chr17:41438598	NA	0.83	11.21	0.58	7.65e-24	Menopause (age at onset);
KIRP	trans	rs894344	0.902	rs4909314	chr8:135623798	A/T	cg06840659	chr5:180237008	MGAT1	0.49	6.02	0.36	6.24e-9	Systolic blood pressure;
KIRP	cis	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg06521331	chr12:34319734	NA	-0.56	-6.91	-0.4	4.17e-11	Morning vs. evening chronotype;
KIRP	cis	rs2273156	1.000	rs60803103	chr14:35414053	A/T	cg09327582	chr14:35236912	BAZ1A	-0.52	-5.8	-0.35	2.04e-8	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.88	9.88	0.53	1.32e-19	Corneal astigmatism;
KIRP	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.61	-8.64	-0.48	7.26e-16	Menarche (age at onset);
KIRP	cis	rs6001982	0.748	rs6001950	chr22:40906635	C/G	cg07138101	chr22:40742427	ADSL	0.66	5.23	0.32	3.64e-7	Breast cancer;
KIRP	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.39	0.38	8.31e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg06871246	chr4:1363661	KIAA1530	0.5	6.28	0.37	1.56e-9	Longevity;
KIRP	cis	rs7929679	0.577	rs10836306	chr11:34797962	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	5.3	0.32	2.52e-7	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
KIRP	cis	rs533123	0.701	rs204054	chr1:29160462	T/C	cg08366446	chr1:29138936	OPRD1	0.9	7.16	0.42	9.15e-12	Schizophrenia;
KIRP	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.46	5.16	0.31	5.03e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg09873164	chr1:152488093	CRCT1	0.6	7.84	0.45	1.38e-13	Hair morphology;
KIRP	cis	rs1862626	0.506	rs4700008	chr5:56044186	A/G	cg14703610	chr5:56206110	C5orf35	0.4	5.08	0.31	7.52e-7	Cancer (pleiotropy);
KIRP	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg16405210	chr4:1374714	KIAA1530	-0.55	-7.68	-0.44	3.74e-13	Obesity-related traits;
KIRP	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23221052	chr5:179740743	GFPT2	-0.61	-6.8	-0.4	7.99e-11	Height;
KIRP	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.2	13.15	0.64	2.81e-30	Nonalcoholic fatty liver disease;
KIRP	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg27494647	chr7:150038898	RARRES2	0.36	5.61	0.34	5.43e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.62	8.26	0.47	8.85e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs76081789	0.536	rs2838300	chr21:44837359	A/G	cg03566291	chr21:44831040	NA	0.61	6.12	0.36	3.7e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg05347473	chr6:146136440	FBXO30	-0.58	-8.18	-0.46	1.49e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9905704	0.681	rs1860262	chr17:56580997	T/C	cg12560992	chr17:57184187	TRIM37	-0.55	-5.11	-0.31	6.62e-7	Testicular germ cell tumor;
KIRP	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg08499158	chr17:42289980	UBTF	-0.51	-6.47	-0.38	5.31e-10	Total body bone mineral density;
KIRP	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21545522	chr1:205238299	TMCC2	0.55	7.33	0.42	3.34e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.59	10.27	0.55	8.01e-21	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.86	0.53	1.5e-19	Multiple sclerosis;
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg21186296	chr8:27182909	PTK2B	0.51	6.48	0.38	4.88e-10	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19865616	chr2:120981005	TMEM185B	0.49	6.2	0.37	2.31e-9	Parkinson's disease;
KIRP	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-6.14	-0.36	3.35e-9	Bladder cancer;
KIRP	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.83	10.1	0.54	2.65e-20	Corneal astigmatism;
KIRP	cis	rs2411233	0.811	rs3850776	chr15:39262872	T/A	cg19287857	chr15:39890699	NA	0.41	5.74	0.34	2.71e-8	Platelet count;
KIRP	cis	rs17381785	0.903	rs35967979	chr4:14917109	T/C	cg12377275	chr4:15005593	CPEB2	0.54	6.38	0.38	8.6e-10	Urate levels in overweight individuals;
KIRP	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.86	-0.4	5.42e-11	Type 2 diabetes;
KIRP	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg20935368	chr5:178288625	ZNF354B	0.42	5.7	0.34	3.49e-8	Sleep duration;
KIRP	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.77	-8.74	-0.49	3.67e-16	Coronary artery disease;
KIRP	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	0.87	9.87	0.53	1.47e-19	Pediatric areal bone mineral density (radius);
KIRP	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.37	6.88	0.4	5.03e-11	Height;
KIRP	cis	rs17023223	0.537	rs61808892	chr1:119599207	C/T	cg05756136	chr1:119680316	WARS2	-0.54	-7.21	-0.42	6.79e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.65	-9.38	-0.51	4.59e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7267005	1.000	rs76265884	chr20:34556070	A/G	cg17201900	chr20:34330562	RBM39	0.89	5.37	0.32	1.85e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg25486957	chr4:152246857	NA	-0.52	-5.73	-0.34	2.91e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.81	9.71	0.53	4.42e-19	Multiple system atrophy;
KIRP	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.53	6.82	0.4	7.02e-11	Tonsillectomy;
KIRP	cis	rs6466055	0.589	rs7805639	chr7:104987284	C/G	cg04380332	chr7:105027541	SRPK2	0.37	5.04	0.31	9.21e-7	Schizophrenia;
KIRP	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.72	-8.98	-0.5	7.29e-17	Huntington's disease progression;
KIRP	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-9.28	-0.51	9.13e-18	Response to antipsychotic treatment;
KIRP	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs7301016	0.948	rs73141045	chr12:62931083	C/G	cg01804193	chr12:63026212	NA	0.54	5.64	0.34	4.68e-8	IgG glycosylation;
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg23985595	chr17:80112537	CCDC57	0.33	4.96	0.3	1.31e-6	Life satisfaction;
KIRP	cis	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg08773314	chr2:239334832	ASB1	-0.53	-5.36	-0.32	1.95e-7	Morning vs. evening chronotype;Chronotype;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg08109505	chr7:140098078	SLC37A3	0.52	6.38	0.38	8.94e-10	Educational attainment;
KIRP	cis	rs42648	0.564	rs6465244	chr7:89820882	A/C	cg25739043	chr7:89950458	NA	-0.37	-5.73	-0.34	2.95e-8	Homocysteine levels;
KIRP	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg02640540	chr1:67518911	SLC35D1	0.43	5.24	0.32	3.47e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.47	6.63	0.39	2.1e-10	Sitting height ratio;
KIRP	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg13180566	chr4:1052158	NA	-0.53	-5.37	-0.32	1.82e-7	Recombination rate (females);
KIRP	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.37	-5.83	-0.35	1.69e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg04607699	chr11:48328132	OR4S1	-0.35	-4.89	-0.3	1.85e-6	HDL cholesterol;
KIRP	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg12560992	chr17:57184187	TRIM37	0.62	5.65	0.34	4.35e-8	Cognitive test performance;
KIRP	cis	rs6988636	0.710	rs73339623	chr8:124140288	A/G	cg15893493	chr8:124194847	FAM83A	0.89	6.61	0.39	2.34e-10	Urinary uromodulin levels;
KIRP	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg17863274	chr19:49399704	TULP2	-0.41	-5.84	-0.35	1.61e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06544989	chr22:39130855	UNC84B	0.51	8.05	0.46	3.44e-14	Menopause (age at onset);
KIRP	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14633965	chr11:46784427	CKAP5;SNORD67	0.48	6.29	0.37	1.42e-9	Interleukin-4 levels;
KIRP	cis	rs911119	0.955	rs59059917	chr20:23595675	C/T	cg16589663	chr20:23618590	CST3	0.68	6.28	0.37	1.49e-9	Chronic kidney disease;
KIRP	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	0.98	8.66	0.48	6.43e-16	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4956211	0.599	rs7437890	chr4:109711658	G/C	cg07086381	chr4:109682776	AGXT2L1	-0.38	-5.16	-0.31	5.19e-7	Systemic lupus erythematosus;
KIRP	cis	rs7766436	0.610	rs13195654	chr6:22601416	C/G	cg13666174	chr6:22585274	NA	-0.36	-4.85	-0.3	2.19e-6	Coronary artery disease;
KIRP	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.64	9.21	0.51	1.53e-17	Resting heart rate;
KIRP	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.91	-0.45	8.86e-14	Type 2 diabetes;
KIRP	cis	rs7945718	0.621	rs10831888	chr11:12665604	T/C	cg25843174	chr11:12811716	TEAD1	0.3	5.39	0.32	1.65e-7	Educational attainment (years of education);
KIRP	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.74	10.91	0.57	7.47e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.53	6.8	0.4	7.84e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07167872	chr1:205819463	PM20D1	-0.41	-4.88	-0.3	1.87e-6	Menarche (age at onset);
KIRP	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg04310649	chr10:35416472	CREM	-0.6	-7.03	-0.41	2.06e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.27	-0.37	1.63e-9	Breast cancer;
KIRP	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg02336718	chr17:17403227	NA	-0.35	-5.47	-0.33	1.1e-7	Total body bone mineral density;
KIRP	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg12454167	chr3:186435060	KNG1	0.65	12.14	0.61	6.87e-27	Blood protein levels;
KIRP	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg12598211	chr12:123634384	NA	-0.4	-4.93	-0.3	1.55e-6	Neutrophil percentage of white cells;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg00094735	chr5:1949198	NA	0.46	5.52	0.33	8.53e-8	Gut microbiome composition (winter);
KIRP	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.97	0.36	8.32e-9	Platelet count;
KIRP	cis	rs7998202	0.667	rs282568	chr13:113371938	A/G	cg04656015	chr13:113407548	ATP11A	-0.53	-5.81	-0.35	1.95e-8	Glycated hemoglobin levels;
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg07216194	chr8:27182965	PTK2B	0.43	5.31	0.32	2.46e-7	Neuroticism;
KIRP	cis	rs11800820	0.647	rs4654279	chr1:246686111	C/T	cg16700716	chr1:246684329	NA	0.57	5.87	0.35	1.43e-8	Obesity-related traits;
KIRP	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.92	15.65	0.71	8.71e-39	Metabolic syndrome;
KIRP	cis	rs7805747	0.961	rs55779150	chr7:151406449	A/T	cg17611936	chr7:151411526	PRKAG2	0.47	6.02	0.36	6.41e-9	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
KIRP	trans	rs199950	1.000	rs199935	chr1:181594087	T/C	cg04237608	chr1:18659049	IGSF21	0.33	6.05	0.36	5.23e-9	Body mass index (change over time);
KIRP	cis	rs6466055	0.720	rs62484712	chr7:105005741	G/A	cg04380332	chr7:105027541	SRPK2	-0.63	-9.3	-0.51	7.98e-18	Schizophrenia;
KIRP	cis	rs504918	0.588	rs11719349	chr3:123978022	A/G	cg05766129	chr3:123988013	KALRN	-0.49	-6.01	-0.36	6.78e-9	Schizophrenia;
KIRP	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.88	13.32	0.65	7.9e-31	Testicular germ cell tumor;
KIRP	cis	rs6688613	0.685	rs10800276	chr1:166858941	A/G	cg07049167	chr1:166818506	POGK	-0.59	-6.59	-0.39	2.68e-10	Refractive astigmatism;
KIRP	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.48	-5.98	-0.36	7.71e-9	Monocyte count;
KIRP	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg00800038	chr16:89945340	TCF25	-0.75	-5.22	-0.32	3.84e-7	Skin colour saturation;
KIRP	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18252515	chr7:66147081	NA	-0.46	-5.33	-0.32	2.28e-7	Aortic root size;
KIRP	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg18882449	chr10:104885122	NT5C2	-0.47	-5.99	-0.36	7.28e-9	Arsenic metabolism;
KIRP	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg21535942	chr1:75199100	CRYZ;TYW3	0.43	5.18	0.31	4.63e-7	Resistin levels;
KIRP	cis	rs11169552	0.510	rs11613488	chr12:50978255	G/A	cg12884762	chr12:50931848	DIP2B	-0.42	-4.9	-0.3	1.74e-6	Colorectal cancer;
KIRP	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.63	8.96	0.5	8.55e-17	Schizophrenia;
KIRP	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg16867584	chr19:49200180	FUT2	0.33	5.26	0.32	3.2e-7	Dietary macronutrient intake;
KIRP	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	0.85	7.43	0.43	1.74e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg24253500	chr15:84953950	NA	0.68	7.83	0.45	1.49e-13	Schizophrenia;
KIRP	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg16141378	chr3:129829833	LOC729375	0.57	7.22	0.42	6.44e-12	Neuroticism;
KIRP	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg15655495	chr12:38532458	NA	-0.25	-4.84	-0.3	2.26e-6	Heart rate;
KIRP	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg08807101	chr21:30365312	RNF160	0.61	7.67	0.44	3.89e-13	Cognitive test performance;
KIRP	cis	rs2594989	0.616	rs6442254	chr3:11474491	T/C	cg01796438	chr3:11312864	ATG7	-0.56	-7.12	-0.41	1.2e-11	Circulating chemerin levels;
KIRP	cis	rs7180079	0.620	rs10851739	chr15:65056043	G/A	cg15337035	chr15:64978493	NA	-0.5	-5.5	-0.33	9.37e-8	Monocyte count;
KIRP	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-6.99	-0.41	2.59e-11	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg16141378	chr3:129829833	LOC729375	0.57	7.59	0.44	6.54e-13	Triglycerides;
KIRP	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg07382826	chr16:28625726	SULT1A1	0.44	5.25	0.32	3.21e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.45	6.34	0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.76	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7565981	0.655	rs17024796	chr2:101423955	G/A	cg02232089	chr2:101440696	NPAS2	-0.61	-5.43	-0.33	1.33e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs7119167	0.722	rs11820929	chr11:73061130	C/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.14	0.31	5.71e-7	Blood protein levels;
KIRP	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.42	-6.2	-0.37	2.39e-9	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.97	-15.79	-0.71	2.93e-39	Menopause (age at onset);
KIRP	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg11569703	chr11:65557185	OVOL1	0.62	11.03	0.58	2.93e-23	Acne (severe);
KIRP	cis	rs1147199	0.585	rs2579375	chr9:87261958	T/C	cg22402007	chr9:87282823	NTRK2	-0.42	-5.25	-0.32	3.26e-7	Body mass index;
KIRP	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	5.05	0.31	8.63e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg19875535	chr5:140030758	IK	-0.67	-9.48	-0.52	2.33e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06212747	chr3:49208901	KLHDC8B	0.88	13.48	0.65	2.2e-31	Menarche (age at onset);
KIRP	cis	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg27487796	chr7:28973253	NA	-0.22	-4.96	-0.3	1.32e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12823128	0.901	rs1349231	chr12:26880352	A/G	cg14081884	chr12:26986758	ITPR2	0.4	4.97	0.3	1.26e-6	Birth weight;
KIRP	cis	rs7551222	0.752	rs4252685	chr1:204496856	C/A	cg20240347	chr1:204465584	NA	-0.46	-8.73	-0.49	4.06e-16	Schizophrenia;
KIRP	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-7.07	-0.41	1.59e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7566780	0.548	rs11889461	chr2:16700727	A/G	cg09580478	chr2:16689509	NA	0.44	5.07	0.31	7.82e-7	Orofacial clefts;Cleft lip with or without cleft palate;
KIRP	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	1.07	19.09	0.77	1.85e-50	Bone mineral density;
KIRP	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.43	5.27	0.32	3.01e-7	Schizophrenia;
KIRP	cis	rs3789045	0.837	rs57450685	chr1:204580832	A/T	cg17419461	chr1:204415978	PIK3C2B	-0.52	-5.38	-0.32	1.73e-7	Educational attainment (college completion);
KIRP	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg01529538	chr14:23388837	RBM23	0.41	5.22	0.32	3.8e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs4478858	0.647	rs1007013	chr1:31710270	C/T	cg00250761	chr1:31883323	NA	-0.32	-5.63	-0.34	4.87e-8	Alcohol dependence;
KIRP	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.77	8.76	0.49	3.18e-16	Systolic blood pressure;
KIRP	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg11707556	chr5:10655725	ANKRD33B	0.53	6.7	0.39	1.4e-10	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19650197	chr19:30156396	PLEKHF1	0.57	7.13	0.41	1.12e-11	Parkinson's disease;
KIRP	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.94	-0.5	9.22e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.82	-12.42	-0.62	7.94e-28	Prostate cancer;
KIRP	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	1.05	15.46	0.7	3.96e-38	Blood protein levels;
KIRP	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg13770153	chr20:60521292	NA	-0.42	-4.99	-0.3	1.15e-6	Body mass index;
KIRP	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg10495392	chr1:46806563	NSUN4	0.47	5.37	0.32	1.84e-7	Menopause (age at onset);
KIRP	cis	rs12282928	1.000	rs2870510	chr11:48321334	G/A	cg26585981	chr11:48327164	OR4S1	0.51	6.22	0.37	2.09e-9	Migraine - clinic-based;
KIRP	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.55	-9.69	-0.53	4.99e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04968132	chr16:27560915	GTF3C1;KIAA0556	0.49	6.48	0.38	5.1e-10	Parkinson's disease;
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.42	-5.14	-0.31	5.51e-7	Obesity-related traits;
KIRP	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg00931491	chr16:28608288	SULT1A2	-0.28	-5.4	-0.33	1.58e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9463078	0.547	rs34907292	chr6:44729708	A/G	cg25276700	chr6:44698697	NA	0.35	5.02	0.3	9.95e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.55	7.12	0.41	1.16e-11	Lung cancer;
KIRP	cis	rs2839627	0.561	rs9977774	chr21:44342476	G/C	cg03543861	chr21:44258195	NA	0.55	6.07	0.36	4.75e-9	Information processing speed;
KIRP	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.2e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.62	9.52	0.52	1.66e-18	Lung cancer;
KIRP	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-6.09	-0.36	4.32e-9	Neuroticism;
KIRP	cis	rs4594175	0.847	rs17252303	chr14:51632246	C/T	cg23942311	chr14:51606299	NA	0.52	6.84	0.4	6.26e-11	Cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg25808839	chr15:63414067	LACTB	0.55	6.76	0.4	9.7e-11	Educational attainment;
KIRP	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.62	7.26	0.42	5.15e-12	Osteoporosis;
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.98	10.28	0.55	7.21e-21	Alzheimer's disease;
KIRP	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.78	-7.87	-0.45	1.16e-13	Bipolar disorder;
KIRP	cis	rs4356932	1.000	rs6532105	chr4:76953895	C/A	cg00809888	chr4:76862425	NAAA	0.44	6.19	0.37	2.53e-9	Blood protein levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00185336	chr7:73153699	ABHD11	0.59	7.06	0.41	1.72e-11	Smoking initiation;
KIRP	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg21419209	chr3:44054225	NA	-0.71	-8.71	-0.49	4.51e-16	Coronary artery disease;
KIRP	cis	rs2635047	0.662	rs8091902	chr18:44748545	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.11	0.31	6.42e-7	Educational attainment;
KIRP	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg02462569	chr6:150064036	NUP43	-0.38	-5.69	-0.34	3.67e-8	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25198584	chr1:4775233	AJAP1	-0.43	-6.49	-0.38	4.79e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs7215564	0.908	rs34199628	chr17:78661675	A/G	cg06153925	chr17:78755379	RPTOR	0.3	4.93	0.3	1.51e-6	Myopia (pathological);
KIRP	cis	rs7113874	1.000	rs10769939	chr11:8683639	C/T	cg08015107	chr11:8618950	NA	-0.35	-5.0	-0.3	1.07e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg21573476	chr21:45109991	RRP1B	-0.62	-8.52	-0.48	1.59e-15	Mean corpuscular volume;
KIRP	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg25319279	chr11:5960081	NA	-0.59	-5.9	-0.35	1.17e-8	DNA methylation (variation);
KIRP	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg16111737	chr12:117408163	FBXW8	-0.57	-5.39	-0.32	1.66e-7	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.43	-5.16	-0.31	4.99e-7	IgG glycosylation;
KIRP	cis	rs7127900	0.851	rs10743176	chr11:2225626	T/C	cg25635251	chr11:2234043	NA	0.54	8.0	0.45	4.81e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs7551222	0.784	rs2045624	chr1:204584385	C/G	cg20240347	chr1:204465584	NA	0.28	5.04	0.31	9.12e-7	Schizophrenia;
KIRP	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.43	-6.08	-0.36	4.66e-9	Monocyte count;
KIRP	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.73	10.82	0.57	1.4e-22	Prostate cancer;
KIRP	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs4919044	0.808	rs1750741	chr10:94804530	G/T	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.98	8.05	0.46	3.45e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23803172	chr1:763119	NCRNA00115;LOC643837	0.42	6.07	0.36	4.8e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.35	0.7	9.06e-38	Chronic sinus infection;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05121388	chr17:60501122	METTL2A	-0.49	-6.83	-0.4	6.6e-11	Myopia;
KIRP	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs16828019	0.777	rs12748235	chr1:41466221	G/A	cg03387723	chr1:41708464	SCMH1	-0.75	-6.0	-0.36	6.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7221595	0.825	rs71366590	chr17:4006685	T/A	cg05562828	chr17:3906858	NA	0.53	5.6	0.34	5.59e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg07001201	chr5:642380	CEP72	0.7	6.58	0.39	2.73e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg23587288	chr2:27483067	SLC30A3	-0.58	-7.14	-0.41	1.05e-11	Blood metabolite levels;
KIRP	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.74	-0.44	2.56e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21486195	chr12:38714149	ALG10B	0.44	7.09	0.41	1.4e-11	Survival in pancreatic cancer;
KIRP	cis	rs7712401	0.562	rs30052	chr5:122305009	A/T	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	7.06	0.41	1.66e-11	Eye color traits;
KIRP	cis	rs7172677	0.737	rs7163083	chr15:75442337	A/C	cg14664628	chr15:75095509	CSK	-0.45	-5.09	-0.31	7.16e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7692976	0.578	rs12506489	chr4:110843148	T/G	cg06981781	chr4:110842888	EGF	-0.26	-5.62	-0.34	5.25e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	1.11	17.82	0.75	3.41e-46	Homoarginine levels;
KIRP	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.82	10.16	0.54	1.72e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs7219021	0.674	rs4793990	chr17:46960760	G/A	cg16584676	chr17:46985605	UBE2Z	0.46	5.29	0.32	2.69e-7	Schizophrenia or bipolar disorder;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg01737828	chr15:75230659	COX5A	0.53	6.06	0.36	5.07e-9	Sleep duration;
KIRP	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.43	-8.52	-0.48	1.62e-15	Urinary metabolites;
KIRP	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg21294424	chr19:58662284	ZNF329	0.63	5.85	0.35	1.59e-8	Cholesterol, total;
KIRP	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg12369402	chr1:90227771	NA	-0.37	-5.36	-0.32	1.87e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.65	7.26	0.42	5.02e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg07843065	chr1:150265600	MRPS21	0.45	6.26	0.37	1.74e-9	Migraine;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.51	0.43	1.07e-12	Lymphocyte counts;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23843414	chr1:8484310	RERE	0.44	6.37	0.38	9.36e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.41	5.05	0.31	8.44e-7	Height;
KIRP	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.48	6.95	0.4	3.34e-11	Urate levels in lean individuals;
KIRP	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg05484376	chr2:27715224	FNDC4	0.39	6.44	0.38	6.39e-10	Total body bone mineral density;
KIRP	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.39	-0.32	1.68e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.47	5.52	0.33	8.39e-8	Lymphocyte percentage of white cells;
KIRP	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.65	-9.25	-0.51	1.16e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg01631408	chr1:248437212	OR2T33	-0.44	-5.62	-0.34	5.09e-8	Common traits (Other);
KIRP	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.96	11.91	0.6	4.12e-26	Vitiligo;
KIRP	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg08499158	chr17:42289980	UBTF	-0.49	-6.31	-0.37	1.28e-9	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs3109167	0.702	rs12707588	chr7:83118251	G/A	cg14519356	chr7:83097669	SEMA3E	0.46	6.28	0.37	1.52e-9	Blood protein levels;
KIRP	cis	rs13102973	0.932	rs13112935	chr4:135829379	T/C	cg14419869	chr4:135874104	NA	0.53	8.85	0.49	1.8e-16	Subjective well-being;
KIRP	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.63	7.36	0.42	2.79e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7587476	0.505	rs777323	chr2:215738485	A/G	cg04004882	chr2:215674386	BARD1	-0.63	-6.14	-0.36	3.21e-9	Neuroblastoma;
KIRP	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.48	5.95	0.35	9.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg12560992	chr17:57184187	TRIM37	0.49	5.39	0.32	1.67e-7	Cognitive test performance;
KIRP	cis	rs785830	0.595	rs573851	chr9:266505	A/C	cg14500300	chr9:211689	NA	0.53	7.16	0.42	9.09e-12	Platelet distribution width;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7851660	0.844	rs10119760	chr9:100624602	G/C	cg13688889	chr9:100608707	NA	-0.7	-9.26	-0.51	1.08e-17	Strep throat;
KIRP	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg13198984	chr17:80129470	CCDC57	0.59	8.96	0.5	8.46e-17	Life satisfaction;
KIRP	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17376030	chr22:41985996	PMM1	0.67	7.19	0.42	7.59e-12	Vitiligo;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg12738264	chr7:148725795	PDIA4	0.54	6.44	0.38	6.37e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7646881	0.767	rs58152433	chr3:158456640	A/G	cg19483011	chr3:158453295	NA	-0.54	-5.94	-0.35	9.93e-9	Tetralogy of Fallot;
KIRP	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg00103785	chr1:155043322	NA	-0.31	-5.46	-0.33	1.18e-7	Serum magnesium levels;
KIRP	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.68	10.93	0.57	6.21e-23	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs889512	0.642	rs28439846	chr16:75280378	G/A	cg03315344	chr16:75512273	CHST6	-0.63	-5.07	-0.31	7.98e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg05861140	chr6:150128134	PCMT1	-0.51	-7.2	-0.42	7.21e-12	Lung cancer;
KIRP	trans	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg24644049	chr4:85504048	CDS1	1.02	6.8	0.4	7.99e-11	Skin colour saturation;
KIRP	cis	rs35740288	0.822	rs56322219	chr15:86276340	A/T	cg17133734	chr15:86042851	AKAP13	-0.49	-5.31	-0.32	2.47e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9912468	0.933	rs35687884	chr17:64321828	C/T	cg19474267	chr17:64306194	PRKCA	0.58	8.28	0.47	7.9e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs8114671	0.933	rs6142327	chr20:33793147	T/A	cg24642439	chr20:33292090	TP53INP2	-0.45	-5.34	-0.32	2.09e-7	Height;
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg02462569	chr6:150064036	NUP43	-0.42	-6.32	-0.37	1.21e-9	Lung cancer;
KIRP	trans	rs9409565	0.826	rs9409546	chr9:97209066	T/C	cg05679027	chr9:99775184	HIATL2	-0.56	-6.71	-0.39	1.33e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10177056	chr2:33740191	RASGRP3	0.52	7.25	0.42	5.29e-12	Survival in pancreatic cancer;
KIRP	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.64	12.24	0.62	3.14e-27	Bone mineral density;
KIRP	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg11608241	chr8:8085544	FLJ10661	0.41	5.17	0.31	4.89e-7	Mood instability;
KIRP	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.42	-6.27	-0.37	1.61e-9	Personality dimensions;
KIRP	cis	rs8053891	0.813	rs16973520	chr16:71996291	T/G	cg04254540	chr16:71951199	KIAA0174	-0.43	-4.98	-0.3	1.18e-6	Coronary artery disease;
KIRP	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.41	4.98	0.3	1.22e-6	Diabetic retinopathy;
KIRP	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.41	-5.77	-0.35	2.42e-8	Electroencephalogram traits;
KIRP	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg23594656	chr7:65796392	TPST1	0.39	5.96	0.36	8.69e-9	Aortic root size;
KIRP	cis	rs2273669	0.915	rs3734650	chr6:109295017	A/G	cg05315195	chr6:109294784	ARMC2	-0.51	-5.7	-0.34	3.34e-8	Prostate cancer;
KIRP	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.67	0.39	1.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.54	-8.36	-0.47	4.7e-15	Huntington's disease progression;
KIRP	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.58	7.69	0.44	3.56e-13	Vitiligo;
KIRP	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.62	9.57	0.52	1.19e-18	Lung cancer;
KIRP	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg27490568	chr2:178487706	NA	0.65	8.83	0.49	2.04e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1568657	0.779	rs2167602	chr15:83649292	C/T	cg01114405	chr6:504249	EXOC2	-0.48	-6.22	-0.37	2.1e-9	Kawasaki disease;
KIRP	cis	rs13315871	1.000	rs11719957	chr3:58415031	A/G	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg11752832	chr7:134001865	SLC35B4	0.47	6.09	0.36	4.33e-9	Mean platelet volume;
KIRP	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg00360474	chr6:37504404	NA	-0.46	-6.27	-0.37	1.65e-9	Cognitive performance;
KIRP	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.11	-0.31	6.61e-7	Pulmonary function;
KIRP	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.68	-7.8	-0.45	1.72e-13	Pancreatic cancer;
KIRP	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg01420254	chr6:26195488	NA	1.15	10.02	0.54	4.92e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.28	-22.66	-0.82	3.82e-62	Breast cancer;
KIRP	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg16672083	chr15:72433130	SENP8	0.45	6.3	0.37	1.37e-9	Red blood cell count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24742512	chr11:12131878	MICAL2	0.5	6.24	0.37	1.88e-9	Parkinson's disease;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.73	-6.65	-0.39	1.86e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.48	-7.13	-0.41	1.14e-11	Lung cancer;
KIRP	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg18882449	chr10:104885122	NT5C2	-0.43	-5.52	-0.33	8.74e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7646881	0.812	rs73015644	chr3:158447744	C/T	cg19483011	chr3:158453295	NA	-0.54	-5.49	-0.33	9.98e-8	Tetralogy of Fallot;
KIRP	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg00241281	chr14:105779794	PACS2	-0.36	-4.97	-0.3	1.24e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg05669848	chr5:237993	SDHA	-0.51	-5.36	-0.32	1.87e-7	Breast cancer;
KIRP	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.87	10.52	0.56	1.28e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg08499158	chr17:42289980	UBTF	-0.69	-9.16	-0.5	2.15e-17	Total body bone mineral density;
KIRP	trans	rs4938303	0.633	rs1960036	chr11:116547409	C/A	cg13754915	chr9:140174272	C9orf167	-0.73	-6.17	-0.37	2.79e-9	Triglycerides;
KIRP	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12016809	chr21:47604291	C21orf56	0.37	4.85	0.3	2.24e-6	Testicular germ cell tumor;
KIRP	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-12.39	-0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg00405596	chr8:11794950	NA	0.48	6.35	0.38	1.02e-9	Mood instability;
KIRP	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.8	-8.15	-0.46	1.9e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg01378222	chr16:28622494	SULT1A1	-0.67	-6.34	-0.37	1.09e-9	Platelet distribution width;
KIRP	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.33	4.97	0.3	1.23e-6	Fibrinogen levels;
KIRP	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.8	-10.56	-0.56	9.5e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.42	7.18	0.42	8.14e-12	Tumor biomarkers;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12199343	chr11:809905	RPLP2	-0.51	-6.18	-0.37	2.6e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.59	-0.39	2.6e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03952484	chr1:149899818	SF3B4	0.73	6.89	0.4	4.77e-11	Lung function (FEV1);
KIRP	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg06012730	chr15:75315579	PPCDC	-0.42	-5.17	-0.31	4.8e-7	Blood trace element (Zn levels);
KIRP	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg09264619	chr17:80180166	NA	0.37	5.25	0.32	3.36e-7	Life satisfaction;
KIRP	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.51	-6.36	-0.38	9.7e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.95	-14.64	-0.68	2.41e-35	Height;
KIRP	cis	rs731174	0.959	rs7527344	chr1:38191560	C/A	cg06917450	chr1:38156652	C1orf109	-0.41	-4.94	-0.3	1.44e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	11.03	0.58	2.99e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg10503236	chr1:231470652	EXOC8	0.47	6.67	0.39	1.63e-10	Hemoglobin concentration;
KIRP	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-6.49	-0.38	4.78e-10	Triglycerides;
KIRP	trans	rs7246760	1.000	rs59771283	chr19:9854958	G/A	cg02900749	chr2:68251473	NA	-1.2	-10.05	-0.54	3.86e-20	Pursuit maintenance gain;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07731455	chr3:14220336	LSM3;XPC	-0.49	-6.15	-0.37	3.07e-9	Interleukin-4 levels;
KIRP	trans	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg12575136	chr18:32820987	ZNF397	0.74	11.12	0.58	1.55e-23	White blood cell count;
KIRP	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.67	0.44	3.98e-13	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6732160	0.588	rs13403748	chr2:73371475	T/C	cg01422370	chr2:73384389	NA	0.52	6.95	0.4	3.35e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4073416	0.542	rs3825639	chr14:66028505	T/C	cg03016385	chr14:66212404	NA	-0.53	-6.36	-0.38	9.84e-10	N-glycan levels;
KIRP	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.94	12.25	0.62	2.87e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.42	-0.33	1.42e-7	Colorectal cancer;
KIRP	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.48	-0.33	1.07e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.44	-5.55	-0.33	7.31e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg11569703	chr11:65557185	OVOL1	0.6	10.48	0.56	1.7e-21	Acne (severe);
KIRP	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg12483005	chr1:23474871	LUZP1	0.39	4.98	0.3	1.22e-6	Height;
KIRP	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs17123764	0.892	rs12314795	chr12:50147864	G/A	cg20471783	chr12:50157085	TMBIM6	0.32	5.01	0.3	1.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11910985	0.546	rs9978916	chr21:48080492	A/C	cg17243659	chr21:48055224	PRMT2	0.94	6.78	0.4	8.98e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs10940138	0.501	rs6872249	chr5:67239774	T/C	ch.5.1281357F	chr5:67228439	NA	-0.53	-8.12	-0.46	2.25e-14	Menarche (age at onset);
KIRP	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.62	8.14	0.46	2.04e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.75e-15	Aortic root size;
KIRP	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg20991723	chr1:152506922	NA	0.43	5.08	0.31	7.31e-7	Hair morphology;
KIRP	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.87	13.57	0.65	1.11e-31	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.08	0.41	1.5e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	14.73	0.68	1.2e-35	Platelet count;
KIRP	cis	rs6714710	0.603	rs34149969	chr2:98342323	C/A	cg26665480	chr2:98280029	ACTR1B	0.66	8.38	0.47	4.09e-15	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.85e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.54	0.48	1.43e-15	Motion sickness;
KIRP	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-8.69	-0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-10.46	-0.55	2.02e-21	Schizophrenia;
KIRP	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.84	-7.34	-0.42	3.14e-12	Body mass index;
KIRP	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.75	-0.49	3.39e-16	Mean corpuscular volume;
KIRP	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.59	-12.15	-0.61	6.18e-27	Diabetic kidney disease;
KIRP	cis	rs228437	0.565	rs7765188	chr6:134961316	T/C	cg24504307	chr6:134963096	NA	0.3	5.16	0.31	5.14e-7	Melanoma;
KIRP	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg13798780	chr7:105162888	PUS7	0.66	6.11	0.36	3.83e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.54	-7.07	-0.41	1.57e-11	Longevity;
KIRP	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg13902645	chr11:5959945	NA	-0.66	-7.41	-0.43	1.99e-12	DNA methylation (variation);
KIRP	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg10840412	chr1:235813424	GNG4	0.68	6.11	0.36	3.91e-9	Bipolar disorder;
KIRP	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	7.14e-8	Breast cancer;
KIRP	trans	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg06521331	chr12:34319734	NA	-0.51	-6.34	-0.37	1.12e-9	Bladder cancer;
KIRP	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.75	9.62	0.52	8.21e-19	Coronary artery disease;
KIRP	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.67	8.65	0.48	6.57e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg21775007	chr8:11205619	TDH	-0.43	-5.64	-0.34	4.59e-8	Monocyte count;
KIRP	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg11288833	chr15:55489084	RSL24D1	0.67	7.89	0.45	9.68e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.74	0.44	2.51e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.44	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08280861	chr8:58055591	NA	0.72	5.92	0.35	1.1e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.02	0.61	1.78e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12210905	1.000	rs6931711	chr6:27145586	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.73	-0.39	1.16e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	1.1	14.96	0.69	2.02e-36	Pulmonary function decline;
KIRP	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.59	8.37	0.47	4.24e-15	Vitiligo;
KIRP	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.0	-16.44	-0.72	1.76e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs10904908	1.000	rs7920112	chr10:17259863	T/C	cg01003015	chr10:17271136	VIM	-0.43	-5.22	-0.32	3.75e-7	Total cholesterol levels;Cholesterol, total;
KIRP	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg26207909	chr14:103986467	CKB	-0.51	-6.39	-0.38	8.45e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.62	-7.75	-0.44	2.48e-13	Longevity;Endometriosis;
KIRP	cis	rs7084402	0.935	rs1896246	chr10:60276068	A/G	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg22089800	chr15:90895588	ZNF774	0.59	8.05	0.46	3.52e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs3105593	1.000	rs3109878	chr15:50836243	T/G	cg08437265	chr15:50716283	USP8	0.37	5.05	0.31	8.41e-7	QT interval;
KIRP	cis	rs7246657	0.722	rs12974225	chr19:38240098	G/T	cg23950597	chr19:37808831	NA	0.53	5.64	0.34	4.6e-8	Coronary artery calcification;
KIRP	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.4	-0.33	1.58e-7	Schizophrenia;
KIRP	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.98	-0.5	7.26e-17	Retinal vascular caliber;
KIRP	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg13047869	chr3:10149882	C3orf24	0.54	5.21	0.32	3.91e-7	Alzheimer's disease;
KIRP	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg17736920	chr1:242011382	EXO1	0.48	5.89	0.35	1.25e-8	Menopause (age at onset);
KIRP	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.84	-12.72	-0.63	7.8e-29	Headache;
KIRP	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.54	-6.91	-0.4	4.24e-11	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg26384229	chr12:38710491	ALG10B	0.66	8.81	0.49	2.28e-16	Morning vs. evening chronotype;
KIRP	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-7.13	-0.41	1.14e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.94	-11.13	-0.58	1.39e-23	White matter hyperintensity burden;
KIRP	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.73	-9.24	-0.51	1.19e-17	Aortic root size;
KIRP	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg11861562	chr11:117069780	TAGLN	-0.38	-4.85	-0.3	2.18e-6	Blood protein levels;
KIRP	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07234876	chr8:600039	NA	0.73	6.45	0.38	5.88e-10	IgG glycosylation;
KIRP	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07308232	chr7:1071921	C7orf50	-0.73	-9.45	-0.52	2.87e-18	Longevity;Endometriosis;
KIRP	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg02792322	chr13:21280448	IL17D	-0.32	-5.02	-0.31	9.77e-7	Dental caries;
KIRP	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg18366169	chr5:1948875	NA	-0.46	-4.9	-0.3	1.78e-6	Gut microbiome composition (winter);
KIRP	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.51	-5.95	-0.35	9.18e-9	Body mass index;
KIRP	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg10047753	chr17:41438598	NA	1.14	17.1	0.74	1.01e-43	Menopause (age at onset);
KIRP	cis	rs7116495	1.000	rs4121395	chr11:71669242	C/T	cg26138937	chr11:71823887	C11orf51	-0.72	-5.85	-0.35	1.53e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg22563815	chr15:78856949	CHRNA5	-0.47	-7.39	-0.43	2.3e-12	Sudden cardiac arrest;
KIRP	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.56	15.11	0.69	6.22e-37	Airflow obstruction;
KIRP	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg05896524	chr21:47604654	C21orf56	0.39	4.93	0.3	1.52e-6	Testicular germ cell tumor;
KIRP	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	10.0	0.54	5.68e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-5.53	-0.33	8.05e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs8102137	0.550	rs34331990	chr19:30321561	A/C	cg10633981	chr11:16779768	C11orf58	-0.39	-6.02	-0.36	6.2e-9	Bladder cancer;
KIRP	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4972806	0.849	rs1542180	chr2:177028767	C/T	cg09355771	chr2:177043147	NA	0.47	6.23	0.37	2.05e-9	IgG glycosylation;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04432377	chr3:45017297	EXOSC7;ZDHHC3	-0.51	-6.56	-0.39	3.2e-10	Interleukin-4 levels;
KIRP	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg09873164	chr1:152488093	CRCT1	0.5	6.37	0.38	9.19e-10	Hair morphology;
KIRP	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	17.41	0.74	8.53e-45	Platelet count;
KIRP	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.87	-14.35	-0.67	2.46e-34	Nonalcoholic fatty liver disease;
KIRP	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.07	-0.64	5.21e-30	Chronic sinus infection;
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg21285383	chr16:89894308	SPIRE2	0.34	6.51	0.38	4.12e-10	Vitiligo;
KIRP	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.45	6.84	0.4	6.2e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.78	9.99	0.54	5.96e-20	Height;
KIRP	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	5.27	0.32	2.91e-7	Response to antipsychotic treatment;
KIRP	cis	rs9879311	0.966	rs4684684	chr3:10411344	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.39	5.26	0.32	3.12e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2629046	0.817	rs1823826	chr2:225077914	C/G	cg06102602	chr12:96895446	NA	-0.44	-6.09	-0.36	4.41e-9	Height;
KIRP	cis	rs7258465	0.896	rs8103660	chr19:18566395	T/C	cg06953865	chr19:18549723	ISYNA1	-0.36	-5.34	-0.32	2.17e-7	Breast cancer;
KIRP	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg14593290	chr7:50529359	DDC	-0.68	-8.27	-0.47	8.73e-15	Malaria;
KIRP	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.82	11.78	0.6	1.08e-25	Bladder cancer;
KIRP	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.64	8.9	0.49	1.21e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.51	-6.64	-0.39	2.05e-10	Type 1 diabetes;
KIRP	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.55	7.59	0.44	6.62e-13	Blood metabolite levels;
KIRP	cis	rs17030434	0.871	rs78151744	chr4:154730266	C/T	cg14289246	chr4:154710475	SFRP2	-0.7	-8.5	-0.48	1.82e-15	Electrocardiographic conduction measures;
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.72	5.73	0.34	2.87e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.51	6.73	0.39	1.15e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg23099349	chr6:26032281	HIST1H3B	0.55	6.33	0.37	1.15e-9	Lung cancer in ever smokers;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20355731	chr12:37942439	NA	0.44	6.14	0.36	3.33e-9	Survival in pancreatic cancer;
KIRP	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.77	9.18	0.51	1.83e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.04	-0.46	3.68e-14	Coronary artery disease;
KIRP	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-6.15	-0.36	3.17e-9	Self-reported allergy;
KIRP	cis	rs11264213	0.901	rs72661636	chr1:36426483	T/C	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.47	7.41	0.43	2.04e-12	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.75	-9.28	-0.51	8.95e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs6681460	0.576	rs7354983	chr1:66988149	T/C	cg13052034	chr1:66999238	SGIP1	0.41	5.39	0.32	1.67e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.59	7.68	0.44	3.69e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs16828019	0.852	rs2268678	chr1:41511053	G/A	cg03387723	chr1:41708464	SCMH1	-0.78	-6.48	-0.38	5.07e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.91	10.04	0.54	4.23e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg18032046	chr6:28092343	ZSCAN16	0.53	5.55	0.33	7.56e-8	Depression;
KIRP	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	4.92	0.3	1.57e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.86	-12.27	-0.62	2.63e-27	Cocaine dependence;
KIRP	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.65	8.82	0.49	2.09e-16	Systemic lupus erythematosus;
KIRP	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg20966754	chr17:47091339	IGF2BP1	-0.31	-5.91	-0.35	1.13e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.72	10.71	0.56	3.26e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg00343986	chr7:65444356	GUSB	-0.4	-4.95	-0.3	1.37e-6	Aortic root size;
KIRP	cis	rs17253792	0.822	rs58589065	chr14:56152478	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.75	5.86	0.35	1.5e-8	Putamen volume;
KIRP	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.7	8.76	0.49	3.14e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Bipolar disorder;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg08692423	chr21:45148864	PDXK	0.45	6.6	0.39	2.54e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1440410	0.798	rs34664017	chr4:144094344	G/T	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	8.99e-10	Ischemic stroke;
KIRP	cis	rs2533291	0.541	rs1242785	chr7:157498327	A/T	cg20030024	chr7:157442494	PTPRN2	-0.55	-5.26	-0.32	3.2e-7	Inflammatory skin disease;
KIRP	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.57	-0.39	2.9e-10	Obesity-related traits;
KIRP	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	9.43	0.52	3.11e-18	Cognitive test performance;
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg01798813	chr17:3906674	NA	0.52	7.25	0.42	5.22e-12	Type 2 diabetes;
KIRP	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.46	5.46	0.33	1.19e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	1.01	10.73	0.56	2.71e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.03	-0.31	9.66e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	11.08	0.58	2.12e-23	Bipolar disorder;
KIRP	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.46	5.08	0.31	7.52e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg05370193	chr1:21551575	ECE1	-0.36	-5.02	-0.3	9.98e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.53	-5.82	-0.35	1.81e-8	Corneal structure;
KIRP	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.83	6.55	0.39	3.3e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7188697	0.922	rs37051	chr16:58558102	C/T	cg21335942	chr16:58549945	SETD6	0.46	5.13	0.31	5.89e-7	QT interval;
KIRP	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.86	-12.55	-0.62	3.08e-28	Educational attainment;
KIRP	cis	rs1903068	0.853	rs73236111	chr4:56019068	A/C	cg20092376	chr4:56023423	NA	0.42	4.94	0.3	1.42e-6	Endometriosis;
KIRP	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.4	-5.45	-0.33	1.23e-7	Height;
KIRP	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg15128208	chr22:42549153	NA	0.66	7.42	0.43	1.91e-12	Birth weight;
KIRP	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.83	-0.63	3.35e-29	Exhaled nitric oxide output;
KIRP	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.69	10.03	0.54	4.59e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.510	rs61815707	chr1:152909018	T/C	cg07796016	chr1:152779584	LCE1C	-0.44	-5.49	-0.33	9.93e-8	Inflammatory skin disease;
KIRP	cis	rs9473924	0.560	rs1928188	chr6:50895842	G/C	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs9462846	0.959	rs7750915	chr6:42882067	C/T	cg02353165	chr6:42928485	GNMT	0.48	5.25	0.32	3.3e-7	Blood protein levels;
KIRP	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.42	-6.02	-0.36	6.31e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.61	-0.34	5.57e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.52	6.72	0.39	1.27e-10	Testicular germ cell tumor;
KIRP	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-7.15	-0.41	9.92e-12	Monocyte count;
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg01763666	chr17:80159506	CCDC57	0.38	5.32	0.32	2.35e-7	Life satisfaction;
KIRP	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg19500275	chr17:80737654	TBCD	0.46	5.36	0.32	1.9e-7	Glycated hemoglobin levels;
KIRP	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg02903104	chr8:1507517	DLGAP2	0.38	5.83	0.35	1.75e-8	Lung cancer;
KIRP	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.5	-6.5	-0.38	4.47e-10	Blood metabolite levels;
KIRP	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.05	11.84	0.6	6.77e-26	Vitiligo;
KIRP	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	6.71	0.39	1.29e-10	Height;
KIRP	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg19500275	chr17:80737654	TBCD	0.49	5.86	0.35	1.45e-8	Glycated hemoglobin levels;
KIRP	trans	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg11693508	chr17:37793320	STARD3	0.55	7.07	0.41	1.58e-11	Neuroticism;
KIRP	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg08461772	chr7:95026248	PON3	0.42	6.06	0.36	5.18e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.47	-6.4	-0.38	7.88e-10	Red blood cell count;
KIRP	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg05315796	chr3:52349193	DNAH1	0.37	5.49	0.33	1.02e-7	Bipolar disorder;
KIRP	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.77	-0.35	2.41e-8	Recombination measurement;
KIRP	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.94	0.54	8.89e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	10.1	0.54	2.68e-20	Blood protein levels;
KIRP	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.63	5.31	0.32	2.41e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs258892	0.895	rs10052974	chr5:72067869	A/G	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07570687	chr10:102243282	WNT8B	0.47	5.74	0.34	2.81e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1116547	0.714	rs60810500	chr5:112767197	G/A	cg12552261	chr5:112820674	MCC	-0.47	-5.08	-0.31	7.52e-7	Cerebral amyloid angiopathy;
KIRP	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg04731861	chr2:219085781	ARPC2	0.26	6.58	0.39	2.78e-10	Pyoderma gangrenosum in inflammatory bowel disease;
KIRP	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	7.88	0.45	1.08e-13	Mood instability;
KIRP	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg01620082	chr3:125678407	NA	0.87	6.25	0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1981331	0.609	rs73907584	chr21:48079678	A/G	cg23283320	chr21:48055893	PRMT2	1.03	7.43	0.43	1.84e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs9323205	0.765	rs12232228	chr14:51658072	A/G	cg23942311	chr14:51606299	NA	0.61	8.46	0.47	2.35e-15	Cancer;
KIRP	cis	rs7712401	0.580	rs4288111	chr5:122388182	A/G	cg19412675	chr5:122181750	SNX24	-0.48	-5.62	-0.34	5.16e-8	Mean platelet volume;
KIRP	cis	rs1559088	0.847	rs10416265	chr19:33605300	A/G	cg24009623	chr19:33667908	NA	0.44	5.57	0.33	6.8e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg27490568	chr2:178487706	NA	0.51	6.84	0.4	6.09e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.21	-0.32	3.9e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.59	-0.34	6.07e-8	Breast cancer;
KIRP	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg11663144	chr21:46675770	NA	-0.55	-7.68	-0.44	3.76e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.33	-0.32	2.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.58	-9.04	-0.5	4.71e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg01631408	chr1:248437212	OR2T33	-0.45	-5.93	-0.35	1.01e-8	Common traits (Other);
KIRP	cis	rs72781680	0.612	rs33913065	chr2:24344060	T/G	cg08917208	chr2:24149416	ATAD2B	0.56	5.02	0.3	9.95e-7	Lymphocyte counts;
KIRP	cis	rs7808935	0.628	rs62451116	chr7:27938980	A/G	cg22168087	chr7:27702803	HIBADH	0.73	7.31	0.42	3.72e-12	Prostate cancer;
KIRP	cis	rs9535307	0.584	rs73194445	chr13:50406547	T/C	cg04663916	chr13:50265991	EBPL	-0.56	-5.4	-0.33	1.56e-7	Obesity-related traits;
KIRP	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.97	-13.65	-0.66	5.96e-32	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.44	5.41	0.33	1.47e-7	Lung cancer;
KIRP	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.62	8.71	0.49	4.53e-16	Multiple system atrophy;
KIRP	cis	rs6681460	0.932	rs4655640	chr1:67089220	T/C	cg13052034	chr1:66999238	SGIP1	0.4	5.42	0.33	1.44e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.52	-6.23	-0.37	2.03e-9	Monocyte count;
KIRP	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.56	5.08	0.31	7.42e-7	Major depressive disorder;
KIRP	cis	rs2404602	0.587	rs17380507	chr15:77235361	C/T	cg23625390	chr15:77176239	SCAPER	0.47	6.07	0.36	4.87e-9	Blood metabolite levels;
KIRP	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs9653442	0.527	rs4850923	chr2:100782256	A/C	cg17356467	chr2:100759845	AFF3	0.39	5.11	0.31	6.5e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9467160	0.581	rs2244216	chr6:24466721	C/T	cg20631270	chr6:24437470	GPLD1	0.43	5.07	0.31	7.68e-7	Liver enzyme levels;
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.72	10.88	0.57	9.24e-23	Menarche (age at onset);
KIRP	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.71	-9.07	-0.5	4e-17	Blood metabolite levels;
KIRP	cis	rs62413470	1.000	rs12196670	chr6:55941044	T/G	cg13327911	chr6:55965977	COL21A1	0.56	4.93	0.3	1.48e-6	Joint mobility (Beighton score);
KIRP	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg24253500	chr15:84953950	NA	0.66	7.65	0.44	4.67e-13	Schizophrenia;
KIRP	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.41	6.97	0.41	2.83e-11	Heart rate;
KIRP	cis	rs4006360	0.520	rs4986664	chr17:39250248	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.91	-0.53	1.1e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.62	5.58	0.34	6.41e-8	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-7.56	-0.43	7.96e-13	Neuroticism;
KIRP	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg12705353	chr12:122356852	WDR66	-0.41	-5.51	-0.33	9.13e-8	Mean corpuscular volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg03876184	chr2:27886755	SUPT7L;SLC4A1AP	0.96	6.18	0.37	2.66e-9	P wave terminal force;
KIRP	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	trans	rs877282	0.583	rs10904562	chr10:819058	T/C	cg22713356	chr15:30763199	NA	0.88	8.71	0.49	4.57e-16	Uric acid levels;
KIRP	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06544989	chr22:39130855	UNC84B	-0.5	-8.7	-0.48	4.99e-16	Menopause (age at onset);
KIRP	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg00405596	chr8:11794950	NA	0.48	6.36	0.38	9.9e-10	Mood instability;
KIRP	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg00579200	chr11:133705235	NA	-0.39	-4.85	-0.3	2.22e-6	Childhood ear infection;
KIRP	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg21294424	chr19:58662284	ZNF329	0.62	5.6	0.34	5.83e-8	Cholesterol, total;
KIRP	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	10.55	0.56	1.04e-21	Personality dimensions;
KIRP	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs6807915	0.541	rs310757	chr3:12281063	C/T	cg02700894	chr3:12045449	SYN2	0.4	5.62	0.34	5.1e-8	Leprosy;
KIRP	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-5.22	-0.32	3.76e-7	Parkinson's disease;
KIRP	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg27029450	chr22:50098074	NA	0.56	5.84	0.35	1.64e-8	Natriuretic peptide levels;
KIRP	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg05220968	chr6:146057943	EPM2A	-0.39	-5.01	-0.3	1.04e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg01238044	chr22:24384105	GSTT1	-0.4	-4.92	-0.3	1.58e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-8.72	-0.49	4.11e-16	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09299390	chr7:1866243	MAD1L1	0.48	6.37	0.38	9.03e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.83	8.85	0.49	1.77e-16	Alzheimer's disease;
KIRP	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.55	8.01	0.45	4.51e-14	Birth weight;
KIRP	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.52	-0.48	1.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs6694270	0.529	rs4076925	chr1:19113026	C/T	cg19637330	chr1:19110922	NA	0.5	5.33	0.32	2.25e-7	Drug-induced liver injury (nitrofurantoin);
KIRP	cis	rs3768617	0.811	rs4285667	chr1:182970225	T/A	cg21523751	chr1:182988639	NA	0.36	5.09	0.31	7.01e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.61	8.74	0.49	3.76e-16	IgG glycosylation;
KIRP	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-6.02	-0.36	6.14e-9	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.67	9.52	0.52	1.73e-18	Colorectal cancer;
KIRP	cis	rs6132905	0.590	rs78684001	chr20:2604244	G/C	cg24848351	chr20:2622020	TMC2	-0.57	-5.19	-0.31	4.47e-7	Mumps;
KIRP	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.43	0.55	2.54e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	1.05	15.66	0.71	8.07e-39	Menopause (age at onset);
KIRP	cis	rs3736485	0.966	rs11636170	chr15:51767087	G/T	cg14296394	chr15:51910925	DMXL2	-0.36	-5.32	-0.32	2.36e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg08975724	chr8:8085496	FLJ10661	-0.69	-9.29	-0.51	8.24e-18	Neuroticism;
KIRP	cis	rs2411233	0.804	rs12911790	chr15:39250642	A/G	cg02291532	chr15:39874776	THBS1	0.49	6.5	0.38	4.41e-10	Platelet count;
KIRP	trans	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg06521331	chr12:34319734	NA	-0.59	-7.15	-0.41	1e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9905704	0.718	rs4793953	chr17:56613104	C/G	cg12560992	chr17:57184187	TRIM37	-0.58	-5.41	-0.33	1.5e-7	Testicular germ cell tumor;
KIRP	cis	rs4474465	1.000	rs4945282	chr11:78188795	G/A	cg27205649	chr11:78285834	NARS2	-0.64	-8.22	-0.46	1.21e-14	Alzheimer's disease (survival time);
KIRP	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.16	-0.42	9.48e-12	Morning vs. evening chronotype;
KIRP	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg06636001	chr8:8085503	FLJ10661	0.65	8.13	0.46	2.09e-14	Systolic blood pressure;
KIRP	cis	rs865483	0.895	rs6607275	chr17:35833208	T/C	cg06716730	chr17:35851459	DUSP14	0.25	6.04	0.36	5.61e-9	Monocyte count;
KIRP	cis	rs6453429	0.720	rs670220	chr5:78366326	T/G	cg08328513	chr5:78365691	BHMT2;DMGDH	-0.28	-5.0	-0.3	1.11e-6	Urinary metabolites;
KIRP	cis	rs2380205	0.651	rs1886057	chr10:5925495	T/C	cg27141509	chr10:5886111	NA	-0.35	-4.99	-0.3	1.16e-6	Breast cancer;
KIRP	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.67	10.19	0.54	1.48e-20	Dupuytren's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11582854	chr19:37569352	ZNF420	0.47	6.43	0.38	6.55e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.53	-7.67	-0.44	3.88e-13	Daytime sleep phenotypes;
KIRP	cis	rs10892173	0.818	rs7947524	chr11:117671091	C/T	cg07621104	chr11:117668040	DSCAML1	0.42	6.2	0.37	2.39e-9	Myopia;
KIRP	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-0.97	-6.53	-0.38	3.77e-10	Inflammatory biomarkers;
KIRP	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.1	-0.5	3.27e-17	Personality dimensions;
KIRP	trans	rs199950	0.746	rs199942	chr1:181597172	C/T	cg04237608	chr1:18659049	IGSF21	0.39	6.57	0.39	2.92e-10	Body mass index (change over time);
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.19	-15.31	-0.7	1.3e-37	Platelet count;
KIRP	trans	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00950418	chr7:105029125	SRPK2	-0.54	-6.75	-0.4	1.05e-10	Height;
KIRP	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs11249608	0.789	rs903989	chr5:178434434	C/T	cg21905437	chr5:178450457	ZNF879	0.48	5.63	0.34	4.84e-8	Pubertal anthropometrics;
KIRP	cis	rs71277158	0.688	rs58417766	chr3:169833247	A/G	cg04067573	chr3:169899625	PHC3	0.65	6.12	0.36	3.63e-9	Prostate cancer;
KIRP	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg21605333	chr4:119757512	SEC24D	1.6	11.7	0.6	1.93e-25	Cannabis dependence symptom count;
KIRP	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg15556689	chr8:8085844	FLJ10661	0.53	6.63	0.39	2.08e-10	Retinal vascular caliber;
KIRP	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg07001201	chr5:642380	CEP72	0.64	6.04	0.36	5.73e-9	Ulcerative colitis;
KIRP	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg23594656	chr7:65796392	TPST1	0.47	7.37	0.43	2.61e-12	Aortic root size;
KIRP	cis	rs13226913	0.967	rs6463657	chr7:7244254	G/A	cg04827551	chr7:7268805	C1GALT1	-0.36	-5.13	-0.31	5.94e-7	Serum galactose-deficient IgA1 levels;
KIRP	cis	rs9308731	0.563	rs11899831	chr2:111932694	G/A	cg04202892	chr2:111875749	ACOXL	0.48	6.48	0.38	4.85e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg00689492	chr4:1303491	MAEA	0.32	5.79	0.35	2.09e-8	Longevity;
KIRP	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.74	10.78	0.57	1.92e-22	Anterior chamber depth;
KIRP	cis	rs10875746	0.951	rs11168433	chr12:48558064	C/G	cg26205652	chr12:48591994	NA	0.8	10.93	0.57	6.43e-23	Longevity (90 years and older);
KIRP	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.91	13.7	0.66	4.06e-32	Mean platelet volume;
KIRP	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg18306943	chr3:40428807	ENTPD3	0.42	5.47	0.33	1.08e-7	Renal cell carcinoma;
KIRP	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-1.12	-17.61	-0.75	1.85e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00889227	chr1:205173544	DSTYK	-0.38	-5.22	-0.32	3.74e-7	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-4.95	-0.3	1.36e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12282928	0.592	rs7119161	chr11:48343565	C/T	cg26585981	chr11:48327164	OR4S1	0.5	6.07	0.36	4.7e-9	Migraine - clinic-based;
KIRP	trans	rs4349753	0.904	rs248565	chr5:144185113	A/T	cg16033277	chr17:80885358	TBCD	0.4	6.24	0.37	1.89e-9	Photic sneeze reflex;
KIRP	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg00981070	chr1:2046702	PRKCZ	0.39	6.59	0.39	2.71e-10	Height;
KIRP	trans	rs28573326	0.504	rs1438114	chr4:166370156	G/T	cg13437084	chr2:26467494	HADHB;HADHA	-0.46	-6.55	-0.39	3.33e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg13289132	chr10:30722225	MAP3K8	0.43	5.44	0.33	1.28e-7	Inflammatory bowel disease;
KIRP	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg00677455	chr12:58241039	CTDSP2	-0.51	-5.75	-0.34	2.6e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg09264619	chr17:80180166	NA	0.38	5.59	0.34	6.15e-8	Life satisfaction;
KIRP	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23281280	chr6:28129359	ZNF389	0.44	4.87	0.3	2.01e-6	Depression;
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg01798813	chr17:3906674	NA	-0.51	-7.08	-0.41	1.47e-11	Type 2 diabetes;
KIRP	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02725872	chr8:58115012	NA	-0.58	-6.98	-0.41	2.7e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg08738300	chr3:44038990	NA	0.66	8.97	0.5	7.81e-17	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg17133734	chr15:86042851	AKAP13	-0.45	-5.62	-0.34	5.07e-8	Interstitial lung disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg05353415	chr7:42276004	GLI3	0.5	6.88	0.4	5.05e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7246657	0.551	rs11084873	chr19:37583910	A/G	cg18154014	chr19:37997991	ZNF793	0.59	5.03	0.31	9.62e-7	Coronary artery calcification;
KIRP	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg23587288	chr2:27483067	SLC30A3	-0.66	-7.46	-0.43	1.46e-12	Blood metabolite levels;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.77	6.48	0.38	4.95e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.98	13.58	0.65	1.03e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.85	-12.17	-0.61	5.51e-27	Longevity;Endometriosis;
KIRP	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg07884673	chr3:53033167	SFMBT1	0.71	5.74	0.34	2.73e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9653442	0.545	rs4851252	chr2:100757280	C/T	cg17356467	chr2:100759845	AFF3	0.38	5.06	0.31	8.34e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20279784	chr6:112408575	TUBE1;C6orf225	-0.44	-5.87	-0.35	1.37e-8	Metabolic traits;
KIRP	cis	rs8177876	0.822	rs56166222	chr16:81101525	A/C	cg08591886	chr16:81111003	C16orf46	-0.7	-5.46	-0.33	1.14e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6832769	0.890	rs1522107	chr4:56380773	A/T	cg09317128	chr4:56265301	TMEM165	0.55	7.12	0.41	1.15e-11	Personality dimensions;
KIRP	cis	rs6546886	0.913	rs6714186	chr2:74240637	C/T	cg14702570	chr2:74259524	NA	-0.28	-5.49	-0.33	9.81e-8	Dialysis-related mortality;
KIRP	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.47	0.38	5.12e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.48	-5.22	-0.32	3.89e-7	Fear of minor pain;
KIRP	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg01879757	chr17:41196368	BRCA1	-0.53	-7.33	-0.42	3.29e-12	Menopause (age at onset);
KIRP	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-20.48	-0.79	4.56e-55	Height;
KIRP	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.75	-8.4	-0.47	3.49e-15	Resting heart rate;
KIRP	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg23594656	chr7:65796392	TPST1	0.39	6.04	0.36	5.75e-9	Aortic root size;
KIRP	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.1	0.54	2.76e-20	Lung cancer in ever smokers;
KIRP	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg14847009	chr1:175162515	KIAA0040	-0.24	-4.99	-0.3	1.17e-6	Alcohol dependence;
KIRP	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.5	-0.52	1.96e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.31	-0.55	5.92e-21	Heart rate;
KIRP	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg21361702	chr7:150065534	REPIN1	0.53	5.79	0.35	2.18e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7130144	0.541	rs1950119	chr11:130462002	A/T	cg26307797	chr11:130446613	NA	0.6	4.91	0.3	1.65e-6	Urate levels in lean individuals;
KIRP	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.59	7.9	0.45	9.03e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg09238746	chr17:78121135	EIF4A3	-0.44	-5.57	-0.33	6.55e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	0.82	9.05	0.5	4.52e-17	Gut microbiome composition (summer);
KIRP	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.7	9.87	0.53	1.44e-19	Obesity-related traits;
KIRP	cis	rs8062405	0.573	rs11645306	chr16:28983936	G/C	cg07382826	chr16:28625726	SULT1A1	-0.5	-5.43	-0.33	1.35e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.11	-0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg09597638	chr17:3907349	NA	0.83	16.7	0.73	2.3e-42	Type 2 diabetes;
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.66	9.47	0.52	2.42e-18	Menarche (age at onset);
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.59	-6.5	-0.38	4.43e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg15644404	chr18:77186268	NFATC1	-1.01	-6.48	-0.38	4.95e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.53	-7.78	-0.44	1.97e-13	Monocyte percentage of white cells;
KIRP	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg23216685	chr1:86174607	ZNHIT6	-0.51	-5.87	-0.35	1.42e-8	Urate levels in overweight individuals;
KIRP	cis	rs364477	0.818	rs279911	chr9:973695	A/C	cg13952963	chr9:998547	NA	0.62	5.87	0.35	1.42e-8	Major depressive disorder;
KIRP	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Bipolar disorder;
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg14338887	chr6:42928500	GNMT	0.47	6.94	0.4	3.44e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.51	-0.56	1.43e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.32	0.32	2.37e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg22105103	chr4:187893119	NA	0.7	10.04	0.54	4.18e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7903847	0.692	rs7900255	chr10:99157575	G/A	cg20016023	chr10:99160130	RRP12	-0.44	-6.09	-0.36	4.2e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg02524346	chr8:600233	NA	-0.92	-5.63	-0.34	4.95e-8	IgG glycosylation;
KIRP	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg01763666	chr17:80159506	CCDC57	0.37	5.09	0.31	7.19e-7	Life satisfaction;
KIRP	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.43	-7.68	-0.44	3.79e-13	Refractive error;
KIRP	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-7.54	-0.43	9.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7082209	1.000	rs7082209	chr10:44814336	C/T	cg13191911	chr10:44806660	NA	0.5	5.17	0.31	4.81e-7	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
KIRP	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg07001201	chr5:642380	CEP72	0.7	6.57	0.39	2.93e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20916646	chr4:852691	GAK	0.78	7.44	0.43	1.71e-12	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg07701084	chr6:150067640	NUP43	0.51	5.58	0.34	6.24e-8	Lung cancer;
KIRP	cis	rs2219968	1.000	rs6473085	chr8:78974505	T/A	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.57	8.68	0.48	5.47e-16	Personality dimensions;
KIRP	cis	rs2016266	0.855	rs6580941	chr12:53662199	T/C	cg16917193	chr12:54089295	NA	0.48	5.94	0.35	9.45e-9	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02717630	chr16:46865118	C16orf87	-0.45	-6.15	-0.37	3.1e-9	Metabolic traits;
KIRP	cis	rs4774899	0.902	rs11633061	chr15:57488193	A/C	cg13626582	chr15:57592083	LOC283663	-0.21	-4.9	-0.3	1.72e-6	Urinary tract infection frequency;
KIRP	cis	rs9400467	0.506	rs12197149	chr6:111656067	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.54	5.06	0.31	8.34e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.65	-9.37	-0.51	4.83e-18	Resting heart rate;
KIRP	cis	rs4689642	0.709	rs4689656	chr4:7225745	A/G	cg21353189	chr4:7228343	SORCS2	0.41	5.5	0.33	9.62e-8	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.37	4.99	0.3	1.15e-6	Dupuytren's disease;
KIRP	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg07884673	chr3:53033167	SFMBT1	0.88	7.01	0.41	2.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.41	-5.6	-0.34	5.73e-8	Schizophrenia;
KIRP	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg26022315	chr17:47021804	SNF8	0.42	5.41	0.33	1.47e-7	Type 2 diabetes;
KIRP	cis	rs17030434	0.906	rs4145339	chr4:154710481	C/T	cg14289246	chr4:154710475	SFRP2	-0.8	-9.43	-0.52	3.16e-18	Electrocardiographic conduction measures;
KIRP	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs62355272	0.931	rs2287900	chr5:35903997	C/T	cg13894535	chr5:35919491	CAPSL	-0.55	-6.58	-0.39	2.8e-10	Lymphocyte counts;
KIRP	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.45	-5.42	-0.33	1.41e-7	Coronary artery disease;
KIRP	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs986417	0.818	rs2057135	chr14:61077022	G/A	cg27398547	chr14:60952738	C14orf39	0.66	6.1	0.36	3.98e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs8054556	1.000	rs4788210	chr16:30013674	C/G	cg06326092	chr16:30034487	C16orf92	0.36	5.02	0.3	9.92e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.86	-0.4	5.65e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.5	-0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg23100626	chr2:96804247	ASTL	0.5	6.89	0.4	4.65e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg03984502	chr1:151805661	RORC	0.41	6.08	0.36	4.53e-9	Inflammatory biomarkers;
KIRP	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg00343986	chr7:65444356	GUSB	0.4	4.98	0.3	1.19e-6	Aortic root size;
KIRP	cis	rs12022452	0.591	rs4660415	chr1:40978491	C/A	cg25568243	chr1:40974465	DEM1	0.53	5.71	0.34	3.16e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27236875	chr2:213403519	ERBB4	0.43	6.39	0.38	8.45e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	9.01	0.5	6.08e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.8	-9.67	-0.52	5.98e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg02378861	chr5:212933	CCDC127	-0.71	-5.61	-0.34	5.43e-8	Fat distribution (HIV);
KIRP	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.39	4.9	0.3	1.74e-6	Alzheimer's disease (late onset);
KIRP	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg23307798	chr14:103986281	CKB	0.73	11.33	0.59	3.08e-24	Body mass index;
KIRP	cis	rs2658782	0.507	rs4457713	chr11:93037430	C/T	cg15737290	chr11:93063684	CCDC67	1.1	14.96	0.69	2.02e-36	Pulmonary function decline;
KIRP	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	7.66	0.44	4.15e-13	Neuroticism;
KIRP	trans	rs12545912	0.739	rs6601344	chr8:9548145	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.67	-0.39	1.66e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.63	-0.39	2.13e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.66	8.36	0.47	4.62e-15	Alcohol dependence;
KIRP	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.82e-7	Life satisfaction;
KIRP	cis	rs11153147	0.502	rs79116221	chr6:109445587	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-5.05	-0.31	8.74e-7	Mean corpuscular volume;
KIRP	cis	rs697003	0.966	rs701929	chr1:211846876	C/T	cg07170222	chr1:211849252	NEK2	0.35	4.89	0.3	1.8e-6	Red cell distribution width;
KIRP	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.86	-0.45	1.17e-13	Myopia (pathological);
KIRP	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg21419209	chr3:44054225	NA	-0.72	-8.88	-0.49	1.4e-16	Coronary artery disease;
KIRP	cis	rs7327064	0.666	rs73169235	chr13:36904145	C/T	cg13455704	chr13:36871754	C13orf38	0.62	5.6	0.34	5.85e-8	Economic and political preferences;
KIRP	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16288997	chr4:185395914	IRF2	0.49	6.12	0.36	3.74e-9	Parkinson's disease;
KIRP	cis	rs6684428	0.706	rs10493187	chr1:56320969	C/T	cg11651538	chr1:56320950	NA	-0.93	-12.86	-0.63	2.63e-29	Airflow obstruction;
KIRP	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg03146154	chr1:46216737	IPP	0.4	5.07	0.31	7.67e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg00334542	chr7:100209784	MOSPD3	-0.79	-6.42	-0.38	7.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.56	-6.45	-0.38	5.99e-10	Bipolar disorder;
KIRP	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg25036284	chr2:26402008	FAM59B	-0.51	-5.37	-0.32	1.85e-7	Gut microbiome composition (summer);
KIRP	cis	rs6701037	1.000	rs6659824	chr1:175125378	C/A	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.22	-0.32	3.78e-7	Alcohol dependence;
KIRP	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg03468072	chr12:39539422	NA	-0.41	-6.01	-0.36	6.68e-9	Morning vs. evening chronotype;
KIRP	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.73	10.87	0.57	9.5e-23	Orofacial clefts;
KIRP	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.36	0.47	4.73e-15	Lung cancer in ever smokers;
KIRP	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg02725872	chr8:58115012	NA	-0.58	-6.49	-0.38	4.71e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.14	-0.36	3.2e-9	Neuroticism;
KIRP	cis	rs7989336	0.605	rs7329346	chr13:96926996	C/T	cg02571835	chr13:96230311	CLDN10	0.39	5.29	0.32	2.72e-7	Obesity;
KIRP	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg26061582	chr7:22766209	IL6	0.42	5.19	0.31	4.42e-7	Lung cancer;
KIRP	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7084402	0.967	rs1658442	chr10:60318897	G/A	cg05938607	chr10:60274200	BICC1	-0.44	-10.77	-0.57	2.01e-22	Refractive error;
KIRP	trans	rs669484	0.541	rs28666049	chr9:10403863	C/T	cg25509871	chr19:40871557	PLD3	-0.65	-6.22	-0.37	2.12e-9	Gestational age at birth (child effect);
KIRP	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg10326726	chr10:51549505	MSMB	-0.6	-9.1	-0.5	3.13e-17	Prostate-specific antigen levels;
KIRP	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.76	-11.83	-0.6	7.58e-26	Neurofibrillary tangles;
KIRP	trans	rs7521492	0.647	rs7540637	chr1:163730212	A/G	cg21988461	chr4:88008667	AFF1	0.38	6.1	0.36	4.11e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg01689657	chr7:91764605	CYP51A1	0.42	6.05	0.36	5.47e-9	Breast cancer;
KIRP	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.64	5.59	0.34	5.92e-8	Height;
KIRP	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.71e-25	Vitiligo;
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg13888710	chr4:39699558	UBE2K	-0.58	-6.22	-0.37	2.13e-9	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg00360474	chr6:37504404	NA	-0.47	-6.68	-0.39	1.58e-10	Cognitive performance;
KIRP	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs9488822	0.676	rs1999929	chr6:116381994	T/C	cg05304507	chr6:116381966	FRK	0.21	5.4	0.33	1.58e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7904368	0.754	rs12246217	chr10:16853349	G/C	cg14835575	chr10:16859367	RSU1	0.78	9.44	0.52	2.92e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.35	0.38	1.02e-9	Morning vs. evening chronotype;
KIRP	cis	rs2191566	0.960	rs367209	chr19:44506249	A/G	cg20607764	chr19:44506953	ZNF230	0.43	5.07	0.31	7.82e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg16255804	chr6:135334527	HBS1L	-0.38	-5.93	-0.35	1.01e-8	Red blood cell count;
KIRP	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg07395648	chr5:131743802	NA	0.36	5.26	0.32	3.07e-7	Acylcarnitine levels;
KIRP	cis	rs1408799	0.789	rs10960753	chr9:12675522	G/T	cg05274944	chr9:12693694	TYRP1	0.38	5.55	0.33	7.42e-8	Eye color;Blue vs. green eyes;
KIRP	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.89	13.14	0.64	3.14e-30	Bladder cancer;
KIRP	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg24642439	chr20:33292090	TP53INP2	-0.62	-7.83	-0.45	1.49e-13	Glomerular filtration rate (creatinine);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26706201	chr11:57103334	SSRP1	-0.46	-6.22	-0.37	2.16e-9	Metabolic traits;
KIRP	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg14456004	chr13:21872349	NA	-1.06	-13.21	-0.64	1.75e-30	White matter hyperintensity burden;
KIRP	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.53	7.04	0.41	1.95e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg08533674	chr1:46993347	NA	0.39	4.98	0.3	1.2e-6	Monobrow;
KIRP	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg02151108	chr14:50098012	C14orf104	-0.6	-8.23	-0.46	1.1e-14	Carotid intima media thickness;
KIRP	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.62	-6.66	-0.39	1.82e-10	Obesity-related traits;
KIRP	cis	rs7951870	1.000	rs16938506	chr11:46454313	A/C	cg16389345	chr11:46697382	NA	-0.48	-5.44	-0.33	1.3e-7	Schizophrenia;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg17885191	chr8:135476712	NA	0.53	6.14	0.36	3.22e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg08514558	chr10:81106712	PPIF	0.4	5.46	0.33	1.16e-7	Height;
KIRP	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg01557791	chr16:72042693	DHODH	0.42	5.18	0.31	4.64e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.88	-11.12	-0.58	1.55e-23	Prostate cancer;
KIRP	cis	rs6453429	0.720	rs670220	chr5:78366326	T/G	cg06501366	chr5:78365687	BHMT2;DMGDH	-0.34	-5.78	-0.35	2.28e-8	Urinary metabolites;
KIRP	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-17.98	-0.75	1.02e-46	Schizophrenia;
KIRP	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.63	-6.64	-0.39	2.01e-10	DNA methylation (variation);
KIRP	cis	rs6499755	0.932	rs31075	chr16:55357238	T/C	cg05099576	chr16:55362342	IRX6	0.25	5.23	0.32	3.54e-7	Hypospadias;
KIRP	cis	rs2944591	0.505	rs2592127	chr2:233791648	G/T	cg11972305	chr2:233791962	NGEF	-0.5	-7.55	-0.43	8.71e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.58	6.64	0.39	2.01e-10	Vitiligo;
KIRP	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg18196295	chr10:418757	DIP2C	-0.42	-4.95	-0.3	1.39e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs12580194	0.593	rs61957943	chr12:55749330	A/G	cg19537932	chr12:55886519	OR6C68	-0.47	-6.26	-0.37	1.68e-9	Cancer;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg05665937	chr4:1216051	CTBP1	0.44	5.61	0.34	5.33e-8	Obesity-related traits;
KIRP	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg26354017	chr1:205819088	PM20D1	-0.6	-5.91	-0.35	1.13e-8	Menarche (age at onset);
KIRP	cis	rs2692947	0.667	rs4144055	chr2:96647856	G/T	cg23100626	chr2:96804247	ASTL	0.43	5.83	0.35	1.77e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9810890	1.000	rs116203743	chr3:128483210	G/A	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg06998765	chr14:75389618	RPS6KL1	-0.23	-4.94	-0.3	1.45e-6	Height;
KIRP	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.69	-8.42	-0.47	3.22e-15	Cognitive function;
KIRP	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11987759	chr7:65425863	GUSB	0.49	6.26	0.37	1.66e-9	Aortic root size;
KIRP	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.96	15.95	0.71	8.53e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg18016565	chr1:150552671	MCL1	0.39	6.0	0.36	7.16e-9	Melanoma;
KIRP	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.78	11.69	0.6	2.11e-25	Total body bone mineral density;
KIRP	cis	rs5770917	1.000	rs762677	chr22:51017713	G/A	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.58	-5.61	-0.34	5.31e-8	Narcolepsy;
KIRP	cis	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg09961663	chr14:61509683	SLC38A6	-0.39	-5.37	-0.32	1.8e-7	Select biomarker traits;
KIRP	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11987759	chr7:65425863	GUSB	0.45	5.32	0.32	2.34e-7	Aortic root size;
KIRP	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-5.2	-0.31	4.2e-7	Aortic root size;
KIRP	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg21361702	chr7:150065534	REPIN1	0.61	5.89	0.35	1.26e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6732160	0.613	rs10179063	chr2:73385111	T/A	cg01422370	chr2:73384389	NA	0.52	7.05	0.41	1.82e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs113123495	0.609	rs2485278	chr19:5645204	A/G	cg26242866	chr19:5711310	LONP1	0.73	4.95	0.3	1.39e-6	Obsessive-compulsive symptoms;
KIRP	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.82	12.83	0.63	3.3e-29	Metabolic syndrome;
KIRP	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.47	-0.43	1.42e-12	Bipolar disorder;
KIRP	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg03161606	chr19:29218774	NA	0.83	8.02	0.46	4.43e-14	Methadone dose in opioid dependence;
KIRP	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-0.98	-6.93	-0.4	3.65e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.37	-0.32	1.79e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.54	-7.48	-0.43	1.29e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.86	14.22	0.67	6.99e-34	Prostate cancer;
KIRP	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.97	0.3	1.25e-6	Educational attainment;
KIRP	cis	rs1800469	0.965	rs11668109	chr19:41863777	A/C	cg08477640	chr19:41863820	B9D2	0.62	7.34	0.42	3.19e-12	Colorectal cancer;
KIRP	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08280861	chr8:58055591	NA	0.72	5.71	0.34	3.31e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.66	5.54	0.33	7.79e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.24	-0.47	1.01e-14	Common traits (Other);
KIRP	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.93	-14.06	-0.67	2.43e-33	Body mass index;
KIRP	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg16414030	chr3:133502952	NA	-0.5	-5.95	-0.35	9.42e-9	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.56	-6.38	-0.38	8.52e-10	Vitiligo;
KIRP	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.45	-6.41	-0.38	7.41e-10	Sitting height ratio;
KIRP	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.68	-8.88	-0.49	1.41e-16	Height;
KIRP	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg25319279	chr11:5960081	NA	-0.57	-5.88	-0.35	1.34e-8	DNA methylation (variation);
KIRP	cis	rs3845905	1.000	rs13089753	chr3:66514467	G/T	cg25742035	chr3:66514413	LRIG1	-1.03	-6.08	-0.36	4.45e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs);Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs9815354	0.723	rs61182696	chr3:42032511	C/T	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.67	8.43	0.47	3e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg21605333	chr4:119757512	SEC24D	0.73	5.72	0.34	3.03e-8	Cannabis dependence symptom count;
KIRP	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.18	14.2	0.67	8.18e-34	Corneal structure;
KIRP	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.94	-10.96	-0.57	4.95e-23	Corneal astigmatism;
KIRP	cis	rs5753037	0.653	rs131277	chr22:30154101	C/A	cg01021169	chr22:30184971	ASCC2	-0.43	-5.96	-0.36	8.49e-9	Type 1 diabetes;
KIRP	cis	rs9308731	0.563	rs11899831	chr2:111932694	G/A	cg04780086	chr2:111875790	ACOXL	0.44	5.9	0.35	1.2e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.81	8.18	0.46	1.52e-14	Eosinophil percentage of granulocytes;
KIRP	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	1.0	17.75	0.75	6.28e-46	Breast cancer;
KIRP	cis	rs9652601	0.779	rs11648679	chr16:11175984	A/G	cg04616529	chr16:11181986	CLEC16A	0.39	5.18	0.31	4.62e-7	Systemic lupus erythematosus;
KIRP	cis	rs3755132	0.929	rs57349592	chr2:15738959	C/T	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.71	8.98	0.5	7.45e-17	Bladder cancer;
KIRP	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.87	-11.4	-0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.83	-0.35	1.72e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	1.04	19.06	0.77	2.33e-50	Heart rate;
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.7	0.66	3.81e-32	Platelet count;
KIRP	cis	rs11955398	0.647	rs57521726	chr5:59984897	A/T	cg02684056	chr5:59996105	DEPDC1B	0.49	5.53	0.33	8.08e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.94	-0.4	3.48e-11	Neuroticism;
KIRP	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-0.82	-9.24	-0.51	1.21e-17	Gut microbiome composition (summer);
KIRP	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.64	6.78	0.4	8.8e-11	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	14.38	0.68	1.89e-34	Alzheimer's disease;
KIRP	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg20991723	chr1:152506922	NA	-0.49	-5.94	-0.35	9.74e-9	Hair morphology;
KIRP	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg09626299	chr10:82213104	TSPAN14	-0.34	-5.14	-0.31	5.7e-7	Post bronchodilator FEV1;
KIRP	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg17356467	chr2:100759845	AFF3	0.55	5.6	0.34	5.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-5.73	-0.34	2.94e-8	Height;
KIRP	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.73	9.28	0.51	8.99e-18	Coronary artery disease;
KIRP	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	8.39	0.47	3.92e-15	Personality dimensions;
KIRP	cis	rs7719624	0.792	rs4976459	chr5:135362573	C/G	cg16684184	chr5:135415129	NA	-0.35	-5.24	-0.32	3.4e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs1823913	0.599	rs35098152	chr2:192151384	T/C	cg12404831	chr2:192114017	MYO1B	0.52	7.27	0.42	4.69e-12	Obesity-related traits;
KIRP	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.52	6.77	0.4	9.4e-11	Menarche (age at onset);
KIRP	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg18350739	chr11:68623251	NA	0.48	7.65	0.44	4.58e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg01320579	chr17:75405842	SEPT9	0.51	8.31	0.47	6.49e-15	Airflow obstruction;
KIRP	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.54	-6.47	-0.38	5.36e-10	Menopause (age at onset);
KIRP	cis	rs6062509	1.000	rs6062509	chr20:62362563	G/T	cg11503966	chr20:62272292	STMN3	0.34	4.94	0.3	1.47e-6	Prostate cancer;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg05923062	chr19:8509833	HNRNPM	0.49	6.21	0.37	2.29e-9	DNA methylation (variation);
KIRP	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	cg21523751	chr1:182988639	NA	0.42	6.58	0.39	2.78e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	12.08	0.61	1.08e-26	Menopause (age at onset);
KIRP	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.84	-0.35	1.61e-8	Mean corpuscular volume;
KIRP	cis	rs11971779	0.680	rs10273527	chr7:139036598	A/C	cg23387468	chr7:139079360	LUC7L2	-0.28	-4.9	-0.3	1.76e-6	Diisocyanate-induced asthma;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg21395147	chr1:211849137	NEK2	-0.89	-6.21	-0.37	2.28e-9	P wave terminal force;
KIRP	cis	rs4740619	0.530	rs10810524	chr9:16036646	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.53e-7	Body mass index;
KIRP	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg08975724	chr8:8085496	FLJ10661	0.6	8.29	0.47	7.41e-15	Neuroticism;
KIRP	cis	rs13064411	0.518	rs1552433	chr3:113225730	C/A	cg18753928	chr3:113234510	CCDC52	-0.5	-6.34	-0.37	1.08e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.76	8.75	0.49	3.5e-16	Corneal astigmatism;
KIRP	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg07382826	chr16:28625726	SULT1A1	0.47	5.29	0.32	2.73e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg21361702	chr7:150065534	REPIN1	0.61	6.05	0.36	5.42e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11255291	1.000	rs7901428	chr10:7732419	C/T	cg26051552	chr10:7670683	ITIH5	0.43	5.58	0.34	6.31e-8	Ovarian reserve;
KIRP	cis	rs2273669	0.504	rs59358669	chr6:109500192	G/A	cg05315195	chr6:109294784	ARMC2	-0.54	-5.15	-0.31	5.47e-7	Prostate cancer;
KIRP	cis	rs12580194	1.000	rs12579915	chr12:55696789	C/T	cg11794356	chr12:55725991	OR6C3	0.46	6.59	0.39	2.64e-10	Cancer;
KIRP	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs12986413	0.651	rs35751290	chr19:2139357	A/G	cg09261902	chr19:2140048	AP3D1	0.67	10.72	0.56	3.09e-22	Height;
KIRP	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg06740227	chr12:86229804	RASSF9	-0.43	-5.37	-0.32	1.8e-7	Major depressive disorder;
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg07216194	chr8:27182965	PTK2B	0.45	5.6	0.34	5.73e-8	Neuroticism;
KIRP	cis	rs9488822	0.585	rs195522	chr6:116245016	G/A	cg05304507	chr6:116381966	FRK	0.2	5.08	0.31	7.42e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.72	9.79	0.53	2.46e-19	Blood protein levels;
KIRP	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-5.35	-0.32	2.05e-7	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17554472	chr22:41940697	POLR3H	0.67	6.91	0.4	4.23e-11	Vitiligo;
KIRP	cis	rs4006360	0.614	rs6416914	chr17:39262850	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.29	-0.42	4.26e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs55962025	0.824	rs61348208	chr4:3089564	C/T	cg06533319	chr4:3265114	C4orf44	0.42	5.1	0.31	6.71e-7	Parental longevity (mother's age at death);
KIRP	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs12496230	0.794	rs7629637	chr3:66863065	G/C	cg17646820	chr3:66848679	NA	0.4	6.56	0.39	3.15e-10	Type 2 diabetes;
KIRP	cis	rs4356975	0.563	rs7679550	chr4:69946905	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.38	4.94	0.3	1.46e-6	Birth weight;
KIRP	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg13798912	chr7:905769	UNC84A	-0.75	-6.71	-0.39	1.32e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.91	15.65	0.71	8.81e-39	Breast cancer;
KIRP	cis	rs1800562	1	rs1800562	chr6:26093141	C/T	cg16482183	chr6:26056742	HIST1H1C	0.91	5.76	0.34	2.51e-8	Hematocrit;Iron status biomarkers (transferrin levels);Diastolic blood pressure;Hemoglobin;Red blood cell count;Cholesterol, total;Hematology traits;Alcohol consumption (transferrin glycosylation);Iron status biomarkers (ferritin levels);LDL cholesterol;Iron status biomarkers;Mean corpuscular hemoglobin;Iron status biomarkers (transferrin saturation);Mean corpuscular volume;Iron status biomarkers (iron levels);Red blood cell traits;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hematological parameters;Hepcidin levels;Cardiovascular disease risk factors;
KIRP	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.68	0.48	5.55e-16	Motion sickness;
KIRP	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-0.82	-9.2	-0.51	1.6e-17	Gut microbiome composition (summer);
KIRP	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg10973622	chr2:86423274	IMMT	0.52	6.66	0.39	1.82e-10	Night sleep phenotypes;
KIRP	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg09873164	chr1:152488093	CRCT1	0.55	7.19	0.42	7.85e-12	Hair morphology;
KIRP	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.67	-7.82	-0.45	1.51e-13	IgG glycosylation;
KIRP	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg23625390	chr15:77176239	SCAPER	0.49	6.4	0.38	7.66e-10	Blood metabolite levels;
KIRP	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.67	-6.59	-0.39	2.61e-10	Lung function (FEV1/FVC);
KIRP	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg09904177	chr6:26538194	HMGN4	0.45	6.06	0.36	5.06e-9	Schizophrenia;
KIRP	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.67	8.88	0.49	1.42e-16	Eye color traits;
KIRP	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.62	-7.98	-0.45	5.7e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs62577244	0.645	rs111342974	chr9:138434448	G/A	cg14097499	chr9:138441348	OBP2A	0.49	6.29	0.37	1.45e-9	Subcutaneous adipose tissue (sex interaction);Subcutaneous adipose tissue;
KIRP	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.82	9.74	0.53	3.61e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg05315796	chr3:52349193	DNAH1	0.42	6.53	0.38	3.73e-10	Bipolar disorder;
KIRP	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-8.85	-0.49	1.71e-16	Bladder cancer;
KIRP	cis	rs9302635	0.745	rs35909200	chr16:72156666	T/G	cg23815491	chr16:72088622	HP	0.41	4.95	0.3	1.4e-6	Blood protein levels;
KIRP	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg13962347	chr6:5174647	LYRM4	0.74	10.36	0.55	4.26e-21	Height;
KIRP	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.6	-7.41	-0.43	2.02e-12	Height;
KIRP	cis	rs4654899	1.000	rs7525438	chr1:21458217	G/A	cg05370193	chr1:21551575	ECE1	0.43	5.94	0.35	9.84e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg23788917	chr6:8435910	SLC35B3	-0.44	-5.47	-0.33	1.12e-7	Motion sickness;
KIRP	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg19875535	chr5:140030758	IK	-0.67	-9.38	-0.51	4.44e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4789693	0.809	rs8071692	chr17:80392333	G/A	cg04308225	chr17:80449738	NA	0.58	5.53	0.33	8.12e-8	Glucocorticoid-induced osteonecrosis;
KIRP	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg01304814	chr3:48885189	PRKAR2A	0.78	5.7	0.34	3.46e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8067545	0.532	rs17759609	chr17:19992514	C/G	cg04132472	chr17:19861366	AKAP10	0.44	5.13	0.31	5.9e-7	Schizophrenia;
KIRP	cis	rs17445240	0.892	rs2312921	chr2:3696140	G/A	cg19825600	chr2:3704501	ALLC	0.63	5.47	0.33	1.12e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-6.91	-0.4	4.02e-11	Response to antipsychotic treatment;
KIRP	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs5995756	0.834	rs132575	chr22:39982721	A/G	cg10455938	chr22:40058150	CACNA1I	-0.45	-6.34	-0.37	1.08e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg03653399	chr8:142233436	SLC45A4	-0.69	-9.37	-0.51	5.01e-18	Immature fraction of reticulocytes;
KIRP	cis	rs1440410	0.835	rs4574353	chr4:144108641	A/G	cg01719995	chr4:144104893	USP38	0.39	5.25	0.32	3.32e-7	Ischemic stroke;
KIRP	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.68	-0.34	3.78e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6995541	0.505	rs7013032	chr8:10706359	C/G	cg12568669	chr8:11666485	FDFT1	0.23	4.85	0.3	2.23e-6	Triglyceride levels;
KIRP	cis	rs745080	1.000	rs729931	chr14:52988585	G/C	cg23333723	chr14:53022898	GPR137C	-0.36	-4.96	-0.3	1.29e-6	Orofacial clefts;
KIRP	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.5	6.88	0.4	4.87e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg24069376	chr3:38537580	EXOG	0.3	4.98	0.3	1.18e-6	Electrocardiographic conduction measures;
KIRP	trans	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg11952622	chr19:58962976	ZNF324B	0.43	5.03	0.31	9.38e-7	Uric acid clearance;
KIRP	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.69	7.24	0.42	5.78e-12	Gut microbiome composition (summer);
KIRP	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.68	7.34	0.42	3.18e-12	Neutrophil percentage of white cells;
KIRP	cis	rs9398803	0.673	rs1262557	chr6:127054588	C/T	cg19875578	chr6:126661172	C6orf173	-0.4	-4.91	-0.3	1.63e-6	Male-pattern baldness;
KIRP	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.44	6.43	0.38	6.55e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg11693508	chr17:37793320	STARD3	0.75	8.05	0.46	3.66e-14	Bipolar disorder;
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg05025164	chr4:1340916	KIAA1530	0.89	11.4	0.59	1.84e-24	Longevity;
KIRP	cis	rs830383	0.615	rs10866605	chr5:165511692	A/G	cg13976338	chr5:165423657	NA	-0.43	-5.19	-0.31	4.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.82	11.91	0.6	3.85e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg21226059	chr5:178986404	RUFY1	0.49	7.9	0.45	9.43e-14	Lung cancer;
KIRP	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.89	13.21	0.64	1.87e-30	Bladder cancer;
KIRP	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg15556689	chr8:8085844	FLJ10661	0.83	11.15	0.58	1.21e-23	Neuroticism;
KIRP	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.47	-6.87	-0.4	5.13e-11	Schizophrenia;
KIRP	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg24304309	chr1:154577895	ADAR	0.38	6.13	0.36	3.4e-9	Blood protein levels;
KIRP	cis	rs56079296	0.929	rs4495212	chr5:121272917	G/C	cg05256605	chr5:121412184	LOX	0.53	5.64	0.34	4.55e-8	Coronary artery disease;
KIRP	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg00857998	chr1:205179979	DSTYK	0.59	6.75	0.4	1.03e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs877426	0.591	rs56188498	chr13:114827804	A/G	cg00571178	chr13:114841904	RASA3	-0.53	-5.93	-0.35	1.04e-8	Facial morphology (factor 14, intercanthal width);
KIRP	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg04691961	chr3:161091175	C3orf57	-0.38	-5.18	-0.31	4.57e-7	Parkinson's disease;
KIRP	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.59	7.61	0.44	6.01e-13	Monocyte count;
KIRP	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.65	0.52	7.02e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11987759	chr7:65425863	GUSB	-0.45	-5.44	-0.33	1.28e-7	Aortic root size;
KIRP	cis	rs1165472	0.760	rs72480630	chr1:56129283	C/A	cg11523071	chr1:56160889	NA	-0.61	-7.63	-0.44	5.13e-13	Paclitaxel-induced neuropathy;
KIRP	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.64	7.96	0.45	6.48e-14	Corneal astigmatism;
KIRP	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.86	-9.92	-0.53	1.03e-19	Schizophrenia;
KIRP	cis	rs490234	0.966	rs534214	chr9:128369224	A/G	cg14078157	chr9:128172775	NA	-0.4	-4.9	-0.3	1.77e-6	Mean arterial pressure;
KIRP	trans	rs55728055	0.661	rs55648708	chr22:32032062	G/A	cg02791973	chr19:1132256	SBNO2	-0.58	-6.36	-0.38	9.58e-10	Age-related hearing impairment;
KIRP	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.54	6.6	0.39	2.45e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1873147	1.000	rs4774469	chr15:63311927	G/A	cg12160578	chr15:63334699	TPM1	-0.48	-5.86	-0.35	1.45e-8	Orofacial clefts;
KIRP	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg09596252	chr17:78655493	RPTOR	-0.46	-5.44	-0.33	1.27e-7	Fractional excretion of uric acid;
KIRP	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg15655495	chr12:38532458	NA	-0.29	-5.23	-0.32	3.55e-7	Bladder cancer;
KIRP	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg27205649	chr11:78285834	NARS2	0.67	8.93	0.49	1.04e-16	Alzheimer's disease (survival time);
KIRP	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-7.87	-0.45	1.1e-13	Personality dimensions;
KIRP	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.63	8.44	0.47	2.68e-15	Aortic root size;
KIRP	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg00629941	chr15:75287862	SCAMP5	-0.49	-5.22	-0.32	3.79e-7	Blood trace element (Zn levels);
KIRP	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg09873164	chr1:152488093	CRCT1	0.57	7.68	0.44	3.7e-13	Hair morphology;
KIRP	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg10047753	chr17:41438598	NA	1.14	17.79	0.75	4.34e-46	Menopause (age at onset);
KIRP	cis	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg21204522	chr6:27730016	NA	-0.75	-5.53	-0.33	7.99e-8	Breast cancer;
KIRP	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.94	14.65	0.68	2.23e-35	Body mass index (adult);
KIRP	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg05938607	chr10:60274200	BICC1	0.44	10.69	0.56	3.62e-22	Refractive error;
KIRP	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.22	-0.32	3.77e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.53	7.99	0.45	5.36e-14	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.17	14.81	0.69	6.35e-36	Platelet count;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14457918	chr22:50608509	PANX2	0.65	6.34	0.37	1.11e-9	Lung function (FEV1);
KIRP	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs244899	0.935	rs244900	chr5:167912022	G/A	cg06604206	chr5:167912465	RARS	-0.56	-8.19	-0.46	1.46e-14	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg11812906	chr14:75593930	NEK9	0.53	5.88	0.35	1.34e-8	Caffeine consumption;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19879265	chr14:105963772	C14orf80	0.48	6.14	0.36	3.28e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs28595532	0.720	rs72670226	chr4:119304136	A/G	cg21605333	chr4:119757512	SEC24D	1.01	6.82	0.4	7e-11	Cannabis dependence symptom count;
KIRP	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg04034577	chr2:241836375	C2orf54	-0.45	-8.87	-0.49	1.49e-16	Urinary metabolites;
KIRP	cis	rs8084125	0.832	rs56301307	chr18:74942711	A/G	cg05528293	chr18:74961138	GALR1	0.5	5.34	0.32	2.08e-7	Obesity-related traits;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	4.79e-8	Lung cancer;
KIRP	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.09	0.46	2.65e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.16	-0.54	1.8e-20	Response to antipsychotic treatment;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.45	6.82	0.4	6.87e-11	Lymphocyte counts;
KIRP	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-6.27	-0.37	1.57e-9	Height;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.96	-0.3	1.33e-6	Life satisfaction;
KIRP	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg16584676	chr17:46985605	UBE2Z	0.47	5.8	0.35	2.06e-8	Type 2 diabetes;
KIRP	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.57	7.17	0.42	8.64e-12	Total body bone mineral density;
KIRP	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg17376030	chr22:41985996	PMM1	-0.45	-5.1	-0.31	6.9e-7	Vitiligo;
KIRP	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21194808	chr1:2205498	SKI	-0.38	-5.9	-0.35	1.19e-8	Coronary artery disease;
KIRP	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.48	6.25	0.37	1.79e-9	Blood protein levels;
KIRP	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.58	-7.22	-0.42	6.32e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12282928	1.000	rs11039676	chr11:48337188	T/C	cg26585981	chr11:48327164	OR4S1	0.52	6.28	0.37	1.54e-9	Migraine - clinic-based;
KIRP	cis	rs6005807	0.668	rs60065194	chr22:28993756	A/G	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg07460842	chr6:66804631	NA	-0.48	-5.83	-0.35	1.73e-8	Blood trace element (Cu levels);
KIRP	cis	rs13102973	0.965	rs11099302	chr4:135880751	G/T	cg14419869	chr4:135874104	NA	0.55	9.2	0.51	1.55e-17	Subjective well-being;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27604613	chr3:105588211	CBLB	0.45	6.36	0.38	9.74e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs357618	0.513	rs7722485	chr5:150886519	A/G	cg22672639	chr5:150884813	FAT2	-0.37	-5.2	-0.31	4.22e-7	Basophil percentage of white cells;
KIRP	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.76	10.64	0.56	5.42e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.44	6.13	0.36	3.5e-9	Red blood cell count;
KIRP	cis	rs7215564	0.908	rs2340770	chr17:78754770	T/C	cg06153925	chr17:78755379	RPTOR	-0.38	-6.32	-0.37	1.25e-9	Myopia (pathological);
KIRP	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg04267008	chr7:1944627	MAD1L1	-0.47	-5.18	-0.31	4.61e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7011049	1.000	rs77668788	chr8:53856407	C/T	cg26025543	chr8:53854495	NA	0.75	7.78	0.44	2.06e-13	Systolic blood pressure;
KIRP	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.55	-0.33	7.51e-8	Pulmonary function;
KIRP	cis	rs7534824	0.625	rs7545402	chr1:101321076	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.82	7.06	0.41	1.66e-11	Refractive astigmatism;
KIRP	cis	rs12995491	0.569	rs6724281	chr2:88529531	T/G	cg18490616	chr2:88469792	THNSL2	-0.41	-5.41	-0.33	1.47e-7	Response to metformin (IC50);
KIRP	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg17644776	chr2:200775616	C2orf69	0.47	5.29	0.32	2.69e-7	Osteoporosis;
KIRP	cis	rs2400749	0.635	rs35741827	chr14:100018097	T/C	cg19965031	chr14:100038389	CCDC85C	-0.42	-5.12	-0.31	6.07e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.5	-7.59	-0.44	6.69e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9393692	0.577	rs9358914	chr6:26262063	G/T	cg13736514	chr6:26305472	NA	-0.65	-7.8	-0.45	1.81e-13	Educational attainment;
KIRP	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02725872	chr8:58115012	NA	-0.74	-8.42	-0.47	3.21e-15	Developmental language disorder (linguistic errors);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07572592	chr17:73937177	FBF1	0.61	6.97	0.41	2.94e-11	Lung cancer in ever smokers;
KIRP	cis	rs3026101	0.671	rs17636147	chr17:5315299	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.51	6.6	0.39	2.48e-10	Body mass index;
KIRP	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg26207909	chr14:103986467	CKB	-0.44	-5.36	-0.32	1.88e-7	Coronary artery disease;
KIRP	cis	rs829661	1.000	rs829673	chr2:30711784	G/A	cg10949345	chr2:30726833	LCLAT1	0.72	10.05	0.54	3.97e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs12580194	0.593	rs7485053	chr12:55770126	T/C	cg11794356	chr12:55725991	OR6C3	-0.54	-7.21	-0.42	6.82e-12	Cancer;
KIRP	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg03060546	chr3:49711283	APEH	-0.69	-5.36	-0.32	1.89e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg03929089	chr4:120376271	NA	0.73	6.51	0.38	4.09e-10	Axial length;
KIRP	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg21573476	chr21:45109991	RRP1B	-0.64	-8.7	-0.48	4.98e-16	Mean corpuscular volume;
KIRP	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.5	5.1	0.31	6.72e-7	Skin colour saturation;
KIRP	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.27	-0.32	2.93e-7	Bipolar disorder;
KIRP	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg15440763	chr7:158190612	PTPRN2	0.41	5.09	0.31	7.02e-7	Obesity-related traits;
KIRP	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.63	8.7	0.49	4.74e-16	Autism;
KIRP	cis	rs829661	0.947	rs829659	chr2:30727866	C/T	cg10949345	chr2:30726833	LCLAT1	0.73	10.53	0.56	1.23e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg07338119	chr7:157211683	NA	-0.48	-6.0	-0.36	7.07e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg00857998	chr1:205179979	DSTYK	0.48	6.11	0.36	3.87e-9	Red blood cell count;
KIRP	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.86	13.72	0.66	3.48e-32	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.62	8.5	0.48	1.79e-15	Colorectal cancer;
KIRP	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.48	5.62	0.34	5.06e-8	Glycated hemoglobin levels;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg09699651	chr6:150184138	LRP11	0.44	5.81	0.35	1.88e-8	Lung cancer;
KIRP	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg05370193	chr1:21551575	ECE1	0.47	6.26	0.37	1.71e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg13319975	chr6:146136371	FBXO30	0.46	6.3	0.37	1.39e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.63	8.96	0.5	8.32e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.69	-8.12	-0.46	2.31e-14	Menarche (age at onset);
KIRP	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.64	-7.51	-0.43	1.12e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.87	-7.81	-0.45	1.64e-13	Cerebrospinal P-tau181p levels;
KIRP	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-7.43	-0.43	1.81e-12	Body mass index;
KIRP	cis	rs1978968	0.731	rs9605466	chr22:18461056	A/T	cg03078520	chr22:18463400	MICAL3	-0.85	-12.25	-0.62	3.04e-27	Presence of antiphospholipid antibodies;
KIRP	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg00857998	chr1:205179979	DSTYK	0.5	5.99	0.36	7.48e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3762637	0.941	rs74467988	chr3:122083140	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.72	-0.34	3.06e-8	LDL cholesterol levels;
KIRP	cis	rs7224685	0.501	rs11650023	chr17:4012850	C/T	cg17441377	chr17:3906640	NA	-0.5	-7.39	-0.43	2.29e-12	Type 2 diabetes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14151426	chr13:113864409	CUL4A;PCID2	0.53	6.05	0.36	5.51e-9	Smoking initiation;
KIRP	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.55	-6.76	-0.4	1.02e-10	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10510057	0.637	rs2917928	chr10:121315890	A/G	cg06765389	chr10:121379685	NA	-0.45	-7.14	-0.41	1.05e-11	Depressive symptoms (stressful life events interaction);
KIRP	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg05669848	chr5:237993	SDHA	-0.5	-5.19	-0.31	4.39e-7	Breast cancer;
KIRP	cis	rs1050631	0.960	rs1789512	chr18:33694542	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.47	-5.92	-0.35	1.09e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.9	0.35	1.2e-8	Bipolar disorder;
KIRP	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg08668510	chr10:1095578	IDI1	0.77	5.26	0.32	3.17e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-8.86	-0.49	1.59e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.15	0.36	3.17e-9	Menopause (age at onset);
KIRP	cis	rs1040	0.727	rs9294977	chr6:169624172	A/G	cg04662567	chr6:169592167	NA	0.49	6.03	0.36	6.1e-9	Joint mobility (Beighton score);
KIRP	trans	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.53e-12	Bladder cancer;
KIRP	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg03258749	chr1:151040405	MLLT11	0.84	12.51	0.62	4e-28	Childhood ear infection;
KIRP	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg19761014	chr17:28927070	LRRC37B2	0.5	4.86	0.3	2.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg06740227	chr12:86229804	RASSF9	0.49	5.91	0.35	1.12e-8	Major depressive disorder;
KIRP	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	1.06	13.26	0.65	1.19e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.82	11.71	0.6	1.87e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.69	8.24	0.47	1.01e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.78	-10.55	-0.56	1.02e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.66	-7.64	-0.44	4.68e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8067545	1.000	rs34291370	chr17:19942335	G/A	cg13482628	chr17:19912719	NA	0.6	8.62	0.48	8.4e-16	Schizophrenia;
KIRP	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg10047753	chr17:41438598	NA	1.05	13.2	0.64	2e-30	Menopause (age at onset);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg16702774	chr17:77771036	CBX8	0.54	6.24	0.37	1.9e-9	Plasma plasminogen activator levels;
KIRP	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08109568	chr15:31115862	NA	-0.76	-10.24	-0.55	9.89e-21	Huntington's disease progression;
KIRP	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.53	-11.22	-0.58	7.44e-24	Refractive error;
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-1.03	-12.12	-0.61	7.75e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.65	7.03	0.41	2.01e-11	Initial pursuit acceleration;
KIRP	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg14664628	chr15:75095509	CSK	0.5	5.92	0.35	1.07e-8	Systemic lupus erythematosus;
KIRP	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.85	13.41	0.65	3.9e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.87	13.0	0.64	9.26e-30	Longevity;
KIRP	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07570687	chr10:102243282	WNT8B	0.48	5.77	0.35	2.42e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg07775547	chr4:1625484	NA	-0.44	-5.19	-0.31	4.34e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs3857747	0.895	rs12669999	chr7:40366686	T/C	cg00420559	chr7:40367873	C7orf10	-0.6	-8.5	-0.48	1.84e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6662572	0.737	rs6429593	chr1:46505235	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.45	0.33	1.21e-7	Blood protein levels;
KIRP	cis	rs77861329	0.748	rs893055	chr3:52177348	T/C	cg08692210	chr3:52188851	WDR51A	0.6	6.05	0.36	5.26e-9	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg23387468	chr7:139079360	LUC7L2	0.3	5.13	0.31	5.77e-7	Diisocyanate-induced asthma;
KIRP	cis	rs16937956	0.597	rs34617462	chr11:8425031	T/C	cg08015107	chr11:8618950	NA	-0.53	-6.99	-0.41	2.63e-11	Body mass index;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs7224685	0.569	rs8066378	chr17:3996334	T/C	cg05562828	chr17:3906858	NA	0.54	5.68	0.34	3.72e-8	Type 2 diabetes;
KIRP	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	1.08	13.84	0.66	1.3e-32	Platelet distribution width;
KIRP	cis	rs2077654	0.556	rs4756888	chr11:17442658	T/C	cg25308976	chr11:17434268	ABCC8	0.63	6.7	0.39	1.4e-10	Gout;
KIRP	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg00792783	chr2:198669748	PLCL1	0.47	5.4	0.33	1.6e-7	Dermatomyositis;
KIRP	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg23307798	chr14:103986281	CKB	0.49	7.12	0.41	1.17e-11	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22526696	chr7:98568096	TRRAP	0.5	6.35	0.38	1.06e-9	Interleukin-4 levels;
KIRP	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg12560992	chr17:57184187	TRIM37	0.61	5.62	0.34	5.09e-8	Cognitive test performance;
KIRP	cis	rs8084125	1.000	rs62105176	chr18:74949427	A/G	cg18461021	chr18:74961002	GALR1	0.6	5.93	0.35	1.01e-8	Obesity-related traits;
KIRP	cis	rs4704187	0.687	rs4345300	chr5:74376571	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08157323	chr14:105688914	BRF1	-0.47	-7.12	-0.41	1.16e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.45	-5.26	-0.32	3.21e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16346588	chr10:242978	ZMYND11	0.48	5.92	0.35	1.08e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.89	-10.56	-0.56	9.59e-22	Post bronchodilator FEV1;
KIRP	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	cg12689670	chr1:183009347	LAMC1	0.42	6.09	0.36	4.24e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg02462569	chr6:150064036	NUP43	0.33	5.08	0.31	7.57e-7	Lung cancer;
KIRP	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.51	-0.52	1.8e-18	Hemoglobin concentration;
KIRP	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.85	-13.13	-0.64	3.37e-30	Eye color traits;
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.07	-0.5	4.01e-17	Blood metabolite levels;
KIRP	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg18132916	chr6:79620363	NA	-0.41	-5.65	-0.34	4.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1050631	0.592	rs1631346	chr18:33709664	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.56	0.33	7.16e-8	Esophageal squamous cell cancer (length of survival);
KIRP	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-1.01	-17.12	-0.74	8.13e-44	Height;
KIRP	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.56	7.43	0.43	1.82e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2904967	0.852	rs488289	chr11:65039264	T/C	cg12562828	chr11:65076843	NA	0.47	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.62e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26314823	chr1:119689570	NA	0.46	6.11	0.36	3.86e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg17133734	chr15:86042851	AKAP13	-0.46	-5.79	-0.35	2.15e-8	Coronary artery disease;
KIRP	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4118325	0.603	rs12743478	chr1:107701106	C/T	cg01939741	chr1:107680714	NA	-0.53	-5.18	-0.31	4.54e-7	AIDS;
KIRP	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg14664628	chr15:75095509	CSK	0.64	6.93	0.4	3.73e-11	Systemic lupus erythematosus;
KIRP	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg18806716	chr10:30721971	MAP3K8	-0.31	-4.88	-0.3	1.93e-6	Inflammatory bowel disease;
KIRP	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.7	-7.35	-0.42	2.99e-12	Vitiligo;
KIRP	cis	rs4664293	0.867	rs1427329	chr2:160604812	C/T	cg08347373	chr2:160653686	CD302	-0.42	-6.63	-0.39	2.06e-10	Monocyte percentage of white cells;
KIRP	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg21253087	chr9:139290292	SNAPC4	-0.47	-6.71	-0.39	1.3100000000000001e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.73	10.94	0.57	6.06e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg26338869	chr17:61819248	STRADA	-0.47	-5.6	-0.34	5.6e-8	Prudent dietary pattern;
KIRP	cis	rs72960926	0.744	rs16884624	chr6:74998293	G/C	cg03266952	chr6:74778945	NA	-0.63	-5.61	-0.34	5.51e-8	Metabolite levels (MHPG);
KIRP	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-7.54	-0.43	9.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.56	-7.03	-0.41	2.06e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs580438	0.510	rs6804189	chr3:13437950	C/T	cg10657019	chr3:13328039	NA	-0.47	-6.07	-0.36	4.88e-9	Myringotomy;
KIRP	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg16574807	chr4:6945745	TBC1D14	0.67	5.98	0.36	7.91e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6088813	1.000	rs6088821	chr20:33987576	G/A	cg14752227	chr20:34000481	UQCC	-0.53	-6.83	-0.4	6.58e-11	Height;
KIRP	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg21827317	chr3:136751795	NA	0.37	5.22	0.32	3.77e-7	Neuroticism;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg12692727	chr7:1102344	C7orf50	0.47	4.98	0.3	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6662572	0.737	rs56140667	chr1:46411715	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.52	0.33	8.75e-8	Blood protein levels;
KIRP	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.77	-10.44	-0.55	2.37e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06212747	chr3:49208901	KLHDC8B	0.88	13.76	0.66	2.46e-32	Menarche (age at onset);
KIRP	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-0.82	-9.14	-0.5	2.4e-17	Gut microbiome composition (summer);
KIRP	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.7	10.46	0.55	2.03e-21	Dupuytren's disease;
KIRP	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.57	-6.69	-0.39	1.5e-10	Height;
KIRP	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.82	11.68	0.6	2.3e-25	Mortality in heart failure;
KIRP	cis	rs4363385	0.588	rs12079087	chr1:153023888	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-6.12	-0.36	3.63e-9	Inflammatory skin disease;
KIRP	trans	rs7594645	1.000	rs7594645	chr2:207646674	A/G	cg04391186	chr7:24446070	NA	0.58	6.08	0.36	4.5e-9	Episodic memory;
KIRP	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.71	10.59	0.56	7.57e-22	Lewy body disease;
KIRP	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.69	-0.39	1.51e-10	Caffeine consumption;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	1.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03934478	chr11:495069	RNH1	0.88	6.84	0.4	6.4e-11	Body mass index;
KIRP	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg10932868	chr11:921992	NA	0.63	8.07	0.46	3.19e-14	Alzheimer's disease (late onset);
KIRP	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	8.28	0.47	8.08e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.48	5.74	0.34	2.83e-8	Glycated hemoglobin levels;
KIRP	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.96	17.61	0.75	1.76e-45	Colorectal adenoma (advanced);
KIRP	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg04369109	chr6:150039330	LATS1	-0.65	-8.55	-0.48	1.35e-15	Lung cancer;
KIRP	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.71	0.68	1.43e-35	Alzheimer's disease;
KIRP	cis	rs73206853	0.764	rs28362526	chr12:110561779	C/A	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15557168	chr22:42548783	NA	0.42	5.49	0.33	9.75e-8	Cognitive function;
KIRP	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg16329650	chr2:213403929	ERBB4	0.81	13.57	0.65	1.11e-31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7301016	0.948	rs10877870	chr12:62923955	A/G	cg01804193	chr12:63026212	NA	0.54	5.64	0.34	4.68e-8	IgG glycosylation;
KIRP	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg18944383	chr4:111397179	ENPEP	0.52	8.36	0.47	4.83e-15	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs745080	0.890	rs67875014	chr14:52927482	T/C	cg23333723	chr14:53022898	GPR137C	-0.39	-5.43	-0.33	1.36e-7	Orofacial clefts;
KIRP	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.67	8.12	0.46	2.32e-14	Pancreatic cancer;
KIRP	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg11833968	chr6:79620685	NA	-0.48	-7.23	-0.42	6.17e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg04657146	chr19:12876947	HOOK2	0.44	5.03	0.31	9.58e-7	Mean corpuscular volume;
KIRP	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.67	8.86	0.49	1.59e-16	Primary sclerosing cholangitis;
KIRP	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.48	-7.26	-0.42	5.17e-12	Bone mineral density;
KIRP	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.07e-12	Blood protein levels;
KIRP	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20135002	chr11:47629003	NA	-0.47	-5.64	-0.34	4.58e-8	Subjective well-being;
KIRP	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.55	-0.33	7.29e-8	Depression;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08284801	chr17:19266230	B9D1	0.54	6.9	0.4	4.33e-11	Parkinson's disease;
KIRP	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg15655495	chr12:38532458	NA	-0.28	-5.24	-0.32	3.39e-7	Bladder cancer;
KIRP	cis	rs12135191	0.771	rs12729455	chr1:236501925	A/C	cg21399712	chr1:236511386	NA	-0.5	-6.43	-0.38	6.56e-10	Urate levels (BMI interaction);
KIRP	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	1.1	12.0	0.61	1.94e-26	Corneal structure;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02737830	chr12:64616354	C12orf66	0.51	6.1	0.36	4.17e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10924970	1.000	rs4660114	chr1:235328341	G/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.02	0.3	1.01e-6	Asthma;
KIRP	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg07827796	chr19:33622959	WDR88	0.53	7.17	0.42	8.85e-12	Bone properties (heel);
KIRP	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.4	-7.09	-0.41	1.43e-11	Coronary artery disease;
KIRP	cis	rs4073221	0.654	rs67148103	chr3:18279461	G/A	cg07694806	chr3:18168406	NA	-0.65	-5.9	-0.35	1.19e-8	Parkinson's disease;
KIRP	cis	rs4704187	0.687	rs28376290	chr5:74454706	C/T	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg00800038	chr16:89945340	TCF25	-0.77	-4.92	-0.3	1.58e-6	Skin colour saturation;
KIRP	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.12	-0.31	6.24e-7	Pulmonary function;
KIRP	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg23479056	chr15:41276147	INO80	0.36	4.91	0.3	1.68e-6	Menopause (age at onset);
KIRP	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg00319359	chr11:70116639	PPFIA1	0.79	7.08	0.41	1.48e-11	Coronary artery disease;
KIRP	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.88	12.34	0.62	1.5e-27	Gestational age at birth (maternal effect);
KIRP	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg03576123	chr11:487126	PTDSS2	0.87	7.71	0.44	3.05e-13	Body mass index;
KIRP	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-7.33	-0.42	3.39e-12	Platelet distribution width;
KIRP	cis	rs787274	1.000	rs786961	chr9:115471346	T/C	cg13803584	chr9:115635662	SNX30	0.72	6.38	0.38	8.8e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3134353	0.769	rs7817485	chr8:101969528	T/C	cg07585502	chr8:101912084	NA	-0.4	-4.89	-0.3	1.84e-6	Body mass index;
KIRP	cis	rs12580194	0.593	rs7959837	chr12:55734511	G/A	cg19537932	chr12:55886519	OR6C68	-0.46	-6.03	-0.36	5.91e-9	Cancer;
KIRP	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg11972305	chr2:233791962	NGEF	0.39	5.39	0.33	1.63e-7	Schizophrenia;
KIRP	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.67	-7.59	-0.44	6.43e-13	Alcohol dependence;
KIRP	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.31	0.37	1.28e-9	Hypertriglyceridemia;
KIRP	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	0.91	11.85	0.6	6.18e-26	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6701037	0.748	rs11583687	chr1:175132049	A/C	cg08873628	chr1:175162347	KIAA0040	0.4	5.69	0.34	3.58e-8	Alcohol dependence;
KIRP	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.55	8.99	0.5	6.59e-17	Total body bone mineral density;
KIRP	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.81	-0.4	7.53e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11874712	1.000	rs8088881	chr18:43664970	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.86	10.81	0.57	1.49e-22	Coronary artery disease;
KIRP	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg24642439	chr20:33292090	TP53INP2	-0.61	-8.02	-0.46	4.42e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs4716602	0.622	rs36071136	chr7:156166303	G/C	cg16983916	chr7:156159713	NA	-0.46	-6.15	-0.36	3.13e-9	Anti-saccade response;
KIRP	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg01631408	chr1:248437212	OR2T33	-0.63	-8.38	-0.47	4.12e-15	Common traits (Other);
KIRP	cis	rs9611198	0.792	rs2092168	chr22:39947068	T/C	cg03390717	chr22:39966585	CACNA1I	0.35	6.24	0.37	1.86e-9	Schizophrenia;
KIRP	trans	rs4294134	0.832	rs11768962	chr7:135254692	C/T	cg15778437	chr11:31839521	PAX6	0.54	6.04	0.36	5.61e-9	Paget's disease;
KIRP	cis	rs6565180	0.525	rs1132812	chr16:30198151	A/G	cg17640201	chr16:30407289	ZNF48	0.44	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.72	0.49	4.36e-16	Bipolar disorder;
KIRP	cis	rs9443189	1.000	rs1280044	chr6:76522602	A/G	cg01950844	chr6:76311363	SENP6	-0.53	-5.11	-0.31	6.35e-7	Prostate cancer;
KIRP	cis	rs7127900	0.583	rs11043140	chr11:2233951	T/C	cg25635251	chr11:2234043	NA	0.44	6.97	0.41	2.85e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.52	6.34	0.37	1.07e-9	Monocyte count;
KIRP	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.36	-5.02	-0.3	9.82e-7	Prostate cancer;
KIRP	cis	rs9962915	1.000	rs1539811	chr18:5595958	C/T	cg12967001	chr18:5544089	EPB41L3	-0.43	-5.45	-0.33	1.21e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.43	5.9	0.35	1.17e-8	Night sleep phenotypes;
KIRP	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02527881	chr3:46936655	PTH1R	-0.42	-6.1	-0.36	4.15e-9	Colorectal cancer;
KIRP	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg22283653	chr8:49824208	NA	0.46	6.51	0.38	4.28e-10	Sudden cardiac arrest;
KIRP	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.72	-6.06	-0.36	5.21e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.54	-0.38	3.61e-10	Neuroticism;
KIRP	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg16917193	chr12:54089295	NA	1.01	21.82	0.81	1.84e-59	Height;
KIRP	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.75	-9.2	-0.51	1.61e-17	Personality dimensions;
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg12705353	chr12:122356852	WDR66	0.47	6.27	0.37	1.59e-9	Mean corpuscular volume;
KIRP	cis	rs9398803	0.865	rs1120786	chr6:126808637	T/G	cg19875578	chr6:126661172	C6orf173	0.51	6.6	0.39	2.47e-10	Male-pattern baldness;
KIRP	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.56	-7.46	-0.43	1.49e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg00647317	chr7:50633725	DDC	-0.46	-6.16	-0.37	2.94e-9	Malaria;
KIRP	cis	rs9400467	0.537	rs12212282	chr6:111524838	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.56	5.27	0.32	2.95e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg12369402	chr1:90227771	NA	-0.36	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.48	5.0	0.3	1.09e-6	Type 2 diabetes;
KIRP	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg23788917	chr6:8435910	SLC35B3	-0.67	-8.66	-0.48	6.13e-16	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10339542	chr17:10600919	C17orf48;SCO1	0.5	6.53	0.38	3.72e-10	Parkinson's disease;
KIRP	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg18132916	chr6:79620363	NA	-0.41	-5.81	-0.35	1.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg05527609	chr1:210001259	C1orf107	-0.53	-5.75	-0.34	2.63e-8	Red blood cell count;
KIRP	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg05130518	chr13:21295590	IL17D	-0.39	-4.9	-0.3	1.77e-6	Dental caries;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg22907277	chr7:1156413	C7orf50	0.86	8.16	0.46	1.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs554111	0.891	rs659046	chr1:21047725	C/T	cg21184320	chr1:21044207	KIF17	-0.46	-6.89	-0.4	4.65e-11	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg15934090	chr1:100435551	SLC35A3	0.52	6.47	0.38	5.26e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg05315796	chr3:52349193	DNAH1	0.43	6.48	0.38	5.01e-10	Bipolar disorder;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg18671773	chr5:141016477	RELL2;HDAC3	0.47	6.06	0.36	4.98e-9	Myopia (pathological);
KIRP	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.99	9.64	0.52	7.53e-19	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg25182066	chr10:30743637	MAP3K8	-0.78	-10.29	-0.55	6.9299999999999992e-21	Inflammatory bowel disease;
KIRP	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg16306078	chr6:126000798	NA	-0.27	-5.09	-0.31	7e-7	Endometrial cancer;
KIRP	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg16179182	chr5:140090404	VTRNA1-1	-0.56	-7.74	-0.44	2.57e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.94	-10.66	-0.56	4.61e-22	Response to antineoplastic agents;
KIRP	cis	rs4713118	0.662	rs149947	chr6:27972433	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.46	-4.95	-0.3	1.39e-6	Parkinson's disease;
KIRP	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.5	6.77	0.4	9.29e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1010254	0.559	rs72808310	chr5:151730307	T/C	cg12297329	chr5:152029980	NA	-0.57	-5.99	-0.36	7.5e-9	Optic nerve measurement (cup area);
KIRP	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs1318772	1.000	rs13162970	chr5:112733357	T/G	cg12552261	chr5:112820674	MCC	0.78	4.97	0.3	1.26e-6	F-cell distribution;
KIRP	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg10755058	chr3:40428713	ENTPD3	-0.42	-5.97	-0.36	8.41e-9	Renal cell carcinoma;
KIRP	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.44	5.97	0.36	8.11e-9	Total body bone mineral density;
KIRP	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-7.22	-0.42	6.59e-12	Vitamin D levels;
KIRP	cis	rs11593576	0.861	rs10824732	chr10:81009788	G/A	cg18737081	chr10:80999807	ZMIZ1	-0.33	-5.2	-0.31	4.14e-7	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27487227	chr17:77813221	CBX4	0.5	6.18	0.37	2.59e-9	Parkinson's disease;
KIRP	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg17724175	chr1:150552817	MCL1	-0.43	-7.13	-0.41	1.09e-11	Blood protein levels;
KIRP	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.55	7.34	0.42	3.07e-12	Height;
KIRP	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg09455208	chr3:40491958	NA	0.32	5.79	0.35	2.14e-8	Renal cell carcinoma;
KIRP	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg16606324	chr3:10149918	C3orf24	0.57	5.26	0.32	3.06e-7	Alzheimer's disease;
KIRP	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg00409905	chr10:38381863	ZNF37A	-0.58	-7.94	-0.45	7.36e-14	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.65	8.91	0.49	1.21e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg04369109	chr6:150039330	LATS1	-0.43	-5.12	-0.31	6.22e-7	Lung cancer;
KIRP	cis	rs4262150	0.883	rs111770575	chr5:152242327	C/T	cg12297329	chr5:152029980	NA	-0.61	-7.69	-0.44	3.58e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	8.25	0.47	9.43e-15	Retinal vascular caliber;
KIRP	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg09165964	chr15:75287851	SCAMP5	-0.36	-4.84	-0.3	2.25e-6	Systemic lupus erythematosus;
KIRP	cis	rs3741151	1.000	rs79078097	chr11:73049771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.87	7.14	0.41	1.03e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.62	5.9	0.35	1.22e-8	Menarche (age at onset);
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.32	0.47	6.21e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.33	12.07	0.61	1.14e-26	Diabetic retinopathy;
KIRP	cis	rs220519	0.757	rs4812127	chr20:37280356	T/G	cg24308336	chr20:37270989	C20orf95	0.23	5.15	0.31	5.37e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20595490	chr2:149215642	MBD5	-0.42	-6.64	-0.39	1.98e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg21360079	chr12:107162445	NA	-0.65	-9.52	-0.52	1.71e-18	Heart rate;
KIRP	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.57	-0.39	2.95e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.68	-9.15	-0.5	2.29e-17	Eye color traits;
KIRP	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17691542	chr6:26056736	HIST1H1C	0.52	6.6	0.39	2.55e-10	Height;
KIRP	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg01689657	chr7:91764605	CYP51A1	0.41	5.85	0.35	1.59e-8	Breast cancer;
KIRP	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.59	-7.83	-0.45	1.43e-13	Mean corpuscular volume;
KIRP	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg06521331	chr12:34319734	NA	-0.48	-5.99	-0.36	7.3e-9	Morning vs. evening chronotype;
KIRP	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg09990169	chr2:241835740	C2orf54	-0.45	-6.8	-0.4	7.86e-11	Urinary metabolites;
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg18052443	chr1:65431702	JAK1	-0.44	-6.09	-0.36	4.33e-9	Type 1 diabetes;
KIRP	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-1.07	-10.29	-0.55	6.96e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.73	0.34	2.86e-8	Motion sickness;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17504765	chr4:96300958	UNC5C	-0.43	-6.65	-0.39	1.88e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9473924	0.542	rs2744504	chr6:50798668	G/C	cg14470998	chr6:50812995	TFAP2B	0.99	8.93	0.49	1.01e-16	Body mass index;
KIRP	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04004882	chr2:215674386	BARD1	0.82	7.83	0.45	1.45e-13	Neuroblastoma;
KIRP	cis	rs4845459	0.967	rs4845447	chr1:152590886	T/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.05	-0.36	5.24e-9	Psoriasis;
KIRP	cis	rs11671005	0.735	rs3764532	chr19:58929222	G/A	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg19847130	chr8:10466454	RP1L1	-0.37	-5.64	-0.34	4.68e-8	Retinal vascular caliber;
KIRP	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg03289416	chr15:75166202	SCAMP2	-0.45	-6.25	-0.37	1.78e-9	Breast cancer;
KIRP	cis	rs7937612	0.931	rs12417581	chr11:120216906	T/A	cg24566217	chr11:120254723	ARHGEF12	-0.48	-6.88	-0.4	4.98e-11	Intraocular pressure;
KIRP	cis	rs72925845	0.577	rs618842	chr17:76429696	G/A	cg03830375	chr17:76426088	DNAH17	0.5	5.14	0.31	5.61e-7	Triglycerides;
KIRP	cis	rs2494663	0.610	rs11265040	chr1:154055579	G/A	cg09895920	chr1:153941186	CREB3L4;SLC39A1	-0.35	-5.1	-0.31	6.7e-7	Mean platelet volume;
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg15147215	chr3:52552868	STAB1	-0.33	-5.85	-0.35	1.59e-8	Electroencephalogram traits;
KIRP	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg06795125	chr2:108905320	SULT1C2	-0.46	-7.9	-0.45	9.38e-14	Blood pressure;
KIRP	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.81	-11.32	-0.59	3.36e-24	Primary tooth development (time to first tooth eruption);
KIRP	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.55	7.23	0.42	6.22e-12	Menarche (age at onset);
KIRP	cis	rs17123764	0.892	rs60094911	chr12:50120288	C/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.47	0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg26207909	chr14:103986467	CKB	-0.52	-6.53	-0.38	3.65e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs812925	0.784	rs6735081	chr2:61460717	C/T	cg15711740	chr2:61764176	XPO1	0.44	4.95	0.3	1.39e-6	Immature fraction of reticulocytes;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg00185336	chr7:73153699	ABHD11	0.7	6.02	0.36	6.43e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs4791746	1.000	rs7219141	chr17:8626010	G/T	cg03115937	chr17:8649504	CCDC42	0.46	5.84	0.35	1.68e-8	Heroin dependence;
KIRP	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg01620082	chr3:125678407	NA	-0.85	-6.05	-0.36	5.31e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg26513180	chr16:89883248	FANCA	0.74	5.13	0.31	5.99e-7	Skin colour saturation;
KIRP	cis	rs6601327	0.635	rs10112972	chr8:9655218	T/A	cg27411982	chr8:10470053	RP1L1	-0.39	-5.0	-0.3	1.09e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.01	-16.32	-0.72	4.43e-41	Dilated cardiomyopathy;
KIRP	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.33	-5.62	-0.34	5.15e-8	Height;
KIRP	cis	rs7794364	0.658	rs12154872	chr7:117512932	A/G	cg21880328	chr7:117514017	CTTNBP2	-0.36	-5.34	-0.32	2.16e-7	Idiopathic osteonecrosis of the femoral head;
KIRP	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.92	-14.33	-0.67	2.8e-34	Calcium levels;
KIRP	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.55	-5.76	-0.34	2.55e-8	Chronic sinus infection;
KIRP	cis	rs2944755	1.000	rs2944755	chr8:141574194	A/G	cg26074100	chr8:141568712	EIF2C2	-0.46	-6.23	-0.37	2.05e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg21285383	chr16:89894308	SPIRE2	0.32	5.95	0.35	8.97e-9	Vitiligo;
KIRP	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.66	-7.8	-0.45	1.8e-13	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.07	11.94	0.61	3.29e-26	Vitiligo;
KIRP	trans	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg06521331	chr12:34319734	NA	-0.5	-6.22	-0.37	2.17e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10073892	0.664	rs10072508	chr5:101878621	C/G	cg19774478	chr5:101632501	SLCO4C1	0.6	5.91	0.35	1.16e-8	Cognitive decline (age-related);
KIRP	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg24747557	chr10:131355152	MGMT	0.39	5.14	0.31	5.55e-7	Response to temozolomide;
KIRP	cis	rs36715	0.909	rs152906	chr5:127551840	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	8.82	0.49	2.12e-16	Breast cancer;
KIRP	cis	rs4494114	0.967	rs9439083	chr1:39344766	C/T	cg25970120	chr1:39325951	RRAGC	-0.4	-5.03	-0.31	9.38e-7	Blood protein levels;
KIRP	cis	rs4776059	0.958	rs933860	chr15:52965468	T/C	cg22715398	chr15:52968154	KIAA1370	-0.67	-7.89	-0.45	9.68e-14	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.17	0.31	4.91e-7	Personality dimensions;
KIRP	cis	rs9463078	0.547	rs1418434	chr6:44748365	C/T	cg25276700	chr6:44698697	NA	-0.35	-5.09	-0.31	7.01e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg05692746	chr2:100937584	LONRF2	-0.39	-5.03	-0.31	9.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10121009	0.635	rs513002	chr9:35321690	G/T	cg15271616	chr9:35490515	RUSC2	0.36	4.87	0.3	2.03e-6	Parkinson's disease;
KIRP	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg04374321	chr14:90722782	PSMC1	-0.62	-8.31	-0.47	6.51e-15	Mortality in heart failure;
KIRP	cis	rs861020	0.916	rs669694	chr1:209950760	C/G	cg09163369	chr1:210001066	C1orf107	0.5	5.36	0.32	1.93e-7	Orofacial clefts;
KIRP	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg03788504	chr6:150331562	NA	-0.32	-5.92	-0.35	1.08e-8	Alopecia areata;
KIRP	cis	rs2637030	0.515	rs256103	chr5:53012475	A/G	cg06476337	chr5:52856530	NDUFS4	0.55	5.93	0.35	1.01e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs6132905	0.590	rs80091120	chr20:2617674	G/A	cg24848351	chr20:2622020	TMC2	-0.59	-5.24	-0.32	3.38e-7	Mumps;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.3.97157383F	chr3:95674693	NA	0.41	6.12	0.36	3.63e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg22705602	chr4:152727874	NA	0.53	9.18	0.51	1.78e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.79	8.99	0.5	6.54e-17	Corneal astigmatism;
KIRP	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.77	12.02	0.61	1.7e-26	Colorectal cancer;
KIRP	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg21984481	chr17:79567631	NPLOC4	-0.36	-5.08	-0.31	7.52e-7	Myopia;
KIRP	cis	rs11264213	0.901	rs6665591	chr1:36411737	A/G	cg27506609	chr1:36549197	TEKT2	0.92	9.62	0.52	8.38e-19	Schizophrenia;
KIRP	cis	rs17123764	0.605	rs12303310	chr12:50065993	G/C	cg02054252	chr12:50078554	FMNL3	0.46	5.29	0.32	2.75e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	7.75	0.44	2.35e-13	Neuroticism;
KIRP	cis	rs2235642	0.551	rs1966171	chr16:1562804	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.2	-4.87	-0.3	1.99e-6	Coronary artery disease;
KIRP	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	1.05	7.75	0.44	2.46e-13	Blood protein levels;
KIRP	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.84	9.77	0.53	2.82e-19	Multiple sclerosis;
KIRP	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	cg12689670	chr1:183009347	LAMC1	0.47	6.47	0.38	5.18e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7246657	0.678	rs2972446	chr19:38129893	G/A	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs520865	0.786	rs567914	chr5:80345602	C/T	cg17330048	chr5:80257322	RASGRF2	-0.44	-6.37	-0.38	9.04e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	1.16	12.17	0.61	5.71e-27	Post bronchodilator FEV1;
KIRP	cis	rs9534288	0.912	rs9526135	chr13:46624992	G/C	cg15192986	chr13:46630673	CPB2	-0.83	-10.14	-0.54	2.09e-20	Blood protein levels;
KIRP	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg26513180	chr16:89883248	FANCA	-0.57	-6.93	-0.4	3.61e-11	Vitiligo;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg19816938	chr17:1082526	ABR	0.47	6.13	0.36	3.55e-9	Sleep duration;
KIRP	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25833597	chr17:30823145	MYO1D	0.5	6.6	0.39	2.54e-10	Schizophrenia;
KIRP	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg04691961	chr3:161091175	C3orf57	-0.48	-7.21	-0.42	6.97e-12	Morning vs. evening chronotype;
KIRP	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.57	7.14	0.41	1.04e-11	Glomerular filtration rate (creatinine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26550872	chr12:69656319	CPSF6	-0.49	-7.57	-0.43	7.51e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	6.16	0.37	2.98e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg24583131	chr6:18265189	DEK	0.74	6.88	0.4	4.95e-11	Lung function (FEV1);
KIRP	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.63	0.34	4.79e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs867371	1.000	rs8041868	chr15:82472326	C/T	cg06066596	chr15:83166174	LOC80154	-0.46	-5.41	-0.33	1.47e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs240764	0.658	rs9322212	chr6:101248474	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-5.09	-0.31	7.14e-7	Neuroticism;
KIRP	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.13	-0.69	5.28e-37	Headache;
KIRP	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg05315796	chr3:52349193	DNAH1	0.53	8.28	0.47	7.94e-15	Bipolar disorder;
KIRP	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg13679303	chr9:96623674	NA	-0.46	-6.39	-0.38	8.35e-10	DNA methylation (variation);
KIRP	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.85	12.32	0.62	1.74e-27	Eye color traits;
KIRP	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.64	7.81	0.45	1.64e-13	Vitiligo;
KIRP	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg02367723	chr1:46378857	MAST2	-0.43	-4.9	-0.3	1.75e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg05347473	chr6:146136440	FBXO30	-0.47	-6.64	-0.39	1.94e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.62	-6.6	-0.39	2.49e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.61	5.18	0.31	4.61e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	6.37	0.38	9.34e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.88	-11.21	-0.58	8.01e-24	Breast cancer;
KIRP	cis	rs6700559	0.605	rs11802836	chr1:200593155	T/C	cg07804481	chr1:200639085	DDX59	0.39	5.03	0.31	9.51e-7	Coronary artery disease;
KIRP	cis	rs75064307	0.559	rs4855643	chr3:108084900	C/T	cg14703454	chr3:108065259	HHLA2	0.44	5.66	0.34	4.19e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs11541718	chr14:103852164	C/G	cg16497661	chr14:103986332	CKB	-0.51	-6.29	-0.37	1.48e-9	Coronary artery disease;
KIRP	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.25	6.69	0.39	1.52e-10	Crohn's disease;
KIRP	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.67	7.9	0.45	9.49e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs35740288	0.770	rs11638278	chr15:86211404	C/T	cg17133734	chr15:86042851	AKAP13	-0.5	-5.5	-0.33	9.27e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.43	0.38	6.48e-10	Retinal vascular caliber;
KIRP	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-8.19	-0.46	1.44e-14	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7175404	0.793	rs16948103	chr15:94034180	A/G	cg23502883	chr15:93959149	NA	-0.45	-5.35	-0.32	2e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs4236601	0.720	rs1052990	chr7:116148370	T/G	cg12739419	chr7:116140593	CAV2	0.45	5.57	0.33	6.52e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.67	-6.59	-0.39	2.6e-10	Psoriasis vulgaris;
KIRP	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.24	-24.64	-0.84	2.24e-68	Exhaled nitric oxide output;
KIRP	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs9912468	0.568	rs8079676	chr17:64236953	A/G	cg19474267	chr17:64306194	PRKCA	-0.4	-5.13	-0.31	5.81e-7	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.79	9.94	0.54	8.47e-20	Sudden cardiac arrest;
KIRP	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg07701084	chr6:150067640	NUP43	0.61	7.95	0.45	6.72e-14	Lung cancer;
KIRP	cis	rs12580194	0.593	rs61556775	chr12:55745640	A/C	cg11794356	chr12:55725991	OR6C3	-0.53	-7.09	-0.41	1.41e-11	Cancer;
KIRP	cis	rs876084	0.722	rs6469893	chr8:121045000	T/C	cg06265175	chr8:121136014	COL14A1	0.44	5.0	0.3	1.09e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.5	8.35	0.47	4.84e-15	Erythrocyte sedimentation rate;
KIRP	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg21132104	chr15:45694354	SPATA5L1	0.77	9.61	0.52	8.89e-19	Homoarginine levels;
KIRP	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg18764771	chr6:116381957	FRK	0.19	5.33	0.32	2.17e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg04691961	chr3:161091175	C3orf57	0.45	6.27	0.37	1.63e-9	Morning vs. evening chronotype;
KIRP	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.42	0.38	7.15e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.21	-0.46	1.22e-14	Cutaneous nevi;
KIRP	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.6	-8.66	-0.48	6.31e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg25358565	chr5:93447407	FAM172A	0.58	6.92	0.4	3.88e-11	Diabetic retinopathy;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg09132121	chr2:178981007	RBM45	0.41	6.27	0.37	1.63e-9	Migraine with aura;
KIRP	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.26	-0.32	3.06e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs8077577	0.895	rs62073615	chr17:18080329	T/A	cg18869244	chr17:18121946	NA	0.47	5.18	0.31	4.67e-7	Obesity-related traits;
KIRP	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.57	6.88	0.4	4.95e-11	Osteoporosis;
KIRP	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.64	-7.43	-0.43	1.83e-12	DNA methylation (variation);
KIRP	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg12573674	chr2:1569213	NA	-0.56	-5.05	-0.31	8.42e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg24488311	chr11:68621650	NA	0.41	5.03	0.31	9.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7665939	0.860	rs72709297	chr4:190144354	T/C	cg14840187	chr4:190284988	NA	-0.97	-6.38	-0.38	8.52e-10	Amyotrophic lateral sclerosis;
KIRP	cis	rs4728302	0.574	rs7804463	chr7:133447651	T/C	cg10665199	chr7:133106180	EXOC4	0.46	5.78	0.35	2.28e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08134592	chr11:1007447	AP2A2	0.4	6.43	0.38	6.58e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg00800038	chr16:89945340	TCF25	-0.78	-5.27	-0.32	3.04e-7	Skin colour saturation;
KIRP	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.78	-11.29	-0.58	4.36e-24	Blood metabolite levels;
KIRP	cis	rs9826463	0.582	rs11707154	chr3:142077131	A/T	cg20824294	chr3:142316082	PLS1	0.44	6.51	0.38	4.17e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs501120	0.564	rs11238905	chr10:44685136	T/A	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-4.96	-0.3	1.33e-6	Cognitive function;
KIRP	cis	rs4908768	0.871	rs7553298	chr1:8770883	A/G	cg03610117	chr1:8450231	RERE	-0.42	-4.88	-0.3	1.95e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs3789045	0.774	rs12028476	chr1:204476361	G/A	cg18185008	chr1:204589407	LRRN2	-0.6	-6.56	-0.39	3.06e-10	Educational attainment (college completion);
KIRP	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.45	6.47	0.38	5.32e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg11130432	chr3:121712080	ILDR1	-0.43	-5.08	-0.31	7.62e-7	Multiple sclerosis;
KIRP	cis	rs4654899	0.802	rs9651021	chr1:21222770	A/C	cg05370193	chr1:21551575	ECE1	0.41	5.34	0.32	2.12e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	6.02	0.36	6.3e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg10381502	chr11:71823885	C11orf51	-1.2	-7.89	-0.45	9.82e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.64	8.39	0.47	3.93e-15	Blood protein levels;
KIRP	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.54	-0.62	3.22e-28	Primary sclerosing cholangitis;
KIRP	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.33	11.96	0.61	2.69e-26	Diabetic retinopathy;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg26683316	chr17:37886653	C17orf37	-0.48	-6.08	-0.36	4.55e-9	Blood metabolite levels;
KIRP	cis	rs5753618	0.561	rs5753543	chr22:31685458	G/A	cg02404636	chr22:31891804	SFI1	-0.49	-5.42	-0.33	1.4e-7	Colorectal cancer;
KIRP	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg10047753	chr17:41438598	NA	1.16	18.73	0.77	3.12e-49	Menopause (age at onset);
KIRP	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.81	0.35	1.94e-8	Morning vs. evening chronotype;
KIRP	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg08742575	chr21:47604166	C21orf56	-0.38	-5.08	-0.31	7.31e-7	Testicular germ cell tumor;
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg03115019	chr17:80708279	FN3K	0.41	4.87	0.3	1.99e-6	Glycated hemoglobin levels;
KIRP	cis	rs9843304	0.616	rs4681174	chr3:149201626	G/A	cg08667024	chr3:149219783	TM4SF4	-0.44	-6.24	-0.37	1.87e-9	Gallstone disease;
KIRP	cis	rs2625529	0.712	rs2054601	chr15:72184968	T/C	cg16672083	chr15:72433130	SENP8	-0.5	-6.23	-0.37	1.98e-9	Red blood cell count;
KIRP	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.75	9.46	0.52	2.57e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-1.06	-16.62	-0.73	4.35e-42	Gut microbiome composition (winter);
KIRP	cis	rs12447804	0.871	rs2118018	chr16:58076422	A/G	cg03859792	chr16:58121049	NA	0.45	5.99	0.36	7.36e-9	Pulmonary function;Pulmonary function (smoking interaction);
KIRP	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.62	6.69	0.39	1.46e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs8114671	0.933	rs6142327	chr20:33793147	T/A	cg07148914	chr20:33460835	GGT7	-0.41	-5.16	-0.31	5.18e-7	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08555325	chr12:77272758	CSRP2	0.54	6.78	0.4	9.09e-11	Parkinson's disease;
KIRP	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg13736514	chr6:26305472	NA	-0.72	-9.61	-0.52	8.81e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg14458575	chr2:238380390	NA	0.57	6.08	0.36	4.54e-9	Prostate cancer;
KIRP	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg04036182	chr15:45458818	NA	-0.46	-6.15	-0.37	3.04e-9	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs3829109	0.564	rs4307444	chr9:139279634	C/T	cg14169450	chr9:139327907	INPP5E	0.61	6.97	0.41	2.96e-11	Peak insulin response;Acute insulin response;
KIRP	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg08992911	chr2:238395768	MLPH	0.41	5.19	0.31	4.4e-7	Prostate cancer;
KIRP	cis	rs73200209	0.744	rs11614312	chr12:116694851	A/G	cg01776926	chr12:116560359	MED13L	0.55	6.13	0.36	3.51e-9	Total body bone mineral density;
KIRP	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.67	6.32	0.37	1.19e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.34	0.62	1.45e-27	Ileal carcinoids;
KIRP	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg00576331	chr11:65640516	EFEMP2	-0.5	-5.56	-0.33	6.98e-8	Crohn's disease;
KIRP	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.39	5.57	0.33	6.71e-8	Ovarian reserve;
KIRP	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.45	5.92	0.35	1.07e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg10326726	chr10:51549505	MSMB	-0.64	-8.46	-0.47	2.38e-15	Prostate-specific antigen levels;
KIRP	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg07884673	chr3:53033167	SFMBT1	0.62	5.67	0.34	4.04e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs13053817	0.898	rs7291001	chr22:29857859	C/G	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.43	-5.28	-0.32	2.84e-7	Carotid atherosclerosis in HIV infection;
KIRP	trans	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.75	-11.0	-0.57	3.77e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.77	9.38	0.51	4.45e-18	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg11031976	chr2:198649780	BOLL	-0.48	-4.95	-0.3	1.35e-6	Ulcerative colitis;
KIRP	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg16141378	chr3:129829833	LOC729375	-0.54	-7.08	-0.41	1.48e-11	Neuroticism;
KIRP	cis	rs1009181	1.000	rs1009181	chr6:26158993	C/T	cg00631329	chr6:26305371	NA	0.49	5.95	0.35	9.33e-9	Childhood ear infection;
KIRP	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.81	12.38	0.62	1.07e-27	Ulcerative colitis;
KIRP	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17554472	chr22:41940697	POLR3H	0.6	6.51	0.38	4.21e-10	Vitiligo;
KIRP	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg04733989	chr22:42467013	NAGA	-0.58	-7.75	-0.44	2.37e-13	Cognitive function;
KIRP	cis	rs1448094	0.967	rs7974794	chr12:86323280	A/G	cg00310523	chr12:86230176	RASSF9	0.37	5.67	0.34	4.08e-8	Major depressive disorder;
KIRP	cis	rs7714584	1.000	rs7724558	chr5:150328866	T/C	cg22134413	chr5:150180641	NA	0.64	5.02	0.3	9.99e-7	Crohn's disease;
KIRP	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.91	14.69	0.68	1.68e-35	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg18806716	chr10:30721971	MAP3K8	-0.3	-4.91	-0.3	1.64e-6	Inflammatory bowel disease;
KIRP	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.5	7.15	0.41	9.65e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg05163923	chr11:71159392	DHCR7	0.71	7.25	0.42	5.31e-12	Vitamin D levels;
KIRP	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg21775007	chr8:11205619	TDH	0.72	10.48	0.56	1.79e-21	Retinal vascular caliber;
KIRP	cis	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg08773314	chr2:239334832	ASB1	-0.54	-5.43	-0.33	1.33e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg03714773	chr7:91764589	CYP51A1	-0.33	-4.88	-0.3	1.94e-6	Breast cancer;
KIRP	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg18190219	chr22:46762943	CELSR1	-0.87	-8.2	-0.46	1.33e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg21684588	chr1:67600265	NA	0.5	5.71	0.34	3.23e-8	Psoriasis;
KIRP	cis	rs6963495	0.556	rs711433	chr7:105153191	A/G	cg19920283	chr7:105172520	RINT1	-0.49	-5.79	-0.35	2.15e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4356932	0.967	rs4432767	chr4:76981312	A/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg21466736	chr12:48725269	NA	-0.46	-5.76	-0.34	2.56e-8	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.7	-7.15	-0.41	1.01e-11	Body mass index;
KIRP	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-5.64	-0.34	4.56e-8	Neuroticism;
KIRP	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.49	-6.22	-0.37	2.17e-9	Body mass index;
KIRP	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.52	-6.58	-0.39	2.82e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg02996583	chr8:142237188	SLC45A4	0.51	6.25	0.37	1.78e-9	Immature fraction of reticulocytes;
KIRP	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg12756093	chr1:115239321	AMPD1	0.52	7.01	0.41	2.34e-11	Autism;
KIRP	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.62	8.14	0.46	2.04e-14	Total cholesterol levels;
KIRP	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg27490568	chr2:178487706	NA	0.52	6.87	0.4	5.17e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg06819605	chr1:977003	AGRN	0.55	7.09	0.41	1.44e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19699250	chr11:124746323	ROBO3	-0.46	-6.11	-0.36	3.96e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs13401104	0.796	rs57900956	chr2:237119214	C/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs2224391	0.590	rs9405813	chr6:5251850	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-5.65	-0.34	4.35e-8	Height;
KIRP	cis	rs6977660	0.619	rs2158379	chr7:19783977	A/G	cg05791153	chr7:19748676	TWISTNB	0.56	5.83	0.35	1.75e-8	Thyroid stimulating hormone;
KIRP	cis	rs1903068	1.000	rs9312658	chr4:56005526	C/A	cg20092376	chr4:56023423	NA	0.41	5.06	0.31	8.23e-7	Endometriosis;
KIRP	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.39	-6.44	-0.38	6.23e-10	Age at first birth;
KIRP	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.18	-0.42	8.35e-12	Hemoglobin concentration;
KIRP	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg18154014	chr19:37997991	ZNF793	0.77	7.88	0.45	1.05e-13	Coronary artery calcification;
KIRP	cis	rs56399783	0.901	rs17132744	chr7:2874982	T/C	cg19731401	chr7:2775893	GNA12	0.67	6.78	0.4	8.85e-11	Childhood ear infection;
KIRP	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.75	11.32	0.59	3.32e-24	Blood metabolite ratios;
KIRP	cis	rs2905347	0.560	rs2961291	chr7:22681504	C/T	cg23521230	chr7:22704884	NA	0.41	5.06	0.31	8.02e-7	Major depression and alcohol dependence;
KIRP	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.5	-7.41	-0.43	1.98e-12	Diastolic blood pressure;
KIRP	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.1	-0.31	6.9e-7	Bladder cancer;
KIRP	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg09699651	chr6:150184138	LRP11	0.46	5.8	0.35	2.05e-8	Lung cancer;
KIRP	cis	rs745080	0.674	rs11850114	chr14:52950645	T/G	cg23333723	chr14:53022898	GPR137C	-0.39	-5.48	-0.33	1.04e-7	Orofacial clefts;
KIRP	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.65	5.84	0.35	1.68e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	8.62	0.48	8.48e-16	Lung cancer in ever smokers;
KIRP	cis	rs1971762	1.000	rs10783594	chr12:54067135	A/C	cg16917193	chr12:54089295	NA	0.69	9.15	0.5	2.25e-17	Height;
KIRP	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg13271783	chr10:134563150	INPP5A	-0.56	-7.26	-0.42	5.09e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.28	0.32	2.78e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.52	-5.7	-0.34	3.41e-8	Breast cancer;
KIRP	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.81	10.82	0.57	1.4e-22	Breast cancer;
KIRP	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.8	12.46	0.62	5.93e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	5.22	0.32	3.79e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg21775007	chr8:11205619	TDH	-0.67	-9.43	-0.52	3.26e-18	Retinal vascular caliber;
KIRP	trans	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19894588	chr14:64061835	NA	0.5	6.81	0.4	7.32e-11	Glioblastoma;Glioma;
KIRP	cis	rs7127900	1.000	rs6579000	chr11:2232042	C/T	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	trans	rs9650657	0.746	rs4841441	chr8:10630898	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.35	-0.38	1.02e-9	Neuroticism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02781660	chr15:58358775	ALDH1A2	0.47	6.2	0.37	2.35e-9	Smoking initiation;
KIRP	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-6.66	-0.39	1.77e-10	Gut microbiome composition (summer);
KIRP	cis	rs3762637	1.000	rs6777596	chr3:122133321	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-5.82	-0.35	1.83e-8	LDL cholesterol levels;
KIRP	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	0.75	10.92	0.57	6.82e-23	Prudent dietary pattern;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08330117	chr8:90770456	RIPK2	0.59	7.24	0.42	5.74e-12	Smoking initiation;
KIRP	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg11608241	chr8:8085544	FLJ10661	0.4	5.02	0.31	9.69e-7	Mood instability;
KIRP	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.53	6.68	0.39	1.55e-10	Height;
KIRP	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.69	0.44	3.46e-13	Obesity-related traits;
KIRP	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	5.07	0.31	7.88e-7	Leprosy;
KIRP	cis	rs6725041	0.819	rs4563169	chr2:213090274	G/A	cg20637307	chr2:213403960	ERBB4	-0.4	-5.2	-0.31	4.17e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg10017260	chr10:834428	NA	-0.5	-5.18	-0.31	4.73e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg15764593	chr10:829463	NA	-0.78	-8.43	-0.47	3.03e-15	Uric acid levels;
KIRP	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	0.79	6.99	0.41	2.64e-11	Obesity-related traits;
KIRP	cis	rs55675132	0.548	rs79671603	chr1:115377698	A/T	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs9584850	0.540	rs61969407	chr13:99119160	C/T	cg20750642	chr13:99100586	FARP1	-0.62	-6.42	-0.38	6.8e-10	Neuroticism;
KIRP	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg15534755	chr11:117069859	TAGLN	0.4	5.11	0.31	6.39e-7	Blood protein levels;
KIRP	cis	rs6088813	1.000	rs6142373	chr20:33983314	T/A	cg14752227	chr20:34000481	UQCC	-0.5	-6.54	-0.39	3.47e-10	Height;
KIRP	trans	rs35100037	0.803	rs62398840	chr5:128611288	T/C	cg23338408	chr14:31289523	NA	-0.61	-6.23	-0.37	2.02e-9	Ankle injury;
KIRP	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.44	-5.34	-0.32	2.16e-7	Testicular germ cell tumor;
KIRP	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.63	7.14	0.41	1.03e-11	Aortic root size;
KIRP	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10489525	0.599	rs34710929	chr1:115606608	G/A	cg01522456	chr1:115632236	TSPAN2	0.51	6.86	0.4	5.43e-11	Autism;
KIRP	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg05623727	chr3:50126028	RBM5	-0.36	-5.23	-0.32	3.7e-7	Body mass index;
KIRP	cis	rs986417	1.000	rs1254292	chr14:60863636	T/C	cg27398547	chr14:60952738	C14orf39	-0.74	-7.41	-0.43	2.01e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-7.52	-0.43	1.05e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.31	-0.32	2.4e-7	Headache;
KIRP	cis	rs4742903	1.000	rs4742905	chr9:106856972	G/C	cg14250997	chr9:106856677	SMC2	0.4	5.18	0.31	4.7e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10714403	chr17:55162284	AKAP1	0.49	6.19	0.37	2.5e-9	Parkinson's disease;
KIRP	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4132509	0.843	rs6671475	chr1:243789342	A/G	cg21452805	chr1:244014465	NA	0.52	5.28	0.32	2.88e-7	RR interval (heart rate);
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg04804543	chr8:142233427	SLC45A4	1.01	17.46	0.74	5.76e-45	Immature fraction of reticulocytes;
KIRP	cis	rs4262150	0.544	rs17549488	chr5:151917354	C/A	cg12297329	chr5:152029980	NA	-0.7	-8.69	-0.48	5.12e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7680126	0.633	rs11737564	chr4:10244470	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-4.85	-0.3	2.18e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs11605924	0.934	rs7945689	chr11:45879006	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.54	-6.82	-0.4	6.83e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2273669	0.915	rs4992382	chr6:109292826	T/A	cg05315195	chr6:109294784	ARMC2	-0.48	-5.5	-0.33	9.66e-8	Prostate cancer;
KIRP	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-0.91	-11.78	-0.6	1.11e-25	Blood protein levels;
KIRP	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.87	14.03	0.67	2.89e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg00800038	chr16:89945340	TCF25	-0.75	-5.31	-0.32	2.47e-7	Skin colour saturation;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23988827	chr10:69676715	SIRT1	0.4	6.29	0.37	1.44e-9	Migraine with aura;
KIRP	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.93	9.57	0.52	1.22e-18	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	0.85	10.54	0.56	1.09e-21	Prostate cancer;
KIRP	cis	rs6838801	0.892	rs28568554	chr4:77576016	T/G	cg17476223	chr4:77663285	SHROOM3	0.55	7.96	0.45	6.17e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs580438	0.569	rs354477	chr3:13359433	G/A	cg10657019	chr3:13328039	NA	0.52	6.68	0.39	1.56e-10	Myringotomy;
KIRP	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.77	-0.49	2.98e-16	Total cholesterol levels;
KIRP	trans	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.93	15.62	0.71	1.14e-38	Metabolic syndrome;
KIRP	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.97	-0.3	1.27e-6	Resting heart rate;
KIRP	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.83	-0.45	1.41e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.84	12.12	0.61	7.84e-27	Eye color traits;
KIRP	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.88	-11.02	-0.58	3.12e-23	Blood protein levels;
KIRP	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.54	-0.43	9.2e-13	Neuroticism;
KIRP	cis	rs7534824	0.582	rs61780297	chr1:101400855	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.83	0.35	1.7e-8	Refractive astigmatism;
KIRP	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg05692746	chr2:100937584	LONRF2	-0.39	-5.03	-0.31	9.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7998202	0.667	rs282579	chr13:113358436	G/C	cg04656015	chr13:113407548	ATP11A	-0.5	-5.37	-0.32	1.8e-7	Glycated hemoglobin levels;
KIRP	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg27494647	chr7:150038898	RARRES2	0.36	5.53	0.33	8.27e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg18225595	chr11:63971243	STIP1	0.64	5.84	0.35	1.68e-8	Mean platelet volume;
KIRP	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.42	-5.22	-0.32	3.78e-7	Aortic root size;
KIRP	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg13444842	chr1:152974279	SPRR3	-0.43	-6.19	-0.37	2.46e-9	Inflammatory skin disease;
KIRP	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.68	8.16	0.46	1.7e-14	Post bronchodilator FEV1;
KIRP	cis	rs6681460	0.966	rs6588215	chr1:67141949	A/G	cg13052034	chr1:66999238	SGIP1	0.47	6.57	0.39	2.98e-10	Presence of antiphospholipid antibodies;
KIRP	trans	rs10861905	0.826	rs10492256	chr12:108777208	G/C	cg10780718	chr1:234616222	TARBP1	-0.72	-6.05	-0.36	5.37e-9	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.92	10.53	0.56	1.2e-21	Corneal astigmatism;
KIRP	cis	rs2963155	0.518	rs72801080	chr5:142751990	T/C	cg17617527	chr5:142782415	NR3C1	0.77	6.58	0.39	2.73e-10	Breast cancer;
KIRP	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-5.01	-0.3	1.02e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.68	8.71	0.49	4.55e-16	Bladder cancer;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	8.02	0.46	4.22e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg10189774	chr4:17578691	LAP3	0.41	4.96	0.3	1.34e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.59	7.63	0.44	5.06e-13	Blood trace element (Cu levels);
KIRP	cis	rs6691722	0.503	rs2274168	chr1:24707211	G/T	cg18323236	chr1:24743029	NIPAL3	0.45	6.51	0.38	4.21e-10	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs394563	0.591	rs237016	chr6:149744859	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.33	-5.44	-0.33	1.29e-7	Dupuytren's disease;
KIRP	cis	rs12230513	0.732	rs61956300	chr12:55812640	T/G	cg19537932	chr12:55886519	OR6C68	-0.61	-7.54	-0.43	9.16e-13	Contrast sensitivity;
KIRP	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg13319975	chr6:146136371	FBXO30	-0.43	-5.73	-0.34	2.97e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9826463	0.582	rs11709758	chr3:142104427	T/C	cg20824294	chr3:142316082	PLS1	0.39	5.77	0.35	2.34e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7737355	0.812	rs9687376	chr5:130918037	A/C	cg06307176	chr5:131281290	NA	0.42	5.02	0.3	9.87e-7	Life satisfaction;
KIRP	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	0.7	6.56	0.39	3.09e-10	Obesity-related traits;
KIRP	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.62	7.8	0.45	1.71e-13	Cognitive test performance;
KIRP	cis	rs1440410	0.798	rs4690779	chr4:144119933	G/A	cg01719995	chr4:144104893	USP38	0.45	6.24	0.37	1.92e-9	Ischemic stroke;
KIRP	cis	rs2733310	1.000	rs2591068	chr15:57495687	C/G	cg13626582	chr15:57592083	LOC283663	-0.31	-7.28	-0.42	4.5e-12	Mean platelet volume;
KIRP	trans	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	8.98	0.5	7.03e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.76	-11.16	-0.58	1.13e-23	Height;
KIRP	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg09594475	chr20:60884601	LAMA5	0.36	4.84	0.3	2.26e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg27147174	chr7:100797783	AP1S1	-0.56	-6.95	-0.41	3.3e-11	Life satisfaction;
KIRP	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg19847130	chr8:10466454	RP1L1	0.41	6.35	0.38	1.04e-9	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	trans	rs933360	0.553	rs2286154	chr7:50827682	A/C	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg22284058	chr8:142237359	SLC45A4	-0.52	-6.48	-0.38	5.08e-10	Immature fraction of reticulocytes;
KIRP	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg04317338	chr11:64019027	PLCB3	0.78	7.24	0.42	5.72e-12	Mean platelet volume;
KIRP	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg12861170	chr19:19639553	YJEFN3	0.49	5.0	0.3	1.11e-6	Bipolar disorder;
KIRP	cis	rs258892	1.000	rs27952	chr5:72316437	G/A	cg21869765	chr5:72125136	TNPO1	-0.51	-6.13	-0.36	3.43e-9	Small cell lung carcinoma;
KIRP	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-8.76	-0.49	3.24e-16	Colorectal cancer;
KIRP	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.83	9.54	0.52	1.52e-18	Platelet count;
KIRP	cis	rs4698790	0.635	rs7439356	chr4:110684744	T/C	cg07850274	chr4:110748770	RRH	0.33	5.04	0.31	9.04e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg24633833	chr3:10029261	TMEM111	0.53	5.41	0.33	1.47e-7	Alzheimer's disease;
KIRP	cis	rs5753618	0.504	rs9606848	chr22:31901867	G/A	cg02404636	chr22:31891804	SFI1	0.56	6.55	0.39	3.35e-10	Colorectal cancer;
KIRP	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-1.06	-13.67	-0.66	5.12e-32	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs12681366	0.663	rs1561648	chr8:95474437	C/T	cg13257157	chr8:95487014	RAD54B	0.41	5.05	0.31	8.78e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs1593	0.531	rs3822055	chr4:187179678	A/G	cg09526685	chr4:187126073	CYP4V2	0.51	5.09	0.31	7.08e-7	Activated partial thromboplastin time;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg16395911	chr14:57700568	EXOC5	0.4	6.05	0.36	5.42e-9	Migraine with aura;
KIRP	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg26876637	chr1:152193138	HRNR	0.71	9.19	0.51	1.71e-17	Atopic dermatitis;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg03759077	chr2:153575599	ARL6IP6	0.51	6.08	0.36	4.48e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg22907277	chr7:1156413	C7orf50	0.69	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.21	-14.09	-0.67	1.95e-33	Breast cancer;
KIRP	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg06742321	chr12:123595122	PITPNM2	0.51	6.4	0.38	7.95e-10	Platelet count;
KIRP	cis	rs7508	0.535	rs4124899	chr8:17785258	A/C	cg01800426	chr8:17659068	MTUS1	-0.42	-5.38	-0.32	1.74e-7	Atrial fibrillation;
KIRP	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.77	11.62	0.6	3.57e-25	Hip circumference;
KIRP	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-4.88	-0.3	1.87e-6	Neuroticism;
KIRP	cis	rs13424612	0.965	rs4149544	chr2:240943162	C/T	cg01812947	chr2:240904978	NDUFA10	0.45	5.76	0.34	2.46e-8	Odorant perception (isobutyraldehyde);
KIRP	cis	rs3821902	0.646	rs58627691	chr3:64015548	T/C	cg09006292	chr3:64049408	NA	-0.48	-5.03	-0.31	9.43e-7	Breast cancer;
KIRP	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.96	9.16	0.5	2.08e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.8	9.68	0.53	5.5e-19	Corneal astigmatism;
KIRP	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg17788362	chr6:86352627	SYNCRIP	0.49	6.45	0.38	5.94e-10	Smooth-surface caries;
KIRP	cis	rs6732160	0.588	rs3891890	chr2:73378049	A/G	cg01422370	chr2:73384389	NA	0.5	6.76	0.4	1.02e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs9311676	0.656	rs7647078	chr3:58369912	C/T	cg06643156	chr3:58380774	PXK	0.35	4.92	0.3	1.56e-6	Systemic lupus erythematosus;
KIRP	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.74	6.81	0.4	7.33e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-0.99	-15.27	-0.7	1.73e-37	Dilated cardiomyopathy;
KIRP	cis	rs2281603	0.951	rs1982440	chr14:64960767	T/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	3.94e-7	Lymphocyte counts;
KIRP	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.63	-0.39	2.11e-10	Bipolar disorder;
KIRP	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg14345882	chr6:26364793	BTN3A2	0.66	4.88	0.3	1.89e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11410354	1	rs11410354	chr11:442472	C/CT	cg19913688	chr11:428466	ANO9	0.93	8.4	0.47	3.56e-15	Breast cancer;
KIRP	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg17252645	chr8:143867129	LY6D	-0.31	-5.02	-0.3	9.87e-7	Urinary tract infection frequency;
KIRP	cis	rs12496230	0.794	rs6795104	chr3:66861887	A/G	cg17646820	chr3:66848679	NA	0.38	6.1	0.36	4.17e-9	Type 2 diabetes;
KIRP	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.64	-0.34	4.64e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs1116547	0.714	rs7709110	chr5:112771323	T/C	cg12552261	chr5:112820674	MCC	-0.47	-5.09	-0.31	7.22e-7	Cerebral amyloid angiopathy;
KIRP	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg13880726	chr7:1868755	MAD1L1	0.48	5.87	0.35	1.41e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.56	6.74	0.4	1.09e-10	Height;
KIRP	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-0.87	-6.7	-0.39	1.39e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs62355272	0.796	rs56123112	chr5:35831103	A/C	cg13894535	chr5:35919491	CAPSL	-0.49	-5.5	-0.33	9.28e-8	Lymphocyte counts;
KIRP	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg18585693	chr11:117668161	DSCAML1	0.31	5.06	0.31	8.27e-7	Myopia;
KIRP	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.93	16.93	0.73	3.87e-43	Coronary artery disease;
KIRP	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.43	5.53	0.33	8.16e-8	Motion sickness;
KIRP	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.94	11.45	0.59	1.33e-24	Smoking behavior;
KIRP	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.83	10.23	0.55	1.1e-20	Corneal astigmatism;
KIRP	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs830383	0.584	rs31771	chr5:165495491	C/T	cg13976338	chr5:165423657	NA	-0.55	-7.02	-0.41	2.14e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.83	10.26	0.55	8.93e-21	Bipolar disorder and schizophrenia;
KIRP	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-7.07	-0.41	1.58e-11	Hemoglobin concentration;
KIRP	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg09344028	chr17:70110421	NA	0.44	9.68	0.53	5.68e-19	Thyroid hormone levels;
KIRP	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.9	-12.01	-0.61	1.92e-26	Platelet distribution width;
KIRP	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg03258749	chr1:151040405	MLLT11	-0.9	-13.06	-0.64	5.63e-30	Childhood ear infection;
KIRP	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.91	13.08	0.64	5.06e-30	Tonsillectomy;
KIRP	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.56	-0.39	3.15e-10	Mean platelet volume;
KIRP	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-11.37	-0.59	2.34e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6907629	1.000	rs6907629	chr6:167569519	A/G	cg13805183	chr6:167554790	NA	-0.37	-5.03	-0.31	9.39e-7	Asthma (childhood onset);
KIRP	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.67	6.45	0.38	5.91e-10	Schizophrenia;
KIRP	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.52	7.89	0.45	9.93e-14	Bone mineral density;
KIRP	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg25019033	chr10:957182	NA	-0.6	-6.09	-0.36	4.36e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg19906672	chr4:6918868	TBC1D14	0.41	4.93	0.3	1.52e-6	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg16558253	chr16:72132732	DHX38	-0.55	-8.2	-0.46	1.33e-14	Fibrinogen levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg19524810	chr5:1112228	SLC12A7	-0.44	-6.02	-0.36	6.4e-9	Metabolic traits;
KIRP	cis	rs780094	0.500	rs12464616	chr2:27827092	C/T	cg05484376	chr2:27715224	FNDC4	-0.38	-5.21	-0.32	3.94e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg05370193	chr1:21551575	ECE1	0.43	6.09	0.36	4.21e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs28595532	0.748	rs113336496	chr4:119336957	C/T	cg21605333	chr4:119757512	SEC24D	0.94	7.19	0.42	7.56e-12	Cannabis dependence symptom count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17987059	chr13:28752067	PAN3	0.44	7.06	0.41	1.71e-11	Survival in pancreatic cancer;
KIRP	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.84	-0.53	1.76e-19	Height;
KIRP	cis	rs17270561	0.609	rs9467572	chr6:25704126	T/G	cg25753631	chr6:25732923	NA	0.27	5.01	0.3	1.04e-6	Iron status biomarkers;
KIRP	cis	rs4073221	0.929	rs7371812	chr3:18281071	C/T	cg07694806	chr3:18168406	NA	0.83	6.9	0.4	4.44e-11	Parkinson's disease;
KIRP	cis	rs1867631	0.585	rs11208940	chr1:67127242	A/G	cg02459107	chr1:67143332	SGIP1	-0.4	-6.02	-0.36	6.41e-9	Menopause (age at onset);
KIRP	cis	rs7394190	0.748	rs11000773	chr10:75534115	G/T	cg04833713	chr10:74871078	NUDT13	0.43	4.86	0.3	2.1e-6	Incident atrial fibrillation;
KIRP	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	0.6	9.06	0.5	4.08e-17	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-12.71	-0.63	8.57e-29	Alzheimer's disease;
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	14.96	0.69	2.09e-36	Platelet count;
KIRP	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-1.01	-16.77	-0.73	1.36e-42	Height;
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.79	7.46	0.43	1.52e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.56	6.89	0.4	4.57e-11	Aortic root size;
KIRP	cis	rs1891275	0.515	rs7093728	chr10:93443617	C/T	cg07889827	chr10:93443413	NA	-0.41	-7.06	-0.41	1.67e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2377585	0.653	rs6487333	chr12:8848929	A/T	cg03761649	chr12:8850719	RIMKLB	-0.5	-5.27	-0.32	3.05e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.84	10.8	0.57	1.6400000000000001e-22	Platelet distribution width;
KIRP	cis	rs883565	0.771	rs3736573	chr3:39129742	A/C	cg01426195	chr3:39028469	NA	-0.67	-10.71	-0.56	3.32e-22	Handedness;
KIRP	cis	rs7027203	0.576	rs7855940	chr9:96535966	C/G	cg14598338	chr9:96623480	NA	-0.46	-7.0	-0.41	2.46e-11	DNA methylation (variation);
KIRP	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.41	4.9	0.3	1.74e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4722404	0.502	rs1872879	chr7:3109430	A/C	cg19214707	chr7:3157722	NA	-0.45	-5.88	-0.35	1.35e-8	Atopic dermatitis;
KIRP	trans	rs7980799	0.935	rs1905408	chr12:33516963	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-6.56	-0.39	3.19e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	6.33	0.37	1.13e-9	Depressive symptoms;
KIRP	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg27490568	chr2:178487706	NA	0.48	6.49	0.38	4.78e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24375607	chr4:120327624	NA	-0.6	-6.54	-0.38	3.57e-10	Corneal astigmatism;
KIRP	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg21775007	chr8:11205619	TDH	-0.48	-6.39	-0.38	8.09e-10	Triglycerides;
KIRP	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.82	10.44	0.55	2.38e-21	Menopause (age at onset);
KIRP	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg17376030	chr22:41985996	PMM1	-0.63	-7.08	-0.41	1.49e-11	Vitiligo;
KIRP	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.63	6.65	0.39	1.85e-10	Gut microbiome composition (summer);
KIRP	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg23307798	chr14:103986281	CKB	0.73	11.33	0.59	3.22e-24	Body mass index;
KIRP	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-11.68	-0.6	2.23e-25	Vitiligo;
KIRP	cis	rs7709377	0.570	rs6876901	chr5:115432690	T/G	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	trans	rs10486722	0.575	rs11770999	chr7:41812252	C/T	cg07952040	chr12:110562126	IFT81	-0.6	-6.09	-0.36	4.42e-9	Pit-and-Fissure caries;
KIRP	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg16482183	chr6:26056742	HIST1H1C	0.39	5.1	0.31	6.7e-7	Schizophrenia;
KIRP	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg18944383	chr4:111397179	ENPEP	0.54	9.48	0.52	2.32e-18	Height;
KIRP	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg05973401	chr12:123451056	ABCB9	0.63	7.53	0.43	9.88e-13	Platelet count;
KIRP	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg20578329	chr17:80767326	TBCD	0.47	6.19	0.37	2.44e-9	Breast cancer;
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg21285383	chr16:89894308	SPIRE2	0.29	5.4	0.33	1.55e-7	Schizophrenia;
KIRP	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17744121	0.584	rs73192185	chr21:30495194	C/G	cg23789846	chr21:30375227	NA	0.8	4.87	0.3	1.97e-6	Visceral fat;
KIRP	cis	rs13132184	0.507	rs933818	chr4:38079294	A/G	cg19090437	chr4:38080799	TBC1D1	-0.51	-5.0	-0.3	1.1e-6	Verbal declarative memory;
KIRP	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.83	-0.45	1.46e-13	Retinal vascular caliber;
KIRP	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.39	-6.7	-0.39	1.38e-10	Heart rate;
KIRP	cis	rs11955175	1.000	rs11960585	chr5:40662007	C/A	cg04002187	chr5:40835754	RPL37	0.66	5.32	0.32	2.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9815354	0.812	rs73077360	chr3:41850054	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs1859156	0.767	rs17429196	chr4:95817017	A/C	cg24204951	chr2:239172084	PER2	0.3	6.71	0.39	1.34e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs2594989	0.943	rs2595004	chr3:11406721	C/T	cg01796438	chr3:11312864	ATG7	-0.69	-7.58	-0.44	6.9e-13	Circulating chemerin levels;
KIRP	cis	rs877636	0.847	rs2017445	chr12:56407072	G/T	cg07515662	chr12:56435880	RPS26	-0.81	-6.28	-0.37	1.5e-9	Cognitive function;
KIRP	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg02461776	chr11:598696	PHRF1	0.73	7.59	0.44	6.47e-13	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.64	7.77	0.44	2.14e-13	Coronary artery disease;
KIRP	cis	rs4302748	0.817	rs11773129	chr7:36186670	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg11621586	chr10:70884670	VPS26A	1.16	14.81	0.69	6.81e-36	Left atrial antero-posterior diameter;
KIRP	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg22916017	chr11:64110731	CCDC88B	0.51	5.63	0.34	4.99e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9513627	0.915	rs73556179	chr13:100122009	G/A	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.97	-0.54	6.88e-20	Triglycerides;
KIRP	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg05861140	chr6:150128134	PCMT1	-0.5	-7.03	-0.41	2.01e-11	Lung cancer;
KIRP	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg02023728	chr11:77925099	USP35	-0.29	-4.95	-0.3	1.41e-6	Alzheimer's disease (survival time);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18862260	chr2:190927550	MSTN	-0.37	-6.1	-0.36	4.09e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.92	13.74	0.66	2.86e-32	Personality dimensions;
KIRP	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07570687	chr10:102243282	WNT8B	0.51	6.24	0.37	1.86e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07775675	chr17:74379922	SPHK1	0.45	6.6	0.39	2.58e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10214930	0.767	rs10081339	chr7:27698594	G/T	cg22168087	chr7:27702803	HIBADH	-0.52	-5.26	-0.32	3.18e-7	Hypospadias;
KIRP	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg15181151	chr6:150070149	PCMT1	0.29	4.86	0.3	2.12e-6	Lung cancer;
KIRP	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg04132472	chr17:19861366	AKAP10	0.67	10.47	0.56	1.9e-21	Schizophrenia;
KIRP	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg05484376	chr2:27715224	FNDC4	0.31	4.87	0.3	2.02e-6	Total body bone mineral density;
KIRP	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.79	-0.35	2.1e-8	IgG glycosylation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26350977	chr1:119630715	WARS2	-0.39	-6.19	-0.37	2.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.47	-9.74	-0.53	3.53e-19	Multiple system atrophy;
KIRP	cis	rs9308731	0.591	rs10439381	chr2:111936459	A/G	cg04780086	chr2:111875790	ACOXL	0.38	5.11	0.31	6.32e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg08501292	chr6:25962987	TRIM38	1.12	7.24	0.42	5.66e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-6.79	-0.4	8.15e-11	Body mass index;
KIRP	cis	rs4664293	0.667	rs2042782	chr2:160646292	G/A	cg08347373	chr2:160653686	CD302	0.36	5.75	0.34	2.6e-8	Monocyte percentage of white cells;
KIRP	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.98	0.3	1.2e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs72781680	0.611	rs55905755	chr2:24330264	T/C	cg06627628	chr2:24431161	ITSN2	-0.59	-5.21	-0.31	4.08e-7	Lymphocyte counts;
KIRP	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.86	-13.2	-0.64	1.96e-30	Eye color traits;
KIRP	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.83	11.85	0.6	6.36e-26	Blood metabolite ratios;
KIRP	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-6.7	-0.39	1.39e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8060686	0.546	rs7188350	chr16:68149316	T/C	cg26727032	chr16:67993705	SLC12A4	-0.67	-7.53	-0.43	9.48e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg01966878	chr4:90757139	SNCA	-0.44	-4.89	-0.3	1.82e-6	Neuroticism;
KIRP	cis	rs9420	0.784	rs12790660	chr11:57667222	T/C	cg19752551	chr11:57585705	CTNND1	-0.74	-10.58	-0.56	8.35e-22	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22988507	chr4:2936131	C4orf10;MFSD10	0.52	7.31	0.42	3.84e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-6.41	-0.38	7.53e-10	Educational attainment;
KIRP	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg15282417	chr9:129245246	FAM125B	0.45	7.84	0.45	1.36e-13	Intraocular pressure;
KIRP	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg02993010	chr8:124780839	FAM91A1	-0.57	-5.73	-0.34	2.91e-8	Pancreatic cancer;
KIRP	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.34	5.1	0.31	6.95e-7	Calcium levels;
KIRP	cis	rs1165472	0.755	rs67405784	chr1:56136733	G/A	cg11523071	chr1:56160889	NA	-0.61	-7.63	-0.44	5.13e-13	Paclitaxel-induced neuropathy;
KIRP	cis	rs9488822	0.676	rs873879	chr6:116391259	A/G	cg26893134	chr6:116381904	FRK	0.19	5.11	0.31	6.52e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.54	-0.48	1.42e-15	Common traits (Other);
KIRP	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.71	8.03	0.46	4.11e-14	Height;
KIRP	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-0.65	-5.49	-0.33	1.02e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg08890418	chr1:21044141	KIF17	-0.34	-5.13	-0.31	6e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.76	-0.34	2.46e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.67	-10.21	-0.55	1.22e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.48	-6.33	-0.37	1.13e-9	Life satisfaction;
KIRP	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.42	0.59	1.57e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs953387	1.000	rs10179271	chr2:136910834	T/C	cg05194412	chr2:137003533	NA	-0.42	-5.52	-0.33	8.6e-8	Arthritis (juvenile idiopathic);
KIRP	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.48	5.79	0.35	2.11e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.86	10.91	0.57	7.52e-23	Coronary artery disease;
KIRP	cis	rs1448094	0.785	rs6539941	chr12:86452813	G/T	cg06740227	chr12:86229804	RASSF9	-0.4	-4.98	-0.3	1.18e-6	Major depressive disorder;
KIRP	cis	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg14210620	chr13:44453864	C13orf31;CCDC122	0.38	4.94	0.3	1.48e-6	Leprosy;
KIRP	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	6.44	0.38	6.37e-10	Personality dimensions;
KIRP	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg16558253	chr16:72132732	DHX38	-0.5	-7.32	-0.42	3.49e-12	Fibrinogen levels;
KIRP	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.48	-5.66	-0.34	4.17e-8	Asthma (sex interaction);
KIRP	trans	rs6599222	0.547	rs41312411	chr3:38621237	C/G	cg19693626	chr11:18158980	MRGPRX3	0.65	6.06	0.36	5.21e-9	PR interval;
KIRP	cis	rs4654899	0.643	rs1408409	chr1:21089781	T/C	cg05370193	chr1:21551575	ECE1	0.36	5.07	0.31	7.65e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	cis	rs7539542	0.556	rs2000331	chr1:202857578	G/T	cg08940984	chr1:202857613	RABIF	0.45	5.69	0.34	3.62e-8	Mean platelet volume;
KIRP	cis	rs12973672	0.904	rs12974791	chr19:35767218	A/G	cg12095397	chr19:35769544	USF2	0.63	6.61	0.39	2.43e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13095912	0.927	rs4686683	chr3:185307363	A/C	cg11274856	chr3:185301563	NA	0.39	5.03	0.31	9.37e-7	Systolic blood pressure;
KIRP	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.5	7.26	0.42	5.08e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1413885	0.549	rs10889546	chr1:65851759	G/A	cg14976592	chr1:65886160	LEPROT;LEPR	0.52	5.75	0.34	2.59e-8	Anticoagulant levels;
KIRP	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.72	0.44	2.91e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.49	-7.32	-0.42	3.6e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs662064	0.962	rs2781232	chr1:10544388	T/C	cg19773385	chr1:10388646	KIF1B	0.41	5.42	0.33	1.44e-7	Asthma;
KIRP	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg19468946	chr17:37922297	IKZF3	-0.38	-5.16	-0.31	5.11e-7	Asthma;
KIRP	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14240646	chr10:27532245	ACBD5	-0.45	-5.04	-0.31	8.99e-7	Breast cancer;
KIRP	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs858239	0.539	rs6976957	chr7:23187333	T/A	cg23682824	chr7:23144976	KLHL7	0.53	6.22	0.37	2.11e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7870753	0.838	rs7038932	chr9:99236326	A/G	cg25260653	chr9:99212216	HABP4	0.49	4.85	0.3	2.18e-6	Height;
KIRP	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.09	0.36	4.29e-9	Breast cancer;
KIRP	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.68	10.14	0.54	2.03e-20	Dupuytren's disease;
KIRP	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg06671706	chr8:8559999	CLDN23	0.49	6.01	0.36	6.8e-9	Obesity-related traits;
KIRP	cis	rs9810890	0.850	rs73198871	chr3:128537238	C/T	cg15033153	chr3:128514015	RAB7A	0.71	5.03	0.31	9.56e-7	Dental caries;
KIRP	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.46	-6.12	-0.36	3.72e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.63	-11.85	-0.6	6.23e-26	Diabetic kidney disease;
KIRP	cis	rs2274459	1.000	rs12662447	chr6:33714673	C/T	cg06253072	chr6:33679850	C6orf125	0.5	4.97	0.3	1.28e-6	Obesity (extreme);
KIRP	cis	rs16936870	0.543	rs12679364	chr8:71292036	T/C	cg14232793	chr8:71155543	NCOA2	0.55	6.33	0.37	1.15e-9	QT interval;
KIRP	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg04006718	chr10:1068667	C10orf110;IDI2	-0.77	-5.07	-0.31	7.96e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg04490037	chr7:50633773	DDC	0.36	4.93	0.3	1.49e-6	Body mass index;
KIRP	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg22974920	chr21:40686053	BRWD1	0.48	5.53	0.33	8.13e-8	Cognitive function;
KIRP	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg04398451	chr17:18023971	MYO15A	0.66	9.18	0.51	1.85e-17	Total body bone mineral density;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19489423	chr19:17653011	FAM129C	0.42	6.23	0.37	1.99e-9	Interleukin-4 levels;
KIRP	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg09631192	chr20:23583594	CST9	-0.52	-5.17	-0.31	4.9e-7	Chronic kidney disease;
KIRP	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.16	0.46	1.74e-14	Motion sickness;
KIRP	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs1298062	0.757	rs1673039	chr19:50977957	C/T	cg11430371	chr19:50961752	MYBPC2	0.36	5.02	0.31	9.74e-7	Age of smoking initiation;
KIRP	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.77	9.11	0.5	2.87e-17	Migraine;Coronary artery disease;
KIRP	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.47	-6.78	-0.4	9.09e-11	Motion sickness;
KIRP	cis	rs6102059	0.692	rs6029188	chr20:39200914	A/G	cg06665391	chr20:39312290	NA	0.41	5.18	0.31	4.58e-7	LDL cholesterol;
KIRP	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	-0.53	-4.91	-0.3	1.7e-6	Total cholesterol levels;
KIRP	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.9	-13.35	-0.65	6.19e-31	Schizophrenia;
KIRP	cis	rs9488822	0.596	rs13192549	chr6:116338352	C/A	cg26893134	chr6:116381904	FRK	0.19	5.32	0.32	2.38e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg22800045	chr5:56110881	MAP3K1	-0.61	-7.02	-0.41	2.15e-11	Initial pursuit acceleration;
KIRP	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.12	-20.81	-0.8	3.78e-56	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2481665	0.709	rs6674784	chr1:62529094	T/A	cg18591186	chr1:62594603	INADL	-0.58	-7.79	-0.44	1.87e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	16.77	0.73	1.33e-42	Platelet count;
KIRP	cis	rs13401104	0.796	rs1466205	chr2:237121194	A/G	cg19324714	chr2:237145437	ASB18	0.48	4.99	0.3	1.13e-6	Educational attainment;
KIRP	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.47	-11.64	-0.6	3.04e-25	Gout;
KIRP	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.39	5.69	0.34	3.61e-8	Eye color traits;
KIRP	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.61	-9.31	-0.51	7.56e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg20528838	chr20:57427730	GNAS	-0.45	-6.15	-0.37	3.19e-9	Height;
KIRP	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.86	12.86	0.63	2.65e-29	Menarche (age at onset);
KIRP	cis	rs11603020	0.950	rs11229063	chr11:57369730	G/A	cg23127183	chr11:57508653	C11orf31	-0.46	-5.42	-0.33	1.41e-7	Blood protein levels;
KIRP	cis	rs4908768	0.906	rs11121223	chr1:8772845	T/A	cg25722041	chr1:8623473	RERE	0.79	9.18	0.51	1.77e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	11.87	0.6	5.24e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4953911	0.893	rs6751660	chr2:135053117	G/C	cg18482303	chr2:135041380	MGAT5	-0.28	-5.26	-0.32	3.17e-7	Multiple sclerosis (severity);
KIRP	cis	rs2625529	0.938	rs2625530	chr15:72126034	G/A	cg16672083	chr15:72433130	SENP8	-0.52	-6.05	-0.36	5.38e-9	Red blood cell count;
KIRP	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.43	7.36	0.42	2.82e-12	Age at first birth;
KIRP	cis	rs5753618	0.539	rs8135344	chr22:31671932	G/T	cg22777020	chr22:31556080	RNF185	-0.5	-5.29	-0.32	2.74e-7	Colorectal cancer;
KIRP	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	3.99e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.54	7.91	0.45	8.52e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg04935436	chr20:30431758	NA	0.56	6.86	0.4	5.47e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.46	0.47	2.47e-15	Motion sickness;
KIRP	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.12	-0.5	2.82e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.67	9.86	0.53	1.56e-19	Lymphocyte counts;
KIRP	cis	rs9534288	0.762	rs3934247	chr13:46549137	C/T	cg15192986	chr13:46630673	CPB2	-0.66	-7.98	-0.45	5.56e-14	Blood protein levels;
KIRP	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg12923728	chr3:195709715	SDHAP1	0.55	6.46	0.38	5.62e-10	Mean corpuscular volume;
KIRP	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.8	-9.98	-0.54	6.27e-20	Corneal astigmatism;
KIRP	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23161317	chr6:28129485	ZNF389	0.42	4.92	0.3	1.57e-6	Depression;
KIRP	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg05484376	chr2:27715224	FNDC4	0.38	6.31	0.37	1.28e-9	Total body bone mineral density;
KIRP	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.77	7.97	0.45	5.88e-14	Gestational age at birth (maternal effect);
KIRP	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.73	7.09	0.41	1.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.53	7.16	0.42	9.34e-12	Blood metabolite levels;
KIRP	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1712517	0.566	rs1163073	chr10:105022934	C/T	cg04362960	chr10:104952993	NT5C2	0.62	7.75	0.44	2.4e-13	Migraine;
KIRP	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24549020	chr5:56110836	MAP3K1	0.56	5.43	0.33	1.38e-7	Initial pursuit acceleration;
KIRP	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.66	-9.42	-0.51	3.52e-18	Colorectal cancer;
KIRP	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.5	-0.52	1.96e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.39	-5.23	-0.32	3.71e-7	Blood metabolite levels;
KIRP	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg01422370	chr2:73384389	NA	0.47	6.35	0.38	1.01e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.37	-5.34	-0.32	2.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg14664628	chr15:75095509	CSK	0.45	5.63	0.34	4.8e-8	Caffeine consumption;
KIRP	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.39	-6.41	-0.38	7.25e-10	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg02536541	chr18:77568900	NA	-0.73	-10.27	-0.55	7.87e-21	Schizophrenia;
KIRP	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-1.14	-9.3	-0.51	7.67e-18	Hip circumference adjusted for BMI;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25341789	chr19:3506185	FZR1	0.53	6.28	0.37	1.54e-9	Smoking initiation;
KIRP	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.44	5.64	0.34	4.55e-8	Height;
KIRP	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.92	5.2	0.31	4.23e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg07169764	chr2:136633963	MCM6	0.53	6.17	0.37	2.74e-9	Mosquito bite size;
KIRP	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg02023728	chr11:77925099	USP35	0.3	5.3	0.32	2.61e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.61	-6.98	-0.41	2.78e-11	Type 2 diabetes;
KIRP	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.51	-6.49	-0.38	4.66e-10	Corneal astigmatism;
KIRP	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.6	7.9	0.45	9.03e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg26876637	chr1:152193138	HRNR	0.72	9.21	0.51	1.46e-17	Atopic dermatitis;
KIRP	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg03808351	chr9:123631620	PHF19	0.41	5.59	0.34	6.15e-8	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	6.95e-7	Life satisfaction;
KIRP	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26526719	chr5:1949144	NA	0.41	4.94	0.3	1.41e-6	Gut microbiome composition (winter);
KIRP	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg08508325	chr11:3079039	CARS	0.31	5.68	0.34	3.7e-8	Calcium levels;
KIRP	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg19875535	chr5:140030758	IK	0.64	8.75	0.49	3.4e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg12598211	chr12:123634384	NA	-0.4	-5.0	-0.3	1.07e-6	Platelet count;
KIRP	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg13147721	chr7:65941812	NA	0.99	6.64	0.39	1.98e-10	Diabetic kidney disease;
KIRP	cis	rs9534288	0.619	rs1326397	chr13:46682122	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-7.87	-0.45	1.13e-13	Blood protein levels;
KIRP	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.45	-0.43	1.62e-12	Response to antipsychotic treatment;
KIRP	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.35	-4.94	-0.3	1.45e-6	Congenital heart disease (maternal effect);
KIRP	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.49e-6	Red blood cell count;
KIRP	cis	rs8084125	0.832	rs62105178	chr18:74950635	C/T	cg26065057	chr18:74961000	GALR1	0.6	6.27	0.37	1.58e-9	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg08662619	chr6:150070041	PCMT1	0.34	5.46	0.33	1.18e-7	Lung cancer;
KIRP	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20135002	chr11:47629003	NA	-0.43	-4.93	-0.3	1.52e-6	Subjective well-being;
KIRP	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.56	7.18	0.42	8.23e-12	Resting heart rate;
KIRP	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.57	6.12	0.36	3.61e-9	Menopause (age at onset);
KIRP	cis	rs612683	0.536	rs1855797	chr1:101027126	A/G	cg09408571	chr1:101003634	GPR88	0.31	7.29	0.42	4.2e-12	Breast cancer;
KIRP	cis	rs867371	1.000	rs4778982	chr15:82475272	T/G	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.33e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.64	9.19	0.51	1.66e-17	Vitiligo;
KIRP	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg12235144	chr12:48398329	COL2A1	0.46	4.88	0.3	1.92e-6	Lung cancer;
KIRP	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	cg12689670	chr1:183009347	LAMC1	-0.41	-5.95	-0.35	9.22e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs490234	0.702	rs13287071	chr9:128268224	T/C	cg14078157	chr9:128172775	NA	-0.64	-7.6	-0.44	6.21e-13	Mean arterial pressure;
KIRP	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	6.34	0.37	1.07e-9	Iron status biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23921743	chr19:2977317	TLE6	0.51	6.6	0.39	2.57e-10	Parkinson's disease;
KIRP	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.68	-0.53	5.4e-19	Mood instability;
KIRP	cis	rs9488822	0.702	rs12196154	chr6:116327471	T/G	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7714584	1.000	rs10058821	chr5:150226385	A/G	cg22134413	chr5:150180641	NA	0.57	5.09	0.31	7.03e-7	Crohn's disease;
KIRP	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-1.22	-10.61	-0.56	6.81e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	1.11	10.04	0.54	4.12e-20	Red blood cell traits;
KIRP	cis	rs4950322	0.570	rs7554833	chr1:146761044	A/G	cg22381352	chr1:146742008	CHD1L	0.45	5.45	0.33	1.22e-7	Protein quantitative trait loci;
KIRP	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg01721255	chr8:58191610	C8orf71	0.47	5.22	0.32	3.89e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg09863252	chr1:54872721	SSBP3	-0.55	-6.08	-0.36	4.48e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg02980000	chr4:1222292	CTBP1	0.92	8.69	0.48	5.29e-16	Systolic blood pressure;
KIRP	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.73	-9.65	-0.52	7.03e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7809950	0.871	rs11771278	chr7:107285925	C/T	cg23024343	chr7:107201750	COG5	0.4	5.99	0.36	7.49e-9	Coronary artery disease;
KIRP	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.24	-0.32	3.46e-7	Calcium levels;
KIRP	cis	rs7941030	0.934	rs7129071	chr11:122527120	G/A	cg20555462	chr11:122535518	UBASH3B	-0.45	-5.44	-0.33	1.27e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs7945718	0.621	rs10831896	chr11:12693361	G/A	cg25843174	chr11:12811716	TEAD1	0.32	5.74	0.34	2.72e-8	Educational attainment (years of education);
KIRP	cis	rs7560272	0.723	rs1083923	chr2:73703374	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.76	0.34	2.48e-8	Schizophrenia;
KIRP	cis	rs1497828	0.913	rs1032599	chr1:217548568	T/A	cg04411442	chr1:217543379	NA	0.31	5.02	0.3	1e-6	Dialysis-related mortality;
KIRP	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.93	0.4	3.71e-11	Retinal vascular caliber;
KIRP	cis	rs12210905	1.000	rs72843609	chr6:27125877	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.33e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7172677	0.737	rs7169545	chr15:75436123	A/G	cg14664628	chr15:75095509	CSK	-0.55	-6.1	-0.36	4.02e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.57	-0.43	7.3e-13	Monocyte count;
KIRP	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg16141378	chr3:129829833	LOC729375	0.52	7.21	0.42	6.69e-12	Triglycerides;
KIRP	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg00204512	chr16:28754710	NA	0.45	5.85	0.35	1.56e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg18335740	chr13:41363409	SLC25A15	0.49	7.18	0.42	8.13e-12	Lewy body disease;
KIRP	cis	rs11779988	0.545	rs208752	chr8:17774258	A/G	cg01800426	chr8:17659068	MTUS1	-0.6	-6.07	-0.36	4.81e-9	Breast cancer;
KIRP	cis	rs7404928	0.681	rs66923906	chr16:23919079	C/T	cg21745164	chr16:23765304	CHP2	-0.61	-6.4	-0.38	7.61e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.35	-0.42	2.98e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg09264619	chr17:80180166	NA	0.48	5.59	0.34	5.96e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg14345882	chr6:26364793	BTN3A2	-0.54	-4.92	-0.3	1.58e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.71	-9.35	-0.51	5.8e-18	Schizophrenia;
KIRP	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg00931491	chr16:28608288	SULT1A2	-0.25	-5.02	-0.3	1.01e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.62	-8.08	-0.46	2.99e-14	Breast cancer;
KIRP	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.62	-6.59	-0.39	2.6200000000000003e-10	DNA methylation (variation);
KIRP	cis	rs2235573	0.868	rs4821737	chr22:38500382	G/T	cg19171272	chr22:38449367	NA	0.62	9.18	0.51	1.82e-17	Glioblastoma;Glioma;
KIRP	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.8	-10.82	-0.57	1.41e-22	Systemic lupus erythematosus;
KIRP	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg00405596	chr8:11794950	NA	0.4	5.12	0.31	6.18e-7	Retinal vascular caliber;
KIRP	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.2	14.15	0.67	1.17e-33	Corneal structure;
KIRP	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	1.09	12.1	0.61	9.74e-27	Psoriasis;
KIRP	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.05	0.36	5.38e-9	Mean corpuscular volume;
KIRP	cis	rs3026101	0.671	rs56061343	chr17:5318502	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.52	5.75	0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.75	10.09	0.54	2.87e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.67	-8.39	-0.47	3.92e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7011049	0.818	rs113433913	chr8:53866718	C/G	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.29e-10	Systolic blood pressure;
KIRP	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.52	7.26	0.42	4.92e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02025192	chr11:115375385	CADM1	-0.49	-6.99	-0.41	2.57e-11	Survival in pancreatic cancer;
KIRP	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg13798912	chr7:905769	UNC84A	0.58	5.88	0.35	1.34e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	10.21	0.55	1.23e-20	Response to antipsychotic treatment;
KIRP	cis	rs6450176	0.538	rs12186486	chr5:53306549	T/A	ch.5.1024479R	chr5:53302184	ARL15	-1.19	-15.12	-0.69	5.53e-37	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs3126085	0.935	rs6676012	chr1:152213203	G/A	cg26876637	chr1:152193138	HRNR	0.74	9.51	0.52	1.77e-18	Atopic dermatitis;
KIRP	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg22974920	chr21:40686053	BRWD1	0.49	5.85	0.35	1.57e-8	Cognitive function;
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-4.99	-0.3	1.17e-6	Life satisfaction;
KIRP	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg07701084	chr6:150067640	NUP43	0.65	8.4	0.47	3.69e-15	Lung cancer;
KIRP	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.46	-5.62	-0.34	5.09e-8	Facial morphology (factor 20);
KIRP	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.68	-10.05	-0.54	3.93e-20	Dupuytren's disease;
KIRP	cis	rs9308731	1.000	rs2241845	chr2:111879100	A/G	cg23466623	chr2:111982296	NA	-0.43	-5.31	-0.32	2.49e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.95	0.5	8.59e-17	Colorectal cancer;
KIRP	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs7615316	0.603	rs13091942	chr3:141956582	T/C	cg20824294	chr3:142316082	PLS1	0.23	5.2	0.31	4.18e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.75	-8.16	-0.46	1.77e-14	Platelet count;
KIRP	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg02527881	chr3:46936655	PTH1R	-0.41	-5.94	-0.35	9.71e-9	Colorectal cancer;
KIRP	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg21919602	chr1:242011447	EXO1	-0.47	-6.01	-0.36	6.81e-9	Menopause (age at onset);
KIRP	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.79	-11.23	-0.58	6.77e-24	Blood metabolite levels;
KIRP	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg14004847	chr7:1930337	MAD1L1	-0.45	-5.02	-0.3	9.95e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02164492	chr11:46414469	NA	0.51	6.3	0.37	1.35e-9	Smoking initiation;
KIRP	cis	rs787274	0.850	rs4979176	chr9:115641181	A/G	cg13803584	chr9:115635662	SNX30	0.69	7.4	0.43	2.13e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg24874828	chr4:187887005	NA	-0.47	-7.02	-0.41	2.21e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg18190219	chr22:46762943	CELSR1	-0.87	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.58	9.64	0.52	7.11e-19	Schizophrenia;
KIRP	cis	rs4356932	0.967	rs13113455	chr4:76972447	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.05	0.36	5.3e-9	Blood protein levels;
KIRP	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg08975724	chr8:8085496	FLJ10661	0.56	7.45	0.43	1.53e-12	Myopia (pathological);
KIRP	cis	rs2278796	0.881	rs11240325	chr1:204955329	A/G	cg04862289	chr1:204966208	NFASC	0.56	7.83	0.45	1.47e-13	Mean platelet volume;
KIRP	cis	rs12681288	1.000	rs2336696	chr8:1033802	T/C	cg08648136	chr8:956695	NA	0.48	6.98	0.41	2.72e-11	Schizophrenia;
KIRP	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg12858261	chr2:113808755	IL1F8	0.46	5.34	0.32	2.16e-7	Protein quantitative trait loci;
KIRP	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.39	5.06	0.31	8.4e-7	Breast cancer;
KIRP	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	trans	rs1941687	0.764	rs1493915	chr18:31377582	G/T	cg27147174	chr7:100797783	AP1S1	-0.68	-8.98	-0.5	7.2e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7508	0.511	rs2237853	chr8:17877880	G/A	cg01800426	chr8:17659068	MTUS1	-0.65	-6.52	-0.38	3.92e-10	Atrial fibrillation;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg13960493	chr9:113658492	LPAR1	0.38	6.45	0.38	5.91e-10	C-reactive protein;
KIRP	cis	rs9876781	0.560	rs2362451	chr3:48399828	C/T	cg11946769	chr3:48343235	NME6	-0.38	-4.9	-0.3	1.73e-6	Longevity;
KIRP	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.4	4.87	0.3	1.96e-6	Menopause (age at onset);
KIRP	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.97	12.85	0.63	2.85e-29	Menopause (age at onset);
KIRP	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg14675211	chr2:100938903	LONRF2	0.47	6.05	0.36	5.46e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg10756647	chr7:56101905	PSPH	1.01	7.35	0.42	2.93e-12	Diabetic kidney disease;
KIRP	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.36	5.3	0.32	2.54e-7	Calcium levels;
KIRP	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.55	6.3	0.37	1.38e-9	Schizophrenia;
KIRP	cis	rs4363385	0.510	rs1500937	chr1:153045483	G/C	cg13444842	chr1:152974279	SPRR3	-0.43	-6.04	-0.36	5.62e-9	Inflammatory skin disease;
KIRP	cis	rs6693295	0.536	rs59080925	chr1:246221360	C/G	cg11798871	chr1:246315928	SMYD3	-0.66	-7.2	-0.42	7.42e-12	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg06212747	chr3:49208901	KLHDC8B	0.59	6.36	0.38	9.52e-10	Menarche (age at onset);
KIRP	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.88	-6.19	-0.37	2.44e-9	Inflammatory biomarkers;
KIRP	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.61	7.61	0.44	5.78e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4805272	1.000	rs4805272	chr19:29319706	A/G	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg01002690	chr4:39529294	UGDH	0.49	6.07	0.36	4.74e-9	Beard thickness;
KIRP	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs6910061	1.000	rs36067344	chr6:11094764	C/T	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	cis	rs12580194	0.593	rs57050414	chr12:55776926	G/A	cg11794356	chr12:55725991	OR6C3	-0.5	-6.51	-0.38	4.3e-10	Cancer;
KIRP	cis	rs2860975	1.000	rs10159983	chr10:96774437	C/T	cg09036531	chr10:96991505	NA	-0.54	-6.93	-0.4	3.75e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.47	6.96	0.41	3.04e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg18016565	chr1:150552671	MCL1	0.34	5.18	0.31	4.54e-7	Melanoma;
KIRP	cis	rs8084125	0.832	rs62105173	chr18:74947147	A/G	cg26065057	chr18:74961000	GALR1	0.6	6.27	0.37	1.59e-9	Obesity-related traits;
KIRP	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07409897	chr20:13619336	TASP1	-0.5	-6.58	-0.39	2.75e-10	Myopia;
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-1.0	-11.8	-0.6	8.89e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg18833306	chr6:118973337	C6orf204	0.39	5.0	0.3	1.07e-6	Electrocardiographic conduction measures;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05760393	chr11:2466141	KCNQ1	0.48	6.38	0.38	8.88e-10	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.38	-0.38	8.85e-10	Aortic root size;
KIRP	cis	rs1850744	0.536	rs13131004	chr4:9612911	C/A	cg15442990	chr4:9534313	NA	0.74	6.24	0.37	1.89e-9	Economic and political preferences;
KIRP	trans	rs225245	0.817	rs225273	chr17:33970935	A/T	cg19694781	chr19:47549865	TMEM160	-0.51	-6.2	-0.37	2.37e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7903847	0.642	rs10786341	chr10:99158607	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-5.85	-0.35	1.57e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs71597109	0.639	rs4699262	chr4:102726005	A/G	cg14855874	chr4:102712397	BANK1	-0.4	-4.95	-0.3	1.38e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.54	6.66	0.39	1.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg24253500	chr15:84953950	NA	0.53	6.1	0.36	4.19e-9	Schizophrenia;
KIRP	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg00931491	chr16:28608288	SULT1A2	-0.25	-5.02	-0.31	9.75e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7737355	0.812	rs11242084	chr5:130935777	T/C	cg25547332	chr5:131281432	NA	0.39	4.91	0.3	1.63e-6	Life satisfaction;
KIRP	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg26531700	chr6:26746687	NA	0.39	5.0	0.3	1.11e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.79	8.19	0.46	1.46e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.49	7.64	0.44	4.95e-13	Testicular germ cell tumor;
KIRP	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.57	7.74	0.44	2.51e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12968192	chr21:44496270	CBS	0.45	6.07	0.36	4.7e-9	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.61	6.64	0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs7542091	0.666	rs7537070	chr1:210043565	A/G	cg22029157	chr1:209979665	IRF6	0.39	5.98	0.36	7.66e-9	Monobrow;
KIRP	cis	rs876084	0.524	rs4633103	chr8:121116156	A/G	cg06265175	chr8:121136014	COL14A1	-0.41	-4.88	-0.3	1.95e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg04935436	chr20:30431758	NA	0.5	6.93	0.4	3.64e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.61	8.25	0.47	9.77e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg17279839	chr7:150038598	RARRES2	0.53	6.6	0.39	2.57e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06360820	chr2:242988706	NA	-0.82	-8.5	-0.48	1.9e-15	Obesity-related traits;
KIRP	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg05347473	chr6:146136440	FBXO30	0.61	8.68	0.48	5.69e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg19507638	chr5:93509721	C5orf36	0.57	5.17	0.31	4.81e-7	Diabetic retinopathy;
KIRP	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs1635	0.826	rs3800324	chr6:28264681	G/A	cg15743358	chr6:28303923	ZNF323	-0.76	-5.47	-0.33	1.13e-7	Schizophrenia;
KIRP	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg27494647	chr7:150038898	RARRES2	0.39	5.78	0.35	2.27e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24110177	chr3:50126178	RBM5	-0.67	-7.64	-0.44	4.87e-13	Menarche (age at onset);
KIRP	trans	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg24644049	chr4:85504048	CDS1	0.9	6.63	0.39	2.11e-10	Skin colour saturation;
KIRP	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.46	-6.46	-0.38	5.45e-10	Height;
KIRP	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg25338242	chr13:114786047	RASA3	0.44	5.14	0.31	5.52e-7	Schizophrenia;
KIRP	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	9.7	0.53	4.64e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10210302	0.504	rs1000141	chr2:234242347	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.46	5.54	0.33	7.95e-8	Crohn's disease;
KIRP	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg05564831	chr3:52568323	NT5DC2	0.32	5.12	0.31	6.21e-7	Bipolar disorder;
KIRP	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-1.1	-21.59	-0.81	1.01e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.76	11.11	0.58	1.68e-23	Hip circumference;
KIRP	cis	rs2625529	0.526	rs8040828	chr15:72492779	C/A	cg16672083	chr15:72433130	SENP8	0.43	5.85	0.35	1.54e-8	Red blood cell count;
KIRP	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.55	-6.69	-0.39	1.53e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg01629716	chr15:45996671	NA	0.36	6.48	0.38	4.85e-10	Waist circumference;Weight;
KIRP	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	8.8	0.49	2.54e-16	Joint mobility (Beighton score);
KIRP	cis	rs8028182	0.636	rs4886703	chr15:75730366	C/T	cg20655648	chr15:75932815	IMP3	0.55	7.0	0.41	2.48e-11	Sudden cardiac arrest;
KIRP	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.68	7.4	0.43	2.12e-12	Smoking initiation;
KIRP	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg08313168	chr12:7315531	NA	0.66	6.07	0.36	4.82e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.61	0.44	5.99e-13	Obesity-related traits;
KIRP	cis	rs7172677	1.000	rs11072525	chr15:75419110	G/A	cg14664628	chr15:75095509	CSK	-0.51	-5.74	-0.34	2.84e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6681460	1.000	rs2147777	chr1:67129254	A/T	cg02459107	chr1:67143332	SGIP1	0.5	7.25	0.42	5.51e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	7.72	0.44	2.87e-13	Personality dimensions;
KIRP	cis	rs4664293	0.836	rs4516379	chr2:160665403	C/T	cg08347373	chr2:160653686	CD302	-0.4	-5.86	-0.35	1.52e-8	Monocyte percentage of white cells;
KIRP	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.56	7.61	0.44	6e-13	Schizophrenia;
KIRP	cis	rs7274811	0.744	rs2071054	chr20:32265839	A/G	cg12710480	chr20:32254216	NECAB3;C20orf134	-0.28	-4.86	-0.3	2.11e-6	Height;
KIRP	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-12.16	-0.61	5.98e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7941600	0.581	rs7103596	chr11:9338052	T/C	cg19415743	chr11:9336845	TMEM41B	0.69	6.05	0.36	5.49e-9	Coronary artery disease;
KIRP	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.75	-10.76	-0.57	2.16e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg23176889	chr5:176863531	GRK6	-0.71	-10.05	-0.54	3.87e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs966423	0.550	rs13002451	chr2:218301341	A/G	cg15335768	chr2:218268053	DIRC3	-0.45	-6.62	-0.39	2.2e-10	Thyroid cancer;
KIRP	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-5.34	-0.32	2.16e-7	Subjective well-being;
KIRP	cis	rs1014246	0.848	rs10787714	chr10:118459384	G/T	cg14919929	chr10:118506882	NA	0.76	9.83	0.53	1.89e-19	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs78487399	0.808	rs72865267	chr2:43726328	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.02	-0.3	9.81e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg16141378	chr3:129829833	LOC729375	0.51	6.38	0.38	8.89e-10	Neuroticism;
KIRP	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg03894339	chr8:19674705	INTS10	-0.48	-5.71	-0.34	3.2e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg04287289	chr16:89883240	FANCA	-0.42	-5.41	-0.33	1.51e-7	Vitiligo;
KIRP	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.56	7.38	0.43	2.44e-12	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs7561273	0.586	rs7589717	chr2:24357463	G/A	cg20701182	chr2:24300061	SF3B14	0.49	6.02	0.36	6.3e-9	Quantitative traits;
KIRP	cis	rs5753037	0.838	rs1894474	chr22:30238074	A/G	cg01021169	chr22:30184971	ASCC2	-0.41	-5.77	-0.35	2.4e-8	Type 1 diabetes;
KIRP	cis	rs72792276	1.000	rs72794386	chr5:127479278	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	7.23	0.42	6.16e-12	Red cell distribution width;
KIRP	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg19767477	chr5:127420684	SLC12A2	-0.36	-5.04	-0.31	8.9e-7	Ileal carcinoids;
KIRP	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.65	10.04	0.54	4.24e-20	Menopause (age at onset);
KIRP	cis	rs16976116	0.851	rs28393427	chr15:55490981	A/G	cg11288833	chr15:55489084	RSL24D1	0.66	7.46	0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg11005552	chr10:105648138	OBFC1	0.4	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs4664293	0.836	rs13032500	chr2:160606251	G/C	cg08347373	chr2:160653686	CD302	-0.41	-6.3	-0.37	1.38e-9	Monocyte percentage of white cells;
KIRP	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg15068132	chr12:102092402	CHPT1	-0.39	-5.05	-0.31	8.47e-7	Blood protein levels;
KIRP	cis	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.9e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.18	0.31	4.61e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs630539	0.655	rs874640	chr17:40843392	G/T	cg10533978	chr17:40842804	CNTNAP1	-0.69	-4.97	-0.3	1.26e-6	Systolic blood pressure change trajectories;
KIRP	cis	rs311392	0.554	rs311386	chr8:55101507	A/G	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.51e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.45	0.38	5.88e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2851682	1.000	rs2851682	chr11:61616012	A/G	cg07689907	chr11:61582574	FADS1	0.7	5.21	0.32	3.92e-7	Gestational age at birth (child effect);Trans fatty acid levels;
KIRP	cis	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg21204522	chr6:27730016	NA	-0.75	-5.53	-0.33	7.99e-8	Breast cancer;
KIRP	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs4262150	0.846	rs72801007	chr5:152196711	C/G	cg12297329	chr5:152029980	NA	-0.63	-8.1	-0.46	2.54e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.01	-0.3	1.04e-6	Obesity-related traits;
KIRP	cis	rs244899	0.935	rs244896	chr5:167918663	G/T	cg06604206	chr5:167912465	RARS	-0.54	-7.81	-0.45	1.63e-13	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.72	-9.82	-0.53	1.97e-19	Colorectal cancer;
KIRP	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.51	-6.01	-0.36	6.48e-9	Coronary artery disease;
KIRP	cis	rs9948	0.881	rs3731941	chr2:97476219	A/G	cg20312557	chr2:97357134	FER1L5	-0.77	-5.41	-0.33	1.47e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.12	20.58	0.8	2.01e-55	Colorectal cancer;
KIRP	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg02640540	chr1:67518911	SLC35D1	0.4	4.92	0.3	1.59e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs6593803	0.732	rs6593806	chr1:147213538	A/T	cg27546670	chr1:147246839	GJA5	0.65	7.69	0.44	3.45e-13	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs12200782	1.000	rs12207181	chr6:26431285	C/T	cg11502198	chr6:26597334	ABT1	-0.73	-4.9	-0.3	1.74e-6	Small cell lung carcinoma;
KIRP	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.58	8.04	0.46	3.75e-14	Brugada syndrome;
KIRP	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.38	0.47	4.19e-15	Motion sickness;
KIRP	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-5.87	-0.35	1.4e-8	IgG glycosylation;
KIRP	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.74	9.75	0.53	3.41e-19	Cognitive function;
KIRP	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.21	-0.55	1.2e-20	Heart rate;
KIRP	cis	rs12210905	0.688	rs12202956	chr6:27356476	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs34390795	1	rs34390795	chr12:133112394	CGT/C	cg06183872	chr12:133049993	NA	0.55	6.59	0.39	2.64e-10	Red blood cell count;
KIRP	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	6.86	0.4	5.69e-11	Systolic blood pressure;
KIRP	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.77	0.4	9.43e-11	Morning vs. evening chronotype;
KIRP	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg25650185	chr19:21324782	ZNF431	-0.49	-5.16	-0.31	4.97e-7	Pain;
KIRP	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.3	-0.47	7.03e-15	Morning vs. evening chronotype;
KIRP	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.53	6.81	0.4	7.49e-11	Coronary heart disease;
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg00933542	chr6:150070202	PCMT1	0.28	5.38	0.32	1.69e-7	Lung cancer;
KIRP	cis	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg13293535	chr8:11597251	GATA4	0.48	6.48	0.38	5.1e-10	Neuroticism;
KIRP	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.52	-6.56	-0.39	3.21e-10	Neurofibrillary tangles;
KIRP	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.1	-0.5	3.27e-17	Personality dimensions;
KIRP	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	trans	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg16141378	chr3:129829833	LOC729375	0.53	6.42	0.38	6.94e-10	Mood instability;
KIRP	trans	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg21775007	chr8:11205619	TDH	-0.46	-6.33	-0.37	1.18e-9	Joint mobility (Beighton score);
KIRP	cis	rs7221595	0.825	rs8069643	chr17:3971237	C/T	cg09597638	chr17:3907349	NA	0.57	6.35	0.38	1.05e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg24060327	chr5:131705240	SLC22A5	0.56	7.47	0.43	1.43e-12	Acylcarnitine levels;
KIRP	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg25486957	chr4:152246857	NA	-0.46	-5.56	-0.33	6.98e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6693295	0.793	rs2787960	chr1:246242240	C/T	cg11798871	chr1:246315928	SMYD3	0.41	4.99	0.3	1.14e-6	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg12560992	chr17:57184187	TRIM37	0.51	5.18	0.31	4.62e-7	Cognitive test performance;
KIRP	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	10.96	0.57	5.14e-23	Lung cancer in ever smokers;
KIRP	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.71	8.2	0.46	1.3e-14	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.56	-0.33	6.85e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg06074448	chr4:187884817	NA	0.59	9.25	0.51	1.09e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.67	-0.63	1.18e-28	Alzheimer's disease;
KIRP	cis	rs300890	0.931	rs300892	chr4:144257151	G/A	cg19876092	chr4:144208277	NA	0.44	7.24	0.42	5.76e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs28655083	1.000	rs7198870	chr16:77072963	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-5.52	-0.33	8.56e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg02807482	chr3:125708958	NA	-0.55	-5.53	-0.33	8.23e-8	Blood pressure (smoking interaction);
KIRP	cis	rs12049351	0.665	rs1838464	chr1:229616693	T/C	cg11742688	chr1:229674241	ABCB10	-0.39	-5.84	-0.35	1.63e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs4664293	0.867	rs7589941	chr2:160584100	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs6546324	0.625	rs6546325	chr2:67861901	C/A	cg15745817	chr2:67799979	NA	-0.69	-7.48	-0.43	1.35e-12	Endometriosis;
KIRP	cis	rs13395090	0.967	rs12105179	chr2:3721729	C/T	cg20493526	chr2:3714936	ALLC	-0.61	-8.0	-0.45	4.91e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs9314323	0.708	rs1594829	chr8:26206077	C/T	cg13160058	chr8:26243215	BNIP3L	0.46	5.62	0.34	5.06e-8	Red cell distribution width;
KIRP	cis	rs7224685	0.501	rs781859	chr17:3923331	C/T	cg21734707	chr17:3908241	ZZEF1	0.66	10.17	0.54	1.59e-20	Type 2 diabetes;
KIRP	cis	rs6991838	0.550	rs12335006	chr8:66531629	T/C	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	12.7	0.63	9.44e-29	Ulcerative colitis;
KIRP	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-1.01	-18.46	-0.76	2.42e-48	Height;
KIRP	cis	rs7923609	0.841	rs10761786	chr10:65336207	T/C	cg01631684	chr10:65280961	REEP3	-0.47	-5.55	-0.33	7.53e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.22e-9	Breast cancer;
KIRP	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg06289844	chr6:126071538	HEY2	0.44	6.42	0.38	6.98e-10	Brugada syndrome;
KIRP	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.78	-0.44	1.95e-13	Retinal vascular caliber;
KIRP	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg20813462	chr7:2646259	IQCE	0.63	6.13	0.36	3.47e-9	Urate levels in lean individuals;
KIRP	cis	rs7903847	0.642	rs11189180	chr10:99143529	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5.05e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg05220968	chr6:146057943	EPM2A	-0.41	-5.28	-0.32	2.82e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7737355	1.000	rs27421	chr5:130743771	C/T	cg25547332	chr5:131281432	NA	-0.49	-5.39	-0.33	1.63e-7	Life satisfaction;
KIRP	cis	rs4132509	1.000	rs6675851	chr1:243787494	G/A	cg21452805	chr1:244014465	NA	0.56	5.61	0.34	5.51e-8	RR interval (heart rate);
KIRP	cis	rs6987853	0.933	rs55881007	chr8:42367290	A/G	cg09913449	chr8:42400586	C8orf40	-0.4	-5.13	-0.31	5.77e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.73	-0.44	2.68e-13	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11442381	chr3:52312806	WDR82	0.49	6.18	0.37	2.63e-9	Parkinson's disease;
KIRP	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg18357526	chr6:26021779	HIST1H4A	0.54	6.04	0.36	5.64e-9	Uric acid levels;
KIRP	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.27	0.32	2.92e-7	Depression;
KIRP	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.13	-0.41	1.13e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11710088	0.599	rs4681509	chr3:149201444	A/G	cg08667024	chr3:149219783	TM4SF4	-0.5	-7.61	-0.44	6e-13	QRS duration;
KIRP	cis	rs981844	0.961	rs56288418	chr4:154668228	C/A	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg24315340	chr6:146058215	EPM2A	0.44	5.49	0.33	1.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg06115741	chr20:33292138	TP53INP2	-0.4	-4.86	-0.3	2.13e-6	Height;
KIRP	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg12042659	chr19:58951599	ZNF132	0.49	6.17	0.37	2.74e-9	Uric acid clearance;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.87	-12.02	-0.61	1.71e-26	Longevity;Endometriosis;
KIRP	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.1	22.97	0.83	3.79e-63	Myeloid white cell count;
KIRP	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg10189774	chr4:17578691	LAP3	0.48	5.77	0.35	2.35e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg08499158	chr17:42289980	UBTF	-0.64	-8.79	-0.49	2.63e-16	Total body bone mineral density;
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-8.86	-0.49	1.64e-16	Platelet count;
KIRP	trans	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.21	-0.42	6.77e-12	Systolic blood pressure;
KIRP	cis	rs73206853	0.563	rs7960749	chr12:111164369	T/C	cg12870014	chr12:110450643	ANKRD13A	0.49	4.85	0.3	2.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.52	6.89	0.4	4.55e-11	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.84	-0.71	1.96e-39	Immature fraction of reticulocytes;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17330983	chr14:23770641	PPP1R3E	0.54	6.39	0.38	8.1e-10	Smoking initiation;
KIRP	cis	rs8053891	0.805	rs12149869	chr16:71995946	T/C	cg04254540	chr16:71951199	KIAA0174	-0.42	-4.88	-0.3	1.92e-6	Coronary artery disease;
KIRP	cis	rs4713675	0.565	rs4711341	chr6:33690797	A/G	cg15676125	chr6:33679581	C6orf125	0.42	5.59	0.34	5.99e-8	Plateletcrit;
KIRP	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg18833306	chr6:118973337	C6orf204	0.4	5.2	0.31	4.23e-7	Electrocardiographic conduction measures;
KIRP	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.2	-0.31	4.18e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-0.62	-6.91	-0.4	4.23e-11	Initial pursuit acceleration;
KIRP	cis	rs13132184	0.510	rs55767827	chr4:38056537	A/G	cg19090437	chr4:38080799	TBC1D1	-0.6	-5.44	-0.33	1.27e-7	Verbal declarative memory;
KIRP	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg21253087	chr9:139290292	SNAPC4	0.48	6.61	0.39	2.43e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9359856	0.517	rs72919948	chr6:90509389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.79	-7.77	-0.44	2.07e-13	Bipolar disorder;
KIRP	cis	rs9810259	0.966	rs13066322	chr3:12269266	C/T	cg02700894	chr3:12045449	SYN2	-0.41	-5.88	-0.35	1.32e-8	Platelet count;
KIRP	trans	rs62056376	0.736	rs62054939	chr17:32645165	T/C	cg06688323	chr4:4858340	NA	-0.58	-6.08	-0.36	4.5e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg05362011	chr13:21860987	NA	-0.46	-4.96	-0.3	1.3e-6	White matter hyperintensity burden;
KIRP	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.51	-6.35	-0.38	1.02e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.76	-11.28	-0.58	4.71e-24	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.56e-24	Height;
KIRP	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	ch.11.340609R	chr11:12831013	TEAD1	0.39	4.98	0.3	1.22e-6	Educational attainment (years of education);
KIRP	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09235308	chr8:145019639	PLEC1;MIR661	-0.39	-6.02	-0.36	6.35e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg02733842	chr7:1102375	C7orf50	-0.48	-5.54	-0.33	7.65e-8	Bronchopulmonary dysplasia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01957599	chr4:89631033	FAM13AOS	0.36	6.41	0.38	7.42e-10	C-reactive protein;
KIRP	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg15488143	chr7:128924101	AHCYL2	0.41	4.86	0.3	2.12e-6	White matter hyperintensity burden;
KIRP	cis	rs4722585	0.533	rs6964215	chr7:26196819	G/A	cg10536999	chr7:26193109	NFE2L3	-0.34	-4.85	-0.3	2.19e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
KIRP	cis	rs7560272	0.501	rs11891140	chr2:73944084	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.49	0.33	1.02e-7	Schizophrenia;
KIRP	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.99	7.94	0.45	7.11e-14	Alzheimer's disease (late onset);
KIRP	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg13409248	chr3:40428643	ENTPD3	0.38	5.14	0.31	5.59e-7	Renal cell carcinoma;
KIRP	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg19847130	chr8:10466454	RP1L1	0.41	5.91	0.35	1.13e-8	Retinal vascular caliber;
KIRP	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06050784	chr16:88016603	BANP	-0.42	-5.15	-0.31	5.41e-7	Menopause (age at onset);
KIRP	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16925090	chr11:101785516	KIAA1377;ANGPTL5	0.5	6.29	0.37	1.43e-9	Smoking initiation;
KIRP	cis	rs6504622	0.577	rs35707546	chr17:45001541	G/A	cg16759221	chr17:45003025	GOSR2	0.35	5.24	0.32	3.42e-7	Orofacial clefts;
KIRP	cis	rs4006360	0.604	rs3843964	chr17:39227984	C/T	cg25341923	chr17:39239918	KRTAP4-7	0.59	9.06	0.5	4.13e-17	Bipolar disorder and schizophrenia;
KIRP	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.54	-7.32	-0.42	3.53e-12	Pulmonary function;
KIRP	cis	rs853679	0.546	rs200490	chr6:27796935	G/T	cg26587870	chr6:27730563	NA	-0.67	-5.22	-0.32	3.89e-7	Depression;
KIRP	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	9.6	0.52	9.55e-19	Cognitive test performance;
KIRP	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.63	8.94	0.5	9.23e-17	Schizophrenia;
KIRP	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	0.91	7.21	0.42	6.82e-12	Age-related hearing impairment;
KIRP	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-9.01	-0.5	6e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg11232368	chr1:97565426	DPYD	0.4	6.17	0.37	2.83e-9	Migraine with aura;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg16139199	chr18:19180362	ESCO1	0.54	6.59	0.39	2.65e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3617	0.573	rs9860296	chr3:52913781	A/G	cg18404041	chr3:52824283	ITIH1	-0.34	-4.88	-0.3	1.89e-6	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.43	-6.4	-0.38	7.79e-10	Refractive error;
KIRP	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg11833968	chr6:79620685	NA	-0.45	-7.0	-0.41	2.43e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg13660082	chr14:53194042	PSMC6	-0.72	-7.67	-0.44	4.01e-13	Alzheimer's disease (late onset);
KIRP	cis	rs2625529	0.730	rs12908882	chr15:72437572	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09093670	chr12:83924766	NA	-0.39	-6.75	-0.4	1.08e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg19468946	chr17:37922297	IKZF3	-0.48	-6.55	-0.39	3.34e-10	Self-reported allergy;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg02626152	chr1:52456480	RAB3B	0.47	6.51	0.38	4.18e-10	Asthma;
KIRP	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg05220968	chr6:146057943	EPM2A	0.4	5.06	0.31	8.13e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.84	-7.06	-0.41	1.68e-11	Initial pursuit acceleration;
KIRP	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.79	-12.32	-0.62	1.68e-27	Prostate cancer;
KIRP	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg23307798	chr14:103986281	CKB	-0.39	-5.18	-0.31	4.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.46e-10	Major depressive disorder;
KIRP	cis	rs1723838	0.826	rs1880643	chr11:73413014	A/C	cg16259171	chr11:73660510	DNAJB13	-0.46	-4.91	-0.3	1.65e-6	Obesity-related traits;
KIRP	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg05082376	chr22:42548792	NA	0.46	5.84	0.35	1.62e-8	Schizophrenia;
KIRP	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.59	6.94	0.4	3.39e-11	Pancreatic cancer;
KIRP	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.61	7.33	0.42	3.3e-12	Body mass index;
KIRP	cis	rs2071426	0.959	rs12359863	chr10:96812230	C/T	cg09036531	chr10:96991505	NA	-0.67	-7.36	-0.42	2.83e-12	Blood metabolite levels;
KIRP	cis	rs9479482	0.638	rs472469	chr6:150383174	T/C	cg03788504	chr6:150331562	NA	-0.31	-5.48	-0.33	1.04e-7	Alopecia areata;
KIRP	cis	rs62413470	1.000	rs7450492	chr6:55935891	C/G	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg03959625	chr15:84868606	LOC388152	0.49	5.98	0.36	7.76e-9	Schizophrenia;
KIRP	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.2	-0.42	7.26e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9308731	0.583	rs7567184	chr2:111931072	C/G	cg04780086	chr2:111875790	ACOXL	0.44	6.02	0.36	6.19e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs42648	0.869	rs1015402	chr7:89913269	C/T	cg25739043	chr7:89950458	NA	-0.47	-7.5	-0.43	1.19e-12	Homocysteine levels;
KIRP	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.8	-10.69	-0.56	3.71e-22	Iron status biomarkers;
KIRP	cis	rs8060686	0.858	rs8057986	chr16:67893879	A/G	cg26727032	chr16:67993705	SLC12A4	-0.79	-9.19	-0.51	1.71e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.91e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	cis	rs7555523	0.887	rs6696454	chr1:165707923	T/C	cg24409356	chr1:165738333	TMCO1	0.7	5.75	0.34	2.65e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.35	1.28e-8	Mean platelet volume;
KIRP	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	1.05	17.52	0.75	3.65e-45	Menopause (age at onset);
KIRP	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.35	-0.32	2.02e-7	Schizophrenia;
KIRP	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg24203234	chr3:128598194	ACAD9	0.44	5.05	0.31	8.45e-7	IgG glycosylation;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.22	-24.51	-0.84	5.66e-68	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11987759	chr7:65425863	GUSB	0.47	6.01	0.36	6.83e-9	Aortic root size;
KIRP	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg02462569	chr6:150064036	NUP43	-0.38	-5.81	-0.35	1.96e-8	Lung cancer;
KIRP	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.9	14.39	0.68	1.73e-34	Dental caries;
KIRP	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg26751094	chr13:95954534	ABCC4	-0.7	-9.74	-0.53	3.65e-19	Blood metabolite levels;
KIRP	cis	rs7106204	0.748	rs28656439	chr11:24207653	G/C	ch.11.24196551F	chr11:24239977	NA	0.79	9.17	0.5	1.92e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Hypertriglyceridemia;
KIRP	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg04780086	chr2:111875790	ACOXL	0.44	6.16	0.37	2.89e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.82	-7.51	-0.43	1.08e-12	QRS interval (sulfonylurea treatment interaction);
KIRP	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.95	12.69	0.63	1e-28	Menopause (age at onset);
KIRP	cis	rs780094	0.500	rs13002853	chr2:27853245	C/G	cg05484376	chr2:27715224	FNDC4	-0.39	-5.23	-0.32	3.67e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg03894339	chr8:19674705	INTS10	0.59	6.9	0.4	4.48e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.51	-6.81	-0.4	7.26e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.61	-0.34	5.44e-8	IgG glycosylation;
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.65	9.83	0.53	1.96e-19	Lung cancer;
KIRP	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg22974920	chr21:40686053	BRWD1	0.45	5.31	0.32	2.4e-7	Cognitive function;
KIRP	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg07001201	chr5:642380	CEP72	0.68	6.4	0.38	7.71e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg10117171	chr1:25599238	RHD	-0.4	-5.46	-0.33	1.19e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg00792783	chr2:198669748	PLCL1	0.47	5.28	0.32	2.77e-7	Dermatomyositis;
KIRP	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.87	-11.83	-0.6	7.08e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg10189774	chr4:17578691	LAP3	0.48	5.84	0.35	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg19623624	chr10:135278901	LOC619207	-0.54	-6.27	-0.37	1.62e-9	Systemic lupus erythematosus;
KIRP	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.56	8.08	0.46	2.96e-14	Calcium levels;
KIRP	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.76	12.66	0.63	1.3e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg05315796	chr3:52349193	DNAH1	0.45	6.95	0.41	3.24e-11	Bipolar disorder;
KIRP	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.5	6.66	0.39	1.78e-10	Testicular germ cell tumor;
KIRP	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg24253500	chr15:84953950	NA	0.68	7.83	0.45	1.49e-13	Schizophrenia;
KIRP	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg05802129	chr4:122689817	NA	-0.6	-7.55	-0.43	8.56e-13	Type 2 diabetes;
KIRP	cis	rs4664293	1.000	rs2357382	chr2:160493125	G/C	cg08347373	chr2:160653686	CD302	-0.39	-5.95	-0.35	9e-9	Monocyte percentage of white cells;
KIRP	trans	rs2292298	0.513	rs3756143	chr4:37640389	T/C	cg20319457	chr2:20133404	WDR35	-0.5	-6.02	-0.36	6.41e-9	IgG glycosylation;
KIRP	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	1.23	11.34	0.59	2.92e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.48	6.43	0.38	6.61e-10	Menopause (age at onset);
KIRP	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.44	4.95	0.3	1.4e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.95	0.45	6.81e-14	Sudden cardiac arrest;
KIRP	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg06917634	chr15:78832804	PSMA4	0.47	4.89	0.3	1.78e-6	Post bronchodilator FEV1;
KIRP	cis	rs12982744	0.613	rs35142206	chr19:2142026	T/C	cg09261902	chr19:2140048	AP3D1	0.43	5.49	0.33	1.01e-7	Osteoarthritis;Height;
KIRP	cis	rs787274	1.000	rs1711739	chr9:115464474	G/A	cg13803584	chr9:115635662	SNX30	0.59	7.38	0.43	2.43e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7119038	0.629	rs10892272	chr11:118602707	C/G	cg19308663	chr11:118741387	NA	0.48	7.89	0.45	1.01e-13	Sjögren's syndrome;
KIRP	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2562456	0.833	rs11666540	chr19:21539352	C/T	cg18461458	chr19:21324796	ZNF431	-0.51	-4.95	-0.3	1.36e-6	Pain;
KIRP	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.42	8.93	0.49	1e-16	Vitiligo;
KIRP	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.43	5.05	0.31	8.54e-7	Mean platelet volume;
KIRP	cis	rs68170813	1.000	rs35531458	chr7:107249855	G/A	cg02696742	chr7:106810147	HBP1	-0.62	-6.14	-0.36	3.31e-9	Coronary artery disease;
KIRP	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg18944383	chr4:111397179	ENPEP	0.47	7.63	0.44	5.02e-13	Coronary artery disease;
KIRP	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg24315340	chr6:146058215	EPM2A	0.39	4.95	0.3	1.4e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-20.07	-0.79	1e-53	Height;
KIRP	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg05370193	chr1:21551575	ECE1	-0.42	-5.95	-0.35	9.4e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1620921	0.901	rs783182	chr6:161168548	G/A	cg01280913	chr6:161186852	NA	-0.41	-5.85	-0.35	1.52e-8	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20992011	chr8:144513000	MAFA	-0.57	-6.13	-0.36	3.42e-9	Menopause (age at onset);
KIRP	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00585698	chr12:123750864	CDK2AP1	-0.43	-5.37	-0.32	1.78e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11584989	chr19:19387371	SF4	0.58	6.48	0.38	4.92e-10	Bipolar disorder;
KIRP	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg26513180	chr16:89883248	FANCA	0.85	14.53	0.68	5.95e-35	Vitiligo;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.62e-11	Lung cancer;
KIRP	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.82	11.61	0.6	3.79e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs72829446	0.530	rs7210231	chr17:7357864	C/A	cg02795151	chr17:7402630	POLR2A	0.72	7.38	0.43	2.49e-12	Androgen levels;
KIRP	trans	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-5.87	-0.35	1.41e-8	Lung cancer;
KIRP	cis	rs4363385	0.510	rs17627288	chr1:152923848	C/T	cg25856811	chr1:152973957	SPRR3	-0.39	-5.38	-0.32	1.76e-7	Inflammatory skin disease;
KIRP	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.43	6.45	0.38	5.87e-10	Major depressive disorder;
KIRP	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg10755058	chr3:40428713	ENTPD3	-0.45	-6.69	-0.39	1.52e-10	Renal cell carcinoma;
KIRP	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.3	-5.64	-0.34	4.73e-8	Monocyte percentage of white cells;
KIRP	cis	rs1847505	0.609	rs75746063	chr13:61483475	T/C	cg25164009	chr13:61490935	NA	0.54	5.59	0.34	6.13e-8	Polychlorinated biphenyl levels;
KIRP	cis	rs11605275	1.000	rs78249104	chr11:20027680	G/T	cg14835545	chr11:20032148	NAV2	-0.72	-4.89	-0.3	1.82e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2505998	0.833	rs2742244	chr10:43603592	G/C	cg15436174	chr10:43711423	RASGEF1A	-0.45	-4.91	-0.3	1.68e-6	Hirschsprung disease;
KIRP	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	11.22	0.58	7.05e-24	Smoking behavior;
KIRP	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs1697938	0.840	rs1806513	chr5:40869406	T/C	cg01087697	chr5:40835557	RPL37	-0.47	-5.17	-0.31	4.78e-7	Multiple system atrophy;
KIRP	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27144592	chr16:783916	NARFL	0.35	4.93	0.3	1.53e-6	Height;
KIRP	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.63	6.72	0.39	1.25e-10	Response to diuretic therapy;
KIRP	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.45	-0.52	2.82e-18	Rheumatoid arthritis;
KIRP	cis	rs4262150	0.846	rs113655983	chr5:152128093	T/C	cg12297329	chr5:152029980	NA	-0.54	-7.01	-0.41	2.25e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.67	9.3	0.51	7.81e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs6754311	0.544	rs11678022	chr2:136809033	A/T	cg07169764	chr2:136633963	MCM6	-0.44	-4.94	-0.3	1.44e-6	Mosquito bite size;
KIRP	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.64	-6.59	-0.39	2.6200000000000003e-10	Gut microbiome composition (summer);
KIRP	cis	rs1555895	0.656	rs4881532	chr10:845449	A/G	cg10017260	chr10:834428	NA	-0.38	-5.31	-0.32	2.51e-7	Survival in rectal cancer;
KIRP	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg24565620	chr2:194026	NA	0.7	8.17	0.46	1.66e-14	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08162257	chr15:90777190	CIB1;C15orf58	0.48	6.18	0.37	2.69e-9	Parkinson's disease;
KIRP	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.46	-6.93	-0.4	3.72e-11	Vitamin D levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23172884	chr10:93169999	LOC100188947;HECTD2	0.5	6.21	0.37	2.3e-9	Parkinson's disease;
KIRP	cis	rs1448094	0.967	rs10746357	chr12:86341044	A/T	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg11812906	chr14:75593930	NEK9	-0.48	-5.78	-0.35	2.24e-8	Neuroticism;
KIRP	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.71	8.35	0.47	5.14e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27583337	chr11:123524786	SCN3B	0.46	6.49	0.38	4.77e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg25039879	chr17:56429692	SUPT4H1	0.59	4.93	0.3	1.49e-6	Cognitive test performance;
KIRP	cis	rs77633900	0.772	rs2957611	chr15:76704878	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-5.56	-0.33	6.91e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg18305652	chr10:134549665	INPP5A	0.48	7.27	0.42	4.84e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.28	0.65	1.06e-30	Bladder cancer;
KIRP	cis	rs7224685	0.911	rs9914106	chr17:4066833	G/A	cg21734707	chr17:3908241	ZZEF1	0.39	4.95	0.3	1.4e-6	Type 2 diabetes;
KIRP	cis	rs9513627	1.000	rs4466950	chr13:100166875	G/T	cg25919922	chr13:100150906	NA	0.74	5.59	0.34	5.88e-8	Obesity-related traits;
KIRP	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.53	6.81	0.4	7.49e-11	Coronary heart disease;
KIRP	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07234876	chr8:600039	NA	0.94	7.45	0.43	1.61e-12	IgG glycosylation;
KIRP	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.53	-6.92	-0.4	3.85e-11	Longevity;
KIRP	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg07636037	chr3:49044803	WDR6	0.51	5.01	0.3	1.06e-6	Menarche (age at onset);
KIRP	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.88	9.41	0.51	3.63e-18	Pulmonary function decline;
KIRP	cis	rs2625529	0.556	rs1552134	chr15:72232898	T/A	cg16672083	chr15:72433130	SENP8	0.45	6.25	0.37	1.82e-9	Red blood cell count;
KIRP	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	1.06	15.18	0.7	3.54e-37	Menopause (age at onset);
KIRP	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg24296786	chr1:45957014	TESK2	0.51	6.18	0.37	2.57e-9	Homocysteine levels;
KIRP	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg08721347	chr1:95538652	ALG14	0.56	6.55	0.39	3.39e-10	Lung cancer in ever smokers;
KIRP	cis	rs7590368	0.651	rs56093996	chr2:10931302	T/C	cg15705551	chr2:10952987	PDIA6	0.65	6.29	0.37	1.44e-9	Educational attainment (years of education);
KIRP	cis	rs7209700	0.547	rs7217214	chr17:45355227	T/C	cg08085267	chr17:45401833	C17orf57	0.56	5.22	0.32	3.76e-7	IgG glycosylation;
KIRP	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06505273	chr16:24850292	NA	0.41	5.65	0.34	4.45e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9473924	0.632	rs9473953	chr6:50925331	A/T	cg03432817	chr6:50765336	NA	-0.34	-5.27	-0.32	3.04e-7	Body mass index;
KIRP	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.73	-10.37	-0.55	3.98e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2273669	0.667	rs11153155	chr6:109359963	G/A	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.77	-9.85	-0.53	1.59e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg19197139	chr17:4613644	ARRB2	-0.64	-6.94	-0.4	3.52e-11	Lymphocyte counts;
KIRP	cis	rs2014572	0.967	rs10413671	chr19:57763489	G/A	cg12963866	chr19:57752005	ZNF805	-0.47	-5.97	-0.36	8.42e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs3760047	0.609	rs2541639	chr16:205035	C/T	cg25425005	chr16:202905	HBZ	-0.43	-5.4	-0.33	1.57e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg07001201	chr5:642380	CEP72	0.69	6.47	0.38	5.38e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs10073892	0.620	rs57189793	chr5:101944178	C/T	cg19774478	chr5:101632501	SLCO4C1	0.49	5.24	0.32	3.4e-7	Cognitive decline (age-related);
KIRP	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.71	-0.53	4.51e-19	Triglycerides;
KIRP	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	8.01	0.45	4.69e-14	Height;
KIRP	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg06453172	chr10:134556979	INPP5A	-0.6	-7.2	-0.42	7.4e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.52	0.33	8.7e-8	Coronary artery disease;
KIRP	cis	rs9972944	0.702	rs987931	chr17:63765911	T/G	cg07283582	chr17:63770753	CCDC46	-0.47	-7.88	-0.45	1.07e-13	Total body bone mineral density;
KIRP	trans	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.62	-6.44	-0.38	6.09e-10	Obesity-related traits;
KIRP	cis	rs3931020	0.566	rs1409782	chr1:75272935	T/A	cg17719053	chr1:75198211	TYW3;CRYZ	0.43	5.95	0.35	9.01e-9	Resistin levels;
KIRP	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg02569458	chr12:86230093	RASSF9	-0.52	-7.64	-0.44	4.79e-13	Major depressive disorder;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg08901578	chr4:187885870	NA	-0.43	-6.55	-0.39	3.37e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.38	-7.73	-0.44	2.83e-13	Type 2 diabetes;
KIRP	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg13180566	chr4:1052158	NA	-0.51	-5.13	-0.31	5.75e-7	Recombination rate (females);
KIRP	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-8.45	-0.47	2.58e-15	Morning vs. evening chronotype;
KIRP	cis	rs4494114	1.000	rs3790441	chr1:39352492	G/A	cg25970120	chr1:39325951	RRAGC	-0.41	-5.07	-0.31	7.65e-7	Blood protein levels;
KIRP	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	5.46	0.33	1.16e-7	Breast cancer;
KIRP	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.56	-8.58	-0.48	1.06e-15	Eosinophil percentage of granulocytes;
KIRP	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.66	-8.15	-0.46	1.8e-14	Multiple sclerosis;
KIRP	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.51	-7.42	-0.43	1.85e-12	Daytime sleep phenotypes;
KIRP	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	7.14	0.41	1.06e-11	Height;
KIRP	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12210905	1.000	rs72843619	chr6:27154830	A/G	cg11502198	chr6:26597334	ABT1	-0.74	-4.91	-0.3	1.66e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.76	10.35	0.55	4.47e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11874712	1.000	rs9962458	chr18:43678625	G/C	cg26436583	chr18:43649176	PSTPIP2	-0.42	-5.7	-0.34	3.41e-8	Migraine - clinic-based;
KIRP	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.51	-6.22	-0.37	2.07e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg14541582	chr5:601475	NA	-0.58	-6.61	-0.39	2.32e-10	Obesity-related traits;
KIRP	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg14228332	chr4:119757509	SEC24D	0.79	4.86	0.3	2.1e-6	Cannabis dependence symptom count;
KIRP	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-5.24	-0.32	3.38e-7	Testicular germ cell tumor;
KIRP	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-8.26	-0.47	9.31e-15	Monocyte percentage of white cells;
KIRP	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4704187	0.687	rs57646262	chr5:74527472	C/T	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.73e-8	Response to amphetamines;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18643762	chr2:119981172	STEAP3	0.49	6.46	0.38	5.53e-10	Parkinson's disease;
KIRP	cis	rs9473924	0.540	rs6458747	chr6:50923072	C/T	cg03432817	chr6:50765336	NA	0.35	5.4	0.33	1.59e-7	Body mass index;
KIRP	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg01849789	chr22:41697279	ZC3H7B	-0.42	-4.97	-0.3	1.28e-6	Neuroticism;
KIRP	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.26	-0.32	3.16e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.01	16.45	0.72	1.68e-41	Multiple system atrophy;
KIRP	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.98	10.12	0.54	2.42e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23138119	chr2:163218380	GCA	-0.48	-8.32	-0.47	6.2e-15	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9547692	0.938	rs4520715	chr13:37459113	C/T	cg01493522	chr13:37497338	NA	-0.45	-5.48	-0.33	1.07e-7	Coronary artery disease;
KIRP	cis	rs9443189	0.865	rs2133190	chr6:76443493	A/G	cg01950844	chr6:76311363	SENP6	-0.62	-6.84	-0.4	6.13e-11	Prostate cancer;
KIRP	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg15117754	chr3:10150083	C3orf24	-0.52	-5.02	-0.3	9.87e-7	Alzheimer's disease;
KIRP	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	8.91	0.49	1.13e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4740619	0.619	rs10810527	chr9:16043350	C/G	cg14451791	chr9:16040625	NA	0.38	4.97	0.3	1.26e-6	Body mass index;
KIRP	cis	rs11209002	0.571	rs7531772	chr1:67555516	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	6.59	0.39	2.63e-10	Crohn's disease;
KIRP	cis	rs7520050	0.807	rs4660312	chr1:46110572	A/G	cg03146154	chr1:46216737	IPP	0.43	5.4	0.33	1.6e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11987759	chr7:65425863	GUSB	0.57	7.71	0.44	3.1e-13	Aortic root size;
KIRP	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.47	-0.48	2.28e-15	Total cholesterol levels;
KIRP	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg02192678	chr8:1495185	DLGAP2	-0.36	-5.3	-0.32	2.59e-7	Lung cancer;
KIRP	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg05220968	chr6:146057943	EPM2A	0.4	5.14	0.31	5.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg23682824	chr7:23144976	KLHL7	0.58	7.03	0.41	2.08e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg01657329	chr11:68192670	LRP5	-0.56	-7.43	-0.43	1.76e-12	Total body bone mineral density;
KIRP	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg21709803	chr11:61594965	FADS2	-0.43	-5.05	-0.31	8.77e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.93	-11.05	-0.58	2.57e-23	White matter hyperintensity burden;
KIRP	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg11584989	chr19:19387371	SF4	-0.41	-5.07	-0.31	7.92e-7	Tonsillectomy;
KIRP	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg01721255	chr8:58191610	C8orf71	0.66	5.64	0.34	4.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg22951263	chr5:87985283	NA	-0.48	-6.82	-0.4	6.97e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7712401	0.601	rs30029	chr5:122283170	A/C	cg19412675	chr5:122181750	SNX24	-0.49	-5.36	-0.32	1.88e-7	Mean platelet volume;
KIRP	cis	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.25	0.32	3.3e-7	Leprosy;
KIRP	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg13334819	chr7:99746414	C7orf59	-0.5	-5.79	-0.35	2.09e-8	Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg01028140	chr2:1542097	TPO	-0.52	-5.88	-0.35	1.34e-8	IgG glycosylation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25439992	chr11:126173954	DCPS	0.47	6.63	0.39	2.08e-10	Survival in pancreatic cancer;
KIRP	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	9.95e-11	Bipolar disorder;
KIRP	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg09137382	chr11:130731461	NA	0.56	8.19	0.46	1.39e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.5	-6.29	-0.37	1.42e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs6466055	0.748	rs10281422	chr7:104844519	G/A	cg04380332	chr7:105027541	SRPK2	-0.63	-9.71	-0.53	4.5e-19	Schizophrenia;
KIRP	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.41	-0.38	7.19e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.76	9.31	0.51	7.19e-18	Response to antipsychotic treatment;
KIRP	cis	rs2411233	0.967	rs11632632	chr15:39283767	T/C	cg02291532	chr15:39874776	THBS1	0.38	5.3	0.32	2.51e-7	Platelet count;
KIRP	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21871465	chr11:3013656	NAP1L4	-0.5	-6.56	-0.39	3.16e-10	Survival in pancreatic cancer;
KIRP	trans	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	0.97	11.06	0.58	2.34e-23	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23903597	chr17:61704154	MAP3K3	0.55	6.86	0.4	5.64e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs61884328	0.852	rs17790390	chr11:47151897	A/G	cg23433285	chr11:47201945	PACSIN3	-0.65	-5.23	-0.32	3.65e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-6.92	-0.4	3.87e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs6499129	0.571	rs56234712	chr16:67241754	T/C	cg04890459	chr16:67204681	NA	0.6	4.98	0.3	1.22e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4262150	0.883	rs72799150	chr5:152110686	G/A	cg12297329	chr5:152029980	NA	-0.66	-8.35	-0.47	4.9e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg10223061	chr2:219282414	VIL1	-0.4	-6.37	-0.38	9.28e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11638352	0.661	rs2114422	chr15:44420244	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.63	-5.75	-0.34	2.64e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9612	1.000	rs346523	chr19:44260681	A/C	cg08581076	chr19:44259116	C19orf61	0.6	6.57	0.39	2.99e-10	Exhaled nitric oxide output;
KIRP	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.73	-7.19	-0.42	7.61e-12	Menarche (age at onset);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg20064047	chr1:155532716	ASH1L;LOC645676	0.55	7.18	0.42	8.44e-12	Myopia (pathological);
KIRP	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.29e-15	Life satisfaction;
KIRP	cis	rs10411936	0.712	rs10414751	chr19:16591695	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.5	5.31	0.32	2.42e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg26174226	chr8:58114915	NA	-0.5	-5.6	-0.34	5.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg12292205	chr6:26970375	C6orf41	0.48	6.96	0.41	3.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.65	6.93	0.4	3.64e-11	Response to diuretic therapy;
KIRP	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-7.03	-0.41	2.05e-11	Body mass index;
KIRP	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.72	10.6	0.56	7.25e-22	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.4	-0.47	3.49e-15	Neuroticism;
KIRP	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.84	15.77	0.71	3.51e-39	Anterior chamber depth;
KIRP	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg05861140	chr6:150128134	PCMT1	-0.48	-6.82	-0.4	6.98e-11	Lung cancer;
KIRP	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.97	-16.01	-0.71	5.3e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.05	11.57	0.59	5.06e-25	Gut microbiome composition (summer);
KIRP	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg23815491	chr16:72088622	HP	0.39	6.3	0.37	1.38e-9	Fibrinogen levels;
KIRP	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.93	12.19	0.61	4.83e-27	Menopause (age at onset);
KIRP	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg18825076	chr15:78729989	IREB2	0.42	5.1	0.31	6.66e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.82	-0.6	7.81e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.5	-6.27	-0.37	1.61e-9	Coronary artery disease;
KIRP	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.67	-8.8	-0.49	2.49e-16	Coronary artery disease;
KIRP	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21545522	chr1:205238299	TMCC2	0.54	7.01	0.41	2.25e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.44	-6.02	-0.36	6.31e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7011507	1.000	rs77951065	chr8:49181163	A/G	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg00262122	chr8:11665843	FDFT1	-0.4	-4.96	-0.3	1.29e-6	Morning vs. evening chronotype;
KIRP	cis	rs11039131	0.787	rs326217	chr11:47303275	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-5.23	-0.32	3.64e-7	Schizophrenia;
KIRP	cis	rs904251	0.605	rs4257849	chr6:37410969	T/G	cg25019722	chr6:37503610	NA	-0.62	-6.31	-0.37	1.32e-9	Cognitive performance;
KIRP	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.46	5.54	0.33	7.69e-8	Longevity;Endometriosis;
KIRP	cis	rs6558530	0.653	rs7001282	chr8:1700188	A/C	cg08198773	chr8:1697536	NA	0.5	6.13	0.36	3.44e-9	Systolic blood pressure;
KIRP	cis	rs6568686	0.627	rs403667	chr6:111910604	T/C	cg22127309	chr6:111907043	TRAF3IP2	0.52	5.18	0.31	4.7e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg13010199	chr12:38710504	ALG10B	0.49	5.93	0.35	1.01e-8	Morning vs. evening chronotype;
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.59	-7.97	-0.45	5.98e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.9	-11.54	-0.59	6.68e-25	Blood protein levels;
KIRP	cis	rs988913	0.957	rs9382405	chr6:54836613	T/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.35	-0.32	1.97e-7	Menarche (age at onset);
KIRP	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00300879	chr1:26503847	CNKSR1	0.48	6.85	0.4	5.85e-11	Height;
KIRP	cis	rs17095355	1.000	rs17095355	chr10:111735750	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.36	-5.15	-0.31	5.23e-7	Biliary atresia;
KIRP	cis	rs4262150	0.960	rs4262151	chr5:152288508	T/C	cg12297329	chr5:152029980	NA	0.47	6.45	0.38	5.91e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.64	-7.56	-0.43	7.75e-13	Resting heart rate;
KIRP	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.66	-9.39	-0.51	4.33e-18	Neuranatomic and neurocognitive phenotypes;
KIRP	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-7.84	-0.45	1.37e-13	Retinal vascular caliber;
KIRP	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg01631408	chr1:248437212	OR2T33	-0.45	-6.08	-0.36	4.44e-9	Common traits (Other);
KIRP	cis	rs8067545	1.000	rs9891739	chr17:19942177	C/T	cg04132472	chr17:19861366	AKAP10	0.5	7.35	0.42	2.88e-12	Schizophrenia;
KIRP	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.63	7.48	0.43	1.34e-12	Type 2 diabetes;
KIRP	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg11693508	chr17:37793320	STARD3	-0.76	-8.33	-0.47	5.56e-15	Bipolar disorder;
KIRP	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.34	-0.32	2.08e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg21699342	chr2:239360505	ASB1	0.47	5.64	0.34	4.77e-8	Multiple system atrophy;
KIRP	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.89	0.45	9.98e-14	Lung cancer in ever smokers;
KIRP	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-1.0	-17.58	-0.75	2.26e-45	Breast cancer;
KIRP	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.62	-8.81	-0.49	2.27e-16	Obesity-related traits;
KIRP	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.25	-6.54	-0.38	3.48e-10	Lung cancer;
KIRP	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.27	28.12	0.87	8.16e-79	IgG glycosylation;
KIRP	cis	rs17123764	0.892	rs11837639	chr12:50151352	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.5	0.33	9.61e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg19602919	chr3:142315213	PLS1	-0.49	-6.23	-0.37	2.01e-9	Myopia;
KIRP	cis	rs12541635	0.677	rs61002083	chr8:106982132	A/G	cg10147462	chr8:107024639	NA	0.35	5.19	0.31	4.34e-7	Age of smoking initiation;
KIRP	trans	rs7939886	0.920	rs11227842	chr11:56079526	C/T	cg03929089	chr4:120376271	NA	0.9	6.2	0.37	2.34e-9	Myopia (pathological);
KIRP	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11987759	chr7:65425863	GUSB	-0.49	-6.68	-0.39	1.55e-10	Aortic root size;
KIRP	cis	rs882732	1.000	rs5510	chr14:95033356	A/G	cg08495878	chr14:95027859	SERPINA4	0.44	5.37	0.32	1.81e-7	Blood protein levels;
KIRP	cis	rs9921338	0.961	rs55707838	chr16:11378075	C/T	cg00044050	chr16:11439710	C16orf75	-0.49	-5.03	-0.31	9.54e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg24375607	chr4:120327624	NA	0.56	6.45	0.38	5.78e-10	Corneal astigmatism;
KIRP	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg17133734	chr15:86042851	AKAP13	-0.45	-5.7	-0.34	3.35e-8	Coronary artery disease;
KIRP	cis	rs8077577	0.945	rs62073611	chr17:18071961	C/G	cg09161412	chr17:18057145	MYO15A	-0.41	-5.23	-0.32	3.62e-7	Obesity-related traits;
KIRP	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.69	-9.17	-0.5	1.97e-17	Blood metabolite levels;
KIRP	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.1	0.69	6.68e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	1.0	15.21	0.7	2.91e-37	Sudden cardiac arrest;
KIRP	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg07636037	chr3:49044803	WDR6	-0.55	-5.06	-0.31	8.26e-7	Menarche (age at onset);
KIRP	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.43	-5.11	-0.31	6.39e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg16141378	chr3:129829833	LOC729375	0.55	6.79	0.4	8.38e-11	Mood instability;
KIRP	cis	rs7129556	1.000	rs7129556	chr11:77300048	A/G	cg12586386	chr11:77299805	AQP11	-0.45	-5.95	-0.35	9.01e-9	Weight loss (gastric bypass surgery);
KIRP	cis	rs959260	0.688	rs9894206	chr17:73360154	T/C	cg20590849	chr17:73267439	MIF4GD	-0.54	-5.43	-0.33	1.33e-7	Systemic lupus erythematosus;
KIRP	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	5.2	0.31	4.17e-7	Personality dimensions;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09699369	chr19:16771803	C19orf42;TMEM38A	-0.53	-6.17	-0.37	2.83e-9	Brain structure;
KIRP	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	0.85	14.32	0.67	2.98e-34	Vitiligo;
KIRP	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg26513180	chr16:89883248	FANCA	0.88	5.84	0.35	1.61e-8	Skin colour saturation;
KIRP	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg05315796	chr3:52349193	DNAH1	0.42	6.43	0.38	6.47e-10	Bipolar disorder;
KIRP	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg14456004	chr13:21872349	NA	1.27	17.57	0.75	2.52e-45	White matter hyperintensity burden;
KIRP	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg00361562	chr2:198649771	BOLL	-0.53	-5.2	-0.31	4.28e-7	Ulcerative colitis;
KIRP	cis	rs13064411	0.518	rs2669909	chr3:113265727	A/G	cg18753928	chr3:113234510	CCDC52	0.46	5.88	0.35	1.32e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs10875746	0.903	rs12313404	chr12:48492048	T/A	cg20731937	chr12:48336164	NA	0.41	5.25	0.32	3.23e-7	Longevity (90 years and older);
KIRP	cis	rs7224685	0.906	rs2304586	chr17:4098998	A/G	cg09695851	chr17:3907499	NA	0.48	5.32	0.32	2.37e-7	Type 2 diabetes;
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg09699651	chr6:150184138	LRP11	0.46	6.16	0.37	2.9e-9	Lung cancer;
KIRP	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.12	-0.41	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs737693	0.607	rs615098	chr11:102720678	A/C	cg19620758	chr11:102826565	MMP13	-0.51	-5.49	-0.33	9.8e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.18	0.31	4.64e-7	Leprosy;
KIRP	cis	rs3779635	0.967	rs750538	chr8:27275726	G/T	cg06815112	chr8:27182871	PTK2B	0.45	5.8	0.35	2e-8	Neuroticism;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19399100	chr4:70519695	NA	0.35	6.16	0.37	2.99e-9	C-reactive protein;
KIRP	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg24848339	chr3:12840334	CAND2	0.36	5.37	0.32	1.85e-7	QRS complex (12-leadsum);
KIRP	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-8.26	-0.47	8.75e-15	Platelet count;
KIRP	trans	rs7999699	0.811	rs4941604	chr13:48307975	A/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.61	-6.92	-0.4	3.84e-11	Hypertension (SNP x SNP interaction);
KIRP	cis	rs7172677	1.000	rs1806794	chr15:75422940	A/G	cg14664628	chr15:75095509	CSK	-0.45	-4.96	-0.3	1.32e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	5.02e-11	Blood metabolite levels;
KIRP	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg13373371	chr19:49828787	SLC6A16	0.44	5.1	0.31	6.92e-7	Multiple sclerosis;
KIRP	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg23894439	chr1:183413866	NA	0.4	5.21	0.32	3.93e-7	Systemic lupus erythematosus;
KIRP	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.57	-7.29	-0.42	4.15e-12	Bipolar disorder;
KIRP	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-9.65	-0.52	6.71e-19	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19930491	chr1:101537712	NA	-0.42	-6.42	-0.38	7e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg00204512	chr16:28754710	NA	0.41	4.84	0.3	2.25e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg07511934	chr16:89386912	ANKRD11	0.41	5.15	0.31	5.27e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	trans	rs1995809	0.793	rs12501143	chr4:147967170	G/A	cg23682866	chr10:43858278	NA	0.61	6.32	0.37	1.19e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.82	9.44	0.52	2.94e-18	Alcohol dependence;Nicotine use;
KIRP	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.91	0.4	4.1e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg21775007	chr8:11205619	TDH	-0.39	-5.18	-0.31	4.58e-7	Morning vs. evening chronotype;
KIRP	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.99	17.25	0.74	3.15e-44	Breast cancer;
KIRP	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg03959625	chr15:84868606	LOC388152	-0.64	-7.13	-0.41	1.14e-11	Schizophrenia;
KIRP	cis	rs3812049	0.506	rs36694	chr5:127548955	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	8.93	0.49	1.04e-16	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg00677455	chr12:58241039	CTDSP2	-0.68	-8.05	-0.46	3.48e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12432903	chr7:1882776	MAD1L1	0.52	4.9	0.3	1.74e-6	Bipolar disorder;
KIRP	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg11833968	chr6:79620685	NA	-0.46	-6.89	-0.4	4.66e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg20701182	chr2:24300061	SF3B14	0.5	5.05	0.31	8.54e-7	Lymphocyte counts;
KIRP	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	1.16	23.16	0.83	9.27e-64	Monocyte count;
KIRP	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	1.25	13.5	0.65	1.89e-31	Eosinophil percentage of granulocytes;
KIRP	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg08461772	chr7:95026248	PON3	0.43	5.98	0.36	7.89e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs6684428	1.000	rs61774843	chr1:56367384	C/T	cg11651538	chr1:56320950	NA	-0.86	-10.11	-0.54	2.52e-20	Airflow obstruction;
KIRP	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13409248	chr3:40428643	ENTPD3	0.39	5.14	0.31	5.63e-7	Renal cell carcinoma;
KIRP	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	7.25	0.42	5.52e-12	Rheumatoid arthritis;
KIRP	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.59	-7.31	-0.42	3.71e-12	Iron status biomarkers;
KIRP	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.85	0.49	1.79e-16	Motion sickness;
KIRP	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg02569458	chr12:86230093	RASSF9	0.41	6.01	0.36	6.53e-9	Major depressive disorder;
KIRP	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.4	5.13	0.31	5.86e-7	Melanoma;
KIRP	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg16898833	chr6:26189333	HIST1H4D	0.67	4.89	0.3	1.84e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7923609	0.841	rs10740131	chr10:65271488	A/T	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.28e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1620921	0.967	rs1247553	chr6:161188103	A/G	cg01280913	chr6:161186852	NA	-0.39	-5.29	-0.32	2.68e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.32	-0.32	2.36e-7	Neuroticism;
KIRP	cis	rs9525927	0.597	rs1330099	chr13:44809426	A/G	cg19190762	chr13:44806055	NA	0.49	5.03	0.31	9.45e-7	Dupuytren's disease;
KIRP	trans	rs12517041	0.935	rs13152937	chr5:23304368	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.86	-0.45	1.22e-13	Calcium levels;
KIRP	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg04935436	chr20:30431758	NA	0.5	6.68	0.39	1.62e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.38e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.39	5.96	0.36	8.49e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs3007168	1.000	rs3007075	chr14:51604860	A/G	cg23942311	chr14:51606299	NA	0.52	5.62	0.34	5.25e-8	Cancer;
KIRP	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.42	-0.38	6.96e-10	Monocyte percentage of white cells;
KIRP	cis	rs6001982	0.667	rs73167066	chr22:40873718	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.91	0.3	1.63e-6	Breast cancer;
KIRP	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.63	7.07	0.41	1.57e-11	Aortic root size;
KIRP	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg05802129	chr4:122689817	NA	-0.46	-6.69	-0.39	1.51e-10	Type 2 diabetes;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg05562828	chr17:3906858	NA	0.76	15.55	0.7	1.98e-38	Type 2 diabetes;
KIRP	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-8.43	-0.47	2.94e-15	Coronary artery disease;
KIRP	cis	rs9653442	0.545	rs12987212	chr2:100761156	C/T	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg23306229	chr2:178417860	TTC30B	0.51	4.92	0.3	1.56e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.83	-0.35	1.75e-8	Height;
KIRP	cis	rs9649213	0.593	rs7797943	chr7:97946902	T/C	cg01877450	chr7:97915802	BRI3	-0.54	-6.88	-0.4	5e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.58	5.72	0.34	3.14e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs45535039	1.000	rs45535039	chr11:119060963	T/C	cg16724696	chr11:118992527	HINFP	0.41	5.06	0.31	8.13e-7	Plateletcrit;
KIRP	cis	rs6800768	0.556	rs73134512	chr3:24089762	G/C	cg10674438	chr3:24145617	LOC152024	-0.4	-5.36	-0.32	1.94e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6466055	0.645	rs4730073	chr7:104855871	A/C	cg04380332	chr7:105027541	SRPK2	-0.54	-8.74	-0.49	3.65e-16	Schizophrenia;
KIRP	cis	rs9378357	0.850	rs7770256	chr6:3294153	G/A	cg03657281	chr6:3270030	SLC22A23	0.66	4.97	0.3	1.23e-6	Obesity-related traits;
KIRP	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.75	-10.73	-0.56	2.79e-22	Waist circumference;Body mass index;
KIRP	cis	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	0.95	14.67	0.68	2e-35	Breast cancer;
KIRP	cis	rs1978968	0.731	rs9605464	chr22:18459922	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.8	-11.35	-0.59	2.7e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.18	-0.46	1.57e-14	Monocyte percentage of white cells;
KIRP	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg04166393	chr7:2884313	GNA12	0.46	5.94	0.35	9.64e-9	Height;
KIRP	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg02931644	chr1:25747376	RHCE	0.36	6.53	0.38	3.83e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg21918786	chr6:109611834	NA	-0.36	-5.07	-0.31	7.69e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	6.32	0.37	1.22e-9	Putamen volume;
KIRP	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	9.99	0.54	6.04e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	5.92	0.35	1.06e-8	Response to antipsychotic treatment;
KIRP	trans	rs783540	0.900	rs4778686	chr15:83310835	C/T	cg16105309	chr15:79090380	ADAMTS7	0.46	6.22	0.37	2.18e-9	Schizophrenia;
KIRP	cis	rs12049351	0.774	rs6704265	chr1:229633056	C/A	cg11742688	chr1:229674241	ABCB10	-0.38	-5.43	-0.33	1.32e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.74	-0.39	1.13e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs72772090	0.708	rs17082200	chr5:96048604	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.53	-4.97	-0.3	1.27e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-10.01	-0.54	5.37e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.7	-10.48	-0.56	1.74e-21	Survival in pancreatic cancer;
KIRP	cis	rs12704876	0.509	rs10257162	chr7:96343642	T/C	cg03808172	chr7:96339361	SHFM1	0.61	8.45	0.47	2.55e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.26	0.42	5.04e-12	Retinal vascular caliber;
KIRP	cis	rs10073892	0.789	rs1376899	chr5:101743703	T/C	cg19774478	chr5:101632501	SLCO4C1	0.67	6.48	0.38	5.1e-10	Cognitive decline (age-related);
KIRP	cis	rs17739794	0.517	rs10106028	chr8:783286	C/A	cg11667643	chr8:748456	NA	-0.43	-4.99	-0.3	1.14e-6	Clozapine-induced cytotoxicity;
KIRP	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.58	-7.36	-0.42	2.83e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.82	-12.53	-0.62	3.53e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs9912468	1.000	rs9909004	chr17:64306133	C/T	cg19474267	chr17:64306194	PRKCA	-0.66	-9.34	-0.51	5.92e-18	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg01721255	chr8:58191610	C8orf71	0.54	5.56	0.33	7.13e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	5.25	0.32	3.22e-7	Cognitive test performance;
KIRP	cis	rs7017914	0.967	rs2100908	chr8:71583310	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.4	-5.0	-0.3	1.1e-6	Bone mineral density;
KIRP	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.9	-0.4	4.51e-11	Response to antipsychotic treatment;
KIRP	cis	rs11671005	0.693	rs11669665	chr19:58931885	G/A	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg27205649	chr11:78285834	NARS2	-0.67	-7.39	-0.43	2.29e-12	Alzheimer's disease (survival time);
KIRP	cis	rs76793172	0.920	rs77799462	chr19:46342500	G/A	cg00442267	chr19:46317840	RSPH6A	-0.78	-6.26	-0.37	1.69e-9	Eosinophil counts;
KIRP	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.43	-5.16	-0.31	4.99e-7	IgG glycosylation;
KIRP	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.57	0.56	9.22e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.42	-5.3	-0.32	2.6e-7	Leprosy;
KIRP	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg16083429	chr3:49237500	CCDC36	0.36	4.85	0.3	2.23e-6	Resting heart rate;
KIRP	cis	rs8070740	0.617	rs1058117	chr17:5323206	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.6	7.99	0.45	5.15e-14	Menopause (age at onset);
KIRP	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg00686598	chr14:53173677	PSMC6	-0.67	-6.08	-0.36	4.6e-9	Alzheimer's disease (late onset);
KIRP	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.54	4.9	0.3	1.76e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.97	17.52	0.75	3.69e-45	Breast cancer;
KIRP	cis	rs4889855	0.530	rs4477776	chr17:78581765	G/A	cg09596252	chr17:78655493	RPTOR	0.47	5.51	0.33	9.18e-8	Fractional excretion of uric acid;
KIRP	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.64	11.44	0.59	1.37e-24	White blood cell count (basophil);
KIRP	cis	rs748404	0.560	rs1869258	chr15:43803621	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.59	7.34	0.42	3.09e-12	Lung cancer;
KIRP	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	11.47	0.59	1.15e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg22852734	chr6:133119734	C6orf192	1.21	11.35	0.59	2.82e-24	Type 2 diabetes nephropathy;
KIRP	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.67	-9.71	-0.53	4.44e-19	Brugada syndrome;
KIRP	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.48	-5.88	-0.35	1.36e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	5.2	0.31	4.28e-7	Breast cancer;
KIRP	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13939156	chr17:80058883	NA	0.49	7.25	0.42	5.43e-12	Life satisfaction;
KIRP	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.63	7.78	0.44	1.99e-13	Corneal astigmatism;
KIRP	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg26751094	chr13:95954534	ABCC4	-0.7	-9.78	-0.53	2.67e-19	Blood metabolite levels;
KIRP	cis	rs16958440	0.737	rs16950096	chr18:44745546	T/C	cg17192377	chr18:44677553	HDHD2	0.89	7.05	0.41	1.82e-11	Sitting height ratio;
KIRP	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.62	5.28	0.32	2.9e-7	Facial emotion recognition (sad faces);
KIRP	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg19847130	chr8:10466454	RP1L1	0.36	5.52	0.33	8.48e-8	Retinal vascular caliber;
KIRP	cis	rs4762326	0.510	rs10777678	chr12:95628466	A/T	cg07737802	chr12:95537812	FGD6	0.37	4.96	0.3	1.29e-6	Endometriosis;
KIRP	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg07701084	chr6:150067640	NUP43	0.58	7.51	0.43	1.1e-12	Lung cancer;
KIRP	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2230307	0.536	rs2784173	chr1:100639752	A/G	cg24955406	chr1:100503596	HIAT1	-0.58	-6.1	-0.36	4.1e-9	Carotid intima media thickness;
KIRP	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg05665937	chr4:1216051	CTBP1	0.44	5.63	0.34	4.96e-8	Obesity-related traits;
KIRP	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	6.95	0.41	3.24e-11	Retinal vascular caliber;
KIRP	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.55	8.75	0.49	3.39e-16	Major depressive disorder;
KIRP	cis	rs7712401	0.601	rs30027	chr5:122283390	T/C	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.75	6.03	0.36	5.83e-9	Inflammatory bowel disease;
KIRP	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.13	-9.78	-0.53	2.7e-19	Body mass index;
KIRP	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.51	-0.33	8.97e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs17221829	0.733	rs10830333	chr11:89399224	T/C	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.62	-0.34	5.07e-8	Anxiety in major depressive disorder;
KIRP	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.95	0.3	1.36e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg27124370	chr19:33622961	WDR88	0.61	7.43	0.43	1.75e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.64	8.34	0.47	5.43e-15	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg04944784	chr2:26401820	FAM59B	-0.67	-7.21	-0.42	6.67e-12	Gut microbiome composition (summer);
KIRP	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg19633962	chr1:26362018	EXTL1	-0.56	-5.06	-0.31	8.33e-7	Height;
KIRP	cis	rs7552404	0.696	rs67487205	chr1:76373756	T/C	cg03433033	chr1:76189801	ACADM	0.73	10.13	0.54	2.2e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg26116260	chr4:7069785	GRPEL1	-0.9	-4.93	-0.3	1.49e-6	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6545883	0.929	rs1900572	chr2:61650715	T/G	cg15711740	chr2:61764176	XPO1	0.62	8.18	0.46	1.57e-14	Tuberculosis;
KIRP	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25319031	chr3:119813310	GSK3B	0.45	6.29	0.37	1.48e-9	Survival in pancreatic cancer;
KIRP	cis	rs17453880	0.929	rs55869831	chr5:151957634	A/C	cg12297329	chr5:152029980	NA	-0.67	-10.15	-0.54	1.92e-20	Subjective well-being;
KIRP	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.79	8.05	0.46	3.48e-14	Lung function (FEV1/FVC);
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.66	9.83	0.53	1.92e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.74e-11	Vitiligo;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.6e-13	Life satisfaction;
KIRP	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg07701084	chr6:150067640	NUP43	0.65	8.34	0.47	5.43e-15	Lung cancer;
KIRP	cis	rs12949688	0.682	rs11657181	chr17:55838543	C/T	cg12582317	chr17:55822272	NA	0.45	6.09	0.36	4.38e-9	Schizophrenia;
KIRP	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.34	-0.47	5.37e-15	Total cholesterol levels;
KIRP	trans	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg19894588	chr14:64061835	NA	-0.48	-6.48	-0.38	4.98e-10	Fat distribution (HIV);
KIRP	trans	rs13170463	0.579	rs11746306	chr5:8039853	G/T	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs2150410	0.915	rs6517528	chr21:40583017	G/A	cg11890956	chr21:40555474	PSMG1	0.75	5.39	0.32	1.68e-7	Temperament (bipolar disorder);
KIRP	cis	rs13102973	0.682	rs7441468	chr4:135886736	C/T	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.75	10.23	0.55	1.07e-20	Red blood cell count;
KIRP	cis	rs6467136	0.818	rs2157751	chr7:127171291	A/G	cg23081781	chr7:127225937	GCC1	-0.38	-5.1	-0.31	6.67e-7	Type 2 diabetes;
KIRP	trans	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg05926928	chr17:57297772	GDPD1	-0.63	-6.53	-0.38	3.72e-10	Opioid sensitivity;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04439516	chr16:57318697	PLLP	-0.49	-6.18	-0.37	2.6e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-15.43	-0.7	4.85e-38	Chronic sinus infection;
KIRP	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-1.2	-10.38	-0.55	3.59e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg10253484	chr15:75165896	SCAMP2	-0.43	-4.99	-0.3	1.15e-6	Breast cancer;
KIRP	cis	rs4780401	0.567	rs8191279	chr16:11764329	G/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-4.87	-0.3	2.02e-6	Rheumatoid arthritis;
KIRP	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.92	-14.81	-0.69	6.66e-36	Height;
KIRP	cis	rs829661	0.948	rs2609954	chr2:30871808	G/A	cg10949345	chr2:30726833	LCLAT1	0.69	8.73	0.49	3.98e-16	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs62380364	0.602	rs591228	chr5:88064809	G/A	cg22951263	chr5:87985283	NA	-0.45	-6.25	-0.37	1.84e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6120849	0.573	rs3746429	chr20:33703607	A/G	cg24642439	chr20:33292090	TP53INP2	-0.68	-6.1	-0.36	4.02e-9	Protein C levels;
KIRP	cis	rs7709377	0.621	rs10075195	chr5:115422705	A/G	cg23108291	chr5:115420582	COMMD10	0.41	4.95	0.3	1.36e-6	Metabolite levels  (X-11787);
KIRP	trans	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg19274270	chr17:78178856	CARD14	0.36	6.48	0.38	4.9e-10	Morning vs. evening chronotype;
KIRP	cis	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg01304814	chr3:48885189	PRKAR2A	0.62	5.56	0.33	7.05e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23337289	chr2:27603239	ZNF513	0.54	7.12	0.41	1.21e-11	Smoking initiation;
KIRP	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.8	10.98	0.57	4.52e-23	Aortic root size;
KIRP	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17507749	chr15:85114479	UBE2QP1	0.76	8.55	0.48	1.35e-15	Schizophrenia;
KIRP	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg27211696	chr2:191398769	TMEM194B	-0.77	-8.98	-0.5	7.2e-17	Diastolic blood pressure;
KIRP	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.95	12.44	0.62	6.68e-28	Menopause (age at onset);
KIRP	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	ch.5.1024479R	chr5:53302184	ARL15	-1.16	-13.58	-0.65	1.02e-31	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg07117364	chr1:16154769	NA	-0.42	-5.08	-0.31	7.37e-7	Dilated cardiomyopathy;
KIRP	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.72	10.18	0.54	1.5e-20	High light scatter reticulocyte count;
KIRP	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg02570527	chr1:10970165	NA	-0.48	-5.53	-0.33	8.05e-8	Body mass index;
KIRP	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg13679303	chr9:96623674	NA	-0.51	-7.22	-0.42	6.58e-12	DNA methylation (variation);
KIRP	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs7937612	1.000	rs11217841	chr11:120238721	C/A	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.07	-0.41	1.61e-11	Intraocular pressure;
KIRP	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	7.84	0.45	1.4e-13	Electroencephalogram traits;
KIRP	cis	rs1440410	0.830	rs12505142	chr4:144180907	A/G	cg01719995	chr4:144104893	USP38	0.39	5.02	0.3	1e-6	Ischemic stroke;
KIRP	cis	rs9420	0.703	rs10896661	chr11:57679029	C/A	cg23127183	chr11:57508653	C11orf31	-0.51	-5.93	-0.35	1.03e-8	Schizophrenia;
KIRP	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.53	-0.33	8.35e-8	Bipolar disorder;
KIRP	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg05785598	chr3:49045655	WDR6	0.3	5.46	0.33	1.19e-7	Parkinson's disease;
KIRP	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg16141378	chr3:129829833	LOC729375	0.48	6.32	0.37	1.22e-9	Mood instability;
KIRP	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-6.94	-0.4	3.53e-11	Type 2 diabetes;
KIRP	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-8.18	-0.46	1.54e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg18944383	chr4:111397179	ENPEP	0.48	8.19	0.46	1.46e-14	Height;
KIRP	cis	rs72829446	0.530	rs9906913	chr17:7411360	G/A	cg02795151	chr17:7402630	POLR2A	0.81	8.25	0.47	9.93e-15	Androgen levels;
KIRP	cis	rs3935685	0.874	rs34906247	chr15:78004204	A/G	cg25212270	chr15:78015279	NA	0.59	7.74	0.44	2.51e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg05295671	chr13:79234353	RNF219	-0.57	-5.74	-0.34	2.78e-8	Large artery stroke;
KIRP	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.65	8.34	0.47	5.24e-15	Body mass index;
KIRP	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg16255804	chr6:135334527	HBS1L	-0.33	-5.32	-0.32	2.28e-7	Red blood cell count;
KIRP	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-7.87	-0.45	1.1e-13	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.05e-8	Retinal vascular caliber;
KIRP	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.88	0.4	5.07e-11	Electroencephalogram traits;
KIRP	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg12501888	chr15:85177176	SCAND2	-0.39	-4.84	-0.3	2.25e-6	P wave terminal force;
KIRP	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.92	12.51	0.62	4.17e-28	Vitamin D levels;
KIRP	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.18	0.42	8.28e-12	Bipolar disorder;
KIRP	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg01879757	chr17:41196368	BRCA1	-0.53	-7.06	-0.41	1.74e-11	Menopause (age at onset);
KIRP	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.66	-8.97	-0.5	7.59e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs524023	1.000	rs10897518	chr11:64360705	A/G	cg09231725	chr11:64357281	SLC22A12	-0.62	-8.35	-0.47	4.87e-15	Urate levels in obese individuals;
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg18209359	chr17:80159595	CCDC57	0.41	5.4	0.33	1.56e-7	Life satisfaction;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg13939156	chr17:80058883	NA	-0.5	-7.35	-0.42	2.97e-12	Life satisfaction;
KIRP	cis	rs7202877	0.706	rs4887813	chr16:75312494	A/G	cg03315344	chr16:75512273	CHST6	0.6	5.78	0.35	2.28e-8	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35740288	0.770	rs10520592	chr15:86114142	G/C	cg10818794	chr15:86012489	AKAP13	-0.46	-5.68	-0.34	3.88e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg15432903	chr11:17409602	KCNJ11	0.76	11.34	0.59	2.99e-24	Type 2 diabetes;
KIRP	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.79	-8.06	-0.46	3.34e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg07395648	chr5:131743802	NA	0.49	6.0	0.36	7.07e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.81	-13.22	-0.64	1.68e-30	Idiopathic membranous nephropathy;
KIRP	cis	rs829661	1.000	rs2692035	chr2:30672835	T/A	cg10949345	chr2:30726833	LCLAT1	0.73	10.31	0.55	6.16e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.47	-7.15	-0.41	9.78e-12	Daytime sleep phenotypes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13369206	chr2:3606108	RNASEH1	0.46	6.03	0.36	5.89e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12365397	0.634	rs12800533	chr11:43295407	G/A	cg07515919	chr11:43391688	TTC17	0.36	4.89	0.3	1.81e-6	Migraine;
KIRP	cis	rs17030434	0.834	rs1456399	chr4:154735242	C/T	cg14289246	chr4:154710475	SFRP2	-0.67	-8.11	-0.46	2.47e-14	Electrocardiographic conduction measures;
KIRP	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.25	-16.09	-0.72	2.77e-40	Type 1 diabetes nephropathy;
KIRP	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.67	-0.52	5.79e-19	Mood instability;
KIRP	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.5	-6.12	-0.36	3.66e-9	Red blood cell count;
KIRP	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	trans	rs1941687	0.797	rs2976	chr18:31403254	T/C	cg27147174	chr7:100797783	AP1S1	-0.53	-6.57	-0.39	2.9e-10	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs3935685	0.874	rs4477663	chr15:78007254	A/G	cg25212270	chr15:78015279	NA	-0.61	-8.23	-0.46	1.1e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs17286411	0.836	rs1834033	chr16:71943781	C/G	cg04254540	chr16:71951199	KIAA0174	-0.38	-4.99	-0.3	1.15e-6	Blood protein levels;
KIRP	cis	rs6793245	0.845	rs4073797	chr3:38590850	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-6.41	-0.38	7.43e-10	QT interval;
KIRP	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-1.06	-10.16	-0.54	1.81e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.1	-0.36	4.16e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.74	9.83	0.53	1.85e-19	Parkinson's disease;
KIRP	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.48	7.45	0.43	1.58e-12	Testicular germ cell tumor;
KIRP	cis	rs35740288	0.770	rs12906580	chr15:86155287	C/T	cg10818794	chr15:86012489	AKAP13	0.45	5.42	0.33	1.42e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7005380	0.581	rs7813430	chr8:120939074	C/T	cg21645572	chr8:120931649	DEPDC6	-0.49	-6.61	-0.39	2.39e-10	Interstitial lung disease;
KIRP	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.51	-7.98	-0.45	5.66e-14	Huntington's disease progression;
KIRP	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg03289416	chr15:75166202	SCAMP2	-0.42	-5.32	-0.32	2.36e-7	Systemic lupus erythematosus;
KIRP	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03647317	chr4:187891568	NA	-0.81	-13.45	-0.65	2.85e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg13798780	chr7:105162888	PUS7	0.67	6.24	0.37	1.91e-9	Bipolar disorder (body mass index interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00145177	chr4:2061018	NAT8L	0.61	7.65	0.44	4.62e-13	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs796825	0.512	rs34964758	chr3:119942440	A/C	cg21790991	chr3:120137480	FSTL1	-0.3	-5.23	-0.32	3.64e-7	HIV-1 susceptibility;
KIRP	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg09596252	chr17:78655493	RPTOR	0.6	7.79	0.44	1.89e-13	Obesity;
KIRP	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg23387468	chr7:139079360	LUC7L2	-0.29	-5.14	-0.31	5.62e-7	Diisocyanate-induced asthma;
KIRP	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg24747557	chr10:131355152	MGMT	0.36	4.91	0.3	1.63e-6	Response to temozolomide;
KIRP	cis	rs2594989	0.673	rs62245959	chr3:11601797	G/T	cg01796438	chr3:11312864	ATG7	0.58	6.28	0.37	1.5e-9	Circulating chemerin levels;
KIRP	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.81	11.17	0.58	1.06e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.14	0.54	2.03e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2970818	0.831	rs4238020	chr12:4616642	C/T	cg14576962	chr12:4671597	NA	0.43	5.13	0.31	5.8e-7	Phosphorus levels;
KIRP	cis	rs3767633	0.925	rs1806594	chr1:161858860	T/C	cg09175582	chr1:161736000	ATF6	0.74	6.03	0.36	5.88e-9	IgG glycosylation;
KIRP	cis	rs10782582	0.609	rs2881785	chr1:76318096	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-6.42	-0.38	7.14e-10	Daytime sleep phenotypes;
KIRP	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.4	5.29	0.32	2.71e-7	Educational attainment;
KIRP	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg26338869	chr17:61819248	STRADA	0.54	6.56	0.39	3.22e-10	Prudent dietary pattern;
KIRP	cis	rs16976116	0.901	rs28499113	chr15:55503621	T/C	cg11288833	chr15:55489084	RSL24D1	0.63	7.05	0.41	1.84e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg13798912	chr7:905769	UNC84A	0.56	5.66	0.34	4.13e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4356932	0.691	rs2273	chr4:76889388	C/T	cg19388996	chr4:76862389	NAAA	-0.43	-5.49	-0.33	1.01e-7	Blood protein levels;
KIRP	cis	rs9826463	0.757	rs73238202	chr3:142205344	C/T	cg20824294	chr3:142316082	PLS1	0.39	6.17	0.37	2.72e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9290877	0.580	rs9865310	chr3:188466638	G/A	cg17392043	chr3:188495102	LPP	-0.54	-6.88	-0.4	4.88e-11	IgE levels;
KIRP	cis	rs8049040	0.547	rs891131	chr16:71432417	G/A	cg08717414	chr16:71523259	ZNF19	-0.56	-6.63	-0.39	2.1e-10	Blood protein levels;
KIRP	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.49	6.17	0.37	2.72e-9	Schizophrenia;
KIRP	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	15.52	0.7	2.43e-38	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.67	10.21	0.55	1.26e-20	Lung cancer;
KIRP	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06544989	chr22:39130855	UNC84B	0.49	8.1	0.46	2.55e-14	Menopause (age at onset);
KIRP	cis	rs56161922	1.000	rs74184055	chr1:207852226	G/A	cg11752769	chr1:207818423	CR1L	-0.77	-4.98	-0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg13736514	chr6:26305472	NA	-0.6	-7.69	-0.44	3.53e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg07001201	chr5:642380	CEP72	0.7	6.53	0.38	3.76e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17467752	chr17:38218738	THRA	-0.5	-6.39	-0.38	8.43e-10	White blood cell count;
KIRP	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs904251	0.772	rs2776906	chr6:37431757	A/G	cg24807547	chr6:37504484	NA	-0.42	-5.38	-0.32	1.7e-7	Cognitive performance;
KIRP	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.44	6.27	0.37	1.62e-9	Ovarian reserve;
KIRP	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg17145862	chr1:211918768	LPGAT1	-0.93	-13.35	-0.65	6.07e-31	Leprosy;
KIRP	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19346786	chr7:2764209	NA	-0.39	-6.64	-0.39	1.96e-10	Height;
KIRP	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg26681399	chr22:41777847	TEF	0.52	5.15	0.31	5.46e-7	Vitiligo;
KIRP	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg22705602	chr4:152727874	NA	-0.36	-5.48	-0.33	1.07e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15594528	chr11:112096869	PTS	0.48	6.03	0.36	5.98e-9	Parkinson's disease;
KIRP	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.71	-0.34	3.17e-8	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.21	0.42	6.74e-12	Prudent dietary pattern;
KIRP	cis	rs6016377	0.737	rs6016380	chr20:39179975	A/G	cg06665391	chr20:39312290	NA	0.45	5.8	0.35	1.99e-8	Birth weight;
KIRP	cis	rs36715	0.953	rs185177	chr5:127547810	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.86	0.49	1.63e-16	Breast cancer;
KIRP	cis	rs62109865	0.655	rs75667306	chr19:12594026	C/T	cg19721055	chr19:12753329	NA	-0.84	-4.96	-0.3	1.31e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-5.86	-0.35	1.44e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs13088645	0.621	rs6767595	chr3:134146845	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.43	5.89	0.35	1.25e-8	Coronary artery disease;
KIRP	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.35	5.41	0.33	1.49e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.45	-5.83	-0.35	1.72e-8	Aortic root size;
KIRP	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg03188948	chr7:1209495	NA	0.76	5.25	0.32	3.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs73198271	0.640	rs7838012	chr8:8656630	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.58	-0.39	2.76e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05586598	chr2:65540924	SPRED2	0.49	6.31	0.37	1.28e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	10.85	0.57	1.17e-22	Cognitive test performance;
KIRP	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.85	12.67	0.63	1.17e-28	Menarche (age at onset);
KIRP	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.92	-0.9	4.05e-92	Myeloid white cell count;
KIRP	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg15105011	chr4:940614	TMEM175	-0.41	-5.46	-0.33	1.18e-7	Parkinson's disease;
KIRP	cis	rs2708977	0.667	rs772156	chr2:97029830	G/A	cg22654517	chr2:96458247	NA	0.31	5.07	0.31	7.94e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-5.65	-0.34	4.47e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	1.18	9.68	0.53	5.45e-19	Lymphocyte counts;
KIRP	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg03482458	chr22:46692211	CN5H6.4;GTSE1	-0.72	-8.29	-0.47	7.22e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg14324370	chr2:177042789	NA	0.77	10.83	0.57	1.33e-22	IgG glycosylation;
KIRP	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.59	-8.31	-0.47	6.36e-15	Motion sickness;
KIRP	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg00982548	chr2:198649783	BOLL	-0.56	-5.04	-0.31	8.87e-7	Ulcerative colitis;
KIRP	cis	rs8106542	0.906	rs1560711	chr19:10742287	C/T	cg23183932	chr19:10823679	QTRT1	0.47	5.38	0.32	1.69e-7	Platelet distribution width;
KIRP	cis	rs1555895	0.576	rs748112	chr10:862889	C/T	cg10017260	chr10:834428	NA	-0.43	-6.57	-0.39	3e-10	Survival in rectal cancer;
KIRP	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.74	0.4	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg19468946	chr17:37922297	IKZF3	-0.45	-6.3	-0.37	1.34e-9	Asthma;
KIRP	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-5.61	-0.34	5.55e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.45	6.13	0.36	3.54e-9	Coronary artery disease;
KIRP	cis	rs76693355	0.512	rs11217874	chr11:120325548	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.44	-5.64	-0.34	4.73e-8	Intraocular pressure;
KIRP	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.69	-8.36	-0.47	4.56e-15	Cognitive function;
KIRP	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.65	-7.72	-0.44	3e-13	Body mass index;
KIRP	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg10117171	chr1:25599238	RHD	-0.42	-5.66	-0.34	4.11e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.72	-8.84	-0.49	1.93e-16	Height;
KIRP	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.54e-10	Fibrinogen levels;
KIRP	cis	rs62413470	1.000	rs62404865	chr6:55944559	T/G	cg13327911	chr6:55965977	COL21A1	0.55	4.89	0.3	1.8e-6	Joint mobility (Beighton score);
KIRP	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.14	-0.41	1.07e-11	Neuroticism;
KIRP	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.83	-13.83	-0.66	1.4e-32	Brugada syndrome;
KIRP	cis	rs6838801	0.630	rs6824297	chr4:77492155	A/C	cg17476223	chr4:77663285	SHROOM3	-0.46	-6.11	-0.36	3.81e-9	Cleft lip with or without cleft palate;
KIRP	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg01251548	chr11:17372745	DKFZp686O24166	-0.39	-5.22	-0.32	3.78e-7	Type 2 diabetes;
KIRP	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.66	-9.3	-0.51	8.15e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.75	-10.63	-0.56	5.74e-22	Bipolar disorder and schizophrenia;
KIRP	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-4.86	-0.3	2.13e-6	Breast cancer;
KIRP	cis	rs62229266	0.804	rs2835259	chr21:37425302	T/C	cg08632701	chr21:37451849	NA	-0.43	-5.38	-0.32	1.72e-7	Mitral valve prolapse;
KIRP	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	10.25	0.55	9.48e-21	Lymphocyte counts;
KIRP	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg08645402	chr16:4508243	NA	0.49	5.87	0.35	1.41e-8	Schizophrenia;
KIRP	cis	rs11245387	0.564	rs7915429	chr10:126510089	T/C	cg08799069	chr10:126477246	METTL10	-0.82	-9.61	-0.52	9.16e-19	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.38	0.43	2.5e-12	Aortic root size;
KIRP	cis	rs7546094	1.000	rs1994604	chr1:113156426	C/T	cg22162597	chr1:113214053	CAPZA1	0.47	6.72	0.39	1.25e-10	Platelet distribution width;
KIRP	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	9.58	0.52	1.1e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg23307798	chr14:103986281	CKB	0.74	11.49	0.59	9.75e-25	Body mass index;
KIRP	cis	rs2802372	0.568	rs1250554	chr10:81067040	C/T	cg18688392	chr10:81059414	ZMIZ1	-0.63	-7.7	-0.44	3.36e-13	Granulocyte count;
KIRP	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg02151108	chr14:50098012	C14orf104	-0.45	-5.67	-0.34	4.05e-8	Carotid intima media thickness;
KIRP	cis	rs9640161	0.658	rs57888387	chr7:150004244	G/A	cg27494647	chr7:150038898	RARRES2	0.4	5.45	0.33	1.21e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.54	-6.55	-0.39	3.32e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg18350739	chr11:68623251	NA	-0.56	-8.12	-0.46	2.31e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg16141378	chr3:129829833	LOC729375	-0.62	-8.46	-0.47	2.42e-15	Triglycerides;
KIRP	cis	rs11997175	0.550	rs7464954	chr8:33832202	A/G	cg04338863	chr8:33670619	NA	0.4	5.15	0.31	5.26e-7	Body mass index;
KIRP	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg15488143	chr7:128924101	AHCYL2	0.63	6.75	0.4	1.08e-10	White matter hyperintensity burden;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14958956	chr10:102722131	FAM178A	0.42	6.5	0.38	4.55e-10	Interleukin-4 levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10771695	chr14:103800476	EIF5	0.46	6.05	0.36	5.47e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg09264619	chr17:80180166	NA	-0.52	-6.18	-0.37	2.64e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.79	10.71	0.56	3.14e-22	Coronary artery disease;
KIRP	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.62	7.8	0.45	1.75e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.68	7.29	0.42	4.34e-12	Lymphocyte counts;
KIRP	cis	rs4702718	0.616	rs9312742	chr5:10734772	C/T	cg14521931	chr5:10832172	NA	-0.42	-5.55	-0.33	7.23e-8	Obesity-related traits;
KIRP	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.59	-9.08	-0.5	3.67e-17	Vitamin D levels;
KIRP	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11987759	chr7:65425863	GUSB	-0.68	-9.19	-0.51	1.74e-17	Aortic root size;
KIRP	trans	rs12517041	1.000	rs2356716	chr5:23308496	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	8.3	0.47	7.17e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs34091987	0.562	rs2216167	chr17:70021748	A/G	cg09344028	chr17:70110421	NA	0.29	5.68	0.34	3.87e-8	Nose size;
KIRP	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.4	10.03	0.54	4.39e-20	Corneal astigmatism;
KIRP	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg05347473	chr6:146136440	FBXO30	0.42	5.65	0.34	4.42e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg03808351	chr9:123631620	PHF19	0.45	6.16	0.37	2.97e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs2150410	0.703	rs391062	chr21:40548267	C/T	cg11890956	chr21:40555474	PSMG1	0.74	5.45	0.33	1.24e-7	Temperament (bipolar disorder);
KIRP	cis	rs10858047	0.943	rs12034144	chr1:115078549	G/A	cg12756093	chr1:115239321	AMPD1	0.53	5.01	0.3	1.03e-6	Autism;
KIRP	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.5	-6.53	-0.38	3.7e-10	Testicular germ cell tumor;
KIRP	trans	rs7246760	0.867	rs889177	chr19:9846225	C/T	cg02900749	chr2:68251473	NA	-1.07	-8.88	-0.49	1.39e-16	Pursuit maintenance gain;
KIRP	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.9	-14.0	-0.67	3.81e-33	Primary sclerosing cholangitis;
KIRP	cis	rs785830	0.749	rs663309	chr9:266795	G/A	cg14500300	chr9:211689	NA	0.53	7.27	0.42	4.86e-12	Platelet distribution width;
KIRP	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.76	6.75	0.4	1.04e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17123764	0.818	rs11169082	chr12:49985408	G/A	cg20471783	chr12:50157085	TMBIM6	0.31	4.88	0.3	1.91e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg15744005	chr10:104629667	AS3MT	-0.28	-5.01	-0.3	1.02e-6	Arsenic metabolism;
KIRP	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg00852783	chr1:26633632	UBXN11	-0.56	-5.83	-0.35	1.74e-8	Obesity-related traits;
KIRP	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.55	-7.65	-0.44	4.58e-13	Prostate cancer;
KIRP	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg04906043	chr13:21280425	IL17D	0.51	6.52	0.38	3.85e-10	Dental caries;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03570498	chr10:131566727	NA	0.46	6.17	0.37	2.8e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.19	0.31	4.42e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.47	-7.04	-0.41	1.89e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.85	12.38	0.62	1.12e-27	Dental caries;
KIRP	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg07511934	chr16:89386912	ANKRD11	0.44	5.41	0.33	1.46e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.68	-7.15	-0.41	9.89e-12	Vitiligo;
KIRP	cis	rs7656342	0.686	rs6822889	chr4:9826757	C/T	cg00071950	chr4:10020882	SLC2A9	0.36	5.08	0.31	7.29e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs12476592	0.602	rs1348806	chr2:63895884	A/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.94	-0.3	1.41e-6	Childhood ear infection;
KIRP	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	0.44	6.13	0.36	3.41e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.67	10.07	0.54	3.34e-20	Retinal vascular caliber;
KIRP	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-0.8	-10.97	-0.57	4.78e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.5	-7.09	-0.41	1.39e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	1.12	8.19	0.46	1.47e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21176488	chr3:188251742	LPP	0.47	6.6	0.39	2.46e-10	Interleukin-4 levels;
KIRP	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg16558253	chr16:72132732	DHX38	-0.36	-4.9	-0.3	1.72e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-8.11	-0.46	2.45e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.64	-7.22	-0.42	6.51e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Body mass index;
KIRP	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg00800038	chr16:89945340	TCF25	-0.68	-6.79	-0.4	8.14e-11	Skin colour saturation;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg05389560	chr12:21654664	RECQL;GOLT1B	0.99	6.77	0.4	9.47e-11	P wave terminal force;
KIRP	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg17279839	chr7:150038598	RARRES2	0.49	6.11	0.36	3.8e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.89	-0.4	4.73e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.74	10.4	0.55	3.22e-21	Red blood cell count;
KIRP	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.72	-8.72	-0.49	4.18e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg22968622	chr17:43663579	NA	-0.67	-8.87	-0.49	1.48e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.75	9.89	0.53	1.27e-19	Morning vs. evening chronotype;
KIRP	cis	rs17221829	0.703	rs12418019	chr11:89391757	T/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs467650	0.509	rs27391	chr5:97980423	A/G	cg12450016	chr5:98112437	RGMB	0.39	5.03	0.31	9.66e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.55	5.91	0.35	1.11e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.7	8.96	0.5	8.39e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.68	9.44	0.52	3.08e-18	Blood protein levels;
KIRP	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.63	8.55	0.48	1.28e-15	Breast cancer;
KIRP	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.92	15.62	0.71	1.14e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.96	16.35	0.72	3.45e-41	Breast cancer;
KIRP	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	10.1	0.54	2.69e-20	Coffee consumption (cups per day);
KIRP	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.09	0.5	3.48e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6132905	0.590	rs79001633	chr20:2626462	T/C	cg24848351	chr20:2622020	TMC2	-0.64	-5.85	-0.35	1.52e-8	Mumps;
KIRP	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.75	9.66	0.52	6.33e-19	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg15181151	chr6:150070149	PCMT1	0.31	5.29	0.32	2.68e-7	Lung cancer;
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg21698718	chr17:80085957	CCDC57	-0.36	-5.28	-0.32	2.91e-7	Life satisfaction;
KIRP	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00944808	chr15:42264708	EHD4	-0.44	-6.06	-0.36	5.18e-9	Metabolic traits;
KIRP	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.56	-8.11	-0.46	2.42e-14	Personality dimensions;
KIRP	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg01028140	chr2:1542097	TPO	-0.52	-5.91	-0.35	1.16e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs28834970	0.675	rs7013346	chr8:27228666	C/A	cg23693289	chr8:27183097	PTK2B	-0.45	-5.22	-0.32	3.89e-7	Alzheimer's disease (late onset);
KIRP	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.72	0.34	3.1e-8	Putamen volume;
KIRP	cis	rs7615316	0.934	rs9869842	chr3:142272314	C/T	cg20824294	chr3:142316082	PLS1	0.22	5.03	0.31	9.38e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg08204369	chr17:73150733	HN1	0.54	6.47	0.38	5.18e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.44	5.15	0.31	5.46e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2516839	1.000	rs2516839	chr1:161013121	A/G	cg12501923	chr17:73937416	FBF1	-0.46	-6.45	-0.38	5.75e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg24315340	chr6:146058215	EPM2A	-0.43	-5.56	-0.33	6.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.46	6.29	0.37	1.41e-9	Leprosy;
KIRP	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg14730097	chr2:233632281	GIGYF2;KCNJ13	0.36	5.08	0.31	7.6e-7	Coronary artery disease;
KIRP	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg07395648	chr5:131743802	NA	-0.35	-4.87	-0.3	1.97e-6	Acylcarnitine levels;
KIRP	trans	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg10756647	chr7:56101905	PSPH	-0.99	-7.25	-0.42	5.45e-12	Diabetic kidney disease;
KIRP	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.64	8.09	0.46	2.71e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg09408571	chr1:101003634	GPR88	-0.22	-4.88	-0.3	1.89e-6	Monocyte count;
KIRP	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg04998671	chr14:104000505	TRMT61A	-0.55	-6.47	-0.38	5.37e-10	Coronary artery disease;
KIRP	trans	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	cg04338863	chr8:33670619	NA	0.43	5.42	0.33	1.45e-7	Body mass index;
KIRP	cis	rs12210905	1.000	rs12209800	chr6:27189517	C/T	cg23155468	chr6:27110703	HIST1H2BK	0.84	6.69	0.39	1.49e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.71	10.26	0.55	8.63e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.51	-6.22	-0.37	2.08e-9	Menopause (age at onset);
KIRP	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.82	-12.56	-0.63	2.8e-28	Blood metabolite levels;
KIRP	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.32	0.62	1.76e-27	Platelet count;
KIRP	trans	rs6601327	0.548	rs13271796	chr8:9653502	A/C	cg15556689	chr8:8085844	FLJ10661	0.53	6.42	0.38	7.13e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg26681399	chr22:41777847	TEF	-0.54	-5.17	-0.31	4.91e-7	Vitiligo;
KIRP	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg04935436	chr20:30431758	NA	0.48	6.42	0.38	6.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs8014252	0.708	rs74062750	chr14:71026052	C/G	cg19730268	chr14:71022823	NA	-0.69	-6.16	-0.37	2.95e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-7.19	-0.42	7.6e-12	Response to antipsychotic treatment;
KIRP	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.63	-10.59	-0.56	8.01e-22	Lung cancer;
KIRP	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.92	12.51	0.62	4.12e-28	Menopause (age at onset);
KIRP	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.85	0.63	2.91e-29	Morning vs. evening chronotype;
KIRP	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.31	12.04	0.61	1.48e-26	Diabetic retinopathy;
KIRP	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg15282417	chr9:129245246	FAM125B	0.44	7.49	0.43	1.21e-12	Intraocular pressure;
KIRP	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.75	-0.44	2.37e-13	Mood instability;
KIRP	cis	rs72960926	0.744	rs72954341	chr6:74947167	A/G	cg03266952	chr6:74778945	NA	-0.61	-5.16	-0.31	5.09e-7	Metabolite levels (MHPG);
KIRP	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.93	0.4	3.71e-11	Mean corpuscular volume;
KIRP	cis	rs7520050	0.807	rs12025621	chr1:46228391	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.18	-0.31	4.68e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs12913538	1.000	rs11071676	chr15:62889661	C/T	cg09983546	chr15:62884068	NA	-0.57	-8.4	-0.47	3.5e-15	Sleep depth;
KIRP	cis	rs3126085	0.515	rs7534742	chr1:152362727	C/T	cg26876637	chr1:152193138	HRNR	-0.57	-6.57	-0.39	2.91e-10	Atopic dermatitis;
KIRP	cis	rs3779635	0.742	rs17447958	chr8:27254636	A/G	cg23736307	chr8:27182930	PTK2B	-0.54	-6.78	-0.4	8.87e-11	Neuroticism;
KIRP	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.39	-4.86	-0.3	2.11e-6	IgG glycosylation;
KIRP	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg20243544	chr17:37824526	PNMT	-0.4	-4.93	-0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.58	7.97	0.45	5.76e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg02775129	chr4:119771670	NA	-0.87	-4.91	-0.3	1.62e-6	Cannabis dependence symptom count;
KIRP	cis	rs7258465	0.931	rs271629	chr19:18623198	G/A	cg10790698	chr19:18539756	SSBP4	-0.34	-7.41	-0.43	2.02e-12	Breast cancer;
KIRP	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.39	-0.32	1.66e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.85	10.68	0.56	4.02e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11134338	0.517	rs2925909	chr5:8992098	T/C	cg18330338	chr5:9047211	SEMA5A	0.36	4.85	0.3	2.17e-6	Obesity-related traits;
KIRP	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg19847130	chr8:10466454	RP1L1	-0.34	-4.98	-0.3	1.2e-6	Retinal vascular caliber;
KIRP	cis	rs580438	0.529	rs2046190	chr3:13404761	A/G	cg10657019	chr3:13328039	NA	0.49	6.38	0.38	8.68e-10	Myringotomy;
KIRP	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg23625390	chr15:77176239	SCAPER	0.54	7.13	0.41	1.1e-11	Blood metabolite levels;
KIRP	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg10189261	chr14:101176105	NA	-0.49	-5.08	-0.31	7.53e-7	Plateletcrit;
KIRP	cis	rs10267417	0.603	rs10224041	chr7:19903837	T/C	cg05791153	chr7:19748676	TWISTNB	0.58	5.63	0.34	4.97e-8	Night sleep phenotypes;
KIRP	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.78	10.03	0.54	4.41e-20	Aortic root size;
KIRP	cis	rs963731	0.649	rs297140	chr2:39319121	A/G	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.55	-6.13	-0.36	3.45e-9	Multiple sclerosis;
KIRP	cis	rs988913	0.581	rs1580891	chr6:54859092	C/T	cg03513858	chr6:54763001	FAM83B	-0.34	-4.9	-0.3	1.76e-6	Menarche (age at onset);
KIRP	trans	rs6601327	0.548	rs13271796	chr8:9653502	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	6.97	0.41	2.88e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.12e-6	Aortic root size;
KIRP	cis	rs11783469	0.524	rs17089283	chr8:23335762	A/T	cg08322043	chr8:23340750	NA	-0.48	-5.48	-0.33	1.07e-7	Reticulocyte count;
KIRP	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.61	8.32	0.47	6.27e-15	Menarche (age at onset);
KIRP	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg01304814	chr3:48885189	PRKAR2A	0.74	5.64	0.34	4.61e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	cis	rs1035491	0.715	rs876353	chr5:63919557	C/T	cg01791865	chr5:63954708	NA	0.32	5.01	0.3	1.05e-6	Body mass index;
KIRP	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.56	5.08	0.31	7.42e-7	Major depressive disorder;
KIRP	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.73	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs394563	0.934	rs384334	chr6:149796172	C/G	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.2	-0.31	4.17e-7	Dupuytren's disease;
KIRP	cis	rs11997175	0.536	rs10096323	chr8:33776507	T/C	ch.8.33884649F	chr8:33765107	NA	0.45	5.37	0.32	1.82e-7	Body mass index;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22252469	chr13:33702794	STARD13	0.51	6.61	0.39	2.31e-10	Interleukin-4 levels;
KIRP	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	0.88	10.02	0.54	4.89e-20	Triglycerides;
KIRP	cis	rs7335046	0.614	rs12583732	chr13:100088858	G/A	cg25919922	chr13:100150906	NA	-0.55	-5.06	-0.31	8.15e-7	Basal cell carcinoma;
KIRP	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27297192	chr10:134578999	INPP5A	0.64	7.96	0.45	6.31e-14	Migraine;
KIRP	cis	rs7677751	0.708	rs6554160	chr4:55077549	T/A	cg17187183	chr4:55093834	PDGFRA	0.79	9.92	0.53	9.93e-20	Corneal astigmatism;
KIRP	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg03929089	chr4:120376271	NA	-0.58	-6.81	-0.4	7.59e-11	HDL cholesterol;
KIRP	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg18209359	chr17:80159595	CCDC57	-0.41	-5.26	-0.32	3.17e-7	Life satisfaction;
KIRP	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	cg12689670	chr1:183009347	LAMC1	0.52	7.24	0.42	5.71e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-6.85	-0.4	5.92e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11209185	0.527	rs11209186	chr1:68434340	A/G	cg22082780	chr1:68452167	NA	-0.39	-5.51	-0.33	9.08e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg05347473	chr6:146136440	FBXO30	0.63	8.92	0.49	1.08e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.83	12.32	0.62	1.79e-27	Menarche (age at onset);
KIRP	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-10.18	-0.54	1.5e-20	Dental caries;
KIRP	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg00857998	chr1:205179979	DSTYK	0.58	7.05	0.41	1.81e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg18490616	chr2:88469792	THNSL2	0.65	5.03	0.31	9.4e-7	Plasma clusterin levels;
KIRP	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	6.41	0.38	7.29e-10	Mean platelet volume;
KIRP	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs829661	0.947	rs1252646	chr2:30741913	C/T	cg10949345	chr2:30726833	LCLAT1	-0.7	-9.96	-0.54	7.63e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs41264869	0.567	rs6670870	chr1:205155177	A/T	cg21214746	chr1:205091277	RBBP5	0.49	6.4	0.38	7.66e-10	Blood protein levels;
KIRP	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.48	-6.86	-0.4	5.43e-11	Blood metabolite levels;
KIRP	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg08975724	chr8:8085496	FLJ10661	0.55	7.43	0.43	1.78e-12	Neuroticism;
KIRP	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.42	5.49	0.33	9.81e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.02	-0.3	9.9e-7	Neutrophil percentage of white cells;
KIRP	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.55e-20	Dupuytren's disease;
KIRP	cis	rs981844	0.857	rs62325139	chr4:154712213	C/T	cg14289246	chr4:154710475	SFRP2	0.68	7.99	0.45	5.29e-14	Response to statins (LDL cholesterol change);
KIRP	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg16141378	chr3:129829833	LOC729375	-0.55	-6.59	-0.39	2.69e-10	Systolic blood pressure;
KIRP	cis	rs3774830	0.714	rs73212742	chr4:5464915	A/G	cg26943120	chr4:5472116	STK32B	0.24	5.87	0.35	1.4e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg03929089	chr4:120376271	NA	-0.57	-6.76	-0.4	1.01e-10	HDL cholesterol;
KIRP	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg12560992	chr17:57184187	TRIM37	0.55	5.11	0.31	6.51e-7	Cognitive test performance;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24583131	chr6:18265189	DEK	0.52	6.03	0.36	5.91e-9	Smoking initiation;
KIRP	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg09582042	chr13:95253676	GPR180	0.29	5.25	0.32	3.34e-7	Triglyceride levels;
KIRP	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18932078	chr1:2524107	MMEL1	0.43	6.05	0.36	5.27e-9	Ulcerative colitis;
KIRP	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg07271561	chr3:50359363	HYAL2	-0.38	-5.18	-0.31	4.66e-7	Schizophrenia;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18635645	chr1:85667791	SYDE2	0.71	6.44	0.38	6.37e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg02297831	chr4:17616191	MED28	0.6	7.66	0.44	4.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8113308	0.810	rs11880193	chr19:52448669	G/C	cg24732339	chr19:52471368	ZNF350	-0.44	-4.92	-0.3	1.57e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.57	7.57	0.43	7.54e-13	Bladder cancer;
KIRP	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg00129232	chr17:37814104	STARD3	-0.52	-6.65	-0.39	1.93e-10	Self-reported allergy;
KIRP	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs7932354	0.528	rs1872896	chr11:47160623	C/T	cg16389345	chr11:46697382	NA	0.4	5.22	0.32	3.73e-7	Bone mineral density (hip);Bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01533539	chr16:89767958	SPATA2L	0.58	7.16	0.42	9.3e-12	Parkinson's disease;
KIRP	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.81	11.14	0.58	1.37e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.55	7.54	0.43	8.79e-13	Schizophrenia;
KIRP	cis	rs7106204	0.534	rs75297923	chr11:24253530	A/G	ch.11.24196551F	chr11:24239977	NA	0.84	6.94	0.4	3.5e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg07701084	chr6:150067640	NUP43	0.63	8.27	0.47	8.28e-15	Lung cancer;
KIRP	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg04132472	chr17:19861366	AKAP10	0.48	6.71	0.39	1.3100000000000001e-10	Schizophrenia;
KIRP	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg13271783	chr10:134563150	INPP5A	0.35	4.89	0.3	1.84e-6	Migraine;
KIRP	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18252515	chr7:66147081	NA	-0.46	-5.51	-0.33	8.96e-8	Aortic root size;
KIRP	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg05791153	chr7:19748676	TWISTNB	0.59	5.84	0.35	1.67e-8	Thyroid stimulating hormone;
KIRP	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.64	0.63	1.51e-28	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-5.58	-0.34	6.22e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4073416	0.508	rs12587057	chr14:66066375	C/T	cg03016385	chr14:66212404	NA	-0.54	-6.57	-0.39	2.89e-10	N-glycan levels;
KIRP	cis	rs8054556	1.000	rs9925102	chr16:29983148	T/C	cg06326092	chr16:30034487	C16orf92	0.34	5.01	0.3	1.06e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg15556689	chr8:8085844	FLJ10661	0.56	6.94	0.4	3.39e-11	Platelet distribution width;
KIRP	cis	rs4400599	0.608	rs4845609	chr1:154181954	G/T	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.4	-5.96	-0.36	8.62e-9	Platelet distribution width;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg07308232	chr7:1071921	C7orf50	-0.58	-5.44	-0.33	1.26e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10152585	chr3:50297680	NA	0.63	8.06	0.46	3.32e-14	Parkinson's disease;
KIRP	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg21918786	chr6:109611834	NA	-0.35	-5.09	-0.31	7.23e-7	Reticulocyte fraction of red cells;
KIRP	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.51	6.76	0.4	1.02e-10	Glioblastoma;Glioma;
KIRP	cis	rs6732160	0.588	rs13390460	chr2:73371476	G/A	cg01422370	chr2:73384389	NA	0.52	6.96	0.41	3.03e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs12449568	0.874	rs11655026	chr17:54416005	C/T	cg04456437	chr3:119217424	C3orf1	0.49	6.15	0.37	3.1e-9	Height;
KIRP	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg17554472	chr22:41940697	POLR3H	0.42	5.12	0.31	6.1e-7	Vitiligo;
KIRP	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15557168	chr22:42548783	NA	-0.45	-5.86	-0.35	1.44e-8	Cognitive function;
KIRP	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg01631408	chr1:248437212	OR2T33	-0.66	-8.34	-0.47	5.37e-15	Common traits (Other);
KIRP	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.61	-6.97	-0.41	2.81e-11	Menarche (age at onset);
KIRP	cis	rs6850606	0.577	rs1901226	chr4:42852974	A/G	cg24533989	chr4:42659536	ATP8A1	0.44	4.89	0.3	1.86e-6	Interferon alpha levels in systemic lupus erythematosus;
KIRP	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.6	-7.67	-0.44	4.02e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.67	8.77	0.49	3.05e-16	Bladder cancer;
KIRP	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg04369109	chr6:150039330	LATS1	-0.48	-5.76	-0.34	2.55e-8	Lung cancer;
KIRP	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	4.94	0.3	1.43e-6	Personality dimensions;
KIRP	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.5	0.7	2.79e-38	Platelet count;
KIRP	cis	rs4730268	1.000	rs4730268	chr7:107443386	C/T	cg18560240	chr7:107437656	SLC26A3	-0.52	-5.04	-0.31	8.87e-7	IgG glycosylation;
KIRP	cis	rs4765905	0.583	rs2238054	chr12:2317644	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.9	-0.4	4.49e-11	Schizophrenia;
KIRP	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg20744362	chr22:50050164	C22orf34	0.33	5.39	0.32	1.67e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs6009824	0.836	rs6009821	chr22:50085697	C/T	cg22070880	chr22:50098194	NA	0.73	8.16	0.46	1.72e-14	Natriuretic peptide levels;
KIRP	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.22	0.7	2.54e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg13819577	chr1:248512075	OR14C36	-0.36	-4.86	-0.3	2.07e-6	Common traits (Other);
KIRP	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg02336718	chr17:17403227	NA	0.33	5.2	0.31	4.1e-7	Total body bone mineral density;
KIRP	cis	rs6256	0.790	rs11607062	chr11:13591741	G/A	cg11976911	chr11:13509032	NA	-0.62	-5.18	-0.31	4.61e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25741597	chr3:147722622	NA	-0.43	-6.68	-0.39	1.61e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg00310523	chr12:86230176	RASSF9	0.42	6.69	0.39	1.49e-10	Major depressive disorder;
KIRP	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg25356066	chr3:128598488	ACAD9	0.47	5.48	0.33	1.05e-7	IgG glycosylation;
KIRP	cis	rs231513	0.954	rs231500	chr17:41973374	T/C	cg26893861	chr17:41843967	DUSP3	-0.46	-4.86	-0.3	2.06e-6	Cognitive function;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17421021	chr10:114879663	TCF7L2	-0.5	-6.9	-0.4	4.38e-11	Inflammatory biomarkers;
KIRP	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.84	11.83	0.6	7.36e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.78	-11.95	-0.61	2.98e-26	Monocyte percentage of white cells;
KIRP	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg00677455	chr12:58241039	CTDSP2	0.55	6.18	0.37	2.64e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.55	-6.53	-0.38	3.74e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.73	-9.33	-0.51	6.39e-18	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs748404	0.697	rs530683	chr15:43568999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.5	-6.47	-0.38	5.4e-10	Lung cancer;
KIRP	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03352830	chr11:487213	PTDSS2	0.73	6.15	0.37	3.05e-9	Body mass index;
KIRP	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.87	12.77	0.63	5.56e-29	Mean corpuscular hemoglobin;
KIRP	cis	rs953387	1.000	rs12616955	chr2:136902666	C/T	cg05194412	chr2:137003533	NA	-0.4	-5.18	-0.31	4.52e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.99	-0.3	1.12e-6	Pulmonary function;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg18173830	chr6:4776623	CDYL	0.7	6.45	0.38	5.89e-10	Lung function (FEV1);
KIRP	trans	rs74233809	0.901	rs3824754	chr10:104614350	C/T	cg17301223	chr8:145106438	OPLAH	-0.44	-6.31	-0.37	1.29e-9	Birth weight;
KIRP	cis	rs883565	0.740	rs11708354	chr3:39115626	A/T	cg01426195	chr3:39028469	NA	-0.67	-11.14	-0.58	1.28e-23	Handedness;
KIRP	cis	rs11710088	0.931	rs1802837	chr3:149193684	T/C	cg08667024	chr3:149219783	TM4SF4	-0.4	-5.64	-0.34	4.74e-8	QRS duration;
KIRP	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg08975724	chr8:8085496	FLJ10661	0.65	8.16	0.46	1.76e-14	Neuroticism;
KIRP	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg20701182	chr2:24300061	SF3B14	0.64	5.53	0.33	8.3e-8	Lymphocyte counts;
KIRP	cis	rs7209700	0.862	rs2015729	chr17:45354493	G/A	cg08085267	chr17:45401833	C17orf57	0.44	5.59	0.34	6.17e-8	IgG glycosylation;
KIRP	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.3	-0.51	7.96e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg11235152	chr1:67600687	NA	0.83	12.52	0.62	3.75e-28	Psoriasis;
KIRP	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.72	10.14	0.54	2.01e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg23625390	chr15:77176239	SCAPER	0.53	6.97	0.41	2.86e-11	Blood metabolite levels;
KIRP	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg08648136	chr8:956695	NA	0.38	5.4	0.33	1.6e-7	Schizophrenia;
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg11641102	chr8:27183873	PTK2B	0.42	5.53	0.33	8.17e-8	Neuroticism;
KIRP	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.84	11.84	0.6	6.71e-26	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg16141378	chr3:129829833	LOC729375	0.5	6.52	0.38	3.93e-10	Mood instability;
KIRP	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.46	-5.62	-0.34	5.03e-8	Cognitive test performance;
KIRP	cis	rs16958440	0.708	rs62096465	chr18:44629624	C/T	cg17192377	chr18:44677553	HDHD2	0.48	5.18	0.31	4.57e-7	Sitting height ratio;
KIRP	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg03146154	chr1:46216737	IPP	0.45	5.56	0.33	7.04e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg18477163	chr1:228402036	OBSCN	0.34	6.7	0.39	1.45e-10	Diastolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25386820	chr18:21242428	ANKRD29	0.51	6.65	0.39	1.93e-10	Smoking initiation;
KIRP	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.98	16.6	0.73	5.19e-42	Breast cancer;
KIRP	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.28	7.47	0.43	1.41e-12	Primary biliary cholangitis;
KIRP	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.78	-0.53	2.63e-19	Hemoglobin concentration;
KIRP	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.58	-7.07	-0.41	1.57e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.73	-8.25	-0.47	9.4e-15	Corneal astigmatism;
KIRP	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.49	-0.48	2.04e-15	Systolic blood pressure;
KIRP	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.45	10.09	0.54	2.96e-20	Alzheimer's disease (late onset);
KIRP	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.6	6.1	0.36	4.01e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.51	-6.7	-0.39	1.38e-10	Aortic root size;
KIRP	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9309473	0.500	rs4852952	chr2:73869907	T/C	cg20560298	chr2:73613845	ALMS1	0.49	6.0	0.36	6.98e-9	Metabolite levels;
KIRP	cis	rs72634258	0.945	rs161802	chr1:8042826	G/T	cg00042356	chr1:8021962	PARK7	0.51	5.18	0.31	4.55e-7	Inflammatory bowel disease;
KIRP	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.46	-5.87	-0.35	1.39e-8	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11117234	chr15:42500502	VPS39	0.51	6.81	0.4	7.63e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12049351	0.774	rs6678721	chr1:229623131	G/C	cg11742688	chr1:229674241	ABCB10	-0.38	-5.59	-0.34	6.16e-8	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24219929	chr15:60884748	RORA	0.53	6.93	0.4	3.77e-11	Parkinson's disease;
KIRP	cis	rs73200209	0.744	rs73200248	chr12:116723726	G/A	cg01776926	chr12:116560359	MED13L	-0.54	-5.78	-0.35	2.25e-8	Total body bone mineral density;
KIRP	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg19292749	chr17:79650816	ARL16;HGS	0.53	4.98	0.3	1.22e-6	Dental caries;
KIRP	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.68	-6.38	-0.38	8.86e-10	Schizophrenia;
KIRP	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.89	-13.1	-0.64	4.26e-30	Personality dimensions;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15551656	chr1:229795142	URB2	0.53	6.18	0.37	2.7e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg07274523	chr3:49395745	GPX1	0.72	8.53	0.48	1.49e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg09137382	chr11:130731461	NA	0.55	8.12	0.46	2.26e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.75	-0.4	1.04e-10	Retinal vascular caliber;
KIRP	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	8.08	0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg24633833	chr3:10029261	TMEM111	0.53	5.18	0.31	4.72e-7	Alzheimer's disease;
KIRP	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg05315796	chr3:52349193	DNAH1	0.44	6.81	0.4	7.64e-11	Bipolar disorder;
KIRP	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.93	12.46	0.62	6.15e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs526231	0.511	rs55810112	chr5:102362349	C/T	cg23492399	chr5:102201601	PAM	-0.47	-5.17	-0.31	4.94e-7	Primary biliary cholangitis;
KIRP	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.45	-0.52	2.81e-18	Response to antipsychotic treatment;
KIRP	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.58	0.59	4.79e-25	Monocyte percentage of white cells;
KIRP	cis	rs9905704	0.671	rs2531733	chr17:56548811	A/G	cg12560992	chr17:57184187	TRIM37	-0.53	-4.92	-0.3	1.57e-6	Testicular germ cell tumor;
KIRP	cis	rs3736485	0.966	rs11070859	chr15:51890802	C/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.19	-0.31	4.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg04362960	chr10:104952993	NT5C2	-0.41	-4.95	-0.3	1.37e-6	Colorectal cancer;
KIRP	cis	rs7721647	0.853	rs1441391	chr5:90862309	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.13	0.31	6e-7	Breast cancer;
KIRP	cis	rs7520050	0.807	rs72688483	chr1:46149209	A/G	cg03146154	chr1:46216737	IPP	0.43	5.25	0.32	3.24e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.44	6.23	0.37	1.95e-9	Coronary artery disease;
KIRP	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.75e-13	Bipolar disorder;
KIRP	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg11833968	chr6:79620685	NA	-0.36	-4.9	-0.3	1.7e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.89e-16	Life satisfaction;
KIRP	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg03609598	chr5:56110824	MAP3K1	0.48	5.55	0.33	7.4e-8	Initial pursuit acceleration;
KIRP	cis	rs2191566	0.614	rs396497	chr19:44494430	A/T	cg18700516	chr19:44507157	ZNF230	-0.43	-4.92	-0.3	1.57e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg00074818	chr8:8560427	CLDN23	0.4	6.52	0.38	3.93e-10	Obesity-related traits;
KIRP	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg26513180	chr16:89883248	FANCA	0.79	5.63	0.34	4.9e-8	Skin colour saturation;
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg10254082	chr7:997346	NA	0.58	4.84	0.3	2.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg23719950	chr11:63933701	MACROD1	-0.66	-6.02	-0.36	6.24e-9	Mean platelet volume;
KIRP	trans	rs1941687	0.831	rs12965856	chr18:31344080	A/G	cg27147174	chr7:100797783	AP1S1	-0.57	-7.11	-0.41	1.26e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.43	-7.88	-0.45	1.08e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.6	7.94	0.45	7.37e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9653442	0.564	rs13013594	chr2:100784190	A/G	cg22139774	chr2:100720529	AFF3	-0.34	-5.27	-0.32	2.99e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs1190552	0.846	rs1044503	chr14:102965996	A/G	cg10241871	chr14:102965420	TECPR2	-0.57	-6.67	-0.39	1.71e-10	Blood protein levels;
KIRP	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.87	-12.01	-0.61	1.9e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.43	7.54	0.43	9.11e-13	Renal cell carcinoma;
KIRP	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg19338460	chr6:170058176	WDR27	-0.66	-7.71	-0.44	3.16e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs7306455	0.558	rs12809276	chr12:95324286	G/A	cg02647998	chr3:12201096	TIMP4;SYN2	-0.85	-6.1	-0.36	4.09e-9	Coronary artery disease;
KIRP	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.61	-8.41	-0.47	3.33e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs960902	0.791	rs2192949	chr2:37723037	A/G	cg25341268	chr2:37734390	NA	0.49	6.44	0.38	6.34e-10	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs1776421	0.950	rs6703329	chr1:53901236	C/A	cg22073262	chr1:53904065	FLJ40434	0.48	5.35	0.32	1.98e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9473924	0.505	rs4111288	chr6:50908094	G/A	cg14470998	chr6:50812995	TFAP2B	0.85	7.8	0.45	1.79e-13	Body mass index;
KIRP	cis	rs1134634	0.520	rs13116304	chr4:15569146	A/C	cg16509355	chr4:15471240	CC2D2A	0.31	5.38	0.32	1.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.85	-13.62	-0.66	7.54e-32	Breast cancer;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.2	-0.31	4.16e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg13010199	chr12:38710504	ALG10B	0.49	6.27	0.37	1.64e-9	Morning vs. evening chronotype;
KIRP	cis	rs909341	0.909	rs2253829	chr20:62373079	G/C	cg11503966	chr20:62272292	STMN3	-0.41	-5.63	-0.34	4.95e-8	Atopic dermatitis;
KIRP	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.63	0.34	4.79e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.77	-11.99	-0.61	2.1e-26	Hepatocellular carcinoma;
KIRP	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg11608241	chr8:8085544	FLJ10661	0.42	5.0	0.3	1.07e-6	Mood instability;
KIRP	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.49	6.4	0.38	7.95e-10	Blood protein levels;
KIRP	cis	rs6901004	0.685	rs354550	chr6:111546484	G/A	cg15721981	chr6:111408429	SLC16A10	-0.52	-7.1	-0.41	1.36e-11	Blood metabolite levels;
KIRP	cis	rs9914988	0.613	rs12948391	chr17:27275621	T/C	cg10538030	chr17:27276405	PHF12	-0.6	-5.13	-0.31	5.77e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.18	0.37	2.66e-9	Mean corpuscular volume;
KIRP	cis	rs6882076	0.883	rs1553318	chr5:156479323	G/C	cg12943317	chr5:156479607	HAVCR1	-0.67	-7.87	-0.45	1.11e-13	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg23166289	chr1:210001082	C1orf107	-0.41	-5.19	-0.31	4.31e-7	Monobrow;
KIRP	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	5.25	0.32	3.3e-7	Resting heart rate;
KIRP	cis	rs789859	1.000	rs789860	chr3:194405630	A/T	cg02072170	chr3:194406190	FAM43A	0.39	5.95	0.35	8.97e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.37	-15.0	-0.69	1.5e-36	Schizophrenia;
KIRP	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg20253172	chr1:3107290	PRDM16	-0.52	-6.54	-0.39	3.43e-10	Migraine;
KIRP	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg02023728	chr11:77925099	USP35	-0.31	-5.38	-0.32	1.75e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.52e-15	Skin colour saturation;
KIRP	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.73	-0.44	2.73e-13	Resting heart rate;
KIRP	cis	rs2708977	0.671	rs582014	chr2:97075826	A/G	cg01950434	chr2:97203154	ARID5A	-0.41	-5.04	-0.31	8.89e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs13385	0.728	rs10055141	chr5:139616609	T/C	cg01860693	chr5:139557145	C5orf32	0.46	5.06	0.31	8.1e-7	Atrial fibrillation;
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg18209359	chr17:80159595	CCDC57	0.42	5.53	0.33	8.26e-8	Life satisfaction;
KIRP	cis	rs6815814	0.861	rs4833095	chr4:38799710	T/C	cg06935464	chr4:38784597	TLR10	0.56	6.81	0.4	7.37e-11	Breast cancer;
KIRP	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg23100626	chr2:96804247	ASTL	0.46	6.34	0.37	1.11e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.58	-0.44	6.86e-13	Neuroticism;
KIRP	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.85	8.58	0.48	1.11e-15	Gastritis;
KIRP	cis	rs6016377	0.638	rs6016373	chr20:39154095	A/G	cg22477343	chr20:39312069	NA	0.42	5.67	0.34	3.89e-8	Birth weight;
KIRP	cis	rs12949688	0.682	rs11871658	chr17:55839058	G/A	cg12582317	chr17:55822272	NA	0.45	6.39	0.38	8.17e-10	Schizophrenia;
KIRP	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.64	6.36	0.38	9.73e-10	Eotaxin levels;
KIRP	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg21775007	chr8:11205619	TDH	0.44	5.94	0.35	9.49e-9	Neuroticism;
KIRP	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.92	13.45	0.65	2.74e-31	Bladder cancer;
KIRP	cis	rs3857747	0.578	rs6462972	chr7:40367949	T/C	cg00420559	chr7:40367873	C7orf10	-0.46	-6.63	-0.39	2.08e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.45	6.03	0.36	5.87e-9	Blood metabolite levels;
KIRP	cis	rs76793172	1.000	rs8112594	chr19:46365672	T/C	cg00442267	chr19:46317840	RSPH6A	-0.7	-6.0	-0.36	7.01e-9	Eosinophil counts;
KIRP	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	6.29	0.37	1.41e-9	Height;
KIRP	cis	rs10875746	0.903	rs12313404	chr12:48492048	T/A	cg26205652	chr12:48591994	NA	0.78	10.5	0.56	1.49e-21	Longevity (90 years and older);
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.69	10.54	0.56	1.08e-21	Menarche (age at onset);
KIRP	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.38	0.59	2.23e-24	Height;
KIRP	cis	rs10073892	0.703	rs13357610	chr5:101640956	T/C	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg16898833	chr6:26189333	HIST1H4D	0.87	6.05	0.36	5.36e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg24315340	chr6:146058215	EPM2A	0.4	5.12	0.31	6.31e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02711726	chr17:80685570	FN3KRP	-0.58	-7.98	-0.45	5.4e-14	Glycated hemoglobin levels;
KIRP	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg15605315	chr1:45957053	TESK2	0.48	5.95	0.35	9.04e-9	High light scatter reticulocyte count;
KIRP	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.54	0.43	9.19e-13	Arsenic metabolism;
KIRP	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.81	-8.45	-0.47	2.62e-15	Gut microbiome composition (summer);
KIRP	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg14517863	chr17:44321492	NA	0.46	5.05	0.31	8.76e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17319581	chr12:69447829	NA	0.49	6.46	0.38	5.51e-10	Interleukin-4 levels;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs13067260	0.655	rs9825014	chr3:123722387	A/G	cg19918027	chr3:123987645	KALRN	-0.62	-5.51	-0.33	9.2e-8	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-0.78	-9.26	-0.51	1.08e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs67257959	0.586	rs111818766	chr19:17158092	G/A	cg16202187	chr19:17186497	HAUS8;MYO9B	0.52	6.19	0.37	2.52e-9	Selective IgA deficiency;
KIRP	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg27205649	chr11:78285834	NARS2	-0.6	-6.8	-0.4	7.69e-11	Testicular germ cell tumor;
KIRP	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs2150410	0.833	rs444130	chr21:40537449	C/A	cg11890956	chr21:40555474	PSMG1	0.75	5.5	0.33	9.38e-8	Temperament (bipolar disorder);
KIRP	cis	rs12220238	0.915	rs2894235	chr10:76082945	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.65	0.39	1.92e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg25288420	chr1:78511713	GIPC2	-0.5	-6.98	-0.41	2.7e-11	Obesity-related traits;
KIRP	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg27487796	chr7:28973253	NA	-0.22	-4.96	-0.3	1.32e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs9815354	0.812	rs73071352	chr3:41828300	A/G	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6800768	0.633	rs6769403	chr3:24148622	T/C	cg10674438	chr3:24145617	LOC152024	-0.52	-6.88	-0.4	4.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg21546286	chr11:48923668	NA	-0.46	-5.82	-0.35	1.8e-8	HDL cholesterol;
KIRP	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg14835575	chr10:16859367	RSU1	0.61	8.06	0.46	3.38e-14	Platelet distribution width;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10523193	chr11:93463762	SNORA25	-0.43	-6.47	-0.38	5.23e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs5753037	0.676	rs6006267	chr22:30216982	C/A	cg01021169	chr22:30184971	ASCC2	-0.49	-6.32	-0.37	1.24e-9	Type 1 diabetes;
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg01114163	chr5:1856713	NA	-0.46	-5.49	-0.33	9.75e-8	Cardiovascular disease risk factors;
KIRP	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.86	13.9	0.66	8.47e-33	Schizophrenia;
KIRP	cis	rs10121009	0.587	rs10738942	chr9:35439202	C/T	cg15271616	chr9:35490515	RUSC2	0.37	5.14	0.31	5.59e-7	Parkinson's disease;
KIRP	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.5	-6.11	-0.36	3.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.91	-0.4	4.24e-11	Menopause (age at onset);
KIRP	cis	rs4141404	0.737	rs5998067	chr22:32043630	C/T	cg02404636	chr22:31891804	SFI1	-0.53	-5.77	-0.35	2.42e-8	Paclitaxel-induced neuropathy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10827011	chr4:980604	IDUA;SLC26A1	0.51	6.91	0.4	4.14e-11	Parkinson's disease;
KIRP	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.65e-11	Tonsillectomy;
KIRP	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg08134877	chr2:44394819	PPM1B	0.49	5.07	0.31	7.84e-7	Height;
KIRP	cis	rs7589728	0.925	rs78829281	chr2:88502293	T/A	cg04511125	chr2:88470314	THNSL2	0.74	5.36	0.32	1.92e-7	Plasma clusterin levels;
KIRP	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg19847130	chr8:10466454	RP1L1	-0.38	-5.37	-0.32	1.78e-7	Retinal vascular caliber;
KIRP	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.46	-0.43	1.52e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9583531	0.509	rs9521923	chr13:111405462	C/T	cg24331049	chr13:111365604	ING1	-0.88	-7.77	-0.44	2.08e-13	Coronary artery disease;
KIRP	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.52	-6.29	-0.37	1.47e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.71	-9.18	-0.51	1.81e-17	Blood metabolite levels;
KIRP	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg07843065	chr1:150265600	MRPS21	0.41	5.33	0.32	2.17e-7	Migraine;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.62	-8.11	-0.46	2.33e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.49	0.48	2.01e-15	Lung cancer in ever smokers;
KIRP	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-10.14	-0.54	2.1e-20	Eye color traits;
KIRP	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg21926883	chr2:100939477	LONRF2	0.41	4.91	0.3	1.64e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.46	-5.45	-0.33	1.23e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.6e-9	Lung cancer;
KIRP	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.6	-8.24	-0.46	1.06e-14	Diastolic blood pressure;
KIRP	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.59	8.03	0.46	4e-14	Height;
KIRP	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.88	14.12	0.67	1.52e-33	Breast cancer;
KIRP	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.65	-9.21	-0.51	1.46e-17	Retinal vascular caliber;
KIRP	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg03834567	chr2:218808745	TNS1	-0.46	-5.47	-0.33	1.11e-7	Ulcerative colitis;
KIRP	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.8	11.01	0.57	3.4e-23	Aortic root size;
KIRP	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.82	-0.35	1.82e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4356932	0.935	rs115936805	chr4:76968068	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.2	0.37	2.36e-9	Blood protein levels;
KIRP	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-6.7	-0.39	1.37e-10	Superior crus of antihelix expression;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03157738	chr19:11308118	KANK2	0.76	6.49	0.38	4.69e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.4.179413987F	chr4:179176993	NA	0.46	6.94	0.4	3.42e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg15691649	chr6:25882328	NA	-0.43	-5.16	-0.31	5.02e-7	Blood metabolite levels;
KIRP	cis	rs1978968	1.000	rs1076544	chr22:18446565	G/A	cg03078520	chr22:18463400	MICAL3	-0.64	-7.63	-0.44	5.29e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.8	-10.97	-0.57	4.83e-23	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.78	-11.42	-0.59	1.64e-24	Asthma;
KIRP	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.6	12.34	0.62	1.48e-27	Diabetic kidney disease;
KIRP	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.84	12.42	0.62	8.19e-28	Blood metabolite levels;
KIRP	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.59	-0.56	7.74e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2975734	0.676	rs4841299	chr8:10112593	A/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-6.79	-0.4	8.35e-11	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.85	-12.41	-0.62	8.55e-28	Ileal carcinoids;
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg09264619	chr17:80180166	NA	-0.39	-5.57	-0.33	6.62e-8	Life satisfaction;
KIRP	cis	rs10463316	0.894	rs869196	chr5:150746287	G/T	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.21	-0.37	2.24e-9	Metabolite levels (Pyroglutamine);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.49	6.23	0.37	2e-9	Asthma;
KIRP	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.54	13.57	0.65	1.08e-31	Airflow obstruction;
KIRP	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.6	10.8	0.57	1.65e-22	Erythrocyte sedimentation rate;
KIRP	cis	rs10875746	0.680	rs4760610	chr12:48418225	C/T	cg20731937	chr12:48336164	NA	0.48	6.13	0.36	3.43e-9	Longevity (90 years and older);
KIRP	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17554472	chr22:41940697	POLR3H	-0.67	-7.01	-0.41	2.34e-11	Vitiligo;
KIRP	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.52	6.15	0.36	3.17e-9	Coronary artery disease;
KIRP	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.04	-0.36	5.69e-9	Height;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24028161	chr20:5100573	PCNA	0.44	6.12	0.36	3.7e-9	Cancer;
KIRP	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-1.06	-11.11	-0.58	1.66e-23	Post bronchodilator FEV1;
KIRP	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12963246	chr6:28129442	ZNF389	0.41	4.87	0.3	2.04e-6	Parkinson's disease;
KIRP	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-4.95	-0.3	1.37e-6	Bipolar disorder;
KIRP	cis	rs4356932	0.935	rs4129781	chr4:76959388	C/G	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs9826463	1.000	rs9862686	chr3:142341201	C/T	cg20824294	chr3:142316082	PLS1	0.34	5.81	0.35	1.9e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.84	10.14	0.54	1.98e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg21479132	chr6:26055353	NA	0.78	5.21	0.32	3.97e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.15	0.31	5.24e-7	Menopause (age at onset);
KIRP	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.51	6.9	0.4	4.38e-11	Airway imaging phenotypes;
KIRP	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg11502198	chr6:26597334	ABT1	0.5	6.26	0.37	1.7e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg03171003	chr2:111875934	NA	0.44	6.29	0.37	1.45e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.48	-5.86	-0.35	1.47e-8	Asthma (sex interaction);
KIRP	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg26876637	chr1:152193138	HRNR	-0.67	-8.92	-0.49	1.07e-16	Atopic dermatitis;
KIRP	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.59	-5.91	-0.35	1.15e-8	Body mass index;
KIRP	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg13319975	chr6:146136371	FBXO30	-0.5	-6.54	-0.38	3.63e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23669159	chr1:150122278	PLEKHO1	0.43	6.3	0.37	1.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.73	0.34	2.86e-8	Motion sickness;
KIRP	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.72	0.34	3.1e-8	Putamen volume;
KIRP	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	cis	rs73206853	0.563	rs7301769	chr12:111171026	T/C	cg12870014	chr12:110450643	ANKRD13A	0.49	4.85	0.3	2.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg01559446	chr3:44596178	ZNF167	-0.35	-5.2	-0.31	4.28e-7	Depressive symptoms;
KIRP	trans	rs994014	0.691	rs58877260	chr4:82271025	C/T	cg04076444	chr16:85646805	KIAA0182	0.51	6.03	0.36	5.82e-9	Height;
KIRP	cis	rs8098244	0.708	rs1262340	chr18:21475153	A/G	cg07121078	chr18:21242319	ANKRD29	0.59	5.18	0.31	4.7e-7	Epithelial ovarian cancer;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;
KIRP	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg16482183	chr6:26056742	HIST1H1C	0.7	7.1	0.41	1.32e-11	Iron status biomarkers;
KIRP	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg23100626	chr2:96804247	ASTL	0.5	7.0	0.41	2.37e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs12532214	0.645	rs6973204	chr7:3178561	C/T	cg19214707	chr7:3157722	NA	0.64	5.56	0.33	6.98e-8	Itch intensity from mosquito bite;
KIRP	trans	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs258892	0.895	rs10473898	chr5:72037813	T/C	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg23067535	chr8:124195133	FAM83A	0.74	6.83	0.4	6.67e-11	Urinary uromodulin levels;
KIRP	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg06647332	chr5:131281008	NA	0.46	5.01	0.3	1.05e-6	Life satisfaction;
KIRP	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.63	-7.9	-0.45	9.23e-14	Educational attainment;
KIRP	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.58	7.86	0.45	1.17e-13	Schizophrenia;
KIRP	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.7	8.51	0.48	1.71e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3126085	0.515	rs11204984	chr1:152331987	T/C	cg26876637	chr1:152193138	HRNR	-0.55	-6.82	-0.4	7.03e-11	Atopic dermatitis;
KIRP	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05220968	chr6:146057943	EPM2A	-0.39	-5.09	-0.31	7.11e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg03115019	chr17:80708279	FN3K	-0.43	-5.11	-0.31	6.34e-7	Glycated hemoglobin levels;
KIRP	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.69	8.34	0.47	5.19e-15	Aortic root size;
KIRP	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.26	-0.42	5.18e-12	Retinal vascular caliber;
KIRP	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg24807547	chr6:37504484	NA	-0.45	-5.68	-0.34	3.73e-8	Cognitive performance;
KIRP	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.76	-10.07	-0.54	3.38e-20	Colorectal cancer;
KIRP	cis	rs6466055	0.777	rs3801282	chr7:104881530	A/G	cg04380332	chr7:105027541	SRPK2	0.64	9.75	0.53	3.45e-19	Schizophrenia;
KIRP	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.82	8.32	0.47	5.99e-15	Methadone dose in opioid dependence;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08555112	chr17:48942811	TOB1	-0.46	-6.43	-0.38	6.43e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.73	-0.44	2.71e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg26384229	chr12:38710491	ALG10B	0.67	8.91	0.49	1.13e-16	Morning vs. evening chronotype;
KIRP	cis	rs6707387	0.598	rs339821	chr2:214298413	G/A	cg08319019	chr2:214017104	IKZF2	0.43	4.94	0.3	1.47e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.98	12.9	0.64	2.02e-29	Homoarginine levels;
KIRP	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg10729496	chr3:10149963	C3orf24	-0.52	-4.95	-0.3	1.41e-6	Alzheimer's disease;
KIRP	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.8	9.57	0.52	1.22e-18	Corneal astigmatism;
KIRP	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	6.54	0.38	3.54e-10	Height;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg08047886	chr11:57425128	CLP1	-0.5	-6.89	-0.4	4.79e-11	Morning vs. evening chronotype;
KIRP	cis	rs4308124	1.000	rs57707030	chr2:112012682	C/A	cg23466623	chr2:111982296	NA	0.4	5.56	0.33	6.85e-8	Vitiligo;
KIRP	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg08975724	chr8:8085496	FLJ10661	-0.71	-9.82	-0.53	2.05e-19	Triglycerides;
KIRP	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.68	-8.5	-0.48	1.83e-15	Recalcitrant atopic dermatitis;
KIRP	cis	rs2548003	0.518	rs2548015	chr5:28726109	A/C	cg11015470	chr5:28928158	NA	0.51	5.66	0.34	4.27e-8	Hip geometry;
KIRP	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs714027	0.566	rs5763751	chr22:30460434	G/T	cg01021169	chr22:30184971	ASCC2	0.43	5.4	0.33	1.55e-7	Lymphocyte counts;
KIRP	cis	rs2299587	0.643	rs6586680	chr8:17891178	C/T	cg01800426	chr8:17659068	MTUS1	-0.42	-5.04	-0.31	9.13e-7	Economic and political preferences;
KIRP	cis	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg21775007	chr8:11205619	TDH	0.39	5.33	0.32	2.18e-7	Monocyte count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15233114	chr10:60145133	TFAM	0.47	6.22	0.37	2.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg17441377	chr17:3906640	NA	0.49	7.25	0.42	5.23e-12	Type 2 diabetes;
KIRP	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	1.22	11.23	0.58	6.87e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg06289844	chr6:126071538	HEY2	0.36	5.12	0.31	6.13e-7	Brugada syndrome;
KIRP	cis	rs2625529	0.652	rs2415128	chr15:72191073	T/C	cg16672083	chr15:72433130	SENP8	0.45	6.24	0.37	1.89e-9	Red blood cell count;
KIRP	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg01631408	chr1:248437212	OR2T33	-0.44	-5.89	-0.35	1.28e-8	Common traits (Other);
KIRP	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg07930552	chr6:133119739	C6orf192	0.69	5.2	0.31	4.14e-7	Type 2 diabetes nephropathy;
KIRP	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg18198730	chr1:247681584	NA	0.6	5.67	0.34	3.94e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs501120	0.925	rs492152	chr10:44757677	C/T	cg09554077	chr10:44749378	NA	0.7	10.63	0.56	5.74e-22	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.71	10.05	0.54	3.99e-20	Mean corpuscular volume;
KIRP	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg10223061	chr2:219282414	VIL1	-0.33	-5.37	-0.32	1.81e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	14.23	0.67	6.32e-34	Electrocardiographic conduction measures;
KIRP	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg09408571	chr1:101003634	GPR88	0.24	5.28	0.32	2.88e-7	Monocyte count;
KIRP	cis	rs4765905	1.000	rs12315711	chr12:2346830	T/A	cg10668781	chr12:2307325	CACNA1C	-0.27	-4.95	-0.3	1.4e-6	Schizophrenia;
KIRP	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-6.08	-0.36	4.61e-9	Schizophrenia;
KIRP	trans	rs17079247	0.841	rs9594005	chr13:85807348	C/T	cg07750655	chr16:5121855	ALG1	-0.58	-6.11	-0.36	3.83e-9	Bipolar disorder (mania);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12051027	chr1:48931095	SPATA6	-0.43	-6.34	-0.37	1.08e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03063185	chr6:86303159	SNX14	0.47	6.11	0.36	3.83e-9	Parkinson's disease;
KIRP	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg19773385	chr1:10388646	KIF1B	-0.73	-11.46	-0.59	1.23e-24	Hepatocellular carcinoma;
KIRP	cis	rs6662572	0.737	rs4573476	chr1:46346721	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.24	0.32	3.37e-7	Blood protein levels;
KIRP	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.0	13.89	0.66	8.76e-33	Response to antipsychotic treatment;
KIRP	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.76	-8.03	-0.46	4.14e-14	Asthma;
KIRP	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	10.2	0.55	1.33e-20	Personality dimensions;
KIRP	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg13147721	chr7:65941812	NA	-1.01	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.47	0.33	1.12e-7	Tonsillectomy;
KIRP	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg02023728	chr11:77925099	USP35	-0.32	-5.09	-0.31	7.22e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	1.2	11.39	0.59	1.97e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.58	-7.14	-0.41	1.04e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.43	5.62	0.34	5.2100000000000003e-08	Homoarginine levels;
KIRP	cis	rs77972916	0.561	rs72788900	chr2:43559087	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-6.47	-0.38	5.17e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.57	7.53	0.43	9.76e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg13606994	chr1:44402422	ARTN	-0.28	-5.63	-0.34	4.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.33	-0.42	3.4e-12	Bipolar disorder;
KIRP	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg05072774	chr3:49840536	C3orf54	-0.39	-5.14	-0.31	5.55e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.45	4.92	0.3	1.59e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs11997175	0.766	rs4442096	chr8:33691039	T/C	ch.8.33884649F	chr8:33765107	NA	0.46	5.77	0.35	2.36e-8	Body mass index;
KIRP	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg12311346	chr5:56204834	C5orf35	-0.37	-5.18	-0.31	4.57e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs34779708	0.931	rs34375045	chr10:35362356	A/C	cg04310649	chr10:35416472	CREM	-0.53	-6.08	-0.36	4.45e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-6.36	-0.38	9.65e-10	Lung function (FEV1/FVC);
KIRP	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg06792538	chr1:2954250	NA	0.41	4.91	0.3	1.69e-6	Plateletcrit;
KIRP	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.41	-5.56	-0.33	6.92e-8	Blood metabolite levels;
KIRP	cis	rs10411936	0.692	rs10413787	chr19:16594967	A/G	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.36	0.32	1.9e-7	White blood cell count;Multiple sclerosis;
KIRP	trans	rs909341	0.818	rs2750483	chr20:62345470	A/G	cg01311341	chr22:25575246	KIAA1671	-0.63	-7.64	-0.44	4.95e-13	Atopic dermatitis;
KIRP	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.65e-30	Eye color traits;
KIRP	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs2033732	0.642	rs1370417	chr8:85056283	A/G	cg05716166	chr8:85095498	RALYL	0.54	6.05	0.36	5.36e-9	Body mass index;
KIRP	cis	rs909341	0.830	rs1623866	chr20:62333022	G/A	cg03999872	chr20:62272968	STMN3	-0.56	-6.49	-0.38	4.57e-10	Atopic dermatitis;
KIRP	cis	rs490234	0.812	rs12341150	chr9:128340770	C/T	cg14078157	chr9:128172775	NA	-0.57	-6.79	-0.4	8.26e-11	Mean arterial pressure;
KIRP	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.41	7.03	0.41	2.03e-11	Heart rate;
KIRP	cis	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg11502198	chr6:26597334	ABT1	-0.84	-5.17	-0.31	4.89e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06992027	chr1:159895302	TAGLN2	0.5	6.69	0.39	1.45e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	13.89	0.66	8.74e-33	Cognitive ability;
KIRP	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21972741	chr5:435613	AHRR	0.53	6.99	0.41	2.54e-11	Cystic fibrosis severity;
KIRP	cis	rs300890	0.536	rs300940	chr4:144173305	C/T	cg01719995	chr4:144104893	USP38	0.4	5.13	0.31	5.85e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg14593290	chr7:50529359	DDC	0.64	8.14	0.46	2.02e-14	Malaria;
KIRP	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg19773385	chr1:10388646	KIF1B	0.43	6.35	0.38	1.05e-9	Hepatocellular carcinoma;
KIRP	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg11833968	chr6:79620685	NA	-0.45	-6.74	-0.4	1.09e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.34	12.2	0.61	4.31e-27	Diabetic retinopathy;
KIRP	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg07052231	chr12:7363540	PEX5	0.4	5.2	0.31	4.19e-7	IgG glycosylation;
KIRP	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.56	-0.33	6.92e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg24747557	chr10:131355152	MGMT	-0.43	-5.69	-0.34	3.63e-8	Response to temozolomide;
KIRP	cis	rs9611519	0.603	rs8142276	chr22:41471447	T/C	cg03806693	chr22:41940476	POLR3H	-0.41	-4.84	-0.3	2.26e-6	Neuroticism;
KIRP	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	1.01	14.42	0.68	1.42e-34	Total cholesterol levels;
KIRP	trans	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Bladder cancer;
KIRP	cis	rs7799006	0.929	rs745565	chr7:2256689	G/C	cg02951883	chr7:2050386	MAD1L1	-0.46	-5.14	-0.31	5.66e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.61	8.11	0.46	2.41e-14	Schizophrenia;
KIRP	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Body mass index;
KIRP	cis	rs7084402	0.967	rs12242287	chr10:60278340	A/G	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg20735989	chr4:730612	PCGF3	-0.48	-6.06	-0.36	5e-9	White blood cell count;
KIRP	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.61	10.02	0.54	4.95e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7870753	0.578	rs7044391	chr9:99159791	C/A	cg25260653	chr9:99212216	HABP4	0.52	5.33	0.32	2.23e-7	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23026246	chr19:41029387	SPTBN4	0.46	6.43	0.38	6.65e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1018697	1.000	rs7092346	chr10:104559764	A/G	cg04362960	chr10:104952993	NT5C2	0.49	5.92	0.35	1.06e-8	Colorectal adenoma (advanced);
KIRP	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg15128208	chr22:42549153	NA	0.72	8.06	0.46	3.27e-14	Birth weight;
KIRP	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg06307176	chr5:131281290	NA	0.56	5.99	0.36	7.6e-9	Life satisfaction;
KIRP	cis	rs9972944	0.756	rs9901885	chr17:63769559	T/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.73	-0.44	2.66e-13	Total body bone mineral density;
KIRP	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg18306943	chr3:40428807	ENTPD3	0.45	6.15	0.37	3.11e-9	Renal cell carcinoma;
KIRP	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.59	6.33	0.37	1.18e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg22974920	chr21:40686053	BRWD1	0.45	5.31	0.32	2.4e-7	Cognitive function;
KIRP	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg06204229	chr3:52865917	ITIH4	0.43	5.07	0.31	7.71e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2354432	0.607	rs4950310	chr1:146659964	A/G	cg25205988	chr1:146714368	CHD1L	1.21	8.49	0.48	2.01e-15	Mitochondrial DNA levels;
KIRP	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.58	-6.09	-0.36	4.26e-9	Obesity-related traits;
KIRP	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.42	-5.13	-0.31	5.79e-7	Tonsillectomy;
KIRP	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs9469913	0.542	rs3800461	chr6:34616322	G/C	cg17674042	chr6:34482479	PACSIN1	-0.61	-6.51	-0.38	4.09e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.16	-0.37	2.98e-9	Systolic blood pressure;
KIRP	cis	rs6191	0.838	rs852983	chr5:142712064	G/A	cg08845721	chr5:142780693	NR3C1	-0.39	-5.26	-0.32	3.16e-7	Night sleep phenotypes;
KIRP	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs11779988	0.545	rs208762	chr8:17806734	G/A	cg01800426	chr8:17659068	MTUS1	-0.64	-6.51	-0.38	4.29e-10	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00933542	chr6:150070202	PCMT1	0.28	5.69	0.34	3.64e-8	Lung cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06115851	chr18:34408868	C18orf10;KIAA1328	-0.59	-6.43	-0.38	6.65e-10	Menopause (age at onset);
KIRP	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.68	8.93	0.49	1.02e-16	Breast cancer;
KIRP	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg07160589	chr1:63988470	ITGB3BP;EFCAB7	0.38	6.52	0.38	3.85e-10	Suicide attempts in major depressive disorder;
KIRP	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.5	6.45	0.38	5.72e-10	Menopause (age at onset);
KIRP	cis	rs757081	0.506	rs11529609	chr11:17063790	G/A	cg15432903	chr11:17409602	KCNJ11	-0.44	-5.29	-0.32	2.7e-7	Systolic blood pressure;
KIRP	cis	rs9612	1.000	rs347519	chr19:44273516	T/C	cg08581076	chr19:44259116	C19orf61	0.54	5.98	0.36	7.69e-9	Exhaled nitric oxide output;
KIRP	cis	rs965513	0.627	rs10124220	chr9:100583074	T/C	cg13688889	chr9:100608707	NA	-0.6	-7.28	-0.42	4.53e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs11671005	0.735	rs12977592	chr19:58961056	C/G	cg13877915	chr19:58951672	ZNF132	0.67	7.39	0.43	2.34e-12	Mean platelet volume;
KIRP	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.53	6.29	0.37	1.41e-9	Macular telangiectasia type 2;
KIRP	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.58	-8.07	-0.46	3.11e-14	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6601327	0.603	rs13275545	chr8:9667914	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.91	-0.4	4.13e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg21573476	chr21:45109991	RRP1B	0.44	5.7	0.34	3.46e-8	Mean corpuscular volume;
KIRP	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14895029	chr7:2775587	GNA12	-0.42	-5.0	-0.3	1.08e-6	Height;
KIRP	cis	rs11622475	1.000	rs2368984	chr14:104372055	A/C	cg20488157	chr14:104394430	TDRD9	0.74	10.51	0.56	1.43e-21	Bipolar disorder;
KIRP	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg03060546	chr3:49711283	APEH	0.74	11.55	0.59	6.17e-25	Resting heart rate;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.78	13.83	0.66	1.49e-32	Height;
KIRP	cis	rs28595532	0.557	rs7696047	chr4:119303024	G/A	cg21605333	chr4:119757512	SEC24D	0.67	6.53	0.38	3.82e-10	Cannabis dependence symptom count;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg27212978	chr4:38869221	FAM114A1;MIR574	0.53	6.8	0.4	7.95e-11	DNA methylation (variation);
KIRP	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg08992911	chr2:238395768	MLPH	0.4	5.07	0.31	7.97e-7	Prostate cancer;
KIRP	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg26784012	chr10:32216390	ARHGAP12	0.33	5.24	0.32	3.47e-7	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.68	-6.76	-0.4	1.01e-10	Breast cancer;
KIRP	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.54	7.04	0.41	1.88e-11	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2016266	0.855	rs1056692	chr12:53687387	A/G	cg16917193	chr12:54089295	NA	-0.5	-6.07	-0.36	4.77e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg14703610	chr5:56206110	C5orf35	0.49	6.77	0.4	9.56e-11	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs1832871	0.672	rs9456295	chr6:158772078	G/A	cg07215822	chr6:158701037	NA	-0.63	-7.32	-0.42	3.45e-12	Height;
KIRP	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	8.43	0.47	2.92e-15	Personality dimensions;
KIRP	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.31	0.51	7.44e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg14593290	chr7:50529359	DDC	-0.77	-9.49	-0.52	2.15e-18	Malaria;
KIRP	cis	rs1413885	0.516	rs6588137	chr1:65837282	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.57	6.06	0.36	5.04e-9	Anticoagulant levels;
KIRP	cis	rs2860975	0.620	rs7077618	chr10:96793457	T/A	cg09036531	chr10:96991505	NA	-0.48	-5.83	-0.35	1.7e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.22	-0.42	6.57e-12	Morning vs. evening chronotype;
KIRP	cis	rs4889855	0.530	rs4303599	chr17:78566700	C/T	cg09596252	chr17:78655493	RPTOR	-0.48	-5.41	-0.33	1.47e-7	Fractional excretion of uric acid;
KIRP	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	1.08	6.22	0.37	2.07e-9	Height;
KIRP	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.82e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6032067	1.000	rs35284867	chr20:43845836	A/T	cg10761708	chr20:43804764	PI3	0.52	5.3	0.32	2.59e-7	Blood protein levels;
KIRP	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.73	9.15	0.5	2.28e-17	Aortic root size;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09255124	chr11:43380251	TTC17	-0.46	-6.67	-0.39	1.71e-10	Survival in pancreatic cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16721257	chr8:130954845	NA	0.46	6.36	0.38	9.9e-10	Survival in pancreatic cancer;
KIRP	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	27.33	0.87	1.76e-76	Chronic sinus infection;
KIRP	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg00129232	chr17:37814104	STARD3	-0.81	-11.94	-0.61	3.26e-26	Asthma;
KIRP	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.51	0.56	1.37e-21	Body mass index;
KIRP	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.39	-5.46	-0.33	1.15e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.69	-0.39	1.52e-10	Menopause (age at onset);
KIRP	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg10547527	chr2:198650123	BOLL	-0.54	-5.05	-0.31	8.73e-7	Ulcerative colitis;
KIRP	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg26876637	chr1:152193138	HRNR	0.73	9.84	0.53	1.76e-19	Atopic dermatitis;
KIRP	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.78	11.09	0.58	1.9e-23	Chronic sinus infection;
KIRP	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg04896959	chr15:78267971	NA	0.52	6.81	0.4	7.57e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-10.34	-0.55	4.65e-21	Chronic sinus infection;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03356760	chr6:37665051	MDGA1	0.48	6.34	0.37	1.1e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4664304	0.754	rs67504285	chr2:160821211	C/T	cg23995753	chr2:160760732	LY75	-0.38	-4.86	-0.3	2.05e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg00553149	chr7:99775558	STAG3;GPC2	-0.46	-5.81	-0.35	1.94e-8	Coronary artery disease;
KIRP	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.85	8.78	0.49	2.78e-16	Bipolar disorder;
KIRP	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg12131826	chr15:77904385	NA	0.48	5.72	0.34	3.02e-8	Type 2 diabetes;
KIRP	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg08975724	chr8:8085496	FLJ10661	0.44	5.38	0.32	1.78e-7	Recombination measurement;
KIRP	cis	rs4591494	0.651	rs9809770	chr3:7926880	G/A	cg06740372	chr3:7957779	NA	-0.36	-4.86	-0.3	2.09e-6	Factor VII;
KIRP	cis	rs8114671	0.967	rs2069945	chr20:33761837	C/G	cg24642439	chr20:33292090	TP53INP2	0.5	5.93	0.35	1.01e-8	Height;
KIRP	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.75	-10.67	-0.56	4.21e-22	Prostate cancer;
KIRP	cis	rs918629	0.754	rs2112566	chr5:95288618	G/A	cg16656078	chr5:95278638	ELL2	-0.5	-7.24	-0.42	5.7e-12	IgG glycosylation;
KIRP	cis	rs72781680	0.560	rs72781698	chr2:24271506	C/T	cg20701182	chr2:24300061	SF3B14	0.95	10.27	0.55	8.01e-21	Lymphocyte counts;
KIRP	cis	rs867371	1.000	rs1846911	chr15:82468650	G/A	cg06066596	chr15:83166174	LOC80154	-0.47	-5.53	-0.33	8.02e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.78	-11.47	-0.59	1.12e-24	Caffeine consumption;
KIRP	cis	rs6901250	0.523	rs592669	chr6:117090944	T/C	cg12892004	chr6:117198278	RFX6	0.37	6.15	0.37	3.11e-9	C-reactive protein levels;
KIRP	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	0.81	6.74	0.39	1.15e-10	Skin colour saturation;
KIRP	cis	rs6909279	0.678	rs9479056	chr6:151848899	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	-0.57	-7.05	-0.41	1.77e-11	Bone mineral density;
KIRP	cis	rs2154427	0.689	rs2833947	chr21:34124930	T/C	cg03746930	chr21:34165763	C21orf62;C21orf49	-0.65	-5.59	-0.34	5.99e-8	Bilirubin levels;
KIRP	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg17366294	chr4:99064904	C4orf37	0.44	6.38	0.38	8.94e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.99	-0.41	2.62e-11	Lung cancer;
KIRP	cis	rs12413816	0.857	rs1571009	chr10:13760975	G/A	cg16485048	chr10:13749193	FRMD4A	0.62	8.8	0.49	2.47e-16	Red cell distribution width;
KIRP	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg01244601	chr4:120671846	NA	-0.4	-5.21	-0.32	3.97e-7	Corneal astigmatism;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.48	4.88	0.3	1.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg27205649	chr11:78285834	NARS2	-0.47	-5.0	-0.3	1.08e-6	Testicular germ cell tumor;
KIRP	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg21186296	chr8:27182909	PTK2B	0.49	6.28	0.37	1.56e-9	Neuroticism;
KIRP	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.49	7.4	0.43	2.17e-12	Total body bone mineral density;
KIRP	cis	rs6450176	1.000	rs6886510	chr5:53303127	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.86	11.03	0.58	2.94e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs8133932	0.576	rs2839039	chr21:47321499	T/G	cg11214348	chr21:47283868	PCBP3	0.47	5.32	0.32	2.28e-7	Schizophrenia;
KIRP	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.0	-0.41	2.37e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7116495	1.000	rs560777	chr11:71770602	C/T	cg18441811	chr11:71824068	C11orf51	0.62	5.11	0.31	6.38e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9296736	1.000	rs7450517	chr6:53902843	G/A	cg04374786	chr6:53939321	C6orf142	0.38	5.07	0.31	8.01e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg20750642	chr13:99100586	FARP1	0.43	5.24	0.32	3.4e-7	Neuroticism;
KIRP	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.22	-5.67	-0.34	4.06e-8	Mean corpuscular volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg14082963	chr4:89444434	PIGY	0.98	6.59	0.39	2.64e-10	P wave terminal force;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg18908524	chr11:64002295	VEGFB	-0.6	-6.61	-0.39	2.35e-10	Menopause (age at onset);
KIRP	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26526719	chr5:1949144	NA	0.45	5.26	0.32	3.2e-7	Gut microbiome composition (winter);
KIRP	cis	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg03511173	chr18:77590860	NA	-0.54	-6.52	-0.38	4.06e-10	Opioid sensitivity;
KIRP	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.29	-0.32	2.74e-7	Breast cancer;
KIRP	cis	rs1448094	0.838	rs28509446	chr12:86312584	A/C	cg02569458	chr12:86230093	RASSF9	0.38	5.55	0.33	7.54e-8	Major depressive disorder;
KIRP	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg04369109	chr6:150039330	LATS1	-0.43	-5.26	-0.32	3.06e-7	Lung cancer;
KIRP	cis	rs3767633	0.764	rs2340722	chr1:161856424	G/A	cg09175582	chr1:161736000	ATF6	0.82	5.22	0.32	3.89e-7	IgG glycosylation;
KIRP	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg04310649	chr10:35416472	CREM	0.54	6.78	0.4	8.61e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.0	-0.3	1.1e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg11970804	chr8:8084126	NA	-0.35	-5.0	-0.3	1.09e-6	Mood instability;
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg26134248	chr17:3907702	NA	0.55	8.2	0.46	1.31e-14	Type 2 diabetes;
KIRP	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.47	5.93	0.35	1.01e-8	Motion sickness;
KIRP	cis	rs2692947	1.000	rs2692947	chr2:96674116	T/C	cg23100626	chr2:96804247	ASTL	0.45	6.63	0.39	2.17e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs33912345	0.750	rs1254304	chr14:60886974	C/A	cg27398547	chr14:60952738	C14orf39	-0.41	-5.47	-0.33	1.08e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.97	0.45	5.92e-14	Aortic root size;
KIRP	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.04	16.04	0.72	3.96e-40	Subjective well-being;
KIRP	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.76	8.11	0.46	2.35e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.58	-6.6	-0.39	2.54e-10	Hypospadias;
KIRP	cis	rs3744061	0.557	rs4544269	chr17:74648646	G/A	cg27546012	chr17:74684504	MXRA7	-0.44	-5.38	-0.32	1.71e-7	Retinal arteriolar caliber;
KIRP	cis	rs6545883	0.772	rs1186709	chr2:61689380	G/A	cg15711740	chr2:61764176	XPO1	-0.6	-7.81	-0.45	1.61e-13	Tuberculosis;
KIRP	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg02725872	chr8:58115012	NA	-0.53	-6.16	-0.37	3.02e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg03929089	chr4:120376271	NA	0.93	6.78	0.4	8.74e-11	Myopia (pathological);
KIRP	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.28	-0.55	7.27e-21	Colorectal cancer;
KIRP	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg12042659	chr19:58951599	ZNF132	0.49	6.03	0.36	6.04e-9	Uric acid clearance;
KIRP	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.54	-6.79	-0.4	8.21e-11	Coronary artery disease;
KIRP	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.66	-9.06	-0.5	4.1e-17	Total body bone mineral density;
KIRP	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.67	-6.74	-0.39	1.14e-10	Migraine;Coronary artery disease;
KIRP	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.08e-10	Axial length;
KIRP	cis	rs12496230	0.794	rs12633969	chr3:66859170	A/C	cg04995300	chr3:66848608	NA	-0.44	-6.76	-0.4	9.85e-11	Type 2 diabetes;
KIRP	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.16	-0.31	5.18e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	1.11	11.59	0.59	4.52e-25	Mitochondrial DNA levels;
KIRP	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg10636054	chr15:40330586	SRP14	1.25	9.92	0.53	9.74e-20	Corneal curvature;
KIRP	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.37	-0.38	9.22e-10	Height;
KIRP	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg17376030	chr22:41985996	PMM1	0.61	6.39	0.38	8.4e-10	Vitiligo;
KIRP	cis	rs7714584	1.000	rs11741861	chr5:150277909	C/T	cg22134413	chr5:150180641	NA	-0.95	-6.85	-0.4	5.75e-11	Crohn's disease;
KIRP	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.39	5.13	0.31	5.77e-7	Educational attainment;
KIRP	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg22771759	chr13:24902376	NA	0.4	5.1	0.31	6.73e-7	Obesity-related traits;
KIRP	trans	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg16141378	chr3:129829833	LOC729375	-0.49	-6.62	-0.39	2.26e-10	Joint mobility (Beighton score);
KIRP	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.36e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg23594656	chr7:65796392	TPST1	0.51	7.93	0.45	7.91e-14	Aortic root size;
KIRP	cis	rs4950322	0.570	rs17160051	chr1:146727388	G/T	cg22381352	chr1:146742008	CHD1L	-0.44	-5.39	-0.33	1.62e-7	Protein quantitative trait loci;
KIRP	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.72	7.11	0.41	1.23e-11	Type 2 diabetes;
KIRP	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	7.37	0.43	2.66e-12	Neuroticism;
KIRP	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.69	9.49	0.52	2.17e-18	Multiple sclerosis;
KIRP	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg06102954	chr21:42741788	MX2	-0.53	-7.43	-0.43	1.8e-12	Melanoma;
KIRP	cis	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.88	-0.3	1.91e-6	Cervical cancer;
KIRP	cis	rs77861329	1.000	rs2304505	chr3:52184760	T/C	cg08692210	chr3:52188851	WDR51A	0.94	7.57	0.43	7.52e-13	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.66	9.36	0.51	5.25e-18	Breast cancer;
KIRP	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.47	-5.69	-0.34	3.61e-8	Ulcerative colitis;
KIRP	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	1.22	10.05	0.54	3.89e-20	Atopic dermatitis;
KIRP	cis	rs4959799	0.655	rs9501974	chr6:3272775	T/C	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.26	-0.32	3.11e-7	Survival in rectal cancer;
KIRP	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.6	-6.85	-0.4	6.02e-11	Bipolar disorder;
KIRP	cis	rs9525562	0.536	rs67733486	chr13:42618232	G/C	cg07025593	chr13:42613794	NA	0.46	5.21	0.32	4.05e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.06	-0.31	8.28e-7	Obesity-related traits;
KIRP	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.54	7.2	0.42	7.18e-12	Testicular germ cell tumor;
KIRP	cis	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.68	4.93	0.3	1.54e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.13	-0.64	3.34e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21214613	chr1:16344536	HSPB7	0.35	4.98	0.3	1.2e-6	Dilated cardiomyopathy;
KIRP	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13409248	chr3:40428643	ENTPD3	0.4	5.27	0.32	2.95e-7	Renal cell carcinoma;
KIRP	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.77	-9.45	-0.52	2.85e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.49	-6.15	-0.37	3.05e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs829661	0.739	rs1252631	chr2:30760754	A/G	cg10949345	chr2:30726833	LCLAT1	1.13	14.14	0.67	1.28e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg08822215	chr16:89438651	ANKRD11	-0.54	-6.88	-0.4	5.05e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg19468946	chr17:37922297	IKZF3	-0.53	-7.26	-0.42	5.21e-12	Self-reported allergy;
KIRP	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg26681399	chr22:41777847	TEF	0.47	5.34	0.32	2.1e-7	Vitiligo;
KIRP	cis	rs546131	0.515	rs7128804	chr11:34857948	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-4.98	-0.3	1.2e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg23791538	chr6:167370224	RNASET2	-0.43	-4.9	-0.3	1.7e-6	Crohn's disease;
KIRP	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg11833968	chr6:79620685	NA	0.45	6.76	0.4	1.01e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2071426	0.959	rs35394919	chr10:96810972	C/T	cg09036531	chr10:96991505	NA	-0.65	-7.1	-0.41	1.37e-11	Blood metabolite levels;
KIRP	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-8.71	-0.49	4.44e-16	Cognitive function;
KIRP	cis	rs7188697	0.922	rs40188	chr16:58567761	T/A	cg21335942	chr16:58549945	SETD6	0.47	5.14	0.31	5.5e-7	QT interval;
KIRP	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg06742321	chr12:123595122	PITPNM2	0.42	5.22	0.32	3.86e-7	Platelet count;
KIRP	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg19592336	chr6:28129416	ZNF389	0.48	5.53	0.33	8.32e-8	Depression;
KIRP	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg05315796	chr3:52349193	DNAH1	0.39	6.19	0.37	2.52e-9	Bipolar disorder;
KIRP	cis	rs9303280	0.806	rs4795400	chr17:38067020	C/T	cg00129232	chr17:37814104	STARD3	-0.44	-5.79	-0.35	2.16e-8	Self-reported allergy;
KIRP	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.8	7.58	0.43	7.19e-13	Inflammatory bowel disease;
KIRP	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.66	11.54	0.59	6.6e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg00629928	chr5:358741	AHRR	0.51	4.97	0.3	1.27e-6	Breast cancer;
KIRP	cis	rs4356975	0.527	rs57102579	chr4:69991194	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.06	0.31	8.15e-7	Obesity-related traits;
KIRP	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg08662619	chr6:150070041	PCMT1	0.34	5.0	0.3	1.1e-6	Lung cancer;
KIRP	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.5	5.1	0.31	6.81e-7	Alzheimer's disease;
KIRP	cis	rs17123764	0.892	rs74087113	chr12:50104104	C/T	cg20471783	chr12:50157085	TMBIM6	0.4	5.31	0.32	2.49e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.08	-13.31	-0.65	8.43e-31	Exhaled nitric oxide output;
KIRP	cis	rs1165472	0.755	rs12566150	chr1:56160904	C/G	cg11523071	chr1:56160889	NA	-0.69	-10.45	-0.55	2.14e-21	Paclitaxel-induced neuropathy;
KIRP	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg17507749	chr15:85114479	UBE2QP1	0.82	8.77	0.49	3.12e-16	Schizophrenia;
KIRP	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-6.05	-0.36	5.27e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12949688	0.845	rs740439	chr17:55804463	G/C	cg12582317	chr17:55822272	NA	0.54	8.59	0.48	9.88e-16	Schizophrenia;
KIRP	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.43	-0.43	1.78e-12	Triglycerides;
KIRP	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.52	6.09	0.36	4.29e-9	Aortic root size;
KIRP	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg15327641	chr2:3715039	ALLC	0.48	4.99	0.3	1.15e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg08807101	chr21:30365312	RNF160	-0.55	-5.38	-0.32	1.72e-7	Cognitive test performance;
KIRP	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg12718519	chr1:2058417	PRKCZ	0.24	5.29	0.32	2.67e-7	Height;
KIRP	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg02002194	chr4:3960332	NA	-0.42	-6.1	-0.36	4.04e-9	Mood instability;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg07701084	chr6:150067640	NUP43	0.69	9.34	0.51	6.21e-18	Lung cancer;
KIRP	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.38	7.33	0.42	3.28e-12	Height;
KIRP	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.39	-13.49	-0.65	2.06e-31	Hip circumference adjusted for BMI;
KIRP	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00290607	chr11:67383545	NA	0.35	4.89	0.3	1.82e-6	Mean corpuscular volume;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10276623	chr14:94770592	SERPINA6	-0.5	-6.57	-0.39	2.95e-10	Inflammatory biomarkers;
KIRP	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.78	0.6	1.1e-25	Longevity;
KIRP	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg14289246	chr4:154710475	SFRP2	-0.52	-6.93	-0.4	3.63e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs785830	0.729	rs560608	chr9:270216	A/C	cg14500300	chr9:211689	NA	0.56	7.32	0.42	3.56e-12	Platelet distribution width;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg00006948	chr4:1768889	NA	0.45	6.06	0.36	5.05e-9	Inflammatory biomarkers;
KIRP	cis	rs6732160	0.574	rs7557055	chr2:73472670	G/A	cg01422370	chr2:73384389	NA	0.42	5.5	0.33	9.44e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	6.22	0.37	2.18e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.41	-0.38	7.48e-10	Glomerular filtration rate;
KIRP	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.91	13.28	0.65	1.08e-30	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg06012730	chr15:75315579	PPCDC	-0.42	-5.22	-0.32	3.88e-7	Blood trace element (Zn levels);
KIRP	cis	rs4356932	0.967	rs10016135	chr4:76974579	T/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.31	-0.37	1.28e-9	Neuroticism;
KIRP	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.71	-0.39	1.33e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02463440	chr8:22132932	PIWIL2	0.45	5.81	0.35	1.93e-8	Hypertriglyceridemia;
KIRP	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.98	-15.99	-0.71	5.95e-40	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05949205	chr7:127225752	GCC1	0.53	6.4	0.38	7.86e-10	Parkinson's disease;
KIRP	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.38	4.92	0.3	1.61e-6	Mean platelet volume;
KIRP	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg14289246	chr4:154710475	SFRP2	-0.52	-6.83	-0.4	6.5e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6009824	0.579	rs34296882	chr22:50098333	C/T	cg27029450	chr22:50098074	NA	0.7	6.74	0.4	1.09e-10	Natriuretic peptide levels;
KIRP	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	0.91	11.68	0.6	2.23e-25	Vitiligo;
KIRP	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg21775007	chr8:11205619	TDH	0.47	6.14	0.36	3.25e-9	Joint mobility (Beighton score);
KIRP	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	7.08	0.41	1.55e-11	Retinal vascular caliber;
KIRP	cis	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.88	-0.3	1.92e-6	Cervical cancer;
KIRP	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.52	5.42	0.33	1.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.15	-0.77	1.18e-50	Height;
KIRP	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.47	-5.77	-0.35	2.37e-8	Obesity-related traits;
KIRP	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.59	7.88	0.45	1.03e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	-0.34	-5.13	-0.31	5.91e-7	Electroencephalogram traits;
KIRP	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	trans	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg09699651	chr6:150184138	LRP11	0.45	5.86	0.35	1.44e-8	Lung cancer;
KIRP	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.64	7.48	0.43	1.33e-12	Alcohol dependence;
KIRP	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-7.14	-0.41	1.06e-11	Morning vs. evening chronotype;
KIRP	cis	rs12431939	0.571	rs12589840	chr14:51720038	A/G	cg23942311	chr14:51606299	NA	0.46	5.16	0.31	5.07e-7	Cancer;
KIRP	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg20243544	chr17:37824526	PNMT	0.46	6.01	0.36	6.61e-9	Asthma;
KIRP	cis	rs80130819	0.515	rs1476608	chr12:48493731	C/T	cg26205652	chr12:48591994	NA	0.49	5.87	0.35	1.38e-8	Prostate cancer;
KIRP	cis	rs918629	0.798	rs6556894	chr5:95289542	G/A	cg16656078	chr5:95278638	ELL2	-0.47	-6.78	-0.4	8.68e-11	IgG glycosylation;
KIRP	cis	rs12643440	0.538	rs56235875	chr4:17138883	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.87	-9.78	-0.53	2.71e-19	Gut microbiome composition (summer);
KIRP	trans	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg12575136	chr18:32820987	ZNF397	0.74	10.9	0.57	7.87e-23	White blood cell count;
KIRP	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.74	6.08	0.36	4.55e-9	Diabetic retinopathy;
KIRP	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg18350739	chr11:68623251	NA	-0.48	-7.47	-0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg16141378	chr3:129829833	LOC729375	0.51	6.24	0.37	1.92e-9	Neuroticism;
KIRP	trans	rs2048656	0.508	rs7387886	chr8:9676575	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.9	-0.4	4.47e-11	Schizophrenia;
KIRP	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg17764715	chr19:33622953	WDR88	-0.61	-7.07	-0.41	1.6e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs8077577	0.895	rs11655588	chr17:18107451	C/T	cg18869244	chr17:18121946	NA	-0.48	-5.51	-0.33	9.16e-8	Obesity-related traits;
KIRP	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.41	5.3	0.32	2.58e-7	Dilated cardiomyopathy;
KIRP	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.53	9.17	0.5	1.95e-17	Vitiligo;
KIRP	cis	rs7623687	0.786	rs73082337	chr3:49009570	C/G	cg07274523	chr3:49395745	GPX1	0.7	4.93	0.3	1.49e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg23601095	chr6:26197514	HIST1H3D	-0.85	-6.05	-0.36	5.32e-9	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	ch.11.340609R	chr11:12831013	TEAD1	0.37	4.88	0.3	1.9e-6	Educational attainment (years of education);
KIRP	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.62	8.35	0.47	4.93e-15	Longevity;Endometriosis;
KIRP	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.95	-13.46	-0.65	2.51e-31	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs9896052	0.535	rs35615150	chr17:73433560	G/A	cg25649188	chr17:73499917	CASKIN2	0.45	5.91	0.35	1.13e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg21546286	chr11:48923668	NA	-0.48	-6.03	-0.36	5.96e-9	HDL cholesterol;
KIRP	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg05717871	chr11:638507	DRD4	-0.39	-5.68	-0.34	3.77e-8	Systemic lupus erythematosus;
KIRP	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg06917634	chr15:78832804	PSMA4	-0.64	-7.74	-0.44	2.59e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs60871478	0.898	rs67785403	chr7:787201	A/G	cg13798912	chr7:905769	UNC84A	0.67	6.4	0.38	7.87e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	11.08	0.58	2.09e-23	Response to antipsychotic treatment;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18946373	chr6:155582926	TFB1M	0.5	6.13	0.36	3.38e-9	Interleukin-4 levels;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.77	11.55	0.59	6.11e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2380205	0.682	rs3750657	chr10:5926079	A/C	cg27141509	chr10:5886111	NA	-0.34	-4.96	-0.3	1.31e-6	Breast cancer;
KIRP	cis	rs911555	0.547	rs8006994	chr14:103841296	C/T	cg26207909	chr14:103986467	CKB	0.4	5.06	0.31	8.15e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.48	-6.47	-0.38	5.28e-10	Multiple sclerosis;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.88	15.05	0.69	1e-36	Nonalcoholic fatty liver disease;
KIRP	trans	rs526821	0.595	rs504661	chr11:55312683	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-6.3	-0.37	1.39e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.4	6.4	0.38	7.77e-10	QRS complex (12-leadsum);
KIRP	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.71	-0.44	3.19e-13	Response to antipsychotic treatment;
KIRP	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg08847533	chr14:75593920	NEK9	0.4	4.86	0.3	2.11e-6	Caffeine consumption;
KIRP	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	1.16	14.94	0.69	2.34e-36	Response to hepatitis C treatment;
KIRP	cis	rs9400467	0.506	rs12207774	chr6:111657576	T/C	cg15721981	chr6:111408429	SLC16A10	0.67	6.03	0.36	5.84e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs630539	0.655	rs35855335	chr17:40842441	T/C	cg10533978	chr17:40842804	CNTNAP1	-0.65	-5.14	-0.31	5.55e-7	Systolic blood pressure change trajectories;
KIRP	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.44	-5.69	-0.34	3.53e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.85	9.82	0.53	2.07e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs8179	0.593	rs6948097	chr7:92281953	C/T	cg15732164	chr7:92237376	CDK6	-0.47	-5.99	-0.36	7.31e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg17376030	chr22:41985996	PMM1	0.62	6.84	0.4	6.27e-11	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19695565	chr14:104095556	KLC1	0.58	7.57	0.43	7.57e-13	Parkinson's disease;
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.62	0.68	3.03e-35	Alzheimer's disease;
KIRP	cis	rs9900972	0.877	rs8064344	chr17:76876974	C/T	cg20937029	chr17:76870563	TIMP2	0.46	5.31	0.32	2.41e-7	Obesity-related traits;
KIRP	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg24642439	chr20:33292090	TP53INP2	0.48	5.59	0.34	6.11e-8	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02413312	chr8:71291551	NCOA2	0.39	6.06	0.36	5.13e-9	Interleukin-4 levels;
KIRP	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.07	-0.36	4.85e-9	Ulcerative colitis;
KIRP	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.81	-13.06	-0.64	5.7e-30	Heart rate;
KIRP	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-4.97	-0.3	1.27e-6	Lung cancer;
KIRP	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.6	-4.97	-0.3	1.23e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.08	-0.31	7.47e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-5.39	-0.33	1.64e-7	Lung cancer;
KIRP	cis	rs4930561	0.765	rs4930229	chr11:67944080	G/A	cg16338278	chr11:67432957	ALDH3B2	0.4	5.1	0.31	6.88e-7	Breast cancer in childhood cancer survivors;IgG glycosylation;
KIRP	cis	rs9912468	0.647	rs12603947	chr17:64244505	T/C	cg19474267	chr17:64306194	PRKCA	-0.49	-6.16	-0.37	2.92e-9	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs6882046	0.513	rs34320	chr5:88021527	T/G	cg22951263	chr5:87985283	NA	-0.47	-6.45	-0.38	5.97e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs74181299	0.684	rs60136636	chr2:65338422	G/A	cg05010058	chr2:65284262	CEP68	-0.45	-5.99	-0.36	7.23e-9	Pulse pressure;
KIRP	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	ch.11.340609R	chr11:12831013	TEAD1	-0.4	-4.98	-0.3	1.2e-6	Educational attainment (years of education);
KIRP	cis	rs4965006	1.000	rs11246900	chr12:132506784	G/T	cg12371263	chr12:132522852	EP400	-0.5	-5.12	-0.31	6.13e-7	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg24253500	chr15:84953950	NA	0.59	6.87	0.4	5.21e-11	Schizophrenia;
KIRP	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.66	8.6	0.48	9.18e-16	Alzheimer's disease;
KIRP	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-7.2	-0.42	7.49e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.9	14.25	0.67	5.27e-34	Mean corpuscular volume;
KIRP	cis	rs11673344	0.526	rs17305823	chr19:38135046	A/G	cg14683738	chr19:37701593	ZNF585B	0.44	5.28	0.32	2.9e-7	Obesity-related traits;
KIRP	cis	rs2273669	0.504	rs78123955	chr6:109434847	T/C	cg05315195	chr6:109294784	ARMC2	-0.54	-5.02	-0.3	1.02e-6	Prostate cancer;
KIRP	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.58	7.24	0.42	5.71e-12	Age-related hearing impairment;
KIRP	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.23	0.46	1.13e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.7	8.71	0.49	4.66e-16	Neutrophil percentage of white cells;
KIRP	cis	rs3799378	0.579	rs9348715	chr6:26375642	C/G	cg14345882	chr6:26364793	BTN3A2	0.31	4.89	0.3	1.84e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12379764	chr21:47803548	PCNT	-0.46	-5.49	-0.33	1.01e-7	Testicular germ cell tumor;
KIRP	cis	rs2742417	0.967	rs2742419	chr3:45731929	G/A	cg04037228	chr3:45636386	LIMD1	0.37	5.44	0.33	1.27e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg07001201	chr5:642380	CEP72	0.68	6.31	0.37	1.32e-9	Obesity-related traits;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg04276977	chr22:32340769	C22orf24;YWHAH	-0.48	-6.58	-0.39	2.78e-10	Metabolic traits;
KIRP	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.78	9.55	0.52	1.42e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	6.62	0.39	2.28e-10	Height;
KIRP	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg10977910	chr1:84465055	TTLL7	0.45	5.35	0.32	2.02e-7	Obesity-related traits;
KIRP	cis	rs10131728	0.892	rs12892839	chr14:81716077	A/G	cg01989461	chr14:81687754	GTF2A1	-0.75	-5.96	-0.36	8.8e-9	IgG glycosylation;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg05565863	chr6:83478050	NA	-0.5	-6.6	-0.39	2.49e-10	Select biomarker traits;
KIRP	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg16141378	chr3:129829833	LOC729375	0.56	7.31	0.42	3.77e-12	Triglycerides;
KIRP	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.61	7.48	0.43	1.35e-12	Coronary heart disease;
KIRP	cis	rs4805272	0.962	rs7255736	chr19:29321419	G/A	cg15000279	chr19:29285009	NA	-0.36	-5.22	-0.32	3.73e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6725041	0.627	rs1521646	chr2:213044255	G/C	cg20637307	chr2:213403960	ERBB4	-0.4	-5.27	-0.32	2.99e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.72	7.8	0.45	1.77e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs9810890	1.000	rs79070677	chr3:128579876	G/T	cg15033153	chr3:128514015	RAB7A	0.69	5.03	0.31	9.52e-7	Dental caries;
KIRP	cis	rs981844	1.000	rs72731674	chr4:154667447	C/A	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg23594656	chr7:65796392	TPST1	0.4	5.65	0.34	4.37e-8	Aortic root size;
KIRP	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14298792	chr15:30685198	CHRFAM7A	0.49	5.8	0.35	2e-8	Huntington's disease progression;
KIRP	cis	rs4671400	0.516	rs62152277	chr2:61503404	C/T	cg15711740	chr2:61764176	XPO1	0.62	6.77	0.4	9.61e-11	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.59	-0.65	9.05e-32	Height;
KIRP	cis	rs9400271	0.504	rs9784763	chr6:109624937	A/G	cg21918786	chr6:109611834	NA	0.36	5.35	0.32	1.99e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.76	-0.44	2.32e-13	Life satisfaction;
KIRP	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	5.4	0.33	1.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg01631408	chr1:248437212	OR2T33	-0.44	-5.82	-0.35	1.82e-8	Common traits (Other);
KIRP	trans	rs7306455	0.558	rs66498225	chr12:95330172	C/T	cg02647998	chr3:12201096	TIMP4;SYN2	-0.89	-6.4	-0.38	7.81e-10	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.41	-5.58	-0.34	6.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg12486944	chr17:80159399	CCDC57	-0.39	-5.25	-0.32	3.28e-7	Life satisfaction;
KIRP	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs34779708	0.931	rs11592404	chr10:35273476	G/A	cg04310649	chr10:35416472	CREM	-0.56	-6.26	-0.37	1.68e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.7	8.28	0.47	7.92e-15	Corneal astigmatism;
KIRP	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.76	10.38	0.55	3.58e-21	Response to bleomycin (chromatid breaks);
KIRP	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.81	-8.54	-0.48	1.46e-15	Hair shape;
KIRP	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg05717871	chr11:638507	DRD4	-0.38	-5.22	-0.32	3.87e-7	Systemic lupus erythematosus;
KIRP	cis	rs6967385	0.560	rs2192833	chr7:12355303	A/T	cg20607287	chr7:12443886	VWDE	0.37	5.01	0.3	1.04e-6	Response to taxane treatment (placlitaxel);
KIRP	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.48e-10	Coronary artery disease;
KIRP	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg03576123	chr11:487126	PTDSS2	0.86	7.53	0.43	9.82e-13	Body mass index;
KIRP	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-4.99	-0.3	1.13e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	6.85	0.4	5.9e-11	Mean platelet volume;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.96	16.75	0.73	1.49e-42	Menarche (age at onset);
KIRP	cis	rs9815354	0.812	rs10510732	chr3:42007339	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.39	0.47	3.87e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg03929089	chr4:120376271	NA	-0.54	-6.04	-0.36	5.7e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.5	-0.38	4.51e-10	Monocyte percentage of white cells;
KIRP	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg20578329	chr17:80767326	TBCD	-0.47	-5.61	-0.34	5.55e-8	Glycated hemoglobin levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09238106	chr11:64242796	NA	-0.44	-6.02	-0.36	6.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg00656387	chr3:40428638	ENTPD3	0.38	4.85	0.3	2.14e-6	Renal cell carcinoma;
KIRP	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.99	9.51	0.52	1.86e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.85	-0.4	6.03e-11	Systolic blood pressure;
KIRP	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg18944383	chr4:111397179	ENPEP	0.53	9.44	0.52	2.9e-18	Height;
KIRP	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs2970992	0.728	rs1040040	chr2:101321225	A/T	cg01042948	chr2:101319752	NA	0.42	6.62	0.39	2.22e-10	Educational attainment;
KIRP	cis	rs7635838	0.892	rs9874535	chr3:11463730	A/G	cg00170343	chr3:11313890	ATG7	0.47	6.04	0.36	5.58e-9	HDL cholesterol;
KIRP	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26314531	chr2:26401878	FAM59B	-0.48	-5.2	-0.31	4.17e-7	Gut microbiome composition (summer);
KIRP	cis	rs9914988	0.667	rs11652544	chr17:27252989	C/T	cg20469991	chr17:27169893	C17orf63	-0.63	-5.25	-0.32	3.26e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.33	0.37	1.18e-9	Retinal vascular caliber;
KIRP	cis	rs4654899	0.865	rs61779073	chr1:21398740	C/A	cg05370193	chr1:21551575	ECE1	0.47	6.22	0.37	2.07e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs13424612	0.965	rs2289407	chr2:240954110	A/G	cg01812947	chr2:240904978	NDUFA10	0.46	5.82	0.35	1.85e-8	Odorant perception (isobutyraldehyde);
KIRP	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.89	-14.2	-0.67	7.63e-34	Prostate cancer;
KIRP	cis	rs17321999	0.516	rs72787741	chr2:30503987	C/G	cg05247661	chr2:30472410	LBH	0.65	5.37	0.32	1.86e-7	Systemic lupus erythematosus;
KIRP	cis	rs2274459	1.000	rs34139049	chr6:33716784	G/A	cg06253072	chr6:33679850	C6orf125	0.51	5.05	0.31	8.48e-7	Obesity (extreme);
KIRP	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg22987457	chr7:157211561	NA	0.42	5.24	0.32	3.43e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01256987	chr12:42539512	GXYLT1	-0.43	-5.65	-0.34	4.32e-8	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.82	11.36	0.59	2.48e-24	Alzheimer's disease (survival time);
KIRP	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07685180	chr8:600429	NA	0.7	4.91	0.3	1.66e-6	IgG glycosylation;
KIRP	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg15691649	chr6:25882328	NA	-0.43	-5.18	-0.31	4.69e-7	Blood metabolite levels;
KIRP	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	8.69	0.48	5.27e-16	Initial pursuit acceleration;
KIRP	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.45	-6.35	-0.38	1.04e-9	Blood metabolite levels;
KIRP	cis	rs427941	0.632	rs201490	chr7:101751910	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.66	0.39	1.79e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs12210905	1.000	rs12205628	chr6:27225959	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.8	-0.4	8.05e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs7011049	0.778	rs72648436	chr8:53881267	G/C	cg26025543	chr8:53854495	NA	0.65	6.88	0.4	4.95e-11	Systolic blood pressure;
KIRP	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg06223162	chr1:101003688	GPR88	0.48	10.1	0.54	2.73e-20	Monocyte count;
KIRP	cis	rs4936894	0.500	rs10893164	chr11:124076981	C/T	cg27160556	chr11:124181099	OR8D1	0.4	5.91	0.35	1.16e-8	Aging (time to death);
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg00738919	chr7:1100172	C7orf50	0.43	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg03060546	chr3:49711283	APEH	0.53	7.25	0.42	5.32e-12	Menarche (age at onset);
KIRP	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg25182066	chr10:30743637	MAP3K8	0.64	8.83	0.49	2.03e-16	Inflammatory bowel disease;
KIRP	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.57	-8.49	-0.48	2.04e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg01765077	chr12:122356316	WDR66	0.63	8.48	0.48	2.16e-15	Mean corpuscular volume;
KIRP	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg00405596	chr8:11794950	NA	-0.42	-5.15	-0.31	5.24e-7	Retinal vascular caliber;
KIRP	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	9.26	0.51	1.05e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg10242476	chr3:46619364	LRRC2;TDGF1	-0.42	-5.09	-0.31	7.09e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg02073558	chr3:44770973	ZNF501	0.56	8.04	0.46	3.73e-14	Depressive symptoms;
KIRP	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg11972305	chr2:233791962	NGEF	0.37	5.1	0.31	6.67e-7	Schizophrenia;
KIRP	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.48	5.75	0.34	2.58e-8	Diastolic blood pressure;
KIRP	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.45	5.61	0.34	5.36e-8	Asthma;
KIRP	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.45	6.18	0.37	2.62e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg12140854	chr5:148520817	ABLIM3	0.46	5.21	0.32	4.07e-7	Breast cancer;
KIRP	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.5	7.82	0.45	1.56e-13	Testicular germ cell tumor;
KIRP	cis	rs918629	0.530	rs11741563	chr5:95240996	C/T	cg16656078	chr5:95278638	ELL2	-0.38	-5.82	-0.35	1.82e-8	IgG glycosylation;
KIRP	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg05347473	chr6:146136440	FBXO30	-0.63	-9.12	-0.5	2.68e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5753618	0.509	rs5997913	chr22:31593959	C/A	cg22777020	chr22:31556080	RNF185	-0.5	-5.25	-0.32	3.32e-7	Colorectal cancer;
KIRP	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg05082376	chr22:42548792	NA	0.46	5.8	0.35	2.01e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.59	-0.48	1.04e-15	Response to antipsychotic treatment;
KIRP	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg22903471	chr2:27725779	GCKR	-0.36	-4.88	-0.3	1.88e-6	Oral cavity cancer;
KIRP	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	16.15	0.72	1.79e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9937943	0.667	rs11862508	chr16:74598688	T/C	cg01733217	chr16:74700730	RFWD3	0.57	5.59	0.34	5.9e-8	Neutrophil percentage of white cells;
KIRP	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg16989719	chr2:238392110	NA	-0.59	-6.06	-0.36	5.08e-9	Prostate cancer;
KIRP	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.87	-10.19	-0.54	1.44e-20	White matter hyperintensity burden;
KIRP	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg02175503	chr12:58329896	NA	0.55	6.02	0.36	6.16e-9	Multiple sclerosis;
KIRP	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg01475377	chr6:109611718	NA	-0.4	-5.42	-0.33	1.42e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg17554472	chr22:41940697	POLR3H	0.68	7.06	0.41	1.73e-11	Vitiligo;
KIRP	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg05220968	chr6:146057943	EPM2A	-0.39	-5.14	-0.31	5.61e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4356932	1.000	rs10003240	chr4:76955330	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.72	0.49	4.16e-16	Motion sickness;
KIRP	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.92	0.66	7.01e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.35e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.55	-6.71	-0.39	1.36e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.49	6.87	0.4	5.37e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4716602	0.596	rs10265482	chr7:156160655	C/G	cg16983916	chr7:156159713	NA	-0.44	-5.57	-0.33	6.57e-8	Anti-saccade response;
KIRP	cis	rs5753618	0.509	rs2079431	chr22:31564334	C/T	cg02404636	chr22:31891804	SFI1	-0.47	-5.2	-0.31	4.17e-7	Colorectal cancer;
KIRP	cis	rs10463316	0.817	rs3846713	chr5:150799739	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.43	-0.38	6.7e-10	Metabolite levels (Pyroglutamine);
KIRP	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.56	-16.05	-0.72	3.89e-40	Hip circumference adjusted for BMI;
KIRP	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg08283408	chr3:49949060	MON1A	-0.41	-5.53	-0.33	7.96e-8	Body mass index;
KIRP	cis	rs11718455	0.548	rs11918413	chr3:43902518	C/A	cg21419209	chr3:44054225	NA	0.45	5.75	0.34	2.62e-8	Coronary artery disease;
KIRP	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22980127	chr19:33182716	NUDT19	1.14	10.27	0.55	8.01e-21	Red blood cell traits;
KIRP	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.87	-0.45	1.1e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-0.99	-15.67	-0.71	7.51e-39	Dilated cardiomyopathy;
KIRP	cis	rs3743266	0.507	rs11637887	chr15:60765216	C/T	cg22293140	chr15:60689852	ANXA2	-0.66	-6.0	-0.36	6.96e-9	Menarche (age at onset);
KIRP	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07685180	chr8:600429	NA	0.68	5.51	0.33	8.83e-8	IgG glycosylation;
KIRP	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.93	0.53	9.52e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15557168	chr22:42548783	NA	-0.42	-5.51	-0.33	9.07e-8	Cognitive function;
KIRP	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.66	-8.72	-0.49	4.26e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-7.57	-0.43	7.59e-13	Vitiligo;
KIRP	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg19171272	chr22:38449367	NA	-0.65	-9.76	-0.53	3.02e-19	Glioblastoma;Glioma;
KIRP	cis	rs7072216	0.922	rs6584191	chr10:100152055	C/G	cg26618903	chr10:100175079	PYROXD2	-0.34	-5.07	-0.31	7.7e-7	Metabolite levels;
KIRP	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.59	5.27	0.32	2.98e-7	Bipolar disorder;
KIRP	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.71	6.53	0.38	3.79e-10	Mean platelet volume;
KIRP	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.7	-9.62	-0.52	8.4e-19	Hemoglobin concentration;
KIRP	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.63	7.41	0.43	2.03e-12	Height;
KIRP	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg23587288	chr2:27483067	SLC30A3	-0.64	-8.35	-0.47	4.95e-15	Blood metabolite levels;
KIRP	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg05340658	chr4:99064831	C4orf37	0.66	7.35	0.42	2.87e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs1823913	0.599	rs17511445	chr2:192144557	A/G	cg12404831	chr2:192114017	MYO1B	-0.53	-7.39	-0.43	2.22e-12	Obesity-related traits;
KIRP	cis	rs4702718	0.674	rs5745264	chr5:10691118	G/A	cg14521931	chr5:10832172	NA	0.38	5.19	0.31	4.31e-7	Obesity-related traits;
KIRP	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.44	0.43	1.65e-12	Aortic root size;
KIRP	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.49	6.39	0.38	8.03e-10	High light scatter reticulocyte count;
KIRP	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.95	14.05	0.67	2.52e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg12315302	chr6:26189340	HIST1H4D	0.86	6.07	0.36	4.86e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.81	11.0	0.57	3.78e-23	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.59	7.9	0.45	9.03e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11874712	1.000	rs9945751	chr18:43673265	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.16e-8	Migraine - clinic-based;
KIRP	cis	rs911119	0.913	rs13037490	chr20:23583725	T/C	cg16589663	chr20:23618590	CST3	0.65	5.86	0.35	1.48e-8	Chronic kidney disease;
KIRP	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.93	0.35	1.01e-8	Colorectal cancer;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg06589507	chr5:179234594	SQSTM1;MGAT4B	0.52	6.04	0.36	5.64e-9	Lung cancer in ever smokers;
KIRP	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg09873164	chr1:152488093	CRCT1	0.57	7.68	0.44	3.7e-13	Hair morphology;
KIRP	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg26875233	chr11:93583750	C11orf90	-0.41	-7.76	-0.44	2.31e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.77	9.17	0.5	1.95e-17	Adiposity;
KIRP	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.53	-7.38	-0.43	2.46e-12	Prostate cancer;
KIRP	cis	rs472402	0.560	rs2288447	chr5:6626091	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-5.02	-0.3	1.01e-6	Response to amphetamines;
KIRP	cis	rs1816752	0.783	rs7139527	chr13:24985512	G/A	cg22771759	chr13:24902376	NA	0.39	5.06	0.31	8.37e-7	Obesity-related traits;
KIRP	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-5.74	-0.34	2.74e-8	Blood metabolite levels;
KIRP	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.85	14.23	0.67	6.13e-34	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18800042	chr5:141238690	PCDH1	0.46	6.29	0.37	1.42e-9	Survival in pancreatic cancer;
KIRP	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg00666640	chr1:248458726	OR2T12	0.46	6.1	0.36	4.08e-9	Common traits (Other);
KIRP	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.54	7.22	0.42	6.58e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg22533281	chr1:70509936	LRRC7	0.41	6.17	0.37	2.72e-9	Migraine with aura;
KIRP	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg02725872	chr8:58115012	NA	-0.53	-5.99	-0.36	7.34e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7258465	1.000	rs271624	chr19:18627953	A/G	cg10790698	chr19:18539756	SSBP4	-0.33	-6.8	-0.4	8.07e-11	Breast cancer;
KIRP	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg19636519	chr7:99541626	NA	0.29	5.19	0.31	4.34e-7	Coronary artery disease;
KIRP	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg07395648	chr5:131743802	NA	-0.59	-8.32	-0.47	5.91e-15	Breast cancer;Mosquito bite size;
KIRP	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.35e-7	Oral cavity cancer;
KIRP	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.65	5.98	0.36	7.87e-9	Lung function (FEV1/FVC);
KIRP	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg08975724	chr8:8085496	FLJ10661	0.54	7.14	0.41	1.06e-11	Retinal vascular caliber;
KIRP	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg05627522	chr15:75251581	NA	0.33	5.02	0.31	9.72e-7	Breast cancer;
KIRP	cis	rs7428	0.924	rs908304	chr2:85573049	G/A	cg24342717	chr2:85555507	TGOLN2	-0.5	-5.8	-0.35	2.02e-8	Ear protrusion;
KIRP	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.94	0.35	9.8e-9	Tonsillectomy;
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg19923238	chr8:142232952	SLC45A4	-0.41	-4.86	-0.3	2.06e-6	Immature fraction of reticulocytes;
KIRP	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg10434728	chr15:90938212	IQGAP1	-0.4	-7.54	-0.43	9.19e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs1570884	0.714	rs2038881	chr13:50135177	A/G	cg08779649	chr13:50194554	NA	0.47	6.62	0.39	2.22e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.8	-8.86	-0.49	1.66e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4843185	0.699	rs2029	chr16:85708846	C/A	cg09480190	chr16:85671771	KIAA0182	-0.47	-5.3	-0.32	2.51e-7	Platelet distribution width;
KIRP	cis	rs975210	1.000	rs975210	chr15:70364352	G/A	cg01666796	chr15:70364327	TLE3	-0.55	-5.69	-0.34	3.58e-8	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg07511934	chr16:89386912	ANKRD11	0.4	5.2	0.31	4.12e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg26965718	chr17:79658957	HGS	-0.6	-5.74	-0.34	2.78e-8	Dental caries;
KIRP	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.8	9.83	0.53	1.88e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-13.25	-0.65	1.37e-30	Alzheimer's disease;
KIRP	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.67	-7.76	-0.44	2.3e-13	Primary sclerosing cholangitis;
KIRP	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg14703610	chr5:56206110	C5orf35	-0.5	-6.99	-0.41	2.5e-11	Coronary artery disease;
KIRP	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.69	-9.44	-0.52	3.05e-18	Crohn's disease;
KIRP	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.1	0.36	4.01e-9	Menopause (age at onset);
KIRP	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg18132916	chr6:79620363	NA	-0.41	-5.62	-0.34	5.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg00784671	chr22:46762841	CELSR1	-0.6	-7.6	-0.44	6.14e-13	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18192808	chr1:15853278	DNAJC16	0.46	6.15	0.37	3.13e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19650632	chr5:133303603	C5orf15	-0.45	-6.31	-0.37	1.26e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.78	-11.57	-0.59	5.44e-25	Height;
KIRP	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.93e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg06307176	chr5:131281290	NA	0.54	5.81	0.35	1.95e-8	Life satisfaction;
KIRP	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.84	-13.56	-0.65	1.18e-31	Blood metabolite levels;
KIRP	cis	rs5753618	0.539	rs2106294	chr22:31645759	C/T	cg02404636	chr22:31891804	SFI1	-0.47	-5.22	-0.32	3.85e-7	Colorectal cancer;
KIRP	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.85	12.32	0.62	1.74e-27	Eye color traits;
KIRP	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg22907277	chr7:1156413	C7orf50	0.79	7.42	0.43	1.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.59	-7.73	-0.44	2.75e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs61823972	0.510	rs11240351	chr1:205044339	C/T	cg21643547	chr1:205240462	TMCC2	-0.43	-6.19	-0.37	2.53e-9	Immature fraction of reticulocytes;Mean corpuscular volume;Mean corpuscular hemoglobin;Mean corpuscular hemoglobin concentration;High light scatter reticulocyte count;
KIRP	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.18	-0.46	1.57e-14	Monocyte percentage of white cells;
KIRP	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.56	7.4	0.43	2.18e-12	Menarche (age at onset);
KIRP	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.48	-5.79	-0.35	2.12e-8	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg07395648	chr5:131743802	NA	-0.35	-5.02	-0.3	9.93e-7	Blood metabolite levels;
KIRP	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg23594656	chr7:65796392	TPST1	0.47	7.41	0.43	2.02e-12	Aortic root size;
KIRP	cis	rs745821	0.701	rs753327	chr18:48108003	T/C	cg18923635	chr18:48083994	NA	-0.43	-5.06	-0.31	8.14e-7	Diastolic blood pressure;
KIRP	cis	rs75920871	0.528	rs2513094	chr11:116806412	T/C	cg04087571	chr11:116723030	SIK3	-0.25	-5.13	-0.31	5.88e-7	Subjective well-being;
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.63	-0.39	2.11e-10	Lymphocyte counts;
KIRP	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.57	-5.86	-0.35	1.51e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9372498	0.505	rs62424202	chr6:118851027	T/C	cg18833306	chr6:118973337	C6orf204	-0.48	-4.96	-0.3	1.32e-6	Diastolic blood pressure;
KIRP	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17376030	chr22:41985996	PMM1	-0.69	-7.61	-0.44	5.93e-13	Vitiligo;
KIRP	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.54	-6.8	-0.4	8.1e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	12.97	0.64	1.18e-29	Smoking behavior;
KIRP	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-10.32	-0.55	5.75e-21	Coronary artery disease;
KIRP	cis	rs6575793	1.000	rs7141087	chr14:101036052	T/C	cg18516195	chr14:101012996	BEGAIN	0.48	6.82	0.4	7.12e-11	Menarche (age at onset);
KIRP	cis	rs4919687	0.514	rs12241712	chr10:104408272	C/A	cg04362960	chr10:104952993	NT5C2	0.52	5.89	0.35	1.28e-8	Colorectal cancer;
KIRP	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-8.84	-0.49	1.82e-16	Eye color traits;
KIRP	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-7.02	-0.41	2.11e-11	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs6467136	0.818	rs4551267	chr7:127175236	C/T	cg23081781	chr7:127225937	GCC1	-0.38	-5.21	-0.32	3.96e-7	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg06050784	chr16:88016603	BANP	0.39	4.91	0.3	1.67e-6	Menopause (age at onset);
KIRP	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg24324837	chr19:49891574	CCDC155	0.63	8.64	0.48	7.31e-16	Multiple sclerosis;
KIRP	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg03627880	chr6:151815985	C6orf97	-0.4	-4.88	-0.3	1.9e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg06636001	chr8:8085503	FLJ10661	-0.74	-10.22	-0.55	1.15e-20	Neuroticism;
KIRP	trans	rs783540	1.000	rs698500	chr15:83237769	T/C	cg16105309	chr15:79090380	ADAMTS7	0.44	6.09	0.36	4.21e-9	Schizophrenia;
KIRP	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg13072238	chr3:49761600	GMPPB	0.56	5.05	0.31	8.61e-7	Menarche (age at onset);
KIRP	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-7.54	-0.43	9.18e-13	Glomerular filtration rate (creatinine);
KIRP	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.41	0.43	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg05802129	chr4:122689817	NA	-0.48	-6.92	-0.4	3.99e-11	Type 2 diabetes;
KIRP	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.6	6.27	0.37	1.64e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27660165	chr1:156784036	SH2D2A	0.48	6.93	0.4	3.65e-11	Smoking initiation;
KIRP	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg13607699	chr17:42295918	UBTF	-0.49	-6.12	-0.36	3.75e-9	Total body bone mineral density;
KIRP	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg01620082	chr3:125678407	NA	-0.88	-6.37	-0.38	9.11e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	15.91	0.71	1.12e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.6	-0.39	2.49e-10	Neuroticism;
KIRP	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg07541023	chr7:19748670	TWISTNB	0.56	5.45	0.33	1.2e-7	Thyroid stimulating hormone;
KIRP	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg09699651	chr6:150184138	LRP11	0.45	5.96	0.36	8.82e-9	Lung cancer;
KIRP	cis	rs239198	0.555	rs9386258	chr6:101286336	C/G	cg09795085	chr6:101329169	ASCC3	0.47	5.4	0.33	1.54e-7	Menarche (age at onset);
KIRP	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-1.07	-23.13	-0.83	1.18e-63	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg09455208	chr3:40491958	NA	0.38	6.86	0.4	5.39e-11	Renal cell carcinoma;
KIRP	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg26207909	chr14:103986467	CKB	-0.38	-4.98	-0.3	1.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7188697	0.922	rs37060	chr16:58566304	C/T	cg21335942	chr16:58549945	SETD6	0.45	5.01	0.3	1.05e-6	QT interval;
KIRP	trans	rs972578	0.715	rs5758969	chr22:43228969	A/C	cg15321293	chr3:36422198	STAC	-0.46	-6.02	-0.36	6.37e-9	Mean platelet volume;
KIRP	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05220968	chr6:146057943	EPM2A	-0.39	-5.14	-0.31	5.61e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9517320	1.000	rs9584857	chr13:99128572	T/C	cg07423050	chr13:99094983	FARP1	0.3	5.03	0.31	9.27e-7	Longevity;
KIRP	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs11779988	0.545	rs415840	chr8:17782134	C/T	cg01800426	chr8:17659068	MTUS1	-0.63	-6.23	-0.37	2.02e-9	Breast cancer;
KIRP	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08822215	chr16:89438651	ANKRD11	-0.37	-4.92	-0.3	1.55e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg00343986	chr7:65444356	GUSB	0.42	5.16	0.31	5.18e-7	Aortic root size;
KIRP	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	cg21523751	chr1:182988639	NA	0.45	7.1	0.41	1.36e-11	Colorectal cancer;
KIRP	trans	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg16789707	chr16:88767723	RNF166	0.34	6.1	0.36	3.99e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg03929089	chr4:120376271	NA	0.68	6.57	0.39	3.05e-10	Axial length;
KIRP	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.69	10.48	0.56	1.75e-21	Menarche (age at onset);
KIRP	cis	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg25276700	chr6:44698697	NA	0.35	4.98	0.3	1.21e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.39	4.84	0.3	2.27e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.92	11.81	0.6	8.74e-26	Menopause (age at onset);
KIRP	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-9.64	-0.52	7.38e-19	Morning vs. evening chronotype;
KIRP	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.83	-12.01	-0.61	1.87e-26	Total body bone mineral density;
KIRP	cis	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg12369402	chr1:90227771	NA	-0.34	-5.0	-0.3	1.07e-6	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6959887	0.926	rs11976145	chr7:35281684	G/C	cg06685737	chr7:35301730	NA	0.43	6.38	0.38	8.67e-10	Birth weight;
KIRP	cis	rs6681460	1.000	rs6680944	chr1:67122565	A/T	cg13052034	chr1:66999238	SGIP1	0.44	6.2	0.37	2.4e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg07274523	chr3:49395745	GPX1	0.71	8.75	0.49	3.41e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02711726	chr17:80685570	FN3KRP	-0.54	-7.17	-0.42	8.77e-12	Glycated hemoglobin levels;
KIRP	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg05347473	chr6:146136440	FBXO30	0.61	8.62	0.48	8.4e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05739825	chr11:125439882	EI24	0.6	6.63	0.39	2.1e-10	Lung cancer in ever smokers;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04722914	chr2:242255165	HDLBP;SEPT2	0.47	6.55	0.39	3.43e-10	Survival in pancreatic cancer;
KIRP	cis	rs6142102	0.924	rs6059662	chr20:32675727	C/T	cg08999081	chr20:33150536	PIGU	-0.55	-6.29	-0.37	1.46e-9	Skin pigmentation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23436918	chr7:16685595	BZW2;ANKMY2	0.54	6.19	0.37	2.51e-9	Smoking initiation;
KIRP	cis	rs1950626	0.750	rs35683125	chr14:101454750	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.63	6.84	0.4	6.12e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.46	6.36	0.38	9.89e-10	Blood protein levels;
KIRP	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.5	-0.38	4.51e-10	Monocyte percentage of white cells;
KIRP	cis	rs5746492	0.515	rs9604802	chr22:18398018	C/T	cg03078520	chr22:18463400	MICAL3	-0.39	-5.32	-0.32	2.37e-7	Eotaxin levels;
KIRP	cis	rs4728302	0.869	rs13221033	chr7:133617487	T/A	cg10665199	chr7:133106180	EXOC4	0.45	5.46	0.33	1.19e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.87	-11.69	-0.6	2.12e-25	Cognitive function;
KIRP	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.41	-6.01	-0.36	6.56e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.65	-5.54	-0.33	7.92e-8	Schizophrenia;
KIRP	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg18944383	chr4:111397179	ENPEP	0.39	6.15	0.37	3.14e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.23	-5.36	-0.32	1.96e-7	Primary biliary cholangitis;
KIRP	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.29	13.26	0.65	1.21e-30	Diabetic retinopathy;
KIRP	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.57	8.73	0.49	3.86e-16	Coronary artery disease;
KIRP	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg05315796	chr3:52349193	DNAH1	0.45	6.95	0.41	3.24e-11	Bipolar disorder;
KIRP	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.22	-0.37	2.14e-9	Body mass index;
KIRP	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg24315340	chr6:146058215	EPM2A	-0.41	-5.25	-0.32	3.28e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.95	-0.61	2.92e-26	Eye color traits;
KIRP	cis	rs7129556	0.737	rs484363	chr11:77492594	A/G	cg12586386	chr11:77299805	AQP11	0.43	5.13	0.31	5.83e-7	Weight loss (gastric bypass surgery);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg20203792	chr4:20701925	PACRGL	0.54	7.33	0.42	3.25e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.58	-7.14	-0.41	1.03e-11	Longevity;Endometriosis;
KIRP	cis	rs7538876	1.000	rs942457	chr1:17739586	G/A	cg07394400	chr1:17752023	RCC2	-0.36	-5.02	-0.31	9.78e-7	Basal cell carcinoma;
KIRP	trans	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg09264619	chr17:80180166	NA	-0.5	-6.03	-0.36	6.1e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs858239	0.539	rs4559148	chr7:23185967	G/A	cg23682824	chr7:23144976	KLHL7	0.49	5.63	0.34	5.03e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28669119	0.749	rs244750	chr5:88147192	T/C	cg18498987	chr5:88179539	MEF2C	0.53	6.53	0.38	3.69e-10	Schizophrenia;
KIRP	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.81	10.98	0.57	4.33e-23	Morning vs. evening chronotype;
KIRP	trans	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg19694781	chr19:47549865	TMEM160	-0.51	-6.23	-0.37	1.97e-9	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.91	-13.07	-0.64	5.47e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg25801113	chr15:45476975	SHF	0.44	8.1	0.46	2.49e-14	Uric acid levels;
KIRP	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.63	5.19	0.31	4.44e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg19442545	chr10:75533431	FUT11	-0.38	-4.89	-0.3	1.83e-6	Inflammatory bowel disease;
KIRP	cis	rs6457821	1.000	rs73411714	chr6:35292405	T/C	cg06087101	chr6:35551932	FKBP5	0.58	5.19	0.31	4.48e-7	Height;
KIRP	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.54e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs909341	0.716	rs71325464	chr20:62363453	A/G	cg11503966	chr20:62272292	STMN3	-0.42	-5.84	-0.35	1.66e-8	Atopic dermatitis;
KIRP	cis	rs42714	0.688	rs174021	chr7:28463758	C/T	cg19638435	chr7:28452093	CREB5	-0.78	-4.97	-0.3	1.24e-6	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
KIRP	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg19554555	chr3:13937349	NA	-0.45	-6.05	-0.36	5.39e-9	Ovarian reserve;
KIRP	cis	rs3026101	0.624	rs17635627	chr17:5296059	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.53	6.97	0.41	2.96e-11	Body mass index;
KIRP	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.77	9.91	0.53	1.07e-19	Schizophrenia;
KIRP	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.91	13.95	0.66	5.81e-33	Selective IgA deficiency;
KIRP	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.16	-10.75	-0.57	2.31e-22	Body mass index;
KIRP	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.06	-19.73	-0.78	1.4e-52	Height;
KIRP	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.82	-11.14	-0.58	1.29e-23	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21561470	chr13:114773108	RASA3	0.45	6.03	0.36	5.97e-9	Interleukin-4 levels;
KIRP	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg21699342	chr2:239360505	ASB1	0.46	5.43	0.33	1.32e-7	Multiple system atrophy;
KIRP	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.3	-0.42	3.87e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg10434728	chr15:90938212	IQGAP1	0.42	8.0	0.45	4.75e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.86	13.35	0.65	5.89e-31	Eye color traits;
KIRP	cis	rs7688540	0.656	rs79657896	chr4:299261	G/A	cg17891759	chr4:299121	NA	-0.5	-5.12	-0.31	6.28e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	1.04	13.98	0.67	4.44e-33	Red cell distribution width;
KIRP	cis	rs6909279	0.933	rs6931664	chr6:151857594	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.49	-6.22	-0.37	2.08e-9	Bone mineral density;
KIRP	cis	rs7638995	0.878	rs17005384	chr3:69181552	A/G	cg26574240	chr3:69171822	LMOD3	0.71	8.21	0.46	1.24e-14	Alzheimer's disease (late onset);
KIRP	cis	rs2150410	0.764	rs8131091	chr21:40635009	G/C	cg11890956	chr21:40555474	PSMG1	0.75	5.43	0.33	1.37e-7	Temperament (bipolar disorder);
KIRP	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.04	-0.58	2.88e-23	Height;
KIRP	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg16306078	chr6:126000798	NA	-0.26	-4.87	-0.3	1.97e-6	Endometrial cancer;
KIRP	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.37	5.0	0.3	1.1e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg14221460	chr8:27183342	PTK2B	0.51	6.68	0.39	1.59e-10	Neuroticism;
KIRP	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg26751094	chr13:95954534	ABCC4	-0.7	-9.67	-0.52	5.81e-19	Blood metabolite levels;
KIRP	cis	rs2562456	0.833	rs11666525	chr19:21599305	G/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.92e-6	Pain;
KIRP	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.71	10.39	0.55	3.36e-21	Glycated hemoglobin levels;
KIRP	cis	rs3733418	0.799	rs13110766	chr4:165956628	C/T	cg10852876	chr4:165953100	TRIM60	-0.46	-5.56	-0.33	7.03e-8	Obesity-related traits;
KIRP	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.18	-0.46	1.53e-14	Response to antipsychotic treatment;
KIRP	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.47	6.09	0.36	4.39e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg27432699	chr2:27873401	GPN1	-0.55	-7.05	-0.41	1.77e-11	Total body bone mineral density;
KIRP	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.94	12.55	0.62	2.96e-28	Vitamin D levels;
KIRP	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg07195126	chr1:160370843	VANGL2	0.48	6.21	0.37	2.24e-9	Breast size;
KIRP	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.89	0.3	1.84e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4262150	0.739	rs3890802	chr5:152081927	G/A	cg12297329	chr5:152029980	NA	-0.67	-8.14	-0.46	2.01e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg26378065	chr17:18585709	ZNF286B	0.4	5.07	0.31	7.66e-7	Educational attainment (years of education);
KIRP	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.97	14.01	0.67	3.45e-33	Cognitive function;
KIRP	cis	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg06521331	chr12:34319734	NA	-0.49	-5.95	-0.35	9.27e-9	Morning vs. evening chronotype;
KIRP	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg19847130	chr8:10466454	RP1L1	-0.36	-5.53	-0.33	8.26e-8	Neuroticism;
KIRP	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	7.35	0.42	2.97e-12	Mean corpuscular volume;
KIRP	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.52	6.27	0.37	1.57e-9	Aortic root size;
KIRP	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs6540559	1.000	rs12070337	chr1:209992127	G/A	cg25204440	chr1:209979598	IRF6	0.51	5.21	0.31	4.09e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs10803016	0.967	rs2574669	chr1:242281003	A/C	cg23840812	chr1:242252992	PLD5	0.39	5.16	0.31	5.08e-7	Coronary artery calcification;
KIRP	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg23533926	chr12:111358616	MYL2	-0.49	-6.44	-0.38	6.27e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.49	-0.38	4.75e-10	Joint mobility (Beighton score);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03965827	chr15:50979356	TRPM7	-0.49	-6.57	-0.39	2.92e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2120243	0.598	rs1500916	chr3:157088042	C/G	cg24825693	chr3:157122686	VEPH1	-0.55	-8.05	-0.46	3.55e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs10073892	1.000	rs10066445	chr5:101677329	T/C	cg19774478	chr5:101632501	SLCO4C1	0.66	6.8	0.4	7.96e-11	Cognitive decline (age-related);
KIRP	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg26681399	chr22:41777847	TEF	0.45	5.17	0.31	4.8e-7	Vitiligo;
KIRP	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg24699146	chr1:24152579	HMGCL	0.43	5.56	0.33	6.97e-8	Immature fraction of reticulocytes;
KIRP	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-5.25	-0.32	3.29e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg04154034	chr17:28927549	LRRC37B2	0.53	5.06	0.31	8.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	1.02	10.44	0.55	2.4e-21	Nonalcoholic fatty liver disease;
KIRP	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg06204229	chr3:52865917	ITIH4	0.56	7.82	0.45	1.51e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg10756647	chr7:56101905	PSPH	0.97	7.18	0.42	8.18e-12	Diabetic kidney disease;
KIRP	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.69	7.49	0.43	1.21e-12	Cholesterol, total;
KIRP	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg06307176	chr5:131281290	NA	0.57	6.4	0.38	7.67e-10	Life satisfaction;
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg12486944	chr17:80159399	CCDC57	-0.41	-5.5	-0.33	9.49e-8	Life satisfaction;
KIRP	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg08999081	chr20:33150536	PIGU	0.47	6.43	0.38	6.71e-10	Height;
KIRP	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.72	0.34	3.08e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg27398547	chr14:60952738	C14orf39	0.67	5.72	0.34	3.02e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.79	6.36	0.38	9.54e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.62	7.26	0.42	5.12e-12	Menopause (age at onset);
KIRP	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	cg04338863	chr8:33670619	NA	0.48	6.2	0.37	2.32e-9	Body mass index;
KIRP	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.67	-9.89	-0.53	1.27e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg00738919	chr7:1100172	C7orf50	0.43	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.56	-6.95	-0.41	3.18e-11	Iron status biomarkers;
KIRP	cis	rs367943	0.688	rs255877	chr5:112753584	A/G	cg12552261	chr5:112820674	MCC	0.56	6.53	0.38	3.72e-10	Type 2 diabetes;
KIRP	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg02503808	chr4:7069936	GRPEL1	0.9	12.1	0.61	9.59e-27	Monocyte percentage of white cells;
KIRP	cis	rs17102423	1.000	rs17102423	chr14:65604728	G/T	cg11161011	chr14:65562177	MAX	-0.47	-5.81	-0.35	1.89e-8	Obesity-related traits;
KIRP	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.73	-7.98	-0.45	5.56e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg01631408	chr1:248437212	OR2T33	-0.65	-8.24	-0.47	1.01e-14	Common traits (Other);
KIRP	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg16586182	chr3:47516702	SCAP	-0.76	-11.02	-0.57	3.2e-23	Colorectal cancer;
KIRP	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.67	-10.26	-0.55	8.37e-21	Hepatocellular carcinoma;
KIRP	cis	rs8067287	0.762	rs62065418	chr17:16820938	G/A	cg26910001	chr17:16838321	NA	-0.57	-5.6	-0.34	5.73e-8	Diabetic kidney disease;
KIRP	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.62	0.39	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg05025164	chr4:1340916	KIAA1530	0.44	5.43	0.33	1.32e-7	Obesity-related traits;
KIRP	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg06618935	chr21:46677482	NA	-0.43	-5.24	-0.32	3.43e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg11784071	chr10:104629166	AS3MT	-0.36	-4.99	-0.3	1.15e-6	Arsenic metabolism;
KIRP	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg13293535	chr8:11597251	GATA4	0.39	5.47	0.33	1.08e-7	Morning vs. evening chronotype;
KIRP	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg26248373	chr2:1572462	NA	-0.8	-10.32	-0.55	5.75e-21	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06235973	chr19:14183619	LOC113230	0.78	6.99	0.41	2.54e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	5.77	0.35	2.4e-8	Mean platelet volume;
KIRP	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.74	9.01	0.5	5.72e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-6.78	-0.4	8.86e-11	Systemic lupus erythematosus;
KIRP	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg21573476	chr21:45109991	RRP1B	-0.63	-8.47	-0.48	2.25e-15	Mean corpuscular volume;
KIRP	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg25182066	chr10:30743637	MAP3K8	-0.63	-8.62	-0.48	8.05e-16	Inflammatory bowel disease;
KIRP	cis	rs7147624	1.000	rs61987807	chr14:66207050	G/T	cg03016385	chr14:66212404	NA	-0.95	-9.55	-0.52	1.33e-18	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06173319	chr16:90148775	NA	0.57	5.27	0.32	2.99e-7	Skin colour saturation;
KIRP	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg23594656	chr7:65796392	TPST1	0.53	8.32	0.47	6.19e-15	Aortic root size;
KIRP	cis	rs7221595	0.778	rs2727072	chr17:3918585	C/G	cg21851534	chr17:3907994	ZZEF1	0.61	7.32	0.42	3.52e-12	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-6.12	-0.36	3.63e-9	Lung cancer;
KIRP	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.98	-0.41	2.8e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.62	-8.41	-0.47	3.33e-15	Colorectal cancer;
KIRP	cis	rs3126085	0.560	rs11588022	chr1:152316952	A/T	cg26876637	chr1:152193138	HRNR	-0.72	-7.14	-0.41	1.06e-11	Atopic dermatitis;
KIRP	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg17757837	chr7:157058334	UBE3C	0.77	10.51	0.56	1.37e-21	Body mass index;
KIRP	trans	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg19694781	chr19:47549865	TMEM160	0.61	8.04	0.46	3.75e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg22325292	chr17:80708367	FN3K	-0.48	-7.2	-0.42	7.31e-12	Glycated hemoglobin levels;
KIRP	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg10047753	chr17:41438598	NA	1.06	13.49	0.65	2.05e-31	Menopause (age at onset);
KIRP	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.69	0.44	3.47e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.97	-16.43	-0.72	1.96e-41	Breast cancer;
KIRP	cis	rs228437	0.802	rs228449	chr6:134903629	A/G	cg24504307	chr6:134963096	NA	-0.42	-6.26	-0.37	1.7e-9	Melanoma;
KIRP	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg25050447	chr17:78165522	CARD14	0.4	4.94	0.3	1.43e-6	Yeast infection;
KIRP	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg06647332	chr5:131281008	NA	0.43	4.89	0.3	1.81e-6	Life satisfaction;
KIRP	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.37	-0.38	9.04e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.47	7.27	0.42	4.71e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs2033732	0.673	rs1550211	chr8:85057571	G/A	cg05716166	chr8:85095498	RALYL	0.54	6.05	0.36	5.36e-9	Body mass index;
KIRP	cis	rs9815354	0.812	rs111967505	chr3:41873157	C/T	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.24	0.32	3.39e-7	Triglycerides;
KIRP	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.86	12.52	0.62	3.88e-28	Glomerular filtration rate (creatinine);
KIRP	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.3	7.17	0.42	8.79e-12	IgG glycosylation;
KIRP	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg23307798	chr14:103986281	CKB	0.5	7.09	0.41	1.41e-11	Body mass index;
KIRP	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	9.88	0.53	1.34e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	1.09	12.24	0.62	3.1e-27	Post bronchodilator FEV1;
KIRP	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg17207736	chr8:142237307	SLC45A4	-0.51	-6.47	-0.38	5.17e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.24	-6.04	-0.36	5.81e-9	Primary biliary cholangitis;
KIRP	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.37	-0.38	9.35e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.59	8.0	0.45	4.79e-14	Longevity;Endometriosis;
KIRP	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg09003973	chr2:102972529	NA	1.18	8.56	0.48	1.24e-15	Gut microbiota (bacterial taxa);
KIRP	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	7.16	0.42	9.09e-12	Iron status biomarkers;
KIRP	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg24324837	chr19:49891574	CCDC155	0.66	8.52	0.48	1.6e-15	Multiple sclerosis;
KIRP	cis	rs5770917	1.000	rs762676	chr22:51017794	A/G	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.56	-5.4	-0.33	1.59e-7	Narcolepsy;
KIRP	cis	rs2795502	0.873	rs1815716	chr10:43410200	G/A	cg11150807	chr10:43354902	NA	0.62	6.87	0.4	5.17e-11	Blood protein levels;
KIRP	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.66	6.45	0.38	5.77e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.77	0.44	2.12e-13	Aortic root size;
KIRP	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.49	-5.96	-0.36	8.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg05527609	chr1:210001259	C1orf107	-0.41	-5.1	-0.31	6.82e-7	Red blood cell count;
KIRP	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.16	-0.37	2.93e-9	Breast cancer;
KIRP	cis	rs2219968	0.828	rs1871788	chr8:78945481	T/C	cg00738934	chr8:78996279	NA	-0.38	-5.23	-0.32	3.62e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg00129232	chr17:37814104	STARD3	-0.72	-9.59	-0.52	1.05e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs7737355	0.738	rs55955246	chr5:131078498	C/G	cg06307176	chr5:131281290	NA	0.46	5.57	0.33	6.6e-8	Life satisfaction;
KIRP	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg21573476	chr21:45109991	RRP1B	-0.59	-8.03	-0.46	4.04e-14	Mean corpuscular volume;
KIRP	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.54	-7.47	-0.43	1.4e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.6	7.76	0.44	2.24e-13	Retinal vascular caliber;
KIRP	cis	rs2880765	0.546	rs11639291	chr15:86064130	G/A	cg15340431	chr15:86040528	AKAP13	-0.46	-5.66	-0.34	4.21e-8	Coronary artery disease;
KIRP	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.62	-8.82	-0.49	2.1e-16	Gut microbiome composition (summer);
KIRP	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.64	-8.17	-0.46	1.62e-14	Glomerular filtration rate;
KIRP	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21545522	chr1:205238299	TMCC2	-0.42	-5.64	-0.34	4.64e-8	Red blood cell count;
KIRP	cis	rs1659258	0.568	rs1271103	chr2:88596890	T/C	cg00685853	chr2:88648947	NA	-0.54	-6.26	-0.37	1.68e-9	Visceral fat;
KIRP	cis	rs13161895	0.646	rs75894617	chr5:179499854	G/C	cg02702477	chr5:179499311	RNF130	1.15	6.17	0.37	2.86e-9	LDL cholesterol;
KIRP	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg25486957	chr4:152246857	NA	-0.48	-5.34	-0.32	2.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.39	-5.49	-0.33	1.01e-7	Dementia with Lewy bodies;
KIRP	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.92	-15.33	-0.7	1.13e-37	Prostate cancer;
KIRP	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg01689657	chr7:91764605	CYP51A1	0.4	5.66	0.34	4.17e-8	Breast cancer;
KIRP	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	8.98	0.5	7.43e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.66	9.23	0.51	1.3e-17	Multiple sclerosis;
KIRP	cis	rs155346	0.571	rs264341	chr5:139354932	A/G	cg24724630	chr5:139362307	NRG2	-0.38	-4.99	-0.3	1.15e-6	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs4654899	0.802	rs4654724	chr1:21177210	C/T	cg05370193	chr1:21551575	ECE1	0.42	5.18	0.31	4.6e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.42	-5.22	-0.32	3.9e-7	Neuroticism;
KIRP	cis	rs13102973	0.666	rs10007311	chr4:135898716	A/T	cg14419869	chr4:135874104	NA	0.46	7.03	0.41	1.98e-11	Subjective well-being;
KIRP	cis	rs3931020	0.671	rs1327088	chr1:75255491	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.76	0.34	2.5e-8	Resistin levels;
KIRP	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg10130564	chr11:117069849	TAGLN	0.4	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg11784071	chr10:104629166	AS3MT	-0.37	-5.1	-0.31	6.65e-7	Arsenic metabolism;
KIRP	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg25801113	chr15:45476975	SHF	0.48	9.27	0.51	1.01e-17	Uric acid levels;
KIRP	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.48	5.43	0.33	1.34e-7	Schizophrenia;
KIRP	trans	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.32	-0.37	1.22e-9	Neuroticism;
KIRP	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg05043794	chr9:111880884	C9orf5	-0.25	-4.97	-0.3	1.27e-6	Menarche (age at onset);
KIRP	trans	rs113098727	0.736	rs11241716	chr5:123176408	A/G	cg26714650	chr12:56694279	CS	-0.57	-6.14	-0.36	3.36e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg24747557	chr10:131355152	MGMT	-0.39	-5.25	-0.32	3.36e-7	Response to temozolomide;
KIRP	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-7.15	-0.41	9.69e-12	Systolic blood pressure;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg23985595	chr17:80112537	CCDC57	0.36	5.2	0.31	4.24e-7	Life satisfaction;
KIRP	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg16482183	chr6:26056742	HIST1H1C	0.63	7.33	0.42	3.36e-12	Iron status biomarkers;
KIRP	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.72	-10.91	-0.57	7.45e-23	Hepatocellular carcinoma;
KIRP	cis	rs11673344	0.526	rs17244713	chr19:38050840	A/G	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.52	-0.33	8.41e-8	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	17.46	0.74	5.75e-45	Platelet count;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg22907277	chr7:1156413	C7orf50	0.57	7.12	0.41	1.2e-11	Longevity;Endometriosis;
KIRP	cis	rs6988636	0.536	rs16898043	chr8:124155886	A/G	cg15893493	chr8:124194847	FAM83A	0.53	4.88	0.3	1.88e-6	Urinary uromodulin levels;
KIRP	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg24699146	chr1:24152579	HMGCL	-0.48	-6.58	-0.39	2.74e-10	Immature fraction of reticulocytes;
KIRP	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg05639522	chr1:247681581	NA	0.58	5.52	0.33	8.67e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9921338	0.961	rs7626	chr16:11445596	C/T	cg00044050	chr16:11439710	C16orf75	-0.54	-5.83	-0.35	1.76e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs4356932	1.000	rs6826163	chr4:76973445	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.72	9.57	0.52	1.16e-18	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.79	9.68	0.53	5.6e-19	Monocyte percentage of white cells;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg17027945	chr15:74284732	STOML1	0.77	6.67	0.39	1.64e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Bladder cancer;
KIRP	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.71	0.49	4.39e-16	Motion sickness;
KIRP	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg03469805	chr14:105330648	KIAA0284	-0.32	-5.87	-0.35	1.44e-8	IgG glycosylation;
KIRP	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg22705602	chr4:152727874	NA	-0.36	-5.5	-0.33	9.36e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.49	6.33	0.37	1.19e-9	Multiple sclerosis;
KIRP	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs754133	0.964	rs894737	chr12:54418143	A/C	cg10005224	chr12:54424964	HOXC4;HOXC5	0.27	5.69	0.34	3.67e-8	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;
KIRP	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.39	8.21	0.46	1.23e-14	Body mass index;
KIRP	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.43	5.56	0.33	6.93e-8	Schizophrenia;
KIRP	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg19468946	chr17:37922297	IKZF3	-0.49	-6.96	-0.41	2.99e-11	Self-reported allergy;
KIRP	cis	rs9381107	0.932	rs16892227	chr6:9425046	A/G	cg14735645	chr6:9486422	NA	-0.45	-5.41	-0.33	1.48e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.24	0.47	1.01e-14	Eosinophil percentage of white cells;
KIRP	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg14593290	chr7:50529359	DDC	-0.51	-7.01	-0.41	2.31e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs4356932	0.703	rs71629034	chr4:76964953	A/G	cg00809888	chr4:76862425	NAAA	0.43	5.8	0.35	2.02e-8	Blood protein levels;
KIRP	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg15660573	chr17:549704	VPS53	-0.59	-7.37	-0.43	2.63e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7707921	0.767	rs862241	chr5:81588011	G/A	cg07807695	chr5:81608485	ATP6AP1L	-0.45	-5.85	-0.35	1.53e-8	Breast cancer;
KIRP	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg15556689	chr8:8085844	FLJ10661	0.69	9.11	0.5	2.96e-17	Neuroticism;
KIRP	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.45	-5.26	-0.32	3.21e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs8060686	0.920	rs2292318	chr16:67985706	C/T	cg04539111	chr16:67997858	SLC12A4	-0.66	-6.81	-0.4	7.4e-11	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7224685	0.501	rs3765	chr17:3926771	T/C	cg09695851	chr17:3907499	NA	0.87	16.56	0.73	6.7e-42	Type 2 diabetes;
KIRP	cis	rs62229266	0.804	rs2835241	chr21:37411380	G/T	cg12218747	chr21:37451666	NA	0.47	5.86	0.35	1.47e-8	Mitral valve prolapse;
KIRP	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.07	-0.5	3.86e-17	Response to antipsychotic treatment;
KIRP	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.59	-6.3	-0.37	1.37e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.86	-11.47	-0.59	1.09e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10425738	0.830	rs3852872	chr19:41416143	C/T	cg09508736	chr19:41385865	CYP2A7	-0.46	-5.04	-0.31	8.98e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
KIRP	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	0.69	5.45	0.33	1.21e-7	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.12	-0.36	3.73e-9	Educational attainment;
KIRP	cis	rs9596863	0.898	rs8000371	chr13:54344502	A/G	ch.13.53330881F	chr13:54432880	NA	0.6	5.82	0.35	1.86e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2219968	1.000	rs6982916	chr8:78972362	A/G	cg00738934	chr8:78996279	NA	-0.4	-5.04	-0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18255839	chr2:239335447	ASB1	0.42	4.99	0.3	1.16e-6	Multiple system atrophy;
KIRP	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.77	-7.69	-0.44	3.56e-13	Bipolar disorder;
KIRP	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.64	0.44	4.83e-13	Bladder cancer;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.66	10.95	0.57	5.36e-23	Lung cancer;
KIRP	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.48	6.64	0.39	1.96e-10	Lewy body disease;
KIRP	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.05	-0.41	1.8e-11	Neuroticism;
KIRP	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg25866889	chr13:114914595	NA	-0.4	-5.54	-0.33	7.6e-8	Schizophrenia;
KIRP	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.74	10.55	0.56	1.08e-21	Parkinson's disease;
KIRP	trans	rs7623291	1.000	rs7623291	chr3:178356237	A/G	cg00294096	chr1:77333749	ST6GALNAC5	0.43	6.02	0.36	6.16e-9	Left ventricular obstructive tract defect (inherited effect);
KIRP	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06505273	chr16:24850292	NA	0.41	5.38	0.32	1.72e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.44	4.04e-13	Bladder cancer;
KIRP	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg15181151	chr6:150070149	PCMT1	0.3	5.2	0.31	4.11e-7	Lung cancer;
KIRP	cis	rs4356932	1.000	rs4859587	chr4:76943296	A/C	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs981844	0.683	rs1037653	chr4:154749992	A/T	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.75	-11.09	-0.58	1.97e-23	Hip circumference;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg09695851	chr17:3907499	NA	-0.82	-15.12	-0.69	5.58e-37	Type 2 diabetes;
KIRP	cis	rs6088813	1.000	rs6142374	chr20:33985568	C/T	cg14752227	chr20:34000481	UQCC	-0.53	-6.83	-0.4	6.58e-11	Height;
KIRP	cis	rs61935443	0.673	rs11107770	chr12:95275147	C/T	cg21533806	chr12:95267307	NA	-0.66	-6.61	-0.39	2.36e-10	Schizophrenia;
KIRP	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg19592336	chr6:28129416	ZNF389	-0.5	-5.87	-0.35	1.42e-8	Depression;
KIRP	cis	rs679087	0.606	rs302344	chr12:29940953	A/G	cg14258853	chr12:29935411	TMTC1	0.47	4.85	0.3	2.16e-6	Schizophrenia;
KIRP	cis	rs7919006	0.590	rs16931904	chr10:76750756	C/T	cg01390419	chr10:76803856	DUPD1	0.46	4.89	0.3	1.81e-6	Weight;
KIRP	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg05802129	chr4:122689817	NA	-0.58	-7.46	-0.43	1.51e-12	Type 2 diabetes;
KIRP	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.47	-6.49	-0.38	4.66e-10	Testicular germ cell tumor;
KIRP	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg00277334	chr10:82204260	NA	-0.62	-6.36	-0.38	9.96e-10	Post bronchodilator FEV1;
KIRP	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg18882449	chr10:104885122	NT5C2	-0.46	-5.88	-0.35	1.32e-8	Arsenic metabolism;
KIRP	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7113874	0.578	rs67067089	chr11:8530027	C/A	cg08015107	chr11:8618950	NA	-0.68	-8.22	-0.46	1.16e-14	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.78	-9.75	-0.53	3.25e-19	Longevity;Endometriosis;
KIRP	cis	rs9972944	0.729	rs6504351	chr17:63765275	C/T	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07570687	chr10:102243282	WNT8B	0.5	6.0	0.36	7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.96	11.35	0.59	2.7e-24	Breast cancer;
KIRP	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg27124370	chr19:33622961	WDR88	0.55	6.83	0.4	6.61e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17830980	chr10:43048298	ZNF37B	-0.48	-6.58	-0.39	2.77e-10	Extrinsic epigenetic age acceleration;
KIRP	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.53	-15.58	-0.7	1.53e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.76	-9.75	-0.53	3.32e-19	Aortic root size;
KIRP	cis	rs13401104	0.796	rs11894118	chr2:237119192	C/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00919280	chr12:41370320	CNTN1	-0.39	-6.19	-0.37	2.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.597	rs9285508	chr6:146262697	G/T	cg23711669	chr6:146136114	FBXO30	-0.82	-9.74	-0.53	3.7e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11783469	0.524	rs17089281	chr8:23335151	T/C	cg08322043	chr8:23340750	NA	-0.51	-5.54	-0.33	7.93e-8	Reticulocyte count;
KIRP	cis	rs7190997	0.525	rs11150619	chr16:31376849	A/G	cg02846316	chr16:31340340	ITGAM	0.42	5.43	0.33	1.38e-7	IgA nephropathy;
KIRP	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg02569458	chr12:86230093	RASSF9	0.42	6.53	0.38	3.75e-10	Major depressive disorder;
KIRP	cis	rs7975161	0.638	rs7137288	chr12:104591886	C/A	cg25273343	chr12:104657179	TXNRD1	-0.48	-5.49	-0.33	1.02e-7	Toenail selenium levels;
KIRP	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.54	-0.33	7.93e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs12142240	0.845	rs4313342	chr1:46801904	T/C	cg14993813	chr1:46806288	NSUN4	-0.59	-6.92	-0.4	3.8e-11	Menopause (age at onset);
KIRP	cis	rs7224685	0.501	rs781820	chr17:3976075	C/G	cg05562828	chr17:3906858	NA	0.72	14.26	0.67	5.1e-34	Type 2 diabetes;
KIRP	cis	rs12367572	0.501	rs2897857	chr12:45481949	A/G	cg04608330	chr12:45269318	NELL2	-0.44	-5.58	-0.34	6.21e-8	Gut microbiome composition (summer);
KIRP	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.01	11.08	0.58	2.1e-23	Cognitive test performance;
KIRP	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.37	-0.43	2.55e-12	Aortic root size;
KIRP	cis	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg02972257	chr16:68554789	NA	-0.51	-4.99	-0.3	1.15e-6	Ulcerative colitis;
KIRP	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05472934	chr7:22766657	IL6	0.8	10.19	0.54	1.41e-20	Lung cancer;
KIRP	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1050631	0.592	rs1785930	chr18:33723718	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.46	5.74	0.34	2.71e-8	Esophageal squamous cell cancer (length of survival);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg07195941	chr17:42386123	RUNDC3A	-0.43	-6.11	-0.36	3.92e-9	Myopia;
KIRP	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg02696790	chr15:75250997	RPP25	0.31	5.24	0.32	3.5e-7	Breast cancer;
KIRP	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg22189786	chr22:42395067	WBP2NL	0.45	5.72	0.34	3.07e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	7.36	0.42	2.67e-12	Schizophrenia;
KIRP	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs7246657	0.722	rs10402671	chr19:38117086	C/T	cg23950597	chr19:37808831	NA	-0.61	-6.53	-0.38	3.7e-10	Coronary artery calcification;
KIRP	cis	rs16858210	0.607	rs57874587	chr3:183584749	C/T	cg25686905	chr3:183603175	PARL	-0.43	-4.86	-0.3	2.13e-6	Menopause (age at onset);
KIRP	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs11677416	1.000	rs59674541	chr2:113553824	A/T	cg23974023	chr2:113544294	IL1A	-0.32	-5.07	-0.31	7.9e-7	Response to antipsychotic treatment in schizophrenia (working memory);
KIRP	cis	rs12145833	0.596	rs12134228	chr1:243447618	C/T	cg02356786	chr1:243265016	LOC731275	0.86	6.02	0.36	6.25e-9	Obesity (early onset extreme);
KIRP	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.76	9.22	0.51	1.35e-17	Post bronchodilator FEV1;
KIRP	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-5.53	-0.33	8.05e-8	Recombination measurement;
KIRP	cis	rs281408	0.559	rs281386	chr19:49217305	A/G	cg13540341	chr19:49222985	MAMSTR	0.35	5.82	0.35	1.8e-8	Urinary metabolites (H-NMR features);
KIRP	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.48	6.51	0.38	4.09e-10	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17554472	chr22:41940697	POLR3H	0.56	6.22	0.37	2.13e-9	Vitiligo;
KIRP	trans	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17712092	chr4:129076599	LARP1B	0.97	14.95	0.69	2.19e-36	Eosinophil percentage of white cells;
KIRP	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.31	-0.62	1.85e-27	Primary sclerosing cholangitis;
KIRP	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.32	-0.32	2.34e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10291648	chr11:126152965	TIRAP	0.52	6.48	0.38	5.05e-10	Parkinson's disease;
KIRP	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-10.32	-0.55	5.76e-21	Schizophrenia;
KIRP	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26207909	chr14:103986467	CKB	0.77	12.12	0.61	7.92e-27	Body mass index;
KIRP	cis	rs4400599	0.594	rs7526644	chr1:154208753	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.37	-5.56	-0.33	6.84e-8	Platelet distribution width;
KIRP	cis	rs12900413	0.673	rs35308090	chr15:90308026	G/T	cg24650279	chr15:90327240	NA	-0.44	-5.47	-0.33	1.11e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs2733201	1.000	rs8036541	chr15:44319377	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-5.77	-0.35	2.38e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs258892	0.895	rs16901102	chr5:72048749	C/T	cg21869765	chr5:72125136	TNPO1	-0.51	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs6142102	0.602	rs4911380	chr20:32546224	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-6.22	-0.37	2.13e-9	Lung cancer;
KIRP	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.54	-7.51	-0.43	1.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg23920097	chr1:209922102	NA	0.44	5.4	0.33	1.6e-7	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13443122	chr2:70142154	MXD1	0.46	6.08	0.36	4.61e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19150007	chr7:119915076	KCND2	0.43	6.34	0.37	1.11e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg02461776	chr11:598696	PHRF1	0.49	5.23	0.32	3.65e-7	Systemic lupus erythematosus;
KIRP	cis	rs2387326	0.671	rs11016104	chr10:129946512	G/A	cg16087940	chr10:129947807	NA	-0.43	-5.9	-0.35	1.19e-8	Select biomarker traits;
KIRP	cis	rs11203032	0.831	rs9651495	chr10:90932381	G/A	cg16672925	chr10:90967113	CH25H	0.74	7.34	0.42	3.14e-12	Heart failure;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg05825950	chr1:207669576	CR1	0.87	6.51	0.38	4.14e-10	P wave terminal force;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15340874	chr1:174969621	CACYBP	0.5	7.13	0.41	1.11e-11	Survival in pancreatic cancer;
KIRP	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.43	5.26	0.32	3.07e-7	Testicular germ cell tumor;
KIRP	cis	rs7404928	0.669	rs77165148	chr16:23885528	C/T	cg21745164	chr16:23765304	CHP2	-0.55	-6.37	-0.38	9.27e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.44	5.97	0.36	8.45e-9	Testicular germ cell tumor;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15536489	chr7:1120860	C7orf50	0.46	6.36	0.38	9.69e-10	Survival in pancreatic cancer;
KIRP	cis	rs231513	0.954	rs231498	chr17:41975251	C/G	cg26893861	chr17:41843967	DUSP3	-0.47	-5.05	-0.31	8.59e-7	Cognitive function;
KIRP	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23903679	chr10:74451845	CCDC109A	0.5	6.18	0.37	2.69e-9	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-0.97	-11.87	-0.6	5.55e-26	Breast cancer;
KIRP	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.76	9.91	0.53	1.09e-19	Bipolar disorder;
KIRP	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg16141378	chr3:129829833	LOC729375	0.57	6.85	0.4	5.8e-11	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15437223	chr10:65132738	JMJD1C;MIR1296	0.45	6.77	0.4	9.14e-11	Interleukin-4 levels;
KIRP	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg15880211	chr22:50250494	ZBED4	0.58	5.17	0.31	4.86e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20134357	chr8:114389383	CSMD3	-0.43	-6.38	-0.38	8.48e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.62	0.39	2.25e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.8	12.28	0.62	2.3e-27	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7999699	0.902	rs57239112	chr13:48321322	A/T	cg23237801	chr1:16476620	EPHA2	0.52	6.48	0.38	5.07e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.58	-7.88	-0.45	1.04e-13	High light scatter reticulocyte count;
KIRP	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg20701182	chr2:24300061	SF3B14	0.49	4.85	0.3	2.23e-6	Lymphocyte counts;
KIRP	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg20723414	chr7:157207071	DNAJB6	0.48	6.04	0.36	5.52e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.48	-0.33	1.03e-7	Menarche (age at onset);
KIRP	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-13.47	-0.65	2.32e-31	Chronic sinus infection;
KIRP	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg00933542	chr6:150070202	PCMT1	0.31	5.91	0.35	1.14e-8	Lung cancer;
KIRP	cis	rs2880765	0.546	rs36098649	chr15:86056807	C/T	cg10818794	chr15:86012489	AKAP13	-0.53	-6.68	-0.39	1.54e-10	Coronary artery disease;
KIRP	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg11016749	chr4:921637	GAK	-0.49	-5.37	-0.32	1.85e-7	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.24	-0.32	3.45e-7	Coronary artery disease;
KIRP	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-11.01	-0.57	3.44e-23	Colorectal cancer;
KIRP	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.88	9.88	0.53	1.28e-19	Gut microbiome composition (summer);
KIRP	trans	rs66573146	1.000	rs6838250	chr4:6973184	C/G	cg07817883	chr1:32538562	TMEM39B	1.47	9.79	0.53	2.51e-19	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3126085	0.825	rs12045492	chr1:152253866	A/T	cg26876637	chr1:152193138	HRNR	0.71	9.39	0.51	4.37e-18	Atopic dermatitis;
KIRP	cis	rs11627756	0.958	rs10131189	chr14:103091440	C/G	cg01864069	chr14:103024347	NA	-0.53	-6.28	-0.37	1.5e-9	Mean platelet volume;
KIRP	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	1.96e-14	Testicular germ cell tumor;
KIRP	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	1.26	17.7	0.75	8.85e-46	Left atrial antero-posterior diameter;
KIRP	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.65	-0.34	4.39e-8	Breast cancer;
KIRP	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6563210	0.789	rs9574877	chr13:36483667	C/T	cg19801062	chr13:36872135	C13orf38	0.42	4.86	0.3	2.09e-6	Height;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12016809	chr21:47604291	C21orf56	-0.52	-7.49	-0.43	1.24e-12	Testicular germ cell tumor;
KIRP	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg25037394	chr1:24152592	HMGCL	-0.38	-4.95	-0.3	1.35e-6	Immature fraction of reticulocytes;
KIRP	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-7.82	-0.45	1.56e-13	Colorectal cancer;
KIRP	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs12714314	0.560	rs2116652	chr2:1941825	A/G	cg20846728	chr2:1843184	MYT1L	-0.38	-6.37	-0.38	9.02e-10	Type 2 diabetes (age of onset);
KIRP	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.65	-5.73	-0.34	2.93e-8	Bipolar disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18775587	chr5:154135052	LARP1	0.51	6.64	0.39	1.97e-10	Parkinson's disease;
KIRP	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.4	-0.55	3.19e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.68	-0.44	3.81e-13	Morning vs. evening chronotype;
KIRP	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg01631408	chr1:248437212	OR2T33	-0.46	-6.34	-0.37	1.11e-9	Common traits (Other);
KIRP	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg24296786	chr1:45957014	TESK2	0.52	5.73	0.34	2.94e-8	Homocysteine levels;
KIRP	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg20220242	chr21:30392188	RWDD2B	0.37	4.86	0.3	2.07e-6	Dental caries;
KIRP	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.76	9.89	0.53	1.24e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg06521331	chr12:34319734	NA	-0.5	-6.23	-0.37	1.97e-9	Bladder cancer;
KIRP	cis	rs41464348	0.748	rs749455	chr2:33501926	A/G	cg16572410	chr2:33467199	LTBP1	0.37	4.85	0.3	2.15e-6	Height;
KIRP	cis	rs7617773	0.539	rs6779517	chr3:48384388	C/T	cg11946769	chr3:48343235	NME6	0.56	7.0	0.41	2.46e-11	Coronary artery disease;
KIRP	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg12549451	chr6:135224345	NA	-0.46	-5.71	-0.34	3.23e-8	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs807669	0.770	rs807458	chr22:19220648	G/A	cg26795923	chr22:19165960	SLC25A1	0.83	5.58	0.33	6.49e-8	Metabolite levels;
KIRP	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg06012730	chr15:75315579	PPCDC	-0.38	-4.87	-0.3	2.03e-6	Blood trace element (Zn levels);
KIRP	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg13395646	chr4:1353034	KIAA1530	-0.38	-5.14	-0.31	5.71e-7	Obesity-related traits;
KIRP	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-6.37	-0.38	9.05e-10	Response to antipsychotic treatment;
KIRP	cis	rs1712517	0.873	rs7894240	chr10:105000369	T/C	cg05636881	chr10:105038444	INA	-0.38	-5.78	-0.35	2.22e-8	Migraine;
KIRP	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg00977110	chr5:151150581	G3BP1	0.62	6.21	0.37	2.24e-9	Preschool internalizing problems;
KIRP	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg15117754	chr3:10150083	C3orf24	0.51	5.11	0.31	6.46e-7	Alzheimer's disease;
KIRP	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg16497661	chr14:103986332	CKB	-0.47	-6.06	-0.36	5.14e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-8.79	-0.49	2.57e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.66	9.89	0.53	1.26e-19	Dupuytren's disease;
KIRP	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.38	-5.09	-0.31	7.21e-7	Electroencephalogram traits;
KIRP	cis	rs4478137	0.501	rs9764	chr4:164245405	A/G	cg06758707	chr4:164254230	NPY1R	-0.51	-5.64	-0.34	4.6e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2997447	0.748	rs2783640	chr1:26430447	T/C	cg19633962	chr1:26362018	EXTL1	-0.56	-5.27	-0.32	3.05e-7	QRS complex (12-leadsum);
KIRP	cis	rs4638749	0.501	rs2378095	chr2:108764899	G/A	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.93	-0.3	1.51e-6	Blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10619411	chr15:101514474	LRRK1	0.5	6.31	0.37	1.29e-9	Interleukin-4 levels;
KIRP	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg24565620	chr2:194026	NA	-0.65	-5.0	-0.3	1.08e-6	Blood protein levels;
KIRP	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg00647317	chr7:50633725	DDC	0.38	5.41	0.33	1.47e-7	Systemic sclerosis;
KIRP	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.8	9.98	0.54	6.5e-20	Corneal astigmatism;
KIRP	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.45	4.97	0.3	1.27e-6	Type 2 diabetes;
KIRP	cis	rs504918	0.556	rs4678105	chr3:124000265	A/G	cg05766129	chr3:123988013	KALRN	-0.44	-5.99	-0.36	7.28e-9	Schizophrenia;
KIRP	cis	rs11583043	0.546	rs6688545	chr1:101590335	G/A	cg17443007	chr1:101659419	NA	0.42	5.92	0.35	1.08e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	13.69	0.66	4.36e-32	Platelet count;
KIRP	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg20387954	chr3:183756860	HTR3D	0.64	9.29	0.51	8.65e-18	Anterior chamber depth;
KIRP	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6540559	1.000	rs2235373	chr1:209963803	G/A	cg22029157	chr1:209979665	IRF6	0.59	7.07	0.41	1.6e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs10208940	0.920	rs10164780	chr2:68766250	A/T	cg12452813	chr2:68675892	NA	0.47	5.06	0.31	8.07e-7	Urate levels in lean individuals;
KIRP	cis	rs13361707	0.700	rs10036575	chr5:40685795	T/C	cg01087697	chr5:40835557	RPL37	-0.5	-5.47	-0.33	1.11e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.62	0.44	5.34e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00852783	chr1:26633632	UBXN11	0.57	7.85	0.45	1.27e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.76	8.8	0.49	2.46e-16	High light scatter reticulocyte count;
KIRP	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-6.05	-0.36	5.47e-9	Coronary artery disease;
KIRP	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	6.88	0.4	4.81e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	1.12	16.18	0.72	1.34e-40	Breast cancer;
KIRP	cis	rs16957091	0.821	rs7182479	chr15:42999565	G/A	cg24196017	chr15:43021976	CDAN1	-0.46	-5.96	-0.36	8.83e-9	MGMT methylation in smokers;
KIRP	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	1.02	22.11	0.82	2.18e-60	Multiple myeloma;
KIRP	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg03146154	chr1:46216737	IPP	0.56	5.85	0.35	1.57e-8	Platelet count;
KIRP	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00149659	chr3:10157352	C3orf10	0.8	8.61	0.48	9.02e-16	Alzheimer's disease;
KIRP	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.67	-10.18	-0.54	1.58e-20	Coronary artery disease;
KIRP	cis	rs6430538	0.621	rs12471304	chr2:135560520	C/T	cg12500956	chr2:135428796	TMEM163	0.43	5.62	0.34	5.07e-8	Parkinson's disease;
KIRP	cis	rs4774899	0.966	rs12898844	chr15:57358508	A/T	cg13626582	chr15:57592083	LOC283663	-0.2	-4.92	-0.3	1.58e-6	Urinary tract infection frequency;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00377133	chr18:3247815	MYL12A	0.49	6.24	0.37	1.9e-9	Parkinson's disease;
KIRP	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg21926883	chr2:100939477	LONRF2	-0.66	-8.98	-0.5	7.19e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.6	-0.56	7.11e-22	Height;
KIRP	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg22974920	chr21:40686053	BRWD1	0.46	5.5	0.33	9.67e-8	Cognitive function;
KIRP	cis	rs986417	0.901	rs7159628	chr14:61010688	A/C	cg27398547	chr14:60952738	C14orf39	0.63	5.2	0.31	4.15e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	5.93	0.35	1.03e-8	Educational attainment;
KIRP	cis	rs17401966	1.000	rs12117765	chr1:10268170	A/G	cg19773385	chr1:10388646	KIF1B	-0.63	-8.06	-0.46	3.32e-14	Hepatocellular carcinoma;
KIRP	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs4730250	0.595	rs7789500	chr7:106915723	A/C	cg02696742	chr7:106810147	HBP1	-0.73	-7.56	-0.43	7.75e-13	Osteoarthritis;
KIRP	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg17644776	chr2:200775616	C2orf69	0.45	4.89	0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg15691649	chr6:25882328	NA	-0.46	-5.53	-0.33	7.98e-8	Blood metabolite levels;
KIRP	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.52	7.75	0.44	2.42e-13	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs13095912	1.000	rs7374856	chr3:185311964	A/C	cg11274856	chr3:185301563	NA	0.5	6.51	0.38	4.31e-10	Systolic blood pressure;
KIRP	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06544989	chr22:39130855	UNC84B	0.49	7.9	0.45	9.6e-14	Menopause (age at onset);
KIRP	cis	rs7301016	0.947	rs10877864	chr12:62893199	T/C	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg11945507	chr8:142233382	SLC45A4	-0.67	-9.64	-0.52	7.07e-19	Immature fraction of reticulocytes;
KIRP	trans	rs2281597	0.664	rs10753290	chr1:34291781	C/T	cg23733260	chr3:107381326	BBX	-0.5	-6.06	-0.36	5.1e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.49	-11.44	-0.59	1.39e-24	Diabetic kidney disease;
KIRP	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.47	7.18	0.42	8.37e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs950881	0.932	rs3771175	chr2:102960210	A/T	cg01254707	chr2:102953421	IL1RL1	0.51	5.14	0.31	5.6e-7	Allergy;
KIRP	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.66	0.34	4.28e-8	Aortic root size;
KIRP	cis	rs2412208	0.664	rs12025462	chr1:7107665	C/T	cg20434152	chr1:7120926	CAMTA1	0.4	5.38	0.32	1.69e-7	Survival in sporadic amyotrophic lateral sclerosis;
KIRP	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-7.5	-0.43	1.13e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.37	-0.62	1.23e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg23719950	chr11:63933701	MACROD1	-0.67	-6.34	-0.37	1.07e-9	Mean platelet volume;
KIRP	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs7119167	0.722	rs11824614	chr11:73062572	T/C	cg17517138	chr11:73019481	ARHGEF17	0.48	5.12	0.31	6.12e-7	Blood protein levels;
KIRP	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	cg07049167	chr1:166818506	POGK	0.45	4.86	0.3	2.05e-6	Refractive astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27146808	chr19:14200528	SAMD1	0.47	6.34	0.37	1.11e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.88e-7	Life satisfaction;
KIRP	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.59	7.95	0.45	6.87e-14	White matter hyperintensity burden;
KIRP	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.75	6.04	0.36	5.77e-9	Inflammatory bowel disease;
KIRP	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07151155	chr5:1473589	LPCAT1	-0.44	-5.9	-0.35	1.21e-8	Breast cancer;
KIRP	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	11.08	0.58	2.02e-23	Exhaled nitric oxide levels;
KIRP	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-5.9	-0.35	1.17e-8	Crohn's disease;
KIRP	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.92	10.76	0.57	2.3e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs7945718	0.875	rs7105783	chr11:12719794	A/G	ch.11.340609R	chr11:12831013	TEAD1	-0.44	-5.37	-0.32	1.8e-7	Educational attainment (years of education);
KIRP	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.69	-6.49	-0.38	4.69e-10	Bipolar disorder;
KIRP	cis	rs10128251	0.746	rs9424194	chr10:5724073	A/G	cg11519256	chr10:5708881	ASB13	0.51	6.47	0.38	5.32e-10	Childhood ear infection;
KIRP	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg18944383	chr4:111397179	ENPEP	0.62	11.31	0.58	3.64e-24	Height;
KIRP	cis	rs73206853	0.698	rs1018134	chr12:111121119	G/A	cg12870014	chr12:110450643	ANKRD13A	0.5	4.86	0.3	2.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg03468072	chr12:39539422	NA	0.44	6.04	0.36	5.62e-9	Morning vs. evening chronotype;
KIRP	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.79	9.9	0.53	1.14e-19	Mean platelet volume;
KIRP	cis	rs909341	0.909	rs2750480	chr20:62342654	G/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.83	-0.4	6.8e-11	Atopic dermatitis;
KIRP	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.55	7.24	0.42	5.82e-12	Economic and political preferences (feminism/equality);
KIRP	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg01620082	chr3:125678407	NA	-1.03	-6.1	-0.36	4.13e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.36	5.55	0.33	7.43e-8	Lung cancer;
KIRP	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.09	-0.41	1.4e-11	Fear of minor pain;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15090198	chr1:22005650	USP48	-0.41	-6.09	-0.36	4.24e-9	Inflammatory biomarkers;
KIRP	cis	rs4671400	0.571	rs2421116	chr2:61488411	A/G	cg15711740	chr2:61764176	XPO1	0.62	7.06	0.41	1.68e-11	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	trans	rs12544026	0.548	rs487863	chr8:102912112	A/T	cg19131667	chr3:17236940	TBC1D5	0.38	6.02	0.36	6.34e-9	Major depression and alcohol dependence;
KIRP	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg04398451	chr17:18023971	MYO15A	0.65	8.48	0.48	2.16e-15	Total body bone mineral density;
KIRP	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.78	-11.6	-0.59	4.14e-25	Obesity-related traits;
KIRP	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg04374321	chr14:90722782	PSMC1	-0.83	-11.72	-0.6	1.73e-25	Mortality in heart failure;
KIRP	cis	rs4716602	0.596	rs10266659	chr7:156159278	A/G	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg09699651	chr6:150184138	LRP11	0.46	5.9	0.35	1.2e-8	Lung cancer;
KIRP	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg18261050	chr1:119551319	NA	0.51	6.79	0.4	8.32e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg02023728	chr11:77925099	USP35	-0.31	-5.05	-0.31	8.57e-7	Alzheimer's disease (survival time);
KIRP	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.68	-0.48	5.47e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg10096100	chr1:26503862	CNKSR1	0.42	5.95	0.35	9.33e-9	Height;
KIRP	cis	rs3733418	0.929	rs12510464	chr4:165919040	A/G	cg08992305	chr4:165878219	TRIM61;C4orf39	-0.51	-5.01	-0.3	1.04e-6	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	1.03	14.63	0.68	2.76e-35	Alzheimer's disease;
KIRP	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg22906224	chr7:99728672	NA	-0.52	-6.29	-0.37	1.45e-9	Coronary artery disease;
KIRP	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.06	-0.31	8.17e-7	Red blood cell count;
KIRP	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg09788416	chr12:39539408	NA	0.4	5.57	0.33	6.61e-8	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.35	5.01	0.3	1.02e-6	IgG glycosylation;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-0.69	-7.05	-0.41	1.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.53	5.69	0.34	3.66e-8	Lung cancer;
KIRP	cis	rs9308731	1.000	rs2241843	chr2:111879381	C/A	cg23466623	chr2:111982296	NA	-0.41	-5.07	-0.31	7.8e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs4253772	0.938	rs45550937	chr22:46638128	C/G	cg24881330	chr22:46731750	TRMU	0.64	5.49	0.33	9.92e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg26207909	chr14:103986467	CKB	-0.53	-6.85	-0.4	5.75e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2249694	0.520	rs11815623	chr10:135329133	A/G	cg20169779	chr10:135381914	SYCE1	-0.58	-6.36	-0.38	9.56e-10	Obesity-related traits;
KIRP	cis	rs7712401	0.562	rs401729	chr5:122264285	G/T	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.52e-7	Mean platelet volume;
KIRP	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	1.02	8.75	0.49	3.43e-16	Arsenic metabolism;
KIRP	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg05072774	chr3:49840536	C3orf54	0.42	5.45	0.33	1.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg24253500	chr15:84953950	NA	0.52	5.99	0.36	7.33e-9	Schizophrenia;
KIRP	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.57	0.39	2.89e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Body mass index;
KIRP	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	1.08	16.95	0.73	3.21e-43	Cognitive function;
KIRP	cis	rs16912285	0.584	rs7131124	chr11:24249455	A/G	ch.11.24196551F	chr11:24239977	NA	0.81	9.17	0.5	1.95e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4262150	0.764	rs12188564	chr5:151936546	G/A	cg12297329	chr5:152029980	NA	-0.66	-8.0	-0.45	4.94e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg11569703	chr11:65557185	OVOL1	-0.49	-8.69	-0.48	5.19e-16	Acne (severe);
KIRP	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg26513180	chr16:89883248	FANCA	0.79	5.27	0.32	2.98e-7	Skin colour saturation;
KIRP	cis	rs7084402	0.935	rs10763553	chr10:60274049	C/A	cg05938607	chr10:60274200	BICC1	0.42	10.0	0.54	5.47e-20	Refractive error;
KIRP	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.66	-6.84	-0.4	6.3e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-1.14	-10.81	-0.57	1.55e-22	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg00321850	chr1:175162397	KIAA0040	-0.36	-6.38	-0.38	8.51e-10	Alcohol dependence;
KIRP	cis	rs7582720	0.945	rs72932709	chr2:203639501	A/G	cg08076091	chr2:203926405	NBEAL1	0.83	8.27	0.47	8.65e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.87	-0.57	9.58e-23	Menopause (age at onset);
KIRP	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg05721485	chr17:44071124	MAPT	0.59	7.47	0.43	1.41e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7534824	0.582	rs17448827	chr1:101421407	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.91	0.35	1.13e-8	Refractive astigmatism;
KIRP	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg26727032	chr16:67993705	SLC12A4	-0.68	-6.07	-0.36	4.78e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.59	-12.45	-0.62	6.65e-28	Diabetic kidney disease;
KIRP	trans	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg25214090	chr10:38739885	LOC399744	0.62	7.28	0.42	4.39e-12	Corneal astigmatism;
KIRP	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.74	-10.85	-0.57	1.15e-22	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.6e-6	Total body bone mineral density;
KIRP	cis	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg07460842	chr6:66804631	NA	-0.49	-6.14	-0.36	3.34e-9	Blood trace element (Cu levels);
KIRP	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.85	12.23	0.61	3.42e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs11161851	0.550	rs11162359	chr1:75461044	G/A	cg11196437	chr1:75593865	LHX8	0.5	8.0	0.45	5.05e-14	Visceral fat;
KIRP	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	13.59	0.65	9.33e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs6959887	0.821	rs4723403	chr7:35278466	C/T	cg06685737	chr7:35301730	NA	0.43	6.29	0.37	1.47e-9	Birth weight;
KIRP	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.9	-9.52	-0.52	1.65e-18	Lung cancer in ever smokers;
KIRP	cis	rs1014246	0.784	rs4751610	chr10:118473730	T/C	cg14919929	chr10:118506882	NA	-0.58	-7.51	-0.43	1.09e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs6973256	0.605	rs12707114	chr7:133345207	C/G	cg10665199	chr7:133106180	EXOC4	0.5	6.37	0.38	9.36e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs911119	0.908	rs8114619	chr20:23601813	G/T	cg09631192	chr20:23583594	CST9	-0.49	-5.07	-0.31	7.76e-7	Chronic kidney disease;
KIRP	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.92	10.74	0.57	2.5e-22	Neuroticism;
KIRP	cis	rs1891275	0.515	rs1080496	chr10:93444262	C/T	cg07889827	chr10:93443413	NA	0.43	7.28	0.42	4.55e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4742903	0.967	rs10820599	chr9:106856691	T/G	cg14250997	chr9:106856677	SMC2	0.4	5.18	0.31	4.7e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.91	11.41	0.59	1.78e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs17213078	0.647	rs17279736	chr2:106757365	C/G	cg16099169	chr2:106886729	NA	0.38	4.88	0.3	1.92e-6	Facial morphology (factor 23);
KIRP	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-0.54	-7.59	-0.44	6.58e-13	Coronary artery disease;
KIRP	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg25036284	chr2:26402008	FAM59B	0.52	5.42	0.33	1.41e-7	Gut microbiome composition (summer);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg03498895	chr8:128749851	MYC	0.48	6.06	0.36	5.13e-9	Educational attainment;
KIRP	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg25456186	chr3:108837069	MORC1	0.42	6.08	0.36	4.63e-9	Serum protein levels (sST2);
KIRP	trans	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg25042112	chr7:64838748	ZNF92	0.59	6.13	0.36	3.53e-9	Pain;
KIRP	cis	rs4302748	0.862	rs73335288	chr7:36185070	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs13272623	0.536	rs11985127	chr8:71743943	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.73	6.76	0.4	9.81e-11	IgG glycosylation;
KIRP	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg06212747	chr3:49208901	KLHDC8B	0.68	6.28	0.37	1.5e-9	Menarche (age at onset);
KIRP	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg06636001	chr8:8085503	FLJ10661	0.65	8.93	0.49	1.03e-16	Retinal vascular caliber;
KIRP	cis	rs9394841	0.667	rs71558769	chr6:41782107	T/C	cg08135965	chr6:41755394	TOMM6	0.52	5.62	0.34	5.13e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs10875746	0.551	rs12322347	chr12:48707698	T/G	cg26205652	chr12:48591994	NA	0.8	10.16	0.54	1.73e-20	Longevity (90 years and older);
KIRP	cis	rs7221595	0.673	rs115725560	chr17:3980493	T/A	cg05562828	chr17:3906858	NA	0.57	6.2	0.37	2.39e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.41	0.51	3.62e-18	Morning vs. evening chronotype;
KIRP	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.68	-9.85	-0.53	1.61e-19	Height;
KIRP	cis	rs7845219	0.544	rs34208552	chr8:95908067	C/G	cg16049864	chr8:95962084	TP53INP1	-0.38	-6.01	-0.36	6.57e-9	Type 2 diabetes;
KIRP	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.73	7.98	0.45	5.66e-14	Corneal astigmatism;
KIRP	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.54	-0.48	1.4e-15	Neuroticism;
KIRP	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.72	-7.98	-0.45	5.66e-14	Corneal astigmatism;
KIRP	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.44	5.61	0.34	5.42e-8	Crohn's disease;
KIRP	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05351357	chr22:49932778	NA	-0.35	-4.98	-0.3	1.21e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs9810890	1.000	rs73210611	chr3:128624504	G/A	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs10488172	0.857	rs17167076	chr7:133116871	A/G	cg10665199	chr7:133106180	EXOC4	0.53	5.62	0.34	5.29e-8	Tonometry;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08642814	chr1:3734907	KIAA0562	0.55	6.97	0.41	2.96e-11	Interleukin-4 levels;
KIRP	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg24069376	chr3:38537580	EXOG	0.3	5.07	0.31	7.92e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.09	-0.46	2.76e-14	Migraine;Coronary artery disease;
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg09699651	chr6:150184138	LRP11	0.47	6.06	0.36	4.98e-9	Lung cancer;
KIRP	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	1.01	14.37	0.68	2.09e-34	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg08501292	chr6:25962987	TRIM38	0.79	5.44	0.33	1.31e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg09253696	chr17:73873529	TRIM47	-0.35	-5.54	-0.33	7.85e-8	Psoriasis;
KIRP	cis	rs3741151	0.686	rs7123985	chr11:73260463	A/C	cg17517138	chr11:73019481	ARHGEF17	0.59	5.27	0.32	3.02e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.15	0.42	9.6e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.66	-0.52	6.38e-19	Morning vs. evening chronotype;
KIRP	cis	rs33912345	0.750	rs10138913	chr14:60943106	T/C	cg27398547	chr14:60952738	C14orf39	0.37	4.93	0.3	1.5e-6	Glaucoma (high intraocular pressure);
KIRP	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg05973401	chr12:123451056	ABCB9	0.63	7.61	0.44	5.79e-13	Platelet count;
KIRP	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg15436174	chr10:43711423	RASGEF1A	0.85	9.42	0.51	3.38e-18	Hirschsprung disease;
KIRP	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.63	9.25	0.51	1.11e-17	Carotid intima media thickness;
KIRP	cis	rs11650175	0.687	rs4791134	chr17:63750241	G/A	cg18091269	chr17:63822838	CCDC46	0.32	5.04	0.31	8.94e-7	Chin dimples;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03470939	chr1:19669159	CAPZB	0.47	6.37	0.38	9.3e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.28	-0.42	4.48e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2120243	0.539	rs12629552	chr3:157086630	T/A	cg24825693	chr3:157122686	VEPH1	-0.56	-8.45	-0.47	2.62e-15	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs3026101	0.671	rs1143206	chr17:5284698	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.97	0.36	8.03e-9	Body mass index;
KIRP	cis	rs7849270	0.959	rs913276	chr9:131917164	C/T	cg13538475	chr9:131942899	NA	-0.35	-5.63	-0.34	4.89e-8	Blood metabolite ratios;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg08901578	chr4:187885870	NA	-0.5	-7.53	-0.43	9.67e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg01522456	chr1:115632236	TSPAN2	-0.39	-5.34	-0.32	2.12e-7	Autism;
KIRP	cis	rs10073892	0.664	rs62369689	chr5:101867571	T/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.23	0.37	1.97e-9	Cognitive decline (age-related);
KIRP	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg18357645	chr12:58087776	OS9	-0.53	-5.07	-0.31	7.81e-7	Multiple sclerosis;
KIRP	cis	rs7116495	0.609	rs1548348	chr11:71750917	A/G	cg07596299	chr11:71824057	C11orf51	-0.91	-6.11	-0.36	3.79e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.83	12.91	0.64	1.8e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.71	-8.77	-0.49	2.96e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-5.43	-0.33	1.34e-7	Skin colour saturation;
KIRP	cis	rs6893300	0.961	rs113829727	chr5:179191896	C/T	cg14593053	chr5:179126677	CANX	-0.56	-6.38	-0.38	8.62e-10	Resting heart rate;
KIRP	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg17646820	chr3:66848679	NA	-0.73	-9.76	-0.53	3.1400000000000002e-19	Type 2 diabetes;
KIRP	cis	rs865483	0.895	rs853191	chr17:35821758	A/T	cg06716730	chr17:35851459	DUSP14	0.25	6.04	0.36	5.61e-9	Monocyte count;
KIRP	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs1448094	0.520	rs12304244	chr12:86272823	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.61	0.39	2.3e-10	Major depressive disorder;
KIRP	cis	rs7523273	0.505	rs35438924	chr1:207881489	T/G	cg22525895	chr1:207977042	MIR29B2	0.48	5.78	0.35	2.2e-8	Schizophrenia;
KIRP	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.82	8.89	0.49	1.38e-16	Corneal astigmatism;
KIRP	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg11189052	chr15:85197271	WDR73	-0.45	-5.66	-0.34	4.19e-8	P wave terminal force;
KIRP	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.52	6.49	0.38	4.74e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07874155	chr5:138089656	CTNNA1	0.63	6.98	0.41	2.77e-11	Lung cancer in ever smokers;
KIRP	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg21775007	chr8:11205619	TDH	0.43	5.34	0.32	2.12e-7	Monocyte count;
KIRP	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11987759	chr7:65425863	GUSB	0.44	5.28	0.32	2.85e-7	Aortic root size;
KIRP	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg06640241	chr16:89574553	SPG7	0.65	8.62	0.48	8.11e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg02725872	chr8:58115012	NA	-0.53	-6.08	-0.36	4.47e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22455342	chr2:225449267	CUL3	0.5	5.77	0.35	2.42e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.55	6.66	0.39	1.82e-10	Height;
KIRP	cis	rs687432	0.812	rs10792125	chr11:57782711	A/C	cg19752551	chr11:57585705	CTNND1	0.67	8.81	0.49	2.26e-16	Parkinson's disease;
KIRP	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.41	-5.88	-0.35	1.34e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.59	5.8	0.35	2.04e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-5.0	-0.3	1.08e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.42	5.57	0.33	6.54e-8	IgG glycosylation;
KIRP	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	8.89	0.49	1.3e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7011507	1.000	rs7829616	chr8:49164888	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4812048	0.602	rs59637156	chr20:57619618	T/C	cg14073986	chr20:57617431	SLMO2	0.67	6.34	0.37	1.07e-9	Mean platelet volume;
KIRP	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.35	-0.42	2.91e-12	Fear of minor pain;
KIRP	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	7.05	0.41	1.78e-11	Height;
KIRP	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.83	9.8	0.53	2.38e-19	Prostate-specific antigen levels;
KIRP	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg21775007	chr8:11205619	TDH	-0.52	-6.99	-0.41	2.58e-11	Retinal vascular caliber;
KIRP	cis	rs16858210	0.520	rs34190894	chr3:183550412	A/T	cg03417191	chr3:183542750	MAP6D1	-0.58	-5.86	-0.35	1.51e-8	Menopause (age at onset);
KIRP	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.56	-6.17	-0.37	2.75e-9	Body mass index;
KIRP	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.3	0.62	2.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg03653399	chr8:142233436	SLC45A4	-0.51	-6.37	-0.38	9.12e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg04132472	chr17:19861366	AKAP10	0.38	4.85	0.3	2.22e-6	Schizophrenia;
KIRP	cis	rs6001982	0.667	rs73167079	chr22:40883088	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	4.89	0.3	1.8e-6	Menarche (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24476842	chr12:72179582	RAB21	-0.42	-6.56	-0.39	3.22e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.45	8.68	0.48	5.59e-16	Educational attainment (years of education);
KIRP	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg10189774	chr4:17578691	LAP3	0.51	6.18	0.37	2.59e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs494562	0.892	rs7753711	chr6:86130699	G/T	cg27039625	chr6:86159096	NT5E	-0.42	-5.36	-0.32	1.95e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg21546286	chr11:48923668	NA	-0.47	-6.03	-0.36	6.06e-9	HDL cholesterol;
KIRP	cis	rs2197308	0.585	rs10878014	chr12:38114496	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.06	0.36	4.95e-9	Morning vs. evening chronotype;
KIRP	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.64	0.39	1.98e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.85	0.3	2.2e-6	Menopause (age at onset);
KIRP	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs10131728	1.000	rs12880414	chr14:81705090	A/G	cg01989461	chr14:81687754	GTF2A1	-0.73	-5.89	-0.35	1.25e-8	IgG glycosylation;
KIRP	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg23166289	chr1:210001082	C1orf107	0.52	6.01	0.36	6.71e-9	Orofacial clefts;
KIRP	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg13385521	chr17:29058706	SUZ12P	0.76	6.65	0.39	1.85e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg12292205	chr6:26970375	C6orf41	-0.62	-7.16	-0.42	9.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs467650	0.509	rs29768	chr5:97981447	A/G	cg12450016	chr5:98112437	RGMB	0.4	5.16	0.31	5.21e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.5	-4.94	-0.3	1.41e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	1.0	17.16	0.74	6.23e-44	Menopause (age at onset);
KIRP	cis	rs7520050	0.966	rs11211234	chr1:46438787	C/A	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1497828	0.956	rs2646821	chr1:217528236	C/T	cg04411442	chr1:217543379	NA	-0.4	-6.27	-0.37	1.57e-9	Dialysis-related mortality;
KIRP	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26526719	chr5:1949144	NA	0.43	5.21	0.32	3.95e-7	Gut microbiome composition (winter);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06508976	chr9:131940586	IER5L	-0.48	-6.07	-0.36	4.89e-9	Neuroticism;
KIRP	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg11584989	chr19:19387371	SF4	-0.55	-5.81	-0.35	1.94e-8	Bipolar disorder;
KIRP	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.72	9.28	0.51	9.31e-18	Bladder cancer;
KIRP	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-9.82	-0.53	2.06e-19	Morning vs. evening chronotype;
KIRP	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.45	-5.21	-0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10782582	0.758	rs11161887	chr1:76386305	A/G	cg10523679	chr1:76189770	ACADM	0.4	5.75	0.34	2.66e-8	Daytime sleep phenotypes;
KIRP	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4851266	0.933	rs6709656	chr2:100806719	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.0	-0.3	1.1e-6	Educational attainment;
KIRP	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	11.9	0.6	4.41e-26	Mean corpuscular hemoglobin;
KIRP	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg21475434	chr5:93447410	FAM172A	0.43	4.96	0.3	1.32e-6	Diabetic retinopathy;
KIRP	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.41	-5.2	-0.31	4.11e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.8	9.14	0.5	2.33e-17	Breast cancer;
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	9.26	0.51	1.05e-17	Alzheimer's disease;
KIRP	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.37	0.43	2.65e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs897080	0.552	rs1067323	chr2:44630018	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.02	0.36	6.29e-9	Height;
KIRP	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.42	-5.0	-0.3	1.1e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs12690897	0.744	rs3934484	chr7:85342835	T/A	cg25658385	chr6:35265341	DEF6	-0.34	-6.1	-0.36	3.98e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs4908768	0.906	rs74324642	chr1:8620172	A/C	cg25722041	chr1:8623473	RERE	0.81	10.13	0.54	2.17e-20	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.95	15.99	0.71	6.1e-40	Menopause (age at onset);
KIRP	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-1.04	-13.71	-0.66	3.76e-32	Exhaled nitric oxide output;
KIRP	cis	rs4234798	1.000	rs4234798	chr4:7219933	G/T	cg18431297	chr4:7219810	SORCS2	-0.66	-8.72	-0.49	4.1e-16	Insulin-like growth factors;
KIRP	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	5.75	0.34	2.62e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.85	0.3	2.21e-6	Menopause (age at onset);
KIRP	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.73	-9.84	-0.53	1.73e-19	Blood metabolite levels;
KIRP	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.6	7.71	0.44	3.11e-13	Breast cancer;
KIRP	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg13259177	chr13:114761607	RASA3	-0.75	-7.6	-0.44	6.18e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg09631192	chr20:23583594	CST9	-0.52	-5.17	-0.31	4.9e-7	Chronic kidney disease;
KIRP	cis	rs239198	0.602	rs9377236	chr6:101289960	A/G	cg09795085	chr6:101329169	ASCC3	0.49	5.7	0.34	3.41e-8	Menarche (age at onset);
KIRP	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.03	-0.5	5.09e-17	Chronic sinus infection;
KIRP	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-7.19	-0.42	7.69e-12	Retinal vascular caliber;
KIRP	cis	rs4273100	1.000	rs4924986	chr17:19242467	C/T	cg18093559	chr17:18951025	GRAP	0.53	5.27	0.32	2.94e-7	Schizophrenia;
KIRP	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg21433313	chr16:3507492	NAT15	0.53	7.38	0.43	2.38e-12	Tuberculosis;
KIRP	cis	rs9398803	0.687	rs1269195	chr6:127031550	C/T	cg19875578	chr6:126661172	C6orf173	-0.42	-5.37	-0.32	1.78e-7	Male-pattern baldness;
KIRP	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05665937	chr4:1216051	CTBP1	0.58	8.07	0.46	3.19e-14	Obesity-related traits;
KIRP	cis	rs2213920	0.679	rs6478168	chr9:118225951	A/T	cg13918206	chr9:118159781	DEC1	0.99	9.95	0.54	8.14e-20	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.57	-5.34	-0.32	2.07e-7	Schizophrenia;
KIRP	cis	rs981844	1.000	rs62325092	chr4:154668674	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg22368619	chr19:3730505	TJP3	0.46	6.32	0.37	1.2e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg04691961	chr3:161091175	C3orf57	-0.44	-5.7	-0.34	3.4e-8	Morning vs. evening chronotype;
KIRP	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.93	14.18	0.67	8.93e-34	Mean platelet volume;
KIRP	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07570687	chr10:102243282	WNT8B	0.55	7.22	0.42	6.53e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.66	-9.04	-0.5	4.78e-17	Educational attainment;
KIRP	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.29	-0.32	2.75e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg06637938	chr14:75390232	RPS6KL1	0.54	7.45	0.43	1.62e-12	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg03159124	chr18:7118077	LAMA1	0.46	6.39	0.38	8.13e-10	Inflammatory biomarkers;
KIRP	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.93	15.35	0.7	9.03e-38	Metabolic syndrome;
KIRP	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.8	-6.65	-0.39	1.87e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-6.16	-0.37	2.9e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8084125	0.832	rs56301307	chr18:74942711	A/G	cg26065057	chr18:74961000	GALR1	0.61	6.22	0.37	2.14e-9	Obesity-related traits;
KIRP	cis	rs7614311	0.681	rs6801346	chr3:63947128	A/G	cg22134162	chr3:63841271	THOC7	0.48	6.08	0.36	4.55e-9	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs17592366	0.838	rs7158310	chr14:35340044	T/C	cg09327582	chr14:35236912	BAZ1A	0.68	5.19	0.31	4.46e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg25063058	chr15:52860530	ARPP19	-0.6	-6.03	-0.36	5.84e-9	Schizophrenia;
KIRP	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.52	-0.38	3.96e-10	Triglycerides;
KIRP	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg15832292	chr6:96025679	MANEA	0.77	6.96	0.41	3.07e-11	Behavioural disinhibition (generation interaction);
KIRP	trans	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg08400319	chr2:242004533	SNED1	0.46	6.44	0.38	6.2e-10	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.46	-4.95	-0.3	1.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8077577	0.747	rs11872031	chr17:18150814	G/A	cg18869244	chr17:18121946	NA	0.47	5.36	0.32	1.9e-7	Obesity-related traits;
KIRP	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg06740227	chr12:86229804	RASSF9	0.46	5.87	0.35	1.42e-8	Major depressive disorder;
KIRP	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg16141378	chr3:129829833	LOC729375	0.49	6.1	0.36	4.17e-9	Joint mobility (Beighton score);
KIRP	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg02461776	chr11:598696	PHRF1	0.68	7.29	0.42	4.2e-12	Systemic lupus erythematosus;
KIRP	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.29	-0.37	1.44e-9	Response to antipsychotic treatment;
KIRP	cis	rs41005	0.597	rs35400177	chr2:8101757	C/T	cg03155496	chr2:8117019	LOC339788	-0.47	-6.7	-0.39	1.42e-10	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.94	15.66	0.71	7.84e-39	Menarche (age at onset);
KIRP	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg08975724	chr8:8085496	FLJ10661	0.53	5.94	0.35	9.44e-9	Neuroticism;
KIRP	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2839627	0.561	rs8126478	chr21:44318668	C/A	cg03543861	chr21:44258195	NA	0.54	5.98	0.36	7.62e-9	Information processing speed;
KIRP	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg02931644	chr1:25747376	RHCE	0.35	6.43	0.38	6.47e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.65	9.46	0.52	2.61e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg02612397	chr6:125855124	NA	-0.33	-4.94	-0.3	1.46e-6	Brugada syndrome;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14305139	chr8:142180543	DENND3	-0.44	-6.19	-0.37	2.52e-9	Survival in pancreatic cancer;
KIRP	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.45	-5.34	-0.32	2.14e-7	Body mass index;
KIRP	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.38	-0.32	1.7e-7	Alzheimer's disease (late onset);
KIRP	cis	rs6568686	0.577	rs174400	chr6:111922979	A/G	cg22127309	chr6:111907043	TRAF3IP2	0.55	5.18	0.31	4.73e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.02	-0.36	6.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.24	14.26	0.67	5.12e-34	Eosinophil percentage of granulocytes;
KIRP	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.7	0.68	1.59e-35	Platelet count;
KIRP	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.72	9.64	0.52	7.51e-19	Hepatocellular carcinoma;
KIRP	cis	rs6832769	0.925	rs3817444	chr4:56375981	A/C	cg09317128	chr4:56265301	TMEM165	0.55	7.01	0.41	2.27e-11	Personality dimensions;
KIRP	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.99	8.67	0.48	5.79e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.42	6.06	0.36	5.18e-9	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg04398451	chr17:18023971	MYO15A	0.66	9.15	0.5	2.18e-17	Total body bone mineral density;
KIRP	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs72960926	0.744	rs7755776	chr6:74967405	C/G	cg03266952	chr6:74778945	NA	0.6	4.86	0.3	2.08e-6	Metabolite levels (MHPG);
KIRP	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.08	-20.54	-0.79	2.82e-55	Colorectal cancer;
KIRP	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-1.16	-21.61	-0.81	9.02e-59	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg15655495	chr12:38532458	NA	0.25	4.93	0.3	1.49e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.85	13.61	0.66	8.17e-32	Dental caries;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24170687	chr15:57598683	LOC283663	0.46	6.2	0.37	2.43e-9	Parkinson's disease;
KIRP	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07570687	chr10:102243282	WNT8B	0.5	6.48	0.38	5.07e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.8	-10.92	-0.57	6.58e-23	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg00405596	chr8:11794950	NA	-0.47	-6.41	-0.38	7.58e-10	Joint mobility (Beighton score);
KIRP	cis	rs7221595	0.825	rs10521127	chr17:3978268	A/G	cg05562828	chr17:3906858	NA	0.57	6.22	0.37	2.11e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9323205	0.834	rs12434435	chr14:51667524	G/T	cg23942311	chr14:51606299	NA	0.57	6.86	0.4	5.66e-11	Cancer;
KIRP	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.56	-7.42	-0.43	1.93e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.64	-9.38	-0.51	4.44e-18	Body mass index;
KIRP	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.63	9.63	0.52	8.01e-19	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg13902645	chr11:5959945	NA	-0.6	-6.31	-0.37	1.26e-9	DNA methylation (variation);
KIRP	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs16828019	0.852	rs12742379	chr1:41526381	A/G	cg24596898	chr1:41849189	NA	0.61	5.0	0.3	1.09e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13427428	chr8:77617480	ZFHX4	0.48	6.46	0.38	5.66e-10	Interleukin-4 levels;
KIRP	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg08992911	chr2:238395768	MLPH	0.44	5.59	0.34	6.08e-8	Prostate cancer;
KIRP	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	1.09	11.27	0.58	4.92e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg18850127	chr7:39170497	POU6F2	0.28	5.51	0.33	8.95e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.4	4.92	0.3	1.55e-6	Tonsillectomy;
KIRP	trans	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg18187862	chr3:45730750	SACM1L	0.51	6.06	0.36	5.08e-9	Primary sclerosing cholangitis;
KIRP	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs9436747	0.585	rs6662904	chr1:65997740	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.53	5.65	0.34	4.46e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.66	6.97	0.41	2.86e-11	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	1.01	14.55	0.68	5.1e-35	Height;
KIRP	cis	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg26585981	chr11:48327164	OR4S1	0.52	6.33	0.37	1.14e-9	Migraine - clinic-based;
KIRP	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19671926	chr4:122722719	EXOSC9	0.49	5.91	0.35	1.11e-8	Type 2 diabetes;
KIRP	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.81	-11.34	-0.59	2.98e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.61	-0.39	2.33e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14625770	chr9:104295276	RNF20	0.5	6.73	0.39	1.2e-10	Interleukin-4 levels;
KIRP	cis	rs3026101	0.671	rs8077933	chr17:5299674	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg19749445	chr14:92493378	TRIP11	-0.47	-6.35	-0.38	1.04e-9	Inflammatory biomarkers;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.61	0.39	2.35e-10	Electroencephalogram traits;
KIRP	cis	rs17459044	1	rs17459044	chr9:131853624	C/T	cg13538475	chr9:131942899	NA	-0.37	-5.78	-0.35	2.28e-8	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-8.7	-0.49	4.81e-16	Response to antipsychotic treatment;
KIRP	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.0	-11.22	-0.58	7.37e-24	Body mass index;
KIRP	trans	rs12967678	1	rs12967678	chr18:12805388	G/A	cg02009311	chr17:79886614	LOC92659;MAFG	-0.72	-6.08	-0.36	4.56e-9	Selective IgA deficiency;
KIRP	cis	rs6662572	0.703	rs4660890	chr1:46297452	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.59	-0.34	5.89e-8	Blood protein levels;
KIRP	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.88	-11.75	-0.6	1.36e-25	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg24375607	chr4:120327624	NA	0.66	7.79	0.45	1.82e-13	Corneal astigmatism;
KIRP	cis	rs1569175	1.000	rs17591301	chr2:200854215	A/G	cg17644776	chr2:200775616	C2orf69	-0.67	-5.07	-0.31	7.79e-7	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.94	-16.23	-0.72	9.52e-41	Height;
KIRP	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.46	-4.84	-0.3	2.26e-6	Fibroblast growth factor basic levels;
KIRP	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	7.02	0.41	2.18e-11	Retinal vascular caliber;
KIRP	cis	rs2224391	0.628	rs2773309	chr6:5248916	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.66	-0.39	1.77e-10	Height;
KIRP	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg16110827	chr15:48056943	SEMA6D	-0.36	-4.85	-0.3	2.23e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs34779708	0.898	rs11595898	chr10:35326263	T/C	cg03585969	chr10:35415529	CREM	0.8	9.71	0.53	4.34e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.8	11.73	0.6	1.55e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg15691649	chr6:25882328	NA	-0.46	-5.68	-0.34	3.7e-8	Blood metabolite levels;
KIRP	trans	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.35	-0.47	5.08e-15	Retinal vascular caliber;
KIRP	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg23601095	chr6:26197514	HIST1H3D	0.98	8.28	0.47	8.02e-15	Gout;Renal underexcretion gout;
KIRP	trans	rs1106684	0.925	rs1477225	chr7:131454962	T/A	cg13607082	chr12:122652224	LRRC43	-0.6	-6.29	-0.37	1.48e-9	Body mass index;
KIRP	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.5	-0.59	8.96e-25	Breast cancer;
KIRP	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22496380	chr5:211416	CCDC127	-0.64	-4.98	-0.3	1.18e-6	Asthma (childhood onset);
KIRP	cis	rs6504340	0.739	rs4793939	chr17:46665235	G/A	cg05487507	chr17:46671861	LOC404266;HOXB5	0.57	6.54	0.38	3.59e-10	Primary tooth development (number of teeth);
KIRP	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.72	-9.24	-0.51	1.19e-17	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1978968	1.000	rs7286219	chr22:18445709	G/C	cg03078520	chr22:18463400	MICAL3	-0.66	-7.79	-0.44	1.84e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs4006360	0.531	rs7502102	chr17:39307041	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-6.52	-0.38	3.88e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.44	6.67	0.39	1.66e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg21361702	chr7:150065534	REPIN1	0.7	7.34	0.42	3.08e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.75	6.48	0.38	4.99e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg20368463	chr18:77673604	PQLC1	0.71	6.37	0.38	9.31e-10	Opioid sensitivity;
KIRP	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	14.8	0.69	6.86e-36	Alzheimer's disease;
KIRP	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg23202291	chr11:1979235	NA	0.42	5.41	0.33	1.51e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.43e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs4349753	0.904	rs693443	chr5:144181430	G/A	cg16033277	chr17:80885358	TBCD	0.41	6.29	0.37	1.44e-9	Photic sneeze reflex;
KIRP	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.58	-7.57	-0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg16306078	chr6:126000798	NA	0.26	4.95	0.3	1.37e-6	Endometrial cancer;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.6	-6.82	-0.4	7.06e-11	Bipolar disorder;
KIRP	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	6.05	0.36	5.27e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg02138098	chr1:2040968	PRKCZ	-0.45	-6.16	-0.37	2.94e-9	Height;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.39	-0.51	4.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.6	8.3	0.47	7.12e-15	Blood protein levels;
KIRP	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.46	-5.59	-0.34	5.93e-8	Testicular germ cell tumor;
KIRP	trans	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.69	8.89	0.49	1.36e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.39	-6.53	-0.38	3.64e-10	Bone mineral density;
KIRP	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.61	7.75	0.44	2.47e-13	Height;
KIRP	cis	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg21546286	chr11:48923668	NA	-0.49	-6.29	-0.37	1.41e-9	HDL cholesterol;
KIRP	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.68	-7.05	-0.41	1.8e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.2	21.77	0.81	2.68e-59	Cognitive function;
KIRP	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.66	-6.8	-0.4	8.11e-11	Corneal structure;
KIRP	cis	rs1620921	0.505	rs2115870	chr6:161207992	A/G	cg01280913	chr6:161186852	NA	-0.62	-8.55	-0.48	1.31e-15	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.41	6.86	0.4	5.5e-11	Huntington's disease progression;
KIRP	cis	rs228437	0.913	rs11154779	chr6:134909194	T/C	cg24504307	chr6:134963096	NA	-0.38	-5.93	-0.35	1.03e-8	Melanoma;
KIRP	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg19773385	chr1:10388646	KIF1B	-0.72	-11.11	-0.58	1.63e-23	Hepatocellular carcinoma;
KIRP	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg05347473	chr6:146136440	FBXO30	0.59	8.45	0.47	2.62e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.92	-0.4	3.84e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19176816	chr10:112679255	NCRNA00081;SHOC2	0.44	6.17	0.37	2.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg14346243	chr4:90757452	SNCA	-0.42	-5.19	-0.31	4.41e-7	Neuroticism;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.5	6.88	0.4	5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg12435725	chr3:58293450	RPP14	-0.54	-5.67	-0.34	4e-8	Cholesterol, total;
KIRP	cis	rs7976059	0.895	rs73109568	chr12:52249003	A/C	cg27042523	chr12:52245356	NA	0.76	11.5	0.59	9.14e-25	Urate levels;
KIRP	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-8.82	-0.49	2.17e-16	Cognitive function;
KIRP	cis	rs3087591	0.708	rs10445402	chr17:29661340	G/T	cg24425628	chr17:29625626	OMG;NF1	0.63	9.23	0.51	1.28e-17	Hip circumference;
KIRP	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-0.89	-9.72	-0.53	4.28e-19	Gut microbiome composition (summer);
KIRP	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.66	9.4	0.51	3.87e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg02415014	chr8:143852576	LYNX1	-0.31	-4.9	-0.3	1.74e-6	Urinary tract infection frequency;
KIRP	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.75	10.54	0.56	1.15e-21	Red blood cell count;
KIRP	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14598338	chr9:96623480	NA	-0.67	-11.42	-0.59	1.63e-24	DNA methylation (variation);
KIRP	cis	rs1056053	0.539	rs3099270	chr6:166571525	T/C	cg11088901	chr6:166572345	T	-0.5	-7.02	-0.41	2.15e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.37	0.43	2.51e-12	Neuroticism;
KIRP	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-6.34	-0.37	1.07e-9	Myopia (pathological);
KIRP	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	trans	rs2548003	0.518	rs2548015	chr5:28726109	A/C	cg23224356	chr2:98206733	ANKRD36B	0.61	6.06	0.36	5.14e-9	Hip geometry;
KIRP	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	8.64	0.48	7.21e-16	Resting heart rate;
KIRP	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.72	9.19	0.51	1.7e-17	Bladder cancer;
KIRP	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg04691961	chr3:161091175	C3orf57	-0.67	-10.97	-0.57	4.82e-23	Morning vs. evening chronotype;
KIRP	cis	rs8022179	0.580	rs8013228	chr14:103842650	A/G	cg16497661	chr14:103986332	CKB	0.48	5.67	0.34	4.02e-8	Monocyte count;
KIRP	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.75	-10.63	-0.56	5.74e-22	Bipolar disorder and schizophrenia;
KIRP	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	0.99	15.92	0.71	1.09e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.45	5.82	0.35	1.83e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs76288851	0.733	rs4292191	chr3:126682227	C/T	cg13821433	chr2:26726535	OTOF	0.57	6.2	0.37	2.38e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07080220	chr10:102295463	HIF1AN	0.8	7.75	0.44	2.46e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4474465	0.541	rs10736814	chr11:78286462	C/G	cg02023728	chr11:77925099	USP35	-0.34	-5.2	-0.31	4.16e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg09655341	chr17:79618100	PDE6G	-0.34	-5.53	-0.33	8.05e-8	Eye color traits;
KIRP	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12311346	chr5:56204834	C5orf35	-0.46	-5.85	-0.35	1.56e-8	Coronary artery disease;
KIRP	cis	rs1538970	0.962	rs7532762	chr1:45864695	C/A	cg05343316	chr1:45956843	TESK2	0.58	6.89	0.4	4.66e-11	Platelet count;
KIRP	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg22974920	chr21:40686053	BRWD1	0.49	5.71	0.34	3.25e-8	Cognitive function;
KIRP	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg10189774	chr4:17578691	LAP3	-0.44	-5.02	-0.3	1.01e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.550	rs6901017	chr6:28152583	T/C	cg26335602	chr6:28129616	ZNF389	0.46	5.13	0.31	5.79e-7	Depression;
KIRP	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.64	0.48	7.4e-16	Motion sickness;
KIRP	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg27490568	chr2:178487706	NA	0.51	6.9	0.4	4.34e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	cg21523751	chr1:182988639	NA	-0.47	-7.33	-0.42	3.4e-12	Colorectal cancer;
KIRP	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg07274523	chr3:49395745	GPX1	0.69	8.5	0.48	1.89e-15	Intelligence (multi-trait analysis);Educational attainment (years of education);
KIRP	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg03714773	chr7:91764589	CYP51A1	0.33	4.92	0.3	1.6e-6	Breast cancer;
KIRP	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg27490568	chr2:178487706	NA	0.47	6.38	0.38	8.62e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.56	6.23	0.37	2.05e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.91	13.42	0.65	3.43e-31	Mean platelet volume;
KIRP	cis	rs9308731	1.000	rs9308731	chr2:111908262	G/A	cg23466623	chr2:111982296	NA	-0.44	-5.52	-0.33	8.41e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg07653901	chr22:50250238	ZBED4	0.44	5.28	0.32	2.87e-7	Schizophrenia;
KIRP	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.44	-0.33	1.27e-7	Neutrophil percentage of white cells;
KIRP	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.43	-5.71	-0.34	3.17e-8	Type 2 diabetes;
KIRP	cis	rs138171347	1	rs138171347	chr17:5183203	AAAAT/A	cg24500398	chr17:5266808	RABEP1	-0.45	-6.85	-0.4	5.76e-11	White blood cell count;
KIRP	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.77	12.47	0.62	5.7e-28	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs4765905	0.610	rs10459125	chr12:2309864	C/T	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.92	-0.4	3.98e-11	Schizophrenia;
KIRP	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.69	-10.55	-0.56	1.07e-21	Paraoxonase activity;
KIRP	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	11.26	0.58	5.59e-24	Personality dimensions;
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg10505658	chr17:80084571	CCDC57	-0.26	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs71403859	0.667	rs12149264	chr16:71720921	T/G	cg08717414	chr16:71523259	ZNF19	-0.93	-8.12	-0.46	2.21e-14	Post bronchodilator FEV1;
KIRP	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg04865290	chr3:52927548	TMEM110	-0.62	-6.22	-0.37	2.17e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg18944383	chr4:111397179	ENPEP	-0.39	-6.18	-0.37	2.59e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.57	8.35	0.47	4.91e-15	Bone mineral density;
KIRP	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.33	0.32	2.23e-7	Personality dimensions;
KIRP	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg20253172	chr1:3107290	PRDM16	0.51	6.36	0.38	9.51e-10	Migraine;
KIRP	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.9	-13.63	-0.66	6.97e-32	Heart rate;
KIRP	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.42	6.76	0.4	1e-10	Migraine;
KIRP	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.44	-5.95	-0.35	8.99e-9	Coronary artery disease;
KIRP	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.16e-7	Aortic root size;
KIRP	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg23205692	chr1:25664452	TMEM50A	-0.35	-4.88	-0.3	1.95e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs918629	0.530	rs1423269	chr5:95255724	A/G	cg16656078	chr5:95278638	ELL2	-0.36	-5.52	-0.33	8.8e-8	IgG glycosylation;
KIRP	cis	rs9513593	1.000	rs9300540	chr13:100018225	T/A	cg21788972	chr13:99853209	UBAC2	0.6	6.34	0.37	1.08e-9	Psoriasis;
KIRP	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.81	11.24	0.58	6.26e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg10434728	chr15:90938212	IQGAP1	0.32	5.39	0.32	1.68e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6142102	1.000	rs4911409	chr20:32710710	G/A	cg08999081	chr20:33150536	PIGU	0.54	6.97	0.41	2.87e-11	Skin pigmentation;
KIRP	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.66	9.47	0.52	2.4e-18	Alcohol dependence;
KIRP	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg24476569	chr13:95954382	ABCC4	-0.6	-9.23	-0.51	1.26e-17	Blood metabolite levels;
KIRP	cis	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg00405596	chr8:11794950	NA	-0.51	-6.64	-0.39	2.03e-10	Triglycerides;
KIRP	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg04731861	chr2:219085781	ARPC2	0.21	5.2	0.31	4.23e-7	Colorectal cancer;
KIRP	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.55	5.81	0.35	1.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.96	-15.24	-0.7	2.17e-37	Height;
KIRP	cis	rs15676	0.783	rs10988121	chr9:131564926	A/T	cg00228799	chr9:131580591	ENDOG	-0.49	-4.99	-0.3	1.14e-6	Blood metabolite levels;
KIRP	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.49	-5.8	-0.35	2.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg10932868	chr11:921992	NA	0.55	7.01	0.41	2.25e-11	Alzheimer's disease (late onset);
KIRP	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.96	15.95	0.71	8.53e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.58	-7.26	-0.42	5.13e-12	Iron status biomarkers;
KIRP	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg26248373	chr2:1572462	NA	-0.62	-5.82	-0.35	1.86e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg10845886	chr2:3471009	TTC15	0.55	7.81	0.45	1.65e-13	Neurofibrillary tangles;
KIRP	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg12559939	chr2:27858050	GPN1	-0.45	-5.71	-0.34	3.28e-8	Oral cavity cancer;
KIRP	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.62	9.43	0.52	3.12e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	1.03	14.21	0.67	7.47e-34	Menopause (age at onset);
KIRP	trans	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg00806126	chr19:22604979	ZNF98	-0.64	-6.86	-0.4	5.4e-11	Pain;
KIRP	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg20701182	chr2:24300061	SF3B14	0.61	5.18	0.31	4.68e-7	Lymphocyte counts;
KIRP	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05601917	chr6:125855416	NA	0.33	5.02	0.3	9.81e-7	Brugada syndrome;
KIRP	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg23815491	chr16:72088622	HP	0.44	6.53	0.38	3.65e-10	Blood protein levels;
KIRP	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.77	9.75	0.53	3.29e-19	Aortic root size;
KIRP	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18252515	chr7:66147081	NA	0.42	4.91	0.3	1.64e-6	Aortic root size;
KIRP	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg16479474	chr6:28041457	NA	-0.45	-5.03	-0.31	9.48e-7	Depression;
KIRP	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.57	7.58	0.43	7.19e-13	Depressive symptoms;
KIRP	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.7	-7.66	-0.44	4.2e-13	DNA methylation (variation);
KIRP	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg06050784	chr16:88016603	BANP	0.43	5.53	0.33	8.31e-8	Menopause (age at onset);
KIRP	cis	rs4819052	0.851	rs11558445	chr21:46685175	A/G	cg11663144	chr21:46675770	NA	-0.63	-9.11	-0.5	2.91e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg07001201	chr5:642380	CEP72	0.64	6.04	0.36	5.73e-9	Obesity-related traits;
KIRP	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg18350739	chr11:68623251	NA	-0.47	-7.23	-0.42	6.23e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg23460707	chr10:133558971	NA	0.36	5.45	0.33	1.22e-7	Survival in rectal cancer;
KIRP	cis	rs4664293	1.000	rs4664293	chr2:160505752	T/C	cg08347373	chr2:160653686	CD302	-0.39	-5.95	-0.35	9e-9	Monocyte percentage of white cells;
KIRP	cis	rs2573652	1.000	rs7163481	chr15:100516916	C/G	cg09918751	chr15:100517450	ADAMTS17	0.72	10.5	0.56	1.45e-21	Height;
KIRP	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg09699651	chr6:150184138	LRP11	0.53	7.1	0.41	1.34e-11	Lung cancer;
KIRP	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.48	-5.86	-0.35	1.47e-8	Asthma (sex interaction);
KIRP	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	6.39	0.38	8.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.45	-9.58	-0.52	1.1e-18	Mean corpuscular volume;
KIRP	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.56	-6.27	-0.37	1.61e-9	Menarche (age at onset);
KIRP	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.18	0.51	1.85e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7998202	0.667	rs282587	chr13:113351662	G/A	cg01025720	chr13:113346439	ATP11A	0.51	4.84	0.3	2.25e-6	Glycated hemoglobin levels;
KIRP	cis	rs4006360	0.632	rs4986668	chr17:39250408	T/G	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.63	8.69	0.48	5.32e-16	Lymphocyte counts;
KIRP	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-8.84	-0.49	1.85e-16	Schizophrenia;
KIRP	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs7941030	0.902	rs7101940	chr11:122534810	A/G	cg20555462	chr11:122535518	UBASH3B	-0.43	-5.39	-0.33	1.63e-7	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs10518128	0.850	rs28719716	chr4:75707675	T/G	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.6	7.9	0.45	9.44e-14	Pancreatic cancer;
KIRP	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	5.93	0.35	1.02e-8	Type 2 diabetes;
KIRP	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	9.43	0.52	3.18e-18	Post bronchodilator FEV1;
KIRP	cis	rs13102973	0.645	rs7692242	chr4:135886041	A/G	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg27432699	chr2:27873401	GPN1	-0.51	-6.81	-0.4	7.39e-11	Menopause (age at onset);
KIRP	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.66	7.1	0.41	1.37e-11	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02475777	chr4:1388615	CRIPAK	0.5	7.16	0.42	9.2e-12	Longevity;
KIRP	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg09201719	chr10:104596890	CYP17A1	0.35	4.91	0.3	1.68e-6	Arsenic metabolism;
KIRP	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.59	-7.08	-0.41	1.52e-11	Coffee consumption (cups per day);
KIRP	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg23594656	chr7:65796392	TPST1	-0.34	-5.04	-0.31	9.12e-7	Calcium levels;
KIRP	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	1.09	19.89	0.79	3.85e-53	Monocyte count;
KIRP	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.55	7.4	0.43	2.1e-12	Mean corpuscular volume;
KIRP	cis	rs12282928	1.000	rs2134554	chr11:48262351	C/T	cg26585981	chr11:48327164	OR4S1	-0.52	-6.29	-0.37	1.44e-9	Migraine - clinic-based;
KIRP	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg07001201	chr5:642380	CEP72	0.69	6.47	0.38	5.38e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg00784671	chr22:46762841	CELSR1	-0.87	-8.41	-0.47	3.47e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6681460	1.000	rs10789210	chr1:67066030	G/A	cg02459107	chr1:67143332	SGIP1	0.47	6.63	0.39	2.13e-10	Presence of antiphospholipid antibodies;
KIRP	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg08975724	chr8:8085496	FLJ10661	-0.69	-8.96	-0.5	8.29e-17	Neuroticism;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10248492	chr1:228647248	NA	0.49	6.28	0.37	1.51e-9	Inflammatory biomarkers;
KIRP	cis	rs6541297	0.699	rs966333	chr1:230305477	T/C	cg20703242	chr1:230279135	GALNT2	0.33	5.06	0.31	8.37e-7	Coronary artery disease;
KIRP	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg10755058	chr3:40428713	ENTPD3	0.34	4.88	0.3	1.9e-6	Renal cell carcinoma;
KIRP	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg25801113	chr15:45476975	SHF	0.43	8.06	0.46	3.28e-14	Uric acid levels;
KIRP	cis	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.03	-0.64	7.39e-30	Height;
KIRP	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg23920097	chr1:209922102	NA	0.42	5.1	0.31	6.82e-7	Red blood cell count;
KIRP	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg08499158	chr17:42289980	UBTF	-0.56	-7.26	-0.42	5.03e-12	Total body bone mineral density;
KIRP	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.8	12.29	0.62	2.26e-27	Ulcerative colitis;
KIRP	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg03235661	chr20:60525775	NA	-0.31	-5.23	-0.32	3.58e-7	Body mass index;
KIRP	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg05370193	chr1:21551575	ECE1	0.45	6.26	0.37	1.67e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.79	-0.35	2.12e-8	Parkinson's disease;
KIRP	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.56	7.45	0.43	1.63e-12	Colorectal cancer;
KIRP	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.52	6.17	0.37	2.84e-9	Parkinson's disease;
KIRP	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg23950597	chr19:37808831	NA	-0.64	-6.91	-0.4	4.23e-11	Coronary artery calcification;
KIRP	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.25	-6.45	-0.38	5.85e-10	Primary biliary cholangitis;
KIRP	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.46	6.88	0.4	4.93e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14042203	chr11:58939802	DTX4	0.49	6.48	0.38	4.87e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.95	-14.7	-0.68	1.58e-35	Height;
KIRP	cis	rs984222	0.508	rs2645303	chr1:119555146	G/T	cg18261050	chr1:119551319	NA	0.34	4.95	0.3	1.39e-6	Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;
KIRP	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.67	-11.0	-0.57	3.76e-23	Urate levels in overweight individuals;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg16386488	chr15:63178693	NA	0.43	6.1	0.36	4.06e-9	Migraine with aura;
KIRP	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.44	5.17	0.31	4.74e-7	Iron status biomarkers;
KIRP	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg02023728	chr11:77925099	USP35	0.29	5.04	0.31	8.95e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2025151	0.591	rs10990610	chr9:99100713	T/C	cg25260653	chr9:99212216	HABP4	0.53	4.9	0.3	1.73e-6	Height;
KIRP	cis	rs1816752	0.819	rs7317504	chr13:24985425	C/T	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01074628	chr11:74204917	LIPT2	0.7	6.5	0.38	4.38e-10	Lung function (FEV1);
KIRP	cis	rs6701037	1.000	rs34493921	chr1:175122759	A/G	cg08873628	chr1:175162347	KIAA0040	-0.36	-5.24	-0.32	3.39e-7	Alcohol dependence;
KIRP	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.72	9.25	0.51	1.12e-17	Dental caries;
KIRP	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6693567	0.565	rs1313570	chr1:150342642	T/C	cg07843065	chr1:150265600	MRPS21	0.43	6.0	0.36	7.03e-9	Migraine;
KIRP	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.61	5.23	0.32	3.61e-7	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02894226	chr20:3190561	ITPA	0.58	6.9	0.4	4.28e-11	Smoking initiation;
KIRP	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	1.24	14.26	0.67	4.76e-34	Eosinophil percentage of granulocytes;
KIRP	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg04132472	chr17:19861366	AKAP10	0.68	10.55	0.56	1.02e-21	Schizophrenia;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg00738919	chr7:1100172	C7orf50	0.44	5.1	0.31	6.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg02151108	chr14:50098012	C14orf104	-0.57	-7.99	-0.45	5.24e-14	Carotid intima media thickness;
KIRP	cis	rs12496230	0.700	rs13078081	chr3:66852901	T/C	cg23477460	chr3:66848765	NA	0.47	5.69	0.34	3.57e-8	Type 2 diabetes;
KIRP	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg21926883	chr2:100939477	LONRF2	-0.58	-7.81	-0.45	1.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.87	13.71	0.66	3.62e-32	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03655016	chr12:49453990	NA	0.5	6.53	0.38	3.66e-10	Parkinson's disease;
KIRP	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-0.41	-5.07	-0.31	7.65e-7	Type 2 diabetes;
KIRP	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg13877915	chr19:58951672	ZNF132	0.6	5.85	0.35	1.54e-8	Mean platelet volume;
KIRP	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-5.99	-0.36	7.21e-9	Asthma;
KIRP	cis	rs4849845	0.889	rs4564775	chr2:121044454	T/C	cg24070213	chr2:121070622	NA	0.39	5.4	0.33	1.6e-7	Mean platelet volume;
KIRP	cis	rs1867631	0.585	rs12062570	chr1:67086285	T/C	cg02459107	chr1:67143332	SGIP1	0.39	5.66	0.34	4.29e-8	Menopause (age at onset);
KIRP	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.4	5.29	0.32	2.71e-7	Educational attainment;
KIRP	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.1	0.69	6.82e-37	Platelet count;
KIRP	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	cg21523751	chr1:182988639	NA	0.45	6.95	0.41	3.19e-11	Hypertriglyceridemia;
KIRP	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.08	0.46	2.96e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-6.62	-0.39	2.2e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg07884673	chr3:53033167	SFMBT1	0.78	6.38	0.38	8.9e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg03146154	chr1:46216737	IPP	-0.41	-5.21	-0.32	3.94e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg01849789	chr22:41697279	ZC3H7B	-0.45	-5.13	-0.31	5.79e-7	Neuroticism;
KIRP	cis	rs12595433	0.522	rs11634528	chr15:63289424	A/G	cg03196360	chr15:63270641	NA	-0.31	-5.66	-0.34	4.22e-8	Obesity-related traits;
KIRP	cis	rs4494114	1.000	rs880303	chr1:39340282	C/T	cg25970120	chr1:39325951	RRAGC	-0.4	-5.03	-0.31	9.38e-7	Blood protein levels;
KIRP	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg18306943	chr3:40428807	ENTPD3	-0.42	-5.5	-0.33	9.66e-8	Renal cell carcinoma;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg27497285	chr9:95432195	IPPK	-0.52	-6.42	-0.38	6.83e-10	Neuroticism;
KIRP	cis	rs7011049	1.000	rs11985687	chr8:53832602	G/A	cg26025543	chr8:53854495	NA	0.71	7.47	0.43	1.36e-12	Systolic blood pressure;
KIRP	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg04025307	chr7:1156635	C7orf50	0.57	6.19	0.37	2.46e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.73	6.45	0.38	5.94e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg13628971	chr7:2884303	GNA12	-0.55	-6.43	-0.38	6.51e-10	Height;
KIRP	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.73	-9.46	-0.52	2.51e-18	Body mass index;
KIRP	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs17221829	0.617	rs11018677	chr11:89362820	C/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.88	-0.3	1.89e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.64	8.43	0.47	2.86e-15	Motion sickness;
KIRP	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.64	6.6	0.39	2.52e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17739167	0.550	rs17687976	chr15:42234824	A/G	cg20935245	chr15:42234343	EHD4	-0.5	-7.88	-0.45	1.03e-13	Monocyte count;
KIRP	cis	rs904251	1.000	rs10947673	chr6:37445079	C/T	cg24807547	chr6:37504484	NA	-0.42	-5.92	-0.35	1.1e-8	Cognitive performance;
KIRP	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.69	10.67	0.56	4.38e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg05938607	chr10:60274200	BICC1	0.42	10.22	0.55	1.11e-20	Refractive error;
KIRP	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.37	-10.46	-0.56	1.94e-21	Diabetic kidney disease;
KIRP	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.54	-12.08	-0.61	1.06e-26	Diabetic kidney disease;
KIRP	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.81	-13.14	-0.64	2.99e-30	Prostate cancer;
KIRP	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.66	10.53	0.56	1.24e-21	Bone mineral density;
KIRP	cis	rs918629	0.761	rs6898371	chr5:95289333	A/G	cg16656078	chr5:95278638	ELL2	-0.47	-6.78	-0.4	8.68e-11	IgG glycosylation;
KIRP	cis	rs1056053	0.514	rs3127332	chr6:166573438	G/A	cg11088901	chr6:166572345	T	-0.52	-7.22	-0.42	6.61e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg23625390	chr15:77176239	SCAPER	0.54	7.29	0.42	4.31e-12	Blood metabolite levels;
KIRP	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.61	0.39	2.43e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.92	-0.4	3.84e-11	Systolic blood pressure;
KIRP	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg21605333	chr4:119757512	SEC24D	1.66	10.42	0.55	2.7e-21	Cannabis dependence symptom count;
KIRP	trans	rs10435736	0.673	rs4879523	chr9:31534673	A/G	cg13395060	chr9:35560319	RUSC2	-0.61	-6.17	-0.37	2.78e-9	Metabolite levels  (X-11787);
KIRP	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg09201719	chr10:104596890	CYP17A1	0.37	5.27	0.32	3.01e-7	Arsenic metabolism;
KIRP	cis	rs9972944	0.651	rs9909246	chr17:63791547	C/G	cg07283582	chr17:63770753	CCDC46	-0.5	-7.85	-0.45	1.24e-13	Total body bone mineral density;
KIRP	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg08132940	chr7:1081526	C7orf50	-0.52	-5.14	-0.31	5.52e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.75	-9.36	-0.51	5.24e-18	Urinary metabolites;
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.43	5.82	0.35	1.87e-8	Menarche (age at onset);
KIRP	cis	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg07460842	chr6:66804631	NA	-0.48	-5.9	-0.35	1.2e-8	Blood trace element (Cu levels);
KIRP	cis	rs6083	0.512	rs17269397	chr15:58857378	A/G	cg05156742	chr15:59063176	FAM63B	-0.5	-6.28	-0.37	1.52e-9	Schizophrenia;
KIRP	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg14784868	chr12:69753453	YEATS4	0.51	5.26	0.32	3.14e-7	Response to diuretic therapy;
KIRP	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.6	0.39	2.57e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8038465	0.874	rs2291011	chr15:74000839	G/A	cg15420318	chr15:73925796	NPTN	0.51	6.52	0.38	4.02e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg16867584	chr19:49200180	FUT2	0.33	5.26	0.32	3.2e-7	Dietary macronutrient intake;
KIRP	cis	rs4974559	0.947	rs10006381	chr4:1359309	C/T	cg02980000	chr4:1222292	CTBP1	0.76	7.48	0.43	1.32e-12	Systolic blood pressure;
KIRP	trans	rs9399599	0.899	rs2786185	chr6:147595554	C/T	cg17422427	chr2:241507521	RNPEPL1	0.46	6.11	0.36	3.93e-9	Plasma plasminogen activator levels;
KIRP	cis	rs1943345	0.731	rs498292	chr11:82903283	C/T	cg07047830	chr11:82868014	PCF11	0.69	9.16	0.5	2.14e-17	Obesity-related traits;
KIRP	cis	rs2671245	0.586	rs9436521	chr1:56137999	G/C	cg11523071	chr1:56160889	NA	0.39	5.53	0.33	8.15e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.84	12.88	0.63	2.28e-29	Height;
KIRP	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	1.01	16.26	0.72	7.23e-41	Menopause (age at onset);
KIRP	cis	rs61884328	0.733	rs61897858	chr11:47235263	A/T	cg23433285	chr11:47201945	PACSIN3	0.67	5.15	0.31	5.29e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg15128208	chr22:42549153	NA	0.37	4.89	0.3	1.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.68	8.99	0.5	6.57e-17	Lymphocyte counts;
KIRP	cis	rs6466055	0.589	rs67909511	chr7:104971848	A/G	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	7e-7	Schizophrenia;
KIRP	cis	rs2970818	0.831	rs10849083	chr12:4642572	G/T	cg14576962	chr12:4671597	NA	-0.43	-5.13	-0.31	5.75e-7	Phosphorus levels;
KIRP	cis	rs1497828	1.000	rs2810769	chr1:217563585	A/T	cg04411442	chr1:217543379	NA	-0.34	-5.29	-0.32	2.65e-7	Dialysis-related mortality;
KIRP	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.31	7.38	0.43	2.47e-12	IgG glycosylation;
KIRP	cis	rs72945132	0.882	rs59681006	chr11:70179401	T/C	cg00319359	chr11:70116639	PPFIA1	0.57	5.8	0.35	2.08e-8	Coronary artery disease;
KIRP	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg04310649	chr10:35416472	CREM	0.56	6.91	0.4	4.07e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.64	-5.23	-0.32	3.64e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.66	-8.1	-0.46	2.53e-14	Aortic root size;
KIRP	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	0.45	5.8	0.35	1.99e-8	Systemic lupus erythematosus;
KIRP	cis	rs3087591	0.521	rs1013948	chr17:29530709	C/T	cg24425628	chr17:29625626	OMG;NF1	0.5	4.88	0.3	1.94e-6	Hip circumference;
KIRP	cis	rs2016266	0.929	rs11170495	chr12:53665202	G/A	cg16917193	chr12:54089295	NA	0.39	4.98	0.3	1.21e-6	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.44	-5.37	-0.32	1.79e-7	Diastolic blood pressure;
KIRP	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg12486944	chr17:80159399	CCDC57	-0.38	-5.17	-0.31	4.82e-7	Life satisfaction;
KIRP	cis	rs7010267	0.712	rs4567065	chr8:120008274	C/A	cg01975934	chr8:119970761	NA	-0.39	-5.0	-0.3	1.11e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.72	10.33	0.55	5.23e-21	Hip circumference;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03129732	chr4:88084297	KLHL8	0.4	6.39	0.38	8.36e-10	C-reactive protein;
KIRP	cis	rs7808935	0.522	rs2107821	chr7:28014731	T/C	cg22168087	chr7:27702803	HIBADH	-0.69	-6.46	-0.38	5.44e-10	Prostate cancer;
KIRP	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg08738300	chr3:44038990	NA	0.68	9.56	0.52	1.28e-18	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.68	0.53	5.7e-19	Prudent dietary pattern;
KIRP	cis	rs986417	0.901	rs4901989	chr14:61014743	G/C	cg27398547	chr14:60952738	C14orf39	0.6	5.05	0.31	8.68e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06481639	chr22:41940642	POLR3H	0.45	5.29	0.32	2.76e-7	Cannabis dependence symptom count;
KIRP	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs4478858	0.684	rs1532861	chr1:31766491	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.41	-0.33	1.52e-7	Alcohol dependence;
KIRP	cis	rs4704187	0.687	rs4324655	chr5:74373360	C/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.11e-8	Response to amphetamines;
KIRP	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.75	-10.34	-0.55	4.91e-21	Blood metabolite levels;
KIRP	cis	rs1215050	0.740	rs185468	chr4:98756242	C/T	cg17366294	chr4:99064904	C4orf37	0.38	5.16	0.31	5.2e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg00405596	chr8:11794950	NA	-0.46	-6.19	-0.37	2.52e-9	Neuroticism;
KIRP	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.7	-10.08	-0.54	3.22e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.6	-6.87	-0.4	5.13e-11	Mean platelet volume;
KIRP	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg24397884	chr7:158709396	WDR60	0.58	7.43	0.43	1.79e-12	Height;
KIRP	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg26048923	chr8:141057285	TRAPPC9	-0.25	-5.09	-0.31	7.14e-7	Pulse pressure;
KIRP	cis	rs4765905	0.671	rs2190771	chr12:2331192	G/T	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.62	-0.34	5.07e-8	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.28	0.32	2.86e-7	Personality dimensions;
KIRP	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26879891	chr1:152191343	HRNR	-0.48	-6.78	-0.4	8.7e-11	Inflammatory skin disease;
KIRP	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg21775007	chr8:11205619	TDH	0.45	6.17	0.37	2.85e-9	Mood instability;
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	9.87	0.53	1.39e-19	Coffee consumption (cups per day);
KIRP	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.46	0.65	2.63e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11871801	0.517	rs668799	chr17:40716235	C/T	cg14558262	chr17:40713999	COASY	0.49	5.25	0.32	3.35e-7	Crohn's disease;
KIRP	cis	rs7221595	0.673	rs115725560	chr17:3980493	T/A	cg21734707	chr17:3908241	ZZEF1	0.53	4.97	0.3	1.26e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.48	-4.99	-0.3	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg20673091	chr1:2541236	MMEL1	0.66	10.22	0.55	1.12e-20	Ulcerative colitis;
KIRP	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg14835575	chr10:16859367	RSU1	0.6	7.98	0.45	5.52e-14	Platelet distribution width;
KIRP	cis	rs1408799	0.669	rs13298902	chr9:12670801	T/C	cg05274944	chr9:12693694	TYRP1	0.4	5.87	0.35	1.37e-8	Eye color;Blue vs. green eyes;
KIRP	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg26513180	chr16:89883248	FANCA	0.83	5.55	0.33	7.43e-8	Skin colour saturation;
KIRP	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg10223061	chr2:219282414	VIL1	-0.4	-6.28	-0.37	1.5e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7010267	0.935	rs11573824	chr8:119959925	A/T	cg01975934	chr8:119970761	NA	-0.42	-5.33	-0.32	2.17e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs12913538	0.547	rs4774440	chr15:62887685	G/T	cg09983546	chr15:62884068	NA	-0.47	-4.84	-0.3	2.26e-6	Sleep depth;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg07148880	chr1:200992788	KIF21B	0.47	6.18	0.37	2.62e-9	Educational attainment;
KIRP	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg07451762	chr16:28383216	NA	0.41	5.37	0.32	1.78e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg21972741	chr5:435613	AHRR	0.51	6.2	0.37	2.43e-9	Cystic fibrosis severity;
KIRP	cis	rs3136516	0.504	rs10838610	chr11:46686260	G/A	cg16389345	chr11:46697382	NA	0.52	6.99	0.41	2.58e-11	Venous thromboembolism;
KIRP	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg26875233	chr11:93583750	C11orf90	-0.37	-6.88	-0.4	4.8e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.6	8.93	0.49	9.95e-17	Itch intensity from mosquito bite;
KIRP	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.3e-12	Morning vs. evening chronotype;
KIRP	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg13206674	chr6:150067644	NUP43	0.52	7.41	0.43	1.96e-12	Testicular germ cell tumor;
KIRP	cis	rs9372498	0.706	rs9489396	chr6:118761703	A/C	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs2380205	0.967	rs7907795	chr10:5888780	T/C	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.76	9.32	0.51	7.08e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7635838	0.892	rs4684773	chr3:11418508	C/T	cg00170343	chr3:11313890	ATG7	0.45	5.76	0.34	2.55e-8	HDL cholesterol;
KIRP	cis	rs7225151	0.710	rs16954523	chr17:5216998	A/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.71	-0.34	3.23e-8	Alzheimer's disease (late onset);
KIRP	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21972741	chr5:435613	AHRR	0.53	7.04	0.41	1.88e-11	Cystic fibrosis severity;
KIRP	cis	rs3745672	0.590	rs10409622	chr19:12168750	C/G	cg20127191	chr19:12306497	NA	-0.73	-5.93	-0.35	1.01e-8	Multiple sclerosis;
KIRP	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	0.95	14.36	0.68	2.23e-34	Eosinophil percentage of white cells;
KIRP	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.19	0.37	2.5e-9	Coronary artery disease;
KIRP	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13727613	chr6:45389871	RUNX2	-0.53	-6.13	-0.36	3.5e-9	Menopause (age at onset);
KIRP	cis	rs4774830	0.744	rs62045232	chr15:56284419	A/G	cg24530489	chr15:56299380	NA	-0.86	-5.26	-0.32	3.12e-7	Delta-5 desaturase activity;
KIRP	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.58	-7.33	-0.42	3.38e-12	Uric acid levels;
KIRP	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08508325	chr11:3079039	CARS	0.3	5.43	0.33	1.37e-7	Calcium levels;
KIRP	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.65	7.87	0.45	1.15e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1215050	0.846	rs783923	chr4:98968686	C/T	cg17366294	chr4:99064904	C4orf37	-0.38	-4.98	-0.3	1.17e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1829883	0.560	rs28521297	chr5:98850409	T/C	cg08333243	chr5:99726346	NA	-0.42	-5.35	-0.32	2e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7127900	0.948	rs71455920	chr11:2226789	A/C	cg25635251	chr11:2234043	NA	0.53	7.93	0.45	7.71e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	0.96	12.26	0.62	2.71e-27	Blood protein levels;
KIRP	cis	rs9653442	0.564	rs2309756	chr2:100780269	G/C	cg07810366	chr2:100720526	AFF3	-0.31	-4.96	-0.3	1.32e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg23422044	chr7:1970798	MAD1L1	-0.69	-6.53	-0.38	3.71e-10	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18798372	chr8:124557975	NA	0.58	7.15	0.41	9.68e-12	Interleukin-4 levels;
KIRP	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	1.13	8.2	0.46	1.34e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20135002	chr11:47629003	NA	-0.49	-5.88	-0.35	1.32e-8	Subjective well-being;
KIRP	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.37	6.4	0.38	7.61e-10	Heart rate;
KIRP	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.43	-6.4	-0.38	7.79e-10	Refractive error;
KIRP	cis	rs11429307	1	rs11429307	chr5:55857025	G/GT	cg15001016	chr5:55860904	NA	-0.32	-5.17	-0.31	4.88e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg09890400	chr1:26503858	CNKSR1	0.42	5.79	0.35	2.14e-8	Height;
KIRP	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg20936604	chr3:58311152	NA	-0.66	-5.01	-0.3	1.03e-6	Cholesterol, total;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg24081819	chr8:27348940	EPHX2	0.62	6.05	0.36	5.46e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	1.97e-7	Life satisfaction;
KIRP	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg02811702	chr13:24901961	NA	0.39	5.2	0.31	4.16e-7	Obesity-related traits;
KIRP	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.77	-10.17	-0.54	1.65e-20	Body mass index;
KIRP	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.31	-0.47	6.3e-15	Mean corpuscular volume;
KIRP	trans	rs1056053	0.514	rs3099269	chr6:166572242	T/A	cg17428496	chr19:2151817	AP3D1	-0.54	-6.06	-0.36	5.1e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	1.06	22.38	0.82	3.02e-61	Parkinson's disease;
KIRP	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg00405596	chr8:11794950	NA	0.47	6.48	0.38	4.85e-10	Mood instability;
KIRP	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.49	5.98	0.36	8.02e-9	Glycated hemoglobin levels;
KIRP	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg10755058	chr3:40428713	ENTPD3	0.36	4.93	0.3	1.49e-6	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16260572	chr12:112037499	ATXN2	0.48	6.13	0.36	3.56e-9	Parkinson's disease;
KIRP	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.07e-11	Blood metabolite levels;
KIRP	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01616529	chr11:638424	DRD4	-0.4	-5.43	-0.33	1.38e-7	Systemic lupus erythematosus;
KIRP	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	9.46	0.52	2.56e-18	Bone mineral density;
KIRP	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-1.01	-18.11	-0.76	3.73e-47	Leprosy;
KIRP	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.78	8.93	0.49	1.03e-16	Post bronchodilator FEV1;
KIRP	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-1.01	-18.55	-0.76	1.2e-48	Height;
KIRP	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.42	9.0	0.5	6.49e-17	Vitiligo;
KIRP	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.9	-14.3	-0.67	3.64e-34	Calcium levels;
KIRP	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.61	-7.53	-0.43	9.34e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08239325	chr14:54944410	GMFB	-0.44	-6.42	-0.38	6.9e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	0.65	9.58	0.52	1.09e-18	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg15556689	chr8:8085844	FLJ10661	0.61	8.37	0.47	4.34e-15	Mood instability;
KIRP	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-10.31	-0.55	5.89e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg07216194	chr8:27182965	PTK2B	0.42	5.23	0.32	3.7e-7	Neuroticism;
KIRP	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg25866889	chr13:114914595	NA	-0.4	-5.56	-0.33	7.16e-8	Schizophrenia;
KIRP	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	9.88	0.53	1.35e-19	Hip circumference;
KIRP	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg09029085	chr17:47094198	IGF2BP1	0.25	5.7	0.34	3.39e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg18032289	chr17:61959525	GH2	-0.39	-4.9	-0.3	1.76e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-8.34	-0.47	5.26e-15	Colorectal cancer;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09039436	chr11:46369515	DGKZ	-0.46	-6.09	-0.36	4.23e-9	Metabolic traits;
KIRP	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.67	-9.5	-0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	8.42	0.47	3.13e-15	Personality dimensions;
KIRP	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.82	-11.14	-0.58	1.29e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.5	-7.78	-0.44	1.96e-13	Huntington's disease progression;
KIRP	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.65	-8.61	-0.48	8.99e-16	Life satisfaction;
KIRP	cis	rs7903847	0.596	rs10786340	chr10:99156563	G/C	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.88	-0.3	1.91e-6	Pulmonary function;
KIRP	cis	rs909341	0.909	rs2427530	chr20:62361737	G/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.84	-0.35	1.66e-8	Atopic dermatitis;
KIRP	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.2	-0.46	1.29e-14	Response to antipsychotic treatment;
KIRP	cis	rs2712184	0.935	rs2712169	chr2:217671349	G/A	cg05032264	chr2:217675019	NA	-0.51	-7.6	-0.44	6.17e-13	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	6.15	0.37	3.07e-9	Mean platelet volume;
KIRP	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg04369109	chr6:150039330	LATS1	-0.49	-6.3	-0.37	1.34e-9	Lung cancer;
KIRP	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.62	6.99	0.41	2.63e-11	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08431062	chr19:16607243	C19orf44;CALR3	0.52	6.26	0.37	1.73e-9	Smoking initiation;
KIRP	cis	rs13006833	0.668	rs2582770	chr2:191136794	A/C	cg21644426	chr2:191273491	MFSD6	0.44	5.33	0.32	2.25e-7	Urinary metabolites;
KIRP	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.73	-9.71	-0.53	4.59e-19	Total body bone mineral density;
KIRP	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.97	16.31	0.72	4.9e-41	Bone mineral density;
KIRP	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.81	13.06	0.64	5.65e-30	Idiopathic membranous nephropathy;
KIRP	cis	rs6748734	0.543	rs73012754	chr2:241754034	G/A	cg26084005	chr2:241760190	KIF1A	0.49	6.09	0.36	4.22e-9	Urinary metabolites;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11854917	chr15:56657615	TEX9	0.43	6.02	0.36	6.29e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9535307	0.615	rs3736830	chr13:50306221	G/C	cg03658251	chr13:50265850	EBPL	0.46	5.05	0.31	8.64e-7	Obesity-related traits;
KIRP	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Electroencephalogram traits;
KIRP	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.81	-11.7	-0.6	1.96e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg12042659	chr19:58951599	ZNF132	0.5	6.09	0.36	4.35e-9	Uric acid clearance;
KIRP	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg06026331	chr20:60912101	LAMA5	0.52	6.61	0.39	2.37e-10	Pelvic organ prolapse;
KIRP	cis	rs734999	0.545	rs9970196	chr1:2574078	T/C	cg11382394	chr1:2564504	MMEL1	0.39	5.03	0.31	9.44e-7	Ulcerative colitis;
KIRP	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg21095983	chr6:86352623	SYNCRIP	0.52	6.87	0.4	5.36e-11	Smooth-surface caries;
KIRP	cis	rs8133932	0.505	rs387320	chr21:47347750	A/G	cg11214348	chr21:47283868	PCBP3	-0.42	-5.43	-0.33	1.33e-7	Schizophrenia;
KIRP	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg10617943	chr7:1981403	MAD1L1	-0.37	-5.1	-0.31	6.88e-7	Neuroticism;
KIRP	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.76	0.44	2.22e-13	Aortic root size;
KIRP	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg21064579	chr19:49206444	FUT2	0.54	7.7	0.44	3.26e-13	Dietary macronutrient intake;
KIRP	trans	rs4742903	0.509	rs12377116	chr9:106959243	A/G	cg06629767	chr10:72238406	KIAA1274	-0.44	-6.09	-0.36	4.22e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs2494938	0.811	rs428101	chr6:40516498	C/T	cg14084896	chr6:40530702	LRFN2	-0.41	-5.16	-0.31	5.08e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg16586182	chr3:47516702	SCAP	0.62	8.22	0.46	1.2e-14	Colorectal cancer;
KIRP	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.8	9.98	0.54	6.44e-20	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg09408571	chr1:101003634	GPR88	-0.23	-5.22	-0.32	3.75e-7	Monocyte count;
KIRP	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	6.06	0.36	5.13e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg17554472	chr22:41940697	POLR3H	-0.7	-7.05	-0.41	1.79e-11	Vitiligo;
KIRP	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.93	0.4	3.67e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs2737618	0.674	rs2821334	chr1:200093887	G/T	cg21825944	chr1:200113062	NR5A2	-0.54	-7.68	-0.44	3.73e-13	Uric acid levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20449327	chr14:59951241	C14orf149;JKAMP	-0.47	-6.78	-0.4	9.06e-11	Metabolic traits;
KIRP	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg20628663	chr10:43360327	NA	0.54	6.34	0.37	1.07e-9	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11663481	chr3:185216613	TMEM41A	0.5	6.25	0.37	1.83e-9	Parkinson's disease;
KIRP	cis	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg19171272	chr22:38449367	NA	-0.66	-9.87	-0.53	1.41e-19	Glioblastoma;Glioma;
KIRP	trans	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.24	-0.37	1.95e-9	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01931797	chr11:77899910	KCTD21;USP35	0.44	6.07	0.36	4.78e-9	Survival in pancreatic cancer;
KIRP	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	7.88	0.45	1.09e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs72772090	0.908	rs17086588	chr5:96044914	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.5	4.96	0.3	1.31e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.42	5.28	0.32	2.82e-7	Aortic root size;
KIRP	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg04166393	chr7:2884313	GNA12	0.44	5.73	0.34	3e-8	Height;
KIRP	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.36	0.42	2.69e-12	Iron status biomarkers;
KIRP	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg11569703	chr11:65557185	OVOL1	0.73	13.88	0.66	9.89e-33	Acne (severe);
KIRP	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg08514558	chr10:81106712	PPIF	0.45	6.43	0.38	6.43e-10	Height;
KIRP	cis	rs2882667	0.898	rs6882526	chr5:138382368	A/G	cg04439458	chr5:138467593	SIL1	-0.45	-7.55	-0.43	8.33e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	0.65	6.45	0.38	5.9e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg09699651	chr6:150184138	LRP11	0.46	6.13	0.36	3.46e-9	Lung cancer;
KIRP	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs3733418	0.929	rs13120990	chr4:165905118	A/G	cg10852876	chr4:165953100	TRIM60	-0.46	-4.99	-0.3	1.14e-6	Obesity-related traits;
KIRP	cis	rs911119	0.913	rs67483168	chr20:23581312	T/C	cg09631192	chr20:23583594	CST9	-0.63	-6.13	-0.36	3.38e-9	Chronic kidney disease;
KIRP	cis	rs34375054	0.623	rs2297478	chr12:125591844	C/T	cg25124228	chr12:125621409	AACS	-0.67	-8.17	-0.46	1.61e-14	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.39	5.44	0.33	1.27e-7	Night sleep phenotypes;
KIRP	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.51	5.87	0.35	1.38e-8	Aortic root size;
KIRP	cis	rs731174	0.840	rs525379	chr1:38151705	T/C	cg14170840	chr1:38155120	C1orf109	-0.41	-5.2	-0.31	4.2e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5753037	0.702	rs36576	chr22:30206291	C/A	cg01021169	chr22:30184971	ASCC2	-0.39	-5.32	-0.32	2.29e-7	Type 1 diabetes;
KIRP	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.49	0.33	9.91e-8	Coronary artery disease;
KIRP	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.92	14.99	0.69	1.65e-36	Longevity;Endometriosis;
KIRP	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.45	5.51	0.33	9.14e-8	Blood protein levels;
KIRP	cis	rs42714	0.614	rs174022	chr7:28464368	A/G	cg19638435	chr7:28452093	CREB5	-0.8	-5.3	-0.32	2.53e-7	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
KIRP	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.55	-6.38	-0.38	8.58e-10	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg15764593	chr10:829463	NA	-0.84	-9.08	-0.5	3.76e-17	Uric acid levels;
KIRP	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14598338	chr9:96623480	NA	0.66	11.3	0.58	4.01e-24	DNA methylation (variation);
KIRP	cis	rs73058052	0.597	rs16981329	chr19:50097932	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.49	5.84	0.35	1.61e-8	Fibrinogen levels;
KIRP	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg09455208	chr3:40491958	NA	0.32	5.31	0.32	2.49e-7	Renal cell carcinoma;
KIRP	cis	rs2250402	0.510	rs75578790	chr15:40332440	A/G	cg20255370	chr15:40268687	EIF2AK4	0.45	5.25	0.32	3.34e-7	Corneal curvature;
KIRP	cis	rs7116495	0.609	rs7924834	chr11:71644333	C/T	cg10381502	chr11:71823885	C11orf51	0.93	6.92	0.4	3.98e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs953387	0.910	rs1123848	chr2:136945029	C/T	cg05194412	chr2:137003533	NA	-0.38	-4.92	-0.3	1.62e-6	Arthritis (juvenile idiopathic);
KIRP	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg17554472	chr22:41940697	POLR3H	-0.66	-7.38	-0.43	2.45e-12	Vitiligo;
KIRP	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	11.78	0.6	1.11e-25	Hip circumference adjusted for BMI;
KIRP	cis	rs3736594	0.513	rs3811644	chr2:27802805	A/G	cg27432699	chr2:27873401	GPN1	0.58	6.16	0.37	2.92e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs17065868	1.000	rs9533909	chr13:45137894	A/G	cg10246903	chr13:45222710	NA	0.69	6.49	0.38	4.79e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs4853036	0.951	rs6710444	chr2:70120632	G/A	cg14915290	chr13:42017708	OR7E37P	-0.48	-6.13	-0.36	3.51e-9	Colorectal or endometrial cancer;
KIRP	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.65	-9.86	-0.53	1.51e-19	Total body bone mineral density;
KIRP	cis	rs6956675	0.915	rs7780762	chr7:62654263	T/C	cg08930214	chr7:62859557	LOC100287834	0.43	5.23	0.32	3.57e-7	Obesity-related traits;
KIRP	cis	rs681343	1.000	rs492602	chr19:49206417	A/G	cg08619932	chr19:49200058	FUT2	0.38	5.95	0.35	9.03e-9	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	cis	rs2290402	0.536	rs56307842	chr4:854232	T/C	cg14517359	chr4:903473	GAK	-0.55	-5.92	-0.35	1.08e-8	Type 2 diabetes;
KIRP	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg17279839	chr7:150038598	RARRES2	0.49	6.32	0.37	1.2e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs73198271	0.595	rs55874147	chr8:8591954	T/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs829883	0.902	rs829884	chr12:98879500	C/G	cg25150519	chr12:98850993	NA	0.87	13.14	0.64	3.09e-30	Colorectal adenoma (advanced);
KIRP	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg16736954	chr20:23401023	NAPB	0.59	4.85	0.3	2.14e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.49	-6.22	-0.37	2.17e-9	Body mass index;
KIRP	cis	rs4728302	0.905	rs7459333	chr7:133628701	G/A	cg10665199	chr7:133106180	EXOC4	-0.42	-4.96	-0.3	1.34e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs8179	0.645	rs11767704	chr7:92256375	C/T	cg15732164	chr7:92237376	CDK6	-0.4	-5.22	-0.32	3.9e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg01631408	chr1:248437212	OR2T33	0.64	8.24	0.47	9.99e-15	Common traits (Other);
KIRP	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19717773	chr7:2847554	GNA12	-0.32	-4.87	-0.3	2.04e-6	Height;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13939156	chr17:80058883	NA	-0.49	-7.36	-0.42	2.8e-12	Life satisfaction;
KIRP	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg13385521	chr17:29058706	SUZ12P	0.59	5.95	0.35	9.36e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.02	-0.46	4.23e-14	Migraine;Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03599729	chr2:200820225	C2orf60;C2orf47	0.48	6.48	0.38	4.84e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-5.34	-0.32	2.14e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg07796016	chr1:152779584	LCE1C	-0.44	-5.76	-0.34	2.57e-8	Inflammatory skin disease;
KIRP	cis	rs6601327	0.665	rs12546411	chr8:9655916	T/A	cg27411982	chr8:10470053	RP1L1	-0.39	-4.9	-0.3	1.71e-6	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.56	6.89	0.4	4.55e-11	Arsenic metabolism;
KIRP	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05872234	chr4:48390346	SLAIN2	-0.46	-7.27	-0.42	4.88e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.75	6.92	0.4	3.79e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg10223061	chr2:219282414	VIL1	0.43	7.0	0.41	2.43e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.82	-11.92	-0.61	3.74e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.79	-8.88	-0.49	1.48e-16	Bronchopulmonary dysplasia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg27228276	chr1:151119210	SEMA6C	-0.54	-6.15	-0.37	3.16e-9	Menopause (age at onset);
KIRP	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	1.26	14.6	0.68	3.45e-35	Eosinophil percentage of granulocytes;
KIRP	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.84	-10.8	-0.57	1.61e-22	Menarche (age at onset);
KIRP	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.56	-15.24	-0.7	2.15e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.72	10.78	0.57	1.95e-22	Calcium levels;
KIRP	cis	rs62413470	0.935	rs12203768	chr6:55959103	C/A	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	trans	rs913655	0.819	rs2495844	chr10:19128597	A/C	cg27106950	chr16:11367916	PRM3	-0.56	-6.14	-0.36	3.3e-9	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
KIRP	cis	rs548987	0.529	rs6456703	chr6:25826119	C/T	cg03264133	chr6:25882463	NA	-0.42	-5.0	-0.3	1.09e-6	Homocysteine levels;
KIRP	cis	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg07460842	chr6:66804631	NA	-0.47	-5.86	-0.35	1.48e-8	Blood trace element (Cu levels);
KIRP	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18252515	chr7:66147081	NA	0.43	4.93	0.3	1.51e-6	Aortic root size;
KIRP	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg27211696	chr2:191398769	TMEM194B	-0.49	-5.97	-0.36	8.38e-9	Diastolic blood pressure;
KIRP	cis	rs4704187	0.687	rs6896474	chr5:74453818	C/G	cg03227963	chr5:74354835	NA	-0.39	-5.49	-0.33	9.83e-8	Response to amphetamines;
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.7	0.66	3.81e-32	Platelet count;
KIRP	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.94	12.28	0.62	2.29e-27	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13603510	chr19:3626908	C19orf29	0.52	6.52	0.38	3.93e-10	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs78487399	0.908	rs12469695	chr2:43833258	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-4.94	-0.3	1.43e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.5	5.75	0.34	2.58e-8	Platelet distribution width;
KIRP	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.87	0.35	1.39e-8	Morning vs. evening chronotype;
KIRP	cis	rs883565	0.527	rs11715262	chr3:39003853	A/T	cg01426195	chr3:39028469	NA	-0.57	-9.06	-0.5	4.32e-17	Handedness;
KIRP	cis	rs4926611	1.000	rs1526907	chr1:54110087	T/C	cg08927728	chr1:54059983	GLIS1	-0.24	-5.2	-0.31	4.1e-7	Hand grip strength;
KIRP	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.51	-0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.51	-0.33	9.16e-8	IgG glycosylation;
KIRP	cis	rs8070740	0.731	rs1071648	chr17:5326089	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	7.5	0.43	1.14e-12	Menopause (age at onset);
KIRP	cis	rs7224685	0.501	rs897026	chr17:3980318	T/C	cg21734707	chr17:3908241	ZZEF1	0.63	9.5	0.52	1.94e-18	Type 2 diabetes;
KIRP	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.18e-11	Blood metabolite levels;
KIRP	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.16	-0.5	2.03e-17	Platelet count;
KIRP	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs888194	0.651	rs10850380	chr12:110002819	A/G	cg05360138	chr12:110035743	NA	0.4	4.89	0.3	1.85e-6	Neuroticism;
KIRP	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.56	-0.39	3.24e-10	Height;
KIRP	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00791764	chr4:53727839	RASL11B	0.45	6.29	0.37	1.47e-9	Optic nerve measurement (cup area);
KIRP	cis	rs7542091	0.518	rs6675416	chr1:210061006	A/G	cg22029157	chr1:209979665	IRF6	-0.41	-5.22	-0.32	3.8e-7	Monobrow;
KIRP	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.66	8.7	0.49	4.74e-16	Neuroticism;
KIRP	cis	rs6594499	0.872	rs13161853	chr5:110446741	C/A	cg04022379	chr5:110408740	TSLP	0.46	7.05	0.41	1.79e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	1.03	11.57	0.59	5.15e-25	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.58	-7.58	-0.43	7.19e-13	Bladder cancer;
KIRP	cis	rs9687846	0.877	rs28650790	chr5:55861464	C/T	cg15001016	chr5:55860904	NA	-0.32	-5.17	-0.31	4.82e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.61	-7.38	-0.43	2.46e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17554472	chr22:41940697	POLR3H	-0.69	-7.16	-0.42	9.48e-12	Vitiligo;
KIRP	cis	rs9308731	0.965	rs6758181	chr2:111886914	C/T	cg23466623	chr2:111982296	NA	-0.41	-5.17	-0.31	4.79e-7	Chronic lymphocytic leukemia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13866795	chr9:135283313	TTF1	-0.47	-6.16	-0.37	2.88e-9	Inflammatory biomarkers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06320982	chr16:58718767	SLC38A7	0.47	6.55	0.39	3.38e-10	Smoking initiation;
KIRP	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg23791538	chr6:167370224	RNASET2	-0.43	-4.9	-0.3	1.7e-6	Crohn's disease;
KIRP	cis	rs4901847	0.967	rs12897032	chr14:58557801	A/G	cg15908186	chr14:58618357	C14orf37	0.43	5.46	0.33	1.14e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg18882449	chr10:104885122	NT5C2	-0.52	-6.69	-0.39	1.45e-10	Arsenic metabolism;
KIRP	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg01403660	chr11:68851641	TPCN2	0.68	6.64	0.39	2.02e-10	Blond vs. brown hair color;
KIRP	cis	rs240764	0.554	rs723742	chr6:101237174	T/A	cg09795085	chr6:101329169	ASCC3	0.45	5.22	0.32	3.85e-7	Neuroticism;
KIRP	cis	rs8028182	0.636	rs62027181	chr15:75839952	A/G	cg20655648	chr15:75932815	IMP3	0.55	7.06	0.41	1.7e-11	Sudden cardiac arrest;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.6	5.64	0.34	4.69e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs427941	0.632	rs201526	chr7:101774333	T/G	cg06246474	chr7:101738831	CUX1	0.52	6.34	0.37	1.08e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14608180	chr9:139872839	PTGDS	0.42	6.26	0.37	1.66e-9	Cancer;
KIRP	cis	rs4664293	0.836	rs13016015	chr2:160646529	A/G	cg08347373	chr2:160653686	CD302	-0.4	-6.18	-0.37	2.71e-9	Monocyte percentage of white cells;
KIRP	cis	rs8077577	0.895	rs62072468	chr17:18118179	A/G	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg03714773	chr7:91764589	CYP51A1	0.35	5.13	0.31	6e-7	Breast cancer;
KIRP	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg01620082	chr3:125678407	NA	-1.14	-7.26	-0.42	5.22e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.57	-0.56	8.87e-22	Chronic sinus infection;
KIRP	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg03468072	chr12:39539422	NA	0.44	5.82	0.35	1.86e-8	Morning vs. evening chronotype;
KIRP	cis	rs282587	0.569	rs9604422	chr13:113410586	C/T	cg04656015	chr13:113407548	ATP11A	0.6	6.52	0.38	4.04e-10	Glycated hemoglobin levels;
KIRP	cis	rs7487075	0.780	rs10785620	chr12:46737252	G/C	cg09050775	chr12:46762708	SLC38A2	-0.39	-4.92	-0.3	1.6e-6	Itch intensity from mosquito bite;
KIRP	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	7.81	0.45	1.66e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg10144569	chr3:42726640	KBTBD5	0.5	5.56	0.33	6.86e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg02462569	chr6:150064036	NUP43	-0.34	-4.94	-0.3	1.47e-6	Lung cancer;
KIRP	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18932078	chr1:2524107	MMEL1	0.43	5.93	0.35	1.02e-8	Ulcerative colitis;
KIRP	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.6	-0.56	7.23e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg09873164	chr1:152488093	CRCT1	0.57	7.68	0.44	3.7e-13	Hair morphology;
KIRP	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-1.05	-12.99	-0.64	9.96e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg10207240	chr12:122356781	WDR66	0.54	7.15	0.41	9.77e-12	Mean corpuscular volume;
KIRP	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg24747557	chr10:131355152	MGMT	0.39	5.26	0.32	3.21e-7	Response to temozolomide;
KIRP	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.4	7.83	0.45	1.48e-13	Height;
KIRP	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg20636351	chr8:55087400	NA	-0.63	-7.83	-0.45	1.45e-13	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20898347	chr17:21117939	TMEM11	-0.52	-6.13	-0.36	3.44e-9	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.57	7.96	0.45	6.5e-14	Schizophrenia;
KIRP	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg13206674	chr6:150067644	NUP43	0.52	7.37	0.43	2.56e-12	Testicular germ cell tumor;
KIRP	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	9.05	0.5	4.54e-17	Triglycerides;
KIRP	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.64	-0.39	1.95e-10	Neuroticism;
KIRP	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.21	0.64	1.83e-30	Tonsillectomy;
KIRP	cis	rs793571	0.774	rs4775096	chr15:59140329	A/G	cg05156742	chr15:59063176	FAM63B	0.5	5.79	0.35	2.15e-8	Schizophrenia;
KIRP	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg21926883	chr2:100939477	LONRF2	-0.6	-8.13	-0.46	2.07e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.85e-6	Lung cancer;
KIRP	cis	rs2278796	0.639	rs6661192	chr1:204971413	A/G	cg04862289	chr1:204966208	NFASC	0.66	9.29	0.51	8.28e-18	Mean platelet volume;
KIRP	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg09238746	chr17:78121135	EIF4A3	0.43	5.54	0.33	7.9e-8	Yeast infection;
KIRP	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.74	10.77	0.57	2.08e-22	Blood metabolite levels;
KIRP	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg23594656	chr7:65796392	TPST1	0.39	5.69	0.34	3.56e-8	Aortic root size;
KIRP	cis	rs13223928	0.572	rs16870744	chr7:3135781	G/A	cg19214707	chr7:3157722	NA	-0.69	-8.67	-0.48	5.79e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.87	16.51	0.72	1.03e-41	Anterior chamber depth;
KIRP	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.61	7.95	0.45	6.64e-14	Response to antipsychotic treatment;
KIRP	cis	rs7582720	1.000	rs72932763	chr2:203678658	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.63e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	0.6	5.24	0.32	3.38e-7	Gut microbiota (bacterial taxa);
KIRP	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.88	-0.4	4.98e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.49	6.24	0.37	1.85e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.93	-9.16	-0.5	2.09e-17	Obesity-related traits;
KIRP	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.62	5.05	0.31	8.81e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7851660	0.874	rs10120412	chr9:100628238	T/C	cg13688889	chr9:100608707	NA	-0.67	-8.84	-0.49	1.83e-16	Strep throat;
KIRP	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg11807153	chr5:140098496	VTRNA1-2	0.34	5.14	0.31	5.64e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.32e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-5.32	-0.32	2.36e-7	Morning vs. evening chronotype;
KIRP	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg11584989	chr19:19387371	SF4	0.4	5.1	0.31	6.85e-7	Tonsillectomy;
KIRP	trans	rs12690897	0.744	rs4512318	chr7:85342053	T/C	cg25658385	chr6:35265341	DEF6	-0.34	-6.19	-0.37	2.54e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg01411142	chr8:19674711	INTS10	0.45	4.92	0.3	1.62e-6	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20328917	chr12:88536565	TMTC3;CEP290	0.44	6.37	0.38	9.05e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.83	10.86	0.57	1.04e-22	Total cholesterol levels;
KIRP	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-1.0	-13.02	-0.64	7.74e-30	Bipolar disorder and schizophrenia;
KIRP	cis	rs2224391	0.578	rs766339	chr6:5243506	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.11	-0.36	3.89e-9	Height;
KIRP	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg05347473	chr6:146136440	FBXO30	0.62	8.78	0.49	2.84e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg10503236	chr1:231470652	EXOC8	-0.53	-7.36	-0.42	2.83e-12	Hemoglobin concentration;
KIRP	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	9.76	0.53	3.23e-19	HIV-1 control;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09059988	chr1:150693299	HORMAD1	-0.47	-6.45	-0.38	6.03e-10	Inflammatory biomarkers;
KIRP	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg07862535	chr7:139043722	LUC7L2	0.48	5.3	0.32	2.56e-7	Diisocyanate-induced asthma;
KIRP	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.85	-0.3	2.19e-6	Eosinophil percentage of white cells;
KIRP	cis	rs1448094	0.842	rs10863155	chr12:86446416	T/C	cg06740227	chr12:86229804	RASSF9	-0.41	-5.18	-0.31	4.67e-7	Major depressive disorder;
KIRP	cis	rs10073892	1.000	rs10479218	chr5:101757805	A/C	cg19774478	chr5:101632501	SLCO4C1	0.61	6.4	0.38	7.63e-10	Cognitive decline (age-related);
KIRP	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg23594656	chr7:65796392	TPST1	-0.43	-6.16	-0.37	2.92e-9	Aortic root size;
KIRP	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.55	-7.44	-0.43	1.71e-12	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.35	-0.32	2e-7	Lung cancer;
KIRP	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.63	-0.56	5.75e-22	Height;
KIRP	cis	rs2150410	0.596	rs7283652	chr21:40660493	C/T	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.44	6.09	0.36	4.33e-9	Systolic blood pressure;
KIRP	cis	rs28834970	0.925	rs6987305	chr8:27208126	G/A	cg18234130	chr8:27182889	PTK2B	-0.47	-5.92	-0.35	1.1e-8	Alzheimer's disease (late onset);
KIRP	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.57	7.64	0.44	4.98e-13	Mean corpuscular volume;
KIRP	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.57	7.52	0.43	9.96e-13	Morning vs. evening chronotype;
KIRP	cis	rs2055942	0.639	rs3792211	chr4:46994495	G/T	cg09812070	chr4:46995689	GABRA4	0.42	5.35	0.32	2.01e-7	Type 2 diabetes;
KIRP	trans	rs1223629	0.826	rs56413348	chr10:96026926	C/T	cg03387497	chr20:17680945	BANF2	0.72	6.51	0.38	4.07e-10	Glucose homeostasis traits;
KIRP	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg07636037	chr3:49044803	WDR6	-0.7	-5.51	-0.33	9.17e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.65	8.7	0.49	4.74e-16	Total body bone mineral density;
KIRP	cis	rs6977660	0.652	rs10275246	chr7:19851059	G/A	cg07541023	chr7:19748670	TWISTNB	0.64	5.54	0.33	7.92e-8	Thyroid stimulating hormone;
KIRP	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02527881	chr3:46936655	PTH1R	-0.4	-5.65	-0.34	4.34e-8	Colorectal cancer;
KIRP	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.69	-10.44	-0.55	2.27e-21	Educational attainment;
KIRP	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.53	6.77	0.4	9.43e-11	Crohn's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12419308	chr1:110052464	AMIGO1	-0.47	-6.3	-0.37	1.39e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.85	-12.25	-0.62	2.88e-27	Height;
KIRP	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg00405596	chr8:11794950	NA	0.48	6.58	0.39	2.79e-10	Mood instability;
KIRP	cis	rs9815354	0.904	rs6776724	chr3:41841270	A/G	cg03022575	chr3:42003672	ULK4	0.54	6.2	0.37	2.33e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.24	-11.92	-0.61	3.72e-26	Atopic dermatitis;
KIRP	cis	rs4889855	0.556	rs61096326	chr17:78543796	G/C	cg09596252	chr17:78655493	RPTOR	-0.49	-5.58	-0.34	6.36e-8	Fractional excretion of uric acid;
KIRP	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg07511668	chr11:68622177	NA	0.4	5.27	0.32	3.05e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg07828340	chr4:882639	GAK	1.17	7.41	0.43	2.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.81	-11.61	-0.59	4.02e-25	Extrinsic epigenetic age acceleration;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg14808521	chr17:685420	GLOD4;RNMTL1	-0.49	-6.34	-0.37	1.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-12.85	-0.63	2.89e-29	Idiopathic membranous nephropathy;
KIRP	cis	rs2067615	1.000	rs2067615	chr12:107149422	A/T	cg21360079	chr12:107162445	NA	0.5	6.57	0.39	3.05e-10	Heart rate;
KIRP	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg01677386	chr11:118938358	VPS11	-0.51	-5.95	-0.35	9.07e-9	Coronary artery disease;
KIRP	cis	rs13065560	0.534	rs4637231	chr3:38909115	T/C	cg01426195	chr3:39028469	NA	-0.37	-6.04	-0.36	5.61e-9	Interleukin-18 levels;
KIRP	trans	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg24644049	chr4:85504048	CDS1	0.93	6.87	0.4	5.17e-11	Skin colour saturation;
KIRP	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg07001201	chr5:642380	CEP72	0.66	6.05	0.36	5.31e-9	Obesity-related traits;
KIRP	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.7	0.48	4.9e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4132509	1.000	rs4132509	chr1:243943084	A/C	cg25706552	chr1:244017396	NA	-0.48	-5.72	-0.34	3.05e-8	RR interval (heart rate);
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg14338887	chr6:42928500	GNMT	0.45	6.4	0.38	7.94e-10	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs258892	0.843	rs16901116	chr5:72053382	A/G	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.9	14.53	0.68	5.83e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.8	10.56	0.56	9.58e-22	Triglycerides;
KIRP	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg04727924	chr7:799746	HEATR2	-0.78	-8.85	-0.49	1.8e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.24	11.93	0.61	3.46e-26	Diabetic retinopathy;
KIRP	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.92	8.99	0.5	6.97e-17	Methadone dose in opioid dependence;
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.48	6.4	0.38	7.61e-10	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4006360	0.535	rs2173202	chr17:39235235	C/T	cg25341923	chr17:39239918	KRTAP4-7	0.57	8.6	0.48	9.39e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08130668	chr2:54557891	C2orf73	0.43	6.38	0.38	8.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg22563815	chr15:78856949	CHRNA5	-0.45	-6.99	-0.41	2.58e-11	Sudden cardiac arrest;
KIRP	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg27347728	chr4:17578864	LAP3	0.41	4.85	0.3	2.15e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg08890418	chr1:21044141	KIF17	-0.35	-5.15	-0.31	5.23e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs2688419	0.514	rs822768	chr3:23051162	A/G	cg00327796	chr3:23032191	NA	-0.39	-4.94	-0.3	1.41e-6	Type 2 diabetes;
KIRP	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26207909	chr14:103986467	CKB	0.76	11.67	0.6	2.49e-25	Body mass index;
KIRP	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.52	6.91	0.4	4.13e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.79	0.63	4.69e-29	Platelet count;
KIRP	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.63	-8.13	-0.46	2.13e-14	Personality dimensions;
KIRP	cis	rs675026	0.889	rs632499	chr6:154425397	A/C	cg07813322	chr6:154414604	OPRM1	-0.49	-6.43	-0.38	6.68e-10	Hypertension;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.91	14.41	0.68	1.58e-34	Menarche (age at onset);
KIRP	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-6.72	-0.39	1.26e-10	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg01777586	chr17:80163174	CCDC57	0.46	4.98	0.3	1.21e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs800082	0.690	rs6440260	chr3:144289214	C/A	cg24215973	chr2:240111563	HDAC4	-0.56	-7.66	-0.44	4.22e-13	Smoking behavior;
KIRP	cis	rs897080	0.515	rs698792	chr2:44683219	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.54	-5.7	-0.34	3.36e-8	Height;
KIRP	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg02297831	chr4:17616191	MED28	-0.47	-5.43	-0.33	1.35e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.58	-7.1	-0.41	1.34e-11	Aortic root size;
KIRP	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg00405596	chr8:11794950	NA	-0.48	-6.4	-0.38	7.84e-10	Joint mobility (Beighton score);
KIRP	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.48	-0.48	2.14e-15	Systolic blood pressure;
KIRP	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.55	-0.39	3.41e-10	Diastolic blood pressure;
KIRP	trans	rs4349753	0.904	rs3902641	chr5:144171859	C/G	cg16033277	chr17:80885358	TBCD	0.4	6.25	0.37	1.82e-9	Photic sneeze reflex;
KIRP	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.81	-0.45	1.63e-13	Mean corpuscular volume;
KIRP	cis	rs4523957	0.928	rs9905529	chr17:2177732	T/C	cg16513277	chr17:2031491	SMG6	-0.6	-8.33	-0.47	5.86e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2718058	0.606	rs2718065	chr7:37859525	A/G	cg15028436	chr7:37888078	TXNDC3	0.48	5.1	0.31	6.94e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg05220968	chr6:146057943	EPM2A	0.39	4.96	0.3	1.31e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg05775895	chr3:12838266	CAND2	0.39	6.45	0.38	5.72e-10	P wave duration;
KIRP	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.54	-6.14	-0.36	3.36e-9	Pulse pressure;
KIRP	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-9.66	-0.52	6.38e-19	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.54	0.33	7.67e-8	Life satisfaction;
KIRP	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12667521	chr19:29218732	NA	0.78	7.02	0.41	2.09e-11	Methadone dose in opioid dependence;
KIRP	cis	rs9400467	0.537	rs9647629	chr6:111501484	C/T	cg15721981	chr6:111408429	SLC16A10	0.78	7.13	0.41	1.14e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.45	6.4	0.38	7.72e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.08	-19.27	-0.78	4.5e-51	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06470936	chr2:206946028	INO80D	0.4	6.61	0.39	2.41e-10	C-reactive protein;
KIRP	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg27239842	chr4:2403781	ZFYVE28	0.45	5.67	0.34	3.93e-8	Influenza A (H1N1) severity;
KIRP	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02725872	chr8:58115012	NA	-0.73	-7.82	-0.45	1.56e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.51	-6.58	-0.39	2.75e-10	Menopause (age at onset);
KIRP	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg02461776	chr11:598696	PHRF1	0.5	5.36	0.32	1.95e-7	Systemic lupus erythematosus;
KIRP	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.69	-7.69	-0.44	3.55e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11997175	0.531	rs113627999	chr8:33737335	G/T	cg04338863	chr8:33670619	NA	0.46	5.59	0.34	5.96e-8	Body mass index;
KIRP	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.58	8.48	0.48	2.1e-15	Ovarian reserve;
KIRP	cis	rs5753037	0.835	rs2007458	chr22:30388706	A/G	cg27665648	chr22:30112403	NA	0.36	5.06	0.31	8.23e-7	Type 1 diabetes;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg05569124	chr11:125495582	CHEK1	-0.53	-6.38	-0.38	8.59e-10	Brain structure;
KIRP	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg04310649	chr10:35416472	CREM	-0.6	-7.13	-0.41	1.15e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13394619	0.875	rs7576826	chr2:11723021	C/T	cg07314298	chr2:11723111	GREB1	-0.62	-9.03	-0.5	5.28e-17	Endometriosis;
KIRP	cis	rs6593803	0.732	rs1692141	chr1:147230217	T/C	cg27546670	chr1:147246839	GJA5	0.69	8.16	0.46	1.68e-14	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15128208	chr22:42549153	NA	-0.44	-5.56	-0.33	7.08e-8	Cognitive function;
KIRP	trans	rs2237436	0.592	rs11760407	chr7:41720763	C/T	cg10588962	chr17:46667587	LOC404266	0.5	6.1	0.36	4.02e-9	Schizophrenia;
KIRP	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg01529538	chr14:23388837	RBM23	0.41	5.22	0.32	3.8e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs3789045	0.520	rs2010432	chr1:204462619	G/T	cg18185008	chr1:204589407	LRRN2	-0.6	-6.33	-0.37	1.18e-9	Educational attainment (college completion);
KIRP	cis	rs10203711	1.000	rs1810140	chr2:239568163	T/C	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg09873164	chr1:152488093	CRCT1	0.49	6.07	0.36	4.83e-9	Hair morphology;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.48	0.33	1.06e-7	Lung cancer;
KIRP	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs1079204	1.000	rs13423003	chr2:219111341	G/C	cg05728596	chr2:219128475	GPBAR1	0.85	6.78	0.4	8.89e-11	Smooth-surface caries;
KIRP	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.58	5.86	0.35	1.5e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.49	6.37	0.38	9.12e-10	Calcium levels;
KIRP	cis	rs7923609	0.967	rs7912893	chr10:65162000	T/A	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13198984	chr17:80129470	CCDC57	0.55	8.24	0.46	1.04e-14	Life satisfaction;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg13790427	chr2:95527312	NA	0.45	6.06	0.36	4.95e-9	Bladder cancer;
KIRP	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.85	-0.45	1.27e-13	Total cholesterol levels;
KIRP	cis	rs17023223	0.581	rs61808932	chr1:119643820	T/C	cg05756136	chr1:119680316	WARS2	-0.59	-7.81	-0.45	1.66e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg01752856	chr8:19471331	CSGALNACT1	-0.4	-6.04	-0.36	5.63e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg22974920	chr21:40686053	BRWD1	0.5	5.88	0.35	1.34e-8	Cognitive function;
KIRP	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.92	14.83	0.69	5.43e-36	Blood protein levels;
KIRP	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg23587288	chr2:27483067	SLC30A3	-0.56	-7.06	-0.41	1.7e-11	Blood metabolite levels;
KIRP	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.61	7.11	0.41	1.24e-11	Platelet count;
KIRP	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	10.37	0.55	3.75e-21	Coffee consumption (cups per day);
KIRP	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.82	-14.45	-0.68	1.15e-34	Post bronchodilator FEV1;
KIRP	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-0.94	-14.49	-0.68	8.25e-35	Breast cancer;
KIRP	trans	rs1864585	0.520	rs73208769	chr8:10665984	A/T	cg26278703	chr11:58910052	FAM111A	0.65	6.44	0.38	6.16e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg05623727	chr3:50126028	RBM5	0.34	4.9	0.3	1.7e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg08992911	chr2:238395768	MLPH	0.53	5.38	0.32	1.7e-7	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19455322	chr3:46735335	ALS2CL	0.45	6.23	0.37	2e-9	Parkinson's disease;
KIRP	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg24253500	chr15:84953950	NA	0.48	5.46	0.33	1.18e-7	Schizophrenia;
KIRP	cis	rs28489187	0.706	rs66811655	chr1:85831544	T/G	cg16011679	chr1:85725395	C1orf52	0.54	6.47	0.38	5.36e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.72	8.77	0.49	2.96e-16	Response to antipsychotic treatment;
KIRP	trans	rs1973993	0.745	rs9437743	chr1:96961723	C/T	cg10631902	chr5:14652156	NA	0.54	7.85	0.45	1.26e-13	Weight;
KIRP	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg06636001	chr8:8085503	FLJ10661	0.71	9.29	0.51	8.27e-18	Neuroticism;
KIRP	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg24130564	chr14:104152367	KLC1	-0.8	-12.44	-0.62	7.1e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.63	7.33	0.42	3.29e-12	Obesity-related traits;
KIRP	cis	rs12213875	0.609	rs12204995	chr6:14601073	T/C	cg01527307	chr6:14500441	NA	-0.41	-5.4	-0.33	1.54e-7	Ovarian reserve;
KIRP	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg22875332	chr1:76189707	ACADM	-0.34	-5.0	-0.3	1.11e-6	Daytime sleep phenotypes;
KIRP	cis	rs501120	0.866	rs607609	chr10:44750209	T/C	cg09554077	chr10:44749378	NA	0.74	12.39	0.62	1.01e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1978968	1.000	rs1978968	chr22:18448113	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	0.66	7.49	0.43	1.2e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.74	-9.47	-0.52	2.47e-18	Facial morphology (factor 19);
KIRP	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg10167378	chr1:228756711	NA	0.89	7.43	0.43	1.76e-12	Chronic lymphocytic leukemia;
KIRP	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.53	-0.48	1.55e-15	Retinal vascular caliber;
KIRP	cis	rs17065868	0.881	rs9595145	chr13:45107348	A/G	cg10246903	chr13:45222710	NA	0.69	6.75	0.4	1.06e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.76	5.82	0.35	1.81e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	12.93	0.64	1.57e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg16586182	chr3:47516702	SCAP	0.68	9.25	0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg26248373	chr2:1572462	NA	-0.77	-9.99	-0.54	5.87e-20	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	6.43	0.38	6.72e-10	Menarche (age at onset);
KIRP	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	12.18	0.61	4.99e-27	Lymphocyte percentage of white cells;
KIRP	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg08738300	chr3:44038990	NA	0.68	9.63	0.52	7.95e-19	Coronary artery disease;
KIRP	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg13736514	chr6:26305472	NA	0.64	8.28	0.47	7.71e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg26174226	chr8:58114915	NA	0.63	7.65	0.44	4.46e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-7.87	-0.45	1.16e-13	Alzheimer's disease;
KIRP	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.88	-12.81	-0.63	4.08e-29	Total body bone mineral density;
KIRP	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg10932868	chr11:921992	NA	0.65	8.68	0.48	5.37e-16	Alzheimer's disease (late onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09862076	chr3:118959840	B4GALT4	0.53	6.5	0.38	4.35e-10	Parkinson's disease;
KIRP	cis	rs12318506	0.826	rs11180434	chr12:75662128	T/C	cg04728562	chr12:75699417	CAPS2	-0.98	-7.33	-0.42	3.31e-12	Coronary artery calcification;
KIRP	cis	rs7916697	0.898	rs1900005	chr10:69998055	A/C	cg18338521	chr10:69995036	NA	0.41	5.33	0.32	2.25e-7	Optic disc area;
KIRP	cis	rs6841333	0.857	rs10031983	chr4:76958071	G/C	cg24176760	chr4:76958061	ART3;CXCL11	-0.44	-4.85	-0.3	2.22e-6	Monokine induced by gamma interferon levels;
KIRP	cis	rs3779635	0.742	rs919491	chr8:27250933	C/T	cg07216194	chr8:27182965	PTK2B	0.47	5.75	0.34	2.62e-8	Neuroticism;
KIRP	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-5.13	-0.31	5.75e-7	Lung cancer;
KIRP	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.7	-9.84	-0.53	1.72e-19	Brugada syndrome;
KIRP	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg04362960	chr10:104952993	NT5C2	0.43	4.98	0.3	1.19e-6	Colorectal cancer;
KIRP	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.82	12.13	0.61	7.59e-27	Blood metabolite ratios;
KIRP	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.04	-0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.61	0.34	5.4e-8	Blood protein levels;
KIRP	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg07843065	chr1:150265600	MRPS21	0.41	5.39	0.32	1.65e-7	Migraine;
KIRP	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.67	8.74	0.49	3.75e-16	Breast cancer;
KIRP	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg17133734	chr15:86042851	AKAP13	-0.43	-5.38	-0.32	1.75e-7	Interstitial lung disease;
KIRP	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.39	8.15	0.46	1.88e-14	Body mass index;
KIRP	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.07	0.31	7.92e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16665614	chr15:61302584	RORA	0.39	6.54	0.38	3.48e-10	C-reactive protein;
KIRP	cis	rs7719624	0.870	rs58759191	chr5:135395827	C/G	cg16684184	chr5:135415129	NA	0.35	5.37	0.32	1.86e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs909341	0.710	rs6089953	chr20:62291008	C/T	cg11503966	chr20:62272292	STMN3	-0.46	-6.4	-0.38	7.73e-10	Atopic dermatitis;
KIRP	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.36e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg24747557	chr10:131355152	MGMT	-0.39	-5.25	-0.32	3.36e-7	Response to temozolomide;
KIRP	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.73	8.96	0.5	8.52e-17	Mammographic density (dense area);
KIRP	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.72	-0.34	3.07e-8	Bipolar disorder;
KIRP	cis	rs876084	0.505	rs9969405	chr8:121107146	A/G	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg15684210	chr5:89755537	MBLAC2	0.43	6.14	0.36	3.33e-9	Migraine with aura;
KIRP	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg18477163	chr1:228402036	OBSCN	-0.33	-7.13	-0.41	1.08e-11	Diastolic blood pressure;
KIRP	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-13.88	-0.66	1.01e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.44	-5.54	-0.33	7.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.18e-7	Aortic root size;
KIRP	cis	rs7618501	0.699	rs9862795	chr3:49915506	A/T	cg24110177	chr3:50126178	RBM5	-0.61	-8.16	-0.46	1.78e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.51	0.48	1.76e-15	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04590956	chr2:70057467	GMCL1	0.58	6.91	0.4	4.25e-11	Smoking initiation;
KIRP	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.78	-11.91	-0.6	4.02e-26	Height;
KIRP	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.71	-10.36	-0.55	4.12e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03010761	chr12:104608278	TXNRD1	0.45	6.19	0.37	2.55e-9	Survival in pancreatic cancer;
KIRP	cis	rs9616064	0.889	rs7284276	chr22:46996137	G/C	cg05621596	chr22:47072043	GRAMD4	-0.59	-6.58	-0.39	2.76e-10	Urate levels in obese individuals;
KIRP	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg26354017	chr1:205819088	PM20D1	0.46	5.09	0.31	7.06e-7	Parkinson's disease;
KIRP	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.8	7.69	0.44	3.49e-13	Menopause (age at onset);
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg04159077	chr10:81110820	PPIF	-0.38	-6.24	-0.37	1.85e-9	Bladder cancer;
KIRP	cis	rs4148660	1.000	rs2138723	chr12:22082612	A/G	cg14669847	chr12:22099120	NA	0.33	5.67	0.34	4.08e-8	Gout;
KIRP	cis	rs6693567	0.565	rs471657	chr1:150276461	G/A	cg07843065	chr1:150265600	MRPS21	-0.47	-6.6	-0.39	2.47e-10	Migraine;
KIRP	cis	rs8756	1.000	rs8756	chr12:66359752	C/A	cg06712651	chr12:66351869	HMGA2	-0.77	-13.41	-0.65	3.77e-31	Height;
KIRP	cis	rs7572644	0.640	rs11891769	chr2:28025580	G/C	cg27432699	chr2:27873401	GPN1	0.5	5.84	0.35	1.64e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.84	12.91	0.64	1.8e-29	Testicular germ cell tumor;
KIRP	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.42	4.93	0.3	1.54e-6	Aortic root size;
KIRP	cis	rs34779708	0.733	rs7081597	chr10:35546331	G/C	cg03585969	chr10:35415529	CREM	0.56	6.53	0.38	3.79e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.93e-18	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg23985595	chr17:80112537	CCDC57	0.37	5.53	0.33	8.06e-8	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg02462569	chr6:150064036	NUP43	-0.4	-6.06	-0.36	5.18e-9	Lung cancer;
KIRP	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg05220968	chr6:146057943	EPM2A	-0.42	-5.61	-0.34	5.45e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7072216	0.666	rs2274248	chr10:100148542	C/T	cg19567339	chr10:100142640	NA	0.48	5.21	0.32	4.03e-7	Metabolite levels;
KIRP	cis	rs3736594	0.559	rs1919129	chr2:27818721	C/G	cg27432699	chr2:27873401	GPN1	0.57	6.71	0.39	1.32e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg10950524	chr7:2139216	MAD1L1	0.31	5.03	0.31	9.43e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg08738300	chr3:44038990	NA	0.66	9.13	0.5	2.65e-17	Coronary artery disease;
KIRP	cis	rs6910061	1.000	rs28860023	chr6:11106765	G/A	cg27233058	chr6:11094804	LOC221710	0.57	5.76	0.34	2.46e-8	Diabetic kidney disease;
KIRP	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.68	-11.27	-0.58	5.17e-24	Urate levels in overweight individuals;
KIRP	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15533453	chr10:2542242	NA	-0.29	-5.04	-0.31	9.2e-7	Age-related hearing impairment;
KIRP	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17554472	chr22:41940697	POLR3H	-0.68	-7.05	-0.41	1.82e-11	Vitiligo;
KIRP	cis	rs2425143	1.000	rs1890470	chr20:34357008	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.1	-0.36	4.01e-9	Blood protein levels;
KIRP	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-0.94	-7.89	-0.45	1.01e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	9.73	0.53	3.81e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2904967	0.929	rs554122	chr11:65033874	T/C	cg12562828	chr11:65076843	NA	0.47	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.7	6.89	0.4	4.72e-11	Prostate cancer;
KIRP	cis	rs1829883	0.775	rs2511964	chr5:98882541	G/T	cg08333243	chr5:99726346	NA	-0.43	-5.45	-0.33	1.22e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.48	6.34	0.37	1.12e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.86	-0.57	1.09e-22	Menopause (age at onset);
KIRP	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.42	6.02	0.36	6.24e-9	Bone mineral density;
KIRP	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.44e-7	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs6991838	0.584	rs4737749	chr8:66539907	A/C	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg11569703	chr11:65557185	OVOL1	-0.31	-4.92	-0.3	1.59e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	0.54	7.76	0.44	2.29e-13	Coronary artery disease;
KIRP	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.02	0.54	4.96e-20	Parkinson's disease;
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-6.81	-0.4	7.25e-11	Platelet count;
KIRP	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	6.08	0.36	4.58e-9	Breast cancer;
KIRP	cis	rs2505998	0.871	rs2505990	chr10:43565348	C/A	cg15436174	chr10:43711423	RASGEF1A	-0.51	-5.08	-0.31	7.53e-7	Hirschsprung disease;
KIRP	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg27205649	chr11:78285834	NARS2	-0.64	-8.25	-0.47	9.47e-15	Alzheimer's disease (survival time);
KIRP	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg02696742	chr7:106810147	HBP1	-0.8	-7.99	-0.45	5.19e-14	Osteoarthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27625283	chr20:50179430	NFATC2	0.43	6.04	0.36	5.76e-9	Parkinson's disease;
KIRP	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.94	-13.45	-0.65	2.76e-31	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg05991184	chr2:219186017	PNKD	0.34	4.89	0.3	1.82e-6	Colorectal cancer;
KIRP	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg25036284	chr2:26402008	FAM59B	-0.6	-5.98	-0.36	7.66e-9	Gut microbiome composition (summer);
KIRP	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7119167	0.901	rs10047442	chr11:73186864	A/T	cg17517138	chr11:73019481	ARHGEF17	0.48	5.1	0.31	6.63e-7	Blood protein levels;
KIRP	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.54	7.57	0.43	7.42e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.81	-9.35	-0.51	5.7e-18	IgG glycosylation;
KIRP	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.7	-8.34	-0.47	5.34e-15	Obesity-related traits;
KIRP	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.82	-11.9	-0.6	4.46e-26	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	1.11	17.59	0.75	2.06e-45	Homoarginine levels;
KIRP	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg19847130	chr8:10466454	RP1L1	0.38	5.67	0.34	3.97e-8	Retinal vascular caliber;
KIRP	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg10381502	chr11:71823885	C11orf51	-1.2	-7.89	-0.45	1.01e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	5.51	0.33	8.96e-8	Body mass index;
KIRP	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.69	-13.0	-0.64	9e-30	White blood cell count (basophil);
KIRP	cis	rs1431005	0.963	rs72725286	chr4:188396809	C/T	cg13810101	chr4:188427966	NA	-0.35	-5.13	-0.31	5.87e-7	Response to statin therapy;
KIRP	cis	rs4689642	0.709	rs11729619	chr4:7224489	T/C	cg21353189	chr4:7228343	SORCS2	0.43	5.46	0.33	1.18e-7	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.35	0.42	3e-12	Aortic root size;
KIRP	cis	rs4474465	0.541	rs11237527	chr11:78219664	C/A	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.48e-7	Alzheimer's disease (survival time);
KIRP	cis	rs12200782	1.000	rs12199239	chr6:26432570	G/C	cg11502198	chr6:26597334	ABT1	-0.73	-4.9	-0.3	1.74e-6	Small cell lung carcinoma;
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.97	-14.1	-0.67	1.79e-33	Longevity;Endometriosis;
KIRP	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17554472	chr22:41940697	POLR3H	0.64	6.8	0.4	7.98e-11	Vitiligo;
KIRP	cis	rs7267005	1.000	rs79497991	chr20:34460714	C/T	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs1440410	0.535	rs4561881	chr4:144040141	C/G	cg01719995	chr4:144104893	USP38	0.45	5.96	0.36	8.79e-9	Ischemic stroke;
KIRP	cis	rs2011503	0.509	rs884480	chr19:19773923	G/A	cg11584989	chr19:19387371	SF4	0.51	5.12	0.31	6.1e-7	Bipolar disorder;
KIRP	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg03808351	chr9:123631620	PHF19	0.44	6.02	0.36	6.3e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00933542	chr6:150070202	PCMT1	0.31	6.11	0.36	3.84e-9	Lung cancer;
KIRP	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	7.29	0.42	4.19e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg10253484	chr15:75165896	SCAMP2	0.5	5.54	0.33	7.74e-8	Systemic lupus erythematosus;
KIRP	cis	rs2694528	0.764	rs112511311	chr5:59872002	G/A	cg11474532	chr5:59995715	DEPDC1B	0.86	6.31	0.37	1.32e-9	Parkinson's disease;
KIRP	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	0.4	4.87	0.3	1.98e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg00262122	chr8:11665843	FDFT1	0.41	5.19	0.31	4.39e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.25	0.32	3.37e-7	Menopause (age at onset);
KIRP	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.58	7.88	0.45	1.03e-13	Height;
KIRP	cis	rs8054556	0.967	rs12918652	chr16:29964357	T/C	cg06326092	chr16:30034487	C16orf92	0.36	5.22	0.32	3.74e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg08017634	chr8:144659831	NAPRT1	0.82	5.2	0.31	4.25e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs4924935	0.509	rs8074020	chr17:18801380	T/C	cg26378065	chr17:18585709	ZNF286B	0.39	4.96	0.3	1.29e-6	Pancreatic cancer;
KIRP	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.83	10.95	0.57	5.27e-23	Primary sclerosing cholangitis;
KIRP	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.73	-9.07	-0.5	3.81e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16874894	chr20:45094014	LOC100240726	0.44	6.87	0.4	5.37e-11	Survival in pancreatic cancer;
KIRP	cis	rs9876781	0.559	rs7610524	chr3:48395372	A/G	cg11946769	chr3:48343235	NME6	0.42	5.21	0.32	3.98e-7	Longevity;
KIRP	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.83	11.85	0.6	6.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs2882667	0.861	rs10037106	chr5:138365490	G/T	cg04439458	chr5:138467593	SIL1	-0.44	-7.36	-0.43	2.68e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.03	-0.31	9.54e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs73200209	0.665	rs17498599	chr12:116597253	C/T	cg01776926	chr12:116560359	MED13L	-0.51	-5.82	-0.35	1.81e-8	Total body bone mineral density;
KIRP	cis	rs6120849	0.901	rs6058194	chr20:33739831	G/A	cg24642439	chr20:33292090	TP53INP2	0.6	6.64	0.39	1.96e-10	Protein C levels;
KIRP	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.81	-10.92	-0.57	6.63e-23	Breast cancer;
KIRP	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9393813	0.516	rs4711152	chr6:27380202	C/T	cg18711553	chr6:27366782	ZNF391	0.37	4.92	0.3	1.61e-6	Bipolar disorder;
KIRP	cis	rs35740288	0.580	rs34635893	chr15:86340248	C/T	cg20737812	chr15:86336631	KLHL25	-0.51	-6.23	-0.37	2e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17270561	0.609	rs9467572	chr6:25704126	T/G	cg16482183	chr6:26056742	HIST1H1C	-0.6	-6.88	-0.4	4.94e-11	Iron status biomarkers;
KIRP	cis	rs7015630	0.563	rs28461337	chr8:90825135	T/G	cg18493113	chr8:90847772	NA	-0.46	-4.93	-0.3	1.49e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.69	9.41	0.51	3.67e-18	Personality dimensions;
KIRP	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg02570527	chr1:10970165	NA	-0.44	-5.42	-0.33	1.42e-7	Body mass index;
KIRP	cis	rs4886920	0.802	rs7164558	chr15:78146382	A/G	cg10461261	chr15:78109450	NA	-0.31	-5.04	-0.31	8.95e-7	Neuroticism;
KIRP	cis	rs60311166	1.000	rs72950430	chr3:52695061	A/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.98	6.14	0.36	3.25e-9	CTACK levels;
KIRP	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg23280166	chr11:118938394	VPS11	0.64	7.62	0.44	5.38e-13	Coronary artery disease;
KIRP	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg09873164	chr1:152488093	CRCT1	0.5	6.38	0.38	8.9e-10	Plantar warts;
KIRP	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.08	0.61	1.08e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2562456	0.833	rs62107541	chr19:21518535	T/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs2120243	0.533	rs1392798	chr3:157056287	A/G	cg24825693	chr3:157122686	VEPH1	0.37	5.69	0.34	3.53e-8	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs41264869	0.628	rs1061132	chr1:205115150	C/A	cg21214746	chr1:205091277	RBBP5	0.53	6.85	0.4	6.03e-11	Blood protein levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg24054508	chr1:38273761	C1orf122;YRDC	0.51	6.43	0.38	6.52e-10	Myopia (pathological);
KIRP	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.69	-8.22	-0.46	1.15e-14	Eosinophil percentage of white cells;
KIRP	cis	rs12519773	0.502	rs4613686	chr5:92498497	A/G	cg18783429	chr5:92414398	NA	0.31	5.33	0.32	2.27e-7	Migraine;
KIRP	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.28	7.3	0.42	3.95e-12	Primary biliary cholangitis;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg13305585	chr1:235530624	TBCE	0.53	6.92	0.4	3.98e-11	Neuroticism;
KIRP	cis	rs9972944	0.729	rs1541610	chr17:63773836	C/T	cg07283582	chr17:63770753	CCDC46	0.52	8.58	0.48	1.06e-15	Total body bone mineral density;
KIRP	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg06115741	chr20:33292138	TP53INP2	0.56	7.12	0.41	1.17e-11	Coronary artery disease;
KIRP	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.56	-6.44	-0.38	6.24e-10	Alzheimer's disease (late onset);
KIRP	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	14.24	0.67	5.77e-34	Electrocardiographic conduction measures;
KIRP	cis	rs751728	0.965	rs756137	chr6:33755890	T/C	cg25922239	chr6:33757077	LEMD2	0.7	8.55	0.48	1.31e-15	Crohn's disease;
KIRP	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg27147174	chr7:100797783	AP1S1	-0.58	-7.5	-0.43	1.14e-12	Life satisfaction;
KIRP	cis	rs1514687	0.534	rs11211654	chr2:1474131	C/T	cg03133821	chr2:1513998	TPO	-0.63	-5.6	-0.34	5.77e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.97	10.88	0.57	9.09e-23	Corneal astigmatism;
KIRP	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg15691649	chr6:25882328	NA	-0.41	-5.11	-0.31	6.52e-7	Blood metabolite levels;
KIRP	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg00405596	chr8:11794950	NA	-0.4	-4.89	-0.3	1.81e-6	Neuroticism;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.58	8.83	0.49	2.02e-16	Vitiligo;
KIRP	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg17145862	chr1:211918768	LPGAT1	0.76	10.56	0.56	9.48e-22	Leprosy;
KIRP	cis	rs9649213	0.574	rs9648908	chr7:97945236	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.96	0.36	8.88e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.5	-8.54	-0.48	1.41e-15	Refractive error;
KIRP	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg16486109	chr11:613632	IRF7	0.44	5.21	0.32	3.99e-7	Systemic lupus erythematosus;
KIRP	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-0.96	-10.42	-0.55	2.73e-21	Height;
KIRP	cis	rs10128264	0.902	rs2802360	chr10:80971196	C/T	cg20744163	chr10:80999841	ZMIZ1	-0.34	-5.65	-0.34	4.37e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.8	11.52	0.59	7.85e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-9.56	-0.52	1.25e-18	Lung cancer;
KIRP	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9556958	0.708	rs4772092	chr13:99166614	A/G	cg20750642	chr13:99100586	FARP1	0.51	7.21	0.42	6.87e-12	Educational attainment (years of education);
KIRP	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18932078	chr1:2524107	MMEL1	-0.48	-6.76	-0.4	1.02e-10	Ulcerative colitis;
KIRP	cis	rs2063714	0.967	rs913971	chr6:157197802	C/T	cg23222435	chr6:157204239	ARID1B	-0.5	-7.34	-0.42	3.12e-12	Sitting height ratio;
KIRP	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg24315340	chr6:146058215	EPM2A	0.45	5.72	0.34	3.01e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg20578329	chr17:80767326	TBCD	-0.95	-8.57	-0.48	1.14e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.56	-0.33	6.9e-8	Colorectal cancer;
KIRP	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs2797160	0.547	rs9401837	chr6:125956853	T/C	cg05901451	chr6:126070800	HEY2	-0.37	-5.11	-0.31	6.4e-7	Endometrial cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05064645	chr7:55086868	EGFR	0.49	6.3	0.37	1.37e-9	Parkinson's disease;
KIRP	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06850241	chr22:41845214	NA	-0.46	-5.25	-0.32	3.24e-7	Vitiligo;
KIRP	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.68	9.49	0.52	2.1e-18	Post bronchodilator FEV1;
KIRP	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg06204229	chr3:52865917	ITIH4	0.46	5.43	0.33	1.38e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.16	-16.4	-0.72	2.47e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg10761708	chr20:43804764	PI3	0.49	5.16	0.31	5.18e-7	Blood protein levels;
KIRP	cis	rs427941	0.632	rs201480	chr7:101747575	A/G	cg06246474	chr7:101738831	CUX1	0.54	6.63	0.39	2.07e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.74	-9.3	-0.51	7.85e-18	Aortic root size;
KIRP	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03934478	chr11:495069	RNH1	-0.82	-6.78	-0.4	8.97e-11	Body mass index;
KIRP	cis	rs2046867	0.908	rs113001746	chr3:72824260	C/T	cg25664220	chr3:72788482	NA	-0.49	-7.2	-0.42	7.29e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg26513180	chr16:89883248	FANCA	0.74	5.16	0.31	4.99e-7	Skin colour saturation;
KIRP	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg07308232	chr7:1071921	C7orf50	-0.55	-6.64	-0.39	2.01e-10	Longevity;Endometriosis;
KIRP	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.57	-7.66	-0.44	4.14e-13	Blood protein levels;
KIRP	cis	rs12478665	1	rs12478665	chr2:210123032	C/T	cg20296298	chr2:210074020	NA	0.46	5.67	0.34	4.02e-8	Hippocampal volume;
KIRP	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg02175308	chr1:109941060	SORT1	-0.3	-5.75	-0.34	2.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.73	0.34	2.92e-8	Personality dimensions;
KIRP	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg15128208	chr22:42549153	NA	0.69	7.92	0.45	8.11e-14	Birth weight;
KIRP	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-8.42	-0.47	3.1e-15	Morning vs. evening chronotype;
KIRP	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.92	-9.03	-0.5	5.14e-17	Vitamin D levels;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11245431	chr2:70056635	GMCL1	0.5	6.11	0.36	3.84e-9	Parkinson's disease;
KIRP	cis	rs80130819	0.688	rs10783232	chr12:48583491	A/G	cg26205652	chr12:48591994	NA	0.49	5.54	0.33	7.57e-8	Prostate cancer;
KIRP	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.47	-6.3	-0.37	1.33e-9	Monocyte count;
KIRP	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	0.99	7.71	0.44	3.02e-13	Arsenic metabolism;
KIRP	cis	rs838147	0.844	rs12982115	chr19:49248640	A/G	cg13540341	chr19:49222985	MAMSTR	0.36	5.75	0.34	2.62e-8	Dietary macronutrient intake;
KIRP	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.39	2.67e-10	Bipolar disorder;
KIRP	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg02696790	chr15:75250997	RPP25	0.31	5.13	0.31	5.77e-7	Caffeine consumption;
KIRP	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg17724175	chr1:150552817	MCL1	0.35	5.74	0.34	2.77e-8	Melanoma;
KIRP	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg04691961	chr3:161091175	C3orf57	-0.51	-7.75	-0.44	2.36e-13	Morning vs. evening chronotype;
KIRP	cis	rs2380205	0.967	rs10905307	chr10:5894500	A/G	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.52e-8	Breast cancer;
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.59	0.34	6.03e-8	Lung cancer;
KIRP	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27144592	chr16:783916	NARFL	0.37	5.11	0.31	6.42e-7	Height;
KIRP	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.81	-0.4	7.64e-11	Monocyte count;
KIRP	cis	rs4908768	0.579	rs75634300	chr1:8872455	C/T	cg25722041	chr1:8623473	RERE	0.58	7.55	0.43	8.29e-13	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.7	-11.05	-0.58	2.51e-23	Hepatocellular carcinoma;
KIRP	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.59	8.39	0.47	3.78e-15	Lewy body disease;
KIRP	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg04034577	chr2:241836375	C2orf54	-0.3	-5.8	-0.35	2.06e-8	Urinary metabolites;
KIRP	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg10517650	chr3:113235015	CCDC52	-0.47	-6.14	-0.36	3.29e-9	Dental caries;
KIRP	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.68	8.34	0.47	5.38e-15	Corneal astigmatism;
KIRP	cis	rs6750047	0.585	rs168054	chr2:38260282	C/G	cg07380506	chr2:38303506	CYP1B1	-0.4	-5.37	-0.32	1.87e-7	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.55	7.22	0.42	6.55e-12	Total body bone mineral density;
KIRP	cis	rs72949976	0.707	rs10932473	chr2:214039057	C/T	cg08319019	chr2:214017104	IKZF2	-0.52	-5.47	-0.33	1.13e-7	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs16912285	0.685	rs16912402	chr11:24313135	C/G	ch.11.24196551F	chr11:24239977	NA	0.69	5.1	0.31	6.89e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.77	8.96	0.5	8.36e-17	Corneal astigmatism;
KIRP	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.61	-8.21	-0.46	1.24e-14	Colorectal cancer;
KIRP	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.53	5.74	0.34	2.83e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg00277334	chr10:82204260	NA	-0.51	-5.55	-0.33	7.55e-8	Post bronchodilator FEV1;
KIRP	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg04087571	chr11:116723030	SIK3	-0.27	-5.66	-0.34	4.16e-8	Subjective well-being;
KIRP	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.3	6.1	0.36	4.05e-9	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.78	9.94	0.54	8.92e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7301016	1.000	rs11614022	chr12:62891329	A/G	cg01804193	chr12:63026212	NA	0.53	5.32	0.32	2.3e-7	IgG glycosylation;
KIRP	cis	rs7729447	0.776	rs17442964	chr5:32693916	G/A	cg16267343	chr5:32710456	NPR3	0.51	5.85	0.35	1.55e-8	Blood pressure;
KIRP	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-8.18	-0.46	1.54e-14	Common traits (Other);
KIRP	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs615632	0.516	rs13279794	chr8:9684014	A/C	cg27411982	chr8:10470053	RP1L1	0.42	5.41	0.33	1.47e-7	Neuroticism;
KIRP	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-5.67	-0.34	3.9e-8	Mean corpuscular volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12848864	chr11:108093218	ATM;NPAT	-0.46	-6.25	-0.37	1.81e-9	Interleukin-4 levels;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg13436085	chr3:183904316	ABCF3	0.93	6.13	0.36	3.46e-9	P wave terminal force;
KIRP	cis	rs4835473	0.932	rs4383567	chr4:144710026	G/A	cg08833778	chr4:144622313	FREM3	0.34	5.01	0.3	1.04e-6	Immature fraction of reticulocytes;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg18125479	chr14:51411049	PYGL	0.5	6.31	0.37	1.29e-9	Sleep duration;
KIRP	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg21605333	chr4:119757512	SEC24D	1.6	11.58	0.59	4.99e-25	Cannabis dependence symptom count;
KIRP	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg22138327	chr13:27999177	GTF3A	-0.98	-7.76	-0.44	2.31e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.94	-0.45	7.19e-14	Eye color traits;
KIRP	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg00031303	chr3:195681400	NA	0.67	7.6	0.44	6.06e-13	Pancreatic cancer;
KIRP	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.45	5.73	0.34	2.91e-8	Life satisfaction;
KIRP	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.45	6.2	0.37	2.33e-9	Sitting height ratio;
KIRP	trans	rs9409565	0.821	rs9299419	chr9:97066584	C/T	cg05679027	chr9:99775184	HIATL2	0.58	6.97	0.41	2.93e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs5753037	0.803	rs131262	chr22:30133044	G/T	cg01021169	chr22:30184971	ASCC2	-0.39	-4.93	-0.3	1.54e-6	Type 1 diabetes;
KIRP	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.66	-12.13	-0.61	7.47e-27	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21129041	chr4:20528506	MIR218-1;SLIT2	-0.41	-6.96	-0.41	3.06e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11825064	0.666	rs61393915	chr11:134496330	C/T	cg06603561	chr11:134479413	NA	-0.78	-6.34	-0.37	1.08e-9	Seasonality;
KIRP	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.11	0.46	2.36e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg01721255	chr8:58191610	C8orf71	0.64	5.87	0.35	1.39e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg12560992	chr17:57184187	TRIM37	0.68	6.54	0.38	3.5e-10	Cognitive test performance;
KIRP	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18932078	chr1:2524107	MMEL1	-0.45	-6.22	-0.37	2.11e-9	Ulcerative colitis;
KIRP	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.88	-0.45	1.03e-13	Retinal vascular caliber;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.75	10.8	0.57	1.65e-22	Lung cancer;
KIRP	cis	rs3752645	1.000	rs11772066	chr7:106747441	C/G	cg02696742	chr7:106810147	HBP1	-0.64	-4.98	-0.3	1.21e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg08989290	chr16:615782	NHLRC4	0.41	6.07	0.36	4.71e-9	Height;
KIRP	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg05347473	chr6:146136440	FBXO30	0.5	7.18	0.42	8.29e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.6	7.21	0.42	6.72e-12	Longevity;Endometriosis;
KIRP	cis	rs72829446	0.530	rs2301609	chr17:7399866	G/A	cg02795151	chr17:7402630	POLR2A	0.75	7.89	0.45	9.98e-14	Androgen levels;
KIRP	cis	rs2425143	1.000	rs6058311	chr20:34321895	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.14	-0.31	5.6e-7	Life satisfaction;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16642003	chr16:30456845	SEPHS2	0.52	7.17	0.42	8.92e-12	Survival in pancreatic cancer;
KIRP	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04317338	chr11:64019027	PLCB3	0.56	6.48	0.38	4.89e-10	Platelet count;
KIRP	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg01411142	chr8:19674711	INTS10	0.45	4.94	0.3	1.43e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.76	8.48	0.48	2.06e-15	Cholesterol, total;
KIRP	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg16558253	chr16:72132732	DHX38	-0.6	-9.04	-0.5	4.93e-17	Fibrinogen levels;
KIRP	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg21827317	chr3:136751795	NA	0.37	5.18	0.31	4.61e-7	Neuroticism;
KIRP	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.87	-11.46	-0.59	1.16e-24	Type 2 diabetes;
KIRP	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	6.49	0.38	4.78e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs2425143	0.730	rs6060624	chr20:34413663	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.84e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg05347473	chr6:146136440	FBXO30	0.56	8.0	0.45	5.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs60154123	0.730	rs12034871	chr1:210475701	T/C	cg09074223	chr1:210466472	NA	0.6	6.26	0.37	1.73e-9	Coronary artery disease;
KIRP	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19346786	chr7:2764209	NA	-0.41	-6.75	-0.4	1.08e-10	Height;
KIRP	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.51	6.21	0.37	2.3e-9	Menopause (age at onset);
KIRP	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.57	7.36	0.42	2.7e-12	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg04519387	chr11:65556438	OVOL1	0.35	5.16	0.31	5.1e-7	Acne (severe);
KIRP	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.36	-5.14	-0.31	5.48e-7	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg20701182	chr2:24300061	SF3B14	0.52	5.04	0.31	9.17e-7	Lymphocyte counts;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg02733842	chr7:1102375	C7orf50	0.53	5.51	0.33	9e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.64	8.26	0.47	8.85e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.62	-6.96	-0.41	3.14e-11	Neuroticism;
KIRP	cis	rs1656402	1.000	rs6749955	chr2:233437917	A/C	cg03852847	chr2:233439513	NA	0.72	12.01	0.61	1.89e-26	Non-small cell lung cancer (survival);
KIRP	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg04691961	chr3:161091175	C3orf57	-0.49	-6.99	-0.41	2.64e-11	Parkinson's disease;
KIRP	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg13010199	chr12:38710504	ALG10B	0.62	7.62	0.44	5.6e-13	Morning vs. evening chronotype;
KIRP	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg23950597	chr19:37808831	NA	-0.64	-6.88	-0.4	5.02e-11	Coronary artery calcification;
KIRP	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg16479474	chr6:28041457	NA	0.51	5.08	0.31	7.32e-7	Parkinson's disease;
KIRP	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg20637307	chr2:213403960	ERBB4	0.95	16.73	0.73	1.74e-42	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg04310649	chr10:35416472	CREM	-0.55	-6.24	-0.37	1.93e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg17108996	chr10:112631584	LOC282997;PDCD4	-0.49	-6.02	-0.36	6.21e-9	Migraine with aura;
KIRP	cis	rs8014252	0.711	rs58069917	chr14:71043557	C/T	cg19730268	chr14:71022823	NA	-0.71	-6.29	-0.37	1.44e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs12643440	0.655	rs7685926	chr4:17196890	G/A	cg22650099	chr4:17144496	NA	-0.62	-6.55	-0.39	3.37e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg23594656	chr7:65796392	TPST1	0.39	5.69	0.34	3.57e-8	Aortic root size;
KIRP	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs4006360	0.505	rs9916287	chr17:39286884	T/G	cg15015397	chr17:39261100	KRTAP4-9	-0.54	-7.11	-0.41	1.24e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs508618	0.731	rs11805033	chr1:231546452	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	5.84	0.35	1.64e-8	Red blood cell count;
KIRP	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.81	8.33	0.47	5.63e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs17065868	0.803	rs9595164	chr13:45205257	A/C	cg10246903	chr13:45222710	NA	0.56	6.03	0.36	6.06e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg14132834	chr19:41945861	ATP5SL	0.59	7.62	0.44	5.5e-13	Height;
KIRP	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.49	-8.25	-0.47	9.35e-15	Pneumonia;
KIRP	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg06121193	chr1:90282411	NA	-0.48	-6.96	-0.41	3.13e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg18709589	chr6:96969512	KIAA0776	-0.42	-4.99	-0.3	1.16e-6	Migraine;Coronary artery disease;
KIRP	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7224685	0.569	rs12453798	chr17:4017079	C/T	cg11204139	chr17:3907470	NA	0.54	5.11	0.31	6.51e-7	Type 2 diabetes;
KIRP	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.05e-8	Common traits (Other);
KIRP	cis	rs2708977	0.965	rs2314109	chr2:97243532	A/G	cg01950434	chr2:97203154	ARID5A	-0.53	-6.62	-0.39	2.27e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.62	9.38	0.51	4.53e-18	Immature fraction of reticulocytes;
KIRP	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg23067535	chr8:124195133	FAM83A	-0.8	-7.37	-0.43	2.62e-12	Urinary uromodulin levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10376100	chr1:236017278	LYST;MIR1537	0.46	6.06	0.36	5.06e-9	Interleukin-4 levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26373528	chr12:122326914	PSMD9	-0.55	-6.02	-0.36	6.36e-9	Menopause (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg09110655	chr11:3876737	STIM1	-0.47	-6.08	-0.36	4.54e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg16606324	chr3:10149918	C3orf24	0.69	5.82	0.35	1.82e-8	Alzheimer's disease;
KIRP	cis	rs7635838	0.892	rs34830847	chr3:11437798	A/C	cg00170343	chr3:11313890	ATG7	0.45	5.74	0.34	2.78e-8	HDL cholesterol;
KIRP	cis	rs12900413	0.687	rs7176948	chr15:90315707	A/C	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.66e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg07395648	chr5:131743802	NA	-0.37	-5.2	-0.31	4.18e-7	Lung function (FEV1/FVC);
KIRP	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg26668828	chr6:292823	DUSP22	-0.62	-7.26	-0.42	5.14e-12	Menopause (age at onset);
KIRP	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.68	9.25	0.51	1.13e-17	Prostate cancer;
KIRP	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.52	-7.41	-0.43	1.96e-12	Fibrinogen levels;
KIRP	cis	rs42648	0.564	rs12155202	chr7:89828124	A/C	cg25739043	chr7:89950458	NA	-0.37	-5.84	-0.35	1.68e-8	Homocysteine levels;
KIRP	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	1.09	12.07	0.61	1.2e-26	Psoriasis;
KIRP	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg22705602	chr4:152727874	NA	-0.53	-9.26	-0.51	1.07e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg11833968	chr6:79620685	NA	-0.47	-6.99	-0.41	2.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11673344	0.526	rs55865869	chr19:38069585	C/G	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.52	-0.33	8.41e-8	Obesity-related traits;
KIRP	trans	rs933360	0.585	rs6593173	chr7:50832939	C/T	cg20003124	chr12:4557277	NA	0.53	6.46	0.38	5.69e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg17275844	chr4:48500942	FRYL	0.42	6.49	0.38	4.72e-10	C-reactive protein;
KIRP	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg24972876	chr7:65420302	NA	0.41	5.61	0.34	5.53e-8	Aortic root size;
KIRP	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.75	0.71	4.13e-39	Chronic sinus infection;
KIRP	cis	rs11161851	0.868	rs277366	chr1:75300917	A/G	cg11196437	chr1:75593865	LHX8	0.41	5.88	0.35	1.3e-8	Visceral fat;
KIRP	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg02367723	chr1:46378857	MAST2	0.43	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.55	-6.42	-0.38	6.79e-10	Aortic root size;
KIRP	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	15.8	0.71	2.71e-39	Platelet count;
KIRP	cis	rs12580194	0.556	rs7955088	chr12:55732963	G/T	cg11794356	chr12:55725991	OR6C3	-0.61	-8.76	-0.49	3.2e-16	Cancer;
KIRP	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.93e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg10664184	chr19:17420304	DDA1	0.71	8.28	0.47	8.17e-15	Systemic lupus erythematosus;
KIRP	cis	rs8756	0.620	rs867633	chr12:66354911	G/A	cg06712651	chr12:66351869	HMGA2	-0.65	-9.55	-0.52	1.42e-18	Height;
KIRP	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg27490568	chr2:178487706	NA	0.4	5.35	0.32	2.05e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.42	5.0	0.3	1.11e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg23736307	chr8:27182930	PTK2B	0.54	6.78	0.4	8.61e-11	Neuroticism;
KIRP	cis	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.4	5.19	0.31	4.3e-7	Leprosy;
KIRP	cis	rs7975161	1.000	rs4964728	chr12:104649733	G/A	cg25273343	chr12:104657179	TXNRD1	-0.61	-6.2	-0.37	2.31e-9	Toenail selenium levels;
KIRP	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.45	-0.33	1.2e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	12.57	0.63	2.63e-28	Platelet count;
KIRP	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	7.28	0.42	4.44e-12	Tonsillectomy;
KIRP	cis	rs2281603	0.570	rs10131416	chr14:64944273	C/G	cg01860774	chr14:64969374	ZBTB25	0.34	5.53	0.33	8.02e-8	Lymphocyte counts;
KIRP	cis	rs55871839	0.559	rs66954327	chr8:59825133	A/G	cg07426533	chr8:59803705	TOX	0.39	5.28	0.32	2.87e-7	Pneumonia;
KIRP	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.62	9.0	0.5	6.36e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg00262122	chr8:11665843	FDFT1	-0.46	-5.71	-0.34	3.18e-8	Triglycerides;
KIRP	cis	rs2223471	0.719	rs9381901	chr6:50765751	A/G	cg14470998	chr6:50812995	TFAP2B	-0.38	-4.91	-0.3	1.63e-6	Subcutaneous adipose tissue;
KIRP	cis	rs1448094	1.000	rs1448094	chr12:86343135	G/T	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.23	0.42	6.01e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg16141378	chr3:129829833	LOC729375	0.58	7.26	0.42	5.16e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.52	0.56	1.26e-21	Cognitive test performance;
KIRP	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23598886	chr18:12777645	NA	-0.65	-5.12	-0.31	6.28e-7	Inflammatory skin disease;
KIRP	cis	rs7258465	0.931	rs76195	chr19:18629830	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.46	-0.43	1.44e-12	Breast cancer;
KIRP	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.62	7.94	0.45	7.32e-14	Resting heart rate;
KIRP	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg14593290	chr7:50529359	DDC	-0.78	-9.51	-0.52	1.87e-18	Malaria;
KIRP	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg09754948	chr16:28834200	ATXN2L	0.46	5.33	0.32	2.23e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-9.48	-0.52	2.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	0.84	11.19	0.58	9.26e-24	Primary sclerosing cholangitis;
KIRP	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg09201719	chr10:104596890	CYP17A1	0.35	5.02	0.3	1e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs748404	0.697	rs473554	chr15:43568207	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.51	0.43	1.1e-12	Lung cancer;
KIRP	cis	rs7335046	0.614	rs72651406	chr13:100083373	G/A	cg25919922	chr13:100150906	NA	-0.57	-4.98	-0.3	1.21e-6	Basal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg09264619	chr17:80180166	NA	-0.38	-5.63	-0.34	5.02e-8	Life satisfaction;
KIRP	cis	rs6662572	0.853	rs2065708	chr1:45977685	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.55	6.12	0.36	3.57e-9	Blood protein levels;
KIRP	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.58	-6.2	-0.37	2.31e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg21360079	chr12:107162445	NA	-0.69	-9.86	-0.53	1.5700000000000001e-19	Heart rate;
KIRP	trans	rs12431410	0.536	rs7159851	chr14:60153768	G/A	cg20601314	chr10:104179541	FBXL15;PSD	-0.57	-6.1	-0.36	4.08e-9	Schizophrenia;
KIRP	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg00277334	chr10:82204260	NA	-0.58	-6.03	-0.36	5.86e-9	Post bronchodilator FEV1;
KIRP	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.81	-11.62	-0.6	3.48e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs9603616	0.899	rs9603603	chr13:40300328	A/C	cg26701198	chr13:40229707	COG6	-0.47	-4.9	-0.3	1.72e-6	Rheumatoid arthritis;
KIRP	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs5753618	0.539	rs5997933	chr22:31672752	A/C	cg22777020	chr22:31556080	RNF185	-0.47	-4.99	-0.3	1.12e-6	Colorectal cancer;
KIRP	cis	rs300774	0.764	rs300756	chr2:233416	G/A	cg10118717	chr2:203439	NA	0.43	5.29	0.32	2.69e-7	Suicide attempts in bipolar disorder;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15268622	chr1:167189846	POU2F1	1.04	7.0	0.41	2.43e-11	P wave terminal force;
KIRP	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg21926883	chr2:100939477	LONRF2	-0.64	-8.81	-0.49	2.33e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg05784532	chr1:230284198	GALNT2	0.43	6.72	0.39	1.22e-10	Coronary artery disease;
KIRP	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.65	-7.71	-0.44	3.02e-13	Longevity;Endometriosis;
KIRP	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg04609801	chr16:28609176	SULT1A2	-0.56	-5.09	-0.31	6.98e-7	Platelet distribution width;
KIRP	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg12384639	chr17:618140	VPS53	0.49	5.96	0.36	8.84e-9	Prostate cancer;
KIRP	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.37	-5.0	-0.3	1.1e-6	Monocyte percentage of white cells;
KIRP	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.72	-10.13	-0.54	2.25e-20	Plateletcrit;Platelet count;
KIRP	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.46	6.13	0.36	3.38e-9	Red blood cell count;
KIRP	cis	rs7852872	0.965	rs7030607	chr9:119245183	G/A	cg13792444	chr9:119245443	ASTN2	0.47	6.74	0.39	1.15e-10	Hippocampal volume;
KIRP	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg09165964	chr15:75287851	SCAMP5	-0.86	-6.0	-0.36	6.85e-9	Lung cancer;
KIRP	cis	rs4262150	0.764	rs10155517	chr5:151937958	G/T	cg12297329	chr5:152029980	NA	-0.62	-7.68	-0.44	3.76e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg06795125	chr2:108905320	SULT1C2	-0.48	-8.37	-0.47	4.32e-15	Blood pressure;
KIRP	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg06453172	chr10:134556979	INPP5A	-0.54	-5.94	-0.35	9.72e-9	Migraine;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg17824465	chr22:51001806	C22orf41	-0.48	-6.48	-0.38	4.95e-10	Morning vs. evening chronotype;
KIRP	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.97	0.41	2.93e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.44	-0.33	1.3e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.66	-9.89	-0.53	1.27e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg07701084	chr6:150067640	NUP43	-0.6	-7.83	-0.45	1.43e-13	Lung cancer;
KIRP	cis	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.4	5.34	0.32	2.14e-7	Leprosy;
KIRP	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg14893161	chr1:205819251	PM20D1	0.53	5.84	0.35	1.67e-8	Parkinson's disease;
KIRP	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.82	-11.48	-0.59	1.06e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.68	-8.28	-0.47	7.74e-15	Cognitive function;
KIRP	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.66	0.6	2.7e-25	Alzheimer's disease;
KIRP	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg00343986	chr7:65444356	GUSB	-0.45	-5.47	-0.33	1.11e-7	Aortic root size;
KIRP	cis	rs17641971	0.619	rs6983929	chr8:49984896	T/C	cg00325661	chr8:49890786	NA	0.44	5.8	0.35	2.04e-8	Blood metabolite levels;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg23736307	chr8:27182930	PTK2B	0.55	6.87	0.4	5.36e-11	Neuroticism;
KIRP	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	1.19	8.78	0.49	2.9e-16	Economic and political preferences (immigration/crime);
KIRP	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.78	10.2	0.55	1.28e-20	Aortic root size;
KIRP	cis	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg07585502	chr8:101912084	NA	-0.64	-8.76	-0.49	3.13e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.99	-15.24	-0.7	2.29e-37	Coronary artery disease;
KIRP	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.51	-0.38	4.26e-10	Hemoglobin concentration;
KIRP	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.36	-0.32	1.92e-7	Bladder cancer;
KIRP	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.7	10.62	0.56	6.1e-22	Dupuytren's disease;
KIRP	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg18493069	chr6:108582623	SNX3	0.94	6.42	0.38	7e-10	P wave terminal force;
KIRP	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg06636001	chr8:8085503	FLJ10661	-0.77	-10.46	-0.55	1.99e-21	Joint mobility (Beighton score);
KIRP	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Corneal astigmatism;
KIRP	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.93	14.68	0.68	1.8e-35	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02834497	chr19:12405873	ZNF44	0.51	6.09	0.36	4.34e-9	Parkinson's disease;
KIRP	cis	rs42648	0.902	rs17874789	chr7:90001160	A/T	cg25739043	chr7:89950458	NA	0.44	6.87	0.4	5.16e-11	Homocysteine levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg14011554	chr9:128657810	PBX3	0.38	6.04	0.36	5.76e-9	C-reactive protein;
KIRP	cis	rs4363506	0.635	rs10765124	chr10:129286181	C/T	cg07804728	chr10:129284050	NA	-0.47	-6.14	-0.36	3.38e-9	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg06935464	chr4:38784597	TLR10	0.5	5.3	0.32	2.6e-7	Breast cancer;
KIRP	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.64	-7.15	-0.41	9.9e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs7078219	0.714	rs12360459	chr10:101286154	A/G	cg07044859	chr10:101282883	NA	-0.33	-4.87	-0.3	1.97e-6	Dental caries;
KIRP	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.42	5.13	0.31	5.87e-7	Melanoma;
KIRP	cis	rs537626	0.542	rs3015959	chr11:69312470	C/G	cg08353955	chr11:69289746	NA	-0.59	-5.4	-0.33	1.58e-7	Breast cancer (early onset);
KIRP	trans	rs4084594	0.532	rs62383078	chr5:63225867	C/T	cg22673688	chr1:246148901	SMYD3	-0.54	-6.03	-0.36	5.97e-9	Schizophrenia;
KIRP	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.04	0.41	1.88e-11	Mean corpuscular volume;
KIRP	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg21775007	chr8:11205619	TDH	0.45	6.03	0.36	5.86e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.67	8.93	0.49	1.02e-16	Morning vs. evening chronotype;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15848628	chr7:100210192	MOSPD3	0.45	6.26	0.37	1.73e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.9	-14.54	-0.68	5.59e-35	Dental caries;
KIRP	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.3	6.11	0.36	3.85e-9	Schizophrenia;
KIRP	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.84	-0.35	1.66e-8	Bipolar disorder;
KIRP	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	0.95	18.3	0.76	8.16e-48	Dental caries;
KIRP	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.56	6.12	0.36	3.7e-9	Schizophrenia;
KIRP	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.71	-0.49	4.64e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1823913	0.599	rs12988037	chr2:192171145	A/G	cg12404831	chr2:192114017	MYO1B	0.5	6.96	0.41	3.03e-11	Obesity-related traits;
KIRP	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Body mass index;
KIRP	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10819733	chr22:24237672	NA	-0.33	-4.95	-0.3	1.39e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.59	-0.48	1.03e-15	Coronary artery disease;
KIRP	cis	rs7709377	0.570	rs1588267	chr5:115434969	T/A	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.59e-7	Metabolite levels  (X-11787);
KIRP	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7560272	0.501	rs2421674	chr2:73955432	G/A	cg20560298	chr2:73613845	ALMS1	0.45	5.4	0.33	1.59e-7	Schizophrenia;
KIRP	cis	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg07460842	chr6:66804631	NA	1.05	13.15	0.64	2.79e-30	Exhaled nitric oxide output;
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.71	10.4	0.55	3.04e-21	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.06	0.31	8.04e-7	Breast cancer;
KIRP	cis	rs6450176	0.638	rs56220547	chr5:53287952	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.18	-14.2	-0.67	7.76e-34	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.42	-5.34	-0.32	2.07e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs72792276	0.908	rs3828656	chr5:127487535	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	7.47	0.43	1.38e-12	Red cell distribution width;
KIRP	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg07884673	chr3:53033167	SFMBT1	1.0	7.75	0.44	2.48e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-8.5	-0.48	1.88e-15	Morning vs. evening chronotype;
KIRP	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.86	7.16	0.42	9.17e-12	Major depressive disorder;
KIRP	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg23796481	chr11:64053134	BAD;GPR137	0.82	7.08	0.41	1.54e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1440410	0.835	rs9790822	chr4:144051901	T/C	cg01719995	chr4:144104893	USP38	0.47	6.55	0.39	3.27e-10	Ischemic stroke;
KIRP	cis	rs4765905	0.671	rs1108074	chr12:2333484	C/T	cg10668781	chr12:2307325	CACNA1C	-0.27	-5.21	-0.32	4.04e-7	Schizophrenia;
KIRP	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg04013166	chr16:89971882	TCF25	0.67	5.64	0.34	4.54e-8	Skin colour saturation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04213235	chr1:145826932	GPR89A	0.54	6.28	0.37	1.49e-9	Smoking initiation;
KIRP	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg16589663	chr20:23618590	CST3	0.73	6.92	0.4	3.79e-11	Chronic kidney disease;
KIRP	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg06027949	chr8:82754900	SNX16	-0.59	-6.43	-0.38	6.44e-10	Diastolic blood pressure;
KIRP	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.62	7.87	0.45	1.16e-13	Prudent dietary pattern;
KIRP	cis	rs11871801	0.517	rs646123	chr17:40720632	G/A	cg14558262	chr17:40713999	COASY	0.46	4.97	0.3	1.24e-6	Crohn's disease;
KIRP	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg08885076	chr2:99613938	TSGA10	-0.4	-5.64	-0.34	4.61e-8	Chronic sinus infection;
KIRP	cis	rs4356932	0.967	rs4478212	chr4:76958899	A/G	cg19388996	chr4:76862389	NAAA	0.38	4.87	0.3	2.04e-6	Blood protein levels;
KIRP	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.48	-0.38	4.89e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.52	7.12	0.41	1.17e-11	Glycated hemoglobin levels;
KIRP	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.4	-4.86	-0.3	2.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2280630	0.529	rs784495	chr3:39178899	C/T	cg01426195	chr3:39028469	NA	0.61	9.79	0.53	2.51e-19	Verbal declarative memory;
KIRP	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	9.87	0.53	1.45e-19	Coffee consumption (cups per day);
KIRP	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24549020	chr5:56110836	MAP3K1	0.5	5.22	0.32	3.85e-7	Initial pursuit acceleration;
KIRP	cis	rs16957091	0.821	rs2412741	chr15:43014044	A/G	cg24196017	chr15:43021976	CDAN1	-0.54	-7.17	-0.42	8.61e-12	MGMT methylation in smokers;
KIRP	cis	rs2131877	0.619	rs7639698	chr3:194870295	G/T	cg19775763	chr3:194786989	NA	-0.45	-5.19	-0.31	4.49e-7	Non-small cell lung cancer;
KIRP	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg00066239	chr17:78472159	NA	-0.27	-5.18	-0.31	4.72e-7	Fractional excretion of uric acid;
KIRP	cis	rs6459788	0.657	rs887627	chr7:157237391	G/A	cg07338119	chr7:157211683	NA	-0.41	-4.95	-0.3	1.37e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs7039377	0.554	rs12351753	chr9:38673105	C/G	cg13837857	chr9:38672315	NA	0.33	5.67	0.34	4.02e-8	Obesity-related traits;
KIRP	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg26502583	chr17:39992600	KLHL10;NT5C3L	-0.65	-4.91	-0.3	1.69e-6	Reticulocyte fraction of red cells;Reticulocyte count;
KIRP	cis	rs240764	0.717	rs6907444	chr6:101163606	G/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.17	-0.31	4.74e-7	Neuroticism;
KIRP	cis	rs7766436	0.848	rs13207207	chr6:22579066	G/A	cg13666174	chr6:22585274	NA	-0.44	-6.01	-0.36	6.8e-9	Coronary artery disease;
KIRP	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg12140854	chr5:148520817	ABLIM3	-0.58	-5.87	-0.35	1.43e-8	Breast cancer;
KIRP	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	4.95	0.3	1.37e-6	Rheumatoid arthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09453983	chr4:146080425	OTUD4	-0.4	-6.25	-0.37	1.8e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.59	-7.51	-0.43	1.12e-12	Retinal vascular caliber;
KIRP	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.84	10.92	0.57	6.63e-23	Cognitive function;
KIRP	cis	rs1629083	0.840	rs10790248	chr11:118125672	G/A	cg18857871	chr11:118064634	AMICA1	0.62	8.29	0.47	7.34e-15	Lung cancer;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg03653399	chr8:142233436	SLC45A4	-0.94	-14.68	-0.68	1.89e-35	Immature fraction of reticulocytes;
KIRP	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.82	0.4	6.82e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg10047753	chr17:41438598	NA	1.14	17.86	0.75	2.59e-46	Menopause (age at onset);
KIRP	cis	rs4273100	1.000	rs868698	chr17:19185211	G/T	cg18093559	chr17:18951025	GRAP	-0.49	-5.12	-0.31	6.03e-7	Schizophrenia;
KIRP	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg27205649	chr11:78285834	NARS2	0.83	12.16	0.61	6.12e-27	Alzheimer's disease (survival time);
KIRP	cis	rs12311304	1.000	rs12317636	chr12:15420288	A/G	cg08258403	chr12:15378311	NA	-0.35	-4.98	-0.3	1.22e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	6.94	0.4	3.4e-11	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.47	-7.64	-0.44	4.88e-13	Platelet distribution width;
KIRP	cis	rs6545883	0.525	rs1621048	chr2:61364216	C/G	cg15711740	chr2:61764176	XPO1	0.57	7.38	0.43	2.48e-12	Tuberculosis;
KIRP	cis	rs55675132	0.510	rs12130524	chr1:115287833	T/C	cg12756093	chr1:115239321	AMPD1	0.65	6.41	0.38	7.5e-10	Schizophrenia;
KIRP	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg18944383	chr4:111397179	ENPEP	0.6	11.1	0.58	1.77e-23	Height;
KIRP	cis	rs7116495	0.609	rs7113436	chr11:71689599	A/T	cg10381502	chr11:71823885	C11orf51	1.04	6.54	0.39	3.44e-10	Severe influenza A (H1N1) infection;
KIRP	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.84	10.83	0.57	1.33e-22	Primary sclerosing cholangitis;
KIRP	cis	rs11834862	0.765	rs10902511	chr12:132689436	C/T	cg05229598	chr12:132699923	GALNT9	-0.58	-6.36	-0.38	9.55e-10	Anti-saccade response;
KIRP	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-5.06	-0.31	8.12e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12541635	0.677	rs11781234	chr8:107012342	G/T	cg10147462	chr8:107024639	NA	0.35	5.34	0.32	2.08e-7	Age of smoking initiation;
KIRP	cis	rs4363385	0.747	rs7521181	chr1:152955223	G/A	cg13444842	chr1:152974279	SPRR3	-0.38	-5.43	-0.33	1.34e-7	Inflammatory skin disease;
KIRP	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-6.15	-0.37	3.11e-9	Personality dimensions;
KIRP	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	10.54	0.56	1.11e-21	Blood protein levels;
KIRP	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg01877450	chr7:97915802	BRI3	-0.57	-7.46	-0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.55	-7.02	-0.41	2.16e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg17764715	chr19:33622953	WDR88	0.61	5.22	0.32	3.86e-7	Bone properties (heel);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18072095	chr5:102595396	C5orf30	0.46	6.46	0.38	5.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg18461458	chr19:21324796	ZNF431	-0.48	-5.06	-0.31	8.19e-7	Pain;
KIRP	cis	rs9815354	0.812	rs59476821	chr3:41946481	A/G	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4073416	0.542	rs2411820	chr14:65946744	C/T	cg03016385	chr14:66212404	NA	-0.54	-6.75	-0.4	1.05e-10	N-glycan levels;
KIRP	cis	rs7005380	0.581	rs4871793	chr8:120941528	A/G	cg21645572	chr8:120931649	DEPDC6	0.49	6.56	0.39	3.09e-10	Interstitial lung disease;
KIRP	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs1420338	0.933	rs10228731	chr7:34150782	G/T	cg01275685	chr7:34179230	BMPER	-0.5	-7.37	-0.43	2.52e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs1712790	0.651	rs4938124	chr11:114631092	G/A	cg19465033	chr11:114479364	NA	0.4	5.31	0.32	2.41e-7	Urinary albumin excretion;
KIRP	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg12315302	chr6:26189340	HIST1H4D	1.0	6.82	0.4	6.86e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg05220968	chr6:146057943	EPM2A	-0.42	-5.61	-0.34	5.45e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.54	-6.71	-0.39	1.34e-10	Coronary artery disease;
KIRP	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg24315340	chr6:146058215	EPM2A	-0.39	-4.93	-0.3	1.49e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg06740227	chr12:86229804	RASSF9	0.45	5.73	0.34	2.85e-8	Major depressive disorder;
KIRP	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.64	8.91	0.49	1.18e-16	Blood protein levels;
KIRP	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg02569458	chr12:86230093	RASSF9	0.53	7.84	0.45	1.37e-13	Major depressive disorder;
KIRP	trans	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg13565492	chr6:43139072	SRF	-0.84	-7.5	-0.43	1.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs662064	0.748	rs2026792	chr1:10594790	A/G	cg19773385	chr1:10388646	KIF1B	-0.38	-5.04	-0.31	8.87e-7	Asthma;
KIRP	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg18171855	chr10:2543474	NA	0.46	6.58	0.39	2.85e-10	Age-related hearing impairment;
KIRP	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.93	15.93	0.71	9.58e-40	Breast cancer;
KIRP	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg24699146	chr1:24152579	HMGCL	0.42	5.49	0.33	1e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg00129232	chr17:37814104	STARD3	-0.4	-4.95	-0.3	1.38e-6	Asthma and hay fever;
KIRP	cis	rs7804356	1.000	rs6461979	chr7:26888918	T/C	cg03456212	chr7:26904342	SKAP2	-0.53	-4.98	-0.3	1.22e-6	Type 1 diabetes;
KIRP	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.25	0.32	3.24e-7	Alzheimer's disease;
KIRP	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.8	-10.53	-0.56	1.23e-21	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.16	-0.46	1.68e-14	Neuroticism;
KIRP	cis	rs10203711	0.966	rs7594129	chr2:239600686	G/T	cg14580085	chr2:239553406	NA	0.4	5.23	0.32	3.61e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg23202291	chr11:1979235	NA	0.42	5.41	0.33	1.51e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
KIRP	cis	rs4073416	0.568	rs7145759	chr14:65884537	C/A	cg03016385	chr14:66212404	NA	-0.55	-6.72	-0.39	1.24e-10	N-glycan levels;
KIRP	cis	rs7116495	0.609	rs4245463	chr11:71743213	C/A	cg26138937	chr11:71823887	C11orf51	-1.11	-7.14	-0.41	1.04e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.43	4.91	0.3	1.66e-6	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11987759	chr7:65425863	GUSB	0.58	7.77	0.44	2.11e-13	Aortic root size;
KIRP	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17777628	chr2:232655051	COPS7B	-0.49	-6.16	-0.37	2.98e-9	Inflammatory biomarkers;
KIRP	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg01831904	chr17:28903510	LRRC37B2	0.8	6.77	0.4	9.43e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9815354	0.953	rs4615050	chr3:41942498	T/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.27	-0.32	3.04e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg06115741	chr20:33292138	TP53INP2	0.36	5.11	0.31	6.56e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg07075026	chr17:47091521	IGF2BP1	-0.4	-7.54	-0.43	8.95e-13	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.4	-4.89	-0.3	1.84e-6	Mean platelet volume;
KIRP	cis	rs7143963	0.580	rs6575931	chr14:103301574	A/G	cg24154132	chr14:103367632	TRAF3	0.27	5.32	0.32	2.38e-7	Body mass index;
KIRP	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs7084402	0.967	rs1649026	chr10:60281400	A/G	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.84e-24	Refractive error;
KIRP	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg24565620	chr2:194026	NA	-0.72	-5.41	-0.33	1.52e-7	Blood protein levels;
KIRP	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	1.09	12.87	0.63	2.43e-29	Breast cancer;
KIRP	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg21918786	chr6:109611834	NA	-0.35	-4.94	-0.3	1.42e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.69	-9.69	-0.53	5e-19	Morning vs. evening chronotype;
KIRP	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg11518657	chr1:67396239	MIER1	0.62	6.1	0.36	4.12e-9	Lymphocyte percentage of white cells;
KIRP	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.78	6.67	0.39	1.67e-10	Initial pursuit acceleration;
KIRP	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.68	8.26	0.47	8.76e-15	Aortic root size;
KIRP	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg26576206	chr19:1064938	ABCA7	0.37	5.14	0.31	5.59e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.48	5.62	0.34	5.18e-8	Mean platelet volume;
KIRP	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.34	5.27	0.32	2.97e-7	Asthma;
KIRP	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12826209	chr6:26865740	GUSBL1	0.46	5.77	0.35	2.39e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.633	rs4793588	chr17:56471051	G/T	cg12560992	chr17:57184187	TRIM37	-0.51	-4.98	-0.3	1.21e-6	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13939156	chr17:80058883	NA	0.54	8.81	0.49	2.38e-16	Life satisfaction;
KIRP	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg04935436	chr20:30431758	NA	0.5	6.93	0.4	3.64e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.58	-9.45	-0.52	2.79e-18	Migraine;
KIRP	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.7	-9.34	-0.51	5.96e-18	Age at first birth;
KIRP	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg06871246	chr4:1363661	KIAA1530	0.53	6.3	0.37	1.35e-9	Longevity;
KIRP	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.64	-8.62	-0.48	8.22e-16	Coronary artery disease;
KIRP	cis	rs7017914	0.967	rs56112621	chr8:71588394	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg06815112	chr8:27182871	PTK2B	0.54	6.93	0.4	3.72e-11	Neuroticism;
KIRP	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.21e-6	Morning vs. evening chronotype;
KIRP	cis	rs7119167	0.722	rs876480	chr11:73086303	A/G	cg17517138	chr11:73019481	ARHGEF17	0.51	5.36	0.32	1.94e-7	Blood protein levels;
KIRP	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.6	7.43	0.43	1.77e-12	Arsenic metabolism;
KIRP	trans	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg24644049	chr4:85504048	CDS1	1.03	6.88	0.4	4.89e-11	Skin colour saturation;
KIRP	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg27068330	chr11:65405492	SIPA1	0.4	5.51	0.33	9.01e-8	Acne (severe);
KIRP	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg00106254	chr7:1943704	MAD1L1	-0.59	-6.42	-0.38	6.99e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14879690	chr4:170912660	MFAP3L	0.53	6.57	0.39	2.99e-10	Interleukin-4 levels;
KIRP	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.68	0.48	5.38e-16	Motion sickness;
KIRP	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.67	9.0	0.5	6.29e-17	Bipolar disorder;
KIRP	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.59	5.45	0.33	1.23e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg20673091	chr1:2541236	MMEL1	0.76	12.37	0.62	1.18e-27	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.67	-7.4	-0.43	2.1e-12	Diabetic retinopathy;
KIRP	cis	rs7680126	0.596	rs10022911	chr4:10140551	A/G	cg11266682	chr4:10021025	SLC2A9	-0.37	-4.96	-0.3	1.33e-6	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.63	0.75	1.53e-45	Chronic sinus infection;
KIRP	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.57	8.26	0.47	9.15e-15	Huntington's disease progression;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg02733842	chr7:1102375	C7orf50	0.49	5.36	0.32	1.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22455342	chr2:225449267	CUL3	0.51	6.01	0.36	6.59e-9	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg22676075	chr6:135203613	NA	0.51	7.28	0.42	4.47e-12	Red blood cell count;
KIRP	cis	rs9473924	0.505	rs9463663	chr6:50902266	G/A	cg14470998	chr6:50812995	TFAP2B	0.85	7.85	0.45	1.25e-13	Body mass index;
KIRP	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.29	-0.47	7.25e-15	Mood instability;
KIRP	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.39	-5.54	-0.33	7.66e-8	Plateletcrit;
KIRP	cis	rs72730918	0.502	rs12904173	chr15:51829995	T/C	cg14296394	chr15:51910925	DMXL2	0.76	10.53	0.56	1.23e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.63	6.85	0.4	5.9e-11	Height;
KIRP	cis	rs4740619	0.619	rs752490	chr9:16032570	C/T	cg14451791	chr9:16040625	NA	-0.41	-5.38	-0.32	1.72e-7	Body mass index;
KIRP	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg08992911	chr2:238395768	MLPH	0.42	5.32	0.32	2.31e-7	Prostate cancer;
KIRP	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg10503236	chr1:231470652	EXOC8	-0.54	-7.44	-0.43	1.66e-12	Hemoglobin concentration;
KIRP	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg18306943	chr3:40428807	ENTPD3	0.47	6.33	0.37	1.16e-9	Renal cell carcinoma;
KIRP	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.91	0.53	1.06e-19	Longevity;
KIRP	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg18833306	chr6:118973337	C6orf204	0.39	4.88	0.3	1.89e-6	Electrocardiographic conduction measures;
KIRP	cis	rs9354308	0.753	rs1938103	chr6:66600308	A/T	cg07460842	chr6:66804631	NA	0.43	5.37	0.32	1.81e-7	Metabolite levels;
KIRP	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06850241	chr22:41845214	NA	0.43	4.95	0.3	1.36e-6	Vitiligo;
KIRP	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.41	-5.8	-0.35	1.98e-8	Height;
KIRP	cis	rs9972944	0.657	rs9904302	chr17:63758238	A/G	cg07283582	chr17:63770753	CCDC46	-0.41	-6.63	-0.39	2.15e-10	Total body bone mineral density;
KIRP	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.74	-7.36	-0.42	2.69e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-8.67	-0.48	6.12e-16	Morning vs. evening chronotype;
KIRP	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.83	12.42	0.62	7.92e-28	Height;
KIRP	cis	rs997154	0.655	rs4981454	chr14:23422186	G/A	cg25600027	chr14:23388339	RBM23	-0.44	-4.89	-0.3	1.79e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg22800045	chr5:56110881	MAP3K1	0.67	7.31	0.42	3.8e-12	Initial pursuit acceleration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26241174	chr14:65381212	CHURC1	0.56	7.16	0.42	9.42e-12	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08843134	chr16:2301653	DCI	0.52	6.43	0.38	6.53e-10	Parkinson's disease;
KIRP	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.88	11.27	0.58	4.89e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.73	9.96	0.54	7.49e-20	Red blood cell count;
KIRP	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.59	-7.33	-0.42	3.32e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10940138	0.830	rs16897180	chr5:67220196	A/C	ch.5.1281357F	chr5:67228439	NA	-0.77	-11.64	-0.6	3.17e-25	Menarche (age at onset);
KIRP	cis	rs4664304	0.595	rs2667004	chr2:160862094	G/A	cg03641300	chr2:160917029	PLA2R1	-0.43	-7.02	-0.41	2.21e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg02023728	chr11:77925099	USP35	0.28	4.85	0.3	2.17e-6	Alzheimer's disease (survival time);
KIRP	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs13132184	0.507	rs68066615	chr4:38094791	G/A	cg14409701	chr4:38048871	TBC1D1	-0.69	-6.56	-0.39	3.13e-10	Verbal declarative memory;
KIRP	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg07827796	chr19:33622959	WDR88	0.51	6.58	0.39	2.77e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	1.03	16.04	0.72	4.04e-40	Cognitive function;
KIRP	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.73	-7.77	-0.44	2.1e-13	Initial pursuit acceleration;
KIRP	cis	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg06521331	chr12:34319734	NA	-0.56	-6.88	-0.4	4.98e-11	Morning vs. evening chronotype;
KIRP	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.43	0.38	6.59e-10	Mean corpuscular volume;
KIRP	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.64	-0.52	7.33e-19	Mean corpuscular volume;
KIRP	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.56	-5.07	-0.31	7.74e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg15038512	chr6:170123185	PHF10	0.46	5.31	0.32	2.45e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs357618	0.531	rs165333	chr5:150877147	A/G	cg22672639	chr5:150884813	FAT2	0.34	4.88	0.3	1.93e-6	Basophil percentage of white cells;
KIRP	cis	rs10128264	0.902	rs1250583	chr10:80975004	A/G	cg20744163	chr10:80999841	ZMIZ1	0.31	5.17	0.31	4.88e-7	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	trans	rs6810798	0.520	rs57997710	chr4:148329382	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-6.46	-0.38	5.67e-10	Coronary artery disease;
KIRP	trans	rs3758086	0.594	rs61053	chr8:23704295	G/T	cg10593727	chr5:176308136	HK3	0.42	6.47	0.38	5.4e-10	Glomerular filtration rate (creatinine);
KIRP	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg18196295	chr10:418757	DIP2C	0.4	4.92	0.3	1.57e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Migraine;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13789236	chr9:79009433	RFK	0.43	6.04	0.36	5.77e-9	Parkinson's disease;
KIRP	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg21523564	chr15:75251491	NA	0.39	6.32	0.37	1.23e-9	Breast cancer;
KIRP	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg23166289	chr1:210001082	C1orf107	-0.53	-5.47	-0.33	1.11e-7	Orofacial clefts;
KIRP	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.04	-0.41	1.94e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.72	-6.63	-0.39	2.15e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-6.39	-0.38	8.14e-10	Lung function (FEV1/FVC);
KIRP	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg05315796	chr3:52349193	DNAH1	-0.44	-6.91	-0.4	4.13e-11	Electroencephalogram traits;
KIRP	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	7.5	0.43	1.19e-12	Hip circumference adjusted for BMI;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04742505	chr7:72936528	BAZ1B	-0.45	-6.05	-0.36	5.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs62158800	0.598	rs1516202	chr2:108281612	G/T	cg17536750	chr4:6642118	MRFAP1	-0.54	-6.04	-0.36	5.51e-9	Facial morphology (factor 22);
KIRP	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg07382826	chr16:28625726	SULT1A1	0.48	5.61	0.34	5.53e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg08076091	chr2:203926405	NBEAL1	0.85	8.77	0.49	3.08e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg24644049	chr4:85504048	CDS1	0.93	6.87	0.4	5.17e-11	Skin colour saturation;
KIRP	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.22	5.27	0.32	3.02e-7	Primary biliary cholangitis;
KIRP	trans	rs7572644	0.640	rs4666014	chr2:28019175	A/G	cg13370754	chr5:80795179	SSBP2	-0.4	-6.07	-0.36	4.72e-9	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs8014252	0.803	rs77359887	chr14:70999238	A/C	cg19730268	chr14:71022823	NA	-0.76	-6.47	-0.38	5.28e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	17.04	0.74	1.55e-43	Homoarginine levels;
KIRP	cis	rs11673344	0.526	rs17244769	chr19:38052933	C/G	cg14683738	chr19:37701593	ZNF585B	-0.46	-5.52	-0.33	8.41e-8	Obesity-related traits;
KIRP	cis	rs1190596	0.558	rs3087686	chr14:102695563	A/G	cg18135206	chr14:102964638	TECPR2	0.46	4.91	0.3	1.64e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.58	7.08	0.41	1.51e-11	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.8	0.35	2.07e-8	Menopause (age at onset);
KIRP	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.57	-7.3	-0.42	3.94e-12	Longevity;Endometriosis;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg02992881	chr13:50699806	DLEU2	-0.45	-6.13	-0.36	3.44e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs4770433	0.503	rs943242	chr13:23916533	T/C	cg16923290	chr13:23949747	SACS	0.61	5.99	0.36	7.56e-9	Protein quantitative trait loci;
KIRP	cis	rs882300	0.934	rs2102895	chr2:136906692	G/A	cg05194412	chr2:137003533	NA	0.42	5.25	0.32	3.31e-7	Multiple sclerosis;Electrocardiographic traits;
KIRP	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg02527881	chr3:46936655	PTH1R	-0.43	-6.19	-0.37	2.51e-9	Colorectal cancer;
KIRP	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-0.95	-12.04	-0.61	1.51e-26	Blood protein levels;
KIRP	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg05347473	chr6:146136440	FBXO30	0.48	7.11	0.41	1.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg20573242	chr4:122745356	CCNA2	0.44	5.41	0.33	1.49e-7	Type 2 diabetes;
KIRP	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg03959625	chr15:84868606	LOC388152	-0.62	-6.5	-0.38	4.44e-10	Schizophrenia;
KIRP	cis	rs10416265	0.527	rs6510337	chr19:33545701	C/T	cg07827796	chr19:33622959	WDR88	0.49	6.25	0.37	1.75e-9	Bone properties (heel);
KIRP	cis	rs6969780	0.915	rs4722657	chr7:27157756	G/A	cg03724423	chr7:27170755	HOXA4	-0.34	-5.14	-0.31	5.65e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg23505145	chr19:12996616	KLF1	0.57	8.41	0.47	3.42e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs300890	0.651	rs300917	chr4:144269849	C/G	cg01601573	chr4:144256835	GAB1	-0.33	-4.92	-0.3	1.61e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03388025	chr16:89894329	SPIRE2	0.27	4.85	0.3	2.17e-6	Hemoglobin concentration;
KIRP	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-20.24	-0.79	2.83e-54	Height;
KIRP	cis	rs2733310	0.948	rs2703593	chr15:57488767	C/T	cg13626582	chr15:57592083	LOC283663	-0.34	-7.82	-0.45	1.53e-13	Mean platelet volume;
KIRP	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.31	-0.32	2.44e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17724171	chr1:6240267	CHD5	0.47	6.66	0.39	1.79e-10	Parkinson's disease;
KIRP	cis	rs6752107	0.967	rs10203952	chr2:234153366	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.7	0.44	3.28e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg18132916	chr6:79620363	NA	-0.42	-5.93	-0.35	9.96e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1050631	0.592	rs14045	chr18:33760194	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.17	0.31	4.96e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg11247378	chr22:39784982	NA	-0.63	-10.24	-0.55	1.03e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs2591576	0.510	rs4868953	chr5:165358649	C/A	cg13976338	chr5:165423657	NA	-0.63	-8.31	-0.47	6.51e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.45	-5.81	-0.35	1.95e-8	Body mass index;
KIRP	trans	rs7084921	0.549	rs9888058	chr10:101859205	C/T	cg13808641	chr9:96006533	WNK2	-0.39	-6.18	-0.37	2.65e-9	Bone mineral density;
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg02462569	chr6:150064036	NUP43	-0.37	-5.59	-0.34	6.11e-8	Lung cancer;
KIRP	cis	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg02795151	chr17:7402630	POLR2A	0.78	8.03	0.46	4.11e-14	IgM levels;
KIRP	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg16898833	chr6:26189333	HIST1H4D	0.8	5.62	0.34	5.2e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg06060754	chr5:176797920	RGS14	0.75	9.69	0.53	4.97e-19	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs687432	0.885	rs11607308	chr11:57808954	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06062590	chr3:99536761	MIR548G;C3orf26	-0.49	-6.26	-0.37	1.67e-9	Myopia;
KIRP	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.21	14.13	0.67	1.39e-33	Sexual dysfunction (female);
KIRP	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.66	8.5	0.48	1.83e-15	Coronary artery disease;
KIRP	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.6	6.98	0.41	2.78e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12137294	0.866	rs1172140	chr1:205213024	G/A	cg21643547	chr1:205240462	TMCC2	-0.5	-6.99	-0.41	2.57e-11	Red cell distribution width;
KIRP	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06850241	chr22:41845214	NA	-0.47	-5.9	-0.35	1.22e-8	Vitiligo;
KIRP	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg05044414	chr3:183734942	ABCC5	0.37	5.55	0.33	7.53e-8	Anterior chamber depth;
KIRP	cis	rs7998202	0.667	rs408220	chr13:113370267	T/C	cg02820901	chr13:113351484	ATP11A	0.62	5.63	0.34	4.82e-8	Glycated hemoglobin levels;
KIRP	cis	rs6545883	0.894	rs7572603	chr2:61552145	C/G	cg15711740	chr2:61764176	XPO1	0.58	7.64	0.44	4.73e-13	Tuberculosis;
KIRP	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.5	-6.12	-0.36	3.66e-9	Red blood cell count;
KIRP	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg14581129	chr12:53358946	NA	-0.35	-5.92	-0.35	1.06e-8	Prostate cancer;
KIRP	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg08603382	chr10:743973	NA	-0.69	-10.9	-0.57	7.84e-23	Psychosis in Alzheimer's disease;
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.62	9.04	0.5	4.67e-17	Lung cancer;
KIRP	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	7.14e-8	Breast cancer;
KIRP	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs6929812	0.967	rs6926142	chr6:27395764	A/G	cg03332623	chr6:27441972	ZNF184	-0.38	-5.32	-0.32	2.33e-7	Neuroticism (multi-trait analysis);
KIRP	cis	rs2591576	0.781	rs6868659	chr5:165429829	A/G	cg13976338	chr5:165423657	NA	-0.75	-10.83	-0.57	1.32e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.37	-7.3	-0.42	4.01e-12	Height;
KIRP	cis	rs4908768	0.906	rs78110809	chr1:8573008	C/T	cg03610117	chr1:8450231	RERE	-0.44	-5.09	-0.31	7.19e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs6102059	0.642	rs55965801	chr20:39204273	T/C	cg06665391	chr20:39312290	NA	0.44	5.52	0.33	8.57e-8	LDL cholesterol;
KIRP	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg18190219	chr22:46762943	CELSR1	-0.75	-7.56	-0.43	8.09e-13	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg15130565	chr3:61546275	PTPRG	0.6	6.8	0.4	7.67e-11	Lung cancer in ever smokers;
KIRP	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.98	15.02	0.69	1.24e-36	Sudden cardiac arrest;
KIRP	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.45	5.2	0.31	4.17e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4273100	0.564	rs10445411	chr17:19265797	C/T	cg18093559	chr17:18951025	GRAP	0.49	5.74	0.34	2.83e-8	Schizophrenia;
KIRP	cis	rs11664298	0.606	rs11081564	chr18:77551586	A/G	cg02536541	chr18:77568900	NA	-0.55	-6.84	-0.4	6.2e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg12292205	chr6:26970375	C6orf41	0.34	4.85	0.3	2.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.09	0.36	4.33e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs16937	0.662	rs10900456	chr1:205145005	C/T	cg00889227	chr1:205173544	DSTYK	-0.38	-5.29	-0.32	2.68e-7	Schizophrenia;
KIRP	cis	rs10489525	0.599	rs11102879	chr1:115603504	C/T	cg01522456	chr1:115632236	TSPAN2	0.53	7.06	0.41	1.71e-11	Autism;
KIRP	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg02811702	chr13:24901961	NA	0.41	5.39	0.33	1.63e-7	Obesity-related traits;
KIRP	cis	rs2019216	0.500	rs7502283	chr17:21878561	G/C	cg22648282	chr17:21454238	C17orf51	-0.53	-6.26	-0.37	1.7e-9	Pelvic organ prolapse;
KIRP	cis	rs883565	0.740	rs9311203	chr3:39072079	T/C	cg01426195	chr3:39028469	NA	-0.67	-11.15	-0.58	1.24e-23	Handedness;
KIRP	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26002218	chr14:103986227	CKB	0.27	5.13	0.31	6e-7	Body mass index;
KIRP	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg24642844	chr7:1081250	C7orf50	-0.91	-7.74	-0.44	2.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg23682824	chr7:23144976	KLHL7	0.46	5.57	0.33	6.76e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	16.99	0.73	2.26e-43	Platelet count;
KIRP	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.53	-6.98	-0.41	2.7e-11	Bipolar disorder;
KIRP	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.83	12.06	0.61	1.3e-26	Blood metabolite ratios;
KIRP	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg21475434	chr5:93447410	FAM172A	0.44	5.11	0.31	6.56e-7	Diabetic retinopathy;
KIRP	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	0.7	5.85	0.35	1.59e-8	IgG glycosylation;
KIRP	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.93	14.95	0.69	2.18e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.72	9.2	0.51	1.61e-17	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs16828019	0.929	rs4131949	chr1:41738637	C/T	cg03387723	chr1:41708464	SCMH1	-0.77	-6.82	-0.4	7.1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg21546286	chr11:48923668	NA	-0.44	-5.37	-0.32	1.82e-7	HDL cholesterol;
KIRP	cis	rs12208915	0.848	rs2321896	chr6:79509744	G/C	cg18132916	chr6:79620363	NA	0.53	4.98	0.3	1.22e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg27411982	chr8:10470053	RP1L1	0.41	4.93	0.3	1.51e-6	Neuroticism;
KIRP	cis	rs9462846	0.959	rs9471954	chr6:42880326	C/A	cg02353165	chr6:42928485	GNMT	0.46	5.22	0.32	3.72e-7	Blood protein levels;
KIRP	cis	rs7116495	0.609	rs6592447	chr11:71641093	A/T	cg07596299	chr11:71824057	C11orf51	-0.88	-6.0	-0.36	6.91e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-7.54	-0.43	9.14e-13	Migraine;Coronary artery disease;
KIRP	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.58	-6.82	-0.4	6.81e-11	Menarche (age at onset);
KIRP	cis	rs4262150	0.842	rs55992747	chr5:152253548	C/T	cg12297329	chr5:152029980	NA	-0.61	-7.67	-0.44	4.02e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs918629	0.798	rs57595413	chr5:95277776	C/T	cg16656078	chr5:95278638	ELL2	-0.46	-6.71	-0.39	1.36e-10	IgG glycosylation;
KIRP	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg26681399	chr22:41777847	TEF	-0.48	-5.23	-0.32	3.69e-7	Vitiligo;
KIRP	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.52	6.32	0.37	1.24e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs514024	0.735	rs2039205	chr9:130375643	G/C	cg13643465	chr9:130375613	STXBP1	0.48	6.21	0.37	2.26e-9	Eating disorders (purging via substances);
KIRP	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg15997130	chr1:24165203	NA	-0.61	-8.53	-0.48	1.54e-15	Immature fraction of reticulocytes;
KIRP	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg07701084	chr6:150067640	NUP43	0.59	7.57	0.43	7.57e-13	Lung cancer;
KIRP	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg01629716	chr15:45996671	NA	0.37	6.6	0.39	2.44e-10	Waist circumference;Weight;
KIRP	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.46	-7.88	-0.45	1.04e-13	Type 2 diabetes;
KIRP	cis	rs9815354	1.000	rs1052501	chr3:41925398	C/T	cg03022575	chr3:42003672	ULK4	-0.47	-5.31	-0.32	2.4e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02123280	chr11:22454233	NA	0.88	6.32	0.37	1.19e-9	P wave terminal force;
KIRP	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg13206674	chr6:150067644	NUP43	0.59	8.6	0.48	9.21e-16	Lung cancer;
KIRP	cis	rs6691722	0.503	rs4140519	chr1:24708304	C/T	cg18323236	chr1:24743029	NIPAL3	0.44	6.25	0.37	1.79e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs17209837	1.000	rs60123540	chr7:87085182	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-8.58	-0.48	1.1e-15	Gallbladder cancer;
KIRP	cis	rs155346	0.901	rs265179	chr5:139365452	C/G	cg01090482	chr5:139365336	NRG2	-0.47	-5.65	-0.34	4.51e-8	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	trans	rs13170463	0.579	rs13166744	chr5:8035082	C/A	cg03862380	chr20:43029895	HNF4A	0.39	6.11	0.36	3.79e-9	Colorectal cancer;
KIRP	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.77	10.14	0.54	2.06e-20	Huntington's disease progression;
KIRP	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.61	-6.99	-0.41	2.51e-11	Menarche (age at onset);
KIRP	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg09417038	chr21:47716443	C21orf57	-0.48	-6.16	-0.37	3e-9	Testicular germ cell tumor;
KIRP	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.79	-12.7	-0.63	9.04e-29	Prostate cancer;
KIRP	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg13615516	chr5:77269221	NA	0.51	7.87	0.45	1.1e-13	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3745672	0.590	rs79219764	chr19:12169962	G/A	cg20127191	chr19:12306497	NA	-0.73	-5.96	-0.35	8.91e-9	Multiple sclerosis;
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg24874828	chr4:187887005	NA	-0.57	-9.27	-0.51	9.47e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-9.29	-0.51	8.71e-18	Triglycerides;
KIRP	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	0.37	4.85	0.3	2.23e-6	Menarche (age at onset);
KIRP	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.73	-11.08	-0.58	2.09e-23	QRS duration;
KIRP	cis	rs1134634	0.520	rs7665390	chr4:15577738	G/A	cg16509355	chr4:15471240	CC2D2A	-0.31	-5.29	-0.32	2.7e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg10254082	chr7:997346	NA	0.48	5.07	0.31	7.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs2708977	0.730	rs596069	chr2:97076642	C/T	cg22654517	chr2:96458247	NA	-0.33	-5.3	-0.32	2.55e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg25019033	chr10:957182	NA	-0.6	-6.27	-0.37	1.59e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg05347473	chr6:146136440	FBXO30	0.61	8.51	0.48	1.79e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.51	-0.38	4.14e-10	Aortic root size;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27023929	chr4:68303581	NA	-0.48	-8.12	-0.46	2.32e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg18190219	chr22:46762943	CELSR1	-0.85	-7.25	-0.42	5.35e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg08501292	chr6:25962987	TRIM38	1.1	8.13	0.46	2.09e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4262150	0.810	rs55648729	chr5:152008902	G/T	cg12297329	chr5:152029980	NA	-0.67	-8.2	-0.46	1.38e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26572548	chr2:102003380	CREG2	0.47	6.18	0.37	2.61e-9	Parkinson's disease;
KIRP	trans	rs412658	0.776	rs12460025	chr19:22318230	A/G	cg17074339	chr11:11642133	GALNTL4	-0.56	-6.63	-0.39	2.17e-10	Telomere length;
KIRP	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23161317	chr6:28129485	ZNF389	0.42	4.93	0.3	1.49e-6	Depression;
KIRP	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg11752832	chr7:134001865	SLC35B4	0.43	5.7	0.34	3.38e-8	Mean platelet volume;
KIRP	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.37	-0.32	1.78e-7	Life satisfaction;
KIRP	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg05082376	chr22:42548792	NA	-0.43	-5.69	-0.34	3.61e-8	Schizophrenia;
KIRP	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.33	-9.88	-0.53	1.34e-19	Diabetic kidney disease;
KIRP	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg00277334	chr10:82204260	NA	-0.62	-6.44	-0.38	6.07e-10	Post bronchodilator FEV1;
KIRP	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg23958373	chr8:599963	NA	-0.99	-6.12	-0.36	3.57e-9	IgG glycosylation;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.88	-13.65	-0.66	5.74e-32	Height;
KIRP	cis	rs889398	0.741	rs4146819	chr16:69923563	C/A	cg09409435	chr16:70099608	PDXDC2	0.41	5.05	0.31	8.49e-7	Body mass index;
KIRP	cis	rs6681460	0.966	rs4655650	chr1:67142286	A/G	cg13052034	chr1:66999238	SGIP1	0.45	6.21	0.37	2.26e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14280576	chr9:133580010	EXOSC2	0.49	6.13	0.36	3.52e-9	Interleukin-4 levels;
KIRP	cis	rs12220238	0.722	rs6480748	chr10:76421529	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.54	5.93	0.35	1e-8	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg06027949	chr8:82754900	SNX16	-0.61	-6.66	-0.39	1.75e-10	Diastolic blood pressure;
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.6	-0.48	9.47e-16	Life satisfaction;
KIRP	cis	rs4363385	0.747	rs11205149	chr1:152958840	C/T	cg13444842	chr1:152974279	SPRR3	-0.35	-4.99	-0.3	1.12e-6	Inflammatory skin disease;
KIRP	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg15147215	chr3:52552868	STAB1	-0.29	-4.91	-0.3	1.68e-6	Electroencephalogram traits;
KIRP	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg11764359	chr7:65958608	NA	0.77	5.02	0.3	9.79e-7	Diabetic kidney disease;
KIRP	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.51	6.69	0.39	1.52e-10	HDL cholesterol levels;
KIRP	cis	rs494562	0.892	rs637346	chr6:86115282	G/C	cg27039625	chr6:86159096	NT5E	0.42	5.16	0.31	5.16e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs282587	0.569	rs9604415	chr13:113393615	G/T	cg04656015	chr13:113407548	ATP11A	0.59	6.45	0.38	5.76e-10	Glycated hemoglobin levels;
KIRP	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.5	-6.61	-0.39	2.36e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.56	-7.15	-0.41	9.95e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2629540	0.580	rs2930796	chr10:126485684	A/G	cg08799069	chr10:126477246	METTL10	0.77	7.48	0.43	1.29e-12	Cocaine dependence;
KIRP	cis	rs7903847	0.642	rs11189192	chr10:99149403	G/A	cg20016023	chr10:99160130	RRP12	-0.44	-6.09	-0.36	4.4e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg06740227	chr12:86229804	RASSF9	0.48	5.97	0.36	8.06e-9	Major depressive disorder;
KIRP	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.29	-0.37	1.46e-9	Height;
KIRP	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg25482853	chr8:67687455	SGK3	0.69	6.45	0.38	5.73e-10	Obesity-related traits;
KIRP	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.44	-5.15	-0.31	5.45e-7	Metabolite levels;
KIRP	cis	rs55675132	0.548	rs6688350	chr1:115356186	A/C	cg12756093	chr1:115239321	AMPD1	-0.54	-5.39	-0.32	1.66e-7	Schizophrenia;
KIRP	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.73	-8.49	-0.48	2e-15	Adiposity;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03398387	chr6:160114178	SOD2	0.59	7.99	0.45	5.22e-14	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.45	-6.98	-0.41	2.66e-11	Inflammatory bowel disease;
KIRP	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.91	-0.35	1.15e-8	Obesity-related traits;
KIRP	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.55	5.93	0.35	1.01e-8	Diisocyanate-induced asthma;
KIRP	cis	rs1801239	0.786	rs45487598	chr10:16958653	G/A	cg24571822	chr10:17009592	CUBN	0.76	6.46	0.38	5.59e-10	Urinary albumin-to-creatinine ratio in non-diabetics;Urinary albumin excretion;
KIRP	cis	rs6545883	0.630	rs12998475	chr2:61437487	T/C	cg15711740	chr2:61764176	XPO1	0.58	7.48	0.43	1.29e-12	Tuberculosis;
KIRP	cis	rs155346	0.546	rs264337	chr5:139352036	A/G	cg24724630	chr5:139362307	NRG2	-0.37	-5.03	-0.31	9.42e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg08501292	chr6:25962987	TRIM38	0.76	5.09	0.31	7.24e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06544989	chr22:39130855	UNC84B	0.45	7.91	0.45	8.45e-14	Menopause (age at onset);
KIRP	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.49	-7.4	-0.43	2.13e-12	Coronary artery disease;
KIRP	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg02297831	chr4:17616191	MED28	0.61	7.6	0.44	6.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg10017260	chr10:834428	NA	-0.42	-6.01	-0.36	6.5e-9	Survival in rectal cancer;
KIRP	cis	rs12210905	0.688	rs9368509	chr6:27379422	A/G	cg08851530	chr6:28072375	NA	-0.75	-4.85	-0.3	2.18e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg11952622	chr19:58962976	ZNF324B	0.44	5.16	0.31	5.06e-7	Uric acid clearance;
KIRP	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg05964544	chr11:70165517	PPFIA1	-0.53	-4.97	-0.3	1.25e-6	Coronary artery disease;
KIRP	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg15327641	chr2:3715039	ALLC	0.46	5.89	0.35	1.27e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg04731861	chr2:219085781	ARPC2	0.29	7.44	0.43	1.71e-12	Colorectal cancer;
KIRP	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.05	-0.41	1.85e-11	Height;
KIRP	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg23796481	chr11:64053134	BAD;GPR137	-0.55	-5.27	-0.32	2.94e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-23.51	-0.83	7.61e-65	Exhaled nitric oxide output;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11291882	chr19:56090781	ZNF579	-0.5	-6.14	-0.36	3.26e-9	Parkinson's disease;
KIRP	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.69	10.46	0.55	2.05e-21	Hip circumference;
KIRP	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.49	-5.09	-0.31	7.02e-7	Schizophrenia;
KIRP	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.34	-0.37	1.1e-9	Body mass index;
KIRP	cis	rs7923609	0.846	rs7090111	chr10:65077994	C/G	cg01631684	chr10:65280961	REEP3	-0.49	-5.69	-0.34	3.64e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7903847	0.642	rs11189183	chr10:99144321	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6832769	0.961	rs13138697	chr4:56363309	G/A	cg09317128	chr4:56265301	TMEM165	0.52	6.49	0.38	4.74e-10	Personality dimensions;
KIRP	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.57	8.52	0.48	1.6e-15	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18779695	chr6:36164024	BRPF3	0.51	6.02	0.36	6.28e-9	Smoking initiation;
KIRP	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10875746	0.903	rs10875740	chr12:48489117	C/T	cg26205652	chr12:48591994	NA	0.78	10.5	0.56	1.49e-21	Longevity (90 years and older);
KIRP	cis	rs2278796	1.000	rs3892249	chr1:204947489	C/G	cg04862289	chr1:204966208	NFASC	0.66	8.99	0.5	6.72e-17	Mean platelet volume;
KIRP	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg16506815	chr2:162101123	NA	0.45	5.38	0.32	1.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.61	0.52	9.07e-19	Parkinson's disease;
KIRP	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg11569703	chr11:65557185	OVOL1	-0.34	-5.49	-0.33	9.98e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.44	5.56	0.33	7.14e-8	Motion sickness;
KIRP	cis	rs6815814	0.904	rs2101521	chr4:38811551	C/T	cg06935464	chr4:38784597	TLR10	0.58	7.2	0.42	7.28e-12	Breast cancer;
KIRP	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.51	-6.44	-0.38	6.32e-10	Electroencephalogram traits;
KIRP	cis	rs17125944	0.686	rs6572869	chr14:53353454	C/T	cg00686598	chr14:53173677	PSMC6	0.68	6.08	0.36	4.54e-9	Alzheimer's disease (late onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15992940	chr5:138609700	SNHG4;MATR3	0.44	6.15	0.37	3.16e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6546324	0.921	rs4619594	chr2:67868480	A/C	cg15745817	chr2:67799979	NA	-0.4	-5.48	-0.33	1.04e-7	Endometriosis;
KIRP	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7999699	0.902	rs4942686	chr13:48312678	A/T	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg12826209	chr6:26865740	GUSBL1	0.45	5.74	0.34	2.78e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.12	-0.54	2.33e-20	Hemoglobin concentration;
KIRP	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg18132916	chr6:79620363	NA	-0.43	-5.78	-0.35	2.23e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2219968	0.887	rs67368685	chr8:78966267	A/G	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs59197085	0.636	rs2307036	chr7:128454537	C/A	cg00734629	chr7:128471146	FLNC	0.47	5.59	0.34	6.09e-8	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg08662619	chr6:150070041	PCMT1	0.35	5.55	0.33	7.23e-8	Lung cancer;
KIRP	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg02462569	chr6:150064036	NUP43	-0.42	-6.43	-0.38	6.72e-10	Lung cancer;
KIRP	cis	rs2304069	0.779	rs245055	chr5:149341279	A/G	cg12661370	chr5:149340060	SLC26A2	-0.53	-5.45	-0.33	1.21e-7	HIV-1 control;
KIRP	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.65	7.93	0.45	7.88e-14	Height;
KIRP	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.48e-6	Red blood cell count;
KIRP	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	4.9	0.3	1.7e-6	Schizophrenia;
KIRP	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	10.44	0.55	2.37e-21	Cognitive test performance;
KIRP	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg04310649	chr10:35416472	CREM	-0.54	-6.05	-0.36	5.37e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.48	-7.62	-0.44	5.56e-13	Platelet distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05310557	chr18:46477250	SMAD7	0.49	6.44	0.38	6.28e-10	Parkinson's disease;
KIRP	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs7737355	0.812	rs6896132	chr5:130773561	C/G	cg25547332	chr5:131281432	NA	0.43	5.24	0.32	3.42e-7	Life satisfaction;
KIRP	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.48	-11.34	-0.59	2.93e-24	Diabetic kidney disease;
KIRP	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg05347473	chr6:146136440	FBXO30	-0.58	-8.35	-0.47	5.07e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1999930	0.527	rs7758899	chr6:116267345	A/C	cg15226275	chr6:116381976	FRK	0.22	4.91	0.3	1.67e-6	Age-related macular degeneration;
KIRP	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg10755058	chr3:40428713	ENTPD3	0.33	4.86	0.3	2.13e-6	Renal cell carcinoma;
KIRP	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg16497661	chr14:103986332	CKB	-0.39	-5.11	-0.31	6.36e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4253311	0.520	rs10000459	chr4:187124459	A/C	cg24794857	chr4:187113578	CYP4V2	0.41	5.96	0.36	8.62e-9	Plasma renin activity levels;Circulating chromogranin peptide levels;Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08202769	chr11:65338440	FAM89B;SSSCA1	0.52	6.74	0.39	1.09e-10	Parkinson's disease;
KIRP	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg02297831	chr4:17616191	MED28	0.54	6.75	0.4	1.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	cg21523751	chr1:182988639	NA	0.45	7.07	0.41	1.61e-11	Hypertriglyceridemia;
KIRP	cis	rs9810890	0.850	rs115864277	chr3:128627244	C/G	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.53	-6.91	-0.4	4.13e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.6	8.81	0.49	2.27e-16	Mean corpuscular volume;
KIRP	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.66	-0.44	4.33e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.72	10.31	0.55	6.15e-21	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.76	5.92	0.35	1.1e-8	Putamen volume;
KIRP	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.92	0.3	1.61e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4663866	1.000	rs34897410	chr2:239182123	T/C	cg16914508	chr2:239161102	PER2	0.71	5.2	0.31	4.11e-7	Irritable bowel syndrome;
KIRP	cis	rs14403	0.874	rs4658574	chr1:243650716	A/G	cg21452805	chr1:244014465	NA	0.5	5.17	0.31	4.96e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg21698718	chr17:80085957	CCDC57	-0.34	-4.94	-0.3	1.43e-6	Life satisfaction;
KIRP	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg24633833	chr3:10029261	TMEM111	0.56	5.13	0.31	5.99e-7	Alzheimer's disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12427896	chr2:111880694	BCL2L11	0.54	7.19	0.42	7.78e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.17	-0.31	4.94e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-0.99	-10.48	-0.56	1.79e-21	Mitochondrial DNA levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17269277	chr4:1796142	FGFR3	0.43	6.02	0.36	6.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs732765	0.734	rs4899530	chr14:75165825	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.4	-4.96	-0.3	1.32e-6	Non-small cell lung cancer;
KIRP	cis	rs2278796	0.639	rs6697344	chr1:204971485	G/T	cg04862289	chr1:204966208	NFASC	0.63	8.79	0.49	2.67e-16	Mean platelet volume;
KIRP	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.58	6.8	0.4	7.73e-11	Height;
KIRP	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs28655083	0.552	rs76055145	chr16:77124905	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.59	-5.02	-0.31	9.76e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6601327	0.603	rs13275545	chr8:9667914	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.43	-0.38	6.75e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7224685	0.569	rs8066580	chr17:3996494	T/C	cg09695851	chr17:3907499	NA	0.54	5.15	0.31	5.3e-7	Type 2 diabetes;
KIRP	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg10932868	chr11:921992	NA	0.54	6.78	0.4	8.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.53	13.51	0.65	1.69e-31	Airflow obstruction;
KIRP	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26617929	chr16:1858877	NA	-0.67	-5.68	-0.34	3.89e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg24699146	chr1:24152579	HMGCL	0.42	5.53	0.33	8.11e-8	Immature fraction of reticulocytes;
KIRP	cis	rs894344	0.650	rs56411737	chr8:135582243	C/T	cg09855544	chr8:135498122	ZFAT	0.4	5.24	0.32	3.38e-7	Systolic blood pressure;
KIRP	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.73	-7.37	-0.43	2.62e-12	Bipolar disorder;
KIRP	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-5.53	-0.33	8.24e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.2	-0.31	4.22e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.57	-6.27	-0.37	1.58e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg22117172	chr7:91764530	CYP51A1	0.45	6.13	0.36	3.48e-9	Breast cancer;
KIRP	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	0.84	8.07	0.46	3.02e-14	Methadone dose in opioid dependence;
KIRP	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.58	-8.06	-0.46	3.34e-14	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03339469	chr19:44259181	C19orf61	0.56	7.28	0.42	4.53e-12	Parkinson's disease;
KIRP	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.92	-6.28	-0.37	1.49e-9	Inflammatory biomarkers;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23629032	chr21:30302708	RNF160	0.39	6.05	0.36	5.26e-9	Migraine with aura;
KIRP	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.68	-9.97	-0.54	7.11e-20	Waist circumference;Body mass index;
KIRP	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06544989	chr22:39130855	UNC84B	0.47	7.39	0.43	2.35e-12	Menopause (age at onset);
KIRP	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.75	7.98	0.45	5.71e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs12049351	0.774	rs4148757	chr1:229693846	A/C	cg11742688	chr1:229674241	ABCB10	-0.42	-6.7	-0.39	1.43e-10	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.42	5.37	0.32	1.84e-7	Schizophrenia;
KIRP	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.98	15.32	0.7	1.2e-37	Diastolic blood pressure;
KIRP	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg18016565	chr1:150552671	MCL1	-0.48	-7.36	-0.42	2.73e-12	Tonsillectomy;
KIRP	cis	rs4692589	1.000	rs7688417	chr4:170938732	C/T	cg19918862	chr4:170955249	NA	0.42	5.07	0.31	7.77e-7	Anxiety disorder;
KIRP	cis	rs7709377	0.546	rs11950936	chr5:115447314	T/A	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.64e-7	Metabolite levels  (X-11787);
KIRP	cis	rs11209185	0.509	rs1938424	chr1:68431722	A/G	cg22082780	chr1:68452167	NA	-0.38	-5.49	-0.33	9.87e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6547631	0.622	rs4832185	chr2:85928814	T/A	cg24620635	chr2:85921963	GNLY	0.31	4.96	0.3	1.31e-6	Blood protein levels;
KIRP	cis	rs2594989	1.000	rs2606756	chr3:11358181	G/A	cg01796438	chr3:11312864	ATG7	-0.69	-7.86	-0.45	1.18e-13	Circulating chemerin levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg08407274	chr16:4784199	ANKS3;C16orf71	0.46	6.36	0.38	9.69e-10	Cancer;
KIRP	cis	rs889398	0.741	rs6499270	chr16:69917740	A/G	cg09409435	chr16:70099608	PDXDC2	-0.41	-5.05	-0.31	8.49e-7	Body mass index;
KIRP	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.59	6.99	0.41	2.53e-11	Obesity-related traits;
KIRP	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.6	-6.2	-0.37	2.31e-9	Chronic sinus infection;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg05637945	chr17:46985753	UBE2Z	-0.49	-6.45	-0.38	5.86e-10	Myopia;
KIRP	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.57	7.14	0.41	1.06e-11	Lung cancer;
KIRP	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.8	-5.88	-0.35	1.34e-8	Blood pressure (smoking interaction);
KIRP	cis	rs10465746	0.935	rs4258241	chr1:84437929	G/A	cg10977910	chr1:84465055	TTLL7	0.48	5.82	0.35	1.82e-8	Obesity-related traits;
KIRP	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg06630425	chr16:818451	MSLN	-0.61	-7.9	-0.45	9.39e-14	Mean corpuscular volume;
KIRP	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg21433313	chr16:3507492	NAT15	0.65	7.18	0.42	8.17e-12	Tuberculosis;
KIRP	cis	rs4776059	1.000	rs62023352	chr15:52889448	T/C	cg25063058	chr15:52860530	ARPP19	0.62	6.8	0.4	7.71e-11	Schizophrenia;
KIRP	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg01689657	chr7:91764605	CYP51A1	0.42	5.94	0.35	9.89e-9	Breast cancer;
KIRP	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	16.43	0.72	1.89e-41	Chronic sinus infection;
KIRP	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.49	6.1	0.36	4.17e-9	Dilated cardiomyopathy;
KIRP	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg08662619	chr6:150070041	PCMT1	0.35	5.62	0.34	5.24e-8	Lung cancer;
KIRP	cis	rs6062509	0.929	rs55791529	chr20:62363858	C/T	cg03999872	chr20:62272968	STMN3	0.4	4.9	0.3	1.75e-6	Prostate cancer;
KIRP	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.29	0.62	2.13e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg16917193	chr12:54089295	NA	1.02	22.08	0.82	2.7e-60	Height;
KIRP	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.01	-0.36	6.53e-9	Parkinson's disease;
KIRP	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.5	-6.99	-0.41	2.64e-11	Blood metabolite levels;
KIRP	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.74	-7.66	-0.44	4.3e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6442310	0.534	rs1151999	chr3:12447153	G/T	cg15873301	chr3:12045459	SYN2	-0.39	-5.06	-0.31	8.39e-7	Hematocrit;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25257709	chr13:39612317	NHLRC3;C13orf23	0.44	6.27	0.37	1.6e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.65	9.46	0.52	2.58e-18	Vitiligo;
KIRP	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg24633833	chr3:10029261	TMEM111	0.53	5.18	0.31	4.72e-7	Alzheimer's disease;
KIRP	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.57	7.61	0.44	5.65e-13	Blood metabolite levels;
KIRP	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg09365446	chr1:150670422	GOLPH3L	-0.39	-4.97	-0.3	1.24e-6	Tonsillectomy;
KIRP	cis	rs12249377	0.519	rs10785972	chr10:92593800	C/T	cg14313238	chr10:92632228	RPP30	0.43	5.26	0.32	3.17e-7	White matter microstructure (global fractional anisotropy);
KIRP	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-18.23	-0.76	1.5e-47	Height;
KIRP	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.89	14.78	0.69	8.58e-36	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs9876781	0.530	rs35516531	chr3:48405765	C/T	cg11946769	chr3:48343235	NME6	0.41	5.04	0.31	9.24e-7	Longevity;
KIRP	cis	rs9473924	0.632	rs9395641	chr6:50906458	A/G	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	trans	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Bladder cancer;
KIRP	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	1.08	8.07	0.46	3.05e-14	Skin colour saturation;
KIRP	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.92	-15.46	-0.7	3.82e-38	Metabolic syndrome;
KIRP	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg01753270	chr2:239240285	TRAF3IP1	-0.46	-5.8	-0.35	2.01e-8	Multiple system atrophy;
KIRP	cis	rs10767971	0.565	rs7104571	chr11:32868844	T/G	cg14042352	chr11:32815968	CCDC73	-0.46	-5.35	-0.32	2.05e-7	Parkinson's disease (age of onset);
KIRP	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.41	-7.27	-0.42	4.76e-12	Refractive error;
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg23985595	chr17:80112537	CCDC57	0.34	5.1	0.31	6.8e-7	Life satisfaction;
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.7	-10.38	-0.55	3.68e-21	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg23985595	chr17:80112537	CCDC57	-0.37	-5.4	-0.33	1.58e-7	Life satisfaction;
KIRP	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg13749939	chr11:796434	SLC25A22	0.45	6.19	0.37	2.45e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs13385	0.769	rs722437	chr5:139545729	A/T	cg01860693	chr5:139557145	C5orf32	0.49	5.1	0.31	6.86e-7	Atrial fibrillation;
KIRP	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.71	-10.04	-0.54	4.16e-20	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26358059	chr10:106014893	GSTO1	0.53	6.63	0.39	2.12e-10	Parkinson's disease;
KIRP	cis	rs10045504	0.502	rs72746032	chr5:38743982	T/C	cg15396434	chr5:38725168	NA	-0.95	-9.53	-0.52	1.58e-18	Night sleep phenotypes;
KIRP	cis	rs1040	0.727	rs7382431	chr6:169621829	A/T	cg04662567	chr6:169592167	NA	-0.49	-6.06	-0.36	5.19e-9	Joint mobility (Beighton score);
KIRP	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg05457628	chr5:178986728	RUFY1	0.52	7.77	0.44	2.06e-13	Lung cancer;
KIRP	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg05315796	chr3:52349193	DNAH1	0.44	6.77	0.4	9.16e-11	Bipolar disorder;
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-8.46	-0.47	2.35e-15	Lymphocyte counts;
KIRP	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg17863274	chr19:49399704	TULP2	-0.41	-5.85	-0.35	1.57e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.8	-11.7	-0.6	1.99e-25	Height;
KIRP	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.75e-32	Mean platelet volume;
KIRP	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg04156418	chr7:157293606	NA	0.39	5.49	0.33	1.01e-7	Inattentive symptoms;
KIRP	trans	rs10921528	0.559	rs10801288	chr1:194190255	A/G	cg04887321	chr16:55090590	NA	-0.43	-6.37	-0.38	9.43e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg24642439	chr20:33292090	TP53INP2	0.49	5.79	0.35	2.1e-8	Height;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg17441377	chr17:3906640	NA	0.57	8.6	0.48	9.55e-16	Type 2 diabetes;
KIRP	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.43	5.15	0.31	5.39e-7	Systemic lupus erythematosus;
KIRP	cis	rs4363506	1.000	rs10765114	chr10:129274752	G/A	cg07804728	chr10:129284050	NA	0.41	5.83	0.35	1.73e-8	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg00129232	chr17:37814104	STARD3	-0.72	-9.59	-0.52	1.02e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.98	14.12	0.67	1.47e-33	Cognitive function;
KIRP	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	cis	rs6832769	1.000	rs6811520	chr4:56315178	T/C	cg09317128	chr4:56265301	TMEM165	0.52	6.46	0.38	5.43e-10	Personality dimensions;
KIRP	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	0.73	6.86	0.4	5.47e-11	Breast cancer;
KIRP	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg03877680	chr5:178157825	ZNF354A	1.02	13.8	0.66	1.8e-32	Neutrophil percentage of white cells;
KIRP	cis	rs9488822	0.676	rs12196579	chr6:116351724	G/T	cg26893134	chr6:116381904	FRK	0.21	5.78	0.35	2.24e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1978968	1.000	rs5992135	chr22:18447114	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-6.79	-0.4	8.23e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	6.01	0.36	6.71e-9	Total body bone mineral density;
KIRP	cis	rs6662572	0.737	rs4660887	chr1:46275959	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.4e-8	Blood protein levels;
KIRP	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg23188588	chr14:78226832	SNW1;C14orf178	0.85	8.28	0.47	8.11e-15	Fibroblast growth factor basic levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16313891	chr14:94640490	PPP4R4	0.53	6.58	0.39	2.74e-10	Parkinson's disease;
KIRP	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.72	7.23	0.42	5.94e-12	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27202017	chr16:2318549	RNPS1	0.49	6.16	0.37	2.96e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11878675	chr2:74211845	NA	0.54	7.12	0.41	1.15e-11	Parkinson's disease;
KIRP	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg03146154	chr1:46216737	IPP	0.47	4.85	0.3	2.18e-6	Platelet count;
KIRP	cis	rs2425143	1.000	rs55761608	chr20:34344226	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-4.98	-0.3	1.18e-6	Blood protein levels;
KIRP	cis	rs10737909	0.510	rs12025158	chr1:15539259	A/G	cg21012057	chr1:15538911	TMEM51	0.63	8.63	0.48	7.9e-16	Migraine;
KIRP	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-8.77	-0.49	3.08e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs2274471	0.645	rs3780375	chr9:5109431	G/A	cg03390472	chr9:5043263	JAK2	-0.45	-5.08	-0.31	7.43e-7	Crohn's disease;
KIRP	cis	rs34779708	0.931	rs35886556	chr10:35334985	C/T	cg03585969	chr10:35415529	CREM	0.8	9.71	0.53	4.34e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.3	-5.41	-0.33	1.51e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg14703610	chr5:56206110	C5orf35	0.5	6.69	0.39	1.46e-10	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.64	-0.39	2.04e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs12496230	0.794	rs4856964	chr3:66858561	C/T	cg04995300	chr3:66848608	NA	0.45	6.95	0.41	3.22e-11	Type 2 diabetes;
KIRP	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.68	9.76	0.53	3.23e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17691542	chr6:26056736	HIST1H1C	0.51	6.45	0.38	5.91e-10	Height;
KIRP	cis	rs6662572	0.686	rs72677546	chr1:46577716	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.7	0.34	3.5e-8	Blood protein levels;
KIRP	cis	rs10924970	0.934	rs10802572	chr1:235426121	A/T	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg17724175	chr1:150552817	MCL1	0.32	5.53	0.33	8.35e-8	Melanoma;
KIRP	cis	rs7202877	0.706	rs247443	chr16:75465073	G/C	cg03315344	chr16:75512273	CHST6	-0.58	-5.32	-0.32	2.29e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg27147174	chr7:100797783	AP1S1	-0.59	-7.51	-0.43	1.07e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.63	-8.11	-0.46	2.4e-14	Lymphocyte counts;
KIRP	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg10932868	chr11:921992	NA	0.61	7.69	0.44	3.57e-13	Alzheimer's disease (late onset);
KIRP	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg26338869	chr17:61819248	STRADA	0.42	4.96	0.3	1.31e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.77	-10.99	-0.57	4.05e-23	Menarche (age at onset);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01524359	chr1:46049306	NASP	0.45	6.32	0.37	1.21e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs4664293	0.934	rs4380179	chr2:160541575	G/T	cg08347373	chr2:160653686	CD302	-0.38	-5.79	-0.35	2.15e-8	Monocyte percentage of white cells;
KIRP	cis	rs7224685	0.501	rs7211478	chr17:3897178	C/T	cg09695851	chr17:3907499	NA	0.9	17.66	0.75	1.28e-45	Type 2 diabetes;
KIRP	cis	rs9399401	0.626	rs6906468	chr6:142769386	A/G	cg03128060	chr6:142623767	GPR126	0.34	5.11	0.31	6.53e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs3540	0.883	rs6496676	chr15:90988384	A/T	cg10434728	chr15:90938212	IQGAP1	0.31	5.09	0.31	7.12e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg25703541	chr22:24373054	LOC391322	-0.81	-12.19	-0.61	4.65e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7539542	0.529	rs16850750	chr1:202880805	A/C	cg19681188	chr1:202830198	LOC148709	-0.45	-4.87	-0.3	1.97e-6	Mean platelet volume;
KIRP	cis	rs10782582	0.609	rs5745325	chr1:76269460	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.22	-0.37	2.09e-9	Daytime sleep phenotypes;
KIRP	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.81	-8.72	-0.49	4.24e-16	Asthma;
KIRP	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.6	5.75	0.34	2.64e-8	Skin colour saturation;
KIRP	cis	rs1050631	0.960	rs3826602	chr18:33688363	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.52	-6.38	-0.38	8.96e-10	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.53	-6.09	-0.36	4.4e-9	Metabolic traits;
KIRP	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg22903657	chr4:1355424	KIAA1530	0.42	5.97	0.36	8.38e-9	Obesity-related traits;
KIRP	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg10117171	chr1:25599238	RHD	-0.39	-5.37	-0.32	1.78e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.13e-7	Retinal vascular caliber;
KIRP	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg02190678	chr16:31089140	ZNF646	0.47	6.28	0.37	1.54e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9630089	0.746	rs4919084	chr10:98967596	G/A	cg25902810	chr10:99078978	FRAT1	0.45	5.23	0.32	3.58e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.45	-5.12	-0.31	6.14e-7	Fear of minor pain;
KIRP	cis	rs4780401	0.755	rs8191285	chr16:11765408	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-5.15	-0.31	5.35e-7	Rheumatoid arthritis;
KIRP	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.32	-6.56	-0.39	3.18e-10	Diastolic blood pressure;
KIRP	cis	rs2599510	0.811	rs2710625	chr2:32822957	G/A	cg02381751	chr2:32503542	YIPF4	0.51	5.82	0.35	1.8e-8	Interleukin-18 levels;
KIRP	cis	rs490234	0.702	rs13284572	chr9:128258270	T/C	cg14078157	chr9:128172775	NA	-0.65	-7.72	-0.44	2.92e-13	Mean arterial pressure;
KIRP	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg00262122	chr8:11665843	FDFT1	-0.43	-5.22	-0.32	3.89e-7	Triglycerides;
KIRP	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg16898833	chr6:26189333	HIST1H4D	0.8	5.27	0.32	2.98e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.54	7.39	0.43	2.22e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg08992911	chr2:238395768	MLPH	0.57	5.47	0.33	1.12e-7	Prostate cancer;
KIRP	cis	rs7172677	1.000	rs4886658	chr15:75414536	A/C	cg14664628	chr15:75095509	CSK	-0.56	-6.17	-0.37	2.75e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg00800038	chr16:89945340	TCF25	-0.67	-6.64	-0.39	1.97e-10	Skin colour saturation;
KIRP	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs860295	0.775	rs822505	chr1:155846528	C/T	cg02153340	chr1:155202674	NA	0.37	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.67	-7.27	-0.42	4.79e-12	Corneal structure;
KIRP	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.04	-0.31	9.21e-7	Life satisfaction;
KIRP	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	5.95	0.35	9.08e-9	Motion sickness;
KIRP	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-7.61	-0.44	5.68e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg21253087	chr9:139290292	SNAPC4	0.47	6.57	0.39	2.99e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg15047889	chr8:124780837	FAM91A1	-0.51	-5.1	-0.31	6.73e-7	Pancreatic cancer;
KIRP	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.24	-0.51	1.22e-17	Total body bone mineral density;
KIRP	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-5.48	-0.33	1.05e-7	IgG glycosylation;
KIRP	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg27205649	chr11:78285834	NARS2	-0.64	-8.34	-0.47	5.51e-15	Alzheimer's disease (survival time);
KIRP	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.38e-7	Ileal carcinoids;
KIRP	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg18016565	chr1:150552671	MCL1	-0.51	-7.85	-0.45	1.28e-13	Urate levels;
KIRP	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg24375607	chr4:120327624	NA	0.59	6.46	0.38	5.48e-10	Corneal astigmatism;
KIRP	cis	rs960902	0.592	rs6753503	chr2:37736167	T/C	cg25341268	chr2:37734390	NA	-0.61	-8.34	-0.47	5.21e-15	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.85	12.37	0.62	1.16e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs72827839	0.846	rs72823530	chr17:46109371	G/A	cg03171361	chr17:47075758	IGF2BP1	-0.49	-4.95	-0.3	1.38e-6	Ease of getting up in the morning;
KIRP	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg07395648	chr5:131743802	NA	-0.54	-7.66	-0.44	4.23e-13	Blood metabolite levels;
KIRP	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.71	-10.79	-0.57	1.78e-22	Hepatocellular carcinoma;
KIRP	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	5.31	0.32	2.4e-7	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	9.11	0.5	2.94e-17	Coronary artery disease;
KIRP	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg13047869	chr3:10149882	C3orf24	0.53	5.23	0.32	3.7e-7	Alzheimer's disease;
KIRP	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg09795085	chr6:101329169	ASCC3	0.41	4.86	0.3	2.09e-6	Neuroticism;
KIRP	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.73	9.72	0.53	4.17e-19	Crohn's disease;
KIRP	cis	rs7116495	1.000	rs949325	chr11:71729656	A/G	cg11196788	chr11:71737549	NUMA1	0.56	5.06	0.31	8.28e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.06	-11.88	-0.6	4.89e-26	Vitiligo;
KIRP	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg21395723	chr22:39101663	GTPBP1	0.47	6.38	0.38	8.73e-10	Menopause (age at onset);
KIRP	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.8	9.37	0.51	4.9e-18	Cocaine dependence;
KIRP	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.76	-10.87	-0.57	9.88e-23	Asthma;
KIRP	cis	rs909341	0.818	rs2259858	chr20:62346459	A/T	cg11503966	chr20:62272292	STMN3	-0.42	-6.06	-0.36	5.11e-9	Atopic dermatitis;
KIRP	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.59	-7.74	-0.44	2.58e-13	Mean corpuscular volume;
KIRP	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.53	7.35	0.42	2.9e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.78	-0.66	2.18e-32	Height;
KIRP	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.8	0.35	2.01e-8	Lung cancer;
KIRP	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	7.0	0.41	2.36e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.58	7.1	0.41	1.35e-11	Osteoporosis;
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg06654118	chr4:1303317	MAEA	0.27	4.94	0.3	1.43e-6	Obesity-related traits;
KIRP	cis	rs7666738	0.515	rs10015315	chr4:98700137	A/G	cg05340658	chr4:99064831	C4orf37	0.65	7.79	0.44	1.84e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-7.24	-0.42	5.82e-12	Vitiligo;
KIRP	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	9.04	0.5	4.64e-17	Coffee consumption (cups per day);
KIRP	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.45	-6.36	-0.38	9.65e-10	Blood metabolite levels;
KIRP	cis	rs41005	0.967	rs41006	chr2:8109348	A/G	cg03155496	chr2:8117019	LOC339788	0.57	9.41	0.51	3.61e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg13165212	chr22:42675999	NA	0.35	5.98	0.36	7.78e-9	Cognitive function;
KIRP	cis	rs2147904	0.934	rs783625	chr1:42365548	C/T	cg16685388	chr1:42384056	HIVEP3	0.28	4.96	0.3	1.31e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg03734594	chr13:111297400	CARS2	0.32	4.94	0.3	1.45e-6	Coronary artery disease;
KIRP	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.1	-0.36	4.18e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg00343986	chr7:65444356	GUSB	0.41	5.03	0.31	9.52e-7	Aortic root size;
KIRP	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.01	0.69	1.35e-36	Lymphocyte percentage of white cells;
KIRP	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg16141378	chr3:129829833	LOC729375	0.53	7.01	0.41	2.27e-11	Retinal vascular caliber;
KIRP	cis	rs2573652	0.657	rs2573668	chr15:100541776	C/T	cg09918751	chr15:100517450	ADAMTS17	0.39	5.25	0.32	3.28e-7	Height;
KIRP	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.44	5.67	0.34	3.97e-8	Body mass index;
KIRP	cis	rs6681460	0.934	rs10889635	chr1:67075575	G/A	cg02459107	chr1:67143332	SGIP1	0.46	6.52	0.38	3.9e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.63	7.24	0.42	5.61e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.44	-6.16	-0.37	2.91e-9	Coronary artery disease;
KIRP	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.44	-11.0	-0.57	3.68e-23	Diastolic blood pressure;
KIRP	cis	rs7011507	1.000	rs56099275	chr8:49115744	C/T	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg24565620	chr2:194026	NA	-0.76	-6.38	-0.38	8.7e-10	Blood protein levels;
KIRP	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.57	8.0	0.45	5.03e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.69	10.4	0.55	3.01e-21	Menarche (age at onset);
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg17441377	chr17:3906640	NA	-0.5	-7.39	-0.43	2.29e-12	Type 2 diabetes;
KIRP	cis	rs7572644	0.699	rs1841068	chr2:28191629	C/T	cg27432699	chr2:27873401	GPN1	-0.43	-5.1	-0.31	6.76e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs6032067	0.641	rs6032006	chr20:43755053	G/A	cg10761708	chr20:43804764	PI3	0.46	5.23	0.32	3.61e-7	Blood protein levels;
KIRP	cis	rs8113308	0.689	rs8112515	chr19:52491250	A/G	cg25782003	chr19:52490127	ZNF350	0.89	8.92	0.49	1.09e-16	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg08662619	chr6:150070041	PCMT1	0.37	5.83	0.35	1.71e-8	Lung cancer;
KIRP	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.32	4.88	0.3	1.94e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7827545	0.545	rs6998092	chr8:135557449	A/G	cg17885191	chr8:135476712	NA	0.65	6.16	0.37	2.87e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.61	-6.73	-0.39	1.16e-10	Urate levels in lean individuals;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg10572858	chr15:72742016	NA	0.42	6.56	0.39	3.21e-10	C-reactive protein;
KIRP	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg02696790	chr15:75250997	RPP25	0.33	5.41	0.33	1.47e-7	Caffeine consumption;
KIRP	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-12.94	-0.64	1.47e-29	Vitiligo;
KIRP	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	1.16	14.72	0.68	1.32e-35	Monocyte percentage of white cells;
KIRP	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg14664628	chr15:75095509	CSK	-0.75	-9.44	-0.52	2.92e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.65	5.7	0.34	3.48e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.65	-7.64	-0.44	4.79e-13	Alcohol dependence;
KIRP	cis	rs2671245	0.933	rs2767519	chr1:56163422	T/G	cg11523071	chr1:56160889	NA	0.41	6.69	0.39	1.52e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.59	8.05	0.46	3.55e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.68	8.12	0.46	2.23e-14	Height;
KIRP	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg02073558	chr3:44770973	ZNF501	0.57	8.03	0.46	4.02e-14	Depressive symptoms;
KIRP	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12963246	chr6:28129442	ZNF389	0.38	4.89	0.3	1.79e-6	Cardiac Troponin-T levels;
KIRP	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg17554472	chr22:41940697	POLR3H	-0.44	-5.03	-0.31	9.57e-7	Neuroticism;
KIRP	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25517755	chr10:38738941	LOC399744	0.39	5.1	0.31	6.67e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs4523957	0.855	rs9896535	chr17:2133205	C/T	cg16513277	chr17:2031491	SMG6	-0.68	-9.43	-0.52	3.2e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22051586	chr4:881820	GAK	-0.53	-7.03	-0.41	2.01e-11	Inflammatory biomarkers;
KIRP	cis	rs6693567	0.565	rs578353	chr1:150287884	C/G	cg09579323	chr1:150459698	TARS2	0.39	4.89	0.3	1.86e-6	Migraine;
KIRP	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg12661370	chr5:149340060	SLC26A2	0.47	5.75	0.34	2.7e-8	HIV-1 control;
KIRP	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.34	-4.85	-0.3	2.16e-6	Monocyte count;
KIRP	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs7923609	0.967	rs7915779	chr10:65244244	G/C	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.86	-0.35	1.46e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.83	8.59	0.48	1.02e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4728302	0.571	rs13309851	chr7:133582364	C/A	cg10665199	chr7:133106180	EXOC4	0.42	4.88	0.3	1.87e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2273669	0.667	rs12215344	chr6:109329641	A/C	cg05315195	chr6:109294784	ARMC2	-0.64	-6.17	-0.37	2.86e-9	Prostate cancer;
KIRP	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.65	-10.09	-0.54	3e-20	Menopause (age at onset);
KIRP	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg00343986	chr7:65444356	GUSB	0.44	5.16	0.31	5.06e-7	Aortic root size;
KIRP	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.67	-6.82	-0.4	6.95e-11	Axial length;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18986451	chr3:100428869	TFG	0.54	6.02	0.36	6.45e-9	Lung cancer in ever smokers;
KIRP	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	1.01	10.54	0.56	1.08e-21	Eosinophilic esophagitis;
KIRP	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg01320130	chr1:67600311	NA	0.38	5.06	0.31	8.25e-7	Psoriasis;
KIRP	cis	rs1978968	0.957	rs55865752	chr22:18444227	G/A	cg03078520	chr22:18463400	MICAL3	-0.66	-7.82	-0.45	1.55e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs737693	0.920	rs17368659	chr11:102742761	G/T	cg19620758	chr11:102826565	MMP13	0.69	5.54	0.33	7.71e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16672503	chr16:67906986	EDC4	0.47	6.02	0.36	6.43e-9	Parkinson's disease;
KIRP	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12560992	chr17:57184187	TRIM37	0.62	7.15	0.41	9.94e-12	Testicular germ cell tumor;
KIRP	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.5	0.38	4.46e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.96	11.47	0.59	1.13e-24	Corneal astigmatism;
KIRP	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg06289844	chr6:126071538	HEY2	-0.39	-5.64	-0.34	4.57e-8	Brugada syndrome;
KIRP	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.55	-6.68	-0.39	1.56e-10	Total body bone mineral density;
KIRP	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.83	-7.8	-0.45	1.75e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg00852783	chr1:26633632	UBXN11	-0.56	-5.75	-0.34	2.68e-8	Obesity-related traits;
KIRP	cis	rs17095355	0.901	rs61881586	chr10:111758419	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.89	-0.35	1.27e-8	Biliary atresia;
KIRP	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg05347473	chr6:146136440	FBXO30	0.47	6.93	0.4	3.72e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06481639	chr22:41940642	POLR3H	0.74	7.97	0.45	6.1e-14	Vitiligo;
KIRP	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs687432	0.812	rs61902761	chr11:57875194	G/A	cg19752551	chr11:57585705	CTNND1	-0.68	-8.75	-0.49	3.43e-16	Parkinson's disease;
KIRP	cis	rs17401966	1.000	rs4348727	chr1:10265606	G/A	cg19773385	chr1:10388646	KIF1B	-0.62	-8.06	-0.46	3.22e-14	Hepatocellular carcinoma;
KIRP	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg15841412	chr13:111365552	ING1	-0.49	-5.58	-0.34	6.21e-8	Coronary artery disease;
KIRP	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	8.96	0.5	8.26e-17	IgG glycosylation;
KIRP	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg19849509	chr2:175204996	NA	-0.53	-6.34	-0.37	1.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg19554555	chr3:13937349	NA	0.54	7.81	0.45	1.65e-13	Ovarian reserve;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg16316519	chr12:8542756	LOC389634	-0.47	-6.71	-0.39	1.37e-10	Myopia;
KIRP	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.35	-7.42	-0.43	1.85e-12	Type 2 diabetes;
KIRP	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg04935436	chr20:30431758	NA	0.38	5.22	0.32	3.83e-7	Subcortical brain region volumes;Putamen volume;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00587304	chr3:172468157	NA	0.48	6.57	0.39	2.99e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-0.93	-12.05	-0.61	1.33e-26	Blood protein levels;
KIRP	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg04369109	chr6:150039330	LATS1	0.45	5.62	0.34	5.25e-8	Lung cancer;
KIRP	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.55	5.17	0.31	4.78e-7	Alzheimer's disease;
KIRP	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.77	-8.78	-0.49	2.89e-16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	trans	rs2319125	0.683	rs8182353	chr17:64048710	A/G	cg16326819	chr2:118771837	CCDC93	0.55	7.02	0.41	2.12e-11	&beta2-Glycoprotein I (β2-GPI) plasma levels;
KIRP	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg16898833	chr6:26189333	HIST1H4D	0.76	5.38	0.32	1.69e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg09165964	chr15:75287851	SCAMP5	-0.9	-8.36	-0.47	4.7e-15	Lung cancer;
KIRP	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.15	-0.31	5.28e-7	Fear of minor pain;
KIRP	cis	rs2288912	0.807	rs3760626	chr19:45457105	A/G	cg13119609	chr19:45449297	APOC2	0.52	7.36	0.42	2.69e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4478037	0.818	rs17522946	chr3:33138777	A/G	cg19404215	chr3:33155277	CRTAP	0.61	5.53	0.33	8.3e-8	Major depressive disorder;
KIRP	cis	rs4664293	0.967	rs1006192	chr2:160567589	G/T	cg08347373	chr2:160653686	CD302	-0.41	-6.27	-0.37	1.6e-9	Monocyte percentage of white cells;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg07458698	chr2:67624494	ETAA1	1.15	7.73	0.44	2.69e-13	P wave terminal force;
KIRP	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg13819577	chr1:248512075	OR14C36	-0.35	-5.06	-0.31	8.09e-7	Common traits (Other);
KIRP	cis	rs2273669	0.588	rs75995854	chr6:109325624	C/A	cg05315195	chr6:109294784	ARMC2	-0.65	-6.34	-0.37	1.07e-9	Prostate cancer;
KIRP	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	9.87	0.53	1.38e-19	Smoking behavior;
KIRP	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	1.06	15.4	0.7	6.36e-38	Cognitive function;
KIRP	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg04935436	chr20:30431758	NA	0.48	5.86	0.35	1.48e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.35	5.01	0.3	1.06e-6	Body mass index;
KIRP	cis	rs8054556	1.000	rs4788198	chr16:29970835	C/T	cg06326092	chr16:30034487	C16orf92	0.36	5.12	0.31	6.29e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.44	-5.74	-0.34	2.72e-8	Mean platelet volume;
KIRP	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg17595323	chr11:93583763	C11orf90	-0.41	-6.81	-0.4	7.59e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.48	-4.93	-0.3	1.52e-6	Obesity (extreme);
KIRP	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.08	-13.79	-0.66	1.93e-32	Corneal structure;
KIRP	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.24e-17	Chronic sinus infection;
KIRP	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg23920097	chr1:209922102	NA	0.46	6.22	0.37	2.1e-9	Red blood cell count;
KIRP	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.48	-7.23	-0.42	5.97e-12	Psoriasis;
KIRP	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg11498726	chr8:26250323	BNIP3L	-0.46	-7.19	-0.42	7.65e-12	Red cell distribution width;
KIRP	cis	rs7078219	0.505	rs11190140	chr10:101291593	T/C	cg07044859	chr10:101282883	NA	-0.28	-5.07	-0.31	7.94e-7	Dental caries;
KIRP	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg20503657	chr10:835505	NA	-0.56	-6.72	-0.39	1.25e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.14	-0.5	2.42e-17	Personality dimensions;
KIRP	cis	rs2172802	0.629	rs1948616	chr4:62487688	A/G	cg04118610	chr4:62707027	LPHN3	-0.58	-7.07	-0.41	1.59e-11	Partial epilepsies;
KIRP	trans	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17183009	chr3:120277827	NA	0.53	6.15	0.37	3.2e-9	Corneal astigmatism;
KIRP	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.89	-12.75	-0.63	6.19e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg00405596	chr8:11794950	NA	-0.46	-6.16	-0.37	2.97e-9	Triglycerides;
KIRP	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	1.06	20.03	0.79	1.42e-53	Heart rate;
KIRP	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs1355223	1.000	rs1355221	chr11:34758609	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-5.16	-0.31	5.02e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2172802	0.570	rs12233859	chr4:62545435	G/A	cg04118610	chr4:62707027	LPHN3	-0.43	-5.25	-0.32	3.26e-7	Partial epilepsies;
KIRP	cis	rs12210905	1.000	rs12210905	chr6:27151309	A/G	cg11502198	chr6:26597334	ABT1	-0.79	-5.04	-0.31	8.88e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1903068	1.000	rs73236109	chr4:56007425	C/T	cg20092376	chr4:56023423	NA	0.41	5.1	0.31	6.74e-7	Endometriosis;
KIRP	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	1.04	17.92	0.75	1.61e-46	Monocyte count;
KIRP	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs8106542	0.906	rs4548995	chr19:10740871	G/C	cg23183932	chr19:10823679	QTRT1	0.43	4.86	0.3	2.05e-6	Platelet distribution width;
KIRP	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs12210905	0.688	rs12213533	chr6:27346021	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs7714584	1.000	rs6862814	chr5:150245259	G/A	cg22134413	chr5:150180641	NA	0.56	5.12	0.31	6.24e-7	Crohn's disease;
KIRP	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg19875535	chr5:140030758	IK	-0.67	-9.49	-0.52	2.16e-18	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08880486	chr17:66287505	ARSG;SLC16A6	0.46	6.23	0.37	2.01e-9	Parkinson's disease;
KIRP	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.46	7.02	0.41	2.19e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.78	-0.4	8.79e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg19645103	chr12:69753606	YEATS4	-0.47	-5.31	-0.32	2.45e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.04	-0.36	5.63e-9	Height;
KIRP	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.53	7.17	0.42	8.84e-12	Mean corpuscular volume;
KIRP	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg07212818	chr11:638076	DRD4	-0.39	-4.95	-0.3	1.4e-6	Systemic lupus erythematosus;
KIRP	cis	rs27434	0.583	rs34760	chr5:96153491	T/C	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.15e-8	Ankylosing spondylitis;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16524936	chr4:1340807	KIAA1530	-0.46	-5.96	-0.35	8.92e-9	Longevity;
KIRP	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-9.41	-0.51	3.73e-18	Morning vs. evening chronotype;
KIRP	cis	rs12311304	0.965	rs7969197	chr12:15362066	G/C	cg08258403	chr12:15378311	NA	0.34	4.98	0.3	1.21e-6	Behavioural disinhibition (generation interaction);
KIRP	cis	rs34779708	0.643	rs4275563	chr10:35545286	G/A	cg03585969	chr10:35415529	CREM	0.6	6.98	0.41	2.79e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13094219	chr2:46926190	SOCS5	0.53	7.18	0.42	8.15e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs2371030	0.965	rs1024896	chr2:211593938	C/T	cg18417063	chr2:211583084	NA	-0.51	-7.31	-0.42	3.82e-12	Non-small cell lung cancer;
KIRP	trans	rs669484	0.541	rs10809092	chr9:10421687	T/C	cg25509871	chr19:40871557	PLD3	-0.67	-6.54	-0.38	3.57e-10	Gestational age at birth (child effect);
KIRP	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg09264619	chr17:80180166	NA	-0.52	-6.0	-0.36	6.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg04362960	chr10:104952993	NT5C2	0.55	6.79	0.4	8.31e-11	Arsenic metabolism;
KIRP	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg09904177	chr6:26538194	HMGN4	0.46	6.2	0.37	2.41e-9	Schizophrenia;
KIRP	cis	rs10982256	0.789	rs2296262	chr9:117265406	C/T	cg13636371	chr9:117264095	DFNB31	-0.4	-5.14	-0.31	5.61e-7	Bipolar disorder;
KIRP	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg23711669	chr6:146136114	FBXO30	0.7	9.55	0.52	1.37e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.52	6.05	0.36	5.5e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs7903847	0.642	rs7903562	chr10:99154782	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-5.66	-0.34	4.1e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg15072625	chr6:86302950	SNX14	0.7	6.59	0.39	2.66e-10	Lung function (FEV1);
KIRP	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.33	0.79	1.39e-54	Chronic sinus infection;
KIRP	cis	rs4363385	0.720	rs883810	chr1:152941345	T/C	cg07796016	chr1:152779584	LCE1C	-0.44	-5.38	-0.32	1.69e-7	Inflammatory skin disease;
KIRP	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg11707556	chr5:10655725	ANKRD33B	0.67	8.3	0.47	6.73e-15	Coronary artery disease;
KIRP	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg04780086	chr2:111875790	ACOXL	0.4	5.43	0.33	1.35e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.99	-10.99	-0.57	3.96e-23	HIV-1 control;
KIRP	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg08461772	chr7:95026248	PON3	0.42	6.09	0.36	4.38e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.92	10.74	0.57	2.5e-22	Neuroticism;
KIRP	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg11344533	chr11:111475393	SIK2	-0.29	-4.97	-0.3	1.24e-6	Primary sclerosing cholangitis;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.01e-8	Life satisfaction;
KIRP	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.12	0.41	1.2e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg06074448	chr4:187884817	NA	-0.77	-13.0	-0.64	9.32e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.56	-6.81	-0.4	7.46e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg06521331	chr12:34319734	NA	-0.54	-6.59	-0.39	2.69e-10	Heart rate;
KIRP	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg13978929	chr19:21580086	ZNF493	0.5	4.88	0.3	1.92e-6	Pain;
KIRP	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.92	-11.42	-0.59	1.65e-24	Diastolic blood pressure;
KIRP	cis	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg21546286	chr11:48923668	NA	-0.45	-5.4	-0.33	1.59e-7	HDL cholesterol;
KIRP	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-8.63	-0.48	7.75e-16	Platelet count;
KIRP	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg19847130	chr8:10466454	RP1L1	0.37	5.53	0.33	8.36e-8	Neuroticism;
KIRP	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-9.49	-0.52	2.17e-18	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg16430402	chr1:5947386	NPHP4	0.53	7.04	0.41	1.88e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	2.02e-7	Life satisfaction;
KIRP	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg17264618	chr3:40429014	ENTPD3	-0.32	-4.93	-0.3	1.52e-6	Renal cell carcinoma;
KIRP	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.09	-0.36	4.33e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2916247	0.954	rs4735059	chr8:93080265	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.53	-6.89	-0.4	4.53e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2380205	0.651	rs7072283	chr10:5918647	C/T	cg27141509	chr10:5886111	NA	-0.36	-5.09	-0.31	7.21e-7	Breast cancer;
KIRP	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.59	5.06	0.31	8.06e-7	Fat distribution (HIV);
KIRP	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.5	6.66	0.39	1.79e-10	Endometrial cancer;
KIRP	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.83	-10.71	-0.56	3.11e-22	Cognitive function;
KIRP	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25517755	chr10:38738941	LOC399744	-0.38	-5.22	-0.32	3.79e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg17654217	chr7:100282651	GIGYF1	0.52	5.14	0.31	5.65e-7	Other erythrocyte phenotypes;
KIRP	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg03060546	chr3:49711283	APEH	0.44	5.56	0.33	7.12e-8	Parkinson's disease;
KIRP	cis	rs6681460	1.000	rs10889641	chr1:67138367	C/T	cg02459107	chr1:67143332	SGIP1	0.52	7.44	0.43	1.73e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg10254082	chr7:997346	NA	0.47	4.9	0.3	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg01879757	chr17:41196368	BRCA1	-0.6	-7.77	-0.44	2.12e-13	Menopause (age at onset);
KIRP	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.33	0.79	1.39e-54	Chronic sinus infection;
KIRP	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.51	-5.82	-0.35	1.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7404928	1.000	rs8182198	chr16:23905225	G/T	cg21745164	chr16:23765304	CHP2	-0.47	-6.12	-0.36	3.63e-9	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs9392653	0.617	rs379169	chr6:5080538	A/G	cg13207534	chr6:5087447	PPP1R3G	0.53	6.08	0.36	4.48e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg01721255	chr8:58191610	C8orf71	-0.55	-5.16	-0.31	4.98e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg05527609	chr1:210001259	C1orf107	0.43	5.28	0.32	2.79e-7	Red blood cell count;
KIRP	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-6.68	-0.39	1.56e-10	Coronary artery disease;
KIRP	cis	rs4886920	0.638	rs12912467	chr15:78120453	C/G	cg10461261	chr15:78109450	NA	0.36	6.13	0.36	3.53e-9	Neuroticism;
KIRP	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg17279839	chr7:150038598	RARRES2	0.55	7.09	0.41	1.42e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12143943	0.934	rs17335392	chr1:204595899	C/T	cg20240347	chr1:204465584	NA	-0.32	-5.55	-0.33	7.3e-8	Cognitive performance;
KIRP	cis	rs1270639	0.732	rs1263558	chr7:157463080	C/T	cg13357408	chr7:157437802	PTPRN2	-0.53	-5.09	-0.31	6.99e-7	Colorectal cancer;
KIRP	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	1.05	19.29	0.78	4e-51	Heart rate;
KIRP	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg07148914	chr20:33460835	GGT7	0.53	7.03	0.41	1.98e-11	Height;
KIRP	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg21775007	chr8:11205619	TDH	0.47	6.57	0.39	2.97e-10	Neuroticism;
KIRP	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg13736514	chr6:26305472	NA	-0.72	-9.22	-0.51	1.38e-17	Educational attainment;
KIRP	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.27	-22.23	-0.82	8.87e-61	Breast cancer;
KIRP	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg07307994	chr2:3828216	NA	0.38	5.54	0.33	7.88e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.68	0.48	5.38e-16	Life satisfaction;
KIRP	cis	rs75920871	0.528	rs7935913	chr11:116944348	A/G	cg04087571	chr11:116723030	SIK3	0.25	5.21	0.32	3.95e-7	Subjective well-being;
KIRP	cis	rs1215050	0.765	rs1588018	chr4:98756324	G/C	cg17366294	chr4:99064904	C4orf37	0.37	5.0	0.3	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12282928	1.000	rs4980423	chr11:48258607	C/G	cg26585981	chr11:48327164	OR4S1	0.54	6.34	0.37	1.09e-9	Migraine - clinic-based;
KIRP	cis	rs5770917	0.522	rs5770916	chr22:51016098	C/T	cg25309564	chr22:51001381	C22orf41	-0.57	-5.27	-0.32	2.94e-7	Narcolepsy;
KIRP	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.87	0.49	1.55e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.68	0.39	1.57e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg02160872	chr5:212506	CCDC127	-0.67	-5.74	-0.34	2.73e-8	Asthma (childhood onset);
KIRP	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.56	-7.41	-0.43	1.97e-12	Menarche (age at onset);
KIRP	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	0.72	9.68	0.53	5.44e-19	Red blood cell count;
KIRP	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg09455208	chr3:40491958	NA	0.33	5.83	0.35	1.72e-8	Renal cell carcinoma;
KIRP	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg13319975	chr6:146136371	FBXO30	-0.48	-6.69	-0.39	1.49e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs16973500	0.808	rs112452788	chr16:71911198	C/T	cg09427745	chr16:71932006	KIAA0174	-0.59	-5.12	-0.31	6.11e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.66	8.62	0.48	8.39e-16	Aortic root size;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20964082	chr1:236442072	ERO1LB	0.42	6.12	0.36	3.64e-9	Interleukin-4 levels;
KIRP	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.1	0.36	4.19e-9	Ovarian reserve;
KIRP	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	10.07	0.54	3.46e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.42	-5.13	-0.31	5.99e-7	IgG glycosylation;
KIRP	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	1.02	13.98	0.67	4.49e-33	Neutrophil percentage of white cells;
KIRP	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.63	-6.98	-0.41	2.66e-11	Neuroticism;
KIRP	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg02487422	chr3:49467188	NICN1	0.38	5.24	0.32	3.43e-7	Parkinson's disease;
KIRP	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.76	-9.8	-0.53	2.28e-19	Aortic root size;
KIRP	cis	rs6561750	1.000	rs1458269	chr13:54434565	C/T	ch.13.53330881F	chr13:54432880	NA	0.37	5.06	0.31	8.33e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs13170463	0.579	rs77360537	chr5:8048338	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs13102973	0.720	rs13137300	chr4:135889460	G/A	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg03060546	chr3:49711283	APEH	-0.67	-5.32	-0.32	2.29e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.84	13.94	0.66	6.14e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	4.87	0.3	2.03e-6	Schizophrenia;
KIRP	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.41	-5.65	-0.34	4.35e-8	Blood metabolite levels;
KIRP	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg08648136	chr8:956695	NA	0.41	6.09	0.36	4.27e-9	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13683282	chr1:40723560	ZMPSTE24	0.48	6.05	0.36	5.4e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg12486944	chr17:80159399	CCDC57	-0.39	-5.28	-0.32	2.91e-7	Life satisfaction;
KIRP	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs4363385	0.509	rs11581802	chr1:152936164	G/A	cg07796016	chr1:152779584	LCE1C	-0.45	-5.68	-0.34	3.7e-8	Inflammatory skin disease;
KIRP	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.78	-8.48	-0.48	2.18e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs6752107	0.901	rs11679791	chr2:234156536	G/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.59	7.58	0.43	7.17e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg11859384	chr17:80120422	CCDC57	-0.44	-5.52	-0.33	8.44e-8	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09730735	chr3:46594000	LRRC2	0.4	6.12	0.36	3.6e-9	Interleukin-4 levels;
KIRP	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg21132104	chr15:45694354	SPATA5L1	-0.54	-6.41	-0.38	7.48e-10	Glomerular filtration rate;
KIRP	cis	rs7116495	0.786	rs1892919	chr11:71712175	G/A	cg11196788	chr11:71737549	NUMA1	0.56	4.98	0.3	1.19e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05316555	chr8:126442587	TRIB1	-0.55	-6.02	-0.36	6.21e-9	Menopause (age at onset);
KIRP	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.78	8.92	0.49	1.08e-16	Corneal astigmatism;
KIRP	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	1.06	17.28	0.74	2.43e-44	Eosinophil percentage of white cells;
KIRP	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.57	-6.05	-0.36	5.3300000000000004e-09	Ulcerative colitis;
KIRP	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.81	11.66	0.6	2.67e-25	Multiple sclerosis;
KIRP	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg18154014	chr19:37997991	ZNF793	-0.93	-10.01	-0.54	5.12e-20	Coronary artery calcification;
KIRP	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg02415014	chr8:143852576	LYNX1	-0.31	-5.07	-0.31	7.74e-7	Urinary tract infection frequency;
KIRP	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.51	8.36	0.47	4.75e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.98	13.44	0.65	3.11e-31	Cognitive ability;
KIRP	cis	rs7546094	1.000	rs2999154	chr1:113222456	G/T	cg22162597	chr1:113214053	CAPZA1	-0.51	-7.29	-0.42	4.24e-12	Platelet distribution width;
KIRP	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.41	0.38	7.53e-10	Hypertriglyceridemia;
KIRP	cis	rs4889855	0.585	rs72855201	chr17:78530597	A/G	cg09596252	chr17:78655493	RPTOR	-0.48	-5.57	-0.33	6.57e-8	Fractional excretion of uric acid;
KIRP	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.42	6.39	0.38	8.4e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg05484376	chr2:27715224	FNDC4	0.36	5.56	0.33	6.89e-8	Total body bone mineral density;
KIRP	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.85	0.49	1.7e-16	Bipolar disorder;
KIRP	trans	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg10756647	chr7:56101905	PSPH	0.98	6.82	0.4	7.04e-11	Diabetic kidney disease;
KIRP	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.57	0.56	9.26e-22	Cognitive test performance;
KIRP	cis	rs10267417	0.603	rs12333603	chr7:19907821	C/G	cg05791153	chr7:19748676	TWISTNB	-0.47	-4.85	-0.3	2.21e-6	Night sleep phenotypes;
KIRP	cis	rs40363	1.000	rs37837	chr16:3508616	G/A	cg05754148	chr16:3507555	NAT15	0.52	5.18	0.31	4.6e-7	Tuberculosis;
KIRP	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg14221460	chr8:27183342	PTK2B	0.47	6.04	0.36	5.74e-9	Neuroticism;
KIRP	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.01	-0.3	1.03e-6	Pulmonary function;
KIRP	cis	rs4356975	0.563	rs11249528	chr4:69955055	C/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs876084	0.505	rs12541796	chr8:121112830	G/A	cg06265175	chr8:121136014	COL14A1	0.52	6.49	0.38	4.81e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.45	-0.47	2.55e-15	Personality dimensions;
KIRP	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg18016565	chr1:150552671	MCL1	0.38	5.97	0.36	8.3e-9	Melanoma;
KIRP	cis	rs11997175	0.603	rs7464053	chr8:33786938	C/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.47	0.33	1.11e-7	Body mass index;
KIRP	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.49	-0.38	4.82e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	1.06	14.98	0.69	1.72e-36	Menopause (age at onset);
KIRP	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.75	-8.63	-0.48	7.97e-16	Pursuit maintenance gain;
KIRP	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.7	-5.14	-0.31	5.51e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13954965	chr2:133175192	GPR39	-0.42	-6.05	-0.36	5.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.95	0.35	9.1e-9	Monocyte percentage of white cells;
KIRP	cis	rs6693567	0.565	rs3125808	chr1:150314272	T/C	cg07843065	chr1:150265600	MRPS21	0.45	6.26	0.37	1.74e-9	Migraine;
KIRP	cis	rs4262150	0.764	rs2961766	chr5:151931892	G/A	cg12297329	chr5:152029980	NA	-0.59	-7.4	-0.43	2.17e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.66	-10.13	-0.54	2.16e-20	Corneal structure;
KIRP	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.65	7.74	0.44	2.53e-13	Testicular germ cell tumor;
KIRP	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.8	-0.49	2.55e-16	Mean corpuscular volume;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg13148511	chr17:4710380	PLD2	0.48	6.06	0.36	5.17e-9	Myopia (pathological);
KIRP	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg15896084	chr13:114927664	NA	0.47	6.18	0.37	2.59e-9	Schizophrenia;
KIRP	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg22563815	chr15:78856949	CHRNA5	0.51	7.87	0.45	1.1e-13	Sudden cardiac arrest;
KIRP	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg19025524	chr12:109796872	NA	-0.57	-8.11	-0.46	2.44e-14	Neuroticism;
KIRP	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg15556689	chr8:8085844	FLJ10661	-0.62	-8.15	-0.46	1.88e-14	Retinal vascular caliber;
KIRP	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.99	14.26	0.67	4.83e-34	Cognitive function;
KIRP	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg06585982	chr3:143692056	C3orf58	0.6	7.64	0.44	4.84e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg19875535	chr5:140030758	IK	-0.67	-9.49	-0.52	2.16e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4252707	1	rs4252707	chr1:204508147	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.59	-6.1	-0.36	4.09e-9	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs2745572	0.557	rs2816299	chr6:1548686	G/A	cg01806741	chr6:1527072	NA	0.33	4.95	0.3	1.39e-6	Glaucoma (high intraocular pressure);Glaucoma (primary open-angle);Intraocular pressure;
KIRP	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.01	-0.61	1.84e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg09555818	chr19:45449301	APOC2	0.51	7.46	0.43	1.45e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4664293	0.867	rs6732987	chr2:160582429	C/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg12963246	chr6:28129442	ZNF389	0.52	6.35	0.38	1.05e-9	Depression;
KIRP	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.27	0.32	2.97e-7	Asthma;
KIRP	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg00405596	chr8:11794950	NA	-0.46	-5.57	-0.33	6.52e-8	Neuroticism;
KIRP	cis	rs7561273	0.586	rs6545302	chr2:24364557	G/T	cg20701182	chr2:24300061	SF3B14	0.49	5.9	0.35	1.2e-8	Quantitative traits;
KIRP	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg01631408	chr1:248437212	OR2T33	-0.64	-8.5	-0.48	1.87e-15	Common traits (Other);
KIRP	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.75	9.21	0.51	1.45e-17	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg14456004	chr13:21872349	NA	-1.11	-13.94	-0.66	6.04e-33	White matter hyperintensity burden;
KIRP	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-1.02	-9.97	-0.54	7.06e-20	HIV-1 control;
KIRP	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	cis	rs667920	0.500	rs34498968	chr3:136195130	T/C	cg15507776	chr3:136538369	TMEM22	-0.68	-6.01	-0.36	6.48e-9	Coronary artery disease;
KIRP	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08822215	chr16:89438651	ANKRD11	-0.48	-6.6	-0.39	2.48e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.58	-7.37	-0.43	2.65e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg26384229	chr12:38710491	ALG10B	0.54	7.1	0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs1485395	0.891	rs10161319	chr12:54036314	C/T	cg16917193	chr12:54089295	NA	0.59	5.76	0.34	2.49e-8	Migraine without aura;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01786151	chr1:41347977	NA	0.49	7.07	0.41	1.57e-11	Survival in pancreatic cancer;
KIRP	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.1	12.58	0.63	2.31e-28	Vitiligo;
KIRP	trans	rs13170463	0.579	rs35029095	chr5:8047822	G/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs4474465	0.850	rs7942371	chr11:78219975	A/G	cg02023728	chr11:77925099	USP35	-0.31	-5.19	-0.31	4.48e-7	Alzheimer's disease (survival time);
KIRP	cis	rs9443189	0.763	rs2748952	chr6:76444360	G/A	cg01950844	chr6:76311363	SENP6	-0.57	-6.21	-0.37	2.2e-9	Prostate cancer;
KIRP	cis	rs1823913	0.927	rs13025919	chr2:192124901	T/C	cg12404831	chr2:192114017	MYO1B	0.6	8.15	0.46	1.83e-14	Obesity-related traits;
KIRP	cis	rs17818399	0.815	rs17768138	chr2:46868217	A/G	cg06386533	chr2:46925753	SOCS5	0.49	5.0	0.3	1.1e-6	Height;
KIRP	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.15	0.31	5.34e-7	Educational attainment;
KIRP	cis	rs3931020	0.705	rs28482086	chr1:75226252	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.41	4.86	0.3	2.1e-6	Resistin levels;
KIRP	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg05315796	chr3:52349193	DNAH1	0.39	5.11	0.31	6.49e-7	Schizophrenia;
KIRP	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg14517359	chr4:903473	GAK	-0.55	-5.67	-0.34	4.02e-8	Type 2 diabetes;
KIRP	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-13.25	-0.65	1.3e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1832871	0.599	rs1754413	chr6:158764741	C/T	cg07215822	chr6:158701037	NA	0.61	9.12	0.5	2.74e-17	Height;
KIRP	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.27e-12	Prudent dietary pattern;
KIRP	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg23307798	chr14:103986281	CKB	-0.41	-5.54	-0.33	7.72e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.38	-5.91	-0.35	1.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg00784671	chr22:46762841	CELSR1	-0.82	-8.17	-0.46	1.6e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3774830	1.000	rs6827240	chr4:5440224	G/T	cg26943120	chr4:5472116	STK32B	0.27	6.7	0.39	1.43e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14573099	chr2:101761014	TBC1D8	-0.45	-6.79	-0.4	8.32e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.63	6.65	0.39	1.86e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	-0.42	-4.93	-0.3	1.5e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs5770917	1.000	rs3180872	chr22:51017394	G/C	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.58	-5.61	-0.34	5.31e-8	Narcolepsy;
KIRP	cis	rs4638749	0.501	rs2378096	chr2:108765031	A/G	cg25838818	chr2:108905173	SULT1C2	-0.35	-5.53	-0.33	8.07e-8	Blood pressure;
KIRP	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.95	-13.82	-0.66	1.55e-32	Coronary artery disease;
KIRP	cis	rs8022179	0.580	rs6575979	chr14:103841018	A/G	cg23307798	chr14:103986281	CKB	0.41	5.09	0.31	7.16e-7	Monocyte count;
KIRP	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.69	-8.56	-0.48	1.25e-15	Schizophrenia;
KIRP	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27297192	chr10:134578999	INPP5A	0.58	7.04	0.41	1.92e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27181554	chr16:1992734	SEPX1	0.43	6.27	0.37	1.62e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.61	6.47	0.38	5.16e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg13679814	chr14:51411399	PYGL	0.47	6.65	0.39	1.85e-10	Colorectal cancer;
KIRP	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.38	-0.38	8.64e-10	Menopause (age at onset);
KIRP	cis	rs1600249	0.562	rs11250144	chr8:11386276	G/C	cg00405596	chr8:11794950	NA	0.45	5.05	0.31	8.8e-7	Rheumatoid arthritis;
KIRP	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.94	-15.44	-0.7	4.73e-38	Breast cancer;
KIRP	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.25	-0.42	5.32e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18810612	chr12:31682496	DENND5B	0.46	6.57	0.39	2.93e-10	Survival in pancreatic cancer;
KIRP	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.69	8.77	0.49	2.99e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.51	-0.33	9.07e-8	Life satisfaction;
KIRP	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.71	-9.28	-0.51	9.35e-18	Menopause (age at onset);
KIRP	cis	rs3750552	0.615	rs4382537	chr9:71955879	C/T	cg24146090	chr9:71939349	FAM189A2	-0.45	-4.99	-0.3	1.13e-6	Bipolar disorder;
KIRP	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25517755	chr10:38738941	LOC399744	-0.51	-6.95	-0.41	3.18e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-5.98	-0.36	7.83e-9	Metabolite levels;
KIRP	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg27236539	chr20:62289627	RTEL1	0.48	5.22	0.32	3.79e-7	Prostate cancer;
KIRP	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.58	-0.34	6.21e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.68	9.62	0.52	8.26e-19	Lung cancer;
KIRP	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg10223061	chr2:219282414	VIL1	0.32	5.38	0.32	1.77e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs6746896	0.708	rs68026712	chr2:97396403	T/C	cg01990225	chr2:97406019	LMAN2L	-0.56	-7.16	-0.42	9.36e-12	Bipolar disorder;
KIRP	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.9	7.71	0.44	3.1e-13	Obesity-related traits;
KIRP	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.45	0.33	1.25e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg24747557	chr10:131355152	MGMT	-0.37	-5.04	-0.31	8.9e-7	Response to temozolomide;
KIRP	cis	rs8084125	1.000	rs7230071	chr18:74955482	A/G	cg15443732	chr18:74961078	GALR1	0.61	5.57	0.33	6.51e-8	Obesity-related traits;
KIRP	cis	rs5995756	0.627	rs1008677	chr22:40009336	C/T	cg10455938	chr22:40058150	CACNA1I	0.4	5.52	0.33	8.78e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	0.97	13.98	0.67	4.33e-33	Total cholesterol levels;
KIRP	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.71	-6.31	-0.37	1.3e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4356975	0.563	rs12505466	chr4:69985662	A/T	cg27372994	chr4:70080453	UGT2B11	0.36	4.85	0.3	2.2e-6	Obesity-related traits;
KIRP	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.34	-0.32	2.12e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.33	-6.68	-0.39	1.63e-10	Urinary metabolites;
KIRP	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs6540559	1.000	rs17015259	chr1:209982923	G/A	cg25204440	chr1:209979598	IRF6	0.44	4.92	0.3	1.6e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg18404041	chr3:52824283	ITIH1	-0.44	-5.37	-0.32	1.82e-7	Schizophrenia;
KIRP	cis	rs2505998	0.957	rs1864408	chr10:43575883	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.52	-5.33	-0.32	2.21e-7	Hirschsprung disease;
KIRP	cis	rs2425143	0.547	rs6141583	chr20:34572834	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-5.31	-0.32	2.44e-7	Blood protein levels;
KIRP	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.75	-7.68	-0.44	3.84e-13	Lung function (FEV1/FVC);
KIRP	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs62380364	0.626	rs618741	chr5:88064012	C/T	cg24804195	chr5:87968844	LOC645323	-0.43	-5.56	-0.33	6.85e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.67	-7.11	-0.41	1.25e-11	Coronary artery calcification;
KIRP	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.5	7.11	0.41	1.24e-11	Body mass index;
KIRP	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	7.34	0.42	3.02e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg14465207	chr2:10951250	PDIA6	0.42	5.11	0.31	6.48e-7	Cardiac Troponin-T levels;
KIRP	cis	rs13102973	0.965	rs7656209	chr4:135875550	G/A	cg14419869	chr4:135874104	NA	0.56	9.41	0.51	3.64e-18	Subjective well-being;
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg09597638	chr17:3907349	NA	-0.75	-13.54	-0.65	1.34e-31	Type 2 diabetes;
KIRP	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	0.8	7.05	0.41	1.76e-11	Obesity-related traits;
KIRP	cis	rs7116495	1.000	rs2511114	chr11:71792147	T/C	cg07596299	chr11:71824057	C11orf51	-0.62	-4.88	-0.3	1.92e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg12315302	chr6:26189340	HIST1H4D	1.16	6.73	0.39	1.16e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.95	13.44	0.65	3.09e-31	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	9.94	0.54	8.96e-20	Smoking behavior;
KIRP	cis	rs7520050	0.966	rs7556436	chr1:46363880	C/T	cg24296786	chr1:45957014	TESK2	-0.39	-4.96	-0.3	1.3e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.55	-6.83	-0.4	6.74e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg00791764	chr4:53727839	RASL11B	0.45	6.2	0.37	2.33e-9	Optic nerve measurement (cup area);
KIRP	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1012068	0.581	rs5749339	chr22:32315735	A/G	cg15333674	chr22:32435499	NA	0.43	4.91	0.3	1.65e-6	Chronic hepatitis C infection;
KIRP	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg22138327	chr13:27999177	GTF3A	0.75	6.78	0.4	9.05e-11	Weight;
KIRP	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.31	-5.65	-0.34	4.37e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.43	-5.07	-0.31	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-1.06	-7.77	-0.44	2.09e-13	Lung cancer in ever smokers;
KIRP	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg16141378	chr3:129829833	LOC729375	0.59	7.84	0.45	1.37e-13	Morning vs. evening chronotype;
KIRP	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.56	-0.33	6.99e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg13206674	chr6:150067644	NUP43	0.58	8.21	0.46	1.22e-14	Lung cancer;
KIRP	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.93	13.47	0.65	2.47e-31	Bladder cancer;
KIRP	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.14	-0.31	5.65e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs45544231	0.569	rs1362550	chr16:52582816	C/G	cg09051775	chr16:52580266	TOX3	-0.42	-5.79	-0.35	2.15e-8	Restless legs syndrome;
KIRP	trans	rs2298574	0.614	rs17468095	chr18:25555446	C/T	cg07241908	chr8:56284622	XKR4	0.73	6.04	0.36	5.58e-9	vWF and FVIII levels;
KIRP	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.47	6.45	0.38	5.98e-10	Birth weight;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg22106847	chr5:118584299	DMXL1	0.44	6.67	0.39	1.72e-10	Migraine with aura;
KIRP	trans	rs2270927	0.790	rs4566770	chr5:75576313	A/G	cg13563193	chr19:33072644	PDCD5	-0.76	-7.2	-0.42	7.43e-12	Mean corpuscular volume;
KIRP	cis	rs3936840	0.647	rs942024	chr14:102979463	C/T	cg18135206	chr14:102964638	TECPR2	0.44	5.47	0.33	1.09e-7	Plateletcrit;
KIRP	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.43	-0.38	6.74e-10	Metabolite levels;
KIRP	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-7.31	-0.42	3.73e-12	Joint mobility (Beighton score);
KIRP	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	4.85	0.3	2.19e-6	Bipolar disorder;
KIRP	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.84	13.32	0.65	7.49e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs1434579	0.526	rs204547	chr19:44947184	T/C	cg15540054	chr19:45004280	ZNF180	-0.4	-4.96	-0.3	1.29e-6	Tuberculosis;
KIRP	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.55	0.43	8.37e-13	Gout;Renal underexcretion gout;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01510332	chr19:59087201	MGC2752	0.56	6.71	0.39	1.3e-10	Smoking initiation;
KIRP	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.77	-10.79	-0.57	1.84e-22	Height;
KIRP	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.64	-8.75	-0.49	3.49e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05347473	chr6:146136440	FBXO30	-0.57	-8.15	-0.46	1.81e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00763768	chr14:99947408	SETD3;CCNK	0.51	6.21	0.37	2.2e-9	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10737307	chr4:57387053	ARL9	-0.44	-6.06	-0.36	4.97e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7737355	1.000	rs27663	chr5:130741438	T/G	cg06307176	chr5:131281290	NA	-0.54	-5.85	-0.35	1.59e-8	Life satisfaction;
KIRP	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg16989719	chr2:238392110	NA	-0.56	-5.99	-0.36	7.27e-9	Prostate cancer;
KIRP	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg14673194	chr17:80132900	CCDC57	0.77	8.69	0.48	5.23e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2273669	0.510	rs78596296	chr6:109374465	T/C	cg05315195	chr6:109294784	ARMC2	-0.61	-6.14	-0.36	3.21e-9	Prostate cancer;
KIRP	cis	rs4658101	0.700	rs6604045	chr1:92051755	C/T	cg09075522	chr1:92031145	NA	0.42	5.17	0.31	4.92e-7	Optic disc area;Vertical cup-disc ratio;
KIRP	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg24304309	chr1:154577895	ADAR	0.38	6.13	0.36	3.4e-9	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.25	0.37	1.84e-9	Bipolar disorder;
KIRP	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.28	-0.32	2.87e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.49	6.1	0.36	4.01e-9	Height;
KIRP	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1978968	0.957	rs34486385	chr22:18444290	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.78	-10.56	-0.56	9.4e-22	Aortic root size;
KIRP	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.3	-0.47	6.76e-15	Mood instability;
KIRP	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.07	-13.13	-0.64	3.39e-30	Exhaled nitric oxide output;
KIRP	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg27490568	chr2:178487706	NA	0.53	7.41	0.43	2.03e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg04025307	chr7:1156635	C7orf50	0.71	5.35	0.32	1.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.21	-0.46	1.27e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg26827852	chr1:89887630	LOC400759	0.35	4.88	0.3	1.87e-6	Carotid intima media thickness;
KIRP	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	6.46	0.38	5.47e-10	Systemic lupus erythematosus;
KIRP	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg27506609	chr1:36549197	TEKT2	-0.41	-5.16	-0.31	4.98e-7	Corneal structure;
KIRP	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.57	-0.56	9.31e-22	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10875746	0.903	rs12306451	chr12:48483241	T/C	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs2862064	1.000	rs1910052	chr5:156429154	T/C	cg12943317	chr5:156479607	HAVCR1	-0.9	-7.81	-0.45	1.64e-13	Platelet count;
KIRP	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	9.54	0.52	1.45e-18	Parkinson's disease;
KIRP	cis	rs2882667	0.754	rs11746434	chr5:138435303	A/G	cg04439458	chr5:138467593	SIL1	-0.53	-7.72	-0.44	2.94e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2074977	0.550	rs11085020	chr19:3446107	C/T	cg08380311	chr19:3435252	NFIC	-0.56	-6.64	-0.39	1.97e-10	Height;
KIRP	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.07	0.36	4.7e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg25486957	chr4:152246857	NA	-0.5	-5.29	-0.32	2.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17095355	1.000	rs11194941	chr10:111744810	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.37	-5.2	-0.31	4.15e-7	Biliary atresia;
KIRP	cis	rs6690583	0.623	rs1371140	chr1:85455362	A/C	cg22153463	chr1:85462885	MCOLN2	0.6	5.53	0.33	8.27e-8	Serum sulfate level;
KIRP	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg09184832	chr6:79620586	NA	-0.42	-5.87	-0.35	1.38e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7246760	1.000	rs1592997	chr19:9900983	G/A	cg02900749	chr2:68251473	NA	-1.05	-8.84	-0.49	1.93e-16	Pursuit maintenance gain;
KIRP	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	5.37	0.32	1.81e-7	Homoarginine levels;
KIRP	cis	rs13034020	0.522	rs13005116	chr2:61241567	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.66	6.29	0.37	1.44e-9	Hodgkin's lymphoma;
KIRP	cis	rs754423	0.515	rs35800326	chr14:52549984	T/C	cg05884192	chr14:52515736	NID2	0.47	5.2	0.31	4.29e-7	Craniofacial microsomia;
KIRP	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	14.11	0.67	1.63e-33	Alzheimer's disease;
KIRP	cis	rs6430538	0.550	rs11902999	chr2:135567151	T/C	cg12500956	chr2:135428796	TMEM163	0.41	5.29	0.32	2.77e-7	Parkinson's disease;
KIRP	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-6.91	-0.4	4.24e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18498877	chr3:52931657	TMEM110	0.5	6.13	0.36	3.48e-9	Parkinson's disease;
KIRP	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.09	-0.31	7.14e-7	Educational attainment;
KIRP	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg05785598	chr3:49045655	WDR6	0.29	5.26	0.32	3.21e-7	Parkinson's disease;
KIRP	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.69	-7.69	-0.44	3.55e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs4523957	0.820	rs9908972	chr17:2103810	A/C	cg16513277	chr17:2031491	SMG6	-0.68	-9.59	-0.52	1.02e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs4363385	0.747	rs9659623	chr1:152965158	C/T	cg01054282	chr9:2842164	KIAA0020	0.47	6.07	0.36	4.8e-9	Inflammatory skin disease;
KIRP	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	1.43	8.4	0.47	3.6e-15	Economic and political preferences (immigration/crime);
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg01765077	chr12:122356316	WDR66	0.63	8.76	0.49	3.22e-16	Mean corpuscular volume;
KIRP	cis	rs9394841	0.620	rs9462746	chr6:41816279	T/A	cg08135965	chr6:41755394	TOMM6	0.52	5.62	0.34	5.25e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg07395648	chr5:131743802	NA	-0.51	-7.4	-0.43	2.09e-12	Breast cancer;
KIRP	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.74	-8.09	-0.46	2.82e-14	Pediatric areal bone mineral density (radius);
KIRP	cis	rs9611198	0.846	rs5757733	chr22:39968173	T/G	cg03390717	chr22:39966585	CACNA1I	0.38	6.83	0.4	6.57e-11	Schizophrenia;
KIRP	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg20169779	chr10:135381914	SYCE1	-0.42	-4.98	-0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg27490568	chr2:178487706	NA	0.49	6.38	0.38	8.64e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2290419	0.730	rs79092605	chr11:68943613	A/G	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg24565620	chr2:194026	NA	0.73	8.48	0.48	2.09e-15	Blood protein levels;
KIRP	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.64	-0.39	1.98e-10	Aortic root size;
KIRP	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08109568	chr15:31115862	NA	-0.78	-9.56	-0.52	1.27e-18	Huntington's disease progression;
KIRP	cis	rs4561483	0.556	rs11570136	chr16:12058832	T/A	cg08843971	chr16:11963173	GSPT1	-0.49	-6.03	-0.36	5.85e-9	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg04369109	chr6:150039330	LATS1	-0.61	-7.28	-0.42	4.6e-12	Lung cancer;
KIRP	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg10207240	chr12:122356781	WDR66	0.6	8.16	0.46	1.78e-14	Mean corpuscular volume;
KIRP	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.68	9.74	0.53	3.63e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.66	-7.57	-0.43	7.28e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg12131826	chr15:77904385	NA	0.51	6.09	0.36	4.35e-9	Type 2 diabetes;
KIRP	cis	rs526231	0.512	rs34797	chr5:102425727	T/C	cg23492399	chr5:102201601	PAM	-0.49	-5.38	-0.32	1.72e-7	Primary biliary cholangitis;
KIRP	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.94	-0.35	9.68e-9	Obesity-related traits;
KIRP	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg05973401	chr12:123451056	ABCB9	0.54	6.12	0.36	3.66e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9790314	0.638	rs6764019	chr3:160638851	A/C	cg03342759	chr3:160939853	NMD3	0.43	4.98	0.3	1.21e-6	Morning vs. evening chronotype;
KIRP	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg01631408	chr1:248437212	OR2T33	-0.36	-4.9	-0.3	1.78e-6	Common traits (Other);
KIRP	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.34	-5.37	-0.32	1.81e-7	Type 2 diabetes;
KIRP	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg23803603	chr1:2058230	PRKCZ	-0.41	-5.92	-0.35	1.07e-8	Height;
KIRP	cis	rs2273669	0.915	rs4992384	chr6:109292806	A/G	cg05315195	chr6:109294784	ARMC2	-0.5	-5.69	-0.34	3.66e-8	Prostate cancer;
KIRP	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg18154014	chr19:37997991	ZNF793	0.71	7.99	0.45	5.15e-14	Coronary artery calcification;
KIRP	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.8	-0.4	7.76e-11	Systemic lupus erythematosus;
KIRP	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-1.0	-15.03	-0.69	1.2e-36	Coronary artery disease;
KIRP	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26314531	chr2:26401878	FAM59B	-0.48	-5.01	-0.3	1.05e-6	Gut microbiome composition (summer);
KIRP	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19700328	chr14:106028568	NA	-0.61	-6.73	-0.39	1.2e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg15663823	chr5:64103336	SDCCAG10	0.45	6.61	0.39	2.41e-10	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17493098	chr2:216946552	PECR;TMEM169	0.5	6.1	0.36	4e-9	Parkinson's disease;
KIRP	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg04935436	chr20:30431758	NA	0.53	6.46	0.38	5.63e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.96	16.05	0.72	3.8e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4073416	0.542	rs7144345	chr14:66111841	G/C	cg03016385	chr14:66212404	NA	-0.54	-6.58	-0.39	2.73e-10	N-glycan levels;
KIRP	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-7.89	-0.45	1.02e-13	Chronic sinus infection;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16395911	chr14:57700568	EXOC5	-0.48	-7.42	-0.43	1.89e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.45	-0.47	2.57e-15	Morning vs. evening chronotype;
KIRP	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg00405596	chr8:11794950	NA	0.52	7.07	0.41	1.62e-11	Mood instability;
KIRP	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.96	13.7	0.66	3.91e-32	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.05	0.41	1.78e-11	Height;
KIRP	cis	rs57590327	0.679	rs35259664	chr3:81586742	C/G	cg07356753	chr3:81810745	GBE1	-0.59	-6.27	-0.37	1.62e-9	Extraversion;
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg11641102	chr8:27183873	PTK2B	0.42	5.5	0.33	9.36e-8	Neuroticism;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg18209359	chr17:80159595	CCDC57	-0.42	-5.54	-0.33	7.96e-8	Life satisfaction;
KIRP	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg03468072	chr12:39539422	NA	0.44	5.98	0.36	7.98e-9	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-19.27	-0.78	4.52e-51	Height;
KIRP	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg25019033	chr10:957182	NA	-0.61	-7.2	-0.42	7.49e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs4666360	1.000	rs10196396	chr2:20337035	C/T	cg07142377	chr2:20335552	NA	0.28	4.84	0.3	2.25e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
KIRP	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.46	-5.76	-0.34	2.53e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.66	-11.52	-0.59	7.9e-25	White blood cell count (basophil);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03922262	chr10:77868130	C10orf11	0.48	6.12	0.36	3.58e-9	Interleukin-4 levels;
KIRP	cis	rs9308731	0.966	rs6753785	chr2:111923630	T/G	cg23466623	chr2:111982296	NA	-0.45	-5.74	-0.34	2.75e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.54	-6.98	-0.41	2.74e-11	Neutrophil percentage of white cells;
KIRP	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg18357526	chr6:26021779	HIST1H4A	0.48	5.61	0.34	5.41e-8	Blood metabolite levels;
KIRP	cis	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg00478599	chr13:78272443	SLAIN1	0.52	6.18	0.37	2.69e-9	Plasma plasminogen activator levels;
KIRP	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.86	9.01	0.5	5.77e-17	Plateletcrit;Mean corpuscular hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24312661	chr15:90728157	SEMA4B	0.58	7.53	0.43	9.6e-13	Parkinson's disease;
KIRP	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.8	-0.35	2.06e-8	Multiple sclerosis;
KIRP	cis	rs8018808	0.905	rs11622359	chr14:77939449	C/T	cg18872420	chr14:78023429	SPTLC2	-0.36	-5.25	-0.32	3.36e-7	Myeloid white cell count;
KIRP	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.63	8.1	0.46	2.52e-14	QT interval;
KIRP	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.09	-15.64	-0.71	9.59e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	8.4	0.47	3.5e-15	Lymphocyte counts;
KIRP	cis	rs1440410	0.798	rs10002867	chr4:144169650	G/T	cg01719995	chr4:144104893	USP38	0.41	5.54	0.33	7.88e-8	Ischemic stroke;
KIRP	cis	rs9475752	0.793	rs28360535	chr6:56869429	G/A	cg22880620	chr6:56820808	BEND6;DST	0.51	5.21	0.32	4.01e-7	Menarche (age at onset);
KIRP	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg07148914	chr20:33460835	GGT7	-0.43	-5.33	-0.32	2.24e-7	Height;
KIRP	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.83	11.24	0.58	6.42e-24	Menarche (age at onset);
KIRP	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg06740227	chr12:86229804	RASSF9	0.45	5.47	0.33	1.12e-7	Major depressive disorder;
KIRP	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.16	-0.69	4.22e-37	Headache;
KIRP	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.87	9.04	0.5	4.85e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.68	-8.51	-0.48	1.71e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9810890	1.000	rs73210607	chr3:128618771	A/G	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg01023714	chr4:10084725	WDR1	0.46	6.04	0.36	5.71e-9	Survival in pancreatic cancer;
KIRP	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg25811766	chr13:21894605	NA	-0.58	-5.66	-0.34	4.12e-8	White matter hyperintensity burden;
KIRP	cis	rs3755132	0.929	rs4668945	chr2:15764078	G/C	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg04087571	chr11:116723030	SIK3	-0.23	-4.99	-0.3	1.16e-6	Subjective well-being;
KIRP	cis	rs7213347	0.707	rs2038677	chr17:2178092	C/G	cg15816464	chr17:2026533	SMG6	0.35	5.3	0.32	2.55e-7	Total body bone mineral density;
KIRP	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.87	0.35	1.41e-8	Diabetic retinopathy;
KIRP	cis	rs7870753	0.838	rs7861282	chr9:99204468	T/C	cg25260653	chr9:99212216	HABP4	0.57	6.04	0.36	5.51e-9	Height;
KIRP	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.42	-0.51	3.52e-18	Response to antipsychotic treatment;
KIRP	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.76	-9.48	-0.52	2.3e-18	Coronary artery disease;
KIRP	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.54	8.02	0.46	4.19e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12580194	0.593	rs7960760	chr12:55722311	A/G	cg11794356	chr12:55725991	OR6C3	-0.59	-8.57	-0.48	1.13e-15	Cancer;
KIRP	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg17365369	chr19:52773256	ZNF766	-0.54	-6.02	-0.36	6.35e-9	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-1.02	-11.87	-0.6	5.52e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7945718	0.810	rs10831910	chr11:12830974	A/G	cg25843174	chr11:12811716	TEAD1	-0.29	-5.17	-0.31	4.75e-7	Educational attainment (years of education);
KIRP	cis	rs2013231	0.560	rs12640722	chr4:48112291	A/T	cg13469425	chr4:48175353	TEC	0.37	5.2	0.31	4.25e-7	Platelet distribution width;
KIRP	cis	rs35740288	0.731	rs2344440	chr15:86161565	T/C	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg07309820	chr7:148901717	ZNF282	-0.38	-4.94	-0.3	1.44e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs7538876	0.903	rs7528427	chr1:17746273	C/T	cg07965774	chr1:17746286	RCC2	0.28	4.97	0.3	1.28e-6	Basal cell carcinoma;
KIRP	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg01879757	chr17:41196368	BRCA1	-0.77	-10.59	-0.56	7.83e-22	Menopause (age at onset);
KIRP	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.72	-0.44	2.93e-13	Body mass index;
KIRP	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.66	-0.34	4.21e-8	Height;
KIRP	cis	rs6977660	0.714	rs12334267	chr7:19810265	A/G	cg05791153	chr7:19748676	TWISTNB	0.67	6.01	0.36	6.76e-9	Thyroid stimulating hormone;
KIRP	cis	rs2658782	0.654	rs2605620	chr11:93247646	C/T	cg15737290	chr11:93063684	CCDC67	0.61	7.18	0.42	8.04e-12	Pulmonary function decline;
KIRP	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-6.66	-0.39	1.78e-10	Personality dimensions;
KIRP	cis	rs1829883	0.667	rs6863168	chr5:98978997	T/A	cg08333243	chr5:99726346	NA	0.44	5.69	0.34	3.57e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg13206674	chr6:150067644	NUP43	0.56	7.98	0.45	5.44e-14	Lung cancer;
KIRP	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.89	-10.48	-0.56	1.68e-21	White matter hyperintensity burden;
KIRP	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17344932	chr17:38183730	MED24;SNORD124	0.44	6.92	0.4	3.94e-11	Myeloid white cell count;
KIRP	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg18709589	chr6:96969512	KIAA0776	0.34	5.18	0.31	4.59e-7	Headache;
KIRP	cis	rs4638749	0.501	rs2378095	chr2:108764899	G/A	cg06795125	chr2:108905320	SULT1C2	-0.29	-5.06	-0.31	8.35e-7	Blood pressure;
KIRP	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg07092213	chr7:1199455	ZFAND2A	-0.48	-5.25	-0.32	3.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.77	9.78	0.53	2.66e-19	Corneal astigmatism;
KIRP	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.95	12.59	0.63	2.25e-28	Homoarginine levels;
KIRP	cis	rs2151522	0.762	rs11757289	chr6:127166406	G/A	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs503734	0.502	rs348879	chr3:100979826	A/T	cg27318481	chr3:100970896	IMPG2	-0.58	-7.94	-0.45	7.01e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg23594656	chr7:65796392	TPST1	-0.44	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs116095464	1.000	rs10054850	chr5:335827	C/G	cg22857025	chr5:266934	NA	-1.11	-7.21	-0.42	6.72e-12	Breast cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15697935	chr1:210500388	HHAT	-0.46	-6.11	-0.36	3.95e-9	Inflammatory biomarkers;
KIRP	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg15556689	chr8:8085844	FLJ10661	-0.69	-8.65	-0.48	6.92e-16	Retinal vascular caliber;
KIRP	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.56	6.69	0.39	1.45e-10	Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg11693508	chr17:37793320	STARD3	0.82	9.89	0.53	1.25e-19	Neuroticism;
KIRP	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.63	9.45	0.52	2.8e-18	Vitiligo;
KIRP	cis	rs62413470	1.000	rs12190671	chr6:55959857	A/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg10755058	chr3:40428713	ENTPD3	-0.41	-5.87	-0.35	1.4e-8	Renal cell carcinoma;
KIRP	cis	rs6593803	0.846	rs1891504	chr1:147209539	T/C	cg27546670	chr1:147246839	GJA5	0.62	7.07	0.41	1.64e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	cis	rs2721195	0.810	rs2721142	chr8:145752467	A/T	cg26752003	chr8:145688521	CYHR1	-0.5	-5.98	-0.36	7.65e-9	Age at first birth;
KIRP	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg03465714	chr1:152285911	FLG	0.49	5.44	0.33	1.25e-7	Atopic dermatitis;
KIRP	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07570687	chr10:102243282	WNT8B	0.5	6.48	0.38	5.07e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg04672837	chr16:48644449	N4BP1	0.51	7.08	0.41	1.53e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg01616529	chr11:638424	DRD4	-0.37	-5.02	-0.3	9.97e-7	Systemic lupus erythematosus;
KIRP	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.96	-0.36	8.59e-9	Height;
KIRP	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg13206674	chr6:150067644	NUP43	0.52	7.41	0.43	1.96e-12	Testicular germ cell tumor;
KIRP	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.34e-15	Bone mineral density;
KIRP	cis	rs28595532	0.640	rs28649792	chr4:119366463	A/C	cg21605333	chr4:119757512	SEC24D	0.94	7.36	0.42	2.77e-12	Cannabis dependence symptom count;
KIRP	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg18850929	chr19:1828978	REXO1	0.42	4.97	0.3	1.23e-6	Bipolar disorder;
KIRP	trans	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg06521331	chr12:34319734	NA	-0.5	-6.22	-0.37	2.17e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg24699146	chr1:24152579	HMGCL	0.47	6.3	0.37	1.36e-9	Immature fraction of reticulocytes;
KIRP	cis	rs687432	0.586	rs895660	chr11:57878487	A/G	cg19752551	chr11:57585705	CTNND1	0.38	5.39	0.33	1.63e-7	Parkinson's disease;
KIRP	cis	rs7578199	0.850	rs11679356	chr2:242356894	C/T	cg01632474	chr2:242799312	PDCD1	0.43	4.99	0.3	1.15e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs12762955	0.519	rs10795306	chr10:1019138	A/T	cg18964960	chr10:1102726	WDR37	-0.57	-6.23	-0.37	2.01e-9	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs1106684	0.929	rs888538	chr7:131454143	G/A	cg13607082	chr12:122652224	LRRC43	-0.6	-6.3	-0.37	1.39e-9	Body mass index;
KIRP	cis	rs909341	0.763	rs1291209	chr20:62330439	T/C	cg11503966	chr20:62272292	STMN3	-0.41	-5.9	-0.35	1.22e-8	Atopic dermatitis;
KIRP	cis	rs9828933	0.938	rs3816157	chr3:63999322	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.82	-8.37	-0.47	4.44e-15	Type 2 diabetes;
KIRP	cis	rs644148	0.836	rs2686777	chr19:45000386	T/C	cg15540054	chr19:45004280	ZNF180	-0.75	-9.26	-0.51	1.07e-17	Personality dimensions;
KIRP	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg22325292	chr17:80708367	FN3K	0.36	4.86	0.3	2.12e-6	Glycated hemoglobin levels;
KIRP	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs4319547	0.637	rs61244464	chr12:123090565	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.5	-6.3	-0.37	1.36e-9	Body mass index;
KIRP	cis	rs2425143	0.730	rs2095819	chr20:34353278	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-6.0	-0.36	7.1e-9	Blood protein levels;
KIRP	cis	rs2997447	0.669	rs61776584	chr1:26438455	T/C	cg19633962	chr1:26362018	EXTL1	-0.49	-4.87	-0.3	2.02e-6	QRS complex (12-leadsum);
KIRP	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.69	8.53	0.48	1.56e-15	Prudent dietary pattern;
KIRP	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg01631408	chr1:248437212	OR2T33	-0.65	-8.45	-0.47	2.6e-15	Common traits (Other);
KIRP	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg10434728	chr15:90938212	IQGAP1	-0.38	-6.97	-0.41	2.98e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.64	8.27	0.47	8.62e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4919044	0.733	rs12413378	chr10:94759305	A/G	cg05127821	chr10:94822908	CYP26C1	-1.2	-8.55	-0.48	1.37e-15	Coronary artery disease;
KIRP	cis	rs4750440	0.585	rs7072791	chr10:14028195	A/C	cg27542038	chr10:14027202	FRMD4A	-0.59	-7.45	-0.43	1.58e-12	Adiponectin levels;
KIRP	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg07856975	chr6:36356162	ETV7	0.42	5.38	0.32	1.69e-7	Platelet distribution width;
KIRP	cis	rs1023500	1.000	rs1023499	chr22:42340582	T/C	cg04733989	chr22:42467013	NAGA	-0.52	-5.7	-0.34	3.34e-8	Schizophrenia;
KIRP	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg04865290	chr3:52927548	TMEM110	-0.62	-6.81	-0.4	7.65e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.34	-0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7582720	0.945	rs72932716	chr2:203642244	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	9.63	0.52	8.09e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg05315796	chr3:52349193	DNAH1	0.4	5.19	0.31	4.35e-7	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.71	-6.11	-0.36	3.95e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1978968	0.956	rs2017932	chr22:18439190	C/A	cg03078520	chr22:18463400	MICAL3	-0.65	-7.78	-0.44	2e-13	Presence of antiphospholipid antibodies;
KIRP	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.32	-0.42	3.41e-12	Mood instability;
KIRP	cis	rs259842	0.669	rs56388438	chr2:180682553	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.39	-5.32	-0.32	2.37e-7	Blood protein levels;
KIRP	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.37	-0.32	1.82e-7	Breast cancer;
KIRP	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg23034840	chr1:205782522	SLC41A1	-0.55	-6.54	-0.38	3.59e-10	Menarche (age at onset);
KIRP	cis	rs1971256	0.500	rs80285688	chr6:151818830	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-6.15	-0.37	3.08e-9	Endometriosis;
KIRP	cis	rs4631830	0.832	rs67289834	chr10:51501304	C/T	cg10326726	chr10:51549505	MSMB	0.65	9.3	0.51	8.07e-18	Prostate-specific antigen levels;
KIRP	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.5	-7.15	-0.41	1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13161895	1.000	rs3719	chr5:179435118	T/C	cg02702477	chr5:179499311	RNF130	-0.69	-5.36	-0.32	1.95e-7	LDL cholesterol;
KIRP	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.81	11.0	0.57	3.87e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg02751453	chr18:77725136	HSBP1L1	0.39	5.08	0.31	7.46e-7	Opioid sensitivity;
KIRP	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.44	5.13	0.31	5.91e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	13.45	0.65	2.72e-31	Platelet count;
KIRP	cis	rs375066	0.592	rs349046	chr19:44300626	C/T	cg11993925	chr19:44307056	LYPD5	-0.36	-5.03	-0.31	9.41e-7	Breast cancer;
KIRP	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.74	-11.05	-0.58	2.59e-23	Neuroticism;
KIRP	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.17	-0.37	2.73e-9	Morning vs. evening chronotype;
KIRP	cis	rs4356932	0.935	rs10031452	chr4:76924933	T/C	cg00809888	chr4:76862425	NAAA	0.45	6.47	0.38	5.26e-10	Blood protein levels;
KIRP	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.35	-0.38	1.01e-9	Coronary artery disease;
KIRP	cis	rs6952809	1.000	rs7350030	chr7:2449157	G/A	cg06995285	chr7:2418615	EIF3B	0.38	5.1	0.31	6.93e-7	Multiple sclerosis;
KIRP	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg10818794	chr15:86012489	AKAP13	-0.49	-6.45	-0.38	5.98e-10	Central corneal thickness;Corneal structure;
KIRP	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg02487422	chr3:49467188	NICN1	0.43	5.65	0.34	4.4e-8	Resting heart rate;
KIRP	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.45	-0.33	1.22e-7	Bipolar disorder;
KIRP	cis	rs1514687	0.534	rs73911839	chr2:1475088	C/T	cg03133821	chr2:1513998	TPO	-0.66	-5.25	-0.32	3.31e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg06740227	chr12:86229804	RASSF9	-0.46	-5.51	-0.33	8.85e-8	Major depressive disorder;
KIRP	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-1.21	-13.96	-0.66	5.37e-33	Breast cancer;
KIRP	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21545522	chr1:205238299	TMCC2	0.42	5.64	0.34	4.76e-8	Red blood cell count;
KIRP	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg07636037	chr3:49044803	WDR6	-0.74	-5.65	-0.34	4.39e-8	Cognitive function;
KIRP	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18252515	chr7:66147081	NA	-0.46	-5.63	-0.34	4.87e-8	Aortic root size;
KIRP	cis	rs7224685	0.501	rs781842	chr17:3958955	C/T	cg05562828	chr17:3906858	NA	0.72	14.38	0.68	1.9e-34	Type 2 diabetes;
KIRP	cis	rs654950	0.875	rs689076	chr1:41999127	C/T	cg06885757	chr1:42089581	HIVEP3	0.45	6.38	0.38	8.96e-10	Airway imaging phenotypes;
KIRP	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.19	-0.31	4.42e-7	Metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01145398	chr10:135075451	NA	0.56	7.17	0.42	9.01e-12	Parkinson's disease;
KIRP	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg07621104	chr11:117668040	DSCAML1	0.49	6.15	0.37	3.09e-9	Myopia;
KIRP	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.44	6.18	0.37	2.67e-9	Testicular germ cell tumor;
KIRP	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg00405596	chr8:11794950	NA	-0.49	-6.43	-0.38	6.54e-10	Retinal vascular caliber;
KIRP	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	1.06	14.4	0.68	1.67e-34	Menopause (age at onset);
KIRP	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg26531700	chr6:26746687	NA	0.41	5.63	0.34	4.97e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7178909	0.866	rs3784388	chr15:90437301	C/T	cg19708238	chr15:90437601	AP3S2	0.59	8.27	0.47	8.25e-15	Common traits (Other);
KIRP	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.5	-4.91	-0.3	1.64e-6	Recombination rate (females);
KIRP	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg07395648	chr5:131743802	NA	-0.39	-5.65	-0.34	4.4e-8	Acylcarnitine levels;
KIRP	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs10181042	0.514	rs1177288	chr2:61352985	A/G	cg15711740	chr2:61764176	XPO1	-0.46	-5.63	-0.34	4.88e-8	Crohn's disease;
KIRP	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg26513180	chr16:89883248	FANCA	0.62	8.75	0.49	3.43e-16	Vitiligo;
KIRP	cis	rs9304742	0.962	rs1808106	chr19:53452944	T/G	cg24044776	chr19:53454761	ZNF816A	-0.41	-6.2	-0.37	2.32e-9	Psoriasis;
KIRP	cis	rs7394190	0.935	rs12570126	chr10:75416789	C/T	cg04833713	chr10:74871078	NUDT13	-0.37	-5.12	-0.31	6.29e-7	Incident atrial fibrillation;
KIRP	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-0.8	-10.58	-0.56	8.28e-22	Urate levels;
KIRP	trans	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg02030672	chr11:45687055	CHST1	0.57	7.07	0.41	1.6e-11	Obesity-related traits;
KIRP	cis	rs6973256	0.605	rs10227672	chr7:133326196	G/C	cg10665199	chr7:133106180	EXOC4	-0.51	-6.55	-0.39	3.4e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg26039829	chr8:22132926	PIWIL2	0.45	5.79	0.35	2.18e-8	Hypertriglyceridemia;
KIRP	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg24253500	chr15:84953950	NA	0.62	6.99	0.41	2.55e-11	Schizophrenia;
KIRP	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.68	8.5	0.48	1.83e-15	Recalcitrant atopic dermatitis;
KIRP	cis	rs7688540	0.771	rs11248013	chr4:311425	T/C	cg17891759	chr4:299121	NA	-0.49	-4.87	-0.3	2.01e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.35	-7.04	-0.41	1.96e-11	Urinary metabolites;
KIRP	cis	rs1861628	0.512	rs10932677	chr2:217627150	A/G	cg06569117	chr2:217657537	NA	0.41	5.62	0.34	5.09e-8	Serum thyroid-stimulating hormone levels;Hypothyroidism;
KIRP	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.11	-0.36	3.95e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs877282	0.898	rs11253338	chr10:759559	C/T	cg17470449	chr10:769945	NA	0.71	7.12	0.41	1.21e-11	Uric acid levels;
KIRP	cis	rs236907	0.859	rs10489252	chr1:171748145	A/T	cg01410279	chr1:171621941	MYOC	-0.49	-5.44	-0.33	1.31e-7	Mean platelet volume;
KIRP	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg13679303	chr9:96623674	NA	-0.51	-7.3	-0.42	3.98e-12	DNA methylation (variation);
KIRP	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.5	6.29	0.37	1.48e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6690583	0.623	rs6672362	chr1:85454881	C/G	cg22153463	chr1:85462885	MCOLN2	0.59	5.33	0.32	2.19e-7	Serum sulfate level;
KIRP	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.35	5.23	0.32	3.54e-7	Educational attainment;
KIRP	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.69	8.34	0.47	5.19e-15	Aortic root size;
KIRP	cis	rs9603616	0.719	rs4275735	chr13:40238841	A/G	cg26701198	chr13:40229707	COG6	0.44	5.23	0.32	3.65e-7	Rheumatoid arthritis;
KIRP	cis	rs11214589	0.747	rs2155462	chr11:113206799	A/C	cg14159747	chr11:113255604	NA	0.4	6.02	0.36	6.18e-9	Neuroticism;
KIRP	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg18190219	chr22:46762943	CELSR1	-0.88	-7.29	-0.42	4.27e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.42	-5.22	-0.32	3.78e-7	Aortic root size;
KIRP	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.82	10.14	0.54	2.07e-20	Platelet distribution width;
KIRP	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.1	-0.36	4.05e-9	Bladder cancer;
KIRP	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.45	-5.3	-0.32	2.61e-7	Body mass index;
KIRP	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.5	6.57	0.39	2.93e-10	Response to temozolomide;
KIRP	cis	rs2734839	0.964	rs2734831	chr11:113293596	G/T	cg14159747	chr11:113255604	NA	-0.34	-4.85	-0.3	2.24e-6	Information processing speed;
KIRP	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.78	-7.23	-0.42	6.03e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg07862535	chr7:139043722	LUC7L2	0.55	6.12	0.36	3.67e-9	Diisocyanate-induced asthma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03651769	chr1:215219381	KCNK2	-0.42	-6.28	-0.37	1.52e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.67	6.3	0.37	1.38e-9	Eotaxin levels;
KIRP	cis	rs804280	0.525	rs17153755	chr8:11611500	C/G	cg26752888	chr8:11627280	NEIL2	-0.43	-4.96	-0.3	1.3e-6	Myopia (pathological);
KIRP	cis	rs4148660	1.000	rs34243384	chr12:22052147	G/A	cg14669847	chr12:22099120	NA	-0.34	-5.85	-0.35	1.54e-8	Gout;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13532854	chr7:155898355	NA	-0.41	-6.11	-0.36	3.94e-9	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24742512	chr11:12131878	MICAL2	0.47	6.34	0.37	1.07e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs3736485	0.934	rs2899476	chr15:51903874	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.22	-0.32	3.83e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7721647	0.777	rs1583907	chr5:90844272	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.4	4.89	0.3	1.78e-6	Breast cancer;
KIRP	cis	rs787274	1.000	rs787271	chr9:115549463	C/T	cg13803584	chr9:115635662	SNX30	-0.7	-8.62	-0.48	8.13e-16	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.41	-5.48	-0.33	1.03e-7	Bipolar disorder;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg06659904	chr16:2812915	SRRM2	-0.45	-6.08	-0.36	4.49e-9	Bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg24480577	chr20:62169334	PTK6	0.44	6.12	0.36	3.71e-9	Survival in pancreatic cancer;
KIRP	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg23625390	chr15:77176239	SCAPER	0.52	6.85	0.4	6.04e-11	Blood metabolite levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12276298	chr10:74927863	ECD;FAM149B1	-0.52	-6.39	-0.38	8.33e-10	Interleukin-4 levels;
KIRP	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg04013166	chr16:89971882	TCF25	0.7	7.33	0.42	3.35e-12	Skin colour saturation;
KIRP	cis	rs12532214	0.690	rs74446924	chr7:3127245	C/T	cg19214707	chr7:3157722	NA	-0.74	-6.14	-0.36	3.26e-9	Itch intensity from mosquito bite;
KIRP	cis	rs12519773	0.534	rs2453763	chr5:92376460	T/A	cg18783429	chr5:92414398	NA	-0.35	-5.84	-0.35	1.67e-8	Migraine;
KIRP	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.68	-9.75	-0.53	3.4e-19	Autism;
KIRP	cis	rs7005380	0.538	rs2056305	chr8:120929105	C/T	cg21645572	chr8:120931649	DEPDC6	0.52	7.24	0.42	5.77e-12	Interstitial lung disease;
KIRP	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-7.76	-0.44	2.28e-13	Obesity-related traits;
KIRP	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-10.08	-0.54	3.1e-20	Coronary artery disease;
KIRP	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.26	-0.37	1.68e-9	Response to antipsychotic treatment;
KIRP	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg10761708	chr20:43804764	PI3	0.5	5.19	0.31	4.45e-7	Blood protein levels;
KIRP	cis	rs2281845	0.929	rs10920126	chr1:201101081	G/A	cg17810781	chr1:201082982	CACNA1S	0.41	6.3	0.37	1.38e-9	Permanent tooth development;
KIRP	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.54	-0.62	3.12e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	9.65	0.52	7.03e-19	Schizophrenia;
KIRP	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg02002194	chr4:3960332	NA	-0.46	-6.17	-0.37	2.74e-9	Systemic lupus erythematosus;
KIRP	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	1.13	8.75	0.49	3.56e-16	Plasma clusterin levels;
KIRP	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7809615	0.792	rs45618033	chr7:99046617	G/A	cg12290671	chr7:99195819	NA	-0.75	-6.99	-0.41	2.57e-11	Blood metabolite ratios;
KIRP	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg16141378	chr3:129829833	LOC729375	0.49	6.33	0.37	1.18e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11264213	0.901	rs649152	chr1:36438649	T/G	cg27506609	chr1:36549197	TEKT2	0.97	10.16	0.54	1.81e-20	Schizophrenia;
KIRP	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.43	5.92	0.35	1.07e-8	Coronary artery disease;
KIRP	cis	rs7584330	0.518	rs78358347	chr2:238413566	C/T	cg08992911	chr2:238395768	MLPH	0.68	5.4	0.33	1.61e-7	Prostate cancer;
KIRP	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.76	-9.78	-0.53	2.73e-19	Aortic root size;
KIRP	cis	rs12472274	0.536	rs12619455	chr2:239080149	A/C	cg17459225	chr2:239074497	NA	0.81	8.71	0.49	4.38e-16	Phospholipid levels (plasma);
KIRP	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg11845111	chr2:191398756	TMEM194B	-0.96	-10.83	-0.57	1.34e-22	Diastolic blood pressure;
KIRP	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg18350739	chr11:68623251	NA	0.33	4.97	0.3	1.27e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.78	-0.53	2.65e-19	Hemoglobin concentration;
KIRP	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg26174226	chr8:58114915	NA	-0.51	-5.06	-0.31	8.02e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06544989	chr22:39130855	UNC84B	-0.49	-8.01	-0.45	4.56e-14	Menopause (age at onset);
KIRP	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg00717180	chr2:96193071	NA	-0.5	-6.1	-0.36	4.05e-9	HDL cholesterol;
KIRP	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg13010199	chr12:38710504	ALG10B	-0.48	-5.71	-0.34	3.29e-8	Morning vs. evening chronotype;
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19077665	chr18:11981602	IMPA2	0.39	5.08	0.31	7.63e-7	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2594989	0.780	rs2454477	chr3:11555842	G/A	cg01796438	chr3:11312864	ATG7	-0.65	-7.51	-0.43	1.11e-12	Circulating chemerin levels;
KIRP	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg04398451	chr17:18023971	MYO15A	-0.66	-9.16	-0.5	2.14e-17	Total body bone mineral density;
KIRP	cis	rs798766	1.000	rs4865463	chr4:1742400	T/C	cg07775547	chr4:1625484	NA	-0.43	-5.13	-0.31	5.77e-7	Bladder cancer;Urinary bladder cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05596267	chr15:34331198	CHRM5;AVEN	0.44	6.44	0.38	6.3e-10	Survival in pancreatic cancer;
KIRP	cis	rs2296225	0.722	rs12403580	chr1:21049518	C/T	cg14666476	chr1:21112556	HP1BP3	0.72	6.92	0.4	3.88e-11	Eosinophilic esophagitis;
KIRP	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg15867164	chr4:3464754	DOK7	-0.34	-5.39	-0.32	1.67e-7	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
KIRP	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg03959625	chr15:84868606	LOC388152	0.47	5.59	0.34	6.05e-8	Schizophrenia;
KIRP	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg04731861	chr2:219085781	ARPC2	0.22	5.25	0.32	3.27e-7	Colorectal cancer;
KIRP	cis	rs2299587	0.573	rs6986123	chr8:17888073	G/A	cg01800426	chr8:17659068	MTUS1	-0.42	-5.12	-0.31	6.07e-7	Economic and political preferences;
KIRP	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.47	5.55	0.33	7.4e-8	Height;
KIRP	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg20573242	chr4:122745356	CCNA2	-0.4	-5.01	-0.3	1.06e-6	Type 2 diabetes;
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg06654118	chr4:1303317	MAEA	0.27	5.08	0.31	7.3e-7	Longevity;
KIRP	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.45	-8.35	-0.47	4.83e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7175404	0.583	rs12591541	chr15:94077313	A/G	cg23502883	chr15:93959149	NA	0.53	5.25	0.32	3.37e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.54e-9	Menopause (age at onset);
KIRP	cis	rs34779708	0.931	rs13376801	chr10:35370443	T/C	cg04310649	chr10:35416472	CREM	-0.59	-7.14	-0.41	1.06e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.06e-8	Motion sickness;
KIRP	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg11846333	chr4:119757529	SEC24D	1.09	6.26	0.37	1.7e-9	Cannabis dependence symptom count;
KIRP	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg03060546	chr3:49711283	APEH	0.59	6.64	0.39	1.98e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs13401104	0.716	rs28821203	chr2:237140475	T/C	cg19324714	chr2:237145437	ASB18	0.54	5.5	0.33	9.37e-8	Educational attainment;
KIRP	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.6	6.78	0.4	8.85e-11	Aortic root size;
KIRP	cis	rs9309473	0.950	rs6711001	chr2:73850820	C/G	cg20560298	chr2:73613845	ALMS1	-0.48	-5.43	-0.33	1.33e-7	Metabolite levels;
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.38	4.99	0.3	1.12e-6	Neuroticism;
KIRP	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.58	7.46	0.43	1.53e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.67	9.87	0.53	1.45e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg17376030	chr22:41985996	PMM1	0.53	6.03	0.36	6.04e-9	Vitiligo;
KIRP	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg01320579	chr17:75405842	SEPT9	0.47	7.63	0.44	5.29e-13	Airflow obstruction;
KIRP	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg19761014	chr17:28927070	LRRC37B2	0.68	5.04	0.31	9.13e-7	Body mass index;
KIRP	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.58	-7.75	-0.44	2.44e-13	Vitiligo;
KIRP	cis	rs911119	0.955	rs6036474	chr20:23604414	G/A	cg16589663	chr20:23618590	CST3	0.53	5.02	0.31	9.74e-7	Chronic kidney disease;
KIRP	cis	rs7751419	0.651	rs7758693	chr6:39104371	C/T	cg08089693	chr6:39098871	NA	-0.67	-9.58	-0.52	1.09e-18	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs17221829	0.668	rs12364732	chr11:89374054	T/G	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg18016565	chr1:150552671	MCL1	0.38	5.74	0.34	2.79e-8	Melanoma;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.4	4.98	0.3	1.18e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.9	-10.73	-0.56	2.67e-22	Response to antipsychotic treatment;
KIRP	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12667521	chr19:29218732	NA	0.61	5.39	0.32	1.66e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4936894	0.500	rs7107539	chr11:124180282	G/T	cg27160556	chr11:124181099	OR8D1	0.46	6.25	0.37	1.84e-9	Aging (time to death);
KIRP	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg07216194	chr8:27182965	PTK2B	0.45	5.53	0.33	8.27e-8	Neuroticism;
KIRP	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.7	8.92	0.49	1.13e-16	Coronary artery disease;
KIRP	cis	rs731174	0.802	rs502776	chr1:38182164	T/A	cg14170840	chr1:38155120	C1orf109	-0.39	-4.93	-0.3	1.49e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.32	-5.29	-0.32	2.72e-7	Height;
KIRP	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg23100626	chr2:96804247	ASTL	0.51	7.01	0.41	2.33e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg10360139	chr7:1886902	MAD1L1	-0.53	-5.91	-0.35	1.13e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.82	10.31	0.55	5.97e-21	Menarche (age at onset);
KIRP	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg00129232	chr17:37814104	STARD3	-0.73	-9.83	-0.53	1.86e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs2594989	0.733	rs6779007	chr3:11583254	C/T	cg01796438	chr3:11312864	ATG7	0.42	5.57	0.33	6.63e-8	Circulating chemerin levels;
KIRP	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.35	0.32	2.03e-7	Parkinson's disease;
KIRP	cis	rs1144	0.537	rs2470950	chr7:104592077	C/T	cg04380332	chr7:105027541	SRPK2	-0.54	-8.12	-0.46	2.3e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.88	-12.16	-0.61	6.02e-27	Obesity-related traits;
KIRP	cis	rs7737355	0.842	rs30733	chr5:130704956	T/A	cg06307176	chr5:131281290	NA	-0.44	-5.39	-0.32	1.69e-7	Life satisfaction;
KIRP	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.3	-5.89	-0.35	1.26e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.32	1.9e-7	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19745314	chr5:170814913	NPM1	0.47	6.03	0.36	6.08e-9	Parkinson's disease;
KIRP	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.46	10.08	0.54	3.24e-20	Height;
KIRP	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.79	10.05	0.54	3.92e-20	Ileal carcinoids;
KIRP	cis	rs876084	0.505	rs4431629	chr8:121108668	C/T	cg22335954	chr8:121166405	COL14A1	-0.37	-4.91	-0.3	1.67e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.39	5.02	0.3	9.95e-7	Blood protein levels;
KIRP	cis	rs6032067	0.777	rs116517830	chr20:43784872	G/A	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg05484376	chr2:27715224	FNDC4	0.38	6.27	0.37	1.6e-9	Total body bone mineral density;
KIRP	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.42	5.34	0.32	2.1e-7	Total body bone mineral density;
KIRP	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.66	8.83	0.49	1.94e-16	Breast cancer;
KIRP	cis	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg26378065	chr17:18585709	ZNF286B	-0.4	-5.02	-0.3	9.82e-7	Educational attainment (years of education);
KIRP	cis	rs6832769	1.000	rs6837710	chr4:56374455	C/T	cg09317128	chr4:56265301	TMEM165	0.53	6.59	0.39	2.64e-10	Personality dimensions;
KIRP	cis	rs1656402	0.906	rs883803	chr2:233458453	C/T	cg03852847	chr2:233439513	NA	0.65	9.74	0.53	3.57e-19	Non-small cell lung cancer (survival);
KIRP	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg07741184	chr6:167504864	NA	0.24	6.39	0.38	8.17e-10	Crohn's disease;
KIRP	cis	rs1147199	0.531	rs1001904	chr9:87271616	C/T	cg22402007	chr9:87282823	NTRK2	-0.4	-4.98	-0.3	1.22e-6	Body mass index;
KIRP	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg11416367	chr17:75137675	SEC14L1	0.55	4.87	0.3	2.04e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs8027181	0.797	rs8033580	chr15:72994968	C/A	cg25996835	chr15:72978165	BBS4;HIGD2B	0.52	7.59	0.44	6.52e-13	Triglyceride levels;
KIRP	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg18657303	chr4:1051139	NA	0.55	5.0	0.3	1.07e-6	Recombination rate (females);
KIRP	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.62	-8.01	-0.45	4.5e-14	Obesity-related traits;
KIRP	trans	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg10756647	chr7:56101905	PSPH	1.03	7.67	0.44	3.93e-13	Diabetic kidney disease;
KIRP	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg04691961	chr3:161091175	C3orf57	-0.54	-8.38	-0.47	4.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs7671266	0.668	rs10007416	chr4:10159457	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-4.91	-0.3	1.69e-6	Cardiovascular disease risk factors;
KIRP	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-1.2	-13.93	-0.66	6.54e-33	Breast cancer;
KIRP	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg17554472	chr22:41940697	POLR3H	0.58	6.71	0.39	1.3e-10	Vitiligo;
KIRP	cis	rs13343954	0.778	rs2016944	chr19:33550010	T/A	cg17764715	chr19:33622953	WDR88	0.68	6.91	0.4	4.17e-11	Colorectal cancer;
KIRP	cis	rs59868192	0.925	rs59114612	chr15:42250515	T/C	cg20935245	chr15:42234343	EHD4	-0.55	-5.4	-0.33	1.58e-7	White blood cell count;
KIRP	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03388025	chr16:89894329	SPIRE2	-0.28	-5.15	-0.31	5.22e-7	Vitiligo;
KIRP	cis	rs12022452	0.506	rs61779163	chr1:41015423	T/C	cg25568243	chr1:40974465	DEM1	0.57	6.16	0.37	3.02e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg09597638	chr17:3907349	NA	0.49	5.65	0.34	4.48e-8	Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	10.41	0.55	2.92e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6901250	0.655	rs1398403	chr6:117122646	T/C	cg05399210	chr6:117082661	FAM162B	-0.38	-5.14	-0.31	5.72e-7	C-reactive protein levels;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.51	-6.61	-0.39	2.38e-10	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.6	7.63	0.44	5.07e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2591576	0.593	rs17066124	chr5:165367231	A/T	cg13976338	chr5:165423657	NA	0.68	9.42	0.51	3.38e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.6	9.92	0.53	9.99e-20	Total body bone mineral density;
KIRP	trans	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.71	9.11	0.5	2.87e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14813579	chr19:2328694	SPPL2B;LSM7	0.52	6.66	0.39	1.76e-10	Parkinson's disease;
KIRP	cis	rs61867294	0.597	rs10884064	chr10:106673074	C/T	cg11455642	chr10:106494954	SORCS3	-0.35	-4.98	-0.3	1.18e-6	Schizophrenia;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg11158902	chr4:6536914	NA	0.45	6.37	0.38	9.11e-10	Morning vs. evening chronotype;
KIRP	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg16586182	chr3:47516702	SCAP	0.63	8.41	0.47	3.27e-15	Colorectal cancer;
KIRP	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.83	7.56	0.43	7.8e-13	Type 2 diabetes;
KIRP	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg19847130	chr8:10466454	RP1L1	0.4	5.64	0.34	4.64e-8	Retinal vascular caliber;
KIRP	cis	rs6001982	0.667	rs74486969	chr22:40870488	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs12210905	1.000	rs12196889	chr6:27156095	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.71	-6.11	-0.36	3.92e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg23000811	chr4:2464397	NA	0.51	6.73	0.39	1.19e-10	DNA methylation (variation);
KIRP	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.71	-8.84	-0.49	1.84e-16	Multiple sclerosis;
KIRP	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06360820	chr2:242988706	NA	-0.85	-8.57	-0.48	1.15e-15	Obesity-related traits;
KIRP	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.44	7.81	0.45	1.65e-13	Systemic lupus erythematosus;
KIRP	cis	rs5167	0.533	rs55778858	chr19:45485465	G/A	cg13119609	chr19:45449297	APOC2	0.39	4.86	0.3	2.14e-6	Blood protein levels;
KIRP	cis	rs72820985	1.000	rs11150315	chr16:80846330	C/G	cg04448709	chr16:81349954	GAN	-0.49	-5.09	-0.31	7.2e-7	Breast cancer;
KIRP	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.78	-11.59	-0.59	4.52e-25	Obesity-related traits;
KIRP	trans	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.11	-0.36	3.93e-9	Neuroticism;
KIRP	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.57	-0.39	2.95e-10	Monocyte percentage of white cells;
KIRP	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg08975724	chr8:8085496	FLJ10661	0.69	9.38	0.51	4.64e-18	Mood instability;
KIRP	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg10167378	chr1:228756711	NA	0.51	5.8	0.35	2.07e-8	Diastolic blood pressure;
KIRP	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.53	6.03	0.36	6e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11860954	chr21:43299419	PRDM15	0.5	6.16	0.37	2.95e-9	Parkinson's disease;
KIRP	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.78	10.16	0.54	1.79e-20	Aortic root size;
KIRP	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.18	-0.31	4.65e-7	Life satisfaction;
KIRP	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg05370193	chr1:21551575	ECE1	0.45	6.15	0.36	3.18e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.65e-7	Life satisfaction;
KIRP	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg19875535	chr5:140030758	IK	0.51	6.38	0.38	8.96e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg00129232	chr17:37814104	STARD3	-0.5	-6.36	-0.38	9.92e-10	Self-reported allergy;
KIRP	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.76	-0.34	2.51e-8	Breast cancer;
KIRP	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.91	0.4	4.14e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg25703934	chr6:139696507	CITED2	-0.48	-6.13	-0.36	3.51e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.59	6.17	0.37	2.85e-9	Gut microbiome composition (summer);
KIRP	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg01529538	chr14:23388837	RBM23	0.39	4.86	0.3	2.1e-6	Cognitive ability (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19522460	chr11:124493152	TBRG1	0.6	7.72	0.44	2.88e-13	Parkinson's disease;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg08901578	chr4:187885870	NA	0.34	5.03	0.31	9.43e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs858239	0.539	rs10279194	chr7:23191083	T/C	cg23682824	chr7:23144976	KLHL7	0.56	6.69	0.39	1.53e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg11995313	chr8:8860691	ERI1	0.4	5.51	0.33	9.02e-8	Joint mobility (Beighton score);
KIRP	cis	rs2742417	0.935	rs2248991	chr3:45754749	G/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs3126085	0.515	rs6668764	chr1:152349078	C/T	cg26876637	chr1:152193138	HRNR	0.54	6.54	0.38	3.57e-10	Atopic dermatitis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg03774026	chr6:119399550	FAM184A	-0.43	-6.26	-0.37	1.71e-9	Myopia;
KIRP	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg05692746	chr2:100937584	LONRF2	-0.41	-5.47	-0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.34	0.47	5.28e-15	Morning vs. evening chronotype;
KIRP	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg24747557	chr10:131355152	MGMT	-0.41	-5.55	-0.33	7.44e-8	Response to temozolomide;
KIRP	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.33	5.24	0.32	3.51e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.57	-7.98	-0.45	5.49e-14	Airway imaging phenotypes;
KIRP	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg17736920	chr1:242011382	EXO1	0.47	5.83	0.35	1.77e-8	Menopause (age at onset);
KIRP	cis	rs904251	0.523	rs2776871	chr6:37481759	A/G	cg25019722	chr6:37503610	NA	-0.95	-15.3	-0.7	1.43e-37	Cognitive performance;
KIRP	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.02	18.14	0.76	3.04e-47	Testicular germ cell tumor;
KIRP	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.51	-5.07	-0.31	7.7e-7	Body mass index (adult);
KIRP	cis	rs315122	0.588	rs548240	chr12:69756291	A/T	cg20891283	chr12:69753455	YEATS4	0.82	6.61	0.39	2.3e-10	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg03959625	chr15:84868606	LOC388152	-0.63	-7.04	-0.41	1.86e-11	Schizophrenia;
KIRP	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.58	-0.39	2.89e-10	Retinal vascular caliber;
KIRP	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	ch.11.340609R	chr11:12831013	TEAD1	-0.4	-4.95	-0.3	1.38e-6	Educational attainment (years of education);
KIRP	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.98	0.36	7.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.84	-0.53	1.76e-19	Height;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg12705353	chr12:122356852	WDR66	0.53	6.99	0.41	2.61e-11	Mean corpuscular volume;
KIRP	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.66	0.6	2.7e-25	Alzheimer's disease;
KIRP	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.95	17.11	0.74	8.82e-44	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.66	-0.52	6.22e-19	Body mass index;
KIRP	cis	rs11249608	0.789	rs7706393	chr5:178437737	G/T	cg21905437	chr5:178450457	ZNF879	-0.49	-5.81	-0.35	1.91e-8	Pubertal anthropometrics;
KIRP	cis	rs7707921	0.829	rs226204	chr5:81610680	G/A	cg08459430	chr5:81571289	RPS23	-0.38	-4.89	-0.3	1.84e-6	Breast cancer;
KIRP	cis	rs71403859	0.570	rs76231867	chr16:71449926	G/A	cg08717414	chr16:71523259	ZNF19	-0.91	-8.69	-0.48	5.13e-16	Post bronchodilator FEV1;
KIRP	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg23307798	chr14:103986281	CKB	0.47	6.74	0.39	1.13e-10	Body mass index;
KIRP	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-12.94	-0.64	1.47e-29	Vitiligo;
KIRP	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg15655495	chr12:38532458	NA	0.27	5.31	0.32	2.4e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.82	8.57	0.48	1.12e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.83	8.04	0.46	3.81e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	trans	rs1859156	0.767	rs67037000	chr4:95837548	G/A	cg24204951	chr2:239172084	PER2	0.31	6.66	0.39	1.8e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg02733842	chr7:1102375	C7orf50	0.45	5.23	0.32	3.65e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.03	0.31	9.3e-7	Leprosy;
KIRP	cis	rs7851660	0.874	rs2417576	chr9:100628707	C/T	cg13688889	chr9:100608707	NA	-0.67	-8.83	-0.49	1.97e-16	Strep throat;
KIRP	cis	rs11628318	0.851	rs4243735	chr14:103023574	T/C	cg12046867	chr14:103022105	NA	-0.59	-7.25	-0.42	5.48e-12	Platelet count;
KIRP	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.17	0.42	8.63e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4955124	0.643	rs17028714	chr3:32041229	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.78	6.47	0.38	5.15e-10	Schizophrenia;
KIRP	cis	rs2151522	0.603	rs1832986	chr6:127191901	G/A	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	9.1	0.5	3.14e-17	Colorectal cancer;
KIRP	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.54	-6.77	-0.4	9.28e-11	Menarche (age at onset);
KIRP	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.12	-10.66	-0.56	4.7e-22	Diabetic kidney disease;
KIRP	cis	rs9596863	0.898	rs7328896	chr13:54334206	A/T	ch.13.53330881F	chr13:54432880	NA	0.6	5.79	0.35	2.16e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg04780086	chr2:111875790	ACOXL	0.44	6.15	0.37	3.11e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs7221595	0.825	rs12951359	chr17:3921731	T/A	cg11204139	chr17:3907470	NA	0.57	5.79	0.35	2.14e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.43	4.89	0.3	1.79e-6	DNA methylation (variation);
KIRP	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg09754948	chr16:28834200	ATXN2L	0.5	5.66	0.34	4.28e-8	Tonsillectomy;Mean corpuscular volume;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg17739026	chr1:27114420	PIGV	0.5	6.39	0.38	8.23e-10	Myopia (pathological);
KIRP	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.35	-5.68	-0.34	3.85e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg24803719	chr17:45855879	NA	0.37	5.79	0.35	2.16e-8	IgG glycosylation;
KIRP	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg18350739	chr11:68623251	NA	-0.48	-7.47	-0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg08501292	chr6:25962987	TRIM38	0.79	5.43	0.33	1.32e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg09699651	chr6:150184138	LRP11	0.49	6.31	0.37	1.28e-9	Lung cancer;
KIRP	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-6.83	-0.4	6.74e-11	Vitiligo;
KIRP	cis	rs5750854	0.705	rs2413601	chr22:39987023	A/T	cg10455938	chr22:40058150	CACNA1I	0.39	5.45	0.33	1.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs73198271	0.710	rs3827808	chr8:8679357	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.19	-0.42	7.87e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.72	7.87	0.45	1.1e-13	Chronic sinus infection;
KIRP	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.75	10.43	0.55	2.56e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1832871	0.672	rs56326208	chr6:158762944	C/T	cg07215822	chr6:158701037	NA	-0.64	-7.4	-0.43	2.13e-12	Height;
KIRP	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.51e-7	Cognitive test performance;
KIRP	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg00677455	chr12:58241039	CTDSP2	-0.52	-5.78	-0.35	2.28e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-6.63	-0.39	2.15e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.94	-7.04	-0.41	1.88e-11	Alzheimer's disease (late onset);
KIRP	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.97	-15.1	-0.69	6.64e-37	Ulcerative colitis;
KIRP	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.96	10.58	0.56	8.27e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg16524936	chr4:1340807	KIAA1530	-0.43	-5.09	-0.31	7.11e-7	Obesity-related traits;
KIRP	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.56	-6.96	-0.41	3.03e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7656342	0.570	rs1980219	chr4:9850621	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-5.85	-0.35	1.54e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg15934090	chr1:100435551	SLC35A3	0.5	6.21	0.37	2.22e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.66	-9.86	-0.53	1.49e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11987759	chr7:65425863	GUSB	-0.48	-5.58	-0.34	6.34e-8	Aortic root size;
KIRP	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.61	-12.17	-0.61	5.43e-27	Diabetic kidney disease;
KIRP	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.82	10.93	0.57	6.17e-23	Morning vs. evening chronotype;
KIRP	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg19468946	chr17:37922297	IKZF3	-0.39	-5.25	-0.32	3.34e-7	Asthma;
KIRP	cis	rs501120	1.000	rs552794	chr10:44771666	G/A	cg09554077	chr10:44749378	NA	0.71	10.94	0.57	6.01e-23	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.5	5.97	0.36	8.34e-9	Common traits (Other);
KIRP	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.35	-5.05	-0.31	8.63e-7	Body mass index;
KIRP	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.51	5.68	0.34	3.73e-8	Schizophrenia;
KIRP	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.48e-11	Morning vs. evening chronotype;
KIRP	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg15737290	chr11:93063684	CCDC67	-0.89	-9.06	-0.5	4.16e-17	Pulmonary function decline;
KIRP	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg19743168	chr1:23544995	NA	0.51	7.04	0.41	1.86e-11	Height;
KIRP	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg03854865	chr6:26224070	HIST1H3E	0.62	4.85	0.3	2.16e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg23102388	chr7:1867652	MAD1L1	-0.44	-6.02	-0.36	6.2e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg24112000	chr20:60950667	NA	-0.7	-7.35	-0.42	2.88e-12	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-1.11	-16.59	-0.73	5.39e-42	Eosinophil percentage of white cells;
KIRP	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg13165212	chr22:42675999	NA	0.29	5.1	0.31	6.67e-7	Cognitive function;
KIRP	cis	rs767764	0.557	rs1671353	chr8:13195489	C/T	cg20744108	chr8:13131569	DLC1	0.46	4.88	0.3	1.87e-6	Nose size;
KIRP	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg04935436	chr20:30431758	NA	0.56	6.86	0.4	5.47e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.74	6.66	0.39	1.78e-10	Diabetic retinopathy;
KIRP	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.71	-8.91	-0.49	1.17e-16	Aortic root size;
KIRP	cis	rs7129556	0.737	rs614495	chr11:77536886	T/A	cg12586386	chr11:77299805	AQP11	0.42	5.57	0.33	6.57e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-5.01	-0.3	1.02e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.95	15.1	0.69	6.74e-37	Intelligence (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04895640	chr1:36807418	STK40	0.49	6.65	0.39	1.93e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg14851346	chr12:38532713	NA	-0.4	-4.96	-0.3	1.29e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.41	-5.63	-0.34	4.95e-8	HIV-1 susceptibility;
KIRP	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.45	5.17	0.31	4.74e-7	Mean corpuscular volume;
KIRP	cis	rs3733418	0.929	rs13110309	chr4:165889672	T/G	cg10852876	chr4:165953100	TRIM60	-0.51	-5.69	-0.34	3.64e-8	Obesity-related traits;
KIRP	cis	rs4886920	0.894	rs4886930	chr15:78127406	G/A	cg10461261	chr15:78109450	NA	-0.36	-5.85	-0.35	1.52e-8	Neuroticism;
KIRP	cis	rs7923609	0.936	rs4405189	chr10:65013935	A/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.66	-0.34	4.21e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg19554555	chr3:13937349	NA	0.48	6.44	0.38	6.13e-10	Ovarian reserve;
KIRP	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	10.45	0.55	2.14e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1829883	1.000	rs2460683	chr5:98778568	A/G	cg08333243	chr5:99726346	NA	-0.38	-5.04	-0.31	8.97e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg00982548	chr2:198649783	BOLL	-0.54	-5.07	-0.31	7.65e-7	Ulcerative colitis;
KIRP	cis	rs4073221	0.697	rs1464046	chr3:18226695	A/G	cg07694806	chr3:18168406	NA	-0.62	-5.71	-0.34	3.29e-8	Parkinson's disease;
KIRP	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg14593290	chr7:50529359	DDC	0.75	9.29	0.51	8.42e-18	Malaria;
KIRP	cis	rs6681460	0.932	rs2044399	chr1:67054080	T/C	cg02459107	chr1:67143332	SGIP1	0.48	6.91	0.4	4.22e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs4237845	0.591	rs10877040	chr12:58326448	T/C	cg02175503	chr12:58329896	NA	0.88	10.58	0.56	8.37e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-7.32	-0.42	3.6e-12	Platelet count;
KIRP	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg19653624	chr11:20408972	PRMT3	-0.69	-6.57	-0.39	2.9e-10	Pursuit maintenance gain;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg20625683	chr15:31088666	NA	0.37	6.04	0.36	5.61e-9	Warfarin maintenance dose;
KIRP	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg01493522	chr13:37497338	NA	-0.45	-5.47	-0.33	1.09e-7	Coronary artery disease;
KIRP	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.14	23.34	0.83	2.65e-64	Triglycerides;
KIRP	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.4	-6.99	-0.41	2.5e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.78	9.88	0.53	1.34e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs2221894	0.616	rs10112345	chr8:28964670	A/G	cg09322573	chr8:28961356	KIF13B	0.26	5.1	0.31	6.83e-7	Obesity-related traits;
KIRP	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.7	-7.54	-0.43	9.17e-13	Migraine;Coronary artery disease;
KIRP	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg19476082	chr7:2414320	EIF3B	0.56	5.16	0.31	5.07e-7	Multiple sclerosis;
KIRP	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-6.56	-0.39	3.08e-10	Educational attainment;
KIRP	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.41	-0.43	2.07e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.88	14.26	0.67	5.01e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg27411982	chr8:10470053	RP1L1	0.43	5.24	0.32	3.38e-7	Retinal vascular caliber;
KIRP	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.53	-5.97	-0.36	8.43e-9	Total cholesterol levels;
KIRP	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.14	-0.5	2.37e-17	Rheumatoid arthritis;
KIRP	cis	rs3741151	0.572	rs12290623	chr11:73121872	C/G	cg17517138	chr11:73019481	ARHGEF17	0.66	5.74	0.34	2.74e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg08133631	chr1:26527909	CATSPER4	-0.44	-5.05	-0.31	8.71e-7	Obesity-related traits;
KIRP	cis	rs7224685	0.569	rs34540447	chr17:3994413	T/C	cg05562828	chr17:3906858	NA	0.55	5.85	0.35	1.57e-8	Type 2 diabetes;
KIRP	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	7.99	0.45	5.23e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.59	-8.51	-0.48	1.7e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6585424	1.000	rs35180576	chr10:81922971	G/A	cg27417294	chr10:81904244	PLAC9	0.57	5.45	0.33	1.25e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6142102	0.812	rs6059574	chr20:32523172	C/G	cg08999081	chr20:33150536	PIGU	-0.49	-6.07	-0.36	4.73e-9	Skin pigmentation;
KIRP	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.78	-10.21	-0.55	1.2e-20	Mood instability;
KIRP	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.77	-10.41	-0.55	2.84e-21	Aortic root size;
KIRP	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg00310523	chr12:86230176	RASSF9	0.46	7.3	0.42	3.89e-12	Major depressive disorder;
KIRP	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg05729581	chr11:3078854	CARS	0.5	6.22	0.37	2.15e-9	Longevity;
KIRP	cis	rs4713675	0.565	rs1555965	chr6:33677400	A/G	cg15676125	chr6:33679581	C6orf125	0.42	5.46	0.33	1.15e-7	Plateletcrit;
KIRP	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg07309820	chr7:148901717	ZNF282	-0.39	-4.91	-0.3	1.68e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg09137382	chr11:130731461	NA	0.55	8.16	0.46	1.79e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs3087591	0.597	rs731759	chr17:29722809	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.5	-6.99	-0.41	2.53e-11	Hip circumference;
KIRP	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg04998671	chr14:104000505	TRMT61A	-0.54	-6.33	-0.37	1.14e-9	Coronary artery disease;
KIRP	cis	rs9290877	0.667	rs6763915	chr3:188458283	A/G	cg17392043	chr3:188495102	LPP	-0.49	-6.34	-0.37	1.1e-9	IgE levels;
KIRP	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg18132916	chr6:79620363	NA	-0.37	-4.93	-0.3	1.48e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.86	0.3	2.05e-6	Alzheimer's disease;
KIRP	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg11214544	chr1:2391121	NA	-0.46	-5.72	-0.34	3.08e-8	Schizophrenia;
KIRP	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg23100626	chr2:96804247	ASTL	0.45	5.66	0.34	4.26e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.45	6.28	0.37	1.52e-9	Red blood cell count;
KIRP	cis	rs1903068	0.853	rs12505096	chr4:56006102	C/A	cg20092376	chr4:56023423	NA	0.42	5.05	0.31	8.61e-7	Endometriosis;
KIRP	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg24060327	chr5:131705240	SLC22A5	-0.48	-6.11	-0.36	3.82e-9	Breast cancer;
KIRP	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13047869	chr3:10149882	C3orf24	0.53	5.06	0.31	8.16e-7	Alzheimer's disease;
KIRP	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg09547025	chr6:142721804	GPR126	-0.38	-4.87	-0.3	2e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.47	7.4	0.43	2.19e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg11584989	chr19:19387371	SF4	0.41	5.27	0.32	2.97e-7	Tonsillectomy;
KIRP	cis	rs4356975	0.563	rs11933459	chr4:69981763	A/G	cg27372994	chr4:70080453	UGT2B11	0.36	4.85	0.3	2.2e-6	Obesity-related traits;
KIRP	cis	rs755109	0.934	rs10760022	chr9:100699830	A/C	cg13688889	chr9:100608707	NA	-0.43	-5.0	-0.3	1.1e-6	Quantitative traits;
KIRP	cis	rs12580194	0.593	rs66516917	chr12:55749131	T/G	cg19537932	chr12:55886519	OR6C68	-0.45	-5.9	-0.35	1.23e-8	Cancer;
KIRP	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.92	0.35	1.09e-8	Motion sickness;
KIRP	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-6.19	-0.37	2.47e-9	Lung cancer;
KIRP	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.66	7.52	0.43	1.03e-12	Height;
KIRP	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg18016565	chr1:150552671	MCL1	0.39	5.9	0.35	1.19e-8	Melanoma;
KIRP	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.72	9.11	0.5	2.97e-17	Vitiligo;
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg04369109	chr6:150039330	LATS1	-0.59	-7.54	-0.43	8.98e-13	Lung cancer;
KIRP	cis	rs1978968	1.000	rs5013014	chr22:18449927	T/C	cg03078520	chr22:18463400	MICAL3	-0.65	-7.57	-0.43	7.33e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.33	0.37	1.13e-9	Educational attainment;
KIRP	cis	rs5995756	0.666	rs3788566	chr22:40006024	G/T	cg10455938	chr22:40058150	CACNA1I	0.37	5.11	0.31	6.37e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.65	9.62	0.52	8.17e-19	Schizophrenia;
KIRP	cis	rs7542091	0.704	rs9429825	chr1:210052133	C/G	cg05527609	chr1:210001259	C1orf107	-0.37	-4.91	-0.3	1.66e-6	Monobrow;
KIRP	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	13.28	0.65	1.01e-30	Platelet count;
KIRP	cis	rs11585357	0.501	rs72646770	chr1:17580767	T/C	cg08277548	chr1:17600880	PADI3	-0.62	-5.29	-0.32	2.67e-7	Hair shape;
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.47	-6.07	-0.36	4.81e-9	QT interval;
KIRP	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg23594656	chr7:65796392	TPST1	-0.38	-5.55	-0.33	7.52e-8	Aortic root size;
KIRP	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.73	8.21	0.46	1.29e-14	Platelet count;
KIRP	cis	rs6540559	1.000	rs7522250	chr1:209962539	T/C	cg22029157	chr1:209979665	IRF6	0.53	6.46	0.38	5.61e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs4478037	1.000	rs4074418	chr3:33161165	G/T	cg19404215	chr3:33155277	CRTAP	0.71	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	cis	rs7646881	0.812	rs73017536	chr3:158460602	C/T	cg19483011	chr3:158453295	NA	-0.56	-5.89	-0.35	1.23e-8	Tetralogy of Fallot;
KIRP	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07570687	chr10:102243282	WNT8B	0.43	5.09	0.31	6.99e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	0.8	6.1	0.36	4e-9	Mitochondrial DNA levels;
KIRP	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.9	10.39	0.55	3.28e-21	Menopause (age at onset);
KIRP	trans	rs9944715	1.000	rs9944767	chr18:43831057	A/G	cg01718231	chr17:29326311	RNF135	0.53	6.16	0.37	2.97e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.43	-5.15	-0.31	5.47e-7	Huntington's disease progression;
KIRP	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg13939156	chr17:80058883	NA	0.47	5.53	0.33	8.16e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.73	6.52	0.38	3.88e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg06289844	chr6:126071538	HEY2	0.35	4.91	0.3	1.62e-6	Brugada syndrome;
KIRP	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg11952622	chr19:58962976	ZNF324B	0.42	4.88	0.3	1.91e-6	Uric acid clearance;
KIRP	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg26513180	chr16:89883248	FANCA	0.84	5.5	0.33	9.72e-8	Skin colour saturation;
KIRP	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg22800045	chr5:56110881	MAP3K1	-0.54	-5.67	-0.34	4.05e-8	Initial pursuit acceleration;
KIRP	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	12.18	0.61	5.05e-27	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10153353	chr11:28349922	METT5D1	-0.41	-6.15	-0.37	3.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.7	-10.6	-0.56	7.2e-22	Schizophrenia;
KIRP	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.54	-0.38	3.61e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10053473	chr17:62856997	LRRC37A3	0.69	7.48	0.43	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06544989	chr22:39130855	UNC84B	0.49	8.57	0.48	1.16e-15	Menopause (age at onset);
KIRP	cis	rs7582720	1.000	rs72932772	chr2:203682304	C/G	cg08076091	chr2:203926405	NBEAL1	0.84	8.69	0.48	5.19e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.31	-5.53	-0.33	8.06e-8	Renal cell carcinoma;
KIRP	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.81	11.0	0.57	3.62e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7215564	0.908	rs35725122	chr17:78663275	A/T	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.51	-6.57	-0.39	2.9e-10	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.88	12.26	0.62	2.79e-27	Breast cancer;
KIRP	trans	rs1581057	0.861	rs7628375	chr3:161819786	T/C	cg09318158	chr19:54191610	MIR1283-1	-0.41	-6.04	-0.36	5.71e-9	Social communication problems;
KIRP	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.57	6.89	0.4	4.77e-11	Aortic root size;
KIRP	cis	rs1978968	1.000	rs1110659	chr22:18444675	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.82	0.49	2.08e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2273669	0.667	rs12195372	chr6:109284223	A/G	cg05315195	chr6:109294784	ARMC2	-0.61	-6.1	-0.36	4.12e-9	Prostate cancer;
KIRP	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	6.18	0.37	2.58e-9	Total body bone mineral density;
KIRP	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.29	6.91	0.4	4.05e-11	IgG glycosylation;
KIRP	cis	rs6681460	1.000	rs2031478	chr1:67123742	C/A	cg02459107	chr1:67143332	SGIP1	0.49	7.17	0.42	8.92e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg23594656	chr7:65796392	TPST1	0.44	5.99	0.36	7.26e-9	Aortic root size;
KIRP	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.87	-11.09	-0.58	1.96e-23	Platelet distribution width;
KIRP	cis	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg21775007	chr8:11205619	TDH	-0.46	-6.28	-0.37	1.56e-9	Retinal vascular caliber;
KIRP	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.6	-6.47	-0.38	5.4e-10	DNA methylation (variation);
KIRP	cis	rs75920871	0.925	rs4936359	chr11:116893724	T/A	cg23684410	chr11:116897558	SIK3	0.57	6.15	0.37	3.05e-9	Subjective well-being;
KIRP	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg12661370	chr5:149340060	SLC26A2	0.45	5.52	0.33	8.52e-8	HIV-1 control;
KIRP	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	0.89	10.53	0.56	1.25e-21	Mosquito bite size;
KIRP	cis	rs412050	0.501	rs78329092	chr22:22126203	C/T	cg17089214	chr22:22089827	YPEL1	0.63	5.82	0.35	1.81e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs7083	1.000	rs535602	chr11:117107775	A/G	cg11523350	chr11:117171073	BACE1	-0.25	-4.88	-0.3	1.93e-6	Blood protein levels;
KIRP	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14598338	chr9:96623480	NA	-0.67	-11.49	-0.59	9.68e-25	DNA methylation (variation);
KIRP	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.0	-0.45	4.83e-14	Mean corpuscular volume;
KIRP	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.86	-0.4	5.63e-11	Aortic root size;
KIRP	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg06243866	chr13:111019493	COL4A2	0.87	15.69	0.71	6.36e-39	Coronary artery disease;
KIRP	cis	rs6539267	0.923	rs4964175	chr12:106753984	A/G	cg00173435	chr12:106696525	TCP11L2	-0.5	-4.89	-0.3	1.86e-6	Tourette syndrome;
KIRP	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.7	-7.48	-0.43	1.35e-12	DNA methylation (variation);
KIRP	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	0.85	7.7	0.44	3.29e-13	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.85	5.18	0.31	4.65e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs73058052	0.597	rs10406941	chr19:50091464	A/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.49	5.9	0.35	1.18e-8	Fibrinogen levels;
KIRP	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.55	7.36	0.42	2.81e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2115536	0.704	rs2163005	chr15:80194480	A/G	cg00225070	chr15:80189496	MTHFS	0.61	7.19	0.42	7.91e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1215050	0.755	rs7696354	chr4:98820330	T/C	cg05340658	chr4:99064831	C4orf37	0.48	5.5	0.33	9.64e-8	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	8.49	0.48	1.98e-15	Post bronchodilator FEV1;
KIRP	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.17	0.37	2.86e-9	Menopause (age at onset);
KIRP	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg13180566	chr4:1052158	NA	-0.53	-5.06	-0.31	8.07e-7	Recombination rate (females);
KIRP	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07346700	chr16:71748967	PHLPP2	0.46	6.52	0.38	3.95e-10	Interleukin-4 levels;
KIRP	cis	rs754423	0.585	rs7157151	chr14:52571583	C/T	cg05884192	chr14:52515736	NID2	0.51	6.29	0.37	1.4e-9	Craniofacial microsomia;
KIRP	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.99	15.83	0.71	2.17e-39	Intelligence (multi-trait analysis);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15133963	chr2:27616316	FTHL3;PPM1G	0.43	6.22	0.37	2.12e-9	Cancer;
KIRP	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.38	-5.06	-0.31	8.2e-7	Monocyte percentage of white cells;
KIRP	cis	rs7106204	0.609	rs12804374	chr11:24338016	A/G	ch.11.24196551F	chr11:24239977	NA	0.76	7.12	0.41	1.18e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg03342759	chr3:160939853	NMD3	0.44	5.35	0.32	1.96e-7	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.74	-9.4	-0.51	4.07e-18	Aortic root size;
KIRP	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg20243544	chr17:37824526	PNMT	-0.4	-4.93	-0.3	1.49e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.64	8.38	0.47	4.07e-15	Childhood ear infection;
KIRP	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg02023728	chr11:77925099	USP35	-0.33	-5.27	-0.32	2.96e-7	Alzheimer's disease (survival time);
KIRP	cis	rs4664304	0.597	rs979129	chr2:160840151	T/C	cg03641300	chr2:160917029	PLA2R1	-0.37	-5.41	-0.33	1.48e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.42	5.7	0.34	3.5e-8	Homoarginine levels;
KIRP	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.39	-5.03	-0.31	9.6e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg05370193	chr1:21551575	ECE1	0.47	6.15	0.37	3.09e-9	Superior frontal gyrus grey matter volume;
KIRP	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.6	-7.29	-0.42	4.13e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1215050	0.704	rs783915	chr4:99023151	C/G	cg17366294	chr4:99064904	C4orf37	0.36	4.98	0.3	1.22e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14364729	chr13:50571210	TRIM13;DLEU2	0.46	6.24	0.37	1.85e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18883852	chr13:45965548	LOC100190939	-0.44	-6.45	-0.38	6.01e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.5	6.64	0.39	1.96e-10	Longevity;Endometriosis;
KIRP	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg08885076	chr2:99613938	TSGA10	0.55	9.66	0.52	6.16e-19	Chronic sinus infection;
KIRP	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.58	0.48	1.11e-15	Morning vs. evening chronotype;
KIRP	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs9815354	0.953	rs1717010	chr3:41946903	G/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.27	-0.32	3.04e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs72829446	0.530	rs7217492	chr17:7396049	C/G	cg02795151	chr17:7402630	POLR2A	0.75	7.89	0.45	9.98e-14	Androgen levels;
KIRP	trans	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg06521331	chr12:34319734	NA	-0.61	-7.22	-0.42	6.27e-12	Bladder cancer;
KIRP	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.67	6.32	0.37	1.19e-9	Neutrophil percentage of white cells;
KIRP	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg08975724	chr8:8085496	FLJ10661	0.55	7.35	0.42	2.93e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs974417	0.529	rs13196850	chr6:97318086	T/C	cg10979063	chr6:97285822	GPR63	0.35	4.91	0.3	1.68e-6	Body mass index;
KIRP	trans	rs4652676	0.954	rs199933	chr1:181747349	G/A	cg01133215	chr6:45399681	RUNX2	-0.39	-6.08	-0.36	4.52e-9	Neuroticism;
KIRP	cis	rs2594989	0.831	rs7642605	chr3:11469503	T/C	cg01796438	chr3:11312864	ATG7	-0.71	-8.19	-0.46	1.42e-14	Circulating chemerin levels;
KIRP	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.71	10.91	0.57	7.41e-23	Blood metabolite ratios;
KIRP	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.78	9.53	0.52	1.64e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg21546286	chr11:48923668	NA	-0.48	-6.16	-0.37	3e-9	HDL cholesterol;
KIRP	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg23250157	chr14:64679961	SYNE2	-0.55	-6.05	-0.36	5.44e-9	Atrial fibrillation;
KIRP	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg03342759	chr3:160939853	NMD3	-0.49	-6.36	-0.38	9.92e-10	Morning vs. evening chronotype;
KIRP	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.91	-12.14	-0.61	6.99e-27	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.57	4.93	0.3	1.53e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3736485	0.966	rs10775144	chr15:51891134	C/T	cg14296394	chr15:51910925	DMXL2	-0.36	-5.35	-0.32	1.98e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg13319975	chr6:146136371	FBXO30	0.47	6.28	0.37	1.55e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.39	0.59	2.1e-24	Height;
KIRP	cis	rs888194	0.628	rs9888325	chr12:110037413	G/T	cg05360138	chr12:110035743	NA	0.46	5.74	0.34	2.83e-8	Neuroticism;
KIRP	cis	rs11605924	0.934	rs7945689	chr11:45879006	C/T	cg23097878	chr11:45879730	CRY2	0.31	6.41	0.38	7.54e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg06204229	chr3:52865917	ITIH4	0.47	5.05	0.31	8.68e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs9584850	0.834	rs12463	chr13:99105302	G/A	cg20750642	chr13:99100586	FARP1	-0.54	-6.52	-0.38	3.93e-10	Neuroticism;
KIRP	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg09060608	chr5:178986726	RUFY1	0.52	8.22	0.46	1.17e-14	Lung cancer;
KIRP	cis	rs4006360	0.575	rs7502215	chr17:39306261	C/T	cg15015397	chr17:39261100	KRTAP4-9	0.39	5.26	0.32	3.07e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.94	10.09	0.54	2.95e-20	Alzheimer's disease;
KIRP	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-5.87	-0.35	1.4e-8	Bipolar disorder;
KIRP	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.24	-15.87	-0.71	1.54e-39	Type 1 diabetes nephropathy;
KIRP	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.47	5.84	0.35	1.64e-8	Height;
KIRP	cis	rs17023223	0.537	rs12064137	chr1:119709749	G/A	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.24	-12.39	-0.62	9.95e-28	Atopic dermatitis;
KIRP	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg00405596	chr8:11794950	NA	-0.46	-6.19	-0.37	2.44e-9	Triglycerides;
KIRP	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.92	-14.71	-0.68	1.48e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.73	10.9	0.57	7.68e-23	Hip circumference;
KIRP	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg05082376	chr22:42548792	NA	-0.46	-5.88	-0.35	1.36e-8	Schizophrenia;
KIRP	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg27205649	chr11:78285834	NARS2	-0.69	-9.08	-0.5	3.55e-17	Alzheimer's disease (survival time);
KIRP	cis	rs71636778	0.722	rs12729652	chr1:27046982	G/A	cg12203394	chr1:27248618	NUDC	0.68	5.35	0.32	1.97e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg02570527	chr1:10970165	NA	-0.42	-5.23	-0.32	3.69e-7	Body mass index;
KIRP	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg05973401	chr12:123451056	ABCB9	0.62	7.43	0.43	1.77e-12	Platelet count;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg10207240	chr12:122356781	WDR66	0.59	7.74	0.44	2.59e-13	Mean corpuscular volume;
KIRP	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.58	-11.75	-0.6	1.36e-25	Diabetic kidney disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24686911	chr14:31029063	G2E3	0.46	6.25	0.37	1.78e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs71597109	0.681	rs13117264	chr4:102719650	A/C	cg14855874	chr4:102712397	BANK1	0.38	5.08	0.31	7.29e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.57	-5.25	-0.32	3.3e-7	Hip geometry;
KIRP	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.51	-6.3	-0.37	1.38e-9	Total cholesterol levels;
KIRP	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	1.01	17.67	0.75	1.13e-45	Breast cancer;
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	13.97	0.67	4.74e-33	Platelet count;
KIRP	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg01988459	chr11:68622903	NA	-0.35	-4.84	-0.3	2.26e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg23625390	chr15:77176239	SCAPER	0.55	7.31	0.42	3.67e-12	Blood metabolite levels;
KIRP	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	7.58	0.44	7.09e-13	Height;
KIRP	cis	rs6088813	0.645	rs6087709	chr20:34017944	C/G	cg14752227	chr20:34000481	UQCC	-0.47	-5.21	-0.32	4e-7	Height;
KIRP	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	5.06	0.31	8.25e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9346649	0.630	rs4708641	chr6:168491416	G/A	cg09211372	chr6:168490623	NA	-0.38	-6.62	-0.39	2.26e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.65	8.83	0.49	1.96e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg24110177	chr3:50126178	RBM5	-0.42	-5.5	-0.33	9.29e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.32	-0.42	3.47e-12	Height;
KIRP	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg25019722	chr6:37503610	NA	-0.75	-8.88	-0.49	1.4e-16	Cognitive performance;
KIRP	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg16306078	chr6:126000798	NA	-0.26	-4.94	-0.3	1.46e-6	Endometrial cancer;
KIRP	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.54	-7.7	-0.44	3.32e-13	Colorectal cancer;
KIRP	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg19554555	chr3:13937349	NA	-0.48	-6.43	-0.38	6.43e-10	Ovarian reserve;
KIRP	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg24804195	chr5:87968844	LOC645323	-0.47	-6.18	-0.37	2.59e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-8.29	-0.47	7.44e-15	Total body bone mineral density;
KIRP	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg23796481	chr11:64053134	BAD;GPR137	0.72	6.22	0.37	2.17e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.56	0.33	6.95e-8	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21225450	chr8:98656257	MTDH	-0.55	-6.19	-0.37	2.45e-9	Interleukin-4 levels;
KIRP	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.51	5.36	0.32	1.87e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs9400467	0.506	rs76813116	chr6:111690733	T/G	cg15721981	chr6:111408429	SLC16A10	0.68	6.15	0.36	3.14e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.63	8.1	0.46	2.58e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg08761264	chr16:28874980	SH2B1	-0.45	-4.88	-0.3	1.94e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg26681399	chr22:41777847	TEF	0.47	4.9	0.3	1.72e-6	Vitiligo;
KIRP	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.49	-5.82	-0.35	1.82e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7215564	0.908	rs4969246	chr17:78740579	G/A	cg06153925	chr17:78755379	RPTOR	-0.38	-6.38	-0.38	8.95e-10	Myopia (pathological);
KIRP	cis	rs7589342	0.501	rs13429800	chr2:106441002	C/T	cg16077055	chr2:106428750	NCK2	0.23	5.14	0.31	5.66e-7	Addiction;
KIRP	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.59	-0.44	6.67e-13	Height;
KIRP	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.33	-0.42	3.32e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00522056	chr2:154335386	RPRM	0.45	6.06	0.36	5.16e-9	Parkinson's disease;
KIRP	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg03684893	chr10:554711	DIP2C	0.39	5.79	0.35	2.17e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.47	5.11	0.31	6.35e-7	Obesity-related traits;
KIRP	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.89	-13.56	-0.65	1.16e-31	Height;
KIRP	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.79	9.05	0.5	4.49e-17	Post bronchodilator FEV1;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15652863	chr10:61697741	NA	0.46	6.43	0.38	6.72e-10	Interleukin-4 levels;
KIRP	cis	rs35883536	1.000	rs34441740	chr1:101137046	C/G	cg06223162	chr1:101003688	GPR88	0.33	6.69	0.39	1.45e-10	Monocyte count;
KIRP	cis	rs6467136	0.668	rs10275319	chr7:127162710	G/A	cg08586737	chr7:127225949	GCC1	-0.38	-5.01	-0.3	1.03e-6	Type 2 diabetes;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.63	-5.63	-0.34	4.87e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7809950	0.768	rs2701678	chr7:107283711	A/G	cg23024343	chr7:107201750	COG5	0.47	6.7	0.39	1.4e-10	Coronary artery disease;
KIRP	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.86	11.66	0.6	2.7e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs12620999	0.941	rs13005377	chr2:238037759	T/C	cg23555395	chr2:238036564	NA	-0.57	-6.72	-0.39	1.27e-10	Systemic lupus erythematosus;
KIRP	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	7.47	0.43	1.36e-12	Obesity-related traits;
KIRP	cis	rs3755132	0.852	rs60319313	chr2:15792803	C/A	cg12888861	chr2:15731646	DDX1	0.4	5.07	0.31	7.96e-7	Wilms tumor;
KIRP	cis	rs3947	0.789	rs8005	chr8:11701096	A/C	cg00262122	chr8:11665843	FDFT1	0.5	5.5	0.33	9.59e-8	Blood protein levels;
KIRP	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.2	12.05	0.61	1.42e-26	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.84	-14.19	-0.67	8.62e-34	Brugada syndrome;
KIRP	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-0.88	-9.32	-0.51	6.83e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.46	-5.58	-0.34	6.31e-8	Body mass index;
KIRP	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg09264619	chr17:80180166	NA	-0.51	-6.08	-0.36	4.63e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg24747557	chr10:131355152	MGMT	-0.46	-6.41	-0.38	7.41e-10	Response to temozolomide;
KIRP	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.56	-8.38	-0.47	4.08e-15	Blood metabolite levels;
KIRP	trans	rs1962073	0.528	rs4582610	chr8:10318343	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.38	-0.38	8.59e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.73	0.49	3.94e-16	Bipolar disorder;
KIRP	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	0.97	12.77	0.63	5.65e-29	Breast cancer;
KIRP	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg17294928	chr15:75287854	SCAMP5	-0.63	-6.23	-0.37	1.98e-9	Blood trace element (Zn levels);
KIRP	cis	rs3770081	1.000	rs3770066	chr2:86392350	A/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.58	5.01	0.3	1.06e-6	Facial emotion recognition (sad faces);
KIRP	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg17376030	chr22:41985996	PMM1	-0.71	-6.48	-0.38	4.94e-10	Vitiligo;
KIRP	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	0.9	10.85	0.57	1.14e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg20936604	chr3:58311152	NA	-0.62	-4.86	-0.3	2.09e-6	Cholesterol, total;
KIRP	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	cg04338863	chr8:33670619	NA	0.43	5.6	0.34	5.71e-8	Body mass index;
KIRP	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg05964544	chr11:70165517	PPFIA1	-0.51	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs8177876	0.731	rs79546329	chr16:81137241	G/A	cg08591886	chr16:81111003	C16orf46	-0.66	-4.85	-0.3	2.18e-6	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg03808351	chr9:123631620	PHF19	0.37	5.27	0.32	2.92e-7	Rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01645753	chr15:83316734	CPEB1	0.48	7.0	0.41	2.39e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12580194	0.593	rs60230359	chr12:55736550	T/C	cg11794356	chr12:55725991	OR6C3	-0.54	-7.2	-0.42	7.43e-12	Cancer;
KIRP	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg13256891	chr4:100009986	ADH5	0.52	6.64	0.39	1.99e-10	Alcohol dependence;
KIRP	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.7	8.4	0.47	3.51e-15	Schizophrenia;
KIRP	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg05457628	chr5:178986728	RUFY1	0.56	9.08	0.5	3.66e-17	Lung cancer;
KIRP	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.69	9.4	0.51	4.08e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11987759	chr7:65425863	GUSB	0.47	6.04	0.36	5.68e-9	Aortic root size;
KIRP	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg00101154	chr16:420108	MRPL28	-0.54	-7.01	-0.41	2.26e-11	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs7712401	0.601	rs35858098	chr5:122334365	A/G	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs6901004	0.803	rs354539	chr6:111517829	T/C	cg15721981	chr6:111408429	SLC16A10	-0.65	-9.45	-0.52	2.88e-18	Blood metabolite levels;
KIRP	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs4006360	0.646	rs8080164	chr17:39292845	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.48	-7.29	-0.42	4.32e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs17023223	0.553	rs72691108	chr1:119762175	G/A	cg18261050	chr1:119551319	NA	0.51	6.5	0.38	4.39e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs17020663	0.771	rs10451616	chr2:101613603	G/A	cg17494863	chr2:101638916	TBC1D8	-0.54	-5.62	-0.34	5.13e-8	Pulse pressure;
KIRP	cis	rs4924590	0.550	rs1426889	chr15:42231658	C/T	cg20935245	chr15:42234343	EHD4	-0.47	-7.2	-0.42	7.24e-12	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
KIRP	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg04132472	chr17:19861366	AKAP10	-0.4	-5.17	-0.31	4.81e-7	Schizophrenia;
KIRP	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.72	-10.35	-0.55	4.4e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg25110126	chr1:46999211	NA	-0.46	-5.48	-0.33	1.05e-7	Monobrow;
KIRP	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.69	-9.87	-0.53	1.41e-19	Childhood ear infection;
KIRP	cis	rs4728302	0.505	rs7793582	chr7:133582851	G/A	cg10665199	chr7:133106180	EXOC4	0.43	5.0	0.3	1.1e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs7147624	0.626	rs72716456	chr14:66258227	G/A	cg03016385	chr14:66212404	NA	0.79	7.17	0.42	8.69e-12	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7224314	1.000	rs7221926	chr17:65352181	A/T	cg01507342	chr17:65387096	PITPNC1	-0.49	-6.87	-0.4	5.33e-11	Diisocyanate-induced asthma;
KIRP	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.46	6.32	0.37	1.25e-9	Testicular germ cell tumor;
KIRP	cis	rs2219968	1.000	rs36124379	chr8:78963505	T/C	cg00738934	chr8:78996279	NA	0.42	5.26	0.32	3.13e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.46	-0.38	5.54e-10	Bipolar disorder;
KIRP	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg21395723	chr22:39101663	GTPBP1	0.43	5.58	0.34	6.3e-8	Menopause (age at onset);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02836541	chr2:42275176	PKDCC	-0.49	-6.7	-0.39	1.37e-10	Metabolic traits;
KIRP	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.69	-8.91	-0.49	1.14e-16	Coronary artery disease;
KIRP	cis	rs13082711	0.911	rs17682229	chr3:27443067	T/C	cg02860705	chr3:27208620	NA	0.58	8.2	0.46	1.31e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7656342	0.607	rs4697908	chr4:9893282	T/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-5.69	-0.34	3.6e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs681343	1.000	rs679574	chr19:49206108	C/G	cg08619932	chr19:49200058	FUT2	0.37	5.71	0.34	3.3e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg01557791	chr16:72042693	DHODH	-0.69	-7.71	-0.44	3.09e-13	Blood protein levels;
KIRP	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.44	-5.24	-0.32	3.4e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg00129232	chr17:37814104	STARD3	-0.74	-9.85	-0.53	1.64e-19	Glomerular filtration rate (creatinine);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg15479073	chr15:59499039	LDHAL6B;MYO1E	0.49	6.13	0.36	3.47e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg26134248	chr17:3907702	NA	0.56	8.24	0.47	1.01e-14	Type 2 diabetes;
KIRP	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21659725	chr3:3221576	CRBN	-0.6	-7.23	-0.42	5.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.7	0.49	4.83e-16	Motion sickness;
KIRP	cis	rs9603616	0.719	rs7325354	chr13:40242097	C/T	cg26701198	chr13:40229707	COG6	0.44	5.17	0.31	4.95e-7	Rheumatoid arthritis;
KIRP	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.83	-13.75	-0.66	2.76e-32	Multiple myeloma;
KIRP	cis	rs2073499	0.808	rs2526383	chr3:50184538	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.51	-4.87	-0.3	2.01e-6	Schizophrenia;
KIRP	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.5	-0.38	4.41e-10	Lung cancer;
KIRP	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.58	7.45	0.43	1.6e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg05425664	chr17:57184151	TRIM37	-0.41	-4.98	-0.3	1.18e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	1.01	15.72	0.71	5.28e-39	Sudden cardiac arrest;
KIRP	cis	rs7826238	0.526	rs876955	chr8:8310884	C/G	cg06636001	chr8:8085503	FLJ10661	0.67	8.28	0.47	7.75e-15	Systolic blood pressure;
KIRP	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.37	-5.07	-0.31	7.99e-7	Total body bone mineral density;
KIRP	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg00745463	chr17:30367425	LRRC37B	0.61	5.15	0.31	5.45e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs4073416	0.518	rs2898820	chr14:65879354	T/G	cg03016385	chr14:66212404	NA	-0.58	-6.91	-0.4	4.13e-11	N-glycan levels;
KIRP	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.5	6.61	0.39	2.4e-10	Hemoglobin concentration;
KIRP	cis	rs7487075	0.859	rs7968173	chr12:46759017	A/T	cg09050775	chr12:46762708	SLC38A2	0.39	4.95	0.3	1.36e-6	Itch intensity from mosquito bite;
KIRP	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg23625390	chr15:77176239	SCAPER	0.52	6.86	0.4	5.46e-11	Blood metabolite levels;
KIRP	cis	rs155346	0.571	rs155347	chr5:139354187	A/T	cg24724630	chr5:139362307	NRG2	-0.38	-5.0	-0.3	1.07e-6	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.38	4.89	0.3	1.78e-6	Testicular germ cell tumor;
KIRP	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.75	-10.28	-0.55	7.44e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg02336718	chr17:17403227	NA	0.33	5.2	0.31	4.1e-7	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08392126	chr6:46459694	NA	0.47	6.16	0.37	2.9e-9	Parkinson's disease;
KIRP	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-7.39	-0.43	2.26e-12	Fear of minor pain;
KIRP	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.45	-5.62	-0.34	5.23e-8	Crohn's disease;
KIRP	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.5	6.88	0.4	4.99e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg09699651	chr6:150184138	LRP11	0.47	5.92	0.35	1.06e-8	Lung cancer;
KIRP	cis	rs1823913	0.637	rs13010441	chr2:192168629	C/G	cg12404831	chr2:192114017	MYO1B	0.54	7.53	0.43	9.86e-13	Obesity-related traits;
KIRP	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg07777115	chr5:623756	CEP72	-0.58	-5.91	-0.35	1.15e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg05721485	chr17:44071124	MAPT	0.6	7.8	0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg06533319	chr4:3265114	C4orf44	0.59	7.75	0.44	2.34e-13	Parental longevity (mother's age at death);
KIRP	cis	rs4006360	0.657	rs72625994	chr17:39253749	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.43	-0.47	2.86e-15	Bipolar disorder and schizophrenia;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13467814	chr2:54013395	LOC100302652;ASB3;ERLEC1	0.56	6.47	0.38	5.15e-10	Lung cancer in ever smokers;
KIRP	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18357526	chr6:26021779	HIST1H4A	0.53	6.78	0.4	9.03e-11	Height;
KIRP	cis	rs5167	0.601	rs73047694	chr19:45497852	G/A	cg13119609	chr19:45449297	APOC2	0.39	4.93	0.3	1.49e-6	Blood protein levels;
KIRP	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.46	6.3	0.37	1.4e-9	Red blood cell count;
KIRP	cis	rs1832871	0.672	rs12529235	chr6:158766950	A/G	cg07215822	chr6:158701037	NA	-0.64	-7.4	-0.43	2.13e-12	Height;
KIRP	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.5	7.19	0.42	7.66e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.96	-16.38	-0.72	2.85e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg21546286	chr11:48923668	NA	0.43	5.36	0.32	1.89e-7	HDL cholesterol;
KIRP	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-8.79	-0.49	2.58e-16	Bipolar disorder;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01423368	chr11:76155379	C11orf30	0.63	7.28	0.42	4.41e-12	Lung cancer in ever smokers;
KIRP	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg03465714	chr1:152285911	FLG	0.49	5.41	0.33	1.48e-7	Atopic dermatitis;
KIRP	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.5	0.33	9.73e-8	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.79	10.87	0.57	9.76e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs859767	0.501	rs6742638	chr2:135407360	T/G	cg12500956	chr2:135428796	TMEM163	-0.42	-5.68	-0.34	3.78e-8	Neuroticism;
KIRP	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.66	-7.76	-0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg05756136	chr1:119680316	WARS2	-0.61	-7.99	-0.45	5.3e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-4.88	-0.3	1.94e-6	Cognitive function;
KIRP	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg18190219	chr22:46762943	CELSR1	-0.87	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg08871354	chr16:85723489	GINS2	0.44	5.16	0.31	5.08e-7	Platelet distribution width;
KIRP	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs4523957	0.890	rs2281727	chr17:2117945	A/G	cg16513277	chr17:2031491	SMG6	-0.69	-9.61	-0.52	8.94e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.51	-7.24	-0.42	5.56e-12	Metabolite levels (small molecules and protein measures);
KIRP	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.64	9.32	0.51	6.89e-18	Vitiligo;
KIRP	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.05e-8	Common traits (Other);
KIRP	cis	rs7011049	0.778	rs66556025	chr8:53866055	A/C	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs9488822	0.662	rs195524	chr6:116247480	G/C	cg05304507	chr6:116381966	FRK	0.2	5.08	0.31	7.31e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.87	12.26	0.62	2.85e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs698833	0.886	rs2289463	chr2:44565447	A/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.3	0.32	2.54e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs6580083	1.000	rs13178677	chr5:153867221	T/C	cg21964928	chr5:153872958	NA	0.42	5.78	0.35	2.23e-8	QRS duration;
KIRP	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg13047869	chr3:10149882	C3orf24	0.57	4.93	0.3	1.51e-6	Alzheimer's disease;
KIRP	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17376030	chr22:41985996	PMM1	-0.83	-9.0	-0.5	6.09e-17	Vitiligo;
KIRP	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08048268	chr3:133502702	NA	-0.44	-5.35	-0.32	2.05e-7	Iron status biomarkers;
KIRP	cis	rs2072732	0.644	rs75787210	chr1:2942465	A/G	cg11731671	chr1:2995604	PRDM16	-0.41	-5.12	-0.31	6.09e-7	Plateletcrit;
KIRP	cis	rs6545883	0.868	rs778755	chr2:61781037	A/G	cg15711740	chr2:61764176	XPO1	0.56	7.28	0.42	4.46e-12	Tuberculosis;
KIRP	cis	rs4700695	0.925	rs10069614	chr5:65396530	A/C	cg21114390	chr5:65439923	SFRS12	-0.53	-5.59	-0.34	5.9e-8	Facial morphology (factor 19);
KIRP	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.51	-5.88	-0.35	1.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg03894339	chr8:19674705	INTS10	-0.51	-6.36	-0.38	9.89e-10	Breast cancer;
KIRP	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg19770292	chr5:1868693	NA	0.4	5.1	0.31	6.7e-7	Cardiovascular disease risk factors;
KIRP	cis	rs10443215	0.700	rs12409162	chr1:56096183	G/A	cg11523071	chr1:56160889	NA	0.34	5.09	0.31	7.08e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
KIRP	cis	rs8028182	0.636	rs10152155	chr15:75701554	A/T	cg20655648	chr15:75932815	IMP3	0.54	6.95	0.41	3.25e-11	Sudden cardiac arrest;
KIRP	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.76	0.34	2.45e-8	Lung cancer;
KIRP	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.69	9.03	0.5	5.21e-17	Bladder cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg25710854	chr17:33902444	PEX12	-0.45	-6.4	-0.38	7.91e-10	Inflammatory biomarkers;
KIRP	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.47	5.82	0.35	1.83e-8	Mean platelet volume;
KIRP	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.56	7.64	0.44	4.79e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1978968	0.826	rs34596632	chr22:18463254	A/C	cg02610425	chr22:18483192	MICAL3	0.42	5.4	0.33	1.57e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg21573476	chr21:45109991	RRP1B	-0.53	-7.14	-0.41	1.05e-11	Mean corpuscular volume;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg27152280	chr5:139423077	NRG2	0.48	6.13	0.36	3.55e-9	Asthma;
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg12486944	chr17:80159399	CCDC57	-0.41	-5.5	-0.33	9.72e-8	Life satisfaction;
KIRP	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg21523564	chr15:75251491	NA	-0.35	-5.9	-0.35	1.17e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7187994	0.848	rs12934432	chr16:84770913	T/A	cg07647771	chr16:84786436	USP10	-0.51	-6.1	-0.36	3.99e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs8028182	0.636	rs4886712	chr15:75812888	C/T	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	trans	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg18187862	chr3:45730750	SACM1L	0.53	6.1	0.36	4.05e-9	Primary sclerosing cholangitis;
KIRP	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg02896835	chr1:92012615	NA	-0.43	-5.65	-0.34	4.35e-8	Breast cancer;
KIRP	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.6	7.65	0.44	4.51e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05665937	chr4:1216051	CTBP1	0.57	7.81	0.45	1.6e-13	Obesity-related traits;
KIRP	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg03388025	chr16:89894329	SPIRE2	0.44	9.29	0.51	8.58e-18	Vitiligo;
KIRP	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs1978968	1.000	rs7286219	chr22:18445709	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.59	-6.92	-0.4	3.83e-11	Presence of antiphospholipid antibodies;
KIRP	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg16141378	chr3:129829833	LOC729375	0.53	6.92	0.4	3.82e-11	Retinal vascular caliber;
KIRP	cis	rs7760535	0.794	rs463860	chr6:111691721	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.49	-6.55	-0.39	3.26e-10	Metabolic traits;
KIRP	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.21	-0.42	6.66e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9653442	0.545	rs2009095	chr2:100765081	C/T	cg07810366	chr2:100720526	AFF3	-0.32	-5.25	-0.32	3.35e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.62	7.33	0.42	3.26e-12	Height;
KIRP	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg21640587	chr11:117668038	DSCAML1	0.44	6.45	0.38	5.82e-10	Myopia;
KIRP	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.58	-7.5	-0.43	1.18e-12	Ulcerative colitis;
KIRP	cis	rs17023223	0.537	rs12064033	chr1:119709558	G/A	cg18261050	chr1:119551319	NA	0.5	6.43	0.38	6.74e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6586163	0.527	rs3824730	chr10:90752128	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.61	7.53	0.43	9.9e-13	Chronic lymphocytic leukemia;
KIRP	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg25182066	chr10:30743637	MAP3K8	0.62	8.53	0.48	1.51e-15	Inflammatory bowel disease;
KIRP	cis	rs2274273	1.000	rs2075603	chr14:55609955	C/A	cg04306507	chr14:55594613	LGALS3	0.46	7.08	0.41	1.53e-11	Protein biomarker;
KIRP	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.58	-0.8	2.03e-55	Height;
KIRP	cis	rs7084402	0.967	rs7921207	chr10:60270235	G/T	cg05938607	chr10:60274200	BICC1	0.42	10.11	0.54	2.53e-20	Refractive error;
KIRP	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.96	14.7	0.68	1.58e-35	Coronary artery disease;
KIRP	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.83	8.72	0.49	4.25e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	1.01	12.31	0.62	1.91e-27	Post bronchodilator FEV1;
KIRP	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.79	12.12	0.61	7.9e-27	Prostate cancer;
KIRP	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	7.52	0.43	1.03e-12	Height;
KIRP	cis	rs9816784	0.525	rs422772	chr3:195806472	C/T	cg01351295	chr3:195700735	SDHAP1	-0.44	-5.03	-0.31	9.57e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.36e-11	Arsenic metabolism;
KIRP	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17554472	chr22:41940697	POLR3H	-0.62	-6.66	-0.39	1.73e-10	Vitiligo;
KIRP	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.81	-12.92	-0.64	1.76e-29	Blood metabolite levels;
KIRP	cis	rs12731740	1.000	rs12404817	chr1:208004531	A/G	cg22525895	chr1:207977042	MIR29B2	-0.64	-4.9	-0.3	1.74e-6	Biomedical quantitative traits;
KIRP	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg17595323	chr11:93583763	C11orf90	0.3	5.14	0.31	5.63e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs13161895	0.713	rs76315806	chr5:179485515	C/G	cg02702477	chr5:179499311	RNF130	1.0	7.0	0.41	2.44e-11	LDL cholesterol;
KIRP	cis	rs282587	0.569	rs403530	chr13:113396380	G/A	cg04656015	chr13:113407548	ATP11A	0.62	7.25	0.42	5.29e-12	Glycated hemoglobin levels;
KIRP	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg23920097	chr1:209922102	NA	-0.47	-5.65	-0.34	4.37e-8	Red blood cell count;
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.79	13.07	0.64	5.17e-30	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.61	6.12	0.36	3.64e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	7.16	0.42	9.43e-12	Height;
KIRP	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs7539542	0.529	rs73089386	chr1:202869582	A/G	cg19681188	chr1:202830198	LOC148709	-0.48	-5.13	-0.31	5.86e-7	Mean platelet volume;
KIRP	cis	rs7923609	0.967	rs3956912	chr10:65205881	C/T	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.71	10.24	0.55	9.66e-21	Intelligence (multi-trait analysis);
KIRP	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg02002194	chr4:3960332	NA	-0.46	-6.63	-0.39	2.06e-10	Joint mobility (Beighton score);
KIRP	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.17	21.24	0.8	1.44e-57	Cognitive function;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg07308232	chr7:1071921	C7orf50	-0.51	-4.86	-0.3	2.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg17612148	chr17:26898533	PIGS	-0.48	-6.05	-0.36	5.44e-9	Myopia;
KIRP	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg10018233	chr7:150070692	REPIN1	0.58	6.81	0.4	7.57e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3745672	0.590	rs10401283	chr19:12167353	C/T	cg20127191	chr19:12306497	NA	-0.66	-5.37	-0.32	1.86e-7	Multiple sclerosis;
KIRP	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.33	0.32	2.18e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	6.93	0.4	3.74e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg12560992	chr17:57184187	TRIM37	0.61	5.21	0.32	3.95e-7	Cognitive test performance;
KIRP	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.83	-10.69	-0.56	3.68e-22	Eosinophil percentage of white cells;
KIRP	cis	rs10864907	0.691	rs4848306	chr2:113598107	G/A	cg03712744	chr2:113669835	IL1F7	-0.39	-5.69	-0.34	3.58e-8	Pulmonary function;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs738321	0.690	rs11570750	chr22:38513138	G/A	cg25457927	chr22:38595422	NA	-0.27	-5.37	-0.32	1.85e-7	Breast cancer;
KIRP	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg00745463	chr17:30367425	LRRC37B	-0.61	-6.31	-0.37	1.29e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg03929089	chr4:120376271	NA	0.67	6.28	0.37	1.53e-9	Intraocular pressure;
KIRP	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.72	6.22	0.37	2.17e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg18944383	chr4:111397179	ENPEP	0.52	9.24	0.51	1.24e-17	Height;
KIRP	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	1.04	20.32	0.79	1.45e-54	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16712232	chr11:19138668	ZDHHC13	0.47	6.11	0.36	3.84e-9	Parkinson's disease;
KIRP	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.88	-12.59	-0.63	2.25e-28	Cocaine dependence;
KIRP	cis	rs3105593	1.000	rs57002197	chr15:50873760	C/T	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.48e-7	QT interval;
KIRP	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-5.35	-0.32	2.02e-7	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg10755058	chr3:40428713	ENTPD3	-0.43	-6.28	-0.37	1.55e-9	Renal cell carcinoma;
KIRP	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.43	-0.38	6.58e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2290402	0.536	rs4690340	chr4:848280	G/T	cg14517359	chr4:903473	GAK	-0.57	-6.22	-0.37	2.18e-9	Type 2 diabetes;
KIRP	cis	rs14403	1.000	rs55655818	chr1:243661222	G/T	cg21452805	chr1:244014465	NA	0.53	5.2	0.31	4.29e-7	Schizophrenia;
KIRP	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg27205649	chr11:78285834	NARS2	-0.51	-5.12	-0.31	6.17e-7	Testicular germ cell tumor;
KIRP	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg20578329	chr17:80767326	TBCD	-0.92	-9.48	-0.52	2.28e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs7116495	1.000	rs7101701	chr11:71762155	A/G	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg18404041	chr3:52824283	ITIH1	0.43	5.4	0.33	1.54e-7	Schizophrenia;
KIRP	cis	rs10875746	0.859	rs12305511	chr12:48582716	C/T	cg26205652	chr12:48591994	NA	-0.8	-10.96	-0.57	5.12e-23	Longevity (90 years and older);
KIRP	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.57	-11.84	-0.6	6.91e-26	Diabetic kidney disease;
KIRP	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg21132104	chr15:45694354	SPATA5L1	0.59	7.25	0.42	5.37e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9596863	0.847	rs9316667	chr13:54399759	C/T	ch.13.53330881F	chr13:54432880	NA	0.63	6.36	0.38	9.53e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9475752	0.793	rs35899012	chr6:56862909	G/A	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs3857747	0.931	rs4332041	chr7:40367897	A/T	cg00420559	chr7:40367873	C7orf10	-0.6	-8.5	-0.48	1.84e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg06647332	chr5:131281008	NA	0.46	5.15	0.31	5.27e-7	Life satisfaction;
KIRP	cis	rs4654899	0.606	rs13376428	chr1:21120027	T/C	cg05370193	chr1:21551575	ECE1	0.36	4.97	0.3	1.24e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.93	0.4	3.73e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg24631222	chr15:78858424	CHRNA5	0.41	5.09	0.31	7.13e-7	Sudden cardiac arrest;
KIRP	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.65	-9.42	-0.51	3.39e-18	Neuroticism;
KIRP	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.39	-6.75	-0.4	1.08e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-7.96	-0.45	6.28e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.12	0.36	3.65e-9	Menopause (age at onset);
KIRP	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-6.06	-0.36	5.13e-9	Response to antipsychotic treatment;
KIRP	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-7.87	-0.45	1.16e-13	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.58	10.8	0.57	1.63e-22	Bone mineral density;
KIRP	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg05714579	chr10:131428358	MGMT	-0.48	-6.26	-0.37	1.68e-9	Response to temozolomide;
KIRP	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17065868	1.000	rs61947995	chr13:45160499	T/C	cg10246903	chr13:45222710	NA	0.75	6.72	0.39	1.26e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg16497661	chr14:103986332	CKB	0.52	7.16	0.42	9.11e-12	Body mass index;
KIRP	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.49	-7.53	-0.43	9.72e-13	Bone mineral density;
KIRP	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.75	-10.3	-0.55	6.24e-21	Tonsillectomy;
KIRP	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.68	-0.56	3.94e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16944820	chr13:45492071	NA	0.43	6.15	0.37	3.04e-9	Survival in pancreatic cancer;
KIRP	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.88	-14.32	-0.67	2.98e-34	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg22437258	chr11:111473054	SIK2	-0.41	-5.03	-0.31	9.42e-7	Primary sclerosing cholangitis;
KIRP	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg12384639	chr17:618140	VPS53	0.47	5.99	0.36	7.26e-9	Prostate cancer;
KIRP	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.9	-10.25	-0.55	9.08e-21	Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01250699	chr8:22225185	SLC39A14	0.53	6.25	0.37	1.82e-9	Smoking initiation;
KIRP	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.77	-0.77	2.27e-49	Schizophrenia;
KIRP	cis	rs16973500	0.711	rs2878491	chr16:71981218	T/G	cg09427745	chr16:71932006	KIAA0174	-0.63	-5.36	-0.32	1.9e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs4906332	1.000	rs11541718	chr14:103852164	C/G	cg04998671	chr14:104000505	TRMT61A	-0.52	-5.84	-0.35	1.68e-8	Coronary artery disease;
KIRP	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.54	-0.48	1.45e-15	Coronary artery disease;
KIRP	cis	rs4664293	0.801	rs6432552	chr2:160574124	A/T	cg08347373	chr2:160653686	CD302	-0.36	-5.54	-0.33	7.65e-8	Monocyte percentage of white cells;
KIRP	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.28	-0.32	2.79e-7	Gut microbiome composition (summer);
KIRP	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg20701182	chr2:24300061	SF3B14	0.5	5.01	0.3	1.04e-6	Lymphocyte counts;
KIRP	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg14092571	chr14:90743983	NA	-0.43	-5.33	-0.32	2.18e-7	Mortality in heart failure;
KIRP	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg03808351	chr9:123631620	PHF19	0.44	6.03	0.36	6.05e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.77	12.14	0.61	7.06e-27	Breast cancer;
KIRP	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg05127821	chr10:94822908	CYP26C1	-1.1	-11.3	-0.58	3.95e-24	Coronary artery disease;
KIRP	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg18404041	chr3:52824283	ITIH1	0.43	5.46	0.33	1.19e-7	Schizophrenia;
KIRP	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg18944383	chr4:111397179	ENPEP	-0.54	-6.33	-0.37	1.18e-9	Axial length;
KIRP	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg13334819	chr7:99746414	C7orf59	-0.52	-5.92	-0.35	1.09e-8	Coronary artery disease;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg21734707	chr17:3908241	ZZEF1	0.47	5.95	0.35	8.96e-9	Type 2 diabetes;
KIRP	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg05527609	chr1:210001259	C1orf107	-0.56	-5.53	-0.33	8.17e-8	Red blood cell count;
KIRP	cis	rs2153157	1.000	rs2153157	chr6:10897488	A/G	cg09105523	chr6:10887672	SYCP2L	-0.38	-5.14	-0.31	5.68e-7	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs9400467	0.506	rs12203741	chr6:111677544	A/T	cg15721981	chr6:111408429	SLC16A10	0.68	6.36	0.38	9.69e-10	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg15704280	chr7:45808275	SEPT13	0.68	6.22	0.37	2.08e-9	Intraocular pressure;
KIRP	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg12315302	chr6:26189340	HIST1H4D	1.08	6.42	0.38	7.16e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg23815491	chr16:72088622	HP	0.52	7.43	0.43	1.74e-12	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1978968	0.751	rs5992138	chr22:18458621	A/C	cg03078520	chr22:18463400	MICAL3	-0.79	-10.13	-0.54	2.27e-20	Presence of antiphospholipid antibodies;
KIRP	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.64	-9.16	-0.5	2.05e-17	Retinal vascular caliber;
KIRP	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.81	0.71	2.5e-39	Headache;
KIRP	cis	rs362272	0.502	rs2857839	chr4:3036630	T/C	cg14003022	chr4:3043019	NA	-0.37	-5.01	-0.3	1.05e-6	Serum sulfate level;
KIRP	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.49	8.71	0.49	4.58e-16	Vitiligo;
KIRP	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg05991184	chr2:219186017	PNKD	-0.38	-5.63	-0.34	4.93e-8	Colorectal cancer;
KIRP	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	trans	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.48	-0.38	4.99e-10	Neuroticism;
KIRP	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg08890418	chr1:21044141	KIF17	-0.42	-6.35	-0.38	1.06e-9	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs4845459	0.967	rs4845450	chr1:152591200	T/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.05	-0.36	5.31e-9	Psoriasis;
KIRP	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17507749	chr15:85114479	UBE2QP1	0.71	8.0	0.45	5.05e-14	Schizophrenia;
KIRP	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02920148	chr11:66056751	YIF1A	0.55	6.68	0.39	1.54e-10	Parkinson's disease;
KIRP	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.7	-7.23	-0.42	6.11e-12	Vitiligo;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06938235	chr12:56498303	PA2G4	0.49	6.04	0.36	5.52e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02204428	chr4:156133923	NPY2R	0.43	6.73	0.39	1.19e-10	Interleukin-4 levels;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg01238044	chr22:24384105	GSTT1	-0.58	-7.57	-0.43	7.59e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7770227	0.837	rs760609	chr6:114708100	A/C	cg18406000	chr6:114650610	NA	-0.41	-5.44	-0.33	1.26e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7119167	0.851	rs12295744	chr11:73279296	C/T	cg17517138	chr11:73019481	ARHGEF17	0.47	4.85	0.3	2.23e-6	Blood protein levels;
KIRP	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07080220	chr10:102295463	HIF1AN	0.73	7.02	0.41	2.16e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7113850	0.541	rs77054343	chr11:24215636	A/G	ch.11.24196551F	chr11:24239977	NA	0.85	5.75	0.34	2.69e-8	Bone fracture in osteoporosis;
KIRP	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.92	10.64	0.56	5.27e-22	Neuroticism;
KIRP	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.76	9.9	0.53	1.13e-19	N-glycan levels;
KIRP	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.86	14.47	0.68	9.84e-35	Prostate cancer;
KIRP	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16717723	chr8:2172215	NA	0.52	6.9	0.4	4.38e-11	Interleukin-4 levels;
KIRP	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg16434002	chr17:42200994	HDAC5	-0.46	-5.47	-0.33	1.13e-7	Total body bone mineral density;
KIRP	cis	rs9921338	0.886	rs3931015	chr16:11415639	G/A	cg00044050	chr16:11439710	C16orf75	0.44	4.89	0.3	1.82e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.43	5.41	0.33	1.47e-7	Platelet count;
KIRP	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17554472	chr22:41940697	POLR3H	0.69	7.08	0.41	1.48e-11	Vitiligo;
KIRP	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.74	-9.01	-0.5	5.9e-17	Cognitive function;
KIRP	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg00204512	chr16:28754710	NA	0.44	5.54	0.33	7.89e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	16.51	0.72	1.03e-41	Platelet count;
KIRP	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.81	-13.14	-0.64	3.16e-30	Prostate cancer;
KIRP	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	8.6	0.48	9.44e-16	Longevity;
KIRP	cis	rs10875746	0.551	rs12322348	chr12:48707699	T/A	cg26205652	chr12:48591994	NA	0.8	10.16	0.54	1.73e-20	Longevity (90 years and older);
KIRP	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.64	5.38	0.32	1.69e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs829661	0.947	rs844194	chr2:30753803	T/G	cg10949345	chr2:30726833	LCLAT1	0.72	10.35	0.55	4.45e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.74	9.58	0.52	1.09e-18	Huntington's disease progression;
KIRP	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg16396542	chr1:89473148	GBP3	0.42	5.97	0.36	8.33e-9	Carotid intima media thickness;
KIRP	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg19913688	chr11:428466	ANO9	0.96	8.44	0.47	2.84e-15	Body mass index;
KIRP	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.44	6.08	0.36	4.59e-9	Coronary artery disease;
KIRP	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg00080972	chr5:178986291	RUFY1	0.4	6.22	0.37	2.13e-9	Lung cancer;
KIRP	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.72	11.15	0.58	1.22e-23	Noise-induced hearing loss;
KIRP	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.18	-0.46	1.55e-14	Mean corpuscular volume;
KIRP	cis	rs77106637	0.530	rs7122044	chr11:72462634	A/G	cg03713592	chr11:72463424	ARAP1	0.54	6.15	0.36	3.15e-9	Type 2 diabetes;
KIRP	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg20387954	chr3:183756860	HTR3D	0.46	5.71	0.34	3.22e-8	Anterior chamber depth;
KIRP	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	-0.45	-5.35	-0.32	2e-7	Lung cancer;
KIRP	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.49	-6.38	-0.38	8.84e-10	Body mass index;
KIRP	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.77	11.63	0.6	3.21e-25	Breast cancer;
KIRP	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg26681399	chr22:41777847	TEF	-0.45	-5.3	-0.32	2.64e-7	Vitiligo;
KIRP	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.42	7.0	0.41	2.48e-11	Age at first birth;
KIRP	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.58	6.25	0.37	1.83e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.71	-8.36	-0.47	4.78e-15	Resting heart rate;
KIRP	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg04733989	chr22:42467013	NAGA	0.58	7.61	0.44	5.69e-13	Cognitive function;
KIRP	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg00360474	chr6:37504404	NA	0.4	5.72	0.34	3.13e-8	Cognitive performance;
KIRP	cis	rs35883536	0.967	rs1577509	chr1:101089253	C/T	cg06223162	chr1:101003688	GPR88	0.32	6.48	0.38	5e-10	Monocyte count;
KIRP	cis	rs9810890	1.000	rs73198849	chr3:128507879	G/C	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs11603020	0.950	rs28362951	chr11:57372526	A/G	cg23127183	chr11:57508653	C11orf31	-0.44	-5.2	-0.31	4.14e-7	Blood protein levels;
KIRP	cis	rs10517025	0.636	rs73235562	chr4:42428724	C/T	cg13587180	chr4:42403248	SHISA3	0.43	4.85	0.3	2.16e-6	Immune reponse to smallpox (secreted IFN-alpha);
KIRP	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.72	0.34	3.1e-8	Menopause (age at onset);
KIRP	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg17145862	chr1:211918768	LPGAT1	-0.91	-12.97	-0.64	1.12e-29	Leprosy;
KIRP	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg10189774	chr4:17578691	LAP3	0.56	6.9	0.4	4.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-0.84	-11.61	-0.59	3.88e-25	Urate levels;
KIRP	cis	rs2279817	0.780	rs1124447	chr1:18007598	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.54	-0.48	1.38e-15	Neuroticism;
KIRP	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12292205	chr6:26970375	C6orf41	-0.68	-7.32	-0.42	3.52e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6987853	0.749	rs2974367	chr8:42431194	G/C	cg09913449	chr8:42400586	C8orf40	0.4	5.46	0.33	1.19e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	ch.8.33884649F	chr8:33765107	NA	0.61	7.67	0.44	3.9e-13	Body mass index;
KIRP	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs11766298	0.702	rs71577870	chr7:128969178	T/C	cg06809055	chr7:129142284	NA	0.67	5.0	0.3	1.08e-6	Response to fenofibrate;
KIRP	cis	rs9815354	0.638	rs56194645	chr3:41843593	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg02002194	chr4:3960332	NA	-0.42	-6.08	-0.36	4.57e-9	Mood instability;
KIRP	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16318349	chr1:154917307	PBXIP1	-0.29	-5.14	-0.31	5.72e-7	Prostate cancer;
KIRP	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	1.15	20.31	0.79	1.64e-54	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21659725	chr3:3221576	CRBN	-0.6	-7.14	-0.41	1.08e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.96	-16.53	-0.73	8.87e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg05457628	chr5:178986728	RUFY1	0.56	8.53	0.48	1.52e-15	Lung cancer;
KIRP	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.39	-5.01	-0.3	1.04e-6	Menarche (age at onset);
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg08132940	chr7:1081526	C7orf50	-0.53	-5.27	-0.32	2.92e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.41	-0.43	1.97e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6142102	0.961	rs4911390	chr20:32565207	T/C	cg08999081	chr20:33150536	PIGU	0.48	5.61	0.34	5.53e-8	Skin pigmentation;
KIRP	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg07636037	chr3:49044803	WDR6	0.55	6.58	0.39	2.77e-10	Resting heart rate;
KIRP	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.88	-13.72	-0.66	3.31e-32	Breast cancer;
KIRP	cis	rs1678542	0.651	rs2888334	chr12:57976647	C/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.0	-0.3	1.11e-6	Rheumatoid arthritis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04819081	chr2:24026544	ATAD2B	-0.43	-6.61	-0.39	2.38e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs714027	0.585	rs73162764	chr22:30358745	G/A	cg27665648	chr22:30112403	NA	0.41	5.66	0.34	4.27e-8	Lymphocyte counts;
KIRP	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	5.49	0.33	1.02e-7	Height;
KIRP	cis	rs4765905	0.610	rs2239021	chr12:2310529	C/T	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.91	-0.4	4.22e-11	Schizophrenia;
KIRP	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg23335576	chr14:104009727	NA	0.37	5.16	0.31	4.99e-7	Body mass index;
KIRP	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.21	13.43	0.65	3.35e-31	Alzheimer's disease;
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.07	-13.44	-0.65	2.92e-31	Alzheimer's disease;
KIRP	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg05802129	chr4:122689817	NA	-0.76	-10.48	-0.56	1.76e-21	Type 2 diabetes;
KIRP	cis	rs6542838	0.641	rs6542841	chr2:99489039	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-5.61	-0.34	5.3e-8	Fear of minor pain;
KIRP	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-5.77	-0.35	2.32e-8	HDL cholesterol;
KIRP	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg19000871	chr14:103996768	TRMT61A	-0.46	-5.2	-0.31	4.2e-7	Reticulocyte count;
KIRP	cis	rs2710642	0.671	rs13009169	chr2:63405218	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.01	-0.3	1.03e-6	LDL cholesterol levels;LDL cholesterol;
KIRP	cis	rs2457480	0.866	rs7079375	chr10:44730310	T/C	cg09554077	chr10:44749378	NA	0.69	7.66	0.44	4.28e-13	Coronary artery disease;
KIRP	cis	rs1712517	0.904	rs6584547	chr10:105065409	C/T	cg05636881	chr10:105038444	INA	0.43	6.12	0.36	3.68e-9	Migraine;
KIRP	cis	rs77688320	0.553	rs2540339	chr2:202280448	C/T	cg06431681	chr2:202330990	STRADB	-0.47	-5.46	-0.33	1.18e-7	Breast cancer;
KIRP	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.95	-14.7	-0.68	1.58e-35	Height;
KIRP	cis	rs259842	0.557	rs10205122	chr2:180723231	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.42	-5.51	-0.33	9.14e-8	Blood protein levels;
KIRP	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.28	0.37	1.5e-9	Morning vs. evening chronotype;
KIRP	cis	rs2275565	0.872	rs4659741	chr1:237051026	C/G	cg17297354	chr1:237056641	MTR	-0.41	-5.33	-0.32	2.21e-7	Homocysteine levels;
KIRP	cis	rs7638995	0.701	rs34890270	chr3:69185678	T/A	cg26574240	chr3:69171822	LMOD3	-0.59	-7.18	-0.42	8.32e-12	Alzheimer's disease (late onset);
KIRP	cis	rs17123764	0.710	rs1049986	chr12:50158544	A/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.93	0.3	1.48e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.46	5.93	0.35	1.04e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.5	-6.45	-0.38	5.74e-10	Menopause (age at onset);
KIRP	trans	rs78049276	0.562	rs55965782	chr4:148378442	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.81	-10.7	-0.56	3.33e-22	Pulse pressure;
KIRP	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs7224685	0.501	rs781848	chr17:3958105	A/C	cg09695851	chr17:3907499	NA	0.83	15.63	0.71	1e-38	Type 2 diabetes;
KIRP	cis	rs1143633	0.662	rs12990810	chr2:113642532	G/T	cg12858261	chr2:113808755	IL1F8	-0.46	-5.06	-0.31	8.04e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-5.53	-0.33	8.35e-8	Menarche (age at onset);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg18502334	chr7:4681577	NA	-0.5	-6.83	-0.4	6.65e-11	Morning vs. evening chronotype;
KIRP	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07167872	chr1:205819463	PM20D1	0.47	5.13	0.31	5.96e-7	Parkinson's disease;
KIRP	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.42e-11	Aortic root size;
KIRP	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg22963979	chr7:1858916	MAD1L1	-0.37	-4.99	-0.3	1.14e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.85	-13.3	-0.65	9.19e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs754423	0.582	rs730532	chr14:52518811	G/A	cg05884192	chr14:52515736	NID2	-0.59	-6.82	-0.4	7.12e-11	Craniofacial microsomia;
KIRP	cis	rs4666002	0.584	rs77353560	chr2:28085544	C/A	cg05484376	chr2:27715224	FNDC4	-0.5	-5.74	-0.34	2.72e-8	Phospholipid levels (plasma);
KIRP	cis	rs4523957	0.614	rs7219693	chr17:2061101	C/A	cg16513277	chr17:2031491	SMG6	-0.78	-11.2	-0.58	8.53e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg04490037	chr7:50633773	DDC	-0.41	-5.03	-0.31	9.57e-7	Malaria;
KIRP	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.93	-15.66	-0.71	8.08e-39	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg00576331	chr11:65640516	EFEMP2	0.58	7.73	0.44	2.8e-13	DNA methylation (variation);
KIRP	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.98	0.54	6.47e-20	Total body bone mineral density;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg11859384	chr17:80120422	CCDC57	0.44	5.62	0.34	5.12e-8	Life satisfaction;
KIRP	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.37	-0.43	2.62e-12	Morning vs. evening chronotype;
KIRP	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg27490568	chr2:178487706	NA	0.47	6.27	0.37	1.57e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17507749	chr15:85114479	UBE2QP1	0.78	8.71	0.49	4.6e-16	Schizophrenia;
KIRP	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.69	11.11	0.58	1.63e-23	Neuroticism;
KIRP	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg25281562	chr12:121454272	C12orf43	0.56	6.31	0.37	1.26e-9	N-glycan levels;
KIRP	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.13	-0.31	5.92e-7	Pulmonary function;
KIRP	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg12969734	chr22:50962224	SCO2	0.49	5.15	0.31	5.26e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg12131826	chr15:77904385	NA	0.38	5.18	0.31	4.54e-7	Type 2 diabetes;
KIRP	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.46	-0.43	1.5e-12	Bladder cancer;
KIRP	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg17105886	chr17:28927953	LRRC37B2	-0.49	-4.97	-0.3	1.28e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.64	0.34	4.71e-8	Breast cancer;
KIRP	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg01403660	chr11:68851641	TPCN2	0.67	6.4	0.38	7.86e-10	Blond vs. brown hair color;
KIRP	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.37	-5.87	-0.35	1.42e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.72	-7.87	-0.45	1.11e-13	Blood pressure (smoking interaction);
KIRP	cis	rs6788895	0.661	rs1533711	chr3:150469996	C/T	cg09723797	chr3:150481914	SIAH2	-0.68	-5.67	-0.34	3.97e-8	Breast cancer;
KIRP	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.34	-0.55	4.72e-21	Chronic sinus infection;
KIRP	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg23565292	chr14:50234668	KLHDC2	-0.44	-5.31	-0.32	2.4e-7	Carotid intima media thickness;
KIRP	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.02	0.64	7.74e-30	Bladder cancer;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.67	6.21	0.37	2.18e-9	Alzheimer's disease;
KIRP	cis	rs7923609	0.934	rs10761763	chr10:65188318	T/C	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.76	0.44	2.22e-13	Aortic root size;
KIRP	cis	rs35740288	0.689	rs11630688	chr15:86253279	C/T	cg17133734	chr15:86042851	AKAP13	-0.5	-5.46	-0.33	1.15e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs17123764	1.000	rs113903668	chr12:50001508	A/G	cg20471783	chr12:50157085	TMBIM6	0.4	5.65	0.34	4.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4740619	0.619	rs10962260	chr9:16039883	T/G	cg14451791	chr9:16040625	NA	-0.41	-5.54	-0.33	7.6e-8	Body mass index;
KIRP	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.85	6.08	0.36	4.63e-9	Putamen volume;
KIRP	cis	rs4664304	0.714	rs66496937	chr2:160738509	A/G	cg06573604	chr2:160760825	LY75	-0.35	-4.85	-0.3	2.17e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.51	-5.9	-0.35	1.22e-8	Alzheimer's disease (late onset);
KIRP	cis	rs34779708	0.677	rs112355105	chr10:35550294	A/T	cg03585969	chr10:35415529	CREM	0.56	6.6	0.39	2.49e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.69	-6.41	-0.38	7.2e-10	Alzheimer's disease (late onset);
KIRP	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-1.06	-13.54	-0.65	1.36e-31	Post bronchodilator FEV1;
KIRP	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.8	11.06	0.58	2.4e-23	Neuroticism;
KIRP	cis	rs10875746	0.551	rs12322347	chr12:48707698	T/G	cg20731937	chr12:48336164	NA	0.45	5.56	0.33	6.88e-8	Longevity (90 years and older);
KIRP	cis	rs12282928	0.959	rs1503192	chr11:48289355	A/G	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs7224685	0.501	rs2054038	chr17:4014391	A/C	cg11204139	chr17:3907470	NA	0.68	10.75	0.57	2.37e-22	Type 2 diabetes;
KIRP	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.12e-25	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15404791	chr6:16147669	MYLIP	0.45	6.54	0.38	3.54e-10	Survival in pancreatic cancer;
KIRP	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.86	11.2	0.58	8.71e-24	Monocyte count;
KIRP	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg26116260	chr4:7069785	GRPEL1	-0.8	-6.63	-0.39	2.16e-10	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.43	-6.32	-0.37	1.21e-9	Height;
KIRP	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4638749	0.501	rs1486192	chr2:108751050	A/G	cg06795125	chr2:108905320	SULT1C2	0.29	5.14	0.31	5.66e-7	Blood pressure;
KIRP	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.76	5.55	0.33	7.23e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28669119	0.778	rs244752	chr5:88144669	T/C	cg18498987	chr5:88179539	MEF2C	0.52	6.4	0.38	7.91e-10	Schizophrenia;
KIRP	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg14972814	chr11:95582409	MTMR2	0.36	5.97	0.36	8.18e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg02696790	chr15:75250997	RPP25	0.32	5.56	0.33	7.11e-8	Breast cancer;
KIRP	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.8	7.76	0.44	2.2e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs6738485	0.567	rs7598745	chr2:106848216	A/T	cg16099169	chr2:106886729	NA	0.43	6.38	0.38	8.83e-10	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs4454254	0.814	rs7815937	chr8:141065441	G/A	cg05910124	chr8:141057427	TRAPPC9	-0.25	-4.97	-0.3	1.27e-6	Pulse pressure;
KIRP	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	10.64	0.56	5.55e-22	Coffee consumption (cups per day);
KIRP	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.77	8.11	0.46	2.34e-14	Gastritis;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01680839	chr14:100150374	CYP46A1	-0.51	-6.28	-0.37	1.53e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg07167872	chr1:205819463	PM20D1	-0.52	-5.02	-0.3	9.82e-7	Menarche (age at onset);
KIRP	trans	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg06521331	chr12:34319734	NA	-0.58	-7.09	-0.41	1.41e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/C	cg21851534	chr17:3907994	ZZEF1	-0.61	-9.51	-0.52	1.79e-18	Type 2 diabetes;
KIRP	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.57	7.66	0.44	4.38e-13	Mean corpuscular volume;
KIRP	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg06204229	chr3:52865917	ITIH4	0.54	5.93	0.35	1.01e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.52	-6.63	-0.39	2.11e-10	Birth weight;
KIRP	cis	rs367943	0.712	rs1366393	chr5:112729472	A/G	cg12552261	chr5:112820674	MCC	0.59	7.1	0.41	1.35e-11	Type 2 diabetes;
KIRP	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	1.96e-14	Testicular germ cell tumor;
KIRP	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg10223061	chr2:219282414	VIL1	0.4	6.43	0.38	6.69e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs748404	0.560	rs570933	chr15:43824030	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.53	6.47	0.38	5.25e-10	Lung cancer;
KIRP	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs7589342	0.501	rs12995849	chr2:106443111	C/T	cg16077055	chr2:106428750	NCK2	0.23	5.14	0.31	5.66e-7	Addiction;
KIRP	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg18357645	chr12:58087776	OS9	-0.53	-6.28	-0.37	1.51e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs2944755	0.845	rs2977459	chr8:141575869	C/A	cg26074100	chr8:141568712	EIF2C2	-0.45	-6.82	-0.4	7.07e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	0.62	8.21	0.46	1.24e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.02	-0.46	4.35e-14	Systemic lupus erythematosus;
KIRP	cis	rs7267005	0.661	rs80015686	chr20:34388820	T/C	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4356932	0.967	rs4386624	chr4:76946139	G/C	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg15556689	chr8:8085844	FLJ10661	0.51	6.84	0.4	6.21e-11	Joint mobility (Beighton score);
KIRP	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg18449003	chr2:25171492	DNAJC27	-0.4	-6.03	-0.36	5.96e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9912468	0.555	rs3744317	chr17:64216644	G/A	cg19474267	chr17:64306194	PRKCA	-0.43	-5.16	-0.31	5.11e-7	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs8014252	0.803	rs11158863	chr14:70981166	G/T	cg19730268	chr14:71022823	NA	0.71	6.24	0.37	1.93e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12016809	chr21:47604291	C21orf56	0.39	5.46	0.33	1.16e-7	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-7.24	-0.42	5.82e-12	Vitiligo;
KIRP	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg26695010	chr11:65641043	EFEMP2	-0.5	-5.01	-0.3	1.03e-6	Crohn's disease;
KIRP	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs9915657	0.660	rs12602039	chr17:70089384	A/G	cg09344028	chr17:70110421	NA	0.4	8.08	0.46	3e-14	Thyroid hormone levels;
KIRP	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.64	-8.03	-0.46	4.15e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6969780	1.000	rs6461985	chr7:27150634	T/C	cg19142026	chr7:27170394	HOXA4	0.4	4.91	0.3	1.67e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.7	6.76	0.4	9.82e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2411233	0.934	rs1824492	chr15:39284513	A/C	cg05886626	chr15:39873553	THBS1	0.33	5.12	0.31	6.21e-7	Platelet count;
KIRP	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg11707556	chr5:10655725	ANKRD33B	0.67	8.48	0.48	2.11e-15	Coronary artery disease;
KIRP	cis	rs77972916	0.536	rs59362315	chr2:43594931	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-6.33	-0.37	1.17e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg17372223	chr3:52568218	NT5DC2	0.37	5.96	0.36	8.7e-9	Electroencephalogram traits;
KIRP	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg08461772	chr7:95026248	PON3	0.34	5.36	0.32	1.88e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg09873164	chr1:152488093	CRCT1	0.6	7.97	0.45	5.93e-14	Hair morphology;
KIRP	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17376030	chr22:41985996	PMM1	0.7	7.2	0.42	7.13e-12	Vitiligo;
KIRP	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg05255149	chr17:80675120	FN3KRP	-0.53	-6.31	-0.37	1.31e-9	Glycated hemoglobin levels;
KIRP	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.4	5.13	0.31	5.86e-7	Melanoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03439086	chr11:64085030	PRDX5;TRMT112	0.48	6.56	0.39	3.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.0	0.3	1.11e-6	Educational attainment;
KIRP	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.56	6.93	0.4	3.64e-11	Aortic root size;
KIRP	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-15.88	-0.71	1.47e-39	Height;
KIRP	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg22283653	chr8:49824208	NA	-0.41	-5.8	-0.35	2.01e-8	Sudden cardiac arrest;
KIRP	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.88	-13.43	-0.65	3.17e-31	Height;
KIRP	cis	rs35000415	0.938	rs35188261	chr7:128683539	G/A	cg19972273	chr7:128594194	NA	0.83	6.11	0.36	3.88e-9	Systemic lupus erythematosus;
KIRP	cis	rs1823913	0.503	rs6434464	chr2:192205846	C/T	cg12404831	chr2:192114017	MYO1B	-0.49	-6.55	-0.39	3.41e-10	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.74	-8.08	-0.46	2.92e-14	Pursuit maintenance gain;
KIRP	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1215050	0.791	rs7434393	chr4:98768576	T/C	cg05340658	chr4:99064831	C4orf37	0.54	6.45	0.38	6e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.5	7.07	0.41	1.58e-11	Mean corpuscular volume;
KIRP	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.74	-0.34	2.74e-8	Breast cancer;
KIRP	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12667521	chr19:29218732	NA	0.61	5.8	0.35	1.98e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-12.07	-0.61	1.15e-26	Exhaled nitric oxide output;
KIRP	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.4	-0.47	3.49e-15	Neuroticism;
KIRP	cis	rs831571	0.774	rs40610	chr3:64009508	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.56	-5.8	-0.35	2.04e-8	Type 2 diabetes;
KIRP	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26314531	chr2:26401878	FAM59B	-0.46	-4.94	-0.3	1.42e-6	Gut microbiome composition (summer);
KIRP	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg11608241	chr8:8085544	FLJ10661	-0.52	-6.72	-0.39	1.26e-10	Triglycerides;
KIRP	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.34	-0.47	5.29e-15	Total cholesterol levels;
KIRP	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg00076555	chr3:49705435	BSN	-0.29	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs13132184	0.507	rs12645411	chr4:38044516	T/C	cg14409701	chr4:38048871	TBC1D1	-0.78	-7.53	-0.43	9.55e-13	Verbal declarative memory;
KIRP	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg13147721	chr7:65941812	NA	-1.01	-7.0	-0.41	2.46e-11	Diabetic kidney disease;
KIRP	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-8.07	-0.46	3.17e-14	Menarche (age at onset);
KIRP	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.78	9.97	0.54	6.94e-20	Coronary artery disease;
KIRP	cis	rs7264396	1.000	rs6088881	chr20:34165609	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.39	4.95	0.3	1.35e-6	Total cholesterol levels;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg00738919	chr7:1100172	C7orf50	0.43	5.16	0.31	5.07e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs968451	0.619	rs2267407	chr22:39747050	G/A	cg24399712	chr22:39784796	NA	-0.44	-5.64	-0.34	4.6e-8	Primary biliary cholangitis;
KIRP	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.7	-0.34	3.46e-8	Fear of minor pain;
KIRP	trans	rs7493138	0.933	rs4127784	chr14:29007295	A/G	cg08496086	chr5:2176142	NA	-0.44	-6.05	-0.36	5.41e-9	Longevity;
KIRP	cis	rs3026101	0.671	rs28619210	chr17:5319053	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.46e-8	Body mass index;
KIRP	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg23594656	chr7:65796392	TPST1	-0.51	-8.04	-0.46	3.83e-14	Aortic root size;
KIRP	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.61	7.63	0.44	5.11e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13361707	0.920	rs3805495	chr5:40755568	C/T	cg01087697	chr5:40835557	RPL37	-0.5	-5.72	-0.34	3.1e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.45	-5.85	-0.35	1.6e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg14664628	chr15:75095509	CSK	0.47	5.87	0.35	1.42e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs13065560	0.533	rs4580488	chr3:38882438	G/T	cg01426195	chr3:39028469	NA	-0.37	-6.0	-0.36	6.86e-9	Interleukin-18 levels;
KIRP	cis	rs357618	1.000	rs165353	chr5:150856757	C/T	cg22672639	chr5:150884813	FAT2	0.35	5.33	0.32	2.21e-7	Basophil percentage of white cells;
KIRP	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.91	8.09	0.46	2.69e-14	Inflammatory bowel disease;
KIRP	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.43	-5.63	-0.34	4.96e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg20744362	chr22:50050164	C22orf34	0.33	5.05	0.31	8.42e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4919044	0.808	rs4917898	chr10:94808637	T/A	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs3857747	0.578	rs6462976	chr7:40396300	C/T	cg00420559	chr7:40367873	C7orf10	0.44	6.35	0.38	1.01e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	0.94	7.22	0.42	6.29e-12	Obesity-related traits;
KIRP	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	cg21523751	chr1:182988639	NA	0.44	6.71	0.39	1.3e-10	Hypertriglyceridemia;
KIRP	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.78	-13.16	-0.64	2.62e-30	Calcium levels;
KIRP	cis	rs258892	0.895	rs266430	chr5:72125176	A/G	cg21869765	chr5:72125136	TNPO1	-0.61	-6.95	-0.41	3.19e-11	Small cell lung carcinoma;
KIRP	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg04226714	chr8:49833948	SNAI2	-0.55	-7.44	-0.43	1.64e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.52	6.85	0.4	5.91e-11	Primary sclerosing cholangitis;
KIRP	cis	rs860295	0.775	rs1749410	chr1:155844065	G/A	cg02153340	chr1:155202674	NA	0.37	4.85	0.3	2.15e-6	Body mass index;
KIRP	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg14703610	chr5:56206110	C5orf35	-0.49	-6.65	-0.39	1.89e-10	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.79	-9.84	-0.53	1.74e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg21546286	chr11:48923668	NA	-0.45	-5.52	-0.33	8.56e-8	HDL cholesterol;
KIRP	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg13173536	chr2:3403300	TTC15	-0.36	-4.9	-0.3	1.77e-6	Obesity-related traits;
KIRP	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg00576331	chr11:65640516	EFEMP2	0.58	7.88	0.45	1.04e-13	DNA methylation (variation);
KIRP	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg15934090	chr1:100435551	SLC35A3	-0.49	-6.04	-0.36	5.53e-9	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs259842	0.663	rs10169684	chr2:180729601	T/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.43	-6.03	-0.36	6.11e-9	Blood protein levels;
KIRP	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg23625390	chr15:77176239	SCAPER	-0.57	-6.52	-0.38	3.87e-10	Blood metabolite levels;
KIRP	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg10047753	chr17:41438598	NA	1.14	18.05	0.75	5.9e-47	Menopause (age at onset);
KIRP	cis	rs2591576	0.874	rs1823012	chr5:165414905	A/G	cg13976338	chr5:165423657	NA	-0.76	-11.34	-0.59	2.93e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg02551604	chr5:131831745	NA	-0.46	-5.34	-0.32	2.11e-7	Asthma (sex interaction);
KIRP	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.74	8.01	0.45	4.73e-14	Uric acid levels;
KIRP	cis	rs3850699	0.683	rs67646802	chr10:104303748	C/T	cg04362960	chr10:104952993	NT5C2	0.47	5.01	0.3	1.06e-6	Prostate cancer;
KIRP	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg16329650	chr2:213403929	ERBB4	0.43	5.91	0.35	1.11e-8	Symmetrical dimethylarginine levels;
KIRP	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.5	-6.41	-0.38	7.29e-10	Coronary artery disease;
KIRP	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg13978929	chr19:21580086	ZNF493	-0.52	-5.1	-0.31	6.94e-7	Pain;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14853946	chr4:6883863	KIAA0232	-0.45	-6.2	-0.37	2.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-9.42	-0.51	3.51e-18	Hemoglobin concentration;
KIRP	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	5.06	0.31	8.16e-7	Breast cancer;
KIRP	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.88	9.81	0.53	2.18e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs2901656	0.967	rs4916186	chr1:172396020	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.42	5.33	0.32	2.27e-7	Red cell distribution width;Platelet distribution width;
KIRP	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.54	0.48	1.45e-15	Motion sickness;
KIRP	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg08975724	chr8:8085496	FLJ10661	-0.61	-7.62	-0.44	5.52e-13	Neuroticism;
KIRP	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg00576331	chr11:65640516	EFEMP2	0.51	5.65	0.34	4.46e-8	Crohn's disease;
KIRP	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-1.07	-7.18	-0.42	8.42e-12	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs16828019	0.777	rs35080169	chr1:41454959	G/A	cg24596898	chr1:41849189	NA	0.64	4.89	0.3	1.85e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.65	7.21	0.42	6.7e-12	Alzheimer's disease (late onset);
KIRP	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg05754148	chr16:3507555	NAT15	0.49	4.95	0.3	1.4e-6	Tuberculosis;
KIRP	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg07741184	chr6:167504864	NA	-0.24	-6.4	-0.38	7.85e-10	Crohn's disease;
KIRP	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg01557791	chr16:72042693	DHODH	-0.4	-4.97	-0.3	1.23e-6	Fibrinogen levels;
KIRP	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.03	-0.5	4.96e-17	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.62	8.16	0.46	1.74e-14	Motion sickness;
KIRP	cis	rs7539542	0.556	rs1042990	chr1:202861566	C/T	cg08940984	chr1:202857613	RABIF	-0.49	-6.0	-0.36	6.83e-9	Mean platelet volume;
KIRP	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.79	9.55	0.52	1.34e-18	Corneal astigmatism;
KIRP	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.58	-7.81	-0.45	1.65e-13	Pulse pressure;
KIRP	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.88	-10.41	-0.55	2.81e-21	Gut microbiome composition (summer);
KIRP	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.57	-6.7	-0.39	1.37e-10	Coronary artery disease;
KIRP	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.75	0.49	3.44e-16	Motion sickness;
KIRP	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg12311346	chr5:56204834	C5orf35	-0.37	-5.21	-0.32	4.02e-7	Coronary artery disease;
KIRP	cis	rs6725041	0.547	rs61696052	chr2:213201295	G/C	cg20637307	chr2:213403960	ERBB4	-0.48	-6.05	-0.36	5.42e-9	QT interval (ambient particulate matter interaction);
KIRP	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.7	-8.42	-0.47	3.18e-15	Obesity-related traits;
KIRP	cis	rs10875746	0.669	rs11168510	chr12:48685555	A/G	cg24011408	chr12:48396354	COL2A1	-0.45	-5.03	-0.31	9.32e-7	Longevity (90 years and older);
KIRP	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg00666640	chr1:248458726	OR2T12	0.45	5.41	0.33	1.47e-7	Common traits (Other);
KIRP	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg00677455	chr12:58241039	CTDSP2	-0.47	-5.22	-0.32	3.84e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-1.15	-8.12	-0.46	2.22e-14	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.75	9.25	0.51	1.09e-17	Blood protein levels;
KIRP	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs10214930	0.752	rs2391448	chr7:27678185	C/T	cg22168087	chr7:27702803	HIBADH	0.5	4.87	0.3	1.98e-6	Hypospadias;
KIRP	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg06156847	chr2:113672199	IL1F7	0.46	6.15	0.37	3.07e-9	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	0.93	8.34	0.47	5.31e-15	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg13978929	chr19:21580086	ZNF493	0.49	4.86	0.3	2.06e-6	Pain;
KIRP	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.49e-20	Coffee consumption (cups per day);
KIRP	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.81	-0.4	7.47e-11	Mood instability;
KIRP	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.73	-9.84	-0.53	1.73e-19	Eye color traits;
KIRP	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg05805236	chr11:65401703	PCNXL3	-0.5	-6.53	-0.38	3.65e-10	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs4253772	0.872	rs41362646	chr22:46633505	G/A	cg00784671	chr22:46762841	CELSR1	-0.6	-6.1	-0.36	4.19e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg16989719	chr2:238392110	NA	-0.38	-5.0	-0.3	1.11e-6	Prostate cancer;
KIRP	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg11621586	chr10:70884670	VPS26A	1.15	14.86	0.69	4.51e-36	Left atrial antero-posterior diameter;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg11641102	chr8:27183873	PTK2B	0.45	5.89	0.35	1.28e-8	Neuroticism;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg10254082	chr7:997346	NA	0.47	4.99	0.3	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.93	-0.4	3.74e-11	Blood pressure;
KIRP	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13047869	chr3:10149882	C3orf24	0.57	5.4	0.33	1.6e-7	Alzheimer's disease;
KIRP	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.25	7.21	0.42	7.04e-12	Type 2 diabetes;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.87	-0.3	2.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26504248	chr17:62223554	SNORA76	0.5	6.6	0.39	2.46e-10	Survival in pancreatic cancer;
KIRP	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg07250515	chr12:56618133	OBFC2B	-0.62	-5.81	-0.35	1.97e-8	Psoriasis vulgaris;
KIRP	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.5	5.03	0.31	9.38e-7	Alzheimer's disease;
KIRP	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg22951263	chr5:87985283	NA	-0.48	-6.82	-0.4	6.97e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs2882667	0.858	rs7724108	chr5:138410922	A/G	cg04439458	chr5:138467593	SIL1	0.48	7.39	0.43	2.23e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12158471	chr5:63802106	RGS7BP	0.48	6.43	0.38	6.43e-10	Parkinson's disease;
KIRP	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg22654517	chr2:96458247	NA	0.34	4.99	0.3	1.13e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19988958	chr2:208576137	CCNYL1	0.46	6.3	0.37	1.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg02696790	chr15:75250997	RPP25	0.32	5.42	0.33	1.46e-7	Breast cancer;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg13724220	chr2:3383413	TTC15	-0.46	-6.28	-0.37	1.53e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs3092073	0.819	rs3848715	chr20:44564682	G/A	cg00125455	chr20:44574271	PCIF1	-0.34	-6.57	-0.39	2.94e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.13e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.63	6.61	0.39	2.3e-10	Gut microbiome composition (summer);
KIRP	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.41	7.98	0.45	5.44e-14	Height;
KIRP	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.48	-11.34	-0.59	2.93e-24	Diabetic kidney disease;
KIRP	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.75	9.11	0.5	3.01e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs17092148	0.945	rs17092080	chr20:33335657	A/G	cg16810054	chr20:33298113	TP53INP2	-0.45	-5.56	-0.33	6.88e-8	Neuroticism;
KIRP	cis	rs7712401	0.580	rs10076327	chr5:122367347	A/G	cg19412675	chr5:122181750	SNX24	0.55	5.91	0.35	1.14e-8	Mean platelet volume;
KIRP	cis	rs17321999	0.909	rs9967884	chr2:30488183	A/G	cg05247661	chr2:30472410	LBH	0.54	6.45	0.38	5.81e-10	Systemic lupus erythematosus;
KIRP	cis	rs7572644	0.699	rs13411592	chr2:28098724	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-5.37	-0.32	1.78e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12826209	chr6:26865740	GUSBL1	0.68	6.09	0.36	4.29e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.7	7.26	0.42	5.21e-12	Vitiligo;
KIRP	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg18279126	chr7:2041391	MAD1L1	0.5	5.21	0.32	4.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.44	5.54	0.33	7.57e-8	Mean platelet volume;
KIRP	cis	rs4262150	0.543	rs72795364	chr5:151918935	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.7	-0.49	4.89e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs4523957	0.583	rs9303251	chr17:2047214	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-12.52	-0.62	3.83e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.64	7.51	0.43	1.07e-12	Testicular germ cell tumor;
KIRP	cis	rs3755132	0.929	rs3770466	chr2:15758293	T/C	cg12888861	chr2:15731646	DDX1	0.42	5.45	0.33	1.19e-7	Wilms tumor;
KIRP	cis	rs427941	0.703	rs201449	chr7:101739054	A/G	cg06246474	chr7:101738831	CUX1	0.54	6.77	0.4	9.34e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs1712517	0.844	rs1163087	chr10:105043289	G/A	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.41e-9	Migraine;
KIRP	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.88	-0.49	1.4e-16	Resting heart rate;
KIRP	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.76	-9.71	-0.53	4.6e-19	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.56	-6.94	-0.4	3.37e-11	Arsenic metabolism;
KIRP	cis	rs8027181	0.839	rs4777532	chr15:73041767	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.61	0.44	5.98e-13	Triglyceride levels;
KIRP	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.7	9.16	0.5	2.13e-17	Blood metabolite levels;
KIRP	cis	rs73193808	0.639	rs2832241	chr21:30552036	A/G	cg03476357	chr21:30257390	N6AMT1	0.42	4.89	0.3	1.82e-6	Coronary artery disease;
KIRP	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.2	-0.46	1.38e-14	Retinal vascular caliber;
KIRP	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.43	-0.33	1.36e-7	Parkinson's disease;
KIRP	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02475777	chr4:1388615	CRIPAK	0.4	5.41	0.33	1.51e-7	Longevity;
KIRP	cis	rs7737355	0.853	rs1468453	chr5:130587459	A/C	cg25547332	chr5:131281432	NA	0.46	5.16	0.31	5.11e-7	Life satisfaction;
KIRP	cis	rs9937943	0.667	rs9938426	chr16:74523739	C/G	cg01733217	chr16:74700730	RFWD3	-0.55	-5.39	-0.32	1.67e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6783573	0.894	rs939408	chr3:46599079	C/A	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.33	-5.25	-0.32	3.32e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs16958440	1.000	rs16958440	chr18:44632884	C/G	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg03959625	chr15:84868606	LOC388152	0.49	5.81	0.35	1.88e-8	Schizophrenia;
KIRP	cis	rs2074977	0.500	rs10153493	chr19:3447745	C/T	cg08380311	chr19:3435252	NFIC	-0.45	-5.5	-0.33	9.49e-8	Height;
KIRP	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg11382394	chr1:2564504	MMEL1	-0.38	-4.96	-0.3	1.34e-6	Ulcerative colitis;
KIRP	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg24154853	chr7:158122151	PTPRN2	0.38	5.44	0.33	1.29e-7	Calcium levels;
KIRP	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg23625390	chr15:77176239	SCAPER	0.52	7.0	0.41	2.4e-11	Blood metabolite levels;
KIRP	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.01	-0.36	6.57e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3087591	0.683	rs4368212	chr17:29639263	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	9.6	0.52	9.69e-19	Hip circumference;
KIRP	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	5.05e-11	Aortic root size;
KIRP	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.42	5.41	0.33	1.47e-7	Aortic root size;
KIRP	cis	rs78545713	0.649	rs114015443	chr6:26221979	A/G	cg23601095	chr6:26197514	HIST1H3D	0.88	5.22	0.32	3.83e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.55	6.89	0.4	4.56e-11	Blood metabolite levels;
KIRP	cis	rs914615	0.552	rs4421576	chr1:155142210	A/G	cg02153340	chr1:155202674	NA	-0.48	-7.21	-0.42	6.92e-12	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs7712401	0.715	rs407392	chr5:122360994	C/T	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg14081859	chr6:56954773	ZNF451	-0.46	-6.16	-0.37	2.91e-9	Myopia;
KIRP	cis	rs6681460	0.671	rs628655	chr1:67213573	T/G	cg13052034	chr1:66999238	SGIP1	-0.42	-5.86	-0.35	1.46e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.4	6.08	0.36	4.46e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1050631	0.592	rs1785909	chr18:33731173	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.47	5.93	0.35	1.02e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.36	-4.97	-0.3	1.25e-6	Neuroticism;
KIRP	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.88	7.52	0.43	1.04e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg15848620	chr12:58087721	OS9	-0.47	-5.37	-0.32	1.81e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs11723261	0.664	rs4627799	chr4:132389	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.44	4.96	0.3	1.35e-6	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06481639	chr22:41940642	POLR3H	-0.62	-7.1	-0.41	1.35e-11	Vitiligo;
KIRP	cis	rs1010254	0.510	rs72806351	chr5:151681110	A/T	cg12297329	chr5:152029980	NA	-0.67	-6.71	-0.39	1.32e-10	Optic nerve measurement (cup area);
KIRP	cis	rs10267417	0.603	rs1557773	chr7:19908586	A/G	cg05791153	chr7:19748676	TWISTNB	-0.56	-5.49	-0.33	1.02e-7	Night sleep phenotypes;
KIRP	cis	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg00745463	chr17:30367425	LRRC37B	-0.98	-6.51	-0.38	4.19e-10	Height;
KIRP	cis	rs7943358	0.758	rs11023685	chr11:15709984	A/G	cg11966998	chr11:15692519	NA	-0.28	-5.78	-0.35	2.3e-8	Gut microbiome composition (summer);
KIRP	cis	rs873917	0.577	rs784612	chr1:40122939	T/C	cg18438793	chr1:40149837	HPCAL4	0.46	6.14	0.36	3.35e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg17279839	chr7:150038598	RARRES2	0.4	5.06	0.31	8.38e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg21775007	chr8:11205619	TDH	-0.53	-6.86	-0.4	5.43e-11	Neuroticism;
KIRP	cis	rs10499694	0.735	rs2044859	chr7:50612562	A/G	cg14593290	chr7:50529359	DDC	0.42	5.92	0.35	1.06e-8	Body mass index;
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg21698718	chr17:80085957	CCDC57	-0.34	-4.99	-0.3	1.12e-6	Life satisfaction;
KIRP	cis	rs9487051	0.714	rs6932503	chr6:109607958	G/A	cg01475377	chr6:109611718	NA	-0.43	-6.1	-0.36	4.05e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.73	10.21	0.55	1.23e-20	Plateletcrit;Platelet count;
KIRP	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.51	-5.0	-0.3	1.11e-6	Breast cancer;
KIRP	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs60871478	0.635	rs4725122	chr7:785318	A/G	cg13798912	chr7:905769	UNC84A	0.57	5.6	0.34	5.64e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg12405258	chr13:114927641	NA	0.47	6.75	0.4	1.03e-10	Schizophrenia;
KIRP	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	5.78	0.35	2.28e-8	Blood metabolite levels;
KIRP	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg14972814	chr11:95582409	MTMR2	0.28	4.88	0.3	1.95e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7011049	1.000	rs72640863	chr8:53841706	A/T	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.63	-6.77	-0.4	9.42e-11	Gut microbiome composition (summer);
KIRP	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-1.0	-15.61	-0.71	1.19e-38	Coronary artery disease;
KIRP	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.58	-7.12	-0.41	1.17e-11	Aortic root size;
KIRP	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.68	0.48	5.63e-16	Prudent dietary pattern;
KIRP	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-7.23	-0.42	6.22e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.5	-4.9	-0.3	1.78e-6	IFN-related cytopenia;
KIRP	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg11130432	chr3:121712080	ILDR1	0.45	5.47	0.33	1.11e-7	Multiple sclerosis;
KIRP	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.34e-10	Corneal astigmatism;
KIRP	cis	rs2457480	0.543	rs1482473	chr10:44707598	G/C	cg09554077	chr10:44749378	NA	0.53	7.29	0.42	4.2e-12	Coronary artery disease;
KIRP	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.56	7.33	0.42	3.4e-12	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs662064	0.962	rs1188525	chr1:10550877	A/G	cg19773385	chr1:10388646	KIF1B	0.41	5.46	0.33	1.16e-7	Asthma;
KIRP	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.65	0.39	1.85e-10	Electroencephalogram traits;
KIRP	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.82	7.28	0.42	4.36e-12	Prostate cancer;
KIRP	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg16141378	chr3:129829833	LOC729375	-0.5	-6.63	-0.39	2.06e-10	Retinal vascular caliber;
KIRP	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.41	5.25	0.32	3.24e-7	Aortic root size;
KIRP	cis	rs42648	0.564	rs11563947	chr7:89808764	C/T	cg25739043	chr7:89950458	NA	0.38	5.95	0.35	8.96e-9	Homocysteine levels;
KIRP	cis	rs9810890	1.000	rs73198816	chr3:128474440	C/T	cg15033153	chr3:128514015	RAB7A	0.69	4.92	0.3	1.58e-6	Dental caries;
KIRP	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.41	-0.38	7.19e-10	Uric acid levels;
KIRP	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.53	-6.08	-0.36	4.61e-9	Initial pursuit acceleration;
KIRP	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg00717180	chr2:96193071	NA	-0.5	-6.09	-0.36	4.31e-9	HDL cholesterol;
KIRP	cis	rs2594989	0.790	rs2443716	chr3:11523670	A/G	cg01796438	chr3:11312864	ATG7	-0.38	-5.06	-0.31	8.13e-7	Circulating chemerin levels;
KIRP	cis	rs1215050	0.791	rs548892	chr4:98724701	C/T	cg17366294	chr4:99064904	C4orf37	0.37	5.0	0.3	1.09e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.64	-9.66	-0.52	6.39e-19	Fibrinogen levels;
KIRP	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.69	10.51	0.56	1.39e-21	Height;
KIRP	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs6991838	0.584	rs10092109	chr8:66539918	C/T	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-7.24	-0.42	5.76e-12	Vitamin D levels;
KIRP	cis	rs11671005	0.735	rs3088284	chr19:58929427	G/A	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs10489525	0.502	rs12026930	chr1:115597836	G/A	cg01522456	chr1:115632236	TSPAN2	0.56	7.56	0.43	7.75e-13	Autism;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg06654118	chr4:1303317	MAEA	0.3	5.4	0.33	1.6e-7	Obesity-related traits;
KIRP	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	cg12689670	chr1:183009347	LAMC1	-0.46	-6.6	-0.39	2.47e-10	Colorectal cancer;
KIRP	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.85	14.23	0.67	6.15e-34	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.87	-0.4	5.18e-11	Bladder cancer;
KIRP	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21214613	chr1:16344536	HSPB7	0.35	4.98	0.3	1.2e-6	Dilated cardiomyopathy;
KIRP	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs10788264	0.504	rs4751887	chr10:124029758	G/A	cg09507567	chr10:124027408	NA	0.26	4.84	0.3	2.25e-6	Total body bone mineral density;
KIRP	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.95	18.19	0.76	2e-47	Dental caries;
KIRP	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg13264159	chr8:625131	ERICH1	-0.72	-6.08	-0.36	4.58e-9	IgG glycosylation;
KIRP	cis	rs2290402	0.536	rs3775127	chr4:886061	G/A	cg00846425	chr4:957561	DGKQ	-0.51	-5.3	-0.32	2.59e-7	Type 2 diabetes;
KIRP	cis	rs3752645	1.000	rs1004570	chr7:106745521	G/T	cg02696742	chr7:106810147	HBP1	-0.6	-5.14	-0.31	5.5e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg17595323	chr11:93583763	C11orf90	-0.32	-5.43	-0.33	1.33e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	cg12689670	chr1:183009347	LAMC1	0.45	6.45	0.38	5.86e-10	Colorectal cancer;
KIRP	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.71	8.99	0.5	6.71e-17	Morning vs. evening chronotype;
KIRP	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg04369109	chr6:150039330	LATS1	-0.46	-5.68	-0.34	3.88e-8	Lung cancer;
KIRP	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg02462569	chr6:150064036	NUP43	-0.43	-6.56	-0.39	3.11e-10	Lung cancer;
KIRP	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-0.6	-8.16	-0.46	1.74e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs72730918	0.564	rs4775954	chr15:51873407	G/T	cg14296394	chr15:51910925	DMXL2	0.8	11.14	0.58	1.31e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.903	rs11168418	chr12:48515754	C/A	cg26205652	chr12:48591994	NA	0.76	10.29	0.55	6.86e-21	Longevity (90 years and older);
KIRP	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.41	-5.37	-0.32	1.79e-7	Menarche (age at onset);
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	8.92e-8	Life satisfaction;
KIRP	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-5.45	-0.33	1.21e-7	Testicular germ cell tumor;
KIRP	cis	rs11718455	0.585	rs17076170	chr3:43917946	C/T	cg21419209	chr3:44054225	NA	-0.67	-7.56	-0.43	7.9e-13	Coronary artery disease;
KIRP	trans	rs6601327	0.602	rs11249956	chr8:9658194	G/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.55	-0.39	3.37e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg08712631	chr7:1960676	MAD1L1	-0.42	-5.52	-0.33	8.5e-8	Neuroticism;
KIRP	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg00262122	chr8:11665843	FDFT1	-0.42	-5.2	-0.31	4.09e-7	Retinal vascular caliber;
KIRP	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.39	-9.3	-0.51	7.92e-18	Asthma (sex interaction);
KIRP	cis	rs9815354	0.812	rs10510729	chr3:41831998	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg13660082	chr14:53194042	PSMC6	-0.7	-7.9	-0.45	9.6e-14	Alzheimer's disease (late onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24266227	chr12:105507504	KIAA1033	-0.42	-6.3	-0.37	1.39e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg23543263	chr13:22245177	FGF9	-0.53	-6.4	-0.38	7.97e-10	Brain structure;
KIRP	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg03171003	chr2:111875934	NA	0.41	5.76	0.34	2.46e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.91	-0.4	4.19e-11	Obesity-related traits;
KIRP	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg01631408	chr1:248437212	OR2T33	-0.7	-9.45	-0.52	2.79e-18	Common traits (Other);
KIRP	cis	rs9488822	0.676	rs7774952	chr6:116380909	A/G	cg26893134	chr6:116381904	FRK	0.19	5.18	0.31	4.7e-7	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21888241	chr11:14541921	PSMA1	0.44	6.1	0.36	4.1e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.48	0.38	5.07e-10	Platelet count;
KIRP	cis	rs73200209	0.912	rs17498914	chr12:116675689	C/G	cg01776926	chr12:116560359	MED13L	-0.47	-5.61	-0.34	5.49e-8	Total body bone mineral density;
KIRP	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs787274	0.718	rs2185768	chr9:115462645	C/T	cg13803584	chr9:115635662	SNX30	0.58	7.18	0.42	8.24e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-0.84	-9.41	-0.51	3.71e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6838801	0.612	rs3733246	chr4:77536781	G/C	cg17476223	chr4:77663285	SHROOM3	0.4	5.78	0.35	2.3e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.4	-0.33	1.55e-7	Aortic root size;
KIRP	trans	rs2048656	0.561	rs12544371	chr8:9542071	T/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.75	-0.4	1.06e-10	Schizophrenia;
KIRP	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-5.36	-0.32	1.89e-7	Triglycerides;
KIRP	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.29	-0.32	2.69e-7	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg07701084	chr6:150067640	NUP43	0.71	9.57	0.52	1.16e-18	Lung cancer;
KIRP	cis	rs7666738	0.546	rs13141117	chr4:98892798	G/A	cg05340658	chr4:99064831	C4orf37	0.66	7.74	0.44	2.64e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.48	-6.19	-0.37	2.57e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.95	0.57	5.62e-23	Cognitive test performance;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg14430582	chr20:42295543	MYBL2	0.44	6.19	0.37	2.53e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.59	7.22	0.42	6.51e-12	Blood metabolite levels;
KIRP	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg22681709	chr2:178499509	PDE11A	0.5	6.07	0.36	4.72e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.52	-6.29	-0.37	1.41e-9	Corneal curvature;
KIRP	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.23	-24.36	-0.84	1.7e-67	Exhaled nitric oxide output;
KIRP	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.49	6.08	0.36	4.53e-9	Mean platelet volume;
KIRP	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7660760	0.763	rs10025889	chr4:177500004	G/T	cg11970806	chr17:56066485	VEZF1	-0.4	-6.14	-0.36	3.3e-9	Left ventricle wall thickness;
KIRP	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21545522	chr1:205238299	TMCC2	0.46	6.39	0.38	8.34e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg04733911	chr16:78082701	NA	-0.45	-5.07	-0.31	7.72e-7	Systolic blood pressure (alcohol consumption interaction);
KIRP	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg01879757	chr17:41196368	BRCA1	-0.73	-10.38	-0.55	3.69e-21	Menopause (age at onset);
KIRP	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.58	7.41	0.43	2.02e-12	Aortic root size;
KIRP	cis	rs62344088	1.000	rs6880143	chr5:137516	C/T	cg22857025	chr5:266934	NA	-0.64	-4.9	-0.3	1.71e-6	Asthma (childhood onset);
KIRP	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg23340505	chr13:114927933	NA	0.32	4.95	0.3	1.37e-6	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.61	5.45	0.33	1.22e-7	Alzheimer's disease;
KIRP	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.46	-5.68	-0.34	3.8e-8	Asthma (sex interaction);
KIRP	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.93	13.65	0.66	5.78e-32	Bladder cancer;
KIRP	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.83	-12.2	-0.61	4.35e-27	Diastolic blood pressure;
KIRP	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg08885076	chr2:99613938	TSGA10	0.53	9.26	0.51	1.02e-17	Chronic sinus infection;
KIRP	cis	rs12681366	0.708	rs13280849	chr8:95396959	C/A	cg13257157	chr8:95487014	RAD54B	0.4	4.93	0.3	1.52e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg06392426	chr19:10676186	KRI1	-0.39	-5.26	-0.32	3.18e-7	Red cell distribution width;
KIRP	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg10189774	chr4:17578691	LAP3	0.47	5.5	0.33	9.48e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-1.01	-19.06	-0.77	2.35e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs7106204	0.764	rs79362440	chr11:24212972	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	8.04	0.46	3.79e-14	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs981844	1.000	rs62325083	chr4:154661775	T/C	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.27e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.95	-16.7	-0.73	2.25e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-8.95	-0.5	9.1e-17	Platelet count;
KIRP	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.69	6.95	0.41	3.26e-11	Vitiligo;
KIRP	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.81	11.4	0.59	1.89e-24	Glomerular filtration rate (creatinine);
KIRP	cis	rs6545883	0.831	rs1186704	chr2:61672991	A/G	cg15711740	chr2:61764176	XPO1	-0.6	-7.97	-0.45	5.9e-14	Tuberculosis;
KIRP	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg25019033	chr10:957182	NA	-0.63	-6.55	-0.39	3.4e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.48	5.75	0.34	2.57e-8	Menopause (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16893488	chr8:71154701	NCOA2	-0.39	-6.13	-0.36	3.53e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg20673091	chr1:2541236	MMEL1	-0.69	-10.69	-0.56	3.7e-22	Ulcerative colitis;
KIRP	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	6.51	0.38	4.26e-10	Initial pursuit acceleration;
KIRP	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.87	0.35	1.41e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.59	11.3	0.58	4.09e-24	Bone mineral density;
KIRP	cis	rs9443189	0.763	rs2647411	chr6:76433692	C/T	cg01950844	chr6:76311363	SENP6	-0.53	-5.57	-0.33	6.56e-8	Prostate cancer;
KIRP	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.12	-0.46	2.3e-14	Systolic blood pressure;
KIRP	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21643547	chr1:205240462	TMCC2	-0.88	-14.11	-0.67	1.62e-33	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg03060546	chr3:49711283	APEH	-0.64	-6.08	-0.36	4.47e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg25007680	chr1:8021821	PARK7	0.66	9.19	0.51	1.68e-17	Response to antidepressants and depression;
KIRP	cis	rs1805008	0.535	rs7196459	chr16:90141477	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.01	-7.46	-0.43	1.44e-12	Skin colour saturation;
KIRP	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.75	-9.65	-0.52	7.02e-19	Pancreatic cancer;
KIRP	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.26	-0.51	1.02e-17	Personality dimensions;
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.72	-10.76	-0.57	2.15e-22	Monocyte percentage of white cells;
KIRP	cis	rs1448094	0.817	rs61929421	chr12:86342330	T/C	cg06740227	chr12:86229804	RASSF9	0.44	5.57	0.33	6.82e-8	Major depressive disorder;
KIRP	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg07636037	chr3:49044803	WDR6	0.72	8.2	0.46	1.37e-14	Menarche (age at onset);
KIRP	cis	rs1079204	1.000	rs7600989	chr2:219119134	G/T	cg05728596	chr2:219128475	GPBAR1	0.86	6.91	0.4	4.14e-11	Smooth-surface caries;
KIRP	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg22778903	chr21:42741698	MX2	0.6	7.94	0.45	7.08e-14	Melanoma;
KIRP	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-9.34	-0.51	5.87e-18	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	0.59	5.64	0.34	4.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2882667	0.858	rs11744972	chr5:138428789	A/G	cg04439458	chr5:138467593	SIL1	-0.5	-7.44	-0.43	1.67e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17252645	chr8:143867129	LY6D	-0.54	-9.82	-0.53	2.07e-19	Urinary tract infection frequency;
KIRP	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.63	7.33	0.42	3.29e-12	Obesity-related traits;
KIRP	cis	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg27411982	chr8:10470053	RP1L1	0.44	5.61	0.34	5.33e-8	Schizophrenia;
KIRP	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.19	16.78	0.73	1.19e-42	Lymphocyte percentage of white cells;
KIRP	cis	rs1823913	0.599	rs13035132	chr2:192130001	C/T	cg12404831	chr2:192114017	MYO1B	0.51	7.1	0.41	1.31e-11	Obesity-related traits;
KIRP	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg00792783	chr2:198669748	PLCL1	0.44	4.95	0.3	1.4e-6	Dermatomyositis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16895254	chr4:26322328	RBPJ	-0.49	-6.22	-0.37	2.15e-9	Interleukin-4 levels;
KIRP	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg13482628	chr17:19912719	NA	0.61	8.69	0.48	5.18e-16	Schizophrenia;
KIRP	cis	rs7113850	0.541	rs74832028	chr11:24232359	A/T	ch.11.24196551F	chr11:24239977	NA	0.9	8.34	0.47	5.17e-15	Bone fracture in osteoporosis;
KIRP	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg02475777	chr4:1388615	CRIPAK	0.38	5.08	0.31	7.41e-7	Obesity-related traits;
KIRP	cis	rs1978968	0.956	rs7291155	chr22:18444599	C/T	cg03078520	chr22:18463400	MICAL3	-0.65	-7.76	-0.44	2.25e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.31	-0.32	2.51e-7	Aortic root size;
KIRP	cis	rs2862064	0.929	rs4704837	chr5:156464212	T/G	cg12943317	chr5:156479607	HAVCR1	-0.91	-8.08	-0.46	2.9e-14	Platelet count;
KIRP	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg24375607	chr4:120327624	NA	-0.46	-4.97	-0.3	1.23e-6	Corneal astigmatism;
KIRP	cis	rs6832769	1.000	rs4580704	chr4:56326707	C/G	cg05960024	chr4:56376020	CLOCK	-0.73	-9.39	-0.51	4.27e-18	Personality dimensions;
KIRP	cis	rs7523050	0.908	rs17621644	chr1:109399023	C/T	cg08274380	chr1:109419600	GPSM2	0.7	6.49	0.38	4.65e-10	Fat distribution (HIV);
KIRP	cis	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg21546286	chr11:48923668	NA	0.44	5.44	0.33	1.31e-7	HDL cholesterol;
KIRP	cis	rs2235573	0.662	rs738442	chr22:38457329	T/C	cg19171272	chr22:38449367	NA	-0.68	-9.65	-0.52	6.83e-19	Glioblastoma;Glioma;
KIRP	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg25600027	chr14:23388339	RBM23	-0.52	-6.42	-0.38	6.88e-10	Cognitive ability (multi-trait analysis);
KIRP	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg03388025	chr16:89894329	SPIRE2	0.44	9.1	0.5	3.27e-17	Vitiligo;
KIRP	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.78	6.83	0.4	6.6e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs4349753	0.904	rs1981611	chr5:144190386	T/A	cg16033277	chr17:80885358	TBCD	0.41	6.28	0.37	1.49e-9	Photic sneeze reflex;
KIRP	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.81	-11.61	-0.59	4.02e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12315302	chr6:26189340	HIST1H4D	0.65	5.08	0.31	7.55e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10924970	0.934	rs3856241	chr1:235429692	G/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.49	-0.33	1.01e-7	HDL cholesterol;
KIRP	cis	rs12282928	1.000	rs10769344	chr11:48333823	G/A	cg26585981	chr11:48327164	OR4S1	0.52	6.28	0.37	1.54e-9	Migraine - clinic-based;
KIRP	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.76	-10.82	-0.57	1.38e-22	Asthma;
KIRP	cis	rs2882667	0.858	rs11957527	chr5:138404895	T/C	cg04439458	chr5:138467593	SIL1	-0.51	-7.7	-0.44	3.4e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg06521331	chr12:34319734	NA	-0.52	-6.55	-0.39	3.3e-10	Heart rate;
KIRP	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.22	14.16	0.67	1.12e-33	Eosinophil percentage of granulocytes;
KIRP	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.5	6.23	0.37	1.97e-9	Resting heart rate;
KIRP	cis	rs35740288	0.857	rs11630274	chr15:86288387	C/T	cg17133734	chr15:86042851	AKAP13	-0.53	-5.77	-0.35	2.39e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19757253	chr2:32853039	TTC27	0.49	6.57	0.39	2.92e-10	Survival in pancreatic cancer;
KIRP	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	1.06	19.32	0.78	3.05e-51	Height;
KIRP	cis	rs35740288	0.822	rs4843092	chr15:86233180	G/A	cg10818794	chr15:86012489	AKAP13	-0.42	-4.92	-0.3	1.57e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg00204512	chr16:28754710	NA	0.4	5.17	0.31	4.94e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.66	7.65	0.44	4.52e-13	Pulmonary function decline;
KIRP	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.57	7.84	0.45	1.4e-13	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06856480	chr19:34850338	NA	0.52	6.63	0.39	2.11e-10	Parkinson's disease;
KIRP	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.07	12.26	0.62	2.69e-27	Uric acid levels;
KIRP	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg06740227	chr12:86229804	RASSF9	0.43	5.48	0.33	1.07e-7	Major depressive disorder;
KIRP	cis	rs300890	0.513	rs72719163	chr4:144051952	T/C	cg01719995	chr4:144104893	USP38	-0.43	-5.57	-0.33	6.75e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs9826463	0.582	rs56370391	chr3:142084647	A/G	cg20824294	chr3:142316082	PLS1	0.41	6.06	0.36	4.95e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25371950	chr2:242786524	NA	0.45	6.35	0.38	1.01e-9	Parkinson's disease;
KIRP	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.61	0.34	5.33e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11179513	chr3:125314524	OSBPL11	0.55	6.74	0.39	1.12e-10	Parkinson's disease;
KIRP	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2905347	0.726	rs2905320	chr7:22704243	C/A	cg23521230	chr7:22704884	NA	0.44	5.54	0.33	7.81e-8	Major depression and alcohol dependence;
KIRP	cis	rs7011049	0.778	rs12375305	chr8:53869051	C/T	cg26025543	chr8:53854495	NA	0.67	6.98	0.41	2.66e-11	Systolic blood pressure;
KIRP	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	8.33	0.47	5.58e-15	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg01721255	chr8:58191610	C8orf71	0.71	5.93	0.35	1.01e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.97	-15.05	-0.69	1.02e-36	Height;
KIRP	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.31	-0.32	2.46e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.28	0.55	7.69e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.52	6.81	0.4	7.24e-11	Breast cancer;
KIRP	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19524238	chr7:2802976	GNA12	-0.37	-5.17	-0.31	4.74e-7	Height;
KIRP	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	1.07	20.34	0.79	1.28e-54	Heart rate;
KIRP	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.5	8.21	0.46	1.23e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00334798	chr11:72929553	P2RY2	-0.42	-6.57	-0.39	3.01e-10	Metabolic traits;
KIRP	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.13	-17.31	-0.74	1.89e-44	Height;
KIRP	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.27	-5.44	-0.33	1.28e-7	Menarche (age at onset);
KIRP	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg10755058	chr3:40428713	ENTPD3	0.34	4.86	0.3	2.1e-6	Renal cell carcinoma;
KIRP	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.46	-6.99	-0.41	2.58e-11	Educational attainment;
KIRP	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg09754948	chr16:28834200	ATXN2L	0.48	5.58	0.34	6.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg00405596	chr8:11794950	NA	-0.44	-5.81	-0.35	1.96e-8	Neuroticism;
KIRP	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg27170947	chr2:26402098	FAM59B	-0.62	-6.9	-0.4	4.49e-11	Gut microbiome composition (summer);
KIRP	cis	rs2718058	0.606	rs2722247	chr7:37869308	C/T	cg15028436	chr7:37888078	TXNDC3	-0.48	-5.16	-0.31	5.11e-7	Alzheimer's disease (late onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01923549	chr6:41774024	USP49	0.49	6.37	0.38	9.41e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	15.12	0.69	5.94e-37	Homoarginine levels;
KIRP	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	1.12	13.39	0.65	4.56e-31	Eosinophil percentage of granulocytes;
KIRP	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11645453	chr3:52864694	ITIH4	0.47	6.52	0.38	3.96e-10	Bipolar disorder;
KIRP	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg27494647	chr7:150038898	RARRES2	0.39	6.07	0.36	4.93e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.6	9.28	0.51	9.27e-18	Personality dimensions;
KIRP	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.75	9.43	0.52	3.22e-18	Coronary artery disease;
KIRP	cis	rs10465746	0.780	rs2389648	chr1:84403031	C/T	cg10977910	chr1:84465055	TTLL7	0.55	7.04	0.41	1.92e-11	Obesity-related traits;
KIRP	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.72	9.83	0.53	1.9e-19	Red blood cell count;
KIRP	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg02376097	chr19:46275166	DMPK	0.48	6.54	0.38	3.59e-10	Coronary artery disease;
KIRP	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg06223162	chr1:101003688	GPR88	-0.51	-10.41	-0.55	2.91e-21	Breast cancer;
KIRP	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.25	7.11	0.41	1.24e-11	Type 2 diabetes;
KIRP	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.51	-8.01	-0.45	4.51e-14	IgG glycosylation;
KIRP	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.99	10.02	0.54	4.92e-20	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4132509	1.000	rs4565696	chr1:243918083	C/T	cg21452805	chr1:244014465	NA	0.59	5.65	0.34	4.48e-8	RR interval (heart rate);
KIRP	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.44	6.49	0.38	4.68e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	cg12689670	chr1:183009347	LAMC1	0.45	6.35	0.38	1.01e-9	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07147063	chr16:67260764	TMEM208;LRRC29	0.48	6.55	0.39	3.31e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.58	-4.85	-0.3	2.17e-6	Gout;Renal underexcretion gout;
KIRP	cis	rs7224685	0.501	rs4790168	chr17:4022457	T/C	cg05562828	chr17:3906858	NA	-0.71	-13.58	-0.65	9.85e-32	Type 2 diabetes;
KIRP	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg21191810	chr6:118973309	C6orf204	-0.43	-5.04	-0.31	9.15e-7	Diastolic blood pressure;
KIRP	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.68	9.92	0.53	9.81e-20	Oral cavity cancer;
KIRP	cis	rs2224391	0.628	rs2753233	chr6:5250982	T/G	cg13962347	chr6:5174647	LYRM4	-0.72	-9.98	-0.54	6.29e-20	Height;
KIRP	cis	rs8177876	0.731	rs76093926	chr16:81112525	G/T	cg08591886	chr16:81111003	C16orf46	-0.72	-5.68	-0.34	3.84e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7534824	0.543	rs72734254	chr1:101382039	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.69	6.04	0.36	5.66e-9	Refractive astigmatism;
KIRP	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.89	9.12	0.5	2.67e-17	Methadone dose in opioid dependence;
KIRP	cis	rs9905704	0.813	rs304269	chr17:56802059	A/G	cg12560992	chr17:57184187	TRIM37	-0.58	-6.79	-0.4	8.57e-11	Testicular germ cell tumor;
KIRP	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg05315796	chr3:52349193	DNAH1	0.46	7.04	0.41	1.86e-11	Electroencephalogram traits;
KIRP	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.62	8.28	0.47	8.01e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg25486957	chr4:152246857	NA	-0.52	-5.63	-0.34	4.99e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.52	6.93	0.4	3.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs6601450	0.519	rs34906836	chr8:10288992	C/A	cg15556689	chr8:8085844	FLJ10661	0.48	6.23	0.37	2e-9	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs662064	0.748	rs2480777	chr1:10597551	C/T	cg19773385	chr1:10388646	KIF1B	-0.39	-5.11	-0.31	6.32e-7	Asthma;
KIRP	cis	rs137699	0.604	rs137702	chr22:39750158	T/C	cg05872129	chr22:39784769	NA	-0.54	-6.16	-0.37	2.87e-9	IgG glycosylation;
KIRP	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs7011049	1.000	rs6988927	chr8:53837496	T/C	cg26025543	chr8:53854495	NA	0.73	7.6	0.44	6.17e-13	Systolic blood pressure;
KIRP	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg04315214	chr1:2043799	PRKCZ	-0.38	-5.9	-0.35	1.18e-8	Height;
KIRP	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	9.09	0.5	3.44e-17	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg04317338	chr11:64019027	PLCB3	-0.4	-5.0	-0.3	1.09e-6	Platelet count;
KIRP	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.86	-13.02	-0.64	7.87e-30	Colorectal cancer;
KIRP	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.47	-0.38	5.19e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg12705353	chr12:122356852	WDR66	0.54	7.15	0.41	1.01e-11	Mean corpuscular volume;
KIRP	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg26811252	chr16:29126840	RRN3P2	0.66	8.69	0.48	5.03e-16	Menopause (age at onset);
KIRP	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.55	5.77	0.35	2.38e-8	Blood trace element (Zn levels);
KIRP	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13939156	chr17:80058883	NA	0.49	7.25	0.42	5.43e-12	Life satisfaction;
KIRP	cis	rs6466055	0.661	rs7808226	chr7:104916166	T/C	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg05552183	chr6:42928497	GNMT	0.71	11.1	0.58	1.78e-23	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg10755058	chr3:40428713	ENTPD3	0.4	5.77	0.35	2.4e-8	Renal cell carcinoma;
KIRP	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg16141378	chr3:129829833	LOC729375	-0.53	-6.6	-0.39	2.55e-10	Retinal vascular caliber;
KIRP	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg05729581	chr11:3078854	CARS	-0.49	-5.98	-0.36	7.94e-9	Longevity;
KIRP	cis	rs7709377	0.597	rs35941525	chr5:115464237	G/T	cg23108291	chr5:115420582	COMMD10	0.41	4.96	0.3	1.31e-6	Metabolite levels  (X-11787);
KIRP	cis	rs7852872	0.603	rs7465849	chr9:119254822	A/G	cg13792444	chr9:119245443	ASTN2	0.4	6.26	0.37	1.7e-9	Hippocampal volume;
KIRP	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	1.0	17.54	0.75	3.22e-45	Breast cancer;
KIRP	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.12	-0.41	1.22e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.27	-0.32	2.94e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8177179	0.570	rs4441652	chr3:133439450	A/G	cg24879335	chr3:133465180	TF	0.44	6.58	0.39	2.74e-10	Iron status biomarkers (transferrin levels);
KIRP	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.38	-0.62	1.13e-27	Exhaled nitric oxide output;
KIRP	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-1.0	-8.05	-0.46	3.49e-14	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13794888	chr15:75917792	SNUPN	0.6	7.28	0.42	4.36e-12	Smoking initiation;
KIRP	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg08847533	chr14:75593920	NEK9	0.52	6.21	0.37	2.3e-9	IgG glycosylation;
KIRP	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg06740227	chr12:86229804	RASSF9	-0.45	-5.44	-0.33	1.3e-7	Major depressive disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09976981	chr22:43564007	TTLL12	0.46	6.09	0.36	4.41e-9	Survival in pancreatic cancer;
KIRP	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.86	13.95	0.66	5.8e-33	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2273669	0.667	rs12214121	chr6:109322554	A/G	cg05315195	chr6:109294784	ARMC2	0.64	6.34	0.37	1.09e-9	Prostate cancer;
KIRP	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.66	0.34	4.17e-8	Skin colour saturation;
KIRP	cis	rs7903847	0.619	rs76094900	chr10:99158164	G/A	cg20016023	chr10:99160130	RRP12	-0.43	-5.82	-0.35	1.87e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.56	-15.24	-0.7	2.15e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg25838818	chr2:108905173	SULT1C2	-0.52	-7.6	-0.44	6.13e-13	Blood pressure;
KIRP	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.6	12.59	0.63	2.18e-28	Diabetic kidney disease;
KIRP	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.35	-7.15	-0.41	9.79e-12	Type 2 diabetes;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg26101402	chr2:200323147	SATB2	-0.43	-6.24	-0.37	1.91e-9	Serum protein levels (sST2);
KIRP	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg24315340	chr6:146058215	EPM2A	-0.43	-5.48	-0.33	1.03e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.99	-0.41	2.63e-11	Blood pressure;
KIRP	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.16	0.83	9.55e-64	Chronic sinus infection;
KIRP	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	10.6	0.56	6.96e-22	Personality dimensions;
KIRP	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg02996583	chr8:142237188	SLC45A4	0.43	5.11	0.31	6.53e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	0.71	7.2	0.42	7.15e-12	Gut microbiome composition (summer);
KIRP	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg05868516	chr6:26286170	HIST1H4H	0.39	5.01	0.3	1.05e-6	Educational attainment;
KIRP	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg08076091	chr2:203926405	NBEAL1	0.85	8.89	0.49	1.33e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23422044	chr7:1970798	MAD1L1	0.69	7.18	0.42	8.39e-12	Bipolar disorder;
KIRP	cis	rs4903604	0.581	rs4903606	chr14:78036935	A/G	cg18872420	chr14:78023429	SPTLC2	0.36	5.54	0.33	7.69e-8	Gut microbiome composition (winter);
KIRP	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg27494647	chr7:150038898	RARRES2	0.39	5.98	0.36	7.75e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.56	6.86	0.4	5.6e-11	Breast cancer;
KIRP	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg23894439	chr1:183413866	NA	0.42	5.52	0.33	8.5e-8	Systemic lupus erythematosus;
KIRP	trans	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg06521331	chr12:34319734	NA	-0.49	-6.2	-0.37	2.31e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.56	7.22	0.42	6.56e-12	Menarche (age at onset);
KIRP	cis	rs1018836	0.923	rs4495387	chr8:91650997	C/T	cg16814680	chr8:91681699	NA	-0.69	-8.23	-0.46	1.12e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3105593	0.575	rs3098174	chr15:50778853	C/T	cg05456662	chr15:50716270	USP8	0.46	6.0	0.36	6.98e-9	QT interval;
KIRP	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	11.16	0.58	1.15e-23	Personality dimensions;
KIRP	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.21	-0.42	6.86e-12	Glomerular filtration rate;
KIRP	cis	rs6545883	0.718	rs6715259	chr2:61851845	G/T	cg15711740	chr2:61764176	XPO1	-0.5	-6.65	-0.39	1.83e-10	Tuberculosis;
KIRP	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.67	-6.9	-0.4	4.28e-11	Body mass index;
KIRP	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg18164611	chr1:46958628	NA	-0.42	-5.21	-0.32	4.05e-7	Monobrow;
KIRP	cis	rs300890	0.513	rs72719159	chr4:144051096	C/G	cg01719995	chr4:144104893	USP38	-0.44	-5.72	-0.34	3.11e-8	Nasopharyngeal carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22559639	chr12:53895182	TARBP2	0.46	6.1	0.36	4.17e-9	Parkinson's disease;
KIRP	cis	rs12579753	0.719	rs11115060	chr12:82269624	C/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.22	-0.37	2.14e-9	Resting heart rate;
KIRP	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg02297831	chr4:17616191	MED28	-0.48	-5.86	-0.35	1.46e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg08126542	chr6:37504118	NA	-0.74	-10.19	-0.54	1.42e-20	Cognitive performance;
KIRP	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.88	-0.35	1.32e-8	Lung cancer;
KIRP	cis	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg06066596	chr15:83166174	LOC80154	-0.52	-5.91	-0.35	1.12e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg04804543	chr8:142233427	SLC45A4	-1.01	-17.53	-0.75	3.48e-45	Immature fraction of reticulocytes;
KIRP	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-6.03	-0.36	5.97e-9	Fear of minor pain;
KIRP	cis	rs687432	0.924	rs56055377	chr11:57705618	A/G	cg19752551	chr11:57585705	CTNND1	-0.7	-9.25	-0.51	1.14e-17	Parkinson's disease;
KIRP	cis	rs7015630	0.657	rs10094579	chr8:90849305	C/A	cg18493113	chr8:90847772	NA	-0.48	-5.06	-0.31	8.18e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg13206674	chr6:150067644	NUP43	0.57	8.23	0.46	1.1e-14	Lung cancer;
KIRP	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg06223162	chr1:101003688	GPR88	0.43	8.88	0.49	1.39e-16	Monocyte count;
KIRP	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.6	-5.98	-0.36	7.67e-9	Body mass index;
KIRP	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.56	-5.26	-0.32	3.17e-7	Hip geometry;
KIRP	cis	rs2281603	0.570	rs73265640	chr14:64949801	A/G	cg01860774	chr14:64969374	ZBTB25	0.34	5.41	0.33	1.46e-7	Lymphocyte counts;
KIRP	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.32e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35740288	0.688	rs12904047	chr15:86212866	A/G	cg17133734	chr15:86042851	AKAP13	-0.5	-5.5	-0.33	9.27e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9400467	0.506	rs78344470	chr6:111761783	G/A	cg15721981	chr6:111408429	SLC16A10	0.68	6.21	0.37	2.24e-9	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	10.41	0.55	2.92e-21	Smoking behavior;
KIRP	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg23791538	chr6:167370224	RNASET2	-0.44	-5.35	-0.32	2.01e-7	Primary biliary cholangitis;
KIRP	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg21747090	chr2:27597821	SNX17	-0.46	-6.02	-0.36	6.23e-9	Total body bone mineral density;
KIRP	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg03468072	chr12:39539422	NA	0.42	6.0	0.36	7.09e-9	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6973256	0.865	rs1133540	chr7:133346380	C/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.39	-0.38	8.28e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg27393277	chr4:177673704	VEGFC	0.43	6.94	0.4	3.47e-11	Migraine with aura;
KIRP	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.21	14.37	0.68	2.07e-34	Uric acid levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02249958	chr10:77160160	C10orf41;ZNF503	0.5	6.05	0.36	5.43e-9	Smoking initiation;
KIRP	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg21361702	chr7:150065534	REPIN1	0.52	5.69	0.34	3.65e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg13206674	chr6:150067644	NUP43	0.52	7.4	0.43	2.22e-12	Testicular germ cell tumor;
KIRP	cis	rs6088813	1.000	rs56306402	chr20:33937704	G/A	cg14752227	chr20:34000481	UQCC	-0.52	-6.91	-0.4	4.24e-11	Height;
KIRP	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg26681399	chr22:41777847	TEF	0.43	5.06	0.31	8.18e-7	Vitiligo;
KIRP	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.86	0.4	5.54e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.41	0.59	1.69e-24	Height;
KIRP	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs7084402	0.967	rs1658470	chr10:60292383	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.45	0.52	2.85e-18	Bladder cancer;
KIRP	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.61	7.48	0.43	1.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.41	-5.11	-0.31	6.42e-7	Personality dimensions;
KIRP	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-1.06	-10.16	-0.54	1.81e-20	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs921943	0.957	rs6859544	chr5:78310877	C/G	cg26802063	chr5:78281964	ARSB	0.5	6.32	0.37	1.2e-9	Blood and toenail selenium levels;Blood trace element (Se levels);
KIRP	cis	rs4233802	0.737	rs3924622	chr2:151156358	C/T	cg25300694	chr2:151184358	NA	0.8	5.48	0.33	1.05e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.21	0.32	3.94e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02972257	chr16:68554789	NA	-0.56	-5.93	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.81	-7.1	-0.41	1.29e-11	Body mass index;
KIRP	cis	rs1978968	1.000	rs28434757	chr22:18451554	G/A	cg03078520	chr22:18463400	MICAL3	-0.66	-7.67	-0.44	3.93e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs2733201	1.000	rs4923969	chr15:44308536	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-5.76	-0.34	2.49e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.59	0.48	9.94e-16	Personality dimensions;
KIRP	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg16141378	chr3:129829833	LOC729375	-0.59	-7.66	-0.44	4.34e-13	Mood instability;
KIRP	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.4	5.15	0.31	5.31e-7	IgG glycosylation;
KIRP	cis	rs867371	0.929	rs7173852	chr15:82461853	A/G	cg00614314	chr15:82944287	LOC80154	0.52	6.19	0.37	2.46e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.71	6.57	0.39	2.9e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg00149659	chr3:10157352	C3orf10	0.61	7.19	0.42	7.55e-12	Alzheimer's disease;
KIRP	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.57	-6.18	-0.37	2.62e-9	Initial pursuit acceleration;
KIRP	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs6580649	0.941	rs72644843	chr12:48465061	A/G	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22931738	chr3:128206823	GATA2	0.44	6.16	0.37	2.88e-9	Parkinson's disease;
KIRP	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg00277334	chr10:82204260	NA	-0.45	-5.14	-0.31	5.54e-7	Post bronchodilator FEV1;
KIRP	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.73	11.75	0.6	1.32e-25	Cancer;
KIRP	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg10761708	chr20:43804764	PI3	0.53	5.53	0.33	7.98e-8	Blood protein levels;
KIRP	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg26084005	chr2:241760190	KIF1A	-0.49	-6.99	-0.41	2.57e-11	Urinary metabolites;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21639988	chr17:79849450	ANAPC11;THOC4	-0.52	-6.33	-0.37	1.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.54	-6.39	-0.38	8.44e-10	Rheumatoid arthritis;
KIRP	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.45	-5.58	-0.34	6.35e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1858037	0.867	rs61226353	chr2:65590771	G/A	cg08085232	chr2:65598271	SPRED2	-0.52	-6.15	-0.37	3.06e-9	Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06045799	chr4:47465578	COMMD8	0.48	6.24	0.37	1.95e-9	Parkinson's disease;
KIRP	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.43	5.02	0.3	9.97e-7	Aortic root size;
KIRP	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.4	-0.33	1.6e-7	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25551362	chr22:36894069	FOXRED2	0.52	6.16	0.37	2.95e-9	Interleukin-4 levels;
KIRP	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg09873164	chr1:152488093	CRCT1	0.51	6.48	0.38	4.87e-10	Hair morphology;
KIRP	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg03289416	chr15:75166202	SCAMP2	-0.44	-6.19	-0.37	2.48e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	1.05	19.73	0.78	1.41e-52	Height;
KIRP	cis	rs6662572	1.000	rs1053941	chr1:46084383	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.48	5.47	0.33	1.13e-7	Blood protein levels;
KIRP	cis	rs73198271	1.000	rs11784958	chr8:8607781	C/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.8	-0.35	2.01e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.92	-0.4	3.97e-11	Type 2 diabetes;
KIRP	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.73	-0.49	4.05e-16	Retinal vascular caliber;
KIRP	cis	rs4595586	0.655	rs4142847	chr12:39395128	C/T	cg26384229	chr12:38710491	ALG10B	0.48	6.14	0.36	3.21e-9	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7084402	0.967	rs1619284	chr10:60302515	C/T	cg05938607	chr10:60274200	BICC1	-0.43	-10.27	-0.55	7.79e-21	Refractive error;
KIRP	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	0.97	10.58	0.56	8.13e-22	Blood protein levels;
KIRP	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.93	16.6	0.73	4.96e-42	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg22535103	chr8:58192502	C8orf71	-0.64	-5.05	-0.31	8.64e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7010267	0.642	rs11992136	chr8:120003727	C/G	cg01975934	chr8:119970761	NA	-0.42	-5.55	-0.33	7.26e-8	Total body bone mineral density (age 45-60);
KIRP	cis	rs290268	0.838	rs1319677	chr9:93565999	A/G	cg02608019	chr9:93564028	SYK	0.8	11.32	0.59	3.4e-24	Platelet count;
KIRP	cis	rs1847505	0.527	rs75961255	chr13:61471645	G/A	cg25164009	chr13:61490935	NA	0.55	5.88	0.35	1.3e-8	Polychlorinated biphenyl levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26378453	chr18:8706260	NA	0.54	6.81	0.4	7.24e-11	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.62	9.57	0.52	1.18e-18	Lung cancer;
KIRP	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg19507638	chr5:93509721	C5orf36	-0.55	-5.02	-0.3	1.02e-6	Diabetic retinopathy;
KIRP	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11718455	0.582	rs6763436	chr3:43913653	A/G	cg21419209	chr3:44054225	NA	0.69	8.03	0.46	4.08e-14	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.44	5.67	0.34	3.99e-8	Motion sickness;
KIRP	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-11.4	-0.59	1.92e-24	Colorectal cancer;
KIRP	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	8.16	0.46	1.72e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	1.02	14.82	0.69	5.98e-36	Menopause (age at onset);
KIRP	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-7.12	-0.41	1.17e-11	Monocyte count;
KIRP	cis	rs6841333	0.857	rs12649185	chr4:76956179	G/A	cg24176760	chr4:76958061	ART3;CXCL11	-0.44	-4.85	-0.3	2.22e-6	Monokine induced by gamma interferon levels;
KIRP	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.9	16.36	0.72	3.33e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg11494091	chr17:61959527	GH2	-0.69	-9.88	-0.53	1.37e-19	Prudent dietary pattern;
KIRP	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.24	-0.37	1.91e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9944715	0.954	rs1808946	chr18:43854860	A/G	cg01718231	chr17:29326311	RNF135	-0.51	-6.21	-0.37	2.22e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg01475377	chr6:109611718	NA	0.36	5.0	0.3	1.08e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg07636037	chr3:49044803	WDR6	0.56	5.3	0.32	2.59e-7	Menarche (age at onset);
KIRP	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.45	5.88	0.35	1.36e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9815354	1.000	rs9866092	chr3:41895967	A/C	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.73	-10.95	-0.57	5.56e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.61	7.98	0.45	5.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2380205	0.967	rs7894083	chr10:5893268	A/C	cg27141509	chr10:5886111	NA	-0.37	-5.33	-0.32	2.22e-7	Breast cancer;
KIRP	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.25e-10	Hypertriglyceridemia;
KIRP	cis	rs1190552	0.894	rs4906203	chr14:102928991	C/T	cg10241871	chr14:102965420	TECPR2	-0.5	-5.63	-0.34	4.93e-8	Blood protein levels;
KIRP	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg10189774	chr4:17578691	LAP3	0.49	5.64	0.34	4.64e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg12119029	chr16:89752879	CDK10	0.24	5.14	0.31	5.63e-7	Vitiligo;
KIRP	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg26811252	chr16:29126840	RRN3P2	0.66	8.88	0.49	1.4e-16	Menopause (age at onset);
KIRP	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg00343127	chr12:129299088	SLC15A4;MGC16384	-0.61	-8.06	-0.46	3.41e-14	Systemic lupus erythematosus;
KIRP	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs9921338	0.961	rs8060767	chr16:11370598	C/G	cg00044050	chr16:11439710	C16orf75	-0.48	-4.96	-0.3	1.33e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.01	-14.8	-0.69	7.27e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1144713	0.600	rs2683489	chr12:32251181	A/G	cg01321189	chr12:32259338	BICD1	0.38	6.09	0.36	4.42e-9	Obesity-related traits;
KIRP	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.51	6.21	0.37	2.19e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs11225247	0.881	rs12291114	chr11:102261549	G/A	cg06323957	chr11:102217781	BIRC2	0.9	5.5	0.33	9.74e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs1656402	1.000	rs1729251	chr2:233428518	G/A	cg03852847	chr2:233439513	NA	0.72	12.18	0.61	5.04e-27	Non-small cell lung cancer (survival);
KIRP	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg23034840	chr1:205782522	SLC41A1	0.59	6.65	0.39	1.88e-10	White blood cell types;
KIRP	cis	rs12580194	0.593	rs7485991	chr12:55789129	T/C	cg19537932	chr12:55886519	OR6C68	-0.52	-6.68	-0.39	1.55e-10	Cancer;
KIRP	cis	rs68170813	0.652	rs77056542	chr7:107089751	G/C	cg02696742	chr7:106810147	HBP1	-0.71	-6.56	-0.39	3.09e-10	Coronary artery disease;
KIRP	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23903597	chr17:61704154	MAP3K3	0.59	7.37	0.43	2.61e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22168489	chr12:122356033	WDR66	0.64	9.27	0.51	9.64e-18	Mean corpuscular volume;
KIRP	cis	rs10929159	0.928	rs6431419	chr2:236919669	C/A	cg20128773	chr2:236923534	AGAP1	0.3	5.23	0.32	3.57e-7	Parkinson's disease;
KIRP	cis	rs494562	0.892	rs544408	chr6:86119110	A/T	cg27039625	chr6:86159096	NT5E	0.44	5.81	0.35	1.9e-8	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7084402	1.000	rs1427201	chr10:60269755	G/T	cg05938607	chr10:60274200	BICC1	0.42	10.11	0.54	2.53e-20	Refractive error;
KIRP	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.51	6.22	0.37	2.07e-9	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-7.51	-0.43	1.09e-12	Coffee consumption (cups per day);
KIRP	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.71	9.18	0.51	1.86e-17	Corneal astigmatism;
KIRP	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14250130	chr10:3109361	PFKP	0.48	6.6	0.39	2.47e-10	Parkinson's disease;
KIRP	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.62	-0.48	8.21e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3540	0.960	rs8025842	chr15:90995471	C/T	cg10434728	chr15:90938212	IQGAP1	0.34	5.86	0.35	1.49e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs8133932	0.654	rs379501	chr21:47360784	T/C	cg11214348	chr21:47283868	PCBP3	-0.39	-5.02	-0.3	9.95e-7	Schizophrenia;
KIRP	cis	rs41005	1.000	rs41004	chr2:8111580	C/T	cg03155496	chr2:8117019	LOC339788	0.59	9.68	0.53	5.47e-19	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg09699651	chr6:150184138	LRP11	0.45	6.01	0.36	6.75e-9	Lung cancer;
KIRP	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg23752985	chr2:85803571	VAMP8	-0.61	-9.18	-0.51	1.78e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg21204522	chr6:27730016	NA	-0.75	-5.53	-0.33	7.99e-8	Breast cancer;
KIRP	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg08807101	chr21:30365312	RNF160	-0.64	-7.33	-0.42	3.39e-12	Cognitive test performance;
KIRP	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Body mass index;
KIRP	cis	rs490234	0.702	rs13285587	chr9:128233058	G/T	cg14078157	chr9:128172775	NA	-0.58	-6.82	-0.4	7.19e-11	Mean arterial pressure;
KIRP	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	9.98	0.54	6.55e-20	Blood protein levels;
KIRP	cis	rs10875746	0.903	rs3782911	chr12:48483492	T/G	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs10814247	0.648	rs10283768	chr9:35219714	C/A	cg15271616	chr9:35490515	RUSC2	-0.38	-5.42	-0.33	1.39e-7	Psoriasis;
KIRP	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.55	7.29	0.42	4.26e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg17986701	chr20:44574422	PCIF1	0.5	7.63	0.44	5.27e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs829661	0.793	rs12468064	chr2:30791695	G/A	cg10949345	chr2:30726833	LCLAT1	1.13	14.25	0.67	5.41e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	6.75	0.4	1.04e-10	Initial pursuit acceleration;
KIRP	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg19507638	chr5:93509721	C5orf36	-0.53	-5.01	-0.3	1.02e-6	Diabetic retinopathy;
KIRP	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg24747557	chr10:131355152	MGMT	-0.42	-5.61	-0.34	5.55e-8	Response to temozolomide;
KIRP	cis	rs507080	1.000	rs507080	chr11:118549582	G/A	cg04173919	chr11:118528438	PHLDB1	0.33	4.87	0.3	1.98e-6	Serum metabolite levels;
KIRP	cis	rs7601312	1.000	rs2194551	chr2:229308646	G/A	cg02542817	chr2:229291442	NA	-0.38	-5.66	-0.34	4.29e-8	Schizophrenia;
KIRP	cis	rs1322639	0.542	rs9689153	chr6:169586825	T/C	cg03254818	chr6:169586852	NA	-0.58	-6.38	-0.38	8.51e-10	Pulse pressure;
KIRP	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg02187348	chr16:89574699	SPG7	0.49	6.11	0.36	3.79e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.76	-9.79	-0.53	2.53e-19	Aortic root size;
KIRP	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.39	0.51	4.14e-18	Morning vs. evening chronotype;
KIRP	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-12.87	-0.63	2.47e-29	Vitiligo;
KIRP	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.48	-6.27	-0.37	1.57e-9	Body mass index;
KIRP	cis	rs7187994	0.848	rs12933308	chr16:84770973	A/G	cg07647771	chr16:84786436	USP10	-0.51	-6.1	-0.36	3.99e-9	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg21937377	chr3:194868750	C3orf21	0.24	5.06	0.31	8.04e-7	Non-small cell lung cancer;
KIRP	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06850241	chr22:41845214	NA	0.47	5.96	0.36	8.81e-9	Vitiligo;
KIRP	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.12	-0.46	2.2e-14	Cutaneous nevi;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.74	6.5	0.38	4.36e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg02151108	chr14:50098012	C14orf104	-0.45	-5.87	-0.35	1.4e-8	Carotid intima media thickness;
KIRP	cis	rs9400467	0.506	rs12199233	chr6:111592317	G/A	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg00629941	chr15:75287862	SCAMP5	-0.49	-5.18	-0.31	4.66e-7	Blood trace element (Zn levels);
KIRP	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-5.22	-0.32	3.82e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7017914	0.934	rs6992879	chr8:71699283	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.52	5.76	0.34	2.5e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.46	-5.6	-0.34	5.69e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Body mass index;
KIRP	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg08461772	chr7:95026248	PON3	0.41	6.0	0.36	7.12e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs3791406	0.500	rs11124180	chr2:240031909	C/G	cg14550559	chr2:240039617	HDAC4	-0.87	-9.3	-0.51	7.93e-18	Skin aging (microtopography measurement);
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg08132940	chr7:1081526	C7orf50	-0.7	-7.04	-0.41	1.91e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg24315340	chr6:146058215	EPM2A	0.43	5.49	0.33	1.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg15605315	chr1:45957053	TESK2	0.41	5.17	0.31	4.8e-7	High light scatter reticulocyte count;
KIRP	cis	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg19847130	chr8:10466454	RP1L1	-0.34	-5.36	-0.32	1.94e-7	Neuroticism;
KIRP	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.71	8.94	0.5	9.39e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg26876637	chr1:152193138	HRNR	0.72	9.74	0.53	3.6e-19	Atopic dermatitis;
KIRP	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.82	-13.17	-0.64	2.37e-30	Pulse pressure;
KIRP	trans	rs1973993	0.662	rs6593607	chr1:96968116	G/A	cg10631902	chr5:14652156	NA	-0.57	-8.16	-0.46	1.74e-14	Weight;
KIRP	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.59	-6.93	-0.4	3.64e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs6967385	0.560	rs10434998	chr7:12348375	C/T	cg06484146	chr7:12443880	VWDE	0.39	4.86	0.3	2.12e-6	Response to taxane treatment (placlitaxel);
KIRP	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg12756093	chr1:115239321	AMPD1	0.56	7.76	0.44	2.34e-13	Autism;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg07030052	chr1:162531143	UAP1	-0.44	-6.22	-0.37	2.13e-9	Morning vs. evening chronotype;
KIRP	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.4	-4.96	-0.3	1.32e-6	Neurofibrillary tangles;
KIRP	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg00647317	chr7:50633725	DDC	-0.41	-5.34	-0.32	2.08e-7	Malaria;
KIRP	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg23565292	chr14:50234668	KLHDC2	-0.42	-5.0	-0.3	1.07e-6	Carotid intima media thickness;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20701810	chr5:93411877	FAM172A	0.47	7.17	0.42	8.98e-12	Interleukin-4 levels;
KIRP	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg18825076	chr15:78729989	IREB2	-0.46	-5.37	-0.32	1.85e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	6.75	0.4	1.03e-10	Personality dimensions;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21872129	chr6:64281996	PTP4A1	0.55	6.36	0.38	9.51e-10	Smoking initiation;
KIRP	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.53e-10	Bipolar disorder;
KIRP	trans	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg19274270	chr17:78178856	CARD14	0.36	6.53	0.38	3.73e-10	Morning vs. evening chronotype;
KIRP	cis	rs3925075	1.000	rs3925075	chr16:31347748	C/T	cg02846316	chr16:31340340	ITGAM	-0.61	-9.73	-0.53	3.94e-19	IgA nephropathy;
KIRP	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg12435725	chr3:58293450	RPP14	-0.44	-5.09	-0.31	6.96e-7	Cholesterol, total;
KIRP	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg23803603	chr1:2058230	PRKCZ	-0.37	-5.41	-0.33	1.52e-7	Height;
KIRP	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.92	0.3	1.61e-6	Menopause (age at onset);
KIRP	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	7.06	0.41	1.73e-11	Rheumatoid arthritis;
KIRP	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg00405596	chr8:11794950	NA	0.44	5.48	0.33	1.05e-7	Retinal vascular caliber;
KIRP	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg05802129	chr4:122689817	NA	-0.46	-6.7	-0.39	1.39e-10	Type 2 diabetes;
KIRP	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg03808351	chr9:123631620	PHF19	-0.46	-6.37	-0.38	9.02e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.52	-0.33	8.69e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg11621586	chr10:70884670	VPS26A	1.23	16.95	0.73	3.27e-43	Left atrial antero-posterior diameter;
KIRP	cis	rs4262150	0.883	rs72802891	chr5:152255602	C/G	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.98e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9309473	0.950	rs6546847	chr2:73785358	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-5.18	-0.31	4.6e-7	Metabolite levels;
KIRP	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.73	-9.08	-0.5	3.76e-17	Urate levels in obese individuals;
KIRP	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.29	-5.72	-0.34	3.11e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg21918786	chr6:109611834	NA	-0.43	-6.26	-0.37	1.71e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.42	5.55	0.33	7.21e-8	Melanoma;
KIRP	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.63	7.44	0.43	1.73e-12	Obesity-related traits;
KIRP	cis	rs1712790	0.535	rs34268295	chr11:114607756	A/C	cg19465033	chr11:114479364	NA	0.44	5.31	0.32	2.44e-7	Urinary albumin excretion;
KIRP	cis	rs10267417	0.603	rs10271293	chr7:19932427	A/G	cg05791153	chr7:19748676	TWISTNB	0.51	4.85	0.3	2.22e-6	Night sleep phenotypes;
KIRP	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.3	-0.42	3.92e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs4660306	0.961	rs11211138	chr1:46015157	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.52	-6.42	-0.38	6.84e-10	Homocysteine levels;
KIRP	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.49	-5.32	-0.32	2.3e-7	Bipolar disorder;
KIRP	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.25	-0.32	3.36e-7	Parkinson's disease;
KIRP	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.48	-0.56	1.68e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23161317	chr6:28129485	ZNF389	-0.46	-5.41	-0.33	1.49e-7	Depression;
KIRP	cis	rs11605924	0.967	rs6485646	chr11:45865764	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.54	-6.8	-0.4	8.02e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.6	-6.74	-0.39	1.12e-10	Initial pursuit acceleration;
KIRP	cis	rs1656402	1.000	rs1071997	chr2:233425541	A/G	cg03852847	chr2:233439513	NA	0.69	11.29	0.58	4.43e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.65	9.54	0.52	1.51e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-0.6	-6.65	-0.39	1.83e-10	Initial pursuit acceleration;
KIRP	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.27	0.32	2.99e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.7e-13	Life satisfaction;
KIRP	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.85	-13.88	-0.66	9.5e-33	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg13010199	chr12:38710504	ALG10B	0.54	6.6	0.39	2.56e-10	Resting heart rate;
KIRP	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg18366169	chr5:1948875	NA	-0.44	-4.97	-0.3	1.24e-6	Gut microbiome composition (winter);
KIRP	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg05669848	chr5:237993	SDHA	-0.48	-5.04	-0.31	8.88e-7	Breast cancer;
KIRP	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg05082376	chr22:42548792	NA	0.46	5.84	0.35	1.62e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.24	-0.32	3.42e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs516946	0.545	rs890221	chr8:41481036	A/T	cg19441908	chr8:41529140	ANK1	0.37	5.04	0.31	8.83e-7	Type 2 diabetes;
KIRP	cis	rs698833	0.532	rs698810	chr2:44703171	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	5.63	0.34	4.86e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.58	-9.48	-0.52	2.3e-18	Lymphocyte counts;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg09263875	chr16:632152	PIGQ	0.76	12.99	0.64	9.69e-30	Height;
KIRP	cis	rs701145	0.537	rs1713815	chr3:153872445	T/C	cg10247383	chr3:153839028	SGEF	-0.6	-5.33	-0.32	2.2e-7	Coronary artery disease;
KIRP	cis	rs2073300	0.826	rs6083136	chr20:23454188	A/G	cg12062639	chr20:23401060	NAPB	0.71	6.66	0.39	1.78e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg26513180	chr16:89883248	FANCA	0.83	5.53	0.33	8.06e-8	Skin colour saturation;
KIRP	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.63	8.19	0.46	1.42e-14	Alcohol dependence;
KIRP	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg24315340	chr6:146058215	EPM2A	-0.45	-5.65	-0.34	4.35e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16746026	chr10:31273335	ZNF438	0.39	6.43	0.38	6.69e-10	C-reactive protein;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25287153	chr1:78408890	NEXN	-0.37	-6.1	-0.36	4.01e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg00277334	chr10:82204260	NA	-0.49	-5.7	-0.34	3.45e-8	Post bronchodilator FEV1;
KIRP	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	6.87	0.4	5.27e-11	Height;
KIRP	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.55	6.94	0.4	3.47e-11	Coronary artery disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10446143	chr21:44394730	PKNOX1	0.59	6.87	0.4	5.25e-11	Smoking initiation;
KIRP	cis	rs7527798	1.000	rs36001492	chr1:207841745	A/T	cg09232269	chr1:207846808	CR1L	-0.41	-4.87	-0.3	2.04e-6	Erythrocyte sedimentation rate;
KIRP	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg15445000	chr17:37608096	MED1	0.45	5.27	0.32	3.02e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg21926883	chr2:100939477	LONRF2	-0.55	-7.42	-0.43	1.95e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg08975724	chr8:8085496	FLJ10661	0.56	7.52	0.43	1.01e-12	Neuroticism;
KIRP	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.69	10.07	0.54	3.41e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg16141378	chr3:129829833	LOC729375	0.58	7.94	0.45	7.34e-14	Morning vs. evening chronotype;
KIRP	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.67	6.73	0.39	1.17e-10	Menarche (age at onset);
KIRP	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg21775007	chr8:11205619	TDH	0.46	6.43	0.38	6.68e-10	Neuroticism;
KIRP	cis	rs7561273	0.586	rs11892283	chr2:24317850	T/C	cg20701182	chr2:24300061	SF3B14	0.49	5.89	0.35	1.28e-8	Quantitative traits;
KIRP	cis	rs4774899	0.934	rs4774250	chr15:57487863	C/T	cg13626582	chr15:57592083	LOC283663	-0.21	-4.92	-0.3	1.59e-6	Urinary tract infection frequency;
KIRP	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	4.99	0.3	1.16e-6	Schizophrenia;
KIRP	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.93	-0.35	1.03e-8	Morning vs. evening chronotype;
KIRP	cis	rs858239	0.899	rs28635122	chr7:23310181	C/T	cg23682824	chr7:23144976	KLHL7	0.44	5.04	0.31	8.99e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.81	11.14	0.58	1.37e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7766436	0.885	rs6908600	chr6:22582002	C/T	cg13666174	chr6:22585274	NA	-0.44	-6.1	-0.36	4.02e-9	Coronary artery disease;
KIRP	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.95	0.45	6.92e-14	Coffee consumption (cups per day);
KIRP	cis	rs259842	0.640	rs6433811	chr2:180699380	T/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.46	-0.33	1.14e-7	Blood protein levels;
KIRP	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.8	10.24	0.55	1.02e-20	Breast cancer;
KIRP	cis	rs2644899	0.859	rs2644898	chr19:41299015	G/A	cg24958765	chr19:41283667	RAB4B	-0.55	-6.04	-0.36	5.77e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.37	5.2	0.31	4.22e-7	Body mass index;
KIRP	cis	rs2279817	0.818	rs867984	chr1:17982559	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-7.71	-0.44	3.11e-13	Neuroticism;
KIRP	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg26384229	chr12:38710491	ALG10B	0.63	8.56	0.48	1.21e-15	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.4	-5.74	-0.34	2.79e-8	Coronary artery disease;
KIRP	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg02002194	chr4:3960332	NA	-0.42	-6.18	-0.37	2.62e-9	Mood instability;
KIRP	cis	rs748404	0.578	rs2244746	chr15:43695083	T/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.41	5.08	0.31	7.47e-7	Lung cancer;
KIRP	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg04731861	chr2:219085781	ARPC2	-0.27	-6.88	-0.4	4.95e-11	Colorectal cancer;
KIRP	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg14650228	chr8:144573510	ZC3H3	-0.68	-4.88	-0.3	1.95e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-5.09	-0.31	7.17e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg00603274	chr11:61596626	FADS2	-0.62	-6.39	-0.38	8.46e-10	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg05973401	chr12:123451056	ABCB9	0.59	5.34	0.32	2.16e-7	Neutrophil percentage of white cells;
KIRP	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg26876637	chr1:152193138	HRNR	0.74	9.89	0.53	1.23e-19	Atopic dermatitis;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg23722778	chr6:46112967	ENPP4	0.39	6.29	0.37	1.42e-9	C-reactive protein;
KIRP	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.37e-10	Coronary artery disease;
KIRP	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg12756093	chr1:115239321	AMPD1	0.53	7.06	0.41	1.65e-11	Autism;
KIRP	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.93	14.39	0.68	1.75e-34	Sudden cardiac arrest;
KIRP	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.44	-5.36	-0.32	1.96e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg08975724	chr8:8085496	FLJ10661	-0.62	-8.0	-0.45	4.76e-14	Neuroticism;
KIRP	cis	rs6500395	0.584	rs1420698	chr16:48740708	C/G	cg04672837	chr16:48644449	N4BP1	0.43	5.24	0.32	3.49e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.49	-0.48	1.94e-15	Retinal vascular caliber;
KIRP	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg19383577	chr16:57279285	ARL2BP	0.47	6.06	0.36	4.97e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6832769	1.000	rs28514423	chr4:56429239	C/T	cg05960024	chr4:56376020	CLOCK	-0.62	-7.95	-0.45	6.61e-14	Personality dimensions;
KIRP	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg17182837	chr8:41585554	ANK1	-0.46	-6.36	-0.38	9.77e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs6499255	1.000	rs11644838	chr16:69812705	G/C	cg15192750	chr16:69999425	NA	0.46	4.86	0.3	2.1e-6	IgE levels;
KIRP	cis	rs7033996	1.000	rs16932798	chr9:35949558	T/C	cg00918944	chr9:35908117	LOC158376	0.38	5.29	0.32	2.76e-7	Urate levels (BMI interaction);
KIRP	cis	rs2916247	1.000	rs7844067	chr8:93026078	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.54	-0.48	1.44e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs5753037	0.869	rs41160	chr22:30407388	C/G	cg27665648	chr22:30112403	NA	-0.36	-5.02	-0.31	9.77e-7	Type 1 diabetes;
KIRP	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg08648136	chr8:956695	NA	0.43	6.63	0.39	2.12e-10	Schizophrenia;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg03510158	chr14:74318586	PTGR2	-0.45	-6.23	-0.37	1.97e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23281280	chr6:28129359	ZNF389	-0.46	-5.02	-0.3	1e-6	Depression;
KIRP	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg12315302	chr6:26189340	HIST1H4D	-1.05	-6.41	-0.38	7.21e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg07395648	chr5:131743802	NA	0.5	6.24	0.37	1.93e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs10875746	0.807	rs12313300	chr12:48470717	G/A	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.76	9.09	0.5	3.47e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg12435725	chr3:58293450	RPP14	-0.53	-5.4	-0.33	1.54e-7	Cholesterol, total;
KIRP	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.88	8.67	0.48	5.87e-16	Monocyte percentage of white cells;
KIRP	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.66	7.99	0.45	5.37e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2859741	0.608	rs534853	chr1:37474726	T/C	cg09363841	chr1:37513479	NA	-0.58	-9.12	-0.5	2.72e-17	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs6942756	0.713	rs692597	chr7:129132554	T/G	cg02491457	chr7:128862824	NA	-0.48	-5.42	-0.33	1.43e-7	White matter hyperintensity burden;
KIRP	cis	rs172166	0.637	rs1225595	chr6:28151340	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.8	-0.35	1.99e-8	Cardiac Troponin-T levels;
KIRP	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg00677455	chr12:58241039	CTDSP2	0.92	12.24	0.62	3.29e-27	Multiple sclerosis;
KIRP	cis	rs72772090	0.539	rs72773969	chr5:96145196	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.83	-7.12	-0.41	1.17e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9815354	1.000	rs2625668	chr3:41905930	T/C	cg03022575	chr3:42003672	ULK4	0.49	5.66	0.34	4.25e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs17401966	0.624	rs6696978	chr1:10209557	C/T	cg19773385	chr1:10388646	KIF1B	0.56	6.95	0.41	3.26e-11	Hepatocellular carcinoma;
KIRP	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg13319975	chr6:146136371	FBXO30	0.41	5.71	0.34	3.24e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.19	0.31	4.45e-7	Schizophrenia;
KIRP	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.56	7.37	0.43	2.52e-12	Coronary artery disease;
KIRP	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.55	-11.57	-0.59	5.23e-25	Diabetic kidney disease;
KIRP	cis	rs17286411	0.800	rs60740701	chr16:71875515	G/A	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.35	-0.32	1.97e-7	Blood protein levels;
KIRP	cis	rs6466055	0.777	rs3779210	chr7:104828098	C/T	cg04380332	chr7:105027541	SRPK2	-0.65	-9.81	-0.53	2.21e-19	Schizophrenia;
KIRP	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	0.8	7.83	0.45	1.5e-13	Prostate cancer;
KIRP	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.13	14.61	0.68	3.05e-35	Gut microbiome composition (summer);
KIRP	cis	rs40363	0.904	rs192228	chr16:3507949	G/T	cg05754148	chr16:3507555	NAT15	0.52	5.12	0.31	6.06e-7	Tuberculosis;
KIRP	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-5.43	-0.33	1.35e-7	Chronic sinus infection;
KIRP	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg13798912	chr7:905769	UNC84A	0.64	6.33	0.37	1.17e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg25182066	chr10:30743637	MAP3K8	-0.62	-7.54	-0.43	9.01e-13	Inflammatory bowel disease;
KIRP	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg21858823	chr1:15850916	CASP9	-0.55	-5.87	-0.35	1.4e-8	Systolic blood pressure;
KIRP	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.93	12.46	0.62	6.15e-28	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg24009623	chr19:33667908	NA	0.48	6.4	0.38	8.01e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.57	7.45	0.43	1.57e-12	Tuberculosis;
KIRP	cis	rs6433857	0.505	rs12471899	chr2:181369856	C/T	cg23363182	chr2:181467187	NA	-0.38	-5.19	-0.31	4.43e-7	Body mass index;
KIRP	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.58	7.31	0.42	3.74e-12	Resting heart rate;
KIRP	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.69	9.9	0.53	1.19e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9876781	0.559	rs7630053	chr3:48398586	G/A	cg11946769	chr3:48343235	NME6	0.42	5.2	0.31	4.17e-7	Longevity;
KIRP	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg17554472	chr22:41940697	POLR3H	0.43	5.2	0.31	4.14e-7	Vitiligo;
KIRP	cis	rs10073892	0.664	rs10072703	chr5:101878923	G/A	cg19774478	chr5:101632501	SLCO4C1	0.6	5.91	0.35	1.16e-8	Cognitive decline (age-related);
KIRP	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.57	6.62	0.39	2.29e-10	Life satisfaction;
KIRP	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07080220	chr10:102295463	HIF1AN	0.89	7.52	0.43	1.02e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg11130432	chr3:121712080	ILDR1	-0.48	-5.71	-0.34	3.23e-8	Multiple sclerosis;
KIRP	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.82	13.34	0.65	6.5e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.77	11.35	0.59	2.69e-24	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg19775406	chr17:5390252	MIS12;DERL2	0.44	6.02	0.36	6.17e-9	Ischemic stroke;
KIRP	cis	rs9659323	0.717	rs61806238	chr1:119536378	G/A	cg18261050	chr1:119551319	NA	0.45	6.11	0.36	3.85e-9	Body mass index;
KIRP	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg10792982	chr14:105748885	BRF1	-0.86	-13.82	-0.66	1.54e-32	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg08885076	chr2:99613938	TSGA10	0.59	10.26	0.55	8.36e-21	Chronic sinus infection;
KIRP	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg10818794	chr15:86012489	AKAP13	-0.51	-7.22	-0.42	6.59e-12	Interstitial lung disease;
KIRP	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg18404041	chr3:52824283	ITIH1	-0.57	-7.47	-0.43	1.42e-12	Bipolar disorder;
KIRP	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	1.02	21.25	0.8	1.34e-57	Multiple myeloma;
KIRP	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg00806126	chr19:22604979	ZNF98	-0.68	-6.86	-0.4	5.68e-11	Pain;
KIRP	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.48	7.44	0.43	1.69e-12	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg06204229	chr3:52865917	ITIH4	0.53	5.93	0.35	1.02e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.98	-0.45	5.55e-14	Neuroticism;
KIRP	cis	rs876084	0.630	rs2037344	chr8:121019737	C/T	cg22335954	chr8:121166405	COL14A1	-0.39	-4.97	-0.3	1.25e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs62056376	0.607	rs7213556	chr17:32592915	C/A	cg17635953	chr13:28535085	NA	0.59	6.04	0.36	5.81e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2172802	0.693	rs11131337	chr4:62491495	T/C	cg04118610	chr4:62707027	LPHN3	-0.52	-6.01	-0.36	6.72e-9	Partial epilepsies;
KIRP	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.64	7.95	0.45	6.66e-14	Body mass index;
KIRP	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg06637938	chr14:75390232	RPS6KL1	0.41	5.6	0.34	5.73e-8	Height;
KIRP	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg11518657	chr1:67396239	MIER1	0.61	6.01	0.36	6.56e-9	Lymphocyte percentage of white cells;
KIRP	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.71	8.42	0.47	3.05e-15	Obesity-related traits;
KIRP	cis	rs2671245	0.565	rs1955318	chr1:56133634	G/A	cg11523071	chr1:56160889	NA	0.39	5.53	0.33	8.02e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.27	5.31	0.32	2.42e-7	Coronary artery disease;
KIRP	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05472934	chr7:22766657	IL6	0.81	10.56	0.56	9.51e-22	Lung cancer;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg26109884	chr6:89347363	RNGTT	-0.46	-6.09	-0.36	4.2e-9	Select biomarker traits;
KIRP	cis	rs7221595	0.825	rs8081260	chr17:3981937	T/C	cg09695851	chr17:3907499	NA	0.59	5.86	0.35	1.52e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01140101	chr1:202113040	ARL8A	0.5	6.1	0.36	4.06e-9	Smoking initiation;
KIRP	cis	rs9905704	0.587	rs2003537	chr17:56611871	C/G	cg12560992	chr17:57184187	TRIM37	-0.56	-5.22	-0.32	3.72e-7	Testicular germ cell tumor;
KIRP	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.42	-4.98	-0.3	1.22e-6	Crohn's disease;
KIRP	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs75229567	0.618	rs10219700	chr12:70201730	A/G	cg10114359	chr12:70132523	RAB3IP	-0.54	-4.89	-0.3	1.82e-6	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs10865541	0.967	rs6755327	chr2:3397281	T/C	cg11642891	chr2:3452563	TTC15	-0.51	-6.54	-0.38	3.48e-10	Obesity-related traits;
KIRP	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg01988459	chr11:68622903	NA	-0.41	-5.57	-0.33	6.79e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.7	-8.89	-0.49	1.34e-16	Coronary artery disease;
KIRP	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.97	11.67	0.6	2.51e-25	Corneal astigmatism;
KIRP	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg14132834	chr19:41945861	ATP5SL	-0.59	-7.63	-0.44	5.21e-13	Height;
KIRP	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.42	4.86	0.3	2.06e-6	Renal function-related traits (BUN);
KIRP	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	6.96e-7	Alzheimer's disease;
KIRP	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg06050784	chr16:88016603	BANP	0.4	5.03	0.31	9.36e-7	Menopause (age at onset);
KIRP	cis	rs71597109	0.681	rs67330256	chr4:102721281	T/C	cg14855874	chr4:102712397	BANK1	0.41	5.43	0.33	1.34e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs6546886	0.871	rs12713810	chr2:74320262	C/G	cg14702570	chr2:74259524	NA	0.27	5.38	0.32	1.77e-7	Dialysis-related mortality;
KIRP	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg05072774	chr3:49840536	C3orf54	-0.41	-5.18	-0.31	4.53e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg16586182	chr3:47516702	SCAP	0.74	10.51	0.56	1.39e-21	Colorectal cancer;
KIRP	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.48	-6.09	-0.36	4.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.81	-8.73	-0.49	3.85e-16	Prostate cancer;
KIRP	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.74	10.7	0.56	3.4e-22	Oral cavity cancer;
KIRP	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.56	7.62	0.44	5.48e-13	Obesity-related traits;
KIRP	cis	rs17209837	1.000	rs60541816	chr7:87127861	G/A	cg00919237	chr7:87102261	ABCB4	-0.69	-6.68	-0.39	1.63e-10	Gallbladder cancer;
KIRP	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.62	8.38	0.47	4.15e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1978968	0.731	rs9605469	chr22:18461231	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.79	-11.2	-0.58	8.59e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.6	7.59	0.44	6.74e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.31	0.76	8.07e-48	Height;
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.73	-9.29	-0.51	8.51e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs526231	0.543	rs28025	chr5:102537379	A/G	cg23492399	chr5:102201601	PAM	-0.51	-5.61	-0.34	5.34e-8	Primary biliary cholangitis;
KIRP	cis	rs239198	0.602	rs9377240	chr6:101323752	C/T	cg09795085	chr6:101329169	ASCC3	0.49	5.79	0.35	2.16e-8	Menarche (age at onset);
KIRP	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.58	-7.14	-0.41	1.05e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2888674	1.000	rs1006581	chr7:150511923	A/G	cg05726600	chr7:150498594	TMEM176B;TMEM176A	-0.34	-5.51	-0.33	9.2e-8	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.9	9.23	0.51	1.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17453880	0.890	rs12522261	chr5:152054825	G/A	cg12297329	chr5:152029980	NA	-0.67	-9.95	-0.54	8.2e-20	Subjective well-being;
KIRP	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.23	-0.32	3.64e-7	Mean platelet volume;
KIRP	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.83	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.91	11.67	0.6	2.47e-25	Breast cancer;
KIRP	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.68	8.74	0.49	3.72e-16	Multiple sclerosis;
KIRP	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.54	-7.52	-0.43	1.05e-12	Motion sickness;
KIRP	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.48	-0.33	1.06e-7	Coronary artery disease;
KIRP	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-5.11	-0.31	6.62e-7	Total body bone mineral density;
KIRP	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg21475434	chr5:93447410	FAM172A	0.77	6.33	0.37	1.17e-9	Diabetic retinopathy;
KIRP	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-5.82	-0.35	1.81e-8	IgG glycosylation;
KIRP	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2274273	0.682	rs1201378	chr14:55493408	A/G	cg04306507	chr14:55594613	LGALS3	-0.43	-6.62	-0.39	2.23e-10	Protein biomarker;
KIRP	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.79	9.09	0.5	3.43e-17	Corneal astigmatism;
KIRP	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.66	-0.39	1.74e-10	Aortic root size;
KIRP	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg07701084	chr6:150067640	NUP43	0.55	7.07	0.41	1.58e-11	Lung cancer;
KIRP	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg23594656	chr7:65796392	TPST1	0.45	7.23	0.42	6.04e-12	Aortic root size;
KIRP	cis	rs9372498	0.536	rs62422220	chr6:118923731	G/A	cg21191810	chr6:118973309	C6orf204	-0.42	-4.86	-0.3	2.14e-6	Diastolic blood pressure;
KIRP	trans	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg06521331	chr12:34319734	NA	-0.54	-6.82	-0.4	7.05e-11	Bladder cancer;
KIRP	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.34	-5.77	-0.35	2.37e-8	Height;
KIRP	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.64	8.99	0.5	6.77e-17	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23413193	chr5:127420015	SLC12A2;FLJ33630	0.57	7.49	0.43	1.25e-12	Parkinson's disease;
KIRP	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.48	0.33	1.03e-7	Coronary artery disease;
KIRP	cis	rs8070740	0.838	rs1050461	chr17:5336210	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.56	6.48	0.38	5.04e-10	Menopause (age at onset);
KIRP	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg11859384	chr17:80120422	CCDC57	-0.42	-5.28	-0.32	2.8e-7	Life satisfaction;
KIRP	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg16586182	chr3:47516702	SCAP	0.69	9.3	0.51	7.72e-18	Colorectal cancer;
KIRP	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11987759	chr7:65425863	GUSB	0.46	5.37	0.32	1.84e-7	Aortic root size;
KIRP	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.56	5.88	0.35	1.3e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26314531	chr2:26401878	FAM59B	-0.48	-5.2	-0.31	4.17e-7	Gut microbiome composition (summer);
KIRP	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.81	11.42	0.59	1.62e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7129556	0.737	rs643388	chr11:77471042	C/T	cg12586386	chr11:77299805	AQP11	0.43	5.11	0.31	6.55e-7	Weight loss (gastric bypass surgery);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18512161	chr6:91296791	MAP3K7	0.57	7.23	0.42	6.06e-12	Parkinson's disease;
KIRP	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.68	6.8	0.4	8.04e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.83	8.9	0.49	1.22e-16	Alzheimer's disease;
KIRP	cis	rs13082711	0.911	rs77037289	chr3:27512971	C/T	cg02860705	chr3:27208620	NA	0.55	7.65	0.44	4.49e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg10047753	chr17:41438598	NA	1.14	18.13	0.76	3.22e-47	Menopause (age at onset);
KIRP	cis	rs78487399	0.808	rs6726917	chr2:43753913	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-4.95	-0.3	1.41e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg13165212	chr22:42675999	NA	0.28	5.04	0.31	9.16e-7	Cognitive function;
KIRP	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg24874828	chr4:187887005	NA	-0.51	-7.71	-0.44	3.05e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.6	-7.09	-0.41	1.39e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	8.95	0.5	8.59e-17	Colorectal cancer;
KIRP	cis	rs883565	0.654	rs6779880	chr3:39022926	G/T	cg01426195	chr3:39028469	NA	0.67	11.09	0.58	1.86e-23	Handedness;
KIRP	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.81	-11.34	-0.59	2.98e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.3	-0.32	2.6e-7	Life satisfaction;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00170564	chr12:107714106	BTBD11	0.61	7.34	0.42	3.02e-12	Smoking initiation;
KIRP	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg10150615	chr22:24372951	LOC391322	-0.55	-6.97	-0.41	2.89e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11671005	0.735	rs35652377	chr19:58929200	A/C	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.66	8.76	0.49	3.31e-16	Motion sickness;
KIRP	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg00204512	chr16:28754710	NA	0.4	5.25	0.32	3.22e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.81	-11.95	-0.61	2.95e-26	Asthma;
KIRP	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.9	13.1	0.64	4.33e-30	Chronic sinus infection;
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg02696790	chr15:75250997	RPP25	0.3	5.14	0.31	5.59e-7	Breast cancer;
KIRP	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg15655495	chr12:38532458	NA	-0.28	-4.99	-0.3	1.13e-6	Bladder cancer;
KIRP	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg03474202	chr17:45855739	NA	-0.52	-8.12	-0.46	2.29e-14	IgG glycosylation;
KIRP	cis	rs3789045	1.000	rs11588857	chr1:204587047	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.54	-5.42	-0.33	1.42e-7	Educational attainment (college completion);
KIRP	cis	rs2073300	1.000	rs6048810	chr20:23446429	G/A	cg12480562	chr20:23434244	CST11	0.6	5.99	0.36	7.24e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-4.92	-0.3	1.56e-6	Cervical cancer;
KIRP	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.18	-0.42	8.42e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.74	-6.9	-0.4	4.5e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.57	-7.11	-0.41	1.23e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7106204	0.534	rs76397001	chr11:24254188	A/C	ch.11.24196551F	chr11:24239977	NA	0.84	6.94	0.4	3.5e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg09253696	chr17:73873529	TRIM47	-0.34	-4.98	-0.3	1.18e-6	Psoriasis;
KIRP	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.93	0.35	1.01e-8	Mean platelet volume;
KIRP	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg12046867	chr14:103022105	NA	-0.51	-6.14	-0.36	3.26e-9	Platelet count;
KIRP	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg17757837	chr7:157058334	UBE3C	0.75	10.08	0.54	3.27e-20	Body mass index;
KIRP	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg01244601	chr4:120671846	NA	-0.4	-5.51	-0.33	8.86e-8	Corneal astigmatism;
KIRP	cis	rs3126085	0.935	rs3120661	chr1:152294402	A/G	cg26876637	chr1:152193138	HRNR	-0.68	-9.05	-0.5	4.37e-17	Atopic dermatitis;
KIRP	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.47e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg25866889	chr13:114914595	NA	-0.39	-5.35	-0.32	2.02e-7	Schizophrenia;
KIRP	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.71	-9.12	-0.5	2.79e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg23950597	chr19:37808831	NA	-0.64	-6.78	-0.4	8.94e-11	Coronary artery calcification;
KIRP	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.44	-6.04	-0.36	5.64e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg11189052	chr15:85197271	WDR73	0.55	5.22	0.32	3.82e-7	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13409248	chr3:40428643	ENTPD3	0.37	5.08	0.31	7.62e-7	Renal cell carcinoma;
KIRP	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.42	-5.03	-0.31	9.54e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1485395	1.000	rs7302357	chr12:53995538	C/T	cg16917193	chr12:54089295	NA	0.69	6.86	0.4	5.63e-11	Migraine without aura;
KIRP	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	1.04	14.62	0.68	2.91e-35	Menopause (age at onset);
KIRP	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	7.09	0.41	1.4e-11	Iron status biomarkers;
KIRP	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.85	8.74	0.49	3.72e-16	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7084402	0.935	rs1658492	chr10:60281267	C/T	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.84e-24	Refractive error;
KIRP	cis	rs580438	0.529	rs9825991	chr3:13433120	C/T	cg10657019	chr3:13328039	NA	-0.5	-6.39	-0.38	8.35e-10	Myringotomy;
KIRP	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.68	9.7	0.53	4.91e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg04369109	chr6:150039330	LATS1	-0.63	-7.9	-0.45	9.34e-14	Lung cancer;
KIRP	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.65	-10.0	-0.54	5.83e-20	Total body bone mineral density;
KIRP	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg24315340	chr6:146058215	EPM2A	0.41	5.14	0.31	5.58e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg14993813	chr1:46806288	NSUN4	-0.62	-7.24	-0.42	5.71e-12	Menopause (age at onset);
KIRP	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.44	-0.47	2.69e-15	Mood instability;
KIRP	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg11266682	chr4:10021025	SLC2A9	0.42	5.24	0.32	3.53e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.17	0.58	1.04e-23	Smoking behavior;
KIRP	cis	rs397969	0.646	rs403021	chr17:19806829	C/T	cg13482628	chr17:19912719	NA	0.49	5.98	0.36	8e-9	Platelet count;
KIRP	cis	rs6540559	0.673	rs17015330	chr1:210012795	T/G	cg22029157	chr1:209979665	IRF6	0.46	5.01	0.3	1.03e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs2120243	0.874	rs7616177	chr3:157153208	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.57	7.83	0.45	1.44e-13	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2718058	0.606	rs1349393	chr7:37869525	C/T	cg15028436	chr7:37888078	TXNDC3	0.47	5.22	0.32	3.73e-7	Alzheimer's disease (late onset);
KIRP	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg04539111	chr16:67997858	SLC12A4	-0.54	-5.32	-0.32	2.34e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.84	9.1	0.5	3.25e-17	Platelet count;
KIRP	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg09754948	chr16:28834200	ATXN2L	0.46	5.43	0.33	1.33e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.41	5.29	0.32	2.71e-7	Childhood ear infection;
KIRP	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.56	7.65	0.44	4.47e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	trans	rs6734238	0.966	rs13410964	chr2:113843283	G/A	cg11332951	chr1:2396472	NA	-0.41	-6.02	-0.36	6.17e-9	Fibrinogen levels;White blood cell count;C-reactive protein levels or total cholesterol levels (pleiotropy);C-reactive protein;C-reactive protein levels;Fibrinogen;
KIRP	trans	rs12517041	1.000	rs1428622	chr5:23286204	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.3	-0.47	7.14e-15	Calcium levels;
KIRP	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg18279126	chr7:2041391	MAD1L1	0.48	5.01	0.3	1.04e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.82	-0.35	1.86e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.66	7.9	0.45	9.18e-14	Obesity-related traits;
KIRP	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.76	0.4	9.81e-11	Platelet count;
KIRP	cis	rs7804356	0.953	rs73069539	chr7:26903661	C/T	cg03456212	chr7:26904342	SKAP2	-0.55	-5.02	-0.3	9.99e-7	Type 1 diabetes;
KIRP	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg04513422	chr13:111522314	C13orf29	-0.6	-7.7	-0.44	3.4e-13	Sitting height ratio;
KIRP	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	11.52	0.59	7.85e-25	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg01378222	chr16:28622494	SULT1A1	-0.66	-6.08	-0.36	4.52e-9	Platelet distribution width;
KIRP	cis	rs34286592	1.000	rs7201519	chr16:29859977	A/G	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	4.89	0.3	1.83e-6	Multiple sclerosis;
KIRP	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg19000871	chr14:103996768	TRMT61A	-0.53	-5.74	-0.34	2.79e-8	Reticulocyte count;
KIRP	cis	rs11209185	0.509	rs12142271	chr1:68446837	A/G	cg22082780	chr1:68452167	NA	0.38	5.5	0.33	9.36e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.43	0.65	3.16e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg13944838	chr5:179740914	GFPT2	-0.64	-7.21	-0.42	7e-12	Height;
KIRP	cis	rs4478858	0.684	rs2050816	chr1:31721708	G/T	cg00250761	chr1:31883323	NA	-0.31	-5.52	-0.33	8.44e-8	Alcohol dependence;
KIRP	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-0.89	-6.23	-0.37	2.06e-9	Inflammatory biomarkers;
KIRP	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg18190219	chr22:46762943	CELSR1	-0.58	-6.26	-0.37	1.74e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-8.58	-0.48	1.11e-15	Cognitive function;
KIRP	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg21926883	chr2:100939477	LONRF2	-0.55	-7.44	-0.43	1.66e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg03808351	chr9:123631620	PHF19	0.44	5.98	0.36	7.84e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.46e-11	Hypertriglyceridemia;
KIRP	cis	rs11628318	0.515	rs11850580	chr14:103156586	C/T	cg01864069	chr14:103024347	NA	0.42	5.03	0.31	9.37e-7	Platelet count;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg18209359	chr17:80159595	CCDC57	-0.42	-5.56	-0.33	6.85e-8	Life satisfaction;
KIRP	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg16558253	chr16:72132732	DHX38	-0.49	-7.0	-0.41	2.48e-11	Fibrinogen levels;
KIRP	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.4e-12	Bipolar disorder;
KIRP	cis	rs1497828	0.956	rs2815240	chr1:217549651	A/T	cg04411442	chr1:217543379	NA	0.31	5.02	0.3	1.02e-6	Dialysis-related mortality;
KIRP	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.78	8.87	0.49	1.56e-16	Corneal astigmatism;
KIRP	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.55	7.03	0.41	2e-11	Eye color traits;
KIRP	cis	rs7520050	0.771	rs4660882	chr1:46116292	C/T	cg24296786	chr1:45957014	TESK2	-0.44	-5.49	-0.33	1e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.57	7.44	0.43	1.71e-12	Height;
KIRP	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.58	-6.34	-0.37	1.06e-9	Alcohol dependence;
KIRP	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.6	-8.19	-0.46	1.46e-14	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13898697	chr1:36641773	MAP7D1	0.48	6.22	0.37	2.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs225245	0.610	rs321608	chr17:33880636	A/G	cg19694781	chr19:47549865	TMEM160	-0.5	-6.15	-0.37	3.1e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.59	7.38	0.43	2.44e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.38	5.53	0.33	8.36e-8	Neuroticism;
KIRP	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.6	6.71	0.39	1.35e-10	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg12131826	chr15:77904385	NA	0.41	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg00277334	chr10:82204260	NA	-0.46	-5.14	-0.31	5.6e-7	Post bronchodilator FEV1;
KIRP	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg14768367	chr16:72042858	DHODH	0.74	4.86	0.3	2.11e-6	LDL cholesterol levels;Total cholesterol levels;
KIRP	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.35	5.72	0.34	3.03e-8	Monocyte count;
KIRP	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.46	5.88	0.35	1.32e-8	Recombination rate (males);
KIRP	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.79	0.44	1.88e-13	Coffee consumption (cups per day);
KIRP	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg02591564	chr12:125578355	AACS	-0.5	-5.15	-0.31	5.47e-7	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8060686	0.841	rs73594554	chr16:67920049	G/A	cg09117114	chr16:67998030	SLC12A4	-0.5	-5.18	-0.31	4.53e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg03060546	chr3:49711283	APEH	-0.71	-5.5	-0.33	9.48e-8	Cognitive function;
KIRP	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg13962347	chr6:5174647	LYRM4	-0.63	-8.65	-0.48	6.93e-16	Height;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg17346426	chr2:216946392	TMEM169;PECR	-0.56	-6.08	-0.36	4.49e-9	Menopause (age at onset);
KIRP	cis	rs10267417	0.603	rs10266969	chr7:19903452	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	5.63	0.34	4.97e-8	Night sleep phenotypes;
KIRP	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.76	8.85	0.49	1.72e-16	High light scatter reticulocyte count;
KIRP	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.67e-19	Prudent dietary pattern;
KIRP	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg25486957	chr4:152246857	NA	-0.5	-5.48	-0.33	1.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.63	8.6	0.48	9.34e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4728302	0.607	rs1593171	chr7:133597442	G/C	cg10665199	chr7:133106180	EXOC4	0.42	4.9	0.3	1.72e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11260421	chr19:35645680	FXYD5	0.47	6.48	0.38	5.04e-10	Parkinson's disease;
KIRP	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.42	5.28	0.32	2.82e-7	Aortic root size;
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.91	-0.35	1.12e-8	Lung cancer;
KIRP	cis	rs11874712	0.899	rs56075249	chr18:43670863	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.44	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs4356975	0.563	rs12508257	chr4:69967639	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.5	-0.7	2.79e-38	Gut microbiome composition (summer);
KIRP	cis	rs12282928	0.700	rs2047815	chr11:48199897	C/T	cg04607699	chr11:48328132	OR4S1	0.38	5.32	0.32	2.34e-7	Migraine - clinic-based;
KIRP	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.54	-0.52	1.43e-18	Gut microbiome composition (summer);
KIRP	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.56	0.56	9.92e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.85	9.52	0.52	1.72e-18	High light scatter reticulocyte count;
KIRP	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg24488311	chr11:68621650	NA	0.48	5.71	0.34	3.25e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg09323728	chr8:95962352	TP53INP1	-0.29	-6.23	-0.37	1.98e-9	Type 2 diabetes;
KIRP	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.78	-10.98	-0.57	4.32e-23	Morning vs. evening chronotype;
KIRP	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.58	-8.8	-0.49	2.46e-16	Psychosis in Alzheimer's disease;
KIRP	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.45	4.98	0.3	1.22e-6	Parkinson's disease;
KIRP	cis	rs7714584	1.000	rs11739677	chr5:150294883	A/G	cg22134413	chr5:150180641	NA	0.84	6.51	0.38	4.25e-10	Crohn's disease;
KIRP	cis	rs236907	0.859	rs17596081	chr1:171746276	G/T	cg01410279	chr1:171621941	MYOC	-0.51	-5.35	-0.32	1.99e-7	Mean platelet volume;
KIRP	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-8.85	-0.49	1.76e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg27494647	chr7:150038898	RARRES2	0.41	6.36	0.38	9.94e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg03653399	chr8:142233436	SLC45A4	0.94	14.16	0.67	1.07e-33	Immature fraction of reticulocytes;
KIRP	cis	rs6430538	0.671	rs10928518	chr2:135567253	T/C	cg12500956	chr2:135428796	TMEM163	0.42	5.28	0.32	2.83e-7	Parkinson's disease;
KIRP	cis	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg26585981	chr11:48327164	OR4S1	-0.43	-5.53	-0.33	8.04e-8	Height;
KIRP	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg00125455	chr20:44574271	PCIF1	0.36	6.69	0.39	1.51e-10	Metabolite levels;
KIRP	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs11153147	0.649	rs11153145	chr6:109300799	C/T	cg05315195	chr6:109294784	ARMC2	-0.63	-6.36	-0.38	9.81e-10	Mean corpuscular volume;
KIRP	cis	rs13095912	1.000	rs13095912	chr3:185302098	G/A	cg11274856	chr3:185301563	NA	0.54	6.93	0.4	3.64e-11	Systolic blood pressure;
KIRP	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg00319359	chr11:70116639	PPFIA1	0.66	6.46	0.38	5.58e-10	Coronary artery disease;
KIRP	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg23479056	chr15:41276147	INO80	0.38	5.13	0.31	5.75e-7	Menopause (age at onset);
KIRP	cis	rs7766436	0.885	rs10946567	chr6:22581302	T/C	cg13666174	chr6:22585274	NA	-0.44	-6.1	-0.36	4.02e-9	Coronary artery disease;
KIRP	trans	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg09699651	chr6:150184138	LRP11	0.49	6.26	0.37	1.69e-9	Lung cancer;
KIRP	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.77	0.35	2.37e-8	Lung cancer;
KIRP	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.4	-4.88	-0.3	1.92e-6	P wave terminal force;
KIRP	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.39	-5.8	-0.35	2.05e-8	Pubertal anthropometrics;
KIRP	cis	rs11731606	0.508	rs12108275	chr4:95298847	T/G	cg20625393	chr4:95128694	SMARCAD1	0.51	4.87	0.3	2.01e-6	Mean platelet volume;
KIRP	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.58	9.15	0.5	2.3e-17	Obesity-related traits;
KIRP	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.04	-0.31	8.88e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06519061	chr1:214588993	PTPN14	-0.41	-6.24	-0.37	1.88e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg22676075	chr6:135203613	NA	0.46	6.45	0.38	5.75e-10	Red blood cell count;
KIRP	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.65	8.73	0.49	4e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg00677455	chr12:58241039	CTDSP2	0.88	8.79	0.49	2.62e-16	Multiple sclerosis;
KIRP	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.87	0.35	1.4e-8	Motion sickness;
KIRP	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg24375607	chr4:120327624	NA	0.43	5.11	0.31	6.59e-7	Diastolic blood pressure;
KIRP	cis	rs1468333	0.964	rs2350306	chr5:137512178	G/A	cg27119451	chr5:137514611	BRD8;KIF20A	-0.44	-5.14	-0.31	5.66e-7	Resting heart rate;
KIRP	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26617929	chr16:1858877	NA	-0.61	-5.46	-0.33	1.17e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-0.77	-12.12	-0.61	7.83e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7771547	0.642	rs628213	chr6:36508646	T/C	cg07856975	chr6:36356162	ETV7	0.36	5.15	0.31	5.28e-7	Platelet distribution width;
KIRP	cis	rs11945232	0.624	rs13130945	chr4:88371491	G/A	cg23841344	chr4:88312519	HSD17B11	-0.6	-6.58	-0.39	2.78e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6701037	1.000	rs7514749	chr1:175122123	A/G	cg00321850	chr1:175162397	KIAA0040	-0.3	-5.19	-0.31	4.43e-7	Alcohol dependence;
KIRP	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	10.4	0.55	3.2e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg01217720	chr7:128294083	FLJ45340	-0.47	-6.97	-0.41	2.81e-11	Breast cancer;
KIRP	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg17376030	chr22:41985996	PMM1	0.61	6.39	0.38	8.4e-10	Vitiligo;
KIRP	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-8.23	-0.46	1.1e-14	Total cholesterol levels;
KIRP	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.46	-6.87	-0.4	5.37e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03746065	chr20:3827354	MAVS	0.54	6.79	0.4	8.54e-11	Parkinson's disease;
KIRP	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.15	-16.0	-0.71	5.48e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.39	5.14	0.31	5.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1873147	1.000	rs4775600	chr15:63311940	A/G	cg12160578	chr15:63334699	TPM1	-0.47	-5.75	-0.34	2.66e-8	Orofacial clefts;
KIRP	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-9.4	-0.51	4.03e-18	Migraine;Coronary artery disease;
KIRP	cis	rs6061231	0.518	rs639836	chr20:60926223	G/A	cg22633769	chr20:60982531	CABLES2	-0.48	-6.05	-0.36	5.37e-9	Colorectal cancer;
KIRP	cis	rs2033732	0.706	rs10958208	chr8:85070836	A/C	cg05716166	chr8:85095498	RALYL	0.55	6.26	0.37	1.66e-9	Body mass index;
KIRP	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg01475377	chr6:109611718	NA	-0.41	-6.01	-0.36	6.79e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.94	0.45	7.14e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs12765878	0.934	rs58543155	chr10:105643244	G/A	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg08885076	chr2:99613938	TSGA10	0.58	9.95	0.54	7.9e-20	Chronic sinus infection;
KIRP	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.77	0.49	2.92e-16	Bipolar disorder;
KIRP	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg08738300	chr3:44038990	NA	0.66	9.0	0.5	6.52e-17	Coronary artery disease;
KIRP	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg00405596	chr8:11794950	NA	0.44	5.52	0.33	8.57e-8	Retinal vascular caliber;
KIRP	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg02751453	chr18:77725136	HSBP1L1	0.39	5.2	0.31	4.21e-7	Opioid sensitivity;
KIRP	trans	rs9693857	0.520	rs6997629	chr8:9353865	G/C	cg06636001	chr8:8085503	FLJ10661	0.59	6.39	0.38	8.1e-10	Systolic blood pressure;
KIRP	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.38	-5.13	-0.31	5.82e-7	Schizophrenia;
KIRP	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.12	-0.31	6.18e-7	Pulmonary function;
KIRP	cis	rs13359291	0.686	rs10052206	chr5:122470488	A/C	cg16368670	chr5:122501738	PRDM6	-0.5	-6.09	-0.36	4.23e-9	Systolic blood pressure;
KIRP	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-1.08	-11.61	-0.59	3.94e-25	Exhaled nitric oxide output;
KIRP	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	9.97	0.54	6.75e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg21858823	chr1:15850916	CASP9	0.55	5.81	0.35	1.89e-8	Systolic blood pressure;
KIRP	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.69	0.48	5.16e-16	Motion sickness;
KIRP	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.54	7.36	0.42	2.74e-12	HDL cholesterol;
KIRP	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.63	-7.25	-0.42	5.42e-12	Blood protein levels;
KIRP	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg11663144	chr21:46675770	NA	-0.42	-4.85	-0.3	2.2e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-7.6	-0.44	6.15e-13	Electroencephalogram traits;
KIRP	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.18	-16.45	-0.72	1.66e-41	Atopic dermatitis;
KIRP	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg13736514	chr6:26305472	NA	-0.67	-8.91	-0.49	1.19e-16	Educational attainment;
KIRP	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.71e-25	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18183014	chr1:47779854	STIL	0.46	6.14	0.36	3.33e-9	Survival in pancreatic cancer;
KIRP	trans	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17183009	chr3:120277827	NA	0.55	6.39	0.38	8.18e-10	Corneal astigmatism;
KIRP	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.66	9.31	0.51	7.64e-18	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.51	-0.38	4.2e-10	Lung cancer;
KIRP	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	cg21523751	chr1:182988639	NA	-0.44	-6.89	-0.4	4.71e-11	Colorectal cancer;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.81	-0.35	1.91e-8	Life satisfaction;
KIRP	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-9.51	-0.52	1.8e-18	Hemoglobin concentration;
KIRP	cis	rs427941	0.655	rs201468	chr7:101742673	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.73	0.39	1.2e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs11997175	0.550	rs7459565	chr8:33836717	C/T	cg04338863	chr8:33670619	NA	0.4	5.0	0.3	1.08e-6	Body mass index;
KIRP	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg20607798	chr8:58055168	NA	0.71	5.53	0.33	8.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.64	7.84	0.45	1.35e-13	Prudent dietary pattern;
KIRP	cis	rs7582720	0.887	rs72932755	chr2:203673563	A/T	cg08076091	chr2:203926405	NBEAL1	0.83	8.63	0.48	7.67e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg11608241	chr8:8085544	FLJ10661	0.55	6.84	0.4	6.1e-11	Neuroticism;
KIRP	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.59	-7.65	-0.44	4.68e-13	White matter hyperintensity burden;
KIRP	trans	rs459571	0.916	rs109536	chr9:136889987	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-7.58	-0.44	7.13e-13	Platelet distribution width;
KIRP	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.88	0.4	5.01e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.4	-4.85	-0.3	2.21e-6	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.16	0.31	4.97e-7	Parkinson's disease;
KIRP	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg25797454	chr6:150327115	RAET1K	0.35	6.41	0.38	7.27e-10	Alopecia areata;
KIRP	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg27205649	chr11:78285834	NARS2	0.53	5.87	0.35	1.42e-8	Testicular germ cell tumor;
KIRP	cis	rs72653721	0.730	rs9468309	chr6:11044080	G/A	cg13562911	chr6:11044106	ELOVL2	0.55	5.55	0.33	7.54e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	trans	rs7939886	0.920	rs11227428	chr11:55941972	C/G	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.28	0.37	1.54e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.8	9.04	0.5	4.85e-17	Corneal astigmatism;
KIRP	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.56	7.11	0.41	1.23e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03358980	chr10:102770406	NA	-0.44	-6.33	-0.37	1.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg07382826	chr16:28625726	SULT1A1	0.48	5.6	0.34	5.69e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05323904	chr16:691677	FAM195A	0.59	6.78	0.4	9.04e-11	Smoking initiation;
KIRP	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg18527119	chr7:66119851	NA	-0.45	-4.86	-0.3	2.14e-6	Aortic root size;
KIRP	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg01721255	chr8:58191610	C8orf71	0.56	5.2	0.31	4.18e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-13.01	-0.64	8.73e-30	Exhaled nitric oxide output;
KIRP	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg00585698	chr12:123750864	CDK2AP1	0.54	5.94	0.35	9.92e-9	Neutrophil percentage of white cells;
KIRP	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11987759	chr7:65425863	GUSB	0.47	6.1	0.36	4.09e-9	Aortic root size;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg01708552	chr7:100815485	C7orf52	0.65	6.71	0.39	1.35e-10	Lung function (FEV1);
KIRP	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg20701182	chr2:24300061	SF3B14	0.5	4.95	0.3	1.41e-6	Lymphocyte counts;
KIRP	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.55	6.81	0.4	7.63e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg14458575	chr2:238380390	NA	0.72	9.32	0.51	6.89e-18	Prostate cancer;
KIRP	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14159672	chr1:205819179	PM20D1	0.61	5.93	0.35	1.01e-8	Menarche (age at onset);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg14748682	chr11:6624841	ILK;RRP8	-0.49	-6.68	-0.39	1.56e-10	Warfarin maintenance dose;
KIRP	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg08499158	chr17:42289980	UBTF	-0.51	-6.5	-0.38	4.39e-10	Total body bone mineral density;
KIRP	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.97e-13	Life satisfaction;
KIRP	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.34	5.27	0.32	2.98e-7	Mean corpuscular volume;
KIRP	cis	rs2554380	0.657	rs11259916	chr15:84361518	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.43	-6.73	-0.39	1.22e-10	Height;
KIRP	cis	rs7246657	0.722	rs3829688	chr19:38077100	T/C	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.83	9.96	0.54	7.25e-20	Corneal astigmatism;
KIRP	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	5.1	0.31	6.79e-7	Total cholesterol levels;
KIRP	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07636037	chr3:49044803	WDR6	-0.84	-10.09	-0.54	2.89e-20	Menarche (age at onset);
KIRP	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.48	-5.85	-0.35	1.58e-8	Iron status biomarkers;
KIRP	cis	rs9309473	1.000	rs6546839	chr2:73680508	G/C	cg20560298	chr2:73613845	ALMS1	-0.47	-5.52	-0.33	8.5e-8	Metabolite levels;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.43	-5.84	-0.35	1.62e-8	Renal function-related traits (BUN);
KIRP	cis	rs8067287	0.802	rs11650590	chr17:16836300	C/T	cg26910001	chr17:16838321	NA	-0.61	-5.8	-0.35	2.03e-8	Diabetic kidney disease;
KIRP	cis	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg06521331	chr12:34319734	NA	-0.45	-5.22	-0.32	3.88e-7	Resting heart rate;
KIRP	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00495681	chr13:53174319	NA	-0.44	-6.13	-0.36	3.4e-9	Lewy body disease;
KIRP	cis	rs9323205	0.765	rs2999390	chr14:51654944	C/G	cg23942311	chr14:51606299	NA	-0.62	-8.75	-0.49	3.47e-16	Cancer;
KIRP	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-1.07	-21.3	-0.81	8.82e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4262150	0.726	rs4398624	chr5:152018343	C/T	cg12297329	chr5:152029980	NA	0.62	8.23	0.46	1.12e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.3	-0.42	4.08e-12	Myopia;Myopia (pathological);
KIRP	cis	rs11264213	1.000	rs11264211	chr1:36270607	A/G	cg27506609	chr1:36549197	TEKT2	0.73	7.14	0.41	1.04e-11	Schizophrenia;
KIRP	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.29	-0.32	2.74e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.52	7.37	0.43	2.54e-12	Systemic lupus erythematosus;
KIRP	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.28	-0.32	2.77e-7	Total body bone mineral density;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.48	6.96	0.41	3.13e-11	Lymphocyte counts;
KIRP	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.75	10.69	0.56	3.74e-22	Heart rate;
KIRP	cis	rs61935443	0.720	rs892493	chr12:95283943	T/C	cg21533806	chr12:95267307	NA	0.65	6.55	0.39	3.42e-10	Schizophrenia;
KIRP	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.48	6.18	0.37	2.58e-9	Systolic blood pressure;
KIRP	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-9.87	-0.53	1.46e-19	Total body bone mineral density;
KIRP	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.25	-0.42	5.52e-12	Glomerular filtration rate;
KIRP	cis	rs12311304	0.965	rs7965695	chr12:15368644	G/A	cg08258403	chr12:15378311	NA	0.37	5.75	0.34	2.64e-8	Behavioural disinhibition (generation interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00891242	chr3:157828165	RSRC1	0.57	7.43	0.43	1.79e-12	Parkinson's disease;
KIRP	cis	rs62413470	1.000	rs12205903	chr6:55960583	C/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.73	8.86	0.49	1.64e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg00806126	chr19:22604979	ZNF98	-0.69	-7.28	-0.42	4.61e-12	Pain;
KIRP	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.74	10.01	0.54	5.2e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2072732	0.861	rs1890338	chr1:2949028	C/T	cg11731671	chr1:2995604	PRDM16	-0.42	-5.3	-0.32	2.52e-7	Plateletcrit;
KIRP	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg06115741	chr20:33292138	TP53INP2	0.55	7.01	0.41	2.26e-11	Coronary artery disease;
KIRP	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg04865290	chr3:52927548	TMEM110	-0.65	-6.81	-0.4	7.34e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.59	-9.24	-0.51	1.21e-17	Lung cancer;
KIRP	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.75	-0.4	1.06e-10	Hemoglobin concentration;
KIRP	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg11833968	chr6:79620685	NA	-0.35	-4.86	-0.3	2.12e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg16329650	chr2:213403929	ERBB4	0.81	13.57	0.65	1.11e-31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg01304814	chr3:48885189	PRKAR2A	0.51	4.9	0.3	1.77e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-13.85	-0.66	1.21e-32	Coronary artery disease;
KIRP	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.5	-0.33	9.69e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6032067	0.759	rs6032043	chr20:43817897	A/C	cg10761708	chr20:43804764	PI3	0.43	4.94	0.3	1.44e-6	Blood protein levels;
KIRP	cis	rs6484504	0.532	rs11031330	chr11:31275073	G/A	cg26647111	chr11:31128758	NA	-0.43	-5.1	-0.31	6.69e-7	Red blood cell count;
KIRP	trans	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg21659725	chr3:3221576	CRBN	0.63	8.31	0.47	6.6e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.82	13.34	0.65	6.5e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs1497828	1.000	rs2815246	chr1:217560463	T/C	cg04411442	chr1:217543379	NA	0.31	5.1	0.31	6.63e-7	Dialysis-related mortality;
KIRP	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35955747	0.633	rs5998002	chr22:31881169	A/G	cg02404636	chr22:31891804	SFI1	-0.41	-5.25	-0.32	3.22e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs981844	0.736	rs1036614	chr4:154639105	G/A	cg14289246	chr4:154710475	SFRP2	0.64	6.71	0.39	1.3e-10	Response to statins (LDL cholesterol change);
KIRP	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.5	-7.2	-0.42	7.49e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.69	-0.39	1.47e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg04369109	chr6:150039330	LATS1	-0.48	-4.97	-0.3	1.23e-6	Lung cancer;
KIRP	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	10.84	0.57	1.21e-22	Hip circumference adjusted for BMI;
KIRP	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.4	-5.73	-0.34	2.87e-8	Multiple sclerosis;Ankylosing spondylitis;
KIRP	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.75	10.56	0.56	9.85e-22	Schizophrenia;
KIRP	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg00360474	chr6:37504404	NA	-0.36	-4.86	-0.3	2.1e-6	Cognitive performance;
KIRP	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.36	-6.85	-0.4	5.96e-11	Type 2 diabetes;
KIRP	cis	rs988913	0.915	rs9475107	chr6:54853342	G/A	cg03513858	chr6:54763001	FAM83B	-0.37	-5.17	-0.31	4.79e-7	Menarche (age at onset);
KIRP	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-20.03	-0.79	1.4e-53	Height;
KIRP	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	7.0	0.41	2.39e-11	Platelet count;
KIRP	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg21972741	chr5:435613	AHRR	0.51	6.28	0.37	1.55e-9	Cystic fibrosis severity;
KIRP	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-0.98	-14.18	-0.67	9.14e-34	Total cholesterol levels;
KIRP	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs6545883	0.868	rs28749199	chr2:61827052	A/G	cg15711740	chr2:61764176	XPO1	-0.62	-8.15	-0.46	1.86e-14	Tuberculosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05969496	chr1:182923750	C1orf14	-0.39	-6.21	-0.37	2.3e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg04804543	chr8:142233427	SLC45A4	0.56	7.23	0.42	6.02e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg05768032	chr16:30646687	NA	0.44	5.79	0.35	2.18e-8	Dementia with Lewy bodies;
KIRP	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.77	-6.27	-0.37	1.64e-9	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-6.84	-0.4	6.11e-11	Life satisfaction;
KIRP	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.68	-6.83	-0.4	6.6e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs9469913	0.740	rs2744964	chr6:34591320	G/C	cg14254433	chr6:34482411	PACSIN1	-0.43	-5.3	-0.32	2.58e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2411233	0.935	rs2898672	chr15:39292434	C/T	cg02291532	chr15:39874776	THBS1	0.41	5.47	0.33	1.08e-7	Platelet count;
KIRP	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.67	6.39	0.38	8.26e-10	Schizophrenia;
KIRP	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.8	13.31	0.65	8.49e-31	Itch intensity from mosquito bite;
KIRP	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg00684032	chr4:1343700	KIAA1530	0.42	5.31	0.32	2.5e-7	Longevity;
KIRP	cis	rs7246657	0.722	rs10410588	chr19:38042410	C/G	cg18154014	chr19:37997991	ZNF793	0.63	6.94	0.4	3.53e-11	Coronary artery calcification;
KIRP	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg23682824	chr7:23144976	KLHL7	0.59	7.3	0.42	4e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.43	-0.38	6.74e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.56	5.01	0.3	1.06e-6	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2273669	0.667	rs12153822	chr6:109315115	T/C	cg05315195	chr6:109294784	ARMC2	-0.63	-6.25	-0.37	1.82e-9	Prostate cancer;
KIRP	cis	rs12643440	0.960	rs16894651	chr4:17208345	C/T	cg22650099	chr4:17144496	NA	-0.51	-6.1	-0.36	3.99e-9	Metabolite levels (Pyroglutamine);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14691865	chr3:49062629	IMPDH2	-0.42	-6.09	-0.36	4.35e-9	Parkinson's disease;
KIRP	cis	rs11671005	0.735	rs12986387	chr19:58927215	C/T	cg13877915	chr19:58951672	ZNF132	0.59	5.84	0.35	1.64e-8	Mean platelet volume;
KIRP	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg17014757	chr1:203156097	CHI3L1	0.66	6.92	0.4	4e-11	YKL-40 levels;
KIRP	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs8067545	0.611	rs2107565	chr17:20088492	C/T	cg13482628	chr17:19912719	NA	-0.49	-6.35	-0.38	1.02e-9	Schizophrenia;
KIRP	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.85	-12.28	-0.62	2.41e-27	Eye color traits;
KIRP	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25517755	chr10:38738941	LOC399744	-0.52	-7.02	-0.41	2.13e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs787274	1.000	rs2645993	chr9:115536267	T/A	cg13803584	chr9:115635662	SNX30	-0.74	-8.4	-0.47	3.67e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8018808	0.935	rs7146784	chr14:77932111	A/G	cg18872420	chr14:78023429	SPTLC2	0.36	5.24	0.32	3.52e-7	Myeloid white cell count;
KIRP	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg18944383	chr4:111397179	ENPEP	0.46	7.39	0.43	2.31e-12	Coronary artery disease;
KIRP	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.54	-6.58	-0.39	2.82e-10	Lymphocyte percentage of white cells;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg02696790	chr15:75250997	RPP25	0.31	5.4	0.33	1.6e-7	Breast cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg22509054	chr15:41198725	NA	0.51	6.48	0.38	4.97e-10	Educational attainment;
KIRP	cis	rs7175404	0.793	rs6497077	chr15:94033192	A/G	cg23502883	chr15:93959149	NA	0.47	5.5	0.33	9.47e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.61	-7.14	-0.41	1.04e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.41	-0.43	2.06e-12	Bipolar disorder;
KIRP	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.21	14.12	0.67	1.49e-33	Uric acid levels;
KIRP	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.44	-5.97	-0.36	8.07e-9	Monocyte count;
KIRP	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.63	-5.27	-0.32	2.91e-7	Schizophrenia;
KIRP	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg07936489	chr17:37558343	FBXL20	-0.47	-5.82	-0.35	1.83e-8	Asthma;
KIRP	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.65	-9.37	-0.51	4.88e-18	Retinal vascular caliber;
KIRP	cis	rs983545	0.508	rs3886559	chr3:16895876	A/G	cg23220897	chr3:16924709	NA	-0.3	-5.03	-0.31	9.45e-7	Blood protein levels;
KIRP	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.43	6.41	0.38	7.32e-10	Information processing speed;
KIRP	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg04824913	chr4:887549	GAK	0.58	5.79	0.35	2.09e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.54	-9.44	-0.52	2.94e-18	Height;
KIRP	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.47	-6.43	-0.38	6.42e-10	Birth weight;
KIRP	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg10932868	chr11:921992	NA	0.65	8.76	0.49	3.21e-16	Alzheimer's disease (late onset);
KIRP	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg06212747	chr3:49208901	KLHDC8B	0.71	8.35	0.47	4.98e-15	Menarche (age at onset);
KIRP	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg00677901	chr16:88017247	BANP	0.42	5.01	0.3	1.04e-6	Menopause (age at onset);
KIRP	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.97e-8	Motion sickness;
KIRP	cis	rs6009824	1.000	rs6009823	chr22:50086334	C/T	cg22070880	chr22:50098194	NA	0.68	7.71	0.44	3.04e-13	Natriuretic peptide levels;
KIRP	cis	rs12580194	0.593	rs61957924	chr12:55744100	T/C	cg11794356	chr12:55725991	OR6C3	-0.6	-8.62	-0.48	8.4e-16	Cancer;
KIRP	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.57	7.57	0.43	7.63e-13	Schizophrenia;
KIRP	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg21926883	chr2:100939477	LONRF2	-0.43	-4.96	-0.3	1.35e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.99	0.3	1.16e-6	Parkinson's disease;
KIRP	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-5.81	-0.35	1.97e-8	Schizophrenia;
KIRP	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg07636037	chr3:49044803	WDR6	-0.44	-5.29	-0.32	2.69e-7	Resting heart rate;
KIRP	cis	rs4908768	0.717	rs12119207	chr1:8829499	A/G	cg25722041	chr1:8623473	RERE	0.64	7.91	0.45	8.48e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15533453	chr10:2542242	NA	0.29	4.96	0.3	1.34e-6	Age-related hearing impairment;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26878675	chr16:88783039	FAM38A	0.52	6.66	0.39	1.74e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13491848	chr4:120991796	NA	-0.44	-7.25	-0.42	5.46e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.79	-0.35	2.19e-8	Yeast infection;
KIRP	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.62	-6.6	-0.39	2.49e-10	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7523273	0.526	rs558248	chr1:208047435	A/G	cg22525895	chr1:207977042	MIR29B2	-0.44	-5.52	-0.33	8.41e-8	Schizophrenia;
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	6.87	0.4	5.19e-11	Lung function (FEV1/FVC);
KIRP	cis	rs12044355	0.827	rs16854783	chr1:231827371	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.52	-6.78	-0.4	8.81e-11	Alzheimer's disease;
KIRP	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.66	6.69	0.39	1.52e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg02030672	chr11:45687055	CHST1	0.63	8.26	0.47	9.08e-15	Obesity-related traits;
KIRP	cis	rs7246657	0.679	rs12461113	chr19:38083188	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.73	10.21	0.55	1.2e-20	Body mass index;
KIRP	cis	rs981844	1.000	rs56232929	chr4:154665700	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.48	0.43	1.34e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.5	7.48	0.43	1.29e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7359257	0.935	rs56108040	chr15:67707833	G/C	cg24579218	chr15:68104479	NA	0.37	5.51	0.33	9.17e-8	Menarche (age at onset);
KIRP	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg18132916	chr6:79620363	NA	-0.4	-5.48	-0.33	1.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.71	9.42	0.52	3.35e-18	Mood instability;
KIRP	cis	rs897080	0.515	rs1065784	chr2:44660777	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.56	0.33	7.02e-8	Height;
KIRP	cis	rs785830	0.749	rs487275	chr9:257349	G/A	cg14500300	chr9:211689	NA	0.53	7.44	0.43	1.66e-12	Platelet distribution width;
KIRP	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4517514	0.509	rs11018869	chr11:89865168	A/G	cg06174606	chr11:89959870	NA	-0.51	-5.11	-0.31	6.39e-7	Trans fatty acid levels;
KIRP	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.8	-0.49	2.43e-16	Neuroticism;
KIRP	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.68	9.19	0.51	1.71e-17	Coronary artery disease;
KIRP	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.45	-6.11	-0.36	3.8e-9	Bone mineral density (spine);
KIRP	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7301016	0.901	rs12369961	chr12:62966584	C/T	cg01804193	chr12:63026212	NA	0.53	5.9	0.35	1.23e-8	IgG glycosylation;
KIRP	cis	rs3779635	0.742	rs55921260	chr8:27251546	G/C	cg14221460	chr8:27183342	PTK2B	0.53	6.81	0.4	7.43e-11	Neuroticism;
KIRP	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.61	-0.34	5.39e-8	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.61	-7.31	-0.42	3.66e-12	Initial pursuit acceleration;
KIRP	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.79	-10.14	-0.54	1.99e-20	Blood trace element (Zn levels);
KIRP	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.97	-0.3	1.26e-6	Prostate cancer;
KIRP	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg22437258	chr11:111473054	SIK2	0.59	6.9	0.4	4.31e-11	Primary sclerosing cholangitis;
KIRP	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.42	-5.79	-0.35	2.1e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4356932	0.967	rs4386624	chr4:76946139	G/C	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.83	11.56	0.59	5.58e-25	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02808829	chr20:34286564	ROMO1;NFS1	0.44	6.09	0.36	4.22e-9	Smoking initiation;
KIRP	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-7.37	-0.43	2.51e-12	Blood pressure;
KIRP	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg18944383	chr4:111397179	ENPEP	-0.43	-7.05	-0.41	1.82e-11	Coronary artery disease;
KIRP	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg06671706	chr8:8559999	CLDN23	0.52	6.07	0.36	4.72e-9	Obesity-related traits;
KIRP	cis	rs2143950	0.765	rs17113838	chr14:35704667	C/T	cg09327582	chr14:35236912	BAZ1A	-0.61	-5.78	-0.35	2.21e-8	Atopic dermatitis;
KIRP	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.64	-7.13	-0.41	1.11e-11	Menarche (age at onset);
KIRP	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs10929159	0.928	rs1349732	chr2:236923716	G/A	cg20128773	chr2:236923534	AGAP1	0.29	5.08	0.31	7.33e-7	Parkinson's disease;
KIRP	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg02487422	chr3:49467188	NICN1	-0.37	-5.29	-0.32	2.77e-7	Menarche (age at onset);
KIRP	cis	rs1420338	0.967	rs10807873	chr7:34171276	C/T	cg01275685	chr7:34179230	BMPER	-0.52	-7.72	-0.44	2.84e-13	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg16141378	chr3:129829833	LOC729375	0.57	6.91	0.4	4.05e-11	Retinal vascular caliber;
KIRP	cis	rs6859018	1.000	rs10072923	chr5:158735776	T/C	cg26646896	chr5:158686746	NA	-0.37	-5.3	-0.32	2.54e-7	Serum sulfate level;
KIRP	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.52	7.22	0.42	6.5e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.15	-0.46	1.86e-14	Response to antipsychotic treatment;
KIRP	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg05347473	chr6:146136440	FBXO30	0.5	7.01	0.41	2.31e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg16586182	chr3:47516702	SCAP	0.66	8.76	0.49	3.15e-16	Colorectal cancer;
KIRP	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs7221595	0.778	rs8077986	chr17:3902951	A/G	cg09597638	chr17:3907349	NA	0.57	5.98	0.36	7.91e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2273669	0.667	rs1407241	chr6:109328432	G/A	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.68	8.89	0.49	1.31e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.73	-0.6	1.61e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12210905	1.000	rs6931711	chr6:27145586	C/T	cg11502198	chr6:26597334	ABT1	-0.79	-5.04	-0.31	8.88e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.56	0.65	1.14e-31	Smoking behavior;
KIRP	cis	rs8077059	1.000	rs8075326	chr17:55813869	G/T	cg12582317	chr17:55822272	NA	0.4	4.98	0.3	1.21e-6	Sex hormone-binding globulin levels;
KIRP	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.39	-4.98	-0.3	1.19e-6	IgG glycosylation;
KIRP	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.56	8.84	0.49	1.9e-16	Schizophrenia;
KIRP	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg19500275	chr17:80737654	TBCD	-0.44	-5.3	-0.32	2.59e-7	Glycated hemoglobin levels;
KIRP	cis	rs311392	0.871	rs402088	chr8:55092805	A/G	cg06042504	chr8:55087323	NA	-0.59	-7.23	-0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg22974920	chr21:40686053	BRWD1	0.49	5.56	0.33	7.17e-8	Cognitive function;
KIRP	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.73	-0.39	1.17e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs62380364	0.558	rs34319	chr5:88023349	A/T	cg22951263	chr5:87985283	NA	-0.46	-6.34	-0.37	1.1e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs74181299	0.712	rs2241161	chr2:65290842	A/C	cg05010058	chr2:65284262	CEP68	-0.43	-5.76	-0.34	2.51e-8	Pulse pressure;
KIRP	cis	rs113123495	0.609	rs2436499	chr19:5638054	C/T	cg26242866	chr19:5711310	LONP1	-0.67	-4.89	-0.3	1.82e-6	Obsessive-compulsive symptoms;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09652807	chr17:2652918	MIR1253	0.48	6.12	0.36	3.74e-9	Parkinson's disease;
KIRP	trans	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Bladder cancer;
KIRP	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg25357022	chr18:77495084	CTDP1	0.41	5.2	0.31	4.15e-7	Monocyte count;
KIRP	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-7.64	-0.44	4.92e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	1.0	9.27	0.51	1e-17	Systolic blood pressure;
KIRP	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg02336718	chr17:17403227	NA	0.33	5.23	0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-7.65	-0.44	4.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.51	6.63	0.39	2.12e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs9475752	0.793	rs79207065	chr6:56842275	T/G	cg22880620	chr6:56820808	BEND6;DST	0.52	5.41	0.33	1.49e-7	Menarche (age at onset);
KIRP	cis	rs7215564	0.908	rs35884143	chr17:78656043	A/G	cg06153925	chr17:78755379	RPTOR	0.33	5.29	0.32	2.68e-7	Myopia (pathological);
KIRP	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06481639	chr22:41940642	POLR3H	-0.73	-7.67	-0.44	3.99e-13	Vitiligo;
KIRP	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.55	-7.19	-0.42	7.57e-12	Height;
KIRP	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.14	-15.45	-0.7	4.3e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg16141378	chr3:129829833	LOC729375	0.52	6.66	0.39	1.82e-10	Retinal vascular caliber;
KIRP	cis	rs829661	0.606	rs2593441	chr2:30813411	C/A	cg10949345	chr2:30726833	LCLAT1	1.13	14.33	0.67	2.92e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	5.59	0.34	6.02e-8	Platelet count;
KIRP	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg04374321	chr14:90722782	PSMC1	0.99	17.37	0.74	1.24e-44	Mortality in heart failure;
KIRP	cis	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg19680485	chr15:31195859	MTMR15	-0.51	-4.99	-0.3	1.14e-6	Hypertriglyceridemia;
KIRP	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.68	8.48	0.48	2.17e-15	Recalcitrant atopic dermatitis;
KIRP	cis	rs10782582	0.586	rs112368938	chr1:76336339	C/T	cg10523679	chr1:76189770	ACADM	-0.46	-6.25	-0.37	1.81e-9	Daytime sleep phenotypes;
KIRP	cis	rs4955124	0.558	rs62244397	chr3:32023969	A/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.75	6.72	0.39	1.25e-10	Schizophrenia;
KIRP	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.41	5.49	0.33	9.77e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.91	0.35	1.16e-8	Bipolar disorder;
KIRP	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	0.94	11.19	0.58	9.06e-24	Vitiligo;
KIRP	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg00933542	chr6:150070202	PCMT1	0.27	5.3	0.32	2.54e-7	Lung cancer;
KIRP	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-0.72	-6.35	-0.38	1.01e-9	Obesity-related traits;
KIRP	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.67	8.69	0.48	5.26e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs13095912	0.785	rs34619288	chr3:185331678	G/C	cg11274856	chr3:185301563	NA	0.63	7.96	0.45	6.29e-14	Systolic blood pressure;
KIRP	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	1.12	8.19	0.46	1.41e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg05886006	chr1:161359784	NA	0.66	6.27	0.37	1.62e-9	Lung function (FEV1);
KIRP	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg03260781	chr1:16346299	HSPB7	0.31	5.05	0.31	8.72e-7	Systolic blood pressure;
KIRP	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.89	12.14	0.61	6.66e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs10875746	0.551	rs1471998	chr12:48712002	C/T	cg20731937	chr12:48336164	NA	0.45	5.51	0.33	8.94e-8	Longevity (90 years and older);
KIRP	cis	rs71277158	0.688	rs7651554	chr3:169768485	C/G	cg04067573	chr3:169899625	PHC3	0.57	5.31	0.32	2.48e-7	Prostate cancer;
KIRP	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.5	-6.32	-0.37	1.24e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs28489187	0.683	rs11161607	chr1:85855855	T/C	cg16011679	chr1:85725395	C1orf52	0.55	6.64	0.39	2.01e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg25486957	chr4:152246857	NA	-0.47	-5.29	-0.32	2.77e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.84	-0.4	6.41e-11	Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.55	-14.09	-0.67	1.91e-33	Airflow obstruction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01087392	chr10:104005670	GBF1	0.46	6.57	0.39	2.92e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg02297831	chr4:17616191	MED28	0.53	6.6	0.39	2.49e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg13699009	chr12:122356056	WDR66	-0.54	-7.37	-0.43	2.59e-12	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02851825	chr11:46722101	ARHGAP1;ZNF408	0.48	6.4	0.38	7.81e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg23009419	chr3:46618597	LRRC2;TDGF1	-0.34	-5.52	-0.33	8.45e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.97	-0.54	6.88e-20	Triglycerides;
KIRP	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.56	0.65	1.14e-31	Smoking behavior;
KIRP	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg06640241	chr16:89574553	SPG7	0.67	8.44	0.47	2.73e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Tonsillectomy;
KIRP	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.28	-0.32	2.87e-7	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.22e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg02175503	chr12:58329896	NA	-0.49	-5.52	-0.33	8.63e-8	Multiple sclerosis;
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs3105169	1.000	rs6468675	chr8:100260559	A/G	cg00191853	chr8:101177733	SPAG1	-0.39	-4.88	-0.3	1.87e-6	Smoking initiation;
KIRP	trans	rs76288851	0.733	rs73201782	chr3:126493103	A/G	cg13821433	chr2:26726535	OTOF	0.58	6.42	0.38	7.02e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.92	0.53	1.02e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.53	10.21	0.55	1.21e-20	Diabetic kidney disease;
KIRP	cis	rs9513593	1.000	rs9585040	chr13:100015539	T/C	cg21788972	chr13:99853209	UBAC2	0.67	6.85	0.4	5.95e-11	Psoriasis;
KIRP	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg00409905	chr10:38381863	ZNF37A	0.53	5.85	0.35	1.58e-8	Obesity (extreme);
KIRP	cis	rs6062509	0.895	rs55946717	chr20:62363869	G/A	cg03999872	chr20:62272968	STMN3	0.4	4.9	0.3	1.75e-6	Prostate cancer;
KIRP	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg27121462	chr16:89883253	FANCA	0.51	6.62	0.39	2.19e-10	Vitiligo;
KIRP	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg13736514	chr6:26305472	NA	-0.65	-8.65	-0.48	6.77e-16	Educational attainment;
KIRP	trans	rs2270927	0.510	rs2972840	chr5:75572956	G/A	cg13563193	chr19:33072644	PDCD5	0.81	6.12	0.36	3.73e-9	Mean corpuscular volume;
KIRP	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.62	-6.8	-0.4	7.76e-11	DNA methylation (variation);
KIRP	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	9.51	0.52	1.78e-18	Lung cancer in ever smokers;
KIRP	cis	rs1056053	0.514	rs3099268	chr6:166572826	T/C	cg11088901	chr6:166572345	T	-0.52	-7.25	-0.42	5.25e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg14593290	chr7:50529359	DDC	-0.76	-9.53	-0.52	1.59e-18	Malaria;
KIRP	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.69	8.15	0.46	1.83e-14	Diabetic retinopathy;
KIRP	cis	rs4654899	0.802	rs12401413	chr1:21236503	T/C	cg05370193	chr1:21551575	ECE1	0.43	5.46	0.33	1.15e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.64	-8.95	-0.5	9.12e-17	Colorectal cancer;
KIRP	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.55	-8.04	-0.46	3.89e-14	Itch intensity from mosquito bite;
KIRP	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs894344	0.902	rs4909314	chr8:135623798	A/T	cg09855544	chr8:135498122	ZFAT	-0.42	-4.96	-0.3	1.32e-6	Systolic blood pressure;
KIRP	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.33	-0.47	5.55e-15	Total cholesterol levels;
KIRP	trans	rs933360	0.585	rs10264904	chr7:50826475	A/T	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg13175981	chr1:150552382	MCL1	0.56	6.99	0.41	2.61e-11	Tonsillectomy;
KIRP	cis	rs16828019	0.929	rs35286837	chr1:41682998	T/G	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.57	-8.68	-0.48	5.51e-16	Idiopathic membranous nephropathy;
KIRP	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.41	-5.9	-0.35	1.17e-8	Height;
KIRP	cis	rs7666738	0.546	rs10010088	chr4:98655945	C/T	cg05340658	chr4:99064831	C4orf37	0.65	7.5	0.43	1.15e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1215050	0.791	rs260893	chr4:98744785	A/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg01877450	chr7:97915802	BRI3	-0.56	-7.18	-0.42	8.04e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg18404041	chr3:52824283	ITIH1	-0.44	-5.29	-0.32	2.72e-7	Schizophrenia;
KIRP	cis	rs7792596	0.514	rs71562850	chr7:94006979	T/A	cg20814616	chr7:94014465	NA	-0.45	-5.21	-0.32	3.91e-7	Intelligence;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23166656	chr7:28893613	NA	0.44	6.67	0.39	1.67e-10	Parkinson's disease;
KIRP	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.46	-6.15	-0.37	3.1e-9	Mean corpuscular volume;
KIRP	cis	rs17065868	1.000	rs61948004	chr13:45174717	C/G	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg06521331	chr12:34319734	NA	-0.61	-7.19	-0.42	7.67e-12	Bladder cancer;
KIRP	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05165339	chr4:1420672	NA	-0.33	-4.99	-0.3	1.14e-6	Longevity;
KIRP	cis	rs1144713	0.531	rs2683491	chr12:32250865	A/T	cg01321189	chr12:32259338	BICD1	0.44	5.36	0.32	1.95e-7	Obesity-related traits;
KIRP	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.41	-5.12	-0.31	6.24e-7	Menarche (age at onset);
KIRP	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	5.11	0.31	6.34e-7	Childhood ear infection;
KIRP	cis	rs60154123	0.504	rs11119458	chr1:210491097	T/A	cg09074223	chr1:210466472	NA	0.54	5.36	0.32	1.89e-7	Coronary artery disease;
KIRP	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.52	2.77e-18	Prostate cancer;
KIRP	trans	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.24e-10	Diabetic kidney disease;
KIRP	cis	rs6142102	0.961	rs2284389	chr20:32656841	C/G	cg08999081	chr20:33150536	PIGU	0.51	6.73	0.39	1.16e-10	Skin pigmentation;
KIRP	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.77	-0.4	9.28e-11	Systolic blood pressure;
KIRP	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg24253500	chr15:84953950	NA	0.64	7.09	0.41	1.42e-11	Schizophrenia;
KIRP	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.59	7.11	0.41	1.22e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.84	15.77	0.71	3.51e-39	Anterior chamber depth;
KIRP	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.12	-20.38	-0.79	9.82e-55	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6893300	0.961	rs3797776	chr5:179193598	C/T	cg14593053	chr5:179126677	CANX	-0.56	-6.38	-0.38	8.62e-10	Resting heart rate;
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.75	0.44	2.41e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.19	-21.55	-0.81	1.4e-58	Ulcerative colitis;
KIRP	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg06289844	chr6:126071538	HEY2	0.35	4.91	0.3	1.63e-6	Brugada syndrome;
KIRP	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	7.35	0.42	2.94e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.39	5.06	0.31	8.4e-7	Breast cancer;
KIRP	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg26513180	chr16:89883248	FANCA	0.68	9.6	0.52	9.94e-19	Vitiligo;
KIRP	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg23594656	chr7:65796392	TPST1	-0.48	-7.34	-0.42	3.17e-12	Aortic root size;
KIRP	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs4664304	0.739	rs66814375	chr2:160716059	C/T	cg23995753	chr2:160760732	LY75	-0.41	-5.52	-0.33	8.72e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs282587	0.592	rs1625013	chr13:113419550	A/T	cg04656015	chr13:113407548	ATP11A	0.58	6.01	0.36	6.76e-9	Glycated hemoglobin levels;
KIRP	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.32	-4.95	-0.3	1.41e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2904967	0.703	rs239261	chr11:64993357	A/G	cg12562828	chr11:65076843	NA	-0.74	-9.03	-0.5	5.09e-17	Mean corpuscular volume;
KIRP	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-7.87	-0.45	1.16e-13	Educational attainment;
KIRP	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.59	6.73	0.39	1.16e-10	Aortic root size;
KIRP	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.71	-9.76	-0.53	3.19e-19	Plateletcrit;Platelet count;
KIRP	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.32	-0.32	2.39e-7	Cholesterol, total;
KIRP	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg17757837	chr7:157058334	UBE3C	-0.82	-11.24	-0.58	6.29e-24	Body mass index;
KIRP	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.49	-5.72	-0.34	3.06e-8	Body mass index;
KIRP	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	1.01	16.56	0.73	6.97e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9400467	0.537	rs73530977	chr6:111504819	C/T	cg15721981	chr6:111408429	SLC16A10	0.78	7.27	0.42	4.84e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg18190219	chr22:46762943	CELSR1	-0.56	-6.62	-0.39	2.2e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs3026101	0.671	rs12602074	chr17:5302778	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg17105886	chr17:28927953	LRRC37B2	0.54	5.52	0.33	8.67e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg14673194	chr17:80132900	CCDC57	-0.65	-7.02	-0.41	2.13e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg01616529	chr11:638424	DRD4	-0.36	-4.89	-0.3	1.86e-6	Systemic lupus erythematosus;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg00800038	chr16:89945340	TCF25	-0.69	-5.05	-0.31	8.53e-7	Skin colour saturation;
KIRP	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg16141378	chr3:129829833	LOC729375	0.49	6.54	0.38	3.45e-10	Neuroticism;
KIRP	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.41	-6.49	-0.38	4.7e-10	Inflammatory bowel disease;
KIRP	cis	rs6684428	0.536	rs12119683	chr1:56388524	T/A	cg11651538	chr1:56320950	NA	0.54	7.84	0.45	1.33e-13	Airflow obstruction;
KIRP	cis	rs11622475	1.000	rs1187448	chr14:104406627	C/T	cg20488157	chr14:104394430	TDRD9	0.71	10.03	0.54	4.39e-20	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.41	-0.33	1.47e-7	Life satisfaction;
KIRP	cis	rs6743226	0.934	rs7565186	chr2:242249822	A/G	cg10021735	chr2:242295487	FARP2	0.5	6.11	0.36	3.96e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.82	10.93	0.57	6.17e-23	Morning vs. evening chronotype;
KIRP	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg26384229	chr12:38710491	ALG10B	-0.67	-9.07	-0.5	3.8e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg06027949	chr8:82754900	SNX16	0.61	6.41	0.38	7.57e-10	Diastolic blood pressure;
KIRP	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs9549367	0.664	rs3794419	chr13:113851874	T/C	cg18105134	chr13:113819100	PROZ	-1.11	-13.87	-0.66	1.04e-32	Platelet distribution width;
KIRP	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg01777586	chr17:80163174	CCDC57	-0.46	-4.9	-0.3	1.76e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4481887	0.800	rs28590733	chr1:248514978	T/C	cg00666640	chr1:248458726	OR2T12	0.37	5.19	0.31	4.46e-7	Common traits (Other);
KIRP	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg26354017	chr1:205819088	PM20D1	0.5	5.15	0.31	5.33e-7	Parkinson's disease;
KIRP	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-10.54	-0.56	1.11e-21	Morning vs. evening chronotype;
KIRP	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.44	6.61	0.39	2.32e-10	Coronary artery disease;
KIRP	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-12.24	-0.62	3.3e-27	Vitiligo;
KIRP	cis	rs10432489	0.708	rs11687566	chr2:181744418	T/C	cg16057262	chr2:182322699	ITGA4	0.58	4.84	0.3	2.27e-6	QT interval;
KIRP	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg06289844	chr6:126071538	HEY2	0.44	6.36	0.38	9.61e-10	Brugada syndrome;
KIRP	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg06115741	chr20:33292138	TP53INP2	0.39	5.25	0.32	3.32e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs12913547	0.670	rs7167532	chr15:67441256	G/T	cg26430287	chr15:67439567	SMAD3	0.32	5.01	0.3	1.02e-6	Corneal structure;
KIRP	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.83	-11.27	-0.58	5.17e-24	Lung cancer;
KIRP	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.5	6.35	0.38	1e-9	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.59	-12.12	-0.61	7.87e-27	Diabetic kidney disease;
KIRP	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.7	7.65	0.44	4.6e-13	Vitiligo;
KIRP	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.4	0.33	1.58e-7	Alzheimer's disease;
KIRP	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	0.49	5.04	0.31	8.82e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs1978968	0.912	rs28478894	chr22:18454600	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.62	-6.94	-0.4	3.4e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.57	-5.63	-0.34	4.83e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs311392	1.000	rs443599	chr8:55088048	T/C	cg11783602	chr8:55087084	NA	-0.58	-6.81	-0.4	7.54e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg02811702	chr13:24901961	NA	0.42	5.51	0.33	9.11e-8	Obesity-related traits;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11079354	chr6:27740361	NA	0.74	6.89	0.4	4.77e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.42	0.38	7.06e-10	Colorectal cancer;
KIRP	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.69	-9.41	-0.51	3.62e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs923375	0.857	rs12601330	chr17:3382791	G/A	cg02458198	chr17:3375211	SPATA22	0.58	5.16	0.31	5.06e-7	Myopia (pathological);
KIRP	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.94	-16.26	-0.72	7.37e-41	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18364779	chr6:26104403	HIST1H4C	0.61	8.02	0.46	4.2e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg16179182	chr5:140090404	VTRNA1-1	0.5	6.8	0.4	7.66e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21214613	chr1:16344536	HSPB7	0.34	5.23	0.32	3.61e-7	Dilated cardiomyopathy;
KIRP	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg00125455	chr20:44574271	PCIF1	0.45	9.17	0.5	1.99e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.32	-6.27	-0.37	1.65e-9	Monocyte percentage of white cells;
KIRP	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.49	6.24	0.37	1.85e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs17772222	0.606	rs1955598	chr14:88823655	C/T	cg01970427	chr1:2006896	PRKCZ	-0.55	-7.06	-0.41	1.65e-11	Coronary artery calcification;
KIRP	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.66	7.54	0.43	9.07e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-7.22	-0.42	6.45e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg14458575	chr2:238380390	NA	-0.55	-5.79	-0.35	2.12e-8	Prostate cancer;
KIRP	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.86	-11.99	-0.61	2.12e-26	Tonsillectomy;
KIRP	cis	rs7707921	0.767	rs178931	chr5:81575601	T/A	cg07807695	chr5:81608485	ATP6AP1L	-0.42	-5.27	-0.32	2.99e-7	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06488666	chr20:33104140	DYNLRB1	0.66	6.05	0.36	5.3e-9	Lung function (FEV1);
KIRP	cis	rs4908768	0.906	rs56163601	chr1:8751897	G/A	cg03610117	chr1:8450231	RERE	-0.51	-5.04	-0.31	9.21e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-6.96	-0.41	3.12e-11	Systemic lupus erythematosus;
KIRP	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg26898376	chr11:64110657	CCDC88B	0.61	5.13	0.31	5.89e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs1497828	0.956	rs2646833	chr1:217545039	A/G	cg04411442	chr1:217543379	NA	0.3	4.86	0.3	2.08e-6	Dialysis-related mortality;
KIRP	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	6.16	0.37	2.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.86	-14.54	-0.68	5.65e-35	Heart rate;
KIRP	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg25019033	chr10:957182	NA	-0.53	-5.88	-0.35	1.36e-8	Eosinophil percentage of granulocytes;
KIRP	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg01620082	chr3:125678407	NA	-1.18	-7.43	-0.43	1.79e-12	Depression;
KIRP	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-18.05	-0.75	5.8e-47	Height;
KIRP	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg13877915	chr19:58951672	ZNF132	0.61	5.99	0.36	7.27e-9	Mean platelet volume;
KIRP	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg14346243	chr4:90757452	SNCA	-0.42	-5.2	-0.31	4.17e-7	Neuroticism;
KIRP	cis	rs2224391	0.554	rs2224392	chr6:5261136	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.47	-0.38	5.11e-10	Height;
KIRP	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.54	6.32	0.37	1.19e-9	Aortic root size;
KIRP	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs61884328	0.852	rs60088916	chr11:47115967	C/T	cg23433285	chr11:47201945	PACSIN3	0.69	5.6	0.34	5.68e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg18477163	chr1:228402036	OBSCN	0.34	6.32	0.37	1.21e-9	Diastolic blood pressure;
KIRP	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.75	-0.53	3.31e-19	Asthma;
KIRP	cis	rs10463316	0.894	rs954341	chr5:150751855	G/A	cg03212797	chr5:150827313	SLC36A1	-0.53	-7.03	-0.41	2.07e-11	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	10.16	0.54	1.76e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs253959	0.545	rs712588	chr5:115654605	T/G	cg23108291	chr5:115420582	COMMD10	-0.53	-6.09	-0.36	4.22e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	7.52	0.43	1.02e-12	Iron status biomarkers;
KIRP	cis	rs6545883	0.929	rs13413337	chr2:61747123	A/G	cg15711740	chr2:61764176	XPO1	-0.58	-7.98	-0.45	5.49e-14	Tuberculosis;
KIRP	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg01843034	chr6:37503916	NA	-0.96	-15.58	-0.7	1.59e-38	Cognitive performance;
KIRP	cis	rs925255	0.776	rs2279990	chr2:28636740	C/T	cg01273330	chr2:28605224	NA	-0.35	-6.01	-0.36	6.74e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg20636351	chr8:55087400	NA	-0.66	-8.16	-0.46	1.7e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg03468072	chr12:39539422	NA	0.44	5.82	0.35	1.86e-8	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg17764715	chr19:33622953	WDR88	0.8	11.5	0.59	9.21e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35740288	0.787	rs11637768	chr15:86223410	C/T	cg17133734	chr15:86042851	AKAP13	-0.48	-5.23	-0.32	3.58e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-9.05	-0.5	4.6e-17	Coffee consumption (cups per day);
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.55	-0.56	1.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.52	-6.95	-0.4	3.35e-11	Type 2 diabetes;
KIRP	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg13198984	chr17:80129470	CCDC57	0.57	8.66	0.48	6.46e-16	Life satisfaction;
KIRP	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.85e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.77	-0.4	9.29e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs34779708	0.931	rs1926554	chr10:35344969	C/T	cg04310649	chr10:35416472	CREM	-0.53	-6.08	-0.36	4.45e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs526231	0.615	rs26818	chr5:102529719	T/C	cg23492399	chr5:102201601	PAM	-0.53	-5.72	-0.34	3.09e-8	Primary biliary cholangitis;
KIRP	cis	rs7851660	0.809	rs10818241	chr9:100661972	A/G	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs4074493	0.963	rs4074492	chr1:231172439	G/A	cg22172038	chr1:231176991	FAM89A	0.28	4.89	0.3	1.81e-6	Carotid plaque burden (smoking interaction);
KIRP	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg21905437	chr5:178450457	ZNF879	0.5	5.87	0.35	1.38e-8	Pubertal anthropometrics;
KIRP	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-5.77	-0.35	2.36e-8	Schizophrenia;
KIRP	cis	rs9840812	0.861	rs511154	chr3:135950921	A/G	cg15507776	chr3:136538369	TMEM22	0.42	5.37	0.32	1.86e-7	Fibrinogen levels;
KIRP	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg14092571	chr14:90743983	NA	0.46	5.87	0.35	1.38e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.58	-6.67	-0.39	1.68e-10	Blood pressure (smoking interaction);
KIRP	trans	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.75	9.41	0.51	3.81e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg16898833	chr6:26189333	HIST1H4D	0.76	5.61	0.34	5.46e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7221595	0.756	rs9900661	chr17:3962450	A/G	cg09597638	chr17:3907349	NA	0.56	6.17	0.37	2.85e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg12315302	chr6:26189340	HIST1H4D	0.7	5.21	0.31	4.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08981532	chr16:2264875	PGP	-0.58	-6.25	-0.37	1.77e-9	Menopause (age at onset);
KIRP	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.72	-8.92	-0.49	1.08e-16	Longevity;Endometriosis;
KIRP	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22509189	chr2:225307070	NA	-0.45	-5.32	-0.32	2.28e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.54	-7.8	-0.45	1.79e-13	Caffeine consumption;
KIRP	cis	rs78761021	0.720	rs874306	chr17:9797994	G/A	cg26853458	chr17:9805074	RCVRN	0.52	5.05	0.31	8.81e-7	Type 2 diabetes;
KIRP	cis	rs240764	0.817	rs239190	chr6:101129067	C/T	cg09795085	chr6:101329169	ASCC3	0.47	5.65	0.34	4.34e-8	Neuroticism;
KIRP	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-5.72	-0.34	3.07e-8	Bipolar disorder;
KIRP	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.42	5.02	0.3	1.01e-6	Tonsillectomy;
KIRP	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26314531	chr2:26401878	FAM59B	0.47	4.9	0.3	1.75e-6	Gut microbiome composition (summer);
KIRP	cis	rs62413470	1.000	rs62404893	chr6:55961216	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg15488143	chr7:128924101	AHCYL2	0.62	6.7	0.39	1.37e-10	White matter hyperintensity burden;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14081859	chr6:56954773	ZNF451	0.48	6.34	0.37	1.1e-9	Parkinson's disease;
KIRP	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg12798992	chr6:167411361	FGFR1OP	0.36	4.87	0.3	1.98e-6	Crohn's disease;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg00170564	chr12:107714106	BTBD11	-0.5	-6.55	-0.39	3.4e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.6	-7.45	-0.43	1.57e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs11671005	0.693	rs11668757	chr19:58928299	A/T	cg13877915	chr19:58951672	ZNF132	0.62	6.02	0.36	6.24e-9	Mean platelet volume;
KIRP	cis	rs494562	0.542	rs554113	chr6:86115244	A/G	cg27039625	chr6:86159096	NT5E	0.42	5.16	0.31	5.11e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg13206674	chr6:150067644	NUP43	0.58	8.42	0.47	3.12e-15	Lung cancer;
KIRP	cis	rs986417	0.818	rs10133871	chr14:61063771	A/C	cg27398547	chr14:60952738	C14orf39	0.6	5.63	0.34	4.79e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.45	-0.38	5.89e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.81	-14.34	-0.67	2.58e-34	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7551222	0.716	rs4951078	chr1:204491802	A/G	cg20240347	chr1:204465584	NA	-0.46	-8.81	-0.49	2.33e-16	Schizophrenia;
KIRP	cis	rs1971256	0.500	rs3912291	chr6:151818210	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-5.53	-0.33	8.09e-8	Endometriosis;
KIRP	cis	rs4389656	0.617	rs12188231	chr5:6761511	T/G	cg10857441	chr5:6722123	POLS	0.41	5.01	0.3	1.06e-6	Coronary artery disease;
KIRP	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.82	-9.61	-0.52	9.15e-19	Body mass index;
KIRP	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.88	9.88	0.53	1.32e-19	Corneal astigmatism;
KIRP	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.71	-9.25	-0.51	1.12e-17	Breast cancer;
KIRP	cis	rs2278796	1.000	rs2278796	chr1:204951209	C/T	cg17449235	chr1:204966235	NFASC	0.55	7.49	0.43	1.26e-12	Mean platelet volume;
KIRP	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.91	11.86	0.6	5.98e-26	Homoarginine levels;
KIRP	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.58	7.85	0.45	1.29e-13	Mean corpuscular volume;
KIRP	cis	rs1497828	0.956	rs2815245	chr1:217559982	A/G	cg04411442	chr1:217543379	NA	0.31	5.04	0.31	8.96e-7	Dialysis-related mortality;
KIRP	cis	rs9612	1.000	rs346526	chr19:44259565	A/G	cg08581076	chr19:44259116	C19orf61	0.6	6.57	0.39	2.99e-10	Exhaled nitric oxide output;
KIRP	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.72	-7.01	-0.41	2.27e-11	Breast cancer;
KIRP	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg12253828	chr6:101329408	ASCC3	0.96	7.77	0.44	2.13e-13	Economic and political preferences (immigration/crime);
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.29	-0.32	2.66e-7	Breast cancer;
KIRP	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	7.91	0.45	8.82e-14	Breast cancer;
KIRP	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg09408571	chr1:101003634	GPR88	0.26	5.8	0.35	2.07e-8	Monocyte count;
KIRP	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg19554555	chr3:13937349	NA	-0.46	-6.2	-0.37	2.42e-9	Ovarian reserve;
KIRP	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.81	10.82	0.57	1.45e-22	Platelet count;
KIRP	cis	rs9981595	1	rs9981595	chr21:40560678	T/G	cg11890956	chr21:40555474	PSMG1	-0.6	-4.99	-0.3	1.15e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.43	5.65	0.34	4.49e-8	Childhood ear infection;
KIRP	trans	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg12989851	chr3:147074517	NA	-0.94	-6.11	-0.36	3.81e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6681460	0.932	rs523956	chr1:67188276	A/G	cg13052034	chr1:66999238	SGIP1	-0.37	-5.32	-0.32	2.34e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.42	7.1	0.41	1.33e-11	Heart rate;
KIRP	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg22764044	chr5:178986830	RUFY1	0.38	5.29	0.32	2.72e-7	Lung cancer;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg11184682	chr3:50365769	TUSC2	-0.53	-6.67	-0.39	1.69e-10	Neuroticism;
KIRP	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	1.1	8.05	0.46	3.62e-14	Skin colour saturation;
KIRP	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs2742417	1.000	rs2742422	chr3:45732820	G/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.4e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.28	-0.32	2.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-5.99	-0.36	7.48e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.66	-6.93	-0.4	3.69e-11	Vitiligo;
KIRP	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-6.25	-0.37	1.82e-9	Fear of minor pain;
KIRP	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.66	6.54	0.38	3.57e-10	Axial length;
KIRP	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.96	-11.9	-0.6	4.32e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs137887	1.000	rs137886	chr22:50464397	A/G	cg17558497	chr22:50464837	TTLL8	0.51	7.71	0.44	3.1400000000000003e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.49	-5.24	-0.32	3.4e-7	Initial pursuit acceleration;
KIRP	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.46	0.52	2.65e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg13293535	chr8:11597251	GATA4	-0.41	-5.29	-0.32	2.66e-7	Retinal vascular caliber;
KIRP	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg21132104	chr15:45694354	SPATA5L1	0.57	6.96	0.41	3.04e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.65	5.56	0.33	7.03e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.58	8.71	0.49	4.68e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	cis	rs73198271	0.628	rs56188408	chr8:8592158	G/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-5.16	-0.31	5.14e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg20744362	chr22:50050164	C22orf34	0.35	5.16	0.31	5.07e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs4805272	1.000	rs888832	chr19:29324563	T/C	cg15000279	chr19:29285009	NA	-0.35	-4.98	-0.3	1.19e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.48	-6.45	-0.38	5.96e-10	Immature fraction of reticulocytes;
KIRP	cis	rs13359291	0.841	rs4836465	chr5:122474938	A/G	cg16368670	chr5:122501738	PRDM6	-0.49	-6.09	-0.36	4.28e-9	Systolic blood pressure;
KIRP	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.38	5.12	0.31	6.27e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg18404041	chr3:52824283	ITIH1	-0.54	-6.99	-0.41	2.6e-11	Bipolar disorder;
KIRP	cis	rs9815354	1.000	rs9873207	chr3:41884750	C/T	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13496359	chr9:109686439	ZNF462;MIR548Q	0.5	6.41	0.38	7.51e-10	Interleukin-4 levels;
KIRP	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	1.15	9.89	0.53	1.23e-19	Lymphocyte counts;
KIRP	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	0.7	6.56	0.39	3.09e-10	Obesity-related traits;
KIRP	cis	rs62344088	0.590	rs62346174	chr5:296308	C/A	cg22496380	chr5:211416	CCDC127	-1.21	-7.39	-0.43	2.26e-12	Asthma (childhood onset);
KIRP	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg07701084	chr6:150067640	NUP43	0.57	7.23	0.42	6.13e-12	Testicular germ cell tumor;
KIRP	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.81	11.03	0.58	3.1e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg07395648	chr5:131743802	NA	-0.58	-8.34	-0.47	5.17e-15	Blood metabolite levels;
KIRP	cis	rs858239	0.899	rs2268747	chr7:23313462	A/G	cg23682824	chr7:23144976	KLHL7	0.44	5.06	0.31	8.41e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.68	-7.38	-0.43	2.47e-12	Initial pursuit acceleration;
KIRP	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	1.02	18.28	0.76	9.53e-48	Heart rate;
KIRP	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg04058563	chr4:185651563	MLF1IP	0.49	6.69	0.39	1.53e-10	Kawasaki disease;
KIRP	cis	rs6429082	0.902	rs704708	chr1:235620134	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.18	0.31	4.54e-7	Adiposity;
KIRP	cis	rs7116495	0.786	rs10736784	chr11:71718911	T/A	cg11196788	chr11:71737549	NUMA1	0.56	5.04	0.31	9.1e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs853679	0.607	rs200489	chr6:27798257	T/C	cg12826209	chr6:26865740	GUSBL1	0.65	4.89	0.3	1.81e-6	Depression;
KIRP	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.4	-0.55	3.23e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.83	6.84	0.4	6.27e-11	Body mass index;
KIRP	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	1.16	22.64	0.82	4.24e-62	Monocyte count;
KIRP	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.39	5.42	0.33	1.4e-7	Homoarginine levels;
KIRP	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg05784532	chr1:230284198	GALNT2	-0.5	-7.55	-0.43	8.33e-13	Coronary artery disease;
KIRP	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg26354017	chr1:205819088	PM20D1	-0.45	-5.69	-0.34	3.67e-8	Menarche (age at onset);
KIRP	cis	rs889398	0.616	rs35808754	chr16:69771710	G/T	cg09409435	chr16:70099608	PDXDC2	-0.44	-5.24	-0.32	3.44e-7	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17133045	chr1:243877447	AKT3	-0.42	-6.42	-0.38	7.05e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.71	7.5	0.43	1.12e-12	Urate levels in lean individuals;
KIRP	cis	rs4704187	0.649	rs1422701	chr5:74510517	T/G	cg03227963	chr5:74354835	NA	0.4	5.83	0.35	1.74e-8	Response to amphetamines;
KIRP	cis	rs4959799	0.546	rs3813480	chr6:3270840	A/G	cg10513992	chr6:3293720	SLC22A23	-0.75	-5.54	-0.33	7.82e-8	Survival in rectal cancer;
KIRP	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.39	-4.97	-0.3	1.28e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.44	7.2	0.42	7.16e-12	Testicular germ cell tumor;
KIRP	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg22437258	chr11:111473054	SIK2	-0.58	-6.7	-0.39	1.38e-10	Primary sclerosing cholangitis;
KIRP	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-7.94	-0.45	7.19e-14	Coffee consumption (cups per day);
KIRP	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg14416269	chr4:6271139	WFS1	0.33	5.16	0.31	5.09e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.3	-0.37	1.36e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7903847	0.642	rs11189206	chr10:99167802	T/C	cg20016023	chr10:99160130	RRP12	-0.4	-5.55	-0.33	7.34e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg07001201	chr5:642380	CEP72	0.67	6.26	0.37	1.71e-9	Obesity-related traits;
KIRP	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg23950597	chr19:37808831	NA	-0.59	-6.39	-0.38	8.04e-10	Coronary artery calcification;
KIRP	cis	rs7267005	1.000	rs7267658	chr20:34540383	C/T	cg17201900	chr20:34330562	RBM39	0.92	5.16	0.31	5.14e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Body mass index;
KIRP	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg26384229	chr12:38710491	ALG10B	-0.54	-7.22	-0.42	6.43e-12	Morning vs. evening chronotype;
KIRP	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg23505145	chr19:12996616	KLF1	0.56	8.14	0.46	1.94e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-5.76	-0.34	2.49e-8	Huntington's disease progression;
KIRP	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg09455208	chr3:40491958	NA	0.34	5.9	0.35	1.19e-8	Renal cell carcinoma;
KIRP	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg22732515	chr19:44031385	ETHE1	0.62	8.87	0.49	1.55e-16	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.6	7.67	0.44	3.98e-13	Body mass index;
KIRP	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.52	6.76	0.4	1e-10	Menopause (age at onset);
KIRP	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg05805236	chr11:65401703	PCNXL3	-0.48	-6.24	-0.37	1.95e-9	Non-alcoholic fatty liver disease histology (lobular);
KIRP	cis	rs882732	0.576	rs2068790	chr14:95033944	C/T	cg08495878	chr14:95027859	SERPINA4	0.5	6.36	0.38	9.99e-10	Blood protein levels;
KIRP	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.72	-0.49	4.24e-16	Mood instability;
KIRP	cis	rs1468333	0.930	rs2269954	chr5:137501003	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.5	5.62	0.34	5.1e-8	Resting heart rate;
KIRP	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.0	-0.5	6.37e-17	Retinal vascular caliber;
KIRP	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.64	5.36	0.32	1.95e-7	Putamen volume;
KIRP	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg13072238	chr3:49761600	GMPPB	-0.57	-5.37	-0.32	1.85e-7	Menarche (age at onset);
KIRP	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-10.16	-0.54	1.8e-20	Response to antipsychotic treatment;
KIRP	cis	rs909341	0.909	rs1151623	chr20:62368606	T/C	cg11503966	chr20:62272292	STMN3	0.38	5.52	0.33	8.65e-8	Atopic dermatitis;
KIRP	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.42	5.73	0.34	2.96e-8	Red blood cell count;
KIRP	cis	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.8	-0.35	2.01e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11700980	1.000	rs11700980	chr21:30154239	T/C	cg08807101	chr21:30365312	RNF160	-0.76	-4.92	-0.3	1.6e-6	QRS complex (12-leadsum);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04188362	chr10:21823475	MLLT10	0.53	7.06	0.41	1.7e-11	Parkinson's disease;
KIRP	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.44	15.0	0.69	1.44e-36	Schizophrenia;
KIRP	cis	rs78487399	0.808	rs10169346	chr2:43741105	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-4.85	-0.3	2.2e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg18016565	chr1:150552671	MCL1	-0.51	-7.78	-0.44	2.04e-13	Urate levels;
KIRP	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.03	-0.36	6.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7640424	0.649	rs13093976	chr3:107864963	A/C	cg09227934	chr3:107805635	CD47	0.33	5.79	0.35	2.09e-8	Body mass index;
KIRP	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.75	-8.54	-0.48	1.4e-15	Platelet count;
KIRP	trans	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg06521331	chr12:34319734	NA	-0.54	-6.89	-0.4	4.52e-11	Heart rate;
KIRP	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg10096100	chr1:26503862	CNKSR1	0.41	5.8	0.35	2.01e-8	Height;
KIRP	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg08126542	chr6:37504118	NA	-0.84	-13.31	-0.65	8.07e-31	Cognitive performance;
KIRP	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg10503236	chr1:231470652	EXOC8	0.5	7.23	0.42	5.91e-12	Hemoglobin concentration;
KIRP	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.63	-0.44	5e-13	Coffee consumption (cups per day);
KIRP	cis	rs57590327	0.503	rs6800295	chr3:81593011	A/G	cg07356753	chr3:81810745	GBE1	-0.58	-7.45	-0.43	1.59e-12	Extraversion;
KIRP	cis	rs6466055	0.777	rs10277120	chr7:104834417	A/T	cg04380332	chr7:105027541	SRPK2	0.61	9.31	0.51	7.3e-18	Schizophrenia;
KIRP	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00585698	chr12:123750864	CDK2AP1	-0.5	-6.45	-0.38	6e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.21	-0.32	3.98e-7	Calcium levels;
KIRP	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg09201719	chr10:104596890	CYP17A1	0.37	5.24	0.32	3.47e-7	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10489202	0.954	rs11586522	chr1:168091031	G/T	cg24449463	chr1:168025552	DCAF6	-0.44	-5.1	-0.31	6.84e-7	Schizophrenia;
KIRP	cis	rs1215050	0.791	rs7688192	chr4:98900798	G/T	cg17366294	chr4:99064904	C4orf37	-0.38	-5.18	-0.31	4.57e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7903847	0.642	rs11189204	chr10:99164394	C/T	cg20016023	chr10:99160130	RRP12	-0.41	-5.57	-0.33	6.58e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6568686	0.730	rs4526232	chr6:111857045	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.52	-5.14	-0.31	5.61e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.78	9.44	0.52	2.97e-18	Response to antipsychotic treatment;
KIRP	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg01631408	chr1:248437212	OR2T33	-0.68	-9.06	-0.5	4.15e-17	Common traits (Other);
KIRP	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.73	-7.8	-0.45	1.71e-13	Blood pressure (smoking interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22803407	chr19:6733691	GPR108	-0.5	-6.6	-0.39	2.56e-10	Parkinson's disease;
KIRP	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09217309	chr6:150244204	RAET1G	0.41	5.05	0.31	8.71e-7	Testicular germ cell tumor;
KIRP	cis	rs3936840	0.539	rs3742441	chr14:102970581	C/G	cg18135206	chr14:102964638	TECPR2	0.45	5.01	0.3	1.04e-6	Plateletcrit;
KIRP	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.79	11.45	0.59	1.27e-24	Heart rate;
KIRP	cis	rs11997175	0.646	rs6468197	chr8:33734894	G/T	ch.8.33884649F	chr8:33765107	NA	0.62	7.79	0.45	1.82e-13	Body mass index;
KIRP	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.98	16.27	0.72	6.75e-41	Uric acid clearance;
KIRP	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-9.39	-0.51	4.2e-18	Joint mobility (Beighton score);
KIRP	cis	rs13401104	0.796	rs72620810	chr2:237117697	A/G	cg19324714	chr2:237145437	ASB18	0.49	5.28	0.32	2.79e-7	Educational attainment;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10669451	chr11:61556984	C11orf10	0.53	6.45	0.38	5.75e-10	Interleukin-4 levels;
KIRP	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-5.03	-0.31	9.57e-7	Educational attainment;
KIRP	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg06935464	chr4:38784597	TLR10	0.53	6.07	0.36	4.87e-9	Breast cancer;
KIRP	cis	rs501120	0.584	rs11592445	chr10:44732945	G/T	cg09554077	chr10:44749378	NA	0.7	7.78	0.44	2.03e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg10755058	chr3:40428713	ENTPD3	0.36	5.02	0.3	1.01e-6	Renal cell carcinoma;
KIRP	cis	rs12049351	0.613	rs10799535	chr1:229657794	T/C	cg11742688	chr1:229674241	ABCB10	-0.36	-5.36	-0.32	1.93e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg08133631	chr1:26527909	CATSPER4	-0.48	-5.5	-0.33	9.42e-8	Obesity-related traits;
KIRP	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs1355223	0.872	rs1258466	chr11:34730066	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-5.13	-0.31	5.96e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs3767633	0.764	rs6687226	chr1:161891556	G/T	cg09175582	chr1:161736000	ATF6	-0.81	-5.24	-0.32	3.47e-7	IgG glycosylation;
KIRP	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg00405596	chr8:11794950	NA	0.47	5.83	0.35	1.76e-8	Retinal vascular caliber;
KIRP	cis	rs17739167	0.550	rs17739125	chr15:42234424	T/C	cg20935245	chr15:42234343	EHD4	-0.5	-7.88	-0.45	1.04e-13	Monocyte count;
KIRP	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.61	-7.73	-0.44	2.79e-13	Personality dimensions;
KIRP	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.8	12.22	0.61	3.62e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs13095912	0.962	rs7644758	chr3:185328197	G/T	cg11274856	chr3:185301563	NA	-0.53	-6.91	-0.4	4.17e-11	Systolic blood pressure;
KIRP	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	6.59	0.39	2.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg01831904	chr17:28903510	LRRC37B2	0.88	7.49	0.43	1.26e-12	Body mass index;
KIRP	cis	rs7903847	0.620	rs61863815	chr10:99124389	A/G	cg20016023	chr10:99160130	RRP12	-0.42	-5.66	-0.34	4.25e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.56	-6.2	-0.37	2.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg22617819	chr1:44378782	ST3GAL3	-0.37	-5.89	-0.35	1.27e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg21775007	chr8:11205619	TDH	-0.4	-5.21	-0.32	4e-7	Triglycerides;
KIRP	cis	rs889398	0.770	rs8052225	chr16:69883653	G/A	cg09409435	chr16:70099608	PDXDC2	0.43	5.14	0.31	5.57e-7	Body mass index;
KIRP	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-5.35	-0.32	2.04e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	1.04	19.56	0.78	4.81e-52	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs11628318	0.563	rs1190344	chr14:103097912	A/G	cg01864069	chr14:103024347	NA	-0.44	-5.37	-0.32	1.87e-7	Platelet count;
KIRP	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.21	0.61	3.9e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg21775007	chr8:11205619	TDH	-0.44	-5.67	-0.34	4.06e-8	Triglycerides;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg12180372	chr14:94547582	DDX24;IFI27L1	-0.45	-6.06	-0.36	5.08e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg18132916	chr6:79620363	NA	-0.41	-5.65	-0.34	4.44e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg04312406	chr1:226497240	LIN9	0.52	6.12	0.36	3.76e-9	Inflammatory biomarkers;
KIRP	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.55	-9.27	-0.51	1e-17	Height;
KIRP	cis	rs2458413	0.542	rs2514670	chr8:105363452	C/G	cg08657449	chr8:105351661	TM7SF4	0.35	5.76	0.34	2.48e-8	Paget's disease;
KIRP	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	9.6	0.52	1e-18	Total body bone mineral density;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg09065880	chr20:55966446	RBM38	0.44	6.29	0.37	1.47e-9	Cancer;
KIRP	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.86	10.25	0.55	9.11e-21	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.67	0.48	5.75e-16	Colorectal cancer;
KIRP	cis	rs11583043	0.874	rs41312668	chr1:101443582	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	6.95	0.4	3.32e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs10924309	0.889	rs1316344	chr1:245859822	C/T	cg00036263	chr1:245852353	KIF26B	-0.48	-6.24	-0.37	1.95e-9	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
KIRP	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg13798912	chr7:905769	UNC84A	0.56	5.66	0.34	4.13e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.71	-7.56	-0.43	8.02e-13	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25247615	chr19:17336996	OCEL1	0.51	6.47	0.38	5.25e-10	Parkinson's disease;
KIRP	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.5	8.41	0.47	3.39e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.56	5.94	0.35	9.81e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	0.94	11.41	0.59	1.74e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg05527609	chr1:210001259	C1orf107	-0.42	-5.12	-0.31	6.12e-7	Red blood cell count;
KIRP	trans	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg25214090	chr10:38739885	LOC399744	0.71	7.89	0.45	9.91e-14	Corneal astigmatism;
KIRP	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.58	6.42	0.38	7.16e-10	Alcohol dependence;
KIRP	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-7.13	-0.41	1.11e-11	Morning vs. evening chronotype;
KIRP	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg25233709	chr10:116636983	FAM160B1	0.36	5.5	0.33	9.53e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg19700328	chr14:106028568	NA	-0.55	-6.23	-0.37	1.99e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs7091068	0.518	rs726817	chr10:95459817	C/T	cg20715218	chr10:95462985	C10orf4	0.5	6.06	0.36	5.07e-9	Urinary tract infection frequency;
KIRP	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	10.03	0.54	4.53e-20	Total body bone mineral density;
KIRP	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.52	-5.52	-0.33	8.64e-8	Body mass index;
KIRP	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.5	-7.2	-0.42	7.49e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg12962167	chr3:53033115	SFMBT1	0.71	5.28	0.32	2.8e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs11138902	0.552	rs11139293	chr9:72165492	G/A	cg14397918	chr9:72078829	APBA1	0.34	5.28	0.32	2.85e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg13736514	chr6:26305472	NA	-0.44	-4.88	-0.3	1.91e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.21	0.46	1.27e-14	IgG glycosylation;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.59	-5.93	-0.35	1.01e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.53	-7.05	-0.41	1.75e-11	Coronary heart disease;
KIRP	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg24375607	chr4:120327624	NA	0.62	6.34	0.37	1.1e-9	Corneal astigmatism;
KIRP	trans	rs7404843	1.000	rs7404843	chr16:15530708	T/G	cg02716450	chr16:28638775	NA	-0.88	-8.86	-0.49	1.59e-16	Testicular germ cell tumor;
KIRP	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg03647239	chr10:116582469	FAM160B1	0.52	5.95	0.35	9.22e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02725872	chr8:58115012	NA	-0.75	-7.65	-0.44	4.53e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	0.93	11.55	0.59	6.24e-25	Vitiligo;
KIRP	cis	rs11605924	1.000	rs12794698	chr11:45871861	G/A	cg23097878	chr11:45879730	CRY2	0.33	6.59	0.39	2.68e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2224391	0.628	rs6913120	chr6:5260505	G/A	cg13962347	chr6:5174647	LYRM4	-0.8	-11.26	-0.58	5.43e-24	Height;
KIRP	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg07001201	chr5:642380	CEP72	0.65	6.54	0.38	3.59e-10	Obesity-related traits;
KIRP	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.91	-13.64	-0.66	6.37e-32	Ulcerative colitis;
KIRP	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-12.02	-0.61	1.67e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6545883	0.507	rs6545855	chr2:61532860	G/C	cg15711740	chr2:61764176	XPO1	0.47	5.86	0.35	1.5e-8	Tuberculosis;
KIRP	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg19592336	chr6:28129416	ZNF389	0.49	5.56	0.33	6.92e-8	Depression;
KIRP	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg01559446	chr3:44596178	ZNF167	-0.37	-5.19	-0.31	4.47e-7	Depressive symptoms;
KIRP	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg07862535	chr7:139043722	LUC7L2	0.45	5.09	0.31	6.97e-7	Diisocyanate-induced asthma;
KIRP	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.48	7.76	0.44	2.22e-13	Major depressive disorder;
KIRP	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13939156	chr17:80058883	NA	-0.49	-7.36	-0.42	2.8e-12	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.77	-11.52	-0.59	7.71e-25	Obesity-related traits;
KIRP	trans	rs353116	0.697	rs353118	chr2:166131911	A/T	cg23361659	chr2:28914775	NA	0.32	6.18	0.37	2.6e-9	Parkinson's disease;
KIRP	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg16606324	chr3:10149918	C3orf24	0.66	5.71	0.34	3.17e-8	Alzheimer's disease;
KIRP	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.89	13.71	0.66	3.53e-32	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17554472	chr22:41940697	POLR3H	-0.64	-6.79	-0.4	8.54e-11	Vitiligo;
KIRP	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	5.88	0.35	1.3e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4262150	0.721	rs11167603	chr5:152282386	C/T	cg12297329	chr5:152029980	NA	-0.45	-6.45	-0.38	5.96e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg15660573	chr17:549704	VPS53	-0.95	-15.19	-0.7	3.18e-37	Prostate cancer;
KIRP	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	0.79	8.26	0.47	8.74e-15	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg13319975	chr6:146136371	FBXO30	-0.43	-5.9	-0.35	1.17e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4478137	0.899	rs10857354	chr4:164239841	A/G	cg06758707	chr4:164254230	NPY1R	0.7	9.06	0.5	4.31e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs2826891	0.603	rs2776109	chr21:23022119	C/T	cg18742814	chr1:41828276	NA	-0.39	-6.04	-0.36	5.71e-9	Longevity;
KIRP	cis	rs10982256	0.622	rs4979410	chr9:117239877	C/T	cg13636371	chr9:117264095	DFNB31	0.55	7.6	0.44	6.05e-13	Bipolar disorder;
KIRP	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg15839431	chr19:19639596	YJEFN3	0.51	5.22	0.32	3.78e-7	Bipolar disorder;
KIRP	cis	rs3105593	0.555	rs3131560	chr15:50775562	T/C	cg05456662	chr15:50716270	USP8	0.36	4.88	0.3	1.89e-6	QT interval;
KIRP	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-8.11	-0.46	2.44e-14	Total cholesterol levels;
KIRP	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.65	10.29	0.55	6.78e-21	Bone mineral density;
KIRP	cis	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg00405596	chr8:11794950	NA	-0.47	-5.88	-0.35	1.36e-8	Triglycerides;
KIRP	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg02106180	chr16:845767	CHTF18	0.38	4.95	0.3	1.35e-6	Mean corpuscular volume;
KIRP	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.74	11.21	0.58	7.65e-24	Orofacial clefts;
KIRP	cis	rs4716602	0.898	rs13243950	chr7:156160996	T/C	cg04090468	chr7:156181990	NA	0.46	5.52	0.33	8.56e-8	Anti-saccade response;
KIRP	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.62	7.44	0.43	1.69e-12	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12419491	chr1:29063485	YTHDF2	0.44	6.1	0.36	4.06e-9	Survival in pancreatic cancer;
KIRP	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs1823913	0.660	rs1454752	chr2:192163394	G/C	cg12404831	chr2:192114017	MYO1B	-0.47	-6.18	-0.37	2.69e-9	Obesity-related traits;
KIRP	cis	rs7221595	0.825	rs2290437	chr17:3923115	G/A	cg05562828	chr17:3906858	NA	0.61	7.36	0.42	2.74e-12	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05665937	chr4:1216051	CTBP1	0.51	7.27	0.42	4.64e-12	Obesity-related traits;
KIRP	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg07713946	chr22:31675144	LIMK2	0.32	5.1	0.31	6.68e-7	Colorectal cancer;
KIRP	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg14768367	chr16:72042858	DHODH	-0.93	-10.35	-0.55	4.53e-21	Blood protein levels;
KIRP	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17507749	chr15:85114479	UBE2QP1	0.72	8.07	0.46	3.02e-14	Schizophrenia;
KIRP	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.73	-8.72	-0.49	4.15e-16	Adiposity;
KIRP	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg16590910	chr6:42928470	GNMT	0.4	5.42	0.33	1.45e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	trans	rs6601327	0.603	rs28634186	chr8:9669335	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.57	-0.39	2.93e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.16	-10.75	-0.57	2.31e-22	Body mass index;
KIRP	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.32	0.51	7.11e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg22974920	chr21:40686053	BRWD1	0.52	5.95	0.35	9.18e-9	Cognitive function;
KIRP	cis	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08380311	chr19:3435252	NFIC	-0.68	-6.46	-0.38	5.66e-10	Height;
KIRP	cis	rs6450176	1.000	rs7736354	chr5:53297591	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.33	-0.59	3.2e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.63	6.76	0.4	9.93e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg27205649	chr11:78285834	NARS2	-0.61	-7.95	-0.45	6.67e-14	Alzheimer's disease (survival time);
KIRP	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.53	6.24	0.37	1.94e-9	Mean platelet volume;
KIRP	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg02725872	chr8:58115012	NA	-0.45	-5.21	-0.32	4.03e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9863706	0.552	rs75216331	chr3:72400260	G/A	cg05607079	chr3:72387937	NA	0.52	5.74	0.34	2.75e-8	Height;
KIRP	cis	rs537626	0.848	rs624797	chr11:69308575	G/T	cg08353955	chr11:69289746	NA	0.74	8.17	0.46	1.63e-14	Breast cancer (early onset);
KIRP	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg04490037	chr7:50633773	DDC	0.36	4.89	0.3	1.8e-6	Body mass index;
KIRP	cis	rs1823913	0.503	rs35868016	chr2:192208808	C/T	cg12404831	chr2:192114017	MYO1B	0.51	7.01	0.41	2.3e-11	Obesity-related traits;
KIRP	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.5	6.13	0.36	3.54e-9	Type 2 diabetes;
KIRP	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.44	-5.86	-0.35	1.51e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	5.2	0.31	4.22e-7	Leprosy;
KIRP	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg21640587	chr11:117668038	DSCAML1	0.43	6.27	0.37	1.62e-9	Myopia;
KIRP	cis	rs2241685	0.621	rs56919961	chr2:1902125	C/T	cg22511877	chr2:1942942	MYT1L	-0.59	-5.44	-0.33	1.26e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg20936604	chr3:58311152	NA	-0.68	-5.58	-0.34	6.31e-8	Cholesterol, total;
KIRP	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	12.43	0.62	7.52e-28	Platelet count;
KIRP	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.68	10.05	0.54	3.86e-20	Dupuytren's disease;
KIRP	cis	rs1448094	0.845	rs7132262	chr12:86346304	C/T	cg00310523	chr12:86230176	RASSF9	0.43	6.64	0.39	1.95e-10	Major depressive disorder;
KIRP	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.02	-0.3	1.01e-6	Pulmonary function;
KIRP	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.86	0.53	1.5700000000000001e-19	Colorectal cancer;
KIRP	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.85	11.54	0.59	6.61e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-8.97	-0.5	7.66e-17	Neuroticism;
KIRP	cis	rs6060717	0.536	rs2425104	chr20:34312346	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg13072238	chr3:49761600	GMPPB	-0.5	-4.95	-0.3	1.37e-6	Menarche (age at onset);
KIRP	cis	rs72843166	0.537	rs10491168	chr17:61441463	A/G	cg19683800	chr17:61518354	CYB561	-0.42	-5.08	-0.31	7.47e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs300890	0.642	rs2196908	chr4:144281959	G/A	cg01719995	chr4:144104893	USP38	-0.42	-5.31	-0.32	2.49e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs17023223	0.537	rs12072768	chr1:119593918	A/G	cg18261050	chr1:119551319	NA	0.5	6.53	0.38	3.75e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs867371	0.964	rs7169961	chr15:82478929	C/T	cg00614314	chr15:82944287	LOC80154	0.54	6.46	0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9815354	0.767	rs73081341	chr3:41900335	A/T	cg03022575	chr3:42003672	ULK4	0.57	5.56	0.33	7.13e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.64	8.78	0.49	2.75e-16	Multiple sclerosis;
KIRP	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.17	-0.31	4.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13108601	chr6:41748242	FRS3;PRICKLE4	0.63	7.42	0.43	1.9e-12	Smoking initiation;
KIRP	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.43	-5.0	-0.3	1.09e-6	Colorectal cancer;
KIRP	cis	rs9400467	0.528	rs1623806	chr6:111665071	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.84	-6.93	-0.4	3.58e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg02640540	chr1:67518911	SLC35D1	-0.54	-5.23	-0.32	3.57e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	15.69	0.71	6.31e-39	Platelet count;
KIRP	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg03146154	chr1:46216737	IPP	0.55	5.5	0.33	9.56e-8	Platelet count;
KIRP	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.55	-6.84	-0.4	6.26e-11	Life satisfaction;
KIRP	cis	rs2562456	0.754	rs11666213	chr19:21605645	G/A	cg18461458	chr19:21324796	ZNF431	-0.54	-5.09	-0.31	7.24e-7	Pain;
KIRP	cis	rs76662990	0.666	rs7734383	chr5:73937854	A/T	cg03335624	chr5:73934942	ENC1	-0.45	-5.08	-0.31	7.62e-7	Residual cognition;
KIRP	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg18944383	chr4:111397179	ENPEP	0.46	7.27	0.42	4.66e-12	Coronary artery disease;
KIRP	cis	rs7766436	0.770	rs11751669	chr6:22571037	A/G	cg13666174	chr6:22585274	NA	-0.48	-6.38	-0.38	8.94e-10	Coronary artery disease;
KIRP	cis	rs1757171	0.504	rs11969056	chr6:37484285	C/T	cg25019722	chr6:37503610	NA	-0.99	-15.6	-0.71	1.34e-38	Cognitive performance;
KIRP	cis	rs9815354	1.000	rs17063649	chr3:41863406	C/T	cg03022575	chr3:42003672	ULK4	0.6	6.9	0.4	4.36e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-0.98	-15.16	-0.7	4.1e-37	Dilated cardiomyopathy;
KIRP	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.03	11.58	0.59	4.71e-25	Vitiligo;
KIRP	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.53	7.06	0.41	1.65e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21487830	chr17:48943706	NA	0.49	6.51	0.38	4.13e-10	Parkinson's disease;
KIRP	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg08885076	chr2:99613938	TSGA10	-0.46	-6.83	-0.4	6.69e-11	Fear of minor pain;
KIRP	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg03468072	chr12:39539422	NA	0.43	5.87	0.35	1.37e-8	Morning vs. evening chronotype;
KIRP	cis	rs629922	1.000	rs629922	chr11:114064825	C/T	cg25009965	chr11:114031120	ZBTB16	-0.42	-5.45	-0.33	1.19e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.71	6.91	0.4	4.17e-11	Breast cancer;
KIRP	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg18105134	chr13:113819100	PROZ	-1.2	-14.52	-0.68	6.29e-35	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13412003	chr19:35455007	ZNF792	0.46	6.15	0.37	3.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg03808351	chr9:123631620	PHF19	0.44	6.02	0.36	6.23e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25036234	chr2:25264781	EFR3B	0.54	6.77	0.4	9.49e-11	Parkinson's disease;
KIRP	cis	rs7737355	0.947	rs6884741	chr5:130894613	A/G	cg06307176	chr5:131281290	NA	0.53	5.8	0.35	2.06e-8	Life satisfaction;
KIRP	cis	rs10463316	0.779	rs1810084	chr5:150777048	A/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-5.78	-0.35	2.21e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-8.69	-0.48	5.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg19847866	chr10:1019161	NA	-0.57	-5.09	-0.31	6.98e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs9653442	0.564	rs7565895	chr2:100774773	G/A	cg17356467	chr2:100759845	AFF3	0.42	5.69	0.34	3.63e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.31	-0.37	1.29e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	0.73	6.4	0.38	7.82e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs76081789	0.536	rs2838301	chr21:44838081	A/G	cg03566291	chr21:44831040	NA	-0.61	-5.05	-0.31	8.65e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg27539214	chr16:67997921	SLC12A4	-0.54	-5.01	-0.3	1.03e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.74	11.07	0.58	2.26e-23	Monocyte percentage of white cells;
KIRP	cis	rs10874312	0.760	rs913181	chr1:82953031	T/A	cg09892671	chr1:82951578	NA	-0.38	-5.41	-0.33	1.49e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg25173405	chr17:45401733	C17orf57	-0.5	-6.63	-0.39	2.06e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.45	-7.53	-0.43	9.34e-13	Type 2 diabetes;
KIRP	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.44	-5.88	-0.35	1.35e-8	Schizophrenia;
KIRP	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.57	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg23736307	chr8:27182930	PTK2B	0.55	6.91	0.4	4.24e-11	Neuroticism;
KIRP	cis	rs2594989	0.943	rs2454504	chr3:11498423	G/A	cg01796438	chr3:11312864	ATG7	-0.6	-7.74	-0.44	2.57e-13	Circulating chemerin levels;
KIRP	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	9.57	0.52	1.21e-18	Coffee consumption (cups per day);
KIRP	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.63	5.32	0.32	2.32e-7	Glioblastoma;
KIRP	cis	rs4253772	1.000	rs4253766	chr22:46623905	C/T	cg09491104	chr22:46646882	C22orf40	-0.5	-5.91	-0.35	1.15e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg23958373	chr8:599963	NA	0.8	6.25	0.37	1.78e-9	IgG glycosylation;
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg17232254	chr10:64927353	JMJD1C	0.43	6.16	0.37	2.91e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.61	-0.39	2.35e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.56	7.72	0.44	2.99e-13	Mean corpuscular volume;
KIRP	cis	rs6001930	0.579	rs73167073	chr22:40879408	A/G	cg07138101	chr22:40742427	ADSL	0.7	5.62	0.34	5.15e-8	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg11833968	chr6:79620685	NA	0.46	6.48	0.38	5.08e-10	Left atrial antero-posterior diameter;
KIRP	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.44	5.99	0.36	7.29e-9	Coronary artery disease;
KIRP	cis	rs12580194	0.593	rs12578879	chr12:55797773	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-6.68	-0.39	1.62e-10	Cancer;
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.57	-5.93	-0.35	1.01e-8	Lung function (FEV1/FVC);
KIRP	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.91	14.22	0.67	6.55e-34	Longevity;Endometriosis;
KIRP	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg11846333	chr4:119757529	SEC24D	1.18	7.1	0.41	1.3e-11	Cannabis dependence symptom count;
KIRP	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg23307798	chr14:103986281	CKB	0.79	13.84	0.66	1.37e-32	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03195600	chr16:11350371	SOCS1	0.49	6.16	0.37	2.87e-9	Parkinson's disease;
KIRP	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.6	-8.14	-0.46	1.94e-14	Life satisfaction;
KIRP	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg23166289	chr1:210001082	C1orf107	-0.51	-5.18	-0.31	4.54e-7	Orofacial clefts;
KIRP	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.49	5.87	0.35	1.41e-8	Menarche (age at onset);
KIRP	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.6	7.85	0.45	1.3e-13	Mean corpuscular volume;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg07216194	chr8:27182965	PTK2B	0.46	5.73	0.34	2.98e-8	Neuroticism;
KIRP	cis	rs11997175	0.545	rs4733458	chr8:33661542	G/T	cg04338863	chr8:33670619	NA	0.44	5.54	0.33	7.73e-8	Body mass index;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg04624059	chr7:99063424	ATP5J2	0.5	6.31	0.37	1.28e-9	Asthma;
KIRP	cis	rs11718455	0.960	rs1852037	chr3:44003720	G/T	cg21419209	chr3:44054225	NA	0.74	9.25	0.51	1.11e-17	Coronary artery disease;
KIRP	cis	rs2617583	0.509	rs748209	chr5:1457554	A/C	cg07151155	chr5:1473589	LPCAT1	-0.42	-5.23	-0.32	3.55e-7	Breast cancer;
KIRP	cis	rs6670533	0.571	rs61358817	chr1:24864789	G/A	cg07475527	chr1:24864545	NA	-1.02	-8.31	-0.47	6.67e-15	Fasting blood insulin (BMI interaction);
KIRP	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg01420254	chr6:26195488	NA	1.17	8.3	0.47	7e-15	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg08999081	chr20:33150536	PIGU	0.4	4.9	0.3	1.75e-6	Height;
KIRP	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg16141378	chr3:129829833	LOC729375	0.49	6.32	0.37	1.21e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02179239	chr10:23002514	PIP4K2A	-0.47	-6.05	-0.36	5.23e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs7729447	0.813	rs4867121	chr5:32692548	T/C	cg16267343	chr5:32710456	NPR3	0.53	6.1	0.36	3.99e-9	Blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06338299	chr10:98591780	LCOR	0.48	6.02	0.36	6.43e-9	Parkinson's disease;
KIRP	cis	rs698833	0.926	rs1067370	chr2:44652343	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	4.98	0.3	1.22e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg25588787	chr5:154027256	NA	0.4	4.92	0.3	1.58e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3026101	0.554	rs1806259	chr17:5315502	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.48e-8	Body mass index;
KIRP	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.41	6.02	0.36	6.41e-9	Lipoprotein (a) levels;
KIRP	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.63	8.45	0.47	2.65e-15	Aortic root size;
KIRP	cis	rs732716	0.889	rs62129355	chr19:4397034	T/C	cg19820705	chr19:4455316	UBXN6	0.67	8.27	0.47	8.46e-15	Mean corpuscular volume;
KIRP	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16405210	chr4:1374714	KIAA1530	-0.47	-6.43	-0.38	6.45e-10	Obesity-related traits;
KIRP	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.29	-0.62	2.2e-27	Blood trace element (Zn levels);
KIRP	cis	rs9400467	0.528	rs17539197	chr6:111769171	C/G	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.68	-0.34	3.69e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg09699651	chr6:150184138	LRP11	0.47	6.05	0.36	5.39e-9	Lung cancer;
KIRP	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg19899395	chr1:46959349	NA	0.38	4.93	0.3	1.48e-6	Monobrow;
KIRP	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.76	6.38	0.38	8.77e-10	Body mass index;
KIRP	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.69	7.22	0.42	6.54e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.64	8.66	0.48	6.45e-16	Menarche (age at onset);
KIRP	cis	rs2916247	0.954	rs66579130	chr8:93054332	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.81	-0.45	1.69e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg01721255	chr8:58191610	C8orf71	0.5	5.33	0.32	2.2e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg10790698	chr19:18539756	SSBP4	-0.34	-7.42	-0.43	1.85e-12	Breast cancer;
KIRP	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg13072238	chr3:49761600	GMPPB	-0.59	-5.62	-0.34	5.22e-8	Menarche (age at onset);
KIRP	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg03060546	chr3:49711283	APEH	0.53	7.05	0.41	1.75e-11	Menarche (age at onset);
KIRP	cis	rs3105593	0.933	rs3131576	chr15:50863658	T/C	cg05456662	chr15:50716270	USP8	0.38	5.03	0.31	9.39e-7	QT interval;
KIRP	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.72	10.21	0.55	1.25e-20	Mood instability;
KIRP	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg03714773	chr7:91764589	CYP51A1	0.36	5.22	0.32	3.73e-7	Breast cancer;
KIRP	cis	rs714515	0.934	rs9425299	chr1:172359100	C/T	cg01573306	chr1:172330400	DNM3	0.44	5.7	0.34	3.45e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-5.34	-0.32	2.1e-7	Endometrial cancer;
KIRP	cis	rs5753618	0.561	rs714909	chr22:31741067	G/A	cg22777020	chr22:31556080	RNF185	0.48	5.16	0.31	4.99e-7	Colorectal cancer;
KIRP	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.04e-10	Height;
KIRP	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg11130432	chr3:121712080	ILDR1	-0.43	-5.08	-0.31	7.62e-7	Multiple sclerosis;
KIRP	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.71	9.09	0.5	3.42e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg06742321	chr12:123595122	PITPNM2	0.44	5.3	0.32	2.54e-7	Height;Educational attainment;Head circumference (infant);
KIRP	trans	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.91	14.44	0.68	1.19e-34	Breast cancer;
KIRP	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.29	0.62	2.12e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.65	-6.16	-0.37	3.03e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.76	-11.62	-0.6	3.64e-25	Prostate cancer;
KIRP	cis	rs10077591	0.691	rs1562229	chr5:165330617	A/G	cg13976338	chr5:165423657	NA	0.58	7.6	0.44	6.04e-13	Schizophrenia;
KIRP	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.6	-0.39	2.46e-10	Retinal vascular caliber;
KIRP	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg10047753	chr17:41438598	NA	0.92	12.67	0.63	1.16e-28	Menopause (age at onset);
KIRP	cis	rs236907	0.859	rs2294718	chr1:171750854	C/G	cg01410279	chr1:171621941	MYOC	-0.52	-5.13	-0.31	5.96e-7	Mean platelet volume;
KIRP	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12826209	chr6:26865740	GUSBL1	0.6	4.94	0.3	1.44e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.71	-6.46	-0.38	5.71e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03480535	chr4:87856849	AFF1	0.45	6.16	0.37	3e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg16497661	chr14:103986332	CKB	0.76	11.36	0.59	2.52e-24	Body mass index;
KIRP	cis	rs10073892	0.744	rs10062241	chr5:101838049	G/A	cg19774478	chr5:101632501	SLCO4C1	0.66	6.54	0.38	3.57e-10	Cognitive decline (age-related);
KIRP	cis	rs6545883	0.859	rs62149714	chr2:61603869	T/G	cg15711740	chr2:61764176	XPO1	0.6	7.75	0.44	2.39e-13	Tuberculosis;
KIRP	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.51	-6.15	-0.37	3.07e-9	Coffee consumption (cups per day);
KIRP	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.76	-10.54	-0.56	1.14e-21	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg25706552	chr1:244017396	NA	0.58	6.69	0.39	1.51e-10	RR interval (heart rate);
KIRP	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-10.93	-0.57	6.47e-23	Response to antipsychotic treatment;
KIRP	cis	rs10046574	0.517	rs7782727	chr7:135200299	A/G	cg27474649	chr7:135195673	CNOT4	0.56	5.28	0.32	2.82e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.48	6.91	0.4	4.08e-11	Response to Dalcetrapib treatment in acute coronary syndrome;
KIRP	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.8	14.77	0.69	8.83e-36	Sjögren's syndrome;
KIRP	cis	rs4262150	0.960	rs4310018	chr5:152286204	C/T	cg12297329	chr5:152029980	NA	0.42	5.9	0.35	1.21e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.44	6.47	0.38	5.29e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.59	-7.43	-0.43	1.73e-12	Extraversion;
KIRP	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg00656387	chr3:40428638	ENTPD3	0.41	5.13	0.31	5.79e-7	Renal cell carcinoma;
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.81	-10.94	-0.57	5.89e-23	Uric acid levels;
KIRP	cis	rs9488822	0.597	rs12214881	chr6:116342187	G/T	cg18764771	chr6:116381957	FRK	0.19	5.24	0.32	3.45e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.76	12.25	0.62	3.06e-27	Ewing sarcoma;
KIRP	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.9	15.03	0.69	1.2e-36	Breast cancer;
KIRP	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg18016565	chr1:150552671	MCL1	0.4	6.22	0.37	2.07e-9	Melanoma;
KIRP	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs7258465	1.000	rs10442	chr19:18545341	A/C	cg06953865	chr19:18549723	ISYNA1	-0.39	-5.97	-0.36	8.33e-9	Breast cancer;
KIRP	cis	rs151997	1.000	rs26063	chr5:50216718	G/A	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.4	5.16	0.31	5.1e-7	Melanoma;
KIRP	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.61	-0.39	2.35e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg16989719	chr2:238392110	NA	-0.6	-8.34	-0.47	5.25e-15	Prostate cancer;
KIRP	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.57	7.04	0.41	1.95e-11	Aortic root size;
KIRP	cis	rs2274459	0.841	rs2281918	chr6:33663055	G/A	cg06253072	chr6:33679850	C6orf125	0.53	5.56	0.33	7.09e-8	Obesity (extreme);
KIRP	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg23750338	chr8:142222470	SLC45A4	0.44	6.36	0.38	9.92e-10	Immature fraction of reticulocytes;
KIRP	cis	rs34779708	0.931	rs4934710	chr10:35350416	T/C	cg03585969	chr10:35415529	CREM	0.79	9.51	0.52	1.78e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.91	-14.91	-0.69	2.98e-36	Urate levels in lean individuals;
KIRP	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13487956	chr18:47340408	SCARNA17;ACAA2	0.5	6.45	0.38	5.93e-10	Parkinson's disease;
KIRP	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	1.01	18.28	0.76	9.79e-48	Bone mineral density;
KIRP	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-5.76	-0.34	2.53e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.4	4.87	0.3	2.04e-6	Renal cell carcinoma;
KIRP	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg05573767	chr6:167171394	RPS6KA2	-0.23	-4.95	-0.3	1.36e-6	Crohn's disease;
KIRP	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg05294307	chr14:35346193	BAZ1A	-0.46	-4.96	-0.3	1.35e-6	Psoriasis;
KIRP	cis	rs4851254	0.550	rs13402289	chr2:100659389	C/T	cg17356467	chr2:100759845	AFF3	0.55	5.91	0.35	1.11e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg20243544	chr17:37824526	PNMT	0.52	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs2274273	0.712	rs9806049	chr14:55525589	C/A	cg04306507	chr14:55594613	LGALS3	0.41	6.2	0.37	2.32e-9	Protein biomarker;
KIRP	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg26441486	chr22:50317300	CRELD2	0.54	7.79	0.44	1.89e-13	Schizophrenia;
KIRP	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg25173405	chr17:45401733	C17orf57	0.45	6.1	0.36	4.05e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.52	6.73	0.39	1.22e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.39	5.94	0.35	9.44e-9	Neuroticism;
KIRP	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.79	8.89	0.49	1.31e-16	Corneal astigmatism;
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.63	8.43	0.47	2.93e-15	Mean corpuscular volume;
KIRP	cis	rs684232	0.901	rs1741275	chr17:630363	C/G	cg15660573	chr17:549704	VPS53	-0.47	-6.0	-0.36	6.88e-9	Prostate cancer;
KIRP	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	6.39	0.38	8.48e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg09264619	chr17:80180166	NA	-0.37	-5.37	-0.32	1.78e-7	Life satisfaction;
KIRP	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg06637938	chr14:75390232	RPS6KL1	0.43	5.99	0.36	7.53e-9	Height;
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07648498	chr16:89883185	FANCA	-0.4	-5.33	-0.32	2.22e-7	Vitiligo;
KIRP	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.67	6.63	0.39	2.08e-10	Axial length;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg01813649	chr6:116421855	NT5DC1	-0.46	-6.27	-0.37	1.57e-9	Metabolic traits;
KIRP	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg00262122	chr8:11665843	FDFT1	0.43	5.3	0.32	2.58e-7	Retinal vascular caliber;
KIRP	cis	rs4664293	0.967	rs10176436	chr2:160515394	G/A	cg08347373	chr2:160653686	CD302	-0.38	-5.83	-0.35	1.75e-8	Monocyte percentage of white cells;
KIRP	cis	rs4664293	0.867	rs7562060	chr2:160587129	T/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg00277334	chr10:82204260	NA	-0.54	-5.69	-0.34	3.6e-8	Post bronchodilator FEV1;
KIRP	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.44	-9.55	-0.52	1.37e-18	Mean corpuscular volume;
KIRP	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.71	-0.34	3.17e-8	Coronary artery disease;
KIRP	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg12598211	chr12:123634384	NA	-0.4	-4.93	-0.3	1.55e-6	Neutrophil percentage of white cells;
KIRP	cis	rs738322	0.901	rs132941	chr22:38545942	T/C	cg25457927	chr22:38595422	NA	-0.34	-7.18	-0.42	8.04e-12	Cutaneous nevi;
KIRP	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg11845111	chr2:191398756	TMEM194B	-0.86	-9.76	-0.53	3.15e-19	Diastolic blood pressure;
KIRP	cis	rs7084402	0.934	rs1658453	chr10:60309602	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.91	-0.57	7.44e-23	Refractive error;
KIRP	cis	rs412050	0.547	rs112153746	chr22:22138691	G/A	cg17089214	chr22:22089827	YPEL1	0.64	5.87	0.35	1.43e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	0.44	6.01	0.36	6.66e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9488822	0.676	rs11757115	chr6:116362619	C/T	cg26893134	chr6:116381904	FRK	0.21	5.6	0.34	5.84e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03517284	chr6:25882590	NA	-0.63	-7.63	-0.44	5.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs829661	0.793	rs7606200	chr2:30790273	G/A	cg10949345	chr2:30726833	LCLAT1	1.01	12.91	0.64	1.88e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg10254082	chr7:997346	NA	0.48	5.03	0.31	9.55e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7577696	0.568	rs7574000	chr2:32342888	A/C	cg02381751	chr2:32503542	YIPF4	-0.53	-5.36	-0.32	1.88e-7	Inflammatory biomarkers;
KIRP	cis	rs7116495	0.609	rs595062	chr11:71809635	C/T	cg26138937	chr11:71823887	C11orf51	1.16	7.55	0.43	8.52e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs7116495	0.609	rs2511120	chr11:71786211	C/T	cg10381502	chr11:71823885	C11orf51	-1.15	-7.55	-0.43	8.26e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs7224685	0.520	rs12453690	chr17:4037678	T/C	cg21851534	chr17:3907994	ZZEF1	-0.61	-9.5	-0.52	1.98e-18	Type 2 diabetes;
KIRP	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.1	-0.31	6.77e-7	Life satisfaction;
KIRP	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.52	-4.95	-0.3	1.36e-6	Height;
KIRP	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.78	11.24	0.58	6.49e-24	Bladder cancer;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.65	10.55	0.56	1.02e-21	Lymphocyte counts;
KIRP	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs17057051	0.591	rs60795589	chr8:27259933	A/T	cg23736307	chr8:27182930	PTK2B	-0.42	-4.85	-0.3	2.22e-6	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs77861329	1.000	rs352149	chr3:52209530	C/A	cg08692210	chr3:52188851	WDR51A	0.92	7.26	0.42	5.03e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg24565620	chr2:194026	NA	-0.72	-5.36	-0.32	1.93e-7	Blood protein levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09014478	chr11:95523067	CEP57;FAM76B	0.43	6.09	0.36	4.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.23e-6	Recombination rate (females);
KIRP	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg10434728	chr15:90938212	IQGAP1	0.39	7.34	0.42	3.11e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.46	5.7	0.34	3.42e-8	Common traits (Other);
KIRP	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg12315302	chr6:26189340	HIST1H4D	1.09	6.06	0.36	5.11e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg22325292	chr17:80708367	FN3K	0.39	5.24	0.32	3.44e-7	Glycated hemoglobin levels;
KIRP	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg11608241	chr8:8085544	FLJ10661	0.44	5.66	0.34	4.17e-8	Mood instability;
KIRP	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg04691961	chr3:161091175	C3orf57	0.65	10.65	0.56	4.85e-22	Morning vs. evening chronotype;
KIRP	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.36	-8.12	-0.46	2.29e-14	Cutaneous nevi;
KIRP	cis	rs238295	0.805	rs6053486	chr20:5530767	T/G	cg24001556	chr20:5591874	RP5-1022P6.2	-0.49	-4.99	-0.3	1.15e-6	Occipital cortical area (total cortical area interaction);
KIRP	cis	rs9826463	0.582	rs2306700	chr3:142123841	C/T	cg20824294	chr3:142316082	PLS1	0.35	5.16	0.31	5.06e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg23505145	chr19:12996616	KLF1	-0.56	-8.08	-0.46	2.98e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg09904177	chr6:26538194	HMGN4	0.4	5.06	0.31	8.38e-7	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22797570	chr3:24563278	NA	0.47	6.45	0.38	5.82e-10	Parkinson's disease;
KIRP	cis	rs981844	0.775	rs17299519	chr4:154762123	C/T	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs33912345	0.750	rs1254269	chr14:60843017	G/A	cg27398547	chr14:60952738	C14orf39	-0.4	-5.29	-0.32	2.71e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs2274273	0.840	rs10136596	chr14:55836773	A/G	cg04306507	chr14:55594613	LGALS3	0.44	6.92	0.4	3.98e-11	Protein biomarker;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15017283	chr11:126138732	FOXRED1;SRPR	0.52	6.49	0.38	4.57e-10	Parkinson's disease;
KIRP	cis	rs3779635	1.000	rs3779635	chr8:27284692	C/T	cg18234130	chr8:27182889	PTK2B	0.43	5.51	0.33	9.19e-8	Neuroticism;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg13441983	chr11:10327014	ADM	0.51	6.2	0.37	2.36e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs662064	0.962	rs668805	chr1:10544547	A/G	cg19773385	chr1:10388646	KIF1B	-0.4	-5.06	-0.31	8.34e-7	Asthma;
KIRP	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs2274273	0.661	rs8019978	chr14:55557284	A/G	cg04306507	chr14:55594613	LGALS3	-0.48	-7.71	-0.44	3.02e-13	Protein biomarker;
KIRP	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg09491104	chr22:46646882	C22orf40	-0.61	-7.64	-0.44	4.75e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg08738300	chr3:44038990	NA	0.66	9.13	0.5	2.65e-17	Coronary artery disease;
KIRP	trans	rs4349753	0.904	rs248563	chr5:144186809	C/T	cg16033277	chr17:80885358	TBCD	0.4	6.28	0.37	1.52e-9	Photic sneeze reflex;
KIRP	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.53	-6.42	-0.38	6.94e-10	Metabolite levels;
KIRP	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.72	10.43	0.55	2.46e-21	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.25	-5.28	-0.32	2.81e-7	Menarche (age at onset);
KIRP	trans	rs7729273	0.956	rs13179974	chr5:7190401	A/G	cg13850847	chr9:136131739	ABO	0.51	6.48	0.38	5.03e-10	Cognitive performance;
KIRP	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg08975724	chr8:8085496	FLJ10661	0.66	9.08	0.5	3.62e-17	Mood instability;
KIRP	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg13047869	chr3:10149882	C3orf24	0.49	4.88	0.3	1.88e-6	Alzheimer's disease;
KIRP	cis	rs2071403	0.799	rs11211643	chr2:1402588	A/G	cg07083862	chr2:1417248	TPO	0.34	5.3	0.32	2.54e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-9.07	-0.5	3.96e-17	Resting heart rate;
KIRP	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg22117172	chr7:91764530	CYP51A1	-0.47	-6.48	-0.38	5.05e-10	Breast cancer;
KIRP	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.37	5.0	0.3	1.1e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.82	-9.74	-0.53	3.65e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs2599510	0.807	rs176416	chr2:32652223	A/G	cg02381751	chr2:32503542	YIPF4	-0.5	-5.86	-0.35	1.46e-8	Interleukin-18 levels;
KIRP	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.16	15.64	0.71	9.75e-39	Corneal structure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20530585	chr3:149376036	WWTR1	0.51	7.13	0.41	1.13e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs72925845	0.519	rs691674	chr17:76424502	C/G	cg03830375	chr17:76426088	DNAH17	0.47	5.0	0.3	1.1e-6	Triglycerides;
KIRP	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg18132916	chr6:79620363	NA	-0.42	-5.73	-0.34	2.85e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.27	7.2	0.42	7.26e-12	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00933542	chr6:150070202	PCMT1	0.29	5.5	0.33	9.45e-8	Lung cancer;
KIRP	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	0.99	15.92	0.71	1.09e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	trans	rs591584	0.802	rs6483346	chr11:94288651	C/G	cg23986671	chr21:28339262	ADAMTS5	-0.5	-6.42	-0.38	7.08e-10	Macrophage Migration Inhibitory Factor levels;
KIRP	cis	rs988913	0.957	rs1393774	chr6:54838449	G/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.28	-0.32	2.86e-7	Menarche (age at onset);
KIRP	cis	rs2910162	0.865	rs4921291	chr5:159920295	G/A	cg03306240	chr5:159912455	MIR146A	0.45	6.74	0.4	1.09e-10	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs885389	1.000	rs867411	chr12:131621789	T/G	cg06374807	chr12:131606857	GPR133	-0.47	-6.18	-0.37	2.6e-9	RR interval (heart rate);
KIRP	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.54	7.28	0.42	4.49e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-8.5	-0.48	1.79e-15	Resting heart rate;
KIRP	cis	rs17641971	0.599	rs2385230	chr8:50015755	A/G	cg00325661	chr8:49890786	NA	0.44	5.69	0.34	3.54e-8	Blood metabolite levels;
KIRP	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.55	7.02	0.41	2.2e-11	Autism;
KIRP	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.87	12.65	0.63	1.38e-28	Bladder cancer;
KIRP	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg13147721	chr7:65941812	NA	-0.97	-6.86	-0.4	5.52e-11	Diabetic kidney disease;
KIRP	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg15488143	chr7:128924101	AHCYL2	0.59	6.42	0.38	6.96e-10	White matter hyperintensity burden;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg05780637	chr2:239989132	HDAC4	0.49	6.29	0.37	1.45e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11718455	0.503	rs4017425	chr3:44028764	C/T	cg08738300	chr3:44038990	NA	0.39	6.03	0.36	6.1e-9	Coronary artery disease;
KIRP	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	17.48	0.74	5.23e-45	Platelet count;
KIRP	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg17595323	chr11:93583763	C11orf90	-0.31	-5.23	-0.32	3.61e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg00931491	chr16:28608288	SULT1A2	0.26	5.07	0.31	7.94e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.58	-0.39	2.81e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs72634258	0.945	rs225131	chr1:8095486	T/C	cg00042356	chr1:8021962	PARK7	0.52	5.34	0.32	2.09e-7	Inflammatory bowel disease;
KIRP	cis	rs1784203	1.000	rs1784203	chr11:93450134	A/G	cg10353388	chr11:93474820	C11orf54;TAF1D	-1.27	-7.63	-0.44	5.09e-13	Waist circumference adjusted for body mass index;
KIRP	cis	rs300890	0.513	rs7685464	chr4:144072438	G/C	cg01719995	chr4:144104893	USP38	-0.43	-5.51	-0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.67	-7.29	-0.42	4.22e-12	DNA methylation (variation);
KIRP	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.14	0.46	1.98e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4262150	0.883	rs55829928	chr5:152189967	T/G	cg12297329	chr5:152029980	NA	-0.65	-8.38	-0.47	4.12e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.64	-9.01	-0.5	5.69e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16420520	chr6:116544548	NT5DC1	-0.4	-6.24	-0.37	1.92e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg04369109	chr6:150039330	LATS1	-0.44	-5.28	-0.32	2.89e-7	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21441505	chr4:1714055	SLBP	0.51	6.64	0.39	2.03e-10	Parkinson's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02126098	chr17:61699788	MAP3K3	0.46	6.28	0.37	1.48e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg04037228	chr3:45636386	LIMD1	-0.35	-5.03	-0.31	9.37e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.41	-7.96	-0.45	6.28e-14	Educational attainment (years of education);
KIRP	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.91	13.0	0.64	9.36e-30	Tonsillectomy;
KIRP	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg01411142	chr8:19674711	INTS10	0.5	5.39	0.33	1.63e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.54	0.38	3.49e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.6	-7.25	-0.42	5.24e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg18016565	chr1:150552671	MCL1	0.4	6.05	0.36	5.34e-9	Melanoma;
KIRP	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-6.57	-0.39	3.05e-10	Total cholesterol levels;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg22903657	chr4:1355424	KIAA1530	-0.53	-7.54	-0.43	9.25e-13	Obesity-related traits;
KIRP	cis	rs5753037	0.869	rs5752992	chr22:30384044	C/T	cg27665648	chr22:30112403	NA	0.36	5.06	0.31	8.23e-7	Type 1 diabetes;
KIRP	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg17294928	chr15:75287854	SCAMP5	0.57	7.64	0.44	4.94e-13	Breast cancer;
KIRP	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.39	6.26	0.37	1.73e-9	Colorectal cancer;
KIRP	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.37	5.61	0.34	5.43e-8	Mean corpuscular volume;
KIRP	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg24826892	chr11:71159390	DHCR7	0.44	5.24	0.32	3.42e-7	Vitamin D levels;
KIRP	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.45	-5.31	-0.32	2.41e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10861661	0.963	rs11113118	chr12:107199142	G/A	cg15890332	chr12:107067104	RFX4	0.35	5.27	0.32	2.98e-7	Triglyceride levels;
KIRP	cis	rs9303280	0.806	rs4795400	chr17:38067020	C/T	cg19468946	chr17:37922297	IKZF3	-0.52	-8.01	-0.45	4.59e-14	Self-reported allergy;
KIRP	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.81	11.47	0.59	1.13e-24	Obesity-related traits;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg22473806	chr4:128839476	MFSD8	0.38	6.31	0.37	1.31e-9	C-reactive protein;
KIRP	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.4	5.21	0.32	4.06e-7	Melanoma;
KIRP	trans	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.81	0.4	7.31e-11	Retinal vascular caliber;
KIRP	cis	rs11997175	0.704	rs11775534	chr8:33695232	G/A	cg04338863	chr8:33670619	NA	0.4	5.43	0.33	1.37e-7	Body mass index;
KIRP	cis	rs3931020	0.530	rs6668736	chr1:75234550	C/T	cg21535942	chr1:75199100	CRYZ;TYW3	0.45	5.93	0.35	1.03e-8	Resistin levels;
KIRP	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg18461458	chr19:21324796	ZNF431	0.48	5.11	0.31	6.53e-7	Pain;
KIRP	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg04315214	chr1:2043799	PRKCZ	-0.39	-5.88	-0.35	1.31e-8	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21774377	chr6:34760070	UHRF1BP1	0.56	6.55	0.39	3.29e-10	Smoking initiation;
KIRP	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-5.55	-0.33	7.46e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.88	0.3	1.87e-6	Tonsillectomy;
KIRP	trans	rs526821	0.595	rs608964	chr11:55339266	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-6.2	-0.37	2.42e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21545522	chr1:205238299	TMCC2	0.55	7.11	0.41	1.22e-11	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg14993813	chr1:46806288	NSUN4	-0.6	-6.81	-0.4	7.38e-11	Menopause (age at onset);
KIRP	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg21395723	chr22:39101663	GTPBP1	0.44	5.37	0.32	1.85e-7	Menopause (age at onset);
KIRP	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg24375607	chr4:120327624	NA	0.49	5.78	0.35	2.24e-8	Corneal astigmatism;
KIRP	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg13010199	chr12:38710504	ALG10B	-0.47	-5.94	-0.35	9.54e-9	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17221829	0.733	rs12421173	chr11:89384488	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg25319279	chr11:5960081	NA	-0.52	-5.02	-0.3	1.01e-6	DNA methylation (variation);
KIRP	cis	rs6142102	0.602	rs2300209	chr20:32643100	T/C	cg08999081	chr20:33150536	PIGU	0.38	4.91	0.3	1.65e-6	Skin pigmentation;
KIRP	trans	rs10936632	0.565	rs7610584	chr3:170153183	C/T	cg25378003	chr6:41472488	NA	0.4	6.07	0.36	4.89e-9	Prostate cancer;
KIRP	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg01620082	chr3:125678407	NA	-1.18	-7.43	-0.43	1.79e-12	Depression;
KIRP	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.58	-5.26	-0.32	3.17e-7	Obesity (extreme);
KIRP	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg11569703	chr11:65557185	OVOL1	0.5	7.56	0.43	7.9e-13	Breast cancer;
KIRP	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg03788504	chr6:150331562	NA	-0.34	-6.37	-0.38	9.31e-10	Alopecia areata;
KIRP	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg13319975	chr6:146136371	FBXO30	-0.47	-6.39	-0.38	8.43e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05414026	chr15:72410489	MYO9A;SENP8	0.47	6.19	0.37	2.44e-9	Survival in pancreatic cancer;
KIRP	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg00599163	chr2:162100495	NA	0.43	5.01	0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg16141378	chr3:129829833	LOC729375	0.58	7.26	0.42	5.01e-12	Retinal vascular caliber;
KIRP	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg05347473	chr6:146136440	FBXO30	0.57	7.99	0.45	5.18e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg19847130	chr8:10466454	RP1L1	0.39	5.86	0.35	1.51e-8	Retinal vascular caliber;
KIRP	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg23594656	chr7:65796392	TPST1	-0.52	-8.09	-0.46	2.75e-14	Aortic root size;
KIRP	cis	rs9650657	0.504	rs6601565	chr8:11032228	T/G	cg00405596	chr8:11794950	NA	-0.5	-6.47	-0.38	5.12e-10	Neuroticism;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg01061575	chr22:45098367	PRR5-ARHGAP8;PRR5	-0.48	-6.15	-0.37	3.05e-9	Neuroticism;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25294785	chr12:44152807	IRAK4;PUS7L	-0.46	-6.38	-0.38	8.83e-10	Metabolic traits;
KIRP	cis	rs714027	1.000	rs4823073	chr22:30512258	G/A	cg27665648	chr22:30112403	NA	-0.41	-5.96	-0.35	8.91e-9	Lymphocyte counts;
KIRP	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg10402321	chr1:26617780	UBXN11	-0.43	-5.56	-0.33	7.19e-8	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg13010199	chr12:38710504	ALG10B	0.62	7.72	0.44	2.96e-13	Morning vs. evening chronotype;
KIRP	trans	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg24644049	chr4:85504048	CDS1	0.81	6.12	0.36	3.7e-9	Skin colour saturation;
KIRP	cis	rs10214930	0.697	rs4722719	chr7:27614922	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.89	0.3	1.84e-6	Hypospadias;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19385386	chr19:34012736	PEPD	0.51	6.57	0.39	2.92e-10	Parkinson's disease;
KIRP	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg11906718	chr8:101322791	RNF19A	0.49	6.52	0.38	4.01e-10	Atrioventricular conduction;
KIRP	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	4.99	0.3	1.13e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10214930	0.697	rs7811436	chr7:27641286	T/C	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg04369109	chr6:150039330	LATS1	-0.5	-6.25	-0.37	1.78e-9	Lung cancer;
KIRP	cis	rs17123764	0.710	rs7962645	chr12:50150939	T/C	cg20471783	chr12:50157085	TMBIM6	0.32	5.01	0.3	1.03e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.75	-5.34	-0.32	2.09e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6832769	0.961	rs480479	chr4:56274330	C/T	cg09317128	chr4:56265301	TMEM165	0.54	7.25	0.42	5.54e-12	Personality dimensions;
KIRP	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg13444842	chr1:152974279	SPRR3	-0.36	-5.11	-0.31	6.48e-7	Inflammatory skin disease;
KIRP	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-1.01	-17.13	-0.74	7.82e-44	Height;
KIRP	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	1.18	8.51	0.48	1.7e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.03	0.41	2.07e-11	Caffeine consumption;
KIRP	cis	rs2400749	0.798	rs2021923	chr14:100034686	C/G	cg19965031	chr14:100038389	CCDC85C	-0.45	-5.46	-0.33	1.15e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.9	-12.2	-0.61	4.33e-27	Cognitive function;
KIRP	cis	rs6495367	1.000	rs28412916	chr15:79378167	A/C	cg17916960	chr15:79447300	NA	0.34	5.61	0.34	5.34e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg15733309	chr7:157513707	PTPRN2	0.42	6.37	0.38	9.08e-10	Bipolar disorder and schizophrenia;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24372485	chr19:2078331	MOBKL2A	0.48	6.22	0.37	2.07e-9	Pancreatic cancer;
KIRP	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-1.05	-19.1	-0.77	1.78e-50	Leprosy;
KIRP	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.59	-6.01	-0.36	6.72e-9	Tuberculosis;
KIRP	trans	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.95	-0.45	6.7e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.69	-13.11	-0.64	3.83e-30	White blood cell count (basophil);
KIRP	cis	rs11608355	0.521	rs9888353	chr12:109843594	G/A	cg19025524	chr12:109796872	NA	-0.49	-6.6	-0.39	2.55e-10	Neuroticism;
KIRP	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.65	-0.44	4.45e-13	Body mass index;
KIRP	trans	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg23484912	chr5:273055	PDCD6	0.64	7.61	0.44	5.8e-13	Pancreatic cancer;
KIRP	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg18932078	chr1:2524107	MMEL1	0.4	5.45	0.33	1.23e-7	Ulcerative colitis;
KIRP	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg19847130	chr8:10466454	RP1L1	-0.34	-4.94	-0.3	1.47e-6	Retinal vascular caliber;
KIRP	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg13010199	chr12:38710504	ALG10B	-0.48	-6.02	-0.36	6.14e-9	Morning vs. evening chronotype;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26327118	chr6:39693366	KIF6	-0.46	-6.46	-0.38	5.53e-10	Metabolic traits;
KIRP	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg22916017	chr11:64110731	CCDC88B	0.45	5.08	0.31	7.56e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.37	-0.47	4.25e-15	Personality dimensions;
KIRP	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg08822215	chr16:89438651	ANKRD11	-0.49	-6.35	-0.38	1.02e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.67	8.82	0.49	2.11e-16	Longevity;
KIRP	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.81	-8.36	-0.47	4.61e-15	Chronic sinus infection;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18538332	chr22:24372958	LOC391322	-0.55	-6.84	-0.4	6.15e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7301016	0.947	rs11174517	chr12:62899757	A/G	cg01804193	chr12:63026212	NA	-0.52	-5.42	-0.33	1.4e-7	IgG glycosylation;
KIRP	trans	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg16700650	chr16:69344975	VPS4A	-0.48	-6.19	-0.37	2.44e-9	Thyroid cancer;
KIRP	cis	rs71597109	0.639	rs35416717	chr4:102726657	C/A	cg14855874	chr4:102712397	BANK1	0.4	5.23	0.32	3.69e-7	Chronic lymphocytic leukemia;
KIRP	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.19	-15.85	-0.71	1.85e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs4711336	1.000	rs3818523	chr6:33660371	G/A	cg15676125	chr6:33679581	C6orf125	0.41	5.52	0.33	8.65e-8	Height;
KIRP	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.85	12.29	0.62	2.19e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.82	-12.27	-0.62	2.48e-27	Morning vs. evening chronotype;
KIRP	cis	rs2282032	1.000	rs45471798	chr14:90744546	C/T	cg04374321	chr14:90722782	PSMC1	0.59	5.64	0.34	4.55e-8	Longevity;
KIRP	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.69	9.23	0.51	1.29e-17	Total body bone mineral density;
KIRP	cis	rs9815354	0.951	rs7626217	chr3:41842415	A/G	cg03022575	chr3:42003672	ULK4	0.54	6.2	0.37	2.33e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1593	0.531	rs2221843	chr4:187144200	C/G	cg09526685	chr4:187126073	CYP4V2	0.57	5.16	0.31	5.19e-7	Activated partial thromboplastin time;
KIRP	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg22563815	chr15:78856949	CHRNA5	-0.46	-7.22	-0.42	6.3e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.78	8.88	0.49	1.4e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.59	7.58	0.44	6.86e-13	Height;
KIRP	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.74	-11.04	-0.58	2.81e-23	Blood metabolite ratios;
KIRP	cis	rs6479891	0.630	rs10995447	chr10:64879521	C/T	cg25356468	chr10:64875536	NA	0.46	5.18	0.31	4.58e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.51e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.87	-11.92	-0.6	3.84e-26	Obesity-related traits;
KIRP	cis	rs13361707	1.000	rs58692207	chr5:40780569	T/C	cg01087697	chr5:40835557	RPL37	-0.45	-5.24	-0.32	3.48e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg02461776	chr11:598696	PHRF1	0.71	7.57	0.43	7.49e-13	Systemic lupus erythematosus;
KIRP	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.79	-8.97	-0.5	7.6e-17	Corneal astigmatism;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg10663220	chr12:13249129	GSG1	-0.52	-6.64	-0.39	1.94e-10	Inflammatory biomarkers;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02958133	chr14:50779008	ATP5S;L2HGDH	0.47	6.12	0.36	3.64e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07202461	chr18:19406765	MIB1;MIR133A1	-0.44	-6.68	-0.39	1.57e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs742614	0.935	rs736264	chr20:32482386	C/T	cg06304546	chr20:32448765	NA	0.51	6.6	0.39	2.54e-10	Stearic acid (18:0) levels;
KIRP	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg21573476	chr21:45109991	RRP1B	-0.62	-8.6	-0.48	9.74e-16	Mean corpuscular volume;
KIRP	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06544989	chr22:39130855	UNC84B	0.43	7.52	0.43	1.03e-12	Menopause (age at onset);
KIRP	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	1.04	12.8	0.63	4.25e-29	Breast cancer;
KIRP	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.84	-12.01	-0.61	1.83e-26	Educational attainment;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04590956	chr2:70057467	GMCL1	-0.5	-6.41	-0.38	7.49e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs13161895	0.941	rs6876648	chr5:179441842	T/C	cg02702477	chr5:179499311	RNF130	-0.69	-5.39	-0.33	1.62e-7	LDL cholesterol;
KIRP	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg06223162	chr1:101003688	GPR88	0.51	10.52	0.56	1.25e-21	Breast cancer;
KIRP	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg00792783	chr2:198669748	PLCL1	-0.46	-5.24	-0.32	3.39e-7	Dermatomyositis;
KIRP	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg20673091	chr1:2541236	MMEL1	-0.72	-11.09	-0.58	1.87e-23	Multiple sclerosis;
KIRP	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.48	11.09	0.58	1.96e-23	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg22676075	chr6:135203613	NA	-0.47	-6.67	-0.39	1.64e-10	Red blood cell count;
KIRP	cis	rs7224685	0.722	rs12945048	chr17:4159244	C/A	cg11204139	chr17:3907470	NA	0.61	6.64	0.39	2.02e-10	Type 2 diabetes;
KIRP	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.73	8.04	0.46	3.87e-14	Corneal astigmatism;
KIRP	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.6	8.29	0.47	7.39e-15	Obesity-related traits;
KIRP	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg16194253	chr14:24768981	DHRS1;C14orf21	0.41	4.91	0.3	1.68e-6	Height;
KIRP	cis	rs13315871	1.000	rs13327709	chr3:58408767	C/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg14675211	chr2:100938903	LONRF2	0.51	6.58	0.39	2.89e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-5.01	-0.3	1.02e-6	Cognitive function;
KIRP	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.43	-0.43	1.76e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs62344088	0.590	rs62346174	chr5:296308	C/A	cg22857025	chr5:266934	NA	-1.2	-7.88	-0.45	1.09e-13	Asthma (childhood onset);
KIRP	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.21	-0.46	1.22e-14	Mood instability;
KIRP	trans	rs972578	0.765	rs5751391	chr22:43261499	G/A	cg15321293	chr3:36422198	STAC	-0.48	-6.22	-0.37	2.13e-9	Mean platelet volume;
KIRP	cis	rs986417	0.901	rs10151423	chr14:60996667	A/G	cg27398547	chr14:60952738	C14orf39	0.66	6.34	0.37	1.12e-9	Gut microbiota (bacterial taxa);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg05522145	chr7:53255065	NA	0.41	6.27	0.37	1.58e-9	Cancer;
KIRP	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.27	-22.18	-0.82	1.27e-60	Breast cancer;
KIRP	cis	rs904251	0.523	rs2776870	chr6:37481364	C/A	cg00360474	chr6:37504404	NA	-0.5	-7.49	-0.43	1.22e-12	Cognitive performance;
KIRP	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.4	-0.47	3.71e-15	Morning vs. evening chronotype;
KIRP	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.75	-10.51	-0.56	1.39e-21	Plateletcrit;Platelet count;
KIRP	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.84	12.15	0.61	6.59e-27	Morning vs. evening chronotype;
KIRP	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg22604316	chr1:46958801	NA	0.45	6.44	0.38	6.06e-10	Monobrow;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21925296	chr8:22102597	POLR3D;MIR320A	0.54	7.01	0.41	2.25e-11	Parkinson's disease;
KIRP	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg20312557	chr2:97357134	FER1L5	-0.75	-5.2	-0.31	4.29e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg07585502	chr8:101912084	NA	-0.63	-7.79	-0.44	1.93e-13	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs10918270	1.000	rs10737521	chr1:161932193	C/T	cg19735514	chr1:161762739	ATF6	-0.35	-4.85	-0.3	2.21e-6	Parkinson's disease (age of onset);
KIRP	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg13736514	chr6:26305472	NA	-0.66	-7.94	-0.45	7.32e-14	Educational attainment;
KIRP	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg16988262	chr1:15930761	NA	0.39	5.11	0.31	6.6e-7	Systolic blood pressure;
KIRP	cis	rs17253792	0.915	rs75296402	chr14:56182491	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.8	5.42	0.33	1.41e-7	Putamen volume;
KIRP	cis	rs6575793	0.553	rs7154024	chr14:101031710	G/T	cg18516195	chr14:101012996	BEGAIN	0.47	5.54	0.33	7.95e-8	Menarche (age at onset);
KIRP	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg05639522	chr1:247681581	NA	-0.62	-6.88	-0.4	4.97e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg03289416	chr15:75166202	SCAMP2	0.51	6.89	0.4	4.67e-11	Breast cancer;
KIRP	cis	rs10489525	0.583	rs1967711	chr1:115630967	C/T	cg01522456	chr1:115632236	TSPAN2	0.8	11.02	0.57	3.19e-23	Autism;
KIRP	cis	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.38	-4.99	-0.3	1.12e-6	Melanoma;
KIRP	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-10.57	-0.56	9.25e-22	Morning vs. evening chronotype;
KIRP	cis	rs11710088	0.740	rs73152634	chr3:149196504	G/A	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.42	-0.33	1.39e-7	QRS duration;
KIRP	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg25706552	chr1:244017396	NA	0.57	6.54	0.38	3.53e-10	RR interval (heart rate);
KIRP	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.27	-0.55	8.11e-21	Hemoglobin concentration;
KIRP	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg12908607	chr1:44402522	ARTN	-0.44	-6.74	-0.39	1.1e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg23803603	chr1:2058230	PRKCZ	-0.39	-6.47	-0.38	5.17e-10	Height;
KIRP	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.62	5.57	0.33	6.66e-8	Alzheimer's disease;
KIRP	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.95	15.84	0.71	2.03e-39	Adiposity;
KIRP	cis	rs858239	0.539	rs870476	chr7:23193271	C/T	cg23682824	chr7:23144976	KLHL7	0.48	5.77	0.35	2.34e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg19970325	chr3:122231286	KPNA1	0.39	6.03	0.36	6.02e-9	C-reactive protein;
KIRP	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.41	6.2	0.37	2.35e-9	Neuroticism;
KIRP	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.85	14.2	0.67	7.74e-34	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg23594656	chr7:65796392	TPST1	-0.36	-5.18	-0.31	4.56e-7	Aortic root size;
KIRP	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7127900	0.904	rs11043132	chr11:2232624	T/C	cg25635251	chr11:2234043	NA	0.52	7.87	0.45	1.16e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.73	8.42	0.47	3.12e-15	Obesity-related traits;
KIRP	cis	rs7651190	1	rs7651190	chr3:41765955	A/G	cg03022575	chr3:42003672	ULK4	0.49	5.52	0.33	8.71e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg07023563	chr1:17989633	ARHGEF10L	0.46	6.06	0.36	4.97e-9	Warfarin maintenance dose;
KIRP	cis	rs7187994	0.848	rs16974558	chr16:84787111	G/A	cg07647771	chr16:84786436	USP10	-0.42	-5.42	-0.33	1.44e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs12476592	0.602	rs6736029	chr2:63789170	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg05784532	chr1:230284198	GALNT2	0.45	7.18	0.42	8e-12	Coronary artery disease;
KIRP	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.61	7.66	0.44	4.37e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.76e-7	Life satisfaction;
KIRP	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-5.09	-0.31	7.14e-7	Neuroticism;
KIRP	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.67	-5.84	-0.35	1.64e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	0.501	rs11652060	chr17:4010412	A/T	cg11204139	chr17:3907470	NA	-0.81	-14.58	-0.68	3.97e-35	Type 2 diabetes;
KIRP	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.52	-11.54	-0.59	6.6e-25	Diabetic kidney disease;
KIRP	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.56	7.45	0.43	1.58e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7221595	0.778	rs36054194	chr17:3900280	C/T	cg05562828	chr17:3906858	NA	0.57	6.77	0.4	9.13e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9653442	0.527	rs10185059	chr2:100790172	C/T	cg22139774	chr2:100720529	AFF3	-0.34	-5.27	-0.32	2.99e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.49	-5.89	-0.35	1.29e-8	Alzheimer's disease (late onset);
KIRP	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg15147215	chr3:52552868	STAB1	0.29	5.13	0.31	5.87e-7	Bipolar disorder;
KIRP	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.69	-7.14	-0.41	1.05e-11	Migraine;Coronary artery disease;
KIRP	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.46	-0.43	1.52e-12	Alzheimer's disease (late onset);
KIRP	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.34	-7.66	-0.44	4.38e-13	Cutaneous nevi;
KIRP	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg01831904	chr17:28903510	LRRC37B2	0.86	7.52	0.43	1.05e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13401104	0.796	rs11887959	chr2:237114894	C/T	cg19324714	chr2:237145437	ASB18	0.45	5.0	0.3	1.1e-6	Educational attainment;
KIRP	trans	rs12517041	1.000	rs10054768	chr5:23278161	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.36	-0.47	4.82e-15	Calcium levels;
KIRP	cis	rs62413470	1.000	rs12213291	chr6:55957074	A/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg21285383	chr16:89894308	SPIRE2	-0.29	-5.5	-0.33	9.38e-8	Vitiligo;
KIRP	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg24101359	chr6:42928495	GNMT	0.51	7.08	0.41	1.46e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7601312	1.000	rs11689857	chr2:229317831	C/T	cg02542817	chr2:229291442	NA	-0.38	-5.66	-0.34	4.29e-8	Schizophrenia;
KIRP	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.51	-7.88	-0.45	1.08e-13	IgG glycosylation;
KIRP	cis	rs3134353	0.932	rs1470764	chr8:101950038	A/G	cg07585502	chr8:101912084	NA	0.4	5.04	0.31	9.2e-7	Body mass index;
KIRP	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg09163369	chr1:210001066	C1orf107	0.49	6.21	0.37	2.25e-9	Orofacial clefts;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.71	8.87	0.49	1.52e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18782564	chr6:158365130	SNX9	0.62	7.89	0.45	9.94e-14	Interleukin-4 levels;
KIRP	cis	rs2904967	0.929	rs2904981	chr11:65003026	C/T	cg09225861	chr11:65069680	NA	-0.48	-6.22	-0.37	2.07e-9	Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg26874164	chr19:58962979	ZNF324B	0.47	6.3	0.37	1.33e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs11169552	0.510	rs11169479	chr12:50922336	A/C	cg12884762	chr12:50931848	DIP2B	-0.42	-4.97	-0.3	1.26e-6	Colorectal cancer;
KIRP	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.14	-0.41	1.05e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs16854884	1.000	rs13068298	chr3:143772247	T/C	cg06585982	chr3:143692056	C3orf58	0.52	6.01	0.36	6.59e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01973587	chr1:228161476	NA	-0.4	-5.08	-0.31	7.64e-7	Diastolic blood pressure;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.48	-5.02	-0.3	1.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.24	0.62	3.19e-27	Bone mineral density;
KIRP	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.56	6.81	0.4	7.65e-11	Total body bone mineral density;
KIRP	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12541635	0.677	rs2029879	chr8:107024695	T/A	cg10147462	chr8:107024639	NA	0.33	4.96	0.3	1.33e-6	Age of smoking initiation;
KIRP	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.42	-5.81	-0.35	1.89e-8	Oropharynx cancer;
KIRP	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.26	-0.37	1.71e-9	Cardiac Troponin-T levels;
KIRP	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-7.93	-0.45	7.72e-14	Bipolar disorder;
KIRP	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.69	-10.08	-0.54	3.27e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.51	-7.38	-0.43	2.5e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.29	0.42	4.13e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.56	7.31	0.42	3.69e-12	Breast cancer;
KIRP	cis	rs259282	0.524	rs4805006	chr19:33124136	G/T	cg02997394	chr19:33096574	ANKRD27	-0.42	-4.86	-0.3	2.05e-6	Schizophrenia;
KIRP	cis	rs6997458	0.813	rs3758078	chr8:86374664	A/G	cg02393479	chr8:86352350	CA3	-0.31	-4.95	-0.3	1.4e-6	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	trans	rs7999699	0.902	rs17337685	chr13:48302520	T/C	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg00800038	chr16:89945340	TCF25	-0.76	-5.28	-0.32	2.78e-7	Skin colour saturation;
KIRP	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.39	6.77	0.4	9.63e-11	Heart rate;
KIRP	cis	rs6662572	0.686	rs113117837	chr1:46278158	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.52	0.33	8.6e-8	Blood protein levels;
KIRP	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg26554054	chr8:600488	NA	0.75	5.72	0.34	3.11e-8	IgG glycosylation;
KIRP	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.45	6.82	0.4	6.99e-11	Coronary artery disease;
KIRP	cis	rs1642645	0.872	rs1408948	chr1:42417706	C/T	cg26038582	chr1:42384390	HIVEP3	-0.27	-4.87	-0.3	2.03e-6	Left ventricular obstructive tract defect (maternal effect);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22081084	chr1:89990230	LRRC8B	0.63	7.39	0.43	2.33e-12	Smoking initiation;
KIRP	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.51	7.3	0.42	4.06e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.45	-6.02	-0.36	6.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs580438	0.510	rs9865654	chr3:13428581	A/G	cg10657019	chr3:13328039	NA	-0.59	-7.81	-0.45	1.62e-13	Myringotomy;
KIRP	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs4356975	0.563	rs7676472	chr4:69955944	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.27e-7	Obesity-related traits;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg14025652	chr1:68698718	GPR177	1.04	6.18	0.37	2.63e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg00405596	chr8:11794950	NA	-0.4	-5.31	-0.32	2.4e-7	Triglycerides;
KIRP	trans	rs587242	1.000	rs663771	chr1:96891855	C/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.88	-9.37	-0.51	4.96e-18	Platelet count;
KIRP	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.47	-6.33	-0.37	1.15e-9	Asthma;
KIRP	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg19913688	chr11:428466	ANO9	-0.72	-5.52	-0.33	8.59e-8	Body mass index;
KIRP	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg08313168	chr12:7315531	NA	0.7	6.42	0.38	7.15e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.48	5.76	0.34	2.51e-8	Longevity;Endometriosis;
KIRP	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg13165212	chr22:42675999	NA	0.39	7.01	0.41	2.26e-11	Cognitive function;
KIRP	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.47	6.04	0.36	5.72e-9	Height;
KIRP	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.93	-12.87	-0.63	2.55e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.67	9.09	0.5	3.37e-17	Cognitive test performance;
KIRP	trans	rs9844985	0.630	rs6766837	chr3:116893069	C/G	cg07747994	chr16:89297799	NA	-0.46	-6.12	-0.36	3.59e-9	Major depression and alcohol dependence;
KIRP	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18252515	chr7:66147081	NA	0.45	5.31	0.32	2.43e-7	Aortic root size;
KIRP	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-0.79	-10.67	-0.56	4.19e-22	Urate levels;
KIRP	cis	rs12936587	0.777	rs12942708	chr17:17528011	A/G	cg01246520	chr17:17644344	RAI1	0.38	6.01	0.36	6.6e-9	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.8	-0.45	1.79e-13	Body mass index;
KIRP	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg16141378	chr3:129829833	LOC729375	-0.53	-6.54	-0.38	3.62e-10	Myopia (pathological);
KIRP	cis	rs11997175	0.603	rs716584	chr8:33779748	C/G	ch.8.33884649F	chr8:33765107	NA	0.43	5.14	0.31	5.57e-7	Body mass index;
KIRP	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg21361702	chr7:150065534	REPIN1	0.69	7.27	0.42	4.76e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.07	-0.36	4.9e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg18402987	chr7:1209562	NA	0.46	5.28	0.32	2.87e-7	Longevity;Endometriosis;
KIRP	cis	rs6011002	0.810	rs6010988	chr20:62278210	G/A	cg23957118	chr20:62200850	PRIC285	0.77	5.0	0.3	1.08e-6	Dental caries;
KIRP	cis	rs3779635	0.742	rs28612364	chr8:27252548	C/T	cg23693289	chr8:27183097	PTK2B	0.57	7.35	0.42	2.97e-12	Neuroticism;
KIRP	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.56	8.68	0.48	5.64e-16	Huntington's disease progression;
KIRP	cis	rs7851660	0.844	rs12343182	chr9:100624259	G/C	cg13688889	chr9:100608707	NA	-0.67	-8.9	-0.49	1.23e-16	Strep throat;
KIRP	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.88	-9.74	-0.53	3.59e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg17554472	chr22:41940697	POLR3H	0.49	5.6	0.34	5.75e-8	Neuroticism;
KIRP	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.69	7.26	0.42	5.13e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.5	-0.52	1.96e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.75	9.43	0.52	3.22e-18	Coronary artery disease;
KIRP	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.81	-0.35	1.92e-8	Diastolic blood pressure;
KIRP	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.59	-0.65	9.63e-32	Exhaled nitric oxide output;
KIRP	trans	rs10982712	0.805	rs1029346	chr9:118121424	C/T	cg23764129	chr11:113846017	HTR3A	0.24	6.11	0.36	3.81e-9	Interleukin-9 levels;
KIRP	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.42	-5.61	-0.34	5.55e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs76793172	0.660	rs3760843	chr19:46288706	A/T	cg11657440	chr19:46296263	DMWD	-0.68	-5.01	-0.3	1.05e-6	Eosinophil counts;
KIRP	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Educational attainment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13784866	chr9:139269562	CARD9	-0.5	-6.99	-0.41	2.57e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.61	-7.74	-0.44	2.51e-13	Resistin levels;
KIRP	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg00852783	chr1:26633632	UBXN11	-0.47	-4.95	-0.3	1.37e-6	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.72	11.41	0.59	1.71e-24	Cancer;
KIRP	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.6	7.74	0.44	2.52e-13	Recalcitrant atopic dermatitis;
KIRP	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.72	7.6	0.44	6.2e-13	Migraine;Coronary artery disease;
KIRP	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.91	12.21	0.61	3.93e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.63	-5.17	-0.31	4.8e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.78	11.51	0.59	8.02e-25	Heart rate;
KIRP	cis	rs1134634	0.520	rs73127647	chr4:15641592	A/G	cg16509355	chr4:15471240	CC2D2A	-0.35	-5.97	-0.36	8.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg17554472	chr22:41940697	POLR3H	0.67	7.13	0.41	1.14e-11	Vitiligo;
KIRP	cis	rs858239	0.539	rs6945510	chr7:23192240	C/T	cg23682824	chr7:23144976	KLHL7	0.56	6.67	0.39	1.71e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg04101203	chr11:20408940	PRMT3	-0.48	-4.92	-0.3	1.61e-6	Pursuit maintenance gain;
KIRP	cis	rs1891275	0.508	rs2096079	chr10:93496667	C/G	cg07889827	chr10:93443413	NA	-0.43	-7.32	-0.42	3.42e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.53	8.52	0.48	1.58e-15	Major depressive disorder;
KIRP	cis	rs7258465	1.000	rs2278238	chr19:18576484	T/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.44	-0.43	1.7e-12	Breast cancer;
KIRP	cis	rs7225151	0.710	rs8077567	chr17:5189416	T/C	cg24500398	chr17:5266808	RABEP1	-0.55	-5.01	-0.3	1.02e-6	Alzheimer's disease (late onset);
KIRP	cis	rs16828019	0.929	rs35286837	chr1:41682998	T/G	cg03387723	chr1:41708464	SCMH1	-0.81	-6.92	-0.4	3.88e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.74	-11.29	-0.58	4.33e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.78	11.12	0.58	1.59e-23	Bladder cancer;
KIRP	cis	rs2904967	0.929	rs10750761	chr11:65002091	A/C	cg12562828	chr11:65076843	NA	-0.36	-4.94	-0.3	1.43e-6	Mean corpuscular volume;
KIRP	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	1.06	8.46	0.47	2.42e-15	LDL cholesterol;
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	4.95	0.3	1.4e-6	Longevity;
KIRP	cis	rs72934535	0.689	rs73060663	chr2:204403662	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.62	5.0	0.3	1.1e-6	Coronary artery disease;
KIRP	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	5.3	0.32	2.63e-7	Renal cell carcinoma;
KIRP	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.67	7.27	0.42	4.82e-12	Vitiligo;
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg01283332	chr5:1856932	NA	-0.5	-6.56	-0.39	3.21e-10	Cardiovascular disease risk factors;
KIRP	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.49	6.16	0.37	2.97e-9	Depressive symptoms;
KIRP	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.87	0.45	1.1e-13	Height;
KIRP	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg00919237	chr7:87102261	ABCB4	-0.76	-9.51	-0.52	1.85e-18	Gallbladder cancer;
KIRP	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg07004394	chr14:106090750	NA	-0.43	-4.9	-0.3	1.71e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.89	-0.57	8.6e-23	Height;
KIRP	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg14972814	chr11:95582409	MTMR2	0.34	5.71	0.34	3.24e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15646626	chr8:6427385	MCPH1	0.51	6.81	0.4	7.53e-11	Interleukin-4 levels;
KIRP	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	0.72	5.62	0.34	5.2e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg01304814	chr3:48885189	PRKAR2A	0.55	5.12	0.31	6.23e-7	Cognitive function;
KIRP	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg17507749	chr15:85114479	UBE2QP1	0.72	6.69	0.39	1.48e-10	Schizophrenia;
KIRP	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.02	0.75	7.41e-47	Chronic sinus infection;
KIRP	cis	rs4262150	0.689	rs4958566	chr5:152014061	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.18e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.67	0.71	7.75e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg26384229	chr12:38710491	ALG10B	0.74	9.84	0.53	1.76e-19	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.53	6.92	0.4	3.88e-11	Schizophrenia;
KIRP	cis	rs2046867	0.908	rs28822756	chr3:72825011	C/T	cg25664220	chr3:72788482	NA	-0.39	-5.94	-0.35	9.46e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg01304814	chr3:48885189	PRKAR2A	0.58	5.1	0.31	6.92e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs9419702	0.614	rs7907614	chr10:133532208	T/C	cg23460707	chr10:133558971	NA	0.37	5.63	0.34	4.98e-8	Survival in rectal cancer;
KIRP	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg10150615	chr22:24372951	LOC391322	0.63	6.85	0.4	5.86e-11	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs1461503	0.512	rs3816621	chr11:122818311	A/G	cg27398637	chr11:122830231	C11orf63	-0.6	-8.24	-0.47	1e-14	Menarche (age at onset);
KIRP	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs9547692	1.000	rs2147168	chr13:37467503	A/C	cg01493522	chr13:37497338	NA	-0.41	-5.32	-0.32	2.31e-7	Coronary artery disease;
KIRP	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs4690686	0.534	rs11133147	chr4:177281718	A/G	cg17059388	chr4:177262070	NA	0.5	6.89	0.4	4.64e-11	Essential tremor;
KIRP	cis	rs4776059	1.000	rs4776066	chr15:52930499	T/C	cg25063058	chr15:52860530	ARPP19	0.53	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	5.45	0.33	1.19e-7	Coronary artery disease;
KIRP	cis	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.1	-0.36	4.15e-9	Small cell lung carcinoma;
KIRP	cis	rs73086581	0.787	rs67202952	chr20:3869099	A/C	cg02187196	chr20:3869020	PANK2	0.58	5.36	0.32	1.94e-7	Response to antidepressants in depression;
KIRP	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs17407555	0.657	rs12505222	chr4:10271136	G/T	cg00071950	chr4:10020882	SLC2A9	0.36	4.87	0.3	1.98e-6	Schizophrenia (age at onset);
KIRP	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg09165964	chr15:75287851	SCAMP5	0.43	5.47	0.33	1.09e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.44	-6.77	-0.4	9.39e-11	Tonsillectomy;
KIRP	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-1.0	-9.14	-0.5	2.33e-17	Blood pressure (smoking interaction);
KIRP	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.64	-9.05	-0.5	4.59e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	-0.41	-5.13	-0.31	6e-7	Leprosy;
KIRP	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.83	6.8	0.4	7.79e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs829883	0.604	rs249841	chr12:98871743	A/G	cg25150519	chr12:98850993	NA	0.56	7.62	0.44	5.4e-13	Colorectal adenoma (advanced);
KIRP	cis	rs960902	0.738	rs7561053	chr2:37743181	G/A	cg25341268	chr2:37734390	NA	-0.54	-7.23	-0.42	5.96e-12	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	1.13	17.14	0.74	7.23e-44	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg18882449	chr10:104885122	NT5C2	-0.38	-4.89	-0.3	1.81e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09699651	chr6:150184138	LRP11	0.61	8.48	0.48	2.14e-15	Testicular germ cell tumor;
KIRP	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.37	-0.32	1.8e-7	Educational attainment (years of education);
KIRP	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.65	-5.63	-0.34	4.82e-8	Schizophrenia;
KIRP	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-9.08	-0.5	3.76e-17	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs3206736	0.803	rs329580	chr7:35091875	C/T	cg06685737	chr7:35301730	NA	-0.46	-6.94	-0.4	3.54e-11	Diastolic blood pressure;
KIRP	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.92	10.68	0.56	4.13e-22	Neuroticism;
KIRP	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.66	8.72	0.49	4.26e-16	Motion sickness;
KIRP	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg23587288	chr2:27483067	SLC30A3	-0.7	-7.44	-0.43	1.71e-12	Blood metabolite levels;
KIRP	cis	rs11673344	0.796	rs16971886	chr19:37487975	G/A	cg14683738	chr19:37701593	ZNF585B	-0.45	-5.2	-0.31	4.16e-7	Obesity-related traits;
KIRP	cis	rs9393813	0.805	rs2205829	chr6:27480227	A/G	cg18711553	chr6:27366782	ZNF391	0.41	6.07	0.36	4.91e-9	Bipolar disorder;
KIRP	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg14345882	chr6:26364793	BTN3A2	0.34	5.59	0.34	5.93e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.63	7.81	0.45	1.6e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-7.4	-0.43	2.14e-12	Bipolar disorder;
KIRP	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-11.06	-0.58	2.35e-23	Dental caries;
KIRP	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00321850	chr1:175162397	KIAA0040	0.36	6.44	0.38	6.4e-10	Alcohol dependence;
KIRP	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.35	-6.97	-0.41	2.96e-11	Monocyte percentage of white cells;
KIRP	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.06e-15	Menarche (age at onset);
KIRP	cis	rs2908197	0.713	rs2961037	chr7:75952212	G/T	cg06959773	chr7:76033795	SRCRB4D;ZP3	-0.3	-4.97	-0.3	1.25e-6	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.73	9.58	0.52	1.11e-18	Sudden cardiac arrest;
KIRP	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg13334819	chr7:99746414	C7orf59	-0.45	-5.0	-0.3	1.08e-6	Coronary artery disease;
KIRP	cis	rs11235843	0.565	rs1723840	chr11:73473885	T/A	cg18195628	chr11:73498948	MRPL48	0.48	4.89	0.3	1.86e-6	Hand grip strength;
KIRP	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-8.66	-0.48	6.21e-16	Coronary artery disease;
KIRP	trans	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg24644049	chr4:85504048	CDS1	0.99	6.96	0.41	3.15e-11	Skin colour saturation;
KIRP	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.35	8.34	0.47	5.51e-15	Asthma (sex interaction);
KIRP	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg05973401	chr12:123451056	ABCB9	0.49	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg16141378	chr3:129829833	LOC729375	0.51	6.66	0.39	1.82e-10	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.77	11.59	0.59	4.46e-25	Type 2 diabetes;
KIRP	cis	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg21546286	chr11:48923668	NA	-0.45	-5.52	-0.33	8.56e-8	HDL cholesterol;
KIRP	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.69	6.48	0.38	4.85e-10	Multiple sclerosis;
KIRP	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08048268	chr3:133502702	NA	-0.43	-5.13	-0.31	5.89e-7	Iron status biomarkers;
KIRP	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00149659	chr3:10157352	C3orf10	0.6	7.2	0.42	7.39e-12	Alzheimer's disease;
KIRP	cis	rs72792276	0.558	rs77140686	chr5:127395687	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	4.9	0.3	1.73e-6	Red cell distribution width;
KIRP	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.55	-6.93	-0.4	3.72e-11	Myeloid white cell count;
KIRP	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg04727924	chr7:799746	HEATR2	-0.69	-6.57	-0.39	2.92e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg25039879	chr17:56429692	SUPT4H1	0.61	5.31	0.32	2.44e-7	Cognitive test performance;
KIRP	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26617929	chr16:1858877	NA	-0.65	-5.28	-0.32	2.77e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg24060327	chr5:131705240	SLC22A5	-0.52	-7.04	-0.41	1.89e-11	Blood metabolite levels;
KIRP	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.64	-0.39	2e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg26695010	chr11:65641043	EFEMP2	0.51	5.1	0.31	6.88e-7	Crohn's disease;
KIRP	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg21605333	chr4:119757512	SEC24D	1.6	11.71	0.6	1.76e-25	Cannabis dependence symptom count;
KIRP	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg16325326	chr1:53192061	ZYG11B	0.72	8.71	0.49	4.52e-16	Monocyte count;
KIRP	cis	rs11126435	0.591	rs6546909	chr2:74746322	A/T	cg08355260	chr2:74729429	LOC151534;LBX2	0.35	5.1	0.31	6.8e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg23102388	chr7:1867652	MAD1L1	-0.47	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg04370829	chr17:406249	NA	0.38	4.89	0.3	1.86e-6	Prostate cancer;
KIRP	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-5.2	-0.31	4.26e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg07520141	chr5:10564205	ANKRD33B	0.56	6.49	0.38	4.73e-10	Sleep duration;
KIRP	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg19899395	chr1:46959349	NA	0.39	5.0	0.3	1.12e-6	Monobrow;
KIRP	cis	rs9912468	0.555	rs4366742	chr17:64212242	T/C	cg19474267	chr17:64306194	PRKCA	-0.42	-5.07	-0.31	7.92e-7	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23598886	chr18:12777645	NA	0.74	6.11	0.36	3.9e-9	Inflammatory skin disease;
KIRP	cis	rs4389656	0.857	rs274703	chr5:6728372	A/C	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.33	-6.77	-0.4	9.29e-11	Breast cancer;
KIRP	cis	rs12999616	1.000	rs12999616	chr2:98324381	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	6.04	0.36	5.72e-9	Colorectal cancer;
KIRP	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.46	-5.41	-0.33	1.5e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	trans	rs12639288	0.962	rs12638639	chr3:167660757	C/T	cg10669451	chr11:61556984	C11orf10	-0.7	-6.25	-0.37	1.77e-9	Hirschsprung disease;
KIRP	cis	rs10046574	0.516	rs7802453	chr7:135200638	T/C	cg27474649	chr7:135195673	CNOT4	0.56	5.28	0.32	2.82e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg00684032	chr4:1343700	KIAA1530	0.48	6.24	0.37	1.88e-9	Obesity-related traits;
KIRP	cis	rs3931020	0.616	rs277381	chr1:75266815	T/A	cg10128416	chr1:75198403	TYW3;CRYZ	-0.45	-5.32	-0.32	2.33e-7	Resistin levels;
KIRP	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg06634786	chr22:41940651	POLR3H	-0.5	-5.44	-0.33	1.31e-7	Neuroticism;
KIRP	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg18225595	chr11:63971243	STIP1	0.65	5.98	0.36	7.85e-9	Mean platelet volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25642048	chr8:74207199	RPL7;RDH10	0.47	6.65	0.39	1.93e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg22974920	chr21:40686053	BRWD1	0.51	6.02	0.36	6.16e-9	Cognitive function;
KIRP	cis	rs8027181	0.839	rs998021	chr15:72999825	T/C	cg25996835	chr15:72978165	BBS4;HIGD2B	0.52	7.59	0.44	6.5e-13	Triglyceride levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09376352	chr11:119076657	CBL	0.44	6.02	0.36	6.38e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.84	9.16	0.5	2.08e-17	Gestational age at birth (maternal effect);
KIRP	cis	rs72634030	0.536	rs72634016	chr17:5185204	C/T	cg20802942	chr17:5185005	RABEP1	0.55	5.4	0.33	1.54e-7	Rheumatoid arthritis;
KIRP	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg09163369	chr1:210001066	C1orf107	0.5	6.13	0.36	3.46e-9	Orofacial clefts;
KIRP	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	0.93	10.43	0.55	2.58e-21	Iron status biomarkers;
KIRP	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg20362242	chr5:692897	TPPP	0.56	4.86	0.3	2.06e-6	Obesity-related traits;
KIRP	cis	rs6540559	0.605	rs3753518	chr1:209977964	G/C	cg22029157	chr1:209979665	IRF6	0.52	5.84	0.35	1.67e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.6	7.64	0.44	4.83e-13	Tonsillectomy;
KIRP	cis	rs3857067	1.000	rs7694631	chr4:95016931	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg18646521	chr2:111875858	NA	0.41	5.8	0.35	2.06e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.96	-0.45	6.43e-14	Retinal vascular caliber;
KIRP	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.59	7.68	0.44	3.69e-13	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.63	-6.21	-0.37	2.18e-9	Lung function (FEV1/FVC);
KIRP	cis	rs2594989	0.831	rs6803125	chr3:11583228	A/G	cg01796438	chr3:11312864	ATG7	0.61	7.57	0.43	7.59e-13	Circulating chemerin levels;
KIRP	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06634786	chr22:41940651	POLR3H	-0.47	-5.21	-0.32	4.03e-7	Vitiligo;
KIRP	cis	rs311392	1.000	rs413974	chr8:55088510	A/G	cg20636351	chr8:55087400	NA	-0.66	-8.27	-0.47	8.29e-15	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24557142	chr4:85818499	WDFY3	-0.41	-6.19	-0.37	2.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6499755	0.712	rs31100	chr16:55371523	A/G	cg05099576	chr16:55362342	IRX6	0.28	5.74	0.34	2.84e-8	Hypospadias;
KIRP	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.58	-5.01	-0.3	1.02e-6	Putamen volume;
KIRP	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.41	-4.92	-0.3	1.56e-6	IgG glycosylation;
KIRP	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg23958373	chr8:599963	NA	-1.02	-6.25	-0.37	1.8e-9	IgG glycosylation;
KIRP	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg02336718	chr17:17403227	NA	0.37	5.6	0.34	5.81e-8	Total body bone mineral density;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16721845	chr11:68518800	MTL5	-0.43	-6.44	-0.38	6.35e-10	Metabolic traits;
KIRP	cis	rs1559088	0.948	rs12610071	chr19:33582687	A/C	cg03563238	chr19:33554763	RHPN2	-0.33	-5.72	-0.34	3.12e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg24644049	chr4:85504048	CDS1	0.99	6.58	0.39	2.83e-10	Skin colour saturation;
KIRP	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg07120806	chr4:1873451	WHSC1	-0.46	-6.55	-0.39	3.39e-10	Serum protein levels (sST2);
KIRP	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg04132472	chr17:19861366	AKAP10	0.67	10.41	0.55	2.83e-21	Schizophrenia;
KIRP	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.43	-5.29	-0.32	2.74e-7	Acne (severe);
KIRP	cis	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.01	-0.36	6.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.78	-0.35	2.27e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.59	-7.19	-0.42	7.88e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.47	-5.96	-0.36	8.56e-9	Schizophrenia (inflammation and infection response interaction);
KIRP	cis	rs1351164	0.947	rs57004880	chr2:218272581	A/C	cg15335768	chr2:218268053	DIRC3	-0.54	-7.11	-0.41	1.27e-11	Height;
KIRP	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.88	-15.14	-0.69	4.89e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg12315302	chr6:26189340	HIST1H4D	0.95	6.56	0.39	3.07e-10	Urinary tract infection frequency;
KIRP	cis	rs6908034	1.000	rs6908034	chr6:19773930	G/A	cg02682789	chr6:19804855	NA	0.5	4.86	0.3	2.05e-6	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
KIRP	cis	rs6968419	0.755	rs6967695	chr7:115896049	G/A	cg02561103	chr7:115862891	TES	-0.41	-5.82	-0.35	1.83e-8	Intraocular pressure;
KIRP	cis	rs963731	0.649	rs297125	chr2:39314969	G/A	cg04010122	chr2:39346883	SOS1	-0.91	-6.45	-0.38	5.74e-10	Corticobasal degeneration;
KIRP	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.65	8.37	0.47	4.31e-15	Height;
KIRP	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg09596252	chr17:78655493	RPTOR	-0.44	-5.18	-0.31	4.67e-7	Fractional excretion of uric acid;
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.42	5.29	0.32	2.73e-7	Longevity;
KIRP	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.53	-5.43	-0.33	1.39e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11614062	0.761	rs11107115	chr12:93972987	A/G	cg18151635	chr12:93972918	NA	-0.54	-5.14	-0.31	5.63e-7	Height;
KIRP	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.62	-6.29	-0.37	1.42e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00777555	chr3:57583074	ARF4	0.51	6.8	0.4	7.88e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs77972916	0.517	rs17406126	chr2:43546632	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.74	-7.14	-0.41	1.02e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.47	-8.39	-0.47	3.75e-15	Height;
KIRP	cis	rs12282928	0.918	rs117447853	chr11:48315758	T/G	cg26585981	chr11:48327164	OR4S1	0.51	6.24	0.37	1.9e-9	Migraine - clinic-based;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17218029	chr1:156722047	HDGF	-0.44	-6.25	-0.37	1.79e-9	Metabolic traits;
KIRP	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.71	-7.53	-0.43	9.55e-13	Initial pursuit acceleration;
KIRP	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg21926883	chr2:100939477	LONRF2	-0.55	-7.58	-0.44	7.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.47	-5.13	-0.31	5.75e-7	Obesity (extreme);
KIRP	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs7173743	0.525	rs8029173	chr15:79134568	G/A	cg00079375	chr15:79125835	NA	0.39	5.6	0.34	5.74e-8	Coronary artery disease;
KIRP	cis	rs698833	0.892	rs1085483	chr2:44616047	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.52	6.21	0.37	2.19e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs4834770	0.746	rs2389747	chr4:120236102	C/T	cg09307838	chr4:120376055	NA	0.49	5.76	0.34	2.53e-8	Blood protein levels;
KIRP	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.42	-5.34	-0.32	2.1e-7	Aortic root size;
KIRP	cis	rs9398803	0.865	rs1572569	chr6:126771687	G/A	cg19875578	chr6:126661172	C6orf173	0.45	5.9	0.35	1.19e-8	Male-pattern baldness;
KIRP	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.7	9.24	0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.29	-5.45	-0.33	1.22e-7	Lung cancer;
KIRP	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.87	10.42	0.55	2.72e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7666738	0.519	rs28539191	chr4:98821552	C/T	cg05340658	chr4:99064831	C4orf37	0.67	7.81	0.45	1.6e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs3803915	0.866	rs7251881	chr19:2169067	G/A	cg09261902	chr19:2140048	AP3D1	-0.54	-4.88	-0.3	1.88e-6	Body mass index;Myocardial infarction;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10392504	chr7:5464594	TNRC18	0.47	6.12	0.36	3.58e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs55675132	0.548	rs12139020	chr1:115444513	G/A	cg12756093	chr1:115239321	AMPD1	0.55	5.49	0.33	1.01e-7	Schizophrenia;
KIRP	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs9346649	0.606	rs7750135	chr6:168490841	C/A	cg09211372	chr6:168490623	NA	-0.38	-6.36	-0.38	9.57e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.68	8.3	0.47	6.97e-15	Neutrophil percentage of white cells;
KIRP	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	16.75	0.73	1.49e-42	Height;
KIRP	cis	rs1978968	0.827	rs5992134	chr22:18433994	G/T	cg03078520	chr22:18463400	MICAL3	-0.59	-7.26	-0.42	5.13e-12	Presence of antiphospholipid antibodies;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02746640	chr7:145689965	NA	-0.43	-6.6	-0.39	2.46e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.49	-6.41	-0.38	7.36e-10	Schizophrenia;
KIRP	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	11.24	0.58	6.07e-24	Birth weight;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg05881135	chr15:99644973	SYNM	0.87	6.34	0.37	1.08e-9	P wave terminal force;
KIRP	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.65	7.93	0.45	7.72e-14	Vitiligo;
KIRP	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.62	0.44	5.34e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg18209359	chr17:80159595	CCDC57	0.43	5.56	0.33	6.93e-8	Life satisfaction;
KIRP	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	12.29	0.62	2.2e-27	Smoking behavior;
KIRP	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.7	-8.29	-0.47	7.61e-15	Blood metabolite levels;
KIRP	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.33	12.15	0.61	6.5e-27	Diabetic retinopathy;
KIRP	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	0.68	6.02	0.36	6.37e-9	Obesity-related traits;
KIRP	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg02023728	chr11:77925099	USP35	0.36	5.55	0.33	7.38e-8	Alzheimer's disease (survival time);
KIRP	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.63	6.37	0.38	9.44e-10	Gastritis;
KIRP	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg05347473	chr6:146136440	FBXO30	0.5	7.01	0.41	2.31e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10073892	0.620	rs10035511	chr5:101940409	C/T	cg19774478	chr5:101632501	SLCO4C1	0.56	5.51	0.33	9e-8	Cognitive decline (age-related);
KIRP	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg03887218	chr1:16534349	ARHGEF19	0.64	8.63	0.48	7.9e-16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs6547631	0.622	rs6740635	chr2:85933527	C/G	cg24620635	chr2:85921963	GNLY	0.32	4.92	0.3	1.58e-6	Blood protein levels;
KIRP	cis	rs73198271	0.565	rs575895	chr8:8594247	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-5.18	-0.31	4.58e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6956675	1.000	rs10231112	chr7:62601257	A/G	cg08930214	chr7:62859557	LOC100287834	0.49	5.69	0.34	3.6e-8	Obesity-related traits;
KIRP	cis	rs77372450	0.636	rs11749144	chr5:157026996	A/G	cg05585991	chr5:157099197	C5orf52	0.44	5.29	0.32	2.66e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg12292205	chr6:26970375	C6orf41	-0.42	-5.77	-0.35	2.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.39e-6	Life satisfaction;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24574691	chr11:129191447	NA	0.5	6.65	0.39	1.84e-10	Interleukin-4 levels;
KIRP	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7937612	1.000	rs7933086	chr11:120269308	A/G	cg24566217	chr11:120254723	ARHGEF12	0.47	6.84	0.4	6.16e-11	Intraocular pressure;
KIRP	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-9.17	-0.5	1.91e-17	Resting heart rate;
KIRP	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.36	-8.4	-0.47	3.65e-15	Asthma (sex interaction);
KIRP	cis	rs73036520	0.646	rs11667235	chr19:45804364	A/C	cg01416317	chr19:45737208	EXOC3L2	0.41	4.92	0.3	1.59e-6	Monocyte percentage of white cells;
KIRP	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.66	-8.96	-0.5	8.32e-17	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7072216	0.922	rs942814	chr10:100151305	A/G	cg26618903	chr10:100175079	PYROXD2	-0.34	-4.96	-0.3	1.34e-6	Metabolite levels;
KIRP	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.43	-0.47	2.96e-15	Common traits (Other);
KIRP	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	cg12689670	chr1:183009347	LAMC1	0.54	7.53	0.43	9.48e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-9.54	-0.52	1.43e-18	Gut microbiome composition (summer);
KIRP	cis	rs10465746	0.570	rs12402130	chr1:84479838	G/A	cg10977910	chr1:84465055	TTLL7	0.47	5.73	0.34	2.96e-8	Obesity-related traits;
KIRP	cis	rs7771547	0.573	rs619011	chr6:36476592	A/G	cg07856975	chr6:36356162	ETV7	0.35	5.08	0.31	7.38e-7	Platelet distribution width;
KIRP	cis	rs12431939	1.000	rs57212982	chr14:51656464	A/G	cg23942311	chr14:51606299	NA	-0.48	-5.12	-0.31	6.14e-7	Cancer;
KIRP	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	10.88	0.57	9.37e-23	Systolic blood pressure;
KIRP	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.46	-0.33	1.16e-7	Parkinson's disease;
KIRP	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08280861	chr8:58055591	NA	0.7	5.07	0.31	7.72e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13082711	0.911	rs73050094	chr3:27519552	T/A	cg02860705	chr3:27208620	NA	0.55	7.49	0.43	1.26e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs698833	0.926	rs698827	chr2:44730496	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.42	-4.98	-0.3	1.19e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.83	11.2	0.58	8.63e-24	Morning vs. evening chronotype;
KIRP	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg18944383	chr4:111397179	ENPEP	-0.53	-6.25	-0.37	1.77e-9	Axial length;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15686105	chr7:23623273	NA	0.48	6.32	0.37	1.24e-9	Interleukin-4 levels;
KIRP	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg10503236	chr1:231470652	EXOC8	0.51	7.2	0.42	7.33e-12	Hemoglobin concentration;
KIRP	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg08076091	chr2:203926405	NBEAL1	0.94	9.12	0.5	2.8e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg06818126	chr11:68850279	TPCN2	0.47	5.4	0.33	1.57e-7	Hair color;
KIRP	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.93e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-14.8	-0.69	6.98e-36	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.43	8.52	0.48	1.65e-15	Coronary artery disease;
KIRP	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg16339924	chr4:17578868	LAP3	0.55	7.36	0.42	2.82e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1345301	0.552	rs67880537	chr2:102864106	A/G	cg12451869	chr2:102867685	NA	0.48	6.81	0.4	7.54e-11	Waist circumference;
KIRP	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg25007680	chr1:8021821	PARK7	0.65	8.93	0.49	9.88e-17	Response to antidepressants and depression;
KIRP	cis	rs62229266	0.740	rs2835233	chr21:37393582	A/G	cg12218747	chr21:37451666	NA	-0.43	-5.4	-0.33	1.58e-7	Mitral valve prolapse;
KIRP	cis	rs7572733	0.515	rs11891555	chr2:198853540	G/T	cg00792783	chr2:198669748	PLCL1	0.46	5.25	0.32	3.21e-7	Dermatomyositis;
KIRP	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.61	-9.0	-0.5	6.12e-17	Brugada syndrome;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17788761	chr1:78340579	FAM73A	-0.43	-6.14	-0.36	3.27e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	9.01	0.5	5.97e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs11955398	0.585	rs1456743	chr5:60007421	T/A	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6807915	0.624	rs7610451	chr3:12293739	G/A	cg02700894	chr3:12045449	SYN2	0.43	5.83	0.35	1.71e-8	Leprosy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11173202	chr22:41843125	TOB2	0.48	6.19	0.37	2.55e-9	Parkinson's disease;
KIRP	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.33	-0.37	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg13147721	chr7:65941812	NA	-0.94	-6.71	-0.39	1.34e-10	Diabetic kidney disease;
KIRP	cis	rs711830	0.931	rs717852	chr2:177031623	C/T	cg13092806	chr2:177043255	NA	0.65	6.88	0.4	5.03e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs424971	0.517	rs8057456	chr16:85953196	A/G	cg02526982	chr16:85309801	NA	-0.35	-5.08	-0.31	7.3e-7	Monocyte count;
KIRP	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs7703051	0.513	rs6895057	chr5:74624234	G/A	cg00601450	chr5:74908170	NA	-0.45	-6.39	-0.38	8.17e-10	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
KIRP	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-6.54	-0.38	3.5e-10	Response to antipsychotic treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00060320	chr3:134369974	KY	0.45	6.03	0.36	5.98e-9	Parkinson's disease;
KIRP	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg06937882	chr20:24974362	C20orf3	-0.47	-5.07	-0.31	7.81e-7	Blood protein levels;
KIRP	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg20003494	chr4:90757398	SNCA	-0.43	-5.34	-0.32	2.13e-7	Neuroticism;
KIRP	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.48	5.73	0.34	2.94e-8	Longevity;Endometriosis;
KIRP	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	0.68	10.17	0.54	1.62e-20	Prudent dietary pattern;
KIRP	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg03808351	chr9:123631620	PHF19	0.43	5.95	0.35	9.15e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs57590327	0.503	rs2372905	chr3:81504592	C/G	cg07356753	chr3:81810745	GBE1	0.49	6.15	0.36	3.14e-9	Extraversion;
KIRP	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13939156	chr17:80058883	NA	0.54	8.78	0.49	2.77e-16	Life satisfaction;
KIRP	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.73	9.21	0.51	1.47e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7119038	0.865	rs10892299	chr11:118726843	C/T	cg19308663	chr11:118741387	NA	0.55	9.65	0.52	6.88e-19	Sjögren's syndrome;
KIRP	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.7	7.35	0.42	2.97e-12	Bipolar disorder;
KIRP	cis	rs7833986	0.877	rs35399547	chr8:57075473	A/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	4.93	0.3	1.49e-6	Height;
KIRP	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.71	-10.2	-0.55	1.29e-20	Educational attainment;
KIRP	cis	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg04691961	chr3:161091175	C3orf57	0.46	6.76	0.4	9.74e-11	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg08885076	chr2:99613938	TSGA10	-0.52	-9.15	-0.5	2.24e-17	Chronic sinus infection;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07730715	chr19:59030951	ZBTB45	-0.47	-6.1	-0.36	4.06e-9	Metabolic traits;
KIRP	trans	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-8.64	-0.48	7.42e-16	Morning vs. evening chronotype;
KIRP	cis	rs28735056	1.000	rs3826576	chr18:77633976	G/A	cg20368463	chr18:77673604	PQLC1	-0.44	-5.52	-0.33	8.66e-8	Schizophrenia;
KIRP	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.82	-14.41	-0.68	1.47e-34	Post bronchodilator FEV1;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg00761755	chr17:1531579	SLC43A2	0.5	6.12	0.36	3.57e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2204008	0.630	rs7314669	chr12:38203602	G/A	cg26384229	chr12:38710491	ALG10B	-0.53	-6.78	-0.4	8.68e-11	Bladder cancer;
KIRP	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-7.3	-0.42	4.08e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg25036284	chr2:26402008	FAM59B	0.52	5.48	0.33	1.06e-7	Gut microbiome composition (summer);
KIRP	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.93	-0.49	1.04e-16	Resting heart rate;
KIRP	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.33	-6.43	-0.38	6.75e-10	Tonsillectomy;
KIRP	cis	rs7224685	0.501	rs6502770	chr17:4007314	A/G	cg26134248	chr17:3907702	NA	0.44	6.23	0.37	2.02e-9	Type 2 diabetes;
KIRP	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg24060327	chr5:131705240	SLC22A5	-0.6	-7.61	-0.44	5.95e-13	Acylcarnitine levels;
KIRP	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg26875233	chr11:93583750	C11orf90	-0.41	-7.69	-0.44	3.6e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.65	9.49	0.52	2.1e-18	Schizophrenia;
KIRP	cis	rs9398803	0.865	rs9388496	chr6:126785062	A/G	cg19875578	chr6:126661172	C6orf173	0.49	6.37	0.38	9.11e-10	Male-pattern baldness;
KIRP	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.42	-7.72	-0.44	2.97e-13	Prostate cancer;
KIRP	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg04192923	chr4:3473232	DOK7	0.45	6.22	0.37	2.15e-9	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
KIRP	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg16586182	chr3:47516702	SCAP	0.83	11.9	0.6	4.44e-26	Colorectal cancer;
KIRP	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-1.13	-17.74	-0.75	6.78e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.34	-5.13	-0.31	5.84e-7	Inflammatory bowel disease;
KIRP	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21659725	chr3:3221576	CRBN	-0.58	-7.15	-0.41	9.79e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4629710	0.538	rs11754401	chr6:131582197	G/A	cg12606694	chr6:131520996	AKAP7	0.53	6.77	0.4	9.63e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg27411982	chr8:10470053	RP1L1	-0.47	-6.22	-0.37	2.12e-9	Neuroticism;
KIRP	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg01620082	chr3:125678407	NA	-1.14	-7.28	-0.42	4.53e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.08	0.46	2.99e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13198984	chr17:80129470	CCDC57	-0.57	-8.58	-0.48	1.09e-15	Life satisfaction;
KIRP	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.58	6.42	0.38	7.11e-10	Coronary artery disease;
KIRP	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg19468946	chr17:37922297	IKZF3	-0.4	-5.42	-0.33	1.45e-7	Asthma;
KIRP	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.75	9.52	0.52	1.65e-18	Alzheimer's disease;
KIRP	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.97	0.5	7.97e-17	Motion sickness;
KIRP	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.86	-0.4	5.51e-11	Systolic blood pressure;
KIRP	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.16	0.37	2.94e-9	Breast cancer;
KIRP	cis	rs2274273	0.588	rs7158791	chr14:55828607	A/G	cg04306507	chr14:55594613	LGALS3	0.38	5.2	0.31	4.28e-7	Protein biomarker;
KIRP	cis	rs17253792	0.545	rs12893061	chr14:56016097	A/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Gout;
KIRP	cis	rs6840360	0.573	rs4696080	chr4:152276465	A/T	cg25486957	chr4:152246857	NA	-0.45	-5.67	-0.34	4.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs77633900	0.772	rs157768	chr15:76833779	C/T	cg21673338	chr15:77095150	SCAPER	-0.65	-6.24	-0.37	1.89e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03388025	chr16:89894329	SPIRE2	0.42	8.69	0.48	5.32e-16	Vitiligo;
KIRP	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.88	0.49	1.45e-16	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg25039879	chr17:56429692	SUPT4H1	0.54	4.93	0.3	1.53e-6	Cognitive test performance;
KIRP	cis	rs4523957	0.583	rs2760741	chr17:2020443	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-11.64	-0.6	3.08e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.45	-0.38	5.76e-10	Aortic root size;
KIRP	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg18477163	chr1:228402036	OBSCN	0.34	6.32	0.37	1.21e-9	Diastolic blood pressure;
KIRP	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg06565975	chr8:143823917	SLURP1	-0.57	-7.87	-0.45	1.16e-13	Urinary tract infection frequency;
KIRP	cis	rs687432	0.812	rs11604630	chr11:57899832	G/T	cg19752551	chr11:57585705	CTNND1	-0.67	-8.58	-0.48	1.06e-15	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.73	0.34	2.9e-8	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25945676	chr5:1067795	SLC12A7	-0.46	-6.11	-0.36	3.85e-9	Parkinson's disease;
KIRP	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg17885191	chr8:135476712	NA	0.49	5.6	0.34	5.6e-8	Hypertension (SNP x SNP interaction);
KIRP	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg07382826	chr16:28625726	SULT1A1	0.47	5.49	0.33	9.99e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.48	6.05	0.36	5.5e-9	Glycated hemoglobin levels;
KIRP	cis	rs10892173	0.818	rs7947524	chr11:117671091	C/T	cg21640587	chr11:117668038	DSCAML1	0.42	6.26	0.37	1.73e-9	Myopia;
KIRP	cis	rs7523050	0.643	rs35885176	chr1:109401868	G/A	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.89	-12.93	-0.64	1.63e-29	Tonsillectomy;
KIRP	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.46	5.74	0.34	2.82e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.76	-10.2	-0.55	1.34e-20	Educational attainment;
KIRP	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.54	6.09	0.36	4.21e-9	Blood metabolite levels;
KIRP	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg10760299	chr15:45669010	GATM	0.35	5.09	0.31	7.03e-7	Homoarginine levels;
KIRP	cis	rs35995292	0.500	rs8180877	chr7:38931258	G/A	cg19327137	chr7:38886074	VPS41	0.79	12.21	0.61	4.11e-27	Subjective well-being (multi-trait analysis);
KIRP	cis	rs17221829	0.673	rs10765225	chr11:89384988	T/C	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg13072238	chr3:49761600	GMPPB	-0.59	-5.62	-0.34	5.22e-8	Menarche (age at onset);
KIRP	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.68	-6.66	-0.39	1.74e-10	Menarche (age at onset);
KIRP	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg27205649	chr11:78285834	NARS2	0.64	7.85	0.45	1.28e-13	Alzheimer's disease (survival time);
KIRP	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg24315340	chr6:146058215	EPM2A	-0.44	-5.8	-0.35	2.07e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg14703610	chr5:56206110	C5orf35	0.48	6.65	0.39	1.83e-10	Coronary artery disease;
KIRP	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg16586182	chr3:47516702	SCAP	0.82	11.64	0.6	3.07e-25	Colorectal cancer;
KIRP	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.95	17.11	0.74	8.82e-44	Intelligence (multi-trait analysis);
KIRP	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.41	0.33	1.48e-7	Schizophrenia;
KIRP	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg12560992	chr17:57184187	TRIM37	0.59	5.56	0.33	7e-8	Cognitive test performance;
KIRP	cis	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg06521331	chr12:34319734	NA	-0.5	-6.14	-0.36	3.36e-9	Morning vs. evening chronotype;
KIRP	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg16473166	chr22:50639996	SELO	0.64	8.17	0.46	1.64e-14	Obesity-related traits;
KIRP	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.75	10.98	0.57	4.4e-23	Prudent dietary pattern;
KIRP	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.65	-8.13	-0.46	2.08e-14	Morning vs. evening chronotype;
KIRP	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.88	-13.57	-0.65	1.05e-31	Height;
KIRP	cis	rs4862750	0.881	rs6813866	chr4:187872161	T/G	cg03647317	chr4:187891568	NA	-0.73	-11.62	-0.6	3.52e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg23479056	chr15:41276147	INO80	0.37	5.12	0.31	6.27e-7	Menopause (age at onset);
KIRP	cis	rs7175404	1.000	rs7167877	chr15:94036172	G/T	cg23502883	chr15:93959149	NA	0.53	5.69	0.34	3.61e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg02187348	chr16:89574699	SPG7	0.43	5.25	0.32	3.23e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg07395648	chr5:131743802	NA	-0.57	-8.38	-0.47	4.17e-15	Blood metabolite levels;
KIRP	cis	rs7075426	0.669	rs3758520	chr10:88233628	C/G	cg07322936	chr10:88137208	NA	0.51	5.51	0.33	9.2e-8	Migraine without aura;
KIRP	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs9815354	0.812	rs73075250	chr3:42063734	A/G	cg03022575	chr3:42003672	ULK4	0.72	7.42	0.43	1.96e-12	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-8.85	-0.49	1.78e-16	Vitiligo;
KIRP	cis	rs17221829	0.673	rs10830324	chr11:89388845	C/T	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.1	0.41	1.32e-11	Lung cancer;
KIRP	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	5.57	0.33	6.6e-8	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg05861140	chr6:150128134	PCMT1	-0.53	-7.6	-0.44	6.12e-13	Lung cancer;
KIRP	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02187348	chr16:89574699	SPG7	0.47	5.89	0.35	1.23e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg01721255	chr8:58191610	C8orf71	0.5	4.89	0.3	1.85e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs11239930	0.538	rs618575	chr1:146552308	A/C	cg16700924	chr1:146552102	NA	-0.44	-4.87	-0.3	2e-6	AIDS progression;
KIRP	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg16309518	chr5:176445507	NA	-0.79	-12.36	-0.62	1.31e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg05952643	chr9:132597404	C9orf78;USP20	0.52	6.85	0.4	5.75e-11	Educational attainment;
KIRP	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg26248373	chr2:1572462	NA	-0.73	-8.62	-0.48	8.19e-16	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg03714773	chr7:91764589	CYP51A1	0.32	4.92	0.3	1.58e-6	Breast cancer;
KIRP	cis	rs3109167	0.623	rs2713190	chr7:83116695	G/T	cg14519356	chr7:83097669	SEMA3E	-0.39	-5.32	-0.32	2.3e-7	Blood protein levels;
KIRP	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.77	10.4	0.55	3.12e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.52	5.36	0.32	1.93e-7	Obesity (extreme);
KIRP	cis	rs4523957	0.928	rs216206	chr17:2196088	C/T	cg16513277	chr17:2031491	SMG6	0.6	8.29	0.47	7.32e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12930096	1.000	rs12444633	chr16:11677857	A/C	cg07439791	chr16:11680400	LITAF	0.7	6.05	0.36	5.37e-9	QT interval;
KIRP	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26617929	chr16:1858877	NA	-0.59	-5.07	-0.31	7.92e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs745080	0.519	rs10140899	chr14:53008807	T/C	cg23333723	chr14:53022898	GPR137C	-0.42	-5.52	-0.33	8.78e-8	Orofacial clefts;
KIRP	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.07	0.58	2.25e-23	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1524927	1.000	rs12704875	chr7:96341385	G/A	cg00227355	chr7:96336147	SHFM1	-0.32	-4.86	-0.3	2.12e-6	Total body bone mineral density;
KIRP	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg07511668	chr11:68622177	NA	0.38	5.03	0.31	9.39e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	10.06	0.54	3.76e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs6750047	0.609	rs2121259	chr2:38269475	T/C	cg07380506	chr2:38303506	CYP1B1	0.45	5.88	0.35	1.31e-8	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs2380205	0.967	rs7897260	chr10:5888427	C/G	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-8.48	-0.48	2.04e-15	Bipolar disorder;
KIRP	cis	rs25422	0.938	rs7356858	chr6:118765814	G/C	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Renal cell carcinoma;
KIRP	cis	rs963731	0.579	rs6544195	chr2:39288486	A/G	cg04010122	chr2:39346883	SOS1	-0.81	-5.6	-0.34	5.62e-8	Corticobasal degeneration;
KIRP	cis	rs424971	0.517	rs8057456	chr16:85953196	A/G	cg06873498	chr16:85652969	KIAA0182	-0.39	-5.42	-0.33	1.45e-7	Monocyte count;
KIRP	cis	rs6893807	0.667	rs1477290	chr5:87988934	T/C	cg24804195	chr5:87968844	LOC645323	0.54	5.25	0.32	3.33e-7	Body mass index;
KIRP	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.66	0.66	5.52e-32	Mean corpuscular hemoglobin;
KIRP	cis	rs2236918	0.687	rs851778	chr1:242037110	A/G	cg17736920	chr1:242011382	EXO1	0.47	5.65	0.34	4.35e-8	Menopause (age at onset);
KIRP	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg26681399	chr22:41777847	TEF	0.48	5.09	0.31	7.08e-7	Vitiligo;
KIRP	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.51	5.47	0.33	1.08e-7	Bipolar disorder;
KIRP	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.19	13.83	0.66	1.44e-32	Sexual dysfunction (female);
KIRP	cis	rs9815354	1.000	rs17061431	chr3:41792655	T/C	cg03022575	chr3:42003672	ULK4	0.53	6.02	0.36	6.15e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3105593	0.932	rs2414072	chr15:50850562	T/A	cg05456662	chr15:50716270	USP8	0.37	4.94	0.3	1.46e-6	QT interval;
KIRP	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.49	-11.44	-0.59	1.39e-24	Diabetic kidney disease;
KIRP	cis	rs11997175	0.545	rs4733457	chr8:33661236	G/A	ch.8.33884649F	chr8:33765107	NA	0.5	5.89	0.35	1.24e-8	Body mass index;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12373573	chr12:85430025	TSPAN19;LRRIQ1	0.46	6.7	0.39	1.43e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs55788414	0.860	rs28697180	chr16:81185079	C/T	cg06400318	chr16:81190750	PKD1L2	-0.88	-8.32	-0.47	5.89e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.75	11.39	0.59	2.1e-24	Resting heart rate;
KIRP	cis	rs6978712	0.591	rs6942979	chr7:127078088	G/A	cg24655706	chr7:127078268	NA	0.68	5.36	0.32	1.88e-7	Medication adherence in chronic diseases;
KIRP	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3857536	0.904	rs1578765	chr6:66883550	G/A	cg07460842	chr6:66804631	NA	-0.37	-4.94	-0.3	1.41e-6	Blood trace element (Cu levels);
KIRP	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg23161317	chr6:28129485	ZNF389	0.46	5.37	0.32	1.83e-7	Depression;
KIRP	cis	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.39	5.0	0.3	1.11e-6	Leprosy;
KIRP	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.47	8.27	0.47	8.46e-15	Bone mineral density;
KIRP	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	cg12689670	chr1:183009347	LAMC1	0.42	6.01	0.36	6.81e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg05082376	chr22:42548792	NA	0.41	5.46	0.33	1.15e-7	Cognitive function;
KIRP	cis	rs9303542	0.625	rs8066613	chr17:46583520	T/A	cg04904318	chr17:46607828	HOXB1	-0.55	-6.09	-0.36	4.41e-9	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs33912345	0.618	rs1313239	chr14:60848489	A/G	cg27398547	chr14:60952738	C14orf39	-0.41	-5.56	-0.33	6.91e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg08533674	chr1:46993347	NA	0.39	4.98	0.3	1.18e-6	Monobrow;
KIRP	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.6	6.84	0.4	6.26e-11	Aortic root size;
KIRP	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs4789452	1.000	rs35825162	chr17:75373188	G/A	cg12985929	chr17:75370611	SEPT9	-0.4	-5.58	-0.34	6.4e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs59197085	0.636	rs60389668	chr7:128452556	T/G	cg00734629	chr7:128471146	FLNC	0.43	4.85	0.3	2.17e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	cg12689670	chr1:183009347	LAMC1	0.46	6.65	0.39	1.84e-10	Hypertriglyceridemia;
KIRP	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.77	-9.25	-0.51	1.11e-17	Iron status biomarkers;
KIRP	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg23791538	chr6:167370224	RNASET2	-0.43	-5.28	-0.32	2.91e-7	Primary biliary cholangitis;
KIRP	cis	rs9815354	0.812	rs60659106	chr3:41949569	G/C	cg03022575	chr3:42003672	ULK4	0.78	7.97	0.45	6.04e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-16.23	-0.72	9.17e-41	Height;
KIRP	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg02158880	chr13:53174818	NA	0.52	6.63	0.39	2.07e-10	Lewy body disease;
KIRP	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.82	0.4	7.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg06443175	chr17:48207519	SAMD14	-0.53	-6.24	-0.37	1.9e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.82	-11.95	-0.61	2.87e-26	Calcium levels;
KIRP	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.59	5.7	0.34	3.37e-8	Plateletcrit;
KIRP	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.26	0.37	1.72e-9	Breast cancer;
KIRP	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01391022	chr12:122360665	WDR66	-0.41	-6.41	-0.38	7.26e-10	Mean corpuscular volume;
KIRP	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-5.97	-0.36	8.4e-9	Response to antipsychotic treatment;
KIRP	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.6	-8.06	-0.46	3.33e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.43	-5.39	-0.33	1.62e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9815354	1.000	rs17063599	chr3:41861676	C/T	cg03022575	chr3:42003672	ULK4	0.6	6.9	0.4	4.36e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.61	-9.47	-0.52	2.45e-18	Sense of smell;
KIRP	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.86	12.69	0.63	1.01e-28	Coronary artery disease;
KIRP	trans	rs933360	0.585	rs11238313	chr7:50826676	G/A	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs2150410	0.833	rs7283439	chr21:40645737	G/A	cg17971929	chr21:40555470	PSMG1	0.71	4.87	0.3	1.96e-6	Temperament (bipolar disorder);
KIRP	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.57	-7.59	-0.44	6.48e-13	Bladder cancer;
KIRP	cis	rs1642645	0.872	rs238675	chr1:42470274	C/T	cg26038582	chr1:42384390	HIVEP3	0.29	5.19	0.31	4.45e-7	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg07777115	chr5:623756	CEP72	-0.53	-5.73	-0.34	2.91e-8	Obesity-related traits;
KIRP	cis	rs6681460	0.932	rs603750	chr1:67177488	A/G	cg02459107	chr1:67143332	SGIP1	0.41	5.97	0.36	8.3e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs1620921	0.967	rs783159	chr6:161185325	C/T	cg01280913	chr6:161186852	NA	-0.36	-4.93	-0.3	1.51e-6	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg21775007	chr8:11205619	TDH	0.71	10.4	0.55	3.03e-21	Retinal vascular caliber;
KIRP	cis	rs3736485	0.966	rs9920124	chr15:51908942	T/A	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.19e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6723108	0.627	rs4954187	chr2:135600418	C/T	cg12500956	chr2:135428796	TMEM163	0.38	4.87	0.3	1.95e-6	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg15181151	chr6:150070149	PCMT1	0.31	5.29	0.32	2.76e-7	Lung cancer;
KIRP	cis	rs75884327	0.584	rs2836901	chr21:40499194	A/G	cg17971929	chr21:40555470	PSMG1	0.58	4.89	0.3	1.78e-6	Daytime sleep phenotypes;
KIRP	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg00800038	chr16:89945340	TCF25	-0.7	-4.9	-0.3	1.71e-6	Skin colour saturation;
KIRP	cis	rs554111	0.660	rs658851	chr1:21079425	T/C	cg08890418	chr1:21044141	KIF17	0.56	8.74	0.49	3.66e-16	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg01763666	chr17:80159506	CCDC57	0.36	4.98	0.3	1.21e-6	Life satisfaction;
KIRP	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg00405596	chr8:11794950	NA	0.48	5.96	0.36	8.51e-9	Retinal vascular caliber;
KIRP	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg05220968	chr6:146057943	EPM2A	-0.39	-4.93	-0.3	1.54e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs78487399	0.519	rs11124929	chr2:43582103	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-6.63	-0.39	2.17e-10	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-8.09	-0.46	2.67e-14	Coffee consumption (cups per day);
KIRP	cis	rs981844	0.712	rs1456397	chr4:154744554	C/G	cg14289246	chr4:154710475	SFRP2	0.54	7.03	0.41	2e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg11502198	chr6:26597334	ABT1	-0.8	-5.42	-0.33	1.39e-7	Small cell lung carcinoma;
KIRP	cis	rs4356975	0.563	rs7441750	chr4:69964521	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs300890	0.513	rs72719151	chr4:144043570	G/A	cg01719995	chr4:144104893	USP38	-0.46	-5.72	-0.34	3.07e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg25037394	chr1:24152592	HMGCL	0.39	5.17	0.31	4.85e-7	Immature fraction of reticulocytes;
KIRP	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.44	5.14	0.31	5.6e-7	Schizophrenia;
KIRP	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg25547332	chr5:131281432	NA	-0.48	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs988913	0.678	rs10434833	chr6:54983383	T/C	cg03513858	chr6:54763001	FAM83B	-0.36	-4.99	-0.3	1.16e-6	Menarche (age at onset);
KIRP	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg14541582	chr5:601475	NA	-0.54	-5.94	-0.35	9.55e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.65	8.45	0.47	2.6e-15	Prudent dietary pattern;
KIRP	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.65	-8.3	-0.47	7.14e-15	Multiple sclerosis;
KIRP	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23903597	chr17:61704154	MAP3K3	-0.59	-7.26	-0.42	5.14e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4886920	0.862	rs11631822	chr15:78107666	A/G	cg10461261	chr15:78109450	NA	-0.32	-5.29	-0.32	2.64e-7	Neuroticism;
KIRP	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.6	-7.08	-0.41	1.46e-11	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs1816752	0.783	rs7317439	chr13:24985077	A/T	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.77	-0.44	2.19e-13	Total cholesterol levels;
KIRP	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg25019033	chr10:957182	NA	-0.59	-7.34	-0.42	3.02e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg12560992	chr17:57184187	TRIM37	0.64	5.87	0.35	1.38e-8	Cognitive test performance;
KIRP	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg07511668	chr11:68622177	NA	0.39	5.2	0.31	4.14e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg10755058	chr3:40428713	ENTPD3	0.35	5.09	0.31	7.27e-7	Renal cell carcinoma;
KIRP	cis	rs300890	0.513	rs9998017	chr4:144105382	T/C	cg01719995	chr4:144104893	USP38	0.42	5.39	0.32	1.66e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs6496667	0.779	rs8032687	chr15:90945186	C/T	cg10434728	chr15:90938212	IQGAP1	0.41	5.29	0.32	2.67e-7	Rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.88	0.53	1.35e-19	Lung cancer;
KIRP	cis	rs1891275	0.515	rs1361552	chr10:93534624	T/C	cg07889827	chr10:93443413	NA	-0.44	-7.51	-0.43	1.09e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg13319975	chr6:146136371	FBXO30	0.47	6.37	0.38	9.26e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12541635	0.639	rs1032545	chr8:107005825	C/T	cg10147462	chr8:107024639	NA	0.35	5.19	0.31	4.32e-7	Age of smoking initiation;
KIRP	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg02336718	chr17:17403227	NA	0.39	5.9	0.35	1.22e-8	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01708552	chr7:100815485	C7orf52	0.51	6.5	0.38	4.53e-10	Smoking initiation;
KIRP	cis	rs8141529	0.600	rs16986825	chr22:29300306	C/T	cg02153584	chr22:29168773	CCDC117	0.56	5.34	0.32	2.07e-7	Lymphocyte counts;
KIRP	cis	rs9914544	0.628	rs67053020	chr17:18680061	G/C	cg26306683	chr17:18585705	ZNF286B	0.4	5.04	0.31	9.17e-7	Educational attainment (years of education);
KIRP	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.37	-0.43	2.57e-12	Aortic root size;
KIRP	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg10547527	chr2:198650123	BOLL	-0.49	-4.87	-0.3	2.04e-6	Ulcerative colitis;
KIRP	cis	rs2150410	0.833	rs1888486	chr21:40683145	A/G	cg11890956	chr21:40555474	PSMG1	0.83	5.8	0.35	2.02e-8	Temperament (bipolar disorder);
KIRP	cis	rs4356975	0.545	rs11249526	chr4:69946652	G/T	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.72	8.27	0.47	8.56e-15	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17875356	chr3:114807036	ZBTB20	-0.43	-6.55	-0.39	3.32e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.94	10.95	0.57	5.56e-23	Neuroticism;
KIRP	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg19507638	chr5:93509721	C5orf36	-0.54	-5.1	-0.31	6.85e-7	Diabetic retinopathy;
KIRP	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg23682824	chr7:23144976	KLHL7	-0.46	-5.77	-0.35	2.32e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs12586317	0.576	rs12586302	chr14:35691074	G/C	cg07166546	chr14:35805898	NA	-0.26	-6.03	-0.36	6.05e-9	Psoriasis;
KIRP	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg04546413	chr19:29218101	NA	0.6	5.34	0.32	2.14e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg15893493	chr8:124194847	FAM83A	-0.75	-6.07	-0.36	4.9e-9	Urinary uromodulin levels;
KIRP	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg03684893	chr10:554711	DIP2C	-0.35	-4.87	-0.3	1.98e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.42	5.44	0.33	1.26e-7	Aortic root size;
KIRP	cis	rs405956	1.000	rs413806	chr6:105555395	G/A	cg22580625	chr6:105627791	POPDC3	-0.61	-6.58	-0.39	2.77e-10	QT interval;
KIRP	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs56079296	0.929	rs10045704	chr5:121277028	A/G	cg05256605	chr5:121412184	LOX	0.52	5.44	0.33	1.3e-7	Coronary artery disease;
KIRP	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs7809615	0.901	rs6947826	chr7:99156520	C/T	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite ratios;
KIRP	cis	rs741951	0.832	rs73372549	chr21:46255779	C/T	cg08823554	chr21:46269191	NA	-0.59	-5.3	-0.32	2.63e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17381785	0.773	rs13119988	chr4:14921247	A/G	cg12377275	chr4:15005593	CPEB2	0.55	6.45	0.38	5.75e-10	Urate levels in overweight individuals;
KIRP	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03934478	chr11:495069	RNH1	0.83	6.78	0.4	8.78e-11	Body mass index;
KIRP	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.44	5.17	0.31	4.74e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8179	0.645	rs2282979	chr7:92264993	T/C	cg15732164	chr7:92237376	CDK6	-0.39	-5.2	-0.31	4.19e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs7178909	0.902	rs8038480	chr15:90441597	T/C	cg19708238	chr15:90437601	AP3S2	0.58	7.84	0.45	1.34e-13	Common traits (Other);
KIRP	cis	rs2274273	0.638	rs67416413	chr14:55702263	A/G	cg04306507	chr14:55594613	LGALS3	0.42	5.58	0.34	6.4e-8	Protein biomarker;
KIRP	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.72	9.26	0.51	1.08e-17	Resting heart rate;
KIRP	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.93	0.57	6.37e-23	Cognitive test performance;
KIRP	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg01391022	chr12:122360665	WDR66	0.34	4.97	0.3	1.23e-6	Mean corpuscular volume;
KIRP	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg01403660	chr11:68851641	TPCN2	0.67	6.58	0.39	2.83e-10	Blond vs. brown hair color;
KIRP	cis	rs6032067	0.929	rs6017512	chr20:43835038	G/A	cg10761708	chr20:43804764	PI3	0.52	5.34	0.32	2.08e-7	Blood protein levels;
KIRP	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06677660	chr19:49140777	SEC1;DBP	-0.5	-5.87	-0.35	1.41e-8	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.63	6.12	0.36	3.66e-9	Menarche (age at onset);
KIRP	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg21918786	chr6:109611834	NA	-0.34	-4.98	-0.3	1.18e-6	Reticulocyte fraction of red cells;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13118410	chr11:49839281	NA	-0.44	-6.15	-0.37	3.13e-9	Survival in pancreatic cancer;
KIRP	cis	rs13185784	0.667	rs62406986	chr5:179644055	G/A	cg23248424	chr5:179741104	GFPT2	0.54	5.41	0.33	1.48e-7	TRAIL levels;
KIRP	cis	rs7712401	0.562	rs246267	chr5:122256104	A/T	cg19412675	chr5:122181750	SNX24	0.48	5.28	0.32	2.78e-7	Mean platelet volume;
KIRP	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg18306943	chr3:40428807	ENTPD3	0.47	6.14	0.36	3.37e-9	Renal cell carcinoma;
KIRP	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.75	-8.19	-0.46	1.42e-14	Chronic sinus infection;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg21186296	chr8:27182909	PTK2B	0.51	6.55	0.39	3.28e-10	Neuroticism;
KIRP	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.78	9.92	0.53	1e-19	Longevity;
KIRP	cis	rs1978968	0.912	rs1110666	chr22:18457720	A/C	cg03078520	chr22:18463400	MICAL3	0.64	7.38	0.43	2.49e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.34	0.32	2.07e-7	Initial pursuit acceleration;
KIRP	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.98	15.2	0.7	3e-37	Diastolic blood pressure;
KIRP	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg02725872	chr8:58115012	NA	-0.55	-6.35	-0.38	1.05e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	-0.55	-6.76	-0.4	1.02e-10	Inflammatory bowel disease;
KIRP	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12379764	chr21:47803548	PCNT	-0.46	-5.46	-0.33	1.18e-7	Testicular germ cell tumor;
KIRP	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg00310523	chr12:86230176	RASSF9	-0.47	-7.66	-0.44	4.25e-13	Major depressive disorder;
KIRP	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs911119	1.000	rs13041070	chr20:23614261	G/A	cg09631192	chr20:23583594	CST9	-0.6	-5.68	-0.34	3.81e-8	Chronic kidney disease;
KIRP	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg07952391	chr2:88470173	THNSL2	0.93	7.58	0.44	7.02e-13	Plasma clusterin levels;
KIRP	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.55	-6.82	-0.4	7.01e-11	Life satisfaction;
KIRP	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.56e-25	Diabetic kidney disease;
KIRP	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg24315340	chr6:146058215	EPM2A	0.42	5.34	0.32	2.11e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.51	-5.34	-0.32	2.13e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg01804193	chr12:63026212	NA	-0.56	-6.1	-0.36	4.01e-9	IgG glycosylation;
KIRP	trans	rs35100037	0.667	rs9885235	chr5:128572774	G/T	cg11636699	chr19:13044490	FARSA	-0.61	-6.03	-0.36	5.95e-9	Ankle injury;
KIRP	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg26384229	chr12:38710491	ALG10B	0.72	9.56	0.52	1.29e-18	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20312821	chr15:65669563	IGDCC3	0.51	6.73	0.39	1.16e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07450135	chr3:13521524	HDAC11	0.58	7.19	0.42	7.77e-12	Parkinson's disease;
KIRP	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.96e-18	Morning vs. evening chronotype;
KIRP	cis	rs6496667	0.779	rs10083670	chr15:91022135	C/T	cg10434728	chr15:90938212	IQGAP1	0.36	4.96	0.3	1.3e-6	Rheumatoid arthritis;
KIRP	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.76	-0.34	2.45e-8	Parkinson's disease;
KIRP	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.95	12.59	0.63	2.25e-28	Homoarginine levels;
KIRP	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.92	0.35	1.1e-8	Monocyte percentage of white cells;
KIRP	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07570687	chr10:102243282	WNT8B	0.5	6.0	0.36	7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1524927	0.966	rs7789402	chr7:96353085	A/G	cg00227355	chr7:96336147	SHFM1	-0.32	-4.84	-0.3	2.27e-6	Total body bone mineral density;
KIRP	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.46	6.17	0.37	2.84e-9	Hemoglobin concentration;
KIRP	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.71	5.06	0.31	8.03e-7	Childhood ear infection;
KIRP	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg24579218	chr15:68104479	NA	-0.39	-5.61	-0.34	5.37e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.49	6.45	0.38	5.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg12560992	chr17:57184187	TRIM37	0.63	6.21	0.37	2.19e-9	Cognitive test performance;
KIRP	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg05347473	chr6:146136440	FBXO30	-0.57	-8.12	-0.46	2.25e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg21546286	chr11:48923668	NA	-0.45	-5.37	-0.32	1.79e-7	HDL cholesterol;
KIRP	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg27432699	chr2:27873401	GPN1	-0.44	-5.61	-0.34	5.34e-8	Total body bone mineral density;
KIRP	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06481639	chr22:41940642	POLR3H	0.64	6.96	0.41	3.15e-11	Vitiligo;
KIRP	cis	rs16857609	0.628	rs1382436	chr2:218336323	A/G	cg15335768	chr2:218268053	DIRC3	0.36	5.28	0.32	2.8e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.37	-15.31	-0.7	1.31e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs12044355	0.927	rs61835382	chr1:231833225	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.49	6.27	0.37	1.59e-9	Alzheimer's disease;
KIRP	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.83	-7.87	-0.45	1.1e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	12.52	0.62	3.89e-28	Menopause (age at onset);
KIRP	cis	rs6450176	0.625	rs67656636	chr5:53288455	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.98	-12.6	-0.63	1.98e-28	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.57	6.97	0.41	2.82e-11	Aortic root size;
KIRP	cis	rs4523957	0.855	rs216212	chr17:2134214	T/C	cg16513277	chr17:2031491	SMG6	0.68	9.38	0.51	4.6e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.8	11.02	0.57	3.22e-23	Total body bone mineral density;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg21698718	chr17:80085957	CCDC57	-0.36	-5.16	-0.31	4.97e-7	Life satisfaction;
KIRP	cis	rs742115	0.510	rs9468839	chr6:11308035	A/T	cg25250968	chr6:11318770	NEDD9	0.4	5.79	0.35	2.16e-8	Coronary artery disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07409897	chr20:13619336	TASP1	-0.45	-6.24	-0.37	1.94e-9	Metabolic traits;
KIRP	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.42	-5.29	-0.32	2.69e-7	Testicular germ cell tumor;
KIRP	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.96	-16.67	-0.73	2.87e-42	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.59	-8.14	-0.46	2.03e-14	Mortality in heart failure;
KIRP	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.25	-0.32	3.3e-7	Educational attainment (years of education);
KIRP	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.1	0.31	6.84e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.71	-9.76	-0.53	3.19e-19	Plateletcrit;Platelet count;
KIRP	cis	rs17057718	0.898	rs1386833	chr3:57152041	C/T	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-4.99	-0.3	1.15e-6	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg07522229	chr6:144164505	LTV1	0.45	6.05	0.36	5.22e-9	Ischemic stroke;
KIRP	cis	rs7523050	0.643	rs35924015	chr1:109404626	T/C	cg08274380	chr1:109419600	GPSM2	1.03	9.36	0.51	5.37e-18	Fat distribution (HIV);
KIRP	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg09873164	chr1:152488093	CRCT1	0.56	7.11	0.41	1.24e-11	Hair morphology;
KIRP	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg19770292	chr5:1868693	NA	0.46	5.42	0.33	1.43e-7	Cardiovascular disease risk factors;
KIRP	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-0.41	-5.11	-0.31	6.43e-7	Type 2 diabetes;
KIRP	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg09201719	chr10:104596890	CYP17A1	0.36	5.16	0.31	5.08e-7	Arsenic metabolism;
KIRP	cis	rs9911578	0.757	rs117987711	chr17:57111269	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	-0.46	-5.3	-0.32	2.63e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10865541	0.870	rs6548161	chr2:3424350	A/G	cg11642891	chr2:3452563	TTC15	-0.54	-6.8	-0.4	8e-11	Obesity-related traits;
KIRP	trans	rs13100616	1.000	rs13079900	chr3:178413064	C/A	cg26530345	chr2:220312410	SPEG	0.49	6.02	0.36	6.17e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs11783469	0.524	rs17089281	chr8:23335151	T/C	cg00472375	chr8:23315376	ENTPD4	0.59	5.7	0.34	3.35e-8	Reticulocyte count;
KIRP	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg25482853	chr8:67687455	SGK3	0.82	7.16	0.42	9.18e-12	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01358029	chr4:4543607	STX18	0.5	6.34	0.37	1.08e-9	Parkinson's disease;
KIRP	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-7.54	-0.43	9.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08307766	chr12:70637393	CNOT2	0.58	7.25	0.42	5.4e-12	Parkinson's disease;
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-6.45	-0.38	5.92e-10	Lung cancer;
KIRP	cis	rs975752	0.867	rs11190443	chr10:102023738	C/T	cg13817732	chr10:102046368	BLOC1S2	0.72	6.01	0.36	6.83e-9	Schizophrenia;
KIRP	cis	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.48	6.35	0.38	1.02e-9	Leprosy;
KIRP	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg03115019	chr17:80708279	FN3K	0.42	5.09	0.31	7.03e-7	Glycated hemoglobin levels;
KIRP	cis	rs7671900	0.965	rs6857133	chr4:88287598	C/T	cg23841344	chr4:88312519	HSD17B11	-0.54	-7.17	-0.42	8.94e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.86	10.98	0.57	4.38e-23	Response to diuretic therapy;
KIRP	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg26876637	chr1:152193138	HRNR	0.77	10.38	0.55	3.52e-21	Atopic dermatitis;
KIRP	cis	rs4253772	0.938	rs10154348	chr22:46638159	C/A	cg18190219	chr22:46762943	CELSR1	-0.61	-5.78	-0.35	2.3e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg04804543	chr8:142233427	SLC45A4	-0.68	-8.64	-0.48	7.01e-16	Immature fraction of reticulocytes;
KIRP	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg02073558	chr3:44770973	ZNF501	0.75	12.07	0.61	1.2e-26	Depressive symptoms;
KIRP	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.73	11.11	0.58	1.66e-23	Menarche (age at onset);
KIRP	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg13453750	chr1:205783389	SLC41A1	0.39	5.81	0.35	1.92e-8	Monocyte percentage of white cells;
KIRP	cis	rs10811516	0.501	rs10757194	chr9:21162415	G/A	cg23029519	chr9:21187344	IFNA4	-0.47	-5.61	-0.34	5.54e-8	Response to mepolizumab in severe asthma;
KIRP	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.77	-0.35	2.33e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.18	0.42	8.44e-12	Lung cancer;
KIRP	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg19292749	chr17:79650816	ARL16;HGS	0.53	4.86	0.3	2.07e-6	Dental caries;
KIRP	cis	rs11016883	1.000	rs11592922	chr10:131492315	G/T	cg14312783	chr10:131504572	MGMT	0.39	4.95	0.3	1.37e-6	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00810752	chr4:113277063	ALPK1	0.44	6.25	0.37	1.76e-9	Survival in pancreatic cancer;
KIRP	cis	rs4262150	0.810	rs72799168	chr5:152140996	T/A	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.57	7.72	0.44	2.83e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.45	0.68	1.13e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg23093090	chr10:104574429	C10orf26	0.32	5.0	0.3	1.12e-6	Waist circumference;Hip circumference;
KIRP	cis	rs9473924	0.632	rs9463654	chr6:50835607	A/G	cg14470998	chr6:50812995	TFAP2B	-0.38	-4.98	-0.3	1.21e-6	Body mass index;
KIRP	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg22764044	chr5:178986830	RUFY1	-0.42	-6.19	-0.37	2.49e-9	Lung cancer;
KIRP	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.92	16.16	0.72	1.65e-40	Menarche (age at onset);
KIRP	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.83	-0.45	1.49e-13	Retinal vascular caliber;
KIRP	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.98	10.28	0.55	7.21e-21	Alzheimer's disease;
KIRP	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07256732	chr16:621771	PIGQ	-0.48	-6.73	-0.39	1.2e-10	Height;
KIRP	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg00343986	chr7:65444356	GUSB	-0.45	-5.39	-0.33	1.62e-7	Aortic root size;
KIRP	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.55	-4.94	-0.3	1.46e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.95	11.51	0.59	8.48e-25	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.95	15.06	0.69	8.95e-37	Metabolite levels;
KIRP	cis	rs7615316	0.779	rs6440078	chr3:142070495	C/T	cg20824294	chr3:142316082	PLS1	0.23	5.47	0.33	1.08e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg21680719	chr1:38466677	FHL3	-0.23	-5.09	-0.31	7.12e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.51	0.59	8.02e-25	Heart rate;
KIRP	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.79	11.52	0.59	7.86e-25	Prostate cancer;
KIRP	cis	rs9815354	0.680	rs73073288	chr3:42027637	G/C	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6968419	0.755	rs6948556	chr7:115895433	T/C	cg02561103	chr7:115862891	TES	-0.41	-5.82	-0.35	1.83e-8	Intraocular pressure;
KIRP	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.04	0.61	1.51e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26378065	chr17:18585709	ZNF286B	0.5	6.5	0.38	4.43e-10	Educational attainment (years of education);
KIRP	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg18209359	chr17:80159595	CCDC57	-0.41	-5.32	-0.32	2.3e-7	Life satisfaction;
KIRP	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.83	0.49	2.04e-16	Motion sickness;
KIRP	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg23100626	chr2:96804247	ASTL	0.46	6.34	0.37	1.11e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs12200782	1.000	rs12207181	chr6:26431285	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.72	-6.27	-0.37	1.63e-9	Small cell lung carcinoma;
KIRP	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg23335576	chr14:104009727	NA	0.37	5.13	0.31	5.79e-7	Body mass index;
KIRP	cis	rs714027	0.585	rs5752978	chr22:30300586	C/G	cg27665648	chr22:30112403	NA	0.42	5.77	0.35	2.41e-8	Lymphocyte counts;
KIRP	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26002218	chr14:103986227	CKB	0.29	5.91	0.35	1.12e-8	Body mass index;
KIRP	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.33	5.96	0.35	8.91e-9	Renal cell carcinoma;
KIRP	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.61	8.24	0.47	1e-14	Prostate cancer;
KIRP	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg22705602	chr4:152727874	NA	-0.61	-9.29	-0.51	8.33e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg27124370	chr19:33622961	WDR88	0.72	10.05	0.54	3.8e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.59	-6.64	-0.39	2e-10	Mean platelet volume;
KIRP	cis	rs714031	0.772	rs4821914	chr22:40091547	A/G	cg21377881	chr22:40064566	CACNA1I	-0.56	-8.24	-0.47	1.03e-14	Schizophrenia;
KIRP	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.09	0.36	4.24e-9	Rheumatoid arthritis;
KIRP	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06634786	chr22:41940651	POLR3H	-0.48	-5.5	-0.33	9.37e-8	Vitiligo;
KIRP	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.73	10.12	0.54	2.37e-20	Multiple sclerosis;
KIRP	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.85	0.4	5.78e-11	Bipolar disorder;
KIRP	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.37	-5.04	-0.31	9.14e-7	Menarche (age at onset);
KIRP	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.46	-6.55	-0.39	3.27e-10	Hemoglobin concentration;
KIRP	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.77	8.34	0.47	5.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.58	7.36	0.42	2.83e-12	Aortic root size;
KIRP	cis	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg21546286	chr11:48923668	NA	0.43	5.35	0.32	1.99e-7	HDL cholesterol;
KIRP	cis	rs17030434	0.784	rs6835960	chr4:154650460	G/A	cg14289246	chr4:154710475	SFRP2	-0.63	-7.66	-0.44	4.2e-13	Electrocardiographic conduction measures;
KIRP	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.57	-0.39	3e-10	Blood pressure;
KIRP	cis	rs240764	0.610	rs41288423	chr6:101166095	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-4.9	-0.3	1.77e-6	Neuroticism;
KIRP	cis	rs6120849	0.901	rs6060278	chr20:33753262	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.04	0.36	5.59e-9	Protein C levels;
KIRP	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg01420254	chr6:26195488	NA	0.67	6.51	0.38	4.18e-10	Gout;Renal underexcretion gout;
KIRP	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.46	5.85	0.35	1.57e-8	Height;
KIRP	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.37	-0.55	3.78e-21	Hemoglobin concentration;
KIRP	cis	rs4955124	0.558	rs62244392	chr3:32020530	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.83	7.19	0.42	7.78e-12	Schizophrenia;
KIRP	trans	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg00405596	chr8:11794950	NA	-0.47	-6.28	-0.37	1.53e-9	Mood instability;
KIRP	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.11e-7	Breast cancer;
KIRP	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg17644776	chr2:200775616	C2orf69	0.58	6.16	0.37	2.93e-9	Schizophrenia;
KIRP	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.27	0.32	3e-7	Tonsillectomy;
KIRP	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs9381107	0.591	rs2294732	chr6:9517257	C/T	cg14735645	chr6:9486422	NA	0.53	5.31	0.32	2.4e-7	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg21427119	chr20:30132790	HM13	-0.53	-6.0	-0.36	6.93e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg23335576	chr14:104009727	NA	0.41	5.56	0.33	7.06e-8	Body mass index;
KIRP	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.54	-6.86	-0.4	5.59e-11	Tuberculosis;
KIRP	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg08847533	chr14:75593920	NEK9	-0.53	-6.32	-0.37	1.19e-9	IgG glycosylation;
KIRP	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.36	-5.49	-0.33	1e-7	Body mass index;
KIRP	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg17724175	chr1:150552817	MCL1	0.36	6.24	0.37	1.87e-9	Tonsillectomy;
KIRP	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-6.44	-0.38	6.15e-10	Aortic root size;
KIRP	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.71	-10.46	-0.55	2.01e-21	Bladder cancer;
KIRP	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.16e-7	Retinal vascular caliber;
KIRP	cis	rs236907	0.859	rs17650340	chr1:171757921	A/T	cg01410279	chr1:171621941	MYOC	-0.51	-5.83	-0.35	1.77e-8	Mean platelet volume;
KIRP	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.43	-5.26	-0.32	3.06e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs34339938	1	rs34339938	chr12:123678364	GAC/G	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.56e-8	Plateletcrit;
KIRP	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	11.18	0.58	9.56e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.73	0.39	1.16e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg08126542	chr6:37504118	NA	-0.7	-9.98	-0.54	6.55e-20	Cognitive performance;
KIRP	cis	rs220519	0.684	rs220514	chr20:37283597	C/T	cg24308336	chr20:37270989	C20orf95	0.24	5.21	0.32	4.02e-7	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.11	-0.31	6.56e-7	Life satisfaction;
KIRP	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.9	11.28	0.58	4.81e-24	Platelet distribution width;
KIRP	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg00792783	chr2:198669748	PLCL1	-0.44	-4.94	-0.3	1.43e-6	Dermatomyositis;
KIRP	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg21827317	chr3:136751795	NA	0.37	5.04	0.31	9.06e-7	Neuroticism;
KIRP	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg01475377	chr6:109611718	NA	-0.39	-5.56	-0.33	7.02e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.86	-11.53	-0.59	7.32e-25	Cognitive function;
KIRP	cis	rs1978968	0.731	rs9605468	chr22:18461180	T/C	cg03078520	chr22:18463400	MICAL3	-0.84	-12.08	-0.61	1.07e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg07274523	chr3:49395745	GPX1	0.72	8.74	0.49	3.58e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.46	-5.03	-0.31	9.57e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs8014252	0.803	rs58092588	chr14:71028678	T/C	cg11204974	chr14:71022665	NA	-0.71	-6.99	-0.41	2.61e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.72	8.86	0.49	1.59e-16	Cognitive function;
KIRP	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg18016565	chr1:150552671	MCL1	-0.37	-5.53	-0.33	8.24e-8	Tonsillectomy;
KIRP	cis	rs10073892	0.660	rs60284576	chr5:101944332	T/C	cg19774478	chr5:101632501	SLCO4C1	0.58	5.71	0.34	3.29e-8	Cognitive decline (age-related);
KIRP	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg14593290	chr7:50529359	DDC	0.82	10.26	0.55	8.43e-21	Malaria;
KIRP	cis	rs1975991	0.686	rs6782041	chr3:187965184	A/G	cg17585528	chr3:187988060	LPP	-0.47	-5.44	-0.33	1.32e-7	White matter integrity (bipolar disorder risk interaction);
KIRP	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg05784532	chr1:230284198	GALNT2	0.43	6.43	0.38	6.51e-10	Coronary artery disease;
KIRP	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg19743168	chr1:23544995	NA	-0.47	-6.26	-0.37	1.69e-9	Height;
KIRP	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg02297831	chr4:17616191	MED28	0.57	6.96	0.41	3.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg11204139	chr17:3907470	NA	0.57	8.03	0.46	3.96e-14	Type 2 diabetes;
KIRP	cis	rs9608946	1.000	rs9608941	chr22:30886886	C/T	cg23383138	chr22:30885012	SEC14L4	0.41	5.02	0.31	9.76e-7	Red cell distribution width;
KIRP	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.63	7.5	0.43	1.16e-12	Obesity-related traits;
KIRP	cis	rs11997175	0.713	rs4327826	chr8:33654807	T/G	cg04338863	chr8:33670619	NA	0.38	4.97	0.3	1.26e-6	Body mass index;
KIRP	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.83	-8.55	-0.48	1.28e-15	Vitamin D levels;
KIRP	cis	rs7224685	0.569	rs34859684	chr17:3982628	G/C	cg05562828	chr17:3906858	NA	0.54	5.98	0.36	7.97e-9	Type 2 diabetes;
KIRP	cis	rs1978968	0.731	rs9605467	chr22:18461166	A/G	cg02610425	chr22:18483192	MICAL3	0.37	5.59	0.34	6.06e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs745080	0.674	rs9323232	chr14:52983876	G/C	cg23333723	chr14:53022898	GPR137C	-0.42	-5.72	-0.34	3.06e-8	Orofacial clefts;
KIRP	cis	rs7236492	0.748	rs11663202	chr18:77209180	T/C	cg15644404	chr18:77186268	NFATC1	-0.94	-7.77	-0.44	2.11e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg08885076	chr2:99613938	TSGA10	-0.37	-5.02	-0.3	1e-6	Chronic sinus infection;
KIRP	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg24304309	chr1:154577895	ADAR	0.38	5.67	0.34	4.05e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg13798912	chr7:905769	UNC84A	0.64	6.33	0.37	1.17e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.73	-6.68	-0.39	1.57e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg25650185	chr19:21324782	ZNF431	0.48	4.97	0.3	1.25e-6	Pain;
KIRP	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs1185460	0.546	rs549893	chr11:118959732	A/G	cg23280166	chr11:118938394	VPS11	-0.58	-6.75	-0.4	1.03e-10	Coronary artery disease;
KIRP	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.53	-6.8	-0.4	7.8e-11	Type 2 diabetes;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg09033563	chr22:24373618	LOC391322	-0.4	-5.24	-0.32	3.53e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.84	11.69	0.6	2.19e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.97	11.5	0.59	9.04e-25	Exhaled nitric oxide levels;
KIRP	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.21	0.51	1.46e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg20991723	chr1:152506922	NA	-0.44	-5.3	-0.32	2.53e-7	Hair morphology;
KIRP	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	1.06	20.58	0.8	2.09e-55	Heart rate;
KIRP	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.63	7.29	0.42	4.16e-12	Monocyte count;
KIRP	cis	rs3857747	0.895	rs11764628	chr7:40364425	T/A	cg00420559	chr7:40367873	C7orf10	-0.6	-8.46	-0.47	2.37e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.12	0.58	1.56e-23	Cognitive test performance;
KIRP	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.64	5.45	0.33	1.21e-7	Bipolar disorder;
KIRP	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg02336718	chr17:17403227	NA	0.38	6.03	0.36	5.96e-9	Total body bone mineral density;
KIRP	cis	rs4356932	1.000	rs7684889	chr4:76963264	T/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.54	-7.21	-0.42	6.7e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35883536	1.000	rs4907918	chr1:101094609	A/G	cg06223162	chr1:101003688	GPR88	-0.32	-6.52	-0.38	4.03e-10	Monocyte count;
KIRP	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg18646521	chr2:111875858	NA	0.4	5.8	0.35	2.08e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs7572644	0.603	rs4666013	chr2:28019106	C/T	cg27432699	chr2:27873401	GPN1	0.49	5.56	0.33	7e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg01320579	chr17:75405842	SEPT9	0.48	7.8	0.45	1.72e-13	Airflow obstruction;
KIRP	trans	rs17706989	0.649	rs75460556	chr16:78538594	A/T	cg23388020	chr14:70512877	SLC8A3	0.63	6.14	0.36	3.24e-9	Response to antipsychotic treatment in schizophrenia (reasoning);
KIRP	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg05043794	chr9:111880884	C9orf5	-0.23	-4.87	-0.3	2.02e-6	Menarche (age at onset);
KIRP	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg00919237	chr7:87102261	ABCB4	-0.7	-9.26	-0.51	1.08e-17	Gallbladder cancer;
KIRP	cis	rs28489187	0.706	rs423105	chr1:85796427	A/G	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	cg04338863	chr8:33670619	NA	0.48	6.3	0.37	1.36e-9	Body mass index;
KIRP	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg10326726	chr10:51549505	MSMB	0.56	7.96	0.45	6.4e-14	Prostate-specific antigen levels;
KIRP	cis	rs9810890	1.000	rs73207993	chr3:128593778	C/T	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.03	0.54	4.6e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg23950597	chr19:37808831	NA	-0.8	-6.17	-0.37	2.81e-9	Coronary artery calcification;
KIRP	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg25356066	chr3:128598488	ACAD9	0.57	6.7	0.39	1.4e-10	IgG glycosylation;
KIRP	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg00129232	chr17:37814104	STARD3	-0.68	-7.48	-0.43	1.32e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-5.49	-0.33	1.01e-7	Lung cancer;
KIRP	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.6	9.79	0.53	2.58e-19	Total body bone mineral density;
KIRP	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.92	15.53	0.7	2.28e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs997295	1.000	rs12914773	chr15:68019958	G/A	cg14210607	chr15:68128175	NA	-0.31	-5.06	-0.31	8.37e-7	Motion sickness;
KIRP	cis	rs3087591	0.600	rs2905808	chr17:29493993	A/T	cg24425628	chr17:29625626	OMG;NF1	0.63	5.68	0.34	3.71e-8	Hip circumference;
KIRP	cis	rs7712401	0.601	rs246287	chr5:122245426	A/T	cg19412675	chr5:122181750	SNX24	0.48	5.35	0.32	2.05e-7	Mean platelet volume;
KIRP	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.41	-5.8	-0.35	2.04e-8	Coronary artery disease;
KIRP	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.73	8.57	0.48	1.13e-15	Type 2 diabetes;
KIRP	cis	rs2904967	0.929	rs554122	chr11:65033874	T/C	cg09225861	chr11:65069680	NA	0.43	5.62	0.34	5.1e-8	Mean corpuscular volume;
KIRP	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.26	-0.37	1.73e-9	Response to antipsychotic treatment;
KIRP	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg16586182	chr3:47516702	SCAP	-0.68	-9.16	-0.5	2.08e-17	Colorectal cancer;
KIRP	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.56	-15.24	-0.7	2.15e-37	Hip circumference adjusted for BMI;
KIRP	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.65	-6.3	-0.37	1.38e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72781680	0.611	rs72797824	chr2:24356456	T/G	cg20701182	chr2:24300061	SF3B14	0.91	10.15	0.54	1.92e-20	Lymphocyte counts;
KIRP	cis	rs9847710	0.818	rs6445558	chr3:53097660	G/T	cg07884673	chr3:53033167	SFMBT1	-0.38	-4.96	-0.3	1.33e-6	Ulcerative colitis;
KIRP	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.57	8.1	0.46	2.61e-14	Multiple system atrophy;
KIRP	cis	rs11138902	0.673	rs2297420	chr9:72109038	C/T	cg14397918	chr9:72078829	APBA1	0.35	5.63	0.34	4.95e-8	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs7601312	0.903	rs1863073	chr2:229277943	A/G	cg02542817	chr2:229291442	NA	-0.54	-8.28	-0.47	7.95e-15	Schizophrenia;
KIRP	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.38	5.47	0.33	1.11e-7	Motion sickness;
KIRP	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg17252645	chr8:143867129	LY6D	-0.31	-4.98	-0.3	1.21e-6	Urinary tract infection frequency;
KIRP	cis	rs9394841	0.692	rs9381097	chr6:41847800	A/G	cg08135965	chr6:41755394	TOMM6	-0.51	-5.42	-0.33	1.41e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs3849570	0.643	rs6797240	chr3:81971856	T/C	cg07356753	chr3:81810745	GBE1	-0.55	-7.38	-0.43	2.45e-12	Waist circumference;Body mass index;
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.9	-15.86	-0.71	1.72e-39	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg07701084	chr6:150067640	NUP43	0.54	6.67	0.39	1.65e-10	Testicular germ cell tumor;
KIRP	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.7	10.44	0.55	2.35e-21	Prostate cancer;
KIRP	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.65	8.27	0.47	8.35e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.72	8.49	0.48	2.01e-15	Neutrophil percentage of white cells;
KIRP	cis	rs2862064	1.000	rs6555787	chr5:156433699	T/C	cg12943317	chr5:156479607	HAVCR1	-0.9	-7.77	-0.44	2.2e-13	Platelet count;
KIRP	cis	rs290268	0.803	rs2780701	chr9:93567281	A/G	cg02608019	chr9:93564028	SYK	0.81	11.08	0.58	2e-23	Platelet count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19754308	chr17:79369319	NA	-0.45	-6.02	-0.36	6.25e-9	Survival in pancreatic cancer;
KIRP	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs73198271	0.710	rs7837843	chr8:8656485	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.72	-0.39	1.23e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12580194	0.593	rs12581959	chr12:55787311	G/A	cg11794356	chr12:55725991	OR6C3	-0.55	-7.05	-0.41	1.76e-11	Cancer;
KIRP	cis	rs6142102	1.000	rs12480839	chr20:32727430	A/G	cg08999081	chr20:33150536	PIGU	0.55	6.92	0.4	3.92e-11	Skin pigmentation;
KIRP	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.73	0.49	3.94e-16	Electroencephalogram traits;
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg18612461	chr15:75251733	NA	0.33	5.06	0.31	8.29e-7	Breast cancer;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg21194723	chr11:60681294	TMEM109	0.49	6.55	0.39	3.32e-10	Ischemic stroke;
KIRP	cis	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg27411982	chr8:10470053	RP1L1	-0.46	-5.36	-0.32	1.88e-7	Neuroticism;
KIRP	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.5	-0.38	4.38e-10	Axial length;
KIRP	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg24747557	chr10:131355152	MGMT	-0.42	-5.76	-0.34	2.52e-8	Response to temozolomide;
KIRP	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.33	-5.5	-0.33	9.71e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	6.65	0.39	1.91e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	10.07	0.54	3.41e-20	Total body bone mineral density;
KIRP	cis	rs7224685	0.569	rs8065660	chr17:4000858	A/G	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.72e-7	Type 2 diabetes;
KIRP	cis	rs4972806	0.814	rs4246626	chr2:177046430	A/C	cg10304824	chr2:177028804	HOXD3	0.26	5.27	0.32	3e-7	IgG glycosylation;
KIRP	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg02807482	chr3:125708958	NA	-0.49	-5.17	-0.31	4.83e-7	Blood pressure (smoking interaction);
KIRP	cis	rs258892	0.895	rs6452660	chr5:72023989	G/A	cg21869765	chr5:72125136	TNPO1	-0.53	-6.12	-0.36	3.58e-9	Small cell lung carcinoma;
KIRP	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.17	0.42	8.63e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg23587288	chr2:27483067	SLC30A3	0.59	7.59	0.44	6.76e-13	Blood metabolite levels;
KIRP	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.71	9.07	0.5	3.86e-17	Coronary artery disease;
KIRP	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.43	6.41	0.38	7.25e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs240764	0.658	rs4571568	chr6:101223955	T/A	cg09795085	chr6:101329169	ASCC3	-0.48	-5.63	-0.34	4.99e-8	Neuroticism;
KIRP	cis	rs1440410	0.798	rs13128884	chr4:144107822	A/G	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg06027949	chr8:82754900	SNX16	-0.45	-5.59	-0.34	6.1e-8	Diastolic blood pressure;
KIRP	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05665937	chr4:1216051	CTBP1	-0.49	-6.71	-0.39	1.34e-10	Obesity-related traits;
KIRP	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg07636037	chr3:49044803	WDR6	-0.73	-5.17	-0.31	4.85e-7	Blood protein levels;
KIRP	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.52	-0.33	8.43e-8	Lung cancer;
KIRP	cis	rs17123764	0.892	rs1012874	chr12:50146950	T/C	cg20471783	chr12:50157085	TMBIM6	0.42	6.02	0.36	6.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	10.33	0.55	5.23e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg13736514	chr6:26305472	NA	0.53	6.75	0.4	1.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.51	-6.14	-0.36	3.28e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg19773385	chr1:10388646	KIF1B	-0.66	-10.17	-0.54	1.7e-20	Hepatocellular carcinoma;
KIRP	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.83	12.35	0.62	1.34e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.35	6.36	0.38	9.52e-10	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.611	rs56113233	chr2:24341085	A/C	cg06627628	chr2:24431161	ITSN2	-0.58	-5.06	-0.31	8.21e-7	Lymphocyte counts;
KIRP	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg06026331	chr20:60912101	LAMA5	0.51	5.57	0.33	6.54e-8	Colorectal cancer;
KIRP	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.41	-7.2	-0.42	7.22e-12	Refractive error;
KIRP	cis	rs4908768	0.906	rs28422051	chr1:8618337	T/C	cg03610117	chr1:8450231	RERE	-0.5	-5.3	-0.32	2.56e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs6832769	0.961	rs6824955	chr4:56317136	A/C	cg09317128	chr4:56265301	TMEM165	0.54	6.87	0.4	5.31e-11	Personality dimensions;
KIRP	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.41	5.94	0.35	9.75e-9	Sitting height ratio;
KIRP	cis	rs933688	0.509	rs2973472	chr5:90519496	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-5.94	-0.35	9.45e-9	Smoking behavior;
KIRP	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.48	6.51	0.38	4.09e-10	Testicular germ cell tumor;
KIRP	cis	rs7215564	0.908	rs7501659	chr17:78662061	C/T	cg06153925	chr17:78755379	RPTOR	0.31	5.07	0.31	7.88e-7	Myopia (pathological);
KIRP	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs13385	0.769	rs4912707	chr5:139624461	A/G	cg01860693	chr5:139557145	C5orf32	0.46	5.09	0.31	7.01e-7	Atrial fibrillation;
KIRP	cis	rs7180079	0.620	rs2733384	chr15:64884386	T/C	cg15337035	chr15:64978493	NA	-0.47	-5.08	-0.31	7.56e-7	Monocyte count;
KIRP	cis	rs55863869	0.892	rs11902709	chr2:179608207	A/G	cg02880032	chr2:179629472	TTN	-0.73	-4.99	-0.3	1.12e-6	QT interval;
KIRP	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg01689657	chr7:91764605	CYP51A1	0.43	6.22	0.37	2.18e-9	Breast cancer;
KIRP	cis	rs75920871	0.925	rs17120241	chr11:116915020	T/C	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	5.24	0.32	3.4e-7	Menarche (age at onset);
KIRP	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.47	6.86	0.4	5.69e-11	Coronary artery disease;
KIRP	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-6.48	-0.38	5.1e-10	Morning vs. evening chronotype;
KIRP	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.57	7.15	0.41	9.84e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.33	-0.32	2.23e-7	Ulcerative colitis;
KIRP	cis	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg21546286	chr11:48923668	NA	-0.45	-5.49	-0.33	1.02e-7	HDL cholesterol;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26095517	chr5:111496724	NCRNA00219;SNORA13	0.5	6.46	0.38	5.43e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06860352	chr19:14142585	IL27RA	0.49	6.36	0.38	9.9e-10	Parkinson's disease;
KIRP	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.23e-7	Obesity-related traits;
KIRP	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-13.15	-0.64	2.91e-30	Chronic sinus infection;
KIRP	cis	rs7536201	1.000	rs11249218	chr1:25300256	A/G	cg23273869	chr1:25296894	NA	-0.39	-5.64	-0.34	4.6e-8	Psoriasis vulgaris;
KIRP	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.36e-11	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09255124	chr11:43380251	TTC17	0.44	6.68	0.39	1.58e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg17724175	chr1:150552817	MCL1	0.34	5.48	0.33	1.04e-7	Melanoma;
KIRP	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg03808351	chr9:123631620	PHF19	0.44	6.0	0.36	6.94e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9372498	0.908	rs17080082	chr6:118700137	C/T	cg18833306	chr6:118973337	C6orf204	-0.59	-4.93	-0.3	1.53e-6	Diastolic blood pressure;
KIRP	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	6.02	0.36	6.43e-9	Menarche (age at onset);
KIRP	cis	rs4664293	0.867	rs16844269	chr2:160599080	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs7255436	0.965	rs28729307	chr19:8452742	A/G	cg10174797	chr19:8464628	RAB11B	0.51	6.38	0.38	8.56e-10	HDL cholesterol;
KIRP	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00864171	chr11:67383662	NA	0.39	4.99	0.3	1.12e-6	Mean corpuscular volume;
KIRP	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg26898376	chr11:64110657	CCDC88B	0.59	4.97	0.3	1.26e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg21546286	chr11:48923668	NA	-0.47	-6.03	-0.36	6.06e-9	HDL cholesterol;
KIRP	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.7	-9.14	-0.5	2.43e-17	Nonalcoholic fatty liver disease;
KIRP	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.73	10.28	0.55	7.48e-21	Prostate cancer;
KIRP	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.44	5.22	0.32	3.78e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.43	-5.93	-0.35	1e-8	Lymphocyte counts;
KIRP	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.76	-8.49	-0.48	2e-15	Platelet count;
KIRP	cis	rs7084402	0.934	rs1649089	chr10:60289695	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg17366294	chr4:99064904	C4orf37	0.43	5.97	0.36	8.07e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg02487422	chr3:49467188	NICN1	0.43	5.84	0.35	1.67e-8	Parkinson's disease;
KIRP	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	1.05	17.14	0.74	7.08e-44	Eosinophil percentage of white cells;
KIRP	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-7.92	-0.45	8.03e-14	Glomerular filtration rate;
KIRP	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg13703089	chr14:106090767	NA	-0.36	-5.13	-0.31	6.02e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.53	5.11	0.31	6.5e-7	Gut microbiome composition (summer);
KIRP	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.79	10.48	0.56	1.75e-21	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.56	7.41	0.43	2e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.84	8.55	0.48	1.28e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12200782	0.932	rs12189841	chr6:26544798	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-5.93	-0.35	1.01e-8	Small cell lung carcinoma;
KIRP	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.43	0.43	1.83e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12986413	0.651	rs2238610	chr19:2146852	T/C	cg09261902	chr19:2140048	AP3D1	0.72	11.51	0.59	8.2e-25	Height;
KIRP	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg16797656	chr11:68205561	LRP5	0.39	5.13	0.31	5.81e-7	Total body bone mineral density;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00530199	chr13:52027382	INTS6	0.48	6.7	0.39	1.41e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.25	5.13	0.31	6.02e-7	Type 2 diabetes;
KIRP	cis	rs1729407	0.933	rs1729405	chr11:116678760	C/T	cg26566898	chr11:117069891	TAGLN	0.39	4.97	0.3	1.24e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.92	12.57	0.63	2.49e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.54	-4.92	-0.3	1.59e-6	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg23803603	chr1:2058230	PRKCZ	0.38	5.95	0.35	9.02e-9	Height;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg15181151	chr6:150070149	PCMT1	0.29	5.0	0.3	1.08e-6	Lung cancer;
KIRP	trans	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg15556689	chr8:8085844	FLJ10661	0.48	6.03	0.36	6.04e-9	Myopia (pathological);
KIRP	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.49	-5.59	-0.34	5.91e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs11779988	0.630	rs7821469	chr8:17894388	G/C	cg01800426	chr8:17659068	MTUS1	-0.41	-4.98	-0.3	1.22e-6	Breast cancer;
KIRP	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg03128060	chr6:142623767	GPR126	0.35	5.04	0.31	8.94e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.3	-0.42	3.89e-12	Aortic root size;
KIRP	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26002218	chr14:103986227	CKB	0.28	5.67	0.34	3.98e-8	Body mass index;
KIRP	cis	rs2236918	1.000	rs1629051	chr1:242026344	A/G	cg17736920	chr1:242011382	EXO1	-0.71	-9.19	-0.51	1.69e-17	Menopause (age at onset);
KIRP	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25220896	chr1:11004296	NA	-0.48	-6.82	-0.4	7.17e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.07	-0.61	1.19e-26	Blood trace element (Zn levels);
KIRP	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.57	-8.28	-0.47	7.71e-15	Bipolar disorder;
KIRP	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg01689657	chr7:91764605	CYP51A1	0.37	5.4	0.33	1.59e-7	Breast cancer;
KIRP	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg14728415	chr7:32535168	LSM5;AVL9	0.47	4.97	0.3	1.28e-6	Cognitive ability;
KIRP	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg16558253	chr16:72132732	DHX38	-0.4	-5.57	-0.33	6.65e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs9488822	0.676	rs4354188	chr6:116327936	T/C	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.76	9.41	0.51	3.81e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg03289416	chr15:75166202	SCAMP2	0.57	7.59	0.44	6.52e-13	Caffeine consumption;
KIRP	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.39	4.9	0.3	1.77e-6	Blood protein levels;
KIRP	cis	rs795484	0.890	rs811247	chr12:118622836	G/T	cg16572268	chr12:118583242	PEBP1	-0.37	-4.97	-0.3	1.24e-6	Morphine dose requirement in tonsillectomy and adenoidectomy surgery;
KIRP	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.38	6.5	0.38	4.41e-10	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-1.1	-21.99	-0.81	5.18e-60	Height;
KIRP	cis	rs7534824	0.625	rs61780287	chr1:101382744	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.65	5.65	0.34	4.45e-8	Refractive astigmatism;
KIRP	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.82	12.23	0.61	3.54e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.84	9.93	0.54	8.97e-20	Homoarginine levels;
KIRP	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.49	-7.52	-0.43	1e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6142102	0.812	rs6059554	chr20:32514092	A/T	cg24642439	chr20:33292090	TP53INP2	0.52	5.77	0.35	2.39e-8	Skin pigmentation;
KIRP	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.52	7.37	0.43	2.53e-12	Coronary artery disease;
KIRP	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg07001201	chr5:642380	CEP72	0.67	6.2	0.37	2.42e-9	Obesity-related traits;
KIRP	cis	rs76533333	0.564	rs34658917	chr13:113417423	C/T	cg04656015	chr13:113407548	ATP11A	0.65	5.25	0.32	3.23e-7	Red cell distribution width;
KIRP	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg16077055	chr2:106428750	NCK2	0.31	6.06	0.36	4.97e-9	Addiction;
KIRP	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26314531	chr2:26401878	FAM59B	-0.5	-4.99	-0.3	1.17e-6	Gut microbiome composition (summer);
KIRP	cis	rs7147624	1.000	rs7153497	chr14:65998415	A/G	cg03016385	chr14:66212404	NA	-0.99	-9.74	-0.53	3.68e-19	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg13565492	chr6:43139072	SRF	-0.94	-8.66	-0.48	6.42e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4713675	0.584	rs3227	chr6:33662295	G/C	cg15676125	chr6:33679581	C6orf125	0.42	5.61	0.34	5.56e-8	Plateletcrit;
KIRP	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg27432699	chr2:27873401	GPN1	-0.43	-5.5	-0.33	9.48e-8	Total body bone mineral density;
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg03161606	chr19:29218774	NA	0.64	6.23	0.37	2e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6102059	0.642	rs55963293	chr20:39204277	T/C	cg22477343	chr20:39312069	NA	0.45	5.82	0.35	1.84e-8	LDL cholesterol;
KIRP	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg16584676	chr17:46985605	UBE2Z	-0.45	-5.57	-0.33	6.6e-8	Type 2 diabetes;
KIRP	cis	rs2916247	1.000	rs10441534	chr8:93056692	A/G	cg10183463	chr8:93005414	RUNX1T1	0.54	7.17	0.42	8.93e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.64	7.92	0.45	8.11e-14	Vitiligo;
KIRP	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.69	-9.49	-0.52	2.06e-18	Alzheimer's disease;
KIRP	cis	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg20368463	chr18:77673604	PQLC1	0.71	5.44	0.33	1.28e-7	Opioid sensitivity;
KIRP	cis	rs12822507	0.757	rs10845588	chr12:12760043	G/A	cg11838227	chr12:12764436	CREBL2	0.46	5.58	0.34	6.18e-8	Systemic lupus erythematosus;
KIRP	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.76	9.49	0.52	2.08e-18	Monocyte percentage of white cells;
KIRP	cis	rs731174	0.759	rs12133523	chr1:38153110	T/A	cg14170840	chr1:38155120	C1orf109	-0.41	-5.25	-0.32	3.33e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16405210	chr4:1374714	KIAA1530	-0.59	-8.43	-0.47	2.99e-15	Longevity;
KIRP	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.94	15.51	0.7	2.56e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg13939156	chr17:80058883	NA	-0.48	-5.58	-0.34	6.19e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg07843065	chr1:150265600	MRPS21	0.44	6.04	0.36	5.65e-9	Migraine;
KIRP	cis	rs273573	0.600	rs7117074	chr11:30986087	A/C	cg14844989	chr11:31128820	NA	0.34	4.89	0.3	1.79e-6	Total body bone mineral density;
KIRP	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	0.87	10.28	0.55	7.26e-21	Pediatric areal bone mineral density (radius);
KIRP	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg01631408	chr1:248437212	OR2T33	0.64	8.76	0.49	3.32e-16	Common traits (Other);
KIRP	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.74	9.25	0.51	1.09e-17	Glomerular filtration rate (creatinine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.3.82825901F	chr3:82743211	NA	0.44	6.03	0.36	5.86e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.68	9.01	0.5	5.71e-17	Bladder cancer;
KIRP	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg16482183	chr6:26056742	HIST1H1C	0.45	5.69	0.34	3.53e-8	Schizophrenia;
KIRP	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg16926213	chr1:1841314	NA	0.31	5.23	0.32	3.64e-7	Body mass index;
KIRP	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.96	12.93	0.64	1.62e-29	Vitamin D levels;
KIRP	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg00738919	chr7:1100172	C7orf50	0.44	5.1	0.31	6.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	11.41	0.59	1.74e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg25457927	chr22:38595422	NA	-0.39	-8.21	-0.46	1.24e-14	Breast cancer;
KIRP	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	0.91	8.81	0.49	2.37e-16	Red blood cell traits;
KIRP	cis	rs7172677	0.737	rs58201389	chr15:75446835	G/A	cg14664628	chr15:75095509	CSK	-0.62	-6.84	-0.4	6.17e-11	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg25547332	chr5:131281432	NA	0.48	5.35	0.32	2.01e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs12496230	0.794	rs4856967	chr3:66864887	T/C	cg17646820	chr3:66848679	NA	0.38	6.2	0.37	2.42e-9	Type 2 diabetes;
KIRP	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.66	-8.63	-0.48	7.55e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.2	-0.46	1.3e-14	Mood instability;
KIRP	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17376030	chr22:41985996	PMM1	-0.81	-8.5	-0.48	1.85e-15	Vitiligo;
KIRP	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg21775007	chr8:11205619	TDH	-0.43	-5.66	-0.34	4.31e-8	Morning vs. evening chronotype;
KIRP	cis	rs7119038	0.774	rs11217020	chr11:118639353	G/A	cg19308663	chr11:118741387	NA	0.58	8.8	0.49	2.4e-16	Sjögren's syndrome;
KIRP	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg11130432	chr3:121712080	ILDR1	-0.42	-4.98	-0.3	1.21e-6	Multiple sclerosis;
KIRP	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg16497661	chr14:103986332	CKB	-0.51	-6.45	-0.38	5.84e-10	Coronary artery disease;
KIRP	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg13206674	chr6:150067644	NUP43	0.5	7.1	0.41	1.34e-11	Lung cancer;
KIRP	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.75	-9.97	-0.54	7.17e-20	Huntington's disease progression;
KIRP	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.68	7.7	0.44	3.36e-13	Schizophrenia;
KIRP	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-12.94	-0.64	1.45e-29	Exhaled nitric oxide output;
KIRP	cis	rs12760731	0.720	rs10798607	chr1:178373110	C/T	cg00404053	chr1:178313656	RASAL2	0.65	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs11877825	0.826	rs3748425	chr18:10581762	A/C	cg07277756	chr18:10589357	NA	0.49	6.04	0.36	5.58e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs829883	0.659	rs11109510	chr12:98911382	A/G	cg25150519	chr12:98850993	NA	-0.76	-9.3	-0.51	8.12e-18	Colorectal adenoma (advanced);
KIRP	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg02487422	chr3:49467188	NICN1	0.41	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs6001982	0.667	rs3827381	chr22:40881402	T/C	cg07138101	chr22:40742427	ADSL	0.7	5.6	0.34	5.6e-8	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00946942	chr5:133703539	CDKL3	-0.42	-6.32	-0.37	1.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg13789015	chr9:136890014	NCRNA00094	0.7	5.97	0.36	8.37e-9	Mosquito bite size;
KIRP	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.45	-7.32	-0.42	3.49e-12	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg04373760	chr16:53404718	NA	0.62	6.77	0.4	9.41e-11	Hypertriglyceridemia;
KIRP	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.59	-7.48	-0.43	1.35e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg00978584	chr2:202122832	CASP8	0.47	6.02	0.36	6.41e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
KIRP	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg00792783	chr2:198669748	PLCL1	0.46	5.21	0.32	3.97e-7	Intracranial aneurysm;
KIRP	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg03563238	chr19:33554763	RHPN2	-0.3	-5.36	-0.32	1.92e-7	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27113440	chr11:22214386	ANO5	0.43	6.99	0.41	2.64e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs34779708	0.658	rs4934715	chr10:35364992	G/T	cg03585969	chr10:35415529	CREM	0.79	9.71	0.53	4.31e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.13e-20	Dupuytren's disease;
KIRP	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg06647332	chr5:131281008	NA	0.44	4.87	0.3	2e-6	Life satisfaction;
KIRP	cis	rs7027203	0.576	rs4509402	chr9:96543377	C/T	cg14598338	chr9:96623480	NA	0.46	7.15	0.41	9.79e-12	DNA methylation (variation);
KIRP	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.63	-7.5	-0.43	1.17e-12	Systemic lupus erythematosus;
KIRP	cis	rs2718812	0.766	rs2589269	chr3:133409977	C/T	cg11941060	chr3:133502564	NA	0.38	4.93	0.3	1.53e-6	Iron status biomarkers;
KIRP	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg24633833	chr3:10029261	TMEM111	0.56	5.52	0.33	8.77e-8	Alzheimer's disease;
KIRP	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.6	-5.98	-0.36	7.67e-9	Body mass index;
KIRP	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg23422044	chr7:1970798	MAD1L1	-0.5	-6.13	-0.36	3.49e-9	Neuroticism;
KIRP	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.92	-8.56	-0.48	1.21e-15	Rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-5.02	-0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.96	-13.4	-0.65	4e-31	Blood protein levels;
KIRP	cis	rs10203711	0.705	rs4663946	chr2:239610287	C/T	cg14580085	chr2:239553406	NA	-0.39	-5.03	-0.31	9.37e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.546	rs28590002	chr4:98722642	C/T	cg05340658	chr4:99064831	C4orf37	0.66	7.88	0.45	1.07e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.93	12.54	0.62	3.3e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19307543	chr8:2091425	MYOM2	-0.42	-6.61	-0.39	2.39e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.58	7.29	0.42	4.19e-12	Fibrinogen levels;
KIRP	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg19847130	chr8:10466454	RP1L1	0.36	5.32	0.32	2.31e-7	Neuroticism;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.53	-6.75	-0.4	1.04e-10	Longevity;Endometriosis;
KIRP	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	0.88	10.3	0.55	6.47e-21	Red cell distribution width;
KIRP	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.95	8.68	0.48	5.59e-16	Rheumatoid arthritis;
KIRP	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.6	8.11	0.46	2.45e-14	Response to temozolomide;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg06872176	chr1:68697386	GPR177	0.92	6.17	0.37	2.76e-9	P wave terminal force;
KIRP	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg00173435	chr12:106696525	TCP11L2	0.74	7.39	0.43	2.28e-12	Tourette syndrome;
KIRP	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	5.48	0.33	1.03e-7	Coronary artery disease;
KIRP	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.8	11.78	0.6	1.11e-25	Blood metabolite ratios;
KIRP	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.48	-5.73	-0.34	2.96e-8	Menarche (age at onset);
KIRP	cis	rs2348418	0.715	rs12307612	chr12:28719646	C/T	cg13890972	chr12:28721907	NA	-0.33	-5.16	-0.31	5.04e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.36e-8	Life satisfaction;
KIRP	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.7	7.74	0.44	2.53e-13	Neutrophil percentage of white cells;
KIRP	cis	rs3736485	0.966	rs11070856	chr15:51853817	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4950322	0.570	rs72691032	chr1:146732774	G/A	cg22381352	chr1:146742008	CHD1L	-0.46	-5.52	-0.33	8.64e-8	Protein quantitative trait loci;
KIRP	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.81	-10.34	-0.55	4.91e-21	Longevity;Endometriosis;
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg03734035	chr10:102289529	NDUFB8	-0.44	-6.05	-0.36	5.24e-9	Hippocampal sclerosis of aging;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09172752	chr15:77197536	NA	0.49	6.52	0.38	3.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs5753618	0.561	rs715510	chr22:31690528	T/A	cg22777020	chr22:31556080	RNF185	-0.5	-5.32	-0.32	2.37e-7	Colorectal cancer;
KIRP	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg22437258	chr11:111473054	SIK2	0.59	6.83	0.4	6.5500000000000006e-11	Primary sclerosing cholangitis;
KIRP	cis	rs4908768	0.906	rs11584261	chr1:8560366	C/A	cg03610117	chr1:8450231	RERE	-0.49	-5.23	-0.32	3.56e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg19906672	chr4:6918868	TBC1D14	0.51	5.23	0.32	3.65e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04886391	chr1:23345709	KDM1A	-0.48	-6.21	-0.37	2.21e-9	Interleukin-4 levels;
KIRP	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg24060327	chr5:131705240	SLC22A5	-0.46	-5.73	-0.34	2.98e-8	Blood metabolite levels;
KIRP	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	0.9	7.01	0.41	2.23e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs554111	0.560	rs592060	chr1:21050958	A/G	cg21184320	chr1:21044207	KIF17	-0.65	-8.82	-0.49	2.22e-16	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs735539	0.645	rs6490601	chr13:21245897	G/A	cg04906043	chr13:21280425	IL17D	-0.48	-5.54	-0.33	7.69e-8	Dental caries;
KIRP	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg00982548	chr2:198649783	BOLL	-0.55	-4.99	-0.3	1.12e-6	Ulcerative colitis;
KIRP	cis	rs12496230	0.830	rs4856963	chr3:66858357	A/T	cg17646820	chr3:66848679	NA	0.4	6.59	0.39	2.73e-10	Type 2 diabetes;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg21994174	chr19:51870364	CLDND2;ETFB	-0.63	-6.56	-0.39	3.16e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.99	-13.68	-0.66	4.79e-32	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20979003	chr3:141205767	RASA2	0.5	6.47	0.38	5.36e-10	Parkinson's disease;
KIRP	cis	rs9905704	0.633	rs2526369	chr17:56469113	T/C	cg12560992	chr17:57184187	TRIM37	-0.56	-5.44	-0.33	1.26e-7	Testicular germ cell tumor;
KIRP	cis	rs490234	0.841	rs7856366	chr9:128442229	A/G	cg14078157	chr9:128172775	NA	-0.5	-5.89	-0.35	1.27e-8	Mean arterial pressure;
KIRP	cis	rs6496667	0.779	rs62020687	chr15:90954396	C/T	cg10434728	chr15:90938212	IQGAP1	0.4	5.13	0.31	5.78e-7	Rheumatoid arthritis;
KIRP	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.86	-12.8	-0.63	4.2e-29	Height;
KIRP	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg03060546	chr3:49711283	APEH	-0.56	-4.95	-0.3	1.4e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.97	-16.77	-0.73	1.28e-42	Height;
KIRP	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg11289296	chr17:74383131	SPHK1	0.48	6.22	0.37	2.11e-9	Survival in pancreatic cancer;
KIRP	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg09904177	chr6:26538194	HMGN4	-0.47	-5.71	-0.34	3.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2273669	0.915	rs1887414	chr6:109292736	C/T	cg05315195	chr6:109294784	ARMC2	0.47	5.36	0.32	1.87e-7	Prostate cancer;
KIRP	cis	rs13006833	0.668	rs2582736	chr2:191144892	A/T	cg25963032	chr2:191064776	C2orf88	0.37	4.9	0.3	1.77e-6	Urinary metabolites;
KIRP	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.71	7.25	0.42	5.52e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9914544	0.545	rs12937933	chr17:18770283	C/G	cg26378065	chr17:18585709	ZNF286B	0.38	4.98	0.3	1.19e-6	Educational attainment (years of education);
KIRP	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.36	-0.62	1.24e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.57	7.66	0.44	4.16e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs7084402	0.967	rs1582827	chr10:60297102	T/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg05802129	chr4:122689817	NA	-0.6	-7.55	-0.43	8.56e-13	Type 2 diabetes;
KIRP	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg13010199	chr12:38710504	ALG10B	0.41	5.35	0.32	2e-7	Heart rate;
KIRP	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg22117172	chr7:91764530	CYP51A1	0.41	5.64	0.34	4.77e-8	Breast cancer;
KIRP	cis	rs12580194	0.593	rs61957937	chr12:55746850	G/C	cg19537932	chr12:55886519	OR6C68	-0.5	-6.47	-0.38	5.14e-10	Cancer;
KIRP	cis	rs9638182	0.582	rs12539351	chr7:72978112	A/G	cg07452164	chr7:72993570	TBL2	0.52	5.91	0.35	1.13e-8	Triglycerides;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06836338	chr17:17942007	ATPAF2;C17orf39	0.56	6.77	0.4	9.51e-11	Smoking initiation;
KIRP	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg05785598	chr3:49045655	WDR6	0.28	5.04	0.31	9.08e-7	Parkinson's disease;
KIRP	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg04865290	chr3:52927548	TMEM110	0.41	5.59	0.34	5.92e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.59	8.85	0.49	1.74e-16	Cancer;
KIRP	cis	rs829883	0.668	rs829882	chr12:98880099	A/G	cg25150519	chr12:98850993	NA	0.55	7.46	0.43	1.44e-12	Colorectal adenoma (advanced);
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.63	0.34	4.83e-8	Lung cancer;
KIRP	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.65	8.59	0.48	1.01e-15	Breast cancer;
KIRP	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg05220968	chr6:146057943	EPM2A	-0.38	-4.95	-0.3	1.35e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.56	8.46	0.47	2.34e-15	Bone mineral density;
KIRP	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg16736954	chr20:23401023	NAPB	0.63	5.0	0.3	1.08e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.99	9.87	0.53	1.44e-19	Alzheimer's disease;
KIRP	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg13611997	chr5:233750	SDHA	-0.45	-5.31	-0.32	2.41e-7	Breast cancer;
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg09704166	chr2:114031854	PAX8;LOC440839	0.26	4.9	0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs1656402	0.954	rs3111399	chr2:233429810	G/A	cg03852847	chr2:233439513	NA	0.72	12.09	0.61	1.01e-26	Non-small cell lung cancer (survival);
KIRP	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg07870213	chr5:140052090	DND1	0.62	7.47	0.43	1.38e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg01557791	chr16:72042693	DHODH	-0.41	-4.98	-0.3	1.19e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.16	-0.37	2.93e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.82	8.27	0.47	8.22e-15	Educational attainment;
KIRP	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg07382826	chr16:28625726	SULT1A1	0.44	5.21	0.32	4.06e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.12	15.23	0.7	2.45e-37	Lymphocyte percentage of white cells;
KIRP	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.69	-8.8	-0.49	2.39e-16	Iron status biomarkers;
KIRP	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.9	9.07	0.5	4.03e-17	Methadone dose in opioid dependence;
KIRP	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.68	5.84	0.35	1.62e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	trans	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg06636001	chr8:8085503	FLJ10661	0.57	7.24	0.42	5.76e-12	Retinal vascular caliber;
KIRP	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg04369109	chr6:150039330	LATS1	-0.58	-7.38	-0.43	2.41e-12	Lung cancer;
KIRP	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.42	0.51	3.42e-18	Prudent dietary pattern;
KIRP	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg27205649	chr11:78285834	NARS2	-0.53	-5.09	-0.31	7.25e-7	Testicular germ cell tumor;
KIRP	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.57	-5.59	-0.34	5.89e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs2296225	0.722	rs12022873	chr1:21046569	G/A	cg14666476	chr1:21112556	HP1BP3	0.67	6.09	0.36	4.41e-9	Eosinophilic esophagitis;
KIRP	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.17	16.49	0.72	1.15e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-5.78	-0.35	2.23e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18252515	chr7:66147081	NA	-0.46	-5.63	-0.34	4.87e-8	Aortic root size;
KIRP	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg00080972	chr5:178986291	RUFY1	0.39	5.86	0.35	1.45e-8	Lung cancer;
KIRP	cis	rs11645898	0.504	rs118034653	chr16:71922944	T/C	cg14768367	chr16:72042858	DHODH	-0.78	-6.83	-0.4	6.67e-11	Blood protein levels;
KIRP	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.78	-0.35	2.3e-8	Breast cancer;
KIRP	cis	rs2124969	0.527	rs56040145	chr2:160983850	A/G	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.25	-0.37	1.84e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7538876	1.000	rs12132197	chr1:17723964	C/A	cg07394400	chr1:17752023	RCC2	-0.34	-4.85	-0.3	2.21e-6	Basal cell carcinoma;
KIRP	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.65	0.44	4.66e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	1.09	20.45	0.79	5.78e-55	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10450421	chr16:68564110	NA	0.53	6.65	0.39	1.87e-10	Parkinson's disease;
KIRP	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	5.82	0.35	1.87e-8	Schizophrenia;
KIRP	trans	rs61904987	0.631	rs61907881	chr11:113759002	C/A	cg02842869	chr17:79921131	NA	0.37	6.24	0.37	1.94e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs12900413	0.687	rs6496601	chr15:90317694	C/T	cg07116693	chr15:90310901	NA	-0.23	-4.99	-0.3	1.14e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11822088	chr1:243398577	CEP170	-0.42	-6.26	-0.37	1.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10203711	0.966	rs4998693	chr2:239564753	G/T	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	5.58	0.34	6.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1620921	0.967	rs783174	chr6:161171919	C/T	cg01280913	chr6:161186852	NA	-0.43	-6.12	-0.36	3.61e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg00977110	chr5:151150581	G3BP1	-0.6	-6.03	-0.36	5.82e-9	Preschool internalizing problems;
KIRP	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.48	6.4	0.38	7.68e-10	Retinal vascular caliber;
KIRP	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.53	-5.03	-0.31	9.68e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.25	-0.32	3.36e-7	Breast cancer;
KIRP	cis	rs11608355	0.521	rs4766595	chr12:109846998	A/T	cg19025524	chr12:109796872	NA	-0.48	-6.46	-0.38	5.52e-10	Neuroticism;
KIRP	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.43	-6.96	-0.41	3.13e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-7.93	-0.45	7.64e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-7.73	-0.44	2.79e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.37	-0.32	1.79e-7	Bipolar disorder;
KIRP	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg01721255	chr8:58191610	C8orf71	0.6	5.53	0.33	8.12e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg23920097	chr1:209922102	NA	-0.43	-5.82	-0.35	1.83e-8	Red blood cell count;
KIRP	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.47	-5.8	-0.35	2.08e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg06900676	chr2:61293330	KIAA1841	0.48	6.81	0.4	7.27e-11	Survival in pancreatic cancer;
KIRP	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.33	5.1	0.31	6.69e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7937612	1.000	rs2305008	chr11:120319064	A/C	cg24566217	chr11:120254723	ARHGEF12	-0.45	-6.67	-0.39	1.64e-10	Intraocular pressure;
KIRP	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.74	11.68	0.6	2.29e-25	Resting heart rate;
KIRP	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg04132472	chr17:19861366	AKAP10	0.42	5.81	0.35	1.97e-8	Schizophrenia;
KIRP	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-5.86	-0.35	1.52e-8	Educational attainment;
KIRP	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg19294448	chr17:6900799	ALOX12	0.38	5.07	0.31	7.99e-7	Tonsillectomy;
KIRP	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	1.03	13.01	0.64	8.2e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.59	7.79	0.44	1.84e-13	Longevity;
KIRP	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg10189774	chr4:17578691	LAP3	0.43	5.13	0.31	5.85e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.6	8.8	0.49	2.46e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.81	11.03	0.58	3.1e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.6	-5.85	-0.35	1.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg18306943	chr3:40428807	ENTPD3	-0.39	-5.32	-0.32	2.38e-7	Renal cell carcinoma;
KIRP	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg22223119	chr13:99095684	FARP1	-0.67	-8.57	-0.48	1.13e-15	Obesity-related traits;
KIRP	cis	rs6681460	1.000	rs1445575	chr1:67052164	C/T	cg13052034	chr1:66999238	SGIP1	0.41	5.65	0.34	4.45e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs364477	0.818	rs279886	chr9:979585	G/T	cg13952963	chr9:998547	NA	0.54	5.0	0.3	1.07e-6	Major depressive disorder;
KIRP	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.56	-0.56	9.73e-22	Height;
KIRP	cis	rs2235544	0.579	rs1537321	chr1:54482236	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.32	-6.14	-0.36	3.26e-9	Multiple myeloma (hyperdiploidy);Thyroid hormone levels;
KIRP	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg19592336	chr6:28129416	ZNF389	-0.49	-5.46	-0.33	1.16e-7	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.67	-0.39	1.65e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11583043	0.872	rs1326380	chr1:101293753	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.66	7.9	0.45	9.24e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18882091	chr7:99058544	ATP5J2	-0.44	-6.05	-0.36	5.25e-9	Inflammatory biomarkers;
KIRP	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.43	10.08	0.54	3.22e-20	Cutaneous nevi;
KIRP	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.09	-0.5	3.39e-17	Retinal vascular caliber;
KIRP	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg04310649	chr10:35416472	CREM	0.55	6.69	0.39	1.48e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg14768367	chr16:72042858	DHODH	-0.64	-7.56	-0.43	7.81e-13	Blood protein levels;
KIRP	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.71	9.67	0.52	5.72e-19	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg12549451	chr6:135224345	NA	-0.46	-5.87	-0.35	1.4e-8	High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs2268361	0.556	rs1558609	chr2:49206359	G/A	cg21843258	chr8:145597415	ADCK5	0.5	6.15	0.37	3.07e-9	Polycystic ovary syndrome;
KIRP	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.81	-0.4	7.39e-11	Morning vs. evening chronotype;
KIRP	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.67	-9.03	-0.5	5.14e-17	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.94	-16.33	-0.72	4.28e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg01988459	chr11:68622903	NA	-0.35	-4.85	-0.3	2.22e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00150737	chr3:131221845	MRPL3	0.5	6.14	0.36	3.28e-9	Parkinson's disease;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg10519680	chr8:37707506	BRF2	0.52	6.56	0.39	3.2e-10	Asthma;
KIRP	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.5	-5.43	-0.33	1.32e-7	Bipolar disorder;
KIRP	cis	rs490234	0.841	rs536861	chr9:128313444	A/C	cg14078157	chr9:128172775	NA	0.4	5.04	0.31	8.88e-7	Mean arterial pressure;
KIRP	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.68	-0.44	3.86e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9972944	0.627	rs28845012	chr17:63760891	G/A	cg07283582	chr17:63770753	CCDC46	-0.44	-7.19	-0.42	7.78e-12	Total body bone mineral density;
KIRP	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.81	-0.49	2.37e-16	Response to antipsychotic treatment;
KIRP	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.52	-6.65	-0.39	1.83e-10	Blood metabolite levels;
KIRP	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.61	8.17	0.46	1.65e-14	Prostate cancer;
KIRP	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg19847130	chr8:10466454	RP1L1	-0.44	-6.44	-0.38	6.12e-10	Retinal vascular caliber;
KIRP	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.76	9.08	0.5	3.64e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.64	-9.14	-0.5	2.33e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21545522	chr1:205238299	TMCC2	0.43	5.75	0.34	2.64e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.63	-0.39	2.06e-10	Total body bone mineral density;
KIRP	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.69	-6.08	-0.36	4.51e-9	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02268225	chr14:100437639	NA	0.44	6.16	0.37	2.98e-9	Survival in pancreatic cancer;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05994458	chr11:13484274	BTBD10	0.64	7.46	0.43	1.53e-12	Lung cancer in ever smokers;
KIRP	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg26412358	chr1:26503933	CNKSR1	0.39	5.36	0.32	1.96e-7	Height;
KIRP	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.97	12.53	0.62	3.52e-28	Smoking behavior;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24098938	chr13:44361212	ENOX1	0.48	6.51	0.38	4.23e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	6.41	0.38	7.56e-10	Iron status biomarkers;
KIRP	trans	rs6601327	0.665	rs9286060	chr8:9653145	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.4	-0.43	2.19e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-4.92	-0.3	1.6e-6	Menarche (age at onset);
KIRP	cis	rs1497828	1.000	rs2646845	chr1:217559136	G/A	cg04411442	chr1:217543379	NA	0.41	6.21	0.37	2.22e-9	Dialysis-related mortality;
KIRP	cis	rs7243821	0.705	rs13381474	chr18:52653211	C/G	cg26630735	chr18:52626848	CCDC68	-0.49	-5.41	-0.33	1.47e-7	Chin dimples;
KIRP	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-6.06	-0.36	5.16e-9	Total body bone mineral density;
KIRP	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	0.99	17.93	0.75	1.5e-46	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9549367	0.588	rs9549360	chr13:113893032	C/G	cg00898013	chr13:113819073	PROZ	-0.55	-5.0	-0.3	1.1e-6	Platelet distribution width;
KIRP	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg02733842	chr7:1102375	C7orf50	0.47	4.87	0.3	2.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.63	8.27	0.47	8.44e-15	Colorectal cancer;
KIRP	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg12131826	chr15:77904385	NA	-0.41	-5.49	-0.33	9.8e-8	Type 2 diabetes;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16045498	chr1:120490955	NOTCH2	-0.42	-6.21	-0.37	2.21e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg11859384	chr17:80120422	CCDC57	0.46	5.89	0.35	1.26e-8	Life satisfaction;
KIRP	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.51	6.85	0.4	5.81e-11	Schizophrenia;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg04942564	chr20:62562232	DNAJC5	-0.46	-6.8	-0.4	7.97e-11	Bladder cancer;
KIRP	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.49	-5.79	-0.35	2.11e-8	Iron status biomarkers;
KIRP	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.5	-6.48	-0.38	4.93e-10	Menopause (age at onset);
KIRP	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23903597	chr17:61704154	MAP3K3	-0.57	-7.24	-0.42	5.59e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.73	10.94	0.57	5.72e-23	Blood metabolite ratios;
KIRP	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg07378217	chr19:58662286	ZNF329	-0.59	-5.39	-0.33	1.65e-7	Cholesterol, total;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg00464773	chr17:79041990	BAIAP2	-0.45	-6.65	-0.39	1.92e-10	Bladder cancer;
KIRP	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	1.05	9.16	0.5	2.13e-17	Fat distribution (HIV);
KIRP	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg00852783	chr1:26633632	UBXN11	0.54	7.51	0.43	1.07e-12	Obesity-related traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25764190	chr19:44037015	ZNF575	0.53	6.2	0.37	2.41e-9	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06620210	chr19:16308754	AP1M1	0.53	6.6	0.39	2.5e-10	Parkinson's disease;
KIRP	cis	rs2708977	0.667	rs772156	chr2:97029830	G/A	cg01950434	chr2:97203154	ARID5A	-0.41	-5.38	-0.32	1.7e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg11693508	chr17:37793320	STARD3	0.81	8.08	0.46	2.96e-14	Neuroticism;
KIRP	cis	rs16912285	0.535	rs6484040	chr11:24309809	C/A	ch.11.24196551F	chr11:24239977	NA	0.83	9.59	0.52	1.02e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-5.36	-0.32	1.87e-7	Neuroticism;
KIRP	cis	rs17331151	0.505	rs13066389	chr3:52565317	C/T	cg04865290	chr3:52927548	TMEM110	-0.54	-5.02	-0.3	1.01e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.83	-13.02	-0.64	8.19e-30	Breast cancer;
KIRP	cis	rs12096438	0.903	rs4523506	chr1:25893221	G/T	cg21452808	chr1:25900135	NA	0.41	6.63	0.39	2.16e-10	Platelet count;Mean platelet volume;
KIRP	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.58	-7.16	-0.42	9.1e-12	Alzheimer's disease (late onset);
KIRP	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.65	-9.89	-0.53	1.24e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.722	rs4802051	chr19:38072328	C/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	2.03e-10	Coronary artery calcification;
KIRP	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg10381502	chr11:71823885	C11orf51	-1.18	-7.21	-0.42	6.73e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs282587	0.502	rs382758	chr13:113400169	C/T	cg04656015	chr13:113407548	ATP11A	0.63	7.32	0.42	3.47e-12	Glycated hemoglobin levels;
KIRP	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg05370193	chr1:21551575	ECE1	0.45	6.22	0.37	2.11e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.57	-6.66	-0.39	1.78e-10	Aortic root size;
KIRP	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.5	5.8	0.35	2.07e-8	Platelet distribution width;
KIRP	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg18306943	chr3:40428807	ENTPD3	0.39	5.53	0.33	8.29e-8	Renal cell carcinoma;
KIRP	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.47	0.33	1.11e-7	Lung cancer;
KIRP	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg17507749	chr15:85114479	UBE2QP1	0.75	7.14	0.41	1.08e-11	Schizophrenia;
KIRP	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.74	-4.96	-0.3	1.33e-6	Facial emotion recognition (sad faces);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17478997	chr7:133030475	EXOC4	-0.42	-6.73	-0.39	1.22e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg23736307	chr8:27182930	PTK2B	0.54	6.9	0.4	4.5e-11	Neuroticism;
KIRP	cis	rs4262150	0.883	rs6579959	chr5:152107383	C/T	cg12297329	chr5:152029980	NA	-0.52	-7.08	-0.41	1.48e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs4751006	0.543	rs7899778	chr10:128780419	A/C	cg05702161	chr10:128779687	DOCK1	-1.11	-8.74	-0.49	3.73e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9398803	0.687	rs3905044	chr6:126972883	A/G	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.25	-0.42	5.28e-12	Bipolar disorder and schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14065008	chr6:128374435	PTPRK	0.44	6.2	0.37	2.32e-9	Interleukin-4 levels;
KIRP	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.55	-0.33	7.26e-8	Coronary artery disease;
KIRP	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.66	-0.34	4.21e-8	Height;
KIRP	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.36	6.65	0.39	1.86e-10	Monocyte percentage of white cells;
KIRP	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg16558253	chr16:72132732	DHX38	0.54	8.03	0.46	3.95e-14	Fibrinogen levels;
KIRP	cis	rs6594499	0.872	rs10059658	chr5:110452815	T/C	cg04022379	chr5:110408740	TSLP	0.47	7.14	0.41	1.05e-11	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9816226	0.591	rs78785910	chr3:185812634	G/A	cg00760338	chr3:185826511	ETV5	-0.74	-6.51	-0.38	4.08e-10	Obesity;Body mass index;
KIRP	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.86	13.81	0.66	1.66e-32	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12578182	chr17:41132637	AARSD1;RUNDC1	0.44	6.08	0.36	4.53e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.48	6.44	0.38	6.18e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg01522456	chr1:115632236	TSPAN2	-0.38	-5.18	-0.31	4.63e-7	Autism;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg13476336	chr17:38255694	NR1D1	0.6	7.3	0.42	3.89e-12	Smoking initiation;
KIRP	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.71	10.69	0.56	3.59e-22	Dupuytren's disease;
KIRP	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg00806126	chr19:22604979	ZNF98	0.68	7.19	0.42	7.56e-12	Pain;
KIRP	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.55	6.49	0.38	4.64e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06057666	chr1:227327429	CDC42BPA	-0.43	-6.29	-0.37	1.45e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	9.0	0.5	6.38e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11037719	chr6:2999695	NQO2	0.58	6.91	0.4	4.13e-11	Smoking initiation;
KIRP	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.63	7.06	0.41	1.73e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg09365446	chr1:150670422	GOLPH3L	0.39	5.13	0.31	5.86e-7	Tonsillectomy;
KIRP	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-5.86	-0.35	1.49e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.34	-0.32	2.14e-7	Primary biliary cholangitis;
KIRP	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.43	-5.33	-0.32	2.25e-7	Aortic root size;
KIRP	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.61	8.85	0.49	1.71e-16	Systemic lupus erythematosus;
KIRP	cis	rs27434	0.561	rs35134	chr5:96159523	A/G	cg16492584	chr5:96139282	ERAP1	-0.42	-5.61	-0.34	5.37e-8	Ankylosing spondylitis;
KIRP	cis	rs7712401	0.601	rs396941	chr5:122318265	G/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.86	-0.49	1.62e-16	Response to antipsychotic treatment;
KIRP	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.06	-0.36	5.18e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20135002	chr11:47629003	NA	-0.46	-5.09	-0.31	7.17e-7	Subjective well-being;
KIRP	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.22e-12	Major depressive disorder;
KIRP	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.71	-9.04	-0.5	4.82e-17	Body mass index;
KIRP	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg00071950	chr4:10020882	SLC2A9	-0.38	-5.38	-0.32	1.75e-7	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9308731	0.688	rs4302219	chr2:111880284	G/T	cg04202892	chr2:111875749	ACOXL	0.5	7.04	0.41	1.93e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs11627756	0.846	rs1190336	chr14:103108478	A/G	cg12046867	chr14:103022105	NA	0.37	5.08	0.31	7.35e-7	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02720600	chr6:76425457	SENP6	-0.42	-6.53	-0.38	3.64e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	9.56	0.52	1.25e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.38	7.44e-10	Height;
KIRP	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26314531	chr2:26401878	FAM59B	-0.46	-4.86	-0.3	2.09e-6	Gut microbiome composition (summer);
KIRP	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.1	0.31	6.66e-7	Breast cancer;
KIRP	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	5.42	0.33	1.41e-7	Educational attainment;
KIRP	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg09324608	chr17:30823087	MYO1D	0.49	6.27	0.37	1.58e-9	Schizophrenia;
KIRP	cis	rs2742417	1.000	rs2742420	chr3:45732237	A/G	cg04037228	chr3:45636386	LIMD1	0.37	5.44	0.33	1.27e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg08999081	chr20:33150536	PIGU	0.46	6.24	0.37	1.87e-9	Height;
KIRP	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.42	5.92	0.35	1.06e-8	Bipolar disorder;
KIRP	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg20744362	chr22:50050164	C22orf34	0.32	4.88	0.3	1.92e-6	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-5.33	-0.32	2.25e-7	Lung cancer;
KIRP	cis	rs4356975	0.563	rs6843382	chr4:69953602	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs1978968	0.912	rs28478894	chr22:18454600	G/A	cg03078520	chr22:18463400	MICAL3	-0.7	-7.82	-0.45	1.52e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs4979906	1.000	rs11002244	chr10:79446207	T/C	cg07817648	chr10:79422355	NA	-0.45	-4.98	-0.3	1.2e-6	Mortality in heart failure;
KIRP	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-21.43	-0.81	3.39e-58	Height;
KIRP	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg25319279	chr11:5960081	NA	-0.57	-5.88	-0.35	1.34e-8	DNA methylation (variation);
KIRP	trans	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg02604675	chr4:185938802	HELT	0.53	6.03	0.36	6.03e-9	Left atrial antero-posterior diameter;
KIRP	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg17691542	chr6:26056736	HIST1H1C	0.5	6.56	0.39	3.08e-10	Height;
KIRP	trans	rs17706989	0.649	rs75460556	chr16:78538594	A/T	cg04420349	chr14:70512963	SLC8A3	0.73	6.42	0.38	7.08e-10	Response to antipsychotic treatment in schizophrenia (reasoning);
KIRP	cis	rs11148252	0.535	rs11616459	chr13:53076400	A/T	cg05335186	chr13:53173507	NA	0.34	5.26	0.32	3.14e-7	Lewy body disease;
KIRP	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-6.11	-0.36	3.93e-9	Lung cancer;
KIRP	cis	rs1978968	0.763	rs9605472	chr22:18463216	A/G	cg03078520	chr22:18463400	MICAL3	-0.84	-12.0	-0.61	2.05e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.63	7.48	0.43	1.31e-12	Longevity;Endometriosis;
KIRP	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.78	0.35	2.24e-8	Menopause (age at onset);
KIRP	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.66	8.35	0.47	5.04e-15	Coronary artery disease;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg24645247	chr1:245028059	HNRNPU	0.55	6.83	0.4	6.43e-11	Educational attainment;
KIRP	cis	rs9912468	0.933	rs67675584	chr17:64324501	A/G	cg19474267	chr17:64306194	PRKCA	0.58	8.28	0.47	7.9e-15	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.61	-8.01	-0.45	4.61e-14	Pancreatic cancer;
KIRP	cis	rs2120243	0.935	rs9681270	chr3:157143996	A/G	cg24825693	chr3:157122686	VEPH1	-0.36	-5.1	-0.31	6.72e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.57	-6.43	-0.38	6.51e-10	Hypospadias;
KIRP	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.64	-12.0	-0.61	2e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs3731896	1.000	rs4674372	chr2:220141963	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-0.51	-5.69	-0.34	3.64e-8	Educational attainment;
KIRP	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.42	-5.34	-0.32	2.09e-7	Type 2 diabetes;
KIRP	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	1.07	7.56	0.43	8.02e-13	Skin colour saturation;
KIRP	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg20243544	chr17:37824526	PNMT	0.45	6.15	0.36	3.14e-9	Asthma;
KIRP	cis	rs4805834	0.719	rs73035335	chr19:33289555	T/G	cg07201929	chr19:33182834	NUDT19	-0.62	-5.24	-0.32	3.4e-7	Creatinine levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg17782706	chr4:184580436	C4orf41;RWDD4A	-0.47	-6.18	-0.37	2.61e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.06	-0.41	1.72e-11	Triglycerides;
KIRP	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	0.94	8.28	0.47	7.84e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7635838	0.819	rs2443709	chr3:11541814	C/T	cg00170343	chr3:11313890	ATG7	0.48	6.03	0.36	5.91e-9	HDL cholesterol;
KIRP	trans	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1999930	0.527	rs2196940	chr6:116270154	T/C	cg15226275	chr6:116381976	FRK	0.22	4.86	0.3	2.08e-6	Age-related macular degeneration;
KIRP	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.72	6.86	0.4	5.53e-11	Gut microbiome composition (summer);
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg10254082	chr7:997346	NA	0.48	5.04	0.31	8.85e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06850241	chr22:41845214	NA	0.44	5.07	0.31	7.87e-7	Vitiligo;
KIRP	trans	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg06521331	chr12:34319734	NA	-0.61	-7.17	-0.42	8.75e-12	Bladder cancer;
KIRP	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18252515	chr7:66147081	NA	0.44	4.99	0.3	1.12e-6	Aortic root size;
KIRP	cis	rs16828019	0.852	rs3766324	chr1:41588653	A/G	cg03387723	chr1:41708464	SCMH1	-0.8	-6.8	-0.4	8.05e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2299587	0.554	rs2073566	chr8:17743655	G/A	cg01800426	chr8:17659068	MTUS1	-0.45	-5.4	-0.33	1.54e-7	Economic and political preferences;
KIRP	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg02297831	chr4:17616191	MED28	0.52	6.57	0.39	3.01e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-0.98	-10.4	-0.55	3.13e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg01616529	chr11:638424	DRD4	-0.45	-5.96	-0.36	8.61e-9	Systemic lupus erythematosus;
KIRP	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	0.93	10.34	0.55	4.76e-21	Triglycerides;
KIRP	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg22906224	chr7:99728672	NA	-0.5	-6.16	-0.37	2.95e-9	Coronary artery disease;
KIRP	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.95	14.84	0.69	5.28e-36	Glomerular filtration rate (creatinine);
KIRP	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.24	-0.47	1.01e-14	Coronary artery disease;
KIRP	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.26	-0.65	1.21e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	0.97	11.28	0.58	4.82e-24	Iron status biomarkers;
KIRP	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.64	0.44	4.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg01304814	chr3:48885189	PRKAR2A	0.58	4.96	0.3	1.31e-6	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
KIRP	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.09	-0.41	1.38e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6584283	0.766	rs7911680	chr10:101293468	A/C	cg07044859	chr10:101282883	NA	-0.28	-4.95	-0.3	1.4e-6	Ulcerative colitis;
KIRP	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1476670	0.545	rs11210947	chr1:44520070	A/G	cg09470012	chr1:44509516	NA	0.32	5.12	0.31	6.21e-7	Eotaxin levels;
KIRP	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.32	8.56	0.48	1.24e-15	Crohn's disease;
KIRP	cis	rs950881	0.932	rs13408569	chr2:102955056	G/C	cg01254707	chr2:102953421	IL1RL1	-0.5	-5.05	-0.31	8.6e-7	Allergy;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03647317	chr4:187891568	NA	-0.81	-13.37	-0.65	5.31e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg00129232	chr17:37814104	STARD3	0.61	7.62	0.44	5.62e-13	Self-reported allergy;
KIRP	cis	rs7119167	0.901	rs7937066	chr11:73124928	C/T	cg17517138	chr11:73019481	ARHGEF17	0.51	5.33	0.32	2.24e-7	Blood protein levels;
KIRP	cis	rs35000415	0.938	rs35234849	chr7:128648953	T/C	cg19972273	chr7:128594194	NA	0.82	6.04	0.36	5.72e-9	Systemic lupus erythematosus;
KIRP	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-7.89	-0.45	9.74e-14	Bipolar disorder;
KIRP	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.39	0.38	8.4e-10	Aortic root size;
KIRP	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg24375607	chr4:120327624	NA	0.61	6.62	0.39	2.24e-10	Corneal astigmatism;
KIRP	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg24315340	chr6:146058215	EPM2A	-0.41	-5.27	-0.32	3.01e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.53	-0.43	9.47e-13	Bipolar disorder;
KIRP	cis	rs311392	0.526	rs311385	chr8:55101380	T/A	cg06042504	chr8:55087323	NA	-0.54	-6.69	-0.39	1.5e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg07741184	chr6:167504864	NA	0.2	5.0	0.3	1.09e-6	Crohn's disease;
KIRP	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg04362960	chr10:104952993	NT5C2	0.43	4.9	0.3	1.71e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs10214930	0.706	rs4722726	chr7:27694208	A/G	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.04e-7	Hypospadias;
KIRP	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.39	0.38	8.28e-10	Systemic lupus erythematosus;
KIRP	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.7	8.21	0.46	1.25e-14	Late-onset Alzheimer's disease;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg23473374	chr14:66058810	FUT8	0.48	6.22	0.37	2.07e-9	Myopia (pathological);
KIRP	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-1.13	-13.41	-0.65	3.78e-31	Red blood cell traits;
KIRP	cis	rs10924970	0.687	rs28593631	chr1:235354572	A/T	cg26050004	chr1:235667680	B3GALNT2	0.4	5.02	0.3	9.82e-7	Asthma;
KIRP	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg23899408	chr19:12877188	HOOK2	0.4	4.99	0.3	1.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
KIRP	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.87	13.17	0.64	2.43e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.52	-7.2	-0.42	7.09e-12	Schizophrenia;
KIRP	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg04374321	chr14:90722782	PSMC1	-0.59	-8.12	-0.46	2.18e-14	Mortality in heart failure;
KIRP	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.56	-7.76	-0.44	2.32e-13	Lung cancer;
KIRP	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.49	-6.59	-0.39	2.68e-10	HDL cholesterol;
KIRP	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.57	-7.15	-0.41	9.69e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17554472	chr22:41940697	POLR3H	-0.62	-6.59	-0.39	2.59e-10	Vitiligo;
KIRP	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.74	7.84	0.45	1.38e-13	Corneal astigmatism;
KIRP	trans	rs263156	0.967	rs190522	chr6:142879060	T/A	cg01789478	chr2:182545485	NEUROD1	-0.37	-6.35	-0.38	1.04e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg24315340	chr6:146058215	EPM2A	0.44	5.46	0.33	1.19e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.88	9.85	0.53	1.64e-19	Gut microbiome composition (summer);
KIRP	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.62	-0.44	5.49e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.34	-0.32	2.14e-7	Retinal vascular caliber;
KIRP	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01765077	chr12:122356316	WDR66	0.47	6.38	0.38	8.68e-10	Mean corpuscular volume;
KIRP	cis	rs921916	1.000	rs6955221	chr7:50234164	G/A	cg02697348	chr7:50199187	C7orf72	0.53	5.08	0.31	7.6e-7	Systemic lupus erythematosus;
KIRP	trans	rs656319	0.513	rs3885723	chr8:9991661	A/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.58	-0.48	1.08e-15	Myopia (pathological);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17669497	chr10:89945974	NA	0.52	6.95	0.41	3.24e-11	Interleukin-4 levels;
KIRP	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg23594656	chr7:65796392	TPST1	-0.41	-5.69	-0.34	3.6e-8	Aortic root size;
KIRP	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg04731861	chr2:219085781	ARPC2	-0.21	-5.29	-0.32	2.71e-7	Colorectal cancer;
KIRP	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg20387954	chr3:183756860	HTR3D	0.49	6.7	0.39	1.43e-10	Anterior chamber depth;
KIRP	cis	rs7546094	1.000	rs6682737	chr1:113136229	T/C	cg22162597	chr1:113214053	CAPZA1	0.46	6.58	0.39	2.76e-10	Platelet distribution width;
KIRP	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.27	-0.55	8.11e-21	Hemoglobin concentration;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg12605148	chr15:28356800	HERC2	-0.5	-6.61	-0.39	2.36e-10	Inflammatory biomarkers;
KIRP	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg19592336	chr6:28129416	ZNF389	0.5	5.66	0.34	4.25e-8	Depression;
KIRP	cis	rs4356932	0.691	rs4859582	chr4:76907213	T/C	cg00809888	chr4:76862425	NAAA	0.51	7.14	0.41	1.05e-11	Blood protein levels;
KIRP	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	7.73	0.44	2.71e-13	Lung cancer in ever smokers;
KIRP	cis	rs4561483	0.603	rs17235629	chr16:11932421	C/T	cg08843971	chr16:11963173	GSPT1	-0.52	-7.16	-0.42	9.27e-12	Testicular germ cell tumor;
KIRP	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg04607699	chr11:48328132	OR4S1	-0.4	-5.75	-0.34	2.62e-8	Migraine - clinic-based;
KIRP	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.62	-6.86	-0.4	5.39e-11	Urate levels in lean individuals;
KIRP	cis	rs490234	0.934	rs571675	chr9:128297692	C/T	cg14078157	chr9:128172775	NA	0.41	5.23	0.32	3.62e-7	Mean arterial pressure;
KIRP	cis	rs12210905	1.000	rs9368499	chr6:27254332	C/T	cg11502198	chr6:26597334	ABT1	-0.85	-4.86	-0.3	2.09e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-7.12	-0.41	1.17e-11	Morning vs. evening chronotype;
KIRP	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.63	-8.58	-0.48	1.07e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg16988262	chr1:15930761	NA	0.38	4.9	0.3	1.71e-6	Systolic blood pressure;
KIRP	cis	rs66696671	0.592	rs3847487	chr10:121378493	C/T	cg06765389	chr10:121379685	NA	-0.43	-6.56	-0.39	3.07e-10	Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50);
KIRP	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg07216194	chr8:27182965	PTK2B	-0.49	-5.79	-0.35	2.17e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.57	5.35	0.32	1.97e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.83	-11.77	-0.6	1.2e-25	Chronic sinus infection;
KIRP	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs7737355	0.704	rs11749484	chr5:131061607	T/C	cg25547332	chr5:131281432	NA	0.39	4.89	0.3	1.85e-6	Life satisfaction;
KIRP	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.47	-5.93	-0.35	1.04e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7221595	0.778	rs2290439	chr17:3924306	A/G	cg05562828	chr17:3906858	NA	0.57	7.36	0.42	2.72e-12	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg10503236	chr1:231470652	EXOC8	-0.52	-7.5	-0.43	1.14e-12	Hemoglobin concentration;
KIRP	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg27205649	chr11:78285834	NARS2	-0.52	-5.8	-0.35	2e-8	Testicular germ cell tumor;
KIRP	cis	rs3087591	0.708	rs9894648	chr17:29653293	T/C	cg24425628	chr17:29625626	OMG;NF1	0.5	6.77	0.4	9.35e-11	Hip circumference;
KIRP	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-7.21	-0.42	7.07e-12	Response to antipsychotic treatment;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg15416064	chr12:49209402	NA	-0.58	-6.38	-0.38	8.61e-10	Menopause (age at onset);
KIRP	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-1.04	-19.23	-0.77	6.52e-51	Height;
KIRP	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg05527609	chr1:210001259	C1orf107	-0.54	-6.07	-0.36	4.78e-9	Red blood cell count;
KIRP	trans	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03710140	chr20:5986599	CRLS1	0.51	6.62	0.39	2.29e-10	Parkinson's disease;
KIRP	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg00601450	chr5:74908170	NA	-0.46	-5.19	-0.31	4.3e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.3	-0.55	6.4e-21	Hemoglobin concentration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11143158	chr3:113557646	GRAMD1C	0.47	6.02	0.36	6.23e-9	Parkinson's disease;
KIRP	cis	rs7789940	0.857	rs12532935	chr7:75939698	G/C	cg10167463	chr7:75959203	YWHAG	-0.44	-5.81	-0.35	1.97e-8	Multiple sclerosis;
KIRP	cis	rs8014252	0.803	rs74712571	chr14:70986751	C/G	cg19730268	chr14:71022823	NA	-0.72	-6.48	-0.38	4.91e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.89	-7.57	-0.43	7.7e-13	Obesity-related traits;
KIRP	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.8	8.03	0.46	4.1e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.61	-7.79	-0.44	1.85e-13	Extraversion;
KIRP	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02467765	chr4:78978708	FRAS1	0.51	6.23	0.37	1.97e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.59	-5.26	-0.32	3.12e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.69	-10.27	-0.55	7.86e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.62	9.76	0.53	3.18e-19	Airway imaging phenotypes;
KIRP	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg02820040	chr2:241836501	C2orf54	-0.24	-5.5	-0.33	9.33e-8	Urinary metabolites;
KIRP	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.12e-6	Aortic root size;
KIRP	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-1.0	-15.22	-0.7	2.69e-37	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13893634	chr17:48229117	PPP1R9B	-0.48	-5.88	-0.35	1.36e-8	Temporomandibular joint disorder;
KIRP	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.97	14.18	0.67	9e-34	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg03959625	chr15:84868606	LOC388152	0.61	6.2	0.37	2.34e-9	Schizophrenia;
KIRP	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.64	8.51	0.48	1.69e-15	Aortic root size;
KIRP	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.37	-0.47	4.39e-15	Mood instability;
KIRP	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.73	10.04	0.54	4.31e-20	Menarche (age at onset);
KIRP	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13948824	chr12:26492184	ITPR2	0.44	6.02	0.36	6.17e-9	Survival in pancreatic cancer;
KIRP	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs57590327	0.508	rs1973805	chr3:81946539	C/A	cg07356753	chr3:81810745	GBE1	-0.54	-7.06	-0.41	1.73e-11	Extraversion;
KIRP	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-6.92	-0.4	3.87e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg26681399	chr22:41777847	TEF	0.53	5.12	0.31	6.27e-7	Vitiligo;
KIRP	cis	rs9513627	0.749	rs73556149	chr13:100117012	G/A	cg25919922	chr13:100150906	NA	-0.74	-5.87	-0.35	1.4e-8	Obesity-related traits;
KIRP	cis	rs6882046	0.513	rs616391	chr5:88038845	C/T	cg22951263	chr5:87985283	NA	-0.48	-6.83	-0.4	6.66e-11	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg10547527	chr2:198650123	BOLL	-0.53	-4.95	-0.3	1.36e-6	Ulcerative colitis;
KIRP	cis	rs3800461	0.544	rs76990047	chr6:34504042	T/G	cg17674042	chr6:34482479	PACSIN1	-0.62	-6.7	-0.39	1.4e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.87	13.78	0.66	2.08e-32	Height;
KIRP	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.69	8.87	0.49	1.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.73	9.69	0.53	5e-19	Cognitive function;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg10550160	chr7:139044797	LUC7L2	-0.45	-6.46	-0.38	5.66e-10	Metabolic traits;
KIRP	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.11	-0.31	6.58e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg05562828	chr17:3906858	NA	0.62	10.71	0.56	3.18e-22	Type 2 diabetes;
KIRP	cis	rs2591576	0.809	rs10035746	chr5:165420160	T/C	cg13976338	chr5:165423657	NA	-0.81	-12.62	-0.63	1.69e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs6504622	0.905	rs3809854	chr17:45029294	T/C	cg24703533	chr17:45055318	NA	0.38	5.31	0.32	2.39e-7	Orofacial clefts;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg23280290	chr7:35734964	HERPUD2	0.96	6.19	0.37	2.47e-9	P wave terminal force;
KIRP	cis	rs73086581	1.000	rs6116130	chr20:3947026	A/T	cg02187196	chr20:3869020	PANK2	0.47	4.9	0.3	1.72e-6	Response to antidepressants in depression;
KIRP	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.61	-7.89	-0.45	1.01e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.64	9.51	0.52	1.85e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg23188588	chr14:78226832	SNW1;C14orf178	0.84	7.8	0.45	1.73e-13	Fibroblast growth factor basic levels;
KIRP	cis	rs7937612	0.931	rs12806740	chr11:120203628	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.85	-0.4	5.96e-11	Intraocular pressure;
KIRP	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	1.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg13147721	chr7:65941812	NA	-0.94	-6.59	-0.39	2.67e-10	Diabetic kidney disease;
KIRP	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs883565	0.582	rs811969	chr3:39180162	A/C	cg01426195	chr3:39028469	NA	0.53	8.44	0.47	2.78e-15	Handedness;
KIRP	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.65	0.48	6.71e-16	Motion sickness;
KIRP	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg06654118	chr4:1303317	MAEA	0.29	5.3	0.32	2.64e-7	Obesity-related traits;
KIRP	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg24009623	chr19:33667908	NA	0.48	6.4	0.38	8.01e-10	Bone properties (heel);
KIRP	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg03060546	chr3:49711283	APEH	-0.65	-6.04	-0.36	5.71e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8018808	0.935	rs11159262	chr14:77928735	A/G	cg18872420	chr14:78023429	SPTLC2	0.36	5.25	0.32	3.27e-7	Myeloid white cell count;
KIRP	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg16141378	chr3:129829833	LOC729375	-0.56	-7.55	-0.43	8.69e-13	Morning vs. evening chronotype;
KIRP	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.61	-6.86	-0.4	5.41e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21545522	chr1:205238299	TMCC2	0.55	7.31	0.42	3.76e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs698833	0.852	rs2582918	chr2:44582275	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.44	0.38	6.34e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7394190	0.688	rs3812629	chr10:75407290	G/A	cg04833713	chr10:74871078	NUDT13	0.51	5.91	0.35	1.11e-8	Incident atrial fibrillation;
KIRP	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg13010199	chr12:38710504	ALG10B	0.47	5.99	0.36	7.28e-9	Morning vs. evening chronotype;
KIRP	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.35	1.28e-8	Mean platelet volume;
KIRP	cis	rs7849270	0.837	rs4642748	chr9:131854947	T/C	cg13538475	chr9:131942899	NA	-0.36	-5.59	-0.34	6.16e-8	Blood metabolite ratios;
KIRP	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.7	-9.85	-0.53	1.61e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.82	6.92	0.4	3.84e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.45	-6.19	-0.37	2.56e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs16854884	0.837	rs13083224	chr3:143801696	C/T	cg06585982	chr3:143692056	C3orf58	0.47	5.76	0.34	2.57e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.56	-6.56	-0.39	3.12e-10	Psoriasis;
KIRP	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg13409248	chr3:40428643	ENTPD3	0.39	5.23	0.32	3.63e-7	Renal cell carcinoma;
KIRP	cis	rs72627509	0.951	rs17087335	chr4:57838583	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-4.92	-0.3	1.62e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs13108043	0.605	rs62306510	chr4:87962634	T/A	cg11209507	chr4:87813803	C4orf36	0.47	5.01	0.3	1.05e-6	Red blood cell count;
KIRP	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg04989706	chr14:50066350	PPIL5	-0.49	-6.09	-0.36	4.25e-9	Carotid intima media thickness;
KIRP	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg07921184	chr16:71880281	ATXN1L	0.48	6.02	0.36	6.19e-9	Educational attainment;
KIRP	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs981844	0.712	rs4571310	chr4:154746832	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-6.97	-0.41	2.92e-11	Response to statins (LDL cholesterol change);
KIRP	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-6.07	-0.36	4.89e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg08992911	chr2:238395768	MLPH	0.53	5.08	0.31	7.49e-7	Prostate cancer;
KIRP	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06544989	chr22:39130855	UNC84B	0.5	8.27	0.47	8.42e-15	Menopause (age at onset);
KIRP	cis	rs42714	0.688	rs56010289	chr7:28468621	C/G	cg19638435	chr7:28452093	CREB5	0.78	4.95	0.3	1.36e-6	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
KIRP	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.0	-0.41	2.42e-11	Myopia (pathological);
KIRP	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	1.03	14.06	0.67	2.43e-33	Blood protein levels;
KIRP	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.66	9.81	0.53	2.24e-19	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg15212455	chr7:39170539	POU6F2	0.26	6.02	0.36	6.29e-9	IgG glycosylation;
KIRP	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.59	-6.35	-0.38	1.02e-9	Osteoporosis;
KIRP	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.76	6.45	0.38	5.83e-10	Body mass index;
KIRP	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.3e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2274273	0.840	rs1045002	chr14:55818517	T/A	cg04306507	chr14:55594613	LGALS3	0.44	6.47	0.38	5.36e-10	Protein biomarker;
KIRP	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.87	10.92	0.57	6.62e-23	Coronary artery disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07260605	chr10:126630534	ZRANB1	-0.43	-6.3	-0.37	1.4e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg24060327	chr5:131705240	SLC22A5	0.67	6.93	0.4	3.73e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs7640424	0.691	rs13075747	chr3:107830164	T/A	cg09227934	chr3:107805635	CD47	-0.31	-5.44	-0.33	1.29e-7	Body mass index;
KIRP	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.61	7.55	0.43	8.47e-13	Chronic lymphocytic leukemia;
KIRP	cis	rs9430161	0.645	rs6675082	chr1:11033797	T/C	cg27631724	chr1:11040367	C1orf127	0.38	7.56	0.43	8.16e-13	Ewing sarcoma;
KIRP	cis	rs12464559	0.522	rs10200512	chr2:152626147	T/C	cg01189475	chr2:152685088	ARL5A	0.56	4.91	0.3	1.67e-6	Response to cognitive-behavioural therapy in anxiety disorder;
KIRP	cis	rs55788414	0.929	rs66463064	chr16:81180995	T/C	cg06400318	chr16:81190750	PKD1L2	-1.19	-7.65	-0.44	4.58e-13	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg13180566	chr4:1052158	NA	-0.49	-5.04	-0.31	9.06e-7	Recombination rate (females);
KIRP	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg16898833	chr6:26189333	HIST1H4D	0.74	5.31	0.32	2.46e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg14458575	chr2:238380390	NA	0.57	7.65	0.44	4.66e-13	Prostate cancer;
KIRP	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg16606324	chr3:10149918	C3orf24	0.56	5.26	0.32	3.19e-7	Alzheimer's disease;
KIRP	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.6	6.94	0.4	3.54e-11	Height;
KIRP	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg23625390	chr15:77176239	SCAPER	0.52	6.91	0.4	4.25e-11	Blood metabolite levels;
KIRP	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.46	5.89	0.35	1.26e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg21775007	chr8:11205619	TDH	0.51	6.72	0.39	1.29e-10	Mood instability;
KIRP	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.82	8.46	0.47	2.38e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg21475434	chr5:93447410	FAM172A	-0.42	-4.91	-0.3	1.68e-6	Diabetic retinopathy;
KIRP	cis	rs3789045	0.688	rs6668637	chr1:204452295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.6	-6.15	-0.37	3.08e-9	Educational attainment (college completion);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00866289	chr14:97037846	NA	-0.41	-6.11	-0.36	3.88e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.42	5.14	0.31	5.58e-7	Lung cancer;
KIRP	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.72	-0.44	2.83e-13	Total cholesterol levels;
KIRP	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.63	-8.5	-0.48	1.81e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs60311166	1.000	rs934839	chr3:52683898	G/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.84	6.54	0.38	3.53e-10	CTACK levels;
KIRP	cis	rs34779708	0.801	rs12255409	chr10:35535425	G/A	cg03585969	chr10:35415529	CREM	0.65	7.75	0.44	2.43e-13	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	5.47	0.33	1.11e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs33912345	0.695	rs1254284	chr14:60856723	A/G	cg27398547	chr14:60952738	C14orf39	-0.41	-5.53	-0.33	8.29e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs4006360	0.543	rs7502165	chr17:39268037	A/C	cg25341923	chr17:39239918	KRTAP4-7	-0.62	-8.07	-0.46	3.15e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg16691251	chr5:66510806	NA	0.43	5.85	0.35	1.53e-8	Breast cancer;
KIRP	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	7.73	0.44	2.69e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.83	11.23	0.58	6.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg16482183	chr6:26056742	HIST1H1C	0.39	4.94	0.3	1.48e-6	Height;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17335440	chr11:48161380	PTPRJ	0.59	6.47	0.38	5.19e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg21775007	chr8:11205619	TDH	-0.45	-6.07	-0.36	4.89e-9	Retinal vascular caliber;
KIRP	cis	rs2594989	0.943	rs9822446	chr3:11420780	C/G	cg01796438	chr3:11312864	ATG7	-0.65	-8.15	-0.46	1.83e-14	Circulating chemerin levels;
KIRP	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14442939	chr10:27389572	ANKRD26	0.69	7.2	0.42	7.39e-12	Breast cancer;
KIRP	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg17764715	chr19:33622953	WDR88	0.67	8.33	0.47	5.54e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.59	8.13	0.46	2.12e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-6.22	-0.37	2.12e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	8.64	0.48	7.24e-16	Platelet count;
KIRP	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg23649088	chr2:200775458	C2orf69	-0.39	-4.92	-0.3	1.58e-6	QT interval;
KIRP	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.91	-14.18	-0.67	9.61e-34	Height;
KIRP	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.69	-6.01	-0.36	6.6e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1823913	0.599	rs17346475	chr2:192153214	A/G	cg12404831	chr2:192114017	MYO1B	-0.52	-7.25	-0.42	5.47e-12	Obesity-related traits;
KIRP	cis	rs9311676	0.656	rs62258120	chr3:58391128	G/A	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-1.01	-11.97	-0.61	2.52e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4474465	1.000	rs11237520	chr11:78201201	G/C	cg02023728	chr11:77925099	USP35	0.34	5.48	0.33	1.06e-7	Alzheimer's disease (survival time);
KIRP	trans	rs2018683	0.711	rs917213	chr7:28968204	A/G	cg19402173	chr7:128379420	CALU	-0.69	-9.06	-0.5	4.04e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6901250	0.759	rs9489040	chr6:117131740	G/A	cg12892004	chr6:117198278	RFX6	0.41	6.65	0.39	1.86e-10	C-reactive protein levels;
KIRP	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg00361562	chr2:198649771	BOLL	-0.52	-5.01	-0.3	1.06e-6	Ulcerative colitis;
KIRP	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.81	-7.15	-0.41	1.01e-11	Body mass index;
KIRP	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-9.05	-0.5	4.51e-17	Resting heart rate;
KIRP	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.65	8.33	0.47	5.62e-15	Colorectal cancer;
KIRP	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg22903471	chr2:27725779	GCKR	-0.63	-9.31	-0.51	7.36e-18	Total body bone mineral density;
KIRP	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.81	-9.05	-0.5	4.45e-17	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg20701182	chr2:24300061	SF3B14	0.48	4.98	0.3	1.2e-6	Asthma;
KIRP	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg10950524	chr7:2139216	MAD1L1	0.31	4.99	0.3	1.13e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs10754283	0.967	rs10801763	chr1:90120822	C/T	cg06121193	chr1:90282411	NA	-0.51	-7.36	-0.42	2.77e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg11235152	chr1:67600687	NA	0.65	9.76	0.53	3.12e-19	Psoriasis;
KIRP	cis	rs7845219	0.544	rs7001535	chr8:95921090	C/G	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.91	-0.3	1.65e-6	Type 2 diabetes;
KIRP	cis	rs6662572	0.703	rs9429090	chr1:46502393	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.33	0.32	2.19e-7	Blood protein levels;
KIRP	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.89	-0.35	1.29e-8	Parkinson's disease;
KIRP	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	6.01	0.36	6.6e-9	Menopause (age at onset);
KIRP	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-5.59	-0.34	6.15e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg08854313	chr1:11322531	MTOR	0.73	9.83	0.53	1.84e-19	Body mass index;
KIRP	cis	rs6141600	0.525	rs6058435	chr20:34829868	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-5.01	-0.3	1.02e-6	Height;Hip circumference;
KIRP	cis	rs6662572	0.737	rs4256763	chr1:46379518	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.46	-5.61	-0.34	5.35e-8	Blood protein levels;
KIRP	cis	rs13067260	0.655	rs6438823	chr3:123723805	C/A	cg19918027	chr3:123987645	KALRN	-0.62	-5.46	-0.33	1.14e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.66	0.39	1.73e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.67	-0.39	1.73e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg16497661	chr14:103986332	CKB	0.4	5.24	0.32	3.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs883565	0.792	rs810743	chr3:39185968	A/G	cg01426195	chr3:39028469	NA	0.53	6.81	0.4	7.55e-11	Handedness;
KIRP	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg15841412	chr13:111365552	ING1	0.54	5.94	0.35	9.84e-9	Coronary artery disease;
KIRP	cis	rs1558375	0.679	rs31670	chr7:87059164	C/T	cg00919237	chr7:87102261	ABCB4	0.49	6.4	0.38	7.67e-10	Gallbladder cancer;
KIRP	cis	rs6973256	0.829	rs17167199	chr7:133333292	C/T	cg10665199	chr7:133106180	EXOC4	-0.49	-6.18	-0.37	2.6e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.5	7.69	0.44	3.43e-13	Testicular germ cell tumor;
KIRP	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg11031976	chr2:198649780	BOLL	-0.51	-4.97	-0.3	1.24e-6	Ulcerative colitis;
KIRP	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-0.99	-10.14	-0.54	2.05e-20	Atopic dermatitis;
KIRP	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.48	-7.62	-0.44	5.56e-13	Platelet distribution width;
KIRP	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg23985595	chr17:80112537	CCDC57	0.37	5.6	0.34	5.58e-8	Life satisfaction;
KIRP	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	0.87	10.32	0.55	5.59e-21	Corneal structure;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg17457637	chr7:27170717	HOXA4	-0.42	-6.0	-0.36	6.94e-9	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.76	8.66	0.48	6.26e-16	Cognitive ability;
KIRP	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.6	6.79	0.4	8.25e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.66	-8.28	-0.47	7.71e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg13180566	chr4:1052158	NA	-0.51	-5.25	-0.32	3.33e-7	Recombination rate (females);
KIRP	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg04013166	chr16:89971882	TCF25	0.64	7.16	0.42	9.37e-12	Skin colour saturation;
KIRP	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg09549813	chr16:4587862	C16orf5	0.35	5.03	0.31	9.62e-7	Schizophrenia;
KIRP	cis	rs71277158	0.688	rs7618919	chr3:169860239	C/T	cg04067573	chr3:169899625	PHC3	0.62	5.86	0.35	1.46e-8	Prostate cancer;
KIRP	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg08989290	chr16:615782	NHLRC4	0.42	6.11	0.36	3.88e-9	Height;
KIRP	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg24101359	chr6:42928495	GNMT	0.52	7.32	0.42	3.42e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs10782582	0.609	rs112431348	chr1:76275571	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.2	-0.37	2.35e-9	Daytime sleep phenotypes;
KIRP	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.63	-9.34	-0.51	6.2e-18	Monocyte percentage of white cells;
KIRP	cis	rs2290419	0.730	rs114820467	chr11:68944052	T/C	cg17042914	chr11:68898666	NA	-0.67	-5.01	-0.3	1.06e-6	Cutaneous malignant melanoma;
KIRP	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg13385521	chr17:29058706	SUZ12P	0.57	5.61	0.34	5.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs838147	0.537	rs485186	chr19:49207206	A/G	cg02804510	chr19:49199965	FUT2	0.34	4.94	0.3	1.41e-6	Dietary macronutrient intake;
KIRP	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg08807101	chr21:30365312	RNF160	-0.53	-5.29	-0.32	2.71e-7	Cognitive test performance;
KIRP	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07570687	chr10:102243282	WNT8B	0.52	6.64	0.39	1.94e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12230513	0.732	rs7957446	chr12:55839631	G/C	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg08999081	chr20:33150536	PIGU	0.47	6.29	0.37	1.48e-9	Height;
KIRP	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.76	9.39	0.51	4.13e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.11	-0.36	3.9e-9	Neuroticism;
KIRP	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg13010199	chr12:38710504	ALG10B	-0.38	-4.86	-0.3	2.08e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.44	-5.49	-0.33	1.02e-7	Crohn's disease;
KIRP	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg16797656	chr11:68205561	LRP5	0.38	5.07	0.31	7.9e-7	Total body bone mineral density;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg09496393	chr6:117002125	KPNA5	0.57	6.87	0.4	5.18e-11	Educational attainment;
KIRP	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg17328964	chr8:145687451	CYHR1	-0.53	-6.66	-0.39	1.78e-10	Age at first birth;
KIRP	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg15590007	chr10:45870220	ALOX5	0.62	5.63	0.34	4.81e-8	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.33	8.71	0.49	4.51e-16	Rheumatoid arthritis;
KIRP	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.71	-8.77	-0.49	2.93e-16	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg16926213	chr1:1841314	NA	0.31	5.33	0.32	2.22e-7	Body mass index;
KIRP	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg05692746	chr2:100937584	LONRF2	-0.38	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs4871297	1.000	rs4871297	chr8:123706155	A/G	cg20250874	chr13:47127354	LRCH1	-0.49	-6.12	-0.36	3.67e-9	Type 1 diabetes nephropathy;
KIRP	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.66	-7.3	-0.42	3.86e-12	Multiple sclerosis;
KIRP	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg22974920	chr21:40686053	BRWD1	0.51	6.09	0.36	4.29e-9	Cognitive function;
KIRP	cis	rs4805834	0.697	rs58026555	chr19:33265013	A/G	cg07201929	chr19:33182834	NUDT19	-0.62	-5.24	-0.32	3.4e-7	Creatinine levels;
KIRP	cis	rs68092024	0.731	rs792840	chr3:99471251	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.42	4.96	0.3	1.33e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs7258465	0.931	rs8107351	chr19:18612758	G/A	cg10790698	chr19:18539756	SSBP4	-0.33	-7.16	-0.42	9.26e-12	Breast cancer;
KIRP	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg12741994	chr3:170137321	CLDN11	-0.49	-4.98	-0.3	1.17e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg10503236	chr1:231470652	EXOC8	-0.53	-7.36	-0.42	2.83e-12	Hemoglobin concentration;
KIRP	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.38	-0.38	8.56e-10	Monocyte percentage of white cells;
KIRP	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg16255804	chr6:135334527	HBS1L	-0.33	-5.35	-0.32	2.02e-7	Red blood cell count;
KIRP	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs7011507	1.000	rs79616345	chr8:49186756	G/A	cg15325961	chr8:49183143	NA	0.61	5.2	0.31	4.17e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs55675132	0.510	rs12120851	chr1:115262845	T/C	cg12756093	chr1:115239321	AMPD1	0.65	6.41	0.38	7.37e-10	Schizophrenia;
KIRP	cis	rs758324	0.947	rs380182	chr5:131319036	A/G	cg06647332	chr5:131281008	NA	-0.44	-4.93	-0.3	1.5e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2802372	0.630	rs1250563	chr10:81047383	C/G	cg18688392	chr10:81059414	ZMIZ1	0.68	8.2	0.46	1.35e-14	Granulocyte count;
KIRP	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg07701084	chr6:150067640	NUP43	0.58	6.29	0.37	1.48e-9	Lung cancer;
KIRP	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.72	12.04	0.61	1.49e-26	Vitiligo;
KIRP	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg11189052	chr15:85197271	WDR73	0.47	4.89	0.3	1.82e-6	Schizophrenia;
KIRP	cis	rs2733310	0.947	rs1660963	chr15:57157876	C/T	cg13626582	chr15:57592083	LOC283663	-0.22	-5.22	-0.32	3.8e-7	Mean platelet volume;
KIRP	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.66	-8.18	-0.46	1.53e-14	Recalcitrant atopic dermatitis;
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.63	9.88	0.53	1.35e-19	Lung cancer;
KIRP	cis	rs4356975	0.545	rs35297888	chr4:69949573	G/A	cg27372994	chr4:70080453	UGT2B11	0.37	4.94	0.3	1.44e-6	Obesity-related traits;
KIRP	trans	rs62056376	0.688	rs62056378	chr17:32671362	G/A	cg09712683	chr2:95692352	MAL	-0.47	-6.06	-0.36	5.05e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01973587	chr1:228161476	NA	-0.4	-5.08	-0.31	7.64e-7	Diastolic blood pressure;
KIRP	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.64	10.59	0.56	7.68e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.44	-0.55	2.26e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg02023728	chr11:77925099	USP35	-0.32	-5.57	-0.33	6.83e-8	Alzheimer's disease (survival time);
KIRP	cis	rs259842	0.761	rs1906012	chr2:180675669	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.39	-0.33	1.64e-7	Blood protein levels;
KIRP	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg02996583	chr8:142237188	SLC45A4	0.42	5.08	0.31	7.37e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg12369402	chr1:90227771	NA	-0.37	-5.35	-0.32	2.05e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	7.57	0.43	7.47e-13	Coffee consumption (cups per day);
KIRP	cis	rs35740288	0.770	rs11636185	chr15:86183118	A/G	cg10818794	chr15:86012489	AKAP13	-0.43	-5.29	-0.32	2.73e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.27	14.17	0.67	9.94e-34	Uric acid levels;
KIRP	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.1	11.61	0.6	3.78e-25	Platelet count;
KIRP	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.37	-0.47	4.25e-15	Personality dimensions;
KIRP	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.83	9.58	0.52	1.1e-18	Neutrophil percentage of white cells;
KIRP	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg09455208	chr3:40491958	NA	0.31	5.74	0.34	2.74e-8	Renal cell carcinoma;
KIRP	cis	rs4919044	0.674	rs11187260	chr10:94809187	A/G	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs6723108	1.000	rs6723108	chr2:135479980	G/T	cg25422880	chr2:135218333	TMEM163	-0.4	-5.41	-0.33	1.47e-7	Type 2 diabetes;
KIRP	cis	rs17095355	0.786	rs58096078	chr10:111734286	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.43	-6.06	-0.36	5.09e-9	Biliary atresia;
KIRP	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.7	-8.34	-0.47	5.34e-15	Obesity-related traits;
KIRP	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06481639	chr22:41940642	POLR3H	-0.67	-7.43	-0.43	1.78e-12	Vitiligo;
KIRP	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.72	9.75	0.53	3.45e-19	Breast cancer;
KIRP	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg00792783	chr2:198669748	PLCL1	0.47	5.25	0.32	3.3e-7	Dermatomyositis;
KIRP	cis	rs4356932	1.000	rs6532142	chr4:76970905	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-6.19	-0.37	2.52e-9	Lung cancer;
KIRP	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.3	-0.32	2.62e-7	Bipolar disorder;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.77	12.42	0.62	8.13e-28	Menarche (age at onset);
KIRP	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	1.1	8.59	0.48	1.01e-15	Skin colour saturation;
KIRP	cis	rs631288	0.557	rs920682	chr1:146657523	C/A	cg25205988	chr1:146714368	CHD1L	1.02	6.1	0.36	4.11e-9	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs835367	1	rs835367	chr1:59762468	A/G	cg09869950	chr1:59783505	FGGY	-0.41	-5.17	-0.31	4.92e-7	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg06636001	chr8:8085503	FLJ10661	0.65	7.99	0.45	5.31e-14	Systemic lupus erythematosus;
KIRP	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.43	8.47	0.48	2.31e-15	Coronary artery disease;
KIRP	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08280861	chr8:58055591	NA	0.81	6.42	0.38	7.03e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs7619833	0.967	rs1494420	chr3:27487705	C/T	cg22620680	chr3:122920514	SEC22A	-0.46	-6.18	-0.37	2.61e-9	Breast cancer;
KIRP	cis	rs2976388	0.967	rs2976387	chr8:143759364	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-6.4	-0.38	7.58e-10	Urinary tract infection frequency;
KIRP	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg25486957	chr4:152246857	NA	-0.43	-5.17	-0.31	4.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2882667	0.824	rs11748097	chr5:138479887	C/A	cg04439458	chr5:138467593	SIL1	-0.48	-7.34	-0.42	3.19e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg07639376	chr16:1584516	IFT140;TMEM204	0.19	5.06	0.31	8.24e-7	Coronary artery disease;
KIRP	cis	rs930036	0.602	rs71415233	chr2:171800295	G/A	cg12801329	chr2:171670795	NA	0.43	4.91	0.3	1.67e-6	Menopause (age at onset);
KIRP	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.12	-0.31	6.03e-7	Schizophrenia;
KIRP	cis	rs838147	0.844	rs12975033	chr19:49249443	A/T	cg08619932	chr19:49200058	FUT2	-0.36	-5.66	-0.34	4.12e-8	Dietary macronutrient intake;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19753255	chr1:45476701	HECTD3;UROD	0.48	6.36	0.38	9.58e-10	Survival in pancreatic cancer;
KIRP	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg18538332	chr22:24372958	LOC391322	-0.47	-5.23	-0.32	3.7e-7	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg27432699	chr2:27873401	GPN1	0.47	6.28	0.37	1.52e-9	Total body bone mineral density;
KIRP	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.29	5.53	0.33	8.07e-8	Monocyte percentage of white cells;
KIRP	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg02297831	chr4:17616191	MED28	-0.49	-5.59	-0.34	6.08e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7236492	0.515	rs8086051	chr18:77173158	C/T	cg15644404	chr18:77186268	NFATC1	-0.95	-6.16	-0.37	2.87e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.47	-5.18	-0.31	4.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.63	-8.22	-0.46	1.14e-14	Obesity-related traits;
KIRP	trans	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg15469184	chr8:337539	NA	0.6	6.92	0.4	3.81e-11	Obesity-related traits;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25762580	chr7:108210082	THAP5;DNAJB9	0.59	6.93	0.4	3.62e-11	Smoking initiation;
KIRP	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.5	6.72	0.39	1.28e-10	Obesity-related traits;
KIRP	cis	rs75920871	0.528	rs1531707	chr11:116944712	G/A	cg04087571	chr11:116723030	SIK3	-0.25	-5.34	-0.32	2.1e-7	Subjective well-being;
KIRP	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg16434002	chr17:42200994	HDAC5	-0.46	-5.68	-0.34	3.74e-8	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg03060546	chr3:49711283	APEH	-0.65	-6.77	-0.4	9.51e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg22563815	chr15:78856949	CHRNA5	-0.49	-7.62	-0.44	5.33e-13	Sudden cardiac arrest;
KIRP	cis	rs12752838	1.000	rs12752838	chr1:8913656	A/G	cg06972019	chr1:8937448	ENO1	-0.35	-5.17	-0.31	4.84e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg24253500	chr15:84953950	NA	0.49	4.85	0.3	2.17e-6	Schizophrenia;
KIRP	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.76	9.48	0.52	2.3e-18	Coronary artery disease;
KIRP	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.66	5.88	0.35	1.32e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20135002	chr11:47629003	NA	-0.4	-4.94	-0.3	1.42e-6	Subjective well-being;
KIRP	trans	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.04	-11.54	-0.59	6.39e-25	Colorectal cancer;
KIRP	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg15655495	chr12:38532458	NA	0.25	5.0	0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.38	0.38	8.77e-10	Protein C levels;
KIRP	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.66	-8.46	-0.47	2.43e-15	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg08668359	chr10:1443807	ADARB2	-0.5	-6.16	-0.37	3.01e-9	Radiation response;
KIRP	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg00507259	chr4:95128692	SMARCAD1	0.39	4.94	0.3	1.44e-6	QT interval;
KIRP	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.53	-0.38	3.75e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg10018233	chr7:150070692	REPIN1	0.58	6.81	0.4	7.57e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg17604480	chr11:99375907	CNTN5	-0.43	-6.83	-0.4	6.44e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.32	4.96	0.3	1.3e-6	QRS complex (12-leadsum);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18294116	chr6:105528070	LIN28B	0.48	6.7	0.39	1.4e-10	Interleukin-4 levels;
KIRP	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.57	6.98	0.41	2.78e-11	Total body bone mineral density;
KIRP	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.64e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.55	6.9	0.4	4.47e-11	Mean corpuscular volume;
KIRP	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg07382826	chr16:28625726	SULT1A1	0.52	6.09	0.36	4.34e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.03	-0.31	9.58e-7	Pulmonary function;
KIRP	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.78	11.69	0.6	2.11e-25	Total body bone mineral density;
KIRP	cis	rs9302690	1.000	rs62037108	chr16:57443171	G/A	cg27017172	chr16:57497170	POLR2C	0.95	7.51	0.43	1.11e-12	Blood protein levels;
KIRP	cis	rs7084402	1.000	rs4113952	chr10:60268599	A/G	cg05938607	chr10:60274200	BICC1	-0.41	-10.08	-0.54	3.13e-20	Refractive error;
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg02493798	chr17:6899577	ALOX12	0.33	6.37	0.38	9.41e-10	Tonsillectomy;
KIRP	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg11569703	chr11:65557185	OVOL1	-0.51	-9.3	-0.51	7.69e-18	Acne (severe);
KIRP	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	0.92	6.81	0.4	7.51e-11	Arsenic metabolism;
KIRP	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg07843065	chr1:150265600	MRPS21	0.45	6.25	0.37	1.75e-9	Migraine;
KIRP	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg06307176	chr5:131281290	NA	0.57	6.41	0.38	7.48e-10	Life satisfaction;
KIRP	cis	rs2281603	0.570	rs10134530	chr14:64950958	C/G	cg01860774	chr14:64969374	ZBTB25	-0.33	-5.22	-0.32	3.8e-7	Lymphocyte counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25417344	chr19:13875786	MRI1	0.49	6.16	0.37	2.87e-9	Parkinson's disease;
KIRP	cis	rs7572644	0.564	rs12995865	chr2:28025066	A/C	cg27432699	chr2:27873401	GPN1	0.49	5.5	0.33	9.58e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.74	-7.29	-0.42	4.27e-12	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09217309	chr6:150244204	RAET1G	0.4	4.89	0.3	1.86e-6	Testicular germ cell tumor;
KIRP	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.68	9.11	0.5	2.94e-17	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg00343986	chr7:65444356	GUSB	-0.46	-5.63	-0.34	4.93e-8	Aortic root size;
KIRP	cis	rs13108904	0.517	rs7671242	chr4:1339875	G/A	cg00689492	chr4:1303491	MAEA	0.29	5.01	0.3	1.03e-6	Obesity-related traits;
KIRP	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.85	11.55	0.59	6.31e-25	Selective IgA deficiency;
KIRP	cis	rs2562456	0.833	rs62110428	chr19:21613656	C/T	cg18461458	chr19:21324796	ZNF431	-0.54	-5.07	-0.31	7.7e-7	Pain;
KIRP	cis	rs10875746	0.855	rs73102067	chr12:48494426	A/C	cg20731937	chr12:48336164	NA	0.41	5.25	0.32	3.23e-7	Longevity (90 years and older);
KIRP	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.99	17.49	0.74	4.54e-45	Breast cancer;
KIRP	cis	rs10491083	0.661	rs2072150	chr17:6564627	C/A	cg08103988	chr17:6558365	NA	0.56	4.98	0.3	1.2e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg18944383	chr4:111397179	ENPEP	0.52	8.39	0.47	3.88e-15	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7870753	0.838	rs10761013	chr9:99201939	T/C	cg25260653	chr9:99212216	HABP4	0.57	6.04	0.36	5.51e-9	Height;
KIRP	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.44	5.43	0.33	1.32e-7	Common traits (Other);
KIRP	cis	rs10875746	0.624	rs11168498	chr12:48655088	A/G	cg20731937	chr12:48336164	NA	0.48	5.99	0.36	7.55e-9	Longevity (90 years and older);
KIRP	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg17644776	chr2:200775616	C2orf69	0.57	6.33	0.37	1.17e-9	Schizophrenia;
KIRP	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.53	7.4	0.43	2.12e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03160445	chr3:100120349	LNP1;TOMM70A	0.69	6.33	0.37	1.16e-9	Lung function (FEV1);
KIRP	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg05754148	chr16:3507555	NAT15	0.56	5.31	0.32	2.44e-7	Tuberculosis;
KIRP	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.19	0.51	1.69e-17	Bipolar disorder;
KIRP	cis	rs17742757	0.522	rs899364	chr8:11329544	G/T	cg19847130	chr8:10466454	RP1L1	0.39	5.42	0.33	1.43e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg22219255	chr6:106525493	NA	0.39	6.08	0.36	4.61e-9	Survival in pancreatic cancer;
KIRP	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg13010199	chr12:38710504	ALG10B	-0.49	-6.42	-0.38	7.07e-10	Morning vs. evening chronotype;
KIRP	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg05721485	chr17:44071124	MAPT	-0.55	-7.56	-0.43	8.12e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3779635	0.967	rs976175	chr8:27269416	A/G	cg14221460	chr8:27183342	PTK2B	0.46	6.08	0.36	4.63e-9	Neuroticism;
KIRP	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg04731861	chr2:219085781	ARPC2	-0.21	-5.32	-0.32	2.29e-7	Colorectal cancer;
KIRP	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.84	9.24	0.51	1.16e-17	High light scatter reticulocyte count;
KIRP	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg23102388	chr7:1867652	MAD1L1	-0.44	-6.14	-0.36	3.36e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg17646820	chr3:66848679	NA	-0.56	-7.81	-0.45	1.62e-13	Type 2 diabetes;
KIRP	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2230307	0.536	rs490669	chr1:100484430	C/T	cg24955406	chr1:100503596	HIAT1	0.69	7.87	0.45	1.13e-13	Carotid intima media thickness;
KIRP	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg20991723	chr1:152506922	NA	-0.45	-5.3	-0.32	2.6e-7	Hair morphology;
KIRP	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg18404041	chr3:52824283	ITIH1	-0.42	-5.16	-0.31	5.14e-7	Schizophrenia;
KIRP	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.9	-0.35	1.21e-8	Type 2 diabetes;
KIRP	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg01631408	chr1:248437212	OR2T33	-0.45	-5.88	-0.35	1.34e-8	Common traits (Other);
KIRP	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.78	11.58	0.59	4.89e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.83	-0.35	1.74e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg00310523	chr12:86230176	RASSF9	-0.56	-8.78	-0.49	2.74e-16	Major depressive disorder;
KIRP	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.81	-10.46	-0.55	2.06e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg11861562	chr11:117069780	TAGLN	0.38	4.97	0.3	1.25e-6	Blood protein levels;
KIRP	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.59	-6.09	-0.36	4.39e-9	Chronic sinus infection;
KIRP	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg09788416	chr12:39539408	NA	0.39	5.26	0.32	3.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg02574844	chr11:5959923	NA	-0.61	-6.65	-0.39	1.84e-10	DNA methylation (variation);
KIRP	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.9	-12.2	-0.61	4.33e-27	Cognitive function;
KIRP	cis	rs7084402	0.967	rs7087998	chr10:60271531	A/G	cg05938607	chr10:60274200	BICC1	0.42	10.19	0.54	1.45e-20	Refractive error;
KIRP	cis	rs7084402	0.902	rs1346300	chr10:60287635	G/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.9	-15.29	-0.7	1.5e-37	Oral cavity cancer;
KIRP	cis	rs8133932	0.654	rs413517	chr21:47347545	C/G	cg11214348	chr21:47283868	PCBP3	-0.44	-5.11	-0.31	6.5e-7	Schizophrenia;
KIRP	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.94	13.19	0.64	2.14e-30	Menopause (age at onset);
KIRP	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.59	6.34	0.37	1.09e-9	Type 2 diabetes;
KIRP	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17376030	chr22:41985996	PMM1	-0.52	-5.6	-0.34	5.82e-8	Vitiligo;
KIRP	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg08134877	chr2:44394819	PPM1B	0.52	5.32	0.32	2.33e-7	Height;
KIRP	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.5	6.57	0.39	3.02e-10	Height;
KIRP	cis	rs9826463	1.000	rs9816275	chr3:142327240	C/G	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7084402	0.967	rs1658446	chr10:60314183	A/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.89	-0.57	8.19e-23	Refractive error;
KIRP	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9815354	1.000	rs9848754	chr3:41753647	C/T	cg03022575	chr3:42003672	ULK4	0.6	5.97	0.36	8.37e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.87	11.89	0.6	4.53e-26	Schizophrenia;
KIRP	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.45	5.69	0.34	3.68e-8	Prostate cancer;
KIRP	cis	rs494562	0.892	rs9353310	chr6:86126199	C/T	cg21730993	chr6:86159210	NT5E	0.57	5.54	0.33	7.89e-8	Blood metabolite levels;Metabolic traits;
KIRP	trans	rs2302464	1.000	rs10011868	chr4:15660828	T/A	cg19145858	chr7:129781681	NA	-0.65	-6.44	-0.38	6.15e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg18833306	chr6:118973337	C6orf204	0.39	4.93	0.3	1.51e-6	Electrocardiographic conduction measures;
KIRP	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	0.95	11.19	0.58	9.43e-24	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	5.55	0.33	7.2e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs17221829	0.614	rs2388202	chr11:89374231	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14888445	chr13:101184494	A2LD1	-0.47	-6.06	-0.36	5.07e-9	Parkinson's disease;
KIRP	cis	rs11264213	0.892	rs12034163	chr1:36191030	C/G	cg27506609	chr1:36549197	TEKT2	0.77	6.82	0.4	6.88e-11	Schizophrenia;
KIRP	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	8.55	0.48	1.29e-15	Psoriasis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15277658	chr10:73421701	CDH23	0.41	6.41	0.38	7.45e-10	Survival in pancreatic cancer;
KIRP	cis	rs9815354	0.903	rs7373694	chr3:42012719	G/A	cg03022575	chr3:42003672	ULK4	-0.48	-5.45	-0.33	1.23e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.69	9.54	0.52	1.52e-18	Caffeine consumption;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.64	8.84	0.49	1.92e-16	Longevity;Endometriosis;
KIRP	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.51	-5.6	-0.34	5.66e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6743226	0.870	rs12624197	chr2:242254737	G/C	cg10021735	chr2:242295487	FARP2	0.51	6.17	0.37	2.75e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs10465746	0.967	rs6576956	chr1:84343885	T/G	cg10977910	chr1:84465055	TTLL7	0.46	5.56	0.33	7.1e-8	Obesity-related traits;
KIRP	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.83	13.38	0.65	4.83e-31	Metabolic syndrome;
KIRP	cis	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg27487796	chr7:28973253	NA	-0.22	-4.99	-0.3	1.12e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	trans	rs12043259	0.730	rs12405886	chr1:204821296	G/A	cg11485465	chr5:54518469	NA	0.38	6.17	0.37	2.85e-9	Addiction;
KIRP	cis	rs2075064	0.814	rs76496856	chr9:126780167	C/T	cg14112217	chr9:126806003	NA	0.36	4.96	0.3	1.3e-6	Waist circumference;
KIRP	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg21497246	chr14:78225524	SNW1;C14orf178	-0.49	-4.89	-0.3	1.79e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg04287289	chr16:89883240	FANCA	-0.39	-5.11	-0.31	6.55e-7	Vitiligo;
KIRP	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg17425144	chr1:10567563	PEX14	0.43	7.78	0.44	2.05e-13	Prostate cancer;
KIRP	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg11657440	chr19:46296263	DMWD	-0.72	-9.27	-0.51	9.83e-18	Coronary artery disease;
KIRP	cis	rs10214930	0.697	rs978447	chr7:27582783	G/A	cg22168087	chr7:27702803	HIBADH	0.47	4.96	0.3	1.31e-6	Hypospadias;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08885201	chr16:69419692	TERF2	-0.53	-6.97	-0.41	2.87e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.31	4.89	0.3	1.78e-6	Parkinson's disease;
KIRP	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg09408571	chr1:101003634	GPR88	-0.22	-4.97	-0.3	1.28e-6	Monocyte count;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18651011	chr5:92953977	FAM172A	0.37	6.19	0.37	2.5e-9	C-reactive protein;
KIRP	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg23950597	chr19:37808831	NA	0.59	6.46	0.38	5.47e-10	Coronary artery calcification;
KIRP	cis	rs6977660	0.660	rs12531278	chr7:19816439	A/T	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs4776059	1.000	rs17614559	chr15:52878719	G/A	cg22715398	chr15:52968154	KIAA1370	-0.56	-6.67	-0.39	1.66e-10	Schizophrenia;
KIRP	cis	rs35883536	1.000	rs871151	chr1:101123737	G/A	cg06223162	chr1:101003688	GPR88	0.34	6.87	0.4	5.33e-11	Monocyte count;
KIRP	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.52	7.2	0.42	7.12e-12	Childhood ear infection;
KIRP	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.9	-0.35	1.22e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs78049276	0.736	rs77028772	chr4:148364920	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.69	-6.79	-0.4	8.17e-11	Pulse pressure;
KIRP	cis	rs34091987	0.560	rs35548382	chr17:70025087	T/C	cg09344028	chr17:70110421	NA	0.29	5.6	0.34	5.77e-8	Nose size;
KIRP	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg10760299	chr15:45669010	GATM	0.34	5.16	0.31	5.16e-7	Homoarginine levels;
KIRP	cis	rs10820614	1	rs10820614	chr9:99196094	G/C	cg25260653	chr9:99212216	HABP4	0.54	5.89	0.35	1.29e-8	Resting heart rate;
KIRP	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg04691961	chr3:161091175	C3orf57	-0.49	-6.81	-0.4	7.56e-11	Parkinson's disease;
KIRP	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	1.1	17.11	0.74	9.32e-44	Homoarginine levels;
KIRP	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg07509240	chr7:65420297	NA	0.34	4.87	0.3	2.02e-6	Calcium levels;
KIRP	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.55	7.5	0.43	1.14e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.64	8.55	0.48	1.33e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.66	-7.21	-0.42	6.85e-12	Diabetic retinopathy;
KIRP	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg05272587	chr13:111038400	COL4A2	0.38	4.95	0.3	1.36e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.76	0.34	2.55e-8	Motion sickness;
KIRP	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.72	7.66	0.44	4.21e-13	Gut microbiome composition (summer);
KIRP	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.34	5.28	0.32	2.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12200782	1.000	rs12204145	chr6:26600156	C/T	cg11502198	chr6:26597334	ABT1	-0.74	-5.22	-0.32	3.81e-7	Small cell lung carcinoma;
KIRP	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg24633833	chr3:10029261	TMEM111	0.55	4.92	0.3	1.61e-6	Alzheimer's disease;
KIRP	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg08499158	chr17:42289980	UBTF	0.67	8.8	0.49	2.54e-16	Total body bone mineral density;
KIRP	cis	rs9826463	0.582	rs6769123	chr3:142107897	A/G	cg20824294	chr3:142316082	PLS1	0.39	5.86	0.35	1.47e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-8.21	-0.46	1.24e-14	Personality dimensions;
KIRP	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.57	-7.75	-0.44	2.41e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9398803	0.698	rs1262553	chr6:127078785	T/C	cg19875578	chr6:126661172	C6orf173	-0.42	-5.5	-0.33	9.37e-8	Male-pattern baldness;
KIRP	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg01420254	chr6:26195488	NA	1.24	11.28	0.58	4.66e-24	Gout;Renal underexcretion gout;
KIRP	trans	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg06521331	chr12:34319734	NA	-0.5	-6.18	-0.37	2.7e-9	Bladder cancer;
KIRP	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-0.91	-12.53	-0.62	3.48e-28	Gut microbiota (bacterial taxa);
KIRP	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.61	5.21	0.32	3.94e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-1.01	-15.85	-0.71	1.84e-39	Personality dimensions;
KIRP	cis	rs6028	0.889	rs742127	chr1:169564167	G/C	cg06350853	chr1:168890140	NA	-0.36	-4.96	-0.3	1.35e-6	Activated partial thromboplastin time;
KIRP	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.43	5.08	0.31	7.48e-7	Menopause (age at onset);
KIRP	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.61	8.23	0.46	1.11e-14	Lymphocyte percentage of white cells;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13982541	chr5:1466431	LPCAT1	0.49	6.21	0.37	2.19e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7737355	0.853	rs7730810	chr5:130781179	T/C	cg06307176	chr5:131281290	NA	-0.42	-5.02	-0.3	9.8e-7	Life satisfaction;
KIRP	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg14825688	chr5:132208181	LEAP2	-0.37	-4.87	-0.3	1.96e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.43e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12532214	0.592	rs112075085	chr7:3172047	A/T	cg19214707	chr7:3157722	NA	-0.76	-6.03	-0.36	6.06e-9	Itch intensity from mosquito bite;
KIRP	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	9.97	0.54	7.15e-20	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26666968	chr1:35542667	NA	-0.46	-6.9	-0.4	4.49e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.59	7.47	0.43	1.36e-12	Body mass index;
KIRP	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg13399544	chr8:144649678	C8orf73	-0.45	-5.47	-0.33	1.11e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs4704187	0.617	rs6898134	chr5:74456731	T/C	cg03227963	chr5:74354835	NA	0.39	5.65	0.34	4.41e-8	Response to amphetamines;
KIRP	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.68	7.68	0.44	3.65e-13	Corneal astigmatism;
KIRP	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg14972814	chr11:95582409	MTMR2	0.29	5.04	0.31	9.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-1.06	-24.61	-0.84	2.82e-68	Breast cancer;
KIRP	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.46	6.72	0.39	1.24e-10	Urate levels in lean individuals;
KIRP	cis	rs9309473	1.000	rs11893881	chr2:73824373	T/A	cg20560298	chr2:73613845	ALMS1	-0.49	-5.65	-0.34	4.5e-8	Metabolite levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02737830	chr12:64616354	C12orf66	0.5	6.57	0.39	3.03e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg14375499	chr17:6899207	ALOX12	-0.33	-5.22	-0.32	3.87e-7	Tonsillectomy;
KIRP	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.67	-7.29	-0.42	4.22e-12	DNA methylation (variation);
KIRP	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg20936604	chr3:58311152	NA	-0.68	-5.58	-0.34	6.31e-8	Cholesterol, total;
KIRP	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.73	6.92	0.4	3.91e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg00677455	chr12:58241039	CTDSP2	0.72	8.74	0.49	3.75e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6028446	0.577	rs58734882	chr20:38139574	C/G	cg22476550	chr20:37590555	DHX35	0.39	4.87	0.3	2.02e-6	Chin dimples;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg15563057	chr5:139493612	PURA	0.48	6.58	0.39	2.84e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7116495	0.881	rs6592451	chr11:71674937	G/A	cg11196788	chr11:71737549	NUMA1	0.55	4.94	0.3	1.45e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg09201719	chr10:104596890	CYP17A1	0.4	5.77	0.35	2.4e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03188948	chr7:1209495	NA	0.51	5.99	0.36	7.54e-9	Longevity;Endometriosis;
KIRP	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12893428	chr3:195717962	SDHAP1	0.44	6.16	0.37	2.89e-9	Pancreatic cancer;
KIRP	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg13160058	chr8:26243215	BNIP3L	-0.48	-7.14	-0.41	1.07e-11	Red cell distribution width;
KIRP	cis	rs4908768	0.859	rs4908770	chr1:8711372	G/A	cg25722041	chr1:8623473	RERE	0.84	9.84	0.53	1.72e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11628318	0.588	rs12185065	chr14:103074636	A/C	cg01864069	chr14:103024347	NA	0.42	5.19	0.31	4.34e-7	Platelet count;
KIRP	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg04369109	chr6:150039330	LATS1	-0.5	-6.38	-0.38	8.8e-10	Lung cancer;
KIRP	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	0.88	7.06	0.41	1.71e-11	Obesity-related traits;
KIRP	cis	rs2120243	0.625	rs4482625	chr3:157096009	G/A	cg24825693	chr3:157122686	VEPH1	-0.49	-7.97	-0.45	6.06e-14	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.75	-9.01	-0.5	5.77e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-7.87	-0.45	1.13e-13	Morning vs. evening chronotype;
KIRP	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg14580859	chr9:123691850	NA	0.35	5.16	0.31	5.14e-7	Rheumatoid arthritis;
KIRP	cis	rs9815354	0.857	rs794894	chr3:42032483	C/T	cg03022575	chr3:42003672	ULK4	-0.53	-5.75	-0.34	2.59e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg00277334	chr10:82204260	NA	-0.46	-5.01	-0.3	1.06e-6	Post bronchodilator FEV1;
KIRP	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.25	-5.07	-0.31	7.95e-7	Lymphocyte counts;
KIRP	cis	rs13401104	0.796	rs1349754	chr2:237119714	G/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.44	5.66	0.34	4.27e-8	Body mass index;
KIRP	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg14952266	chr13:112191215	NA	0.37	4.91	0.3	1.67e-6	Hepatitis;
KIRP	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.83	10.22	0.55	1.11e-20	Post bronchodilator FEV1;
KIRP	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg22676075	chr6:135203613	NA	0.47	6.6	0.39	2.47e-10	Red blood cell count;
KIRP	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg02336718	chr17:17403227	NA	-0.34	-5.29	-0.32	2.7e-7	Total body bone mineral density;
KIRP	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-5.74	-0.34	2.78e-8	Schizophrenia;
KIRP	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg25650185	chr19:21324782	ZNF431	0.47	4.9	0.3	1.77e-6	Pain;
KIRP	cis	rs16828019	0.789	rs34216154	chr1:41670907	G/A	cg08144172	chr1:41849203	NA	0.62	4.87	0.3	1.96e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.57	7.67	0.44	3.94e-13	HDL cholesterol;
KIRP	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs2290402	0.536	rs12509561	chr4:850701	C/T	cg00846425	chr4:957561	DGKQ	-0.48	-5.09	-0.31	7.05e-7	Type 2 diabetes;
KIRP	cis	rs573521	1.000	rs679620	chr11:102713620	T/C	cg19620758	chr11:102826565	MMP13	0.36	4.92	0.3	1.61e-6	Cerebrospinal fluid levels of Alzheimer's disease-related proteins;
KIRP	cis	rs3736594	0.959	rs10209020	chr2:27980944	C/T	cg27432699	chr2:27873401	GPN1	-0.53	-6.94	-0.4	3.55e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs7582720	1.000	rs6705330	chr2:203662197	A/G	cg08076091	chr2:203926405	NBEAL1	0.84	8.35	0.47	5.01e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6782228	0.675	rs9813845	chr3:128399623	G/C	cg18648031	chr3:128330563	NA	0.27	5.62	0.34	5.09e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	trans	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg07393940	chr7:158741817	NA	0.46	6.29	0.37	1.48e-9	Life satisfaction;
KIRP	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.64	-8.4	-0.47	3.52e-15	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg07216194	chr8:27182965	PTK2B	0.43	5.37	0.32	1.79e-7	Neuroticism;
KIRP	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.57	7.42	0.43	1.9e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.74	-9.05	-0.5	4.42e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18252515	chr7:66147081	NA	0.48	5.58	0.34	6.39e-8	Aortic root size;
KIRP	cis	rs9308731	0.583	rs7596789	chr2:111932616	G/A	cg03171003	chr2:111875934	NA	0.42	5.74	0.34	2.78e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.74	8.33	0.47	5.57e-15	Corneal astigmatism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09837559	chr3:132182603	DNAJC13	-0.44	-6.59	-0.39	2.6200000000000003e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.83	0.49	2.04e-16	Motion sickness;
KIRP	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg18154014	chr19:37997991	ZNF793	0.74	7.83	0.45	1.41e-13	Coronary artery calcification;
KIRP	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.55	7.46	0.43	1.53e-12	Blood metabolite levels;
KIRP	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.76	8.83	0.49	2.04e-16	Corneal astigmatism;
KIRP	cis	rs7808935	0.914	rs11971132	chr7:27985867	G/C	cg22168087	chr7:27702803	HIBADH	0.77	7.92	0.45	8.26e-14	Prostate cancer;
KIRP	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg04111992	chr7:158790115	NA	-0.41	-5.35	-0.32	1.98e-7	Facial morphology (factor 20);
KIRP	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.65	-12.36	-0.62	1.27e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs58688157	0.572	rs936472	chr11:593453	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.49	-6.33	-0.37	1.18e-9	Systemic lupus erythematosus;
KIRP	cis	rs960902	0.747	rs62135566	chr2:37718930	C/T	cg25341268	chr2:37734390	NA	0.64	8.41	0.47	3.46e-15	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg25801113	chr15:45476975	SHF	-0.44	-8.15	-0.46	1.87e-14	Uric acid levels;
KIRP	trans	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	cg04338863	chr8:33670619	NA	0.48	6.61	0.39	2.32e-10	Body mass index;
KIRP	cis	rs7246657	0.722	rs2927742	chr19:38133618	T/C	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs78545713	0.649	rs77727979	chr6:26222026	T/A	cg01420254	chr6:26195488	NA	1.21	7.59	0.44	6.71e-13	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	8.9	0.49	1.24e-16	Platelet count;
KIRP	cis	rs7646881	0.812	rs73017541	chr3:158460796	T/G	cg19483011	chr3:158453295	NA	-0.55	-5.66	-0.34	4.15e-8	Tetralogy of Fallot;
KIRP	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.65	-7.99	-0.45	5.12e-14	Aortic root size;
KIRP	cis	rs2860975	0.936	rs1934973	chr10:96783601	A/C	cg09036531	chr10:96991505	NA	-0.52	-6.59	-0.39	2.65e-10	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.81	-14.68	-0.68	1.77e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg00405596	chr8:11794950	NA	-0.52	-6.84	-0.4	6.29e-11	Neuroticism;
KIRP	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4006360	0.554	rs1848810	chr17:39236025	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-8.66	-0.48	6.38e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18570751	chr11:61735315	FTH1	0.48	6.45	0.38	6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4664293	1.000	rs6432540	chr2:160450703	G/A	cg08347373	chr2:160653686	CD302	-0.38	-5.78	-0.35	2.26e-8	Monocyte percentage of white cells;
KIRP	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.49e-13	IgG glycosylation;
KIRP	cis	rs3112255	0.567	rs2942884	chr2:101323578	C/T	cg01042948	chr2:101319752	NA	0.44	6.81	0.4	7.27e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	1.08	9.36	0.51	5.11e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7267005	1.000	rs76821563	chr20:34487898	G/A	cg17201900	chr20:34330562	RBM39	0.91	5.16	0.31	5.05e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg10756647	chr7:56101905	PSPH	0.92	6.5	0.38	4.32e-10	Diabetic kidney disease;
KIRP	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.88	12.19	0.61	4.81e-27	Blood protein levels;
KIRP	cis	rs2456568	0.564	rs7119708	chr11:93626641	T/C	cg26875233	chr11:93583750	C11orf90	0.36	7.04	0.41	1.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23978390	chr7:1156363	C7orf50	0.59	8.07	0.46	3.05e-14	Longevity;Endometriosis;
KIRP	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg03235661	chr20:60525775	NA	-0.34	-5.16	-0.31	5.12e-7	Body mass index;
KIRP	trans	rs9650657	0.812	rs11250072	chr8:10632121	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.28	-0.37	1.55e-9	Neuroticism;
KIRP	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.53	-0.38	3.8e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs931127	0.658	rs4244812	chr11:65480768	A/G	cg11569703	chr11:65557185	OVOL1	0.46	8.03	0.46	4.06e-14	Systemic lupus erythematosus;
KIRP	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.44	6.76	0.4	1.01e-10	Multiple sclerosis;
KIRP	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-1.1	-22.11	-0.82	2.2e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Parkinson's disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18093693	chr15:72668265	HEXA;C15orf34	0.73	6.16	0.37	3.01e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs17666538	1.000	rs61122136	chr8:585027	G/C	cg07234876	chr8:600039	NA	-1.03	-6.29	-0.37	1.47e-9	IgG glycosylation;
KIRP	cis	rs8028182	0.636	rs8030802	chr15:75813153	A/G	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs4262150	0.810	rs72797203	chr5:151952877	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11987759	chr7:65425863	GUSB	0.47	6.02	0.36	6.33e-9	Aortic root size;
KIRP	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.45	-8.39	-0.47	3.79e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg02574844	chr11:5959923	NA	-0.57	-5.9	-0.35	1.18e-8	DNA methylation (variation);
KIRP	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg06671706	chr8:8559999	CLDN23	0.51	5.67	0.34	4.06e-8	Obesity-related traits;
KIRP	cis	rs7551222	0.714	rs930947	chr1:204541197	G/A	cg20240347	chr1:204465584	NA	-0.37	-6.22	-0.37	2.12e-9	Schizophrenia;
KIRP	cis	rs1122900	1.000	rs56039629	chr5:36683903	C/T	cg24186104	chr5:36689192	NA	-0.45	-7.36	-0.42	2.79e-12	Aggressive periodontitis;
KIRP	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.12	-0.36	3.64e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.41	-5.41	-0.33	1.47e-7	Body mass index;
KIRP	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg02297831	chr4:17616191	MED28	0.53	6.7	0.39	1.38e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg18209359	chr17:80159595	CCDC57	0.39	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.5	-7.0	-0.41	2.41e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg02336718	chr17:17403227	NA	0.39	6.25	0.37	1.82e-9	Total body bone mineral density;
KIRP	trans	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.75	-0.4	1.03e-10	Obesity-related traits;
KIRP	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg25173405	chr17:45401733	C17orf57	-0.43	-5.57	-0.33	6.7e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.45	-5.24	-0.32	3.53e-7	Reticulocyte count;
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13198984	chr17:80129470	CCDC57	0.56	8.55	0.48	1.32e-15	Life satisfaction;
KIRP	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.51	6.62	0.39	2.26e-10	Testicular germ cell tumor;
KIRP	cis	rs2594989	0.895	rs2594980	chr3:11381387	C/T	cg01796438	chr3:11312864	ATG7	-0.37	-4.86	-0.3	2.12e-6	Circulating chemerin levels;
KIRP	cis	rs2671245	0.933	rs1165478	chr1:56167918	A/G	cg11523071	chr1:56160889	NA	0.42	6.74	0.39	1.12e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs9398803	0.651	rs4895813	chr6:126975786	G/T	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.93e-7	Male-pattern baldness;
KIRP	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.66	6.56	0.39	3.14e-10	Menarche (age at onset);
KIRP	cis	rs240764	0.658	rs9377214	chr6:101212146	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-5.25	-0.32	3.32e-7	Neuroticism;
KIRP	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.58	-5.4	-0.33	1.54e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.8	8.21	0.46	1.23e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg21775007	chr8:11205619	TDH	-0.4	-5.31	-0.32	2.44e-7	Triglycerides;
KIRP	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.69	8.07	0.46	3.13e-14	Smoking initiation;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02758870	chr4:100871523	LOC256880;H2AFZ	0.46	6.1	0.36	4.02e-9	Parkinson's disease;
KIRP	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.35	-0.42	2.85e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg06795125	chr2:108905320	SULT1C2	-0.48	-8.37	-0.47	4.43e-15	Blood pressure;
KIRP	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg04267008	chr7:1944627	MAD1L1	0.47	5.03	0.31	9.48e-7	Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs897080	0.552	rs1067378	chr2:44648047	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.53	5.49	0.33	9.79e-8	Height;
KIRP	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20135002	chr11:47629003	NA	-0.47	-5.47	-0.33	1.1e-7	Subjective well-being;
KIRP	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg21698718	chr17:80085957	CCDC57	0.36	5.27	0.32	3.03e-7	Life satisfaction;
KIRP	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.29	-24.09	-0.84	1.11e-66	IgG glycosylation;
KIRP	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	12.57	0.63	2.57e-28	Monocyte percentage of white cells;
KIRP	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.85	-0.35	1.54e-8	Bipolar disorder;
KIRP	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.84	-9.36	-0.51	5.23e-18	Platelet count;
KIRP	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.23	0.51	1.28e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.28	-0.47	7.71e-15	Obesity-related traits;
KIRP	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.13	12.6	0.63	1.98e-28	Platelet count;
KIRP	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.26e-9	Schizophrenia;
KIRP	trans	rs61931739	0.620	rs7138912	chr12:33701863	G/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.09	-0.36	4.24e-9	Morning vs. evening chronotype;
KIRP	cis	rs9398803	0.723	rs2793051	chr6:127064918	C/T	cg19875578	chr6:126661172	C6orf173	-0.37	-4.85	-0.3	2.15e-6	Male-pattern baldness;
KIRP	cis	rs7116495	0.881	rs676721	chr11:71770638	G/A	cg26138937	chr11:71823887	C11orf51	-0.71	-5.64	-0.34	4.59e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs3779635	0.967	rs750538	chr8:27275726	G/T	cg21186296	chr8:27182909	PTK2B	0.43	5.47	0.33	1.09e-7	Neuroticism;
KIRP	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg07541023	chr7:19748670	TWISTNB	0.54	5.72	0.34	3.1e-8	Thyroid stimulating hormone;
KIRP	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.49	-6.01	-0.36	6.64e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6438504	0.922	rs4314161	chr3:118941098	G/A	cg25372693	chr3:118959985	B4GALT4	-0.32	-5.49	-0.33	1.02e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg08741688	chr4:3415352	RGS12	-0.46	-5.01	-0.3	1.06e-6	Serum sulfate level;
KIRP	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.4	5.19	0.31	4.41e-7	Neuroticism;
KIRP	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg00852783	chr1:26633632	UBXN11	-0.53	-5.41	-0.33	1.5e-7	Obesity-related traits;
KIRP	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg24699146	chr1:24152579	HMGCL	0.48	6.68	0.39	1.55e-10	Immature fraction of reticulocytes;
KIRP	cis	rs4363385	0.510	rs11588463	chr1:152901984	T/C	cg07796016	chr1:152779584	LCE1C	-0.44	-5.49	-0.33	9.76e-8	Inflammatory skin disease;
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg13198984	chr17:80129470	CCDC57	0.6	9.15	0.5	2.23e-17	Life satisfaction;
KIRP	cis	rs72820985	1.000	rs12443565	chr16:80842419	C/A	cg04448709	chr16:81349954	GAN	-0.49	-4.89	-0.3	1.81e-6	Breast cancer;
KIRP	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.29	28.07	0.87	1.16e-78	IgG glycosylation;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23679073	chr2:187350909	ZC3H15	0.48	6.38	0.38	8.83e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23903597	chr17:61704154	MAP3K3	-0.59	-7.34	-0.42	3.09e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg13660082	chr14:53194042	PSMC6	-0.75	-8.38	-0.47	4.14e-15	Alzheimer's disease (late onset);
KIRP	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg13319975	chr6:146136371	FBXO30	-0.45	-5.95	-0.35	9.13e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.65	-8.51	-0.48	1.77e-15	Blood metabolite levels;
KIRP	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.59	-7.16	-0.42	9.24e-12	Multiple sclerosis;
KIRP	cis	rs2019216	0.502	rs1842113	chr17:21872137	G/A	cg22648282	chr17:21454238	C17orf51	-0.51	-6.5	-0.38	4.53e-10	Pelvic organ prolapse;
KIRP	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.48	5.81	0.35	1.97e-8	Neuroticism;
KIRP	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.38	5.19	0.31	4.41e-7	Lewy body disease;
KIRP	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.86	-0.4	5.65e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg17376030	chr22:41985996	PMM1	-0.77	-8.15	-0.46	1.81e-14	Vitiligo;
KIRP	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.51	-6.67	-0.39	1.66e-10	Primary sclerosing cholangitis;
KIRP	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg23594656	chr7:65796392	TPST1	-0.51	-8.06	-0.46	3.3e-14	Aortic root size;
KIRP	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.74	8.75	0.49	3.45e-16	High light scatter reticulocyte count;
KIRP	cis	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.31	0.32	2.47e-7	Neuroticism;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.45	0.43	1.61e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg17524265	chr8:144659883	NAPRT1	0.8	5.21	0.31	4.08e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg16917193	chr12:54089295	NA	0.89	17.0	0.73	2.23e-43	Height;
KIRP	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.44	-5.13	-0.31	5.82e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg20387954	chr3:183756860	HTR3D	0.64	9.53	0.52	1.62e-18	Anterior chamber depth;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11184237	chr15:75748191	SIN3A	0.49	6.8	0.4	7.82e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3947	1.000	rs1736082	chr8:11703420	C/T	cg21775007	chr8:11205619	TDH	-0.47	-4.84	-0.3	2.26e-6	Blood protein levels;
KIRP	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg12549451	chr6:135224345	NA	0.42	5.07	0.31	7.82e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs796364	0.616	rs2103094	chr2:200687954	T/C	cg17644776	chr2:200775616	C2orf69	0.57	5.23	0.32	3.56e-7	Schizophrenia;
KIRP	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg13962347	chr6:5174647	LYRM4	-0.61	-8.33	-0.47	5.67e-15	Height;
KIRP	cis	rs4865169	0.595	rs4865165	chr4:57765546	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.4	-4.91	-0.3	1.65e-6	Breast cancer;
KIRP	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg12311346	chr5:56204834	C5orf35	-0.38	-5.23	-0.32	3.69e-7	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg09264619	chr17:80180166	NA	0.51	6.09	0.36	4.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2281603	0.951	rs12586212	chr14:64980047	T/C	cg25009451	chr14:65006716	HSPA2	0.48	5.21	0.32	4.05e-7	Lymphocyte counts;
KIRP	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.59	-0.34	5.93e-8	Neuroticism;
KIRP	cis	rs11997175	0.524	rs12164218	chr8:33669658	G/C	cg04338863	chr8:33670619	NA	0.46	5.45	0.33	1.23e-7	Body mass index;
KIRP	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.23e-15	Skin colour saturation;
KIRP	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.83	9.13	0.5	2.66e-17	Platelet count;
KIRP	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.25	0.42	5.39e-12	Bipolar disorder;
KIRP	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg23920097	chr1:209922102	NA	-0.45	-5.39	-0.33	1.62e-7	Red blood cell count;
KIRP	trans	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg18016565	chr1:150552671	MCL1	0.36	5.51	0.33	8.88e-8	Tonsillectomy;
KIRP	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.53	6.16	0.37	3.03e-9	Blood metabolite levels;
KIRP	cis	rs10802346	0.636	rs4548405	chr1:246393283	A/G	cg15962031	chr1:246363574	SMYD3	0.76	5.57	0.33	6.66e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-9.62	-0.52	8.72e-19	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg04369109	chr6:150039330	LATS1	-0.63	-8.12	-0.46	2.27e-14	Lung cancer;
KIRP	cis	rs9815354	0.638	rs73073267	chr3:42021163	A/T	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.76	0.34	2.56e-8	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10791954	chr19:54641515	CNOT3	0.55	7.0	0.41	2.48e-11	Parkinson's disease;
KIRP	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.68	-9.2	-0.51	1.56e-17	Huntington's disease progression;
KIRP	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.86	13.0	0.64	9.27e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg13319975	chr6:146136371	FBXO30	0.46	6.18	0.37	2.65e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.61	-9.02	-0.5	5.46e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03508928	chr3:47324552	KIF9;KLHL18	0.55	6.97	0.41	2.93e-11	Parkinson's disease;
KIRP	cis	rs73193808	0.627	rs2832218	chr21:30524185	T/G	cg23789846	chr21:30375227	NA	0.78	5.08	0.31	7.43e-7	Coronary artery disease;
KIRP	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg03855291	chr11:639423	DRD4	-0.34	-4.9	-0.3	1.71e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7215564	0.730	rs34579757	chr17:78700077	G/A	cg06153925	chr17:78755379	RPTOR	0.47	6.26	0.37	1.74e-9	Myopia (pathological);
KIRP	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg05997131	chr22:39077908	TOMM22	-0.45	-4.95	-0.3	1.35e-6	Menopause (age at onset);
KIRP	cis	rs12725198	1.000	rs12725833	chr1:16080618	G/A	cg26036626	chr1:16085597	FBLIM1	-0.36	-4.94	-0.3	1.47e-6	Cardiac Troponin-T levels;
KIRP	cis	rs7224685	0.501	rs812996	chr17:3965674	T/C	cg09695851	chr17:3907499	NA	0.82	15.2	0.7	2.96e-37	Type 2 diabetes;
KIRP	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.95	-0.41	3.25e-11	Hemoglobin concentration;
KIRP	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.64	9.36	0.51	5.15e-18	Hip circumference;
KIRP	cis	rs13102973	0.645	rs6535055	chr4:135886101	A/C	cg14419869	chr4:135874104	NA	0.4	6.34	0.37	1.09e-9	Subjective well-being;
KIRP	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg14972814	chr11:95582409	MTMR2	0.29	5.0	0.3	1.09e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.36	-5.49	-0.33	1e-7	Body mass index;
KIRP	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.19	-0.37	2.52e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.87	14.06	0.67	2.44e-33	Blood protein levels;
KIRP	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg18306943	chr3:40428807	ENTPD3	0.41	5.73	0.34	2.91e-8	Renal cell carcinoma;
KIRP	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.46	7.44	0.43	1.69e-12	Testicular germ cell tumor;
KIRP	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.62	-7.63	-0.44	5.24e-13	Colorectal cancer;
KIRP	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.77	0.53	2.93e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg12559939	chr2:27858050	GPN1	-0.4	-4.92	-0.3	1.56e-6	Total body bone mineral density;
KIRP	cis	rs4517514	0.509	rs2156434	chr11:89896417	A/G	cg06174606	chr11:89959870	NA	-0.57	-5.91	-0.35	1.11e-8	Trans fatty acid levels;
KIRP	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.79	-14.1	-0.67	1.78e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg25486957	chr4:152246857	NA	-0.54	-5.83	-0.35	1.72e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6001982	0.667	rs6001935	chr22:40886993	T/C	cg07138101	chr22:40742427	ADSL	0.7	5.62	0.34	5.15e-8	Breast cancer;
KIRP	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg11382394	chr1:2564504	MMEL1	-0.45	-5.74	-0.34	2.83e-8	Ulcerative colitis;
KIRP	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.76	11.48	0.59	1.06e-24	Hip circumference;
KIRP	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.5	5.22	0.32	3.88e-7	Subjective well-being;
KIRP	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	1.09	8.24	0.47	1.01e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.57	9.59	0.52	1.01e-18	Lung cancer;
KIRP	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg22541963	chr20:60982533	CABLES2	-0.41	-5.12	-0.31	6.06e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg17885191	chr8:135476712	NA	0.51	6.05	0.36	5.39e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs975752	0.867	rs7358099	chr10:101955002	A/T	cg13817732	chr10:102046368	BLOC1S2	-0.7	-5.89	-0.35	1.24e-8	Schizophrenia;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg00879184	chr10:21823423	MLLT10	-0.5	-6.05	-0.36	5.37e-9	Migraine with aura;
KIRP	cis	rs7404928	0.681	rs59790099	chr16:23869285	G/A	cg21745164	chr16:23765304	CHP2	-0.52	-6.51	-0.38	4.29e-10	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg21775007	chr8:11205619	TDH	-0.53	-6.86	-0.4	5.68e-11	Neuroticism;
KIRP	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg07142400	chr12:6602447	NCAPD2;MRPL51	-0.54	-5.27	-0.32	2.94e-7	Hip geometry;
KIRP	cis	rs988913	0.914	rs9396006	chr6:54787888	G/A	cg03513858	chr6:54763001	FAM83B	-0.39	-5.48	-0.33	1.05e-7	Menarche (age at onset);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22596895	chr1:93602507	MTF2	-0.41	-6.03	-0.36	6.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs865483	0.895	rs853211	chr17:35828164	T/C	cg06716730	chr17:35851459	DUSP14	0.25	6.08	0.36	4.64e-9	Monocyte count;
KIRP	cis	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg21546286	chr11:48923668	NA	0.47	5.97	0.36	8.24e-9	HDL cholesterol;
KIRP	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.26	-0.37	1.68e-9	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg26784012	chr10:32216390	ARHGAP12	0.31	4.97	0.3	1.25e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.97	10.42	0.55	2.69e-21	Type 2 diabetes nephropathy;
KIRP	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg08021120	chr3:195498017	MUC4	-0.53	-4.93	-0.3	1.55e-6	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.61	-7.62	-0.44	5.45e-13	Breast cancer;
KIRP	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-6.35	-0.38	1.05e-9	Common traits (Other);
KIRP	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12560992	chr17:57184187	TRIM37	0.61	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.62	-9.31	-0.51	7.61e-18	Body mass index;
KIRP	cis	rs6939532	0.544	rs10946816	chr6:26361946	C/G	cg12826209	chr6:26865740	GUSBL1	0.46	5.31	0.32	2.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg00405596	chr8:11794950	NA	-0.37	-5.07	-0.31	8e-7	Neuroticism;
KIRP	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.71	9.05	0.5	4.61e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-0.57	-8.71	-0.49	4.54e-16	Trans fatty acid levels;
KIRP	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.67	-9.18	-0.51	1.85e-17	Breast cancer;
KIRP	cis	rs1784581	0.599	rs1789992	chr6:162401854	A/G	cg17173639	chr6:162384350	PARK2	-0.59	-9.4	-0.51	3.99e-18	Itch intensity from mosquito bite;
KIRP	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.5	-5.12	-0.31	6.02e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.09	0.36	4.3e-9	Alzheimer's disease (late onset);
KIRP	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.91	15.76	0.71	3.59e-39	Headache;
KIRP	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg08462924	chr1:41848221	NA	0.49	6.81	0.4	7.32e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.8	10.35	0.55	4.36e-21	Platelet count;
KIRP	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg21926883	chr2:100939477	LONRF2	-0.59	-8.64	-0.48	7.41e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.63	-8.2	-0.46	1.34e-14	Obesity-related traits;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg17422427	chr2:241507521	RNPEPL1	0.48	6.03	0.36	6.11e-9	Asthma;
KIRP	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg11657323	chr11:64116250	CCDC88B	-0.41	-5.67	-0.34	3.89e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg13206674	chr6:150067644	NUP43	0.52	7.4	0.43	2.22e-12	Testicular germ cell tumor;
KIRP	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg04990556	chr1:26633338	UBXN11	0.68	6.63	0.39	2.12e-10	Obesity-related traits;
KIRP	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26207909	chr14:103986467	CKB	0.54	7.13	0.41	1.09e-11	Body mass index;
KIRP	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg10503236	chr1:231470652	EXOC8	0.48	6.28	0.37	1.48e-9	Red blood cell count;
KIRP	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg20607798	chr8:58055168	NA	0.59	5.45	0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.43	5.05	0.31	8.58e-7	Tonsillectomy;
KIRP	cis	rs829661	0.656	rs9636423	chr2:30686039	G/A	cg10949345	chr2:30726833	LCLAT1	0.54	7.15	0.41	1.01e-11	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6725041	0.542	rs17344880	chr2:213046616	C/T	cg20637307	chr2:213403960	ERBB4	-0.42	-5.65	-0.34	4.49e-8	QT interval (ambient particulate matter interaction);
KIRP	cis	rs72829446	0.530	rs17732878	chr17:7362359	C/T	cg02795151	chr17:7402630	POLR2A	-0.77	-7.79	-0.44	1.92e-13	Androgen levels;
KIRP	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.9	-11.94	-0.61	3.29e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg08097877	chr11:29180890	NA	0.44	6.19	0.37	2.47e-9	Survival in pancreatic cancer;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.61	-8.32	-0.47	6.11e-15	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00358451	chr1:249141919	ZNF672	-0.42	-6.15	-0.37	3.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6142102	0.962	rs2206448	chr20:32709525	G/A	cg08999081	chr20:33150536	PIGU	0.49	6.38	0.38	8.63e-10	Skin pigmentation;
KIRP	cis	rs4006360	0.577	rs4986669	chr17:39250341	C/A	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-1.32	-13.07	-0.64	5.24e-30	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs12282928	0.959	rs1483122	chr11:48327186	T/A	cg26585981	chr11:48327164	OR4S1	-0.49	-5.86	-0.35	1.49e-8	Migraine - clinic-based;
KIRP	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.33	0.59	3.17e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.21	0.61	3.91e-27	Ileal carcinoids;
KIRP	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg23173402	chr1:227635558	NA	0.63	5.14	0.31	5.52e-7	Major depressive disorder;
KIRP	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg03060546	chr3:49711283	APEH	0.45	5.78	0.35	2.24e-8	Parkinson's disease;
KIRP	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.75	9.21	0.51	1.44e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.64	8.01	0.46	4.47e-14	Breast cancer;
KIRP	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.59	7.77	0.44	2.08e-13	Bladder cancer;
KIRP	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg24807547	chr6:37504484	NA	-0.4	-5.23	-0.32	3.58e-7	Cognitive performance;
KIRP	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-12.35	-0.62	1.4e-27	Cognitive function;
KIRP	cis	rs75920871	0.528	rs7935834	chr11:116944437	C/G	cg04087571	chr11:116723030	SIK3	-0.25	-5.24	-0.32	3.48e-7	Subjective well-being;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02199070	chr1:70031930	NA	0.38	6.09	0.36	4.42e-9	Warfarin maintenance dose;
KIRP	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg06026331	chr20:60912101	LAMA5	-0.47	-6.28	-0.37	1.5e-9	Colorectal cancer;
KIRP	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.73	9.44	0.52	2.98e-18	Response to antipsychotic treatment;
KIRP	cis	rs11134338	0.565	rs1379566	chr5:9019532	A/G	cg18330338	chr5:9047211	SEMA5A	-0.36	-4.91	-0.3	1.66e-6	Obesity-related traits;
KIRP	cis	rs2599510	0.811	rs2710615	chr2:32791222	A/T	cg02381751	chr2:32503542	YIPF4	0.46	5.23	0.32	3.61e-7	Interleukin-18 levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07987262	chr19:19314408	NR2C2AP	0.52	6.4	0.38	7.89e-10	Parkinson's disease;
KIRP	cis	rs807669	0.935	rs712963	chr22:19156543	A/G	cg02655711	chr22:19163373	SLC25A1	0.8	13.15	0.64	2.84e-30	Metabolite levels;
KIRP	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.5	-5.48	-0.33	1.05e-7	Depression;
KIRP	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.57	7.6	0.44	6.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.64	9.41	0.51	3.8e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg03433033	chr1:76189801	ACADM	0.5	7.4	0.43	2.21e-12	Daytime sleep phenotypes;
KIRP	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.62	-7.31	-0.42	3.66e-12	Height;
KIRP	cis	rs2574975	0.651	rs2574956	chr10:52124468	C/T	cg10034176	chr10:52120283	SGMS1	-0.54	-7.41	-0.43	2.08e-12	Response to amphetamines;
KIRP	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg17524265	chr8:144659883	NAPRT1	0.79	5.05	0.31	8.58e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs966423	0.550	rs4674176	chr2:218301119	C/G	cg15335768	chr2:218268053	DIRC3	0.41	5.98	0.36	7.82e-9	Thyroid cancer;
KIRP	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.71	10.72	0.56	2.97e-22	Lewy body disease;
KIRP	cis	rs258892	0.842	rs34956	chr5:72203696	T/C	cg21869765	chr5:72125136	TNPO1	0.58	6.41	0.38	7.55e-10	Small cell lung carcinoma;
KIRP	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.79	9.18	0.51	1.77e-17	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01560739	chr3:32023198	OSBPL10;ZNF860	0.46	6.5	0.38	4.44e-10	Parkinson's disease;
KIRP	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.73	-9.18	-0.51	1.78e-17	Aortic root size;
KIRP	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.51	6.23	0.37	2.06e-9	Menopause (age at onset);
KIRP	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg07511668	chr11:68622177	NA	-0.35	-5.03	-0.31	9.36e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26818010	chr10:134567672	INPP5A	-0.77	-8.71	-0.49	4.51e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	0.98	15.14	0.69	4.74e-37	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg04865290	chr3:52927548	TMEM110	-0.62	-6.81	-0.4	7.65e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-13.22	-0.64	1.66e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9653442	0.545	rs4850921	chr2:100762699	G/T	cg22139774	chr2:100720529	AFF3	-0.35	-5.48	-0.33	1.06e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.82	6.68	0.39	1.55e-10	Initial pursuit acceleration;
KIRP	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-0.59	-8.97	-0.5	7.68e-17	Trans fatty acid levels;
KIRP	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg14768367	chr16:72042858	DHODH	-0.88	-9.61	-0.52	9.26e-19	Blood protein levels;
KIRP	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.87	10.3	0.55	6.21e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	7.84	0.45	1.36e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2016266	0.502	rs7398676	chr12:53630558	A/C	cg04065151	chr12:53682969	ESPL1	0.4	5.01	0.3	1.06e-6	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.74	9.08	0.5	3.55e-17	Monocyte percentage of white cells;
KIRP	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg07424592	chr7:64974309	NA	0.75	4.89	0.3	1.84e-6	Diabetic kidney disease;
KIRP	cis	rs526231	0.543	rs246901	chr5:102584178	G/A	cg23492399	chr5:102201601	PAM	-0.59	-6.2	-0.37	2.4e-9	Primary biliary cholangitis;
KIRP	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg19913688	chr11:428466	ANO9	-0.66	-4.96	-0.3	1.34e-6	Body mass index;
KIRP	cis	rs7106204	0.514	rs7118022	chr11:24253352	C/T	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs4594175	0.886	rs11157801	chr14:51622918	C/T	cg23942311	chr14:51606299	NA	0.52	6.75	0.4	1.06e-10	Cancer;
KIRP	cis	rs6504622	0.905	rs736603	chr17:45024745	G/T	cg24703533	chr17:45055318	NA	0.38	5.28	0.32	2.86e-7	Orofacial clefts;
KIRP	cis	rs7845219	0.544	rs4735330	chr8:95917770	A/C	cg23172400	chr8:95962367	TP53INP1	-0.31	-6.17	-0.37	2.84e-9	Type 2 diabetes;
KIRP	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.53	7.15	0.41	9.89e-12	Mean corpuscular volume;
KIRP	trans	rs1952138	0.561	rs2038916	chr10:53262141	A/G	cg05871607	chr1:28241317	RPA2	0.58	6.49	0.38	4.74e-10	IgG glycosylation;
KIRP	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	6.77	0.4	9.39e-11	Menarche (age at onset);
KIRP	trans	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg24644049	chr4:85504048	CDS1	0.93	6.87	0.4	5.17e-11	Skin colour saturation;
KIRP	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.27e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.87	14.16	0.67	1.06e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.99	-16.13	-0.72	1.95e-40	Chronic sinus infection;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08377569	chr16:30538014	ZNF768	-0.48	-6.58	-0.39	2.89e-10	Metabolic traits;
KIRP	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18252515	chr7:66147081	NA	-0.44	-5.44	-0.33	1.31e-7	Aortic root size;
KIRP	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg11584989	chr19:19387371	SF4	-0.41	-5.23	-0.32	3.59e-7	Tonsillectomy;
KIRP	cis	rs10267417	0.603	rs10245287	chr7:19938738	C/G	cg05791153	chr7:19748676	TWISTNB	-0.48	-5.1	-0.31	6.76e-7	Night sleep phenotypes;
KIRP	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.58	0.39	2.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs494562	0.892	rs7750970	chr6:86128570	A/T	cg21730993	chr6:86159210	NT5E	0.51	5.19	0.31	4.35e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg09597638	chr17:3907349	NA	-0.75	-14.32	-0.67	3.12e-34	Type 2 diabetes;
KIRP	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	0.7	6.5	0.38	4.39e-10	Obesity-related traits;
KIRP	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg12384639	chr17:618140	VPS53	-0.48	-6.0	-0.36	6.91e-9	Prostate cancer;
KIRP	cis	rs9900972	0.721	rs11656224	chr17:76867996	A/G	cg00961940	chr17:76876995	TIMP2	0.52	6.5	0.38	4.47e-10	Obesity-related traits;
KIRP	cis	rs16976116	0.806	rs117064453	chr15:55492319	T/A	cg11288833	chr15:55489084	RSL24D1	0.67	7.35	0.42	3.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.93	13.9	0.66	8.54e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.6	9.79	0.53	2.58e-19	Total body bone mineral density;
KIRP	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.41	-5.19	-0.31	4.33e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1629083	0.790	rs1613643	chr11:118068521	T/G	cg18857871	chr11:118064634	AMICA1	0.74	10.69	0.56	3.62e-22	Lung cancer;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18252515	chr7:66147081	NA	0.46	5.48	0.33	1.04e-7	Aortic root size;
KIRP	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.91	12.35	0.62	1.41e-27	Triglycerides;
KIRP	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg21051989	chr6:90121833	RRAGD	-0.46	-6.06	-0.36	5.2e-9	Myopia;
KIRP	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.74	8.57	0.48	1.17e-15	High light scatter reticulocyte count;
KIRP	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-7.87	-0.45	1.1e-13	Personality dimensions;
KIRP	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.53	-7.54	-0.43	8.84e-13	Breast cancer;
KIRP	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.89	14.0	0.67	3.84e-33	Mean corpuscular volume;
KIRP	cis	rs7481311	0.956	rs6484311	chr11:27531764	G/A	cg18117895	chr11:27722066	BDNF	0.47	5.15	0.31	5.32e-7	Body mass index;Weight;
KIRP	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.24	-0.62	3.21e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg24253500	chr15:84953950	NA	0.63	6.64	0.39	2.03e-10	Bipolar disorder lithium response (categorical) or schizophrenia;
KIRP	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg08738300	chr3:44038990	NA	0.68	9.56	0.52	1.28e-18	Coronary artery disease;
KIRP	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg07701084	chr6:150067640	NUP43	0.64	8.24	0.46	1.05e-14	Lung cancer;
KIRP	cis	rs9488822	0.676	rs13210143	chr6:116389636	G/A	cg18764771	chr6:116381957	FRK	0.18	4.92	0.3	1.61e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	8.82	0.49	2.11e-16	Colorectal cancer;
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.57	7.62	0.44	5.34e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.72	7.06	0.41	1.68e-11	Methadone dose in opioid dependence;
KIRP	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg20243544	chr17:37824526	PNMT	0.49	6.72	0.39	1.24e-10	Asthma;
KIRP	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00149659	chr3:10157352	C3orf10	-0.59	-7.04	-0.41	1.86e-11	Alzheimer's disease;
KIRP	cis	rs6540559	0.611	rs17015226	chr1:209970096	C/G	cg22029157	chr1:209979665	IRF6	0.5	5.96	0.36	8.47e-9	Cleft lip with or without cleft palate;
KIRP	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.8	8.37	0.47	4.3e-15	Cerebrospinal P-tau181p levels;
KIRP	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg08668510	chr10:1095578	IDI1	0.79	5.38	0.32	1.69e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	1.02	10.21	0.55	1.22e-20	Psoriasis;
KIRP	cis	rs7601312	0.967	rs6758459	chr2:229308855	C/T	cg02542817	chr2:229291442	NA	-0.37	-5.28	-0.32	2.87e-7	Schizophrenia;
KIRP	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.83	-13.85	-0.66	1.22e-32	Brugada syndrome;
KIRP	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.75	8.53	0.48	1.52e-15	Corneal astigmatism;
KIRP	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.66	-0.44	4.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg05673287	chr15:77411982	SGK269	-0.39	-4.88	-0.3	1.86e-6	Type 2 diabetes;
KIRP	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg07382826	chr16:28625726	SULT1A1	0.48	5.56	0.33	7.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-14.23	-0.67	6.09e-34	Gut microbiome composition (summer);
KIRP	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.79	11.35	0.59	2.84e-24	Blood metabolite levels;
KIRP	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg20240347	chr1:204465584	NA	-0.4	-7.67	-0.44	3.94e-13	Schizophrenia;
KIRP	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	8.12	0.46	2.2e-14	IgG glycosylation;
KIRP	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.81	-0.49	2.23e-16	Triglycerides;
KIRP	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	26.1	0.86	7.88e-73	Chronic sinus infection;
KIRP	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.54	-7.89	-0.45	1.02e-13	Diisocyanate-induced asthma;
KIRP	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg10932868	chr11:921992	NA	0.65	8.76	0.49	3.21e-16	Alzheimer's disease (late onset);
KIRP	cis	rs2294693	0.581	rs4714426	chr6:41017596	C/G	cg14769373	chr6:40998127	UNC5CL	-0.42	-4.86	-0.3	2.07e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.8	6.95	0.41	3.23e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.75	6.75	0.4	1.08e-10	Diabetic retinopathy;
KIRP	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg24488311	chr11:68621650	NA	0.43	5.03	0.31	9.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg17757837	chr7:157058334	UBE3C	0.78	10.43	0.55	2.54e-21	Body mass index;
KIRP	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.83	9.78	0.53	2.8e-19	Post bronchodilator FEV1;
KIRP	cis	rs2274273	0.686	rs17253695	chr14:55574610	A/T	cg04306507	chr14:55594613	LGALS3	-0.41	-5.45	-0.33	1.21e-7	Protein biomarker;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10532362	chr17:39992352	NT5C3L	-0.48	-6.18	-0.37	2.61e-9	Myopia;
KIRP	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.48	-0.38	4.96e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg03308469	chr5:72924940	RGNEF	0.44	6.3	0.37	1.34e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs10267417	0.535	rs117655512	chr7:19944403	T/G	cg05791153	chr7:19748676	TWISTNB	0.51	5.12	0.31	6.3e-7	Night sleep phenotypes;
KIRP	cis	rs7714670	0.817	rs6453022	chr5:73076511	C/A	cg04480106	chr5:72934606	RGNEF	-0.39	-5.18	-0.31	4.56e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.73	8.26	0.47	9.03e-15	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg09264619	chr17:80180166	NA	-0.39	-5.67	-0.34	3.97e-8	Life satisfaction;
KIRP	cis	rs3105593	1.000	rs3131589	chr15:50841053	G/C	cg05456662	chr15:50716270	USP8	0.4	4.93	0.3	1.49e-6	QT interval;
KIRP	cis	rs860295	0.702	rs10796946	chr1:155429490	A/T	cg02153340	chr1:155202674	NA	-0.56	-7.68	-0.44	3.69e-13	Body mass index;
KIRP	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg23307798	chr14:103986281	CKB	0.76	13.18	0.64	2.21e-30	Body mass index;
KIRP	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg18882449	chr10:104885122	NT5C2	-0.5	-6.41	-0.38	7.5e-10	Arsenic metabolism;
KIRP	cis	rs12780845	1.000	rs7072634	chr10:17240918	C/A	cg01003015	chr10:17271136	VIM	0.46	4.96	0.3	1.29e-6	Homocysteine levels;
KIRP	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg10977910	chr1:84465055	TTLL7	0.44	5.3	0.32	2.54e-7	Obesity-related traits;
KIRP	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg13852791	chr20:30311386	BCL2L1	0.63	6.54	0.38	3.61e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg21361702	chr7:150065534	REPIN1	0.58	5.69	0.34	3.57e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs970548	0.643	rs7068039	chr10:45932264	T/C	cg15590007	chr10:45870220	ALOX5	0.43	4.97	0.3	1.23e-6	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
KIRP	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg02023728	chr11:77925099	USP35	0.33	5.33	0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg00579200	chr11:133705235	NA	-0.39	-4.92	-0.3	1.56e-6	Childhood ear infection;
KIRP	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.51	5.78	0.35	2.21e-8	Coronary artery disease;
KIRP	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg00074818	chr8:8560427	CLDN23	0.41	6.53	0.38	3.83e-10	Obesity-related traits;
KIRP	cis	rs897080	0.515	rs1067343	chr2:44621042	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	6.24	0.37	1.85e-9	Height;
KIRP	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg07689907	chr11:61582574	FADS1	0.47	5.9	0.35	1.23e-8	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg00334542	chr7:100209784	MOSPD3	-0.79	-6.42	-0.38	7.16e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.44	-5.21	-0.32	3.97e-7	Tonsillectomy;
KIRP	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.28	-0.51	8.84e-18	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6504663	0.558	rs2412325	chr17:48546232	G/C	cg00901687	chr17:48585270	MYCBPAP	0.45	6.15	0.37	3.11e-9	Visceral fat;
KIRP	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg02503808	chr4:7069936	GRPEL1	0.44	5.22	0.32	3.76e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.45	-0.33	1.19e-7	Colorectal cancer;
KIRP	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg25039879	chr17:56429692	SUPT4H1	0.62	5.48	0.33	1.06e-7	Cognitive test performance;
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	12.83	0.63	3.31e-29	Platelet count;
KIRP	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.85	-8.45	-0.47	2.61e-15	Coronary artery calcification;
KIRP	cis	rs7945071	0.851	rs2724438	chr11:110295881	T/A	cg04157658	chr11:110243994	NA	0.36	4.96	0.3	1.31e-6	Cognitive function;
KIRP	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.42	5.29	0.32	2.71e-7	Cystic fibrosis severity;
KIRP	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-6.59	-0.39	2.73e-10	Developmental language disorder (linguistic errors);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05527272	chr21:45079307	HSF2BP;RRP1B	0.43	6.04	0.36	5.78e-9	Survival in pancreatic cancer;
KIRP	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg08975724	chr8:8085496	FLJ10661	-0.67	-8.22	-0.46	1.15e-14	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04588972	chr19:51339405	NA	0.45	6.49	0.38	4.7e-10	Parkinson's disease;
KIRP	cis	rs6746082	0.550	rs682888	chr2:25757709	T/C	cg23192403	chr2:25781496	DTNB	-0.26	-5.18	-0.31	4.56e-7	Multiple myeloma;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg18927565	chr5:110847930	STARD4	-0.48	-6.4	-0.38	7.74e-10	Myopia;
KIRP	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg25600027	chr14:23388339	RBM23	-0.51	-6.22	-0.37	2.16e-9	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.72	9.86	0.53	1.49e-19	Mean corpuscular volume;
KIRP	cis	rs6539288	0.691	rs10746071	chr12:107353595	C/T	cg15890332	chr12:107067104	RFX4	-0.33	-5.52	-0.33	8.68e-8	Total body bone mineral density;
KIRP	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.68	-9.56	-0.52	1.28e-18	Rheumatoid arthritis;
KIRP	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg24060327	chr5:131705240	SLC22A5	0.42	5.3	0.32	2.59e-7	Breast cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25474507	chr19:18335359	PDE4C	-0.5	-6.19	-0.37	2.49e-9	Interleukin-4 levels;
KIRP	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.3	-0.32	2.57e-7	Neutrophil percentage of white cells;
KIRP	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15369054	chr17:80825471	TBCD	0.74	8.55	0.48	1.29e-15	Breast cancer;
KIRP	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.11	-0.5	2.86e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs57994353	0.600	rs13295852	chr9:139308426	G/A	cg21253087	chr9:139290292	SNAPC4	0.54	5.46	0.33	1.14e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg23522862	chr17:79829415	ARHGDIA	0.51	6.03	0.36	5.95e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.68	5.21	0.32	3.99e-7	Major depressive disorder;
KIRP	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg00553149	chr7:99775558	STAG3;GPC2	-0.45	-5.64	-0.34	4.77e-8	Coronary artery disease;
KIRP	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg02475777	chr4:1388615	CRIPAK	-0.55	-5.29	-0.32	2.69e-7	Recombination rate (females);
KIRP	cis	rs12435908	0.748	rs12437427	chr14:65987200	C/T	cg23373153	chr14:65346875	NA	-0.53	-4.89	-0.3	1.8e-6	Ischemic stroke;
KIRP	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg14972814	chr11:95582409	MTMR2	0.35	5.78	0.35	2.21e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	9.83	0.53	1.89e-19	Coffee consumption (cups per day);
KIRP	cis	rs6499255	0.951	rs10454066	chr16:69699005	A/T	cg15192750	chr16:69999425	NA	0.47	5.09	0.31	7.23e-7	IgE levels;
KIRP	cis	rs6466055	0.589	rs6950894	chr7:104652671	G/A	cg04380332	chr7:105027541	SRPK2	0.4	5.33	0.32	2.26e-7	Schizophrenia;
KIRP	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	1.04	13.11	0.64	3.86e-30	Exhaled nitric oxide output;
KIRP	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-8.57	-0.48	1.17e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg19773385	chr1:10388646	KIF1B	-0.7	-9.52	-0.52	1.75e-18	Hepatocellular carcinoma;
KIRP	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg16691251	chr5:66510806	NA	0.43	5.62	0.34	5.03e-8	Breast cancer;
KIRP	cis	rs11239930	0.517	rs3011809	chr1:146549141	G/A	cg16700924	chr1:146552102	NA	-0.44	-4.86	-0.3	2.06e-6	AIDS progression;
KIRP	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg26022315	chr17:47021804	SNF8	0.42	5.49	0.33	9.96e-8	Type 2 diabetes;
KIRP	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-11.98	-0.61	2.39e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg01475377	chr6:109611718	NA	-0.37	-5.07	-0.31	7.66e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs4742903	0.935	rs4587392	chr9:106972508	G/A	cg14250997	chr9:106856677	SMC2	0.37	4.89	0.3	1.8e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs16828019	0.852	rs71648534	chr1:41613747	G/T	cg18742814	chr1:41828276	NA	0.66	5.77	0.35	2.37e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-5.76	-0.34	2.49e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs756777	0.878	rs56683818	chr9:136664457	T/C	cg14069709	chr9:136671979	VAV2	-0.46	-5.31	-0.32	2.48e-7	IgG glycosylation;
KIRP	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.91	-14.67	-0.68	2.05e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs11212617	1.000	rs624366	chr11:108154097	C/G	cg21628297	chr11:107977510	CUL5	-0.29	-4.85	-0.3	2.16e-6	Response to metformin in type 2 diabetes (glycemic);
KIRP	cis	rs62229266	0.605	rs2835275	chr21:37460001	C/T	cg12218747	chr21:37451666	NA	-0.58	-8.37	-0.47	4.34e-15	Mitral valve prolapse;
KIRP	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.75	0.4	1.08e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs73200209	0.744	rs41452748	chr12:116509432	A/T	cg01776926	chr12:116560359	MED13L	-0.55	-6.13	-0.36	3.53e-9	Total body bone mineral density;
KIRP	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.97	-16.73	-0.73	1.84e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.63	0.44	5.01e-13	Iron status biomarkers;
KIRP	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	1.07	22.78	0.82	1.54e-62	Parkinson's disease;
KIRP	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.07	-18.88	-0.77	9.72e-50	Schizophrenia;
KIRP	trans	rs12517041	1.000	rs1820748	chr5:23323355	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.86	-7.59	-0.44	6.79e-13	Calcium levels;
KIRP	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg23682824	chr7:23144976	KLHL7	0.47	5.69	0.34	3.52e-8	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg20993868	chr7:22813445	NA	0.63	9.17	0.5	1.91e-17	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg17425144	chr1:10567563	PEX14	0.31	5.45	0.33	1.24e-7	Hepatocellular carcinoma;
KIRP	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg10503236	chr1:231470652	EXOC8	0.46	6.51	0.38	4.2e-10	Hemoglobin concentration;
KIRP	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	9.35	0.51	5.8e-18	Mood instability;
KIRP	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.45	-5.53	-0.33	8.32e-8	Childhood ear infection;
KIRP	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.56	7.61	0.44	5.78e-13	Gout;
KIRP	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg25338242	chr13:114786047	RASA3	0.41	4.85	0.3	2.23e-6	Schizophrenia;
KIRP	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs78487399	0.908	rs11904361	chr2:43848664	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-5.05	-0.31	8.79e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg19500275	chr17:80737654	TBCD	-0.5	-6.06	-0.36	4.97e-9	Glycated hemoglobin levels;
KIRP	cis	rs1595825	0.891	rs6707521	chr2:198713231	A/G	cg00361562	chr2:198649771	BOLL	0.53	5.2	0.31	4.28e-7	Ulcerative colitis;
KIRP	cis	rs1950626	0.623	rs3742401	chr14:101453344	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.53	6.14	0.36	3.37e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.58	8.99	0.5	6.65e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.76	-10.16	-0.54	1.81e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.7	7.06	0.41	1.67e-11	Menarche (age at onset);
KIRP	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs6669119	0.668	rs75509607	chr1:19093763	C/T	cg26220594	chr1:19110978	NA	0.66	6.02	0.36	6.47e-9	Percentage gas trapping;
KIRP	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg07636037	chr3:49044803	WDR6	0.57	5.41	0.33	1.53e-7	Menarche (age at onset);
KIRP	cis	rs4073221	0.860	rs17403715	chr3:18254381	C/T	cg07694806	chr3:18168406	NA	-0.71	-6.4	-0.38	7.77e-10	Parkinson's disease;
KIRP	cis	rs17666538	1.000	rs73177066	chr8:585750	C/T	cg02524346	chr8:600233	NA	-0.92	-5.63	-0.34	4.95e-8	IgG glycosylation;
KIRP	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.42	5.71	0.34	3.24e-8	Night sleep phenotypes;
KIRP	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.92	-0.4	3.89e-11	Type 2 diabetes;
KIRP	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg26518628	chr1:97050305	NA	-0.84	-8.67	-0.48	6.01e-16	Cannabis dependence symptom count;
KIRP	trans	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.34	0.37	1.1e-9	Retinal vascular caliber;
KIRP	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg07689907	chr11:61582574	FADS1	0.48	6.07	0.36	4.74e-9	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs1958560	0.897	rs8016322	chr14:66051536	G/A	cg03016385	chr14:66212404	NA	-0.44	-5.5	-0.33	9.52e-8	Menarche (age at onset);
KIRP	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg20295408	chr7:1910781	MAD1L1	0.54	6.09	0.36	4.35e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs7646881	1.000	rs59217052	chr3:158452456	C/T	cg19483011	chr3:158453295	NA	-0.56	-6.22	-0.37	2.17e-9	Tetralogy of Fallot;
KIRP	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg07451762	chr16:28383216	NA	0.4	5.2	0.31	4.27e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.81	12.85	0.63	2.96e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs10073892	0.743	rs10067263	chr5:101657535	C/T	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.15e-10	Cognitive decline (age-related);
KIRP	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg00074818	chr8:8560427	CLDN23	0.41	6.57	0.39	3.02e-10	Obesity-related traits;
KIRP	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg18694418	chr7:2742484	AMZ1	0.45	4.98	0.3	1.19e-6	Height;
KIRP	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg19743168	chr1:23544995	NA	0.48	6.48	0.38	5.09e-10	Height;
KIRP	cis	rs1497828	0.956	rs2815239	chr1:217546728	G/A	cg04411442	chr1:217543379	NA	0.31	5.02	0.3	1e-6	Dialysis-related mortality;
KIRP	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg09699651	chr6:150184138	LRP11	0.42	5.37	0.32	1.83e-7	Lung cancer;
KIRP	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.81	11.03	0.58	3.1e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.61	-7.4	-0.43	2.11e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.49	-5.37	-0.32	1.8e-7	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg11266682	chr4:10021025	SLC2A9	0.39	4.95	0.3	1.39e-6	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs2671245	1.000	rs2819474	chr1:56178294	C/A	cg11523071	chr1:56160889	NA	0.38	5.89	0.35	1.23e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-9.9	-0.53	1.18e-19	Schizophrenia;
KIRP	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg15358701	chr1:161410459	NA	-0.65	-6.26	-0.37	1.67e-9	Rheumatoid arthritis;
KIRP	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19926776	chr19:18682709	UBA52	0.57	7.15	0.41	9.67e-12	Parkinson's disease;
KIRP	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.07	-7.75	-0.44	2.42e-13	Mitochondrial DNA levels;
KIRP	cis	rs7712401	0.601	rs35256179	chr5:122334255	C/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs9308731	1.000	rs2015454	chr2:111872148	A/G	cg23466623	chr2:111982296	NA	-0.46	-5.8	-0.35	2.02e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.58	-6.3	-0.37	1.34e-9	DNA methylation (variation);
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.15	13.02	0.64	8.06e-30	Platelet count;
KIRP	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21545522	chr1:205238299	TMCC2	0.42	5.63	0.34	4.92e-8	Red blood cell count;
KIRP	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.27	-0.32	2.99e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.43	-0.33	1.36e-7	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15586420	chr15:90294517	MESP1	0.56	6.82	0.4	7.05e-11	Smoking initiation;
KIRP	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg07810366	chr2:100720526	AFF3	0.31	5.6	0.34	5.77e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs17065868	0.764	rs9533867	chr13:45038659	G/A	cg10246903	chr13:45222710	NA	0.59	4.95	0.3	1.36e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg08975724	chr8:8085496	FLJ10661	0.57	7.47	0.43	1.41e-12	Myopia (pathological);
KIRP	cis	rs7763441	0.567	rs13196905	chr6:2429573	T/C	cg18740289	chr6:2437142	NA	-0.46	-5.71	-0.34	3.19e-8	Monobrow;
KIRP	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.69	-4.99	-0.3	1.14e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs16958440	0.581	rs60726022	chr18:44679813	A/G	cg17192377	chr18:44677553	HDHD2	0.65	6.32	0.37	1.22e-9	Sitting height ratio;
KIRP	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.43	-8.13	-0.46	2.18e-14	Educational attainment (years of education);
KIRP	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg13482628	chr17:19912719	NA	0.57	7.93	0.45	7.6e-14	Schizophrenia;
KIRP	cis	rs13361707	0.959	rs1002423	chr5:40767458	C/T	cg01087697	chr5:40835557	RPL37	-0.47	-5.35	-0.32	2.03e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10519155	chr20:60757898	GTPBP5	0.57	7.31	0.42	3.72e-12	Parkinson's disease;
KIRP	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	14.43	0.68	1.28e-34	Alzheimer's disease;
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg22907277	chr7:1156413	C7orf50	0.56	6.87	0.4	5.19e-11	Longevity;Endometriosis;
KIRP	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.44	-5.28	-0.32	2.89e-7	Response to bleomycin (chromatid breaks);
KIRP	cis	rs3806843	0.568	rs2530232	chr5:140082878	A/G	cg19875535	chr5:140030758	IK	-0.72	-10.07	-0.54	3.42e-20	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.67	-7.85	-0.45	1.29e-13	Systemic lupus erythematosus;
KIRP	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.59	7.22	0.42	6.51e-12	Blood metabolite levels;
KIRP	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-8.31	-0.47	6.53e-15	Total cholesterol levels;
KIRP	cis	rs17221829	0.733	rs11018699	chr11:89379962	A/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.97	-0.3	1.23e-6	Anxiety in major depressive disorder;
KIRP	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.48	-0.33	1.07e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg00857998	chr1:205179979	DSTYK	0.62	7.38	0.43	2.41e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	trans	rs909341	0.678	rs2738778	chr20:62291830	C/T	cg01311341	chr22:25575246	KIAA1671	-0.69	-7.68	-0.44	3.87e-13	Atopic dermatitis;
KIRP	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg03653399	chr8:142233436	SLC45A4	-0.95	-14.83	-0.69	5.6e-36	Immature fraction of reticulocytes;
KIRP	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.38	5.15	0.31	5.35e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.55	-5.94	-0.35	9.7e-9	Eosinophil percentage of white cells;
KIRP	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg20578329	chr17:80767326	TBCD	-0.66	-7.55	-0.43	8.36e-13	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22988507	chr4:2936131	C4orf10;MFSD10	0.54	7.06	0.41	1.65e-11	Parkinson's disease;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.67	7.84	0.45	1.37e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg00852783	chr1:26633632	UBXN11	-0.57	-5.69	-0.34	3.57e-8	Obesity-related traits;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg08577743	chr9:38621011	C9orf122;ANKRD18A	0.53	6.24	0.37	1.86e-9	Sleep duration;
KIRP	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.63	-7.28	-0.42	4.62e-12	Longevity;Endometriosis;
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.34	-6.61	-0.39	2.32e-10	Lymphocyte counts;
KIRP	cis	rs11168854	0.719	rs11168890	chr12:49543913	A/G	cg24176009	chr12:49580217	TUBA1A	-0.36	-4.89	-0.3	1.82e-6	Body mass index;
KIRP	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg06611532	chr13:114900021	NA	0.22	5.01	0.3	1.02e-6	Schizophrenia;
KIRP	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.42	5.37	0.32	1.78e-7	Aortic root size;
KIRP	cis	rs11264213	1.000	rs12083902	chr1:36275112	G/A	cg27506609	chr1:36549197	TEKT2	0.73	7.14	0.41	1.04e-11	Schizophrenia;
KIRP	cis	rs13006833	0.668	rs291466	chr2:191184475	A/G	cg21644426	chr2:191273491	MFSD6	0.46	5.69	0.34	3.52e-8	Urinary metabolites;
KIRP	cis	rs3112255	0.901	rs2942892	chr2:101294132	C/T	cg01042948	chr2:101319752	NA	0.44	6.28	0.37	1.54e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	6.97	0.41	2.93e-11	Coffee consumption (cups per day);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02396668	chr19:50528878	VRK3;ZNF473	0.52	6.33	0.37	1.18e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg00504896	chr12:9437009	LOC642846	-0.55	-7.74	-0.44	2.54e-13	Breast size;
KIRP	cis	rs4900538	0.750	rs12590618	chr14:102808330	C/T	cg18135206	chr14:102964638	TECPR2	-0.79	-9.97	-0.54	7.19e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.45	-8.39	-0.47	3.72e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg18478394	chr8:109455254	TTC35	-0.51	-6.26	-0.37	1.71e-9	Dupuytren's disease;
KIRP	cis	rs11203032	0.831	rs7477966	chr10:90924258	A/G	cg16672925	chr10:90967113	CH25H	0.78	7.68	0.44	3.81e-13	Heart failure;
KIRP	cis	rs4690686	0.769	rs7656505	chr4:177274867	A/T	cg17059388	chr4:177262070	NA	0.57	8.06	0.46	3.41e-14	Essential tremor;
KIRP	cis	rs73206853	0.841	rs73206854	chr12:110731375	C/T	cg12870014	chr12:110450643	ANKRD13A	0.5	4.86	0.3	2.05e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg13010199	chr12:38710504	ALG10B	0.62	7.72	0.44	2.96e-13	Morning vs. evening chronotype;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.68	-8.49	-0.48	1.97e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.75	11.04	0.58	2.82e-23	Prudent dietary pattern;
KIRP	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.58	0.39	2.76e-10	Diabetic retinopathy;
KIRP	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.72	7.06	0.41	1.71e-11	Axial length;
KIRP	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	9.12	0.5	2.8e-17	Post bronchodilator FEV1;
KIRP	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.65	9.16	0.5	2.16e-17	Fibrinogen levels;
KIRP	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Parkinson's disease;
KIRP	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg12315302	chr6:26189340	HIST1H4D	0.67	4.94	0.3	1.42e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22491279	chr19:8008671	TIMM44	-0.56	-6.49	-0.38	4.78e-10	Interleukin-4 levels;
KIRP	trans	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg10756647	chr7:56101905	PSPH	1.08	8.46	0.47	2.39e-15	Diabetic kidney disease;
KIRP	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.77e-6	Bipolar disorder;
KIRP	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg16512390	chr1:228756714	NA	0.73	5.88	0.35	1.37e-8	Chronic lymphocytic leukemia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22124368	chr6:170774538	NA	0.47	6.31	0.37	1.25e-9	Interleukin-4 levels;
KIRP	trans	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg03929089	chr4:120376271	NA	0.7	6.52	0.38	3.92e-10	Intraocular pressure;
KIRP	cis	rs7851660	0.809	rs35324451	chr9:100660136	A/T	cg13688889	chr9:100608707	NA	-0.66	-8.26	-0.47	9.06e-15	Strep throat;
KIRP	cis	rs9596863	1.000	rs9568946	chr13:54430220	T/C	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg03060546	chr3:49711283	APEH	0.44	5.81	0.35	1.9e-8	Parkinson's disease;
KIRP	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg05555928	chr11:63887634	MACROD1	0.48	4.88	0.3	1.93e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03737788	chr10:79492045	NA	0.42	6.17	0.37	2.73e-9	Survival in pancreatic cancer;
KIRP	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg04539111	chr16:67997858	SLC12A4	-0.65	-6.61	-0.39	2.37e-10	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4073582	1.000	rs4073582	chr11:66050712	G/A	cg16950941	chr11:66035639	RAB1B	0.46	5.67	0.34	3.91e-8	Gout;
KIRP	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.59	7.32	0.42	3.5e-12	Schizophrenia;
KIRP	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-6.07	-0.36	4.81e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs17428704	0.571	rs12110267	chr5:14368563	A/G	cg26595256	chr5:14380529	TRIO	-1.06	-6.4	-0.38	7.84e-10	Electroencephalogram traits;
KIRP	cis	rs394563	0.967	rs369643	chr6:149799798	A/G	cg07828024	chr6:149772892	ZC3H12D	-0.29	-4.89	-0.3	1.8e-6	Dupuytren's disease;
KIRP	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg12559939	chr2:27858050	GPN1	0.42	5.36	0.32	1.95e-7	Oral cavity cancer;
KIRP	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.72	9.25	0.51	1.15e-17	Corneal astigmatism;
KIRP	cis	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg19180546	chr13:44453867	C13orf31;CCDC122	0.41	5.5	0.33	9.53e-8	Leprosy;
KIRP	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg02527881	chr3:46936655	PTH1R	-0.43	-6.14	-0.36	3.24e-9	Colorectal cancer;
KIRP	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg06558623	chr16:89946397	TCF25	1.17	7.92	0.45	8.02e-14	Skin colour saturation;
KIRP	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.78	13.64	0.66	6.51e-32	Height;
KIRP	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg27247782	chr7:158767135	NA	0.46	5.58	0.34	6.24e-8	Facial morphology (factor 20);
KIRP	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.74	9.38	0.51	4.57e-18	Aortic root size;
KIRP	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.58	-7.54	-0.43	8.77e-13	Bladder cancer;
KIRP	trans	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg13565492	chr6:43139072	SRF	-0.77	-8.95	-0.5	8.96e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg25173405	chr17:45401733	C17orf57	0.42	5.34	0.32	2.13e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.84	14.4	0.68	1.66e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg21475434	chr5:93447410	FAM172A	0.43	4.96	0.3	1.32e-6	Diabetic retinopathy;
KIRP	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	12.52	0.62	3.71e-28	Mean platelet volume;
KIRP	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg14221460	chr8:27183342	PTK2B	0.45	5.84	0.35	1.66e-8	Neuroticism;
KIRP	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.49	-6.37	-0.38	9.11e-10	Body mass index;
KIRP	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg15327641	chr2:3715039	ALLC	0.46	5.95	0.35	9.14e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.7	-0.73	2.25e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg26752003	chr8:145688521	CYHR1	0.7	9.22	0.51	1.36e-17	Age at first birth;
KIRP	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	6.93	0.4	3.67e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.53	7.43	0.43	1.81e-12	Coronary artery disease;
KIRP	cis	rs240764	0.658	rs7740006	chr6:101220432	T/C	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.65	9.25	0.51	1.1e-17	Mean platelet volume;
KIRP	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg04315214	chr1:2043799	PRKCZ	-0.35	-5.57	-0.33	6.51e-8	Height;
KIRP	cis	rs10982256	0.774	rs13286280	chr9:117246504	C/T	cg13636371	chr9:117264095	DFNB31	0.58	8.05	0.46	3.48e-14	Bipolar disorder;
KIRP	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg21747090	chr2:27597821	SNX17	-0.52	-6.76	-0.4	1.02e-10	Total body bone mineral density;
KIRP	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.6	8.24	0.46	1.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	10.46	0.55	2.06e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00255919	chr5:131827918	IRF1	0.27	5.74	0.34	2.71e-8	Asthma (sex interaction);
KIRP	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.66	-12.19	-0.61	4.87e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg18357526	chr6:26021779	HIST1H4A	0.39	5.14	0.31	5.62e-7	Height;
KIRP	cis	rs4665630	0.522	rs75866363	chr2:24046426	G/A	cg08063864	chr2:24346004	PFN4;LOC375190	0.95	5.28	0.32	2.81e-7	Hypertension;
KIRP	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.53	6.81	0.4	7.26e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg13165212	chr22:42675999	NA	0.41	6.98	0.41	2.75e-11	Cognitive function;
KIRP	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.26	-0.51	1.07e-17	Personality dimensions;
KIRP	cis	rs9879311	0.643	rs1473183	chr3:10411827	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.46	5.61	0.34	5.35e-8	Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.75	10.43	0.55	2.42e-21	Diastolic blood pressure;
KIRP	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg01411142	chr8:19674711	INTS10	0.45	4.92	0.3	1.62e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.08	0.41	1.48e-11	Bipolar disorder;
KIRP	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.62	0.6	3.51e-25	Morning vs. evening chronotype;
KIRP	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.73	-7.98	-0.45	5.56e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	0.46	5.46	0.33	1.17e-7	Colorectal cancer;
KIRP	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11987759	chr7:65425863	GUSB	0.7	10.1	0.54	2.75e-20	Corneal structure;
KIRP	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.82	-13.24	-0.64	1.46e-30	Idiopathic membranous nephropathy;
KIRP	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.95	-0.35	9.15e-9	Pulmonary function;
KIRP	cis	rs4805272	1.000	rs11672592	chr19:29320798	A/C	cg15000279	chr19:29285009	NA	-0.37	-5.41	-0.33	1.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs9843304	0.528	rs12488126	chr3:149192676	G/A	cg08667024	chr3:149219783	TM4SF4	0.57	8.65	0.48	6.79e-16	Gallstone disease;
KIRP	cis	rs4728302	0.869	rs10224575	chr7:133590875	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	5.55	0.33	7.44e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20699899	chr15:101143162	LINS1;ASB7	0.5	6.87	0.4	5.08e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg08999081	chr20:33150536	PIGU	0.47	6.29	0.37	1.48e-9	Height;
KIRP	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg11901034	chr3:128598214	ACAD9	0.41	5.29	0.32	2.77e-7	IgG glycosylation;
KIRP	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg13319975	chr6:146136371	FBXO30	-0.51	-7.12	-0.41	1.19e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7011507	1.000	rs79796347	chr8:49135992	C/T	cg15325961	chr8:49183143	NA	0.62	5.31	0.32	2.48e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg06360820	chr2:242988706	NA	-0.96	-8.28	-0.47	7.84e-15	Obesity-related traits;
KIRP	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11987759	chr7:65425863	GUSB	-0.47	-6.0	-0.36	7.09e-9	Aortic root size;
KIRP	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.64	-0.68	2.54e-35	Primary sclerosing cholangitis;
KIRP	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.64	-9.33	-0.51	6.46e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17641971	0.684	rs12545097	chr8:49951977	A/G	cg00325661	chr8:49890786	NA	0.38	4.92	0.3	1.59e-6	Blood metabolite levels;
KIRP	cis	rs501120	0.584	rs1746034	chr10:44714768	T/C	cg09554077	chr10:44749378	NA	0.69	7.61	0.44	5.93e-13	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg17764715	chr19:33622953	WDR88	0.81	11.53	0.59	7.08e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg12131826	chr15:77904385	NA	0.5	5.91	0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.71	7.79	0.44	1.85e-13	Corneal astigmatism;
KIRP	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.53	-6.5	-0.38	4.53e-10	Total body bone mineral density;
KIRP	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.78	0.4	9.06e-11	Lung cancer;
KIRP	cis	rs2274273	0.600	rs35112084	chr14:55781100	T/A	cg04306507	chr14:55594613	LGALS3	0.39	5.42	0.33	1.44e-7	Protein biomarker;
KIRP	cis	rs4713675	0.546	rs10947435	chr6:33718075	G/A	cg15676125	chr6:33679581	C6orf125	0.39	4.95	0.3	1.36e-6	Plateletcrit;
KIRP	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg13798780	chr7:105162888	PUS7	-0.66	-6.09	-0.36	4.31e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg13565492	chr6:43139072	SRF	-0.87	-8.09	-0.46	2.69e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	7.71	0.44	3.08e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6772849	0.896	rs4557179	chr3:128366726	A/C	cg08795948	chr3:128337044	NA	0.49	6.28	0.37	1.56e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg16141378	chr3:129829833	LOC729375	-0.58	-7.32	-0.42	3.56e-12	Neuroticism;
KIRP	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.86	7.17	0.42	8.58e-12	Fat distribution (HIV);
KIRP	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg17644776	chr2:200775616	C2orf69	-0.59	-5.94	-0.35	9.57e-9	Schizophrenia;
KIRP	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.72	7.95	0.45	6.85e-14	Corneal astigmatism;
KIRP	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.81	7.83	0.45	1.41e-13	Eosinophil percentage of granulocytes;
KIRP	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	1.05	17.02	0.74	1.89e-43	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg02415014	chr8:143852576	LYNX1	0.33	5.14	0.31	5.51e-7	Urinary tract infection frequency;
KIRP	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs9815354	0.716	rs76313799	chr3:41931751	A/C	cg03022575	chr3:42003672	ULK4	0.77	7.99	0.45	5.18e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.58	9.15	0.5	2.2e-17	Mean corpuscular volume;
KIRP	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.17e-16	Motion sickness;
KIRP	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	4.84	0.3	2.26e-6	Cognitive test performance;
KIRP	trans	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg06521331	chr12:34319734	NA	-0.58	-7.07	-0.41	1.61e-11	Bladder cancer;
KIRP	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg06026331	chr20:60912101	LAMA5	-0.48	-6.43	-0.38	6.6e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs74181299	0.684	rs9797989	chr2:65336529	T/C	cg05010058	chr2:65284262	CEP68	-0.43	-5.86	-0.35	1.45e-8	Pulse pressure;
KIRP	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg21782813	chr7:2030301	MAD1L1	-0.37	-4.85	-0.3	2.16e-6	Schizophrenia;
KIRP	cis	rs76793172	1.000	rs77756656	chr19:46320718	C/G	cg00442267	chr19:46317840	RSPH6A	-0.77	-6.07	-0.36	4.86e-9	Eosinophil counts;
KIRP	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg06204229	chr3:52865917	ITIH4	0.42	5.06	0.31	8.33e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16844539	chr2:225363361	CUL3	-0.42	-6.69	-0.39	1.47e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg18132916	chr6:79620363	NA	-0.43	-5.92	-0.35	1.08e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs5753037	0.838	rs5752975	chr22:30274335	C/G	cg27665648	chr22:30112403	NA	0.35	4.96	0.3	1.31e-6	Type 1 diabetes;
KIRP	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.71	-0.63	8.66e-29	Alzheimer's disease;
KIRP	cis	rs12230513	0.732	rs7960126	chr12:55813605	T/G	cg19537932	chr12:55886519	OR6C68	-0.67	-6.84	-0.4	6.16e-11	Contrast sensitivity;
KIRP	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.51	6.3	0.37	1.35e-9	Menarche (age at onset);
KIRP	cis	rs8060686	0.920	rs3809630	chr16:67879400	G/A	cg26727032	chr16:67993705	SLC12A4	-0.56	-5.08	-0.31	7.54e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs981844	1.000	rs2606329	chr4:154654643	A/C	cg14289246	chr4:154710475	SFRP2	0.66	7.41	0.43	2.08e-12	Response to statins (LDL cholesterol change);
KIRP	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8018808	0.875	rs176781	chr14:77887681	C/T	cg18872420	chr14:78023429	SPTLC2	0.34	4.92	0.3	1.6e-6	Myeloid white cell count;
KIRP	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	0.81	8.77	0.49	3.1e-16	Gut microbiome composition (summer);
KIRP	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg07384165	chr1:10488281	NA	-0.42	-5.24	-0.32	3.45e-7	Breast cancer;
KIRP	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.72	-10.09	-0.54	2.86e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.53	7.05	0.41	1.84e-11	Breast cancer;
KIRP	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-5.1	-0.31	6.72e-7	Cognitive function;
KIRP	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg24498760	chr8:49746867	NA	0.41	5.06	0.31	8.1e-7	Blood metabolite ratios;
KIRP	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.55	-7.6	-0.44	6.16e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.66	-12.44	-0.62	6.87e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.86	13.31	0.65	8.16e-31	Longevity;
KIRP	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg21475434	chr5:93447410	FAM172A	0.76	6.49	0.38	4.81e-10	Diabetic retinopathy;
KIRP	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.83	-0.49	2e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.6	8.01	0.45	4.5e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.66	-8.36	-0.47	4.55e-15	Obesity-related traits;
KIRP	cis	rs7520050	0.966	rs9429183	chr1:46524582	G/A	cg03146154	chr1:46216737	IPP	-0.41	-5.39	-0.32	1.69e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7173743	1.000	rs11632020	chr15:79143759	C/T	cg00079375	chr15:79125835	NA	-0.39	-5.51	-0.33	8.86e-8	Coronary artery disease;
KIRP	cis	rs2147904	0.704	rs809173	chr1:42363381	C/T	cg26038582	chr1:42384390	HIVEP3	0.24	5.04	0.31	9.16e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	7.32	0.42	3.62e-12	Obesity-related traits;
KIRP	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg15128208	chr22:42549153	NA	0.74	8.01	0.46	4.46e-14	Birth weight;
KIRP	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg24631222	chr15:78858424	CHRNA5	0.83	10.57	0.56	8.73e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-7.92	-0.45	8.38e-14	Aortic root size;
KIRP	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-7.6	-0.44	6.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.3	-0.42	3.92e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg04289385	chr6:36355825	ETV7	0.46	7.25	0.42	5.4e-12	Platelet distribution width;
KIRP	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg11833968	chr6:79620685	NA	-0.37	-5.29	-0.32	2.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	ch.11.42038R	chr11:967971	AP2A2	0.41	5.38	0.32	1.75e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.51	-11.6	-0.59	4.35e-25	Diabetic kidney disease;
KIRP	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg13147721	chr7:65941812	NA	-0.94	-6.8	-0.4	7.98e-11	Diabetic kidney disease;
KIRP	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.35	5.26	0.32	3.08e-7	Multiple sclerosis;
KIRP	cis	rs9890032	0.520	rs2321926	chr17:29041552	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.41	-5.27	-0.32	3.01e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg13611997	chr5:233750	SDHA	-0.41	-4.92	-0.3	1.58e-6	Breast cancer;
KIRP	cis	rs1150668	0.796	rs9468372	chr6:28379361	T/A	cg18815343	chr6:28367644	ZSCAN12	-0.39	-5.63	-0.34	4.95e-8	Pubertal anthropometrics;
KIRP	cis	rs9392653	0.655	rs376210	chr6:5080264	C/T	cg13207534	chr6:5087447	PPP1R3G	0.44	5.47	0.33	1.09e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg21995919	chr2:182322279	ITGA4	0.45	6.31	0.37	1.28e-9	DNA methylation (variation);
KIRP	cis	rs4356975	0.563	rs6846298	chr4:69954996	C/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.91	12.16	0.61	5.73e-27	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.74	0.49	3.75e-16	Bipolar disorder;
KIRP	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.71	-10.36	-0.55	4.28e-21	Retinal vascular caliber;
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.44	6.28	0.37	1.54e-9	Lymphocyte counts;
KIRP	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.85	13.6	0.66	8.72e-32	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18403285	chr11:1317034	TOLLIP	0.49	6.65	0.39	1.87e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.26	14.46	0.68	1e-34	Corneal structure;
KIRP	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.53	6.84	0.4	6.23e-11	IgG glycosylation;
KIRP	cis	rs1448094	0.967	rs10047659	chr12:86338278	C/A	cg06740227	chr12:86229804	RASSF9	0.4	5.11	0.31	6.53e-7	Major depressive disorder;
KIRP	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs311392	0.902	rs681000	chr8:55094043	C/T	cg06042504	chr8:55087323	NA	-0.61	-7.44	-0.43	1.68e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg25547332	chr5:131281432	NA	0.49	5.92	0.35	1.1e-8	Life satisfaction;
KIRP	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.79	14.92	0.69	2.7e-36	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09586080	chr16:86543543	FOXF1	0.55	7.08	0.41	1.48e-11	Parkinson's disease;
KIRP	trans	rs6049003	0.668	rs6049061	chr20:23726803	T/C	cg27261597	chr1:209604378	LOC642587;MIR205	-0.36	-6.27	-0.37	1.64e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.03	-0.36	6.11e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.25	-0.32	3.32e-7	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-4.95	-0.3	1.37e-6	Aortic root size;
KIRP	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg00319359	chr11:70116639	PPFIA1	0.65	6.29	0.37	1.41e-9	Coronary artery disease;
KIRP	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.14	-0.41	1.08e-11	Joint mobility (Beighton score);
KIRP	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11987759	chr7:65425863	GUSB	0.61	8.17	0.46	1.61e-14	Aortic root size;
KIRP	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.51	7.04	0.41	1.89e-11	Night sleep phenotypes;
KIRP	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg02023728	chr11:77925099	USP35	0.33	4.9	0.3	1.73e-6	Alzheimer's disease (survival time);
KIRP	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg20302533	chr7:39170763	POU6F2	0.3	6.37	0.38	9.39e-10	IgG glycosylation;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11350889	chr5:34656553	RAI14	-0.5	-6.38	-0.38	8.55e-10	Myopia;
KIRP	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.61	-6.4	-0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20135002	chr11:47629003	NA	-0.47	-5.53	-0.33	8.06e-8	Subjective well-being;
KIRP	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg10755058	chr3:40428713	ENTPD3	0.47	6.51	0.38	4.26e-10	Renal cell carcinoma;
KIRP	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg00343986	chr7:65444356	GUSB	0.44	5.45	0.33	1.24e-7	Aortic root size;
KIRP	cis	rs6540559	0.546	rs735693	chr1:210033988	A/C	cg22029157	chr1:209979665	IRF6	0.49	5.11	0.31	6.38e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs7903847	0.642	rs11189172	chr10:99135215	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-5.4	-0.33	1.6e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg18478394	chr8:109455254	TTC35	0.61	7.66	0.44	4.38e-13	Dupuytren's disease;
KIRP	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.77	8.85	0.49	1.72e-16	Corneal astigmatism;
KIRP	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg05347473	chr6:146136440	FBXO30	0.57	8.03	0.46	3.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg04025307	chr7:1156635	C7orf50	0.56	6.12	0.36	3.75e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.97	-15.87	-0.71	1.57e-39	Monocyte count;
KIRP	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9972944	0.902	rs12939558	chr17:63772152	A/G	cg07283582	chr17:63770753	CCDC46	0.52	8.33	0.47	5.6e-15	Total body bone mineral density;
KIRP	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.35	-0.38	1.03e-9	Mood instability;
KIRP	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg17644776	chr2:200775616	C2orf69	0.57	6.09	0.36	4.36e-9	Schizophrenia;
KIRP	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.95	0.3	1.36e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.75	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-8.02	-0.46	4.42e-14	Vitiligo;
KIRP	cis	rs7808935	0.591	rs62451117	chr7:27942357	T/C	cg05786569	chr7:27702416	HIBADH	0.53	5.36	0.32	1.96e-7	Prostate cancer;
KIRP	cis	rs7601312	1.000	rs11691395	chr2:229318607	G/A	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg20578329	chr17:80767326	TBCD	0.61	7.43	0.43	1.81e-12	Breast cancer;
KIRP	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.28	-0.32	2.85e-7	Pulmonary function;
KIRP	cis	rs2692947	0.826	rs7423942	chr2:96645257	G/A	cg23100626	chr2:96804247	ASTL	0.46	6.8	0.4	7.86e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.43	5.45	0.33	1.21e-7	Total body bone mineral density;
KIRP	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg05562828	chr17:3906858	NA	0.52	7.55	0.43	8.23e-13	Type 2 diabetes;
KIRP	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.08	-0.41	1.46e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg09006292	chr3:64049408	NA	-0.54	-4.94	-0.3	1.43e-6	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	12.44	0.62	6.89e-28	Platelet count;
KIRP	cis	rs2230307	0.518	rs12046458	chr1:100703069	C/T	cg24955406	chr1:100503596	HIAT1	-0.64	-6.77	-0.4	9.36e-11	Carotid intima media thickness;
KIRP	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg21775007	chr8:11205619	TDH	0.66	9.73	0.53	3.81e-19	Retinal vascular caliber;
KIRP	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.35	-0.32	1.98e-7	Pulmonary function;
KIRP	cis	rs17818399	0.574	rs6544907	chr2:46868319	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	5.69	0.34	3.55e-8	Height;
KIRP	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4786125	0.665	rs1873704	chr16:6907021	C/G	cg03623568	chr16:6915990	A2BP1	-0.42	-4.94	-0.3	1.45e-6	Heart rate variability traits (SDNN);
KIRP	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg25767906	chr1:53392781	SCP2	-0.34	-4.86	-0.3	2.09e-6	Monocyte count;
KIRP	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.42	-5.29	-0.32	2.66e-7	Neutrophil percentage of white cells;
KIRP	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17376030	chr22:41985996	PMM1	0.8	8.21	0.46	1.24e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-0.9	-10.53	-0.56	1.17e-21	Gut microbiome composition (summer);
KIRP	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg25547332	chr5:131281432	NA	0.47	5.34	0.32	2.15e-7	Life satisfaction;
KIRP	cis	rs2346177	0.846	rs6714738	chr2:46646164	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-5.68	-0.34	3.7e-8	HDL cholesterol;
KIRP	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg06115741	chr20:33292138	TP53INP2	-0.41	-5.51	-0.33	9.05e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.42	6.03	0.36	5.98e-9	Lung cancer;
KIRP	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg22705602	chr4:152727874	NA	-0.53	-9.2	-0.51	1.64e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08085267	chr17:45401833	C17orf57	-0.53	-6.67	-0.39	1.7e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs16973500	0.808	rs112452788	chr16:71911198	C/T	cg00732059	chr16:71740210	PHLPP2	-0.58	-5.59	-0.34	6.05e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg23791538	chr6:167370224	RNASET2	-0.49	-5.87	-0.35	1.4e-8	Primary biliary cholangitis;
KIRP	trans	rs1864729	1.000	rs2853320	chr8:98283523	C/G	cg08679828	chr8:102218111	ZNF706	-0.73	-6.66	-0.39	1.78e-10	Estradiol plasma levels (breast cancer);
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.55	-6.92	-0.4	4e-11	Testicular germ cell tumor;
KIRP	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.09	0.46	2.82e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg10755058	chr3:40428713	ENTPD3	0.44	6.17	0.37	2.75e-9	Renal cell carcinoma;
KIRP	cis	rs1656402	0.906	rs2276560	chr2:233450919	C/T	cg03852847	chr2:233439513	NA	-0.7	-9.95	-0.54	8.21e-20	Non-small cell lung cancer (survival);
KIRP	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.45	-5.58	-0.34	6.39e-8	Response to bleomycin (chromatid breaks);
KIRP	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-7.57	-0.43	7.7e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16318349	chr1:154917307	PBXIP1	0.28	4.96	0.3	1.32e-6	Prostate cancer;
KIRP	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg00933542	chr6:150070202	PCMT1	0.27	5.04	0.31	8.9e-7	Lung cancer;
KIRP	cis	rs3736485	0.932	rs2278990	chr15:51914662	G/A	cg14296394	chr15:51910925	DMXL2	-0.34	-5.16	-0.31	5.12e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.8	11.04	0.58	2.76e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.0	0.36	6.88e-9	Height;
KIRP	cis	rs988913	0.957	rs6908170	chr6:54821152	C/T	cg03513858	chr6:54763001	FAM83B	-0.42	-5.72	-0.34	3.16e-8	Menarche (age at onset);
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.75	-7.76	-0.44	2.26e-13	Platelet count;
KIRP	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	6.56	0.39	3.19e-10	Prudent dietary pattern;
KIRP	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.27	12.12	0.61	7.83e-27	Diabetic retinopathy;
KIRP	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg05315796	chr3:52349193	DNAH1	0.43	6.43	0.38	6.42e-10	Electroencephalogram traits;
KIRP	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	11.87	0.6	5.61e-26	Bipolar disorder;
KIRP	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg03060546	chr3:49711283	APEH	0.71	7.52	0.43	1.03e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg07701084	chr6:150067640	NUP43	0.71	10.3	0.55	6.43e-21	Lung cancer;
KIRP	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg03929089	chr4:120376271	NA	-0.69	-7.0	-0.41	2.4e-11	Axial length;
KIRP	cis	rs10411936	0.626	rs8113060	chr19:16596795	G/C	cg10248733	chr19:16607483	C19orf44;CALR3	0.51	5.36	0.32	1.9e-7	White blood cell count;Multiple sclerosis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03680898	chr3:93646378	PROS1	-0.4	-6.43	-0.38	6.55e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg13628971	chr7:2884303	GNA12	0.44	5.39	0.32	1.68e-7	Height;
KIRP	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	9.01	0.5	5.73e-17	Resting heart rate;
KIRP	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.15	0.58	1.19e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.46	7.65	0.44	4.61e-13	Testicular germ cell tumor;
KIRP	cis	rs9815354	0.953	rs6795797	chr3:41862250	A/G	cg03022575	chr3:42003672	ULK4	0.5	5.75	0.34	2.62e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11264213	0.901	rs74879824	chr1:36413117	T/A	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg00277334	chr10:82204260	NA	-0.47	-5.41	-0.33	1.51e-7	Post bronchodilator FEV1;
KIRP	cis	rs4273100	0.512	rs2233072	chr17:19281828	T/G	cg18093559	chr17:18951025	GRAP	0.5	5.92	0.35	1.1e-8	Schizophrenia;
KIRP	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg12705353	chr12:122356852	WDR66	0.55	7.11	0.41	1.23e-11	Mean corpuscular volume;
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.6	7.96	0.45	6.21e-14	Longevity;
KIRP	cis	rs7116495	1.000	rs4944242	chr11:71667141	G/T	cg11196788	chr11:71737549	NUMA1	0.56	4.99	0.3	1.14e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.02	0.3	9.82e-7	Bipolar disorder;
KIRP	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg19875535	chr5:140030758	IK	-0.67	-9.69	-0.53	5.2e-19	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.49	5.59	0.34	5.88e-8	DNA methylation (variation);
KIRP	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.64	7.36	0.42	2.7e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg19849509	chr2:175204996	NA	-0.54	-6.4	-0.38	7.67e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12580194	0.593	rs12099808	chr12:55731178	T/A	cg19537932	chr12:55886519	OR6C68	-0.51	-6.51	-0.38	4.15e-10	Cancer;
KIRP	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.24	-5.19	-0.31	4.49e-7	Type 2 diabetes;
KIRP	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg03806693	chr22:41940476	POLR3H	-0.44	-5.29	-0.32	2.68e-7	Neuroticism;
KIRP	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.59	7.29	0.42	4.1e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg17410650	chr12:54324560	NA	-0.48	-6.78	-0.4	8.98e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
KIRP	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.66	6.84	0.4	6.12e-11	Bipolar disorder (body mass index interaction);
KIRP	cis	rs2273156	0.500	rs17103104	chr14:35690978	C/G	cg09327582	chr14:35236912	BAZ1A	-0.65	-5.97	-0.36	8.26e-9	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg16141378	chr3:129829833	LOC729375	0.58	7.08	0.41	1.53e-11	Retinal vascular caliber;
KIRP	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg19847130	chr8:10466454	RP1L1	0.34	4.91	0.3	1.7e-6	Neuroticism;
KIRP	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	7.1	0.41	1.32e-11	Renal function-related traits (BUN);
KIRP	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.52	5.93	0.35	1.02e-8	Menopause (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09398166	chr15:74666346	NA	0.53	6.19	0.37	2.5e-9	Smoking initiation;
KIRP	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg04306507	chr14:55594613	LGALS3	0.52	8.16	0.46	1.72e-14	Protein biomarker;
KIRP	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg26513180	chr16:89883248	FANCA	-0.39	-5.08	-0.31	7.6e-7	Vitiligo;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22688969	chr11:121174513	SC5DL	-0.45	-6.83	-0.4	6.75e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4959799	0.557	rs6901135	chr6:3273694	T/C	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.26	-0.32	3.11e-7	Survival in rectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17053845	chr2:74375133	BOLA3	0.54	6.92	0.4	3.84e-11	Parkinson's disease;
KIRP	cis	rs2191566	0.576	rs393536	chr19:44493018	T/C	cg18700516	chr19:44507157	ZNF230	0.46	5.39	0.32	1.66e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4523957	0.893	rs12950555	chr17:2156910	C/G	cg16513277	chr17:2031491	SMG6	0.58	8.04	0.46	3.74e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.36	5.03	0.31	9.35e-7	Menarche (age at onset);
KIRP	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg17788362	chr6:86352627	SYNCRIP	0.48	6.52	0.38	4.03e-10	Smooth-surface caries;
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs12220238	0.722	rs7073340	chr10:76402277	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.56	6.12	0.36	3.63e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg05692746	chr2:100937584	LONRF2	-0.39	-4.97	-0.3	1.23e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg24296786	chr1:45957014	TESK2	-0.54	-6.97	-0.41	2.9e-11	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs904251	0.772	rs1812186	chr6:37465916	T/C	cg24807547	chr6:37504484	NA	-0.43	-5.58	-0.33	6.46e-8	Cognitive performance;
KIRP	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.7	10.86	0.57	1.04e-22	Resting heart rate;
KIRP	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.74	11.7	0.6	1.91e-25	Calcium levels;
KIRP	cis	rs708547	0.914	rs58228066	chr4:57735787	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.72	-8.23	-0.46	1.08e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06173319	chr16:90148775	NA	0.54	5.5	0.33	9.53e-8	Skin colour saturation;
KIRP	cis	rs10782582	0.758	rs11161859	chr1:76370600	T/C	cg10523679	chr1:76189770	ACADM	-0.36	-5.27	-0.32	3.03e-7	Daytime sleep phenotypes;
KIRP	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.55	8.22	0.46	1.15e-14	Itch intensity from mosquito bite;
KIRP	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg18944383	chr4:111397179	ENPEP	0.55	9.27	0.51	9.87e-18	Coronary artery disease;
KIRP	cis	rs9815354	1.000	rs9818169	chr3:41860599	A/G	cg03022575	chr3:42003672	ULK4	0.59	6.86	0.4	5.69e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs12982744	0.613	rs2238606	chr19:2144989	T/C	cg09261902	chr19:2140048	AP3D1	0.42	5.39	0.33	1.64e-7	Osteoarthritis;Height;
KIRP	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg24747557	chr10:131355152	MGMT	0.46	6.41	0.38	7.41e-10	Response to temozolomide;
KIRP	cis	rs4474465	0.920	rs7941889	chr11:78154401	T/G	cg27205649	chr11:78285834	NARS2	-0.57	-6.81	-0.4	7.33e-11	Alzheimer's disease (survival time);
KIRP	cis	rs959260	1.000	rs4788891	chr17:73391145	A/G	cg20590849	chr17:73267439	MIF4GD	-0.57	-6.09	-0.36	4.32e-9	Systemic lupus erythematosus;
KIRP	cis	rs1559088	0.847	rs8100392	chr19:33605933	T/C	cg17764715	chr19:33622953	WDR88	0.66	8.39	0.47	3.81e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.26	-0.42	5.08e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.68	-6.04	-0.36	5.7e-9	Weight;
KIRP	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.61	8.85	0.49	1.78e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.58	0.48	1.09e-15	Morning vs. evening chronotype;
KIRP	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.43	-7.01	-0.41	2.25e-11	Refractive error;
KIRP	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg17757837	chr7:157058334	UBE3C	0.78	10.52	0.56	1.31e-21	Body mass index;
KIRP	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg25256661	chr17:7137939	DVL2	-0.81	-11.73	-0.6	1.53e-25	Diastolic blood pressure;
KIRP	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.02	0.3	1.02e-6	Retinal vascular caliber;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg09040699	chr11:8009242	EIF3F	0.5	6.18	0.37	2.7e-9	Asthma;
KIRP	trans	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.07	-0.41	1.59e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	7.25e-7	Alzheimer's disease;
KIRP	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	15.29	0.7	1.53e-37	Colorectal cancer;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.45	-5.75	-0.34	2.61e-8	Initial pursuit acceleration;
KIRP	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.44	5.53	0.33	8.36e-8	Platelet count;
KIRP	cis	rs4786125	0.636	rs7187960	chr16:6919183	G/T	cg03623568	chr16:6915990	A2BP1	-0.44	-5.33	-0.32	2.27e-7	Heart rate variability traits (SDNN);
KIRP	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.3	0.42	3.86e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.75	11.54	0.59	6.45e-25	Colorectal cancer;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg08132940	chr7:1081526	C7orf50	-0.58	-6.21	-0.37	2.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12823128	0.766	rs11611508	chr12:26927428	T/G	cg14081884	chr12:26986758	ITPR2	0.39	4.9	0.3	1.76e-6	Birth weight;
KIRP	cis	rs9549367	0.664	rs3794419	chr13:113851874	T/C	cg00898013	chr13:113819073	PROZ	-0.54	-5.43	-0.33	1.34e-7	Platelet distribution width;
KIRP	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-7.66	-0.44	4.37e-13	Neuroticism;
KIRP	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	5.73	0.34	2.98e-8	Personality dimensions;
KIRP	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg22800045	chr5:56110881	MAP3K1	-0.58	-6.89	-0.4	4.56e-11	Initial pursuit acceleration;
KIRP	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs11016883	1.000	rs7073892	chr10:131493946	G/A	cg14312783	chr10:131504572	MGMT	0.39	4.85	0.3	2.15e-6	Waist-to-hip circumference ratio (ever vs never smoking interaction);
KIRP	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	15.8	0.71	2.68e-39	Body mass index (adult);
KIRP	cis	rs7432375	0.583	rs1609391	chr3:136615268	G/A	cg15507776	chr3:136538369	TMEM22	0.43	5.61	0.34	5.35e-8	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.88	15.78	0.71	3.09e-39	Dental caries;
KIRP	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.53	-6.32	-0.37	1.19e-9	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14595558	chr4:7789738	AFAP1	-0.51	-6.67	-0.39	1.66e-10	Parkinson's disease;
KIRP	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg22437258	chr11:111473054	SIK2	0.63	7.69	0.44	3.63e-13	Primary sclerosing cholangitis;
KIRP	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	0.94	11.19	0.58	9.06e-24	Vitiligo;
KIRP	cis	rs7536201	1.000	rs10794667	chr1:25304552	C/T	cg23273869	chr1:25296894	NA	-0.35	-5.01	-0.3	1.03e-6	Psoriasis vulgaris;
KIRP	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.66	0.34	4.28e-8	Aortic root size;
KIRP	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.52	2.77e-18	Prostate cancer;
KIRP	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	8.35	0.47	4.86e-15	Total body bone mineral density;
KIRP	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.65	-8.11	-0.46	2.34e-14	Aortic root size;
KIRP	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg01689657	chr7:91764605	CYP51A1	0.4	5.65	0.34	4.53e-8	Breast cancer;
KIRP	cis	rs365132	1.000	rs353478	chr5:176370988	T/C	cg16309518	chr5:176445507	NA	-0.89	-13.99	-0.67	4.13e-33	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-0.59	-7.9	-0.45	9.46e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.07	-0.36	4.9e-9	IgG glycosylation;
KIRP	cis	rs2554380	0.800	rs8034055	chr15:84411895	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.46	-6.45	-0.38	5.89e-10	Height;
KIRP	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	14.03	0.67	2.94e-33	Ulcerative colitis;
KIRP	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg15790184	chr11:494944	RNH1	0.42	5.2	0.31	4.15e-7	Systemic lupus erythematosus;
KIRP	cis	rs775227	0.574	rs60131925	chr3:113034768	T/C	cg18753928	chr3:113234510	CCDC52	-0.55	-5.46	-0.33	1.18e-7	Dental caries;
KIRP	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg06640241	chr16:89574553	SPG7	0.62	7.25	0.42	5.37e-12	Multiple myeloma (IgH translocation);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg11668638	chr6:42952412	PPP2R5D	0.67	6.23	0.37	2.01e-9	Lung function (FEV1);
KIRP	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.67	-8.16	-0.46	1.71e-14	Aortic root size;
KIRP	cis	rs2223471	0.546	rs489991	chr6:50601906	G/A	cg03432817	chr6:50765336	NA	-0.37	-5.63	-0.34	4.95e-8	Subcutaneous adipose tissue;
KIRP	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	12.2	0.61	4.24e-27	Menopause (age at onset);
KIRP	cis	rs12900413	0.687	rs28465116	chr15:90310152	T/C	cg24650279	chr15:90327240	NA	-0.41	-5.23	-0.32	3.7e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.64	7.83	0.45	1.45e-13	Multiple sclerosis;
KIRP	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.93	13.42	0.65	3.39e-31	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.96	13.93	0.66	6.44e-33	Alcohol dependence;
KIRP	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.99e-8	Height;
KIRP	cis	rs4919044	0.641	rs12357515	chr10:94725508	A/G	cg05127821	chr10:94822908	CYP26C1	-0.98	-7.87	-0.45	1.14e-13	Coronary artery disease;
KIRP	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg15083037	chr5:83017644	HAPLN1	0.53	8.06	0.46	3.37e-14	Prostate cancer;
KIRP	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.59	7.55	0.43	8.24e-13	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg05865280	chr17:75406074	SEPT9	0.53	12.45	0.62	6.67e-28	Airflow obstruction;
KIRP	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-19.26	-0.78	4.82e-51	Height;
KIRP	cis	rs4262150	0.764	rs2961765	chr5:151931175	C/T	cg12297329	chr5:152029980	NA	-0.53	-6.73	-0.39	1.21e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.76	-9.78	-0.53	2.67e-19	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.18	0.37	2.71e-9	Platelet count;
KIRP	cis	rs6032067	0.810	rs62208441	chr20:43839360	T/G	cg10761708	chr20:43804764	PI3	0.49	5.6	0.34	5.84e-8	Blood protein levels;
KIRP	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-8.86	-0.49	1.62e-16	Lymphocyte counts;
KIRP	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.54	6.09	0.36	4.21e-9	Blood metabolite levels;
KIRP	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.24	13.38	0.65	4.91e-31	Uric acid levels;
KIRP	cis	rs9399135	0.743	rs7745098	chr6:135415004	C/T	cg24558204	chr6:135376177	HBS1L	0.43	5.37	0.32	1.82e-7	Red blood cell count;
KIRP	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.27	12.12	0.61	7.96e-27	Diabetic retinopathy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18796520	chr12:4758272	NDUFA9	0.54	6.4	0.38	7.81e-10	Smoking initiation;
KIRP	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg04025307	chr7:1156635	C7orf50	0.79	12.33	0.62	1.57e-27	Longevity;Endometriosis;
KIRP	cis	rs9535307	0.745	rs2181185	chr13:50311925	C/T	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg01320579	chr17:75405842	SEPT9	0.47	7.76	0.44	2.21e-13	Airflow obstruction;
KIRP	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.51	6.89	0.4	4.7e-11	Testicular germ cell tumor;
KIRP	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.48	-5.67	-0.34	4.02e-8	Alzheimer's disease (late onset);
KIRP	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg23307798	chr14:103986281	CKB	-0.44	-5.89	-0.35	1.27e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.66	-8.25	-0.47	9.88e-15	Systemic lupus erythematosus;
KIRP	cis	rs6842047	0.520	rs4253425	chr4:187205929	T/C	cg02012338	chr4:187126139	CYP4V2	0.7	5.43	0.33	1.33e-7	Blood protein levels;
KIRP	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.65	-8.51	-0.48	1.77e-15	Monocyte count;
KIRP	cis	rs7224685	0.569	rs12452393	chr17:3985427	G/A	cg21734707	chr17:3908241	ZZEF1	0.52	4.87	0.3	2.04e-6	Type 2 diabetes;
KIRP	cis	rs10465746	0.746	rs6663949	chr1:84452853	T/C	cg10977910	chr1:84465055	TTLL7	0.6	7.62	0.44	5.36e-13	Obesity-related traits;
KIRP	cis	rs12220238	0.841	rs11000993	chr10:76084111	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.68	6.64	0.39	1.96e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs526821	0.595	rs624478	chr11:55340778	C/G	cg15704280	chr7:45808275	SEPT13	-0.51	-6.19	-0.37	2.48e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg12486944	chr17:80159399	CCDC57	0.39	5.23	0.32	3.61e-7	Life satisfaction;
KIRP	cis	rs2494938	0.730	rs1737679	chr6:40527525	G/A	cg14084896	chr6:40530702	LRFN2	-0.45	-5.83	-0.35	1.7e-8	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg18944383	chr4:111397179	ENPEP	-0.52	-6.09	-0.36	4.37e-9	Intraocular pressure;
KIRP	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg04865290	chr3:52927548	TMEM110	-0.61	-6.77	-0.4	9.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.43	-6.34	-0.37	1.07e-9	Coronary artery disease;
KIRP	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.64	-8.1	-0.46	2.58e-14	Personality dimensions;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06620762	chr15:76136437	UBE2Q2	0.59	7.08	0.41	1.51e-11	Smoking initiation;
KIRP	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.16	-0.37	3.02e-9	Bladder cancer;
KIRP	cis	rs3857747	0.792	rs10259706	chr7:40419192	T/G	cg00420559	chr7:40367873	C7orf10	0.62	8.07	0.46	3.17e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg00495681	chr13:53174319	NA	0.38	5.13	0.31	5.91e-7	Lewy body disease;
KIRP	trans	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg25042112	chr7:64838748	ZNF92	0.59	6.33	0.37	1.17e-9	Pain;
KIRP	cis	rs8028182	0.636	rs4886716	chr15:75856022	G/C	cg20655648	chr15:75932815	IMP3	0.52	6.64	0.39	1.94e-10	Sudden cardiac arrest;
KIRP	cis	rs4740619	0.619	rs4741557	chr9:16031080	C/T	cg14451791	chr9:16040625	NA	0.41	5.31	0.32	2.44e-7	Body mass index;
KIRP	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	3.99e-21	Mean corpuscular hemoglobin;
KIRP	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	8.17	0.46	1.59e-14	Neuroticism;
KIRP	cis	rs8177876	0.731	rs7188508	chr16:81113702	T/C	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17376030	chr22:41985996	PMM1	-0.81	-8.45	-0.47	2.55e-15	Vitiligo;
KIRP	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.46	6.47	0.38	5.31e-10	Red blood cell count;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.76	12.65	0.63	1.4e-28	Vitiligo;
KIRP	cis	rs12912292	1	rs12912292	chr15:56038707	G/A	cg17396834	chr15:56014697	PRTG	-0.53	-7.96	-0.45	6.35e-14	Testicular germ cell tumor;
KIRP	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg18404041	chr3:52824283	ITIH1	-0.43	-5.07	-0.31	7.69e-7	Schizophrenia;
KIRP	cis	rs10875746	0.551	rs3751273	chr12:48739438	T/C	cg26205652	chr12:48591994	NA	0.79	10.05	0.54	3.96e-20	Longevity (90 years and older);
KIRP	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg03684893	chr10:554711	DIP2C	-0.37	-5.46	-0.33	1.14e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs10073892	0.784	rs10052669	chr5:101622966	G/A	cg19774478	chr5:101632501	SLCO4C1	0.61	6.11	0.36	3.83e-9	Cognitive decline (age-related);
KIRP	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.23	-0.37	1.96e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg04369109	chr6:150039330	LATS1	-0.67	-8.22	-0.46	1.16e-14	Lung cancer;
KIRP	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg02153340	chr1:155202674	NA	0.37	5.11	0.31	6.5e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.47	7.11	0.41	1.25e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg03394422	chr14:75389280	RPS6KL1	-0.39	-4.95	-0.3	1.39e-6	Caffeine consumption;
KIRP	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6684514	1.000	rs12122180	chr1:156244559	G/A	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs12230513	0.732	rs61957765	chr12:55868561	T/C	cg19537932	chr12:55886519	OR6C68	-0.59	-7.34	-0.42	3.06e-12	Contrast sensitivity;
KIRP	cis	rs10465746	0.780	rs4907190	chr1:84409168	T/C	cg10977910	chr1:84465055	TTLL7	0.55	7.06	0.41	1.69e-11	Obesity-related traits;
KIRP	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.34	-4.93	-0.3	1.54e-6	Monocyte count;
KIRP	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs2644899	0.750	rs2604869	chr19:41283693	G/A	cg24958765	chr19:41283667	RAB4B	0.59	6.58	0.39	2.74e-10	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs6668534	0.679	rs10753610	chr1:161663823	C/G	cg26561570	chr1:161602002	FCGR3B	-0.4	-4.96	-0.3	1.3e-6	Blood protein levels;
KIRP	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg00857998	chr1:205179979	DSTYK	0.51	6.28	0.37	1.51e-9	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg21184320	chr1:21044207	KIF17	-0.36	-5.41	-0.33	1.52e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs2046867	0.862	rs9827405	chr3:72827115	C/T	cg25664220	chr3:72788482	NA	-0.42	-6.41	-0.38	7.55e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4664293	0.836	rs13401087	chr2:160617468	G/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs7582720	1.000	rs79633844	chr2:203683990	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.13	10.28	0.55	7.64e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.86	10.77	0.57	2.12e-22	Coronary artery disease;
KIRP	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.49	-7.1	-0.41	1.35e-11	Bipolar disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11967563	chr10:3186147	PITRM1	0.46	6.2	0.37	2.4e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.18e-7	Breast cancer;
KIRP	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.1e-9	Cognitive function;
KIRP	cis	rs1035144	0.506	rs2371416	chr14:81275672	A/T	cg06600135	chr14:81408086	NA	-0.56	-7.53	-0.43	9.9e-13	Male sexual orientation;
KIRP	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	6.42	0.38	7.12e-10	Personality dimensions;
KIRP	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg06289844	chr6:126071538	HEY2	0.44	6.55	0.39	3.33e-10	Brugada syndrome;
KIRP	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.47e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.82	-11.68	-0.6	2.33e-25	Dental caries;
KIRP	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.69	-5.41	-0.33	1.51e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.5	-6.98	-0.41	2.78e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-4.92	-0.3	1.61e-6	Ulcerative colitis;
KIRP	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.71	7.69	0.44	3.59e-13	Corneal astigmatism;
KIRP	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg23602478	chr1:26503979	CNKSR1	0.46	6.66	0.39	1.75e-10	Height;
KIRP	cis	rs8077577	0.708	rs28364628	chr17:18163262	C/T	cg16794390	chr17:18148240	FLII	0.45	4.92	0.3	1.56e-6	Obesity-related traits;
KIRP	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg04733989	chr22:42467013	NAGA	0.54	7.48	0.43	1.35e-12	Cognitive function;
KIRP	cis	rs73058052	0.597	rs10404887	chr19:50096421	C/G	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	6.03	0.36	6.06e-9	Fibrinogen levels;
KIRP	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.29	7.75	0.44	2.39e-13	Crohn's disease;
KIRP	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	cg04338863	chr8:33670619	NA	0.48	6.32	0.37	1.19e-9	Body mass index;
KIRP	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg16141378	chr3:129829833	LOC729375	-0.58	-7.36	-0.42	2.74e-12	Mood instability;
KIRP	cis	rs2904967	0.929	rs611910	chr11:65049278	A/G	cg09225861	chr11:65069680	NA	0.41	4.96	0.3	1.32e-6	Mean corpuscular volume;
KIRP	cis	rs714027	1.000	rs2412973	chr22:30529631	C/A	cg27665648	chr22:30112403	NA	-0.41	-5.94	-0.35	9.87e-9	Lymphocyte counts;
KIRP	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg03060546	chr3:49711283	APEH	-0.65	-6.7	-0.39	1.37e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3741151	0.686	rs12288753	chr11:73136261	A/T	cg17517138	chr11:73019481	ARHGEF17	0.69	5.87	0.35	1.39e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg13206674	chr6:150067644	NUP43	0.61	9.02	0.5	5.62e-17	Lung cancer;
KIRP	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-0.86	-10.04	-0.54	4.28e-20	Pediatric areal bone mineral density (radius);
KIRP	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg09408571	chr1:101003634	GPR88	0.24	5.18	0.31	4.71e-7	Breast cancer;
KIRP	cis	rs2150410	0.831	rs56151678	chr21:40526973	T/G	cg11890956	chr21:40555474	PSMG1	-0.75	-5.46	-0.33	1.15e-7	Temperament (bipolar disorder);
KIRP	cis	rs13315871	1.000	rs13320620	chr3:58408845	A/G	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.62	0.44	5.57e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6700559	0.692	rs12126676	chr1:200600820	T/C	cg07804481	chr1:200639085	DDX59	0.53	6.95	0.4	3.36e-11	Coronary artery disease;
KIRP	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg13271783	chr10:134563150	INPP5A	-0.62	-7.96	-0.45	6.31e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.18	0.42	8.4e-12	Prudent dietary pattern;
KIRP	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg24189917	chr7:1970923	MAD1L1	-0.55	-4.9	-0.3	1.72e-6	Bipolar disorder;
KIRP	cis	rs12210905	0.688	rs72839471	chr6:27316959	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.34	-0.37	1.07e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00451651	chr8:100252466	VPS13B	-0.46	-7.04	-0.41	1.9e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs11634944	1.000	rs12916854	chr15:25200902	A/G	cg10471437	chr16:28074462	GSG1L	0.51	6.24	0.37	1.9e-9	Interleukin-8 levels;
KIRP	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.39	-5.45	-0.33	1.21e-7	Endometrial cancer;
KIRP	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg22117172	chr7:91764530	CYP51A1	-0.45	-6.34	-0.37	1.07e-9	Breast cancer;
KIRP	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.5	-7.06	-0.41	1.7e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs7116495	1.000	rs7127865	chr11:71747781	G/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg00405596	chr8:11794950	NA	-0.43	-5.33	-0.32	2.21e-7	Neuroticism;
KIRP	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg22974920	chr21:40686053	BRWD1	0.5	6.12	0.36	3.62e-9	Cognitive function;
KIRP	cis	rs13102973	0.965	rs6853276	chr4:135881445	A/T	cg14419869	chr4:135874104	NA	0.54	9.18	0.51	1.84e-17	Subjective well-being;
KIRP	trans	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	6.73	0.39	1.16e-10	Electroencephalogram traits;
KIRP	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06481639	chr22:41940642	POLR3H	0.57	6.4	0.38	7.94e-10	Vitiligo;
KIRP	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg25319279	chr11:5960081	NA	-0.6	-6.17	-0.37	2.87e-9	DNA methylation (variation);
KIRP	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.59	-6.4	-0.38	7.75e-10	Bipolar disorder;
KIRP	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg00677455	chr12:58241039	CTDSP2	0.6	7.35	0.42	3e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg21738971	chr2:106810986	UXS1	0.53	6.44	0.38	6.38e-10	Myopia (pathological);
KIRP	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.72	-8.8	-0.49	2.44e-16	Cognitive function;
KIRP	cis	rs6499188	0.510	rs9923262	chr16:68613106	A/G	cg02972257	chr16:68554789	NA	-0.72	-6.68	-0.39	1.61e-10	Ulcerative colitis;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Blood metabolite levels;
KIRP	trans	rs7863100	0.711	rs35083940	chr9:18641557	T/G	cg13196806	chr10:133996309	JAKMIP3	0.6	6.06	0.36	5.14e-9	Hip circumference (psychosocial stress interaction);
KIRP	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.64	8.85	0.49	1.76e-16	Heart rate;
KIRP	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg05072774	chr3:49840536	C3orf54	-0.42	-4.92	-0.3	1.55e-6	Resting heart rate;
KIRP	trans	rs7084921	0.578	rs11190393	chr10:101869988	C/T	cg13808641	chr9:96006533	WNK2	-0.41	-6.25	-0.37	1.76e-9	Bone mineral density;
KIRP	cis	rs7127900	0.948	rs114099824	chr11:2227193	C/G	cg25635251	chr11:2234043	NA	0.53	7.92	0.45	8.28e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs2742417	1.000	rs938362	chr3:45746365	T/C	cg04037228	chr3:45636386	LIMD1	0.35	5.03	0.31	9.66e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs909341	0.909	rs2750480	chr20:62342654	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.91	-0.4	4.04e-11	Atopic dermatitis;
KIRP	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	7.82	0.45	1.5e-13	Coffee consumption (cups per day);
KIRP	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg10047753	chr17:41438598	NA	1.14	17.86	0.75	2.67e-46	Menopause (age at onset);
KIRP	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.86	11.54	0.59	6.5e-25	Longevity;
KIRP	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.99	15.19	0.7	3.19e-37	Sudden cardiac arrest;
KIRP	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg13271783	chr10:134563150	INPP5A	-0.61	-7.88	-0.45	1.06e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg03929089	chr4:120376271	NA	1.0	7.01	0.41	2.3e-11	Myopia (pathological);
KIRP	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg15934090	chr1:100435551	SLC35A3	0.52	6.49	0.38	4.8e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs13170463	0.579	rs77901373	chr5:8037342	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	trans	rs7999699	0.870	rs17337706	chr13:48302571	C/T	cg23237801	chr1:16476620	EPHA2	0.51	6.26	0.37	1.74e-9	Colorectal cancer (diet interaction);
KIRP	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.58	7.72	0.44	2.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.62	8.06	0.46	3.3e-14	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg02002194	chr4:3960332	NA	-0.44	-6.48	-0.38	4.92e-10	Mood instability;
KIRP	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs783540	0.521	rs1259176	chr15:83270898	G/A	cg16105309	chr15:79090380	ADAMTS7	0.58	7.05	0.41	1.76e-11	Schizophrenia;
KIRP	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	8.14	0.46	1.99e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.36	-6.24	-0.37	1.88e-9	Refractive error;
KIRP	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs72781680	0.611	rs55868657	chr2:24295385	G/A	cg20701182	chr2:24300061	SF3B14	0.99	10.84	0.57	1.2e-22	Lymphocyte counts;
KIRP	cis	rs78487399	0.710	rs79165612	chr2:43624252	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-5.14	-0.31	5.56e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg24807547	chr6:37504484	NA	-0.62	-10.0	-0.54	5.65e-20	Cognitive performance;
KIRP	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.87	10.84	0.57	1.22e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg00814883	chr7:100076585	TSC22D4	-0.52	-5.02	-0.3	9.79e-7	Lung function (FEV1/FVC);
KIRP	cis	rs6504950	0.790	rs8066833	chr17:53025475	A/G	cg26251398	chr17:52985966	TOM1L1	0.42	5.2	0.31	4.12e-7	Breast cancer;
KIRP	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.36	-0.38	9.8e-10	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.94	-9.04	-0.5	4.79e-17	IgG glycosylation;
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg11641102	chr8:27183873	PTK2B	0.47	6.09	0.36	4.25e-9	Neuroticism;
KIRP	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.49	6.08	0.36	4.6e-9	Arsenic metabolism;
KIRP	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg02151108	chr14:50098012	C14orf104	-0.51	-7.03	-0.41	2.07e-11	Carotid intima media thickness;
KIRP	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg21775007	chr8:11205619	TDH	-0.46	-6.28	-0.37	1.54e-9	Neuroticism;
KIRP	cis	rs15300	1.000	rs15300	chr6:8413412	A/G	cg21535247	chr6:8435926	SLC35B3	0.89	4.91	0.3	1.64e-6	Pursuit maintenance gain;
KIRP	cis	rs829661	0.947	rs829578	chr2:30680232	G/T	cg10949345	chr2:30726833	LCLAT1	0.73	10.16	0.54	1.73e-20	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.46	6.26	0.37	1.67e-9	Coronary artery disease;
KIRP	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.93	-0.4	3.62e-11	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15018694	chr5:102463772	HISPPD1	-0.4	-6.2	-0.37	2.37e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg13206674	chr6:150067644	NUP43	0.49	6.88	0.4	4.79e-11	Lung cancer;
KIRP	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.63	-7.48	-0.43	1.32e-12	Systemic lupus erythematosus;
KIRP	cis	rs3743266	0.507	rs62003261	chr15:60761489	T/C	cg22293140	chr15:60689852	ANXA2	-0.63	-5.69	-0.34	3.64e-8	Menarche (age at onset);
KIRP	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.35	6.23	0.37	2.06e-9	Renal cell carcinoma;
KIRP	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	0.99	15.92	0.71	1.09e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs6752107	0.967	rs10203952	chr2:234153366	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.54	7.14	0.41	1.05e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg13512537	chr8:22265999	SLC39A14	-0.43	-5.82	-0.35	1.85e-8	Verbal declarative memory;
KIRP	cis	rs2598107	0.601	rs2167268	chr7:37942528	A/C	cg25225232	chr7:37962694	EPDR1	-0.42	-4.96	-0.3	1.34e-6	Dupuytren's disease;
KIRP	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg11271282	chr2:238384023	NA	0.45	5.2	0.31	4.1e-7	Prostate cancer;
KIRP	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.22	-0.51	1.35e-17	Response to antipsychotic treatment;
KIRP	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg24631222	chr15:78858424	CHRNA5	0.44	5.66	0.34	4.28e-8	Sudden cardiac arrest;
KIRP	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14598338	chr9:96623480	NA	0.61	9.35	0.51	5.5e-18	DNA methylation (variation);
KIRP	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg18964960	chr10:1102726	WDR37	-0.64	-7.08	-0.41	1.47e-11	Response to angiotensin II receptor blocker therapy;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09119654	chr2:61293073	KIAA1841	-0.5	-6.74	-0.39	1.13e-10	Metabolic traits;
KIRP	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.63	-7.37	-0.43	2.55e-12	Resting heart rate;
KIRP	cis	rs9815354	0.812	rs57162396	chr3:41896031	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	11.24	0.58	6.22e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.81	-0.45	1.69e-13	Tonsillectomy;
KIRP	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.28	17.56	0.75	2.69e-45	Corneal structure;
KIRP	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg04306507	chr14:55594613	LGALS3	0.42	6.35	0.38	1.04e-9	Protein biomarker;
KIRP	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.68	-0.34	3.72e-8	Aortic root size;
KIRP	cis	rs8060598	0.528	rs4785227	chr16:50842197	G/T	cg26811425	chr16:49870782	NA	0.26	4.88	0.3	1.9e-6	Leprosy;
KIRP	cis	rs6832769	0.826	rs58894703	chr4:56358538	G/A	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.8	9.9	0.53	1.12e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9400467	0.506	rs12196873	chr6:111598058	G/T	cg15721981	chr6:111408429	SLC16A10	-0.75	-6.87	-0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.61	7.64	0.44	4.85e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.43	-0.38	6.44e-10	QT interval;
KIRP	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.58	-8.98	-0.5	7.15e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.04	-13.28	-0.65	1.02e-30	Vitiligo;
KIRP	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg17509989	chr5:176798049	RGS14	0.88	10.62	0.56	6.29e-22	Urinary electrolytes (magnesium/calcium ratio);
KIRP	cis	rs4356975	0.563	rs55834557	chr4:69966594	A/T	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.53	-6.48	-0.38	5.06e-10	Type 2 diabetes;
KIRP	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg11584989	chr19:19387371	SF4	-0.41	-5.19	-0.31	4.43e-7	Tonsillectomy;
KIRP	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.57	0.33	6.79e-8	Tonsillectomy;
KIRP	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12292205	chr6:26970375	C6orf41	-0.68	-8.0	-0.45	5.04e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg11173246	chr11:841376	TSPAN4;POLR2L	-0.36	-5.25	-0.32	3.34e-7	Mean platelet volume;
KIRP	cis	rs883565	0.654	rs7642737	chr3:39032469	T/C	cg01426195	chr3:39028469	NA	-0.69	-11.72	-0.6	1.71e-25	Handedness;
KIRP	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-7.11	-0.41	1.24e-11	Electroencephalogram traits;
KIRP	cis	rs56161922	1.000	rs11118363	chr1:207859251	G/A	cg11752769	chr1:207818423	CR1L	0.77	4.98	0.3	1.2e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs12210905	0.688	rs60888769	chr6:27490922	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.76	-5.47	-0.33	1.12e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.62	-5.44	-0.33	1.28e-7	Body mass index;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg01302165	chr20:35492437	C20orf117	0.49	6.24	0.37	1.94e-9	Myopia (pathological);
KIRP	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.4e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.53	-6.1	-0.36	4.19e-9	Inhibitory control;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21016266	chr12:122356598	WDR66	0.62	8.66	0.48	6.5e-16	Mean corpuscular volume;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg02050903	chr11:44117243	EXT2	-0.48	-6.41	-0.38	7.5e-10	Myopia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg08907819	chr7:70255804	AUTS2	-0.49	-6.64	-0.39	2.04e-10	Inflammatory biomarkers;
KIRP	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02725872	chr8:58115012	NA	-0.57	-6.79	-0.4	8.48e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg16950941	chr11:66035639	RAB1B	0.53	7.36	0.42	2.7e-12	Gout;
KIRP	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.43	-0.55	2.54e-21	Height;
KIRP	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg12292205	chr6:26970375	C6orf41	-0.4	-5.44	-0.33	1.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4776059	1.000	rs35372377	chr15:52882281	G/A	cg25063058	chr15:52860530	ARPP19	0.62	6.75	0.4	1.07e-10	Schizophrenia;
KIRP	cis	rs8084125	0.765	rs72981157	chr18:74944238	A/G	cg26065057	chr18:74961000	GALR1	0.61	6.15	0.37	3.07e-9	Obesity-related traits;
KIRP	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg21361702	chr7:150065534	REPIN1	0.62	6.52	0.38	3.99e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg13010199	chr12:38710504	ALG10B	0.59	8.18	0.46	1.53e-14	Morning vs. evening chronotype;
KIRP	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.52	-7.04	-0.41	1.96e-11	Breast cancer;
KIRP	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg24642844	chr7:1081250	C7orf50	-0.83	-7.0	-0.41	2.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11209185	0.509	rs9436791	chr1:68452857	A/C	cg22082780	chr1:68452167	NA	0.37	5.43	0.33	1.36e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.29	-4.92	-0.3	1.59e-6	Monocyte count;
KIRP	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.16	0.37	2.99e-9	Ovarian reserve;
KIRP	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.56	-7.86	-0.45	1.17e-13	Motion sickness;
KIRP	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.12	-0.64	3.53e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.62	5.01	0.3	1.06e-6	Developmental language disorder (linguistic errors);
KIRP	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.72	-0.53	4.15e-19	Triglycerides;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.55	-6.58	-0.39	2.77e-10	Longevity;Endometriosis;
KIRP	cis	rs10489202	0.535	rs12736786	chr1:167988283	C/G	cg24449463	chr1:168025552	DCAF6	-0.58	-7.84	-0.45	1.34e-13	Schizophrenia;
KIRP	cis	rs7534824	0.625	rs61780281	chr1:101324152	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.66	5.73	0.34	2.86e-8	Refractive astigmatism;
KIRP	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg09795085	chr6:101329169	ASCC3	-0.5	-6.02	-0.36	6.19e-9	Neuroticism;
KIRP	cis	rs258892	0.843	rs4260644	chr5:72031375	A/T	cg21869765	chr5:72125136	TNPO1	-0.53	-6.05	-0.36	5.23e-9	Small cell lung carcinoma;
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg11204139	chr17:3907470	NA	0.86	16.53	0.73	8.36e-42	Type 2 diabetes;
KIRP	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.79	8.48	0.48	2.11e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.56	7.78	0.44	1.99e-13	Multiple system atrophy;
KIRP	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.9	16.24	0.72	8.56e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg01028140	chr2:1542097	TPO	-0.52	-5.92	-0.35	1.08e-8	IgG glycosylation;
KIRP	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.33	-5.27	-0.32	3.01e-7	Asthma;
KIRP	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg06121193	chr1:90282411	NA	-0.51	-7.18	-0.42	8.02e-12	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	0.42	5.33	0.32	2.27e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.29	-0.51	8.7e-18	Response to antipsychotic treatment;
KIRP	cis	rs2851682	0.706	rs2727270	chr11:61603237	C/T	cg07689907	chr11:61582574	FADS1	0.61	4.88	0.3	1.9e-6	Gestational age at birth (child effect);Trans fatty acid levels;
KIRP	cis	rs4789452	0.509	rs2627208	chr17:75353102	A/G	cg01320579	chr17:75405842	SEPT9	-0.34	-5.62	-0.34	5.07e-8	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9311676	0.632	rs6774577	chr3:58361716	A/G	cg06643156	chr3:58380774	PXK	0.36	5.11	0.31	6.46e-7	Systemic lupus erythematosus;
KIRP	cis	rs7737355	0.947	rs6884741	chr5:130894613	A/G	cg25547332	chr5:131281432	NA	0.45	5.0	0.3	1.08e-6	Life satisfaction;
KIRP	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg16141378	chr3:129829833	LOC729375	0.63	8.68	0.48	5.72e-16	Triglycerides;
KIRP	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.94	12.56	0.63	2.71e-28	Coronary artery disease;
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg23978390	chr7:1156363	C7orf50	0.55	5.42	0.33	1.41e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	1.17	9.34	0.51	6.2e-18	LDL cholesterol;
KIRP	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg00361562	chr2:198649771	BOLL	-0.51	-4.92	-0.3	1.55e-6	Ulcerative colitis;
KIRP	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.61	-10.01	-0.54	5.32e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Corneal astigmatism;
KIRP	cis	rs7225151	0.803	rs78531165	chr17:5179846	T/C	cg24500398	chr17:5266808	RABEP1	-0.58	-5.83	-0.35	1.78e-8	Alzheimer's disease (late onset);
KIRP	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	1.11	15.56	0.7	1.84e-38	Breast cancer;
KIRP	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg20140201	chr2:241835670	C2orf54	-0.35	-5.32	-0.32	2.31e-7	Urinary metabolites;
KIRP	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg08822215	chr16:89438651	ANKRD11	0.43	5.21	0.32	4.03e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs9309473	1.000	rs11689392	chr2:73622026	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-5.45	-0.33	1.23e-7	Metabolite levels;
KIRP	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.38e-10	Diabetic retinopathy;
KIRP	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg12856521	chr11:46389249	DGKZ	0.53	6.98	0.41	2.73e-11	Crohn's disease;
KIRP	cis	rs6991838	0.584	rs11985628	chr8:66542739	T/C	cg13398993	chr8:66546079	ARMC1	0.45	5.23	0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs258892	0.895	rs266437	chr5:72167441	G/C	cg21869765	chr5:72125136	TNPO1	0.58	6.27	0.37	1.63e-9	Small cell lung carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11074378	chr7:5938227	C7orf28A	0.48	6.68	0.39	1.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs12615966	0.872	rs72830429	chr2:105367977	T/C	cg16465502	chr2:105461796	NA	0.68	6.04	0.36	5.51e-9	Pancreatic cancer;
KIRP	trans	rs526821	0.595	rs485555	chr11:55323570	A/G	cg15704280	chr7:45808275	SEPT13	0.51	6.07	0.36	4.81e-9	Pediatric bone mineral density (spine);
KIRP	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg17376030	chr22:41985996	PMM1	-0.54	-6.59	-0.39	2.69e-10	Vitiligo;
KIRP	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.07	0.31	7.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12936587	1.000	rs12936587	chr17:17543722	G/A	cg01246520	chr17:17644344	RAI1	-0.35	-5.84	-0.35	1.68e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg16898833	chr6:26189333	HIST1H4D	0.98	5.91	0.35	1.14e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.42	-5.38	-0.32	1.76e-7	Blood metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14794577	chr12:53774438	SP1	0.51	6.56	0.39	3.1e-10	Parkinson's disease;
KIRP	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	4.04e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-11.83	-0.6	7.35e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Hypertriglyceridemia;
KIRP	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg24633833	chr3:10029261	TMEM111	0.56	5.51	0.33	9.17e-8	Alzheimer's disease;
KIRP	cis	rs7923609	1.000	rs4399232	chr10:64999490	C/T	cg01631684	chr10:65280961	REEP3	-0.48	-5.72	-0.34	3.1e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs1864585	0.520	rs12155811	chr8:10673513	C/T	cg26278703	chr11:58910052	FAM111A	0.65	6.34	0.37	1.07e-9	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-5.02	-0.31	9.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg07636037	chr3:49044803	WDR6	-0.74	-5.59	-0.34	6.11e-8	Cognitive function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26816363	chr19:46295874	DMWD	0.54	6.89	0.4	4.6e-11	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15605097	chr11:75479463	DGAT2	0.47	6.32	0.37	1.22e-9	Parkinson's disease;
KIRP	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg24747557	chr10:131355152	MGMT	-0.38	-5.23	-0.32	3.71e-7	Response to temozolomide;
KIRP	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.91	12.67	0.63	1.17e-28	Cognitive function;
KIRP	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.59	-8.44	-0.47	2.81e-15	Myopia (pathological);
KIRP	cis	rs7614311	0.636	rs73117045	chr3:63910613	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-5.26	-0.32	3.07e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs10073892	0.583	rs28417846	chr5:101976873	T/A	cg19774478	chr5:101632501	SLCO4C1	0.53	5.47	0.33	1.09e-7	Cognitive decline (age-related);
KIRP	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.59	-7.44	-0.43	1.7e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.53	-7.26	-0.42	5.02e-12	Height;
KIRP	cis	rs34779708	0.931	rs66887762	chr10:35330577	C/T	cg03585969	chr10:35415529	CREM	0.83	9.97	0.54	6.96e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-9.36	-0.51	5.34e-18	Total body bone mineral density;
KIRP	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg15192750	chr16:69999425	NA	0.46	4.9	0.3	1.77e-6	IgE levels;
KIRP	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-1.21	-14.09	-0.67	1.95e-33	Breast cancer;
KIRP	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.79	-10.42	-0.55	2.63e-21	Body mass index;
KIRP	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	9.48	0.52	2.32e-18	Alzheimer's disease;
KIRP	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.65	7.51	0.43	1.07e-12	Corneal astigmatism;
KIRP	cis	rs7072216	0.922	rs59667296	chr10:100146313	A/T	cg26618903	chr10:100175079	PYROXD2	-0.35	-5.25	-0.32	3.3e-7	Metabolite levels;
KIRP	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg15181151	chr6:150070149	PCMT1	0.31	5.18	0.31	4.7e-7	Lung cancer;
KIRP	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.66	8.08	0.46	2.94e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12311346	chr5:56204834	C5orf35	-0.49	-6.61	-0.39	2.34e-10	Coronary artery disease;
KIRP	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.69	9.4	0.51	3.85e-18	Blood metabolite levels;
KIRP	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg00931491	chr16:28608288	SULT1A2	-0.26	-4.85	-0.3	2.16e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.65	8.76	0.49	3.33e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.52	6.83	0.4	6.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.73	8.26	0.47	9.17e-15	Corneal astigmatism;
KIRP	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.34	-0.37	1.09e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.96	11.73	0.6	1.61e-25	Corneal astigmatism;
KIRP	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg26513180	chr16:89883248	FANCA	0.82	5.42	0.33	1.43e-7	Skin colour saturation;
KIRP	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.53	5.75	0.34	2.59e-8	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03093398	chr4:76598524	G3BP2	0.47	6.44	0.38	6.38e-10	Survival in pancreatic cancer;
KIRP	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.76	9.48	0.52	2.28e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12049351	0.774	rs4148760	chr1:229673934	G/C	cg11742688	chr1:229674241	ABCB10	-0.42	-6.83	-0.4	6.49e-11	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.87	0.49	1.53e-16	Life satisfaction;
KIRP	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.24	-0.55	9.68e-21	Hypospadias;
KIRP	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg02367723	chr1:46378857	MAST2	0.42	4.85	0.3	2.21e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11628318	0.614	rs7155489	chr14:103123119	C/T	cg12046867	chr14:103022105	NA	0.56	6.18	0.37	2.63e-9	Platelet count;
KIRP	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.61	8.25	0.47	9.9e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs1832871	0.619	rs827861	chr6:158710074	C/A	cg07215822	chr6:158701037	NA	-0.58	-8.46	-0.47	2.48e-15	Height;
KIRP	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.02	0.41	2.22e-11	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04312406	chr1:226497240	LIN9	0.5	6.1	0.36	4.1e-9	Parkinson's disease;
KIRP	cis	rs6088813	1.000	rs4911494	chr20:33971914	C/T	cg14752227	chr20:34000481	UQCC	-0.52	-6.88	-0.4	5.02e-11	Height;
KIRP	cis	rs2880765	0.546	rs8042776	chr15:86055629	T/C	cg10818794	chr15:86012489	AKAP13	-0.54	-6.95	-0.41	3.24e-11	Coronary artery disease;
KIRP	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg27205649	chr11:78285834	NARS2	0.62	7.38	0.43	2.44e-12	Alzheimer's disease (survival time);
KIRP	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.98	9.73	0.53	3.96e-19	Body mass index;
KIRP	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.44	-4.97	-0.3	1.26e-6	HDL cholesterol;
KIRP	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg21466736	chr12:48725269	NA	0.42	5.24	0.32	3.38e-7	Glycated hemoglobin levels;
KIRP	cis	rs4699052	0.893	rs4699058	chr4:104171321	T/A	cg16532752	chr4:104119610	CENPE	-0.42	-5.07	-0.31	8e-7	Testicular germ cell tumor;
KIRP	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-13.95	-0.66	5.53e-33	Blood trace element (Zn levels);
KIRP	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.07	-0.31	7.68e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-8.61	-0.48	8.64e-16	Resting heart rate;
KIRP	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.67	8.97	0.5	7.97e-17	Motion sickness;
KIRP	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.86	-9.64	-0.52	7.22e-19	Lymphocyte counts;Red cell distribution width;
KIRP	cis	rs55962025	0.804	rs362268	chr4:3242148	C/G	cg13731523	chr4:3047190	NA	0.34	5.27	0.32	2.97e-7	Parental longevity (mother's age at death);
KIRP	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.45	6.04	0.36	5.68e-9	Hemoglobin concentration;
KIRP	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.55	6.58	0.39	2.81e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.39	5.17	0.31	4.77e-7	Longevity;
KIRP	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07570687	chr10:102243282	WNT8B	-0.5	-6.83	-0.4	6.76e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.45	-5.48	-0.33	1.07e-7	Iron status biomarkers;
KIRP	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.85	10.5	0.56	1.45e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.41	5.0	0.3	1.07e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg07001201	chr5:642380	CEP72	0.59	5.77	0.35	2.36e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg22604316	chr1:46958801	NA	-0.34	-4.91	-0.3	1.67e-6	Monobrow;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22051586	chr4:881820	GAK	0.52	6.52	0.38	3.88e-10	Interleukin-4 levels;
KIRP	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-4.95	-0.3	1.4e-6	Large artery stroke;
KIRP	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.88	0.6	4.88e-26	Ileal carcinoids;
KIRP	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.72	8.66	0.48	6.42e-16	Alcohol dependence;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg21224049	chr4:668623	ATP5I	0.54	7.18	0.42	8.4e-12	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg16141378	chr3:129829833	LOC729375	-0.52	-7.18	-0.42	8.08e-12	Neuroticism;
KIRP	cis	rs8060686	0.668	rs9932414	chr16:68219969	A/G	cg26727032	chr16:67993705	SLC12A4	-0.74	-9.03	-0.5	5.03e-17	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.79	-10.86	-0.57	1.06e-22	Educational attainment;
KIRP	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.9	-12.41	-0.62	9.06e-28	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.34	-0.32	2.11e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.16	-0.31	5.07e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.1	-12.58	-0.63	2.31e-28	Vitiligo;
KIRP	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	0.82	9.79	0.53	2.49e-19	Prostate cancer;
KIRP	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.94	10.91	0.57	7.2e-23	Neuroticism;
KIRP	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg10932868	chr11:921992	NA	0.55	6.9	0.4	4.3e-11	Alzheimer's disease (late onset);
KIRP	cis	rs4746818	1.000	rs1506769	chr10:70959710	T/C	cg11621586	chr10:70884670	VPS26A	1.08	13.27	0.65	1.12e-30	Left atrial antero-posterior diameter;
KIRP	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg27411982	chr8:10470053	RP1L1	0.42	5.47	0.33	1.08e-7	Retinal vascular caliber;
KIRP	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs282587	0.569	rs401223	chr13:113375721	C/T	cg04656015	chr13:113407548	ATP11A	-0.59	-6.78	-0.4	8.84e-11	Glycated hemoglobin levels;
KIRP	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.88	-0.4	4.81e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1208285	0.564	rs9375993	chr6:134204997	A/T	cg06643013	chr6:134217242	NA	-0.44	-5.12	-0.31	6.29e-7	Infantile hypertrophic pyloric stenosis;
KIRP	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg00343986	chr7:65444356	GUSB	0.44	5.15	0.31	5.36e-7	Aortic root size;
KIRP	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg16339924	chr4:17578868	LAP3	-0.63	-8.18	-0.46	1.56e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.43	6.48	0.38	4.9e-10	Neuroticism;
KIRP	cis	rs3829109	0.564	rs12378717	chr9:139286060	G/C	cg21253087	chr9:139290292	SNAPC4	0.47	4.89	0.3	1.83e-6	Peak insulin response;Acute insulin response;
KIRP	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	1.0	18.13	0.76	3.17e-47	Leprosy;
KIRP	cis	rs7707921	0.767	rs862242	chr5:81587566	C/T	cg07807695	chr5:81608485	ATP6AP1L	0.44	5.77	0.35	2.38e-8	Breast cancer;
KIRP	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-8.03	-0.46	3.95e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.83	15.76	0.71	3.84e-39	Anterior chamber depth;
KIRP	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.32	5.09	0.31	6.98e-7	Inflammatory bowel disease;
KIRP	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.69	-7.24	-0.42	5.67e-12	Urate levels in lean individuals;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11374977	chr7:127026595	ZNF800	-0.45	-6.89	-0.4	4.58e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.34e-15	Bone mineral density;
KIRP	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.51	-6.2	-0.37	2.36e-9	Ulcerative colitis;
KIRP	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg24476569	chr13:95954382	ABCC4	-0.6	-9.24	-0.51	1.24e-17	Blood metabolite levels;
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06544989	chr22:39130855	UNC84B	0.51	8.37	0.47	4.3e-15	Menopause (age at onset);
KIRP	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg17724175	chr1:150552817	MCL1	0.32	5.4	0.33	1.59e-7	Melanoma;
KIRP	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20135002	chr11:47629003	NA	-0.45	-4.96	-0.3	1.33e-6	Subjective well-being;
KIRP	cis	rs8077577	0.945	rs62072496	chr17:18124743	G/A	cg09161412	chr17:18057145	MYO15A	-0.41	-5.09	-0.31	6.96e-7	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00166722	chr3:10149974	C3orf24	0.48	4.93	0.3	1.53e-6	Alzheimer's disease;
KIRP	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.5	0.33	9.7e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1961637	0.960	rs10460430	chr2:223906286	A/C	cg02552189	chr2:223891284	NA	-0.39	-5.22	-0.32	3.72e-7	Oropharynx cancer;
KIRP	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.68	-8.4	-0.47	3.6e-15	Extraversion;
KIRP	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg01620082	chr3:125678407	NA	-1.05	-6.81	-0.4	7.28e-11	Depression;
KIRP	cis	rs11710088	0.895	rs66609533	chr3:149200132	T/C	cg08667024	chr3:149219783	TM4SF4	-0.38	-5.54	-0.33	7.6e-8	QRS duration;
KIRP	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg16497661	chr14:103986332	CKB	-0.41	-5.25	-0.32	3.3e-7	Coronary artery disease;
KIRP	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg23307798	chr14:103986281	CKB	-0.38	-5.08	-0.31	7.64e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.62	-7.14	-0.41	1.07e-11	Blood trace element (Cu levels);
KIRP	cis	rs6681460	0.966	rs10789215	chr1:67151185	C/T	cg02459107	chr1:67143332	SGIP1	-0.51	-7.22	-0.42	6.45e-12	Presence of antiphospholipid antibodies;
KIRP	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.01	-7.57	-0.43	7.63e-13	Mitochondrial DNA levels;
KIRP	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg04398451	chr17:18023971	MYO15A	0.67	8.89	0.49	1.32e-16	Total body bone mineral density;
KIRP	cis	rs35740288	0.770	rs11630968	chr15:86118001	C/T	cg10818794	chr15:86012489	AKAP13	-0.45	-5.49	-0.33	1.01e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg08742575	chr21:47604166	C21orf56	0.43	5.8	0.35	2e-8	Testicular germ cell tumor;
KIRP	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.41	5.11	0.31	6.37e-7	Lung cancer;
KIRP	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.46	-6.46	-0.38	5.64e-10	Coronary artery disease;
KIRP	cis	rs12973672	0.812	rs10421096	chr19:35764559	C/T	cg12095397	chr19:35769544	USF2	0.68	6.3	0.37	1.39e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.65	-9.27	-0.51	9.83e-18	Retinal vascular caliber;
KIRP	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs12044355	0.927	rs11585959	chr1:231833718	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.49	-5.89	-0.35	1.23e-8	Alzheimer's disease;
KIRP	cis	rs6967385	0.560	rs12539290	chr7:12344101	T/G	cg20607287	chr7:12443886	VWDE	0.39	4.96	0.3	1.31e-6	Response to taxane treatment (placlitaxel);
KIRP	cis	rs738722	0.514	rs6005790	chr22:28876170	C/G	cg16849201	chr22:29715310	NA	0.32	5.32	0.32	2.34e-7	Optic cup area;Esophageal cancer and gastric cancer;
KIRP	cis	rs240764	0.555	rs6919283	chr6:101235769	C/T	cg09795085	chr6:101329169	ASCC3	0.45	5.22	0.32	3.85e-7	Neuroticism;
KIRP	cis	rs6693295	1.000	rs35757106	chr1:246219473	C/T	cg11798871	chr1:246315928	SMYD3	-0.44	-5.27	-0.32	3.03e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs9682041	1.000	rs4955588	chr3:170072864	C/A	cg11886554	chr3:170076028	SKIL	0.56	5.86	0.35	1.46e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg24796726	chr7:884288	UNC84A	-0.6	-5.26	-0.32	3.14e-7	Initial pursuit acceleration;
KIRP	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg00149659	chr3:10157352	C3orf10	0.92	9.81	0.53	2.19e-19	Alzheimer's disease;
KIRP	cis	rs1568889	0.877	rs17310076	chr11:28147590	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	8.13	0.46	2.13e-14	Bipolar disorder;
KIRP	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-7.62	-0.44	5.62e-13	Bipolar disorder;
KIRP	cis	rs4664304	0.739	rs66814375	chr2:160716059	C/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-6.34	-0.37	1.12e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.2	-21.42	-0.81	3.66e-58	Cognitive function;
KIRP	trans	rs2302464	1.000	rs10939630	chr4:15658481	A/G	cg03228132	chr7:129781429	NA	-0.6	-6.6	-0.39	2.47e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.48	6.66	0.39	1.76e-10	Testicular germ cell tumor;
KIRP	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.78	10.06	0.54	3.62e-20	Neutrophil percentage of white cells;
KIRP	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.76	11.1	0.58	1.74e-23	Hip circumference;
KIRP	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg01557791	chr16:72042693	DHODH	-0.4	-4.97	-0.3	1.23e-6	Fibrinogen levels;
KIRP	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg04398451	chr17:18023971	MYO15A	0.66	8.56	0.48	1.28e-15	Total body bone mineral density;
KIRP	cis	rs4132509	0.948	rs320322	chr1:243750755	G/A	cg25706552	chr1:244017396	NA	-0.6	-8.31	-0.47	6.5e-15	RR interval (heart rate);
KIRP	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.25	-0.42	5.41e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg13147721	chr7:65941812	NA	1.02	7.05	0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.64	-7.03	-0.41	2e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg07395648	chr5:131743802	NA	-0.38	-5.59	-0.34	6.13e-8	Acylcarnitine levels;
KIRP	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg20295408	chr7:1910781	MAD1L1	-0.48	-5.35	-0.32	2.03e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.58	-0.39	2.8e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6669919	0.967	rs11119752	chr1:211675765	A/G	cg10512769	chr1:211675356	NA	-0.65	-10.18	-0.54	1.51e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs1147199	0.585	rs72737615	chr9:87244660	G/A	cg22402007	chr9:87282823	NTRK2	0.4	4.88	0.3	1.93e-6	Body mass index;
KIRP	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.61	6.63	0.39	2.06e-10	Exhaled nitric oxide output;
KIRP	cis	rs9323205	0.954	rs4898682	chr14:51639577	C/T	cg23942311	chr14:51606299	NA	-0.57	-6.96	-0.41	3.06e-11	Cancer;
KIRP	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg22676075	chr6:135203613	NA	0.55	6.8	0.4	7.68e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.93	13.57	0.65	1.06e-31	Bladder cancer;
KIRP	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.85	5.08	0.31	7.48e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg00024416	chr22:24240387	NA	0.42	5.7	0.34	3.41e-8	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg22100476	chr1:43638037	WDR65;EBNA1BP2	0.95	6.12	0.36	3.69e-9	P wave terminal force;
KIRP	cis	rs6445967	1.000	rs34611088	chr3:58312923	G/A	cg16569813	chr3:58235849	ABHD6	-0.33	-4.92	-0.3	1.56e-6	Platelet count;
KIRP	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg09873164	chr1:152488093	CRCT1	0.57	7.68	0.44	3.7e-13	Hair morphology;
KIRP	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.56	0.33	7.12e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.73	-9.31	-0.51	7.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.42	0.62	7.93e-28	Smoking behavior;
KIRP	cis	rs8077577	0.945	rs62073604	chr17:18065888	T/C	cg09161412	chr17:18057145	MYO15A	-0.39	-5.07	-0.31	7.9e-7	Obesity-related traits;
KIRP	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg09631192	chr20:23583594	CST9	-0.55	-5.29	-0.32	2.71e-7	Chronic kidney disease;
KIRP	cis	rs9649213	0.574	rs34717219	chr7:97962271	A/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg00405596	chr8:11794950	NA	-0.4	-4.89	-0.3	1.81e-6	Neuroticism;
KIRP	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.67	-0.34	4.08e-8	Triglycerides;
KIRP	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.98e-14	Body mass index;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05977900	chr3:182512126	ATP11B	0.52	6.1	0.36	4.05e-9	Smoking initiation;
KIRP	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg05791153	chr7:19748676	TWISTNB	0.68	5.86	0.35	1.46e-8	Thyroid stimulating hormone;
KIRP	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.62	-8.45	-0.47	2.65e-15	Total body bone mineral density;
KIRP	cis	rs412050	0.502	rs17759796	chr22:22190163	A/C	cg17089214	chr22:22089827	YPEL1	-0.6	-5.37	-0.32	1.82e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg05127821	chr10:94822908	CYP26C1	-1.1	-11.26	-0.58	5.26e-24	Coronary artery disease;
KIRP	cis	rs7523273	0.597	rs4844620	chr1:207980901	C/T	cg22525895	chr1:207977042	MIR29B2	-0.57	-5.2	-0.31	4.29e-7	Schizophrenia;
KIRP	cis	rs4356932	1.000	rs10021768	chr4:76951764	C/T	cg19388996	chr4:76862389	NAAA	-0.42	-5.2	-0.31	4.21e-7	Blood protein levels;
KIRP	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.55	-7.53	-0.43	9.34e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg24315340	chr6:146058215	EPM2A	0.45	5.64	0.34	4.75e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3936840	0.514	rs8007356	chr14:102975266	G/A	cg18135206	chr14:102964638	TECPR2	0.49	6.14	0.36	3.26e-9	Plateletcrit;
KIRP	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg16396542	chr1:89473148	GBP3	0.41	5.67	0.34	4.02e-8	Carotid intima media thickness;
KIRP	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14893161	chr1:205819251	PM20D1	0.48	5.41	0.33	1.49e-7	Parkinson's disease;
KIRP	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg12598211	chr12:123634384	NA	0.43	5.31	0.32	2.49e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg06740227	chr12:86229804	RASSF9	0.5	6.48	0.38	5.1e-10	Major depressive disorder;
KIRP	cis	rs11608355	0.538	rs10850074	chr12:109800531	T/C	cg19025524	chr12:109796872	NA	-0.44	-5.95	-0.35	9.3e-9	Neuroticism;
KIRP	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg13180566	chr4:1052158	NA	-0.53	-5.37	-0.32	1.81e-7	Recombination rate (females);
KIRP	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-5.33	-0.32	2.23e-7	Height;
KIRP	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg15655495	chr12:38532458	NA	-0.29	-5.28	-0.32	2.87e-7	Bladder cancer;
KIRP	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.61	8.99	0.5	6.8e-17	Prostate-specific antigen levels (conditioned on lead SNPs);
KIRP	cis	rs2223471	0.837	rs2817357	chr6:50762018	C/T	cg03432817	chr6:50765336	NA	0.53	9.26	0.51	1.08e-17	Subcutaneous adipose tissue;
KIRP	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.76	0.4	1.02e-10	Lung cancer;
KIRP	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg05526886	chr2:227700861	RHBDD1	0.42	5.1	0.31	6.77e-7	Pulmonary function;
KIRP	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.58	-7.11	-0.41	1.28e-11	Aortic root size;
KIRP	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.78	-0.4	8.63e-11	QT interval;
KIRP	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.56	-0.43	7.87e-13	Bipolar disorder;
KIRP	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg25039879	chr17:56429692	SUPT4H1	0.57	5.06	0.31	8.36e-7	Cognitive test performance;
KIRP	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.45	6.47	0.38	5.32e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.23	-16.96	-0.73	2.94e-43	Type 1 diabetes nephropathy;
KIRP	cis	rs2242116	0.900	rs1001284	chr3:46933960	C/G	cg02527881	chr3:46936655	PTH1R	-0.57	-8.8	-0.49	2.47e-16	Birth weight;
KIRP	trans	rs921874	0.586	rs2512485	chr11:86757921	G/C	cg22937172	chr2:240168862	HDAC4	0.5	6.45	0.38	5.81e-10	Total body bone mineral density;
KIRP	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.61	-0.39	2.37e-10	Lung cancer;
KIRP	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.47	6.9	0.4	4.28e-11	Blood metabolite levels;
KIRP	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs2594989	0.836	rs347607	chr3:11268021	A/C	cg01796438	chr3:11312864	ATG7	0.6	6.96	0.41	3.09e-11	Circulating chemerin levels;
KIRP	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg07777115	chr5:623756	CEP72	-0.52	-5.67	-0.34	3.89e-8	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10323490	chr2:88469007	THNSL2	-0.44	-6.82	-0.4	6.84e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1355223	0.872	rs12785367	chr11:34715269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.07	-0.31	7.78e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg12140854	chr5:148520817	ABLIM3	-0.53	-5.6	-0.34	5.74e-8	Breast cancer;
KIRP	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.87	11.39	0.59	1.96e-24	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg05370193	chr1:21551575	ECE1	0.41	5.81	0.35	1.95e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.69	-8.83	-0.49	1.96e-16	Vitiligo;
KIRP	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.71	7.95	0.45	6.83e-14	Height;
KIRP	cis	rs3744061	0.520	rs9908979	chr17:74645486	T/G	cg27546012	chr17:74684504	MXRA7	-0.51	-6.43	-0.38	6.4e-10	Retinal arteriolar caliber;
KIRP	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.11e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.64	-7.73	-0.44	2.75e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.63	0.48	7.76e-16	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.3	-0.42	3.97e-12	Neuroticism;
KIRP	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg01620082	chr3:125678407	NA	-1.16	-7.26	-0.42	4.96e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2733310	1.000	rs2733310	chr15:57498691	T/G	cg13626582	chr15:57592083	LOC283663	-0.33	-7.74	-0.44	2.62e-13	Mean platelet volume;
KIRP	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.17	12.83	0.63	3.51e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg02002194	chr4:3960332	NA	-0.47	-7.0	-0.41	2.36e-11	Mood instability;
KIRP	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg12623918	chr2:306882	NA	0.46	5.83	0.35	1.73e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg08648136	chr8:956695	NA	0.37	5.42	0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs3752645	1.000	rs11509187	chr7:106774453	T/C	cg02696742	chr7:106810147	HBP1	-0.57	-4.93	-0.3	1.52e-6	Bladder cancer (smoking interaction);
KIRP	cis	rs9309473	1.000	rs2056486	chr2:73717567	G/T	cg20560298	chr2:73613845	ALMS1	-0.49	-5.8	-0.35	2e-8	Metabolite levels;
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.86	-11.81	-0.6	8.7e-26	Longevity;
KIRP	cis	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg21546286	chr11:48923668	NA	-0.46	-5.91	-0.35	1.13e-8	HDL cholesterol;
KIRP	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg02696790	chr15:75250997	RPP25	0.3	5.21	0.32	3.95e-7	Breast cancer;
KIRP	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg20651018	chr11:3035856	CARS	-0.35	-4.96	-0.3	1.29e-6	Longevity;
KIRP	cis	rs4742903	0.967	rs10820600	chr9:106856692	T/C	cg14250997	chr9:106856677	SMC2	0.4	5.18	0.31	4.7e-7	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.6	7.89	0.45	1.01e-13	Joint mobility (Beighton score);
KIRP	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.72	7.33	0.42	3.35e-12	Coronary artery calcification;
KIRP	cis	rs997295	1.000	rs12914773	chr15:68019958	G/A	cg24579218	chr15:68104479	NA	0.37	5.61	0.34	5.54e-8	Motion sickness;
KIRP	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.53	6.79	0.4	8.27e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.62	-0.39	2.26e-10	Obesity-related traits;
KIRP	cis	rs559928	0.502	rs4963223	chr11:64193418	A/G	cg05555928	chr11:63887634	MACROD1	-0.41	-4.91	-0.3	1.63e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4664304	0.708	rs7564243	chr2:160726868	G/A	cg06573604	chr2:160760825	LY75	-0.34	-4.93	-0.3	1.54e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	0.93	14.16	0.67	1.11e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24110177	chr3:50126178	RBM5	-0.43	-5.5	-0.33	9.33e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs73200209	0.744	rs17498872	chr12:116669888	A/T	cg01776926	chr12:116560359	MED13L	-0.56	-6.1	-0.36	4.1e-9	Total body bone mineral density;
KIRP	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.52	-6.5	-0.38	4.51e-10	Coronary artery disease;
KIRP	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg09873164	chr1:152488093	CRCT1	0.58	7.57	0.43	7.36e-13	Hair morphology;
KIRP	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.11	-0.41	1.25e-11	Neuroticism;
KIRP	cis	rs865483	0.895	rs1112173	chr17:35760056	C/T	cg06716730	chr17:35851459	DUSP14	-0.24	-5.57	-0.33	6.6e-8	Monocyte count;
KIRP	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.8	11.79	0.6	1.03e-25	Heart rate;
KIRP	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	8.17	0.46	1.6e-14	Retinal vascular caliber;
KIRP	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.73	11.72	0.6	1.75e-25	Corneal structure;
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	trans	rs72634258	0.554	rs4562654	chr1:7934423	A/T	cg26848524	chr8:55294566	NA	-0.43	-6.12	-0.36	3.66e-9	Inflammatory bowel disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17349461	chr15:60632336	NA	0.53	7.01	0.41	2.31e-11	Interleukin-4 levels;
KIRP	cis	rs2274273	1.000	rs15870	chr14:55619311	A/G	cg04306507	chr14:55594613	LGALS3	0.47	7.22	0.42	6.4e-12	Protein biomarker;
KIRP	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.91	11.32	0.59	3.51e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.64	8.03	0.46	3.98e-14	Type 1 diabetes;
KIRP	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18252515	chr7:66147081	NA	-0.45	-5.11	-0.31	6.44e-7	Aortic root size;
KIRP	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.76	-10.52	-0.56	1.3e-21	Hypospadias;
KIRP	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.79	8.65	0.48	6.72e-16	Corneal astigmatism;
KIRP	cis	rs35740288	0.770	rs11634177	chr15:86148390	A/G	cg10818794	chr15:86012489	AKAP13	0.44	5.24	0.32	3.4e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.46	-5.48	-0.33	1.05e-7	Osteoporosis;
KIRP	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg09788416	chr12:39539408	NA	0.42	5.31	0.32	2.46e-7	Morning vs. evening chronotype;
KIRP	cis	rs115344852	0.585	rs1016069	chr6:28440418	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.42	-4.93	-0.3	1.48e-6	Epithelial ovarian cancer;
KIRP	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg24130564	chr14:104152367	KLC1	-0.45	-5.24	-0.32	3.53e-7	Reticulocyte count;
KIRP	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.89	-0.57	8.58e-23	Exhaled nitric oxide output;
KIRP	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.44	-8.37	-0.47	4.45e-15	Educational attainment (years of education);
KIRP	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.22e-9	Colorectal cancer;
KIRP	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg12598211	chr12:123634384	NA	-0.42	-5.06	-0.31	8.14e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1215050	0.791	rs983187	chr4:98816350	A/T	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.33	-4.86	-0.3	2.14e-6	Monocyte count;
KIRP	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.22e-15	Motion sickness;
KIRP	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg01028140	chr2:1542097	TPO	-0.64	-6.14	-0.36	3.36e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg00504896	chr12:9437009	LOC642846	-0.56	-7.54	-0.43	8.76e-13	Breast size;
KIRP	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.81	8.58	0.48	1.1e-15	Corneal astigmatism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08555924	chr18:29026301	DSG3	-0.42	-6.06	-0.36	4.99e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.74	8.78	0.49	2.79e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg08499158	chr17:42289980	UBTF	-0.65	-8.36	-0.47	4.58e-15	Total body bone mineral density;
KIRP	cis	rs7224685	0.501	rs781850	chr17:3957124	C/T	cg11204139	chr17:3907470	NA	-0.82	-15.15	-0.69	4.47e-37	Type 2 diabetes;
KIRP	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg16141378	chr3:129829833	LOC729375	0.56	7.3	0.42	3.97e-12	Neuroticism;
KIRP	trans	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg13565492	chr6:43139072	SRF	-0.85	-7.8	-0.45	1.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10073892	0.703	rs9327822	chr5:101638065	T/C	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg12559939	chr2:27858050	GPN1	-0.4	-4.88	-0.3	1.89e-6	Total body bone mineral density;
KIRP	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg06671706	chr8:8559999	CLDN23	-0.51	-6.15	-0.36	3.2e-9	Obesity-related traits;
KIRP	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg20526800	chr20:33880825	FAM83C	-0.4	-4.89	-0.3	1.81e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg12861170	chr19:19639553	YJEFN3	-0.47	-5.3	-0.32	2.6e-7	Bipolar disorder;
KIRP	cis	rs7221595	0.825	rs4790552	chr17:3923366	G/A	cg09695851	chr17:3907499	NA	0.63	6.76	0.4	9.9e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.78	13.58	0.65	9.89e-32	Height;
KIRP	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.13	14.61	0.68	3.05e-35	Gut microbiome composition (summer);
KIRP	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg16511985	chr3:153974050	SGEF	0.38	5.36	0.32	1.95e-7	Coronary artery disease;
KIRP	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.49	6.02	0.36	6.36e-9	Menarche (age at onset);
KIRP	cis	rs4356932	1.000	rs4417995	chr4:76945999	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs9914544	0.591	rs9900052	chr17:18699398	G/A	cg26306683	chr17:18585705	ZNF286B	0.39	4.99	0.3	1.13e-6	Educational attainment (years of education);
KIRP	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.39	5.09	0.31	7.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	8.99	0.5	6.78e-17	Smoking behavior;
KIRP	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.57	7.3	0.42	3.86e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg06558623	chr16:89946397	TCF25	1.11	7.86	0.45	1.19e-13	Skin colour saturation;
KIRP	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg09184832	chr6:79620586	NA	-0.52	-7.34	-0.42	3.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg24459738	chr19:57751996	ZNF805	-0.58	-7.21	-0.42	6.96e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs710913	0.587	rs6690413	chr1:40086292	T/C	cg27567593	chr1:39956653	BMP8A	-0.4	-5.58	-0.34	6.39e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg00066239	chr17:78472159	NA	0.26	4.88	0.3	1.93e-6	Fractional excretion of uric acid;
KIRP	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg26875137	chr12:53738046	NA	-0.37	-4.91	-0.3	1.64e-6	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg03468072	chr12:39539422	NA	0.43	6.25	0.37	1.83e-9	Morning vs. evening chronotype;
KIRP	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.81	7.84	0.45	1.36e-13	Systemic lupus erythematosus;
KIRP	cis	rs16976116	0.901	rs11852763	chr15:55494606	T/C	cg11288833	chr15:55489084	RSL24D1	0.6	6.67	0.39	1.72e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg26727032	chr16:67993705	SLC12A4	-0.57	-5.18	-0.31	4.69e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg04369109	chr6:150039330	LATS1	-0.47	-5.65	-0.34	4.53e-8	Lung cancer;
KIRP	trans	rs933360	0.523	rs6960912	chr7:50840632	A/T	cg20003124	chr12:4557277	NA	0.53	6.33	0.37	1.13e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	trans	rs4650994	0.816	rs2811301	chr1:178594196	T/C	cg05059571	chr16:84539110	KIAA1609	0.56	7.35	0.42	2.94e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.51	6.54	0.39	3.46e-10	Testicular germ cell tumor;
KIRP	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.51	-0.52	1.86e-18	Triglycerides;
KIRP	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs9913156	0.793	rs55884013	chr17:4579301	G/A	cg00122941	chr17:4613640	ARRB2	0.79	8.35	0.47	4.95e-15	Lymphocyte counts;
KIRP	cis	rs4690686	0.500	rs17062804	chr4:177262892	A/G	cg17059388	chr4:177262070	NA	0.87	12.68	0.63	1.12e-28	Essential tremor;
KIRP	cis	rs9488822	0.596	rs13206506	chr6:116324460	A/G	cg15226275	chr6:116381976	FRK	0.24	6.26	0.37	1.69e-9	Cholesterol, total;LDL cholesterol;
KIRP	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.71	8.57	0.48	1.19e-15	Corneal astigmatism;
KIRP	cis	rs7116495	0.786	rs1894003	chr11:71750276	A/G	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-5.53	-0.33	8.17e-8	Metabolite levels;
KIRP	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-1.16	-10.75	-0.57	2.31e-22	Body mass index;
KIRP	cis	rs6568686	0.553	rs9372301	chr6:111903329	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.54	-5.23	-0.32	3.68e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs501120	0.584	rs11511598	chr10:44716036	C/T	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.83	-9.99	-0.54	6.01e-20	Body mass index;
KIRP	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17376030	chr22:41985996	PMM1	0.7	7.37	0.43	2.66e-12	Vitiligo;
KIRP	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.72	9.4	0.51	3.84e-18	Prudent dietary pattern;
KIRP	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.62	8.01	0.45	4.54e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs732716	0.853	rs12459922	chr19:4455862	A/G	cg03719555	chr19:4455413	UBXN6	0.48	7.27	0.42	4.87e-12	Mean corpuscular volume;
KIRP	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-8.97	-0.5	8e-17	Response to antipsychotic treatment;
KIRP	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11645453	chr3:52864694	ITIH4	-0.33	-5.11	-0.31	6.41e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg06636001	chr8:8085503	FLJ10661	0.6	7.93	0.45	7.44e-14	Joint mobility (Beighton score);
KIRP	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.43	-5.28	-0.32	2.83e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6088813	0.961	rs1886691	chr20:33986271	T/C	cg14752227	chr20:34000481	UQCC	-0.51	-6.61	-0.39	2.37e-10	Height;
KIRP	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05776053	chr2:74358815	NA	0.54	5.7	0.34	3.41e-8	Gestational age at birth (maternal effect);
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg22325292	chr17:80708367	FN3K	0.37	5.0	0.3	1.07e-6	Glycated hemoglobin levels;
KIRP	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg05805236	chr11:65401703	PCNXL3	-0.56	-7.24	-0.42	5.67e-12	Acne (severe);
KIRP	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.7	-0.39	1.43e-10	Longevity;Endometriosis;
KIRP	cis	rs7923609	0.967	rs10761766	chr10:65190327	G/A	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.58	8.66	0.48	6.23e-16	Fat distribution (HIV);
KIRP	trans	rs4352210	0.963	rs9309009	chr2:37754020	C/T	cg22675453	chr15:52970418	KIAA1370	0.44	6.08	0.36	4.62e-9	RR interval (heart rate);
KIRP	cis	rs981844	0.753	rs1105491	chr4:154726634	A/C	cg14289246	chr4:154710475	SFRP2	0.55	6.88	0.4	4.99e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg03733263	chr8:22462867	KIAA1967	0.99	16.26	0.72	7.23e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg24579218	chr15:68104479	NA	-0.37	-5.35	-0.32	1.97e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
KIRP	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg23533926	chr12:111358616	MYL2	-0.49	-6.46	-0.38	5.68e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10875746	0.855	rs12310999	chr12:48447658	A/G	cg20731937	chr12:48336164	NA	0.4	5.14	0.31	5.6e-7	Longevity (90 years and older);
KIRP	cis	rs212524	0.867	rs212532	chr1:21588603	C/G	cg08890418	chr1:21044141	KIF17	0.4	5.33	0.32	2.17e-7	Height;
KIRP	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.63	-9.13	-0.5	2.63e-17	Colorectal cancer;
KIRP	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.51	7.83	0.45	1.48e-13	Bone mineral density;
KIRP	cis	rs2071403	0.509	rs11675434	chr2:1407815	A/G	cg07083862	chr2:1417248	TPO	-0.33	-5.12	-0.31	6.22e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg25486957	chr4:152246857	NA	-0.55	-5.96	-0.36	8.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.67	9.58	0.52	1.14e-18	Dupuytren's disease;
KIRP	cis	rs9381040	0.537	rs9462669	chr6:41013659	C/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.53	-6.45	-0.38	5.73e-10	Alzheimer's disease (late onset);
KIRP	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.36	4.89	0.3	1.83e-6	Vitiligo;
KIRP	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg08132940	chr7:1081526	C7orf50	-0.65	-5.17	-0.31	4.88e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4363385	0.510	rs2339386	chr1:152892307	C/T	cg13444842	chr1:152974279	SPRR3	-0.49	-6.9	-0.4	4.3e-11	Inflammatory skin disease;
KIRP	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg07701084	chr6:150067640	NUP43	0.6	6.5	0.38	4.35e-10	Lung cancer;
KIRP	cis	rs2802372	0.542	rs1250556	chr10:81066577	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.65	-8.0	-0.45	4.98e-14	Granulocyte count;
KIRP	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.89	-11.92	-0.61	3.64e-26	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs3087591	0.683	rs2525564	chr17:29652531	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	9.23	0.51	1.29e-17	Hip circumference;
KIRP	cis	rs6558530	0.692	rs6981804	chr8:1700284	C/A	cg08198773	chr8:1697536	NA	0.52	6.24	0.37	1.9e-9	Systolic blood pressure;
KIRP	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.92	-13.91	-0.66	7.82e-33	Ulcerative colitis;
KIRP	cis	rs13385	0.769	rs12717954	chr5:139595299	C/T	cg01860693	chr5:139557145	C5orf32	0.49	5.38	0.32	1.75e-7	Atrial fibrillation;
KIRP	trans	rs3741489	1.000	rs10781661	chr12:133431979	G/A	cg24132527	chr5:140019269	TMCO6	1.16	9.31	0.51	7.62e-18	Cognitive function;
KIRP	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.59	8.84	0.49	1.84e-16	Blood metabolite levels;
KIRP	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-1.03	-7.08	-0.41	1.46e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg02660097	chr11:68866761	NA	0.4	5.16	0.31	5.17e-7	Blond vs. brown hair color;
KIRP	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.48	5.95	0.35	8.96e-9	Initial pursuit acceleration;
KIRP	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11613427	chr3:52932208	TMEM110	-0.32	-5.25	-0.32	3.24e-7	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg14703610	chr5:56206110	C5orf35	0.51	5.93	0.35	1.01e-8	Initial pursuit acceleration;
KIRP	cis	rs4787491	0.729	rs11642399	chr16:30059593	T/G	cg06326092	chr16:30034487	C16orf92	0.5	7.72	0.44	2.95e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
KIRP	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-9.21	-0.51	1.51e-17	Colorectal cancer;
KIRP	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.6	-7.27	-0.42	4.88e-12	Mosquito bite size;
KIRP	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.51	-6.57	-0.39	2.93e-10	Initial pursuit acceleration in psychotic disorders;
KIRP	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.33	0.62	1.63e-27	Bipolar disorder;
KIRP	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.47	5.89	0.35	1.23e-8	Initial pursuit acceleration;
KIRP	cis	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg19847130	chr8:10466454	RP1L1	-0.33	-5.05	-0.31	8.65e-7	Neuroticism;
KIRP	cis	rs698833	0.852	rs4953092	chr2:44565293	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	5.91	0.35	1.11e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs4073416	0.542	rs1953415	chr14:65988034	A/G	cg03016385	chr14:66212404	NA	-0.52	-6.2	-0.37	2.41e-9	N-glycan levels;
KIRP	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.46	6.29	0.37	1.43e-9	Coronary artery disease;
KIRP	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	1.06	20.94	0.8	1.35e-56	Parkinson's disease;
KIRP	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg24375607	chr4:120327624	NA	0.59	6.85	0.4	5.75e-11	Corneal astigmatism;
KIRP	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg25801113	chr15:45476975	SHF	-0.44	-8.18	-0.46	1.54e-14	Uric acid levels;
KIRP	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg04306507	chr14:55594613	LGALS3	0.53	8.25	0.47	9.8e-15	Protein biomarker;
KIRP	cis	rs10924970	0.967	rs10925192	chr1:235400826	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg03160526	chr17:80928410	B3GNTL1	0.42	5.2	0.31	4.11e-7	Glycated hemoglobin levels;
KIRP	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-5.39	-0.33	1.63e-7	Educational attainment;
KIRP	cis	rs7202877	0.572	rs4888371	chr16:75308781	G/A	cg03315344	chr16:75512273	CHST6	0.54	5.39	0.32	1.67e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.5	-6.33	-0.37	1.15e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6662572	0.686	rs884443	chr1:46484421	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.58	0.34	6.35e-8	Blood protein levels;
KIRP	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg23920097	chr1:209922102	NA	-0.48	-5.63	-0.34	4.96e-8	Red blood cell count;
KIRP	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.71	9.78	0.53	2.8e-19	Aortic root size;
KIRP	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.87	14.56	0.68	4.54e-35	Prostate cancer;
KIRP	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg16497661	chr14:103986332	CKB	0.75	11.17	0.58	1.07e-23	Body mass index;
KIRP	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg08890418	chr1:21044141	KIF17	0.35	5.25	0.32	3.32e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.46	-0.33	1.18e-7	Colorectal cancer;
KIRP	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg26875233	chr11:93583750	C11orf90	-0.4	-7.17	-0.42	8.98e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.54	-8.85	-0.49	1.78e-16	Eye color traits;
KIRP	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.53	8.01	0.45	4.56e-14	Itch intensity from mosquito bite;
KIRP	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg21573476	chr21:45109991	RRP1B	0.65	8.96	0.5	8.01e-17	Mean corpuscular volume;
KIRP	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.71	11.08	0.58	2.08e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs9488822	0.585	rs529574	chr6:116268158	T/A	cg26893134	chr6:116381904	FRK	-0.2	-5.31	-0.32	2.43e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.87	13.61	0.66	8.3e-32	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.67	-0.48	6.12e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.54	5.58	0.34	6.18e-8	Type 2 diabetes;
KIRP	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg01403660	chr11:68851641	TPCN2	0.65	6.32	0.37	1.24e-9	Blond vs. brown hair color;
KIRP	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.82	-11.5	-0.59	8.59e-25	Total body bone mineral density;
KIRP	cis	rs11718455	0.526	rs67553643	chr3:43928130	C/T	cg21419209	chr3:44054225	NA	-0.63	-7.37	-0.43	2.66e-12	Coronary artery disease;
KIRP	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22117172	chr7:91764530	CYP51A1	0.49	6.87	0.4	5.09e-11	Breast cancer;
KIRP	cis	rs7224685	0.569	rs67815988	chr17:3998312	A/C	cg11204139	chr17:3907470	NA	0.54	5.18	0.31	4.55e-7	Type 2 diabetes;
KIRP	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.68	-10.56	-0.56	9.87e-22	Educational attainment;
KIRP	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg15488143	chr7:128924101	AHCYL2	0.62	6.79	0.4	8.54e-11	White matter hyperintensity burden;
KIRP	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg05717871	chr11:638507	DRD4	-0.39	-5.27	-0.32	2.97e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23903597	chr17:61704154	MAP3K3	-0.61	-7.97	-0.45	5.99e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg24315340	chr6:146058215	EPM2A	0.42	5.2	0.31	4.17e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg01966878	chr4:90757139	SNCA	-0.44	-5.08	-0.31	7.49e-7	Neuroticism;
KIRP	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg11584989	chr19:19387371	SF4	0.4	5.18	0.31	4.57e-7	Tonsillectomy;
KIRP	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.66	7.88	0.45	1.04e-13	Type 2 diabetes;
KIRP	cis	rs9323205	0.911	rs12587611	chr14:51641399	C/T	cg23942311	chr14:51606299	NA	-0.61	-7.51	-0.43	1.08e-12	Cancer;
KIRP	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.61	6.82	0.4	7.11e-11	Schizophrenia;
KIRP	cis	rs10861661	0.856	rs4964190	chr12:107216359	C/T	cg15890332	chr12:107067104	RFX4	0.3	4.87	0.3	1.99e-6	Triglyceride levels;
KIRP	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.0	0.61	1.96e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.89	0.35	1.28e-8	Menopause (age at onset);
KIRP	trans	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg06521331	chr12:34319734	NA	-0.58	-7.09	-0.41	1.41e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7688540	0.771	rs10027325	chr4:282608	G/A	cg17891759	chr4:299121	NA	-0.44	-5.15	-0.31	5.38e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs10102274	1.000	rs10504899	chr8:91780660	T/C	cg16814680	chr8:91681699	NA	-0.8	-4.9	-0.3	1.73e-6	Cerebrospinal fluid clusterin levels;
KIRP	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.85	-11.65	-0.6	2.97e-25	Morning vs. evening chronotype;
KIRP	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg26811252	chr16:29126840	RRN3P2	0.63	8.36	0.47	4.76e-15	Menopause (age at onset);
KIRP	cis	rs2977993	1	rs2977993	chr9:131608786	G/A	cg00228799	chr9:131580591	ENDOG	0.59	6.7	0.39	1.39e-10	Schizophrenia;
KIRP	cis	rs1712517	0.744	rs11191641	chr10:105052940	C/T	cg05636881	chr10:105038444	INA	0.45	6.6	0.39	2.54e-10	Migraine;
KIRP	cis	rs11605275	1.000	rs77993017	chr11:20031388	C/G	cg14835545	chr11:20032148	NAV2	-0.8	-6.14	-0.36	3.25e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg24881330	chr22:46731750	TRMU	0.78	5.47	0.33	1.11e-7	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10325536	chr4:3512392	NA	-0.43	-6.08	-0.36	4.55e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08276333	chr1:162756615	NA	-0.43	-7.18	-0.42	8.32e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-13.38	-0.65	4.75e-31	Body mass index;
KIRP	cis	rs929596	0.531	rs2741012	chr2:234508963	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-5.96	-0.36	8.69e-9	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg19773385	chr1:10388646	KIF1B	-0.72	-11.02	-0.57	3.19e-23	Hepatocellular carcinoma;
KIRP	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.51	6.32	0.37	1.19e-9	Subjective well-being;
KIRP	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg15128208	chr22:42549153	NA	0.39	5.16	0.31	5.11e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs6977660	0.714	rs12536561	chr7:19816659	G/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg08888203	chr3:10149979	C3orf24	0.49	5.18	0.31	4.67e-7	Alzheimer's disease;
KIRP	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg21775007	chr8:11205619	TDH	0.45	6.14	0.36	3.3e-9	Mood instability;
KIRP	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.33	5.68	0.34	3.83e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20887711	chr4:1340912	KIAA1530	0.42	5.26	0.32	3.06e-7	Obesity-related traits;
KIRP	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	1.07	16.84	0.73	7.37e-43	Cognitive function;
KIRP	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23708337	chr7:1209742	NA	0.41	5.06	0.31	8.05e-7	Longevity;Endometriosis;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg08132940	chr7:1081526	C7orf50	-0.46	-5.28	-0.32	2.86e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.61	-8.38	-0.47	3.97e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg13010199	chr12:38710504	ALG10B	0.69	8.94	0.5	9.48e-17	Morning vs. evening chronotype;
KIRP	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.46e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg15764593	chr10:829463	NA	-0.83	-8.94	-0.5	9.56e-17	Uric acid levels;
KIRP	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg01557791	chr16:72042693	DHODH	-0.43	-5.27	-0.32	2.95e-7	Fibrinogen levels;
KIRP	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg05072774	chr3:49840536	C3orf54	-0.41	-5.14	-0.31	5.59e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.67	6.11	0.36	3.84e-9	Lung function (FEV1);
KIRP	cis	rs963731	0.579	rs997344	chr2:39281730	G/C	cg04010122	chr2:39346883	SOS1	-0.86	-5.88	-0.35	1.33e-8	Corticobasal degeneration;
KIRP	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg21361702	chr7:150065534	REPIN1	0.51	5.02	0.31	9.72e-7	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.92	-12.22	-0.61	3.72e-27	Platelet distribution width;
KIRP	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.56	-6.35	-0.38	1.01e-9	Vitiligo;
KIRP	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg05347473	chr6:146136440	FBXO30	0.47	6.68	0.39	1.55e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg03060546	chr3:49711283	APEH	0.69	5.97	0.36	8.36e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs11877825	0.685	rs2099871	chr18:10578676	G/A	cg07277756	chr18:10589357	NA	0.48	5.89	0.35	1.23e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg00631329	chr6:26305371	NA	-0.69	-9.16	-0.5	2.15e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.24	-6.4	-0.38	7.97e-10	Mean corpuscular volume;
KIRP	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.8	13.06	0.64	5.71e-30	Schizophrenia;
KIRP	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg00977110	chr5:151150581	G3BP1	0.6	6.1	0.36	4.03e-9	Preschool internalizing problems;
KIRP	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.58	7.45	0.43	1.59e-12	Lymphocyte counts;
KIRP	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.46	6.38	0.38	8.92e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg19338460	chr6:170058176	WDR27	-0.66	-7.7	-0.44	3.27e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg10253484	chr15:75165896	SCAMP2	0.67	7.28	0.42	4.49e-12	Systemic lupus erythematosus;
KIRP	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.88	13.23	0.64	1.57e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg19767477	chr5:127420684	SLC12A2	0.34	5.0	0.3	1.09e-6	Ileal carcinoids;
KIRP	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.91	-0.3	1.69e-6	Coronary artery disease;
KIRP	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.99	17.26	0.74	2.76e-44	Breast cancer;
KIRP	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-12.74	-0.63	6.89e-29	Exhaled nitric oxide output;
KIRP	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs9840812	0.623	rs1394092	chr3:136196071	C/T	cg15507776	chr3:136538369	TMEM22	0.43	5.49	0.33	9.96e-8	Fibrinogen levels;
KIRP	cis	rs2346160	0.899	rs206977	chr6:167690746	G/C	cg27333441	chr6:167680455	NA	-0.44	-5.74	-0.34	2.71e-8	Parental extreme longevity (95 years and older);
KIRP	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg24505687	chr6:33548425	BAK1	0.27	5.27	0.32	3.01e-7	Platelet count;
KIRP	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.52	6.4	0.38	7.73e-10	Subjective well-being;
KIRP	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.24	0.32	3.5e-7	Neuroticism;
KIRP	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg23324259	chr8:82754387	SNX16	0.44	4.88	0.3	1.9e-6	Diastolic blood pressure;
KIRP	cis	rs1440410	0.835	rs6817849	chr4:144076001	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg00745463	chr17:30367425	LRRC37B	0.53	5.0	0.3	1.08e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg03462096	chr14:56157197	NA	0.45	6.12	0.36	3.73e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg20090558	chr2:73403173	NA	-0.51	-6.35	-0.38	1.01e-9	Menopause (age at onset);
KIRP	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	9.95	0.54	7.83e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.75	-10.97	-0.57	4.82e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg15488143	chr7:128924101	AHCYL2	0.6	6.55	0.39	3.4e-10	White matter hyperintensity burden;
KIRP	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg04369109	chr6:150039330	LATS1	-0.56	-7.06	-0.41	1.66e-11	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08739755	chr2:172815385	HAT1	0.46	6.27	0.37	1.65e-9	Interleukin-4 levels;
KIRP	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg23594656	chr7:65796392	TPST1	0.5	7.83	0.45	1.45e-13	Aortic root size;
KIRP	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.71	-13.06	-0.64	5.65e-30	Body mass index;
KIRP	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.74	-0.44	2.53e-13	Neuroticism;
KIRP	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg08501292	chr6:25962987	TRIM38	1.1	7.6	0.44	6.02e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21016266	chr12:122356598	WDR66	0.65	8.95	0.5	8.92e-17	Mean corpuscular volume;
KIRP	cis	rs904251	0.561	rs4714071	chr6:37474393	C/T	cg24807547	chr6:37504484	NA	-0.53	-7.66	-0.44	4.22e-13	Cognitive performance;
KIRP	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.68	-9.06	-0.5	4.28e-17	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.71	10.0	0.54	5.69e-20	Blood protein levels;
KIRP	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.82	10.66	0.56	4.79e-22	Platelet count;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg13989455	chr1:12628244	DHRS3	0.56	6.02	0.36	6.23e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg05784532	chr1:230284198	GALNT2	0.41	6.2	0.37	2.38e-9	Coronary artery disease;
KIRP	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg06204229	chr3:52865917	ITIH4	0.53	5.93	0.35	1.02e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs13170463	0.579	rs6872802	chr5:8042435	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.72	9.51	0.52	1.82e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs1448094	0.617	rs2221319	chr12:86468064	C/A	cg00310523	chr12:86230176	RASSF9	-0.43	-6.23	-0.37	1.99e-9	Major depressive disorder;
KIRP	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.82	10.3	0.55	6.46e-21	Macular telangiectasia type 2;
KIRP	cis	rs1971762	0.509	rs10783592	chr12:54037430	G/A	cg16917193	chr12:54089295	NA	0.82	13.82	0.66	1.54e-32	Height;
KIRP	cis	rs61884328	0.852	rs12576839	chr11:47082464	C/T	cg23433285	chr11:47201945	PACSIN3	0.79	6.35	0.38	1.04e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs7173743	0.525	rs4608303	chr15:79136713	T/C	cg00079375	chr15:79125835	NA	0.4	5.61	0.34	5.33e-8	Coronary artery disease;
KIRP	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg23978390	chr7:1156363	C7orf50	0.57	5.64	0.34	4.7e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg24209194	chr3:40518798	ZNF619	0.42	5.47	0.33	1.1e-7	Renal cell carcinoma;
KIRP	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.34	-0.32	2.15e-7	Aortic root size;
KIRP	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg08901578	chr4:187885870	NA	-0.45	-6.69	-0.39	1.46e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2070997	0.816	rs6597642	chr9:133725767	C/T	cg24663490	chr6:27832932	HIST1H2AL	-0.62	-6.09	-0.36	4.34e-9	Response to amphetamines;
KIRP	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.68	-8.17	-0.46	1.58e-14	Blood protein levels;
KIRP	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.66	-10.13	-0.54	2.18e-20	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs580438	0.529	rs4684932	chr3:13412073	G/A	cg10657019	chr3:13328039	NA	-0.52	-6.79	-0.4	8.22e-11	Myringotomy;
KIRP	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg04202892	chr2:111875749	ACOXL	0.46	6.48	0.38	5.07e-10	Chronic lymphocytic leukemia;
KIRP	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.89	-0.45	9.74e-14	Retinal vascular caliber;
KIRP	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.63	8.05	0.46	3.45e-14	Anxiety disorder;
KIRP	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg07451762	chr16:28383216	NA	-0.42	-5.58	-0.33	6.45e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.7	-6.42	-0.38	7.01e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-1.06	-13.18	-0.64	2.33e-30	Exhaled nitric oxide output;
KIRP	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.72	-8.55	-0.48	1.29e-15	Vitamin D levels;
KIRP	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.7	10.4	0.55	3.12e-21	Dupuytren's disease;
KIRP	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg17182837	chr8:41585554	ANK1	-0.48	-4.99	-0.3	1.14e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs240764	0.604	rs9322173	chr6:101203889	G/A	cg09795085	chr6:101329169	ASCC3	0.45	5.18	0.31	4.69e-7	Neuroticism;
KIRP	cis	rs77633900	0.772	rs2944377	chr15:76699652	C/A	cg21673338	chr15:77095150	SCAPER	-0.63	-5.56	-0.33	6.91e-8	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs17121403	0.661	rs11810989	chr1:100443397	C/T	cg24955406	chr1:100503596	HIAT1	0.78	5.08	0.31	7.35e-7	Pulmonary function decline;
KIRP	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg19468946	chr17:37922297	IKZF3	-0.51	-6.94	-0.4	3.53e-11	Self-reported allergy;
KIRP	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.16	-0.31	5.15e-7	Life satisfaction;
KIRP	cis	rs1350445	0.662	rs2125301	chr11:91946830	G/T	cg14848783	chr11:92600066	FAT3	0.46	5.37	0.32	1.83e-7	Subclinical atherosclerosis traits (other);
KIRP	cis	rs9403317	0.960	rs11751835	chr6:141836735	C/T	cg15052665	chr6:141804349	NA	0.42	5.06	0.31	8.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4262150	0.774	rs17453740	chr5:151976143	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.15	-0.46	1.9e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.93	-8.62	-0.48	8.09e-16	Platelet count;
KIRP	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg16141378	chr3:129829833	LOC729375	0.51	6.67	0.39	1.7e-10	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05025164	chr4:1340916	KIAA1530	0.57	7.73	0.44	2.71e-13	Obesity-related traits;
KIRP	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs10073892	0.830	rs28469696	chr5:101625750	G/T	cg19774478	chr5:101632501	SLCO4C1	0.66	6.41	0.38	7.17e-10	Cognitive decline (age-related);
KIRP	cis	rs4748857	0.836	rs4748854	chr10:23598880	C/T	cg12804278	chr10:23633326	C10orf67	0.42	5.18	0.31	4.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg11845111	chr2:191398756	TMEM194B	-0.68	-7.41	-0.43	1.96e-12	Diastolic blood pressure;
KIRP	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.78	10.19	0.54	1.48e-20	Systemic lupus erythematosus;
KIRP	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg00122941	chr17:4613640	ARRB2	-0.51	-5.93	-0.35	1.04e-8	Lymphocyte counts;
KIRP	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.96	13.05	0.64	6.47e-30	Multiple sclerosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13442152	chr1:168044891	DCAF6	0.45	6.48	0.38	4.97e-10	Survival in pancreatic cancer;
KIRP	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09414673	chr7:1022797	CYP2W1	0.38	5.16	0.31	5.06e-7	Longevity;Endometriosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17247435	chr13:28713452	PAN3;LOC100288730	0.55	7.63	0.44	5.11e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4073416	0.542	rs4902404	chr14:66047022	T/C	cg03016385	chr14:66212404	NA	-0.52	-6.3	-0.37	1.36e-9	N-glycan levels;
KIRP	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg03733263	chr8:22462867	KIAA1967	-0.81	-11.88	-0.6	5.1e-26	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.65	-7.69	-0.44	3.59e-13	Resting heart rate;
KIRP	cis	rs17209837	0.607	rs1473152	chr7:87080350	A/C	cg00919237	chr7:87102261	ABCB4	-0.74	-9.21	-0.51	1.43e-17	Gallbladder cancer;
KIRP	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.39e-10	Bipolar disorder;
KIRP	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.35	5.97	0.36	8.23e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.72	10.88	0.57	9.24e-23	Menarche (age at onset);
KIRP	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.47	-10.56	-0.56	9.7e-22	Alzheimer's disease (late onset);
KIRP	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.72	9.58	0.52	1.15e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg26876637	chr1:152193138	HRNR	-0.78	-9.73	-0.53	3.79e-19	Atopic dermatitis;
KIRP	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg00074818	chr8:8560427	CLDN23	0.36	5.88	0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs11264213	0.901	rs72661623	chr1:36398368	G/A	cg27506609	chr1:36549197	TEKT2	1.19	7.1	0.41	1.31e-11	Schizophrenia;
KIRP	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg26516362	chr5:178986906	RUFY1	0.47	8.44	0.47	2.72e-15	Lung cancer;
KIRP	trans	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg03929089	chr4:120376271	NA	0.89	6.41	0.38	7.4e-10	Axial length;
KIRP	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg01338139	chr15:38987640	C15orf53	-0.56	-6.24	-0.37	1.93e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	-0.62	-7.54	-0.43	9.01e-13	Inflammatory bowel disease;
KIRP	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg02570527	chr1:10970165	NA	-0.41	-5.04	-0.31	8.96e-7	Body mass index;
KIRP	cis	rs72960926	0.744	rs72952273	chr6:74926284	C/T	cg03266952	chr6:74778945	NA	-0.63	-5.37	-0.32	1.79e-7	Metabolite levels (MHPG);
KIRP	cis	rs1958560	0.932	rs61987994	chr14:66070733	A/G	cg03016385	chr14:66212404	NA	-0.55	-6.76	-0.4	9.94e-11	Menarche (age at onset);
KIRP	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.69	-8.35	-0.47	4.94e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27213352	chr17:32907731	TMEM132E;C17orf102	0.44	6.13	0.36	3.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.7	0.8	8.7e-56	Prudent dietary pattern;
KIRP	cis	rs975210	0.556	rs2291986	chr15:70368432	C/T	cg12349571	chr15:70364359	TLE3	0.44	5.54	0.33	7.61e-8	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs71636778	0.543	rs34409791	chr1:27245363	A/G	cg12203394	chr1:27248618	NUDC	0.61	5.37	0.32	1.82e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.69	-6.98	-0.41	2.72e-11	Obesity-related traits;
KIRP	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg26681399	chr22:41777847	TEF	-0.51	-5.34	-0.32	2.07e-7	Vitiligo;
KIRP	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.58	-0.39	2.75e-10	Recombination measurement;
KIRP	cis	rs193541	0.632	rs154512	chr5:122195040	T/C	cg19412675	chr5:122181750	SNX24	0.59	6.31	0.37	1.29e-9	Glucose homeostasis traits;
KIRP	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg08885076	chr2:99613938	TSGA10	-0.52	-7.11	-0.41	1.22e-11	Chronic sinus infection;
KIRP	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg21890820	chr11:65308645	LTBP3	0.41	5.2	0.31	4.19e-7	Bone mineral density;
KIRP	cis	rs4782151	1.000	rs35158055	chr16:9329684	G/A	ch.16.364290R	chr16:9436357	NA	0.32	4.94	0.3	1.44e-6	Cervical cancer;
KIRP	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	-0.4	-5.34	-0.32	2.17e-7	Menarche (age at onset);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg06766450	chr1:16766999	NECAP2	0.76	6.5	0.38	4.4e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.87	-8.95	-0.5	9.1e-17	Platelet count;
KIRP	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.55	5.99	0.36	7.37e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg23479056	chr15:41276147	INO80	0.36	4.94	0.3	1.47e-6	Menopause (age at onset);
KIRP	cis	rs17767294	0.708	rs17693877	chr6:27707046	G/A	cg08851530	chr6:28072375	NA	0.9	5.51	0.33	8.9e-8	Parkinson's disease;
KIRP	cis	rs1559088	1.000	rs12985438	chr19:33559368	G/A	cg07827796	chr19:33622959	WDR88	0.42	4.99	0.3	1.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-5.31	-0.32	2.45e-7	Testicular germ cell tumor;
KIRP	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.79	-6.74	-0.39	1.11e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.73	6.18	0.37	2.66e-9	Body mass index;
KIRP	cis	rs745821	0.783	rs61148001	chr18:48133241	C/T	cg18923635	chr18:48083994	NA	0.54	5.94	0.35	9.49e-9	Diastolic blood pressure;
KIRP	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg23985595	chr17:80112537	CCDC57	-0.33	-4.95	-0.3	1.4e-6	Life satisfaction;
KIRP	cis	rs2071403	0.966	rs9677074	chr2:1409353	G/C	cg07083862	chr2:1417248	TPO	0.34	5.41	0.33	1.51e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg04025307	chr7:1156635	C7orf50	0.54	5.65	0.34	4.42e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.55	-7.43	-0.43	1.74e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs11877825	0.826	rs4121955	chr18:10569879	C/A	cg07277756	chr18:10589357	NA	0.49	6.17	0.37	2.83e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.71	-13.91	-0.66	7.61e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.06	-0.46	3.27e-14	Bone mineral density;
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg05665937	chr4:1216051	CTBP1	0.39	4.95	0.3	1.41e-6	Longevity;
KIRP	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs7394190	0.630	rs113799665	chr10:75575138	C/T	cg04833713	chr10:74871078	NUDT13	0.46	5.1	0.31	6.83e-7	Incident atrial fibrillation;
KIRP	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21747090	chr2:27597821	SNX17	-0.48	-6.66	-0.39	1.75e-10	Total body bone mineral density;
KIRP	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg26022315	chr17:47021804	SNF8	0.41	5.37	0.32	1.79e-7	Type 2 diabetes;
KIRP	cis	rs7172677	0.960	rs1602360	chr15:75420761	G/A	cg14664628	chr15:75095509	CSK	-0.47	-5.33	-0.32	2.26e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs9783347	0.925	rs3825025	chr11:18343822	C/G	cg15585147	chr11:18324498	HPS5	0.44	5.95	0.35	9.4e-9	Pancreatic cancer;
KIRP	cis	rs1524927	0.966	rs1524920	chr7:96362894	C/T	cg00227355	chr7:96336147	SHFM1	0.33	4.95	0.3	1.37e-6	Total body bone mineral density;
KIRP	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg04827223	chr11:72435913	ARAP1	-0.6	-7.0	-0.41	2.39e-11	Type 2 diabetes;
KIRP	cis	rs7635838	0.827	rs9826044	chr3:11458075	A/G	cg00170343	chr3:11313890	ATG7	0.46	5.9	0.35	1.17e-8	HDL cholesterol;
KIRP	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.76	-10.39	-0.55	3.23e-21	Prostate cancer;
KIRP	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	16.66	0.73	3.04e-42	Platelet count;
KIRP	cis	rs7215564	0.818	rs34760119	chr17:78604583	G/T	cg06153925	chr17:78755379	RPTOR	0.38	5.27	0.32	2.98e-7	Myopia (pathological);
KIRP	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.09	-0.36	4.28e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg02038168	chr22:39784481	NA	-0.39	-4.91	-0.3	1.67e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg16590910	chr6:42928470	GNMT	-0.44	-6.33	-0.37	1.18e-9	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4523957	0.553	rs2641440	chr17:2027182	G/C	cg16513277	chr17:2031491	SMG6	-0.85	-12.62	-0.63	1.67e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs28830936	0.966	rs28680296	chr15:42121538	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.31	-6.67	-0.39	1.68e-10	Diastolic blood pressure;
KIRP	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-5.43	-0.33	1.34e-7	Metabolite levels;
KIRP	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-1.17	-12.62	-0.63	1.71e-28	Breast cancer;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg09699651	chr6:150184138	LRP11	0.52	6.87	0.4	5.15e-11	Lung cancer;
KIRP	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.51	-6.26	-0.37	1.67e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs151997	0.671	rs27907	chr5:50193797	C/G	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.32e-12	Callous-unemotional behaviour;
KIRP	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg04037228	chr3:45636386	LIMD1	0.36	5.31	0.32	2.5e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg10326726	chr10:51549505	MSMB	-0.56	-8.36	-0.47	4.81e-15	Prostate-specific antigen levels;
KIRP	trans	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg20587970	chr11:113659929	NA	-0.68	-7.21	-0.42	6.78e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	0.93	8.33	0.47	5.65e-15	Blood protein levels;
KIRP	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.68	7.88	0.45	1.07e-13	Corneal astigmatism;
KIRP	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg04398451	chr17:18023971	MYO15A	-0.66	-9.24	-0.51	1.22e-17	Total body bone mineral density;
KIRP	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg07930552	chr6:133119739	C6orf192	1.07	9.37	0.51	5.02e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-13.2	-0.64	2e-30	Blood metabolite levels;
KIRP	cis	rs4919044	0.599	rs10882131	chr10:94711319	C/T	cg05127821	chr10:94822908	CYP26C1	-0.9	-7.56	-0.43	8.09e-13	Coronary artery disease;
KIRP	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg03060546	chr3:49711283	APEH	-0.73	-5.63	-0.34	4.91e-8	Cognitive function;
KIRP	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg19731401	chr7:2775893	GNA12	0.8	7.5	0.43	1.12e-12	Childhood ear infection;
KIRP	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.75	9.38	0.51	4.64e-18	Coronary artery disease;
KIRP	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg08761264	chr16:28874980	SH2B1	-0.45	-5.15	-0.31	5.37e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.56	-5.03	-0.31	9.64e-7	Bipolar disorder;
KIRP	cis	rs4478858	0.647	rs11581476	chr1:31717675	C/T	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.67e-8	Alcohol dependence;
KIRP	cis	rs7700895	0.737	rs1043381	chr5:95221337	C/T	cg16656078	chr5:95278638	ELL2	-0.36	-5.51	-0.33	9.15e-8	IgG glycosylation;
KIRP	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.86	-0.4	5.41e-11	Eye color traits;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg15254786	chr2:207630414	MDH1B;FASTKD2	-0.48	-6.11	-0.36	3.85e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg07777115	chr5:623756	CEP72	-0.56	-5.76	-0.34	2.48e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs876084	0.505	rs6469899	chr8:121102762	C/T	cg22335954	chr8:121166405	COL14A1	-0.37	-4.95	-0.3	1.38e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2014572	0.933	rs8107516	chr19:57758445	A/G	cg24459738	chr19:57751996	ZNF805	-0.59	-7.23	-0.42	5.95e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.42	5.34	0.32	2.16e-7	Melanoma;
KIRP	cis	rs7224685	0.569	rs8066707	chr17:3996550	T/C	cg11204139	chr17:3907470	NA	0.55	5.26	0.32	3.1e-7	Type 2 diabetes;
KIRP	cis	rs17453880	0.929	rs59126622	chr5:151999934	G/T	cg12297329	chr5:152029980	NA	-0.7	-10.55	-0.56	1.04e-21	Subjective well-being;
KIRP	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-6.26	-0.37	1.69e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-12.7	-0.63	9.64e-29	Chronic sinus infection;
KIRP	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	cg12689670	chr1:183009347	LAMC1	0.47	6.64	0.39	1.96e-10	Colorectal cancer;
KIRP	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2574704	0.886	rs7614263	chr3:11650269	T/C	cg07643000	chr3:11666825	VGLL4	0.41	5.93	0.35	1.03e-8	Body mass index;
KIRP	cis	rs7766436	0.885	rs13199041	chr6:22577718	A/G	cg13666174	chr6:22585274	NA	-0.43	-5.95	-0.35	9.12e-9	Coronary artery disease;
KIRP	cis	rs7113874	0.659	rs7931834	chr11:8525293	G/A	cg08015107	chr11:8618950	NA	-0.51	-6.79	-0.4	8.28e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg06307176	chr5:131281290	NA	0.53	5.81	0.35	1.93e-8	Life satisfaction;
KIRP	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.82	9.2	0.51	1.61e-17	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
KIRP	cis	rs74181299	0.591	rs1894875	chr2:65363579	G/A	cg05010058	chr2:65284262	CEP68	-0.5	-6.75	-0.4	1.03e-10	Pulse pressure;
KIRP	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.72	9.82	0.53	2.1e-19	Morning vs. evening chronotype;
KIRP	cis	rs6545883	0.791	rs2600665	chr2:61405795	G/T	cg15711740	chr2:61764176	XPO1	-0.6	-7.69	-0.44	3.49e-13	Tuberculosis;
KIRP	cis	rs300890	1.000	rs300895	chr4:144255838	A/G	cg19876092	chr4:144208277	NA	0.45	7.33	0.42	3.37e-12	Nasopharyngeal carcinoma;
KIRP	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6800768	0.633	rs6807599	chr3:24145588	A/C	cg10674438	chr3:24145617	LOC152024	-0.52	-6.82	-0.4	6.87e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg17724175	chr1:150552817	MCL1	0.35	5.93	0.35	1.05e-8	Melanoma;
KIRP	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg11608241	chr8:8085544	FLJ10661	-0.51	-6.77	-0.4	9.42e-11	Triglycerides;
KIRP	cis	rs1298062	0.861	rs2431821	chr19:50995098	G/A	cg11430371	chr19:50961752	MYBPC2	0.39	5.42	0.33	1.45e-7	Age of smoking initiation;
KIRP	cis	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg04607699	chr11:48328132	OR4S1	-0.35	-4.95	-0.3	1.37e-6	Coronary artery disease;
KIRP	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26207909	chr14:103986467	CKB	0.74	10.66	0.56	4.51e-22	Body mass index;
KIRP	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.76	11.46	0.59	1.24e-24	Oral cavity cancer;
KIRP	cis	rs10073892	1.000	rs72779945	chr5:101727868	T/C	cg19774478	chr5:101632501	SLCO4C1	0.68	6.99	0.41	2.56e-11	Cognitive decline (age-related);
KIRP	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.43	5.57	0.33	6.64e-8	Renal cell carcinoma;
KIRP	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.33	12.1	0.61	9.12e-27	Diabetic retinopathy;
KIRP	cis	rs3741798	1.000	rs61922049	chr12:12497395	C/T	cg08615371	chr12:12503544	MANSC1	0.96	8.49	0.48	2.04e-15	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.93	13.06	0.64	5.87e-30	Cognitive function;
KIRP	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-0.76	-8.98	-0.5	7.37e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg18595228	chr15:67193261	NA	0.56	5.07	0.31	7.79e-7	Lung cancer (smoking interaction);
KIRP	cis	rs9584850	0.574	rs60492361	chr13:99172653	T/C	cg20750642	chr13:99100586	FARP1	-0.54	-5.71	-0.34	3.26e-8	Neuroticism;
KIRP	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.76	10.01	0.54	5.42e-20	Systolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00691125	chr1:169455409	SLC19A2	0.49	6.07	0.36	4.85e-9	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10237542	chr1:51168010	FAF1	-0.44	-6.32	-0.37	1.19e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.4	-6.09	-0.36	4.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.94	16.37	0.72	3.04e-41	Mortality in heart failure;
KIRP	cis	rs2273669	0.915	rs6935782	chr6:109289881	A/G	cg05315195	chr6:109294784	ARMC2	-0.54	-6.02	-0.36	6.22e-9	Prostate cancer;
KIRP	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.54	8.91	0.49	1.16e-16	Eye color traits;
KIRP	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	6.41	0.38	7.32e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg00343986	chr7:65444356	GUSB	0.39	4.86	0.3	2.12e-6	Aortic root size;
KIRP	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-1.06	-12.25	-0.62	2.92e-27	Height;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs904251	0.523	rs2776872	chr6:37482787	C/G	cg01843034	chr6:37503916	NA	-0.95	-15.24	-0.7	2.21e-37	Cognitive performance;
KIRP	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg00405596	chr8:11794950	NA	0.59	8.22	0.46	1.14e-14	Neuroticism;
KIRP	trans	rs2048656	0.578	rs4841235	chr8:9683358	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-7.1	-0.41	1.33e-11	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24764865	chr14:36295508	BRMS1L	0.54	7.27	0.42	4.78e-12	Parkinson's disease;
KIRP	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.45	6.3	0.37	1.4e-9	Childhood ear infection;
KIRP	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.82	12.13	0.61	7.54e-27	Longevity;
KIRP	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg23719950	chr11:63933701	MACROD1	-0.69	-6.71	-0.39	1.36e-10	Mean platelet volume;
KIRP	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg05082376	chr22:42548792	NA	-0.47	-6.04	-0.36	5.7e-9	Schizophrenia;
KIRP	cis	rs4595586	0.655	rs11831502	chr12:39310127	A/T	cg26384229	chr12:38710491	ALG10B	0.49	6.37	0.38	9.21e-10	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg23985595	chr17:80112537	CCDC57	0.38	5.92	0.35	1.09e-8	Life satisfaction;
KIRP	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.6	-0.39	2.48e-10	Coronary artery disease;
KIRP	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs7709377	0.595	rs11958648	chr5:115445224	C/T	cg23108291	chr5:115420582	COMMD10	0.41	4.92	0.3	1.56e-6	Metabolite levels  (X-11787);
KIRP	cis	rs55788414	1.000	rs35667589	chr16:81180829	A/T	cg06400318	chr16:81190750	PKD1L2	-1.19	-7.65	-0.44	4.58e-13	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg02073558	chr3:44770973	ZNF501	0.56	7.89	0.45	9.82e-14	Depressive symptoms;
KIRP	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-9.31	-0.51	7.62e-18	Platelet count;
KIRP	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg23411274	chr6:26421120	BTN2A3	-0.31	-4.87	-0.3	2.02e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	9.99	0.54	5.9e-20	Cognitive test performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12793879	chr15:32322659	CHRNA7	0.48	6.11	0.36	3.85e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05776053	chr2:74358815	NA	0.48	5.16	0.31	5.18e-7	Gestational age at birth (maternal effect);
KIRP	cis	rs909341	0.909	rs1295810	chr20:62330484	G/A	cg03999872	chr20:62272968	STMN3	-0.56	-6.49	-0.38	4.57e-10	Atopic dermatitis;
KIRP	cis	rs7919006	0.590	rs4746251	chr10:76780153	C/T	cg01390419	chr10:76803856	DUPD1	-0.53	-5.18	-0.31	4.71e-7	Weight;
KIRP	cis	rs7246657	0.722	rs2075284	chr19:38189616	T/C	cg18154014	chr19:37997991	ZNF793	-0.61	-6.69	-0.39	1.52e-10	Coronary artery calcification;
KIRP	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-12.81	-0.63	3.94e-29	Morning vs. evening chronotype;
KIRP	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg11693508	chr17:37793320	STARD3	0.68	7.24	0.42	5.6e-12	Bipolar disorder;
KIRP	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.42	5.29	0.32	2.77e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.54	-8.43	-0.47	3.01e-15	Itch intensity from mosquito bite;
KIRP	cis	rs311392	0.867	rs364484	chr8:55093492	G/T	cg06042504	chr8:55087323	NA	-0.59	-7.23	-0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg23985595	chr17:80112537	CCDC57	-0.34	-5.19	-0.31	4.45e-7	Life satisfaction;
KIRP	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.52	7.15	0.41	9.73e-12	Mean corpuscular volume;
KIRP	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-10.68	-0.56	3.94e-22	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.36	0.38	9.69e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs78487399	0.710	rs75514072	chr2:43750224	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.18	-0.31	4.59e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-1.19	-10.23	-0.55	1.04e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.61	-0.52	8.92e-19	Response to antipsychotic treatment;
KIRP	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs4006360	0.575	rs67524820	chr17:39318208	T/C	cg25341923	chr17:39239918	KRTAP4-7	0.39	5.6	0.34	5.82e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs918959	0.793	rs16867352	chr2:181549768	C/T	cg04166432	chr2:181843717	UBE2E3	0.67	5.01	0.3	1.03e-6	Systemic lupus erythematosus;
KIRP	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs734999	0.549	rs3828154	chr1:2524943	G/A	cg18932078	chr1:2524107	MMEL1	0.41	5.64	0.34	4.57e-8	Ulcerative colitis;
KIRP	cis	rs365132	0.875	rs547798	chr5:176326721	C/A	cg16309518	chr5:176445507	NA	-0.79	-12.16	-0.61	5.89e-27	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg18350739	chr11:68623251	NA	-0.48	-7.14	-0.41	1.05e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg13482628	chr17:19912719	NA	0.6	8.38	0.47	4.08e-15	Schizophrenia;
KIRP	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05665937	chr4:1216051	CTBP1	0.47	6.51	0.38	4.21e-10	Obesity-related traits;
KIRP	cis	rs12496230	0.909	rs13075691	chr3:66857626	T/A	cg23477460	chr3:66848765	NA	0.41	5.15	0.31	5.33e-7	Type 2 diabetes;
KIRP	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.16	-0.5	2.11e-17	Personality dimensions;
KIRP	cis	rs255758	0.768	rs31127	chr5:53314757	A/G	cg22592108	chr5:53304441	ARL15	0.48	6.12	0.36	3.66e-9	Rheumatoid arthritis;
KIRP	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg05564831	chr3:52568323	NT5DC2	0.43	6.84	0.4	6.24e-11	Electroencephalogram traits;
KIRP	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.06	-0.36	5.04e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.42	7.24	0.42	5.87e-12	Renal cell carcinoma;
KIRP	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.26	0.32	3.07e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3779635	0.712	rs2059968	chr8:27259151	A/T	cg18234130	chr8:27182889	PTK2B	0.53	6.84	0.4	6.3e-11	Neuroticism;
KIRP	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg22138327	chr13:27999177	GTF3A	0.97	7.48	0.43	1.35e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg00800038	chr16:89945340	TCF25	-0.78	-5.24	-0.32	3.43e-7	Skin colour saturation;
KIRP	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg10932868	chr11:921992	NA	0.64	8.57	0.48	1.13e-15	Alzheimer's disease (late onset);
KIRP	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg02725872	chr8:58115012	NA	-0.56	-5.85	-0.35	1.54e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4363385	0.510	rs6664380	chr1:153030365	G/T	cg13444842	chr1:152974279	SPRR3	-0.44	-6.44	-0.38	6.37e-10	Inflammatory skin disease;
KIRP	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg15839431	chr19:19639596	YJEFN3	-0.48	-5.33	-0.32	2.27e-7	Bipolar disorder;
KIRP	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.51	-5.56	-0.33	6.93e-8	Total body bone mineral density;
KIRP	cis	rs4638749	0.501	rs1003018	chr2:108760922	G/T	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.94	-0.3	1.43e-6	Blood pressure;
KIRP	cis	rs981844	0.712	rs897611	chr4:154755519	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.43	5.3	0.32	2.55e-7	Testicular germ cell tumor;
KIRP	cis	rs4704187	0.687	rs13360638	chr5:74433258	G/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs28489187	0.706	rs2268667	chr1:85793746	A/G	cg16011679	chr1:85725395	C1orf52	-0.56	-6.78	-0.4	8.61e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	trans	rs9650657	0.740	rs6980805	chr8:10679842	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.24	-0.37	1.95e-9	Neuroticism;
KIRP	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg05255149	chr17:80675120	FN3KRP	0.45	4.88	0.3	1.92e-6	Glycated hemoglobin levels;
KIRP	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	7.0	0.41	2.35e-11	Platelet count;
KIRP	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.46	6.35	0.38	1.02e-9	Sitting height ratio;
KIRP	trans	rs6601327	0.635	rs10112972	chr8:9655218	T/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.83	-0.4	6.54e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-7.84	-0.45	1.37e-13	Bipolar disorder;
KIRP	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg14129931	chr18:74513950	NA	0.56	6.61	0.39	2.34e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
KIRP	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg11833968	chr6:79620685	NA	-0.41	-6.23	-0.37	2.01e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.46	6.33	0.37	1.16e-9	Testicular germ cell tumor;
KIRP	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.56	6.98	0.41	2.66e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12210905	1.000	rs116005859	chr6:27155485	G/A	cg11502198	chr6:26597334	ABT1	-0.74	-4.91	-0.3	1.66e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs2084898	0.550	rs470941	chr11:119999755	C/T	cg07435449	chr11:120005650	TRIM29	0.48	6.32	0.37	1.22e-9	Stroke (pediatric);
KIRP	cis	rs72720396	0.803	rs114993052	chr1:91190855	T/A	cg13456504	chr1:91191583	NA	0.57	6.16	0.37	2.9e-9	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs6575793	0.553	rs7140556	chr14:101036458	G/T	cg18516195	chr14:101012996	BEGAIN	0.43	5.3	0.32	2.53e-7	Menarche (age at onset);
KIRP	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.81	11.1	0.58	1.75e-23	Colorectal cancer;
KIRP	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.7	9.85	0.53	1.65e-19	Caffeine consumption;
KIRP	cis	rs2120243	0.539	rs4679793	chr3:157122661	A/C	cg24825693	chr3:157122686	VEPH1	0.54	8.91	0.49	1.16e-16	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg24558718	chr10:853215	NA	1.01	6.22	0.37	2.17e-9	Thrombomodulin levels in ischemic stroke;
KIRP	trans	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg02773041	chr1:40204384	PPIE	0.59	7.85	0.45	1.25e-13	Blood protein levels;
KIRP	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.53	-6.97	-0.41	2.82e-11	Alzheimer's disease;
KIRP	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.45	0.55	2.19e-21	Hip circumference;
KIRP	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.55	7.65	0.44	4.68e-13	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs12913538	0.862	rs1550053	chr15:62890532	G/C	cg09983546	chr15:62884068	NA	0.55	8.15	0.46	1.82e-14	Sleep depth;
KIRP	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg27147174	chr7:100797783	AP1S1	-0.7	-8.95	-0.5	8.96e-17	Life satisfaction;
KIRP	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06481639	chr22:41940642	POLR3H	0.7	7.11	0.41	1.24e-11	Vitiligo;
KIRP	cis	rs7172677	0.732	rs55922358	chr15:75313967	G/C	cg10253484	chr15:75165896	SCAMP2	0.69	7.73	0.44	2.74e-13	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs10940138	0.501	rs6877885	chr5:67249661	G/C	ch.5.1281357F	chr5:67228439	NA	-0.5	-7.4	-0.43	2.19e-12	Menarche (age at onset);
KIRP	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg21479132	chr6:26055353	NA	0.81	5.66	0.34	4.13e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg03959625	chr15:84868606	LOC388152	-0.62	-7.35	-0.42	2.97e-12	Schizophrenia;
KIRP	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg26513180	chr16:89883248	FANCA	0.81	5.39	0.32	1.68e-7	Skin colour saturation;
KIRP	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg15655495	chr12:38532458	NA	-0.28	-5.26	-0.32	3.1e-7	Bladder cancer;
KIRP	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.69	9.36	0.51	5.34e-18	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg02462569	chr6:150064036	NUP43	-0.34	-5.07	-0.31	7.9e-7	Lung cancer;
KIRP	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.08	-0.31	7.31e-7	Bipolar disorder;
KIRP	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg00074818	chr8:8560427	CLDN23	0.39	5.89	0.35	1.25e-8	Obesity-related traits;
KIRP	trans	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.27	-0.37	1.58e-9	Neuroticism;
KIRP	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg25390334	chr2:241827778	C2orf54	-0.35	-4.95	-0.3	1.41e-6	Urinary metabolites;
KIRP	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-5.41	-0.33	1.52e-7	Metabolite levels;
KIRP	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.59	-6.8	-0.4	7.97e-11	Vitiligo;
KIRP	cis	rs17123764	0.892	rs56906356	chr12:50118377	G/A	cg20471783	chr12:50157085	TMBIM6	0.42	5.99	0.36	7.49e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6969780	0.915	rs3801320	chr7:27164364	C/A	cg14359292	chr7:27170892	HOXA4	0.35	5.04	0.31	8.98e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg04013166	chr16:89971882	TCF25	0.57	6.0	0.36	6.96e-9	Skin colour saturation;
KIRP	cis	rs501120	0.564	rs2804036	chr10:44680405	A/G	cg09554077	chr10:44749378	NA	0.51	6.75	0.4	1.08e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg21858823	chr1:15850916	CASP9	0.54	5.81	0.35	1.92e-8	Systolic blood pressure;
KIRP	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg06212747	chr3:49208901	KLHDC8B	0.67	8.01	0.45	4.7e-14	Menarche (age at onset);
KIRP	cis	rs6438504	0.922	rs12630690	chr3:118930464	A/T	cg25372693	chr3:118959985	B4GALT4	-0.31	-5.1	-0.31	6.79e-7	Clozapine-induced cytotoxicity;
KIRP	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs60311166	1.000	rs6780397	chr3:52767599	T/C	cg13174197	chr3:52720522	GNL3;PBRM1	1.0	7.06	0.41	1.65e-11	CTACK levels;
KIRP	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg09263875	chr16:632152	PIGQ	0.73	12.31	0.62	1.93e-27	Height;
KIRP	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg08975724	chr8:8085496	FLJ10661	0.68	9.31	0.51	7.25e-18	Triglycerides;
KIRP	cis	rs2034088	0.931	rs7217763	chr17:421437	A/G	cg01214346	chr17:406501	NA	-0.45	-5.61	-0.34	5.55e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg22563815	chr15:78856949	CHRNA5	-0.47	-7.28	-0.42	4.45e-12	Sudden cardiac arrest;
KIRP	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg11752832	chr7:134001865	SLC35B4	0.43	5.52	0.33	8.46e-8	Mean platelet volume;
KIRP	trans	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg24644049	chr4:85504048	CDS1	1.09	6.99	0.41	2.59e-11	Skin colour saturation;
KIRP	cis	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg24253500	chr15:84953950	NA	0.62	6.56	0.39	3.16e-10	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.63	-8.44	-0.47	2.8e-15	Motion sickness;
KIRP	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.67	-7.26	-0.42	4.99e-12	Corneal structure;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg07701084	chr6:150067640	NUP43	0.7	9.9	0.53	1.13e-19	Lung cancer;
KIRP	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	1.02	14.3	0.67	3.57e-34	Menarche (age at onset);
KIRP	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg17077180	chr1:38461687	NA	-0.39	-5.02	-0.31	9.73e-7	Coronary artery disease;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg23698023	chr8:27181813	PTK2B	0.34	5.08	0.31	7.57e-7	Neuroticism;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03274021	chr8:130952480	FAM49B	0.47	6.31	0.37	1.3e-9	Asthma;
KIRP	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.46	5.84	0.35	1.61e-8	Subjective well-being;
KIRP	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg02336718	chr17:17403227	NA	-0.34	-5.3	-0.32	2.52e-7	Total body bone mineral density;
KIRP	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg05973401	chr12:123451056	ABCB9	0.61	7.12	0.41	1.17e-11	Platelet count;
KIRP	cis	rs3126085	0.560	rs1858485	chr1:152334530	A/G	cg26876637	chr1:152193138	HRNR	-0.55	-6.37	-0.38	9.13e-10	Atopic dermatitis;
KIRP	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.94	15.05	0.69	9.72e-37	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg26043149	chr18:55253948	FECH	0.51	6.52	0.38	3.91e-10	Bone mineral density;
KIRP	cis	rs944289	0.576	rs1820604	chr14:36639206	C/G	cg21129253	chr14:36638564	NA	0.27	4.96	0.3	1.29e-6	Thyroid cancer;
KIRP	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.88	-8.63	-0.48	8.01e-16	Coronary artery calcification;
KIRP	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.62	-7.46	-0.43	1.49e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	11.07	0.58	2.19e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.99	-16.75	-0.73	1.52e-42	Breast cancer;
KIRP	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08508325	chr11:3079039	CARS	0.31	5.44	0.33	1.27e-7	Calcium levels;
KIRP	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg17470723	chr8:74884337	TCEB1	-0.64	-8.11	-0.46	2.33e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs494562	0.803	rs727870	chr6:86131156	A/G	cg27039625	chr6:86159096	NT5E	0.38	4.95	0.3	1.4e-6	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.52	6.81	0.4	7.36e-11	Total body bone mineral density;
KIRP	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.79	11.09	0.58	1.86e-23	Body mass index;
KIRP	cis	rs42648	0.633	rs11563909	chr7:89935704	A/G	cg25739043	chr7:89950458	NA	-0.42	-6.75	-0.4	1.07e-10	Homocysteine levels;
KIRP	cis	rs7903847	0.642	rs7078782	chr10:99168604	C/T	cg20016023	chr10:99160130	RRP12	-0.41	-5.57	-0.33	6.68e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00149659	chr3:10157352	C3orf10	0.83	9.03	0.5	5.11e-17	Alzheimer's disease;
KIRP	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg00129232	chr17:37814104	STARD3	-0.49	-5.85	-0.35	1.57e-8	Self-reported allergy;
KIRP	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg04374321	chr14:90722782	PSMC1	0.51	5.68	0.34	3.73e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7078219	0.505	rs41290504	chr10:101293035	C/A	cg07044859	chr10:101282883	NA	-0.31	-5.57	-0.33	6.57e-8	Dental caries;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09059670	chr5:79552137	SERINC5	0.49	6.35	0.38	1.02e-9	Parkinson's disease;
KIRP	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.03	0.41	2.07e-11	Caffeine consumption;
KIRP	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs6684514	1.000	rs2241106	chr1:156218910	C/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.63	-0.34	5.02e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.8	-0.49	2.52e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs60311166	1.000	rs72947583	chr3:52617358	C/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.95	6.53	0.38	3.78e-10	CTACK levels;
KIRP	cis	rs41563	0.674	rs2192932	chr7:104653265	A/G	cg04380332	chr7:105027541	SRPK2	0.62	9.33	0.51	6.41e-18	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.63	9.35	0.51	5.59e-18	Vitiligo;
KIRP	cis	rs9346649	0.630	rs6913441	chr6:168491271	C/T	cg09211372	chr6:168490623	NA	-0.4	-6.98	-0.41	2.68e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.88	11.71	0.6	1.77e-25	Response to diuretic therapy;
KIRP	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg09658497	chr7:2847517	GNA12	-0.33	-5.18	-0.31	4.68e-7	Height;
KIRP	trans	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.5	-0.38	4.52e-10	Neuroticism;
KIRP	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg14972814	chr11:95582409	MTMR2	0.34	5.56	0.33	7.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.63	-9.31	-0.51	7.19e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg27205649	chr11:78285834	NARS2	0.72	8.0	0.45	4.85e-14	Alzheimer's disease (survival time);
KIRP	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.78	-10.52	-0.56	1.27e-21	Aortic root size;
KIRP	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.58	7.31	0.42	3.73e-12	Monocyte count;
KIRP	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg05717871	chr11:638507	DRD4	-0.37	-4.96	-0.3	1.33e-6	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.95	0.3	1.38e-6	Lung cancer;
KIRP	cis	rs4356975	0.563	rs6600885	chr4:69969667	A/G	cg27372994	chr4:70080453	UGT2B11	0.41	5.49	0.33	9.82e-8	Obesity-related traits;
KIRP	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.67	-6.65	-0.39	1.92e-10	Bipolar disorder;
KIRP	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	1.09	8.01	0.45	4.71e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg04362960	chr10:104952993	NT5C2	0.43	4.9	0.3	1.71e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-0.41	-5.11	-0.31	6.43e-7	Type 2 diabetes;
KIRP	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.64	8.67	0.48	5.75e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1514687	0.534	rs11211654	chr2:1474131	C/T	cg13703866	chr2:1479523	TPO	-0.67	-5.66	-0.34	4.21e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.7	-8.45	-0.47	2.51e-15	Cognitive function;
KIRP	cis	rs2151522	0.762	rs35669634	chr6:127188248	G/A	cg21431617	chr6:127135037	NA	0.29	5.13	0.31	5.85e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.7	9.28	0.51	9.25e-18	Bladder cancer;
KIRP	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg27205649	chr11:78285834	NARS2	-0.54	-5.16	-0.31	5.15e-7	Testicular germ cell tumor;
KIRP	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg18478394	chr8:109455254	TTC35	0.5	6.11	0.36	3.78e-9	Dupuytren's disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03333116	chr16:112444	RHBDF1	-0.47	-6.35	-0.38	1.02e-9	Survival in pancreatic cancer;
KIRP	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg20578329	chr17:80767326	TBCD	0.62	6.47	0.38	5.2400000000000005e-10	Breast cancer;
KIRP	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.79	7.23	0.42	6.16e-12	Mean platelet volume;
KIRP	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.85	-12.97	-0.64	1.18e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9847710	1.000	rs6770152	chr3:53100214	A/C	cg07884673	chr3:53033167	SFMBT1	0.41	5.25	0.32	3.21e-7	Ulcerative colitis;
KIRP	cis	rs1975974	0.511	rs56047890	chr17:21733405	G/A	cg18423549	chr17:21743878	NA	-0.48	-5.1	-0.31	6.77e-7	Psoriasis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09172752	chr15:77197536	NA	-0.47	-6.18	-0.37	2.69e-9	Metabolic traits;
KIRP	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs992157	0.730	rs4280446	chr2:219184721	T/C	cg05991184	chr2:219186017	PNKD	-0.43	-6.26	-0.37	1.74e-9	Colorectal cancer;
KIRP	cis	rs34779708	0.931	rs2384283	chr10:35326789	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg16989719	chr2:238392110	NA	-0.7	-6.97	-0.41	2.92e-11	Prostate cancer;
KIRP	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg02503808	chr4:7069936	GRPEL1	0.93	12.63	0.63	1.59e-28	Monocyte percentage of white cells;
KIRP	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.48	-0.56	1.68e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4959270	0.933	rs57182179	chr6:460515	C/T	cg13299325	chr6:447777	NA	0.25	5.12	0.31	6.12e-7	Limited cutaneous systemic scleroderma;
KIRP	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.79	7.43	0.43	1.75e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14768946	chr2:191878941	STAT1	0.47	6.28	0.37	1.54e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.6	-9.32	-0.51	6.84e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg04539111	chr16:67997858	SLC12A4	-0.56	-4.93	-0.3	1.53e-6	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.51	0.52	1.89e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.37	5.55	0.33	7.42e-8	Alcoholic chronic pancreatitis;
KIRP	trans	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.84e-12	Bladder cancer;
KIRP	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.74	10.45	0.55	2.19e-21	Body mass index;
KIRP	cis	rs7033996	1.000	rs7046469	chr9:35923384	T/G	cg00918944	chr9:35908117	LOC158376	0.36	5.0	0.3	1.08e-6	Urate levels (BMI interaction);
KIRP	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg14458575	chr2:238380390	NA	-0.46	-5.26	-0.32	3.13e-7	Prostate cancer;
KIRP	cis	rs7572644	0.699	rs10177845	chr2:28124171	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-5.35	-0.32	2.05e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.56	-0.43	8.21e-13	Lung cancer;
KIRP	cis	rs1978968	0.956	rs12159837	chr22:18447491	G/A	cg02610425	chr22:18483192	MICAL3	0.36	5.07	0.31	7.93e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs12586317	0.576	rs6571702	chr14:35650558	C/A	cg07166546	chr14:35805898	NA	-0.28	-6.69	-0.39	1.48e-10	Psoriasis;
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21016266	chr12:122356598	WDR66	0.6	8.14	0.46	1.97e-14	Mean corpuscular volume;
KIRP	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.58	7.17	0.42	8.64e-12	Metabolite levels;
KIRP	cis	rs73200209	0.626	rs55984419	chr12:116578042	G/A	cg01776926	chr12:116560359	MED13L	-0.55	-5.65	-0.34	4.4e-8	Total body bone mineral density;
KIRP	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.93	8.19	0.46	1.4e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.44	-5.78	-0.35	2.23e-8	Body mass index;
KIRP	cis	rs4780401	0.693	rs8191277	chr16:11764082	A/G	cg01061890	chr16:11836724	TXNDC11	-0.43	-5.21	-0.32	4.07e-7	Rheumatoid arthritis;
KIRP	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.19	-0.51	1.66e-17	Platelet count;
KIRP	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.73	-10.25	-0.55	8.96e-21	Red blood cell count;
KIRP	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.6	-0.63	2.03e-28	Electrocardiographic conduction measures;
KIRP	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.42	-5.19	-0.31	4.43e-7	Blood metabolite levels;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg09264619	chr17:80180166	NA	0.37	5.38	0.32	1.76e-7	Life satisfaction;
KIRP	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.86	-12.38	-0.62	1.08e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs75920871	0.920	rs61905687	chr11:116862144	T/C	cg23684410	chr11:116897558	SIK3	0.56	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg01763666	chr17:80159506	CCDC57	-0.38	-5.14	-0.31	5.7e-7	Life satisfaction;
KIRP	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00938859	chr5:1591904	SDHAP3	0.59	8.0	0.45	5.05e-14	Breast cancer;
KIRP	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.53	0.38	3.8e-10	Rheumatoid arthritis;
KIRP	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg26750617	chr12:132293702	NA	-0.42	-5.34	-0.32	2.07e-7	Migraine;
KIRP	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg21775007	chr8:11205619	TDH	0.42	5.38	0.32	1.69e-7	Neuroticism;
KIRP	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.45	-5.24	-0.32	3.53e-7	Reticulocyte count;
KIRP	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.58	-5.26	-0.32	3.1e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13319406	0.508	rs6788208	chr3:189832890	A/G	cg03343083	chr3:189718843	LEPREL1	0.55	5.6	0.34	5.86e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7719624	0.632	rs13189180	chr5:135400035	A/G	cg16684184	chr5:135415129	NA	-0.36	-5.55	-0.33	7.55e-8	Response to cytidine analogues (gemcitabine);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19721680	chr1:244816665	PPPDE1	-0.46	-6.25	-0.37	1.81e-9	Survival in pancreatic cancer;
KIRP	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.11	-17.98	-0.75	1.02e-46	Schizophrenia;
KIRP	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.03	-0.36	5.9e-9	Height;
KIRP	cis	rs73206853	0.764	rs57033697	chr12:110550992	G/A	cg12870014	chr12:110450643	ANKRD13A	0.53	5.53	0.33	8.25e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.63	-7.36	-0.42	2.69e-12	Breast cancer;
KIRP	trans	rs13170463	0.737	rs35900324	chr5:8049430	T/C	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs6102059	0.525	rs6093368	chr20:39197871	A/C	cg06665391	chr20:39312290	NA	0.44	5.43	0.33	1.37e-7	LDL cholesterol;
KIRP	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16414030	chr3:133502952	NA	-0.51	-5.73	-0.34	2.9e-8	Iron status biomarkers;
KIRP	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	9.87	0.53	1.38e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg02336718	chr17:17403227	NA	0.39	5.89	0.35	1.28e-8	Total body bone mineral density;
KIRP	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.99	-16.23	-0.72	9.36e-41	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	5.58	0.34	6.3e-8	Educational attainment;
KIRP	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00318877	chr11:28190822	METT5D1	-0.42	-6.88	-0.4	4.93e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.49	-6.33	-0.37	1.13e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg18306943	chr3:40428807	ENTPD3	0.4	5.6	0.34	5.64e-8	Renal cell carcinoma;
KIRP	cis	rs6963495	0.615	rs2697021	chr7:105151029	A/C	cg19920283	chr7:105172520	RINT1	0.54	6.33	0.37	1.13e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.31	-0.37	1.26e-9	QT interval;
KIRP	cis	rs16958440	0.541	rs62095459	chr18:44621382	A/T	cg17192377	chr18:44677553	HDHD2	0.43	4.91	0.3	1.7e-6	Sitting height ratio;
KIRP	cis	rs11645898	0.574	rs17604349	chr16:72210865	C/T	cg14768367	chr16:72042858	DHODH	-0.74	-8.15	-0.46	1.8e-14	Blood protein levels;
KIRP	cis	rs10924970	0.967	rs2152954	chr1:235417780	A/G	cg26050004	chr1:235667680	B3GALNT2	0.4	4.94	0.3	1.42e-6	Asthma;
KIRP	cis	rs624899	0.522	rs645584	chr19:11612466	A/G	cg08877591	chr19:11648452	CNN1	-0.54	-5.87	-0.35	1.4e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.87	12.91	0.64	1.87e-29	Mean platelet volume;
KIRP	cis	rs4713675	0.510	rs1014933	chr6:33677235	A/G	cg15676125	chr6:33679581	C6orf125	0.42	5.46	0.33	1.15e-7	Plateletcrit;
KIRP	cis	rs6546324	0.625	rs2861689	chr2:67838604	C/G	cg15745817	chr2:67799979	NA	-0.65	-7.5	-0.43	1.14e-12	Endometriosis;
KIRP	cis	rs11166927	0.934	rs7015426	chr8:140802688	C/G	cg16909799	chr8:140841666	TRAPPC9	0.67	9.78	0.53	2.62e-19	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg19476082	chr7:2414320	EIF3B	0.57	5.26	0.32	3.14e-7	Multiple sclerosis;
KIRP	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg11965913	chr1:205819406	PM20D1	0.54	6.21	0.37	2.3e-9	Prostate-specific antigen levels;
KIRP	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg01304814	chr3:48885189	PRKAR2A	0.71	5.63	0.34	4.97e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg15556689	chr8:8085844	FLJ10661	0.55	7.28	0.42	4.44e-12	Retinal vascular caliber;
KIRP	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg06766960	chr11:133703094	NA	0.57	7.03	0.41	2e-11	Childhood ear infection;
KIRP	cis	rs580438	1.000	rs184793	chr3:13343360	C/T	cg10657019	chr3:13328039	NA	0.79	10.35	0.55	4.45e-21	Myringotomy;
KIRP	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg23752985	chr2:85803571	VAMP8	-0.61	-9.02	-0.5	5.54e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs997295	1.000	rs34583567	chr15:67983281	G/T	cg24579218	chr15:68104479	NA	0.37	5.64	0.34	4.56e-8	Motion sickness;
KIRP	cis	rs41005	1.000	rs12692349	chr2:8114312	G/A	cg03155496	chr2:8117019	LOC339788	-0.58	-9.29	-0.51	8.5e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs6691722	0.544	rs7551707	chr1:24696892	G/A	cg18323236	chr1:24743029	NIPAL3	0.42	6.13	0.36	3.56e-9	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg18477163	chr1:228402036	OBSCN	0.35	6.57	0.39	2.96e-10	Diastolic blood pressure;
KIRP	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg10495392	chr1:46806563	NSUN4	-0.48	-5.42	-0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.56	-0.43	8.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.967	rs6672381	chr1:2502834	A/G	cg18854424	chr1:2615690	NA	0.34	5.37	0.32	1.86e-7	Ulcerative colitis;
KIRP	cis	rs2862064	0.932	rs1553319	chr5:156479001	T/A	cg12943317	chr5:156479607	HAVCR1	-0.89	-8.0	-0.45	4.85e-14	Platelet count;
KIRP	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.93	0.35	1.01e-8	Motion sickness;
KIRP	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	20.76	0.8	5.49e-56	Prudent dietary pattern;
KIRP	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-7.79	-0.44	1.92e-13	Systemic lupus erythematosus;
KIRP	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg26068271	chr17:76253126	NA	0.51	7.4	0.43	2.18e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs2120243	0.592	rs1869857	chr3:157123357	G/T	cg24825693	chr3:157122686	VEPH1	0.51	8.65	0.48	6.78e-16	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg13409248	chr3:40428643	ENTPD3	-0.39	-5.48	-0.33	1.06e-7	Renal cell carcinoma;
KIRP	cis	rs7587476	0.906	rs62201985	chr2:215658638	A/G	cg04004882	chr2:215674386	BARD1	0.87	8.12	0.46	2.19e-14	Neuroblastoma;
KIRP	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg12486944	chr17:80159399	CCDC57	-0.39	-5.16	-0.31	5.2e-7	Life satisfaction;
KIRP	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.77	-0.35	2.34e-8	Amyotrophic lateral sclerosis (age of onset);
KIRP	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.99	14.32	0.67	3.06e-34	Cognitive function;
KIRP	cis	rs42648	0.935	rs42664	chr7:89984409	A/G	cg25739043	chr7:89950458	NA	-0.44	-6.91	-0.4	4.07e-11	Homocysteine levels;
KIRP	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.66	-0.34	4.21e-8	Crohn's disease;
KIRP	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg02534363	chr3:47050950	NBEAL2	-0.28	-4.89	-0.3	1.8e-6	Colorectal cancer;
KIRP	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg13147721	chr7:65941812	NA	-1.02	-7.08	-0.41	1.52e-11	Diabetic kidney disease;
KIRP	cis	rs918629	0.679	rs3822750	chr5:95276260	C/A	cg16656078	chr5:95278638	ELL2	-0.44	-6.22	-0.37	2.13e-9	IgG glycosylation;
KIRP	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg24579218	chr15:68104479	NA	-0.47	-7.8	-0.45	1.81e-13	Restless legs syndrome;
KIRP	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	13.14	0.64	3.03e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs62355272	0.861	rs56133736	chr5:35842908	T/C	cg13894535	chr5:35919491	CAPSL	-0.51	-5.67	-0.34	4.05e-8	Lymphocyte counts;
KIRP	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.52	7.48	0.43	1.33e-12	Schizophrenia;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15755476	chr11:47510670	CUGBP1	0.53	7.82	0.45	1.59e-13	Interleukin-4 levels;
KIRP	cis	rs1050631	1.000	rs1539822	chr18:33695943	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.51	6.28	0.37	1.56e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg11502198	chr6:26597334	ABT1	-0.49	-6.26	-0.37	1.75e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-11.4	-0.59	1.9e-24	Vitiligo;
KIRP	cis	rs4713675	0.524	rs4713672	chr6:33705066	G/A	cg15676125	chr6:33679581	C6orf125	0.41	5.19	0.31	4.41e-7	Plateletcrit;
KIRP	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.75	8.72	0.49	4.34e-16	High light scatter reticulocyte count;
KIRP	cis	rs7712401	0.601	rs30059	chr5:122297509	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg04310649	chr10:35416472	CREM	-0.57	-6.88	-0.4	4.92e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.45	6.29	0.37	1.4e-9	Systolic blood pressure;
KIRP	cis	rs737693	0.607	rs674546	chr11:102730639	A/G	cg19620758	chr11:102826565	MMP13	0.53	5.69	0.34	3.63e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg07701084	chr6:150067640	NUP43	0.7	9.9	0.53	1.15e-19	Lung cancer;
KIRP	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.8	10.98	0.57	4.52e-23	Aortic root size;
KIRP	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.5	-6.72	-0.39	1.23e-10	Red cell distribution width;
KIRP	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08439880	chr3:133502540	NA	-0.51	-6.23	-0.37	1.98e-9	Iron status biomarkers;
KIRP	cis	rs12643440	0.574	rs12651694	chr4:17139359	G/A	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg18478394	chr8:109455254	TTC35	0.55	6.65	0.39	1.85e-10	Dupuytren's disease;
KIRP	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg03146154	chr1:46216737	IPP	0.54	5.53	0.33	8.34e-8	Platelet count;
KIRP	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg09137382	chr11:130731461	NA	0.54	7.94	0.45	7.38e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-5.03	-0.31	9.5e-7	Ulcerative colitis;
KIRP	cis	rs71277158	0.572	rs77964281	chr3:169916180	T/C	cg04067573	chr3:169899625	PHC3	0.72	6.77	0.4	9.28e-11	Prostate cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg19749445	chr14:92493378	TRIP11	0.49	6.32	0.37	1.21e-9	Interleukin-4 levels;
KIRP	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.67	6.41	0.38	7.38e-10	Eotaxin levels;
KIRP	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04530015	chr2:215796436	ABCA12	0.37	5.27	0.32	3.05e-7	Neuroblastoma (high-risk);
KIRP	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg13393036	chr8:95962371	TP53INP1	-0.32	-6.12	-0.36	3.62e-9	Type 2 diabetes;
KIRP	cis	rs4236601	0.720	rs6466580	chr7:116154726	T/C	cg12739419	chr7:116140593	CAV2	0.46	5.84	0.35	1.6e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs2742417	0.967	rs2742426	chr3:45735901	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg05347473	chr6:146136440	FBXO30	0.51	7.07	0.41	1.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg04362960	chr10:104952993	NT5C2	0.43	4.98	0.3	1.19e-6	Prostate cancer;
KIRP	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.76	-9.25	-0.51	1.14e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg06026331	chr20:60912101	LAMA5	-0.48	-6.43	-0.38	6.6e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.47	-0.38	5.37e-10	Monocyte percentage of white cells;
KIRP	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.88	9.88	0.53	1.32e-19	Corneal astigmatism;
KIRP	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg19636519	chr7:99541626	NA	0.38	6.98	0.41	2.7e-11	Coronary artery disease;
KIRP	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.57	-6.53	-0.38	3.8e-10	Vitiligo;
KIRP	cis	rs7224685	0.501	rs4790169	chr17:4022665	G/A	cg09597638	chr17:3907349	NA	-0.75	-13.89	-0.66	9.07e-33	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14579157	chr2:99061273	INPP4A	0.46	6.27	0.37	1.58e-9	Survival in pancreatic cancer;
KIRP	cis	rs12580194	0.593	rs60774348	chr12:55757717	A/G	cg19537932	chr12:55886519	OR6C68	-0.5	-6.48	-0.38	5.02e-10	Cancer;
KIRP	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg05861140	chr6:150128134	PCMT1	-0.47	-6.37	-0.38	9.31e-10	Lung cancer;
KIRP	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.45	-6.04	-0.36	5.8e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.61	7.14	0.41	1.03e-11	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	10.22	0.55	1.18e-20	Post bronchodilator FEV1;
KIRP	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.13	-19.59	-0.78	3.88e-52	Triglycerides;
KIRP	cis	rs400736	0.860	rs2294890	chr1:8086527	T/G	cg25007680	chr1:8021821	PARK7	0.63	8.42	0.47	3.19e-15	Response to antidepressants and depression;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.59	7.69	0.44	3.48e-13	Longevity;Endometriosis;
KIRP	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.3	5.92	0.35	1.06e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.31	5.06	0.31	8.14e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.36	-5.32	-0.32	2.37e-7	Body mass index;
KIRP	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.75	-7.81	-0.45	1.62e-13	Vitiligo;
KIRP	cis	rs2273156	1.000	rs7153068	chr14:35459481	A/T	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.39	-0.33	1.64e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	4.95	0.3	1.4e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg17145862	chr1:211918768	LPGAT1	0.76	10.65	0.56	4.93e-22	Leprosy;
KIRP	cis	rs10849605	1.000	rs55791720	chr12:1066834	T/C	cg22243222	chr12:1059299	RAD52	-0.37	-5.1	-0.31	6.85e-7	Lung cancer;
KIRP	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.52	6.76	0.4	9.81e-11	Birth weight;
KIRP	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg16558253	chr16:72132732	DHX38	-0.4	-5.44	-0.33	1.31e-7	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.73e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs8054556	0.669	rs9972866	chr16:30018982	C/G	cg06326092	chr16:30034487	C16orf92	0.43	6.45	0.38	5.92e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg26043149	chr18:55253948	FECH	-0.52	-6.01	-0.36	6.48e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs1816752	0.783	rs7317712	chr13:24985503	C/T	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg08975724	chr8:8085496	FLJ10661	0.52	6.56	0.39	3.07e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.4	-5.15	-0.31	5.3e-7	IgG glycosylation;
KIRP	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs1858037	0.867	rs871974	chr2:65557287	C/T	cg08085232	chr2:65598271	SPRED2	0.51	6.22	0.37	2.14e-9	Rheumatoid arthritis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg04769705	chr14:69262517	C14orf181	-0.52	-6.21	-0.37	2.29e-9	Interleukin-4 levels;
KIRP	cis	rs17125944	0.686	rs7158114	chr14:53353471	C/G	cg00686598	chr14:53173677	PSMC6	-0.69	-6.43	-0.38	6.46e-10	Alzheimer's disease (late onset);
KIRP	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg21854759	chr1:92012499	NA	-0.47	-6.05	-0.36	5.32e-9	Breast cancer;
KIRP	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.75	10.25	0.55	9.26e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg26371346	chr8:56986568	SNORD54;RPS20	0.58	5.55	0.33	7.46e-8	Height;
KIRP	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg16339924	chr4:17578868	LAP3	0.65	8.95	0.5	8.84e-17	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg13840032	chr18:46385379	KIAA0427	0.58	6.27	0.37	1.57e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg11815991	chr20:30193098	ID1	-0.51	-5.12	-0.31	6.21e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.35	6.05	0.36	5.43e-9	Refractive error;
KIRP	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.44	6.0	0.36	7e-9	Hemoglobin concentration;
KIRP	trans	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg07211511	chr3:129823064	LOC729375	-0.66	-7.36	-0.42	2.79e-12	Blood pressure (smoking interaction);
KIRP	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.36	-5.65	-0.34	4.32e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13082711	0.520	rs2724494	chr3:27563920	C/A	cg02860705	chr3:27208620	NA	0.4	5.34	0.32	2.14e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-5.13	-0.31	5.83e-7	Inflammatory skin disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26007049	chr14:96000930	GLRX5;SNHG10;SCARNA13	-0.54	-6.13	-0.36	3.52e-9	Interleukin-4 levels;
KIRP	cis	rs9831754	0.756	rs2872626	chr3:78435049	A/T	cg06138941	chr3:78371609	NA	-0.8	-11.33	-0.59	3.14e-24	Calcium levels;
KIRP	cis	rs7224685	0.871	rs8081968	chr17:3984117	C/T	cg17441377	chr17:3906640	NA	0.46	6.06	0.36	5.07e-9	Type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.23	-0.37	1.96e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6499755	0.768	rs31086	chr16:55362542	C/G	cg05099576	chr16:55362342	IRX6	0.33	6.7	0.39	1.4e-10	Hypospadias;
KIRP	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg09699651	chr6:150184138	LRP11	0.49	6.24	0.37	1.88e-9	Lung cancer;
KIRP	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.4	-0.55	3.15e-21	Hypospadias;
KIRP	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.91	-10.6	-0.56	7.12e-22	Exhaled nitric oxide output;
KIRP	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg18944383	chr4:111397179	ENPEP	0.55	9.27	0.51	9.87e-18	Coronary artery disease;
KIRP	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.55	6.75	0.4	1.04e-10	Subjective well-being;
KIRP	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	7.41	0.43	2.04e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.27	0.42	4.81e-12	Lung cancer;
KIRP	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg12963246	chr6:28129442	ZNF389	0.5	6.17	0.37	2.84e-9	Depression;
KIRP	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg13628971	chr7:2884303	GNA12	0.4	5.33	0.32	2.19e-7	Height;
KIRP	cis	rs1270639	1.000	rs1270639	chr7:157455459	C/T	cg13357408	chr7:157437802	PTPRN2	-0.62	-5.0	-0.3	1.09e-6	Colorectal cancer;
KIRP	cis	rs796825	0.530	rs34998142	chr3:119939802	T/C	cg21790991	chr3:120137480	FSTL1	-0.3	-5.23	-0.32	3.64e-7	HIV-1 susceptibility;
KIRP	cis	rs13185784	0.703	rs17627536	chr5:179678603	G/A	cg02891314	chr5:179741120	GFPT2	0.54	5.27	0.32	2.95e-7	TRAIL levels;
KIRP	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.59	-6.84	-0.4	6.29e-11	Menarche (age at onset);
KIRP	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.31	-0.37	1.32e-9	Systolic blood pressure;
KIRP	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg00405596	chr8:11794950	NA	-0.44	-5.72	-0.34	3.01e-8	Triglycerides;
KIRP	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.92	11.58	0.59	4.79e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.91e-9	Morning vs. evening chronotype;
KIRP	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.82	10.04	0.54	4.3e-20	IgE levels in asthmatics (D.p. specific);
KIRP	trans	rs78049276	0.688	rs1878406	chr4:148393664	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.66	-7.16	-0.42	9.03e-12	Pulse pressure;
KIRP	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg02038168	chr22:39784481	NA	-0.42	-5.07	-0.31	7.85e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs7923609	0.934	rs10822153	chr10:65056813	C/A	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.63	-0.34	4.78e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.46	-0.47	2.47e-15	Mood instability;
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	cis	rs2929278	0.588	rs688009	chr15:44156302	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.5	5.97	0.36	8.44e-9	Schizophrenia;
KIRP	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.61	-9.87	-0.53	1.47e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs13185784	0.625	rs4270655	chr5:179645244	A/G	cg23248424	chr5:179741104	GFPT2	-0.49	-5.25	-0.32	3.22e-7	TRAIL levels;
KIRP	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.31	-0.42	3.83e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs4888378	0.535	rs9319483	chr16:75345791	T/C	cg07303275	chr16:75499416	TMEM170A	-0.49	-6.21	-0.37	2.19e-9	Coronary artery disease;
KIRP	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.75	6.5	0.38	4.54e-10	Diabetic retinopathy;
KIRP	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.53	6.69	0.39	1.51e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.54e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.21	22.77	0.82	1.66e-62	Cognitive function;
KIRP	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg15893493	chr8:124194847	FAM83A	0.83	7.09	0.41	1.38e-11	Urinary uromodulin levels;
KIRP	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg26681399	chr22:41777847	TEF	-0.49	-5.08	-0.31	7.51e-7	Vitiligo;
KIRP	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.92	-0.4	3.9e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg24644049	chr4:85504048	CDS1	0.99	6.58	0.39	2.83e-10	Skin colour saturation;
KIRP	cis	rs17095355	0.642	rs57822924	chr10:111702078	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.41	-5.62	-0.34	5.05e-8	Biliary atresia;
KIRP	cis	rs904251	0.698	rs2646926	chr6:37424988	G/A	cg25019722	chr6:37503610	NA	-0.69	-8.11	-0.46	2.38e-14	Cognitive performance;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10827090	chr21:17252050	USP25	0.39	6.12	0.36	3.75e-9	Migraine with aura;
KIRP	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg17376030	chr22:41985996	PMM1	-0.54	-6.67	-0.39	1.64e-10	Vitiligo;
KIRP	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg02487422	chr3:49467188	NICN1	0.42	5.14	0.31	5.66e-7	Resting heart rate;
KIRP	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-6.52	-0.38	4.03e-10	Obesity (extreme);
KIRP	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg15704280	chr7:45808275	SEPT13	0.86	6.32	0.37	1.19e-9	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg23205692	chr1:25664452	TMEM50A	0.37	5.19	0.31	4.47e-7	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg02807482	chr3:125708958	NA	-0.52	-5.03	-0.31	9.42e-7	Blood pressure (smoking interaction);
KIRP	cis	rs12230513	0.732	rs60450959	chr12:55861373	A/T	cg11794356	chr12:55725991	OR6C3	-0.54	-6.49	-0.38	4.57e-10	Contrast sensitivity;
KIRP	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.87	-0.3	2.03e-6	Lung cancer;
KIRP	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg07827796	chr19:33622959	WDR88	0.43	5.05	0.31	8.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24438779	chr18:158551	USP14	0.58	7.39	0.43	2.32e-12	Parkinson's disease;
KIRP	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg00405596	chr8:11794950	NA	0.45	5.58	0.34	6.42e-8	Retinal vascular caliber;
KIRP	cis	rs5747327	0.874	rs5746451	chr22:18126020	T/C	cg19898043	chr22:18121309	BCL2L13	-0.4	-4.97	-0.3	1.28e-6	Myeloid white cell count;Granulocyte count;
KIRP	cis	rs13185784	0.667	rs4700728	chr5:179647551	T/G	cg13944838	chr5:179740914	GFPT2	-0.47	-4.86	-0.3	2.14e-6	TRAIL levels;
KIRP	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg10144569	chr3:42726640	KBTBD5	0.53	5.65	0.34	4.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-6.14	-0.36	3.37e-9	Neuroticism;
KIRP	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.81	11.77	0.6	1.15e-25	Blood metabolite ratios;
KIRP	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	11.88	0.6	4.88e-26	Ileal carcinoids;
KIRP	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.67	8.84	0.49	1.89e-16	Morning vs. evening chronotype;
KIRP	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.34	4.89	0.3	1.79e-6	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs6058796	1.000	rs6141777	chr20:31249947	C/T	cg13636640	chr20:31349939	DNMT3B	0.57	4.91	0.3	1.69e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg26384229	chr12:38710491	ALG10B	-0.67	-9.03	-0.5	5.17e-17	Morning vs. evening chronotype;
KIRP	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg11784071	chr10:104629166	AS3MT	-0.38	-5.28	-0.32	2.83e-7	Arsenic metabolism;
KIRP	cis	rs7923609	1.000	rs10761742	chr10:65085048	A/G	cg01631684	chr10:65280961	REEP3	-0.51	-5.98	-0.36	7.88e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18635645	chr1:85667791	SYDE2	0.54	6.64	0.39	2.02e-10	Smoking initiation;
KIRP	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.82	-9.82	-0.53	2.03e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.64	11.8	0.6	9.15e-26	Blood protein levels;
KIRP	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.92	15.53	0.7	2.28e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.67	-8.16	-0.46	1.72e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg16988262	chr1:15930761	NA	0.38	5.04	0.31	9.19e-7	Systolic blood pressure;
KIRP	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg12405258	chr13:114927641	NA	0.49	7.04	0.41	1.95e-11	Schizophrenia;
KIRP	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg18657303	chr4:1051139	NA	0.55	4.99	0.3	1.12e-6	Recombination rate (females);
KIRP	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg12623918	chr2:306882	NA	0.44	5.28	0.32	2.9e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.71	-9.03	-0.5	5.18e-17	Coronary artery disease;
KIRP	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg11266682	chr4:10021025	SLC2A9	0.33	4.85	0.3	2.24e-6	Blood metabolite levels;
KIRP	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.56	7.01	0.41	2.34e-11	Asthma (sex interaction);
KIRP	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg18306943	chr3:40428807	ENTPD3	0.46	5.88	0.35	1.33e-8	Renal cell carcinoma;
KIRP	cis	rs6499129	0.702	rs16957210	chr16:67218375	T/G	cg06566678	chr16:67305560	SLC9A5	-0.54	-5.19	-0.31	4.47e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.83	-12.05	-0.61	1.35e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9972944	0.729	rs6504348	chr17:63763049	C/T	cg07283582	chr17:63770753	CCDC46	-0.46	-7.66	-0.44	4.18e-13	Total body bone mineral density;
KIRP	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.79	11.27	0.58	5.17e-24	Menarche (age at onset);
KIRP	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg15128208	chr22:42549153	NA	-0.44	-5.5	-0.33	9.42e-8	Cognitive function;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg10681125	chr19:18316102	RAB3A	0.5	6.02	0.36	6.15e-9	Educational attainment;
KIRP	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.9	-12.01	-0.61	1.92e-26	Platelet distribution width;
KIRP	cis	rs3779635	0.742	rs3824104	chr8:27256263	T/C	cg21186296	chr8:27182909	PTK2B	0.5	6.42	0.38	6.96e-10	Neuroticism;
KIRP	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.62	-5.74	-0.34	2.79e-8	Narcolepsy;
KIRP	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	12.59	0.63	2.14e-28	Monocyte percentage of white cells;
KIRP	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg00981070	chr1:2046702	PRKCZ	-0.32	-5.7	-0.34	3.49e-8	Height;
KIRP	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.53	-6.81	-0.4	7.34e-11	Menopause (age at onset);
KIRP	trans	rs7246760	1.000	rs56754106	chr19:9937789	T/A	cg02900749	chr2:68251473	NA	-1.09	-9.22	-0.51	1.35e-17	Pursuit maintenance gain;
KIRP	trans	rs263156	0.874	rs263131	chr6:142943747	G/T	cg01789478	chr2:182545485	NEUROD1	0.36	6.32	0.37	1.23e-9	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.11	12.12	0.61	8.3e-27	Vitiligo;
KIRP	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.43	7.54	0.43	9.11e-13	Renal cell carcinoma;
KIRP	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-9.63	-0.52	8.02e-19	Parkinson's disease;
KIRP	cis	rs7215564	0.818	rs36034584	chr17:78671478	A/G	cg06153925	chr17:78755379	RPTOR	0.34	5.44	0.33	1.26e-7	Myopia (pathological);
KIRP	cis	rs6504950	0.924	rs2628316	chr17:53219837	C/T	cg26251398	chr17:52985966	TOM1L1	-0.37	-4.96	-0.3	1.3e-6	Breast cancer;
KIRP	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.77	0.35	2.42e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	1.1	20.16	0.79	5.08e-54	Bone mineral density;
KIRP	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.08	8.83	0.49	2.07e-16	Alzheimer's disease;
KIRP	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg02073558	chr3:44770973	ZNF501	0.6	8.48	0.48	2.06e-15	Depressive symptoms;
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg25263898	chr1:36774223	C1orf113	-0.42	-6.06	-0.36	4.96e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg13206674	chr6:150067644	NUP43	0.5	7.1	0.41	1.34e-11	Lung cancer;
KIRP	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.34	7.02	0.41	2.14e-11	Urinary metabolites;
KIRP	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg20999797	chr1:1681921	NA	0.51	7.83	0.45	1.46e-13	Body mass index;
KIRP	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg02807482	chr3:125708958	NA	-0.5	-5.31	-0.32	2.45e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg00079375	chr15:79125835	NA	-0.37	-5.46	-0.33	1.15e-7	Coronary artery disease;
KIRP	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.6	8.13	0.46	2.09e-14	Blood protein levels;
KIRP	cis	rs11605924	1.000	rs1401419	chr11:45879739	T/C	ch.11.939596F	chr11:45881766	CRY2	-0.54	-6.82	-0.4	6.83e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.85	11.44	0.59	1.43e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15500862	chr3:32612681	DYNC1LI1	0.59	7.5	0.43	1.17e-12	Parkinson's disease;
KIRP	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg07936489	chr17:37558343	FBXL20	-0.51	-6.62	-0.39	2.22e-10	Asthma;
KIRP	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg23594656	chr7:65796392	TPST1	-0.45	-7.11	-0.41	1.28e-11	Aortic root size;
KIRP	cis	rs2587695	0.935	rs1992248	chr2:120283173	A/T	cg07176264	chr2:120281999	SCTR	-0.31	-4.93	-0.3	1.5e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs4908768	0.906	rs6678982	chr1:8577185	C/A	cg25722041	chr1:8623473	RERE	0.7	9.31	0.51	7.4e-18	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9921338	0.961	rs72773825	chr16:11412448	A/G	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.38	-0.38	8.56e-10	Monocyte percentage of white cells;
KIRP	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg18225595	chr11:63971243	STIP1	0.65	5.89	0.35	1.24e-8	Mean platelet volume;
KIRP	cis	rs7712401	0.560	rs13168225	chr5:122347264	C/T	cg19412675	chr5:122181750	SNX24	-0.55	-5.92	-0.35	1.06e-8	Mean platelet volume;
KIRP	cis	rs2733310	0.895	rs1657939	chr15:57107863	G/T	cg13626582	chr15:57592083	LOC283663	-0.23	-5.12	-0.31	6.27e-7	Mean platelet volume;
KIRP	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.64	8.26	0.47	8.85e-15	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg23985595	chr17:80112537	CCDC57	-0.33	-4.86	-0.3	2.09e-6	Life satisfaction;
KIRP	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg18944383	chr4:111397179	ENPEP	0.47	7.55	0.43	8.31e-13	Coronary artery disease;
KIRP	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg01028140	chr2:1542097	TPO	-0.51	-5.86	-0.35	1.47e-8	IgG glycosylation;
KIRP	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg10223061	chr2:219282414	VIL1	0.42	6.94	0.4	3.51e-11	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-8.0	-0.45	4.77e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.09	-0.31	7.19e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg02462569	chr6:150064036	NUP43	-0.43	-6.44	-0.38	6.25e-10	Lung cancer;
KIRP	cis	rs6882076	1.000	rs7724832	chr5:156381370	C/T	cg12943317	chr5:156479607	HAVCR1	-0.57	-6.71	-0.39	1.34e-10	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
KIRP	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.82	-0.45	1.58e-13	Neuroticism;
KIRP	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg02151108	chr14:50098012	C14orf104	-0.5	-6.63	-0.39	2.1e-10	Carotid intima media thickness;
KIRP	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.96	11.58	0.59	4.73e-25	Corneal astigmatism;
KIRP	cis	rs9815354	0.812	rs73069356	chr3:41752845	G/A	cg03022575	chr3:42003672	ULK4	0.75	7.2	0.42	7.38e-12	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs3743162	0.553	rs4842994	chr15:85415799	A/G	cg11189052	chr15:85197271	WDR73	-0.5	-4.96	-0.3	1.32e-6	Alzheimer's disease (age of onset);
KIRP	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.41	-5.59	-0.34	5.93e-8	Aortic root size;
KIRP	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.62	8.26	0.47	9e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7116495	1.000	rs12293885	chr11:71816092	T/A	cg26138937	chr11:71823887	C11orf51	0.69	5.51	0.33	9.2e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.51	6.27	0.37	1.58e-9	Diastolic blood pressure;
KIRP	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	0.65	9.28	0.51	9.41e-18	Obesity-related traits;
KIRP	cis	rs2289681	0.583	rs2289674	chr17:42953409	A/G	cg15193461	chr17:42977049	CCDC103;EFTUD2	-0.52	-5.56	-0.33	7.07e-8	Cognitive function;
KIRP	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg01879757	chr17:41196368	BRCA1	-0.77	-10.65	-0.56	4.85e-22	Menopause (age at onset);
KIRP	cis	rs9900972	0.918	rs8082041	chr17:76876542	A/G	cg00961940	chr17:76876995	TIMP2	0.53	6.76	0.4	9.99e-11	Obesity-related traits;
KIRP	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg17757837	chr7:157058334	UBE3C	0.78	10.52	0.56	1.31e-21	Body mass index;
KIRP	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	6.26	0.37	1.66e-9	Schizophrenia;
KIRP	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.87	0.3	1.96e-6	Breast cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10055580	chr17:46707781	NA	0.44	6.15	0.37	3.2e-9	Survival in pancreatic cancer;
KIRP	cis	rs5743890	0.620	rs4963038	chr11:1347906	C/T	cg06066251	chr11:1309984	TOLLIP	0.6	5.33	0.32	2.22e-7	Idiopathic pulmonary fibrosis;
KIRP	cis	rs7113874	0.659	rs2166470	chr11:8523172	A/T	cg08015107	chr11:8618950	NA	0.5	6.61	0.39	2.32e-10	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.93	13.19	0.64	2.07e-30	Bladder cancer;
KIRP	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg07884673	chr3:53033167	SFMBT1	-0.79	-6.74	-0.39	1.12e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00000622	chr15:23034447	NIPA2	0.51	6.23	0.37	1.97e-9	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22336774	chr19:7600718	PNPLA6	0.59	7.42	0.43	1.87e-12	Parkinson's disease;
KIRP	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.53	7.15	0.41	9.67e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.88	12.37	0.62	1.16e-27	Schizophrenia;
KIRP	cis	rs9372498	0.908	rs56255677	chr6:118695402	A/G	cg18833306	chr6:118973337	C6orf204	-0.59	-4.93	-0.3	1.53e-6	Diastolic blood pressure;
KIRP	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.29	0.47	7.29e-15	Eosinophil percentage of white cells;
KIRP	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg21360079	chr12:107162445	NA	-0.67	-9.38	-0.51	4.68e-18	Heart rate;
KIRP	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg08662619	chr6:150070041	PCMT1	0.36	5.88	0.35	1.32e-8	Lung cancer;
KIRP	cis	rs239198	0.602	rs11758174	chr6:101322595	G/A	cg09795085	chr6:101329169	ASCC3	0.49	5.69	0.34	3.58e-8	Menarche (age at onset);
KIRP	cis	rs4073221	0.789	rs13078687	chr3:18223442	C/T	cg07694806	chr3:18168406	NA	-0.7	-6.21	-0.37	2.23e-9	Parkinson's disease;
KIRP	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.77	10.16	0.54	1.73e-20	Aortic root size;
KIRP	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.7	-0.6	1.96e-25	Diabetic kidney disease;
KIRP	cis	rs62355272	0.931	rs67207043	chr5:35888203	G/A	cg13894535	chr5:35919491	CAPSL	-0.41	-5.06	-0.31	8.18e-7	Lymphocyte counts;
KIRP	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.57	-6.3	-0.37	1.34e-9	DNA methylation (variation);
KIRP	cis	rs9815354	0.761	rs12635286	chr3:42051836	T/C	cg03022575	chr3:42003672	ULK4	0.73	7.59	0.44	6.65e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.56	-8.94	-0.5	9.8e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg01294253	chr9:136912663	BRD3	0.43	5.54	0.33	7.57e-8	Platelet distribution width;
KIRP	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.53	5.65	0.34	4.39e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.79	-10.43	-0.55	2.57e-21	Coronary artery disease;
KIRP	cis	rs11581903	0.568	rs11205978	chr1:53076057	G/A	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.89	7.39	0.43	2.31e-12	Joint mobility (Beighton score);
KIRP	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg21905437	chr5:178450457	ZNF879	0.51	5.91	0.35	1.11e-8	Pubertal anthropometrics;
KIRP	cis	rs4356932	1.000	rs4637430	chr4:76962223	G/T	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.72	-8.33	-0.47	5.55e-15	Corneal astigmatism;
KIRP	cis	rs12826942	0.797	rs71453348	chr12:42696445	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	4.88	0.3	1.87e-6	Coronary artery disease;
KIRP	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg02336718	chr17:17403227	NA	-0.33	-5.12	-0.31	6.2e-7	Total body bone mineral density;
KIRP	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-10.78	-0.57	1.94e-22	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg14914422	chr1:46958856	NA	0.42	5.25	0.32	3.35e-7	Monobrow;
KIRP	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.71	-9.44	-0.52	3e-18	Coronary artery disease;
KIRP	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs3791406	0.654	rs747787	chr2:240032319	G/A	cg13090969	chr2:240043331	HDAC4	-0.43	-4.94	-0.3	1.42e-6	Skin aging (microtopography measurement);
KIRP	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.83	12.65	0.63	1.39e-28	Colorectal cancer;
KIRP	cis	rs35343117	1	rs35343117	chr15:86079115	C/G	cg10818794	chr15:86012489	AKAP13	-0.55	-7.36	-0.43	2.67e-12	Psoriasis;
KIRP	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg24011408	chr12:48396354	COL2A1	-0.39	-5.34	-0.32	2.08e-7	Plateletcrit;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg01763666	chr17:80159506	CCDC57	-0.38	-5.34	-0.32	2.09e-7	Life satisfaction;
KIRP	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg04166393	chr7:2884313	GNA12	0.62	7.36	0.42	2.71e-12	Height;
KIRP	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg00343986	chr7:65444356	GUSB	-0.44	-5.23	-0.32	3.7e-7	Cotinine glucuronidation;
KIRP	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.63	6.99	0.41	2.59e-11	Gut microbiome composition (summer);
KIRP	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg03680517	chr10:43632967	CSGALNACT2	0.38	4.95	0.3	1.36e-6	Hirschsprung disease;
KIRP	cis	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg00405596	chr8:11794950	NA	-0.48	-5.98	-0.36	7.86e-9	Neuroticism;
KIRP	cis	rs2882667	0.858	rs11242442	chr5:138380489	C/T	cg04439458	chr5:138467593	SIL1	-0.51	-7.63	-0.44	5.01e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.51	-8.59	-0.48	1.02e-15	Height;
KIRP	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.62	7.21	0.42	6.76e-12	Prudent dietary pattern;
KIRP	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg23262073	chr20:60523788	NA	-0.6	-6.01	-0.36	6.51e-9	Body mass index;
KIRP	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg02336718	chr17:17403227	NA	0.4	6.2	0.37	2.35e-9	Total body bone mineral density;
KIRP	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.53	7.66	0.44	4.25e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6882046	0.513	rs185291	chr5:88006764	T/C	cg24804195	chr5:87968844	LOC645323	-0.45	-6.05	-0.36	5.41e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.3	-5.37	-0.32	1.79e-7	Monocyte percentage of white cells;
KIRP	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg23188430	chr6:125850052	NA	-0.32	-4.92	-0.3	1.62e-6	Brugada syndrome;
KIRP	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg08885076	chr2:99613938	TSGA10	0.46	7.84	0.45	1.38e-13	Chronic sinus infection;
KIRP	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.79	0.6	9.92e-26	Heart rate;
KIRP	trans	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg10756647	chr7:56101905	PSPH	1.05	8.52	0.48	1.6e-15	Diabetic kidney disease;
KIRP	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	10.44	0.55	2.4e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg15557168	chr22:42548783	NA	-0.37	-5.15	-0.31	5.37e-7	Cognitive function;
KIRP	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg03808351	chr9:123631620	PHF19	-0.44	-6.06	-0.36	5.16e-9	Hip circumference adjusted for BMI;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03074872	chr20:45035404	ELMO2	0.45	6.22	0.37	2.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.4	-4.97	-0.3	1.27e-6	Response to temozolomide;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg18136681	chr1:24969531	SRRM1	-0.47	-6.58	-0.39	2.8e-10	Metabolic traits;
KIRP	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.87	10.03	0.54	4.63e-20	Corneal structure;
KIRP	cis	rs8067545	0.532	rs56371654	chr17:19960362	G/T	cg04132472	chr17:19861366	AKAP10	0.43	4.98	0.3	1.2e-6	Schizophrenia;
KIRP	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.04	0.31	9.21e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg09904177	chr6:26538194	HMGN4	-0.47	-5.71	-0.34	3.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-6.02	-0.36	6.17e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.63	10.23	0.55	1.04e-20	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg06521331	chr12:34319734	NA	-0.65	-7.75	-0.44	2.4e-13	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg10189774	chr4:17578691	LAP3	0.55	6.89	0.4	4.64e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg07169764	chr2:136633963	MCM6	0.54	6.31	0.37	1.25e-9	Mosquito bite size;
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	15.04	0.69	1.05e-36	Platelet count;
KIRP	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-20.58	-0.8	2.03e-55	Height;
KIRP	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.39	-0.38	8.46e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	trans	rs6062509	0.895	rs6062497	chr20:62336258	C/T	cg01311341	chr22:25575246	KIAA1671	0.51	6.39	0.38	8.24e-10	Prostate cancer;
KIRP	cis	rs3784262	0.771	rs4775005	chr15:58208165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.44	6.14	0.36	3.21e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs1823913	0.637	rs2356354	chr2:192135696	T/C	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.51e-9	Obesity-related traits;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.78	9.85	0.53	1.69e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg21827317	chr3:136751795	NA	0.35	4.87	0.3	1.96e-6	Neuroticism;
KIRP	cis	rs2150410	0.915	rs8130774	chr21:40661457	A/G	cg11890956	chr21:40555474	PSMG1	0.83	5.83	0.35	1.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs870825	0.929	rs870822	chr4:185588200	C/T	cg04058563	chr4:185651563	MLF1IP	1.0	10.76	0.57	2.29e-22	Blood protein levels;
KIRP	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg16482183	chr6:26056742	HIST1H1C	0.61	7.01	0.41	2.28e-11	Iron status biomarkers;
KIRP	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.78	-0.35	2.22e-8	Neuroticism;
KIRP	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	1.06	13.6	0.66	8.37e-32	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg03060546	chr3:49711283	APEH	-0.74	-5.12	-0.31	6.23e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.42	6.95	0.41	3.24e-11	Testicular germ cell tumor;
KIRP	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.91	-0.53	1.04e-19	Hemoglobin concentration;
KIRP	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg15660573	chr17:549704	VPS53	0.63	7.9	0.45	9.4e-14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg27365978	chr10:106093659	ITPRIP	-0.38	-4.87	-0.3	1.96e-6	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-4.85	-0.3	2.24e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7818345	0.904	rs6997164	chr8:19287856	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.46	6.44	0.38	6.09e-10	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.32	5.09	0.31	7.21e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.59	7.78	0.44	1.95e-13	Longevity;
KIRP	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.08	0.41	1.48e-11	Rheumatoid arthritis;
KIRP	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07570687	chr10:102243282	WNT8B	0.5	6.0	0.36	7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.42	5.98	0.36	7.65e-9	Endometrial cancer;
KIRP	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg27411982	chr8:10470053	RP1L1	-0.4	-5.29	-0.32	2.74e-7	Morning vs. evening chronotype;
KIRP	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11613427	chr3:52932208	TMEM110	0.31	5.03	0.31	9.29e-7	Schizophrenia;
KIRP	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg20243544	chr17:37824526	PNMT	0.44	4.96	0.3	1.29e-6	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.47	-0.52	2.41e-18	Personality dimensions;
KIRP	cis	rs7552404	0.545	rs12748741	chr1:76351193	A/G	cg22875332	chr1:76189707	ACADM	-0.45	-5.99	-0.36	7.54e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.48	-7.42	-0.43	1.89e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2644899	0.750	rs2249835	chr19:41269766	G/A	cg24958765	chr19:41283667	RAB4B	-0.61	-6.85	-0.4	5.72e-11	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.9	11.01	0.57	3.51e-23	Homoarginine levels;
KIRP	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.57	-8.14	-0.46	1.97e-14	Breast cancer;
KIRP	trans	rs2166775	1.000	rs7626610	chr3:143501570	G/T	cg06611874	chr16:19566878	C16orf62	0.53	6.59	0.39	2.61e-10	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg26174226	chr8:58114915	NA	-0.5	-5.68	-0.34	3.88e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg19847130	chr8:10466454	RP1L1	0.39	5.86	0.35	1.46e-8	Neuroticism;
KIRP	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg09873164	chr1:152488093	CRCT1	-0.53	-6.81	-0.4	7.52e-11	Hair morphology;
KIRP	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-7.64	-0.44	4.74e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs300890	0.536	rs300938	chr4:144172791	C/G	cg01719995	chr4:144104893	USP38	-0.4	-5.17	-0.31	4.91e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	1.07	17.85	0.75	2.8600000000000002e-46	Intelligence (multi-trait analysis);
KIRP	trans	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg06521331	chr12:34319734	NA	-0.52	-6.4	-0.38	7.64e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.72	8.46	0.47	2.42e-15	Schizophrenia;
KIRP	cis	rs4936894	0.500	rs10893191	chr11:124121469	C/A	cg27160556	chr11:124181099	OR8D1	-0.46	-6.67	-0.39	1.65e-10	Aging (time to death);
KIRP	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg06115741	chr20:33292138	TP53INP2	0.38	5.17	0.31	4.83e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.71	10.43	0.55	2.52e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	1.11	17.36	0.74	1.28e-44	Homoarginine levels;
KIRP	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg03235661	chr20:60525775	NA	0.35	4.86	0.3	2.1e-6	Body mass index;
KIRP	cis	rs240764	0.658	rs9404053	chr6:101254456	G/A	cg09795085	chr6:101329169	ASCC3	-0.43	-5.1	-0.31	6.71e-7	Neuroticism;
KIRP	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg23594656	chr7:65796392	TPST1	-0.49	-7.45	-0.43	1.57e-12	Aortic root size;
KIRP	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.42	-5.08	-0.31	7.32e-7	Iron status biomarkers;
KIRP	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg00343986	chr7:65444356	GUSB	-0.49	-6.14	-0.36	3.31e-9	Aortic root size;
KIRP	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg10755058	chr3:40428713	ENTPD3	0.34	4.88	0.3	1.9e-6	Renal cell carcinoma;
KIRP	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg14768367	chr16:72042858	DHODH	-1.05	-11.32	-0.59	3.35e-24	Blood protein levels;
KIRP	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.75	11.49	0.59	9.37e-25	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6545883	0.929	rs2593625	chr2:61668769	C/T	cg15711740	chr2:61764176	XPO1	-0.6	-8.0	-0.45	4.99e-14	Tuberculosis;
KIRP	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4141404	0.787	rs4820042	chr22:31589056	T/C	cg02404636	chr22:31891804	SFI1	-0.48	-5.3	-0.32	2.54e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs4972806	0.814	rs6710370	chr2:177045969	T/C	cg14324370	chr2:177042789	NA	0.75	10.36	0.55	4.28e-21	IgG glycosylation;
KIRP	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.74	-8.58	-0.48	1.11e-15	Monocyte count;
KIRP	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg04455712	chr21:45112962	RRP1B	0.5	6.79	0.4	8.32e-11	Mean corpuscular volume;
KIRP	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg06219351	chr7:158114137	PTPRN2	-0.57	-6.49	-0.38	4.68e-10	Response to amphetamines;
KIRP	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg21427119	chr20:30132790	HM13	-0.55	-6.25	-0.37	1.83e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg26384229	chr12:38710491	ALG10B	0.54	7.29	0.42	4.23e-12	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-1.0	-16.93	-0.73	3.77e-43	Height;
KIRP	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.61	8.12	0.46	2.29e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05601917	chr6:125855416	NA	0.33	4.99	0.3	1.17e-6	Brugada syndrome;
KIRP	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg24879335	chr3:133465180	TF	0.52	8.13	0.46	2.08e-14	Iron status biomarkers;
KIRP	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-1.05	-9.23	-0.51	1.32e-17	Obesity-related traits;
KIRP	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13866795	chr9:135283313	TTF1	0.45	6.19	0.37	2.49e-9	Survival in pancreatic cancer;
KIRP	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.42	-0.38	6.96e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg24304309	chr1:154577895	ADAR	-0.31	-4.85	-0.3	2.19e-6	Blood protein levels;
KIRP	cis	rs4074493	0.928	rs4310430	chr1:231172881	T/G	cg22172038	chr1:231176991	FAM89A	0.3	5.07	0.31	7.82e-7	Carotid plaque burden (smoking interaction);
KIRP	cis	rs10267417	0.673	rs13437871	chr7:19957718	T/A	cg05791153	chr7:19748676	TWISTNB	0.47	4.96	0.3	1.31e-6	Night sleep phenotypes;
KIRP	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.78	9.61	0.52	9.14e-19	Bipolar disorder;
KIRP	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs9608946	1.000	rs17738540	chr22:30888527	C/T	cg23383138	chr22:30885012	SEC14L4	0.4	4.93	0.3	1.52e-6	Red cell distribution width;
KIRP	cis	rs7538876	0.967	rs6695531	chr1:17720088	T/G	cg07394400	chr1:17752023	RCC2	-0.37	-5.29	-0.32	2.77e-7	Basal cell carcinoma;
KIRP	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg13877915	chr19:58951672	ZNF132	0.61	5.99	0.36	7.27e-9	Mean platelet volume;
KIRP	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg04935436	chr20:30431758	NA	0.53	6.56	0.39	3.18e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.66	0.34	4.29e-8	Educational attainment;
KIRP	cis	rs12600304	0.529	rs12930821	chr16:58054671	G/C	cg08699646	chr16:58019359	TEPP	0.4	5.17	0.31	4.85e-7	Aggressiveness in attention deficit hyperactivity disorder;
KIRP	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.71	7.82	0.45	1.51e-13	Corneal astigmatism;
KIRP	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.5	-0.38	4.42e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Bipolar disorder;
KIRP	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.62	-6.95	-0.41	3.24e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs6442310	1.000	rs6442310	chr3:12358230	T/A	cg22839075	chr3:12045461	SYN2	-0.42	-5.63	-0.34	5e-8	Hematocrit;
KIRP	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.64	6.18	0.37	2.59e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.91	-9.92	-0.53	9.98e-20	Pulmonary function decline;
KIRP	cis	rs831571	1.000	rs166230	chr3:64053207	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.58	5.66	0.34	4.24e-8	Type 2 diabetes;
KIRP	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26314531	chr2:26401878	FAM59B	-0.47	-5.01	-0.3	1.02e-6	Gut microbiome composition (summer);
KIRP	cis	rs1873147	0.569	rs11636033	chr15:63311091	G/T	cg12160578	chr15:63334699	TPM1	-0.62	-6.65	-0.39	1.84e-10	Orofacial clefts;
KIRP	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg04727924	chr7:799746	HEATR2	-0.79	-8.95	-0.5	8.95e-17	Cerebrospinal P-tau181p levels;
KIRP	cis	rs273218	0.573	rs16882051	chr5:53342979	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.06	-12.43	-0.62	7.78e-28	Migraine;
KIRP	cis	rs12210905	1.000	rs12198077	chr6:27169307	A/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.04	-0.31	8.88e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg15117754	chr3:10150083	C3orf24	0.5	5.01	0.3	1.03e-6	Alzheimer's disease;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg00738919	chr7:1100172	C7orf50	0.44	5.15	0.31	5.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.74	0.44	2.65e-13	Mood instability;
KIRP	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg04691961	chr3:161091175	C3orf57	-0.53	-8.44	-0.47	2.72e-15	Morning vs. evening chronotype;
KIRP	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg21361702	chr7:150065534	REPIN1	0.55	5.92	0.35	1.1e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg00656387	chr3:40428638	ENTPD3	0.4	5.1	0.31	6.79e-7	Renal cell carcinoma;
KIRP	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.34	-6.48	-0.38	5e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.73	-11.21	-0.58	7.65e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.35	5.52	0.33	8.53e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs17123764	0.818	rs11169076	chr12:49975408	G/T	cg20471783	chr12:50157085	TMBIM6	0.33	5.11	0.31	6.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs16936870	0.571	rs2926715	chr8:71151197	T/C	cg14232793	chr8:71155543	NCOA2	-0.58	-7.09	-0.41	1.41e-11	QT interval;
KIRP	cis	rs7503807	0.688	rs12952285	chr17:78596158	C/G	cg09596252	chr17:78655493	RPTOR	-0.53	-6.01	-0.36	6.64e-9	Obesity;
KIRP	cis	rs1978968	0.763	rs8137857	chr22:18465616	T/C	cg03078520	chr22:18463400	MICAL3	-0.85	-12.0	-0.61	1.97e-26	Presence of antiphospholipid antibodies;
KIRP	cis	rs10267417	0.535	rs6960579	chr7:19869364	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	5.5	0.33	9.27e-8	Night sleep phenotypes;
KIRP	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg15841412	chr13:111365552	ING1	0.52	5.74	0.34	2.85e-8	Coronary artery disease;
KIRP	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg14228332	chr4:119757509	SEC24D	0.76	4.86	0.3	2.09e-6	Cannabis dependence symptom count;
KIRP	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.68	9.09	0.5	3.38e-17	DNA methylation (variation);
KIRP	cis	rs2274273	0.840	rs7144737	chr14:55822946	C/T	cg04306507	chr14:55594613	LGALS3	0.44	6.72	0.39	1.27e-10	Protein biomarker;
KIRP	cis	rs4523957	0.788	rs2169357	chr17:2096441	C/T	cg16513277	chr17:2031491	SMG6	-0.69	-10.03	-0.54	4.66e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg20701182	chr2:24300061	SF3B14	0.65	5.51	0.33	9.09e-8	Lymphocyte counts;
KIRP	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.57	-5.21	-0.32	3.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg03959625	chr15:84868606	LOC388152	-0.5	-6.03	-0.36	6e-9	Schizophrenia;
KIRP	cis	rs865483	0.895	rs878520	chr17:35762107	C/G	cg06716730	chr17:35851459	DUSP14	-0.25	-5.82	-0.35	1.8e-8	Monocyte count;
KIRP	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.76	-9.78	-0.53	2.73e-19	Aortic root size;
KIRP	cis	rs2599510	0.748	rs6718214	chr2:32550485	T/C	cg02381751	chr2:32503542	YIPF4	-0.47	-5.64	-0.34	4.71e-8	Interleukin-18 levels;
KIRP	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.44	-5.14	-0.31	5.65e-7	Body mass index;
KIRP	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-10.53	-0.56	1.2e-21	Coronary artery disease;
KIRP	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg20243544	chr17:37824526	PNMT	0.47	5.36	0.32	1.9e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.7	-7.62	-0.44	5.63e-13	Blood pressure (smoking interaction);
KIRP	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg07843065	chr1:150265600	MRPS21	0.4	5.46	0.33	1.16e-7	Migraine;
KIRP	cis	rs7215564	0.908	rs2340773	chr17:78744395	T/C	cg06153925	chr17:78755379	RPTOR	-0.38	-6.26	-0.37	1.73e-9	Myopia (pathological);
KIRP	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg11382394	chr1:2564504	MMEL1	0.4	5.2	0.31	4.26e-7	Ulcerative colitis;
KIRP	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.95	11.18	0.58	9.82e-24	Eosinophil percentage of granulocytes;
KIRP	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.44	6.29	0.37	1.45e-9	Bone mineral density;
KIRP	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.86	0.45	1.17e-13	Coffee consumption (cups per day);
KIRP	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	1.03	14.51	0.68	6.68e-35	Menopause (age at onset);
KIRP	cis	rs6893300	0.785	rs7705530	chr5:179190994	C/T	cg14593053	chr5:179126677	CANX	-0.58	-7.25	-0.42	5.28e-12	Resting heart rate;
KIRP	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.38	0.38	8.52e-10	Axial length;
KIRP	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.36	0.51	5.19e-18	IgG glycosylation;
KIRP	cis	rs4664293	0.802	rs7563417	chr2:160584273	A/C	cg08347373	chr2:160653686	CD302	-0.45	-6.69	-0.39	1.53e-10	Monocyte percentage of white cells;
KIRP	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg27205649	chr11:78285834	NARS2	0.63	8.18	0.46	1.57e-14	Alzheimer's disease (survival time);
KIRP	cis	rs7084402	1.000	rs11006169	chr10:60269326	T/A	cg05938607	chr10:60274200	BICC1	0.42	10.11	0.54	2.53e-20	Refractive error;
KIRP	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg24881330	chr22:46731750	TRMU	0.77	5.43	0.33	1.33e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg24375607	chr4:120327624	NA	0.54	6.39	0.38	8.12e-10	Corneal astigmatism;
KIRP	trans	rs4742903	0.509	rs10991161	chr9:106963159	G/A	cg06629767	chr10:72238406	KIAA1274	-0.45	-6.22	-0.37	2.14e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg07395648	chr5:131743802	NA	-0.54	-7.64	-0.44	4.84e-13	Breast cancer;
KIRP	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg05072774	chr3:49840536	C3orf54	0.43	5.47	0.33	1.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	cg12689670	chr1:183009347	LAMC1	0.52	7.18	0.42	8.43e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.13	-0.5	2.52e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.93	-15.5	-0.7	2.88e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.8	9.69	0.53	5.11e-19	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.08	-0.31	7.32e-7	Life satisfaction;
KIRP	cis	rs41264869	0.568	rs61822628	chr1:205124444	G/C	cg21214746	chr1:205091277	RBBP5	0.52	6.69	0.39	1.46e-10	Blood protein levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg09015484	chr9:96929106	NA	0.5	6.54	0.38	3.45e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg18850127	chr7:39170497	POU6F2	0.28	5.4	0.33	1.55e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10129255	0.518	rs12590732	chr14:107187851	C/T	cg23076370	chr14:107095027	NA	0.41	5.08	0.31	7.58e-7	Kawasaki disease;
KIRP	cis	rs6028335	0.674	rs66526549	chr20:37588360	A/G	cg16355469	chr20:37678765	NA	0.56	5.45	0.33	1.22e-7	Alcohol and nicotine co-dependence;
KIRP	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg00800038	chr16:89945340	TCF25	-0.78	-5.27	-0.32	3.04e-7	Skin colour saturation;
KIRP	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.74	10.33	0.55	5.18e-21	Red blood cell count;
KIRP	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg06611532	chr13:114900021	NA	0.21	4.87	0.3	1.98e-6	Schizophrenia;
KIRP	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs7646501	0.677	rs7431344	chr3:24070473	T/C	cg21910673	chr3:24143257	LOC152024	0.38	5.25	0.32	3.28e-7	Cognitive ability;Intelligence;
KIRP	cis	rs16828019	0.632	rs12749196	chr1:41460783	G/A	cg03387723	chr1:41708464	SCMH1	-0.75	-6.0	-0.36	6.86e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2273669	0.915	rs7738483	chr6:109341834	C/T	cg05315195	chr6:109294784	ARMC2	-0.5	-5.69	-0.34	3.52e-8	Prostate cancer;
KIRP	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg04362960	chr10:104952993	NT5C2	0.65	7.59	0.44	6.5e-13	Arsenic metabolism;
KIRP	cis	rs11893307	0.507	rs1465305	chr2:191585392	C/G	cg11845111	chr2:191398756	TMEM194B	-0.44	-4.88	-0.3	1.92e-6	Mean platelet volume;
KIRP	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg11833968	chr6:79620685	NA	-0.37	-5.14	-0.31	5.48e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2377585	0.563	rs11046832	chr12:8847970	T/G	cg03761649	chr12:8850719	RIMKLB	0.5	4.94	0.3	1.44e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.39	-5.44	-0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs9584850	0.915	rs7983438	chr13:99103317	T/C	cg20750642	chr13:99100586	FARP1	-0.55	-6.63	-0.39	2.1e-10	Neuroticism;
KIRP	trans	rs6749447	0.959	rs7585865	chr2:169026089	G/A	cg10223061	chr2:219282414	VIL1	-0.37	-6.07	-0.36	4.88e-9	Blood pressure;
KIRP	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.85	10.04	0.54	4.07e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg05347473	chr6:146136440	FBXO30	0.56	8.05	0.46	3.63e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.59	-7.19	-0.42	7.53e-12	Aortic root size;
KIRP	cis	rs4132509	0.779	rs6656918	chr1:243706224	G/A	cg25706552	chr1:244017396	NA	-0.54	-7.54	-0.43	9.1e-13	RR interval (heart rate);
KIRP	cis	rs4849845	0.925	rs3980213	chr2:121004979	A/G	cg24070213	chr2:121070622	NA	0.37	5.1	0.31	6.92e-7	Mean platelet volume;
KIRP	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.66	10.43	0.55	2.55e-21	Bone mineral density;
KIRP	cis	rs9649213	0.593	rs2107716	chr7:97944744	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	5.92	0.35	1.1e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.06	0.64	5.78e-30	Exhaled nitric oxide output;
KIRP	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg03929089	chr4:120376271	NA	-0.64	-6.45	-0.38	5.91e-10	Axial length;
KIRP	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.75	-7.06	-0.41	1.74e-11	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs754423	0.515	rs2144983	chr14:52548843	C/T	cg05884192	chr14:52515736	NID2	-0.48	-5.87	-0.35	1.44e-8	Craniofacial microsomia;
KIRP	cis	rs7851660	0.809	rs10739526	chr9:100662671	T/C	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	8.16	0.46	1.73e-14	Glomerular filtration rate;
KIRP	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.75	11.83	0.6	7.41e-26	Resting heart rate;
KIRP	cis	rs829661	0.532	rs9789517	chr2:30785824	C/G	cg10949345	chr2:30726833	LCLAT1	-0.42	-5.88	-0.35	1.36e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.19	-0.46	1.44e-14	Triglycerides;
KIRP	cis	rs9398803	0.865	rs4559102	chr6:126773580	G/A	cg19875578	chr6:126661172	C6orf173	0.49	6.37	0.38	9.11e-10	Male-pattern baldness;
KIRP	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	20.29	0.79	1.84e-54	Chronic sinus infection;
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg24782087	chr4:77870838	SEPT11	-0.57	-6.74	-0.39	1.12e-10	Brain structure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00968021	chr1:70876888	CTH	0.49	6.93	0.4	3.76e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.58	-7.58	-0.44	7.08e-13	Pulse pressure;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg23736307	chr8:27182930	PTK2B	0.52	6.76	0.4	9.74e-11	Neuroticism;
KIRP	cis	rs2033732	0.706	rs1370419	chr8:85068424	G/A	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg17279839	chr7:150038598	RARRES2	-0.52	-6.71	-0.39	1.3100000000000001e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs3755132	1.000	rs7559969	chr2:15724122	G/T	cg12888861	chr2:15731646	DDX1	0.37	4.85	0.3	2.19e-6	Wilms tumor;
KIRP	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg21360079	chr12:107162445	NA	0.7	10.12	0.54	2.42e-20	Heart rate;
KIRP	cis	rs4654899	0.714	rs12133972	chr1:21091338	A/T	cg05370193	chr1:21551575	ECE1	0.42	5.58	0.33	6.46e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs909341	0.903	rs1291205	chr20:62328829	C/G	cg03999872	chr20:62272968	STMN3	-0.56	-6.52	-0.38	3.89e-10	Atopic dermatitis;
KIRP	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.47e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg23845249	chr11:68861649	NA	0.57	8.22	0.46	1.18e-14	Blond vs. brown hair color;
KIRP	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.22	-0.32	3.78e-7	Fear of minor pain;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.69	9.74	0.53	3.49e-19	Renal function-related traits (BUN);
KIRP	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg03959625	chr15:84868606	LOC388152	0.45	5.34	0.32	2.07e-7	Schizophrenia;
KIRP	trans	rs11165623	0.564	rs6593611	chr1:97001996	T/C	cg10631902	chr5:14652156	NA	-0.5	-6.7	-0.39	1.4e-10	Hip circumference;Waist circumference;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05073720	chr18:60386672	PHLPP1	-0.47	-6.95	-0.41	3.24e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg26784012	chr10:32216390	ARHGAP12	0.31	4.97	0.3	1.23e-6	Bipolar disorder with mood-incongruent psychosis;
KIRP	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-13.8	-0.66	1.76e-32	Heart rate;
KIRP	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-9.03	-0.5	5.07e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.34	12.32	0.62	1.74e-27	Diabetic retinopathy;
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg10207240	chr12:122356781	WDR66	0.6	7.82	0.45	1.56e-13	Mean corpuscular volume;
KIRP	cis	rs12824058	1.000	rs12824058	chr12:130804334	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	5.57	0.33	6.79e-8	Menopause (age at onset);
KIRP	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.74	0.49	3.7e-16	Lung cancer in ever smokers;
KIRP	cis	rs7601312	1.000	rs11673816	chr2:229318577	A/G	cg02542817	chr2:229291442	NA	-0.38	-5.74	-0.34	2.73e-8	Schizophrenia;
KIRP	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg26513180	chr16:89883248	FANCA	-0.4	-4.99	-0.3	1.16e-6	Vitiligo;
KIRP	cis	rs12540874	0.518	rs12718674	chr7:50627130	T/C	cg04490037	chr7:50633773	DDC	0.37	4.9	0.3	1.75e-6	Systemic sclerosis;
KIRP	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg02887458	chr19:19495540	GATAD2A	0.48	5.75	0.34	2.65e-8	Bipolar disorder;
KIRP	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg19025524	chr12:109796872	NA	-0.4	-5.38	-0.32	1.74e-7	Neuroticism;
KIRP	cis	rs9400271	0.632	rs9398192	chr6:109587236	C/T	cg01475377	chr6:109611718	NA	-0.37	-5.33	-0.32	2.21e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.71	10.27	0.55	8.12e-21	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg14517863	chr17:44321492	NA	0.49	5.59	0.34	6.05e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6546324	0.540	rs4671811	chr2:67827416	G/A	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.7e-13	Endometriosis;
KIRP	cis	rs2976388	1.000	rs2920283	chr8:143757037	T/C	cg17252645	chr8:143867129	LY6D	-0.3	-4.86	-0.3	2.08e-6	Urinary tract infection frequency;
KIRP	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs9398803	0.966	rs9388487	chr6:126678268	G/T	cg19875578	chr6:126661172	C6orf173	0.48	6.25	0.37	1.8e-9	Male-pattern baldness;
KIRP	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.71	8.86	0.49	1.59e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4776059	1.000	rs11857150	chr15:52922216	G/A	cg22715398	chr15:52968154	KIAA1370	-0.59	-7.17	-0.42	8.63e-12	Schizophrenia;
KIRP	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.33	-0.32	2.23e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	0.895	rs10737453	chr1:21221078	A/G	cg05370193	chr1:21551575	ECE1	-0.36	-4.87	-0.3	1.99e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg03060546	chr3:49711283	APEH	-0.58	-5.14	-0.31	5.53e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	7.86	0.45	1.24e-13	Iron status biomarkers;
KIRP	cis	rs7560272	0.723	rs7585119	chr2:73724679	A/T	cg20560298	chr2:73613845	ALMS1	-0.49	-6.04	-0.36	5.74e-9	Schizophrenia;
KIRP	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg25486957	chr4:152246857	NA	-0.57	-5.96	-0.36	8.66e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg17279839	chr7:150038598	RARRES2	0.53	6.84	0.4	6.09e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.52	6.29	0.37	1.44e-9	Homocysteine levels;
KIRP	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.68	-7.84	-0.45	1.33e-13	Lung cancer;Squamous cell lung carcinoma;
KIRP	trans	rs78049276	0.512	rs7659823	chr4:148398877	C/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.84	-12.11	-0.61	8.73e-27	Pulse pressure;
KIRP	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg17691542	chr6:26056736	HIST1H1C	0.49	6.46	0.38	5.69e-10	Height;
KIRP	cis	rs4664304	0.900	rs3828327	chr2:160742095	G/A	cg23995753	chr2:160760732	LY75	-0.43	-5.77	-0.35	2.42e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2403221	0.547	rs11042502	chr11:9847630	A/G	cg07197493	chr11:9884649	SBF2	-0.35	-4.88	-0.3	1.9e-6	Smoking initiation;
KIRP	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg14972814	chr11:95582409	MTMR2	0.3	5.15	0.31	5.35e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2625529	0.652	rs2957724	chr15:72248474	A/C	cg16672083	chr15:72433130	SENP8	0.43	6.09	0.36	4.25e-9	Red blood cell count;
KIRP	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg09455208	chr3:40491958	NA	0.31	5.56	0.33	6.84e-8	Renal cell carcinoma;
KIRP	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg07843065	chr1:150265600	MRPS21	0.43	5.86	0.35	1.46e-8	Migraine;
KIRP	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg08313168	chr12:7315531	NA	0.66	6.07	0.36	4.82e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg25650185	chr19:21324782	ZNF431	-0.48	-5.02	-0.31	9.72e-7	Pain;
KIRP	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg21775007	chr8:11205619	TDH	0.47	6.35	0.38	1.01e-9	Mood instability;
KIRP	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-7.42	-0.43	1.9e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg22117172	chr7:91764530	CYP51A1	-0.44	-5.97	-0.36	8.03e-9	Breast cancer;
KIRP	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.89	10.52	0.56	1.3e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg03605463	chr16:89740564	NA	-0.4	-4.85	-0.3	2.16e-6	Vitiligo;
KIRP	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg16141378	chr3:129829833	LOC729375	0.6	8.37	0.47	4.29e-15	Neuroticism;
KIRP	cis	rs9488822	0.651	rs521985	chr6:116264940	G/A	cg05304507	chr6:116381966	FRK	-0.22	-5.68	-0.34	3.77e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg08280861	chr8:58055591	NA	0.64	5.86	0.35	1.45e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.54	-5.54	-0.33	7.93e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.49	6.45	0.38	6.02e-10	High light scatter reticulocyte count;
KIRP	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.33	5.15	0.31	5.22e-7	Blood metabolite levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg18543035	chr10:8374526	NA	0.45	6.01	0.36	6.5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04165120	chr20:443331	TBC1D20	-0.46	-6.23	-0.37	2e-9	Survival in pancreatic cancer;
KIRP	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg27170947	chr2:26402098	FAM59B	-0.48	-5.51	-0.33	9.16e-8	Gut microbiome composition (summer);
KIRP	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg03894339	chr8:19674705	INTS10	0.53	6.41	0.38	7.56e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg23985595	chr17:80112537	CCDC57	0.37	5.52	0.33	8.41e-8	Life satisfaction;
KIRP	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg00745463	chr17:30367425	LRRC37B	-0.84	-7.79	-0.45	1.83e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg02367723	chr1:46378857	MAST2	0.42	4.9	0.3	1.72e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4561483	0.583	rs11647580	chr16:11957609	G/C	cg08843971	chr16:11963173	GSPT1	0.54	7.56	0.43	7.81e-13	Testicular germ cell tumor;
KIRP	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.53	8.74	0.49	3.73e-16	Rheumatoid arthritis;
KIRP	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg20991723	chr1:152506922	NA	-0.45	-5.48	-0.33	1.04e-7	Hair morphology;
KIRP	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg00122941	chr17:4613640	ARRB2	0.82	8.71	0.49	4.44e-16	Lymphocyte counts;
KIRP	cis	rs9896052	0.614	rs11077791	chr17:73474629	T/G	cg25649188	chr17:73499917	CASKIN2	0.49	6.37	0.38	9.44e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.47	-0.62	5.47e-28	Electrocardiographic conduction measures;
KIRP	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg26554054	chr8:600488	NA	0.66	5.32	0.32	2.31e-7	IgG glycosylation;
KIRP	cis	rs17023223	0.537	rs7532510	chr1:119594236	A/G	cg05756136	chr1:119680316	WARS2	-0.55	-7.45	-0.43	1.55e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg18657303	chr4:1051139	NA	0.53	4.96	0.3	1.31e-6	Recombination rate (females);
KIRP	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.66	10.62	0.56	6.25e-22	Obesity-related traits;
KIRP	cis	rs16828019	0.704	rs12024115	chr1:41534357	C/T	cg24596898	chr1:41849189	NA	0.62	5.02	0.3	9.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19231632	chr19:49661071	TRPM4	0.54	6.57	0.39	3.02e-10	Parkinson's disease;
KIRP	cis	rs769267	0.501	rs2074295	chr19:19369435	A/G	cg11584989	chr19:19387371	SF4	0.5	5.85	0.35	1.53e-8	Tonsillectomy;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.53	-6.72	-0.39	1.23e-10	Longevity;Endometriosis;
KIRP	cis	rs17267292	0.960	rs10507992	chr13:93319713	C/T	cg07725536	chr13:93211487	GPC5	0.44	4.85	0.3	2.15e-6	Metabolite levels;
KIRP	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.77	-11.93	-0.61	3.3e-26	Prostate cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03484612	chr15:75095495	CSK	0.55	7.2	0.42	7.49e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9322225	chr6:150184882	G/C	cg13206674	chr6:150067644	NUP43	0.58	8.05	0.46	3.58e-14	Lung cancer;
KIRP	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg20312557	chr2:97357134	FER1L5	-0.73	-5.2	-0.31	4.24e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10198271	chr20:55966838	RBM38	0.46	6.78	0.4	8.76e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.58	-7.07	-0.41	1.59e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.71	-10.85	-0.57	1.16e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.37	-5.55	-0.33	7.47e-8	Coronary artery disease;
KIRP	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg10326726	chr10:51549505	MSMB	-0.56	-8.22	-0.46	1.19e-14	Prostate-specific antigen levels;
KIRP	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.39	-0.43	2.22e-12	Morning vs. evening chronotype;
KIRP	cis	rs4400599	0.758	rs60633748	chr1:154121510	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.34	-4.87	-0.3	1.95e-6	Platelet distribution width;
KIRP	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg26875233	chr11:93583750	C11orf90	0.38	7.15	0.41	1.01e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.7	-0.44	3.26e-13	Total cholesterol levels;
KIRP	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs1635	0.826	rs3800327	chr6:28264928	G/C	cg15743358	chr6:28303923	ZNF323	-0.65	-5.08	-0.31	7.58e-7	Schizophrenia;
KIRP	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.16	-0.37	2.93e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-16.04	-0.71	4.09e-40	Coronary artery disease;
KIRP	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.73	-7.41	-0.43	1.96e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.49	-6.41	-0.38	7.55e-10	Schizophrenia;
KIRP	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	1.02	13.22	0.64	1.71e-30	Response to antineoplastic agents;
KIRP	cis	rs1440410	0.835	rs4513514	chr4:144139712	T/A	cg01719995	chr4:144104893	USP38	0.43	5.99	0.36	7.24e-9	Ischemic stroke;
KIRP	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.03	-0.31	9.44e-7	Retinal vascular caliber;
KIRP	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06481639	chr22:41940642	POLR3H	0.47	5.55	0.33	7.25e-8	Vitiligo;
KIRP	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.65	0.34	4.47e-8	Lung cancer;
KIRP	cis	rs11225247	0.881	rs11604271	chr11:102250601	A/C	cg06323957	chr11:102217781	BIRC2	0.9	5.34	0.32	2.15e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg03124231	chr4:174255570	HMGB2	0.61	6.97	0.41	2.89e-11	Lung cancer in ever smokers;
KIRP	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg24110177	chr3:50126178	RBM5	-0.44	-5.59	-0.34	6.15e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09419486	chr15:60690242	ANXA2	-0.47	-6.06	-0.36	5.17e-9	Myopia;
KIRP	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.58	-5.01	-0.3	1.02e-6	Putamen volume;
KIRP	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg10760299	chr15:45669010	GATM	0.35	5.07	0.31	7.97e-7	Homoarginine levels;
KIRP	cis	rs10865541	0.632	rs7584720	chr2:3403708	A/G	cg11642891	chr2:3452563	TTC15	-0.47	-6.2	-0.37	2.33e-9	Obesity-related traits;
KIRP	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.41	5.48	0.33	1.04e-7	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg12486944	chr17:80159399	CCDC57	0.39	5.24	0.32	3.53e-7	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	1.09	16.11	0.72	2.43e-40	Breast cancer;
KIRP	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-0.73	-9.1	-0.5	3.19e-17	Uric acid levels;
KIRP	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.78	10.11	0.54	2.59e-20	Aortic root size;
KIRP	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg24253500	chr15:84953950	NA	0.54	6.03	0.36	5.98e-9	Schizophrenia;
KIRP	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.85	12.09	0.61	1e-26	Mean platelet volume;
KIRP	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg19338460	chr6:170058176	WDR27	-1.22	-9.64	-0.52	7.39e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2380205	0.967	rs907688	chr10:5900822	C/T	cg27141509	chr10:5886111	NA	0.35	5.12	0.31	6.2e-7	Breast cancer;
KIRP	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg14983838	chr19:29218262	NA	0.57	5.11	0.31	6.52e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	trans	rs1546939	0.576	rs17490751	chr14:26666540	A/T	cg26572165	chr1:160807694	CD244	0.34	6.13	0.36	3.46e-9	Mammographic density (non-dense area);
KIRP	cis	rs981844	0.775	rs17371545	chr4:154763980	A/G	cg14289246	chr4:154710475	SFRP2	-0.65	-7.58	-0.44	6.98e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs2014572	0.967	rs8111977	chr19:57759158	T/A	cg24459738	chr19:57751996	ZNF805	-0.58	-7.17	-0.42	8.82e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs1669338	0.510	rs3804788	chr3:3169466	C/A	cg16797762	chr3:3221439	CRBN	-0.66	-6.12	-0.36	3.62e-9	White matter integrity;
KIRP	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.22	-0.32	3.88e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg12419862	chr22:24373484	LOC391322	0.63	7.71	0.44	3.11e-13	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs28489187	0.683	rs11161611	chr1:85868679	C/A	cg16011679	chr1:85725395	C1orf52	-0.5	-6.11	-0.36	3.82e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg12843872	chr7:90894352	FZD1	0.51	6.67	0.39	1.67e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06340200	chr16:11836643	TXNDC11	0.49	6.07	0.36	4.83e-9	Parkinson's disease;
KIRP	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-7.53	-0.43	9.56e-13	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.74	10.31	0.55	6.18e-21	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs259282	0.589	rs6510271	chr19:33117666	T/C	cg02997394	chr19:33096574	ANKRD27	-0.48	-4.98	-0.3	1.19e-6	Schizophrenia;
KIRP	cis	rs7572644	0.640	rs11127125	chr2:28023120	T/C	cg27432699	chr2:27873401	GPN1	0.48	5.51	0.33	9.08e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg10996143	chr20:1373995	FKBP1A	0.75	6.91	0.4	4.07e-11	Lung function (FEV1);
KIRP	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg07689907	chr11:61582574	FADS1	0.58	7.12	0.41	1.15e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.67	9.5	0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.56	6.25	0.37	1.78e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18883852	chr13:45965548	LOC100190939	0.47	6.66	0.39	1.81e-10	Survival in pancreatic cancer;
KIRP	cis	rs2395528	0.597	rs2249463	chr10:80118422	T/C	cg08356028	chr10:80217969	NA	0.41	5.94	0.35	9.58e-9	Conduct disorder (maternal expressed emotions interaction);
KIRP	cis	rs2034650	0.563	rs2412523	chr15:40709686	C/G	cg08996748	chr15:40651036	DISP2	-0.36	-5.16	-0.31	5.01e-7	Interstitial lung disease;
KIRP	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.51	-6.36	-0.38	9.7e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13798912	chr7:905769	UNC84A	-0.77	-7.07	-0.41	1.58e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg12962167	chr3:53033115	SFMBT1	0.81	5.92	0.35	1.07e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg26850624	chr5:429559	AHRR	0.34	6.41	0.38	7.39e-10	Cystic fibrosis severity;
KIRP	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05025164	chr4:1340916	KIAA1530	0.45	5.99	0.36	7.45e-9	Obesity-related traits;
KIRP	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.51	6.93	0.4	3.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg15660573	chr17:549704	VPS53	-0.95	-14.9	-0.69	3.25e-36	Prostate cancer;
KIRP	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.61e-11	Aortic root size;
KIRP	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg19468946	chr17:37922297	IKZF3	-0.49	-6.71	-0.39	1.32e-10	Self-reported allergy;
KIRP	cis	rs3857067	0.967	rs7668980	chr4:95037320	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.04	-0.31	9.01e-7	QT interval;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23076906	chr19:56652683	ZNF444	0.44	6.33	0.37	1.17e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	0.89	8.82	0.49	2.13e-16	Blood pressure (smoking interaction);
KIRP	cis	rs13359291	0.658	rs17149944	chr5:122456098	G/A	cg16368670	chr5:122501738	PRDM6	-0.47	-5.14	-0.31	5.48e-7	Systolic blood pressure;
KIRP	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg23601095	chr6:26197514	HIST1H3D	0.84	5.93	0.35	1.03e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06850241	chr22:41845214	NA	-0.43	-4.92	-0.3	1.61e-6	Vitiligo;
KIRP	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg09137382	chr11:130731461	NA	0.55	8.03	0.46	4.12e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg21918786	chr6:109611834	NA	-0.4	-5.55	-0.33	7.56e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg00553149	chr7:99775558	STAG3;GPC2	-0.48	-6.1	-0.36	4e-9	Coronary artery disease;
KIRP	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-5.98	-0.36	7.98e-9	Menopause (age at onset);
KIRP	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.61	9.58	0.52	1.11e-18	Bone mineral density;
KIRP	cis	rs4849845	0.812	rs3931844	chr2:121039263	G/A	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs1577917	0.545	rs9450325	chr6:86475814	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	7.13	0.41	1.14e-11	Response to antipsychotic treatment;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.78	9.85	0.53	1.69e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	10.72	0.56	2.97e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4851254	0.618	rs35300735	chr2:100667829	G/A	cg22139774	chr2:100720529	AFF3	-0.4	-5.08	-0.31	7.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs73206853	0.640	rs871921	chr12:111115113	G/C	cg12870014	chr12:110450643	ANKRD13A	0.51	6.29	0.37	1.41e-9	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.56	-7.51	-0.43	1.06e-12	Systolic blood pressure;
KIRP	cis	rs529866	0.500	rs918739	chr16:11439733	G/T	cg00044050	chr16:11439710	C16orf75	-0.58	-6.77	-0.4	9.18e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg17252645	chr8:143867129	LY6D	0.3	4.89	0.3	1.86e-6	Urinary tract infection frequency;
KIRP	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg24315340	chr6:146058215	EPM2A	-0.46	-6.14	-0.36	3.3e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9815354	0.680	rs75308766	chr3:42031894	G/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs5753618	0.561	rs5753609	chr22:31819212	A/G	cg02404636	chr22:31891804	SFI1	0.54	6.47	0.38	5.38e-10	Colorectal cancer;
KIRP	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.16	-0.64	2.69e-30	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg10792982	chr14:105748885	BRF1	-0.72	-11.19	-0.58	9.35e-24	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19221500	chr21:46309899	ITGB2	0.47	6.7	0.39	1.45e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8084125	0.938	rs62105163	chr18:74943673	C/T	cg26065057	chr18:74961000	GALR1	0.76	7.48	0.43	1.35e-12	Obesity-related traits;
KIRP	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12311346	chr5:56204834	C5orf35	-0.42	-5.31	-0.32	2.51e-7	Coronary artery disease;
KIRP	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.39	-5.31	-0.32	2.5e-7	Coronary artery disease;
KIRP	cis	rs10849605	0.698	rs7955986	chr12:1067254	C/T	cg02055889	chr12:1059459	RAD52	0.59	8.02	0.46	4.2e-14	Lung cancer;
KIRP	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg10818794	chr15:86012489	AKAP13	-0.51	-7.23	-0.42	6.15e-12	Coronary artery disease;
KIRP	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.65	-8.92	-0.49	1.12e-16	Lymphocyte counts;
KIRP	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg07451762	chr16:28383216	NA	0.43	5.6	0.34	5.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.72	-9.43	-0.52	3.13e-18	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg10729496	chr3:10149963	C3orf24	0.52	4.86	0.3	2.05e-6	Alzheimer's disease;
KIRP	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg07166546	chr14:35805898	NA	-0.28	-6.3	-0.37	1.4e-9	Psoriasis;
KIRP	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.52	-6.65	-0.39	1.91e-10	Longevity;
KIRP	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg24505687	chr6:33548425	BAK1	0.27	5.25	0.32	3.37e-7	Platelet count;
KIRP	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg12801552	chr17:20467831	NA	0.39	6.33	0.37	1.17e-9	Cancer;
KIRP	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.56	-8.37	-0.47	4.35e-15	Carotid intima media thickness;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg15454043	chr8:16942004	EFHA2	0.48	7.51	0.43	1.08e-12	Survival in pancreatic cancer;
KIRP	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.4	-5.0	-0.3	1.1e-6	Aortic root size;
KIRP	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.84	-0.45	1.35e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	19.92	0.79	3.29e-53	Prudent dietary pattern;
KIRP	cis	rs7945718	0.870	rs3890065	chr11:12758767	C/G	cg25843174	chr11:12811716	TEAD1	0.35	6.48	0.38	4.87e-10	Educational attainment (years of education);
KIRP	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09640425	chr7:158790006	NA	-0.4	-4.87	-0.3	2.03e-6	Facial morphology (factor 20);
KIRP	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.18	-0.31	4.61e-7	Metabolite levels;
KIRP	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg21361702	chr7:150065534	REPIN1	0.62	6.51	0.38	4.15e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.56	-7.51	-0.43	1.09e-12	Calcium levels;
KIRP	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21986225	chr4:141295029	SCOC	0.49	6.16	0.37	2.99e-9	Parkinson's disease;
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02475777	chr4:1388615	CRIPAK	0.37	4.88	0.3	1.95e-6	Obesity-related traits;
KIRP	cis	rs1134634	0.520	rs2041671	chr4:15552198	A/G	cg16509355	chr4:15471240	CC2D2A	-0.31	-5.15	-0.31	5.47e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.44	9.81	0.53	2.17e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.43	5.73	0.34	2.87e-8	Testicular germ cell tumor;
KIRP	cis	rs6429082	0.744	rs903347	chr1:235586613	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.79	-10.72	-0.56	2.93e-22	Adiposity;
KIRP	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	5.03	0.31	9.45e-7	Neuroticism;
KIRP	cis	rs6256	1.000	rs80103568	chr11:13603741	C/T	cg11976911	chr11:13509032	NA	-0.63	-5.29	-0.32	2.67e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.99	10.44	0.55	2.4e-21	Alzheimer's disease;
KIRP	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg25039879	chr17:56429692	SUPT4H1	0.7	6.5	0.38	4.52e-10	Cognitive test performance;
KIRP	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg07382826	chr16:28625726	SULT1A1	-0.43	-5.22	-0.32	3.8e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg11945507	chr8:142233382	SLC45A4	0.91	15.09	0.69	7.01e-37	Immature fraction of reticulocytes;
KIRP	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.85	12.71	0.63	8.56e-29	Eosinophil percentage of white cells;
KIRP	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-6.98	-0.41	2.8e-11	Coronary artery disease;
KIRP	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg26875233	chr11:93583750	C11orf90	-0.41	-7.54	-0.43	8.88e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs4851254	0.961	rs11682173	chr2:100759810	C/T	cg17356467	chr2:100759845	AFF3	0.61	7.94	0.45	7.02e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs35740288	0.929	rs11630585	chr15:86306004	C/A	cg17133734	chr15:86042851	AKAP13	-0.49	-5.3	-0.32	2.54e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.35	-0.42	2.93e-12	Triglycerides;
KIRP	cis	rs7802124	0.530	rs10270569	chr7:116182782	C/T	cg05166801	chr7:116143459	CAV2	0.47	5.47	0.33	1.12e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.62	7.19	0.42	7.86e-12	Height;
KIRP	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03934478	chr11:495069	RNH1	0.93	6.2	0.37	2.42e-9	Body mass index;
KIRP	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	6.21	0.37	2.23e-9	Rheumatoid arthritis;
KIRP	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg10818794	chr15:86012489	AKAP13	-0.47	-6.62	-0.39	2.28e-10	Interstitial lung disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15658376	chr5:177631524	HNRNPAB	0.49	6.19	0.37	2.47e-9	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg20274553	chr6:169939263	WDR27	0.41	6.32	0.37	1.2e-9	Interleukin-4 levels;
KIRP	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg16255804	chr6:135334527	HBS1L	-0.31	-4.9	-0.3	1.75e-6	Red blood cell count;
KIRP	cis	rs4006360	0.547	rs9901868	chr17:39232963	A/G	cg25341923	chr17:39239918	KRTAP4-7	-0.57	-8.87	-0.49	1.49e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg01210520	chr9:35072637	VCP	0.58	6.43	0.38	6.69e-10	Lung cancer in ever smokers;
KIRP	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.49	0.33	9.78e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg18209359	chr17:80159595	CCDC57	0.41	5.4	0.33	1.57e-7	Life satisfaction;
KIRP	cis	rs10267417	0.603	rs4994102	chr7:19939704	T/A	cg05791153	chr7:19748676	TWISTNB	0.51	5.05	0.31	8.64e-7	Night sleep phenotypes;
KIRP	cis	rs4851254	0.920	rs11123816	chr2:100783653	G/A	cg17356467	chr2:100759845	AFF3	0.6	7.0	0.41	2.38e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg13180566	chr4:1052158	NA	-0.5	-5.14	-0.31	5.67e-7	Recombination rate (females);
KIRP	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg23601095	chr6:26197514	HIST1H3D	0.84	5.96	0.36	8.77e-9	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs526231	0.543	rs62362544	chr5:102334247	C/T	cg23492399	chr5:102201601	PAM	-0.48	-5.54	-0.33	7.6e-8	Primary biliary cholangitis;
KIRP	cis	rs1440410	0.835	rs6827229	chr4:144140376	G/A	cg01719995	chr4:144104893	USP38	0.44	6.02	0.36	6.35e-9	Ischemic stroke;
KIRP	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.53	6.68	0.39	1.56e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	1.01	10.8	0.57	1.62e-22	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg09165964	chr15:75287851	SCAMP5	0.48	5.92	0.35	1.09e-8	Caffeine consumption;
KIRP	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05025164	chr4:1340916	KIAA1530	0.55	7.43	0.43	1.83e-12	Longevity;
KIRP	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs35740288	0.770	rs4843081	chr15:86153044	T/C	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-13.74	-0.66	2.95e-32	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25248750	chr8:99077132	C8orf47	0.48	6.27	0.37	1.64e-9	Parkinson's disease;
KIRP	cis	rs7923609	0.967	rs7909269	chr10:65177766	G/A	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.37e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg12292205	chr6:26970375	C6orf41	0.34	4.86	0.3	2.09e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg10790698	chr19:18539756	SSBP4	-0.34	-7.5	-0.43	1.14e-12	Breast cancer;
KIRP	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.57	-7.09	-0.41	1.42e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg03235661	chr20:60525775	NA	-0.32	-5.28	-0.32	2.88e-7	Body mass index;
KIRP	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg01879757	chr17:41196368	BRCA1	-0.74	-9.03	-0.5	5.11e-17	Menopause (age at onset);
KIRP	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.72	9.09	0.5	3.31e-17	Corneal astigmatism;
KIRP	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg12940923	chr8:10282607	MSRA	-0.38	-4.9	-0.3	1.74e-6	Neuroticism;
KIRP	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.63	8.35	0.47	4.86e-15	Motion sickness;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18753424	chr3:43026757	FAM198A	0.43	6.43	0.38	6.71e-10	Interleukin-4 levels;
KIRP	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg07741184	chr6:167504864	NA	-0.23	-6.11	-0.36	3.89e-9	Crohn's disease;
KIRP	trans	rs6928977	0.660	rs12203875	chr6:135860414	C/T	cg16035531	chr6:155644853	NA	0.42	6.17	0.37	2.85e-9	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;
KIRP	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg05347473	chr6:146136440	FBXO30	-0.59	-8.48	-0.48	2.15e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1215050	0.740	rs9994227	chr4:98767094	T/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12153243	1.000	rs17342419	chr5:142900260	T/G	cg13907255	chr5:142895549	NA	-0.38	-5.1	-0.31	6.85e-7	Migraine;
KIRP	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg04731861	chr2:219085781	ARPC2	-0.3	-7.74	-0.44	2.63e-13	Colorectal cancer;
KIRP	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.77	7.13	0.41	1.12e-11	Cerebrospinal P-tau181p levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25260653	chr9:99212216	HABP4	-0.49	-6.5	-0.38	4.32e-10	Metabolic traits;
KIRP	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.42	-5.25	-0.32	3.35e-7	Platelet count;
KIRP	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	1.0	16.59	0.73	5.35e-42	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs11209002	0.567	rs2815385	chr1:67542083	A/G	cg02640540	chr1:67518911	SLC35D1	0.54	5.91	0.35	1.11e-8	Crohn's disease;
KIRP	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.49	-0.43	1.24e-12	Platelet count;
KIRP	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg24375607	chr4:120327624	NA	0.54	6.22	0.37	2.17e-9	Corneal astigmatism;
KIRP	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.66	0.48	6.3e-16	Motion sickness;
KIRP	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.01	14.61	0.68	3.17e-35	Blood pressure (smoking interaction);
KIRP	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.47	5.99	0.36	7.59e-9	QT interval;
KIRP	cis	rs7737355	1.000	rs9327608	chr5:130650134	G/A	cg06647332	chr5:131281008	NA	0.48	5.32	0.32	2.34e-7	Life satisfaction;
KIRP	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg08805041	chr16:621841	PIGQ	-0.36	-4.95	-0.3	1.39e-6	Height;
KIRP	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg16141378	chr3:129829833	LOC729375	-0.53	-6.61	-0.39	2.3e-10	Retinal vascular caliber;
KIRP	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg13147721	chr7:65941812	NA	-1.01	-7.07	-0.41	1.64e-11	Diabetic kidney disease;
KIRP	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg23102388	chr7:1867652	MAD1L1	-0.42	-5.21	-0.32	4.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-6.2	-0.37	2.38e-9	Height;
KIRP	cis	rs34375054	0.660	rs35941060	chr12:125594245	G/A	cg25124228	chr12:125621409	AACS	-0.67	-8.17	-0.46	1.61e-14	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg23791538	chr6:167370224	RNASET2	-0.48	-5.79	-0.35	2.11e-8	Primary biliary cholangitis;
KIRP	cis	rs7508	0.668	rs10087428	chr8:17918454	G/T	cg01800426	chr8:17659068	MTUS1	-0.43	-5.11	-0.31	6.45e-7	Atrial fibrillation;
KIRP	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.42	0.33	1.39e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg13160058	chr8:26243215	BNIP3L	0.49	7.2	0.42	7.08e-12	Red cell distribution width;
KIRP	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg18132916	chr6:79620363	NA	-0.43	-5.85	-0.35	1.59e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7870753	0.838	rs16910858	chr9:99234557	G/T	cg25260653	chr9:99212216	HABP4	-0.55	-5.96	-0.36	8.71e-9	Height;
KIRP	cis	rs1505368	0.533	rs7560905	chr2:213261808	C/T	cg20637307	chr2:213403960	ERBB4	0.5	6.75	0.4	1.03e-10	Symmetrical dimethylarginine levels;
KIRP	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg05964544	chr11:70165517	PPFIA1	-0.52	-5.29	-0.32	2.65e-7	Coronary artery disease;
KIRP	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.52	8.98	0.5	7.28e-17	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.76	-0.53	3.2e-19	Idiopathic membranous nephropathy;
KIRP	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.64	7.74	0.44	2.57e-13	Obesity-related traits;
KIRP	cis	rs4664293	0.867	rs12692563	chr2:160602811	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.45	6.4e-14	Aortic root size;
KIRP	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg13147721	chr7:65941812	NA	-0.97	-6.86	-0.4	5.62e-11	Diabetic kidney disease;
KIRP	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg24296786	chr1:45957014	TESK2	0.62	8.37	0.47	4.3e-15	High light scatter reticulocyte count;
KIRP	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.62	-7.7	-0.44	3.34e-13	Longevity;
KIRP	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.47	-6.71	-0.39	1.35e-10	Monocyte percentage of white cells;
KIRP	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	1.02	17.84	0.75	3.04e-46	Parkinson's disease;
KIRP	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg18154014	chr19:37997991	ZNF793	0.94	9.74	0.53	3.71e-19	Coronary artery calcification;
KIRP	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.66	-9.21	-0.51	1.47e-17	Brugada syndrome;
KIRP	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.9	12.16	0.61	5.71e-27	Menopause (age at onset);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12530353	chr6:8435731	SLC35B3	-0.55	-6.14	-0.36	3.34e-9	Menopause (age at onset);
KIRP	cis	rs4656940	0.574	rs6691072	chr1:160776555	G/C	cg17331569	chr1:160788135	LY9	-0.45	-5.43	-0.33	1.34e-7	Crohn's disease;
KIRP	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg08885076	chr2:99613938	TSGA10	-0.55	-9.67	-0.52	6.06e-19	Chronic sinus infection;
KIRP	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg27499820	chr13:21296301	IL17D	-0.31	-4.87	-0.3	1.95e-6	Dental caries;
KIRP	cis	rs4713675	0.565	rs4713670	chr6:33699882	C/T	cg15676125	chr6:33679581	C6orf125	-0.39	-5.08	-0.31	7.49e-7	Plateletcrit;
KIRP	cis	rs6681460	1.000	rs7521111	chr1:67121634	T/C	cg13052034	chr1:66999238	SGIP1	0.44	6.21	0.37	2.19e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg25309564	chr22:51001381	C22orf41	0.73	5.1	0.31	6.68e-7	Narcolepsy;
KIRP	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg17554472	chr22:41940697	POLR3H	0.43	5.19	0.31	4.36e-7	Vitiligo;
KIRP	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	1.16	9.38	0.51	4.62e-18	Hip circumference adjusted for BMI;
KIRP	cis	rs13102973	0.965	rs9998499	chr4:135869362	G/A	cg14419869	chr4:135874104	NA	-0.61	-11.1	-0.58	1.81e-23	Subjective well-being;
KIRP	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.28	0.62	2.4200000000000002e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg00042356	chr1:8021962	PARK7	0.84	7.16	0.42	9.46e-12	Inflammatory bowel disease;
KIRP	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Life satisfaction;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg12022895	chr7:149570992	ATP6V0E2;LOC401431	-0.47	-6.05	-0.36	5.47e-9	Myopia;
KIRP	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.01	0.67	3.42e-33	Chronic sinus infection;
KIRP	cis	rs7546094	0.508	rs12042407	chr1:113183879	A/T	cg22162597	chr1:113214053	CAPZA1	-0.44	-5.76	-0.34	2.5e-8	Platelet distribution width;
KIRP	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-12.21	-0.61	4.17e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-6.39	-0.38	8.07e-10	Breast cancer;
KIRP	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.61	-8.05	-0.46	3.59e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg23594656	chr7:65796392	TPST1	-0.51	-8.16	-0.46	1.78e-14	Aortic root size;
KIRP	cis	rs889512	0.642	rs13337017	chr16:75272367	C/T	cg03315344	chr16:75512273	CHST6	-0.68	-5.12	-0.31	6.2e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs8077577	0.747	rs7215678	chr17:18139793	A/C	cg18869244	chr17:18121946	NA	-0.46	-5.24	-0.32	3.47e-7	Obesity-related traits;
KIRP	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.48	5.62	0.34	5.19e-8	Diastolic blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21064505	chr6:169902441	WDR27	-0.4	-6.11	-0.36	3.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs698833	0.819	rs2340810	chr2:44536546	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.53	-6.17	-0.37	2.79e-9	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg01843034	chr6:37503916	NA	-0.73	-8.37	-0.47	4.32e-15	Cognitive performance;
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.55	-0.39	3.34e-10	Lung cancer;
KIRP	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	11.73	0.6	1.53e-25	Alzheimer's disease;
KIRP	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg05484376	chr2:27715224	FNDC4	0.32	5.36	0.32	1.93e-7	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg21775007	chr8:11205619	TDH	0.44	5.71	0.34	3.31e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7927771	0.832	rs1542321	chr11:47379615	G/A	cg20307385	chr11:47447363	PSMC3	0.49	5.21	0.32	3.98e-7	Subjective well-being;
KIRP	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06850241	chr22:41845214	NA	-0.47	-5.31	-0.32	2.43e-7	Vitiligo;
KIRP	cis	rs1448094	0.836	rs7484454	chr12:86425576	A/G	cg06740227	chr12:86229804	RASSF9	0.4	5.07	0.31	7.93e-7	Major depressive disorder;
KIRP	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.1	0.31	6.84e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs7116495	0.609	rs10751191	chr11:71680920	C/T	cg18441811	chr11:71824068	C11orf51	-0.77	-5.23	-0.32	3.54e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	5.44	0.33	1.3e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg07382826	chr16:28625726	SULT1A1	0.45	5.31	0.32	2.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.1e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.83	-0.45	1.48e-13	Retinal vascular caliber;
KIRP	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.79	12.03	0.61	1.61e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.66	7.94	0.45	7.11e-14	Post bronchodilator FEV1;
KIRP	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg07001201	chr5:642380	CEP72	0.67	6.26	0.37	1.71e-9	Obesity-related traits;
KIRP	cis	rs6504950	0.800	rs9916547	chr17:53006890	G/A	cg26251398	chr17:52985966	TOM1L1	0.45	6.04	0.36	5.68e-9	Breast cancer;
KIRP	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.7	-7.26	-0.42	5.04e-12	Initial pursuit acceleration;
KIRP	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg24375607	chr4:120327624	NA	0.74	8.37	0.47	4.36e-15	Corneal astigmatism;
KIRP	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18932078	chr1:2524107	MMEL1	-0.43	-6.04	-0.36	5.62e-9	Ulcerative colitis;
KIRP	cis	rs798554	0.591	rs1636248	chr7:2882030	T/C	cg13628971	chr7:2884303	GNA12	0.46	6.04	0.36	5.56e-9	Height;
KIRP	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.26e-21	Psoriasis;
KIRP	cis	rs240764	0.658	rs9399694	chr6:101257877	A/G	cg09795085	chr6:101329169	ASCC3	-0.43	-5.1	-0.31	6.71e-7	Neuroticism;
KIRP	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg14593290	chr7:50529359	DDC	0.41	5.16	0.31	5.21e-7	Malaria;
KIRP	cis	rs9937943	0.673	rs12922972	chr16:74494522	T/A	cg01733217	chr16:74700730	RFWD3	0.6	5.56	0.33	7.09e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg07741184	chr6:167504864	NA	0.23	6.1	0.36	4.01e-9	Crohn's disease;
KIRP	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg02002194	chr4:3960332	NA	-0.46	-6.66	-0.39	1.74e-10	Mood instability;
KIRP	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg04865290	chr3:52927548	TMEM110	-0.64	-6.76	-0.4	1.01e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	5.27	0.32	2.91e-7	Neuroticism;
KIRP	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.35	-0.78	2.56e-51	Height;
KIRP	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.08	12.51	0.62	3.95e-28	Uric acid levels;
KIRP	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg13798912	chr7:905769	UNC84A	0.55	5.62	0.34	5.29e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.94	12.25	0.62	2.87e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.65	7.62	0.44	5.63e-13	Height;
KIRP	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg07884673	chr3:53033167	SFMBT1	0.99	7.37	0.43	2.61e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.65	-0.56	5.13e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7646501	0.765	rs3856622	chr3:24054013	G/A	cg21910673	chr3:24143257	LOC152024	0.36	4.89	0.3	1.81e-6	Cognitive ability;Intelligence;
KIRP	cis	rs1062177	0.855	rs6884630	chr5:151268997	A/T	cg00977110	chr5:151150581	G3BP1	0.58	6.13	0.36	3.44e-9	Preschool internalizing problems;
KIRP	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg10223061	chr2:219282414	VIL1	-0.37	-6.09	-0.36	4.34e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs287982	1.000	rs287981	chr2:9971562	A/G	cg10881225	chr2:9984929	TAF1B	-0.41	-4.95	-0.3	1.4e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.64	-0.34	4.64e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7246865	0.510	rs34833670	chr19:17172983	T/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.52	6.59	0.39	2.68e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg23594656	chr7:65796392	TPST1	-0.43	-5.95	-0.35	9e-9	Aortic root size;
KIRP	trans	rs6601327	0.898	rs1458942	chr8:9406602	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.6	-0.39	2.46e-10	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17994379	chr17:43025264	KIF18B	0.59	6.86	0.4	5.5e-11	Smoking initiation;
KIRP	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg15428835	chr7:75027521	TRIM73;TRIM74	0.41	5.31	0.32	2.44e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11225247	0.881	rs12271457	chr11:102247928	C/T	cg06323957	chr11:102217781	BIRC2	0.93	5.97	0.36	8.17e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.53	-7.49	-0.43	1.23e-12	Asthma;
KIRP	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.13	14.03	0.67	2.93e-33	Gut microbiome composition (summer);
KIRP	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.05	14.83	0.69	5.82e-36	Cognitive ability;
KIRP	cis	rs7116495	0.786	rs1573501	chr11:71735693	C/T	cg07596299	chr11:71824057	C11orf51	-0.87	-5.44	-0.33	1.27e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.48	5.39	0.32	1.67e-7	Systemic lupus erythematosus;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.4e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg05785598	chr3:49045655	WDR6	0.28	4.96	0.3	1.29e-6	Parkinson's disease;
KIRP	cis	rs742134	0.915	rs4988417	chr22:43520258	A/C	cg07713796	chr22:43435589	TTLL1	0.51	4.84	0.3	2.26e-6	Prostate cancer;
KIRP	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	0.82	7.19	0.42	7.71e-12	Severe influenza A (H1N1) infection;
KIRP	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg23422044	chr7:1970798	MAD1L1	-0.45	-5.68	-0.34	3.76e-8	Neuroticism;
KIRP	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14895029	chr7:2775587	GNA12	0.43	5.18	0.31	4.7e-7	Height;
KIRP	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg09699651	chr6:150184138	LRP11	0.44	5.58	0.34	6.17e-8	Lung cancer;
KIRP	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.7	7.63	0.44	5.08e-13	Corneal astigmatism;
KIRP	cis	rs754423	0.662	rs3825594	chr14:52507206	G/A	cg05884192	chr14:52515736	NID2	0.55	5.76	0.34	2.56e-8	Craniofacial microsomia;
KIRP	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg08975724	chr8:8085496	FLJ10661	0.59	7.98	0.45	5.47e-14	Mood instability;
KIRP	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.77e-6	Bipolar disorder;
KIRP	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.47	5.66	0.34	4.29e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.54	8.33	0.47	5.59e-15	Lung cancer;
KIRP	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.4	5.29	0.32	2.66e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg08773314	chr2:239334832	ASB1	-0.53	-5.25	-0.32	3.29e-7	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg08283408	chr3:49949060	MON1A	-0.41	-5.53	-0.33	7.96e-8	Body mass index;
KIRP	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg09344028	chr17:70110421	NA	0.39	8.09	0.46	2.83e-14	Thyroid hormone levels;
KIRP	cis	rs7084402	0.967	rs1658435	chr10:60327527	A/G	cg05938607	chr10:60274200	BICC1	-0.44	-10.51	-0.56	1.4e-21	Refractive error;
KIRP	cis	rs10465746	0.967	rs28567085	chr1:84428859	G/A	cg10977910	chr1:84465055	TTLL7	0.48	5.81	0.35	1.97e-8	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00501421	chr3:58291814	RPP14	-0.47	-6.05	-0.36	5.5e-9	Interleukin-4 levels;
KIRP	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.44	5.05	0.31	8.48e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs1873147	0.954	rs4774467	chr15:63311425	T/C	cg12160578	chr15:63334699	TPM1	-0.46	-5.59	-0.34	5.99e-8	Orofacial clefts;
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.85	-12.17	-0.61	5.7e-27	Longevity;Endometriosis;
KIRP	cis	rs9810890	1.000	rs73207983	chr3:128577690	T/A	cg15033153	chr3:128514015	RAB7A	0.69	5.03	0.31	9.52e-7	Dental caries;
KIRP	trans	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg07393940	chr7:158741817	NA	0.44	6.1	0.36	4.12e-9	Life satisfaction;
KIRP	cis	rs3736485	0.934	rs7170330	chr15:51859313	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.45e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs59197085	0.636	rs56377531	chr7:128460745	C/T	cg00734629	chr7:128471146	FLNC	0.43	4.85	0.3	2.23e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	cis	rs4845875	0.535	rs4846045	chr1:11840380	A/G	cg24844545	chr1:11908347	NPPA	0.35	4.88	0.3	1.89e-6	Midregional pro atrial natriuretic peptide levels;
KIRP	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19717773	chr7:2847554	GNA12	-0.36	-5.38	-0.32	1.71e-7	Height;
KIRP	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.79	-11.17	-0.58	1.02e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.73	-9.96	-0.54	7.6e-20	Ear protrusion;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.11.104864706F	chr11:105359496	NA	0.42	6.38	0.38	8.55e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	1.2	11.39	0.59	2.07e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11723795	chr14:91975931	SMEK1	-0.54	-6.29	-0.37	1.43e-9	Interleukin-4 levels;
KIRP	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg21573476	chr21:45109991	RRP1B	-0.64	-8.6	-0.48	9.73e-16	Mean corpuscular volume;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg23359706	chr19:11491839	EPOR	0.46	6.67	0.39	1.67e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.47	7.24	0.42	5.69e-12	Coronary artery disease;
KIRP	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.81	-14.44	-0.68	1.19e-34	Body mass index;
KIRP	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-12.11	-0.61	9.02e-27	Alzheimer's disease;
KIRP	cis	rs10214930	0.650	rs4348389	chr7:27628950	A/G	cg22168087	chr7:27702803	HIBADH	0.47	4.98	0.3	1.19e-6	Hypospadias;
KIRP	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg25486957	chr4:152246857	NA	-0.44	-5.14	-0.31	5.73e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs33912345	0.695	rs1268618	chr14:60897181	A/C	cg27398547	chr14:60952738	C14orf39	-0.41	-5.59	-0.34	6.13e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.33	-6.74	-0.39	1.12e-10	Urinary metabolites;
KIRP	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-23.65	-0.83	2.79e-65	Exhaled nitric oxide output;
KIRP	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg09060608	chr5:178986726	RUFY1	0.51	7.63	0.44	5.26e-13	Lung cancer;
KIRP	cis	rs1043515	0.748	rs11657530	chr17:36942814	T/C	cg20826740	chr17:37024042	NA	0.35	4.87	0.3	2.01e-6	Height;
KIRP	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	6.52	0.38	3.93e-10	Rheumatoid arthritis;
KIRP	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg13962347	chr6:5174647	LYRM4	-0.62	-8.61	-0.48	9.08e-16	Height;
KIRP	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05601917	chr6:125855416	NA	0.33	4.87	0.3	2.02e-6	Endometrial cancer;
KIRP	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg13354988	chr2:263656	ACP1;SH3YL1	0.38	4.91	0.3	1.66e-6	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg26752003	chr8:145688521	CYHR1	0.71	9.28	0.51	9.25e-18	Age at first birth;
KIRP	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.73	7.11	0.41	1.22e-11	Vitiligo;
KIRP	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.45	0.33	1.2e-7	Tonsillectomy;
KIRP	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Blood protein levels;
KIRP	cis	rs17253792	0.571	rs112129578	chr14:56028415	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.86	5.69	0.34	3.52e-8	Putamen volume;
KIRP	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg03959625	chr15:84868606	LOC388152	0.51	6.02	0.36	6.19e-9	Schizophrenia;
KIRP	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.72	9.28	0.51	9.32e-18	Coronary artery disease;
KIRP	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.84	12.13	0.61	7.61e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg07803811	chr1:43423981	SLC2A1	0.47	6.15	0.37	3.05e-9	Red cell distribution width;
KIRP	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg21401794	chr1:90099060	LRRC8C	0.7	9.72	0.53	4.04e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.73	0.39	1.2e-10	Lung cancer;
KIRP	cis	rs9394841	0.536	rs6899876	chr6:41796970	A/G	cg08135965	chr6:41755394	TOMM6	0.45	5.07	0.31	7.94e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs15300	1.000	rs15300	chr6:8413412	A/G	cg07606381	chr6:8435919	SLC35B3	0.98	5.29	0.32	2.68e-7	Pursuit maintenance gain;
KIRP	cis	rs735860	0.726	rs209518	chr6:53208016	C/A	cg10236188	chr6:53219634	NA	0.41	5.47	0.33	1.12e-7	Glaucoma;
KIRP	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.83	-12.12	-0.61	7.99e-27	Extrinsic epigenetic age acceleration;
KIRP	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.68	8.74	0.49	3.71e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.59	-7.26	-0.42	5.19e-12	Iron status biomarkers;
KIRP	cis	rs10761750	1	rs10761750	chr10:65128619	G/A	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.54	-0.33	7.66e-8	Vascular endothelial growth factor levels;
KIRP	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.09	-0.31	7.03e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.57	-7.74	-0.44	2.59e-13	Autism;
KIRP	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.67	8.62	0.48	8.38e-16	Height;
KIRP	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-0.93	-12.12	-0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-10.22	-0.55	1.13e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.26	0.47	8.87e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs28489187	0.683	rs67611930	chr1:85846592	A/G	cg16011679	chr1:85725395	C1orf52	0.52	6.31	0.37	1.3e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg26516362	chr5:178986906	RUFY1	0.42	7.23	0.42	6.18e-12	Lung cancer;
KIRP	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.61	-6.48	-0.38	4.96e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2072732	0.861	rs6661908	chr1:2950334	C/T	cg11731671	chr1:2995604	PRDM16	-0.44	-5.55	-0.33	7.54e-8	Plateletcrit;
KIRP	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.82	-12.15	-0.61	6.54e-27	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.32	-5.24	-0.32	3.44e-7	Height;
KIRP	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg21573476	chr21:45109991	RRP1B	-0.57	-7.85	-0.45	1.27e-13	Mean corpuscular volume;
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.67	0.34	3.96e-8	Lung cancer;
KIRP	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06505273	chr16:24850292	NA	0.42	5.26	0.32	3.13e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg25664220	chr3:72788482	NA	-0.36	-5.06	-0.31	8.31e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.53	-7.69	-0.44	3.51e-13	Daytime sleep phenotypes;
KIRP	cis	rs7224685	0.501	rs781845	chr17:3958341	A/G	cg11204139	chr17:3907470	NA	-0.81	-15.36	-0.7	8.99e-38	Type 2 diabetes;
KIRP	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	trans	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg16700650	chr16:69344975	VPS4A	0.48	6.62	0.39	2.25e-10	Caffeine consumption;
KIRP	cis	rs7236492	0.748	rs11660128	chr18:77227950	G/T	cg15644404	chr18:77186268	NFATC1	-0.92	-7.32	-0.42	3.54e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.47	6.87	0.4	5.15e-11	Lewy body disease;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg05061393	chr2:220043337	FAM134A	-0.44	-6.11	-0.36	3.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg03647239	chr10:116582469	FAM160B1	0.51	5.98	0.36	7.63e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.52	6.47	0.38	5.28e-10	Height;
KIRP	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg17652424	chr22:38574118	PLA2G6	-0.29	-6.16	-0.37	2.87e-9	Cutaneous nevi;
KIRP	cis	rs6132905	0.590	rs2092656	chr20:2625850	A/T	cg24848351	chr20:2622020	TMC2	-0.64	-5.85	-0.35	1.52e-8	Mumps;
KIRP	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg15655495	chr12:38532458	NA	-0.28	-4.95	-0.3	1.37e-6	Bladder cancer;
KIRP	cis	rs16936870	0.543	rs2979633	chr8:71074564	G/A	cg14232793	chr8:71155543	NCOA2	-0.55	-6.77	-0.4	9.41e-11	QT interval;
KIRP	cis	rs6693295	0.887	rs2787993	chr1:246231383	A/G	cg11798871	chr1:246315928	SMYD3	-0.45	-5.61	-0.34	5.48e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.89	0.3	1.86e-6	Menopause (age at onset);
KIRP	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.59	7.44	0.43	1.73e-12	Tonsillectomy;
KIRP	cis	rs2737618	0.630	rs2821328	chr1:200082051	G/A	cg21825944	chr1:200113062	NR5A2	-0.55	-7.87	-0.45	1.11e-13	Uric acid levels;
KIRP	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg02404636	chr22:31891804	SFI1	-0.49	-5.42	-0.33	1.4e-7	Colorectal cancer;
KIRP	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg18306943	chr3:40428807	ENTPD3	0.46	5.96	0.36	8.83e-9	Renal cell carcinoma;
KIRP	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg00106254	chr7:1943704	MAD1L1	-0.62	-6.73	-0.39	1.16e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs16936870	0.543	rs2977980	chr8:71171858	T/G	cg14232793	chr8:71155543	NCOA2	-0.54	-6.54	-0.38	3.53e-10	QT interval;
KIRP	trans	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg07393940	chr7:158741817	NA	0.46	6.29	0.37	1.48e-9	Life satisfaction;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Blood metabolite levels;
KIRP	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.84	-9.74	-0.53	3.59e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.83	12.01	0.61	1.81e-26	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01585758	chr2:203102753	SUMO1	0.52	6.08	0.36	4.44e-9	Smoking initiation;
KIRP	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg02187348	chr16:89574699	SPG7	0.41	4.89	0.3	1.86e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs17608059	0.901	rs11078215	chr17:13906934	T/C	cg11395062	chr17:14139857	CDRT15	0.57	7.49	0.43	1.27e-12	Temperament;
KIRP	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	7.32	0.42	3.48e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs8010715	0.816	rs2332224	chr14:24598544	C/G	cg23112188	chr14:24563095	PCK2	-0.35	-5.15	-0.31	5.3e-7	IgG glycosylation;
KIRP	cis	rs533123	0.818	rs556408	chr1:29166323	C/A	cg08366446	chr1:29138936	OPRD1	0.63	6.11	0.36	3.81e-9	Schizophrenia;
KIRP	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg18209359	chr17:80159595	CCDC57	0.41	5.35	0.32	2.02e-7	Life satisfaction;
KIRP	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.81	12.08	0.61	1.11e-26	Blood metabolite ratios;
KIRP	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg09873164	chr1:152488093	CRCT1	0.58	7.43	0.43	1.81e-12	Hair morphology;
KIRP	cis	rs904092	0.720	rs1230025	chr4:100186376	A/T	cg12011299	chr4:100065546	ADH4	0.49	4.94	0.3	1.46e-6	Alcohol dependence;
KIRP	cis	rs4646404	0.509	rs4646352	chr17:17473853	C/T	cg01246520	chr17:17644344	RAI1	-0.33	-5.56	-0.33	7.07e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs73198271	1.000	rs4840356	chr8:8607527	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-5.8	-0.35	2.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1373549	1.000	rs1822739	chr12:46470509	G/C	cg21957191	chr20:1960655	PDYN	0.46	6.08	0.36	4.68e-9	Hippocampal atrophy;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg10050877	chr8:130952333	FAM49B	0.49	6.03	0.36	6.12e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs300890	0.615	rs3805251	chr4:144295952	C/T	cg01719995	chr4:144104893	USP38	-0.41	-5.16	-0.31	5.12e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs806321	0.534	rs1149865	chr13:50902103	C/T	cg10393508	chr13:50950265	NA	-0.45	-6.4	-0.38	7.67e-10	Multiple sclerosis;
KIRP	cis	rs6120849	0.754	rs3746436	chr20:33586193	C/T	cg08999081	chr20:33150536	PIGU	0.48	5.0	0.3	1.08e-6	Protein C levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg20536432	chr5:82500668	XRCC4	0.42	6.68	0.39	1.63e-10	Migraine with aura;
KIRP	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.93	-0.4	3.73e-11	Hemoglobin concentration;
KIRP	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg08313168	chr12:7315531	NA	0.68	6.18	0.37	2.61e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.42	-5.78	-0.35	2.2e-8	Aortic root size;
KIRP	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.71	0.34	3.3e-8	Melanoma;
KIRP	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg11845111	chr2:191398756	TMEM194B	-0.71	-7.83	-0.45	1.46e-13	Diastolic blood pressure;
KIRP	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg07870213	chr5:140052090	DND1	-0.62	-8.04	-0.46	3.67e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2742417	0.967	rs1534875	chr3:45741043	T/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.61	7.64	0.44	4.92e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg00982548	chr2:198649783	BOLL	-0.59	-5.55	-0.33	7.48e-8	Ulcerative colitis;
KIRP	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.54	0.48	1.42e-15	Motion sickness;
KIRP	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.29	-0.32	2.74e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1957429	0.520	rs230723	chr14:65316017	C/T	cg23373153	chr14:65346875	NA	-0.58	-4.9	-0.3	1.73e-6	Pediatric areal bone mineral density (radius);
KIRP	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6681460	1.000	rs10889641	chr1:67138367	C/T	cg13052034	chr1:66999238	SGIP1	0.46	6.24	0.37	1.88e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg13679303	chr9:96623674	NA	0.45	5.9	0.35	1.2e-8	DNA methylation (variation);
KIRP	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg19847130	chr8:10466454	RP1L1	0.32	4.85	0.3	2.24e-6	Morning vs. evening chronotype;
KIRP	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.94	12.21	0.61	4e-27	Menopause (age at onset);
KIRP	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.69	-7.06	-0.41	1.65e-11	Body mass index;
KIRP	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.49	6.62	0.39	2.27e-10	Migraine;
KIRP	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.5	-7.03	-0.41	2.02e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs17079247	0.841	rs9635066	chr13:85812000	A/G	cg07750655	chr16:5121855	ALG1	-0.58	-6.01	-0.36	6.47e-9	Bipolar disorder (mania);
KIRP	cis	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.61	6.73	0.39	1.22e-10	Aortic root size;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg23698023	chr8:27181813	PTK2B	0.34	5.14	0.31	5.54e-7	Neuroticism;
KIRP	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg07701084	chr6:150067640	NUP43	0.55	7.07	0.41	1.58e-11	Lung cancer;
KIRP	cis	rs1348850	0.874	rs714598	chr2:178455311	T/A	cg27490568	chr2:178487706	NA	0.5	6.4	0.38	7.61e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1983891	0.955	rs4714487	chr6:41547312	T/C	cg20194872	chr6:41519635	FOXP4	0.57	7.32	0.42	3.43e-12	Prostate cancer;
KIRP	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg01689657	chr7:91764605	CYP51A1	-0.37	-5.4	-0.33	1.56e-7	Breast cancer;
KIRP	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.94	15.66	0.71	7.84e-39	Menarche (age at onset);
KIRP	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.47	-5.68	-0.34	3.72e-8	Testicular germ cell tumor;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg13906792	chr15:75199810	C15orf17	-0.37	-5.41	-0.33	1.52e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-0.61	-6.87	-0.4	5.12e-11	Initial pursuit acceleration;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg26734522	chr7:4245514	SDK1	0.38	6.21	0.37	2.24e-9	Serum protein levels (sST2);
KIRP	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	8.43	0.47	2.97e-15	Myopia (pathological);
KIRP	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.64	-6.98	-0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16682257	chr1:245411712	KIF26B	0.4	6.38	0.38	8.75e-10	Survival in pancreatic cancer;
KIRP	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg22974920	chr21:40686053	BRWD1	0.49	5.59	0.34	6e-8	Cognitive function;
KIRP	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg06637938	chr14:75390232	RPS6KL1	0.41	5.63	0.34	4.91e-8	Height;
KIRP	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.54	-0.38	3.63e-10	Educational attainment;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02214595	chr16:67143798	C16orf70	-0.44	-6.39	-0.38	8.26e-10	Metabolic traits;
KIRP	cis	rs9462846	0.959	rs9462845	chr6:42860958	A/G	cg13397359	chr6:42928475	GNMT	0.43	4.89	0.3	1.83e-6	Blood protein levels;
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.83	-14.92	-0.69	2.79e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg05973401	chr12:123451056	ABCB9	0.6	5.53	0.33	8.18e-8	Neutrophil percentage of white cells;
KIRP	trans	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg16141378	chr3:129829833	LOC729375	0.48	6.32	0.37	1.2e-9	Mood instability;
KIRP	cis	rs9905704	0.645	rs34852567	chr17:57027770	T/C	cg12560992	chr17:57184187	TRIM37	0.57	5.04	0.31	9.08e-7	Testicular germ cell tumor;
KIRP	cis	rs8067545	0.536	rs62067482	chr17:19947275	G/A	cg13482628	chr17:19912719	NA	0.45	5.17	0.31	4.75e-7	Schizophrenia;
KIRP	cis	rs883565	0.740	rs6796837	chr3:39076188	C/T	cg01426195	chr3:39028469	NA	-0.67	-11.15	-0.58	1.24e-23	Handedness;
KIRP	cis	rs4523957	0.928	rs375245	chr17:2199754	G/A	cg16513277	chr17:2031491	SMG6	0.61	8.32	0.47	5.92e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	cis	rs10782582	0.609	rs1159215	chr1:76317869	A/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.17	-0.37	2.75e-9	Daytime sleep phenotypes;
KIRP	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.58	6.74	0.39	1.13e-10	Pancreatic cancer;
KIRP	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg01988459	chr11:68622903	NA	-0.42	-5.81	-0.35	1.97e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.43	5.14	0.31	5.5e-7	Aortic root size;
KIRP	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg09699651	chr6:150184138	LRP11	0.49	6.28	0.37	1.53e-9	Lung cancer;
KIRP	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.65	8.36	0.47	4.57e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.85	12.42	0.62	7.85e-28	Mean platelet volume;
KIRP	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg10617943	chr7:1981403	MAD1L1	-0.37	-5.08	-0.31	7.59e-7	Neuroticism;
KIRP	cis	rs3748682	0.808	rs12728438	chr1:38349400	G/A	cg12658694	chr1:38397304	INPP5B	0.56	6.04	0.36	5.52e-9	Hypothyroidism;
KIRP	cis	rs986417	1.000	rs10149915	chr14:60943110	G/A	cg27398547	chr14:60952738	C14orf39	0.74	7.4	0.43	2.18e-12	Gut microbiota (bacterial taxa);
KIRP	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg00931491	chr16:28608288	SULT1A2	-0.25	-4.97	-0.3	1.28e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg07148914	chr20:33460835	GGT7	-0.54	-7.18	-0.42	8.4e-12	Height;
KIRP	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15128208	chr22:42549153	NA	-0.42	-5.22	-0.32	3.88e-7	Cognitive function;
KIRP	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg21132104	chr15:45694354	SPATA5L1	0.59	7.31	0.42	3.65e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg19645103	chr12:69753606	YEATS4	-0.47	-5.41	-0.33	1.53e-7	Response to diuretic therapy;
KIRP	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg25730555	chr22:47059586	GRAMD4	0.51	6.1	0.36	4.1e-9	Urate levels in obese individuals;
KIRP	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.51	-7.27	-0.42	4.85e-12	Daytime sleep phenotypes;
KIRP	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.44	5.53	0.33	8.25e-8	Motion sickness;
KIRP	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08805041	chr16:621841	PIGQ	-0.37	-5.12	-0.31	6.13e-7	Height;
KIRP	cis	rs6993770	0.628	rs4734869	chr8:106512828	A/T	cg12797828	chr8:106520928	ZFPM2	-0.33	-4.88	-0.3	1.94e-6	Interleukin-12p70 levels;Plateletcrit;Vascular endothelial growth factor levels;Platelet distribution width;Platelet count;Mean platelet volume;
KIRP	cis	rs909341	0.716	rs71325464	chr20:62363453	A/G	cg03999872	chr20:62272968	STMN3	-0.59	-6.8	-0.4	7.85e-11	Atopic dermatitis;
KIRP	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg14458575	chr2:238380390	NA	0.6	8.06	0.46	3.4e-14	Prostate cancer;
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07256732	chr16:621771	PIGQ	-0.48	-6.68	-0.39	1.57e-10	Height;
KIRP	trans	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.35	-0.38	1.04e-9	Neuroticism;
KIRP	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg01422370	chr2:73384389	NA	0.41	5.43	0.33	1.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.72	-9.86	-0.53	1.58e-19	Late-onset Alzheimer's disease;
KIRP	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.99	10.28	0.55	7.37e-21	Eosinophilic esophagitis;
KIRP	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg16309518	chr5:176445507	NA	-0.88	-13.79	-0.66	2.04e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs6725041	0.547	rs6753945	chr2:213204574	T/C	cg16329650	chr2:213403929	ERBB4	-0.39	-5.01	-0.3	1.03e-6	QT interval (ambient particulate matter interaction);
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg16096096	chr2:64246349	VPS54	-0.47	-6.23	-0.37	2.06e-9	Blood metabolite levels;
KIRP	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.51	6.27	0.37	1.65e-9	Menopause (age at onset);
KIRP	cis	rs7870753	0.838	rs7865488	chr9:99244581	C/A	cg25260653	chr9:99212216	HABP4	0.49	4.85	0.3	2.18e-6	Height;
KIRP	cis	rs7301016	0.846	rs11174575	chr12:63026392	G/A	cg01804193	chr12:63026212	NA	0.59	6.35	0.38	1.04e-9	IgG glycosylation;
KIRP	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg03146154	chr1:46216737	IPP	0.56	5.93	0.35	1.04e-8	Platelet count;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg09960727	chr20:39765952	PLCG1	-0.58	-6.4	-0.38	7.91e-10	Menopause (age at onset);
KIRP	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg18944383	chr4:111397179	ENPEP	0.44	7.05	0.41	1.77e-11	Coronary artery disease;
KIRP	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg18306943	chr3:40428807	ENTPD3	0.43	5.94	0.35	9.7e-9	Renal cell carcinoma;
KIRP	cis	rs5752326	0.558	rs4822727	chr22:26889564	C/T	cg20819150	chr22:26891497	TFIP11	0.57	5.32	0.32	2.36e-7	Ischemic stroke;
KIRP	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.83	9.94	0.54	8.42e-20	Post bronchodilator FEV1;
KIRP	cis	rs4965006	1.000	rs4965006	chr12:132419533	A/G	cg00588090	chr12:132412438	PUS1	-0.61	-6.38	-0.38	8.76e-10	Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs78369473	1.000	rs72832048	chr16:81863031	C/G	cg06838028	chr22:41604442	L3MBTL2	1.11	6.25	0.37	1.81e-9	Stem cell factor levels;
KIRP	cis	rs490234	0.783	rs4838278	chr9:128403509	T/C	cg14078157	chr9:128172775	NA	-0.56	-6.5	-0.38	4.48e-10	Mean arterial pressure;
KIRP	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	8.5	0.48	1.85e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-11.84	-0.6	6.64e-26	Chronic sinus infection;
KIRP	cis	rs7721647	0.821	rs1661037	chr5:90838345	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.19	0.31	4.51e-7	Breast cancer;
KIRP	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.67	8.12	0.46	2.32e-14	Pancreatic cancer;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06419771	chr15:42264912	EHD4	-0.54	-6.93	-0.4	3.61e-11	Neuroticism;
KIRP	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.64	10.78	0.57	1.98e-22	Lung cancer;
KIRP	cis	rs2882667	1.000	rs2060222	chr5:138308466	C/T	cg04439458	chr5:138467593	SIL1	-0.45	-6.99	-0.41	2.52e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08439880	chr3:133502540	NA	-0.57	-7.06	-0.41	1.72e-11	Iron status biomarkers;
KIRP	cis	rs4356932	1.000	rs10017657	chr4:76985178	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg01629716	chr15:45996671	NA	0.37	6.69	0.39	1.52e-10	Waist circumference;Weight;
KIRP	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.87	13.21	0.64	1.81e-30	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs12282928	0.959	rs1109905	chr11:48284000	T/C	cg26585981	chr11:48327164	OR4S1	-0.5	-6.05	-0.36	5.27e-9	Migraine - clinic-based;
KIRP	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.57	-8.6	-0.48	9.41e-16	Coronary artery disease;
KIRP	trans	rs7824557	0.505	rs4841504	chr8:11024663	C/A	cg15556689	chr8:8085844	FLJ10661	-0.68	-9.51	-0.52	1.78e-18	Retinal vascular caliber;
KIRP	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs10761482	0.500	rs10821779	chr10:62274525	A/G	cg01186212	chr10:62110162	ANK3	-0.31	-5.25	-0.32	3.3e-7	Schizophrenia;
KIRP	cis	rs6893300	0.785	rs12522263	chr5:179176692	T/A	cg14593053	chr5:179126677	CANX	-0.57	-7.03	-0.41	2.06e-11	Resting heart rate;
KIRP	cis	rs2976388	0.935	rs2920284	chr8:143756919	A/G	cg17252645	chr8:143867129	LY6D	-0.3	-4.86	-0.3	2.08e-6	Urinary tract infection frequency;
KIRP	cis	rs997295	1.000	rs4363822	chr15:67992583	A/G	cg14210607	chr15:68128175	NA	-0.3	-4.98	-0.3	1.18e-6	Motion sickness;
KIRP	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg01200585	chr1:228362443	C1orf69	0.51	6.55	0.39	3.42e-10	Diastolic blood pressure;
KIRP	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg08280861	chr8:58055591	NA	0.67	6.12	0.36	3.62e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg12549451	chr6:135224345	NA	0.41	5.02	0.3	9.89e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs3779635	0.904	rs750539	chr8:27275794	T/C	cg23736307	chr8:27182930	PTK2B	0.48	6.05	0.36	5.35e-9	Neuroticism;
KIRP	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.35	0.32	1.98e-7	Coronary artery disease;
KIRP	cis	rs2279817	0.780	rs77072467	chr1:17979675	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-7.82	-0.45	1.56e-13	Neuroticism;
KIRP	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06998765	chr14:75389618	RPS6KL1	0.27	5.33	0.32	2.24e-7	Caffeine consumption;
KIRP	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg01025720	chr13:113346439	ATP11A	0.52	5.02	0.31	9.76e-7	Glycated hemoglobin levels;
KIRP	cis	rs9488822	0.676	rs3798227	chr6:116324898	A/G	cg05304507	chr6:116381966	FRK	0.22	5.92	0.35	1.05e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1978968	1.000	rs5992926	chr22:18449876	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.74	-0.4	1.09e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg00792783	chr2:198669748	PLCL1	0.45	5.07	0.31	7.87e-7	Dermatomyositis;
KIRP	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.81	10.88	0.57	9.2e-23	Aortic root size;
KIRP	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg07645718	chr20:61493192	TCFL5	0.76	6.14	0.36	3.35e-9	Obesity-related traits;
KIRP	cis	rs10911232	0.526	rs41475048	chr1:183058452	C/T	cg12689670	chr1:183009347	LAMC1	-0.56	-6.12	-0.36	3.59e-9	Hypertriglyceridemia;
KIRP	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg02807482	chr3:125708958	NA	-0.49	-5.39	-0.32	1.68e-7	Blood pressure (smoking interaction);
KIRP	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg07701084	chr6:150067640	NUP43	0.55	7.07	0.41	1.58e-11	Lung cancer;
KIRP	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg11987759	chr7:65425863	GUSB	-0.58	-7.99	-0.45	5.29e-14	Calcium levels;
KIRP	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg21360079	chr12:107162445	NA	-0.68	-9.52	-0.52	1.73e-18	Heart rate;
KIRP	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.8	-10.89	-0.57	8.67e-23	Total body bone mineral density;
KIRP	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.87	9.04	0.5	4.85e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg27141850	chr2:20869434	GDF7	0.29	5.0	0.3	1.07e-6	Abdominal aortic aneurysm;
KIRP	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-6.08	-0.36	4.67e-9	Colorectal cancer;
KIRP	cis	rs1620921	0.783	rs1782618	chr6:161230368	A/G	cg01280913	chr6:161186852	NA	-0.38	-5.32	-0.32	2.32e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21016266	chr12:122356598	WDR66	0.46	6.26	0.37	1.7e-9	Mean corpuscular volume;
KIRP	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.65	9.25	0.51	1.11e-17	Anterior chamber depth;
KIRP	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg04935436	chr20:30431758	NA	0.46	5.84	0.35	1.67e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg16486109	chr11:613632	IRF7	0.43	5.18	0.31	4.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg13256891	chr4:100009986	ADH5	0.53	6.66	0.39	1.82e-10	Alcohol dependence;
KIRP	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.82	10.2	0.55	1.36e-20	Corneal astigmatism;
KIRP	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-5.63	-0.34	4.83e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg16988262	chr1:15930761	NA	0.39	5.16	0.31	5.1e-7	Systolic blood pressure;
KIRP	cis	rs1983891	0.865	rs10947980	chr6:41525739	A/G	cg20194872	chr6:41519635	FOXP4	0.46	5.67	0.34	4.02e-8	Prostate cancer;
KIRP	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg09408571	chr1:101003634	GPR88	0.23	5.2	0.31	4.21e-7	Monocyte count;
KIRP	trans	rs2302464	1.000	rs28396343	chr4:15556045	G/A	cg09847882	chr11:128812978	TP53AIP1	0.45	6.23	0.37	2.05e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg25703541	chr22:24373054	LOC391322	-0.65	-9.16	-0.5	2.08e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.5	-5.41	-0.33	1.53e-7	Serum thyroid-stimulating hormone levels;
KIRP	cis	rs7224685	0.906	rs2278524	chr17:4081975	A/G	cg11204139	chr17:3907470	NA	-0.56	-6.84	-0.4	6.28e-11	Type 2 diabetes;
KIRP	cis	rs4950322	0.542	rs72692942	chr1:146790180	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg06115741	chr20:33292138	TP53INP2	0.4	5.31	0.32	2.39e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs10899021	0.920	rs11236181	chr11:74345823	A/C	cg25880958	chr11:74394337	NA	-0.5	-5.04	-0.31	8.93e-7	Response to metformin (IC50);
KIRP	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.53	8.74	0.49	3.73e-16	Rheumatoid arthritis;
KIRP	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs16936870	0.571	rs7815798	chr8:71232887	C/G	cg14232793	chr8:71155543	NCOA2	0.56	6.47	0.38	5.27e-10	QT interval;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18500431	chr7:1709489	NA	0.52	6.56	0.39	3.24e-10	Smoking initiation;
KIRP	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.74	9.33	0.51	6.23e-18	Coronary artery disease;
KIRP	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17502267	chr15:59981239	BNIP2	0.46	6.3	0.37	1.37e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.54	-0.38	3.55e-10	Blood pressure;
KIRP	cis	rs6442310	0.534	rs2028759	chr3:12418612	C/T	cg02700894	chr3:12045449	SYN2	0.45	6.25	0.37	1.81e-9	Hematocrit;
KIRP	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.15	0.37	3.09e-9	Ovarian reserve;
KIRP	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.01	0.5	5.79e-17	Alzheimer's disease;
KIRP	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg13482628	chr17:19912719	NA	-0.53	-7.02	-0.41	2.17e-11	Schizophrenia;
KIRP	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.43	-6.22	-0.37	2.13e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg13010199	chr12:38710504	ALG10B	0.63	7.84	0.45	1.38e-13	Morning vs. evening chronotype;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05573182	chr20:39318437	MAFB	0.55	6.49	0.38	4.78e-10	Smoking initiation;
KIRP	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08280861	chr8:58055591	NA	0.7	5.92	0.35	1.07e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg12560992	chr17:57184187	TRIM37	0.63	6.74	0.39	1.13e-10	Testicular germ cell tumor;
KIRP	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.55	-0.33	7.44e-8	Depression;
KIRP	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-4.97	-0.3	1.23e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-8.59	-0.48	1.02e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.45	10.15	0.54	1.94e-20	Alzheimer's disease (late onset);
KIRP	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg24881330	chr22:46731750	TRMU	0.65	4.93	0.3	1.48e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg00343986	chr7:65444356	GUSB	-0.39	-4.86	-0.3	2.12e-6	Aortic root size;
KIRP	cis	rs3112255	0.512	rs11123842	chr2:101337982	A/G	cg01042948	chr2:101319752	NA	-0.35	-4.9	-0.3	1.75e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	1.18	10.78	0.57	1.95e-22	Gout;Renal underexcretion gout;
KIRP	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.79	8.08	0.46	2.95e-14	Hip geometry;
KIRP	cis	rs7116495	0.609	rs7113520	chr11:71691946	G/A	cg18441811	chr11:71824068	C11orf51	-0.83	-5.58	-0.34	6.41e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.38	-7.38	-0.43	2.49e-12	Monocyte percentage of white cells;
KIRP	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-7.57	-0.43	7.55e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	8.72	0.49	4.26e-16	Coronary artery disease;
KIRP	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-4.86	-0.3	2.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8523	0.901	rs2295602	chr6:11005842	A/G	cg13562911	chr6:11044106	ELOVL2	0.43	5.69	0.34	3.55e-8	Red blood cell fatty acid levels;
KIRP	cis	rs4954585	0.683	rs11678502	chr2:136994454	C/T	cg05194412	chr2:137003533	NA	0.54	7.39	0.43	2.23e-12	Colorectal cancer;
KIRP	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.75	6.19	0.37	2.44e-9	Diabetic retinopathy;
KIRP	cis	rs7246657	0.722	rs11083432	chr19:38182633	A/G	cg23950597	chr19:37808831	NA	0.48	5.38	0.32	1.75e-7	Coronary artery calcification;
KIRP	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27297192	chr10:134578999	INPP5A	0.59	7.26	0.42	5.17e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9921338	1.000	rs8055427	chr16:11436883	T/A	cg00044050	chr16:11439710	C16orf75	-0.54	-5.77	-0.35	2.35e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9596863	1.000	rs7328970	chr13:54424225	G/C	ch.13.53330881F	chr13:54432880	NA	-0.52	-5.64	-0.34	4.68e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg19468946	chr17:37922297	IKZF3	-0.41	-5.38	-0.32	1.75e-7	Asthma;
KIRP	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.51	7.07	0.41	1.57e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs7927997	0.931	rs7926914	chr11:76301255	G/T	cg17647271	chr11:76299819	NA	-0.37	-4.99	-0.3	1.14e-6	Gut microbiota (functional units);Crohn's disease;
KIRP	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg15488143	chr7:128924101	AHCYL2	0.63	6.75	0.4	1.08e-10	White matter hyperintensity burden;
KIRP	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs6456042	0.893	rs1056053	chr6:166571443	C/T	cg11088901	chr6:166572345	T	-0.34	-4.95	-0.3	1.39e-6	Asthma;
KIRP	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.4	3.46e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs5167	0.505	rs7257468	chr19:45453144	C/T	cg20090143	chr19:45452003	APOC2	0.34	5.42	0.33	1.41e-7	Blood protein levels;
KIRP	cis	rs3736485	0.966	rs4144941	chr15:51796806	A/G	cg14296394	chr15:51910925	DMXL2	-0.35	-5.11	-0.31	6.62e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-5.55	-0.33	7.29e-8	Schizophrenia;
KIRP	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg07338119	chr7:157211683	NA	-0.47	-6.08	-0.36	4.63e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	0.93	14.39	0.68	1.73e-34	Breast cancer;
KIRP	cis	rs877282	0.755	rs2486578	chr10:785227	C/T	cg17470449	chr10:769945	NA	-0.57	-6.06	-0.36	5.09e-9	Uric acid levels;
KIRP	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.82	7.42	0.43	1.85e-12	Obesity-related traits;
KIRP	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg01849789	chr22:41697279	ZC3H7B	-0.45	-5.34	-0.32	2.06e-7	Neuroticism;
KIRP	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.93	13.52	0.65	1.67e-31	Bladder cancer;
KIRP	cis	rs151997	1.000	rs152854	chr5:50223206	G/A	cg06027927	chr5:50259733	NA	-0.61	-7.65	-0.44	4.63e-13	Callous-unemotional behaviour;
KIRP	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.57	7.41	0.43	2.04e-12	Breast cancer;
KIRP	cis	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg27487796	chr7:28973253	NA	-0.23	-5.2	-0.31	4.2e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs3931020	0.508	rs11485298	chr1:75217752	C/T	cg26855724	chr1:75198818	TYW3;CRYZ	0.44	5.46	0.33	1.16e-7	Resistin levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01154392	chr12:48167362	SLC48A1	-0.57	-6.36	-0.38	9.83e-10	Menopause (age at onset);
KIRP	cis	rs793571	0.590	rs347115	chr15:59082959	C/T	cg05156742	chr15:59063176	FAM63B	0.61	7.72	0.44	2.85e-13	Schizophrenia;
KIRP	cis	rs7103411	0.637	rs7116850	chr11:27645530	C/T	cg18117895	chr11:27722066	BDNF	-0.42	-4.95	-0.3	1.36e-6	Menarche (age at onset);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	12.31	0.62	1.89e-27	Menarche (age at onset);
KIRP	trans	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg06521331	chr12:34319734	NA	-0.52	-6.41	-0.38	7.47e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.85	-10.78	-0.57	1.85e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.17	-0.42	8.51e-12	Bone mineral density;
KIRP	cis	rs7010267	0.740	rs1905786	chr8:119951692	T/C	cg13268132	chr8:119964037	TNFRSF11B	0.39	4.93	0.3	1.55e-6	Total body bone mineral density (age 45-60);
KIRP	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg16497661	chr14:103986332	CKB	-0.4	-5.34	-0.32	2.1e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.7	8.48	0.48	2.12e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.31	-0.32	2.41e-7	Menarche (age at onset);
KIRP	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg13736514	chr6:26305472	NA	0.5	6.3	0.37	1.38e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.83	-7.12	-0.41	1.17e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.08	-13.49	-0.65	2.11e-31	Exhaled nitric oxide output;
KIRP	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	8.06	0.46	3.37e-14	Mood instability;
KIRP	cis	rs10875746	0.669	rs10875792	chr12:48697423	T/A	cg26205652	chr12:48591994	NA	0.79	9.88	0.53	1.3e-19	Longevity (90 years and older);
KIRP	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg01879757	chr17:41196368	BRCA1	-0.77	-10.62	-0.56	6.15e-22	Menopause (age at onset);
KIRP	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.6	7.25	0.42	5.48e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg00656387	chr3:40428638	ENTPD3	-0.38	-5.18	-0.31	4.7e-7	Renal cell carcinoma;
KIRP	cis	rs8067354	0.645	rs1874548	chr17:57841357	A/G	cg02344993	chr17:57696989	CLTC	0.56	5.01	0.3	1.06e-6	Hemoglobin concentration;
KIRP	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg07862535	chr7:139043722	LUC7L2	0.48	5.39	0.32	1.66e-7	Diisocyanate-induced asthma;
KIRP	trans	rs9409565	0.762	rs60964095	chr9:97175774	G/T	cg05679027	chr9:99775184	HIATL2	-0.57	-6.92	-0.4	3.85e-11	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.65	8.83	0.49	1.96e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.02	0.75	7.41e-47	Chronic sinus infection;
KIRP	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg18171855	chr10:2543474	NA	0.38	4.92	0.3	1.61e-6	Age-related hearing impairment;
KIRP	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg27426351	chr10:43362370	NA	0.37	5.29	0.32	2.64e-7	Blood protein levels;
KIRP	cis	rs9478638	0.507	rs2184406	chr6:155629678	T/C	cg07943832	chr6:155568918	TIAM2	-0.46	-6.56	-0.39	3.21e-10	Electroencephalogram traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11708118	chr12:6862968	MLF2	0.48	6.37	0.38	9.16e-10	Parkinson's disease;
KIRP	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.86	10.76	0.57	2.24e-22	Platelet distribution width;
KIRP	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.99	-0.69	1.56e-36	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg20102397	chr11:73019677	ARHGEF17	-0.49	-6.41	-0.38	7.46e-10	Metabolic traits;
KIRP	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.47	-7.03	-0.41	2.08e-11	Neuroticism;
KIRP	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	0.73	10.67	0.56	4.41e-22	Prudent dietary pattern;
KIRP	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.38	-4.87	-0.3	1.98e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.58	-11.9	-0.6	4.31e-26	Gout;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg25637520	chr19:5043247	KDM4B	0.49	6.07	0.36	4.77e-9	Interleukin-4 levels;
KIRP	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg17145862	chr1:211918768	LPGAT1	-0.92	-13.45	-0.65	2.73e-31	Leprosy;
KIRP	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg18478394	chr8:109455254	TTC35	0.48	5.95	0.35	8.93e-9	Dupuytren's disease;
KIRP	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg08283408	chr3:49949060	MON1A	-0.35	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9469913	0.740	rs2092344	chr6:34570922	G/C	cg14254433	chr6:34482411	PACSIN1	-0.44	-5.35	-0.32	2.03e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00629928	chr5:358741	AHRR	0.47	5.04	0.31	9.05e-7	Breast cancer;
KIRP	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.48	0.38	5.07e-10	Platelet count;
KIRP	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg08499158	chr17:42289980	UBTF	-0.51	-6.5	-0.38	4.39e-10	Total body bone mineral density;
KIRP	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg25730555	chr22:47059586	GRAMD4	0.49	5.85	0.35	1.56e-8	Urate levels in obese individuals;
KIRP	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.58	-8.13	-0.46	2.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.43	-6.87	-0.4	5.11e-11	Eye color traits;
KIRP	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg03834567	chr2:218808745	TNS1	0.42	5.28	0.32	2.82e-7	Ulcerative colitis;
KIRP	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.21	16.44	0.72	1.79e-41	Lymphocyte percentage of white cells;
KIRP	cis	rs8060686	0.858	rs13334918	chr16:67901343	A/G	cg04539111	chr16:67997858	SLC12A4	-0.45	-5.21	-0.32	4.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg26441486	chr22:50317300	CRELD2	0.5	7.18	0.42	8.23e-12	Schizophrenia;
KIRP	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg18132916	chr6:79620363	NA	-0.4	-5.5	-0.33	9.45e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1891275	0.515	rs7092884	chr10:93483872	A/C	cg07889827	chr10:93443413	NA	0.43	7.33	0.42	3.3e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg00933542	chr6:150070202	PCMT1	0.26	4.98	0.3	1.2e-6	Lung cancer;
KIRP	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25072359	chr17:41440525	NA	0.46	6.18	0.37	2.66e-9	Menopause (age at onset);
KIRP	cis	rs6693567	0.565	rs10157197	chr1:150250636	G/A	cg07843065	chr1:150265600	MRPS21	-0.4	-5.57	-0.33	6.81e-8	Migraine;
KIRP	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg18882449	chr10:104885122	NT5C2	-0.38	-4.98	-0.3	1.19e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-7.69	-0.44	3.46e-13	Pancreatic cancer;
KIRP	cis	rs500492	0.542	rs400354	chr16:1074526	T/G	cg03495660	chr16:1074500	NA	0.54	5.91	0.35	1.11e-8	Polycystic ovary syndrome;
KIRP	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg23950597	chr19:37808831	NA	-0.64	-6.86	-0.4	5.43e-11	Coronary artery calcification;
KIRP	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg25173405	chr17:45401733	C17orf57	0.44	5.66	0.34	4.21e-8	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4936894	0.500	rs12577620	chr11:124101649	T/C	cg27160556	chr11:124181099	OR8D1	-0.44	-6.47	-0.38	5.33e-10	Aging (time to death);
KIRP	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-0.78	-9.26	-0.51	1.03e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg06636001	chr8:8085503	FLJ10661	0.56	6.52	0.38	4.04e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.75	11.38	0.59	2.17e-24	Hip circumference;
KIRP	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.99	-15.84	-0.71	1.98e-39	Primary sclerosing cholangitis;
KIRP	cis	rs6832769	1.000	rs28572116	chr4:56424344	A/T	cg09317128	chr4:56265301	TMEM165	-0.55	-7.03	-0.41	2.03e-11	Personality dimensions;
KIRP	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	1.06	17.98	0.75	9.98e-47	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg09699651	chr6:150184138	LRP11	0.46	5.95	0.35	9.27e-9	Lung cancer;
KIRP	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg23533419	chr12:54090519	NA	-0.32	-5.13	-0.31	5.78e-7	Height;
KIRP	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.87e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg27411982	chr8:10470053	RP1L1	-0.39	-5.18	-0.31	4.71e-7	Neuroticism;
KIRP	cis	rs112427907	1	rs112427907	chr3:47995270	G/A	cg04507495	chr3:47563649	NA	1.13	5.77	0.35	2.35e-8	Stem cell growth factor beta levels;
KIRP	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg11645453	chr3:52864694	ITIH4	0.36	5.06	0.31	8.18e-7	Bipolar disorder;
KIRP	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.89	0.53	1.22e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.52	-7.29	-0.42	4.11e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg00603274	chr11:61596626	FADS2	-0.62	-5.9	-0.35	1.21e-8	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs12725198	1.000	rs12725198	chr1:16080171	A/G	cg18133145	chr1:16060689	PLEKHM2	0.59	6.48	0.38	4.85e-10	Cardiac Troponin-T levels;
KIRP	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg18451016	chr1:38461880	NA	0.37	5.18	0.31	4.61e-7	Coronary artery disease;
KIRP	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg26373071	chr5:1325741	CLPTM1L	0.47	6.6	0.39	2.45e-10	Lung cancer;
KIRP	cis	rs2299587	0.932	rs7837060	chr8:17810141	T/C	cg01800426	chr8:17659068	MTUS1	-0.43	-5.21	-0.32	4.01e-7	Economic and political preferences;
KIRP	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.09	-0.5	3.39e-17	Retinal vascular caliber;
KIRP	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg18016565	chr1:150552671	MCL1	0.37	5.63	0.34	4.85e-8	Melanoma;
KIRP	cis	rs1950626	0.716	rs34158896	chr14:101447373	T/C	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.63	6.89	0.4	4.67e-11	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg06521331	chr12:34319734	NA	-0.59	-7.22	-0.42	6.65e-12	Bladder cancer;
KIRP	cis	rs16976116	0.704	rs7183895	chr15:55513712	G/A	cg11288833	chr15:55489084	RSL24D1	0.48	5.55	0.33	7.28e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	9.39	0.51	4.31e-18	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	1.1	8.14	0.46	1.92e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.78	11.5	0.59	8.7e-25	Total body bone mineral density;
KIRP	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	1.0	8.98	0.5	7.28e-17	Systolic blood pressure;
KIRP	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.98	13.57	0.65	1.12e-31	Menopause (age at onset);
KIRP	cis	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg18131467	chr2:239335373	ASB1	-0.74	-6.01	-0.36	6.53e-9	Lung function (FEV1/FVC);
KIRP	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg05361325	chr10:32636312	EPC1	-0.67	-6.39	-0.38	8.44e-10	Sexual dysfunction (female);
KIRP	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg24826892	chr11:71159390	DHCR7	0.43	5.13	0.31	6.01e-7	Vitamin D levels;
KIRP	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg19847130	chr8:10466454	RP1L1	0.35	5.19	0.31	4.36e-7	Neuroticism;
KIRP	cis	rs830383	0.584	rs31772	chr5:165495408	C/T	cg13976338	chr5:165423657	NA	0.54	7.05	0.41	1.79e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.7	7.78	0.44	1.96e-13	Obesity-related traits;
KIRP	cis	rs10267417	0.527	rs118003052	chr7:19942818	A/G	cg05791153	chr7:19748676	TWISTNB	0.5	4.96	0.3	1.33e-6	Night sleep phenotypes;
KIRP	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg27205649	chr11:78285834	NARS2	0.62	7.38	0.43	2.44e-12	Alzheimer's disease (survival time);
KIRP	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg05370193	chr1:21551575	ECE1	0.43	6.09	0.36	4.29e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg23978390	chr7:1156363	C7orf50	0.47	6.16	0.37	2.94e-9	Longevity;Endometriosis;
KIRP	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.77	11.76	0.6	1.21e-25	Hip circumference;
KIRP	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg00204512	chr16:28754710	NA	0.41	5.26	0.32	3.08e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-8.86	-0.49	1.64e-16	Platelet count;
KIRP	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.59	7.28	0.42	4.37e-12	Lymphocyte counts;
KIRP	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.85	11.73	0.6	1.62e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.91	14.4	0.68	1.62e-34	Dental caries;
KIRP	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.6	-8.55	-0.48	1.35e-15	Systemic lupus erythematosus;
KIRP	cis	rs7078219	0.965	rs10883358	chr10:101273857	C/T	cg07044859	chr10:101282883	NA	-0.35	-6.0	-0.36	7.08e-9	Dental caries;
KIRP	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-9.26	-0.51	1.04e-17	Morning vs. evening chronotype;
KIRP	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.59	-5.06	-0.31	8.25e-7	Schizophrenia;
KIRP	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.54	-6.65	-0.39	1.83e-10	Metabolite levels;
KIRP	cis	rs59227481	1	rs59227481	chr12:110007993	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.44	-6.52	-0.38	4e-10	Age-related nuclear cataracts;
KIRP	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg13798780	chr7:105162888	PUS7	0.65	5.89	0.35	1.26e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.59	-6.45	-0.38	5.81e-10	Aortic root size;
KIRP	trans	rs6810798	0.695	rs2562874	chr4:148254264	C/G	cg13149281	chr14:23389818	RBM23;PRMT5	0.52	6.28	0.37	1.56e-9	Coronary artery disease;
KIRP	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.48	7.34	0.42	3.09e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06937024	chr6:35695489	FKBP5;LOC285847	0.47	6.14	0.36	3.22e-9	Parkinson's disease;
KIRP	cis	rs6732160	0.588	rs62151795	chr2:73376840	G/A	cg01422370	chr2:73384389	NA	0.51	6.9	0.4	4.39e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg21775007	chr8:11205619	TDH	-0.43	-5.39	-0.32	1.66e-7	Triglycerides;
KIRP	cis	rs7113874	0.802	rs10128597	chr11:8694830	G/A	cg08015107	chr11:8618950	NA	-0.48	-6.22	-0.37	2.08e-9	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-9.93	-0.54	9.09e-20	Hemoglobin concentration;
KIRP	cis	rs2594989	0.733	rs2616538	chr3:11581076	G/T	cg01796438	chr3:11312864	ATG7	-0.42	-5.54	-0.33	7.8e-8	Circulating chemerin levels;
KIRP	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.3	-6.16	-0.37	2.93e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs953387	0.910	rs16833335	chr2:136949744	C/T	cg05194412	chr2:137003533	NA	-0.38	-4.98	-0.3	1.19e-6	Arthritis (juvenile idiopathic);
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13939156	chr17:80058883	NA	0.5	7.51	0.43	1.07e-12	Life satisfaction;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg21523564	chr15:75251491	NA	0.39	6.29	0.37	1.46e-9	Breast cancer;
KIRP	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg26513180	chr16:89883248	FANCA	0.84	5.61	0.34	5.45e-8	Skin colour saturation;
KIRP	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.69	9.66	0.52	6.22e-19	Mood instability;
KIRP	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg08975724	chr8:8085496	FLJ10661	0.52	6.5	0.38	4.44e-10	Retinal vascular caliber;
KIRP	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.49	6.06	0.36	5.05e-9	Menopause (age at onset);
KIRP	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.71	-6.55	-0.39	3.32e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.77	5.58	0.34	6.23e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.86	9.91	0.53	1.09e-19	Neutrophil percentage of white cells;
KIRP	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg25356066	chr3:128598488	ACAD9	0.52	5.97	0.36	8.35e-9	IgG glycosylation;
KIRP	cis	rs4805834	0.668	rs17272190	chr19:33321775	C/G	cg07201929	chr19:33182834	NUDT19	-0.58	-4.93	-0.3	1.5e-6	Creatinine levels;
KIRP	cis	rs656319	0.638	rs670044	chr8:9892529	G/T	cg27411982	chr8:10470053	RP1L1	0.39	5.02	0.31	9.73e-7	Myopia (pathological);
KIRP	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.75	-0.34	2.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg02297831	chr4:17616191	MED28	0.64	8.11	0.46	2.44e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13198984	chr17:80129470	CCDC57	0.56	8.46	0.47	2.42e-15	Life satisfaction;
KIRP	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs11997175	0.603	rs7386384	chr8:33782471	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.44	0.33	1.27e-7	Body mass index;
KIRP	cis	rs2253017	0.723	rs2818989	chr13:21386851	A/C	cg04906043	chr13:21280425	IL17D	-0.44	-5.17	-0.31	4.76e-7	PR segment;
KIRP	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg03188948	chr7:1209495	NA	0.77	5.43	0.33	1.36e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg17736920	chr1:242011382	EXO1	0.45	5.62	0.34	5.06e-8	Menopause (age at onset);
KIRP	cis	rs7729447	0.776	rs7738037	chr5:32696549	C/T	cg16267343	chr5:32710456	NPR3	0.5	5.85	0.35	1.54e-8	Blood pressure;
KIRP	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.63	-7.98	-0.45	5.42e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs6743226	0.934	rs7604465	chr2:242249828	C/T	cg10021735	chr2:242295487	FARP2	0.5	6.11	0.36	3.96e-9	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs9506514	0.617	rs9509352	chr13:21295149	A/G	cg27499820	chr13:21296301	IL17D	-0.31	-5.08	-0.31	7.29e-7	Coronary artery calcification;
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	trans	rs12043259	0.892	rs4950968	chr1:204823663	G/A	cg11485465	chr5:54518469	NA	0.41	6.42	0.38	6.85e-10	Addiction;
KIRP	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.18	-0.42	8.18e-12	Body mass index;
KIRP	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.91	14.8	0.69	7.19e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4523957	0.928	rs216219	chr17:2147291	T/C	cg16513277	chr17:2031491	SMG6	0.58	7.94	0.45	7.06e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg16606324	chr3:10149918	C3orf24	0.71	5.99	0.36	7.39e-9	Alzheimer's disease;
KIRP	cis	rs78487399	0.908	rs6715003	chr2:43808659	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.7	-0.34	3.42e-8	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg27205649	chr11:78285834	NARS2	-0.54	-5.22	-0.32	3.88e-7	Testicular germ cell tumor;
KIRP	cis	rs11225247	1.000	rs11225247	chr11:102280751	A/C	cg06323957	chr11:102217781	BIRC2	0.9	5.62	0.34	5.17e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs17221829	0.562	rs10830306	chr11:89366979	G/A	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs6882046	0.513	rs1081158	chr5:88004616	C/T	cg22951263	chr5:87985283	NA	-0.46	-6.53	-0.38	3.66e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs2997447	0.846	rs61775431	chr1:26411275	T/G	cg19633962	chr1:26362018	EXTL1	-0.69	-5.76	-0.34	2.48e-8	QRS complex (12-leadsum);
KIRP	cis	rs7829987	0.786	rs13261739	chr8:17456610	C/G	cg25490175	chr8:17104473	VPS37A;CNOT7	0.72	5.12	0.31	6.3e-7	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs2617583	0.509	rs2937650	chr5:1458018	C/T	cg07151155	chr5:1473589	LPCAT1	0.39	4.92	0.3	1.59e-6	Breast cancer;
KIRP	cis	rs6001982	0.584	rs74767555	chr22:40826733	G/A	cg07138101	chr22:40742427	ADSL	0.64	4.93	0.3	1.49e-6	Breast cancer;
KIRP	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.67	9.43	0.52	3.21e-18	Lymphocyte counts;
KIRP	cis	rs5766691	1.000	rs4823597	chr22:47531320	A/G	cg15757745	chr22:47558489	TBC1D22A	0.42	5.18	0.31	4.71e-7	Longevity;
KIRP	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-9.18	-0.51	1.83e-17	Resting heart rate;
KIRP	cis	rs6466055	0.669	rs6948885	chr7:104664879	C/T	cg04380332	chr7:105027541	SRPK2	-0.62	-9.34	-0.51	5.87e-18	Schizophrenia;
KIRP	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.54	-8.09	-0.46	2.73e-14	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.86	10.5	0.56	1.46e-21	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	trans	rs7748513	1.000	rs9471494	chr6:41157344	C/G	cg02259934	chr19:4566484	NA	0.67	6.14	0.36	3.32e-9	C-reactive protein;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10013645	chr10:35501529	CREM	-0.41	-6.04	-0.36	5.75e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7107174	0.688	rs3740677	chr11:77928036	A/C	cg27205649	chr11:78285834	NARS2	-0.47	-5.44	-0.33	1.31e-7	Testicular germ cell tumor;
KIRP	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.77	-11.06	-0.58	2.41e-23	Height;
KIRP	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg07395648	chr5:131743802	NA	-0.57	-7.88	-0.45	1.05e-13	Breast cancer;Mosquito bite size;
KIRP	cis	rs6753739	0.745	rs6751990	chr2:219912295	T/C	cg01749213	chr2:219906749	CCDC108	0.44	5.2	0.31	4.24e-7	Height;
KIRP	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.84	11.76	0.6	1.22e-25	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02912112	chr2:187120710	NA	-0.41	-6.21	-0.37	2.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.9	-15.48	-0.7	3.44e-38	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg21361702	chr7:150065534	REPIN1	0.7	7.35	0.42	2.87e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6496667	0.908	rs76967190	chr15:90856021	A/C	cg10434728	chr15:90938212	IQGAP1	0.36	5.0	0.3	1.08e-6	Rheumatoid arthritis;
KIRP	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg16141378	chr3:129829833	LOC729375	0.62	7.94	0.45	7.1e-14	Neuroticism;
KIRP	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.65	9.48	0.52	2.29e-18	Lymphocyte counts;
KIRP	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg00405596	chr8:11794950	NA	0.59	8.37	0.47	4.45e-15	Neuroticism;
KIRP	cis	rs858239	0.602	rs6953996	chr7:23175946	A/G	cg23682824	chr7:23144976	KLHL7	0.51	5.9	0.35	1.2e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs9534288	0.619	rs6561290	chr13:46682460	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-7.8	-0.45	1.75e-13	Blood protein levels;
KIRP	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.97	15.07	0.69	8.68e-37	Triglycerides;
KIRP	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.47	6.29	0.37	1.48e-9	Breast cancer;
KIRP	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg21775007	chr8:11205619	TDH	-0.39	-5.04	-0.31	9.2e-7	Neuroticism;
KIRP	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg23752985	chr2:85803571	VAMP8	0.46	5.32	0.32	2.34e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.2	13.91	0.66	7.79e-33	Sexual dysfunction (female);
KIRP	cis	rs7113850	0.541	rs7116120	chr11:24235050	A/G	ch.11.24196551F	chr11:24239977	NA	0.86	7.99	0.45	5.31e-14	Bone fracture in osteoporosis;
KIRP	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg15192750	chr16:69999425	NA	0.46	4.9	0.3	1.77e-6	IgE levels;
KIRP	cis	rs687432	0.812	rs35401618	chr11:57851041	A/G	cg19752551	chr11:57585705	CTNND1	-0.69	-8.83	-0.49	1.98e-16	Parkinson's disease;
KIRP	cis	rs72829446	0.530	rs7217492	chr17:7396049	C/G	cg17788227	chr17:7347145	FGF11;CHRNB1	0.47	5.03	0.31	9.42e-7	Androgen levels;
KIRP	cis	rs79565040	1	rs79565040	chr1:8917398	T/TTA	cg06972019	chr1:8937448	ENO1	-0.34	-4.99	-0.3	1.14e-6	White blood cell count (basophil);
KIRP	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.64	-7.55	-0.43	8.74e-13	Menarche (age at onset);
KIRP	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.43	5.22	0.32	3.89e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-9.73	-0.53	3.75e-19	Chronic sinus infection;
KIRP	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.51	11.99	0.61	2.14e-26	Diabetic kidney disease;
KIRP	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg23533926	chr12:111358616	MYL2	-0.53	-7.15	-0.41	9.97e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.52e-7	Tonsillectomy;
KIRP	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.78	0.4	9.11e-11	Menarche (age at onset);
KIRP	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg17470723	chr8:74884337	TCEB1	0.64	8.24	0.47	1.02e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5752326	0.510	rs5761541	chr22:26859465	G/T	cg20819150	chr22:26891497	TFIP11	0.53	4.98	0.3	1.18e-6	Ischemic stroke;
KIRP	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg17554472	chr22:41940697	POLR3H	0.45	5.37	0.32	1.84e-7	Vitiligo;
KIRP	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg08885076	chr2:99613938	TSGA10	-0.68	-12.14	-0.61	6.97e-27	Chronic sinus infection;
KIRP	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg12623918	chr2:306882	NA	0.43	5.3	0.32	2.55e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg23587288	chr2:27483067	SLC30A3	0.54	6.86	0.4	5.67e-11	Blood metabolite levels;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.83	14.72	0.68	1.33e-35	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg10047753	chr17:41438598	NA	-0.83	-11.53	-0.59	6.88e-25	Menopause (age at onset);
KIRP	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.55	5.63	0.34	5.02e-8	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7712401	0.601	rs36099390	chr5:122317719	G/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18252515	chr7:66147081	NA	0.45	5.45	0.33	1.21e-7	Aortic root size;
KIRP	cis	rs62109865	0.655	rs62113561	chr19:12619953	A/G	cg19721055	chr19:12753329	NA	-0.84	-4.95	-0.3	1.39e-6	Antibody status in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4908768	0.657	rs12144099	chr1:8816175	G/A	cg25722041	chr1:8623473	RERE	0.57	7.39	0.43	2.3e-12	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg16606324	chr3:10149918	C3orf24	0.73	6.04	0.36	5.55e-9	Alzheimer's disease;
KIRP	cis	rs58950470	0.521	rs7950197	chr11:65446126	T/C	cg11569703	chr11:65557185	OVOL1	0.34	5.53	0.33	8.25e-8	Schizophrenia;
KIRP	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.65	9.34	0.51	6.11e-18	Retinal vascular caliber;
KIRP	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg06223162	chr1:101003688	GPR88	0.47	9.69	0.53	5.26e-19	Monocyte count;
KIRP	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	cis	rs6466055	0.661	rs6972563	chr7:104842960	T/C	cg04380332	chr7:105027541	SRPK2	0.37	4.96	0.3	1.32e-6	Schizophrenia;
KIRP	cis	rs6546886	0.957	rs4853003	chr2:74248871	A/G	cg14702570	chr2:74259524	NA	-0.33	-6.7	-0.39	1.41e-10	Dialysis-related mortality;
KIRP	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.62	6.13	0.36	3.49e-9	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25345767	chr1:226070210	TMEM63A	0.55	7.1	0.41	1.31e-11	Parkinson's disease;
KIRP	cis	rs2275565	0.872	rs1805087	chr1:237048500	A/G	cg17297354	chr1:237056641	MTR	-0.42	-5.55	-0.33	7.21e-8	Homocysteine levels;
KIRP	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg15128208	chr22:42549153	NA	-0.41	-5.05	-0.31	8.45e-7	Cognitive function;
KIRP	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg20673091	chr1:2541236	MMEL1	-0.67	-10.45	-0.55	2.18e-21	Ulcerative colitis;
KIRP	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.62	-5.45	-0.33	1.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg17554472	chr22:41940697	POLR3H	-0.46	-5.21	-0.32	4.05e-7	Neuroticism;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	13.21	0.64	1.74e-30	Platelet count;
KIRP	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.7	-9.14	-0.5	2.41e-17	Menopause (age at onset);
KIRP	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.16	0.31	5.17e-7	Educational attainment;
KIRP	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg00405596	chr8:11794950	NA	-0.4	-4.98	-0.3	1.2e-6	Systolic blood pressure;
KIRP	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.73	-9.67	-0.52	5.87e-19	Longevity;Endometriosis;
KIRP	cis	rs34779708	0.702	rs35969476	chr10:35544318	G/A	cg03585969	chr10:35415529	CREM	0.61	7.03	0.41	2.02e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.67	9.99	0.54	5.91e-20	Hip circumference;
KIRP	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.41	0.38	7.44e-10	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07089783	chr10:31607955	ZEB1;LOC220930	0.53	7.82	0.45	1.56e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.01	0.71	5.22e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg10495392	chr1:46806563	NSUN4	-0.48	-5.44	-0.33	1.29e-7	Menopause (age at onset);
KIRP	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg02660097	chr11:68866761	NA	0.4	4.97	0.3	1.26e-6	Blond vs. brown hair color;
KIRP	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.48	0.38	4.94e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.54	0.52	1.53e-18	Total body bone mineral density;
KIRP	cis	rs3857747	0.765	rs9718577	chr7:40365512	G/T	cg00420559	chr7:40367873	C7orf10	-0.6	-8.35	-0.47	4.92e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26314531	chr2:26401878	FAM59B	0.47	4.85	0.3	2.16e-6	Gut microbiome composition (summer);
KIRP	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2236918	0.710	rs851781	chr1:242034868	C/T	cg21919602	chr1:242011447	EXO1	-0.47	-5.93	-0.35	1.01e-8	Menopause (age at onset);
KIRP	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg14250997	chr9:106856677	SMC2	0.44	6.22	0.37	2.16e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.23	-6.81	-0.4	7.54e-11	Type 2 diabetes;
KIRP	cis	rs6142102	0.625	rs1883707	chr20:32552587	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-5.74	-0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg21253087	chr9:139290292	SNAPC4	-0.43	-5.62	-0.34	5.28e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs41005	1.000	rs41005	chr2:8111231	A/G	cg03155496	chr2:8117019	LOC339788	-0.57	-9.38	-0.51	4.54e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs311392	0.902	rs419813	chr8:55092385	A/T	cg06042504	chr8:55087323	NA	-0.59	-7.23	-0.42	6.12e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg01879757	chr17:41196368	BRCA1	-0.51	-7.01	-0.41	2.24e-11	Menopause (age at onset);
KIRP	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.77	7.03	0.41	2e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg04132472	chr17:19861366	AKAP10	0.47	6.61	0.39	2.42e-10	Schizophrenia;
KIRP	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg20243544	chr17:37824526	PNMT	0.38	5.07	0.31	7.68e-7	Self-reported allergy;
KIRP	cis	rs78487399	0.808	rs77852659	chr2:43761652	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-4.93	-0.3	1.48e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs2916247	0.954	rs2165905	chr8:93006556	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.63	-8.61	-0.48	8.66e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2806561	0.780	rs12751560	chr1:23407081	C/A	cg19743168	chr1:23544995	NA	-0.49	-6.58	-0.39	2.74e-10	Height;
KIRP	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg07001201	chr5:642380	CEP72	0.69	6.55	0.39	3.4e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs13343954	0.778	rs10425798	chr19:33541539	C/G	cg17764715	chr19:33622953	WDR88	0.69	7.54	0.43	8.85e-13	Colorectal cancer;
KIRP	trans	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg10756647	chr7:56101905	PSPH	0.96	7.24	0.42	5.7e-12	Diabetic kidney disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13369206	chr2:3606108	RNASEH1	0.55	6.85	0.4	6.04e-11	Parkinson's disease;
KIRP	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg10760299	chr15:45669010	GATM	0.35	5.13	0.31	5.76e-7	Homoarginine levels;
KIRP	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	5.28	0.32	2.78e-7	Renal cell carcinoma;
KIRP	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg15448220	chr1:150897856	SETDB1	-0.4	-5.19	-0.31	4.35e-7	Monocyte chemoattractant protein-1 levels;
KIRP	cis	rs12973672	0.904	rs10424619	chr19:35768237	A/T	cg12095397	chr19:35769544	USF2	0.7	6.74	0.4	1.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.68	-9.44	-0.52	2.88e-18	Brugada syndrome;
KIRP	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.89	11.78	0.6	1.06e-25	Orofacial clefts;
KIRP	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.58e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6691722	0.583	rs7532539	chr1:24694427	A/G	cg18323236	chr1:24743029	NIPAL3	0.39	5.52	0.33	8.45e-8	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg08684580	chr7:98029266	BAIAP2L1	-0.31	-4.89	-0.3	1.8e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.71	0.53	4.34e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.3	0.37	1.36e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.79	-9.93	-0.53	9.54e-20	Parkinson's disease;
KIRP	cis	rs78487399	0.808	rs13405076	chr2:43735353	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.06	-0.31	8.28e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs9810890	1.000	rs73207982	chr3:128575430	G/C	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.42e-7	Dental caries;
KIRP	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.46	4.91	0.3	1.65e-6	Type 2 diabetes;
KIRP	cis	rs4704846	0.614	rs6555827	chr5:156492438	C/T	cg12943317	chr5:156479607	HAVCR1	0.59	5.68	0.34	3.88e-8	Blood protein levels;
KIRP	cis	rs6601327	0.635	rs7844461	chr8:9653055	T/A	cg27411982	chr8:10470053	RP1L1	0.41	5.22	0.32	3.76e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs13424612	1.000	rs1465880	chr2:240932326	G/A	cg01812947	chr2:240904978	NDUFA10	0.47	5.93	0.35	1.02e-8	Odorant perception (isobutyraldehyde);
KIRP	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.48	5.86	0.35	1.45e-8	Longevity;
KIRP	cis	rs10214930	0.813	rs961725	chr7:27658070	G/A	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs9914544	0.545	rs4510081	chr17:18798846	A/C	cg26378065	chr17:18585709	ZNF286B	0.38	4.88	0.3	1.94e-6	Educational attainment (years of education);
KIRP	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.62	6.88	0.4	4.82e-11	Crohn's disease;
KIRP	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg16141378	chr3:129829833	LOC729375	0.57	7.81	0.45	1.7e-13	Triglycerides;
KIRP	cis	rs12643440	0.538	rs62296726	chr4:17143914	T/C	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg23736307	chr8:27182930	PTK2B	0.48	6.05	0.36	5.35e-9	Neuroticism;
KIRP	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg17554472	chr22:41940697	POLR3H	0.59	6.41	0.38	7.48e-10	Vitiligo;
KIRP	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.67	-0.34	4.02e-8	Aortic root size;
KIRP	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.87	13.37	0.65	5.1e-31	Menarche (age at onset);
KIRP	cis	rs2505998	1.000	rs2505998	chr10:43570925	A/G	cg15436174	chr10:43711423	RASGEF1A	-0.51	-5.21	-0.32	3.97e-7	Hirschsprung disease;
KIRP	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	15.2	0.7	3.17e-37	Electrocardiographic conduction measures;
KIRP	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22907277	chr7:1156413	C7orf50	0.56	6.98	0.41	2.67e-11	Longevity;Endometriosis;
KIRP	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg10755058	chr3:40428713	ENTPD3	0.34	4.88	0.3	1.9e-6	Renal cell carcinoma;
KIRP	cis	rs7224685	0.569	rs68060817	chr17:3995188	T/C	cg09695851	chr17:3907499	NA	0.54	4.96	0.3	1.31e-6	Type 2 diabetes;
KIRP	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.92	14.9	0.69	3.12e-36	Intelligence (multi-trait analysis);
KIRP	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.7e-10	Red blood cell count;
KIRP	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg05775895	chr3:12838266	CAND2	0.45	7.44	0.43	1.68e-12	QRS complex (12-leadsum);
KIRP	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg09904177	chr6:26538194	HMGN4	0.66	9.57	0.52	1.23e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs76917914	0.820	rs7020081	chr9:100823360	C/A	cg03040243	chr9:100819229	NANS	0.63	6.81	0.4	7.41e-11	Immature fraction of reticulocytes;
KIRP	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.09	-19.0	-0.77	3.6e-50	Triglycerides;
KIRP	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.58	7.22	0.42	6.44e-12	Breast cancer;
KIRP	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.34	5.35	0.32	2.06e-7	Asthma;
KIRP	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.87	14.07	0.67	2.2e-33	Breast cancer;
KIRP	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.53	7.1	0.41	1.31e-11	HDL cholesterol;
KIRP	cis	rs7215564	0.908	rs4536520	chr17:78660239	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg10541930	chr10:131909085	NA	0.48	6.51	0.38	4.19e-10	Cancer;
KIRP	cis	rs4927850	0.666	rs4927853	chr3:195752053	G/C	cg01181863	chr3:195395398	SDHAP2	-0.8	-9.13	-0.5	2.6e-17	Pancreatic cancer;
KIRP	trans	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.19	-0.42	7.63e-12	Bladder cancer;
KIRP	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.67	7.69	0.44	3.53e-13	Corneal astigmatism;
KIRP	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.53	6.9	0.4	4.37e-11	HDL cholesterol;
KIRP	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.41	5.48	0.33	1.04e-7	Hypertriglyceridemia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12536527	chr7:81637024	CACNA2D1	-0.45	-6.75	-0.4	1.03e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12643440	0.538	rs62296722	chr4:17140970	T/G	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.67	-9.27	-0.51	9.92e-18	Rheumatoid arthritis;
KIRP	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-8.05	-0.46	3.52e-14	Triglycerides;
KIRP	cis	rs241257	0.621	rs241271	chr1:4626255	T/C	cg11735846	chr1:4770935	AJAP1	-0.4	-6.07	-0.36	4.81e-9	Anxiety disorder;
KIRP	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.88	12.59	0.63	2.22e-28	Mean platelet volume;
KIRP	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	11.46	0.59	1.17e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg03146154	chr1:46216737	IPP	-0.47	-6.19	-0.37	2.5e-9	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.49	-6.92	-0.4	3.84e-11	Height;
KIRP	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.5	-0.43	1.17e-12	Morning vs. evening chronotype;
KIRP	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-7.98	-0.45	5.51e-14	Bone mineral density;
KIRP	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-16.01	-0.71	5.21e-40	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07463429	chr12:70133063	RAB3IP	0.55	6.86	0.4	5.7e-11	Parkinson's disease;
KIRP	cis	rs4654899	0.865	rs10493006	chr1:21375904	G/A	cg05370193	chr1:21551575	ECE1	0.46	5.88	0.35	1.36e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg00507259	chr4:95128692	SMARCAD1	0.42	5.34	0.32	2.13e-7	QT interval;
KIRP	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	1.15	14.89	0.69	3.57e-36	Response to hepatitis C treatment;
KIRP	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.68	-0.53	5.44e-19	Exhaled nitric oxide output;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg10553028	chr3:32280480	CMTM8	0.57	7.33	0.42	3.31e-12	Educational attainment;
KIRP	cis	rs3134353	0.704	rs2386921	chr8:101975378	C/T	cg07585502	chr8:101912084	NA	0.43	5.5	0.33	9.45e-8	Body mass index;
KIRP	cis	rs7116495	1.000	rs677279	chr11:71770469	G/A	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-5.84	-0.35	1.65e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6691722	0.506	rs11587667	chr1:24715435	C/G	cg18323236	chr1:24743029	NIPAL3	0.52	7.55	0.43	8.65e-13	Response to interferon beta in multiple sclerosis;
KIRP	cis	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg07460842	chr6:66804631	NA	0.48	5.76	0.34	2.5e-8	Metabolite levels;
KIRP	cis	rs2014572	0.967	rs7248000	chr19:57762139	C/T	cg12963866	chr19:57752005	ZNF805	-0.49	-6.16	-0.37	2.87e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg16586182	chr3:47516702	SCAP	0.69	9.3	0.51	7.72e-18	Colorectal cancer;
KIRP	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.81	-11.61	-0.6	3.8e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	1.06	22.62	0.82	5.02e-62	Parkinson's disease;
KIRP	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.03	11.6	0.59	4.19e-25	Cannabis dependence symptom count;
KIRP	cis	rs7224685	0.501	rs781839	chr17:3961489	C/T	cg09597638	chr17:3907349	NA	0.74	14.02	0.67	3.17e-33	Type 2 diabetes;
KIRP	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg13482628	chr17:19912719	NA	0.57	8.02	0.46	4.34e-14	Schizophrenia;
KIRP	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg06671706	chr8:8559999	CLDN23	0.51	6.04	0.36	5.65e-9	Obesity-related traits;
KIRP	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.59	-7.2	-0.42	7.35e-12	Red cell distribution width;
KIRP	trans	rs2997105	1.000	rs11839457	chr13:56345359	C/T	cg08528735	chr3:184428879	MAGEF1	0.55	6.2	0.37	2.36e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00149659	chr3:10157352	C3orf10	0.56	6.79	0.4	8.24e-11	Alzheimer's disease;
KIRP	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.6	6.7	0.39	1.38e-10	Aortic root size;
KIRP	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg20887711	chr4:1340912	KIAA1530	0.45	5.51	0.33	9.09e-8	Longevity;
KIRP	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.5	6.61	0.39	2.32e-10	Schizophrenia;
KIRP	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.79	6.87	0.4	5.26e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg24060327	chr5:131705240	SLC22A5	0.7	6.93	0.4	3.7e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs4631830	0.540	rs4935090	chr10:51491125	A/T	cg10326726	chr10:51549505	MSMB	0.54	7.34	0.42	3.03e-12	Prostate-specific antigen levels;
KIRP	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.19	0.42	7.89e-12	Lung cancer;
KIRP	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.88	13.49	0.65	2.11e-31	Ulcerative colitis;
KIRP	cis	rs7212590	0.655	rs8072050	chr17:58010972	G/A	cg10252138	chr17:58120427	NA	-0.67	-5.48	-0.33	1.05e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.31	-0.51	7.24e-18	Response to antipsychotic treatment;
KIRP	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg16865965	chr2:85811662	VAMP5	-0.32	-4.9	-0.3	1.77e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	0.83	12.49	0.62	4.86e-28	Body mass index;
KIRP	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg10381502	chr11:71823885	C11orf51	1.04	6.94	0.4	3.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs3779635	0.710	rs28566530	chr8:27252633	T/C	cg06815112	chr8:27182871	PTK2B	0.53	6.81	0.4	7.43e-11	Neuroticism;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg21237687	chr17:6899380	ALOX12	0.28	4.95	0.3	1.37e-6	Tonsillectomy;
KIRP	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg00495681	chr13:53174319	NA	0.82	12.12	0.61	7.9e-27	Lewy body disease;
KIRP	cis	rs1014246	0.813	rs11197797	chr10:118454499	C/T	cg14919929	chr10:118506882	NA	0.75	9.59	0.52	1.07e-18	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.77	10.14	0.54	2.06e-20	Huntington's disease progression;
KIRP	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.6	7.77	0.44	2.06e-13	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25053232	chr7:2394393	EIF3B	0.47	6.49	0.38	4.62e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg19468946	chr17:37922297	IKZF3	-0.37	-4.93	-0.3	1.52e-6	Glomerular filtration rate (creatinine);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg25722142	chr6:139695762	CITED2	0.74	6.84	0.4	6.18e-11	Lung function (FEV1);
KIRP	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg22325292	chr17:80708367	FN3K	0.46	6.93	0.4	3.59e-11	Glycated hemoglobin levels;
KIRP	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg14580859	chr9:123691850	NA	0.38	5.31	0.32	2.44e-7	Rheumatoid arthritis;
KIRP	cis	rs1345301	1.000	rs13405355	chr2:102878206	C/T	cg12451869	chr2:102867685	NA	0.4	5.91	0.35	1.13e-8	Waist circumference;
KIRP	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	12.46	0.62	6.1e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.98	15.84	0.71	1.92e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs10518128	1.000	rs28428724	chr4:75711826	T/C	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	trans	rs35607894	0.500	rs7156200	chr14:72457682	G/T	cg09954251	chr8:1278972	NA	-0.54	-6.1	-0.36	4.02e-9	Schizophrenia;
KIRP	cis	rs2071426	0.959	rs11572139	chr10:96808886	A/G	cg09036531	chr10:96991505	NA	0.54	6.21	0.37	2.18e-9	Blood metabolite levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00994032	chr14:50315768	SDCCAG1	0.41	6.09	0.36	4.24e-9	C-reactive protein;
KIRP	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.38	0.38	8.79e-10	Myopia (pathological);
KIRP	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.67	-10.14	-0.54	2.07e-20	Hepatocellular carcinoma;
KIRP	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg05714579	chr10:131428358	MGMT	-0.54	-7.06	-0.41	1.73e-11	Response to temozolomide;
KIRP	cis	rs963731	0.649	rs1470915	chr2:39247336	G/A	cg04010122	chr2:39346883	SOS1	-0.96	-6.66	-0.39	1.79e-10	Corticobasal degeneration;
KIRP	cis	rs6545883	0.965	rs766447	chr2:61735569	C/T	cg15711740	chr2:61764176	XPO1	-0.59	-7.97	-0.45	5.88e-14	Tuberculosis;
KIRP	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	16.0	0.71	5.54e-40	Platelet count;
KIRP	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg26528668	chr16:1614120	IFT140	0.41	5.14	0.31	5.55e-7	Coronary artery disease;
KIRP	cis	rs7712401	0.601	rs246273	chr5:122280975	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg17554472	chr22:41940697	POLR3H	0.43	5.2	0.31	4.17e-7	Vitiligo;
KIRP	cis	rs2071403	0.901	rs56217611	chr2:1400070	T/C	cg07083862	chr2:1417248	TPO	0.33	5.14	0.31	5.59e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25517755	chr10:38738941	LOC399744	-0.4	-5.6	-0.34	5.58e-8	Extrinsic epigenetic age acceleration;
KIRP	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg23594656	chr7:65796392	TPST1	-0.44	-6.04	-0.36	5.67e-9	Aortic root size;
KIRP	cis	rs516946	1.000	rs6989203	chr8:41523745	A/G	cg19441908	chr8:41529140	ANK1	-0.48	-6.8	-0.4	7.74e-11	Type 2 diabetes;
KIRP	cis	rs7258465	1.000	rs2303697	chr19:18546678	T/C	cg10790698	chr19:18539756	SSBP4	-0.35	-7.62	-0.44	5.65e-13	Breast cancer;
KIRP	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.21	19.88	0.79	4.44e-53	Cognitive function;
KIRP	cis	rs698833	0.892	rs1067403	chr2:44675851	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.51	5.79	0.35	2.17e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.38	-4.96	-0.3	1.29e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg00495681	chr13:53174319	NA	0.4	5.48	0.33	1.03e-7	Lewy body disease;
KIRP	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg01879757	chr17:41196368	BRCA1	-0.73	-10.2	-0.55	1.34e-20	Menopause (age at onset);
KIRP	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.77	-0.35	2.42e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs72634030	0.536	rs72634021	chr17:5219435	C/G	cg20802942	chr17:5185005	RABEP1	0.52	4.99	0.3	1.17e-6	Rheumatoid arthritis;
KIRP	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.97	12.78	0.63	5.14e-29	Cognitive function;
KIRP	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.63	7.39	0.43	2.24e-12	Arsenic metabolism;
KIRP	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.5	6.16	0.37	2.98e-9	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg13699009	chr12:122356056	WDR66	0.73	11.92	0.61	3.59e-26	Mean corpuscular volume;
KIRP	cis	rs17123764	1.000	rs7301209	chr12:49946051	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.91	0.3	1.68e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg00800569	chr2:239229395	TRAF3IP1	0.44	5.1	0.31	6.84e-7	Multiple system atrophy;
KIRP	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.35e-6	Obesity-related traits;
KIRP	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg09754948	chr16:28834200	ATXN2L	-0.46	-5.02	-0.3	1.01e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg17764715	chr19:33622953	WDR88	0.8	11.5	0.59	9.21e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.47	6.9	0.4	4.51e-11	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg25801113	chr15:45476975	SHF	-0.45	-8.19	-0.46	1.41e-14	Uric acid levels;
KIRP	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg23625390	chr15:77176239	SCAPER	0.53	6.96	0.41	3.07e-11	Blood metabolite levels;
KIRP	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg03734594	chr13:111297400	CARS2	-0.35	-5.6	-0.34	5.67e-8	Coronary artery disease;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23708337	chr7:1209742	NA	0.41	5.14	0.31	5.72e-7	Longevity;Endometriosis;
KIRP	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.49	-7.09	-0.41	1.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.73	-11.51	-0.59	8.24e-25	Vitiligo;
KIRP	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	0.74	10.88	0.57	9.01e-23	Prudent dietary pattern;
KIRP	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.63	-7.02	-0.41	2.16e-11	Vitiligo;
KIRP	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.29	-0.32	2.66e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs6142102	0.923	rs4911379	chr20:32535305	A/C	cg08999081	chr20:33150536	PIGU	0.51	6.12	0.36	3.61e-9	Skin pigmentation;
KIRP	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-11.78	-0.6	1.06e-25	Systemic lupus erythematosus;
KIRP	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18932078	chr1:2524107	MMEL1	0.43	5.98	0.36	7.76e-9	Ulcerative colitis;
KIRP	cis	rs6142102	0.886	rs4911147	chr20:32667607	C/A	cg08999081	chr20:33150536	PIGU	0.53	6.32	0.37	1.23e-9	Skin pigmentation;
KIRP	trans	rs1106684	1.000	rs59269529	chr7:131460556	C/A	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.56	7.05	0.41	1.77e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs71520386	0.632	rs1029738	chr7:22874047	C/A	cg15401507	chr7:22894281	NA	0.4	5.03	0.31	9.56e-7	Fibrinogen levels;
KIRP	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-8.3	-0.47	7.11e-15	Glomerular filtration rate;
KIRP	cis	rs6684428	0.706	rs10888941	chr1:56333935	T/G	cg11651538	chr1:56320950	NA	-0.9	-11.69	-0.6	2.12e-25	Airflow obstruction;
KIRP	cis	rs1620921	0.505	rs13196324	chr6:161201842	A/T	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	1.11	7.89	0.45	9.87e-14	Skin colour saturation;
KIRP	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg06606381	chr12:133084897	FBRSL1	-1.08	-6.37	-0.38	9.1e-10	Depression;
KIRP	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg07382826	chr16:28625726	SULT1A1	0.49	5.75	0.34	2.7e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg23307798	chr14:103986281	CKB	-0.46	-6.27	-0.37	1.58e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg04733989	chr22:42467013	NAGA	0.48	6.03	0.36	5.93e-9	Cognitive function;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00861824	chr1:207963099	CD46	-0.42	-6.52	-0.38	4.01e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg04369109	chr6:150039330	LATS1	-0.41	-4.89	-0.3	1.8e-6	Lung cancer;
KIRP	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11622362	chr11:34938112	PDHX;APIP	-0.48	-6.08	-0.36	4.64e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.51	0.38	4.2e-10	Axial length;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24425342	chr19:3114929	GNA11	-0.52	-6.42	-0.38	7.13e-10	Parkinson's disease;
KIRP	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.54	-7.11	-0.41	1.23e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05165064	chr20:18037039	OVOL2	0.51	7.0	0.41	2.37e-11	Smoking initiation;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	9.04	0.5	4.75e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	trans	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg06521331	chr12:34319734	NA	-0.49	-6.21	-0.37	2.24e-9	Bladder cancer;
KIRP	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.61	-6.63	-0.39	2.16e-10	Aortic root size;
KIRP	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.32	5.54	0.33	7.95e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.49	-5.53	-0.33	8.17e-8	Chronic sinus infection;
KIRP	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.84	-8.37	-0.47	4.4e-15	Coronary artery calcification;
KIRP	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	9.06	0.5	4.17e-17	Resting heart rate;
KIRP	cis	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg21546286	chr11:48923668	NA	0.4	4.86	0.3	2.13e-6	HDL cholesterol;
KIRP	cis	rs758324	0.704	rs40401	chr5:131396478	C/T	cg25547332	chr5:131281432	NA	-0.41	-5.1	-0.31	6.8e-7	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.64	-6.81	-0.4	7.27e-11	Alcohol dependence;
KIRP	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg00677455	chr12:58241039	CTDSP2	-0.51	-5.75	-0.34	2.6e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.49	-9.09	-0.5	3.31e-17	Cystic fibrosis severity;
KIRP	trans	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg10756647	chr7:56101905	PSPH	1.09	8.55	0.48	1.29e-15	Diabetic kidney disease;
KIRP	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.24	0.51	1.23e-17	Lymphocyte counts;
KIRP	cis	rs7536201	1.000	rs7550552	chr1:25299602	C/T	cg23273869	chr1:25296894	NA	-0.39	-5.64	-0.34	4.6e-8	Psoriasis vulgaris;
KIRP	cis	rs1823913	0.599	rs67781530	chr2:192160334	T/C	cg12404831	chr2:192114017	MYO1B	0.53	7.36	0.42	2.79e-12	Obesity-related traits;
KIRP	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.91	0.64	1.83e-29	Platelet count;
KIRP	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs74065827	0.643	rs75058955	chr14:78283710	C/T	cg18985109	chr14:78266276	ADCK1	-0.71	-5.05	-0.31	8.41e-7	Response to paliperidone in schizophrenia (positive Marder score);Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg00129232	chr17:37814104	STARD3	0.7	8.54	0.48	1.41e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg06115741	chr20:33292138	TP53INP2	0.38	5.12	0.31	6.18e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.79	-9.7	-0.53	4.92e-19	Corneal astigmatism;
KIRP	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.42	-5.59	-0.34	6.16e-8	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg16497661	chr14:103986332	CKB	0.75	11.17	0.58	1.07e-23	Body mass index;
KIRP	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-8.32	-0.47	6.16e-15	Retinal vascular caliber;
KIRP	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg19650706	chr5:140594406	PCDHB13	0.47	5.13	0.31	5.8e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	1.0	17.83	0.75	3.29e-46	Leprosy;
KIRP	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.96	16.81	0.73	9.3e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs4262150	0.810	rs72797284	chr5:152031650	A/G	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.05e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs575018	0.774	rs4467676	chr5:100592459	C/T	cg03848127	chr5:100126093	NA	0.45	5.45	0.33	1.24e-7	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7923609	0.967	rs7920058	chr10:65293924	T/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.54	-0.33	7.62e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.98	11.54	0.59	6.8e-25	Corneal astigmatism;
KIRP	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.67	0.44	3.93e-13	Tonsillectomy;
KIRP	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.7	-6.33	-0.37	1.13e-9	Yeast infection;
KIRP	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg17372223	chr3:52568218	NT5DC2	0.34	5.71	0.34	3.17e-8	Bipolar disorder;
KIRP	cis	rs4356932	1.000	rs10014837	chr4:76941818	G/A	cg00809888	chr4:76862425	NAAA	0.45	6.27	0.37	1.59e-9	Blood protein levels;
KIRP	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg11783602	chr8:55087084	NA	-0.48	-5.99	-0.36	7.41e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7084402	1.000	rs34774248	chr10:60269691	A/G	cg05938607	chr10:60274200	BICC1	0.42	10.11	0.54	2.53e-20	Refractive error;
KIRP	trans	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg00938859	chr5:1591904	SDHAP3	-0.51	-6.95	-0.41	3.26e-11	Breast cancer;
KIRP	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.99	-11.87	-0.6	5.51e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg05768032	chr16:30646687	NA	0.44	5.2	0.31	4.16e-7	Multiple myeloma;
KIRP	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.87	12.56	0.63	2.78e-28	Glomerular filtration rate (creatinine);
KIRP	cis	rs12282928	0.885	rs4472898	chr11:48260983	T/A	cg26585981	chr11:48327164	OR4S1	-0.5	-6.03	-0.36	6.1e-9	Migraine - clinic-based;
KIRP	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg21361702	chr7:150065534	REPIN1	0.55	5.7	0.34	3.45e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg12292205	chr6:26970375	C6orf41	0.33	4.86	0.3	2.08e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6547631	0.622	rs1837115	chr2:85928411	C/A	cg24620635	chr2:85921963	GNLY	0.31	4.98	0.3	1.2e-6	Blood protein levels;
KIRP	trans	rs74233809	0.901	rs3824754	chr10:104614350	C/T	cg26199906	chr8:145106246	OPLAH	-0.48	-6.27	-0.37	1.58e-9	Birth weight;
KIRP	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg27487796	chr7:28973253	NA	-0.22	-5.08	-0.31	7.33e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg02975922	chr3:195473998	MUC4	-0.54	-6.3	-0.37	1.33e-9	Pancreatic cancer;
KIRP	cis	rs6456156	0.819	rs4709148	chr6:167521676	T/C	cg07741184	chr6:167504864	NA	0.2	5.03	0.31	9.64e-7	Primary biliary cholangitis;
KIRP	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.99	15.0	0.69	1.53e-36	Sudden cardiac arrest;
KIRP	cis	rs9815354	0.812	rs73071341	chr3:41826211	C/T	cg03022575	chr3:42003672	ULK4	0.81	8.47	0.48	2.2e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg25173405	chr17:45401733	C17orf57	-0.48	-6.26	-0.37	1.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6882716	0.636	rs10043680	chr5:10804522	A/G	cg14521931	chr5:10832172	NA	0.8	9.49	0.52	2.15e-18	Alcohol consumption (maxi-drinks);
KIRP	cis	rs4728302	0.607	rs7793732	chr7:133582953	G/T	cg10665199	chr7:133106180	EXOC4	0.43	5.0	0.3	1.1e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg09608008	chr11:66529885	C11orf80	-0.43	-6.25	-0.37	1.75e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	0.8	7.0	0.41	2.41e-11	Severe influenza A (H1N1) infection;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg18604133	chr13:27746144	USP12	0.55	7.27	0.42	4.72e-12	DNA methylation (variation);
KIRP	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg11859384	chr17:80120422	CCDC57	0.44	5.53	0.33	8.19e-8	Life satisfaction;
KIRP	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.36	5.42	0.33	1.44e-7	Calcium levels;
KIRP	cis	rs17401966	0.540	rs1536262	chr1:10438687	C/T	cg17425144	chr1:10567563	PEX14	-0.3	-5.18	-0.31	4.7e-7	Hepatocellular carcinoma;
KIRP	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.83	-14.59	-0.68	3.59e-35	Post bronchodilator FEV1;
KIRP	cis	rs11605924	0.934	rs7945565	chr11:45878992	A/G	cg23097878	chr11:45879730	CRY2	0.3	5.84	0.35	1.68e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01083340	chr11:66176265	NA	0.53	6.09	0.36	4.2e-9	Smoking initiation;
KIRP	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg12315302	chr6:26189340	HIST1H4D	0.86	6.07	0.36	4.77e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1712517	0.545	rs3740381	chr10:105046689	G/C	cg04362960	chr10:104952993	NT5C2	-0.59	-7.31	-0.42	3.85e-12	Migraine;
KIRP	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.67	-7.7	-0.44	3.37e-13	Carotid intima media thickness;
KIRP	cis	rs7007076	0.710	rs73703640	chr8:124716097	G/A	cg00283535	chr8:124749564	ANXA13	0.56	6.18	0.37	2.67e-9	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.74	8.37	0.47	4.33e-15	Corneal astigmatism;
KIRP	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.93	13.87	0.66	1.02e-32	Tonsillectomy;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03317280	chr1:228675123	RNF187	0.46	6.09	0.36	4.35e-9	Parkinson's disease;
KIRP	trans	rs12517041	0.872	rs67191421	chr5:23281046	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-8.31	-0.47	6.31e-15	Calcium levels;
KIRP	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.8	10.82	0.57	1.4e-22	Morning vs. evening chronotype;
KIRP	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.6	-0.39	2.57e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg11569703	chr11:65557185	OVOL1	-0.48	-8.45	-0.47	2.61e-15	Acne (severe);
KIRP	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.94	14.12	0.67	1.53e-33	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg06027949	chr8:82754900	SNX16	-0.58	-6.29	-0.37	1.46e-9	Diastolic blood pressure;
KIRP	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00376283	chr12:123451042	ABCB9	0.67	8.13	0.46	2.05e-14	Neutrophil percentage of white cells;
KIRP	cis	rs6009824	0.891	rs11090995	chr22:50085210	G/A	cg22070880	chr22:50098194	NA	0.79	8.71	0.49	4.66e-16	Natriuretic peptide levels;
KIRP	trans	rs199950	0.866	rs798065	chr1:181600123	G/T	cg04237608	chr1:18659049	IGSF21	0.36	6.1	0.36	4.16e-9	Body mass index (change over time);
KIRP	cis	rs9469913	0.799	rs9462016	chr6:34739790	C/A	cg17674042	chr6:34482479	PACSIN1	-0.38	-5.17	-0.31	4.73e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg16606324	chr3:10149918	C3orf24	0.56	5.25	0.32	3.27e-7	Alzheimer's disease;
KIRP	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02725872	chr8:58115012	NA	-0.75	-7.81	-0.45	1.68e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.77	-9.9	-0.53	1.12e-19	Aortic root size;
KIRP	cis	rs6684514	0.961	rs10908501	chr1:156285513	G/T	cg16558208	chr1:156270281	VHLL	-0.45	-5.95	-0.35	9.29e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.63	-6.88	-0.4	4.82e-11	DNA methylation (variation);
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-5.16	-0.31	5.16e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg23985595	chr17:80112537	CCDC57	-0.37	-5.44	-0.33	1.26e-7	Life satisfaction;
KIRP	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.65	10.23	0.55	1.1e-20	Bone mineral density;
KIRP	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.98	10.47	0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.76	-10.79	-0.57	1.74e-22	Waist circumference;Body mass index;
KIRP	cis	rs7224685	0.501	rs2727067	chr17:3997843	G/A	cg09695851	chr17:3907499	NA	-0.82	-14.29	-0.67	3.85e-34	Type 2 diabetes;
KIRP	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.59	6.34	0.37	1.11e-9	Gut microbiome composition (summer);
KIRP	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.68	-8.0	-0.45	4.86e-14	IgG glycosylation;
KIRP	cis	rs12282928	0.657	rs10838826	chr11:48219812	G/T	cg04607699	chr11:48328132	OR4S1	-0.38	-5.32	-0.32	2.38e-7	Migraine - clinic-based;
KIRP	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.76	-8.57	-0.48	1.15e-15	Platelet count;
KIRP	cis	rs1847505	0.716	rs7321236	chr13:61516730	C/T	cg25164009	chr13:61490935	NA	-0.6	-7.23	-0.42	6.05e-12	Polychlorinated biphenyl levels;
KIRP	cis	rs9310709	0.538	rs822770	chr3:23032988	T/C	cg00327796	chr3:23032191	NA	0.49	6.77	0.4	9.61e-11	Chronic kidney disease and serum creatinine levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25631650	chr19:633157	POLRMT	0.59	7.18	0.42	8.45e-12	Smoking initiation;
KIRP	cis	rs2742417	1.000	rs2673039	chr3:45748435	A/G	cg04037228	chr3:45636386	LIMD1	0.36	5.27	0.32	2.95e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg05220968	chr6:146057943	EPM2A	-0.38	-4.95	-0.3	1.37e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.46	5.73	0.34	2.93e-8	Height;
KIRP	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.11	-12.68	-0.63	1.07e-28	Vitiligo;
KIRP	cis	rs78487399	0.808	rs7601093	chr2:43710807	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-5.3	-0.32	2.54e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.93	11.5	0.59	9.16e-25	Alzheimer's disease;
KIRP	cis	rs78487399	0.908	rs7559723	chr2:43832049	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-5.33	-0.32	2.27e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.55	-0.33	7.4e-8	Coronary artery disease;
KIRP	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg13939156	chr17:80058883	NA	-0.48	-5.58	-0.34	6.19e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.19e-16	Bipolar disorder;
KIRP	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg05636881	chr10:105038444	INA	-0.59	-5.11	-0.31	6.6e-7	Arsenic metabolism;
KIRP	cis	rs11997175	0.525	rs67217084	chr8:33888133	T/C	cg04338863	chr8:33670619	NA	0.45	5.4	0.33	1.58e-7	Body mass index;
KIRP	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.61	6.88	0.4	4.9e-11	Neutrophil percentage of white cells;
KIRP	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg11502198	chr6:26597334	ABT1	0.41	4.97	0.3	1.24e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg01338139	chr15:38987640	C15orf53	-0.56	-6.2	-0.37	2.4e-9	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.78	7.2	0.42	7.12e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3790645	1.000	rs897641	chr1:26881806	C/A	cg23229016	chr1:26872525	RPS6KA1	0.22	5.84	0.35	1.64e-8	Glucose homeostasis traits;
KIRP	cis	rs2242116	0.632	rs10049237	chr3:46941626	T/C	cg02527881	chr3:46936655	PTH1R	-0.56	-6.37	-0.38	9.43e-10	Birth weight;
KIRP	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg11846333	chr4:119757529	SEC24D	0.96	5.94	0.35	9.75e-9	Cannabis dependence symptom count;
KIRP	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.55	-7.46	-0.43	1.45e-12	Response to temozolomide;
KIRP	trans	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg24315340	chr6:146058215	EPM2A	-0.44	-5.79	-0.35	2.08e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	7.17	0.42	8.6e-12	Iron status biomarkers;
KIRP	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg23166289	chr1:210001082	C1orf107	0.42	5.26	0.32	3.12e-7	Orofacial clefts;
KIRP	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg05044414	chr3:183734942	ABCC5	0.38	5.83	0.35	1.72e-8	Anterior chamber depth;
KIRP	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg07395648	chr5:131743802	NA	-0.36	-4.96	-0.3	1.32e-6	Blood metabolite levels;
KIRP	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg01631408	chr1:248437212	OR2T33	-0.61	-8.2	-0.46	1.33e-14	Common traits (Other);
KIRP	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.72	9.61	0.52	9.13e-19	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.75	11.18	0.58	9.9e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg24203234	chr3:128598194	ACAD9	0.43	4.9	0.3	1.74e-6	IgG glycosylation;
KIRP	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg07777115	chr5:623756	CEP72	-0.56	-5.71	-0.34	3.33e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12230513	0.732	rs60450959	chr12:55861373	A/T	cg19537932	chr12:55886519	OR6C68	-0.63	-7.67	-0.44	4.06e-13	Contrast sensitivity;
KIRP	trans	rs12043259	0.892	rs11240295	chr1:204824764	G/A	cg11485465	chr5:54518469	NA	0.41	6.53	0.38	3.76e-10	Addiction;
KIRP	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17467752	chr17:38218738	THRA	-0.54	-6.86	-0.4	5.45e-11	Myeloid white cell count;
KIRP	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg05418105	chr22:50981406	NA	0.65	8.07	0.46	3.16e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.52	-7.11	-0.41	1.27e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.69	-10.89	-0.57	8.28e-23	Educational attainment;
KIRP	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg04025307	chr7:1156635	C7orf50	0.81	8.35	0.47	5.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.38	10.57	0.56	9.14e-22	Prostate cancer;
KIRP	cis	rs2274273	0.840	rs66486619	chr14:55869555	T/G	cg04306507	chr14:55594613	LGALS3	0.46	7.19	0.42	7.71e-12	Protein biomarker;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04304255	chr13:67155091	PCDH9	-0.41	-6.08	-0.36	4.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg06636001	chr8:8085503	FLJ10661	0.58	7.76	0.44	2.32e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	trans	rs9844985	0.630	rs6766837	chr3:116893069	C/G	cg12278631	chr1:51312119	FAF1	-0.4	-6.15	-0.37	3.1e-9	Major depression and alcohol dependence;
KIRP	cis	rs4908768	0.629	rs12410886	chr1:8878809	A/C	cg25722041	chr1:8623473	RERE	0.67	8.39	0.47	3.78e-15	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7546094	1.000	rs3103450	chr1:113197730	G/A	cg22162597	chr1:113214053	CAPZA1	-0.5	-7.06	-0.41	1.67e-11	Platelet distribution width;
KIRP	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12963246	chr6:28129442	ZNF389	0.38	4.86	0.3	2.14e-6	Cardiac Troponin-T levels;
KIRP	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19346786	chr7:2764209	NA	-0.54	-9.02	-0.5	5.45e-17	Height;
KIRP	cis	rs6496044	0.568	rs1351196	chr15:86077404	T/C	cg17133734	chr15:86042851	AKAP13	-0.4	-4.9	-0.3	1.73e-6	Interstitial lung disease;
KIRP	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	8.15	0.46	1.82e-14	Response to antipsychotic treatment;
KIRP	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.91	-0.4	4.19e-11	Obesity-related traits;
KIRP	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg26373071	chr5:1325741	CLPTM1L	0.54	7.15	0.41	1.02e-11	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09698166	chr20:21106763	PLK1S1	0.65	7.61	0.44	5.74e-13	Smoking initiation;
KIRP	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.36	5.13	0.31	5.94e-7	Educational attainment;
KIRP	cis	rs12311304	0.965	rs7965989	chr12:15361715	G/T	cg08258403	chr12:15378311	NA	0.35	5.39	0.33	1.61e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.92	-0.4	3.89e-11	Type 2 diabetes;
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg01798813	chr17:3906674	NA	0.53	7.44	0.43	1.71e-12	Type 2 diabetes;
KIRP	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.92	-0.4	3.85e-11	Neuroticism;
KIRP	cis	rs10267417	0.604	rs7785317	chr7:19853482	G/T	cg05791153	chr7:19748676	TWISTNB	-0.47	-5.04	-0.31	8.98e-7	Night sleep phenotypes;
KIRP	cis	rs9972944	0.756	rs9907969	chr17:63754860	G/T	cg07283582	chr17:63770753	CCDC46	-0.42	-7.03	-0.41	2.08e-11	Total body bone mineral density;
KIRP	cis	rs11203032	1.000	rs17117126	chr10:90964026	A/G	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs3112255	0.846	rs13423120	chr2:101281354	A/C	cg01042948	chr2:101319752	NA	-0.42	-5.99	-0.36	7.48e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg16989719	chr2:238392110	NA	-0.63	-5.89	-0.35	1.29e-8	Prostate cancer;
KIRP	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	0.98	8.37	0.47	4.3e-15	Systolic blood pressure;
KIRP	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg12826209	chr6:26865740	GUSBL1	0.46	5.89	0.35	1.27e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg14703610	chr5:56206110	C5orf35	0.49	6.76	0.4	1e-10	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg21546286	chr11:48923668	NA	-0.47	-5.97	-0.36	8.44e-9	HDL cholesterol;
KIRP	cis	rs1318772	1.000	rs421515	chr5:112808643	C/A	cg12552261	chr5:112820674	MCC	-0.8	-5.11	-0.31	6.49e-7	F-cell distribution;
KIRP	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs11997175	0.624	rs79944133	chr8:33730588	A/G	cg04338863	chr8:33670619	NA	0.43	4.96	0.3	1.35e-6	Body mass index;
KIRP	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg06640241	chr16:89574553	SPG7	0.79	11.51	0.59	8.36e-25	Multiple myeloma (IgH translocation);
KIRP	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.14	9.07	0.5	3.85e-17	Skin colour saturation;
KIRP	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg01403660	chr11:68851641	TPCN2	0.66	6.45	0.38	5.94e-10	Blond vs. brown hair color;
KIRP	cis	rs7224685	0.501	rs8075429	chr17:3907308	A/G	cg21734707	chr17:3908241	ZZEF1	0.68	10.53	0.56	1.21e-21	Type 2 diabetes;
KIRP	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg17145862	chr1:211918768	LPGAT1	0.59	6.6	0.39	2.58e-10	Crohn's disease;
KIRP	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.85	11.52	0.59	7.82e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.94	-13.88	-0.66	9.86e-33	Longevity;Endometriosis;
KIRP	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg14664628	chr15:75095509	CSK	0.47	5.87	0.35	1.42e-8	Systemic lupus erythematosus;
KIRP	cis	rs7258465	0.965	rs7256534	chr19:18586791	C/T	cg01065977	chr19:18549689	ISYNA1	-0.39	-5.9	-0.35	1.17e-8	Breast cancer;
KIRP	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	trans	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg13565492	chr6:43139072	SRF	-0.87	-8.09	-0.46	2.69e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.71	-9.31	-0.51	7.28e-18	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10875746	0.859	rs4760622	chr12:48591960	C/A	cg26205652	chr12:48591994	NA	0.81	11.39	0.59	2e-24	Longevity (90 years and older);
KIRP	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg13256891	chr4:100009986	ADH5	0.62	7.56	0.43	8.09e-13	Alcohol dependence;
KIRP	cis	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg06521331	chr12:34319734	NA	-0.45	-5.51	-0.33	8.98e-8	Morning vs. evening chronotype;
KIRP	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-10.51	-0.56	1.36e-21	Morning vs. evening chronotype;
KIRP	cis	rs1595825	0.891	rs77032596	chr2:198603185	T/G	cg11031976	chr2:198649780	BOLL	-0.5	-4.85	-0.3	2.21e-6	Ulcerative colitis;
KIRP	cis	rs12643440	0.538	rs6843399	chr4:17140263	A/G	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	trans	rs12517041	1.000	rs1560177	chr5:23322987	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.86	-7.69	-0.44	3.49e-13	Calcium levels;
KIRP	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.19	-22.95	-0.83	4.47e-63	Myeloid white cell count;
KIRP	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg09795085	chr6:101329169	ASCC3	-0.5	-6.01	-0.36	6.65e-9	Neuroticism;
KIRP	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.74e-7	Schizophrenia;
KIRP	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.06	-0.36	5.01e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13401104	0.796	rs10929169	chr2:237115532	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs10782582	0.609	rs79835994	chr1:76287508	G/T	cg03433033	chr1:76189801	ACADM	-0.46	-6.48	-0.38	5.09e-10	Daytime sleep phenotypes;
KIRP	cis	rs2151522	0.762	rs9401916	chr6:127166454	A/G	cg21431617	chr6:127135037	NA	0.3	5.43	0.33	1.34e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05665937	chr4:1216051	CTBP1	-0.51	-7.01	-0.41	2.31e-11	Obesity-related traits;
KIRP	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.63	10.15	0.54	1.91e-20	HDL cholesterol levels;
KIRP	cis	rs2213920	1.000	rs2213920	chr9:118271584	C/T	cg13918206	chr9:118159781	DEC1	0.79	8.41	0.47	3.27e-15	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs7583236	0.500	rs7601899	chr2:70335973	C/G	cg19638749	chr2:70312615	NA	0.53	5.07	0.31	7.76e-7	Obesity-related traits;
KIRP	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.84	-13.48	-0.65	2.26e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.07	0.41	1.63e-11	Bipolar disorder;
KIRP	cis	rs71636778	0.631	rs1883660	chr1:27191411	A/T	cg12203394	chr1:27248618	NUDC	0.66	5.41	0.33	1.52e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs17065868	1.000	rs9533902	chr13:45123938	C/A	cg10246903	chr13:45222710	NA	0.7	6.56	0.39	3.23e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.61	-6.89	-0.4	4.68e-11	Mean platelet volume;
KIRP	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17507749	chr15:85114479	UBE2QP1	0.68	7.48	0.43	1.3e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.75	-12.1	-0.61	9.52e-27	Menarche (age at onset);
KIRP	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06212747	chr3:49208901	KLHDC8B	0.7	9.06	0.5	4.25e-17	Parkinson's disease;
KIRP	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-10.4	-0.55	3.19e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg19906672	chr4:6918868	TBC1D14	0.57	5.68	0.34	3.73e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2219968	0.798	rs4397393	chr8:78937569	G/C	cg00738934	chr8:78996279	NA	-0.37	-5.02	-0.3	1e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs12210905	1.000	rs41269245	chr6:27100096	G/A	cg11502198	chr6:26597334	ABT1	-0.78	-5.16	-0.31	5.02e-7	Hip circumference adjusted for BMI;
KIRP	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-11.4	-0.59	1.92e-24	Colorectal cancer;
KIRP	cis	rs9308731	0.583	rs10211562	chr2:111930796	G/T	cg18646521	chr2:111875858	NA	0.38	5.34	0.32	2.14e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	1.0	12.81	0.63	4.06e-29	Neutrophil percentage of white cells;
KIRP	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.03	0.61	1.65e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10073892	0.667	rs9327842	chr5:101697838	T/C	cg19774478	chr5:101632501	SLCO4C1	0.48	5.65	0.34	4.52e-8	Cognitive decline (age-related);
KIRP	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-6.96	-0.41	3e-11	Mean corpuscular volume;
KIRP	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.71	0.49	4.51e-16	Life satisfaction;
KIRP	cis	rs10924970	0.588	rs61836189	chr1:235512330	A/T	cg26050004	chr1:235667680	B3GALNT2	0.47	5.03	0.31	9.63e-7	Asthma;
KIRP	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg00319359	chr11:70116639	PPFIA1	0.82	6.53	0.38	3.84e-10	Coronary artery disease;
KIRP	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	0.83	10.99	0.57	4e-23	Primary sclerosing cholangitis;
KIRP	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.46	-5.86	-0.35	1.47e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg11608241	chr8:8085544	FLJ10661	0.45	5.68	0.34	3.85e-8	Systolic blood pressure;
KIRP	cis	rs6256	0.929	rs56272325	chr11:13508857	C/G	cg11976911	chr11:13509032	NA	-0.62	-5.19	-0.31	4.5e-7	Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel;
KIRP	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.82	0.4	6.84e-11	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12102766	chr2:105954037	C2orf49	0.5	6.27	0.37	1.62e-9	Parkinson's disease;
KIRP	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg18944383	chr4:111397179	ENPEP	0.53	9.44	0.52	2.95e-18	Height;
KIRP	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg03808351	chr9:123631620	PHF19	0.4	5.53	0.33	8.06e-8	Rheumatoid arthritis;
KIRP	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg13264159	chr8:625131	ERICH1	0.81	6.46	0.38	5.58e-10	IgG glycosylation;
KIRP	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.74	0.34	2.76e-8	Morning vs. evening chronotype;
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.54	6.53	0.38	3.66e-10	Menopause (age at onset);
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	1.04	22.53	0.82	9.43e-62	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.79	9.62	0.52	8.68e-19	Educational attainment;
KIRP	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.38	-10.55	-0.56	1.07e-21	Diabetic kidney disease;
KIRP	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.51	-0.38	4.08e-10	Triglycerides;
KIRP	cis	rs2371030	0.965	rs2216403	chr2:211573391	G/T	cg18417063	chr2:211583084	NA	-0.51	-7.55	-0.43	8.58e-13	Non-small cell lung cancer;
KIRP	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.5	6.19	0.37	2.54e-9	Height;
KIRP	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.6	6.58	0.39	2.79e-10	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01836936	chr17:21156233	C17orf103	0.53	6.48	0.38	5.07e-10	Parkinson's disease;
KIRP	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg05785598	chr3:49045655	WDR6	0.28	4.96	0.3	1.32e-6	Parkinson's disease;
KIRP	cis	rs6463523	0.933	rs79984239	chr7:766220	A/G	cg14391382	chr7:866102	UNC84A	0.54	6.9	0.4	4.5e-11	Subjective well-being;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg03041860	chr2:208489911	FAM119A	0.51	6.16	0.37	2.91e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4843185	0.646	rs35953313	chr16:85710476	T/A	cg26571870	chr16:85723150	GINS2	-0.44	-4.95	-0.3	1.36e-6	Platelet distribution width;
KIRP	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.45	5.91	0.35	1.12e-8	Calcium levels;
KIRP	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg21017887	chr14:105400489	NA	0.54	8.97	0.5	7.93e-17	Rheumatoid arthritis;
KIRP	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.91	14.1	0.67	1.79e-33	Testicular germ cell tumor;
KIRP	cis	rs67257959	0.708	rs13343952	chr19:17197064	G/C	cg16202187	chr19:17186497	HAUS8;MYO9B	0.51	5.84	0.35	1.65e-8	Selective IgA deficiency;
KIRP	cis	rs17209837	1.000	rs2302386	chr7:87091944	A/G	cg00919237	chr7:87102261	ABCB4	-0.74	-7.48	-0.43	1.35e-12	Gallbladder cancer;
KIRP	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10053473	chr17:62856997	LRRC37A3	0.69	7.48	0.43	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg02696742	chr7:106810147	HBP1	-0.81	-7.97	-0.45	6.05e-14	Coronary artery disease;
KIRP	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	13.33	0.65	7.22e-31	Menopause (age at onset);
KIRP	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg06212747	chr3:49208901	KLHDC8B	0.69	7.63	0.44	5.05e-13	Menarche (age at onset);
KIRP	cis	rs259282	0.538	rs6510272	chr19:33117842	C/A	cg02997394	chr19:33096574	ANKRD27	-0.51	-5.1	-0.31	6.78e-7	Schizophrenia;
KIRP	cis	rs734999	0.505	rs4445406	chr1:2539400	T/C	cg20673091	chr1:2541236	MMEL1	0.73	12.06	0.61	1.28e-26	Ulcerative colitis;
KIRP	cis	rs6546324	0.625	rs4671812	chr2:67832486	C/T	cg15745817	chr2:67799979	NA	-0.7	-7.53	-0.43	9.7e-13	Endometriosis;
KIRP	cis	rs904251	0.580	rs62408367	chr6:37444813	G/A	cg25019722	chr6:37503610	NA	-0.84	-12.15	-0.61	6.44e-27	Cognitive performance;
KIRP	cis	rs501120	0.929	rs2576354	chr10:44750393	G/A	cg09554077	chr10:44749378	NA	0.67	9.7	0.53	4.64e-19	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg23231163	chr10:75533350	FUT11	0.33	4.9	0.3	1.72e-6	Inflammatory bowel disease;
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	14.44	0.68	1.19e-34	Alzheimer's disease;
KIRP	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.47	-5.78	-0.35	2.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg16497661	chr14:103986332	CKB	0.76	11.36	0.59	2.52e-24	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20774722	chr17:19551893	ALDH3A2	0.47	6.33	0.37	1.13e-9	Parkinson's disease;
KIRP	trans	rs1056053	0.539	rs3099270	chr6:166571525	T/C	cg17428496	chr19:2151817	AP3D1	-0.55	-6.17	-0.37	2.79e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg24375607	chr4:120327624	NA	-0.47	-5.14	-0.31	5.48e-7	Corneal astigmatism;
KIRP	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.23	0.42	6.02e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg03258011	chr17:54857409	NA	-0.48	-6.56	-0.39	3.23e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg13147721	chr7:65941812	NA	0.98	6.81	0.4	7.36e-11	Diabetic kidney disease;
KIRP	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.97	16.14	0.72	1.85e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg00204512	chr16:28754710	NA	0.45	5.86	0.35	1.46e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg08975724	chr8:8085496	FLJ10661	-0.55	-6.69	-0.39	1.51e-10	Neuroticism;
KIRP	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.42	-9.51	-0.52	1.81e-18	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg00666640	chr1:248458726	OR2T12	0.42	4.87	0.3	1.95e-6	Common traits (Other);
KIRP	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.64	7.72	0.44	2.86e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.51	0.38	4.21e-10	Colorectal cancer;
KIRP	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.73	11.92	0.61	3.76e-26	Longevity;Endometriosis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg15264303	chr12:7013902	LRRC23	0.93	6.5	0.38	4.48e-10	P wave terminal force;
KIRP	cis	rs9398803	0.830	rs1159619	chr6:126801144	C/A	cg19875578	chr6:126661172	C6orf173	0.51	6.61	0.39	2.37e-10	Male-pattern baldness;
KIRP	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg08761264	chr16:28874980	SH2B1	-0.46	-5.41	-0.33	1.46e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.62	10.16	0.54	1.76e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs3790645	1.000	rs1064196	chr1:26887592	C/T	cg23229016	chr1:26872525	RPS6KA1	-0.22	-5.75	-0.34	2.6e-8	Glucose homeostasis traits;
KIRP	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg06719391	chr11:2554330	KCNQ1	1.05	7.43	0.43	1.76e-12	P wave terminal force;
KIRP	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.87	-11.26	-0.58	5.47e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.6	8.01	0.45	4.49e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg21775007	chr8:11205619	TDH	-0.43	-5.61	-0.34	5.51e-8	Triglycerides;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.63	9.28	0.51	8.86e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	9.78	0.53	2.77e-19	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-7.56	-0.43	8.06e-13	Initial pursuit acceleration;
KIRP	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-8.54	-0.48	1.38e-15	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.68	9.84	0.53	1.75e-19	Dupuytren's disease;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04322344	chr3:131221642	MRPL3	0.75	6.31	0.37	1.26e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg05861140	chr6:150128134	PCMT1	-0.47	-6.09	-0.36	4.35e-9	Lung cancer;
KIRP	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-19.38	-0.78	1.92e-51	Height;
KIRP	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.62	-10.1	-0.54	2.76e-20	Morning vs. evening chronotype;
KIRP	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg07827796	chr19:33622959	WDR88	0.43	5.05	0.31	8.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs2273156	0.706	rs7144617	chr14:35498059	C/T	cg09327582	chr14:35236912	BAZ1A	-0.51	-5.19	-0.31	4.35e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.69	-7.62	-0.44	5.48e-13	Vitiligo;
KIRP	cis	rs4253772	0.938	rs41378347	chr22:46636976	G/A	cg00784671	chr22:46762841	CELSR1	-0.53	-5.78	-0.35	2.31e-8	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg17788362	chr6:86352627	SYNCRIP	0.49	6.52	0.38	3.97e-10	Smooth-surface caries;
KIRP	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.83	12.05	0.61	1.34e-26	Breast cancer;
KIRP	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.81	-9.93	-0.53	9.23e-20	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.42	-0.33	1.39e-7	Aortic root size;
KIRP	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-5.46	-0.33	1.17e-7	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs11989744	0.500	rs1438456	chr8:23566909	T/C	cg03492747	chr16:86543808	FOXF1	-0.52	-6.51	-0.38	4.2e-10	Waist-hip ratio;
KIRP	cis	rs2274273	0.684	rs2340921	chr14:55563705	A/G	cg04306507	chr14:55594613	LGALS3	0.5	7.82	0.45	1.55e-13	Protein biomarker;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10448954	chr16:89593394	SPG7	0.58	6.96	0.41	3.15e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-1.03	-12.73	-0.63	7.45e-29	Vitiligo;
KIRP	cis	rs7870753	0.578	rs10990980	chr9:99170901	G/A	cg25260653	chr9:99212216	HABP4	0.54	5.05	0.31	8.59e-7	Height;
KIRP	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg24807547	chr6:37504484	NA	-0.44	-5.67	-0.34	3.92e-8	Cognitive performance;
KIRP	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.43	4.95	0.3	1.4e-6	Schizophrenia;
KIRP	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.58	-7.38	-0.43	2.45e-12	Aortic root size;
KIRP	cis	rs6088813	0.645	rs6088836	chr20:34016207	G/A	cg14752227	chr20:34000481	UQCC	0.47	5.23	0.32	3.66e-7	Height;
KIRP	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.48	7.14	0.41	1.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.94	-0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.57	-6.47	-0.38	5.18e-10	Height;
KIRP	cis	rs7870753	0.730	rs2897257	chr9:99164516	A/G	cg25260653	chr9:99212216	HABP4	0.53	5.66	0.34	4.22e-8	Height;
KIRP	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.25	5.09	0.31	7.17e-7	Coronary artery disease;
KIRP	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.53	-6.63	-0.39	2.09e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04232466	chr8:21988724	HR	0.6	7.96	0.45	6.51e-14	Smoking initiation;
KIRP	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.78	9.63	0.52	8.1e-19	Mean corpuscular hemoglobin;
KIRP	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-1.02	-19.79	-0.78	8.33e-53	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.99	14.09	0.67	1.83e-33	Cognitive function;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg11301795	chr4:187892539	NA	-1.01	-18.16	-0.76	2.5e-47	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18252515	chr7:66147081	NA	0.43	4.92	0.3	1.56e-6	Aortic root size;
KIRP	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.55	0.33	7.25e-8	Educational attainment;
KIRP	cis	rs11608355	0.521	rs6606709	chr12:109846714	A/C	cg19025524	chr12:109796872	NA	-0.49	-6.66	-0.39	1.83e-10	Neuroticism;
KIRP	cis	rs12615966	0.651	rs72830470	chr2:105406694	C/T	cg16465502	chr2:105461796	NA	0.95	7.92	0.45	8.2e-14	Pancreatic cancer;
KIRP	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg26384229	chr12:38710491	ALG10B	0.7	9.44	0.52	2.95e-18	Morning vs. evening chronotype;
KIRP	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.63	10.42	0.55	2.7e-21	Coronary artery disease;
KIRP	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg07636037	chr3:49044803	WDR6	0.57	6.46	0.38	5.72e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.71	8.93	0.49	1.05e-16	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7215564	0.818	rs4889881	chr17:78664157	T/C	cg06153925	chr17:78755379	RPTOR	0.33	5.34	0.32	2.1e-7	Myopia (pathological);
KIRP	cis	rs7674212	0.540	rs2711897	chr4:104023567	C/T	cg16532752	chr4:104119610	CENPE	-0.44	-5.35	-0.32	2.03e-7	Type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.83	11.57	0.59	5.4e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.75	0.49	3.57e-16	Prudent dietary pattern;
KIRP	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg16797656	chr11:68205561	LRP5	0.37	4.87	0.3	2.01e-6	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.54	-6.81	-0.4	7.59e-11	Lung cancer;
KIRP	cis	rs7224685	1.000	rs1377807	chr17:4045440	C/G	cg05562828	chr17:3906858	NA	0.51	7.96	0.45	6.42e-14	Type 2 diabetes;
KIRP	cis	rs6466055	0.720	rs1204060	chr7:104963064	T/C	cg04380332	chr7:105027541	SRPK2	0.63	9.44	0.52	3e-18	Schizophrenia;
KIRP	trans	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17712092	chr4:129076599	LARP1B	-0.55	-6.26	-0.37	1.66e-9	Breast cancer;
KIRP	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg15655495	chr12:38532458	NA	0.27	5.27	0.32	2.98e-7	Bladder cancer;
KIRP	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.84	-11.6	-0.59	4.04e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.28	0.47	8.15e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1448094	1.000	rs7305284	chr12:86343786	C/T	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg06740227	chr12:86229804	RASSF9	0.5	5.84	0.35	1.67e-8	Major depressive disorder;
KIRP	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg14289826	chr9:140003911	NA	0.47	9.1	0.5	3.18e-17	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.78	11.36	0.59	2.61e-24	Heart rate;
KIRP	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.3	-0.51	8.05e-18	Response to antipsychotic treatment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21411233	chr1:155145515	TRIM46;KRTCAP2	0.53	7.25	0.42	5.23e-12	Parkinson's disease;
KIRP	cis	rs8067545	0.553	rs35254155	chr17:19923633	C/G	cg13482628	chr17:19912719	NA	0.45	5.16	0.31	5.08e-7	Schizophrenia;
KIRP	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.5	5.4	0.33	1.58e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs730566	0.640	rs6442112	chr3:48316034	A/G	cg11946769	chr3:48343235	NME6	0.48	5.27	0.32	3.03e-7	Prion diseases;
KIRP	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg08700190	chr5:6636046	SRD5A1	-0.49	-6.03	-0.36	6.09e-9	Response to amphetamines;
KIRP	cis	rs9815354	1.000	rs9866759	chr3:41758418	T/C	cg03022575	chr3:42003672	ULK4	0.5	5.58	0.34	6.33e-8	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.46	-5.7	-0.34	3.34e-8	Crohn's disease;
KIRP	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg19554555	chr3:13937349	NA	-0.46	-6.2	-0.37	2.42e-9	Ovarian reserve;
KIRP	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg05347473	chr6:146136440	FBXO30	-0.58	-8.14	-0.46	1.98e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26083396	chr7:128049885	IMPDH1	-0.44	-6.13	-0.36	3.55e-9	Metabolic traits;
KIRP	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.73	-8.95	-0.5	9.05e-17	Cognitive function;
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.63	0.34	4.87e-8	Lung cancer;
KIRP	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.19	14.15	0.67	1.15e-33	Uric acid levels;
KIRP	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg00361562	chr2:198649771	BOLL	-0.48	-5.01	-0.3	1.02e-6	Ulcerative colitis;
KIRP	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg07827796	chr19:33622959	WDR88	0.43	5.05	0.31	8.65e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs10773046	0.740	rs11057383	chr12:124369421	T/C	cg18594669	chr12:124364423	DNAH10	0.37	4.93	0.3	1.54e-6	Osteoarthritis (hip);
KIRP	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg11833968	chr6:79620685	NA	-0.39	-5.73	-0.34	2.87e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg27624424	chr6:160112604	SOD2	0.55	6.52	0.38	3.94e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.77	-10.99	-0.57	3.9e-23	Height;
KIRP	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.99	14.13	0.67	1.37e-33	Subjective well-being;
KIRP	cis	rs504918	0.556	rs73188162	chr3:123967920	A/G	cg05766129	chr3:123988013	KALRN	-0.44	-5.3	-0.32	2.55e-7	Schizophrenia;
KIRP	cis	rs858239	0.867	rs10250602	chr7:23303701	T/C	cg23682824	chr7:23144976	KLHL7	0.45	5.22	0.32	3.87e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs8077577	0.895	rs62072464	chr17:18108314	T/C	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs2380205	0.967	rs4497300	chr10:5898241	C/G	cg27141509	chr10:5886111	NA	-0.38	-5.55	-0.33	7.49e-8	Breast cancer;
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11987759	chr7:65425863	GUSB	-0.68	-9.55	-0.52	1.36e-18	Aortic root size;
KIRP	cis	rs11628318	0.614	rs10782496	chr14:103079725	C/G	cg01864069	chr14:103024347	NA	-0.42	-5.22	-0.32	3.89e-7	Platelet count;
KIRP	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.5	-6.14	-0.36	3.3e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.89	-10.22	-0.55	1.13e-20	Corneal astigmatism;
KIRP	cis	rs4141404	0.737	rs5998058	chr22:32006408	C/T	cg02404636	chr22:31891804	SFI1	0.51	5.74	0.34	2.73e-8	Paclitaxel-induced neuropathy;
KIRP	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9843304	0.528	rs11919764	chr3:149187235	C/T	cg08667024	chr3:149219783	TM4SF4	-0.61	-9.28	-0.51	8.89e-18	Gallstone disease;
KIRP	trans	rs7939886	0.920	rs17150117	chr11:55941186	T/C	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg15655495	chr12:38532458	NA	0.25	4.92	0.3	1.56e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.69	9.9	0.53	1.19e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs10782582	0.758	rs11161859	chr1:76370600	T/C	cg10283277	chr11:111472630	SIK2	-0.31	-6.3	-0.37	1.38e-9	Daytime sleep phenotypes;
KIRP	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg23531748	chr20:60969906	CABLES2	0.36	5.0	0.3	1.11e-6	Colorectal cancer;
KIRP	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg07382826	chr16:28625726	SULT1A1	0.47	5.42	0.33	1.44e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg19338460	chr6:170058176	WDR27	-0.42	-5.55	-0.33	7.28e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.24	11.89	0.6	4.51e-26	Diabetic retinopathy;
KIRP	cis	rs4478858	0.735	rs6679365	chr1:31787866	A/C	cg00250761	chr1:31883323	NA	0.31	5.39	0.32	1.69e-7	Alcohol dependence;
KIRP	cis	rs2594989	0.733	rs2447605	chr3:11574296	C/G	cg01796438	chr3:11312864	ATG7	0.45	5.83	0.35	1.73e-8	Circulating chemerin levels;
KIRP	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.52	-6.96	-0.41	3.08e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.05	-0.41	1.82e-11	Gut microbiome composition (summer);
KIRP	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.48	7.42	0.43	1.89e-12	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-6.41	-0.38	7.34e-10	Bipolar disorder;
KIRP	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.79	12.61	0.63	1.83e-28	Schizophrenia;
KIRP	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg09033563	chr22:24373618	LOC391322	-0.39	-5.12	-0.31	6.21e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg24304309	chr1:154577895	ADAR	0.38	5.74	0.34	2.72e-8	Blood protein levels;
KIRP	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.8	11.0	0.57	3.64e-23	Aortic root size;
KIRP	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg13628971	chr7:2884303	GNA12	0.46	6.07	0.36	4.76e-9	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04597389	chr17:79935740	ASPSCR1	0.48	6.95	0.41	3.22e-11	Survival in pancreatic cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15904908	chr15:43213022	TTBK2	0.45	6.11	0.36	3.78e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-8.97	-0.5	7.59e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.61	5.24	0.32	3.43e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2635047	0.615	rs2571005	chr18:44714365	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-7.32	-0.42	3.53e-12	Educational attainment;
KIRP	cis	rs7771547	0.855	rs9368942	chr6:36566513	C/G	cg04289385	chr6:36355825	ETV7	0.39	5.37	0.32	1.85e-7	Platelet distribution width;
KIRP	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg00919237	chr7:87102261	ABCB4	-0.73	-9.08	-0.5	3.58e-17	Gallbladder cancer;
KIRP	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26207909	chr14:103986467	CKB	0.74	10.61	0.56	6.71e-22	Body mass index;
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-6.88	-0.4	5e-11	Lymphocyte counts;
KIRP	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-4.98	-0.3	1.2e-6	Life satisfaction;
KIRP	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	1.2	11.08	0.58	2.01e-23	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.33	-0.37	1.12e-9	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs8027181	0.839	rs9460	chr15:73044575	C/T	cg25996835	chr15:72978165	BBS4;HIGD2B	0.51	7.61	0.44	5.98e-13	Triglyceride levels;
KIRP	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.65	6.79	0.4	8.16e-11	Bipolar disorder;
KIRP	cis	rs7221595	0.825	rs8074860	chr17:3986657	C/G	cg21734707	chr17:3908241	ZZEF1	0.52	4.84	0.3	2.27e-6	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg18612461	chr15:75251733	NA	0.33	5.12	0.31	6.14e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs11627756	0.957	rs12434778	chr14:103142135	G/T	cg01864069	chr14:103024347	NA	0.55	6.44	0.38	6.22e-10	Mean platelet volume;
KIRP	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.04	0.31	8.94e-7	Electroencephalogram traits;
KIRP	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11987759	chr7:65425863	GUSB	-0.49	-6.36	-0.38	9.64e-10	Aortic root size;
KIRP	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.68	-0.39	1.54e-10	Myopia (pathological);
KIRP	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg24189917	chr7:1970923	MAD1L1	-0.55	-4.94	-0.3	1.45e-6	Bipolar disorder;
KIRP	trans	rs76288851	0.799	rs73205610	chr3:126585833	G/T	cg13821433	chr2:26726535	OTOF	0.58	6.49	0.38	4.61e-10	Alcoholic chronic pancreatitis;
KIRP	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.58	6.84	0.4	6.22e-11	Platelet count;
KIRP	cis	rs1656402	0.906	rs7607107	chr2:233452344	T/G	cg03852847	chr2:233439513	NA	-0.66	-8.55	-0.48	1.29e-15	Non-small cell lung cancer (survival);
KIRP	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg22117172	chr7:91764530	CYP51A1	0.4	5.55	0.33	7.36e-8	Breast cancer;
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg04660111	chr19:49199234	FUT2	0.36	5.46	0.33	1.14e-7	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs7017914	0.967	rs1902614	chr8:71656167	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.13	-0.36	3.41e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg25930748	chr6:82957449	IBTK	-0.45	-6.08	-0.36	4.46e-9	Metabolic traits;
KIRP	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg17133734	chr15:86042851	AKAP13	0.48	5.99	0.36	7.27e-9	Coronary artery disease;
KIRP	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg01181863	chr3:195395398	SDHAP2	-0.7	-9.22	-0.51	1.39e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17691542	chr6:26056736	HIST1H1C	0.53	6.63	0.39	2.08e-10	Height;
KIRP	cis	rs732765	0.734	rs10438025	chr14:75183239	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.45	-4.88	-0.3	1.9e-6	Non-small cell lung cancer;
KIRP	cis	rs6684428	0.610	rs12123610	chr1:56312992	A/T	cg11651538	chr1:56320950	NA	0.73	7.72	0.44	2.99e-13	Airflow obstruction;
KIRP	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs34734847	0.871	rs2239760	chr12:121163518	C/A	cg21892295	chr12:121157589	UNC119B	-0.38	-5.29	-0.32	2.75e-7	Mean corpuscular volume;
KIRP	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.79	10.96	0.57	5.03e-23	Aortic root size;
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.5	-6.5	-0.38	4.37e-10	Testicular germ cell tumor;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg09028132	chr20:37078135	SNORA60;SNHG11	0.58	6.03	0.36	6.01e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.98e-34	Menopause (age at onset);
KIRP	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg01304814	chr3:48885189	PRKAR2A	0.59	5.31	0.32	2.44e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1816752	0.774	rs2862895	chr13:24984466	T/A	cg22771759	chr13:24902376	NA	0.38	4.89	0.3	1.86e-6	Obesity-related traits;
KIRP	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg21890820	chr11:65308645	LTBP3	0.44	5.51	0.33	9.22e-8	Bone mineral density;
KIRP	cis	rs7666738	0.515	rs13142498	chr4:98792443	G/T	cg05340658	chr4:99064831	C4orf37	0.66	7.68	0.44	3.69e-13	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg12560992	chr17:57184187	TRIM37	0.59	5.24	0.32	3.47e-7	Cognitive test performance;
KIRP	cis	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg03342759	chr3:160939853	NMD3	0.41	4.84	0.3	2.26e-6	Morning vs. evening chronotype;
KIRP	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.5	7.13	0.41	1.11e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1873147	1.000	rs1873147	chr15:63312632	G/A	cg12160578	chr15:63334699	TPM1	-0.47	-5.77	-0.35	2.39e-8	Orofacial clefts;
KIRP	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.57	-7.08	-0.41	1.54e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs8084125	0.765	rs72981159	chr18:74945042	A/G	cg05528293	chr18:74961138	GALR1	0.5	5.35	0.32	2.03e-7	Obesity-related traits;
KIRP	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.48	-5.84	-0.35	1.6e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	trans	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg24537038	chr9:99213506	HABP4	0.47	6.06	0.36	5.19e-9	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	4.96	0.3	1.3e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg18643199	chr10:82363313	SH2D4B	-0.54	-4.98	-0.3	1.22e-6	Post bronchodilator FEV1;
KIRP	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.47	7.32	0.42	3.54e-12	Tumor biomarkers;
KIRP	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.44	-5.15	-0.31	5.29e-7	Height;
KIRP	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg20302533	chr7:39170763	POU6F2	0.29	6.36	0.38	9.85e-10	IgG glycosylation;
KIRP	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg23649088	chr2:200775458	C2orf69	-0.57	-4.96	-0.3	1.31e-6	Schizophrenia;
KIRP	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg17443007	chr1:101659419	NA	0.39	5.53	0.33	8.14e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.46	5.99	0.36	7.42e-9	Coronary artery disease;
KIRP	trans	rs7404843	0.925	rs7404803	chr16:15530454	T/C	cg02716450	chr16:28638775	NA	-0.87	-8.83	-0.49	1.96e-16	Testicular germ cell tumor;
KIRP	cis	rs12716641	0.760	rs4240690	chr8:6897512	G/A	cg26123975	chr8:6873754	DEFA1;DEFA3;DEFA1B	-0.35	-4.9	-0.3	1.75e-6	IgA nephropathy;
KIRP	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.82	-13.76	-0.66	2.47e-32	Brugada syndrome;
KIRP	trans	rs9386485	0.547	rs11152931	chr6:106345283	A/G	cg24301724	chr12:131617044	GPR133	0.32	6.02	0.36	6.17e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
KIRP	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg22676075	chr6:135203613	NA	-0.47	-6.71	-0.39	1.32e-10	Red blood cell count;
KIRP	cis	rs6753739	0.871	rs10932796	chr2:220021512	T/C	cg01749213	chr2:219906749	CCDC108	0.42	5.28	0.32	2.82e-7	Height;
KIRP	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.39	-5.36	-0.32	1.95e-7	Height;
KIRP	cis	rs6977660	0.943	rs10274447	chr7:19850640	C/T	cg05791153	chr7:19748676	TWISTNB	0.51	5.58	0.34	6.21e-8	Thyroid stimulating hormone;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12503257	chr17:8924773	NTN1	0.48	6.27	0.37	1.63e-9	Parkinson's disease;
KIRP	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	5.65	0.34	4.49e-8	Educational attainment;
KIRP	cis	rs2281603	0.951	rs1453009	chr14:64995694	G/A	cg25009451	chr14:65006716	HSPA2	0.48	5.2	0.31	4.12e-7	Lymphocyte counts;
KIRP	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.58	-7.15	-0.42	9.59e-12	Diastolic blood pressure;
KIRP	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.55	7.58	0.44	7.12e-13	Gout;
KIRP	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg04935436	chr20:30431758	NA	0.47	6.35	0.38	1.04e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg13906792	chr15:75199810	C15orf17	-0.38	-5.47	-0.33	1.1e-7	Breast cancer;
KIRP	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.47	-0.33	1.11e-7	Chronic sinus infection;
KIRP	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.41	-0.43	2.03e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2150410	0.831	rs67382266	chr21:40527341	A/C	cg11890956	chr21:40555474	PSMG1	-0.75	-5.46	-0.33	1.15e-7	Temperament (bipolar disorder);
KIRP	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg00800038	chr16:89945340	TCF25	-0.89	-7.26	-0.42	4.94e-12	Skin colour saturation;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg18234130	chr8:27182889	PTK2B	0.55	7.16	0.42	9.4e-12	Neuroticism;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg02987984	chr7:101457447	NA	-0.47	-6.04	-0.36	5.63e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.35	4.89	0.3	1.8e-6	Motion sickness;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg23334365	chr11:67806337	TCIRG1	0.44	6.14	0.36	3.22e-9	Survival in pancreatic cancer;
KIRP	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg02175503	chr12:58329896	NA	0.74	8.91	0.49	1.13e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg23698023	chr8:27181813	PTK2B	0.36	5.39	0.32	1.65e-7	Neuroticism;
KIRP	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-4.99	-0.3	1.16e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg11784071	chr10:104629166	AS3MT	-0.39	-5.44	-0.33	1.25e-7	Arsenic metabolism;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg04804543	chr8:142233427	SLC45A4	1.02	16.94	0.73	3.57e-43	Immature fraction of reticulocytes;
KIRP	cis	rs732716	0.785	rs34080966	chr19:4417845	C/T	cg03719555	chr19:4455413	UBXN6	-0.47	-7.34	-0.42	3.03e-12	Mean corpuscular volume;
KIRP	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.23e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7301016	0.846	rs7296573	chr12:63033041	A/C	cg01804193	chr12:63026212	NA	0.59	6.28	0.37	1.49e-9	IgG glycosylation;
KIRP	cis	rs909341	0.680	rs2427534	chr20:62366478	A/G	cg03999872	chr20:62272968	STMN3	-0.6	-6.86	-0.4	5.6e-11	Atopic dermatitis;
KIRP	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06481639	chr22:41940642	POLR3H	0.69	7.01	0.41	2.31e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs75646498	0.677	rs8042917	chr15:29868600	C/T	cg08904058	chr15:29859427	FAM189A1	-0.46	-6.15	-0.36	3.15e-9	Diisocyanate-induced asthma;
KIRP	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.59	9.82	0.53	2.03e-19	Schizophrenia;
KIRP	trans	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg04837231	chr1:7885239	PER3	0.41	6.03	0.36	6.06e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs300774	0.841	rs410690	chr2:203346	G/A	cg10118717	chr2:203439	NA	0.42	5.21	0.32	3.98e-7	Suicide attempts in bipolar disorder;
KIRP	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.18	20.51	0.79	3.48e-55	Cognitive function;
KIRP	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.76	10.1	0.54	2.75e-20	Menopause (age at onset);
KIRP	cis	rs847851	1.000	rs2473615	chr6:34893910	C/G	cg25473981	chr6:34433676	PACSIN1	0.42	5.2	0.31	4.2e-7	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs6918152	1.000	rs12206548	chr6:506231	C/T	cg08733086	chr1:154947035	CKS1B;SHC1	-0.51	-6.02	-0.36	6.22e-9	Black vs. red hair color;Black vs. blond hair color;
KIRP	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.14	24.03	0.84	1.74e-66	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg01763666	chr17:80159506	CCDC57	-0.36	-4.97	-0.3	1.28e-6	Life satisfaction;
KIRP	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.77	11.57	0.59	5.11e-25	Height;
KIRP	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs526231	0.543	rs32851	chr5:102468671	A/G	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg24375607	chr4:120327624	NA	0.56	5.82	0.35	1.86e-8	Corneal astigmatism;
KIRP	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.49	6.76	0.4	9.93e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs57786342	0.569	rs8019383	chr14:69277341	A/G	cg03189333	chr14:69283534	NA	-0.43	-4.9	-0.3	1.74e-6	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs6430538	0.671	rs6740829	chr2:135573264	A/G	cg12500956	chr2:135428796	TMEM163	0.42	5.31	0.32	2.49e-7	Parkinson's disease;
KIRP	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.44	0.33	1.3e-7	Breast cancer;
KIRP	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg26727032	chr16:67993705	SLC12A4	-0.63	-6.22	-0.37	2.17e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.68	7.13	0.41	1.1e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg07636037	chr3:49044803	WDR6	-0.67	-6.79	-0.4	8.58e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg13010199	chr12:38710504	ALG10B	0.54	6.57	0.39	2.92e-10	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.85	-0.45	1.31e-13	Triglycerides;
KIRP	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.6	-6.6	-0.39	2.44e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs6838801	0.675	rs3733247	chr4:77536598	G/A	cg17476223	chr4:77663285	SHROOM3	0.4	5.72	0.34	3.09e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg06521331	chr12:34319734	NA	-0.58	-7.03	-0.41	1.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.9	14.26	0.67	5.04e-34	Height;
KIRP	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg17470449	chr10:769945	NA	0.71	7.2	0.42	7.13e-12	Uric acid levels;
KIRP	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg24633833	chr3:10029261	TMEM111	0.56	4.88	0.3	1.89e-6	Alzheimer's disease;
KIRP	cis	rs7106204	0.514	rs7117803	chr11:24253214	A/T	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg19767477	chr5:127420684	SLC12A2	-0.35	-5.03	-0.31	9.39e-7	Ileal carcinoids;
KIRP	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg25281562	chr12:121454272	C12orf43	0.48	5.22	0.32	3.78e-7	N-glycan levels;
KIRP	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg12559939	chr2:27858050	GPN1	0.47	5.9	0.35	1.22e-8	Oral cavity cancer;
KIRP	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg19539972	chr4:7069911	GRPEL1	-0.81	-5.16	-0.31	5.01e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg00129232	chr17:37814104	STARD3	0.62	7.76	0.44	2.31e-13	Self-reported allergy;
KIRP	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.54	6.2	0.37	2.31e-9	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg21186296	chr8:27182909	PTK2B	0.48	6.21	0.37	2.23e-9	Neuroticism;
KIRP	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	1.09	22.49	0.82	1.34e-61	Parkinson's disease;
KIRP	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg09788416	chr12:39539408	NA	0.39	5.18	0.31	4.53e-7	Morning vs. evening chronotype;
KIRP	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.12	14.65	0.68	2.34e-35	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg04310649	chr10:35416472	CREM	-0.59	-7.06	-0.41	1.66e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.69	10.62	0.56	6.38e-22	Lung cancer;
KIRP	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg00857998	chr1:205179979	DSTYK	0.59	7.34	0.42	3.12e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.54	-6.36	-0.38	9.73e-10	HDL cholesterol;
KIRP	cis	rs6125597	0.967	rs6067037	chr20:47913578	C/T	cg03212862	chr20:47662828	CSE1L	-0.41	-5.25	-0.32	3.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	5.91	0.35	1.16e-8	Systolic blood pressure;
KIRP	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	trans	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg06521331	chr12:34319734	NA	-0.54	-6.75	-0.4	1.03e-10	Heart rate;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg02462569	chr6:150064036	NUP43	-0.42	-6.36	-0.38	9.7e-10	Lung cancer;
KIRP	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg19052272	chr2:3704530	ALLC	0.69	8.99	0.5	6.8e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	10.41	0.55	2.87e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.96	-14.35	-0.68	2.41e-34	Personality dimensions;
KIRP	cis	rs2573652	1.000	rs2573625	chr15:100513158	A/G	cg09918751	chr15:100517450	ADAMTS17	0.7	10.69	0.56	3.61e-22	Height;
KIRP	cis	rs228437	1.000	rs1535118	chr6:134912447	C/T	cg24504307	chr6:134963096	NA	-0.5	-7.27	-0.42	4.67e-12	Melanoma;
KIRP	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg17554472	chr22:41940697	POLR3H	-0.45	-5.47	-0.33	1.13e-7	Neuroticism;
KIRP	cis	rs3857067	1.000	rs1904095	chr4:95012530	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.85	-0.3	2.16e-6	QT interval;
KIRP	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.68	10.29	0.55	6.98e-21	Dupuytren's disease;
KIRP	cis	rs13033859	0.758	rs4009	chr2:125309	C/T	cg10118717	chr2:203439	NA	-0.38	-5.81	-0.35	1.95e-8	Mitochondrial DNA levels;
KIRP	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.48	8.03	0.46	4.01e-14	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs883565	0.569	rs1298712	chr3:39169693	A/G	cg01426195	chr3:39028469	NA	0.5	8.01	0.45	4.48e-14	Handedness;
KIRP	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26314531	chr2:26401878	FAM59B	-0.53	-5.43	-0.33	1.36e-7	Gut microbiome composition (summer);
KIRP	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.47	6.07	0.36	4.71e-9	Blood metabolite levels;
KIRP	cis	rs35000415	0.938	rs12531711	chr7:128617466	A/G	cg19972273	chr7:128594194	NA	0.8	6.02	0.36	6.23e-9	Systemic lupus erythematosus;
KIRP	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.82	-10.27	-0.55	7.88e-21	Menarche (age at onset);
KIRP	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.36	4.94	0.3	1.48e-6	Coronary artery disease;
KIRP	cis	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg20368463	chr18:77673604	PQLC1	-0.44	-5.59	-0.34	5.9e-8	Schizophrenia;
KIRP	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.57	-11.84	-0.6	6.67e-26	Diabetic kidney disease;
KIRP	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg06740227	chr12:86229804	RASSF9	0.49	5.91	0.35	1.15e-8	Major depressive disorder;
KIRP	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs28830936	0.535	rs2289743	chr15:41860698	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.24	-4.94	-0.3	1.47e-6	Diastolic blood pressure;
KIRP	cis	rs116979167	0.575	rs1728649	chr7:105170570	A/G	cg19920283	chr7:105172520	RINT1	0.53	5.95	0.35	9.01e-9	Bipolar disorder (body mass index interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12838843	chr3:141205758	RASA2	0.52	6.59	0.39	2.65e-10	Parkinson's disease;
KIRP	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.88	13.49	0.65	2.09e-31	Anterior chamber depth;
KIRP	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.38	5.08	0.31	7.43e-7	Bipolar disorder;
KIRP	cis	rs9914544	0.545	rs3764445	chr17:18767923	C/T	cg26378065	chr17:18585709	ZNF286B	0.37	4.89	0.3	1.78e-6	Educational attainment (years of education);
KIRP	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.84	-11.89	-0.6	4.63e-26	Lung cancer;
KIRP	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg10377582	chr12:51612794	POU6F1	-0.3	-4.9	-0.3	1.72e-6	Cisplatin-induced ototoxicity;
KIRP	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.92	15.31	0.7	1.24e-37	Metabolic syndrome;
KIRP	cis	rs72730918	0.564	rs2414112	chr15:51903024	C/T	cg14296394	chr15:51910925	DMXL2	-0.77	-10.81	-0.57	1.55e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg01116966	chr5:133450017	TCF7	0.47	6.65	0.39	1.83e-10	Body mass index in non-asthmatics;
KIRP	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg18016565	chr1:150552671	MCL1	0.39	5.9	0.35	1.19e-8	Melanoma;
KIRP	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg00677455	chr12:58241039	CTDSP2	0.96	12.48	0.62	4.92e-28	Multiple sclerosis;
KIRP	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-0.42	-5.4	-0.33	1.58e-7	Acne (severe);
KIRP	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.65	9.77	0.53	3.01e-19	Age-related hearing impairment;
KIRP	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs1876905	0.597	rs1150076	chr6:111548430	A/G	cg15721981	chr6:111408429	SLC16A10	0.55	5.0	0.3	1.1e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs35079168	0.661	rs3118529	chr9:137304915	C/T	cg13941235	chr9:137270186	RXRA	-0.25	-5.18	-0.31	4.52e-7	Intelligence;
KIRP	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.49	-5.31	-0.32	2.4e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs2599510	0.755	rs67257914	chr2:32804018	G/A	cg02381751	chr2:32503542	YIPF4	0.46	5.22	0.32	3.78e-7	Interleukin-18 levels;
KIRP	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg13072238	chr3:49761600	GMPPB	-0.57	-4.93	-0.3	1.54e-6	Menarche (age at onset);
KIRP	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.52	-11.16	-0.58	1.14e-23	Refractive error;
KIRP	cis	rs4423214	0.592	rs10898234	chr11:71236684	A/G	cg05163923	chr11:71159392	DHCR7	-0.69	-6.71	-0.39	1.33e-10	Vitamin D levels;
KIRP	cis	rs1816752	0.721	rs7399656	chr13:24989846	A/G	cg02811702	chr13:24901961	NA	0.41	5.41	0.33	1.51e-7	Obesity-related traits;
KIRP	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.62	-6.76	-0.4	1.01e-10	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg21546286	chr11:48923668	NA	-0.48	-6.11	-0.36	3.82e-9	HDL cholesterol;
KIRP	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.43	6.34	0.37	1.07e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg21346818	chr17:46970413	ATP5G1	-0.43	-6.12	-0.36	3.62e-9	Survival in pancreatic cancer;
KIRP	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.64	8.18	0.46	1.52e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs6684514	1.000	rs12038217	chr1:156248297	C/T	cg16558208	chr1:156270281	VHLL	-0.45	-6.04	-0.36	5.8e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg03060546	chr3:49711283	APEH	0.43	5.55	0.33	7.55e-8	Parkinson's disease;
KIRP	cis	rs6840360	0.606	rs10028035	chr4:152347825	T/G	cg25486957	chr4:152246857	NA	-0.42	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7923609	0.967	rs2393966	chr10:65134814	T/G	cg01631684	chr10:65280961	REEP3	-0.48	-5.61	-0.34	5.47e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg13147721	chr7:65941812	NA	-1.0	-7.02	-0.41	2.19e-11	Diabetic kidney disease;
KIRP	cis	rs9962915	0.967	rs1785382	chr18:5590926	C/T	cg12967001	chr18:5544089	EPB41L3	-0.39	-4.86	-0.3	2.09e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg02158880	chr13:53174818	NA	0.42	5.71	0.34	3.23e-8	Lewy body disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25228773	chr19:2328682	SPPL2B;LSM7	0.49	6.02	0.36	6.19e-9	Parkinson's disease;
KIRP	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.84	8.39	0.47	3.93e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg07384165	chr1:10488281	NA	-0.5	-6.4	-0.38	7.92e-10	Prostate cancer;
KIRP	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg00977110	chr5:151150581	G3BP1	-0.62	-6.17	-0.37	2.8e-9	Preschool internalizing problems;
KIRP	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	1.03	19.06	0.77	2.28e-50	Heart rate;
KIRP	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.4	-0.33	1.55e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs2412819	0.599	rs2470120	chr15:43929070	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.49	6.07	0.36	4.72e-9	Lung cancer;
KIRP	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg24375607	chr4:120327624	NA	0.39	5.01	0.3	1.04e-6	Diastolic blood pressure;
KIRP	cis	rs829661	0.739	rs7592355	chr2:30793862	C/G	cg10949345	chr2:30726833	LCLAT1	1.02	13.06	0.64	5.57e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg06606381	chr12:133084897	FBRSL1	-1.0	-6.1	-0.36	4.03e-9	Depression;
KIRP	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg12315302	chr6:26189340	HIST1H4D	1.05	6.07	0.36	4.92e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg02079421	chr21:47851545	PCNT	0.47	6.1	0.36	3.99e-9	Pancreatic cancer;
KIRP	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.46	-5.91	-0.35	1.14e-8	Response to temozolomide;
KIRP	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.19	13.83	0.66	1.39e-32	Sexual dysfunction (female);
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg11814155	chr7:99998594	ZCWPW1	0.62	5.61	0.34	5.54e-8	Platelet count;
KIRP	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.56	7.91	0.45	8.61e-14	Dupuytren's disease;
KIRP	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.59	7.67	0.44	3.98e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs2274273	0.870	rs10149420	chr14:55854257	T/C	cg04306507	chr14:55594613	LGALS3	0.52	8.24	0.47	1.01e-14	Protein biomarker;
KIRP	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg02811702	chr13:24901961	NA	0.4	5.32	0.32	2.36e-7	Obesity-related traits;
KIRP	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.59	-7.38	-0.43	2.38e-12	Red cell distribution width;
KIRP	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.43	5.31	0.32	2.49e-7	Aortic root size;
KIRP	cis	rs1185460	0.546	rs2508948	chr11:118951642	A/T	cg23280166	chr11:118938394	VPS11	-0.44	-5.24	-0.32	3.43e-7	Coronary artery disease;
KIRP	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg02475777	chr4:1388615	CRIPAK	0.37	4.89	0.3	1.86e-6	Obesity-related traits;
KIRP	cis	rs11138902	0.649	rs13286400	chr9:72148579	C/G	cg14397918	chr9:72078829	APBA1	-0.32	-5.14	-0.31	5.66e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Life satisfaction;
KIRP	trans	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg01311341	chr22:25575246	KIAA1671	-0.58	-6.3	-0.37	1.35e-9	Glioblastoma;
KIRP	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg02415014	chr8:143852576	LYNX1	-0.34	-5.34	-0.32	2.08e-7	Urinary tract infection frequency;
KIRP	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.6	-7.19	-0.42	7.77e-12	Initial pursuit acceleration;
KIRP	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	5.89	0.35	1.27e-8	Mean platelet volume;
KIRP	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg01872077	chr2:219646372	CYP27A1	-0.41	-5.72	-0.34	3.15e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg09065629	chr16:1709722	CRAMP1L	0.83	5.91	0.35	1.14e-8	Snoring;
KIRP	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	0.55	6.6	0.39	2.5e-10	Prudent dietary pattern;
KIRP	cis	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg09264619	chr17:80180166	NA	-0.51	-6.07	-0.36	4.85e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs34382810	0.602	rs1860056	chr12:2311836	A/T	cg10668781	chr12:2307325	CACNA1C	-0.26	-4.88	-0.3	1.94e-6	Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);Psychosis proneness (hypomanic personality scale);
KIRP	cis	rs8084125	1.000	rs8084125	chr18:74952758	T/C	cg26065057	chr18:74961000	GALR1	0.79	7.83	0.45	1.44e-13	Obesity-related traits;
KIRP	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg10047753	chr17:41438598	NA	1.13	18.15	0.76	2.7e-47	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15697935	chr1:210500388	HHAT	0.54	7.1	0.41	1.36e-11	Interleukin-4 levels;
KIRP	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg01721255	chr8:58191610	C8orf71	0.54	5.68	0.34	3.86e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-10.45	-0.55	2.24e-21	Chronic sinus infection;
KIRP	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.21	0.64	1.79e-30	Bladder cancer;
KIRP	cis	rs7808935	0.958	rs67152137	chr7:27975919	G/C	cg22168087	chr7:27702803	HIBADH	0.63	6.85	0.4	6.01e-11	Prostate cancer;
KIRP	cis	rs2708977	0.643	rs35071802	chr2:97402064	T/C	cg26665480	chr2:98280029	ACTR1B	0.41	4.84	0.3	2.26e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.92	0.35	1.05e-8	Total cholesterol levels;
KIRP	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.73	0.49	3.94e-16	Electroencephalogram traits;
KIRP	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.28	-0.47	7.71e-15	Obesity-related traits;
KIRP	cis	rs6594713	0.605	rs66540465	chr5:112840706	G/A	cg12552261	chr5:112820674	MCC	0.55	4.94	0.3	1.48e-6	Brain cytoarchitecture;
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13939156	chr17:80058883	NA	0.5	7.53	0.43	9.89e-13	Life satisfaction;
KIRP	cis	rs1555895	0.543	rs749297	chr10:861837	A/G	cg10017260	chr10:834428	NA	-0.41	-5.78	-0.35	2.22e-8	Survival in rectal cancer;
KIRP	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-0.64	-5.89	-0.35	1.28e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16818443	chr4:2965195	GRK4;NOP14	0.51	7.16	0.42	9.05e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg08975724	chr8:8085496	FLJ10661	0.61	7.54	0.43	8.87e-13	Retinal vascular caliber;
KIRP	trans	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.8200000000000003e-11	Bladder cancer;
KIRP	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.58	-7.2	-0.42	7.15e-12	Fibrinogen levels;
KIRP	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.59	9.82	0.53	2.03e-19	Schizophrenia;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg02858985	chr1:115322961	SIKE1	-0.44	-6.27	-0.37	1.59e-9	Warfarin maintenance dose;
KIRP	cis	rs7224685	0.569	rs7221595	chr17:4007594	C/T	cg09597638	chr17:3907349	NA	-0.51	-5.24	-0.32	3.52e-7	Type 2 diabetes;
KIRP	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.58	-7.5	-0.43	1.16e-12	Monocyte count;
KIRP	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg00857998	chr1:205179979	DSTYK	0.59	7.31	0.42	3.82e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.55	-8.77	-0.49	3.09e-16	Lymphocyte counts;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg13049961	chr5:139498384	NA	0.41	6.34	0.37	1.07e-9	Migraine with aura;
KIRP	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.92	-14.72	-0.68	1.38e-35	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19171272	chr22:38449367	NA	-0.58	-8.71	-0.49	4.58e-16	Glioblastoma;Glioma;
KIRP	cis	rs7870753	0.945	rs7870253	chr9:99231096	T/A	cg25260653	chr9:99212216	HABP4	0.54	6.03	0.36	6.07e-9	Height;
KIRP	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.8	-0.4	8.07e-11	Neuroticism;
KIRP	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-1.06	-18.1	-0.76	4.11e-47	Gut microbiome composition (winter);
KIRP	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg17376030	chr22:41985996	PMM1	0.53	6.42	0.38	6.78e-10	Vitiligo;
KIRP	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.72	8.88	0.49	1.45e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs17453880	0.890	rs28842566	chr5:152048590	A/G	cg12297329	chr5:152029980	NA	-0.71	-10.5	-0.56	1.47e-21	Subjective well-being;
KIRP	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.47	7.08	0.41	1.53e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.63	8.43	0.47	2.99e-15	Lymphocyte counts;
KIRP	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg10503236	chr1:231470652	EXOC8	-0.53	-7.58	-0.43	7.19e-13	Hemoglobin concentration;
KIRP	cis	rs8070740	0.898	rs8074617	chr17:5323989	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.36	0.43	2.68e-12	Menopause (age at onset);
KIRP	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.39	0.38	8.4e-10	Aortic root size;
KIRP	cis	rs71597109	0.568	rs11940244	chr4:102727575	G/T	cg14855874	chr4:102712397	BANK1	0.4	5.2	0.31	4.14e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.78	8.84	0.49	1.86e-16	Corneal astigmatism;
KIRP	cis	rs13315871	1.000	rs4585221	chr3:58415567	C/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.46	-0.33	1.19e-7	Cholesterol, total;
KIRP	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg02073558	chr3:44770973	ZNF501	0.62	8.89	0.49	1.32e-16	Depressive symptoms;
KIRP	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg26384229	chr12:38710491	ALG10B	-0.45	-5.96	-0.36	8.57e-9	Bladder cancer;
KIRP	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg09165964	chr15:75287851	SCAMP5	-0.92	-8.45	-0.47	2.61e-15	Lung cancer;
KIRP	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-5.58	-0.34	6.35e-8	Educational attainment;
KIRP	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg14289246	chr4:154710475	SFRP2	-0.52	-6.83	-0.4	6.5e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs1322639	0.614	rs9294967	chr6:169565406	C/T	cg04662567	chr6:169592167	NA	0.66	5.04	0.31	9.05e-7	Pulse pressure;
KIRP	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.97e-44	Breast cancer;
KIRP	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg09754948	chr16:28834200	ATXN2L	0.48	5.58	0.34	6.23e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.48	-5.58	-0.34	6.36e-8	Colorectal cancer;
KIRP	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg25338242	chr13:114786047	RASA3	0.41	4.9	0.3	1.73e-6	Schizophrenia;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg02996583	chr8:142237188	SLC45A4	-0.49	-5.98	-0.36	7.63e-9	Immature fraction of reticulocytes;
KIRP	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	1.3	11.89	0.6	4.75e-26	Diabetic retinopathy;
KIRP	cis	rs7714670	1.000	rs13172686	chr5:73073424	T/C	cg04480106	chr5:72934606	RGNEF	-0.38	-5.12	-0.31	6.04e-7	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg12573674	chr2:1569213	NA	-0.56	-5.23	-0.32	3.58e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg21360079	chr12:107162445	NA	-0.73	-10.28	-0.55	7.25e-21	Heart rate;
KIRP	trans	rs16867225	1.000	rs75152665	chr2:181031327	T/A	cg18179931	chr3:194119058	GP5	-0.41	-6.47	-0.38	5.23e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg05347473	chr6:146136440	FBXO30	-0.64	-9.4	-0.51	4.09e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.25e-10	Protein C levels;
KIRP	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.52	-12.6	-0.63	2.03e-28	Hip circumference adjusted for BMI;
KIRP	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg20991723	chr1:152506922	NA	-0.42	-4.98	-0.3	1.22e-6	Hair morphology;
KIRP	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.4	-0.33	1.55e-7	Metabolite levels;
KIRP	cis	rs2733310	0.842	rs7164914	chr15:57531656	G/A	cg13626582	chr15:57592083	LOC283663	0.26	5.92	0.35	1.09e-8	Mean platelet volume;
KIRP	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg27624424	chr6:160112604	SOD2	0.55	6.52	0.38	3.94e-10	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs681343	1.000	rs681343	chr19:49206462	C/T	cg08619932	chr19:49200058	FUT2	0.38	5.92	0.35	1.07e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg00800569	chr2:239229395	TRAF3IP1	0.46	4.95	0.3	1.35e-6	Multiple system atrophy;
KIRP	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.65	8.27	0.47	8.32e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.7	-6.77	-0.4	9.41e-11	Arsenic metabolism;
KIRP	cis	rs2224391	0.628	rs9405261	chr6:5249702	C/T	cg13962347	chr6:5174647	LYRM4	-0.72	-9.98	-0.54	6.29e-20	Height;
KIRP	cis	rs17065868	1.000	rs9533921	chr13:45158608	G/A	cg10246903	chr13:45222710	NA	0.71	6.57	0.39	3e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.9	-13.33	-0.65	7.34e-31	Height;
KIRP	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.75	9.43	0.52	3.22e-18	Height;
KIRP	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg21017887	chr14:105400489	NA	0.55	9.18	0.51	1.8e-17	Systemic lupus erythematosus;
KIRP	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg08992911	chr2:238395768	MLPH	0.72	6.74	0.39	1.12e-10	Prostate cancer;
KIRP	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.71	-11.25	-0.58	5.64e-24	Hepatocellular carcinoma;
KIRP	cis	rs4664304	0.816	rs67045814	chr2:160821119	A/C	cg23995753	chr2:160760732	LY75	-0.38	-4.86	-0.3	2.05e-6	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.43	-5.04	-0.31	8.95e-7	Lung cancer;
KIRP	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.74	8.73	0.49	3.91e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs970821	0.667	rs2060111	chr8:124737893	A/G	cg00283535	chr8:124749564	ANXA13	0.33	5.47	0.33	1.08e-7	Breast cancer;
KIRP	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg22906224	chr7:99728672	NA	-0.5	-6.12	-0.36	3.58e-9	Coronary artery disease;
KIRP	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg18944383	chr4:111397179	ENPEP	0.52	9.1	0.5	3.17e-17	Height;
KIRP	cis	rs10214930	0.752	rs6966091	chr7:27660013	A/C	cg22168087	chr7:27702803	HIBADH	0.52	5.12	0.31	6.2e-7	Hypospadias;
KIRP	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.51	-6.0	-0.36	6.86e-9	Alzheimer's disease (late onset);
KIRP	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.64	0.34	4.55e-8	Height;
KIRP	cis	rs2017305	0.764	rs2487710	chr10:70782126	C/A	cg01024728	chr10:70782572	NA	0.6	4.87	0.3	2.02e-6	Depression (quantitative trait);
KIRP	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.29	-12.52	-0.62	3.71e-28	Atopic dermatitis;
KIRP	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-7.07	-0.41	1.55e-11	Coffee consumption (cups per day);
KIRP	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg16497661	chr14:103986332	CKB	-0.47	-6.14	-0.36	3.28e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.58	6.75	0.4	1.05e-10	Pancreatic cancer;
KIRP	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg04132472	chr17:19861366	AKAP10	0.4	5.2	0.31	4.17e-7	Schizophrenia;
KIRP	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg27432699	chr2:27873401	GPN1	-0.51	-6.63	-0.39	2.12e-10	Total body bone mineral density;
KIRP	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.05e-15	Motion sickness;
KIRP	cis	rs9549328	0.800	rs9549621	chr13:113633579	G/A	cg17524180	chr13:113633600	MCF2L	-0.3	-5.47	-0.33	1.13e-7	Systolic blood pressure;
KIRP	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	12.52	0.62	3.75e-28	Eye color traits;
KIRP	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.48	6.48	0.38	4.86e-10	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
KIRP	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	9.47	0.52	2.34e-18	Total body bone mineral density;
KIRP	cis	rs1656402	1.000	rs1656397	chr2:233428927	G/C	cg03852847	chr2:233439513	NA	0.72	12.18	0.61	5.04e-27	Non-small cell lung cancer (survival);
KIRP	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.54	6.61	0.39	2.36e-10	Monocyte count;
KIRP	cis	rs7538876	0.967	rs6695531	chr1:17720088	T/G	cg07965774	chr1:17746286	RCC2	0.28	4.89	0.3	1.81e-6	Basal cell carcinoma;
KIRP	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-0.86	-10.23	-0.55	1.08e-20	Corneal structure;
KIRP	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg09137382	chr11:130731461	NA	-0.55	-8.16	-0.46	1.78e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1620921	0.563	rs2243944	chr6:161280766	C/G	cg01280913	chr6:161186852	NA	-0.39	-5.18	-0.31	4.72e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg26207909	chr14:103986467	CKB	0.54	7.12	0.41	1.19e-11	Body mass index;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	0.85	6.35	0.38	1.01e-9	IgG glycosylation;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg06620762	chr15:76136437	UBE2Q2	-0.47	-6.04	-0.36	5.59e-9	Neuroticism;
KIRP	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg14132834	chr19:41945861	ATP5SL	-0.62	-8.45	-0.47	2.6e-15	Height;
KIRP	cis	rs787274	1.000	rs1965335	chr9:115504483	C/T	cg13803584	chr9:115635662	SNX30	0.72	7.78	0.44	2.04e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2242116	0.896	rs724448	chr3:46935734	A/C	cg23352942	chr3:46931381	PTH1R	-0.51	-7.04	-0.41	1.87e-11	Birth weight;
KIRP	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg24642439	chr20:33292090	TP53INP2	0.69	10.6	0.56	7.3e-22	Glomerular filtration rate (creatinine);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg19654209	chr19:13976743	NA	0.46	6.29	0.37	1.43e-9	DNA methylation (variation);
KIRP	cis	rs9394841	0.667	rs9471667	chr6:41776681	T/C	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs2904967	0.852	rs560097	chr11:65042530	A/C	cg12562828	chr11:65076843	NA	0.6	8.91	0.49	1.19e-16	Mean corpuscular volume;
KIRP	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg16989719	chr2:238392110	NA	-0.53	-7.2	-0.42	7.19e-12	Prostate cancer;
KIRP	cis	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.43	-5.33	-0.32	2.18e-7	Leprosy;
KIRP	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg02574844	chr11:5959923	NA	-0.54	-5.31	-0.32	2.44e-7	DNA methylation (variation);
KIRP	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg15744005	chr10:104629667	AS3MT	-0.3	-6.05	-0.36	5.42e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg18132916	chr6:79620363	NA	-0.37	-5.08	-0.31	7.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs8106542	0.865	rs8105546	chr19:10741202	G/A	cg23183932	chr19:10823679	QTRT1	0.43	4.9	0.3	1.72e-6	Platelet distribution width;
KIRP	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg05555928	chr11:63887634	MACROD1	-0.57	-5.33	-0.32	2.23e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg05043794	chr9:111880884	C9orf5	-0.27	-5.42	-0.33	1.44e-7	Menarche (age at onset);
KIRP	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg06197360	chr20:60970103	CABLES2	-0.51	-5.97	-0.36	8.03e-9	Colorectal cancer;
KIRP	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg11569703	chr11:65557185	OVOL1	0.48	8.67	0.48	5.78e-16	Acne (severe);
KIRP	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.67	9.21	0.51	1.5e-17	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.74	-5.61	-0.34	5.52e-8	Breast cancer;
KIRP	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.67	6.8	0.4	7.72e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	0.84	7.14	0.41	1.05e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs41264869	0.628	rs10494860	chr1:205167799	C/G	cg21214746	chr1:205091277	RBBP5	0.5	6.35	0.38	1.04e-9	Blood protein levels;
KIRP	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg13319975	chr6:146136371	FBXO30	-0.56	-7.66	-0.44	4.24e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs42648	0.508	rs39204	chr7:89734318	C/A	cg25739043	chr7:89950458	NA	-0.37	-5.68	-0.34	3.86e-8	Homocysteine levels;
KIRP	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.83	-0.45	1.43e-13	Gut microbiome composition (summer);
KIRP	cis	rs651907	0.640	rs771575	chr3:101619359	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	5.14	0.31	5.65e-7	Colorectal cancer;
KIRP	cis	rs10782582	0.609	rs1796827	chr1:76391536	A/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.43	-0.38	6.58e-10	Daytime sleep phenotypes;
KIRP	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg17724175	chr1:150552817	MCL1	0.32	5.3	0.32	2.54e-7	Urate levels;
KIRP	cis	rs4478137	0.931	rs11100488	chr4:164237660	C/A	cg06758707	chr4:164254230	NPY1R	0.76	10.13	0.54	2.14e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.85	-10.96	-0.57	5.21e-23	Cognitive function;
KIRP	cis	rs5753618	0.583	rs71324184	chr22:31752061	C/G	cg02404636	chr22:31891804	SFI1	0.56	6.75	0.4	1.03e-10	Colorectal cancer;
KIRP	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg21775007	chr8:11205619	TDH	-0.48	-6.31	-0.37	1.28e-9	Neuroticism;
KIRP	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.64	8.01	0.45	4.67e-14	Non-response to antidepressants and depression;
KIRP	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.77	-11.47	-0.59	1.08e-24	Obesity-related traits;
KIRP	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg07952391	chr2:88470173	THNSL2	-0.89	-6.95	-0.4	3.34e-11	Plasma clusterin levels;
KIRP	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg17554472	chr22:41940697	POLR3H	-0.44	-5.44	-0.33	1.31e-7	Vitiligo;
KIRP	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00684032	chr4:1343700	KIAA1530	0.6	8.11	0.46	2.42e-14	Obesity-related traits;
KIRP	trans	rs2998286	0.822	rs2807734	chr10:28801965	G/A	cg10174683	chr16:85619974	NA	-0.67	-6.08	-0.36	4.54e-9	Sum eosinophil basophil counts;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Eosinophil counts;
KIRP	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg25547332	chr5:131281432	NA	0.46	5.09	0.31	7e-7	Life satisfaction;
KIRP	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.45	6.8	0.4	8.04e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.81	12.72	0.63	7.96e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.19	21.27	0.8	1.16e-57	Cognitive function;
KIRP	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg11839771	chr15:80205821	ST20	-0.37	-5.3	-0.32	2.52e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.78	10.8	0.57	1.7e-22	Response to bleomycin (chromatid breaks);
KIRP	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26207909	chr14:103986467	CKB	0.5	6.7	0.39	1.43e-10	Body mass index;
KIRP	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg01631408	chr1:248437212	OR2T33	-0.45	-6.03	-0.36	6.09e-9	Common traits (Other);
KIRP	cis	rs11583043	1.000	rs6700743	chr1:101447384	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.67	7.97	0.45	6.06e-14	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	trans	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg07211511	chr3:129823064	LOC729375	-0.7	-7.25	-0.42	5.37e-12	Blood pressure (smoking interaction);
KIRP	cis	rs17321999	0.516	rs72787745	chr2:30506543	T/C	cg05247661	chr2:30472410	LBH	0.62	5.05	0.31	8.76e-7	Systemic lupus erythematosus;
KIRP	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	12.69	0.63	1.01e-28	Smoking behavior;
KIRP	trans	rs12043259	0.730	rs4951134	chr1:204815578	G/A	cg11485465	chr5:54518469	NA	0.39	6.76	0.4	9.86e-11	Addiction;
KIRP	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg00629928	chr5:358741	AHRR	0.5	4.86	0.3	2.09e-6	Breast cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg16263701	chr12:48213605	HDAC7	0.48	6.21	0.37	2.21e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.54	-0.33	7.72e-8	Breast cancer;
KIRP	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg17441377	chr17:3906640	NA	0.58	8.71	0.49	4.49e-16	Type 2 diabetes;
KIRP	cis	rs2150410	0.665	rs13050584	chr21:40574090	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs4253772	0.938	rs78336060	chr22:46641597	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-6.15	-0.36	3.14e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.42	-5.54	-0.33	7.67e-8	Blood metabolite levels;
KIRP	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.94	-16.19	-0.72	1.29e-40	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs17431357	1.000	rs73221372	chr12:120899189	C/T	cg25045489	chr12:120971538	RNF10	-0.65	-4.98	-0.3	1.2e-6	Insulin resistance/response;
KIRP	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.05e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-9.23	-0.51	1.28e-17	Platelet count;
KIRP	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.49	-5.44	-0.33	1.27e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6450176	1.000	rs3776702	chr5:53305419	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.89	-11.4	-0.59	1.95e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg21775007	chr8:11205619	TDH	0.43	5.91	0.35	1.16e-8	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs13064411	0.518	rs9870996	chr3:113238375	A/C	cg18753928	chr3:113234510	CCDC52	-0.51	-6.39	-0.38	8.12e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.42	-5.21	-0.32	4.04e-7	Diastolic blood pressure;
KIRP	cis	rs7116495	0.609	rs628025	chr11:71802351	A/C	cg07596299	chr11:71824057	C11orf51	-0.9	-5.21	-0.31	4.09e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.79	9.73	0.53	3.91e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg04132472	chr17:19861366	AKAP10	0.43	5.99	0.36	7.45e-9	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24537383	chr1:64239633	ROR1	0.52	6.41	0.38	7.49e-10	Parkinson's disease;
KIRP	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.68	9.71	0.53	4.53e-19	Retinal vascular caliber;
KIRP	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.4	-4.89	-0.3	1.85e-6	Tonsillectomy;
KIRP	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.48	6.16	0.37	3.02e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs2635047	0.736	rs2247777	chr18:44746739	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.34	5.15	0.31	5.41e-7	Educational attainment;
KIRP	cis	rs7246657	0.722	rs8110865	chr19:38047387	G/A	cg18154014	chr19:37997991	ZNF793	0.62	6.74	0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg02297831	chr4:17616191	MED28	0.56	6.53	0.38	3.69e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1593	0.531	rs2221843	chr4:187144200	C/G	cg02012338	chr4:187126139	CYP4V2	0.56	4.98	0.3	1.21e-6	Activated partial thromboplastin time;
KIRP	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg19554555	chr3:13937349	NA	-0.42	-5.76	-0.34	2.54e-8	Ovarian reserve;
KIRP	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.74	-7.45	-0.43	1.62e-12	Large artery stroke;
KIRP	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.61	-7.36	-0.42	2.69e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg19760965	chr3:194868843	C3orf21	0.32	5.19	0.31	4.45e-7	Non-small cell lung cancer;
KIRP	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.06	-0.31	8.3e-7	Bladder cancer;
KIRP	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.62	7.91	0.45	8.66e-14	Body mass index (adult);
KIRP	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.55	-6.79	-0.4	8.27e-11	Waist circumference;Hip circumference;
KIRP	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	1.0	12.91	0.64	1.89e-29	Neutrophil percentage of white cells;
KIRP	cis	rs73198271	0.562	rs17631022	chr8:8662197	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.18	-0.31	4.53e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12208915	0.848	rs9359351	chr6:79492533	A/G	cg18132916	chr6:79620363	NA	0.52	4.91	0.3	1.68e-6	Left atrial antero-posterior diameter;
KIRP	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.63e-8	Life satisfaction;
KIRP	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg26174226	chr8:58114915	NA	-0.62	-7.29	-0.42	4.1e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.45	-0.47	2.55e-15	Personality dimensions;
KIRP	cis	rs4356975	0.563	rs7437174	chr4:69952603	C/A	cg27372994	chr4:70080453	UGT2B11	0.38	4.98	0.3	1.22e-6	Obesity-related traits;
KIRP	cis	rs9469913	0.733	rs2814986	chr6:34602685	T/C	cg14254433	chr6:34482411	PACSIN1	-0.43	-5.32	-0.32	2.29e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-9.02	-0.5	5.52e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg02733842	chr7:1102375	C7orf50	0.43	5.01	0.3	1.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs78049276	0.736	rs6841581	chr4:148401190	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.72	-8.71	-0.49	4.51e-16	Pulse pressure;
KIRP	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg24611264	chr11:120008944	TRIM29	0.26	4.88	0.3	1.87e-6	Stroke (pediatric);
KIRP	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg04374321	chr14:90722782	PSMC1	0.99	18.13	0.76	3.17e-47	Mortality in heart failure;
KIRP	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg01631408	chr1:248437212	OR2T33	-0.59	-5.82	-0.35	1.83e-8	Common traits (Other);
KIRP	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.47	5.96	0.36	8.62e-9	Height;
KIRP	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg01877450	chr7:97915802	BRI3	-0.53	-6.97	-0.41	2.92e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.83	0.69	5.41e-36	Alzheimer's disease;
KIRP	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.88	-14.1	-0.67	1.74e-33	Urate levels in lean individuals;
KIRP	cis	rs7923609	0.967	rs7896783	chr10:65162153	G/A	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.92	14.05	0.67	2.64e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.46e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16792347	chr8:95802202	DPY19L4	-0.39	-6.18	-0.37	2.61e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1981331	0.609	rs117296583	chr21:48053238	C/T	cg23283320	chr21:48055893	PRMT2	1.45	9.1	0.5	3.26e-17	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	1.0	17.16	0.74	6.23e-44	Menopause (age at onset);
KIRP	cis	rs494562	0.892	rs515980	chr6:86119917	C/T	cg21730993	chr6:86159210	NT5E	0.49	5.05	0.31	8.73e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.8	11.4	0.59	1.83e-24	Obesity-related traits;
KIRP	cis	rs963731	0.522	rs297148	chr2:39323166	A/G	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs17453880	0.676	rs2961761	chr5:151953547	A/G	cg12297329	chr5:152029980	NA	-0.51	-6.86	-0.4	5.45e-11	Subjective well-being;
KIRP	cis	rs6893807	0.778	rs13174131	chr5:87959538	T/G	cg24804195	chr5:87968844	LOC645323	0.54	5.33	0.32	2.22e-7	Body mass index;
KIRP	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg24879335	chr3:133465180	TF	0.53	8.33	0.47	5.73e-15	Iron status biomarkers;
KIRP	cis	rs9581857	0.547	rs9581878	chr13:28104552	T/A	cg22138327	chr13:27999177	GTF3A	0.72	5.8	0.35	2.02e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-4.97	-0.3	1.25e-6	Aortic root size;
KIRP	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg25039879	chr17:56429692	SUPT4H1	0.55	6.68	0.39	1.6e-10	Primary tooth development (time to first tooth eruption);
KIRP	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg21643547	chr1:205240462	TMCC2	-0.72	-10.96	-0.57	5.23e-23	Red blood cell count;
KIRP	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.88	-9.25	-0.51	1.14e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg17376030	chr22:41985996	PMM1	-0.64	-6.74	-0.39	1.1e-10	Vitiligo;
KIRP	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.5	-5.9	-0.35	1.18e-8	Systolic blood pressure;
KIRP	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.52	7.52	0.43	1.02e-12	Obesity-related traits;
KIRP	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg23752985	chr2:85803571	VAMP8	0.56	8.04	0.46	3.78e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9972944	0.756	rs6504352	chr17:63765287	C/T	cg07283582	chr17:63770753	CCDC46	-0.48	-7.91	-0.45	8.54e-14	Total body bone mineral density;
KIRP	trans	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg26043149	chr18:55253948	FECH	-0.51	-6.2	-0.37	2.35e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg07777115	chr5:623756	CEP72	-0.57	-5.74	-0.34	2.83e-8	Lung disease severity in cystic fibrosis;
KIRP	trans	rs7939886	0.841	rs11227702	chr11:56034774	A/C	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.53	0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg08862778	chr1:11322643	MTOR	0.7	6.59	0.39	2.64e-10	Lung function (FEV1);
KIRP	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg02023728	chr11:77925099	USP35	0.29	5.0	0.3	1.07e-6	Alzheimer's disease (survival time);
KIRP	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.19	-0.31	4.39e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7539542	0.535	rs1578679	chr1:202905250	C/T	cg08940984	chr1:202857613	RABIF	0.45	5.3	0.32	2.57e-7	Mean platelet volume;
KIRP	cis	rs1559088	0.847	rs10423531	chr19:33600140	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-5.74	-0.34	2.82e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.9	0.88	4.82e-81	Chronic sinus infection;
KIRP	cis	rs787274	0.867	rs786969	chr9:115449556	C/G	cg13803584	chr9:115635662	SNX30	0.52	5.79	0.35	2.13e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg20935368	chr5:178288625	ZNF354B	0.48	6.65	0.39	1.92e-10	Sleep duration;
KIRP	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.86	12.16	0.61	6.12e-27	Primary sclerosing cholangitis;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16815379	chr1:165797173	UCK2	-0.5	-7.14	-0.41	1.05e-11	Metabolic traits;
KIRP	cis	rs2882667	0.931	rs10075951	chr5:138355963	G/T	cg04439458	chr5:138467593	SIL1	-0.43	-7.2	-0.42	7.29e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07673023	chr2:27434729	C2orf28;SLC5A6	-0.48	-6.65	-0.39	1.84e-10	Metabolic traits;
KIRP	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-0.98	-15.72	-0.71	5.11e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs986417	1.000	rs1254291	chr14:60863570	A/T	cg27398547	chr14:60952738	C14orf39	-0.65	-5.94	-0.35	9.56e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.61	7.06	0.41	1.72e-11	HDL cholesterol;
KIRP	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg13482628	chr17:19912719	NA	0.62	9.02	0.5	5.63e-17	Schizophrenia;
KIRP	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.54	7.08	0.41	1.47e-11	HDL cholesterol;
KIRP	cis	rs9394841	0.667	rs9471653	chr6:41755410	C/G	cg08135965	chr6:41755394	TOMM6	0.5	5.34	0.32	2.11e-7	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs5770917	1.000	rs3213446	chr22:51015674	C/T	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.63	-5.79	-0.35	2.18e-8	Narcolepsy;
KIRP	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	7.3	0.42	3.96e-12	Triglycerides;
KIRP	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.64	7.06	0.41	1.72e-11	Height;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13983640	chr6:41010223	TSPO2	0.45	6.05	0.36	5.49e-9	Survival in pancreatic cancer;
KIRP	cis	rs10924970	0.934	rs12402243	chr1:235431792	A/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs503734	0.502	rs348885	chr3:100976219	C/G	cg27318481	chr3:100970896	IMPG2	-0.58	-7.93	-0.45	7.83e-14	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg05315796	chr3:52349193	DNAH1	0.4	6.46	0.38	5.42e-10	Bipolar disorder;
KIRP	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.34	-7.46	-0.43	1.53e-12	Cutaneous nevi;
KIRP	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg01872077	chr2:219646372	CYP27A1	0.42	5.45	0.33	1.2e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.48	-0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs2916247	1.000	rs72671424	chr8:93056264	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.55	-7.03	-0.41	2.01e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.52	-6.52	-0.38	3.99e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	cg12689670	chr1:183009347	LAMC1	0.42	6.09	0.36	4.24e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs4253772	0.872	rs45576734	chr22:46638365	A/G	cg24881330	chr22:46731750	TRMU	0.64	5.49	0.33	9.92e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg13798780	chr7:105162888	PUS7	0.66	6.14	0.36	3.37e-9	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg02487422	chr3:49467188	NICN1	0.43	5.96	0.36	8.84e-9	Menarche (age at onset);
KIRP	cis	rs742614	0.533	rs736953	chr20:32415089	G/T	cg06304546	chr20:32448765	NA	-0.77	-11.92	-0.61	3.77e-26	Stearic acid (18:0) levels;
KIRP	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg05370193	chr1:21551575	ECE1	0.43	6.13	0.36	3.51e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.68	8.3	0.47	7.03e-15	Aortic root size;
KIRP	cis	rs6782228	0.606	rs2001950	chr3:128419756	A/G	cg18648031	chr3:128330563	NA	0.25	4.93	0.3	1.52e-6	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.76	-11.15	-0.58	1.19e-23	Obesity-related traits;
KIRP	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg15083037	chr5:83017644	HAPLN1	-0.56	-8.05	-0.46	3.64e-14	Prostate cancer;
KIRP	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.52	-7.29	-0.42	4.33e-12	Diisocyanate-induced asthma;
KIRP	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg01304814	chr3:48885189	PRKAR2A	0.8	5.82	0.35	1.79e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs68170813	0.652	rs79295036	chr7:107193669	C/A	cg02696742	chr7:106810147	HBP1	-0.76	-7.17	-0.42	8.71e-12	Coronary artery disease;
KIRP	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.48	7.13	0.41	1.13e-11	Major depressive disorder;
KIRP	cis	rs112591243	0.685	rs117443865	chr21:47959731	C/G	cg12379764	chr21:47803548	PCNT	0.73	4.96	0.3	1.31e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg19592336	chr6:28129416	ZNF389	0.48	5.54	0.33	7.73e-8	Depression;
KIRP	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg21775007	chr8:11205619	TDH	-0.49	-6.3	-0.37	1.33e-9	Joint mobility (Beighton score);
KIRP	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg27205649	chr11:78285834	NARS2	0.68	8.92	0.49	1.09e-16	Alzheimer's disease (survival time);
KIRP	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg01320579	chr17:75405842	SEPT9	0.47	7.76	0.44	2.23e-13	Airflow obstruction;
KIRP	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg07701084	chr6:150067640	NUP43	0.52	6.7	0.39	1.42e-10	Testicular germ cell tumor;
KIRP	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.15	23.82	0.84	7.74e-66	Schizophrenia;
KIRP	cis	rs2224391	0.628	rs2773299	chr6:5242169	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-5.76	-0.34	2.46e-8	Height;
KIRP	cis	rs1476670	0.690	rs6677372	chr1:44505789	G/A	cg09470012	chr1:44509516	NA	0.32	5.24	0.32	3.38e-7	Eotaxin levels;
KIRP	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-1.1	-17.84	-0.75	3.08e-46	Homoarginine levels;
KIRP	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.45	7.64	0.44	4.91e-13	Type 2 diabetes;
KIRP	cis	rs6466055	0.661	rs73186041	chr7:104916716	G/C	cg04380332	chr7:105027541	SRPK2	0.36	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25333258	chr7:44365029	CAMK2B	-0.45	-6.03	-0.36	6.07e-9	Myopia;
KIRP	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg06647332	chr5:131281008	NA	0.45	4.94	0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs477895	0.713	rs7944061	chr11:63956839	A/T	cg23719950	chr11:63933701	MACROD1	-0.64	-6.86	-0.4	5.5e-11	Mean platelet volume;
KIRP	cis	rs6504663	0.558	rs11871603	chr17:48559037	T/G	cg00901687	chr17:48585270	MYCBPAP	0.39	5.0	0.3	1.07e-6	Visceral fat;
KIRP	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg20560298	chr2:73613845	ALMS1	0.43	5.25	0.32	3.26e-7	Metabolite levels;
KIRP	cis	rs8113308	0.810	rs55810059	chr19:52450728	G/A	cg25782003	chr19:52490127	ZNF350	0.54	5.11	0.31	6.44e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs7560272	0.501	rs11126417	chr2:73974315	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-4.97	-0.3	1.28e-6	Schizophrenia;
KIRP	cis	rs6693567	0.516	rs519126	chr1:150288859	T/G	cg09579323	chr1:150459698	TARS2	-0.4	-5.04	-0.31	9.22e-7	Migraine;
KIRP	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg12315302	chr6:26189340	HIST1H4D	0.76	5.14	0.31	5.47e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg00405596	chr8:11794950	NA	-0.46	-6.14	-0.36	3.32e-9	Mood instability;
KIRP	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg03482458	chr22:46692211	CN5H6.4;GTSE1	0.66	6.49	0.38	4.56e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs501120	0.564	rs1626459	chr10:44691548	T/C	cg09554077	chr10:44749378	NA	0.5	6.95	0.41	3.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9816226	0.938	rs73052046	chr3:185832414	C/T	cg00760338	chr3:185826511	ETV5	-0.86	-8.28	-0.47	7.93e-15	Obesity;Body mass index;
KIRP	cis	rs1062177	0.855	rs1346489	chr5:151266534	C/T	cg00977110	chr5:151150581	G3BP1	0.59	6.19	0.37	2.45e-9	Preschool internalizing problems;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg09238957	chr16:46723420	ORC6L;VPS35	1.03	6.85	0.4	6.06e-11	P wave terminal force;
KIRP	cis	rs4006360	0.522	rs2874188	chr17:39244590	T/C	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.69	-0.48	5.07e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.64	-9.44	-0.52	3.06e-18	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2224391	0.628	rs2753230	chr6:5248538	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.58	6.91	0.4	4.19e-11	Height;
KIRP	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-8.25	-0.47	9.62e-15	Total cholesterol levels;
KIRP	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.81	11.76	0.6	1.26e-25	Itch intensity from mosquito bite;
KIRP	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.91	10.89	0.57	8.28e-23	Bipolar disorder;
KIRP	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg23172400	chr8:95962367	TP53INP1	-0.35	-7.04	-0.41	1.88e-11	Type 2 diabetes;
KIRP	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-7.49	-0.43	1.26e-12	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.73	0.34	2.94e-8	Motion sickness;
KIRP	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.76	9.99	0.54	6.25e-20	Breast cancer;
KIRP	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.3	-0.37	1.4e-9	Response to antipsychotic treatment;
KIRP	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg19760965	chr3:194868843	C3orf21	0.32	5.19	0.31	4.45e-7	Non-small cell lung cancer;
KIRP	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.52	6.91	0.4	4.2e-11	Multiple myeloma (IgH translocation);
KIRP	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg00405596	chr8:11794950	NA	-0.47	-6.03	-0.36	5.82e-9	Mood instability;
KIRP	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.8	-8.66	-0.48	6.21e-16	Coronary artery disease;
KIRP	cis	rs7737355	0.704	rs11749484	chr5:131061607	T/C	cg06307176	chr5:131281290	NA	0.41	4.94	0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.59	8.16	0.46	1.69e-14	Vitiligo;
KIRP	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg02336718	chr17:17403227	NA	0.34	5.21	0.32	3.99e-7	Total body bone mineral density;
KIRP	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.04	-0.46	3.68e-14	Osteoarthritis;
KIRP	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.45	-0.33	1.22e-7	Life satisfaction;
KIRP	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg09455208	chr3:40491958	NA	0.33	5.85	0.35	1.53e-8	Renal cell carcinoma;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10941835	chr20:50419348	SALL4	0.56	6.07	0.36	4.79e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg06565975	chr8:143823917	SLURP1	0.45	7.01	0.41	2.26e-11	Urinary tract infection frequency;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg16104446	chr8:48873951	MCM4;PRKDC	0.49	6.16	0.37	3.01e-9	Asthma;
KIRP	cis	rs10518128	1.000	rs60932020	chr4:75712138	C/T	cg20122727	chr4:75719957	BTC	0.55	5.64	0.34	4.74e-8	Electroencephalogram traits;
KIRP	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	6.75	0.4	1.03e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.78	-0.44	2.06e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	1.18	14.87	0.69	4.12e-36	White matter hyperintensity burden;
KIRP	cis	rs9290877	0.564	rs9883953	chr3:188474856	A/C	cg17392043	chr3:188495102	LPP	0.54	6.68	0.39	1.61e-10	IgE levels;
KIRP	trans	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg00938859	chr5:1591904	SDHAP3	0.55	6.16	0.37	2.88e-9	Breast cancer;
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.59	-0.34	5.98e-8	Life satisfaction;
KIRP	cis	rs1440410	0.804	rs12647238	chr4:144062657	T/G	cg01719995	chr4:144104893	USP38	0.45	5.69	0.34	3.56e-8	Ischemic stroke;
KIRP	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00149659	chr3:10157352	C3orf10	0.58	6.91	0.4	4.13e-11	Alzheimer's disease;
KIRP	cis	rs1448094	0.785	rs7955173	chr12:86447214	G/A	cg00310523	chr12:86230176	RASSF9	-0.39	-6.03	-0.36	6.09e-9	Major depressive disorder;
KIRP	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.86	10.86	0.57	1.1e-22	Coronary artery disease;
KIRP	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg20607798	chr8:58055168	NA	0.62	4.94	0.3	1.47e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg21546286	chr11:48923668	NA	-0.45	-5.49	-0.33	1e-7	HDL cholesterol;
KIRP	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.78	10.56	0.56	9.92e-22	Monocyte count;
KIRP	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg06212747	chr3:49208901	KLHDC8B	0.55	6.28	0.37	1.55e-9	Resting heart rate;
KIRP	cis	rs2296342	0.652	rs2296338	chr6:33630816	G/A	cg14003231	chr6:33640908	ITPR3	0.28	5.02	0.31	9.72e-7	Schizophrenia;
KIRP	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg19077165	chr18:44547161	KATNAL2	0.47	5.83	0.35	1.71e-8	Personality dimensions;
KIRP	cis	rs10073892	0.703	rs10038372	chr5:101639664	A/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg12962167	chr3:53033115	SFMBT1	0.61	4.87	0.3	2.02e-6	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs8084125	0.832	rs62105180	chr18:74951197	C/G	cg05528293	chr18:74961138	GALR1	0.55	6.01	0.36	6.7e-9	Obesity-related traits;
KIRP	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg17691542	chr6:26056736	HIST1H1C	0.41	5.55	0.33	7.52e-8	Schizophrenia;
KIRP	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg04306507	chr14:55594613	LGALS3	0.53	8.38	0.47	3.99e-15	Protein biomarker;
KIRP	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg12658694	chr1:38397304	INPP5B	-0.69	-8.93	-0.49	1.03e-16	Coronary artery disease;
KIRP	cis	rs16976116	0.951	rs12385963	chr15:55482851	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.52	0.43	1.02e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.88	11.81	0.6	8.33e-26	Schizophrenia;
KIRP	cis	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.41	-0.43	2.02e-12	Morning vs. evening chronotype;
KIRP	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg01420254	chr6:26195488	NA	0.81	7.98	0.45	5.52e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.52	7.0	0.41	2.36e-11	Multiple myeloma (IgH translocation);
KIRP	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg06636001	chr8:8085503	FLJ10661	0.61	8.59	0.48	9.92e-16	Neuroticism;
KIRP	cis	rs7737355	0.947	rs4706028	chr5:130946227	T/C	cg06307176	chr5:131281290	NA	0.54	6.03	0.36	6.06e-9	Life satisfaction;
KIRP	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	1.0	20.25	0.79	2.59e-54	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1408799	0.750	rs1121541	chr9:12667049	C/T	cg05274944	chr9:12693694	TYRP1	0.36	5.09	0.31	7.01e-7	Eye color;Blue vs. green eyes;
KIRP	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg02503808	chr4:7069936	GRPEL1	0.47	6.28	0.37	1.53e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
KIRP	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg05973401	chr12:123451056	ABCB9	0.58	5.24	0.32	3.52e-7	Neutrophil percentage of white cells;
KIRP	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.27	24.51	0.84	5.55e-68	IgG glycosylation;
KIRP	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.55	7.29	0.42	4.13e-12	Eye color traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23259713	chr10:43680087	CSGALNACT2	-0.4	-6.05	-0.36	5.43e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6568686	0.786	rs2146459	chr6:111815963	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.58	-5.29	-0.32	2.66e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs918629	0.761	rs17085333	chr5:95280848	A/T	cg16656078	chr5:95278638	ELL2	0.51	7.28	0.42	4.6e-12	IgG glycosylation;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg00001245	chr3:15106710	MRPS25	-0.44	-6.02	-0.36	6.29e-9	Metabolic traits;
KIRP	cis	rs17286411	0.836	rs7350856	chr16:71951094	G/T	cg04254540	chr16:71951199	KIAA0174	-0.38	-5.1	-0.31	6.65e-7	Blood protein levels;
KIRP	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg27494647	chr7:150038898	RARRES2	0.44	6.24	0.37	1.92e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg04374321	chr14:90722782	PSMC1	0.91	15.84	0.71	1.98e-39	Mortality in heart failure;
KIRP	cis	rs10140922	0.567	rs2415263	chr14:35630319	A/C	cg07166546	chr14:35805898	NA	0.22	5.25	0.32	3.33e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg04998671	chr14:104000505	TRMT61A	0.54	6.45	0.38	5.9e-10	Coronary artery disease;
KIRP	cis	rs1559088	0.600	rs58173463	chr19:33596749	C/T	cg24009623	chr19:33667908	NA	0.49	6.58	0.39	2.82e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg20936604	chr3:58311152	NA	0.64	5.6	0.34	5.83e-8	Cholesterol, total;
KIRP	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	6.03	0.36	5.94e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs754423	0.515	rs12436363	chr14:52544565	T/C	cg05884192	chr14:52515736	NID2	0.47	5.2	0.31	4.29e-7	Craniofacial microsomia;
KIRP	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg18032289	chr17:61959525	GH2	-0.43	-5.06	-0.31	8.32e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6901004	0.565	rs6900341	chr6:111794409	T/G	cg15721981	chr6:111408429	SLC16A10	-0.55	-6.84	-0.4	6.35e-11	Blood metabolite levels;
KIRP	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-5.8	-0.35	2.01e-8	Lung cancer;
KIRP	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.44e-7	Menopause (age at onset);
KIRP	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.43	-5.58	-0.34	6.31e-8	Crohn's disease;
KIRP	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg04132472	chr17:19861366	AKAP10	-0.42	-5.44	-0.33	1.29e-7	Schizophrenia;
KIRP	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.55	8.54	0.48	1.43e-15	Major depressive disorder;
KIRP	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg00074818	chr8:8560427	CLDN23	0.42	6.32	0.37	1.25e-9	Obesity-related traits;
KIRP	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg07424592	chr7:64974309	NA	0.75	4.93	0.3	1.51e-6	Diabetic kidney disease;
KIRP	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.58	-7.16	-0.42	9.33e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.83	9.71	0.53	4.56e-19	Multiple sclerosis;
KIRP	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.45	-5.65	-0.34	4.35e-8	QT interval;
KIRP	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-8.38	-0.47	3.97e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.78	10.63	0.56	5.96e-22	Coffee consumption (cups per day);
KIRP	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.48	-5.81	-0.35	1.93e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.43	-5.23	-0.32	3.61e-7	Eosinophil percentage of white cells;
KIRP	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-5.34	-0.32	2.11e-7	Neuroticism;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg00738919	chr7:1100172	C7orf50	0.44	5.1	0.31	6.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs743757	0.878	rs1467913	chr3:50525017	G/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.45	5.2	0.31	4.25e-7	Diastolic blood pressure;
KIRP	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg03609598	chr5:56110824	MAP3K1	0.58	5.66	0.34	4.17e-8	Initial pursuit acceleration;
KIRP	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.99	-16.32	-0.72	4.63e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.5	-5.98	-0.36	7.83e-9	Menarche (age at onset);
KIRP	cis	rs6500395	0.962	rs55782524	chr16:48557493	A/G	cg04672837	chr16:48644449	N4BP1	0.47	6.08	0.36	4.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.72	9.69	0.53	5.15e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs12431939	0.947	rs56026555	chr14:51649066	G/T	cg23942311	chr14:51606299	NA	-0.59	-5.05	-0.31	8.45e-7	Cancer;
KIRP	cis	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg11266682	chr4:10021025	SLC2A9	0.41	5.12	0.31	6.03e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.58	-7.57	-0.43	7.66e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.569	rs67815988	chr17:3998312	A/C	cg09597638	chr17:3907349	NA	0.52	5.24	0.32	3.53e-7	Type 2 diabetes;
KIRP	cis	rs35740288	0.703	rs10520598	chr15:86173381	T/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.46	-0.33	1.16e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs364477	0.762	rs9299104	chr9:1001254	C/T	cg13952963	chr9:998547	NA	-0.62	-5.45	-0.33	1.23e-7	Major depressive disorder;
KIRP	cis	rs7224685	0.501	rs2466944	chr17:3922203	A/G	cg11204139	chr17:3907470	NA	0.85	16.24	0.72	8.71e-41	Type 2 diabetes;
KIRP	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	1.03	17.72	0.75	7.56e-46	Multiple system atrophy;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15844609	chr19:38806846	YIF1B	0.51	6.03	0.36	5.85e-9	Smoking initiation;
KIRP	cis	rs3857536	0.730	rs4710584	chr6:66953453	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.46	-0.33	1.19e-7	Blood trace element (Cu levels);
KIRP	trans	rs208520	0.909	rs9345809	chr6:67017543	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	7.31	0.42	3.83e-12	Exhaled nitric oxide output;
KIRP	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.56	6.59	0.39	2.72e-10	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg23950597	chr19:37808831	NA	-0.64	-6.86	-0.4	5.43e-11	Coronary artery calcification;
KIRP	cis	rs9826463	1.000	rs4398471	chr3:142333969	A/G	cg20824294	chr3:142316082	PLS1	0.32	5.63	0.34	4.9e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1538970	0.924	rs4660855	chr1:45899795	A/G	cg05343316	chr1:45956843	TESK2	0.71	8.03	0.46	4.02e-14	Platelet count;
KIRP	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.41	-14.63	-0.68	2.76e-35	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7615316	0.934	rs6792259	chr3:142301439	A/T	cg20824294	chr3:142316082	PLS1	0.22	4.97	0.3	1.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.92	-12.57	-0.63	2.65e-28	Cognitive function;
KIRP	cis	rs7766436	0.524	rs1317258	chr6:22513446	G/A	cg13666174	chr6:22585274	NA	-0.4	-5.25	-0.32	3.33e-7	Coronary artery disease;
KIRP	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.6	-0.39	2.51e-10	Neuroticism;
KIRP	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg12131826	chr15:77904385	NA	0.45	6.13	0.36	3.57e-9	Type 2 diabetes;
KIRP	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.28	24.76	0.84	9.44e-69	IgG glycosylation;
KIRP	cis	rs9513627	0.749	rs73556143	chr13:100116907	G/A	cg25919922	chr13:100150906	NA	-0.74	-5.87	-0.35	1.4e-8	Obesity-related traits;
KIRP	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.42	-5.58	-0.34	6.41e-8	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.98	0.3	1.21e-6	Menopause (age at onset);
KIRP	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg07653901	chr22:50250238	ZBED4	-0.6	-6.53	-0.38	3.84e-10	Schizophrenia;
KIRP	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07570687	chr10:102243282	WNT8B	0.51	6.78	0.4	8.76e-11	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.46	0.43	1.46e-12	Aortic root size;
KIRP	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.97	0.36	8.43e-9	Menopause (age at onset);
KIRP	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg20169779	chr10:135381914	SYCE1	0.44	5.13	0.31	5.97e-7	Obesity-related traits;
KIRP	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.94	16.07	0.72	3.25e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg21573476	chr21:45109991	RRP1B	-0.52	-6.97	-0.41	2.85e-11	Mean corpuscular volume;
KIRP	cis	rs3105593	1.000	rs11636964	chr15:50899616	A/G	cg08437265	chr15:50716283	USP8	0.39	4.93	0.3	1.5e-6	QT interval;
KIRP	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.97	11.46	0.59	1.16e-24	Corneal astigmatism;
KIRP	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg11846333	chr4:119757529	SEC24D	1.17	7.18	0.42	8.16e-12	Cannabis dependence symptom count;
KIRP	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	14.29	0.67	3.82e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs263156	0.934	rs196353	chr6:142880223	C/T	cg01789478	chr2:182545485	NEUROD1	-0.39	-6.6	-0.39	2.57e-10	Ear morphology;Lobe size;Lobe attachment;
KIRP	cis	rs6669919	0.597	rs10863905	chr1:211684429	A/G	cg10512769	chr1:211675356	NA	-0.57	-8.17	-0.46	1.67e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.47	-6.38	-0.38	8.77e-10	Schizophrenia;
KIRP	cis	rs6969780	0.915	rs7341470	chr7:27184842	T/C	cg22997113	chr7:27170241	HOXA4	-0.37	-5.28	-0.32	2.85e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg16141378	chr3:129829833	LOC729375	0.48	6.04	0.36	5.62e-9	Neuroticism;
KIRP	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.48	6.81	0.4	7.59e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs241257	0.621	rs241271	chr1:4626255	T/C	cg12065138	chr1:4771201	AJAP1	-0.37	-5.38	-0.32	1.73e-7	Anxiety disorder;
KIRP	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg01320579	chr17:75405842	SEPT9	0.48	7.83	0.45	1.48e-13	Airflow obstruction;
KIRP	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.71	9.19	0.51	1.72e-17	Prudent dietary pattern;
KIRP	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg03289416	chr15:75166202	SCAMP2	-0.4	-5.29	-0.32	2.72e-7	Systemic lupus erythematosus;
KIRP	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.07	-19.72	-0.78	1.43e-52	Height;
KIRP	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg16329650	chr2:213403929	ERBB4	-0.4	-5.48	-0.33	1.04e-7	Symmetrical dimethylarginine levels;
KIRP	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg07395648	chr5:131743802	NA	-0.52	-6.56	-0.39	3.1e-10	Breast cancer;
KIRP	cis	rs6969780	1.000	rs1801085	chr7:27168590	A/G	cg26364809	chr7:27145159	NA	-0.62	-5.79	-0.35	2.09e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg24826892	chr11:71159390	DHCR7	0.42	5.11	0.31	6.49e-7	Vitamin D levels;
KIRP	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.27	26.3	0.86	1.93e-73	IgG glycosylation;
KIRP	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.37	5.11	0.31	6.6e-7	Coronary artery disease;
KIRP	cis	rs239198	0.577	rs34716527	chr6:101284416	T/C	cg09795085	chr6:101329169	ASCC3	0.49	5.68	0.34	3.88e-8	Menarche (age at onset);
KIRP	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg06365898	chr1:16533907	ARHGEF19	0.5	6.97	0.41	2.85e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	-0.32	-4.94	-0.3	1.47e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg17279839	chr7:150038598	RARRES2	0.45	6.13	0.36	3.52e-9	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.39	-5.01	-0.3	1.04e-6	Menarche (age at onset);
KIRP	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg23564664	chr2:113997917	PAX8;LOC654433;LOC440839	-0.25	-5.02	-0.3	1.02e-6	Lymphocyte counts;
KIRP	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.57	-6.39	-0.38	8.05e-10	White matter hyperintensity burden;
KIRP	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg24253500	chr15:84953950	NA	0.51	5.87	0.35	1.37e-8	Schizophrenia;
KIRP	cis	rs4805272	0.512	rs765484	chr19:29344663	A/G	cg04546413	chr19:29218101	NA	0.62	5.73	0.34	2.91e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7833787	1.000	rs6993404	chr8:18705723	C/T	cg17701159	chr8:18705777	PSD3	0.39	7.42	0.43	1.92e-12	Obesity-related traits;
KIRP	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.26	-16.91	-0.73	4.36e-43	Breast cancer;
KIRP	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.8	-0.35	2.07e-8	Pulmonary function;
KIRP	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.3	6.08	0.36	4.61e-9	Schizophrenia;
KIRP	cis	rs490234	0.841	rs2790035	chr9:128439923	C/T	cg14078157	chr9:128172775	NA	0.4	5.05	0.31	8.76e-7	Mean arterial pressure;
KIRP	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg12560992	chr17:57184187	TRIM37	0.63	6.64	0.39	2.01e-10	Testicular germ cell tumor;
KIRP	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.68	8.43	0.47	2.86e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.56	7.77	0.44	2.08e-13	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.57	7.63	0.44	5.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs897080	0.515	rs1067333	chr2:44626710	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.42	0.38	6.81e-10	Height;
KIRP	cis	rs10875746	0.855	rs2269936	chr12:48425235	G/A	cg20731937	chr12:48336164	NA	0.41	5.26	0.32	3.19e-7	Longevity (90 years and older);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14469928	chr2:125733618	NA	0.37	6.08	0.36	4.58e-9	Survival in pancreatic cancer;
KIRP	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-7.41	-0.43	2.06e-12	Bipolar disorder;
KIRP	cis	rs698833	0.926	rs786620	chr2:44595803	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	5.13	0.31	5.75e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.59	-5.47	-0.33	1.08e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.27	-5.5	-0.33	9.52e-8	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg02070205	chr10:30722105	MAP3K8	-0.37	-4.92	-0.3	1.57e-6	Inflammatory bowel disease;
KIRP	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg09473613	chr1:24152604	HMGCL	0.43	5.59	0.34	5.91e-8	Immature fraction of reticulocytes;
KIRP	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.93	-14.67	-0.68	2.04e-35	Height;
KIRP	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg26727032	chr16:67993705	SLC12A4	-0.62	-6.19	-0.37	2.54e-9	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16361282	chr20:34742394	EPB41L1	0.47	6.09	0.36	4.2e-9	Parkinson's disease;
KIRP	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg21452805	chr1:244014465	NA	0.7	5.92	0.35	1.07e-8	RR interval (heart rate);
KIRP	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-6.64	-0.39	1.94e-10	Colorectal cancer;
KIRP	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg10402321	chr1:26617780	UBXN11	-0.43	-5.61	-0.34	5.39e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.47	5.93	0.35	1e-8	IgG glycosylation;
KIRP	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg12861170	chr19:19639553	YJEFN3	-0.49	-5.07	-0.31	8e-7	Bipolar disorder;
KIRP	cis	rs7224685	0.569	rs28481302	chr17:4011527	T/G	cg11204139	chr17:3907470	NA	0.53	4.93	0.3	1.52e-6	Type 2 diabetes;
KIRP	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg26893134	chr6:116381904	FRK	0.2	5.71	0.34	3.19e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.27	-0.32	3.01e-7	Menarche (age at onset);
KIRP	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg01990225	chr2:97406019	LMAN2L	-1.05	-7.05	-0.41	1.77e-11	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg06204229	chr3:52865917	ITIH4	0.55	7.78	0.44	1.98e-13	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.7e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg15045802	chr19:1857434	KLF16	0.43	6.32	0.37	1.19e-9	Cancer;
KIRP	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6504950	0.830	rs12937006	chr17:53030461	C/T	cg26251398	chr17:52985966	TOM1L1	0.42	5.2	0.31	4.12e-7	Breast cancer;
KIRP	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.57	-0.39	3e-10	Blood pressure;
KIRP	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.03	-0.41	2.04e-11	Chronic sinus infection;
KIRP	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs8014252	0.803	rs74062743	chr14:71023411	G/T	cg11204974	chr14:71022665	NA	-0.71	-6.99	-0.41	2.61e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg03398387	chr6:160114178	SOD2	0.53	6.49	0.38	4.7e-10	Asthma;
KIRP	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.83	13.38	0.65	4.83e-31	Metabolic syndrome;
KIRP	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.81	11.47	0.59	1.13e-24	Obesity-related traits;
KIRP	cis	rs12586317	0.508	rs8015350	chr14:35635230	A/T	cg07166546	chr14:35805898	NA	-0.29	-6.77	-0.4	9.27e-11	Psoriasis;
KIRP	cis	rs2916247	0.954	rs12056584	chr8:93141987	T/C	cg10183463	chr8:93005414	RUNX1T1	0.4	4.93	0.3	1.51e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg04733989	chr22:42467013	NAGA	0.55	7.49	0.43	1.25e-12	Cognitive function;
KIRP	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg13332499	chr17:408570	NA	-0.61	-8.49	-0.48	1.96e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg25772418	chr12:131519998	GPR133	-0.41	-5.85	-0.35	1.56e-8	Longevity;
KIRP	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-6.21	-0.37	2.2e-9	Axial length;
KIRP	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.76	9.38	0.51	4.71e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg04865290	chr3:52927548	TMEM110	-0.58	-7.2	-0.42	7.36e-12	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4363506	0.668	rs11018146	chr10:129280509	G/A	cg07804728	chr10:129284050	NA	0.4	5.31	0.32	2.41e-7	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);Amyotrophic lateral sclerosis;
KIRP	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg05370193	chr1:21551575	ECE1	0.46	6.13	0.36	3.41e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9815354	0.812	rs60796012	chr3:41908668	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.67	6.65	0.39	1.93e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.74	9.52	0.52	1.65e-18	Coronary artery disease;
KIRP	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.82	0.49	2.11e-16	Motion sickness;
KIRP	cis	rs28834970	0.928	rs73223431	chr8:27219987	C/T	cg11641102	chr8:27183873	PTK2B	-0.39	-4.85	-0.3	2.15e-6	Alzheimer's disease (late onset);
KIRP	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.28	0.76	1.02e-47	Chronic sinus infection;
KIRP	trans	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.12	0.41	1.2e-11	Mean corpuscular volume;
KIRP	cis	rs7116495	1.000	rs947932	chr11:71656705	A/G	cg26138937	chr11:71823887	C11orf51	-0.71	-5.72	-0.34	3.08e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.96	14.67	0.68	1.91e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7937612	1.000	rs7131597	chr11:120303939	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.9	-0.4	4.5e-11	Intraocular pressure;
KIRP	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-9.58	-0.52	1.11e-18	Response to antipsychotic treatment;
KIRP	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.61	9.1	0.5	3.18e-17	Hip circumference;
KIRP	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg02792322	chr13:21280448	IL17D	0.31	5.2	0.31	4.1e-7	Dental caries;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.07	-13.44	-0.65	2.92e-31	Alzheimer's disease;
KIRP	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.39	4.94	0.3	1.43e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-0.78	-11.37	-0.59	2.3e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs75920871	0.688	rs61905679	chr11:116834787	C/T	cg23684410	chr11:116897558	SIK3	0.57	6.1	0.36	3.99e-9	Subjective well-being;
KIRP	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	cis	rs6499755	0.768	rs31098	chr16:55369098	T/A	cg05099576	chr16:55362342	IRX6	0.33	6.7	0.39	1.4e-10	Hypospadias;
KIRP	cis	rs11264213	0.686	rs625306	chr1:36454016	T/C	cg27506609	chr1:36549197	TEKT2	0.96	10.29	0.55	7.02e-21	Schizophrenia;
KIRP	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	14.7	0.68	1.53e-35	Smoking behavior;
KIRP	cis	rs4481887	0.508	rs7349159	chr1:248386242	C/T	cg01631408	chr1:248437212	OR2T33	-0.49	-6.13	-0.36	3.54e-9	Common traits (Other);
KIRP	cis	rs4523957	0.855	rs12601834	chr17:2112431	C/T	cg16513277	chr17:2031491	SMG6	-0.68	-9.49	-0.52	2.17e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg00647317	chr7:50633725	DDC	-0.45	-5.84	-0.35	1.66e-8	Malaria;
KIRP	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08235889	chr16:1660574	IFT140	-0.49	-6.39	-0.38	8.16e-10	Myopia;
KIRP	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	0.55	8.06	0.46	3.26e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs13161895	1.000	rs4700853	chr5:179473328	G/A	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.37	7.89	0.45	9.69e-14	Body mass index;
KIRP	cis	rs4908768	0.815	rs11589090	chr1:8525615	C/T	cg25722041	chr1:8623473	RERE	0.77	8.87	0.49	1.49e-16	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg26412358	chr1:26503933	CNKSR1	0.4	5.65	0.34	4.46e-8	Height;
KIRP	cis	rs9535307	0.518	rs73194439	chr13:50403217	G/C	cg04663916	chr13:50265991	EBPL	-0.58	-5.77	-0.35	2.35e-8	Obesity-related traits;
KIRP	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg22974920	chr21:40686053	BRWD1	0.52	6.17	0.37	2.73e-9	Cognitive function;
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-9.24	-0.51	1.24e-17	Platelet count;
KIRP	cis	rs2274273	0.743	rs7161656	chr14:55524530	A/G	cg04306507	chr14:55594613	LGALS3	0.41	6.1	0.36	4.04e-9	Protein biomarker;
KIRP	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg14820908	chr5:178986412	RUFY1	0.36	5.16	0.31	5.14e-7	Lung cancer;
KIRP	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07308232	chr7:1071921	C7orf50	0.75	10.13	0.54	2.23e-20	Longevity;Endometriosis;
KIRP	cis	rs7011049	0.778	rs73603203	chr8:53871618	C/T	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	0.97	10.63	0.56	5.58e-22	Blood protein levels;
KIRP	trans	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg19694781	chr19:47549865	TMEM160	-0.51	-6.23	-0.37	1.97e-9	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.51	-5.58	-0.34	6.23e-8	Body mass index;
KIRP	cis	rs4975616	0.933	rs13356727	chr5:1312457	G/A	cg26373071	chr5:1325741	CLPTM1L	-0.55	-7.14	-0.41	1.07e-11	Lung cancer;
KIRP	cis	rs3126085	0.515	rs2146119	chr1:152368898	G/A	cg26876637	chr1:152193138	HRNR	-0.5	-6.16	-0.37	2.99e-9	Atopic dermatitis;
KIRP	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs244293	0.701	rs4793784	chr17:53038430	A/G	cg07707039	chr17:53042137	COX11	-0.39	-5.0	-0.3	1.11e-6	Menarche (age at onset);
KIRP	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	trans	rs9650657	0.812	rs10089615	chr8:10634132	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.02	-0.36	6.4e-9	Neuroticism;
KIRP	cis	rs13401104	0.786	rs56257332	chr2:237107405	G/A	cg19324714	chr2:237145437	ASB18	0.47	4.87	0.3	1.98e-6	Educational attainment;
KIRP	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg03929089	chr4:120376271	NA	0.7	6.27	0.37	1.63e-9	Axial length;
KIRP	cis	rs7539542	0.529	rs3182429	chr1:202888947	T/C	cg19681188	chr1:202830198	LOC148709	-0.48	-5.14	-0.31	5.68e-7	Mean platelet volume;
KIRP	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	0.81	8.9	0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg23281280	chr6:28129359	ZNF389	0.48	5.22	0.32	3.83e-7	Depression;
KIRP	cis	rs4356932	0.691	rs2273	chr4:76889388	C/T	cg00809888	chr4:76862425	NAAA	-0.49	-6.88	-0.4	4.88e-11	Blood protein levels;
KIRP	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg05220968	chr6:146057943	EPM2A	0.39	5.0	0.3	1.11e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2802372	1.000	rs2802372	chr10:81047575	G/T	cg18688392	chr10:81059414	ZMIZ1	0.46	5.98	0.36	7.75e-9	Granulocyte count;
KIRP	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg06219351	chr7:158114137	PTPRN2	-0.61	-8.71	-0.49	4.4e-16	Calcium levels;
KIRP	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg18306943	chr3:40428807	ENTPD3	0.46	6.18	0.37	2.64e-9	Renal cell carcinoma;
KIRP	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.59	7.69	0.44	3.48e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	8.24	0.47	1.01e-14	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.79	13.14	0.64	3.14e-30	Calcium levels;
KIRP	cis	rs9434723	0.844	rs9434729	chr1:9303940	G/C	cg04199779	chr1:9294473	H6PD	0.45	5.42	0.33	1.42e-7	Height;
KIRP	cis	rs78487399	0.614	rs13422551	chr2:43724682	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-5.04	-0.31	8.85e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg00343986	chr7:65444356	GUSB	-0.45	-5.43	-0.33	1.36e-7	Aortic root size;
KIRP	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.64	0.34	4.69e-8	Lung cancer;
KIRP	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg13414629	chr9:132935646	FREQ	0.53	7.07	0.41	1.59e-11	Alzheimer's disease (cognitive decline);
KIRP	cis	rs496547	0.686	rs591756	chr11:118678881	T/C	cg19308663	chr11:118741387	NA	-0.29	-5.13	-0.31	5.8e-7	Hip minimal joint space width;
KIRP	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg21775007	chr8:11205619	TDH	0.71	10.4	0.55	3.03e-21	Retinal vascular caliber;
KIRP	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.81	11.43	0.59	1.54e-24	Aortic root size;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19289870	chr15:77154861	SCAPER	-0.42	-6.47	-0.38	5.3e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06528214	chr1:178995107	FAM20B	0.53	6.67	0.39	1.68e-10	Parkinson's disease;
KIRP	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.19	-0.61	4.63e-27	Ulcerative colitis;
KIRP	cis	rs77633900	0.772	rs157789	chr15:76805703	T/A	cg21673338	chr15:77095150	SCAPER	-0.64	-5.87	-0.35	1.4e-8	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01353569	chr7:106810328	HBP1	0.62	7.38	0.43	2.45e-12	Smoking initiation;
KIRP	cis	rs62229266	0.771	rs2835232	chr21:37393427	G/A	cg12218747	chr21:37451666	NA	-0.43	-5.4	-0.33	1.58e-7	Mitral valve prolapse;
KIRP	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg16586182	chr3:47516702	SCAP	-0.69	-9.23	-0.51	1.26e-17	Colorectal cancer;
KIRP	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-0.97	-18.15	-0.76	2.72e-47	Dental caries;
KIRP	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg08992911	chr2:238395768	MLPH	-0.42	-4.99	-0.3	1.13e-6	Prostate cancer;
KIRP	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg17724175	chr1:150552817	MCL1	0.38	6.19	0.37	2.53e-9	Melanoma;
KIRP	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg21161173	chr5:140098174	VTRNA1-2	-0.37	-4.85	-0.3	2.15e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg08280861	chr8:58055591	NA	0.51	4.98	0.3	1.18e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.17	-0.31	4.87e-7	Pulmonary function;
KIRP	trans	rs1973993	0.603	rs76555736	chr1:96989051	C/A	cg10631902	chr5:14652156	NA	-0.53	-6.35	-0.38	1.04e-9	Weight;
KIRP	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg14768367	chr16:72042858	DHODH	0.49	6.06	0.36	4.95e-9	Fibrinogen levels;
KIRP	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg23985595	chr17:80112537	CCDC57	0.34	5.1	0.31	6.8e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.59e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs728478	1.000	rs9912732	chr17:57447965	A/G	cg16535752	chr17:57448097	YPEL2	-0.22	-5.26	-0.32	3.13e-7	QT interval;
KIRP	cis	rs829661	0.793	rs2593458	chr2:30870507	A/G	cg10949345	chr2:30726833	LCLAT1	1.08	13.23	0.64	1.55e-30	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	trans	rs7980799	0.935	rs7294492	chr12:33548530	C/T	cg26384229	chr12:38710491	ALG10B	-0.5	-6.39	-0.38	8.4e-10	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.73	-10.45	-0.55	2.18e-21	Menopause (age at onset);
KIRP	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.6	8.15	0.46	1.85e-14	Total body bone mineral density;
KIRP	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.7	-9.48	-0.52	2.31e-18	Metabolic syndrome;
KIRP	cis	rs16912285	0.786	rs112633506	chr11:24250766	G/A	ch.11.24196551F	chr11:24239977	NA	0.73	4.97	0.3	1.25e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.49	6.33	0.37	1.14e-9	Menopause (age at onset);
KIRP	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg05347473	chr6:146136440	FBXO30	0.5	7.19	0.42	7.84e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4400599	0.618	rs1194602	chr1:154231943	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	-0.43	-6.25	-0.37	1.82e-9	Platelet distribution width;
KIRP	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg20487152	chr13:99095054	FARP1	0.43	6.36	0.38	9.57e-10	Neuroticism;
KIRP	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg20673091	chr1:2541236	MMEL1	0.78	12.69	0.63	9.81e-29	Ulcerative colitis;
KIRP	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.67	9.37	0.51	4.72e-18	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.4	-5.86	-0.35	1.44e-8	Colorectal cancer;
KIRP	cis	rs965604	1.000	rs1062980	chr15:78792527	T/C	cg24631222	chr15:78858424	CHRNA5	0.41	5.03	0.31	9.59e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs80130819	0.688	rs11168455	chr12:48592792	G/A	cg26205652	chr12:48591994	NA	0.48	5.39	0.33	1.62e-7	Prostate cancer;
KIRP	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg21231944	chr12:82153410	PPFIA2	-0.41	-5.01	-0.3	1.03e-6	Resting heart rate;
KIRP	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.71	7.9	0.45	9.5e-14	Initial pursuit acceleration;
KIRP	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.36	4.92	0.3	1.61e-6	Coronary artery disease;
KIRP	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg12262378	chr17:6899522	ALOX12	-0.32	-5.74	-0.34	2.79e-8	Tonsillectomy;
KIRP	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg17376030	chr22:41985996	PMM1	0.84	8.99	0.5	6.66e-17	Vitiligo;
KIRP	cis	rs10751667	1.000	rs10902233	chr11:925510	A/G	cg10932868	chr11:921992	NA	0.56	7.04	0.41	1.88e-11	Alzheimer's disease (late onset);
KIRP	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg10047753	chr17:41438598	NA	1.16	18.75	0.77	2.5e-49	Menopause (age at onset);
KIRP	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.45	0.38	6.02e-10	Menarche (age at onset);
KIRP	cis	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg06521331	chr12:34319734	NA	-0.4	-4.92	-0.3	1.61e-6	Resting heart rate;
KIRP	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-6.86	-0.4	5.65e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.53	6.81	0.4	7.26e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21755725	chr19:50708619	MYH14	0.5	6.29	0.37	1.48e-9	Smoking initiation;
KIRP	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg06521331	chr12:34319734	NA	-0.55	-6.81	-0.4	7.37e-11	Heart rate;
KIRP	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg17470723	chr8:74884337	TCEB1	0.62	7.92	0.45	8.29e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg12315302	chr6:26189340	HIST1H4D	1.09	6.27	0.37	1.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21385522	chr1:16154831	NA	0.48	6.14	0.36	3.28e-9	Dilated cardiomyopathy;
KIRP	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg22676075	chr6:135203613	NA	0.52	7.56	0.43	8.09e-13	Red blood cell count;
KIRP	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.48	-5.65	-0.34	4.32e-8	Carotid intima media thickness;
KIRP	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.44	-5.68	-0.34	3.86e-8	Height;
KIRP	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	0.95	12.19	0.61	4.87e-27	Blood protein levels;
KIRP	cis	rs2573652	1.000	rs12441080	chr15:100516968	A/G	cg09918751	chr15:100517450	ADAMTS17	0.63	9.06	0.5	4.31e-17	Height;
KIRP	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26207909	chr14:103986467	CKB	-0.75	-11.45	-0.59	1.34e-24	Body mass index;
KIRP	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.77	7.12	0.41	1.2e-11	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg10666761	chr15:55909920	PRTG	-0.41	-6.06	-0.36	4.95e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00399650	chr7:141402322	KIAA1147	0.68	8.32	0.47	6.2e-15	Smoking initiation;
KIRP	cis	rs28489187	0.706	rs3087894	chr1:85787118	G/C	cg16011679	chr1:85725395	C1orf52	0.53	6.42	0.38	6.91e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7870753	0.578	rs10820564	chr9:99171631	G/A	cg25260653	chr9:99212216	HABP4	0.54	5.05	0.31	8.59e-7	Height;
KIRP	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg16388071	chr6:169726476	NA	-0.4	-5.53	-0.33	8.06e-8	Obesity-related traits;
KIRP	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg22676075	chr6:135203613	NA	0.51	7.38	0.43	2.47e-12	Red blood cell count;
KIRP	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-7.02	-0.41	2.21e-11	Skin colour saturation;
KIRP	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.84	10.52	0.56	1.3e-21	Cognitive function;
KIRP	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg02751453	chr18:77725136	HSBP1L1	0.38	5.06	0.31	8.13e-7	Opioid sensitivity;
KIRP	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.7	-0.73	2.25e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.31	-7.67	-0.44	4.04e-13	Primary biliary cholangitis;
KIRP	trans	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.45	6.11	0.36	3.81e-9	Mean corpuscular volume;
KIRP	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.57	8.05	0.46	3.48e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.45	0.33	1.21e-7	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg14440974	chr22:39074834	NA	-0.38	-4.95	-0.3	1.4e-6	Menopause (age at onset);
KIRP	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg04935436	chr20:30431758	NA	0.49	6.58	0.39	2.74e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.7	8.62	0.48	8.17e-16	Neutrophil percentage of white cells;
KIRP	cis	rs2348418	0.715	rs1355471	chr12:28721725	A/G	cg13890972	chr12:28721907	NA	0.32	5.05	0.31	8.74e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.39	-5.2	-0.31	4.22e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.47	-5.61	-0.34	5.42e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.58	5.82	0.35	1.78e-8	Alcohol dependence;
KIRP	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.78	-11.73	-0.6	1.51e-25	Obesity-related traits;
KIRP	cis	rs3743266	0.507	rs9630426	chr15:60739053	C/T	cg22293140	chr15:60689852	ANXA2	-0.63	-5.74	-0.34	2.81e-8	Menarche (age at onset);
KIRP	cis	rs5753618	0.583	rs9606839	chr22:31802710	A/C	cg02404636	chr22:31891804	SFI1	0.52	5.92	0.35	1.1e-8	Colorectal cancer;
KIRP	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg04226714	chr8:49833948	SNAI2	-0.51	-6.96	-0.41	3.11e-11	Life satisfaction;
KIRP	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg19445457	chr11:5799446	OR52N5	-0.39	-4.86	-0.3	2.13e-6	DNA methylation (variation);
KIRP	cis	rs7258465	0.931	rs7249020	chr19:18608147	A/G	cg10790698	chr19:18539756	SSBP4	-0.33	-7.16	-0.42	9.2e-12	Breast cancer;
KIRP	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg23307798	chr14:103986281	CKB	0.76	13.18	0.64	2.31e-30	Body mass index;
KIRP	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg06636001	chr8:8085503	FLJ10661	0.69	8.88	0.49	1.41e-16	Retinal vascular caliber;
KIRP	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg00864860	chr1:7907996	UTS2	-0.5	-5.99	-0.36	7.48e-9	Crohn's disease;
KIRP	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	10.58	0.56	8.3e-22	Platelet count;
KIRP	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.68	-8.07	-0.46	3.17e-14	Blood protein levels;
KIRP	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg25547332	chr5:131281432	NA	0.47	5.28	0.32	2.91e-7	Life satisfaction;
KIRP	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.5	6.35	0.38	1.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg11062466	chr8:58055876	NA	0.57	5.4	0.33	1.6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg20169779	chr10:135381914	SYCE1	0.67	7.15	0.41	9.83e-12	Gout;
KIRP	cis	rs13065560	0.714	rs4280575	chr3:38937645	C/T	cg01426195	chr3:39028469	NA	0.37	5.71	0.34	3.25e-8	Interleukin-18 levels;
KIRP	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.73	6.27	0.37	1.65e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.61	6.72	0.39	1.23e-10	Gut microbiome composition (summer);
KIRP	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.42	8.43	0.47	2.93e-15	Mean corpuscular volume;
KIRP	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	6.2	0.37	2.34e-9	Neuroticism;
KIRP	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.36	8.54	0.48	1.38e-15	Asthma (sex interaction);
KIRP	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs2120243	0.539	rs4680358	chr3:157069275	A/G	cg24825693	chr3:157122686	VEPH1	-0.55	-8.57	-0.48	1.18e-15	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.41	5.08	0.31	7.44e-7	Common traits (Other);
KIRP	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.47	-5.13	-0.31	5.86e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.56	7.17	0.42	8.86e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg03714773	chr7:91764589	CYP51A1	0.39	5.64	0.34	4.58e-8	Breast cancer;
KIRP	cis	rs514024	0.668	rs2039204	chr9:130371107	T/A	cg13643465	chr9:130375613	STXBP1	0.41	5.52	0.33	8.65e-8	Eating disorders (purging via substances);
KIRP	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00005849	chr2:237071182	NA	0.43	6.29	0.37	1.46e-9	Electrocardiographic conduction measures;
KIRP	cis	rs830383	0.512	rs830385	chr5:165478869	T/C	cg13976338	chr5:165423657	NA	0.63	6.15	0.36	3.19e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs12517041	1.000	rs7721619	chr5:23292676	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs2371030	1.000	rs12473077	chr2:211565470	G/C	cg18417063	chr2:211583084	NA	0.52	7.58	0.44	7.01e-13	Non-small cell lung cancer;
KIRP	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg12623918	chr2:306882	NA	0.46	5.76	0.34	2.44e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.5	-5.29	-0.32	2.67e-7	Breast cancer;
KIRP	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg01657329	chr11:68192670	LRP5	-0.5	-5.38	-0.32	1.73e-7	Total body bone mineral density;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg05535760	chr7:792225	HEATR2	0.85	8.77	0.49	3.06e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.21e-16	Life satisfaction;
KIRP	cis	rs6662572	0.671	rs10749861	chr1:46440252	A/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.45	-5.58	-0.34	6.18e-8	Blood protein levels;
KIRP	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.63	8.88	0.49	1.45e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.47	-6.14	-0.36	3.37e-9	Platelet count;
KIRP	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg25019033	chr10:957182	NA	-0.66	-7.67	-0.44	4.1e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs57590327	0.679	rs34674953	chr3:81605113	T/G	cg07356753	chr3:81810745	GBE1	-0.58	-6.31	-0.37	1.26e-9	Extraversion;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07139301	chr3:170746207	SLC2A2	0.48	6.92	0.4	3.8e-11	Parkinson's disease;
KIRP	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.56	7.12	0.41	1.21e-11	Retinal vascular caliber;
KIRP	cis	rs3750965	1.000	rs61881024	chr11:68837794	A/G	cg06818126	chr11:68850279	TPCN2	-0.46	-5.33	-0.32	2.23e-7	Hair color;
KIRP	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg01631408	chr1:248437212	OR2T33	-0.61	-8.07	-0.46	3.05e-14	Common traits (Other);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09289335	chr20:42144161	L3MBTL	0.49	6.29	0.37	1.42e-9	Interleukin-4 levels;
KIRP	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19293748	chr19:53237645	ZNF611	0.48	7.02	0.41	2.11e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.9	12.04	0.61	1.48e-26	Homoarginine levels;
KIRP	cis	rs13361707	1.000	rs58751240	chr5:40791501	C/T	cg01087697	chr5:40835557	RPL37	-0.46	-5.3	-0.32	2.54e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs9831754	0.704	rs1512491	chr3:78470954	T/C	cg06138941	chr3:78371609	NA	0.66	9.1	0.5	3.18e-17	Calcium levels;
KIRP	cis	rs2295359	0.637	rs12044149	chr1:67600686	G/T	cg11235152	chr1:67600687	NA	1.04	16.02	0.71	4.97e-40	Psoriasis;
KIRP	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	7.86	0.45	1.2e-13	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.63	7.66	0.44	4.28e-13	Vitiligo;
KIRP	cis	rs1642645	0.831	rs348128	chr1:42488361	T/C	cg26038582	chr1:42384390	HIVEP3	0.28	5.08	0.31	7.42e-7	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg05315796	chr3:52349193	DNAH1	0.44	6.76	0.4	1.02e-10	Bipolar disorder;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg01765077	chr12:122356316	WDR66	0.59	8.12	0.46	2.21e-14	Mean corpuscular volume;
KIRP	cis	rs9372498	0.572	rs56082110	chr6:118909480	A/G	cg21191810	chr6:118973309	C6orf204	-0.44	-4.89	-0.3	1.84e-6	Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg15181151	chr6:150070149	PCMT1	0.3	5.09	0.31	7.18e-7	Lung cancer;
KIRP	cis	rs6545883	0.929	rs2694625	chr2:61616055	G/A	cg15711740	chr2:61764176	XPO1	0.61	7.83	0.45	1.48e-13	Tuberculosis;
KIRP	cis	rs34779708	0.931	rs59418206	chr10:35331624	G/A	cg04310649	chr10:35416472	CREM	-0.54	-6.01	-0.36	6.58e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.59	-6.73	-0.39	1.18e-10	Menarche (age at onset);
KIRP	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg13010199	chr12:38710504	ALG10B	0.49	6.21	0.37	2.2e-9	Morning vs. evening chronotype;
KIRP	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.94	9.41	0.51	3.79e-18	Neuroticism;
KIRP	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg21625330	chr8:9911636	MSRA	-0.39	-5.17	-0.31	4.77e-7	Neuroticism;
KIRP	trans	rs617219	0.889	rs949645	chr5:78442522	A/T	cg27180880	chr18:74844787	MBP	-0.57	-6.07	-0.36	4.9e-9	Betaine levels in individuals undergoing cardiac evaluation;
KIRP	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg08499158	chr17:42289980	UBTF	-0.71	-9.61	-0.52	9.27e-19	Total body bone mineral density;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03076246	chr16:67906784	EDC4	0.65	6.24	0.37	1.92e-9	Lung function (FEV1);
KIRP	cis	rs28655083	1.000	rs1875582	chr16:77063147	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.5	5.69	0.34	3.55e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg25007680	chr1:8021821	PARK7	0.63	8.62	0.48	8.14e-16	Response to antidepressants and depression;
KIRP	cis	rs6676180	0.514	rs868675	chr1:119773596	A/G	cg05756136	chr1:119680316	WARS2	-0.47	-6.86	-0.4	5.56e-11	Monobrow;
KIRP	cis	rs997295	0.713	rs12905509	chr15:67994108	A/G	cg24579218	chr15:68104479	NA	0.35	4.97	0.3	1.25e-6	Motion sickness;
KIRP	cis	rs7916697	0.593	rs10762198	chr10:70023053	A/G	cg06988349	chr10:69991859	ATOH7	-0.39	-5.16	-0.31	5.04e-7	Optic disc area;
KIRP	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	1.06	18.8	0.77	1.68e-49	Gut microbiome composition (winter);
KIRP	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.67	-10.34	-0.55	4.89e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4686799	0.876	rs1648714	chr3:186440483	T/C	cg12454167	chr3:186435060	KNG1	0.36	4.97	0.3	1.28e-6	Small vessel stroke;
KIRP	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.89	13.27	0.65	1.15e-30	Mean platelet volume;
KIRP	cis	rs10214930	0.813	rs1608663	chr7:27623776	C/T	cg22168087	chr7:27702803	HIBADH	0.52	5.08	0.31	7.38e-7	Hypospadias;
KIRP	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg10189774	chr4:17578691	LAP3	0.55	6.76	0.4	9.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg06307176	chr5:131281290	NA	-0.55	-5.98	-0.36	7.7e-9	Life satisfaction;
KIRP	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13198984	chr17:80129470	CCDC57	0.59	8.79	0.49	2.58e-16	Life satisfaction;
KIRP	cis	rs35146811	0.555	rs2525539	chr7:99545309	A/G	cg22906224	chr7:99728672	NA	-0.48	-5.82	-0.35	1.8e-8	Coronary artery disease;
KIRP	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.75	-9.2	-0.51	1.61e-17	Personality dimensions;
KIRP	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4273100	1.000	rs16960158	chr17:19163052	A/C	cg18093559	chr17:18951025	GRAP	-0.65	-6.29	-0.37	1.42e-9	Schizophrenia;
KIRP	cis	rs7646881	1.000	rs7646881	chr3:158453279	C/A	cg19483011	chr3:158453295	NA	-0.56	-6.27	-0.37	1.65e-9	Tetralogy of Fallot;
KIRP	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg03465714	chr1:152285911	FLG	-0.43	-6.16	-0.37	2.99e-9	Inflammatory skin disease;
KIRP	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-14.9	-0.69	3.13e-36	Chronic sinus infection;
KIRP	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg18478394	chr8:109455254	TTC35	0.58	7.27	0.42	4.78e-12	Dupuytren's disease;
KIRP	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg01294253	chr9:136912663	BRD3	0.43	5.54	0.33	7.89e-8	Platelet distribution width;
KIRP	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-6.0	-0.36	6.92e-9	Prudent dietary pattern;
KIRP	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.4	0.43	2.16e-12	Aortic root size;
KIRP	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.15	-17.96	-0.75	1.18e-46	Ulcerative colitis;
KIRP	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg18209359	chr17:80159595	CCDC57	0.42	5.53	0.33	8.26e-8	Life satisfaction;
KIRP	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg07636037	chr3:49044803	WDR6	-0.72	-5.94	-0.35	9.89e-9	Blood protein levels;
KIRP	cis	rs17030434	1.000	rs732680	chr4:154725211	G/A	cg14289246	chr4:154710475	SFRP2	-0.82	-9.73	-0.53	3.92e-19	Electrocardiographic conduction measures;
KIRP	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.47	5.91	0.35	1.15e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.57	-7.83	-0.45	1.43e-13	Motion sickness;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15929587	chr14:24701962	GMPR2;NEDD8	0.49	6.21	0.37	2.2e-9	Parkinson's disease;
KIRP	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	1.16	9.29	0.51	8.59e-18	LDL cholesterol;
KIRP	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg18944383	chr4:111397179	ENPEP	0.52	9.09	0.5	3.45e-17	Height;
KIRP	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-7.47	-0.43	1.42e-12	Bipolar disorder;
KIRP	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg09571762	chr12:39539558	NA	0.33	4.89	0.3	1.8e-6	Morning vs. evening chronotype;
KIRP	cis	rs78579285	0.510	rs78759106	chr16:88788535	T/C	cg09054528	chr16:88821542	FAM38A	-0.59	-4.98	-0.3	1.22e-6	Joint mobility (Beighton score);
KIRP	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg27147174	chr7:100797783	AP1S1	-0.57	-7.3	-0.42	4.08e-12	Life satisfaction;
KIRP	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.63	6.93	0.4	3.67e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs2034650	0.506	rs1984793	chr15:40699373	G/T	cg08996748	chr15:40651036	DISP2	-0.36	-5.16	-0.31	4.99e-7	Interstitial lung disease;
KIRP	trans	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg25042112	chr7:64838748	ZNF92	-0.6	-6.42	-0.38	6.88e-10	Pain;
KIRP	cis	rs2658782	0.724	rs2248655	chr11:93254612	T/C	cg15737290	chr11:93063684	CCDC67	0.67	7.78	0.44	1.99e-13	Pulmonary function decline;
KIRP	cis	rs7542091	0.635	rs985431	chr1:210043948	A/T	cg22029157	chr1:209979665	IRF6	0.38	5.88	0.35	1.35e-8	Monobrow;
KIRP	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg16586182	chr3:47516702	SCAP	-0.69	-9.3	-0.51	7.72e-18	Colorectal cancer;
KIRP	cis	rs4262150	0.810	rs72797213	chr5:151960514	A/T	cg12297329	chr5:152029980	NA	-0.68	-8.33	-0.47	5.86e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs1050631	0.564	rs684890	chr18:33744677	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.43	5.62	0.34	5.14e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg24315340	chr6:146058215	EPM2A	-0.41	-5.18	-0.31	4.69e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2273156	1.000	rs12050390	chr14:35461079	A/C	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.47	-0.33	1.1e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9815354	0.857	rs12108064	chr3:42016217	C/T	cg03022575	chr3:42003672	ULK4	0.69	6.83	0.4	6.77e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1062177	0.901	rs1549622	chr5:151266049	A/G	cg00977110	chr5:151150581	G3BP1	0.6	5.66	0.34	4.23e-8	Preschool internalizing problems;
KIRP	cis	rs9815354	0.909	rs11717540	chr3:41932938	G/A	cg03022575	chr3:42003672	ULK4	-0.46	-5.25	-0.32	3.36e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7903847	0.642	rs61863819	chr10:99142400	T/C	cg20016023	chr10:99160130	RRP12	-0.41	-5.43	-0.33	1.35e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg15557168	chr22:42548783	NA	-0.42	-5.77	-0.35	2.34e-8	Cognitive function;
KIRP	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg05554000	chr7:158905015	VIPR2	-0.4	-4.91	-0.3	1.66e-6	Facial morphology (factor 20);
KIRP	trans	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg02030672	chr11:45687055	CHST1	0.56	6.94	0.4	3.45e-11	Obesity-related traits;
KIRP	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg22676075	chr6:135203613	NA	0.47	6.56	0.39	3.19e-10	Red blood cell count;
KIRP	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26002218	chr14:103986227	CKB	0.26	4.95	0.3	1.41e-6	Body mass index;
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.7	9.61	0.52	9.01e-19	Longevity;
KIRP	cis	rs6091737	0.954	rs6022697	chr20:52343011	A/T	cg11837293	chr20:52356911	NA	-0.39	-4.95	-0.3	1.36e-6	Calcium levels;
KIRP	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.43	6.26	0.37	1.75e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.85	-11.98	-0.61	2.33e-26	Total body bone mineral density;
KIRP	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.74	9.84	0.53	1.82e-19	Red blood cell count;
KIRP	cis	rs785830	0.520	rs554243	chr9:269510	A/G	cg14500300	chr9:211689	NA	0.41	4.94	0.3	1.43e-6	Platelet distribution width;
KIRP	cis	rs7180079	0.620	rs1466527	chr15:64727203	C/G	cg15337035	chr15:64978493	NA	-0.46	-5.08	-0.31	7.64e-7	Monocyte count;
KIRP	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg16103275	chr6:290800	DUSP22	0.47	6.11	0.36	3.83e-9	Menopause (age at onset);
KIRP	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg06307176	chr5:131281290	NA	0.54	5.9	0.35	1.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	9.83	0.53	1.87e-19	Post bronchodilator FEV1;
KIRP	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	0.55	6.63	0.39	2.11e-10	Prudent dietary pattern;
KIRP	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.69	10.35	0.55	4.54e-21	Dupuytren's disease;
KIRP	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.69	9.86	0.53	1.53e-19	Retinal vascular caliber;
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg09695851	chr17:3907499	NA	0.84	15.65	0.71	8.62e-39	Type 2 diabetes;
KIRP	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-6.4	-0.38	7.74e-10	Dilated cardiomyopathy;
KIRP	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg22431228	chr1:16359049	CLCNKA	-0.49	-6.56	-0.39	3.1e-10	Dilated cardiomyopathy;
KIRP	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.18	-0.46	1.53e-14	Response to antipsychotic treatment;
KIRP	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-8.31	-0.47	6.52e-15	Personality dimensions;
KIRP	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.08	10.25	0.55	9.56e-21	Lung cancer in ever smokers;
KIRP	trans	rs12431410	0.536	rs1952033	chr14:60152245	A/G	cg20601314	chr10:104179541	FBXL15;PSD	-0.56	-6.28	-0.37	1.51e-9	Schizophrenia;
KIRP	cis	rs870825	0.518	rs2696051	chr4:185604780	G/T	cg04058563	chr4:185651563	MLF1IP	-0.63	-7.82	-0.45	1.52e-13	Blood protein levels;
KIRP	cis	rs2625529	0.668	rs34487006	chr15:72462350	G/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.98	-0.36	8e-9	Red blood cell count;
KIRP	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	0.99	10.46	0.55	1.97e-21	Cannabis dependence symptom count;
KIRP	cis	rs3815700	0.614	rs259255	chr19:33151765	T/C	cg02997394	chr19:33096574	ANKRD27	1.29	8.23	0.46	1.08e-14	Eosinophilic esophagitis;
KIRP	cis	rs6859018	1.000	rs3213097	chr5:158748679	A/T	cg26646896	chr5:158686746	NA	-0.34	-4.94	-0.3	1.47e-6	Serum sulfate level;
KIRP	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg08499158	chr17:42289980	UBTF	-0.66	-8.45	-0.47	2.5e-15	Total body bone mineral density;
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg23698023	chr8:27181813	PTK2B	0.33	4.85	0.3	2.19e-6	Neuroticism;
KIRP	cis	rs10875595	0.836	rs3749780	chr5:140682757	C/T	cg24830062	chr5:140700576	TAF7	-0.56	-5.43	-0.33	1.34e-7	Pulmonary function decline;
KIRP	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.54	6.62	0.39	2.27e-10	Total body bone mineral density;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04381741	chr7:108210905	THAP5;DNAJB9	-0.45	-6.06	-0.36	5.18e-9	Survival in pancreatic cancer;
KIRP	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.04	0.31	9.09e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs745821	1.000	rs745821	chr18:48142854	T/G	cg18923635	chr18:48083994	NA	0.42	4.9	0.3	1.71e-6	Diastolic blood pressure;
KIRP	cis	rs16976116	0.643	rs7181237	chr15:55517231	C/G	cg11288833	chr15:55489084	RSL24D1	0.47	5.34	0.32	2.16e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg16141378	chr3:129829833	LOC729375	0.61	7.75	0.44	2.44e-13	Neuroticism;
KIRP	cis	rs6960043	0.782	rs4721401	chr7:15064896	T/G	cg19272540	chr7:15055459	NA	-0.23	-6.77	-0.4	9.42e-11	Type 2 diabetes;
KIRP	cis	rs9834373	0.821	rs13314576	chr3:78485637	T/C	cg06138941	chr3:78371609	NA	-0.38	-5.04	-0.31	9.08e-7	Protein quantitative trait loci;
KIRP	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg08501292	chr6:25962987	TRIM38	0.72	4.98	0.3	1.2e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg16482183	chr6:26056742	HIST1H1C	0.53	5.79	0.35	2.18e-8	Iron status biomarkers;
KIRP	cis	rs41271473	0.800	rs12133951	chr1:228791179	A/C	cg10167378	chr1:228756711	NA	0.64	5.25	0.32	3.28e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs1318772	0.867	rs13171389	chr5:112907818	C/T	cg12552261	chr5:112820674	MCC	0.88	5.63	0.34	4.78e-8	F-cell distribution;
KIRP	cis	rs2456568	0.695	rs877341	chr11:93689293	C/T	cg26875233	chr11:93583750	C11orf90	0.33	6.24	0.37	1.92e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs367943	0.666	rs12332129	chr5:112977983	A/G	cg12552261	chr5:112820674	MCC	0.5	5.82	0.35	1.79e-8	Type 2 diabetes;
KIRP	cis	rs1832871	0.672	rs111782080	chr6:158765385	G/A	cg07215822	chr6:158701037	NA	-0.64	-7.4	-0.43	2.13e-12	Height;
KIRP	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg02023728	chr11:77925099	USP35	-0.33	-5.33	-0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.74	8.16	0.46	1.68e-14	Corneal astigmatism;
KIRP	cis	rs7737355	0.738	rs3776011	chr5:130868840	C/T	cg25547332	chr5:131281432	NA	0.39	4.9	0.3	1.76e-6	Life satisfaction;
KIRP	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg25251562	chr2:3704773	ALLC	-0.36	-4.85	-0.3	2.17e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg07395648	chr5:131743802	NA	-0.36	-5.07	-0.31	7.89e-7	Blood metabolite levels;
KIRP	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.18	12.61	0.63	1.83e-28	Eosinophil percentage of granulocytes;
KIRP	cis	rs367943	0.666	rs6594704	chr5:112692834	A/T	cg12552261	chr5:112820674	MCC	0.52	6.12	0.36	3.63e-9	Type 2 diabetes;
KIRP	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.52	-6.36	-0.38	9.9e-10	Metabolite levels;
KIRP	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg10664184	chr19:17420304	DDA1	0.72	8.45	0.47	2.64e-15	Systemic lupus erythematosus;
KIRP	cis	rs4959270	0.506	rs4263621	chr6:435471	G/A	cg13299325	chr6:447777	NA	0.25	5.05	0.31	8.55e-7	Limited cutaneous systemic scleroderma;
KIRP	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18357526	chr6:26021779	HIST1H4A	0.51	6.71	0.39	1.29e-10	Height;
KIRP	cis	rs2494938	0.552	rs846510	chr6:40573839	A/G	cg14084896	chr6:40530702	LRFN2	-0.4	-4.93	-0.3	1.54e-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04374321	chr14:90722782	PSMC1	0.89	14.57	0.68	4.26e-35	Mortality in heart failure;
KIRP	cis	rs10416265	0.502	rs7245411	chr19:33543029	A/T	cg27124370	chr19:33622961	WDR88	0.69	9.52	0.52	1.72e-18	Bone properties (heel);
KIRP	cis	rs6142102	0.961	rs1883524	chr20:32626107	G/A	cg08999081	chr20:33150536	PIGU	0.52	6.73	0.39	1.18e-10	Skin pigmentation;
KIRP	trans	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg00953403	chr17:74099816	EXOC7	-0.46	-6.1	-0.36	4.08e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs7721647	0.821	rs332518	chr5:90849062	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.42	5.2	0.31	4.2e-7	Breast cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22022442	chr12:31811083	C12orf72	-0.43	-6.26	-0.37	1.68e-9	Inflammatory biomarkers;
KIRP	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	13.6	0.66	8.77e-32	Platelet count;
KIRP	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg24747557	chr10:131355152	MGMT	-0.38	-5.16	-0.31	4.99e-7	Response to temozolomide;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15967449	chr19:49999284	RPS11	0.46	6.03	0.36	5.87e-9	Parkinson's disease;
KIRP	cis	rs3739034	0.639	rs4954177	chr2:135543933	A/T	cg15546071	chr2:135691756	CCNT2	-0.55	-5.33	-0.32	2.25e-7	Gut microbiome composition (winter);
KIRP	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg23024343	chr7:107201750	COG5	0.4	4.88	0.3	1.9e-6	Coronary artery disease;
KIRP	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.95	-16.7	-0.73	2.25e-42	Intelligence (multi-trait analysis);
KIRP	cis	rs714027	1.000	rs6006356	chr22:30503171	G/A	cg27665648	chr22:30112403	NA	-0.41	-5.88	-0.35	1.32e-8	Lymphocyte counts;
KIRP	cis	rs859767	0.501	rs6724777	chr2:135407292	C/T	cg25422880	chr2:135218333	TMEM163	0.34	5.04	0.31	8.92e-7	Neuroticism;
KIRP	cis	rs7737355	0.812	rs6868007	chr5:130824810	T/C	cg06307176	chr5:131281290	NA	0.47	5.63	0.34	4.81e-8	Life satisfaction;
KIRP	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.52	-6.32	-0.37	1.23e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.12	0.41	1.2e-11	Bipolar disorder;
KIRP	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-1.02	-17.2	-0.74	4.46e-44	Height;
KIRP	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.83	12.44	0.62	6.97e-28	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs10073892	1.000	rs55843474	chr5:101764961	A/C	cg19774478	chr5:101632501	SLCO4C1	0.61	6.42	0.38	6.89e-10	Cognitive decline (age-related);
KIRP	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg08461772	chr7:95026248	PON3	0.39	5.29	0.32	2.7e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.56	-5.92	-0.35	1.05e-8	Ulcerative colitis;
KIRP	cis	rs9400467	0.506	rs12200758	chr6:111710844	A/G	cg15721981	chr6:111408429	SLC16A10	0.68	6.2	0.37	2.4e-9	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs1133146	1.000	rs1133146	chr19:53666660	A/G	cg18724069	chr5:39721760	NA	0.4	6.27	0.37	1.57e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs1424233	1.000	rs11640999	chr16:79676333	C/T	cg11120865	chr14:21853037	SUPT16H	0.37	6.03	0.36	5.91e-9	Obesity;
KIRP	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.72	-5.75	-0.34	2.57e-8	Diabetic retinopathy;
KIRP	cis	rs7011049	0.841	rs116352923	chr8:53870151	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-0.81	-8.88	-0.49	1.45e-16	Hip circumference adjusted for BMI;
KIRP	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.31	0.55	5.9e-21	Hip circumference;
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg18657303	chr4:1051139	NA	0.54	4.97	0.3	1.24e-6	Recombination rate (females);
KIRP	trans	rs7246760	0.867	rs68041339	chr19:9818851	A/G	cg02900749	chr2:68251473	NA	-1.19	-10.02	-0.54	4.82e-20	Pursuit maintenance gain;
KIRP	cis	rs2019216	0.542	rs1850564	chr17:21911794	T/C	cg22648282	chr17:21454238	C17orf51	-0.52	-6.79	-0.4	8.36e-11	Pelvic organ prolapse;
KIRP	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs17321999	1.000	rs3817143	chr2:30482285	G/A	cg05247661	chr2:30472410	LBH	0.77	7.82	0.45	1.6e-13	Systemic lupus erythematosus;
KIRP	cis	rs7818345	0.737	rs17407149	chr8:19274848	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.4	5.38	0.32	1.69e-7	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.89	11.02	0.57	3.25e-23	Smoking behavior;
KIRP	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07570687	chr10:102243282	WNT8B	0.44	5.15	0.31	5.41e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7187994	0.848	rs7185949	chr16:84779248	T/G	cg11201751	chr16:85158047	NA	0.47	4.85	0.3	2.22e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg17507749	chr15:85114479	UBE2QP1	0.89	9.93	0.53	9.33e-20	Schizophrenia;
KIRP	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.35	8.26	0.47	9.24e-15	Asthma (sex interaction);
KIRP	cis	rs681343	0.746	rs633372	chr19:49209226	G/A	cg08619932	chr19:49200058	FUT2	0.36	5.66	0.34	4.12e-8	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
KIRP	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg10818794	chr15:86012489	AKAP13	-0.48	-6.71	-0.39	1.32e-10	Interstitial lung disease;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02438591	chr16:2205559	TRAF7;SNORD60	0.44	6.06	0.36	5.01e-9	Survival in pancreatic cancer;
KIRP	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg01877450	chr7:97915802	BRI3	-0.55	-7.11	-0.41	1.24e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6815814	0.851	rs4129009	chr4:38774889	T/C	cg06935464	chr4:38784597	TLR10	0.5	4.86	0.3	2.06e-6	Breast cancer;
KIRP	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg04691961	chr3:161091175	C3orf57	-0.36	-5.32	-0.32	2.39e-7	Kawasaki disease;
KIRP	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg22974920	chr21:40686053	BRWD1	0.44	5.08	0.31	7.31e-7	Cognitive function;
KIRP	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg08461772	chr7:95026248	PON3	0.4	5.59	0.34	6.05e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.46	5.55	0.33	7.55e-8	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs3124314	1.000	rs4845420	chr1:152141204	A/T	cg13071333	chr1:152595882	LCE3A	0.35	4.95	0.3	1.38e-6	Hair morphology;
KIRP	cis	rs9921338	0.924	rs7193645	chr16:11381036	A/G	cg00044050	chr16:11439710	C16orf75	-0.49	-5.0	-0.3	1.07e-6	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg08648136	chr8:956695	NA	0.42	5.93	0.35	1.05e-8	Schizophrenia;
KIRP	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.8	0.4	7.72e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg11815991	chr20:30193098	ID1	-0.51	-5.12	-0.31	6.21e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs929596	0.564	rs2741042	chr2:234565917	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-5.64	-0.34	4.69e-8	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs4356975	0.563	rs34318523	chr4:69966853	T/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.73	-8.63	-0.48	7.65e-16	Multiple sclerosis;
KIRP	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg01849466	chr14:104193079	ZFYVE21	-0.41	-5.03	-0.31	9.57e-7	Schizophrenia;
KIRP	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg25019722	chr6:37503610	NA	-0.72	-9.26	-0.51	1.08e-17	Cognitive performance;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg04791456	chr3:57505743	DNAH12	-0.43	-6.06	-0.36	5.12e-9	Bladder cancer;
KIRP	cis	rs2077654	0.556	rs4148624	chr11:17444024	A/G	cg25308976	chr11:17434268	ABCC8	0.54	5.99	0.36	7.37e-9	Gout;
KIRP	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg18882449	chr10:104885122	NT5C2	-0.5	-6.47	-0.38	5.22e-10	Arsenic metabolism;
KIRP	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.55	-6.77	-0.4	9.61e-11	Uric acid levels;
KIRP	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg22117172	chr7:91764530	CYP51A1	0.47	6.49	0.38	4.77e-10	Breast cancer;
KIRP	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg13482628	chr17:19912719	NA	-0.53	-7.0	-0.41	2.49e-11	Schizophrenia;
KIRP	cis	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	cis	rs6684514	0.922	rs11264475	chr1:156306918	G/A	cg16558208	chr1:156270281	VHLL	-0.43	-5.69	-0.34	3.67e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg08885076	chr2:99613938	TSGA10	-0.37	-5.13	-0.31	5.83e-7	Chronic sinus infection;
KIRP	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.57	-5.72	-0.34	3.07e-8	Pubertal anthropometrics;
KIRP	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg24747557	chr10:131355152	MGMT	-0.37	-5.04	-0.31	8.9e-7	Response to temozolomide;
KIRP	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	1.03	11.32	0.59	3.36e-24	Alzheimer's disease;
KIRP	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.27	5.4	0.33	1.53e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.22	-24.37	-0.84	1.56e-67	IgG glycosylation;
KIRP	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	1.08	11.95	0.61	2.92e-26	Psoriasis;
KIRP	cis	rs2380205	0.538	rs1976655	chr10:5922729	T/C	cg27141509	chr10:5886111	NA	-0.39	-4.89	-0.3	1.81e-6	Breast cancer;
KIRP	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg07001201	chr5:642380	CEP72	0.68	6.21	0.37	2.29e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg16872172	chr3:49449542	TCTA;RHOA	-0.43	-6.06	-0.36	5.13e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs290268	0.838	rs290989	chr9:93561836	T/C	cg02608019	chr9:93564028	SYK	0.82	11.76	0.6	1.24e-25	Platelet count;
KIRP	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.64	10.55	0.56	1.06e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg24253500	chr15:84953950	NA	0.65	7.22	0.42	6.53e-12	Schizophrenia;
KIRP	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg25124228	chr12:125621409	AACS	-0.75	-9.06	-0.5	4.17e-17	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11336847	1	rs11336847	chr2:27748992	AT/A	cg05484376	chr2:27715224	FNDC4	0.32	5.04	0.31	9.2e-7	Granulocyte percentage of myeloid white cells;Monocyte percentage of white cells;
KIRP	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06212747	chr3:49208901	KLHDC8B	0.77	11.07	0.58	2.27e-23	Parkinson's disease;
KIRP	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg06565975	chr8:143823917	SLURP1	-0.56	-7.73	-0.44	2.81e-13	Urinary tract infection frequency;
KIRP	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.59	-8.18	-0.46	1.56e-14	Menarche (age at onset);
KIRP	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.46	-5.63	-0.34	4.97e-8	Psychosis in Alzheimer's disease;
KIRP	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg25173405	chr17:45401733	C17orf57	0.48	6.42	0.38	6.95e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7615316	0.844	rs7641330	chr3:142305638	T/C	cg20824294	chr3:142316082	PLS1	0.27	5.98	0.36	7.75e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs12476592	0.571	rs7577952	chr2:63787212	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24221642	chr17:60557243	TLK2	0.46	6.39	0.38	8.18e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23281280	chr6:28129359	ZNF389	-0.46	-5.15	-0.31	5.31e-7	Depression;
KIRP	cis	rs7116495	0.609	rs2852365	chr11:71715218	T/C	cg26138937	chr11:71823887	C11orf51	-1.11	-7.79	-0.44	1.92e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.62	9.97	0.54	7.09e-20	Coronary artery disease;
KIRP	cis	rs6693567	0.565	rs497128	chr1:150269952	A/G	cg07843065	chr1:150265600	MRPS21	-0.51	-7.36	-0.42	2.76e-12	Migraine;
KIRP	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg00074818	chr8:8560427	CLDN23	0.37	5.99	0.36	7.38e-9	Obesity-related traits;
KIRP	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	5.25	0.32	3.29e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4478137	0.501	rs6828399	chr4:164228471	T/C	cg06758707	chr4:164254230	NPY1R	-0.49	-5.6	-0.34	5.69e-8	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.45	5.32	0.32	2.34e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.58	-7.49	-0.43	1.21e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.77	8.71	0.49	4.65e-16	Cognitive test performance;
KIRP	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg02297831	chr4:17616191	MED28	0.6	7.65	0.44	4.42e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-1.01	-13.13	-0.64	3.27e-30	Platelet distribution width;
KIRP	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.45	6.19	0.37	2.47e-9	Total body bone mineral density;
KIRP	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg11843606	chr2:227700838	RHBDD1	0.38	4.84	0.3	2.25e-6	Pulmonary function;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11408656	chr1:226497275	LIN9	0.47	6.3	0.37	1.34e-9	Parkinson's disease;
KIRP	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg08501292	chr6:25962987	TRIM38	1.11	8.17	0.46	1.64e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6832769	1.000	rs1522111	chr4:56329563	T/A	cg09317128	chr4:56265301	TMEM165	0.55	7.11	0.41	1.25e-11	Personality dimensions;
KIRP	cis	rs698833	0.852	rs698761	chr2:44547574	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-5.15	-0.31	5.41e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1950626	0.833	rs35436326	chr14:101396148	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.61	6.85	0.4	5.99e-11	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.77	-9.36	-0.51	5.22e-18	Multiple sclerosis;
KIRP	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.62	-0.34	5.24e-8	Colorectal cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10089324	chr1:51984752	EPS15	0.54	6.26	0.37	1.71e-9	Smoking initiation;
KIRP	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.82	8.46	0.47	2.38e-15	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg10755058	chr3:40428713	ENTPD3	0.37	5.1	0.31	6.93e-7	Renal cell carcinoma;
KIRP	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg27560282	chr6:52926821	ICK	-0.47	-6.55	-0.39	3.4e-10	Hippocampal sclerosis of aging;
KIRP	cis	rs56775891	0.537	rs7236339	chr18:77579773	C/T	cg24058013	chr18:77568902	NA	-0.64	-7.89	-0.45	9.84e-14	Schizophrenia;
KIRP	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg00149659	chr3:10157352	C3orf10	0.77	6.28	0.37	1.56e-9	Alzheimer's disease;
KIRP	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.7	-8.45	-0.47	2.51e-15	Cognitive function;
KIRP	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-0.78	-9.26	-0.51	1.08e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg02297831	chr4:17616191	MED28	0.6	7.62	0.44	5.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-12.06	-0.61	1.27e-26	Chronic sinus infection;
KIRP	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg19847130	chr8:10466454	RP1L1	0.37	5.62	0.34	5.05e-8	Retinal vascular caliber;
KIRP	cis	rs7523273	0.606	rs2724398	chr1:207993699	A/G	cg22525895	chr1:207977042	MIR29B2	-0.67	-9.21	-0.51	1.45e-17	Schizophrenia;
KIRP	cis	rs1823913	0.503	rs35672076	chr2:192208633	C/T	cg12404831	chr2:192114017	MYO1B	0.51	7.01	0.41	2.3e-11	Obesity-related traits;
KIRP	cis	rs72781680	0.611	rs72781695	chr2:24266744	T/C	cg20701182	chr2:24300061	SF3B14	0.91	10.13	0.54	2.24e-20	Lymphocyte counts;
KIRP	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg13939156	chr17:80058883	NA	0.48	7.14	0.41	1.05e-11	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg27278001	chr14:101451739	SNORD114-25	-0.4	-6.13	-0.36	3.46e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg02462569	chr6:150064036	NUP43	-0.34	-5.15	-0.31	5.38e-7	Lung cancer;
KIRP	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg10189774	chr4:17578691	LAP3	0.54	6.81	0.4	7.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.95	-0.3	1.35e-6	Life satisfaction;
KIRP	cis	rs3812111	0.510	rs1931892	chr6:116594511	A/C	cg18828861	chr6:116576566	TSPYL4	0.42	4.87	0.3	1.98e-6	Age-related macular degeneration;
KIRP	cis	rs1858037	0.867	rs876933	chr2:65609437	C/T	cg08085232	chr2:65598271	SPRED2	-0.53	-6.27	-0.37	1.6e-9	Rheumatoid arthritis;
KIRP	cis	rs2976388	1.000	rs2294008	chr8:143761931	C/T	cg06565975	chr8:143823917	SLURP1	-0.43	-6.36	-0.38	9.7e-10	Urinary tract infection frequency;
KIRP	cis	rs427941	0.632	rs201493	chr7:101754865	T/C	cg06246474	chr7:101738831	CUX1	0.51	6.11	0.36	3.94e-9	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.66	8.46	0.47	2.38e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06270147	chr10:73078971	SLC29A3	0.5	6.88	0.4	5.03e-11	Parkinson's disease;
KIRP	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg25039879	chr17:56429692	SUPT4H1	0.59	4.93	0.3	1.49e-6	Cognitive test performance;
KIRP	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs3931020	0.508	rs28568334	chr1:75199299	C/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.43	5.24	0.32	3.48e-7	Resistin levels;
KIRP	cis	rs904251	0.965	rs62406516	chr6:37439364	C/T	cg01843034	chr6:37503916	NA	-0.7	-8.89	-0.49	1.34e-16	Cognitive performance;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26150071	chr1:34629559	CSMD2	0.45	6.05	0.36	5.38e-9	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14562851	chr1:12660012	DHRS3	0.45	6.1	0.36	4.15e-9	Interleukin-4 levels;
KIRP	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.7e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.74	10.36	0.55	4.22e-21	Red blood cell count;
KIRP	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.77	9.05	0.5	4.6e-17	Corneal astigmatism;
KIRP	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg06766960	chr11:133703094	NA	-0.73	-9.84	-0.53	1.82e-19	Childhood ear infection;
KIRP	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.68e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg11846333	chr4:119757529	SEC24D	1.03	6.12	0.36	3.69e-9	Cannabis dependence symptom count;
KIRP	cis	rs6684514	1.000	rs12134983	chr1:156290409	T/C	cg16558208	chr1:156270281	VHLL	-0.45	-5.95	-0.35	9.29e-9	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs17101923	1.000	rs7487625	chr12:66319996	A/C	cg06712651	chr12:66351869	HMGA2	-0.58	-6.59	-0.39	2.64e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.88	13.62	0.66	7.32e-32	Platelet count;
KIRP	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-9.47	-0.52	2.47e-18	Response to antipsychotic treatment;
KIRP	cis	rs748404	0.697	rs555001	chr15:43545728	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.5	0.38	4.43e-10	Lung cancer;
KIRP	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg25182066	chr10:30743637	MAP3K8	-0.61	-7.4	-0.43	2.17e-12	Inflammatory bowel disease;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg16590910	chr6:42928470	GNMT	0.38	5.31	0.32	2.4e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg15117754	chr3:10150083	C3orf24	0.54	5.34	0.32	2.08e-7	Alzheimer's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01603234	chr1:218990709	NA	0.4	6.55	0.39	3.37e-10	C-reactive protein;
KIRP	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.5	5.95	0.35	8.94e-9	Metabolite levels;
KIRP	cis	rs73200209	0.744	rs17498760	chr12:116636803	C/G	cg01776926	chr12:116560359	MED13L	-0.57	-6.21	-0.37	2.3e-9	Total body bone mineral density;
KIRP	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs2708977	0.699	rs631746	chr2:97065499	A/G	cg22654517	chr2:96458247	NA	0.32	5.15	0.31	5.38e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs629922	0.586	rs620095	chr11:114061226	G/T	cg25009965	chr11:114031120	ZBTB16	0.44	4.9	0.3	1.74e-6	Paneth cell defects in Crohn's disease;
KIRP	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.72	-6.58	-0.39	2.75e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg13147721	chr7:65941812	NA	1.03	7.15	0.41	1.01e-11	Diabetic kidney disease;
KIRP	cis	rs12190007	0.508	rs6605537	chr6:169730781	G/A	cg16388071	chr6:169726476	NA	0.54	7.84	0.45	1.35e-13	Obesity-related traits;
KIRP	cis	rs35883536	0.846	rs964905	chr1:101087131	T/C	cg06223162	chr1:101003688	GPR88	-0.32	-6.46	-0.38	5.69e-10	Monocyte count;
KIRP	cis	rs12580194	0.593	rs61957887	chr12:55721734	C/T	cg11794356	chr12:55725991	OR6C3	-0.59	-8.57	-0.48	1.13e-15	Cancer;
KIRP	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.98	14.12	0.67	1.47e-33	Cognitive function;
KIRP	cis	rs2591576	0.736	rs6555669	chr5:165415115	G/A	cg13976338	chr5:165423657	NA	-0.78	-11.88	-0.6	4.86e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.67	-7.28	-0.42	4.41e-12	DNA methylation (variation);
KIRP	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.59	9.65	0.52	6.94e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-4.92	-0.3	1.58e-6	Breast cancer;Mosquito bite size;
KIRP	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg09571762	chr12:39539558	NA	0.37	5.13	0.31	5.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.59	-5.84	-0.35	1.63e-8	Total cholesterol levels;
KIRP	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg13147721	chr7:65941812	NA	-1.04	-6.86	-0.4	5.42e-11	Diabetic kidney disease;
KIRP	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.69	8.52	0.48	1.61e-15	Platelet count;
KIRP	cis	rs9533799	0.508	rs11619528	chr13:44826355	T/C	cg19190762	chr13:44806055	NA	0.44	4.85	0.3	2.21e-6	Amyotrophic lateral sclerosis;
KIRP	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.78	13.97	0.67	4.83e-33	Height;
KIRP	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg25547332	chr5:131281432	NA	-0.47	-5.33	-0.32	2.22e-7	Life satisfaction;
KIRP	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	5.71	0.34	3.31e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg19404215	chr3:33155277	CRTAP	-0.54	-5.34	-0.32	2.12e-7	Major depressive disorder;
KIRP	trans	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg23484912	chr5:273055	PDCD6	0.59	7.12	0.41	1.19e-11	Pancreatic cancer;
KIRP	cis	rs12476592	0.602	rs4671065	chr2:63791131	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	0.58	7.82	0.45	1.58e-13	Prostate cancer;
KIRP	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg24874828	chr4:187887005	NA	-0.49	-7.06	-0.41	1.74e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.95e-15	Aortic root size;
KIRP	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg16989719	chr2:238392110	NA	-0.65	-6.24	-0.37	1.92e-9	Prostate cancer;
KIRP	cis	rs8028689	0.737	rs8041209	chr15:28443658	A/C	cg07567273	chr15:28361795	HERC2	0.54	4.91	0.3	1.65e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.97	-16.58	-0.73	5.97e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs80207740	1.000	rs76008177	chr8:21802272	C/T	cg17168535	chr8:21777572	XPO7	0.69	6.6	0.39	2.52e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04004882	chr2:215674386	BARD1	-0.63	-6.56	-0.39	3.17e-10	Neuroblastoma;
KIRP	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.53	8.07	0.46	3.08e-14	Bone mineral density;
KIRP	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.7	7.91	0.45	8.9e-14	Obesity-related traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09849967	chr3:49138870	QARS	0.49	6.1	0.36	4.12e-9	Interleukin-4 levels;
KIRP	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.82	-12.94	-0.64	1.44e-29	Dental caries;
KIRP	cis	rs13102973	0.965	rs7693757	chr4:135856609	C/T	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.12e-16	Subjective well-being;
KIRP	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg02974968	chr1:160236444	NA	-0.49	-6.7	-0.39	1.44e-10	Squamous cell lung carcinoma;
KIRP	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.33	-0.42	3.23e-12	Neuroticism;
KIRP	cis	rs2964802	0.505	rs7447014	chr5:10814212	T/C	cg14521931	chr5:10832172	NA	-0.74	-11.27	-0.58	4.96e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs5167	0.677	rs73047643	chr19:45457393	T/C	cg13119609	chr19:45449297	APOC2	0.41	4.88	0.3	1.91e-6	Blood protein levels;
KIRP	cis	rs7119038	0.607	rs12365699	chr11:118743286	C/T	cg19308663	chr11:118741387	NA	0.66	9.44	0.52	2.95e-18	Sjögren's syndrome;
KIRP	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.5	-6.09	-0.36	4.42e-9	Urate levels in overweight individuals;
KIRP	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9398803	0.713	rs9401891	chr6:126894135	G/T	cg19875578	chr6:126661172	C6orf173	0.43	5.49	0.33	1e-7	Male-pattern baldness;
KIRP	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg02887458	chr19:19495540	GATAD2A	0.47	5.73	0.34	2.95e-8	Bipolar disorder;
KIRP	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.55	6.69	0.39	1.47e-10	Height;
KIRP	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.46	5.82	0.35	1.86e-8	Recombination rate (males);
KIRP	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2882667	0.931	rs10069528	chr5:138354027	A/G	cg04439458	chr5:138467593	SIL1	-0.44	-7.31	-0.42	3.83e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs11997175	0.550	rs7463110	chr8:33837033	A/C	cg04338863	chr8:33670619	NA	0.39	4.91	0.3	1.63e-6	Body mass index;
KIRP	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg08126542	chr6:37504118	NA	-0.72	-10.06	-0.54	3.75e-20	Cognitive performance;
KIRP	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.62	-9.49	-0.52	2.15e-18	Pulse pressure;
KIRP	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg06026331	chr20:60912101	LAMA5	0.52	5.42	0.33	1.41e-7	Colorectal cancer;
KIRP	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.66	9.06	0.5	4.09e-17	Colorectal cancer;
KIRP	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.68	8.61	0.48	8.86e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6430538	0.621	rs749017	chr2:135573659	G/C	cg12500956	chr2:135428796	TMEM163	0.39	5.17	0.31	4.96e-7	Parkinson's disease;
KIRP	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.48	-6.31	-0.37	1.26e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg11235152	chr1:67600687	NA	-0.83	-12.74	-0.63	7.02e-29	Psoriasis;
KIRP	cis	rs6893300	0.961	rs11738269	chr5:179209059	A/C	cg14593053	chr5:179126677	CANX	0.57	6.53	0.38	3.72e-10	Resting heart rate;
KIRP	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg12573674	chr2:1569213	NA	-0.51	-5.61	-0.34	5.45e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.9	-10.55	-0.56	1.03e-21	White matter hyperintensity burden;
KIRP	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg09184832	chr6:79620586	NA	-0.38	-4.93	-0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg04691540	chr1:179198414	ABL2	-0.54	-6.06	-0.36	4.97e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg10434728	chr15:90938212	IQGAP1	0.43	8.18	0.46	1.51e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.11	8.74	0.49	3.66e-16	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12580194	0.593	rs7487419	chr12:55769801	C/G	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.54	-6.29	-0.37	1.42e-9	Aortic root size;
KIRP	cis	rs988913	1.000	rs6926997	chr6:54817326	C/G	cg03513858	chr6:54763001	FAM83B	-0.38	-5.57	-0.33	6.59e-8	Menarche (age at onset);
KIRP	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg25547332	chr5:131281432	NA	0.47	5.48	0.33	1.03e-7	Life satisfaction;
KIRP	cis	rs936229	0.906	rs9210	chr15:75128501	T/C	cg14664628	chr15:75095509	CSK	-1.15	-19.26	-0.78	5.1e-51	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs604222	0.520	rs6777406	chr3:193583127	A/C	cg05635121	chr17:7154132	C17orf81;DULLARD	0.48	6.09	0.36	4.22e-9	Major depressive disorder;
KIRP	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg03806693	chr22:41940476	POLR3H	-0.47	-5.7	-0.34	3.42e-8	Neuroticism;
KIRP	cis	rs28834970	0.675	rs17057051	chr8:27227554	C/T	cg21186296	chr8:27182909	PTK2B	0.47	5.21	0.32	3.92e-7	Alzheimer's disease (late onset);
KIRP	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.49	6.86	0.4	5.57e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs9311676	0.656	rs11917567	chr3:58382254	C/T	cg06643156	chr3:58380774	PXK	0.36	4.99	0.3	1.16e-6	Systemic lupus erythematosus;
KIRP	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.57	7.06	0.41	1.71e-11	Arsenic metabolism;
KIRP	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg24972876	chr7:65420302	NA	0.41	5.61	0.34	5.53e-8	Calcium levels;
KIRP	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.29	10.41	0.55	2.91e-21	Prostate cancer;
KIRP	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.82	-11.17	-0.58	1.09e-23	Longevity;
KIRP	cis	rs77972916	0.536	rs7589361	chr2:43589328	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.52	-6.26	-0.37	1.69e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2594989	0.943	rs6784861	chr3:11465568	T/C	cg01796438	chr3:11312864	ATG7	-0.66	-7.77	-0.44	2.07e-13	Circulating chemerin levels;
KIRP	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.67	0.48	6.01e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs963731	0.649	rs2888585	chr2:39246683	C/T	cg04010122	chr2:39346883	SOS1	-0.91	-6.14	-0.36	3.23e-9	Corticobasal degeneration;
KIRP	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.55	8.61	0.48	8.93e-16	Schizophrenia;
KIRP	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.7	-8.25	-0.47	9.41e-15	Diabetic retinopathy;
KIRP	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.83	12.04	0.61	1.52e-26	Bladder cancer;
KIRP	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.73	-9.52	-0.52	1.66e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.21	0.7	2.93e-37	Chronic sinus infection;
KIRP	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-1.1	-15.66	-0.71	8.4e-39	Multiple sclerosis;
KIRP	cis	rs1800469	1.000	rs1800469	chr19:41860296	A/G	cg09537434	chr19:41945824	ATP5SL	-0.53	-5.85	-0.35	1.55e-8	Colorectal cancer;
KIRP	cis	rs7937612	1.000	rs10892576	chr11:120294423	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.15	-0.41	1.01e-11	Intraocular pressure;
KIRP	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.91	-0.45	8.98e-14	Neuroticism;
KIRP	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.5	-5.23	-0.32	3.66e-7	Corneal structure;
KIRP	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	1.15	8.87	0.49	1.53e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg26727032	chr16:67993705	SLC12A4	-0.66	-5.48	-0.33	1.03e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.92	10.92	0.57	6.67e-23	Corneal astigmatism;
KIRP	cis	rs6546324	0.625	rs2902007	chr2:67795462	A/T	cg15745817	chr2:67799979	NA	-0.64	-7.02	-0.41	2.15e-11	Endometriosis;
KIRP	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg17143192	chr8:8559678	CLDN23	0.59	7.17	0.42	8.65e-12	Obesity-related traits;
KIRP	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg04990556	chr1:26633338	UBXN11	0.66	6.67	0.39	1.66e-10	Obesity-related traits;
KIRP	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.66	-7.77	-0.44	2.13e-13	Mean platelet volume;
KIRP	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg07148914	chr20:33460835	GGT7	-0.54	-7.2	-0.42	7.5e-12	Height;
KIRP	cis	rs7538876	1.000	rs7545115	chr1:17724331	G/T	cg07394400	chr1:17752023	RCC2	-0.34	-4.85	-0.3	2.21e-6	Basal cell carcinoma;
KIRP	cis	rs12692119	0.614	rs6431192	chr2:127631294	C/T	cg25501666	chr2:127640322	NA	-0.45	-5.05	-0.31	8.43e-7	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.75	9.54	0.52	1.53e-18	Aortic root size;
KIRP	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	10.53	0.56	1.25e-21	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7572644	0.640	rs4666015	chr2:28019367	G/A	cg27432699	chr2:27873401	GPN1	0.49	5.47	0.33	1.1e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs838147	0.815	rs28400015	chr19:49250633	G/A	cg13540341	chr19:49222985	MAMSTR	0.32	5.16	0.31	5.15e-7	Dietary macronutrient intake;
KIRP	cis	rs6546324	0.592	rs2861648	chr2:67803908	C/T	cg15745817	chr2:67799979	NA	-0.65	-7.15	-0.41	9.85e-12	Endometriosis;
KIRP	cis	rs74225573	1	rs74225573	chr1:11280994	T/C	cg18435880	chr1:11160013	EXOSC10	0.88	5.26	0.32	3.21e-7	Corneal curvature;
KIRP	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg23127183	chr11:57508653	C11orf31	0.52	6.72	0.39	1.26e-10	Schizophrenia;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg08132940	chr7:1081526	C7orf50	-0.6	-6.05	-0.36	5.4e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg18306943	chr3:40428807	ENTPD3	0.45	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	cis	rs7010267	0.642	rs9969672	chr8:120006080	T/A	cg01975934	chr8:119970761	NA	-0.42	-5.55	-0.33	7.26e-8	Total body bone mineral density (age 45-60);
KIRP	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg07541023	chr7:19748670	TWISTNB	0.64	5.71	0.34	3.24e-8	Thyroid stimulating hormone;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg20887711	chr4:1340912	KIAA1530	0.52	6.56	0.39	3.07e-10	Longevity;
KIRP	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg03929089	chr4:120376271	NA	0.69	6.11	0.36	3.84e-9	Axial length;
KIRP	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11584989	chr19:19387371	SF4	0.59	6.57	0.39	2.98e-10	Bipolar disorder;
KIRP	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg23205692	chr1:25664452	TMEM50A	0.36	5.24	0.32	3.38e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.59	-6.33	-0.37	1.13e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-6.86	-0.4	5.71e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg14768367	chr16:72042858	DHODH	-0.42	-4.89	-0.3	1.85e-6	Fibrinogen levels;
KIRP	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06634786	chr22:41940651	POLR3H	0.5	5.36	0.32	1.95e-7	Vitiligo;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg02084834	chr2:201983708	CFLAR	0.46	6.37	0.38	9.34e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.71	-10.32	-0.55	5.71e-21	Brugada syndrome;
KIRP	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.79	10.17	0.54	1.61e-20	Platelet count;
KIRP	cis	rs829661	0.793	rs2602808	chr2:30840358	A/G	cg10949345	chr2:30726833	LCLAT1	-1.04	-12.94	-0.64	1.47e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs3105593	1.000	rs3848130	chr15:50892111	A/G	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.26e-7	QT interval;
KIRP	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.11	0.41	1.27e-11	Mean corpuscular volume;
KIRP	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.62	-7.62	-0.44	5.36e-13	Colorectal cancer;
KIRP	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg14768367	chr16:72042858	DHODH	0.51	6.36	0.38	9.87e-10	Fibrinogen levels;
KIRP	cis	rs9556958	0.635	rs4529985	chr13:99167120	G/C	cg20750642	chr13:99100586	FARP1	0.51	7.33	0.42	3.28e-12	Educational attainment (years of education);
KIRP	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.02	17.05	0.74	1.46e-43	Schizophrenia;
KIRP	cis	rs501120	1.000	rs605445	chr10:44756779	C/T	cg09554077	chr10:44749378	NA	0.72	11.38	0.59	2.26e-24	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs9596863	0.851	rs9568913	chr13:54340500	A/G	ch.13.53330881F	chr13:54432880	NA	0.49	4.95	0.3	1.39e-6	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	0.96	18.16	0.76	2.42e-47	Dental caries;
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.14	13.78	0.66	2.07e-32	Platelet count;
KIRP	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	cg21523751	chr1:182988639	NA	0.35	4.98	0.3	1.21e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg04132472	chr17:19861366	AKAP10	0.43	5.88	0.35	1.35e-8	Schizophrenia;
KIRP	cis	rs12785387	1	rs12785387	chr11:120221987	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.42	-5.33	-0.32	2.25e-7	Intraocular pressure;
KIRP	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg17372223	chr3:52568218	NT5DC2	0.31	4.93	0.3	1.5e-6	Bipolar disorder;
KIRP	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.51	-0.65	1.76e-31	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.11	-0.46	2.43e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	0.8	7.83	0.45	1.5e-13	Prostate cancer;
KIRP	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.61	-8.33	-0.47	5.52e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.62	9.24	0.51	1.2e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg08885076	chr2:99613938	TSGA10	0.53	9.27	0.51	9.88e-18	Chronic sinus infection;
KIRP	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	11.73	0.6	1.53e-25	Alzheimer's disease;
KIRP	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg07001201	chr5:642380	CEP72	0.69	6.47	0.38	5.38e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs17123764	0.892	rs7136052	chr12:50110736	A/T	cg20471783	chr12:50157085	TMBIM6	0.31	4.89	0.3	1.83e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.61	8.68	0.48	5.67e-16	Lung cancer;
KIRP	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg10792982	chr14:105748885	BRF1	0.86	13.33	0.65	7.25e-31	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	7.42	0.43	1.94e-12	Coronary artery disease;
KIRP	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg05315796	chr3:52349193	DNAH1	0.4	6.43	0.38	6.59e-10	Electroencephalogram traits;
KIRP	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg06223162	chr1:101003688	GPR88	0.35	7.36	0.43	2.67e-12	Monocyte count;
KIRP	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.9	-10.39	-0.55	3.36e-21	Corneal astigmatism;
KIRP	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg07636037	chr3:49044803	WDR6	0.53	6.27	0.37	1.58e-9	Resting heart rate;
KIRP	cis	rs6800768	0.633	rs59461522	chr3:24100377	G/A	cg10674438	chr3:24145617	LOC152024	-0.51	-6.48	-0.38	5.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg20673091	chr1:2541236	MMEL1	-0.67	-10.16	-0.54	1.8e-20	Ulcerative colitis;
KIRP	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-6.29	-0.37	1.47e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.56	5.59	0.34	6.09e-8	Initial pursuit acceleration;
KIRP	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.64	-8.27	-0.47	8.56e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4356932	0.967	rs13111790	chr4:76972402	G/C	cg19388996	chr4:76862389	NAAA	0.4	5.16	0.31	5.05e-7	Blood protein levels;
KIRP	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.86	0.4	5.46e-11	Tonsillectomy;
KIRP	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg13266496	chr6:110720918	DDO	-0.36	-5.87	-0.35	1.41e-8	Platelet distribution width;
KIRP	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.87	0.35	1.39e-8	Depressive symptoms;
KIRP	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.61	-8.03	-0.46	4e-14	Retinal vascular caliber;
KIRP	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01391022	chr12:122360665	WDR66	-0.43	-6.72	-0.39	1.27e-10	Mean corpuscular volume;
KIRP	cis	rs73198271	1.000	rs11776513	chr8:8609057	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-4.94	-0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg01703355	chr3:152067880	MBNL1	0.4	6.38	0.38	8.61e-10	C-reactive protein;
KIRP	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg16586182	chr3:47516702	SCAP	0.68	9.12	0.5	2.8e-17	Colorectal cancer;
KIRP	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.72	-0.34	3.12e-8	Breast cancer;
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.58	-7.8	-0.45	1.77e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6568686	0.786	rs9481155	chr6:111829239	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.56	-5.21	-0.32	3.99e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg26531700	chr6:26746687	NA	-0.4	-5.46	-0.33	1.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1829883	0.866	rs1523391	chr5:98794214	A/C	cg08333243	chr5:99726346	NA	-0.41	-5.46	-0.33	1.19e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg00800569	chr2:239229395	TRAF3IP1	0.41	4.96	0.3	1.32e-6	Multiple system atrophy;
KIRP	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg22189786	chr22:42395067	WBP2NL	0.45	5.7	0.34	3.5e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.83	-13.07	-0.64	5.34e-30	Dental caries;
KIRP	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.57	-9.14	-0.5	2.44e-17	Lymphocyte counts;
KIRP	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg04731861	chr2:219085781	ARPC2	0.29	7.4	0.43	2.19e-12	Colorectal cancer;
KIRP	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg02390115	chr1:21767211	NBPF3	0.63	8.9	0.49	1.22e-16	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.68	-7.65	-0.44	4.43e-13	Systemic lupus erythematosus;
KIRP	cis	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg04691961	chr3:161091175	C3orf57	0.46	6.78	0.4	8.85e-11	Morning vs. evening chronotype;
KIRP	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.53	-6.16	-0.37	2.92e-9	Coffee consumption (cups per day);
KIRP	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg14952266	chr13:112191215	NA	0.45	6.71	0.39	1.32e-10	Hepatitis;
KIRP	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.39	13.03	0.64	7.52e-30	Opioid sensitivity;
KIRP	cis	rs9815354	1.000	rs6768563	chr3:41865541	G/A	cg03022575	chr3:42003672	ULK4	0.53	5.69	0.34	3.56e-8	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02767960	chr2:220435506	INHA;OBSL1	0.53	6.6	0.39	2.5e-10	Parkinson's disease;
KIRP	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg05340658	chr4:99064831	C4orf37	0.58	7.22	0.42	6.61e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7572263	0.959	rs10804167	chr2:209049840	C/T	cg23998903	chr2:209048830	C2orf80	0.32	5.56	0.33	6.86e-8	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs7700895	0.737	rs3777208	chr5:95228836	A/G	cg16656078	chr5:95278638	ELL2	-0.4	-6.06	-0.36	5.11e-9	IgG glycosylation;
KIRP	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg04289385	chr6:36355825	ETV7	0.4	5.3	0.32	2.63e-7	Platelet distribution width;
KIRP	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg09264619	chr17:80180166	NA	-0.35	-5.09	-0.31	7.04e-7	Life satisfaction;
KIRP	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.56	-8.41	-0.47	3.37e-15	Educational attainment;
KIRP	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-10.91	-0.57	7.37e-23	Total body bone mineral density;
KIRP	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg22437258	chr11:111473054	SIK2	0.61	7.13	0.41	1.11e-11	Primary sclerosing cholangitis;
KIRP	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-6.89	-0.4	4.72e-11	Height;
KIRP	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg06204229	chr3:52865917	ITIH4	0.56	6.54	0.38	3.51e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7712401	0.601	rs436546	chr5:122322790	G/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-1.29	-13.51	-0.65	1.7e-31	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.89	17.68	0.75	1.09e-45	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-9.81	-0.53	2.2e-19	Chronic sinus infection;
KIRP	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.96	13.66	0.66	5.25e-32	Cognitive function;
KIRP	cis	rs2625529	0.775	rs4777477	chr15:72269612	G/A	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.1e-9	Red blood cell count;
KIRP	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.66	8.75	0.49	3.4e-16	Eye color traits;
KIRP	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.49	0.43	1.25e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg25418670	chr11:30344373	C11orf46	-0.6	-5.25	-0.32	3.31e-7	Morning vs. evening chronotype;
KIRP	cis	rs883565	0.792	rs784491	chr3:39174462	T/C	cg01426195	chr3:39028469	NA	0.57	8.26	0.47	8.77e-15	Handedness;
KIRP	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.74	11.18	0.58	9.66e-24	Oral cavity cancer;
KIRP	trans	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg16141378	chr3:129829833	LOC729375	-0.49	-6.08	-0.36	4.45e-9	Joint mobility (Beighton score);
KIRP	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.45	-6.39	-0.38	8.37e-10	Body mass index;
KIRP	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.58	-7.51	-0.43	1.1e-12	Total body bone mineral density;
KIRP	cis	rs1045714	0.943	rs56063345	chr7:2653504	C/G	cg20813462	chr7:2646259	IQCE	0.69	6.15	0.37	3.11e-9	Urate levels in lean individuals;
KIRP	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.6	0.81	1e-58	Prudent dietary pattern;
KIRP	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.28	0.42	4.54e-12	Testicular germ cell tumor;
KIRP	cis	rs838147	0.507	rs1704773	chr19:49209566	A/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.46	-6.06	-0.36	4.99e-9	Dietary macronutrient intake;
KIRP	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.69	9.3	0.51	8.02e-18	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.16	0.54	1.76e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.8	-11.56	-0.59	5.74e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg18209359	chr17:80159595	CCDC57	0.42	5.48	0.33	1.05e-7	Life satisfaction;
KIRP	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12379764	chr21:47803548	PCNT	-0.41	-4.94	-0.3	1.46e-6	Testicular germ cell tumor;
KIRP	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22149154	chr3:4345082	SETMAR	0.46	6.14	0.36	3.22e-9	Parkinson's disease;
KIRP	cis	rs1448094	0.817	rs11117115	chr12:86331021	A/G	cg02569458	chr12:86230093	RASSF9	0.36	5.27	0.32	3.03e-7	Major depressive disorder;
KIRP	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	5.44	0.33	1.32e-7	Homoarginine levels;
KIRP	cis	rs7172677	1.000	rs11072525	chr15:75419110	G/A	cg10253484	chr15:75165896	SCAMP2	-0.45	-5.0	-0.3	1.1e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg05370193	chr1:21551575	ECE1	0.45	5.7	0.34	3.43e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg06640241	chr16:89574553	SPG7	0.81	12.19	0.61	4.57e-27	Multiple myeloma (IgH translocation);
KIRP	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.69	7.25	0.42	5.28e-12	Influenza A (H1N1) severity;
KIRP	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14769373	chr6:40998127	UNC5CL	-0.62	-6.6	-0.39	2.46e-10	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01577001	chr19:982767	NA	0.45	6.11	0.36	3.93e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.95	12.59	0.63	2.25e-28	Homoarginine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07484315	chr14:39572299	SEC23A	0.51	6.58	0.39	2.87e-10	Parkinson's disease;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.45	-5.17	-0.31	4.96e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.81	11.06	0.58	2.35e-23	Body mass index;
KIRP	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.6	6.78	0.4	8.85e-11	Aortic root size;
KIRP	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg16077055	chr2:106428750	NCK2	0.29	5.85	0.35	1.57e-8	Addiction;
KIRP	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.16e-13	Neuroticism;
KIRP	cis	rs6681460	0.934	rs4655635	chr1:67068240	T/G	cg13052034	chr1:66999238	SGIP1	0.4	5.72	0.34	3.02e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.21	0.72	1.05e-40	Electrocardiographic conduction measures;
KIRP	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.38	-4.97	-0.3	1.28e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg06766960	chr11:133703094	NA	-0.46	-5.94	-0.35	9.78e-9	Childhood ear infection;
KIRP	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg11987759	chr7:65425863	GUSB	-0.47	-6.32	-0.37	1.19e-9	Calcium levels;
KIRP	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.27	-5.85	-0.35	1.53e-8	Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg05861140	chr6:150128134	PCMT1	-0.46	-6.19	-0.37	2.53e-9	Lung cancer;
KIRP	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg09163369	chr1:210001066	C1orf107	-0.53	-5.73	-0.34	2.87e-8	Orofacial clefts;
KIRP	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg01238044	chr22:24384105	GSTT1	-0.47	-5.85	-0.35	1.54e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg16141378	chr3:129829833	LOC729375	-0.5	-6.17	-0.37	2.72e-9	Retinal vascular caliber;
KIRP	cis	rs10465746	0.780	rs1570691	chr1:84370393	A/C	cg10977910	chr1:84465055	TTLL7	0.55	6.86	0.4	5.6e-11	Obesity-related traits;
KIRP	cis	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg11608241	chr8:8085544	FLJ10661	-0.43	-4.88	-0.3	1.91e-6	Recombination measurement;
KIRP	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.33	6.36	0.38	9.79e-10	Alcohol dependence;
KIRP	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg23791538	chr6:167370224	RNASET2	0.42	5.3	0.32	2.52e-7	Crohn's disease;
KIRP	cis	rs2742234	0.955	rs2435384	chr10:43673731	G/T	cg15436174	chr10:43711423	RASGEF1A	-0.63	-7.45	-0.43	1.55e-12	Hirschsprung disease;
KIRP	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-6.04	-0.36	5.76e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.05e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2522056	0.932	rs2522064	chr5:131806488	G/A	cg07395648	chr5:131743802	NA	0.52	6.22	0.37	2.08e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs61884328	0.789	rs3751097	chr11:46916693	C/T	cg23433285	chr11:47201945	PACSIN3	0.66	5.04	0.31	8.97e-7	Total body bone mineral density (age over 60);
KIRP	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.5	-6.72	-0.39	1.23e-10	Longevity;
KIRP	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	cg12689670	chr1:183009347	LAMC1	0.44	6.32	0.37	1.25e-9	Fuchs's corneal dystrophy;
KIRP	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg16141378	chr3:129829833	LOC729375	-0.54	-7.2	-0.42	7.19e-12	Mood instability;
KIRP	cis	rs4363385	0.747	rs1577963	chr1:152961882	T/C	cg13444842	chr1:152974279	SPRR3	-0.36	-5.0	-0.3	1.08e-6	Inflammatory skin disease;
KIRP	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.12	0.41	1.18e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg24060327	chr5:131705240	SLC22A5	0.59	7.93	0.45	7.7e-14	Breast cancer;
KIRP	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.72	-0.39	1.25e-10	Monocyte percentage of white cells;
KIRP	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	9.24	0.51	1.22e-17	Cognitive test performance;
KIRP	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg09904177	chr6:26538194	HMGN4	-0.5	-6.07	-0.36	4.72e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.83	10.78	0.57	1.86e-22	Mean platelet volume;
KIRP	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg04166393	chr7:2884313	GNA12	0.48	6.51	0.38	4.16e-10	Height;
KIRP	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg01097406	chr16:89675127	NA	-0.29	-4.88	-0.3	1.87e-6	Vitiligo;
KIRP	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.56	8.42	0.47	3.24e-15	Weight;
KIRP	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg11150807	chr10:43354902	NA	-0.66	-7.43	-0.43	1.79e-12	Blood protein levels;
KIRP	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.68	10.04	0.54	4.23e-20	Dupuytren's disease;
KIRP	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.57	5.63	0.34	5e-8	Height;
KIRP	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	6.18	0.37	2.67e-9	Menarche (age at onset);
KIRP	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-1.14	-9.88	-0.53	1.28e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs2964802	0.505	rs6897847	chr5:10831632	T/C	cg14521931	chr5:10832172	NA	-0.74	-11.2	-0.58	8.4e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs1656402	1.000	rs1656399	chr2:233427803	C/T	cg03852847	chr2:233439513	NA	0.69	11.3	0.58	4e-24	Non-small cell lung cancer (survival);
KIRP	cis	rs939317	0.635	rs843371	chr3:183994536	A/G	cg09405238	chr3:183994500	ECE2	0.56	6.19	0.37	2.49e-9	Menarche (age at onset);
KIRP	cis	rs10197940	0.686	rs11675385	chr2:152262042	G/A	cg19508488	chr2:152266495	RIF1	0.55	6.1	0.36	4.17e-9	Lung cancer;
KIRP	cis	rs12210905	0.920	rs72839469	chr6:27304539	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.41	-0.38	7.43e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26416381	chr12:116674276	MED13L	0.46	6.51	0.38	4.28e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.86	0.49	1.67e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1448094	0.872	rs4919777	chr12:86358491	C/T	cg02569458	chr12:86230093	RASSF9	0.36	5.22	0.32	3.85e-7	Major depressive disorder;
KIRP	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg04519387	chr11:65556438	OVOL1	0.35	5.41	0.33	1.52e-7	Acne (severe);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg17617805	chr17:56595405	MTMR4	0.53	6.85	0.4	5.91e-11	Educational attainment;
KIRP	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs4523957	0.928	rs12938295	chr17:2160854	A/G	cg16513277	chr17:2031491	SMG6	0.58	8.01	0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.77	-10.87	-0.57	1e-22	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	6.02	0.36	6.37e-9	Type 2 diabetes;
KIRP	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.46	6.37	0.38	9.13e-10	Testicular germ cell tumor;
KIRP	cis	rs56161922	0.908	rs55689175	chr1:207859699	G/C	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs12230513	0.732	rs6581047	chr12:55832001	C/G	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg18357526	chr6:26021779	HIST1H4A	0.39	4.95	0.3	1.38e-6	Height;
KIRP	cis	rs28489187	0.617	rs233133	chr1:85796557	G/T	cg16011679	chr1:85725395	C1orf52	0.44	5.51	0.33	8.94e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9814567	0.537	rs9879993	chr3:134162559	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	9.03	0.5	5.07e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg22903471	chr2:27725779	GCKR	-0.62	-9.3	-0.51	8e-18	Total body bone mineral density;
KIRP	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.55	-7.28	-0.42	4.54e-12	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.43	5.3	0.32	2.55e-7	Testicular germ cell tumor;
KIRP	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.44	5.67	0.34	3.93e-8	Crohn's disease;
KIRP	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10992471	0.528	rs4744135	chr9:95251874	A/C	cg13798575	chr9:95087839	CENPP;NOL8	0.42	4.97	0.3	1.25e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg15128208	chr22:42549153	NA	0.7	7.61	0.44	5.97e-13	Birth weight;
KIRP	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg22676075	chr6:135203613	NA	0.47	6.84	0.4	6.37e-11	Red blood cell count;
KIRP	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.8	-10.63	-0.56	5.9e-22	Systemic lupus erythematosus;
KIRP	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg01529538	chr14:23388837	RBM23	0.41	5.17	0.31	4.86e-7	Cognitive ability (multi-trait analysis);
KIRP	cis	rs7635838	0.892	rs4684775	chr3:11436413	A/G	cg00170343	chr3:11313890	ATG7	0.44	5.66	0.34	4.16e-8	HDL cholesterol;
KIRP	cis	rs2882667	0.638	rs6895690	chr5:138465851	C/T	cg04439458	chr5:138467593	SIL1	-0.35	-5.59	-0.34	6.17e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.58	-6.7	-0.39	1.43e-10	Longevity;Endometriosis;
KIRP	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg05044414	chr3:183734942	ABCC5	0.38	5.86	0.35	1.45e-8	Anterior chamber depth;
KIRP	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg11945507	chr8:142233382	SLC45A4	-0.91	-15.68	-0.71	7.07e-39	Immature fraction of reticulocytes;
KIRP	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg19468946	chr17:37922297	IKZF3	-0.38	-5.16	-0.31	5.11e-7	Asthma;
KIRP	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.89	-0.4	4.74e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg24558204	chr6:135376177	HBS1L	-0.49	-6.33	-0.37	1.14e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.63	0.44	5.31e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs73206853	0.764	rs55929416	chr12:110622543	C/T	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-5.02	-0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg12292205	chr6:26970375	C6orf41	0.42	6.31	0.37	1.27e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.57	7.32	0.42	3.44e-12	Aortic root size;
KIRP	cis	rs478607	0.831	rs61884374	chr11:64388929	A/G	cg09231725	chr11:64357281	SLC22A12	-0.66	-5.19	-0.31	4.41e-7	Urate levels;
KIRP	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg26384229	chr12:38710491	ALG10B	0.72	9.65	0.52	6.98e-19	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.512	rs36085438	chr19:33562145	G/A	cg27124370	chr19:33622961	WDR88	0.56	5.53	0.33	8.22e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-9.08	-0.5	3.6e-17	Schizophrenia;
KIRP	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	1.0	10.6	0.56	7.27e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6499755	0.932	rs1370386	chr16:55340167	G/C	cg05099576	chr16:55362342	IRX6	0.27	5.6	0.34	5.77e-8	Hypospadias;
KIRP	cis	rs2797160	0.547	rs9401836	chr6:125956736	T/C	cg05901451	chr6:126070800	HEY2	-0.37	-5.11	-0.31	6.4e-7	Endometrial cancer;
KIRP	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.63	7.56	0.43	7.78e-13	Longevity;Endometriosis;
KIRP	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.66	-7.77	-0.44	2.09e-13	Resting heart rate;
KIRP	cis	rs4589502	1.000	rs79390908	chr15:67130924	C/T	cg09911534	chr15:67153556	NA	-0.54	-4.95	-0.3	1.39e-6	Lung cancer (smoking interaction);
KIRP	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.95	11.38	0.59	2.22e-24	Corneal astigmatism;
KIRP	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs62413470	1.000	rs17751067	chr6:55944196	T/A	cg13327911	chr6:55965977	COL21A1	0.55	4.87	0.3	2.03e-6	Joint mobility (Beighton score);
KIRP	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg01689657	chr7:91764605	CYP51A1	0.36	5.34	0.32	2.1e-7	Breast cancer;
KIRP	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg20991723	chr1:152506922	NA	-0.44	-5.21	-0.32	3.98e-7	Hair morphology;
KIRP	cis	rs8177876	0.822	rs79926943	chr16:81105610	G/C	cg08591886	chr16:81111003	C16orf46	-0.69	-5.68	-0.34	3.89e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg09699651	chr6:150184138	LRP11	0.47	6.35	0.38	1.03e-9	Lung cancer;
KIRP	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.52	7.53	0.43	9.34e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg24611264	chr11:120008944	TRIM29	-0.27	-4.94	-0.3	1.45e-6	Stroke (pediatric);
KIRP	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.62	-6.69	-0.39	1.53e-10	Gut microbiome composition (summer);
KIRP	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.95	11.93	0.61	3.35e-26	Smoking behavior;
KIRP	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.74	9.64	0.52	7.54e-19	N-glycan levels;
KIRP	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg23950597	chr19:37808831	NA	-0.68	-7.16	-0.42	9.28e-12	Coronary artery calcification;
KIRP	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.89	0.4	4.66e-11	Height;
KIRP	cis	rs11718455	0.653	rs28533958	chr3:43974179	C/A	cg21419209	chr3:44054225	NA	-0.75	-9.21	-0.51	1.48e-17	Coronary artery disease;
KIRP	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg09408571	chr1:101003634	GPR88	0.26	5.51	0.33	9.07e-8	Breast cancer;
KIRP	cis	rs2014572	0.967	rs10421632	chr19:57764770	G/A	cg12963866	chr19:57752005	ZNF805	-0.48	-5.98	-0.36	7.89e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18252515	chr7:66147081	NA	0.47	5.43	0.33	1.32e-7	Aortic root size;
KIRP	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	cg12689670	chr1:183009347	LAMC1	0.47	6.71	0.39	1.36e-10	Colorectal cancer;
KIRP	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg00800038	chr16:89945340	TCF25	-0.75	-5.26	-0.32	3.08e-7	Skin colour saturation;
KIRP	cis	rs7589728	0.925	rs80065975	chr2:88502758	G/A	cg04511125	chr2:88470314	THNSL2	0.71	5.21	0.32	4.06e-7	Plasma clusterin levels;
KIRP	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.51	7.07	0.41	1.6e-11	Dupuytren's disease;
KIRP	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.57	0.56	9.26e-22	Cognitive test performance;
KIRP	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.73	9.2	0.51	1.64e-17	Vitiligo;
KIRP	cis	rs4262150	0.810	rs10046082	chr5:151961446	C/T	cg12297329	chr5:152029980	NA	-0.65	-8.07	-0.46	3.07e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.45	5.46	0.33	1.17e-7	Body mass index;
KIRP	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.97	11.76	0.6	1.24e-25	Corneal astigmatism;
KIRP	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14598338	chr9:96623480	NA	-0.67	-11.49	-0.59	9.68e-25	DNA methylation (variation);
KIRP	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.66	5.13	0.31	6e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg11757124	chr7:157526947	PTPRN2	-0.48	-5.98	-0.36	8.02e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6753739	0.871	rs6724718	chr2:220004243	A/G	cg01749213	chr2:219906749	CCDC108	-0.4	-5.08	-0.31	7.29e-7	Height;
KIRP	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg24642439	chr20:33292090	TP53INP2	0.86	11.75	0.6	1.39e-25	Coronary artery disease;
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg05255149	chr17:80675120	FN3KRP	0.5	5.37	0.32	1.82e-7	Glycated hemoglobin levels;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg02853781	chr1:19229053	ALDH4A1	0.5	6.13	0.36	3.4e-9	Myopia (pathological);
KIRP	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.85	-9.24	-0.51	1.23e-17	Cognitive test performance;
KIRP	cis	rs2562456	0.833	rs62110429	chr19:21613786	C/T	cg18461458	chr19:21324796	ZNF431	-0.54	-5.09	-0.31	7.24e-7	Pain;
KIRP	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.25	0.42	5.27e-12	Prudent dietary pattern;
KIRP	cis	rs7326068	0.595	rs2762988	chr13:21370780	T/A	cg04906043	chr13:21280425	IL17D	-0.43	-4.99	-0.3	1.16e-6	Schizophrenia, bipolar disorder and depression (combined);
KIRP	cis	rs2411233	1.000	rs6492851	chr15:39279903	A/G	cg02291532	chr15:39874776	THBS1	0.39	5.31	0.32	2.42e-7	Platelet count;
KIRP	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg17133734	chr15:86042851	AKAP13	-0.44	-5.41	-0.33	1.47e-7	Coronary artery disease;
KIRP	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.56	0.43	7.84e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.65	-7.12	-0.41	1.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg05370193	chr1:21551575	ECE1	0.42	5.97	0.36	8.41e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	4.99	0.3	1.13e-6	Leprosy;
KIRP	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.96	13.01	0.64	8.29e-30	Menopause (age at onset);
KIRP	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg23752985	chr2:85803571	VAMP8	0.63	9.63	0.52	8.08e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg16606324	chr3:10149918	C3orf24	0.56	5.23	0.32	3.7e-7	Alzheimer's disease;
KIRP	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-0.77	-9.84	-0.53	1.75e-19	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs72772090	0.539	rs11748328	chr5:96169916	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-6.55	-0.39	3.42e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06734816	chr6:116422381	NT5DC1	0.68	6.32	0.37	1.24e-9	Lung function (FEV1);
KIRP	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg26022315	chr17:47021804	SNF8	0.43	5.49	0.33	9.78e-8	Type 2 diabetes;
KIRP	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.56	7.17	0.42	8.87e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs10267417	0.603	rs79323924	chr7:19924321	T/G	cg05791153	chr7:19748676	TWISTNB	0.52	5.07	0.31	7.72e-7	Night sleep phenotypes;
KIRP	cis	rs17739794	0.517	rs10106028	chr8:783286	C/A	cg01971667	chr8:817044	NA	-0.58	-7.38	-0.43	2.36e-12	Clozapine-induced cytotoxicity;
KIRP	cis	rs7188697	0.922	rs11862156	chr16:58596753	C/T	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.3	-5.24	-0.32	3.43e-7	Height;
KIRP	cis	rs3741798	1.000	rs77559638	chr12:12499909	T/A	cg08615371	chr12:12503544	MANSC1	1.03	8.79	0.49	2.58e-16	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7258465	1.000	rs271623	chr19:18628947	A/G	cg06953865	chr19:18549723	ISYNA1	-0.38	-5.64	-0.34	4.64e-8	Breast cancer;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03157738	chr19:11308118	KANK2	0.74	7.01	0.41	2.29e-11	Lung function (FEV1);
KIRP	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg06212747	chr3:49208901	KLHDC8B	0.49	5.34	0.32	2.13e-7	Resting heart rate;
KIRP	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.69	9.92	0.53	1.03e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs17221829	0.733	rs10830327	chr11:89389122	G/A	cg02982614	chr11:89391479	FOLH1B	-0.31	-5.07	-0.31	7.75e-7	Anxiety in major depressive disorder;
KIRP	cis	rs7116495	0.786	rs678193	chr11:71770273	A/C	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	6.54	0.38	3.54e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.49	-6.49	-0.38	4.83e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.16	12.91	0.64	1.8e-29	Nonalcoholic fatty liver disease;
KIRP	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg08207895	chr3:50388901	TUSC4;CYB561D2	-0.51	-5.12	-0.31	6.24e-7	Schizophrenia;
KIRP	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg27490568	chr2:178487706	NA	0.53	7.2	0.42	7.2e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg04132472	chr17:19861366	AKAP10	-0.4	-5.13	-0.31	5.87e-7	Schizophrenia;
KIRP	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg10397082	chr2:1609832	NA	0.57	5.15	0.31	5.36e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2223471	0.602	rs9395619	chr6:50724669	G/T	cg03432817	chr6:50765336	NA	-0.36	-5.23	-0.32	3.7e-7	Subcutaneous adipose tissue;
KIRP	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.79	-10.43	-0.55	2.57e-21	Coronary artery disease;
KIRP	cis	rs4356932	0.691	rs2242471	chr4:76878716	G/C	cg00809888	chr4:76862425	NAAA	-0.5	-7.0	-0.41	2.45e-11	Blood protein levels;
KIRP	cis	rs7221595	0.825	rs8078629	chr17:3983964	A/C	cg21734707	chr17:3908241	ZZEF1	0.53	5.03	0.31	9.67e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	trans	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg10756647	chr7:56101905	PSPH	1.0	7.55	0.43	8.51e-13	Diabetic kidney disease;
KIRP	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.95	-14.85	-0.69	4.91e-36	Height;
KIRP	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	0.63	5.23	0.32	3.62e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs737008	0.800	rs535998	chr16:11366003	G/C	cg00044050	chr16:11439710	C16orf75	-0.44	-5.35	-0.32	2.05e-7	Obesity-related traits;
KIRP	cis	rs12195424	0.558	rs77156915	chr6:56299661	T/C	cg20782286	chr6:56298173	NA	-0.66	-5.16	-0.31	5.16e-7	Cerebrospinal fluid clusterin levels;
KIRP	cis	rs6032067	1.000	rs6032066	chr20:43857700	C/T	cg10761708	chr20:43804764	PI3	0.51	5.25	0.32	3.26e-7	Blood protein levels;
KIRP	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg14458575	chr2:238380390	NA	0.55	5.9	0.35	1.2e-8	Prostate cancer;
KIRP	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.76	-10.76	-0.57	2.19e-22	Plateletcrit;Platelet count;
KIRP	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.85	13.64	0.66	6.36e-32	Systemic lupus erythematosus;
KIRP	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-6.41	-0.38	7.31e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg19913688	chr11:428466	ANO9	-0.74	-5.43	-0.33	1.36e-7	Body mass index;
KIRP	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.72	6.62	0.39	2.3e-10	Methadone dose in opioid dependence;
KIRP	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.81	-9.3	-0.51	7.82e-18	Multiple sclerosis;
KIRP	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg05315796	chr3:52349193	DNAH1	0.45	6.78	0.4	8.86e-11	Bipolar disorder;
KIRP	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.53e-13	Corneal astigmatism;
KIRP	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg22907277	chr7:1156413	C7orf50	0.71	4.99	0.3	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2795502	0.766	rs947549	chr10:43265880	G/C	cg20628663	chr10:43360327	NA	-0.62	-5.75	-0.34	2.62e-8	Blood protein levels;
KIRP	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.86	-11.86	-0.6	5.81e-26	Monocyte count;
KIRP	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.16	0.46	1.73e-14	Eosinophil percentage of white cells;
KIRP	cis	rs6855629	0.808	rs6818637	chr4:106097339	T/C	cg08924430	chr4:106067052	TET2	0.35	5.1	0.31	6.86e-7	Height;
KIRP	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-1.38	-10.91	-0.57	7.38e-23	Plateletcrit;
KIRP	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.42	-0.33	1.44e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1874124	0.778	rs1335920	chr1:221018288	C/T	cg22888665	chr1:221052729	HLX	0.51	4.93	0.3	1.54e-6	Cholesterol, total;
KIRP	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.8	-11.02	-0.57	3.18e-23	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg03929089	chr4:120376271	NA	0.7	6.23	0.37	1.98e-9	Axial length;
KIRP	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg00319359	chr11:70116639	PPFIA1	0.56	5.81	0.35	1.93e-8	Coronary artery disease;
KIRP	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg17507749	chr15:85114479	UBE2QP1	0.84	9.71	0.53	4.36e-19	Schizophrenia;
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg13394990	chr13:113537737	ATP11A	0.42	6.14	0.36	3.22e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.68	-7.95	-0.45	6.58e-14	Migraine;Coronary artery disease;
KIRP	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg14829360	chr17:73884958	NA	-0.46	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.83	-9.94	-0.54	8.81e-20	Post bronchodilator FEV1;
KIRP	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.81	-11.61	-0.59	4.02e-25	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg27205649	chr11:78285834	NARS2	-0.53	-5.07	-0.31	7.98e-7	Testicular germ cell tumor;
KIRP	cis	rs3825932	0.736	rs1036939	chr15:79237324	C/A	cg25744700	chr15:79237217	CTSH	0.41	5.08	0.31	7.32e-7	Type 1 diabetes;
KIRP	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.23	0.42	5.99e-12	Height;
KIRP	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg27572855	chr1:25598939	RHD	0.47	7.87	0.45	1.11e-13	Plateletcrit;Mean corpuscular volume;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20067089	chr7:100025868	ZCWPW1	0.41	6.03	0.36	5.92e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9815354	1.000	rs1717014	chr3:41917395	C/T	cg03022575	chr3:42003672	ULK4	0.47	5.31	0.32	2.42e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg07274523	chr3:49395745	GPX1	0.72	8.8	0.49	2.54e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9409565	0.826	rs9409564	chr9:97248166	C/T	cg04523069	chr9:97136363	HIATL1	0.49	6.46	0.38	5.53e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	trans	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg10756647	chr7:56101905	PSPH	0.91	6.41	0.38	7.32e-10	Diabetic kidney disease;
KIRP	cis	rs11955175	0.717	rs112304996	chr5:40867592	A/T	cg17351974	chr5:40835760	RPL37	0.67	4.98	0.3	1.2e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18364779	chr6:26104403	HIST1H4C	-0.51	-5.61	-0.34	5.57e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.37	6.33	0.37	1.12e-9	Heart rate;
KIRP	cis	rs929596	0.518	rs13401281	chr2:234628679	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-9.29	-0.51	8.49e-18	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs7712401	0.715	rs424262	chr5:122348012	G/A	cg19412675	chr5:122181750	SNX24	-0.44	-4.93	-0.3	1.51e-6	Mean platelet volume;
KIRP	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.44	-0.52	2.97e-18	Triglycerides;
KIRP	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.56	0.43	7.89e-13	Menarche (age at onset);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg12496657	chr2:105488809	NA	0.56	6.19	0.37	2.49e-9	Lung cancer in ever smokers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12948796	chr2:234160305	ATG16L1	0.55	6.83	0.4	6.77e-11	Parkinson's disease;
KIRP	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg04804543	chr8:142233427	SLC45A4	-1.02	-17.71	-0.75	8.42e-46	Immature fraction of reticulocytes;
KIRP	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.63	7.12	0.41	1.19e-11	Alcohol dependence;
KIRP	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg13206674	chr6:150067644	NUP43	0.58	8.31	0.47	6.61e-15	Lung cancer;
KIRP	cis	rs7766436	0.848	rs13200143	chr6:22586212	T/G	cg13666174	chr6:22585274	NA	-0.48	-6.42	-0.38	6.85e-10	Coronary artery disease;
KIRP	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.63	7.61	0.44	5.99e-13	Obesity-related traits;
KIRP	cis	rs877282	0.520	rs12360072	chr10:813082	C/T	cg15764593	chr10:829463	NA	-0.39	-5.05	-0.31	8.61e-7	Uric acid levels;
KIRP	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	0.62	8.08	0.46	2.99e-14	Gut microbiota (bacterial taxa);
KIRP	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	0.98	15.89	0.71	1.38e-39	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg27411982	chr8:10470053	RP1L1	0.44	5.63	0.34	4.78e-8	Neuroticism;
KIRP	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg00982548	chr2:198649783	BOLL	-0.57	-5.2	-0.31	4.25e-7	Ulcerative colitis;
KIRP	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.35	-5.08	-0.31	7.32e-7	Ovarian reserve;
KIRP	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg09238746	chr17:78121135	EIF4A3	0.74	9.34	0.51	6.19e-18	Yeast infection;
KIRP	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.44	-0.33	1.29e-7	Alcohol dependence;
KIRP	cis	rs6693295	0.729	rs10399630	chr1:246212561	A/T	cg11798871	chr1:246315928	SMYD3	-0.42	-5.16	-0.31	5e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs253959	0.545	rs712594	chr5:115657459	A/T	cg23108291	chr5:115420582	COMMD10	-0.51	-5.69	-0.34	3.66e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs975752	0.867	rs3808916	chr10:101947737	C/T	cg13817732	chr10:102046368	BLOC1S2	0.7	5.85	0.35	1.56e-8	Schizophrenia;
KIRP	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg22676075	chr6:135203613	NA	0.52	7.54	0.43	8.95e-13	Red blood cell count;
KIRP	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	1.07	19.53	0.78	6.4e-52	Caffeine consumption;
KIRP	cis	rs80282103	0.867	rs7099063	chr10:1078547	C/G	cg08668510	chr10:1095578	IDI1	0.59	5.01	0.3	1.05e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs10865541	0.902	rs10206964	chr2:3425948	T/C	cg11642891	chr2:3452563	TTC15	-0.54	-6.95	-0.4	3.33e-11	Obesity-related traits;
KIRP	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg11906718	chr8:101322791	RNF19A	-0.49	-6.53	-0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.6	8.12	0.46	2.25e-14	Prostate cancer;
KIRP	cis	rs17681684	0.505	rs62064492	chr17:9803713	G/A	cg26853458	chr17:9805074	RCVRN	0.57	5.35	0.32	2.03e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs2073499	0.935	rs57842657	chr3:50227787	T/A	cg24032752	chr3:50388670	TUSC4;CYB561D2	0.67	4.94	0.3	1.44e-6	Schizophrenia;
KIRP	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.75	9.62	0.52	8.21e-19	Coronary artery disease;
KIRP	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.47	6.22	0.37	2.08e-9	Blood protein levels;
KIRP	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg18944383	chr4:111397179	ENPEP	0.53	9.24	0.51	1.17e-17	Height;
KIRP	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg04672837	chr16:48644449	N4BP1	0.5	6.9	0.4	4.38e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg19773385	chr1:10388646	KIF1B	-0.66	-10.01	-0.54	5.2e-20	Hepatocellular carcinoma;
KIRP	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.41	5.06	0.31	8.37e-7	Asthma;
KIRP	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg05315796	chr3:52349193	DNAH1	0.4	6.45	0.38	5.79e-10	Bipolar disorder;
KIRP	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.63	-6.43	-0.38	6.49e-10	DNA methylation (variation);
KIRP	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg04691961	chr3:161091175	C3orf57	-0.48	-6.57	-0.39	3e-10	Parkinson's disease;
KIRP	cis	rs58785573	0.581	rs3209570	chr4:38699657	G/A	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.41	-5.3	-0.32	2.55e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07570687	chr10:102243282	WNT8B	0.48	5.98	0.36	7.99e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg24110177	chr3:50126178	RBM5	0.44	5.67	0.34	4.02e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9534288	0.797	rs1134071	chr13:46562935	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg11608241	chr8:8085544	FLJ10661	-0.38	-4.86	-0.3	2.05e-6	Mood instability;
KIRP	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.3	11.51	0.59	8.5e-25	Diabetic retinopathy;
KIRP	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg24879335	chr3:133465180	TF	-0.38	-5.66	-0.34	4.26e-8	Iron status biomarkers;
KIRP	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.53	-7.43	-0.43	1.8e-12	Plateletcrit;Platelet count;
KIRP	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.98	15.84	0.71	1.92e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs7536201	1.000	rs12036815	chr1:25300632	C/T	cg23273869	chr1:25296894	NA	-0.39	-5.57	-0.33	6.75e-8	Psoriasis vulgaris;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07251136	chr5:95158433	GLRX	0.53	6.12	0.36	3.65e-9	Smoking initiation;
KIRP	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.11	-0.5	3.06e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg07001201	chr5:642380	CEP72	0.63	6.12	0.36	3.67e-9	Obesity-related traits;
KIRP	trans	rs1462872	0.736	rs327352	chr8:31799330	A/G	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs58649573	0.509	rs10760308	chr9:126788294	G/A	cg14112217	chr9:126806003	NA	0.37	5.26	0.32	3.18e-7	Post-traumatic stress disorder;
KIRP	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg23307798	chr14:103986281	CKB	0.72	11.6	0.59	4.22e-25	Body mass index;
KIRP	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	9.19	0.51	1.69e-17	Bipolar disorder;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03738868	chr7:100281714	GIGYF1	0.48	6.07	0.36	4.84e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs3126085	0.515	rs11204994	chr1:152358640	G/T	cg26876637	chr1:152193138	HRNR	-0.52	-6.66	-0.39	1.83e-10	Atopic dermatitis;
KIRP	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs3779635	0.710	rs2241651	chr8:27255635	A/G	cg07216194	chr8:27182965	PTK2B	0.45	5.6	0.34	5.73e-8	Neuroticism;
KIRP	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.89	-9.16	-0.5	2.14e-17	Monocyte percentage of white cells;
KIRP	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.63	6.69	0.39	1.54e-10	Alcohol dependence;
KIRP	cis	rs981844	0.890	rs56184506	chr4:154685889	G/T	cg14289246	chr4:154710475	SFRP2	0.67	7.6	0.44	6.3e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.46	5.62	0.34	5.13e-8	Blood protein levels;
KIRP	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg14132834	chr19:41945861	ATP5SL	-0.54	-7.19	-0.42	7.69e-12	Height;
KIRP	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg19847866	chr10:1019161	NA	0.46	5.32	0.32	2.38e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.37	6.21	0.37	2.19e-9	Heart rate;
KIRP	cis	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg07585502	chr8:101912084	NA	-0.63	-8.62	-0.48	8.49e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg02038168	chr22:39784481	NA	-0.42	-5.17	-0.31	4.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4671458	1.000	rs72813412	chr2:63365500	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-5.69	-0.34	3.68e-8	Subjective well-being;
KIRP	cis	rs4478137	0.824	rs4691907	chr4:164223658	G/T	cg06758707	chr4:164254230	NPY1R	0.77	10.3	0.55	6.36e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs17023223	0.537	rs1057990	chr1:119575232	T/C	cg18261050	chr1:119551319	NA	0.52	6.89	0.4	4.64e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-8.02	-0.46	4.29e-14	Body mass index;
KIRP	cis	rs17293817	0.647	rs2255595	chr10:1455543	A/G	cg02851212	chr10:1451418	ADARB2	0.39	5.5	0.33	9.74e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.8	9.57	0.52	1.22e-18	Corneal astigmatism;
KIRP	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.84	11.42	0.59	1.65e-24	Morning vs. evening chronotype;
KIRP	trans	rs9650657	0.836	rs891556	chr8:10623633	G/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.27	-0.37	1.65e-9	Neuroticism;
KIRP	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.75	0.4	1.03e-10	Lung cancer;
KIRP	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.02	0.69	1.25e-36	Headache;
KIRP	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg24253500	chr15:84953950	NA	0.53	6.08	0.36	4.51e-9	Schizophrenia;
KIRP	cis	rs4132509	0.744	rs320305	chr1:243859909	G/T	cg21452805	chr1:244014465	NA	0.53	5.47	0.33	1.11e-7	RR interval (heart rate);
KIRP	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.75	0.34	2.6e-8	Platelet count;
KIRP	cis	rs1867631	1.000	rs7546090	chr1:67083981	G/A	cg13052034	chr1:66999238	SGIP1	0.47	6.57	0.39	3.01e-10	Menopause (age at onset);
KIRP	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg22437258	chr11:111473054	SIK2	0.66	7.98	0.45	5.44e-14	Primary sclerosing cholangitis;
KIRP	cis	rs4950322	0.570	rs17360443	chr1:146751410	G/T	cg22381352	chr1:146742008	CHD1L	-0.47	-5.58	-0.34	6.32e-8	Protein quantitative trait loci;
KIRP	cis	rs1823913	0.562	rs17347499	chr2:192165842	C/T	cg12404831	chr2:192114017	MYO1B	0.53	7.2	0.42	7.44e-12	Obesity-related traits;
KIRP	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.55	-4.86	-0.3	2.12e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs17065868	1.000	rs12184878	chr13:45115319	C/T	cg10246903	chr13:45222710	NA	0.72	6.4	0.38	7.86e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.67	-9.5	-0.52	1.95e-18	Colorectal cancer;
KIRP	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg21095983	chr6:86352623	SYNCRIP	0.52	6.8	0.4	7.78e-11	Smooth-surface caries;
KIRP	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg07001201	chr5:642380	CEP72	0.66	6.6	0.39	2.44e-10	Obesity-related traits;
KIRP	cis	rs1448094	0.967	rs2121892	chr12:86324556	G/T	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.8e-7	Major depressive disorder;
KIRP	cis	rs6743226	0.811	rs12471975	chr2:242154849	C/T	cg10021735	chr2:242295487	FARP2	0.43	5.26	0.32	3.14e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg23565292	chr14:50234668	KLHDC2	-0.44	-5.37	-0.32	1.86e-7	Carotid intima media thickness;
KIRP	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	cg12689670	chr1:183009347	LAMC1	0.42	5.83	0.35	1.78e-8	Fuchs's corneal dystrophy;
KIRP	trans	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg01620082	chr3:125678407	NA	-1.24	-7.57	-0.43	7.7e-13	Breast cancer;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.45	6.33	0.37	1.13e-9	Coronary artery disease;
KIRP	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg04398451	chr17:18023971	MYO15A	-0.68	-9.36	-0.51	5.35e-18	Total body bone mineral density;
KIRP	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg02487422	chr3:49467188	NICN1	0.4	5.54	0.33	7.64e-8	Parkinson's disease;
KIRP	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	1.06	15.18	0.7	3.54e-37	Menopause (age at onset);
KIRP	cis	rs838147	0.844	rs12611211	chr19:49248331	G/A	cg08619932	chr19:49200058	FUT2	-0.36	-5.5	-0.33	9.41e-8	Dietary macronutrient intake;
KIRP	cis	rs7558370	0.520	rs76221161	chr2:3700123	A/G	cg19825600	chr2:3704501	ALLC	0.59	4.99	0.3	1.16e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs5753037	0.869	rs5763581	chr22:30290633	A/G	cg27665648	chr22:30112403	NA	0.39	5.48	0.33	1.04e-7	Type 1 diabetes;
KIRP	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-0.84	-8.39	-0.47	3.82e-15	Obesity-related traits;
KIRP	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg08901578	chr4:187885870	NA	-0.54	-8.93	-0.49	1.03e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg09264619	chr17:80180166	NA	-0.52	-6.07	-0.36	4.7e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-6.54	-0.38	3.56e-10	Aortic root size;
KIRP	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg23555395	chr2:238036564	NA	0.43	5.24	0.32	3.47e-7	Systemic lupus erythematosus;
KIRP	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-7.85	-0.45	1.32e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs12044355	0.927	rs11122321	chr1:231835610	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.46	5.55	0.33	7.25e-8	Alzheimer's disease;
KIRP	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg08890418	chr1:21044141	KIF17	-0.43	-6.5	-0.38	4.51e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	9.97	0.54	6.83e-20	Cognitive ability;
KIRP	cis	rs11700980	0.901	rs17726585	chr21:30158534	A/C	cg08807101	chr21:30365312	RNF160	-0.76	-4.92	-0.3	1.6e-6	QRS complex (12-leadsum);
KIRP	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.6	7.18	0.42	8.3e-12	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg21479132	chr6:26055353	NA	0.81	5.67	0.34	4.09e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	5.34	0.32	2.15e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-7.35	-0.42	2.87e-12	Vitiligo;
KIRP	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	1.17	15.61	0.71	1.25e-38	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs3733418	0.697	rs13111010	chr4:165956741	C/T	cg10852876	chr4:165953100	TRIM60	-0.43	-5.07	-0.31	7.75e-7	Obesity-related traits;
KIRP	cis	rs4845459	0.967	rs1886734	chr1:152591142	A/C	cg07796016	chr1:152779584	LCE1C	-0.49	-6.05	-0.36	5.31e-9	Psoriasis;
KIRP	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg09455208	chr3:40491958	NA	0.33	5.67	0.34	3.9e-8	Renal cell carcinoma;
KIRP	cis	rs12413361	0.583	rs7089982	chr10:31119222	G/C	cg10523352	chr10:31093542	NA	-0.39	-4.9	-0.3	1.7e-6	Height;
KIRP	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.86	0.45	1.19e-13	Corneal astigmatism;
KIRP	cis	rs3779635	1.000	rs725788	chr8:27265371	T/C	cg14221460	chr8:27183342	PTK2B	0.44	5.87	0.35	1.42e-8	Neuroticism;
KIRP	cis	rs6568686	0.735	rs7762054	chr6:111870742	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.51	4.89	0.3	1.83e-6	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.63	0.39	2.1e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.53	6.69	0.39	1.53e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs62229266	0.557	rs4817760	chr21:37395301	T/C	cg08632701	chr21:37451849	NA	-0.45	-5.52	-0.33	8.4e-8	Mitral valve prolapse;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26248878	chr14:60952781	C14orf39	-0.43	-6.04	-0.36	5.51e-9	Interleukin-4 levels;
KIRP	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.44	5.63	0.34	5.01e-8	Motion sickness;
KIRP	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg11382394	chr1:2564504	MMEL1	0.39	4.96	0.3	1.32e-6	Ulcerative colitis;
KIRP	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.77	-8.43	-0.47	2.88e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg08999081	chr20:33150536	PIGU	0.47	6.28	0.37	1.52e-9	Height;
KIRP	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.73	12.2	0.61	4.53e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.53	6.77	0.4	9.49e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg02527881	chr3:46936655	PTH1R	-0.44	-6.46	-0.38	5.56e-10	Colorectal cancer;
KIRP	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg07936489	chr17:37558343	FBXL20	-0.55	-7.32	-0.42	3.53e-12	Asthma;
KIRP	cis	rs6693567	0.545	rs1694380	chr1:150292341	A/G	cg07843065	chr1:150265600	MRPS21	0.49	7.03	0.41	2e-11	Migraine;
KIRP	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.5	-0.38	4.32e-10	Blood pressure;
KIRP	cis	rs16958440	1.000	rs2289130	chr18:44626630	T/G	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.61	-6.93	-0.4	3.63e-11	Mean arterial pressure;
KIRP	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg16558253	chr16:72132732	DHX38	-0.52	-7.51	-0.43	1.06e-12	Fibrinogen levels;
KIRP	cis	rs56399783	0.901	rs17241904	chr7:2875574	C/T	cg19731401	chr7:2775893	GNA12	0.7	6.81	0.4	7.58e-11	Childhood ear infection;
KIRP	cis	rs714515	0.836	rs2001129	chr1:172333248	A/C	cg01573306	chr1:172330400	DNM3	0.46	5.95	0.35	9.06e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.11	15.18	0.7	3.65e-37	Corneal structure;
KIRP	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.54	-7.72	-0.44	3e-13	Bipolar disorder;
KIRP	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.61	-7.69	-0.44	3.5e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg10932868	chr11:921992	NA	0.64	8.66	0.48	6.44e-16	Alzheimer's disease (late onset);
KIRP	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg01378222	chr16:28622494	SULT1A1	-0.66	-6.08	-0.36	4.52e-9	Platelet distribution width;
KIRP	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg02367723	chr1:46378857	MAST2	-0.44	-5.16	-0.31	5.18e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg17718321	chr1:152188247	HRNR	0.44	5.34	0.32	2.16e-7	Inflammatory skin disease;
KIRP	cis	rs13161895	0.877	rs75654641	chr5:179486021	C/T	cg02702477	chr5:179499311	RNF130	1.01	6.96	0.41	3.12e-11	LDL cholesterol;
KIRP	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.96	-0.41	3.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10924970	0.967	rs4659678	chr1:235396697	A/G	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04946603	chr15:41221376	DLL4	0.42	6.06	0.36	5.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.44	-5.34	-0.32	2.07e-7	Body mass index;
KIRP	cis	rs4262150	0.544	rs56097272	chr5:151899155	G/A	cg12297329	chr5:152029980	NA	-0.71	-8.79	-0.49	2.7e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs7590368	0.715	rs72779451	chr2:10959407	A/C	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	cis	rs4233802	1.000	rs4366927	chr2:151138525	T/C	cg25300694	chr2:151184358	NA	0.87	6.81	0.4	7.38e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg07689907	chr11:61582574	FADS1	0.42	5.17	0.31	4.87e-7	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.72	8.25	0.47	9.89e-15	Cognitive ability;
KIRP	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.15	-0.41	9.87e-12	Monocyte count;
KIRP	cis	rs904251	0.523	rs10807184	chr6:37483713	C/T	cg01843034	chr6:37503916	NA	-0.96	-14.51	-0.68	7.13e-35	Cognitive performance;
KIRP	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-1.17	-10.16	-0.54	1.83e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.42	6.58	0.39	2.74e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.58	5.41	0.33	1.48e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs6500602	0.563	rs3810818	chr16:4432029	A/C	cg08645402	chr16:4508243	NA	0.48	6.24	0.37	1.94e-9	Schizophrenia;
KIRP	cis	rs4356932	0.967	rs6856958	chr4:76952356	T/G	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-7.27	-0.42	4.63e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs1062177	1.000	rs12653926	chr5:151250248	C/A	cg00977110	chr5:151150581	G3BP1	0.62	6.13	0.36	3.54e-9	Preschool internalizing problems;
KIRP	cis	rs4728302	0.607	rs6975860	chr7:133589584	T/G	cg10665199	chr7:133106180	EXOC4	0.43	5.04	0.31	9.21e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06544989	chr22:39130855	UNC84B	-0.44	-7.74	-0.44	2.65e-13	Menopause (age at onset);
KIRP	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg09455208	chr3:40491958	NA	0.35	6.27	0.37	1.64e-9	Renal cell carcinoma;
KIRP	cis	rs7923609	0.841	rs7920036	chr10:65293860	T/C	cg01631684	chr10:65280961	REEP3	-0.5	-5.9	-0.35	1.17e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg19554555	chr3:13937349	NA	-0.46	-6.23	-0.37	2e-9	Ovarian reserve;
KIRP	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg02462569	chr6:150064036	NUP43	-0.33	-4.89	-0.3	1.86e-6	Lung cancer;
KIRP	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25517755	chr10:38738941	LOC399744	-0.52	-7.17	-0.42	8.81e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72730918	0.590	rs12324531	chr15:51921358	T/C	cg14296394	chr15:51910925	DMXL2	-0.78	-10.94	-0.57	6.04e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg21174375	chr14:64681225	SYNE2	0.59	7.2	0.42	7.25e-12	Atrial fibrillation;
KIRP	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-7.94	-0.45	7.18e-14	Retinal vascular caliber;
KIRP	cis	rs16828019	0.777	rs3738369	chr1:41486408	G/A	cg18742814	chr1:41828276	NA	0.62	5.52	0.33	8.65e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	12.52	0.62	3.74e-28	Menopause (age at onset);
KIRP	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg02336718	chr17:17403227	NA	0.32	5.04	0.31	8.91e-7	Total body bone mineral density;
KIRP	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.46	6.65	0.39	1.87e-10	Sitting height ratio;
KIRP	cis	rs7246967	0.611	rs16999598	chr19:22943125	A/G	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.61	6.94	0.4	3.4e-11	Type 2 diabetes;
KIRP	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg20503657	chr10:835505	NA	0.5	6.09	0.36	4.41e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.29	-0.32	2.66e-7	Coronary artery disease;
KIRP	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg17554472	chr22:41940697	POLR3H	0.68	6.94	0.4	3.5e-11	Vitiligo;
KIRP	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.41	-5.53	-0.33	7.98e-8	Bone mineral density (hip);Bone mineral density (spine);
KIRP	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.65	8.44	0.47	2.82e-15	Height;
KIRP	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg05692746	chr2:100937584	LONRF2	-0.4	-5.33	-0.32	2.22e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4664304	0.708	rs7564243	chr2:160726868	G/A	cg03641300	chr2:160917029	PLA2R1	-0.42	-6.44	-0.38	6.21e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9308731	0.966	rs4849442	chr2:111934219	C/T	cg23466623	chr2:111982296	NA	-0.46	-5.75	-0.34	2.68e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.46	-5.62	-0.34	5.18e-8	Height;
KIRP	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg22800045	chr5:56110881	MAP3K1	0.8	8.52	0.48	1.59e-15	Initial pursuit acceleration;
KIRP	cis	rs9323205	0.871	rs2999393	chr14:51655167	G/T	cg23942311	chr14:51606299	NA	0.6	7.43	0.43	1.78e-12	Cancer;
KIRP	cis	rs7180079	0.620	rs520694	chr15:64888243	G/T	cg15337035	chr15:64978493	NA	0.51	5.33	0.32	2.28e-7	Monocyte count;
KIRP	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.77	-8.59	-0.48	1.02e-15	Platelet count;
KIRP	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.44	-5.08	-0.31	7.43e-7	Kawasaki disease;
KIRP	cis	rs7613051	0.580	rs11720449	chr3:33066467	C/T	cg27203090	chr3:33138513	GLB1;TMPPE	-0.6	-5.15	-0.31	5.44e-7	Atopic dermatitis;
KIRP	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg03060546	chr3:49711283	APEH	-0.53	-7.19	-0.42	7.88e-12	Menarche (age at onset);
KIRP	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg11569703	chr11:65557185	OVOL1	-0.37	-5.82	-0.35	1.78e-8	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg23682824	chr7:23144976	KLHL7	0.46	5.48	0.33	1.03e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6568686	0.577	rs383515	chr6:111916668	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.53	5.13	0.31	5.74e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.58	7.95	0.45	6.86e-14	Depressive symptoms;
KIRP	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg13114125	chr14:105738426	BRF1	-0.77	-10.31	-0.55	6.12e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4478858	0.735	rs4494186	chr1:31857847	G/A	cg00250761	chr1:31883323	NA	0.33	5.56	0.33	6.91e-8	Alcohol dependence;
KIRP	cis	rs1190552	0.639	rs3742446	chr14:102975572	C/T	cg10241871	chr14:102965420	TECPR2	-0.49	-5.32	-0.32	2.28e-7	Blood protein levels;
KIRP	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg23216685	chr1:86174607	ZNHIT6	-0.61	-8.91	-0.49	1.15e-16	Urate levels in overweight individuals;
KIRP	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.57	8.1	0.46	2.51e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02613156	chr2:32394762	SLC30A6	-0.43	-6.04	-0.36	5.7e-9	Select biomarker traits;
KIRP	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.68	9.37	0.51	4.74e-18	Body mass index;
KIRP	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg15556689	chr8:8085844	FLJ10661	0.61	7.57	0.43	7.54e-13	Neuroticism;
KIRP	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg05315796	chr3:52349193	DNAH1	0.38	6.02	0.36	6.24e-9	Bipolar disorder;
KIRP	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg21360079	chr12:107162445	NA	-0.67	-9.7	-0.53	4.79e-19	Heart rate;
KIRP	cis	rs7084402	0.935	rs717453	chr10:60268398	C/T	cg05938607	chr10:60274200	BICC1	0.41	9.89	0.53	1.27e-19	Refractive error;
KIRP	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.63	-0.39	2.12e-10	Total body bone mineral density;
KIRP	cis	rs8060686	0.623	rs58388686	chr16:68075439	A/G	cg26727032	chr16:67993705	SLC12A4	-0.66	-7.64	-0.44	4.81e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2151522	0.762	rs2326549	chr6:127187691	G/A	cg21431617	chr6:127135037	NA	0.28	5.01	0.3	1.05e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg13147721	chr7:65941812	NA	-0.94	-6.7	-0.39	1.4e-10	Diabetic kidney disease;
KIRP	cis	rs910316	0.836	rs6574212	chr14:75671659	G/A	cg11812906	chr14:75593930	NEK9	-0.73	-10.19	-0.54	1.47e-20	Height;
KIRP	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg18527119	chr7:66119851	NA	-0.45	-4.88	-0.3	1.87e-6	Aortic root size;
KIRP	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg08807101	chr21:30365312	RNF160	0.56	6.2	0.37	2.36e-9	Cognitive test performance;
KIRP	trans	rs4131099	0.793	rs11644493	chr16:51371079	A/G	cg02207200	chr8:17353980	SLC7A2	0.56	6.29	0.37	1.43e-9	Personality dimensions;
KIRP	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.52	4.99	0.3	1.15e-6	Recombination rate (females);
KIRP	cis	rs3736594	0.559	rs62141292	chr2:27784300	A/C	cg27432699	chr2:27873401	GPN1	0.55	6.08	0.36	4.57e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg03641300	chr2:160917029	PLA2R1	-0.52	-8.05	-0.46	3.46e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg11858474	chr10:81107246	PPIF	0.53	6.41	0.38	7.31e-10	Plasma plasminogen activator levels;
KIRP	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.48	-7.32	-0.42	3.58e-12	Vitamin D levels;
KIRP	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.65	-10.03	-0.54	4.41e-20	Heart rate;
KIRP	cis	rs6840360	0.904	rs73862064	chr4:152503100	T/A	cg22705602	chr4:152727874	NA	-0.42	-6.62	-0.39	2.22e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.56	-7.24	-0.42	5.88e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs6001982	0.667	rs75523053	chr22:40868239	G/T	cg07138101	chr22:40742427	ADSL	0.71	4.93	0.3	1.54e-6	Breast cancer;
KIRP	cis	rs6466055	0.669	rs6950620	chr7:104770386	A/G	cg04380332	chr7:105027541	SRPK2	0.55	8.65	0.48	6.71e-16	Schizophrenia;
KIRP	trans	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg06521331	chr12:34319734	NA	-0.5	-6.22	-0.37	2.17e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2219968	0.828	rs4412362	chr8:78930579	C/T	cg00738934	chr8:78996279	NA	-0.37	-5.02	-0.3	9.8e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12716641	0.722	rs4418364	chr8:6897885	C/T	cg26123975	chr8:6873754	DEFA1;DEFA3;DEFA1B	-0.36	-4.94	-0.3	1.44e-6	IgA nephropathy;
KIRP	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg27124370	chr19:33622961	WDR88	0.6	7.37	0.43	2.59e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.48	6.07	0.36	4.82e-9	Height;
KIRP	cis	rs7737355	0.898	rs3775999	chr5:130970090	T/C	cg06647332	chr5:131281008	NA	0.46	4.96	0.3	1.34e-6	Life satisfaction;
KIRP	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.48	-0.38	5.03e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.54	-8.24	-0.47	1.04e-14	Huntington's disease progression;
KIRP	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg26513180	chr16:89883248	FANCA	0.84	5.61	0.34	5.45e-8	Skin colour saturation;
KIRP	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg21204522	chr6:27730016	NA	-0.69	-5.29	-0.32	2.66e-7	Depression;
KIRP	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg15162869	chr22:32027605	PISD	-0.66	-4.84	-0.3	2.27e-6	Age-related hearing impairment;
KIRP	cis	rs6504622	0.557	rs11654971	chr17:44998563	G/A	cg16759221	chr17:45003025	GOSR2	0.35	5.29	0.32	2.74e-7	Orofacial clefts;
KIRP	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg16434002	chr17:42200994	HDAC5	-0.46	-5.68	-0.34	3.74e-8	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg21108841	chr4:24914750	CCDC149	0.47	5.86	0.35	1.44e-8	Heschl's gyrus morphology;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24342377	chr7:97868109	TECPR1	-0.48	-6.96	-0.41	3.04e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg02461776	chr11:598696	PHRF1	0.59	6.41	0.38	7.37e-10	Systemic lupus erythematosus;
KIRP	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg04398451	chr17:18023971	MYO15A	-0.71	-8.25	-0.47	9.8e-15	Total body bone mineral density;
KIRP	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg22356347	chr1:167427500	CD247	-0.43	-5.88	-0.35	1.33e-8	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs6901250	0.632	rs688961	chr6:117089080	A/T	cg05399210	chr6:117082661	FAM162B	-0.44	-6.17	-0.37	2.83e-9	C-reactive protein levels;
KIRP	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.43	6.57	0.39	2.94e-10	Schizophrenia;
KIRP	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.32	-6.71	-0.39	1.35e-10	Diastolic blood pressure;
KIRP	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs56775891	0.527	rs71367545	chr18:77576337	G/A	cg24058013	chr18:77568902	NA	-0.6	-6.76	-0.4	1e-10	Schizophrenia;
KIRP	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.13	0.41	1.15e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg16898833	chr6:26189333	HIST1H4D	0.81	5.81	0.35	1.95e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg08807101	chr21:30365312	RNF160	-0.63	-7.24	-0.42	5.69e-12	Cognitive test performance;
KIRP	cis	rs2882667	0.628	rs13167462	chr5:138177261	G/A	cg04439458	chr5:138467593	SIL1	-0.42	-5.39	-0.32	1.66e-7	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9420	0.754	rs631791	chr11:57675410	A/G	cg23127183	chr11:57508653	C11orf31	0.49	5.55	0.33	7.44e-8	Schizophrenia;
KIRP	trans	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg10756647	chr7:56101905	PSPH	0.91	6.44	0.38	6.21e-10	Diabetic kidney disease;
KIRP	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.37	7.12	0.41	1.21e-11	Multiple system atrophy;
KIRP	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg07741184	chr6:167504864	NA	0.24	6.42	0.38	7e-10	Crohn's disease;
KIRP	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.26	5.26	0.32	3.17e-7	Coronary artery disease;
KIRP	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg06627628	chr2:24431161	ITSN2	-0.52	-5.95	-0.35	9.34e-9	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	cis	rs1823913	0.637	rs13019567	chr2:192163462	C/T	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.57e-9	Obesity-related traits;
KIRP	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-10.1	-0.54	2.73e-20	Colorectal cancer;
KIRP	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg16583315	chr14:65563665	MAX	-0.34	-5.11	-0.31	6.6e-7	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg06558623	chr16:89946397	TCF25	1.03	7.71	0.44	3.02e-13	Skin colour saturation;
KIRP	cis	rs3751972	0.911	rs8078361	chr17:26230480	C/T	cg18091275	chr17:26120155	NOS2	-0.42	-5.31	-0.32	2.51e-7	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg21775007	chr8:11205619	TDH	-0.42	-5.27	-0.32	3.01e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg04935436	chr20:30431758	NA	0.5	6.58	0.39	2.79e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs7116495	1.000	rs677279	chr11:71770469	G/A	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg07701084	chr6:150067640	NUP43	0.73	10.07	0.54	3.42e-20	Lung cancer;
KIRP	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg13798780	chr7:105162888	PUS7	0.49	5.13	0.31	5.79e-7	Bipolar disorder (body mass index interaction);
KIRP	trans	rs7716219	0.731	rs7704138	chr5:54944262	C/T	cg13423371	chr9:138701748	CAMSAP1	0.43	6.03	0.36	6.11e-9	Height;
KIRP	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.4	-0.33	1.59e-7	Total body bone mineral density;
KIRP	cis	rs6504950	0.800	rs9900816	chr17:53012057	G/A	cg26251398	chr17:52985966	TOM1L1	0.45	6.06	0.36	5.02e-9	Breast cancer;
KIRP	cis	rs7215564	0.908	rs2315923	chr17:78693678	A/G	cg06153925	chr17:78755379	RPTOR	0.36	5.7	0.34	3.38e-8	Myopia (pathological);
KIRP	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	1.03	13.01	0.64	8.2e-30	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg17376030	chr22:41985996	PMM1	-0.51	-6.28	-0.37	1.48e-9	Vitiligo;
KIRP	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg02297831	chr4:17616191	MED28	-0.6	-7.45	-0.43	1.59e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.61	8.15	0.46	1.9e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg06808227	chr14:105710500	BRF1	-0.78	-9.83	-0.53	1.88e-19	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	5.45	0.33	1.24e-7	Height;
KIRP	cis	rs17453880	0.929	rs4537047	chr5:151953565	A/G	cg12297329	chr5:152029980	NA	-0.68	-10.18	-0.54	1.55e-20	Subjective well-being;
KIRP	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs17428704	0.571	rs57017859	chr5:14362930	A/G	cg26595256	chr5:14380529	TRIO	-0.82	-6.11	-0.36	3.96e-9	Electroencephalogram traits;
KIRP	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.46	5.92	0.35	1.08e-8	Life satisfaction;
KIRP	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg13319975	chr6:146136371	FBXO30	-0.43	-5.75	-0.34	2.7e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg18461458	chr19:21324796	ZNF431	-0.47	-4.88	-0.3	1.89e-6	Pain;
KIRP	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.54	6.74	0.39	1.12e-10	Urate levels in overweight individuals;
KIRP	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg01631408	chr1:248437212	OR2T33	-0.36	-5.0	-0.3	1.1e-6	Common traits (Other);
KIRP	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg05775895	chr3:12838266	CAND2	-0.44	-7.43	-0.43	1.75e-12	QRS complex (12-leadsum);
KIRP	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg27539214	chr16:67997921	SLC12A4	-0.55	-5.07	-0.31	7.95e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg15744005	chr10:104629667	AS3MT	-0.31	-6.39	-0.38	8.05e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs981946	0.510	rs11756418	chr6:3347748	G/C	cg18842474	chr6:3356384	SLC22A23	0.47	6.03	0.36	6.09e-9	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
KIRP	cis	rs501120	0.657	rs1704222	chr10:44710465	T/A	cg09554077	chr10:44749378	NA	0.65	7.29	0.42	4.21e-12	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.83	10.44	0.55	2.34e-21	Gestational age at birth (maternal effect);
KIRP	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg10434728	chr15:90938212	IQGAP1	0.3	4.96	0.3	1.3e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-1.0	-15.54	-0.7	2.11e-38	Coronary artery disease;
KIRP	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg17376030	chr22:41985996	PMM1	-0.53	-6.05	-0.36	5.3e-9	Vitiligo;
KIRP	cis	rs9488822	0.651	rs521985	chr6:116264940	G/A	cg18764771	chr6:116381957	FRK	-0.21	-5.61	-0.34	5.42e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6952809	0.961	rs7796798	chr7:2450794	T/A	cg06995285	chr7:2418615	EIF3B	0.37	4.92	0.3	1.62e-6	Multiple sclerosis;
KIRP	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00864171	chr11:67383662	NA	0.39	5.21	0.32	4.04e-7	Mean corpuscular volume;
KIRP	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg11995313	chr8:8860691	ERI1	0.38	5.22	0.32	3.78e-7	Joint mobility (Beighton score);
KIRP	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg12962167	chr3:53033115	SFMBT1	0.76	5.68	0.34	3.74e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg14972814	chr11:95582409	MTMR2	0.36	5.88	0.35	1.3e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg06766960	chr11:133703094	NA	-0.66	-8.36	-0.47	4.78e-15	Childhood ear infection;
KIRP	cis	rs3829109	0.564	rs3812578	chr9:139299673	G/C	cg14169450	chr9:139327907	INPP5E	0.5	5.97	0.36	8.44e-9	Peak insulin response;Acute insulin response;
KIRP	cis	rs2281603	0.570	rs1470851	chr14:64976120	C/G	cg01860774	chr14:64969374	ZBTB25	0.35	5.62	0.34	5.13e-8	Lymphocyte counts;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20386818	chr1:220836705	MARK1	-0.43	-6.48	-0.38	4.91e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg04132472	chr17:19861366	AKAP10	0.42	5.72	0.34	3.09e-8	Schizophrenia;
KIRP	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg22705602	chr4:152727874	NA	-0.55	-9.75	-0.53	3.31e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.15	20.9	0.8	1.81e-56	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.71	10.35	0.55	4.59e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.77	11.25	0.58	5.66e-24	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6723108	0.515	rs55687393	chr2:135540231	C/G	cg12500956	chr2:135428796	TMEM163	0.42	5.33	0.32	2.27e-7	Type 2 diabetes;
KIRP	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg26898376	chr11:64110657	CCDC88B	-0.48	-5.52	-0.33	8.63e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.41	-6.1	-0.36	4.01e-9	Height;
KIRP	cis	rs7709377	0.595	rs116024534	chr5:115440929	T/C	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.64e-7	Metabolite levels  (X-11787);
KIRP	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.69	9.27	0.51	9.59e-18	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg22325292	chr17:80708367	FN3K	0.43	6.44	0.38	6.25e-10	Glycated hemoglobin levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg21607453	chr9:98783545	NCRNA00092	-0.44	-6.2	-0.37	2.36e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg05347473	chr6:146136440	FBXO30	0.56	8.05	0.46	3.63e-14	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25261059	chr19:44031185	ETHE1	0.48	6.17	0.37	2.77e-9	Parkinson's disease;
KIRP	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.34	10.85	0.57	1.11e-22	Economic and political preferences (immigration/crime);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08910705	chr8:79711103	IL7	0.46	6.66	0.39	1.76e-10	Interleukin-4 levels;
KIRP	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg26554054	chr8:600488	NA	0.76	5.86	0.35	1.48e-8	IgG glycosylation;
KIRP	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-4.94	-0.3	1.45e-6	Testicular germ cell tumor;
KIRP	cis	rs7737355	0.853	rs1468453	chr5:130587459	A/C	cg06647332	chr5:131281008	NA	0.46	5.09	0.31	7.22e-7	Life satisfaction;
KIRP	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.49	6.15	0.37	3.07e-9	Mean platelet volume;
KIRP	cis	rs12249377	0.519	rs66650915	chr10:92592468	T/C	cg14313238	chr10:92632228	RPP30	0.45	5.54	0.33	7.86e-8	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg08885076	chr2:99613938	TSGA10	-0.54	-7.34	-0.42	3.14e-12	Chronic sinus infection;
KIRP	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg14541582	chr5:601475	NA	-0.48	-5.15	-0.31	5.39e-7	Lung disease severity in cystic fibrosis;
KIRP	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21659725	chr3:3221576	CRBN	-0.5	-6.22	-0.37	2.16e-9	Body mass index;
KIRP	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg05347473	chr6:146136440	FBXO30	0.48	6.73	0.39	1.16e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06481639	chr22:41940642	POLR3H	0.62	7.16	0.42	9.41e-12	Vitiligo;
KIRP	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.98	13.11	0.64	3.87e-30	Breast cancer;
KIRP	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.65	7.97	0.45	5.76e-14	Obesity-related traits;
KIRP	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-7.02	-0.41	2.17e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-5.94	-0.35	9.9e-9	Prudent dietary pattern;
KIRP	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	-0.41	-4.9	-0.3	1.78e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.608	rs4314885	chr1:209902704	G/A	cg23920097	chr1:209922102	NA	-0.4	-5.47	-0.33	1.09e-7	Red blood cell count;
KIRP	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg21366198	chr4:185655624	MLF1IP	-0.47	-6.05	-0.36	5.43e-9	Kawasaki disease;
KIRP	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.65	8.7	0.49	4.76e-16	Motion sickness;
KIRP	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.15	-0.31	5.45e-7	Metabolite levels;
KIRP	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.77	-11.48	-0.59	1.07e-24	Morning vs. evening chronotype;
KIRP	cis	rs1847505	0.593	rs1355904	chr13:61412681	C/T	cg25164009	chr13:61490935	NA	0.47	5.3	0.32	2.55e-7	Polychlorinated biphenyl levels;
KIRP	cis	rs17776563	0.959	rs1348004	chr15:89113450	C/G	cg05013243	chr15:89149849	MIR1179	0.41	5.39	0.32	1.67e-7	Thyroid hormone levels;
KIRP	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg19767477	chr5:127420684	SLC12A2	-0.38	-5.47	-0.33	1.09e-7	Ileal carcinoids;
KIRP	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg12654155	chr4:185238627	NA	-0.42	-5.69	-0.34	3.61e-8	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
KIRP	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	cis	rs1891275	0.515	rs7911755	chr10:93489817	G/A	cg07889827	chr10:93443413	NA	-0.43	-7.32	-0.42	3.42e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg18404041	chr3:52824283	ITIH1	0.36	5.06	0.31	8.34e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.83	11.78	0.6	1.05e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs909341	0.909	rs1151622	chr20:62365556	A/G	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.91	-0.4	4.04e-11	Atopic dermatitis;
KIRP	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg18833306	chr6:118973337	C6orf204	0.42	5.32	0.32	2.37e-7	Electrocardiographic conduction measures;
KIRP	cis	rs4006360	0.537	rs12602811	chr17:39245273	C/T	cg15015397	chr17:39261100	KRTAP4-9	-0.57	-8.64	-0.48	7.43e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.83	-10.3	-0.55	6.29e-21	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.35	-0.32	2.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.92	14.83	0.69	5.43e-36	Blood protein levels;
KIRP	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.77	-11.1	-0.58	1.77e-23	Morning vs. evening chronotype;
KIRP	cis	rs56161922	0.915	rs12562739	chr1:207856658	T/A	cg09557387	chr1:207818395	CR1L	1.07	6.31	0.37	1.26e-9	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs4740619	0.619	rs4740631	chr9:16030126	G/C	cg14451791	chr9:16040625	NA	-0.41	-5.53	-0.33	8.36e-8	Body mass index;
KIRP	cis	rs9581857	0.547	rs7989917	chr13:28071271	G/A	cg22138327	chr13:27999177	GTF3A	0.84	7.25	0.42	5.4e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7714584	1.000	rs17727568	chr5:150244688	A/G	cg22134413	chr5:150180641	NA	0.96	7.09	0.41	1.44e-11	Crohn's disease;
KIRP	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.34	5.07	0.31	7.86e-7	Calcium levels;
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg00933542	chr6:150070202	PCMT1	0.31	5.81	0.35	1.94e-8	Lung cancer;
KIRP	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.78	11.36	0.59	2.61e-24	Heart rate;
KIRP	trans	rs526821	0.595	rs517627	chr11:55356489	C/T	cg15704280	chr7:45808275	SEPT13	-0.51	-6.12	-0.36	3.57e-9	Pediatric bone mineral density (spine);
KIRP	trans	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg08400319	chr2:242004533	SNED1	0.45	6.19	0.37	2.52e-9	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs2411233	1.000	rs11070166	chr15:39280797	G/T	cg02291532	chr15:39874776	THBS1	0.38	5.11	0.31	6.58e-7	Platelet count;
KIRP	cis	rs4356932	1.000	rs4309862	chr4:76945981	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs10486003	0.867	rs74362320	chr7:97221446	C/A	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.62	-4.94	-0.3	1.42e-6	Response to platinum-based agents;
KIRP	cis	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg26585981	chr11:48327164	OR4S1	-0.47	-5.67	-0.34	4.09e-8	HDL cholesterol;
KIRP	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.64	8.43	0.47	2.86e-15	Motion sickness;
KIRP	cis	rs8060686	0.668	rs255056	chr16:68016185	G/C	cg04539111	chr16:67997858	SLC12A4	-0.49	-5.15	-0.31	5.27e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg10189774	chr4:17578691	LAP3	0.44	4.91	0.3	1.64e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg27446573	chr6:127587934	RNF146	0.73	9.28	0.51	9.34e-18	Breast cancer;
KIRP	cis	rs6438504	0.885	rs4591498	chr3:118926656	T/C	cg25372693	chr3:118959985	B4GALT4	0.34	5.64	0.34	4.55e-8	Clozapine-induced cytotoxicity;
KIRP	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg08603382	chr10:743973	NA	0.43	6.17	0.37	2.77e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.6	-5.12	-0.31	6.15e-7	Putamen volume;
KIRP	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs7937682	0.593	rs1113851	chr11:111354161	G/A	cg09085632	chr11:111637200	PPP2R1B	0.43	5.48	0.33	1.07e-7	Primary sclerosing cholangitis;
KIRP	cis	rs7624766	0.555	rs7618832	chr3:160488395	A/C	cg22637730	chr3:160473554	PPM1L	0.44	5.52	0.33	8.38e-8	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg00784671	chr22:46762841	CELSR1	-0.6	-8.53	-0.48	1.47e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7221595	0.825	rs8076743	chr17:3916537	A/T	cg05562828	chr17:3906858	NA	0.65	7.2	0.42	7.19e-12	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-6.7	-0.39	1.43e-10	Morning vs. evening chronotype;
KIRP	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg04865290	chr3:52927548	TMEM110	0.41	5.59	0.34	5.92e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.61	8.99	0.5	6.63e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.54	0.56	1.09e-21	Cognitive test performance;
KIRP	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.54	0.38	3.54e-10	Prudent dietary pattern;
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg12262378	chr17:6899522	ALOX12	0.34	6.06	0.36	5.21e-9	Tonsillectomy;
KIRP	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.58	7.64	0.44	4.94e-13	Bladder cancer;
KIRP	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg24315340	chr6:146058215	EPM2A	0.45	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg23899408	chr19:12877188	HOOK2	-0.44	-5.31	-0.32	2.47e-7	Mean corpuscular volume;
KIRP	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.58	7.62	0.44	5.32e-13	Blood protein levels;
KIRP	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.01	-0.36	6.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs4849845	0.886	rs934724	chr2:121012869	T/C	cg24070213	chr2:121070622	NA	0.38	5.12	0.31	6.19e-7	Mean platelet volume;
KIRP	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.76	-9.48	-0.52	2.3e-18	Coronary artery disease;
KIRP	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg04202892	chr2:111875749	ACOXL	0.45	6.14	0.36	3.33e-9	Chronic lymphocytic leukemia;
KIRP	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.93	10.35	0.55	4.42e-21	Blood protein levels;
KIRP	trans	rs921874	0.673	rs10466732	chr11:86734939	C/T	cg25327343	chr8:120221797	MAL2	-0.41	-6.08	-0.36	4.59e-9	Total body bone mineral density;
KIRP	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.54	7.23	0.42	6.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.82	7.39	0.43	2.24e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2299587	0.560	rs3913555	chr8:17781810	A/C	cg01800426	chr8:17659068	MTUS1	-0.62	-7.55	-0.43	8.6e-13	Economic and political preferences;
KIRP	cis	rs8133932	0.608	rs373267	chr21:47343320	G/T	cg11214348	chr21:47283868	PCBP3	-0.47	-5.35	-0.32	2.02e-7	Schizophrenia;
KIRP	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg08992911	chr2:238395768	MLPH	0.41	5.11	0.31	6.57e-7	Prostate cancer;
KIRP	cis	rs4819052	0.851	rs2256000	chr21:46685909	T/C	cg06618935	chr21:46677482	NA	-0.37	-4.97	-0.3	1.27e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg05926928	chr17:57297772	GDPD1	0.54	6.38	0.38	8.5e-10	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
KIRP	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg22951263	chr5:87985283	NA	0.47	6.63	0.39	2.05e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.57	7.63	0.44	5.16e-13	Brugada syndrome;
KIRP	cis	rs714515	0.586	rs4916265	chr1:172450774	A/G	cg01573306	chr1:172330400	DNM3	-0.42	-5.19	-0.31	4.43e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.68	9.05	0.5	4.62e-17	Breast cancer;
KIRP	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.61	0.39	2.43e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg17554472	chr22:41940697	POLR3H	-0.49	-5.7	-0.34	3.46e-8	Neuroticism;
KIRP	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.67	9.5	0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg05507819	chr15:63340323	TPM1	0.45	5.04	0.31	8.82e-7	HDL cholesterol;
KIRP	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.59	-9.48	-0.52	2.28e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-0.52	-5.77	-0.35	2.36e-8	Type 2 diabetes;
KIRP	cis	rs3829109	0.504	rs11145890	chr9:139293851	C/G	cg14169450	chr9:139327907	INPP5E	0.47	5.76	0.34	2.48e-8	Peak insulin response;Acute insulin response;
KIRP	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.55	-0.39	3.39e-10	Monocyte percentage of white cells;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.51	5.12	0.31	6.16e-7	Alzheimer's disease;
KIRP	cis	rs501120	0.584	rs1704226	chr10:44678387	C/A	cg09554077	chr10:44749378	NA	0.57	5.95	0.35	9.05e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10814247	0.592	rs72725052	chr9:35504061	C/T	cg15271616	chr9:35490515	RUSC2	0.4	5.2	0.31	4.1e-7	Psoriasis;
KIRP	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.53	-6.84	-0.4	6.31e-11	Blood metabolite levels;
KIRP	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.77	-10.77	-0.57	2.04e-22	Fibrinogen levels;
KIRP	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg20140201	chr2:241835670	C2orf54	-0.31	-4.92	-0.3	1.59e-6	Urinary metabolites;
KIRP	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.72	8.85	0.49	1.76e-16	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs78487399	0.808	rs76993899	chr2:43671157	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-4.89	-0.3	1.85e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs3744061	0.530	rs12450896	chr17:74629867	C/T	cg27546012	chr17:74684504	MXRA7	0.51	5.8	0.35	2.05e-8	Retinal arteriolar caliber;
KIRP	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	6.53	0.38	3.64e-10	Breast cancer;
KIRP	cis	rs1420338	1.000	rs918038	chr7:34153768	A/G	cg01275685	chr7:34179230	BMPER	-0.5	-7.29	-0.42	4.13e-12	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.29	-0.37	1.44e-9	Response to antipsychotic treatment;
KIRP	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.48	7.64	0.44	4.9e-13	Glucocorticoid-induced osteonecrosis (age 10 years and older);
KIRP	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg06647332	chr5:131281008	NA	-0.44	-5.14	-0.31	5.52e-7	Life satisfaction;
KIRP	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg05804037	chr4:1090086	RNF212	-0.34	-4.92	-0.3	1.59e-6	Recombination rate (males);
KIRP	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg07395648	chr5:131743802	NA	-0.36	-5.0	-0.3	1.08e-6	Blood metabolite levels;
KIRP	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.12	-0.5	2.82e-17	Mood instability;
KIRP	cis	rs12949688	0.538	rs3883321	chr17:55804006	C/G	cg12582317	chr17:55822272	NA	0.36	5.44	0.33	1.26e-7	Schizophrenia;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.5	6.16	0.37	2.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.75e-15	Aortic root size;
KIRP	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg15128208	chr22:42549153	NA	0.39	5.09	0.31	7.19e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.44	-5.48	-0.33	1.03e-7	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs13100616	1.000	rs6765202	chr3:178413546	T/C	cg26530345	chr2:220312410	SPEG	0.49	6.02	0.36	6.17e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.7	0.48	4.93e-16	Motion sickness;
KIRP	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg00629928	chr5:358741	AHRR	0.53	5.36	0.32	1.92e-7	Breast cancer;
KIRP	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.49	-7.02	-0.41	2.16e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg25482853	chr8:67687455	SGK3	0.79	6.99	0.41	2.64e-11	Obesity-related traits;
KIRP	cis	rs1215050	0.744	rs966380	chr4:98435389	C/T	cg05340658	chr4:99064831	C4orf37	0.46	4.91	0.3	1.63e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg13786083	chr1:19110734	NA	-0.44	-5.07	-0.31	7.84e-7	Drug-induced liver injury (nitrofurantoin);
KIRP	trans	rs963167	0.789	rs2647530	chr11:9105636	C/T	cg27293353	chr6:57182516	PRIM2	0.77	6.3	0.37	1.33e-9	&beta2-Glycoprotein I (β2-GPI) plasma levels;
KIRP	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg00495681	chr13:53174319	NA	0.45	6.23	0.37	2e-9	Lewy body disease;
KIRP	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.51	5.64	0.34	4.58e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg12573674	chr2:1569213	NA	-0.52	-5.05	-0.31	8.47e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7172677	1.000	rs7177528	chr15:75409594	T/C	cg14082893	chr15:75400931	NA	0.36	5.3	0.32	2.57e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12933314	chr7:4815160	KIAA0415	0.6	7.05	0.41	1.83e-11	Smoking initiation;
KIRP	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.73	10.49	0.56	1.66e-21	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.8	10.74	0.56	2.62e-22	Morning vs. evening chronotype;
KIRP	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	0.9	12.11	0.61	8.93e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-4.95	-0.3	1.4e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg12963246	chr6:28129442	ZNF389	0.44	5.23	0.32	3.59e-7	Depression;
KIRP	cis	rs2275620	0.526	rs2146017	chr10:96677971	G/T	cg09036531	chr10:96991505	NA	-0.46	-5.48	-0.33	1.07e-7	Gout;
KIRP	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.26	-0.42	4.93e-12	Type 2 diabetes;
KIRP	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg03959625	chr15:84868606	LOC388152	0.52	6.08	0.36	4.64e-9	Schizophrenia;
KIRP	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.04	17.65	0.75	1.36e-45	Multiple system atrophy;
KIRP	cis	rs735539	0.521	rs2585901	chr13:21420271	G/A	cg04906043	chr13:21280425	IL17D	-0.44	-5.15	-0.31	5.33e-7	Dental caries;
KIRP	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg20493526	chr2:3714936	ALLC	0.46	5.9	0.35	1.18e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17376030	chr22:41985996	PMM1	0.76	8.15	0.46	1.89e-14	Vitiligo;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18912965	chr14:91526996	RPS6KA5	0.47	6.21	0.37	2.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs5498	1.000	rs885743	chr19:10406635	T/A	cg10604476	chr19:10403908	ICAM5	0.36	5.62	0.34	5.2e-8	Lymphocyte counts;Soluble ICAM-1;Blood protein levels;
KIRP	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs2625529	0.730	rs2929527	chr15:72282270	T/G	cg16672083	chr15:72433130	SENP8	0.42	6.07	0.36	4.84e-9	Red blood cell count;
KIRP	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg18016565	chr1:150552671	MCL1	0.34	5.06	0.31	8.04e-7	Melanoma;
KIRP	cis	rs4356932	0.967	rs6532161	chr4:76978366	G/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06173319	chr16:90148775	NA	0.57	5.27	0.32	2.99e-7	Skin colour saturation;
KIRP	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07570687	chr10:102243282	WNT8B	0.38	4.85	0.3	2.23e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7808935	0.522	rs2107822	chr7:28014734	A/G	cg22168087	chr7:27702803	HIBADH	-0.69	-6.46	-0.38	5.44e-10	Prostate cancer;
KIRP	cis	rs4740619	0.619	rs10756739	chr9:16036716	G/C	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.53e-7	Body mass index;
KIRP	cis	rs4711336	1.000	rs2296741	chr6:33659557	C/T	cg15676125	chr6:33679581	C6orf125	0.42	5.67	0.34	4.07e-8	Height;
KIRP	cis	rs6142102	0.961	rs6088361	chr20:32557326	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	6.74	0.4	1.09e-10	Skin pigmentation;
KIRP	cis	rs829883	0.902	rs1620317	chr12:98890566	T/C	cg25150519	chr12:98850993	NA	0.86	12.97	0.64	1.12e-29	Colorectal adenoma (advanced);
KIRP	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.06	-0.36	5.13e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9513627	1.000	rs2390279	chr13:100208705	A/G	cg25919922	chr13:100150906	NA	-0.75	-5.86	-0.35	1.44e-8	Obesity-related traits;
KIRP	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg15676125	chr6:33679581	C6orf125	0.39	5.05	0.31	8.79e-7	Plateletcrit;
KIRP	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg06585982	chr3:143692056	C3orf58	-0.58	-7.34	-0.42	3.11e-12	Economic and political preferences (feminism/equality);
KIRP	cis	rs7692976	0.868	rs2237052	chr4:110911025	A/G	cg06981781	chr4:110842888	EGF	-0.24	-5.21	-0.32	3.99e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-1.04	-8.18	-0.46	1.51e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-9.73	-0.53	3.85e-19	Morning vs. evening chronotype;
KIRP	cis	rs300890	0.733	rs300911	chr4:144276755	T/G	cg01601573	chr4:144256835	GAB1	0.35	4.89	0.3	1.78e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs1298062	0.790	rs2463245	chr19:50967250	C/G	cg11430371	chr19:50961752	MYBPC2	0.39	5.26	0.32	3.15e-7	Age of smoking initiation;
KIRP	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg17644776	chr2:200775616	C2orf69	0.58	6.16	0.37	2.93e-9	Schizophrenia;
KIRP	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg09184832	chr6:79620586	NA	-0.5	-7.14	-0.41	1.07e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg19875535	chr5:140030758	IK	0.62	8.5	0.48	1.8e-15	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg06212747	chr3:49208901	KLHDC8B	0.65	9.12	0.5	2.84e-17	Resting heart rate;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.49	6.68	0.39	1.59e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12477012	chr1:46049214	NASP	0.54	6.39	0.38	8.05e-10	Smoking initiation;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16311410	chr22:31892793	SFI1	0.58	6.84	0.4	6.27e-11	Smoking initiation;
KIRP	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg23484912	chr5:273055	PDCD6	0.58	7.25	0.42	5.52e-12	Pancreatic cancer;
KIRP	trans	rs877282	0.583	rs11253429	chr10:823234	A/C	cg22713356	chr15:30763199	NA	0.9	8.85	0.49	1.8e-16	Uric acid levels;
KIRP	trans	rs9650657	0.740	rs7002282	chr8:10666993	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.08	-0.36	4.58e-9	Neuroticism;
KIRP	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-9.23	-0.51	1.27e-17	Migraine;Coronary artery disease;
KIRP	cis	rs1057510	0.858	rs73047807	chr12:6704169	C/G	cg13857086	chr12:6580257	VAMP1	0.61	4.9	0.3	1.72e-6	Myopia (pathological);
KIRP	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	0.93	14.16	0.67	1.11e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.43	5.69	0.34	3.58e-8	Homoarginine levels;
KIRP	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg06307176	chr5:131281290	NA	0.53	5.93	0.35	1.02e-8	Life satisfaction;
KIRP	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg18646521	chr2:111875858	NA	0.4	5.82	0.35	1.87e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.45	0.33	1.23e-7	Breast cancer;
KIRP	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg14851346	chr12:38532713	NA	-0.4	-4.96	-0.3	1.3e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17101923	0.853	rs12811995	chr12:66327978	T/C	cg06712651	chr12:66351869	HMGA2	-0.58	-6.04	-0.36	5.67e-9	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs7015630	0.697	rs34699769	chr8:90853347	T/C	cg18493113	chr8:90847772	NA	-0.55	-6.16	-0.37	2.94e-9	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg08975724	chr8:8085496	FLJ10661	0.54	6.12	0.36	3.67e-9	Neuroticism;
KIRP	cis	rs2494938	0.655	rs846519	chr6:40539716	A/G	cg14084896	chr6:40530702	LRFN2	-0.42	-5.14	-0.31	5.53e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23751407	chr10:122739127	NA	0.47	6.52	0.38	3.89e-10	Parkinson's disease;
KIRP	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg20673091	chr1:2541236	MMEL1	0.77	12.33	0.62	1.62e-27	Ulcerative colitis;
KIRP	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg11130432	chr3:121712080	ILDR1	-0.44	-5.24	-0.32	3.47e-7	Multiple sclerosis;
KIRP	cis	rs9308433	0.529	rs11120298	chr1:214500620	A/G	cg06198575	chr1:214491504	SMYD2	0.48	6.05	0.36	5.25e-9	IgG glycosylation;
KIRP	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-9.84	-0.53	1.73e-19	Morning vs. evening chronotype;
KIRP	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg21775007	chr8:11205619	TDH	-0.53	-6.75	-0.4	1.04e-10	Neuroticism;
KIRP	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg12856521	chr11:46389249	DGKZ	0.62	7.64	0.44	4.86e-13	Crohn's disease;
KIRP	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.4e-7	Life satisfaction;
KIRP	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg03959625	chr15:84868606	LOC388152	0.63	7.04	0.41	1.86e-11	Schizophrenia;
KIRP	cis	rs2599510	0.783	rs2038534	chr2:32659489	G/A	cg02381751	chr2:32503542	YIPF4	0.44	5.05	0.31	8.68e-7	Interleukin-18 levels;
KIRP	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg23950597	chr19:37808831	NA	0.62	6.71	0.39	1.37e-10	Coronary artery calcification;
KIRP	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.69	-7.6	-0.44	6.35e-13	Vitiligo;
KIRP	cis	rs394563	0.591	rs11155641	chr6:149648595	G/A	cg16235748	chr6:149772707	ZC3H12D	0.35	5.59	0.34	6e-8	Dupuytren's disease;
KIRP	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.86	-0.35	1.47e-8	Morning vs. evening chronotype;
KIRP	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg24579218	chr15:68104479	NA	-0.43	-6.08	-0.36	4.48e-9	Obesity;
KIRP	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.62	-9.17	-0.5	1.97e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg05044414	chr3:183734942	ABCC5	0.38	5.8	0.35	2.05e-8	Anterior chamber depth;
KIRP	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.92	15.43	0.7	4.9e-38	Metabolic syndrome;
KIRP	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs2671245	0.565	rs9436981	chr1:56141388	A/G	cg11523071	chr1:56160889	NA	0.41	5.98	0.36	7.94e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.63	-7.58	-0.44	7.02e-13	Aortic root size;
KIRP	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg01338139	chr15:38987640	C15orf53	-0.51	-5.45	-0.33	1.24e-7	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg13319975	chr6:146136371	FBXO30	-0.47	-6.44	-0.38	6.3e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2151522	0.762	rs13207638	chr6:127180020	A/T	cg21431617	chr6:127135037	NA	0.29	5.23	0.32	3.58e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg22974920	chr21:40686053	BRWD1	0.49	5.86	0.35	1.47e-8	Cognitive function;
KIRP	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg02248941	chr16:2239361	CASKIN1	0.39	5.45	0.33	1.22e-7	Height;
KIRP	cis	rs7178909	0.902	rs8034116	chr15:90441568	A/G	cg19708238	chr15:90437601	AP3S2	0.58	7.86	0.45	1.17e-13	Common traits (Other);
KIRP	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.4	-5.13	-0.31	5.99e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.56	7.51	0.43	1.07e-12	Caffeine consumption;
KIRP	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.57	-7.82	-0.45	1.54e-13	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg09238746	chr17:78121135	EIF4A3	-0.42	-5.37	-0.32	1.79e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg12335473	chr3:15140786	ZFYVE20	-0.47	-6.14	-0.36	3.26e-9	Morning vs. evening chronotype;
KIRP	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg21918786	chr6:109611834	NA	-0.4	-5.56	-0.33	6.98e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs2387326	0.680	rs11016097	chr10:129942948	T/C	cg16087940	chr10:129947807	NA	-0.36	-4.85	-0.3	2.21e-6	Select biomarker traits;
KIRP	cis	rs2862064	1.000	rs4407618	chr5:156445875	A/C	cg12943317	chr5:156479607	HAVCR1	-0.73	-7.24	-0.42	5.85e-12	Platelet count;
KIRP	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.62	-7.48	-0.43	1.32e-12	Blood protein levels;
KIRP	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-10.44	-0.55	2.36e-21	Colorectal cancer;
KIRP	cis	rs7539542	0.556	rs10732292	chr1:202891366	T/C	cg08940984	chr1:202857613	RABIF	0.45	5.44	0.33	1.29e-7	Mean platelet volume;
KIRP	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg08885076	chr2:99613938	TSGA10	0.53	9.28	0.51	9.4e-18	Chronic sinus infection;
KIRP	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	6.97	0.41	2.97e-11	Height;
KIRP	cis	rs9513627	1.000	rs73556172	chr13:100121684	A/G	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.98	-11.38	-0.59	2.16e-24	Colorectal cancer;
KIRP	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg13165212	chr22:42675999	NA	0.32	5.63	0.34	4.79e-8	Cognitive function;
KIRP	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg04414720	chr1:150670196	GOLPH3L	-0.42	-5.38	-0.32	1.73e-7	Blood protein levels;
KIRP	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg06671706	chr8:8559999	CLDN23	0.56	6.48	0.38	5.04e-10	Obesity-related traits;
KIRP	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-8.61	-0.48	9.16e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20135002	chr11:47629003	NA	-0.46	-5.44	-0.33	1.29e-7	Subjective well-being;
KIRP	cis	rs13315871	0.615	rs7625655	chr3:58337723	C/T	cg12435725	chr3:58293450	RPP14	0.38	5.48	0.33	1.06e-7	Cholesterol, total;
KIRP	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg05347473	chr6:146136440	FBXO30	0.48	6.78	0.4	9.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.85	11.59	0.59	4.56e-25	Selective IgA deficiency;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16473610	chr16:67062946	CBFB	0.5	6.89	0.4	4.55e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg12131826	chr15:77904385	NA	0.5	6.0	0.36	6.99e-9	Type 2 diabetes;
KIRP	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg22705602	chr4:152727874	NA	-0.54	-9.59	-0.52	1.04e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg24130564	chr14:104152367	KLC1	-0.53	-7.14	-0.41	1.03e-11	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06221695	chr2:27546071	MPV17	0.53	7.18	0.42	8.03e-12	Parkinson's disease;
KIRP	trans	rs13172324	0.649	rs34777750	chr5:7404185	C/T	cg18545596	chr22:40322629	GRAP2	-0.72	-6.41	-0.38	7.58e-10	Myopia (pathological);
KIRP	cis	rs9913711	0.868	rs7216619	chr17:70079708	C/A	cg09344028	chr17:70110421	NA	0.39	7.7	0.44	3.35e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-1.06	-13.18	-0.64	2.33e-30	Exhaled nitric oxide output;
KIRP	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.9	15.56	0.7	1.82e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs2882667	0.858	rs6882112	chr5:138413735	C/T	cg04439458	chr5:138467593	SIL1	0.46	6.92	0.4	3.8e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6499755	0.932	rs12928690	chr16:55343565	C/T	cg05099576	chr16:55362342	IRX6	0.27	5.72	0.34	3.12e-8	Hypospadias;
KIRP	cis	rs208520	0.909	rs60604603	chr6:67022955	T/C	cg07460842	chr6:66804631	NA	0.89	7.62	0.44	5.55e-13	Exhaled nitric oxide output;
KIRP	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg17960426	chr8:142067321	NA	-0.57	-6.56	-0.39	3.24e-10	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-5.17	-0.31	4.84e-7	Neuroticism;
KIRP	cis	rs10073892	0.743	rs10214232	chr5:101656170	A/G	cg19774478	chr5:101632501	SLCO4C1	0.64	6.63	0.39	2.1e-10	Cognitive decline (age-related);
KIRP	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg06742321	chr12:123595122	PITPNM2	0.48	5.59	0.34	6.11e-8	Neutrophil percentage of white cells;
KIRP	cis	rs3822411	0.541	rs2964786	chr5:10742092	C/T	cg14521931	chr5:10832172	NA	0.52	6.45	0.38	5.81e-10	Sum eosinophil basophil counts;
KIRP	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.13	0.64	3.37e-30	Bladder cancer;
KIRP	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.29	7.67	0.44	3.94e-13	Primary biliary cholangitis;
KIRP	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.88	12.76	0.63	5.74e-29	Coronary artery disease;
KIRP	cis	rs2649	0.518	rs4556742	chr15:63864433	C/T	cg22599514	chr15:63798201	USP3	0.48	5.99	0.36	7.55e-9	Aortic root size;
KIRP	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg23601095	chr6:26197514	HIST1H3D	1.02	8.6	0.48	9.47e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.73	8.94	0.5	9.54e-17	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-5.69	-0.34	3.59e-8	Mood instability;
KIRP	cis	rs1116547	0.714	rs6864278	chr5:112774379	C/A	cg12552261	chr5:112820674	MCC	-0.48	-5.21	-0.32	3.99e-7	Cerebral amyloid angiopathy;
KIRP	cis	rs7536201	1.000	rs11249213	chr1:25293237	G/A	cg23273869	chr1:25296894	NA	-0.37	-5.05	-0.31	8.54e-7	Psoriasis vulgaris;
KIRP	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg23387468	chr7:139079360	LUC7L2	0.29	4.9	0.3	1.72e-6	Diisocyanate-induced asthma;
KIRP	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg07701084	chr6:150067640	NUP43	0.6	7.87	0.45	1.1e-13	Lung cancer;
KIRP	cis	rs6700559	0.565	rs11807125	chr1:200592295	C/T	cg07804481	chr1:200639085	DDX59	0.43	5.53	0.33	8.26e-8	Coronary artery disease;
KIRP	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg16341495	chr8:142228727	SLC45A4	0.43	5.3	0.32	2.52e-7	Immature fraction of reticulocytes;
KIRP	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg16558253	chr16:72132732	DHX38	-0.56	-6.22	-0.37	2.09e-9	Coronary artery disease;
KIRP	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg13962347	chr6:5174647	LYRM4	-0.76	-10.76	-0.57	2.19e-22	Height;
KIRP	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.11	0.31	6.42e-7	Educational attainment;
KIRP	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.65	-9.14	-0.5	2.36e-17	Retinal vascular caliber;
KIRP	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.41	5.31	0.32	2.45e-7	Melanoma;
KIRP	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08280861	chr8:58055591	NA	0.72	6.59	0.39	2.68e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9815354	0.638	rs60525434	chr3:42044286	T/G	cg03022575	chr3:42003672	ULK4	0.73	7.55	0.43	8.61e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1656402	1.000	rs1190455	chr2:233435153	A/G	cg03852847	chr2:233439513	NA	-0.72	-12.0	-0.61	2.03e-26	Non-small cell lung cancer (survival);
KIRP	cis	rs4849845	0.925	rs4849841	chr2:121012359	G/T	cg24070213	chr2:121070622	NA	0.38	5.15	0.31	5.43e-7	Mean platelet volume;
KIRP	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.89	12.2	0.61	4.36e-27	Breast cancer;
KIRP	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.49	-5.12	-0.31	6.04e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.91	10.68	0.56	4.11e-22	Corneal astigmatism;
KIRP	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.46	-6.61	-0.39	2.4e-10	Refractive error;
KIRP	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg19554555	chr3:13937349	NA	-0.47	-6.35	-0.38	1.02e-9	Ovarian reserve;
KIRP	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg21360079	chr12:107162445	NA	-0.67	-9.39	-0.51	4.28e-18	Heart rate;
KIRP	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.18e-24	Menopause (age at onset);
KIRP	cis	rs4716602	0.542	rs10261485	chr7:156159775	C/T	cg16983916	chr7:156159713	NA	-0.44	-5.56	-0.33	6.97e-8	Anti-saccade response;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21600965	chr6:42989367	C6orf153	0.55	7.09	0.41	1.42e-11	Parkinson's disease;
KIRP	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	5.43	0.33	1.37e-7	Total cholesterol levels;
KIRP	cis	rs11161851	0.609	rs1327093	chr1:75369429	C/T	cg11196437	chr1:75593865	LHX8	-0.48	-7.59	-0.44	6.78e-13	Visceral fat;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13051728	chr14:68086375	ARG2	0.49	6.69	0.39	1.47e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-8.3	-0.47	6.95e-15	Platelet count;
KIRP	cis	rs55962025	0.883	rs61792530	chr4:3145866	T/C	cg13731523	chr4:3047190	NA	0.31	4.92	0.3	1.62e-6	Parental longevity (mother's age at death);
KIRP	cis	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg13181695	chr2:31749899	SRD5A2	-0.33	-5.03	-0.31	9.37e-7	Inflammatory biomarkers;
KIRP	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15369054	chr17:80825471	TBCD	0.68	7.91	0.45	8.48e-14	Breast cancer;
KIRP	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg21984481	chr17:79567631	NPLOC4	-0.49	-7.44	-0.43	1.73e-12	Eye color traits;
KIRP	cis	rs2219968	0.923	rs2101106	chr8:78948481	A/C	cg00738934	chr8:78996279	NA	0.4	5.1	0.31	6.94e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg03929089	chr4:120376271	NA	-0.54	-6.33	-0.37	1.18e-9	HDL cholesterol;
KIRP	cis	rs17253792	0.822	rs74053651	chr14:56125366	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.75	5.94	0.35	9.62e-9	Putamen volume;
KIRP	cis	rs7191700	0.836	rs10163410	chr16:11430615	G/C	cg00044050	chr16:11439710	C16orf75	0.47	4.93	0.3	1.49e-6	Multiple sclerosis;
KIRP	cis	rs2479106	0.727	rs2159793	chr9:126701763	T/C	cg16191174	chr9:126692580	DENND1A	0.61	7.9	0.45	9.46e-14	Polycystic ovary syndrome;
KIRP	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.83	9.44	0.52	3.01e-18	Glomerular filtration rate (creatinine);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01776903	chr15:38543564	SPRED1	0.57	6.8	0.4	8e-11	Smoking initiation;
KIRP	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17376030	chr22:41985996	PMM1	0.76	8.04	0.46	3.87e-14	Vitiligo;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.56	-7.91	-0.45	8.76e-14	Longevity;
KIRP	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.32	-0.37	1.25e-9	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs9488822	0.702	rs6909746	chr6:116352750	C/T	cg26893134	chr6:116381904	FRK	0.21	5.6	0.34	5.84e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg00579200	chr11:133705235	NA	-0.44	-5.96	-0.36	8.74e-9	Childhood ear infection;
KIRP	cis	rs6772849	0.804	rs9832430	chr3:128412897	C/T	cg08795948	chr3:128337044	NA	0.41	4.89	0.3	1.85e-6	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	1.05	14.53	0.68	5.73e-35	Platelet distribution width;
KIRP	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.53	-0.38	3.79e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg21253087	chr9:139290292	SNAPC4	0.46	5.01	0.3	1.05e-6	White blood cell count;
KIRP	cis	rs9972944	0.729	rs7209787	chr17:63769896	G/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.79	-0.44	1.85e-13	Total body bone mineral density;
KIRP	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg01420254	chr6:26195488	NA	1.15	10.17	0.54	1.67e-20	Gout;Renal underexcretion gout;
KIRP	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg11693508	chr17:37793320	STARD3	0.74	8.13	0.46	2.18e-14	Bipolar disorder;
KIRP	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg02297831	chr4:17616191	MED28	0.55	6.91	0.4	4.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg00405596	chr8:11794950	NA	-0.39	-5.0	-0.3	1.09e-6	Neuroticism;
KIRP	trans	rs13170463	0.579	rs113234528	chr5:8042006	A/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs6674970	0.541	rs2902811	chr1:151010521	G/C	cg03258749	chr1:151040405	MLLT11	-0.86	-12.89	-0.63	2.13e-29	Childhood ear infection;
KIRP	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	0.88	13.41	0.65	3.77e-31	Body mass index;
KIRP	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.73	6.47	0.38	5.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg04373760	chr16:53404718	NA	0.63	6.72	0.39	1.24e-10	Hypertriglyceridemia;
KIRP	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.46	-0.33	1.17e-7	Coronary artery disease;
KIRP	cis	rs6772849	0.805	rs61159406	chr3:128336009	G/A	cg08795948	chr3:128337044	NA	0.38	4.98	0.3	1.19e-6	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.48	-6.8	-0.4	8.02e-11	Height;
KIRP	cis	rs56146971	0.763	rs2064961	chr14:91868814	A/G	cg16433844	chr14:91963127	SMEK1	-0.57	-5.32	-0.32	2.3e-7	Alzheimer disease and age of onset;
KIRP	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg05555928	chr11:63887634	MACROD1	-0.57	-5.22	-0.32	3.83e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg26354017	chr1:205819088	PM20D1	-0.6	-5.93	-0.35	9.97e-9	Menarche (age at onset);
KIRP	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.47	-0.38	5.2e-10	Type 2 diabetes;
KIRP	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg24796726	chr7:884288	UNC84A	-0.59	-5.39	-0.32	1.67e-7	Initial pursuit acceleration;
KIRP	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.4	-5.61	-0.34	5.48e-8	Dementia with Lewy bodies;
KIRP	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg05347473	chr6:146136440	FBXO30	0.62	8.82	0.49	2.08e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg20617956	chr10:82168530	C10orf58	-0.46	-6.66	-0.39	1.82e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.65	6.97	0.41	2.9e-11	Response to diuretic therapy;
KIRP	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-5.65	-0.34	4.33e-8	Coronary artery disease;
KIRP	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg09699651	chr6:150184138	LRP11	0.44	5.31	0.32	2.45e-7	Lung cancer;
KIRP	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	1.08	20.53	0.79	3.08e-55	Height;
KIRP	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.45	-0.43	1.62e-12	Triglycerides;
KIRP	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.7	-8.03	-0.46	4.13e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2548003	0.541	rs1160444	chr5:28763652	G/A	cg22863700	chr5:28928346	NA	0.59	6.09	0.36	4.2e-9	Hip geometry;
KIRP	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg25174290	chr11:3078921	CARS	-0.56	-6.04	-0.36	5.56e-9	Calcium levels;
KIRP	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.62	-8.49	-0.48	2.02e-15	Autism;
KIRP	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.86	-12.74	-0.63	6.65e-29	Height;
KIRP	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg16141378	chr3:129829833	LOC729375	0.5	6.1	0.36	4.01e-9	Neuroticism;
KIRP	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg23682824	chr7:23144976	KLHL7	0.49	5.63	0.34	5.03e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.57	5.91	0.35	1.11e-8	Total cholesterol levels;
KIRP	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.72	9.77	0.53	2.84e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg02336718	chr17:17403227	NA	0.33	5.23	0.32	3.68e-7	Total body bone mineral density;
KIRP	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.51	5.35	0.32	2.03e-7	Lung function (FEV1/FVC);
KIRP	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg08761264	chr16:28874980	SH2B1	-0.49	-5.68	-0.34	3.81e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg04731861	chr2:219085781	ARPC2	-0.2	-5.08	-0.31	7.3e-7	Colorectal cancer;
KIRP	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg27411982	chr8:10470053	RP1L1	-0.4	-5.15	-0.31	5.32e-7	Triglycerides;
KIRP	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg11031976	chr2:198649780	BOLL	-0.54	-5.18	-0.31	4.72e-7	Ulcerative colitis;
KIRP	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.88	-12.23	-0.62	3.38e-27	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12549025	0.536	rs9644075	chr8:23359961	C/G	cg08322043	chr8:23340750	NA	-0.52	-5.25	-0.32	3.34e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.46	6.58	0.39	2.79e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6832769	1.000	rs6832769	chr4:56298194	C/T	cg05960024	chr4:56376020	CLOCK	0.67	8.65	0.48	6.92e-16	Personality dimensions;
KIRP	trans	rs3816183	0.716	rs6720801	chr2:43079844	G/C	cg00374015	chr3:126737226	PLXNA1	-0.52	-6.04	-0.36	5.71e-9	Hypospadias;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.72	6.54	0.38	3.49e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10296688	chr13:52598408	UTP14C;ALG11	0.62	6.91	0.4	4.24e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg09841001	chr17:79455736	NA	0.44	5.21	0.32	4.05e-7	Myopia;
KIRP	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg01616529	chr11:638424	DRD4	-0.37	-5.06	-0.31	8.4e-7	Systemic lupus erythematosus;
KIRP	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.86	9.68	0.53	5.46e-19	High light scatter reticulocyte count;
KIRP	trans	rs2594989	0.831	rs66488222	chr3:11576289	C/T	cg02538783	chr10:35102505	PARD3	0.37	6.49	0.38	4.78e-10	Circulating chemerin levels;
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.79	-13.86	-0.66	1.17e-32	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07269271	chr12:8234745	NECAP1	0.49	6.8	0.4	8.04e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.44	-5.8	-0.35	2.01e-8	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg07870213	chr5:140052090	DND1	-0.56	-7.3	-0.42	3.95e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.76	10.78	0.57	1.97e-22	Lung cancer;
KIRP	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.25	-5.38	-0.32	1.73e-7	Menarche (age at onset);
KIRP	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	1.11	8.27	0.47	8.6e-15	Skin colour saturation;
KIRP	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	17.44	0.74	6.65e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs9840812	0.522	rs699165	chr3:136224697	A/G	cg15507776	chr3:136538369	TMEM22	0.42	5.23	0.32	3.59e-7	Fibrinogen levels;
KIRP	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.26	-17.25	-0.74	2.96e-44	Breast cancer;
KIRP	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg07274523	chr3:49395745	GPX1	0.56	5.12	0.31	6.13e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs911119	0.657	rs13039144	chr20:23633755	A/G	cg16589663	chr20:23618590	CST3	0.6	5.25	0.32	3.29e-7	Chronic kidney disease;
KIRP	cis	rs735539	0.517	rs9552241	chr13:21127569	C/G	cg04906043	chr13:21280425	IL17D	0.53	6.35	0.38	1.03e-9	Dental caries;
KIRP	cis	rs6910061	0.957	rs58680949	chr6:11103062	G/C	cg27233058	chr6:11094804	LOC221710	0.5	5.03	0.31	9.44e-7	Diabetic kidney disease;
KIRP	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20135002	chr11:47629003	NA	-0.37	-4.96	-0.3	1.32e-6	Subjective well-being;
KIRP	cis	rs812925	0.519	rs967968	chr2:61656056	C/G	cg15711740	chr2:61764176	XPO1	0.45	5.77	0.35	2.39e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg19847130	chr8:10466454	RP1L1	-0.33	-5.09	-0.31	7.06e-7	Retinal vascular caliber;
KIRP	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.82	-7.18	-0.42	8.11e-12	Hip circumference adjusted for BMI;
KIRP	cis	rs6132905	0.590	rs112911492	chr20:2627936	T/C	cg24848351	chr20:2622020	TMC2	-0.55	-5.19	-0.31	4.31e-7	Mumps;
KIRP	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg25801113	chr15:45476975	SHF	-0.46	-7.92	-0.45	8.01e-14	Uric acid levels;
KIRP	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.0	10.82	0.57	1.47e-22	Cognitive test performance;
KIRP	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg07308232	chr7:1071921	C7orf50	-0.51	-5.06	-0.31	8.05e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	8.18	0.46	1.48e-14	Joint mobility (Beighton score);
KIRP	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.6	7.86	0.45	1.2e-13	Systemic lupus erythematosus;
KIRP	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.44	-5.46	-0.33	1.17e-7	Aortic root size;
KIRP	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	7.96	0.45	6.5e-14	Total body bone mineral density;
KIRP	cis	rs6840360	1.000	rs17360475	chr4:152671640	C/G	cg22705602	chr4:152727874	NA	0.5	7.97	0.45	5.96e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg05370193	chr1:21551575	ECE1	0.41	5.81	0.35	1.91e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg06289844	chr6:126071538	HEY2	0.4	5.9	0.35	1.2e-8	Brugada syndrome;
KIRP	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06212747	chr3:49208901	KLHDC8B	0.88	13.48	0.65	2.2e-31	Menarche (age at onset);
KIRP	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.48	5.09	0.31	7.06e-7	Alzheimer's disease;
KIRP	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.46	-0.43	1.52e-12	Alzheimer's disease (late onset);
KIRP	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg14091149	chr1:16273971	ZBTB17	0.37	5.52	0.33	8.39e-8	Dilated cardiomyopathy;
KIRP	cis	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg26585981	chr11:48327164	OR4S1	-0.43	-5.29	-0.32	2.7e-7	HDL cholesterol;
KIRP	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.42	5.58	0.34	6.4e-8	Childhood ear infection;
KIRP	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.39	0.51	4.38e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.56	6.75	0.4	1.08e-10	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21643547	chr1:205240462	TMCC2	-0.7	-10.64	-0.56	5.51e-22	Red blood cell count;
KIRP	cis	rs732716	0.740	rs62129356	chr19:4400314	C/T	cg03719555	chr19:4455413	UBXN6	0.5	7.53	0.43	9.8e-13	Mean corpuscular volume;
KIRP	cis	rs9372498	0.536	rs7356947	chr6:118767920	A/G	cg18833306	chr6:118973337	C6orf204	-0.46	-4.95	-0.3	1.4e-6	Diastolic blood pressure;
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.68	-7.94	-0.45	7.12e-14	Longevity;Endometriosis;
KIRP	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	7.91	0.45	8.67e-14	Post bronchodilator FEV1;
KIRP	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.78	-10.98	-0.57	4.32e-23	Morning vs. evening chronotype;
KIRP	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg18404041	chr3:52824283	ITIH1	-0.46	-5.88	-0.35	1.35e-8	Schizophrenia;
KIRP	cis	rs9534288	0.619	rs9526146	chr13:46680854	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-7.76	-0.44	2.32e-13	Blood protein levels;
KIRP	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg23188430	chr6:125850052	NA	-0.34	-5.31	-0.32	2.48e-7	Brugada syndrome;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg16020556	chr5:96126443	ERAP1	0.48	6.35	0.38	1.01e-9	Interleukin-4 levels;
KIRP	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg01657329	chr11:68192670	LRP5	-0.49	-5.28	-0.32	2.77e-7	Total body bone mineral density;
KIRP	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg19407955	chr1:165599744	MGST3	-0.48	-5.42	-0.33	1.45e-7	Total ventricular volume;
KIRP	cis	rs501120	1.000	rs518594	chr10:44757107	T/C	cg09554077	chr10:44749378	NA	0.73	11.42	0.59	1.65e-24	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.52	-6.9	-0.4	4.34e-11	Bipolar disorder;
KIRP	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.92	13.12	0.64	3.66e-30	Bladder cancer;
KIRP	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.67	9.65	0.52	6.87e-19	Intelligence (multi-trait analysis);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18585464	chr15:48429067	SLC24A5	-0.44	-6.74	-0.39	1.11e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.5	6.63	0.39	2.1e-10	Longevity;Endometriosis;
KIRP	cis	rs1448094	0.791	rs11117122	chr12:86337749	A/C	cg02569458	chr12:86230093	RASSF9	0.37	5.36	0.32	1.95e-7	Major depressive disorder;
KIRP	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg09455208	chr3:40491958	NA	0.35	6.31	0.37	1.29e-9	Renal cell carcinoma;
KIRP	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.94	16.31	0.72	4.84e-41	Breast cancer;
KIRP	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg06307176	chr5:131281290	NA	0.53	5.82	0.35	1.78e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs394563	0.781	rs61516098	chr6:149794289	A/T	cg03678062	chr6:149772716	ZC3H12D	-0.32	-4.9	-0.3	1.76e-6	Dupuytren's disease;
KIRP	cis	rs2279817	0.863	rs12757678	chr1:17983680	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-8.33	-0.47	5.51e-15	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25402610	chr7:127807500	NA	0.42	6.4	0.38	7.76e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs526231	0.543	rs34779	chr5:102452768	A/G	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.82	-8.57	-0.48	1.12e-15	Gut microbiome composition (summer);
KIRP	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22618164	chr12:122356400	WDR66	0.67	9.16	0.5	2.1e-17	Mean corpuscular volume;
KIRP	cis	rs4730250	0.707	rs257375	chr7:106799043	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-9.09	-0.5	3.39e-17	Osteoarthritis;
KIRP	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg08888203	chr3:10149979	C3orf24	0.46	4.89	0.3	1.79e-6	Alzheimer's disease;
KIRP	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg05527609	chr1:210001259	C1orf107	-0.51	-5.58	-0.34	6.2e-8	Red blood cell count;
KIRP	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.72	9.35	0.51	5.77e-18	Coronary artery disease;
KIRP	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg05347473	chr6:146136440	FBXO30	0.62	8.93	0.49	9.98e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	1.0	17.72	0.75	7.68e-46	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg02462569	chr6:150064036	NUP43	-0.43	-6.46	-0.38	5.59e-10	Lung cancer;
KIRP	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg04166393	chr7:2884313	GNA12	0.47	6.0	0.36	6.91e-9	Height;
KIRP	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg21546286	chr11:48923668	NA	-0.47	-6.15	-0.36	3.17e-9	HDL cholesterol;
KIRP	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg00631329	chr6:26305371	NA	-0.71	-9.06	-0.5	4.06e-17	Educational attainment;
KIRP	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg23950597	chr19:37808831	NA	0.59	6.39	0.38	8.04e-10	Coronary artery calcification;
KIRP	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	7.92	0.45	8.32e-14	Coffee consumption (cups per day);
KIRP	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.84	-0.6	6.9e-26	Longevity;
KIRP	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.76	9.14	0.5	2.34e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.33	-0.32	2.27e-7	Primary biliary cholangitis;
KIRP	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg11839771	chr15:80205821	ST20	-0.43	-6.45	-0.38	5.73e-10	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.69	-8.32	-0.47	5.99e-15	Blood protein levels;
KIRP	trans	rs12517041	1.000	rs74322845	chr5:23293404	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	trans	rs7142881	0.815	rs6571438	chr14:32080009	C/T	cg06037943	chr4:109088038	LEF1;LOC641518	-0.49	-6.13	-0.36	3.53e-9	Response to iloperidone treatment (QT prolongation);
KIRP	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg16141378	chr3:129829833	LOC729375	0.51	6.07	0.36	4.82e-9	Neuroticism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09268874	chr1:85140335	SSX2IP	-0.46	-7.08	-0.41	1.52e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7520050	0.966	rs12561806	chr1:46396776	C/T	cg03146154	chr1:46216737	IPP	-0.41	-5.27	-0.32	2.93e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.3	-0.42	3.87e-12	Aortic root size;
KIRP	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7113874	0.659	rs57757082	chr11:8528653	T/A	cg08015107	chr11:8618950	NA	-0.51	-6.78	-0.4	8.79e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs4950322	0.518	rs114226486	chr1:146801833	A/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.63e-7	Protein quantitative trait loci;
KIRP	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.63	9.16	0.5	2.03e-17	Resting heart rate;
KIRP	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg12140854	chr5:148520817	ABLIM3	-0.53	-5.98	-0.36	7.62e-9	Breast cancer;
KIRP	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg21427119	chr20:30132790	HM13	-0.53	-6.0	-0.36	6.93e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.5	6.67	0.39	1.7e-10	Depressive symptoms;
KIRP	cis	rs918629	0.798	rs3777162	chr5:95293412	G/A	cg16656078	chr5:95278638	ELL2	-0.47	-6.75	-0.4	1.09e-10	IgG glycosylation;
KIRP	trans	rs11165623	0.564	rs11165658	chr1:96985670	A/G	cg10631902	chr5:14652156	NA	-0.52	-6.94	-0.4	3.56e-11	Hip circumference;Waist circumference;
KIRP	cis	rs9473924	0.632	rs9463654	chr6:50835607	A/G	cg03432817	chr6:50765336	NA	-0.35	-5.38	-0.32	1.74e-7	Body mass index;
KIRP	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.57	-6.99	-0.41	2.57e-11	Aortic root size;
KIRP	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-6.81	-0.4	7.42e-11	Total cholesterol levels;
KIRP	cis	rs2273669	0.667	rs11754955	chr6:109287459	A/G	cg05315195	chr6:109294784	ARMC2	-0.63	-6.21	-0.37	2.29e-9	Prostate cancer;
KIRP	cis	rs77972916	0.536	rs62137421	chr2:43594091	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.37	-0.32	1.78e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs9513627	1.000	rs9517755	chr13:100168408	C/A	cg25919922	chr13:100150906	NA	0.66	5.18	0.31	4.56e-7	Obesity-related traits;
KIRP	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg17644776	chr2:200775616	C2orf69	0.56	4.89	0.3	1.86e-6	Schizophrenia;
KIRP	cis	rs904251	0.734	rs2797790	chr6:37447075	A/G	cg21415424	chr6:37503074	NA	0.33	4.95	0.3	1.39e-6	Cognitive performance;
KIRP	cis	rs2273669	0.915	rs3734651	chr6:109295040	T/C	cg05315195	chr6:109294784	ARMC2	-0.51	-5.79	-0.35	2.19e-8	Prostate cancer;
KIRP	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.13	-0.41	1.15e-11	Bone mineral density;
KIRP	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06481639	chr22:41940642	POLR3H	0.71	7.25	0.42	5.26e-12	Vitiligo;
KIRP	cis	rs12282928	1.000	rs12294937	chr11:48337466	T/C	cg26585981	chr11:48327164	OR4S1	0.52	6.28	0.37	1.54e-9	Migraine - clinic-based;
KIRP	cis	rs17023223	0.537	rs1057991	chr1:119575170	C/A	cg18261050	chr1:119551319	NA	0.52	6.89	0.4	4.64e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg04731861	chr2:219085781	ARPC2	-0.22	-5.58	-0.34	6.19e-8	Colorectal cancer;
KIRP	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg02258303	chr16:87377426	FBXO31	-0.61	-8.93	-0.49	1.01e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13149662	chr12:122017211	KDM2B	0.42	6.15	0.37	3.19e-9	Parkinson's disease;
KIRP	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.56	-0.43	8.05e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.45	5.59	0.34	5.96e-8	Testicular germ cell tumor;
KIRP	cis	rs7590368	1.000	rs13429247	chr2:10960529	A/G	cg15705551	chr2:10952987	PDIA6	0.45	4.92	0.3	1.56e-6	Educational attainment (years of education);
KIRP	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-0.41	-5.51	-0.33	9.08e-8	Acne (severe);
KIRP	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.95e-10	Hypertriglyceridemia;
KIRP	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg13147721	chr7:65941812	NA	-1.01	-6.86	-0.4	5.39e-11	Diabetic kidney disease;
KIRP	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.53	-8.14	-0.46	1.96e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg02811702	chr13:24901961	NA	0.43	5.53	0.33	8.37e-8	Obesity-related traits;
KIRP	cis	rs9467160	0.834	rs17247566	chr6:24450404	A/C	cg20631270	chr6:24437470	GPLD1	-0.46	-4.91	-0.3	1.69e-6	Liver enzyme levels;
KIRP	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.9	-14.34	-0.67	2.55e-34	Height;
KIRP	cis	rs17095355	0.901	rs7069128	chr10:111760075	C/T	cg00817464	chr10:111662876	XPNPEP1	0.42	6.09	0.36	4.33e-9	Biliary atresia;
KIRP	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.33	8.71	0.49	4.51e-16	Rheumatoid arthritis;
KIRP	trans	rs12517041	1.000	rs10057246	chr5:23294721	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.9	-8.58	-0.48	1.09e-15	Calcium levels;
KIRP	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg18501202	chr6:125855421	NA	-0.34	-5.14	-0.31	5.65e-7	Brugada syndrome;
KIRP	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.52	-7.12	-0.41	1.17e-11	Obesity-related traits;
KIRP	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg24203234	chr3:128598194	ACAD9	0.44	5.01	0.3	1.06e-6	IgG glycosylation;
KIRP	cis	rs6088813	1.000	rs6579234	chr20:33983485	A/G	cg14752227	chr20:34000481	UQCC	-0.5	-6.54	-0.39	3.47e-10	Height;
KIRP	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg03115019	chr17:80708279	FN3K	-0.43	-5.21	-0.32	4.05e-7	Glycated hemoglobin levels;
KIRP	cis	rs7756236	0.521	rs9462209	chr6:36628042	T/G	cg08179530	chr6:36648295	CDKN1A	0.45	5.88	0.35	1.35e-8	QRS duration;
KIRP	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-17.08	-0.74	1.11e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg15691649	chr6:25882328	NA	-0.42	-5.13	-0.31	5.92e-7	Blood metabolite levels;
KIRP	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs7106204	0.748	rs6484024	chr11:24210079	T/C	ch.11.24196551F	chr11:24239977	NA	0.8	9.34	0.51	6.16e-18	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg05418105	chr22:50981406	NA	0.42	5.37	0.32	1.86e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.69	10.21	0.55	1.25e-20	Prostate cancer;
KIRP	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.78	7.81	0.45	1.67e-13	Bipolar disorder;
KIRP	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg24375607	chr4:120327624	NA	0.57	6.53	0.38	3.64e-10	Corneal astigmatism;
KIRP	cis	rs7539542	0.529	rs7536140	chr1:202878808	C/T	cg19681188	chr1:202830198	LOC148709	-0.46	-4.95	-0.3	1.38e-6	Mean platelet volume;
KIRP	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18932078	chr1:2524107	MMEL1	-0.46	-6.36	-0.38	1e-9	Ulcerative colitis;
KIRP	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg24642439	chr20:33292090	TP53INP2	0.51	5.76	0.34	2.56e-8	Height;
KIRP	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg11846333	chr4:119757529	SEC24D	1.17	7.05	0.41	1.77e-11	Cannabis dependence symptom count;
KIRP	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.59	-7.64	-0.44	4.94e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.95	15.73	0.71	4.59e-39	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg19592336	chr6:28129416	ZNF389	0.52	5.88	0.35	1.36e-8	Depression;
KIRP	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.79	9.45	0.52	2.81e-18	Corneal astigmatism;
KIRP	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	cis	rs9584850	0.834	rs7334078	chr13:99120484	C/T	cg20750642	chr13:99100586	FARP1	0.52	6.28	0.37	1.48e-9	Neuroticism;
KIRP	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg05896524	chr21:47604654	C21orf56	-0.46	-5.57	-0.33	6.67e-8	Testicular germ cell tumor;
KIRP	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg27205649	chr11:78285834	NARS2	0.71	7.9	0.45	9.56e-14	Alzheimer's disease (survival time);
KIRP	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg16511985	chr3:153974050	SGEF	0.39	5.34	0.32	2.1e-7	Coronary artery disease;
KIRP	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.84	13.25	0.65	1.35e-30	Prostate cancer;
KIRP	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg15269541	chr15:43626905	ADAL	-0.41	-4.89	-0.3	1.79e-6	Lung cancer in ever smokers;
KIRP	trans	rs9300039	0.803	rs12275923	chr11:41861950	A/C	cg02094273	chr11:86636018	NA	0.5	6.03	0.36	5.97e-9	Type 2 diabetes;
KIRP	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.5	-5.61	-0.34	5.56e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	-0.41	-4.98	-0.3	1.21e-6	Lung cancer;
KIRP	cis	rs11166927	0.901	rs7014257	chr8:140802694	G/T	cg16909799	chr8:140841666	TRAPPC9	0.71	10.4	0.55	3.09e-21	Pediatric non-alcoholic fatty liver disease activity score;
KIRP	cis	rs12468557	0.527	rs11685955	chr2:211485476	T/A	cg07063745	chr2:211341572	LANCL1;CPS1	-0.46	-5.89	-0.35	1.26e-8	Body mass index in asthmatics;
KIRP	cis	rs2617583	0.967	rs2937640	chr5:1443604	C/T	cg07151155	chr5:1473589	LPCAT1	-0.42	-5.86	-0.35	1.49e-8	Breast cancer;
KIRP	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.84	-0.53	1.76e-19	Height;
KIRP	cis	rs2841233	0.681	rs2582558	chr14:105347488	A/G	cg01147727	chr14:105363015	KIAA0284	0.38	4.93	0.3	1.49e-6	IgG glycosylation;
KIRP	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg09365446	chr1:150670422	GOLPH3L	-0.38	-5.02	-0.3	9.82e-7	Tonsillectomy;
KIRP	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.31	-7.05	-0.41	1.78e-11	Mean corpuscular volume;
KIRP	cis	rs45544231	0.569	rs4784224	chr16:52580247	C/A	cg09051775	chr16:52580266	TOX3	-0.41	-5.56	-0.33	7.04e-8	Restless legs syndrome;
KIRP	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.78	-9.43	-0.52	3.18e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.36	-8.12	-0.46	2.29e-14	Cutaneous nevi;
KIRP	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.55	-7.1	-0.41	1.34e-11	Breast cancer;
KIRP	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.48	-11.49	-0.59	9.53e-25	Diabetic kidney disease;
KIRP	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg18402987	chr7:1209562	NA	0.72	4.85	0.3	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.17	10.24	0.55	1e-20	Skin colour saturation;
KIRP	cis	rs1635	0.574	rs16893827	chr6:28197469	T/C	cg24848467	chr6:28134517	ZNF389	-0.78	-5.04	-0.31	8.92e-7	Schizophrenia;
KIRP	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.7	9.12	0.5	2.73e-17	Cognitive function;
KIRP	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg12435725	chr3:58293450	RPP14	-0.5	-5.18	-0.31	4.68e-7	Cholesterol, total;
KIRP	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.39e-11	Arsenic metabolism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg06798480	chr3:9439221	SETD5;LOC440944	-0.56	-6.45	-0.38	5.84e-10	Interleukin-4 levels;
KIRP	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.53	-6.75	-0.4	1.08e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6882046	0.513	rs447801	chr5:88002653	T/C	cg22951263	chr5:87985283	NA	-0.47	-6.71	-0.39	1.35e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.41	0.33	1.49e-7	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.23	-0.46	1.08e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.0	-0.3	1.1e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg01677386	chr11:118938358	VPS11	-0.44	-4.92	-0.3	1.61e-6	Coronary artery disease;
KIRP	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.5	-0.33	9.44e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1823913	0.503	rs35562914	chr2:192203695	A/G	cg12404831	chr2:192114017	MYO1B	0.51	7.02	0.41	2.18e-11	Obesity-related traits;
KIRP	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg19752551	chr11:57585705	CTNND1	0.8	13.22	0.64	1.61e-30	Schizophrenia;
KIRP	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.42	-5.38	-0.32	1.71e-7	Abdominal aortic aneurysm;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.23	-4.9	-0.3	1.74e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg15880211	chr22:50250494	ZBED4	-0.67	-7.48	-0.43	1.3e-12	Schizophrenia;
KIRP	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.75	-10.65	-0.56	5.04e-22	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.86	9.7	0.53	4.77e-19	High light scatter reticulocyte count;
KIRP	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	2.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs112591243	0.570	rs17393980	chr21:47971060	C/T	cg26904215	chr21:47823096	PCNT	-0.8	-5.15	-0.31	5.31e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.54	7.04	0.41	1.91e-11	Bladder cancer;
KIRP	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.42	-5.51	-0.33	8.98e-8	Abdominal aortic aneurysm;
KIRP	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.86	14.22	0.67	6.99e-34	Prostate cancer;
KIRP	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21545522	chr1:205238299	TMCC2	-0.55	-7.36	-0.43	2.68e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.53	7.85	0.45	1.29e-13	Major depressive disorder;
KIRP	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.95	15.42	0.7	5.39e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	6.28	0.37	1.48e-9	Height;
KIRP	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg12549451	chr6:135224345	NA	0.42	5.07	0.31	7.82e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.66	12.59	0.63	2.27e-28	Bone mineral density;
KIRP	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg25753631	chr6:25732923	NA	-0.28	-5.3	-0.32	2.53e-7	Iron status biomarkers;
KIRP	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg01943577	chr7:158741284	NA	-0.37	-5.11	-0.31	6.57e-7	Height;
KIRP	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.55	6.48	0.38	4.93e-10	Multiple sclerosis;
KIRP	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.99	-0.41	2.54e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.55	7.03	0.41	2e-11	Eye color traits;
KIRP	cis	rs7404928	0.957	rs7205440	chr16:23902624	T/G	cg21745164	chr16:23765304	CHP2	-0.36	-5.16	-0.31	4.99e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-6.57	-0.39	3e-10	Mean corpuscular volume;
KIRP	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg25547332	chr5:131281432	NA	-0.45	-5.35	-0.32	2.01e-7	Life satisfaction;
KIRP	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.54	-7.2	-0.42	7.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.8	-0.45	1.71e-13	Gut microbiome composition (summer);
KIRP	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg05315796	chr3:52349193	DNAH1	-0.41	-6.02	-0.36	6.27e-9	Bipolar disorder;
KIRP	cis	rs9790314	0.613	rs13092102	chr3:160598093	C/G	cg04691961	chr3:161091175	C3orf57	0.45	6.38	0.38	8.8e-10	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.94	-0.45	7.17e-14	Triglycerides;
KIRP	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04013166	chr16:89971882	TCF25	0.59	4.95	0.3	1.36e-6	Skin colour saturation;
KIRP	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.58	8.48	0.48	2.04e-15	Ovarian reserve;
KIRP	cis	rs3026101	0.671	rs1071705	chr17:5290033	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs15676	0.733	rs2900269	chr9:131569878	G/T	cg00228799	chr9:131580591	ENDOG	0.55	5.87	0.35	1.41e-8	Blood metabolite levels;
KIRP	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	1.12	8.27	0.47	8.52e-15	Skin colour saturation;
KIRP	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg06115741	chr20:33292138	TP53INP2	0.46	6.27	0.37	1.64e-9	Coronary artery disease;
KIRP	cis	rs1891275	0.515	rs7098763	chr10:93444827	C/T	cg07889827	chr10:93443413	NA	-0.41	-7.03	-0.41	2.04e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs62025270	0.547	rs416916	chr15:86192416	G/A	cg10818794	chr15:86012489	AKAP13	0.41	4.94	0.3	1.43e-6	Idiopathic pulmonary fibrosis;
KIRP	cis	rs7714584	1.000	rs7705542	chr5:150228318	G/A	cg22134413	chr5:150180641	NA	0.58	5.21	0.32	3.98e-7	Crohn's disease;
KIRP	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg05220968	chr6:146057943	EPM2A	0.39	5.09	0.31	7.06e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg22676075	chr6:135203613	NA	0.51	7.3	0.42	3.94e-12	Red blood cell count;
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.79	-12.12	-0.61	8e-27	Multiple myeloma (IgH translocation);
KIRP	cis	rs6546324	0.625	rs2861645	chr2:67800338	T/A	cg15745817	chr2:67799979	NA	-0.64	-7.02	-0.41	2.15e-11	Endometriosis;
KIRP	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.3	5.06	0.31	8.08e-7	Electrocardiographic conduction measures;
KIRP	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg05973401	chr12:123451056	ABCB9	0.56	6.45	0.38	5.88e-10	Neutrophil percentage of white cells;
KIRP	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	7.93	0.45	7.46e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.47	-0.48	2.2e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	1.1	18.36	0.76	5.28e-48	Cognitive function;
KIRP	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg01620082	chr3:125678407	NA	0.99	7.21	0.42	6.91e-12	Depression;
KIRP	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.77	-0.53	2.99e-19	Neuroticism;
KIRP	cis	rs10958369	0.613	rs7829521	chr8:54433888	C/T	cg12485204	chr8:54507357	NA	0.42	5.41	0.33	1.51e-7	Response to antineoplastic agents;
KIRP	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	7.38	0.43	2.5e-12	Aortic root size;
KIRP	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg00864860	chr1:7907996	UTS2	-0.54	-6.39	-0.38	8.17e-10	Crohn's disease;
KIRP	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.54	7.76	0.44	2.32e-13	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg18693004	chr7:21521627	SP4	-0.44	-6.69	-0.39	1.49e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.94	7.67	0.44	4.09e-13	Alzheimer's disease (late onset);
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg23130739	chr14:100563887	EVL	0.44	6.73	0.39	1.2e-10	Warfarin maintenance dose;
KIRP	cis	rs2219968	1.000	rs13276048	chr8:78975258	G/A	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg15556689	chr8:8085844	FLJ10661	0.57	7.5	0.43	1.15e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12476592	0.602	rs964880	chr2:63826932	C/A	cg17519650	chr2:63277830	OTX1	-0.46	-5.15	-0.31	5.47e-7	Childhood ear infection;
KIRP	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.45	6.09	0.36	4.38e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7870753	0.628	rs7862759	chr9:99135738	G/A	cg25260653	chr9:99212216	HABP4	0.49	5.04	0.31	8.85e-7	Height;
KIRP	cis	rs4908768	0.906	rs6656249	chr1:8581015	A/C	cg25722041	chr1:8623473	RERE	0.68	8.98	0.5	7.29e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.96	10.2	0.55	1.37e-20	Gut microbiome composition (summer);
KIRP	cis	rs7712401	0.601	rs185009	chr5:122273767	A/G	cg19412675	chr5:122181750	SNX24	0.47	5.2	0.31	4.22e-7	Mean platelet volume;
KIRP	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.98	0.36	8.01e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.83	8.71	0.49	4.58e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg23587288	chr2:27483067	SLC30A3	-0.67	-7.63	-0.44	5.13e-13	Blood metabolite levels;
KIRP	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg16797656	chr11:68205561	LRP5	0.37	4.88	0.3	1.93e-6	Total body bone mineral density;
KIRP	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.49	-6.22	-0.37	2.17e-9	Body mass index;
KIRP	cis	rs193541	0.632	rs2407402	chr5:122107105	G/C	cg19412675	chr5:122181750	SNX24	0.57	5.96	0.36	8.7e-9	Glucose homeostasis traits;
KIRP	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.53	7.41	0.43	1.97e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg23594656	chr7:65796392	TPST1	0.38	5.5	0.33	9.3e-8	Aortic root size;
KIRP	cis	rs3779635	0.844	rs56330356	chr8:27278847	A/G	cg23736307	chr8:27182930	PTK2B	0.46	5.78	0.35	2.21e-8	Neuroticism;
KIRP	cis	rs4073416	0.510	rs2268956	chr14:66090145	G/A	cg03016385	chr14:66212404	NA	-0.54	-6.6	-0.39	2.57e-10	N-glycan levels;
KIRP	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg19592336	chr6:28129416	ZNF389	0.53	5.91	0.35	1.14e-8	Depression;
KIRP	cis	rs6545883	0.868	rs6545887	chr2:61828818	C/G	cg15711740	chr2:61764176	XPO1	-0.59	-8.1	-0.46	2.51e-14	Tuberculosis;
KIRP	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg02023728	chr11:77925099	USP35	-0.31	-5.36	-0.32	1.89e-7	Alzheimer's disease (survival time);
KIRP	cis	rs1165472	0.806	rs7529271	chr1:56150184	C/A	cg11523071	chr1:56160889	NA	-0.64	-8.22	-0.46	1.14e-14	Paclitaxel-induced neuropathy;
KIRP	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17507749	chr15:85114479	UBE2QP1	0.77	8.64	0.48	7.44e-16	Schizophrenia;
KIRP	cis	rs701145	0.585	rs1727949	chr3:153875713	A/G	cg10247383	chr3:153839028	SGEF	-0.61	-5.5	-0.33	9.61e-8	Coronary artery disease;
KIRP	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.11	0.64	4.03e-30	Exhaled nitric oxide output;
KIRP	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.42	-5.04	-0.31	9.05e-7	Body mass index;
KIRP	cis	rs42648	0.564	rs10257064	chr7:89802596	G/A	cg25739043	chr7:89950458	NA	-0.34	-5.29	-0.32	2.7e-7	Homocysteine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg12533308	chr21:47878746	DIP2A	0.51	6.5	0.38	4.36e-10	Parkinson's disease;
KIRP	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg22903657	chr4:1355424	KIAA1530	0.39	5.47	0.33	1.11e-7	Obesity-related traits;
KIRP	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg25801113	chr15:45476975	SHF	0.42	7.83	0.45	1.46e-13	Uric acid levels;
KIRP	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg20673091	chr1:2541236	MMEL1	0.68	9.63	0.52	7.73e-19	Ulcerative colitis;
KIRP	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg00361562	chr2:198649771	BOLL	-0.49	-5.04	-0.31	9.11e-7	Ulcerative colitis;
KIRP	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg14159672	chr1:205819179	PM20D1	-0.42	-5.29	-0.32	2.76e-7	Menarche (age at onset);
KIRP	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.48	-6.71	-0.39	1.35e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg08975724	chr8:8085496	FLJ10661	0.52	6.59	0.39	2.66e-10	Neuroticism;
KIRP	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.44	-5.87	-0.35	1.41e-8	Coronary artery disease;
KIRP	cis	rs4363385	0.530	rs6663448	chr1:152894627	C/T	cg25856811	chr1:152973957	SPRR3	-0.39	-5.49	-0.33	9.93e-8	Inflammatory skin disease;
KIRP	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.42	-7.39	-0.43	2.22e-12	Refractive error;
KIRP	cis	rs3204270	0.759	rs62075725	chr17:79611510	A/G	cg18367735	chr17:79674897	NA	0.66	6.18	0.37	2.69e-9	Dental caries;
KIRP	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	1.05	19.07	0.77	2.22e-50	Systemic lupus erythematosus;
KIRP	cis	rs6540559	0.673	rs17015183	chr1:209948711	A/C	cg22029157	chr1:209979665	IRF6	0.52	5.89	0.35	1.28e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg02527881	chr3:46936655	PTH1R	-0.37	-5.32	-0.32	2.32e-7	Colorectal cancer;
KIRP	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg11608241	chr8:8085544	FLJ10661	-0.4	-5.13	-0.31	5.86e-7	Mood instability;
KIRP	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.75	9.72	0.53	4.24e-19	Coronary artery disease;
KIRP	cis	rs10782582	0.622	rs10873795	chr1:76373684	T/C	cg10523679	chr1:76189770	ACADM	-0.36	-5.16	-0.31	5.06e-7	Daytime sleep phenotypes;
KIRP	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.4	-5.8	-0.35	2.07e-8	Height;
KIRP	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02972257	chr16:68554789	NA	-0.65	-6.68	-0.39	1.61e-10	Ulcerative colitis;
KIRP	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.88	0.45	1.06e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg26879696	chr10:114206778	VTI1A;ZDHHC6	-0.6	-7.38	-0.43	2.44e-12	Interleukin-4 levels;
KIRP	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.51	-0.38	4.14e-10	Aortic root size;
KIRP	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	15.39	0.7	6.8e-38	Alzheimer's disease;
KIRP	cis	rs11874712	0.527	rs7359800	chr18:43649187	G/C	cg26436583	chr18:43649176	PSTPIP2	-0.48	-6.98	-0.41	2.69e-11	Migraine - clinic-based;
KIRP	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg07636037	chr3:49044803	WDR6	-0.77	-5.22	-0.32	3.83e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23954489	chr18:30050398	FAM59A	-0.49	-6.36	-0.38	9.85e-10	Metabolic traits;
KIRP	cis	rs6466055	0.720	rs35757884	chr7:105020534	G/T	cg04380332	chr7:105027541	SRPK2	-0.65	-9.75	-0.53	3.44e-19	Schizophrenia;
KIRP	cis	rs5753037	0.869	rs41159	chr22:30407364	A/G	cg27665648	chr22:30112403	NA	0.35	4.95	0.3	1.37e-6	Type 1 diabetes;
KIRP	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18357526	chr6:26021779	HIST1H4A	0.52	6.72	0.39	1.23e-10	Height;
KIRP	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.71	6.66	0.39	1.74e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg14673194	chr17:80132900	CCDC57	-0.73	-7.91	-0.45	8.6e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg13453750	chr1:205783389	SLC41A1	-0.46	-6.91	-0.4	4.23e-11	Menarche (age at onset);
KIRP	cis	rs16828019	0.568	rs2236129	chr1:41617914	C/G	cg03387723	chr1:41708464	SCMH1	-0.73	-5.05	-0.31	8.73e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg21681396	chr1:34630803	CSMD2	-0.51	-6.33	-0.37	1.14e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-8.51	-0.48	1.74e-15	Neuroticism;
KIRP	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.78	-11.05	-0.58	2.57e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.72	-9.69	-0.53	5.02e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg01877450	chr7:97915802	BRI3	-0.54	-7.08	-0.41	1.46e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9810890	1.000	rs73198852	chr3:128508858	A/C	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg01689657	chr7:91764605	CYP51A1	0.4	5.58	0.34	6.33e-8	Breast cancer;
KIRP	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	0.7	5.95	0.35	9.08e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	ch.8.33884649F	chr8:33765107	NA	0.61	7.67	0.44	3.9e-13	Body mass index;
KIRP	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15369054	chr17:80825471	TBCD	-0.59	-6.65	-0.39	1.84e-10	Breast cancer;
KIRP	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.82	-0.4	6.94e-11	Heart rate;
KIRP	cis	rs7809950	0.817	rs2701679	chr7:107283908	A/G	cg23024343	chr7:107201750	COG5	0.47	6.7	0.39	1.4e-10	Coronary artery disease;
KIRP	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.69	7.71	0.44	3.21e-13	Exhaled nitric oxide output;
KIRP	cis	rs4919687	0.550	rs12775883	chr10:104485301	G/A	cg04362960	chr10:104952993	NT5C2	0.44	5.1	0.31	6.9e-7	Colorectal cancer;
KIRP	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.67	-0.66	5.1e-32	Monocyte count;
KIRP	cis	rs11718455	0.921	rs1404482	chr3:43997282	A/G	cg21419209	chr3:44054225	NA	-0.71	-8.83	-0.49	2.07e-16	Coronary artery disease;
KIRP	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.5	-6.55	-0.39	3.35e-10	Calcium levels;
KIRP	cis	rs9815354	0.680	rs73073296	chr3:42028074	G/A	cg03022575	chr3:42003672	ULK4	0.8	7.66	0.44	4.31e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.56	6.85	0.4	5.8200000000000003e-11	Aortic root size;
KIRP	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.25	5.24	0.32	3.43e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23486345	chr6:99797485	C6orf168	-0.46	-6.99	-0.41	2.5e-11	Metabolic traits;
KIRP	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg09571762	chr12:39539558	NA	0.34	4.98	0.3	1.21e-6	Morning vs. evening chronotype;
KIRP	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.93	-14.58	-0.68	3.92e-35	Systemic lupus erythematosus;
KIRP	cis	rs1050631	0.592	rs13425	chr18:33760150	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.17	0.31	4.96e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg14092571	chr14:90743983	NA	-0.39	-4.99	-0.3	1.14e-6	Mortality in heart failure;
KIRP	cis	rs3126085	0.560	rs12027445	chr1:152344787	A/T	cg26876637	chr1:152193138	HRNR	-0.57	-6.22	-0.37	2.11e-9	Atopic dermatitis;
KIRP	cis	rs914615	0.552	rs4460629	chr1:155135335	T/C	cg02153340	chr1:155202674	NA	-0.47	-7.07	-0.41	1.63e-11	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.78	6.79	0.4	8.53e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg07689907	chr11:61582574	FADS1	0.58	7.11	0.41	1.24e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs4356932	0.967	rs4478212	chr4:76958899	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	1.1	17.65	0.75	1.38e-45	Migraine;
KIRP	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	0.98	11.74	0.6	1.4e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24040576	chr1:246670459	SMYD3	0.49	6.13	0.36	3.5e-9	Parkinson's disease;
KIRP	cis	rs8179	0.514	rs11773884	chr7:92285123	A/G	cg15732164	chr7:92237376	CDK6	-0.37	-4.84	-0.3	2.27e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg16584676	chr17:46985605	UBE2Z	0.5	6.14	0.36	3.34e-9	Type 2 diabetes;
KIRP	cis	rs6142102	1.000	rs4911412	chr20:32716435	A/G	cg08999081	chr20:33150536	PIGU	0.5	5.94	0.35	9.48e-9	Skin pigmentation;
KIRP	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.72	-9.14	-0.5	2.33e-17	Coronary artery disease;
KIRP	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.61	-5.14	-0.31	5.71e-7	Putamen volume;
KIRP	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg00990874	chr7:1149470	C7orf50	-0.67	-7.22	-0.42	6.58e-12	Bronchopulmonary dysplasia;
KIRP	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg14972814	chr11:95582409	MTMR2	0.35	5.76	0.34	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.82	-11.21	-0.58	7.92e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.6	6.22	0.37	2.18e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg12315302	chr6:26189340	HIST1H4D	0.73	5.27	0.32	3.01e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg25039879	chr17:56429692	SUPT4H1	0.56	5.09	0.31	7.28e-7	Cognitive test performance;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10296688	chr13:52598408	UTP14C;ALG11	0.47	6.34	0.37	1.09e-9	Survival in pancreatic cancer;
KIRP	trans	rs12517041	0.935	rs1835047	chr5:23296627	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.96	-0.5	8.24e-17	Calcium levels;
KIRP	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14420117	chr14:74724299	VSX2	0.53	6.3	0.37	1.37e-9	Inflammatory biomarkers;
KIRP	cis	rs10491083	0.661	rs55748285	chr17:6557329	G/A	cg13067509	chr17:6538498	KIAA0753	0.76	7.16	0.42	9.06e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg22764044	chr5:178986830	RUFY1	0.44	6.32	0.37	1.21e-9	Lung cancer;
KIRP	cis	rs7640424	0.618	rs35798995	chr3:107914313	G/A	cg09227934	chr3:107805635	CD47	-0.36	-6.11	-0.36	3.85e-9	Body mass index;
KIRP	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.56	7.09	0.41	1.43e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.21	-31.45	-0.89	3.68e-88	Myeloid white cell count;
KIRP	cis	rs4865169	0.623	rs6838975	chr4:57739816	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.66	-8.02	-0.46	4.37e-14	Breast cancer;
KIRP	cis	rs8010715	0.636	rs2277482	chr14:24587795	C/T	cg23112188	chr14:24563095	PCK2	-0.34	-4.98	-0.3	1.2e-6	IgG glycosylation;
KIRP	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.63	11.04	0.58	2.73e-23	Bone mineral density;
KIRP	cis	rs4955124	0.818	rs4955220	chr3:32043207	A/G	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.65	5.91	0.35	1.14e-8	Schizophrenia;
KIRP	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.96	-13.25	-0.65	1.36e-30	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7831492	0.564	rs57596574	chr8:41609843	G/A	cg17182837	chr8:41585554	ANK1	-0.5	-6.87	-0.4	5.11e-11	Colorectal cancer;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12016809	chr21:47604291	C21orf56	0.49	7.08	0.41	1.5e-11	Testicular germ cell tumor;
KIRP	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	5.76	0.34	2.53e-8	Bipolar disorder;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17823829	chr1:202765754	KDM5B	0.46	6.92	0.4	4e-11	Survival in pancreatic cancer;
KIRP	trans	rs7819412	0.669	rs2409743	chr8:11070360	C/G	cg08975724	chr8:8085496	FLJ10661	-0.73	-10.02	-0.54	4.84e-20	Triglycerides;
KIRP	cis	rs853679	0.546	rs200954	chr6:27838764	C/G	cg21204522	chr6:27730016	NA	-0.71	-5.42	-0.33	1.41e-7	Depression;
KIRP	cis	rs7529073	0.815	rs1431983	chr1:214148772	A/C	cg24083324	chr1:214162604	PROX1	0.4	5.85	0.35	1.52e-8	Schizophrenia;
KIRP	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	1.3	9.0	0.5	6.34e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1050631	1.000	rs1785914	chr18:33700796	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.52	-6.31	-0.37	1.3e-9	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.58	-0.48	1.08e-15	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.65	5.22	0.32	3.81e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-10.31	-0.55	6.17e-21	Triglycerides;
KIRP	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.6	-7.77	-0.44	2.17e-13	Prudent dietary pattern;
KIRP	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg06565975	chr8:143823917	SLURP1	0.47	7.39	0.43	2.31e-12	Urinary tract infection frequency;
KIRP	cis	rs9547692	0.938	rs9547689	chr13:37451861	G/A	cg01493522	chr13:37497338	NA	-0.46	-5.54	-0.33	7.63e-8	Coronary artery disease;
KIRP	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.81	-8.89	-0.49	1.38e-16	Neuroblastoma;
KIRP	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-9.09	-0.5	3.46e-17	Retinal vascular caliber;
KIRP	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg24098013	chr12:12878779	APOLD1	0.64	6.43	0.38	6.77e-10	Lymphocyte counts;
KIRP	cis	rs2278796	0.881	rs11240325	chr1:204955329	A/G	cg17449235	chr1:204966235	NFASC	0.47	6.33	0.37	1.15e-9	Mean platelet volume;
KIRP	cis	rs554111	0.593	rs9426660	chr1:21520449	A/G	cg21184320	chr1:21044207	KIF17	0.39	5.85	0.35	1.53e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg08773314	chr2:239334832	ASB1	0.38	7.27	0.42	4.66e-12	Multiple system atrophy;
KIRP	cis	rs1163251	0.729	rs686362	chr1:120221011	T/C	cg19096424	chr1:120255104	PHGDH	0.45	5.43	0.33	1.35e-7	Blood metabolite levels;
KIRP	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07570687	chr10:102243282	WNT8B	0.43	5.08	0.31	7.3e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7870753	0.628	rs10820604	chr9:99192494	A/G	cg25260653	chr9:99212216	HABP4	0.57	5.8	0.35	2.02e-8	Height;
KIRP	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-9.16	-0.5	2.04e-17	Bladder cancer;
KIRP	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs714027	0.605	rs5763775	chr22:30503007	G/T	cg01021169	chr22:30184971	ASCC2	0.44	5.57	0.33	6.75e-8	Lymphocyte counts;
KIRP	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg13482628	chr17:19912719	NA	0.53	6.98	0.41	2.69e-11	Schizophrenia;
KIRP	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.91	13.25	0.65	1.37e-30	Total body bone mineral density;
KIRP	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.65	-7.91	-0.45	8.66e-14	Vitiligo;
KIRP	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.41	4.93	0.3	1.52e-6	Tonsillectomy;
KIRP	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.98	11.14	0.58	1.34e-23	Bronchopulmonary dysplasia;
KIRP	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	1.09	11.27	0.58	4.92e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	9.8	0.53	2.38e-19	Response to antipsychotic treatment;
KIRP	cis	rs7894051	1.000	rs4345885	chr10:135191311	T/C	cg24905316	chr10:135186343	ECHS1	0.56	5.18	0.31	4.53e-7	Lifespan;
KIRP	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.29	-5.14	-0.31	5.55e-7	Monocyte percentage of white cells;
KIRP	trans	rs4263408	0.934	rs9683743	chr4:39703194	A/C	cg26662261	chr17:71228709	C17orf80;FAM104A	-0.43	-6.11	-0.36	3.88e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg00852783	chr1:26633632	UBXN11	-0.56	-5.76	-0.34	2.49e-8	Obesity-related traits;
KIRP	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-12.28	-0.62	2.34e-27	Vitiligo;
KIRP	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.4	5.07	0.31	7.92e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg01872077	chr2:219646372	CYP27A1	0.38	4.98	0.3	1.19e-6	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.85	-9.76	-0.53	3.05e-19	Exhaled nitric oxide output;
KIRP	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.59	0.75	2.19e-45	Chronic sinus infection;
KIRP	cis	rs9488822	0.662	rs195532	chr6:116253765	T/G	cg26893134	chr6:116381904	FRK	0.19	5.14	0.31	5.72e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.71	8.34	0.47	5.26e-15	Corneal astigmatism;
KIRP	cis	rs2688608	0.967	rs2633299	chr10:75656754	T/G	cg19442545	chr10:75533431	FUT11	-0.36	-4.9	-0.3	1.72e-6	Inflammatory bowel disease;
KIRP	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.85	-0.3	2.15e-6	Type 2 diabetes;
KIRP	cis	rs6969780	0.915	rs886339	chr7:27190670	A/C	cg11410718	chr7:27170412	HOXA4	-0.44	-5.6	-0.34	5.81e-8	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2019216	0.903	rs1817415	chr17:21893338	C/G	cg22648282	chr17:21454238	C17orf51	-0.38	-5.06	-0.31	8.07e-7	Pelvic organ prolapse;
KIRP	cis	rs6120849	0.707	rs6088703	chr20:33676049	T/A	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.57	-7.81	-0.45	1.62e-13	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg22974920	chr21:40686053	BRWD1	0.5	6.03	0.36	6.1e-9	Cognitive function;
KIRP	trans	rs7710178	0.938	rs365187	chr5:155986686	G/C	cg23165310	chr3:181422217	SOX2OT	0.74	6.09	0.36	4.4e-9	Airway responsiveness in chronic obstructive pulmonary disease;
KIRP	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.88	6.27	0.37	1.63e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.66	-7.51	-0.43	1.1e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs12282928	0.625	rs12276188	chr11:48350692	G/A	cg26585981	chr11:48327164	OR4S1	0.5	6.07	0.36	4.69e-9	Migraine - clinic-based;
KIRP	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.63	-6.61	-0.39	2.41e-10	Menarche (age at onset);
KIRP	cis	rs9311676	0.656	rs11130635	chr3:58379143	A/G	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs6539288	0.677	rs2287163	chr12:107349294	C/T	cg21360079	chr12:107162445	NA	-0.46	-5.67	-0.34	4.01e-8	Total body bone mineral density;
KIRP	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	1.01	10.68	0.56	3.86e-22	Height;
KIRP	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.49	5.63	0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.47	5.37	0.32	1.83e-7	Schizophrenia;
KIRP	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg13319975	chr6:146136371	FBXO30	0.47	6.44	0.38	6.31e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23977631	chr2:100938799	LONRF2	0.49	6.29	0.37	1.4e-9	Parkinson's disease;
KIRP	cis	rs7923609	0.967	rs3740331	chr10:65192288	G/A	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.42	6.41	0.38	7.17e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08582346	chr17:26727727	SLC46A1;SARM1	0.54	6.5	0.38	4.39e-10	Interleukin-4 levels;
KIRP	cis	rs282587	0.560	rs422046	chr13:113419191	T/C	cg04656015	chr13:113407548	ATP11A	0.59	6.51	0.38	4.16e-10	Glycated hemoglobin levels;
KIRP	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg09455208	chr3:40491958	NA	0.35	6.1	0.36	4.11e-9	Renal cell carcinoma;
KIRP	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg19875535	chr5:140030758	IK	-0.57	-7.12	-0.41	1.18e-11	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15616946	chr18:11689206	GNAL	0.54	6.81	0.4	7.62e-11	Parkinson's disease;
KIRP	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg18944383	chr4:111397179	ENPEP	0.49	7.54	0.43	9.22e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg07843065	chr1:150265600	MRPS21	0.48	6.69	0.39	1.47e-10	Migraine;
KIRP	cis	rs7027203	0.557	rs2265568	chr9:96513098	C/T	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.88e-10	DNA methylation (variation);
KIRP	cis	rs2860975	1.000	rs2226070	chr10:96776721	C/T	cg09036531	chr10:96991505	NA	-0.53	-6.66	-0.39	1.78e-10	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg08761264	chr16:28874980	SH2B1	-0.42	-4.89	-0.3	1.8e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7429990	0.803	rs11714518	chr3:48156635	T/C	cg11946769	chr3:48343235	NME6	-0.44	-5.34	-0.32	2.11e-7	Educational attainment (years of education);
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.88	-0.45	1.04e-13	Aortic root size;
KIRP	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	1.0	13.22	0.64	1.65e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.39	7.83	0.45	1.45e-13	Diastolic blood pressure;
KIRP	trans	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg16141378	chr3:129829833	LOC729375	0.53	6.64	0.39	1.94e-10	Mood instability;
KIRP	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg13753209	chr17:57696993	CLTC	0.52	5.11	0.31	6.36e-7	Hemoglobin concentration;
KIRP	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	5.79	0.35	2.09e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg13206674	chr6:150067644	NUP43	0.63	8.5	0.48	1.89e-15	Lung cancer;
KIRP	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.64	8.55	0.48	1.3e-15	Motion sickness;
KIRP	cis	rs55692468	0.761	rs62180804	chr2:153359512	G/T	cg04681845	chr2:153283485	FMNL2	0.47	5.87	0.35	1.42e-8	Intraocular pressure;
KIRP	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg12288994	chr5:1860383	NA	0.5	6.61	0.39	2.33e-10	Cardiovascular disease risk factors;
KIRP	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.58	8.16	0.46	1.76e-14	Longevity;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12891197	chr22:38902464	DDX17	-0.45	-6.23	-0.37	2.04e-9	Survival in pancreatic cancer;
KIRP	cis	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.41	-5.14	-0.31	5.7e-7	Leprosy;
KIRP	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg17470723	chr8:74884337	TCEB1	0.64	8.23	0.46	1.08e-14	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10123733	chr1:53704257	MAGOH	0.44	6.07	0.36	4.8e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg03959625	chr15:84868606	LOC388152	0.47	5.49	0.33	9.89e-8	Schizophrenia;
KIRP	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.7	-9.71	-0.53	4.48e-19	Mean corpuscular volume;
KIRP	cis	rs253959	0.774	rs185263	chr5:115642513	T/C	cg23108291	chr5:115420582	COMMD10	-0.46	-5.39	-0.33	1.63e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	8.83	0.49	2.07e-16	Retinal vascular caliber;
KIRP	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06481639	chr22:41940642	POLR3H	0.5	5.53	0.33	8.11e-8	Vitiligo;
KIRP	cis	rs9479482	0.686	rs9397137	chr6:150382002	G/A	cg03788504	chr6:150331562	NA	-0.34	-6.12	-0.36	3.66e-9	Alopecia areata;
KIRP	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.23	-0.37	1.97e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4363385	0.510	rs12083211	chr1:153032131	A/T	cg07796016	chr1:152779584	LCE1C	0.46	5.89	0.35	1.3e-8	Inflammatory skin disease;
KIRP	cis	rs7737355	0.773	rs4706023	chr5:130882379	T/C	cg06307176	chr5:131281290	NA	0.41	4.94	0.3	1.43e-6	Life satisfaction;
KIRP	cis	rs7712401	0.601	rs30049	chr5:122306097	G/A	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg03684893	chr10:554711	DIP2C	0.42	6.07	0.36	4.7e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs12643440	0.919	rs13143674	chr4:17197723	G/A	cg22650099	chr4:17144496	NA	-0.49	-5.54	-0.33	7.8e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4589502	0.841	rs55855162	chr15:67140523	C/A	cg12317470	chr15:67143691	NA	0.59	5.36	0.32	1.93e-7	Lung cancer (smoking interaction);
KIRP	cis	rs1629083	0.967	rs869638	chr11:118100411	C/G	cg18857871	chr11:118064634	AMICA1	0.56	7.37	0.43	2.66e-12	Lung cancer;
KIRP	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06481639	chr22:41940642	POLR3H	0.68	6.89	0.4	4.54e-11	Cannabis dependence symptom count;
KIRP	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.79	12.86	0.63	2.62e-29	Dupuytren's disease;
KIRP	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.8	11.54	0.59	6.63e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg17724175	chr1:150552817	MCL1	0.35	5.81	0.35	1.92e-8	Melanoma;
KIRP	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.71	8.99	0.5	6.74e-17	Bladder cancer;
KIRP	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.64	8.55	0.48	1.33e-15	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Parkinson's disease;
KIRP	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.6e-6	Total body bone mineral density;
KIRP	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-8.96	-0.5	8.32e-17	Obesity-related traits;
KIRP	cis	rs6952809	1.000	rs12671804	chr7:2449740	C/T	cg25507518	chr7:2405875	EIF3B	0.37	4.92	0.3	1.6e-6	Multiple sclerosis;
KIRP	cis	rs4262150	0.883	rs4958587	chr5:152251201	T/C	cg12297329	chr5:152029980	NA	-0.62	-8.21	-0.46	1.29e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.33	-0.37	1.15e-9	Blood pressure;
KIRP	cis	rs7538876	0.967	rs6678552	chr1:17720391	G/A	cg01904812	chr1:17746340	RCC2	0.29	4.94	0.3	1.43e-6	Basal cell carcinoma;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11212172	chr10:53459438	PRKG1;CSTF2T	0.62	7.76	0.44	2.21e-13	Smoking initiation;
KIRP	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2279817	1.000	rs4920620	chr1:18023154	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.66	9.87	0.53	1.44e-19	Neuroticism;
KIRP	cis	rs7719624	0.756	rs13168506	chr5:135396452	A/G	cg16684184	chr5:135415129	NA	0.38	5.8	0.35	2.07e-8	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7520050	0.807	rs28378621	chr1:46189554	T/C	cg03146154	chr1:46216737	IPP	0.45	5.51	0.33	9.05e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-6.09	-0.36	4.37e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.39	0.59	2.01e-24	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs9513627	1.000	rs7334274	chr13:100120801	G/A	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.4	-5.83	-0.35	1.7e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs867371	0.896	rs6495647	chr15:82537049	C/G	cg00614314	chr15:82944287	LOC80154	0.53	6.32	0.37	1.21e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-6.18	-0.37	2.68e-9	Personality dimensions;
KIRP	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.43	-5.57	-0.33	6.53e-8	Motion sickness;
KIRP	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.52	6.31	0.37	1.26e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs500492	0.508	rs449566	chr16:1074581	C/T	cg03495660	chr16:1074500	NA	0.54	5.91	0.35	1.11e-8	Polycystic ovary syndrome;
KIRP	cis	rs2862064	0.818	rs4704840	chr5:156484648	G/C	cg12943317	chr5:156479607	HAVCR1	-0.89	-7.52	-0.43	1.05e-12	Platelet count;
KIRP	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg06898279	chr14:60629192	DHRS7	0.41	5.92	0.35	1.08e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.18	-0.54	1.5e-20	Coffee consumption (cups per day);
KIRP	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg21926883	chr2:100939477	LONRF2	-0.57	-7.9	-0.45	9.53e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg22907277	chr7:1156413	C7orf50	0.86	8.16	0.46	1.73e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	7.6	0.44	6.05e-13	Lymphocyte counts;
KIRP	cis	rs9475752	0.793	rs28360536	chr6:56831647	C/T	cg22880620	chr6:56820808	BEND6;DST	0.51	5.22	0.32	3.9e-7	Menarche (age at onset);
KIRP	cis	rs7671266	0.518	rs16895984	chr4:10284727	C/T	cg11266682	chr4:10021025	SLC2A9	0.36	5.71	0.34	3.29e-8	Cardiovascular disease risk factors;
KIRP	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.5	-7.79	-0.44	1.91e-13	IgG glycosylation;
KIRP	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.49	5.32	0.32	2.3e-7	Menarche (age at onset);
KIRP	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.61	-7.34	-0.42	3.02e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg04519387	chr11:65556438	OVOL1	0.33	4.96	0.3	1.31e-6	Acne (severe);
KIRP	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.84	11.67	0.6	2.47e-25	Tonsillectomy;
KIRP	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.11e-20	Dupuytren's disease;
KIRP	cis	rs3105593	1.000	rs3105593	chr15:50845018	C/T	cg08437265	chr15:50716283	USP8	0.36	4.93	0.3	1.53e-6	QT interval;
KIRP	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.48	-7.22	-0.42	6.59e-12	Vitamin D levels;
KIRP	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg00784671	chr22:46762841	CELSR1	-0.91	-8.32	-0.47	6.21e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	15.95	0.71	8.01e-40	Homoarginine levels;
KIRP	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs57994353	0.540	rs11145919	chr9:139302526	G/T	cg21253087	chr9:139290292	SNAPC4	0.45	5.07	0.31	7.89e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg00079169	chr19:2811669	THOP1	0.51	5.57	0.33	6.53e-8	Total cholesterol levels;
KIRP	cis	rs71403859	0.502	rs17280181	chr16:71523514	C/T	cg08717414	chr16:71523259	ZNF19	-1.31	-13.31	-0.65	8.28e-31	Post bronchodilator FEV1;
KIRP	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg25174290	chr11:3078921	CARS	-0.68	-8.86	-0.49	1.59e-16	Calcium levels;
KIRP	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg05347473	chr6:146136440	FBXO30	-0.58	-8.36	-0.47	4.83e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.4e-8	Life satisfaction;
KIRP	cis	rs854765	0.616	rs8070624	chr17:17843396	G/A	cg02336718	chr17:17403227	NA	0.34	5.19	0.31	4.3e-7	Total body bone mineral density;
KIRP	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-6.96	-0.41	3.15e-11	Height;
KIRP	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.7	8.5	0.48	1.89e-15	Blood metabolite levels;
KIRP	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.59	6.97	0.41	2.83e-11	Corneal astigmatism;
KIRP	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24063238	chr17:56085336	SFRS1	0.59	6.58	0.39	2.8e-10	Lung cancer in ever smokers;
KIRP	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	5.01	0.3	1.03e-6	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.48	6.12	0.36	3.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.61	-7.94	-0.45	7.15e-14	Cocaine dependence;
KIRP	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-11.06	-0.58	2.41e-23	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.58	-9.46	-0.52	2.56e-18	Prostate cancer;
KIRP	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.76	8.79	0.49	2.61e-16	High light scatter reticulocyte count;
KIRP	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg11235152	chr1:67600687	NA	0.82	12.25	0.62	2.96e-27	Psoriasis;
KIRP	cis	rs10214930	0.671	rs6959495	chr7:27692292	T/C	cg22168087	chr7:27702803	HIBADH	0.47	5.04	0.31	8.89e-7	Hypospadias;
KIRP	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.87	13.15	0.64	2.98e-30	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.48	6.22	0.37	2.12e-9	Childhood ear infection;
KIRP	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.83	-12.22	-0.61	3.75e-27	Ulcerative colitis;
KIRP	cis	rs77688320	0.553	rs1558637	chr2:202263374	G/T	cg06431681	chr2:202330990	STRADB	-0.48	-5.55	-0.33	7.27e-8	Breast cancer;
KIRP	cis	rs9896933	0.943	rs6502023	chr17:80909608	T/G	cg15369054	chr17:80825471	TBCD	-0.55	-5.11	-0.31	6.58e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.38	-5.3	-0.32	2.59e-7	Coronary artery disease;
KIRP	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.07	9.58	0.52	1.1e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg09873164	chr1:152488093	CRCT1	0.5	6.37	0.38	9.19e-10	Hair morphology;
KIRP	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.75	9.23	0.51	1.32e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.92	15.91	0.71	1.1e-39	Platelet distribution width;
KIRP	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.66	-8.08	-0.46	2.98e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg05973401	chr12:123451056	ABCB9	0.59	6.94	0.4	3.44e-11	Neutrophil percentage of white cells;
KIRP	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg11189052	chr15:85197271	WDR73	0.54	5.77	0.35	2.42e-8	Schizophrenia;
KIRP	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.85	11.93	0.61	3.36e-26	Breast cancer;
KIRP	cis	rs6693295	0.536	rs12118406	chr1:246230312	G/A	cg11798871	chr1:246315928	SMYD3	-0.66	-7.25	-0.42	5.45e-12	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg13906792	chr15:75199810	C15orf17	-0.36	-5.24	-0.32	3.37e-7	Breast cancer;
KIRP	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.38	-5.55	-0.33	7.56e-8	Height;
KIRP	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg09699651	chr6:150184138	LRP11	0.47	6.13	0.36	3.55e-9	Lung cancer;
KIRP	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-8.18	-0.46	1.5e-14	Schizophrenia;
KIRP	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.68	-9.38	-0.51	4.45e-18	Huntington's disease progression;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg23522427	chr7:150675308	KCNH2	-0.55	-6.72	-0.39	1.26e-10	Menopause (age at onset);
KIRP	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg04691961	chr3:161091175	C3orf57	-0.36	-5.25	-0.32	3.24e-7	Kawasaki disease;
KIRP	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg08134877	chr2:44394819	PPM1B	0.5	4.86	0.3	2.11e-6	Height;
KIRP	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg00074818	chr8:8560427	CLDN23	0.43	6.44	0.38	6.06e-10	Obesity-related traits;
KIRP	cis	rs2483058	0.767	rs11579993	chr1:206618875	A/G	cg19452316	chr1:206680966	RASSF5	0.41	5.52	0.33	8.49e-8	Cholesterol and Triglycerides;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19641644	chr7:44365627	CAMK2B	0.45	6.19	0.37	2.51e-9	Smoking initiation;
KIRP	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg17554472	chr22:41940697	POLR3H	-0.7	-7.48	-0.43	1.3e-12	Vitiligo;
KIRP	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.44	0.47	2.72e-15	Lung cancer in ever smokers;
KIRP	cis	rs2288912	0.807	rs10423208	chr19:45453656	G/A	cg13119609	chr19:45449297	APOC2	0.53	7.64	0.44	4.75e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg04289385	chr6:36355825	ETV7	0.43	6.55	0.39	3.27e-10	Platelet distribution width;
KIRP	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	13.56	0.65	1.2e-31	Chronic sinus infection;
KIRP	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg03959625	chr15:84868606	LOC388152	0.52	6.08	0.36	4.64e-9	Schizophrenia;
KIRP	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.85	7.0	0.41	2.44e-11	Mean platelet volume;
KIRP	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-7.53	-0.43	9.83e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg04132472	chr17:19861366	AKAP10	0.4	5.2	0.31	4.17e-7	Schizophrenia;
KIRP	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.79	12.86	0.63	2.62e-29	Dupuytren's disease;
KIRP	cis	rs35883536	0.528	rs1577511	chr1:101030859	G/A	cg09408571	chr1:101003634	GPR88	0.24	5.36	0.32	1.91e-7	Monocyte count;
KIRP	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.45	-0.43	1.58e-12	Body mass index;
KIRP	cis	rs754466	0.561	rs11002344	chr10:79709725	A/T	cg17075019	chr10:79541650	NA	-0.69	-5.75	-0.34	2.67e-8	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs865483	0.861	rs72828246	chr17:35766475	A/G	cg06716730	chr17:35851459	DUSP14	-0.24	-5.74	-0.34	2.79e-8	Monocyte count;
KIRP	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg20701182	chr2:24300061	SF3B14	0.49	4.86	0.3	2.07e-6	Lymphocyte counts;
KIRP	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.21	14.22	0.67	6.91e-34	Corneal structure;
KIRP	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14769373	chr6:40998127	UNC5CL	-0.63	-6.76	-0.4	9.77e-11	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs8084125	0.832	rs62105166	chr18:74944518	A/G	cg18461021	chr18:74961002	GALR1	0.52	5.3	0.32	2.59e-7	Obesity-related traits;
KIRP	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-9.22	-0.51	1.34e-17	Response to antipsychotic treatment;
KIRP	cis	rs981844	0.683	rs1105496	chr4:154756755	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs11610422	1.000	rs11610422	chr12:31412669	C/T	cg14306366	chr12:31406441	NA	0.59	6.12	0.36	3.66e-9	Coronary artery disease;
KIRP	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.65	-9.14	-0.5	2.38e-17	Retinal vascular caliber;
KIRP	cis	rs2591576	0.555	rs930599	chr5:165423738	G/A	cg13976338	chr5:165423657	NA	-0.88	-14.39	-0.68	1.72e-34	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg18944383	chr4:111397179	ENPEP	-0.53	-6.23	-0.37	2.03e-9	Axial length;
KIRP	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.5	-8.97	-0.5	7.7e-17	Lymphocyte counts;
KIRP	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	9.36	0.51	5.23e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-11.5	-0.59	8.96e-25	Breast cancer;
KIRP	cis	rs13401104	0.633	rs72620804	chr2:237111501	T/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.68	7.69	0.44	3.43e-13	Height;
KIRP	cis	rs4566357	0.930	rs6436647	chr2:227922958	G/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.09	-0.31	7.24e-7	Coronary artery disease;
KIRP	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg23594656	chr7:65796392	TPST1	-0.45	-6.84	-0.4	6.11e-11	Aortic root size;
KIRP	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg18209359	chr17:80159595	CCDC57	-0.42	-5.54	-0.33	7.91e-8	Life satisfaction;
KIRP	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.76	-9.75	-0.53	3.29e-19	Longevity;Endometriosis;
KIRP	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg04025307	chr7:1156635	C7orf50	0.57	5.74	0.34	2.81e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.96	0.57	4.96e-23	Cognitive test performance;
KIRP	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg07775547	chr4:1625484	NA	0.43	5.22	0.32	3.8e-7	Bladder cancer;Urinary bladder cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg22524267	chr4:4543474	STX18	0.48	6.19	0.37	2.5e-9	Smoking initiation;
KIRP	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.69	-9.26	-0.51	1.03e-17	Total body bone mineral density;
KIRP	cis	rs7751419	0.651	rs7758693	chr6:39104371	C/T	cg25014318	chr6:39016776	GLP1R	0.36	5.17	0.31	4.77e-7	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs11997175	0.510	rs10503953	chr8:33797783	C/T	ch.8.33884649F	chr8:33765107	NA	0.46	5.61	0.34	5.3e-8	Body mass index;
KIRP	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.59	-7.15	-0.41	1e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.29	-0.42	4.1e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.71	-7.22	-0.42	6.47e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.24	-4.95	-0.3	1.41e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.8	11.2	0.58	8.21e-24	Mean platelet volume;Platelet distribution width;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg16247931	chr14:102771650	RAGE	-0.46	-6.32	-0.37	1.24e-9	Morning vs. evening chronotype;
KIRP	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg24579218	chr15:68104479	NA	-0.55	-9.03	-0.5	5.18e-17	Restless legs syndrome;
KIRP	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6142102	0.886	rs6142098	chr20:32688294	A/C	cg08999081	chr20:33150536	PIGU	0.54	7.14	0.41	1.08e-11	Skin pigmentation;
KIRP	trans	rs13132184	0.507	rs35266215	chr4:38048878	C/T	cg26279261	chr19:17346089	NR2F6	-0.59	-6.04	-0.36	5.6e-9	Verbal declarative memory;
KIRP	cis	rs861020	0.560	rs649275	chr1:209950681	T/C	cg09163369	chr1:210001066	C1orf107	0.43	5.58	0.34	6.28e-8	Orofacial clefts;
KIRP	cis	rs3924048	0.574	rs12410270	chr1:12612843	G/A	cg00291366	chr1:12616550	NA	0.47	6.64	0.39	2e-10	Optic cup area;
KIRP	trans	rs17079247	0.841	rs9575847	chr13:85809885	C/T	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs7224685	0.569	rs12940782	chr17:3992712	T/C	cg09695851	chr17:3907499	NA	0.57	5.29	0.32	2.64e-7	Type 2 diabetes;
KIRP	cis	rs815815	0.608	rs6751198	chr2:47396274	C/T	cg27223769	chr2:47403360	CALM2	-0.69	-7.89	-0.45	1e-13	Dialysis-related mortality;
KIRP	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-8.45	-0.47	2.66e-15	Colorectal cancer;
KIRP	cis	rs1595825	0.891	rs114426561	chr2:198698891	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-5.63	-0.34	4.81e-8	Ulcerative colitis;
KIRP	cis	rs71597109	0.639	rs4698969	chr4:102725955	A/G	cg14855874	chr4:102712397	BANK1	-0.41	-5.49	-0.33	1e-7	Chronic lymphocytic leukemia;
KIRP	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg16141378	chr3:129829833	LOC729375	0.51	6.72	0.39	1.26e-10	Mood instability;
KIRP	cis	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.03	-0.41	1.99e-11	Morning vs. evening chronotype;
KIRP	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg26531700	chr6:26746687	NA	0.41	5.5	0.33	9.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.95	11.15	0.58	1.26e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11987759	chr7:65425863	GUSB	0.51	6.82	0.4	6.98e-11	Aortic root size;
KIRP	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.69	-7.01	-0.41	2.28e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg01631408	chr1:248437212	OR2T33	-0.53	-7.25	-0.42	5.4e-12	Common traits (Other);
KIRP	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.59	-5.91	-0.35	1.16e-8	White matter hyperintensity burden;
KIRP	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg18132916	chr6:79620363	NA	-0.4	-5.62	-0.34	5.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.26	7.08	0.41	1.48e-11	Crohn's disease;
KIRP	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-11.45	-0.59	1.29e-24	Exhaled nitric oxide output;
KIRP	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.65	-7.95	-0.45	6.58e-14	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4774830	0.744	rs62046391	chr15:56310688	C/T	cg24530489	chr15:56299380	NA	-0.88	-5.09	-0.31	7e-7	Delta-5 desaturase activity;
KIRP	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg23845249	chr11:68861649	NA	0.57	8.22	0.46	1.18e-14	Blond vs. brown hair color;
KIRP	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12826209	chr6:26865740	GUSBL1	0.68	6.27	0.37	1.63e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	6.42	0.38	6.84e-10	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.59	6.06	0.36	5.01e-9	Total cholesterol levels;
KIRP	trans	rs1941687	0.831	rs12958029	chr18:31388680	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-6.21	-0.37	2.25e-9	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.51	-6.78	-0.4	8.68e-11	Hip circumference;Waist circumference;
KIRP	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11987759	chr7:65425863	GUSB	-0.51	-6.82	-0.4	7.14e-11	Aortic root size;
KIRP	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs17095355	1.000	rs12247564	chr10:111721400	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.38	-5.28	-0.32	2.9e-7	Biliary atresia;
KIRP	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg17517138	chr11:73019481	ARHGEF17	0.75	6.22	0.37	2.09e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7221595	0.825	rs8081260	chr17:3981937	T/C	cg21734707	chr17:3908241	ZZEF1	0.53	5.03	0.31	9.67e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg16141378	chr3:129829833	LOC729375	0.52	6.88	0.4	4.81e-11	Morning vs. evening chronotype;
KIRP	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.61	-7.08	-0.41	1.47e-11	Menarche (age at onset);
KIRP	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.51	5.47	0.33	1.1e-7	Menarche (age at onset);
KIRP	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg10556349	chr10:835070	NA	0.62	5.8	0.35	2.04e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs10982256	1.000	rs4979413	chr9:117259548	A/G	cg13636371	chr9:117264095	DFNB31	0.58	8.16	0.46	1.71e-14	Bipolar disorder;
KIRP	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.97	-0.41	2.87e-11	Bone mineral density;
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg08132940	chr7:1081526	C7orf50	-0.7	-7.05	-0.41	1.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	cg12689670	chr1:183009347	LAMC1	0.45	6.4	0.38	7.73e-10	Hypertriglyceridemia;
KIRP	cis	rs7011507	1.000	rs76739624	chr8:49176549	C/T	cg15325961	chr8:49183143	NA	0.59	5.0	0.3	1.11e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-0.8	-7.59	-0.44	6.5e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg18973457	chr13:112320951	NA	0.43	6.14	0.36	3.25e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs10802346	0.636	rs12753925	chr1:246425670	T/G	cg15962031	chr1:246363574	SMYD3	0.79	5.92	0.35	1.07e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs2742417	0.935	rs2742393	chr3:45757417	T/A	cg04037228	chr3:45636386	LIMD1	0.35	5.24	0.32	3.51e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg16988262	chr1:15930761	NA	0.39	5.18	0.31	4.69e-7	Systolic blood pressure;
KIRP	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.55	-6.61	-0.39	2.33e-10	Mosquito bite size;
KIRP	cis	rs2554380	0.943	rs11636516	chr15:84361773	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.66	-9.12	-0.5	2.8e-17	Height;
KIRP	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-0.84	-11.47	-0.59	1.09e-24	Uric acid levels;
KIRP	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.66	-8.17	-0.46	1.6e-14	Aortic root size;
KIRP	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs7534824	0.625	rs61782081	chr1:101507074	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.71	5.71	0.34	3.22e-8	Refractive astigmatism;
KIRP	cis	rs6738485	0.601	rs7566680	chr2:106851657	G/A	cg16099169	chr2:106886729	NA	-0.47	-7.03	-0.41	1.97e-11	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg13165212	chr22:42675999	NA	0.3	5.26	0.32	3.1e-7	Cognitive function;
KIRP	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg22117172	chr7:91764530	CYP51A1	0.46	6.43	0.38	6.53e-10	Breast cancer;
KIRP	cis	rs16857609	0.628	rs2373066	chr2:218352374	C/T	cg15335768	chr2:218268053	DIRC3	-0.4	-5.73	-0.34	3e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.82	8.55	0.48	1.34e-15	Gastritis;
KIRP	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg03289416	chr15:75166202	SCAMP2	-0.42	-5.48	-0.33	1.06e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.65	9.58	0.52	1.09e-18	Menarche (age at onset);
KIRP	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg03468072	chr12:39539422	NA	0.43	5.91	0.35	1.11e-8	Morning vs. evening chronotype;
KIRP	cis	rs2387326	0.767	rs11016098	chr10:129942982	A/G	cg16087940	chr10:129947807	NA	-0.36	-4.85	-0.3	2.24e-6	Select biomarker traits;
KIRP	cis	rs4908768	0.535	rs2784738	chr1:8466217	G/A	cg03610117	chr1:8450231	RERE	-0.72	-8.99	-0.5	6.8e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.98	18.98	0.77	4.33e-50	Electrocardiographic conduction measures;
KIRP	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05514531	chr3:81791282	GBE1	-0.44	-6.66	-0.39	1.78e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg23978390	chr7:1156363	C7orf50	0.51	5.45	0.33	1.22e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	16.51	0.72	1.04e-41	Chronic sinus infection;
KIRP	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg27490568	chr2:178487706	NA	0.47	6.61	0.39	2.31e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-5.71	-0.34	3.28e-8	Neuroticism;
KIRP	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg23594656	chr7:65796392	TPST1	0.46	6.2	0.37	2.34e-9	Aortic root size;
KIRP	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.47	-7.16	-0.42	9.28e-12	Coronary artery disease;
KIRP	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg08198773	chr8:1697536	NA	0.41	5.46	0.33	1.17e-7	Systolic blood pressure;
KIRP	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.41	-5.98	-0.36	7.67e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.52	-5.75	-0.34	2.63e-8	Glomerular filtration rate (creatinine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06086933	chr1:100326491	AGL	-0.44	-6.86	-0.4	5.56e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg19077165	chr18:44547161	KATNAL2	0.48	5.77	0.35	2.34e-8	Personality dimensions;
KIRP	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg23594656	chr7:65796392	TPST1	0.5	7.69	0.44	3.45e-13	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03407547	chr17:7255461	KCTD11	0.5	6.32	0.37	1.21e-9	Parkinson's disease;
KIRP	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs3017493	0.786	rs74344478	chr11:70681107	G/A	cg03578926	chr11:70508032	SHANK2	0.29	4.85	0.3	2.23e-6	Renal transplant outcome;
KIRP	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg21366198	chr4:185655624	MLF1IP	-0.36	-5.02	-0.3	9.97e-7	Kawasaki disease;
KIRP	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.79	-10.97	-0.57	4.82e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	5.09	0.31	7.22e-7	Menopause (age at onset);
KIRP	cis	rs2904967	0.571	rs1212391	chr11:65017277	T/A	cg09225861	chr11:65069680	NA	-0.44	-5.73	-0.34	2.99e-8	Mean corpuscular volume;
KIRP	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.61	8.98	0.5	7.06e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.65	-9.37	-0.51	4.88e-18	Retinal vascular caliber;
KIRP	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	6.72	0.39	1.23e-10	Iron status biomarkers;
KIRP	trans	rs9371601	0.859	rs490448	chr6:152720411	T/A	cg05529123	chr2:66910386	NA	-0.47	-6.49	-0.38	4.8e-10	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.51	-5.32	-0.32	2.29e-7	Corneal structure;
KIRP	cis	rs7951870	0.645	rs2070852	chr11:46744925	C/G	cg16389345	chr11:46697382	NA	0.44	5.34	0.32	2.1e-7	Schizophrenia;
KIRP	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.56	7.29	0.42	4.12e-12	Autism;
KIRP	cis	rs4664293	0.867	rs73967903	chr2:160574125	G/A	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs7011049	1.000	rs28867471	chr8:53838179	C/T	cg26025543	chr8:53854495	NA	0.61	6.65	0.39	1.84e-10	Systolic blood pressure;
KIRP	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg23335576	chr14:104009727	NA	0.57	7.06	0.41	1.7e-11	Body mass index;
KIRP	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-4.97	-0.3	1.26e-6	Prostate cancer;
KIRP	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-6.08	-0.36	4.6e-9	Height;
KIRP	cis	rs712039	0.652	rs853227	chr17:35797529	C/T	cg16670864	chr17:35848621	DUSP14	0.41	4.94	0.3	1.48e-6	Tuberculosis;
KIRP	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.18	0.37	2.6e-9	Menopause (age at onset);
KIRP	cis	rs711830	1.000	rs2857540	chr2:177026698	G/T	cg13092806	chr2:177043255	NA	0.64	6.62	0.39	2.23e-10	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-6.55	-0.39	3.3e-10	Neuroticism;
KIRP	cis	rs754423	0.674	rs979481	chr14:52533443	A/G	cg16066272	chr14:52535949	NID2	0.33	4.97	0.3	1.24e-6	Craniofacial microsomia;
KIRP	cis	rs4356932	0.875	rs10034055	chr4:76970539	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.01	0.36	6.55e-9	Blood protein levels;
KIRP	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.95	10.44	0.55	2.39e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6563943	0.892	rs8059833	chr16:83639311	C/T	cg01935413	chr16:83636749	CDH13	0.45	6.62	0.39	2.27e-10	Height;
KIRP	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg06115741	chr20:33292138	TP53INP2	-0.39	-5.27	-0.32	2.93e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.6	7.64	0.44	4.96e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9905704	0.633	rs2018966	chr17:56477565	C/T	cg12560992	chr17:57184187	TRIM37	-0.57	-5.45	-0.33	1.22e-7	Testicular germ cell tumor;
KIRP	cis	rs710216	0.595	rs4660697	chr1:43458250	T/C	cg03128534	chr1:43423976	SLC2A1	-0.49	-5.59	-0.34	5.89e-8	Red cell distribution width;
KIRP	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg12315302	chr6:26189340	HIST1H4D	0.79	5.56	0.33	7.03e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg26681399	chr22:41777847	TEF	-0.42	-4.99	-0.3	1.13e-6	Neuroticism;
KIRP	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg21395723	chr22:39101663	GTPBP1	0.46	6.05	0.36	5.28e-9	Menopause (age at onset);
KIRP	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.82	9.78	0.53	2.76e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg04374321	chr14:90722782	PSMC1	0.92	15.24	0.7	2.17e-37	Mortality in heart failure;
KIRP	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.08	-13.15	-0.64	2.8e-30	Vitiligo;
KIRP	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.52	-0.43	1.01e-12	Myopia (pathological);
KIRP	cis	rs357618	0.581	rs165328	chr5:150873771	T/C	cg22672639	chr5:150884813	FAT2	0.34	4.87	0.3	2e-6	Basophil percentage of white cells;
KIRP	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09491104	chr22:46646882	C22orf40	-0.58	-6.57	-0.39	2.99e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.03e-11	Morning vs. evening chronotype;
KIRP	trans	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-11.25	-0.58	5.72e-24	Triglycerides;
KIRP	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg21747090	chr2:27597821	SNX17	-0.46	-6.61	-0.39	2.34e-10	Total body bone mineral density;
KIRP	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg22117172	chr7:91764530	CYP51A1	-0.42	-5.64	-0.34	4.7e-8	Breast cancer;
KIRP	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.49	-5.47	-0.33	1.09e-7	Colorectal cancer;
KIRP	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-5.41	-0.33	1.47e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03395044	chr6:80268304	NA	-0.43	-6.72	-0.39	1.23e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg02811702	chr13:24901961	NA	0.4	5.33	0.32	2.23e-7	Obesity-related traits;
KIRP	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.4	10.02	0.54	4.85e-20	Corneal astigmatism;
KIRP	cis	rs9443189	0.950	rs1280039	chr6:76514940	C/T	cg01950844	chr6:76311363	SENP6	0.51	5.12	0.31	6.3e-7	Prostate cancer;
KIRP	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.83	8.85	0.49	1.73e-16	Lymphocyte counts;Red cell distribution width;
KIRP	trans	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg03929089	chr4:120376271	NA	0.74	6.83	0.4	6.78e-11	Intraocular pressure;
KIRP	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg03609598	chr5:56110824	MAP3K1	-0.42	-4.93	-0.3	1.5e-6	Coronary artery disease;
KIRP	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06544989	chr22:39130855	UNC84B	-0.51	-8.37	-0.47	4.3e-15	Menopause (age at onset);
KIRP	cis	rs988913	0.541	rs9464196	chr6:54997649	A/G	cg03513858	chr6:54763001	FAM83B	0.33	4.96	0.3	1.29e-6	Menarche (age at onset);
KIRP	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg12826209	chr6:26865740	GUSBL1	-0.43	-5.28	-0.32	2.85e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12852000	chr3:32030804	ZNF860	-0.41	-6.45	-0.38	5.99e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.68	9.65	0.52	6.89e-19	Lung cancer;
KIRP	cis	rs4073416	0.518	rs8013442	chr14:65871861	A/G	cg03016385	chr14:66212404	NA	-0.57	-6.84	-0.4	6.22e-11	N-glycan levels;
KIRP	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-22.18	-0.82	1.27e-60	Height;
KIRP	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.18	-0.46	1.54e-14	Personality dimensions;
KIRP	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg15655495	chr12:38532458	NA	-0.31	-6.12	-0.36	3.71e-9	Bladder cancer;
KIRP	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg27422857	chr2:105853526	NA	0.4	5.34	0.32	2.12e-7	Type 2 diabetes;
KIRP	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.58	-7.99	-0.45	5.14e-14	Motion sickness;
KIRP	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg13857086	chr12:6580257	VAMP1	0.87	8.53	0.48	1.48e-15	Hip geometry;
KIRP	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.59	-5.0	-0.3	1.07e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.63	-7.53	-0.43	9.77e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg27205649	chr11:78285834	NARS2	0.84	12.2	0.61	4.39e-27	Alzheimer's disease (survival time);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05380910	chr13:39564046	STOML3	-0.43	-6.74	-0.39	1.12e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg16268157	chr7:99778414	STAG3	-0.55	-5.98	-0.36	7.85e-9	Lung function (FEV1/FVC);
KIRP	cis	rs7175404	1.000	rs7166579	chr15:94042678	G/A	cg23502883	chr15:93959149	NA	0.57	5.91	0.35	1.11e-8	Attention deficit hyperactivity disorder;
KIRP	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg15556689	chr8:8085844	FLJ10661	0.58	7.53	0.43	9.58e-13	Retinal vascular caliber;
KIRP	cis	rs11874712	0.899	rs11664764	chr18:43675364	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.91	-0.35	1.16e-8	Migraine - clinic-based;
KIRP	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg04398451	chr17:18023971	MYO15A	0.69	9.58	0.52	1.15e-18	Total body bone mineral density;
KIRP	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg26876637	chr1:152193138	HRNR	-0.83	-8.78	-0.49	2.8e-16	Atopic dermatitis;
KIRP	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.48	-0.38	5.06e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.63	-9.01	-0.5	5.91e-17	Longevity;Endometriosis;
KIRP	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.47	8.04	0.46	3.85e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg21094737	chr17:80964568	B3GNTL1	0.42	6.75	0.4	1.07e-10	Serum protein levels (sST2);
KIRP	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg09658497	chr7:2847517	GNA12	-0.35	-4.89	-0.3	1.84e-6	Height;
KIRP	cis	rs1843834	0.721	rs1601730	chr2:225590153	G/A	cg22509189	chr2:225307070	NA	-0.44	-5.23	-0.32	3.54e-7	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs4654899	0.582	rs4654729	chr1:21224253	T/C	cg08890418	chr1:21044141	KIF17	-0.35	-5.24	-0.32	3.4e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg18209359	chr17:80159595	CCDC57	-0.4	-5.44	-0.33	1.3e-7	Life satisfaction;
KIRP	cis	rs2591576	0.546	rs3910939	chr5:165431725	C/T	cg13976338	chr5:165423657	NA	0.78	12.68	0.63	1.08e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.69	8.87	0.49	1.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.42	-5.15	-0.31	5.28e-7	IgG glycosylation;
KIRP	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.39	4.93	0.3	1.5e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg20573242	chr4:122745356	CCNA2	0.41	5.11	0.31	6.54e-7	Type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg11833968	chr6:79620685	NA	-0.47	-7.1	-0.41	1.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs367615	0.879	rs2201015	chr5:108947450	C/T	cg17395555	chr5:108820864	NA	0.46	5.05	0.31	8.72e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs4073221	0.547	rs35087715	chr3:18326931	C/G	cg07694806	chr3:18168406	NA	-0.68	-5.91	-0.35	1.12e-8	Parkinson's disease;
KIRP	cis	rs68170813	0.652	rs8180747	chr7:107106308	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-6.72	-0.39	1.22e-10	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.53	-0.33	8.24e-8	Lung cancer;
KIRP	cis	rs6005807	0.640	rs7289534	chr22:29016057	C/T	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22878388	chr2:105853796	NA	-0.44	-6.97	-0.41	2.85e-11	Type 2 diabetes;
KIRP	cis	rs7246657	0.722	rs2287229	chr19:38188652	G/A	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs953387	0.956	rs4954572	chr2:136926719	G/T	cg05194412	chr2:137003533	NA	-0.38	-5.06	-0.31	8.21e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs2411233	0.837	rs1368803	chr15:39256705	C/T	cg05886626	chr15:39873553	THBS1	0.35	5.12	0.31	6.17e-7	Platelet count;
KIRP	cis	rs3136516	0.504	rs17787804	chr11:46506885	C/T	cg16389345	chr11:46697382	NA	-0.52	-7.01	-0.41	2.24e-11	Venous thromboembolism;
KIRP	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg25486957	chr4:152246857	NA	-0.55	-5.94	-0.35	9.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2398893	0.889	rs2039313	chr9:96781684	C/G	cg14459158	chr9:96720562	NA	-0.28	-5.0	-0.3	1.07e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.56	0.39	3.17e-10	Monocyte percentage of white cells;
KIRP	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.45	-5.33	-0.32	2.27e-7	Carotid intima media thickness;
KIRP	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-4.9	-0.3	1.75e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.64	10.52	0.56	1.32e-21	Neuroticism;
KIRP	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.45	6.7	0.39	1.41e-10	Major depressive disorder;
KIRP	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.0	-0.3	1.09e-6	Coronary artery disease;
KIRP	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-1.15	-9.85	-0.53	1.67e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.51	6.37	0.38	9.46e-10	Mean platelet volume;
KIRP	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05025164	chr4:1340916	KIAA1530	0.61	8.23	0.46	1.09e-14	Longevity;
KIRP	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg01181863	chr3:195395398	SDHAP2	-0.84	-9.55	-0.52	1.33e-18	Pancreatic cancer;
KIRP	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg03929089	chr4:120376271	NA	-0.7	-6.38	-0.38	8.63e-10	Intraocular pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11164766	chr15:65477583	CLPX	0.54	6.85	0.4	5.72e-11	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg07322296	chr22:50661779	TUBGCP6	0.54	6.91	0.4	4.04e-11	Interleukin-4 levels;
KIRP	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg00274965	chr21:34405681	NA	0.4	6.38	0.38	8.93e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7011507	0.947	rs79654709	chr8:49156111	G/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs780094	0.500	rs1919127	chr2:27801493	T/C	cg05484376	chr2:27715224	FNDC4	-0.37	-5.53	-0.33	8e-8	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.85	10.68	0.56	3.98e-22	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.47	-6.35	-0.38	1.06e-9	Longevity;
KIRP	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.81	0.49	2.36e-16	Motion sickness;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13909320	chr9:125026858	MRRF;RBM18	0.44	6.24	0.37	1.88e-9	Survival in pancreatic cancer;
KIRP	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg16346588	chr10:242978	ZMYND11	-0.42	-5.0	-0.3	1.08e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg24296786	chr1:45957014	TESK2	0.51	5.65	0.34	4.39e-8	Homocysteine levels;
KIRP	cis	rs13161895	1.000	rs35135297	chr5:179469532	T/C	cg02702477	chr5:179499311	RNF130	0.73	5.68	0.34	3.84e-8	LDL cholesterol;
KIRP	cis	rs9905704	0.645	rs831952	chr17:56669583	T/C	cg12560992	chr17:57184187	TRIM37	0.53	4.93	0.3	1.54e-6	Testicular germ cell tumor;
KIRP	cis	rs7027203	0.557	rs2265569	chr9:96512505	T/C	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.88e-10	DNA methylation (variation);
KIRP	cis	rs17221829	0.699	rs7118152	chr11:89383654	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.85	-0.3	2.14e-6	Anxiety in major depressive disorder;
KIRP	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg23172400	chr8:95962367	TP53INP1	-0.32	-6.23	-0.37	2.02e-9	Type 2 diabetes;
KIRP	cis	rs4950322	0.570	rs72691054	chr1:146749611	T/C	cg22381352	chr1:146742008	CHD1L	-0.46	-5.49	-0.33	1.01e-7	Protein quantitative trait loci;
KIRP	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.52	7.74	0.44	2.56e-13	Immature fraction of reticulocytes;
KIRP	cis	rs4132509	1.000	rs6675851	chr1:243787494	G/A	cg25706552	chr1:244017396	NA	0.52	6.55	0.39	3.31e-10	RR interval (heart rate);
KIRP	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.74	9.13	0.5	2.51e-17	Vitiligo;
KIRP	cis	rs1832871	0.619	rs262821	chr6:158665197	C/T	cg07215822	chr6:158701037	NA	-0.61	-9.0	-0.5	6.1e-17	Height;
KIRP	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.6	-6.53	-0.38	3.68e-10	Colorectal adenoma (advanced);
KIRP	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.52	-7.42	-0.43	1.86e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.17	0.31	4.78e-7	Childhood ear infection;
KIRP	trans	rs78547569	1.000	rs981071	chr13:44394894	A/G	cg19414419	chr1:8877760	RERE	-0.91	-6.13	-0.36	3.38e-9	Response to paliperidone in schizophrenia (Multivariate);Response to paliperidone in schizophrenia (negative Marder score);
KIRP	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg07862535	chr7:139043722	LUC7L2	0.47	5.26	0.32	3.18e-7	Diisocyanate-induced asthma;
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.54	-0.33	7.62e-8	Longevity;Endometriosis;
KIRP	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	16.36	0.72	3.43e-41	Electrocardiographic conduction measures;
KIRP	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg22903471	chr2:27725779	GCKR	0.4	5.58	0.34	6.24e-8	Oral cavity cancer;
KIRP	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	0.98	14.0	0.67	3.67e-33	Primary sclerosing cholangitis;
KIRP	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg01879757	chr17:41196368	BRCA1	-0.56	-7.43	-0.43	1.8e-12	Menopause (age at onset);
KIRP	cis	rs453301	0.579	rs10096850	chr8:8798222	A/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.71	-0.39	1.35e-10	Joint mobility (Beighton score);
KIRP	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.6	0.34	5.68e-8	Melanoma;
KIRP	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	10.41	0.55	2.87e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.66	7.49	0.43	1.21e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2301573	1.000	rs75404673	chr3:129296782	G/A	cg15504747	chr3:129312979	PLXND1	-0.47	-5.04	-0.31	9.19e-7	Hip circumference;
KIRP	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg15556689	chr8:8085844	FLJ10661	0.64	8.07	0.46	3.17e-14	Retinal vascular caliber;
KIRP	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.41	-5.1	-0.31	6.84e-7	Eosinophil percentage of white cells;
KIRP	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg05973401	chr12:123451056	ABCB9	0.62	7.44	0.43	1.7e-12	Platelet count;
KIRP	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.69	-10.3	-0.55	6.59e-21	Waist circumference;Body mass index;
KIRP	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	0.9	10.51	0.56	1.39e-21	Testicular germ cell tumor;
KIRP	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg25486957	chr4:152246857	NA	-0.5	-5.29	-0.32	2.65e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.72	-0.44	2.97e-13	IgG glycosylation;
KIRP	cis	rs12249377	0.519	rs11597471	chr10:92598767	C/G	cg14313238	chr10:92632228	RPP30	0.5	6.02	0.36	6.45e-9	White matter microstructure (global fractional anisotropy);
KIRP	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg08885076	chr2:99613938	TSGA10	0.53	9.26	0.51	1.06e-17	Chronic sinus infection;
KIRP	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg14541582	chr5:601475	NA	-0.54	-6.08	-0.36	4.58e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07570687	chr10:102243282	WNT8B	0.43	5.3	0.32	2.54e-7	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg00343986	chr7:65444356	GUSB	-0.46	-5.63	-0.34	5.01e-8	Aortic root size;
KIRP	cis	rs9826463	0.818	rs9858204	chr3:142299855	C/T	cg20824294	chr3:142316082	PLS1	0.33	5.98	0.36	7.64e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg03060546	chr3:49711283	APEH	-0.71	-5.89	-0.35	1.29e-8	Blood protein levels;
KIRP	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.57	-6.54	-0.39	3.44e-10	Initial pursuit acceleration;
KIRP	cis	rs73200209	0.744	rs17498802	chr12:116642212	T/G	cg01776926	chr12:116560359	MED13L	-0.56	-6.24	-0.37	1.91e-9	Total body bone mineral density;
KIRP	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.43	-0.43	1.82e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg00631329	chr6:26305371	NA	0.53	6.77	0.4	9.64e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.66	-9.48	-0.52	2.32e-18	Prudent dietary pattern;
KIRP	cis	rs3026101	0.671	rs1806240	chr17:5298320	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs6546324	1.000	rs6710685	chr2:67858666	T/C	cg15745817	chr2:67799979	NA	-0.43	-5.71	-0.34	3.21e-8	Endometriosis;
KIRP	trans	rs933360	0.553	rs10268643	chr7:50826492	T/C	cg20003124	chr12:4557277	NA	0.53	6.55	0.39	3.4e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg05669848	chr5:237993	SDHA	-0.48	-4.96	-0.3	1.3e-6	Breast cancer;
KIRP	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.89	13.59	0.65	9.01e-32	Longevity;Endometriosis;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg16011496	chr8:63057206	NA	0.4	6.09	0.36	4.2e-9	Cancer;
KIRP	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg23920097	chr1:209922102	NA	-0.44	-5.9	-0.35	1.18e-8	Red blood cell count;
KIRP	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-0.79	-10.96	-0.57	5.22e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs17092148	1.000	rs1884431	chr20:33338585	G/A	cg16810054	chr20:33298113	TP53INP2	-0.44	-5.46	-0.33	1.15e-7	Neuroticism;
KIRP	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg21427119	chr20:30132790	HM13	-0.41	-4.95	-0.3	1.36e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs992157	0.764	rs4423579	chr2:219185033	G/T	cg00012203	chr2:219082015	ARPC2	0.66	8.66	0.48	6.27e-16	Colorectal cancer;
KIRP	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg03894339	chr8:19674705	INTS10	0.46	5.43	0.33	1.36e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs12615966	0.651	rs60920571	chr2:105408284	C/G	cg16465502	chr2:105461796	NA	0.95	7.88	0.45	1.05e-13	Pancreatic cancer;
KIRP	cis	rs2294693	0.634	rs728477	chr6:41015167	T/C	cg14769373	chr6:40998127	UNC5CL	-0.47	-5.12	-0.31	6.28e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.65	0.48	6.69e-16	Prudent dietary pattern;
KIRP	cis	rs6977660	0.714	rs6945297	chr7:19814029	A/C	cg05791153	chr7:19748676	TWISTNB	0.61	5.79	0.35	2.13e-8	Thyroid stimulating hormone;
KIRP	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.42	-5.46	-0.33	1.16e-7	Body mass index;
KIRP	cis	rs988913	0.957	rs9367597	chr6:54784652	C/T	cg03513858	chr6:54763001	FAM83B	-0.4	-5.51	-0.33	8.9e-8	Menarche (age at onset);
KIRP	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.56	-7.24	-0.42	5.78e-12	Morning vs. evening chronotype;
KIRP	cis	rs12780845	0.929	rs35932553	chr10:17213315	A/T	cg01003015	chr10:17271136	VIM	0.46	4.97	0.3	1.28e-6	Homocysteine levels;
KIRP	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.66	8.46	0.47	2.43e-15	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.57	-0.39	3e-10	Blood pressure;
KIRP	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.84	-11.74	-0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg15488143	chr7:128924101	AHCYL2	0.62	6.63	0.39	2.17e-10	White matter hyperintensity burden;
KIRP	cis	rs55675132	0.548	rs75634202	chr1:115375464	C/G	cg12756093	chr1:115239321	AMPD1	0.54	5.27	0.32	2.97e-7	Schizophrenia;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg00738919	chr7:1100172	C7orf50	0.42	4.97	0.3	1.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.59	-6.16	-0.37	2.87e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg18850127	chr7:39170497	POU6F2	0.28	5.56	0.33	7.07e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg10503236	chr1:231470652	EXOC8	0.47	6.67	0.39	1.63e-10	Hemoglobin concentration;
KIRP	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.56	5.69	0.34	3.68e-8	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs55986470	0.817	rs59736380	chr2:239404689	A/G	cg18131467	chr2:239335373	ASB1	-0.72	-5.32	-0.32	2.31e-7	Chronotype;
KIRP	cis	rs7773324	1.000	rs7773324	chr6:382559	A/G	cg23785612	chr6:387171	NA	0.4	5.15	0.31	5.41e-7	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs12615966	0.858	rs17030286	chr2:105381220	T/G	cg16465502	chr2:105461796	NA	0.64	5.8	0.35	2.02e-8	Pancreatic cancer;
KIRP	cis	rs2851682	0.706	rs2727271	chr11:61603358	A/T	cg07689907	chr11:61582574	FADS1	0.61	4.88	0.3	1.9e-6	Gestational age at birth (child effect);Trans fatty acid levels;
KIRP	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.59	-6.43	-0.38	6.58e-10	Corneal astigmatism;
KIRP	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02034447	chr16:89574710	SPG7	0.39	4.88	0.3	1.87e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs7560272	0.501	rs6750494	chr2:73946496	G/A	cg20560298	chr2:73613845	ALMS1	0.45	5.29	0.32	2.64e-7	Schizophrenia;
KIRP	cis	rs7395581	0.959	rs901746	chr11:47260319	A/G	cg26139080	chr11:47293733	MADD	-0.39	-4.91	-0.3	1.63e-6	HDL cholesterol;
KIRP	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11987759	chr7:65425863	GUSB	-0.46	-6.36	-0.38	9.72e-10	Aortic root size;
KIRP	cis	rs282587	0.502	rs374433	chr13:113420269	G/C	cg04656015	chr13:113407548	ATP11A	0.52	5.22	0.32	3.88e-7	Glycated hemoglobin levels;
KIRP	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15664640	chr17:80829946	TBCD	-0.72	-6.36	-0.38	9.68e-10	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs9815354	0.812	rs74947509	chr3:42006323	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.82	0.49	2.15e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.77	9.99	0.54	6.22e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.4	5.02	0.3	1.01e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.36	0.38	9.73e-10	Neuroticism;
KIRP	cis	rs698833	0.561	rs698820	chr2:44716323	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.17	0.31	4.91e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	9.99e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs28489187	0.706	rs233060	chr1:85798943	C/T	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.73	0.44	2.79e-13	Height;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00318877	chr11:28190822	METT5D1	0.36	6.13	0.36	3.41e-9	C-reactive protein;
KIRP	trans	rs1864729	1.000	rs2583506	chr8:98281847	G/A	cg08679828	chr8:102218111	ZNF706	-0.71	-6.5	-0.38	4.35e-10	Estradiol plasma levels (breast cancer);
KIRP	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.85	-10.51	-0.56	1.36e-21	Vitamin D levels;
KIRP	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg01877450	chr7:97915802	BRI3	-0.57	-7.46	-0.43	1.51e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-0.54	-7.45	-0.43	1.61e-12	Coronary artery disease;
KIRP	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-11.03	-0.58	3.07e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10073892	0.743	rs10073051	chr5:101656932	A/G	cg19774478	chr5:101632501	SLCO4C1	0.65	6.74	0.39	1.14e-10	Cognitive decline (age-related);
KIRP	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.63	0.34	5.02e-8	Total cholesterol levels;
KIRP	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.43	-5.93	-0.35	1e-8	Lymphocyte counts;
KIRP	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.72	0.34	3.1e-8	Total cholesterol levels;
KIRP	cis	rs9469913	0.799	rs2744947	chr6:34657809	A/T	cg14254433	chr6:34482411	PACSIN1	-0.41	-5.13	-0.31	5.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg06521331	chr12:34319734	NA	-0.44	-5.04	-0.31	8.97e-7	Resting heart rate;
KIRP	cis	rs10782582	0.586	rs11161902	chr1:76392498	C/G	cg10523679	chr1:76189770	ACADM	-0.45	-5.93	-0.35	1.03e-8	Daytime sleep phenotypes;
KIRP	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-1.0	-12.99	-0.64	9.96e-30	Platelet distribution width;
KIRP	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	0.99	18.45	0.76	2.6e-48	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.62	8.31	0.47	6.33e-15	Prostate cancer;
KIRP	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.84	12.19	0.61	4.61e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.33	-0.32	2.24e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-6.7	-0.39	1.45e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.57	8.61	0.48	8.59e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg05347473	chr6:146136440	FBXO30	0.46	6.59	0.39	2.65e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg25801113	chr15:45476975	SHF	-0.44	-8.13	-0.46	2.15e-14	Uric acid levels;
KIRP	cis	rs9815354	0.951	rs17063653	chr3:41863817	A/G	cg03022575	chr3:42003672	ULK4	0.6	7.01	0.41	2.28e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9308731	0.931	rs616130	chr2:111912681	C/A	cg23466623	chr2:111982296	NA	-0.41	-4.87	-0.3	2.02e-6	Chronic lymphocytic leukemia;
KIRP	cis	rs830383	0.575	rs830237	chr5:165405678	A/C	cg13976338	chr5:165423657	NA	-0.54	-5.92	-0.35	1.06e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg24955955	chr5:415729	AHRR	0.77	6.27	0.37	1.59e-9	Fat distribution (HIV);
KIRP	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg07001201	chr5:642380	CEP72	0.66	6.6	0.39	2.44e-10	Obesity-related traits;
KIRP	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21747090	chr2:27597821	SNX17	-0.49	-6.7	-0.39	1.43e-10	Total body bone mineral density;
KIRP	cis	rs8103278	0.662	rs16980051	chr19:46345886	T/C	cg11657440	chr19:46296263	DMWD	-0.64	-8.4	-0.47	3.61e-15	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18252515	chr7:66147081	NA	0.46	5.72	0.34	3.13e-8	Aortic root size;
KIRP	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.89	13.63	0.66	7.02e-32	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg01879757	chr17:41196368	BRCA1	-0.77	-10.8	-0.57	1.61e-22	Menopause (age at onset);
KIRP	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.61	-6.51	-0.38	4.24e-10	DNA methylation (variation);
KIRP	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.83	11.07	0.58	2.15e-23	Cognitive function;
KIRP	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.17	-0.31	4.94e-7	Red blood cell count;
KIRP	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.25	-6.54	-0.38	3.48e-10	Crohn's disease;
KIRP	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs748404	0.588	rs2255410	chr15:43831097	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	6.55	0.39	3.26e-10	Lung cancer;
KIRP	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg24747557	chr10:131355152	MGMT	-0.4	-5.39	-0.32	1.67e-7	Response to temozolomide;
KIRP	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg24804195	chr5:87968844	LOC645323	-0.45	-5.94	-0.35	9.67e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg10755058	chr3:40428713	ENTPD3	-0.47	-6.58	-0.39	2.83e-10	Renal cell carcinoma;
KIRP	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-8.31	-0.47	6.3e-15	Blood protein levels;
KIRP	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.82	6.89	0.4	4.67e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25649261	chr6:138725556	HEBP2	0.42	6.11	0.36	3.89e-9	Survival in pancreatic cancer;
KIRP	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg24488311	chr11:68621650	NA	-0.42	-5.33	-0.32	2.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.78	11.58	0.59	4.89e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg12405258	chr13:114927641	NA	0.48	6.94	0.4	3.41e-11	Schizophrenia;
KIRP	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.74	11.53	0.59	7.34e-25	Monocyte percentage of white cells;
KIRP	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.75	-9.98	-0.54	6.67e-20	Multiple sclerosis;
KIRP	cis	rs12096438	1.000	rs7491	chr1:25895238	C/T	cg21452808	chr1:25900135	NA	0.41	6.61	0.39	2.3e-10	Platelet count;Mean platelet volume;
KIRP	cis	rs4356932	1.000	rs6850515	chr4:76973751	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg01304814	chr3:48885189	PRKAR2A	0.74	5.64	0.34	4.61e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg24874828	chr4:187887005	NA	-0.48	-7.07	-0.41	1.56e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.47	6.39	0.38	8.46e-10	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	1.09	17.34	0.74	1.51e-44	Homoarginine levels;
KIRP	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.96	-16.42	-0.72	1.98e-41	Height;
KIRP	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-10.39	-0.55	3.29e-21	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg23985595	chr17:80112537	CCDC57	-0.34	-5.19	-0.31	4.45e-7	Life satisfaction;
KIRP	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg04202892	chr2:111875749	ACOXL	0.5	6.81	0.4	7.37e-11	Chronic lymphocytic leukemia;
KIRP	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg05941025	chr16:89927596	SPIRE2	0.32	5.08	0.31	7.31e-7	Vitiligo;
KIRP	cis	rs17065868	1.000	rs9533925	chr13:45182917	T/C	cg10246903	chr13:45222710	NA	0.71	6.28	0.37	1.5e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.55	8.53	0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg12046867	chr14:103022105	NA	-0.54	-6.99	-0.41	2.6e-11	Platelet count;
KIRP	cis	rs877426	0.681	rs75632431	chr13:114814916	A/G	cg00571178	chr13:114841904	RASA3	-0.49	-5.17	-0.31	4.92e-7	Facial morphology (factor 14, intercanthal width);
KIRP	trans	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg10756647	chr7:56101905	PSPH	0.92	6.69	0.39	1.47e-10	Diabetic kidney disease;
KIRP	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-6.35	-0.38	1.06e-9	Capecitabine sensitivity;
KIRP	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg19683494	chr5:74908142	NA	-0.46	-5.31	-0.32	2.49e-7	Age-related disease endophenotypes;
KIRP	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.67	7.01	0.41	2.32e-11	Diisocyanate-induced asthma;
KIRP	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.78	11.82	0.6	7.63e-26	Breast cancer;
KIRP	cis	rs7582720	1.000	rs72932741	chr2:203661048	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.16	10.03	0.54	4.61e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2013441	0.613	rs11204422	chr17:19996429	A/T	cg13482628	chr17:19912719	NA	-0.45	-6.08	-0.36	4.5e-9	Obesity-related traits;
KIRP	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.72	-6.68	-0.39	1.59e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs240764	0.554	rs6570970	chr6:101233082	C/A	cg09795085	chr6:101329169	ASCC3	0.45	5.22	0.32	3.85e-7	Neuroticism;
KIRP	trans	rs2326458	0.515	rs11862286	chr16:84983235	C/T	cg05707211	chr8:37330004	NA	0.54	6.17	0.37	2.84e-9	Height;
KIRP	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	cis	rs2904967	0.778	rs603286	chr11:65095801	G/A	cg12562828	chr11:65076843	NA	0.46	6.99	0.41	2.56e-11	Mean corpuscular volume;
KIRP	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg10018233	chr7:150070692	REPIN1	0.58	7.48	0.43	1.29e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs10982256	0.870	rs10817625	chr9:117247587	A/T	cg13636371	chr9:117264095	DFNB31	0.59	8.29	0.47	7.47e-15	Bipolar disorder;
KIRP	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg03315344	chr16:75512273	CHST6	0.54	5.15	0.31	5.27e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	1.05	17.11	0.74	9.33e-44	Intelligence (multi-trait analysis);
KIRP	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs12995491	0.933	rs13008732	chr2:88528771	G/A	cg04511125	chr2:88470314	THNSL2	-0.43	-5.38	-0.32	1.75e-7	Response to metformin (IC50);
KIRP	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg04998671	chr14:104000505	TRMT61A	-0.56	-6.6	-0.39	2.48e-10	Coronary artery disease;
KIRP	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.12	-0.61	8.19e-27	Eye color traits;
KIRP	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-0.8	-9.32	-0.51	6.86e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26207909	chr14:103986467	CKB	0.74	10.59	0.56	7.51e-22	Body mass index;
KIRP	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.59	-7.5	-0.43	1.16e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.75	0.49	3.5e-16	Bipolar disorder;
KIRP	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg09491104	chr22:46646882	C22orf40	-0.58	-6.57	-0.39	2.99e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg19116668	chr7:99932089	PMS2L1	0.44	5.2	0.31	4.21e-7	Coronary artery disease;
KIRP	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.77	9.65	0.52	6.89e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.38	-5.07	-0.31	7.93e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.96	0.41	3.15e-11	Schizophrenia;
KIRP	cis	rs74181299	0.684	rs11126029	chr2:65338264	C/T	cg05010058	chr2:65284262	CEP68	-0.42	-5.68	-0.34	3.84e-8	Pulse pressure;
KIRP	cis	rs9311474	0.713	rs352169	chr3:52236762	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.61	0.39	2.34e-10	Electroencephalogram traits;
KIRP	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.49	6.23	0.37	2.03e-9	Menopause (age at onset);
KIRP	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.74	10.35	0.55	4.48e-21	Diastolic blood pressure;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22911074	chr5:6632973	NSUN2;SRD5A1	0.44	6.04	0.36	5.77e-9	Parkinson's disease;
KIRP	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-8.59	-0.48	1.01e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg13147721	chr7:65941812	NA	0.8	6.63	0.39	2.17e-10	Diabetic kidney disease;
KIRP	cis	rs62380364	0.565	rs13158247	chr5:88030670	C/T	cg24804195	chr5:87968844	LOC645323	-0.45	-5.9	-0.35	1.19e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs13170463	0.579	rs78181509	chr5:8043907	G/A	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.47	7.41	0.43	2.04e-12	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.72	7.89	0.45	9.76e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00149659	chr3:10157352	C3orf10	0.82	9.01	0.5	5.79e-17	Alzheimer's disease;
KIRP	cis	rs494003	1.000	rs11227284	chr11:65503224	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.49	5.03	0.31	9.49e-7	Systemic lupus erythematosus;
KIRP	cis	rs1978968	0.731	rs9617648	chr22:18460059	G/T	cg02610425	chr22:18483192	MICAL3	0.38	5.68	0.34	3.78e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.62	-6.77	-0.4	9.48e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.55	4.89	0.3	1.81e-6	Other erythrocyte phenotypes;
KIRP	cis	rs11877825	0.826	rs9961960	chr18:10570303	A/G	cg07277756	chr18:10589357	NA	-0.47	-6.09	-0.36	4.24e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-8.05	-0.46	3.43e-14	Height;
KIRP	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg01620082	chr3:125678407	NA	-1.12	-7.03	-0.41	2.06e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg05756136	chr1:119680316	WARS2	-0.61	-8.49	-0.48	2.01e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.73	11.6	0.59	4.11e-25	Menarche (age at onset);
KIRP	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg20060108	chr2:102954350	IL1RL1	-0.67	-5.94	-0.35	9.81e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg19468946	chr17:37922297	IKZF3	-0.49	-6.76	-0.4	9.95e-11	Self-reported allergy;
KIRP	cis	rs7224685	0.501	rs1052617	chr17:3909404	C/A	cg01798813	chr17:3906674	NA	0.57	7.96	0.45	6.47e-14	Type 2 diabetes;
KIRP	cis	rs9323205	0.723	rs61987304	chr14:51741213	A/G	cg23942311	chr14:51606299	NA	-0.52	-4.91	-0.3	1.69e-6	Cancer;
KIRP	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.98	-0.36	7.64e-9	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10820693	chr2:237994591	COPS8	0.49	6.14	0.36	3.24e-9	Parkinson's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10464529	chr16:58030730	ZNF319	0.5	6.14	0.36	3.33e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9898058	0.556	rs1135034	chr17:47783663	C/T	cg06375292	chr17:47786311	SLC35B1	-0.75	-6.21	-0.37	2.21e-9	Milk allergy;
KIRP	cis	rs73206853	0.764	rs7312939	chr12:110564108	G/A	cg12870014	chr12:110450643	ANKRD13A	0.56	5.61	0.34	5.37e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg15655495	chr12:38532458	NA	-0.29	-5.16	-0.31	4.97e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.99	17.22	0.74	3.97e-44	Breast cancer;
KIRP	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.4	5.35	0.32	1.99e-7	Blood protein levels;
KIRP	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg05714579	chr10:131428358	MGMT	0.46	5.82	0.35	1.78e-8	Response to temozolomide;
KIRP	cis	rs6725041	0.717	rs12185587	chr2:213101298	T/C	cg20637307	chr2:213403960	ERBB4	-0.42	-5.56	-0.33	6.89e-8	QT interval (ambient particulate matter interaction);
KIRP	cis	rs7520050	0.966	rs6700597	chr1:46284246	G/A	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.53e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg08975724	chr8:8085496	FLJ10661	0.48	5.95	0.35	9.09e-9	Joint mobility (Beighton score);
KIRP	cis	rs1805008	0.568	rs118174802	chr16:90143567	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.06	-6.63	-0.39	2.11e-10	Skin colour saturation;
KIRP	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.34	0.47	5.37e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.23	0.51	1.31e-17	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs311392	0.526	rs167474	chr8:55101321	A/C	cg20636351	chr8:55087400	NA	-0.53	-6.6	-0.39	2.54e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11955398	0.546	rs10050803	chr5:60038225	G/A	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.21	-0.32	4.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs41005	0.805	rs10469618	chr2:8117622	C/T	cg03155496	chr2:8117019	LOC339788	-0.68	-12.33	-0.62	1.67e-27	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs7615316	0.789	rs9846960	chr3:142308070	G/A	cg20824294	chr3:142316082	PLS1	0.27	5.98	0.36	7.75e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.44	-6.3	-0.37	1.4e-9	Height;
KIRP	cis	rs34779708	0.898	rs4934695	chr10:35280605	C/T	cg04310649	chr10:35416472	CREM	-0.53	-5.97	-0.36	8.41e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs7106204	0.686	rs12791623	chr11:24277924	A/T	ch.11.24196551F	chr11:24239977	NA	0.73	6.02	0.36	6.28e-9	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18357526	chr6:26021779	HIST1H4A	0.52	6.72	0.39	1.24e-10	Iron status biomarkers;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs918629	0.716	rs6881355	chr5:95274795	C/T	cg16656078	chr5:95278638	ELL2	-0.46	-6.7	-0.39	1.38e-10	IgG glycosylation;
KIRP	cis	rs8044868	0.512	rs4788461	chr16:72156000	C/A	cg16558253	chr16:72132732	DHX38	-0.41	-5.53	-0.33	8.21e-8	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs4919044	0.808	rs1222605	chr10:94804200	T/C	cg05127821	chr10:94822908	CYP26C1	-1.06	-11.15	-0.58	1.2e-23	Coronary artery disease;
KIRP	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg04935436	chr20:30431758	NA	0.53	6.52	0.38	4.05e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19346786	chr7:2764209	NA	-0.37	-6.31	-0.37	1.26e-9	Height;
KIRP	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.53	6.38	0.38	8.65e-10	Menopause (age at onset);
KIRP	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg05861140	chr6:150128134	PCMT1	-0.54	-7.76	-0.44	2.31e-13	Lung cancer;
KIRP	cis	rs13401104	0.587	rs7569760	chr2:237145713	A/C	cg19324714	chr2:237145437	ASB18	0.56	6.52	0.38	3.97e-10	Educational attainment;
KIRP	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs13401104	0.754	rs10929175	chr2:237117204	A/C	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs9596863	0.898	rs13378790	chr13:54372312	T/C	ch.13.53330881F	chr13:54432880	NA	0.62	5.99	0.36	7.52e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.87	-14.61	-0.68	3.22e-35	Prostate cancer;
KIRP	cis	rs12580194	0.593	rs7314118	chr12:55737403	A/C	cg11794356	chr12:55725991	OR6C3	-0.6	-8.61	-0.48	8.63e-16	Cancer;
KIRP	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-8.04	-0.46	3.77e-14	Asthma;
KIRP	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.14	-0.54	2.03e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg01631408	chr1:248437212	OR2T33	-0.62	-8.23	-0.46	1.08e-14	Common traits (Other);
KIRP	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.88	13.73	0.66	3.08e-32	Coronary artery disease;
KIRP	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg06606381	chr12:133084897	FBRSL1	-1.07	-6.38	-0.38	8.73e-10	Depression;
KIRP	cis	rs7508	0.511	rs208056	chr8:17822884	C/T	cg01800426	chr8:17659068	MTUS1	-0.56	-5.59	-0.34	6.09e-8	Atrial fibrillation;
KIRP	cis	rs10073892	0.956	rs10041652	chr5:101816228	G/A	cg19774478	chr5:101632501	SLCO4C1	0.6	6.24	0.37	1.93e-9	Cognitive decline (age-related);
KIRP	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	13.5	0.65	1.84e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs2733310	0.793	rs8035485	chr15:57236325	G/A	cg13626582	chr15:57592083	LOC283663	0.27	6.22	0.37	2.17e-9	Mean platelet volume;
KIRP	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg23752985	chr2:85803571	VAMP8	-0.47	-5.64	-0.34	4.62e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.3	-0.32	2.54e-7	Parkinson's disease;
KIRP	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-6.55	-0.39	3.26e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.47	6.68	0.39	1.6e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13198984	chr17:80129470	CCDC57	-0.5	-7.77	-0.44	2.14e-13	Life satisfaction;
KIRP	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg18016565	chr1:150552671	MCL1	0.38	5.35	0.32	1.98e-7	Melanoma;
KIRP	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg25801113	chr15:45476975	SHF	0.42	7.81	0.45	1.61e-13	Uric acid levels;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg08239325	chr14:54944410	GMFB	0.4	6.09	0.36	4.21e-9	C-reactive protein;
KIRP	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs5753618	0.561	rs737887	chr22:31696615	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.32	-0.32	2.37e-7	Colorectal cancer;
KIRP	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.9	13.61	0.66	7.87e-32	Anterior chamber depth;
KIRP	cis	rs10486003	1.000	rs6957084	chr7:97198579	G/T	cg05663341	chr7:96634660	DLX6AS;DLX6	-0.57	-5.07	-0.31	7.71e-7	Response to platinum-based agents;
KIRP	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.71	-0.44	3.13e-13	Initial pursuit acceleration;
KIRP	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-8.1	-0.46	2.52e-14	Chronic sinus infection;
KIRP	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.95	11.35	0.59	2.68e-24	Corneal astigmatism;
KIRP	cis	rs3857747	0.827	rs10229210	chr7:40440573	G/A	cg00420559	chr7:40367873	C7orf10	-0.56	-7.76	-0.44	2.2e-13	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs231513	1.000	rs231526	chr17:41951277	T/C	cg26893861	chr17:41843967	DUSP3	-0.61	-5.24	-0.32	3.5e-7	Cognitive function;
KIRP	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg06550200	chr5:1325588	CLPTM1L	0.79	10.3	0.55	6.43e-21	Lung cancer;
KIRP	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg11584989	chr19:19387371	SF4	0.45	5.75	0.34	2.6e-8	Tonsillectomy;
KIRP	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	1.21	10.58	0.56	8.56e-22	Atopic dermatitis;
KIRP	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.7	-12.88	-0.63	2.31e-29	White blood cell count (basophil);
KIRP	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.94	-15.04	-0.69	1.06e-36	Height;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg27338695	chr8:41435702	AGPAT6	0.53	6.28	0.37	1.49e-9	Electroencephalogram traits;
KIRP	cis	rs72634258	0.945	rs2641116	chr1:8029494	T/G	cg00042356	chr1:8021962	PARK7	0.59	5.82	0.35	1.83e-8	Inflammatory bowel disease;
KIRP	cis	rs2197308	0.594	rs9705810	chr12:37895003	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-8.37	-0.47	4.44e-15	Morning vs. evening chronotype;
KIRP	cis	rs4713675	0.584	rs9394163	chr6:33682414	A/G	cg15676125	chr6:33679581	C6orf125	0.42	5.52	0.33	8.79e-8	Plateletcrit;
KIRP	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.54	7.25	0.42	5.47e-12	Bladder cancer;
KIRP	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	1.08	11.82	0.6	7.81e-26	Eosinophil percentage of granulocytes;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2006771	0.810	rs4820988	chr22:32065807	G/A	cg02404636	chr22:31891804	SFI1	-0.48	-5.91	-0.35	1.11e-8	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs12458130	0.892	rs539715	chr18:8667407	A/G	cg25899954	chr18:8660164	NA	-0.6	-5.76	-0.34	2.52e-8	Inflammatory skin disease;
KIRP	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-12.98	-0.64	1.1e-29	Vitiligo;
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.5	6.69	0.39	1.53e-10	Testicular germ cell tumor;
KIRP	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg03929089	chr4:120376271	NA	0.71	6.33	0.37	1.16e-9	Axial length;
KIRP	cis	rs6974574	1.000	rs940347	chr7:38110425	A/G	cg10754659	chr7:38110151	NA	-0.37	-5.0	-0.3	1.08e-6	Height;
KIRP	cis	rs4356932	1.000	rs6825045	chr4:76957558	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs6738485	0.561	rs7590731	chr2:106810233	C/A	cg23362669	chr2:106776913	UXS1	0.21	5.13	0.31	5.77e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg10503236	chr1:231470652	EXOC8	-0.53	-7.46	-0.43	1.52e-12	Hemoglobin concentration;
KIRP	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.56	0.33	6.98e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg16077055	chr2:106428750	NCK2	0.27	5.28	0.32	2.84e-7	Addiction;
KIRP	cis	rs3829109	0.564	rs11789379	chr9:139285260	T/C	cg14169450	chr9:139327907	INPP5E	0.59	6.83	0.4	6.62e-11	Peak insulin response;Acute insulin response;
KIRP	trans	rs7868992	0.515	rs902496	chr9:116989776	G/T	cg20347090	chr12:3602093	PRMT8	0.56	6.06	0.36	5.08e-9	Tourette syndrome;
KIRP	cis	rs7187994	0.895	rs16974453	chr16:84758510	C/T	cg07647771	chr16:84786436	USP10	-0.44	-5.57	-0.33	6.57e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg24253500	chr15:84953950	NA	0.49	4.85	0.3	2.17e-6	Schizophrenia;
KIRP	cis	rs9308731	0.644	rs7602904	chr2:111880600	C/T	cg18646521	chr2:111875858	NA	0.37	5.3	0.32	2.59e-7	Chronic lymphocytic leukemia;
KIRP	cis	rs9463078	0.547	rs1338908	chr6:44728812	C/T	cg25276700	chr6:44698697	NA	0.35	5.06	0.31	8.28e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.71	-10.69	-0.56	3.73e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9880211	0.800	rs13314357	chr3:136487559	A/G	cg21827317	chr3:136751795	NA	-0.47	-5.0	-0.3	1.11e-6	Body mass index;Height;
KIRP	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg23307798	chr14:103986281	CKB	0.73	11.33	0.59	3.22e-24	Body mass index;
KIRP	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg24253500	chr15:84953950	NA	-0.5	-5.77	-0.35	2.4e-8	Schizophrenia;
KIRP	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.64	-7.5	-0.43	1.14e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9488822	0.549	rs195527	chr6:116250858	T/C	cg05304507	chr6:116381966	FRK	0.2	4.99	0.3	1.15e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg24747557	chr10:131355152	MGMT	-0.44	-5.89	-0.35	1.24e-8	Response to temozolomide;
KIRP	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.0	-12.83	-0.63	3.4e-29	Exhaled nitric oxide output;
KIRP	cis	rs5753618	0.561	rs9609264	chr22:31746719	C/G	cg22777020	chr22:31556080	RNF185	0.48	5.05	0.31	8.79e-7	Colorectal cancer;
KIRP	cis	rs501120	0.584	rs11238925	chr10:44703730	A/G	cg09554077	chr10:44749378	NA	0.56	5.95	0.35	9.34e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.8	-10.57	-0.56	8.87e-22	Chronic sinus infection;
KIRP	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg12598211	chr12:123634384	NA	-0.44	-5.34	-0.32	2.11e-7	Neutrophil percentage of white cells;
KIRP	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg02574844	chr11:5959923	NA	0.44	4.95	0.3	1.35e-6	DNA methylation (variation);
KIRP	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg06223162	chr1:101003688	GPR88	0.4	7.51	0.43	1.08e-12	Monocyte count;
KIRP	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.8	11.03	0.58	3.1e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9653442	0.564	rs4851261	chr2:100786717	A/G	cg07810366	chr2:100720526	AFF3	-0.32	-5.1	-0.31	6.76e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.66	8.93	0.49	1.01e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs3026101	0.671	rs56019636	chr17:5297551	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.75	10.64	0.56	5.4e-22	Chronic sinus infection;
KIRP	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.41	-4.98	-0.3	1.22e-6	Response to bleomycin (chromatid breaks);
KIRP	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg10760299	chr15:45669010	GATM	0.35	5.11	0.31	6.47e-7	Homoarginine levels;
KIRP	cis	rs78487399	0.731	rs13408697	chr2:43706244	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.51	-5.1	-0.31	6.67e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.12	-19.09	-0.77	1.85e-50	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26607248	chr1:202979751	TMEM183A;TMEM183B	-0.43	-6.83	-0.4	6.74e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg21523564	chr15:75251491	NA	0.36	5.75	0.34	2.59e-8	Breast cancer;
KIRP	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.82	-7.34	-0.42	3.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.51	5.4	0.33	1.54e-7	Schizophrenia;
KIRP	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.39	-0.43	2.35e-12	Morning vs. evening chronotype;
KIRP	cis	rs6466055	0.686	rs56269269	chr7:104846634	G/A	cg04380332	chr7:105027541	SRPK2	0.37	4.97	0.3	1.27e-6	Schizophrenia;
KIRP	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg13264159	chr8:625131	ERICH1	0.75	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05665937	chr4:1216051	CTBP1	0.58	8.09	0.46	2.78e-14	Obesity-related traits;
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	trans	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg10756647	chr7:56101905	PSPH	1.07	8.32	0.47	6.01e-15	Diabetic kidney disease;
KIRP	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg21395723	chr22:39101663	GTPBP1	0.38	4.88	0.3	1.92e-6	Menopause (age at onset);
KIRP	cis	rs2071426	0.959	rs6583967	chr10:96814475	C/T	cg09036531	chr10:96991505	NA	0.56	6.47	0.38	5.31e-10	Blood metabolite levels;
KIRP	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg07777115	chr5:623756	CEP72	-0.58	-5.68	-0.34	3.85e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20135002	chr11:47629003	NA	-0.47	-5.47	-0.33	1.1e-7	Subjective well-being;
KIRP	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.1	0.41	1.35e-11	Aortic root size;
KIRP	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg04317338	chr11:64019027	PLCB3	0.45	5.43	0.33	1.37e-7	Platelet count;
KIRP	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg14972814	chr11:95582409	MTMR2	0.36	6.06	0.36	5.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg04865290	chr3:52927548	TMEM110	-0.6	-6.66	-0.39	1.73e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.85	13.61	0.66	8.14e-32	Prostate cancer;
KIRP	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11584989	chr19:19387371	SF4	0.57	6.09	0.36	4.34e-9	Bipolar disorder;
KIRP	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.41	-7.39	-0.43	2.29e-12	Refractive error;
KIRP	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.93	15.83	0.71	2.11e-39	Breast cancer;
KIRP	cis	rs9354308	0.753	rs10455590	chr6:66598194	A/G	cg07460842	chr6:66804631	NA	-0.45	-5.56	-0.33	6.89e-8	Metabolite levels;
KIRP	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs35123781	0.580	rs431184	chr5:138962408	G/A	cg12205435	chr5:138714322	SLC23A1	-0.39	-5.18	-0.31	4.55e-7	Schizophrenia;
KIRP	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.35	-5.02	-0.31	9.72e-7	Lymphocyte counts;
KIRP	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg22907277	chr7:1156413	C7orf50	0.49	5.5	0.33	9.39e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg21775007	chr8:11205619	TDH	0.46	6.11	0.36	3.9e-9	Neuroticism;
KIRP	cis	rs865483	0.929	rs9906140	chr17:35857151	A/G	cg06716730	chr17:35851459	DUSP14	-0.24	-5.66	-0.34	4.15e-8	Monocyte count;
KIRP	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.39	-5.88	-0.35	1.35e-8	Psoriasis;
KIRP	cis	rs4742903	0.509	rs58883324	chr9:106969430	T/C	cg14250997	chr9:106856677	SMC2	0.37	4.92	0.3	1.57e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg04455712	chr21:45112962	RRP1B	-0.55	-7.39	-0.43	2.35e-12	Mean corpuscular volume;
KIRP	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.63	-9.07	-0.5	3.92e-17	Testicular germ cell tumor;
KIRP	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg11814155	chr7:99998594	ZCWPW1	0.53	5.34	0.32	2.09e-7	Platelet count;
KIRP	cis	rs2412819	0.542	rs62018894	chr15:43912987	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.47	5.76	0.34	2.55e-8	Lung cancer;
KIRP	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.73	-8.7	-0.49	4.81e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-13.62	-0.66	7.45e-32	Gut microbiome composition (summer);
KIRP	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg12062639	chr20:23401060	NAPB	0.79	6.85	0.4	5.75e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2387326	0.767	rs76961244	chr10:129940561	A/C	cg16087940	chr10:129947807	NA	-0.36	-4.88	-0.3	1.87e-6	Select biomarker traits;
KIRP	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.7	9.81	0.53	2.21e-19	Retinal vascular caliber;
KIRP	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg13206674	chr6:150067644	NUP43	0.57	8.31	0.47	6.53e-15	Lung cancer;
KIRP	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg27205649	chr11:78285834	NARS2	0.68	9.02	0.5	5.33e-17	Alzheimer's disease (survival time);
KIRP	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg23978390	chr7:1156363	C7orf50	0.42	5.07	0.31	7.76e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg15896084	chr13:114927664	NA	0.52	7.13	0.41	1.13e-11	Schizophrenia;
KIRP	cis	rs6083	0.571	rs56010348	chr15:58848120	T/G	cg05156742	chr15:59063176	FAM63B	-0.5	-6.17	-0.37	2.86e-9	Schizophrenia;
KIRP	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg17724175	chr1:150552817	MCL1	-0.29	-4.85	-0.3	2.16e-6	Melanoma;
KIRP	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg06565975	chr8:143823917	SLURP1	-0.58	-7.93	-0.45	7.55e-14	Urinary tract infection frequency;
KIRP	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg00343986	chr7:65444356	GUSB	-0.45	-5.55	-0.33	7.3900000000000007e-08	Aortic root size;
KIRP	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg05709478	chr1:6581295	PLEKHG5	0.56	5.03	0.31	9.44e-7	Body mass index;
KIRP	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg13147721	chr7:65941812	NA	-0.85	-5.88	-0.35	1.36e-8	Diabetic kidney disease;
KIRP	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg25482853	chr8:67687455	SGK3	0.79	6.99	0.41	2.64e-11	Obesity-related traits;
KIRP	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.45	6.63	0.39	2.1e-10	Lymphocyte counts;
KIRP	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	6.07	0.36	4.83e-9	Cognitive test performance;
KIRP	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg19610905	chr11:61596333	FADS2	-0.48	-7.25	-0.42	5.51e-12	Trans fatty acid levels;
KIRP	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.52	6.45	0.38	5.9e-10	Monocyte count;
KIRP	cis	rs714031	0.967	rs5757763	chr22:40065005	A/G	cg21377881	chr22:40064566	CACNA1I	-0.7	-11.23	-0.58	6.85e-24	Schizophrenia;
KIRP	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	13.54	0.65	1.33e-31	Alzheimer's disease;
KIRP	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.66	-7.29	-0.42	4.24e-12	Gut microbiome composition (summer);
KIRP	cis	rs7106204	0.609	rs12276488	chr11:24250211	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.75	0.49	3.45e-16	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.84	-13.09	-0.64	4.62e-30	Intelligence (multi-trait analysis);
KIRP	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.62	-0.34	5.2e-8	Metabolite levels;
KIRP	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg03465714	chr1:152285911	FLG	-0.44	-5.35	-0.32	2.03e-7	Atopic dermatitis;
KIRP	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg00806126	chr19:22604979	ZNF98	-0.69	-7.28	-0.42	4.61e-12	Pain;
KIRP	cis	rs501120	0.810	rs622472	chr10:44749211	A/C	cg09554077	chr10:44749378	NA	0.73	12.26	0.62	2.82e-27	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.47	6.81	0.4	7.49e-11	Optic cup area;
KIRP	cis	rs4794202	0.579	rs9896712	chr17:45884543	G/A	cg02219949	chr17:45927392	SP6	0.63	7.47	0.43	1.44e-12	Alzheimer's disease (cognitive decline);
KIRP	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.61	-7.68	-0.44	3.68e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	5.03	0.31	9.59e-7	Lymphocyte percentage of white cells;
KIRP	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.69	9.12	0.5	2.85e-17	Bladder cancer;
KIRP	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg11150807	chr10:43354902	NA	-0.67	-7.34	-0.42	3.07e-12	Blood protein levels;
KIRP	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18252515	chr7:66147081	NA	-0.48	-5.55	-0.33	7.44e-8	Aortic root size;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg04558112	chr16:69788908	NOB1	0.51	6.09	0.36	4.32e-9	Plasma plasminogen activator levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24129947	chr15:43213015	TTBK2	0.46	6.62	0.39	2.21e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs12143943	0.934	rs1563827	chr1:204579139	C/T	cg20240347	chr1:204465584	NA	-0.36	-6.64	-0.39	2.05e-10	Cognitive performance;
KIRP	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.94	-6.5	-0.38	4.36e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.84	12.64	0.63	1.53e-28	Uric acid clearance;
KIRP	cis	rs787274	1.000	rs787296	chr9:115541703	A/G	cg13803584	chr9:115635662	SNX30	-0.74	-6.65	-0.39	1.93e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg03641300	chr2:160917029	PLA2R1	-0.47	-7.16	-0.42	9.33e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg06521331	chr12:34319734	NA	-0.59	-7.0	-0.41	2.48e-11	Bladder cancer;
KIRP	cis	rs28595532	0.516	rs17594740	chr4:119246754	C/T	cg21605333	chr4:119757512	SEC24D	0.77	5.62	0.34	5.09e-8	Cannabis dependence symptom count;
KIRP	cis	rs73200209	0.869	rs55971373	chr12:116527374	G/T	cg01776926	chr12:116560359	MED13L	-0.47	-5.53	-0.33	8.09e-8	Total body bone mineral density;
KIRP	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.68	-9.04	-0.5	4.71e-17	Blood metabolite levels;
KIRP	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.84	-11.02	-0.58	3.15e-23	Obesity-related traits;
KIRP	cis	rs11955398	0.604	rs4700379	chr5:59872392	G/A	cg02684056	chr5:59996105	DEPDC1B	0.46	5.31	0.32	2.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg25037394	chr1:24152592	HMGCL	0.37	5.05	0.31	8.81e-7	Immature fraction of reticulocytes;
KIRP	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.63e-13	Corneal astigmatism;
KIRP	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.61	8.6	0.48	9.65e-16	Lymphocyte counts;
KIRP	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg27411982	chr8:10470053	RP1L1	-0.39	-4.89	-0.3	1.82e-6	Triglycerides;
KIRP	cis	rs1434579	0.865	rs12983504	chr19:44942959	G/A	cg15540054	chr19:45004280	ZNF180	0.54	5.8	0.35	2e-8	Tuberculosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09963654	chr16:2806322	SRRM2	0.47	6.15	0.37	3.14e-9	Survival in pancreatic cancer;
KIRP	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg13010199	chr12:38710504	ALG10B	-0.51	-6.54	-0.38	3.56e-10	Morning vs. evening chronotype;
KIRP	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.63	-7.39	-0.43	2.25e-12	Type 2 diabetes;
KIRP	cis	rs10214930	0.697	rs1030003	chr7:27639859	A/C	cg22168087	chr7:27702803	HIBADH	0.47	5.01	0.3	1.04e-6	Hypospadias;
KIRP	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.85	-0.4	5.97e-11	Joint mobility (Beighton score);
KIRP	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	ch.11.42038R	chr11:967971	AP2A2	0.42	5.49	0.33	1.02e-7	Alzheimer's disease (late onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09848324	chr4:56458183	PDCL2	0.49	6.2	0.37	2.41e-9	Interleukin-4 levels;
KIRP	cis	rs2411233	0.868	rs12899419	chr15:39261036	A/C	cg02291532	chr15:39874776	THBS1	0.4	5.21	0.32	4.05e-7	Platelet count;
KIRP	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.83	12.6	0.63	2.07e-28	Menarche (age at onset);
KIRP	cis	rs17401966	0.540	rs7546368	chr1:10418826	G/A	cg19773385	chr1:10388646	KIF1B	-0.42	-6.16	-0.37	2.92e-9	Hepatocellular carcinoma;
KIRP	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.86	0.35	1.5e-8	Morning vs. evening chronotype;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg10254082	chr7:997346	NA	0.48	5.16	0.31	5.02e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.59	6.15	0.37	3.11e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg20302533	chr7:39170763	POU6F2	0.26	5.42	0.33	1.45e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg11608241	chr8:8085544	FLJ10661	-0.5	-6.25	-0.37	1.77e-9	Retinal vascular caliber;
KIRP	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.56	5.73	0.34	2.9e-8	Total cholesterol levels;
KIRP	cis	rs4972539	0.784	rs74417392	chr2:174086285	C/T	cg04505972	chr2:173508040	NA	-0.44	-5.73	-0.34	2.95e-8	Parental longevity (mother's age at death);
KIRP	cis	rs2077654	0.822	rs4148634	chr11:17429872	G/A	cg25308976	chr11:17434268	ABCC8	1.08	11.19	0.58	8.85e-24	Gout;
KIRP	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.73	0.39	1.17e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.59	7.03	0.41	2.01e-11	Obesity-related traits;
KIRP	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg20713898	chr8:124780851	FAM91A1	-0.61	-6.72	-0.39	1.28e-10	Pancreatic cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg10959786	chr13:74708124	KLF12	0.49	6.51	0.38	4.29e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs2275565	0.872	rs4659734	chr1:237030788	T/C	cg17297354	chr1:237056641	MTR	-0.53	-5.82	-0.35	1.85e-8	Homocysteine levels;
KIRP	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.31	-0.37	1.29e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.68	0.48	5.36e-16	Prudent dietary pattern;
KIRP	cis	rs9826463	1.000	rs7647212	chr3:142322055	G/A	cg20824294	chr3:142316082	PLS1	0.31	5.27	0.32	3.05e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7561273	0.586	rs12477718	chr2:24330539	A/G	cg20701182	chr2:24300061	SF3B14	0.49	6.0	0.36	7.17e-9	Quantitative traits;
KIRP	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.6	-9.5	-0.52	1.92e-18	Neuroticism;
KIRP	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg10505658	chr17:80084571	CCDC57	-0.26	-4.9	-0.3	1.71e-6	Life satisfaction;
KIRP	cis	rs73200209	0.912	rs55841728	chr12:116645455	C/A	cg01776926	chr12:116560359	MED13L	-0.47	-5.63	-0.34	4.79e-8	Total body bone mineral density;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg08662619	chr6:150070041	PCMT1	0.36	5.98	0.36	7.89e-9	Lung cancer;
KIRP	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-8.59	-0.48	1.04e-15	Response to antipsychotic treatment;
KIRP	cis	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg18904891	chr8:8559673	CLDN23	0.56	6.49	0.38	4.75e-10	Obesity-related traits;
KIRP	trans	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg10756647	chr7:56101905	PSPH	1.0	7.46	0.43	1.52e-12	Diabetic kidney disease;
KIRP	cis	rs2290402	0.572	rs3736087	chr4:876318	C/T	cg14517359	chr4:903473	GAK	-0.54	-5.65	-0.34	4.35e-8	Type 2 diabetes;
KIRP	cis	rs9972944	0.729	rs1895035	chr17:63777711	G/A	cg07283582	chr17:63770753	CCDC46	0.52	8.57	0.48	1.2e-15	Total body bone mineral density;
KIRP	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.58	-5.84	-0.35	1.62e-8	Platelet distribution width;
KIRP	cis	rs7301016	0.520	rs73126004	chr12:63004975	T/C	cg01804193	chr12:63026212	NA	0.45	5.6	0.34	5.78e-8	IgG glycosylation;
KIRP	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg16584676	chr17:46985605	UBE2Z	-0.48	-6.1	-0.36	4.03e-9	Type 2 diabetes;
KIRP	cis	rs6120849	0.754	rs8501	chr20:33590584	T/C	cg24642439	chr20:33292090	TP53INP2	0.63	6.37	0.38	9.09e-10	Protein C levels;
KIRP	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.75	-9.68	-0.53	5.59e-19	Coronary artery disease;
KIRP	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg27205649	chr11:78285834	NARS2	0.68	9.04	0.5	4.75e-17	Alzheimer's disease (survival time);
KIRP	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs1562975	0.609	rs62316329	chr4:109419399	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.42	5.2	0.31	4.22e-7	Height;
KIRP	cis	rs6504622	0.791	rs61671555	chr17:45037857	C/T	cg24703533	chr17:45055318	NA	0.38	5.11	0.31	6.37e-7	Orofacial clefts;
KIRP	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg01522456	chr1:115632236	TSPAN2	-0.49	-6.27	-0.37	1.64e-9	Autism;
KIRP	cis	rs73206853	0.697	rs56084592	chr12:110577910	T/A	cg12870014	chr12:110450643	ANKRD13A	0.53	5.58	0.34	6.21e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6142102	0.961	rs6059649	chr20:32643877	C/T	cg08999081	chr20:33150536	PIGU	0.51	6.05	0.36	5.27e-9	Skin pigmentation;
KIRP	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg05156742	chr15:59063176	FAM63B	0.55	6.73	0.39	1.16e-10	Schizophrenia;
KIRP	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.6	-8.25	-0.47	9.64e-15	Rheumatoid arthritis;
KIRP	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.57	7.02	0.41	2.09e-11	Aortic root size;
KIRP	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.88	10.53	0.56	1.25e-21	Corneal astigmatism;
KIRP	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg08533674	chr1:46993347	NA	-0.39	-4.98	-0.3	1.18e-6	Monobrow;
KIRP	trans	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17183009	chr3:120277827	NA	0.56	6.45	0.38	5.9e-10	Corneal astigmatism;
KIRP	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg18350739	chr11:68623251	NA	-0.51	-7.67	-0.44	3.91e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.56	8.1	0.46	2.51e-14	Fat distribution (HIV);
KIRP	cis	rs55675132	0.548	rs10494169	chr1:115363532	T/C	cg12756093	chr1:115239321	AMPD1	0.53	5.44	0.33	1.28e-7	Schizophrenia;
KIRP	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.6	7.81	0.45	1.7e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.61	-7.09	-0.41	1.38e-11	Mean platelet volume;
KIRP	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-6.23	-0.37	1.95e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg09029085	chr17:47094198	IGF2BP1	0.24	5.6	0.34	5.63e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs27434	0.583	rs151911	chr5:96157084	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.06e-8	Ankylosing spondylitis;
KIRP	cis	rs4400599	0.901	rs2494670	chr1:154101057	T/C	cg26808167	chr1:154192205	UBAP2L;C1orf43	0.35	5.01	0.3	1.04e-6	Platelet distribution width;
KIRP	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg15880211	chr22:50250494	ZBED4	-0.44	-5.29	-0.32	2.64e-7	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg13147721	chr7:65941812	NA	-0.97	-6.9	-0.4	4.46e-11	Diabetic kidney disease;
KIRP	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	1.11	17.89	0.75	2.12e-46	Homoarginine levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01753966	chr4:3531945	LRPAP1	0.5	6.1	0.36	4.11e-9	Interleukin-4 levels;
KIRP	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-7.36	-0.42	2.7e-12	Cognitive test performance;
KIRP	cis	rs7923609	1.000	rs10761727	chr10:64995493	C/T	cg01631684	chr10:65280961	REEP3	-0.48	-5.67	-0.34	4.07e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg19016782	chr12:123741754	C12orf65	-0.38	-4.88	-0.3	1.94e-6	Neutrophil percentage of white cells;
KIRP	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg20573242	chr4:122745356	CCNA2	0.41	5.07	0.31	7.84e-7	Type 2 diabetes;
KIRP	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg01097406	chr16:89675127	NA	0.35	5.45	0.33	1.2e-7	Vitiligo;
KIRP	cis	rs10465746	0.570	rs2147950	chr1:84465545	C/T	cg10977910	chr1:84465055	TTLL7	0.48	5.8	0.35	2.03e-8	Obesity-related traits;
KIRP	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.05	-0.41	1.82e-11	Systolic blood pressure;
KIRP	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg23442198	chr4:187126114	CYP4V2	-0.83	-7.31	-0.42	3.66e-12	Blood protein levels;
KIRP	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg17133734	chr15:86042851	AKAP13	-0.44	-5.41	-0.33	1.47e-7	Coronary artery disease;
KIRP	trans	rs4742903	0.935	rs10991165	chr9:106973498	A/G	cg19866939	chr13:114821703	RASA3	-0.42	-6.19	-0.37	2.48e-9	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7520050	0.933	rs6680211	chr1:46315007	C/G	cg03146154	chr1:46216737	IPP	-0.4	-5.05	-0.31	8.66e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs4889855	0.530	rs7209279	chr17:78598055	T/A	cg09596252	chr17:78655493	RPTOR	0.51	5.86	0.35	1.51e-8	Fractional excretion of uric acid;
KIRP	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg10047753	chr17:41438598	NA	-0.83	-11.11	-0.58	1.63e-23	Menopause (age at onset);
KIRP	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-6.6	-0.39	2.45e-10	Obesity-related traits;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg23657707	chr19:1050977	ABCA7	0.47	6.36	0.38	1e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.68	-8.19	-0.46	1.39e-14	Neuroticism;
KIRP	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.69	9.86	0.53	1.53e-19	Retinal vascular caliber;
KIRP	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg00491522	chr10:135256596	NA	0.56	5.98	0.36	7.67e-9	Systemic lupus erythematosus;
KIRP	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs7777754	1.000	rs7777754	chr7:50666033	A/C	cg14593290	chr7:50529359	DDC	-0.4	-5.11	-0.31	6.35e-7	Response to zileuton treatment in asthma (FEV1 change interaction);
KIRP	cis	rs28595532	0.720	rs72670224	chr4:119301885	G/T	cg21605333	chr4:119757512	SEC24D	1.01	6.82	0.4	7e-11	Cannabis dependence symptom count;
KIRP	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.52	6.27	0.37	1.63e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04591132	chr7:72985577	TBL2	0.47	6.15	0.37	3.15e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6001982	0.748	rs10483204	chr22:40870794	T/C	cg07138101	chr22:40742427	ADSL	0.71	5.78	0.35	2.23e-8	Breast cancer;
KIRP	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg23172400	chr8:95962367	TP53INP1	-0.36	-7.55	-0.43	8.69e-13	Type 2 diabetes;
KIRP	trans	rs863345	0.526	rs857676	chr1:158615702	G/A	cg10848522	chr2:75937996	C2orf3	0.46	6.02	0.36	6.41e-9	Pneumococcal bacteremia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18931014	chr10:134161582	LRRC27	-0.46	-6.16	-0.37	2.98e-9	Inflammatory biomarkers;
KIRP	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg10189774	chr4:17578691	LAP3	0.48	5.71	0.34	3.17e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.5	5.27	0.32	2.99e-7	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.99	0.54	6.21e-20	Body mass index;
KIRP	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.68	8.95	0.5	9.04e-17	Bladder cancer;
KIRP	cis	rs56775891	0.527	rs71367545	chr18:77576337	G/A	cg02536541	chr18:77568900	NA	-0.63	-7.16	-0.42	9.03e-12	Schizophrenia;
KIRP	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg07001201	chr5:642380	CEP72	0.68	6.21	0.37	2.29e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.65	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs2150410	0.915	rs2272577	chr21:40684427	C/T	cg11890956	chr21:40555474	PSMG1	0.82	5.74	0.34	2.71e-8	Temperament (bipolar disorder);
KIRP	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg03609598	chr5:56110824	MAP3K1	-0.46	-5.2	-0.31	4.22e-7	Coronary artery disease;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18798372	chr8:124557975	NA	-0.51	-6.53	-0.38	3.69e-10	Inflammatory biomarkers;
KIRP	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg27471124	chr11:109292789	C11orf87	0.5	5.83	0.35	1.76e-8	Schizophrenia;
KIRP	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg25319279	chr11:5960081	NA	-0.49	-5.21	-0.32	4.03e-7	DNA methylation (variation);
KIRP	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg17385448	chr1:15911702	AGMAT	0.25	4.9	0.3	1.73e-6	Systolic blood pressure;
KIRP	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07234876	chr8:600039	NA	0.81	6.28	0.37	1.51e-9	IgG glycosylation;
KIRP	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg04990556	chr1:26633338	UBXN11	-0.59	-7.15	-0.41	9.66e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs7712401	0.601	rs246303	chr5:122251717	C/G	cg19412675	chr5:122181750	SNX24	0.47	5.13	0.31	5.99e-7	Mean platelet volume;
KIRP	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg04731861	chr2:219085781	ARPC2	0.3	7.57	0.43	7.44e-13	Colorectal cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26128977	chr13:50699776	DLEU2	0.51	6.65	0.39	1.86e-10	Parkinson's disease;
KIRP	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg05333889	chr7:157238977	NA	-0.51	-7.67	-0.44	4.1e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	trans	rs2997105	1.000	rs1826897	chr13:56409376	C/T	cg08528735	chr3:184428879	MAGEF1	-0.61	-6.19	-0.37	2.48e-9	Response to platinum-based chemotherapy (cisplatin);
KIRP	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.58	7.51	0.43	1.09e-12	Corneal astigmatism;
KIRP	cis	rs4765905	0.610	rs2238049	chr12:2306128	A/G	cg10668781	chr12:2307325	CACNA1C	-0.31	-6.25	-0.37	1.83e-9	Schizophrenia;
KIRP	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg02297831	chr4:17616191	MED28	0.55	6.36	0.38	9.73e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35000415	0.873	rs12539741	chr7:128596805	C/T	cg19972273	chr7:128594194	NA	0.85	6.25	0.37	1.81e-9	Systemic lupus erythematosus;
KIRP	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg27494647	chr7:150038898	RARRES2	0.38	5.67	0.34	3.95e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.82	7.82	0.45	1.55e-13	Menopause (age at onset);
KIRP	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.78	11.68	0.6	2.21e-25	Breast cancer;
KIRP	cis	rs737008	0.922	rs11074957	chr16:11378151	G/A	cg00044050	chr16:11439710	C16orf75	-0.64	-7.69	-0.44	3.57e-13	Obesity-related traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13096721	chr1:51185450	FAF1	-0.41	-6.12	-0.36	3.58e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg16473166	chr22:50639996	SELO	0.74	8.68	0.48	5.67e-16	Late-onset Alzheimer's disease;
KIRP	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg07636037	chr3:49044803	WDR6	0.41	4.97	0.3	1.25e-6	Resting heart rate;
KIRP	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.39	2.67e-10	Bipolar disorder;
KIRP	cis	rs7011049	1.000	rs72643583	chr8:53847269	C/G	cg26025543	chr8:53854495	NA	0.75	7.86	0.45	1.16e-13	Systolic blood pressure;
KIRP	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	9.77e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72730918	0.590	rs1456295	chr15:51979655	C/T	cg14296394	chr15:51910925	DMXL2	-0.74	-10.56	-0.56	9.66e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg04539111	chr16:67997858	SLC12A4	-0.53	-5.29	-0.32	2.67e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.44	4.04e-13	Bladder cancer;
KIRP	cis	rs12049351	0.774	rs6701186	chr1:229626486	C/G	cg11742688	chr1:229674241	ABCB10	-0.39	-5.8	-0.35	2.05e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.54	-6.82	-0.4	7.1e-11	Total body bone mineral density;
KIRP	cis	rs714515	0.900	rs9425291	chr1:172312769	A/G	cg01573306	chr1:172330400	DNM3	0.49	6.46	0.38	5.54e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs1816752	0.819	rs4769349	chr13:24982832	A/G	cg22771759	chr13:24902376	NA	-0.41	-5.32	-0.32	2.39e-7	Obesity-related traits;
KIRP	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.62	6.99	0.41	2.54e-11	Aortic root size;
KIRP	cis	rs76793172	0.623	rs2014377	chr19:46269313	G/C	cg00442267	chr19:46317840	RSPH6A	0.66	5.69	0.34	3.62e-8	Eosinophil counts;
KIRP	cis	rs8133932	0.736	rs4818804	chr21:47282631	T/C	cg11214348	chr21:47283868	PCBP3	0.45	4.89	0.3	1.81e-6	Schizophrenia;
KIRP	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.69	-9.25	-0.51	1.11e-17	Height;
KIRP	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg06481639	chr22:41940642	POLR3H	0.44	5.15	0.31	5.42e-7	Vitiligo;
KIRP	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg24110177	chr3:50126178	RBM5	0.43	5.65	0.34	4.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6684428	1.000	rs55693755	chr1:56369906	T/A	cg11651538	chr1:56320950	NA	-0.86	-10.11	-0.54	2.52e-20	Airflow obstruction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16209045	chr19:2328691	SPPL2B;LSM7	0.54	6.74	0.39	1.11e-10	Parkinson's disease;
KIRP	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg10169327	chr19:45448959	APOC2	0.33	4.99	0.3	1.16e-6	Blood protein levels;
KIRP	cis	rs16828019	0.852	rs11209545	chr1:41576357	T/G	cg03387723	chr1:41708464	SCMH1	-0.8	-6.73	-0.39	1.18e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg24636327	chr6:129614085	LAMA2	0.43	6.4	0.38	7.66e-10	Migraine with aura;
KIRP	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg21775007	chr8:11205619	TDH	-0.38	-4.92	-0.3	1.61e-6	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.79	8.89	0.49	1.31e-16	Corneal astigmatism;
KIRP	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.86	-13.24	-0.64	1.47e-30	Breast cancer;
KIRP	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.61	-5.19	-0.31	4.3e-7	Putamen volume;
KIRP	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg00409905	chr10:38381863	ZNF37A	-0.59	-7.56	-0.43	7.86e-13	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg25486957	chr4:152246857	NA	-0.43	-5.16	-0.31	5.02e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.5	6.38	0.38	8.88e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg07936489	chr17:37558343	FBXL20	-0.52	-6.66	-0.39	1.75e-10	Asthma;
KIRP	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-6.93	-0.4	3.63e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-5.74	-0.34	2.8e-8	Response to antipsychotic treatment;
KIRP	cis	rs829661	1.000	rs829631	chr2:30746128	C/T	cg10949345	chr2:30726833	LCLAT1	0.72	10.43	0.55	2.43e-21	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg16898833	chr6:26189333	HIST1H4D	0.79	5.71	0.34	3.28e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg17264618	chr3:40429014	ENTPD3	0.32	4.98	0.3	1.18e-6	Renal cell carcinoma;
KIRP	cis	rs742614	0.533	rs6120395	chr20:32451693	A/G	cg06304546	chr20:32448765	NA	-0.92	-13.77	-0.66	2.24e-32	Stearic acid (18:0) levels;
KIRP	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.43	5.14	0.31	5.66e-7	Body mass index;
KIRP	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg17554472	chr22:41940697	POLR3H	0.64	6.59	0.39	2.58e-10	Vitiligo;
KIRP	cis	rs4959799	0.557	rs9501971	chr6:3272565	G/A	cg10513992	chr6:3293720	SLC22A23	-0.71	-5.25	-0.32	3.34e-7	Survival in rectal cancer;
KIRP	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.43	4.87	0.3	1.97e-6	Schizophrenia;
KIRP	cis	rs4356932	1.000	rs6850515	chr4:76973751	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.44	6.64	0.39	2.04e-10	Major depressive disorder;
KIRP	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg02461776	chr11:598696	PHRF1	0.69	7.57	0.43	7.45e-13	Systemic lupus erythematosus;
KIRP	cis	rs1440410	0.804	rs4131029	chr4:144143578	C/T	cg01719995	chr4:144104893	USP38	0.39	5.09	0.31	7.11e-7	Ischemic stroke;
KIRP	cis	rs7178909	0.872	rs28468074	chr15:90435600	C/T	cg19708238	chr15:90437601	AP3S2	0.58	8.07	0.46	3.18e-14	Common traits (Other);
KIRP	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-5.06	-0.31	8.26e-7	Schizophrenia;
KIRP	cis	rs12913538	0.855	rs11071677	chr15:62896909	T/A	cg09983546	chr15:62884068	NA	0.56	7.75	0.44	2.45e-13	Sleep depth;
KIRP	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.63	-0.56	5.75e-22	Height;
KIRP	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg01475377	chr6:109611718	NA	-0.42	-5.77	-0.35	2.35e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg24747557	chr10:131355152	MGMT	-0.39	-5.15	-0.31	5.33e-7	Response to temozolomide;
KIRP	cis	rs4959799	0.655	rs56149410	chr6:3278465	C/A	cg03657281	chr6:3270030	SLC22A23	0.74	5.28	0.32	2.87e-7	Survival in rectal cancer;
KIRP	trans	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg00405596	chr8:11794950	NA	-0.46	-6.15	-0.37	3.2e-9	Mood instability;
KIRP	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg23387468	chr7:139079360	LUC7L2	0.29	5.02	0.31	9.74e-7	Diisocyanate-induced asthma;
KIRP	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg00405596	chr8:11794950	NA	-0.38	-5.05	-0.31	8.48e-7	Neuroticism;
KIRP	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg12591125	chr7:1885375	MAD1L1	0.54	5.42	0.33	1.42e-7	Bipolar disorder;
KIRP	cis	rs7615316	0.902	rs7428496	chr3:142320532	A/T	cg20824294	chr3:142316082	PLS1	0.23	4.98	0.3	1.21e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1978968	0.788	rs12169946	chr22:18468105	A/G	cg03078520	chr22:18463400	MICAL3	-0.63	-7.58	-0.44	7.09e-13	Presence of antiphospholipid antibodies;
KIRP	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.79	9.42	0.51	3.36e-18	Corneal astigmatism;
KIRP	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.22	-0.42	6.44e-12	Rheumatoid arthritis;
KIRP	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.31	-5.23	-0.32	3.71e-7	Height;
KIRP	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg01320579	chr17:75405842	SEPT9	0.49	8.06	0.46	3.23e-14	Airflow obstruction;
KIRP	cis	rs17854409	0.764	rs8114722	chr20:61478492	G/A	cg06598544	chr20:61472147	COL9A3	-0.93	-4.99	-0.3	1.16e-6	Obesity-related traits;
KIRP	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg21798802	chr22:38057573	PDXP	0.43	5.21	0.32	3.94e-7	Fat distribution (HIV);
KIRP	cis	rs10170310	0.608	rs10928657	chr2:139291769	G/A	cg03782584	chr2:139258740	SPOPL	0.3	4.94	0.3	1.45e-6	Response to antipsychotic treatment;
KIRP	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.81	-0.49	2.37e-16	Response to antipsychotic treatment;
KIRP	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.98	-17.08	-0.74	1.11e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg19197139	chr17:4613644	ARRB2	0.75	7.82	0.45	1.53e-13	Lymphocyte counts;
KIRP	cis	rs911119	0.913	rs6048923	chr20:23578206	C/T	cg09631192	chr20:23583594	CST9	-0.64	-6.19	-0.37	2.44e-9	Chronic kidney disease;
KIRP	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.87	8.66	0.48	6.53e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	0.55	6.54	0.38	3.54e-10	Prudent dietary pattern;
KIRP	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg22705602	chr4:152727874	NA	-0.55	-9.67	-0.52	6.06e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg20607798	chr8:58055168	NA	0.77	5.98	0.36	7.94e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg04398451	chr17:18023971	MYO15A	0.69	9.33	0.51	6.47e-18	Total body bone mineral density;
KIRP	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg22117172	chr7:91764530	CYP51A1	0.44	5.98	0.36	7.72e-9	Breast cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg01648131	chr19:58838208	ZSCAN22	0.51	6.12	0.36	3.57e-9	Educational attainment;
KIRP	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	trans	rs28595532	0.557	rs28657902	chr4:119305491	C/T	cg26518628	chr1:97050305	NA	-0.82	-8.35	-0.47	4.98e-15	Cannabis dependence symptom count;
KIRP	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.88	10.25	0.55	9.11e-21	Corneal astigmatism;
KIRP	cis	rs35934224	0.783	rs7288061	chr22:19864239	C/T	cg11182965	chr22:19864308	TXNRD2	-0.48	-5.82	-0.35	1.86e-8	Glaucoma (primary open-angle);
KIRP	cis	rs55962025	0.883	rs362336	chr4:3213832	G/A	cg06533319	chr4:3265114	C4orf44	0.47	5.4	0.33	1.55e-7	Parental longevity (mother's age at death);
KIRP	cis	rs2348418	0.715	rs10843206	chr12:28722756	C/T	cg13890972	chr12:28721907	NA	-0.33	-5.17	-0.31	4.74e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.75	10.77	0.57	2.1e-22	Mood instability;
KIRP	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.46	5.9	0.35	1.2e-8	IgG glycosylation;
KIRP	cis	rs7737355	1.000	rs2551036	chr5:130648994	G/A	cg06647332	chr5:131281008	NA	0.47	5.24	0.32	3.52e-7	Life satisfaction;
KIRP	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg24972876	chr7:65420302	NA	-0.44	-6.34	-0.37	1.09e-9	Calcium levels;
KIRP	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg06124975	chr6:107810578	SOBP	0.47	6.09	0.36	4.33e-9	Sleep duration;
KIRP	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg07395648	chr5:131743802	NA	0.58	8.6	0.48	9.6e-16	Blood metabolite levels;
KIRP	cis	rs57561814	0.655	rs8180726	chr7:22749306	A/C	cg26061582	chr7:22766209	IL6	0.71	5.52	0.33	8.52e-8	Tonsillectomy;
KIRP	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-6.33	-0.37	1.17e-9	Aortic root size;
KIRP	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-0.66	-8.88	-0.49	1.4e-16	Morning vs. evening chronotype;
KIRP	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.47	-7.1	-0.41	1.37e-11	Vitamin D levels;
KIRP	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs7221595	0.825	rs62072388	chr17:3899567	C/A	cg09597638	chr17:3907349	NA	0.56	5.86	0.35	1.5e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg12042659	chr19:58951599	ZNF132	0.5	6.09	0.36	4.35e-9	Uric acid clearance;
KIRP	cis	rs1215050	0.765	rs6852699	chr4:98767505	T/C	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	1.02	16.64	0.73	3.78e-42	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.41	-4.84	-0.3	2.25e-6	Blood metabolite levels;
KIRP	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg23985595	chr17:80112537	CCDC57	0.39	6.04	0.36	5.63e-9	Life satisfaction;
KIRP	trans	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-7.61	-0.44	5.85e-13	Colorectal cancer;
KIRP	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs35740288	0.651	rs34257708	chr15:86184267	G/A	cg20737812	chr15:86336631	KLHL25	-0.52	-5.81	-0.35	1.94e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.38	-5.06	-0.31	8.37e-7	Renal function-related traits (BUN);
KIRP	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	1.08	9.8	0.53	2.33e-19	Pulse pressure;
KIRP	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg18944383	chr4:111397179	ENPEP	0.62	11.32	0.59	3.56e-24	Height;
KIRP	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.54	-5.81	-0.35	1.93e-8	Depression;
KIRP	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	5.85	0.35	1.55e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs4356932	0.935	rs6532083	chr4:76929201	A/G	cg00809888	chr4:76862425	NAAA	0.46	6.48	0.38	4.93e-10	Blood protein levels;
KIRP	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.57	7.11	0.41	1.24e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4908768	0.906	rs114812780	chr1:8528854	G/T	cg25722041	chr1:8623473	RERE	0.78	9.91	0.53	1.09e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs10073892	0.664	rs1502840	chr5:101896920	C/A	cg19774478	chr5:101632501	SLCO4C1	0.59	5.8	0.35	2e-8	Cognitive decline (age-related);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15700489	chr1:28975001	RNU11	-0.55	-6.66	-0.39	1.74e-10	Interleukin-4 levels;
KIRP	cis	rs9400467	0.528	rs456865	chr6:111632928	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.41	-5.26	-0.32	3.18e-7	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg13264159	chr8:625131	ERICH1	-0.73	-5.52	-0.33	8.64e-8	IgG glycosylation;
KIRP	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.84	-15.53	-0.7	2.2e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2304069	0.779	rs245055	chr5:149341279	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.76	-8.27	-0.47	8.34e-15	HIV-1 control;
KIRP	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg18944383	chr4:111397179	ENPEP	0.54	9.46	0.52	2.52e-18	Height;
KIRP	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.5	6.94	0.4	3.41e-11	Red blood cell count;
KIRP	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.69	-9.11	-0.5	3.02e-17	Glomerular filtration rate;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg07454192	chr8:74888262	TMEM70	0.56	6.22	0.37	2.14e-9	Lung cancer in ever smokers;
KIRP	cis	rs10073892	0.703	rs59723886	chr5:101635199	A/G	cg19774478	chr5:101632501	SLCO4C1	0.63	6.34	0.37	1.11e-9	Cognitive decline (age-related);
KIRP	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.47	6.64	0.39	1.97e-10	Sitting height ratio;
KIRP	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	8.37	0.47	4.26e-15	Eosinophil percentage of white cells;
KIRP	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.5	-0.38	4.47e-10	Lung cancer;
KIRP	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.8	9.9	0.53	1.17e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs367943	0.712	rs6594707	chr5:112700503	C/T	cg12552261	chr5:112820674	MCC	0.56	6.64	0.39	1.98e-10	Type 2 diabetes;
KIRP	trans	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.5	6.74	0.39	1.09e-10	Mean corpuscular volume;
KIRP	cis	rs4950322	0.570	rs2354428	chr1:146749181	T/C	cg22381352	chr1:146742008	CHD1L	-0.46	-5.48	-0.33	1.07e-7	Protein quantitative trait loci;
KIRP	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-0.97	-6.55	-0.39	3.29e-10	Inflammatory biomarkers;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02614683	chr11:68153951	LRP5	-0.45	-6.06	-0.36	5e-9	Parkinson's disease;
KIRP	cis	rs6832769	0.961	rs6817663	chr4:56447215	A/G	cg09317128	chr4:56265301	TMEM165	-0.5	-6.43	-0.38	6.67e-10	Personality dimensions;
KIRP	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg13482628	chr17:19912719	NA	-0.52	-6.75	-0.4	1.06e-10	Schizophrenia;
KIRP	cis	rs58688157	0.960	rs112006329	chr11:617228	G/A	cg02461776	chr11:598696	PHRF1	0.52	5.48	0.33	1.05e-7	Systemic lupus erythematosus;
KIRP	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.62	-7.0	-0.41	2.39e-11	Response to antineoplastic agents;
KIRP	cis	rs57590327	0.716	rs56106807	chr3:81765270	A/G	cg07356753	chr3:81810745	GBE1	-0.7	-8.03	-0.46	3.95e-14	Extraversion;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08875431	chr11:2422401	TSSC4	-0.49	-6.14	-0.36	3.36e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.19	-14.3	-0.67	3.62e-34	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	11.95	0.61	2.94e-26	Alzheimer's disease;
KIRP	cis	rs4702718	0.651	rs5745271	chr5:10690749	T/G	cg14521931	chr5:10832172	NA	0.39	5.13	0.31	5.89e-7	Obesity-related traits;
KIRP	cis	rs12230513	0.732	rs67290413	chr12:55869876	T/C	cg19537932	chr12:55886519	OR6C68	-0.59	-7.34	-0.42	3.06e-12	Contrast sensitivity;
KIRP	cis	rs2798269	0.668	rs1199950	chr13:22091153	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.43	-5.3	-0.32	2.54e-7	PR segment;
KIRP	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg00262122	chr8:11665843	FDFT1	-0.43	-5.28	-0.32	2.81e-7	Triglycerides;
KIRP	cis	rs6466055	0.777	rs10281886	chr7:104835888	T/C	cg04380332	chr7:105027541	SRPK2	-0.62	-9.28	-0.51	9.33e-18	Schizophrenia;
KIRP	cis	rs4356932	0.967	rs7436646	chr4:76955229	T/G	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg25182066	chr10:30743637	MAP3K8	0.68	5.83	0.35	1.78e-8	Itch intensity from mosquito bite;
KIRP	cis	rs16937956	0.597	rs4584570	chr11:8406036	G/A	cg08015107	chr11:8618950	NA	-0.56	-7.14	-0.41	1.07e-11	Body mass index;
KIRP	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-7.08	-0.41	1.49e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.98	12.9	0.64	2.02e-29	Homoarginine levels;
KIRP	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg13319975	chr6:146136371	FBXO30	-0.62	-8.17	-0.46	1.61e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg18240062	chr17:79603768	NPLOC4	-0.85	-12.33	-0.62	1.67e-27	Eye color traits;
KIRP	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.11	-0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-7.27	-0.42	4.65e-12	Schizophrenia;
KIRP	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs11628318	0.853	rs4906224	chr14:103025040	C/T	cg01864069	chr14:103024347	NA	-1.0	-13.15	-0.64	2.9e-30	Platelet count;
KIRP	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg02951883	chr7:2050386	MAD1L1	-0.54	-6.19	-0.37	2.49e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs3857747	0.578	rs59337346	chr7:40371204	A/G	cg00420559	chr7:40367873	C7orf10	-0.45	-6.49	-0.38	4.58e-10	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg21014159	chr11:117668035	DSCAML1	0.42	6.45	0.38	6.04e-10	Myopia;
KIRP	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.19	-14.3	-0.67	3.62e-34	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs77688320	0.517	rs2287054	chr2:202319038	G/A	cg06431681	chr2:202330990	STRADB	0.54	6.81	0.4	7.3e-11	Breast cancer;
KIRP	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.41	6.94	0.4	3.42e-11	Heart rate;
KIRP	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.9	-13.52	-0.65	1.59e-31	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg22800045	chr5:56110881	MAP3K1	0.74	7.75	0.44	2.34e-13	Initial pursuit acceleration;
KIRP	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-10.43	-0.55	2.48e-21	Pancreatic cancer;
KIRP	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.8	-9.6	-0.52	9.89e-19	Corneal astigmatism;
KIRP	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg14972814	chr11:95582409	MTMR2	0.29	5.09	0.31	6.99e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs4234798	0.500	rs7661066	chr4:7219878	C/T	cg18431297	chr4:7219810	SORCS2	0.67	8.99	0.5	6.98e-17	Insulin-like growth factors;
KIRP	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.54	-6.94	-0.4	3.43e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs965513	1.000	rs7021576	chr9:100540541	C/T	cg13688889	chr9:100608707	NA	-0.6	-7.48	-0.43	1.33e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs4728302	0.869	rs6955240	chr7:133581873	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.74e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg05861140	chr6:150128134	PCMT1	-0.51	-7.12	-0.41	1.18e-11	Lung cancer;
KIRP	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg03672602	chr19:19754555	GMIP	0.55	6.85	0.4	5.79e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg08975724	chr8:8085496	FLJ10661	-0.6	-7.77	-0.44	2.07e-13	Neuroticism;
KIRP	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.84	-14.4	-0.68	1.66e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.75	9.99	0.54	5.98e-20	Bipolar disorder;
KIRP	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.93	-0.35	1e-8	IgG glycosylation;
KIRP	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.38	-5.01	-0.3	1.02e-6	Blood metabolite levels;
KIRP	cis	rs2802372	0.542	rs1250558	chr10:81065201	G/A	cg18688392	chr10:81059414	ZMIZ1	-0.65	-8.0	-0.45	4.98e-14	Granulocyte count;
KIRP	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg05360138	chr12:110035743	NA	0.42	5.17	0.31	4.94e-7	Neuroticism;
KIRP	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg05555928	chr11:63887634	MACROD1	-0.54	-5.13	-0.31	5.91e-7	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17383334	chr3:97741670	GABRR3	0.38	6.02	0.36	6.27e-9	Survival in pancreatic cancer;
KIRP	cis	rs503734	0.504	rs348873	chr3:100930665	C/T	cg27318481	chr3:100970896	IMPG2	-0.51	-6.54	-0.39	3.47e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09796911	chr12:69668318	MIR1279	0.47	6.52	0.38	3.9e-10	Interleukin-4 levels;
KIRP	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.4	-0.33	1.6e-7	Bladder cancer;
KIRP	cis	rs6732160	0.574	rs12465780	chr2:73472012	A/G	cg01422370	chr2:73384389	NA	-0.43	-5.78	-0.35	2.25e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07498975	chr1:101338750	EXTL2	0.41	6.06	0.36	5.05e-9	Migraine with aura;
KIRP	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg06795125	chr2:108905320	SULT1C2	-0.47	-7.94	-0.45	7.22e-14	Blood pressure;
KIRP	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.42e-6	Life satisfaction;
KIRP	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.79	10.77	0.57	2.04e-22	Aortic root size;
KIRP	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.56	-0.39	3.18e-10	Morning vs. evening chronotype;
KIRP	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03934478	chr11:495069	RNH1	0.83	6.8	0.4	8.1e-11	Body mass index;
KIRP	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg12598211	chr12:123634384	NA	-0.45	-5.52	-0.33	8.53e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.85	14.11	0.67	1.6e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.61	-0.39	2.4e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.61	7.4	0.43	2.09e-12	Platelet count;
KIRP	cis	rs3744061	0.569	rs2240769	chr17:74718155	C/T	cg27546012	chr17:74684504	MXRA7	-0.77	-10.14	-0.54	2.02e-20	Retinal arteriolar caliber;
KIRP	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-8.13	-0.46	2.12e-14	Migraine;Coronary artery disease;
KIRP	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg18225595	chr11:63971243	STIP1	0.63	5.66	0.34	4.12e-8	Mean platelet volume;
KIRP	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.69	-9.64	-0.52	7.46e-19	Primary sclerosing cholangitis;
KIRP	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.9	-13.97	-0.67	4.85e-33	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs1559088	0.948	rs12460195	chr19:33584479	G/A	cg24009623	chr19:33667908	NA	0.5	6.25	0.37	1.81e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.77	-10.36	-0.55	4.28e-21	Huntington's disease progression;
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-8.33	-0.47	5.73e-15	Obesity-related traits;
KIRP	trans	rs7246760	1.000	rs28802413	chr19:9901617	T/C	cg02900749	chr2:68251473	NA	-0.96	-8.75	-0.49	3.55e-16	Pursuit maintenance gain;
KIRP	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.9	-14.39	-0.68	1.8e-34	Height;
KIRP	cis	rs684232	0.602	rs34167561	chr17:509268	G/A	cg04370829	chr17:406249	NA	0.39	4.88	0.3	1.89e-6	Prostate cancer;
KIRP	cis	rs12282928	0.885	rs1503176	chr11:48269191	C/T	cg26585981	chr11:48327164	OR4S1	-0.52	-6.29	-0.37	1.44e-9	Migraine - clinic-based;
KIRP	trans	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17183009	chr3:120277827	NA	0.53	6.16	0.37	3.01e-9	Corneal astigmatism;
KIRP	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.87	10.95	0.57	5.41e-23	Coronary artery disease;
KIRP	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg09323728	chr8:95962352	TP53INP1	-0.24	-4.92	-0.3	1.57e-6	Type 2 diabetes;
KIRP	trans	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg04373760	chr16:53404718	NA	0.62	6.67	0.39	1.71e-10	Hypertriglyceridemia;
KIRP	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.72	7.31	0.42	3.63e-12	Resting heart rate;
KIRP	cis	rs12936587	0.633	rs12949039	chr17:17509721	A/C	cg01246520	chr17:17644344	RAI1	-0.37	-5.63	-0.34	5.01e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.49	0.33	1e-7	Lung cancer;
KIRP	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs4132509	1.000	rs10927078	chr1:243983830	C/T	cg25706552	chr1:244017396	NA	0.63	7.15	0.41	9.65e-12	RR interval (heart rate);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg07236445	chr8:120868172	DSCC1	-0.51	-6.49	-0.38	4.69e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs1883415	0.534	rs2760143	chr6:24479472	C/T	cg20631270	chr6:24437470	GPLD1	0.39	4.99	0.3	1.13e-6	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6545883	0.560	rs11677776	chr2:61503113	T/C	cg15711740	chr2:61764176	XPO1	0.45	5.55	0.33	7.45e-8	Tuberculosis;
KIRP	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	1.08	9.26	0.51	1.03e-17	Blood protein levels;
KIRP	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg23985595	chr17:80112537	CCDC57	-0.38	-5.77	-0.35	2.32e-8	Life satisfaction;
KIRP	cis	rs7178909	0.835	rs8035374	chr15:90395198	G/A	cg19708238	chr15:90437601	AP3S2	0.53	7.22	0.42	6.27e-12	Common traits (Other);
KIRP	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.66	0.48	6.38e-16	Motion sickness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23151374	chr4:164415611	C4orf43	0.66	8.01	0.45	4.68e-14	Smoking initiation;
KIRP	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs73206853	0.841	rs111612251	chr12:111017607	T/C	cg12870014	chr12:110450643	ANKRD13A	0.5	5.16	0.31	5.11e-7	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg08975724	chr8:8085496	FLJ10661	0.55	7.12	0.41	1.18e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.79	-10.14	-0.54	1.99e-20	Blood trace element (Zn levels);
KIRP	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg16497661	chr14:103986332	CKB	-0.51	-6.49	-0.38	4.77e-10	Coronary artery disease;
KIRP	cis	rs698833	0.518	rs2033951	chr2:44556298	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	5.0	0.3	1.1e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.65	-9.5	-0.52	1.94e-18	Retinal vascular caliber;
KIRP	cis	rs12153243	1.000	rs57450351	chr5:142906561	T/C	cg13907255	chr5:142895549	NA	-0.37	-5.03	-0.31	9.29e-7	Migraine;
KIRP	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.8	0.35	2.04e-8	Neutrophil percentage of white cells;
KIRP	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg12591125	chr7:1885375	MAD1L1	0.64	6.16	0.37	2.99e-9	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02606018	chr12:10658281	NA	-0.48	-6.76	-0.4	9.95e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.46	-6.48	-0.38	4.87e-10	Coronary artery disease;
KIRP	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06555155	chr6:158981441	TMEM181	-0.57	-6.19	-0.37	2.51e-9	Menopause (age at onset);
KIRP	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.89	0.4	4.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg07636037	chr3:49044803	WDR6	0.66	6.58	0.39	2.79e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00700008	chr4:120138107	USP53	-0.44	-7.11	-0.41	1.26e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.58	7.63	0.44	5.07e-13	Retinal vascular caliber;
KIRP	cis	rs9790314	0.613	rs11716265	chr3:160602111	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-6.5	-0.38	4.38e-10	Morning vs. evening chronotype;
KIRP	cis	rs7224685	0.569	rs68060817	chr17:3995188	T/C	cg11204139	chr17:3907470	NA	0.54	5.0	0.3	1.11e-6	Type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.61e-8	Life satisfaction;
KIRP	cis	rs2274459	0.818	rs13206228	chr6:33719383	C/G	cg06253072	chr6:33679850	C6orf125	0.53	5.18	0.31	4.54e-7	Obesity (extreme);
KIRP	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg08462924	chr1:41848221	NA	0.44	6.43	0.38	6.44e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10214930	0.697	rs6462031	chr7:27589490	T/C	cg22168087	chr7:27702803	HIBADH	0.47	4.93	0.3	1.52e-6	Hypospadias;
KIRP	cis	rs9940149	1.000	rs9940149	chr16:300641	C/T	cg26484247	chr16:313425	ITFG3	0.45	5.38	0.32	1.71e-7	Type 2 diabetes;
KIRP	cis	rs16828019	0.929	rs4131949	chr1:41738637	C/T	cg18742814	chr1:41828276	NA	0.62	5.64	0.34	4.54e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6783573	0.711	rs3806701	chr3:46617337	G/A	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.67	-7.59	-0.44	6.5e-13	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19524238	chr7:2802976	GNA12	-0.36	-4.99	-0.3	1.12e-6	Height;
KIRP	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.99	-11.09	-0.58	1.92e-23	Gut microbiome composition (summer);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13876462	chr9:103236040	TMEFF1	0.47	6.72	0.39	1.23e-10	Parkinson's disease;
KIRP	cis	rs6888304	0.589	rs7728556	chr5:31037966	A/G	cg10919204	chr5:31193340	CDH6	0.39	4.97	0.3	1.28e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7923609	0.902	rs10822158	chr10:65094383	A/G	cg08743896	chr10:65200160	JMJD1C	-0.37	-5.5	-0.33	9.48e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg04733989	chr22:42467013	NAGA	0.58	7.56	0.43	7.79e-13	Cognitive function;
KIRP	cis	rs7116495	0.881	rs1939243	chr11:71742735	A/G	cg18441811	chr11:71824068	C11orf51	0.64	4.94	0.3	1.42e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg23594656	chr7:65796392	TPST1	-0.36	-5.47	-0.33	1.1e-7	Aortic root size;
KIRP	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg09658497	chr7:2847517	GNA12	-0.34	-4.86	-0.3	2.14e-6	Height;
KIRP	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.53	6.29	0.37	1.41e-9	Blood metabolite levels;
KIRP	cis	rs4664308	0.618	rs3792192	chr2:160886875	G/A	cg03641300	chr2:160917029	PLA2R1	-0.64	-10.03	-0.54	4.66e-20	Idiopathic membranous nephropathy;
KIRP	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	1.06	22.01	0.81	4.69e-60	Parkinson's disease;
KIRP	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg25039879	chr17:56429692	SUPT4H1	0.59	5.23	0.32	3.59e-7	Cognitive test performance;
KIRP	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.43	5.32	0.32	2.34e-7	Body mass index;
KIRP	cis	rs4660306	0.744	rs11211113	chr1:45923668	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.53	6.32	0.37	1.25e-9	Homocysteine levels;
KIRP	cis	rs4740619	0.619	rs7040690	chr9:16038049	G/C	cg14451791	chr9:16040625	NA	-0.42	-5.55	-0.33	7.45e-8	Body mass index;
KIRP	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.33	8.71	0.49	4.51e-16	Crohn's disease;
KIRP	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-4.85	-0.3	2.16e-6	Lymphocyte counts;
KIRP	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg22153407	chr1:230290089	GALNT2	0.38	4.86	0.3	2.14e-6	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs4908768	0.911	rs953535	chr1:8776719	A/C	cg25722041	chr1:8623473	RERE	0.63	8.17	0.46	1.6e-14	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg04132472	chr17:19861366	AKAP10	-0.39	-5.04	-0.31	8.93e-7	Schizophrenia;
KIRP	cis	rs17102423	0.559	rs3783720	chr14:65475411	A/G	cg11161011	chr14:65562177	MAX	-0.65	-7.34	-0.42	3.16e-12	Obesity-related traits;
KIRP	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg21419209	chr3:44054225	NA	-0.75	-9.22	-0.51	1.4e-17	Coronary artery disease;
KIRP	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.85	10.09	0.54	2.99e-20	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.72	-11.24	-0.58	6.35e-24	Hepatocellular carcinoma;
KIRP	cis	rs743757	1.000	rs2236979	chr3:50486895	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.51	5.64	0.34	4.66e-8	Diastolic blood pressure;
KIRP	cis	rs7009516	0.625	rs6997507	chr8:24254123	G/A	cg01759110	chr8:24241694	ADAMDEC1	-0.28	-5.94	-0.35	9.62e-9	Hair greying;
KIRP	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	0.97	10.7	0.56	3.35e-22	Type 2 diabetes nephropathy;
KIRP	cis	rs12476592	0.602	rs6546007	chr2:63724795	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.99	-0.3	1.12e-6	Childhood ear infection;
KIRP	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7084783	0.519	rs4918025	chr10:105342866	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.46	5.88	0.35	1.37e-8	Fear of pain;
KIRP	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.72	11.8	0.6	9.24e-26	Hepatocellular carcinoma;
KIRP	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00149659	chr3:10157352	C3orf10	0.83	8.87	0.49	1.55e-16	Alzheimer's disease;
KIRP	cis	rs4700695	1.000	rs3846481	chr5:65417803	T/C	cg21114390	chr5:65439923	SFRS12	-0.58	-5.63	-0.34	4.89e-8	Facial morphology (factor 19);
KIRP	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.61	-7.57	-0.43	7.48e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.4	-5.48	-0.33	1.05e-7	Endometrial cancer;
KIRP	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.6	7.43	0.43	1.77e-12	Arsenic metabolism;
KIRP	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg26507422	chr16:88990409	CBFA2T3	0.35	4.97	0.3	1.23e-6	Social autistic-like traits;
KIRP	trans	rs9844985	0.630	rs6766837	chr3:116893069	C/G	cg16965475	chr1:52870119	ORC1L;PRPF38A	0.46	6.16	0.37	2.89e-9	Major depression and alcohol dependence;
KIRP	cis	rs6882716	1.000	rs4702730	chr5:10799879	T/A	cg14521931	chr5:10832172	NA	-0.81	-8.92	-0.49	1.06e-16	Alcohol consumption (maxi-drinks);
KIRP	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg11650704	chr1:154556575	ADAR	-0.45	-5.59	-0.34	5.91e-8	Blood protein levels;
KIRP	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg16989719	chr2:238392110	NA	-0.54	-7.38	-0.43	2.48e-12	Prostate cancer;
KIRP	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.84	11.19	0.58	9.23e-24	Menarche (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27309282	chr4:1016081	FGFRL1	0.5	6.76	0.4	1e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.46	-6.37	-0.38	9.03e-10	Blood metabolite levels;
KIRP	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.78	-10.36	-0.55	4.27e-21	Iron status biomarkers;
KIRP	cis	rs9810259	0.508	rs9853146	chr3:12299313	C/T	cg02700894	chr3:12045449	SYN2	0.41	5.63	0.34	4.94e-8	Platelet count;
KIRP	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	7.95	0.45	6.89e-14	Neuroticism;
KIRP	cis	rs13315871	1.000	rs71311868	chr3:58392874	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-5.04	-0.31	9.12e-7	Cholesterol, total;
KIRP	trans	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.4	-0.43	2.15e-12	Bladder cancer;
KIRP	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	0.54	6.52	0.38	3.89e-10	Prudent dietary pattern;
KIRP	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs7224314	1.000	rs57672368	chr17:65358688	G/C	cg01507342	chr17:65387096	PITPNC1	-0.5	-6.85	-0.4	5.93e-11	Diisocyanate-induced asthma;
KIRP	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.43	-0.33	1.37e-7	Life satisfaction;
KIRP	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg09990169	chr2:241835740	C2orf54	-0.44	-6.62	-0.39	2.25e-10	Urinary metabolites;
KIRP	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg03468072	chr12:39539422	NA	0.44	6.02	0.36	6.22e-9	Morning vs. evening chronotype;
KIRP	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.99	15.84	0.71	1.95e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg10223061	chr2:219282414	VIL1	0.29	4.87	0.3	2.04e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg26398791	chr1:38455867	SF3A3	-0.41	-5.2	-0.31	4.24e-7	Coronary artery disease;
KIRP	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg14703610	chr5:56206110	C5orf35	0.51	7.12	0.41	1.15e-11	Coronary artery disease;
KIRP	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg22676075	chr6:135203613	NA	0.49	7.06	0.41	1.72e-11	Red blood cell count;
KIRP	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg20896738	chr21:46707857	POFUT2;LOC642852	0.42	4.94	0.3	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.72e-7	Life satisfaction;
KIRP	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.55	7.18	0.42	8.35e-12	Mean corpuscular volume;
KIRP	cis	rs4666002	0.917	rs2068834	chr2:27839539	A/G	cg05484376	chr2:27715224	FNDC4	-0.33	-4.98	-0.3	1.19e-6	Phospholipid levels (plasma);
KIRP	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.63	6.38	0.38	8.49e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.19	-0.46	1.39e-14	Monocyte percentage of white cells;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg22182451	chr15:72486158	GRAMD2	-0.46	-6.02	-0.36	6.4e-9	Inflammatory biomarkers;
KIRP	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg25319279	chr11:5960081	NA	0.62	6.44	0.38	6.33e-10	DNA methylation (variation);
KIRP	cis	rs914615	0.507	rs4971085	chr1:155138222	T/C	cg02153340	chr1:155202674	NA	-0.48	-7.29	-0.42	4.17e-12	Urinary albumin-to-creatinine ratio;
KIRP	trans	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs4363385	0.510	rs6673356	chr1:153041903	C/T	cg13444842	chr1:152974279	SPRR3	0.36	5.17	0.31	4.93e-7	Inflammatory skin disease;
KIRP	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.71	9.52	0.52	1.65e-18	Response to diuretic therapy;
KIRP	cis	rs7116495	1.000	rs73539532	chr11:71815684	C/A	cg26138937	chr11:71823887	C11orf51	0.69	5.51	0.33	9.2e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.52	-6.53	-0.38	3.73e-10	Coronary artery disease;
KIRP	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg15117754	chr3:10150083	C3orf24	0.5	5.03	0.31	9.37e-7	Alzheimer's disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg07936541	chr2:98206095	ANKRD36B	0.48	6.54	0.38	3.49e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg05315796	chr3:52349193	DNAH1	0.46	7.1	0.41	1.37e-11	Electroencephalogram traits;
KIRP	cis	rs116095464	1.000	rs10054850	chr5:335827	C/G	cg22496380	chr5:211416	CCDC127	-1.21	-7.49	-0.43	1.23e-12	Breast cancer;
KIRP	cis	rs7671900	0.687	rs12642212	chr4:88275366	G/A	cg23841344	chr4:88312519	HSD17B11	-0.44	-5.63	-0.34	4.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg01721255	chr8:58191610	C8orf71	0.66	5.64	0.34	4.59e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	4.94	0.3	1.45e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.24	-6.14	-0.36	3.21e-9	Mean corpuscular volume;
KIRP	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg01689657	chr7:91764605	CYP51A1	0.45	6.5	0.38	4.44e-10	Breast cancer;
KIRP	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.92	-16.8	-0.73	1.04e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.96	13.94	0.66	6.09e-33	Menopause (age at onset);
KIRP	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.66	6.5	0.38	4.46e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8014252	0.803	rs60120955	chr14:71061733	A/C	cg11204974	chr14:71022665	NA	-0.68	-7.12	-0.41	1.21e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs1816752	0.875	rs947305	chr13:25034979	G/T	cg02811702	chr13:24901961	NA	0.38	4.95	0.3	1.36e-6	Obesity-related traits;
KIRP	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg24631222	chr15:78858424	CHRNA5	0.81	9.74	0.53	3.52e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.61	7.61	0.44	5.78e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1823913	0.637	rs6722183	chr2:192197929	A/G	cg12404831	chr2:192114017	MYO1B	-0.44	-5.85	-0.35	1.56e-8	Obesity-related traits;
KIRP	cis	rs4523957	0.928	rs8065650	chr17:2180823	A/G	cg16513277	chr17:2031491	SMG6	0.6	8.35	0.47	5.1e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg07856975	chr6:36356162	ETV7	-0.43	-5.69	-0.34	3.69e-8	Platelet distribution width;
KIRP	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg24633833	chr3:10029261	TMEM111	0.55	5.29	0.32	2.7e-7	Alzheimer's disease;
KIRP	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.67	9.03	0.5	5.26e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.93	11.21	0.58	8.01e-24	Post bronchodilator FEV1;
KIRP	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-9.67	-0.52	5.92e-19	Coronary artery disease;
KIRP	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.92	-12.3	-0.62	2.06e-27	Cognitive function;
KIRP	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.68	9.98	0.54	6.55e-20	Dupuytren's disease;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.37	-0.38	9.26e-10	Height;
KIRP	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.47	-5.05	-0.31	8.56e-7	Initial pursuit acceleration;
KIRP	cis	rs13082711	0.906	rs34775440	chr3:27447333	G/T	cg02860705	chr3:27208620	NA	0.57	7.74	0.44	2.6e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg08975724	chr8:8085496	FLJ10661	-0.69	-8.92	-0.49	1.09e-16	Joint mobility (Beighton score);
KIRP	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.84	12.11	0.61	8.46e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.94	-0.35	9.92e-9	Prostate cancer;
KIRP	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg26174226	chr8:58114915	NA	-0.6	-7.15	-0.41	1.02e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs33912345	0.695	rs1254293	chr14:60864583	A/C	cg27398547	chr14:60952738	C14orf39	0.39	5.22	0.32	3.83e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg10207240	chr12:122356781	WDR66	0.62	8.04	0.46	3.86e-14	Mean corpuscular volume;
KIRP	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.54	7.28	0.42	4.42e-12	Schizophrenia;
KIRP	cis	rs10129255	0.536	rs17113249	chr14:107134290	A/G	cg23076370	chr14:107095027	NA	-0.45	-5.65	-0.34	4.43e-8	Kawasaki disease;
KIRP	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	6.32	0.37	1.23e-9	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg20637307	chr2:213403960	ERBB4	-0.54	-7.5	-0.43	1.15e-12	Symmetrical dimethylarginine levels;
KIRP	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg07395648	chr5:131743802	NA	0.37	5.1	0.31	6.9e-7	Blood metabolite levels;
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.54	7.45	0.43	1.63e-12	Mean corpuscular volume;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg08054078	chr16:57318744	PLLP	-0.48	-6.14	-0.36	3.24e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg12648482	chr13:52768676	THSD1P	0.45	6.4	0.38	7.97e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17253792	0.545	rs34136598	chr14:56013238	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.81	5.35	0.32	2.05e-7	Putamen volume;
KIRP	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg25482853	chr8:67687455	SGK3	0.8	7.01	0.41	2.32e-11	Obesity-related traits;
KIRP	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.18	-0.46	1.53e-14	Mood instability;
KIRP	cis	rs17401966	0.522	rs6541085	chr1:10285709	A/G	cg17425144	chr1:10567563	PEX14	-0.28	-4.89	-0.3	1.85e-6	Hepatocellular carcinoma;
KIRP	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.39e-13	Life satisfaction;
KIRP	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.77	-7.35	-0.42	2.95e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01314398	chr2:85765810	MAT2A	-0.56	-6.15	-0.37	3.16e-9	Menopause (age at onset);
KIRP	cis	rs11955175	1.000	rs11953942	chr5:40674713	C/A	cg05478818	chr5:40835740	RPL37	0.7	5.44	0.33	1.32e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg02569458	chr12:86230093	RASSF9	-0.43	-6.39	-0.38	8.06e-10	Major depressive disorder;
KIRP	cis	rs1971762	0.545	rs3864905	chr12:54058324	C/T	cg16917193	chr12:54089295	NA	0.92	17.04	0.74	1.64e-43	Height;
KIRP	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06739403	chr13:35516903	NBEA	0.44	6.15	0.37	3.2e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs950776	0.613	rs12915539	chr15:78940795	T/A	cg22563815	chr15:78856949	CHRNA5	0.43	5.69	0.34	3.58e-8	Sudden cardiac arrest;
KIRP	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg25482853	chr8:67687455	SGK3	0.8	7.05	0.41	1.76e-11	Obesity-related traits;
KIRP	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg05768032	chr16:30646687	NA	0.4	4.93	0.3	1.49e-6	Dementia with Lewy bodies;
KIRP	cis	rs1165472	0.502	rs17112625	chr1:56140172	A/G	cg11523071	chr1:56160889	NA	-0.54	-6.35	-0.38	1.03e-9	Paclitaxel-induced neuropathy;
KIRP	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.93	14.08	0.67	2.01e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6832769	1.000	rs10034433	chr4:56421176	A/T	cg09317128	chr4:56265301	TMEM165	-0.54	-7.25	-0.42	5.29e-12	Personality dimensions;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04633058	chr17:48474099	LRRC59	0.74	6.51	0.38	4.24e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs918629	0.530	rs3777201	chr5:95234630	G/T	cg16656078	chr5:95278638	ELL2	-0.39	-5.92	-0.35	1.1e-8	IgG glycosylation;
KIRP	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg15655495	chr12:38532458	NA	-0.29	-5.16	-0.31	5.02e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg04944784	chr2:26401820	FAM59B	-0.66	-7.18	-0.42	8.1e-12	Gut microbiome composition (summer);
KIRP	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.63	8.06	0.46	3.33e-14	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-9.4	-0.51	3.99e-18	Total body bone mineral density;
KIRP	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg21905437	chr5:178450457	ZNF879	0.45	4.93	0.3	1.49e-6	Pubertal anthropometrics;
KIRP	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.44	5.04	0.31	8.92e-7	Height;
KIRP	cis	rs35740288	0.770	rs1157519	chr15:86161658	T/G	cg17133734	chr15:86042851	AKAP13	-0.51	-5.73	-0.34	2.96e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs6546886	0.957	rs4364046	chr2:74256305	A/G	cg14702570	chr2:74259524	NA	0.3	6.15	0.37	3.08e-9	Dialysis-related mortality;
KIRP	cis	rs8032158	1.000	rs60482539	chr15:56180297	A/C	cg02198044	chr15:56286336	NEDD4	-0.42	-4.93	-0.3	1.54e-6	Keloid;
KIRP	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg26681399	chr22:41777847	TEF	-0.46	-5.39	-0.33	1.61e-7	Vitiligo;
KIRP	cis	rs6832769	1.000	rs28670674	chr4:56407103	G/A	cg09317128	chr4:56265301	TMEM165	-0.51	-6.39	-0.38	8.26e-10	Personality dimensions;
KIRP	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	8.31	0.47	6.67e-15	Eosinophil percentage of white cells;
KIRP	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.53	7.64	0.44	4.87e-13	Mean corpuscular volume;
KIRP	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg12692727	chr7:1102344	C7orf50	0.48	5.13	0.31	5.79e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.81	11.25	0.58	6.04e-24	Aortic root size;
KIRP	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.54	-7.39	-0.43	2.32e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg13939156	chr17:80058883	NA	-0.48	-5.5	-0.33	9.56e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6782228	0.651	rs9289332	chr3:128387884	C/G	cg18648031	chr3:128330563	NA	0.27	5.51	0.33	9.15e-8	Monocyte count;Myeloid white cell count;Sum neutrophil eosinophil counts;Lymphocyte percentage of white cells;White blood cell count;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;
KIRP	cis	rs9815354	0.904	rs9848992	chr3:41875297	C/T	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	9.12	0.5	2.67e-17	Cognitive test performance;
KIRP	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.49	4.93	0.3	1.48e-6	Alzheimer's disease;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.94	12.24	0.62	3.33e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.42	-6.61	-0.39	2.39e-10	Eye color traits;
KIRP	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg13819577	chr1:248512075	OR14C36	-0.39	-5.12	-0.31	6.07e-7	Common traits (Other);
KIRP	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg22437258	chr11:111473054	SIK2	0.63	7.67	0.44	4.08e-13	Primary sclerosing cholangitis;
KIRP	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg12923728	chr3:195709715	SDHAP1	-0.8	-8.91	-0.49	1.13e-16	Pancreatic cancer;
KIRP	cis	rs56104184	0.779	rs17206693	chr19:49360252	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.76	-8.5	-0.48	1.81e-15	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.51	-0.33	9.08e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg20387954	chr3:183756860	HTR3D	0.49	7.18	0.42	8.33e-12	Anterior chamber depth;
KIRP	cis	rs4765905	0.610	rs10848628	chr12:2312489	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.82	-0.4	7.16e-11	Schizophrenia;
KIRP	cis	rs2055729	0.507	rs814424	chr8:9942924	C/T	cg21625330	chr8:9911636	MSRA	0.58	6.01	0.36	6.8e-9	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.58	7.72	0.44	2.9e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs5753618	0.504	rs9609303	chr22:31896309	C/T	cg02404636	chr22:31891804	SFI1	0.54	5.92	0.35	1.06e-8	Colorectal cancer;
KIRP	cis	rs4006360	0.601	rs7214364	chr17:39236678	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	1.03e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg15655495	chr12:38532458	NA	0.27	5.4	0.33	1.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg14092571	chr14:90743983	NA	0.42	5.2	0.31	4.27e-7	Mortality in heart failure;
KIRP	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.23	0.61	3.57e-27	Bone mineral density;
KIRP	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.55	7.16	0.42	9.06e-12	Urate levels in overweight individuals;
KIRP	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs600806	0.778	rs9661614	chr1:110021837	T/C	cg02175308	chr1:109941060	SORT1	0.27	5.13	0.31	5.98e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.52	-0.38	3.88e-10	Educational attainment;
KIRP	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg06609049	chr19:2785107	THOP1	0.82	10.38	0.55	3.64e-21	Total cholesterol levels;
KIRP	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg25019033	chr10:957182	NA	-0.71	-9.32	-0.51	6.92e-18	Eosinophil percentage of granulocytes;
KIRP	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-1.01	-15.66	-0.71	8.32e-39	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.99	-16.05	-0.72	3.89e-40	Monocyte count;
KIRP	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg26149184	chr10:133730230	NA	0.41	4.84	0.3	2.26e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs1941687	0.831	rs11877286	chr18:31386764	T/C	cg27147174	chr7:100797783	AP1S1	-0.56	-6.85	-0.4	5.77e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg12855166	chr17:30846586	MYO1D	-0.42	-5.81	-0.35	1.92e-8	Schizophrenia;
KIRP	cis	rs1712517	0.873	rs1163086	chr10:105039579	A/G	cg05636881	chr10:105038444	INA	0.45	6.63	0.39	2.09e-10	Migraine;
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg23736307	chr8:27182930	PTK2B	0.53	6.54	0.38	3.6e-10	Neuroticism;
KIRP	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg01620082	chr3:125678407	NA	-1.02	-6.59	-0.39	2.65e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg08603382	chr10:743973	NA	-0.67	-10.26	-0.55	8.61e-21	Psychosis in Alzheimer's disease;
KIRP	cis	rs244293	0.730	rs3213757	chr17:53041857	A/G	cg07707039	chr17:53042137	COX11	-0.39	-4.96	-0.3	1.32e-6	Menarche (age at onset);
KIRP	cis	rs6693567	0.565	rs1260458	chr1:150347454	C/T	cg09579323	chr1:150459698	TARS2	0.4	5.01	0.3	1.04e-6	Migraine;
KIRP	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-0.94	-6.18	-0.37	2.68e-9	Inflammatory biomarkers;
KIRP	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg14541582	chr5:601475	NA	-0.58	-6.64	-0.39	2.04e-10	Obesity-related traits;
KIRP	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	0.99	17.83	0.75	3.37e-46	Menarche (age at onset);
KIRP	cis	rs62413470	1.000	rs12212143	chr6:55965055	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	8.58	0.48	1.07e-15	Coffee consumption (cups per day);
KIRP	trans	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg16141378	chr3:129829833	LOC729375	-0.58	-7.74	-0.44	2.51e-13	Neuroticism;
KIRP	cis	rs629922	1.000	rs510358	chr11:114064983	A/G	cg25009965	chr11:114031120	ZBTB16	0.39	5.0	0.3	1.1e-6	Paneth cell defects in Crohn's disease;
KIRP	trans	rs1995809	0.793	rs80193496	chr4:147967617	C/T	cg23682866	chr10:43858278	NA	0.61	6.32	0.37	1.19e-9	Plasma amyloid beta peptide concentrations (ABx-40);
KIRP	trans	rs1864585	0.505	rs10503410	chr8:10652352	A/G	cg26278703	chr11:58910052	FAM111A	0.66	6.58	0.39	2.82e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.66	-6.18	-0.37	2.62e-9	Bipolar disorder;
KIRP	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.94	-0.4	3.36e-11	Vitiligo;
KIRP	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-1.03	-12.9	-0.64	2.06e-29	Exhaled nitric oxide output;
KIRP	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	9.23e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs12476592	0.602	rs6546004	chr2:63639529	T/C	cg17519650	chr2:63277830	OTX1	-0.44	-4.89	-0.3	1.85e-6	Childhood ear infection;
KIRP	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg24253500	chr15:84953950	NA	0.62	6.57	0.39	3.05e-10	Schizophrenia;
KIRP	cis	rs712039	0.565	rs1714988	chr17:35744048	G/A	cg16670864	chr17:35848621	DUSP14	0.44	5.14	0.31	5.48e-7	Tuberculosis;
KIRP	cis	rs12976411	0.575	rs35798291	chr19:32826264	T/C	cg02282382	chr19:32836354	ZNF507	0.62	5.2	0.31	4.16e-7	Coronary artery disease;
KIRP	cis	rs4595586	0.679	rs1156706	chr12:39372641	G/A	cg26384229	chr12:38710491	ALG10B	0.48	6.16	0.37	2.98e-9	Morning vs. evening chronotype;
KIRP	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg12661370	chr5:149340060	SLC26A2	0.45	5.53	0.33	8.28e-8	HIV-1 control;
KIRP	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.71	8.43	0.47	3.04e-15	DNA methylation (variation);
KIRP	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-6.11	-0.36	3.94e-9	Bladder cancer;
KIRP	cis	rs2249694	0.520	rs7911139	chr10:135323525	T/C	cg20169779	chr10:135381914	SYCE1	-0.6	-6.71	-0.39	1.34e-10	Obesity-related traits;
KIRP	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.8	-0.45	1.74e-13	Neuroticism;
KIRP	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.41	-0.33	1.52e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.62	7.87	0.45	1.1e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg26384229	chr12:38710491	ALG10B	0.61	8.37	0.47	4.46e-15	Morning vs. evening chronotype;
KIRP	cis	rs2014572	1.000	rs3746231	chr19:57760057	G/A	cg12963866	chr19:57752005	ZNF805	-0.49	-6.15	-0.36	3.19e-9	Hyperactive-impulsive symptoms;
KIRP	cis	rs11078597	0.731	rs34962442	chr17:1640529	C/T	cg17514665	chr17:1657533	SERPINF2	0.45	5.59	0.34	6.03e-8	Serum albumin level;
KIRP	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg10018233	chr7:150070692	REPIN1	0.69	8.32	0.47	6.02e-15	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.64	-0.48	7.16e-16	Response to antipsychotic treatment;
KIRP	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.45	5.71	0.34	3.2e-8	White matter hyperintensity burden;
KIRP	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.74	7.82	0.45	1.54e-13	Corneal astigmatism;
KIRP	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-6.85	-0.4	5.99e-11	Mood instability;
KIRP	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg18478394	chr8:109455254	TTC35	0.5	6.09	0.36	4.23e-9	Dupuytren's disease;
KIRP	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.44	-4.89	-0.3	1.83e-6	Alzheimer's disease (late onset);
KIRP	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.7	9.16	0.5	2.14e-17	Prudent dietary pattern;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02983885	chr19:42772892	NA	0.53	6.48	0.38	4.92e-10	Smoking initiation;
KIRP	cis	rs4664304	0.620	rs2048437	chr2:160712065	C/T	cg03641300	chr2:160917029	PLA2R1	0.37	5.55	0.33	7.44e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.0	-12.08	-0.61	1.13e-26	White matter hyperintensity burden;
KIRP	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg24807547	chr6:37504484	NA	-0.55	-8.27	-0.47	8.59e-15	Cognitive performance;
KIRP	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg14169450	chr9:139327907	INPP5E	0.59	6.65	0.39	1.9e-10	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs7688540	0.771	rs79366248	chr4:266659	T/C	cg10134910	chr4:1076041	RNF212	-0.24	-4.85	-0.3	2.19e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg08975724	chr8:8085496	FLJ10661	-0.66	-8.92	-0.49	1.09e-16	Triglycerides;
KIRP	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg04374321	chr14:90722782	PSMC1	-0.9	-13.35	-0.65	6.05e-31	Mortality in heart failure;
KIRP	cis	rs12986413	0.559	rs1859951	chr19:2142633	C/G	cg09261902	chr19:2140048	AP3D1	0.71	11.71	0.6	1.77e-25	Height;
KIRP	cis	rs35892873	0.920	rs9865702	chr3:126092351	A/G	cg15490784	chr3:126061950	KLF15	0.51	6.6	0.39	2.5e-10	Male-pattern baldness;
KIRP	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg24747557	chr10:131355152	MGMT	0.42	5.76	0.34	2.49e-8	Response to temozolomide;
KIRP	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.84	-7.07	-0.41	1.63e-11	Obesity-related traits;
KIRP	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg05791153	chr7:19748676	TWISTNB	-0.73	-6.64	-0.39	2.03e-10	Thyroid stimulating hormone;
KIRP	cis	rs33912345	0.695	rs1254253	chr14:60822340	G/A	cg27398547	chr14:60952738	C14orf39	-0.42	-5.61	-0.34	5.38e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.47	-7.12	-0.41	1.18e-11	Coronary artery disease;
KIRP	cis	rs4950322	0.570	rs6703892	chr1:146759306	T/C	cg22381352	chr1:146742008	CHD1L	-0.46	-5.49	-0.33	9.88e-8	Protein quantitative trait loci;
KIRP	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.95	13.43	0.65	3.29e-31	Menopause (age at onset);
KIRP	cis	rs12476592	0.602	rs11898615	chr2:63748284	C/A	cg17519650	chr2:63277830	OTX1	-0.42	-4.88	-0.3	1.93e-6	Childhood ear infection;
KIRP	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.7	10.07	0.54	3.49e-20	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg13607699	chr17:42295918	UBTF	0.46	5.7	0.34	3.39e-8	Total body bone mineral density;
KIRP	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg26384229	chr12:38710491	ALG10B	0.52	6.67	0.39	1.72e-10	Morning vs. evening chronotype;
KIRP	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.89	13.02	0.64	7.97e-30	Bladder cancer;
KIRP	cis	rs1971762	0.527	rs7952858	chr12:54039692	C/G	cg16917193	chr12:54089295	NA	0.84	13.85	0.66	1.19e-32	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14592024	chr15:48624386	DUT	-0.5	-6.19	-0.37	2.49e-9	Interleukin-4 levels;
KIRP	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg09571762	chr12:39539558	NA	0.36	5.02	0.3	1e-6	Morning vs. evening chronotype;
KIRP	cis	rs1823913	0.637	rs6750360	chr2:192167815	A/G	cg12404831	chr2:192114017	MYO1B	-0.46	-6.19	-0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.74	-8.22	-0.46	1.15e-14	Corneal astigmatism;
KIRP	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.95	11.63	0.6	3.22e-25	Bipolar disorder;
KIRP	cis	rs10046574	0.519	rs112479683	chr7:135203288	G/A	cg27474649	chr7:135195673	CNOT4	0.56	5.26	0.32	3.06e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg15839431	chr19:19639596	YJEFN3	0.48	5.17	0.31	4.81e-7	Bipolar disorder;
KIRP	cis	rs829883	1.000	rs2908843	chr12:98889332	C/G	cg25150519	chr12:98850993	NA	-0.87	-13.17	-0.64	2.43e-30	Colorectal adenoma (advanced);
KIRP	cis	rs612683	0.599	rs2809823	chr1:101003762	C/A	cg06223162	chr1:101003688	GPR88	0.64	16.16	0.72	1.61e-40	Breast cancer;
KIRP	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.86	-0.49	1.65e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg02002194	chr4:3960332	NA	-0.45	-6.48	-0.38	4.95e-10	Mood instability;
KIRP	cis	rs7116495	0.737	rs7102192	chr11:71648169	G/A	cg26138937	chr11:71823887	C11orf51	-0.68	-5.39	-0.33	1.62e-7	Severe influenza A (H1N1) infection;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg16868751	chr10:96162146	TBC1D12	0.64	6.05	0.36	5.31e-9	Lung function (FEV1);
KIRP	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-33.17	-0.9	8.9e-93	Myeloid white cell count;
KIRP	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg20673091	chr1:2541236	MMEL1	-0.68	-10.63	-0.56	5.94e-22	Ulcerative colitis;
KIRP	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Parkinson's disease;
KIRP	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg07777115	chr5:623756	CEP72	-0.57	-5.81	-0.35	1.97e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.51	-6.91	-0.4	4.03e-11	Neuroticism;
KIRP	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.66	8.51	0.48	1.71e-15	Red blood cell count;
KIRP	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.61	7.41	0.43	1.97e-12	Blood metabolite levels;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg03315869	chr11:134146676	GLB1L3	-0.44	-6.11	-0.36	3.88e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.61	-9.12	-0.5	2.78e-17	Monocyte percentage of white cells;
KIRP	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23903597	chr17:61704154	MAP3K3	-0.54	-6.43	-0.38	6.58e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10267417	0.603	rs10241914	chr7:19932429	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	5.11	0.31	6.44e-7	Night sleep phenotypes;
KIRP	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg22563815	chr15:78856949	CHRNA5	-0.47	-7.32	-0.42	3.43e-12	Sudden cardiac arrest;
KIRP	cis	rs6815814	0.904	rs73236629	chr4:38825449	G/T	cg06935464	chr4:38784597	TLR10	0.57	5.68	0.34	3.77e-8	Breast cancer;
KIRP	cis	rs10737909	1.000	rs10737909	chr1:15548636	A/C	cg21012057	chr1:15538911	TMEM51	0.46	6.08	0.36	4.53e-9	Migraine;
KIRP	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.67	-9.36	-0.51	5.11e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs3755132	1.000	rs67764681	chr2:15724383	T/C	cg12888861	chr2:15731646	DDX1	0.37	4.86	0.3	2.08e-6	Wilms tumor;
KIRP	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg27205649	chr11:78285834	NARS2	0.67	8.93	0.49	1.04e-16	Alzheimer's disease (survival time);
KIRP	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg21775007	chr8:11205619	TDH	0.44	5.97	0.36	8.43e-9	Neuroticism;
KIRP	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg10207240	chr12:122356781	WDR66	0.61	8.08	0.46	2.84e-14	Mean corpuscular volume;
KIRP	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.73	-0.39	1.19e-10	Capecitabine sensitivity;
KIRP	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.71	-11.1	-0.58	1.82e-23	Ulcerative colitis;
KIRP	cis	rs708547	0.836	rs781554	chr4:57717537	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.75	-8.22	-0.46	1.19e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9625935	0.917	rs5752993	chr22:30387160	C/T	cg01021169	chr22:30184971	ASCC2	-0.43	-4.91	-0.3	1.62e-6	Tonsillectomy;
KIRP	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg04132472	chr17:19861366	AKAP10	0.38	4.85	0.3	2.22e-6	Schizophrenia;
KIRP	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	7.72	0.44	2.89e-13	Neuroticism;
KIRP	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.88	9.59	0.52	1.03e-18	Methadone dose in opioid dependence;
KIRP	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.42	-6.65	-0.39	1.91e-10	Body mass index;
KIRP	cis	rs72730918	0.590	rs1456297	chr15:51964210	C/A	cg14296394	chr15:51910925	DMXL2	-0.77	-10.84	-0.57	1.22e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.65	9.65	0.52	6.81e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs6540559	1.000	rs742214	chr1:209960925	T/C	cg22029157	chr1:209979665	IRF6	0.55	6.57	0.39	2.94e-10	Cleft lip with or without cleft palate;
KIRP	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg16988262	chr1:15930761	NA	0.39	5.12	0.31	6.13e-7	Systolic blood pressure;
KIRP	cis	rs9943753	0.525	rs6606708	chr12:109833146	T/C	cg19025524	chr12:109796872	NA	-0.46	-6.27	-0.37	1.61e-9	HDL cholesterol;
KIRP	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg02961200	chr2:178257176	LOC100130691;AGPS	0.76	6.97	0.41	2.87e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	6.04	0.36	5.73e-9	Systolic blood pressure;
KIRP	cis	rs10267417	0.522	rs34452666	chr7:19936665	T/G	cg05791153	chr7:19748676	TWISTNB	0.49	4.86	0.3	2.07e-6	Night sleep phenotypes;
KIRP	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22117172	chr7:91764530	CYP51A1	0.47	6.5	0.38	4.44e-10	Breast cancer;
KIRP	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.57	0.39	3.05e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg16232979	chr19:16187631	TPM4	-0.46	-6.09	-0.36	4.32e-9	Metabolic traits;
KIRP	trans	rs399593	0.666	rs424712	chr10:30905322	T/G	cg02831383	chr1:3329820	PRDM16	0.59	6.08	0.36	4.48e-9	Dental caries;
KIRP	cis	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg07460842	chr6:66804631	NA	0.48	5.76	0.34	2.5e-8	Metabolite levels;
KIRP	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4908768	0.535	rs2708628	chr1:8450448	T/C	cg25722041	chr1:8623473	RERE	0.4	4.84	0.3	2.26e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.88	-13.24	-0.65	1.4e-30	Longevity;
KIRP	trans	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg06521331	chr12:34319734	NA	-0.51	-6.16	-0.37	2.87e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.86	12.6	0.63	2.08e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg23601095	chr6:26197514	HIST1H3D	0.92	7.51	0.43	1.08e-12	Gout;Renal underexcretion gout;
KIRP	cis	rs6693567	0.565	rs10888578	chr1:150260993	A/G	cg07843065	chr1:150265600	MRPS21	-0.48	-6.8	-0.4	7.72e-11	Migraine;
KIRP	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.47	5.18	0.31	4.71e-7	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.88	-11.71	-0.6	1.82e-25	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.47	6.28	0.37	1.55e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	1.05	19.39	0.78	1.85e-51	Heart rate;
KIRP	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20135002	chr11:47629003	NA	-0.43	-5.06	-0.31	8.19e-7	Subjective well-being;
KIRP	cis	rs17428704	0.571	rs16903423	chr5:14370985	A/C	cg26595256	chr5:14380529	TRIO	-0.83	-6.54	-0.38	3.58e-10	Electroencephalogram traits;
KIRP	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.77	12.21	0.61	4.1e-27	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.67	-7.33	-0.42	3.26e-12	Blood pressure (smoking interaction);
KIRP	cis	rs7116495	0.609	rs10736783	chr11:71654143	G/A	cg18441811	chr11:71824068	C11orf51	-0.81	-5.43	-0.33	1.33e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.8	-11.57	-0.59	5.39e-25	Glomerular filtration rate (creatinine);
KIRP	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.68	-4.86	-0.3	2.1e-6	Facial emotion recognition (sad faces);
KIRP	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.4	5.7	0.34	3.41e-8	Tuberculosis;
KIRP	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	9.42	0.52	3.35e-18	Mean corpuscular hemoglobin;
KIRP	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.06	-0.36	5.02e-9	Aortic root size;
KIRP	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg00409905	chr10:38381863	ZNF37A	-0.59	-6.84	-0.4	6.29e-11	Obesity (extreme);
KIRP	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.27	0.65	1.09e-30	Bladder cancer;
KIRP	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg16141378	chr3:129829833	LOC729375	0.48	6.32	0.37	1.21e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.66	-9.12	-0.5	2.79e-17	Hip circumference;
KIRP	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.08	-15.4	-0.7	6.16e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg11031976	chr2:198649780	BOLL	-0.55	-5.3	-0.32	2.54e-7	Ulcerative colitis;
KIRP	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.27	-5.63	-0.34	5.01e-8	Type 2 diabetes;
KIRP	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg12927641	chr6:109611667	NA	-0.4	-5.2	-0.31	4.14e-7	Reticulocyte fraction of red cells;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg19787424	chr10:73648638	NA	0.48	6.39	0.38	8.04e-10	Asthma;
KIRP	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg26727032	chr16:67993705	SLC12A4	-0.58	-5.19	-0.31	4.41e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.66	7.2	0.42	7.33e-12	Vitiligo;
KIRP	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg03351412	chr1:154909251	PMVK	-0.42	-5.6	-0.34	5.74e-8	Prostate cancer;
KIRP	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.61	-5.98	-0.36	7.92e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg07701084	chr6:150067640	NUP43	0.7	9.39	0.51	4.25e-18	Lung cancer;
KIRP	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.44	-0.33	1.27e-7	Bipolar disorder;
KIRP	cis	rs2219968	0.828	rs13248588	chr8:78880744	A/G	cg00738934	chr8:78996279	NA	-0.37	-5.05	-0.31	8.64e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg23625390	chr15:77176239	SCAPER	0.53	6.93	0.4	3.71e-11	Blood metabolite levels;
KIRP	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.81	8.99	0.5	6.57e-17	Bipolar disorder;
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03762994	chr17:6899332	ALOX12	0.3	5.19	0.31	4.3e-7	Tonsillectomy;
KIRP	cis	rs28489187	0.629	rs2012683	chr1:85841485	C/T	cg16011679	chr1:85725395	C1orf52	0.52	6.45	0.38	5.92e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs4925386	0.808	rs1760073	chr20:60926106	A/G	cg06026331	chr20:60912101	LAMA5	-0.51	-6.69	-0.39	1.52e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.58	7.0	0.41	2.42e-11	Schizophrenia;
KIRP	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.43	-0.33	1.32e-7	Aortic root size;
KIRP	cis	rs12049351	0.631	rs2166160	chr1:229670091	T/C	cg11742688	chr1:229674241	ABCB10	-0.35	-5.25	-0.32	3.21e-7	Circulating myeloperoxidase levels (plasma);
KIRP	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg17145862	chr1:211918768	LPGAT1	-0.91	-12.97	-0.64	1.12e-29	Leprosy;
KIRP	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.49	0.62	4.56e-28	Ileal carcinoids;
KIRP	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.72	0.53	4.19e-19	Prudent dietary pattern;
KIRP	cis	rs7009516	0.819	rs13257101	chr8:24223583	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.3	-6.1	-0.36	4e-9	Hair greying;
KIRP	cis	rs7113850	0.541	rs75850541	chr11:24211467	C/G	ch.11.24196551F	chr11:24239977	NA	0.92	7.45	0.43	1.61e-12	Bone fracture in osteoporosis;
KIRP	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.45	-6.36	-0.38	9.6e-10	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.75	0.71	4.13e-39	Chronic sinus infection;
KIRP	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.52	-6.93	-0.4	3.75e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg17376030	chr22:41985996	PMM1	-0.54	-5.73	-0.34	2.93e-8	Vitiligo;
KIRP	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.55	7.45	0.43	1.56e-12	Multiple system atrophy;
KIRP	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.51	-8.01	-0.45	4.51e-14	IgG glycosylation;
KIRP	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg05484376	chr2:27715224	FNDC4	0.34	5.54	0.33	7.6e-8	Total body bone mineral density;
KIRP	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.45	-0.33	1.22e-7	Coronary artery disease;
KIRP	cis	rs10901296	0.660	rs2772033	chr9:133757080	G/A	cg13397898	chr9:133768931	QRFP	0.3	5.35	0.32	2e-7	Bilirubin levels;
KIRP	cis	rs72634258	0.945	rs36016881	chr1:8051241	A/G	cg00042356	chr1:8021962	PARK7	0.84	7.16	0.42	9.46e-12	Inflammatory bowel disease;
KIRP	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.48	-6.93	-0.4	3.71e-11	Schizophrenia;
KIRP	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.69	7.95	0.45	6.63e-14	Corneal astigmatism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06931615	chr19:20748176	ZNF737	0.56	6.98	0.41	2.81e-11	Parkinson's disease;
KIRP	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.59	7.54	0.43	9.05e-13	Corneal astigmatism;
KIRP	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.58	7.19	0.42	7.88e-12	Systemic lupus erythematosus;
KIRP	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg16141378	chr3:129829833	LOC729375	0.52	6.6	0.39	2.48e-10	Retinal vascular caliber;
KIRP	cis	rs6032067	0.929	rs2868238	chr20:43826993	C/G	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.94	0.4	3.48e-11	Educational attainment;
KIRP	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg10326726	chr10:51549505	MSMB	-0.56	-8.36	-0.47	4.81e-15	Prostate-specific antigen levels;
KIRP	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.36	-5.03	-0.31	9.49e-7	Menarche (age at onset);
KIRP	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	8.86	0.49	1.66e-16	Motion sickness;
KIRP	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.52	7.19	0.42	7.79e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.94	15.66	0.71	7.88e-39	Chronic sinus infection;
KIRP	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.75	8.15	0.46	1.89e-14	Corneal astigmatism;
KIRP	trans	rs11009175	0.512	rs6481832	chr10:33381781	G/A	cg24437859	chr12:7066614	PTPN6	-0.33	-6.02	-0.36	6.46e-9	Depression (quantitative trait);
KIRP	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg13978929	chr19:21580086	ZNF493	0.51	4.98	0.3	1.22e-6	Pain;
KIRP	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.53	5.25	0.32	3.29e-7	Initial pursuit acceleration;
KIRP	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg05721485	chr17:44071124	MAPT	0.5	6.92	0.4	3.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7221595	0.825	rs12450845	chr17:3972784	G/A	cg11204139	chr17:3907470	NA	0.59	5.73	0.34	2.98e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21171335	chr12:122356390	WDR66	0.63	8.37	0.47	4.48e-15	Mean corpuscular volume;
KIRP	cis	rs12210905	0.920	rs72839453	chr6:27265761	A/G	cg11502198	chr6:26597334	ABT1	-0.8	-4.94	-0.3	1.43e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.38	-5.16	-0.31	5.18e-7	Metabolite levels;
KIRP	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg00149659	chr3:10157352	C3orf10	0.51	5.98	0.36	7.64e-9	Alzheimer's disease;
KIRP	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.94	16.07	0.72	3.36e-40	Height;
KIRP	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg26554054	chr8:600488	NA	-0.66	-4.94	-0.3	1.46e-6	IgG glycosylation;
KIRP	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg12501888	chr15:85177176	SCAND2	-0.43	-5.34	-0.32	2.12e-7	P wave terminal force;
KIRP	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12805190	chr12:131784955	NA	0.4	6.26	0.37	1.68e-9	Survival in pancreatic cancer;
KIRP	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg21775007	chr8:11205619	TDH	-0.54	-6.82	-0.4	7.17e-11	Neuroticism;
KIRP	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.78	-10.58	-0.56	8.35e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.92	14.91	0.69	2.93e-36	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs5167	0.525	rs11083752	chr19:45454363	G/A	cg13119609	chr19:45449297	APOC2	0.53	7.53	0.43	9.56e-13	Blood protein levels;
KIRP	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.89	14.39	0.68	1.85e-34	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs2629046	0.764	rs2450039	chr2:225079246	C/T	cg06102602	chr12:96895446	NA	-0.45	-6.15	-0.37	3.18e-9	Height;
KIRP	cis	rs8077577	0.895	rs13284	chr17:18112130	C/T	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.39	-5.03	-0.31	9.65e-7	Crohn's disease;
KIRP	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20456258	chr4:962124	DGKQ	0.39	6.8	0.4	7.94e-11	Sjögren's syndrome;
KIRP	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.67	9.64	0.52	7.12e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg10253484	chr15:75165896	SCAMP2	0.52	5.72	0.34	3.14e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs8067354	0.645	rs2665403	chr17:57889985	G/A	cg02344993	chr17:57696989	CLTC	0.56	5.19	0.31	4.39e-7	Hemoglobin concentration;
KIRP	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.76	0.4	9.7e-11	Lung cancer;
KIRP	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg00543991	chr22:32367038	NA	0.53	4.85	0.3	2.17e-6	Childhood ear infection;
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.74	6.56	0.39	3.15e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg21252483	chr19:49399788	TULP2	-0.39	-7.53	-0.43	9.84e-13	Red cell distribution width;
KIRP	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.83	-12.04	-0.61	1.49e-26	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.41	-5.07	-0.31	7.81e-7	IgG glycosylation;
KIRP	cis	rs748404	0.578	rs1058298	chr15:43700930	G/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	0.46	5.68	0.34	3.76e-8	Lung cancer;
KIRP	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg10760299	chr15:45669010	GATM	0.34	5.09	0.31	6.96e-7	Homoarginine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22135941	chr3:118753705	IGSF11	0.48	6.06	0.36	5.21e-9	Parkinson's disease;
KIRP	cis	rs12208915	0.806	rs9361444	chr6:79500073	T/C	cg18132916	chr6:79620363	NA	0.56	5.29	0.32	2.65e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg27432699	chr2:27873401	GPN1	-0.49	-6.21	-0.37	2.24e-9	Total body bone mineral density;
KIRP	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-7.46	-0.43	1.48e-12	Retinal vascular caliber;
KIRP	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.76	-8.99	-0.5	6.81e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs4262150	0.767	rs10037537	chr5:152326018	C/T	cg12297329	chr5:152029980	NA	0.43	5.79	0.35	2.1e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14159672	chr1:205819179	PM20D1	0.51	5.86	0.35	1.5e-8	Parkinson's disease;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-4.9	-0.3	1.73e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.69	8.53	0.48	1.53e-15	Multiple sclerosis;
KIRP	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg07001201	chr5:642380	CEP72	0.7	6.58	0.39	2.86e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.61	-8.78	-0.49	2.89e-16	Diastolic blood pressure;
KIRP	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.44	5.64	0.34	4.72e-8	Motion sickness;
KIRP	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.56	-0.39	3.19e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.7	9.46	0.52	2.6e-18	Waist circumference;Body mass index;
KIRP	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12315302	chr6:26189340	HIST1H4D	0.73	5.78	0.35	2.24e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.57	6.9	0.4	4.47e-11	Obesity-related traits;
KIRP	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.75	-12.02	-0.61	1.71e-26	Rheumatoid arthritis;
KIRP	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.79	11.6	0.59	4.23e-25	Heart rate;
KIRP	cis	rs4963124	0.886	rs10902216	chr11:739392	G/C	cg01741372	chr11:783889	NA	0.49	5.34	0.32	2.14e-7	Proteinuria and chronic kidney disease;
KIRP	cis	rs10498514	1.000	rs17101854	chr14:64906265	A/G	cg25134081	chr14:64931936	AKAP5	-0.93	-5.28	-0.32	2.79e-7	Cognitive performance;
KIRP	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.36	-5.09	-0.31	6.97e-7	Coronary artery disease;
KIRP	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg16558253	chr16:72132732	DHX38	0.61	9.39	0.51	4.29e-18	Fibrinogen levels;
KIRP	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.61	-7.45	-0.43	1.61e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg16736954	chr20:23401023	NAPB	-0.62	-4.97	-0.3	1.28e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4664293	0.967	rs10202187	chr2:160427646	C/T	cg08347373	chr2:160653686	CD302	-0.42	-5.94	-0.35	9.88e-9	Monocyte percentage of white cells;
KIRP	cis	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg21546286	chr11:48923668	NA	-0.48	-6.14	-0.36	3.36e-9	HDL cholesterol;
KIRP	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg03060546	chr3:49711283	APEH	-0.61	-6.06	-0.36	5.06e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs748404	0.631	rs28702649	chr15:43648629	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.56	7.2	0.42	7.36e-12	Lung cancer;
KIRP	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.55	6.45	0.38	5.99e-10	Monocyte count;
KIRP	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.69	-10.08	-0.54	3.13e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.87	13.31	0.65	8.56e-31	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg02367723	chr1:46378857	MAST2	-0.42	-4.85	-0.3	2.15e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.88	8.57	0.48	1.18e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	10.39	0.55	3.32e-21	Hip circumference;
KIRP	cis	rs2279817	0.731	rs11203434	chr1:18010189	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-9.27	-0.51	9.59e-18	Neuroticism;
KIRP	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg17145862	chr1:211918768	LPGAT1	0.78	11.09	0.58	1.93e-23	Leprosy;
KIRP	cis	rs9488822	0.676	rs11153594	chr6:116354591	A/G	cg05304507	chr6:116381966	FRK	-0.2	-5.32	-0.32	2.37e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg20253172	chr1:3107290	PRDM16	-0.5	-6.24	-0.37	1.91e-9	Migraine;
KIRP	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.4	4.88	0.3	1.9e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	8.27	0.47	8.3e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.4	0.38	7.84e-10	Diabetic retinopathy;
KIRP	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.73	7.98	0.45	5.66e-14	Corneal astigmatism;
KIRP	cis	rs8523	0.774	rs9295764	chr6:11045196	A/G	cg13562911	chr6:11044106	ELOVL2	0.43	5.64	0.34	4.67e-8	Red blood cell fatty acid levels;
KIRP	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg22256960	chr15:77711686	NA	-0.44	-5.61	-0.34	5.37e-8	Type 2 diabetes;
KIRP	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg04315214	chr1:2043799	PRKCZ	-0.37	-5.85	-0.35	1.57e-8	Height;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg06613666	chr12:46123163	ARID2;LOC400027	0.53	6.5	0.38	4.32e-10	Smoking initiation;
KIRP	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg00409905	chr10:38381863	ZNF37A	0.53	5.85	0.35	1.58e-8	Obesity (extreme);
KIRP	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg09491104	chr22:46646882	C22orf40	-0.48	-5.22	-0.32	3.86e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7845219	0.544	rs7017487	chr8:95922752	A/G	cg16049864	chr8:95962084	TP53INP1	0.38	6.05	0.36	5.3e-9	Type 2 diabetes;
KIRP	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	1.23	12.74	0.63	6.73e-29	Red blood cell traits;
KIRP	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.89	13.77	0.66	2.36e-32	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg05564831	chr3:52568323	NT5DC2	-0.31	-5.0	-0.3	1.07e-6	Electroencephalogram traits;
KIRP	cis	rs2150410	0.833	rs8127537	chr21:40560436	C/T	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg18837035	chr15:81426597	C15orf26	0.52	5.88	0.35	1.36e-8	QT interval (drug interaction);
KIRP	cis	rs17012589	0.571	rs10862974	chr12:85748972	G/T	cg13239252	chr12:85430145	TSPAN19;LRRIQ1	0.38	5.03	0.31	9.46e-7	Bone mineral density (Ward's triangle area);
KIRP	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.37	5.89	0.35	1.23e-8	Type 2 diabetes;
KIRP	cis	rs734999	0.549	rs6670198	chr1:2520527	T/C	cg20673091	chr1:2541236	MMEL1	0.79	12.45	0.62	6.25e-28	Ulcerative colitis;
KIRP	cis	rs1656402	1.000	rs1190438	chr2:233423259	G/T	cg03852847	chr2:233439513	NA	0.7	11.53	0.59	6.86e-25	Non-small cell lung cancer (survival);
KIRP	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg17736920	chr1:242011382	EXO1	0.48	5.89	0.35	1.25e-8	Menopause (age at onset);
KIRP	cis	rs712039	0.652	rs7226252	chr17:35794912	C/G	cg16670864	chr17:35848621	DUSP14	0.43	5.39	0.32	1.68e-7	Tuberculosis;
KIRP	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.74	-10.27	-0.55	8.3e-21	Colorectal cancer;
KIRP	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.45	5.15	0.31	5.36e-7	Parkinson's disease;
KIRP	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.66	-5.34	-0.32	2.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.87	9.72	0.53	4.04e-19	Gut microbiome composition (summer);
KIRP	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.62	-7.66	-0.44	4.26e-13	Menarche (age at onset);
KIRP	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg12591125	chr7:1885375	MAD1L1	0.61	5.97	0.36	8.14e-9	Bipolar disorder;
KIRP	cis	rs16973500	0.808	rs57807129	chr16:71948043	T/C	cg09427745	chr16:71932006	KIAA0174	-0.59	-5.1	-0.31	6.74e-7	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg01872077	chr2:219646372	CYP27A1	0.42	5.55	0.33	7.34e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg07701084	chr6:150067640	NUP43	0.73	10.15	0.54	1.94e-20	Lung cancer;
KIRP	cis	rs4363385	0.510	rs56241316	chr1:152901748	A/G	cg13444842	chr1:152974279	SPRR3	-0.46	-6.61	-0.39	2.35e-10	Inflammatory skin disease;
KIRP	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.83	12.62	0.63	1.68e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.58	7.67	0.44	4.04e-13	Bladder cancer;
KIRP	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.42	-5.3	-0.32	2.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1045902	0.967	rs10207625	chr2:73464808	T/C	cg01422370	chr2:73384389	NA	0.43	5.76	0.34	2.44e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25504222	chr19:4639508	TNFAIP8L1	0.48	7.16	0.42	9.16e-12	Survival in pancreatic cancer;
KIRP	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-6.68	-0.39	1.55e-10	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14867604	chr14:100438440	NA	0.48	6.15	0.37	3.11e-9	Parkinson's disease;
KIRP	cis	rs8018808	0.935	rs11627016	chr14:77881138	T/C	cg20045696	chr14:77926864	AHSA1	0.45	5.43	0.33	1.33e-7	Myeloid white cell count;
KIRP	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg19743168	chr1:23544995	NA	0.46	6.21	0.37	2.28e-9	Height;
KIRP	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.83	10.89	0.57	8.63e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg25173405	chr17:45401733	C17orf57	-0.5	-6.63	-0.39	2.06e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg13978929	chr19:21580086	ZNF493	-0.51	-5.05	-0.31	8.53e-7	Pain;
KIRP	cis	rs504918	0.588	rs73188160	chr3:123965749	A/G	cg05766129	chr3:123988013	KALRN	-0.43	-5.25	-0.32	3.3e-7	Schizophrenia;
KIRP	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.51	5.46	0.33	1.17e-7	Obesity (extreme);
KIRP	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.52	-6.15	-0.36	3.13e-9	Aortic root size;
KIRP	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg16388071	chr6:169726476	NA	-0.37	-5.07	-0.31	7.99e-7	Obesity-related traits;
KIRP	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg08648136	chr8:956695	NA	0.49	7.7	0.44	3.35e-13	Schizophrenia;
KIRP	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.45	5.62	0.34	5.15e-8	Asthma;
KIRP	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.03	0.36	6.08e-9	Putamen volume;
KIRP	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.69	7.98	0.45	5.61e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.45	7.37	0.43	2.6e-12	Superior crus of antihelix expression;
KIRP	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	cg12689670	chr1:183009347	LAMC1	0.56	7.9	0.45	9.36e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs6977660	0.714	rs28371050	chr7:19816882	C/T	cg07541023	chr7:19748670	TWISTNB	0.56	5.48	0.33	1.03e-7	Thyroid stimulating hormone;
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg27496793	chr2:46926433	SOCS5	0.54	6.69	0.39	1.54e-10	QT interval;
KIRP	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg09873164	chr1:152488093	CRCT1	0.52	6.54	0.38	3.5e-10	Hair morphology;
KIRP	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg03315344	chr16:75512273	CHST6	0.57	5.41	0.33	1.46e-7	Type 2 diabetes;Type 1 diabetes;
KIRP	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.84	13.94	0.66	6.14e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.697	rs1095389	chr15:43566671	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.5	6.47	0.38	5.4e-10	Lung cancer;
KIRP	cis	rs4523957	0.890	rs11078024	chr17:2189324	T/C	cg16513277	chr17:2031491	SMG6	0.6	8.26	0.47	8.76e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg06636001	chr8:8085503	FLJ10661	0.59	8.27	0.47	8.62e-15	Myopia (pathological);
KIRP	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.55	0.33	7.4e-8	Blood protein levels;
KIRP	trans	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.59	-6.03	-0.36	5.89e-9	Obesity-related traits;
KIRP	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-0.76	-12.16	-0.61	6.15e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12560992	chr17:57184187	TRIM37	0.6	6.98	0.41	2.66e-11	Testicular germ cell tumor;
KIRP	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg11465639	chr17:19241549	NA	0.39	4.88	0.3	1.94e-6	Schizophrenia;
KIRP	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.58	-6.48	-0.38	4.93e-10	LDL cholesterol levels;
KIRP	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.65	8.36	0.47	4.74e-15	Height;
KIRP	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg00074818	chr8:8560427	CLDN23	0.41	6.33	0.37	1.12e-9	Obesity-related traits;
KIRP	cis	rs17209837	1.000	rs2302387	chr7:87092185	G/A	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.84	-12.5	-0.62	4.32e-28	Metabolic syndrome;
KIRP	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	7.67	0.44	4.1e-13	Calcium levels;
KIRP	cis	rs2237878	0.673	rs1971929	chr11:2773371	C/G	cg17820828	chr11:2813298	KCNQ1	0.37	4.91	0.3	1.63e-6	Protein quantitative trait loci;
KIRP	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg02996583	chr8:142237188	SLC45A4	-0.47	-5.72	-0.34	3.09e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-6.04	-0.36	5.72e-9	Bipolar disorder and schizophrenia;
KIRP	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg21775007	chr8:11205619	TDH	0.47	6.09	0.36	4.31e-9	Mood instability;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18881247	chr2:157189314	NR4A2	0.46	6.13	0.36	3.46e-9	Parkinson's disease;
KIRP	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg08283408	chr3:49949060	MON1A	-0.35	-4.98	-0.3	1.17e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.05	-18.77	-0.77	2.12e-49	Multiple system atrophy;
KIRP	trans	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg06521331	chr12:34319734	NA	-0.57	-6.99	-0.41	2.52e-11	Heart rate;
KIRP	cis	rs35123781	0.502	rs440662	chr5:139003472	T/C	cg12205435	chr5:138714322	SLC23A1	-0.38	-5.11	-0.31	6.56e-7	Schizophrenia;
KIRP	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg10167378	chr1:228756711	NA	0.51	5.82	0.35	1.82e-8	Diastolic blood pressure;
KIRP	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-6.67	-0.39	1.71e-10	Initial pursuit acceleration;
KIRP	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	11.03	0.58	3.11e-23	Coronary artery disease;
KIRP	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg26875233	chr11:93583750	C11orf90	-0.41	-7.72	-0.44	2.9e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.02	0.31	9.74e-7	Schizophrenia;
KIRP	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00321850	chr1:175162397	KIAA0040	0.36	6.49	0.38	4.64e-10	Alcohol dependence;
KIRP	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.47	7.19	0.42	7.98e-12	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg07274523	chr3:49395745	GPX1	0.71	8.28	0.47	8.05e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg16268157	chr7:99778414	STAG3	-0.51	-5.29	-0.32	2.72e-7	Lung function (FEV1/FVC);
KIRP	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg16434002	chr17:42200994	HDAC5	0.49	6.09	0.36	4.41e-9	Total body bone mineral density;
KIRP	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg16141378	chr3:129829833	LOC729375	0.53	7.07	0.41	1.64e-11	Retinal vascular caliber;
KIRP	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg14683738	chr19:37701593	ZNF585B	0.47	4.86	0.3	2.06e-6	Coronary artery calcification;
KIRP	cis	rs7188697	0.922	rs37036	chr16:58553348	T/C	cg21335942	chr16:58549945	SETD6	0.47	5.15	0.31	5.3e-7	QT interval;
KIRP	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg04865290	chr3:52927548	TMEM110	-0.62	-6.84	-0.4	6.08e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.49	-7.55	-0.43	8.46e-13	Lymphocyte counts;
KIRP	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.56	8.16	0.46	1.7e-14	Fat distribution (HIV);
KIRP	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06505273	chr16:24850292	NA	-0.36	-4.91	-0.3	1.63e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg00857998	chr1:205179979	DSTYK	0.51	6.46	0.38	5.6e-10	Red blood cell count;
KIRP	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg20387954	chr3:183756860	HTR3D	0.64	9.43	0.52	3.29e-18	Anterior chamber depth;
KIRP	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg04672837	chr16:48644449	N4BP1	0.53	7.64	0.44	4.8e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs5752326	0.510	rs739291	chr22:26877539	C/T	cg20819150	chr22:26891497	TFIP11	0.53	5.0	0.3	1.11e-6	Ischemic stroke;
KIRP	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.48	-6.54	-0.38	3.48e-10	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6921919	0.583	rs4254981	chr6:28371402	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.45	-6.4	-0.38	7.66e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg19180546	chr13:44453867	C13orf31;CCDC122	0.47	6.47	0.38	5.22e-10	Leprosy;
KIRP	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02725872	chr8:58115012	NA	-0.7	-7.98	-0.45	5.66e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.44	-5.31	-0.32	2.5e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.69	-7.8	-0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7665939	0.860	rs72709297	chr4:190144354	T/C	cg01790032	chr4:190285510	NA	-0.84	-5.14	-0.31	5.68e-7	Amyotrophic lateral sclerosis;
KIRP	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.38	-0.38	8.48e-10	Height;
KIRP	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.83	5.25	0.32	3.26e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg24633833	chr3:10029261	TMEM111	0.53	5.13	0.31	5.83e-7	Alzheimer's disease;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg23690444	chr14:81902736	NA	0.5	6.23	0.37	1.97e-9	Educational attainment;
KIRP	cis	rs6001982	0.667	rs74278065	chr22:40885710	T/C	cg07138101	chr22:40742427	ADSL	0.71	4.85	0.3	2.2e-6	Breast cancer;
KIRP	cis	rs10267417	0.657	rs6963367	chr7:19857873	A/C	cg05791153	chr7:19748676	TWISTNB	0.52	4.99	0.3	1.15e-6	Night sleep phenotypes;
KIRP	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg10259518	chr2:233765616	NGEF	0.36	5.26	0.32	3.2e-7	Coronary artery disease;
KIRP	cis	rs55871839	0.684	rs10095333	chr8:59815629	G/A	cg07426533	chr8:59803705	TOX	-0.49	-8.21	-0.46	1.27e-14	Pneumonia;
KIRP	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.64	9.46	0.52	2.6e-18	Endometriosis;
KIRP	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg25251562	chr2:3704773	ALLC	-0.37	-5.13	-0.31	5.89e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.45	0.47	2.65e-15	Motion sickness;
KIRP	cis	rs74181299	0.784	rs2723082	chr2:65289623	C/T	cg05010058	chr2:65284262	CEP68	0.43	5.66	0.34	4.3e-8	Pulse pressure;
KIRP	cis	rs35740288	0.857	rs11632034	chr15:86284072	C/T	cg17133734	chr15:86042851	AKAP13	-0.5	-5.45	-0.33	1.2e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs7221595	0.778	rs9916457	chr17:3929659	A/C	cg09695851	chr17:3907499	NA	0.53	6.44	0.38	6.17e-10	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.57	-0.59	5.22e-25	Chronic sinus infection;
KIRP	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-5.5	-0.33	9.58e-8	Lung cancer;
KIRP	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg07636037	chr3:49044803	WDR6	0.45	5.39	0.33	1.62e-7	Resting heart rate;
KIRP	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg10761708	chr20:43804764	PI3	0.49	5.17	0.31	4.96e-7	Blood protein levels;
KIRP	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.64	6.19	0.37	2.44e-9	Schizophrenia;
KIRP	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg18016565	chr1:150552671	MCL1	0.41	6.1	0.36	4.14e-9	Tonsillectomy;
KIRP	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg06204229	chr3:52865917	ITIH4	0.53	7.91	0.45	8.92e-14	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs9308731	0.583	rs4848406	chr2:111933758	G/A	cg04202892	chr2:111875749	ACOXL	0.47	6.39	0.38	8.26e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg22676075	chr6:135203613	NA	-0.51	-7.37	-0.43	2.62e-12	Red blood cell count;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15249629	chr21:45196311	CSTB	0.5	6.04	0.36	5.76e-9	DNA methylation (variation);
KIRP	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg12963246	chr6:28129442	ZNF389	0.39	4.95	0.3	1.4e-6	Cardiac Troponin-T levels;
KIRP	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg01616529	chr11:638424	DRD4	-0.44	-5.72	-0.34	3.01e-8	Systemic lupus erythematosus;
KIRP	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	1.08	16.83	0.73	8.23e-43	Homoarginine levels;
KIRP	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.13	-0.5	2.65e-17	Colorectal cancer;
KIRP	cis	rs9905704	0.918	rs68139131	chr17:56717249	A/G	cg12560992	chr17:57184187	TRIM37	0.62	6.66	0.39	1.79e-10	Testicular germ cell tumor;
KIRP	cis	rs748404	0.560	rs572837	chr15:43823813	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.51	0.38	4.26e-10	Lung cancer;
KIRP	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg03468072	chr12:39539422	NA	0.41	5.97	0.36	8.09e-9	Morning vs. evening chronotype;
KIRP	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.45	6.09	0.36	4.42e-9	Schizophrenia;
KIRP	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18364779	chr6:26104403	HIST1H4C	0.43	4.93	0.3	1.54e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg27490568	chr2:178487706	NA	0.46	5.99	0.36	7.55e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	1.08	9.74	0.53	3.54e-19	Pulse pressure;
KIRP	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.7	10.44	0.55	2.37e-21	Prostate cancer;
KIRP	cis	rs4523957	0.583	rs2641442	chr17:2035071	C/T	cg16513277	chr17:2031491	SMG6	-0.86	-12.81	-0.63	4.03e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg00852783	chr1:26633632	UBXN11	-0.5	-4.93	-0.3	1.51e-6	Obesity-related traits;
KIRP	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	1.1	17.21	0.74	4.32e-44	Homoarginine levels;
KIRP	cis	rs9400467	0.528	rs12190634	chr6:111725160	A/G	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.71	-0.34	3.22e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs62380364	0.613	rs254781	chr5:88000636	C/T	cg22951263	chr5:87985283	NA	-0.48	-6.8	-0.4	7.99e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs7539542	0.516	rs10732291	chr1:202891168	G/A	cg08940984	chr1:202857613	RABIF	0.45	5.52	0.33	8.4e-8	Mean platelet volume;
KIRP	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.63	7.49	0.43	1.25e-12	Obesity-related traits;
KIRP	cis	rs2073499	1.000	rs57319506	chr3:50285677	T/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.64	5.23	0.32	3.64e-7	Schizophrenia;
KIRP	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg05347473	chr6:146136440	FBXO30	0.5	6.9	0.4	4.32e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6910061	1.000	rs2327335	chr6:11119047	A/G	cg27233058	chr6:11094804	LOC221710	-0.59	-6.24	-0.37	1.95e-9	Diabetic kidney disease;
KIRP	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.25	-5.27	-0.32	3.01e-7	Menarche (age at onset);
KIRP	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg06671706	chr8:8559999	CLDN23	0.57	6.56	0.39	3.1e-10	Obesity-related traits;
KIRP	cis	rs7523050	0.908	rs17621536	chr1:109396908	A/G	cg08274380	chr1:109419600	GPSM2	0.65	6.2	0.37	2.43e-9	Fat distribution (HIV);
KIRP	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01616529	chr11:638424	DRD4	-0.36	-4.96	-0.3	1.32e-6	Systemic lupus erythematosus;
KIRP	trans	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg18335740	chr13:41363409	SLC25A15	0.47	6.85	0.4	5.73e-11	Lewy body disease;
KIRP	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg18944383	chr4:111397179	ENPEP	-0.41	-6.78	-0.4	8.79e-11	Coronary artery disease;
KIRP	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18252515	chr7:66147081	NA	0.46	5.48	0.33	1.04e-7	Aortic root size;
KIRP	cis	rs4938330	0.739	rs11216266	chr11:116950150	T/C	cg04087571	chr11:116723030	SIK3	-0.25	-5.33	-0.32	2.26e-7	Blood protein levels;
KIRP	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.69	-9.33	-0.51	6.51e-18	Eye color traits;
KIRP	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.5	-6.22	-0.37	2.11e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.47	-4.95	-0.3	1.41e-6	Blood metabolite levels;
KIRP	cis	rs73198271	0.563	rs74556999	chr8:8548459	C/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.74	-0.34	2.77e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg04990556	chr1:26633338	UBXN11	-0.6	-7.49	-0.43	1.26e-12	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs8084125	0.832	rs62105174	chr18:74948324	G/A	cg26065057	chr18:74961000	GALR1	0.61	6.22	0.37	2.14e-9	Obesity-related traits;
KIRP	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.57	-7.29	-0.42	4.26e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.47	-0.43	1.41e-12	Retinal vascular caliber;
KIRP	cis	rs1776421	1.000	rs1766644	chr1:53901838	G/A	cg22073262	chr1:53904065	FLJ40434	0.46	5.06	0.31	8.35e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg13010199	chr12:38710504	ALG10B	0.54	6.72	0.39	1.23e-10	Morning vs. evening chronotype;
KIRP	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg18016565	chr1:150552671	MCL1	0.41	6.09	0.36	4.42e-9	Melanoma;
KIRP	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.72	8.69	0.48	5.15e-16	Breast cancer;
KIRP	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.86	-11.03	-0.58	3.03e-23	Cognitive function;
KIRP	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.59	-7.54	-0.43	8.97e-13	Diastolic blood pressure;
KIRP	cis	rs35955747	0.722	rs5997898	chr22:31572963	A/C	cg02404636	chr22:31891804	SFI1	-0.37	-4.91	-0.3	1.69e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs16828019	0.852	rs35992757	chr1:41652862	C/T	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	1.09	12.1	0.61	9.74e-27	Psoriasis;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.07	-13.44	-0.65	2.92e-31	Alzheimer's disease;
KIRP	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.48e-6	Red blood cell count;
KIRP	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-6.71	-0.39	1.36e-10	Aortic root size;
KIRP	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.73	-8.63	-0.48	7.99e-16	Blood metabolite levels;
KIRP	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg19752551	chr11:57585705	CTNND1	-0.82	-13.3	-0.65	9.27e-31	Schizophrenia;
KIRP	cis	rs7096127	0.682	rs1543739	chr10:24534194	A/G	cg04122385	chr10:24535410	KIAA1217;PRINS	0.41	4.93	0.3	1.52e-6	Lobe attachment (rater scored);
KIRP	cis	rs10421328	0.821	rs4808976	chr19:19759299	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.48	5.51	0.33	9.07e-8	Parental longevity (combined parental age at death);
KIRP	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg16558253	chr16:72132732	DHX38	-0.55	-7.85	-0.45	1.26e-13	Fibrinogen levels;
KIRP	cis	rs236907	0.859	rs2143369	chr1:171767372	A/G	cg01410279	chr1:171621941	MYOC	-0.46	-5.42	-0.33	1.45e-7	Mean platelet volume;
KIRP	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.53	-8.17	-0.46	1.61e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg04727924	chr7:799746	HEATR2	-0.79	-8.95	-0.5	8.95e-17	Cerebrospinal P-tau181p levels;
KIRP	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.45	5.91	0.35	1.14e-8	Height;
KIRP	cis	rs1440410	0.571	rs4333135	chr4:144039589	G/T	cg01719995	chr4:144104893	USP38	-0.46	-5.99	-0.36	7.44e-9	Ischemic stroke;
KIRP	cis	rs4849845	0.573	rs33971369	chr2:121024987	A/G	cg24070213	chr2:121070622	NA	0.4	6.2	0.37	2.4e-9	Mean platelet volume;
KIRP	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg00750074	chr16:89608354	SPG7	-0.44	-6.1	-0.36	4e-9	Multiple myeloma (IgH translocation);
KIRP	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.65	0.44	4.5e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.92	-14.27	-0.67	4.56e-34	Height;
KIRP	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg24879335	chr3:133465180	TF	0.5	7.99	0.45	5.16e-14	Iron status biomarkers;
KIRP	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.4e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.69	6.04	0.36	5.69e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	-0.36	-4.89	-0.3	1.79e-6	Coronary artery disease;
KIRP	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg11663144	chr21:46675770	NA	-0.58	-8.32	-0.47	6.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.94	15.72	0.71	4.91e-39	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03352322	chr19:52693048	PPP2R1A	0.54	6.78	0.4	8.83e-11	Parkinson's disease;
KIRP	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg15556689	chr8:8085844	FLJ10661	0.64	8.07	0.46	3.17e-14	Retinal vascular caliber;
KIRP	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs12580194	0.593	rs115471673	chr12:55766516	A/G	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs6893807	1.000	rs13163173	chr5:87943620	C/A	cg24804195	chr5:87968844	LOC645323	0.53	5.59	0.34	5.96e-8	Body mass index;
KIRP	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.52	6.53	0.38	3.73e-10	Mean platelet volume;
KIRP	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	1.17	13.76	0.66	2.52e-32	Red blood cell traits;
KIRP	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.91	-10.18	-0.54	1.49e-20	Blood protein levels;
KIRP	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg03609598	chr5:56110824	MAP3K1	-0.48	-5.48	-0.33	1.03e-7	Initial pursuit acceleration;
KIRP	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.46	-5.73	-0.34	3e-8	Schizophrenia;
KIRP	cis	rs76288851	0.542	rs9851451	chr3:126746690	A/G	cg00307254	chr3:126706825	PLXNA1	-0.47	-5.96	-0.36	8.64e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.57	-7.47	-0.43	1.41e-12	Bladder cancer;
KIRP	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.61	-7.15	-0.41	9.78e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.0	15.56	0.7	1.76e-38	Bipolar disorder;
KIRP	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.77	8.74	0.49	3.69e-16	Blood pressure (smoking interaction);
KIRP	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg23594656	chr7:65796392	TPST1	0.37	5.28	0.32	2.86e-7	Aortic root size;
KIRP	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg09596252	chr17:78655493	RPTOR	0.59	7.71	0.44	3.15e-13	Obesity;
KIRP	cis	rs17428704	0.571	rs7715916	chr5:14389469	C/T	cg26595256	chr5:14380529	TRIO	-0.84	-6.47	-0.38	5.2400000000000005e-10	Electroencephalogram traits;
KIRP	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg15893493	chr8:124194847	FAM83A	0.87	7.33	0.42	3.23e-12	Urinary uromodulin levels;
KIRP	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.73	-10.22	-0.55	1.15e-20	Plateletcrit;Platelet count;
KIRP	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.13	14.55	0.68	5.11e-35	Mean corpuscular hemoglobin;
KIRP	cis	rs12431939	0.947	rs56156789	chr14:51633899	C/G	cg23942311	chr14:51606299	NA	-0.62	-5.34	-0.32	2.13e-7	Cancer;
KIRP	cis	rs4742903	0.967	rs4743689	chr9:106909300	G/A	cg14250997	chr9:106856677	SMC2	0.38	4.99	0.3	1.14e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.29	-0.32	2.68e-7	Educational attainment (years of education);
KIRP	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg16141378	chr3:129829833	LOC729375	-0.51	-7.07	-0.41	1.57e-11	Neuroticism;
KIRP	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg00405596	chr8:11794950	NA	0.59	8.37	0.47	4.5e-15	Neuroticism;
KIRP	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg13409248	chr3:40428643	ENTPD3	0.4	5.29	0.32	2.75e-7	Renal cell carcinoma;
KIRP	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.67	9.68	0.53	5.42e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs12049351	0.613	rs3738185	chr1:229635267	T/G	cg11742688	chr1:229674241	ABCB10	-0.4	-5.66	-0.34	4.3e-8	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs2295359	0.963	rs12030867	chr1:67627620	T/C	cg12940439	chr1:67600707	NA	0.4	5.96	0.36	8.69e-9	Psoriasis;
KIRP	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg07309820	chr7:148901717	ZNF282	-0.38	-4.94	-0.3	1.44e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs865483	0.895	rs4795200	chr17:35817105	A/G	cg06716730	chr17:35851459	DUSP14	0.25	6.06	0.36	5.03e-9	Monocyte count;
KIRP	cis	rs41264869	0.689	rs12039805	chr1:205107793	G/A	cg21214746	chr1:205091277	RBBP5	0.52	6.63	0.39	2.1e-10	Blood protein levels;
KIRP	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.75	-9.86	-0.53	1.51e-19	Schizophrenia;
KIRP	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg05234568	chr11:5960015	NA	-0.6	-6.18	-0.37	2.71e-9	DNA methylation (variation);
KIRP	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.81	10.06	0.54	3.61e-20	Corneal astigmatism;
KIRP	trans	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg05347473	chr6:146136440	FBXO30	0.61	8.74	0.49	3.82e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17221829	0.739	rs72971036	chr11:89370552	G/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-7.17	-0.42	8.5e-12	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg05340658	chr4:99064831	C4orf37	0.67	8.12	0.46	2.18e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17095355	0.792	rs61881587	chr10:111759710	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.11	-0.36	3.85e-9	Biliary atresia;
KIRP	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg16558253	chr16:72132732	DHX38	0.49	7.18	0.42	8e-12	Prostate cancer;
KIRP	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg24488311	chr11:68621650	NA	0.42	5.33	0.32	2.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg11569703	chr11:65557185	OVOL1	-0.32	-4.91	-0.3	1.69e-6	Eosinophil percentage of white cells;
KIRP	cis	rs6991838	0.530	rs35038843	chr8:66522498	T/A	cg13398993	chr8:66546079	ARMC1	-0.45	-5.23	-0.32	3.69e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12476592	0.602	rs4671508	chr2:63654140	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-4.9	-0.3	1.74e-6	Childhood ear infection;
KIRP	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs12780845	1.000	rs7912093	chr10:17203934	A/T	cg01003015	chr10:17271136	VIM	0.46	4.97	0.3	1.28e-6	Homocysteine levels;
KIRP	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg02336718	chr17:17403227	NA	-0.33	-5.1	-0.31	6.68e-7	Strep throat;
KIRP	trans	rs2048656	0.578	rs4841235	chr8:9683358	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.67	0.39	1.72e-10	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05207121	chr12:112451024	ERP29;TMEM116	0.5	6.17	0.37	2.82e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06647332	chr5:131281008	NA	0.45	4.96	0.3	1.32e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.43	5.64	0.34	4.61e-8	Blood metabolite levels;
KIRP	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.96	-0.41	3.1e-11	Monocyte percentage of white cells;
KIRP	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg09137382	chr11:130731461	NA	0.51	7.37	0.43	2.52e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6681460	1.000	rs2147777	chr1:67129254	A/T	cg13052034	chr1:66999238	SGIP1	0.44	6.11	0.36	3.88e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.05e-6	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg24631222	chr15:78858424	CHRNA5	0.76	9.08	0.5	3.53e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.6	7.14	0.41	1.05e-11	Schizophrenia;
KIRP	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg20891283	chr12:69753455	YEATS4	0.73	6.22	0.37	2.16e-9	Response to diuretic therapy;
KIRP	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg05721485	chr17:44071124	MAPT	0.57	7.59	0.44	6.58e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-5.01	-0.3	1.04e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.52	7.3	0.42	4.05e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.61	-8.21	-0.46	1.23e-14	Aortic root size;
KIRP	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.96	12.93	0.64	1.62e-29	Vitamin D levels;
KIRP	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.06	0.67	2.32e-33	Platelet count;
KIRP	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	1.06	20.02	0.79	1.53e-53	Heart rate;
KIRP	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.8	11.0	0.57	3.86e-23	Neuroticism;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg17482927	chr17:63133259	RGS9	0.65	6.51	0.38	4.26e-10	Lung function (FEV1);
KIRP	cis	rs6570726	0.516	rs9322025	chr6:145729196	C/T	cg23711669	chr6:146136114	FBXO30	0.46	6.11	0.36	3.78e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs34421088	0.531	rs2245232	chr8:11400944	G/T	cg16141378	chr3:129829833	LOC729375	0.62	8.0	0.45	5.04e-14	Neuroticism;
KIRP	cis	rs4666002	0.956	rs10179872	chr2:27778572	G/A	cg05484376	chr2:27715224	FNDC4	-0.37	-5.51	-0.33	8.99e-8	Phospholipid levels (plasma);
KIRP	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.76	7.87	0.45	1.15e-13	Resting heart rate;
KIRP	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.7	0.39	1.4e-10	Colorectal cancer;
KIRP	cis	rs7116495	1.000	rs2511079	chr11:71804154	C/T	cg07596299	chr11:71824057	C11orf51	-0.61	-4.91	-0.3	1.7e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs10073892	0.621	rs10055641	chr5:101641516	C/T	cg19774478	chr5:101632501	SLCO4C1	0.63	6.4	0.38	7.99e-10	Cognitive decline (age-related);
KIRP	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg25124228	chr12:125621409	AACS	-0.51	-5.93	-0.35	9.96e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	6.2	0.37	2.37e-9	Menarche (age at onset);
KIRP	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg16584676	chr17:46985605	UBE2Z	0.46	5.68	0.34	3.86e-8	Type 2 diabetes;
KIRP	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-7.14	-0.41	1.07e-11	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.51	5.31	0.32	2.4e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.77	10.01	0.54	5.38e-20	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.76	-0.44	2.29e-13	Total cholesterol levels;
KIRP	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg03388025	chr16:89894329	SPIRE2	0.41	8.28	0.47	8e-15	Schizophrenia;
KIRP	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.91	-14.07	-0.67	2.26e-33	Sudden cardiac arrest;
KIRP	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.77	-0.44	2.19e-13	Total cholesterol levels;
KIRP	cis	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg21546286	chr11:48923668	NA	-0.49	-6.29	-0.37	1.41e-9	HDL cholesterol;
KIRP	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	0.57	5.75	0.34	2.62e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	5.21	0.32	3.97e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.36	5.39	0.32	1.66e-7	Lung cancer;
KIRP	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.47	5.67	0.34	4.02e-8	Schizophrenia;
KIRP	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.8	8.79	0.49	2.58e-16	High light scatter reticulocyte count;
KIRP	cis	rs78487399	0.908	rs55640722	chr2:43846040	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-5.44	-0.33	1.27e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.89	10.02	0.54	5.03e-20	Corneal astigmatism;
KIRP	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.77	-11.12	-0.58	1.59e-23	Response to temozolomide;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05460370	chr3:45635690	LIMD1	0.48	6.02	0.36	6.17e-9	Parkinson's disease;
KIRP	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.49	-6.79	-0.4	8.35e-11	Gut microbiome composition (summer);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12004115	chr2:198570073	MARS2	0.48	6.44	0.38	6.15e-10	Survival in pancreatic cancer;
KIRP	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg23978390	chr7:1156363	C7orf50	0.41	5.33	0.32	2.27e-7	Longevity;Endometriosis;
KIRP	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.11	0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	0.95	7.09	0.41	1.41e-11	IgG glycosylation;
KIRP	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.41	-0.47	3.44e-15	Mean corpuscular volume;
KIRP	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.47	-6.88	-0.4	4.93e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg11906718	chr8:101322791	RNF19A	0.49	6.53	0.38	3.72e-10	Atrioventricular conduction;
KIRP	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg24826892	chr11:71159390	DHCR7	-0.45	-5.07	-0.31	7.76e-7	Vitamin D levels;
KIRP	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.68	-10.36	-0.55	4.04e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.63	7.52	0.43	1.01e-12	Obesity-related traits;
KIRP	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg26681399	chr22:41777847	TEF	-0.49	-4.91	-0.3	1.63e-6	Vitiligo;
KIRP	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.91	0.49	1.2e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg03959625	chr15:84868606	LOC388152	0.71	8.4	0.47	3.58e-15	Schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18308527	chr3:33481283	UBP1	0.47	6.2	0.37	2.36e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.19	-0.51	1.66e-17	Platelet count;
KIRP	cis	rs62355272	0.559	rs1008756	chr5:35905927	A/C	cg13894535	chr5:35919491	CAPSL	-0.36	-4.89	-0.3	1.86e-6	Lymphocyte counts;
KIRP	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.5	-6.64	-0.39	2.04e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.54	-7.91	-0.45	8.78e-14	Coronary artery disease;
KIRP	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11987759	chr7:65425863	GUSB	0.44	5.25	0.32	3.34e-7	Aortic root size;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.54	5.41	0.33	1.53e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21385522	chr1:16154831	NA	0.65	7.52	0.43	1.02e-12	Dilated cardiomyopathy;
KIRP	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.91	13.63	0.66	6.67e-32	Mean corpuscular volume;
KIRP	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24564603	chr7:158456404	NCAPG2	-0.4	-4.85	-0.3	2.16e-6	Height;
KIRP	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg10755058	chr3:40428713	ENTPD3	0.37	5.3	0.32	2.58e-7	Renal cell carcinoma;
KIRP	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg09163369	chr1:210001066	C1orf107	0.48	6.09	0.36	4.22e-9	Orofacial clefts;
KIRP	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-7.53	-0.43	9.33e-13	Response to antipsychotic treatment;
KIRP	cis	rs10518128	1.000	rs112074927	chr4:75716421	G/A	cg20122727	chr4:75719957	BTC	0.6	6.03	0.36	5.86e-9	Electroencephalogram traits;
KIRP	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs15676	0.783	rs7858732	chr9:131563540	A/G	cg00228799	chr9:131580591	ENDOG	-0.52	-5.44	-0.33	1.27e-7	Blood metabolite levels;
KIRP	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg24130564	chr14:104152367	KLC1	-0.47	-6.28	-0.37	1.56e-9	Body mass index;
KIRP	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.38	0.55	3.66e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg13397359	chr6:42928475	GNMT	0.55	7.92	0.45	7.95e-14	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.04	-0.31	8.94e-7	Pulmonary function;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14169450	chr9:139327907	INPP5E	0.5	7.2	0.42	7.49e-12	Monocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15657206	chr11:10772781	CTR9	0.48	6.11	0.36	3.93e-9	Parkinson's disease;
KIRP	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13198984	chr17:80129470	CCDC57	-0.59	-8.73	-0.49	4.04e-16	Life satisfaction;
KIRP	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg00409905	chr10:38381863	ZNF37A	0.59	6.46	0.38	5.48e-10	Obesity (extreme);
KIRP	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	1.1	16.93	0.73	3.61e-43	Homoarginine levels;
KIRP	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg01721255	chr8:58191610	C8orf71	0.46	4.98	0.3	1.22e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.5	10.14	0.54	2.08e-20	Monocyte percentage of white cells;
KIRP	cis	rs8067287	0.762	rs11650981	chr17:16824038	A/G	cg26910001	chr17:16838321	NA	-0.58	-5.75	-0.34	2.65e-8	Diabetic kidney disease;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg26378680	chr10:33269778	NA	0.5	6.03	0.36	6.1e-9	DNA methylation (variation);
KIRP	cis	rs7580658	0.521	rs2404535	chr2:127947709	A/G	cg16751203	chr2:127950803	CYP27C1	-0.4	-5.48	-0.33	1.07e-7	Protein C levels;
KIRP	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs16973500	0.808	rs112121746	chr16:71874983	G/A	cg00732059	chr16:71740210	PHLPP2	-0.58	-5.54	-0.33	7.89e-8	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg19500275	chr17:80737654	TBCD	-0.49	-5.86	-0.35	1.46e-8	Glycated hemoglobin levels;
KIRP	cis	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg06521331	chr12:34319734	NA	-0.61	-7.26	-0.42	5.22e-12	Morning vs. evening chronotype;
KIRP	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg16584676	chr17:46985605	UBE2Z	0.5	6.14	0.36	3.28e-9	Type 2 diabetes;
KIRP	cis	rs1062746	0.528	rs11646030	chr16:87339278	T/C	cg02258303	chr16:87377426	FBXO31	-0.42	-5.19	-0.31	4.4e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
KIRP	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.42	0.47	3.14e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg24826892	chr11:71159390	DHCR7	0.47	5.13	0.31	5.8e-7	Vitamin D levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12698834	chr17:18128735	LLGL1	0.54	7.94	0.45	7.23e-14	Survival in pancreatic cancer;
KIRP	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.34	-0.42	3.02e-12	Neuroticism;
KIRP	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.84	9.75	0.53	3.27e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg06671706	chr8:8559999	CLDN23	0.56	6.32	0.37	1.21e-9	Obesity-related traits;
KIRP	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-9.94	-0.54	8.96e-20	Response to antipsychotic treatment;
KIRP	cis	rs7017914	0.967	rs6991329	chr8:71593425	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.42	-5.26	-0.32	3.07e-7	Bone mineral density;
KIRP	cis	rs2151522	0.603	rs7745882	chr6:127195622	C/A	cg21431617	chr6:127135037	NA	0.3	5.24	0.32	3.5e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.81	-0.4	7.57e-11	Joint mobility (Beighton score);
KIRP	cis	rs6977660	0.714	rs7357319	chr7:19817525	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.93	-14.39	-0.68	1.75e-34	Sudden cardiac arrest;
KIRP	cis	rs75920871	0.925	rs4936362	chr11:116952200	C/T	cg23684410	chr11:116897558	SIK3	0.55	5.63	0.34	4.84e-8	Subjective well-being;
KIRP	cis	rs1448094	0.842	rs10863159	chr12:86459140	T/C	cg00310523	chr12:86230176	RASSF9	-0.43	-6.68	-0.39	1.61e-10	Major depressive disorder;
KIRP	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg00376283	chr12:123451042	ABCB9	0.82	11.0	0.57	3.86e-23	Platelet count;
KIRP	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.41	-8.45	-0.47	2.61e-15	Coronary artery disease;
KIRP	cis	rs7147624	0.938	rs7147231	chr14:66212371	A/G	cg03016385	chr14:66212404	NA	-0.96	-9.91	-0.53	1.08e-19	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.64	7.12	0.41	1.2e-11	Alcohol dependence;
KIRP	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.77	9.31	0.51	7.36e-18	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.81	7.75	0.44	2.48e-13	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.69	10.97	0.57	4.53e-23	Lung cancer;
KIRP	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg27147174	chr7:100797783	AP1S1	-0.75	-9.94	-0.54	8.9e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.64	8.52	0.48	1.62e-15	Motion sickness;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg27532560	chr4:187881888	NA	-0.77	-12.72	-0.63	8.06e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg13939156	chr17:80058883	NA	0.5	5.69	0.34	3.54e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	ch.11.42038R	chr11:967971	AP2A2	0.45	5.92	0.35	1.07e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg26516362	chr5:178986906	RUFY1	0.44	7.79	0.44	1.92e-13	Lung cancer;
KIRP	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.71	7.53	0.43	9.65e-13	Lymphocyte counts;
KIRP	cis	rs6466055	0.565	rs12534381	chr7:104947195	T/C	cg04380332	chr7:105027541	SRPK2	0.37	5.09	0.31	7.09e-7	Schizophrenia;
KIRP	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.52	-6.35	-0.38	1e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.76	-9.44	-0.52	3.01e-18	Menarche (age at onset);
KIRP	cis	rs698833	0.926	rs1067367	chr2:44654905	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.54	6.4	0.38	7.95e-10	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.75	-10.95	-0.57	5.25e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.45	6.13	0.36	3.44e-9	Sitting height ratio;
KIRP	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.55	6.42	0.38	6.89e-10	Body mass index (adult);
KIRP	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg16589663	chr20:23618590	CST3	0.73	6.92	0.4	3.79e-11	Chronic kidney disease;
KIRP	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.76	6.69	0.39	1.51e-10	Cognitive function;
KIRP	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00889227	chr1:205173544	DSTYK	-0.39	-5.44	-0.33	1.28e-7	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs73086581	1.000	rs17286349	chr20:3914302	G/A	cg02187196	chr20:3869020	PANK2	0.51	4.96	0.3	1.31e-6	Response to antidepressants in depression;
KIRP	trans	rs10895140	0.756	rs4312036	chr11:101519352	C/T	cg20466045	chr21:30445936	CCT8	0.49	6.13	0.36	3.49e-9	Menarche (age at onset);
KIRP	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-9.18	-0.51	1.83e-17	Resting heart rate;
KIRP	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	1.01	18.78	0.77	2.07e-49	Parkinson's disease;
KIRP	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.85	9.7	0.53	4.95e-19	Iron status biomarkers;
KIRP	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16179182	chr5:140090404	VTRNA1-1	0.57	7.75	0.44	2.37e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22712703	chr1:38061501	GNL2	-0.56	-6.39	-0.38	8.44e-10	Interleukin-4 levels;
KIRP	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.71	8.99	0.5	6.71e-17	Morning vs. evening chronotype;
KIRP	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09314708	chr11:132812991	OPCML	0.54	7.57	0.43	7.54e-13	Smoking initiation;
KIRP	cis	rs12220238	0.822	rs73286281	chr10:76083337	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.65	0.39	1.92e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.22	0.32	3.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg11189052	chr15:85197271	WDR73	0.53	4.99	0.3	1.14e-6	Schizophrenia;
KIRP	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg16497661	chr14:103986332	CKB	0.86	14.86	0.69	4.41e-36	Body mass index;
KIRP	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg25418670	chr11:30344373	C11orf46	-0.61	-5.25	-0.32	3.3e-7	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9659323	0.650	rs10802064	chr1:119458137	A/G	cg18261050	chr1:119551319	NA	0.38	4.92	0.3	1.58e-6	Body mass index;
KIRP	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	8.17	0.46	1.68e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.63	5.39	0.33	1.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.72	9.71	0.53	4.46e-19	Crohn's disease;
KIRP	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg24747557	chr10:131355152	MGMT	-0.47	-6.4	-0.38	7.98e-10	Response to temozolomide;
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg10534938	chr5:1868639	NA	0.38	5.16	0.31	4.98e-7	Cardiovascular disease risk factors;
KIRP	cis	rs4835473	0.932	rs6852195	chr4:144663737	G/A	cg08833778	chr4:144622313	FREM3	0.35	5.09	0.31	7.26e-7	Immature fraction of reticulocytes;
KIRP	trans	rs921874	0.586	rs2001411	chr11:86771583	A/G	cg20852851	chr2:240168848	HDAC4	0.46	6.13	0.36	3.48e-9	Total body bone mineral density;
KIRP	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.56	-9.38	-0.51	4.7e-18	Prostate cancer;
KIRP	cis	rs6540559	0.673	rs41305104	chr1:209950848	G/A	cg22029157	chr1:209979665	IRF6	0.48	4.91	0.3	1.67e-6	Cleft lip with or without cleft palate;
KIRP	cis	rs6832769	1.000	rs7668147	chr4:56339384	C/T	cg05960024	chr4:56376020	CLOCK	0.63	8.17	0.46	1.65e-14	Personality dimensions;
KIRP	cis	rs2274273	0.624	rs7155954	chr14:55750943	G/A	cg04306507	chr14:55594613	LGALS3	0.4	5.53	0.33	8.26e-8	Protein biomarker;
KIRP	cis	rs4073221	0.654	rs13066958	chr3:18307712	T/A	cg07694806	chr3:18168406	NA	-0.66	-5.95	-0.35	9.4e-9	Parkinson's disease;
KIRP	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	6.18	0.37	2.61e-9	Personality dimensions;
KIRP	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg24169773	chr3:122142474	KPNA1	-0.53	-5.5	-0.33	9.42e-8	LDL cholesterol levels;
KIRP	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.55	-0.33	7.41e-8	Coronary artery disease;
KIRP	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg00321850	chr1:175162397	KIAA0040	0.34	6.27	0.37	1.63e-9	Alcohol dependence;
KIRP	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.75	8.39	0.47	3.71e-15	Corneal astigmatism;
KIRP	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.49	6.0	0.36	6.94e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-1.09	-8.55	-0.48	1.34e-15	Atopic dermatitis;
KIRP	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.59	7.53	0.43	9.43e-13	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.51	-6.24	-0.37	1.89e-9	Uric acid levels;
KIRP	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-9.12	-0.5	2.74e-17	Myopia (pathological);
KIRP	cis	rs62413470	0.935	rs17683955	chr6:55955250	A/G	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs7084402	0.870	rs1896245	chr10:60276083	T/G	cg05938607	chr10:60274200	BICC1	0.46	11.23	0.58	6.99e-24	Refractive error;
KIRP	cis	rs8018808	0.935	rs7146595	chr14:77932017	A/C	cg20045696	chr14:77926864	AHSA1	0.45	5.46	0.33	1.18e-7	Myeloid white cell count;
KIRP	cis	rs4886920	0.672	rs4886926	chr15:78122112	G/A	cg10461261	chr15:78109450	NA	0.36	6.1	0.36	4.05e-9	Neuroticism;
KIRP	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg08885076	chr2:99613938	TSGA10	0.56	9.76	0.53	3.13e-19	Chronic sinus infection;
KIRP	cis	rs5769707	0.681	rs6009803	chr22:50051007	A/G	cg20744362	chr22:50050164	C22orf34	0.36	5.35	0.32	2.04e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4073221	0.628	rs34742900	chr3:18203974	T/G	cg07694806	chr3:18168406	NA	-0.63	-5.85	-0.35	1.58e-8	Parkinson's disease;
KIRP	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	6.84	0.4	6.19e-11	Educational attainment;
KIRP	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.52	6.05	0.36	5.3e-9	Aortic root size;
KIRP	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg16989719	chr2:238392110	NA	-0.53	-5.97	-0.36	8.03e-9	Prostate cancer;
KIRP	cis	rs6450176	0.909	rs3776712	chr5:53304179	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.88	-11.25	-0.58	5.91e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg02640540	chr1:67518911	SLC35D1	0.49	4.89	0.3	1.83e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.6	-6.46	-0.38	5.42e-10	Corneal astigmatism;
KIRP	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.59	7.33	0.42	3.3e-12	Tuberculosis;
KIRP	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg14664628	chr15:75095509	CSK	0.44	5.46	0.33	1.17e-7	Caffeine consumption;
KIRP	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.76	-9.82	-0.53	1.99e-19	Aortic root size;
KIRP	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.56	7.68	0.44	3.65e-13	Economic and political preferences (feminism/equality);
KIRP	cis	rs2267137	0.903	rs715494	chr22:29782433	G/T	cg07256473	chr22:29710276	RASL10A	-0.44	-6.78	-0.4	8.62e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs867371	1.000	rs867370	chr15:82438262	T/A	cg06066596	chr15:83166174	LOC80154	0.44	5.27	0.32	3e-7	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2278796	0.608	rs11240332	chr1:204969317	C/T	cg04862289	chr1:204966208	NFASC	0.64	9.03	0.5	5.09e-17	Mean platelet volume;
KIRP	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.58	-4.94	-0.3	1.42e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg16141378	chr3:129829833	LOC729375	0.52	6.77	0.4	9.39e-11	Retinal vascular caliber;
KIRP	cis	rs8177876	0.822	rs4306521	chr16:81114893	T/C	cg08591886	chr16:81111003	C16orf46	-0.59	-5.76	-0.34	2.45e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00292664	chr10:71078354	HK1	0.49	6.17	0.37	2.8e-9	Parkinson's disease;
KIRP	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.56	8.06	0.46	3.34e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.52	6.26	0.37	1.72e-9	Coronary artery disease;
KIRP	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg02503808	chr4:7069936	GRPEL1	1.0	12.28	0.62	2.28e-27	Monocyte percentage of white cells;
KIRP	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-5.55	-0.33	7.28e-8	Testicular germ cell tumor;
KIRP	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.64	8.16	0.46	1.76e-14	Prudent dietary pattern;
KIRP	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.31	12.44	0.62	7.1e-28	Diabetic retinopathy;
KIRP	cis	rs7809615	0.901	rs28862110	chr7:99183531	T/C	cg12290671	chr7:99195819	NA	-0.7	-6.73	-0.39	1.21e-10	Blood metabolite ratios;
KIRP	cis	rs6499755	0.768	rs116563840	chr16:55362376	G/A	cg05099576	chr16:55362342	IRX6	0.35	7.02	0.41	2.1e-11	Hypospadias;
KIRP	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.63	7.31	0.42	3.81e-12	Schizophrenia;
KIRP	cis	rs2901460	0.509	rs6750080	chr2:62071542	C/T	cg02183531	chr2:62113199	CCT4	-0.49	-5.06	-0.31	8.41e-7	Mean corpuscular volume;
KIRP	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg04398451	chr17:18023971	MYO15A	-0.87	-13.53	-0.65	1.52e-31	Total body bone mineral density;
KIRP	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg23387468	chr7:139079360	LUC7L2	0.31	5.46	0.33	1.17e-7	Diisocyanate-induced asthma;
KIRP	trans	rs7867456	0.546	rs10757178	chr9:21046674	A/G	cg02613418	chr15:68723914	ITGA11	0.38	6.05	0.36	5.26e-9	Axial length;
KIRP	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.13	-0.46	2.16e-14	Response to antipsychotic treatment;
KIRP	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08280861	chr8:58055591	NA	0.77	6.14	0.36	3.31e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.61	7.21	0.42	6.95e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.5	7.16	0.42	9.02e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg23752985	chr2:85803571	VAMP8	0.6	9.13	0.5	2.61e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg23594656	chr7:65796392	TPST1	-0.48	-7.28	-0.42	4.38e-12	Aortic root size;
KIRP	cis	rs1656402	1.000	rs1550097	chr2:233428275	C/T	cg03852847	chr2:233439513	NA	0.71	11.93	0.61	3.53e-26	Non-small cell lung cancer (survival);
KIRP	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.43	-5.22	-0.32	3.77e-7	Tonsillectomy;
KIRP	cis	rs394563	0.839	rs584916	chr6:149790319	A/C	cg03678062	chr6:149772716	ZC3H12D	-0.38	-6.02	-0.36	6.14e-9	Dupuytren's disease;
KIRP	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg19847130	chr8:10466454	RP1L1	0.43	6.42	0.38	7e-10	Joint mobility (Beighton score);
KIRP	cis	rs9488822	0.585	rs195525	chr6:116248273	C/T	cg15226275	chr6:116381976	FRK	0.22	5.48	0.33	1.03e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-6.73	-0.39	1.19e-10	Capecitabine sensitivity;
KIRP	cis	rs7119038	0.509	rs10790261	chr11:118579747	C/T	cg19308663	chr11:118741387	NA	-0.42	-6.5	-0.38	4.46e-10	Sjögren's syndrome;
KIRP	cis	rs7224685	0.859	rs34348519	chr17:4094140	G/C	cg05562828	chr17:3906858	NA	0.46	5.66	0.34	4.24e-8	Type 2 diabetes;
KIRP	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.69	10.01	0.54	5.13e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17554472	chr22:41940697	POLR3H	-0.53	-5.94	-0.35	9.78e-9	Vitiligo;
KIRP	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg07001201	chr5:642380	CEP72	0.5	5.96	0.36	8.86e-9	Obesity-related traits;
KIRP	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-4.96	-0.3	1.33e-6	Coronary artery disease;
KIRP	cis	rs6088813	0.663	rs2425056	chr20:33909245	G/A	cg14752227	chr20:34000481	UQCC	0.48	6.15	0.36	3.17e-9	Height;
KIRP	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg23188430	chr6:125850052	NA	-0.35	-5.47	-0.33	1.11e-7	Brugada syndrome;
KIRP	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.43	-5.24	-0.32	3.38e-7	Aortic root size;
KIRP	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg27121462	chr16:89883253	FANCA	0.53	7.07	0.41	1.56e-11	Vitiligo;
KIRP	cis	rs12476592	0.516	rs11883730	chr2:63592230	A/C	cg17519650	chr2:63277830	OTX1	0.44	5.01	0.3	1.02e-6	Childhood ear infection;
KIRP	cis	rs76533333	0.646	rs12861423	chr13:113387084	C/A	cg04656015	chr13:113407548	ATP11A	0.72	5.99	0.36	7.52e-9	Red cell distribution width;
KIRP	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-6.1	-0.36	4.08e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg23594656	chr7:65796392	TPST1	-0.47	-7.48	-0.43	1.27e-12	Aortic root size;
KIRP	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg08807101	chr21:30365312	RNF160	0.62	7.48	0.43	1.35e-12	Pancreatic cancer;
KIRP	cis	rs34779708	0.931	rs11597392	chr10:35288575	T/C	cg03585969	chr10:35415529	CREM	0.81	9.81	0.53	2.14e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg26876637	chr1:152193138	HRNR	-0.76	-8.55	-0.48	1.32e-15	Atopic dermatitis;
KIRP	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.78	12.93	0.64	1.56e-29	Vitiligo;
KIRP	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.28	14.66	0.68	2.19e-35	Uric acid levels;
KIRP	cis	rs282587	0.569	rs395246	chr13:113415392	C/A	cg04656015	chr13:113407548	ATP11A	0.58	6.33	0.37	1.12e-9	Glycated hemoglobin levels;
KIRP	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg24315340	chr6:146058215	EPM2A	-0.46	-6.14	-0.36	3.3e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg20578329	chr17:80767326	TBCD	0.53	7.12	0.41	1.19e-11	Breast cancer;
KIRP	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg04374321	chr14:90722782	PSMC1	-0.84	-11.8	-0.6	8.92e-26	Mortality in heart failure;
KIRP	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.73	9.61	0.52	9.25e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13487956	chr18:47340408	SCARNA17;ACAA2	0.44	6.11	0.36	3.82e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6545883	0.542	rs7584500	chr2:61692115	T/C	cg15711740	chr2:61764176	XPO1	-0.44	-5.45	-0.33	1.24e-7	Tuberculosis;
KIRP	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.45	6.57	0.39	3.01e-10	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs3857067	1.000	rs12502725	chr4:94999873	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-5.08	-0.31	7.37e-7	QT interval;
KIRP	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.7	10.35	0.55	4.54e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10073892	0.660	rs11746498	chr5:101955098	T/A	cg19774478	chr5:101632501	SLCO4C1	0.53	5.43	0.33	1.38e-7	Cognitive decline (age-related);
KIRP	cis	rs698833	0.758	rs7586188	chr2:44544955	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	5.9	0.35	1.17e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.46	7.06	0.41	1.66e-11	Resting heart rate;
KIRP	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.75	0.4	1.04e-10	Bipolar disorder;
KIRP	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg11845111	chr2:191398756	TMEM194B	-0.66	-7.15	-0.41	9.77e-12	Diastolic blood pressure;
KIRP	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.49	5.99	0.36	7.6e-9	HDL cholesterol;
KIRP	cis	rs6570726	0.516	rs10484700	chr6:145728933	C/T	cg23711669	chr6:146136114	FBXO30	0.47	6.24	0.37	1.89e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.55	-0.43	8.23e-13	Mean corpuscular volume;
KIRP	cis	rs9547996	0.917	rs7321585	chr13:38263176	G/C	cg13634560	chr13:38173852	POSTN	-0.36	-5.11	-0.31	6.52e-7	Diastolic blood pressure;
KIRP	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.38	-5.77	-0.35	2.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.81	11.5	0.59	8.87e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg20430773	chr1:16534157	ARHGEF19	0.42	5.1	0.31	6.75e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs11158198	0.620	rs1998102	chr14:58598811	T/C	cg15908186	chr14:58618357	C14orf37	0.42	5.08	0.31	7.5e-7	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-7.77	-0.44	2.12e-13	Platelet distribution width;
KIRP	cis	rs7404095	0.664	rs12928014	chr16:23867909	A/G	cg21745164	chr16:23765304	CHP2	0.35	5.06	0.31	8.3e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15557168	chr22:42548783	NA	0.42	5.38	0.32	1.77e-7	Cognitive function;
KIRP	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.31	-4.85	-0.3	2.24e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-6.87	-0.4	5.11e-11	Response to antipsychotic treatment;
KIRP	trans	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs710913	0.618	rs6587	chr1:40089945	A/G	cg27567593	chr1:39956653	BMP8A	-0.36	-5.05	-0.31	8.79e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg16141378	chr3:129829833	LOC729375	-0.57	-7.71	-0.44	3.03e-13	Neuroticism;
KIRP	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-9.41	-0.51	3.65e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14331002	chr19:11201349	LDLR	0.49	6.84	0.4	6.08e-11	Parkinson's disease;
KIRP	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg16141378	chr3:129829833	LOC729375	0.52	6.43	0.38	6.71e-10	Neuroticism;
KIRP	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9653442	0.545	rs13032454	chr2:100756009	T/C	cg17356467	chr2:100759845	AFF3	0.42	5.63	0.34	4.93e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-10.61	-0.56	6.67e-22	Morning vs. evening chronotype;
KIRP	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg11833968	chr6:79620685	NA	-0.45	-6.77	-0.4	9.12e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2120243	0.539	rs1869859	chr3:157107762	G/T	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6938	0.534	rs34063670	chr15:75247156	C/G	cg21523564	chr15:75251491	NA	0.46	7.64	0.44	4.92e-13	Breast cancer;
KIRP	cis	rs10267417	0.603	rs10264784	chr7:19909530	T/C	cg05791153	chr7:19748676	TWISTNB	0.49	4.98	0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.43	7.55	0.43	8.43e-13	Renal cell carcinoma;
KIRP	cis	rs9810890	0.557	rs73207984	chr3:128578177	T/C	cg15033153	chr3:128514015	RAB7A	0.69	5.03	0.31	9.52e-7	Dental caries;
KIRP	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg24110177	chr3:50126178	RBM5	-0.62	-7.14	-0.41	1.06e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg26207909	chr14:103986467	CKB	-0.44	-5.36	-0.32	1.88e-7	Coronary artery disease;
KIRP	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg06871246	chr4:1363661	KIAA1530	-0.56	-6.98	-0.41	2.75e-11	Longevity;
KIRP	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06544989	chr22:39130855	UNC84B	0.48	7.25	0.42	5.5e-12	Menopause (age at onset);
KIRP	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.59	0.39	2.61e-10	Retinal vascular caliber;
KIRP	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.39	5.36	0.32	1.88e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.4	6.19	0.37	2.56e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.65	9.55	0.52	1.4e-18	Dupuytren's disease;
KIRP	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg27205649	chr11:78285834	NARS2	-0.67	-8.66	-0.48	6.41e-16	Alzheimer's disease (survival time);
KIRP	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	1.12	8.19	0.46	1.44e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.52	6.17	0.37	2.77e-9	Breast cancer;
KIRP	cis	rs4774899	0.899	rs12906335	chr15:57487091	A/T	cg13626582	chr15:57592083	LOC283663	-0.21	-4.92	-0.3	1.59e-6	Urinary tract infection frequency;
KIRP	cis	rs7243821	0.705	rs8095648	chr18:52636910	A/G	cg26630735	chr18:52626848	CCDC68	0.56	5.63	0.34	5.02e-8	Chin dimples;
KIRP	cis	rs6546886	0.912	rs6756474	chr2:74282706	C/T	cg14702570	chr2:74259524	NA	0.31	5.98	0.36	7.77e-9	Dialysis-related mortality;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.78	14.06	0.67	2.43e-33	Height;
KIRP	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.97	-14.99	-0.69	1.54e-36	Height;
KIRP	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg08648136	chr8:956695	NA	0.38	5.17	0.31	4.83e-7	Schizophrenia;
KIRP	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.98	8.09	0.46	2.68e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs9929215	1.000	rs9929215	chr16:86521490	C/G	cg21981144	chr19:45248572	NA	-0.55	-6.09	-0.36	4.31e-9	Colorectal cancer;
KIRP	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg04727924	chr7:799746	HEATR2	-0.79	-8.95	-0.5	8.95e-17	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6977660	0.607	rs13239423	chr7:19816571	T/C	cg05791153	chr7:19748676	TWISTNB	0.6	5.73	0.34	2.87e-8	Thyroid stimulating hormone;
KIRP	cis	rs2120243	0.538	rs4680360	chr3:157094479	C/T	cg24825693	chr3:157122686	VEPH1	0.57	8.71	0.49	4.62e-16	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg13628971	chr7:2884303	GNA12	0.39	4.87	0.3	2.02e-6	Height;
KIRP	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.82	-11.41	-0.59	1.75e-24	Total body bone mineral density;
KIRP	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	0.84	11.1	0.58	1.73e-23	Primary sclerosing cholangitis;
KIRP	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-9.1	-0.5	3.17e-17	Parkinson's disease;
KIRP	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.42	-5.38	-0.32	1.76e-7	Aortic root size;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg13794888	chr15:75917792	SNUPN	0.56	6.29	0.37	1.46e-9	Lung cancer in ever smokers;
KIRP	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg21523564	chr15:75251491	NA	0.37	6.26	0.37	1.68e-9	Breast cancer;
KIRP	cis	rs2285002	0.745	rs229674	chr14:65281472	G/C	cg23373153	chr14:65346875	NA	-0.37	-5.01	-0.3	1.05e-6	Red cell distribution width;
KIRP	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.61	6.84	0.4	6.19e-11	Primary sclerosing cholangitis;
KIRP	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg16342193	chr10:102329863	NA	-0.38	-4.98	-0.3	1.19e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.65	-9.09	-0.5	3.37e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs448720	0.806	rs11071966	chr15:68163774	G/A	cg24579218	chr15:68104479	NA	0.43	6.3	0.37	1.39e-9	Cognitive performance;
KIRP	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.67	-0.44	3.89e-13	Total cholesterol levels;
KIRP	cis	rs12282928	1.000	rs7129742	chr11:48326592	G/A	cg26585981	chr11:48327164	OR4S1	0.51	6.22	0.37	2.09e-9	Migraine - clinic-based;
KIRP	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21747090	chr2:27597821	SNX17	-0.49	-6.7	-0.39	1.38e-10	Menopause (age at onset);
KIRP	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg03959625	chr15:84868606	LOC388152	0.71	8.44	0.47	2.69e-15	Schizophrenia;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11388258	chr1:151484008	CGN	-0.48	-6.31	-0.37	1.28e-9	Myopia;
KIRP	cis	rs7017914	1.000	rs7017914	chr8:71591203	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21545522	chr1:205238299	TMCC2	0.55	7.31	0.42	3.69e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9815354	0.812	rs73073229	chr3:42007850	T/C	cg03022575	chr3:42003672	ULK4	0.83	8.7	0.49	4.83e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.79	-13.98	-0.67	4.41e-33	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.74	0.49	3.65e-16	Prudent dietary pattern;
KIRP	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg08662619	chr6:150070041	PCMT1	0.35	5.56	0.33	6.91e-8	Lung cancer;
KIRP	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-7.82	-0.45	1.54e-13	Calcium levels;
KIRP	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg01689657	chr7:91764605	CYP51A1	0.39	5.72	0.34	3.11e-8	Breast cancer;
KIRP	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.59	-7.29	-0.42	4.17e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs603424	0.551	rs525190	chr10:102087038	C/T	cg10365880	chr10:102089681	PKD2L1	-0.66	-5.23	-0.32	3.6e-7	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
KIRP	cis	rs6901004	0.803	rs4947107	chr6:111442505	C/T	cg15721981	chr6:111408429	SLC16A10	-0.63	-8.86	-0.49	1.65e-16	Blood metabolite levels;
KIRP	cis	rs28655083	1.000	rs1843457	chr16:77072400	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-5.67	-0.34	3.94e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2562456	0.833	rs2154302	chr19:21490411	G/A	cg24072202	chr19:22235272	ZNF257	-0.53	-4.89	-0.3	1.82e-6	Pain;
KIRP	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg16473166	chr22:50639996	SELO	0.68	8.59	0.48	1.04e-15	Late-onset Alzheimer's disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17143565	chr17:33569990	SLFN5	0.44	6.16	0.37	2.97e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg19694781	chr19:47549865	TMEM160	0.49	6.12	0.36	3.64e-9	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs6496667	0.779	rs8033897	chr15:90947842	T/G	cg10434728	chr15:90938212	IQGAP1	0.39	5.14	0.31	5.56e-7	Rheumatoid arthritis;
KIRP	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-12.17	-0.61	5.65e-27	Dental caries;
KIRP	cis	rs4805272	1.000	rs7254025	chr19:29326106	G/C	cg15000279	chr19:29285009	NA	-0.37	-5.27	-0.32	2.96e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.95	-16.45	-0.72	1.6e-41	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.11	-0.41	1.24e-11	Triglycerides;
KIRP	cis	rs3931020	0.657	rs277368	chr1:75230606	C/T	cg10128416	chr1:75198403	TYW3;CRYZ	-0.47	-5.67	-0.34	4.02e-8	Resistin levels;
KIRP	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.59	-0.44	6.59e-13	Life satisfaction;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18957973	chr2:97303987	KIAA1310	0.59	7.48	0.43	1.3e-12	Parkinson's disease;
KIRP	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg07541023	chr7:19748670	TWISTNB	0.67	5.83	0.35	1.75e-8	Thyroid stimulating hormone;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07803864	chr10:5446998	TUBAL3	0.42	6.34	0.37	1.08e-9	Migraine with aura;
KIRP	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg21699342	chr2:239360505	ASB1	-0.48	-4.89	-0.3	1.84e-6	Morning vs. evening chronotype;Chronotype;
KIRP	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg00343986	chr7:65444356	GUSB	-0.4	-4.91	-0.3	1.63e-6	Aortic root size;
KIRP	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.62	0.52	8.18e-19	Prudent dietary pattern;
KIRP	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg00147788	chr6:125855365	NA	-0.33	-5.03	-0.31	9.65e-7	Brugada syndrome;
KIRP	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-6.65	-0.39	1.87e-10	QT interval;
KIRP	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.92	-11.13	-0.58	1.47e-23	Diastolic blood pressure;
KIRP	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.57	-6.0	-0.36	6.84e-9	Ulcerative colitis;
KIRP	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.81	9.06	0.5	4.09e-17	Alzheimer's disease;
KIRP	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.58	-7.1	-0.41	1.33e-11	Obesity-related traits;
KIRP	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg21775007	chr8:11205619	TDH	0.52	6.83	0.4	6.58e-11	Joint mobility (Beighton score);
KIRP	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.52	7.53	0.43	9.34e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	cg04338863	chr8:33670619	NA	0.4	5.21	0.32	4.02e-7	Body mass index;
KIRP	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg23131131	chr22:24373011	LOC391322	-0.6	-7.39	-0.43	2.23e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.27	27.67	0.87	1.73e-77	IgG glycosylation;
KIRP	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.83	-11.19	-0.58	9.01e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/G	cg15757745	chr22:47558489	TBC1D22A	-0.64	-7.42	-0.43	1.9e-12	Longevity;
KIRP	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.52	6.62	0.39	2.24e-10	Coronary heart disease;
KIRP	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg01960748	chr1:24522592	NA	-0.76	-7.11	-0.41	1.25e-11	Psoriasis vulgaris;
KIRP	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg17207736	chr8:142237307	SLC45A4	-0.52	-6.63	-0.39	2.15e-10	Immature fraction of reticulocytes;
KIRP	cis	rs236907	0.859	rs17650310	chr1:171757204	A/G	cg01410279	chr1:171621941	MYOC	-0.53	-6.02	-0.36	6.25e-9	Mean platelet volume;
KIRP	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.45	6.34	0.37	1.1e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.44	9.9	0.53	1.13e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2522056	1.000	rs2706395	chr5:131796803	A/T	cg07395648	chr5:131743802	NA	0.55	6.57	0.39	2.99e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.59	8.12	0.46	2.23e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg18932078	chr1:2524107	MMEL1	0.39	5.21	0.32	4.03e-7	Ulcerative colitis;
KIRP	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs4901847	1.000	rs4901847	chr14:58559241	C/T	cg15908186	chr14:58618357	C14orf37	0.43	5.43	0.33	1.34e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.91	13.97	0.67	4.61e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs1318772	1.000	rs255859	chr5:112743480	C/T	cg12552261	chr5:112820674	MCC	0.77	4.97	0.3	1.24e-6	F-cell distribution;
KIRP	cis	rs10982256	0.875	rs11789406	chr9:117246188	G/A	cg13636371	chr9:117264095	DFNB31	0.56	7.48	0.43	1.33e-12	Bipolar disorder;
KIRP	cis	rs981844	0.885	rs17370924	chr4:154645593	A/G	cg14289246	chr4:154710475	SFRP2	0.68	7.19	0.42	7.94e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.49	6.06	0.36	4.96e-9	Height;
KIRP	cis	rs4363385	0.510	rs7541328	chr1:152894142	C/G	cg13444842	chr1:152974279	SPRR3	-0.47	-6.67	-0.39	1.71e-10	Inflammatory skin disease;
KIRP	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg00361562	chr2:198649771	BOLL	-0.52	-5.14	-0.31	5.66e-7	Ulcerative colitis;
KIRP	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.74	7.61	0.44	5.7e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.92	-0.35	1.06e-8	Response to antipsychotic treatment;
KIRP	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	6.26	0.37	1.69e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	1.1	8.58	0.48	1.05e-15	Skin colour saturation;
KIRP	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.49	5.27	0.32	2.95e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg19460391	chr5:86709603	CCNH	-0.36	-6.08	-0.36	4.68e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs17401966	1.000	rs12757820	chr1:10266671	A/T	cg19773385	chr1:10388646	KIF1B	-0.62	-8.06	-0.46	3.22e-14	Hepatocellular carcinoma;
KIRP	cis	rs9513627	1.000	rs9585075	chr13:100128634	G/A	cg25919922	chr13:100150906	NA	-0.67	-5.16	-0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	9.93	0.54	9.03e-20	Ileal carcinoids;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17139369	chr19:8478169	MARCH2	0.5	7.17	0.42	8.58e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.54	7.09	0.41	1.41e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg01631408	chr1:248437212	OR2T33	-0.61	-8.46	-0.47	2.44e-15	Common traits (Other);
KIRP	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-0.78	-9.21	-0.51	1.44e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.45	-6.44	-0.38	6.1e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	10.47	0.56	1.86e-21	Parkinson's disease;
KIRP	cis	rs1978968	0.956	rs35972244	chr22:18434038	C/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.68	-7.6	-0.44	6.1e-13	Presence of antiphospholipid antibodies;
KIRP	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg10503236	chr1:231470652	EXOC8	-0.5	-7.09	-0.41	1.41e-11	Hemoglobin concentration;
KIRP	cis	rs1816752	0.721	rs7399656	chr13:24989846	A/G	cg22771759	chr13:24902376	NA	0.37	4.86	0.3	2.08e-6	Obesity-related traits;
KIRP	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.79	10.27	0.55	8.27e-21	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	7.08	0.41	1.48e-11	Rheumatoid arthritis;
KIRP	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.7	-9.69	-0.53	5e-19	Schizophrenia;
KIRP	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg00277334	chr10:82204260	NA	-0.62	-6.44	-0.38	6.07e-10	Post bronchodilator FEV1;
KIRP	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	1.07	12.9	0.64	2.01e-29	Red blood cell traits;
KIRP	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.59	0.48	1.04e-15	Motion sickness;
KIRP	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.35	-5.61	-0.34	5.33e-8	Cancer (pleiotropy);
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg04080417	chr5:1859792	NA	-0.63	-8.06	-0.46	3.33e-14	Cardiovascular disease risk factors;
KIRP	cis	rs72792276	1.000	rs72794361	chr5:127435188	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	7.21	0.42	6.83e-12	Red cell distribution width;
KIRP	cis	rs2904967	0.929	rs592050	chr11:65030189	C/G	cg09225861	chr11:65069680	NA	0.43	5.62	0.34	5.1e-8	Mean corpuscular volume;
KIRP	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg17652424	chr22:38574118	PLA2G6	0.28	5.74	0.34	2.75e-8	Cutaneous nevi;
KIRP	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg06521331	chr12:34319734	NA	-0.48	-6.0	-0.36	7.15e-9	Morning vs. evening chronotype;
KIRP	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg16950941	chr11:66035639	RAB1B	0.46	5.68	0.34	3.71e-8	Gout;
KIRP	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.97	-13.7	-0.66	3.81e-32	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs258892	0.793	rs3846639	chr5:72019847	G/A	cg21869765	chr5:72125136	TNPO1	-0.48	-5.61	-0.34	5.5e-8	Small cell lung carcinoma;
KIRP	cis	rs904251	0.772	rs756202	chr6:37460350	C/A	cg08126542	chr6:37504118	NA	-0.6	-7.1	-0.41	1.33e-11	Cognitive performance;
KIRP	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.96	13.08	0.64	4.89e-30	Cognitive function;
KIRP	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.76	8.85	0.49	1.71e-16	Adiposity;
KIRP	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.53	-5.27	-0.32	3.03e-7	Pubertal anthropometrics;
KIRP	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg14458575	chr2:238380390	NA	0.52	6.89	0.4	4.55e-11	Prostate cancer;
KIRP	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.63	8.77	0.49	2.94e-16	Autism;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg01988459	chr11:68622903	NA	-0.42	-5.74	-0.34	2.78e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.0	9.3	0.51	7.89e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg21186296	chr8:27182909	PTK2B	0.48	6.21	0.37	2.23e-9	Neuroticism;
KIRP	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.53	7.01	0.41	2.27e-11	Multiple myeloma (IgH translocation);
KIRP	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.55	7.34	0.42	3.2e-12	Blood metabolite levels;
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg04369109	chr6:150039330	LATS1	-0.51	-6.49	-0.38	4.72e-10	Lung cancer;
KIRP	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.54	-6.43	-0.38	6.61e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg05457628	chr5:178986728	RUFY1	0.53	8.28	0.47	8.12e-15	Lung cancer;
KIRP	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.61	6.26	0.37	1.7e-9	DNA methylation (variation);
KIRP	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg13147721	chr7:65941812	NA	-0.95	-6.77	-0.4	9.25e-11	Diabetic kidney disease;
KIRP	cis	rs8067354	0.645	rs2665400	chr17:57880201	G/A	cg02344993	chr17:57696989	CLTC	0.61	5.85	0.35	1.57e-8	Hemoglobin concentration;
KIRP	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg17757837	chr7:157058334	UBE3C	0.78	10.5	0.56	1.54e-21	Body mass index;
KIRP	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.69	10.22	0.55	1.17e-20	Dupuytren's disease;
KIRP	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.58	-9.26	-0.51	1.01e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs75229567	0.618	rs1599745	chr12:70186029	A/G	cg10114359	chr12:70132523	RAB3IP	0.63	5.57	0.33	6.75e-8	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs9815354	0.857	rs13087502	chr3:42015110	A/G	cg03022575	chr3:42003672	ULK4	0.56	6.5	0.38	4.42e-10	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.16	0.37	2.9e-9	Platelet count;
KIRP	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.42	6.42	0.38	7.01e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-8.76	-0.49	3.31e-16	Chronic sinus infection;
KIRP	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	0.93	13.56	0.65	1.22e-31	Dupuytren's disease;
KIRP	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg27624424	chr6:160112604	SOD2	0.46	4.94	0.3	1.43e-6	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7601312	1.000	rs34216152	chr2:229317367	C/A	cg02542817	chr2:229291442	NA	-0.37	-5.42	-0.33	1.4e-7	Schizophrenia;
KIRP	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11584989	chr19:19387371	SF4	0.57	6.09	0.36	4.34e-9	Bipolar disorder;
KIRP	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg10210624	chr19:58662595	ZNF329	0.62	5.66	0.34	4.13e-8	Cholesterol, total;
KIRP	cis	rs2296225	1.000	rs3753047	chr1:21050270	C/T	cg14666476	chr1:21112556	HP1BP3	0.85	5.29	0.32	2.73e-7	Eosinophilic esophagitis;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg09916155	chr16:1728187	HN1L	0.55	6.59	0.39	2.64e-10	Plasma plasminogen activator levels;
KIRP	cis	rs5753618	0.561	rs4141404	chr22:31675185	A/C	cg02404636	chr22:31891804	SFI1	-0.49	-5.4	-0.33	1.56e-7	Colorectal cancer;
KIRP	cis	rs9912468	0.594	rs11079645	chr17:64228090	G/T	cg19474267	chr17:64306194	PRKCA	-0.41	-5.21	-0.32	3.99e-7	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg09699651	chr6:150184138	LRP11	0.47	6.1	0.36	3.98e-9	Lung cancer;
KIRP	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg03235661	chr20:60525775	NA	-0.36	-5.61	-0.34	5.36e-8	Body mass index;
KIRP	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg14675211	chr2:100938903	LONRF2	0.46	6.09	0.36	4.31e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg24633833	chr3:10029261	TMEM111	0.51	4.85	0.3	2.24e-6	Alzheimer's disease;
KIRP	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg08975724	chr8:8085496	FLJ10661	-0.62	-7.79	-0.44	1.93e-13	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06287708	chr2:179345168	MIR548N;PLEKHA3	0.46	6.03	0.36	6.04e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.47	6.48	0.38	4.98e-10	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs6580649	0.941	rs78649179	chr12:48508196	T/A	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg24023618	chr6:114292459	HDAC2	0.49	6.47	0.38	5.19e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	trans	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg25214090	chr10:38739885	LOC399744	0.59	6.97	0.41	2.93e-11	Corneal astigmatism;
KIRP	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.85	10.24	0.55	1.02e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.42	-5.51	-0.33	8.86e-8	Menopause (age at onset);
KIRP	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg21926883	chr2:100939477	LONRF2	-0.66	-9.15	-0.5	2.17e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg18016565	chr1:150552671	MCL1	0.35	5.47	0.33	1.12e-7	Tonsillectomy;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg02733842	chr7:1102375	C7orf50	0.42	5.02	0.3	1.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg13482628	chr17:19912719	NA	0.57	8.05	0.46	3.61e-14	Schizophrenia;
KIRP	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg05484376	chr2:27715224	FNDC4	0.37	6.05	0.36	5.4e-9	Menopause (age at onset);
KIRP	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs2301888	0.830	rs2240336	chr1:17674402	C/T	cg01790353	chr1:17674483	PADI4	0.46	6.2	0.37	2.4e-9	Rheumatoid arthritis;
KIRP	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg11569703	chr11:65557185	OVOL1	0.78	14.98	0.69	1.78e-36	Acne (severe);
KIRP	cis	rs6707387	0.624	rs114455892	chr2:214381130	A/C	cg08319019	chr2:214017104	IKZF2	0.46	5.35	0.32	2.05e-7	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs9400467	0.506	rs79788276	chr6:111599214	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs882732	1.000	rs10133253	chr14:95033681	A/G	cg05186455	chr14:95027692	SERPINA4	-0.37	-5.6	-0.34	5.79e-8	Blood protein levels;
KIRP	cis	rs73058052	0.569	rs2116922	chr19:50103252	G/A	cg13432900	chr19:49999314	RPS11	0.39	4.88	0.3	1.89e-6	Fibrinogen levels;
KIRP	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.73	5.29	0.32	2.65e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7851660	0.844	rs10123699	chr9:100637859	A/G	cg13688889	chr9:100608707	NA	-0.67	-8.74	-0.49	3.63e-16	Strep throat;
KIRP	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.3	5.51	0.33	9.19e-8	Educational attainment (years of education);
KIRP	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-7.68	-0.44	3.87e-13	Mood instability;
KIRP	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	5.04	0.31	8.84e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg13147721	chr7:65941812	NA	-1.0	-6.87	-0.4	5.16e-11	Diabetic kidney disease;
KIRP	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg01763666	chr17:80159506	CCDC57	-0.36	-4.96	-0.3	1.3e-6	Life satisfaction;
KIRP	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.63	8.18	0.46	1.49e-14	Response to antipsychotic treatment;
KIRP	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-8.39	-0.47	3.82e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.51	0.38	4.13e-10	Menarche (age at onset);
KIRP	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg22906224	chr7:99728672	NA	0.5	6.12	0.36	3.6e-9	Coronary artery disease;
KIRP	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.8	11.49	0.59	9.34e-25	Mean corpuscular hemoglobin;
KIRP	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.96	13.72	0.66	3.47e-32	Cognitive function;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg08901578	chr4:187885870	NA	-0.51	-7.93	-0.45	7.7e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	6.76	0.4	1e-10	Coronary artery disease;
KIRP	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.58	7.66	0.44	4.26e-13	Systemic lupus erythematosus;
KIRP	cis	rs12580194	0.593	rs11832308	chr12:55755506	C/A	cg11794356	chr12:55725991	OR6C3	-0.55	-7.7	-0.44	3.25e-13	Cancer;
KIRP	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	1.04	19.06	0.77	2.33e-50	Heart rate;
KIRP	cis	rs4262150	0.726	rs11956651	chr5:152011814	C/T	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.94e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.5	6.01	0.36	6.51e-9	Alzheimer's disease (late onset);
KIRP	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg13514129	chr1:39547527	MACF1	0.55	8.11	0.46	2.36e-14	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg18806716	chr10:30721971	MAP3K8	-0.37	-5.6	-0.34	5.65e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.82	-12.97	-0.64	1.15e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4262150	0.544	rs17548854	chr5:151901555	C/A	cg12297329	chr5:152029980	NA	-0.71	-8.79	-0.49	2.7e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06850241	chr22:41845214	NA	-0.42	-4.92	-0.3	1.57e-6	Vitiligo;
KIRP	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg00981070	chr1:2046702	PRKCZ	0.45	6.45	0.38	6.02e-10	Height;
KIRP	cis	rs4253772	0.872	rs79700435	chr22:46638211	G/A	cg00784671	chr22:46762841	CELSR1	-0.5	-5.52	-0.33	8.46e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9649213	0.593	rs1076272	chr7:98031005	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.34	0.32	2.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21659725	chr3:3221576	CRBN	-0.58	-6.86	-0.4	5.71e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs2230307	0.656	rs12145880	chr1:100446008	C/G	cg24955406	chr1:100503596	HIAT1	0.56	5.57	0.33	6.57e-8	Carotid intima media thickness;
KIRP	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg03315344	chr16:75512273	CHST6	0.7	10.33	0.55	5.23e-21	Dupuytren's disease;
KIRP	cis	rs4356932	0.967	rs6856958	chr4:76952356	T/G	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.62e-9	Blood protein levels;
KIRP	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.92	14.65	0.68	2.36e-35	Testicular germ cell tumor;
KIRP	trans	rs3858145	0.588	rs115455464	chr10:70038498	T/C	cg04882175	chr6:131122610	NA	-0.59	-6.99	-0.41	2.63e-11	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	6.76	0.4	9.91e-11	Retinal vascular caliber;
KIRP	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg19476082	chr7:2414320	EIF3B	0.56	5.16	0.31	5.07e-7	Multiple sclerosis;
KIRP	trans	rs13126513	0.528	rs1121886	chr4:100394210	A/G	cg00747184	chr14:55878680	KIAA0831	-0.45	-6.46	-0.38	5.69e-10	Metabolite levels (MHPG);
KIRP	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg22705602	chr4:152727874	NA	-0.54	-9.6	-0.52	9.56e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg11569703	chr11:65557185	OVOL1	0.8	15.53	0.7	2.33e-38	Acne (severe);
KIRP	cis	rs7106204	0.609	rs55751762	chr11:24296146	C/T	ch.11.24196551F	chr11:24239977	NA	0.71	5.26	0.32	3.16e-7	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.56	7.58	0.43	7.23e-13	Endometrial cancer;
KIRP	cis	rs823156	0.598	rs823072	chr1:205773652	C/T	cg14159672	chr1:205819179	PM20D1	0.52	5.63	0.34	4.85e-8	Parkinson's disease;
KIRP	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg22875332	chr1:76189707	ACADM	-0.34	-4.99	-0.3	1.16e-6	Daytime sleep phenotypes;
KIRP	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.5	-7.61	-0.44	5.97e-13	Educational attainment;
KIRP	cis	rs10256972	0.616	rs3802141	chr7:1131356	T/C	cg09414673	chr7:1022797	CYP2W1	0.4	5.22	0.32	3.72e-7	Longevity;Endometriosis;
KIRP	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.6	-8.38	-0.47	3.99e-15	Brugada syndrome;
KIRP	cis	rs10849893	0.554	rs10849888	chr12:121892786	A/G	cg01154721	chr12:121881891	KDM2B	-0.52	-6.66	-0.39	1.81e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs922692	0.744	rs11639044	chr15:79083814	C/T	cg04896959	chr15:78267971	NA	0.5	6.5	0.38	4.35e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	cis	rs6959887	0.962	rs7790964	chr7:35299884	C/T	cg06685737	chr7:35301730	NA	0.45	6.44	0.38	6.39e-10	Birth weight;
KIRP	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08280861	chr8:58055591	NA	0.7	5.07	0.31	7.72e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.54	-0.43	9.24e-13	Type 2 diabetes;
KIRP	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg00579200	chr11:133705235	NA	-0.39	-4.85	-0.3	2.22e-6	Childhood ear infection;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24933605	chr2:216177085	ATIC	0.43	6.02	0.36	6.22e-9	Parkinson's disease;
KIRP	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	5.64	0.34	4.76e-8	Mean platelet volume;
KIRP	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.34	-7.51	-0.43	1.06e-12	Cutaneous nevi;
KIRP	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.64	11.8	0.6	9.15e-26	Blood protein levels;
KIRP	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.81	-9.19	-0.51	1.66e-17	Platelet count;
KIRP	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg05082376	chr22:42548792	NA	-0.46	-5.45	-0.33	1.21e-7	Schizophrenia;
KIRP	cis	rs10193935	0.901	rs6713242	chr2:42470794	C/T	cg27598129	chr2:42591480	NA	-0.77	-5.87	-0.35	1.37e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.29	-0.32	2.77e-7	Retinal vascular caliber;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg04914305	chr19:17416447	MRPL34	-0.51	-6.14	-0.36	3.29e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17067123	0.614	rs72712851	chr4:180066258	A/G	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.14	16.07	0.72	3.35e-40	Lymphocyte percentage of white cells;
KIRP	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-7.99	-0.45	5.22e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.83	10.44	0.55	2.34e-21	Gestational age at birth (maternal effect);
KIRP	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-11.85	-0.6	6.38e-26	Chronic sinus infection;
KIRP	cis	rs9473924	0.618	rs61236902	chr6:50813055	C/G	cg14470998	chr6:50812995	TFAP2B	1.01	9.04	0.5	4.86e-17	Body mass index;
KIRP	cis	rs12986413	0.789	rs12976923	chr19:2173136	G/A	cg09261902	chr19:2140048	AP3D1	0.43	5.18	0.31	4.7e-7	Height;
KIRP	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.9	-12.15	-0.61	6.3e-27	Gut microbiota (bacterial taxa);
KIRP	cis	rs6753739	0.826	rs10164493	chr2:219948092	A/G	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	cis	rs4356932	1.000	rs7683657	chr4:76962643	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.06	0.36	4.99e-9	Blood protein levels;
KIRP	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg15340874	chr1:174969621	CACYBP	0.52	6.12	0.36	3.73e-9	Plasma plasminogen activator levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg23182539	chr10:121355708	TIAL1	-0.52	-6.81	-0.4	7.42e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg03959625	chr15:84868606	LOC388152	0.63	6.98	0.41	2.75e-11	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23422036	chr7:12250390	TMEM106B	0.47	6.1	0.36	4.17e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22280173	chr3:50358981	HYAL2	0.55	6.72	0.39	1.27e-10	Parkinson's disease;
KIRP	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.74	-10.83	-0.57	1.33e-22	Neurofibrillary tangles;
KIRP	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg22138327	chr13:27999177	GTF3A	0.79	9.0	0.5	6.24e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	0.92	12.34	0.62	1.5e-27	Homoarginine levels;
KIRP	cis	rs1816752	0.819	rs7988388	chr13:24986813	C/A	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.86	8.6	0.48	9.56e-16	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs34779708	0.801	rs34592588	chr10:35540134	A/G	cg03585969	chr10:35415529	CREM	0.6	7.08	0.41	1.53e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2278796	0.639	rs11240331	chr1:204968339	C/T	cg04862289	chr1:204966208	NFASC	0.67	9.35	0.51	5.68e-18	Mean platelet volume;
KIRP	trans	rs6738485	0.613	rs11685300	chr2:106766480	C/T	cg18225258	chr22:19776197	GNB1L	0.47	6.26	0.37	1.74e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs2871865	0.620	rs1573891	chr15:99186488	G/C	cg03437748	chr15:99193247	IGF1R	0.56	5.17	0.31	4.79e-7	Height;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15034779	chr3:49027243	P4HTM	-0.52	-6.66	-0.39	1.73e-10	Myopia;
KIRP	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg18357526	chr6:26021779	HIST1H4A	0.51	6.14	0.36	3.26e-9	Blood metabolite levels;
KIRP	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.56	7.28	0.42	4.62e-12	Vitiligo;
KIRP	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg03171003	chr2:111875934	NA	0.41	5.81	0.35	1.88e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	0.8	7.58	0.43	7.17e-13	Left atrial antero-posterior diameter;
KIRP	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg05834625	chr6:170176447	C6orf70	0.47	4.89	0.3	1.83e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.62	8.97	0.5	7.74e-17	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1832871	0.521	rs878585	chr6:158815897	C/T	cg07215822	chr6:158701037	NA	-0.54	-6.29	-0.37	1.48e-9	Height;
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg23736307	chr8:27182930	PTK2B	0.55	7.01	0.41	2.28e-11	Neuroticism;
KIRP	cis	rs3026101	0.671	rs8077472	chr17:5299359	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22022881	chr2:105853494	NA	-0.36	-5.51	-0.33	9.06e-8	Type 2 diabetes;
KIRP	cis	rs7561273	0.586	rs11900665	chr2:24298198	T/C	cg20701182	chr2:24300061	SF3B14	0.46	5.64	0.34	4.75e-8	Quantitative traits;
KIRP	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg07648498	chr16:89883185	FANCA	0.42	5.57	0.33	6.53e-8	Vitiligo;
KIRP	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg25281562	chr12:121454272	C12orf43	0.5	5.58	0.34	6.25e-8	N-glycan levels;
KIRP	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg10018233	chr7:150070692	REPIN1	0.63	7.67	0.44	4.02e-13	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11987759	chr7:65425863	GUSB	0.49	6.32	0.37	1.25e-9	Aortic root size;
KIRP	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg05220968	chr6:146057943	EPM2A	0.4	5.13	0.31	5.86e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg24365846	chr2:55844806	SMEK2	0.49	6.76	0.4	9.99e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg14993813	chr1:46806288	NSUN4	-0.6	-6.81	-0.4	7.38e-11	Menopause (age at onset);
KIRP	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.05	11.84	0.6	6.77e-26	Vitiligo;
KIRP	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	11.06	0.58	2.43e-23	Lymphocyte percentage of white cells;
KIRP	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg05914723	chr15:78953907	NA	0.45	5.41	0.33	1.51e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15900387	chr1:150738905	CTSS	0.48	6.48	0.38	5.04e-10	Interleukin-4 levels;
KIRP	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.75	-9.38	-0.51	4.58e-18	Adiposity;
KIRP	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.62	8.37	0.47	4.34e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs7572644	0.640	rs12617113	chr2:28059937	A/G	cg27432699	chr2:27873401	GPN1	0.49	5.82	0.35	1.79e-8	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.57	0.39	2.91e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg26371346	chr8:56986568	SNORD54;RPS20	0.52	4.85	0.3	2.14e-6	Height;
KIRP	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.52	7.09	0.41	1.41e-11	Gout;
KIRP	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Colorectal cancer;
KIRP	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.65	-9.12	-0.5	2.83e-17	Economic and political preferences (feminism/equality);
KIRP	cis	rs1629083	0.967	rs56315433	chr11:118114576	C/A	cg18857871	chr11:118064634	AMICA1	0.63	8.52	0.48	1.65e-15	Lung cancer;
KIRP	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg21184320	chr1:21044207	KIF17	-0.37	-5.65	-0.34	4.51e-8	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04788575	chr1:168170646	TIPRL	-0.45	-6.86	-0.4	5.64e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4302748	0.909	rs11763993	chr7:36172486	G/A	cg24442661	chr7:36192818	EEPD1	0.61	6.64	0.39	2.01e-10	Platelet count;
KIRP	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	1.09	22.74	0.82	2.06e-62	Parkinson's disease;
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.95	-0.3	1.36e-6	Life satisfaction;
KIRP	cis	rs9469913	0.740	rs2814973	chr6:34569720	C/T	cg14254433	chr6:34482411	PACSIN1	-0.46	-5.51	-0.33	9.1e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs6568686	0.679	rs7776184	chr6:111809918	G/A	cg15721981	chr6:111408429	SLC16A10	-0.67	-5.81	-0.35	1.96e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs4302748	0.862	rs57854543	chr7:36184158	C/G	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04366801	chr1:26947443	NA	0.48	6.46	0.38	5.6e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg26590003	chr5:72512115	NA	0.46	6.42	0.38	6.96e-10	Parkinson's disease;
KIRP	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.78	-6.64	-0.39	1.96e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg02725872	chr8:58115012	NA	-0.52	-5.92	-0.35	1.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	cg04338863	chr8:33670619	NA	0.47	6.22	0.37	2.17e-9	Body mass index;
KIRP	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20307385	chr11:47447363	PSMC3	-0.52	-5.47	-0.33	1.13e-7	Subjective well-being;
KIRP	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg16917193	chr12:54089295	NA	0.86	16.56	0.73	6.71e-42	Height;
KIRP	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg16141378	chr3:129829833	LOC729375	0.63	8.55	0.48	1.36e-15	Triglycerides;
KIRP	cis	rs752010	0.619	rs4393146	chr1:42118766	A/G	cg06885757	chr1:42089581	HIVEP3	0.83	13.21	0.64	1.86e-30	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg07395648	chr5:131743802	NA	-0.36	-5.04	-0.31	8.96e-7	Blood metabolite levels;
KIRP	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs6988636	0.710	rs17316158	chr8:124157607	A/C	cg15893493	chr8:124194847	FAM83A	0.87	7.12	0.41	1.22e-11	Urinary uromodulin levels;
KIRP	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.51	8.44	0.47	2.71e-15	Testicular germ cell tumor;
KIRP	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg12560992	chr17:57184187	TRIM37	0.54	5.09	0.31	7.27e-7	Cognitive test performance;
KIRP	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg06935464	chr4:38784597	TLR10	-0.51	-5.04	-0.31	8.99e-7	Breast cancer;
KIRP	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg00982548	chr2:198649783	BOLL	-0.56	-5.47	-0.33	1.13e-7	Ulcerative colitis;
KIRP	cis	rs253959	0.607	rs254150	chr5:115643715	T/C	cg23108291	chr5:115420582	COMMD10	-0.45	-5.08	-0.31	7.36e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.55	-7.3	-0.42	4.07e-12	Morning vs. evening chronotype;
KIRP	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.5	6.5	0.38	4.51e-10	HDL cholesterol levels;
KIRP	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.84	12.84	0.63	3.16e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8103278	0.507	rs2041975	chr19:46238555	T/C	cg11657440	chr19:46296263	DMWD	0.93	15.07	0.69	8.59e-37	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg07701084	chr6:150067640	NUP43	0.58	7.43	0.43	1.81e-12	Lung cancer;
KIRP	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg12940439	chr1:67600707	NA	0.34	5.27	0.32	2.92e-7	Psoriasis;
KIRP	trans	rs12690897	0.744	rs10261522	chr7:85335684	T/C	cg25658385	chr6:35265341	DEF6	-0.34	-6.1	-0.36	4.18e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27297192	chr10:134578999	INPP5A	0.65	8.01	0.45	4.68e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg18306943	chr3:40428807	ENTPD3	0.46	6.17	0.37	2.73e-9	Renal cell carcinoma;
KIRP	cis	rs8060686	0.623	rs2301814	chr16:68105171	C/G	cg26727032	chr16:67993705	SLC12A4	-0.67	-7.58	-0.44	7.09e-13	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.57	-6.31	-0.37	1.28e-9	Total cholesterol levels;
KIRP	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg02367723	chr1:46378857	MAST2	-0.42	-4.85	-0.3	2.18e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs372883	0.935	rs379592	chr21:30706470	A/G	cg24692254	chr21:30365293	RNF160	-0.39	-4.89	-0.3	1.82e-6	Pancreatic cancer;
KIRP	cis	rs11997175	0.603	rs4739381	chr8:33806892	C/A	cg04338863	chr8:33670619	NA	0.38	4.86	0.3	2.05e-6	Body mass index;
KIRP	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	15.44	0.7	4.72e-38	Alzheimer's disease;
KIRP	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg24498760	chr8:49746867	NA	0.41	4.9	0.3	1.74e-6	Blood metabolite ratios;
KIRP	cis	rs7870753	1.000	rs10820633	chr9:99214796	G/A	cg25260653	chr9:99212216	HABP4	0.54	6.02	0.36	6.21e-9	Height;
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg01283332	chr5:1856932	NA	-0.49	-6.23	-0.37	2.05e-9	Cardiovascular disease risk factors;
KIRP	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	0.47	6.06	0.36	5.05e-9	Systemic lupus erythematosus;
KIRP	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg16497661	chr14:103986332	CKB	-0.39	-5.18	-0.31	4.72e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.49	-6.58	-0.39	2.79e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.45	-9.27	-0.51	1.01e-17	Rheumatoid arthritis;
KIRP	cis	rs2625529	0.775	rs4777489	chr15:72430434	C/T	cg16672083	chr15:72433130	SENP8	0.48	5.9	0.35	1.18e-8	Red blood cell count;
KIRP	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg18753928	chr3:113234510	CCDC52	-0.53	-5.85	-0.35	1.6e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2120243	0.572	rs6441129	chr3:157125828	A/G	cg24825693	chr3:157122686	VEPH1	0.55	9.0	0.5	6.24e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs12367572	0.623	rs10880718	chr12:45362806	G/C	cg04608330	chr12:45269318	NELL2	-0.41	-5.57	-0.33	6.64e-8	Gut microbiome composition (summer);
KIRP	cis	rs4302748	0.865	rs59011914	chr7:36185290	C/T	cg24442661	chr7:36192818	EEPD1	0.59	6.64	0.39	1.96e-10	Platelet count;
KIRP	cis	rs2790457	0.518	rs2993984	chr10:28798656	A/T	cg05705492	chr10:28955341	NA	-0.48	-7.4	-0.43	2.17e-12	Multiple myeloma;
KIRP	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.23	25.07	0.85	1.04e-69	IgG glycosylation;
KIRP	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.83	-0.35	1.73e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-8.19	-0.46	1.46e-14	Coronary artery disease;
KIRP	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.57	0.43	7.28e-13	Arsenic metabolism;
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg09699651	chr6:150184138	LRP11	0.5	6.74	0.39	1.13e-10	Lung cancer;
KIRP	cis	rs10924970	0.967	rs7553200	chr1:235467940	C/T	cg26050004	chr1:235667680	B3GALNT2	0.4	4.94	0.3	1.41e-6	Asthma;
KIRP	cis	rs3741798	1.000	rs61922054	chr12:12499472	A/G	cg08615371	chr12:12503544	MANSC1	1.0	8.87	0.49	1.57e-16	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg24315340	chr6:146058215	EPM2A	-0.41	-5.02	-0.3	9.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	cg21523751	chr1:182988639	NA	0.44	6.91	0.4	4.2e-11	Hypertriglyceridemia;
KIRP	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.89	6.57	0.39	2.98e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg18200150	chr17:30822561	MYO1D	0.48	5.94	0.35	9.86e-9	Schizophrenia;
KIRP	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.37	5.0	0.3	1.08e-6	Monocyte count;
KIRP	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.58	-6.09	-0.36	4.26e-9	Obesity-related traits;
KIRP	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg23791538	chr6:167370224	RNASET2	-0.47	-5.66	-0.34	4.19e-8	Crohn's disease;
KIRP	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.12	14.92	0.69	2.74e-36	Lymphocyte percentage of white cells;
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg23594656	chr7:65796392	TPST1	-0.33	-4.86	-0.3	2.08e-6	Aortic root size;
KIRP	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg19000871	chr14:103996768	TRMT61A	-0.48	-5.21	-0.32	3.99e-7	Reticulocyte count;
KIRP	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.09	-0.36	4.4e-9	Breast cancer;
KIRP	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg24375607	chr4:120327624	NA	0.57	6.44	0.38	6.14e-10	Corneal astigmatism;
KIRP	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.82	-11.15	-0.58	1.2e-23	Tonsillectomy;
KIRP	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.59	0.39	2.68e-10	Colorectal cancer;
KIRP	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.28	-0.62	2.43e-27	Alzheimer's disease;
KIRP	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.62	9.22	0.51	1.38e-17	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.64	9.71	0.53	4.59e-19	Lung cancer;
KIRP	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs3931020	0.688	rs968358	chr1:75193989	G/T	cg10128416	chr1:75198403	TYW3;CRYZ	0.45	5.47	0.33	1.09e-7	Resistin levels;
KIRP	cis	rs4765905	0.610	rs2239020	chr12:2310452	A/G	cg10668781	chr12:2307325	CACNA1C	-0.34	-6.91	-0.4	4.22e-11	Schizophrenia;
KIRP	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg04202892	chr2:111875749	ACOXL	0.46	6.49	0.38	4.63e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.18	0.37	2.66e-9	Lung cancer;
KIRP	cis	rs876084	0.505	rs7815878	chr8:121103137	C/T	cg06265175	chr8:121136014	COL14A1	0.5	6.28	0.37	1.49e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg02733842	chr7:1102375	C7orf50	0.58	5.93	0.35	9.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg02807482	chr3:125708958	NA	-0.54	-5.22	-0.32	3.84e-7	Blood pressure (smoking interaction);
KIRP	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25517755	chr10:38738941	LOC399744	-0.38	-5.38	-0.32	1.7e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs7424096	0.515	rs17497343	chr2:37173032	T/C	cg14987922	chr2:37194071	STRN	0.46	5.33	0.32	2.24e-7	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg11965913	chr1:205819406	PM20D1	0.61	6.03	0.36	6.02e-9	Menarche (age at onset);
KIRP	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg01631408	chr1:248437212	OR2T33	-0.68	-8.66	-0.48	6.45e-16	Common traits (Other);
KIRP	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg06121193	chr1:90282411	NA	-0.48	-6.94	-0.4	3.55e-11	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs742614	0.533	rs13041078	chr20:32435497	G/T	cg06304546	chr20:32448765	NA	-0.76	-11.43	-0.59	1.52e-24	Stearic acid (18:0) levels;
KIRP	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg13444842	chr1:152974279	SPRR3	-0.36	-5.13	-0.31	5.83e-7	Inflammatory skin disease;
KIRP	cis	rs9362426	1.000	rs6930076	chr6:88088654	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.46	5.54	0.33	7.9e-8	Depressive episodes in bipolar disorder;
KIRP	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.55	-6.27	-0.37	1.6e-9	Waist circumference adjusted for body mass index;
KIRP	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.54	-8.34	-0.47	5.29e-15	Lung cancer;
KIRP	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.68	-9.67	-0.52	5.91e-19	Extrinsic epigenetic age acceleration;
KIRP	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg04733989	chr22:42467013	NAGA	-0.54	-7.35	-0.42	3.01e-12	Cognitive function;
KIRP	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.55	7.65	0.44	4.45e-13	Major depressive disorder;
KIRP	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.92	11.82	0.6	7.64e-26	Gestational age at birth (maternal effect);
KIRP	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg17252645	chr8:143867129	LY6D	-0.31	-4.87	-0.3	2e-6	Urinary tract infection frequency;
KIRP	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	1.02	19.12	0.77	1.49e-50	Heart rate;
KIRP	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2278796	0.639	rs4951153	chr1:204970844	C/A	cg17449235	chr1:204966235	NFASC	0.56	7.58	0.44	6.89e-13	Mean platelet volume;
KIRP	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.03	-0.31	9.64e-7	Coronary artery disease;
KIRP	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.77	9.93	0.53	9.38e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg15247329	chr7:2764246	NA	-0.36	-4.97	-0.3	1.27e-6	Height;
KIRP	cis	rs2904967	0.778	rs612392	chr11:65123246	T/G	cg12562828	chr11:65076843	NA	0.88	11.47	0.59	1.15e-24	Mean corpuscular volume;
KIRP	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg13180566	chr4:1052158	NA	-0.54	-5.49	-0.33	9.89e-8	Recombination rate (females);
KIRP	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.5	5.5	0.33	9.6e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.41	4.85	0.3	2.2e-6	Menopause (age at onset);
KIRP	cis	rs1832871	0.541	rs2183217	chr6:158879993	T/G	cg07215822	chr6:158701037	NA	-0.51	-5.58	-0.33	6.48e-8	Height;
KIRP	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg06365898	chr1:16533907	ARHGEF19	0.47	6.62	0.39	2.25e-10	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.9	12.16	0.61	5.92e-27	Bipolar disorder;
KIRP	cis	rs11650175	0.702	rs232089	chr17:63733729	C/T	cg18091269	chr17:63822838	CCDC46	0.32	4.91	0.3	1.66e-6	Chin dimples;
KIRP	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.86	-12.36	-0.62	1.24e-27	Glomerular filtration rate (creatinine);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08531917	chr13:46549535	ZC3H13	-0.42	-6.02	-0.36	6.18e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.46	7.1	0.41	1.35e-11	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.92	12.8	0.63	4.45e-29	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.48	5.77	0.35	2.37e-8	Blood protein levels;
KIRP	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.84	13.52	0.65	1.58e-31	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.44e-6	Life satisfaction;
KIRP	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.5	-7.46	-0.43	1.51e-12	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.45	6.05	0.36	5.42e-9	Mean corpuscular volume;
KIRP	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.64	9.63	0.52	8.08e-19	Lung cancer;
KIRP	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11987759	chr7:65425863	GUSB	0.69	9.7	0.53	4.65e-19	Calcium levels;
KIRP	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.72	7.59	0.44	6.48e-13	Lymphocyte counts;
KIRP	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg00254258	chr1:3105189	PRDM16	0.57	7.36	0.42	2.83e-12	Migraine;
KIRP	trans	rs3013648	0.777	rs11149329	chr13:85393162	A/G	cg21827674	chr12:133007847	NA	-0.73	-6.59	-0.39	2.7e-10	Huntington's disease progression;
KIRP	cis	rs4073416	0.542	rs7145500	chr14:65884212	G/A	cg03016385	chr14:66212404	NA	-0.55	-6.77	-0.4	9.51e-11	N-glycan levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23685149	chr10:99205954	ZDHHC16;EXOSC1	0.49	6.07	0.36	4.88e-9	Parkinson's disease;
KIRP	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.9	16.24	0.72	8.56e-41	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg08193333	chr13:27998609	GTF3A	0.47	5.06	0.31	8.39e-7	Schizophrenia;
KIRP	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.43	0.47	2.86e-15	Personality dimensions;
KIRP	cis	rs7258465	1.000	rs34256197	chr19:18606472	G/A	cg10790698	chr19:18539756	SSBP4	-0.35	-7.46	-0.43	1.49e-12	Breast cancer;
KIRP	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.5	6.6	0.39	2.47e-10	High light scatter reticulocyte count;
KIRP	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11987759	chr7:65425863	GUSB	0.47	6.02	0.36	6.34e-9	Aortic root size;
KIRP	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	16.77	0.73	1.33e-42	Height;
KIRP	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.52	-7.33	-0.42	3.27e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Parkinson's disease;
KIRP	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.89	-0.35	1.23e-8	Response to antipsychotic treatment;
KIRP	cis	rs12643440	0.538	rs12650732	chr4:17141641	A/T	cg22650099	chr4:17144496	NA	-0.73	-9.0	-0.5	6.51e-17	Metabolite levels (Pyroglutamine);
KIRP	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg06212747	chr3:49208901	KLHDC8B	0.61	5.96	0.35	8.9e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg20991723	chr1:152506922	NA	-0.46	-5.5	-0.33	9.59e-8	Hair morphology;
KIRP	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	5.47	0.33	1.11e-7	Height;
KIRP	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.53	-6.08	-0.36	4.52e-9	Body mass index;
KIRP	cis	rs3741151	0.686	rs60860405	chr11:73248673	A/C	cg17517138	chr11:73019481	ARHGEF17	0.6	5.31	0.32	2.46e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12550012	chr3:106959716	LOC344595;LOC100302640	0.54	6.56	0.39	3.23e-10	Smoking initiation;
KIRP	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg02570527	chr1:10970165	NA	-0.4	-4.98	-0.3	1.18e-6	Body mass index;
KIRP	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	1.0	15.85	0.71	1.76e-39	Vitamin D levels;
KIRP	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.96	17.73	0.75	6.91e-46	Colorectal adenoma (advanced);
KIRP	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg06671706	chr8:8559999	CLDN23	0.57	6.42	0.38	7.1e-10	Obesity-related traits;
KIRP	cis	rs6001982	0.667	rs12159970	chr22:40819154	G/A	cg07138101	chr22:40742427	ADSL	0.65	4.98	0.3	1.2e-6	Breast cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07742499	chr19:55851016	SUV420H2	0.48	6.51	0.38	4.25e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg05360138	chr12:110035743	NA	0.49	5.54	0.33	7.95e-8	Neuroticism;
KIRP	cis	rs17023223	0.537	rs2645300	chr1:119603067	C/A	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	2.94e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	15.39	0.7	6.8e-38	Alzheimer's disease;
KIRP	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-5.95	-0.35	9.31e-9	Neuroticism;
KIRP	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.53	5.72	0.34	3.08e-8	Recombination rate (females);
KIRP	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg24253500	chr15:84953950	NA	0.53	6.01	0.36	6.66e-9	Schizophrenia;
KIRP	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.79	8.99	0.5	6.85e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg19116668	chr7:99932089	PMS2L1	0.41	4.99	0.3	1.13e-6	Coronary artery disease;
KIRP	cis	rs2073499	0.935	rs3755832	chr3:50305234	G/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.7	4.91	0.3	1.63e-6	Schizophrenia;
KIRP	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.98	12.85	0.63	2.83e-29	Intelligence (multi-trait analysis);
KIRP	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.93	9.22	0.51	1.35e-17	Methadone dose in opioid dependence;
KIRP	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.25	-0.42	5.5e-12	Retinal vascular caliber;
KIRP	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.43	5.67	0.34	3.89e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7737355	0.773	rs1422870	chr5:130942624	G/T	cg25547332	chr5:131281432	NA	0.41	5.11	0.31	6.47e-7	Life satisfaction;
KIRP	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg03788504	chr6:150331562	NA	0.3	5.58	0.34	6.43e-8	Alopecia areata;
KIRP	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.52	-7.68	-0.44	3.83e-13	IgG glycosylation;
KIRP	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.83	-8.54	-0.48	1.4e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-9.21	-0.51	1.49e-17	Chronic sinus infection;
KIRP	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.65	-7.22	-0.42	6.58e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg21419209	chr3:44054225	NA	-0.75	-9.26	-0.51	1.08e-17	Coronary artery disease;
KIRP	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.33	0.47	5.81e-15	Lung cancer in ever smokers;
KIRP	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg05347473	chr6:146136440	FBXO30	0.57	8.14	0.46	1.94e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.41	5.26	0.32	3.18e-7	Aortic root size;
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg04369109	chr6:150039330	LATS1	-0.53	-6.57	-0.39	2.97e-10	Lung cancer;
KIRP	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.47	-8.21	-0.46	1.23e-14	Type 2 diabetes;
KIRP	cis	rs9896052	0.649	rs6501801	chr17:73447030	A/G	cg25649188	chr17:73499917	CASKIN2	-0.47	-5.85	-0.35	1.52e-8	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs112591243	0.685	rs2839338	chr21:47987984	C/T	cg12379764	chr21:47803548	PCNT	0.67	5.09	0.31	7.04e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs4936894	0.500	rs10790668	chr11:124179502	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-6.23	-0.37	1.99e-9	Aging (time to death);
KIRP	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.71	8.16	0.46	1.74e-14	Height;
KIRP	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.6	0.34	5.71e-8	Personality dimensions;
KIRP	cis	rs10875746	0.768	rs4760676	chr12:48421663	G/A	cg26205652	chr12:48591994	NA	0.78	10.17	0.54	1.7e-20	Longevity (90 years and older);
KIRP	cis	rs854765	0.663	rs9906673	chr17:17746197	C/T	cg04398451	chr17:18023971	MYO15A	0.66	8.87	0.49	1.52e-16	Total body bone mineral density;
KIRP	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg14593290	chr7:50529359	DDC	0.67	8.3	0.47	6.94e-15	Malaria;
KIRP	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.41	7.98	0.45	5.44e-14	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25777557	chr3:159706538	IL12A	0.47	6.19	0.37	2.44e-9	Parkinson's disease;
KIRP	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg02475777	chr4:1388615	CRIPAK	0.4	5.37	0.32	1.85e-7	Longevity;
KIRP	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg06740227	chr12:86229804	RASSF9	0.47	5.98	0.36	7.66e-9	Major depressive disorder;
KIRP	cis	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg00806126	chr19:22604979	ZNF98	-0.59	-6.34	-0.37	1.08e-9	Pain;
KIRP	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	9.94	0.54	8.81e-20	Total body bone mineral density;
KIRP	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.92	15.38	0.7	7.33e-38	Ulcerative colitis;
KIRP	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.79	-8.91	-0.49	1.21e-16	Gut microbiome composition (summer);
KIRP	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg13147721	chr7:65941812	NA	-0.9	-6.47	-0.38	5.32e-10	Diabetic kidney disease;
KIRP	cis	rs4332428	0.881	rs34702521	chr10:4981775	C/A	cg19648686	chr10:5044992	AKR1C2	-0.9	-7.85	-0.45	1.27e-13	Height;
KIRP	cis	rs7017914	0.811	rs4272413	chr8:71636187	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.06	-0.31	8.18e-7	Bone mineral density;
KIRP	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06481639	chr22:41940642	POLR3H	0.5	5.95	0.35	9.24e-9	Vitiligo;
KIRP	cis	rs16958440	0.737	rs16958699	chr18:44654846	T/C	cg17192377	chr18:44677553	HDHD2	0.73	6.65	0.39	1.85e-10	Sitting height ratio;
KIRP	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.75	10.13	0.54	2.18e-20	Resting heart rate;
KIRP	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-5.61	-0.34	5.47e-8	Testicular germ cell tumor;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg00996875	chr1:9825174	CLSTN1	0.42	6.04	0.36	5.75e-9	C-reactive protein;
KIRP	cis	rs7640424	0.635	rs162069	chr3:107839341	A/G	cg09227934	chr3:107805635	CD47	0.29	5.09	0.31	6.97e-7	Body mass index;
KIRP	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-8.01	-0.45	4.74e-14	Morning vs. evening chronotype;
KIRP	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg16898833	chr6:26189333	HIST1H4D	0.68	4.9	0.3	1.73e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-6.86	-0.4	5.66e-11	Hemoglobin concentration;
KIRP	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	8.06	0.46	3.29e-14	Platelet count;
KIRP	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.58	7.77	0.44	2.13e-13	Coronary artery disease;
KIRP	cis	rs62413470	1.000	rs12203653	chr6:55964693	G/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg03644281	chr6:41068752	NFYA;LOC221442	-0.45	-5.27	-0.32	3e-7	Alzheimer's disease (late onset);
KIRP	cis	rs708547	0.874	rs781551	chr4:57718406	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.73	-8.07	-0.46	3.05e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg07052231	chr12:7363540	PEX5	0.38	5.08	0.31	7.34e-7	IgG glycosylation;
KIRP	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	4.9	0.3	1.76e-6	Schizophrenia;
KIRP	cis	rs6703335	0.632	rs10927025	chr1:243639218	A/G	cg25706552	chr1:244017396	NA	0.38	5.77	0.35	2.41e-8	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
KIRP	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg11945507	chr8:142233382	SLC45A4	-0.43	-5.59	-0.34	5.91e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7113874	1.000	rs12575252	chr11:8694073	C/G	cg08015107	chr11:8618950	NA	-0.35	-4.9	-0.3	1.74e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg02640540	chr1:67518911	SLC35D1	0.4	4.98	0.3	1.21e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-7.65	-0.44	4.56e-13	Body mass index;
KIRP	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.72	-9.71	-0.53	4.38e-19	Personality dimensions;
KIRP	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg17507749	chr15:85114479	UBE2QP1	0.8	8.39	0.47	3.74e-15	Schizophrenia;
KIRP	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.4	-5.25	-0.32	3.29e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg02733842	chr7:1102375	C7orf50	0.56	5.75	0.34	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg09183102	chr16:56691574	MT1F	0.46	6.11	0.36	3.92e-9	Neuroticism;
KIRP	cis	rs7105934	1.000	rs12284127	chr11:69243067	C/A	cg24478926	chr11:69237550	NA	-0.59	-5.66	-0.34	4.29e-8	Renal cell carcinoma;
KIRP	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.23	-0.37	2.05e-9	Breast cancer;
KIRP	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.68	-10.64	-0.56	5.42e-22	Educational attainment;
KIRP	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg23594656	chr7:65796392	TPST1	0.43	6.02	0.36	6.47e-9	Aortic root size;
KIRP	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg08133631	chr1:26527909	CATSPER4	-0.46	-5.15	-0.31	5.36e-7	Obesity-related traits;
KIRP	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.28	-0.32	2.84e-7	Triglycerides;
KIRP	cis	rs12946454	0.521	rs66827053	chr17:43250653	A/G	cg10701640	chr17:43249399	NA	0.52	12.38	0.62	1.11e-27	Systolic blood pressure;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05098125	chr11:31443409	DNAJC24	-0.4	-6.12	-0.36	3.61e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg09137382	chr11:130731461	NA	0.55	8.14	0.46	1.98e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11834862	0.765	rs10902511	chr12:132689436	C/T	cg19601865	chr12:132687172	GALNT9	-0.44	-4.93	-0.3	1.51e-6	Anti-saccade response;
KIRP	cis	rs6732160	0.631	rs7557285	chr2:73442812	G/A	cg01422370	chr2:73384389	NA	0.4	5.28	0.32	2.84e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.65	-5.48	-0.33	1.03e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.81	-12.41	-0.62	8.67e-28	Breast cancer;
KIRP	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.72	9.23	0.51	1.32e-17	Bladder cancer;
KIRP	cis	rs28595532	0.748	rs115651241	chr4:119363509	C/T	cg21605333	chr4:119757512	SEC24D	1.13	8.43	0.47	3.01e-15	Cannabis dependence symptom count;
KIRP	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg12131826	chr15:77904385	NA	0.41	5.39	0.32	1.66e-7	Type 2 diabetes;
KIRP	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.69	-7.66	-0.44	4.24e-13	Menarche (age at onset);
KIRP	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-5.63	-0.34	4.97e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg16574807	chr4:6945745	TBC1D14	0.8	5.09	0.31	7.13e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	cis	rs870825	0.872	rs12506750	chr4:185571123	C/T	cg04058563	chr4:185651563	MLF1IP	1.06	10.0	0.54	5.43e-20	Blood protein levels;
KIRP	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	1.06	23.05	0.83	2.1e-63	Parkinson's disease;
KIRP	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.64	7.12	0.41	1.2e-11	Smoking initiation;
KIRP	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.46	5.89	0.35	1.25e-8	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs7221595	0.825	rs8069643	chr17:3971237	C/T	cg11204139	chr17:3907470	NA	0.58	6.16	0.37	2.99e-9	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.4	-4.85	-0.3	2.2e-6	Resting heart rate;
KIRP	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg14338887	chr6:42928500	GNMT	0.46	6.89	0.4	4.73e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs4644046	1.000	rs4644046	chr6:51385009	A/C	cg14335767	chr8:124286570	ZHX1	0.46	6.1	0.36	4.05e-9	Coronary artery disease;
KIRP	cis	rs963731	0.649	rs422854	chr2:39185048	C/T	cg04010122	chr2:39346883	SOS1	-0.78	-5.46	-0.33	1.16e-7	Corticobasal degeneration;
KIRP	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg04731861	chr2:219085781	ARPC2	-0.2	-5.08	-0.31	7.3e-7	Colorectal cancer;
KIRP	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.33	5.86	0.35	1.5e-8	Migraine;
KIRP	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg03929089	chr4:120376271	NA	-0.58	-6.83	-0.4	6.71e-11	HDL cholesterol;
KIRP	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.5	-5.75	-0.34	2.67e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.48	-6.16	-0.37	2.88e-9	IgG glycosylation;
KIRP	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22468733	chr15:66790247	SNAPC5	0.57	6.56	0.39	3.2e-10	Lung cancer in ever smokers;
KIRP	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.54	-4.85	-0.3	2.17e-6	Other erythrocyte phenotypes;
KIRP	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-8.0	-0.45	5.01e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.59	7.21	0.42	6.69e-12	Corneal astigmatism;
KIRP	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg04166393	chr7:2884313	GNA12	0.67	7.88	0.45	1.07e-13	Height;
KIRP	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg05347473	chr6:146136440	FBXO30	-0.57	-8.08	-0.46	2.93e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.74	8.99	0.5	6.66e-17	Mammographic density (dense area);
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg16405210	chr4:1374714	KIAA1530	-0.67	-9.2	-0.51	1.61e-17	Longevity;
KIRP	cis	rs10929159	0.928	rs13025044	chr2:236916549	G/A	cg20128773	chr2:236923534	AGAP1	0.3	5.15	0.31	5.45e-7	Parkinson's disease;
KIRP	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg16524733	chr11:117070046	TAGLN	0.39	4.96	0.3	1.3e-6	Blood protein levels;
KIRP	cis	rs253959	0.921	rs13172482	chr5:115451836	C/A	cg23108291	chr5:115420582	COMMD10	0.41	4.95	0.3	1.37e-6	Bipolar disorder and schizophrenia;
KIRP	trans	rs12043259	0.730	rs750087	chr1:204810161	G/A	cg11485465	chr5:54518469	NA	0.35	6.33	0.37	1.13e-9	Addiction;
KIRP	trans	rs1422110	0.616	rs6452689	chr5:85445059	A/T	cg01787110	chr1:109008453	NBPF6	0.76	9.59	0.52	1.02e-18	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.98	-16.63	-0.73	4.05e-42	Multiple myeloma;
KIRP	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg24642844	chr7:1081250	C7orf50	-0.37	-4.95	-0.3	1.39e-6	Longevity;Endometriosis;
KIRP	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.88	-0.4	5.04e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13939156	chr17:80058883	NA	-0.5	-7.52	-0.43	1.04e-12	Life satisfaction;
KIRP	cis	rs2880765	0.527	rs35184622	chr15:86073035	A/G	cg17133734	chr15:86042851	AKAP13	-0.58	-7.13	-0.41	1.11e-11	Coronary artery disease;
KIRP	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.9	10.3	0.55	6.53e-21	Corneal astigmatism;
KIRP	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.72	8.66	0.48	6.42e-16	Alcohol dependence;
KIRP	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.92	15.35	0.7	9.3e-38	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg21774377	chr6:34760070	UHRF1BP1	0.49	6.12	0.36	3.63e-9	Asthma;
KIRP	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	1.09	11.74	0.6	1.5e-25	Psoriasis;
KIRP	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.55	6.77	0.4	9.19e-11	Total body bone mineral density;
KIRP	cis	rs228437	0.586	rs7763955	chr6:134939628	C/A	cg24504307	chr6:134963096	NA	0.29	4.89	0.3	1.84e-6	Melanoma;
KIRP	cis	rs11638352	1.000	rs6493094	chr15:44310790	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	-0.72	-5.55	-0.33	7.4e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs2732480	1.000	rs2732480	chr12:48736303	A/C	cg21466736	chr12:48725269	NA	0.37	5.17	0.31	4.94e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.56	-0.33	7.1e-8	IgG glycosylation;
KIRP	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.76	8.77	0.49	3.02e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs4853525	0.522	rs62179715	chr2:191570072	C/T	cg11845111	chr2:191398756	TMEM194B	-0.46	-5.01	-0.3	1.03e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg00241281	chr14:105779794	PACS2	0.34	5.05	0.31	8.73e-7	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.61	0.39	2.35e-10	Colorectal cancer;
KIRP	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.27	0.32	2.98e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs9290877	0.704	rs9846214	chr3:188412858	T/C	cg17392043	chr3:188495102	LPP	-0.4	-4.98	-0.3	1.18e-6	IgE levels;
KIRP	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg06740227	chr12:86229804	RASSF9	-0.48	-5.88	-0.35	1.34e-8	Major depressive disorder;
KIRP	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	1.01	15.0	0.69	1.51e-36	Alcohol dependence;
KIRP	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.63	-7.57	-0.43	7.67e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg03653399	chr8:142233436	SLC45A4	-0.95	-14.87	-0.69	4.21e-36	Immature fraction of reticulocytes;
KIRP	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.56	7.13	0.41	1.1e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11638352	0.661	rs2615286	chr15:44417068	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-4.92	-0.3	1.59e-6	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs12995491	0.731	rs12992162	chr2:88508773	G/C	cg04511125	chr2:88470314	THNSL2	-0.47	-5.86	-0.35	1.48e-8	Response to metformin (IC50);
KIRP	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.33	-0.42	3.21e-12	Type 2 diabetes;
KIRP	cis	rs11209002	0.567	rs983110	chr1:67539215	A/T	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg08975724	chr8:8085496	FLJ10661	0.7	9.33	0.51	6.29e-18	Mood instability;
KIRP	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg05370193	chr1:21551575	ECE1	0.44	6.03	0.36	5.9e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18252515	chr7:66147081	NA	-0.45	-5.47	-0.33	1.09e-7	Aortic root size;
KIRP	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.58	0.59	5.02e-25	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18250916	chr5:612533	CEP72	0.46	6.1	0.36	4.03e-9	Parkinson's disease;
KIRP	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.7	7.04	0.41	1.87e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	8.98	0.5	7.38e-17	Migraine;Coronary artery disease;
KIRP	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg23803603	chr1:2058230	PRKCZ	0.38	5.67	0.34	3.96e-8	Height;
KIRP	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs7474896	0.895	rs2749559	chr10:38211422	G/A	cg00409905	chr10:38381863	ZNF37A	0.63	5.29	0.32	2.65e-7	Obesity (extreme);
KIRP	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.74	12.91	0.64	1.89e-29	Weight;
KIRP	cis	rs1829883	0.600	rs2461966	chr5:98733594	A/G	cg08333243	chr5:99726346	NA	0.37	4.86	0.3	2.13e-6	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs9308731	0.505	rs10169613	chr2:111934977	C/T	cg04780086	chr2:111875790	ACOXL	0.41	5.69	0.34	3.57e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs883565	0.740	rs6599003	chr3:39093326	A/G	cg01426195	chr3:39028469	NA	0.66	10.96	0.57	5.11e-23	Handedness;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg20859525	chr6:80714300	TTK	0.59	7.2	0.42	7.36e-12	Smoking initiation;
KIRP	cis	rs6442310	0.534	rs2938392	chr3:12434608	G/A	cg22839075	chr3:12045461	SYN2	0.38	5.49	0.33	9.96e-8	Hematocrit;
KIRP	cis	rs4523957	0.715	rs6503321	chr17:2096580	G/A	cg16513277	chr17:2031491	SMG6	-0.62	-9.01	-0.5	5.8e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9986765	0.609	rs73452600	chr7:142828104	C/A	cg11323483	chr7:142828068	PIP	-0.66	-5.72	-0.34	3.05e-8	Cancer;Dermatomyositis;
KIRP	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg24253500	chr15:84953950	NA	0.62	6.61	0.39	2.35e-10	Schizophrenia;
KIRP	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg25019033	chr10:957182	NA	-0.61	-6.5	-0.38	4.33e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg00405596	chr8:11794950	NA	0.42	5.35	0.32	2e-7	Retinal vascular caliber;
KIRP	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg10047753	chr17:41438598	NA	1.07	17.39	0.74	9.86e-45	Menopause (age at onset);
KIRP	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.81	-11.71	-0.6	1.81e-25	Dental caries;
KIRP	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg11479156	chr11:70672388	SHANK2	-0.5	-4.88	-0.3	1.88e-6	Renal transplant outcome;
KIRP	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg16558253	chr16:72132732	DHX38	-0.37	-4.86	-0.3	2.07e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Dermatomyositis;
KIRP	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg00405596	chr8:11794950	NA	-0.45	-5.58	-0.34	6.19e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg02836325	chr17:76403955	PGS1	-0.37	-5.96	-0.36	8.48e-9	HDL cholesterol levels;
KIRP	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-8.48	-0.48	2.16e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9488822	0.676	rs6918059	chr6:116349041	C/T	cg15226275	chr6:116381976	FRK	0.23	6.19	0.37	2.51e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6684428	1.000	rs55769330	chr1:56357825	G/C	cg11651538	chr1:56320950	NA	-0.88	-10.33	-0.55	5.28e-21	Airflow obstruction;
KIRP	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg07451762	chr16:28383216	NA	0.41	5.36	0.32	1.93e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.49	-7.1	-0.41	1.36e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg23803603	chr1:2058230	PRKCZ	-0.41	-5.97	-0.36	8.26e-9	Height;
KIRP	cis	rs10988449	1.000	rs56326212	chr9:132371921	G/A	cg18327994	chr9:132372705	NA	-0.58	-5.36	-0.32	1.94e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11490986	chr7:143599184	FAM115A	0.56	7.87	0.45	1.1e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg07862535	chr7:139043722	LUC7L2	-0.46	-5.39	-0.32	1.66e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.63	-7.34	-0.42	3.06e-12	Dental caries;
KIRP	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	ch.10.1909607F	chr10:91522494	KIF20B	-0.52	-6.36	-0.38	1e-9	QT interval;
KIRP	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg04374321	chr14:90722782	PSMC1	0.5	5.51	0.33	9.23e-8	Gut microbiota (bacterial taxa);
KIRP	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.71	9.34	0.51	5.87e-18	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.81	-8.33	-0.47	5.59e-15	Schizophrenia;
KIRP	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg12405258	chr13:114927641	NA	0.43	6.07	0.36	4.91e-9	Schizophrenia;
KIRP	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg04306507	chr14:55594613	LGALS3	0.53	8.29	0.47	7.59e-15	Protein biomarker;
KIRP	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.62	-5.89	-0.35	1.29e-8	Breast cancer;
KIRP	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.88	12.81	0.63	4.08e-29	Mean platelet volume;
KIRP	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.65	7.56	0.43	8.16e-13	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.19	15.25	0.7	2.09e-37	Platelet count;
KIRP	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg15358701	chr1:161410459	NA	-0.59	-5.66	-0.34	4.11e-8	Rheumatoid arthritis;
KIRP	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg09788416	chr12:39539408	NA	0.39	5.26	0.32	3.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs7129556	0.954	rs11237220	chr11:77268460	G/A	cg12586386	chr11:77299805	AQP11	0.47	5.76	0.34	2.54e-8	Weight loss (gastric bypass surgery);
KIRP	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg13010199	chr12:38710504	ALG10B	-0.48	-6.16	-0.37	2.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs7215564	0.908	rs4889883	chr17:78664374	C/A	cg06153925	chr17:78755379	RPTOR	0.32	5.24	0.32	3.44e-7	Myopia (pathological);
KIRP	cis	rs17209837	1.000	rs58083477	chr7:87117706	T/C	cg00919237	chr7:87102261	ABCB4	-0.66	-6.64	-0.39	1.99e-10	Gallbladder cancer;
KIRP	cis	rs6681460	0.634	rs994396	chr1:67012236	G/A	cg13052034	chr1:66999238	SGIP1	0.43	5.8	0.35	2.02e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.59	-5.42	-0.33	1.45e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10267417	0.603	rs4994101	chr7:19939660	C/G	cg05791153	chr7:19748676	TWISTNB	0.51	5.05	0.31	8.64e-7	Night sleep phenotypes;
KIRP	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.49	-6.24	-0.37	1.86e-9	Waist-hip ratio;
KIRP	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg02297831	chr4:17616191	MED28	0.59	7.54	0.43	8.98e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.65	0.48	6.58e-16	Motion sickness;
KIRP	cis	rs830383	0.538	rs13354366	chr5:165422195	A/G	cg13976338	chr5:165423657	NA	-0.52	-6.13	-0.36	3.54e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	12.79	0.63	4.52e-29	Platelet count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08175029	chr3:23848512	UBE2E1	0.46	6.27	0.37	1.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7246865	0.813	rs13346655	chr19:17176757	C/G	cg18440316	chr19:18077727	KCNN1	-0.38	-5.44	-0.33	1.26e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs6681460	0.932	rs492109	chr1:67187133	C/A	cg02459107	chr1:67143332	SGIP1	-0.38	-5.58	-0.33	6.48e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	10.37	0.55	4.01e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg08076091	chr2:203926405	NBEAL1	0.91	9.46	0.52	2.52e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg06742321	chr12:123595122	PITPNM2	0.41	5.02	0.3	9.97e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg12751644	chr20:60527061	NA	-0.4	-4.86	-0.3	2.1e-6	Body mass index;
KIRP	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg20896738	chr21:46707857	POFUT2;LOC642852	0.52	5.72	0.34	3.12e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7640424	0.649	rs13094403	chr3:107930210	G/T	cg09227934	chr3:107805635	CD47	-0.36	-6.11	-0.36	3.85e-9	Body mass index;
KIRP	cis	rs965513	1.000	rs7030241	chr9:100550375	T/A	cg13688889	chr9:100608707	NA	-0.61	-7.73	-0.44	2.73e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs6690583	0.623	rs111687161	chr1:85443533	A/G	cg22153463	chr1:85462885	MCOLN2	0.6	5.03	0.31	9.66e-7	Serum sulfate level;
KIRP	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.47	-6.02	-0.36	6.18e-9	Obesity-related traits;
KIRP	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg03045169	chr17:62503007	CCDC45;DDX5	0.69	6.31	0.37	1.26e-9	Lung function (FEV1);
KIRP	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg08975724	chr8:8085496	FLJ10661	0.55	6.24	0.37	1.92e-9	Neuroticism;
KIRP	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.51	-7.14	-0.41	1.07e-11	Pubertal anthropometrics;
KIRP	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.61	8.04	0.46	3.77e-14	Systemic lupus erythematosus;
KIRP	cis	rs7116495	1.000	rs2298457	chr11:71734211	T/C	cg26138937	chr11:71823887	C11orf51	-0.7	-5.65	-0.34	4.46e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs17079247	0.841	rs9575848	chr13:85810437	G/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg17366294	chr4:99064904	C4orf37	-0.37	-5.13	-0.31	5.85e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.54	6.24	0.37	1.9e-9	Aortic root size;
KIRP	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.93	-15.79	-0.71	2.82e-39	Mortality in heart failure;
KIRP	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.42	-4.84	-0.3	2.25e-6	Blood metabolite levels;
KIRP	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.78	-11.6	-0.59	4.09e-25	Obesity-related traits;
KIRP	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-7.73	-0.44	2.76e-13	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg12720444	chr1:235825993	LYST	-0.4	-6.13	-0.36	3.55e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.8	11.13	0.58	1.42e-23	Aortic root size;
KIRP	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg18944383	chr4:111397179	ENPEP	0.54	9.58	0.52	1.1e-18	Height;
KIRP	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.83	8.93	0.49	1.05e-16	Alzheimer's disease;
KIRP	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.41	-0.38	7.53e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs72781680	0.611	rs2303287	chr2:24302246	A/G	cg06627628	chr2:24431161	ITSN2	0.57	4.99	0.3	1.15e-6	Lymphocyte counts;
KIRP	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.65	-6.95	-0.41	3.3e-11	DNA methylation (variation);
KIRP	cis	rs4356932	0.656	rs13126007	chr4:76862255	G/A	cg00809888	chr4:76862425	NAAA	-0.49	-6.87	-0.4	5.21e-11	Blood protein levels;
KIRP	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg21395723	chr22:39101663	GTPBP1	0.44	5.39	0.32	1.66e-7	Menopause (age at onset);
KIRP	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg05973401	chr12:123451056	ABCB9	0.57	6.58	0.39	2.74e-10	Neutrophil percentage of white cells;
KIRP	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg26874229	chr2:105853672	NA	-0.39	-5.39	-0.32	1.65e-7	Type 2 diabetes;
KIRP	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg13409248	chr3:40428643	ENTPD3	0.41	5.33	0.32	2.22e-7	Renal cell carcinoma;
KIRP	cis	rs3857747	0.537	rs10245007	chr7:40464894	T/C	cg00420559	chr7:40367873	C7orf10	-0.37	-5.15	-0.31	5.38e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg00585698	chr12:123750864	CDK2AP1	-0.51	-6.41	-0.38	7.33e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	0.8	7.15	0.41	1.01e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-12.31	-0.62	1.93e-27	Chronic sinus infection;
KIRP	cis	rs9398803	0.698	rs853979	chr6:127057941	A/T	cg19875578	chr6:126661172	C6orf173	-0.37	-4.86	-0.3	2.05e-6	Male-pattern baldness;
KIRP	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.56	-7.18	-0.42	8.14e-12	Glomerular filtration rate;
KIRP	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg13628971	chr7:2884303	GNA12	0.6	7.02	0.41	2.16e-11	Height;
KIRP	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-15.9	-0.71	1.25e-39	Hemostatic factors and hematological phenotypes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00260888	chr20:30865478	KIF3B	0.51	6.73	0.39	1.17e-10	Parkinson's disease;
KIRP	cis	rs981844	1.000	rs2606327	chr4:154653629	C/T	cg14289246	chr4:154710475	SFRP2	0.65	7.26	0.42	5.13e-12	Response to statins (LDL cholesterol change);
KIRP	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg27490568	chr2:178487706	NA	0.5	6.57	0.39	2.92e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10849893	0.538	rs7961855	chr12:121829943	C/T	cg01154721	chr12:121881891	KDM2B	-0.41	-5.5	-0.33	9.34e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.34	-4.85	-0.3	2.18e-6	Congenital heart disease (maternal effect);
KIRP	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg08313168	chr12:7315531	NA	0.69	6.35	0.38	1.04e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg23995753	chr2:160760732	LY75	-0.42	-5.62	-0.34	5.04e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg23950597	chr19:37808831	NA	-0.73	-6.44	-0.38	6.25e-10	Coronary artery calcification;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs6563943	1.000	rs9934609	chr16:83638578	C/T	cg01935413	chr16:83636749	CDH13	0.4	5.59	0.34	5.98e-8	Height;
KIRP	cis	rs654128	0.590	rs339346	chr6:117218693	T/G	cg12892004	chr6:117198278	RFX6	-0.41	-5.24	-0.32	3.46e-7	Telomere length;
KIRP	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg21775007	chr8:11205619	TDH	0.46	5.76	0.34	2.47e-8	Systolic blood pressure;
KIRP	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.59	-7.37	-0.43	2.64e-12	Body mass index;
KIRP	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg22437258	chr11:111473054	SIK2	-0.56	-6.54	-0.38	3.52e-10	Primary sclerosing cholangitis;
KIRP	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs2591576	0.576	rs1119846	chr5:165362895	G/T	cg13976338	chr5:165423657	NA	-0.62	-8.22	-0.46	1.17e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg00800038	chr16:89945340	TCF25	0.63	6.35	0.38	1.02e-9	Skin colour saturation;
KIRP	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.83	-9.91	-0.53	1.04e-19	Body mass index;
KIRP	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.63	5.09	0.31	7.06e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.15	8.95	0.5	8.95e-17	Mitochondrial DNA levels;
KIRP	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.88	-12.16	-0.61	6.02e-27	Obesity-related traits;
KIRP	cis	rs7523050	0.643	rs67091034	chr1:109402567	C/G	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05099464	chr11:120302922	ARHGEF12	0.5	6.91	0.4	4.06e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg14689365	chr7:158441557	NCAPG2	0.4	5.08	0.31	7.46e-7	Height;
KIRP	trans	rs13170463	0.579	rs13183355	chr5:8039089	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg18806716	chr10:30721971	MAP3K8	-0.32	-5.21	-0.31	4.09e-7	Inflammatory bowel disease;
KIRP	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg11584989	chr19:19387371	SF4	-0.4	-5.16	-0.31	5.21e-7	Tonsillectomy;
KIRP	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg21919602	chr1:242011447	EXO1	-0.46	-5.94	-0.35	9.77e-9	Menopause (age at onset);
KIRP	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-7.07	-0.41	1.57e-11	Alzheimer's disease (late onset);
KIRP	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg23387468	chr7:139079360	LUC7L2	-0.29	-5.11	-0.31	6.49e-7	Diisocyanate-induced asthma;
KIRP	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.28	-22.8	-0.82	1.3e-62	Breast cancer;
KIRP	cis	rs829661	0.793	rs2602785	chr2:30871179	A/T	cg10949345	chr2:30726833	LCLAT1	1.09	13.34	0.65	6.7e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Body mass index;
KIRP	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg01629716	chr15:45996671	NA	0.37	6.6	0.39	2.48e-10	Waist circumference;Weight;
KIRP	cis	rs6960043	0.575	rs10224343	chr7:15032808	C/A	cg19272540	chr7:15055459	NA	-0.21	-5.55	-0.33	7.53e-8	Type 2 diabetes;
KIRP	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg18753928	chr3:113234510	CCDC52	-0.47	-6.01	-0.36	6.67e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg22467129	chr15:76604101	ETFA	-0.44	-6.13	-0.36	3.53e-9	Blood metabolite levels;
KIRP	cis	rs860295	0.702	rs11264397	chr1:155611485	G/C	cg02153340	chr1:155202674	NA	-0.49	-6.66	-0.39	1.76e-10	Body mass index;
KIRP	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg11859384	chr17:80120422	CCDC57	0.44	5.53	0.33	8.19e-8	Life satisfaction;
KIRP	cis	rs7937612	1.000	rs6589811	chr11:120235703	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.07	-0.41	1.61e-11	Intraocular pressure;
KIRP	trans	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg06521331	chr12:34319734	NA	-0.59	-7.1	-0.41	1.35e-11	Bladder cancer;
KIRP	cis	rs16828019	0.704	rs4996176	chr1:41488168	G/T	cg18742814	chr1:41828276	NA	0.62	5.52	0.33	8.65e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs684232	0.800	rs371318	chr17:555816	A/G	cg15660573	chr17:549704	VPS53	-0.51	-6.44	-0.38	6.21e-10	Prostate cancer;
KIRP	cis	rs6723226	0.557	rs62136260	chr2:32575447	T/C	cg02381751	chr2:32503542	YIPF4	-0.5	-5.84	-0.35	1.69e-8	Intelligence (multi-trait analysis);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14633965	chr11:46784427	CKAP5;SNORD67	0.47	6.81	0.4	7.43e-11	Survival in pancreatic cancer;
KIRP	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.01	-11.87	-0.6	5.26e-26	Colorectal cancer;
KIRP	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg08501292	chr6:25962987	TRIM38	1.03	8.19	0.46	1.42e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	6.95e-7	Life satisfaction;
KIRP	cis	rs7116495	1.000	rs73539532	chr11:71815684	C/A	cg18441811	chr11:71824068	C11orf51	0.6	4.87	0.3	2.01e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs4601821	0.895	rs2282511	chr11:113244177	A/C	cg14159747	chr11:113255604	NA	0.36	5.18	0.31	4.72e-7	Alcoholic chronic pancreatitis;
KIRP	cis	rs212524	1.000	rs212525	chr1:21584585	A/G	cg08890418	chr1:21044141	KIF17	0.37	5.02	0.31	9.74e-7	Height;
KIRP	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.12	-9.77	-0.53	2.86e-19	Body mass index;
KIRP	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	6.98	0.41	2.66e-11	Tonsillectomy;
KIRP	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg03959625	chr15:84868606	LOC388152	0.44	5.16	0.31	5.16e-7	Schizophrenia;
KIRP	cis	rs6835098	0.500	rs13112928	chr4:174158132	A/G	cg08422745	chr4:174089978	GALNT7	0.56	7.48	0.43	1.34e-12	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs1359582	0.736	rs7913742	chr10:90376864	C/A	cg15661332	chr10:90342814	RNLS	0.58	6.24	0.37	1.95e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg10326726	chr10:51549505	MSMB	0.59	8.66	0.48	6.26e-16	Prostate-specific antigen levels;
KIRP	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg02002194	chr4:3960332	NA	-0.45	-6.65	-0.39	1.84e-10	Mood instability;
KIRP	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	ch.11.340609R	chr11:12831013	TEAD1	-0.43	-5.32	-0.32	2.33e-7	Educational attainment (years of education);
KIRP	cis	rs72653721	0.617	rs60043068	chr6:11035426	A/C	cg13562911	chr6:11044106	ELOVL2	0.52	5.64	0.34	4.76e-8	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
KIRP	cis	rs7615316	1.000	rs6440099	chr3:142356226	C/T	cg20824294	chr3:142316082	PLS1	0.24	5.32	0.32	2.33e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1832871	0.965	rs2105333	chr6:158755437	T/G	cg07215822	chr6:158701037	NA	0.52	6.74	0.39	1.11e-10	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17495092	chr1:39456765	AKIRIN1	0.49	6.24	0.37	1.87e-9	Parkinson's disease;
KIRP	cis	rs7523050	0.643	rs36047249	chr1:109401499	T/C	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02788597	chr15:44828908	EIF3J	0.47	6.02	0.36	6.14e-9	Parkinson's disease;
KIRP	cis	rs7011507	0.891	rs74367488	chr8:49158670	G/C	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.45	9.91	0.53	1.04e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg00689492	chr4:1303491	MAEA	0.31	5.64	0.34	4.55e-8	Longevity;
KIRP	cis	rs11910985	0.546	rs9977877	chr21:48080493	G/A	cg23283320	chr21:48055893	PRMT2	1.15	8.66	0.48	6.52e-16	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs4776059	0.550	rs8032394	chr15:52868032	G/A	cg22715398	chr15:52968154	KIAA1370	-0.49	-5.18	-0.31	4.59e-7	Schizophrenia;
KIRP	cis	rs6973256	0.862	rs11762935	chr7:133327950	G/T	cg10665199	chr7:133106180	EXOC4	-0.51	-6.49	-0.38	4.7e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.61	5.5	0.33	9.67e-8	Alzheimer's disease;
KIRP	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.56	-7.09	-0.41	1.42e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.74	11.68	0.6	2.29e-25	Resting heart rate;
KIRP	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg25418670	chr11:30344373	C11orf46	-0.59	-4.95	-0.3	1.39e-6	Morning vs. evening chronotype;
KIRP	cis	rs10267417	0.673	rs7800568	chr7:19953452	C/T	cg05791153	chr7:19748676	TWISTNB	-0.45	-4.86	-0.3	2.06e-6	Night sleep phenotypes;
KIRP	cis	rs9831754	0.756	rs12714468	chr3:78445878	A/T	cg06138941	chr3:78371609	NA	-0.82	-11.19	-0.58	9.24e-24	Calcium levels;
KIRP	cis	rs1978968	0.913	rs12158823	chr22:18439420	G/A	cg02610425	chr22:18483192	MICAL3	0.36	5.0	0.3	1.1e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg04369109	chr6:150039330	LATS1	-0.47	-4.89	-0.3	1.85e-6	Lung cancer;
KIRP	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg07274523	chr3:49395745	GPX1	0.71	8.75	0.49	3.41e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.61	-8.18	-0.46	1.54e-14	Rheumatoid arthritis;
KIRP	trans	rs4650994	0.816	rs2811303	chr1:178595646	G/T	cg05059571	chr16:84539110	KIAA1609	0.55	7.24	0.42	5.64e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs8060686	0.920	rs73594556	chr16:67925435	G/A	cg09117114	chr16:67998030	SLC12A4	-0.49	-5.17	-0.31	4.87e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	1.0	11.57	0.59	5.15e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs4663866	1.000	rs4663867	chr2:239159964	G/C	cg17283117	chr2:239148619	HES6	0.7	5.04	0.31	8.88e-7	Irritable bowel syndrome;
KIRP	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.37	-4.85	-0.3	2.22e-6	Monocyte percentage of white cells;
KIRP	cis	rs714027	0.585	rs960987	chr22:30343477	C/T	cg01021169	chr22:30184971	ASCC2	-0.4	-4.9	-0.3	1.78e-6	Lymphocyte counts;
KIRP	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.51	-6.76	-0.4	1.01e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg00042356	chr1:8021962	PARK7	0.81	6.94	0.4	3.38e-11	Inflammatory bowel disease;
KIRP	cis	rs2299587	0.554	rs2073567	chr8:17754034	G/A	cg01800426	chr8:17659068	MTUS1	-0.44	-5.22	-0.32	3.79e-7	Economic and political preferences;
KIRP	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg09788416	chr12:39539408	NA	0.42	5.33	0.32	2.25e-7	Morning vs. evening chronotype;
KIRP	cis	rs6568686	0.786	rs4458728	chr6:111840562	A/C	cg15721981	chr6:111408429	SLC16A10	0.65	5.73	0.34	2.87e-8	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.02	-0.57	3.31e-23	Height;
KIRP	cis	rs6743226	0.901	rs12478458	chr2:242237856	A/G	cg10021735	chr2:242295487	FARP2	0.47	5.81	0.35	1.98e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
KIRP	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.47	-6.42	-0.38	7.13e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg12131826	chr15:77904385	NA	-0.49	-5.92	-0.35	1.09e-8	Type 2 diabetes;
KIRP	cis	rs6684514	0.961	rs112017075	chr1:156327716	G/A	cg16558208	chr1:156270281	VHLL	-0.43	-5.38	-0.32	1.73e-7	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg22800045	chr5:56110881	MAP3K1	0.72	7.71	0.44	3.04e-13	Initial pursuit acceleration;
KIRP	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	5.78	0.35	2.25e-8	Response to antipsychotic treatment;
KIRP	cis	rs1847505	0.563	rs3127053	chr13:61412076	G/T	cg25164009	chr13:61490935	NA	-0.44	-5.01	-0.3	1.05e-6	Polychlorinated biphenyl levels;
KIRP	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.57	6.18	0.37	2.61e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.91	11.04	0.58	2.84e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg09904177	chr6:26538194	HMGN4	-0.46	-5.66	-0.34	4.23e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.83	-12.37	-0.62	1.17e-27	Neurofibrillary tangles;
KIRP	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.76	9.79	0.53	2.47e-19	Height;
KIRP	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11645453	chr3:52864694	ITIH4	-0.33	-5.08	-0.31	7.49e-7	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2273156	1.000	rs8018114	chr14:35470019	T/C	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.45	-0.33	1.25e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.69	8.01	0.45	4.73e-14	Red cell distribution width;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21815479	chr8:37887900	EIF4EBP1	0.51	6.39	0.38	8.39e-10	Parkinson's disease;
KIRP	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg02570527	chr1:10970165	NA	-0.42	-5.12	-0.31	6.11e-7	Body mass index;
KIRP	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.6	-6.43	-0.38	6.59e-10	Lung disease severity in cystic fibrosis;
KIRP	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.71	8.43	0.47	2.97e-15	Corneal astigmatism;
KIRP	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg03468072	chr12:39539422	NA	0.45	5.94	0.35	9.85e-9	Heart rate;
KIRP	cis	rs6977660	0.619	rs4721823	chr7:19785888	G/C	cg07541023	chr7:19748670	TWISTNB	0.53	5.14	0.31	5.48e-7	Thyroid stimulating hormone;
KIRP	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.69	8.34	0.47	5.19e-15	Aortic root size;
KIRP	cis	rs1497828	1.000	rs1391285	chr1:217561468	C/T	cg04411442	chr1:217543379	NA	0.3	4.92	0.3	1.61e-6	Dialysis-related mortality;
KIRP	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg22974920	chr21:40686053	BRWD1	-0.51	-6.1	-0.36	4e-9	Cognitive function;
KIRP	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg11204139	chr17:3907470	NA	0.57	7.45	0.43	1.59e-12	Type 2 diabetes;
KIRP	cis	rs9513593	1.000	rs747848	chr13:100036182	C/T	cg21788972	chr13:99853209	UBAC2	0.57	6.08	0.36	4.63e-9	Psoriasis;
KIRP	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	trans	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg13565492	chr6:43139072	SRF	-0.96	-8.87	-0.49	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg24315340	chr6:146058215	EPM2A	0.39	4.95	0.3	1.4e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	6.8	0.4	7.76e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.66	8.4	0.47	3.67e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs7209700	0.547	rs55845779	chr17:45354751	G/A	cg08085267	chr17:45401833	C17orf57	0.57	5.4	0.33	1.54e-7	IgG glycosylation;
KIRP	cis	rs2573652	0.963	rs2573649	chr15:100514040	C/G	cg09918751	chr15:100517450	ADAMTS17	-0.68	-10.23	-0.55	1.11e-20	Height;
KIRP	trans	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg13565492	chr6:43139072	SRF	-0.94	-8.64	-0.48	7.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19717773	chr7:2847554	GNA12	-0.4	-6.13	-0.36	3.45e-9	Height;
KIRP	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg22676075	chr6:135203613	NA	0.49	7.05	0.41	1.76e-11	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.09	17.89	0.75	2.13e-46	Primary sclerosing cholangitis;
KIRP	cis	rs11955398	0.625	rs11745077	chr5:59955716	C/T	cg02684056	chr5:59996105	DEPDC1B	0.44	4.98	0.3	1.18e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.501	rs7221546	chr17:3911450	A/G	cg21851534	chr17:3907994	ZZEF1	0.71	11.75	0.6	1.3e-25	Type 2 diabetes;
KIRP	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.57	8.17	0.46	1.66e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg05887092	chr17:76393375	PGS1	0.54	7.5	0.43	1.16e-12	HDL cholesterol levels;
KIRP	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-6.26	-0.37	1.74e-9	Skin colour saturation;
KIRP	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.53	6.16	0.37	3.03e-9	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18798372	chr8:124557975	NA	-0.45	-6.21	-0.37	2.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg26769984	chr7:1090371	C7orf50	0.49	5.18	0.31	4.67e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg22718636	chr4:961658	DGKQ	0.45	6.28	0.37	1.51e-9	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
KIRP	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.7	-0.39	1.41e-10	Immature fraction of reticulocytes;
KIRP	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg25039879	chr17:56429692	SUPT4H1	0.55	4.94	0.3	1.44e-6	Cognitive test performance;
KIRP	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.66	-8.17	-0.46	1.6e-14	Aortic root size;
KIRP	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.64	9.23	0.51	1.27e-17	Prostate cancer;
KIRP	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg02487422	chr3:49467188	NICN1	0.36	5.02	0.3	9.79e-7	Parkinson's disease;
KIRP	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg15436174	chr10:43711423	RASGEF1A	0.8	8.25	0.47	9.76e-15	Hirschsprung disease;
KIRP	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.03e-8	Motion sickness;
KIRP	cis	rs3099143	0.803	rs28618274	chr15:77220243	C/T	cg21673338	chr15:77095150	SCAPER	-0.52	-5.47	-0.33	1.11e-7	Recalcitrant atopic dermatitis;
KIRP	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06627825	chr2:68290170	C1D	-0.4	-6.02	-0.36	6.35e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg16405210	chr4:1374714	KIAA1530	-0.47	-5.86	-0.35	1.47e-8	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	1.13	12.06	0.61	1.23e-26	Psoriasis;
KIRP	cis	rs2425143	1.000	rs11907811	chr20:34428078	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.54	-5.01	-0.3	1.06e-6	Blood protein levels;
KIRP	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.37	6.34	0.37	1.06e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15516684	chr19:52675034	ZNF836	0.48	6.09	0.36	4.4e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg14927855	chr7:155151427	NA	0.7	8.15	0.46	1.83e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.38	-6.8	-0.4	7.98e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.61	-7.28	-0.42	4.55e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg11833968	chr6:79620685	NA	-0.37	-5.12	-0.31	6.06e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg16141378	chr3:129829833	LOC729375	0.57	6.93	0.4	3.7e-11	Systemic lupus erythematosus;
KIRP	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.68	10.13	0.54	2.17e-20	Dupuytren's disease;
KIRP	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.4	-5.05	-0.31	8.44e-7	Leprosy;
KIRP	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg01620082	chr3:125678407	NA	-0.91	-6.52	-0.38	4.05e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg26408565	chr15:76604113	ETFA	-0.44	-5.82	-0.35	1.82e-8	Blood metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20258753	chr7:90016008	GTPBP10	-0.43	-6.09	-0.36	4.3e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs981844	0.775	rs17371336	chr4:154749525	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.68	0.44	3.66e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.5	5.99	0.36	7.44e-9	Longevity;Endometriosis;
KIRP	cis	rs17023223	0.537	rs55836852	chr1:119725401	G/A	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.47	-5.05	-0.31	8.56e-7	Initial pursuit acceleration;
KIRP	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.84	9.32	0.51	6.79e-18	Bipolar disorder;
KIRP	cis	rs909341	0.678	rs6011018	chr20:62303622	T/G	cg03999872	chr20:62272968	STMN3	0.6	6.87	0.4	5.25e-11	Atopic dermatitis;
KIRP	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.62	8.16	0.46	1.73e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1656402	1.000	rs1656398	chr2:233427852	C/T	cg03852847	chr2:233439513	NA	-0.72	-12.35	-0.62	1.4e-27	Non-small cell lung cancer (survival);
KIRP	cis	rs6570726	0.516	rs10457779	chr6:145736663	C/T	cg23711669	chr6:146136114	FBXO30	0.49	6.45	0.38	5.76e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9790314	0.582	rs11922752	chr3:160600599	G/C	cg04691961	chr3:161091175	C3orf57	0.43	6.25	0.37	1.78e-9	Morning vs. evening chronotype;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg04575325	chr6:160210070	MRPL18;TCP1	0.54	6.26	0.37	1.72e-9	Sleep duration;
KIRP	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-0.75	-11.1	-0.58	1.77e-23	Prudent dietary pattern;
KIRP	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21214613	chr1:16344536	HSPB7	0.33	5.08	0.31	7.3e-7	Dilated cardiomyopathy;
KIRP	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.97	16.94	0.73	3.57e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4765905	0.610	rs2239019	chr12:2310310	G/T	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.73	-0.34	2.87e-8	Schizophrenia;
KIRP	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.29	-5.76	-0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.2	-0.42	7.48e-12	Fear of minor pain;
KIRP	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.75	-11.77	-0.6	1.12e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.94	-14.67	-0.68	1.97e-35	Sudden cardiac arrest;
KIRP	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.82	-10.74	-0.56	2.62e-22	Vitamin D levels;
KIRP	cis	rs12210905	0.688	rs72843177	chr6:27367414	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.43	-0.38	6.64e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg26384229	chr12:38710491	ALG10B	-0.74	-9.77	-0.53	2.93e-19	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg09307838	chr4:120376055	NA	0.67	6.77	0.4	9.34e-11	Corneal astigmatism;
KIRP	trans	rs9290065	0.686	rs1839021	chr3:160623669	T/G	cg19274270	chr17:78178856	CARD14	0.34	6.06	0.36	5.17e-9	Kawasaki disease;
KIRP	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-5.12	-0.31	6.1e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg24498760	chr8:49746867	NA	0.41	4.93	0.3	1.5e-6	Blood metabolite ratios;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23521262	chr10:114323333	VTI1A	-0.42	-6.7	-0.39	1.45e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg22903657	chr4:1355424	KIAA1530	-0.42	-5.92	-0.35	1.05e-8	Obesity-related traits;
KIRP	cis	rs9625935	0.518	rs9614086	chr22:30259608	A/C	cg01021169	chr22:30184971	ASCC2	0.44	6.11	0.36	3.8e-9	Tonsillectomy;
KIRP	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.63	9.67	0.52	5.72e-19	Lung cancer;
KIRP	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.59	-8.4	-0.47	3.59e-15	Obesity-related traits;
KIRP	cis	rs34779708	0.868	rs2384352	chr10:35492832	A/G	cg04310649	chr10:35416472	CREM	-0.59	-6.77	-0.4	9.23e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-8.22	-0.46	1.15e-14	Neuroticism;
KIRP	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg02336718	chr17:17403227	NA	0.38	5.84	0.35	1.62e-8	Total body bone mineral density;
KIRP	cis	rs5753037	0.504	rs140114	chr22:30133881	C/T	cg01021169	chr22:30184971	ASCC2	-0.48	-6.39	-0.38	8.23e-10	Type 1 diabetes;
KIRP	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-5.31	-0.32	2.4e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.46	9.55	0.52	1.42e-18	Monocyte percentage of white cells;
KIRP	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.75	9.99	0.54	5.89e-20	Breast cancer;
KIRP	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg16558253	chr16:72132732	DHX38	-0.6	-8.95	-0.5	8.84e-17	Fibrinogen levels;
KIRP	cis	rs904251	0.523	rs1776454	chr6:37482099	C/T	cg24807547	chr6:37504484	NA	-0.63	-10.27	-0.55	7.92e-21	Cognitive performance;
KIRP	trans	rs9650657	0.504	rs6986032	chr8:11032240	C/T	cg08975724	chr8:8085496	FLJ10661	-0.7	-9.48	-0.52	2.21e-18	Neuroticism;
KIRP	cis	rs4236601	0.720	rs17588172	chr7:116154015	G/T	cg12739419	chr7:116140593	CAV2	-0.44	-5.68	-0.34	3.71e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs6959887	0.962	rs12538541	chr7:35297932	G/C	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs4845459	0.933	rs6662654	chr1:152593081	G/T	cg07796016	chr1:152779584	LCE1C	-0.49	-5.95	-0.35	9.1e-9	Psoriasis;
KIRP	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg10636054	chr15:40330586	SRP14	0.82	7.42	0.43	1.85e-12	Response to haloperidol in psychosis;
KIRP	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.61	-5.76	-0.34	2.45e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-5.11	-0.31	6.62e-7	Lung cancer;
KIRP	cis	rs4389656	0.767	rs274704	chr5:6728340	A/G	cg10857441	chr5:6722123	POLS	-0.47	-6.65	-0.39	1.84e-10	Coronary artery disease;
KIRP	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg10950924	chr17:47092072	IGF2BP1	-0.5	-6.46	-0.38	5.72e-10	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	trans	rs12043259	0.730	rs6699817	chr1:204813453	A/G	cg11485465	chr5:54518469	NA	0.38	6.58	0.39	2.78e-10	Addiction;
KIRP	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg06212747	chr3:49208901	KLHDC8B	0.68	6.31	0.37	1.29e-9	Menarche (age at onset);
KIRP	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.75	8.79	0.49	2.57e-16	Adiposity;
KIRP	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.45	0.43	1.62e-12	Aortic root size;
KIRP	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.58	7.43	0.43	1.82e-12	Aortic root size;
KIRP	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.86	11.17	0.58	1.04e-23	Gestational age at birth (maternal effect);
KIRP	cis	rs6545883	0.965	rs6734830	chr2:61731112	G/A	cg15711740	chr2:61764176	XPO1	-0.58	-7.97	-0.45	6.07e-14	Tuberculosis;
KIRP	cis	rs11779988	0.516	rs426498	chr8:17897158	T/C	cg01800426	chr8:17659068	MTUS1	-0.46	-4.91	-0.3	1.64e-6	Breast cancer;
KIRP	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	10.42	0.55	2.73e-21	Bone mineral density;
KIRP	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.64	8.74	0.49	3.62e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-5.64	-0.34	4.65e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg02175503	chr12:58329896	NA	0.66	7.39	0.43	2.35e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.57	7.76	0.44	2.25e-13	Mean corpuscular volume;
KIRP	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg11764359	chr7:65958608	NA	0.43	5.08	0.31	7.43e-7	Calcium levels;
KIRP	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg11234688	chr2:1609660	NA	-0.54	-5.02	-0.3	1.01e-6	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6001982	0.665	rs73167062	chr22:40864848	G/C	cg07138101	chr22:40742427	ADSL	0.73	5.15	0.31	5.41e-7	Breast cancer;
KIRP	cis	rs13130787	0.802	rs13130754	chr4:94896255	A/T	cg11021082	chr4:95130006	SMARCAD1	0.4	5.04	0.31	8.9e-7	Colorectal cancer;
KIRP	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-11.09	-0.58	1.89e-23	Colorectal cancer;
KIRP	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg01657329	chr11:68192670	LRP5	-0.5	-5.37	-0.32	1.85e-7	Total body bone mineral density;
KIRP	cis	rs8093481	1.000	rs11661737	chr18:10696043	T/C	cg21165219	chr18:10698044	FAM38B	-0.43	-5.31	-0.32	2.48e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg15371732	chr17:78194151	SLC26A11;SGSH	0.54	6.12	0.36	3.61e-9	Cystic fibrosis severity;
KIRP	cis	rs365132	0.875	rs353495	chr5:176430723	T/C	cg16309518	chr5:176445507	NA	-0.77	-11.61	-0.6	3.78e-25	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs1971762	0.762	rs4759282	chr12:54072435	C/A	cg09709951	chr12:54017699	ATF7	0.41	5.11	0.31	6.5e-7	Height;
KIRP	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.47	-7.7	-0.44	3.25e-13	Pneumonia;
KIRP	cis	rs9947276	0.925	rs3843968	chr18:72503052	A/G	cg13203249	chr18:72265586	LOC400657	0.4	4.86	0.3	2.11e-6	Alcohol dependence (age at onset);
KIRP	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-0.65	-5.41	-0.33	1.52e-7	Blood pressure (smoking interaction);
KIRP	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.97	-0.3	1.23e-6	Renal cell carcinoma;
KIRP	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02972257	chr16:68554789	NA	-0.72	-7.16	-0.42	9.37e-12	Ulcerative colitis;
KIRP	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.88	9.75	0.53	3.42e-19	Gut microbiome composition (summer);
KIRP	cis	rs2273156	1.000	rs8019179	chr14:35447795	T/C	cg09327582	chr14:35236912	BAZ1A	-0.49	-5.44	-0.33	1.29e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.45	-5.29	-0.32	2.65e-7	Monocyte count;
KIRP	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.58	-6.63	-0.39	2.06e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs714027	0.565	rs9614099	chr22:30288338	A/T	cg01021169	chr22:30184971	ASCC2	-0.41	-5.08	-0.31	7.49e-7	Lymphocyte counts;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14103574	chr5:162932455	MAT2B	0.48	6.33	0.37	1.14e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1881797	0.527	rs78486847	chr1:247638515	C/T	cg05639522	chr1:247681581	NA	0.77	5.06	0.31	8.23e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg24642439	chr20:33292090	TP53INP2	-0.47	-5.67	-0.34	4.03e-8	Height;
KIRP	cis	rs7017914	0.967	rs13264669	chr8:71626772	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg00792783	chr2:198669748	PLCL1	0.47	5.21	0.32	3.94e-7	Dermatomyositis;
KIRP	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.76	10.99	0.57	4.07e-23	Body mass index;
KIRP	cis	rs9596863	1.000	rs9568939	chr13:54411497	A/C	ch.13.53330881F	chr13:54432880	NA	0.66	6.68	0.39	1.56e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg06815112	chr8:27182871	PTK2B	0.49	6.24	0.37	1.9e-9	Neuroticism;
KIRP	cis	rs9937943	0.667	rs35126294	chr16:74651005	T/C	cg01733217	chr16:74700730	RFWD3	0.63	5.92	0.35	1.08e-8	Neutrophil percentage of white cells;
KIRP	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.86e-15	Prudent dietary pattern;
KIRP	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5750854	0.503	rs5750861	chr22:40026141	C/A	cg21377881	chr22:40064566	CACNA1I	-0.42	-5.75	-0.34	2.68e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05665937	chr4:1216051	CTBP1	0.56	7.84	0.45	1.34e-13	Obesity-related traits;
KIRP	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.65	8.38	0.47	4.06e-15	Prudent dietary pattern;
KIRP	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg01411142	chr8:19674711	INTS10	0.45	4.92	0.3	1.62e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.43	5.38	0.32	1.69e-7	Melanoma;
KIRP	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	cg12689670	chr1:183009347	LAMC1	0.51	7.19	0.42	7.55e-12	Fuchs's corneal dystrophy;
KIRP	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg13397359	chr6:42928475	GNMT	0.42	4.95	0.3	1.41e-6	Blood protein levels;
KIRP	cis	rs151997	1.000	rs72758246	chr5:50246783	G/C	cg06027927	chr5:50259733	NA	0.57	7.15	0.41	1e-11	Callous-unemotional behaviour;
KIRP	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg16506815	chr2:162101123	NA	-0.45	-5.34	-0.32	2.09e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-6.18	-0.37	2.65e-9	Inflammatory skin disease;
KIRP	cis	rs2992756	1.000	rs2992756	chr1:18807339	T/C	cg05040210	chr1:18807594	KLHDC7A	-0.3	-5.47	-0.33	1.09e-7	Breast cancer;
KIRP	cis	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs6580649	0.941	rs57380031	chr12:48452237	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg08204369	chr17:73150733	HN1	0.46	6.04	0.36	5.52e-9	Ischemic stroke;
KIRP	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.61	-9.45	-0.52	2.72e-18	Sense of smell;
KIRP	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07343612	chr16:622815	PIGQ	-0.88	-13.28	-0.65	1.0500000000000001e-30	Height;
KIRP	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg05370193	chr1:21551575	ECE1	0.38	5.1	0.31	6.68e-7	Superior frontal gyrus grey matter volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26930889	chr14:39519326	SEC23A	-0.42	-6.88	-0.4	5.06e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs11603020	0.851	rs10896631	chr11:57381263	T/C	cg23127183	chr11:57508653	C11orf31	-0.46	-5.33	-0.32	2.18e-7	Blood protein levels;
KIRP	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.79	10.28	0.55	7.62e-21	Platelet count;
KIRP	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg23188588	chr14:78226832	SNW1;C14orf178	0.8	8.03	0.46	4.1e-14	Fibroblast growth factor basic levels;
KIRP	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	6.09	0.36	4.32e-9	Platelet count;
KIRP	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg09904177	chr6:26538194	HMGN4	0.42	5.27	0.32	3.02e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	5.3	0.32	2.58e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	0.576	rs11084707	chr19:33612873	C/T	cg17764715	chr19:33622953	WDR88	0.82	11.94	0.61	3.15e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg25588787	chr5:154027256	NA	0.44	5.01	0.3	1.06e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg12315302	chr6:26189340	HIST1H4D	0.91	6.25	0.37	1.79e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.7	-7.88	-0.45	1.06e-13	Menarche (age at onset);
KIRP	cis	rs12765878	0.967	rs10883948	chr10:105667552	G/T	cg11005552	chr10:105648138	OBFC1	0.41	5.84	0.35	1.63e-8	Coronary artery disease;
KIRP	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg18904891	chr8:8559673	CLDN23	0.69	7.73	0.44	2.68e-13	Obesity-related traits;
KIRP	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.51	0.38	4.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.58	7.09	0.41	1.37e-11	Aortic root size;
KIRP	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg21551340	chr2:1609508	NA	0.52	5.04	0.31	8.99e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.98	14.71	0.68	1.42e-35	Chronic sinus infection;
KIRP	cis	rs12900413	0.687	rs28653538	chr15:90304964	T/C	cg24650279	chr15:90327240	NA	-0.43	-5.42	-0.33	1.43e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25928603	chr2:200323017	SATB2	-0.51	-6.51	-0.38	4.11e-10	Migraine with aura;
KIRP	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg21475434	chr5:93447410	FAM172A	-0.45	-5.26	-0.32	3.18e-7	Diabetic retinopathy;
KIRP	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	1.02	11.37	0.59	2.45e-24	IgG glycosylation;
KIRP	cis	rs798766	1.000	rs3752749	chr4:1737262	T/C	cg07775547	chr4:1625484	NA	-0.44	-5.35	-0.32	2.03e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-6.84	-0.4	6.21e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.82	-11.5	-0.59	9.2e-25	Total body bone mineral density;
KIRP	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg23422044	chr7:1970798	MAD1L1	-0.71	-7.1	-0.41	1.33e-11	Bipolar disorder;
KIRP	cis	rs8008758	1.000	rs8013718	chr14:101689506	C/T	cg26224664	chr14:101693935	NA	-0.41	-4.99	-0.3	1.12e-6	Body mass index (alcohol intake interaction);
KIRP	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.77	8.88	0.49	1.48e-16	Cocaine dependence;
KIRP	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.73	9.31	0.51	7.59e-18	Total cholesterol levels;
KIRP	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Bladder cancer;
KIRP	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.53	-5.75	-0.34	2.68e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.78	10.82	0.57	1.42e-22	Aortic root size;
KIRP	trans	rs9465187	0.609	rs9477827	chr6:18691231	G/T	cg07924874	chr19:58609793	ZSCAN18	0.47	6.28	0.37	1.5e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7923609	0.936	rs4405189	chr10:65013935	A/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.67	-0.34	4.04e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7937612	1.000	rs10790382	chr11:120288372	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.88	-0.4	4.93e-11	Intraocular pressure;
KIRP	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg13319975	chr6:146136371	FBXO30	-0.46	-6.65	-0.39	1.92e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6662572	0.737	rs77017199	chr1:46532407	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.44	5.18	0.31	4.64e-7	Blood protein levels;
KIRP	cis	rs501120	0.584	rs10900003	chr10:44698044	C/A	cg09554077	chr10:44749378	NA	0.51	5.54	0.33	7.93e-8	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.49	6.34	0.37	1.09e-9	Blood metabolite levels;
KIRP	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-9.57	-0.52	1.2e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg19592336	chr6:28129416	ZNF389	0.51	5.79	0.35	2.18e-8	Depression;
KIRP	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.98	17.81	0.75	3.91e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs10849605	0.698	rs7955986	chr12:1067254	C/T	cg22243222	chr12:1059299	RAD52	-0.37	-4.84	-0.3	2.27e-6	Lung cancer;
KIRP	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-5.63	-0.34	4.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4262150	0.842	rs56208248	chr5:152138598	A/G	cg12297329	chr5:152029980	NA	-0.66	-8.33	-0.47	5.79e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs13102973	0.899	rs4479760	chr4:135867474	T/C	cg14419869	chr4:135874104	NA	0.55	9.43	0.52	3.2e-18	Subjective well-being;
KIRP	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg26248373	chr2:1572462	NA	-0.69	-7.44	-0.43	1.69e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.44	-0.7	4.63e-38	Chronic sinus infection;
KIRP	trans	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg24644049	chr4:85504048	CDS1	0.93	6.88	0.4	4.86e-11	Skin colour saturation;
KIRP	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	15.1	0.69	6.82e-37	Platelet count;
KIRP	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.5	7.09	0.41	1.41e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.85	11.93	0.61	3.44e-26	Total body bone mineral density;
KIRP	cis	rs7172677	0.737	rs6495153	chr15:75437010	C/G	cg14664628	chr15:75095509	CSK	-0.45	-5.1	-0.31	6.77e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg09408571	chr1:101003634	GPR88	-0.24	-5.54	-0.33	7.85e-8	Monocyte count;
KIRP	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg24154853	chr7:158122151	PTPRN2	-0.36	-5.28	-0.32	2.84e-7	Calcium levels;
KIRP	cis	rs2733310	0.947	rs1158246	chr15:57185969	A/G	cg13626582	chr15:57592083	LOC283663	0.25	5.89	0.35	1.26e-8	Mean platelet volume;
KIRP	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.9	14.15	0.67	1.15e-33	Mean corpuscular volume;
KIRP	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs75920871	0.841	rs61905709	chr11:116897834	C/T	cg23684410	chr11:116897558	SIK3	0.55	5.88	0.35	1.36e-8	Subjective well-being;
KIRP	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg22906224	chr7:99728672	NA	0.48	5.74	0.34	2.71e-8	Coronary artery disease;
KIRP	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg18478394	chr8:109455254	TTC35	0.52	6.43	0.38	6.47e-10	Dupuytren's disease;
KIRP	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.79	11.37	0.59	2.42e-24	Caffeine consumption;
KIRP	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg06640241	chr16:89574553	SPG7	0.65	8.46	0.47	2.36e-15	Multiple myeloma (IgH translocation);
KIRP	cis	rs4955124	0.558	rs12632509	chr3:32024275	T/C	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.79	6.81	0.4	7.29e-11	Schizophrenia;
KIRP	cis	rs7188697	0.922	rs8047769	chr16:58591987	G/A	cg21335942	chr16:58549945	SETD6	-0.47	-5.17	-0.31	4.83e-7	QT interval;
KIRP	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-5.88	-0.35	1.33e-8	Blood metabolite levels;
KIRP	cis	rs7577696	0.597	rs212689	chr2:32437338	G/A	cg02381751	chr2:32503542	YIPF4	0.62	6.05	0.36	5.4e-9	Inflammatory biomarkers;
KIRP	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg02461776	chr11:598696	PHRF1	0.71	7.57	0.43	7.49e-13	Systemic lupus erythematosus;
KIRP	cis	rs6987853	0.933	rs2974340	chr8:42397731	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.05	0.31	8.55e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg18944383	chr4:111397179	ENPEP	0.52	8.34	0.47	5.49e-15	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg22437258	chr11:111473054	SIK2	0.66	7.99	0.45	5.16e-14	Primary sclerosing cholangitis;
KIRP	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg25801113	chr15:45476975	SHF	0.44	8.1	0.46	2.49e-14	Uric acid levels;
KIRP	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg27124370	chr19:33622961	WDR88	0.61	7.43	0.43	1.75e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg09365446	chr1:150670422	GOLPH3L	0.39	5.08	0.31	7.29e-7	Tonsillectomy;
KIRP	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg20673091	chr1:2541236	MMEL1	0.66	10.03	0.54	4.47e-20	Ulcerative colitis;
KIRP	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg13319975	chr6:146136371	FBXO30	-0.49	-7.03	-0.41	1.97e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg04369109	chr6:150039330	LATS1	-0.49	-6.4	-0.38	7.82e-10	Lung cancer;
KIRP	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg02187348	chr16:89574699	SPG7	0.46	5.69	0.34	3.51e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	1.01	15.81	0.71	2.41e-39	Vitamin D levels;
KIRP	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.6	-7.17	-0.42	8.71e-12	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.69	11.19	0.58	9.02e-24	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg03929089	chr4:120376271	NA	0.92	6.59	0.39	2.71e-10	Myopia (pathological);
KIRP	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg18850127	chr7:39170497	POU6F2	0.31	5.7	0.34	3.45e-8	IgG glycosylation;
KIRP	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.55	6.44	0.38	6.24e-10	Aortic root size;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.38	-4.86	-0.3	2.13e-6	IgG glycosylation;
KIRP	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg05315796	chr3:52349193	DNAH1	0.41	6.46	0.38	5.5e-10	Electroencephalogram traits;
KIRP	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.7	8.78	0.49	2.9e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg14458575	chr2:238380390	NA	0.69	6.76	0.4	9.77e-11	Prostate cancer;
KIRP	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.82	-10.12	-0.54	2.37e-20	Menarche (age at onset);
KIRP	cis	rs7582720	0.945	rs72932707	chr2:203639395	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.12	9.63	0.52	8.09e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-1.08	-21.37	-0.81	5.39e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4765905	0.671	rs4765904	chr12:2332393	A/C	cg10668781	chr12:2307325	CACNA1C	-0.3	-5.62	-0.34	5.07e-8	Schizophrenia;
KIRP	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg13271783	chr10:134563150	INPP5A	-0.52	-6.64	-0.39	1.99e-10	Migraine;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg01688141	chr8:23539808	NKX3-1	-0.5	-6.89	-0.4	4.65e-11	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs1620921	0.505	rs1965092	chr6:161204889	C/T	cg01280913	chr6:161186852	NA	-0.58	-7.9	-0.45	9.1e-14	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.39	9.6	0.52	9.95e-19	Corneal astigmatism;
KIRP	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.0	11.27	0.58	5.18e-24	Smoking behavior;
KIRP	cis	rs4523957	0.583	rs8068508	chr17:2047624	A/G	cg16513277	chr17:2031491	SMG6	-0.87	-12.89	-0.64	2.08e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs520865	0.732	rs143877	chr5:80346332	C/T	cg17330048	chr5:80257322	RASGRF2	-0.46	-6.63	-0.39	2.11e-10	Superior frontal gyrus grey matter volume;
KIRP	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.55	-5.88	-0.35	1.3e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-1.01	-17.27	-0.74	2.69e-44	Bone mineral density;
KIRP	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.99	14.37	0.68	2.16e-34	Monocyte count;
KIRP	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs9604529	0.759	rs111556560	chr13:114623063	G/A	cg24241305	chr13:114826075	RASA3	-0.58	-4.91	-0.3	1.69e-6	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg08957018	chr22:42487540	NDUFA6	0.62	7.54	0.43	9.01e-13	Smoking initiation;
KIRP	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.91	15.51	0.7	2.66e-38	Longevity;Endometriosis;
KIRP	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-8.47	-0.48	2.28e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg26617929	chr16:1858877	NA	-0.7	-5.79	-0.35	2.17e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg20750642	chr13:99100586	FARP1	0.41	5.04	0.31	8.99e-7	Neuroticism;
KIRP	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.87	6.39	0.38	8.25e-10	Putamen volume;
KIRP	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	8.06	0.46	3.39e-14	Migraine;Coronary artery disease;
KIRP	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22117172	chr7:91764530	CYP51A1	0.46	6.29	0.37	1.41e-9	Breast cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10837265	chr1:26758824	DHDDS	0.51	6.55	0.39	3.43e-10	Parkinson's disease;
KIRP	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg05527609	chr1:210001259	C1orf107	-0.44	-5.37	-0.32	1.8e-7	Red blood cell count;
KIRP	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.45	-5.81	-0.35	1.9e-8	Asthma (bronchodilator response);
KIRP	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23903597	chr17:61704154	MAP3K3	-0.59	-7.15	-0.41	1.01e-11	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg10790698	chr19:18539756	SSBP4	-0.34	-7.5	-0.43	1.17e-12	Breast cancer;
KIRP	cis	rs10982256	0.904	rs4527950	chr9:117267472	G/T	cg13636371	chr9:117264095	DFNB31	-0.39	-5.01	-0.3	1.06e-6	Bipolar disorder;
KIRP	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-6.92	-0.4	3.82e-11	Height;
KIRP	cis	rs55692468	0.771	rs10191361	chr2:153340848	G/A	cg04681845	chr2:153283485	FMNL2	-0.48	-5.91	-0.35	1.13e-8	Intraocular pressure;
KIRP	cis	rs2860975	0.580	rs11572120	chr10:96815303	A/C	cg09036531	chr10:96991505	NA	-0.47	-5.77	-0.35	2.36e-8	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07685180	chr8:600429	NA	0.7	5.16	0.31	5.08e-7	IgG glycosylation;
KIRP	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-0.81	-8.19	-0.46	1.42e-14	Lung cancer;
KIRP	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.86	11.04	0.58	2.73e-23	Coronary artery disease;
KIRP	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg13962347	chr6:5174647	LYRM4	-0.6	-8.28	-0.47	7.86e-15	Height;
KIRP	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.88	8.5	0.48	1.81e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8030485	0.716	rs12899109	chr15:79410970	T/C	cg17916960	chr15:79447300	NA	0.37	6.58	0.39	2.77e-10	Left ventricle wall thickness;
KIRP	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg25664220	chr3:72788482	NA	-0.36	-5.26	-0.32	3.17e-7	Motion sickness;
KIRP	cis	rs2916247	0.955	rs2920462	chr8:92985508	G/A	cg10183463	chr8:93005414	RUNX1T1	0.58	7.41	0.43	2.02e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17376030	chr22:41985996	PMM1	-0.81	-8.57	-0.48	1.14e-15	Vitiligo;
KIRP	cis	rs9503598	0.517	rs11242860	chr6:3463536	A/C	cg00476032	chr6:3446245	SLC22A23	0.45	6.32	0.37	1.2e-9	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	9.5	0.52	1.99e-18	Cognitive test performance;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg06461811	chr16:2097673	TSC2;NTHL1	-0.49	-6.44	-0.38	6.21e-10	Myopia;
KIRP	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Bladder cancer;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg21195307	chr9:134378745	POMT1	-0.56	-6.23	-0.37	2.05e-9	Menopause (age at onset);
KIRP	cis	rs9815354	0.953	rs1717003	chr3:41937000	C/T	cg03022575	chr3:42003672	ULK4	-0.46	-5.25	-0.32	3.36e-7	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7615316	0.698	rs9843148	chr3:142244592	A/G	cg20824294	chr3:142316082	PLS1	0.26	5.11	0.31	6.41e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04234680	chr14:51562550	TRIM9	-0.43	-6.12	-0.36	3.58e-9	Gut microbiota (bacterial taxa);
KIRP	cis	rs62380364	0.565	rs40504	chr5:88011139	G/C	cg22951263	chr5:87985283	NA	-0.44	-6.15	-0.37	3.08e-9	Intelligence (multi-trait analysis);
KIRP	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg13615516	chr5:77269221	NA	0.52	8.25	0.47	9.76e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.84	11.08	0.58	2.11e-23	Primary sclerosing cholangitis;
KIRP	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg22732515	chr19:44031385	ETHE1	0.68	9.73	0.53	3.96e-19	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.47e-6	Coronary artery disease;
KIRP	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg12560992	chr17:57184187	TRIM37	0.61	5.52	0.33	8.6e-8	Cognitive test performance;
KIRP	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.78	-12.14	-0.61	7.11e-27	Prostate cancer;
KIRP	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg14952266	chr13:112191215	NA	0.45	6.7	0.39	1.41e-10	Hepatitis;
KIRP	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg05072774	chr3:49840536	C3orf54	0.43	5.57	0.33	6.8e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg06417478	chr19:12876846	HOOK2	0.42	5.18	0.31	4.53e-7	Bipolar disorder;
KIRP	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg09873164	chr1:152488093	CRCT1	-0.47	-5.72	-0.34	3.1e-8	Hair morphology;
KIRP	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg09165964	chr15:75287851	SCAMP5	0.38	5.25	0.32	3.31e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg01378222	chr16:28622494	SULT1A1	-0.56	-6.3	-0.37	1.39e-9	Platelet distribution width;
KIRP	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg05964544	chr11:70165517	PPFIA1	-0.62	-6.8	-0.4	8.1e-11	Coronary artery disease;
KIRP	cis	rs2071403	0.871	rs55781504	chr2:1406343	T/A	cg07083862	chr2:1417248	TPO	0.31	4.88	0.3	1.87e-6	Thyroid peroxidase antibody positivity;
KIRP	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.52	-0.65	1.61e-31	Height;
KIRP	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg06212747	chr3:49208901	KLHDC8B	0.78	6.05	0.36	5.43e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs1805008	0.703	rs78418891	chr16:90049749	A/G	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-1.17	-7.84	-0.45	1.39e-13	Skin colour saturation;
KIRP	cis	rs6032067	0.759	rs6104052	chr20:43808783	T/G	cg10761708	chr20:43804764	PI3	0.43	4.92	0.3	1.59e-6	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27250368	chr8:144679336	EEF1D;TIGD5	0.54	6.77	0.4	9.46e-11	Parkinson's disease;
KIRP	trans	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg16141378	chr3:129829833	LOC729375	0.49	6.26	0.37	1.73e-9	Mood instability;
KIRP	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg18586891	chr4:952366	TMEM175	0.59	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-6.44	-0.38	6.2e-10	Asthma;
KIRP	cis	rs77633900	0.614	rs2468113	chr15:76851421	G/C	cg21673338	chr15:77095150	SCAPER	-0.6	-6.25	-0.37	1.84e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3.03e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.8	9.73	0.53	3.95e-19	Corneal astigmatism;
KIRP	cis	rs9816226	0.591	rs76880877	chr3:185802628	A/C	cg00760338	chr3:185826511	ETV5	-0.73	-6.4	-0.38	7.82e-10	Obesity;Body mass index;
KIRP	cis	rs10782582	0.569	rs2131557	chr1:76388589	A/C	cg10523679	chr1:76189770	ACADM	0.52	7.39	0.43	2.34e-12	Daytime sleep phenotypes;
KIRP	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg22963979	chr7:1858916	MAD1L1	-0.51	-6.63	-0.39	2.08e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.46	5.86	0.35	1.45e-8	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17321999	0.516	rs7579019	chr2:30501989	G/A	cg05247661	chr2:30472410	LBH	0.63	5.5	0.33	9.46e-8	Systemic lupus erythematosus;
KIRP	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg14673194	chr17:80132900	CCDC57	0.73	8.16	0.46	1.76e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4481887	0.790	rs6695468	chr1:248424596	G/A	cg01631408	chr1:248437212	OR2T33	-0.64	-7.82	-0.45	1.55e-13	Common traits (Other);
KIRP	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.92	14.63	0.68	2.7900000000000003e-35	Height;
KIRP	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg13512537	chr8:22265999	SLC39A14	-0.39	-5.24	-0.32	3.42e-7	Verbal declarative memory;
KIRP	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg10433463	chr1:1889099	KIAA1751	-0.35	-5.38	-0.32	1.77e-7	Body mass index;
KIRP	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.65	-7.56	-0.43	8.12e-13	Menopause (age at onset);
KIRP	cis	rs282587	0.597	rs438116	chr13:113392149	G/C	cg04656015	chr13:113407548	ATP11A	0.59	6.45	0.38	5.76e-10	Glycated hemoglobin levels;
KIRP	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs883565	0.655	rs7649923	chr3:39102137	G/A	cg01426195	chr3:39028469	NA	-0.74	-12.99	-0.64	1.01e-29	Handedness;
KIRP	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg16306078	chr6:126000798	NA	-0.26	-4.97	-0.3	1.26e-6	Endometrial cancer;
KIRP	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg17644776	chr2:200775616	C2orf69	-0.68	-5.99	-0.36	7.41e-9	Response to treatment for acute lymphoblastic leukemia;
KIRP	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.58	-6.76	-0.4	1e-10	Schizophrenia;
KIRP	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	1.16	15.39	0.7	6.71e-38	Left atrial antero-posterior diameter;
KIRP	cis	rs9309473	0.500	rs4852953	chr2:73869908	G/A	cg20560298	chr2:73613845	ALMS1	0.49	6.0	0.36	6.98e-9	Metabolite levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22986488	chr8:95565801	KIAA1429	0.49	6.33	0.37	1.13e-9	Parkinson's disease;
KIRP	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.39	5.33	0.32	2.21e-7	Homoarginine levels;
KIRP	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg10223061	chr2:219282414	VIL1	-0.41	-6.66	-0.39	1.8e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.67	-7.85	-0.45	1.29e-13	Systemic lupus erythematosus;
KIRP	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.67	9.49	0.52	2.16e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.32	5.11	0.31	6.33e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg10716548	chr6:1802524	GMDS	-0.47	-6.27	-0.37	1.57e-9	Select biomarker traits;
KIRP	cis	rs1669338	0.588	rs6788122	chr3:3171897	T/C	cg16797762	chr3:3221439	CRBN	-0.6	-6.15	-0.36	3.18e-9	White matter integrity;
KIRP	trans	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg00405596	chr8:11794950	NA	0.48	6.15	0.37	3.03e-9	Mood instability;
KIRP	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg06408034	chr1:45671987	ZSWIM5	-0.52	-6.6	-0.39	2.44e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg27411982	chr8:10470053	RP1L1	0.42	5.24	0.32	3.43e-7	Neuroticism;
KIRP	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.51	9.24	0.51	1.24e-17	Bone mineral density;
KIRP	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.58	-7.76	-0.44	2.33e-13	White matter hyperintensity burden;
KIRP	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.91	13.94	0.66	5.91e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.47	-7.33	-0.42	3.34e-12	Huntington's disease progression;
KIRP	cis	rs13108043	0.605	rs13136338	chr4:87958943	C/T	cg11209507	chr4:87813803	C4orf36	0.47	4.97	0.3	1.27e-6	Red blood cell count;
KIRP	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.64	6.95	0.4	3.36e-11	Platelet count;
KIRP	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.51	-6.21	-0.37	2.28e-9	Ulcerative colitis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06808430	chr7:102984880	DNAJC2	0.43	6.08	0.36	4.66e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	cg12689670	chr1:183009347	LAMC1	0.44	6.38	0.38	8.65e-10	Colorectal cancer;
KIRP	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg22617819	chr1:44378782	ST3GAL3	-0.33	-5.49	-0.33	9.76e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg01988459	chr11:68622903	NA	-0.43	-5.9	-0.35	1.19e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.52	-5.13	-0.31	5.91e-7	Breast cancer;
KIRP	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.53	6.55	0.39	3.37e-10	Asthma (sex interaction);
KIRP	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg19847130	chr8:10466454	RP1L1	0.38	5.75	0.34	2.61e-8	Retinal vascular caliber;
KIRP	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.85	-14.73	-0.68	1.2e-35	QRS duration;
KIRP	cis	rs4740619	0.619	rs1410451	chr9:16039579	G/A	cg14451791	chr9:16040625	NA	-0.42	-5.48	-0.33	1.07e-7	Body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg00356811	chr19:4639239	TNFAIP8L1	-0.45	-6.38	-0.38	8.75e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs447921	0.861	rs17596582	chr17:74438120	A/T	cg17201438	chr17:74438067	UBE2O	-0.47	-5.11	-0.31	6.53e-7	Mitochondrial DNA levels;
KIRP	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	8.71	0.49	4.63e-16	Coronary artery disease;
KIRP	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg11815991	chr20:30193098	ID1	-0.51	-5.12	-0.31	6.21e-7	Mean corpuscular hemoglobin;
KIRP	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21643547	chr1:205240462	TMCC2	-0.72	-11.27	-0.58	4.96e-24	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.97	12.81	0.63	3.86e-29	Homoarginine levels;
KIRP	cis	rs7565981	1.000	rs7565981	chr2:101424331	A/G	cg02232089	chr2:101440696	NPAS2	0.54	5.12	0.31	6.31e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs4356932	1.000	rs4616778	chr4:76981206	C/T	cg19388996	chr4:76862389	NAAA	-0.41	-5.23	-0.32	3.63e-7	Blood protein levels;
KIRP	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.38	5.23	0.32	3.62e-7	Red cell distribution width;
KIRP	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg25319279	chr11:5960081	NA	-0.53	-5.65	-0.34	4.49e-8	DNA methylation (variation);
KIRP	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg18154014	chr19:37997991	ZNF793	0.62	6.81	0.4	7.54e-11	Coronary artery calcification;
KIRP	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-6.91	-0.4	4.13e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs9972944	0.902	rs59009755	chr17:63772263	C/T	cg07283582	chr17:63770753	CCDC46	0.52	8.4	0.47	3.7e-15	Total body bone mineral density;
KIRP	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	cis	rs10214930	0.606	rs4719900	chr7:27568121	T/A	cg22168087	chr7:27702803	HIBADH	0.47	4.89	0.3	1.79e-6	Hypospadias;
KIRP	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.7	-8.06	-0.46	3.43e-14	Corneal astigmatism;
KIRP	cis	rs255758	0.813	rs194281	chr5:53320203	C/T	cg22592108	chr5:53304441	ARL15	0.46	6.02	0.36	6.47e-9	Rheumatoid arthritis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg01604592	chr1:44679056	DMAP1	-0.49	-6.59	-0.39	2.69e-10	Myopia;
KIRP	cis	rs894344	0.812	rs894358	chr8:135600716	C/G	cg09855544	chr8:135498122	ZFAT	0.42	5.62	0.34	5.23e-8	Systolic blood pressure;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24251339	chr6:136571565	FAM54A	0.55	6.11	0.36	3.88e-9	Lung cancer in ever smokers;
KIRP	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.65	-9.67	-0.52	6.02e-19	Body mass index;
KIRP	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.48	4.87	0.3	2.03e-6	Alzheimer's disease;
KIRP	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg05791153	chr7:19748676	TWISTNB	0.67	6.03	0.36	6.13e-9	Thyroid stimulating hormone;
KIRP	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg18192325	chr2:105854051	NA	-0.38	-5.1	-0.31	6.84e-7	Type 2 diabetes;
KIRP	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg06742321	chr12:123595122	PITPNM2	0.41	4.97	0.3	1.27e-6	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1448094	0.645	rs8181635	chr12:86465136	C/T	cg02569458	chr12:86230093	RASSF9	-0.39	-5.32	-0.32	2.32e-7	Major depressive disorder;
KIRP	cis	rs6442310	0.512	rs1175542	chr3:12466214	G/A	cg15873301	chr3:12045459	SYN2	-0.39	-5.25	-0.32	3.25e-7	Hematocrit;
KIRP	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-5.02	-0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs6959887	0.926	rs6462599	chr7:35292420	G/A	cg06685737	chr7:35301730	NA	0.46	6.73	0.39	1.16e-10	Birth weight;
KIRP	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg05342945	chr12:48394962	COL2A1	-0.49	-5.02	-0.3	1e-6	Lung cancer;
KIRP	cis	rs4262150	0.810	rs4473761	chr5:151973508	C/G	cg12297329	chr5:152029980	NA	-0.68	-8.23	-0.46	1.08e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs2033732	0.643	rs9643459	chr8:85058753	A/G	cg05716166	chr8:85095498	RALYL	0.53	6.0	0.36	6.95e-9	Body mass index;
KIRP	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-11.83	-0.6	7.35e-26	Glomerular filtration rate (creatinine);
KIRP	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.98	-0.45	5.55e-14	Retinal vascular caliber;
KIRP	cis	rs7998202	0.614	rs423117	chr13:113346107	C/T	cg04656015	chr13:113407548	ATP11A	0.53	5.52	0.33	8.58e-8	Glycated hemoglobin levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg00253171	chr16:78291326	WWOX	-0.42	-6.14	-0.36	3.28e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs15676	0.838	rs2280841	chr9:131600111	T/C	cg00228799	chr9:131580591	ENDOG	0.59	6.62	0.39	2.27e-10	Blood metabolite levels;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg06009330	chr2:70485380	PCYOX1	-0.43	-6.18	-0.37	2.67e-9	Metabolic traits;
KIRP	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-5.23	-0.32	3.63e-7	Total body bone mineral density;
KIRP	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.66	-12.05	-0.61	1.34e-26	White blood cell count (basophil);
KIRP	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg09165964	chr15:75287851	SCAMP5	0.55	7.09	0.41	1.43e-11	Caffeine consumption;
KIRP	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg13147721	chr7:65941812	NA	-0.9	-6.43	-0.38	6.58e-10	Diabetic kidney disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16232979	chr19:16187631	TPM4	0.47	6.25	0.37	1.84e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.83	12.81	0.63	4.15e-29	Testicular germ cell tumor;
KIRP	cis	rs4132509	1.000	rs10927059	chr1:243852079	T/C	cg25706552	chr1:244017396	NA	0.56	7.3	0.42	4.03e-12	RR interval (heart rate);
KIRP	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.9	-15.6	-0.71	1.3e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20456276	chr12:51157683	ATF1	0.47	6.41	0.38	7.22e-10	Survival in pancreatic cancer;
KIRP	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg02527881	chr3:46936655	PTH1R	-0.58	-9.14	-0.5	2.39e-17	Birth weight;
KIRP	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.51	-7.85	-0.45	1.3e-13	Huntington's disease progression;
KIRP	cis	rs79839061	0.667	rs73207777	chr4:836046	A/G	cg07828340	chr4:882639	GAK	1.12	7.09	0.41	1.4e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06307176	chr5:131281290	NA	0.55	5.94	0.35	9.53e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs17453880	0.852	rs6882013	chr5:152049652	T/C	cg12297329	chr5:152029980	NA	-0.71	-10.56	-0.56	9.55e-22	Subjective well-being;
KIRP	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06544989	chr22:39130855	UNC84B	0.51	8.37	0.47	4.3e-15	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11074549	chr14:75642944	TMED10	0.47	6.1	0.36	3.99e-9	Parkinson's disease;
KIRP	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.88	12.8	0.63	4.49e-29	Mean platelet volume;
KIRP	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg15841412	chr13:111365552	ING1	-0.49	-5.47	-0.33	1.12e-7	Coronary artery disease;
KIRP	cis	rs12580194	0.593	rs7488940	chr12:55802591	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-6.67	-0.39	1.72e-10	Cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02720697	chr19:3359204	NFIC	0.49	6.82	0.4	7.16e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg15704280	chr7:45808275	SEPT13	-0.82	-11.07	-0.58	2.24e-23	Height;
KIRP	cis	rs1816752	0.740	rs6490924	chr13:25007052	G/A	cg22771759	chr13:24902376	NA	-0.4	-5.13	-0.31	5.9e-7	Obesity-related traits;
KIRP	cis	rs7870753	0.578	rs10990975	chr9:99169419	T/G	cg25260653	chr9:99212216	HABP4	0.54	5.0	0.3	1.08e-6	Height;
KIRP	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.34	-0.55	4.65e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6815814	0.768	rs6835514	chr4:38894380	C/T	cg06935464	chr4:38784597	TLR10	-0.52	-5.93	-0.35	1.03e-8	Breast cancer;
KIRP	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.75	10.53	0.56	1.18e-21	Red blood cell count;
KIRP	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	5.08	0.31	7.57e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	1.03	7.47	0.43	1.44e-12	Skin colour saturation;
KIRP	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg04166393	chr7:2884313	GNA12	0.46	6.03	0.36	5.95e-9	Height;
KIRP	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg07424592	chr7:64974309	NA	0.75	4.92	0.3	1.59e-6	Diabetic kidney disease;
KIRP	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg15848620	chr12:58087721	OS9	-0.51	-5.96	-0.36	8.53e-9	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	0.95	10.84	0.57	1.2e-22	Corneal structure;
KIRP	trans	rs61931739	0.620	rs1482981	chr12:33691763	C/G	cg26384229	chr12:38710491	ALG10B	-0.51	-6.12	-0.36	3.72e-9	Morning vs. evening chronotype;
KIRP	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg23601095	chr6:26197514	HIST1H3D	1.1	8.19	0.46	1.46e-14	Gout;Renal underexcretion gout;
KIRP	cis	rs7621025	0.664	rs6439657	chr3:136494639	C/T	cg15507776	chr3:136538369	TMEM22	-0.46	-5.82	-0.35	1.87e-8	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;
KIRP	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg12131826	chr15:77904385	NA	0.44	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.61	7.41	0.43	2.04e-12	Vitamin D levels;
KIRP	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg16797656	chr11:68205561	LRP5	0.37	4.96	0.3	1.34e-6	Total body bone mineral density;
KIRP	cis	rs4356932	0.967	rs4859586	chr4:76943235	T/C	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs988913	0.918	rs7739399	chr6:54855538	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.44	-0.33	1.29e-7	Menarche (age at onset);
KIRP	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.74	-10.52	-0.56	1.29e-21	Hypospadias;
KIRP	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.66	-0.39	1.74e-10	Blood pressure;
KIRP	cis	rs4908768	0.859	rs11121211	chr1:8714239	C/T	cg25722041	chr1:8623473	RERE	0.79	7.03	0.41	2.08e-11	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12292205	chr6:26970375	C6orf41	-0.69	-8.21	-0.46	1.22e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs716804	0.905	rs1372809	chr11:10244105	C/G	cg09106984	chr6:34004360	GRM4	-0.39	-6.26	-0.37	1.7e-9	Neuroticism;
KIRP	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-6.64	-0.39	1.97e-10	Urinary tract infection frequency;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04902049	chr1:36622448	MAP7D1	0.57	6.71	0.39	1.35e-10	Smoking initiation;
KIRP	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.6	7.33	0.42	3.33e-12	Obesity-related traits;
KIRP	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.71	-6.6	-0.39	2.48e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	trans	rs1424233	1.000	rs10514464	chr16:79680413	A/G	cg11120865	chr14:21853037	SUPT16H	0.37	6.17	0.37	2.73e-9	Obesity;
KIRP	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11987759	chr7:65425863	GUSB	-0.53	-7.11	-0.41	1.23e-11	Aortic root size;
KIRP	cis	rs2117029	0.586	rs11168884	chr12:49539892	C/T	cg24176009	chr12:49580217	TUBA1A	-0.37	-5.01	-0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg06521331	chr12:34319734	NA	-0.5	-6.24	-0.37	1.92e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.51	-9.04	-0.5	4.64e-17	Height;
KIRP	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs2241685	0.764	rs12471967	chr2:1941173	G/A	cg22511877	chr2:1942942	MYT1L	-0.65	-6.09	-0.36	4.21e-9	Attention deficit hyperactivity disorder;
KIRP	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.46	5.83	0.35	1.77e-8	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23990949	chr1:43282943	CCDC23;ERMAP	0.46	6.21	0.37	2.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-5.77	-0.35	2.4e-8	Schizophrenia;
KIRP	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.45	6.2	0.37	2.32e-9	Dupuytren's disease;
KIRP	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.5	7.22	0.42	6.65e-12	Blood protein levels;
KIRP	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-5.03	-0.31	9.52e-7	Skin colour saturation;
KIRP	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.59	7.75	0.44	2.35e-13	Response to antipsychotic treatment;
KIRP	cis	rs6016377	0.798	rs6016381	chr20:39180436	T/C	cg22477343	chr20:39312069	NA	0.44	5.74	0.34	2.81e-8	Birth weight;
KIRP	cis	rs9596863	1.000	rs9971999	chr13:54410316	G/A	ch.13.53330881F	chr13:54432880	NA	0.58	5.63	0.34	4.81e-8	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg13010199	chr12:38710504	ALG10B	0.45	5.86	0.35	1.5e-8	Morning vs. evening chronotype;
KIRP	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.65	-10.46	-0.56	1.94e-21	Morning vs. evening chronotype;
KIRP	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg10504392	chr12:110044639	NA	0.28	5.63	0.34	4.93e-8	Neuroticism;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg04369109	chr6:150039330	LATS1	-0.53	-6.61	-0.39	2.39e-10	Lung cancer;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg25937216	chr8:58172855	NA	-0.48	-5.44	-0.33	1.29e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs16854884	1.000	rs34730687	chr3:143813193	A/G	cg06585982	chr3:143692056	C3orf58	0.5	5.09	0.31	7.12e-7	Economic and political preferences (feminism/equality);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02353448	chr8:103439648	NA	0.49	6.14	0.36	3.3e-9	Interleukin-4 levels;
KIRP	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.45	-6.12	-0.36	3.75e-9	Blood protein levels;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg22907277	chr7:1156413	C7orf50	0.68	6.56	0.39	3.09e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.6	7.48	0.43	1.31e-12	Arsenic metabolism;
KIRP	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.08	0.31	7.56e-7	Menopause (age at onset);
KIRP	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.44	6.62	0.39	2.22e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.5	7.4	0.43	2.21e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg10189774	chr4:17578691	LAP3	0.47	5.56	0.33	6.96e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.55	6.13	0.36	3.52e-9	Coronary artery disease;
KIRP	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.35	-5.07	-0.31	7.89e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg11608241	chr8:8085544	FLJ10661	-0.47	-5.81	-0.35	1.9e-8	Joint mobility (Beighton score);
KIRP	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.64	12.39	0.62	1.02e-27	Bone mineral density;
KIRP	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.79e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.11	-13.3	-0.65	8.69e-31	Exhaled nitric oxide output;
KIRP	cis	rs4791746	0.894	rs8077402	chr17:8620785	T/C	cg03115937	chr17:8649504	CCDC42	-0.55	-6.03	-0.36	6.03e-9	Heroin dependence;
KIRP	cis	rs9880211	1.000	rs9826454	chr3:135953220	A/G	cg15507776	chr3:136538369	TMEM22	0.45	4.87	0.3	2e-6	Body mass index;Height;
KIRP	cis	rs7870753	0.628	rs7860871	chr9:99187403	A/G	cg25260653	chr9:99212216	HABP4	0.57	6.11	0.36	3.89e-9	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01219382	chr4:184328462	NA	-0.57	-6.55	-0.39	3.37e-10	Interleukin-4 levels;
KIRP	cis	rs1816752	0.783	rs7317712	chr13:24985503	C/T	cg22771759	chr13:24902376	NA	0.38	4.94	0.3	1.47e-6	Obesity-related traits;
KIRP	cis	rs55692468	0.606	rs6759772	chr2:153322724	C/T	cg04681845	chr2:153283485	FMNL2	-0.52	-6.6	-0.39	2.46e-10	Intraocular pressure;
KIRP	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.45	-6.16	-0.37	3.01e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg00310523	chr12:86230176	RASSF9	0.56	8.49	0.48	1.97e-15	Major depressive disorder;
KIRP	cis	rs6545883	0.839	rs778764	chr2:61785680	C/T	cg15711740	chr2:61764176	XPO1	-0.56	-7.16	-0.42	9.35e-12	Tuberculosis;
KIRP	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.58	0.59	4.79e-25	Monocyte percentage of white cells;
KIRP	trans	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg16141378	chr3:129829833	LOC729375	-0.53	-7.08	-0.41	1.52e-11	Joint mobility (Beighton score);
KIRP	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg23978390	chr7:1156363	C7orf50	0.54	5.9	0.35	1.21e-8	Bronchopulmonary dysplasia;
KIRP	cis	rs11997175	0.603	rs6468199	chr8:33738770	A/C	ch.8.33884649F	chr8:33765107	NA	0.63	7.7	0.44	3.33e-13	Body mass index;
KIRP	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg05527609	chr1:210001259	C1orf107	-0.47	-5.21	-0.32	4.08e-7	Red blood cell count;
KIRP	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg19847130	chr8:10466454	RP1L1	0.37	5.58	0.34	6.28e-8	Triglycerides;
KIRP	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.87	-11.08	-0.58	2.09e-23	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12210905	0.688	rs72843191	chr6:27383301	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.42	-0.38	6.8e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.77	8.8	0.49	2.43e-16	Systolic blood pressure;
KIRP	cis	rs2033732	0.706	rs7826406	chr8:85061639	G/A	cg05716166	chr8:85095498	RALYL	0.53	6.01	0.36	6.75e-9	Body mass index;
KIRP	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-11.65	-0.6	2.95e-25	Mortality in heart failure;
KIRP	cis	rs4253772	0.938	rs14842	chr22:46639457	A/T	cg18190219	chr22:46762943	CELSR1	-0.7	-5.95	-0.35	9.02e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.5	6.74	0.39	1.14e-10	Ulcerative colitis;
KIRP	cis	rs7113874	0.534	rs2311392	chr11:8490436	A/C	cg08015107	chr11:8618950	NA	-0.71	-8.64	-0.48	7.16e-16	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.87	0.49	1.55e-16	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4409675	1.000	rs2815701	chr1:28244854	T/C	cg23691781	chr1:28212827	C1orf38	0.34	6.83	0.4	6.56e-11	Corneal astigmatism;
KIRP	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg13319975	chr6:146136371	FBXO30	-0.38	-4.98	-0.3	1.19e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg01721255	chr8:58191610	C8orf71	0.49	4.88	0.3	1.87e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.75	5.73	0.34	2.89e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg20673091	chr1:2541236	MMEL1	0.79	12.91	0.64	1.81e-29	Ulcerative colitis;
KIRP	cis	rs2916247	1.000	rs11776021	chr8:93025183	A/G	cg10183463	chr8:93005414	RUNX1T1	0.57	7.53	0.43	9.41e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs72772090	0.710	rs17478897	chr5:96062617	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.64	-5.44	-0.33	1.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs539514	0.587	rs7320602	chr13:76332868	A/G	cg04757411	chr13:76259545	LMO7	-0.47	-6.79	-0.4	8.15e-11	Type 1 diabetes;
KIRP	cis	rs1485395	0.945	rs3852552	chr12:54009395	C/T	cg16917193	chr12:54089295	NA	0.62	5.89	0.35	1.27e-8	Migraine without aura;
KIRP	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.02	0.31	9.7e-7	Childhood ear infection;
KIRP	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg18105134	chr13:113819100	PROZ	-1.13	-14.66	-0.68	2.11e-35	Platelet distribution width;
KIRP	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.14	22.32	0.82	4.46e-61	Schizophrenia;
KIRP	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg07395648	chr5:131743802	NA	-0.36	-4.96	-0.3	1.34e-6	Blood metabolite levels;
KIRP	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.42	0.33	1.41e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg14458575	chr2:238380390	NA	0.56	5.79	0.35	2.17e-8	Prostate cancer;
KIRP	cis	rs7814319	0.933	rs7002575	chr8:97242124	G/A	cg20787634	chr8:97240163	UQCRB	-0.7	-11.67	-0.6	2.5e-25	Lung function (FVC);
KIRP	cis	rs2274273	0.624	rs67795323	chr14:55797833	G/A	cg04306507	chr14:55594613	LGALS3	0.39	5.36	0.32	1.93e-7	Protein biomarker;
KIRP	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.3	-6.87	-0.4	5.31e-11	Mean corpuscular volume;
KIRP	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-8.32	-0.47	6.22e-15	Personality dimensions;
KIRP	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	7.74	0.44	2.56e-13	Menarche (age at onset);
KIRP	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg13157960	chr19:33183277	NUDT19	0.59	5.1	0.31	6.78e-7	Red blood cell traits;
KIRP	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	6.66	0.39	1.77e-10	Height;
KIRP	cis	rs4702718	0.674	rs3776414	chr5:10689562	T/G	cg14521931	chr5:10832172	NA	0.41	5.5	0.33	9.49e-8	Obesity-related traits;
KIRP	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg00074818	chr8:8560427	CLDN23	0.41	6.19	0.37	2.54e-9	Obesity-related traits;
KIRP	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13606994	chr1:44402422	ARTN	-0.27	-5.04	-0.31	9.22e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.58	-6.48	-0.38	4.94e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.66	6.59	0.39	2.67e-10	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg05370193	chr1:21551575	ECE1	0.44	6.13	0.36	3.5e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.76e-8	Life satisfaction;
KIRP	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	8.53	0.48	1.55e-15	Mean corpuscular hemoglobin;
KIRP	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-5.07	-0.31	7.93e-7	Psoriasis;
KIRP	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.03	0.31	9.61e-7	Schizophrenia;
KIRP	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg17652424	chr22:38574118	PLA2G6	-0.26	-5.57	-0.33	6.7e-8	Cutaneous nevi;
KIRP	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-4.94	-0.3	1.44e-6	Blood metabolite levels;
KIRP	trans	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.68	-0.39	1.59e-10	Schizophrenia;
KIRP	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg09231725	chr11:64357281	SLC22A12	-0.48	-5.23	-0.32	3.61e-7	Body mass index;Urate levels;
KIRP	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.77	-9.0	-0.5	6.39e-17	Monocyte percentage of white cells;
KIRP	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg06742321	chr12:123595122	PITPNM2	0.41	5.02	0.3	9.97e-7	Neutrophil percentage of white cells;
KIRP	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg00343986	chr7:65444356	GUSB	0.43	5.1	0.31	6.89e-7	Aortic root size;
KIRP	cis	rs7635838	0.819	rs4684782	chr3:11518755	C/T	cg00170343	chr3:11313890	ATG7	-0.48	-6.21	-0.37	2.26e-9	HDL cholesterol;
KIRP	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.74	8.57	0.48	1.15e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg08353955	chr11:69289746	NA	-0.84	-7.73	-0.44	2.66e-13	Breast cancer (early onset);
KIRP	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.97	15.84	0.71	1.94e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg01631408	chr1:248437212	OR2T33	-0.62	-8.33	-0.47	5.57e-15	Common traits (Other);
KIRP	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg26248373	chr2:1572462	NA	-0.62	-5.82	-0.35	1.86e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	1.12	18.66	0.77	4.99e-49	Cognitive function;
KIRP	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.9	-0.6	4.4e-26	Eye color traits;
KIRP	cis	rs9815354	1.000	rs7622259	chr3:41881351	A/T	cg03022575	chr3:42003672	ULK4	0.52	5.97	0.36	8.36e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	1.21	12.77	0.63	5.49e-29	Alzheimer's disease;
KIRP	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg19468946	chr17:37922297	IKZF3	-0.5	-7.36	-0.43	2.67e-12	Self-reported allergy;
KIRP	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg03609598	chr5:56110824	MAP3K1	-0.44	-4.94	-0.3	1.43e-6	Coronary artery disease;
KIRP	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg15117754	chr3:10150083	C3orf24	0.54	5.15	0.31	5.25e-7	Alzheimer's disease;
KIRP	trans	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg04373760	chr16:53404718	NA	0.62	6.79	0.4	8.37e-11	Hypertriglyceridemia;
KIRP	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg26874164	chr19:58962979	ZNF324B	0.47	5.58	0.33	6.45e-8	Uric acid clearance;
KIRP	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.87	-13.05	-0.64	6.19e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg25566285	chr7:158114605	PTPRN2	0.72	8.81	0.49	2.28e-16	Response to amphetamines;
KIRP	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs67366981	1.000	rs17105547	chr14:77698358	G/A	cg22824376	chr14:77648248	TMEM63C	0.84	6.4	0.38	7.79e-10	Obsessive-compulsive symptoms;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17473923	chr12:89745478	DUSP6	0.49	6.24	0.37	1.94e-9	Parkinson's disease;
KIRP	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.04	-18.25	-0.76	1.27e-47	Prudent dietary pattern;
KIRP	cis	rs9653442	0.564	rs11123809	chr2:100758137	C/T	cg17356467	chr2:100759845	AFF3	0.42	6.04	0.36	5.62e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12826209	chr6:26865740	GUSBL1	0.47	6.0	0.36	6.92e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	0.73	6.7	0.39	1.41e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.42	5.26	0.32	3.17e-7	Aortic root size;
KIRP	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.53	6.47	0.38	5.26e-10	Asthma;
KIRP	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg08975724	chr8:8085496	FLJ10661	0.49	5.57	0.33	6.65e-8	Myopia (pathological);
KIRP	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.76	12.71	0.63	8.52e-29	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02561205	chr11:65479380	KAT5	0.51	6.81	0.4	7.59e-11	Parkinson's disease;
KIRP	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	1.0	10.02	0.54	5.01e-20	Lymphocyte counts;
KIRP	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.73	-10.8	-0.57	1.7e-22	Coronary artery disease;
KIRP	cis	rs11264213	0.901	rs72661643	chr1:36451599	A/G	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.48	5.32	0.32	2.38e-7	Body mass index (adult);
KIRP	cis	rs1448094	0.617	rs1502799	chr12:86474921	T/C	cg06740227	chr12:86229804	RASSF9	-0.44	-5.27	-0.32	2.95e-7	Major depressive disorder;
KIRP	cis	rs600806	0.850	rs2140924	chr1:109935775	A/C	cg02175308	chr1:109941060	SORT1	-0.27	-4.94	-0.3	1.47e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1318772	0.577	rs57625584	chr5:112973379	T/A	cg12552261	chr5:112820674	MCC	0.72	4.94	0.3	1.47e-6	F-cell distribution;
KIRP	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg02487422	chr3:49467188	NICN1	0.44	5.65	0.34	4.32e-8	Resting heart rate;
KIRP	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.51	-6.3	-0.37	1.35e-9	Body mass index;
KIRP	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07988820	chr12:82153109	PPFIA2	0.59	7.27	0.42	4.7e-12	Resting heart rate;
KIRP	cis	rs8014252	0.803	rs74062746	chr14:71024944	A/G	cg11204974	chr14:71022665	NA	-0.71	-6.99	-0.41	2.61e-11	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.8	13.14	0.64	3.15e-30	Longevity;Endometriosis;
KIRP	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.55	-6.44	-0.38	6.2e-10	Systemic lupus erythematosus;
KIRP	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.73	7.33	0.42	3.31e-12	Bipolar disorder;
KIRP	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg17507749	chr15:85114479	UBE2QP1	0.8	8.24	0.47	1.02e-14	Schizophrenia;
KIRP	cis	rs9987353	0.620	rs34455383	chr8:9066458	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.28	-0.37	1.51e-9	Recombination measurement;
KIRP	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg08501292	chr6:25962987	TRIM38	1.07	7.71	0.44	3.12e-13	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg01631408	chr1:248437212	OR2T33	0.45	6.09	0.36	4.42e-9	Common traits (Other);
KIRP	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg14169450	chr9:139327907	INPP5E	-0.56	-7.13	-0.41	1.09e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	12.52	0.62	3.74e-28	Menopause (age at onset);
KIRP	cis	rs472402	0.560	rs2288444	chr5:6619923	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.13	-0.31	5.76e-7	Response to amphetamines;
KIRP	cis	rs16976116	0.502	rs7165565	chr15:55452689	T/C	cg11288833	chr15:55489084	RSL24D1	-0.5	-4.84	-0.3	2.25e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.99	-12.9	-0.64	1.97e-29	Platelet distribution width;
KIRP	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.55	-6.82	-0.4	6.91e-11	Platelet distribution width;
KIRP	cis	rs2862064	0.745	rs2902133	chr5:156445687	G/A	cg12943317	chr5:156479607	HAVCR1	-0.79	-7.32	-0.42	3.52e-12	Platelet count;
KIRP	cis	rs6684514	0.922	rs12037778	chr1:156284864	A/G	cg16558208	chr1:156270281	VHLL	-0.44	-5.9	-0.35	1.21e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19524238	chr7:2802976	GNA12	0.37	5.44	0.33	1.3e-7	Height;
KIRP	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.64	-7.75	-0.44	2.35e-13	Facial morphology (factor 19);
KIRP	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.54	-6.0	-0.36	7.03e-9	DNA methylation (variation);
KIRP	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.34	6.91	0.4	4.14e-11	Body mass index;
KIRP	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg09491104	chr22:46646882	C22orf40	-0.53	-6.02	-0.36	6.47e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.36	5.37	0.32	1.84e-7	Survival in rectal cancer;
KIRP	cis	rs740698	0.529	rs9895414	chr17:60793399	A/C	cg13195520	chr17:60813227	MARCH10	-0.59	-9.3	-0.51	7.88e-18	Pulse pressure;
KIRP	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs2970992	0.728	rs1028045	chr2:101321075	G/A	cg01042948	chr2:101319752	NA	-0.49	-7.3	-0.42	4e-12	Educational attainment;
KIRP	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	cg21523751	chr1:182988639	NA	0.45	7.19	0.42	7.9e-12	Colorectal cancer;
KIRP	cis	rs1006703	0.544	rs35299172	chr17:3834598	C/T	cg06463185	chr17:3833770	ATP2A3	0.48	5.12	0.31	6.18e-7	Glucose homeostasis traits;
KIRP	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg12292205	chr6:26970375	C6orf41	0.34	4.85	0.3	2.2e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg13206674	chr6:150067644	NUP43	0.54	7.66	0.44	4.26e-13	Testicular germ cell tumor;
KIRP	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg23216685	chr1:86174607	ZNHIT6	0.51	6.67	0.39	1.69e-10	Urate levels in overweight individuals;
KIRP	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.7	-13.15	-0.64	2.79e-30	White blood cell count (basophil);
KIRP	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.95	11.04	0.58	2.71e-23	Corneal astigmatism;
KIRP	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	11.39	0.59	2.1e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs4764487	0.735	rs1990384	chr12:6342921	G/T	cg08284733	chr12:6341482	CD9	0.57	9.48	0.52	2.22e-18	Mean platelet volume;
KIRP	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	6.87	0.4	5.13e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs7083	1.000	rs507880	chr11:117137255	G/T	cg11523350	chr11:117171073	BACE1	-0.27	-5.35	-0.32	1.97e-7	Blood protein levels;
KIRP	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.92	13.94	0.66	6.07e-33	Intelligence (multi-trait analysis);
KIRP	cis	rs16912285	0.688	rs12805482	chr11:24346955	C/A	ch.11.24196551F	chr11:24239977	NA	0.67	5.97	0.36	8.18e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.6	-6.45	-0.38	5.72e-10	Corneal astigmatism;
KIRP	cis	rs9399401	0.925	rs9496346	chr6:142669338	A/G	cg03128060	chr6:142623767	GPR126	0.31	5.0	0.3	1.1e-6	Chronic obstructive pulmonary disease;
KIRP	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg05220968	chr6:146057943	EPM2A	-0.41	-5.15	-0.31	5.36e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9905704	0.671	rs2068710	chr17:56594535	C/G	cg12560992	chr17:57184187	TRIM37	-0.56	-5.36	-0.32	1.91e-7	Testicular germ cell tumor;
KIRP	cis	rs9309711	0.961	rs11686236	chr2:3471549	G/A	cg10845886	chr2:3471009	TTC15	-0.81	-11.79	-0.6	9.71e-26	Neurofibrillary tangles;
KIRP	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg24874828	chr4:187887005	NA	-0.47	-7.0	-0.41	2.36e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9549328	0.800	rs9549619	chr13:113632620	C/G	cg17524180	chr13:113633600	MCF2L	-0.3	-5.61	-0.34	5.33e-8	Systolic blood pressure;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27309920	chr12:6798957	ZNF384	0.54	6.5	0.38	4.35e-10	Smoking initiation;
KIRP	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg04310649	chr10:35416472	CREM	-0.59	-6.96	-0.41	3.15e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg00684032	chr4:1343700	KIAA1530	0.45	5.41	0.33	1.48e-7	Longevity;
KIRP	cis	rs4764487	0.626	rs4764541	chr12:6313411	A/G	cg08284733	chr12:6341482	CD9	0.33	5.31	0.32	2.43e-7	Mean platelet volume;
KIRP	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	1.1	8.16	0.46	1.73e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs1030268	0.651	rs35711160	chr7:133595233	A/G	cg10665199	chr7:133106180	EXOC4	0.55	5.29	0.32	2.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg13010199	chr12:38710504	ALG10B	-0.48	-5.88	-0.35	1.33e-8	Morning vs. evening chronotype;
KIRP	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg15556689	chr8:8085844	FLJ10661	0.62	7.82	0.45	1.5700000000000001e-13	Retinal vascular caliber;
KIRP	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.97	11.67	0.6	2.51e-25	Corneal astigmatism;
KIRP	cis	rs6969780	0.915	rs17471520	chr7:27178790	T/C	cg26364809	chr7:27145159	NA	-0.59	-5.36	-0.32	1.89e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg16434002	chr17:42200994	HDAC5	-0.55	-6.78	-0.4	8.93e-11	Total body bone mineral density;
KIRP	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.35	0.38	1.04e-9	Intraocular pressure;
KIRP	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.38	-5.05	-0.31	8.77e-7	Neuroticism;
KIRP	cis	rs7225151	0.710	rs55913010	chr17:5246150	A/G	cg24500398	chr17:5266808	RABEP1	-0.58	-5.79	-0.35	2.09e-8	Alzheimer's disease (late onset);
KIRP	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg01522456	chr1:115632236	TSPAN2	-0.37	-5.03	-0.31	9.55e-7	Autism;
KIRP	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs4253772	0.515	rs77797820	chr22:46771270	C/T	cg18190219	chr22:46762943	CELSR1	-0.94	-6.73	-0.39	1.18e-10	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.99	10.52	0.56	1.32e-21	Exhaled nitric oxide output;
KIRP	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg15997130	chr1:24165203	NA	-0.5	-5.96	-0.36	8.64e-9	Immature fraction of reticulocytes;
KIRP	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg22117172	chr7:91764530	CYP51A1	0.42	5.98	0.36	7.64e-9	Breast cancer;
KIRP	cis	rs96067	0.805	rs2231317	chr1:36603290	C/T	cg24686825	chr1:36642396	MAP7D1	-0.43	-5.08	-0.31	7.44e-7	Corneal structure;
KIRP	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27297192	chr10:134578999	INPP5A	0.48	5.95	0.35	9.31e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg12262378	chr17:6899522	ALOX12	0.33	5.77	0.35	2.36e-8	Tonsillectomy;
KIRP	trans	rs656319	0.580	rs13279701	chr8:9969450	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-6.65	-0.39	1.92e-10	Myopia (pathological);
KIRP	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg19507638	chr5:93509721	C5orf36	-0.57	-5.02	-0.3	1.01e-6	Diabetic retinopathy;
KIRP	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg16482183	chr6:26056742	HIST1H1C	0.44	5.61	0.34	5.43e-8	Schizophrenia;
KIRP	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-8.75	-0.49	3.48e-16	Mood instability;
KIRP	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.8	0.35	2.05e-8	Motion sickness;
KIRP	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg10047753	chr17:41438598	NA	1.16	18.83	0.77	1.42e-49	Menopause (age at onset);
KIRP	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12963246	chr6:28129442	ZNF389	-0.48	-6.01	-0.36	6.48e-9	Depression;
KIRP	cis	rs988913	0.706	rs10755776	chr6:54938402	A/C	cg03513858	chr6:54763001	FAM83B	-0.36	-5.12	-0.31	6.16e-7	Menarche (age at onset);
KIRP	cis	rs7084402	0.967	rs3001714	chr10:60285494	A/G	cg05938607	chr10:60274200	BICC1	-0.45	-10.8	-0.57	1.63e-22	Refractive error;
KIRP	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg18350739	chr11:68623251	NA	-0.52	-7.6	-0.44	6.14e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7106204	0.514	rs7126508	chr11:24255147	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs13170463	0.579	rs34410484	chr5:8048305	G/C	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.65	7.66	0.44	4.16e-13	Dental caries;
KIRP	cis	rs6956675	0.915	rs7786464	chr7:62615322	C/A	cg08930214	chr7:62859557	LOC100287834	0.51	5.95	0.35	9.3e-9	Obesity-related traits;
KIRP	trans	rs1133906	0.522	rs1029357	chr7:92762681	A/G	cg14519598	chr9:36906608	PAX5	0.56	6.23	0.37	2.06e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.62	-10.25	-0.55	9.41e-21	Obesity-related traits;
KIRP	trans	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg18648031	chr3:128330563	NA	-0.3	-6.61	-0.39	2.37e-10	Interleukin-6 levels;
KIRP	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-0.97	-9.41	-0.51	3.72e-18	Hip circumference adjusted for BMI;
KIRP	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.86	-10.68	-0.56	4.03e-22	Dupuytren's disease;
KIRP	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg07148914	chr20:33460835	GGT7	-0.43	-5.31	-0.32	2.46e-7	Height;
KIRP	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg22916017	chr11:64110731	CCDC88B	0.51	5.67	0.34	4.06e-8	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs4660306	0.677	rs11211110	chr1:45904815	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-6.62	-0.39	2.23e-10	Homocysteine levels;
KIRP	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg08975724	chr8:8085496	FLJ10661	0.58	7.68	0.44	3.86e-13	Neuroticism;
KIRP	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-23.45	-0.83	1.19e-64	Myeloid white cell count;
KIRP	cis	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg16898833	chr6:26189333	HIST1H4D	0.7	5.57	0.33	6.75e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.58	7.34	0.42	3.1e-12	Aortic root size;
KIRP	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg21360079	chr12:107162445	NA	-0.69	-10.03	-0.54	4.42e-20	Heart rate;
KIRP	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.43	0.52	3.18e-18	IgG glycosylation;
KIRP	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2708977	0.933	rs2579502	chr2:97198800	A/G	cg01950434	chr2:97203154	ARID5A	-0.57	-7.28	-0.42	4.44e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs2522056	1.000	rs2057655	chr5:131807624	A/G	cg24060327	chr5:131705240	SLC22A5	-0.59	-6.07	-0.36	4.82e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs6693567	0.565	rs4926422	chr1:150315436	T/C	cg09579323	chr1:150459698	TARS2	0.4	5.07	0.31	7.86e-7	Migraine;
KIRP	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-1.03	-12.7	-0.63	9.51e-29	Breast cancer;
KIRP	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.58	6.65	0.39	1.84e-10	Axial length;
KIRP	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg20896738	chr21:46707857	POFUT2;LOC642852	0.43	5.1	0.31	6.87e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg00310523	chr12:86230176	RASSF9	0.47	7.57	0.43	7.65e-13	Major depressive disorder;
KIRP	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg10818794	chr15:86012489	AKAP13	-0.51	-7.39	-0.43	2.31e-12	Coronary artery disease;
KIRP	cis	rs2916247	0.954	rs7845969	chr8:93022087	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.6	-7.87	-0.45	1.15e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-9.86	-0.53	1.52e-19	Asthma;
KIRP	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.5	-6.26	-0.37	1.74e-9	Longevity;Endometriosis;
KIRP	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg13010199	chr12:38710504	ALG10B	0.55	6.72	0.39	1.23e-10	Resting heart rate;
KIRP	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg08662619	chr6:150070041	PCMT1	0.32	5.05	0.31	8.5e-7	Testicular germ cell tumor;
KIRP	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.73	-9.25	-0.51	1.14e-17	Coronary artery disease;
KIRP	cis	rs11673344	0.526	rs35153242	chr19:38151742	C/T	cg14683738	chr19:37701593	ZNF585B	0.44	5.32	0.32	2.28e-7	Obesity-related traits;
KIRP	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.58	-7.92	-0.45	8.23e-14	Diastolic blood pressure;
KIRP	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg18944383	chr4:111397179	ENPEP	0.62	11.32	0.59	3.56e-24	Height;
KIRP	cis	rs8133932	0.555	rs374331	chr21:47338218	A/G	cg11214348	chr21:47283868	PCBP3	-0.44	-5.12	-0.31	6.18e-7	Schizophrenia;
KIRP	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12826209	chr6:26865740	GUSBL1	0.45	5.67	0.34	3.98e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	0.9	14.03	0.67	3.01e-33	Breast cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19605749	chr14:93582412	ITPK1	-0.5	-6.18	-0.37	2.64e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.81	-11.86	-0.6	5.94e-26	Height;
KIRP	cis	rs1050631	0.564	rs1789549	chr18:33722425	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.46	0.33	1.17e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs2904967	0.929	rs626802	chr11:65021612	C/A	cg12562828	chr11:65076843	NA	-0.47	-7.19	-0.42	7.79e-12	Mean corpuscular volume;
KIRP	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-4.98	-0.3	1.21e-6	Pulmonary function;
KIRP	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg05315796	chr3:52349193	DNAH1	0.46	7.01	0.41	2.23e-11	Electroencephalogram traits;
KIRP	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg16586182	chr3:47516702	SCAP	0.83	11.83	0.6	7.38e-26	Colorectal cancer;
KIRP	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.68	-0.44	3.74e-13	Lung cancer;
KIRP	cis	rs1448094	0.817	rs10863122	chr12:86346047	T/C	cg02569458	chr12:86230093	RASSF9	0.38	5.52	0.33	8.68e-8	Major depressive disorder;
KIRP	cis	rs7258465	0.965	rs7254249	chr19:18591745	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.91	-0.35	1.12e-8	Breast cancer;
KIRP	cis	rs7916697	0.947	rs7916410	chr10:69995667	T/C	cg18338521	chr10:69995036	NA	0.41	5.13	0.31	5.96e-7	Optic disc area;
KIRP	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.58	-8.74	-0.49	3.59e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg26384229	chr12:38710491	ALG10B	0.71	9.62	0.52	8.5e-19	Morning vs. evening chronotype;
KIRP	cis	rs7215564	0.730	rs4889877	chr17:78662459	A/C	cg06153925	chr17:78755379	RPTOR	0.32	5.21	0.32	3.97e-7	Myopia (pathological);
KIRP	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg15117754	chr3:10150083	C3orf24	0.55	5.24	0.32	3.5e-7	Alzheimer's disease;
KIRP	cis	rs882732	0.576	rs12895360	chr14:95038922	T/C	cg08495878	chr14:95027859	SERPINA4	-0.44	-5.54	-0.33	7.8e-8	Blood protein levels;
KIRP	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.44	5.05	0.31	8.44e-7	Schizophrenia;
KIRP	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.44	-6.09	-0.36	4.2e-9	Lymphocyte counts;
KIRP	cis	rs311392	0.525	rs2013503	chr8:55104343	C/T	cg20636351	chr8:55087400	NA	-0.54	-6.62	-0.39	2.2e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.26	-5.42	-0.33	1.45e-7	Menarche (age at onset);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00861635	chr16:3285425	ZNF200	-0.47	-6.14	-0.36	3.31e-9	Myopia;
KIRP	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg23803603	chr1:2058230	PRKCZ	0.37	5.56	0.33	7.18e-8	Height;
KIRP	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.76	-11.62	-0.6	3.64e-25	Prostate cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08078213	chr17:79479165	ACTG1	0.48	6.6	0.39	2.49e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.41	6.01	0.36	6.73e-9	Menarche (age at onset);
KIRP	cis	rs11169552	0.510	rs55877451	chr12:50987378	G/A	cg12884762	chr12:50931848	DIP2B	-0.42	-4.93	-0.3	1.49e-6	Colorectal cancer;
KIRP	cis	rs9914544	1.000	rs1634409	chr17:18836177	C/T	cg26306683	chr17:18585705	ZNF286B	0.66	7.93	0.45	7.8e-14	Educational attainment (years of education);
KIRP	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.06	20.06	0.79	1.06e-53	Testicular germ cell tumor;
KIRP	cis	rs6005807	0.719	rs7293232	chr22:29015590	T/G	cg12565055	chr22:29076175	TTC28	0.58	5.03	0.31	9.62e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.79	-9.16	-0.5	2.08e-17	Post bronchodilator FEV1;
KIRP	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.89e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18252515	chr7:66147081	NA	-0.41	-4.86	-0.3	2.13e-6	Aortic root size;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.61	-7.72	-0.44	2.85e-13	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.33	0.51	6.33e-18	Lymphocyte counts;
KIRP	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg02297831	chr4:17616191	MED28	0.58	7.45	0.43	1.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.43	5.42	0.33	1.44e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs72634258	0.786	rs4405150	chr1:8173672	T/C	cg00042356	chr1:8021962	PARK7	-0.51	-4.97	-0.3	1.28e-6	Inflammatory bowel disease;
KIRP	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	5.81	0.35	1.93e-8	Bipolar disorder;
KIRP	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg26022315	chr17:47021804	SNF8	0.42	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg18132916	chr6:79620363	NA	-0.4	-5.47	-0.33	1.12e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-16.37	-0.72	2.95e-41	Height;
KIRP	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.53	6.84	0.4	6.23e-11	IgG glycosylation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26956494	chr5:64313909	SDCCAG10	0.46	6.96	0.41	3.01e-11	Survival in pancreatic cancer;
KIRP	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg12559939	chr2:27858050	GPN1	0.4	4.9	0.3	1.74e-6	Total body bone mineral density;
KIRP	cis	rs4481887	0.830	rs4364913	chr1:248515635	C/A	cg00666640	chr1:248458726	OR2T12	0.37	4.87	0.3	2.02e-6	Common traits (Other);
KIRP	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.69	9.63	0.52	7.81e-19	Post bronchodilator FEV1;
KIRP	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg08126542	chr6:37504118	NA	-0.72	-10.06	-0.54	3.75e-20	Cognitive performance;
KIRP	cis	rs6594713	0.717	rs2972690	chr5:112945945	T/C	cg12552261	chr5:112820674	MCC	-0.53	-5.05	-0.31	8.55e-7	Brain cytoarchitecture;
KIRP	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg06226150	chr20:62369956	SLC2A4RG;LIME1	-0.31	-4.88	-0.3	1.87e-6	Prostate cancer;
KIRP	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05025164	chr4:1340916	KIAA1530	0.42	5.23	0.32	3.6e-7	Obesity-related traits;
KIRP	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg16141378	chr3:129829833	LOC729375	0.61	8.12	0.46	2.31e-14	Neuroticism;
KIRP	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.69	9.73	0.53	4e-19	Prostate cancer;
KIRP	trans	rs9443189	0.950	rs6938349	chr6:76484280	A/T	cg06311355	chr22:24577269	SUSD2	0.31	6.09	0.36	4.33e-9	Prostate cancer;
KIRP	cis	rs6693567	0.565	rs834243	chr1:150339290	C/A	cg09579323	chr1:150459698	TARS2	0.4	5.01	0.3	1.04e-6	Migraine;
KIRP	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	4.96	0.3	1.34e-6	Tonsillectomy;
KIRP	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.33	6.05	0.36	5.31e-9	Renal cell carcinoma;
KIRP	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg13319975	chr6:146136371	FBXO30	0.46	6.11	0.36	3.89e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.58	7.96	0.45	6.45e-14	Coronary artery disease;
KIRP	cis	rs7394190	1.000	rs7394190	chr10:75421648	G/A	cg04833713	chr10:74871078	NUDT13	0.41	5.62	0.34	5.13e-8	Incident atrial fibrillation;
KIRP	cis	rs7116495	1.000	rs3750908	chr11:71822401	A/G	cg11196788	chr11:71737549	NUMA1	-0.55	-4.86	-0.3	2.07e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg04013166	chr16:89971882	TCF25	0.67	5.64	0.34	4.54e-8	Skin colour saturation;
KIRP	cis	rs6901250	0.569	rs686708	chr6:117091683	A/G	cg12892004	chr6:117198278	RFX6	0.39	6.32	0.37	1.25e-9	C-reactive protein levels;
KIRP	cis	rs7301016	0.817	rs7302456	chr12:62997643	G/T	cg01804193	chr12:63026212	NA	0.53	5.87	0.35	1.42e-8	IgG glycosylation;
KIRP	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.45	6.76	0.4	1.01e-10	Major depressive disorder;
KIRP	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-19.3	-0.78	3.74e-51	Height;
KIRP	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg06565975	chr8:143823917	SLURP1	0.47	7.49	0.43	1.24e-12	Urinary tract infection frequency;
KIRP	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.57	-4.89	-0.3	1.83e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs6723108	0.534	rs1016120	chr2:135547289	G/A	cg25422880	chr2:135218333	TMEM163	-0.44	-6.14	-0.36	3.29e-9	Type 2 diabetes;
KIRP	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18252515	chr7:66147081	NA	-0.44	-5.11	-0.31	6.59e-7	Aortic root size;
KIRP	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15128208	chr22:42549153	NA	-0.43	-5.4	-0.33	1.58e-7	Cognitive function;
KIRP	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.53	7.39	0.43	2.27e-12	Mean corpuscular volume;
KIRP	cis	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg08501292	chr6:25962987	TRIM38	0.91	6.48	0.38	5.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1215050	0.791	rs2865942	chr4:98737709	G/C	cg05340658	chr4:99064831	C4orf37	0.57	6.84	0.4	6.26e-11	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.96	-14.67	-0.68	1.99e-35	Coronary artery disease;
KIRP	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg13271783	chr10:134563150	INPP5A	-0.54	-6.8	-0.4	8.01e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg05360138	chr12:110035743	NA	0.6	5.94	0.35	9.7e-9	Neuroticism;
KIRP	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.84	0.49	1.83e-16	Bipolar disorder;
KIRP	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.7	10.6	0.56	7.4e-22	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	trans	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg03929089	chr4:120376271	NA	0.73	6.51	0.38	4.09e-10	Axial length;
KIRP	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.87	12.71	0.63	8.45e-29	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-1.0	-7.1	-0.41	1.34e-11	Obesity (early onset extreme);
KIRP	cis	rs7937612	1.000	rs4938804	chr11:120273865	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.48	-7.29	-0.42	4.33e-12	Intraocular pressure;
KIRP	cis	rs7180079	0.620	rs11071815	chr15:65089346	T/G	cg15337035	chr15:64978493	NA	-0.48	-5.27	-0.32	3.01e-7	Monocyte count;
KIRP	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.79	-9.86	-0.53	1.55e-19	Blood trace element (Zn levels);
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.5	-5.7	-0.34	3.4e-8	Longevity;Endometriosis;
KIRP	cis	rs8033133	0.560	rs11161166	chr15:25324677	A/T	cg14481604	chr15:25334117	SNORD116-22	0.4	4.93	0.3	1.49e-6	Blood osmolality (transformed sodium);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24122247	chr3:10068142	FANCD2;CIDECP	0.49	6.07	0.36	4.85e-9	Parkinson's disease;
KIRP	cis	rs584438	0.873	rs1009570	chr17:38596425	A/G	cg09213124	chr17:38599508	IGFBP4	0.3	5.14	0.31	5.49e-7	Height;
KIRP	cis	rs8018808	0.935	rs4223	chr14:77893276	A/G	cg18872420	chr14:78023429	SPTLC2	-0.34	-5.07	-0.31	7.8e-7	Myeloid white cell count;
KIRP	trans	rs12659622	0.850	rs4702087	chr5:15609920	A/G	cg09887955	chr1:202129854	PTPN7	0.52	6.09	0.36	4.42e-9	Obesity-related traits;
KIRP	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6546886	0.912	rs4852326	chr2:74272418	T/C	cg14702570	chr2:74259524	NA	-0.29	-5.69	-0.34	3.68e-8	Dialysis-related mortality;
KIRP	cis	rs6539288	0.677	rs2216221	chr12:107327231	A/T	cg21360079	chr12:107162445	NA	-0.44	-5.52	-0.33	8.74e-8	Total body bone mineral density;
KIRP	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg00405596	chr8:11794950	NA	-0.49	-6.58	-0.39	2.89e-10	Monocyte count;
KIRP	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.6	9.26	0.51	1.05e-17	Personality dimensions;
KIRP	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.89	11.4	0.59	1.88e-24	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs13361707	0.685	rs3763074	chr5:40838022	A/C	cg01087697	chr5:40835557	RPL37	-0.4	-4.95	-0.3	1.36e-6	Gastric cancer;Non-cardia gastric cancer;
KIRP	trans	rs6432860	0.642	rs6756388	chr2:166730160	C/A	cg13971571	chr8:6693247	XKR5	0.53	6.49	0.38	4.66e-10	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;
KIRP	cis	rs2380220	0.872	rs7750757	chr6:95997118	A/G	cg04719120	chr6:96025338	MANEA	0.59	5.07	0.31	7.76e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg25036284	chr2:26402008	FAM59B	-0.52	-5.42	-0.33	1.41e-7	Gut microbiome composition (summer);
KIRP	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg16141378	chr3:129829833	LOC729375	0.49	6.06	0.36	5.21e-9	Neuroticism;
KIRP	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg13699009	chr12:122356056	WDR66	0.73	11.76	0.6	1.28e-25	Mean corpuscular volume;
KIRP	cis	rs6545883	0.811	rs778753	chr2:61780200	T/A	cg15711740	chr2:61764176	XPO1	-0.56	-7.29	-0.42	4.29e-12	Tuberculosis;
KIRP	cis	rs732716	0.785	rs62129354	chr19:4396505	G/A	cg19820705	chr19:4455316	UBXN6	0.68	8.36	0.47	4.75e-15	Mean corpuscular volume;
KIRP	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.66	-6.78	-0.4	8.62e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.48	6.48	0.38	4.92e-10	Red blood cell count;
KIRP	cis	rs732716	0.819	rs12459919	chr19:4434503	C/T	cg21720385	chr19:4455239	UBXN6	0.71	8.82	0.49	2.1e-16	Mean corpuscular volume;
KIRP	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-9.06	-0.5	4.28e-17	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-9.2	-0.51	1.54e-17	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.63	7.24	0.42	5.64e-12	Prudent dietary pattern;
KIRP	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	8.43	0.47	2.97e-15	Neuroticism;
KIRP	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.81	11.17	0.58	1.05e-23	Aortic root size;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg20935368	chr5:178288625	ZNF354B	0.42	5.66	0.34	4.29e-8	Sleep duration;
KIRP	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg21775007	chr8:11205619	TDH	-0.46	-6.33	-0.37	1.14e-9	Neuroticism;
KIRP	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Tonsillectomy;
KIRP	cis	rs3736594	0.879	rs4666011	chr2:27980912	G/C	cg27432699	chr2:27873401	GPN1	0.48	5.63	0.34	4.98e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	1.08	17.53	0.75	3.39e-45	Cognitive function;
KIRP	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg18154014	chr19:37997991	ZNF793	0.7	7.7	0.44	3.27e-13	Coronary artery calcification;
KIRP	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.83	12.42	0.62	8.08e-28	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.67	-7.98	-0.45	5.74e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.48	-0.43	1.33e-12	Morning vs. evening chronotype;
KIRP	cis	rs3931020	0.548	rs2134836	chr1:75271646	C/T	cg17719053	chr1:75198211	TYW3;CRYZ	0.43	5.95	0.35	9.01e-9	Resistin levels;
KIRP	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-1.09	-17.92	-0.75	1.62e-46	Cognitive function;
KIRP	cis	rs7224685	0.501	rs711178	chr17:3922918	A/G	cg01798813	chr17:3906674	NA	0.56	7.94	0.45	7e-14	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg09699651	chr6:150184138	LRP11	0.54	7.11	0.41	1.27e-11	Lung cancer;
KIRP	cis	rs9912789	0.875	rs9892075	chr17:79186737	T/C	cg09314803	chr17:79180344	AZI1	-0.67	-10.72	-0.56	2.99e-22	Frontotemporal dementia;
KIRP	cis	rs6662572	0.737	rs56301932	chr1:46422086	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.64	0.34	4.72e-8	Blood protein levels;
KIRP	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg26811252	chr16:29126840	RRN3P2	0.63	8.41	0.47	3.42e-15	Menopause (age at onset);
KIRP	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.59	8.05	0.46	3.55e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9311676	0.632	rs11130631	chr3:58366128	G/C	cg06643156	chr3:58380774	PXK	0.36	5.1	0.31	6.66e-7	Systemic lupus erythematosus;
KIRP	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg16482183	chr6:26056742	HIST1H1C	0.43	5.02	0.31	9.71e-7	Iron status biomarkers;
KIRP	cis	rs13006833	1.000	rs13006833	chr2:191205499	G/C	cg21644426	chr2:191273491	MFSD6	0.47	5.74	0.34	2.8e-8	Urinary metabolites;
KIRP	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11987759	chr7:65425863	GUSB	0.49	6.3	0.37	1.39e-9	Aortic root size;
KIRP	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.17	-0.46	1.59e-14	Mean corpuscular volume;
KIRP	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.56	7.33	0.42	3.3e-12	Obesity-related traits;
KIRP	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.89	11.69	0.6	2.1e-25	Bipolar disorder and schizophrenia;
KIRP	cis	rs11718455	0.538	rs1524887	chr3:44016371	C/T	cg08738300	chr3:44038990	NA	0.48	7.31	0.42	3.74e-12	Coronary artery disease;
KIRP	trans	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg13565492	chr6:43139072	SRF	-0.8	-7.66	-0.44	4.16e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.82	-0.35	1.8e-8	Breast cancer;
KIRP	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg15676125	chr6:33679581	C6orf125	0.39	5.05	0.31	8.64e-7	Plateletcrit;
KIRP	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg21452805	chr1:244014465	NA	0.7	5.92	0.35	1.07e-8	RR interval (heart rate);
KIRP	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21214613	chr1:16344536	HSPB7	0.36	5.14	0.31	5.54e-7	Dilated cardiomyopathy;
KIRP	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.72	10.38	0.55	3.56e-21	High light scatter reticulocyte count;
KIRP	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg06636001	chr8:8085503	FLJ10661	0.75	10.61	0.56	6.47e-22	Mood instability;
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs244731	0.881	rs62397242	chr5:176738538	C/A	cg16006841	chr5:176797999	RGS14	0.62	6.83	0.4	6.78e-11	Urate levels in lean individuals;
KIRP	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.66	-10.07	-0.54	3.5e-20	Total body bone mineral density;
KIRP	trans	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg24644049	chr4:85504048	CDS1	1.02	6.8	0.4	7.99e-11	Skin colour saturation;
KIRP	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg12140854	chr5:148520817	ABLIM3	-0.52	-5.97	-0.36	8.03e-9	Breast cancer;
KIRP	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg00277334	chr10:82204260	NA	-0.45	-4.95	-0.3	1.41e-6	Post bronchodilator FEV1;
KIRP	cis	rs698833	0.886	rs4953091	chr2:44565266	A/C	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-5.16	-0.31	5.18e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1440410	0.835	rs13116414	chr4:144147626	T/G	cg01719995	chr4:144104893	USP38	0.38	5.06	0.31	8.38e-7	Ischemic stroke;
KIRP	cis	rs6563210	0.789	rs9545680	chr13:36482548	G/C	cg19801062	chr13:36872135	C13orf38	-0.48	-5.34	-0.32	2.14e-7	Height;
KIRP	cis	rs9400467	0.528	rs458486	chr6:111696852	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.8	-0.35	1.98e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg19847130	chr8:10466454	RP1L1	-0.38	-5.39	-0.33	1.63e-7	Retinal vascular caliber;
KIRP	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.52	-6.58	-0.39	2.82e-10	High light scatter reticulocyte count;
KIRP	cis	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg12315302	chr6:26189340	HIST1H4D	0.83	5.21	0.32	4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.4	-5.05	-0.31	8.73e-7	Carotid intima media thickness;
KIRP	cis	rs12580194	0.593	rs67015069	chr12:55759968	T/A	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.56	6.79	0.4	8.15e-11	Monocyte count;
KIRP	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg23985595	chr17:80112537	CCDC57	-0.35	-5.04	-0.31	9.06e-7	Life satisfaction;
KIRP	cis	rs1971762	0.545	rs10783585	chr12:53977317	T/G	cg16917193	chr12:54089295	NA	0.72	11.7	0.6	1.9e-25	Height;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03503288	chr13:20660277	ZMYM2	-0.39	-6.11	-0.36	3.79e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.67	-0.56	4.28e-22	Chronic sinus infection;
KIRP	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg07148914	chr20:33460835	GGT7	-0.53	-7.27	-0.42	4.8e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg19847130	chr8:10466454	RP1L1	0.37	5.63	0.34	4.87e-8	Triglycerides;
KIRP	cis	rs1983891	1.000	rs913074	chr6:41538545	T/C	cg20194872	chr6:41519635	FOXP4	0.48	6.22	0.37	2.07e-9	Prostate cancer;
KIRP	cis	rs6088813	0.635	rs17323916	chr20:33910581	G/A	cg14752227	chr20:34000481	UQCC	0.45	5.05	0.31	8.42e-7	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08555160	chr16:69166339	CHTF8;CIRH1A	0.47	6.15	0.37	3.17e-9	Parkinson's disease;
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.87	0.3	1.97e-6	Lung cancer;
KIRP	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.46	5.28	0.32	2.77e-7	Height;
KIRP	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg18198730	chr1:247681584	NA	0.6	5.67	0.34	3.94e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg22117172	chr7:91764530	CYP51A1	0.42	5.94	0.35	9.56e-9	Breast cancer;
KIRP	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg02475777	chr4:1388615	CRIPAK	0.54	5.01	0.3	1.02e-6	Recombination rate (females);
KIRP	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg02297831	chr4:17616191	MED28	0.54	6.84	0.4	6.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2594989	0.943	rs901865	chr3:11300707	T/C	cg01796438	chr3:11312864	ATG7	-0.6	-7.01	-0.41	2.34e-11	Circulating chemerin levels;
KIRP	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg01065977	chr19:18549689	ISYNA1	-0.41	-6.37	-0.38	9.06e-10	Breast cancer;
KIRP	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.88	9.81	0.53	2.15e-19	Gut microbiome composition (summer);
KIRP	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg11234688	chr2:1609660	NA	0.58	5.28	0.32	2.79e-7	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs12540874	0.524	rs4947684	chr7:50637799	G/A	cg04490037	chr7:50633773	DDC	0.38	4.92	0.3	1.58e-6	Systemic sclerosis;
KIRP	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg01028140	chr2:1542097	TPO	-0.64	-6.39	-0.38	8.32e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg18944383	chr4:111397179	ENPEP	0.4	6.22	0.37	2.14e-9	Height;
KIRP	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.99	-11.4	-0.59	1.92e-24	Colorectal cancer;
KIRP	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.77	9.95	0.54	8.22e-20	Coronary artery disease;
KIRP	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-6.12	-0.36	3.7e-9	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-8.7	-0.49	4.74e-16	Total body bone mineral density;
KIRP	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.66	10.06	0.54	3.76e-20	Coronary artery disease;
KIRP	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.89	-0.57	8.2000000000000006e-23	Menopause (age at onset);
KIRP	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.74	9.36	0.51	5.23e-18	Prudent dietary pattern;
KIRP	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg20140201	chr2:241835670	C2orf54	-0.35	-5.32	-0.32	2.31e-7	Urinary metabolites;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16529639	chr3:32726786	CNOT10	0.55	6.15	0.37	3.1e-9	Lung cancer in ever smokers;
KIRP	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg16141378	chr3:129829833	LOC729375	0.55	7.43	0.43	1.83e-12	Neuroticism;
KIRP	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.63	-8.58	-0.48	1.09e-15	Hip circumference adjusted for BMI;
KIRP	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-1.1	-20.79	-0.8	4.34e-56	Height;
KIRP	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg02570527	chr1:10970165	NA	-0.42	-5.12	-0.31	6.11e-7	Body mass index;
KIRP	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg03959625	chr15:84868606	LOC388152	0.72	8.6	0.48	9.33e-16	Schizophrenia;
KIRP	cis	rs5753037	0.869	rs5763591	chr22:30298186	A/G	cg27665648	chr22:30112403	NA	0.39	5.48	0.33	1.04e-7	Type 1 diabetes;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg24642844	chr7:1081250	C7orf50	-0.53	-6.63	-0.39	2.07e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9843304	0.616	rs34783865	chr3:149205792	A/G	cg08667024	chr3:149219783	TM4SF4	-0.43	-5.85	-0.35	1.59e-8	Gallstone disease;
KIRP	cis	rs4356932	1.000	rs11097212	chr4:76952879	A/G	cg19388996	chr4:76862389	NAAA	0.39	5.03	0.31	9.27e-7	Blood protein levels;
KIRP	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.68	6.09	0.36	4.43e-9	Schizophrenia;
KIRP	cis	rs12210905	0.541	rs56099947	chr6:27490937	G/T	cg08851530	chr6:28072375	NA	0.87	5.01	0.3	1.04e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.61	8.11	0.46	2.4e-14	Lung cancer;
KIRP	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg01620082	chr3:125678407	NA	-1.16	-7.26	-0.42	4.96e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg07001201	chr5:642380	CEP72	0.7	6.47	0.38	5.25e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg07167872	chr1:205819463	PM20D1	0.46	5.03	0.31	9.67e-7	Parkinson's disease;
KIRP	cis	rs4936894	0.500	rs4936917	chr11:124179656	G/T	cg27160556	chr11:124181099	OR8D1	-0.45	-6.4	-0.38	7.61e-10	Aging (time to death);
KIRP	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg00129232	chr17:37814104	STARD3	0.64	7.42	0.43	1.88e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.23	0.46	1.12e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.56	6.84	0.4	6.39e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.81	-12.75	-0.63	6.13e-29	Dental caries;
KIRP	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg14972814	chr11:95582409	MTMR2	0.35	5.76	0.34	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs4356932	0.967	rs13113632	chr4:76972516	C/T	cg19388996	chr4:76862389	NAAA	0.4	5.16	0.31	5.05e-7	Blood protein levels;
KIRP	cis	rs6901250	0.523	rs592669	chr6:117090944	T/C	cg05399210	chr6:117082661	FAM162B	-0.48	-6.87	-0.4	5.16e-11	C-reactive protein levels;
KIRP	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.87	-11.08	-0.58	2.1e-23	Parkinson's disease;
KIRP	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg10761708	chr20:43804764	PI3	0.5	5.2	0.31	4.22e-7	Blood protein levels;
KIRP	cis	rs9309473	1.000	rs3738848	chr2:73761881	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-5.26	-0.32	3.06e-7	Metabolite levels;
KIRP	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg19610905	chr11:61596333	FADS2	-0.55	-8.32	-0.47	6e-15	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg02775129	chr4:119771670	NA	-0.82	-4.88	-0.3	1.94e-6	Cannabis dependence symptom count;
KIRP	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.57	0.73	6.1e-42	Electrocardiographic conduction measures;
KIRP	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.34	5.28	0.32	2.89e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.25	-0.37	1.85e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-0.79	-7.7	-0.44	3.32e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg19313758	chr11:64889193	FAU;MRPL49	0.48	6.24	0.37	1.93e-9	Pneumonia;
KIRP	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	1.01	20.02	0.79	1.42e-53	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.44	0.38	6.19e-10	Putamen volume;
KIRP	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.63	7.74	0.44	2.64e-13	Corneal astigmatism;
KIRP	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.69	8.86	0.49	1.62e-16	Blood metabolite levels;
KIRP	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.4	-5.23	-0.32	3.59e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg16586182	chr3:47516702	SCAP	0.68	9.16	0.5	2.08e-17	Colorectal cancer;
KIRP	cis	rs11673344	0.526	rs1871196	chr19:38146923	T/G	cg14683738	chr19:37701593	ZNF585B	-0.44	-5.34	-0.32	2.12e-7	Obesity-related traits;
KIRP	cis	rs2274273	0.588	rs2880103	chr14:55737832	A/C	cg04306507	chr14:55594613	LGALS3	0.4	5.55	0.33	7.5e-8	Protein biomarker;
KIRP	cis	rs4671458	0.948	rs72813478	chr2:63526869	T/C	cg17519650	chr2:63277830	OTX1	-0.53	-5.38	-0.32	1.74e-7	Subjective well-being;
KIRP	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg21361702	chr7:150065534	REPIN1	0.6	6.38	0.38	8.61e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00300879	chr1:26503847	CNKSR1	0.47	6.55	0.39	3.25e-10	Height;
KIRP	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg12692727	chr7:1102344	C7orf50	0.45	4.9	0.3	1.7e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09640425	chr7:158790006	NA	-0.4	-4.87	-0.3	2.03e-6	Facial morphology (factor 20);
KIRP	cis	rs1847505	0.957	rs1394311	chr13:61523310	C/T	cg25164009	chr13:61490935	NA	-0.58	-6.35	-0.38	1.02e-9	Polychlorinated biphenyl levels;
KIRP	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg12598211	chr12:123634384	NA	-0.44	-5.38	-0.32	1.71e-7	Neutrophil percentage of white cells;
KIRP	cis	rs490234	0.934	rs13293237	chr9:128430966	T/C	cg14078157	chr9:128172775	NA	-0.58	-6.96	-0.41	3.09e-11	Mean arterial pressure;
KIRP	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg17554472	chr22:41940697	POLR3H	0.65	6.61	0.39	2.39e-10	Vitiligo;
KIRP	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg07843065	chr1:150265600	MRPS21	0.44	6.22	0.37	2.14e-9	Migraine;
KIRP	cis	rs2071426	0.652	rs11812285	chr10:96760812	A/C	cg09036531	chr10:96991505	NA	-0.45	-5.25	-0.32	3.21e-7	Blood metabolite levels;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg09400194	chr10:81107848	PPIF	0.5	6.02	0.36	6.26e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg19554555	chr3:13937349	NA	-0.46	-6.17	-0.37	2.84e-9	Ovarian reserve;
KIRP	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.59	6.95	0.41	3.29e-11	Corneal astigmatism;
KIRP	cis	rs3857747	0.861	rs4723962	chr7:40453414	A/T	cg00420559	chr7:40367873	C7orf10	-0.56	-7.95	-0.45	6.97e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9346649	0.967	rs6915427	chr6:168490000	A/T	cg09211372	chr6:168490623	NA	-0.31	-5.62	-0.34	5.28e-8	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
KIRP	cis	rs9914544	1.000	rs1634411	chr17:18833810	C/T	cg26378065	chr17:18585709	ZNF286B	0.6	7.24	0.42	5.79e-12	Educational attainment (years of education);
KIRP	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	cg04338863	chr8:33670619	NA	0.41	5.24	0.32	3.42e-7	Body mass index;
KIRP	cis	rs6859018	0.658	rs112377695	chr5:158748012	C/T	cg26646896	chr5:158686746	NA	-0.34	-4.94	-0.3	1.47e-6	Serum sulfate level;
KIRP	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	16.29	0.72	5.64e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg23307798	chr14:103986281	CKB	0.76	13.18	0.64	2.21e-30	Body mass index;
KIRP	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	10.72	0.56	3.05e-22	Lung cancer in ever smokers;
KIRP	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.46	-6.61	-0.39	2.43e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1050631	1.000	rs2236718	chr18:33705135	G/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.46	5.89	0.35	1.23e-8	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.26	-0.51	1.04e-17	Rheumatoid arthritis;
KIRP	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.19	-16.05	-0.72	3.66e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg07148914	chr20:33460835	GGT7	-0.55	-7.24	-0.42	5.68e-12	Height;
KIRP	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg03808351	chr9:123631620	PHF19	0.43	5.85	0.35	1.57e-8	Hip circumference adjusted for BMI;
KIRP	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-8.37	-0.47	4.31e-15	Life satisfaction;
KIRP	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.66	-6.1	-0.36	4.05e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.75	-10.29	-0.55	7.08e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg21518248	chr2:162101506	NA	-0.44	-5.23	-0.32	3.55e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.41	6.3	0.37	1.36e-9	Lipoprotein (a) levels;
KIRP	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg26913058	chr16:419975	MRPL28	-0.45	-5.48	-0.33	1.04e-7	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4356932	1.000	rs6844097	chr4:76950757	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.89	0.3	1.8e-6	Blood protein levels;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.73	0.44	2.69e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg07382826	chr16:28625726	SULT1A1	0.49	5.79	0.35	2.12e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.92	13.42	0.65	3.47e-31	Bladder cancer;
KIRP	cis	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg24476569	chr13:95954382	ABCC4	-0.59	-9.17	-0.5	2.02e-17	Blood metabolite levels;
KIRP	cis	rs77861329	0.920	rs9846049	chr3:52120214	A/G	cg08692210	chr3:52188851	WDR51A	0.93	7.57	0.43	7.38e-13	Macrophage inflammatory protein 1b levels;
KIRP	trans	rs17079247	0.841	rs1038737	chr13:85805632	G/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.82e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg09936142	chr19:10668400	KRI1	-0.42	-4.9	-0.3	1.71e-6	Inflammatory skin disease;
KIRP	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.74	9.46	0.52	2.63e-18	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs7615316	0.934	rs2227928	chr3:142281612	A/G	cg20824294	chr3:142316082	PLS1	0.22	4.99	0.3	1.15e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg01879757	chr17:41196368	BRCA1	-0.79	-10.89	-0.57	8.2000000000000006e-23	Menopause (age at onset);
KIRP	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	6.07	0.36	4.85e-9	Colorectal cancer;
KIRP	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg03929089	chr4:120376271	NA	0.7	6.14	0.36	3.33e-9	Axial length;
KIRP	cis	rs78487399	0.808	rs6544668	chr2:43732488	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-5.06	-0.31	8.28e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.54	-6.86	-0.4	5.57e-11	Type 2 diabetes;
KIRP	cis	rs4356975	0.563	rs58544196	chr4:69963458	C/A	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs7770628	0.682	rs7772437	chr6:161115245	A/T	cg14663533	chr6:160955178	LPA	0.41	5.5	0.33	9.32e-8	Protein quantitative trait loci;Lipoprotein (a) levels;
KIRP	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-10.23	-0.55	1.06e-20	Total body bone mineral density;
KIRP	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.76	6.66	0.39	1.78e-10	Body mass index;
KIRP	cis	rs5756391	0.546	rs5756405	chr22:37310954	A/G	cg16356956	chr22:37317934	CSF2RB	0.42	5.74	0.34	2.72e-8	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg01620082	chr3:125678407	NA	-1.14	-7.3	-0.42	4.03e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-9.09	-0.5	3.49e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg07541023	chr7:19748670	TWISTNB	0.93	7.84	0.45	1.37e-13	Thyroid stimulating hormone;
KIRP	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	1.09	10.46	0.55	2.05e-21	Nonalcoholic fatty liver disease;
KIRP	cis	rs9653442	1.000	rs9653442	chr2:100825367	A/G	cg22139774	chr2:100720529	AFF3	0.31	5.28	0.32	2.8e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs8179	0.700	rs42039	chr7:92244422	A/G	cg15732164	chr7:92237376	CDK6	0.57	7.18	0.42	8.26e-12	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs57590327	0.503	rs6776737	chr3:81513729	T/C	cg07356753	chr3:81810745	GBE1	0.49	6.19	0.37	2.46e-9	Extraversion;
KIRP	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg08198773	chr8:1697536	NA	0.51	6.25	0.37	1.76e-9	Systolic blood pressure;
KIRP	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.81	-11.01	-0.57	3.43e-23	Total body bone mineral density;
KIRP	cis	rs79881201	1.000	rs79881201	chr5:110427795	C/T	cg04022379	chr5:110408740	TSLP	-0.39	-4.91	-0.3	1.64e-6	Sum eosinophil basophil counts;
KIRP	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg27490568	chr2:178487706	NA	-0.49	-6.6	-0.39	2.58e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg03563238	chr19:33554763	RHPN2	-0.32	-6.1	-0.36	4.05e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.61	-7.71	-0.44	3.07e-13	Extraversion;
KIRP	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.71	10.77	0.57	2.12e-22	Menarche (age at onset);
KIRP	cis	rs7179456	0.545	rs507801	chr15:59053345	T/G	cg05156742	chr15:59063176	FAM63B	0.49	6.14	0.36	3.31e-9	Asperger disorder;
KIRP	cis	rs1448094	0.935	rs11117120	chr12:86336447	G/A	cg00310523	chr12:86230176	RASSF9	0.38	5.82	0.35	1.82e-8	Major depressive disorder;
KIRP	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	1.17	10.23	0.55	1.06e-20	Skin colour saturation;
KIRP	cis	rs4356932	1.000	rs4619915	chr4:76955201	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.72e-9	Blood protein levels;
KIRP	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.77	-10.02	-0.54	4.71e-20	Aortic root size;
KIRP	cis	rs4356932	0.688	rs59291856	chr4:76970801	T/C	cg00809888	chr4:76862425	NAAA	0.43	5.92	0.35	1.06e-8	Blood protein levels;
KIRP	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.86	12.43	0.62	7.54e-28	Glomerular filtration rate (creatinine);
KIRP	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	8.01	0.45	4.74e-14	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7949566	0.557	rs2230278	chr11:126277216	C/T	cg05055844	chr11:126275997	ST3GAL4	0.39	5.1	0.31	6.87e-7	Platelet distribution width;Mean platelet volume;
KIRP	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg04727924	chr7:799746	HEATR2	-0.71	-7.35	-0.42	2.97e-12	Cerebrospinal P-tau181p levels;
KIRP	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.57	6.55	0.39	3.31e-10	Height;
KIRP	cis	rs311392	0.967	rs4463399	chr8:55089449	T/C	cg06042504	chr8:55087323	NA	-0.61	-7.37	-0.43	2.53e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.91	-13.7	-0.66	4.07e-32	Chronic sinus infection;
KIRP	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.6	6.81	0.4	7.28e-11	Type 2 diabetes;
KIRP	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg16141378	chr3:129829833	LOC729375	0.57	7.9	0.45	9.6e-14	Triglycerides;
KIRP	cis	rs9462846	0.725	rs9471969	chr6:42906384	G/T	cg02353165	chr6:42928485	GNMT	0.64	7.23	0.42	5.94e-12	Blood protein levels;
KIRP	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.49	6.57	0.39	2.92e-10	Migraine;
KIRP	cis	rs62355272	0.793	rs10472982	chr5:35824593	T/C	cg13894535	chr5:35919491	CAPSL	-0.46	-5.4	-0.33	1.55e-7	Lymphocyte counts;
KIRP	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg00800038	chr16:89945340	TCF25	-0.54	-5.35	-0.32	2.05e-7	Skin colour saturation;
KIRP	cis	rs909341	0.909	rs2427532	chr20:62363817	G/A	cg03999872	chr20:62272968	STMN3	-0.59	-6.83	-0.4	6.8e-11	Atopic dermatitis;
KIRP	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	6.21	0.37	2.22e-9	Platelet count;
KIRP	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.63	8.73	0.49	3.84e-16	Multiple sclerosis;
KIRP	cis	rs748404	0.516	rs523156	chr15:43811843	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.49	-5.74	-0.34	2.8e-8	Lung cancer;
KIRP	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.78	10.24	0.55	1e-20	Aortic root size;
KIRP	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg20673091	chr1:2541236	MMEL1	0.66	9.9	0.53	1.12e-19	Ulcerative colitis;
KIRP	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.87	9.04	0.5	4.85e-17	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs2979489	0.891	rs2979511	chr8:30394968	G/A	cg26383811	chr8:30366931	RBPMS	-0.45	-6.18	-0.37	2.6e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg21827317	chr3:136751795	NA	0.37	5.41	0.33	1.5e-7	Neuroticism;Schizophrenia;
KIRP	cis	rs13102973	0.931	rs13134190	chr4:135854932	T/C	cg14419869	chr4:135874104	NA	0.52	8.61	0.48	9.12e-16	Subjective well-being;
KIRP	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg18154014	chr19:37997991	ZNF793	0.9	9.2	0.51	1.56e-17	Coronary artery calcification;
KIRP	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.48	-5.98	-0.36	7.77e-9	Crohn's disease;
KIRP	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.62	5.94	0.35	9.76e-9	Breast cancer;
KIRP	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg20637307	chr2:213403960	ERBB4	0.93	16.28	0.72	6.22e-41	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.76	-10.47	-0.56	1.82e-21	Blood metabolite levels;
KIRP	cis	rs6681460	1.000	rs10789210	chr1:67066030	G/A	cg13052034	chr1:66999238	SGIP1	0.39	5.34	0.32	2.06e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7251806	1	rs7251806	chr19:16499569	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.62	6.0	0.36	7.02e-9	Lymphocyte counts;
KIRP	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg18306943	chr3:40428807	ENTPD3	0.45	5.91	0.35	1.12e-8	Renal cell carcinoma;
KIRP	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg08885076	chr2:99613938	TSGA10	0.53	9.19	0.51	1.67e-17	Chronic sinus infection;
KIRP	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg09914555	chr8:142094789	NA	-0.47	-6.11	-0.36	3.81e-9	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.73	11.51	0.59	8.09e-25	Resting heart rate;
KIRP	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg08198773	chr8:1697536	NA	0.41	5.46	0.33	1.17e-7	Systolic blood pressure;
KIRP	cis	rs10129255	0.518	rs8010020	chr14:107186255	A/G	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.31	5.07e-7	Kawasaki disease;
KIRP	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.17	-15.67	-0.71	7.26e-39	Gut microbiome composition (summer);
KIRP	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.74	0.34	2.84e-8	Lung cancer;
KIRP	cis	rs2219968	1.000	rs12056614	chr8:78962648	A/T	cg00738934	chr8:78996279	NA	0.41	5.14	0.31	5.49e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg14703610	chr5:56206110	C5orf35	0.49	6.79	0.4	8.35e-11	Coronary artery disease;
KIRP	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.63	-9.94	-0.54	8.35e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs2712184	0.729	rs4674115	chr2:217659628	C/G	cg05032264	chr2:217675019	NA	-0.49	-7.16	-0.42	9.34e-12	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs1829883	0.775	rs2682162	chr5:98921173	T/G	cg08333243	chr5:99726346	NA	0.43	5.53	0.33	8.08e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg13877915	chr19:58951672	ZNF132	0.61	5.9	0.35	1.22e-8	Mean platelet volume;
KIRP	cis	rs6545883	0.929	rs6545877	chr2:61741947	T/C	cg15711740	chr2:61764176	XPO1	-0.61	-8.27	-0.47	8.31e-15	Tuberculosis;
KIRP	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-7.75	-0.44	2.48e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.92	14.02	0.67	3.18e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.53	-0.48	1.5e-15	Calcium levels;
KIRP	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.69	8.95	0.5	8.78e-17	Resting heart rate;
KIRP	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-6.75	-0.4	1.06e-10	Total body bone mineral density;
KIRP	cis	rs4356932	1.000	rs7377856	chr4:76964096	T/C	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg19338460	chr6:170058176	WDR27	-1.21	-12.47	-0.62	5.37e-28	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.24	0.62	3.22e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg15655495	chr12:38532458	NA	-0.3	-5.29	-0.32	2.64e-7	Bladder cancer;
KIRP	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg16141378	chr3:129829833	LOC729375	-0.56	-6.96	-0.41	3.02e-11	Neuroticism;
KIRP	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-4.91	-0.3	1.7e-6	Type 2 diabetes;
KIRP	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg05966235	chr16:28915196	ATP2A1	-0.44	-4.93	-0.3	1.49e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.61	-9.6	-0.52	9.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs3017493	0.786	rs12295625	chr11:70671860	A/G	cg11479156	chr11:70672388	SHANK2	0.5	5.2	0.31	4.12e-7	Renal transplant outcome;
KIRP	trans	rs1440410	0.830	rs6833582	chr4:144181992	C/G	cg26402253	chr7:87849886	SRI	0.46	6.24	0.37	1.88e-9	Ischemic stroke;
KIRP	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg24881330	chr22:46731750	TRMU	0.69	5.59	0.34	5.97e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg01689657	chr7:91764605	CYP51A1	0.36	4.98	0.3	1.19e-6	Breast cancer;
KIRP	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-6.65	-0.39	1.83e-10	Longevity;Endometriosis;
KIRP	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.57	-9.43	-0.52	3.16e-18	Prostate cancer;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.62	4.89	0.3	1.8e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.39	6.65	0.39	1.89e-10	Heart rate;
KIRP	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg17507749	chr15:85114479	UBE2QP1	0.8	8.21	0.46	1.29e-14	Schizophrenia;
KIRP	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.91	13.65	0.66	5.87e-32	Mean platelet volume;
KIRP	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.56	7.51	0.43	1.12e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.68	10.02	0.54	4.85e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg14541582	chr5:601475	NA	-0.58	-6.52	-0.38	3.94e-10	Obesity-related traits;
KIRP	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12893428	chr3:195717962	SDHAP1	0.41	5.61	0.34	5.39e-8	Pancreatic cancer;
KIRP	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.66	-11.76	-0.6	1.28e-25	White blood cell count (basophil);
KIRP	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.64	7.59	0.44	6.8e-13	Resting heart rate;
KIRP	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs9653442	0.545	rs11900482	chr2:100758709	G/C	cg17356467	chr2:100759845	AFF3	0.42	5.66	0.34	4.23e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg13319975	chr6:146136371	FBXO30	-0.49	-7.02	-0.41	2.1e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12143943	0.835	rs4951383	chr1:204452278	A/G	cg20240347	chr1:204465584	NA	-0.37	-6.84	-0.4	6.3e-11	Cognitive performance;
KIRP	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	cg21523751	chr1:182988639	NA	0.45	7.14	0.41	1.07e-11	Fuchs's corneal dystrophy;
KIRP	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.19	0.42	7.76e-12	Aortic root size;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11005552	chr10:105648138	OBFC1	-0.46	-6.16	-0.37	2.97e-9	Interleukin-4 levels;
KIRP	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.76	-9.52	-0.52	1.7e-18	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7011049	0.722	rs115570683	chr8:53867155	T/C	cg26025543	chr8:53854495	NA	0.58	6.28	0.37	1.49e-9	Systolic blood pressure;
KIRP	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.68	5.71	0.34	3.18e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.32	-0.37	1.25e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs17023223	0.537	rs2645302	chr1:119590398	A/C	cg05756136	chr1:119680316	WARS2	-0.57	-7.77	-0.44	2.18e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg01238044	chr22:24384105	GSTT1	-0.55	-7.27	-0.42	4.66e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg17595323	chr11:93583763	C11orf90	-0.37	-6.23	-0.37	1.95e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.66	0.48	6.38e-16	Motion sickness;
KIRP	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.89	-13.95	-0.66	5.42e-33	Breast cancer;
KIRP	cis	rs8523	0.901	rs4532436	chr6:10983971	C/G	cg13562911	chr6:11044106	ELOVL2	0.41	5.37	0.32	1.79e-7	Red blood cell fatty acid levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09618694	chr3:56591190	CCDC66	-0.56	-6.45	-0.38	5.91e-10	Interleukin-4 levels;
KIRP	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg26022315	chr17:47021804	SNF8	0.41	5.36	0.32	1.91e-7	Type 2 diabetes;
KIRP	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg18944383	chr4:111397179	ENPEP	0.69	12.28	0.62	2.43e-27	Coronary artery disease;
KIRP	cis	rs4742903	1.000	rs4742903	chr9:106856793	G/C	cg14250997	chr9:106856677	SMC2	0.37	4.86	0.3	2.07e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.81	0.4	7.55e-11	Lung cancer;
KIRP	cis	rs17095355	1.000	rs13377046	chr10:111729228	T/A	cg00817464	chr10:111662876	XPNPEP1	-0.42	-5.95	-0.35	9.2e-9	Biliary atresia;
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs624899	0.655	rs73514607	chr19:11632207	G/A	cg08877591	chr19:11648452	CNN1	-0.65	-5.07	-0.31	7.99e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23281280	chr6:28129359	ZNF389	0.48	5.19	0.31	4.36e-7	Depression;
KIRP	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg20169779	chr10:135381914	SYCE1	-0.42	-4.99	-0.3	1.15e-6	Obesity-related traits;
KIRP	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	1.0	13.11	0.64	4.03e-30	Red cell distribution width;
KIRP	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02927292	chr1:36501817	EIF2C3	-0.43	-6.25	-0.37	1.75e-9	Select biomarker traits;
KIRP	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13409248	chr3:40428643	ENTPD3	0.37	5.08	0.31	7.43e-7	Renal cell carcinoma;
KIRP	cis	rs4356932	1.000	rs10025102	chr4:76955358	G/A	cg19388996	chr4:76862389	NAAA	0.38	4.88	0.3	1.88e-6	Blood protein levels;
KIRP	cis	rs1045714	0.895	rs4719602	chr7:2647800	G/A	cg20813462	chr7:2646259	IQCE	0.66	6.23	0.37	2.01e-9	Urate levels in lean individuals;
KIRP	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg13482628	chr17:19912719	NA	0.58	8.22	0.46	1.15e-14	Schizophrenia;
KIRP	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg02811702	chr13:24901961	NA	0.4	5.32	0.32	2.36e-7	Obesity-related traits;
KIRP	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.14	15.08	0.69	8.12e-37	Gut microbiome composition (summer);
KIRP	cis	rs714027	0.585	rs9306468	chr22:30374281	T/C	cg01021169	chr22:30184971	ASCC2	-0.45	-5.32	-0.32	2.28e-7	Lymphocyte counts;
KIRP	cis	rs55728055	0.661	rs9621295	chr22:32007153	G/A	cg01338084	chr22:32026380	PISD	0.88	5.27	0.32	2.92e-7	Age-related hearing impairment;
KIRP	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.73	-5.85	-0.35	1.58e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.63	-8.34	-0.47	5.21e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg07701084	chr6:150067640	NUP43	0.7	9.87	0.53	1.44e-19	Lung cancer;
KIRP	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.75	11.24	0.58	6.24e-24	Oral cavity cancer;
KIRP	cis	rs8077577	0.638	rs4386179	chr17:18134774	A/G	cg18869244	chr17:18121946	NA	-0.47	-5.36	-0.32	1.91e-7	Obesity-related traits;
KIRP	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.46	5.87	0.35	1.41e-8	Aortic root size;
KIRP	cis	rs240764	0.817	rs239204	chr6:101135580	T/C	cg09795085	chr6:101329169	ASCC3	0.46	5.53	0.33	8.13e-8	Neuroticism;
KIRP	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.66	6.49	0.38	4.59e-10	Axial length;
KIRP	cis	rs77688320	0.573	rs59674665	chr2:202379604	A/G	cg06431681	chr2:202330990	STRADB	-0.44	-5.14	-0.31	5.48e-7	Breast cancer;
KIRP	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.46	-6.64	-0.39	2.03e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26526719	chr5:1949144	NA	0.43	5.18	0.31	4.58e-7	Gut microbiome composition (winter);
KIRP	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26240231	chr7:1148101	C7orf50	-0.4	-4.86	-0.3	2.05e-6	Bronchopulmonary dysplasia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.5	6.65	0.39	1.86e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs1371867	0.846	rs2919471	chr8:101232701	T/C	cg11906718	chr8:101322791	RNF19A	-0.68	-8.57	-0.48	1.15e-15	Atrioventricular conduction;
KIRP	cis	rs1147199	0.585	rs1201364	chr9:87267378	C/T	cg22402007	chr9:87282823	NTRK2	0.4	5.23	0.32	3.7e-7	Body mass index;
KIRP	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.47	-6.98	-0.41	2.7e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.61	8.2	0.46	1.29e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs4389656	1.000	rs71600236	chr5:6721700	C/G	cg10857441	chr5:6722123	POLS	0.46	5.81	0.35	1.95e-8	Coronary artery disease;
KIRP	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg06640241	chr16:89574553	SPG7	0.67	8.98	0.5	7.12e-17	Multiple myeloma (IgH translocation);
KIRP	cis	rs17123764	0.818	rs11169092	chr12:50008602	C/G	cg20471783	chr12:50157085	TMBIM6	0.31	4.9	0.3	1.71e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1832871	0.655	rs4292552	chr6:158722888	G/A	cg07215822	chr6:158701037	NA	-0.65	-7.45	-0.43	1.63e-12	Height;
KIRP	cis	rs17065868	0.764	rs9533858	chr13:45032743	C/G	cg10246903	chr13:45222710	NA	0.59	4.99	0.3	1.16e-6	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg17724175	chr1:150552817	MCL1	0.35	5.8	0.35	2.01e-8	Melanoma;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg00001245	chr3:15106710	MRPS25	-0.5	-6.67	-0.39	1.64e-10	Myopia;
KIRP	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-9.84	-0.53	1.77e-19	Chronic sinus infection;
KIRP	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg01721255	chr8:58191610	C8orf71	0.5	5.04	0.31	9.22e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	9.79	0.53	2.44e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs362272	0.525	rs2798286	chr4:3046173	A/G	cg14003022	chr4:3043019	NA	-0.37	-5.05	-0.31	8.48e-7	Serum sulfate level;
KIRP	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	5.64	0.34	4.6e-8	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.7	-9.44	-0.52	2.97e-18	Prudent dietary pattern;
KIRP	cis	rs9359856	0.518	rs10944447	chr6:90194008	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.56	-5.98	-0.36	7.67e-9	Bipolar disorder;
KIRP	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.83	10.23	0.55	1.1e-20	Corneal astigmatism;
KIRP	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg24747557	chr10:131355152	MGMT	0.38	5.04	0.31	9.08e-7	Response to temozolomide;
KIRP	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.6	-7.57	-0.43	7.53e-13	Height;
KIRP	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.18	21.46	0.81	2.71e-58	Cognitive function;
KIRP	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.97	16.14	0.72	1.85e-40	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1443512	0.812	rs1975470	chr12:54336841	G/A	cg17410650	chr12:54324560	NA	-0.45	-5.72	-0.34	3.15e-8	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg02725872	chr8:58115012	NA	-0.63	-5.65	-0.34	4.43e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs6545883	0.860	rs6749226	chr2:61509783	G/A	cg15711740	chr2:61764176	XPO1	0.61	7.98	0.45	5.42e-14	Tuberculosis;
KIRP	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg11657440	chr19:46296263	DMWD	-0.74	-9.65	-0.52	6.73e-19	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg24807547	chr6:37504484	NA	-0.52	-7.71	-0.44	3.2e-13	Cognitive performance;
KIRP	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.66	-8.01	-0.45	4.73e-14	Aortic root size;
KIRP	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.47	6.54	0.39	3.46e-10	Sitting height ratio;
KIRP	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg13010199	chr12:38710504	ALG10B	0.51	6.23	0.37	2.05e-9	Morning vs. evening chronotype;
KIRP	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.27	-0.32	2.92e-7	Pulmonary function;
KIRP	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.67	6.83	0.4	6.73e-11	Corneal astigmatism;
KIRP	cis	rs17592366	0.517	rs4982222	chr14:35301997	T/C	cg09327582	chr14:35236912	BAZ1A	0.56	5.86	0.35	1.51e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;
KIRP	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.65	7.57	0.43	7.33e-13	Schizophrenia;
KIRP	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.71	-9.28	-0.51	9.15e-18	Total body bone mineral density;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg08949011	chr10:99400449	PI4K2A	-0.47	-6.34	-0.37	1.08e-9	Myopia;
KIRP	trans	rs11082321	0.867	rs11082322	chr18:20776883	C/G	cg15812386	chr19:36422730	NA	0.66	6.05	0.36	5.31e-9	Breast cancer;
KIRP	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16576597	chr16:28551801	NUPR1	0.36	5.25	0.32	3.24e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg17691542	chr6:26056736	HIST1H1C	0.46	6.0	0.36	6.91e-9	Schizophrenia;
KIRP	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.7	-8.06	-0.46	3.37e-14	Corneal astigmatism;
KIRP	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg18850127	chr7:39170497	POU6F2	0.29	5.3	0.32	2.53e-7	IgG glycosylation;
KIRP	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05025164	chr4:1340916	KIAA1530	0.44	5.62	0.34	5.1e-8	Obesity-related traits;
KIRP	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	1.01	12.37	0.62	1.23e-27	Post bronchodilator FEV1;
KIRP	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.69e-7	Life satisfaction;
KIRP	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-7.87	-0.45	1.1e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg00092383	chr7:157075207	NA	0.58	6.03	0.36	5.98e-9	Type 2 diabetes;
KIRP	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg20891283	chr12:69753455	YEATS4	0.63	6.56	0.39	3.1e-10	Response to diuretic therapy;
KIRP	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg01689657	chr7:91764605	CYP51A1	0.36	5.26	0.32	3.09e-7	Breast cancer;
KIRP	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg04013166	chr16:89971882	TCF25	0.67	5.63	0.34	4.83e-8	Skin colour saturation;
KIRP	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.15	-0.31	5.22e-7	Bladder cancer;
KIRP	cis	rs4236601	1.000	rs10257125	chr7:116162306	A/T	cg05166801	chr7:116143459	CAV2	0.48	5.95	0.35	9.23e-9	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.7	5.62	0.34	5.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.58	6.78	0.4	8.95e-11	Coronary artery disease;
KIRP	cis	rs12210905	0.688	rs12212348	chr6:27361242	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.82	-6.52	-0.38	3.91e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.37	5.0	0.3	1.11e-6	Red cell distribution width;Reticulocyte count;
KIRP	cis	rs7582720	1.000	rs72932741	chr2:203661048	A/T	cg08076091	chr2:203926405	NBEAL1	0.84	8.35	0.47	5.01e-15	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.82	-13.79	-0.66	1.93e-32	Testicular germ cell tumor;
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-5.72	-0.34	3.02e-8	Lung cancer;
KIRP	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg22916017	chr11:64110731	CCDC88B	0.56	6.29	0.37	1.47e-9	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg14353649	chr10:135191496	PAOX	-0.48	-5.09	-0.31	7.02e-7	Lifespan;
KIRP	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg01879757	chr17:41196368	BRCA1	-0.78	-10.93	-0.57	6.39e-23	Menopause (age at onset);
KIRP	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg03929089	chr4:120376271	NA	0.76	6.75	0.4	1.05e-10	Intraocular pressure;
KIRP	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg09163369	chr1:210001066	C1orf107	0.49	6.17	0.37	2.76e-9	Orofacial clefts;
KIRP	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg26002218	chr14:103986227	CKB	0.28	5.32	0.32	2.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.55	7.65	0.44	4.41e-13	Schizophrenia;
KIRP	cis	rs2273156	1.000	rs12050402	chr14:35461816	C/T	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.47	-0.33	1.1e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-1.02	-9.58	-0.52	1.15e-18	Metabolite levels (HVA/5-HIAA ratio);
KIRP	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg21684588	chr1:67600265	NA	0.42	4.94	0.3	1.41e-6	Psoriasis;
KIRP	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-7.49	-0.43	1.21e-12	Body mass index;
KIRP	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.77	-10.29	-0.55	6.74e-21	Huntington's disease progression;
KIRP	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg17168535	chr8:21777572	XPO7	0.7	9.66	0.52	6.38e-19	Mean corpuscular volume;
KIRP	cis	rs7904368	0.754	rs11254231	chr10:16870246	A/G	cg14835575	chr10:16859367	RSU1	0.81	9.62	0.52	8.16e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs3779635	0.742	rs11994437	chr8:27252881	G/A	cg23693289	chr8:27183097	PTK2B	0.58	7.4	0.43	2.12e-12	Neuroticism;
KIRP	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.57	-5.71	-0.34	3.19e-8	Platelet distribution width;
KIRP	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg10017260	chr10:834428	NA	-0.56	-5.45	-0.33	1.21e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs35264875	0.808	rs921675	chr11:68869034	A/G	cg01403660	chr11:68851641	TPCN2	-0.65	-8.19	-0.46	1.44e-14	Blond vs. brown hair color;
KIRP	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.71	8.32	0.47	6.19e-15	Blood protein levels;
KIRP	cis	rs9815354	0.812	rs11129935	chr3:41985203	A/C	cg03022575	chr3:42003672	ULK4	0.8	8.3	0.47	6.83e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg24488311	chr11:68621650	NA	0.48	5.64	0.34	4.57e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.67	-9.51	-0.52	1.82e-18	Intelligence (multi-trait analysis);
KIRP	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	7.81	0.45	1.66e-13	Neuroticism;
KIRP	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg27205649	chr11:78285834	NARS2	0.68	8.92	0.49	1.08e-16	Alzheimer's disease (survival time);
KIRP	cis	rs12913538	0.575	rs12437908	chr15:62889549	A/G	cg09983546	chr15:62884068	NA	0.47	5.71	0.34	3.16e-8	Sleep depth;
KIRP	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.7	8.8	0.49	2.44e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs1144	0.537	rs2470943	chr7:104583843	C/T	cg04380332	chr7:105027541	SRPK2	-0.53	-7.94	-0.45	7.15e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.52	6.74	0.39	1.1e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1593	0.531	rs4253299	chr4:187171355	A/G	cg09526685	chr4:187126073	CYP4V2	0.58	5.11	0.31	6.5e-7	Activated partial thromboplastin time;
KIRP	cis	rs1799949	0.757	rs9915489	chr17:41173226	A/T	cg25072359	chr17:41440525	NA	0.47	6.31	0.37	1.27e-9	Menopause (age at onset);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg04579211	chr15:41221939	DLL4	0.63	6.19	0.37	2.49e-9	Lung function (FEV1);
KIRP	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.29	0.32	2.72e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4849845	0.889	rs10203096	chr2:121033490	T/A	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg24253500	chr15:84953950	NA	0.63	6.82	0.4	6.92e-11	Schizophrenia;
KIRP	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.62	-8.44	-0.47	2.81e-15	Total body bone mineral density;
KIRP	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-10.96	-0.57	4.91e-23	Breast cancer;
KIRP	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg06634786	chr22:41940651	POLR3H	-0.46	-5.5	-0.33	9.41e-8	Neuroticism;
KIRP	cis	rs4805272	0.820	rs10408080	chr19:29341652	T/C	cg15000279	chr19:29285009	NA	0.4	6.02	0.36	6.18e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg21294424	chr19:58662284	ZNF329	0.62	5.6	0.34	5.83e-8	Cholesterol, total;
KIRP	trans	rs7246760	0.867	rs12462694	chr19:9778032	C/T	cg02900749	chr2:68251473	NA	-1.15	-9.29	-0.51	8.25e-18	Pursuit maintenance gain;
KIRP	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	12.11	0.61	8.6e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg02344993	chr17:57696989	CLTC	0.56	5.41	0.33	1.53e-7	Hemoglobin concentration;
KIRP	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.62	-6.81	-0.4	7.64e-11	Vitiligo;
KIRP	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06634786	chr22:41940651	POLR3H	0.42	5.0	0.3	1.11e-6	Vitiligo;
KIRP	cis	rs12210905	0.688	rs9393814	chr6:27372978	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.83	-6.44	-0.38	6.23e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	1.35	9.86	0.53	1.54e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg25036284	chr2:26402008	FAM59B	-0.59	-5.94	-0.35	9.91e-9	Gut microbiome composition (summer);
KIRP	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.99	13.13	0.64	3.34e-30	Smoking behavior;
KIRP	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05665937	chr4:1216051	CTBP1	-0.54	-7.67	-0.44	4.11e-13	Obesity-related traits;
KIRP	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg20060108	chr2:102954350	IL1RL1	-0.59	-5.32	-0.32	2.3e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg05784532	chr1:230284198	GALNT2	-0.48	-6.99	-0.41	2.61e-11	Coronary artery disease;
KIRP	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg01579765	chr21:45077557	HSF2BP	0.42	8.69	0.48	5.01e-16	Mean corpuscular volume;
KIRP	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg06637938	chr14:75390232	RPS6KL1	0.42	5.88	0.35	1.36e-8	Height;
KIRP	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg08501292	chr6:25962987	TRIM38	0.8	5.5	0.33	9.45e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.63	-6.72	-0.39	1.24e-10	Obesity-related traits;
KIRP	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.24	-6.56	-0.39	3.18e-10	Mean corpuscular volume;
KIRP	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg02012338	chr4:187126139	CYP4V2	0.69	5.3	0.32	2.55e-7	Blood protein levels;
KIRP	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.33	-0.37	1.17e-9	Body mass index;
KIRP	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg07636037	chr3:49044803	WDR6	-0.74	-5.53	-0.33	8.35e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4950322	0.570	rs72691095	chr1:146769990	G/C	cg22381352	chr1:146742008	CHD1L	-0.44	-5.27	-0.32	2.96e-7	Protein quantitative trait loci;
KIRP	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.36	0.42	2.82e-12	Height;
KIRP	cis	rs9810890	1.000	rs73198824	chr3:128486699	C/T	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg06217071	chr17:408420	NA	0.73	11.29	0.58	4.15e-24	Hip circumference adjusted for BMI;
KIRP	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-5.61	-0.34	5.39e-8	Height;
KIRP	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.57	-7.32	-0.42	3.44e-12	Eye color traits;
KIRP	cis	rs12311304	0.965	rs7955309	chr12:15368198	T/C	cg08258403	chr12:15378311	NA	0.37	5.66	0.34	4.28e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.17	-0.54	1.66e-20	Alzheimer's disease (late onset);
KIRP	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.12	-9.72	-0.53	4.15e-19	Body mass index;
KIRP	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.71	-9.84	-0.53	1.8e-19	Colorectal cancer;
KIRP	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg00079375	chr15:79125835	NA	0.36	5.27	0.32	3.02e-7	Coronary artery disease;
KIRP	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.11	8.22	0.46	1.15e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.59	-0.34	6.07e-8	Depression;
KIRP	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.32	6.14	0.36	3.24e-9	Educational attainment (years of education);
KIRP	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.33	5.0	0.3	1.1e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.71	-9.35	-0.51	5.48e-18	Personality dimensions;
KIRP	trans	rs7951870	0.945	rs58147945	chr11:46500654	C/G	cg01183821	chr12:46123850	ARID2	-0.63	-6.16	-0.37	3e-9	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04902921	chr1:184723906	EDEM3	0.51	6.45	0.38	6.05e-10	Parkinson's disease;
KIRP	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg01689657	chr7:91764605	CYP51A1	0.45	6.53	0.38	3.64e-10	Breast cancer;
KIRP	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-8.27	-0.47	8.47e-15	QT interval;
KIRP	cis	rs10518128	0.702	rs9991257	chr4:75706212	C/A	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs12949688	0.651	rs4793915	chr17:55838163	C/T	cg12582317	chr17:55822272	NA	0.45	6.1	0.36	4.15e-9	Schizophrenia;
KIRP	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.94	12.13	0.61	7.31e-27	Homoarginine levels;
KIRP	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs909341	0.868	rs2738758	chr20:62349625	C/G	cg03999872	chr20:62272968	STMN3	0.55	6.44	0.38	6.12e-10	Atopic dermatitis;
KIRP	cis	rs7209700	0.547	rs11649785	chr17:45355720	G/A	cg08085267	chr17:45401833	C17orf57	0.57	5.4	0.33	1.54e-7	IgG glycosylation;
KIRP	cis	rs6738485	0.861	rs13014335	chr2:106802805	A/G	cg16099169	chr2:106886729	NA	-0.42	-6.07	-0.36	4.8e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs56079296	0.866	rs4368760	chr5:121272374	G/C	cg05256605	chr5:121412184	LOX	0.47	5.25	0.32	3.21e-7	Coronary artery disease;
KIRP	trans	rs1133906	0.522	rs61132891	chr7:92744674	A/G	cg14519598	chr9:36906608	PAX5	0.6	6.17	0.37	2.81e-9	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs13394619	0.605	rs12476152	chr2:11747960	T/C	cg07314298	chr2:11723111	GREB1	0.49	6.92	0.4	3.88e-11	Endometriosis;
KIRP	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.43	5.84	0.35	1.61e-8	Total body bone mineral density;
KIRP	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.4	6.76	0.4	1.01e-10	Renal cell carcinoma;
KIRP	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	5.87	0.35	1.38e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-7.6	-0.44	6.32e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg00262122	chr8:11665843	FDFT1	0.51	6.14	0.36	3.23e-9	Myopia (pathological);
KIRP	cis	rs2671245	0.933	rs2819477	chr1:56157725	C/T	cg11523071	chr1:56160889	NA	0.42	6.74	0.39	1.11e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7246967	0.673	rs62120125	chr19:22955099	T/A	cg03230154	chr19:22817176	ZNF492	0.5	4.97	0.3	1.26e-6	Bronchopulmonary dysplasia;
KIRP	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg01988459	chr11:68622903	NA	-0.39	-5.11	-0.31	6.6e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg00931491	chr16:28608288	SULT1A2	-0.26	-5.17	-0.31	4.88e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg14580859	chr9:123691850	NA	0.36	5.08	0.31	7.33e-7	Rheumatoid arthritis;
KIRP	cis	rs10207628	0.698	rs7566991	chr2:127880933	T/A	cg06223080	chr2:127868745	NA	-0.65	-8.44	-0.47	2.72e-15	Psychosis and Alzheimer's disease;
KIRP	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.66	-0.48	6.53e-16	Retinal vascular caliber;
KIRP	cis	rs9596863	1.000	rs9596860	chr13:54431215	G/A	ch.13.53330881F	chr13:54432880	NA	0.66	6.71	0.39	1.3e-10	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg05347473	chr6:146136440	FBXO30	-0.57	-8.26	-0.47	9.09e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.76	-0.53	3.2e-19	Idiopathic membranous nephropathy;
KIRP	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg03959625	chr15:84868606	LOC388152	0.49	5.75	0.34	2.58e-8	Schizophrenia;
KIRP	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	8.79	0.49	2.58e-16	Alzheimer's disease;
KIRP	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.57	-11.5	-0.59	9.06e-25	Diabetic kidney disease;
KIRP	cis	rs7565981	1.000	rs72627412	chr2:101428412	T/C	cg02232089	chr2:101440696	NPAS2	-0.57	-5.23	-0.32	3.63e-7	Creutzfeldt-Jakob disease (variant);
KIRP	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.99	-17.79	-0.75	4.56e-46	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07343612	chr16:622815	PIGQ	-0.89	-13.51	-0.65	1.74e-31	Height;
KIRP	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05025164	chr4:1340916	KIAA1530	0.41	4.95	0.3	1.37e-6	Obesity-related traits;
KIRP	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg26338869	chr17:61819248	STRADA	0.54	6.43	0.38	6.54e-10	Prudent dietary pattern;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg01737828	chr15:75230659	COX5A	0.56	6.5	0.38	4.45e-10	Smoking initiation;
KIRP	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.68	-11.23	-0.58	6.81e-24	Hip circumference;Waist circumference;
KIRP	cis	rs75920871	0.660	rs7930783	chr11:116959039	G/A	cg04087571	chr11:116723030	SIK3	-0.28	-5.62	-0.34	5.05e-8	Subjective well-being;
KIRP	cis	rs909341	0.808	rs2263805	chr20:62351150	T/C	cg11503966	chr20:62272292	STMN3	-0.42	-5.84	-0.35	1.66e-8	Atopic dermatitis;
KIRP	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-0.88	-13.74	-0.66	2.82e-32	Total body bone mineral density;
KIRP	cis	rs2273156	0.929	rs7144646	chr14:35454701	C/G	cg09327582	chr14:35236912	BAZ1A	-0.48	-5.31	-0.32	2.4e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs8018808	0.875	rs7250	chr14:77935520	G/A	cg20045696	chr14:77926864	AHSA1	0.45	5.44	0.33	1.28e-7	Myeloid white cell count;
KIRP	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg24879335	chr3:133465180	TF	0.34	4.95	0.3	1.39e-6	Iron status biomarkers;
KIRP	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg13180566	chr4:1052158	NA	-0.5	-5.07	-0.31	7.96e-7	Recombination rate (females);
KIRP	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.75	-10.95	-0.57	5.25e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9880211	0.898	rs73231903	chr3:136561625	T/A	cg21827317	chr3:136751795	NA	-0.46	-4.91	-0.3	1.64e-6	Body mass index;Height;
KIRP	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18252515	chr7:66147081	NA	-0.45	-5.55	-0.33	7.55e-8	Aortic root size;
KIRP	cis	rs6690583	0.623	rs12030730	chr1:85454109	C/G	cg22153463	chr1:85462885	MCOLN2	0.59	5.34	0.32	2.09e-7	Serum sulfate level;
KIRP	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.94	-12.83	-0.63	3.46e-29	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg00225070	chr15:80189496	MTHFS	0.49	5.96	0.36	8.47e-9	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1559088	0.948	rs6510346	chr19:33598526	T/A	cg07827796	chr19:33622959	WDR88	0.41	4.94	0.3	1.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13418717	1.000	rs13418717	chr2:127662897	A/T	cg25501666	chr2:127640322	NA	-0.69	-5.21	-0.32	3.96e-7	Heart failure;
KIRP	cis	rs748404	0.697	rs524547	chr15:43551023	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.35	0.42	2.92e-12	Lung cancer;
KIRP	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg04002187	chr5:40835754	RPL37	0.77	5.79	0.35	2.11e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.7	-10.12	-0.54	2.33e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg24229701	chr12:130821962	PIWIL1	-0.41	-5.77	-0.35	2.36e-8	Menopause (age at onset);
KIRP	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-9.52	-0.52	1.75e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.17e-16	Motion sickness;
KIRP	cis	rs2013441	0.670	rs12937327	chr17:19978984	C/T	cg13482628	chr17:19912719	NA	0.47	5.34	0.32	2.11e-7	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.39	0.62	9.87e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.86	12.6	0.63	2.08e-28	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	14.12	0.67	1.47e-33	Electrocardiographic conduction measures;
KIRP	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg12591125	chr7:1885375	MAD1L1	0.48	5.29	0.32	2.67e-7	Bipolar disorder;
KIRP	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.59	6.47	0.38	5.35e-10	Alcohol dependence;
KIRP	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.45	5.64	0.34	4.65e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg16926213	chr1:1841314	NA	0.31	5.23	0.32	3.64e-7	Body mass index;
KIRP	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.39e-10	Bipolar disorder;
KIRP	cis	rs1629083	0.967	rs56356019	chr11:118114893	A/G	cg18857871	chr11:118064634	AMICA1	0.63	8.52	0.48	1.65e-15	Lung cancer;
KIRP	trans	rs1530530	1.000	rs3803221	chr13:25241724	A/G	cg00237391	chr6:35265643	DEF6	0.5	6.07	0.36	4.89e-9	Obesity-related traits;
KIRP	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.5	7.19	0.42	7.66e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.6	8.85	0.49	1.77e-16	Blood metabolite levels;
KIRP	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg19770292	chr5:1868693	NA	0.43	5.13	0.31	5.78e-7	Cardiovascular disease risk factors;
KIRP	cis	rs959260	1.000	rs4789183	chr17:73380221	G/A	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg25173405	chr17:45401733	C17orf57	-0.48	-6.26	-0.37	1.71e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.75	-0.34	2.6e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg01403660	chr11:68851641	TPCN2	0.69	6.8	0.4	8.02e-11	Blond vs. brown hair color;
KIRP	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg22617819	chr1:44378782	ST3GAL3	-0.35	-5.77	-0.35	2.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4646404	0.582	rs3760188	chr17:17487440	C/T	cg01246520	chr17:17644344	RAI1	-0.33	-5.5	-0.33	9.65e-8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
KIRP	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg25182066	chr10:30743637	MAP3K8	-0.64	-8.59	-0.48	1.01e-15	Inflammatory bowel disease;
KIRP	cis	rs6732160	0.845	rs6546805	chr2:73386115	G/T	cg01422370	chr2:73384389	NA	0.44	5.94	0.35	9.71e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.99	11.27	0.58	4.95e-24	Smoking behavior;
KIRP	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg02475777	chr4:1388615	CRIPAK	0.55	5.13	0.31	5.97e-7	Recombination rate (females);
KIRP	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.67	-7.53	-0.43	9.86e-13	Gut microbiome composition (summer);
KIRP	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.25	6.54	0.38	3.55e-10	Crohn's disease;
KIRP	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.86	13.32	0.65	7.88e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	7.84	0.45	1.36e-13	Menarche (age at onset);
KIRP	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.83	11.52	0.59	7.6e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg13482628	chr17:19912719	NA	0.66	9.97	0.54	7.04e-20	Schizophrenia;
KIRP	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg13010199	chr12:38710504	ALG10B	0.69	8.99	0.5	6.78e-17	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg18209359	chr17:80159595	CCDC57	0.41	5.43	0.33	1.38e-7	Life satisfaction;
KIRP	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6088813	1.000	rs2248393	chr20:33926103	C/G	cg14752227	chr20:34000481	UQCC	0.5	6.58	0.39	2.78e-10	Height;
KIRP	cis	rs580438	0.510	rs1531739	chr3:13431888	G/T	cg10657019	chr3:13328039	NA	-0.53	-6.86	-0.4	5.53e-11	Myringotomy;
KIRP	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg23601095	chr6:26197514	HIST1H3D	1.03	8.53	0.48	1.5e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg09873164	chr1:152488093	CRCT1	0.51	6.43	0.38	6.44e-10	Hair morphology;
KIRP	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.9	-13.19	-0.64	2.18e-30	Height;
KIRP	cis	rs748404	0.697	rs491804	chr15:43560825	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.84	0.4	6.41e-11	Lung cancer;
KIRP	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg22676075	chr6:135203613	NA	0.5	7.29	0.42	4.31e-12	Red blood cell count;
KIRP	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-9.03	-0.5	4.97e-17	Mood instability;
KIRP	cis	rs5762813	0.561	rs13058031	chr22:29273966	G/A	cg02153584	chr22:29168773	CCDC117	0.6	5.16	0.31	5.08e-7	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs1712517	0.771	rs11191672	chr10:105138961	C/T	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.41e-9	Migraine;
KIRP	cis	rs12282928	0.836	rs1503177	chr11:48269178	A/G	cg26585981	chr11:48327164	OR4S1	-0.51	-6.21	-0.37	2.18e-9	Migraine - clinic-based;
KIRP	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg13395646	chr4:1353034	KIAA1530	-0.39	-5.26	-0.32	3.2e-7	Obesity-related traits;
KIRP	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.12	-0.36	3.62e-9	Mood instability;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg03682872	chr6:158402912	SYNJ2	0.52	6.12	0.36	3.71e-9	Inflammatory biomarkers;
KIRP	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.97	-0.36	8.45e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs35740288	0.770	rs11634707	chr15:86151867	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-5.32	-0.32	2.29e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg04842962	chr6:43655489	MRPS18A	1.06	12.19	0.61	4.89e-27	IgG glycosylation;
KIRP	cis	rs61160187	0.510	rs4400080	chr5:60040636	A/G	cg02684056	chr5:59996105	DEPDC1B	-0.42	-5.08	-0.31	7.61e-7	Educational attainment (years of education);Educational attainment (college completion);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg04730839	chr6:42985884	KLHDC3	0.46	6.88	0.4	4.89e-11	Survival in pancreatic cancer;
KIRP	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg22974920	chr21:40686053	BRWD1	0.49	5.97	0.36	8.23e-9	Cognitive function;
KIRP	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.08	9.68	0.53	5.4e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg10503236	chr1:231470652	EXOC8	-0.49	-6.67	-0.39	1.64e-10	Hemoglobin concentration;
KIRP	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.52	7.17	0.42	8.96e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg27411982	chr8:10470053	RP1L1	0.43	5.25	0.32	3.21e-7	Neuroticism;
KIRP	trans	rs6901152	0.525	rs4896651	chr6:143691393	A/G	cg11424472	chr17:29036859	NA	-0.45	-6.31	-0.37	1.3e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12560992	chr17:57184187	TRIM37	0.62	7.21	0.42	6.98e-12	Testicular germ cell tumor;
KIRP	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.63	8.03	0.46	4.04e-14	Tonsillectomy;
KIRP	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg23340505	chr13:114927933	NA	0.31	4.92	0.3	1.56e-6	Schizophrenia;
KIRP	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.45	-6.44	-0.38	6.23e-10	Schizophrenia;
KIRP	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.6	8.78	0.49	2.9e-16	Menarche (age at onset);
KIRP	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19171272	chr22:38449367	NA	-0.57	-8.52	-0.48	1.67e-15	Glioblastoma;Glioma;
KIRP	cis	rs3762637	1.000	rs78381804	chr3:122222262	A/T	cg24169773	chr3:122142474	KPNA1	-0.56	-5.75	-0.34	2.57e-8	LDL cholesterol levels;
KIRP	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg17063962	chr7:91808500	NA	-0.84	-13.17	-0.64	2.53e-30	Breast cancer;
KIRP	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg00405596	chr8:11794950	NA	0.62	8.71	0.49	4.42e-16	Neuroticism;
KIRP	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.74	-7.85	-0.45	1.32e-13	Blood pressure (smoking interaction);
KIRP	trans	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.72	-7.84	-0.45	1.33e-13	Menarche (age at onset);
KIRP	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.12	22.72	0.82	2.45e-62	Platelet distribution width;
KIRP	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.18	0.31	4.58e-7	Educational attainment;
KIRP	cis	rs2979489	0.891	rs2979504	chr8:30386641	C/T	cg26383811	chr8:30366931	RBPMS	-0.45	-6.19	-0.37	2.52e-9	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs501916	0.796	rs628501	chr15:48027328	C/G	cg16110827	chr15:48056943	SEMA6D	-0.39	-5.25	-0.32	3.31e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs806215	1.000	rs712704	chr7:127258208	A/G	cg25922125	chr7:127225783	GCC1	-0.55	-5.61	-0.34	5.55e-8	Type 2 diabetes;
KIRP	cis	rs4689642	0.709	rs35194996	chr4:7226477	G/C	cg21353189	chr4:7228343	SORCS2	0.41	5.46	0.33	1.14e-7	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	0.85	14.03	0.67	2.91e-33	Vitiligo;
KIRP	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg19773385	chr1:10388646	KIF1B	-0.66	-10.08	-0.54	3.16e-20	Hepatocellular carcinoma;
KIRP	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg00319359	chr11:70116639	PPFIA1	0.58	5.97	0.36	8.28e-9	Coronary artery disease;
KIRP	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-9.54	-0.52	1.45e-18	Neuroticism;
KIRP	cis	rs4730268	0.821	rs7790720	chr7:107441502	A/G	cg18560240	chr7:107437656	SLC26A3	-0.5	-5.45	-0.33	1.23e-7	IgG glycosylation;
KIRP	cis	rs6662572	0.851	rs55654017	chr1:46249299	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.45	5.35	0.32	2e-7	Blood protein levels;
KIRP	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg00631329	chr6:26305371	NA	-0.71	-8.93	-0.49	1.01e-16	Educational attainment;
KIRP	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg08761264	chr16:28874980	SH2B1	-0.45	-5.05	-0.31	8.5e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.56	8.55	0.48	1.31e-15	Bone mineral density;
KIRP	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18867708	chr6:26865862	GUSBL1	0.47	5.89	0.35	1.26e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.78	10.29	0.55	7.15e-21	Systemic lupus erythematosus;
KIRP	cis	rs9913711	0.868	rs7216619	chr17:70079708	C/A	cg00953355	chr17:70114129	NA	-0.39	-4.95	-0.3	1.4e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.51	6.01	0.36	6.76e-9	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
KIRP	cis	rs12786942	0.569	rs12276736	chr11:101315197	A/T	cg03942599	chr11:101341554	TRPC6	0.56	7.79	0.44	1.88e-13	Facial depth;
KIRP	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.47	6.15	0.36	3.17e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg21475434	chr5:93447410	FAM172A	0.44	5.11	0.31	6.56e-7	Diabetic retinopathy;
KIRP	trans	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg00938859	chr5:1591904	SDHAP3	0.59	7.81	0.45	1.64e-13	Breast cancer;
KIRP	cis	rs1144	0.536	rs2428162	chr7:104595664	T/C	cg04380332	chr7:105027541	SRPK2	-0.46	-6.87	-0.4	5.2e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.49	11.36	0.59	2.51e-24	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.46	-5.63	-0.34	4.83e-8	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.64	-6.93	-0.4	3.7e-11	Initial pursuit acceleration;
KIRP	cis	rs12311304	0.901	rs9787991	chr12:15417022	C/T	cg08258403	chr12:15378311	NA	0.39	5.71	0.34	3.18e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg02487422	chr3:49467188	NICN1	0.37	5.17	0.31	4.79e-7	Parkinson's disease;
KIRP	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.65	-0.52	6.81e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs17681684	0.541	rs17810219	chr17:9764998	A/G	cg26853458	chr17:9805074	RCVRN	0.54	5.08	0.31	7.55e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	cis	rs34779708	0.897	rs12830	chr10:35302705	C/T	cg03585969	chr10:35415529	CREM	0.83	9.89	0.53	1.22e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs3789045	0.866	rs61817482	chr1:204570347	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.59	-5.67	-0.34	3.96e-8	Educational attainment (college completion);
KIRP	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.78	-10.31	-0.55	6.08e-21	Aortic root size;
KIRP	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg22437258	chr11:111473054	SIK2	-0.54	-5.9	-0.35	1.18e-8	Primary sclerosing cholangitis;
KIRP	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.69	9.4	0.51	4.08e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg08975724	chr8:8085496	FLJ10661	-0.61	-8.29	-0.47	7.66e-15	Mood instability;
KIRP	cis	rs427941	0.703	rs201451	chr7:101739550	G/A	cg06246474	chr7:101738831	CUX1	0.54	6.71	0.39	1.36e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	6.78	0.4	9e-11	Retinal vascular caliber;
KIRP	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg20255370	chr15:40268687	EIF2AK4	-0.57	-6.35	-0.38	1.01e-9	Corneal curvature;
KIRP	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.51	0.38	4.17e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.92	14.02	0.67	3.13e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06544989	chr22:39130855	UNC84B	0.5	7.91	0.45	8.82e-14	Menopause (age at onset);
KIRP	cis	rs769267	0.501	rs2074295	chr19:19369435	A/G	cg03709012	chr19:19516395	GATAD2A	0.55	5.93	0.35	1e-8	Tonsillectomy;
KIRP	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.93	15.81	0.71	2.53e-39	Prudent dietary pattern;
KIRP	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.55	7.45	0.43	1.56e-12	Colorectal cancer;
KIRP	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.64	7.68	0.44	3.7e-13	Height;
KIRP	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg22139774	chr2:100720529	AFF3	-0.41	-5.05	-0.31	8.62e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08377569	chr16:30538014	ZNF768	0.54	7.05	0.41	1.78e-11	Parkinson's disease;
KIRP	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg09699651	chr6:150184138	LRP11	0.44	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs12500482	0.509	rs1203784	chr4:2427108	T/C	cg26605046	chr4:2439731	NA	-0.37	-5.52	-0.33	8.59e-8	Cognitive function;
KIRP	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.38	0.38	8.57e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg24747557	chr10:131355152	MGMT	-0.37	-5.04	-0.31	8.9e-7	Response to temozolomide;
KIRP	trans	rs89107	0.967	rs72965660	chr6:118594621	A/G	cg07337129	chr16:30035757	C16orf92;FAM57B	0.42	6.05	0.36	5.24e-9	Cardiac structure and function;
KIRP	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg03060546	chr3:49711283	APEH	-0.67	-5.86	-0.35	1.46e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6910061	0.957	rs6916541	chr6:11095258	C/A	cg27233058	chr6:11094804	LOC221710	0.57	5.87	0.35	1.37e-8	Diabetic kidney disease;
KIRP	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg13256891	chr4:100009986	ADH5	-0.62	-6.61	-0.39	2.4e-10	Alcohol dependence;
KIRP	cis	rs7017914	0.967	rs13261712	chr8:71732264	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.45	-7.65	-0.44	4.56e-13	Renal cell carcinoma;
KIRP	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg20312557	chr2:97357134	FER1L5	-0.73	-5.27	-0.32	2.91e-7	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg23601095	chr6:26197514	HIST1H3D	-1.03	-8.52	-0.48	1.6e-15	Gout;Renal underexcretion gout;
KIRP	cis	rs73086581	0.891	rs55871214	chr20:3965706	A/C	cg02187196	chr20:3869020	PANK2	0.5	5.02	0.3	9.9e-7	Response to antidepressants in depression;
KIRP	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg24009623	chr19:33667908	NA	-0.49	-6.07	-0.36	4.73e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2970818	0.831	rs2970810	chr12:4608103	A/G	cg14576962	chr12:4671597	NA	-0.43	-5.18	-0.31	4.6e-7	Phosphorus levels;
KIRP	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg01403660	chr11:68851641	TPCN2	0.69	6.8	0.4	8.02e-11	Blond vs. brown hair color;
KIRP	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg23950597	chr19:37808831	NA	-0.64	-6.84	-0.4	6.32e-11	Coronary artery calcification;
KIRP	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.83	-15.06	-0.69	8.88e-37	Body mass index;
KIRP	cis	rs172166	0.637	rs1233691	chr6:28153897	T/G	cg02631126	chr6:28058918	ZSCAN12L1	0.44	5.1	0.31	6.76e-7	Cardiac Troponin-T levels;
KIRP	trans	rs12527818	0.544	rs12662631	chr6:93842446	C/T	cg01407341	chr15:97326798	SPATA8	0.49	6.31	0.37	1.28e-9	Response to hepatitis C treatment;
KIRP	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	4.94	0.3	1.45e-6	Menopause (age at onset);
KIRP	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01391022	chr12:122360665	WDR66	-0.41	-6.41	-0.38	7.28e-10	Mean corpuscular volume;
KIRP	cis	rs981844	1.000	rs2579917	chr4:154652648	T/G	cg14289246	chr4:154710475	SFRP2	0.65	7.04	0.41	1.89e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg23682824	chr7:23144976	KLHL7	0.58	6.97	0.41	2.89e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs4704187	0.687	rs1363577	chr5:74463185	T/G	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.75	6.7	0.39	1.39e-10	Diabetic retinopathy;
KIRP	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg04990556	chr1:26633338	UBXN11	0.69	6.74	0.39	1.14e-10	Obesity-related traits;
KIRP	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.55	-6.99	-0.41	2.54e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.69	7.21	0.42	6.87e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg08761264	chr16:28874980	SH2B1	-0.46	-5.41	-0.33	1.46e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg22676075	chr6:135203613	NA	0.5	7.18	0.42	8.21e-12	Red blood cell count;
KIRP	cis	rs4920343	0.645	rs851115	chr1:19070229	T/A	cg19637330	chr1:19110922	NA	0.4	5.02	0.3	1.01e-6	Knee osteoarthritis;
KIRP	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg23324259	chr8:82754387	SNX16	0.44	4.99	0.3	1.17e-6	Diastolic blood pressure;
KIRP	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.63	7.51	0.43	1.11e-12	Blood metabolite levels;
KIRP	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.73	10.42	0.55	2.66e-21	Extrinsic epigenetic age acceleration;
KIRP	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.66	0.52	6.57e-19	Corneal astigmatism;
KIRP	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14820908	chr5:178986412	RUFY1	0.44	6.29	0.37	1.46e-9	Lung cancer;
KIRP	cis	rs4073416	0.542	rs10145146	chr14:66075004	C/T	cg03016385	chr14:66212404	NA	-0.54	-6.57	-0.39	2.96e-10	N-glycan levels;
KIRP	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-8.05	-0.46	3.43e-14	Height;
KIRP	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.54e-16	Motion sickness;
KIRP	cis	rs13065560	0.594	rs4336049	chr3:38922068	G/A	cg01426195	chr3:39028469	NA	-0.44	-7.01	-0.41	2.25e-11	Interleukin-18 levels;
KIRP	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.64	8.22	0.46	1.16e-14	DNA methylation (variation);
KIRP	cis	rs4692589	0.581	rs34149802	chr4:170960284	A/G	cg19918862	chr4:170955249	NA	0.58	6.32	0.37	1.25e-9	Anxiety disorder;
KIRP	trans	rs2352908	0.678	rs2352922	chr14:49470907	C/T	cg14470332	chr9:69180795	LOC440896	0.61	6.33	0.37	1.12e-9	Social communication problems;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.54	-6.04	-0.36	5.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12149695	0.966	rs4499236	chr16:27254131	C/T	cg02411582	chr16:27232615	JMJD5	0.42	5.02	0.3	1.01e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs524023	0.874	rs7102344	chr11:64396569	A/T	cg09231725	chr11:64357281	SLC22A12	0.59	7.89	0.45	9.83e-14	Urate levels in obese individuals;
KIRP	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg05527609	chr1:210001259	C1orf107	-0.41	-5.1	-0.31	6.85e-7	Red blood cell count;
KIRP	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.59	7.32	0.42	3.55e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.79	-8.36	-0.47	4.71e-15	Coronary artery disease;
KIRP	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	cis	rs9625935	0.752	rs140108	chr22:30130776	T/C	cg01021169	chr22:30184971	ASCC2	-0.45	-5.04	-0.31	8.94e-7	Tonsillectomy;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.76	6.94	0.4	3.36e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.58e-10	Morning vs. evening chronotype;
KIRP	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg17376030	chr22:41985996	PMM1	0.42	5.08	0.31	7.44e-7	Vitiligo;
KIRP	cis	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg25547332	chr5:131281432	NA	0.47	5.23	0.32	3.69e-7	Life satisfaction;
KIRP	cis	rs3736485	0.966	rs8042840	chr15:51908498	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.18	-0.31	4.73e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-5.82	-0.35	1.85e-8	Pulmonary function;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20887711	chr4:1340912	KIAA1530	0.46	5.75	0.34	2.63e-8	Longevity;
KIRP	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.86	10.56	0.56	9.42e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs7646881	1.000	rs73015655	chr3:158451882	A/C	cg19483011	chr3:158453295	NA	-0.56	-6.34	-0.37	1.12e-9	Tetralogy of Fallot;
KIRP	cis	rs735539	0.521	rs9550672	chr13:21428380	G/T	cg04906043	chr13:21280425	IL17D	-0.43	-5.06	-0.31	8.16e-7	Dental caries;
KIRP	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.66	-9.36	-0.51	5.2e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.46	8.78	0.49	2.83e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
KIRP	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.81	0.4	7.48e-11	Menarche (age at onset);
KIRP	cis	rs7923609	0.967	rs10761762	chr10:65184717	T/C	cg01631684	chr10:65280961	REEP3	-0.52	-6.1	-0.36	4.12e-9	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.18	-0.61	5.18e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg20587970	chr11:113659929	NA	-1.24	-8.95	-0.5	8.77e-17	Height;
KIRP	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-8.23	-0.46	1.07e-14	Colorectal cancer;
KIRP	cis	rs4363385	0.530	rs10888529	chr1:153050654	G/T	cg07796016	chr1:152779584	LCE1C	-0.41	-5.21	-0.32	3.92e-7	Inflammatory skin disease;
KIRP	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-6.94	-0.4	3.46e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.53	5.06	0.31	8.36e-7	Alzheimer's disease;
KIRP	cis	rs745080	0.634	rs1379735	chr14:53032916	C/T	cg23333723	chr14:53022898	GPR137C	-0.42	-5.96	-0.36	8.76e-9	Orofacial clefts;
KIRP	cis	rs3768617	0.811	rs10911232	chr1:183052533	C/T	cg12689670	chr1:183009347	LAMC1	0.54	7.63	0.44	5.05e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg20887711	chr4:1340912	KIAA1530	0.59	7.43	0.43	1.82e-12	Longevity;
KIRP	cis	rs7561273	0.609	rs6720226	chr2:24295853	A/G	cg20701182	chr2:24300061	SF3B14	0.44	5.42	0.33	1.4e-7	Quantitative traits;
KIRP	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg25866889	chr13:114914595	NA	-0.4	-5.61	-0.34	5.56e-8	Schizophrenia;
KIRP	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg19847130	chr8:10466454	RP1L1	-0.43	-6.53	-0.38	3.79e-10	Retinal vascular caliber;
KIRP	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	5.37	0.32	1.85e-7	Educational attainment;
KIRP	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.7	8.95	0.5	8.69e-17	Morning vs. evening chronotype;
KIRP	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg23933602	chr10:16859644	RSU1	0.58	6.33	0.37	1.15e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.78	9.21	0.51	1.46e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-5.56	-0.33	7.11e-8	Neuroticism;
KIRP	cis	rs6783573	0.965	rs3806703	chr3:46618501	T/C	cg20941258	chr3:46618668	LRRC2;TDGF1	-0.36	-5.74	-0.34	2.84e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2273669	0.504	rs1539596	chr6:109408428	C/G	cg05315195	chr6:109294784	ARMC2	-0.59	-4.88	-0.3	1.95e-6	Prostate cancer;
KIRP	cis	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg09363841	chr1:37513479	NA	-0.37	-5.27	-0.32	3.01e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs7404928	0.794	rs72777936	chr16:23874201	A/T	cg05497750	chr16:23765381	CHP2	-0.45	-5.33	-0.32	2.24e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg07395648	chr5:131743802	NA	-0.58	-8.06	-0.46	3.42e-14	Acylcarnitine levels;
KIRP	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg08847533	chr14:75593920	NEK9	0.51	6.15	0.37	3.1e-9	IgG glycosylation;
KIRP	cis	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg02972257	chr16:68554789	NA	0.5	4.92	0.3	1.6e-6	Colorectal cancer;
KIRP	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.93	12.24	0.62	3.17e-27	Menopause (age at onset);
KIRP	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.94	-0.35	9.6e-9	IgG glycosylation;
KIRP	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg12940439	chr1:67600707	NA	0.43	6.44	0.38	6.31e-10	Psoriasis;
KIRP	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.41	-5.78	-0.35	2.22e-8	Monocyte count;
KIRP	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.91	6.41	0.38	7.2e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1009181	1.000	rs1009181	chr6:26158993	C/T	cg13736514	chr6:26305472	NA	0.5	6.05	0.36	5.27e-9	Childhood ear infection;
KIRP	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.07	-0.36	4.72e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4262150	0.690	rs6871699	chr5:152014666	T/C	cg12297329	chr5:152029980	NA	-0.62	-8.13	-0.46	2.18e-14	Bipolar disorder and schizophrenia;
KIRP	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.76	-8.79	-0.49	2.71e-16	Platelet distribution width;
KIRP	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17554472	chr22:41940697	POLR3H	-0.66	-6.93	-0.4	3.59e-11	Vitiligo;
KIRP	cis	rs4356932	0.967	rs12509593	chr4:76987746	T/G	cg00809888	chr4:76862425	NAAA	0.44	6.21	0.37	2.22e-9	Blood protein levels;
KIRP	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.57	-5.71	-0.34	3.22e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8028182	0.636	rs4486847	chr15:75728531	C/G	cg20655648	chr15:75932815	IMP3	0.55	7.0	0.41	2.48e-11	Sudden cardiac arrest;
KIRP	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-7.33	-0.42	3.25e-12	Initial pursuit acceleration;
KIRP	cis	rs5167	0.504	rs7257476	chr19:45453165	C/T	cg10169327	chr19:45448959	APOC2	0.33	5.06	0.31	8.25e-7	Blood protein levels;
KIRP	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.94	16.3	0.72	5.23e-41	Metabolic syndrome;
KIRP	cis	rs9488822	0.676	rs868943	chr6:116337503	G/A	cg18764771	chr6:116381957	FRK	0.18	5.28	0.32	2.81e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9393813	0.626	rs7772739	chr6:27318848	G/A	cg18711553	chr6:27366782	ZNF391	0.4	5.47	0.33	1.09e-7	Bipolar disorder;
KIRP	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.76	8.76	0.49	3.12e-16	Coronary artery disease;
KIRP	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg07636037	chr3:49044803	WDR6	0.54	5.12	0.31	6.26e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs78545713	0.541	rs111465843	chr6:26222823	G/A	cg01420254	chr6:26195488	NA	1.21	7.59	0.44	6.71e-13	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg01689657	chr7:91764605	CYP51A1	0.48	7.18	0.42	8.22e-12	Breast cancer;
KIRP	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg16141378	chr3:129829833	LOC729375	-0.51	-6.69	-0.39	1.5e-10	Neuroticism;
KIRP	cis	rs244293	0.730	rs11079142	chr17:53021955	A/G	cg07707039	chr17:53042137	COX11	-0.4	-5.03	-0.31	9.32e-7	Menarche (age at onset);
KIRP	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg13978929	chr19:21580086	ZNF493	0.49	4.86	0.3	2.06e-6	Pain;
KIRP	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.18	-21.71	-0.81	4.4e-59	Ulcerative colitis;
KIRP	cis	rs1440410	0.804	rs13146326	chr4:144076741	C/A	cg01719995	chr4:144104893	USP38	0.45	5.61	0.34	5.39e-8	Ischemic stroke;
KIRP	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg04935436	chr20:30431758	NA	0.53	6.43	0.38	6.48e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4716602	0.542	rs35137250	chr7:156161066	T/C	cg16983916	chr7:156159713	NA	-0.45	-5.63	-0.34	4.94e-8	Anti-saccade response;
KIRP	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	0.54	6.41	0.38	7.37e-10	Prudent dietary pattern;
KIRP	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.53	6.77	0.4	9.43e-11	Crohn's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg02308954	chr3:15140799	ZFYVE20	-0.51	-6.06	-0.36	5.2e-9	Interleukin-4 levels;
KIRP	cis	rs17123764	0.792	rs11169073	chr12:49968426	T/C	cg20471783	chr12:50157085	TMBIM6	0.31	4.95	0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.36	5.41	0.33	1.49e-7	Multiple sclerosis;
KIRP	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.72	0.34	3e-8	Bipolar disorder;
KIRP	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg24253500	chr15:84953950	NA	0.52	5.84	0.35	1.66e-8	Schizophrenia;
KIRP	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.65	-6.8	-0.4	7.76e-11	Menarche (age at onset);
KIRP	cis	rs7010267	0.869	rs1982763	chr8:119947828	C/T	cg01975934	chr8:119970761	NA	0.39	5.23	0.32	3.71e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.88	-12.59	-0.63	2.18e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg25753631	chr6:25732923	NA	-0.28	-5.2	-0.31	4.27e-7	Iron status biomarkers;
KIRP	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.55	6.77	0.4	9.13e-11	Arsenic metabolism;
KIRP	cis	rs9535307	0.745	rs1407440	chr13:50286218	T/C	cg04663916	chr13:50265991	EBPL	0.67	7.01	0.41	2.29e-11	Obesity-related traits;
KIRP	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg09323728	chr8:95962352	TP53INP1	-0.28	-5.94	-0.35	9.47e-9	Type 2 diabetes;
KIRP	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.68	9.13	0.5	2.65e-17	Coronary artery disease;
KIRP	cis	rs2033732	0.673	rs920226	chr8:85054989	A/T	cg05716166	chr8:85095498	RALYL	0.54	6.05	0.36	5.36e-9	Body mass index;
KIRP	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg07701084	chr6:150067640	NUP43	0.56	7.28	0.42	4.54e-12	Testicular germ cell tumor;
KIRP	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	ch.8.33884649F	chr8:33765107	NA	0.59	7.33	0.42	3.21e-12	Body mass index;
KIRP	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg06640241	chr16:89574553	SPG7	0.73	9.81	0.53	2.26e-19	Multiple myeloma (IgH translocation);
KIRP	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.47	-0.52	2.42e-18	Gut microbiome composition (summer);
KIRP	cis	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg19847130	chr8:10466454	RP1L1	0.39	5.74	0.34	2.84e-8	Neuroticism;
KIRP	cis	rs7011507	1.000	rs74451002	chr8:49191234	C/A	cg15325961	chr8:49183143	NA	0.59	5.15	0.31	5.43e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.45	-5.44	-0.33	1.29e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18876405	chr7:65276391	NA	0.41	5.05	0.31	8.81e-7	Aortic root size;
KIRP	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg06795125	chr2:108905320	SULT1C2	-0.39	-7.24	-0.42	5.6e-12	Blood pressure;
KIRP	cis	rs9603616	1.000	rs12875311	chr13:40342557	G/A	cg26701198	chr13:40229707	COG6	-0.46	-5.14	-0.31	5.53e-7	Rheumatoid arthritis;
KIRP	cis	rs2380220	0.606	rs7754906	chr6:95992429	C/T	cg15832292	chr6:96025679	MANEA	0.72	7.17	0.42	8.67e-12	Behavioural disinhibition (generation interaction);
KIRP	cis	rs5770917	1.000	rs5770911	chr22:51011241	C/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.63	-4.91	-0.3	1.67e-6	Narcolepsy;
KIRP	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.19	-0.46	1.45e-14	Monocyte percentage of white cells;
KIRP	cis	rs2737618	0.698	rs2737678	chr1:200088041	C/T	cg21825944	chr1:200113062	NR5A2	-0.58	-7.96	-0.45	6.25e-14	Uric acid levels;
KIRP	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg04609801	chr16:28609176	SULT1A2	-0.47	-5.6	-0.34	5.77e-8	Platelet distribution width;
KIRP	trans	rs12517041	1.000	rs10805749	chr5:23300740	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-7.75	-0.44	2.43e-13	Calcium levels;
KIRP	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.7	9.85	0.53	1.65e-19	Caffeine consumption;
KIRP	cis	rs8067545	0.750	rs1421174	chr17:19950190	G/T	cg04132472	chr17:19861366	AKAP10	0.43	5.89	0.35	1.26e-8	Schizophrenia;
KIRP	cis	rs11825064	0.673	rs80332462	chr11:134496895	C/T	cg06603561	chr11:134479413	NA	-1.12	-7.83	-0.45	1.42e-13	Seasonality;
KIRP	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.55	7.09	0.41	1.45e-11	Longevity;
KIRP	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg08603382	chr10:743973	NA	-0.58	-8.51	-0.48	1.77e-15	Psychosis in Alzheimer's disease;
KIRP	cis	rs7903847	0.596	rs7922512	chr10:99155685	C/A	cg20016023	chr10:99160130	RRP12	-0.44	-6.1	-0.36	4.11e-9	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2733310	0.790	rs2733323	chr15:57534229	G/T	cg13626582	chr15:57592083	LOC283663	0.26	5.92	0.35	1.08e-8	Mean platelet volume;
KIRP	cis	rs7258465	0.897	rs1043327	chr19:18554972	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.5	-0.43	1.13e-12	Breast cancer;
KIRP	cis	rs7011049	1.000	rs78977297	chr8:53858902	T/C	cg26025543	chr8:53854495	NA	0.75	7.43	0.43	1.75e-12	Systolic blood pressure;
KIRP	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg26681399	chr22:41777847	TEF	-0.45	-4.97	-0.3	1.24e-6	Vitiligo;
KIRP	cis	rs4691139	0.644	rs939083	chr4:165931481	A/C	cg10852876	chr4:165953100	TRIM60	-0.37	-5.02	-0.3	9.81e-7	Ovarian cancer in BRCA1 mutation carriers;
KIRP	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.61	-6.47	-0.38	5.31e-10	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9653442	0.900	rs2309837	chr2:100837567	T/C	cg07810366	chr2:100720526	AFF3	-0.29	-4.94	-0.3	1.48e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg13319975	chr6:146136371	FBXO30	-0.46	-6.1	-0.36	4.01e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.79	7.91	0.45	8.62e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg02570527	chr1:10970165	NA	-0.4	-4.85	-0.3	2.2e-6	Body mass index;
KIRP	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg04025307	chr7:1156635	C7orf50	0.81	8.35	0.47	5.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3820928	0.904	rs2217359	chr2:227759892	C/T	cg05526886	chr2:227700861	RHBDD1	-0.48	-5.81	-0.35	1.97e-8	Pulmonary function;
KIRP	cis	rs7998202	0.667	rs388382	chr13:113353999	G/T	cg04656015	chr13:113407548	ATP11A	-0.53	-5.77	-0.35	2.38e-8	Glycated hemoglobin levels;
KIRP	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-9.17	-0.5	1.95e-17	Mood instability;
KIRP	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.29	-0.37	1.44e-9	Response to antipsychotic treatment;
KIRP	cis	rs41005	0.967	rs17433703	chr2:8115300	A/G	cg03155496	chr2:8117019	LOC339788	0.64	11.57	0.59	5.44e-25	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg05347473	chr6:146136440	FBXO30	-0.64	-9.38	-0.51	4.5e-18	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.63	-8.47	-0.48	2.28e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg12315302	chr6:26189340	HIST1H4D	1.09	6.45	0.38	5.72e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	6.5	0.38	4.42e-10	Breast cancer;
KIRP	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg00405596	chr8:11794950	NA	-0.51	-6.72	-0.39	1.22e-10	Triglycerides;
KIRP	trans	rs13170463	0.522	rs11749511	chr5:8051901	A/G	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs4950322	0.570	rs66580541	chr1:146780541	T/G	cg22381352	chr1:146742008	CHD1L	-0.45	-5.41	-0.33	1.52e-7	Protein quantitative trait loci;
KIRP	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.96	0.36	8.82e-9	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg22228783	chr18:74844034	MBP	-0.45	-6.12	-0.36	3.59e-9	Metabolic traits;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14588259	chr20:50702859	ZFP64	0.53	6.77	0.4	9.13e-11	Interleukin-4 levels;
KIRP	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.43e-6	Life satisfaction;
KIRP	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-1.08	-22.0	-0.81	4.94e-60	Height;
KIRP	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg16574807	chr4:6945745	TBC1D14	0.64	5.81	0.35	1.94e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.04	-0.54	4.34e-20	Hemoglobin concentration;
KIRP	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs853679	0.546	rs200996	chr6:27811828	G/A	cg26587870	chr6:27730563	NA	-0.67	-5.22	-0.32	3.89e-7	Depression;
KIRP	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.69	-0.39	1.47e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs6901250	0.655	rs1398403	chr6:117122646	T/C	cg12892004	chr6:117198278	RFX6	0.42	6.93	0.4	3.64e-11	C-reactive protein levels;
KIRP	cis	rs2236918	0.710	rs1635507	chr1:242028358	G/T	cg17736920	chr1:242011382	EXO1	0.72	9.29	0.51	8.79e-18	Menopause (age at onset);
KIRP	cis	rs897080	0.515	rs698815	chr2:44706974	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.55	5.91	0.35	1.15e-8	Height;
KIRP	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs7845219	0.544	rs7016078	chr8:95922615	G/A	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.44	-0.38	6.24e-10	Type 2 diabetes;
KIRP	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	1.07	15.22	0.7	2.52e-37	Menopause (age at onset);
KIRP	cis	rs2625529	0.824	rs35112434	chr15:72448326	G/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.98	-0.36	7.69e-9	Red blood cell count;
KIRP	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.64	5.96	0.36	8.48e-9	Gut microbiome composition (summer);
KIRP	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.3	5.39	0.33	1.64e-7	Calcium levels;
KIRP	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg01631408	chr1:248437212	OR2T33	-0.69	-9.32	-0.51	7.04e-18	Common traits (Other);
KIRP	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg01420254	chr6:26195488	NA	1.16	10.2	0.55	1.31e-20	Gout;Renal underexcretion gout;
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.79	11.14	0.58	1.28e-23	Obesity-related traits;
KIRP	cis	rs3779635	0.742	rs11783759	chr8:27245790	C/T	cg21186296	chr8:27182909	PTK2B	0.51	6.54	0.38	3.49e-10	Neuroticism;
KIRP	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.61	-6.18	-0.37	2.63e-9	White matter integrity;
KIRP	cis	rs4658101	0.689	rs6604044	chr1:92051670	C/T	cg09075522	chr1:92031145	NA	0.44	5.45	0.33	1.24e-7	Optic disc area;Vertical cup-disc ratio;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10171557	chr20:34256821	NFS1	0.39	6.17	0.37	2.85e-9	Survival in pancreatic cancer;
KIRP	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg05370193	chr1:21551575	ECE1	-0.37	-5.01	-0.3	1.03e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg13319975	chr6:146136371	FBXO30	-0.48	-6.74	-0.39	1.12e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11673344	0.566	rs1968251	chr19:37947907	A/G	cg14683738	chr19:37701593	ZNF585B	0.44	5.09	0.31	6.97e-7	Obesity-related traits;
KIRP	cis	rs2742417	0.532	rs2742433	chr3:45738107	C/T	cg04037228	chr3:45636386	LIMD1	0.44	5.85	0.35	1.58e-8	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7175404	1.000	rs28601612	chr15:94036833	C/T	cg23502883	chr15:93959149	NA	0.53	5.69	0.34	3.61e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.83	8.9	0.49	1.22e-16	Alzheimer's disease;
KIRP	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg02297831	chr4:17616191	MED28	-0.47	-5.85	-0.35	1.53e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.47	-5.76	-0.34	2.56e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4654899	0.680	rs10916900	chr1:21239059	C/G	cg05370193	chr1:21551575	ECE1	0.37	5.23	0.32	3.58e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	6.98	0.41	2.81e-11	Rheumatoid arthritis;
KIRP	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	15.22	0.7	2.51e-37	Homoarginine levels;
KIRP	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.6	-6.94	-0.4	3.39e-11	Diabetic retinopathy;
KIRP	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg13010199	chr12:38710504	ALG10B	-0.38	-4.86	-0.3	2.08e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.87	11.08	0.58	2.11e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-0.88	-10.94	-0.57	5.91e-23	Vitiligo;
KIRP	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg26338869	chr17:61819248	STRADA	0.54	6.31	0.37	1.29e-9	Prudent dietary pattern;
KIRP	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.2	0.37	2.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg03060546	chr3:49711283	APEH	-0.57	-4.9	-0.3	1.71e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs35771425	1.000	rs55961005	chr1:211567891	C/T	cg10512769	chr1:211675356	NA	-0.51	-5.1	-0.31	6.66e-7	Educational attainment (years of education);
KIRP	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.12	14.47	0.68	9.49e-35	Platelet count;
KIRP	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg02175308	chr1:109941060	SORT1	-0.3	-5.79	-0.35	2.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg04132472	chr17:19861366	AKAP10	0.47	6.58	0.39	2.76e-10	Schizophrenia;
KIRP	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.27	-0.55	8.17e-21	Hemoglobin concentration;
KIRP	cis	rs735539	0.517	rs7325243	chr13:21133294	G/A	cg04906043	chr13:21280425	IL17D	-0.47	-5.35	-0.32	2.05e-7	Dental caries;
KIRP	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg13319975	chr6:146136371	FBXO30	-0.48	-6.33	-0.37	1.16e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22117172	chr7:91764530	CYP51A1	0.5	7.13	0.41	1.11e-11	Breast cancer;
KIRP	cis	rs3736485	0.966	rs2414113	chr15:51903896	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.22	-0.32	3.83e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	8.42	0.47	3.15e-15	Bone mineral density;
KIRP	cis	rs9972944	1.000	rs9972944	chr17:63771079	A/G	cg07283582	chr17:63770753	CCDC46	0.48	7.94	0.45	7.1e-14	Total body bone mineral density;
KIRP	trans	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg24644049	chr4:85504048	CDS1	0.76	6.47	0.38	5.37e-10	Skin colour saturation;
KIRP	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.55	-7.14	-0.41	1.07e-11	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.64	8.3	0.47	7.09e-15	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.19	0.51	1.65e-17	Colorectal cancer;
KIRP	cis	rs2281603	0.570	rs11627387	chr14:64923977	G/A	cg01860774	chr14:64969374	ZBTB25	0.32	5.1	0.31	6.68e-7	Lymphocyte counts;
KIRP	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg21919602	chr1:242011447	EXO1	-0.46	-5.86	-0.35	1.49e-8	Menopause (age at onset);
KIRP	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.51	10.54	0.56	1.08e-21	Monocyte percentage of white cells;
KIRP	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.6	-7.54	-0.43	9.29e-13	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.54	-7.47	-0.43	1.39e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	6.16	0.37	2.92e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg01522456	chr1:115632236	TSPAN2	-0.36	-5.02	-0.3	1.01e-6	Autism;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg06815112	chr8:27182871	PTK2B	0.55	7.0	0.41	2.36e-11	Neuroticism;
KIRP	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.95	-16.43	-0.72	1.97e-41	Metabolic syndrome;
KIRP	cis	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg12315302	chr6:26189340	HIST1H4D	0.68	5.12	0.31	6.2e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2274273	1.000	rs7140872	chr14:55612744	C/T	cg04306507	chr14:55594613	LGALS3	0.47	7.22	0.42	6.4e-12	Protein biomarker;
KIRP	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.11	-0.31	6.56e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.88	10.88	0.57	9.01e-23	Vitiligo;
KIRP	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg02297831	chr4:17616191	MED28	0.57	6.96	0.41	3.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.67	-9.5	-0.52	1.95e-18	Colorectal cancer;
KIRP	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.61	-7.19	-0.42	7.71e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg24747557	chr10:131355152	MGMT	0.38	5.29	0.32	2.64e-7	Response to temozolomide;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg06163994	chr8:132854760	NA	-0.43	-6.03	-0.36	5.87e-9	Inflammatory biomarkers;
KIRP	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.65	-5.41	-0.33	1.46e-7	Chickenpox;
KIRP	cis	rs925946	0.565	rs11030088	chr11:27646247	G/A	cg18117895	chr11:27722066	BDNF	-0.53	-5.17	-0.31	4.81e-7	Body mass index;Weight;
KIRP	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg05938607	chr10:60274200	BICC1	0.42	10.22	0.55	1.11e-20	Refractive error;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg04780880	chr14:56072109	KTN1	0.42	6.16	0.37	2.98e-9	C-reactive protein;
KIRP	trans	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00950418	chr7:105029125	SRPK2	-0.53	-6.58	-0.39	2.86e-10	Height;
KIRP	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg15556689	chr8:8085844	FLJ10661	0.51	6.94	0.4	3.43e-11	Neuroticism;
KIRP	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	14.84	0.69	5.28e-36	Chronic sinus infection;
KIRP	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg24633833	chr3:10029261	TMEM111	0.52	4.98	0.3	1.17e-6	Alzheimer's disease;
KIRP	cis	rs5770917	1.000	rs17848459	chr22:51012311	G/T	cg19112186	chr22:51016638	CPT1B;CHKB-CPT1B	-0.54	-5.15	-0.31	5.35e-7	Narcolepsy;
KIRP	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.61	-9.6	-0.52	9.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg19773385	chr1:10388646	KIF1B	-0.7	-10.66	-0.56	4.55e-22	Hepatocellular carcinoma;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg18812198	chr11:68715658	NA	0.46	7.11	0.41	1.25e-11	Survival in pancreatic cancer;
KIRP	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.62	8.53	0.48	1.48e-15	Lymphocyte counts;
KIRP	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06544989	chr22:39130855	UNC84B	0.51	8.16	0.46	1.68e-14	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25691754	chr5:140027351	NDUFA2;IK	0.44	6.34	0.37	1.11e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg16558253	chr16:72132732	DHX38	-0.53	-7.43	-0.43	1.83e-12	Fibrinogen levels;
KIRP	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	16.09	0.72	2.71e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg02297831	chr4:17616191	MED28	-0.51	-6.43	-0.38	6.59e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.14	12.14	0.61	6.95e-27	Platelet count;
KIRP	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg08923054	chr8:41654455	ANK1	0.76	8.22	0.46	1.18e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg02175503	chr12:58329896	NA	0.58	6.36	0.38	9.69e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg22852734	chr6:133119734	C6orf192	1.12	7.47	0.43	1.41e-12	Type 2 diabetes nephropathy;
KIRP	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-6.92	-0.4	3.86e-11	Educational attainment;
KIRP	cis	rs7714584	1.000	rs11748158	chr5:150226345	C/T	cg22134413	chr5:150180641	NA	0.56	5.04	0.31	9.13e-7	Crohn's disease;
KIRP	cis	rs7209700	0.963	rs1000232	chr17:45356561	T/C	cg25173405	chr17:45401733	C17orf57	0.39	4.97	0.3	1.24e-6	IgG glycosylation;
KIRP	cis	rs698833	0.813	rs3768919	chr2:44512971	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	5.19	0.31	4.38e-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.73	0.34	2.94e-8	Height;
KIRP	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-1.12	-18.72	-0.77	3.2e-49	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-6.94	-0.4	3.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs259842	0.663	rs10211004	chr2:180687663	T/C	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.45	-6.68	-0.39	1.61e-10	Blood protein levels;
KIRP	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg00507259	chr4:95128692	SMARCAD1	0.41	5.24	0.32	3.37e-7	QT interval;
KIRP	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg10503236	chr1:231470652	EXOC8	-0.5	-6.96	-0.41	3.16e-11	Hemoglobin concentration;
KIRP	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg06050784	chr16:88016603	BANP	0.44	5.49	0.33	1.01e-7	Menopause (age at onset);
KIRP	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.42	-0.65	3.62e-31	Monocyte count;
KIRP	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-11.1	-0.58	1.77e-23	Morning vs. evening chronotype;
KIRP	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.62	5.12	0.31	6.07e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-8.55	-0.48	1.32e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.85	11.92	0.6	3.81e-26	Monocyte count;
KIRP	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.45	-10.09	-0.54	2.85e-20	Alzheimer's disease (late onset);
KIRP	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.76	-0.34	2.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6815814	0.898	rs2174284	chr4:38859339	C/T	cg06935464	chr4:38784597	TLR10	0.53	5.39	0.32	1.65e-7	Breast cancer;
KIRP	cis	rs447921	0.861	rs36119142	chr17:74454336	T/G	cg17201438	chr17:74438067	UBE2O	0.46	4.98	0.3	1.21e-6	Mitochondrial DNA levels;
KIRP	cis	rs728616	0.681	rs35014047	chr10:81912397	A/C	cg27417294	chr10:81904244	PLAC9	0.56	5.02	0.3	1e-6	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	trans	rs7246760	1.000	rs68176351	chr19:9864222	G/A	cg02900749	chr2:68251473	NA	-1.19	-10.09	-0.54	3.04e-20	Pursuit maintenance gain;
KIRP	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.45	-0.47	2.51e-15	Neuroticism;
KIRP	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg05362011	chr13:21860987	NA	-0.46	-4.95	-0.3	1.36e-6	White matter hyperintensity burden;
KIRP	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg11522683	chr6:37501428	NA	-0.41	-5.46	-0.33	1.16e-7	Cognitive performance;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg03433549	chr12:56498817	PA2G4	0.74	6.36	0.38	9.67e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs13132184	0.507	rs933818	chr4:38079294	A/G	cg14409701	chr4:38048871	TBC1D1	-0.75	-7.25	-0.42	5.26e-12	Verbal declarative memory;
KIRP	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs6783573	0.535	rs12637699	chr3:46628443	C/T	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.63	-8.01	-0.45	4.65e-14	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11671005	0.504	rs7257669	chr19:59064939	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.44	-5.32	-0.32	2.28e-7	Mean platelet volume;
KIRP	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.51	-6.09	-0.36	4.37e-9	Longevity;
KIRP	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	4.92	0.3	1.59e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7224685	0.569	rs35578550	chr17:3996470	A/G	cg09695851	chr17:3907499	NA	0.55	5.14	0.31	5.57e-7	Type 2 diabetes;
KIRP	cis	rs6500395	0.588	rs8046716	chr16:48560941	A/G	cg04672837	chr16:48644449	N4BP1	-0.39	-5.42	-0.33	1.4e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-7.36	-0.42	2.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.26	-4.95	-0.3	1.39e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs1345301	0.935	rs11691721	chr2:102876679	G/A	cg12451869	chr2:102867685	NA	0.39	5.7	0.34	3.37e-8	Waist circumference;
KIRP	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg07701084	chr6:150067640	NUP43	0.57	7.26	0.42	4.94e-12	Lung cancer;
KIRP	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.55	-7.19	-0.42	7.76e-12	Monocyte count;
KIRP	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg01877450	chr7:97915802	BRI3	-0.56	-7.17	-0.42	8.81e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg09163369	chr1:210001066	C1orf107	0.53	5.73	0.34	2.87e-8	Orofacial clefts;
KIRP	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.98	-10.47	-0.56	1.93e-21	Exhaled nitric oxide output;
KIRP	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.42	-6.29	-0.37	1.43e-9	Obesity-related traits;
KIRP	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg01879757	chr17:41196368	BRCA1	-0.79	-11.16	-0.58	1.12e-23	Menopause (age at onset);
KIRP	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg18154014	chr19:37997991	ZNF793	0.7	7.63	0.44	5.01e-13	Coronary artery calcification;
KIRP	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.91	14.42	0.68	1.42e-34	Height;
KIRP	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-6.67	-0.39	1.7e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg18478394	chr8:109455254	TTC35	0.52	6.54	0.38	3.52e-10	Dupuytren's disease;
KIRP	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg01244601	chr4:120671846	NA	-0.39	-5.17	-0.31	4.91e-7	Corneal astigmatism;
KIRP	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	cg04338863	chr8:33670619	NA	0.47	6.19	0.37	2.54e-9	Body mass index;
KIRP	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.81	-14.63	-0.68	2.63e-35	Calcium levels;
KIRP	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg03465714	chr1:152285911	FLG	0.48	5.47	0.33	1.11e-7	Atopic dermatitis;
KIRP	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.31	0.51	7.53e-18	Morning vs. evening chronotype;
KIRP	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.6	7.93	0.45	7.53e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs72829446	0.530	rs2301609	chr17:7399866	G/A	cg17788227	chr17:7347145	FGF11;CHRNB1	0.47	5.03	0.31	9.42e-7	Androgen levels;
KIRP	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg06115741	chr20:33292138	TP53INP2	0.39	5.17	0.31	4.84e-7	Glomerular filtration rate (creatinine);
KIRP	trans	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg16141378	chr3:129829833	LOC729375	0.49	6.13	0.36	3.53e-9	Myopia (pathological);
KIRP	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.58	6.42	0.38	7.11e-10	Coronary artery disease;
KIRP	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg17133734	chr15:86042851	AKAP13	-0.44	-5.39	-0.32	1.69e-7	Coronary artery disease;
KIRP	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.91	15.47	0.7	3.54e-38	Headache;
KIRP	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.68	6.83	0.4	6.53e-11	Vitiligo;
KIRP	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03157738	chr19:11308118	KANK2	0.66	7.97	0.45	5.77e-14	Smoking initiation;
KIRP	cis	rs9362426	1.000	rs242271	chr6:88082029	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.43	5.14	0.31	5.63e-7	Depressive episodes in bipolar disorder;
KIRP	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg26084005	chr2:241760190	KIF1A	-0.39	-5.23	-0.32	3.58e-7	Urinary metabolites;
KIRP	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18364779	chr6:26104403	HIST1H4C	0.38	5.1	0.31	6.88e-7	Schizophrenia;
KIRP	cis	rs9513627	1.000	rs73556178	chr13:100121947	T/C	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.49	-5.83	-0.35	1.73e-8	Glomerular filtration rate;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00933542	chr6:150070202	PCMT1	0.29	5.73	0.34	2.91e-8	Lung cancer;
KIRP	cis	rs7129556	0.813	rs11237249	chr11:77341135	G/A	cg12586386	chr11:77299805	AQP11	0.51	6.14	0.36	3.22e-9	Weight loss (gastric bypass surgery);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22885777	chr19:15947555	NA	0.43	6.17	0.37	2.76e-9	Parkinson's disease;
KIRP	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg18225595	chr11:63971243	STIP1	0.68	6.12	0.36	3.71e-9	Mean platelet volume;
KIRP	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.34	-0.32	2.12e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs7155603	0.700	rs17103360	chr14:75959341	A/G	cg01624173	chr14:75981868	NA	0.53	6.14	0.36	3.3e-9	Rheumatoid arthritis;
KIRP	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.67	-7.22	-0.42	6.57e-12	Corneal structure;
KIRP	cis	rs1832871	0.683	rs11756200	chr6:158657736	A/G	cg07215822	chr6:158701037	NA	-0.64	-7.34	-0.42	3.03e-12	Height;
KIRP	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg13147721	chr7:65941812	NA	-0.99	-6.77	-0.4	9.48e-11	Diabetic kidney disease;
KIRP	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07256732	chr16:621771	PIGQ	-0.46	-6.44	-0.38	6.15e-10	Height;
KIRP	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.53	-6.21	-0.37	2.25e-9	Ulcerative colitis;
KIRP	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.6	7.53	0.43	9.74e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg08501292	chr6:25962987	TRIM38	0.79	5.3	0.32	2.62e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9367716	0.741	rs9396266	chr6:57107322	C/T	cg03371099	chr6:57305889	PRIM2	0.48	6.15	0.37	3.11e-9	Coronary artery disease;
KIRP	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg05805236	chr11:65401703	PCNXL3	-0.55	-6.98	-0.41	2.73e-11	Acne (severe);
KIRP	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.64	0.6	3.05e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs3857747	0.931	rs10261478	chr7:40388695	G/A	cg00420559	chr7:40367873	C7orf10	0.65	8.26	0.47	9.14e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg19180546	chr13:44453867	C13orf31;CCDC122	0.47	6.14	0.36	3.36e-9	Leprosy;
KIRP	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg21858823	chr1:15850916	CASP9	0.53	5.16	0.31	4.97e-7	Systolic blood pressure;
KIRP	cis	rs829661	0.739	rs2593459	chr2:30870789	T/C	cg10949345	chr2:30726833	LCLAT1	1.09	13.34	0.65	6.7e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs5753618	1.000	rs5753618	chr22:31838518	C/T	cg02404636	chr22:31891804	SFI1	0.47	5.0	0.3	1.09e-6	Colorectal cancer;
KIRP	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg00277334	chr10:82204260	NA	-0.46	-5.28	-0.32	2.84e-7	Post bronchodilator FEV1;
KIRP	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.69	10.33	0.55	5.26e-21	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05384413	chr15:101142580	LINS1;ASB7	0.49	6.02	0.36	6.32e-9	Parkinson's disease;
KIRP	cis	rs2274273	0.712	rs7144652	chr14:55537718	G/A	cg04306507	chr14:55594613	LGALS3	0.44	6.7	0.39	1.4e-10	Protein biomarker;
KIRP	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.83e-18	Bipolar disorder;
KIRP	cis	rs11638352	0.661	rs1820484	chr15:44429885	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.22	0.32	3.89e-7	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.67	-8.31	-0.47	6.46e-15	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7116495	1.000	rs3793938	chr11:71823133	G/A	cg26138937	chr11:71823887	C11orf51	0.71	5.63	0.34	4.81e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg13319975	chr6:146136371	FBXO30	-0.44	-6.4	-0.38	7.91e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2671245	0.586	rs9436980	chr1:56133676	A/G	cg11523071	chr1:56160889	NA	0.4	6.09	0.36	4.36e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg10017260	chr10:834428	NA	-0.44	-6.25	-0.37	1.77e-9	Survival in rectal cancer;
KIRP	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.55	-8.2	-0.46	1.38e-14	Coronary artery disease;
KIRP	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg26876637	chr1:152193138	HRNR	0.73	9.51	0.52	1.88e-18	Atopic dermatitis;
KIRP	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg20991723	chr1:152506922	NA	-0.49	-5.94	-0.35	9.82e-9	Hair morphology;
KIRP	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.54	4.87	0.3	2.01e-6	Bipolar disorder;
KIRP	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg19752551	chr11:57585705	CTNND1	-0.82	-13.57	-0.65	1.08e-31	Schizophrenia;
KIRP	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg09904177	chr6:26538194	HMGN4	0.54	6.31	0.37	1.29e-9	Small cell lung carcinoma;
KIRP	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg15655495	chr12:38532458	NA	-0.25	-4.84	-0.3	2.26e-6	Heart rate;
KIRP	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg10818794	chr15:86012489	AKAP13	-0.53	-7.47	-0.43	1.39e-12	Coronary artery disease;
KIRP	cis	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg21546286	chr11:48923668	NA	-0.45	-5.73	-0.34	2.9e-8	HDL cholesterol;
KIRP	cis	rs7221595	0.756	rs35102999	chr17:3892700	G/A	cg21851534	chr17:3907994	ZZEF1	0.55	5.45	0.33	1.21e-7	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg16255804	chr6:135334527	HBS1L	-0.31	-4.93	-0.3	1.52e-6	Red blood cell count;
KIRP	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg06917634	chr15:78832804	PSMA4	0.53	5.89	0.35	1.27e-8	Sudden cardiac arrest;
KIRP	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg02996583	chr8:142237188	SLC45A4	-0.49	-6.05	-0.36	5.27e-9	Immature fraction of reticulocytes;
KIRP	cis	rs9815354	1.000	rs9823254	chr3:41894768	G/C	cg03022575	chr3:42003672	ULK4	0.64	6.79	0.4	8.29e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.49	-5.89	-0.35	1.29e-8	Response to antidepressants in depression;
KIRP	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.52	0.38	3.91e-10	Hypertriglyceridemia;
KIRP	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.11	-0.36	3.82e-9	Morning vs. evening chronotype;
KIRP	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.78	11.46	0.59	1.22e-24	Total body bone mineral density;
KIRP	cis	rs1712790	0.614	rs4938127	chr11:114633642	G/A	cg19465033	chr11:114479364	NA	0.4	5.31	0.32	2.41e-7	Urinary albumin excretion;
KIRP	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.56	-7.64	-0.44	4.98e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg00277334	chr10:82204260	NA	-0.48	-5.58	-0.34	6.34e-8	Post bronchodilator FEV1;
KIRP	cis	rs6142102	0.659	rs6057945	chr20:32517180	A/T	cg08999081	chr20:33150536	PIGU	0.48	5.61	0.34	5.36e-8	Skin pigmentation;
KIRP	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23598886	chr18:12777645	NA	0.68	5.66	0.34	4.25e-8	Inflammatory skin disease;
KIRP	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.68	-12.76	-0.63	5.67e-29	White blood cell count (basophil);
KIRP	cis	rs12213875	0.569	rs12202914	chr6:14599821	T/G	cg01527307	chr6:14500441	NA	-0.4	-5.31	-0.32	2.51e-7	Ovarian reserve;
KIRP	cis	rs812925	0.553	rs1177307	chr2:61387388	T/C	cg15711740	chr2:61764176	XPO1	-0.43	-5.14	-0.31	5.73e-7	Immature fraction of reticulocytes;
KIRP	cis	rs2309757	1	rs2309757	chr2:100807725	T/C	cg07810366	chr2:100720526	AFF3	-0.32	-5.0	-0.3	1.1e-6	Educational attainment (college completion);
KIRP	cis	rs909685	0.590	rs3747177	chr22:39746168	C/A	cg24399712	chr22:39784796	NA	-0.43	-5.42	-0.33	1.42e-7	Rheumatoid arthritis;
KIRP	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.7e-10	Red blood cell count;
KIRP	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg10018233	chr7:150070692	REPIN1	0.56	7.08	0.41	1.5e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg10363578	chr11:89956357	CHORDC1	-0.49	-6.59	-0.39	2.71e-10	Migraine with aura;
KIRP	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.68	-7.39	-0.43	2.32e-12	Menarche (age at onset);
KIRP	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.76	-10.79	-0.57	1.74e-22	Waist circumference;Body mass index;
KIRP	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg27490568	chr2:178487706	NA	0.6	7.73	0.44	2.71e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.74	-11.19	-0.58	8.78e-24	Lung cancer;
KIRP	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	1.0	15.33	0.7	1.08e-37	Sudden cardiac arrest;
KIRP	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	6.71	0.39	1.3e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.73	9.99	0.54	5.96e-20	Response to antipsychotic treatment;
KIRP	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	11.83	0.6	7.32e-26	Monocyte percentage of white cells;
KIRP	cis	rs11783469	0.522	rs13281304	chr8:23266922	T/C	cg00472375	chr8:23315376	ENTPD4	0.53	5.5	0.33	9.34e-8	Reticulocyte count;
KIRP	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.89	-10.84	-0.57	1.27e-22	Gut microbiome composition (summer);
KIRP	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.66	-8.17	-0.46	1.6e-14	Aortic root size;
KIRP	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg08499158	chr17:42289980	UBTF	-0.48	-6.3	-0.37	1.37e-9	Bone mineral density (hip);Bone mineral density;
KIRP	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-7.06	-0.41	1.69e-11	Myopia (pathological);
KIRP	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-9.4	-0.51	4.06e-18	Neuroticism;
KIRP	cis	rs4664304	0.620	rs11895141	chr2:160716449	T/A	cg03641300	chr2:160917029	PLA2R1	0.35	5.2	0.31	4.11e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.98	-13.56	-0.65	1.16e-31	Ulcerative colitis;
KIRP	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.61	-6.66	-0.39	1.79e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	9.03	0.5	5.27e-17	Lung cancer in ever smokers;
KIRP	cis	rs4853525	0.522	rs1860167	chr2:191582387	G/A	cg11845111	chr2:191398756	TMEM194B	-0.44	-4.89	-0.3	1.81e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs12496230	0.794	rs725161	chr3:66860401	G/A	cg04995300	chr3:66848608	NA	0.45	6.97	0.41	2.88e-11	Type 2 diabetes;
KIRP	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg07499259	chr1:12188502	TNFRSF8	0.42	6.06	0.36	5.1e-9	Myopia;
KIRP	cis	rs8070740	0.786	rs12761	chr17:5326145	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.59	7.5	0.43	1.14e-12	Menopause (age at onset);
KIRP	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg06647332	chr5:131281008	NA	0.46	5.0	0.3	1.08e-6	Life satisfaction;
KIRP	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.84	12.28	0.62	2.35e-27	Eosinophil percentage of white cells;
KIRP	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.75	-0.34	2.59e-8	Colorectal cancer;
KIRP	cis	rs4684776	0.676	rs2067472	chr3:11299190	G/C	cg00170343	chr3:11313890	ATG7	-0.49	-4.87	-0.3	1.97e-6	Small vessel stroke;
KIRP	cis	rs10056811	0.538	rs3923323	chr5:74372141	C/T	cg19683494	chr5:74908142	NA	-0.54	-4.87	-0.3	1.96e-6	Coronary artery disease;
KIRP	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg21926883	chr2:100939477	LONRF2	0.54	7.52	0.43	1.04e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.57	-6.68	-0.39	1.56e-10	Initial pursuit acceleration;
KIRP	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.52	-6.56	-0.39	3.08e-10	Cancer;
KIRP	cis	rs732716	0.853	rs1127888	chr19:4454083	C/T	cg03719555	chr19:4455413	UBXN6	0.49	7.45	0.43	1.62e-12	Mean corpuscular volume;
KIRP	cis	rs679087	0.833	rs302342	chr12:29939628	A/G	cg14258853	chr12:29935411	TMTC1	-0.61	-6.72	-0.39	1.28e-10	Schizophrenia;
KIRP	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg22117172	chr7:91764530	CYP51A1	0.45	6.23	0.37	2.02e-9	Breast cancer;
KIRP	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.35	-0.38	1.05e-9	Schizophrenia;
KIRP	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg18279126	chr7:2041391	MAD1L1	0.47	4.94	0.3	1.42e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg23594656	chr7:65796392	TPST1	-0.47	-7.53	-0.43	9.42e-13	Aortic root size;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17577923	chr7:12727243	ARL4A	0.41	6.02	0.36	6.23e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg26828218	chr2:219264796	CTDSP1	0.49	6.09	0.36	4.24e-9	Myopia (pathological);
KIRP	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg05768032	chr16:30646687	NA	0.46	5.54	0.33	7.61e-8	Multiple myeloma;
KIRP	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16414030	chr3:133502952	NA	-0.51	-5.97	-0.36	8.19e-9	Iron status biomarkers;
KIRP	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg13072238	chr3:49761600	GMPPB	0.57	5.3	0.32	2.61e-7	Menarche (age at onset);
KIRP	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg27205649	chr11:78285834	NARS2	-0.67	-7.65	-0.44	4.67e-13	Alzheimer's disease (survival time);
KIRP	cis	rs13385	0.769	rs59453051	chr5:139558212	T/G	cg01860693	chr5:139557145	C5orf32	0.49	5.46	0.33	1.17e-7	Atrial fibrillation;
KIRP	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg21698718	chr17:80085957	CCDC57	0.36	5.16	0.31	5.15e-7	Life satisfaction;
KIRP	trans	rs6601327	0.670	rs4128198	chr8:9433499	T/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.85	0.4	5.98e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.63	-8.08	-0.46	2.85e-14	Body mass index;
KIRP	cis	rs57994353	0.600	rs10870163	chr9:139315594	G/A	cg21253087	chr9:139290292	SNAPC4	0.53	5.41	0.33	1.47e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg06565975	chr8:143823917	SLURP1	-0.44	-6.64	-0.39	1.97e-10	Urinary tract infection frequency;
KIRP	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg06671706	chr8:8559999	CLDN23	0.49	5.78	0.35	2.27e-8	Obesity-related traits;
KIRP	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg01302019	chr3:143689584	C3orf58	-0.38	-5.57	-0.33	6.63e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg24253500	chr15:84953950	NA	0.64	7.08	0.41	1.55e-11	Schizophrenia;
KIRP	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.44	6.63	0.39	2.06e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg03235661	chr20:60525775	NA	-0.3	-4.97	-0.3	1.25e-6	Body mass index;
KIRP	cis	rs10046574	0.561	rs7781454	chr7:135205422	A/G	cg27474649	chr7:135195673	CNOT4	0.5	5.0	0.3	1.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg13319975	chr6:146136371	FBXO30	-0.49	-7.17	-0.42	8.78e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg26207909	chr14:103986467	CKB	0.53	7.06	0.41	1.7e-11	Body mass index;
KIRP	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.72	-8.12	-0.46	2.27e-14	Pursuit maintenance gain;
KIRP	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.44	5.77	0.35	2.38e-8	Height;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg02462569	chr6:150064036	NUP43	-0.35	-5.48	-0.33	1.03e-7	Lung cancer;
KIRP	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.94	9.58	0.52	1.1e-18	Gut microbiome composition (summer);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04312413	chr1:186340995	TPR;MIR548F1	-0.39	-6.09	-0.36	4.43e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.81	-8.38	-0.47	3.99e-15	Gut microbiome composition (summer);
KIRP	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg19338460	chr6:170058176	WDR27	-0.61	-7.1	-0.41	1.37e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10940138	0.501	rs3953388	chr5:67248570	C/G	ch.5.1281357F	chr5:67228439	NA	-0.5	-7.4	-0.43	2.19e-12	Menarche (age at onset);
KIRP	cis	rs11169552	0.510	rs4768906	chr12:51106823	T/G	cg12884762	chr12:50931848	DIP2B	-0.44	-5.23	-0.32	3.69e-7	Colorectal cancer;
KIRP	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg08603382	chr10:743973	NA	0.63	10.14	0.54	2.1e-20	Psychosis in Alzheimer's disease;
KIRP	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.78	7.62	0.44	5.57e-13	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs6433857	0.505	rs7561255	chr2:181369216	A/G	cg23363182	chr2:181467187	NA	-0.4	-5.72	-0.34	3.14e-8	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16398128	chr5:16465888	ZNF622	0.48	6.13	0.36	3.43e-9	Parkinson's disease;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg22292462	chr13:45799592	GTF2F2	0.5	6.94	0.4	3.54e-11	Interleukin-4 levels;
KIRP	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.34	19.21	0.77	7.28e-51	Corneal structure;
KIRP	cis	rs1915919	0.794	rs4398451	chr3:20010886	T/C	cg12877253	chr3:19992400	RAB5A	-0.37	-5.29	-0.32	2.7e-7	Post-traumatic stress disorder;
KIRP	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	10.13	0.54	2.14e-20	Monocyte percentage of white cells;
KIRP	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg20651018	chr11:3035856	CARS	-0.35	-4.87	-0.3	2.01e-6	Longevity;
KIRP	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.65	-7.32	-0.42	3.61e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.4	-6.29	-0.37	1.46e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg25838818	chr2:108905173	SULT1C2	-0.41	-6.35	-0.38	1.04e-9	Blood pressure;
KIRP	cis	rs959260	1.000	rs6501786	chr17:73378775	A/T	cg20590849	chr17:73267439	MIF4GD	0.6	6.46	0.38	5.69e-10	Systemic lupus erythematosus;
KIRP	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.34	6.57	0.39	3e-10	Monocyte percentage of white cells;
KIRP	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg09408571	chr1:101003634	GPR88	-0.24	-5.35	-0.32	1.97e-7	Breast cancer;
KIRP	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.47	6.57	0.39	2.95e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs16976116	0.901	rs62020097	chr15:55491007	A/T	cg11288833	chr15:55489084	RSL24D1	0.66	7.46	0.43	1.44e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg10633746	chr17:18164442	SMCR7	0.51	6.04	0.36	5.69e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.74	-7.62	-0.44	5.38e-13	Hair shape;
KIRP	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.79	-9.97	-0.54	7.13e-20	Longevity;
KIRP	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.4	-6.75	-0.4	1.06e-10	Refractive error;
KIRP	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	11.73	0.6	1.57e-25	Alzheimer's disease;
KIRP	cis	rs7404928	0.718	rs11644103	chr16:23860388	T/A	cg05497750	chr16:23765381	CHP2	-0.44	-5.19	-0.31	4.39e-7	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg09873164	chr1:152488093	CRCT1	0.56	7.1	0.41	1.34e-11	Hair morphology;
KIRP	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-13.95	-0.66	5.47e-33	Primary sclerosing cholangitis;
KIRP	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.6	-7.18	-0.42	8.22e-12	Monocyte percentage of white cells;
KIRP	cis	rs6838801	1.000	rs6838801	chr4:77549559	G/T	cg17476223	chr4:77663285	SHROOM3	0.5	6.84	0.4	6.32e-11	Cleft lip with or without cleft palate;
KIRP	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg14456004	chr13:21872349	NA	-1.11	-13.85	-0.66	1.2e-32	White matter hyperintensity burden;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13407422	chr20:25371439	ABHD12	0.54	7.5	0.43	1.16e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06481639	chr22:41940642	POLR3H	-0.71	-7.1	-0.41	1.32e-11	Vitiligo;
KIRP	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg11657440	chr19:46296263	DMWD	-0.74	-9.69	-0.53	5.01e-19	Coronary artery disease;
KIRP	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	8.94	0.5	9.6e-17	Lung cancer in ever smokers;
KIRP	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.78	-11.32	-0.59	3.56e-24	Height;
KIRP	cis	rs6732160	0.564	rs60796597	chr2:73382914	C/T	cg01422370	chr2:73384389	NA	0.53	7.07	0.41	1.59e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2483058	0.767	rs963894	chr1:206625429	G/A	cg19452316	chr1:206680966	RASSF5	0.41	5.54	0.33	7.78e-8	Cholesterol and Triglycerides;
KIRP	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.23	0.32	3.59e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg07382826	chr16:28625726	SULT1A1	0.5	6.02	0.36	6.35e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg18132916	chr6:79620363	NA	-0.41	-5.65	-0.34	4.52e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg15655495	chr12:38532458	NA	0.27	5.32	0.32	2.38e-7	Bladder cancer;
KIRP	cis	rs2905347	0.757	rs1006509	chr7:22698466	C/T	cg23521230	chr7:22704884	NA	-0.4	-5.26	-0.32	3.07e-7	Major depression and alcohol dependence;
KIRP	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.71	-10.51	-0.56	1.41e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg04702396	chr17:15466718	FAM18B2	0.48	6.11	0.36	3.84e-9	Educational attainment (years of education);
KIRP	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20887711	chr4:1340912	KIAA1530	-0.43	-5.29	-0.32	2.71e-7	Obesity-related traits;
KIRP	cis	rs2273156	1.000	rs12050404	chr14:35461870	G/A	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.47	-0.33	1.1e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg17554472	chr22:41940697	POLR3H	-0.44	-5.42	-0.33	1.41e-7	Vitiligo;
KIRP	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs4006360	0.543	rs7502165	chr17:39268037	A/C	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.26	-0.42	5.02e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg26513180	chr16:89883248	FANCA	0.54	7.05	0.41	1.82e-11	Vitiligo;
KIRP	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.53	8.06	0.46	3.41e-14	Itch intensity from mosquito bite;
KIRP	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg21395723	chr22:39101663	GTPBP1	0.4	5.33	0.32	2.26e-7	Menopause (age at onset);
KIRP	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.14	0.31	5.53e-7	Menopause (age at onset);
KIRP	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06558623	chr16:89946397	TCF25	1.11	8.1	0.46	2.63e-14	Skin colour saturation;
KIRP	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg10189774	chr4:17578691	LAP3	0.54	6.49	0.38	4.61e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.66	8.82	0.49	2.18e-16	Bladder cancer;
KIRP	cis	rs4356975	0.563	rs7662029	chr4:69961912	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.55	-0.39	3.26e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs35740288	0.770	rs11635190	chr15:86148531	C/T	cg17133734	chr15:86042851	AKAP13	-0.52	-5.71	-0.34	3.29e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.4	-6.28	-0.37	1.54e-9	Body mass index;
KIRP	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.35	0.38	1.01e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.51	-0.33	8.88e-8	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg27570636	chr1:214454189	SMYD2	0.52	7.04	0.41	1.94e-11	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs3752645	1.000	rs6960708	chr7:106777203	A/G	cg02696742	chr7:106810147	HBP1	-0.61	-5.42	-0.33	1.44e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs2444240	0.505	rs566935	chr11:120055477	C/G	cg04390734	chr11:120039366	NA	-0.38	-6.07	-0.36	4.7e-9	Corneal curvature;
KIRP	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.96	8.03	0.46	4.17e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.8	7.95	0.45	6.88e-14	Neuroblastoma;
KIRP	cis	rs4908768	0.906	rs7539382	chr1:8579301	C/T	cg03610117	chr1:8450231	RERE	-0.49	-5.33	-0.32	2.18e-7	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg09344028	chr17:70110421	NA	0.42	9.16	0.5	2.08e-17	Thyroid hormone levels;
KIRP	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18252515	chr7:66147081	NA	-0.46	-5.36	-0.32	1.88e-7	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03361817	chr10:63663270	ARID5B	0.53	6.62	0.39	2.2e-10	Parkinson's disease;
KIRP	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.59	-0.39	2.67e-10	Bipolar disorder;
KIRP	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.75	-8.79	-0.49	2.69e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.28	0.47	8.15e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10782582	0.592	rs7513194	chr1:76382664	A/C	cg03433033	chr1:76189801	ACADM	0.48	7.18	0.42	8.24e-12	Daytime sleep phenotypes;
KIRP	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.75	-6.89	-0.4	4.69e-11	Cerebrospinal P-tau181p levels;
KIRP	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	6.18	0.37	2.71e-9	Platelet count;
KIRP	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg15556689	chr8:8085844	FLJ10661	0.64	8.21	0.46	1.25e-14	Retinal vascular caliber;
KIRP	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg20243544	chr17:37824526	PNMT	0.48	6.68	0.39	1.63e-10	Asthma;
KIRP	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg13798780	chr7:105162888	PUS7	0.63	5.66	0.34	4.2e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.48	5.36	0.32	1.88e-7	Coronary artery disease;
KIRP	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02359409	chr6:42947317	PEX6	-0.52	-7.29	-0.42	4.29e-12	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.83	9.64	0.52	7.45e-19	Systolic blood pressure;
KIRP	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg19847130	chr8:10466454	RP1L1	0.36	5.35	0.32	1.98e-7	Triglycerides;
KIRP	cis	rs7590368	0.715	rs56321198	chr2:10959292	C/A	cg15705551	chr2:10952987	PDIA6	0.6	5.35	0.32	1.98e-7	Educational attainment (years of education);
KIRP	trans	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-6.15	-0.37	3.17e-9	Neuroticism;
KIRP	cis	rs2071426	0.622	rs11188131	chr10:96768411	C/T	cg09036531	chr10:96991505	NA	-0.46	-5.34	-0.32	2.1e-7	Blood metabolite levels;
KIRP	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg10360139	chr7:1886902	MAD1L1	-0.44	-4.9	-0.3	1.7e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs11997175	0.603	rs6468205	chr8:33778642	T/A	ch.8.33884649F	chr8:33765107	NA	0.46	5.55	0.33	7.35e-8	Body mass index;
KIRP	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg24579218	chr15:68104479	NA	0.54	8.52	0.48	1.66e-15	Restless legs syndrome;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03041860	chr2:208489911	FAM119A	0.58	6.79	0.4	8.13e-11	Smoking initiation;
KIRP	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.51	0.52	1.78e-18	Corneal astigmatism;
KIRP	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg23985595	chr17:80112537	CCDC57	-0.34	-4.99	-0.3	1.15e-6	Life satisfaction;
KIRP	cis	rs7017914	0.967	rs7013657	chr8:71637559	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.08	-0.31	7.39e-7	Bone mineral density;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg23736307	chr8:27182930	PTK2B	0.54	6.85	0.4	5.94e-11	Neuroticism;
KIRP	cis	rs9815354	0.812	rs17218504	chr3:41987278	A/G	cg03022575	chr3:42003672	ULK4	0.8	8.3	0.47	6.83e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg23029597	chr12:123009494	RSRC2	-0.41	-5.16	-0.31	5.09e-7	Body mass index;
KIRP	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.68	9.62	0.52	8.27e-19	Retinal vascular caliber;
KIRP	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.35	-0.32	2.02e-7	Breast cancer;
KIRP	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg14972814	chr11:95582409	MTMR2	0.35	5.81	0.35	1.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.89	-10.1	-0.54	2.81e-20	White matter hyperintensity burden;
KIRP	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.89	11.87	0.6	5.31e-26	Cognitive function;
KIRP	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-10.37	-0.55	3.84e-21	Colorectal cancer;
KIRP	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.58	5.76	0.34	2.48e-8	Total cholesterol levels;
KIRP	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.49	-0.48	1.95e-15	Personality dimensions;
KIRP	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.57	0.39	2.94e-10	Hypertriglyceridemia;
KIRP	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.45	6.13	0.36	3.44e-9	Sitting height ratio;
KIRP	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-5.52	-0.33	8.77e-8	Parkinson's disease;
KIRP	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs732716	0.889	rs11085074	chr19:4386352	A/G	cg03719555	chr19:4455413	UBXN6	0.51	7.71	0.44	3.06e-13	Mean corpuscular volume;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg27121462	chr16:89883253	FANCA	0.64	9.29	0.51	8.63e-18	Vitiligo;
KIRP	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg12131826	chr15:77904385	NA	-0.41	-4.9	-0.3	1.73e-6	Type 2 diabetes;
KIRP	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg00631329	chr6:26305371	NA	-0.6	-7.75	-0.44	2.35e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs6907629	0.776	rs2297468	chr6:167580179	C/G	cg21144340	chr6:167633022	NA	-0.38	-4.86	-0.3	2.12e-6	Asthma (childhood onset);
KIRP	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg01872077	chr2:219646372	CYP27A1	-0.38	-5.14	-0.31	5.58e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg00262122	chr8:11665843	FDFT1	-0.45	-5.52	-0.33	8.54e-8	Triglycerides;
KIRP	cis	rs7181230	0.845	rs4923852	chr15:40377865	A/G	cg00868766	chr15:40364524	NA	-0.31	-4.87	-0.3	2.04e-6	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.79	9.09	0.5	3.36e-17	Corneal astigmatism;
KIRP	cis	rs6753739	0.826	rs10171368	chr2:219933777	A/G	cg01749213	chr2:219906749	CCDC108	0.44	5.48	0.33	1.04e-7	Height;
KIRP	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg01620082	chr3:125678407	NA	-1.06	-6.79	-0.4	8.38e-11	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg21858823	chr1:15850916	CASP9	0.51	5.5	0.33	9.5e-8	Systolic blood pressure;
KIRP	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-10.12	-0.54	2.34e-20	Body mass index;
KIRP	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-1.18	-9.85	-0.53	1.64e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs9604529	0.759	rs73579379	chr13:114620782	G/A	cg13259177	chr13:114761607	RASA3	-0.64	-5.52	-0.33	8.41e-8	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg17595323	chr11:93583763	C11orf90	-0.37	-6.29	-0.37	1.47e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs2658782	0.615	rs2605615	chr11:93233068	G/A	cg15737290	chr11:93063684	CCDC67	0.7	7.72	0.44	2.86e-13	Pulmonary function decline;
KIRP	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.93	14.38	0.68	1.9e-34	Height;
KIRP	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.2	0.51	1.57e-17	Lymphocyte counts;
KIRP	cis	rs7173743	0.525	rs7403393	chr15:79135802	C/G	cg00079375	chr15:79125835	NA	0.4	5.61	0.34	5.33e-8	Coronary artery disease;
KIRP	cis	rs11783469	0.524	rs2235116	chr8:23337410	C/T	cg00472375	chr8:23315376	ENTPD4	-0.49	-5.14	-0.31	5.7e-7	Reticulocyte count;
KIRP	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.71	8.89	0.49	1.35e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2979489	0.591	rs62508371	chr8:30422060	C/T	cg26383811	chr8:30366931	RBPMS	-0.37	-5.12	-0.31	6.07e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.54	-6.77	-0.4	9.29e-11	Arsenic metabolism;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.57	-8.57	-0.48	1.16e-15	Menarche (age at onset);
KIRP	cis	rs714031	0.934	rs9607667	chr22:40077488	C/T	cg21377881	chr22:40064566	CACNA1I	-0.7	-10.79	-0.57	1.74e-22	Schizophrenia;
KIRP	cis	rs9634489	0.588	rs1925121	chr13:96938780	C/G	cg02571835	chr13:96230311	CLDN10	-0.36	-5.17	-0.31	4.94e-7	Body mass index;
KIRP	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23903597	chr17:61704154	MAP3K3	-0.63	-8.19	-0.46	1.4e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.63	0.39	2.1e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs860295	0.651	rs12239114	chr1:155322142	G/A	cg02153340	chr1:155202674	NA	-0.57	-7.54	-0.43	9.07e-13	Body mass index;
KIRP	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg11569703	chr11:65557185	OVOL1	0.35	5.23	0.32	3.55e-7	Eosinophil percentage of white cells;
KIRP	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.38	-0.62	1.12e-27	Exhaled nitric oxide output;
KIRP	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg16077055	chr2:106428750	NCK2	0.28	5.67	0.34	4e-8	Addiction;
KIRP	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg15848620	chr12:58087721	OS9	0.46	5.21	0.32	4.08e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs7707921	0.723	rs226197	chr5:81574925	G/A	cg07807695	chr5:81608485	ATP6AP1L	-0.42	-5.27	-0.32	2.95e-7	Breast cancer;
KIRP	cis	rs3770081	1.000	rs74607112	chr2:86305534	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.73	-4.88	-0.3	1.94e-6	Facial emotion recognition (sad faces);
KIRP	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg12940923	chr8:10282607	MSRA	-0.39	-5.1	-0.31	6.7e-7	Triglycerides;
KIRP	cis	rs6088813	1.000	rs6087702	chr20:33995945	T/A	cg14752227	chr20:34000481	UQCC	-0.5	-6.54	-0.39	3.47e-10	Height;
KIRP	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg02725872	chr8:58115012	NA	-0.57	-6.51	-0.38	4.27e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.5	-7.86	-0.45	1.21e-13	Huntington's disease progression;
KIRP	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg23387468	chr7:139079360	LUC7L2	0.31	5.29	0.32	2.72e-7	Diisocyanate-induced asthma;
KIRP	cis	rs12997796	0.556	rs35594332	chr2:86982651	G/A	cg25203885	chr2:87302643	LOC285074	-0.76	-5.97	-0.36	8.34e-9	Schizophrenia;
KIRP	cis	rs2273669	0.588	rs111353760	chr6:109306493	T/G	cg05315195	chr6:109294784	ARMC2	-0.63	-6.36	-0.38	1e-9	Prostate cancer;
KIRP	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg09137382	chr11:130731461	NA	0.54	7.71	0.44	3.13e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21851386	chr18:45457590	SMAD2	0.5	6.26	0.37	1.7e-9	Parkinson's disease;
KIRP	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg03289416	chr15:75166202	SCAMP2	0.53	7.16	0.42	9.57e-12	Breast cancer;
KIRP	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg08662619	chr6:150070041	PCMT1	0.37	6.27	0.37	1.6e-9	Lung cancer;
KIRP	cis	rs9513627	0.833	rs112671387	chr13:100123073	A/G	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-6.88	-0.4	5.06e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg05991184	chr2:219186017	PNKD	0.36	5.06	0.31	8.39e-7	Colorectal cancer;
KIRP	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17691542	chr6:26056736	HIST1H1C	0.5	6.5	0.38	4.45e-10	Height;
KIRP	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-7.73	-0.44	2.69e-13	Platelet count;
KIRP	cis	rs10073892	0.543	rs12653030	chr5:101887158	C/T	cg19774478	chr5:101632501	SLCO4C1	0.6	5.86	0.35	1.49e-8	Cognitive decline (age-related);
KIRP	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-8.6	-0.48	9.49e-16	Neuroticism;
KIRP	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-7.07	-0.41	1.55e-11	Morning vs. evening chronotype;
KIRP	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg16414030	chr3:133502952	NA	0.52	5.98	0.36	7.79e-9	Alcohol consumption (transferrin glycosylation);
KIRP	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg09324608	chr17:30823087	MYO1D	-0.42	-5.22	-0.32	3.75e-7	Schizophrenia;
KIRP	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg02811702	chr13:24901961	NA	0.43	5.71	0.34	3.31e-8	Obesity-related traits;
KIRP	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.73	8.39	0.47	3.94e-15	Cognitive ability;
KIRP	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg06647332	chr5:131281008	NA	0.47	5.36	0.32	1.9e-7	Life satisfaction;
KIRP	trans	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg08413026	chr12:132380000	ULK1	0.47	6.33	0.37	1.13e-9	Caffeine consumption;
KIRP	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	6.07	0.36	4.93e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs300890	0.583	rs2012599	chr4:144196860	T/C	cg19876092	chr4:144208277	NA	0.32	5.16	0.31	4.98e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs2288327	0.643	rs1559908	chr2:179336347	C/T	cg11548914	chr2:179343871	FKBP7;PLEKHA3;MIR548N	-0.59	-5.81	-0.35	1.91e-8	Atrial fibrillation;
KIRP	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg00852783	chr1:26633632	UBXN11	-0.52	-5.11	-0.31	6.42e-7	Obesity-related traits;
KIRP	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.59	6.82	0.4	6.92e-11	Monocyte percentage of white cells;
KIRP	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12282928	0.876	rs4980428	chr11:48296661	G/T	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg07511934	chr16:89386912	ANKRD11	-0.42	-5.16	-0.31	5.2e-7	Multiple myeloma (IgH translocation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18855466	chr2:201171404	SPATS2L	0.5	6.08	0.36	4.66e-9	Parkinson's disease;
KIRP	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg18904891	chr8:8559673	CLDN23	-0.62	-6.78	-0.4	8.97e-11	Obesity-related traits;
KIRP	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg22437258	chr11:111473054	SIK2	-0.54	-5.9	-0.35	1.18e-8	Primary sclerosing cholangitis;
KIRP	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg05721485	chr17:44071124	MAPT	0.56	7.42	0.43	1.85e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg24824245	chr12:22198725	CMAS	-0.59	-6.22	-0.37	2.11e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg17554472	chr22:41940697	POLR3H	0.47	5.27	0.32	2.92e-7	Vitiligo;
KIRP	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg13319975	chr6:146136371	FBXO30	-0.46	-6.28	-0.37	1.51e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.77	-10.26	-0.55	8.82e-21	Menarche (age at onset);
KIRP	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg00310523	chr12:86230176	RASSF9	-0.5	-7.91	-0.45	8.92e-14	Major depressive disorder;
KIRP	cis	rs7106204	0.514	rs2099890	chr11:24255948	C/T	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg13010199	chr12:38710504	ALG10B	0.66	8.75	0.49	3.48e-16	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg02073558	chr3:44770973	ZNF501	0.7	11.02	0.57	3.21e-23	Depressive symptoms;
KIRP	cis	rs7007076	0.609	rs6470181	chr8:124751588	C/T	cg00283535	chr8:124749564	ANXA13	-0.64	-7.94	-0.45	7.05e-14	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.86	-12.93	-0.64	1.59e-29	Body mass index;
KIRP	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.63	6.95	0.4	3.35e-11	Smoking initiation;
KIRP	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg27147174	chr7:100797783	AP1S1	-0.54	-6.84	-0.4	6.11e-11	Life satisfaction;
KIRP	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.72	-7.77	-0.44	2.11e-13	Gut microbiome composition (summer);
KIRP	cis	rs16858210	0.657	rs73177515	chr3:183566825	T/A	cg25686905	chr3:183603175	PARL	-0.44	-4.96	-0.3	1.3e-6	Menopause (age at onset);
KIRP	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg19875535	chr5:140030758	IK	0.65	9.32	0.51	6.91e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg15252951	chr6:33757062	LEMD2	0.46	5.48	0.33	1.06e-7	Crohn's disease;
KIRP	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg06219351	chr7:158114137	PTPRN2	0.55	7.86	0.45	1.17e-13	Calcium levels;
KIRP	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg24315340	chr6:146058215	EPM2A	-0.47	-5.85	-0.35	1.55e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg04554929	chr8:105342491	NA	-0.41	-6.05	-0.36	5.24e-9	Paget's disease;
KIRP	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.22	0.37	2.13e-9	Mean corpuscular volume;
KIRP	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.47	-5.04	-0.31	9.11e-7	Schizophrenia;
KIRP	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.53	-0.43	9.46e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg01988459	chr11:68622903	NA	-0.43	-5.97	-0.36	8.05e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.47	0.38	5.35e-10	Putamen volume;
KIRP	cis	rs13088645	0.532	rs9835166	chr3:134166224	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.5	6.71	0.39	1.35e-10	Coronary artery disease;
KIRP	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.39	-5.23	-0.32	3.68e-7	Bipolar disorder;
KIRP	trans	rs13170463	0.579	rs34602647	chr5:8049721	G/A	cg03862380	chr20:43029895	HNF4A	0.42	6.28	0.37	1.53e-9	Colorectal cancer;
KIRP	cis	rs13161895	1.000	rs17079968	chr5:179443423	C/T	cg02702477	chr5:179499311	RNF130	0.69	5.39	0.33	1.62e-7	LDL cholesterol;
KIRP	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.4	6.8	0.4	7.91e-11	Heart rate;
KIRP	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg11663144	chr21:46675770	NA	-0.7	-8.7	-0.49	4.87e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.48	-0.48	2.13e-15	Retinal vascular caliber;
KIRP	cis	rs754423	0.515	rs768022	chr14:52553180	G/C	cg05884192	chr14:52515736	NID2	-0.43	-5.11	-0.31	6.53e-7	Craniofacial microsomia;
KIRP	cis	rs11874712	1.000	rs1800637	chr18:43670190	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.41	-5.9	-0.35	1.2e-8	Migraine - clinic-based;
KIRP	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg25801113	chr15:45476975	SHF	0.48	9.43	0.52	3.12e-18	Uric acid levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg16347917	chr1:243491053	SDCCAG8	-0.4	-6.4	-0.38	7.68e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.07	0.31	7.67e-7	Educational attainment;
KIRP	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg05973401	chr12:123451056	ABCB9	0.56	6.49	0.38	4.58e-10	Neutrophil percentage of white cells;
KIRP	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.52	-8.13	-0.46	2.16e-14	Intelligence (multi-trait analysis);
KIRP	trans	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg00405596	chr8:11794950	NA	0.47	6.16	0.37	2.93e-9	Joint mobility (Beighton score);
KIRP	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.68	10.07	0.54	3.52e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg05361325	chr10:32636312	EPC1	-0.66	-6.28	-0.37	1.53e-9	Sexual dysfunction (female);
KIRP	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.51	-6.58	-0.39	2.79e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg09264619	chr17:80180166	NA	-0.52	-6.17	-0.37	2.85e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg00319359	chr11:70116639	PPFIA1	0.56	5.84	0.35	1.67e-8	Coronary artery disease;
KIRP	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg24642439	chr20:33292090	TP53INP2	0.53	6.85	0.4	6.03e-11	Height;
KIRP	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg23460707	chr10:133558971	NA	0.36	5.45	0.33	1.22e-7	Survival in rectal cancer;
KIRP	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-13.33	-0.65	6.94e-31	Exhaled nitric oxide output;
KIRP	cis	rs13401104	0.796	rs1968708	chr2:237110654	G/A	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.48	-6.43	-0.38	6.74e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg00629928	chr5:358741	AHRR	0.51	4.97	0.3	1.27e-6	Breast cancer;
KIRP	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg25039879	chr17:56429692	SUPT4H1	0.61	5.49	0.33	9.87e-8	Cognitive test performance;
KIRP	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.78	-10.58	-0.56	8.56e-22	Aortic root size;
KIRP	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg17517138	chr11:73019481	ARHGEF17	0.76	6.3	0.37	1.37e-9	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs741677	1.000	rs741677	chr17:463843	C/T	cg13332499	chr17:408570	NA	-0.38	-5.03	-0.31	9.61e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-1.0	-17.01	-0.74	2.04e-43	Height;
KIRP	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.51	-0.38	4.25e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11955175	1.000	rs75728011	chr5:40797505	A/C	cg17351974	chr5:40835760	RPL37	0.66	5.02	0.3	1.01e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs9479482	0.648	rs912558	chr6:150385730	G/T	cg25797454	chr6:150327115	RAET1K	-0.28	-5.03	-0.31	9.53e-7	Alopecia areata;
KIRP	cis	rs72949976	0.934	rs10197392	chr2:214038178	G/A	cg08319019	chr2:214017104	IKZF2	-0.62	-6.88	-0.4	5.03e-11	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs4765905	0.703	rs2238048	chr12:2300207	A/G	cg10668781	chr12:2307325	CACNA1C	-0.36	-7.24	-0.42	5.64e-12	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.65	6.33	0.37	1.15e-9	Platelet count;
KIRP	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg00319359	chr11:70116639	PPFIA1	0.58	6.03	0.36	5.92e-9	Coronary artery disease;
KIRP	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.59	-6.71	-0.39	1.37e-10	Type 2 diabetes;
KIRP	cis	rs137699	0.687	rs4821887	chr22:39756985	C/T	cg05872129	chr22:39784769	NA	-0.55	-6.42	-0.38	6.95e-10	IgG glycosylation;
KIRP	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.78	10.19	0.54	1.48e-20	Systemic lupus erythematosus;
KIRP	cis	rs4713675	0.546	rs791903	chr6:33702645	G/C	cg25922239	chr6:33757077	LEMD2	-0.4	-4.93	-0.3	1.54e-6	Plateletcrit;
KIRP	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.2	14.28	0.67	4.16e-34	Uric acid levels;
KIRP	cis	rs2652822	0.509	rs4774478	chr15:63434763	A/G	cg02713581	chr15:63449717	RPS27L	0.46	5.17	0.31	4.77e-7	Metabolic traits;
KIRP	cis	rs4700695	0.841	rs36303	chr5:65350374	A/G	cg21114390	chr5:65439923	SFRS12	-0.57	-5.19	-0.31	4.33e-7	Facial morphology (factor 19);
KIRP	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.91	0.35	1.11e-8	Life satisfaction;
KIRP	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg24058013	chr18:77568902	NA	-0.72	-11.06	-0.58	2.39e-23	Schizophrenia;
KIRP	cis	rs34779708	0.897	rs9787566	chr10:35279455	T/A	cg03585969	chr10:35415529	CREM	0.84	10.06	0.54	3.71e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs2278796	0.639	rs6661192	chr1:204971413	A/G	cg17449235	chr1:204966235	NFASC	0.57	7.83	0.45	1.42e-13	Mean platelet volume;
KIRP	cis	rs12949688	0.870	rs9906591	chr17:55816832	T/C	cg12582317	chr17:55822272	NA	0.61	9.99	0.54	6.01e-20	Schizophrenia;
KIRP	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.79	9.05	0.5	4.5e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg04226714	chr8:49833948	SNAI2	-0.51	-6.93	-0.4	3.63e-11	Life satisfaction;
KIRP	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	10.89	0.57	8.4e-23	Lung cancer in ever smokers;
KIRP	cis	rs5756391	0.546	rs9607392	chr22:37315592	C/T	cg16356956	chr22:37317934	CSF2RB	0.37	5.12	0.31	6.02e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.43	-0.55	2.54e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs2979489	0.945	rs34960391	chr8:30332723	G/A	cg26383811	chr8:30366931	RBPMS	-0.39	-5.34	-0.32	2.1e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs4144743	1.000	rs66738981	chr17:45325538	T/A	cg18085866	chr17:45331354	ITGB3	-0.81	-8.86	-0.49	1.59e-16	Body mass index;
KIRP	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg20243544	chr17:37824526	PNMT	0.5	7.5	0.43	1.16e-12	Asthma;
KIRP	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.69	10.4	0.55	3.11e-21	Schizophrenia;
KIRP	cis	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg26585981	chr11:48327164	OR4S1	-0.43	-5.53	-0.33	8.04e-8	Height;
KIRP	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21747090	chr2:27597821	SNX17	-0.5	-6.95	-0.41	3.22e-11	Menopause (age at onset);
KIRP	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-6.21	-0.37	2.2e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg25486957	chr4:152246857	NA	-0.45	-5.46	-0.33	1.17e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg03128534	chr1:43423976	SLC2A1	-0.62	-7.27	-0.42	4.77e-12	Red cell distribution width;
KIRP	cis	rs4481887	0.705	rs6698503	chr1:248425247	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.2	0.31	4.21e-7	Common traits (Other);
KIRP	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.51	-6.43	-0.38	6.45e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.738	rs10051609	chr5:130877080	G/C	cg06307176	chr5:131281290	NA	0.41	4.94	0.3	1.43e-6	Life satisfaction;
KIRP	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.62	7.31	0.42	3.82e-12	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	1.05	9.38	0.51	4.65e-18	Lymphocyte counts;
KIRP	cis	rs9400467	0.508	rs61269242	chr6:111803059	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.52	-0.33	8.44e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.6	7.92	0.45	8.3e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.64	8.51	0.48	1.72e-15	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09963654	chr16:2806322	SRRM2	-0.44	-6.04	-0.36	5.65e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs629922	0.893	rs648181	chr11:114047590	G/A	cg25009965	chr11:114031120	ZBTB16	0.42	5.52	0.33	8.75e-8	Paneth cell defects in Crohn's disease;
KIRP	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg03474202	chr17:45855739	NA	-0.37	-5.47	-0.33	1.08e-7	IgG glycosylation;
KIRP	cis	rs4664293	0.867	rs2098976	chr2:160593775	T/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg24644049	chr4:85504048	CDS1	0.99	6.75	0.4	1.07e-10	Skin colour saturation;
KIRP	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	5.55	0.33	7.25e-8	Educational attainment;
KIRP	cis	rs71277158	0.688	rs6781454	chr3:169823096	T/C	cg04067573	chr3:169899625	PHC3	0.64	6.1	0.36	4.1e-9	Prostate cancer;
KIRP	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg02807482	chr3:125708958	NA	-0.54	-5.1	-0.31	6.86e-7	Blood pressure (smoking interaction);
KIRP	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg08992911	chr2:238395768	MLPH	0.42	4.96	0.3	1.34e-6	Prostate cancer;
KIRP	cis	rs405956	0.932	rs9391266	chr6:105558047	G/A	cg22580625	chr6:105627791	POPDC3	-0.61	-6.58	-0.39	2.77e-10	QT interval;
KIRP	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.09	0.31	7.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.59	8.34	0.47	5.25e-15	Monocyte percentage of white cells;
KIRP	cis	rs2742234	1.000	rs1864395	chr10:43655697	G/A	cg02780029	chr10:43622663	RET	-0.35	-5.33	-0.32	2.23e-7	Hirschsprung disease;
KIRP	trans	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg16141378	chr3:129829833	LOC729375	0.5	6.2	0.37	2.38e-9	Retinal vascular caliber;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14653418	chr10:32217953	ARHGAP12	0.47	6.25	0.37	1.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg00981070	chr1:2046702	PRKCZ	-0.42	-6.96	-0.41	3.09e-11	Height;
KIRP	trans	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg07211511	chr3:129823064	LOC729375	-0.7	-7.23	-0.42	6.08e-12	Blood pressure (smoking interaction);
KIRP	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg07701084	chr6:150067640	NUP43	0.6	6.5	0.38	4.35e-10	Lung cancer;
KIRP	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg06935464	chr4:38784597	TLR10	0.5	5.17	0.31	4.74e-7	Breast cancer;
KIRP	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg18404041	chr3:52824283	ITIH1	0.41	4.99	0.3	1.17e-6	Schizophrenia;
KIRP	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg08992911	chr2:238395768	MLPH	0.66	6.39	0.38	8.38e-10	Prostate cancer;
KIRP	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-5.08	-0.31	7.37e-7	Fibroblast growth factor basic levels;
KIRP	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11987759	chr7:65425863	GUSB	-0.51	-6.83	-0.4	6.49e-11	Aortic root size;
KIRP	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-4.95	-0.3	1.41e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-6.72	-0.39	1.27e-10	Neuroticism;
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg04660111	chr19:49199234	FUT2	0.36	5.46	0.33	1.15e-7	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg04539111	chr16:67997858	SLC12A4	-0.55	-5.5	-0.33	9.54e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.47	7.16	0.42	9.4e-12	Resting heart rate;
KIRP	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.73	-8.55	-0.48	1.35e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.8	-8.33	-0.47	5.77e-15	Body mass index;
KIRP	cis	rs7221595	0.825	rs62072388	chr17:3899567	C/A	cg09695851	chr17:3907499	NA	0.6	5.91	0.35	1.13e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.8	10.91	0.57	7.4e-23	Response to antipsychotic treatment;
KIRP	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.64	8.5	0.48	1.91e-15	Calcium levels;
KIRP	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg08662619	chr6:150070041	PCMT1	0.35	5.59	0.34	6.03e-8	Lung cancer;
KIRP	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.35	-4.94	-0.3	1.41e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs12130219	1.000	rs12733173	chr1:152173972	C/T	cg25272121	chr1:152190972	HRNR	0.42	4.96	0.3	1.3e-6	Inflammatory skin disease;
KIRP	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-0.9	-12.04	-0.61	1.47e-26	Blood protein levels;
KIRP	cis	rs13401104	0.716	rs11687393	chr2:237143805	G/C	cg26422059	chr2:237146110	ASB18	0.51	5.22	0.32	3.77e-7	Educational attainment;
KIRP	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg11608241	chr8:8085544	FLJ10661	-0.51	-7.04	-0.41	1.91e-11	Neuroticism;
KIRP	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg05666200	chr11:89790683	NA	-0.49	-5.22	-0.32	3.76e-7	White blood cell types;
KIRP	cis	rs13315871	0.790	rs9825431	chr3:58406694	G/C	cg12435725	chr3:58293450	RPP14	-0.51	-5.45	-0.33	1.23e-7	Cholesterol, total;
KIRP	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg26207909	chr14:103986467	CKB	-0.49	-6.23	-0.37	1.96e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.52	6.36	0.38	9.75e-10	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg06145435	chr7:1022769	CYP2W1	0.34	5.25	0.32	3.27e-7	Longevity;Endometriosis;
KIRP	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg26441486	chr22:50317300	CRELD2	0.48	5.64	0.34	4.56e-8	Schizophrenia;
KIRP	cis	rs17092148	0.636	rs6058107	chr20:33288546	T/C	cg24642439	chr20:33292090	TP53INP2	0.55	5.54	0.33	7.96e-8	Neuroticism;
KIRP	cis	rs9921338	0.961	rs56010295	chr16:11378907	G/A	cg00044050	chr16:11439710	C16orf75	-0.49	-5.02	-0.3	9.87e-7	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg21174375	chr14:64681225	SYNE2	0.43	4.85	0.3	2.15e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07546684	chr6:149867573	PPIL4	0.45	6.52	0.38	3.91e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg10818794	chr15:86012489	AKAP13	0.5	7.04	0.41	1.92e-11	Coronary artery disease;
KIRP	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.65	8.37	0.47	4.31e-15	Height;
KIRP	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.56	7.25	0.42	5.32e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg13147721	chr7:65941812	NA	0.92	6.52	0.38	4.03e-10	Diabetic kidney disease;
KIRP	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg24112000	chr20:60950667	NA	-0.66	-8.42	-0.47	3.14e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg16127683	chr15:40268777	EIF2AK4	-0.55	-6.46	-0.38	5.43e-10	Corneal curvature;
KIRP	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-9.39	-0.51	4.34e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	1.02	12.49	0.62	4.74e-28	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg05347473	chr6:146136440	FBXO30	0.59	8.39	0.47	3.96e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	1.09	18.98	0.77	4.2e-50	Schizophrenia;
KIRP	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.43	5.4	0.33	1.54e-7	Menopause (age at onset);
KIRP	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg16558253	chr16:72132732	DHX38	-0.55	-8.08	-0.46	2.84e-14	Fibrinogen levels;
KIRP	cis	rs7213347	0.579	rs8072532	chr17:2045273	G/A	cg15816464	chr17:2026533	SMG6	0.44	6.57	0.39	3.04e-10	Total body bone mineral density;
KIRP	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg20295408	chr7:1910781	MAD1L1	-0.5	-5.88	-0.35	1.3e-8	Bipolar disorder and schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg07867023	chr3:51428648	RBM15B	0.59	7.54	0.43	9.08e-13	Parkinson's disease;
KIRP	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg27432699	chr2:27873401	GPN1	-0.47	-6.07	-0.36	4.81e-9	Total body bone mineral density;
KIRP	trans	rs61931739	0.620	rs11829476	chr12:33699285	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-6.09	-0.36	4.24e-9	Morning vs. evening chronotype;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13752545	chr9:38071235	NA	0.37	6.12	0.36	3.63e-9	Survival in pancreatic cancer;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg07701084	chr6:150067640	NUP43	0.7	9.33	0.51	6.38e-18	Lung cancer;
KIRP	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.46	6.54	0.38	3.58e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs78049276	0.736	rs6842241	chr4:148400819	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.78	-10.46	-0.55	2.07e-21	Pulse pressure;
KIRP	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02475777	chr4:1388615	CRIPAK	0.4	5.32	0.32	2.33e-7	Longevity;
KIRP	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg06212747	chr3:49208901	KLHDC8B	0.63	8.86	0.49	1.6e-16	Resting heart rate;
KIRP	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.45	5.88	0.35	1.3e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg12315302	chr6:26189340	HIST1H4D	0.94	6.51	0.38	4.13e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.82	0.35	1.79e-8	Motion sickness;
KIRP	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg05692746	chr2:100937584	LONRF2	-0.46	-5.42	-0.33	1.41e-7	Educational attainment;
KIRP	cis	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg07585502	chr8:101912084	NA	-0.65	-8.71	-0.49	4.51e-16	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg08501292	chr6:25962987	TRIM38	1.05	7.49	0.43	1.24e-12	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1106684	1.000	rs11764472	chr7:131460385	A/C	cg13607082	chr12:122652224	LRRC43	-0.64	-6.6	-0.39	2.47e-10	Body mass index;
KIRP	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg15507776	chr3:136538369	TMEM22	0.38	5.18	0.31	4.55e-7	Neuroticism;
KIRP	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	1.08	17.47	0.74	5.61e-45	Cognitive function;
KIRP	cis	rs6977660	0.714	rs12672320	chr7:19813594	G/T	cg05791153	chr7:19748676	TWISTNB	0.59	5.62	0.34	5.05e-8	Thyroid stimulating hormone;
KIRP	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg08085267	chr17:45401833	C17orf57	-0.67	-8.27	-0.47	8.2e-15	Coronary artery disease;
KIRP	cis	rs6908034	0.607	rs73378506	chr6:19819987	T/C	cg02682789	chr6:19804855	NA	0.73	5.77	0.35	2.43e-8	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
KIRP	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.04	-0.46	3.68e-14	Coronary artery disease;
KIRP	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.78	8.71	0.49	4.57e-16	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.66	9.08	0.5	3.71e-17	Coronary artery disease;
KIRP	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	7.97	0.45	5.85e-14	Personality dimensions;
KIRP	cis	rs12210905	0.687	rs72843622	chr6:27161152	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.71	-6.11	-0.36	3.92e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg01864069	chr14:103024347	NA	0.9	10.49	0.56	1.63e-21	Platelet count;
KIRP	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg21605333	chr4:119757512	SEC24D	1.66	11.8	0.6	8.89e-26	Cannabis dependence symptom count;
KIRP	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg26207909	chr14:103986467	CKB	0.38	4.87	0.3	1.98e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.8	10.7	0.56	3.47e-22	Platelet count;
KIRP	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg11189052	chr15:85197271	WDR73	0.51	5.26	0.32	3.2e-7	Schizophrenia;
KIRP	cis	rs539514	0.690	rs607095	chr13:76316165	A/T	cg04757411	chr13:76259545	LMO7	-0.35	-4.93	-0.3	1.53e-6	Type 1 diabetes;
KIRP	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg16497661	chr14:103986332	CKB	0.89	15.52	0.7	2.53e-38	Body mass index;
KIRP	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg21361702	chr7:150065534	REPIN1	0.69	7.5	0.43	1.17e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2791713	0.626	rs11581299	chr1:207163744	A/G	cg24040043	chr1:207224982	YOD1	-0.28	-4.84	-0.3	2.26e-6	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
KIRP	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg20896738	chr21:46707857	POFUT2;LOC642852	-0.43	-5.11	-0.31	6.53e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.43	-5.54	-0.33	7.61e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg19893067	chr17:80732956	TBCD	-0.35	-4.86	-0.3	2.12e-6	Glycated hemoglobin levels;
KIRP	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg04317338	chr11:64019027	PLCB3	0.8	6.04	0.36	5.51e-9	Mean platelet volume;
KIRP	cis	rs10875746	0.669	rs61941003	chr12:48619625	G/A	cg26205652	chr12:48591994	NA	0.81	10.25	0.55	9.37e-21	Longevity (90 years and older);
KIRP	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg08975724	chr8:8085496	FLJ10661	0.55	7.12	0.41	1.18e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg03146154	chr1:46216737	IPP	-0.4	-5.11	-0.31	6.49e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg21605333	chr4:119757512	SEC24D	1.62	11.6	0.59	4.1e-25	Cannabis dependence symptom count;
KIRP	cis	rs9308731	0.583	rs10211562	chr2:111930796	G/T	cg04202892	chr2:111875749	ACOXL	0.48	6.58	0.39	2.82e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs2278796	0.528	rs4951151	chr1:204970302	T/C	cg17449235	chr1:204966235	NFASC	0.56	7.23	0.42	5.97e-12	Mean platelet volume;
KIRP	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.59	-9.01	-0.5	5.73e-17	Coronary artery disease;
KIRP	cis	rs33912345	0.695	rs1254257	chr14:60832179	T/C	cg27398547	chr14:60952738	C14orf39	-0.42	-5.63	-0.34	4.9e-8	Glaucoma (high intraocular pressure);
KIRP	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg04691961	chr3:161091175	C3orf57	-0.48	-7.07	-0.41	1.62e-11	Morning vs. evening chronotype;
KIRP	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg05484376	chr2:27715224	FNDC4	0.36	5.71	0.34	3.21e-8	Total body bone mineral density;
KIRP	cis	rs6681460	0.898	rs536527	chr1:67193793	A/C	cg02459107	chr1:67143332	SGIP1	0.38	5.44	0.33	1.26e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg06223162	chr1:101003688	GPR88	-0.4	-8.61	-0.48	9e-16	Breast cancer;
KIRP	cis	rs28834970	0.675	rs6557994	chr8:27232018	A/G	cg06815112	chr8:27182871	PTK2B	-0.44	-5.24	-0.32	3.41e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg11189052	chr15:85197271	WDR73	-0.48	-5.81	-0.35	1.9e-8	P wave terminal force;
KIRP	cis	rs629922	0.671	rs1184748	chr11:114037061	A/G	cg25009965	chr11:114031120	ZBTB16	0.45	5.77	0.35	2.42e-8	Paneth cell defects in Crohn's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg02047359	chr10:75174015	ANXA7	0.63	7.68	0.44	3.7e-13	Smoking initiation;
KIRP	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21545522	chr1:205238299	TMCC2	0.49	6.5	0.38	4.47e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	0.82	7.35	0.42	2.84e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg22138327	chr13:27999177	GTF3A	1.0	7.6	0.44	6.04e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.53	6.42	0.38	6.91e-10	Subjective well-being;
KIRP	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.7	7.59	0.44	6.69e-13	DNA methylation (variation);
KIRP	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.41	-4.94	-0.3	1.46e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.48	-5.15	-0.31	5.24e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.61	-6.82	-0.4	7.11e-11	Gut microbiome composition (summer);
KIRP	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg14416269	chr4:6271139	WFS1	0.33	4.95	0.3	1.35e-6	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.38	-5.33	-0.32	2.23e-7	Bipolar disorder;
KIRP	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg11906718	chr8:101322791	RNF19A	0.65	8.3	0.47	6.77e-15	Atrioventricular conduction;
KIRP	cis	rs1551570	0.563	rs4804122	chr19:10241944	C/T	cg16327482	chr19:10226339	EIF3G	0.38	4.89	0.3	1.83e-6	Narcolepsy;
KIRP	cis	rs6546886	0.912	rs9309478	chr2:74305203	G/C	cg14702570	chr2:74259524	NA	-0.27	-5.44	-0.33	1.27e-7	Dialysis-related mortality;
KIRP	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.4	5.12	0.31	6.29e-7	Childhood ear infection;
KIRP	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg27205649	chr11:78285834	NARS2	-0.67	-8.7	-0.49	4.89e-16	Alzheimer's disease (survival time);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21872093	chr1:168544874	XCL1	-0.43	-6.04	-0.36	5.58e-9	Inflammatory biomarkers;
KIRP	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg23387468	chr7:139079360	LUC7L2	0.29	4.98	0.3	1.19e-6	Diisocyanate-induced asthma;
KIRP	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	cg21523751	chr1:182988639	NA	0.41	6.41	0.38	7.35e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg07274523	chr3:49395745	GPX1	0.69	8.33	0.47	5.52e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg19257562	chr1:2043853	PRKCZ	0.4	6.51	0.38	4.3e-10	Height;
KIRP	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.69	-9.15	-0.5	2.2e-17	Huntington's disease progression;
KIRP	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.38	-7.99	-0.45	5.29e-14	Body mass index;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26116724	chr1:10270521	KIF1B	-0.54	-6.75	-0.4	1.03e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.41	-5.05	-0.31	8.51e-7	Blood protein levels;
KIRP	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-5.19	-0.31	4.45e-7	Electroencephalogram traits;
KIRP	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg10556349	chr10:835070	NA	0.61	5.67	0.34	3.93e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.51	7.2	0.42	7.27e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg19847130	chr8:10466454	RP1L1	-0.34	-4.88	-0.3	1.89e-6	Retinal vascular caliber;
KIRP	cis	rs6142102	0.625	rs1883705	chr20:32552878	C/T	cg24642439	chr20:33292090	TP53INP2	0.49	5.74	0.34	2.77e-8	Skin pigmentation;
KIRP	cis	rs2281603	0.570	rs11623457	chr14:64958106	A/C	cg01860774	chr14:64969374	ZBTB25	0.33	5.37	0.32	1.8e-7	Lymphocyte counts;
KIRP	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.6	-7.25	-0.42	5.36e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	1.05	15.04	0.69	1.04e-36	Cognitive function;
KIRP	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.44	5.65	0.34	4.33e-8	Type 2 diabetes;
KIRP	cis	rs10858047	0.883	rs222493	chr1:115128087	A/G	cg12756093	chr1:115239321	AMPD1	-0.69	-6.52	-0.38	4.07e-10	Autism;
KIRP	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06481639	chr22:41940642	POLR3H	0.77	7.84	0.45	1.33e-13	Vitiligo;
KIRP	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg25019722	chr6:37503610	NA	-0.97	-15.34	-0.7	1.04e-37	Cognitive performance;
KIRP	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg00981070	chr1:2046702	PRKCZ	0.33	5.55	0.33	7.2e-8	Height;
KIRP	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-11.57	-0.59	5.14e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25517755	chr10:38738941	LOC399744	-0.5	-6.77	-0.4	9.31e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3931020	0.657	rs277368	chr1:75230606	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.43	-5.01	-0.3	1.03e-6	Resistin levels;
KIRP	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.54	-0.33	7.66e-8	Alcohol dependence;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg01081584	chr15:40268610	EIF2AK4	-0.54	-6.54	-0.39	3.45e-10	Corneal curvature;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14879690	chr4:170912660	MFAP3L	-0.53	-6.87	-0.4	5.29e-11	Inflammatory biomarkers;
KIRP	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.82	-11.94	-0.61	3.3e-26	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg08000102	chr2:233561755	GIGYF2	-0.76	-9.72	-0.53	4.19e-19	Coronary artery disease;
KIRP	cis	rs6956675	1.000	rs10229492	chr7:62580546	G/A	cg08930214	chr7:62859557	LOC100287834	0.52	5.94	0.35	9.69e-9	Obesity-related traits;
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.04	0.36	5.51e-9	Lung cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg11709150	chr1:2440438	PANK4	0.48	6.08	0.36	4.47e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg00250761	chr1:31883323	NA	-0.31	-5.45	-0.33	1.22e-7	Alcohol dependence;
KIRP	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.75	5.75	0.34	2.65e-8	Developmental language disorder (linguistic errors);
KIRP	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	6.9	0.4	4.42e-11	Neuroticism;
KIRP	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.52	-0.33	8.66e-8	Life satisfaction;
KIRP	cis	rs7534824	0.625	rs7521668	chr1:101491108	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.93	-7.66	-0.44	4.39e-13	Refractive astigmatism;
KIRP	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg27147174	chr7:100797783	AP1S1	-0.75	-9.84	-0.53	1.8e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.62	9.32	0.51	6.96e-18	Height;
KIRP	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg21395723	chr22:39101663	GTPBP1	0.41	5.1	0.31	6.94e-7	Menopause (age at onset);
KIRP	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.75	0.44	2.42e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg01028140	chr2:1542097	TPO	-0.72	-6.58	-0.39	2.82e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg15655495	chr12:38532458	NA	-0.25	-4.84	-0.3	2.26e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.66	9.53	0.52	1.55e-18	Lymphocyte counts;
KIRP	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.72	-8.61	-0.48	8.94e-16	Corneal astigmatism;
KIRP	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.47	-6.93	-0.4	3.7e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg12042659	chr19:58951599	ZNF132	0.5	6.27	0.37	1.57e-9	Uric acid clearance;
KIRP	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.03	-0.41	2.03e-11	Bipolar disorder;
KIRP	cis	rs6546324	0.625	rs4671813	chr2:67841835	A/T	cg15745817	chr2:67799979	NA	-0.69	-7.44	-0.43	1.72e-12	Endometriosis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg20750606	chr13:21714611	SAP18	0.46	6.57	0.39	2.94e-10	Survival in pancreatic cancer;
KIRP	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-5.44	-0.33	1.26e-7	Lung cancer;
KIRP	cis	rs3779635	0.710	rs17375548	chr8:27248573	T/A	cg14221460	chr8:27183342	PTK2B	0.52	6.85	0.4	5.83e-11	Neuroticism;
KIRP	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg22437258	chr11:111473054	SIK2	-0.51	-5.93	-0.35	1.04e-8	Primary sclerosing cholangitis;
KIRP	trans	rs7531932	0.742	rs10889929	chr1:72153144	T/G	cg20667729	chr19:43691878	PSG5	-0.42	-6.15	-0.37	3.19e-9	Schizophrenia;
KIRP	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg18171855	chr10:2543474	NA	0.49	6.17	0.37	2.73e-9	Age-related hearing impairment;
KIRP	cis	rs17065868	0.881	rs61947996	chr13:45164330	A/G	cg10246903	chr13:45222710	NA	0.74	6.66	0.39	1.75e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10849893	0.576	rs10774592	chr12:121825447	G/A	cg01154721	chr12:121881891	KDM2B	-0.37	-4.89	-0.3	1.79e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-6.19	-0.37	2.46e-9	Chronic sinus infection;
KIRP	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg03289416	chr15:75166202	SCAMP2	0.44	6.22	0.37	2.17e-9	Breast cancer;
KIRP	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-9.87	-0.53	1.46e-19	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	ch.8.33884649F	chr8:33765107	NA	0.59	7.42	0.43	1.91e-12	Body mass index;
KIRP	cis	rs372883	0.519	rs2832274	chr21:30600189	A/T	cg24692254	chr21:30365293	RNF160	0.84	11.97	0.61	2.62e-26	Pancreatic cancer;
KIRP	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.49	-6.05	-0.36	5.28e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.69	-7.41	-0.43	1.97e-12	Gut microbiome composition (summer);
KIRP	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg01631408	chr1:248437212	OR2T33	-0.64	-8.54	-0.48	1.4e-15	Common traits (Other);
KIRP	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.39	-5.7	-0.34	3.49e-8	Height;
KIRP	cis	rs6693295	0.877	rs59285308	chr1:246325076	T/G	cg11798871	chr1:246315928	SMYD3	-0.56	-6.27	-0.37	1.62e-9	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.97	14.92	0.69	2.81e-36	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs7615316	1.000	rs1357529	chr3:142351097	T/G	cg20824294	chr3:142316082	PLS1	0.25	5.41	0.33	1.49e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.72	-10.85	-0.57	1.18e-22	Hepatocellular carcinoma;
KIRP	cis	rs10267417	0.673	rs12668741	chr7:19932981	G/A	cg05791153	chr7:19748676	TWISTNB	0.46	4.87	0.3	1.98e-6	Night sleep phenotypes;
KIRP	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg19045956	chr2:200819837	C2orf60;C2orf47	0.47	5.87	0.35	1.43e-8	Osteoporosis;
KIRP	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg01689657	chr7:91764605	CYP51A1	0.36	5.01	0.3	1.02e-6	Breast cancer;
KIRP	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs7523273	0.565	rs1359147	chr1:207886150	C/T	cg22525895	chr1:207977042	MIR29B2	0.45	5.79	0.35	2.14e-8	Schizophrenia;
KIRP	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg08994789	chr17:28903642	LRRC37B2	0.77	9.05	0.5	4.45e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7656342	0.686	rs1401440	chr4:9832512	C/T	cg00071950	chr4:10020882	SLC2A9	0.36	4.97	0.3	1.27e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg07621104	chr11:117668040	DSCAML1	0.48	5.94	0.35	9.87e-9	Myopia;
KIRP	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.49	-6.01	-0.36	6.67e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7582720	1.000	rs72932731	chr2:203650410	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	9.98	0.54	6.57e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg21546286	chr11:48923668	NA	-0.47	-6.03	-0.36	6.06e-9	HDL cholesterol;
KIRP	cis	rs71403859	0.504	rs12926413	chr16:71972325	T/C	cg08717414	chr16:71523259	ZNF19	-0.66	-5.13	-0.31	5.77e-7	Post bronchodilator FEV1;
KIRP	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg08989290	chr16:615782	NHLRC4	0.41	6.06	0.36	5.12e-9	Height;
KIRP	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-11.74	-0.6	1.44e-25	Monocyte count;
KIRP	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.17	-21.89	-0.81	1.13e-59	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-5.52	-0.33	8.45e-8	Schizophrenia;
KIRP	cis	rs7225151	0.710	rs77752862	chr17:5222071	C/T	cg24500398	chr17:5266808	RABEP1	-0.57	-5.61	-0.34	5.32e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6545883	0.929	rs7563678	chr2:61741811	C/T	cg15711740	chr2:61764176	XPO1	0.59	8.14	0.46	1.93e-14	Tuberculosis;
KIRP	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg09904177	chr6:26538194	HMGN4	0.4	4.95	0.3	1.4e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-10.31	-0.55	5.91e-21	Response to antipsychotic treatment;
KIRP	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg13736514	chr6:26305472	NA	-0.48	-5.22	-0.32	3.8e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs1723838	0.826	rs1723834	chr11:73512648	A/G	cg10190253	chr17:21730938	NA	-0.7	-6.4	-0.38	7.68e-10	Obesity-related traits;
KIRP	cis	rs11671005	0.610	rs2305122	chr19:59056752	G/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.6	-6.71	-0.39	1.35e-10	Mean platelet volume;
KIRP	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg21573476	chr21:45109991	RRP1B	-0.68	-9.94	-0.54	8.9e-20	Mean corpuscular volume;
KIRP	cis	rs9513627	0.920	rs7335315	chr13:100121308	G/A	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg04025307	chr7:1156635	C7orf50	0.56	6.2	0.37	2.32e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.44	5.2	0.31	4.2e-7	Aortic root size;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg18156793	chr20:32031936	SNTA1	0.68	6.4	0.38	7.64e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg11906718	chr8:101322791	RNF19A	0.65	8.26	0.47	9.06e-15	Atrioventricular conduction;
KIRP	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg22437258	chr11:111473054	SIK2	0.64	7.68	0.44	3.84e-13	Primary sclerosing cholangitis;
KIRP	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg23100626	chr2:96804247	ASTL	0.53	8.24	0.46	1.06e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.76	6.39	0.38	8.34e-10	Diabetic retinopathy;
KIRP	cis	rs9972944	0.756	rs2318869	chr17:63767736	C/G	cg07283582	chr17:63770753	CCDC46	-0.47	-7.77	-0.44	2.08e-13	Total body bone mineral density;
KIRP	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.67	9.87	0.53	1.43e-19	Colorectal cancer;
KIRP	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21972741	chr5:435613	AHRR	0.53	6.93	0.4	3.62e-11	Cystic fibrosis severity;
KIRP	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	1.11	15.86	0.71	1.72e-39	Pulmonary function decline;
KIRP	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg08076091	chr2:203926405	NBEAL1	0.85	9.18	0.51	1.84e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6681460	0.966	rs10889644	chr1:67145322	C/A	cg13052034	chr1:66999238	SGIP1	0.47	6.52	0.38	4.06e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg00405596	chr8:11794950	NA	-0.39	-5.08	-0.31	7.48e-7	Triglycerides;
KIRP	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-5.71	-0.34	3.21e-8	Neuroticism;
KIRP	cis	rs4704187	0.687	rs2059159	chr5:74451178	G/C	cg03227963	chr5:74354835	NA	0.39	5.72	0.34	3.06e-8	Response to amphetamines;
KIRP	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.16	0.64	2.56e-30	Eye color traits;
KIRP	cis	rs16858210	0.826	rs35494670	chr3:183606357	T/G	cg25686905	chr3:183603175	PARL	-0.44	-5.67	-0.34	4.02e-8	Menopause (age at onset);
KIRP	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.58	6.71	0.39	1.34e-10	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs778371	0.749	rs2675964	chr2:233793676	A/G	cg08000102	chr2:233561755	GIGYF2	-0.48	-5.27	-0.32	3.02e-7	Schizophrenia;
KIRP	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.86	-0.49	1.59e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-10.0	-0.54	5.65e-20	Response to antipsychotic treatment;
KIRP	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg27205649	chr11:78285834	NARS2	-0.56	-6.39	-0.38	8.31e-10	Testicular germ cell tumor;
KIRP	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg00405596	chr8:11794950	NA	-0.42	-5.55	-0.33	7.46e-8	Neuroticism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24313756	chr6:14913283	NA	0.46	6.18	0.37	2.68e-9	Interleukin-4 levels;
KIRP	cis	rs4073221	1.000	rs4074941	chr3:18277909	A/G	cg07694806	chr3:18168406	NA	-0.85	-7.15	-0.42	9.6e-12	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.53	0.33	8.04e-8	Putamen volume;
KIRP	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg19847130	chr8:10466454	RP1L1	0.32	4.87	0.3	1.96e-6	Triglycerides;
KIRP	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.83	11.81	0.6	8.49e-26	Body mass index;
KIRP	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg21775007	chr8:11205619	TDH	0.48	6.32	0.37	1.2e-9	Neuroticism;
KIRP	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.93	11.35	0.59	2.69e-24	Migraine;
KIRP	cis	rs10875746	0.903	rs3782911	chr12:48483492	T/G	cg20731937	chr12:48336164	NA	0.4	5.16	0.31	5.02e-7	Longevity (90 years and older);
KIRP	cis	rs4692589	1.000	rs4692784	chr4:170938581	A/G	cg19918862	chr4:170955249	NA	0.42	5.07	0.31	7.77e-7	Anxiety disorder;
KIRP	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg06618935	chr21:46677482	NA	-0.41	-5.11	-0.31	6.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2573652	0.722	rs11636047	chr15:100543341	A/G	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.28	-0.42	4.4e-12	Height;
KIRP	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.4	5.29	0.32	2.71e-7	Educational attainment;
KIRP	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.52	7.18	0.42	8.26e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.88	12.26	0.62	2.79e-27	Breast cancer;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07308232	chr7:1071921	C7orf50	-0.5	-6.32	-0.37	1.19e-9	Longevity;Endometriosis;
KIRP	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg22654517	chr2:96458247	NA	0.34	5.02	0.3	9.8e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.76	8.16	0.46	1.72e-14	Parkinson's disease;
KIRP	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg14541582	chr5:601475	NA	-0.54	-5.94	-0.35	9.55e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.52	6.36	0.38	9.93e-10	Lung cancer;
KIRP	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	8.9	0.49	1.29e-16	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	1.19	12.9	0.64	2.07e-29	Alzheimer's disease;
KIRP	cis	rs4654899	0.772	rs7548269	chr1:21089472	T/C	cg05370193	chr1:21551575	ECE1	0.47	5.98	0.36	7.98e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg27121462	chr16:89883253	FANCA	0.53	6.9	0.4	4.35e-11	Vitiligo;
KIRP	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	9.28	0.51	9.29e-18	Smoking behavior;
KIRP	cis	rs4704187	0.663	rs4704189	chr5:74487375	A/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.61	8.52	0.48	1.59e-15	Lymphocyte counts;
KIRP	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.47	5.7	0.34	3.34e-8	HDL cholesterol;
KIRP	trans	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg14791747	chr16:20752902	THUMPD1	0.63	6.73	0.39	1.16e-10	Cognitive test performance;
KIRP	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg06795125	chr2:108905320	SULT1C2	-0.46	-7.95	-0.45	6.63e-14	Blood pressure;
KIRP	cis	rs9972944	0.756	rs7222190	chr17:63764953	T/C	cg07283582	chr17:63770753	CCDC46	-0.47	-7.65	-0.44	4.66e-13	Total body bone mineral density;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18880390	chr1:175162128	KIAA0040	0.57	7.1	0.41	1.34e-11	Smoking initiation;
KIRP	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg16306078	chr6:126000798	NA	0.26	4.94	0.3	1.46e-6	Endometrial cancer;
KIRP	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2795502	0.935	rs2744060	chr10:43262616	C/G	cg11150807	chr10:43354902	NA	-0.63	-5.52	-0.33	8.55e-8	Blood protein levels;
KIRP	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg01475377	chr6:109611718	NA	-0.36	-4.92	-0.3	1.6e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs1144	0.537	rs2430486	chr7:104584410	C/T	cg04380332	chr7:105027541	SRPK2	-0.54	-7.93	-0.45	7.77e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg02336718	chr17:17403227	NA	0.4	6.05	0.36	5.27e-9	Total body bone mineral density;
KIRP	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	5.39	0.33	1.61e-7	Height;
KIRP	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg17145862	chr1:211918768	LPGAT1	0.74	10.06	0.54	3.69e-20	Leprosy;
KIRP	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-0.8	-12.93	-0.64	1.6e-29	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
KIRP	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.62	-8.45	-0.47	2.65e-15	Total body bone mineral density;
KIRP	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg00784671	chr22:46762841	CELSR1	-0.6	-7.6	-0.44	6.14e-13	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	0.99	7.71	0.44	3.02e-13	Arsenic metabolism;
KIRP	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.8	7.67	0.44	3.88e-13	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg11635098	chr7:100497156	NA	-0.66	-7.06	-0.41	1.7e-11	Resting heart rate;
KIRP	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg05887092	chr17:76393375	PGS1	0.53	7.27	0.42	4.63e-12	HDL cholesterol levels;
KIRP	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.47	5.61	0.34	5.57e-8	Huntington's disease progression;
KIRP	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.74	7.64	0.44	4.69e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07256732	chr16:621771	PIGQ	-0.45	-6.38	-0.38	8.6e-10	Height;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17811310	chr19:34012326	PEPD	-0.48	-6.56	-0.39	3.18e-10	Metabolic traits;
KIRP	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.89	-0.45	9.77e-14	Personality dimensions;
KIRP	cis	rs9913156	0.707	rs9902000	chr17:4582426	A/C	cg19197139	chr17:4613644	ARRB2	-0.54	-6.04	-0.36	5.65e-9	Lymphocyte counts;
KIRP	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05665937	chr4:1216051	CTBP1	-0.49	-6.68	-0.39	1.61e-10	Obesity-related traits;
KIRP	cis	rs8014252	0.803	rs17108246	chr14:71054992	G/A	cg11204974	chr14:71022665	NA	-0.74	-7.31	-0.42	3.65e-12	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs4764487	0.760	rs4764488	chr12:6332910	A/G	cg08284733	chr12:6341482	CD9	0.53	9.01	0.5	6.02e-17	Mean platelet volume;
KIRP	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.47	5.22	0.32	3.81e-7	Glycated hemoglobin levels;
KIRP	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg09699651	chr6:150184138	LRP11	0.45	5.82	0.35	1.8e-8	Lung cancer;
KIRP	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg00310523	chr12:86230176	RASSF9	0.47	7.36	0.42	2.75e-12	Major depressive disorder;
KIRP	cis	rs34779708	0.897	rs35784065	chr10:35353574	C/T	cg03585969	chr10:35415529	CREM	0.79	9.51	0.52	1.78e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.15	-0.37	3.14e-9	Neuroticism;
KIRP	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.7	8.46	0.47	2.41e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3134353	0.932	rs983583	chr8:101961910	T/C	cg07585502	chr8:101912084	NA	-0.4	-4.91	-0.3	1.63e-6	Body mass index;
KIRP	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg00149659	chr3:10157352	C3orf10	0.83	9.02	0.5	5.6e-17	Alzheimer's disease;
KIRP	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	0.94	10.82	0.57	1.4e-22	Menopause (age at onset);
KIRP	cis	rs930036	0.655	rs6761759	chr2:171944915	A/G	cg12801329	chr2:171670795	NA	0.44	4.88	0.3	1.93e-6	Menopause (age at onset);
KIRP	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg03959625	chr15:84868606	LOC388152	0.66	7.97	0.45	6.05e-14	Schizophrenia;
KIRP	cis	rs28489187	0.706	rs173026	chr1:85804249	G/A	cg16011679	chr1:85725395	C1orf52	0.5	6.26	0.37	1.74e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06544989	chr22:39130855	UNC84B	0.47	8.07	0.46	3.12e-14	Menopause (age at onset);
KIRP	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg00262122	chr8:11665843	FDFT1	-0.43	-5.22	-0.32	3.83e-7	Triglycerides;
KIRP	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg25272121	chr1:152190972	HRNR	0.42	4.92	0.3	1.59e-6	Inflammatory skin disease;
KIRP	cis	rs4764487	0.735	rs3782717	chr12:6332310	C/G	cg08284733	chr12:6341482	CD9	0.52	8.83	0.49	1.95e-16	Mean platelet volume;
KIRP	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg15507776	chr3:136538369	TMEM22	0.4	5.45	0.33	1.19e-7	Neuroticism;
KIRP	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg16255804	chr6:135334527	HBS1L	-0.32	-5.09	-0.31	7.14e-7	Red blood cell count;
KIRP	cis	rs3931020	0.548	rs12145183	chr1:75272480	G/A	cg17719053	chr1:75198211	TYW3;CRYZ	0.43	5.95	0.35	9.01e-9	Resistin levels;
KIRP	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg05220968	chr6:146057943	EPM2A	0.39	4.85	0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg14952266	chr13:112191215	NA	0.46	6.77	0.4	9.5e-11	Hepatitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23849311	chr20:24451890	TMEM90B	0.47	6.54	0.38	3.62e-10	Parkinson's disease;
KIRP	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg19507638	chr5:93509721	C5orf36	-0.61	-5.14	-0.31	5.5e-7	Diabetic retinopathy;
KIRP	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.49	-6.11	-0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.84	9.95	0.54	7.91e-20	Multiple sclerosis;
KIRP	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.99	10.26	0.55	8.48e-21	HIV-1 control;
KIRP	cis	rs986417	0.818	rs2092722	chr14:61062890	T/A	cg27398547	chr14:60952738	C14orf39	0.6	5.63	0.34	4.79e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.66	8.23	0.46	1.13e-14	Dilated cardiomyopathy;
KIRP	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg02640540	chr1:67518911	SLC35D1	0.41	4.96	0.3	1.34e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs829661	0.793	rs12053428	chr2:30775299	G/A	cg10949345	chr2:30726833	LCLAT1	1.13	14.28	0.67	4.33e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.41	5.85	0.35	1.52e-8	Endometrial cancer;
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg06079273	chr8:97247865	UQCRB	-0.42	-6.17	-0.37	2.74e-9	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg06995285	chr7:2418615	EIF3B	0.62	7.43	0.43	1.74e-12	Multiple sclerosis;
KIRP	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg10047753	chr17:41438598	NA	0.99	14.93	0.69	2.55e-36	Menopause (age at onset);
KIRP	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg13453750	chr1:205783389	SLC41A1	-0.45	-7.08	-0.41	1.54e-11	Menarche (age at onset);
KIRP	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg21489266	chr3:46619131	LRRC2;TDGF1	-0.51	-7.05	-0.41	1.81e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.72	9.11	0.5	2.98e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.59	-5.83	-0.35	1.74e-8	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
KIRP	cis	rs2073300	1.000	rs112057098	chr20:23448901	C/T	cg12062639	chr20:23401060	NAPB	0.8	6.97	0.41	2.85e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs41563	0.609	rs4727614	chr7:104600854	C/A	cg04380332	chr7:105027541	SRPK2	-0.6	-8.93	-0.49	9.86e-17	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.06	12.18	0.61	5.08e-27	Vitiligo;
KIRP	cis	rs4356932	0.967	rs13128319	chr4:76975206	A/G	cg00809888	chr4:76862425	NAAA	-0.45	-6.43	-0.38	6.76e-10	Blood protein levels;
KIRP	trans	rs4733781	0.765	rs62524625	chr8:131084728	C/T	cg15131647	chr1:153650884	NPR1	-0.37	-6.08	-0.36	4.56e-9	Tuberculosis;
KIRP	cis	rs501120	0.810	rs535176	chr10:44747059	C/T	cg09554077	chr10:44749378	NA	0.77	12.92	0.64	1.67e-29	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg08885076	chr2:99613938	TSGA10	-0.66	-11.52	-0.59	7.69e-25	Chronic sinus infection;
KIRP	cis	rs526231	0.511	rs6881612	chr5:102377013	C/T	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	cis	rs228437	0.913	rs4896078	chr6:134910571	A/T	cg24504307	chr6:134963096	NA	-0.47	-7.37	-0.43	2.66e-12	Melanoma;
KIRP	cis	rs4460629	0.742	rs7368345	chr1:155080090	C/T	cg02153340	chr1:155202674	NA	0.37	5.32	0.32	2.31e-7	Serum magnesium levels;
KIRP	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg01097406	chr16:89675127	NA	0.42	6.46	0.38	5.42e-10	Vitiligo;
KIRP	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.8	-8.71	-0.49	4.64e-16	Coronary artery disease;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg27532560	chr4:187881888	NA	0.75	12.48	0.62	5.05e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg07537917	chr2:241836409	C2orf54	-0.26	-5.41	-0.33	1.48e-7	Urinary metabolites;
KIRP	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg02297831	chr4:17616191	MED28	0.6	7.69	0.44	3.57e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.25e-8	Life satisfaction;
KIRP	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.35	19.06	0.77	2.43e-50	Corneal structure;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg08662619	chr6:150070041	PCMT1	0.39	6.27	0.37	1.58e-9	Lung cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15918956	chr3:79079292	ROBO1	-0.44	-7.06	-0.41	1.67e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg10615990	chr5:179050688	HNRNPH1	-0.49	-6.81	-0.4	7.3e-11	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05760641	chr4:668293	ATP5I	0.56	6.86	0.4	5.44e-11	Parkinson's disease;
KIRP	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg25753631	chr6:25732923	NA	-0.27	-5.11	-0.31	6.38e-7	Iron status biomarkers;
KIRP	cis	rs10982256	0.817	rs2297815	chr9:117266965	C/T	cg13636371	chr9:117264095	DFNB31	-0.4	-5.21	-0.32	4e-7	Bipolar disorder;
KIRP	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg01721255	chr8:58191610	C8orf71	0.52	5.1	0.31	6.7e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg06027949	chr8:82754900	SNX16	-0.45	-5.61	-0.34	5.37e-8	Diastolic blood pressure;
KIRP	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.99	-13.88	-0.66	9.5e-33	Response to antipsychotic treatment;
KIRP	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg01864069	chr14:103024347	NA	0.88	10.27	0.55	8.23e-21	Platelet count;
KIRP	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.8	9.45	0.52	2.78e-18	Corneal astigmatism;
KIRP	cis	rs12050794	0.636	rs3759902	chr15:72525274	C/G	cg16672083	chr15:72433130	SENP8	0.41	5.71	0.34	3.25e-8	Metabolite levels (HVA/MHPG ratio);
KIRP	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.62	-10.01	-0.54	5.06e-20	Morning vs. evening chronotype;
KIRP	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg11031976	chr2:198649780	BOLL	-0.48	-4.9	-0.3	1.72e-6	Ulcerative colitis;
KIRP	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg00982548	chr2:198649783	BOLL	-0.57	-5.15	-0.31	5.42e-7	Ulcerative colitis;
KIRP	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.62	0.39	2.24e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06615912	chr11:64008691	FKBP2	0.51	6.46	0.38	5.67e-10	Parkinson's disease;
KIRP	cis	rs10849893	0.538	rs10744762	chr12:121839701	A/C	cg01154721	chr12:121881891	KDM2B	0.39	5.29	0.32	2.64e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	8.5	0.48	1.87e-15	Motion sickness;
KIRP	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.18	-0.51	1.81e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.86	11.61	0.6	3.78e-25	Triglycerides;
KIRP	cis	rs7221595	0.778	rs8077986	chr17:3902951	A/G	cg21851534	chr17:3907994	ZZEF1	0.56	5.58	0.33	6.48e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs3850699	0.886	rs12773600	chr10:104418228	C/G	cg04362960	chr10:104952993	NT5C2	0.56	6.06	0.36	4.97e-9	Prostate cancer;
KIRP	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.47	-5.87	-0.35	1.42e-8	Blood metabolite levels;
KIRP	cis	rs2635047	0.662	rs8091902	chr18:44748545	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.24	0.37	1.93e-9	Educational attainment;
KIRP	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.75	-10.4	-0.55	3.05e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03298319	chr14:33403060	NA	-0.51	-6.65	-0.39	1.83e-10	Interleukin-4 levels;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg23961059	chr19:57874869	ZNF547;TRAPPC2P1	0.65	6.23	0.37	2e-9	Lung function (FEV1);
KIRP	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.84	-10.18	-0.54	1.59e-20	Bipolar disorder and schizophrenia;
KIRP	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg18944383	chr4:111397179	ENPEP	0.52	8.55	0.48	1.34e-15	Coronary artery disease;
KIRP	cis	rs7116495	0.867	rs612255	chr11:71778664	A/G	cg07596299	chr11:71824057	C11orf51	-0.86	-5.78	-0.35	2.22e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.46	-5.92	-0.35	1.07e-8	Neutrophil percentage of white cells;
KIRP	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	8.53	0.48	1.56e-15	Intelligence (multi-trait analysis);
KIRP	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.51	-6.78	-0.4	8.68e-11	Hip circumference;Waist circumference;
KIRP	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg00982548	chr2:198649783	BOLL	-0.54	-5.07	-0.31	7.65e-7	Ulcerative colitis;
KIRP	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.57	8.29	0.47	7.21e-15	Reticulocyte count;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02241357	chr4:80885279	ANTXR2	0.43	6.78	0.4	8.68e-11	Migraine with aura;
KIRP	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg17306686	chr7:157230923	NA	0.54	8.05	0.46	3.53e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.99	-17.24	-0.74	3.33e-44	Longevity;Endometriosis;
KIRP	cis	rs6142102	1.000	rs2378078	chr20:32714728	C/T	cg08999081	chr20:33150536	PIGU	0.45	5.5	0.33	9.62e-8	Skin pigmentation;
KIRP	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.39	0.38	8.1e-10	Neuroticism;
KIRP	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg06223162	chr1:101003688	GPR88	-0.44	-9.11	-0.5	2.91e-17	Monocyte count;
KIRP	cis	rs472402	0.560	rs10037161	chr5:6624294	C/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-5.29	-0.32	2.66e-7	Response to amphetamines;
KIRP	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-14.65	-0.68	2.34e-35	Alzheimer's disease;
KIRP	cis	rs4363385	0.647	rs56412380	chr1:153000705	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-6.17	-0.37	2.8e-9	Inflammatory skin disease;
KIRP	trans	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	6.11	0.36	3.92e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9810890	1.000	rs73210615	chr3:128641464	A/G	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg26938153	chr7:137686926	CREB3L2	0.59	6.53	0.38	3.83e-10	Lung cancer in ever smokers;
KIRP	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.91	10.65	0.56	4.83e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs7849270	1.000	rs7868408	chr9:131917864	G/A	cg13538475	chr9:131942899	NA	-0.35	-5.63	-0.34	4.89e-8	Blood metabolite ratios;
KIRP	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.62	8.16	0.46	1.73e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg03465714	chr1:152285911	FLG	0.51	5.79	0.35	2.1e-8	Atopic dermatitis;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg15914863	chr7:1022675	CYP2W1	0.3	4.85	0.3	2.23e-6	Longevity;Endometriosis;
KIRP	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.7	0.34	3.36e-8	Blood protein levels;
KIRP	cis	rs9525927	0.597	rs9316076	chr13:44808445	T/C	cg19190762	chr13:44806055	NA	0.48	4.93	0.3	1.5e-6	Dupuytren's disease;
KIRP	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.99	13.35	0.65	6.06e-31	Menopause (age at onset);
KIRP	cis	rs829661	0.793	rs829564	chr2:30694846	C/T	cg10949345	chr2:30726833	LCLAT1	1.14	14.01	0.67	3.64e-33	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs78487399	0.831	rs10495903	chr2:43806918	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.2	-0.31	4.26e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg07716437	chr15:52100755	TMOD2	0.51	7.8	0.45	1.77e-13	Migraine with aura;
KIRP	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg12486944	chr17:80159399	CCDC57	0.38	5.06	0.31	8.26e-7	Life satisfaction;
KIRP	cis	rs12643440	0.960	rs474634	chr4:17198043	A/G	cg22650099	chr4:17144496	NA	0.41	5.14	0.31	5.5e-7	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg19000871	chr14:103996768	TRMT61A	-0.42	-5.33	-0.32	2.18e-7	Coronary artery disease;
KIRP	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.99	15.73	0.71	4.54e-39	Uric acid clearance;
KIRP	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg05082376	chr22:42548792	NA	0.46	5.84	0.35	1.62e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.98	-15.95	-0.71	8.26e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs7709377	0.595	rs11952043	chr5:115445009	A/G	cg23108291	chr5:115420582	COMMD10	0.42	5.08	0.31	7.64e-7	Metabolite levels  (X-11787);
KIRP	cis	rs7116495	1.000	rs607446	chr11:71789252	G/A	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.13	-0.31	5.87e-7	Bladder cancer;
KIRP	cis	rs6679073	0.556	rs75506911	chr1:205666272	C/T	cg23034840	chr1:205782522	SLC41A1	-0.93	-5.71	-0.34	3.21e-8	Prostate-specific antigen levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25043643	chr14:102609274	WDR20	-0.46	-6.44	-0.38	6.28e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg08132940	chr7:1081526	C7orf50	-0.7	-7.05	-0.41	1.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.27	-0.32	3.03e-7	Skin colour saturation;
KIRP	cis	rs7553864	0.966	rs11161937	chr1:87614510	A/G	cg17420885	chr1:87600446	LOC339524	-0.49	-6.63	-0.39	2.11e-10	Smoking behavior;
KIRP	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs16854884	1.000	rs17668478	chr3:143794370	G/A	cg06585982	chr3:143692056	C3orf58	0.54	5.53	0.33	7.97e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.67	7.25	0.42	5.22e-12	Huntington's disease progression;
KIRP	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.61	7.52	0.43	1.03e-12	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17078980	chr3:196366421	LRRC33	0.4	6.31	0.37	1.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.69	-8.44	-0.47	2.67e-15	Extraversion;
KIRP	cis	rs6516091	0.640	rs6117070	chr20:6061606	A/G	cg25325723	chr20:6104886	FERMT1	-0.52	-5.08	-0.31	7.29e-7	Abdominal aortic aneurysm;
KIRP	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.55	4.89	0.3	1.84e-6	Bipolar disorder;
KIRP	cis	rs6125597	0.967	rs6067025	chr20:47854020	T/C	cg03212862	chr20:47662828	CSE1L	-0.42	-5.38	-0.32	1.75e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6832769	0.961	rs28713343	chr4:56457091	C/T	cg05960024	chr4:56376020	CLOCK	-0.63	-8.14	-0.46	2.02e-14	Personality dimensions;
KIRP	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.23	-35.15	-0.91	6.94e-98	Myeloid white cell count;
KIRP	cis	rs9488822	0.614	rs195529	chr6:116251893	T/C	cg18764771	chr6:116381957	FRK	0.19	5.02	0.3	1.01e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg27490568	chr2:178487706	NA	0.54	7.35	0.42	2.85e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	6.22	0.37	2.15e-9	Menarche (age at onset);
KIRP	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg08992911	chr2:238395768	MLPH	0.56	5.23	0.32	3.66e-7	Prostate cancer;
KIRP	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg12091567	chr17:66097778	LOC651250	-0.79	-9.57	-0.52	1.16e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.61	6.4	0.38	7.81e-10	Gut microbiome composition (summer);
KIRP	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.57	-0.52	1.16e-18	Gut microbiome composition (summer);
KIRP	cis	rs12615966	1.000	rs61013045	chr2:105370775	G/A	cg16465502	chr2:105461796	NA	0.68	6.06	0.36	5.11e-9	Pancreatic cancer;
KIRP	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	0.75	10.62	0.56	6.26e-22	Prudent dietary pattern;
KIRP	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg07930552	chr6:133119739	C6orf192	0.83	5.64	0.34	4.59e-8	Type 2 diabetes nephropathy;
KIRP	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.02	-11.08	-0.58	2.02e-23	Alzheimer's disease;
KIRP	cis	rs13102973	0.897	rs10434068	chr4:135840331	A/G	cg14419869	chr4:135874104	NA	0.55	9.17	0.5	2e-17	Subjective well-being;
KIRP	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.78	-10.87	-0.57	9.9e-23	Blood metabolite levels;
KIRP	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg26597838	chr10:835615	NA	-0.51	-6.22	-0.37	2.12e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.68	8.16	0.46	1.7e-14	Height;
KIRP	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg00981070	chr1:2046702	PRKCZ	0.45	6.45	0.38	6.02e-10	Height;
KIRP	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	6.22	0.37	2.07e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10489525	0.599	rs7516121	chr1:115604317	A/G	cg01522456	chr1:115632236	TSPAN2	0.53	7.06	0.41	1.71e-11	Autism;
KIRP	cis	rs7215564	0.908	rs74000898	chr17:78653532	A/C	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00149659	chr3:10157352	C3orf10	0.84	9.19	0.51	1.69e-17	Alzheimer's disease;
KIRP	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.79	-0.35	2.13e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.51	6.64	0.39	2.03e-10	Hemoglobin concentration;
KIRP	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16414030	chr3:133502952	NA	-0.51	-5.86	-0.35	1.47e-8	Iron status biomarkers;
KIRP	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.82	11.91	0.6	3.85e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg11031976	chr2:198649780	BOLL	-0.55	-5.3	-0.32	2.54e-7	Ulcerative colitis;
KIRP	cis	rs1723838	0.826	rs17244671	chr11:73574422	A/C	cg10064339	chr11:73693792	UCP2	0.93	5.07	0.31	7.92e-7	Obesity-related traits;
KIRP	cis	rs7116495	0.609	rs2845860	chr11:71716661	C/T	cg07596299	chr11:71824057	C11orf51	-0.93	-6.17	-0.37	2.72e-9	Severe influenza A (H1N1) infection;
KIRP	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.58	-8.39	-0.47	3.84e-15	Pelvic organ prolapse;
KIRP	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.72	-11.04	-0.58	2.74e-23	Hepatocellular carcinoma;
KIRP	trans	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	7.53	0.43	9.42e-13	Intelligence (multi-trait analysis);
KIRP	trans	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg24644049	chr4:85504048	CDS1	1.01	6.62	0.39	2.17e-10	Skin colour saturation;
KIRP	cis	rs7714584	1.000	rs11748151	chr5:150226292	C/T	cg22134413	chr5:150180641	NA	0.57	5.09	0.31	7.03e-7	Crohn's disease;
KIRP	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	15.46	0.7	3.87e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.88	-9.9	-0.53	1.18e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg13628971	chr7:2884303	GNA12	0.61	7.0	0.41	2.41e-11	Height;
KIRP	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs4702718	0.549	rs267982	chr5:10715677	C/T	cg14521931	chr5:10832172	NA	-0.48	-6.46	-0.38	5.66e-10	Obesity-related traits;
KIRP	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22117172	chr7:91764530	CYP51A1	-0.44	-5.94	-0.35	9.44e-9	Breast cancer;
KIRP	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.89	-11.59	-0.59	4.44e-25	Prostate cancer;
KIRP	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.58	7.94	0.45	7.33e-14	Mean corpuscular volume;
KIRP	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	6.39	0.38	8.29e-10	Protein C levels;
KIRP	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.89e-14	Alcohol dependence;
KIRP	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg03563238	chr19:33554763	RHPN2	-0.33	-6.05	-0.36	5.24e-9	Bone properties (heel);
KIRP	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.6	8.68	0.48	5.5e-16	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg14952266	chr13:112191215	NA	0.45	6.65	0.39	1.86e-10	Hepatitis;
KIRP	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg17724175	chr1:150552817	MCL1	0.34	5.75	0.34	2.62e-8	Tonsillectomy;
KIRP	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg27129171	chr3:47204927	SETD2	0.42	5.33	0.32	2.25e-7	Birth weight;
KIRP	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	cg21523751	chr1:182988639	NA	0.35	4.95	0.3	1.41e-6	Fuchs's corneal dystrophy;
KIRP	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.62	8.68	0.48	5.44e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg14730097	chr2:233632281	GIGYF2;KCNJ13	-0.35	-5.16	-0.31	5.19e-7	Coronary artery disease;
KIRP	cis	rs12580194	0.593	rs61957941	chr12:55748058	G/A	cg11794356	chr12:55725991	OR6C3	-0.53	-7.09	-0.41	1.41e-11	Cancer;
KIRP	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	12.97	0.64	1.18e-29	Smoking behavior;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15644539	chr6:139802112	NA	0.54	7.04	0.41	1.91e-11	Interleukin-4 levels;
KIRP	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg06307176	chr5:131281290	NA	-0.51	-5.55	-0.33	7.46e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg24060327	chr5:131705240	SLC22A5	0.61	6.23	0.37	1.98e-9	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs2294693	0.891	rs9381024	chr6:40984262	A/C	cg14769373	chr6:40998127	UNC5CL	0.53	5.13	0.31	5.9e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg11317459	chr13:21872234	NA	-1.02	-11.88	-0.6	5.1e-26	White matter hyperintensity burden;
KIRP	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg24315340	chr6:146058215	EPM2A	0.4	5.14	0.31	5.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg06521331	chr12:34319734	NA	-0.5	-6.2	-0.37	2.38e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2278796	0.918	rs2290138	chr1:204956325	C/G	cg17449235	chr1:204966235	NFASC	-0.47	-6.41	-0.38	7.26e-10	Mean platelet volume;
KIRP	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.78	-6.61	-0.39	2.33e-10	Developmental language disorder (linguistic errors);
KIRP	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	8.31	0.47	6.55e-15	Lung cancer in ever smokers;
KIRP	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg22117172	chr7:91764530	CYP51A1	0.45	6.32	0.37	1.19e-9	Breast cancer;
KIRP	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.35	-0.32	1.99e-7	Lung cancer;
KIRP	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.97	10.93	0.57	6.37e-23	Cognitive test performance;
KIRP	cis	rs3779635	0.742	rs11787212	chr8:27245721	A/C	cg14221460	chr8:27183342	PTK2B	0.54	7.06	0.41	1.69e-11	Neuroticism;
KIRP	cis	rs9400467	0.506	rs76110409	chr6:111603132	C/A	cg15721981	chr6:111408429	SLC16A10	0.76	6.98	0.41	2.66e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs7225151	0.710	rs12601720	chr17:5248682	G/T	cg24500398	chr17:5266808	RABEP1	-0.58	-5.7	-0.34	3.46e-8	Alzheimer's disease (late onset);
KIRP	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.48	-5.69	-0.34	3.65e-8	Urate levels in overweight individuals;
KIRP	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.81	11.63	0.6	3.22e-25	Response to antipsychotic treatment;
KIRP	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg01475377	chr6:109611718	NA	-0.41	-5.63	-0.34	4.79e-8	Reticulocyte fraction of red cells;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg14293102	chr19:2232170	DOT1L	0.6	6.89	0.4	4.74e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-5.72	-0.34	3.09e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.5	-6.76	-0.4	9.77e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg00647317	chr7:50633725	DDC	-0.43	-5.63	-0.34	4.81e-8	Malaria;
KIRP	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg16691251	chr5:66510806	NA	0.43	5.62	0.34	5.03e-8	Breast cancer;
KIRP	cis	rs2223471	0.870	rs2744498	chr6:50754851	A/C	cg03432817	chr6:50765336	NA	-0.53	-8.9	-0.49	1.23e-16	Subcutaneous adipose tissue;
KIRP	trans	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg06521331	chr12:34319734	NA	-0.55	-6.85	-0.4	5.79e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg00585698	chr12:123750864	CDK2AP1	0.51	5.12	0.31	6.03e-7	Neutrophil percentage of white cells;
KIRP	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.84	-12.81	-0.63	4.05e-29	Extrinsic epigenetic age acceleration;
KIRP	cis	rs28489187	0.706	rs233099	chr1:85826194	T/C	cg16011679	chr1:85725395	C1orf52	0.49	6.12	0.36	3.72e-9	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs9815354	0.761	rs73079307	chr3:41862273	A/C	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.85	7.0	0.41	2.44e-11	Mean platelet volume;
KIRP	cis	rs1030877	1.000	rs2254301	chr2:105880734	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.67	10.54	0.56	1.13e-21	Obesity-related traits;
KIRP	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.65	8.55	0.48	1.33e-15	Motion sickness;
KIRP	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg17470723	chr8:74884337	TCEB1	0.63	8.21	0.46	1.21e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6539288	0.745	rs2041895	chr12:107350088	C/G	cg26297688	chr12:107349093	C12orf23	-0.39	-5.34	-0.32	2.08e-7	Total body bone mineral density;
KIRP	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.03	-13.39	-0.65	4.6e-31	Exhaled nitric oxide output;
KIRP	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg04310649	chr10:35416472	CREM	-0.57	-6.68	-0.39	1.57e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg14593290	chr7:50529359	DDC	0.67	8.2	0.46	1.31e-14	Malaria;
KIRP	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg18833306	chr6:118973337	C6orf204	0.41	5.13	0.31	5.81e-7	Electrocardiographic conduction measures;
KIRP	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg26335602	chr6:28129616	ZNF389	0.43	4.85	0.3	2.18e-6	Depression;
KIRP	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg26248373	chr2:1572462	NA	-0.69	-7.38	-0.43	2.39e-12	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.9	-9.45	-0.52	2.88e-18	Alzheimer's disease;
KIRP	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.85	-12.45	-0.62	6.2e-28	Prudent dietary pattern;
KIRP	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.84	-10.39	-0.55	3.26e-21	Menarche (age at onset);
KIRP	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg00325661	chr8:49890786	NA	0.44	5.77	0.35	2.43e-8	Sudden cardiac arrest;
KIRP	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg00792783	chr2:198669748	PLCL1	0.46	5.36	0.32	1.95e-7	Intracranial aneurysm;
KIRP	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg01721255	chr8:58191610	C8orf71	0.5	5.44	0.33	1.27e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	13.87	0.66	1.08e-32	Platelet count;
KIRP	cis	rs6499755	0.870	rs31074	chr16:55357170	A/C	cg05099576	chr16:55362342	IRX6	0.24	5.05	0.31	8.56e-7	Hypospadias;
KIRP	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg20255370	chr15:40268687	EIF2AK4	-0.53	-7.42	-0.43	1.92e-12	Response to haloperidol in psychosis;
KIRP	cis	rs13202913	0.639	rs9383892	chr6:151747152	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	5.11	0.31	6.6e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.46	5.97	0.36	8.17e-9	Gout;
KIRP	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg19148410	chr11:111250352	POU2AF1	0.41	5.91	0.35	1.14e-8	Primary biliary cholangitis;
KIRP	trans	rs1422110	0.647	rs10063838	chr5:85530546	T/C	cg01787110	chr1:109008453	NBPF6	-0.78	-9.48	-0.52	2.29e-18	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.49	-6.05	-0.36	5.23e-9	Facial morphology (factor 20);
KIRP	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg01378222	chr16:28622494	SULT1A1	0.6	6.59	0.39	2.67e-10	Platelet distribution width;
KIRP	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg05802129	chr4:122689817	NA	-0.46	-6.77	-0.4	9.43e-11	Type 2 diabetes;
KIRP	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.55	-0.33	7.44e-8	Depression;
KIRP	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.63	-7.45	-0.43	1.55e-12	Prudent dietary pattern;
KIRP	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg05802129	chr4:122689817	NA	-0.51	-7.14	-0.41	1.04e-11	Type 2 diabetes;
KIRP	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.85	12.28	0.62	2.38e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.83	13.29	0.65	9.56e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg21775007	chr8:11205619	TDH	0.44	5.62	0.34	5.18e-8	Monocyte count;
KIRP	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.87	12.24	0.62	3.17e-27	Schizophrenia;
KIRP	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.75	-0.4	1.06e-10	Hemoglobin concentration;
KIRP	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.06e-11	Bipolar disorder;
KIRP	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.64	8.2	0.46	1.35e-14	Pancreatic cancer;
KIRP	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.57	0.33	6.61e-8	Lung cancer;
KIRP	cis	rs867371	1.000	rs8041868	chr15:82472326	C/T	cg00614314	chr15:82944287	LOC80154	0.54	6.37	0.38	9.12e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg23649088	chr2:200775458	C2orf69	-0.67	-5.84	-0.35	1.64e-8	Schizophrenia;
KIRP	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.77	-9.52	-0.52	1.73e-18	Huntington's disease progression;
KIRP	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg10932868	chr11:921992	NA	0.69	9.38	0.51	4.48e-18	Alzheimer's disease (late onset);
KIRP	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00933542	chr6:150070202	PCMT1	0.29	5.76	0.34	2.46e-8	Lung cancer;
KIRP	cis	rs11874712	1.000	rs28757346	chr18:43696540	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.38	-5.24	-0.32	3.44e-7	Migraine - clinic-based;
KIRP	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.81	-0.4	7.5e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg05998816	chr21:47859926	PCNT	0.52	5.62	0.34	5.14e-8	Lymphocyte counts;
KIRP	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg27205649	chr11:78285834	NARS2	0.7	9.08	0.5	3.68e-17	Alzheimer's disease (survival time);
KIRP	cis	rs883565	0.569	rs6599273	chr3:38998552	T/G	cg01426195	chr3:39028469	NA	-0.56	-8.86	-0.49	1.62e-16	Handedness;
KIRP	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.45	4.9	0.3	1.74e-6	Endometriosis;Drug-induced torsades de pointes;
KIRP	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.73	10.5	0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.24	-0.32	3.46e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.85	12.55	0.62	2.89e-28	Breast cancer;
KIRP	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg21918786	chr6:109611834	NA	-0.4	-5.58	-0.34	6.38e-8	Reticulocyte fraction of red cells;
KIRP	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.72	7.68	0.44	3.76e-13	Lymphocyte counts;
KIRP	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.78	-7.74	-0.44	2.58e-13	Chronic sinus infection;
KIRP	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg15556689	chr8:8085844	FLJ10661	0.54	7.23	0.42	6.22e-12	Retinal vascular caliber;
KIRP	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg05669848	chr5:237993	SDHA	0.48	5.0	0.3	1.09e-6	Breast cancer;
KIRP	cis	rs7395662	0.745	rs10838830	chr11:48233932	A/G	cg21546286	chr11:48923668	NA	0.44	5.52	0.33	8.65e-8	HDL cholesterol;
KIRP	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg17724175	chr1:150552817	MCL1	0.36	6.19	0.37	2.49e-9	Melanoma;
KIRP	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.81	-0.45	1.62e-13	Total cholesterol levels;
KIRP	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg05340658	chr4:99064831	C4orf37	0.83	11.26	0.58	5.3e-24	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9826463	0.582	rs7642634	chr3:142110818	T/C	cg20824294	chr3:142316082	PLS1	0.39	5.84	0.35	1.67e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-7.68	-0.44	3.68e-13	Aortic root size;
KIRP	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg03258749	chr1:151040405	MLLT11	-0.7	-10.24	-0.55	1e-20	Childhood ear infection;
KIRP	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.61	-7.61	-0.44	5.87e-13	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.92	-15.35	-0.7	9.39e-38	Chronic sinus infection;
KIRP	cis	rs9473924	0.505	rs2223869	chr6:50904239	C/T	cg14470998	chr6:50812995	TFAP2B	0.84	7.63	0.44	5.09e-13	Body mass index;
KIRP	cis	rs76917914	0.820	rs7046514	chr9:100815088	C/T	cg03040243	chr9:100819229	NANS	0.62	6.47	0.38	5.32e-10	Immature fraction of reticulocytes;
KIRP	cis	rs17023223	0.509	rs10923740	chr1:119600287	C/T	cg18261050	chr1:119551319	NA	0.55	7.3	0.42	3.9e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-9.86	-0.53	1.53e-19	Morning vs. evening chronotype;
KIRP	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg26022315	chr17:47021804	SNF8	0.41	5.19	0.31	4.48e-7	Type 2 diabetes;
KIRP	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg00806126	chr19:22604979	ZNF98	0.69	7.17	0.42	8.78e-12	Pain;
KIRP	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.39	4.92	0.3	1.61e-6	Blood protein levels;
KIRP	cis	rs4728302	0.869	rs6969899	chr7:133597490	A/G	cg10665199	chr7:133106180	EXOC4	0.43	5.3	0.32	2.58e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs3857067	0.806	rs4693374	chr4:95086164	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.08	-0.36	4.57e-9	QT interval;
KIRP	cis	rs4704187	0.687	rs7700965	chr5:74356857	T/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.13e-8	Response to amphetamines;
KIRP	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg16049864	chr8:95962084	TP53INP1	-0.35	-5.52	-0.33	8.43e-8	Type 2 diabetes;
KIRP	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg25019033	chr10:957182	NA	-0.59	-7.02	-0.41	2.15e-11	Eosinophil percentage of granulocytes;
KIRP	cis	rs933360	0.553	rs6979369	chr7:50831871	A/C	cg14240098	chr7:50518052	FIGNL1	0.43	4.92	0.3	1.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Area under the curve of insulin levels;Insulin levels adjusted for BMI;Ratio of the area under the curve for insulin and the area under the curve for glucose;Incremental insulin;
KIRP	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.54	-7.01	-0.41	2.34e-11	Schizophrenia;
KIRP	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.48	5.86	0.35	1.46e-8	Asthma;
KIRP	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.66	8.92	0.49	1.06e-16	Multiple sclerosis;
KIRP	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	8.65	0.48	6.73e-16	Lung function (FEV1/FVC);
KIRP	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.28	5.73	0.34	2.87e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6504340	0.739	rs4793589	chr17:46667863	G/C	cg05487507	chr17:46671861	LOC404266;HOXB5	0.56	6.51	0.38	4.3e-10	Primary tooth development (number of teeth);
KIRP	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg18755752	chr8:142205143	DENND3	0.44	5.29	0.32	2.73e-7	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg03060546	chr3:49711283	APEH	-0.62	-6.1	-0.36	4.16e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg04132472	chr17:19861366	AKAP10	-0.4	-5.25	-0.32	3.29e-7	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.64	-6.26	-0.37	1.72e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.72	-7.58	-0.43	7.23e-13	Initial pursuit acceleration;
KIRP	cis	rs16912285	0.688	rs12284649	chr11:24316260	T/A	ch.11.24196551F	chr11:24239977	NA	0.75	8.43	0.47	2.94e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs4742903	0.527	rs10820607	chr9:106888750	A/C	cg14250997	chr9:106856677	SMC2	0.43	5.93	0.35	1.02e-8	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.48	6.01	0.36	6.48e-9	Height;
KIRP	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.71	8.95	0.5	9.12e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg17385448	chr1:15911702	AGMAT	-0.24	-4.84	-0.3	2.25e-6	Systolic blood pressure;
KIRP	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg19025524	chr12:109796872	NA	0.43	5.73	0.34	2.89e-8	Neuroticism;
KIRP	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg01529538	chr14:23388837	RBM23	0.41	5.15	0.31	5.27e-7	Cognitive ability (multi-trait analysis);
KIRP	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	6.88	0.4	4.91e-11	Mean corpuscular volume;
KIRP	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg19875535	chr5:140030758	IK	0.52	6.52	0.38	3.87e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-10.24	-0.55	1.01e-20	Morning vs. evening chronotype;
KIRP	cis	rs6088813	0.961	rs6060373	chr20:33914208	C/T	cg14752227	chr20:34000481	UQCC	-0.47	-5.94	-0.35	9.87e-9	Height;
KIRP	cis	rs6545883	0.895	rs6545871	chr2:61692203	G/T	cg15711740	chr2:61764176	XPO1	-0.6	-7.74	-0.44	2.64e-13	Tuberculosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11528984	chr1:228353883	C1orf69	0.51	7.08	0.41	1.52e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.79	11.84	0.6	6.55e-26	Breast cancer;
KIRP	cis	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg26585981	chr11:48327164	OR4S1	-0.41	-4.98	-0.3	1.21e-6	HDL cholesterol;
KIRP	cis	rs6977660	0.714	rs12333747	chr7:19814394	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.36	0.32	1.88e-7	Thyroid stimulating hormone;
KIRP	cis	rs258892	0.895	rs57787613	chr5:72047278	C/A	cg21869765	chr5:72125136	TNPO1	-0.5	-5.64	-0.34	4.56e-8	Small cell lung carcinoma;
KIRP	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.91	10.38	0.55	3.73e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.77	7.91	0.45	8.81e-14	Uric acid levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11064206	chr12:123459532	OGFOD2;ABCB9	0.56	6.45	0.38	5.96e-10	Smoking initiation;
KIRP	cis	rs829661	0.741	rs2602789	chr2:30869420	T/C	cg10949345	chr2:30726833	LCLAT1	1.08	13.31	0.65	8.61e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9303401	0.564	rs4968396	chr17:57247805	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.5	5.93	0.35	1.03e-8	Cognitive test performance;
KIRP	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	0.94	10.92	0.57	6.94e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg24848339	chr3:12840334	CAND2	0.34	5.0	0.3	1.08e-6	QRS complex (12-leadsum);
KIRP	cis	rs6142102	0.961	rs909884	chr20:32646063	G/T	cg24642439	chr20:33292090	TP53INP2	0.61	6.63	0.39	2.13e-10	Skin pigmentation;
KIRP	cis	rs7173743	0.525	rs7402877	chr15:79132814	T/C	cg00079375	chr15:79125835	NA	0.4	5.78	0.35	2.31e-8	Coronary artery disease;
KIRP	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.85	-12.2	-0.61	4.53e-27	Total body bone mineral density;
KIRP	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg06637938	chr14:75390232	RPS6KL1	0.53	7.58	0.43	7.22e-13	Height;
KIRP	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg08847533	chr14:75593920	NEK9	-0.52	-6.21	-0.37	2.28e-9	IgG glycosylation;
KIRP	cis	rs7680126	0.632	rs6834645	chr4:10150174	G/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-5.16	-0.31	5.17e-7	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4262150	0.960	rs4463219	chr5:152288557	G/T	cg12297329	chr5:152029980	NA	0.41	5.65	0.34	4.39e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg06521331	chr12:34319734	NA	0.47	5.91	0.35	1.14e-8	Morning vs. evening chronotype;
KIRP	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg00074818	chr8:8560427	CLDN23	0.42	6.34	0.37	1.07e-9	Obesity-related traits;
KIRP	trans	rs201779	0.702	rs9568394	chr13:50938859	A/G	cg04487479	chr6:70993328	COL9A1	-0.62	-6.79	-0.4	8.55e-11	Left atrial antero-posterior diameter;
KIRP	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.68	8.93	0.49	1.01e-16	Morning vs. evening chronotype;
KIRP	trans	rs7939886	0.920	rs11227638	chr11:56019585	A/T	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs9653442	0.564	rs11902705	chr2:100795207	A/G	cg17356467	chr2:100759845	AFF3	-0.4	-5.57	-0.33	6.73e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs11161851	0.935	rs277367	chr1:75300318	A/C	cg11196437	chr1:75593865	LHX8	0.38	5.56	0.33	6.95e-8	Visceral fat;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg01375172	chr16:23464338	COG7	0.54	6.2	0.37	2.34e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg23594656	chr7:65796392	TPST1	0.47	7.48	0.43	1.34e-12	Aortic root size;
KIRP	cis	rs7267005	0.661	rs112277543	chr20:34392122	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs4971059	0.629	rs4246529	chr1:155115260	T/C	cg02153340	chr1:155202674	NA	-0.43	-6.09	-0.36	4.27e-9	Breast cancer;
KIRP	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	9.53	0.52	1.59e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg21419209	chr3:44054225	NA	-0.71	-8.83	-0.49	2.07e-16	Coronary artery disease;
KIRP	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg23594656	chr7:65796392	TPST1	-0.52	-8.26	-0.47	8.75e-15	Aortic root size;
KIRP	cis	rs7009516	0.745	rs1492414	chr8:24224911	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.24	4.97	0.3	1.28e-6	Hair greying;
KIRP	cis	rs8044995	0.636	rs12447119	chr16:68297928	G/A	cg04539111	chr16:67997858	SLC12A4	-0.6	-4.96	-0.3	1.29e-6	Schizophrenia;
KIRP	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg04369109	chr6:150039330	LATS1	-0.49	-6.27	-0.37	1.64e-9	Lung cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg07172597	chr19:42817659	TMEM145	0.5	6.26	0.37	1.68e-9	Smoking initiation;
KIRP	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg05526886	chr2:227700861	RHBDD1	-0.5	-5.97	-0.36	8.06e-9	Pulmonary function;
KIRP	trans	rs7939886	0.920	rs12223785	chr11:56058820	T/A	cg03929089	chr4:120376271	NA	0.94	6.5	0.38	4.4e-10	Myopia (pathological);
KIRP	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg09571762	chr12:39539558	NA	0.37	5.19	0.31	4.51e-7	Morning vs. evening chronotype;
KIRP	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg13606994	chr1:44402422	ARTN	-0.27	-4.92	-0.3	1.55e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg12131826	chr15:77904385	NA	0.44	5.86	0.35	1.52e-8	Type 2 diabetes;
KIRP	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	6.62	0.39	2.27e-10	Rheumatoid arthritis;
KIRP	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg17372223	chr3:52568218	NT5DC2	0.35	5.72	0.34	3.09e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg24727182	chr4:109684250	AGXT2L1	0.5	6.9	0.4	4.31e-11	Smoking initiation;
KIRP	cis	rs8077577	0.895	rs11655588	chr17:18107451	C/T	cg09161412	chr17:18057145	MYO15A	0.37	4.9	0.3	1.71e-6	Obesity-related traits;
KIRP	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.72	7.59	0.44	6.74e-13	HIV-1 control;
KIRP	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg00677455	chr12:58241039	CTDSP2	0.61	7.45	0.43	1.61e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6540556	0.859	rs12131636	chr1:209942435	G/C	cg05527609	chr1:210001259	C1orf107	-0.62	-6.79	-0.4	8.52e-11	Red blood cell count;
KIRP	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg04733989	chr22:42467013	NAGA	0.56	7.33	0.42	3.25e-12	Cognitive function;
KIRP	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg07148914	chr20:33460835	GGT7	-0.43	-5.33	-0.32	2.24e-7	Height;
KIRP	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	0.66	5.89	0.35	1.24e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs830233	0.689	rs56283030	chr5:165430030	C/T	cg13976338	chr5:165423657	NA	-0.72	-7.76	-0.44	2.33e-13	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs514024	0.700	rs472144	chr9:130489558	A/G	cg13643465	chr9:130375613	STXBP1	0.43	5.76	0.34	2.51e-8	Eating disorders (purging via substances);
KIRP	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15557168	chr22:42548783	NA	-0.46	-5.98	-0.36	7.67e-9	Cognitive function;
KIRP	cis	rs889512	0.731	rs8063014	chr16:75297673	G/A	cg03315344	chr16:75512273	CHST6	-0.65	-5.04	-0.31	8.83e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.84	-12.93	-0.64	1.59e-29	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg12549451	chr6:135224345	NA	-0.41	-5.02	-0.3	1.02e-6	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.35	-0.47	4.99e-15	Mood instability;
KIRP	cis	rs9815354	0.680	rs73830596	chr3:42028223	G/A	cg03022575	chr3:42003672	ULK4	0.79	7.66	0.44	4.22e-13	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg03808351	chr9:123631620	PHF19	0.38	5.16	0.31	5.04e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs1823913	0.637	rs1378162	chr2:192163249	G/T	cg12404831	chr2:192114017	MYO1B	0.54	7.48	0.43	1.32e-12	Obesity-related traits;
KIRP	cis	rs1215050	0.791	rs2695472	chr4:98855127	T/C	cg17366294	chr4:99064904	C4orf37	-0.37	-5.03	-0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	8.54	0.48	1.41e-15	Colorectal cancer;
KIRP	cis	rs10924970	0.967	rs1933246	chr1:235391446	T/C	cg26050004	chr1:235667680	B3GALNT2	0.41	5.01	0.3	1.06e-6	Asthma;
KIRP	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16405210	chr4:1374714	KIAA1530	-0.82	-11.86	-0.6	5.77e-26	Longevity;
KIRP	cis	rs62229266	0.740	rs4817759	chr21:37389559	G/A	cg08632701	chr21:37451849	NA	-0.42	-5.3	-0.32	2.59e-7	Mitral valve prolapse;
KIRP	cis	rs10421328	0.784	rs8107058	chr19:19759651	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.47	5.46	0.33	1.14e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.9	-10.89	-0.57	8.71e-23	Response to antipsychotic treatment;
KIRP	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-7.32	-0.42	3.59e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7173743	0.525	rs8027870	chr15:79134045	A/G	cg00079375	chr15:79125835	NA	0.39	5.56	0.33	7.07e-8	Coronary artery disease;
KIRP	cis	rs60311166	1.000	rs7647992	chr3:52631344	G/T	cg13174197	chr3:52720522	GNL3;PBRM1	0.91	5.6	0.34	5.58e-8	CTACK levels;
KIRP	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg26248373	chr2:1572462	NA	-0.69	-7.58	-0.44	6.89e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	9.04	0.5	4.72e-17	Colorectal cancer;
KIRP	cis	rs6732160	0.588	rs1430345	chr2:73370682	A/G	cg01422370	chr2:73384389	NA	0.51	6.97	0.41	2.81e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.1	-0.36	4.07e-9	Systolic blood pressure;
KIRP	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg11635098	chr7:100497156	NA	0.53	6.29	0.37	1.41e-9	Resting heart rate;
KIRP	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg10167378	chr1:228756711	NA	0.89	7.41	0.43	2.01e-12	Chronic lymphocytic leukemia;
KIRP	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.73	-9.18	-0.51	1.79e-17	Coronary artery disease;
KIRP	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.58	7.09	0.41	1.39e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-7.71	-0.44	3.17e-13	Mean corpuscular volume;
KIRP	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.8	-8.79	-0.49	2.68e-16	Coronary artery disease;
KIRP	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15369054	chr17:80825471	TBCD	-0.49	-5.06	-0.31	8.35e-7	Breast cancer;
KIRP	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.52	-7.69	-0.44	3.49e-13	IgG glycosylation;
KIRP	cis	rs8054556	0.539	rs12596543	chr16:30029135	A/G	cg06326092	chr16:30034487	C16orf92	0.46	7.02	0.41	2.14e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg16482183	chr6:26056742	HIST1H1C	0.39	5.17	0.31	4.85e-7	Schizophrenia;
KIRP	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg18882449	chr10:104885122	NT5C2	-0.5	-6.41	-0.38	7.5e-10	Arsenic metabolism;
KIRP	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg00074818	chr8:8560427	CLDN23	0.4	6.22	0.37	2.07e-9	Obesity-related traits;
KIRP	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg05802129	chr4:122689817	NA	-0.64	-8.17	-0.46	1.64e-14	Type 2 diabetes;
KIRP	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.77	6.34	0.37	1.11e-9	Fat distribution (HIV);
KIRP	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.91	-12.64	-0.63	1.49e-28	Menopause (age at onset);
KIRP	cis	rs7602568	1.000	rs2175094	chr2:28587020	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-5.35	-0.32	1.97e-7	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.6	-8.01	-0.46	4.46e-14	Mood instability;
KIRP	trans	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	6.05	0.36	5.23e-9	Metabolite levels;
KIRP	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-0.77	-7.06	-0.41	1.72e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs10214930	0.697	rs10951171	chr7:27611607	C/T	cg22168087	chr7:27702803	HIBADH	0.47	4.91	0.3	1.66e-6	Hypospadias;
KIRP	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.84	12.7	0.63	9.44e-29	Ulcerative colitis;
KIRP	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg16497277	chr3:49208875	KLHDC8B	-0.45	-5.71	-0.34	3.3e-8	Parkinson's disease;
KIRP	cis	rs6832769	0.857	rs28377791	chr4:56473181	T/C	cg09317128	chr4:56265301	TMEM165	-0.44	-5.3	-0.32	2.53e-7	Personality dimensions;
KIRP	trans	rs10242455	0.702	rs28668326	chr7:98998153	G/A	cg09045935	chr12:6379348	NA	0.87	6.11	0.36	3.81e-9	Blood metabolite levels;
KIRP	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg23649088	chr2:200775458	C2orf69	-0.59	-5.05	-0.31	8.48e-7	Schizophrenia;
KIRP	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs7011507	1.000	rs4347021	chr8:49171144	A/C	cg15325961	chr8:49183143	NA	-0.59	-4.99	-0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.72	8.83	0.49	2.07e-16	Monocyte count;
KIRP	cis	rs858239	1.000	rs199351	chr7:23300049	A/C	cg23682824	chr7:23144976	KLHL7	0.43	4.9	0.3	1.74e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18252515	chr7:66147081	NA	-0.45	-5.48	-0.33	1.04e-7	Aortic root size;
KIRP	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23161317	chr6:28129485	ZNF389	0.48	5.57	0.33	6.55e-8	Depression;
KIRP	cis	rs4262150	0.739	rs4958328	chr5:152127005	C/A	cg12297329	chr5:152029980	NA	-0.66	-8.35	-0.47	4.9e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.61	10.06	0.54	3.66e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg06636001	chr8:8085503	FLJ10661	0.63	9.04	0.5	4.92e-17	Neuroticism;
KIRP	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.66	9.61	0.52	9.07e-19	Dupuytren's disease;
KIRP	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg06223162	chr1:101003688	GPR88	-0.43	-8.8	-0.49	2.41e-16	Monocyte count;
KIRP	cis	rs10267417	0.603	rs9654951	chr7:19945169	C/G	cg05791153	chr7:19748676	TWISTNB	0.51	5.12	0.31	6.3e-7	Night sleep phenotypes;
KIRP	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.64	-0.39	2.03e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.6	-8.09	-0.46	2.78e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs539514	0.627	rs9544035	chr13:76293789	C/T	cg04757411	chr13:76259545	LMO7	-0.36	-5.09	-0.31	7.19e-7	Type 1 diabetes;
KIRP	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00933542	chr6:150070202	PCMT1	0.27	5.06	0.31	8.12e-7	Lung cancer;
KIRP	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg15507776	chr3:136538369	TMEM22	0.53	7.33	0.42	3.35e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.73	8.81	0.49	2.29e-16	Alcohol dependence;
KIRP	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	0.82	10.08	0.54	3.14e-20	Prostate cancer;
KIRP	trans	rs10123671	1.000	rs10123671	chr9:29161218	C/T	cg01782798	chr16:70680365	IL34	-0.56	-6.06	-0.36	4.97e-9	Schizophrenia;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg02733842	chr7:1102375	C7orf50	0.44	5.18	0.31	4.56e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12540874	0.524	rs4947684	chr7:50637799	G/A	cg00647317	chr7:50633725	DDC	0.5	7.21	0.42	7.02e-12	Systemic sclerosis;
KIRP	cis	rs13427251	0.653	rs11123787	chr2:100156940	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.44	-5.73	-0.34	2.85e-8	Chronic sinus infection;
KIRP	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.38e-7	Bipolar disorder;
KIRP	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg10932868	chr11:921992	NA	0.63	8.36	0.47	4.72e-15	Alzheimer's disease (late onset);
KIRP	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.8	-8.85	-0.49	1.73e-16	Body mass index;
KIRP	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg00409905	chr10:38381863	ZNF37A	-0.56	-6.27	-0.37	1.65e-9	Obesity (extreme);
KIRP	cis	rs7903847	0.642	rs7074511	chr10:99140177	G/A	cg20016023	chr10:99160130	RRP12	-0.42	-5.89	-0.35	1.28e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg12549451	chr6:135224345	NA	-0.38	-5.08	-0.31	7.31e-7	Red blood cell count;
KIRP	cis	rs7011049	0.573	rs114491022	chr8:53867161	T/G	cg26025543	chr8:53854495	NA	0.58	6.28	0.37	1.49e-9	Systolic blood pressure;
KIRP	trans	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.31	-0.42	3.66e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs400736	0.894	rs226253	chr1:8027706	T/C	cg25007680	chr1:8021821	PARK7	0.64	8.53	0.48	1.47e-15	Response to antidepressants and depression;
KIRP	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs11165623	0.792	rs12123543	chr1:96964549	T/C	cg10631902	chr5:14652156	NA	-0.57	-8.55	-0.48	1.29e-15	Hip circumference;Waist circumference;
KIRP	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.67	9.0	0.5	6.46e-17	Breast cancer;
KIRP	cis	rs2441986	0.857	rs11229292	chr11:57984777	A/G	cg19752551	chr11:57585705	CTNND1	0.36	4.87	0.3	2.04e-6	Systolic blood pressure;
KIRP	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg07068956	chr7:100330872	ZAN	-0.44	-5.21	-0.32	3.99e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.84	11.25	0.58	5.64e-24	Morning vs. evening chronotype;
KIRP	cis	rs988913	0.957	rs6459035	chr6:54757520	A/G	cg03513858	chr6:54763001	FAM83B	-0.34	-4.93	-0.3	1.48e-6	Menarche (age at onset);
KIRP	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.82	9.0	0.5	6.22e-17	Alzheimer's disease;
KIRP	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg18132916	chr6:79620363	NA	-0.41	-5.79	-0.35	2.16e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg19000871	chr14:103996768	TRMT61A	-0.83	-9.6	-0.52	9.92e-19	Coronary artery disease;
KIRP	cis	rs12986413	0.846	rs12609327	chr19:2183000	A/C	cg09261902	chr19:2140048	AP3D1	0.61	9.27	0.51	9.49e-18	Height;
KIRP	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg09699651	chr6:150184138	LRP11	0.44	5.69	0.34	3.68e-8	Lung cancer;
KIRP	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg06212747	chr3:49208901	KLHDC8B	0.68	7.92	0.45	8.3e-14	Menarche (age at onset);
KIRP	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.6	-7.21	-0.42	6.83e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	5.99	0.36	7.48e-9	Height;
KIRP	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22618164	chr12:122356400	WDR66	0.62	8.57	0.48	1.15e-15	Mean corpuscular volume;
KIRP	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.59	0.39	2.6200000000000003e-10	Educational attainment;
KIRP	cis	rs796825	0.530	rs34829073	chr3:119943371	C/T	cg21790991	chr3:120137480	FSTL1	-0.3	-5.23	-0.32	3.64e-7	HIV-1 susceptibility;
KIRP	cis	rs4690686	0.769	rs7660827	chr4:177274542	T/C	cg17059388	chr4:177262070	NA	0.55	7.59	0.44	6.75e-13	Essential tremor;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05149425	chr12:129308602	SLC15A4	0.55	6.62	0.39	2.18e-10	Parkinson's disease;
KIRP	cis	rs7751419	0.651	rs10947780	chr6:39093663	T/C	cg08089693	chr6:39098871	NA	-0.69	-9.9	-0.53	1.11e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
KIRP	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg08501292	chr6:25962987	TRIM38	0.79	5.43	0.33	1.38e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg16497661	chr14:103986332	CKB	-0.52	-6.73	-0.39	1.17e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs12444979	0.507	rs8062735	chr16:19839538	C/T	cg01587771	chr1:24117398	LYPLA2	-0.52	-6.27	-0.37	1.63e-9	Body mass index;
KIRP	cis	rs12445022	0.632	rs12920915	chr16:87577521	C/T	cg08031982	chr16:87577539	NA	0.37	5.94	0.35	9.58e-9	Small vessel stroke;Systemic juvenile idiopathic arthritis;
KIRP	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg02023728	chr11:77925099	USP35	0.35	5.46	0.33	1.17e-7	Alzheimer's disease (survival time);
KIRP	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg23594656	chr7:65796392	TPST1	0.47	7.39	0.43	2.23e-12	Aortic root size;
KIRP	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg07274523	chr3:49395745	GPX1	0.69	8.58	0.48	1.08e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg02336718	chr17:17403227	NA	-0.33	-5.09	-0.31	7.05e-7	Total body bone mineral density;
KIRP	cis	rs860295	0.580	rs10908463	chr1:155286258	C/T	cg02153340	chr1:155202674	NA	-0.59	-7.71	-0.44	3.06e-13	Body mass index;
KIRP	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.18e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs9815354	0.812	rs73073234	chr3:42012071	C/T	cg03022575	chr3:42003672	ULK4	0.8	8.07	0.46	3.15e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg03806693	chr22:41940476	POLR3H	-0.47	-5.68	-0.34	3.7e-8	Neuroticism;
KIRP	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.71	-13.32	-0.65	7.92e-31	Obesity-related traits;
KIRP	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.56	6.18	0.37	2.62e-9	Hypospadias;
KIRP	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg23565292	chr14:50234668	KLHDC2	-0.44	-5.31	-0.32	2.4e-7	Carotid intima media thickness;
KIRP	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg00701064	chr4:6280414	WFS1	0.46	10.24	0.55	9.69e-21	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	trans	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg01311341	chr22:25575246	KIAA1671	-0.6	-6.54	-0.38	3.45e-10	Glioblastoma;
KIRP	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg15556689	chr8:8085844	FLJ10661	0.52	6.42	0.38	6.86e-10	Schizophrenia;
KIRP	cis	rs7116495	0.609	rs2155142	chr11:71642524	A/G	cg07596299	chr11:71824057	C11orf51	0.8	5.12	0.31	6.09e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.43	-5.38	-0.32	1.7e-7	Personality dimensions;
KIRP	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg04731861	chr2:219085781	ARPC2	0.28	7.4	0.43	2.17e-12	Colorectal cancer;
KIRP	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg03929089	chr4:120376271	NA	0.67	6.62	0.39	2.23e-10	Axial length;
KIRP	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.41	6.72	0.39	1.27e-10	Testicular germ cell tumor;
KIRP	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg16917193	chr12:54089295	NA	0.86	16.58	0.73	6.05e-42	Height;
KIRP	trans	rs17834760	0.955	rs62423545	chr6:62041599	A/G	cg08476511	chr6:168435923	KIF25	0.53	6.12	0.36	3.75e-9	Antipsychotic drug-induced QTc interval change in schizophrenia;
KIRP	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg02570527	chr1:10970165	NA	-0.39	-4.89	-0.3	1.86e-6	Body mass index;
KIRP	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg13798912	chr7:905769	UNC84A	0.59	5.89	0.35	1.27e-8	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg11502198	chr6:26597334	ABT1	-0.79	-5.37	-0.32	1.8e-7	Small cell lung carcinoma;
KIRP	cis	rs1408799	0.523	rs2762464	chr9:12709586	A/T	cg05274944	chr9:12693694	TYRP1	0.43	6.43	0.38	6.41e-10	Eye color;Blue vs. green eyes;
KIRP	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-1.11	-20.35	-0.79	1.18e-54	Monocyte count;
KIRP	cis	rs2860975	1.000	rs11492718	chr10:96787377	A/T	cg09036531	chr10:96991505	NA	-0.52	-6.59	-0.39	2.65e-10	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs6832769	0.925	rs11133383	chr4:56317045	A/G	cg05960024	chr4:56376020	CLOCK	-0.54	-6.8	-0.4	7.67e-11	Personality dimensions;
KIRP	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.72	7.72	0.44	3.01e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs12681288	0.782	rs2600498	chr8:1026520	A/G	cg08648136	chr8:956695	NA	0.4	5.43	0.33	1.35e-7	Schizophrenia;
KIRP	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.44	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	trans	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg25288420	chr1:78511713	GIPC2	0.51	6.95	0.41	3.18e-11	Obesity-related traits;
KIRP	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.73	9.94	0.54	8.89e-20	Hip circumference adjusted for BMI;
KIRP	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg09165964	chr15:75287851	SCAMP5	0.47	5.85	0.35	1.58e-8	Caffeine consumption;
KIRP	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg09699651	chr6:150184138	LRP11	0.48	6.49	0.38	4.69e-10	Lung cancer;
KIRP	cis	rs4722404	0.502	rs13234017	chr7:3110587	C/A	cg19214707	chr7:3157722	NA	-0.53	-6.32	-0.37	1.19e-9	Atopic dermatitis;
KIRP	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.57	11.84	0.6	6.83e-26	Diabetic kidney disease;
KIRP	cis	rs472402	0.623	rs7707877	chr5:6635946	C/G	cg08700190	chr5:6636046	SRD5A1	-0.48	-6.06	-0.36	5.09e-9	Response to amphetamines;
KIRP	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18932078	chr1:2524107	MMEL1	-0.41	-5.5	-0.33	9.63e-8	Ulcerative colitis;
KIRP	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12893428	chr3:195717962	SDHAP1	0.5	6.66	0.39	1.75e-10	Pancreatic cancer;
KIRP	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-6.96	-0.41	3.03e-11	Height;
KIRP	cis	rs7017914	0.967	rs7814648	chr8:71603984	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.93e-7	Bone mineral density;
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	0.87	14.57	0.68	4.21e-35	Vitiligo;
KIRP	cis	rs7688540	0.771	rs61795002	chr4:242797	G/A	cg17891759	chr4:299121	NA	-0.5	-5.08	-0.31	7.47e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs240764	0.817	rs240154	chr6:101065792	G/T	cg09795085	chr6:101329169	ASCC3	0.47	5.48	0.33	1.07e-7	Neuroticism;
KIRP	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg02931644	chr1:25747376	RHCE	0.35	6.37	0.38	9.31e-10	Plateletcrit;Mean corpuscular volume;
KIRP	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.3	1.01e-6	Schizophrenia;
KIRP	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg07001201	chr5:642380	CEP72	0.68	6.38	0.38	8.52e-10	Obesity-related traits;
KIRP	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.56	6.71	0.39	1.3e-10	Aortic root size;
KIRP	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.65	7.32	0.42	3.49e-12	Recalcitrant atopic dermatitis;
KIRP	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.75	10.52	0.56	1.32e-21	Parkinson's disease;
KIRP	cis	rs12900413	0.562	rs28557101	chr15:90298149	C/T	cg24650279	chr15:90327240	NA	-0.42	-5.25	-0.32	3.32e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.28	0.51	9.37e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9914988	0.667	rs11655019	chr17:27255191	T/C	cg20469991	chr17:27169893	C17orf63	-0.63	-5.25	-0.32	3.26e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.49	-5.15	-0.31	5.24e-7	Breast cancer;
KIRP	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-6.14	-0.36	3.35e-9	Bladder cancer;
KIRP	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg08989290	chr16:615782	NHLRC4	0.4	5.93	0.35	1.03e-8	Height;
KIRP	cis	rs4950322	0.570	rs72692951	chr1:146792269	G/A	cg22381352	chr1:146742008	CHD1L	-0.45	-5.3	-0.32	2.56e-7	Protein quantitative trait loci;
KIRP	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg04369109	chr6:150039330	LATS1	-0.53	-6.61	-0.39	2.39e-10	Lung cancer;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg10881149	chr6:10695206	C6orf52;PAK1IP1	0.63	6.12	0.36	3.68e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	6.2	0.37	2.35e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06481639	chr22:41940642	POLR3H	0.68	6.89	0.4	4.73e-11	Vitiligo;
KIRP	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg08134877	chr2:44394819	PPM1B	0.51	5.14	0.31	5.7e-7	Height;
KIRP	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg13397359	chr6:42928475	GNMT	0.63	9.37	0.51	4.79e-18	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg07387570	chr22:46663686	TTC38	0.67	6.22	0.37	2.09e-9	Lung function (FEV1);
KIRP	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.68	0.48	5.55e-16	Motion sickness;
KIRP	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg04990556	chr1:26633338	UBXN11	-0.61	-7.54	-0.43	9.27e-13	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg20965017	chr5:231967	SDHA	-0.6	-7.04	-0.41	1.94e-11	Breast cancer;
KIRP	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.5	-6.18	-0.37	2.6e-9	Menopause (age at onset);
KIRP	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.58	7.46	0.43	1.52e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-19.23	-0.77	6.45e-51	Height;
KIRP	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.81	-9.88	-0.53	1.36e-19	Post bronchodilator FEV1;
KIRP	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg08885076	chr2:99613938	TSGA10	-0.39	-5.54	-0.33	7.8e-8	Bipolar disorder;
KIRP	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg16497661	chr14:103986332	CKB	0.39	5.09	0.31	7e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg15034464	chr19:4182587	SIRT6;ANKRD24	0.56	6.71	0.39	1.3e-10	DNA methylation (variation);
KIRP	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.1	-0.61	9.43e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg16141378	chr3:129829833	LOC729375	0.53	6.54	0.38	3.54e-10	Joint mobility (Beighton score);
KIRP	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg27205649	chr11:78285834	NARS2	0.82	10.47	0.56	1.85e-21	Alzheimer's disease (survival time);
KIRP	cis	rs12496230	0.794	rs6782706	chr3:66859345	C/T	cg17646820	chr3:66848679	NA	0.39	6.38	0.38	8.73e-10	Type 2 diabetes;
KIRP	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.19	-0.37	2.44e-9	Systolic blood pressure;
KIRP	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.93	14.83	0.69	5.77e-36	Coronary artery disease;
KIRP	cis	rs6968419	0.755	rs17138483	chr7:115893845	A/C	cg02561103	chr7:115862891	TES	-0.41	-5.82	-0.35	1.83e-8	Intraocular pressure;
KIRP	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.72	-10.67	-0.56	4.41e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.72	-10.25	-0.55	9.3e-21	Facial morphology (factor 21, depth of nasal alae);
KIRP	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.4	-5.65	-0.34	4.46e-8	Headache;
KIRP	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg01028140	chr2:1542097	TPO	-0.6	-6.09	-0.36	4.38e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07570687	chr10:102243282	WNT8B	0.5	5.78	0.35	2.28e-8	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-18.16	-0.76	2.53e-47	Schizophrenia;
KIRP	cis	rs2073300	1.000	rs6036418	chr20:23449698	A/G	cg12062639	chr20:23401060	NAPB	0.73	6.84	0.4	6.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.59	-7.27	-0.42	4.78e-12	Glomerular filtration rate;
KIRP	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg24699146	chr1:24152579	HMGCL	0.48	6.87	0.4	5.21e-11	Immature fraction of reticulocytes;
KIRP	trans	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg24644049	chr4:85504048	CDS1	1.0	6.95	0.41	3.31e-11	Skin colour saturation;
KIRP	cis	rs28489187	0.617	rs233068	chr1:85805355	G/A	cg16011679	chr1:85725395	C1orf52	0.44	5.51	0.33	8.94e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg10047753	chr17:41438598	NA	1.12	17.86	0.75	2.5e-46	Menopause (age at onset);
KIRP	cis	rs10045504	0.502	rs17456635	chr5:38745456	G/A	cg15396434	chr5:38725168	NA	-0.96	-9.57	-0.52	1.21e-18	Night sleep phenotypes;
KIRP	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	cg12689670	chr1:183009347	LAMC1	0.42	6.0	0.36	6.99e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs11700980	0.636	rs73190119	chr21:30303685	C/A	cg08807101	chr21:30365312	RNF160	-0.54	-4.96	-0.3	1.31e-6	QRS complex (12-leadsum);
KIRP	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.63	8.39	0.47	3.9e-15	Neuroticism;
KIRP	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.67	9.58	0.52	1.08e-18	Dupuytren's disease;
KIRP	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.82	-12.03	-0.61	1.61e-26	Prudent dietary pattern;
KIRP	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.64	8.27	0.47	8.7e-15	Eosinophil percentage of white cells;
KIRP	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.67	-7.86	-0.45	1.2e-13	Pulmonary function decline;
KIRP	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg10189774	chr4:17578691	LAP3	-0.51	-5.31	-0.32	2.43e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-6.33	-0.37	1.17e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.57	7.6	0.44	6.22e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs11779988	0.545	rs421290	chr8:17766416	G/C	cg01800426	chr8:17659068	MTUS1	-0.56	-5.68	-0.34	3.76e-8	Breast cancer;
KIRP	trans	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg18187862	chr3:45730750	SACM1L	-0.68	-7.21	-0.42	6.77e-12	Primary sclerosing cholangitis;
KIRP	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.72	-7.83	-0.45	1.41e-13	Breast cancer;
KIRP	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg16141378	chr3:129829833	LOC729375	0.5	6.5	0.38	4.48e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.67	-9.43	-0.52	3.17e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22993707	chr3:11888340	C3orf31	0.46	6.32	0.37	1.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10203711	1.000	rs4663941	chr2:239574279	A/G	cg14580085	chr2:239553406	NA	0.38	5.02	0.3	9.99e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.29	6.53	0.38	3.84e-10	IgG glycosylation;
KIRP	cis	rs3857747	0.827	rs4257934	chr7:40401647	T/C	cg00420559	chr7:40367873	C7orf10	-0.61	-8.34	-0.47	5.42e-15	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg02336718	chr17:17403227	NA	0.39	5.98	0.36	7.7e-9	Total body bone mineral density;
KIRP	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00791764	chr4:53727839	RASL11B	0.37	5.42	0.33	1.44e-7	Optic nerve measurement (cup area);
KIRP	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.48	6.67	0.39	1.72e-10	Red blood cell count;
KIRP	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg24324837	chr19:49891574	CCDC155	0.62	7.72	0.44	2.84e-13	Multiple sclerosis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23372537	chr19:10138480	NA	0.51	7.16	0.42	9.04e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.3	4.88	0.3	1.93e-6	Multiple sclerosis or amyotrophic lateral sclerosis;
KIRP	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.4	4.95	0.3	1.4e-6	Diabetic retinopathy;
KIRP	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg15655495	chr12:38532458	NA	-0.3	-5.27	-0.32	3.04e-7	Bladder cancer;
KIRP	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg13206674	chr6:150067644	NUP43	0.49	6.88	0.4	4.79e-11	Lung cancer;
KIRP	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg25019722	chr6:37503610	NA	-0.81	-11.02	-0.57	3.18e-23	Cognitive performance;
KIRP	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg05941025	chr16:89927596	SPIRE2	0.38	6.01	0.36	6.77e-9	Vitiligo;
KIRP	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg05973401	chr12:123451056	ABCB9	0.61	7.19	0.42	7.62e-12	Platelet count;
KIRP	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg12692727	chr7:1102344	C7orf50	0.48	5.16	0.31	5.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.8	0.49	2.51e-16	Bipolar disorder;
KIRP	cis	rs2019216	0.564	rs907707	chr17:21910083	G/C	cg22648282	chr17:21454238	C17orf51	-0.52	-6.61	-0.39	2.4e-10	Pelvic organ prolapse;
KIRP	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.87	-11.46	-0.59	1.16e-24	Type 2 diabetes;
KIRP	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-12.0	-0.61	2.07e-26	Morning vs. evening chronotype;
KIRP	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-8.81	-0.49	2.33e-16	Personality dimensions;
KIRP	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg06521852	chr22:38141419	TRIOBP	0.36	4.97	0.3	1.28e-6	Optic cup area;Vertical cup-disc ratio;
KIRP	cis	rs829661	0.843	rs829617	chr2:30748039	T/C	cg10949345	chr2:30726833	LCLAT1	1.0	12.79	0.63	4.54e-29	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg03714773	chr7:91764589	CYP51A1	0.38	5.5	0.33	9.57e-8	Breast cancer;
KIRP	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23903597	chr17:61704154	MAP3K3	-0.61	-7.97	-0.45	5.99e-14	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7010267	0.935	rs4319131	chr8:119947651	A/G	cg01975934	chr8:119970761	NA	0.42	5.49	0.33	9.83e-8	Total body bone mineral density (age 45-60);
KIRP	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg04607699	chr11:48328132	OR4S1	-0.39	-5.57	-0.33	6.55e-8	Migraine - clinic-based;
KIRP	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-0.84	-9.28	-0.51	8.92e-18	Post bronchodilator FEV1;
KIRP	cis	rs10861342	1.000	rs10861357	chr12:105544254	C/T	cg23923672	chr12:105501055	KIAA1033	0.86	6.92	0.4	3.87e-11	IgG glycosylation;
KIRP	cis	rs11203032	0.831	rs2211599	chr10:90929547	G/A	cg16672925	chr10:90967113	CH25H	0.73	7.26	0.42	5.11e-12	Heart failure;
KIRP	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg27144592	chr16:783916	NARFL	0.38	5.41	0.33	1.48e-7	Height;
KIRP	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	1.03	14.17	0.67	9.92e-34	Menopause (age at onset);
KIRP	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	1.0	15.45	0.7	4.41e-38	Chronic sinus infection;
KIRP	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg08076091	chr2:203926405	NBEAL1	0.85	8.63	0.48	7.88e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7224685	0.911	rs11651767	chr17:4073398	A/G	cg26134248	chr17:3907702	NA	-0.48	-6.16	-0.37	2.88e-9	Type 2 diabetes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17977474	chr19:14073064	RFX1	-0.4	-6.18	-0.37	2.69e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg25281562	chr12:121454272	C12orf43	-0.45	-4.96	-0.3	1.33e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7772486	0.875	rs2748497	chr6:146319417	C/T	cg05347473	chr6:146136440	FBXO30	0.49	6.73	0.39	1.22e-10	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg13514129	chr1:39547527	MACF1	0.52	7.44	0.43	1.7e-12	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs1010254	0.510	rs72806385	chr5:151704007	G/A	cg12297329	chr5:152029980	NA	-0.63	-6.45	-0.38	5.82e-10	Optic nerve measurement (cup area);
KIRP	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs7215564	0.730	rs34405143	chr17:78585681	G/C	cg06153925	chr17:78755379	RPTOR	0.46	6.17	0.37	2.74e-9	Myopia (pathological);
KIRP	cis	rs11825064	0.673	rs79389752	chr11:134496974	A/T	cg06603561	chr11:134479413	NA	-1.12	-7.83	-0.45	1.42e-13	Seasonality;
KIRP	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.98	-0.3	1.21e-6	Schizophrenia;
KIRP	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.41	4.99	0.3	1.12e-6	Recombination rate (males);
KIRP	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-5.07	-0.31	7.66e-7	Coronary artery disease;
KIRP	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg13264159	chr8:625131	ERICH1	0.86	6.09	0.36	4.24e-9	IgG glycosylation;
KIRP	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-12.86	-0.63	2.8e-29	Alzheimer's disease;
KIRP	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.98	-0.41	2.8e-11	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg06521331	chr12:34319734	NA	-0.61	-7.23	-0.42	5.98e-12	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7612445	0.818	rs73172223	chr3:179171224	T/C	cg01750654	chr3:179170617	GNB4	-0.85	-8.53	-0.48	1.55e-15	Resting heart rate;Heart rate;
KIRP	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.44	-5.15	-0.31	5.45e-7	Metabolite levels;
KIRP	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.63	10.34	0.55	4.86e-21	Lung cancer;
KIRP	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.72	10.32	0.55	5.55e-21	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg10818794	chr15:86012489	AKAP13	-0.58	-8.24	-0.47	1.03e-14	Interstitial lung disease;
KIRP	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.75	6.75	0.4	1.08e-10	Diabetic retinopathy;
KIRP	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg13334819	chr7:99746414	C7orf59	-0.55	-5.64	-0.34	4.66e-8	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg16479474	chr6:28041457	NA	0.44	4.95	0.3	1.41e-6	Depression;
KIRP	cis	rs9398803	0.865	rs9398808	chr6:126758791	G/T	cg19875578	chr6:126661172	C6orf173	0.5	6.42	0.38	6.87e-10	Male-pattern baldness;
KIRP	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.55	-6.66	-0.39	1.78e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7683574	0.560	rs13136075	chr4:9714968	G/A	cg15442990	chr4:9534313	NA	0.4	4.88	0.3	1.93e-6	Lung cancer;
KIRP	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg06050784	chr16:88016603	BANP	0.44	5.58	0.33	6.47e-8	Menopause (age at onset);
KIRP	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.67	0.52	5.8e-19	Prudent dietary pattern;
KIRP	cis	rs2413595	1.000	rs738288	chr22:39907661	C/T	cg10455938	chr22:40058150	CACNA1I	0.42	5.71	0.34	3.19e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg05756136	chr1:119680316	WARS2	-0.61	-8.34	-0.47	5.43e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1484642	0.530	rs17151071	chr8:9956672	C/G	cg15537082	chr8:9762300	MIR124-1;LOC157627	0.57	5.13	0.31	5.74e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg17376030	chr22:41985996	PMM1	-0.52	-6.39	-0.38	8.44e-10	Vitiligo;
KIRP	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.87	12.45	0.62	6.64e-28	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19482537	chr5:156692823	CYFIP2	0.47	6.66	0.39	1.82e-10	Parkinson's disease;
KIRP	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.28	7.44	0.43	1.72e-12	Primary biliary cholangitis;
KIRP	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg06115741	chr20:33292138	TP53INP2	-0.4	-5.4	-0.33	1.54e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs4356932	0.967	rs28681694	chr4:76972594	A/C	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.64e-9	Blood protein levels;
KIRP	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg00647317	chr7:50633725	DDC	-0.41	-5.47	-0.33	1.08e-7	Malaria;
KIRP	cis	rs9400467	0.528	rs12214380	chr6:111796937	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.43	-5.52	-0.33	8.44e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.52	6.62	0.39	2.3e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg01718733	chr15:29409410	APBA2	0.42	6.06	0.36	5.07e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg16586182	chr3:47516702	SCAP	0.43	5.44	0.33	1.32e-7	Birth weight;
KIRP	cis	rs4363385	0.530	rs61815714	chr1:152921380	C/T	cg25856811	chr1:152973957	SPRR3	-0.39	-5.38	-0.32	1.77e-7	Inflammatory skin disease;
KIRP	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.5	-6.49	-0.38	4.8e-10	Coronary artery disease;
KIRP	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23161317	chr6:28129485	ZNF389	0.44	4.88	0.3	1.88e-6	Depression;
KIRP	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg01629716	chr15:45996671	NA	0.37	6.66	0.39	1.75e-10	Waist circumference;Weight;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17457156	chr13:95248351	TGDS	0.43	6.26	0.37	1.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.55	-6.86	-0.4	5.68e-11	Monocyte count;
KIRP	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg05255149	chr17:80675120	FN3KRP	0.47	5.21	0.32	4.05e-7	Glycated hemoglobin levels;
KIRP	cis	rs526231	0.543	rs26523	chr5:102456254	C/T	cg23492399	chr5:102201601	PAM	-0.54	-5.89	-0.35	1.27e-8	Primary biliary cholangitis;
KIRP	cis	rs501120	0.925	rs1746050	chr10:44777188	C/A	cg09554077	chr10:44749378	NA	0.68	9.76	0.53	3.08e-19	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg06766960	chr11:133703094	NA	-0.75	-9.92	-0.53	9.97e-20	Childhood ear infection;
KIRP	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.43	0.52	3.2e-18	IgG glycosylation;
KIRP	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg07541023	chr7:19748670	TWISTNB	-0.64	-5.99	-0.36	7.59e-9	Thyroid stimulating hormone;
KIRP	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	8.7	0.49	4.73e-16	Breast cancer;
KIRP	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	4.89	0.3	1.81e-6	Schizophrenia;
KIRP	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-12.07	-0.61	1.2e-26	Eye color traits;
KIRP	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs2594989	0.887	rs7640360	chr3:11584889	T/G	cg01796438	chr3:11312864	ATG7	0.6	7.26	0.42	5.05e-12	Circulating chemerin levels;
KIRP	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	0.98	11.74	0.6	1.4e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg01559446	chr3:44596178	ZNF167	-0.41	-5.83	-0.35	1.75e-8	Depressive symptoms;
KIRP	cis	rs7523050	0.908	rs12404382	chr1:109397129	G/A	cg08274380	chr1:109419600	GPSM2	0.65	6.2	0.37	2.43e-9	Fat distribution (HIV);
KIRP	cis	rs1816752	0.819	rs9511240	chr13:24985906	G/A	cg02811702	chr13:24901961	NA	0.39	5.09	0.31	7.17e-7	Obesity-related traits;
KIRP	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs4253772	0.515	rs77797820	chr22:46771270	C/T	cg00784671	chr22:46762841	CELSR1	-0.92	-7.99	-0.45	5.07e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg13092806	chr2:177043255	NA	0.59	8.01	0.45	4.64e-14	IgG glycosylation;
KIRP	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg13385521	chr17:29058706	SUZ12P	0.59	5.95	0.35	9.36e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.5	-6.13	-0.36	3.48e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs16828019	0.852	rs11209531	chr1:41571021	C/T	cg18742814	chr1:41828276	NA	0.6	5.41	0.33	1.52e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg13902645	chr11:5959945	NA	-0.61	-6.39	-0.38	8.28e-10	DNA methylation (variation);
KIRP	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.67	0.39	1.63e-10	Mean corpuscular volume;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18810342	chr3:5019075	NA	0.51	6.22	0.37	2.13e-9	Smoking initiation;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg18802706	chr17:78902434	RPTOR	0.53	6.07	0.36	4.83e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.19	-0.37	2.45e-9	Breast cancer;
KIRP	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-6.51	-0.38	4.18e-10	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg05938607	chr10:60274200	BICC1	-0.46	-11.25	-0.58	5.96e-24	Refractive error;
KIRP	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.6	-7.01	-0.41	2.29e-11	Menarche (age at onset);
KIRP	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg15934090	chr1:100435551	SLC35A3	0.53	6.55	0.39	3.31e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg17644776	chr2:200775616	C2orf69	0.61	5.63	0.34	4.87e-8	Schizophrenia;
KIRP	trans	rs9650657	0.783	rs28570522	chr8:10630568	A/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.15	-0.37	3.13e-9	Neuroticism;
KIRP	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	6.89	0.4	4.56e-11	Monocyte count;
KIRP	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg08999081	chr20:33150536	PIGU	0.45	5.75	0.34	2.68e-8	Height;
KIRP	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.49	5.14	0.31	5.57e-7	Alzheimer's disease;
KIRP	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1497828	0.956	rs2818975	chr1:217550732	T/G	cg04411442	chr1:217543379	NA	0.41	6.17	0.37	2.8e-9	Dialysis-related mortality;
KIRP	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg26876637	chr1:152193138	HRNR	0.71	9.66	0.52	6.38e-19	Atopic dermatitis;
KIRP	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.56	7.3	0.42	3.93e-12	Eye color traits;
KIRP	cis	rs11209002	0.567	rs2224501	chr1:67532526	G/T	cg02640540	chr1:67518911	SLC35D1	0.57	6.21	0.37	2.23e-9	Crohn's disease;
KIRP	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20135002	chr11:47629003	NA	-0.45	-5.04	-0.31	9.13e-7	Subjective well-being;
KIRP	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.83	-10.71	-0.56	3.11e-22	Cognitive function;
KIRP	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-1.08	-9.8	-0.53	2.33e-19	Pulse pressure;
KIRP	cis	rs4849845	0.653	rs3933618	chr2:121035552	T/G	cg24070213	chr2:121070622	NA	0.39	5.94	0.35	9.73e-9	Mean platelet volume;
KIRP	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg16898833	chr6:26189333	HIST1H4D	0.95	5.77	0.35	2.32e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7949030	0.596	rs11231137	chr11:62315699	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.54	7.47	0.43	1.42e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs28655083	0.879	rs1502444	chr16:77059172	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-6.05	-0.36	5.23e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg23594656	chr7:65796392	TPST1	-0.45	-7.06	-0.41	1.74e-11	Aortic root size;
KIRP	cis	rs2302729	0.545	rs3794291	chr12:2769665	C/T	cg19945202	chr12:2788847	CACNA1C	-0.75	-11.07	-0.58	2.16e-23	Sleep quality;
KIRP	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.2	13.21	0.64	1.84e-30	Nonalcoholic fatty liver disease;
KIRP	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.4	5.22	0.32	3.83e-7	Testicular germ cell tumor;
KIRP	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.62	-7.39	-0.43	2.22e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg05360138	chr12:110035743	NA	0.49	5.54	0.33	7.95e-8	Neuroticism;
KIRP	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg26022315	chr17:47021804	SNF8	0.39	4.93	0.3	1.52e-6	Type 2 diabetes;
KIRP	cis	rs5753618	0.504	rs5753659	chr22:31893613	A/G	cg02404636	chr22:31891804	SFI1	0.53	5.91	0.35	1.16e-8	Colorectal cancer;
KIRP	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs2617583	0.904	rs2937639	chr5:1443728	A/G	cg07151155	chr5:1473589	LPCAT1	-0.45	-6.09	-0.36	4.23e-9	Breast cancer;
KIRP	cis	rs10203711	1.000	rs6731675	chr2:239566943	T/C	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.86	-12.48	-0.62	5.16e-28	Eye color traits;
KIRP	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg06671706	chr8:8559999	CLDN23	0.51	6.3	0.37	1.39e-9	Obesity-related traits;
KIRP	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg15282417	chr9:129245246	FAM125B	0.45	7.99	0.45	5.1e-14	Intraocular pressure;
KIRP	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg03808351	chr9:123631620	PHF19	0.51	5.97	0.36	8.24e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs5758511	0.573	rs4501042	chr22:42245763	C/T	cg15128208	chr22:42549153	NA	-0.44	-4.96	-0.3	1.34e-6	Birth weight;
KIRP	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-6.02	-0.36	6.16e-9	Height;
KIRP	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.55	-6.49	-0.38	4.67e-10	Axial length;
KIRP	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg04362960	chr10:104952993	NT5C2	0.56	6.95	0.41	3.22e-11	Arsenic metabolism;
KIRP	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.09	0.61	1.03e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.49	6.3	0.37	1.34e-9	Body mass index;
KIRP	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.78	11.96	0.61	2.75e-26	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg03609598	chr5:56110824	MAP3K1	0.6	5.96	0.36	8.71e-9	Initial pursuit acceleration;
KIRP	cis	rs7084402	1.000	rs28426375	chr10:60285478	T/A	cg05938607	chr10:60274200	BICC1	-0.45	-10.8	-0.57	1.63e-22	Refractive error;
KIRP	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg21858823	chr1:15850916	CASP9	0.53	5.66	0.34	4.11e-8	Systolic blood pressure;
KIRP	cis	rs73086581	1.000	rs6052196	chr20:3945824	T/C	cg02187196	chr20:3869020	PANK2	0.47	4.9	0.3	1.72e-6	Response to antidepressants in depression;
KIRP	cis	rs629922	0.642	rs655988	chr11:114072365	A/G	cg25009965	chr11:114031120	ZBTB16	0.43	5.25	0.32	3.26e-7	Paneth cell defects in Crohn's disease;
KIRP	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.93	-13.32	-0.65	7.76e-31	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02450613	chr5:37840089	GDNF	0.45	6.15	0.37	3.1e-9	Parkinson's disease;
KIRP	cis	rs10861342	1.000	rs11112403	chr12:105586649	A/G	cg23923672	chr12:105501055	KIAA1033	0.81	6.81	0.4	7.55e-11	IgG glycosylation;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg15428792	chr12:11151430	PRR4;TAS2R20;PRH1	0.53	6.01	0.36	6.49e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2290419	0.504	rs117786030	chr11:68939448	A/G	cg17042914	chr11:68898666	NA	-0.7	-5.13	-0.31	5.91e-7	Cutaneous malignant melanoma;
KIRP	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg22676075	chr6:135203613	NA	-0.52	-6.6	-0.39	2.46e-10	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg00277334	chr10:82204260	NA	-0.44	-4.86	-0.3	2.05e-6	Post bronchodilator FEV1;
KIRP	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	4.9	0.3	1.74e-6	Height;
KIRP	cis	rs17023223	0.537	rs1057991	chr1:119575170	C/A	cg05756136	chr1:119680316	WARS2	-0.56	-7.53	-0.43	9.6e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19799760	chr19:14629225	DNAJB1	0.51	6.28	0.37	1.53e-9	Parkinson's disease;
KIRP	cis	rs9513627	1.000	rs9517758	chr13:100179397	T/A	cg25919922	chr13:100150906	NA	0.72	5.38	0.32	1.69e-7	Obesity-related traits;
KIRP	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.39	13.11	0.64	3.84e-30	Opioid sensitivity;
KIRP	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.96	11.55	0.59	6.24e-25	Corneal astigmatism;
KIRP	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1559088	0.901	rs12610053	chr19:33582606	A/G	cg03563238	chr19:33554763	RHPN2	-0.33	-5.72	-0.34	3.12e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg13010199	chr12:38710504	ALG10B	0.45	5.71	0.34	3.25e-8	Morning vs. evening chronotype;
KIRP	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.66	-0.34	4.23e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs6708331	0.540	rs9679269	chr2:70381828	C/T	cg05298696	chr2:70188691	ASPRV1	-0.46	-6.1	-0.36	4.14e-9	Obesity-related traits;
KIRP	cis	rs311392	0.934	rs376589	chr8:55088289	G/A	cg20636351	chr8:55087400	NA	-0.63	-7.69	-0.44	3.48e-13	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg24579218	chr15:68104479	NA	-0.43	-6.26	-0.37	1.67e-9	Obesity;
KIRP	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg16179182	chr5:140090404	VTRNA1-1	0.55	7.62	0.44	5.34e-13	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25382566	chr11:64851788	CDCA5;ZFPL1	0.54	6.62	0.39	2.18e-10	Parkinson's disease;
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg09231725	chr11:64357281	SLC22A12	-0.65	-8.81	-0.49	2.29e-16	Urate levels in obese individuals;
KIRP	cis	rs9816226	0.591	rs75160594	chr3:185810481	C/G	cg00760338	chr3:185826511	ETV5	-0.74	-6.44	-0.38	6.29e-10	Obesity;Body mass index;
KIRP	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.88	-13.14	-0.64	3.21e-30	Neuroticism;
KIRP	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2745572	0.557	rs2745569	chr6:1547631	C/T	cg01806741	chr6:1527072	NA	0.33	4.99	0.3	1.12e-6	Glaucoma (high intraocular pressure);Glaucoma (primary open-angle);Intraocular pressure;
KIRP	cis	rs4074493	1.000	rs6700792	chr1:231170013	C/T	cg22172038	chr1:231176991	FAM89A	-0.28	-4.84	-0.3	2.24e-6	Carotid plaque burden (smoking interaction);
KIRP	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.48	7.32	0.42	3.61e-12	Resting heart rate;
KIRP	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	8.33	0.47	5.55e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg06521331	chr12:34319734	NA	-0.53	-6.47	-0.38	5.4e-10	Bladder cancer;
KIRP	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg08738300	chr3:44038990	NA	-0.64	-9.12	-0.5	2.73e-17	Coronary artery disease;
KIRP	cis	rs41357746	0.525	rs57030473	chr15:67776678	A/G	cg24579218	chr15:68104479	NA	0.37	5.02	0.3	9.82e-7	Total body bone mineral density;
KIRP	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.91	13.99	0.67	4.07e-33	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg26441486	chr22:50317300	CRELD2	0.42	6.68	0.39	1.56e-10	Schizophrenia;
KIRP	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg06935464	chr4:38784597	TLR10	0.53	5.33	0.32	2.22e-7	Breast cancer;
KIRP	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg08975724	chr8:8085496	FLJ10661	-0.54	-6.05	-0.36	5.3300000000000004e-09	Neuroticism;
KIRP	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.66	-7.85	-0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-4.93	-0.3	1.51e-6	Cognitive function;
KIRP	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg09184832	chr6:79620586	NA	0.54	7.23	0.42	5.93e-12	Left atrial antero-posterior diameter;
KIRP	trans	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg13565492	chr6:43139072	SRF	-0.94	-8.68	-0.48	5.62e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg12486944	chr17:80159399	CCDC57	0.4	5.32	0.32	2.35e-7	Life satisfaction;
KIRP	trans	rs7246760	1.000	rs57736549	chr19:9937558	A/G	cg02900749	chr2:68251473	NA	-1.09	-9.22	-0.51	1.35e-17	Pursuit maintenance gain;
KIRP	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg16584676	chr17:46985605	UBE2Z	0.5	6.14	0.36	3.34e-9	Type 2 diabetes;
KIRP	cis	rs1035491	0.715	rs3846478	chr5:63922006	G/A	cg01791865	chr5:63954708	NA	0.33	5.21	0.32	4.06e-7	Body mass index;
KIRP	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg15448220	chr1:150897856	SETDB1	0.42	5.56	0.33	7.11e-8	Melanoma;
KIRP	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg05457628	chr5:178986728	RUFY1	0.63	10.43	0.55	2.5e-21	Lung cancer;
KIRP	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg05709478	chr1:6581295	PLEKHG5	-0.64	-6.33	-0.37	1.16e-9	Body mass index;
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.68	-10.2	-0.55	1.37e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3752645	1.000	rs17153823	chr7:106730211	A/G	cg02696742	chr7:106810147	HBP1	-0.64	-5.32	-0.32	2.36e-7	Bladder cancer (smoking interaction);
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg14460003	chr20:31173015	NA	-0.49	-7.21	-0.42	6.95e-12	Serum protein levels (sST2);
KIRP	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg01475377	chr6:109611718	NA	-0.38	-5.17	-0.31	4.8e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs9659323	0.689	rs7545737	chr1:119533823	C/T	cg18261050	chr1:119551319	NA	-0.41	-5.2	-0.31	4.1e-7	Body mass index;
KIRP	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.78	-9.82	-0.53	2.11e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs11645898	0.872	rs7206422	chr16:72152652	C/T	cg14768367	chr16:72042858	DHODH	-0.9	-8.84	-0.49	1.87e-16	Blood protein levels;
KIRP	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.3	-6.02	-0.36	6.21e-9	Schizophrenia;
KIRP	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.52	7.24	0.42	5.86e-12	Childhood ear infection;
KIRP	cis	rs35123781	1.000	rs599946	chr5:139057461	A/G	cg10513866	chr5:139070639	NA	0.35	4.9	0.3	1.71e-6	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg07701084	chr6:150067640	NUP43	0.71	10.0	0.54	5.74e-20	Lung cancer;
KIRP	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7572644	0.713	rs4666020	chr2:28046028	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-5.45	-0.33	1.22e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	7.09	0.41	1.41e-11	Bipolar disorder;
KIRP	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	11.06	0.58	2.39e-23	Nonalcoholic fatty liver disease;
KIRP	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-7.51	-0.43	1.07e-12	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg00360474	chr6:37504404	NA	-0.46	-6.53	-0.38	3.8e-10	Cognitive performance;
KIRP	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg03342759	chr3:160939853	NMD3	-0.57	-7.14	-0.41	1.02e-11	Morning vs. evening chronotype;
KIRP	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg18209359	chr17:80159595	CCDC57	0.4	5.17	0.31	4.92e-7	Life satisfaction;
KIRP	cis	rs960902	0.714	rs10198396	chr2:37742142	A/G	cg25341268	chr2:37734390	NA	-0.58	-7.89	-0.45	9.69e-14	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg05692746	chr2:100937584	LONRF2	-0.46	-5.42	-0.33	1.39e-7	Educational attainment;
KIRP	cis	rs7224685	0.530	rs36019144	chr17:3987499	T/C	cg21851534	chr17:3907994	ZZEF1	0.51	4.84	0.3	2.27e-6	Type 2 diabetes;
KIRP	cis	rs4936894	0.500	rs11601414	chr11:124077618	G/T	cg27160556	chr11:124181099	OR8D1	0.45	6.39	0.38	8.33e-10	Aging (time to death);
KIRP	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17453880	0.929	rs4958322	chr5:152020639	A/G	cg12297329	chr5:152029980	NA	-0.72	-10.87	-0.57	9.59e-23	Subjective well-being;
KIRP	cis	rs2574975	0.679	rs2842109	chr10:52133138	C/T	cg10034176	chr10:52120283	SGMS1	-0.53	-7.19	-0.42	7.55e-12	Response to amphetamines;
KIRP	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg25037394	chr1:24152592	HMGCL	0.36	4.97	0.3	1.28e-6	Immature fraction of reticulocytes;
KIRP	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg09165964	chr15:75287851	SCAMP5	0.93	8.74	0.49	3.58e-16	Lung cancer;
KIRP	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.7	9.78	0.53	2.7e-19	Schizophrenia;
KIRP	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg11608241	chr8:8085544	FLJ10661	0.39	5.01	0.3	1.04e-6	Mood instability;
KIRP	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26207909	chr14:103986467	CKB	0.75	11.54	0.59	6.48e-25	Body mass index;
KIRP	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03605463	chr16:89740564	NA	0.48	5.44	0.33	1.3e-7	Vitiligo;
KIRP	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg05973401	chr12:123451056	ABCB9	0.59	6.94	0.4	3.44e-11	Neutrophil percentage of white cells;
KIRP	cis	rs7116495	0.588	rs547208	chr11:71779668	A/G	cg26138937	chr11:71823887	C11orf51	-0.69	-5.56	-0.33	6.9e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg22800045	chr5:56110881	MAP3K1	0.8	8.58	0.48	1.1e-15	Initial pursuit acceleration;
KIRP	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.7	10.08	0.54	3.12e-20	Lymphocyte counts;
KIRP	cis	rs7523273	0.526	rs2724394	chr1:208017072	T/A	cg22525895	chr1:207977042	MIR29B2	-0.63	-8.63	-0.48	7.88e-16	Schizophrenia;
KIRP	cis	rs712039	0.583	rs853223	chr17:35791149	T/C	cg16670864	chr17:35848621	DUSP14	0.43	5.36	0.32	1.89e-7	Tuberculosis;
KIRP	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg21919602	chr1:242011447	EXO1	-0.46	-5.91	-0.35	1.11e-8	Menopause (age at onset);
KIRP	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.69	-0.34	3.64e-8	Bipolar disorder;
KIRP	cis	rs6988636	0.710	rs73339621	chr8:124138936	C/T	cg15893493	chr8:124194847	FAM83A	0.89	6.61	0.39	2.34e-10	Urinary uromodulin levels;
KIRP	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-7.73	-0.44	2.69e-13	Lung cancer;
KIRP	cis	rs5753037	0.869	rs5763646	chr22:30359410	T/C	cg01021169	chr22:30184971	ASCC2	-0.4	-5.21	-0.32	3.96e-7	Type 1 diabetes;
KIRP	trans	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg22529645	chr1:3704559	LRRC47	-0.45	-6.07	-0.36	4.81e-9	QRS complex (12-leadsum);
KIRP	cis	rs56873913	0.904	rs7251295	chr19:50096859	G/C	cg09250473	chr19:50168907	IRF3;BCL2L12	0.5	5.98	0.36	7.61e-9	Schizophrenia;
KIRP	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-6.8	-0.4	7.85e-11	Response to antipsychotic treatment;
KIRP	cis	rs55788414	0.932	rs12103303	chr16:81181497	A/G	cg06400318	chr16:81190750	PKD1L2	-0.85	-7.85	-0.45	1.27e-13	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-1.05	-9.36	-0.51	5.32e-18	Thyroid stimulating hormone;
KIRP	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.18	15.85	0.71	1.84e-39	Platelet count;
KIRP	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.49	-6.07	-0.36	4.83e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs4936894	0.500	rs4935881	chr11:124178948	G/A	cg27160556	chr11:124181099	OR8D1	-0.47	-6.69	-0.39	1.46e-10	Aging (time to death);
KIRP	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.71	9.52	0.52	1.65e-18	Crohn's disease;
KIRP	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-8.93	-0.49	9.87e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7033996	0.818	rs6476495	chr9:35924550	G/T	cg00918944	chr9:35908117	LOC158376	0.35	5.15	0.31	5.4e-7	Urate levels (BMI interaction);
KIRP	cis	rs71520386	0.632	rs10224419	chr7:22870016	A/G	cg00626422	chr7:22894849	SNORD93	-0.34	-4.9	-0.3	1.71e-6	Fibrinogen levels;
KIRP	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-6.7	-0.39	1.38e-10	Axial length;
KIRP	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg11952622	chr19:58962976	ZNF324B	0.42	4.93	0.3	1.51e-6	Uric acid clearance;
KIRP	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.46	-6.46	-0.38	5.61e-10	Barrett's esophagus;
KIRP	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg15744005	chr10:104629667	AS3MT	-0.29	-5.97	-0.36	8.36e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.86	9.7	0.53	4.77e-19	High light scatter reticulocyte count;
KIRP	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg10189774	chr4:17578691	LAP3	0.53	6.59	0.39	2.71e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25654697	chr7:7680075	RPA3	0.52	6.1	0.36	3.99e-9	Smoking initiation;
KIRP	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	1.2	11.39	0.59	2.07e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20466045	chr21:30445936	CCT8	-0.42	-6.12	-0.36	3.59e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.75	0.34	2.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.13	9.79	0.53	2.48e-19	Lung cancer in ever smokers;
KIRP	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12560992	chr17:57184187	TRIM37	0.64	7.32	0.42	3.51e-12	Testicular germ cell tumor;
KIRP	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.66	8.7	0.48	4.95e-16	Breast cancer;
KIRP	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg10047753	chr17:41438598	NA	1.14	17.99	0.75	9.7e-47	Menopause (age at onset);
KIRP	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.49	-0.48	2e-15	Coronary artery disease;
KIRP	cis	rs9535307	0.522	rs9316476	chr13:50409652	G/T	cg04663916	chr13:50265991	EBPL	-0.55	-5.29	-0.32	2.73e-7	Obesity-related traits;
KIRP	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg05220968	chr6:146057943	EPM2A	-0.4	-5.17	-0.31	4.79e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.98	13.16	0.64	2.73e-30	Cognitive function;
KIRP	cis	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg12315302	chr6:26189340	HIST1H4D	1.3	7.44	0.43	1.63e-12	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.87	9.72	0.53	4.04e-19	Gut microbiome composition (summer);
KIRP	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg22366001	chr1:2066006	PRKCZ	0.39	5.25	0.32	3.37e-7	Height;
KIRP	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.98	-0.5	7.43e-17	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10463316	0.817	rs6897109	chr5:150777738	T/C	cg03212797	chr5:150827313	SLC36A1	-0.47	-6.03	-0.36	5.97e-9	Metabolite levels (Pyroglutamine);
KIRP	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg09455208	chr3:40491958	NA	0.34	5.84	0.35	1.66e-8	Renal cell carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg07825270	chr5:173415991	C5orf47	-0.42	-6.42	-0.38	6.84e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6693567	0.565	rs698913	chr1:150299145	G/A	cg07843065	chr1:150265600	MRPS21	0.45	6.26	0.37	1.74e-9	Migraine;
KIRP	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.6	0.52	9.99e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs11955398	0.521	rs4298206	chr5:60012235	T/C	cg02684056	chr5:59996105	DEPDC1B	-0.43	-4.96	-0.3	1.32e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11050527	chr8:54755511	ATP6V1H	0.63	7.6	0.44	6.37e-13	Smoking initiation;
KIRP	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg19773385	chr1:10388646	KIF1B	-0.73	-10.14	-0.54	2e-20	Hepatocellular carcinoma;
KIRP	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.65	-8.11	-0.46	2.47e-14	Systemic lupus erythematosus;
KIRP	trans	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.88	-0.4	4.96e-11	Bladder cancer;
KIRP	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.97	12.49	0.62	4.82e-28	Menopause (age at onset);
KIRP	cis	rs36715	1.000	rs251213	chr5:127545605	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	8.86	0.49	1.63e-16	Breast cancer;
KIRP	cis	rs11203032	0.634	rs3802658	chr10:90965691	C/T	cg16672925	chr10:90967113	CH25H	-0.8	-7.98	-0.45	5.43e-14	Heart failure;
KIRP	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.97	15.55	0.7	1.92e-38	Intelligence (multi-trait analysis);
KIRP	cis	rs10814247	0.702	rs7031461	chr9:35193743	G/A	cg15271616	chr9:35490515	RUSC2	-0.37	-5.22	-0.32	3.72e-7	Psoriasis;
KIRP	cis	rs7129556	0.775	rs11237263	chr11:77378805	A/G	cg12586386	chr11:77299805	AQP11	0.44	5.83	0.35	1.72e-8	Weight loss (gastric bypass surgery);
KIRP	cis	rs12311304	1.000	rs12309210	chr12:15388361	T/C	cg08258403	chr12:15378311	NA	0.39	5.68	0.34	3.77e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs2916247	0.954	rs1484559	chr8:93111532	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.47	-5.84	-0.35	1.64e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg02138098	chr1:2040968	PRKCZ	-0.43	-6.04	-0.36	5.79e-9	Height;
KIRP	cis	rs4704187	0.595	rs6859176	chr5:74379425	T/C	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs4805272	1.000	rs7257353	chr19:29323124	C/T	cg15000279	chr19:29285009	NA	-0.37	-5.26	-0.32	3.15e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.54	6.36	0.38	9.65e-10	Response to antipsychotic treatment;
KIRP	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.4	-7.79	-0.44	1.86e-13	Monocyte percentage of white cells;
KIRP	cis	rs10129255	0.518	rs10150460	chr14:107133196	C/G	cg23076370	chr14:107095027	NA	0.44	5.47	0.33	1.12e-7	Kawasaki disease;
KIRP	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.43	-5.17	-0.31	4.84e-7	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.81	7.83	0.45	1.41e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg00738919	chr7:1100172	C7orf50	0.43	5.07	0.31	8e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.83	11.0	0.57	3.8e-23	Morning vs. evening chronotype;
KIRP	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.6e-6	Total body bone mineral density;
KIRP	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg03060546	chr3:49711283	APEH	-0.69	-5.36	-0.32	1.89e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg07068956	chr7:100330872	ZAN	0.41	5.36	0.32	1.91e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.76	9.07	0.5	3.95e-17	Diastolic blood pressure;
KIRP	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg19045956	chr2:200819837	C2orf60;C2orf47	-0.45	-5.62	-0.34	5.06e-8	Osteoporosis;
KIRP	cis	rs151286246	1	rs151286246	chr5:35852969	CT/C	cg13894535	chr5:35919491	CAPSL	-0.41	-5.07	-0.31	7.71e-7	Lymphocyte percentage of white cells;Neutrophil percentage of white cells;
KIRP	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg19636519	chr7:99541626	NA	0.3	5.41	0.33	1.46e-7	Coronary artery disease;
KIRP	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg21475434	chr5:93447410	FAM172A	-0.43	-4.92	-0.3	1.6e-6	Diabetic retinopathy;
KIRP	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06771106	chr2:113671356	IL1F7	0.42	4.9	0.3	1.73e-6	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2594989	0.943	rs346073	chr3:11298181	G/A	cg01796438	chr3:11312864	ATG7	-0.59	-6.86	-0.4	5.6e-11	Circulating chemerin levels;
KIRP	cis	rs7011049	1.000	rs7818958	chr8:53870354	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs55692468	0.883	rs6714213	chr2:153357383	G/T	cg04681845	chr2:153283485	FMNL2	-0.49	-6.15	-0.36	3.14e-9	Intraocular pressure;
KIRP	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.68	8.63	0.48	7.57e-16	Resting heart rate;
KIRP	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.82	9.9	0.53	1.11e-19	Corneal astigmatism;
KIRP	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg15147215	chr3:52552868	STAB1	0.27	4.86	0.3	2.08e-6	Electroencephalogram traits;
KIRP	cis	rs7666738	0.515	rs13434650	chr4:98889886	A/G	cg05340658	chr4:99064831	C4orf37	0.66	7.89	0.45	9.64e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg08132940	chr7:1081526	C7orf50	-0.46	-5.3	-0.32	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg00129232	chr17:37814104	STARD3	-0.51	-6.34	-0.37	1.11e-9	Self-reported allergy;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg21515243	chr18:21033072	RIOK3	0.5	6.65	0.39	1.87e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.91	-12.9	-0.64	2.03e-29	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs7212590	0.655	rs16943969	chr17:58031153	A/G	cg10252138	chr17:58120427	NA	-0.67	-5.48	-0.33	1.05e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.81	-11.3	-0.58	3.91e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4805272	0.962	rs4805274	chr19:29322218	A/G	cg15000279	chr19:29285009	NA	-0.37	-5.31	-0.32	2.51e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.84	8.72	0.49	4.16e-16	Cerebrospinal P-tau181p levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg25367318	chr6:138725211	HEBP2	0.58	6.82	0.4	7.07e-11	Smoking initiation;
KIRP	cis	rs1832871	0.965	rs10945541	chr6:158740218	A/G	cg07215822	chr6:158701037	NA	0.5	6.37	0.38	9.45e-10	Height;
KIRP	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03998655	chr16:1424607	UNKL	-0.43	-6.03	-0.36	5.81e-9	Pancreatic cancer;
KIRP	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg13289132	chr10:30722225	MAP3K8	-0.39	-4.85	-0.3	2.21e-6	Inflammatory bowel disease;
KIRP	cis	rs3857747	0.861	rs4723961	chr7:40451459	G/A	cg00420559	chr7:40367873	C7orf10	-0.59	-8.15	-0.46	1.84e-14	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-5.65	-0.34	4.49e-8	Life satisfaction;
KIRP	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.42	-5.95	-0.35	9.22e-9	Bone mineral density;
KIRP	trans	rs4650994	0.789	rs2761471	chr1:178599348	A/C	cg05059571	chr16:84539110	KIAA1609	0.56	7.24	0.42	5.83e-12	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg06937882	chr20:24974362	C20orf3	-0.5	-5.25	-0.32	3.3e-7	Blood protein levels;
KIRP	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg10792982	chr14:105748885	BRF1	0.92	12.83	0.63	3.56e-29	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-4.89	-0.3	1.8e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg01689657	chr7:91764605	CYP51A1	-0.44	-6.38	-0.38	8.95e-10	Breast cancer;
KIRP	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2235642	0.582	rs2072990	chr16:1567651	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.36	-0.32	1.92e-7	Coronary artery disease;
KIRP	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg02023728	chr11:77925099	USP35	0.35	5.51	0.33	8.91e-8	Alzheimer's disease (survival time);
KIRP	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg16586182	chr3:47516702	SCAP	-0.76	-10.93	-0.57	6.32e-23	Colorectal cancer;
KIRP	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26314531	chr2:26401878	FAM59B	-0.48	-5.01	-0.3	1.03e-6	Gut microbiome composition (summer);
KIRP	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg24011408	chr12:48396354	COL2A1	0.42	5.76	0.34	2.49e-8	Platelet count;
KIRP	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.6	-8.19	-0.46	1.46e-14	Breast cancer;
KIRP	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.58	7.57	0.43	7.38e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs212524	0.967	rs212526	chr1:21584941	C/T	cg08890418	chr1:21044141	KIF17	-0.43	-5.65	-0.34	4.4e-8	Height;
KIRP	trans	rs12517041	1.000	rs6894144	chr5:23312635	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	cis	rs11169552	0.510	rs4238108	chr12:51059691	T/C	cg12884762	chr12:50931848	DIP2B	-0.45	-5.08	-0.31	7.38e-7	Colorectal cancer;
KIRP	trans	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg24644049	chr4:85504048	CDS1	1.02	6.8	0.4	7.99e-11	Skin colour saturation;
KIRP	cis	rs11264213	0.786	rs72659698	chr1:36314688	G/A	cg27506609	chr1:36549197	TEKT2	0.98	5.49	0.33	9.99e-8	Schizophrenia;
KIRP	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg10117171	chr1:25599238	RHD	-0.4	-5.36	-0.32	1.87e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07570687	chr10:102243282	WNT8B	0.39	4.9	0.3	1.7e-6	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-10.57	-0.56	8.95e-22	Chronic sinus infection;
KIRP	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg09596252	chr17:78655493	RPTOR	-0.58	-7.66	-0.44	4.24e-13	Obesity;
KIRP	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.95	-0.3	1.39e-6	Schizophrenia;
KIRP	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.66	-10.01	-0.54	5.16e-20	Glomerular filtration rate (creatinine);
KIRP	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	6.24	0.37	1.9e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs13427251	0.692	rs10206082	chr2:100160024	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-5.54	-0.33	7.82e-8	Chronic sinus infection;
KIRP	cis	rs514024	0.708	rs574771	chr9:130483831	C/T	cg13643465	chr9:130375613	STXBP1	0.45	5.68	0.34	3.8e-8	Eating disorders (purging via substances);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20099054	chr8:71581315	LACTB2;XKR9	0.51	6.32	0.37	1.23e-9	Parkinson's disease;
KIRP	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg08499158	chr17:42289980	UBTF	-0.67	-8.87	-0.49	1.49e-16	Total body bone mineral density;
KIRP	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg24375607	chr4:120327624	NA	-0.55	-6.39	-0.38	8.21e-10	Corneal astigmatism;
KIRP	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.92	-0.45	8.22e-14	Bone mineral density;
KIRP	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.74	-8.21	-0.46	1.25e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg16497661	chr14:103986332	CKB	-0.87	-14.99	-0.69	1.57e-36	Body mass index;
KIRP	cis	rs9290877	0.580	rs13314127	chr3:188469964	C/T	cg17392043	chr3:188495102	LPP	-0.55	-7.08	-0.41	1.49e-11	IgE levels;
KIRP	cis	rs687432	0.885	rs1113334	chr11:57743333	G/C	cg19752551	chr11:57585705	CTNND1	-0.69	-9.09	-0.5	3.28e-17	Parkinson's disease;
KIRP	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.13	15.01	0.69	1.35e-36	Platelet count;
KIRP	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg06885757	chr1:42089581	HIVEP3	-0.5	-7.29	-0.42	4.32e-12	Airway imaging phenotypes;
KIRP	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.74	7.38	0.43	2.46e-12	Vitiligo;
KIRP	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.37	5.3	0.32	2.61e-7	Coronary artery disease;
KIRP	cis	rs9783347	0.961	rs4150653	chr11:18374782	G/A	cg15585147	chr11:18324498	HPS5	0.42	5.7	0.34	3.38e-8	Pancreatic cancer;
KIRP	cis	rs13095912	1.000	rs4686666	chr3:185342847	T/C	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.1e-11	Systolic blood pressure;
KIRP	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-5.62	-0.34	5.09e-8	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg12315302	chr6:26189340	HIST1H4D	1.13	6.81	0.4	7.56e-11	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.15	-0.46	1.9e-14	Myopia (pathological);
KIRP	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.69	10.43	0.55	2.54e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg08761264	chr16:28874980	SH2B1	-0.51	-5.8	-0.35	2.03e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.42	-4.92	-0.3	1.62e-6	Aortic root size;
KIRP	cis	rs3770081	1.000	rs6750765	chr2:86300308	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-4.95	-0.3	1.4e-6	Facial emotion recognition (sad faces);
KIRP	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg16586182	chr3:47516702	SCAP	-0.72	-10.22	-0.55	1.16e-20	Colorectal cancer;
KIRP	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg26384229	chr12:38710491	ALG10B	-0.45	-5.78	-0.35	2.21e-8	Morning vs. evening chronotype;
KIRP	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg16497661	chr14:103986332	CKB	-0.5	-6.41	-0.38	7.5e-10	Coronary artery disease;
KIRP	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.68	-5.85	-0.35	1.53e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.3	-5.07	-0.31	7.69e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7527798	0.571	rs12045913	chr1:207844625	A/G	cg09232269	chr1:207846808	CR1L	-0.35	-5.05	-0.31	8.43e-7	Erythrocyte sedimentation rate;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09775785	chr19:1863133	KLF16	0.5	6.06	0.36	5.17e-9	Parkinson's disease;
KIRP	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg09324608	chr17:30823087	MYO1D	0.48	6.2	0.37	2.34e-9	Schizophrenia;
KIRP	cis	rs17123764	0.786	rs10506288	chr12:50160130	C/T	cg20471783	chr12:50157085	TMBIM6	-0.41	-5.36	-0.32	1.87e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6959887	0.962	rs7790968	chr7:35299896	C/T	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.76	10.49	0.56	1.58e-21	Mood instability;
KIRP	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.46	6.28	0.37	1.55e-9	Systolic blood pressure;
KIRP	cis	rs8179	0.593	rs73232024	chr7:92277315	G/A	cg15732164	chr7:92237376	CDK6	-0.5	-6.46	-0.38	5.68e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17691542	chr6:26056736	HIST1H1C	0.46	5.95	0.35	9.23e-9	Height;
KIRP	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg26531700	chr6:26746687	NA	0.41	5.58	0.33	6.47e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	0.74	10.83	0.57	1.32e-22	Prudent dietary pattern;
KIRP	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg23594656	chr7:65796392	TPST1	-0.4	-5.68	-0.34	3.81e-8	Aortic root size;
KIRP	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg08501292	chr6:25962987	TRIM38	0.99	5.89	0.35	1.28e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7845219	0.544	rs2945554	chr8:95939594	C/A	cg13393036	chr8:95962371	TP53INP1	-0.33	-6.35	-0.38	1.02e-9	Type 2 diabetes;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg07098314	chr17:39823360	NA	0.49	6.05	0.36	5.3300000000000004e-09	Sleep duration;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg02551244	chr2:23608357	KLHL29	0.51	6.1	0.36	4.05e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs904251	0.523	rs2797794	chr6:37480604	T/C	cg01843034	chr6:37503916	NA	-0.96	-15.55	-0.7	1.97e-38	Cognitive performance;
KIRP	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9400467	0.506	rs3204954	chr6:111628597	C/G	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.92	0.3	1.57e-6	Blood metabolite levels;Amino acid levels;
KIRP	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-8.16	-0.46	1.71e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs12580194	0.593	rs61956269	chr12:55768023	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-6.69	-0.39	1.52e-10	Cancer;
KIRP	cis	rs11825064	0.725	rs80266720	chr11:134477952	G/A	cg06603561	chr11:134479413	NA	-0.65	-5.07	-0.31	7.69e-7	Seasonality;
KIRP	cis	rs4523957	0.559	rs170040	chr17:2165714	C/T	cg16513277	chr17:2031491	SMG6	0.5	5.58	0.34	6.25e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg05991184	chr2:219186017	PNKD	-0.36	-5.36	-0.32	1.91e-7	Colorectal cancer;
KIRP	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg07827796	chr19:33622959	WDR88	0.42	4.99	0.3	1.13e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs4722166	0.532	rs6963591	chr7:22757270	G/T	cg05472934	chr7:22766657	IL6	-0.52	-6.98	-0.41	2.71e-11	Lung cancer;
KIRP	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.82	11.92	0.61	3.64e-26	Eye color traits;
KIRP	cis	rs10129255	0.518	rs2006284	chr14:107132201	G/A	cg23076370	chr14:107095027	NA	-0.44	-5.52	-0.33	8.78e-8	Kawasaki disease;
KIRP	cis	rs4791746	0.901	rs6503149	chr17:8620135	C/G	cg03115937	chr17:8649504	CCDC42	-0.53	-6.37	-0.38	9.46e-10	Heroin dependence;
KIRP	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg13180566	chr4:1052158	NA	-0.52	-5.46	-0.33	1.17e-7	Recombination rate (females);
KIRP	cis	rs240764	0.658	rs4839792	chr6:101253788	A/T	cg09795085	chr6:101329169	ASCC3	-0.43	-5.1	-0.31	6.71e-7	Neuroticism;
KIRP	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg23533926	chr12:111358616	MYL2	-0.53	-7.16	-0.42	9.48e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg26513180	chr16:89883248	FANCA	0.82	5.64	0.34	4.71e-8	Skin colour saturation;
KIRP	cis	rs4356932	0.967	rs4547819	chr4:76977768	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs17065868	1.000	rs9525972	chr13:45095716	T/C	cg10246903	chr13:45222710	NA	0.69	6.75	0.4	1.06e-10	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg09904177	chr6:26538194	HMGN4	-0.44	-6.03	-0.36	5.83e-9	Schizophrenia;
KIRP	cis	rs6500395	0.735	rs2883641	chr16:48664446	T/C	cg04672837	chr16:48644449	N4BP1	0.41	5.4	0.33	1.54e-7	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg02475777	chr4:1388615	CRIPAK	-0.54	-5.1	-0.31	6.92e-7	Recombination rate (females);
KIRP	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.46	5.93	0.35	1.01e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.5	7.96	0.45	6.42e-14	Testicular germ cell tumor;
KIRP	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.47	-6.22	-0.37	2.11e-9	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg00814883	chr7:100076585	TSC22D4	-0.52	-4.9	-0.3	1.74e-6	Lung function (FEV1/FVC);
KIRP	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg16682046	chr11:82612617	PRCP;C11orf82	0.52	6.11	0.36	3.92e-9	Smoking initiation;
KIRP	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg15448220	chr1:150897856	SETDB1	0.39	5.14	0.31	5.7e-7	Melanoma;
KIRP	cis	rs1359582	0.793	rs4934415	chr10:90375019	A/G	cg15661332	chr10:90342814	RNLS	0.58	6.1	0.36	4.14e-9	Depressive and manic episodes in bipolar disorder;
KIRP	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.79	13.08	0.64	5e-30	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg08934869	chr5:94927243	ARSK	0.47	6.35	0.38	1.05e-9	Interleukin-4 levels;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg19372772	chr2:264904	ACP1;SH3YL1	0.56	6.81	0.4	7.63e-11	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18657341	chr19:47569185	ZC3H4	-0.48	-6.36	-0.38	9.84e-10	Parkinson's disease;
KIRP	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.79	0.66	2.02e-32	Tonsillectomy;
KIRP	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg15181151	chr6:150070149	PCMT1	0.31	5.27	0.32	2.96e-7	Lung cancer;
KIRP	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg02336718	chr17:17403227	NA	0.37	5.6	0.34	5.81e-8	Total body bone mineral density;
KIRP	cis	rs35955747	0.934	rs5994397	chr22:31826150	G/C	cg02404636	chr22:31891804	SFI1	-0.38	-5.18	-0.31	4.53e-7	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs10924970	1.000	rs7339935	chr1:235337761	T/C	cg26050004	chr1:235667680	B3GALNT2	0.4	4.86	0.3	2.07e-6	Asthma;
KIRP	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.11	7.86	0.45	1.18e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs6995541	0.508	rs11250082	chr8:10703794	C/T	cg01434694	chr16:88837185	FAM38A	0.35	6.43	0.38	6.56e-10	Triglyceride levels;
KIRP	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.17	16.65	0.73	3.32e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12963246	chr6:28129442	ZNF389	0.51	6.32	0.37	1.21e-9	Depression;
KIRP	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.22	-15.06	-0.69	9.31e-37	Platelet count;
KIRP	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs17384381	0.861	rs34561661	chr1:85777250	C/T	cg16011679	chr1:85725395	C1orf52	0.83	8.0	0.45	4.97e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2916247	1.000	rs4477079	chr8:93059038	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.59	-7.74	-0.44	2.63e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs17065868	1.000	rs9533878	chr13:45073536	T/A	cg10246903	chr13:45222710	NA	0.58	6.02	0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs2120243	0.539	rs2085315	chr3:157112622	T/G	cg24825693	chr3:157122686	VEPH1	-0.55	-9.19	-0.51	1.66e-17	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.77	12.41	0.62	8.84e-28	Tourette's syndrome or obsessive-compulsive disorder;
KIRP	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg23625390	chr15:77176239	SCAPER	0.54	7.01	0.41	2.29e-11	Blood metabolite levels;
KIRP	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.64	6.98	0.41	2.8e-11	Gut microbiome composition (summer);
KIRP	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.51	7.11	0.41	1.27e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.73	-9.55	-0.52	1.35e-18	Late-onset Alzheimer's disease;
KIRP	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg25828445	chr12:7781288	NA	0.55	5.49	0.33	9.82e-8	HDL cholesterol levels;
KIRP	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg02527881	chr3:46936655	PTH1R	-0.38	-5.39	-0.33	1.63e-7	Colorectal cancer;
KIRP	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.97	14.36	0.68	2.24e-34	Menarche (age at onset);
KIRP	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg17366294	chr4:99064904	C4orf37	-0.37	-5.17	-0.31	4.82e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.63	-7.77	-0.44	2.11e-13	Dental caries;
KIRP	cis	rs9311676	0.656	rs7642652	chr3:58373667	C/T	cg06643156	chr3:58380774	PXK	0.35	4.97	0.3	1.27e-6	Systemic lupus erythematosus;
KIRP	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17554472	chr22:41940697	POLR3H	0.71	7.15	0.41	9.81e-12	Vitiligo;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21075678	chr7:137557164	NA	0.45	6.44	0.38	6.08e-10	Interleukin-4 levels;
KIRP	cis	rs2367563	0.741	rs7311331	chr12:96064549	A/G	cg19013339	chr12:96052514	NTN4	0.39	6.24	0.37	1.87e-9	Allergic dermatitis (nickel);
KIRP	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg00262122	chr8:11665843	FDFT1	-0.46	-5.53	-0.33	7.96e-8	Triglycerides;
KIRP	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	1.14	13.75	0.66	2.75e-32	Type 2 diabetes nephropathy;
KIRP	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg18357526	chr6:26021779	HIST1H4A	0.42	5.44	0.33	1.27e-7	Height;
KIRP	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	1.02	10.76	0.57	2.19e-22	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6546886	0.912	rs13387010	chr2:74294654	A/G	cg14702570	chr2:74259524	NA	-0.26	-5.15	-0.31	5.4e-7	Dialysis-related mortality;
KIRP	cis	rs12318506	0.793	rs71460129	chr12:75699427	C/T	cg04728562	chr12:75699417	CAPS2	-1.3	-10.29	-0.55	7.03e-21	Coronary artery calcification;
KIRP	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13047869	chr3:10149882	C3orf24	0.6	5.52	0.33	8.73e-8	Alzheimer's disease;
KIRP	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.48	-7.11	-0.41	1.24e-11	Electroencephalogram traits;
KIRP	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.37	0.43	2.6e-12	Major depressive disorder;
KIRP	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg25182066	chr10:30743637	MAP3K8	0.58	7.7	0.44	3.3e-13	Inflammatory bowel disease;
KIRP	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.93	-14.61	-0.68	3.12e-35	Systemic lupus erythematosus;
KIRP	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg09658497	chr7:2847517	GNA12	-0.36	-5.05	-0.31	8.52e-7	Height;
KIRP	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg00745463	chr17:30367425	LRRC37B	-0.85	-7.97	-0.45	5.81e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs71636778	0.631	rs60314236	chr1:27155166	C/T	cg12203394	chr1:27248618	NUDC	0.7	5.48	0.33	1.07e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs427941	1.000	rs423452	chr7:101848790	G/A	cg06246474	chr7:101738831	CUX1	-0.53	-6.44	-0.38	6.26e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg26668828	chr6:292823	DUSP22	-0.61	-7.04	-0.41	1.92e-11	Menopause (age at onset);
KIRP	cis	rs13315871	0.929	rs11717700	chr3:58250876	T/A	cg12435725	chr3:58293450	RPP14	-0.51	-4.96	-0.3	1.34e-6	Cholesterol, total;
KIRP	cis	rs1505368	0.505	rs6760554	chr2:213255417	C/T	cg20637307	chr2:213403960	ERBB4	0.51	6.87	0.4	5.25e-11	Symmetrical dimethylarginine levels;
KIRP	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.73	-7.81	-0.45	1.68e-13	Vitiligo;
KIRP	cis	rs7078219	0.714	rs12413565	chr10:101285116	C/A	cg07044859	chr10:101282883	NA	-0.33	-4.87	-0.3	1.98e-6	Dental caries;
KIRP	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg01879757	chr17:41196368	BRCA1	-0.78	-10.91	-0.57	7.13e-23	Menopause (age at onset);
KIRP	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg04490037	chr7:50633773	DDC	-0.42	-5.1	-0.31	6.87e-7	Malaria;
KIRP	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg20295408	chr7:1910781	MAD1L1	-0.51	-6.11	-0.36	3.92e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.92	11.4	0.59	1.88e-24	Response to antineoplastic agents;
KIRP	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	cis	rs9309473	0.519	rs1815027	chr2:73831840	T/C	cg20560298	chr2:73613845	ALMS1	0.46	5.71	0.34	3.27e-8	Metabolite levels;
KIRP	cis	rs2016266	0.855	rs1379610	chr12:53681683	A/G	cg16917193	chr12:54089295	NA	-0.5	-6.17	-0.37	2.72e-9	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg07309820	chr7:148901717	ZNF282	-0.39	-4.91	-0.3	1.68e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg18944383	chr4:111397179	ENPEP	0.49	8.18	0.46	1.54e-14	Height;
KIRP	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.66	7.64	0.44	4.9e-13	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24110177	chr3:50126178	RBM5	-0.42	-5.62	-0.34	5.04e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg12798833	chr22:18958832	DGCR5	-0.43	-5.49	-0.33	1.02e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23657190	chr10:134682430	NA	-0.43	-6.31	-0.37	1.26e-9	Parkinson's disease;
KIRP	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.47	5.82	0.35	1.83e-8	Mean platelet volume;
KIRP	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg23127183	chr11:57508653	C11orf31	-0.54	-6.99	-0.41	2.6e-11	Schizophrenia;
KIRP	cis	rs9783347	1.000	rs1140047	chr11:18327684	G/T	cg15585147	chr11:18324498	HPS5	0.47	6.39	0.38	8.09e-10	Pancreatic cancer;
KIRP	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg00990874	chr7:1149470	C7orf50	-0.75	-7.64	-0.44	4.84e-13	Bronchopulmonary dysplasia;
KIRP	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg13206674	chr6:150067644	NUP43	0.51	7.23	0.42	6.04e-12	Testicular germ cell tumor;
KIRP	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.63	-5.56	-0.33	6.85e-8	Body mass index;
KIRP	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.4	-0.33	1.54e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg17372223	chr3:52568218	NT5DC2	0.38	6.19	0.37	2.47e-9	Electroencephalogram traits;
KIRP	trans	rs17079247	0.841	rs1907008	chr13:85808566	A/G	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs2219968	1.000	rs7003907	chr8:78976336	A/G	cg00738934	chr8:78996279	NA	0.39	4.87	0.3	2.03e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs3751972	0.911	rs9630740	chr17:26242756	C/G	cg18091275	chr17:26120155	NOS2	-0.53	-6.34	-0.37	1.07e-9	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs785830	0.558	rs2479326	chr9:258914	G/C	cg14500300	chr9:211689	NA	0.41	5.55	0.33	7.35e-8	Platelet distribution width;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg15045943	chr5:171614719	STK10	0.52	6.32	0.37	1.2e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg00931491	chr16:28608288	SULT1A2	-0.25	-4.97	-0.3	1.28e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-0.66	-7.79	-0.44	1.87e-13	Initial pursuit acceleration;
KIRP	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg04166393	chr7:2884313	GNA12	0.6	7.34	0.42	3.19e-12	Height;
KIRP	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg25019033	chr10:957182	NA	-0.62	-7.27	-0.42	4.76e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg16898833	chr6:26189333	HIST1H4D	0.97	5.85	0.35	1.54e-8	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7224685	0.569	rs58357241	chr17:3996641	T/C	cg11204139	chr17:3907470	NA	0.54	5.0	0.3	1.11e-6	Type 2 diabetes;
KIRP	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.41	-5.57	-0.33	6.61e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04374321	chr14:90722782	PSMC1	0.9	14.55	0.68	5.12e-35	Mortality in heart failure;
KIRP	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg01391022	chr12:122360665	WDR66	0.37	5.03	0.31	9.4e-7	Mean corpuscular volume;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.85	7.96	0.45	6.34e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg01843034	chr6:37503916	NA	-0.82	-11.5	-0.59	9.23e-25	Cognitive performance;
KIRP	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.81	9.77	0.53	2.83e-19	Corneal astigmatism;
KIRP	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg24058013	chr18:77568902	NA	-0.74	-10.76	-0.57	2.21e-22	Schizophrenia;
KIRP	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25517755	chr10:38738941	LOC399744	0.38	5.09	0.31	7.18e-7	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3924048	0.574	rs34494202	chr1:12612868	G/A	cg00291366	chr1:12616550	NA	0.47	6.65	0.39	1.92e-10	Optic cup area;
KIRP	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.47	-6.09	-0.36	4.38e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs911119	0.913	rs13038990	chr20:23589053	C/T	cg16589663	chr20:23618590	CST3	0.5	5.02	0.3	9.87e-7	Chronic kidney disease;
KIRP	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.24	-0.32	3.5e-7	Life satisfaction;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05181186	chr4:85504391	CDS1	0.48	6.5	0.38	4.47e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1620921	0.967	rs1406891	chr6:161187080	C/T	cg01280913	chr6:161186852	NA	0.39	5.12	0.31	6.08e-7	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.5	-5.3	-0.32	2.53e-7	Chronic sinus infection;
KIRP	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg15083037	chr5:83017644	HAPLN1	-0.61	-8.83	-0.49	1.95e-16	Prostate cancer;
KIRP	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.4	-5.0	-0.3	1.11e-6	Coronary artery disease;
KIRP	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-9.73	-0.53	3.76e-19	Response to antipsychotic treatment;
KIRP	cis	rs77861329	1.000	rs876782	chr3:52107909	C/T	cg08692210	chr3:52188851	WDR51A	-0.92	-7.51	-0.43	1.09e-12	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.35	-10.28	-0.55	7.71e-21	Diabetic kidney disease;
KIRP	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7224685	0.506	rs12452569	chr17:4023667	T/A	cg05562828	chr17:3906858	NA	0.52	5.45	0.33	1.2e-7	Type 2 diabetes;
KIRP	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.39	5.46	0.33	1.14e-7	Electroencephalogram traits;
KIRP	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.49	-5.46	-0.33	1.17e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs5753037	0.640	rs131260	chr22:30132964	A/C	cg01021169	chr22:30184971	ASCC2	-0.45	-6.28	-0.37	1.54e-9	Type 1 diabetes;
KIRP	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.52	-5.42	-0.33	1.39e-7	Subjective well-being;
KIRP	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.82	-8.24	-0.46	1.05e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	cis	rs9372498	0.536	rs9320656	chr6:118894468	A/G	cg21191810	chr6:118973309	C6orf204	0.45	5.12	0.31	6.13e-7	Diastolic blood pressure;
KIRP	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.86	9.54	0.52	1.52e-18	Gut microbiome composition (summer);
KIRP	cis	rs55692468	0.520	rs62180799	chr2:153302108	G/A	cg04681845	chr2:153283485	FMNL2	0.56	7.25	0.42	5.46e-12	Intraocular pressure;
KIRP	cis	rs6725041	0.766	rs7560301	chr2:213091598	C/T	cg20637307	chr2:213403960	ERBB4	-0.39	-5.12	-0.31	6.15e-7	QT interval (ambient particulate matter interaction);
KIRP	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg00677455	chr12:58241039	CTDSP2	-0.54	-6.56	-0.39	3.09e-10	Multiple sclerosis;
KIRP	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.67	6.36	0.38	1e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg22437258	chr11:111473054	SIK2	0.57	6.84	0.4	6.29e-11	Primary sclerosing cholangitis;
KIRP	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg12062639	chr20:23401060	NAPB	0.83	7.19	0.42	7.56e-12	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.79	11.16	0.58	1.13e-23	Obesity-related traits;
KIRP	cis	rs4805834	0.623	rs58018786	chr19:33310148	A/G	cg07201929	chr19:33182834	NUDT19	-0.59	-4.95	-0.3	1.39e-6	Creatinine levels;
KIRP	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.62	8.08	0.46	2.85e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.83	11.89	0.6	4.58e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs514406	0.679	rs11206006	chr1:53218380	A/G	cg25767906	chr1:53392781	SCP2	0.45	5.73	0.34	2.98e-8	Monocyte count;
KIRP	cis	rs3540	0.513	rs2601182	chr15:90925430	A/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.66	0.44	4.33e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	trans	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg10756647	chr7:56101905	PSPH	1.08	8.58	0.48	1.08e-15	Diabetic kidney disease;
KIRP	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.59	8.54	0.48	1.41e-15	Fat distribution (HIV);
KIRP	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.9	15.35	0.7	9.57e-38	Headache;
KIRP	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.75	-12.02	-0.61	1.71e-26	Rheumatoid arthritis;
KIRP	cis	rs652260	0.646	rs693941	chr19:7903851	C/T	cg26014689	chr19:7917955	EVI5L	-0.42	-5.92	-0.35	1.08e-8	Menarche (age at onset);
KIRP	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.48	-6.23	-0.37	1.97e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg07856975	chr6:36356162	ETV7	0.42	5.45	0.33	1.19e-7	Platelet distribution width;
KIRP	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs7327064	0.666	rs9547431	chr13:36930263	G/T	cg13455704	chr13:36871754	C13orf38	0.59	5.27	0.32	2.96e-7	Economic and political preferences;
KIRP	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.6	7.67	0.44	3.98e-13	Body mass index;
KIRP	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	1.11	16.31	0.72	4.73e-41	Breast cancer;
KIRP	cis	rs7937612	0.897	rs1893261	chr11:120198093	A/G	cg24566217	chr11:120254723	ARHGEF12	0.47	6.99	0.41	2.56e-11	Intraocular pressure;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg12934804	chr14:68086549	ARG2	-0.56	-6.03	-0.36	6.05e-9	Menopause (age at onset);
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg15181151	chr6:150070149	PCMT1	0.29	4.86	0.3	2.12e-6	Lung cancer;
KIRP	cis	rs2223471	0.967	rs760899	chr6:50693607	T/C	cg03432817	chr6:50765336	NA	-0.52	-8.31	-0.47	6.66e-15	Subcutaneous adipose tissue;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg25019777	chr4:53525403	USP46	0.5	6.65	0.39	1.87e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg23517279	chr6:96025343	MANEA	0.59	5.3	0.32	2.62e-7	Behavioural disinhibition (generation interaction);
KIRP	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.52	-5.75	-0.34	2.63e-8	Fear of minor pain;
KIRP	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	6.02	0.36	6.3e-9	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg07395648	chr5:131743802	NA	-0.44	-6.01	-0.36	6.69e-9	Blood metabolite levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg02047359	chr10:75174015	ANXA7	-0.48	-6.03	-0.36	5.96e-9	Neuroticism;
KIRP	cis	rs3755132	0.929	rs6734471	chr2:15765425	C/T	cg12888861	chr2:15731646	DDX1	0.4	5.29	0.32	2.67e-7	Wilms tumor;
KIRP	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.47	-7.09	-0.41	1.42e-11	Daytime sleep phenotypes;
KIRP	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.47	-5.24	-0.32	3.44e-7	White matter hyperintensity burden;
KIRP	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg21466736	chr12:48725269	NA	0.41	5.11	0.31	6.58e-7	Glycated hemoglobin levels;
KIRP	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	7.73	0.44	2.81e-13	Height;
KIRP	cis	rs2916247	0.954	rs28475789	chr8:93128465	C/T	cg10183463	chr8:93005414	RUNX1T1	0.42	5.03	0.31	9.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.31	-0.55	5.85e-21	Hemoglobin concentration;
KIRP	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.83	11.54	0.59	6.69e-25	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.45	4.91	0.3	1.67e-6	Plasminogen activator inhibitor type 1 levels (PAI-1);
KIRP	cis	rs33912345	0.695	rs1313244	chr14:60877348	C/G	cg27398547	chr14:60952738	C14orf39	-0.4	-5.44	-0.33	1.3e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.2	0.61	4.23e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.5	6.99	0.41	2.57e-11	Coronary artery disease;
KIRP	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg06995285	chr7:2418615	EIF3B	0.62	7.43	0.43	1.82e-12	Multiple sclerosis;
KIRP	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg23752985	chr2:85803571	VAMP8	0.57	8.2	0.46	1.33e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg16898833	chr6:26189333	HIST1H4D	0.94	5.57	0.33	6.51e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24342377	chr7:97868109	TECPR1	-0.49	-6.6	-0.39	2.44e-10	Parkinson's disease;
KIRP	cis	rs62413470	1.000	rs1028390	chr6:55935791	T/C	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs3755605	0.520	rs28857583	chr3:169935364	G/A	cg02973263	chr3:169940162	PRKCI	0.43	4.85	0.3	2.19e-6	Testicular germ cell tumor;
KIRP	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.52	7.33	0.42	3.21e-12	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.62	5.28	0.32	2.87e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.95	16.06	0.72	3.57e-40	Breast cancer;
KIRP	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.52	-6.58	-0.39	2.86e-10	Type 2 diabetes;
KIRP	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.09	-15.11	-0.69	6.18e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.46	6.65	0.39	1.87e-10	Sitting height ratio;
KIRP	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg02023728	chr11:77925099	USP35	-0.33	-5.33	-0.32	2.26e-7	Alzheimer's disease (survival time);
KIRP	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg23422044	chr7:1970798	MAD1L1	-0.66	-6.53	-0.38	3.77e-10	Bipolar disorder;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg06620762	chr15:76136437	UBE2Q2	0.55	6.68	0.39	1.55e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-6.9	-0.4	4.33e-11	Body mass index;
KIRP	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.61	-9.6	-0.52	9.47e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.69	-8.3	-0.47	6.94e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4938330	0.600	rs2239010	chr11:117089006	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-8.79	-0.49	2.7e-16	Blood trace element (Zn levels);
KIRP	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02034447	chr16:89574710	SPG7	0.4	5.0	0.3	1.11e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs17384381	0.953	rs12717763	chr1:85808164	A/T	cg16011679	chr1:85725395	C1orf52	0.86	8.54	0.48	1.43e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10221833	0.636	rs355891	chr2:165634983	T/C	cg03182029	chr2:165697222	COBLL1	0.44	4.84	0.3	2.25e-6	Response to statin therapy;
KIRP	cis	rs2531992	0.686	rs2041247	chr16:4032581	A/G	cg05927578	chr16:4029543	ADCY9	0.47	5.3	0.32	2.59e-7	Waist circumference;
KIRP	cis	rs4713675	0.565	rs3818524	chr6:33660695	G/C	cg14003231	chr6:33640908	ITPR3	0.29	5.23	0.32	3.62e-7	Plateletcrit;
KIRP	cis	rs9815354	0.812	rs73071358	chr3:41830487	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.44	0.47	2.73e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg07741184	chr6:167504864	NA	0.24	6.43	0.38	6.44e-10	Crohn's disease;
KIRP	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.69	7.67	0.44	4.13e-13	Height;
KIRP	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg19592336	chr6:28129416	ZNF389	0.44	4.94	0.3	1.44e-6	Parkinson's disease;
KIRP	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.38	-5.49	-0.33	9.91e-8	Plateletcrit;
KIRP	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg23625390	chr15:77176239	SCAPER	0.54	7.01	0.41	2.26e-11	Blood metabolite levels;
KIRP	cis	rs920590	0.643	rs7012694	chr8:19662732	C/T	cg03894339	chr8:19674705	INTS10	0.41	4.95	0.3	1.39e-6	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg08501292	chr6:25962987	TRIM38	1.09	7.89	0.45	9.64e-14	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4638749	0.501	rs6715622	chr2:108759372	A/C	cg25838818	chr2:108905173	SULT1C2	-0.33	-4.94	-0.3	1.43e-6	Blood pressure;
KIRP	cis	rs72627123	0.867	rs75773875	chr14:74498053	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.92	6.3	0.37	1.34e-9	Morning vs. evening chronotype;
KIRP	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg13679303	chr9:96623674	NA	-0.46	-6.47	-0.38	5.27e-10	DNA methylation (variation);
KIRP	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg15556689	chr8:8085844	FLJ10661	-0.66	-8.72	-0.49	4.17e-16	Joint mobility (Beighton score);
KIRP	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	7.13	0.41	1.11e-11	Schizophrenia;
KIRP	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.79	10.31	0.55	6.1e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs796825	0.530	rs55762220	chr3:119956606	T/C	cg21790991	chr3:120137480	FSTL1	-0.29	-4.96	-0.3	1.34e-6	HIV-1 susceptibility;
KIRP	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg02375832	chr11:62437615	C11orf48	-0.42	-5.39	-0.33	1.61e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs6969780	0.915	rs11983200	chr7:27186596	A/G	cg26364809	chr7:27145159	NA	-0.57	-4.94	-0.3	1.43e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.35	4.94	0.3	1.42e-6	IgG glycosylation;
KIRP	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg24253500	chr15:84953950	NA	0.62	6.99	0.41	2.55e-11	Schizophrenia;
KIRP	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg06243866	chr13:111019493	COL4A2	-0.76	-11.63	-0.6	3.38e-25	White matter hyperintensity burden;
KIRP	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg18032289	chr17:61959525	GH2	-0.38	-4.95	-0.3	1.4e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	17.43	0.74	7.26e-45	Height;
KIRP	cis	rs8179	0.514	rs6954290	chr7:92283098	G/T	cg15732164	chr7:92237376	CDK6	-0.43	-6.21	-0.37	2.28e-9	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs9649213	0.593	rs7789380	chr7:97956180	G/A	cg01877450	chr7:97915802	BRI3	-0.56	-7.25	-0.42	5.29e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg10664184	chr19:17420304	DDA1	0.72	8.46	0.47	2.38e-15	Systemic lupus erythematosus;
KIRP	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	cg12689670	chr1:183009347	LAMC1	0.42	5.95	0.35	8.95e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg10503236	chr1:231470652	EXOC8	-0.51	-7.19	-0.42	7.79e-12	Hemoglobin concentration;
KIRP	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.76	-9.25	-0.51	1.14e-17	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg03065383	chr2:96011964	KCNIP3	-0.55	-6.05	-0.36	5.22e-9	Menopause (age at onset);
KIRP	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg07382826	chr16:28625726	SULT1A1	0.53	6.31	0.37	1.28e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg08975724	chr8:8085496	FLJ10661	0.62	8.7	0.49	4.82e-16	Mood instability;
KIRP	cis	rs7011507	1.000	rs74536146	chr8:49156338	C/T	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4664293	0.867	rs1427328	chr2:160618575	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg26384229	chr12:38710491	ALG10B	0.65	8.71	0.49	4.42e-16	Morning vs. evening chronotype;
KIRP	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg25319279	chr11:5960081	NA	-0.57	-5.78	-0.35	2.25e-8	DNA methylation (variation);
KIRP	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-6.11	-0.36	3.9e-9	Aortic root size;
KIRP	cis	rs7674212	0.541	rs2720458	chr4:104052963	C/G	cg16532752	chr4:104119610	CENPE	-0.45	-5.41	-0.33	1.46e-7	Type 2 diabetes;
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	1.01	10.49	0.56	1.6e-21	Alzheimer's disease;
KIRP	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.66	-7.33	-0.42	3.21e-12	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs4523957	0.928	rs216190	chr17:2187457	C/T	cg16513277	chr17:2031491	SMG6	0.61	8.49	0.48	1.97e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg07741184	chr6:167504864	NA	0.23	6.28	0.37	1.56e-9	Crohn's disease;
KIRP	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.57	7.82	0.45	1.53e-13	Menarche (age at onset);
KIRP	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.57	7.22	0.42	6.65e-12	Aortic root size;
KIRP	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24397884	chr7:158709396	WDR60	0.73	9.78	0.53	2.8e-19	Height;
KIRP	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.72	9.69	0.53	5.19e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.67	8.64	0.48	7.17e-16	Prudent dietary pattern;
KIRP	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.56	7.34	0.42	3.18e-12	Coronary artery disease;
KIRP	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg27462398	chr1:86174642	ZNHIT6	-0.58	-8.52	-0.48	1.65e-15	Urate levels in overweight individuals;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21138277	chr11:93276595	C11orf75	0.48	6.35	0.38	1.02e-9	Parkinson's disease;
KIRP	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	8.94	0.5	9.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	9.35	0.51	5.74e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.75	9.51	0.52	1.88e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4849845	0.598	rs3933620	chr2:121034936	A/T	cg24070213	chr2:121070622	NA	0.41	6.44	0.38	6.16e-10	Mean platelet volume;
KIRP	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14125423	chr2:14782249	NA	0.46	6.58	0.39	2.85e-10	Survival in pancreatic cancer;
KIRP	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg15557168	chr22:42548783	NA	-0.4	-5.52	-0.33	8.8e-8	Cognitive function;
KIRP	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-7.5	-0.43	1.18e-12	Longevity;
KIRP	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20135002	chr11:47629003	NA	-0.47	-5.27	-0.32	3.05e-7	Subjective well-being;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24941931	chr19:16607335	C19orf44;CALR3	-0.59	-7.01	-0.41	2.25e-11	Interleukin-4 levels;
KIRP	trans	rs6601327	0.635	rs28828176	chr8:9663453	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.38	-0.38	8.55e-10	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.63	-8.4	-0.47	3.54e-15	Cognitive test performance;
KIRP	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg18882449	chr10:104885122	NT5C2	-0.4	-5.11	-0.31	6.58e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.8	10.12	0.54	2.38e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.69	0.48	5.01e-16	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg00745463	chr17:30367425	LRRC37B	-0.67	-6.63	-0.39	2.13e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs10073892	0.743	rs61566297	chr5:101658411	T/G	cg19774478	chr5:101632501	SLCO4C1	0.65	6.74	0.39	1.14e-10	Cognitive decline (age-related);
KIRP	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-8.39	-0.47	3.76e-15	Mean corpuscular volume;
KIRP	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.26	-5.5	-0.33	9.36e-8	Menarche (age at onset);
KIRP	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.58	-6.73	-0.39	1.22e-10	Initial pursuit acceleration;
KIRP	trans	rs12690897	0.704	rs4534077	chr7:85337215	C/A	cg03355690	chr6:35265616	DEF6	-0.31	-6.03	-0.36	5.86e-9	Macrophage inflammatory protein 1a levels;
KIRP	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05776053	chr2:74358815	NA	0.52	5.4	0.33	1.57e-7	Gestational age at birth (maternal effect);
KIRP	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg02487422	chr3:49467188	NICN1	0.43	6.05	0.36	5.24e-9	Menarche (age at onset);
KIRP	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.98	12.58	0.63	2.45e-28	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.697	rs473016	chr15:43558823	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.55	7.35	0.42	2.92e-12	Lung cancer;
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.44	5.66	0.34	4.27e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg21775007	chr8:11205619	TDH	-0.41	-5.41	-0.33	1.49e-7	Retinal vascular caliber;
KIRP	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.63	8.34	0.47	5.19e-15	Motion sickness;
KIRP	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs4834770	1.000	rs4336213	chr4:120236469	G/T	cg09307838	chr4:120376055	NA	0.43	5.05	0.31	8.6e-7	Blood protein levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01324724	chr10:104005490	GBF1	0.5	6.28	0.37	1.5e-9	Parkinson's disease;
KIRP	cis	rs7010267	0.935	rs11573829	chr8:119959623	T/C	cg01975934	chr8:119970761	NA	-0.42	-5.33	-0.32	2.17e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs17067123	0.539	rs75564322	chr4:180066838	A/G	cg26610307	chr4:180072759	NA	-0.47	-5.2	-0.31	4.18e-7	Response to hepatitis C treatment;
KIRP	cis	rs7119038	0.818	rs56758835	chr11:118615340	G/A	cg19308663	chr11:118741387	NA	0.56	8.7	0.49	4.87e-16	Sjögren's syndrome;
KIRP	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg16346588	chr10:242978	ZMYND11	-0.41	-4.88	-0.3	1.87e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.68	-9.09	-0.5	3.49e-17	Coronary artery disease;
KIRP	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg16497661	chr14:103986332	CKB	0.81	13.69	0.66	4.18e-32	Body mass index;
KIRP	cis	rs9217	0.841	rs7225954	chr17:7397274	G/A	cg02795151	chr17:7402630	POLR2A	-0.58	-7.25	-0.42	5.22e-12	Height;
KIRP	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg02961200	chr2:178257176	LOC100130691;AGPS	0.77	7.7	0.44	3.4e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.32	-6.39	-0.38	8.13e-10	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg04287289	chr16:89883240	FANCA	-0.39	-5.03	-0.31	9.4e-7	Vitiligo;
KIRP	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06481639	chr22:41940642	POLR3H	-0.65	-6.84	-0.4	6.39e-11	Vitiligo;
KIRP	cis	rs57590327	0.679	rs13082940	chr3:81547264	C/T	cg07356753	chr3:81810745	GBE1	0.59	6.56	0.39	3.18e-10	Extraversion;
KIRP	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.38	-0.32	1.72e-7	Bipolar disorder;
KIRP	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg06060754	chr5:176797920	RGS14	-0.6	-6.95	-0.4	3.33e-11	Urate levels in lean individuals;
KIRP	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	7.93	0.45	7.65e-14	Response to antipsychotic treatment;
KIRP	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg24315340	chr6:146058215	EPM2A	-0.43	-5.48	-0.33	1.07e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.83	-0.66	1.49e-32	Height;
KIRP	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.46	-5.28	-0.32	2.85e-7	Lung function (FVC);Lung function (FEV1);
KIRP	trans	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg02030672	chr11:45687055	CHST1	-0.57	-7.11	-0.41	1.29e-11	Obesity-related traits;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg14795281	chr19:13953361	NA	0.46	6.26	0.37	1.75e-9	Cancer;
KIRP	cis	rs9533799	1.000	rs7999059	chr13:44807194	C/A	cg19190762	chr13:44806055	NA	0.61	8.34	0.47	5.16e-15	Amyotrophic lateral sclerosis;
KIRP	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	1.18	8.83	0.49	2e-16	Economic and political preferences (immigration/crime);
KIRP	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.62	-0.34	5.03e-8	Autism;
KIRP	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg00792783	chr2:198669748	PLCL1	0.48	5.39	0.33	1.63e-7	Intracranial aneurysm;
KIRP	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.55	-7.9	-0.45	9.28e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	trans	rs6601327	0.665	rs10113155	chr8:9655358	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.26	-0.42	5.17e-12	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.59	-7.8	-0.45	1.75e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg04025307	chr7:1156635	C7orf50	0.81	8.37	0.47	4.35e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9653442	0.564	rs6707067	chr2:100767232	G/A	cg17356467	chr2:100759845	AFF3	0.42	6.02	0.36	6.33e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs4363385	0.588	rs6661059	chr1:153027257	A/T	cg13444842	chr1:152974279	SPRR3	-0.43	-6.29	-0.37	1.46e-9	Inflammatory skin disease;
KIRP	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg12559939	chr2:27858050	GPN1	-0.42	-5.06	-0.31	8.1e-7	Total body bone mineral density;
KIRP	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.87	-10.89	-0.57	8.3300000000000006e-23	Vitamin D levels;
KIRP	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg24315340	chr6:146058215	EPM2A	-0.4	-5.05	-0.31	8.77e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg15282417	chr9:129245246	FAM125B	0.42	7.03	0.41	1.99e-11	Intraocular pressure;
KIRP	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	1.31	12.44	0.62	7.1e-28	Diabetic retinopathy;
KIRP	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg05973401	chr12:123451056	ABCB9	0.51	5.47	0.33	1.09e-7	Neutrophil percentage of white cells;
KIRP	cis	rs2904967	1.000	rs626555	chr11:65063553	A/T	cg09225861	chr11:65069680	NA	0.45	5.84	0.35	1.66e-8	Mean corpuscular volume;
KIRP	cis	rs9488822	0.585	rs550480	chr6:116264354	C/A	cg15226275	chr6:116381976	FRK	-0.22	-5.66	-0.34	4.28e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg18806716	chr10:30721971	MAP3K8	-0.43	-6.84	-0.4	6.25e-11	Inflammatory bowel disease;
KIRP	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg00666640	chr1:248458726	OR2T12	0.47	5.76	0.34	2.48e-8	Common traits (Other);
KIRP	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09713475	chr16:1961667	HS3ST6	0.54	5.31	0.32	2.44e-7	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.66	-5.85	-0.35	1.54e-8	Yeast infection;
KIRP	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.68	10.75	0.57	2.32e-22	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs5167	0.525	rs10402642	chr19:45453878	G/A	cg13119609	chr19:45449297	APOC2	0.53	7.64	0.44	4.76e-13	Blood protein levels;
KIRP	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.99	15.28	0.7	1.62e-37	Personality dimensions;
KIRP	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-8.93	-0.49	1.03e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg05791153	chr7:19748676	TWISTNB	0.66	5.98	0.36	7.75e-9	Thyroid stimulating hormone;
KIRP	cis	rs4671458	1.000	rs4671460	chr2:63397203	T/C	cg17519650	chr2:63277830	OTX1	-0.56	-5.63	-0.34	4.82e-8	Subjective well-being;
KIRP	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.14	0.46	1.94e-14	Morning vs. evening chronotype;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12379764	chr21:47803548	PCNT	-0.4	-4.85	-0.3	2.16e-6	Testicular germ cell tumor;
KIRP	cis	rs6688613	0.685	rs61815130	chr1:166910465	T/C	cg07049167	chr1:166818506	POGK	0.45	4.99	0.3	1.17e-6	Refractive astigmatism;
KIRP	cis	rs7923609	0.846	rs9787438	chr10:65038030	G/C	cg08743896	chr10:65200160	JMJD1C	-0.35	-5.1	-0.31	6.68e-7	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg06115741	chr20:33292138	TP53INP2	0.4	4.89	0.3	1.86e-6	Height;
KIRP	cis	rs4953318	1.000	rs4953318	chr2:46355051	A/C	cg12428440	chr2:46370979	PRKCE	0.36	5.19	0.31	4.32e-7	Red blood cell count;Hematocrit;Red blood cell traits;
KIRP	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg07777115	chr5:623756	CEP72	-0.57	-5.82	-0.35	1.85e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09256448	chr16:638327	NA	0.36	5.06	0.31	8.34e-7	Height;
KIRP	cis	rs62413470	0.872	rs12207715	chr6:55954319	A/T	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.69	-8.12	-0.46	2.2e-14	Blood protein levels;
KIRP	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg13047869	chr3:10149882	C3orf24	0.6	5.11	0.31	6.61e-7	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.77	9.99	0.54	5.85e-20	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06398481	chr20:35492283	C20orf117	0.52	6.26	0.37	1.72e-9	Parkinson's disease;
KIRP	cis	rs7116495	0.609	rs10793014	chr11:71698838	A/G	cg07596299	chr11:71824057	C11orf51	-0.84	-5.63	-0.34	5.01e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg10326726	chr10:51549505	MSMB	0.59	8.11	0.46	2.42e-14	Prostate-specific antigen levels;
KIRP	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.66	-10.02	-0.54	4.93e-20	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.37	0.43	2.62e-12	Bladder cancer;
KIRP	cis	rs10129255	0.556	rs6576222	chr14:107184681	G/A	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.75	-9.69	-0.53	5.1e-19	Chronic sinus infection;
KIRP	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.79	10.65	0.56	5.06e-22	Platelet count;
KIRP	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.59	-8.69	-0.48	5.09e-16	Immature fraction of reticulocytes;
KIRP	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.39	-7.09	-0.41	1.37e-11	Refractive error;
KIRP	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg11972305	chr2:233791962	NGEF	-0.41	-5.01	-0.3	1.03e-6	Schizophrenia;
KIRP	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Body mass index;
KIRP	cis	rs2274273	0.743	rs13379159	chr14:55540801	C/T	cg04306507	chr14:55594613	LGALS3	0.44	6.7	0.39	1.4e-10	Protein biomarker;
KIRP	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg19025524	chr12:109796872	NA	-0.41	-5.43	-0.33	1.38e-7	Neuroticism;
KIRP	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg14675211	chr2:100938903	LONRF2	0.47	6.08	0.36	4.53e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg18154014	chr19:37997991	ZNF793	0.7	7.68	0.44	3.85e-13	Coronary artery calcification;
KIRP	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.95	-14.79	-0.69	7.78e-36	Height;
KIRP	cis	rs4523957	0.786	rs9897624	chr17:2121745	A/G	cg16513277	chr17:2031491	SMG6	-0.69	-9.62	-0.52	8.54e-19	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg00405596	chr8:11794950	NA	0.53	6.52	0.38	3.88e-10	Mood instability;
KIRP	trans	rs6475448	0.778	rs10123816	chr9:20549873	C/T	cg10007692	chr19:14640546	TECR	-0.45	-6.1	-0.36	4.11e-9	Response to montelukast in asthma (change in FEV1);
KIRP	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg02524346	chr8:600233	NA	0.76	5.87	0.35	1.42e-8	IgG glycosylation;
KIRP	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.77	0.44	2.12e-13	Calcium levels;
KIRP	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05025164	chr4:1340916	KIAA1530	0.42	5.29	0.32	2.73e-7	Obesity-related traits;
KIRP	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg04374321	chr14:90722782	PSMC1	0.99	18.13	0.76	3.17e-47	Mortality in heart failure;
KIRP	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.66	-9.19	-0.51	1.75e-17	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21620778	chr2:175548020	WIPF1	0.42	6.03	0.36	6.09e-9	Parkinson's disease;
KIRP	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.82	-9.32	-0.51	7.08e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7523273	0.565	rs3927459	chr1:207883907	A/C	cg22525895	chr1:207977042	MIR29B2	0.43	5.01	0.3	1.06e-6	Schizophrenia;
KIRP	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.49	5.68	0.34	3.71e-8	Metabolite levels;
KIRP	cis	rs684232	0.800	rs865702	chr17:568153	A/T	cg15660573	chr17:549704	VPS53	-0.45	-5.48	-0.33	1.07e-7	Prostate cancer;
KIRP	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg21573476	chr21:45109991	RRP1B	-0.63	-8.54	-0.48	1.44e-15	Mean corpuscular volume;
KIRP	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	0.75	10.96	0.57	4.93e-23	Prudent dietary pattern;
KIRP	cis	rs4740619	0.619	rs10810517	chr9:16026664	C/T	cg14451791	chr9:16040625	NA	-0.42	-5.49	-0.33	9.77e-8	Body mass index;
KIRP	cis	rs13132184	0.507	rs73241092	chr4:38094897	G/A	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.17	-0.31	4.95e-7	Verbal declarative memory;
KIRP	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg01444801	chr10:135216882	MTG1	-0.38	-4.96	-0.3	1.32e-6	Systemic lupus erythematosus;
KIRP	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg14703610	chr5:56206110	C5orf35	0.5	6.99	0.41	2.6e-11	Coronary artery disease;
KIRP	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.53	6.86	0.4	5.51e-11	Reticulocyte count;
KIRP	cis	rs4664304	0.742	rs67017730	chr2:160732793	T/G	cg06573604	chr2:160760825	LY75	-0.37	-5.14	-0.31	5.48e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6662572	0.906	rs11582058	chr1:46245423	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.42	-4.98	-0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.57	-7.11	-0.41	1.26e-11	Body mass index;
KIRP	cis	rs526231	0.547	rs34780	chr5:102453557	G/A	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.45	-5.31	-0.32	2.41e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7258465	1.000	rs4808134	chr19:18608579	G/A	cg01065977	chr19:18549689	ISYNA1	-0.4	-6.08	-0.36	4.64e-9	Breast cancer;
KIRP	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg18944383	chr4:111397179	ENPEP	-0.53	-9.27	-0.51	9.73e-18	Coronary artery disease;
KIRP	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.75	9.43	0.52	3.22e-18	Coronary artery disease;
KIRP	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg00409905	chr10:38381863	ZNF37A	0.53	5.85	0.35	1.58e-8	Obesity (extreme);
KIRP	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	9.46	0.52	2.61e-18	Cognitive test performance;
KIRP	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg08508325	chr11:3079039	CARS	0.33	6.16	0.37	2.93e-9	Calcium levels;
KIRP	cis	rs4253772	0.938	rs11704979	chr22:46632994	G/A	cg24881330	chr22:46731750	TRMU	0.66	4.93	0.3	1.49e-6	LDL cholesterol;Cholesterol, total;
KIRP	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-6.08	-0.36	4.66e-9	Triglycerides;
KIRP	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg13819577	chr1:248512075	OR14C36	-0.38	-5.05	-0.31	8.57e-7	Common traits (Other);
KIRP	cis	rs1832871	0.711	rs6920506	chr6:158695017	T/A	cg07215822	chr6:158701037	NA	-0.64	-7.51	-0.43	1.1e-12	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20065903	chr7:766203	HEATR2;PRKAR1B	0.47	6.09	0.36	4.29e-9	Parkinson's disease;
KIRP	cis	rs7779181	0.855	rs215610	chr7:32339594	G/A	cg13207630	chr7:32358064	NA	-0.44	-5.4	-0.33	1.61e-7	Body mass index;
KIRP	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.47	-5.97	-0.36	8.15e-9	Height;
KIRP	cis	rs74181299	0.750	rs13421845	chr2:65336033	G/A	cg05010058	chr2:65284262	CEP68	-0.53	-7.42	-0.43	1.84e-12	Pulse pressure;
KIRP	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.93	-14.59	-0.68	3.69e-35	Systemic lupus erythematosus;
KIRP	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.75	7.56	0.43	8.2e-13	Bipolar disorder;
KIRP	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.64	8.55	0.48	1.32e-15	Calcium levels;
KIRP	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg15655495	chr12:38532458	NA	-0.28	-5.05	-0.31	8.72e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg05775895	chr3:12838266	CAND2	-0.37	-6.04	-0.36	5.8e-9	QRS complex (12-leadsum);
KIRP	cis	rs78487399	0.808	rs7575024	chr2:43666991	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-4.94	-0.3	1.42e-6	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05393424	chr1:91403111	ZNF644	-0.4	-6.08	-0.36	4.57e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg14458575	chr2:238380390	NA	0.56	7.72	0.44	2.95e-13	Prostate cancer;
KIRP	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.84	-13.91	-0.66	7.82e-33	Post bronchodilator FEV1;
KIRP	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg01872077	chr2:219646372	CYP27A1	-0.42	-5.78	-0.35	2.27e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg21545522	chr1:205238299	TMCC2	0.41	5.54	0.33	7.73e-8	Red blood cell count;
KIRP	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg25547332	chr5:131281432	NA	-0.51	-6.15	-0.37	3.04e-9	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg13906792	chr15:75199810	C15orf17	0.37	5.25	0.32	3.21e-7	Breast cancer;
KIRP	trans	rs12517041	0.935	rs28493622	chr5:23282147	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.89	-8.49	-0.48	1.92e-15	Calcium levels;
KIRP	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg11879182	chr18:77439856	CTDP1	0.51	6.44	0.38	6.07e-10	Monocyte count;
KIRP	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.32	8.17	0.46	1.64e-14	Primary biliary cholangitis;
KIRP	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.32	-6.64	-0.39	2.05e-10	Diastolic blood pressure;
KIRP	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	10.25	0.55	9.48e-21	Lymphocyte counts;
KIRP	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06173319	chr16:90148775	NA	0.56	5.21	0.32	3.91e-7	Skin colour saturation;
KIRP	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg19000871	chr14:103996768	TRMT61A	-0.43	-5.51	-0.33	8.85e-8	Coronary artery disease;
KIRP	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs12210905	0.688	rs12213471	chr6:27406063	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-5.74	-0.34	2.75e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18932078	chr1:2524107	MMEL1	-0.46	-6.48	-0.38	4.84e-10	Ulcerative colitis;
KIRP	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg17133734	chr15:86042851	AKAP13	-0.41	-4.97	-0.3	1.24e-6	Interstitial lung disease;
KIRP	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.8	9.2	0.51	1.58e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1035491	0.715	rs2366902	chr5:63923702	T/C	cg01791865	chr5:63954708	NA	0.33	5.2	0.31	4.12e-7	Body mass index;
KIRP	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg08885076	chr2:99613938	TSGA10	-0.53	-8.92	-0.49	1.11e-16	Chronic sinus infection;
KIRP	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19346786	chr7:2764209	NA	-0.3	-5.17	-0.31	4.92e-7	Height;
KIRP	cis	rs904251	0.504	rs2797795	chr6:37480683	T/C	cg01843034	chr6:37503916	NA	-0.96	-15.55	-0.7	1.97e-38	Cognitive performance;
KIRP	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.45	-7.63	-0.44	5.2e-13	Facial morphology (factor 23);
KIRP	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.9	-0.3	1.72e-6	Pulmonary function;
KIRP	cis	rs7258465	0.965	rs271622	chr19:18629277	A/G	cg01065977	chr19:18549689	ISYNA1	-0.4	-5.93	-0.35	1e-8	Breast cancer;
KIRP	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.71	-9.84	-0.53	1.76e-19	Ear protrusion;
KIRP	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-1.09	-7.74	-0.44	2.51e-13	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg23565292	chr14:50234668	KLHDC2	0.4	4.84	0.3	2.26e-6	Carotid intima media thickness;
KIRP	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	19.23	0.77	6.33e-51	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09541373	chr19:55919383	UBE2S	0.52	6.7	0.39	1.41e-10	Parkinson's disease;
KIRP	cis	rs7246657	0.722	rs3101746	chr19:38146400	T/A	cg14683738	chr19:37701593	ZNF585B	-0.46	-4.85	-0.3	2.24e-6	Coronary artery calcification;
KIRP	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg18357526	chr6:26021779	HIST1H4A	0.4	5.24	0.32	3.39e-7	Height;
KIRP	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.06	13.89	0.66	8.64e-33	Corneal structure;
KIRP	cis	rs10129255	0.500	rs988133	chr14:107184963	A/G	cg23076370	chr14:107095027	NA	-0.41	-5.02	-0.3	1.01e-6	Kawasaki disease;
KIRP	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17554472	chr22:41940697	POLR3H	-0.64	-6.79	-0.4	8.54e-11	Vitiligo;
KIRP	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-9.5	-0.52	2e-18	Chronic sinus infection;
KIRP	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.95	15.54	0.7	2.14e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs33912345	0.750	rs986418	chr14:60858793	C/T	cg27398547	chr14:60952738	C14orf39	-0.39	-5.13	-0.31	5.79e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg06307176	chr5:131281290	NA	0.56	6.37	0.38	9.09e-10	Life satisfaction;
KIRP	cis	rs3789045	0.520	rs2010432	chr1:204462619	G/T	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.14	-0.36	3.33e-9	Educational attainment (college completion);
KIRP	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.26	7.46	0.43	1.47e-12	Type 2 diabetes;
KIRP	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg05861140	chr6:150128134	PCMT1	-0.43	-5.86	-0.35	1.49e-8	Lung cancer;
KIRP	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.53	8.81	0.49	2.24e-16	Eye color traits;
KIRP	cis	rs7224685	0.569	rs12453798	chr17:4017079	C/T	cg09597638	chr17:3907349	NA	0.52	5.2	0.31	4.13e-7	Type 2 diabetes;
KIRP	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg06521331	chr12:34319734	NA	-0.53	-6.54	-0.38	3.56e-10	Morning vs. evening chronotype;
KIRP	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg18753928	chr3:113234510	CCDC52	0.48	6.11	0.36	3.89e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	trans	rs10948472	0.563	rs12189617	chr6:48892996	T/C	cg07932300	chr6:139454928	HECA	0.41	6.07	0.36	4.71e-9	Interleukin-12p70 levels;
KIRP	cis	rs2235642	0.582	rs8051374	chr16:1566284	T/C	cg07639376	chr16:1584516	IFT140;TMEM204	-0.2	-5.55	-0.33	7.53e-8	Coronary artery disease;
KIRP	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.48	6.06	0.36	5.18e-9	Prudent dietary pattern;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13678112	chr14:89029552	ZC3H14	0.52	6.31	0.37	1.3e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg26174226	chr8:58114915	NA	-0.62	-7.29	-0.42	4.1e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs742071	0.527	rs7541797	chr1:18951985	C/G	cg22389438	chr1:18926496	NA	-0.38	-5.55	-0.33	7.3e-8	Nonsyndromic cleft lip with cleft palate;Orofacial clefts;
KIRP	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg02775129	chr4:119771670	NA	-0.86	-4.91	-0.3	1.67e-6	Cannabis dependence symptom count;
KIRP	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.45	5.11	0.31	6.4e-7	Schizophrenia;
KIRP	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.85	11.16	0.58	1.14e-23	Coronary artery disease;
KIRP	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.02	-0.57	3.2e-23	Height;
KIRP	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs7665939	0.932	rs72709227	chr4:190121479	C/T	cg14840187	chr4:190284988	NA	-0.74	-5.94	-0.35	9.48e-9	Amyotrophic lateral sclerosis;
KIRP	cis	rs4722166	0.532	rs4719711	chr7:22755688	A/G	cg05472934	chr7:22766657	IL6	-0.52	-6.81	-0.4	7.26e-11	Lung cancer;
KIRP	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.33	6.76	0.4	9.95e-11	Body mass index;
KIRP	cis	rs7937682	0.601	rs2187388	chr11:111387116	C/T	cg09085632	chr11:111637200	PPP2R1B	0.51	6.55	0.39	3.38e-10	Primary sclerosing cholangitis;
KIRP	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.94	-17.46	-0.74	5.79e-45	Dental caries;
KIRP	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-1.0	-15.86	-0.71	1.67e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	0.691	rs9307050	chr4:76905649	G/A	cg19388996	chr4:76862389	NAAA	0.43	5.53	0.33	8.36e-8	Blood protein levels;
KIRP	cis	rs10203711	1.000	rs2334022	chr2:239565612	T/C	cg14580085	chr2:239553406	NA	0.39	5.23	0.32	3.71e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.73	9.7	0.53	4.66e-19	Breast cancer;
KIRP	cis	rs4481887	0.508	rs4390207	chr1:248400174	C/T	cg01631408	chr1:248437212	OR2T33	-0.46	-5.24	-0.32	3.41e-7	Common traits (Other);
KIRP	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.68	6.5	0.38	4.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.43	5.56	0.33	7.16e-8	Melanoma;
KIRP	cis	rs3093024	0.904	rs3093017	chr6:167541258	C/G	cg07741184	chr6:167504864	NA	-0.29	-7.79	-0.44	1.88e-13	Rheumatoid arthritis;
KIRP	cis	rs9400467	0.528	rs110732	chr6:111679869	G/T	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.66	8.34	0.47	5.36e-15	Coronary artery disease;
KIRP	cis	rs33912345	0.750	rs10133771	chr14:60945522	G/A	cg27398547	chr14:60952738	C14orf39	0.37	4.93	0.3	1.5e-6	Glaucoma (high intraocular pressure);
KIRP	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.49	-5.05	-0.31	8.45e-7	Pubertal anthropometrics;
KIRP	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.69	-9.15	-0.5	2.19e-17	Personality dimensions;
KIRP	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.16	0.37	2.96e-9	Breast cancer;
KIRP	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.71	-10.08	-0.54	3.2e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.5	-7.9	-0.45	9.22e-14	Huntington's disease progression;
KIRP	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg04374321	chr14:90722782	PSMC1	-0.84	-11.7	-0.6	1.98e-25	Mortality in heart failure;
KIRP	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-7.57	-0.43	7.39e-13	Total cholesterol levels;
KIRP	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.76	8.32	0.47	5.98e-15	Uric acid levels;
KIRP	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs580438	0.792	rs89910	chr3:13326987	T/C	cg10657019	chr3:13328039	NA	0.89	13.0	0.64	9.47e-30	Myringotomy;
KIRP	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-8.35	-0.47	5.04e-15	Joint mobility (Beighton score);
KIRP	cis	rs745080	0.596	rs8018284	chr14:52960655	A/C	cg23333723	chr14:53022898	GPR137C	-0.4	-5.56	-0.33	6.97e-8	Orofacial clefts;
KIRP	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg03877680	chr5:178157825	ZNF354A	1.02	13.44	0.65	3.13e-31	Neutrophil percentage of white cells;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15166898	chr19:59008294	NA	-0.45	-6.82	-0.4	7.11e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	8.24	0.47	1.01e-14	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.58	6.22	0.37	2.1e-9	Schizophrenia;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg23099349	chr6:26032281	HIST1H3B	0.47	6.06	0.36	5.13e-9	Asthma;
KIRP	cis	rs16975963	0.644	rs11666662	chr19:38154702	A/T	cg18030218	chr19:38865513	PSMD8	-0.53	-4.86	-0.3	2.06e-6	Longevity;
KIRP	cis	rs2594989	0.639	rs2442781	chr3:11483769	A/G	cg01796438	chr3:11312864	ATG7	0.41	5.74	0.34	2.74e-8	Circulating chemerin levels;
KIRP	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	9.02	0.5	5.33e-17	Exhaled nitric oxide output;
KIRP	cis	rs6142102	0.961	rs4911411	chr20:32715842	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.39	0.38	8.42e-10	Skin pigmentation;
KIRP	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg00241281	chr14:105779794	PACS2	-0.36	-4.99	-0.3	1.12e-6	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	1.01	12.81	0.63	3.96e-29	Vitiligo;
KIRP	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg15871215	chr5:81402204	ATG10	0.5	6.56	0.39	3.09e-10	Breast cancer;
KIRP	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg07309820	chr7:148901717	ZNF282	-0.41	-5.07	-0.31	8.01e-7	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.77	10.42	0.55	2.61e-21	Adiposity;
KIRP	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.43	7.11	0.41	1.27e-11	Testicular germ cell tumor;
KIRP	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	7.85	0.45	1.28e-13	Eosinophil percentage of white cells;
KIRP	cis	rs155346	0.625	rs264346	chr5:139360300	C/T	cg24724630	chr5:139362307	NRG2	0.38	5.09	0.31	7.06e-7	Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia;
KIRP	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	6.2	0.37	2.42e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs3736594	0.513	rs62138966	chr2:27819172	G/A	cg27432699	chr2:27873401	GPN1	0.57	6.25	0.37	1.78e-9	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg23127183	chr11:57508653	C11orf31	-0.55	-7.07	-0.41	1.62e-11	Schizophrenia;
KIRP	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.3	-5.86	-0.35	1.44e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg05156742	chr15:59063176	FAM63B	0.52	6.16	0.37	2.9e-9	Schizophrenia;
KIRP	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.63	-6.47	-0.38	5.15e-10	Vitiligo;
KIRP	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.53	7.35	0.42	2.9e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs986417	0.901	rs12883305	chr14:61006690	A/G	cg27398547	chr14:60952738	C14orf39	0.67	6.64	0.39	1.97e-10	Gut microbiota (bacterial taxa);
KIRP	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg05973401	chr12:123451056	ABCB9	0.59	6.92	0.4	3.87e-11	Schizophrenia;
KIRP	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs41264869	0.628	rs6593930	chr1:205161949	C/T	cg21214746	chr1:205091277	RBBP5	0.5	6.44	0.38	6.37e-10	Blood protein levels;
KIRP	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg14338887	chr6:42928500	GNMT	0.47	6.99	0.41	2.59e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	7.04	0.41	1.94e-11	Height;
KIRP	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-7.38	-0.43	2.45e-12	Bipolar disorder;
KIRP	cis	rs9309473	1.000	rs6740223	chr2:73653332	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-5.8	-0.35	2.02e-8	Metabolite levels;
KIRP	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.08	-18.15	-0.76	2.75e-47	Schizophrenia;
KIRP	cis	rs775227	0.574	rs13064411	chr3:113046640	A/G	cg10517650	chr3:113235015	CCDC52	-0.47	-5.44	-0.33	1.31e-7	Dental caries;
KIRP	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg16255804	chr6:135334527	HBS1L	-0.32	-5.06	-0.31	8.17e-7	Red blood cell count;
KIRP	cis	rs2625529	0.652	rs2957736	chr15:72265344	A/G	cg16672083	chr15:72433130	SENP8	0.45	6.36	0.38	9.73e-10	Red blood cell count;
KIRP	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.54	6.1	0.36	4.16e-9	Blood metabolite levels;
KIRP	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.75	9.89	0.53	1.27e-19	Morning vs. evening chronotype;
KIRP	cis	rs2573652	1.000	rs2727198	chr15:100513722	T/C	cg09918751	chr15:100517450	ADAMTS17	-0.71	-10.86	-0.57	1.07e-22	Height;
KIRP	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg19767477	chr5:127420684	SLC12A2	-0.35	-4.9	-0.3	1.76e-6	Ileal carcinoids;
KIRP	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg01631408	chr1:248437212	OR2T33	-0.65	-8.81	-0.49	2.27e-16	Common traits (Other);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg01708552	chr7:100815485	C7orf52	0.52	7.0	0.41	2.36e-11	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.65	7.18	0.42	8.21e-12	Corneal astigmatism;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15830441	chr13:21348144	N6AMT2	-0.49	-6.28	-0.37	1.56e-9	Myopia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13614659	chr20:17949644	SNX5;C20orf72	0.55	7.06	0.41	1.74e-11	Parkinson's disease;
KIRP	cis	rs72627123	0.867	rs78496651	chr14:74480070	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.87	5.68	0.34	3.7e-8	Morning vs. evening chronotype;
KIRP	cis	rs1570884	0.857	rs4942848	chr13:50141345	A/G	cg08779649	chr13:50194554	NA	-0.46	-5.67	-0.34	3.9e-8	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7224685	0.501	rs781827	chr17:3962965	G/A	cg09695851	chr17:3907499	NA	0.83	15.23	0.7	2.42e-37	Type 2 diabetes;
KIRP	cis	rs10203711	0.933	rs12692238	chr2:239553940	T/C	cg14580085	chr2:239553406	NA	0.39	5.15	0.31	5.32e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.45	6.45	0.38	5.81e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg14456004	chr13:21872349	NA	-1.11	-13.94	-0.66	6.04e-33	White matter hyperintensity burden;
KIRP	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg05072774	chr3:49840536	C3orf54	0.43	5.5	0.33	9.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.49	5.73	0.34	2.9e-8	Diastolic blood pressure;
KIRP	cis	rs7614311	0.639	rs111234932	chr3:63842449	C/T	cg22134162	chr3:63841271	THOC7	-0.46	-5.11	-0.31	6.52e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	1.03	10.28	0.55	7.37e-21	Psoriasis;
KIRP	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.78	8.21	0.46	1.26e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg18944383	chr4:111397179	ENPEP	0.44	7.21	0.42	6.72e-12	Height;
KIRP	cis	rs6988636	0.710	rs73339623	chr8:124140288	A/G	cg22384356	chr8:124195192	FAM83A	-0.54	-4.89	-0.3	1.82e-6	Urinary uromodulin levels;
KIRP	cis	rs1555895	0.680	rs11253448	chr10:841115	T/C	cg10017260	chr10:834428	NA	-0.44	-6.39	-0.38	8.17e-10	Survival in rectal cancer;
KIRP	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg02733842	chr7:1102375	C7orf50	0.56	5.76	0.34	2.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg27205649	chr11:78285834	NARS2	0.58	6.71	0.39	1.3100000000000001e-10	Testicular germ cell tumor;
KIRP	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg09184832	chr6:79620586	NA	0.57	8.1	0.46	2.57e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.94	15.45	0.7	4.11e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.49	6.65	0.39	1.83e-10	Breast cancer;
KIRP	cis	rs8060686	0.641	rs8059305	chr16:68036666	A/C	cg26727032	chr16:67993705	SLC12A4	-0.66	-7.22	-0.42	6.65e-12	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg14517863	chr17:44321492	NA	0.36	4.9	0.3	1.76e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7688540	0.771	rs7686546	chr4:240614	G/A	cg17891759	chr4:299121	NA	-0.5	-5.09	-0.31	7.04e-7	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs9478638	0.507	rs9371882	chr6:155638741	G/A	cg07943832	chr6:155568918	TIAM2	-0.46	-6.45	-0.38	5.77e-10	Electroencephalogram traits;
KIRP	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.61	9.12	0.5	2.82e-17	Menarche (age at onset);
KIRP	cis	rs11078597	0.731	rs2070863	chr17:1648502	C/T	cg17514665	chr17:1657533	SERPINF2	0.44	5.46	0.33	1.18e-7	Serum albumin level;
KIRP	cis	rs4786125	0.665	rs6500858	chr16:6906111	T/C	cg03623568	chr16:6915990	A2BP1	-0.42	-4.96	-0.3	1.32e-6	Heart rate variability traits (SDNN);
KIRP	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs6662572	0.901	rs58692133	chr1:46067269	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.46	5.39	0.33	1.63e-7	Blood protein levels;
KIRP	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-0.66	-6.73	-0.39	1.18e-10	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.92	8.99	0.5	6.97e-17	Methadone dose in opioid dependence;
KIRP	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.62	4.94	0.3	1.47e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	1.02	18.28	0.76	9.53e-48	Heart rate;
KIRP	cis	rs2223471	0.652	rs2744488	chr6:50768062	C/A	cg03432817	chr6:50765336	NA	-0.5	-8.23	-0.46	1.11e-14	Subcutaneous adipose tissue;
KIRP	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg01849466	chr14:104193079	ZFYVE21	0.42	5.1	0.31	6.92e-7	Schizophrenia;
KIRP	cis	rs8077577	0.747	rs62072544	chr17:18243873	C/T	cg18869244	chr17:18121946	NA	0.45	5.06	0.31	8.21e-7	Obesity-related traits;
KIRP	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-0.79	-10.94	-0.57	5.98e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.51	-7.27	-0.42	4.74e-12	Daytime sleep phenotypes;
KIRP	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.53	-7.39	-0.43	2.29e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.34	-5.4	-0.33	1.56e-7	Inflammatory bowel disease;
KIRP	cis	rs12643440	0.843	rs12643260	chr4:17231324	C/T	cg22650099	chr4:17144496	NA	-0.5	-5.91	-0.35	1.16e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg02725872	chr8:58115012	NA	-0.61	-6.33	-0.37	1.15e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs883565	0.528	rs9818979	chr3:38963835	C/G	cg01426195	chr3:39028469	NA	0.48	7.43	0.43	1.81e-12	Handedness;
KIRP	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg05579598	chr16:88989069	CBFA2T3	0.24	5.01	0.3	1.02e-6	Social autistic-like traits;
KIRP	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg03563238	chr19:33554763	RHPN2	-0.33	-5.62	-0.34	5.2e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.78	-10.08	-0.54	3.15e-20	Iron status biomarkers;
KIRP	cis	rs6977660	0.943	rs10263564	chr7:19842898	G/C	cg05791153	chr7:19748676	TWISTNB	0.47	5.25	0.32	3.26e-7	Thyroid stimulating hormone;
KIRP	cis	rs2274471	0.699	rs7033053	chr9:5042987	G/A	cg03390472	chr9:5043263	JAK2	-0.47	-5.34	-0.32	2.09e-7	Crohn's disease;
KIRP	cis	rs68170813	0.559	rs56933300	chr7:106953278	A/AGGACCTCGGCAGAAGCC	cg02696742	chr7:106810147	HBP1	-0.65	-6.03	-0.36	6.06e-9	Coronary artery disease;
KIRP	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08280861	chr8:58055591	NA	0.71	5.8	0.35	2.06e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg18478394	chr8:109455254	TTC35	0.52	6.43	0.38	6.47e-10	Dupuytren's disease;
KIRP	cis	rs6686643	0.868	rs9333461	chr1:165618320	G/T	cg16553119	chr1:165599451	MGST3	-0.42	-5.21	-0.32	3.91e-7	Total ventricular volume;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg03970961	chr1:154292240	AQP10	-0.44	-6.14	-0.36	3.36e-9	Survival in pancreatic cancer;
KIRP	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-21.55	-0.81	1.37e-58	Prudent dietary pattern;
KIRP	cis	rs889512	0.642	rs7185352	chr16:75300248	G/C	cg03315344	chr16:75512273	CHST6	-0.67	-5.16	-0.31	5.03e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg23369114	chr19:14198698	NA	-0.44	-6.1	-0.36	4.04e-9	Inflammatory biomarkers;
KIRP	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg01877450	chr7:97915802	BRI3	-0.55	-7.19	-0.42	7.73e-12	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.11	0.64	4.03e-30	Exhaled nitric oxide output;
KIRP	trans	rs12043259	0.892	rs55895258	chr1:204791786	A/G	cg11485465	chr5:54518469	NA	0.38	6.31	0.37	1.26e-9	Addiction;
KIRP	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.5	7.07	0.41	1.63e-11	Lewy body disease;
KIRP	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.15	15.17	0.7	3.81e-37	Platelet count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11965514	chr8:124253535	C8orf76	0.51	6.16	0.37	2.9e-9	Parkinson's disease;
KIRP	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs16958440	1.000	rs62096478	chr18:44662409	A/G	cg17192377	chr18:44677553	HDHD2	0.73	6.62	0.39	2.29e-10	Sitting height ratio;
KIRP	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	0.94	12.2	0.61	4.49e-27	Blood protein levels;
KIRP	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg09408571	chr1:101003634	GPR88	0.24	5.47	0.33	1.12e-7	Monocyte count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08012303	chr16:11036238	DEXI	0.48	6.05	0.36	5.4e-9	Parkinson's disease;
KIRP	cis	rs732716	0.819	rs12459919	chr19:4434503	C/T	cg19820705	chr19:4455316	UBXN6	0.67	8.29	0.47	7.37e-15	Mean corpuscular volume;
KIRP	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg25801113	chr15:45476975	SHF	-0.45	-8.19	-0.46	1.41e-14	Uric acid levels;
KIRP	cis	rs815306	1	rs815306	chr1:76168624	A/G	cg03433033	chr1:76189801	ACADM	0.38	5.97	0.36	8.42e-9	Daytime sleep phenotypes;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10335543	chr14:102829157	TECPR2;CINP	0.52	6.98	0.41	2.74e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7187994	0.848	rs8046664	chr16:84749859	T/C	cg07647771	chr16:84786436	USP10	-0.39	-5.1	-0.31	6.79e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs27434	0.583	rs193482	chr5:96157846	A/G	cg16492584	chr5:96139282	ERAP1	-0.41	-5.51	-0.33	9.06e-8	Ankylosing spondylitis;
KIRP	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg04369109	chr6:150039330	LATS1	-0.47	-5.69	-0.34	3.57e-8	Lung cancer;
KIRP	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg12598211	chr12:123634384	NA	-0.41	-5.07	-0.31	7.97e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg13180566	chr4:1052158	NA	0.57	5.76	0.34	2.48e-8	Recombination rate (females);
KIRP	cis	rs73198271	0.694	rs114184516	chr8:8647082	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.44	-0.38	6.18e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6835098	0.692	rs6553679	chr4:174072292	C/T	cg08422745	chr4:174089978	GALNT7	-0.7	-9.29	-0.51	8.56e-18	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	trans	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.53	-6.93	-0.4	3.62e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-5.9	-0.35	1.18e-8	HDL cholesterol;
KIRP	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.63	8.56	0.48	1.25e-15	Morning vs. evening chronotype;
KIRP	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg19847130	chr8:10466454	RP1L1	-0.33	-4.99	-0.3	1.12e-6	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.63	6.86	0.4	5.45e-11	Gut microbiome composition (summer);
KIRP	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg20488157	chr14:104394430	TDRD9	0.74	10.8	0.57	1.61e-22	Bipolar disorder;
KIRP	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.62	6.7	0.39	1.4e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs1468333	1.000	rs2906128	chr5:137550054	C/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.49	5.46	0.33	1.16e-7	Resting heart rate;
KIRP	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.9	13.33	0.65	7.32e-31	Coronary artery disease;
KIRP	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg11845111	chr2:191398756	TMEM194B	0.64	8.61	0.48	8.73e-16	Pulse pressure;
KIRP	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.66	9.28	0.51	9.06e-18	Morning vs. evening chronotype;
KIRP	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	8.11	0.46	2.36e-14	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.41	4.94	0.3	1.41e-6	HDL cholesterol;
KIRP	cis	rs300890	0.507	rs1510879	chr4:144323036	T/A	cg01719995	chr4:144104893	USP38	-0.44	-5.48	-0.33	1.07e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.26	-0.37	1.66e-9	Schizophrenia;
KIRP	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg22027985	chr11:4115532	RRM1	-0.43	-4.92	-0.3	1.58e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06481639	chr22:41940642	POLR3H	-0.67	-6.47	-0.38	5.19e-10	Vitiligo;
KIRP	cis	rs4595586	0.566	rs7307174	chr12:39368862	A/G	cg13010199	chr12:38710504	ALG10B	0.44	5.52	0.33	8.63e-8	Morning vs. evening chronotype;
KIRP	cis	rs9513593	1.000	rs12100212	chr13:99966921	C/T	cg21788972	chr13:99853209	UBAC2	0.56	5.89	0.35	1.28e-8	Psoriasis;
KIRP	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg17340268	chr14:105411764	AHNAK2	0.39	5.01	0.3	1.03e-6	Rheumatoid arthritis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22856434	chr14:65346628	NA	0.47	6.58	0.39	2.81e-10	Parkinson's disease;
KIRP	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg10755058	chr3:40428713	ENTPD3	0.47	6.55	0.39	3.25e-10	Renal cell carcinoma;
KIRP	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.74	-8.12	-0.46	2.2e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg27347728	chr4:17578864	LAP3	0.4	4.89	0.3	1.85e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg16989719	chr2:238392110	NA	-0.52	-6.92	-0.4	3.94e-11	Prostate cancer;
KIRP	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.6	5.42	0.33	1.41e-7	Alzheimer's disease;
KIRP	trans	rs225245	0.817	rs225269	chr17:33967931	G/T	cg19694781	chr19:47549865	TMEM160	-0.52	-6.31	-0.37	1.3e-9	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.77	9.94	0.54	8.77e-20	Gut microbiome composition (winter);
KIRP	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.68	9.7	0.53	4.9e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg23422044	chr7:1970798	MAD1L1	-0.48	-6.19	-0.37	2.43e-9	Neuroticism;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18121006	chr10:99984296	C10orf28	0.47	6.9	0.4	4.46e-11	Migraine with aura;
KIRP	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.64	7.74	0.44	2.59e-13	Corneal astigmatism;
KIRP	cis	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg21204522	chr6:27730016	NA	-0.69	-5.27	-0.32	3e-7	Breast cancer;
KIRP	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.38	6.28	0.37	1.51e-9	Perceived unattractiveness to mosquitoes;
KIRP	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg26384229	chr12:38710491	ALG10B	0.69	9.52	0.52	1.66e-18	Morning vs. evening chronotype;
KIRP	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg20966754	chr17:47091339	IGF2BP1	0.27	5.37	0.32	1.78e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-8.47	-0.48	2.28e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.49	4.94	0.3	1.47e-6	Alzheimer's disease;
KIRP	cis	rs7221595	0.825	rs8076743	chr17:3916537	A/T	cg21851534	chr17:3907994	ZZEF1	0.6	5.89	0.35	1.28e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.26	0.32	3.15e-7	Asthma (childhood onset);
KIRP	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.44	-5.08	-0.31	7.45e-7	Alzheimer's disease (late onset);
KIRP	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.56	6.89	0.4	4.72e-11	QRS duration;
KIRP	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg08885076	chr2:99613938	TSGA10	-0.61	-10.98	-0.57	4.51e-23	Chronic sinus infection;
KIRP	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg27205649	chr11:78285834	NARS2	0.57	5.73	0.34	2.96e-8	Testicular germ cell tumor;
KIRP	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg06636001	chr8:8085503	FLJ10661	0.7	9.2	0.51	1.55e-17	Retinal vascular caliber;
KIRP	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	13.53	0.65	1.49e-31	Platelet count;
KIRP	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg09417038	chr21:47716443	C21orf57	-0.37	-5.07	-0.31	7.77e-7	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.74	-8.1	-0.46	2.53e-14	Vitiligo;
KIRP	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg02023728	chr11:77925099	USP35	0.34	5.41	0.33	1.52e-7	Alzheimer's disease (survival time);
KIRP	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-7.48	-0.43	1.28e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.66	6.45	0.38	5.77e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg08761264	chr16:28874980	SH2B1	-0.5	-5.8	-0.35	2.01e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs154659	0.887	rs154660	chr16:89667637	C/G	cg01710450	chr16:89662404	CPNE7	-0.63	-8.58	-0.48	1.11e-15	Tanning;
KIRP	cis	rs2411233	0.868	rs11853815	chr15:39257395	A/C	cg05886626	chr15:39873553	THBS1	0.34	5.05	0.31	8.78e-7	Platelet count;
KIRP	cis	rs4953911	0.586	rs876887	chr2:135077185	A/G	cg18482303	chr2:135041380	MGAT5	-0.28	-5.33	-0.32	2.23e-7	Multiple sclerosis (severity);
KIRP	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.43	6.03	0.36	5.85e-9	Testicular germ cell tumor;
KIRP	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg18944383	chr4:111397179	ENPEP	0.55	9.7	0.53	4.74e-19	Height;
KIRP	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg06307176	chr5:131281290	NA	0.55	6.11	0.36	3.97e-9	Life satisfaction;
KIRP	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-8.66	-0.48	6.28e-16	Lymphocyte counts;
KIRP	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg03647239	chr10:116582469	FAM160B1	0.52	6.01	0.36	6.8e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg15764593	chr10:829463	NA	-0.83	-8.9	-0.49	1.26e-16	Uric acid levels;
KIRP	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05601917	chr6:125855416	NA	-0.33	-4.96	-0.3	1.29e-6	Brugada syndrome;
KIRP	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg01493522	chr13:37497338	NA	-0.42	-5.41	-0.33	1.5e-7	Coronary artery disease;
KIRP	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg23625390	chr15:77176239	SCAPER	0.53	7.24	0.42	5.6e-12	Blood metabolite levels;
KIRP	cis	rs501120	1.000	rs503859	chr10:44753560	G/C	cg09554077	chr10:44749378	NA	0.74	12.03	0.61	1.57e-26	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg09163369	chr1:210001066	C1orf107	0.49	6.2	0.37	2.32e-9	Orofacial clefts;
KIRP	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-8.5	-0.48	1.89e-15	Response to antipsychotic treatment;
KIRP	cis	rs9815354	0.812	rs73073226	chr3:42005838	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.82	0.49	2.15e-16	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg16497661	chr14:103986332	CKB	0.5	6.78	0.4	9.09e-11	Body mass index;
KIRP	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.26	0.32	3.11e-7	Educational attainment;
KIRP	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.56	6.68	0.39	1.62e-10	HDL cholesterol;
KIRP	cis	rs6901004	0.803	rs9320360	chr6:111462272	G/T	cg15721981	chr6:111408429	SLC16A10	-0.56	-7.65	-0.44	4.4e-13	Blood metabolite levels;
KIRP	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.61	-7.68	-0.44	3.68e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs13170463	0.579	rs6869783	chr5:8036974	T/C	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg08999081	chr20:33150536	PIGU	-0.41	-5.32	-0.32	2.39e-7	Height;
KIRP	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg14440974	chr22:39074834	NA	-0.38	-4.87	-0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.58	5.55	0.33	7.48e-8	Skin colour saturation;
KIRP	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg23166289	chr1:210001082	C1orf107	0.43	5.44	0.33	1.28e-7	Orofacial clefts;
KIRP	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs17321999	0.516	rs13396720	chr2:30502938	C/T	cg05247661	chr2:30472410	LBH	0.65	5.66	0.34	4.28e-8	Systemic lupus erythematosus;
KIRP	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.61	7.03	0.41	2.02e-11	Developmental language disorder (linguistic errors);
KIRP	trans	rs12517041	1.000	rs16892385	chr5:23306170	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.84	-7.61	-0.44	5.89e-13	Calcium levels;
KIRP	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10104451	chr8:143696006	ARC	-0.68	-7.41	-0.43	1.98e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.85	11.54	0.59	6.61e-25	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg00149659	chr3:10157352	C3orf10	0.62	7.19	0.42	7.66e-12	Alzheimer's disease;
KIRP	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg10104451	chr8:143696006	ARC	-0.68	-7.44	-0.43	1.7e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.22e-9	Breast cancer;
KIRP	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg27490568	chr2:178487706	NA	0.71	9.58	0.52	1.08e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg03714773	chr7:91764589	CYP51A1	0.4	5.73	0.34	2.9e-8	Breast cancer;
KIRP	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg27490568	chr2:178487706	NA	0.53	7.3	0.42	3.99e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.68	10.46	0.55	2.06e-21	Brugada syndrome;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17683390	chr7:73184622	CLDN3	0.45	6.09	0.36	4.27e-9	Parkinson's disease;
KIRP	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12667521	chr19:29218732	NA	0.78	6.97	0.41	2.86e-11	Methadone dose in opioid dependence;
KIRP	cis	rs904251	0.600	rs12211110	chr6:37466232	A/G	cg08126542	chr6:37504118	NA	-0.71	-9.86	-0.53	1.51e-19	Cognitive performance;
KIRP	cis	rs7301016	0.802	rs73139054	chr12:62842227	T/C	cg01804193	chr12:63026212	NA	0.6	6.15	0.36	3.17e-9	IgG glycosylation;
KIRP	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.61	9.6	0.52	1e-18	C-reactive protein levels;
KIRP	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.06	-0.31	8.16e-7	Neutrophil percentage of white cells;
KIRP	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.61	7.64	0.44	4.93e-13	Breast cancer;
KIRP	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.53	-7.43	-0.43	1.73e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg17986701	chr20:44574422	PCIF1	0.47	7.37	0.43	2.62e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg04978709	chr7:75101039	POM121C	-0.51	-7.09	-0.41	1.45e-11	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg23985595	chr17:80112537	CCDC57	0.33	5.19	0.31	4.5e-7	Life satisfaction;
KIRP	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.87	13.46	0.65	2.53e-31	Prostate cancer;
KIRP	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.51	6.69	0.39	1.47e-10	Menopause (age at onset);
KIRP	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.52	7.31	0.42	3.75e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.71	7.79	0.44	1.85e-13	Gestational age at birth (maternal effect);
KIRP	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.74	10.26	0.55	8.73e-21	Red blood cell count;
KIRP	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg13514129	chr1:39547527	MACF1	0.58	8.48	0.48	2.04e-15	Fractional exhaled nitric oxide (childhood);
KIRP	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg18944383	chr4:111397179	ENPEP	0.48	8.15	0.46	1.83e-14	Height;
KIRP	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-6.24	-0.37	1.91e-9	Response to antipsychotic treatment;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-5.69	-0.34	3.64e-8	Life satisfaction;
KIRP	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg12046867	chr14:103022105	NA	-0.55	-7.06	-0.41	1.7e-11	Platelet count;
KIRP	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg16179182	chr5:140090404	VTRNA1-1	0.54	7.52	0.43	1.01e-12	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-6.6	-0.39	2.53e-10	Response to antipsychotic treatment;
KIRP	cis	rs7551222	0.646	rs10900590	chr1:204451086	C/T	cg20240347	chr1:204465584	NA	-0.42	-7.57	-0.43	7.31e-13	Schizophrenia;
KIRP	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.25	27.34	0.87	1.6e-76	IgG glycosylation;
KIRP	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	1.02	10.66	0.56	4.48e-22	Exhaled nitric oxide output;
KIRP	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-7.4	-0.43	2.12e-12	Response to antipsychotic treatment;
KIRP	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg18132916	chr6:79620363	NA	0.37	5.03	0.31	9.35e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg21775007	chr8:11205619	TDH	0.5	6.86	0.4	5.45e-11	Mood instability;
KIRP	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg03970086	chr16:88974840	CBFA2T3	0.46	5.84	0.35	1.62e-8	Social autistic-like traits;
KIRP	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.79	10.82	0.57	1.44e-22	Aortic root size;
KIRP	cis	rs7236492	0.872	rs78536295	chr18:77229738	G/A	cg15644404	chr18:77186268	NFATC1	-0.92	-7.25	-0.42	5.48e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	8.02	0.46	4.44e-14	Hip circumference adjusted for BMI;
KIRP	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	1.06	8.83	0.49	1.95e-16	Arsenic metabolism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00066508	chr12:110355602	TCHP	0.49	6.97	0.41	2.9100000000000002e-11	Survival in pancreatic cancer;
KIRP	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg20261243	chr20:44718728	NCOA5	0.46	6.07	0.36	4.88e-9	Lung adenocarcinoma;
KIRP	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg06204229	chr3:52865917	ITIH4	0.47	5.42	0.33	1.39e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	1.08	6.22	0.37	2.07e-9	Height;
KIRP	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.63	-7.09	-0.41	1.4e-11	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11239019	chr17:40172096	NKIRAS2	0.51	6.37	0.38	9.42e-10	Parkinson's disease;
KIRP	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.68	10.14	0.54	2.12e-20	Age-related hearing impairment;
KIRP	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.84	-11.55	-0.59	6.11e-25	Total body bone mineral density;
KIRP	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.5	6.38	0.38	8.88e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg11906718	chr8:101322791	RNF19A	0.49	6.52	0.38	4.01e-10	Atrioventricular conduction;
KIRP	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg02733842	chr7:1102375	C7orf50	-0.54	-6.15	-0.37	3.12e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg21395723	chr22:39101663	GTPBP1	0.43	5.36	0.32	1.9e-7	Menopause (age at onset);
KIRP	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.93	14.08	0.67	2.01e-33	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.33	5.27	0.32	2.97e-7	Asthma (childhood onset);
KIRP	cis	rs62380364	0.507	rs34321	chr5:88020319	C/G	cg22951263	chr5:87985283	NA	-0.47	-6.53	-0.38	3.75e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs12318506	0.826	rs13377894	chr12:75661825	A/G	cg04728562	chr12:75699417	CAPS2	-1.0	-7.05	-0.41	1.8e-11	Coronary artery calcification;
KIRP	cis	rs9309711	0.813	rs11690865	chr2:3471950	C/T	cg10845886	chr2:3471009	TTC15	-0.75	-10.94	-0.57	5.81e-23	Neurofibrillary tangles;
KIRP	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg12315302	chr6:26189340	HIST1H4D	0.77	5.17	0.31	4.93e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.69	7.09	0.41	1.39e-11	Platelet distribution width;
KIRP	cis	rs7700895	0.702	rs6890954	chr5:95229429	T/C	cg16656078	chr5:95278638	ELL2	-0.39	-5.88	-0.35	1.33e-8	IgG glycosylation;
KIRP	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.83	6.96	0.41	3.1e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg21161173	chr5:140098174	VTRNA1-2	0.4	5.19	0.31	4.46e-7	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg08975724	chr8:8085496	FLJ10661	0.62	7.81	0.45	1.64e-13	Neuroticism;
KIRP	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.98	12.89	0.63	2.15e-29	Smoking behavior;
KIRP	cis	rs644148	0.967	rs613876	chr19:44968788	T/C	cg15540054	chr19:45004280	ZNF180	-0.65	-7.27	-0.42	4.65e-12	Personality dimensions;
KIRP	cis	rs6466055	0.508	rs6966728	chr7:104618318	C/T	cg04380332	chr7:105027541	SRPK2	-0.4	-5.39	-0.33	1.65e-7	Schizophrenia;
KIRP	cis	rs1511802	0.666	rs4862662	chr4:187118662	A/C	cg24794857	chr4:187113578	CYP4V2	-0.41	-5.92	-0.35	1.07e-8	Blood protein levels;
KIRP	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg03653399	chr8:142233436	SLC45A4	-0.5	-6.03	-0.36	5.93e-9	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg19847130	chr8:10466454	RP1L1	-0.35	-5.07	-0.31	7.99e-7	Retinal vascular caliber;
KIRP	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9469913	0.740	rs2814983	chr6:34591207	A/G	cg14254433	chr6:34482411	PACSIN1	-0.43	-5.3	-0.32	2.58e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-6.09	-0.36	4.41e-9	Axial length;
KIRP	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-8.21	-0.46	1.27e-14	Glomerular filtration rate;
KIRP	cis	rs1448094	0.617	rs1393612	chr12:86474576	T/C	cg00310523	chr12:86230176	RASSF9	-0.42	-6.19	-0.37	2.55e-9	Major depressive disorder;
KIRP	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.58	6.57	0.39	2.94e-10	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs6733011	0.578	rs11893888	chr2:99495239	A/C	cg08885076	chr2:99613938	TSGA10	-0.34	-4.95	-0.3	1.41e-6	Bipolar disorder;
KIRP	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.53	-5.9	-0.35	1.21e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs1823913	0.599	rs2168166	chr2:192152789	G/A	cg12404831	chr2:192114017	MYO1B	0.52	7.27	0.42	4.69e-12	Obesity-related traits;
KIRP	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	11.78	0.6	1.04e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	5.05	0.31	8.75e-7	Resting heart rate;
KIRP	cis	rs61884328	0.852	rs59689332	chr11:47037806	G/A	cg23433285	chr11:47201945	PACSIN3	0.75	6.06	0.36	5.16e-9	Total body bone mineral density (age over 60);
KIRP	cis	rs71636778	0.543	rs71636796	chr1:27243095	T/C	cg12203394	chr1:27248618	NUDC	0.61	5.37	0.32	1.82e-7	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.31	0.59	3.62e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7937612	0.897	rs7126413	chr11:120207405	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.47	-6.67	-0.39	1.72e-10	Intraocular pressure;
KIRP	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.52	-0.56	1.26e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.39	9.49	0.52	2.11e-18	Corneal astigmatism;
KIRP	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg04935436	chr20:30431758	NA	0.47	5.85	0.35	1.58e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.26	0.32	3.14e-7	Smoking behavior;
KIRP	trans	rs5756813	0.668	rs5756805	chr22:38144618	A/G	cg19894588	chr14:64061835	NA	-0.49	-6.04	-0.36	5.73e-9	Optic cup area;Vertical cup-disc ratio;
KIRP	trans	rs972578	0.645	rs2007395	chr22:43271171	T/C	cg15321293	chr3:36422198	STAC	-0.48	-6.24	-0.37	1.94e-9	Mean platelet volume;
KIRP	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.63	0.52	7.83e-19	Prudent dietary pattern;
KIRP	cis	rs4262150	0.883	rs72799142	chr5:152100732	A/C	cg12297329	chr5:152029980	NA	-0.67	-8.4	-0.47	3.61e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-5.07	-0.31	7.7e-7	Pulmonary function;
KIRP	cis	rs3857067	1.000	rs2199603	chr4:95016174	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-5.05	-0.31	8.78e-7	QT interval;
KIRP	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg17143192	chr8:8559678	CLDN23	0.67	7.87	0.45	1.13e-13	Obesity-related traits;
KIRP	cis	rs7615316	0.579	rs28541536	chr3:141959375	A/G	cg20824294	chr3:142316082	PLS1	0.22	5.26	0.32	3.08e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg25801113	chr15:45476975	SHF	-0.45	-8.32	-0.47	6.19e-15	Uric acid levels;
KIRP	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26002218	chr14:103986227	CKB	0.27	5.13	0.31	6e-7	Body mass index;
KIRP	cis	rs6681460	1.000	rs9662943	chr1:67121132	A/G	cg13052034	chr1:66999238	SGIP1	-0.43	-5.76	-0.34	2.47e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.71	-11.25	-0.58	5.64e-24	Hepatocellular carcinoma;
KIRP	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg24315340	chr6:146058215	EPM2A	-0.44	-5.43	-0.33	1.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7113874	0.959	rs11042023	chr11:8662516	T/C	cg08015107	chr11:8618950	NA	0.35	4.94	0.3	1.46e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	6.17	0.37	2.77e-9	Mean platelet volume;
KIRP	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg11569703	chr11:65557185	OVOL1	0.37	5.66	0.34	4.16e-8	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
KIRP	cis	rs830233	0.565	rs17460660	chr5:165461092	G/A	cg13976338	chr5:165423657	NA	-0.63	-6.16	-0.37	3e-9	QT interval (sulfonylurea treatment interaction);
KIRP	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.8	-12.48	-0.62	5.21e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3789045	0.774	rs4252697	chr1:204501383	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.28	-0.37	1.52e-9	Educational attainment (college completion);
KIRP	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.48	-7.91	-0.45	8.69e-14	Height;
KIRP	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg11569703	chr11:65557185	OVOL1	-0.62	-10.8	-0.57	1.69e-22	Acne (severe);
KIRP	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.44	5.43	0.33	1.38e-7	Aortic root size;
KIRP	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg16141378	chr3:129829833	LOC729375	-0.53	-6.99	-0.41	2.54e-11	Mood instability;
KIRP	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	5.44	0.33	1.29e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.8	9.65	0.52	6.59e-19	Multiple system atrophy;
KIRP	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.61	-9.62	-0.52	8.68e-19	Sense of smell;
KIRP	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg01238044	chr22:24384105	GSTT1	-0.57	-7.45	-0.43	1.61e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.82	11.33	0.59	3.25e-24	Age at first birth;
KIRP	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg22705602	chr4:152727874	NA	-0.35	-5.37	-0.32	1.83e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-10.88	-0.57	8.82e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.81	9.82	0.53	2.01e-19	Corneal astigmatism;
KIRP	cis	rs4523957	0.928	rs216180	chr17:2172416	C/G	cg16513277	chr17:2031491	SMG6	0.6	8.33	0.47	5.86e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg12486944	chr17:80159399	CCDC57	0.38	5.05	0.31	8.41e-7	Life satisfaction;
KIRP	cis	rs367943	0.712	rs6867397	chr5:112725759	C/T	cg12552261	chr5:112820674	MCC	-0.57	-6.82	-0.4	7.06e-11	Type 2 diabetes;
KIRP	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.46	-5.77	-0.35	2.4e-8	Blood metabolite levels;
KIRP	cis	rs2594989	0.733	rs9861286	chr3:11568144	C/T	cg01796438	chr3:11312864	ATG7	0.41	5.5	0.33	9.36e-8	Circulating chemerin levels;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg08949862	chr2:63277672	OTX1	-0.46	-6.91	-0.4	4.18e-11	Blood metabolite levels;
KIRP	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg26531700	chr6:26746687	NA	0.51	7.23	0.42	5.92e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg05255149	chr17:80675120	FN3KRP	0.48	5.26	0.32	3.13e-7	Glycated hemoglobin levels;
KIRP	cis	rs2278796	0.918	rs11240326	chr1:204955416	G/A	cg17449235	chr1:204966235	NFASC	0.47	6.33	0.37	1.15e-9	Mean platelet volume;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg18538332	chr22:24372958	LOC391322	0.55	6.63	0.39	2.11e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.56	0.39	3.08e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6032067	0.929	rs17425504	chr20:43880089	T/C	cg10761708	chr20:43804764	PI3	0.47	4.95	0.3	1.39e-6	Blood protein levels;
KIRP	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg06647332	chr5:131281008	NA	-0.46	-5.04	-0.31	8.93e-7	Life satisfaction;
KIRP	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18252515	chr7:66147081	NA	-0.44	-5.39	-0.33	1.64e-7	Aortic root size;
KIRP	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg08885076	chr2:99613938	TSGA10	0.55	9.62	0.52	8.57e-19	Chronic sinus infection;
KIRP	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg25797454	chr6:150327115	RAET1K	0.33	6.23	0.37	2.05e-9	Alopecia areata;
KIRP	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg18477163	chr1:228402036	OBSCN	-0.34	-6.71	-0.39	1.3100000000000001e-10	Diastolic blood pressure;
KIRP	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.47	6.38	0.38	8.84e-10	Migraine;
KIRP	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg18944383	chr4:111397179	ENPEP	0.61	11.33	0.59	3.13e-24	Height;
KIRP	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.52	6.03	0.36	6.04e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg00310523	chr12:86230176	RASSF9	0.47	7.59	0.44	6.6e-13	Major depressive disorder;
KIRP	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	16.07	0.72	3.18e-40	Platelet count;
KIRP	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.55	-6.44	-0.38	6.15e-10	Aortic root size;
KIRP	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.47	5.33	0.32	2.24e-7	Schizophrenia;
KIRP	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg24633833	chr3:10029261	TMEM111	0.55	5.22	0.32	3.85e-7	Alzheimer's disease;
KIRP	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	1.1	8.15	0.46	1.82e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs10046574	0.519	rs10250947	chr7:135211017	T/G	cg27474649	chr7:135195673	CNOT4	0.54	5.15	0.31	5.31e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	7.11	0.41	1.23e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.92	14.89	0.69	3.42e-36	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.13	0.36	3.47e-9	Mean corpuscular volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg17528648	chr5:38846100	OSMR	-0.43	-6.23	-0.37	1.99e-9	Metabolic traits;
KIRP	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg06671706	chr8:8559999	CLDN23	0.5	6.14	0.36	3.31e-9	Obesity-related traits;
KIRP	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.79	12.35	0.62	1.43e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3120667	0.720	rs72698981	chr1:152440927	T/A	cg26876637	chr1:152193138	HRNR	-0.65	-5.73	-0.34	2.86e-8	Eating disorders;
KIRP	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.49	6.22	0.37	2.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.44	-7.13	-0.41	1.13e-11	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg08132940	chr7:1081526	C7orf50	-0.57	-5.76	-0.34	2.56e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.67	7.53	0.43	9.61e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13053350	chr15:89055844	DET1	0.42	6.34	0.37	1.08e-9	Interleukin-4 levels;
KIRP	cis	rs115344852	0.557	rs2859351	chr6:28456195	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.43	-5.02	-0.31	9.76e-7	Epithelial ovarian cancer;
KIRP	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12292205	chr6:26970375	C6orf41	-0.6	-6.71	-0.39	1.33e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs9900062	0.546	rs2428352	chr17:62694738	C/T	cg02097616	chr17:62675921	NA	-0.5	-6.32	-0.37	1.2e-9	QT interval;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg05686990	chr2:216964242	TMEM169	0.45	6.41	0.38	7.47e-10	Survival in pancreatic cancer;
KIRP	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.55	-6.14	-0.36	3.29e-9	Coronary artery disease;
KIRP	cis	rs2531992	0.563	rs2531988	chr16:4028417	T/G	cg05927578	chr16:4029543	ADCY9	0.52	5.62	0.34	5.06e-8	Waist circumference;
KIRP	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.22	20.54	0.79	2.8e-55	Cognitive function;
KIRP	cis	rs77861329	1.000	rs164639	chr3:52210872	A/G	cg08692210	chr3:52188851	WDR51A	-0.8	-6.48	-0.38	4.88e-10	Macrophage inflammatory protein 1b levels;
KIRP	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg14972814	chr11:95582409	MTMR2	0.36	5.94	0.35	9.76e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2273669	0.504	rs117426315	chr6:109450464	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-5.14	-0.31	5.53e-7	Prostate cancer;
KIRP	cis	rs2519796	0.509	rs635277	chr9:136822180	C/G	cg13751417	chr9:136814406	VAV2	-0.52	-6.86	-0.4	5.44e-11	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs501120	0.564	rs4948857	chr10:44683281	C/T	cg09554077	chr10:44749378	NA	0.52	7.01	0.41	2.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.37	-6.76	-0.4	9.67e-11	Monocyte percentage of white cells;
KIRP	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg04310649	chr10:35416472	CREM	-0.57	-6.94	-0.4	3.38e-11	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	1.04	16.05	0.72	3.91e-40	Homoarginine levels;
KIRP	cis	rs918629	0.567	rs6885567	chr5:95258754	T/G	cg16656078	chr5:95278638	ELL2	-0.35	-5.3	-0.32	2.61e-7	IgG glycosylation;
KIRP	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.82	9.78	0.53	2.76e-19	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.71	10.46	0.55	1.96e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg17736920	chr1:242011382	EXO1	0.48	5.89	0.35	1.25e-8	Menopause (age at onset);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg07134589	chr8:110551993	EBAG9	0.49	6.88	0.4	4.83e-11	Survival in pancreatic cancer;
KIRP	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg01097406	chr16:89675127	NA	-0.31	-5.09	-0.31	7.17e-7	Vitiligo;
KIRP	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.64	-9.39	-0.51	4.21e-18	Facial morphology (factor 21, depth of nasal alae);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13766830	chr19:15443073	NA	0.52	6.51	0.38	4.24e-10	Parkinson's disease;
KIRP	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg25174290	chr11:3078921	CARS	-0.68	-8.81	-0.49	2.27e-16	Calcium levels;
KIRP	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg08738300	chr3:44038990	NA	0.67	9.04	0.5	4.83e-17	Coronary artery disease;
KIRP	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg01988459	chr11:68622903	NA	-0.48	-6.21	-0.37	2.22e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg23335576	chr14:104009727	NA	0.36	5.27	0.32	2.96e-7	Body mass index;
KIRP	cis	rs7646881	0.812	rs75267618	chr3:158443816	T/C	cg19483011	chr3:158453295	NA	-0.52	-5.52	-0.33	8.5e-8	Tetralogy of Fallot;
KIRP	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.56	-7.56	-0.43	7.76e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg23161317	chr6:28129485	ZNF389	0.48	5.77	0.35	2.33e-8	Depression;
KIRP	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.55	-6.42	-0.38	7.09e-10	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7246657	0.722	rs2972430	chr19:38182111	C/T	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	1.02	13.93	0.66	6.7e-33	Menopause (age at onset);
KIRP	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.47	6.44	0.38	6.31e-10	Schizophrenia;
KIRP	cis	rs10214930	0.813	rs11764753	chr7:27672959	T/C	cg22168087	chr7:27702803	HIBADH	0.51	5.07	0.31	7.97e-7	Hypospadias;
KIRP	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.71	9.84	0.53	1.83e-19	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg06637938	chr14:75390232	RPS6KL1	0.5	7.11	0.41	1.23e-11	Height;
KIRP	cis	rs62229266	0.804	rs2835231	chr21:37390598	C/T	cg08632701	chr21:37451849	NA	-0.45	-5.62	-0.34	5.14e-8	Mitral valve prolapse;
KIRP	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.47	-5.51	-0.33	9.19e-8	Urate levels in overweight individuals;
KIRP	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	12.25	0.62	2.91e-27	Lymphocyte percentage of white cells;
KIRP	cis	rs7246657	0.509	rs10426093	chr19:37615629	G/A	cg23950597	chr19:37808831	NA	-0.7	-6.08	-0.36	4.56e-9	Coronary artery calcification;
KIRP	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg16989719	chr2:238392110	NA	-0.4	-4.88	-0.3	1.87e-6	Prostate cancer;
KIRP	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.49	-0.43	1.21e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs17023223	0.553	rs56234947	chr1:119707744	G/A	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg04691961	chr3:161091175	C3orf57	-0.45	-7.07	-0.41	1.59e-11	Morning vs. evening chronotype;
KIRP	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs11955398	0.604	rs1445852	chr5:59891304	C/T	cg14460003	chr20:31173015	NA	0.45	6.03	0.36	6.01e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg15896084	chr13:114927664	NA	0.49	6.66	0.39	1.77e-10	Schizophrenia;
KIRP	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	9.63	0.52	7.69e-19	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg13798912	chr7:905769	UNC84A	0.54	5.47	0.33	1.09e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.81	-11.33	-0.59	3.15e-24	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6693567	0.565	rs1694379	chr1:150292417	C/A	cg07843065	chr1:150265600	MRPS21	0.41	5.65	0.34	4.38e-8	Migraine;
KIRP	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-8.46	-0.47	2.33e-15	Morning vs. evening chronotype;
KIRP	cis	rs1497828	0.956	rs2815229	chr1:217535088	T/C	cg04411442	chr1:217543379	NA	-0.43	-6.58	-0.39	2.73e-10	Dialysis-related mortality;
KIRP	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.46	6.61	0.39	2.37e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs12496230	0.794	rs6549423	chr3:66866672	G/A	cg17646820	chr3:66848679	NA	0.39	6.29	0.37	1.41e-9	Type 2 diabetes;
KIRP	cis	rs36715	0.904	rs36701	chr5:127552529	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	7.42	0.43	1.95e-12	Breast cancer;
KIRP	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg24375607	chr4:120327624	NA	0.4	4.88	0.3	1.89e-6	Diastolic blood pressure;
KIRP	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	5.11	0.31	6.35e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg00129232	chr17:37814104	STARD3	-0.7	-9.1	-0.5	3.06e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.77	12.14	0.61	7.01e-27	Dupuytren's disease;
KIRP	cis	rs524023	0.914	rs11606370	chr11:64378452	C/A	cg09231725	chr11:64357281	SLC22A12	0.6	8.05	0.46	3.44e-14	Urate levels in obese individuals;
KIRP	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.61	-8.73	-0.49	3.88e-16	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg23100626	chr2:96804247	ASTL	0.44	5.65	0.34	4.5e-8	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs6714710	0.535	rs17488834	chr2:98354139	G/T	cg26665480	chr2:98280029	ACTR1B	0.59	6.93	0.4	3.58e-11	Posterior cortical atrophy and Alzheimer's disease;
KIRP	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	5.8	0.35	1.99e-8	Educational attainment;
KIRP	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-6.57	-0.39	2.95e-10	Longevity;Endometriosis;
KIRP	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.43	5.13	0.31	5.96e-7	Lung function (FEV1/FVC);
KIRP	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg04025307	chr7:1156635	C7orf50	0.72	5.57	0.33	6.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3925075	1.000	rs4411512	chr16:31347445	C/T	cg02846316	chr16:31340340	ITGAM	0.61	9.6	0.52	9.5e-19	IgA nephropathy;
KIRP	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg13293535	chr8:11597251	GATA4	0.38	5.29	0.32	2.75e-7	Morning vs. evening chronotype;
KIRP	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg07701084	chr6:150067640	NUP43	0.56	7.28	0.42	4.54e-12	Testicular germ cell tumor;
KIRP	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.39	-6.17	-0.37	2.72e-9	Body mass index;
KIRP	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.72	-8.36	-0.47	4.59e-15	Resting heart rate;
KIRP	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.77	12.32	0.62	1.71e-27	Menarche (age at onset);
KIRP	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7937612	0.931	rs7115714	chr11:120294861	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.07	-0.41	1.58e-11	Intraocular pressure;
KIRP	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg25019033	chr10:957182	NA	-0.57	-6.08	-0.36	4.5e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs6684428	1.000	rs10888947	chr1:56375280	C/T	cg11651538	chr1:56320950	NA	-0.9	-11.01	-0.57	3.55e-23	Airflow obstruction;
KIRP	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg27170947	chr2:26402098	FAM59B	-0.58	-6.5	-0.38	4.37e-10	Gut microbiome composition (summer);
KIRP	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg02487422	chr3:49467188	NICN1	0.42	5.68	0.34	3.73e-8	Parkinson's disease;
KIRP	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg00677455	chr12:58241039	CTDSP2	0.99	12.95	0.64	1.38e-29	Multiple sclerosis;
KIRP	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.75	-10.87	-0.57	1.02e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs748404	0.650	rs518234	chr15:43573421	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	5.8	0.35	2.04e-8	Lung cancer;
KIRP	cis	rs9473924	0.542	rs9463650	chr6:50822081	C/T	cg14470998	chr6:50812995	TFAP2B	0.82	7.6	0.44	6.29e-13	Body mass index;
KIRP	cis	rs2692947	0.800	rs2692936	chr2:96745729	G/A	cg23100626	chr2:96804247	ASTL	0.47	5.99	0.36	7.46e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.77	8.82	0.49	2.21e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1950626	0.623	rs34448411	chr14:101429287	G/A	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	0.54	6.15	0.36	3.15e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg14703610	chr5:56206110	C5orf35	0.49	6.37	0.38	9.22e-10	Coronary artery disease;
KIRP	cis	rs10488172	0.605	rs10248809	chr7:133655448	A/G	cg10665199	chr7:133106180	EXOC4	-0.47	-4.88	-0.3	1.93e-6	Tonometry;
KIRP	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg09754948	chr16:28834200	ATXN2L	-0.48	-4.99	-0.3	1.13e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg27490568	chr2:178487706	NA	0.57	7.69	0.44	3.5e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6142102	0.625	rs4911137	chr20:32535463	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.58	0.33	6.45e-8	Skin pigmentation;
KIRP	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.74	10.28	0.55	7.36e-21	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg06935464	chr4:38784597	TLR10	0.5	5.3	0.32	2.6e-7	Breast cancer;
KIRP	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.7	12.04	0.61	1.44e-26	Cardiovascular disease risk factors;
KIRP	trans	rs9531006	0.641	rs4885688	chr13:80581413	C/T	cg06666157	chr19:4791552	FEM1A	0.53	6.08	0.36	4.52e-9	Sleep duration;
KIRP	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.44	-6.03	-0.36	6.09e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs35740288	0.822	rs2306225	chr15:86227952	A/G	cg17133734	chr15:86042851	AKAP13	-0.48	-5.24	-0.32	3.41e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.4	4.92	0.3	1.56e-6	Common traits (Other);
KIRP	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg21775007	chr8:11205619	TDH	-0.39	-5.02	-0.31	9.76e-7	Neuroticism;
KIRP	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	cg21523751	chr1:182988639	NA	0.36	5.08	0.31	7.53e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg25019033	chr10:957182	NA	-0.59	-7.24	-0.42	5.86e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs6761276	0.649	rs3827763	chr2:113831289	C/T	cg12858261	chr2:113808755	IL1F8	-0.46	-5.42	-0.33	1.44e-7	Protein quantitative trait loci;
KIRP	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06481639	chr22:41940642	POLR3H	-0.45	-5.47	-0.33	1.11e-7	Vitiligo;
KIRP	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.96	-0.41	3.13e-11	Joint mobility (Beighton score);
KIRP	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.0	-10.74	-0.56	2.67e-22	Alzheimer's disease;
KIRP	cis	rs8018808	0.935	rs11625365	chr14:77908588	A/G	cg20045696	chr14:77926864	AHSA1	0.46	5.47	0.33	1.11e-7	Myeloid white cell count;
KIRP	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	5.81	0.35	1.95e-8	Educational attainment;
KIRP	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.61	-9.45	-0.52	2.72e-18	Sense of smell;
KIRP	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06481639	chr22:41940642	POLR3H	-0.65	-6.84	-0.4	6.39e-11	Vitiligo;
KIRP	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg16141378	chr3:129829833	LOC729375	0.59	7.47	0.43	1.42e-12	Triglycerides;
KIRP	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.42	-5.15	-0.31	5.42e-7	Neurofibrillary tangles;
KIRP	cis	rs4774899	0.966	rs12050751	chr15:57495060	A/G	cg13626582	chr15:57592083	LOC283663	-0.2	-5.04	-0.31	9.02e-7	Urinary tract infection frequency;
KIRP	cis	rs7534824	0.860	rs77569119	chr1:101605342	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.88	5.49	0.33	1.01e-7	Refractive astigmatism;
KIRP	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg08283408	chr3:49949060	MON1A	-0.42	-5.45	-0.33	1.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg20991723	chr1:152506922	NA	-0.45	-5.47	-0.33	1.11e-7	Hair morphology;
KIRP	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.58	8.02	0.46	4.37e-14	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg18306943	chr3:40428807	ENTPD3	0.47	6.05	0.36	5.41e-9	Renal cell carcinoma;
KIRP	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg21573476	chr21:45109991	RRP1B	-0.5	-6.67	-0.39	1.64e-10	Mean corpuscular volume;
KIRP	cis	rs7258465	0.965	rs7253990	chr19:18604085	C/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.47	-0.43	1.4e-12	Breast cancer;
KIRP	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg11846333	chr4:119757529	SEC24D	1.17	7.18	0.42	8.16e-12	Cannabis dependence symptom count;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08128228	chr1:167191360	POU2F1	-0.48	-6.56	-0.39	3.15e-10	Metabolic traits;
KIRP	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg20966754	chr17:47091339	IGF2BP1	-0.28	-5.26	-0.32	3.18e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-7.64	-0.44	4.75e-13	Blood pressure;
KIRP	cis	rs17666538	0.901	rs73177064	chr8:585293	C/G	cg07234876	chr8:600039	NA	-1.03	-6.29	-0.37	1.47e-9	IgG glycosylation;
KIRP	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.97	13.25	0.65	1.29e-30	Menopause (age at onset);
KIRP	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.17	0.37	2.86e-9	Menopause (age at onset);
KIRP	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	8.64	0.48	7.27e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2071403	0.966	rs11682968	chr2:1412230	C/T	cg07083862	chr2:1417248	TPO	0.33	5.27	0.32	2.93e-7	Thyroid peroxidase antibody positivity;
KIRP	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.71	9.08	0.5	3.61e-17	Bladder cancer;
KIRP	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg00800038	chr16:89945340	TCF25	-0.77	-5.31	-0.32	2.5e-7	Skin colour saturation;
KIRP	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.58	6.87	0.4	5.24e-11	Mosquito bite size;
KIRP	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg00933542	chr6:150070202	PCMT1	0.28	5.36	0.32	1.93e-7	Lung cancer;
KIRP	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg26811252	chr16:29126840	RRN3P2	0.75	9.87	0.53	1.46e-19	Menopause (age at onset);
KIRP	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg18490616	chr2:88469792	THNSL2	0.67	5.4	0.33	1.56e-7	Plasma clusterin levels;
KIRP	trans	rs10186876	0.543	rs3853705	chr2:44261892	A/G	cg18143693	chr14:67999927	PLEKHH1	-0.59	-6.05	-0.36	5.48e-9	Hand grip strength;
KIRP	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg07068956	chr7:100330872	ZAN	-0.57	-6.34	-0.38	1.06e-9	Other erythrocyte phenotypes;
KIRP	cis	rs6132905	0.590	rs7269323	chr20:2627197	A/G	cg24848351	chr20:2622020	TMC2	-0.66	-5.91	-0.35	1.15e-8	Mumps;
KIRP	cis	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg12923728	chr3:195709715	SDHAP1	-0.54	-6.17	-0.37	2.74e-9	Pancreatic cancer;
KIRP	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.5	-6.64	-0.39	2.04e-10	Blood metabolite levels;
KIRP	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.44	5.3	0.32	2.58e-7	Body mass index;
KIRP	cis	rs7520050	0.778	rs2088102	chr1:46032974	T/C	cg15605315	chr1:45957053	TESK2	0.4	5.16	0.31	5.14e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	7.27	0.42	4.78e-12	Height;
KIRP	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.8	11.83	0.6	7.21e-26	Glomerular filtration rate (creatinine);
KIRP	cis	rs734999	0.545	rs10910111	chr1:2542653	A/G	cg20673091	chr1:2541236	MMEL1	0.78	12.7	0.63	9.02e-29	Ulcerative colitis;
KIRP	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11987759	chr7:65425863	GUSB	0.61	7.99	0.45	5.33e-14	Aortic root size;
KIRP	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.75	-9.79	-0.53	2.46e-19	Coronary artery disease;
KIRP	cis	rs7224685	0.817	rs9901620	chr17:4165741	G/C	cg09695851	chr17:3907499	NA	0.6	6.53	0.38	3.84e-10	Type 2 diabetes;
KIRP	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	1.99e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11861097	chr20:2794877	C20orf141	0.47	6.15	0.37	3.15e-9	Interleukin-4 levels;
KIRP	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.82	11.49	0.59	9.7e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg16497661	chr14:103986332	CKB	0.4	5.23	0.32	3.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg19077165	chr18:44547161	KATNAL2	0.45	5.63	0.34	4.91e-8	Personality dimensions;
KIRP	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.59	-5.01	-0.3	1.04e-6	Other erythrocyte phenotypes;
KIRP	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.77	-10.16	-0.54	1.73e-20	Coffee consumption (cups per day);
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.62	9.59	0.52	1.07e-18	Lung cancer;
KIRP	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	cis	rs778371	0.649	rs283465	chr2:233666787	G/A	cg08000102	chr2:233561755	GIGYF2	0.74	9.23	0.51	1.25e-17	Schizophrenia;
KIRP	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-8.98	-0.5	7.44e-17	Schizophrenia;
KIRP	trans	rs593982	1.000	rs576663	chr11:65498942	G/T	cg16063989	chr7:139929855	NA	0.45	6.19	0.37	2.5e-9	Atopic dermatitis;
KIRP	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10053473	chr17:62856997	LRRC37A3	0.69	7.48	0.43	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.47	5.2	0.31	4.21e-7	HDL cholesterol;
KIRP	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.93	-0.35	1.01e-8	Fear of minor pain;
KIRP	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.97	11.09	0.58	1.96e-23	Pulmonary function decline;
KIRP	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg18016565	chr1:150552671	MCL1	-0.36	-5.41	-0.33	1.52e-7	Tonsillectomy;
KIRP	cis	rs6062509	0.965	rs4809330	chr20:62349586	A/G	cg11503966	chr20:62272292	STMN3	0.36	5.31	0.32	2.42e-7	Prostate cancer;
KIRP	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg16141378	chr3:129829833	LOC729375	0.6	7.97	0.45	5.82e-14	Neuroticism;
KIRP	cis	rs2274273	0.682	rs10145268	chr14:55504514	T/C	cg04306507	chr14:55594613	LGALS3	0.42	6.36	0.38	9.96e-10	Protein biomarker;
KIRP	cis	rs17428704	0.571	rs11949708	chr5:14349344	T/G	cg26595256	chr5:14380529	TRIO	-0.82	-6.14	-0.36	3.34e-9	Electroencephalogram traits;
KIRP	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.59	7.85	0.45	1.24e-13	Response to temozolomide;
KIRP	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.36	-0.38	9.95e-10	Triglycerides;
KIRP	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.79	-10.29	-0.55	7e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	6.45	0.38	5.84e-10	Coronary artery disease;
KIRP	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg16736954	chr20:23401023	NAPB	0.63	5.1	0.31	6.75e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.46	-5.78	-0.35	2.26e-8	Total body bone mineral density;
KIRP	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.83	-11.9	-0.6	4.27e-26	Eye color traits;
KIRP	cis	rs10465746	0.780	rs2389649	chr1:84379449	C/T	cg10977910	chr1:84465055	TTLL7	0.52	6.48	0.38	5.08e-10	Obesity-related traits;
KIRP	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg20240347	chr1:204465584	NA	-0.4	-7.67	-0.44	3.94e-13	Schizophrenia;
KIRP	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.83	8.61	0.48	8.71e-16	Cerebrospinal P-tau181p levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08307766	chr12:70637393	CNOT2	-0.56	-6.02	-0.36	6.31e-9	Menopause (age at onset);
KIRP	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg14593290	chr7:50529359	DDC	-0.36	-4.89	-0.3	1.79e-6	Systemic sclerosis;
KIRP	cis	rs4132509	0.843	rs12034588	chr1:243784392	T/A	cg25706552	chr1:244017396	NA	0.58	7.02	0.41	2.12e-11	RR interval (heart rate);
KIRP	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.16	0.31	5.04e-7	Asthma;
KIRP	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.93	11.36	0.59	2.52e-24	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
KIRP	cis	rs4862750	0.914	rs10027250	chr4:187873460	T/C	cg11301795	chr4:187892539	NA	-1.02	-18.22	-0.76	1.62e-47	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.56	9.15	0.5	2.31e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg18833306	chr6:118973337	C6orf204	0.39	4.88	0.3	1.89e-6	Electrocardiographic conduction measures;
KIRP	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs524023	0.874	rs475642	chr11:64424691	C/A	cg09231725	chr11:64357281	SLC22A12	0.6	8.05	0.46	3.44e-14	Urate levels in obese individuals;
KIRP	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21643547	chr1:205240462	TMCC2	-0.83	-12.81	-0.63	4.1e-29	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg25319279	chr11:5960081	NA	-0.67	-6.66	-0.39	1.79e-10	DNA methylation (variation);
KIRP	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg24998770	chr7:37888106	TXNDC3	0.47	6.22	0.37	2.07e-9	Alzheimer's disease (late onset);
KIRP	cis	rs960902	0.935	rs6708411	chr2:37718181	A/C	cg25341268	chr2:37734390	NA	-0.5	-6.79	-0.4	8.4e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-7.01	-0.41	2.24e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs7818345	0.967	rs4617172	chr8:19273362	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.27	0.37	1.64e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg10189774	chr4:17578691	LAP3	0.55	6.81	0.4	7.55e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6988985	0.791	rs11781816	chr8:143997795	C/T	cg10324643	chr8:143916377	GML	-0.43	-5.05	-0.31	8.62e-7	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
KIRP	trans	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg24644049	chr4:85504048	CDS1	1.01	6.64	0.39	2.04e-10	Skin colour saturation;
KIRP	cis	rs4776059	1.000	rs62023352	chr15:52889448	T/C	cg22715398	chr15:52968154	KIAA1370	-0.67	-8.08	-0.46	2.96e-14	Schizophrenia;
KIRP	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.68	9.27	0.51	9.99e-18	Hemoglobin concentration;
KIRP	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg21573476	chr21:45109991	RRP1B	-0.76	-10.64	-0.56	5.46e-22	Mean corpuscular volume;
KIRP	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.23	-0.42	5.9e-12	Type 2 diabetes;
KIRP	cis	rs6723108	1.000	rs1942055	chr2:135498924	C/G	cg25422880	chr2:135218333	TMEM163	0.4	5.41	0.33	1.52e-7	Type 2 diabetes;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg12738349	chr22:24236284	MIF	0.44	6.44	0.38	6.14e-10	Survival in pancreatic cancer;
KIRP	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.7	-6.78	-0.4	9.07e-11	Vitiligo;
KIRP	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg00738919	chr7:1100172	C7orf50	0.43	4.99	0.3	1.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2963155	1.000	rs2963155	chr5:142756004	C/T	cg17617527	chr5:142782415	NR3C1	-0.59	-6.68	-0.39	1.6e-10	Breast cancer;
KIRP	cis	rs7246657	0.722	rs16958863	chr19:38124235	A/G	cg14683738	chr19:37701593	ZNF585B	0.46	4.88	0.3	1.94e-6	Coronary artery calcification;
KIRP	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.73	10.06	0.54	3.62e-20	Response to antipsychotic treatment;
KIRP	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.65	7.67	0.44	4.05e-13	Aortic root size;
KIRP	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg08017634	chr8:144659831	NAPRT1	0.83	5.38	0.32	1.78e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg10504392	chr12:110044639	NA	0.26	5.16	0.31	5.03e-7	Neuroticism;
KIRP	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg08533674	chr1:46993347	NA	0.45	5.59	0.34	6.17e-8	Monobrow;
KIRP	cis	rs12541635	0.677	rs2880950	chr8:106983624	C/A	cg10147462	chr8:107024639	NA	0.35	5.19	0.31	4.34e-7	Age of smoking initiation;
KIRP	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg17376030	chr22:41985996	PMM1	-0.48	-5.91	-0.35	1.16e-8	Vitiligo;
KIRP	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs17023223	0.537	rs2645295	chr1:119582448	C/T	cg18261050	chr1:119551319	NA	0.54	7.25	0.42	5.52e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs12476592	0.602	rs262509	chr2:63885708	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-4.85	-0.3	2.21e-6	Childhood ear infection;
KIRP	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg12591125	chr7:1885375	MAD1L1	0.64	6.4	0.38	7.92e-10	Bipolar disorder;
KIRP	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg04672837	chr16:48644449	N4BP1	-0.48	-6.47	-0.38	5.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg07636037	chr3:49044803	WDR6	-0.73	-5.17	-0.31	4.93e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00889227	chr1:205173544	DSTYK	-0.38	-5.48	-0.33	1.06e-7	Red blood cell count;
KIRP	cis	rs1497828	0.956	rs2646808	chr1:217523045	G/C	cg04411442	chr1:217543379	NA	-0.3	-4.88	-0.3	1.92e-6	Dialysis-related mortality;
KIRP	cis	rs6545883	0.929	rs2421203	chr2:61669248	C/A	cg15711740	chr2:61764176	XPO1	-0.6	-7.99	-0.45	5.18e-14	Tuberculosis;
KIRP	cis	rs4594175	0.926	rs12101170	chr14:51611902	T/C	cg23942311	chr14:51606299	NA	0.51	6.75	0.4	1.04e-10	Cancer;
KIRP	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg11995313	chr8:8860691	ERI1	-0.42	-5.68	-0.34	3.87e-8	Joint mobility (Beighton score);
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg09264619	chr17:80180166	NA	-0.4	-5.87	-0.35	1.44e-8	Life satisfaction;
KIRP	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.51	6.69	0.39	1.54e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.64	0.52	7.43e-19	Prudent dietary pattern;
KIRP	cis	rs4234798	1.000	rs4234797	chr4:7219907	C/T	cg18431297	chr4:7219810	SORCS2	0.69	8.99	0.5	6.77e-17	Insulin-like growth factors;
KIRP	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.76	8.8	0.49	2.46e-16	High light scatter reticulocyte count;
KIRP	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg06212747	chr3:49208901	KLHDC8B	0.64	5.99	0.36	7.49e-9	Menarche (age at onset);
KIRP	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg14683738	chr19:37701593	ZNF585B	0.49	4.84	0.3	2.27e-6	Coronary artery calcification;
KIRP	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg08885076	chr2:99613938	TSGA10	0.55	9.66	0.52	6.16e-19	Chronic sinus infection;
KIRP	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.98	-10.24	-0.55	1.03e-20	Schizophrenia;
KIRP	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg07862535	chr7:139043722	LUC7L2	0.47	5.27	0.32	2.94e-7	Diisocyanate-induced asthma;
KIRP	cis	rs13108904	0.651	rs875475	chr4:1192409	G/A	cg16405210	chr4:1374714	KIAA1530	-0.44	-5.38	-0.32	1.7e-7	Obesity-related traits;
KIRP	cis	rs2882667	0.728	rs10068786	chr5:138276944	C/T	cg04439458	chr5:138467593	SIL1	-0.37	-4.97	-0.3	1.26e-6	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.1	-8.31	-0.47	6.47e-15	Mitochondrial DNA levels;
KIRP	cis	rs12780845	0.522	rs7900703	chr10:17237617	T/C	cg01003015	chr10:17271136	VIM	-0.47	-6.17	-0.37	2.84e-9	Homocysteine levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09800235	chr12:133250183	POLE	-0.51	-6.59	-0.39	2.73e-10	Inflammatory biomarkers;
KIRP	cis	rs11825064	0.725	rs78340072	chr11:134476970	T/C	cg06603561	chr11:134479413	NA	-1.16	-7.95	-0.45	6.79e-14	Seasonality;
KIRP	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg00129232	chr17:37814104	STARD3	-0.68	-7.41	-0.43	2.05e-12	Glomerular filtration rate (creatinine);
KIRP	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg03235661	chr20:60525775	NA	-0.34	-5.22	-0.32	3.82e-7	Body mass index;
KIRP	cis	rs4728302	0.607	rs7782545	chr7:133587689	C/T	cg10665199	chr7:133106180	EXOC4	0.43	5.04	0.31	9.21e-7	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs1468333	1.000	rs6867242	chr5:137561186	T/C	cg27119451	chr5:137514611	BRD8;KIF20A	0.46	5.37	0.32	1.82e-7	Resting heart rate;
KIRP	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.51	5.91	0.35	1.15e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.49	6.11	0.36	3.83e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg24203234	chr3:128598194	ACAD9	0.43	4.89	0.3	1.8e-6	IgG glycosylation;
KIRP	cis	rs2742417	0.967	rs9825559	chr3:45740278	T/C	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg17724175	chr1:150552817	MCL1	0.34	5.77	0.35	2.35e-8	Tonsillectomy;
KIRP	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg01338084	chr22:32026380	PISD	0.98	6.82	0.4	6.85e-11	Age-related hearing impairment;
KIRP	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg02487422	chr3:49467188	NICN1	0.42	5.99	0.36	7.54e-9	Menarche (age at onset);
KIRP	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg15556689	chr8:8085844	FLJ10661	0.57	7.15	0.41	9.83e-12	Platelet distribution width;
KIRP	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg13877915	chr19:58951672	ZNF132	0.6	5.9	0.35	1.18e-8	Mean platelet volume;
KIRP	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg22349387	chr12:9600060	DDX12	-0.34	-4.87	-0.3	2.03e-6	Breast size;
KIRP	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg08761264	chr16:28874980	SH2B1	0.53	6.15	0.36	3.18e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18252515	chr7:66147081	NA	-0.45	-5.49	-0.33	1.01e-7	Aortic root size;
KIRP	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg18306943	chr3:40428807	ENTPD3	0.46	6.17	0.37	2.75e-9	Renal cell carcinoma;
KIRP	cis	rs2594989	0.887	rs2437684	chr3:11593261	C/T	cg01796438	chr3:11312864	ATG7	0.44	5.56	0.33	6.92e-8	Circulating chemerin levels;
KIRP	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.48	9.81	0.53	2.12e-19	Monocyte percentage of white cells;
KIRP	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.79	10.49	0.56	1.59e-21	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.26	0.7	1.89e-37	Chronic sinus infection;
KIRP	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.79	10.1	0.54	2.75e-20	Menopause (age at onset);
KIRP	trans	rs11989744	0.500	rs7826966	chr8:23569106	G/T	cg03492747	chr16:86543808	FOXF1	-0.54	-7.07	-0.41	1.61e-11	Waist-hip ratio;
KIRP	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg09788416	chr12:39539408	NA	0.39	5.3	0.32	2.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs5753618	0.583	rs34545960	chr22:31812462	G/A	cg02404636	chr22:31891804	SFI1	0.51	5.74	0.34	2.82e-8	Colorectal cancer;
KIRP	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11987759	chr7:65425863	GUSB	-0.6	-7.96	-0.45	6.4e-14	Aortic root size;
KIRP	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg07862535	chr7:139043722	LUC7L2	-0.47	-5.35	-0.32	2.03e-7	Diisocyanate-induced asthma;
KIRP	cis	rs72634258	0.786	rs7523335	chr1:8180210	G/A	cg00042356	chr1:8021962	PARK7	0.5	4.97	0.3	1.23e-6	Inflammatory bowel disease;
KIRP	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.65	-9.87	-0.53	1.43e-19	Glomerular filtration rate (creatinine);
KIRP	cis	rs838147	0.537	rs632111	chr19:49208978	A/G	cg16867584	chr19:49200180	FUT2	0.32	5.16	0.31	5.09e-7	Dietary macronutrient intake;
KIRP	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	cg21523751	chr1:182988639	NA	0.45	6.94	0.4	3.48e-11	Hypertriglyceridemia;
KIRP	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26002218	chr14:103986227	CKB	0.27	5.37	0.32	1.81e-7	Body mass index;
KIRP	cis	rs2904967	0.759	rs625427	chr11:65003812	T/C	cg12562828	chr11:65076843	NA	-0.61	-8.96	-0.5	8.02e-17	Mean corpuscular volume;
KIRP	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	cg21523751	chr1:182988639	NA	0.42	6.57	0.39	2.98e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg15705551	chr2:10952987	PDIA6	0.57	6.57	0.39	2.91e-10	Cardiac Troponin-T levels;
KIRP	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg07930552	chr6:133119739	C6orf192	0.98	6.32	0.37	1.22e-9	Type 2 diabetes nephropathy;
KIRP	cis	rs42648	0.935	rs7803012	chr7:90026166	A/T	cg25739043	chr7:89950458	NA	0.45	6.97	0.41	2.86e-11	Homocysteine levels;
KIRP	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.59	8.12	0.46	2.23e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs698813	0.703	rs2053457	chr2:44572164	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.56	6.25	0.37	1.82e-9	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg20430773	chr1:16534157	ARHGEF19	-0.6	-7.41	-0.43	2.01e-12	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2230307	0.536	rs700533	chr1:100483822	A/G	cg24955406	chr1:100503596	HIAT1	0.69	7.87	0.45	1.13e-13	Carotid intima media thickness;
KIRP	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs34779708	0.931	rs4934704	chr10:35332164	C/T	cg04310649	chr10:35416472	CREM	-0.59	-7.19	-0.42	7.61e-12	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Tonsillectomy;
KIRP	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg07701084	chr6:150067640	NUP43	0.65	8.35	0.47	4.97e-15	Lung cancer;
KIRP	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.42	-8.78	-0.49	2.86e-16	Vitiligo;
KIRP	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.5	-5.54	-0.33	7.7e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg24253500	chr15:84953950	NA	0.51	5.86	0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs7215564	0.908	rs34950888	chr17:78661779	T/G	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs2019216	0.500	rs1356483	chr17:21934029	A/C	cg22648282	chr17:21454238	C17orf51	-0.49	-5.71	-0.34	3.17e-8	Pelvic organ prolapse;
KIRP	cis	rs6580649	0.941	rs57054831	chr12:48486892	C/T	cg26205652	chr12:48591994	NA	-0.5	-5.93	-0.35	1e-8	Lung cancer;
KIRP	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.21	-0.42	6.66e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.92	-0.3	1.58e-6	Life satisfaction;
KIRP	cis	rs6684428	0.656	rs10888945	chr1:56362002	C/T	cg11651538	chr1:56320950	NA	-0.62	-7.97	-0.45	6.03e-14	Airflow obstruction;
KIRP	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg25811766	chr13:21894605	NA	-0.62	-6.14	-0.36	3.21e-9	White matter hyperintensity burden;
KIRP	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12963246	chr6:28129442	ZNF389	0.49	6.06	0.36	4.98e-9	Depression;
KIRP	cis	rs9409154	0.528	rs7862745	chr9:118170889	G/A	cg13918206	chr9:118159781	DEC1	-0.39	-4.96	-0.3	1.32e-6	Visceral adipose tissue adjusted for BMI;
KIRP	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg12486944	chr17:80159399	CCDC57	0.38	5.05	0.31	8.43e-7	Life satisfaction;
KIRP	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.57	-7.11	-0.41	1.24e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.81	10.39	0.55	3.28e-21	Mean platelet volume;
KIRP	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs3774830	0.846	rs11732645	chr4:5454829	C/T	cg26943120	chr4:5472116	STK32B	0.27	6.47	0.38	5.38e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg25182066	chr10:30743637	MAP3K8	0.54	7.29	0.42	4.13e-12	Inflammatory bowel disease;
KIRP	cis	rs7536201	1.000	rs7523328	chr1:25294195	G/A	cg23273869	chr1:25296894	NA	-0.35	-4.86	-0.3	2.11e-6	Psoriasis vulgaris;
KIRP	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg10729496	chr3:10149963	C3orf24	0.55	4.95	0.3	1.36e-6	Alzheimer's disease;
KIRP	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-21.88	-0.81	1.23e-59	Myeloid white cell count;
KIRP	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.76	-8.09	-0.46	2.77e-14	Asthma;
KIRP	cis	rs8079658	0.762	rs2024272	chr17:63869115	C/T	cg18091269	chr17:63822838	CCDC46	0.36	5.18	0.31	4.53e-7	Post bronchodilator FEV1;
KIRP	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	0.96	14.58	0.68	4.01e-35	Eosinophil percentage of white cells;
KIRP	cis	rs887829	0.694	rs7583278	chr2:234617407	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.6	-7.83	-0.45	1.5e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg00129232	chr17:37814104	STARD3	0.66	8.46	0.47	2.46e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs7599312	0.586	rs7571561	chr2:213386267	T/C	cg20637307	chr2:213403960	ERBB4	0.43	4.99	0.3	1.12e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	0.77	6.87	0.4	5.09e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9972944	0.902	rs9972885	chr17:63771264	G/T	cg07283582	chr17:63770753	CCDC46	0.45	7.61	0.44	5.78e-13	Total body bone mineral density;
KIRP	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg00852783	chr1:26633632	UBXN11	-0.58	-5.88	-0.35	1.36e-8	Obesity-related traits;
KIRP	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.67	8.73	0.49	3.97e-16	Schizophrenia;
KIRP	cis	rs4865169	0.934	rs12650737	chr4:57892475	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-5.9	-0.35	1.22e-8	Breast cancer;
KIRP	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.61	8.57	0.48	1.16e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.75	9.89	0.53	1.22e-19	Morning vs. evening chronotype;
KIRP	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg15358701	chr1:161410459	NA	-0.68	-6.31	-0.37	1.32e-9	Rheumatoid arthritis;
KIRP	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg02811702	chr13:24901961	NA	0.43	5.46	0.33	1.15e-7	Obesity-related traits;
KIRP	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.73	9.21	0.51	1.49e-17	Aortic root size;
KIRP	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg06636001	chr8:8085503	FLJ10661	-0.66	-8.52	-0.48	1.65e-15	Neuroticism;
KIRP	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	4.94	0.3	1.48e-6	Longevity;
KIRP	cis	rs7712401	0.562	rs30073	chr5:122290509	A/T	cg19412675	chr5:122181750	SNX24	0.48	5.39	0.33	1.64e-7	Mean platelet volume;
KIRP	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.52	0.38	3.86e-10	Neuroticism;
KIRP	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma (childhood onset);
KIRP	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg27147174	chr7:100797783	AP1S1	-0.7	-9.17	-0.5	1.89e-17	Life satisfaction;
KIRP	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	1.01	14.17	0.67	1.03e-33	Response to antipsychotic treatment;
KIRP	cis	rs1497828	0.956	rs1497835	chr1:217562287	C/T	cg04411442	chr1:217543379	NA	0.42	6.39	0.38	8.4e-10	Dialysis-related mortality;
KIRP	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.52	6.96	0.41	3.16e-11	Breast cancer;
KIRP	cis	rs427941	0.632	rs201500	chr7:101757806	G/C	cg06246474	chr7:101738831	CUX1	0.56	6.88	0.4	4.96e-11	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs1209950	0.512	rs374575	chr21:40193914	C/T	cg02119577	chr21:40195074	ETS2	-0.38	-5.09	-0.31	7.23e-7	Non-small cell lung cancer (survival);
KIRP	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg05802129	chr4:122689817	NA	-0.46	-6.72	-0.39	1.25e-10	Type 2 diabetes;
KIRP	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.05e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.45e-8	Motion sickness;
KIRP	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23161317	chr6:28129485	ZNF389	-0.48	-5.58	-0.34	6.37e-8	Depression;
KIRP	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg26373071	chr5:1325741	CLPTM1L	0.55	7.09	0.41	1.37e-11	Lung cancer;
KIRP	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.71	9.31	0.51	7.4e-18	Morning vs. evening chronotype;
KIRP	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg01522456	chr1:115632236	TSPAN2	-0.42	-5.48	-0.33	1.05e-7	Autism;
KIRP	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.04	-0.36	5.75e-9	Ulcerative colitis;
KIRP	cis	rs12153243	0.714	rs1946237	chr5:142895450	A/T	cg13907255	chr5:142895549	NA	-0.39	-5.05	-0.31	8.69e-7	Migraine;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg23549367	chr3:189720477	LEPREL1	0.51	6.43	0.38	6.49e-10	Interleukin-4 levels;
KIRP	cis	rs6001982	0.665	rs6001920	chr22:40850066	T/C	cg07138101	chr22:40742427	ADSL	0.67	5.51	0.33	9.2e-8	Breast cancer;
KIRP	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg25797454	chr6:150327115	RAET1K	-0.35	-6.48	-0.38	5.02e-10	Alopecia areata;
KIRP	cis	rs7714584	0.793	rs11949375	chr5:150202980	T/C	cg22134413	chr5:150180641	NA	0.58	5.31	0.32	2.44e-7	Crohn's disease;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg09699651	chr6:150184138	LRP11	0.49	6.54	0.38	3.58e-10	Lung cancer;
KIRP	cis	rs151997	0.962	rs152687	chr5:50208563	A/G	cg06027927	chr5:50259733	NA	0.61	7.65	0.44	4.53e-13	Callous-unemotional behaviour;
KIRP	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg00204512	chr16:28754710	NA	0.43	5.29	0.32	2.7e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs2594989	0.831	rs9840982	chr3:11564940	C/A	cg01796438	chr3:11312864	ATG7	0.6	7.3	0.42	4.08e-12	Circulating chemerin levels;
KIRP	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg00319359	chr11:70116639	PPFIA1	0.58	5.95	0.35	9.19e-9	Coronary artery disease;
KIRP	cis	rs13385	0.769	rs11538394	chr5:139574050	G/A	cg01860693	chr5:139557145	C5orf32	0.49	4.99	0.3	1.17e-6	Atrial fibrillation;
KIRP	trans	rs76288851	0.733	rs73203604	chr3:126541652	C/T	cg13821433	chr2:26726535	OTOF	0.53	6.11	0.36	3.88e-9	Alcoholic chronic pancreatitis;
KIRP	cis	rs4262150	0.767	rs17550343	chr5:151945366	C/G	cg12297329	chr5:152029980	NA	-0.66	-8.06	-0.46	3.26e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.42	5.53	0.33	8.13e-8	Melanoma;
KIRP	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.62	7.12	0.41	1.16e-11	IgG glycosylation;
KIRP	trans	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg06521331	chr12:34319734	NA	0.51	6.28	0.37	1.5e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7551222	0.716	rs4245738	chr1:204506107	C/T	cg20240347	chr1:204465584	NA	-0.46	-8.79	-0.49	2.69e-16	Schizophrenia;
KIRP	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg06740227	chr12:86229804	RASSF9	0.47	5.73	0.34	2.96e-8	Major depressive disorder;
KIRP	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg10017260	chr10:834428	NA	-0.41	-5.86	-0.35	1.46e-8	Survival in rectal cancer;
KIRP	trans	rs35110281	0.755	rs8127297	chr21:45063847	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	7.13	0.41	1.09e-11	Mean corpuscular volume;
KIRP	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.8	10.31	0.55	6.12e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs244899	0.967	rs2432642	chr5:167921047	C/G	cg13011109	chr5:167955758	FBLL1	0.37	5.09	0.31	7.27e-7	Response to platinum-based chemotherapy (carboplatin);
KIRP	cis	rs909341	0.909	rs2253823	chr20:62372956	C/T	cg03999872	chr20:62272968	STMN3	-0.58	-6.55	-0.39	3.32e-10	Atopic dermatitis;
KIRP	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.77	-9.2	-0.51	1.54e-17	Corneal structure;
KIRP	cis	rs7709377	0.595	rs12109104	chr5:115615708	A/G	cg23108291	chr5:115420582	COMMD10	0.44	5.4	0.33	1.56e-7	Metabolite levels  (X-11787);
KIRP	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg15655495	chr12:38532458	NA	-0.29	-5.17	-0.31	4.89e-7	Bladder cancer;
KIRP	trans	rs1106684	1.000	rs1106684	chr7:131453665	C/G	cg13607082	chr12:122652224	LRRC43	0.65	6.85	0.4	5.91e-11	Body mass index;
KIRP	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg00012203	chr2:219082015	ARPC2	-0.41	-5.17	-0.31	4.89e-7	Ulcerative colitis;
KIRP	cis	rs8093481	1.000	rs11660953	chr18:10695561	C/T	cg21165219	chr18:10698044	FAM38B	0.42	5.21	0.32	4.05e-7	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.76	-11.06	-0.58	2.4e-23	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg18404041	chr3:52824283	ITIH1	-0.47	-5.79	-0.35	2.16e-8	Schizophrenia;
KIRP	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.95	14.46	0.68	1e-34	Triglycerides;
KIRP	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg04691961	chr3:161091175	C3orf57	-0.64	-9.57	-0.52	1.2e-18	Morning vs. evening chronotype;
KIRP	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.4	5.25	0.32	3.29e-7	Cardiovascular disease risk factors;
KIRP	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg17376030	chr22:41985996	PMM1	0.81	8.29	0.47	7.22e-15	Vitiligo;
KIRP	cis	rs867371	1.000	rs1501372	chr15:82468455	C/T	cg00614314	chr15:82944287	LOC80154	0.54	6.46	0.38	5.41e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-4.87	-0.3	1.96e-6	Skin colour saturation;
KIRP	cis	rs1559088	0.948	rs10408093	chr19:33597816	T/C	cg03563238	chr19:33554763	RHPN2	-0.32	-5.67	-0.34	3.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-8.27	-0.47	8.69e-15	Monocyte percentage of white cells;
KIRP	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.62	-7.71	-0.44	3.1e-13	Longevity;
KIRP	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg26531700	chr6:26746687	NA	0.38	5.16	0.31	4.99e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17416285	0.537	rs61772594	chr1:56983288	C/T	cg12180551	chr1:56975583	PPAP2B	0.46	4.99	0.3	1.14e-6	Coronary artery disease;
KIRP	cis	rs60311166	1.000	rs57319306	chr3:52575251	G/C	cg13174197	chr3:52720522	GNL3;PBRM1	0.9	5.55	0.33	7.28e-8	CTACK levels;
KIRP	cis	rs1829883	1.000	rs1403661	chr5:98777056	T/A	cg08333243	chr5:99726346	NA	-0.38	-5.04	-0.31	8.97e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-5.92	-0.35	1.1e-8	Obesity-related traits;
KIRP	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.73	-9.66	-0.52	6.42e-19	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg09264619	chr17:80180166	NA	-0.39	-5.64	-0.34	4.6e-8	Life satisfaction;
KIRP	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-0.94	-6.86	-0.4	5.67e-11	Mitochondrial DNA levels;
KIRP	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg24375607	chr4:120327624	NA	-0.48	-5.21	-0.32	3.95e-7	Corneal astigmatism;
KIRP	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg02297831	chr4:17616191	MED28	0.57	7.19	0.42	7.61e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.77	8.83	0.49	1.96e-16	Corneal astigmatism;
KIRP	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg08700190	chr5:6636046	SRD5A1	-0.48	-5.94	-0.35	9.51e-9	Response to amphetamines;
KIRP	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.48	6.67	0.39	1.64e-10	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-0.96	-11.67	-0.6	2.43e-25	Vitiligo;
KIRP	cis	rs77669868	0.810	rs686494	chr11:114070160	A/G	cg01914181	chr11:114070210	ZBTB16	-0.5	-5.1	-0.31	6.91e-7	Monocyte percentage of white cells;
KIRP	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.64	7.77	0.44	2.14e-13	Coronary artery disease;
KIRP	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.04	-17.04	-0.74	1.61e-43	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg01849466	chr14:104193079	ZFYVE21	-0.61	-8.04	-0.46	3.77e-14	Schizophrenia;
KIRP	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.55	7.18	0.42	8.35e-12	Mean corpuscular volume;
KIRP	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.62	6.89	0.4	4.52e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs2290402	0.536	rs4690339	chr4:854712	T/C	cg14517359	chr4:903473	GAK	-0.57	-6.22	-0.37	2.13e-9	Type 2 diabetes;
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.7	9.29	0.51	8.26e-18	Obesity-related traits;
KIRP	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg09873164	chr1:152488093	CRCT1	0.56	7.09	0.41	1.44e-11	Hair morphology;
KIRP	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg03563238	chr19:33554763	RHPN2	-0.33	-5.63	-0.34	4.87e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.33	5.67	0.34	4.07e-8	Height;
KIRP	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.94	12.02	0.61	1.79e-26	Breast cancer;
KIRP	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs7119167	0.686	rs7944099	chr11:73052311	A/G	cg17517138	chr11:73019481	ARHGEF17	0.49	5.17	0.31	4.78e-7	Blood protein levels;
KIRP	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg08283408	chr3:49949060	MON1A	-0.42	-5.45	-0.33	1.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs838147	0.537	rs603985	chr19:49207257	T/C	cg07051648	chr19:49177693	NTN5;SEC1	-0.45	-5.86	-0.35	1.49e-8	Dietary macronutrient intake;
KIRP	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.77	11.3	0.58	3.86e-24	Total body bone mineral density;
KIRP	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg02389323	chr16:88786976	FAM38A	0.78	6.72	0.39	1.25e-10	Plateletcrit;
KIRP	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17376030	chr22:41985996	PMM1	0.67	7.02	0.41	2.09e-11	Vitiligo;
KIRP	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.49	5.73	0.34	2.93e-8	Mean corpuscular hemoglobin;
KIRP	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg24611264	chr11:120008944	TRIM29	-0.28	-4.93	-0.3	1.5e-6	Stroke (pediatric);
KIRP	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.02	13.28	0.65	1.07e-30	Exhaled nitric oxide output;
KIRP	cis	rs2483058	0.531	rs17433769	chr1:206637799	C/G	cg19452316	chr1:206680966	RASSF5	-0.42	-5.31	-0.32	2.49e-7	Cholesterol and Triglycerides;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00993674	chr21:45661322	ICOSLG	0.56	6.92	0.4	3.99e-11	Smoking initiation;
KIRP	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.19	-15.89	-0.71	1.32e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	0.47	5.52	0.33	8.73e-8	Childhood ear infection;
KIRP	cis	rs8113308	0.810	rs7259622	chr19:52445737	C/T	cg24732339	chr19:52471368	ZNF350	-0.44	-4.92	-0.3	1.57e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-10.21	-0.55	1.23e-20	Total body bone mineral density;
KIRP	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg24747557	chr10:131355152	MGMT	-0.41	-5.4	-0.33	1.57e-7	Response to temozolomide;
KIRP	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-5.5	-0.33	9.36e-8	IgG glycosylation;
KIRP	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-19.75	-0.78	1.15e-52	Height;
KIRP	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-7.0	-0.41	2.48e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.58	-0.34	6.34e-8	Total body bone mineral density;
KIRP	cis	rs394563	0.967	rs444784	chr6:149798366	C/G	cg07828024	chr6:149772892	ZC3H12D	-0.29	-4.93	-0.3	1.5e-6	Dupuytren's disease;
KIRP	cis	rs7719624	0.756	rs13188659	chr5:135396468	T/A	cg16684184	chr5:135415129	NA	0.38	5.69	0.34	3.56e-8	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.59	7.36	0.42	2.79e-12	Tonsillectomy;
KIRP	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.49	-6.77	-0.4	9.2e-11	Birth weight;
KIRP	trans	rs7246760	1.000	rs12460571	chr19:9881746	C/A	cg02900749	chr2:68251473	NA	-1.05	-8.87	-0.49	1.51e-16	Pursuit maintenance gain;
KIRP	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg01428437	chr1:1852164	TMEM52	0.28	4.84	0.3	2.27e-6	Body mass index;
KIRP	cis	rs501120	0.584	rs906944	chr10:44705439	G/A	cg09554077	chr10:44749378	NA	0.63	6.95	0.41	3.31e-11	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.92	10.97	0.57	4.84e-23	Schizophrenia;
KIRP	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.64	7.12	0.41	1.2e-11	Smoking initiation;
KIRP	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.09	-0.36	4.35e-9	Morning vs. evening chronotype;
KIRP	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-9.2	-0.51	1.55e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.45	-9.08	-0.5	3.68e-17	Rheumatoid arthritis;
KIRP	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.7	8.1	0.46	2.61e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.7	8.84	0.49	1.91e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.46	5.57	0.33	6.83e-8	Longevity;Endometriosis;
KIRP	cis	rs17123764	0.786	rs58446833	chr12:50116733	T/C	cg20471783	chr12:50157085	TMBIM6	0.32	4.95	0.3	1.38e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs6893300	0.542	rs7736300	chr5:179196898	G/A	cg14593053	chr5:179126677	CANX	0.75	11.54	0.59	6.49e-25	Resting heart rate;
KIRP	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.71	8.6	0.48	9.24e-16	Type 2 diabetes;
KIRP	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg07689907	chr11:61582574	FADS1	0.49	6.07	0.36	4.74e-9	Trans fatty acid levels;
KIRP	cis	rs7808935	0.628	rs72598551	chr7:27939885	C/T	cg22168087	chr7:27702803	HIBADH	0.73	7.29	0.42	4.25e-12	Prostate cancer;
KIRP	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg17507749	chr15:85114479	UBE2QP1	0.82	9.21	0.51	1.51e-17	Schizophrenia;
KIRP	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.23	0.32	3.63e-7	Childhood ear infection;
KIRP	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg08885076	chr2:99613938	TSGA10	-0.45	-6.64	-0.39	1.94e-10	Fear of minor pain;
KIRP	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.58	-7.12	-0.41	1.17e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg22800045	chr5:56110881	MAP3K1	0.6	6.16	0.37	2.95e-9	Type 2 diabetes;
KIRP	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.75	10.09	0.54	2.96e-20	Morning vs. evening chronotype;
KIRP	cis	rs12580194	0.593	rs7489047	chr12:55759851	A/G	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.61	-9.46	-0.52	2.63e-18	Sense of smell;
KIRP	cis	rs8053891	0.615	rs34042070	chr16:72101525	C/G	cg01557791	chr16:72042693	DHODH	-0.55	-5.12	-0.31	6.19e-7	Coronary artery disease;
KIRP	cis	rs1010254	0.510	rs55689355	chr5:151756636	C/G	cg12297329	chr5:152029980	NA	-0.69	-6.79	-0.4	8.25e-11	Optic nerve measurement (cup area);
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.71	0.34	3.33e-8	Lung cancer;
KIRP	cis	rs16828019	0.852	rs12729448	chr1:41509834	G/A	cg18742814	chr1:41828276	NA	0.69	5.91	0.35	1.12e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7116495	0.609	rs7942626	chr11:71703849	G/A	cg26138937	chr11:71823887	C11orf51	-1.01	-6.94	-0.4	3.55e-11	Severe influenza A (H1N1) infection;
KIRP	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg12311346	chr5:56204834	C5orf35	-0.37	-5.18	-0.31	4.57e-7	Coronary artery disease;
KIRP	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	15.13	0.69	5.33e-37	Platelet count;
KIRP	cis	rs738322	0.719	rs34066050	chr22:38612604	G/A	cg25457927	chr22:38595422	NA	0.41	8.95	0.5	8.68e-17	Cutaneous nevi;
KIRP	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.45	-6.27	-0.37	1.63e-9	Schizophrenia;
KIRP	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-10.42	-0.55	2.75e-21	Response to antipsychotic treatment;
KIRP	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg20487152	chr13:99095054	FARP1	0.37	5.0	0.3	1.07e-6	Neuroticism;
KIRP	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg24631222	chr15:78858424	CHRNA5	-0.76	-9.13	-0.5	2.52e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg27205649	chr11:78285834	NARS2	-0.49	-5.36	-0.32	1.92e-7	Testicular germ cell tumor;
KIRP	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.47	7.16	0.42	9.4e-12	Resting heart rate;
KIRP	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02807482	chr3:125708958	NA	-0.55	-5.51	-0.33	8.82e-8	Blood pressure (smoking interaction);
KIRP	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.21	13.43	0.65	3.13e-31	Alzheimer's disease;
KIRP	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.82	-13.94	-0.66	6.2e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.36	4.97	0.3	1.28e-6	Coronary artery disease;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18367020	chr2:73461259	CCT7;C2orf7	0.44	6.35	0.38	1.06e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg15140703	chr7:99775532	STAG3;GPC2	0.36	4.94	0.3	1.46e-6	Coronary artery disease;
KIRP	cis	rs2067615	0.896	rs2589266	chr12:107255986	T/G	cg21360079	chr12:107162445	NA	-0.43	-5.34	-0.32	2.14e-7	Heart rate;
KIRP	cis	rs2278796	0.639	rs11240330	chr1:204968258	C/A	cg04862289	chr1:204966208	NFASC	0.68	9.61	0.52	8.84e-19	Mean platelet volume;
KIRP	cis	rs10211205	1.000	rs10190985	chr2:236611155	C/G	cg13770573	chr2:236586376	AGAP1	-0.55	-5.97	-0.36	8.35e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02725872	chr8:58115012	NA	-0.7	-6.93	-0.4	3.61e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs4728302	0.838	rs10225454	chr7:133591535	G/C	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.59	-8.08	-0.46	2.87e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.83	8.94	0.5	9.28e-17	Bronchopulmonary dysplasia;
KIRP	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23903597	chr17:61704154	MAP3K3	-0.66	-8.76	-0.49	3.24e-16	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg10932868	chr11:921992	NA	0.65	8.77	0.49	3.03e-16	Alzheimer's disease (late onset);
KIRP	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg20387954	chr3:183756860	HTR3D	0.62	9.06	0.5	4.19e-17	Anterior chamber depth;
KIRP	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg26207909	chr14:103986467	CKB	-0.47	-5.98	-0.36	7.64e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.35	-5.03	-0.31	9.31e-7	Monocyte count;
KIRP	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg00405596	chr8:11794950	NA	-0.49	-6.52	-0.38	3.88e-10	Retinal vascular caliber;
KIRP	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg27147174	chr7:100797783	AP1S1	0.62	7.73	0.44	2.8e-13	Life satisfaction;
KIRP	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg01657329	chr11:68192670	LRP5	-0.51	-5.53	-0.33	8.3e-8	Total body bone mineral density;
KIRP	cis	rs11225247	1.000	rs12269847	chr11:102269743	G/C	cg06323957	chr11:102217781	BIRC2	0.98	6.08	0.36	4.57e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg01338139	chr15:38987640	C15orf53	-0.52	-5.73	-0.34	2.99e-8	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
KIRP	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg02297831	chr4:17616191	MED28	0.6	7.69	0.44	3.61e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.57	-6.07	-0.36	4.85e-9	Ulcerative colitis;
KIRP	cis	rs368755101	1	rs368755101	chr2:100762215	AG/A	cg07810366	chr2:100720526	AFF3	-0.32	-5.2	-0.31	4.23e-7	Plateletcrit;Red blood cell count;
KIRP	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.77	12.11	0.61	8.41e-27	Intelligence (multi-trait analysis);
KIRP	cis	rs6466055	0.516	rs7784126	chr7:104731338	T/A	cg04380332	chr7:105027541	SRPK2	-0.4	-5.48	-0.33	1.03e-7	Schizophrenia;
KIRP	cis	rs12976411	0.575	rs34398998	chr19:32820820	C/A	cg02282382	chr19:32836354	ZNF507	0.62	5.17	0.31	4.93e-7	Coronary artery disease;
KIRP	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg05220968	chr6:146057943	EPM2A	-0.38	-5.19	-0.31	4.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09930748	chr19:36359327	APLP1	-0.45	-6.3	-0.37	1.37e-9	Metabolic traits;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg09666561	chr16:30406910	ZNF48	-0.46	-6.09	-0.36	4.35e-9	Myopia;
KIRP	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.23	-0.55	1.04e-20	Hemoglobin concentration;
KIRP	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17408935	chr17:35843206	NA	0.5	6.15	0.37	3.06e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg12486944	chr17:80159399	CCDC57	0.4	5.34	0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs734999	0.588	rs6701238	chr1:2520500	G/A	cg20673091	chr1:2541236	MMEL1	0.79	12.45	0.62	6.25e-28	Ulcerative colitis;
KIRP	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg03713592	chr11:72463424	ARAP1	0.58	6.34	0.37	1.07e-9	Type 2 diabetes;
KIRP	cis	rs7714584	1.000	rs12054923	chr5:150249059	A/G	cg22134413	chr5:150180641	NA	0.74	6.56	0.39	3.22e-10	Crohn's disease;
KIRP	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg26513180	chr16:89883248	FANCA	0.75	5.37	0.32	1.83e-7	Skin colour saturation;
KIRP	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-7.14	-0.41	1.07e-11	Retinal vascular caliber;
KIRP	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.06e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17691542	chr6:26056736	HIST1H1C	0.83	8.31	0.47	6.34e-15	Iron status biomarkers;
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg04733989	chr22:42467013	NAGA	0.46	5.75	0.34	2.65e-8	Cognitive function;
KIRP	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg26695010	chr11:65641043	EFEMP2	-0.41	-5.13	-0.31	5.95e-7	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg07636037	chr3:49044803	WDR6	0.5	5.65	0.34	4.53e-8	Resting heart rate;
KIRP	cis	rs6499755	1.000	rs6499755	chr16:55341135	T/C	cg05099576	chr16:55362342	IRX6	0.28	5.84	0.35	1.66e-8	Hypospadias;
KIRP	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.61	10.61	0.56	6.74e-22	Lung cancer;
KIRP	cis	rs861020	0.527	rs614662	chr1:209962419	C/T	cg09163369	chr1:210001066	C1orf107	0.41	5.3	0.32	2.54e-7	Orofacial clefts;
KIRP	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg25173405	chr17:45401733	C17orf57	0.42	5.39	0.32	1.66e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg01770232	chr7:22766155	IL6	0.94	7.03	0.41	1.98e-11	Tonsillectomy;
KIRP	cis	rs4728302	0.838	rs6954700	chr7:133588739	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.74e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg02319466	chr17:76381040	PGS1	0.45	6.26	0.37	1.69e-9	HDL cholesterol levels;
KIRP	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.64	-7.25	-0.42	5.38e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	trans	rs12043259	0.892	rs12405298	chr1:204821552	T/C	cg11485465	chr5:54518469	NA	0.38	6.17	0.37	2.85e-9	Addiction;
KIRP	cis	rs12311304	1.000	rs56232194	chr12:15383683	G/C	cg08258403	chr12:15378311	NA	0.38	5.64	0.34	4.6e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.63	7.15	0.41	9.68e-12	Obesity-related traits;
KIRP	cis	rs9304742	0.821	rs2011496	chr19:53455877	C/T	cg09915433	chr19:53449742	NA	-0.39	-5.44	-0.33	1.28e-7	Psoriasis;
KIRP	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.8	-13.05	-0.64	6.42e-30	Prostate cancer;
KIRP	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg23307798	chr14:103986281	CKB	-0.44	-5.96	-0.36	8.61e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg05315796	chr3:52349193	DNAH1	0.44	6.62	0.39	2.3e-10	Bipolar disorder;
KIRP	cis	rs9815354	0.812	rs73071315	chr3:41805887	T/C	cg03022575	chr3:42003672	ULK4	0.82	8.35	0.47	4.88e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs4566357	0.930	rs12621916	chr2:227923564	T/C	cg11843606	chr2:227700838	RHBDD1	-0.41	-5.07	-0.31	7.96e-7	Coronary artery disease;
KIRP	cis	rs4478037	1.000	rs58995409	chr3:33161404	T/C	cg19404215	chr3:33155277	CRTAP	0.71	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg18914023	chr14:74868443	NA	0.5	6.68	0.39	1.56e-10	Smoking initiation;
KIRP	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg01200585	chr1:228362443	C1orf69	0.41	5.13	0.31	5.97e-7	Diastolic blood pressure;
KIRP	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg03929089	chr4:120376271	NA	0.56	6.75	0.4	1.03e-10	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg18306943	chr3:40428807	ENTPD3	0.44	5.77	0.35	2.41e-8	Renal cell carcinoma;
KIRP	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.39	5.07	0.31	7.87e-7	Systemic lupus erythematosus;
KIRP	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg05669848	chr5:237993	SDHA	-0.48	-4.97	-0.3	1.27e-6	Breast cancer;
KIRP	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11987759	chr7:65425863	GUSB	-0.61	-8.15	-0.46	1.86e-14	Aortic root size;
KIRP	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.97	0.54	6.78e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.51	6.24	0.37	1.88e-9	Urinary tract infection frequency;
KIRP	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.66	8.76	0.49	3.27e-16	Eosinophil percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22762745	chr3:195602360	TNK2	-0.51	-6.69	-0.39	1.5e-10	Parkinson's disease;
KIRP	cis	rs12580194	0.593	rs11171416	chr12:55731490	A/G	cg19537932	chr12:55886519	OR6C68	-0.48	-6.38	-0.38	8.78e-10	Cancer;
KIRP	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.83	9.75	0.53	3.24e-19	Corneal astigmatism;
KIRP	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg26338869	chr17:61819248	STRADA	0.54	6.31	0.37	1.29e-9	Prudent dietary pattern;
KIRP	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.23	0.64	1.57e-30	Eye color traits;
KIRP	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-9.04	-0.5	4.66e-17	Total cholesterol levels;
KIRP	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg04727924	chr7:799746	HEATR2	-0.64	-6.51	-0.38	4.25e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg09555818	chr19:45449301	APOC2	0.41	5.33	0.32	2.25e-7	Blood protein levels;
KIRP	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-5.18	-0.31	4.63e-7	Educational attainment (years of education);
KIRP	cis	rs501120	0.584	rs11238891	chr10:44670992	A/C	cg09554077	chr10:44749378	NA	-0.58	-6.17	-0.37	2.84e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg09788416	chr12:39539408	NA	0.39	5.19	0.31	4.37e-7	Morning vs. evening chronotype;
KIRP	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.35	4.9	0.3	1.7e-6	Coronary artery disease;
KIRP	cis	rs490234	0.775	rs12341245	chr9:128340941	C/T	cg14078157	chr9:128172775	NA	-0.54	-6.38	-0.38	8.61e-10	Mean arterial pressure;
KIRP	cis	rs9309473	1.000	rs10184268	chr2:73627044	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-5.45	-0.33	1.23e-7	Metabolite levels;
KIRP	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	6.45	0.38	5.92e-10	Personality dimensions;
KIRP	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.63	6.44	0.38	6.4e-10	Lung function (FEV1/FVC);
KIRP	cis	rs35883536	0.584	rs56112014	chr1:101037431	A/G	cg06223162	chr1:101003688	GPR88	-0.41	-8.02	-0.46	4.44e-14	Monocyte count;
KIRP	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.54	14.07	0.67	2.13e-33	Airflow obstruction;
KIRP	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10813240	chr12:124422061	CCDC92	0.51	6.4	0.38	7.64e-10	Interleukin-4 levels;
KIRP	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.69	-12.42	-0.62	8.19e-28	White blood cell count (basophil);
KIRP	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	10.79	0.57	1.72e-22	Total body bone mineral density;
KIRP	trans	rs7939886	0.920	rs11231794	chr11:55765776	T/C	cg03929089	chr4:120376271	NA	0.97	6.95	0.41	3.17e-11	Myopia (pathological);
KIRP	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg11833968	chr6:79620685	NA	-0.45	-6.82	-0.4	7.14e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs6800768	0.633	rs6769284	chr3:24148448	T/G	cg10674438	chr3:24145617	LOC152024	-0.52	-6.88	-0.4	4.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4523957	0.859	rs9891227	chr17:2164311	G/A	cg16513277	chr17:2031491	SMG6	-0.58	-8.01	-0.45	4.57e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.83	11.49	0.59	9.86e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7116495	1.000	rs541022	chr11:71783056	G/A	cg26138937	chr11:71823887	C11orf51	-0.64	-5.18	-0.31	4.64e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs963731	0.649	rs79361942	chr2:39336315	G/A	cg04010122	chr2:39346883	SOS1	0.93	6.39	0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.23	0.46	1.07e-14	Aortic root size;
KIRP	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.81	8.01	0.45	4.47e-14	Inflammatory bowel disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg02585790	chr2:232329254	NCL	-0.44	-6.06	-0.36	5.06e-9	Metabolic traits;
KIRP	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.78	-10.12	-0.54	2.38e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs1712517	0.904	rs10883863	chr10:105161879	G/A	cg05636881	chr10:105038444	INA	-0.4	-5.61	-0.34	5.31e-8	Migraine;
KIRP	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg02462569	chr6:150064036	NUP43	-0.33	-4.97	-0.3	1.28e-6	Lung cancer;
KIRP	cis	rs526231	0.543	rs34787	chr5:102458903	G/C	cg23492399	chr5:102201601	PAM	-0.48	-5.34	-0.32	2.09e-7	Primary biliary cholangitis;
KIRP	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg01689657	chr7:91764605	CYP51A1	-0.4	-5.74	-0.34	2.79e-8	Breast cancer;
KIRP	cis	rs267939	0.501	rs267958	chr5:10737997	A/G	cg14521931	chr5:10832172	NA	-0.54	-7.16	-0.42	9.03e-12	Gut microbiota (functional units);Ulcerative colitis;
KIRP	cis	rs1846974	1	rs1846974	chr5:87969927	G/A	cg24804195	chr5:87968844	LOC645323	0.54	5.29	0.32	2.65e-7	Body mass index;
KIRP	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg11707556	chr5:10655725	ANKRD33B	0.58	7.21	0.42	6.91e-12	Coronary artery disease;
KIRP	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.78	6.51	0.38	4.31e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.41	-0.47	3.36e-15	Inflammatory bowel disease;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06925236	chr11:68039653	C11orf24	0.74	7.1	0.41	1.35e-11	Lung function (FEV1);
KIRP	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.59	5.06	0.31	8.35e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs17057718	1.000	rs1386832	chr3:57152006	A/G	cg25799109	chr3:57102900	ARHGEF3;SPATA12	-0.38	-4.99	-0.3	1.15e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg07952391	chr2:88470173	THNSL2	0.9	6.95	0.41	3.21e-11	Plasma clusterin levels;
KIRP	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19741408	chr1:90460434	ZNF326;LOC492303	0.73	6.94	0.4	3.52e-11	Lung function (FEV1);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24992690	chr2:160472234	BAZ2B	-0.48	-6.03	-0.36	6.07e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.65	8.42	0.47	3.17e-15	Prudent dietary pattern;
KIRP	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.62	0.48	8.33e-16	Morning vs. evening chronotype;
KIRP	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	0.68	6.02	0.36	6.37e-9	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21214630	chr9:127631857	ARPC5L	0.51	6.66	0.39	1.76e-10	Parkinson's disease;
KIRP	cis	rs904251	0.525	rs12200378	chr6:37425304	A/G	cg11522683	chr6:37501428	NA	-0.36	-4.85	-0.3	2.18e-6	Cognitive performance;
KIRP	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg14345882	chr6:26364793	BTN3A2	0.55	5.09	0.31	7.27e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg10818794	chr15:86012489	AKAP13	-0.5	-7.12	-0.41	1.19e-11	Coronary artery disease;
KIRP	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg03060546	chr3:49711283	APEH	0.43	5.57	0.33	6.71e-8	Parkinson's disease;
KIRP	cis	rs11264213	0.901	rs2791962	chr1:36371168	T/C	cg27506609	chr1:36549197	TEKT2	0.97	10.12	0.54	2.45e-20	Schizophrenia;
KIRP	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg20295408	chr7:1910781	MAD1L1	-0.51	-5.37	-0.32	1.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs860295	0.702	rs10908472	chr1:155544256	T/C	cg02153340	chr1:155202674	NA	-0.55	-7.41	-0.43	1.97e-12	Body mass index;
KIRP	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.62	6.86	0.4	5.5e-11	Aortic root size;
KIRP	cis	rs12210905	1.000	rs12205628	chr6:27225959	C/A	cg11502198	chr6:26597334	ABT1	-0.84	-5.17	-0.31	4.89e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg17182837	chr8:41585554	ANK1	-0.45	-6.32	-0.37	1.25e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
KIRP	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg02297831	chr4:17616191	MED28	0.52	6.58	0.39	2.87e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.58	-4.95	-0.3	1.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.39	-0.72	2.71e-41	Height;
KIRP	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg01475377	chr6:109611718	NA	-0.38	-5.16	-0.31	5.21e-7	Reticulocyte fraction of red cells;
KIRP	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.75	7.65	0.44	4.46e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.47	-6.66	-0.39	1.82e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.58	7.27	0.42	4.71e-12	Arsenic metabolism;
KIRP	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.48	6.84	0.4	6.41e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg20465933	chr4:152376761	FAM160A1	0.46	5.86	0.35	1.51e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.64	-7.48	-0.43	1.31e-12	Height;
KIRP	cis	rs77956314	0.818	rs12296869	chr12:117431203	G/A	cg02017074	chr12:117425053	FBXW8	-0.86	-6.79	-0.4	8.41e-11	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.79	-9.74	-0.53	3.66e-19	Iron status biomarkers;
KIRP	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13606994	chr1:44402422	ARTN	-0.29	-5.46	-0.33	1.17e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01391022	chr12:122360665	WDR66	-0.4	-6.17	-0.37	2.84e-9	Mean corpuscular volume;
KIRP	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.89	13.57	0.65	1.08e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs2882667	0.898	rs12719519	chr5:138375687	G/A	cg04439458	chr5:138467593	SIL1	-0.44	-7.46	-0.43	1.46e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-1.08	-22.45	-0.82	1.69e-61	Height;
KIRP	cis	rs10518128	1.000	rs72867592	chr4:75706767	C/T	cg20122727	chr4:75719957	BTC	0.58	5.84	0.35	1.65e-8	Electroencephalogram traits;
KIRP	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.86	11.5	0.59	8.78e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.47	-5.36	-0.32	1.94e-7	Neuroticism;
KIRP	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.55	-7.08	-0.41	1.47e-11	Joint mobility (Beighton score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13490827	chr1:46269305	MAST2	0.53	6.75	0.4	1.05e-10	Parkinson's disease;
KIRP	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg00677455	chr12:58241039	CTDSP2	0.99	12.95	0.64	1.35e-29	Multiple sclerosis;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg26496372	chr5:37379396	WDR70	0.51	6.41	0.38	7.45e-10	Asthma;
KIRP	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.48	6.18	0.37	2.58e-9	Systolic blood pressure;
KIRP	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg22633769	chr20:60982531	CABLES2	-0.51	-6.58	-0.39	2.82e-10	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg23601095	chr6:26197514	HIST1H3D	0.92	7.55	0.43	8.37e-13	Gout;Renal underexcretion gout;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26291519	chr15:76640005	NA	0.43	6.55	0.39	3.26e-10	Survival in pancreatic cancer;
KIRP	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg22356347	chr1:167427500	CD247	-0.46	-6.17	-0.37	2.75e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	5.58	0.34	6.32e-8	Menopause (age at onset);
KIRP	cis	rs1669338	0.588	rs62228634	chr3:3184985	A/G	cg16797762	chr3:3221439	CRBN	-0.6	-6.14	-0.36	3.21e-9	White matter integrity;
KIRP	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg10932868	chr11:921992	NA	0.63	8.41	0.47	3.42e-15	Alzheimer's disease (late onset);
KIRP	cis	rs7178909	0.902	rs2043881	chr15:90439960	G/A	cg19708238	chr15:90437601	AP3S2	0.6	8.27	0.47	8.64e-15	Common traits (Other);
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02969716	chr4:65755046	NA	-0.38	-6.25	-0.37	1.82e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.4	-6.3	-0.37	1.4e-9	PR interval;
KIRP	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg23625390	chr15:77176239	SCAPER	0.55	7.39	0.43	2.23e-12	Blood metabolite levels;
KIRP	cis	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg26585981	chr11:48327164	OR4S1	-0.4	-4.86	-0.3	2.1e-6	HDL cholesterol;
KIRP	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg13798912	chr7:905769	UNC84A	0.53	5.39	0.33	1.64e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.51	-6.77	-0.4	9.33e-11	Immature fraction of reticulocytes;
KIRP	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg17279839	chr7:150038598	RARRES2	0.46	6.4	0.38	8.01e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg03342759	chr3:160939853	NMD3	-0.6	-7.96	-0.45	6.15e-14	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg05861140	chr6:150128134	PCMT1	-0.54	-7.76	-0.44	2.31e-13	Lung cancer;
KIRP	cis	rs3849570	0.695	rs6809528	chr3:81872048	A/C	cg07356753	chr3:81810745	GBE1	-0.5	-6.57	-0.39	2.97e-10	Waist circumference;Body mass index;
KIRP	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.7	0.49	4.84e-16	Life satisfaction;
KIRP	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-4.99	-0.3	1.13e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.38	-4.85	-0.3	2.21e-6	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14240646	chr10:27532245	ACBD5	-0.51	-5.54	-0.33	7.81e-8	Breast cancer;
KIRP	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg20194872	chr6:41519635	FOXP4	0.57	7.34	0.42	3.16e-12	Prostate cancer;
KIRP	cis	rs4356932	0.691	rs4282209	chr4:76919536	A/G	cg00809888	chr4:76862425	NAAA	0.49	6.94	0.4	3.44e-11	Blood protein levels;
KIRP	cis	rs2904967	0.526	rs171193	chr11:64982599	A/G	cg12562828	chr11:65076843	NA	-0.36	-5.34	-0.32	2.15e-7	Mean corpuscular volume;
KIRP	cis	rs17221829	0.733	rs117029483	chr11:89365918	C/T	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg20243544	chr17:37824526	PNMT	0.45	6.19	0.37	2.45e-9	Asthma;
KIRP	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12292205	chr6:26970375	C6orf41	-0.65	-7.27	-0.42	4.63e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg13606994	chr1:44402422	ARTN	-0.27	-5.46	-0.33	1.15e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs16958440	1.000	rs62096476	chr18:44658621	T/C	cg17192377	chr18:44677553	HDHD2	0.73	6.62	0.39	2.29e-10	Sitting height ratio;
KIRP	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.8	9.3	0.51	7.88e-18	Post bronchodilator FEV1;
KIRP	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg21108841	chr4:24914750	CCDC149	0.46	5.74	0.34	2.79e-8	Heschl's gyrus morphology;
KIRP	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.46	6.38	0.38	8.85e-10	Sitting height ratio;
KIRP	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-6.67	-0.39	1.64e-10	Schizophrenia;
KIRP	cis	rs9398803	0.687	rs4243491	chr6:126938536	T/C	cg19875578	chr6:126661172	C6orf173	0.42	5.36	0.32	1.94e-7	Male-pattern baldness;
KIRP	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.34	-0.37	1.1e-9	Alcohol dependence;
KIRP	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs743757	0.697	rs763030	chr3:50528092	G/C	cg08207895	chr3:50388901	TUSC4;CYB561D2	0.44	4.87	0.3	1.96e-6	Diastolic blood pressure;
KIRP	cis	rs12496230	0.794	rs6549423	chr3:66866672	G/A	cg04995300	chr3:66848608	NA	0.43	6.5	0.38	4.44e-10	Type 2 diabetes;
KIRP	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.32e-12	Major depressive disorder;
KIRP	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.54	8.57	0.48	1.17e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.61	-7.62	-0.44	5.64e-13	Coronary artery disease;
KIRP	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.43	5.5	0.33	9.68e-8	Aortic root size;
KIRP	cis	rs16828019	0.852	rs2300649	chr1:41569203	T/C	cg03387723	chr1:41708464	SCMH1	-0.76	-6.7	-0.39	1.41e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs7577696	0.568	rs177082	chr2:32438350	A/T	cg02381751	chr2:32503542	YIPF4	0.62	6.05	0.36	5.4e-9	Inflammatory biomarkers;
KIRP	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.44	5.57	0.33	6.56e-8	Gout;
KIRP	trans	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg16141378	chr3:129829833	LOC729375	0.49	6.7	0.39	1.38e-10	Mood instability;
KIRP	cis	rs698833	0.892	rs786418	chr2:44688413	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.57	0.33	6.64e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg21926883	chr2:100939477	LONRF2	-0.52	-6.95	-0.41	3.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4654899	0.865	rs12123300	chr1:21323568	T/C	cg05370193	chr1:21551575	ECE1	0.48	5.96	0.36	8.64e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.56	6.67	0.39	1.69e-10	Menopause (age at onset);
KIRP	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg04733989	chr22:42467013	NAGA	0.55	7.49	0.43	1.25e-12	Cognitive function;
KIRP	cis	rs11825064	0.562	rs77914414	chr11:134513571	G/A	cg06603561	chr11:134479413	NA	-0.97	-7.06	-0.41	1.74e-11	Seasonality;
KIRP	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-0.53	-7.49	-0.43	1.23e-12	Coronary artery disease;
KIRP	cis	rs2625529	0.526	rs11634622	chr15:72562327	G/A	cg16672083	chr15:72433130	SENP8	0.39	5.49	0.33	1.01e-7	Red blood cell count;
KIRP	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	5.78	0.35	2.26e-8	Height;
KIRP	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.87	-0.4	5.28e-11	Aortic root size;
KIRP	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg21858823	chr1:15850916	CASP9	0.54	5.81	0.35	1.92e-8	Systolic blood pressure;
KIRP	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-14.83	-0.69	5.8e-36	Coronary artery disease;
KIRP	cis	rs6832769	0.857	rs61072181	chr4:56483377	C/G	cg09317128	chr4:56265301	TMEM165	-0.44	-5.41	-0.33	1.47e-7	Personality dimensions;
KIRP	cis	rs4774830	0.744	rs62046389	chr15:56307688	T/G	cg24530489	chr15:56299380	NA	-0.81	-5.48	-0.33	1.03e-7	Delta-5 desaturase activity;
KIRP	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg21775007	chr8:11205619	TDH	0.5	6.81	0.4	7.37e-11	Mood instability;
KIRP	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-7.08	-0.41	1.47e-11	Retinal vascular caliber;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03073431	chr7:44887862	H2AFV	0.47	6.43	0.38	6.65e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7714584	0.793	rs12653039	chr5:150252631	G/A	cg22134413	chr5:150180641	NA	0.75	6.0	0.36	6.93e-9	Crohn's disease;
KIRP	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.53	-6.42	-0.38	6.94e-10	Metabolite levels;
KIRP	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.68	-8.39	-0.47	3.9e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg04778012	chr7:99775508	STAG3;GPC2	0.4	5.41	0.33	1.53e-7	Coronary artery disease;
KIRP	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.69	8.33	0.47	5.59e-15	Neutrophil percentage of white cells;
KIRP	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.82	10.11	0.54	2.48e-20	Corneal astigmatism;
KIRP	cis	rs6449957	0.966	rs73126520	chr5:67475425	C/T	cg09038926	chr5:67483109	NA	-0.41	-5.36	-0.32	1.91e-7	Cleft lip with or without cleft palate;
KIRP	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg24296786	chr1:45957014	TESK2	0.51	5.69	0.34	3.65e-8	Homocysteine levels;
KIRP	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg23188430	chr6:125850052	NA	-0.33	-5.09	-0.31	6.95e-7	Brugada syndrome;
KIRP	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg01877450	chr7:97915802	BRI3	0.53	6.98	0.41	2.7e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.38	-5.03	-0.31	9.49e-7	Total body bone mineral density;
KIRP	cis	rs829661	0.532	rs11127276	chr2:30794215	C/T	cg10949345	chr2:30726833	LCLAT1	0.43	6.17	0.37	2.86e-9	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs554111	0.634	rs7551785	chr1:21524297	C/G	cg08890418	chr1:21044141	KIF17	0.45	6.73	0.39	1.2e-10	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	6.79	0.4	8.3e-11	Rheumatoid arthritis;
KIRP	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg00405596	chr8:11794950	NA	0.57	7.87	0.45	1.15e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.56	6.75	0.4	1.05e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3105593	0.933	rs7176874	chr15:50829980	T/C	cg08437265	chr15:50716283	USP8	0.4	5.32	0.32	2.29e-7	QT interval;
KIRP	cis	rs7116495	1.000	rs73543609	chr11:71816619	G/T	cg18441811	chr11:71824068	C11orf51	0.6	4.87	0.3	2.01e-6	Severe influenza A (H1N1) infection;
KIRP	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg16141378	chr3:129829833	LOC729375	-0.58	-7.02	-0.41	2.12e-11	Mood instability;
KIRP	cis	rs7180079	0.620	rs12442852	chr15:64677413	A/G	cg15337035	chr15:64978493	NA	0.5	5.43	0.33	1.34e-7	Monocyte count;
KIRP	cis	rs2387326	0.672	rs10829344	chr10:129944569	A/C	cg16087940	chr10:129947807	NA	-0.36	-5.0	-0.3	1.08e-6	Select biomarker traits;
KIRP	cis	rs2219968	0.962	rs7828745	chr8:78947372	G/A	cg00738934	chr8:78996279	NA	0.4	5.18	0.31	4.65e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg05791153	chr7:19748676	TWISTNB	-0.66	-6.22	-0.37	2.17e-9	Thyroid stimulating hormone;
KIRP	trans	rs193541	0.621	rs898391	chr5:122082166	T/C	cg05232207	chr8:969542	NA	-0.55	-6.11	-0.36	3.97e-9	Glucose homeostasis traits;
KIRP	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg27411982	chr8:10470053	RP1L1	0.42	5.15	0.31	5.26e-7	Retinal vascular caliber;
KIRP	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.28	-0.32	2.85e-7	Life satisfaction;
KIRP	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.46	-5.65	-0.34	4.43e-8	Longevity;Endometriosis;
KIRP	cis	rs1978968	0.956	rs7291155	chr22:18444599	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.93	-0.4	3.74e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-6.32	-0.37	1.19e-9	Lung cancer;
KIRP	cis	rs9962915	0.967	rs1785410	chr18:5594917	C/T	cg12967001	chr18:5544089	EPB41L3	-0.4	-4.93	-0.3	1.55e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.63	9.36	0.51	5.24e-18	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.37	7.41	0.43	2.07e-12	Diastolic blood pressure;
KIRP	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg15038512	chr6:170123185	PHF10	0.47	5.3	0.32	2.52e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13181604	chr14:24701136	NEDD8;GMPR2	0.54	6.77	0.4	9.44e-11	Parkinson's disease;
KIRP	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg24315340	chr6:146058215	EPM2A	0.43	5.38	0.32	1.75e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.22	15.39	0.7	6.8e-38	Alzheimer's disease;
KIRP	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg17863274	chr19:49399704	TULP2	-0.41	-5.84	-0.35	1.61e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg20243544	chr17:37824526	PNMT	0.43	4.94	0.3	1.44e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg13731523	chr4:3047190	NA	-0.35	-6.2	-0.37	2.37e-9	Serum sulfate level;
KIRP	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.68	9.74	0.53	3.63e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs4356932	0.935	rs115936805	chr4:76968068	C/T	cg19388996	chr4:76862389	NAAA	0.39	4.95	0.3	1.38e-6	Blood protein levels;
KIRP	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg18586891	chr4:952366	TMEM175	0.62	5.11	0.31	6.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg13482628	chr17:19912719	NA	0.53	6.84	0.4	6.26e-11	Schizophrenia;
KIRP	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg03342759	chr3:160939853	NMD3	-0.49	-6.36	-0.38	9.92e-10	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg09455208	chr3:40491958	NA	0.34	5.93	0.35	9.94e-9	Renal cell carcinoma;
KIRP	cis	rs45544231	0.569	rs1362546	chr16:52549935	C/T	cg09051775	chr16:52580266	TOX3	-0.38	-5.21	-0.32	4.07e-7	Restless legs syndrome;
KIRP	cis	rs17209837	0.920	rs4148817	chr7:87087397	C/G	cg00919237	chr7:87102261	ABCB4	-0.8	-8.75	-0.49	3.51e-16	Gallbladder cancer;
KIRP	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg12861170	chr19:19639553	YJEFN3	-0.47	-5.31	-0.32	2.43e-7	Bipolar disorder;
KIRP	cis	rs1511802	0.501	rs7683132	chr4:187116039	A/G	cg24794857	chr4:187113578	CYP4V2	0.38	5.35	0.32	2.04e-7	Blood protein levels;
KIRP	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17286258	chr2:198299746	SF3B1	-0.54	-6.28	-0.37	1.56e-9	Interleukin-4 levels;
KIRP	cis	rs12230513	0.732	rs7294659	chr12:55866519	T/C	cg19537932	chr12:55886519	OR6C68	-0.59	-7.2	-0.42	7.1e-12	Contrast sensitivity;
KIRP	cis	rs2669010	1.000	rs2632233	chr12:76992831	G/A	cg14998926	chr12:77026162	NA	-0.44	-5.78	-0.35	2.21e-8	Systemic lupus erythematosus;
KIRP	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.52	-6.51	-0.38	4.28e-10	Alzheimer's disease (late onset);
KIRP	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.79	-8.69	-0.48	5.01e-16	Coronary artery disease;
KIRP	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.76	0.81	2.97e-59	Prudent dietary pattern;
KIRP	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	1.01	17.52	0.75	3.77e-45	Systemic lupus erythematosus;
KIRP	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	8.01	0.45	4.59e-14	Coffee consumption (cups per day);
KIRP	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.79	13.14	0.64	3.14e-30	Calcium levels;
KIRP	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg21775007	chr8:11205619	TDH	0.69	9.67	0.52	5.84e-19	Retinal vascular caliber;
KIRP	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.81	-11.52	-0.59	7.88e-25	Dental caries;
KIRP	cis	rs3818717	0.539	rs12950737	chr17:17678573	G/A	cg04398451	chr17:18023971	MYO15A	0.46	5.76	0.34	2.55e-8	Lymphocyte counts;
KIRP	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.65	9.29	0.51	8.74e-18	Retinal vascular caliber;
KIRP	cis	rs11910985	0.546	rs113970410	chr21:48080896	C/G	cg17243659	chr21:48055224	PRMT2	1.37	8.45	0.47	2.6e-15	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.78	10.16	0.54	1.79e-20	Aortic root size;
KIRP	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.43	-10.87	-0.57	9.88e-23	Diabetic kidney disease;
KIRP	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg03929089	chr4:120376271	NA	0.7	6.23	0.37	2.02e-9	Axial length;
KIRP	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	5.57	0.33	6.77e-8	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg18209359	chr17:80159595	CCDC57	-0.42	-5.45	-0.33	1.2e-7	Life satisfaction;
KIRP	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13047869	chr3:10149882	C3orf24	0.61	5.6	0.34	5.83e-8	Alzheimer's disease;
KIRP	cis	rs7851660	0.874	rs1955143	chr9:100634579	A/T	cg13688889	chr9:100608707	NA	-0.67	-8.84	-0.49	1.91e-16	Strep throat;
KIRP	cis	rs829661	0.793	rs2593455	chr2:30815301	A/G	cg10949345	chr2:30726833	LCLAT1	1.13	14.27	0.67	4.5e-34	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg01689657	chr7:91764605	CYP51A1	0.44	6.31	0.37	1.31e-9	Breast cancer;
KIRP	trans	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.2	0.37	2.38e-9	Mean corpuscular volume;
KIRP	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg16179182	chr5:140090404	VTRNA1-1	0.56	7.74	0.44	2.56e-13	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	5.91	0.35	1.15e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3779635	0.713	rs4733063	chr8:27302885	A/G	cg06815112	chr8:27182871	PTK2B	0.42	5.37	0.32	1.8e-7	Neuroticism;
KIRP	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.88	0.35	1.32e-8	Aortic root size;
KIRP	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.85	10.3	0.55	6.46e-21	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs12823128	0.729	rs2100209	chr12:26933387	C/T	cg14081884	chr12:26986758	ITPR2	0.4	5.01	0.3	1.02e-6	Birth weight;
KIRP	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.79	-12.9	-0.64	2.03e-29	Electrocardiographic conduction measures;
KIRP	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.63	-0.56	5.75e-22	Height;
KIRP	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.72	10.16	0.54	1.75e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg27087555	chr16:88793112	FAM38A	-1.47	-13.47	-0.65	2.39e-31	Plateletcrit;
KIRP	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg05914723	chr15:78953907	NA	0.57	5.1	0.31	6.93e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
KIRP	trans	rs6987004	0.749	rs56036407	chr8:34411777	C/A	cg14242269	chr7:158770159	NA	-0.54	-6.05	-0.36	5.36e-9	Pulmonary function decline;
KIRP	cis	rs3779635	0.904	rs11135992	chr8:27276617	C/T	cg23736307	chr8:27182930	PTK2B	0.49	6.16	0.37	2.99e-9	Neuroticism;
KIRP	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-5.55	-0.33	7.4e-8	Mean corpuscular volume;
KIRP	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	5.3	0.32	2.61e-7	Bipolar disorder;
KIRP	cis	rs5753618	0.561	rs2413049	chr22:31686144	A/G	cg22777020	chr22:31556080	RNF185	-0.5	-5.32	-0.32	2.37e-7	Colorectal cancer;
KIRP	cis	rs2273669	0.667	rs75675305	chr6:109324353	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-6.34	-0.37	1.07e-9	Prostate cancer;
KIRP	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg00277334	chr10:82204260	NA	-0.47	-5.41	-0.33	1.51e-7	Post bronchodilator FEV1;
KIRP	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg25547332	chr5:131281432	NA	0.47	5.24	0.32	3.42e-7	Life satisfaction;
KIRP	trans	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.5	-5.61	-0.34	5.36e-8	Neuroticism;
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg16145915	chr7:1198662	ZFAND2A	-0.65	-5.97	-0.36	8.18e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9400271	0.632	rs4427037	chr6:109585612	G/C	cg01475377	chr6:109611718	NA	-0.38	-5.61	-0.34	5.34e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg13047869	chr3:10149882	C3orf24	0.53	5.26	0.32	3.18e-7	Alzheimer's disease;
KIRP	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg12962167	chr3:53033115	SFMBT1	0.7	5.39	0.33	1.63e-7	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.32	5.0	0.3	1.07e-6	Parkinson's disease;
KIRP	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06647332	chr5:131281008	NA	0.43	4.93	0.3	1.51e-6	Life satisfaction;
KIRP	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-5.01	-0.3	1.06e-6	Blood metabolite levels;
KIRP	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg06792538	chr1:2954250	NA	0.41	4.91	0.3	1.69e-6	Plateletcrit;
KIRP	cis	rs1829883	0.898	rs2688941	chr5:98769659	A/G	cg08333243	chr5:99726346	NA	0.4	5.3	0.32	2.57e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.55	7.57	0.43	7.46e-13	Tuberculosis;
KIRP	cis	rs4308124	1.000	rs62160391	chr2:112008835	C/A	cg04571233	chr2:111982156	NA	-0.42	-5.48	-0.33	1.07e-7	Vitiligo;
KIRP	cis	rs7252505	1.000	rs12460349	chr19:33584491	C/T	cg17764715	chr19:33622953	WDR88	0.64	5.23	0.32	3.66e-7	Colorectal cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg21816491	chr1:211487219	RCOR3	-0.42	-6.56	-0.39	3.16e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.85	0.49	1.74e-16	Motion sickness;
KIRP	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg14972814	chr11:95582409	MTMR2	0.34	5.69	0.34	3.62e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs829661	0.793	rs2609925	chr2:30824088	T/G	cg10949345	chr2:30726833	LCLAT1	1.15	13.84	0.66	1.35e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg26513180	chr16:89883248	FANCA	-0.4	-5.01	-0.3	1.05e-6	Vitiligo;
KIRP	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.92	-10.53	-0.56	1.19e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.63	10.39	0.55	3.29e-21	Coronary artery disease;
KIRP	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.79	10.17	0.54	1.62e-20	Migraine;Coronary artery disease;
KIRP	cis	rs3026101	0.671	rs56190856	chr17:5297149	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.47	5.97	0.36	8.23e-9	Body mass index;
KIRP	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-11.72	-0.6	1.67e-25	Dental caries;
KIRP	cis	rs981844	0.712	rs1037648	chr4:154737877	T/C	cg14289246	chr4:154710475	SFRP2	-0.54	-7.06	-0.41	1.74e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.43	-9.26	-0.51	1.04e-17	Mean corpuscular volume;
KIRP	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.67	-0.34	4.03e-8	Life satisfaction;
KIRP	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg04369109	chr6:150039330	LATS1	-0.47	-5.58	-0.34	6.27e-8	Lung cancer;
KIRP	trans	rs9371601	0.859	rs548985	chr6:152718614	C/G	cg05529123	chr2:66910386	NA	-0.46	-6.25	-0.37	1.77e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg06360820	chr2:242988706	NA	-1.2	-8.46	-0.47	2.36e-15	Obesity-related traits;
KIRP	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.49	6.15	0.36	3.16e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs457352	0.614	rs469204	chr21:31234590	T/A	cg11059873	chr5:155794596	SGCD	0.49	6.17	0.37	2.76e-9	Periodontitis (DPAL);
KIRP	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.12	-0.41	1.18e-11	Caffeine consumption;
KIRP	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.9	-11.93	-0.61	3.52e-26	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.82	9.97	0.54	6.75e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs12042938	1.000	rs823158	chr1:231782650	C/T	cg24499839	chr1:231762238	TSNAX-DISC1;DISC1	-0.37	-5.21	-0.32	3.98e-7	Neuranatomic and neurocognitive phenotypes;
KIRP	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg00677455	chr12:58241039	CTDSP2	0.6	6.81	0.4	7.52e-11	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg02297831	chr4:17616191	MED28	0.52	6.57	0.39	2.91e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.52	5.36	0.32	1.95e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	8.18	0.46	1.5e-14	IgG glycosylation;
KIRP	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg00405596	chr8:11794950	NA	0.45	5.62	0.34	5.11e-8	Retinal vascular caliber;
KIRP	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.77	7.64	0.44	4.82e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg16898833	chr6:26189333	HIST1H4D	0.95	5.77	0.35	2.35e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12210905	1.000	rs12192049	chr6:27056739	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.81	-6.87	-0.4	5.21e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg15128208	chr22:42549153	NA	0.73	8.1	0.46	2.52e-14	Birth weight;
KIRP	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.55	5.98	0.36	7.71e-9	Menopause (age at onset);
KIRP	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.46	5.74	0.34	2.78e-8	Asthma;
KIRP	cis	rs7033996	1.000	rs55911539	chr9:35948347	A/G	cg00918944	chr9:35908117	LOC158376	0.38	5.34	0.32	2.12e-7	Urate levels (BMI interaction);
KIRP	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg18171855	chr10:2543474	NA	0.45	6.44	0.38	6.1e-10	Age-related hearing impairment;
KIRP	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg24441899	chr7:4244372	SDK1	-0.52	-7.43	-0.43	1.83e-12	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
KIRP	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg00278547	chr2:177037212	HOXD3	-0.39	-5.17	-0.31	4.91e-7	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.98	15.73	0.71	4.61e-39	Intelligence (multi-trait analysis);
KIRP	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	1.02	13.9	0.66	8.23e-33	Menopause (age at onset);
KIRP	cis	rs3790645	1.000	rs282175	chr1:26895802	A/G	cg23229016	chr1:26872525	RPS6KA1	0.22	5.98	0.36	7.84e-9	Glucose homeostasis traits;
KIRP	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg08662619	chr6:150070041	PCMT1	0.34	4.99	0.3	1.14e-6	Lung cancer;
KIRP	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.69	8.79	0.49	2.58e-16	Alzheimer's disease;
KIRP	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.39	-4.85	-0.3	2.19e-6	Eosinophil percentage of white cells;
KIRP	cis	rs2970992	0.728	rs2309920	chr2:101329860	C/T	cg01042948	chr2:101319752	NA	0.42	5.91	0.35	1.15e-8	Educational attainment;
KIRP	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.63	-8.38	-0.47	4.19e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.44	6.62	0.39	2.25e-10	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs7520050	0.966	rs2486447	chr1:46545724	G/A	cg03146154	chr1:46216737	IPP	-0.41	-5.25	-0.32	3.22e-7	Red blood cell count;Reticulocyte count;
KIRP	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.41	-0.72	2.16e-41	Height;
KIRP	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-7.76	-0.44	2.25e-13	Neuroticism;
KIRP	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg15047889	chr8:124780837	FAM91A1	-0.48	-4.86	-0.3	2.12e-6	Pancreatic cancer;
KIRP	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg01763666	chr17:80159506	CCDC57	-0.37	-5.09	-0.31	7.2e-7	Life satisfaction;
KIRP	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.82	0.4	6.88e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.8	14.97	0.69	1.82e-36	Lymphocyte counts;
KIRP	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12826209	chr6:26865740	GUSBL1	0.42	5.05	0.31	8.41e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg19338460	chr6:170058176	WDR27	-0.63	-7.39	-0.43	2.26e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10140922	0.864	rs72666622	chr14:35820138	T/A	cg07166546	chr14:35805898	NA	-0.28	-6.77	-0.4	9.33e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08280861	chr8:58055591	NA	0.7	5.93	0.35	1.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg05991184	chr2:219186017	PNKD	0.36	5.02	0.3	9.84e-7	Colorectal cancer;
KIRP	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg08975724	chr8:8085496	FLJ10661	0.6	7.83	0.45	1.43e-13	Joint mobility (Beighton score);
KIRP	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg18753928	chr3:113234510	CCDC52	-0.49	-6.19	-0.37	2.48e-9	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.38	-4.85	-0.3	2.22e-6	Pulmonary function;
KIRP	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.8	8.87	0.49	1.53e-16	Bipolar disorder;
KIRP	cis	rs9788682	0.655	rs578776	chr15:78888400	G/A	cg24631222	chr15:78858424	CHRNA5	0.71	9.54	0.52	1.46e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs1030877	1.000	rs2241797	chr2:105885961	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.67	10.54	0.56	1.13e-21	Obesity-related traits;
KIRP	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.21	0.46	1.25e-14	IgG glycosylation;
KIRP	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.3	-8.28	-0.47	7.92e-15	Diabetic kidney disease;
KIRP	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.36	-5.58	-0.34	6.31e-8	Headache;
KIRP	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.83	-12.13	-0.61	7.56e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg20703242	chr1:230279135	GALNT2	0.42	7.27	0.42	4.81e-12	Coronary artery disease;
KIRP	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg16586182	chr3:47516702	SCAP	-0.54	-6.49	-0.38	4.63e-10	Birth weight;
KIRP	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.56	-7.21	-0.42	6.73e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-12.57	-0.63	2.64e-28	Vitiligo;
KIRP	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	9.74	0.53	3.52e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg04662567	chr6:169592167	NA	-0.7	-5.92	-0.35	1.1e-8	Pulse pressure;
KIRP	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg04226714	chr8:49833948	SNAI2	-0.48	-6.71	-0.39	1.36e-10	Life satisfaction;
KIRP	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg16482183	chr6:26056742	HIST1H1C	0.62	7.11	0.41	1.28e-11	Iron status biomarkers;
KIRP	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11645453	chr3:52864694	ITIH4	0.33	4.87	0.3	2.02e-6	Bipolar disorder;
KIRP	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.59	7.83	0.45	1.44e-13	Diastolic blood pressure;
KIRP	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg00666640	chr1:248458726	OR2T12	0.46	5.62	0.34	5.05e-8	Common traits (Other);
KIRP	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.72	10.52	0.56	1.26e-21	Body mass index;
KIRP	cis	rs17065868	1.000	rs9525992	chr13:45183906	G/A	cg10246903	chr13:45222710	NA	0.68	6.17	0.37	2.86e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.62	-6.71	-0.39	1.3100000000000001e-10	DNA methylation (variation);
KIRP	cis	rs2625529	0.938	rs9120	chr15:72115763	G/A	cg16672083	chr15:72433130	SENP8	-0.53	-6.49	-0.38	4.58e-10	Red blood cell count;
KIRP	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7005380	0.581	rs7007672	chr8:120919221	G/A	cg21645572	chr8:120931649	DEPDC6	0.5	7.05	0.41	1.8e-11	Interstitial lung disease;
KIRP	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-8.35	-0.47	4.94e-15	Joint mobility (Beighton score);
KIRP	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg09699651	chr6:150184138	LRP11	0.43	5.59	0.34	5.99e-8	Lung cancer;
KIRP	cis	rs7560272	0.538	rs12233112	chr2:73931764	G/A	cg20560298	chr2:73613845	ALMS1	0.48	5.79	0.35	2.16e-8	Schizophrenia;
KIRP	cis	rs6684514	1.000	rs10908495	chr1:156263940	T/C	cg16558208	chr1:156270281	VHLL	-0.43	-5.76	-0.34	2.45e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.67	8.67	0.48	5.79e-16	Bipolar disorder and schizophrenia;
KIRP	trans	rs12517041	0.872	rs28839222	chr5:23312044	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.88	-7.77	-0.44	2.07e-13	Calcium levels;
KIRP	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.88	13.24	0.64	1.46e-30	Testicular germ cell tumor;
KIRP	cis	rs12980942	0.591	rs3760660	chr19:41769025	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.6	4.84	0.3	2.25e-6	Coronary artery disease;
KIRP	cis	rs6547631	0.844	rs1436968	chr2:85903470	C/G	cg24620635	chr2:85921963	GNLY	0.34	5.07	0.31	7.66e-7	Blood protein levels;
KIRP	cis	rs10073892	0.667	rs62372161	chr5:101613608	C/A	cg19774478	chr5:101632501	SLCO4C1	0.57	6.08	0.36	4.45e-9	Cognitive decline (age-related);
KIRP	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15128208	chr22:42549153	NA	0.44	5.65	0.34	4.37e-8	Cognitive function;
KIRP	trans	rs1864585	0.520	rs17776427	chr8:10672972	G/T	cg26278703	chr11:58910052	FAM111A	0.64	6.49	0.38	4.67e-10	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs860295	0.702	rs4971095	chr1:155606224	G/A	cg02153340	chr1:155202674	NA	0.43	5.86	0.35	1.47e-8	Body mass index;
KIRP	trans	rs6601327	0.571	rs35874762	chr8:9565392	C/A	cg16141378	chr3:129829833	LOC729375	0.49	6.32	0.37	1.22e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	10.27	0.55	8.3e-21	Ileal carcinoids;
KIRP	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.78	7.22	0.42	6.29e-12	Vitiligo;
KIRP	cis	rs1978968	1.000	rs7286607	chr22:18444657	T/C	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs787274	0.557	rs4979184	chr9:115667362	G/A	cg13803584	chr9:115635662	SNX30	-0.64	-5.61	-0.34	5.54e-8	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs17023223	0.537	rs6677107	chr1:119708765	C/T	cg18261050	chr1:119551319	NA	0.5	6.43	0.38	6.74e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs1829883	0.605	rs12656351	chr5:98986296	A/G	cg08333243	chr5:99726346	NA	0.42	5.54	0.33	7.86e-8	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg09264619	chr17:80180166	NA	-0.37	-5.46	-0.33	1.13e-7	Life satisfaction;
KIRP	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	ch.11.42038R	chr11:967971	AP2A2	0.46	6.09	0.36	4.3e-9	Alzheimer's disease (late onset);
KIRP	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.39	-7.09	-0.41	1.37e-11	Refractive error;
KIRP	cis	rs17401966	0.558	rs6541090	chr1:10402842	A/G	cg19773385	chr1:10388646	KIF1B	-0.43	-6.19	-0.37	2.49e-9	Hepatocellular carcinoma;
KIRP	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.49	-8.25	-0.47	9.47e-15	Height;
KIRP	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg12560992	chr17:57184187	TRIM37	0.62	6.62	0.39	2.19e-10	Testicular germ cell tumor;
KIRP	trans	rs1018836	0.786	rs4734237	chr8:91533361	A/C	cg18563348	chr7:100420040	EPHB4	0.4	6.19	0.37	2.54e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9400467	0.506	rs3204953	chr6:111628626	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.92	0.3	1.57e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4865875	1.000	rs10805463	chr5:54100354	A/G	cg22421804	chr5:54100067	NA	-0.38	-4.97	-0.3	1.24e-6	Sense of smell;
KIRP	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.57	7.65	0.44	4.43e-13	Obesity-related traits;
KIRP	cis	rs4901847	0.967	rs12433260	chr14:58552893	T/C	cg15908186	chr14:58618357	C14orf37	0.43	5.48	0.33	1.06e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.66	6.73	0.39	1.16e-10	Vitiligo;
KIRP	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg03959625	chr15:84868606	LOC388152	0.49	5.81	0.35	1.88e-8	Schizophrenia;
KIRP	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg07775547	chr4:1625484	NA	-0.47	-5.73	-0.34	2.92e-8	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg11987759	chr7:65425863	GUSB	0.6	8.26	0.47	8.96e-15	Calcium levels;
KIRP	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg15733309	chr7:157513707	PTPRN2	0.44	6.74	0.39	1.14e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg00405596	chr8:11794950	NA	-0.44	-5.41	-0.33	1.46e-7	Neuroticism;
KIRP	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20887711	chr4:1340912	KIAA1530	-0.46	-5.65	-0.34	4.41e-8	Obesity-related traits;
KIRP	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg23594656	chr7:65796392	TPST1	-0.48	-7.28	-0.42	4.38e-12	Aortic root size;
KIRP	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.76	-9.74	-0.53	3.6e-19	Parkinson's disease;
KIRP	cis	rs4713675	0.565	rs3818530	chr6:33661222	C/G	cg15676125	chr6:33679581	C6orf125	0.4	5.35	0.32	1.99e-7	Plateletcrit;
KIRP	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg13271783	chr10:134563150	INPP5A	-0.63	-7.97	-0.45	6.01e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs1950626	0.623	rs4402490	chr14:101445453	A/G	cg02351406	chr14:101447389	SNORD114-20;SNORD114-21	-0.53	-6.08	-0.36	4.6e-9	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs5770917	1.000	rs12627787	chr22:51012381	C/T	cg24363820	chr22:51016703	CPT1B;CHKB-CPT1B	-0.56	-5.38	-0.32	1.75e-7	Narcolepsy;
KIRP	cis	rs2425143	0.818	rs11167280	chr20:34560526	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.55	-4.92	-0.3	1.59e-6	Blood protein levels;
KIRP	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg05791153	chr7:19748676	TWISTNB	0.54	5.84	0.35	1.6e-8	Thyroid stimulating hormone;
KIRP	cis	rs9614461	0.702	rs16993867	chr22:45733199	A/G	cg23503501	chr22:45809793	SMC1B;RIBC2	0.52	5.42	0.33	1.42e-7	Tonsillectomy;
KIRP	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg05964544	chr11:70165517	PPFIA1	-0.53	-5.03	-0.31	9.64e-7	Coronary artery disease;
KIRP	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.26	-0.47	8.97e-15	Response to antipsychotic treatment;
KIRP	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.86	10.9	0.57	7.83e-23	Coronary artery disease;
KIRP	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.45	-6.34	-0.37	1.07e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.9	13.49	0.65	2.1e-31	Mean platelet volume;
KIRP	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg08000102	chr2:233561755	GIGYF2	0.75	9.56	0.52	1.28e-18	Schizophrenia;
KIRP	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.46	-5.45	-0.33	1.23e-7	Neuroticism;
KIRP	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg08901578	chr4:187885870	NA	-0.46	-6.96	-0.41	3.08e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17221829	0.673	rs11018700	chr11:89382066	A/C	cg02982614	chr11:89391479	FOLH1B	-0.33	-5.37	-0.32	1.84e-7	Anxiety in major depressive disorder;
KIRP	cis	rs7719624	0.870	rs10042825	chr5:135396084	A/T	cg16684184	chr5:135415129	NA	0.35	5.26	0.32	3.12e-7	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.92	-12.71	-0.63	8.49e-29	Cognitive function;
KIRP	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg26207909	chr14:103986467	CKB	-0.45	-5.48	-0.33	1.03e-7	Coronary artery disease;
KIRP	cis	rs7119038	0.774	rs11217037	chr11:118677086	G/A	cg19308663	chr11:118741387	NA	0.57	9.39	0.51	4.36e-18	Sjögren's syndrome;
KIRP	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg21698718	chr17:80085957	CCDC57	0.34	4.86	0.3	2.1e-6	Life satisfaction;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg19747990	chr5:83588224	EDIL3	0.42	6.43	0.38	6.53e-10	Migraine with aura;
KIRP	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg21573476	chr21:45109991	RRP1B	-0.64	-8.7	-0.48	4.98e-16	Mean corpuscular volume;
KIRP	cis	rs9993696	1	rs9993696	chr4:2187377	T/G	cg10457066	chr4:2065925	NAT8L	-0.5	-5.71	-0.34	3.18e-8	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.66	9.63	0.52	7.87e-19	Dupuytren's disease;
KIRP	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	6.03	0.36	5.92e-9	Aortic root size;
KIRP	cis	rs4481887	0.705	rs6698503	chr1:248425247	G/A	cg01631408	chr1:248437212	OR2T33	-0.64	-7.82	-0.45	1.55e-13	Common traits (Other);
KIRP	cis	rs1978968	1.000	rs5013012	chr22:18450149	A/G	cg02610425	chr22:18483192	MICAL3	0.37	5.12	0.31	6.11e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg01689657	chr7:91764605	CYP51A1	0.36	5.15	0.31	5.4e-7	Breast cancer;
KIRP	cis	rs13359291	0.841	rs73800148	chr5:122481027	T/A	cg16368670	chr5:122501738	PRDM6	-0.49	-6.03	-0.36	6.01e-9	Systolic blood pressure;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg25937714	chr3:44036492	NA	0.43	6.53	0.38	3.77e-10	Educational attainment;
KIRP	trans	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg06521331	chr12:34319734	NA	-0.53	-6.53	-0.38	3.8e-10	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.97	-14.59	-0.68	3.63e-35	Coronary artery disease;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.62	-0.44	5.47e-13	Life satisfaction;
KIRP	cis	rs7870753	0.838	rs7848376	chr9:99248069	G/A	cg25260653	chr9:99212216	HABP4	0.55	5.9	0.35	1.18e-8	Height;
KIRP	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.8	11.42	0.59	1.63e-24	Morning vs. evening chronotype;
KIRP	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	7.64	0.44	4.82e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.9	12.97	0.64	1.2e-29	Morning vs. evening chronotype;
KIRP	cis	rs7534824	0.625	rs61782084	chr1:101515298	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.67	5.68	0.34	3.81e-8	Refractive astigmatism;
KIRP	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.51	-6.39	-0.38	8.37e-10	Longevity;
KIRP	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg26874164	chr19:58962979	ZNF324B	0.46	5.37	0.32	1.82e-7	Uric acid clearance;
KIRP	cis	rs1847505	0.874	rs1394314	chr13:61521491	A/G	cg25164009	chr13:61490935	NA	-0.58	-6.37	-0.38	9.34e-10	Polychlorinated biphenyl levels;
KIRP	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg04013166	chr16:89971882	TCF25	0.68	5.68	0.34	3.85e-8	Skin colour saturation;
KIRP	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.19	26.3	0.86	1.92e-73	Chronic sinus infection;
KIRP	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.84	-13.56	-0.65	1.17e-31	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg09408571	chr1:101003634	GPR88	0.24	5.47	0.33	1.12e-7	Monocyte count;
KIRP	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg01721255	chr8:58191610	C8orf71	0.51	5.04	0.31	8.99e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	trans	rs9329221	0.508	rs6601455	chr8:10273426	A/G	cg16141378	chr3:129829833	LOC729375	-0.49	-6.02	-0.36	6.14e-9	Neuroticism;
KIRP	cis	rs7267005	0.661	rs76013929	chr20:34427657	G/T	cg17201900	chr20:34330562	RBM39	0.99	5.55	0.33	7.42e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.47	-4.96	-0.3	1.34e-6	Age at smoking initiation in chronic obstructive pulmonary disease;
KIRP	cis	rs2562456	0.754	rs11673234	chr19:21507602	A/C	cg18461458	chr19:21324796	ZNF431	-0.52	-5.04	-0.31	8.96e-7	Pain;
KIRP	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-9.28	-0.51	9.43e-18	Extrinsic epigenetic age acceleration;
KIRP	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg01620082	chr3:125678407	NA	-0.94	-6.45	-0.38	5.76e-10	Lung cancer in ever smokers;
KIRP	cis	rs1832871	1.000	rs827856	chr6:158705887	G/A	cg07215822	chr6:158701037	NA	-0.49	-6.28	-0.37	1.48e-9	Height;
KIRP	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg26149184	chr10:133730230	NA	0.43	5.08	0.31	7.62e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.51	-6.68	-0.39	1.61e-10	Body mass index;
KIRP	cis	rs11650494	0.901	rs74659133	chr17:47336931	C/T	cg08112188	chr17:47440006	ZNF652	1.39	9.69	0.53	5.05e-19	Prostate cancer;
KIRP	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.49	-6.05	-0.36	5.28e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8053891	0.855	rs8053861	chr16:71997675	C/G	cg04254540	chr16:71951199	KIAA0174	-0.43	-5.04	-0.31	8.87e-7	Coronary artery disease;
KIRP	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.5	7.56	0.43	8e-13	Resting heart rate;
KIRP	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg12441052	chr11:66313700	ZDHHC24;ACTN3	-0.51	-5.24	-0.32	3.53e-7	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg16141378	chr3:129829833	LOC729375	0.53	6.86	0.4	5.66e-11	Neuroticism;
KIRP	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.59	6.43	0.38	6.62e-10	Aortic root size;
KIRP	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg08901578	chr4:187885870	NA	-0.46	-6.82	-0.4	7.16e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs736408	1.000	rs4687552	chr3:52838402	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	7.05	0.41	1.77e-11	Bipolar disorder;
KIRP	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.34	-4.94	-0.3	1.42e-6	Schizophrenia;
KIRP	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.31	-0.47	6.71e-15	Response to antipsychotic treatment;
KIRP	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-9.74	-0.53	3.55e-19	Response to antipsychotic treatment;
KIRP	cis	rs262150	0.788	rs2657389	chr7:158763795	G/A	cg09640425	chr7:158790006	NA	-0.44	-5.34	-0.32	2.07e-7	Facial morphology (factor 20);
KIRP	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.51	-0.33	8.95e-8	Bipolar disorder;
KIRP	trans	rs6921919	0.583	rs9468355	chr6:28341877	A/G	cg16944159	chr2:62132759	COMMD1	-0.57	-6.32	-0.37	1.25e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.34	-6.34	-0.37	1.1e-9	Mean corpuscular volume;
KIRP	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17539620	0.630	rs62432757	chr6:154854650	T/A	cg20019720	chr6:154832845	CNKSR3	0.46	5.79	0.35	2.13e-8	Lipoprotein (a) levels;
KIRP	cis	rs703980	0.585	rs703978	chr10:80944147	C/G	cg18737081	chr10:80999807	ZMIZ1	0.32	5.19	0.31	4.39e-7	Type 2 diabetes;
KIRP	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg14825688	chr5:132208181	LEAP2	-0.37	-4.87	-0.3	1.96e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs6753739	0.871	rs6436110	chr2:219980953	A/C	cg01749213	chr2:219906749	CCDC108	0.43	5.36	0.32	1.9e-7	Height;
KIRP	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.48	5.77	0.35	2.38e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg22951263	chr5:87985283	NA	-0.47	-6.66	-0.39	1.79e-10	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg25319279	chr11:5960081	NA	-0.68	-6.93	-0.4	3.57e-11	DNA methylation (variation);
KIRP	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.65	8.27	0.47	8.57e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9905704	0.846	rs304262	chr17:56814456	A/G	cg12560992	chr17:57184187	TRIM37	0.58	6.97	0.41	2.86e-11	Testicular germ cell tumor;
KIRP	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg00807237	chr7:934156	C7orf20	0.45	5.34	0.32	2.14e-7	Subjective well-being;
KIRP	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08822215	chr16:89438651	ANKRD11	0.42	5.74	0.34	2.71e-8	Multiple myeloma (IgH translocation);
KIRP	cis	rs427941	0.703	rs201457	chr7:101741338	C/A	cg06246474	chr7:101738831	CUX1	0.54	6.72	0.39	1.27e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.77	12.03	0.61	1.59e-26	Colorectal cancer;
KIRP	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg20140201	chr2:241835670	C2orf54	0.36	5.42	0.33	1.44e-7	Urinary metabolites;
KIRP	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg01763666	chr17:80159506	CCDC57	-0.37	-4.98	-0.3	1.19e-6	Life satisfaction;
KIRP	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.63	-8.19	-0.46	1.39e-14	Iron status biomarkers;
KIRP	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg04132472	chr17:19861366	AKAP10	0.67	10.49	0.56	1.57e-21	Schizophrenia;
KIRP	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08439880	chr3:133502540	NA	0.49	6.13	0.36	3.49e-9	Iron status biomarkers;
KIRP	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-6.0	-0.36	7.02e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.8	-8.23	-0.46	1.08e-14	Lung cancer in ever smokers;
KIRP	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-1.04	-12.83	-0.63	3.43e-29	Breast cancer;
KIRP	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg03714773	chr7:91764589	CYP51A1	0.38	5.58	0.33	6.46e-8	Breast cancer;
KIRP	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg15556689	chr8:8085844	FLJ10661	0.56	6.9	0.4	4.41e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg00656387	chr3:40428638	ENTPD3	0.39	4.92	0.3	1.56e-6	Renal cell carcinoma;
KIRP	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg10223061	chr2:219282414	VIL1	0.41	6.38	0.38	8.79e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg04691961	chr3:161091175	C3orf57	-0.66	-11.15	-0.58	1.2e-23	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg13010199	chr12:38710504	ALG10B	0.47	6.01	0.36	6.61e-9	Morning vs. evening chronotype;
KIRP	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg21174375	chr14:64681225	SYNE2	-0.65	-8.89	-0.49	1.38e-16	Atrial fibrillation;
KIRP	cis	rs4423214	0.547	rs11234030	chr11:71236967	G/A	cg05163923	chr11:71159392	DHCR7	-0.69	-6.71	-0.39	1.33e-10	Vitamin D levels;
KIRP	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.49	5.26	0.32	3.17e-7	Breast cancer;
KIRP	cis	rs17209837	0.915	rs12672720	chr7:87126438	A/G	cg00919237	chr7:87102261	ABCB4	-0.69	-6.68	-0.39	1.63e-10	Gallbladder cancer;
KIRP	cis	rs34271465	1	rs34271465	chr2:165513065	CA/C	cg03182029	chr2:165697222	COBLL1	0.37	4.93	0.3	1.53e-6	Systolic blood pressure;
KIRP	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg11846333	chr4:119757529	SEC24D	1.1	6.32	0.37	1.19e-9	Cannabis dependence symptom count;
KIRP	cis	rs11723261	0.546	rs57839456	chr4:148289	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.47	4.88	0.3	1.89e-6	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.93	-9.19	-0.51	1.69e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.53	-5.83	-0.35	1.7e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.79	6.66	0.39	1.82e-10	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg20701182	chr2:24300061	SF3B14	0.53	5.13	0.31	5.91e-7	Lymphocyte counts;
KIRP	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.56	6.67	0.39	1.71e-10	Obesity-related traits;
KIRP	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg02807482	chr3:125708958	NA	-0.53	-5.03	-0.31	9.38e-7	Blood pressure (smoking interaction);
KIRP	cis	rs7656342	0.653	rs35629527	chr4:9864232	C/T	cg00071950	chr4:10020882	SLC2A9	0.35	4.85	0.3	2.17e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs10203711	1.000	rs7582256	chr2:239587446	C/T	cg14580085	chr2:239553406	NA	0.38	4.97	0.3	1.24e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2249694	0.520	rs7096321	chr10:135324536	A/G	cg20169779	chr10:135381914	SYCE1	-0.6	-6.53	-0.38	3.67e-10	Obesity-related traits;
KIRP	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.96	8.84	0.49	1.82e-16	Type 2 diabetes;
KIRP	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	10.02	0.54	4.84e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.41	-0.47	3.46e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00361562	chr2:198649771	BOLL	0.49	5.2	0.31	4.1e-7	Ulcerative colitis;
KIRP	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.87	10.36	0.55	4.21e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs11138902	0.673	rs12378318	chr9:72136263	C/T	cg14397918	chr9:72078829	APBA1	0.33	5.2	0.31	4.11e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27425459	chr2:105697589	MRPS9	0.52	6.88	0.4	4.83e-11	Interleukin-4 levels;
KIRP	cis	rs1847202	0.927	rs13081361	chr3:72947895	T/C	cg06781948	chr3:72941472	GXYLT2	0.42	5.64	0.34	4.75e-8	Motion sickness;
KIRP	cis	rs4908768	0.906	rs12409937	chr1:8538302	G/C	cg25722041	chr1:8623473	RERE	0.77	9.81	0.53	2.16e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7851660	0.809	rs7022148	chr9:100660824	T/C	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	ch.11.42038R	chr11:967971	AP2A2	0.38	4.99	0.3	1.13e-6	Alzheimer's disease (late onset);
KIRP	cis	rs9815354	0.767	rs111708447	chr3:41809583	G/A	cg03022575	chr3:42003672	ULK4	0.81	8.32	0.47	6.13e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs7712401	0.601	rs173480	chr5:122254131	C/A	cg19412675	chr5:122181750	SNX24	0.48	5.24	0.32	3.51e-7	Mean platelet volume;
KIRP	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg04374321	chr14:90722782	PSMC1	-0.59	-7.57	-0.43	7.59e-13	Mortality in heart failure;
KIRP	cis	rs9308731	0.583	rs6726007	chr2:111932122	A/T	cg04780086	chr2:111875790	ACOXL	0.44	5.9	0.35	1.2e-8	Chronic lymphocytic leukemia;
KIRP	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.64	7.54	0.43	9.29e-13	Aortic root size;
KIRP	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.84	10.33	0.55	5.15e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg11131117	chr7:1891496	MAD1L1	0.41	5.14	0.31	5.49e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.67	-9.08	-0.5	3.71e-17	Rheumatoid arthritis;
KIRP	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	10.06	0.54	3.55e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs12282928	1.000	rs10769343	chr11:48321098	G/A	cg26585981	chr11:48327164	OR4S1	0.52	6.3	0.37	1.4e-9	Migraine - clinic-based;
KIRP	cis	rs883565	0.655	rs1608728	chr3:39089560	C/T	cg01426195	chr3:39028469	NA	-0.74	-12.95	-0.64	1.31e-29	Handedness;
KIRP	trans	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg02030672	chr11:45687055	CHST1	-0.57	-7.13	-0.41	1.1e-11	Obesity-related traits;
KIRP	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg26513180	chr16:89883248	FANCA	0.83	5.56	0.33	6.99e-8	Skin colour saturation;
KIRP	cis	rs73198271	0.960	rs11778970	chr8:8609334	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.94	-0.35	9.6e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs7215564	0.908	rs36077104	chr17:78661757	T/A	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg22681709	chr2:178499509	PDE11A	-0.61	-8.94	-0.5	9.36e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-8.26	-0.47	8.91e-15	Bipolar disorder;
KIRP	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.82	11.28	0.58	4.64e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg16553119	chr1:165599451	MGST3	-0.43	-4.99	-0.3	1.15e-6	Total ventricular volume;
KIRP	cis	rs6450176	0.909	rs6884936	chr5:53293198	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.0	-0.57	3.88e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	cis	rs7267005	1.000	rs17093205	chr20:34463705	T/C	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg11645453	chr3:52864694	ITIH4	-0.35	-5.38	-0.32	1.77e-7	Body mass index;
KIRP	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.61	-5.17	-0.31	4.9e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	0.92	12.62	0.63	1.72e-28	Monocyte percentage of white cells;
KIRP	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg06871246	chr4:1363661	KIAA1530	-0.54	-6.58	-0.39	2.75e-10	Longevity;
KIRP	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-1.0	-15.08	-0.69	7.83e-37	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01616529	chr11:638424	DRD4	-0.42	-5.7	-0.34	3.44e-8	Systemic lupus erythematosus;
KIRP	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.36	-7.12	-0.41	1.17e-11	Monocyte percentage of white cells;
KIRP	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg01721255	chr8:58191610	C8orf71	0.51	5.08	0.31	7.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.64	9.62	0.52	8.37e-19	Lung cancer;
KIRP	trans	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	6.14	0.36	3.23e-9	Mean corpuscular volume;
KIRP	trans	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg05926928	chr17:57297772	GDPD1	0.96	10.02	0.54	4.99e-20	Opioid sensitivity;
KIRP	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-6.18	-0.37	2.58e-9	Hematocrit;
KIRP	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg06637938	chr14:75390232	RPS6KL1	0.54	7.63	0.44	5.25e-13	Height;
KIRP	cis	rs7119167	0.901	rs6592523	chr11:73109877	T/C	cg17517138	chr11:73019481	ARHGEF17	0.47	4.92	0.3	1.6e-6	Blood protein levels;
KIRP	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg24315340	chr6:146058215	EPM2A	0.4	4.99	0.3	1.14e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs754423	0.515	rs1950733	chr14:52563772	G/A	cg05884192	chr14:52515736	NID2	-0.47	-5.54	-0.33	7.96e-8	Craniofacial microsomia;
KIRP	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg12559939	chr2:27858050	GPN1	-0.43	-5.35	-0.32	1.97e-7	Oral cavity cancer;
KIRP	cis	rs7223966	0.618	rs9906903	chr17:61634508	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.47	5.61	0.34	5.48e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs2717559	0.541	rs34497317	chr8:143889053	T/A	cg17252645	chr8:143867129	LY6D	-0.37	-5.85	-0.35	1.55e-8	Urinary tract infection frequency;
KIRP	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg07541023	chr7:19748670	TWISTNB	0.84	7.3	0.42	4.04e-12	Thyroid stimulating hormone;
KIRP	cis	rs4722404	0.800	rs7809262	chr7:3141137	A/G	cg19214707	chr7:3157722	NA	-0.41	-4.95	-0.3	1.35e-6	Atopic dermatitis;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg11442381	chr3:52312806	WDR82	-0.51	-6.72	-0.39	1.29e-10	Myopia;
KIRP	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04871131	chr7:94954202	PON1	0.61	8.12	0.46	2.23e-14	Paraoxonase activity;
KIRP	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.97	11.76	0.6	1.24e-25	Corneal astigmatism;
KIRP	cis	rs2860975	0.967	rs11188134	chr10:96774255	G/C	cg09036531	chr10:96991505	NA	-0.54	-6.93	-0.4	3.75e-11	Immune response to smallpox vaccine (IL-6);
KIRP	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg15038512	chr6:170123185	PHF10	0.46	5.03	0.31	9.36e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg15507776	chr3:136538369	TMEM22	0.4	5.37	0.32	1.84e-7	Neuroticism;
KIRP	cis	rs10782582	0.609	rs5745469	chr1:76347394	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-6.05	-0.36	5.49e-9	Daytime sleep phenotypes;
KIRP	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg13047869	chr3:10149882	C3orf24	0.53	5.26	0.32	3.18e-7	Alzheimer's disease;
KIRP	cis	rs10129255	0.500	rs4774008	chr14:107137290	A/T	cg23076370	chr14:107095027	NA	-0.46	-5.62	-0.34	5.1e-8	Kawasaki disease;
KIRP	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.54	5.82	0.35	1.86e-8	Vitiligo;
KIRP	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.65	9.67	0.52	5.92e-19	Menarche (age at onset);
KIRP	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg02336718	chr17:17403227	NA	0.31	4.92	0.3	1.58e-6	Total body bone mineral density;
KIRP	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.74	-11.25	-0.58	5.68e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs934734	0.563	rs1858036	chr2:65598241	A/G	cg08085232	chr2:65598271	SPRED2	-0.57	-7.22	-0.42	6.48e-12	Rheumatoid arthritis;
KIRP	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg23950597	chr19:37808831	NA	0.59	6.39	0.38	8.04e-10	Coronary artery calcification;
KIRP	cis	rs3736485	0.903	rs11630743	chr15:51750609	C/T	cg14296394	chr15:51910925	DMXL2	-0.36	-5.34	-0.32	2.15e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg17941049	chr3:63904683	ATXN7	0.49	5.01	0.3	1.04e-6	Type 2 diabetes;
KIRP	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.52e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.41	8.39	0.47	3.76e-15	Vitiligo;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14693961	chr19:42388097	ARHGEF1	0.51	6.8	0.4	7.87e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg13010199	chr12:38710504	ALG10B	0.62	7.71	0.44	3.18e-13	Morning vs. evening chronotype;
KIRP	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg11062466	chr8:58055876	NA	0.54	4.96	0.3	1.29e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs3744061	0.557	rs9909137	chr17:74648029	G/A	cg27546012	chr17:74684504	MXRA7	-0.44	-5.38	-0.32	1.71e-7	Retinal arteriolar caliber;
KIRP	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-9.95	-0.54	8.11e-20	Triglycerides;
KIRP	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-6.9	-0.4	4.51e-11	Response to antipsychotic treatment;
KIRP	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.83	8.73	0.49	4.01e-16	Methadone dose in opioid dependence;
KIRP	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.61	8.68	0.48	5.57e-16	Colorectal cancer;
KIRP	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18110333	chr6:292329	DUSP22	-0.6	-6.91	-0.4	4.09e-11	Menopause (age at onset);
KIRP	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.62	8.2	0.46	1.3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs35771425	1.000	rs12739630	chr1:211591687	G/A	cg10512769	chr1:211675356	NA	-0.51	-5.1	-0.31	6.66e-7	Educational attainment (years of education);
KIRP	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-5.49	-0.33	9.75e-8	Vitiligo;
KIRP	cis	rs66573146	1.000	rs55913461	chr4:7017509	C/T	cg00086871	chr4:6988644	TBC1D14	0.88	5.13	0.31	5.91e-7	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg12856521	chr11:46389249	DGKZ	0.63	7.34	0.42	3.12e-12	Crohn's disease;
KIRP	cis	rs290268	0.838	rs290993	chr9:93559572	G/A	cg02608019	chr9:93564028	SYK	0.82	11.52	0.59	7.58e-25	Platelet count;
KIRP	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.59	6.55	0.39	3.29e-10	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs684232	0.901	rs461251	chr17:619162	A/G	cg15660573	chr17:549704	VPS53	0.53	6.61	0.39	2.34e-10	Prostate cancer;
KIRP	cis	rs258892	0.947	rs62360681	chr5:72187013	T/G	cg21869765	chr5:72125136	TNPO1	0.58	6.45	0.38	5.86e-10	Small cell lung carcinoma;
KIRP	cis	rs2598107	0.601	rs71546610	chr7:37956395	G/A	cg25225232	chr7:37962694	EPDR1	-0.41	-4.88	-0.3	1.92e-6	Dupuytren's disease;
KIRP	cis	rs2692947	0.695	rs12464148	chr2:96596710	G/C	cg23100626	chr2:96804247	ASTL	0.45	6.67	0.39	1.67e-10	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs11690462	0.534	rs6546949	chr2:26592429	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.4	-5.16	-0.31	5.04e-7	Coronary artery disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06925975	chr1:23946267	NA	0.44	6.18	0.37	2.58e-9	Parkinson's disease;
KIRP	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg23307798	chr14:103986281	CKB	0.79	14.0	0.67	3.78e-33	Body mass index;
KIRP	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.45	-4.84	-0.3	2.26e-6	Urate levels in overweight individuals;
KIRP	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.71	9.16	0.5	2.14e-17	Morning vs. evening chronotype;
KIRP	cis	rs6083	0.536	rs4528512	chr15:58852226	A/T	cg05156742	chr15:59063176	FAM63B	0.44	5.48	0.33	1.07e-7	Schizophrenia;
KIRP	cis	rs953387	0.956	rs4954396	chr2:136927557	A/C	cg05194412	chr2:137003533	NA	-0.38	-5.06	-0.31	8.21e-7	Arthritis (juvenile idiopathic);
KIRP	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	10.34	0.55	4.92e-21	Hip circumference;
KIRP	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg08975724	chr8:8085496	FLJ10661	0.55	7.21	0.42	6.74e-12	Neuroticism;
KIRP	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg13798780	chr7:105162888	PUS7	0.48	5.12	0.31	6.16e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg20578329	chr17:80767326	TBCD	-0.63	-7.32	-0.42	3.43e-12	Breast cancer;
KIRP	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.25	-15.92	-0.71	1.02e-39	Breast cancer;
KIRP	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg21605333	chr4:119757512	SEC24D	1.66	11.81	0.6	8.23e-26	Cannabis dependence symptom count;
KIRP	cis	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg08224773	chr8:11311868	FAM167A	0.35	6.14	0.36	3.3e-9	Rheumatoid arthritis;
KIRP	cis	rs7106204	0.534	rs113519220	chr11:24251432	T/C	ch.11.24196551F	chr11:24239977	NA	0.73	4.97	0.3	1.25e-6	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg04132472	chr17:19861366	AKAP10	0.67	10.41	0.55	2.83e-21	Schizophrenia;
KIRP	cis	rs6987853	0.661	rs6988493	chr8:42351328	C/T	cg09913449	chr8:42400586	C8orf40	-0.37	-4.97	-0.3	1.23e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.21	-0.32	3.96e-7	Coronary artery disease;
KIRP	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.49	-8.27	-0.47	8.48e-15	Pneumonia;
KIRP	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg02931644	chr1:25747376	RHCE	-0.37	-6.73	-0.39	1.21e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.5	6.44	0.38	6.35e-10	Blood metabolite levels;
KIRP	cis	rs2119480	0.963	rs11619800	chr13:111332886	G/A	cg24331049	chr13:111365604	ING1	0.45	5.4	0.33	1.54e-7	Diastolic blood pressure;
KIRP	cis	rs6840360	0.582	rs7691601	chr4:152321631	A/G	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.44e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.69	-9.48	-0.52	2.28e-18	Hemoglobin concentration;
KIRP	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.55	5.35	0.32	1.98e-7	Schizophrenia;
KIRP	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	14.03	0.67	3.08e-33	Platelet count;
KIRP	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg23719950	chr11:63933701	MACROD1	-0.68	-6.65	-0.39	1.91e-10	Mean platelet volume;
KIRP	cis	rs7582720	0.945	rs72932759	chr2:203674288	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.63e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs960902	0.561	rs4517954	chr2:37734421	G/A	cg25341268	chr2:37734390	NA	-0.64	-9.1	-0.5	3.24e-17	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg14217534	chr12:49525474	TUBA1B	0.74	6.16	0.37	3.03e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02912187	chr19:18314776	RAB3A	0.53	6.65	0.39	1.83e-10	Parkinson's disease;
KIRP	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.44	6.37	0.38	9.48e-10	Reticulocyte fraction of red cells;
KIRP	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.48	6.02	0.36	6.23e-9	Height;
KIRP	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg05802129	chr4:122689817	NA	-0.71	-9.46	-0.52	2.67e-18	Type 2 diabetes;
KIRP	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg05347473	chr6:146136440	FBXO30	0.47	6.86	0.4	5.51e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg21401794	chr1:90099060	LRRC8C	0.7	9.86	0.53	1.51e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg13819577	chr1:248512075	OR14C36	-0.36	-5.09	-0.31	7.07e-7	Common traits (Other);
KIRP	cis	rs15676	0.783	rs11515530	chr9:131576367	C/T	cg00228799	chr9:131580591	ENDOG	-0.56	-6.18	-0.37	2.58e-9	Blood metabolite levels;
KIRP	cis	rs1891275	0.515	rs1986941	chr10:93444343	C/T	cg07889827	chr10:93443413	NA	-0.41	-7.03	-0.41	2.04e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg16141378	chr3:129829833	LOC729375	-0.52	-6.5	-0.38	4.49e-10	Retinal vascular caliber;
KIRP	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg03060546	chr3:49711283	APEH	0.47	6.26	0.37	1.69e-9	Parkinson's disease;
KIRP	cis	rs9303280	0.806	rs36095411	chr17:38031865	T/G	cg00129232	chr17:37814104	STARD3	-0.56	-6.94	-0.4	3.55e-11	Self-reported allergy;
KIRP	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	10.49	0.56	1.66e-21	Hip circumference;
KIRP	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	12.82	0.63	3.63e-29	Platelet count;
KIRP	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.48	-6.03	-0.36	6.01e-9	Red blood cell count;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg27344430	chr5:41587931	NA	-0.4	-6.09	-0.36	4.37e-9	Select biomarker traits;
KIRP	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg00024416	chr22:24240387	NA	-0.33	-4.92	-0.3	1.57e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.66	-11.03	-0.58	3.05e-23	Menopause (age at onset);
KIRP	cis	rs9584850	0.789	rs7988345	chr13:99117685	A/G	cg20750642	chr13:99100586	FARP1	-0.48	-5.58	-0.34	6.41e-8	Neuroticism;
KIRP	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.63	-8.14	-0.46	1.92e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs3779635	0.742	rs17376241	chr8:27256918	G/A	cg18234130	chr8:27182889	PTK2B	0.54	6.97	0.41	2.83e-11	Neuroticism;
KIRP	cis	rs10073892	0.711	rs10074392	chr5:101596412	A/G	cg19774478	chr5:101632501	SLCO4C1	0.6	5.92	0.35	1.1e-8	Cognitive decline (age-related);
KIRP	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg13206674	chr6:150067644	NUP43	0.58	8.5	0.48	1.84e-15	Lung cancer;
KIRP	cis	rs4006360	0.506	rs8080177	chr17:39301645	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.58	-7.56	-0.43	7.91e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-0.7	-7.13	-0.41	1.14e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg25039879	chr17:56429692	SUPT4H1	0.58	5.17	0.31	4.95e-7	Cognitive test performance;
KIRP	cis	rs6681460	0.565	rs2147776	chr1:67107403	T/C	cg13052034	chr1:66999238	SGIP1	0.4	5.7	0.34	3.33e-8	Presence of antiphospholipid antibodies;
KIRP	cis	rs5995756	0.600	rs5757748	chr22:40010636	T/A	cg10455938	chr22:40058150	CACNA1I	0.41	5.68	0.34	3.89e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06850241	chr22:41845214	NA	-0.45	-5.64	-0.34	4.58e-8	Vitiligo;
KIRP	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.03	-0.31	9.58e-7	Pulmonary function;
KIRP	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg13798912	chr7:905769	UNC84A	0.58	5.28	0.32	2.86e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs12580194	0.556	rs73119000	chr12:55736662	G/A	cg19537932	chr12:55886519	OR6C68	-0.48	-6.34	-0.37	1.12e-9	Cancer;
KIRP	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.65	8.49	0.48	2e-15	Coronary artery disease;
KIRP	cis	rs6110278	0.685	rs6110289	chr20:14414757	T/G	cg17696268	chr20:14319035	FLRT3;MACROD2	-0.36	-4.98	-0.3	1.19e-6	Mean platelet volume;
KIRP	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.51	5.99	0.36	7.42e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs10242455	0.702	rs28377312	chr7:98984213	G/A	cg18809830	chr7:99032528	PTCD1	-0.93	-5.22	-0.32	3.75e-7	Blood metabolite levels;
KIRP	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08439880	chr3:133502540	NA	-0.5	-6.21	-0.37	2.28e-9	Iron status biomarkers;
KIRP	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg24375607	chr4:120327624	NA	0.57	5.77	0.35	2.34e-8	Corneal astigmatism;
KIRP	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.47	5.77	0.35	2.33e-8	HDL cholesterol;
KIRP	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg20673091	chr1:2541236	MMEL1	0.49	6.91	0.4	4.01e-11	Ulcerative colitis;
KIRP	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.47	5.96	0.36	8.64e-9	Depressive symptoms;
KIRP	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.17	0.64	2.5e-30	Bladder cancer;
KIRP	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-7.93	-0.45	7.84e-14	Glomerular filtration rate;
KIRP	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.43	6.01	0.36	6.8e-9	Testicular germ cell tumor;
KIRP	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg21573476	chr21:45109991	RRP1B	0.64	8.65	0.48	6.96e-16	Mean corpuscular volume;
KIRP	cis	rs75920871	0.920	rs61907605	chr11:116820071	T/A	cg23684410	chr11:116897558	SIK3	0.55	6.02	0.36	6.32e-9	Subjective well-being;
KIRP	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg08533674	chr1:46993347	NA	-0.4	-5.22	-0.32	3.88e-7	Monobrow;
KIRP	cis	rs876084	0.630	rs4871824	chr8:121005591	C/T	cg06265175	chr8:121136014	COL14A1	-0.43	-4.93	-0.3	1.48e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00689492	chr4:1303491	MAEA	0.29	5.09	0.31	7.23e-7	Obesity-related traits;
KIRP	cis	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg26585981	chr11:48327164	OR4S1	-0.45	-5.54	-0.33	7.93e-8	HDL cholesterol;
KIRP	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg00806126	chr19:22604979	ZNF98	0.68	7.05	0.41	1.82e-11	Pain;
KIRP	cis	rs9303542	0.694	rs9906950	chr17:46577167	A/G	cg04904318	chr17:46607828	HOXB1	0.45	5.72	0.34	3.09e-8	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg17108064	chr15:78857060	CHRNA5	0.35	5.13	0.31	5.92e-7	Sudden cardiac arrest;
KIRP	cis	rs16858210	0.874	rs11918588	chr3:183601715	C/A	cg25686905	chr3:183603175	PARL	-0.46	-5.95	-0.35	9.24e-9	Menopause (age at onset);
KIRP	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.59	6.61	0.39	2.33e-10	Height;
KIRP	cis	rs7570971	0.517	rs10187402	chr2:135771974	C/G	cg07169764	chr2:136633963	MCM6	0.51	5.85	0.35	1.52e-8	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06481639	chr22:41940642	POLR3H	0.68	7.98	0.45	5.57e-14	Vitiligo;
KIRP	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs1318772	0.932	rs7736165	chr5:112866157	G/A	cg12552261	chr5:112820674	MCC	-0.76	-5.36	-0.32	1.91e-7	F-cell distribution;
KIRP	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.45	5.41	0.33	1.47e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.74	-9.81	-0.53	2.13e-19	Huntington's disease progression;
KIRP	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg05991184	chr2:219186017	PNKD	0.36	5.06	0.31	8.39e-7	Colorectal cancer;
KIRP	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg25019033	chr10:957182	NA	-0.52	-6.74	-0.39	1.1e-10	Eosinophil percentage of granulocytes;
KIRP	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.78	-11.08	-0.58	2.09e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg16926213	chr1:1841314	NA	-0.29	-5.04	-0.31	8.92e-7	Body mass index;
KIRP	cis	rs514024	0.700	rs555022	chr9:130491726	T/C	cg13643465	chr9:130375613	STXBP1	0.42	5.71	0.34	3.25e-8	Eating disorders (purging via substances);
KIRP	cis	rs7011507	0.945	rs75644990	chr8:49162000	C/A	cg15325961	chr8:49183143	NA	0.6	5.11	0.31	6.49e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2742417	1.000	rs2742368	chr3:45752293	C/A	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.92	14.65	0.68	2.32e-35	Blood protein levels;
KIRP	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg17554472	chr22:41940697	POLR3H	-0.5	-5.65	-0.34	4.52e-8	Neuroticism;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06602594	chr15:85259794	SEC11A	0.44	6.24	0.37	1.91e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs12780845	0.505	rs7085742	chr10:17248828	G/C	cg01003015	chr10:17271136	VIM	-0.47	-6.02	-0.36	6.16e-9	Homocysteine levels;
KIRP	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.81	-0.49	2.28e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg00758881	chr16:58534681	NDRG4	-0.71	-4.92	-0.3	1.61e-6	Schizophrenia;
KIRP	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-6.05	-0.36	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-6.26	-0.37	1.66e-9	Bipolar disorder;
KIRP	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.94	-0.54	8.61e-20	Response to antipsychotic treatment;
KIRP	cis	rs58785573	0.553	rs36023504	chr4:38698924	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.45	-4.99	-0.3	1.14e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg25486957	chr4:152246857	NA	-0.45	-5.47	-0.33	1.08e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.86	-13.37	-0.65	5.33e-31	Extrinsic epigenetic age acceleration;
KIRP	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.77	10.52	0.56	1.31e-21	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.45	5.59	0.34	6.12e-8	Melanoma;
KIRP	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.64	6.78	0.4	8.86e-11	Vitiligo;
KIRP	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg26681399	chr22:41777847	TEF	-0.48	-5.02	-0.31	9.76e-7	Vitiligo;
KIRP	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.81	-12.85	-0.63	2.87e-29	Blood metabolite levels;
KIRP	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.86	10.75	0.57	2.31e-22	Coronary artery disease;
KIRP	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg26384229	chr12:38710491	ALG10B	0.6	8.34	0.47	5.28e-15	Morning vs. evening chronotype;
KIRP	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17507749	chr15:85114479	UBE2QP1	0.72	8.16	0.46	1.79e-14	Schizophrenia;
KIRP	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4262150	0.883	rs72799153	chr5:152112858	A/T	cg12297329	chr5:152029980	NA	-0.66	-8.35	-0.47	4.9e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg11987759	chr7:65425863	GUSB	0.59	7.87	0.45	1.12e-13	Calcium levels;
KIRP	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg11344533	chr11:111475393	SIK2	-0.29	-4.97	-0.3	1.24e-6	Primary sclerosing cholangitis;
KIRP	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg20701182	chr2:24300061	SF3B14	0.49	5.08	0.31	7.48e-7	Asthma;
KIRP	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	6.79	0.4	8.5e-11	Menarche (age at onset);
KIRP	cis	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg06521331	chr12:34319734	NA	-0.63	-7.44	-0.43	1.68e-12	Morning vs. evening chronotype;
KIRP	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.71	8.55	0.48	1.31e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg08662619	chr6:150070041	PCMT1	0.35	5.44	0.33	1.3e-7	Lung cancer;
KIRP	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg17845761	chr1:175162550	KIAA0040	-0.33	-6.26	-0.37	1.67e-9	Alcohol dependence;
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg21285383	chr16:89894308	SPIRE2	0.33	6.3	0.37	1.33e-9	Vitiligo;
KIRP	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.64	-8.71	-0.49	4.38e-16	Lymphocyte counts;
KIRP	cis	rs8103278	0.507	rs10401971	chr19:46261982	C/T	cg11657440	chr19:46296263	DMWD	0.93	14.99	0.69	1.6e-36	Coronary artery disease;
KIRP	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg05861140	chr6:150128134	PCMT1	-0.37	-4.94	-0.3	1.46e-6	Lung cancer;
KIRP	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.17	-0.46	1.64e-14	Monocyte percentage of white cells;
KIRP	cis	rs11955175	0.850	rs111959286	chr5:40704141	A/T	cg17351974	chr5:40835760	RPL37	0.64	5.37	0.32	1.81e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs1440410	0.598	rs9308167	chr4:144032234	T/G	cg01719995	chr4:144104893	USP38	0.46	6.06	0.36	5.14e-9	Ischemic stroke;
KIRP	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg18850127	chr7:39170497	POU6F2	0.28	5.15	0.31	5.23e-7	IgG glycosylation;
KIRP	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg19743168	chr1:23544995	NA	0.52	7.27	0.42	4.82e-12	Height;
KIRP	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg23387468	chr7:139079360	LUC7L2	0.29	5.0	0.3	1.09e-6	Diisocyanate-induced asthma;
KIRP	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.66	7.93	0.45	7.58e-14	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs7215564	0.818	rs35638109	chr17:78657367	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.12	0.31	6.29e-7	Myopia (pathological);
KIRP	cis	rs7570971	1.000	rs7570971	chr2:135837906	C/A	cg07169764	chr2:136633963	MCM6	0.44	5.11	0.31	6.33e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
KIRP	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg13395646	chr4:1353034	KIAA1530	-0.37	-4.91	-0.3	1.67e-6	Obesity-related traits;
KIRP	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg19468946	chr17:37922297	IKZF3	-0.51	-7.02	-0.41	2.09e-11	Self-reported allergy;
KIRP	cis	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg21546286	chr11:48923668	NA	-0.43	-5.22	-0.32	3.84e-7	HDL cholesterol;
KIRP	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.54	6.98	0.41	2.81e-11	Coronary heart disease;
KIRP	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.49	6.03	0.36	5.92e-9	HDL cholesterol;
KIRP	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg09873164	chr1:152488093	CRCT1	0.61	7.9	0.45	9.45e-14	Hair morphology;
KIRP	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg05791153	chr7:19748676	TWISTNB	0.67	6.09	0.36	4.32e-9	Thyroid stimulating hormone;
KIRP	cis	rs6005807	0.719	rs2144922	chr22:28923317	A/G	cg12565055	chr22:29076175	TTC28	0.62	4.91	0.3	1.69e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg11945507	chr8:142233382	SLC45A4	0.9	15.91	0.71	1.12e-39	Immature fraction of reticulocytes;
KIRP	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.46	-6.31	-0.37	1.27e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13198984	chr17:80129470	CCDC57	-0.57	-8.69	-0.48	5.27e-16	Life satisfaction;
KIRP	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg15181151	chr6:150070149	PCMT1	0.3	5.0	0.3	1.11e-6	Lung cancer;
KIRP	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.7	-8.31	-0.47	6.6e-15	Coronary artery disease;
KIRP	cis	rs273218	1.000	rs156385	chr5:53370749	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.61	6.95	0.4	3.32e-11	Migraine;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg03469122	chr7:107380932	NA	0.49	6.61	0.39	2.4e-10	Interleukin-4 levels;
KIRP	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-9.76	-0.53	3.24e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg14458575	chr2:238380390	NA	0.75	7.51	0.43	1.12e-12	Prostate cancer;
KIRP	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg02975922	chr3:195473998	MUC4	-0.54	-6.35	-0.38	1.06e-9	Pancreatic cancer;
KIRP	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg01849789	chr22:41697279	ZC3H7B	-0.46	-5.43	-0.33	1.35e-7	Neuroticism;
KIRP	trans	rs669484	0.541	rs10959100	chr9:10425867	G/A	cg25509871	chr19:40871557	PLD3	-0.68	-6.57	-0.39	3.02e-10	Gestational age at birth (child effect);
KIRP	cis	rs3779635	0.742	rs2115805	chr8:27258086	G/A	cg18234130	chr8:27182889	PTK2B	0.52	6.81	0.4	7.6e-11	Neuroticism;
KIRP	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg10495392	chr1:46806563	NSUN4	0.48	5.45	0.33	1.24e-7	Menopause (age at onset);
KIRP	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg07636037	chr3:49044803	WDR6	0.54	5.2	0.31	4.21e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs8079658	1.000	rs62065085	chr17:63822828	G/C	cg18091269	chr17:63822838	CCDC46	-0.56	-7.8	-0.45	1.76e-13	Post bronchodilator FEV1;
KIRP	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	8.66	0.48	6.17e-16	Electroencephalogram traits;
KIRP	cis	rs57994353	0.828	rs11146021	chr9:139327858	A/G	cg21253087	chr9:139290292	SNAPC4	-0.43	-4.93	-0.3	1.52e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg21854759	chr1:92012499	NA	-0.46	-5.91	-0.35	1.16e-8	Breast cancer;
KIRP	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.57	6.18	0.37	2.59e-9	Alcohol dependence;
KIRP	cis	rs6701037	1.000	rs7512413	chr1:175124789	C/T	cg00958927	chr1:175162553	KIAA0040	-0.29	-4.96	-0.3	1.31e-6	Alcohol dependence;
KIRP	cis	rs13401104	0.587	rs62190973	chr2:237145231	T/A	cg02367144	chr2:237146137	ASB18	0.4	5.25	0.32	3.26e-7	Educational attainment;
KIRP	cis	rs8008758	1.000	rs12432879	chr14:101688977	A/G	cg26224664	chr14:101693935	NA	0.39	4.87	0.3	1.96e-6	Body mass index (alcohol intake interaction);
KIRP	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.73	-9.87	-0.53	1.38e-19	Metabolic syndrome;
KIRP	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03407747	chr17:6899364	ALOX12	0.3	5.47	0.33	1.1e-7	Tonsillectomy;
KIRP	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.5	7.57	0.43	7.61e-13	Immature fraction of reticulocytes;
KIRP	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg14952266	chr13:112191215	NA	0.45	6.6	0.39	2.52e-10	Hepatitis;
KIRP	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-11.78	-0.6	1.06e-25	Systemic lupus erythematosus;
KIRP	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00853445	chr19:41107573	LTBP4	0.48	6.68	0.39	1.55e-10	Parkinson's disease;
KIRP	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.85	13.6	0.66	8.39e-32	Prostate cancer;
KIRP	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.25	-34.58	-0.91	1.88e-96	Myeloid white cell count;
KIRP	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg17294928	chr15:75287854	SCAMP5	-0.69	-6.15	-0.37	3.12e-9	Lung cancer;
KIRP	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg02151108	chr14:50098012	C14orf104	-0.57	-7.99	-0.45	5.08e-14	Carotid intima media thickness;
KIRP	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg25182066	chr10:30743637	MAP3K8	-0.62	-7.55	-0.43	8.3e-13	Inflammatory bowel disease;
KIRP	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06850241	chr22:41845214	NA	-0.4	-5.08	-0.31	7.41e-7	Vitiligo;
KIRP	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg25319279	chr11:5960081	NA	-0.58	-6.03	-0.36	6.13e-9	DNA methylation (variation);
KIRP	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg14768367	chr16:72042858	DHODH	-0.77	-8.38	-0.47	4.04e-15	Blood protein levels;
KIRP	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	ch.11.42038R	chr11:967971	AP2A2	0.38	4.9	0.3	1.7e-6	Alzheimer's disease (late onset);
KIRP	cis	rs580438	0.529	rs7616685	chr3:13429290	A/G	cg10657019	chr3:13328039	NA	-0.57	-7.56	-0.43	8.08e-13	Myringotomy;
KIRP	cis	rs6547631	0.622	rs2118402	chr2:85931078	A/G	cg24620635	chr2:85921963	GNLY	0.32	5.13	0.31	5.95e-7	Blood protein levels;
KIRP	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg26207909	chr14:103986467	CKB	-0.43	-5.21	-0.32	3.96e-7	Coronary artery disease;
KIRP	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg19554555	chr3:13937349	NA	-0.46	-6.28	-0.37	1.49e-9	Ovarian reserve;
KIRP	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.52	5.14	0.31	5.55e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.41	5.59	0.34	5.94e-8	Homoarginine levels;
KIRP	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.71	7.26	0.42	5.21e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg12140854	chr5:148520817	ABLIM3	-0.54	-6.14	-0.36	3.34e-9	Breast cancer;
KIRP	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.93	13.96	0.66	5.25e-33	Personality dimensions;
KIRP	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-7.49	-0.43	1.21e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg07274523	chr3:49395745	GPX1	0.69	8.6	0.48	9.42e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg03060546	chr3:49711283	APEH	0.52	6.87	0.4	5.09e-11	Menarche (age at onset);
KIRP	cis	rs9826463	0.759	rs115683937	chr3:142335548	G/A	cg20824294	chr3:142316082	PLS1	0.47	6.57	0.39	3.02e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg00409905	chr10:38381863	ZNF37A	0.57	6.15	0.36	3.14e-9	Obesity (extreme);
KIRP	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.52	6.68	0.39	1.61e-10	IgG glycosylation;
KIRP	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg06027949	chr8:82754900	SNX16	-0.56	-7.09	-0.41	1.41e-11	Diastolic blood pressure;
KIRP	cis	rs2172802	0.599	rs2088462	chr4:62512727	G/C	cg04118610	chr4:62707027	LPHN3	-0.44	-5.39	-0.33	1.64e-7	Partial epilepsies;
KIRP	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg00631329	chr6:26305371	NA	0.53	6.77	0.4	9.64e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.57	-7.56	-0.43	7.96e-13	Aortic root size;
KIRP	cis	rs9810890	1.000	rs115284166	chr3:128492511	A/G	cg15033153	chr3:128514015	RAB7A	0.7	4.98	0.3	1.21e-6	Dental caries;
KIRP	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg08989290	chr16:615782	NHLRC4	0.42	6.23	0.37	1.98e-9	Height;
KIRP	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg23422044	chr7:1970798	MAD1L1	-0.51	-6.13	-0.36	3.46e-9	Bipolar disorder;
KIRP	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	5.6	0.34	5.8e-8	Homoarginine levels;
KIRP	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg10326726	chr10:51549505	MSMB	0.58	8.3	0.47	7.07e-15	Prostate-specific antigen levels;
KIRP	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg10434728	chr15:90938212	IQGAP1	0.4	7.67	0.44	3.98e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.79	10.06	0.54	3.7e-20	Menopause (age at onset);
KIRP	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.68	9.23	0.51	1.29e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2072732	0.861	rs77840846	chr1:2968983	G/C	cg11731671	chr1:2995604	PRDM16	-0.52	-5.7	-0.34	3.38e-8	Plateletcrit;
KIRP	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.65	9.61	0.52	8.78e-19	Monocyte percentage of white cells;
KIRP	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg19847130	chr8:10466454	RP1L1	0.35	5.05	0.31	8.43e-7	Retinal vascular caliber;
KIRP	cis	rs12620999	0.941	rs4663240	chr2:238036632	G/T	cg23555395	chr2:238036564	NA	-0.57	-6.72	-0.39	1.27e-10	Systemic lupus erythematosus;
KIRP	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg00792783	chr2:198669748	PLCL1	0.46	5.18	0.31	4.61e-7	Dermatomyositis;
KIRP	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.83	11.98	0.61	2.31e-26	Bone mineral density;
KIRP	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-5.72	-0.34	3.13e-8	Life satisfaction;
KIRP	trans	rs6902257	0.590	rs2168107	chr6:81310440	C/T	cg06063519	chr15:99274532	IGF1R	-0.64	-6.17	-0.37	2.86e-9	Obesity-related traits;
KIRP	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.76	-0.4	1.02e-10	Morning vs. evening chronotype;
KIRP	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg03060546	chr3:49711283	APEH	0.48	6.34	0.37	1.08e-9	Parkinson's disease;
KIRP	cis	rs7635838	0.596	rs4684765	chr3:11261085	G/C	cg00170343	chr3:11313890	ATG7	0.5	6.62	0.39	2.18e-10	HDL cholesterol;
KIRP	cis	rs9462846	1.000	rs9471942	chr6:42861532	C/T	cg05552183	chr6:42928497	GNMT	0.44	5.06	0.31	8.38e-7	Blood protein levels;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00419759	chr1:114301964	PHTF1	-0.5	-6.5	-0.38	4.36e-10	Neuroticism;
KIRP	cis	rs6832769	1.000	rs9684708	chr4:56430381	G/A	cg05960024	chr4:56376020	CLOCK	-0.71	-9.15	-0.5	2.18e-17	Personality dimensions;
KIRP	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.71	9.9	0.53	1.12e-19	Mean corpuscular volume;
KIRP	cis	rs10782582	0.586	rs12130324	chr1:76370012	A/G	cg03433033	chr1:76189801	ACADM	-0.47	-6.86	-0.4	5.67e-11	Daytime sleep phenotypes;
KIRP	cis	rs4727443	0.932	rs7803714	chr7:99585150	G/T	cg22004693	chr7:99632812	ZKSCAN1	0.4	5.37	0.32	1.86e-7	Interstitial lung disease;
KIRP	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg05347473	chr6:146136440	FBXO30	0.48	7.09	0.41	1.4e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72730918	0.590	rs2606134	chr15:51973650	G/C	cg14296394	chr15:51910925	DMXL2	-0.74	-10.0	-0.54	5.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.82	11.9	0.6	4.19e-26	Bladder cancer;
KIRP	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg02403541	chr12:121454288	C12orf43	0.75	9.56	0.52	1.29e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg17757837	chr7:157058334	UBE3C	-0.62	-6.36	-0.38	9.68e-10	Type 2 diabetes;
KIRP	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.43	-15.9	-0.71	1.25e-39	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs7332672	0.620	rs2015342	chr13:100060497	C/T	cg25919922	chr13:100150906	NA	0.46	5.15	0.31	5.23e-7	Eosinophil counts;
KIRP	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.92	9.92	0.53	1.02e-19	Type 2 diabetes nephropathy;
KIRP	cis	rs236907	0.812	rs35400839	chr1:171743312	G/A	cg01410279	chr1:171621941	MYOC	-0.53	-5.32	-0.32	2.34e-7	Mean platelet volume;
KIRP	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg26248373	chr2:1572462	NA	-0.65	-6.28	-0.37	1.51e-9	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg05347473	chr6:146136440	FBXO30	0.51	7.3	0.42	4.02e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.61	-7.79	-0.44	1.91e-13	Colorectal cancer;
KIRP	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.66	-8.21	-0.46	1.29e-14	Recalcitrant atopic dermatitis;
KIRP	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.39e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.7	10.34	0.55	4.76e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.42	5.65	0.34	4.43e-8	Homoarginine levels;
KIRP	cis	rs9815354	0.904	rs9852991	chr3:41875455	C/A	cg03022575	chr3:42003672	ULK4	0.65	6.99	0.41	2.59e-11	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.7	8.41	0.47	3.38e-15	Alcohol dependence;
KIRP	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.56	7.41	0.43	2.08e-12	Breast cancer;
KIRP	cis	rs7561273	0.609	rs2160943	chr2:24288775	G/A	cg20701182	chr2:24300061	SF3B14	0.44	5.41	0.33	1.5e-7	Quantitative traits;
KIRP	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg17294928	chr15:75287854	SCAMP5	-0.62	-5.6	-0.34	5.71e-8	Lung cancer;
KIRP	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg01988459	chr11:68622903	NA	-0.38	-5.49	-0.33	1e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.41	5.19	0.31	4.46e-7	Educational attainment;
KIRP	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.47	5.97	0.36	8.29e-9	Motion sickness;
KIRP	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg06204229	chr3:52865917	ITIH4	0.47	5.84	0.35	1.66e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg21605333	chr4:119757512	SEC24D	1.56	10.56	0.56	9.77e-22	Cannabis dependence symptom count;
KIRP	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg16482183	chr6:26056742	HIST1H1C	0.62	6.95	0.41	3.2e-11	Iron status biomarkers;
KIRP	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.85	11.36	0.59	2.58e-24	Morning vs. evening chronotype;
KIRP	cis	rs2177596	0.549	rs4592846	chr2:227948866	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-6.17	-0.37	2.79e-9	Body mass index;
KIRP	trans	rs1106684	1.000	rs66645003	chr7:131463451	T/C	cg13607082	chr12:122652224	LRRC43	-0.66	-6.64	-0.39	1.99e-10	Body mass index;
KIRP	trans	rs6055685	1.000	rs6108126	chr20:8211226	A/T	cg13423151	chr9:107526487	NIPSNAP3B	0.56	6.02	0.36	6.26e-9	Suicide ideation score in major depressive disorder;
KIRP	cis	rs7187994	0.790	rs12922301	chr16:84794870	A/G	cg07647771	chr16:84786436	USP10	-0.42	-5.39	-0.32	1.68e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs6541297	0.699	rs12065546	chr1:230295245	C/T	cg05784532	chr1:230284198	GALNT2	0.45	6.07	0.36	4.8e-9	Coronary artery disease;
KIRP	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg02993010	chr8:124780839	FAM91A1	0.51	4.99	0.3	1.14e-6	Pancreatic cancer;
KIRP	cis	rs1050631	0.564	rs1785929	chr18:33725165	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.42	5.44	0.33	1.27e-7	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs7688540	0.771	rs11723261	chr4:282499	A/G	cg10134910	chr4:1076041	RNF212	-0.24	-4.85	-0.3	2.19e-6	Facial morphology (factor 6, height of vermillion lower lip);
KIRP	cis	rs2554380	0.943	rs2585049	chr15:84352873	A/C	cg14598478	chr15:84363061	ADAMTSL3	0.56	7.9	0.45	9.2e-14	Height;
KIRP	cis	rs10811516	0.501	rs7024604	chr9:21174878	C/G	cg23029519	chr9:21187344	IFNA4	-0.44	-5.28	-0.32	2.9e-7	Response to mepolizumab in severe asthma;
KIRP	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.68	-10.23	-0.55	1.04e-20	Heart rate;
KIRP	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-6.04	-0.36	5.61e-9	QT interval;
KIRP	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg21926883	chr2:100939477	LONRF2	-0.52	-6.9	-0.4	4.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.57	-0.39	3.02e-10	Aortic root size;
KIRP	cis	rs2688608	0.934	rs2675679	chr10:75658581	C/T	cg23231163	chr10:75533350	FUT11	-0.33	-5.08	-0.31	7.51e-7	Inflammatory bowel disease;
KIRP	cis	rs3784262	0.669	rs4646579	chr15:58329528	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-4.87	-0.3	2.04e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
KIRP	cis	rs10761482	0.639	rs2067612	chr10:62212334	T/C	cg01186212	chr10:62110162	ANK3	-0.31	-5.21	-0.32	3.9e-7	Schizophrenia;
KIRP	cis	rs75920871	0.588	rs688456	chr11:116722551	G/T	cg04087571	chr11:116723030	SIK3	-0.31	-6.38	-0.38	8.66e-10	Subjective well-being;
KIRP	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.46	5.74	0.34	2.78e-8	Asthma;
KIRP	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.68	8.99	0.5	6.75e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	cg21523751	chr1:182988639	NA	0.36	5.29	0.32	2.68e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.79	12.46	0.62	6.14e-28	Coronary artery disease;
KIRP	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.33	-5.06	-0.31	8.36e-7	Psoriasis;
KIRP	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.47	-4.92	-0.3	1.56e-6	Initial pursuit acceleration;
KIRP	cis	rs7520050	0.831	rs61783169	chr1:46256327	T/C	cg24296786	chr1:45957014	TESK2	0.43	5.19	0.31	4.32e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.49	6.02	0.36	6.15e-9	Initial pursuit acceleration;
KIRP	cis	rs3754214	0.823	rs494041	chr1:150270026	T/C	cg09579323	chr1:150459698	TARS2	-0.4	-5.04	-0.31	9.22e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.89	7.9	0.45	9.38e-14	Diisocyanate-induced asthma;
KIRP	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg27121462	chr16:89883253	FANCA	-0.51	-6.59	-0.39	2.64e-10	Vitiligo;
KIRP	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17507749	chr15:85114479	UBE2QP1	0.77	8.61	0.48	8.76e-16	Schizophrenia;
KIRP	cis	rs2929278	0.617	rs12908467	chr15:44047430	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.52	-6.29	-0.37	1.42e-9	Schizophrenia;
KIRP	trans	rs669484	0.541	rs4741033	chr9:10430378	A/C	cg25509871	chr19:40871557	PLD3	-0.65	-6.19	-0.37	2.55e-9	Gestational age at birth (child effect);
KIRP	cis	rs4925386	0.681	rs2427294	chr20:60927257	G/A	cg24112000	chr20:60950667	NA	-0.66	-8.28	-0.47	7.68e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg08501292	chr6:25962987	TRIM38	0.77	5.24	0.32	3.4e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.65	-5.73	-0.34	2.87e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.63	-8.02	-0.46	4.23e-14	Diastolic blood pressure;
KIRP	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg26373071	chr5:1325741	CLPTM1L	-0.51	-6.59	-0.39	2.69e-10	Lung cancer;
KIRP	cis	rs1891498	0.571	rs12409049	chr1:147236467	C/T	cg27546670	chr1:147246839	GJA5	-0.77	-10.29	-0.55	7.18e-21	Cognitive performance;
KIRP	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.79	-11.36	-0.59	2.52e-24	Blood metabolite levels;
KIRP	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg27398637	chr11:122830231	C11orf63	-0.76	-10.04	-0.54	4.29e-20	Menarche (age at onset);
KIRP	cis	rs62355272	0.674	rs35081631	chr5:35815846	G/C	cg13894535	chr5:35919491	CAPSL	-0.42	-4.93	-0.3	1.5e-6	Lymphocyte counts;
KIRP	cis	rs1021993	0.545	rs1507331	chr1:209516897	C/G	cg24446417	chr1:209558027	NA	-0.48	-4.96	-0.3	1.33e-6	Gut microbiome composition (winter);
KIRP	cis	rs72960926	0.744	rs72959615	chr6:74991323	C/T	cg03266952	chr6:74778945	NA	-0.76	-5.78	-0.35	2.28e-8	Metabolite levels (MHPG);
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.48	6.31	0.37	1.26e-9	Menarche (age at onset);
KIRP	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg08975724	chr8:8085496	FLJ10661	0.65	8.49	0.48	1.94e-15	Systolic blood pressure;
KIRP	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	0.97	16.79	0.73	1.16e-42	Menarche (age at onset);
KIRP	trans	rs704178	0.967	rs829079	chr12:21999108	A/C	cg20897728	chr5:784915	NA	-0.47	-6.34	-0.37	1.08e-9	Hippocampal sclerosis of aging;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23954489	chr18:30050398	FAM59A	0.49	6.46	0.38	5.66e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg01721255	chr8:58191610	C8orf71	0.54	5.59	0.34	6.14e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs17101923	1.000	rs10878346	chr12:66320873	C/T	cg06712651	chr12:66351869	HMGA2	-0.57	-6.47	-0.38	5.35e-10	Primary tooth development (number of teeth);Primary tooth development (time to first tooth eruption);
KIRP	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg00147788	chr6:125855365	NA	-0.33	-5.15	-0.31	5.46e-7	Brugada syndrome;
KIRP	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.12	0.67	1.51e-33	Alzheimer's disease;
KIRP	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.71	8.6	0.48	9.28e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg09699651	chr6:150184138	LRP11	0.45	5.83	0.35	1.72e-8	Lung cancer;
KIRP	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-4.91	-0.3	1.66e-6	Lung cancer;
KIRP	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	6.41	0.38	7.23e-10	Prudent dietary pattern;
KIRP	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.6	-7.82	-0.45	1.56e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs4262150	0.883	rs72804789	chr5:152322621	C/T	cg12297329	chr5:152029980	NA	-0.63	-8.33	-0.47	5.52e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18252515	chr7:66147081	NA	0.42	4.89	0.3	1.86e-6	Aortic root size;
KIRP	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg10503236	chr1:231470652	EXOC8	-0.52	-7.5	-0.43	1.14e-12	Hemoglobin concentration;
KIRP	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	0.55	6.59	0.39	2.73e-10	Prudent dietary pattern;
KIRP	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg24642844	chr7:1081250	C7orf50	-0.66	-6.7	-0.39	1.38e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.9	-14.2	-0.67	7.61e-34	Breast cancer;
KIRP	cis	rs62103177	0.713	rs3744886	chr18:77659561	G/T	cg03511173	chr18:77590860	NA	0.6	5.1	0.31	6.73e-7	Opioid sensitivity;
KIRP	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.29	-6.34	-0.37	1.11e-9	Asthma (sex interaction);
KIRP	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg01620082	chr3:125678407	NA	-0.85	-6.31	-0.37	1.26e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.8	-13.42	-0.65	3.44e-31	Prostate cancer;
KIRP	cis	rs12788925	0.504	rs7124873	chr11:102803476	A/G	cg19620758	chr11:102826565	MMP13	-0.41	-5.04	-0.31	8.96e-7	Coronary artery disease;
KIRP	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.58	-5.83	-0.35	1.74e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.46	5.86	0.35	1.48e-8	Motion sickness;
KIRP	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.97	16.94	0.73	3.57e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9653442	0.527	rs10176782	chr2:100782827	C/A	cg17356467	chr2:100759845	AFF3	0.44	5.63	0.34	4.78e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs2281603	0.857	rs3783722	chr14:64997966	T/A	cg25009451	chr14:65006716	HSPA2	0.48	5.25	0.32	3.26e-7	Lymphocyte counts;
KIRP	cis	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg21546286	chr11:48923668	NA	-0.45	-5.5	-0.33	9.64e-8	HDL cholesterol;
KIRP	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.62	-7.41	-0.43	1.98e-12	Glomerular filtration rate;
KIRP	cis	rs7551222	0.892	rs7539399	chr1:204590044	A/G	cg20240347	chr1:204465584	NA	0.3	5.05	0.31	8.41e-7	Schizophrenia;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg12636108	chr5:176036956	GPRIN1	0.54	7.39	0.43	2.34e-12	Myopia (pathological);
KIRP	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.67	-7.19	-0.42	7.77e-12	Blood pressure (smoking interaction);
KIRP	cis	rs6032067	0.866	rs1007137	chr20:43816593	T/C	cg10761708	chr20:43804764	PI3	0.43	4.94	0.3	1.44e-6	Blood protein levels;
KIRP	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.56	0.33	7.14e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs2131877	0.599	rs28573813	chr3:194846413	G/A	cg16306870	chr3:194868790	C3orf21	0.21	4.95	0.3	1.4e-6	Non-small cell lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13920838	chr9:35095103	PIGO	0.51	6.3	0.37	1.37e-9	Interleukin-4 levels;
KIRP	cis	rs6684514	1.000	rs12024813	chr1:156224529	C/A	cg16558208	chr1:156270281	VHLL	-0.45	-5.85	-0.35	1.58e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	trans	rs6025261	0.529	rs11699056	chr20:55546323	A/C	cg04643103	chr1:150039325	VPS45	-0.46	-6.07	-0.36	4.74e-9	Verbal memory performance (delayed recall level);
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.49	4.99	0.3	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	0.96	13.05	0.64	6.45e-30	Ulcerative colitis;
KIRP	cis	rs7113874	0.527	rs12790154	chr11:8405148	G/A	cg08015107	chr11:8618950	NA	-0.62	-7.51	-0.43	1.07e-12	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6921919	0.525	rs9468360	chr6:28344438	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.43	-6.22	-0.37	2.09e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11987759	chr7:65425863	GUSB	0.5	6.74	0.39	1.14e-10	Aortic root size;
KIRP	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.46	-5.72	-0.34	3.12e-8	P wave terminal force;
KIRP	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.79	-12.67	-0.63	1.16e-28	Prostate cancer;
KIRP	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg03493300	chr10:104813866	CNNM2	0.36	4.89	0.3	1.79e-6	Arsenic metabolism;
KIRP	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18252515	chr7:66147081	NA	-0.45	-5.49	-0.33	9.78e-8	Aortic root size;
KIRP	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.84	-11.94	-0.61	3.07e-26	Educational attainment;
KIRP	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-4.93	-0.3	1.5e-6	Joint mobility (Beighton score);
KIRP	trans	rs13170463	0.649	rs35929705	chr5:8035648	C/G	cg03862380	chr20:43029895	HNF4A	0.4	6.12	0.36	3.71e-9	Colorectal cancer;
KIRP	cis	rs9826463	0.582	rs73238186	chr3:142141180	A/C	cg20824294	chr3:142316082	PLS1	0.44	6.35	0.38	1.02e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.64	7.81	0.45	1.66e-13	Corneal astigmatism;
KIRP	cis	rs300890	0.583	rs2012599	chr4:144196860	T/C	cg01719995	chr4:144104893	USP38	0.41	5.16	0.31	5.07e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs10214930	0.813	rs759270	chr7:27646461	T/G	cg22168087	chr7:27702803	HIBADH	0.51	5.09	0.31	7.04e-7	Hypospadias;
KIRP	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg18225595	chr11:63971243	STIP1	0.66	6.0	0.36	6.95e-9	Mean platelet volume;
KIRP	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-10.06	-0.54	3.69e-20	Coffee consumption (cups per day);
KIRP	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	11.49	0.59	9.76e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.46	6.52	0.38	3.88e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs8060686	0.516	rs7189794	chr16:68277727	T/C	cg26727032	chr16:67993705	SLC12A4	-0.69	-7.64	-0.44	4.92e-13	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg04132472	chr17:19861366	AKAP10	0.39	5.0	0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.58	6.55	0.39	3.25e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-0.97	-10.4	-0.55	3.15e-21	Blood pressure (smoking interaction);
KIRP	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.36	0.47	4.77e-15	Electroencephalogram traits;
KIRP	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.37	0.62	1.22e-27	Ileal carcinoids;
KIRP	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg25173405	chr17:45401733	C17orf57	-0.47	-6.09	-0.36	4.39e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.6	7.19	0.42	7.7e-12	Smoking initiation;
KIRP	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg04691961	chr3:161091175	C3orf57	0.44	6.47	0.38	5.15e-10	Morning vs. evening chronotype;
KIRP	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.53	-6.31	-0.37	1.32e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs698813	0.604	rs10865200	chr2:44482884	G/C	cg04920474	chr2:44395004	PPM1B	0.37	4.95	0.3	1.36e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
KIRP	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.73	11.61	0.59	3.96e-25	Monocyte percentage of white cells;
KIRP	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.29	-0.32	2.69e-7	Life satisfaction;
KIRP	cis	rs9473924	0.632	rs9381920	chr6:50937195	C/T	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg01864069	chr14:103024347	NA	0.9	10.49	0.56	1.63e-21	Platelet count;
KIRP	cis	rs4494114	1.000	rs4388668	chr1:39360730	A/T	cg25970120	chr1:39325951	RRAGC	-0.4	-4.92	-0.3	1.57e-6	Blood protein levels;
KIRP	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg24315340	chr6:146058215	EPM2A	0.39	4.93	0.3	1.54e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-5.46	-0.33	1.14e-7	Schizophrenia (age at onset);
KIRP	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.91	-0.3	1.64e-6	Breast cancer;
KIRP	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	14.0	0.67	3.71e-33	Chronic sinus infection;
KIRP	cis	rs4862750	0.914	rs6814259	chr4:187872337	T/C	cg03452623	chr4:187889614	NA	-1.04	-18.85	-0.77	1.15e-49	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg00982548	chr2:198649783	BOLL	-0.53	-4.93	-0.3	1.48e-6	Ulcerative colitis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16427096	chr16:1202468	CACNA1H	0.51	7.42	0.43	1.89e-12	Parkinson's disease;
KIRP	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.25	-17.44	-0.74	6.65e-45	Lymphocyte percentage of white cells;
KIRP	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.95	-0.3	1.4e-6	Schizophrenia;
KIRP	trans	rs12517041	1.000	rs12519798	chr5:23290006	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.92	-0.49	1.11e-16	Calcium levels;
KIRP	cis	rs4478037	0.822	rs3924695	chr3:33122085	C/T	cg19404215	chr3:33155277	CRTAP	0.57	5.29	0.32	2.72e-7	Major depressive disorder;
KIRP	cis	rs150641967	1	rs150641967	chr19:19370340	TGACA/T	cg03709012	chr19:19516395	GATAD2A	1.2	6.7	0.39	1.45e-10	Triglyceride levels;Very low density lipoprotein cholesterol levels;Low density lipoprotein cholesterol;Total cholesterol levels;
KIRP	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-10.34	-0.55	4.77e-21	Heart rate;
KIRP	cis	rs7737355	0.947	rs6864145	chr5:130637861	C/T	cg25547332	chr5:131281432	NA	0.48	5.41	0.33	1.49e-7	Life satisfaction;
KIRP	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-5.87	-0.35	1.4e-8	Primary biliary cholangitis;
KIRP	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.63	9.4	0.51	3.87e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.53	-5.62	-0.34	5.12e-8	Body mass index;
KIRP	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg19338460	chr6:170058176	WDR27	-0.66	-7.61	-0.44	6.02e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.51	-7.47	-0.43	1.42e-12	Bipolar disorder;
KIRP	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.48	-5.9	-0.35	1.18e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.32	0.65	7.86e-31	Eye color traits;
KIRP	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.8	-10.92	-0.57	6.58e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11987759	chr7:65425863	GUSB	-0.5	-6.81	-0.4	7.38e-11	Aortic root size;
KIRP	cis	rs4523957	0.890	rs6503324	chr17:2100512	C/T	cg16513277	chr17:2031491	SMG6	-0.69	-10.04	-0.54	4.25e-20	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.55	-7.02	-0.41	2.21e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs300890	0.642	rs300912	chr4:144276717	A/G	cg01601573	chr4:144256835	GAB1	-0.35	-4.86	-0.3	2.07e-6	Nasopharyngeal carcinoma;
KIRP	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.6	-7.33	-0.42	3.38e-12	Blood trace element (Zn levels);
KIRP	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.97	11.47	0.59	1.15e-24	Corneal astigmatism;
KIRP	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg11062466	chr8:58055876	NA	0.56	4.91	0.3	1.68e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg03161606	chr19:29218774	NA	0.83	8.02	0.46	4.43e-14	Methadone dose in opioid dependence;
KIRP	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg02023728	chr11:77925099	USP35	-0.36	-5.32	-0.32	2.3e-7	Alzheimer's disease (survival time);
KIRP	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.73	-7.35	-0.42	2.89e-12	Bipolar disorder;
KIRP	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg21926883	chr2:100939477	LONRF2	-0.43	-5.59	-0.34	5.88e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs7404928	0.526	rs2575382	chr16:23833644	G/A	cg21745164	chr16:23765304	CHP2	-0.75	-8.78	-0.49	2.87e-16	Primary biliary cholangitis;Rheumatoid arthritis;
KIRP	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.56	-7.74	-0.44	2.53e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.69	-0.44	3.55e-13	Platelet count;
KIRP	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.83	0.49	2.04e-16	Motion sickness;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg17507573	chr15:79382998	RASGRF1	0.47	6.6	0.39	2.48e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.79	-10.84	-0.57	1.24e-22	Calcium levels;
KIRP	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.62	0.8	1.57e-55	Prudent dietary pattern;
KIRP	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.56	8.2	0.46	1.31e-14	Reticulocyte fraction of red cells;
KIRP	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.76	-5.45	-0.33	1.25e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.66	9.06	0.5	4.28e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs1867631	1.000	rs10789213	chr1:67128201	T/C	cg13052034	chr1:66999238	SGIP1	0.47	6.63	0.39	2.11e-10	Menopause (age at onset);
KIRP	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg15839431	chr19:19639596	YJEFN3	-0.51	-5.35	-0.32	2.01e-7	Bipolar disorder;
KIRP	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.66	7.54	0.43	9.16e-13	Corneal astigmatism;
KIRP	trans	rs6506900	0.666	rs8091847	chr18:28902270	C/T	cg10906284	chr12:63544430	AVPR1A	0.37	6.02	0.36	6.35e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg22676075	chr6:135203613	NA	0.45	6.47	0.38	5.13e-10	Red blood cell count;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.35	-6.79	-0.4	8.37e-11	Lymphocyte counts;
KIRP	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-9.24	-0.51	1.17e-17	Glomerular filtration rate (creatinine);
KIRP	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.39	5.44	0.33	1.27e-7	Coronary artery disease;
KIRP	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.59	7.31	0.42	3.69e-12	Schizophrenia;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	7.76	0.44	2.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1957429	1.000	rs1957431	chr14:65353187	A/G	cg23373153	chr14:65346875	NA	0.82	9.63	0.52	7.98e-19	Pediatric areal bone mineral density (radius);
KIRP	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	12.14	0.61	6.67e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs10875746	0.551	rs2054904	chr12:48724354	C/G	cg26205652	chr12:48591994	NA	0.8	10.18	0.54	1.58e-20	Longevity (90 years and older);
KIRP	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	9.88	0.53	1.3e-19	Lung cancer in ever smokers;
KIRP	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.47	-11.7	-0.6	1.96e-25	Diabetic kidney disease;
KIRP	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.43	5.94	0.35	9.54e-9	Red blood cell count;
KIRP	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg25797454	chr6:150327115	RAET1K	0.33	6.04	0.36	5.74e-9	Alopecia areata;
KIRP	trans	rs6738485	0.557	rs12988865	chr2:106854386	G/A	cg14715136	chr2:108537789	NA	0.39	6.28	0.37	1.55e-9	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03766516	chr19:3627160	C19orf29	0.52	6.51	0.38	4.29e-10	Parkinson's disease;
KIRP	trans	rs972578	0.651	rs5759002	chr22:43263432	C/T	cg15321293	chr3:36422198	STAC	0.48	6.12	0.36	3.6e-9	Mean platelet volume;
KIRP	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg20813462	chr7:2646259	IQCE	-0.62	-6.04	-0.36	5.66e-9	Urate levels in lean individuals;
KIRP	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	cg21523751	chr1:182988639	NA	0.41	6.31	0.37	1.31e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg04804543	chr8:142233427	SLC45A4	0.54	7.07	0.41	1.61e-11	Birth weight;
KIRP	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.79	-12.28	-0.62	2.37e-27	Prostate cancer;
KIRP	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg27432699	chr2:27873401	GPN1	-0.57	-7.3	-0.42	3.96e-12	Menopause (age at onset);
KIRP	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.59	6.15	0.37	3.11e-9	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg09699651	chr6:150184138	LRP11	0.51	6.66	0.39	1.82e-10	Lung cancer;
KIRP	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg09408571	chr1:101003634	GPR88	-0.33	-7.66	-0.44	4.2e-13	Breast cancer;
KIRP	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-0.61	-9.08	-0.5	3.69e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs5753037	0.809	rs2074706	chr22:30200893	G/C	cg01021169	chr22:30184971	ASCC2	-0.4	-4.92	-0.3	1.57e-6	Type 1 diabetes;
KIRP	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.93	12.04	0.61	1.51e-26	Cognitive function;
KIRP	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg18882449	chr10:104885122	NT5C2	-0.4	-5.15	-0.31	5.4e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg02733842	chr7:1102375	C7orf50	0.59	6.04	0.36	5.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs4237845	0.591	rs4590915	chr12:58335130	G/A	cg02175503	chr12:58329896	NA	0.88	10.58	0.56	8.37e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.84	0.49	1.91e-16	Bipolar disorder;
KIRP	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.96	11.57	0.59	5.43e-25	Corneal astigmatism;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg01090926	chr14:75137805	KIAA0317	0.49	6.63	0.39	2.09e-10	Interleukin-4 levels;
KIRP	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08048268	chr3:133502702	NA	-0.47	-5.49	-0.33	1.01e-7	Iron status biomarkers;
KIRP	cis	rs3789045	0.826	rs12040520	chr1:204564762	G/A	cg18185008	chr1:204589407	LRRN2	-0.61	-6.63	-0.39	2.1e-10	Educational attainment (college completion);
KIRP	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-6.28	-0.37	1.49e-9	Neuroticism;
KIRP	cis	rs7737355	0.947	rs17167760	chr5:130782699	A/G	cg06307176	chr5:131281290	NA	-0.54	-5.85	-0.35	1.54e-8	Life satisfaction;
KIRP	cis	rs4523957	0.928	rs8077545	chr17:2184555	A/G	cg16513277	chr17:2031491	SMG6	-0.6	-8.29	-0.47	7.3e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg03060546	chr3:49711283	APEH	-0.58	-5.17	-0.31	4.83e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-5.52	-0.33	8.79e-8	Lung cancer;
KIRP	cis	rs5766691	0.965	rs5766693	chr22:47532641	T/C	cg15757745	chr22:47558489	TBC1D22A	-0.42	-5.09	-0.31	7.01e-7	Longevity;
KIRP	cis	rs10782582	0.609	rs111914775	chr1:76319036	C/T	cg03433033	chr1:76189801	ACADM	-0.45	-6.34	-0.37	1.06e-9	Daytime sleep phenotypes;
KIRP	cis	rs4789452	1.000	rs34596832	chr17:75373170	C/T	cg05184938	chr17:75369939	SEPT9	-0.38	-5.19	-0.31	4.34e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg06640241	chr16:89574553	SPG7	0.68	8.93	0.49	1.04e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs365132	0.818	rs251843	chr5:176476106	A/G	cg16309518	chr5:176445507	NA	-0.77	-11.32	-0.59	3.35e-24	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.45	-6.52	-0.38	3.94e-10	Hemoglobin concentration;
KIRP	cis	rs7180079	0.563	rs7180635	chr15:65048912	C/T	cg15337035	chr15:64978493	NA	-0.51	-5.46	-0.33	1.16e-7	Monocyte count;
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13198984	chr17:80129470	CCDC57	0.58	8.68	0.48	5.38e-16	Life satisfaction;
KIRP	cis	rs12134133	1.000	rs7526831	chr1:207438606	G/C	cg00797651	chr1:207494336	CD55	0.33	4.89	0.3	1.85e-6	Posterior cortical atrophy and Alzheimer's disease;Blood protein levels;
KIRP	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-5.74	-0.34	2.77e-8	IgG glycosylation;
KIRP	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg14972814	chr11:95582409	MTMR2	0.35	5.82	0.35	1.83e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs644148	0.738	rs2686767	chr19:44995037	G/C	cg15540054	chr19:45004280	ZNF180	-0.52	-5.97	-0.36	8.08e-9	Personality dimensions;
KIRP	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.96	10.5	0.56	1.48e-21	Cognitive test performance;
KIRP	cis	rs66561647	0.857	rs60975849	chr8:128961097	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.58	7.15	0.41	9.84e-12	Hemoglobin concentration;
KIRP	trans	rs1106684	1.000	rs11763240	chr7:131461988	G/A	cg13607082	chr12:122652224	LRRC43	-0.66	-6.72	-0.39	1.25e-10	Body mass index;
KIRP	cis	rs8106657	1.000	rs2335524	chr19:7785698	C/T	cg06379095	chr19:7735239	RETN	0.39	4.98	0.3	1.18e-6	Blood protein levels;
KIRP	trans	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.6	-8.21	-0.46	1.27e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.48	-0.56	1.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10875746	0.669	rs10875779	chr12:48629869	G/A	cg24011408	chr12:48396354	COL2A1	-0.45	-5.19	-0.31	4.45e-7	Longevity (90 years and older);
KIRP	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg01629716	chr15:45996671	NA	0.37	6.67	0.39	1.7e-10	Waist circumference;Weight;
KIRP	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	0.9	13.14	0.64	3.03e-30	Dupuytren's disease;
KIRP	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-1.1	-17.98	-0.75	1.05e-46	Strep throat;
KIRP	trans	rs3858145	0.588	rs61854837	chr10:70042370	C/G	cg04882175	chr6:131122610	NA	-0.62	-7.44	-0.43	1.67e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
KIRP	cis	rs580438	0.529	rs4684129	chr3:13409484	G/A	cg10657019	chr3:13328039	NA	-0.52	-6.79	-0.4	8.22e-11	Myringotomy;
KIRP	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.44	-6.06	-0.36	5.04e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.6	-8.05	-0.46	3.52e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.58	5.38	0.32	1.7e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08428129	chr22:19744239	TBX1	0.45	6.7	0.39	1.45e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg20003494	chr4:90757398	SNCA	-0.39	-5.32	-0.32	2.36e-7	Neuroticism;
KIRP	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs7116495	0.609	rs567026	chr11:71769952	C/T	cg10381502	chr11:71823885	C11orf51	1.18	8.3	0.47	6.9e-15	Severe influenza A (H1N1) infection;
KIRP	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg05315796	chr3:52349193	DNAH1	0.44	6.86	0.4	5.7e-11	Bipolar disorder;
KIRP	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	1.0	11.25	0.58	5.81e-24	Iron status biomarkers;
KIRP	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.18	15.0	0.69	1.45e-36	Platelet count;
KIRP	cis	rs3105593	1.000	rs11070807	chr15:50974505	A/G	cg05456662	chr15:50716270	USP8	0.43	5.02	0.3	1.01e-6	QT interval;
KIRP	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg00677455	chr12:58241039	CTDSP2	-0.61	-7.27	-0.42	4.85e-12	Multiple sclerosis;
KIRP	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	1.0	8.18	0.46	1.56e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1978968	1.000	rs5013014	chr22:18449927	T/C	cg02610425	chr22:18483192	MICAL3	0.37	5.12	0.31	6.11e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs4494114	1.000	rs9438973	chr1:39344879	G/A	cg25970120	chr1:39325951	RRAGC	-0.41	-5.19	-0.31	4.49e-7	Blood protein levels;
KIRP	cis	rs1440410	0.835	rs11933603	chr4:144133857	G/A	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg14703610	chr5:56206110	C5orf35	0.46	6.13	0.36	3.56e-9	Breast cancer;Breast cancer (early onset);
KIRP	cis	rs35934224	0.504	rs10372	chr22:19837298	G/A	cg11182965	chr22:19864308	TXNRD2	-0.38	-5.19	-0.31	4.49e-7	Glaucoma (primary open-angle);
KIRP	cis	rs7833787	0.896	rs2029610	chr8:18706981	A/G	cg17701159	chr8:18705777	PSD3	-0.39	-7.11	-0.41	1.25e-11	Obesity-related traits;
KIRP	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg21132104	chr15:45694354	SPATA5L1	0.57	6.95	0.4	3.31e-11	Response to fenofibrate (adiponectin levels);
KIRP	trans	rs877282	0.583	rs11595057	chr10:819203	A/C	cg22713356	chr15:30763199	NA	0.83	8.23	0.46	1.08e-14	Uric acid levels;
KIRP	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03352830	chr11:487213	PTDSS2	0.73	6.15	0.37	3.05e-9	Body mass index;
KIRP	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg11502198	chr6:26597334	ABT1	-0.5	-6.11	-0.36	3.88e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	1.15	9.97	0.54	6.81e-20	Lymphocyte counts;
KIRP	cis	rs1776421	1.000	rs6657140	chr1:53901293	C/T	cg22073262	chr1:53904065	FLJ40434	0.47	5.21	0.32	3.92e-7	PR interval in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.64	8.85	0.49	1.76e-16	Morning vs. evening chronotype;
KIRP	cis	rs17767294	0.614	rs72845061	chr6:27653261	G/A	cg08851530	chr6:28072375	NA	0.95	5.15	0.31	5.36e-7	Parkinson's disease;
KIRP	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.62	6.66	0.39	1.81e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4664304	0.658	rs2667008	chr2:160865095	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.48	-0.43	1.35e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs62246343	0.504	rs7652415	chr3:9505238	C/T	cg06887414	chr3:128369476	RPN1	-0.61	-6.12	-0.36	3.76e-9	Fibrinogen levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19942640	chr5:33440671	TARS	0.53	6.86	0.4	5.55e-11	Parkinson's disease;
KIRP	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg02975922	chr3:195473998	MUC4	-0.6	-6.99	-0.41	2.57e-11	Pancreatic cancer;
KIRP	cis	rs96067	0.607	rs274134	chr1:36580554	T/C	cg27506609	chr1:36549197	TEKT2	-0.71	-5.27	-0.32	2.92e-7	Corneal structure;
KIRP	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.65	7.43	0.43	1.82e-12	Gut microbiome composition (summer);
KIRP	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.82	8.05	0.46	3.6e-14	Neuroblastoma;
KIRP	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg26116260	chr4:7069785	GRPEL1	-0.8	-6.63	-0.39	2.16e-10	Granulocyte percentage of myeloid white cells;
KIRP	trans	rs800082	0.501	rs10935507	chr3:144214631	A/T	cg24215973	chr2:240111563	HDAC4	0.5	6.5	0.38	4.36e-10	Smoking behavior;
KIRP	trans	rs6601327	0.602	rs11249956	chr8:9658194	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-6.92	-0.4	3.96e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	6.84	0.4	6.39e-11	Iron status biomarkers;
KIRP	cis	rs7712401	0.562	rs62377399	chr5:122324679	G/A	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00745463	chr17:30367425	LRRC37B	0.8	5.97	0.36	8.46e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.69	8.29	0.47	7.17e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs10073892	0.830	rs62372214	chr5:101641080	G/T	cg19774478	chr5:101632501	SLCO4C1	0.66	6.47	0.38	5.11e-10	Cognitive decline (age-related);
KIRP	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-10.55	-0.56	1.05e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13939156	chr17:80058883	NA	-0.5	-7.52	-0.43	1.04e-12	Life satisfaction;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg10996143	chr20:1373995	FKBP1A	0.76	6.41	0.38	7.52e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg13512537	chr8:22265999	SLC39A14	-0.38	-4.95	-0.3	1.37e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	5.11	0.31	6.46e-7	Educational attainment;
KIRP	cis	rs3540	0.513	rs1072879	chr15:90922038	C/T	cg10434728	chr15:90938212	IQGAP1	0.41	7.63	0.44	5.18e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs12823128	0.766	rs4436638	chr12:26911289	C/T	cg14081884	chr12:26986758	ITPR2	0.38	4.95	0.3	1.36e-6	Birth weight;
KIRP	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22618164	chr12:122356400	WDR66	0.66	9.06	0.5	4.25e-17	Mean corpuscular volume;
KIRP	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg13395646	chr4:1353034	KIAA1530	-0.41	-5.4	-0.33	1.55e-7	Obesity-related traits;
KIRP	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.91	10.99	0.57	3.93e-23	Eosinophil percentage of granulocytes;
KIRP	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	1.17	11.61	0.59	3.93e-25	Red blood cell traits;
KIRP	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.49	6.02	0.36	6.43e-9	Menopause (age at onset);
KIRP	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.23	-0.42	6.22e-12	Type 2 diabetes;
KIRP	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg23958373	chr8:599963	NA	1.04	7.68	0.44	3.69e-13	IgG glycosylation;
KIRP	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.43	4.89	0.3	1.81e-6	Height;
KIRP	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg26752003	chr8:145688521	CYHR1	0.72	9.42	0.51	3.46e-18	Age at first birth;
KIRP	cis	rs8179	0.645	rs56201652	chr7:92278116	G/A	cg15732164	chr7:92237376	CDK6	-0.48	-6.6	-0.39	2.44e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs3849570	0.565	rs1851926	chr3:81977231	A/C	cg07356753	chr3:81810745	GBE1	-0.55	-7.28	-0.42	4.5e-12	Waist circumference;Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24422297	chr17:20059411	CYTSB	0.49	6.11	0.36	3.81e-9	Parkinson's disease;
KIRP	cis	rs5753618	0.583	rs5749268	chr22:31809152	G/A	cg02404636	chr22:31891804	SFI1	0.51	5.74	0.34	2.82e-8	Colorectal cancer;
KIRP	cis	rs10788972	0.903	rs1547467	chr1:54497040	T/C	cg25741118	chr1:54482237	LDLRAD1	-0.3	-5.1	-0.31	6.74e-7	Parkinson disease and lewy body pathology;
KIRP	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.48	-0.43	1.32e-12	Colorectal cancer;
KIRP	trans	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg02030672	chr11:45687055	CHST1	0.56	6.95	0.41	3.33e-11	Obesity-related traits;
KIRP	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.66	0.44	4.2e-13	Tonsillectomy;
KIRP	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg03468072	chr12:39539422	NA	0.41	5.98	0.36	7.94e-9	Morning vs. evening chronotype;
KIRP	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.68	6.8	0.4	8.04e-11	Vitiligo;
KIRP	cis	rs7116495	0.609	rs2735787	chr11:71717873	T/C	cg10381502	chr11:71823885	C11orf51	-1.15	-8.08	-0.46	2.83e-14	Severe influenza A (H1N1) infection;
KIRP	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.65	-8.56	-0.48	1.22e-15	Hypospadias;
KIRP	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.26	5.26	0.32	3.1e-7	Coronary artery disease;
KIRP	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg13180566	chr4:1052158	NA	-0.53	-5.37	-0.32	1.82e-7	Recombination rate (females);
KIRP	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-0.77	-11.4	-0.59	1.85e-24	Intelligence (multi-trait analysis);
KIRP	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg08975724	chr8:8085496	FLJ10661	-0.6	-8.18	-0.46	1.53e-14	Neuroticism;
KIRP	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.5	-0.33	9.51e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6693295	0.729	rs10737782	chr1:246215358	C/T	cg11798871	chr1:246315928	SMYD3	-0.42	-5.26	-0.32	3.17e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg15655495	chr12:38532458	NA	-0.3	-5.16	-0.31	5.06e-7	Bladder cancer;
KIRP	cis	rs7116495	1.000	rs7116495	chr11:71762085	C/T	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.6	7.91	0.45	8.8e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7615316	1.000	rs2140432	chr3:142343552	A/G	cg20824294	chr3:142316082	PLS1	-0.22	-4.97	-0.3	1.23e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.42	4.87	0.3	2.01e-6	Menopause (age at onset);
KIRP	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.54	-8.85	-0.49	1.79e-16	Eye color traits;
KIRP	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg13409248	chr3:40428643	ENTPD3	0.4	5.29	0.32	2.75e-7	Renal cell carcinoma;
KIRP	cis	rs73526541	0.588	rs80327531	chr8:1066542	T/A	cg01049933	chr8:1047734	NA	0.76	5.75	0.34	2.66e-8	Verbal memory performance (immediate recall change);
KIRP	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg14825094	chr17:61818420	STRADA	-0.42	-4.91	-0.3	1.65e-6	Height;
KIRP	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00933542	chr6:150070202	PCMT1	0.31	6.01	0.36	6.63e-9	Lung cancer;
KIRP	cis	rs7116495	1.000	rs7101701	chr11:71762155	A/G	cg18441811	chr11:71824068	C11orf51	-0.62	-5.02	-0.3	9.8e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs6568686	0.627	rs174377	chr6:111908646	C/A	cg22127309	chr6:111907043	TRAF3IP2	0.52	5.12	0.31	6.06e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs12681366	0.683	rs56285115	chr8:95401472	C/A	cg13257157	chr8:95487014	RAD54B	0.4	4.93	0.3	1.52e-6	Nonsyndromic cleft lip with cleft palate;
KIRP	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.76	-8.35	-0.47	5.1e-15	Parkinson's disease;
KIRP	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-6.09	-0.36	4.35e-9	Response to antipsychotic treatment;
KIRP	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg15839431	chr19:19639596	YJEFN3	-0.54	-5.46	-0.33	1.15e-7	Bipolar disorder;
KIRP	cis	rs2562456	0.833	rs55756795	chr19:21510059	C/T	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.37	-5.03	-0.31	9.45e-7	Neuroticism;
KIRP	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg16077055	chr2:106428750	NCK2	0.25	4.85	0.3	2.2e-6	Addiction;
KIRP	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.3	-6.1	-0.36	4.04e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg27147174	chr7:100797783	AP1S1	-0.54	-6.6	-0.39	2.45e-10	Life satisfaction;
KIRP	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg19997662	chr15:101784653	CHSY1	-0.72	-11.16	-0.58	1.13e-23	Corneal structure;
KIRP	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.4	0.38	7.67e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1448094	0.967	rs10863109	chr12:86328415	A/G	cg06740227	chr12:86229804	RASSF9	0.4	5.13	0.31	5.8e-7	Major depressive disorder;
KIRP	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.25	-0.47	9.36e-15	Extrinsic epigenetic age acceleration;
KIRP	cis	rs6585424	0.778	rs12257082	chr10:81922121	C/G	cg27417294	chr10:81904244	PLAC9	0.56	5.46	0.33	1.14e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg06521331	chr12:34319734	NA	-0.59	-7.16	-0.42	9.22e-12	Morning vs. evening chronotype;
KIRP	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	7.71	0.44	3.18e-13	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg26516489	chr15:41625261	NUSAP1;OIP5	-0.45	-6.13	-0.36	3.46e-9	Morning vs. evening chronotype;
KIRP	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.78	-10.82	-0.57	1.44e-22	Inflammatory bowel disease;
KIRP	cis	rs10988449	0.891	rs10988454	chr9:132390131	C/G	cg18327994	chr9:132372705	NA	0.51	5.14	0.31	5.59e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17507749	chr15:85114479	UBE2QP1	-0.46	-5.43	-0.33	1.32e-7	P wave terminal force;
KIRP	cis	rs4356932	0.691	rs10008757	chr4:76903036	A/G	cg19388996	chr4:76862389	NAAA	0.43	5.43	0.33	1.36e-7	Blood protein levels;
KIRP	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23161317	chr6:28129485	ZNF389	0.47	5.47	0.33	1.12e-7	Depression;
KIRP	trans	rs7819412	0.521	rs13256092	chr8:11000377	A/T	cg08975724	chr8:8085496	FLJ10661	-0.56	-6.53	-0.38	3.68e-10	Triglycerides;
KIRP	cis	rs918629	0.530	rs2829	chr5:95258447	T/C	cg16656078	chr5:95278638	ELL2	-0.38	-5.76	-0.34	2.52e-8	IgG glycosylation;
KIRP	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.47	6.04	0.36	5.72e-9	Height;
KIRP	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.93	-14.8	-0.69	6.99e-36	Height;
KIRP	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	1.05	22.57	0.82	7.3e-62	Breast cancer;
KIRP	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg17691542	chr6:26056736	HIST1H1C	0.66	7.96	0.45	6.23e-14	Iron status biomarkers;
KIRP	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg05484376	chr2:27715224	FNDC4	0.38	6.21	0.37	2.21e-9	Total body bone mineral density;
KIRP	cis	rs7336332	0.574	rs9512699	chr13:28029896	G/A	cg22138327	chr13:27999177	GTF3A	-0.73	-7.29	-0.42	4.24e-12	Weight;
KIRP	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	cg12689670	chr1:183009347	LAMC1	0.55	7.66	0.44	4.28e-13	Fuchs's corneal dystrophy;
KIRP	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.41	5.32	0.32	2.3e-7	Childhood ear infection;
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg23693289	chr8:27183097	PTK2B	0.57	7.21	0.42	7.05e-12	Neuroticism;
KIRP	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg07138768	chr7:917805	C7orf20	0.35	5.52	0.33	8.39e-8	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs1983891	1.000	rs1983891	chr6:41536427	A/G	cg20194872	chr6:41519635	FOXP4	-0.57	-7.34	-0.42	3.16e-12	Prostate cancer;
KIRP	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg18154014	chr19:37997991	ZNF793	0.87	8.28	0.47	7.8e-15	Coronary artery calcification;
KIRP	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	1.22	7.13	0.41	1.09e-11	LDL cholesterol;
KIRP	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg05370193	chr1:21551575	ECE1	0.47	6.15	0.37	3.09e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg05785598	chr3:49045655	WDR6	0.3	5.49	0.33	9.82e-8	Parkinson's disease;
KIRP	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.47	6.55	0.39	3.33e-10	Coronary artery disease;
KIRP	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	0.92	13.48	0.65	2.25e-31	Dupuytren's disease;
KIRP	cis	rs9309473	0.539	rs6732440	chr2:73827099	T/G	cg20560298	chr2:73613845	ALMS1	0.46	5.66	0.34	4.18e-8	Metabolite levels;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14251936	chr19:44417025	ZNF45	0.46	6.21	0.37	2.18e-9	Survival in pancreatic cancer;
KIRP	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg18404041	chr3:52824283	ITIH1	-0.54	-7.07	-0.41	1.55e-11	Bipolar disorder;
KIRP	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.56	8.31	0.47	6.68e-15	Weight;
KIRP	cis	rs2219968	0.962	rs9643732	chr8:78946230	G/A	cg00738934	chr8:78996279	NA	0.39	5.04	0.31	9.24e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.71	-8.36	-0.47	4.78e-15	Resting heart rate;
KIRP	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.43	-5.31	-0.32	2.51e-7	Aortic root size;
KIRP	cis	rs3026101	0.624	rs7426	chr17:5288983	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	6.86	0.4	5.45e-11	Body mass index;
KIRP	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs5762813	0.566	rs4055	chr22:29352495	A/C	cg02153584	chr22:29168773	CCDC117	0.57	5.56	0.33	6.98e-8	Hematocrit;Hemoglobin concentration;
KIRP	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11987759	chr7:65425863	GUSB	0.5	6.76	0.4	9.68e-11	Aortic root size;
KIRP	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.56	6.99	0.41	2.54e-11	Menopause (age at onset);
KIRP	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21545522	chr1:205238299	TMCC2	0.55	7.33	0.42	3.34e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg08822215	chr16:89438651	ANKRD11	-0.49	-6.65	-0.39	1.89e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.61	7.7	0.44	3.35e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg02002194	chr4:3960332	NA	0.44	6.33	0.37	1.16e-9	Neuroticism;
KIRP	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-7.31	-0.42	3.64e-12	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg13319975	chr6:146136371	FBXO30	-0.47	-6.47	-0.38	5.17e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	6.8	0.4	7.76e-11	Menarche (age at onset);
KIRP	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg19847130	chr8:10466454	RP1L1	0.43	6.23	0.37	1.96e-9	Joint mobility (Beighton score);
KIRP	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.62	-7.66	-0.44	4.33e-13	Response to antipsychotic treatment;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14647515	chr10:98741349	C10orf12	0.45	6.46	0.38	5.66e-10	Migraine with aura;
KIRP	cis	rs785830	0.558	rs517616	chr9:258376	A/C	cg14500300	chr9:211689	NA	0.41	5.53	0.33	8.25e-8	Platelet distribution width;
KIRP	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.86	7.85	0.45	1.31e-13	Type 2 diabetes;
KIRP	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.32	5.83	0.35	1.77e-8	Calcium levels;
KIRP	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg02060794	chr3:52273307	TWF2	-0.61	-6.33	-0.37	1.17e-9	Hematocrit;Hemoglobin concentration;Red blood cell count;
KIRP	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg18225595	chr11:63971243	STIP1	0.64	5.79	0.35	2.09e-8	Mean platelet volume;
KIRP	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg23594656	chr7:65796392	TPST1	0.46	7.18	0.42	8.36e-12	Aortic root size;
KIRP	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.95	-13.43	-0.65	3.32e-31	Schizophrenia;
KIRP	cis	rs4886920	0.605	rs12912080	chr15:78126758	T/C	cg10461261	chr15:78109450	NA	0.36	6.18	0.37	2.68e-9	Neuroticism;
KIRP	cis	rs1215050	0.791	rs260902	chr4:98764694	G/A	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.56	-0.39	3.19e-10	Response to antipsychotic treatment;
KIRP	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.24e-6	Cannabis dependence symptom count;
KIRP	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.14	9.52	0.52	1.74e-18	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg26531700	chr6:26746687	NA	0.47	6.72	0.39	1.28e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-1.04	-20.44	-0.79	6.04e-55	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs6432860	0.671	rs745035	chr2:166727564	C/G	cg13971571	chr8:6693247	XKR5	0.53	6.7	0.39	1.39e-10	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;
KIRP	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg02487422	chr3:49467188	NICN1	0.42	5.43	0.33	1.35e-7	Resting heart rate;
KIRP	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Bipolar disorder;
KIRP	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.8	7.09	0.41	1.44e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg06640241	chr16:89574553	SPG7	0.78	11.49	0.59	9.51e-25	Multiple myeloma (IgH translocation);
KIRP	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg10434728	chr15:90938212	IQGAP1	0.44	8.51	0.48	1.76e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs16912285	0.688	rs12279442	chr11:24317174	C/G	ch.11.24196551F	chr11:24239977	NA	0.8	9.1	0.5	3.07e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs12681288	0.748	rs2701932	chr8:1026946	C/G	cg08648136	chr8:956695	NA	0.45	5.86	0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.76	8.13	0.46	2.11e-14	Uric acid levels;
KIRP	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.29	5.87	0.35	1.44e-8	Schizophrenia;
KIRP	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg04370829	chr17:406249	NA	0.38	4.89	0.3	1.86e-6	Prostate cancer;
KIRP	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg11965913	chr1:205819406	PM20D1	-0.6	-5.89	-0.35	1.26e-8	Menarche (age at onset);
KIRP	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.77	-7.8	-0.45	1.74e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs79387448	0.810	rs76229479	chr2:103123912	A/C	cg09003973	chr2:102972529	NA	0.64	5.1	0.31	6.84e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	10.02	0.54	5.01e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs4363385	0.510	rs6673356	chr1:153041903	C/T	cg07796016	chr1:152779584	LCE1C	0.41	5.22	0.32	3.77e-7	Inflammatory skin disease;
KIRP	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg16497277	chr3:49208875	KLHDC8B	-0.42	-5.44	-0.33	1.27e-7	Parkinson's disease;
KIRP	trans	rs1422110	0.513	rs987280	chr5:85448604	C/T	cg01787110	chr1:109008453	NBPF6	-0.54	-7.2	-0.42	7.41e-12	Attention function in attention deficit hyperactive disorder;
KIRP	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	1.07	15.51	0.7	2.64e-38	Menopause (age at onset);
KIRP	cis	rs1829883	0.775	rs2249509	chr5:98921277	G/T	cg08333243	chr5:99726346	NA	0.4	5.07	0.31	7.85e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg00684032	chr4:1343700	KIAA1530	-0.55	-7.31	-0.42	3.68e-12	Obesity-related traits;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg17168838	chr19:54663528	LENG1	0.97	6.65	0.39	1.86e-10	P wave terminal force;
KIRP	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg24375607	chr4:120327624	NA	0.57	6.53	0.38	3.76e-10	Corneal astigmatism;
KIRP	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg13147721	chr7:65941812	NA	0.94	5.9	0.35	1.22e-8	Diabetic kidney disease;
KIRP	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg23067535	chr8:124195133	FAM83A	-0.79	-7.29	-0.42	4.31e-12	Urinary uromodulin levels;
KIRP	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.96	-14.23	-0.67	6.27e-34	Primary sclerosing cholangitis;
KIRP	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.61	5.02	0.3	1.01e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	5.68	0.34	3.74e-8	Birth weight;
KIRP	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg21573476	chr21:45109991	RRP1B	-0.75	-10.0	-0.54	5.64e-20	Mean corpuscular volume;
KIRP	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.65	6.5	0.38	4.41e-10	Axial length;
KIRP	cis	rs16957091	0.738	rs1197548	chr15:42928764	A/G	cg24196017	chr15:43021976	CDAN1	0.43	5.48	0.33	1.07e-7	MGMT methylation in smokers;
KIRP	cis	rs838147	0.508	rs507766	chr19:49208543	T/C	cg08619932	chr19:49200058	FUT2	0.35	5.25	0.32	3.32e-7	Dietary macronutrient intake;
KIRP	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-0.96	-9.36	-0.51	5.21e-18	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.86	-0.35	1.48e-8	Depression;
KIRP	cis	rs6681460	0.837	rs6669023	chr1:67171868	G/T	cg13052034	chr1:66999238	SGIP1	0.37	5.19	0.31	4.3e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg10223061	chr2:219282414	VIL1	0.4	6.27	0.37	1.6e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.91	13.02	0.64	7.74e-30	Bladder cancer;
KIRP	cis	rs4006360	0.546	rs1848812	chr17:39235917	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	1.03e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-1.03	-20.85	-0.8	2.71e-56	Birth weight;
KIRP	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg26441486	chr22:50317300	CRELD2	0.51	5.88	0.35	1.36e-8	Schizophrenia;
KIRP	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.63	7.95	0.45	6.71e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.89	-12.97	-0.64	1.13e-29	Tonsillectomy;
KIRP	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.58	8.86	0.49	1.68e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg12661370	chr5:149340060	SLC26A2	0.45	5.52	0.33	8.52e-8	HIV-1 control;
KIRP	cis	rs10203711	0.933	rs4994752	chr2:239567309	C/A	cg14580085	chr2:239553406	NA	0.39	5.12	0.31	6.02e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg19743168	chr1:23544995	NA	0.5	6.97	0.41	2.85e-11	Height;
KIRP	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.59	-12.1	-0.61	9.57e-27	Diabetic kidney disease;
KIRP	cis	rs8077577	0.747	rs3829956	chr17:18219835	A/G	cg18869244	chr17:18121946	NA	0.44	5.16	0.31	5.04e-7	Obesity-related traits;
KIRP	cis	rs988913	1.000	rs988913	chr6:54756308	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.62	-0.34	5.27e-8	Menarche (age at onset);
KIRP	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs9914578	0.573	rs7213049	chr17:2001657	C/T	cg16513277	chr17:2031491	SMG6	-0.57	-5.24	-0.32	3.42e-7	Body mass index;
KIRP	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-10.2	-0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg16141378	chr3:129829833	LOC729375	-0.56	-7.47	-0.43	1.4e-12	Mood instability;
KIRP	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg23422044	chr7:1970798	MAD1L1	-0.44	-5.66	-0.34	4.17e-8	Neuroticism;
KIRP	cis	rs1699337	1.000	rs709149	chr3:12450354	C/T	cg02700894	chr3:12045449	SYN2	-0.38	-5.01	-0.3	1.05e-6	Cholesterol, total;
KIRP	cis	rs2574975	0.509	rs1720424	chr10:52203230	T/C	cg10034176	chr10:52120283	SGMS1	0.39	5.55	0.33	7.21e-8	Response to amphetamines;
KIRP	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.7	10.37	0.55	3.84e-21	Prostate cancer;
KIRP	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.63	8.0	0.45	4.79e-14	Obesity-related traits;
KIRP	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-5.02	-0.3	1e-6	Mean platelet volume;
KIRP	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg23594656	chr7:65796392	TPST1	0.44	6.0	0.36	6.87e-9	Aortic root size;
KIRP	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg10761708	chr20:43804764	PI3	0.53	5.55	0.33	7.52e-8	Blood protein levels;
KIRP	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-14.56	-0.68	4.7e-35	Electrocardiographic conduction measures;
KIRP	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.72	10.51	0.56	1.37e-21	Heart rate;
KIRP	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg25281562	chr12:121454272	C12orf43	-0.46	-5.1	-0.31	6.89e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.4	6.47	0.38	5.31e-10	Birth weight;
KIRP	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg13334819	chr7:99746414	C7orf59	-0.44	-4.93	-0.3	1.53e-6	Coronary artery disease;
KIRP	cis	rs10872587	0.555	rs2265470	chr6:146219232	T/C	cg23711669	chr6:146136114	FBXO30	0.79	8.54	0.48	1.44e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.62	-9.01	-0.5	5.94e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg22903471	chr2:27725779	GCKR	0.41	5.75	0.34	2.66e-8	Oral cavity cancer;
KIRP	cis	rs7572644	0.699	rs4233719	chr2:28079344	C/A	cg27432699	chr2:27873401	GPN1	0.45	5.39	0.33	1.61e-7	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
KIRP	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.76	-10.79	-0.57	1.8e-22	Height;
KIRP	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg25486957	chr4:152246857	NA	-0.42	-5.03	-0.31	9.34e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg18882449	chr10:104885122	NT5C2	-0.39	-4.93	-0.3	1.49e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs11671005	0.695	rs11673069	chr19:58934918	C/G	cg13877915	chr19:58951672	ZNF132	0.62	6.02	0.36	6.24e-9	Mean platelet volume;
KIRP	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.68	-9.21	-0.51	1.51e-17	Blood metabolite levels;
KIRP	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.52	-8.12	-0.46	2.18e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs7587476	0.861	rs3768716	chr2:215635794	T/C	cg04004882	chr2:215674386	BARD1	0.78	6.51	0.38	4.31e-10	Neuroblastoma;
KIRP	cis	rs7395581	0.918	rs3781622	chr11:47348702	T/C	cg26139080	chr11:47293733	MADD	-0.43	-5.31	-0.32	2.5e-7	HDL cholesterol;
KIRP	trans	rs1512651	0.592	rs363888	chr13:56685968	A/C	cg13405456	chr8:74880618	TCEB1	0.44	6.08	0.36	4.51e-9	Warfarin maintenance dose;
KIRP	cis	rs71636778	0.543	rs113002196	chr1:27200156	T/C	cg12203394	chr1:27248618	NUDC	0.66	4.99	0.3	1.16e-6	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3779635	0.967	rs750538	chr8:27275726	G/T	cg23693289	chr8:27183097	PTK2B	0.47	5.94	0.35	9.64e-9	Neuroticism;
KIRP	cis	rs501120	0.584	rs11595159	chr10:44680608	T/C	cg09554077	chr10:44749378	NA	0.57	5.95	0.35	9.05e-9	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg00629941	chr15:75287862	SCAMP5	-0.48	-5.16	-0.31	5.16e-7	Blood trace element (Zn levels);
KIRP	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg05220968	chr6:146057943	EPM2A	0.39	4.85	0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg10756647	chr7:56101905	PSPH	-0.99	-6.99	-0.41	2.53e-11	Diabetic kidney disease;
KIRP	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	14.66	0.68	2.07e-35	Platelet count;
KIRP	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg15407257	chr20:23621136	NA	-0.33	-4.89	-0.3	1.8e-6	Chronic kidney disease;
KIRP	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.5	-5.86	-0.35	1.51e-8	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-9.28	-0.51	8.89e-18	Personality dimensions;
KIRP	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg05347473	chr6:146136440	FBXO30	0.5	6.91	0.4	4.08e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.32	0.51	6.71e-18	Lymphocyte counts;
KIRP	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.44	5.07	0.31	7.74e-7	Schizophrenia;
KIRP	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.73	5.91	0.35	1.11e-8	Diabetic retinopathy;
KIRP	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg27189623	chr16:705930	WDR90	0.43	5.89	0.35	1.3e-8	Height;
KIRP	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.77	-0.4	9.38e-11	Alcohol dependence;
KIRP	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.86	11.49	0.59	9.64e-25	Breast cancer;
KIRP	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.85	-10.23	-0.55	1.07e-20	Longevity;Endometriosis;
KIRP	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.54	7.31	0.42	3.85e-12	Height;
KIRP	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg23281280	chr6:28129359	ZNF389	0.47	5.17	0.31	4.96e-7	Parkinson's disease;
KIRP	cis	rs858239	0.537	rs6942981	chr7:23231548	C/T	cg23682824	chr7:23144976	KLHL7	0.45	4.87	0.3	1.95e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs5770917	1.000	rs1557503	chr22:51013072	G/A	cg08260245	chr22:51016501	CPT1B;CHKB-CPT1B	-0.65	-5.96	-0.35	8.91e-9	Narcolepsy;
KIRP	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg15556689	chr8:8085844	FLJ10661	0.64	8.29	0.47	7.52e-15	Mood instability;
KIRP	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.45	5.23	0.32	3.57e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg17376030	chr22:41985996	PMM1	0.59	6.54	0.38	3.51e-10	Vitiligo;
KIRP	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg13256891	chr4:100009986	ADH5	0.52	6.6	0.39	2.46e-10	Alcohol dependence;
KIRP	cis	rs4901847	0.967	rs7492608	chr14:58554401	T/C	cg15908186	chr14:58618357	C14orf37	0.43	5.51	0.33	9.22e-8	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.62	-9.51	-0.52	1.87e-18	Menopause (age at onset);
KIRP	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.0	10.54	0.56	1.09e-21	Cognitive test performance;
KIRP	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.16	16.74	0.73	1.69e-42	Breast cancer;
KIRP	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.41	6.18	0.37	2.64e-9	Multiple sclerosis;
KIRP	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg26681399	chr22:41777847	TEF	-0.53	-5.46	-0.33	1.16e-7	Vitiligo;
KIRP	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg02660097	chr11:68866761	NA	0.36	5.46	0.33	1.14e-7	Blond vs. brown hair color;
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg16080015	chr7:5085479	RBAK	0.51	6.53	0.38	3.77e-10	Myopia (pathological);
KIRP	trans	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.5	6.05	0.36	5.23e-9	Metabolite levels;
KIRP	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-9.24	-0.51	1.23e-17	Heart rate;
KIRP	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs10046574	0.519	rs9656456	chr7:135202208	G/A	cg27474649	chr7:135195673	CNOT4	0.56	5.28	0.32	2.82e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.88	11.63	0.6	3.4e-25	Primary sclerosing cholangitis;
KIRP	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg00977110	chr5:151150581	G3BP1	0.62	6.19	0.37	2.44e-9	Preschool internalizing problems;
KIRP	cis	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg13293535	chr8:11597251	GATA4	0.46	6.29	0.37	1.43e-9	Neuroticism;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg12180372	chr14:94547582	DDX24;IFI27L1	0.47	6.13	0.36	3.57e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.58	7.43	0.43	1.81e-12	Aortic root size;
KIRP	cis	rs2278796	0.752	rs6677763	chr1:204951540	A/G	cg04862289	chr1:204966208	NFASC	0.39	5.63	0.34	4.78e-8	Mean platelet volume;
KIRP	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.54	-6.27	-0.37	1.62e-9	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.62	7.17	0.42	8.49e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs7119038	0.818	rs11217032	chr11:118669605	T/A	cg19308663	chr11:118741387	NA	0.6	9.95	0.54	8.33e-20	Sjögren's syndrome;
KIRP	cis	rs2594989	0.943	rs2244617	chr3:11503097	T/C	cg01796438	chr3:11312864	ATG7	-0.68	-8.21	-0.46	1.27e-14	Circulating chemerin levels;
KIRP	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg05564831	chr3:52568323	NT5DC2	0.34	5.54	0.33	7.69e-8	Bipolar disorder;
KIRP	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.57	7.41	0.43	1.98e-12	Schizophrenia;
KIRP	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg19116668	chr7:99932089	PMS2L1	-0.51	-5.8	-0.35	2.05e-8	Coronary artery disease;
KIRP	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg00250761	chr1:31883323	NA	-0.3	-5.38	-0.32	1.71e-7	Alcohol dependence;
KIRP	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.79	10.18	0.54	1.58e-20	Platelet count;
KIRP	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg05669848	chr5:237993	SDHA	-0.47	-4.96	-0.3	1.31e-6	Breast cancer;
KIRP	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.78	-8.08	-0.46	2.84e-14	Migraine;Coronary artery disease;
KIRP	cis	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg07585502	chr8:101912084	NA	-0.63	-7.79	-0.44	1.93e-13	Attention deficit hyperactivity disorder and conduct disorder;
KIRP	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.5	6.59	0.39	2.7e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs9650657	0.836	rs3905581	chr8:10603705	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.36	-0.38	9.51e-10	Neuroticism;
KIRP	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg06565975	chr8:143823917	SLURP1	-0.48	-7.36	-0.42	2.83e-12	Urinary tract infection frequency;
KIRP	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg22974920	chr21:40686053	BRWD1	0.48	5.75	0.34	2.6e-8	Cognitive function;
KIRP	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	5.02	0.3	9.88e-7	Breast cancer;
KIRP	cis	rs2380205	0.689	rs907690	chr10:5901367	C/T	cg27141509	chr10:5886111	NA	-0.4	-5.6	-0.34	5.74e-8	Breast cancer;
KIRP	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg09455208	chr3:40491958	NA	0.32	5.53	0.33	8.29e-8	Renal cell carcinoma;
KIRP	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.86	-11.23	-0.58	6.87e-24	Monocyte count;
KIRP	cis	rs73206853	0.563	rs34378671	chr12:111163204	C/T	cg12870014	chr12:110450643	ANKRD13A	0.49	4.85	0.3	2.22e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.45	-5.67	-0.34	3.96e-8	P wave terminal force;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg11867950	chr14:31890052	NA	-0.54	-6.7	-0.39	1.38e-10	Interleukin-4 levels;
KIRP	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.44	5.11	0.31	6.41e-7	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg10345337	chr14:65569751	MAX	-0.46	-6.14	-0.36	3.37e-9	Survival in pancreatic cancer;
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg00331096	chr20:22564947	FOXA2	0.53	6.41	0.38	7.43e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.55	6.99	0.41	2.5e-11	Eye color traits;
KIRP	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg04025307	chr7:1156635	C7orf50	0.56	6.24	0.37	1.85e-9	Bronchopulmonary dysplasia;
KIRP	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.42	-5.3	-0.32	2.57e-7	Childhood ear infection;
KIRP	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg24633833	chr3:10029261	TMEM111	0.53	4.91	0.3	1.64e-6	Alzheimer's disease;
KIRP	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.41	5.27	0.32	3.02e-7	Melanoma;
KIRP	cis	rs62229266	0.804	rs62230822	chr21:37429945	T/C	cg08632701	chr21:37451849	NA	-0.45	-5.55	-0.33	7.29e-8	Mitral valve prolapse;
KIRP	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.55	7.66	0.44	4.33e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg08992911	chr2:238395768	MLPH	0.42	5.35	0.32	2e-7	Prostate cancer;
KIRP	cis	rs7523273	0.565	rs2104303	chr1:207886684	C/T	cg22525895	chr1:207977042	MIR29B2	-0.48	-5.91	-0.35	1.16e-8	Schizophrenia;
KIRP	cis	rs584438	0.873	rs598892	chr17:38600092	G/A	cg11961138	chr17:38599366	IGFBP4	-0.26	-4.85	-0.3	2.17e-6	Height;
KIRP	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.22	-32.38	-0.9	1.15e-90	Myeloid white cell count;
KIRP	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg06935464	chr4:38784597	TLR10	0.54	5.38	0.32	1.69e-7	Breast cancer;
KIRP	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg09658497	chr7:2847517	GNA12	-0.36	-4.99	-0.3	1.14e-6	Height;
KIRP	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.47	-5.59	-0.34	5.92e-8	Initial pursuit acceleration;
KIRP	cis	rs12019361	0.541	rs56364292	chr7:87188092	C/T	cg00919237	chr7:87102261	ABCB4	-0.57	-4.87	-0.3	2e-6	Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN);
KIRP	cis	rs231513	0.871	rs231522	chr17:41954602	A/G	cg26893861	chr17:41843967	DUSP3	-0.58	-5.06	-0.31	8.04e-7	Cognitive function;
KIRP	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	cg04338863	chr8:33670619	NA	0.43	5.01	0.3	1.04e-6	Body mass index;
KIRP	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.6	-6.71	-0.39	1.32e-10	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.23	-0.55	1.04e-20	Hemoglobin concentration;
KIRP	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.81	-11.94	-0.61	3.17e-26	Headache;
KIRP	cis	rs7551222	0.681	rs4252686	chr1:204496895	A/G	cg20240347	chr1:204465584	NA	-0.46	-8.73	-0.49	4.06e-16	Schizophrenia;
KIRP	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.73	6.08	0.36	4.54e-9	Crohn's disease;
KIRP	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.72	9.26	0.51	1.03e-17	Bladder cancer;
KIRP	cis	rs6968419	0.747	rs58595078	chr7:115881458	A/G	cg02561103	chr7:115862891	TES	-0.43	-6.15	-0.36	3.16e-9	Intraocular pressure;
KIRP	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg05022225	chr19:49866942	DKKL1;TEAD2	0.46	5.81	0.35	1.91e-8	Multiple sclerosis;
KIRP	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.33	5.23	0.32	3.65e-7	Parkinson's disease;
KIRP	cis	rs4389656	0.857	rs274679	chr5:6751426	A/C	cg10857441	chr5:6722123	POLS	-0.46	-6.5	-0.38	4.48e-10	Coronary artery disease;
KIRP	trans	rs9944715	0.954	rs8093407	chr18:43849464	A/G	cg01718231	chr17:29326311	RNF135	-0.52	-6.07	-0.36	4.71e-9	Red cell distribution width;Mean corpuscular volume;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09623085	chr6:170471364	NA	0.44	6.08	0.36	4.6e-9	Interleukin-4 levels;
KIRP	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg17385448	chr1:15911702	AGMAT	0.26	5.14	0.31	5.67e-7	Systolic blood pressure;
KIRP	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg01879757	chr17:41196368	BRCA1	-0.74	-10.65	-0.56	5.13e-22	Menopause (age at onset);
KIRP	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg01879757	chr17:41196368	BRCA1	-0.79	-10.81	-0.57	1.52e-22	Menopause (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17386128	chr2:173420391	PDK1	0.5	6.25	0.37	1.83e-9	Parkinson's disease;
KIRP	cis	rs12230513	0.732	rs7966770	chr12:55844717	T/C	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20445465	chr7:122953117	NA	-0.37	-6.04	-0.36	5.65e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg08975724	chr8:8085496	FLJ10661	0.49	6.26	0.37	1.72e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.64	7.71	0.44	3.13e-13	Obesity-related traits;
KIRP	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg13010199	chr12:38710504	ALG10B	-0.49	-6.1	-0.36	4.02e-9	Heart rate;Heart rate variability traits (RMSSD);
KIRP	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-8.56	-0.48	1.26e-15	Neuroticism;
KIRP	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.89	-10.53	-0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs656319	0.591	rs17734690	chr8:9713196	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-5.51	-0.33	8.91e-8	Myopia (pathological);
KIRP	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg21132104	chr15:45694354	SPATA5L1	0.59	7.29	0.42	4.33e-12	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.43	-4.91	-0.3	1.66e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.04	-0.41	1.87e-11	Bladder cancer;
KIRP	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg17182837	chr8:41585554	ANK1	-0.48	-5.0	-0.3	1.1e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2070997	0.756	rs7026988	chr9:133667899	C/T	cg13397898	chr9:133768931	QRFP	0.29	4.91	0.3	1.62e-6	Response to amphetamines;
KIRP	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg05484376	chr2:27715224	FNDC4	0.38	6.25	0.37	1.78e-9	Total body bone mineral density;
KIRP	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22396632	chr1:3079212	PRDM16	0.38	5.06	0.31	8.22e-7	Migraine;
KIRP	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.73	7.74	0.44	2.62e-13	Vitiligo;
KIRP	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.57	6.41	0.38	7.47e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg03929089	chr4:120376271	NA	0.93	6.82	0.4	7.22e-11	Myopia (pathological);
KIRP	cis	rs7560272	0.723	rs2421548	chr2:73641240	A/G	cg20560298	chr2:73613845	ALMS1	0.4	4.94	0.3	1.46e-6	Schizophrenia;
KIRP	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.56	-7.67	-0.44	3.9e-13	Type 2 diabetes;
KIRP	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.81	11.97	0.61	2.45e-26	Menopause (age at onset);
KIRP	cis	rs954108	0.966	rs9508155	chr13:29372016	C/T	cg11788234	chr13:29393811	NA	0.54	6.73	0.39	1.15e-10	Obesity-related traits;
KIRP	cis	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg27411982	chr8:10470053	RP1L1	0.44	5.42	0.33	1.41e-7	Neuroticism;
KIRP	cis	rs876084	0.505	rs62526984	chr8:121128068	A/G	cg22335954	chr8:121166405	COL14A1	-0.38	-5.06	-0.31	8.07e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg22857025	chr5:266934	NA	-0.83	-7.09	-0.41	1.44e-11	Asthma (childhood onset);
KIRP	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.43	-6.19	-0.37	2.44e-9	Height;
KIRP	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.75	7.51	0.43	1.06e-12	Resting heart rate;
KIRP	cis	rs514024	0.729	rs557630	chr9:130491998	C/T	cg13643465	chr9:130375613	STXBP1	-0.44	-5.73	-0.34	2.93e-8	Eating disorders (purging via substances);
KIRP	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs7721647	0.853	rs1813756	chr5:90863382	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.41	5.04	0.31	8.88e-7	Breast cancer;
KIRP	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg01689657	chr7:91764605	CYP51A1	-0.41	-5.98	-0.36	7.69e-9	Breast cancer;
KIRP	cis	rs7520050	0.807	rs4353138	chr1:46219803	C/T	cg24296786	chr1:45957014	TESK2	0.48	5.74	0.34	2.8e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs3857067	1.000	rs1588384	chr4:95001354	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.96	-0.3	1.29e-6	QT interval;
KIRP	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.54	7.63	0.44	5.08e-13	Extrinsic epigenetic age acceleration;
KIRP	cis	rs714027	0.605	rs5763779	chr22:30504652	A/G	cg27665648	chr22:30112403	NA	-0.42	-5.66	-0.34	4.3e-8	Lymphocyte counts;
KIRP	cis	rs10203711	0.901	rs907104	chr2:239564564	T/G	cg14580085	chr2:239553406	NA	0.39	5.19	0.31	4.51e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg05868516	chr6:26286170	HIST1H4H	0.39	5.01	0.3	1.06e-6	Educational attainment;
KIRP	cis	rs4356975	0.563	rs4293848	chr4:69965502	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	5.03	0.31	9.36e-7	Obesity-related traits;
KIRP	cis	rs1448094	0.791	rs10863124	chr12:86352548	A/T	cg00310523	chr12:86230176	RASSF9	0.4	6.31	0.37	1.31e-9	Major depressive disorder;
KIRP	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	8.48	0.48	2.05e-15	Motion sickness;
KIRP	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg02151108	chr14:50098012	C14orf104	-0.55	-7.34	-0.42	3.03e-12	Carotid intima media thickness;
KIRP	cis	rs7932354	0.710	rs6485702	chr11:46898771	T/C	cg16389345	chr11:46697382	NA	0.44	5.49	0.33	9.96e-8	Bone mineral density (hip);Bone mineral density;
KIRP	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.64	5.36	0.32	1.87e-7	Diabetic retinopathy;
KIRP	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11987759	chr7:65425863	GUSB	0.57	7.65	0.44	4.67e-13	Aortic root size;
KIRP	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-15.9	-0.71	1.23e-39	Chronic sinus infection;
KIRP	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.89	-12.34	-0.62	1.44e-27	Personality dimensions;
KIRP	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg07148914	chr20:33460835	GGT7	0.4	4.95	0.3	1.37e-6	Height;
KIRP	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23161317	chr6:28129485	ZNF389	0.5	5.96	0.35	8.9e-9	Depression;
KIRP	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-8.49	-0.48	2e-15	Coronary artery disease;
KIRP	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.61	8.79	0.49	2.66e-16	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-1.0	-11.67	-0.6	2.48e-25	White matter hyperintensity burden;
KIRP	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.64	-7.73	-0.44	2.81e-13	Obesity-related traits;
KIRP	cis	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg06066596	chr15:83166174	LOC80154	0.47	5.62	0.34	5.08e-8	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs12913538	0.513	rs12441930	chr15:62889367	C/G	cg09983546	chr15:62884068	NA	0.49	6.06	0.36	5.04e-9	Sleep depth;
KIRP	cis	rs12424086	0.617	rs61921611	chr12:66367726	T/C	cg06712651	chr12:66351869	HMGA2	-0.64	-8.38	-0.47	4.19e-15	Permanent tooth development;Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	14.91	0.69	2.99e-36	Alzheimer's disease;
KIRP	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.49	-6.28	-0.37	1.49e-9	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs8033133	0.602	rs4906699	chr15:25321029	A/G	cg14481604	chr15:25334117	SNORD116-22	0.47	5.84	0.35	1.61e-8	Blood osmolality (transformed sodium);
KIRP	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-0.9	-12.15	-0.61	6.3e-27	Blood trace element (Zn levels);
KIRP	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg11621586	chr10:70884670	VPS26A	1.15	14.45	0.68	1.11e-34	Left atrial antero-posterior diameter;
KIRP	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg20387954	chr3:183756860	HTR3D	0.47	6.63	0.39	2.06e-10	Anterior chamber depth;
KIRP	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	7.42	0.43	1.95e-12	Coronary artery disease;
KIRP	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-5.45	-0.33	1.2e-7	Pulmonary function;
KIRP	cis	rs2011503	0.739	rs8108659	chr19:19680738	T/A	cg11584989	chr19:19387371	SF4	-0.51	-5.29	-0.32	2.65e-7	Bipolar disorder;
KIRP	cis	rs7827545	0.545	rs16905172	chr8:135556373	A/G	cg17885191	chr8:135476712	NA	0.67	6.23	0.37	2e-9	Hypertension (SNP x SNP interaction);
KIRP	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.73	-10.5	-0.56	1.48e-21	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg22800045	chr5:56110881	MAP3K1	0.82	8.72	0.49	4.14e-16	Initial pursuit acceleration;
KIRP	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg13010199	chr12:38710504	ALG10B	0.67	8.59	0.48	9.95e-16	Morning vs. evening chronotype;
KIRP	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	cg04338863	chr8:33670619	NA	0.49	6.37	0.38	9.14e-10	Body mass index;
KIRP	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.41	4.96	0.3	1.3e-6	Tonsillectomy;
KIRP	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.81	11.43	0.59	1.54e-24	Aortic root size;
KIRP	cis	rs13185784	0.703	rs17627536	chr5:179678603	G/A	cg13944838	chr5:179740914	GFPT2	0.54	5.19	0.31	4.35e-7	TRAIL levels;
KIRP	cis	rs2387326	0.638	rs75285784	chr10:129940551	A/C	cg16087940	chr10:129947807	NA	-0.36	-4.88	-0.3	1.87e-6	Select biomarker traits;
KIRP	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.4	-5.0	-0.3	1.1e-6	Aortic root size;
KIRP	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	7.8	0.45	1.8e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.31	0.32	2.44e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.31	-12.44	-0.62	7.1e-28	Diabetic retinopathy;
KIRP	cis	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg26587870	chr6:27730563	NA	-0.65	-4.92	-0.3	1.56e-6	Breast cancer;
KIRP	cis	rs6088813	0.702	rs6060378	chr20:33923001	T/G	cg14752227	chr20:34000481	UQCC	0.49	6.21	0.37	2.25e-9	Height;
KIRP	cis	rs7766436	0.885	rs13211957	chr6:22573415	C/T	cg13666174	chr6:22585274	NA	-0.46	-6.06	-0.36	5.07e-9	Coronary artery disease;
KIRP	cis	rs9826463	1.000	rs2140433	chr3:142343691	C/G	cg20824294	chr3:142316082	PLS1	-0.29	-5.38	-0.32	1.71e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.22	-16.92	-0.73	3.94e-43	Breast cancer;
KIRP	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	0.89	6.53	0.38	3.72e-10	IgG glycosylation;
KIRP	cis	rs6921919	0.583	rs9461458	chr6:28355875	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.44	-6.4	-0.38	7.67e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.52	6.68	0.39	1.57e-10	Multiple myeloma (IgH translocation);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg00540891	chr10:43572244	RET	0.48	6.49	0.38	4.6e-10	Parkinson's disease;
KIRP	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.7	8.48	0.48	2.12e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs8028182	0.636	rs8023815	chr15:75814704	G/A	cg20655648	chr15:75932815	IMP3	0.54	6.78	0.4	9.08e-11	Sudden cardiac arrest;
KIRP	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.87	0.35	1.4e-8	Motion sickness;
KIRP	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg12559939	chr2:27858050	GPN1	0.44	5.52	0.33	8.81e-8	Oral cavity cancer;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01839850	chr22:38240395	ANKRD54;MIR658	0.47	6.16	0.37	3.02e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs7209700	0.574	rs3851806	chr17:45350919	G/C	cg18085866	chr17:45331354	ITGB3	-0.58	-5.42	-0.33	1.4e-7	IgG glycosylation;
KIRP	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg02975922	chr3:195473998	MUC4	-0.47	-5.13	-0.31	5.81e-7	Pancreatic cancer;
KIRP	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg18196295	chr10:418757	DIP2C	-0.4	-5.06	-0.31	8.36e-7	Psychosis in Alzheimer's disease;
KIRP	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg25838818	chr2:108905173	SULT1C2	-0.42	-6.57	-0.39	3e-10	Blood pressure;
KIRP	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg00484396	chr16:3507460	NAT15	0.52	5.29	0.32	2.66e-7	Tuberculosis;
KIRP	cis	rs10208940	0.920	rs11893513	chr2:68760647	C/T	cg12452813	chr2:68675892	NA	0.47	5.06	0.31	8.07e-7	Urate levels in lean individuals;
KIRP	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.55	8.59	0.48	1.03e-15	Major depressive disorder;
KIRP	cis	rs151997	0.538	rs1345777	chr5:50263788	A/G	cg06027927	chr5:50259733	NA	-0.52	-6.59	-0.39	2.64e-10	Callous-unemotional behaviour;
KIRP	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.68	8.22	0.46	1.14e-14	Neutrophil percentage of white cells;
KIRP	cis	rs34779708	0.931	rs13376871	chr10:35369056	A/G	cg03585969	chr10:35415529	CREM	0.76	9.39	0.51	4.29e-18	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13047869	chr3:10149882	C3orf24	0.55	5.38	0.32	1.74e-7	Alzheimer's disease;
KIRP	cis	rs3026101	0.671	rs3026140	chr17:5313522	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.86	0.35	1.48e-8	Body mass index;
KIRP	cis	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg21775007	chr8:11205619	TDH	-0.39	-5.16	-0.31	5e-7	Morning vs. evening chronotype;
KIRP	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.47	-5.65	-0.34	4.45e-8	Alzheimer's disease (late onset);
KIRP	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.61	5.2	0.31	4.22e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.93	-0.3	1.53e-6	Life satisfaction;
KIRP	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-0.83	-11.0	-0.57	3.64e-23	Urate levels;
KIRP	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-8.1	-0.46	2.5e-14	Response to antipsychotic treatment;
KIRP	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.88	-15.14	-0.69	4.89e-37	Intelligence (multi-trait analysis);
KIRP	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.23e-11	Blood pressure;
KIRP	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg16497277	chr3:49208875	KLHDC8B	0.4	5.18	0.31	4.52e-7	Menarche (age at onset);
KIRP	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.49	6.57	0.39	2.99e-10	Personality dimensions;
KIRP	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg19717773	chr7:2847554	GNA12	0.28	4.94	0.3	1.46e-6	Plateletcrit;
KIRP	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg26681399	chr22:41777847	TEF	-0.42	-4.95	-0.3	1.39e-6	Neuroticism;
KIRP	cis	rs7221595	0.778	rs2290439	chr17:3924306	A/G	cg09597638	chr17:3907349	NA	0.58	7.05	0.41	1.82e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs33912345	0.750	rs12434902	chr14:60944259	T/G	cg27398547	chr14:60952738	C14orf39	0.37	4.93	0.3	1.5e-6	Glaucoma (high intraocular pressure);
KIRP	cis	rs72730918	0.564	rs4774594	chr15:51851999	C/T	cg14296394	chr15:51910925	DMXL2	-0.77	-10.59	-0.56	7.77e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.31	5.59	0.34	6.07e-8	Calcium levels;
KIRP	cis	rs11574514	1.000	rs7195415	chr16:67689057	G/A	cg26727032	chr16:67993705	SLC12A4	-0.72	-5.81	-0.35	1.97e-8	Crohn's disease;
KIRP	cis	rs42714	0.688	rs174023	chr7:28465718	G/A	cg19638435	chr7:28452093	CREB5	-0.78	-4.95	-0.3	1.36e-6	Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals;
KIRP	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.58	7.86	0.45	1.21e-13	Mean corpuscular volume;
KIRP	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-6.06	-0.36	5.02e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg08461772	chr7:95026248	PON3	0.42	6.07	0.36	4.73e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg23594656	chr7:65796392	TPST1	-0.36	-5.54	-0.33	7.9e-8	Aortic root size;
KIRP	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg06618935	chr21:46677482	NA	-0.44	-5.54	-0.33	7.6e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg18190219	chr22:46762943	CELSR1	-0.66	-7.93	-0.45	7.9e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.69	7.19	0.42	7.79e-12	Vitiligo;
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg23985595	chr17:80112537	CCDC57	-0.33	-4.86	-0.3	2.09e-6	Life satisfaction;
KIRP	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.59	8.65	0.48	6.76e-16	Blood metabolite levels;
KIRP	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg00405596	chr8:11794950	NA	-0.47	-5.96	-0.36	8.63e-9	Monocyte count;
KIRP	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11987759	chr7:65425863	GUSB	-0.47	-5.62	-0.34	5.13e-8	Aortic root size;
KIRP	cis	rs12693043	0.727	rs35923732	chr2:175413376	G/A	cg11778734	chr2:175439522	WIPF1	-0.58	-8.22	-0.46	1.16e-14	Urate levels (BMI interaction);
KIRP	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg10189774	chr4:17578691	LAP3	0.46	5.46	0.33	1.17e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	trans	rs587242	0.911	rs61786490	chr1:96897274	T/G	cg10631902	chr5:14652156	NA	0.52	6.05	0.36	5.47e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
KIRP	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	cg21523751	chr1:182988639	NA	0.45	7.0	0.41	2.49e-11	Colorectal cancer;
KIRP	cis	rs1420338	0.933	rs12540602	chr7:34174056	G/A	cg01275685	chr7:34179230	BMPER	-0.61	-9.27	-0.51	9.76e-18	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
KIRP	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	9.36	0.51	5.19e-18	IgG glycosylation;
KIRP	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.47	6.76	0.4	9.79e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg26513180	chr16:89883248	FANCA	-0.41	-5.2	-0.31	4.2e-7	Vitiligo;
KIRP	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-4.99	-0.3	1.15e-6	Coronary artery disease;
KIRP	cis	rs259842	0.800	rs194674	chr2:180708309	C/T	cg05687686	chr2:180726697	MIR1258;ZNF385B	0.36	5.29	0.32	2.74e-7	Blood protein levels;
KIRP	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg10167378	chr1:228756711	NA	0.9	7.19	0.42	7.66e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs4253772	0.938	rs41371446	chr22:46637272	T/C	cg24881330	chr22:46731750	TRMU	0.66	4.98	0.3	1.19e-6	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4972806	0.776	rs2072589	chr2:177042871	C/T	cg10304824	chr2:177028804	HOXD3	0.28	5.7	0.34	3.47e-8	IgG glycosylation;
KIRP	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.76	-0.34	2.48e-8	Body mass index;
KIRP	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg16434002	chr17:42200994	HDAC5	0.48	5.37	0.32	1.8e-7	Total body bone mineral density;
KIRP	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs698833	0.624	rs7564087	chr2:44693647	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	5.54	0.33	7.69e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg02297831	chr4:17616191	MED28	0.62	7.75	0.44	2.47e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg13798780	chr7:105162888	PUS7	0.65	5.83	0.35	1.74e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg17724175	chr1:150552817	MCL1	0.36	6.24	0.37	1.87e-9	Tonsillectomy;
KIRP	cis	rs4478037	1.000	rs4074417	chr3:33161153	A/C	cg19404215	chr3:33155277	CRTAP	0.71	6.58	0.39	2.84e-10	Major depressive disorder;
KIRP	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.58	-6.57	-0.39	3.01e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.1	10.74	0.56	2.57e-22	Lung cancer in ever smokers;
KIRP	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.7	9.71	0.53	4.55e-19	Mean corpuscular volume;
KIRP	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-9.71	-0.53	4.34e-19	Morning vs. evening chronotype;
KIRP	cis	rs7562790	0.624	rs2160366	chr2:36661672	C/T	cg09467607	chr2:36825704	FEZ2	0.43	5.24	0.32	3.4e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs1448094	0.717	rs7137122	chr12:86290702	T/C	cg00310523	chr12:86230176	RASSF9	0.41	6.25	0.37	1.75e-9	Major depressive disorder;
KIRP	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.94	15.89	0.71	1.31e-39	Menopause (age at onset);
KIRP	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg14893161	chr1:205819251	PM20D1	0.5	5.1	0.31	6.9e-7	Parkinson's disease;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg22627950	chr7:44622302	TMED4	-0.48	-6.18	-0.37	2.67e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg07511934	chr16:89386912	ANKRD11	0.47	6.29	0.37	1.45e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.79	0.4	8.44e-11	Hypertriglyceridemia;
KIRP	cis	rs7106204	0.562	rs7109606	chr11:24251314	G/T	ch.11.24196551F	chr11:24239977	NA	0.87	10.53	0.56	1.21e-21	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.84	-9.75	-0.53	3.32e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg22974920	chr21:40686053	BRWD1	-0.45	-5.2	-0.31	4.12e-7	Cognitive function;
KIRP	cis	rs7209700	0.862	rs2015729	chr17:45354493	G/A	cg18085866	chr17:45331354	ITGB3	-0.4	-5.0	-0.3	1.07e-6	IgG glycosylation;
KIRP	cis	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg06521331	chr12:34319734	NA	-0.53	-6.57	-0.39	3.03e-10	Morning vs. evening chronotype;
KIRP	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-0.97	-9.5	-0.52	2.01e-18	Blood protein levels;
KIRP	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.95	11.56	0.59	5.59e-25	Alzheimer's disease;
KIRP	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-11.89	-0.6	4.58e-26	Vitiligo;
KIRP	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg14375499	chr17:6899207	ALOX12	-0.39	-5.89	-0.35	1.25e-8	Tonsillectomy;
KIRP	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.56	-5.83	-0.35	1.7e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-5.95	-0.35	9.08e-9	Cardiac Troponin-T levels;
KIRP	cis	rs2845885	1.000	rs2845885	chr11:63869062	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.63	6.13	0.36	3.49e-9	Body mass index;
KIRP	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg23894439	chr1:183413866	NA	0.4	5.37	0.32	1.85e-7	Systemic lupus erythematosus;
KIRP	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.53	7.03	0.41	1.99e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.88	0.53	1.29e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.65	-9.3	-0.51	8.03e-18	Menarche (age at onset);
KIRP	cis	rs9513593	1.000	rs9585019	chr13:99850487	T/C	cg21788972	chr13:99853209	UBAC2	0.53	5.65	0.34	4.51e-8	Psoriasis;
KIRP	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.59	9.47	0.52	2.38e-18	Neuroticism;
KIRP	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.84	16.09	0.72	2.76e-40	Anterior chamber depth;
KIRP	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.72	-10.39	-0.55	3.26e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.66	10.94	0.57	5.93e-23	Cardiovascular disease risk factors;
KIRP	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg05082376	chr22:42548792	NA	-0.47	-6.04	-0.36	5.7e-9	Schizophrenia;
KIRP	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	1.0	15.99	0.71	5.89e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg13010199	chr12:38710504	ALG10B	0.47	6.02	0.36	6.17e-9	Morning vs. evening chronotype;
KIRP	cis	rs7180079	0.620	rs11631879	chr15:64690389	C/T	cg15337035	chr15:64978493	NA	-0.49	-5.29	-0.32	2.73e-7	Monocyte count;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04127825	chr1:167503222	NA	0.53	6.29	0.37	1.42e-9	Smoking initiation;
KIRP	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.74	8.78	0.49	2.79e-16	Lymphocyte percentage of white cells;
KIRP	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.48	-0.33	1.07e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.82	-11.01	-0.57	3.59e-23	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6467136	0.715	rs10231675	chr7:127162706	T/G	cg08586737	chr7:127225949	GCC1	-0.38	-5.01	-0.3	1.03e-6	Type 2 diabetes;
KIRP	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.87	9.05	0.5	4.54e-17	Exhaled nitric oxide output;
KIRP	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg09904177	chr6:26538194	HMGN4	-0.43	-5.72	-0.34	3.07e-8	Schizophrenia;
KIRP	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	6.52	0.38	3.92e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs7560272	0.501	rs11894953	chr2:73964631	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-5.51	-0.33	8.94e-8	Schizophrenia;
KIRP	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg21775007	chr8:11205619	TDH	0.46	6.11	0.36	3.9e-9	Neuroticism;
KIRP	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg26811252	chr16:29126840	RRN3P2	0.76	10.21	0.55	1.27e-20	Menopause (age at onset);
KIRP	cis	rs6120849	0.754	rs6120788	chr20:33583716	C/T	cg24642439	chr20:33292090	TP53INP2	0.66	6.63	0.39	2.09e-10	Protein C levels;
KIRP	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.61	-0.39	2.38e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs28655083	1.000	rs1843456	chr16:77072393	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-5.58	-0.34	6.4e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs9488822	0.636	rs12524932	chr6:116330266	G/A	cg15226275	chr6:116381976	FRK	0.21	5.98	0.36	7.62e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.05	9.04	0.5	4.77e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg25432323	chr16:70322827	AARS	0.7	8.27	0.47	8.3e-15	Lung cancer in ever smokers;
KIRP	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.55	7.39	0.43	2.25e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg20651018	chr11:3035856	CARS	0.35	4.86	0.3	2.08e-6	Longevity;
KIRP	cis	rs4762326	0.816	rs7967229	chr12:95643298	A/T	cg07737802	chr12:95537812	FGD6	0.46	6.45	0.38	5.9e-10	Endometriosis;
KIRP	cis	rs7852872	0.965	rs7040792	chr9:119248993	T/C	cg13792444	chr9:119245443	ASTN2	0.39	5.75	0.34	2.7e-8	Hippocampal volume;
KIRP	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg11584989	chr19:19387371	SF4	0.4	5.19	0.31	4.47e-7	Tonsillectomy;
KIRP	cis	rs7224685	0.501	rs781825	chr17:3966064	A/G	cg09597638	chr17:3907349	NA	0.75	14.01	0.67	3.54e-33	Type 2 diabetes;
KIRP	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.66	-6.87	-0.4	5.23e-11	Vitiligo;
KIRP	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-1.07	-17.7	-0.75	9.08e-46	Intelligence (multi-trait analysis);
KIRP	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.52	6.64	0.39	2.01e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.63	9.58	0.52	1.11e-18	Lung cancer;
KIRP	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg27462398	chr1:86174642	ZNHIT6	-0.45	-5.23	-0.32	3.69e-7	Urate levels in overweight individuals;
KIRP	cis	rs2574704	1.000	rs6767687	chr3:11652848	A/G	cg07643000	chr3:11666825	VGLL4	0.41	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.81	7.77	0.44	2.16e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg20701182	chr2:24300061	SF3B14	0.58	5.19	0.31	4.41e-7	Lymphocyte counts;
KIRP	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg00806126	chr19:22604979	ZNF98	-0.64	-6.45	-0.38	5.85e-10	Pain;
KIRP	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.41	5.37	0.32	1.79e-7	Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.67	9.44	0.52	2.96e-18	Morning vs. evening chronotype;
KIRP	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.53	12.71	0.63	8.93e-29	Airflow obstruction;
KIRP	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.49	5.76	0.34	2.55e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg15997130	chr1:24165203	NA	0.6	8.78	0.49	2.84e-16	Immature fraction of reticulocytes;
KIRP	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	1.11	13.21	0.64	1.79e-30	Type 2 diabetes nephropathy;
KIRP	cis	rs8113308	0.810	rs8105910	chr19:52447068	A/G	cg24732339	chr19:52471368	ZNF350	-0.44	-4.92	-0.3	1.57e-6	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	0.93	17.08	0.74	1.13e-43	Dental caries;
KIRP	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.53	8.86	0.49	1.68e-16	Rheumatoid arthritis;
KIRP	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.43	-5.33	-0.32	2.22e-7	Aortic root size;
KIRP	cis	rs1440410	0.798	rs1605581	chr4:144166787	A/C	cg01719995	chr4:144104893	USP38	0.41	5.54	0.33	7.88e-8	Ischemic stroke;
KIRP	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.55	0.33	7.33e-8	Blood protein levels;
KIRP	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg15128208	chr22:42549153	NA	0.4	5.2	0.31	4.12e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs12765878	0.557	rs2984133	chr10:105670848	T/A	cg11005552	chr10:105648138	OBFC1	-0.39	-5.03	-0.31	9.47e-7	Coronary artery disease;
KIRP	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.66	9.76	0.53	3.16e-19	Lymphocyte counts;
KIRP	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg10047753	chr17:41438598	NA	1.14	18.23	0.76	1.48e-47	Menopause (age at onset);
KIRP	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.65	-8.04	-0.46	3.87e-14	Extraversion;
KIRP	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05665937	chr4:1216051	CTBP1	-0.44	-5.52	-0.33	8.64e-8	Obesity-related traits;
KIRP	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.17	0.54	1.63e-20	Cognitive test performance;
KIRP	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06481639	chr22:41940642	POLR3H	0.73	7.66	0.44	4.18e-13	Vitiligo;
KIRP	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.88	-11.2	-0.58	8.77e-24	Vitamin D levels;
KIRP	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg04306507	chr14:55594613	LGALS3	0.47	7.17	0.42	8.97e-12	Protein biomarker;
KIRP	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg13615516	chr5:77269221	NA	0.52	8.27	0.47	8.6e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg10503236	chr1:231470652	EXOC8	-0.51	-7.32	-0.42	3.51e-12	Hemoglobin concentration;
KIRP	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg16179182	chr5:140090404	VTRNA1-1	-0.41	-5.1	-0.31	6.73e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg22875332	chr1:76189707	ACADM	-0.34	-5.04	-0.31	8.94e-7	Daytime sleep phenotypes;
KIRP	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06481639	chr22:41940642	POLR3H	-0.51	-5.8	-0.35	1.99e-8	Vitiligo;
KIRP	cis	rs6708331	0.517	rs2028879	chr2:70354637	C/T	cg05298696	chr2:70188691	ASPRV1	-0.43	-5.71	-0.34	3.28e-8	Obesity-related traits;
KIRP	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg23166289	chr1:210001082	C1orf107	0.47	5.75	0.34	2.61e-8	Orofacial clefts;
KIRP	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-0.95	-11.15	-0.58	1.23e-23	White matter hyperintensity burden;
KIRP	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.81	10.33	0.55	5.35e-21	Mean corpuscular hemoglobin;
KIRP	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg06873352	chr17:61820015	STRADA	-0.55	-6.86	-0.4	5.48e-11	Prudent dietary pattern;
KIRP	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.43	-5.68	-0.34	3.86e-8	Menarche (age at onset);
KIRP	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	8.88	0.49	1.46e-16	Bipolar disorder;
KIRP	cis	rs4523957	0.855	rs143499	chr17:2132324	T/C	cg16513277	chr17:2031491	SMG6	0.69	9.52	0.52	1.67e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.76	12.21	0.61	4.16e-27	Ewing sarcoma;
KIRP	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.42	8.83	0.49	2.01e-16	Vitiligo;
KIRP	cis	rs6969780	1.000	rs739734	chr7:27159405	C/T	cg19142026	chr7:27170394	HOXA4	0.42	4.97	0.3	1.23e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg01097406	chr16:89675127	NA	-0.29	-4.92	-0.3	1.58e-6	Vitiligo;
KIRP	trans	rs10790917	0.586	rs10893749	chr11:127664841	A/C	cg18423962	chr11:111945365	C11orf57;PIH1D2	0.47	6.04	0.36	5.8e-9	Colorectal cancer;
KIRP	cis	rs1823913	0.599	rs17412635	chr2:192159560	A/G	cg12404831	chr2:192114017	MYO1B	-0.54	-7.61	-0.44	5.77e-13	Obesity-related traits;
KIRP	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.44	6.03	0.36	5.84e-9	Breast cancer (estrogen-receptor negative);Breast cancer;
KIRP	cis	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg21204522	chr6:27730016	NA	-0.73	-5.58	-0.34	6.26e-8	Breast cancer;
KIRP	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	10.12	0.54	2.31e-20	Mean corpuscular hemoglobin;
KIRP	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	13.17	0.64	2.54e-30	Eye color traits;
KIRP	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg27398547	chr14:60952738	C14orf39	-0.6	-5.66	-0.34	4.15e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs35955747	0.869	rs5753576	chr22:31757735	C/T	cg02404636	chr22:31891804	SFI1	0.38	5.01	0.3	1.03e-6	Neutrophil count;Sum basophil neutrophil counts;
KIRP	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.54	7.22	0.42	6.28e-12	Intelligence (multi-trait analysis);
KIRP	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.24	-21.84	-0.81	1.67e-59	IgG glycosylation;
KIRP	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-7.02	-0.41	2.14e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.46	-6.96	-0.41	3.11e-11	Fractional excretion of uric acid;
KIRP	cis	rs35771425	1.000	rs35513231	chr1:211619503	T/C	cg10512769	chr1:211675356	NA	-0.49	-4.96	-0.3	1.29e-6	Educational attainment (years of education);
KIRP	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25517755	chr10:38738941	LOC399744	-0.5	-6.9	-0.4	4.33e-11	Extrinsic epigenetic age acceleration;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20659463	chr18:9102542	NDUFV2	0.48	6.08	0.36	4.48e-9	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.75	0.34	2.65e-8	Motion sickness;
KIRP	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.59	0.39	2.58e-10	Mean corpuscular volume;
KIRP	cis	rs11718455	0.585	rs1491708	chr3:43911578	C/T	cg21419209	chr3:44054225	NA	-0.62	-7.21	-0.42	6.89e-12	Coronary artery disease;
KIRP	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.66	8.21	0.46	1.29e-14	Height;
KIRP	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg18944383	chr4:111397179	ENPEP	0.53	8.79	0.49	2.61e-16	Coronary artery disease;
KIRP	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg24315340	chr6:146058215	EPM2A	0.42	5.34	0.32	2.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg06636001	chr8:8085503	FLJ10661	0.69	8.83	0.49	2.03e-16	Retinal vascular caliber;
KIRP	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.9	6.71	0.39	1.37e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	6.47	0.38	5.22e-10	Menarche (age at onset);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17518899	chr12:50017006	PRPF40B	0.53	6.36	0.38	1e-9	Smoking initiation;
KIRP	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03388025	chr16:89894329	SPIRE2	0.31	5.82	0.35	1.85e-8	Vitiligo;
KIRP	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg09517075	chr8:22133004	PIWIL2	0.5	6.5	0.38	4.36e-10	Hypertriglyceridemia;
KIRP	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.57	-7.29	-0.42	4.1e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.69	0.48	5.02e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.9	-12.06	-0.61	1.25e-26	Bipolar disorder and schizophrenia;
KIRP	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg27432699	chr2:27873401	GPN1	-0.43	-5.47	-0.33	1.09e-7	Total body bone mineral density;
KIRP	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg22676075	chr6:135203613	NA	0.49	7.16	0.42	9.22e-12	Red blood cell count;
KIRP	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.78	10.88	0.57	9.37e-23	Total body bone mineral density;
KIRP	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	23.61	0.83	3.67e-65	Chronic sinus infection;
KIRP	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg04132472	chr17:19861366	AKAP10	0.47	6.58	0.39	2.73e-10	Schizophrenia;
KIRP	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.52	6.44	0.38	6.21e-10	Asthma;
KIRP	cis	rs8523	0.838	rs3778167	chr6:11033468	T/C	cg13562911	chr6:11044106	ELOVL2	0.42	5.4	0.33	1.54e-7	Red blood cell fatty acid levels;
KIRP	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	10.38	0.55	3.66e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.63	8.03	0.46	4.15e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs4481887	0.508	rs6666148	chr1:248402758	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-5.3	-0.32	2.55e-7	Common traits (Other);
KIRP	cis	rs8027181	0.804	rs7178130	chr15:72978202	A/G	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.54	-8.08	-0.46	2.89e-14	Triglyceride levels;
KIRP	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg13628971	chr7:2884303	GNA12	0.39	5.07	0.31	7.99e-7	Height;
KIRP	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.64	-7.48	-0.43	1.31e-12	Height;
KIRP	cis	rs1040	1.000	rs1040	chr6:169616347	T/C	cg04662567	chr6:169592167	NA	-0.43	-5.16	-0.31	5.18e-7	Joint mobility (Beighton score);
KIRP	cis	rs6714788	0.565	rs7558817	chr2:100654482	C/A	cg17356467	chr2:100759845	AFF3	0.38	5.12	0.31	6.19e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg07001201	chr5:642380	CEP72	0.67	6.24	0.37	1.93e-9	Obesity-related traits;
KIRP	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.8	11.53	0.59	7.06e-25	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg14132834	chr19:41945861	ATP5SL	-0.58	-7.83	-0.45	1.41e-13	Height;
KIRP	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-9.52	-0.52	1.69e-18	Response to antipsychotic treatment;
KIRP	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg19454999	chr17:41278357	BRCA1;NBR2	0.51	5.83	0.35	1.73e-8	Menopause (age at onset);
KIRP	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.48	-5.54	-0.33	7.93e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.09	-0.31	7.05e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.51	-6.69	-0.39	1.48e-10	Blood protein levels;Circulating chemerin levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg14634336	chr6:111804804	REV3L	0.52	6.18	0.37	2.66e-9	Smoking initiation;
KIRP	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg15655495	chr12:38532458	NA	-0.28	-5.21	-0.31	4.09e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19882132	chr14:106167949	NA	-0.41	-5.07	-0.31	7.7e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg08126542	chr6:37504118	NA	0.71	10.33	0.55	5.2e-21	Cognitive performance;
KIRP	cis	rs57994353	0.663	rs4418446	chr9:139305024	G/A	cg14169450	chr9:139327907	INPP5E	0.51	5.44	0.33	1.26e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.71	7.73	0.44	2.74e-13	Corneal astigmatism;
KIRP	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.74	-10.08	-0.54	3.1e-20	Hemoglobin concentration;
KIRP	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg10223061	chr2:219282414	VIL1	0.29	4.86	0.3	2.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs13102973	0.600	rs13122485	chr4:135834437	G/A	cg14419869	chr4:135874104	NA	0.5	8.3	0.47	7.16e-15	Subjective well-being;
KIRP	cis	rs7274811	0.652	rs291686	chr20:32010851	T/C	cg03904042	chr20:32255491	NECAB3;C20orf134	0.42	5.12	0.31	6.13e-7	Height;
KIRP	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23598886	chr18:12777645	NA	0.73	6.03	0.36	5.96e-9	Inflammatory skin disease;
KIRP	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.69	-10.13	-0.54	2.19e-20	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.17	18.46	0.76	2.35e-48	Height;
KIRP	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-5.84	-0.35	1.65e-8	IgG glycosylation;
KIRP	cis	rs6539288	0.677	rs1348566	chr12:107325648	C/T	cg15890332	chr12:107067104	RFX4	0.34	5.57	0.33	6.7e-8	Total body bone mineral density;
KIRP	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.65	8.26	0.47	9.02e-15	Prudent dietary pattern;
KIRP	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.62	-6.71	-0.39	1.3e-10	Alcohol dependence;
KIRP	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.75	12.1	0.61	9.41e-27	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.52	5.36	0.32	1.93e-7	Obesity (extreme);
KIRP	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.74	-8.75	-0.49	3.37e-16	Pancreatic cancer;
KIRP	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-7.52	-0.43	1.03e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs7246760	0.881	rs68018725	chr19:9855919	C/T	cg02900749	chr2:68251473	NA	-1.06	-8.71	-0.49	4.62e-16	Pursuit maintenance gain;
KIRP	cis	rs3105169	1.000	rs4735607	chr8:100222436	T/C	cg00191853	chr8:101177733	SPAG1	-0.39	-4.89	-0.3	1.86e-6	Smoking initiation;
KIRP	cis	rs2151522	0.762	rs9401919	chr6:127189308	G/C	cg21431617	chr6:127135037	NA	0.29	5.14	0.31	5.57e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03192963	chr3:37034909	EPM2AIP1;MLH1	0.52	6.21	0.37	2.27e-9	Smoking initiation;
KIRP	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	8.67	0.48	6.06e-16	Personality dimensions;
KIRP	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-7.85	-0.45	1.27e-13	Platelet count;
KIRP	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	9.12	0.5	2.84e-17	Resting heart rate;
KIRP	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg24009623	chr19:33667908	NA	0.45	5.49	0.33	9.81e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs2274273	0.563	rs79163357	chr14:55738449	G/A	cg04306507	chr14:55594613	LGALS3	0.41	5.59	0.34	5.91e-8	Protein biomarker;
KIRP	cis	rs6684514	1.000	rs6684514	chr1:156255456	G/A	cg16558208	chr1:156270281	VHLL	-0.44	-5.89	-0.35	1.28e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.7	9.19	0.51	1.65e-17	Colorectal cancer;
KIRP	cis	rs2554380	0.760	rs1946367	chr15:84425263	G/T	cg14598478	chr15:84363061	ADAMTSL3	-0.46	-6.44	-0.38	6.31e-10	Height;
KIRP	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.31	-6.2	-0.37	2.31e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg02462569	chr6:150064036	NUP43	-0.33	-4.94	-0.3	1.43e-6	Lung cancer;
KIRP	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg09788416	chr12:39539408	NA	0.39	5.31	0.32	2.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg15128208	chr22:42549153	NA	0.52	5.24	0.32	3.38e-7	Birth weight;
KIRP	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.69	-7.79	-0.44	1.91e-13	Smoking initiation;
KIRP	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-8.59	-0.48	1.04e-15	Morning vs. evening chronotype;
KIRP	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg15556689	chr8:8085844	FLJ10661	0.63	8.0	0.45	4.75e-14	Systolic blood pressure;
KIRP	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg11211951	chr8:145729740	GPT	0.45	7.52	0.43	1.01e-12	Age at first birth;
KIRP	cis	rs3120667	0.790	rs7521839	chr1:152384759	A/G	cg26876637	chr1:152193138	HRNR	-0.54	-6.01	-0.36	6.74e-9	Eating disorders;
KIRP	cis	rs1867631	0.585	rs4655642	chr1:67090083	A/G	cg02459107	chr1:67143332	SGIP1	0.39	5.81	0.35	1.95e-8	Menopause (age at onset);
KIRP	cis	rs3779635	0.742	rs1045511	chr8:27255146	C/T	cg21186296	chr8:27182909	PTK2B	0.53	6.65	0.39	1.91e-10	Neuroticism;
KIRP	cis	rs11638352	1.000	rs1820485	chr15:44430332	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-6.06	-0.36	5.1e-9	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs8079658	0.904	rs11658957	chr17:63775115	C/T	cg18091269	chr17:63822838	CCDC46	-0.52	-6.46	-0.38	5.71e-10	Post bronchodilator FEV1;
KIRP	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	8.64	0.48	7.17e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg05802129	chr4:122689817	NA	-0.59	-7.35	-0.42	2.87e-12	Type 2 diabetes;
KIRP	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.41	-5.17	-0.31	4.86e-7	Blood metabolite levels;
KIRP	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	0.6	5.22	0.32	3.84e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg00277334	chr10:82204260	NA	0.49	5.65	0.34	4.35e-8	Post bronchodilator FEV1;
KIRP	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.71	9.18	0.51	1.86e-17	Corneal astigmatism;
KIRP	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg07930552	chr6:133119739	C6orf192	1.07	9.37	0.51	5.02e-18	Type 2 diabetes nephropathy;
KIRP	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.57	-6.97	-0.41	2.87e-11	Alzheimer's disease (late onset);
KIRP	cis	rs7213347	0.555	rs2760751	chr17:2028106	A/G	cg15816464	chr17:2026533	SMG6	0.36	5.12	0.31	6.23e-7	Total body bone mineral density;
KIRP	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.97	0.36	8.32e-9	Platelet count;
KIRP	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16414030	chr3:133502952	NA	-0.51	-5.99	-0.36	7.22e-9	Iron status biomarkers;
KIRP	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg08076091	chr2:203926405	NBEAL1	0.85	8.63	0.48	7.88e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs2745572	0.515	rs2250686	chr6:1549144	A/G	cg01806741	chr6:1527072	NA	0.33	4.96	0.3	1.31e-6	Glaucoma (high intraocular pressure);Glaucoma (primary open-angle);Intraocular pressure;
KIRP	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg20673091	chr1:2541236	MMEL1	-0.69	-10.69	-0.56	3.7e-22	Ulcerative colitis;
KIRP	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18932078	chr1:2524107	MMEL1	0.45	6.22	0.37	2.13e-9	Ulcerative colitis;
KIRP	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg18016565	chr1:150552671	MCL1	0.41	6.2	0.37	2.43e-9	Melanoma;
KIRP	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg07777115	chr5:623756	CEP72	-0.59	-6.04	-0.36	5.56e-9	Obesity-related traits;
KIRP	cis	rs4974559	0.947	rs28678404	chr4:1374919	G/A	cg02980000	chr4:1222292	CTBP1	0.86	8.27	0.47	8.43e-15	Systolic blood pressure;
KIRP	cis	rs259842	0.584	rs7588510	chr2:180732409	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.4	-5.04	-0.31	9.07e-7	Blood protein levels;
KIRP	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-4.95	-0.3	1.36e-6	Psoriasis;
KIRP	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.4	-5.14	-0.31	5.48e-7	IgG glycosylation;
KIRP	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg08847533	chr14:75593920	NEK9	-0.53	-6.09	-0.36	4.25e-9	IgG glycosylation;
KIRP	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg03714773	chr7:91764589	CYP51A1	0.39	5.66	0.34	4.2e-8	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11996870	chr7:91795403	LOC401387	0.51	6.25	0.37	1.85e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.98	-17.43	-0.74	7.75e-45	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11987759	chr7:65425863	GUSB	0.51	6.8	0.4	7.82e-11	Aortic root size;
KIRP	cis	rs687432	0.650	rs2441970	chr11:57868140	C/A	cg19752551	chr11:57585705	CTNND1	-0.4	-5.61	-0.34	5.41e-8	Parkinson's disease;
KIRP	cis	rs28834970	0.675	rs7013346	chr8:27228666	C/A	cg14221460	chr8:27183342	PTK2B	-0.43	-5.2	-0.31	4.3e-7	Alzheimer's disease (late onset);
KIRP	cis	rs78545713	0.892	rs11751286	chr6:26241361	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.62	-5.35	-0.32	2.01e-7	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs9912468	0.595	rs8064837	chr17:64242703	C/G	cg19474267	chr17:64306194	PRKCA	0.4	5.08	0.31	7.38e-7	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs4262150	0.842	rs4246036	chr5:152205430	C/T	cg12297329	chr5:152029980	NA	0.5	6.65	0.39	1.84e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.7	0.34	3.39e-8	Total cholesterol levels;
KIRP	cis	rs62355272	0.900	rs6872233	chr5:35831703	C/T	cg13894535	chr5:35919491	CAPSL	-0.4	-5.07	-0.31	7.93e-7	Lymphocyte counts;
KIRP	cis	rs6783573	1.000	rs12185926	chr3:46602999	C/G	cg16875182	chr3:46619291	LRRC2;TDGF1	-0.5	-6.17	-0.37	2.79e-9	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg00852783	chr1:26633632	UBXN11	0.52	7.49	0.43	1.23e-12	Obesity-related traits;
KIRP	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19346786	chr7:2764209	NA	-0.41	-6.75	-0.4	1.08e-10	Height;
KIRP	trans	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21643547	chr1:205240462	TMCC2	-0.71	-10.81	-0.57	1.5e-22	Red blood cell count;
KIRP	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg13010199	chr12:38710504	ALG10B	0.47	5.98	0.36	7.71e-9	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.65	-8.23	-0.46	1.1e-14	Sudden cardiac arrest;
KIRP	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs66573146	1.000	rs56350643	chr4:7017591	G/A	cg00086871	chr4:6988644	TBC1D14	0.88	5.13	0.31	5.91e-7	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.68	8.04	0.46	3.77e-14	Gestational age at birth (maternal effect);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25307771	chr13:91067121	NA	0.37	6.42	0.38	6.87e-10	Survival in pancreatic cancer;
KIRP	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.69	9.14	0.5	2.47e-17	Resting heart rate;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg21029468	chr3:23987787	NR1D2	0.51	6.39	0.38	8.42e-10	C-reactive protein;
KIRP	cis	rs1465370	0.720	rs7811462	chr7:130017487	G/A	cg03229158	chr7:130009420	NA	0.33	4.87	0.3	2.01e-6	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.28	-5.67	-0.34	3.99e-8	Diastolic blood pressure;
KIRP	cis	rs372883	0.901	rs8133749	chr21:30615935	C/T	cg24692254	chr21:30365293	RNF160	-0.39	-5.03	-0.31	9.26e-7	Pancreatic cancer;
KIRP	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg18478394	chr8:109455254	TTC35	0.57	7.13	0.41	1.08e-11	Dupuytren's disease;
KIRP	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.62	5.84	0.35	1.65e-8	Alzheimer's disease;
KIRP	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.48	5.95	0.35	8.96e-9	Initial pursuit acceleration;
KIRP	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg14345882	chr6:26364793	BTN3A2	0.54	4.95	0.3	1.39e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	0.49	6.27	0.37	1.63e-9	Prudent dietary pattern;
KIRP	cis	rs12936587	0.583	rs34664666	chr17:17513404	G/A	cg01246520	chr17:17644344	RAI1	-0.37	-5.67	-0.34	4.03e-8	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
KIRP	cis	rs7221595	0.825	rs12942967	chr17:3921834	C/T	cg05562828	chr17:3906858	NA	0.61	6.92	0.4	3.99e-11	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.82	12.06	0.61	1.24e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg15252951	chr6:33757062	LEMD2	-0.42	-5.04	-0.31	8.85e-7	Crohn's disease;
KIRP	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg23601095	chr6:26197514	HIST1H3D	0.92	7.55	0.43	8.37e-13	Gout;Renal underexcretion gout;
KIRP	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg16141378	chr3:129829833	LOC729375	0.49	6.18	0.37	2.67e-9	Joint mobility (Beighton score);
KIRP	cis	rs6457821	1.000	rs6920146	chr6:35312267	G/A	cg06087101	chr6:35551932	FKBP5	0.58	5.19	0.31	4.48e-7	Height;
KIRP	cis	rs1215050	0.791	rs1585088	chr4:98675071	C/A	cg05340658	chr4:99064831	C4orf37	-0.5	-6.07	-0.36	4.87e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12292205	chr6:26970375	C6orf41	-0.64	-7.1	-0.41	1.36e-11	Intelligence (multi-trait analysis);
KIRP	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg23533926	chr12:111358616	MYL2	0.48	6.33	0.37	1.18e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs3779635	0.840	rs2322718	chr8:27257787	A/C	cg21186296	chr8:27182909	PTK2B	0.48	6.23	0.37	2e-9	Neuroticism;
KIRP	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg23594656	chr7:65796392	TPST1	0.52	8.24	0.47	1.01e-14	Aortic root size;
KIRP	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.33	-0.37	1.14e-9	Joint mobility (Beighton score);
KIRP	cis	rs75920871	1.000	rs61907591	chr11:116796855	T/A	cg23684410	chr11:116897558	SIK3	0.54	5.99	0.36	7.57e-9	Subjective well-being;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06440065	chr19:30206617	C19orf12	0.46	6.23	0.37	1.98e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg05370193	chr1:21551575	ECE1	-0.37	-5.07	-0.31	7.77e-7	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs930036	0.604	rs7594177	chr2:172038043	G/A	cg12801329	chr2:171670795	NA	0.43	4.96	0.3	1.29e-6	Menopause (age at onset);
KIRP	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.53	6.67	0.39	1.68e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17507749	chr15:85114479	UBE2QP1	0.47	5.26	0.32	3.09e-7	Schizophrenia;
KIRP	cis	rs115344852	0.575	rs2531820	chr6:28456719	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.43	-5.09	-0.31	6.99e-7	Epithelial ovarian cancer;
KIRP	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-0.67	-5.27	-0.32	2.92e-7	IgG glycosylation;
KIRP	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.84	-0.53	1.77e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.16	-0.61	5.99e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6466055	0.720	rs6466064	chr7:105024217	T/C	cg04380332	chr7:105027541	SRPK2	-0.63	-9.37	-0.51	5.05e-18	Schizophrenia;
KIRP	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg24879335	chr3:133465180	TF	0.34	4.99	0.3	1.12e-6	Iron status biomarkers;
KIRP	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-6.92	-0.4	3.98e-11	Morning vs. evening chronotype;
KIRP	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs3736485	0.966	rs2124878	chr15:51906337	C/T	cg14296394	chr15:51910925	DMXL2	-0.35	-5.2	-0.31	4.16e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs10207628	0.653	rs7601287	chr2:127881243	G/A	cg06223080	chr2:127868745	NA	-0.65	-8.44	-0.47	2.72e-15	Psychosis and Alzheimer's disease;
KIRP	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.63	-7.81	-0.45	1.62e-13	Tonsillectomy;
KIRP	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	5.24	0.32	3.54e-7	Bipolar disorder;
KIRP	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg23950597	chr19:37808831	NA	-0.63	-6.76	-0.4	1.01e-10	Coronary artery calcification;
KIRP	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.46	-6.54	-0.38	3.49e-10	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs3779635	0.742	rs28671003	chr8:27248667	G/A	cg14221460	chr8:27183342	PTK2B	0.53	6.97	0.41	2.94e-11	Neuroticism;
KIRP	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.6	6.78	0.4	8.82e-11	Subjective well-being;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08740862	chr11:62314417	AHNAK	-0.48	-6.73	-0.39	1.21e-10	Metabolic traits;
KIRP	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg05220968	chr6:146057943	EPM2A	-0.42	-5.34	-0.32	2.11e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.09	0.31	7.13e-7	Breast cancer;
KIRP	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg01879757	chr17:41196368	BRCA1	-0.79	-10.85	-0.57	1.15e-22	Menopause (age at onset);
KIRP	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.59	7.33	0.42	3.36e-12	Breast cancer;
KIRP	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg21605333	chr4:119757512	SEC24D	1.63	12.03	0.61	1.63e-26	Cannabis dependence symptom count;
KIRP	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg13010199	chr12:38710504	ALG10B	0.47	5.97	0.36	8.09e-9	Morning vs. evening chronotype;
KIRP	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg20991723	chr1:152506922	NA	-0.43	-5.03	-0.31	9.25e-7	Hair morphology;
KIRP	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.28	7.45	0.43	1.54e-12	Primary biliary cholangitis;
KIRP	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.84	-13.46	-0.65	2.56e-31	Headache;
KIRP	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.44	5.64	0.34	4.62e-8	Body mass index;
KIRP	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.52	6.64	0.39	2.01e-10	Multiple myeloma (IgH translocation);
KIRP	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg16309518	chr5:176445507	NA	-0.9	-14.23	-0.67	6.26e-34	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs4478037	0.749	rs72856153	chr3:33111182	T/G	cg19404215	chr3:33155277	CRTAP	0.57	5.11	0.31	6.58e-7	Major depressive disorder;
KIRP	cis	rs728478	1.000	rs9903669	chr17:57431766	C/G	cg16535752	chr17:57448097	YPEL2	0.22	5.16	0.31	5.05e-7	QT interval;
KIRP	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.56	7.0	0.41	2.36e-11	Arsenic metabolism;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg14447399	chr5:162930290	MAT2B	-0.42	-6.15	-0.37	3.07e-9	Migraine with aura;
KIRP	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.14	-0.36	3.33e-9	Parkinson's disease;
KIRP	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.77	-8.53	-0.48	1.48e-15	Corneal astigmatism;
KIRP	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.48	6.77	0.4	9.42e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.39	-7.04	-0.41	1.9e-11	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg21643547	chr1:205240462	TMCC2	-0.53	-7.78	-0.44	1.96e-13	Red blood cell count;
KIRP	trans	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.44	6.16	0.37	2.93e-9	Mean corpuscular volume;
KIRP	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg12119029	chr16:89752879	CDK10	0.24	4.89	0.3	1.82e-6	Vitiligo;
KIRP	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.56	-8.2	-0.46	1.3e-14	Monocyte percentage of white cells;
KIRP	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg04306507	chr14:55594613	LGALS3	0.52	8.14	0.46	2e-14	Protein biomarker;
KIRP	cis	rs15676	0.783	rs10988134	chr9:131595407	C/T	cg00228799	chr9:131580591	ENDOG	-0.56	-6.08	-0.36	4.5e-9	Blood metabolite levels;
KIRP	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg12131826	chr15:77904385	NA	0.41	4.88	0.3	1.95e-6	Type 2 diabetes;
KIRP	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.88	9.88	0.53	1.32e-19	Corneal astigmatism;
KIRP	cis	rs8077577	0.708	rs2290503	chr17:18135753	T/C	cg18869244	chr17:18121946	NA	-0.42	-4.88	-0.3	1.9e-6	Obesity-related traits;
KIRP	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.32	8.58	0.48	1.08e-15	Crohn's disease;
KIRP	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.87	13.73	0.66	3.03e-32	Longevity;
KIRP	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.62	8.11	0.46	2.48e-14	Longevity;Endometriosis;
KIRP	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg09788416	chr12:39539408	NA	0.41	5.28	0.32	2.77e-7	Morning vs. evening chronotype;
KIRP	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg04362960	chr10:104952993	NT5C2	0.62	6.95	0.41	3.21e-11	Arsenic metabolism;
KIRP	cis	rs1971256	0.500	rs75278317	chr6:151821271	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-6.07	-0.36	4.79e-9	Endometriosis;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg16979575	chr11:118799782	NA	-0.58	-6.44	-0.38	6.36e-10	Menopause (age at onset);
KIRP	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.64	-7.94	-0.45	7.38e-14	Corneal astigmatism;
KIRP	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.89	-13.8	-0.66	1.76e-32	Height;
KIRP	cis	rs853679	0.607	rs201002	chr6:27808192	A/G	cg19041857	chr6:27730383	NA	-0.6	-4.86	-0.3	2.05e-6	Depression;
KIRP	cis	rs17065868	0.764	rs9533854	chr13:45021880	A/T	cg10246903	chr13:45222710	NA	0.52	5.06	0.31	8.11e-7	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs13315871	0.929	rs1047335	chr3:58280942	A/G	cg12435725	chr3:58293450	RPP14	-0.44	-5.04	-0.31	8.86e-7	Cholesterol, total;
KIRP	cis	rs11718455	0.767	rs4682924	chr3:43992760	G/A	cg21419209	chr3:44054225	NA	-0.75	-9.2	-0.51	1.55e-17	Coronary artery disease;
KIRP	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.99	8.09	0.46	2.82e-14	Body mass index;
KIRP	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg21132104	chr15:45694354	SPATA5L1	0.55	6.37	0.38	8.98e-10	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.45	-5.65	-0.34	4.53e-8	Blood metabolite levels;
KIRP	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.3	-5.2	-0.31	4.24e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	5.74	0.34	2.71e-8	Mean platelet volume;
KIRP	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg21775007	chr8:11205619	TDH	-0.45	-5.75	-0.34	2.66e-8	Retinal vascular caliber;
KIRP	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.29	7.6	0.44	6.21e-13	Primary biliary cholangitis;
KIRP	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg21573476	chr21:45109991	RRP1B	-0.76	-10.64	-0.56	5.46e-22	Mean corpuscular volume;
KIRP	cis	rs1823913	1.000	rs12623832	chr2:192125644	A/C	cg12404831	chr2:192114017	MYO1B	-0.5	-6.76	-0.4	9.74e-11	Obesity-related traits;
KIRP	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg23791538	chr6:167370224	RNASET2	-0.43	-5.32	-0.32	2.34e-7	Primary biliary cholangitis;
KIRP	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg21401794	chr1:90099060	LRRC8C	0.68	9.74	0.53	3.54e-19	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4356975	0.563	rs4364327	chr4:69973692	C/T	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg22974920	chr21:40686053	BRWD1	0.51	6.15	0.36	3.15e-9	Cognitive function;
KIRP	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg07701084	chr6:150067640	NUP43	0.68	8.4	0.47	3.7e-15	Lung cancer;
KIRP	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs687432	0.924	rs2089747	chr11:57745042	G/A	cg19752551	chr11:57585705	CTNND1	-0.69	-9.1	-0.5	3.23e-17	Parkinson's disease;
KIRP	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.94	-10.44	-0.55	2.32e-21	Blood protein levels;
KIRP	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-8.68	-0.48	5.49e-16	Vitiligo;
KIRP	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg13206674	chr6:150067644	NUP43	0.69	10.52	0.56	1.31e-21	Lung cancer;
KIRP	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.3	0.65	8.98e-31	Bladder cancer;
KIRP	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg13198984	chr17:80129470	CCDC57	0.55	7.98	0.45	5.63e-14	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22379573	chr1:197704774	DENND1B	-0.4	-6.07	-0.36	4.91e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg24579218	chr15:68104479	NA	-0.41	-6.43	-0.38	6.52e-10	Restless legs syndrome;
KIRP	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg23992470	chr4:843637	GAK	0.6	4.86	0.3	2.05e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg04025307	chr7:1156635	C7orf50	0.47	5.54	0.33	7.93e-8	Bronchopulmonary dysplasia;
KIRP	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	6.59	0.39	2.7e-10	Acne (severe);
KIRP	cis	rs71636778	0.722	rs17162315	chr1:27176431	A/T	cg12203394	chr1:27248618	NUDC	0.68	5.54	0.33	7.87e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.76	-8.2	-0.46	1.35e-14	Gut microbiome composition (summer);
KIRP	trans	rs9850225	0.719	rs9862709	chr3:80467009	C/G	cg11026330	chr4:18023101	LCORL	-0.47	-6.13	-0.36	3.4e-9	Erectile dysfunction in type 1 diabetes;
KIRP	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.79	8.18	0.46	1.48e-14	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg11972305	chr2:233791962	NGEF	0.43	5.4	0.33	1.61e-7	Schizophrenia;
KIRP	cis	rs6500395	0.802	rs13330784	chr16:48661530	A/C	cg04672837	chr16:48644449	N4BP1	0.45	6.31	0.37	1.29e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.56	7.13	0.41	1.1e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg11972305	chr2:233791962	NGEF	-0.43	-5.46	-0.33	1.16e-7	Schizophrenia;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24192786	chr5:122917781	CSNK1G3	-0.45	-7.14	-0.41	1.05e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.86	-13.44	-0.65	2.98e-31	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg06521331	chr12:34319734	NA	-0.59	-7.14	-0.41	1.08e-11	Morning vs. evening chronotype;
KIRP	trans	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg06521331	chr12:34319734	NA	-0.52	-6.46	-0.38	5.64e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	1.09	21.6	0.81	9.81e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.95	16.33	0.72	4.21e-41	Height;
KIRP	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-0.69	-7.0	-0.41	2.36e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.66	9.38	0.51	4.58e-18	Coenzyme Q10 levels;
KIRP	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg06156847	chr2:113672199	IL1F7	-0.43	-6.07	-0.36	4.92e-9	Pulmonary function;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg23479034	chr5:109852826	TMEM232	0.4	6.12	0.36	3.65e-9	Migraine with aura;
KIRP	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	9.78	0.53	2.64e-19	Total body bone mineral density;
KIRP	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs3026101	0.671	rs9789012	chr17:5301070	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg02297831	chr4:17616191	MED28	0.59	7.1	0.41	1.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs300890	0.760	rs6823434	chr4:144199853	G/A	cg19876092	chr4:144208277	NA	0.43	7.1	0.41	1.32e-11	Nasopharyngeal carcinoma;
KIRP	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg09264619	chr17:80180166	NA	0.51	6.09	0.36	4.21e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg16141378	chr3:129829833	LOC729375	0.52	6.41	0.38	7.42e-10	Joint mobility (Beighton score);
KIRP	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.67	5.2	0.31	4.15e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs8093481	0.523	rs614661	chr18:10685822	A/G	cg21165219	chr18:10698044	FAM38B	-0.37	-4.87	-0.3	2e-6	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.81	9.65	0.52	6.66e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg16141378	chr3:129829833	LOC729375	-0.51	-6.69	-0.39	1.5e-10	Systolic blood pressure;
KIRP	cis	rs2562456	0.833	rs1932087	chr19:21521427	G/A	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.95e-6	Pain;
KIRP	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg03714773	chr7:91764589	CYP51A1	0.4	5.8	0.35	1.99e-8	Breast cancer;
KIRP	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg09165964	chr15:75287851	SCAMP5	0.51	6.72	0.39	1.24e-10	Breast cancer;
KIRP	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg24250549	chr1:154909240	PMVK	0.48	6.42	0.38	6.78e-10	Prostate cancer;
KIRP	cis	rs7215564	0.908	rs35821645	chr17:78652479	G/A	cg06153925	chr17:78755379	RPTOR	0.32	5.21	0.32	3.97e-7	Myopia (pathological);
KIRP	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.65	8.66	0.48	6.42e-16	Motion sickness;
KIRP	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg25182066	chr10:30743637	MAP3K8	-0.63	-8.61	-0.48	8.8e-16	Inflammatory bowel disease;
KIRP	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg23950597	chr19:37808831	NA	-0.79	-6.77	-0.4	9.21e-11	Coronary artery calcification;
KIRP	cis	rs2505998	0.833	rs2251674	chr10:43605392	A/G	cg15436174	chr10:43711423	RASGEF1A	0.45	4.94	0.3	1.44e-6	Hirschsprung disease;
KIRP	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg22903471	chr2:27725779	GCKR	-0.45	-4.85	-0.3	2.18e-6	Blood metabolite levels;
KIRP	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg05526886	chr2:227700861	RHBDD1	-0.45	-5.37	-0.32	1.83e-7	Pulmonary function;
KIRP	cis	rs2249694	0.520	rs7096203	chr10:135324505	A/C	cg20169779	chr10:135381914	SYCE1	-0.6	-6.6	-0.39	2.52e-10	Obesity-related traits;
KIRP	cis	rs2963155	0.518	rs72801090	chr5:142774692	C/T	cg17617527	chr5:142782415	NR3C1	0.77	7.8	0.45	1.79e-13	Breast cancer;
KIRP	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-0.4	-5.03	-0.31	9.57e-7	Type 2 diabetes;
KIRP	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.74	5.99	0.36	7.45e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.61	-8.18	-0.46	1.55e-14	Testicular germ cell tumor;
KIRP	cis	rs12580194	0.593	rs61956275	chr12:55786423	G/A	cg11794356	chr12:55725991	OR6C3	-0.52	-6.88	-0.4	4.9e-11	Cancer;
KIRP	cis	rs787274	1.000	rs787285	chr9:115536743	A/G	cg13803584	chr9:115635662	SNX30	-0.72	-6.34	-0.37	1.12e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10561989	chr14:35408569	C14orf19	0.54	6.06	0.36	5.02e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.42	-8.28	-0.47	7.66e-15	Refractive error;
KIRP	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.54	-5.84	-0.35	1.67e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.96	12.78	0.63	4.97e-29	Menopause (age at onset);
KIRP	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg05315796	chr3:52349193	DNAH1	0.4	6.5	0.38	4.39e-10	Electroencephalogram traits;
KIRP	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	0.92	10.33	0.55	5.01e-21	Eosinophil percentage of granulocytes;
KIRP	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg26751094	chr13:95954534	ABCC4	-0.58	-8.1	-0.46	2.61e-14	Blood metabolite levels;
KIRP	cis	rs7011507	0.945	rs79961909	chr8:49182812	A/G	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs3820928	0.560	rs12620324	chr2:227950021	C/T	cg05526886	chr2:227700861	RHBDD1	-0.46	-5.03	-0.31	9.25e-7	Pulmonary function;
KIRP	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.73	8.52	0.48	1.57e-15	Corneal astigmatism;
KIRP	cis	rs6142618	0.840	rs4911544	chr20:30696392	G/C	cg09796376	chr20:30640595	HCK	-0.37	-5.07	-0.31	7.96e-7	Inflammatory bowel disease;
KIRP	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg01493522	chr13:37497338	NA	-0.43	-5.43	-0.33	1.37e-7	Coronary artery disease;
KIRP	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21545522	chr1:205238299	TMCC2	0.43	5.75	0.34	2.64e-8	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.44	15.08	0.69	7.77e-37	Schizophrenia;
KIRP	cis	rs6681460	1.000	rs7524818	chr1:67072031	C/T	cg02459107	chr1:67143332	SGIP1	0.48	6.77	0.4	9.6e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg00857998	chr1:205179979	DSTYK	0.64	7.59	0.44	6.77e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg00933542	chr6:150070202	PCMT1	0.27	4.92	0.3	1.62e-6	Lung cancer;
KIRP	cis	rs7707921	0.767	rs862244	chr5:81586801	G/A	cg07807695	chr5:81608485	ATP6AP1L	-0.45	-5.85	-0.35	1.53e-8	Breast cancer;
KIRP	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.82	-12.74	-0.63	6.8e-29	Breast cancer;
KIRP	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-6.92	-0.4	3.81e-11	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg18132916	chr6:79620363	NA	-0.41	-5.71	-0.34	3.31e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg07741184	chr6:167504864	NA	-0.24	-6.45	-0.38	5.79e-10	Crohn's disease;
KIRP	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.75	8.44	0.47	2.76e-15	Response to diuretic therapy;
KIRP	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.02	11.42	0.59	1.68e-24	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg15934090	chr1:100435551	SLC35A3	0.52	6.41	0.38	7.22e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.59	-9.62	-0.52	8.68e-19	Neuroticism;
KIRP	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg17691542	chr6:26056736	HIST1H1C	0.66	7.85	0.45	1.29e-13	Iron status biomarkers;
KIRP	cis	rs9400467	0.537	rs12213673	chr6:111544839	C/T	cg15721981	chr6:111408429	SLC16A10	0.81	7.37	0.43	2.63e-12	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg09324608	chr17:30823087	MYO1D	0.47	6.1	0.36	4.1e-9	Schizophrenia;
KIRP	cis	rs4281086	0.648	rs7834351	chr8:10378405	A/G	cg01072821	chr8:10382165	T-SP1	-0.37	-5.41	-0.33	1.49e-7	Obesity-related traits;
KIRP	cis	rs1413885	0.516	rs716592	chr1:65843982	C/T	cg13202122	chr1:65886182	LEPROT;LEPR	-0.42	-4.99	-0.3	1.14e-6	Anticoagulant levels;
KIRP	cis	rs7714584	0.793	rs7709721	chr5:150246858	A/G	cg22134413	chr5:150180641	NA	0.56	5.12	0.31	6.24e-7	Crohn's disease;
KIRP	cis	rs5756391	0.546	rs4821566	chr22:37314507	C/G	cg16356956	chr22:37317934	CSF2RB	0.39	5.46	0.33	1.18e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg11608241	chr8:8085544	FLJ10661	-0.46	-5.66	-0.34	4.11e-8	Joint mobility (Beighton score);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13723693	chr17:80656731	RAB40B	0.51	6.29	0.37	1.45e-9	Parkinson's disease;
KIRP	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg20587970	chr11:113659929	NA	-0.88	-9.49	-0.52	2.04e-18	Hip circumference adjusted for BMI;
KIRP	trans	rs7999699	0.967	rs3851160	chr13:48329584	T/G	cg23237801	chr1:16476620	EPHA2	0.53	6.52	0.38	3.9e-10	Colorectal cancer (diet interaction);
KIRP	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg25801113	chr15:45476975	SHF	0.42	7.82	0.45	1.58e-13	Uric acid levels;
KIRP	cis	rs2884670	1.000	rs2884670	chr12:4675218	C/T	cg14576962	chr12:4671597	NA	-0.36	-5.11	-0.31	6.34e-7	Allergic rhinitis;
KIRP	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.81	-9.07	-0.5	3.95e-17	Coronary artery disease;
KIRP	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-4.98	-0.3	1.21e-6	Oral cavity cancer;
KIRP	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.56	6.76	0.4	1.01e-10	Epstein-Barr virus copy number in lymphoblastoid cell lines;
KIRP	cis	rs4356975	0.563	rs7698645	chr4:69971910	T/A	cg27372994	chr4:70080453	UGT2B11	0.41	5.43	0.33	1.35e-7	Obesity-related traits;
KIRP	cis	rs904251	0.523	rs1757191	chr6:37482871	C/T	cg08126542	chr6:37504118	NA	-0.83	-13.14	-0.64	3.21e-30	Cognitive performance;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14915263	chr20:49127137	PTPN1	0.45	6.13	0.36	3.38e-9	Survival in pancreatic cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04278170	chr19:12902111	JUNB	0.49	6.21	0.37	2.22e-9	Parkinson's disease;
KIRP	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg01689657	chr7:91764605	CYP51A1	0.43	6.11	0.36	3.79e-9	Breast cancer;
KIRP	cis	rs714027	0.585	rs5763670	chr22:30383758	C/G	cg27665648	chr22:30112403	NA	0.41	5.62	0.34	5.2e-8	Lymphocyte counts;
KIRP	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13198984	chr17:80129470	CCDC57	-0.53	-7.93	-0.45	7.52e-14	Life satisfaction;
KIRP	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg15605315	chr1:45957053	TESK2	0.42	4.92	0.3	1.61e-6	Homocysteine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10123224	chr1:104068567	RNPC3	0.49	6.35	0.38	1.02e-9	Parkinson's disease;
KIRP	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	8.08	0.46	2.99e-14	Aortic root size;
KIRP	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg07068956	chr7:100330872	ZAN	0.4	5.28	0.32	2.85e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
KIRP	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.85	0.45	1.26e-13	Sudden cardiac arrest;
KIRP	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.56	-6.54	-0.38	3.49e-10	Menopause (age at onset);
KIRP	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.49	0.38	4.74e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.59	6.05	0.36	5.46e-9	Vitiligo;
KIRP	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.77	9.82	0.53	2.1e-19	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-5.13	-0.31	5.78e-7	Metabolite levels;
KIRP	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg05090351	chr10:126851162	NA	0.45	7.46	0.43	1.52e-12	Menarche (age at onset);
KIRP	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.84	-15.53	-0.7	2.2e-38	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.89	10.53	0.56	1.22e-21	Glomerular filtration rate (creatinine);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg18494192	chr6:116448231	COL10A1;NT5DC1	0.4	6.21	0.37	2.27e-9	C-reactive protein;
KIRP	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.83	12.55	0.62	2.95e-28	Longevity;
KIRP	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.72	5.88	0.35	1.36e-8	Diabetic retinopathy;
KIRP	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg23995753	chr2:160760732	LY75	-0.4	-5.34	-0.32	2.11e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg23791538	chr6:167370224	RNASET2	-0.39	-4.89	-0.3	1.86e-6	Rheumatoid arthritis;
KIRP	cis	rs7834745	0.553	rs1485286	chr8:119950668	C/T	cg01975934	chr8:119970761	NA	0.45	5.04	0.31	8.82e-7	Eosinophil counts;Sum eosinophil basophil counts;
KIRP	cis	rs7870753	0.838	rs10820739	chr9:99263821	A/G	cg25260653	chr9:99212216	HABP4	0.53	5.77	0.35	2.33e-8	Height;
KIRP	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg13906792	chr15:75199810	C15orf17	-0.37	-5.41	-0.33	1.52e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg14132834	chr19:41945861	ATP5SL	-0.6	-7.75	-0.44	2.38e-13	Height;
KIRP	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg10017260	chr10:834428	NA	-0.53	-5.36	-0.32	1.88e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs9905704	0.914	rs2643120	chr17:56826949	A/T	cg12560992	chr17:57184187	TRIM37	0.57	6.35	0.38	1.03e-9	Testicular germ cell tumor;
KIRP	cis	rs4356932	1.000	rs4422436	chr4:76977784	A/G	cg00809888	chr4:76862425	NAAA	0.43	6.12	0.36	3.65e-9	Blood protein levels;
KIRP	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.69	10.96	0.57	4.9e-23	Lung cancer;
KIRP	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14442939	chr10:27389572	ANKRD26	0.47	5.13	0.31	5.85e-7	Breast cancer;
KIRP	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg11965913	chr1:205819406	PM20D1	-0.49	-5.68	-0.34	3.88e-8	Parkinson's disease;
KIRP	cis	rs13102973	0.640	rs13151892	chr4:135831375	G/A	cg14419869	chr4:135874104	NA	0.49	8.08	0.46	3.01e-14	Subjective well-being;
KIRP	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg18944383	chr4:111397179	ENPEP	0.47	7.55	0.43	8.34e-13	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10407722	chr4:2372761	ZFYVE28	-0.45	-6.11	-0.36	3.91e-9	Parkinson's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg05185946	chr5:118791606	HSD17B4	-0.41	-6.35	-0.38	1.06e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.71	10.62	0.56	6.11e-22	Coronary artery disease;
KIRP	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	0.97	11.47	0.59	1.09e-24	Testicular germ cell tumor;
KIRP	cis	rs4711336	1.000	rs764754	chr6:33658310	C/T	cg14003231	chr6:33640908	ITPR3	0.27	4.94	0.3	1.44e-6	Height;
KIRP	cis	rs193541	0.593	rs1035372	chr5:122169448	C/A	cg19412675	chr5:122181750	SNX24	0.57	5.98	0.36	7.94e-9	Glucose homeostasis traits;
KIRP	cis	rs8067545	1.000	rs56142708	chr17:19934963	A/C	cg13482628	chr17:19912719	NA	0.59	8.27	0.47	8.2e-15	Schizophrenia;
KIRP	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.8	-12.63	-0.63	1.66e-28	Idiopathic membranous nephropathy;
KIRP	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.52	-4.88	-0.3	1.94e-6	Other erythrocyte phenotypes;
KIRP	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.68	-8.14	-0.46	1.98e-14	Obesity-related traits;
KIRP	cis	rs812925	0.659	rs2167565	chr2:61476458	C/T	cg15711740	chr2:61764176	XPO1	0.44	5.1	0.31	6.8e-7	Immature fraction of reticulocytes;
KIRP	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.47	0.48	2.2e-15	Morning vs. evening chronotype;
KIRP	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg09596252	chr17:78655493	RPTOR	0.56	7.42	0.43	1.94e-12	Obesity;
KIRP	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.72	-5.54	-0.33	7.74e-8	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.93	15.81	0.71	2.48e-39	Metabolic syndrome;
KIRP	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.59	7.84	0.45	1.41e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg26207909	chr14:103986467	CKB	-0.44	-5.3	-0.32	2.63e-7	Coronary artery disease;
KIRP	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg08885076	chr2:99613938	TSGA10	-0.37	-5.29	-0.32	2.65e-7	Chronic sinus infection;
KIRP	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg21395723	chr22:39101663	GTPBP1	0.42	5.15	0.31	5.35e-7	Menopause (age at onset);
KIRP	cis	rs714515	0.934	rs10797996	chr1:172353311	C/T	cg01573306	chr1:172330400	DNM3	0.45	5.83	0.35	1.69e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.44	5.69	0.34	3.52e-8	IgG glycosylation;
KIRP	cis	rs3762637	0.823	rs9849013	chr3:122250605	A/G	cg24169773	chr3:122142474	KPNA1	-0.6	-6.65	-0.39	1.92e-10	LDL cholesterol levels;
KIRP	cis	rs9400467	0.506	rs10456872	chr6:111586667	C/T	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg06521331	chr12:34319734	NA	-0.5	-6.05	-0.36	5.43e-9	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg18306943	chr3:40428807	ENTPD3	0.44	5.89	0.35	1.26e-8	Renal cell carcinoma;
KIRP	cis	rs8056742	1.000	rs11648527	chr16:85093913	A/G	cg07295974	chr16:85045150	ZDHHC7	0.55	4.98	0.3	1.18e-6	Amyotrophic lateral sclerosis;
KIRP	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	1.04	14.46	0.68	1.03e-34	Menopause (age at onset);
KIRP	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg13736514	chr6:26305472	NA	-0.67	-8.08	-0.46	2.9e-14	Educational attainment;
KIRP	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-5.83	-0.35	1.75e-8	Metabolite levels;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg03145767	chr18:54325624	WDR7	-0.45	-6.49	-0.38	4.58e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg00792783	chr2:198669748	PLCL1	0.47	5.26	0.32	3.19e-7	Dermatomyositis;
KIRP	cis	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14849639	chr18:12948029	SEH1L	0.48	6.58	0.39	2.75e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.49	-6.41	-0.38	7.17e-10	Blood metabolite levels;
KIRP	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.43	-5.38	-0.32	1.75e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21174435	chr2:69871627	AAK1	0.46	6.39	0.38	8.34e-10	Parkinson's disease;
KIRP	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.47	-5.15	-0.31	5.34e-7	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.62	-7.61	-0.44	5.7e-13	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs13385	0.769	rs28631068	chr5:139565741	C/T	cg01860693	chr5:139557145	C5orf32	0.49	5.28	0.32	2.88e-7	Atrial fibrillation;
KIRP	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.67	7.06	0.41	1.66e-11	Lymphocyte counts;
KIRP	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.54	5.35	0.32	2.01e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs77633900	0.614	rs2468122	chr15:76918686	A/C	cg21673338	chr15:77095150	SCAPER	-0.47	-5.31	-0.32	2.45e-7	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs61884328	0.777	rs61142746	chr11:47008125	C/T	cg23433285	chr11:47201945	PACSIN3	0.69	5.55	0.33	7.35e-8	Total body bone mineral density (age over 60);
KIRP	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.51	6.93	0.4	3.59e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg22664697	chr19:2819641	ZNF554	0.49	6.28	0.37	1.48e-9	Parkinson's disease;
KIRP	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.6	-5.11	-0.31	6.53e-7	Putamen volume;
KIRP	cis	rs1723838	0.510	rs2471904	chr11:73690599	G/A	cg10064339	chr11:73693792	UCP2	0.89	5.87	0.35	1.44e-8	Obesity-related traits;
KIRP	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg21132104	chr15:45694354	SPATA5L1	0.59	7.25	0.42	5.5e-12	Response to fenofibrate (adiponectin levels);
KIRP	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-0.75	-7.68	-0.44	3.83e-13	Hip circumference adjusted for BMI;
KIRP	cis	rs2299587	0.554	rs3913558	chr8:17747909	T/G	cg01800426	chr8:17659068	MTUS1	-0.44	-5.27	-0.32	2.92e-7	Economic and political preferences;
KIRP	cis	rs4953911	0.660	rs1866456	chr2:135076641	C/T	cg18482303	chr2:135041380	MGAT5	-0.3	-5.49	-0.33	1.01e-7	Multiple sclerosis (severity);
KIRP	cis	rs2213920	0.679	rs6415819	chr9:118212492	A/C	cg13918206	chr9:118159781	DEC1	0.98	9.84	0.53	1.79e-19	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg16144447	chr1:36184773	C1orf216	0.43	6.25	0.37	1.77e-9	Survival in pancreatic cancer;
KIRP	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg24881330	chr22:46731750	TRMU	0.8	5.8	0.35	2.05e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg03289416	chr15:75166202	SCAMP2	0.44	6.25	0.37	1.81e-9	Breast cancer;
KIRP	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.65	8.74	0.49	3.58e-16	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg01872077	chr2:219646372	CYP27A1	0.39	5.06	0.31	8.16e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs8028182	0.549	rs4886696	chr15:75664570	A/T	cg20655648	chr15:75932815	IMP3	-0.53	-6.73	-0.39	1.15e-10	Sudden cardiac arrest;
KIRP	cis	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg21775007	chr8:11205619	TDH	0.42	5.15	0.31	5.24e-7	Monocyte count;
KIRP	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg03714773	chr7:91764589	CYP51A1	-0.36	-5.22	-0.32	3.73e-7	Breast cancer;
KIRP	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg00405596	chr8:11794950	NA	0.43	5.47	0.33	1.12e-7	Retinal vascular caliber;
KIRP	cis	rs6772849	0.930	rs4857916	chr3:128376014	C/G	cg08795948	chr3:128337044	NA	0.49	6.21	0.37	2.22e-9	Monocyte percentage of white cells;Monocyte count;
KIRP	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-9.4	-0.51	3.91e-18	Coronary artery disease;
KIRP	cis	rs6783573	1.000	rs6783573	chr3:46600520	A/G	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.38	-4.95	-0.3	1.41e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.55	7.81	0.45	1.63e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18252515	chr7:66147081	NA	-0.45	-5.24	-0.32	3.43e-7	Aortic root size;
KIRP	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.95	-13.48	-0.65	2.19e-31	Cognitive function;
KIRP	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.41	7.01	0.41	2.33e-11	Tumor biomarkers;
KIRP	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	cis	rs2346160	1.000	rs4709159	chr6:167664918	C/T	cg04673565	chr6:167680447	NA	-0.4	-5.27	-0.32	2.95e-7	Parental extreme longevity (95 years and older);
KIRP	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-16.32	-0.72	4.43e-41	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.88	11.18	0.58	9.9e-24	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-0.72	-6.35	-0.38	1.01e-9	Obesity-related traits;
KIRP	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.81	-10.89	-0.57	8.76e-23	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6580649	0.941	rs7296913	chr12:48488920	G/A	cg26205652	chr12:48591994	NA	-0.5	-5.93	-0.35	1e-8	Lung cancer;
KIRP	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.42	-5.1	-0.31	6.68e-7	IgG glycosylation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13850887	chr2:241993303	SNED1	0.47	6.09	0.36	4.35e-9	Survival in pancreatic cancer;
KIRP	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.6	-9.35	-0.51	5.5e-18	Coronary artery disease;
KIRP	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-0.91	-14.41	-0.68	1.51e-34	Stearic acid (18:0) levels;
KIRP	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	10.23	0.55	1.09e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.23	-34.36	-0.91	7.18e-96	Myeloid white cell count;
KIRP	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg05639522	chr1:247681581	NA	0.77	5.24	0.32	3.5e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg27211696	chr2:191398769	TMEM194B	-0.54	-6.45	-0.38	5.83e-10	Diastolic blood pressure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg15834928	chr10:134145566	LRRC27	-0.45	-6.15	-0.37	3.14e-9	Metabolic traits;
KIRP	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.4	-5.01	-0.3	1.04e-6	Neutrophil percentage of white cells;
KIRP	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.7	7.81	0.45	1.68e-13	Obesity-related traits;
KIRP	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.44	5.35	0.32	2.01e-7	Schizophrenia;
KIRP	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg14689365	chr7:158441557	NCAPG2	0.44	5.47	0.33	1.12e-7	Height;
KIRP	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.51	6.37	0.38	9.46e-10	Mean platelet volume;
KIRP	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg00647317	chr7:50633725	DDC	0.39	5.71	0.34	3.29e-8	Systemic sclerosis;
KIRP	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg08353955	chr11:69289746	NA	0.8	7.63	0.44	5.15e-13	Breast cancer (early onset);
KIRP	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg05669848	chr5:237993	SDHA	-0.51	-5.31	-0.32	2.46e-7	Breast cancer;
KIRP	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg13319975	chr6:146136371	FBXO30	-0.45	-5.97	-0.36	8.34e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.86	13.15	0.64	2.76e-30	Colorectal cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg19094126	chr13:30881323	KATNAL1	-0.5	-6.21	-0.37	2.25e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg02696790	chr15:75250997	RPP25	0.3	5.27	0.32	3.03e-7	Breast cancer;
KIRP	cis	rs75064307	0.626	rs11711542	chr3:108072801	C/T	cg14703454	chr3:108065259	HHLA2	0.53	6.39	0.38	8.41e-10	Intelligence (multi-trait analysis);
KIRP	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg06606381	chr12:133084897	FBRSL1	-1.05	-6.29	-0.37	1.41e-9	Depression;
KIRP	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg18306943	chr3:40428807	ENTPD3	0.39	5.48	0.33	1.05e-7	Renal cell carcinoma;
KIRP	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.68	9.3	0.51	8.18e-18	Morning vs. evening chronotype;
KIRP	cis	rs9400467	0.568	rs4947121	chr6:111834954	T/C	cg15721981	chr6:111408429	SLC16A10	-0.5	-5.68	-0.34	3.86e-8	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg17554472	chr22:41940697	POLR3H	-0.61	-6.53	-0.38	3.74e-10	Vitiligo;
KIRP	cis	rs7180079	0.620	rs4777553	chr15:65066017	A/G	cg15337035	chr15:64978493	NA	-0.5	-5.4	-0.33	1.57e-7	Monocyte count;
KIRP	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.52	0.48	1.66e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg25753631	chr6:25732923	NA	-0.27	-4.99	-0.3	1.14e-6	Iron status biomarkers;
KIRP	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.7	-7.35	-0.42	2.88e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.66	-8.73	-0.49	4.02e-16	Heart rate;
KIRP	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg23711669	chr6:146136114	FBXO30	0.66	9.12	0.5	2.83e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.66	9.73	0.53	3.81e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.67	10.81	0.57	1.49e-22	Pulse pressure;
KIRP	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.73	7.93	0.45	7.76e-14	Gut microbiome composition (summer);
KIRP	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06647332	chr5:131281008	NA	0.45	4.92	0.3	1.59e-6	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg00074818	chr8:8560427	CLDN23	0.42	6.32	0.37	1.25e-9	Obesity-related traits;
KIRP	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.61	-7.39	-0.43	2.3e-12	Coffee consumption (cups per day);
KIRP	cis	rs9810890	1.000	rs114261227	chr3:128469760	A/C	cg15033153	chr3:128514015	RAB7A	0.77	6.22	0.37	2.14e-9	Dental caries;
KIRP	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.1	-8.31	-0.47	6.47e-15	Mitochondrial DNA levels;
KIRP	cis	rs10875746	0.855	rs10875728	chr12:48426392	T/G	cg20731937	chr12:48336164	NA	0.38	5.17	0.31	4.94e-7	Longevity (90 years and older);
KIRP	trans	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs1867631	1.000	rs1867631	chr1:67046126	C/A	cg13052034	chr1:66999238	SGIP1	0.49	7.06	0.41	1.72e-11	Menopause (age at onset);
KIRP	cis	rs10421328	0.784	rs12983292	chr19:19787767	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.45	5.13	0.31	5.85e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg02524346	chr8:600233	NA	0.91	6.78	0.4	8.95e-11	IgG glycosylation;
KIRP	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg05926928	chr17:57297772	GDPD1	-0.68	-6.65	-0.39	1.91e-10	Opioid sensitivity;
KIRP	cis	rs8067545	1.000	rs2108980	chr17:19920518	G/A	cg04132472	chr17:19861366	AKAP10	0.51	7.45	0.43	1.57e-12	Schizophrenia;
KIRP	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-9.78	-0.53	2.77e-19	Triglycerides;
KIRP	cis	rs13065560	0.562	rs6786732	chr3:38920203	C/T	cg01426195	chr3:39028469	NA	-0.41	-6.22	-0.37	2.12e-9	Interleukin-18 levels;
KIRP	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.79	5.56	0.33	6.92e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.53	-7.31	-0.42	3.72e-12	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4523957	0.651	rs7212342	chr17:2084305	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-11.62	-0.6	3.67e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs909341	0.868	rs2236508	chr20:62333115	G/A	cg11503966	chr20:62272292	STMN3	-0.41	-5.87	-0.35	1.41e-8	Atopic dermatitis;
KIRP	cis	rs17092148	1.000	rs17092148	chr20:33435161	A/C	cg16810054	chr20:33298113	TP53INP2	-0.4	-5.0	-0.3	1.08e-6	Neuroticism;
KIRP	cis	rs6467136	0.765	rs4731370	chr7:127210207	G/A	cg08586737	chr7:127225949	GCC1	-0.38	-4.86	-0.3	2.1e-6	Type 2 diabetes;
KIRP	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.51	5.91	0.35	1.11e-8	Calcium levels;
KIRP	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg07870213	chr5:140052090	DND1	-0.61	-7.42	-0.43	1.9e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.89	6.03	0.36	6.08e-9	Putamen volume;
KIRP	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg12131826	chr15:77904385	NA	0.42	5.58	0.34	6.37e-8	Type 2 diabetes;
KIRP	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg12131826	chr15:77904385	NA	0.41	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg14683738	chr19:37701593	ZNF585B	0.48	4.92	0.3	1.61e-6	Coronary artery calcification;
KIRP	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.51	-8.81	-0.49	2.28e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-9.41	-0.51	3.57e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg21361702	chr7:150065534	REPIN1	0.54	5.83	0.35	1.75e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04374321	chr14:90722782	PSMC1	0.93	15.9	0.71	1.27e-39	Mortality in heart failure;
KIRP	trans	rs13019227	0.642	rs979975	chr2:137768441	A/G	cg12599275	chr1:3011274	PRDM16	0.79	6.35	0.38	1.04e-9	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	0.96	14.01	0.67	3.45e-33	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg17691542	chr6:26056736	HIST1H1C	0.48	6.21	0.37	2.22e-9	Height;
KIRP	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg24498760	chr8:49746867	NA	0.4	4.97	0.3	1.24e-6	Blood metabolite ratios;
KIRP	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	0.67	4.89	0.3	1.83e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs17253792	0.659	rs34330219	chr14:56017375	G/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg09455208	chr3:40491958	NA	-0.35	-6.13	-0.36	3.43e-9	Renal cell carcinoma;
KIRP	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	6.1	0.36	4.13e-9	Ulcerative colitis;Inflammatory bowel disease;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg07377662	chr17:81037199	METRNL	-0.46	-6.02	-0.36	6.39e-9	Metabolic traits;
KIRP	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.16	-14.65	-0.68	2.4e-35	Gut microbiome composition (summer);
KIRP	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22168489	chr12:122356033	WDR66	0.68	10.23	0.55	1.05e-20	Mean corpuscular volume;
KIRP	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.91	14.66	0.68	2.15e-35	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2288327	0.557	rs7588593	chr2:179352450	T/C	cg14011486	chr1:26737247	LIN28	0.69	6.84	0.4	6.36e-11	Atrial fibrillation;
KIRP	cis	rs4253772	0.938	rs41427746	chr22:46637239	T/C	cg00784671	chr22:46762841	CELSR1	-0.54	-7.18	-0.42	7.99e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1867631	0.565	rs10749764	chr1:67149706	G/C	cg13052034	chr1:66999238	SGIP1	0.49	6.93	0.4	3.73e-11	Menopause (age at onset);
KIRP	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg01620082	chr3:125678407	NA	-0.89	-6.4	-0.38	7.68e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg04132472	chr17:19861366	AKAP10	0.44	6.12	0.36	3.71e-9	Schizophrenia;
KIRP	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-6.08	-0.36	4.6e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.82	-0.35	1.78e-8	Bipolar disorder;
KIRP	cis	rs7180079	0.620	rs561055	chr15:64862638	A/T	cg15337035	chr15:64978493	NA	-0.46	-5.02	-0.3	9.8e-7	Monocyte count;
KIRP	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.71	10.06	0.54	3.61e-20	Hip circumference;
KIRP	cis	rs12643440	0.511	rs10489115	chr4:17127327	C/G	cg22650099	chr4:17144496	NA	0.69	7.27	0.42	4.72e-12	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4006360	0.610	rs7503043	chr17:39295561	G/A	cg15015397	chr17:39261100	KRTAP4-9	-0.56	-7.78	-0.44	1.99e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.91	10.72	0.56	2.92e-22	Eosinophil percentage of granulocytes;
KIRP	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.74	-8.21	-0.46	1.26e-14	Mean corpuscular hemoglobin;
KIRP	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7243821	0.672	rs11664679	chr18:52689219	A/G	cg26630735	chr18:52626848	CCDC68	0.64	6.32	0.37	1.21e-9	Chin dimples;
KIRP	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg01629716	chr15:45996671	NA	-0.38	-6.84	-0.4	6.26e-11	Waist circumference;Weight;
KIRP	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	1.34	11.45	0.59	1.27e-24	Sexual dysfunction (female);
KIRP	cis	rs597583	0.671	rs634867	chr11:117411041	G/A	cg27161313	chr11:117392002	DSCAML1	-0.56	-5.13	-0.31	5.85e-7	Putamen volume;
KIRP	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	0.9	13.86	0.66	1.17e-32	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs793571	0.715	rs11071399	chr15:59139255	A/G	cg05156742	chr15:59063176	FAM63B	-0.53	-6.02	-0.36	6.28e-9	Schizophrenia;
KIRP	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	5.6	0.34	5.72e-8	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02711726	chr17:80685570	FN3KRP	-0.49	-7.12	-0.41	1.16e-11	Glycated hemoglobin levels;
KIRP	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg01378222	chr16:28622494	SULT1A1	-0.67	-6.11	-0.36	3.89e-9	Platelet distribution width;
KIRP	cis	rs59197085	0.534	rs2307039	chr7:128449355	A/G	cg00734629	chr7:128471146	FLNC	0.43	4.85	0.3	2.18e-6	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05876325	chr8:144699783	TSTA3	0.55	7.33	0.42	3.23e-12	Parkinson's disease;
KIRP	cis	rs11169552	0.510	rs4768903	chr12:51045449	A/G	cg12884762	chr12:50931848	DIP2B	-0.45	-5.16	-0.31	4.98e-7	Colorectal cancer;
KIRP	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg14228332	chr4:119757509	SEC24D	0.79	4.86	0.3	2.08e-6	Cannabis dependence symptom count;
KIRP	cis	rs35160687	0.829	rs13017143	chr2:86466549	C/T	cg10973622	chr2:86423274	IMMT	-0.42	-4.98	-0.3	1.17e-6	Night sleep phenotypes;
KIRP	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg00262122	chr8:11665843	FDFT1	0.41	5.07	0.31	7.66e-7	Myopia (pathological);
KIRP	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17554472	chr22:41940697	POLR3H	-0.68	-7.04	-0.41	1.87e-11	Vitiligo;
KIRP	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.61	5.5	0.33	9.67e-8	Alzheimer's disease;
KIRP	cis	rs1559088	0.948	rs7259333	chr19:33579128	T/C	cg17764715	chr19:33622953	WDR88	0.68	8.45	0.47	2.5e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.87	-11.09	-0.58	1.98e-23	Parkinson's disease;
KIRP	cis	rs7558233	0.614	rs763456	chr2:23675180	A/G	cg00747342	chr2:23700632	KLHL29	0.57	5.06	0.31	8.37e-7	Cannabis use (initiation);
KIRP	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg08807101	chr21:30365312	RNF160	0.58	7.01	0.41	2.33e-11	Selective IgA deficiency;
KIRP	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.05	-13.26	-0.65	1.24e-30	Exhaled nitric oxide output;
KIRP	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg02023728	chr11:77925099	USP35	0.31	5.35	0.32	2.04e-7	Alzheimer's disease (survival time);
KIRP	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg07884673	chr3:53033167	SFMBT1	0.88	7.01	0.41	2.24e-11	Immune reponse to smallpox (secreted IL-2);
KIRP	trans	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg03929089	chr4:120376271	NA	0.84	6.2	0.37	2.38e-9	Axial length;
KIRP	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	trans	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg06521331	chr12:34319734	NA	-0.59	-7.02	-0.41	2.21e-11	Bladder cancer;
KIRP	trans	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg04702396	chr17:15466718	FAM18B2	0.5	6.52	0.38	3.88e-10	Educational attainment (years of education);
KIRP	cis	rs752010	0.545	rs6600379	chr1:42053497	T/C	cg06885757	chr1:42089581	HIVEP3	0.37	5.15	0.31	5.29e-7	Lupus nephritis in systemic lupus erythematosus;
KIRP	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg05315796	chr3:52349193	DNAH1	0.44	6.78	0.4	9.07e-11	Bipolar disorder;
KIRP	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg25124228	chr12:125621409	AACS	-0.68	-9.31	-0.51	7.57e-18	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg22863700	chr5:28928346	NA	0.62	6.42	0.38	7.05e-10	Hip geometry;
KIRP	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg17595323	chr11:93583763	C11orf90	-0.37	-6.24	-0.37	1.88e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs10754283	0.535	rs1215507	chr1:90088895	A/G	cg22140614	chr4:887730	GAK	-0.45	-6.64	-0.39	2.05e-10	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg24881330	chr22:46731750	TRMU	0.78	5.59	0.34	5.9e-8	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.58	7.63	0.44	4.99e-13	Obesity-related traits;
KIRP	cis	rs1018836	0.700	rs12678527	chr8:91527411	T/C	cg16814680	chr8:91681699	NA	-0.62	-7.05	-0.41	1.81e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7656342	0.622	rs2102872	chr4:9831358	T/C	cg00071950	chr4:10020882	SLC2A9	0.36	4.94	0.3	1.43e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg18306943	chr3:40428807	ENTPD3	0.46	6.18	0.37	2.59e-9	Renal cell carcinoma;
KIRP	cis	rs6088813	0.645	rs8123889	chr20:34013252	G/A	cg14752227	chr20:34000481	UQCC	0.47	5.24	0.32	3.5e-7	Height;
KIRP	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.88	-12.48	-0.62	5.3e-28	Primary sclerosing cholangitis;
KIRP	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.96	11.42	0.59	1.61e-24	Corneal astigmatism;
KIRP	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg24699146	chr1:24152579	HMGCL	0.42	5.43	0.33	1.34e-7	Immature fraction of reticulocytes;
KIRP	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg18753928	chr3:113234510	CCDC52	-0.63	-5.77	-0.35	2.33e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.28	5.57	0.33	6.67e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-6.32	-0.37	1.25e-9	Lung cancer;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04975846	chr16:88923880	TRAPPC2L;GALNS	0.56	7.73	0.44	2.78e-13	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4262150	0.774	rs12188960	chr5:152214214	C/G	cg12297329	chr5:152029980	NA	-0.6	-7.5	-0.43	1.19e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs12120353	0.529	rs1515670	chr1:4626286	A/G	cg12065138	chr1:4771201	AJAP1	-0.67	-5.49	-0.33	1.01e-7	Anxiety disorder;
KIRP	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.7	4.9	0.3	1.71e-6	Childhood ear infection;
KIRP	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.55	5.58	0.34	6.23e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.33	-5.63	-0.34	4.84e-8	Height;
KIRP	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg24375607	chr4:120327624	NA	0.49	5.73	0.34	2.95e-8	Corneal astigmatism;
KIRP	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-8.54	-0.48	1.39e-15	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg04657146	chr19:12876947	HOOK2	0.41	5.24	0.32	3.54e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
KIRP	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-6.53	-0.38	3.78e-10	Morning vs. evening chronotype;
KIRP	cis	rs8113308	0.515	rs73066986	chr19:52466058	A/G	cg25782003	chr19:52490127	ZNF350	0.85	6.15	0.37	3.05e-9	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs2273156	0.570	rs114200987	chr14:35586916	T/G	cg09327582	chr14:35236912	BAZ1A	-0.5	-5.05	-0.31	8.58e-7	Immunoglobulin light chain (AL) amyloidosis;
KIRP	cis	rs9826463	1.000	rs6773213	chr3:142345397	A/C	cg20824294	chr3:142316082	PLS1	0.33	5.56	0.33	7.02e-8	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs4750440	0.540	rs11258766	chr10:14016196	G/A	cg27542038	chr10:14027202	FRMD4A	-0.56	-7.23	-0.42	5.92e-12	Adiponectin levels;
KIRP	cis	rs4690686	0.760	rs1377838	chr4:177282547	G/T	cg17059388	chr4:177262070	NA	0.57	7.99	0.45	5.36e-14	Essential tremor;
KIRP	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg04374321	chr14:90722782	PSMC1	0.94	16.17	0.72	1.45e-40	Mortality in heart failure;
KIRP	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg18944383	chr4:111397179	ENPEP	0.62	11.43	0.59	1.52e-24	Height;
KIRP	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg24558204	chr6:135376177	HBS1L	-0.63	-8.17	-0.46	1.66e-14	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.46	4.93	0.3	1.5e-6	Eosinophil percentage of granulocytes;
KIRP	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	0.91	6.91	0.4	4.12e-11	Obesity-related traits;
KIRP	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg21605333	chr4:119757512	SEC24D	1.66	12.18	0.61	5.17e-27	Cannabis dependence symptom count;
KIRP	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	cis	rs10875746	0.624	rs10875777	chr12:48622071	T/C	cg20731937	chr12:48336164	NA	0.42	5.59	0.34	6.17e-8	Longevity (90 years and older);
KIRP	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.55	-6.79	-0.4	8.6e-11	Type 2 diabetes;
KIRP	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg17595323	chr11:93583763	C11orf90	-0.41	-6.81	-0.4	7.59e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-6.96	-0.41	3.1e-11	Monocyte percentage of white cells;
KIRP	cis	rs6009824	1.000	rs6009823	chr22:50086334	C/T	cg18178197	chr22:50098317	NA	0.59	7.12	0.41	1.18e-11	Natriuretic peptide levels;
KIRP	cis	rs853679	0.550	rs1150689	chr6:28165099	T/C	cg19592336	chr6:28129416	ZNF389	0.48	5.56	0.33	6.98e-8	Depression;
KIRP	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.57	-7.17	-0.42	8.55e-12	Metabolite levels;
KIRP	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg07382826	chr16:28625726	SULT1A1	0.49	5.71	0.34	3.22e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13855472	chr1:222886563	C1orf58;AIDA	0.43	6.03	0.36	6.02e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16922275	chr15:59063609	FAM63B	0.49	6.46	0.38	5.63e-10	Parkinson's disease;
KIRP	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg06050784	chr16:88016603	BANP	0.4	5.07	0.31	7.9e-7	Menopause (age at onset);
KIRP	cis	rs787274	1.000	rs1418410	chr9:115465282	A/G	cg13803584	chr9:115635662	SNX30	0.6	6.71	0.39	1.33e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg26248373	chr2:1572462	NA	-0.69	-7.58	-0.44	6.89e-13	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs72829446	0.530	rs2228132	chr17:7411770	C/T	cg02795151	chr17:7402630	POLR2A	0.83	8.39	0.47	3.96e-15	Androgen levels;
KIRP	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.55	-9.19	-0.51	1.67e-17	Bone mineral density;
KIRP	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg23250157	chr14:64679961	SYNE2	0.52	5.68	0.34	3.89e-8	Atrial fibrillation;
KIRP	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.86	12.44	0.62	7.19e-28	Ileal carcinoids;
KIRP	cis	rs1595825	0.891	rs73054808	chr2:198602283	C/T	cg00982548	chr2:198649783	BOLL	-0.55	-5.11	-0.31	6.51e-7	Ulcerative colitis;
KIRP	cis	rs1570884	1.000	rs1570884	chr13:50121511	A/G	cg08779649	chr13:50194554	NA	0.48	6.47	0.38	5.11e-10	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.79	9.7	0.53	4.67e-19	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.97	9.23	0.51	1.33e-17	Body mass index;
KIRP	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	1.06	14.83	0.69	5.58e-36	Menopause (age at onset);
KIRP	cis	rs17065868	0.730	rs77026857	chr13:45204440	G/A	cg10246903	chr13:45222710	NA	0.55	5.93	0.35	9.98e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs807029	0.577	rs11190786	chr10:102757442	A/G	cg04662943	chr10:102668895	NA	0.46	5.05	0.31	8.51e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7804356	0.906	rs73069540	chr7:26904770	C/T	cg03456212	chr7:26904342	SKAP2	-0.57	-5.18	-0.31	4.55e-7	Type 1 diabetes;
KIRP	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.71	9.07	0.5	4e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs6142102	0.812	rs2377955	chr20:32525370	A/G	cg08999081	chr20:33150536	PIGU	0.5	5.92	0.35	1.08e-8	Skin pigmentation;
KIRP	cis	rs741702	0.928	rs2965214	chr19:13029188	G/A	cg11738485	chr19:12877000	HOOK2	0.4	4.9	0.3	1.72e-6	Red blood cell traits;
KIRP	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg01689657	chr7:91764605	CYP51A1	0.41	5.91	0.35	1.15e-8	Breast cancer;
KIRP	cis	rs9325144	0.836	rs7489197	chr12:38750065	C/T	cg26384229	chr12:38710491	ALG10B	-0.53	-6.35	-0.38	1.04e-9	Morning vs. evening chronotype;
KIRP	cis	rs3789045	1.000	rs45501495	chr1:204596454	C/T	cg08641003	chr1:204589008	LRRN2	-0.52	-6.68	-0.39	1.59e-10	Educational attainment (college completion);
KIRP	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg00784671	chr22:46762841	CELSR1	-0.7	-8.53	-0.48	1.49e-15	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg19610905	chr11:61596333	FADS2	-0.47	-6.22	-0.37	2.12e-9	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.49	-5.8	-0.35	2.06e-8	Response to antipsychotic treatment;
KIRP	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg25486957	chr4:152246857	NA	-0.51	-5.56	-0.33	6.92e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg08392591	chr16:89556376	ANKRD11	0.41	4.99	0.3	1.14e-6	Multiple myeloma (IgH translocation);
KIRP	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.79	-8.76	-0.49	3.15e-16	Coronary artery disease;
KIRP	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	1.04	14.46	0.68	1.03e-34	Menopause (age at onset);
KIRP	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-6.65	-0.39	1.92e-10	Response to antipsychotic treatment;
KIRP	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	1.12	8.18	0.46	1.49e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg09003973	chr2:102972529	NA	0.58	5.96	0.36	8.56e-9	Blood protein levels;
KIRP	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.41	5.16	0.31	5.01e-7	Longevity;
KIRP	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg10755058	chr3:40428713	ENTPD3	0.36	5.28	0.32	2.77e-7	Renal cell carcinoma;
KIRP	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.83	10.02	0.54	4.79e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-1.07	-17.11	-0.74	9.1e-44	Cognitive function;
KIRP	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	4.93	0.3	1.53e-6	Obesity-related traits;
KIRP	cis	rs7534824	0.625	rs61780288	chr1:101389945	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.85	7.18	0.42	8.47e-12	Refractive astigmatism;
KIRP	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	1.23	10.34	0.55	4.97e-21	Gut microbiota (bacterial taxa);
KIRP	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.95	7.97	0.45	5.77e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.9	10.1	0.54	2.73e-20	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.66	8.23	0.46	1.13e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs7546094	0.935	rs4839254	chr1:113140926	C/T	cg22162597	chr1:113214053	CAPZA1	0.41	5.52	0.33	8.6e-8	Platelet distribution width;
KIRP	cis	rs8133932	0.654	rs7410105	chr21:47332181	A/G	cg11214348	chr21:47283868	PCBP3	0.48	5.14	0.31	5.47e-7	Schizophrenia;
KIRP	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg12315302	chr6:26189340	HIST1H4D	0.71	4.95	0.3	1.36e-6	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	7.82	0.45	1.56e-13	Mean corpuscular volume;
KIRP	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg13798780	chr7:105162888	PUS7	0.61	4.95	0.3	1.39e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs4253772	0.550	rs9615347	chr22:46728153	A/G	cg18190219	chr22:46762943	CELSR1	-0.88	-7.2	-0.42	7.39e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.73	9.64	0.52	7.44e-19	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	1.13	8.31	0.47	6.51e-15	Skin colour saturation;
KIRP	cis	rs73058052	0.935	rs3745474	chr19:50086806	C/T	cg09250473	chr19:50168907	IRF3;BCL2L12	0.61	6.92	0.4	3.82e-11	Fibrinogen levels;
KIRP	cis	rs12496230	0.794	rs6782706	chr3:66859345	C/T	cg04995300	chr3:66848608	NA	0.45	6.99	0.41	2.61e-11	Type 2 diabetes;
KIRP	cis	rs6969780	0.841	rs2301720	chr7:27196069	A/C	cg19142026	chr7:27170394	HOXA4	-0.35	-4.85	-0.3	2.2e-6	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-4.86	-0.3	2.09e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4692589	0.606	rs13127322	chr4:170935169	C/T	cg19918862	chr4:170955249	NA	0.52	5.77	0.35	2.41e-8	Anxiety disorder;
KIRP	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg13010199	chr12:38710504	ALG10B	0.55	6.72	0.39	1.23e-10	Resting heart rate;
KIRP	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.7	7.95	0.45	6.57e-14	Height;
KIRP	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.74	8.49	0.48	1.93e-15	Cognitive ability;
KIRP	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.68	8.96	0.5	8.21e-17	Motion sickness;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg09371620	chr12:46319990	SFRS2IP	0.44	6.57	0.39	3.02e-10	Survival in pancreatic cancer;
KIRP	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.61	5.99	0.36	7.58e-9	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs2625529	0.641	rs2035379	chr15:72293202	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-5.97	-0.36	8.12e-9	Red blood cell count;
KIRP	cis	rs7909074	1.000	rs4481983	chr10:45400428	G/T	cg05187965	chr10:45406764	TMEM72	-0.32	-7.54	-0.43	8.94e-13	Mean corpuscular volume;
KIRP	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	1.11	17.91	0.75	1.81e-46	Homoarginine levels;
KIRP	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.98	10.96	0.57	4.96e-23	Cognitive test performance;
KIRP	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	1.1	22.51	0.82	1.15e-61	Height;
KIRP	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.87	8.31	0.47	6.52e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	10.68	0.56	4.02e-22	Personality dimensions;
KIRP	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg04490037	chr7:50633773	DDC	0.36	4.96	0.3	1.31e-6	Body mass index;
KIRP	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.37	-5.75	-0.34	2.57e-8	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.36	0.38	9.79e-10	Educational attainment;
KIRP	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg18461458	chr19:21324796	ZNF431	0.47	4.88	0.3	1.88e-6	Pain;
KIRP	cis	rs12579753	0.667	rs7485761	chr12:82301259	C/G	cg07988820	chr12:82153109	PPFIA2	-0.47	-5.67	-0.34	3.93e-8	Resting heart rate;
KIRP	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.41	5.5	0.33	9.28e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg07295964	chr5:175223982	CPLX2	-0.54	-6.04	-0.36	5.64e-9	Menopause (age at onset);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg08491221	chr17:27717337	TAOK1	-0.56	-6.28	-0.37	1.52e-9	Menopause (age at onset);
KIRP	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.51	6.56	0.39	3.18e-10	HDL cholesterol levels;
KIRP	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg25019033	chr10:957182	NA	-0.58	-5.96	-0.36	8.65e-9	Eosinophil percentage of granulocytes;
KIRP	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.97	-16.83	-0.73	7.94e-43	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg19338460	chr6:170058176	WDR27	-1.22	-9.65	-0.52	6.62e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg04995300	chr3:66848608	NA	0.73	9.13	0.5	2.6e-17	Type 2 diabetes;
KIRP	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.62	-9.36	-0.51	5.24e-18	Schizophrenia;
KIRP	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.7	-5.61	-0.34	5.41e-8	Diabetic retinopathy;
KIRP	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg25036284	chr2:26402008	FAM59B	-0.55	-5.52	-0.33	8.46e-8	Gut microbiome composition (summer);
KIRP	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.45	7.2	0.42	7.32e-12	Testicular germ cell tumor;
KIRP	cis	rs4006360	0.541	rs6503606	chr17:39309901	A/T	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-6.55	-0.39	3.29e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg15848620	chr12:58087721	OS9	-0.43	-5.0	-0.3	1.1e-6	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.53	-0.48	1.49e-15	Calcium levels;
KIRP	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-1.05	-12.53	-0.62	3.37e-28	Breast cancer;
KIRP	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg02297831	chr4:17616191	MED28	0.58	7.16	0.42	9.27e-12	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10046671	chr1:956299	AGRN	-0.51	-6.32	-0.37	1.22e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.68	-7.37	-0.43	2.64e-12	Gut microbiome composition (summer);
KIRP	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg11846333	chr4:119757529	SEC24D	1.11	6.59	0.39	2.64e-10	Cannabis dependence symptom count;
KIRP	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg16179182	chr5:140090404	VTRNA1-1	-0.4	-5.01	-0.3	1.03e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg08885076	chr2:99613938	TSGA10	-0.61	-10.98	-0.57	4.51e-23	Chronic sinus infection;
KIRP	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.74	9.56	0.52	1.33e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg27124370	chr19:33622961	WDR88	0.6	7.41	0.43	1.99e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	5.07	0.31	7.69e-7	Menarche (age at onset);
KIRP	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.2	13.24	0.64	1.47e-30	Nonalcoholic fatty liver disease;
KIRP	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg23216685	chr1:86174607	ZNHIT6	-0.6	-8.53	-0.48	1.51e-15	Urate levels in overweight individuals;
KIRP	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg05887092	chr17:76393375	PGS1	0.54	7.48	0.43	1.33e-12	HDL cholesterol levels;
KIRP	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg19773385	chr1:10388646	KIF1B	-0.71	-10.03	-0.54	4.58e-20	Hepatocellular carcinoma;
KIRP	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg25547332	chr5:131281432	NA	0.47	5.29	0.32	2.72e-7	Life satisfaction;
KIRP	cis	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg08501292	chr6:25962987	TRIM38	-0.84	-6.18	-0.37	2.71e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11987759	chr7:65425863	GUSB	0.58	7.64	0.44	4.93e-13	Aortic root size;
KIRP	cis	rs10435719	0.746	rs58007588	chr8:11794969	A/G	cg00262122	chr8:11665843	FDFT1	0.4	4.99	0.3	1.16e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg27490568	chr2:178487706	NA	0.65	8.28	0.47	7.87e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.85	-12.15	-0.61	6.46e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.45	-5.26	-0.32	3.21e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg10495392	chr1:46806563	NSUN4	0.46	5.28	0.32	2.86e-7	Menopause (age at onset);
KIRP	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.61	8.25	0.47	9.77e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs8179	0.645	rs10953072	chr7:92256339	A/C	cg15732164	chr7:92237376	CDK6	-0.39	-5.18	-0.31	4.63e-7	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
KIRP	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg18306943	chr3:40428807	ENTPD3	-0.44	-6.09	-0.36	4.43e-9	Renal cell carcinoma;
KIRP	cis	rs57338032	0.891	rs72738729	chr15:78750052	T/C	cg06917634	chr15:78832804	PSMA4	0.57	5.07	0.31	7.97e-7	CTACK levels;
KIRP	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18255839	chr2:239335447	ASB1	0.43	5.14	0.31	5.52e-7	Multiple system atrophy;
KIRP	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.66	7.76	0.44	2.24e-13	Alcohol dependence;
KIRP	cis	rs2273669	0.667	rs12196024	chr6:109302258	C/T	cg05315195	chr6:109294784	ARMC2	-0.61	-6.22	-0.37	2.14e-9	Prostate cancer;
KIRP	cis	rs2230307	0.831	rs558270	chr1:100499285	G/C	cg24955406	chr1:100503596	HIAT1	0.56	5.62	0.34	5.04e-8	Carotid intima media thickness;
KIRP	cis	rs4234798	0.500	rs10937793	chr4:7219614	C/T	cg18431297	chr4:7219810	SORCS2	0.67	8.99	0.5	6.98e-17	Insulin-like growth factors;
KIRP	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.86	-13.51	-0.65	1.77e-31	Menarche (age at onset);
KIRP	cis	rs336284	0.502	rs6977549	chr7:35334583	T/C	cg06685737	chr7:35301730	NA	0.44	4.89	0.3	1.81e-6	Suicide;Suicide behavior;
KIRP	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg03060546	chr3:49711283	APEH	-0.59	-5.01	-0.3	1.05e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg00074818	chr8:8560427	CLDN23	0.43	6.48	0.38	4.83e-10	Obesity-related traits;
KIRP	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.27	-0.47	8.32e-15	Triglycerides;
KIRP	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.7	-9.09	-0.5	3.49e-17	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg04013166	chr16:89971882	TCF25	0.57	5.98	0.36	7.8e-9	Skin colour saturation;
KIRP	cis	rs57590327	0.503	rs1461611	chr3:81512061	C/A	cg07356753	chr3:81810745	GBE1	0.49	6.19	0.37	2.46e-9	Extraversion;
KIRP	cis	rs1566497	0.754	rs10000851	chr4:169743239	C/T	cg21985951	chr4:169930107	CBR4	-0.44	-5.41	-0.33	1.46e-7	Pulse pressure;
KIRP	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg07001201	chr5:642380	CEP72	0.65	5.92	0.35	1.08e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs7187994	0.848	rs34179694	chr16:84776522	A/G	cg11201751	chr16:85158047	NA	0.47	4.89	0.3	1.8e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg00629941	chr15:75287862	SCAMP5	0.56	6.24	0.37	1.86e-9	Electroencephalogram traits;
KIRP	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg06740227	chr12:86229804	RASSF9	0.51	6.7	0.39	1.44e-10	Major depressive disorder;
KIRP	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.55	-8.11	-0.46	2.44e-14	Idiopathic membranous nephropathy;
KIRP	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg00800569	chr2:239229395	TRAF3IP1	-0.43	-5.06	-0.31	8.12e-7	Multiple system atrophy;
KIRP	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.62	5.14	0.31	5.55e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7264396	0.563	rs6060558	chr20:34271092	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.59	-6.44	-0.38	6.21e-10	Total cholesterol levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14296488	chr21:44527812	U2AF1	0.59	7.62	0.44	5.46e-13	Parkinson's disease;
KIRP	cis	rs4849845	0.889	rs4848581	chr2:121018687	C/T	cg24070213	chr2:121070622	NA	0.4	5.35	0.32	1.99e-7	Mean platelet volume;
KIRP	trans	rs12431410	0.536	rs2182140	chr14:60149259	A/G	cg20601314	chr10:104179541	FBXL15;PSD	0.56	6.14	0.36	3.21e-9	Schizophrenia;
KIRP	cis	rs6669919	0.647	rs894985	chr1:211673760	A/G	cg10512769	chr1:211675356	NA	-0.44	-6.33	-0.37	1.16e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.24	0.47	1.01e-14	Breast cancer;
KIRP	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg10503236	chr1:231470652	EXOC8	-0.49	-6.75	-0.4	1.05e-10	Hemoglobin concentration;
KIRP	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg24826892	chr11:71159390	DHCR7	0.43	4.89	0.3	1.82e-6	Vitamin D levels;
KIRP	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	12.71	0.63	8.46e-29	Smoking behavior;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg10230314	chr22:30552801	HORMAD2	0.4	6.04	0.36	5.72e-9	Interleukin-4 levels;
KIRP	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg27532560	chr4:187881888	NA	-0.73	-12.12	-0.61	7.87e-27	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	7.31	0.42	3.75e-12	Total body bone mineral density;
KIRP	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-7.15	-0.41	9.87e-12	Monocyte count;
KIRP	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-5.43	-0.33	1.37e-7	Neuroticism;
KIRP	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.42	6.2	0.37	2.31e-9	Testicular germ cell tumor;
KIRP	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.54	8.19	0.46	1.4e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	0.96	16.16	0.72	1.6e-40	Ulcerative colitis;
KIRP	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg02725872	chr8:58115012	NA	-0.48	-6.03	-0.36	6.06e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.791	rs4699318	chr4:98664370	T/G	cg05340658	chr4:99064831	C4orf37	-0.49	-6.02	-0.36	6.3e-9	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg15147215	chr3:52552868	STAB1	-0.28	-4.96	-0.3	1.31e-6	Bipolar disorder;
KIRP	cis	rs5753618	0.554	rs5753648	chr22:31879465	A/G	cg02404636	chr22:31891804	SFI1	0.55	6.05	0.36	5.5e-9	Colorectal cancer;
KIRP	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg15704280	chr7:45808275	SEPT13	0.83	6.08	0.36	4.54e-9	Myopia (pathological);
KIRP	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg04369109	chr6:150039330	LATS1	-0.49	-6.3	-0.37	1.33e-9	Lung cancer;
KIRP	cis	rs539514	0.690	rs776527	chr13:76317794	G/A	cg04757411	chr13:76259545	LMO7	-0.35	-4.93	-0.3	1.54e-6	Type 1 diabetes;
KIRP	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.44	5.44	0.33	1.3e-7	Common traits (Other);
KIRP	trans	rs3128341	0.818	rs12143571	chr1:72822096	T/A	cg16299813	chr17:79632380	C17orf90;CCDC137	-0.34	-6.1	-0.36	4.18e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg22974920	chr21:40686053	BRWD1	0.5	6.01	0.36	6.51e-9	Cognitive function;
KIRP	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	1.17	10.23	0.55	1.06e-20	Skin colour saturation;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17233517	chr17:45285328	MYL4	-0.44	-6.05	-0.36	5.3e-9	Inflammatory biomarkers;
KIRP	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg20363699	chr7:23626180	CLK2P	-0.4	-5.42	-0.33	1.41e-7	Schizophrenia;
KIRP	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg18154014	chr19:37997991	ZNF793	0.68	6.1	0.36	4.08e-9	Coronary artery calcification;
KIRP	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.27	-22.03	-0.81	3.97e-60	Breast cancer;
KIRP	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.48	5.88	0.35	1.35e-8	Glycated hemoglobin levels;
KIRP	cis	rs2456568	0.571	rs12807496	chr11:93693064	A/G	cg26875233	chr11:93583750	C11orf90	0.29	5.32	0.32	2.32e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg15750102	chr4:107237686	AIMP1;TBCK	0.5	6.06	0.36	5.12e-9	Smoking initiation;
KIRP	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	7.84	0.45	1.36e-13	Aortic root size;
KIRP	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.85	12.97	0.64	1.18e-29	Prostate cancer;
KIRP	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.71	7.95	0.45	6.72e-14	Initial pursuit acceleration;
KIRP	cis	rs2274459	0.841	rs34778247	chr6:33658552	C/A	cg06253072	chr6:33679850	C6orf125	0.5	4.9	0.3	1.74e-6	Obesity (extreme);
KIRP	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.64	5.67	0.34	3.99e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs7224685	1.000	rs7224685	chr17:4014384	G/T	cg09695851	chr17:3907499	NA	0.59	7.86	0.45	1.2e-13	Type 2 diabetes;
KIRP	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.73	-8.43	-0.47	3.03e-15	Gut microbiome composition (summer);
KIRP	cis	rs1620921	0.774	rs783154	chr6:161229780	G/T	cg01280913	chr6:161186852	NA	-0.42	-6.04	-0.36	5.53e-9	Lipoprotein (a) - cholesterol levels;
KIRP	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.5	6.09	0.36	4.22e-9	Longevity;Endometriosis;
KIRP	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.52	9.11	0.5	3.03e-17	Airflow obstruction;
KIRP	cis	rs2077654	0.822	rs7944045	chr11:17439590	C/T	cg25308976	chr11:17434268	ABCC8	1.09	11.16	0.58	1.1e-23	Gout;
KIRP	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-5.94	-0.35	9.68e-9	Obesity-related traits;
KIRP	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.18	27.42	0.87	9.04e-77	Schizophrenia;
KIRP	cis	rs2979489	0.945	rs12548554	chr8:30346544	G/A	cg26383811	chr8:30366931	RBPMS	-0.4	-5.5	-0.33	9.39e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg12392857	chr11:134237795	GLB1L2	0.5	6.25	0.37	1.82e-9	Interleukin-4 levels;
KIRP	cis	rs7129556	0.737	rs72949616	chr11:77464370	C/T	cg12586386	chr11:77299805	AQP11	0.44	5.2	0.31	4.19e-7	Weight loss (gastric bypass surgery);
KIRP	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.71	9.89	0.53	1.22e-19	Mean corpuscular volume;
KIRP	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	7.35	0.42	3e-12	Prudent dietary pattern;
KIRP	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg05805236	chr11:65401703	PCNXL3	-0.49	-6.58	-0.39	2.88e-10	Acne (severe);
KIRP	cis	rs829661	0.793	rs2602783	chr2:30872655	G/T	cg10949345	chr2:30726833	LCLAT1	1.09	13.36	0.65	5.56e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.54	0.38	3.46e-10	Morning vs. evening chronotype;
KIRP	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.43	5.9	0.35	1.18e-8	Coronary artery disease;
KIRP	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg23387468	chr7:139079360	LUC7L2	-0.29	-5.09	-0.31	7.14e-7	Diisocyanate-induced asthma;
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg23736307	chr8:27182930	PTK2B	0.53	6.75	0.4	1.05e-10	Neuroticism;
KIRP	cis	rs7546668	1.000	rs4233533	chr1:15829187	G/A	cg21858823	chr1:15850916	CASP9	0.45	4.94	0.3	1.42e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg12598211	chr12:123634384	NA	-0.41	-5.08	-0.31	7.6e-7	Schizophrenia;
KIRP	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.73	-10.51	-0.56	1.37e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4077515	0.649	rs3087886	chr9:139301583	T/C	cg21253087	chr9:139290292	SNAPC4	0.42	5.5	0.33	9.45e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.75	-10.95	-0.57	5.25e-23	Extrinsic epigenetic age acceleration;
KIRP	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg00262122	chr8:11665843	FDFT1	0.44	5.59	0.34	6.02e-8	Myopia (pathological);
KIRP	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg27490568	chr2:178487706	NA	-0.88	-10.34	-0.55	4.8e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05310071	chr17:16120569	PIGL	0.6	7.01	0.41	2.3e-11	Lung cancer in ever smokers;
KIRP	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-16.47	-0.72	1.38e-41	Ulcerative colitis;
KIRP	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg11846333	chr4:119757529	SEC24D	1.04	6.0	0.36	7.19e-9	Cannabis dependence symptom count;
KIRP	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08048268	chr3:133502702	NA	-0.4	-4.97	-0.3	1.23e-6	Iron status biomarkers;
KIRP	cis	rs1215050	0.755	rs6843393	chr4:98822619	C/G	cg17366294	chr4:99064904	C4orf37	0.37	5.03	0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13047869	chr3:10149882	C3orf24	0.56	5.63	0.34	4.97e-8	Alzheimer's disease;
KIRP	cis	rs4835473	0.932	rs13152209	chr4:144697241	G/A	cg08833778	chr4:144622313	FREM3	0.34	4.85	0.3	2.24e-6	Immature fraction of reticulocytes;
KIRP	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg12963246	chr6:28129442	ZNF389	0.5	6.19	0.37	2.51e-9	Depression;
KIRP	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.43	5.66	0.34	4.16e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg13482628	chr17:19912719	NA	0.58	8.06	0.46	3.41e-14	Schizophrenia;
KIRP	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg16141378	chr3:129829833	LOC729375	0.5	6.1	0.36	4.01e-9	Neuroticism;
KIRP	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg16558253	chr16:72132732	DHX38	0.49	7.18	0.42	8e-12	Prostate cancer;
KIRP	cis	rs7601312	0.903	rs11680904	chr2:229297803	T/C	cg02542817	chr2:229291442	NA	-0.56	-8.62	-0.48	8.17e-16	Schizophrenia;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg18989174	chr7:149470820	ZNF467	-0.49	-7.5	-0.43	1.19e-12	Serum protein levels (sST2);
KIRP	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg11569703	chr11:65557185	OVOL1	0.67	11.93	0.61	3.38e-26	Acne (severe);
KIRP	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	18.05	0.75	6.05e-47	Chronic sinus infection;
KIRP	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.71e-10	Hypertriglyceridemia;
KIRP	cis	rs9473924	0.542	rs56240592	chr6:50815514	T/A	cg14470998	chr6:50812995	TFAP2B	1.02	9.01	0.5	5.88e-17	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08949862	chr2:63277672	OTX1	0.49	7.22	0.42	6.51e-12	Parkinson's disease;
KIRP	cis	rs8084125	1.000	rs7229560	chr18:74955538	C/T	cg05528293	chr18:74961138	GALR1	0.56	5.65	0.34	4.41e-8	Obesity-related traits;
KIRP	trans	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg06521331	chr12:34319734	NA	-0.56	-6.8	-0.4	7.9e-11	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs55788414	0.932	rs9929066	chr16:81182157	G/A	cg06400318	chr16:81190750	PKD1L2	-0.87	-8.29	-0.47	7.58e-15	Left ventricular obstructive tract defect (maternal effect);
KIRP	cis	rs9896933	0.614	rs3785511	chr17:80886316	G/T	cg20578329	chr17:80767326	TBCD	0.92	8.27	0.47	8.55e-15	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19556438	chr19:33793146	CEBPA;LOC80054	0.54	7.35	0.42	2.86e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.66	-6.5	-0.38	4.4e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.76	6.4	0.38	7.84e-10	Diabetic retinopathy;
KIRP	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.55	-6.79	-0.4	8.28e-11	Alzheimer's disease (late onset);
KIRP	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg05721485	chr17:44071124	MAPT	-0.54	-7.46	-0.43	1.52e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs75064307	0.734	rs2124736	chr3:108095365	G/A	cg03329597	chr3:108125523	MYH15	-0.51	-5.02	-0.3	9.82e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg03609598	chr5:56110824	MAP3K1	-0.68	-7.12	-0.41	1.16e-11	Initial pursuit acceleration;
KIRP	cis	rs2637030	0.559	rs923609	chr5:52912249	G/A	cg06476337	chr5:52856530	NDUFS4	0.55	5.98	0.36	7.65e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	6.51	0.38	4.26e-10	Initial pursuit acceleration;
KIRP	cis	rs4972539	0.784	rs6746658	chr2:174087310	T/A	cg04505972	chr2:173508040	NA	-0.45	-5.95	-0.35	9.39e-9	Parental longevity (mother's age at death);
KIRP	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.74	6.09	0.36	4.43e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.5	-0.43	1.19e-12	Triglycerides;
KIRP	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07167872	chr1:205819463	PM20D1	0.41	4.88	0.3	1.9e-6	Menarche (age at onset);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02285115	chr14:50329706	NA	0.47	6.14	0.36	3.24e-9	Parkinson's disease;
KIRP	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.65	5.8	0.35	2.03e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.47	6.0	0.36	6.85e-9	Height;
KIRP	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.37	4.94	0.3	1.47e-6	Lewy body disease;
KIRP	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	6.79	0.4	8.44e-11	Electroencephalogram traits;
KIRP	cis	rs6988636	1.000	rs11993411	chr8:124180537	T/C	cg23067535	chr8:124195133	FAM83A	-0.61	-5.92	-0.35	1.09e-8	Urinary uromodulin levels;
KIRP	cis	rs4683702	1.000	rs4683702	chr3:142617138	A/C	cg22826874	chr3:142608218	PCOLCE2	-0.37	-5.6	-0.34	5.68e-8	Blood protein levels;
KIRP	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.56	6.86	0.4	5.45e-11	Blood protein levels;
KIRP	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg05220968	chr6:146057943	EPM2A	-0.38	-4.84	-0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.55	-6.09	-0.36	4.25e-9	Menarche (age at onset);
KIRP	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.63	8.55	0.48	1.31e-15	Morning vs. evening chronotype;
KIRP	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	5.73	0.34	2.9e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg10845886	chr2:3471009	TTC15	-0.54	-7.87	-0.45	1.13e-13	Neurofibrillary tangles;
KIRP	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg10253484	chr15:75165896	SCAMP2	-0.48	-5.67	-0.34	4.09e-8	Breast cancer;
KIRP	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.51	7.23	0.42	5.97e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg24579896	chr14:56047964	C14orf33;KTN1	0.88	6.38	0.38	8.71e-10	Putamen volume;
KIRP	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg07621104	chr11:117668040	DSCAML1	0.45	6.15	0.37	3.1e-9	Myopia;
KIRP	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg06640241	chr16:89574553	SPG7	-0.64	-7.84	-0.45	1.37e-13	Multiple myeloma (IgH translocation);
KIRP	trans	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg14791747	chr16:20752902	THUMPD1	0.63	6.73	0.39	1.16e-10	Cognitive test performance;
KIRP	cis	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg07460842	chr6:66804631	NA	-0.56	-7.39	-0.43	2.35e-12	Blood trace element (Cu levels);
KIRP	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg04990556	chr1:26633338	UBXN11	0.64	6.07	0.36	4.77e-9	Obesity-related traits;
KIRP	cis	rs7520050	0.807	rs6429576	chr1:46216575	T/C	cg15605315	chr1:45957053	TESK2	-0.39	-4.98	-0.3	1.18e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.45	-6.02	-0.36	6.34e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg01448562	chr3:133502909	NA	-0.42	-5.19	-0.31	4.41e-7	Iron status biomarkers (transferrin levels);
KIRP	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg00405596	chr8:11794950	NA	0.48	6.06	0.36	5.16e-9	Retinal vascular caliber;
KIRP	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.67	-12.13	-0.61	7.38e-27	White blood cell count (basophil);
KIRP	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg02336718	chr17:17403227	NA	-0.4	-6.14	-0.36	3.28e-9	Total body bone mineral density;
KIRP	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	11.17	0.58	1.09e-23	Hip circumference adjusted for BMI;
KIRP	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25517755	chr10:38738941	LOC399744	-0.51	-7.01	-0.41	2.22e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs10761482	0.769	rs1417380	chr10:62111286	T/C	cg01186212	chr10:62110162	ANK3	-0.28	-4.87	-0.3	2.02e-6	Schizophrenia;
KIRP	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.44	5.25	0.32	3.28e-7	Longevity;Endometriosis;
KIRP	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg04731861	chr2:219085781	ARPC2	0.28	7.25	0.42	5.45e-12	Colorectal cancer;
KIRP	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.84	11.59	0.59	4.36e-25	Platelet distribution width;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23676042	chr8:114389438	CSMD3	-0.47	-7.57	-0.43	7.39e-13	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.47	-7.18	-0.42	8.38e-12	Coronary artery disease;
KIRP	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg03808351	chr9:123631620	PHF19	0.37	5.09	0.31	7.26e-7	Rheumatoid arthritis;
KIRP	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg02534363	chr3:47050950	NBEAL2	-0.29	-4.92	-0.3	1.59e-6	Colorectal cancer;
KIRP	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg16606324	chr3:10149918	C3orf24	0.59	5.42	0.33	1.45e-7	Alzheimer's disease;
KIRP	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.49	-6.33	-0.37	1.13e-9	IgG glycosylation;
KIRP	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.53	-0.48	1.5e-15	Calcium levels;
KIRP	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.73	8.66	0.48	6.48e-16	Small cell lung carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg19751179	chr13:52586563	ATP7B;ALG11	0.44	6.38	0.38	8.54e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg10223061	chr2:219282414	VIL1	0.29	4.95	0.3	1.4e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	7.65	0.44	4.51e-13	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.6	-6.72	-0.39	1.24e-10	Neuroticism;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg25971741	chr6:15343116	JARID2	0.54	7.53	0.43	9.55e-13	Survival in pancreatic cancer;
KIRP	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg26893134	chr6:116381904	FRK	0.2	5.7	0.34	3.5e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7923609	0.846	rs10740115	chr10:65094990	G/A	cg01631684	chr10:65280961	REEP3	-0.48	-5.64	-0.34	4.71e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg13962347	chr6:5174647	LYRM4	-0.75	-10.77	-0.57	2.12e-22	Height;
KIRP	cis	rs1962073	0.667	rs11250004	chr8:10270958	T/G	cg27411982	chr8:10470053	RP1L1	-0.41	-4.99	-0.3	1.15e-6	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
KIRP	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg05721485	chr17:44071124	MAPT	-0.54	-7.41	-0.43	2.07e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	0.65	7.63	0.44	5.07e-13	Dental caries;
KIRP	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg00717180	chr2:96193071	NA	-0.49	-6.05	-0.36	5.46e-9	Coronary artery disease;
KIRP	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg13319975	chr6:146136371	FBXO30	0.46	6.17	0.37	2.78e-9	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg13789711	chr9:139743225	PHPT1	0.51	6.03	0.36	5.9e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs6466055	0.777	rs6466053	chr7:104923929	C/T	cg04380332	chr7:105027541	SRPK2	0.64	9.69	0.53	5.05e-19	Schizophrenia;
KIRP	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.6	-5.29	-0.32	2.75e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.65	-7.98	-0.45	5.43e-14	Corneal structure;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg08345776	chr10:71993218	PPA1	-0.44	-6.11	-0.36	3.87e-9	Metabolic traits;
KIRP	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg13397898	chr9:133768931	QRFP	-0.33	-5.82	-0.35	1.87e-8	Bilirubin levels;
KIRP	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	1.07	18.24	0.76	1.35e-47	Bone mineral density;
KIRP	trans	rs10895140	0.756	rs4312036	chr11:101519352	C/T	cg00833344	chr2:150426294	MMADHC	0.45	6.15	0.37	3.18e-9	Menarche (age at onset);
KIRP	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg24315340	chr6:146058215	EPM2A	-0.45	-5.71	-0.34	3.17e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7224685	0.501	rs2247194	chr17:3921307	C/G	cg21851534	chr17:3907994	ZZEF1	0.69	11.53	0.59	7.12e-25	Type 2 diabetes;
KIRP	cis	rs8060686	0.858	rs20549	chr16:67969930	A/G	cg04539111	chr16:67997858	SLC12A4	-0.47	-5.33	-0.32	2.27e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1355223	0.902	rs11605785	chr11:34751387	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-5.45	-0.33	1.19e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.26	-21.82	-0.81	1.84e-59	Breast cancer;
KIRP	cis	rs3105593	1.000	rs11070800	chr15:50907347	C/T	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.51e-7	QT interval;
KIRP	cis	rs7215564	0.730	rs35718970	chr17:78585662	T/C	cg06153925	chr17:78755379	RPTOR	0.42	5.85	0.35	1.55e-8	Myopia (pathological);
KIRP	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs8027181	0.839	rs7167076	chr15:73028873	G/A	cg25996835	chr15:72978165	BBS4;HIGD2B	-0.51	-7.3	-0.42	3.89e-12	Triglyceride levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg09996344	chr7:66093369	KCTD7	0.49	6.89	0.4	4.76e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	0.86	12.07	0.61	1.17e-26	Homoarginine levels;
KIRP	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg03465714	chr1:152285911	FLG	0.49	5.34	0.32	2.08e-7	Atopic dermatitis;
KIRP	cis	rs740160	0.558	rs68164591	chr7:98904440	C/T	cg12290671	chr7:99195819	NA	-0.53	-5.04	-0.31	8.85e-7	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs3754214	0.857	rs9126	chr1:150259400	A/C	cg07843065	chr1:150265600	MRPS21	-0.46	-6.42	-0.38	6.86e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg00576331	chr11:65640516	EFEMP2	-0.5	-5.56	-0.33	6.98e-8	Crohn's disease;
KIRP	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg19445457	chr11:5799446	OR52N5	-0.5	-5.59	-0.34	5.96e-8	DNA methylation (variation);
KIRP	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg13939156	chr17:80058883	NA	0.49	5.63	0.34	4.8e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.49	5.92	0.35	1.1e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg19507638	chr5:93509721	C5orf36	-0.62	-5.68	-0.34	3.7e-8	Diabetic retinopathy;
KIRP	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg00599163	chr2:162100495	NA	0.43	5.01	0.3	1.04e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg19507638	chr5:93509721	C5orf36	-0.57	-5.18	-0.31	4.69e-7	Diabetic retinopathy;
KIRP	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-5.21	-0.32	4.04e-7	Ulcerative colitis;
KIRP	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg09033563	chr22:24373618	LOC391322	-0.4	-5.34	-0.32	2.07e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7560272	0.501	rs12713789	chr2:73945600	A/G	cg20560298	chr2:73613845	ALMS1	0.46	5.49	0.33	1.02e-7	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.32	-0.32	2.34e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-0.87	-12.26	-0.62	2.69e-27	Blood trace element (Zn levels);
KIRP	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.25	7.24	0.42	5.79e-12	Type 2 diabetes;
KIRP	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.83	-11.66	-0.6	2.68e-25	Height;
KIRP	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.27	0.32	2.98e-7	Renal cell carcinoma;
KIRP	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs6496667	0.779	rs62020693	chr15:90961504	A/G	cg10434728	chr15:90938212	IQGAP1	0.37	4.97	0.3	1.27e-6	Rheumatoid arthritis;
KIRP	cis	rs494562	0.892	rs640093	chr6:86115866	C/T	cg27039625	chr6:86159096	NT5E	0.45	5.23	0.32	3.69e-7	Blood metabolite levels;Metabolic traits;
KIRP	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg15436174	chr10:43711423	RASGEF1A	0.86	9.07	0.5	3.78e-17	Hirschsprung disease;
KIRP	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.41	5.19	0.31	4.44e-7	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.7	8.47	0.48	2.21e-15	Monocyte count;
KIRP	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg09137382	chr11:130731461	NA	0.56	8.18	0.46	1.49e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs1062753	0.527	rs62240998	chr22:42354701	T/A	cg15128208	chr22:42549153	NA	0.43	5.73	0.34	2.92e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg01689657	chr7:91764605	CYP51A1	-0.39	-5.6	-0.34	5.66e-8	Breast cancer;
KIRP	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg26384229	chr12:38710491	ALG10B	0.54	7.23	0.42	6.01e-12	Morning vs. evening chronotype;
KIRP	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.68	-8.07	-0.46	3.21e-14	Diabetic retinopathy;
KIRP	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.46	-4.95	-0.3	1.36e-6	Psoriasis;
KIRP	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg05347473	chr6:146136440	FBXO30	0.48	6.94	0.4	3.5e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg09873164	chr1:152488093	CRCT1	0.51	6.43	0.38	6.44e-10	Hair morphology;
KIRP	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg06636001	chr8:8085503	FLJ10661	0.62	8.71	0.49	4.47e-16	Neuroticism;
KIRP	cis	rs732716	0.785	rs56272533	chr19:4420042	T/C	cg21720385	chr19:4455239	UBXN6	0.69	8.54	0.48	1.38e-15	Mean corpuscular volume;
KIRP	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.65	9.16	0.5	2.03e-17	Depressive symptoms (multi-trait analysis);
KIRP	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg23505145	chr19:12996616	KLF1	0.55	8.1	0.46	2.65e-14	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg00576331	chr11:65640516	EFEMP2	-0.44	-5.38	-0.32	1.75e-7	DNA methylation (variation);
KIRP	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-1.05	-12.94	-0.64	1.51e-29	Exhaled nitric oxide output;
KIRP	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg15655495	chr12:38532458	NA	0.25	4.87	0.3	2.02e-6	Bladder cancer;
KIRP	cis	rs7624766	0.518	rs9815499	chr3:160491722	T/A	cg22637730	chr3:160473554	PPM1L	0.44	5.52	0.33	8.38e-8	Response to methotrexate in rheumatoid arthritis;
KIRP	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13939156	chr17:80058883	NA	-0.51	-7.57	-0.43	7.49e-13	Life satisfaction;
KIRP	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg16497661	chr14:103986332	CKB	-0.54	-7.06	-0.41	1.71e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.99	-14.03	-0.67	2.99e-33	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.38	-0.38	8.54e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg10144569	chr3:42726640	KBTBD5	-0.48	-5.0	-0.3	1.11e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.83	0.63	3.5e-29	Smoking behavior;
KIRP	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.72	-6.68	-0.39	1.6e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.87	-0.35	1.38e-8	Parkinson's disease;
KIRP	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg11693508	chr17:37793320	STARD3	0.8	8.38	0.47	4.13e-15	Bipolar disorder;
KIRP	cis	rs362296	0.597	rs3129320	chr4:3265130	G/C	cg06533319	chr4:3265114	C4orf44	0.59	7.95	0.45	6.9e-14	Parental longevity (mother's age at death);
KIRP	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg12046867	chr14:103022105	NA	0.51	6.04	0.36	5.74e-9	Platelet count;
KIRP	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg04310649	chr10:35416472	CREM	-0.54	-6.1	-0.36	4.03e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.62	-8.88	-0.49	1.43e-16	Coronary artery disease;
KIRP	cis	rs7539542	0.529	rs57756744	chr1:202859028	G/A	cg19681188	chr1:202830198	LOC148709	-0.48	-5.26	-0.32	3.07e-7	Mean platelet volume;
KIRP	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-0.81	-8.9	-0.49	1.25e-16	Gut microbiome composition (summer);
KIRP	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.09	-14.32	-0.67	3.03e-34	Corneal structure;
KIRP	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg26876637	chr1:152193138	HRNR	0.76	9.24	0.51	1.21e-17	Atopic dermatitis;
KIRP	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg08975724	chr8:8085496	FLJ10661	-0.64	-8.78	-0.49	2.84e-16	Mood instability;
KIRP	cis	rs311392	0.554	rs311390	chr8:55102401	G/A	cg06042504	chr8:55087323	NA	-0.54	-6.74	-0.39	1.15e-10	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs9488822	0.585	rs195517	chr6:116241584	G/A	cg18764771	chr6:116381957	FRK	0.19	5.07	0.31	7.78e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.57	7.02	0.41	2.18e-11	Breast cancer;
KIRP	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.98	17.15	0.74	6.8e-44	Breast cancer;
KIRP	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.82	11.75	0.6	1.33e-25	Eosinophil percentage of white cells;
KIRP	cis	rs9912468	0.621	rs7342920	chr17:64244645	T/G	cg19474267	chr17:64306194	PRKCA	-0.49	-6.11	-0.36	3.77e-9	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.55	6.78	0.4	8.91e-11	Coffee consumption (cups per day);
KIRP	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.57	7.07	0.41	1.57e-11	Height;
KIRP	cis	rs7714584	1.000	rs75294883	chr5:150196503	T/C	cg22134413	chr5:150180641	NA	1.06	7.02	0.41	2.16e-11	Crohn's disease;
KIRP	cis	rs6740322	0.748	rs6544636	chr2:43487486	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.84	-11.46	-0.59	1.23e-24	Coronary artery disease;
KIRP	cis	rs6952809	1.000	rs28712717	chr7:2449590	T/C	cg23289794	chr7:2394357	EIF3B	-0.4	-4.88	-0.3	1.91e-6	Multiple sclerosis;
KIRP	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.8	-10.48	-0.56	1.74e-21	Body mass index;
KIRP	cis	rs16828019	0.852	rs12742803	chr1:41648131	G/A	cg18742814	chr1:41828276	NA	0.65	5.74	0.34	2.83e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Blood metabolite levels;
KIRP	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.57	-7.22	-0.42	6.3e-12	Cognitive test performance;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg23300289	chr9:132146083	NA	-0.47	-6.91	-0.4	4.22e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs637571	0.546	rs11227309	chr11:65584512	A/C	cg26695010	chr11:65641043	EFEMP2	0.55	6.88	0.4	4.96e-11	Eosinophil percentage of white cells;
KIRP	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg24253500	chr15:84953950	NA	0.65	7.46	0.43	1.46e-12	Schizophrenia;
KIRP	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg04731861	chr2:219085781	ARPC2	-0.23	-5.51	-0.33	9.26e-8	Colorectal cancer;
KIRP	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.91	-12.31	-0.62	1.9e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg22974920	chr21:40686053	BRWD1	-0.42	-4.9	-0.3	1.74e-6	Cognitive function;
KIRP	cis	rs7692976	0.608	rs929446	chr4:110883344	C/T	cg06981781	chr4:110842888	EGF	-0.23	-5.15	-0.31	5.38e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7225151	1.000	rs7225151	chr17:5137047	G/A	cg24500398	chr17:5266808	RABEP1	-0.53	-5.44	-0.33	1.28e-7	Alzheimer's disease (late onset);
KIRP	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg08992911	chr2:238395768	MLPH	0.55	5.27	0.32	2.91e-7	Prostate cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21985352	chr17:76356152	SOCS3	0.51	6.12	0.36	3.73e-9	Parkinson's disease;
KIRP	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.81	-10.09	-0.54	2.89e-20	Longevity;
KIRP	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg09491104	chr22:46646882	C22orf40	-0.5	-5.35	-0.32	2e-7	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs4523957	0.620	rs898749	chr17:2085185	G/A	cg16513277	chr17:2031491	SMG6	-0.8	-11.62	-0.6	3.67e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2273669	0.667	rs12206606	chr6:109353519	C/A	cg05315195	chr6:109294784	ARMC2	-0.63	-6.31	-0.37	1.29e-9	Prostate cancer;
KIRP	cis	rs59698941	0.527	rs1557852	chr5:132181800	G/A	cg14825688	chr5:132208181	LEAP2	-0.37	-4.93	-0.3	1.52e-6	Apolipoprotein A-IV levels;
KIRP	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-5.85	-0.35	1.55e-8	Personality dimensions;
KIRP	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg04369109	chr6:150039330	LATS1	-0.51	-6.1	-0.36	3.98e-9	Lung cancer;
KIRP	cis	rs10858047	0.941	rs72696094	chr1:115067229	T/C	cg12756093	chr1:115239321	AMPD1	0.65	6.15	0.36	3.19e-9	Autism;
KIRP	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.41	6.41	0.38	7.24e-10	Hypertriglyceridemia;
KIRP	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	5.81	0.35	1.88e-8	Age-related macular degeneration (geographic atrophy);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg12064201	chr15:101606006	LRRK1	0.45	6.44	0.38	6.27e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg24253500	chr15:84953950	NA	0.52	5.84	0.35	1.61e-8	Schizophrenia;
KIRP	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.8	12.18	0.61	5.18e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg04935436	chr20:30431758	NA	0.5	6.83	0.4	6.48e-11	Monocyte count;
KIRP	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg12042659	chr19:58951599	ZNF132	0.49	6.05	0.36	5.28e-9	Uric acid clearance;
KIRP	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg21161173	chr5:140098174	VTRNA1-2	-0.38	-4.86	-0.3	2.12e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4654899	0.965	rs6692244	chr1:21396886	C/A	cg05370193	chr1:21551575	ECE1	0.44	6.13	0.36	3.5e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.54	-5.71	-0.34	3.3e-8	Chronic sinus infection;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg13316368	chr7:116821262	ST7OT3;ST7	0.41	6.05	0.36	5.3300000000000004e-09	Survival in pancreatic cancer;
KIRP	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11987759	chr7:65425863	GUSB	0.57	7.71	0.44	3.1e-13	Aortic root size;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17192681	chr2:10953115	PDIA6	-0.67	-7.05	-0.41	1.83e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9403317	0.960	rs9376628	chr6:141860331	G/T	cg15052665	chr6:141804349	NA	0.41	5.04	0.31	9.2e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6499755	0.841	rs31082	chr16:55361493	C/T	cg05099576	chr16:55362342	IRX6	0.31	6.36	0.38	9.87e-10	Hypospadias;
KIRP	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.93	13.12	0.64	3.53e-30	Menopause (age at onset);
KIRP	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	1.16	10.2	0.55	1.31e-20	Gout;Renal underexcretion gout;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16899367	chr7:73097788	WBSCR22;DNAJC30	0.48	6.33	0.37	1.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.48	-6.13	-0.36	3.52e-9	Cerebrospinal fluid biomarker levels;
KIRP	trans	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.21	-0.42	6.98e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg04311557	chr16:71523289	ZNF19	-0.54	-4.86	-0.3	2.06e-6	Post bronchodilator FEV1;
KIRP	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.52	5.16	0.31	5.15e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs965513	1.000	rs7020976	chr9:100547972	T/C	cg13688889	chr9:100608707	NA	-0.61	-7.82	-0.45	1.58e-13	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg17595323	chr11:93583763	C11orf90	0.38	6.1	0.36	4.2e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs8044868	0.512	rs12935266	chr16:72157000	C/G	cg16558253	chr16:72132732	DHX38	-0.38	-4.99	-0.3	1.14e-6	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
KIRP	cis	rs812925	0.502	rs2053750	chr2:61656273	T/A	cg15711740	chr2:61764176	XPO1	0.44	5.5	0.33	9.54e-8	Immature fraction of reticulocytes;
KIRP	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg12140854	chr5:148520817	ABLIM3	-0.55	-6.14	-0.36	3.35e-9	Breast cancer;
KIRP	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02711726	chr17:80685570	FN3KRP	-0.56	-7.57	-0.43	7.52e-13	Glycated hemoglobin levels;
KIRP	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg16141378	chr3:129829833	LOC729375	-0.61	-8.28	-0.47	7.67e-15	Neuroticism;
KIRP	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg05527609	chr1:210001259	C1orf107	0.41	5.07	0.31	7.94e-7	Red blood cell count;
KIRP	cis	rs1185460	1.000	rs7938944	chr11:118954066	T/C	cg01677386	chr11:118938358	VPS11	-0.47	-5.36	-0.32	1.95e-7	Coronary artery disease;
KIRP	cis	rs12900413	0.687	rs12908489	chr15:90304269	A/G	cg24650279	chr15:90327240	NA	-0.4	-4.99	-0.3	1.15e-6	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg01304814	chr3:48885189	PRKAR2A	0.61	4.97	0.3	1.24e-6	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13198984	chr17:80129470	CCDC57	0.58	8.67	0.48	5.76e-16	Life satisfaction;
KIRP	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg03714773	chr7:91764589	CYP51A1	-0.37	-5.31	-0.32	2.39e-7	Breast cancer;
KIRP	cis	rs7582720	1.000	rs72932767	chr2:203679306	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.63e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-8.02	-0.46	4.18e-14	Coffee consumption (cups per day);
KIRP	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.73	10.39	0.55	3.28e-21	Oral cavity cancer;
KIRP	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg02475777	chr4:1388615	CRIPAK	0.51	4.87	0.3	2.02e-6	Recombination rate (females);
KIRP	cis	rs7870753	0.838	rs16910870	chr9:99247103	A/G	cg25260653	chr9:99212216	HABP4	0.52	5.46	0.33	1.17e-7	Height;
KIRP	cis	rs4356932	0.811	rs68156651	chr4:76972468	T/C	cg19388996	chr4:76862389	NAAA	0.4	5.16	0.31	5.05e-7	Blood protein levels;
KIRP	cis	rs4664304	0.900	rs17231993	chr2:160741415	C/T	cg23995753	chr2:160760732	LY75	-0.43	-5.82	-0.35	1.81e-8	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-9.59	-0.52	1.01e-18	Hip circumference;
KIRP	trans	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg19694781	chr19:47549865	TMEM160	-0.58	-7.63	-0.44	5.15e-13	Response to radiotherapy in cancer (late toxicity);
KIRP	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg14541582	chr5:601475	NA	-0.58	-6.61	-0.39	2.42e-10	Obesity-related traits;
KIRP	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	5.72	0.34	3.13e-8	Birth weight;
KIRP	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	7.74	0.44	2.51e-13	Retinal vascular caliber;
KIRP	cis	rs67385638	0.962	rs72872549	chr11:5290053	C/T	cg12559170	chr11:5275217	HBG2	0.48	6.53	0.38	3.66e-10	Hemoglobin levels;
KIRP	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg16898833	chr6:26189333	HIST1H4D	0.66	5.01	0.3	1.05e-6	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg27205649	chr11:78285834	NARS2	-0.66	-8.48	-0.48	2.1e-15	Alzheimer's disease (survival time);
KIRP	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg00933542	chr6:150070202	PCMT1	-0.29	-5.46	-0.33	1.15e-7	Lung cancer;
KIRP	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.44	-5.46	-0.33	1.14e-7	Iron status biomarkers;
KIRP	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg17507749	chr15:85114479	UBE2QP1	0.77	8.85	0.49	1.8e-16	Schizophrenia;
KIRP	cis	rs28834970	0.675	rs6557994	chr8:27232018	A/G	cg23693289	chr8:27183097	PTK2B	-0.44	-5.16	-0.31	5e-7	Alzheimer's disease (late onset);
KIRP	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	16.57	0.73	6.1e-42	Electrocardiographic conduction measures;
KIRP	cis	rs3825932	0.961	rs10400881	chr15:79234384	G/C	cg25744700	chr15:79237217	CTSH	0.42	5.15	0.31	5.46e-7	Type 1 diabetes;
KIRP	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg15147215	chr3:52552868	STAB1	-0.28	-5.05	-0.31	8.76e-7	Cognitive function;
KIRP	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.69	8.56	0.48	1.21e-15	Itch intensity from mosquito bite;
KIRP	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-0.6	-7.99	-0.45	5.16e-14	Morning vs. evening chronotype;
KIRP	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg10755058	chr3:40428713	ENTPD3	0.38	5.2	0.31	4.16e-7	Renal cell carcinoma;
KIRP	cis	rs9547996	0.796	rs9547968	chr13:38166068	C/G	cg13634560	chr13:38173852	POSTN	-0.41	-5.59	-0.34	5.87e-8	Diastolic blood pressure;
KIRP	cis	rs10518128	1.000	rs72867588	chr4:75706640	A/G	cg20122727	chr4:75719957	BTC	0.58	5.86	0.35	1.49e-8	Electroencephalogram traits;
KIRP	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg10223061	chr2:219282414	VIL1	-0.36	-5.98	-0.36	7.88e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	13.79	0.66	2.03e-32	Platelet count;
KIRP	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.62	6.94	0.4	3.51e-11	Aortic root size;
KIRP	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.85	9.53	0.52	1.55e-18	Iron status biomarkers;
KIRP	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.58	7.18	0.42	8.24e-12	Cognitive test performance;
KIRP	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg05220968	chr6:146057943	EPM2A	0.38	4.84	0.3	2.25e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg14467794	chr3:32086860	NA	-0.44	-6.78	-0.4	9.1e-11	Inflammatory biomarkers;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg00545796	chr16:1573581	IFT140	0.48	6.03	0.36	5.87e-9	Pancreatic cancer;
KIRP	trans	rs8064024	0.680	rs2063101	chr16:4916348	A/G	cg21293562	chr15:96901651	NA	-0.47	-6.07	-0.36	4.69e-9	Cancer;
KIRP	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg07952391	chr2:88470173	THNSL2	0.9	6.95	0.41	3.21e-11	Plasma clusterin levels;
KIRP	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg17376030	chr22:41985996	PMM1	0.81	8.29	0.47	7.22e-15	Vitiligo;
KIRP	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	1.01	15.98	0.71	6.8e-40	Bipolar disorder;
KIRP	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg07653901	chr22:50250238	ZBED4	0.46	5.4	0.33	1.55e-7	Schizophrenia;
KIRP	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.76	-9.8	-0.53	2.28e-19	Aortic root size;
KIRP	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg20965017	chr5:231967	SDHA	-0.59	-6.91	-0.4	4.14e-11	Breast cancer;
KIRP	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.93	10.92	0.57	6.58e-23	Corneal astigmatism;
KIRP	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg22117172	chr7:91764530	CYP51A1	0.5	7.01	0.41	2.34e-11	Breast cancer;
KIRP	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg26084005	chr2:241760190	KIF1A	-0.51	-6.87	-0.4	5.36e-11	Urinary metabolites;
KIRP	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg19338460	chr6:170058176	WDR27	-1.24	-12.58	-0.63	2.41e-28	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10782582	0.609	rs56159153	chr1:76353498	T/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.25	-0.37	1.8e-9	Daytime sleep phenotypes;
KIRP	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.54	6.92	0.4	3.79e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	1.0	17.17	0.74	5.52e-44	Menopause (age at onset);
KIRP	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg07828340	chr4:882639	GAK	1.11	9.18	0.5	1.89e-17	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04468334	chr7:149414901	KRBA1	-0.44	-6.53	-0.38	3.84e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-6.49	-0.38	4.7e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-8.23	-0.46	1.07e-14	Response to antipsychotic treatment;
KIRP	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg07962218	chr7:65219954	SNORA22;CCT6P1	-0.36	-5.37	-0.32	1.83e-7	Calcium levels;
KIRP	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg18154014	chr19:37997991	ZNF793	0.75	7.66	0.44	4.38e-13	Coronary artery calcification;
KIRP	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg04080417	chr5:1859792	NA	-0.59	-7.4	-0.43	2.2e-12	Cardiovascular disease risk factors;
KIRP	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.59	-9.19	-0.51	1.69e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	trans	rs853308	0.967	rs2687813	chr8:133931051	G/A	cg06478102	chr15:73992274	CD276	-0.48	-6.05	-0.36	5.49e-9	Vitiligo;
KIRP	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17376030	chr22:41985996	PMM1	0.75	7.85	0.45	1.32e-13	Vitiligo;
KIRP	cis	rs7301016	0.948	rs12370404	chr12:62923340	T/C	cg01804193	chr12:63026212	NA	0.54	5.64	0.34	4.68e-8	IgG glycosylation;
KIRP	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	7.03	0.41	2.05e-11	Mean corpuscular volume;
KIRP	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg16898833	chr6:26189333	HIST1H4D	0.82	5.76	0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs10788972	1.000	rs10788972	chr1:54572243	C/A	cg25741118	chr1:54482237	LDLRAD1	-0.29	-5.13	-0.31	5.88e-7	Parkinson disease and lewy body pathology;
KIRP	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1497828	0.956	rs1013386	chr1:217566215	C/T	cg04411442	chr1:217543379	NA	0.43	6.41	0.38	7.29e-10	Dialysis-related mortality;
KIRP	trans	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg16141378	chr3:129829833	LOC729375	0.49	6.1	0.36	4.15e-9	Triglycerides;
KIRP	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.0	13.11	0.64	4.03e-30	Exhaled nitric oxide output;
KIRP	cis	rs362272	0.525	rs2471347	chr4:3044435	A/G	cg13731523	chr4:3047190	NA	0.37	7.15	0.41	9.73e-12	Serum sulfate level;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11032070	chr20:31172387	NA	0.54	6.31	0.37	1.28e-9	Smoking initiation;
KIRP	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg04837898	chr3:45731254	SACM1L	0.36	4.91	0.3	1.7e-6	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs3779635	0.904	rs10087410	chr8:27275904	T/C	cg18234130	chr8:27182889	PTK2B	0.47	6.02	0.36	6.35e-9	Neuroticism;
KIRP	cis	rs12704876	0.509	rs1464808	chr7:96363633	A/T	cg03808172	chr7:96339361	SHFM1	0.56	7.53	0.43	9.72e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg04490037	chr7:50633773	DDC	-0.42	-5.12	-0.31	6.28e-7	Malaria;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04414865	chr1:169342772	BLZF1	-0.44	-7.05	-0.41	1.78e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10802346	0.891	rs10924647	chr1:246423728	G/T	cg15962031	chr1:246363574	SMYD3	0.6	5.64	0.34	4.72e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-5.42	-0.33	1.39e-7	Aortic root size;
KIRP	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-1.1	-21.39	-0.81	4.81e-58	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.38	5.33	0.32	2.26e-7	Coronary artery disease;
KIRP	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.37	-5.18	-0.31	4.62e-7	Plateletcrit;
KIRP	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.37	16.99	0.73	2.34e-43	Uric acid levels;
KIRP	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.4	-5.1	-0.31	6.84e-7	IgG glycosylation;
KIRP	cis	rs10875746	0.859	rs11558768	chr12:48577789	C/T	cg20731937	chr12:48336164	NA	0.43	5.47	0.33	1.09e-7	Longevity (90 years and older);
KIRP	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.87e-7	Bipolar disorder;
KIRP	trans	rs12043259	0.730	rs2065160	chr1:204790977	A/G	cg11485465	chr5:54518469	NA	0.35	6.21	0.37	2.2e-9	Addiction;
KIRP	cis	rs59868192	0.850	rs16972308	chr15:42237991	G/A	cg20935245	chr15:42234343	EHD4	-0.5	-4.89	-0.3	1.86e-6	White blood cell count;
KIRP	trans	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg06521331	chr12:34319734	NA	-0.55	-6.8	-0.4	7.8e-11	Heart rate;
KIRP	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg03128945	chr5:622914	CEP72	-0.47	-6.73	-0.39	1.16e-10	Obesity-related traits;
KIRP	cis	rs2411233	0.804	rs12911790	chr15:39250642	A/G	cg05886626	chr15:39873553	THBS1	0.35	5.16	0.31	5.14e-7	Platelet count;
KIRP	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.53	6.86	0.4	5.51e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	0.83	10.99	0.57	4e-23	Primary sclerosing cholangitis;
KIRP	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-0.89	-12.59	-0.63	2.2e-28	Primary sclerosing cholangitis;
KIRP	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg07843065	chr1:150265600	MRPS21	0.42	5.71	0.34	3.21e-8	Migraine;
KIRP	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg23335576	chr14:104009727	NA	0.35	4.98	0.3	1.18e-6	Body mass index;
KIRP	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg00745463	chr17:30367425	LRRC37B	0.53	5.0	0.3	1.08e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.78	6.58	0.39	2.87e-10	Body mass index;
KIRP	cis	rs7551222	0.752	rs6594016	chr1:204539462	G/A	cg20240347	chr1:204465584	NA	-0.44	-8.34	-0.47	5.25e-15	Schizophrenia;
KIRP	cis	rs867559	0.505	rs4527981	chr9:129464803	C/T	cg13452961	chr9:129468985	NA	0.52	5.24	0.32	3.47e-7	Body mass index;
KIRP	cis	rs17095355	0.901	rs11194947	chr10:111763731	A/T	cg00817464	chr10:111662876	XPNPEP1	-0.42	-6.14	-0.36	3.25e-9	Biliary atresia;
KIRP	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg20240347	chr1:204465584	NA	0.42	8.16	0.46	1.71e-14	Schizophrenia;
KIRP	cis	rs7172677	0.737	rs6495154	chr15:75437262	G/C	cg14082893	chr15:75400931	NA	0.34	5.02	0.31	9.7e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs6545883	0.783	rs7579651	chr2:61800279	C/G	cg15711740	chr2:61764176	XPO1	-0.61	-8.37	-0.47	4.25e-15	Tuberculosis;
KIRP	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	6.05	0.36	5.3e-9	Schizophrenia;
KIRP	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg09455208	chr3:40491958	NA	0.32	5.7	0.34	3.35e-8	Renal cell carcinoma;
KIRP	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg18154014	chr19:37997991	ZNF793	0.81	8.31	0.47	6.33e-15	Coronary artery calcification;
KIRP	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.82	12.2	0.61	4.38e-27	Menarche (age at onset);
KIRP	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg23479056	chr15:41276147	INO80	-0.39	-5.72	-0.34	3.13e-8	Menopause (age at onset);
KIRP	cis	rs2290402	0.536	rs17165130	chr4:875339	A/C	cg14517359	chr4:903473	GAK	0.54	5.67	0.34	3.9e-8	Type 2 diabetes;
KIRP	cis	rs9815354	0.812	rs73830516	chr3:41876056	A/G	cg03022575	chr3:42003672	ULK4	0.82	8.55	0.48	1.35e-15	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.51	6.82	0.4	7.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-0.84	-9.25	-0.51	1.13e-17	Blood pressure (smoking interaction);
KIRP	cis	rs13102973	0.863	rs13129178	chr4:135858219	A/C	cg14419869	chr4:135874104	NA	0.53	8.8	0.49	2.5e-16	Subjective well-being;
KIRP	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.09	-0.41	1.46e-11	Joint mobility (Beighton score);
KIRP	cis	rs7945718	0.781	rs11022513	chr11:12840986	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-6.09	-0.36	4.21e-9	Educational attainment (years of education);
KIRP	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	9.06	0.5	4.16e-17	Response to antipsychotic treatment;
KIRP	cis	rs7760535	0.931	rs466923	chr6:111662977	T/C	cg22127309	chr6:111907043	TRAF3IP2	-0.44	-5.81	-0.35	1.89e-8	Metabolic traits;
KIRP	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg09263875	chr16:632152	PIGQ	0.73	12.31	0.62	1.93e-27	Height;
KIRP	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg02461776	chr11:598696	PHRF1	0.5	5.42	0.33	1.39e-7	Systemic lupus erythematosus;
KIRP	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg08975724	chr8:8085496	FLJ10661	0.56	7.54	0.43	9.17e-13	Myopia (pathological);
KIRP	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg05941025	chr16:89927596	SPIRE2	0.34	5.37	0.32	1.86e-7	Vitiligo;
KIRP	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.77	11.38	0.59	2.27e-24	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs35883536	1.000	rs11586815	chr1:101089079	C/T	cg06223162	chr1:101003688	GPR88	0.31	6.3	0.37	1.35e-9	Monocyte count;
KIRP	trans	rs604222	0.520	rs6777406	chr3:193583127	A/C	cg04949346	chr2:169746998	SPC25	0.51	6.19	0.37	2.52e-9	Major depressive disorder;
KIRP	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	cg12689670	chr1:183009347	LAMC1	0.58	8.06	0.46	3.31e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg00852783	chr1:26633632	UBXN11	-0.55	-5.63	-0.34	5.02e-8	Obesity-related traits;
KIRP	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg10189774	chr4:17578691	LAP3	0.49	5.79	0.35	2.15e-8	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg25173405	chr17:45401733	C17orf57	-0.45	-6.01	-0.36	6.62e-9	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg02570527	chr1:10970165	NA	0.47	5.04	0.31	8.87e-7	Body mass index;
KIRP	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.57	6.65	0.39	1.85e-10	Initial pursuit acceleration;
KIRP	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg03714773	chr7:91764589	CYP51A1	-0.35	-5.25	-0.32	3.3e-7	Breast cancer;
KIRP	cis	rs6032067	0.929	rs35880287	chr20:43821001	G/A	cg10761708	chr20:43804764	PI3	0.53	5.54	0.33	7.66e-8	Blood protein levels;
KIRP	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg18964960	chr10:1102726	WDR37	-0.55	-6.11	-0.36	3.87e-9	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg14255062	chr9:123606675	PSMD5;LOC253039	0.33	5.11	0.31	6.61e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.82	9.89	0.53	1.23e-19	Corneal astigmatism;
KIRP	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.45	-5.44	-0.33	1.3e-7	Monocyte percentage of white cells;
KIRP	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg03735888	chr19:58951602	ZNF132	0.45	5.35	0.32	2.02e-7	Uric acid clearance;
KIRP	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg05721485	chr17:44071124	MAPT	0.57	7.35	0.42	2.96e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.75	10.13	0.54	2.13e-20	Menarche (age at onset);
KIRP	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06544989	chr22:39130855	UNC84B	-0.52	-8.34	-0.47	5.31e-15	Menopause (age at onset);
KIRP	trans	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg16141378	chr3:129829833	LOC729375	0.5	6.56	0.39	3.23e-10	Mood instability;
KIRP	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg13731523	chr4:3047190	NA	-0.37	-6.14	-0.36	3.21e-9	Serum sulfate level;
KIRP	cis	rs16912285	0.688	rs7124856	chr11:24324926	C/T	ch.11.24196551F	chr11:24239977	NA	0.8	9.0	0.5	6.14e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg02344993	chr17:57696989	CLTC	0.54	5.11	0.31	6.59e-7	Hemoglobin concentration;
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	6.94	0.4	3.55e-11	Lymphocyte counts;
KIRP	cis	rs10114408	0.959	rs10126012	chr9:96634101	C/T	cg14598338	chr9:96623480	NA	-0.34	-5.07	-0.31	7.75e-7	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7712401	0.601	rs385547	chr5:122321833	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs2273669	0.667	rs2273668	chr6:109323519	G/T	cg05315195	chr6:109294784	ARMC2	-0.63	-5.99	-0.36	7.6e-9	Prostate cancer;
KIRP	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg04370829	chr17:406249	NA	0.39	4.92	0.3	1.55e-6	Prostate cancer;
KIRP	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.42	0.52	3.36e-18	Bipolar disorder;
KIRP	cis	rs6725041	0.690	rs7581138	chr2:213101989	C/T	cg20637307	chr2:213403960	ERBB4	-0.42	-5.56	-0.33	6.89e-8	QT interval (ambient particulate matter interaction);
KIRP	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.66	-8.09	-0.46	2.68e-14	Schizophrenia;
KIRP	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.77	10.95	0.57	5.59e-23	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.81	11.74	0.6	1.4e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg11952622	chr19:58962976	ZNF324B	0.43	4.98	0.3	1.22e-6	Uric acid clearance;
KIRP	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.54	5.09	0.31	7.26e-7	Alzheimer's disease;
KIRP	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg23594656	chr7:65796392	TPST1	0.52	8.16	0.46	1.7e-14	Aortic root size;
KIRP	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22903657	chr4:1355424	KIAA1530	-0.5	-7.1	-0.41	1.33e-11	Obesity-related traits;
KIRP	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.73	7.34	0.42	3.18e-12	Bipolar disorder;
KIRP	cis	rs17023223	0.537	rs2765534	chr1:119597792	A/C	cg18261050	chr1:119551319	NA	0.49	6.56	0.39	3.12e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs2278796	0.639	rs12139426	chr1:204970708	A/G	cg17449235	chr1:204966235	NFASC	-0.55	-7.43	-0.43	1.76e-12	Mean platelet volume;
KIRP	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	7.5	0.43	1.17e-12	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg16586182	chr3:47516702	SCAP	-0.69	-9.48	-0.52	2.26e-18	Colorectal cancer;
KIRP	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	6.39	0.38	8.19e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs960902	0.583	rs6544089	chr2:37758745	C/T	cg25341268	chr2:37734390	NA	0.57	7.11	0.41	1.24e-11	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg23175918	chr11:65086974	CDC42EP2	0.4	6.11	0.36	3.96e-9	Serum protein levels (sST2);
KIRP	cis	rs8038465	0.638	rs7495543	chr15:73955133	G/C	cg15420318	chr15:73925796	NPTN	0.61	8.7	0.49	4.85e-16	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7172809	0.573	rs17383078	chr15:77484746	C/T	cg05673287	chr15:77411982	SGK269	0.42	4.87	0.3	2e-6	Glucose homeostasis traits;
KIRP	cis	rs3925075	0.525	rs929868	chr16:31280282	G/A	cg02846316	chr16:31340340	ITGAM	0.43	5.17	0.31	4.77e-7	IgA nephropathy;
KIRP	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.8	-11.29	-0.58	4.18e-24	Extrinsic epigenetic age acceleration;
KIRP	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.51	5.26	0.32	3.14e-7	Smoking behavior;
KIRP	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.64	8.11	0.46	2.43e-14	Aortic root size;
KIRP	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg23422044	chr7:1970798	MAD1L1	-0.44	-5.76	-0.34	2.55e-8	Neuroticism;
KIRP	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.75	-0.34	2.61e-8	Educational attainment;
KIRP	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.5	-7.13	-0.41	1.11e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.53	-6.45	-0.38	5.75e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.8	-10.92	-0.57	6.76e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1440410	0.835	rs7685075	chr4:144054699	C/G	cg01719995	chr4:144104893	USP38	0.46	6.37	0.38	9.02e-10	Ischemic stroke;
KIRP	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.76	6.84	0.4	6.35e-11	Diabetic retinopathy;
KIRP	cis	rs4803455	0.586	rs4803457	chr19:41861359	T/C	cg08477640	chr19:41863820	B9D2	0.42	5.22	0.32	3.87e-7	Migraine;Coronary artery disease;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00453349	chr2:110371869	SEPT10;ANKRD57	-0.57	-6.14	-0.36	3.35e-9	Menopause (age at onset);
KIRP	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg01620082	chr3:125678407	NA	-1.02	-6.59	-0.39	2.65e-10	Gait speed in old age;Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7116495	0.737	rs12274803	chr11:71546291	C/T	cg10381502	chr11:71823885	C11orf51	0.82	5.54	0.33	7.96e-8	Severe influenza A (H1N1) infection;
KIRP	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-10.56	-0.56	9.73e-22	Height;
KIRP	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg23188430	chr6:125850052	NA	0.33	5.22	0.32	3.8e-7	Brugada syndrome;
KIRP	trans	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-6.3	-0.37	1.39e-9	Neuroticism;
KIRP	cis	rs3857067	0.967	rs964843	chr4:95032367	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.39	-4.92	-0.3	1.61e-6	QT interval;
KIRP	cis	rs4656940	0.600	rs535241	chr1:160764402	C/T	cg17331569	chr1:160788135	LY9	0.46	5.42	0.33	1.41e-7	Crohn's disease;
KIRP	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg21747090	chr2:27597821	SNX17	-0.36	-4.87	-0.3	1.97e-6	Total body bone mineral density;
KIRP	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	14.15	0.67	1.17e-33	Alzheimer's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg20536369	chr19:2427244	TIMM13	0.45	6.1	0.36	4.06e-9	Parkinson's disease;
KIRP	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	7.93	0.45	7.75e-14	Neuroticism;
KIRP	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg03959625	chr15:84868606	LOC388152	0.53	6.16	0.37	2.98e-9	Schizophrenia;
KIRP	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.68	-7.91	-0.45	8.88e-14	Alcohol dependence;
KIRP	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.09	-0.5	3.33e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg13906792	chr15:75199810	C15orf17	0.37	5.56	0.33	6.96e-8	Breast cancer;
KIRP	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.77	-9.63	-0.52	7.77e-19	Height;
KIRP	cis	rs12282928	0.959	rs11039635	chr11:48299098	T/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.24	-0.37	1.89e-9	Migraine - clinic-based;
KIRP	cis	rs12101261	0.580	rs3783950	chr14:81448282	C/G	cg06600135	chr14:81408086	NA	-0.42	-5.26	-0.32	3.17e-7	Graves' disease;
KIRP	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg15181151	chr6:150070149	PCMT1	0.29	4.92	0.3	1.59e-6	Lung cancer;
KIRP	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg19554555	chr3:13937349	NA	-0.46	-6.23	-0.37	2e-9	Ovarian reserve;
KIRP	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg19116668	chr7:99932089	PMS2L1	0.42	4.99	0.3	1.17e-6	Coronary artery disease;
KIRP	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-5.03	-0.31	9.45e-7	Neuroticism;
KIRP	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg20302533	chr7:39170763	POU6F2	0.24	4.9	0.3	1.71e-6	IgG glycosylation;
KIRP	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.66	8.14	0.46	1.92e-14	Breast cancer;
KIRP	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06544989	chr22:39130855	UNC84B	0.5	9.17	0.5	1.89e-17	Menopause (age at onset);
KIRP	cis	rs6700559	0.740	rs10919999	chr1:200649759	G/A	cg07804481	chr1:200639085	DDX59	0.5	6.6	0.39	2.52e-10	Coronary artery disease;
KIRP	cis	rs1682859	0.767	rs329645	chr11:133813168	C/T	cg18057887	chr11:133800913	IGSF9B	-0.41	-4.93	-0.3	1.5e-6	Obesity-related traits;
KIRP	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.92	-12.43	-0.62	7.21e-28	Longevity;Endometriosis;
KIRP	cis	rs7105934	1.000	rs7939830	chr11:69234733	C/T	cg24478926	chr11:69237550	NA	-0.6	-5.35	-0.32	1.98e-7	Renal cell carcinoma;
KIRP	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.39	5.59	0.34	5.98e-8	Electroencephalogram traits;
KIRP	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg24253500	chr15:84953950	NA	0.52	5.92	0.35	1.06e-8	Schizophrenia;
KIRP	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.44	6.64	0.39	2.04e-10	Major depressive disorder;
KIRP	cis	rs5995756	0.627	rs1008677	chr22:40009336	C/T	cg21377881	chr22:40064566	CACNA1I	-0.39	-5.22	-0.32	3.84e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg08477640	chr19:41863820	B9D2	0.44	5.33	0.32	2.25e-7	Migraine;Coronary artery disease;
KIRP	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg27347728	chr4:17578864	LAP3	0.4	4.95	0.3	1.37e-6	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7941030	0.841	rs61679561	chr11:122535146	A/G	cg20555462	chr11:122535518	UBASH3B	-0.47	-5.87	-0.35	1.39e-8	HDL cholesterol;Cholesterol, total;
KIRP	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg02891314	chr5:179741120	GFPT2	-0.61	-6.85	-0.4	5.78e-11	Height;
KIRP	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.55	7.7	0.44	3.26e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.6	8.68	0.48	5.53e-16	Heart rate;
KIRP	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.68	-9.26	-0.51	1.07e-17	Personality dimensions;
KIRP	cis	rs11203032	1.000	rs61853072	chr10:90961500	A/T	cg16672925	chr10:90967113	CH25H	0.82	8.56	0.48	1.2e-15	Heart failure;
KIRP	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.58	7.32	0.42	3.58e-12	Arsenic metabolism;
KIRP	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.42	-5.91	-0.35	1.11e-8	Blood metabolite levels;
KIRP	cis	rs3126085	0.935	rs12407156	chr1:152295942	A/G	cg26876637	chr1:152193138	HRNR	-0.83	-8.38	-0.47	4.04e-15	Atopic dermatitis;
KIRP	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-6.02	-0.36	6.38e-9	Body mass index;
KIRP	cis	rs78487399	0.808	rs76684055	chr2:43665943	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.14	-0.31	5.69e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg18200150	chr17:30822561	MYO1D	-0.49	-6.13	-0.36	3.4e-9	Schizophrenia;
KIRP	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.65	-5.41	-0.33	1.47e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.37	5.43	0.33	1.38e-7	Lymphocyte counts;
KIRP	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	0.8	7.73	0.44	2.7e-13	Prostate cancer;
KIRP	cis	rs8014252	0.803	rs74062743	chr14:71023411	G/T	cg19730268	chr14:71022823	NA	-0.69	-6.16	-0.37	2.95e-9	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.28	0.37	1.53e-9	Axial length;
KIRP	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs2380205	0.935	rs907686	chr10:5900693	G/A	cg27141509	chr10:5886111	NA	-0.35	-5.12	-0.31	6.2e-7	Breast cancer;
KIRP	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg06740227	chr12:86229804	RASSF9	0.47	5.52	0.33	8.65e-8	Major depressive disorder;
KIRP	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	6.92	0.4	3.91e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.19	0.42	7.97e-12	Lung cancer;
KIRP	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg02415014	chr8:143852576	LYNX1	-0.32	-4.96	-0.3	1.33e-6	Urinary tract infection frequency;
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg04369109	chr6:150039330	LATS1	-0.58	-7.43	-0.43	1.77e-12	Lung cancer;
KIRP	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg24315340	chr6:146058215	EPM2A	-0.38	-4.85	-0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.75	11.24	0.58	6.24e-24	Oral cavity cancer;
KIRP	cis	rs2273669	0.667	rs6899723	chr6:109362749	T/G	cg05315195	chr6:109294784	ARMC2	-0.66	-6.53	-0.38	3.76e-10	Prostate cancer;
KIRP	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13047869	chr3:10149882	C3orf24	0.53	5.2	0.31	4.11e-7	Alzheimer's disease;
KIRP	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.68	9.3	0.51	8.18e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.61	-9.91	-0.53	1.06e-19	Prostate cancer;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg26228943	chr4:47487307	ATP10D	-0.46	-6.43	-0.38	6.54e-10	Migraine with aura;
KIRP	cis	rs2594989	0.887	rs7617657	chr3:11447873	G/T	cg01796438	chr3:11312864	ATG7	0.61	6.82	0.4	6.88e-11	Circulating chemerin levels;
KIRP	cis	rs6546886	0.917	rs12713803	chr2:74238681	A/G	cg14702570	chr2:74259524	NA	-0.33	-6.62	-0.39	2.26e-10	Dialysis-related mortality;
KIRP	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg15896084	chr13:114927664	NA	0.44	5.77	0.35	2.34e-8	Schizophrenia;
KIRP	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.27	0.32	2.97e-7	Asthma (childhood onset);
KIRP	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.74	-9.53	-0.52	1.56e-18	Neutrophil percentage of white cells;
KIRP	cis	rs11622475	0.626	rs34533310	chr14:104352233	C/T	cg12183467	chr14:104352244	NA	-0.39	-5.41	-0.33	1.47e-7	Bipolar disorder;
KIRP	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.73	-9.07	-0.5	3.99e-17	Huntington's disease progression;
KIRP	cis	rs6438504	0.735	rs11707683	chr3:118911857	C/A	cg25372693	chr3:118959985	B4GALT4	0.32	5.16	0.31	4.98e-7	Clozapine-induced cytotoxicity;
KIRP	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.63	-8.48	-0.48	2.1e-15	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-6.25	-0.37	1.81e-9	Longevity;Endometriosis;
KIRP	cis	rs3779635	0.742	rs2241650	chr8:27255325	C/T	cg23736307	chr8:27182930	PTK2B	0.54	6.9	0.4	4.5e-11	Neuroticism;
KIRP	cis	rs2278796	0.608	rs6700188	chr1:204969066	A/G	cg17947172	chr1:204966197	NFASC	0.66	8.86	0.49	1.64e-16	Mean platelet volume;
KIRP	cis	rs73206853	0.764	rs7980838	chr12:110672978	T/A	cg12870014	chr12:110450643	ANKRD13A	0.53	5.62	0.34	5.16e-8	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg01689657	chr7:91764605	CYP51A1	0.41	5.78	0.35	2.26e-8	Breast cancer;
KIRP	cis	rs9469913	0.799	rs9469860	chr6:34724815	C/T	cg17674042	chr6:34482479	PACSIN1	-0.39	-5.27	-0.32	2.93e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg14664628	chr15:75095509	CSK	0.64	6.93	0.4	3.73e-11	Systemic lupus erythematosus;
KIRP	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg05973401	chr12:123451056	ABCB9	0.6	7.05	0.41	1.84e-11	Platelet count;
KIRP	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg01877450	chr7:97915802	BRI3	-0.57	-7.39	-0.43	2.32e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs7809615	0.901	rs11555142	chr7:99032593	G/T	cg12290671	chr7:99195819	NA	-0.69	-6.29	-0.37	1.48e-9	Blood metabolite ratios;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg15110900	chr19:17501938	NA	0.41	6.42	0.38	7.01e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg10223061	chr2:219282414	VIL1	0.29	4.9	0.3	1.74e-6	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	1.01	14.51	0.68	6.81e-35	Height;
KIRP	cis	rs10073892	0.703	rs60647834	chr5:101623780	T/A	cg19774478	chr5:101632501	SLCO4C1	0.57	5.79	0.35	2.13e-8	Cognitive decline (age-related);
KIRP	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg24874828	chr4:187887005	NA	-0.49	-7.06	-0.41	1.73e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg10756647	chr7:56101905	PSPH	0.97	7.05	0.41	1.76e-11	Diabetic kidney disease;
KIRP	cis	rs7267005	1.000	rs76054912	chr20:34466665	C/T	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs2290402	1.000	rs2290402	chr4:941518	C/T	cg00846425	chr4:957561	DGKQ	-0.59	-5.91	-0.35	1.13e-8	Type 2 diabetes;
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg06871246	chr4:1363661	KIAA1530	-0.59	-7.03	-0.41	1.97e-11	Longevity;
KIRP	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.79	9.37	0.51	4.9e-18	Corneal astigmatism;
KIRP	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-10.42	-0.55	2.67e-21	Morning vs. evening chronotype;
KIRP	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg04731861	chr2:219085781	ARPC2	0.29	7.45	0.43	1.53e-12	Colorectal cancer;
KIRP	cis	rs4683702	1.000	rs6794287	chr3:142602666	C/T	cg22826874	chr3:142608218	PCOLCE2	-0.39	-5.69	-0.34	3.64e-8	Blood protein levels;
KIRP	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg11266682	chr4:10021025	SLC2A9	0.41	5.16	0.31	5.15e-7	Gout;Urate levels;Serum uric acid levels;
KIRP	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11987759	chr7:65425863	GUSB	0.5	6.47	0.38	5.22e-10	Aortic root size;
KIRP	cis	rs7572263	0.959	rs7583625	chr2:209048739	A/G	cg23998903	chr2:209048830	C2orf80	-0.32	-5.44	-0.33	1.29e-7	Glioma;Non-glioblastoma glioma;
KIRP	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg13206674	chr6:150067644	NUP43	0.58	8.45	0.47	2.59e-15	Lung cancer;
KIRP	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.96	11.46	0.59	1.18e-24	Corneal astigmatism;
KIRP	cis	rs829661	0.739	rs2609952	chr2:30870795	A/G	cg10949345	chr2:30726833	LCLAT1	1.09	13.34	0.65	6.7e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	cis	rs1050631	1.000	rs1107840	chr18:33707164	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.52	6.42	0.38	7.1e-10	Esophageal squamous cell cancer (length of survival);
KIRP	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.56	9.27	0.51	9.89e-18	Total body bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09526975	chr10:13390462	SEPHS1	0.54	6.74	0.39	1.13e-10	Parkinson's disease;
KIRP	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg02389323	chr16:88786976	FAM38A	1.02	7.76	0.44	2.24e-13	Plateletcrit;
KIRP	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	1.1	8.15	0.46	1.82e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs12586317	0.557	rs8004288	chr14:35679288	A/G	cg07166546	chr14:35805898	NA	-0.26	-6.03	-0.36	6.05e-9	Psoriasis;
KIRP	trans	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg13565492	chr6:43139072	SRF	-0.77	-7.1	-0.41	1.34e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.96	-14.43	-0.68	1.29e-34	Coronary artery disease;
KIRP	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.34	5.28	0.32	2.86e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg18016565	chr1:150552671	MCL1	-0.48	-7.35	-0.42	2.95e-12	Tonsillectomy;
KIRP	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg16558253	chr16:72132732	DHX38	-0.54	-8.03	-0.46	4.02e-14	Fibrinogen levels;
KIRP	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg16606324	chr3:10149918	C3orf24	0.55	5.09	0.31	6.98e-7	Alzheimer's disease;
KIRP	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg18016565	chr1:150552671	MCL1	-0.35	-5.36	-0.32	1.94e-7	Tonsillectomy;
KIRP	cis	rs9398803	0.723	rs1022573	chr6:127054914	C/A	cg19875578	chr6:126661172	C6orf173	-0.42	-5.49	-0.33	9.77e-8	Male-pattern baldness;
KIRP	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg08662619	chr6:150070041	PCMT1	0.35	5.57	0.33	6.55e-8	Lung cancer;
KIRP	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg16989719	chr2:238392110	NA	-0.52	-6.29	-0.37	1.4e-9	Prostate cancer;
KIRP	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.61	-9.13	-0.5	2.63e-17	Educational attainment;
KIRP	cis	rs9309473	0.607	rs58962779	chr2:73555801	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-5.79	-0.35	2.09e-8	Metabolite levels;
KIRP	cis	rs2191566	0.960	rs11083732	chr19:44520743	T/C	cg18700516	chr19:44507157	ZNF230	-0.45	-5.21	-0.32	4.05e-7	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs7692976	0.578	rs3796944	chr4:110873926	A/G	cg06981781	chr4:110842888	EGF	-0.24	-5.23	-0.32	3.67e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.6	0.39	2.57e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.51	6.62	0.39	2.25e-10	Height;
KIRP	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg06481639	chr22:41940642	POLR3H	-0.41	-4.94	-0.3	1.45e-6	Neuroticism;
KIRP	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.71	9.02	0.5	5.33e-17	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11987759	chr7:65425863	GUSB	-0.5	-6.43	-0.38	6.48e-10	Aortic root size;
KIRP	cis	rs10875746	0.669	rs10875770	chr12:48600520	A/G	cg20731937	chr12:48336164	NA	0.41	5.57	0.33	6.65e-8	Longevity (90 years and older);
KIRP	cis	rs654384	0.836	rs12701427	chr7:4176472	A/G	cg04612959	chr7:4183976	SDK1	-0.3	-4.87	-0.3	2.04e-6	Positive affect;
KIRP	cis	rs11710088	0.740	rs13069729	chr3:149190879	A/G	cg08667024	chr3:149219783	TM4SF4	0.41	5.16	0.31	5.14e-7	QRS duration;
KIRP	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.78	8.96	0.5	8.13e-17	Corneal astigmatism;
KIRP	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05665937	chr4:1216051	CTBP1	0.55	7.62	0.44	5.4e-13	Obesity-related traits;
KIRP	cis	rs1318772	0.800	rs17332053	chr5:112916596	A/G	cg12552261	chr5:112820674	MCC	-0.85	-4.99	-0.3	1.14e-6	F-cell distribution;
KIRP	cis	rs35740288	0.770	rs4843086	chr15:86162874	G/A	cg10818794	chr15:86012489	AKAP13	-0.48	-5.34	-0.32	2.13e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02711726	chr17:80685570	FN3KRP	-0.58	-7.76	-0.44	2.3e-13	Glycated hemoglobin levels;
KIRP	cis	rs6005807	0.719	rs12165893	chr22:29033545	T/C	cg12565055	chr22:29076175	TTC28	0.6	5.24	0.32	3.44e-7	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
KIRP	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg00101154	chr16:420108	MRPL28	-0.47	-5.56	-0.33	7.01e-8	Bone mineral density (spine);Bone mineral density;
KIRP	cis	rs17286411	0.836	rs4788572	chr16:71921783	A/G	cg04254540	chr16:71951199	KIAA0174	-0.4	-5.26	-0.32	3.13e-7	Blood protein levels;
KIRP	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-7.21	-0.42	6.76e-12	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs4236601	0.679	rs12668473	chr7:116145639	C/T	cg05166801	chr7:116143459	CAV2	0.49	5.9	0.35	1.2e-8	Intraocular pressure;Glaucoma (primary open-angle);
KIRP	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg08999081	chr20:33150536	PIGU	0.46	6.03	0.36	6.03e-9	Coronary artery disease;
KIRP	cis	rs2594989	0.895	rs2606739	chr3:11394611	C/A	cg01796438	chr3:11312864	ATG7	-0.73	-8.3	-0.47	6.72e-15	Circulating chemerin levels;
KIRP	cis	rs4006360	0.575	rs447608	chr17:39308497	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.36	-5.25	-0.32	3.35e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs11625487	0.609	rs78371022	chr14:77971029	G/A	cg20045696	chr14:77926864	AHSA1	-0.75	-5.46	-0.33	1.16e-7	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
KIRP	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg21698718	chr17:80085957	CCDC57	0.35	5.03	0.31	9.52e-7	Life satisfaction;
KIRP	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs9296736	0.524	rs16884633	chr6:53902171	C/T	cg04374786	chr6:53939321	C6orf142	-0.51	-5.16	-0.31	5.19e-7	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg02807482	chr3:125708958	NA	-0.5	-4.86	-0.3	2.08e-6	Blood pressure (smoking interaction);
KIRP	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-0.99	-16.4	-0.72	2.39e-41	Height;
KIRP	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.79	-11.62	-0.6	3.51e-25	Intelligence (multi-trait analysis);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18116813	chr6:91225725	MAP3K7	0.47	6.14	0.36	3.31e-9	Migraine with aura;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg23967809	chr8:141647658	NA	0.5	6.42	0.38	6.78e-10	Smoking initiation;
KIRP	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13939156	chr17:80058883	NA	0.54	8.78	0.49	2.81e-16	Life satisfaction;
KIRP	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	12.33	0.62	1.63e-27	Bipolar disorder;
KIRP	cis	rs1318772	0.932	rs11739848	chr5:112948757	A/G	cg12552261	chr5:112820674	MCC	0.74	5.43	0.33	1.37e-7	F-cell distribution;
KIRP	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg16989719	chr2:238392110	NA	-0.47	-6.1	-0.36	4.08e-9	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.25	-0.32	3.29e-7	Life satisfaction;
KIRP	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-4.93	-0.3	1.52e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	0.54	6.51	0.38	4.28e-10	Prudent dietary pattern;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg19613905	chr15:56757180	MNS1	0.54	6.39	0.38	8.28e-10	Smoking initiation;
KIRP	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.77	-10.0	-0.54	5.58e-20	Aortic root size;
KIRP	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	7.55	0.43	8.31e-13	Eosinophil percentage of white cells;
KIRP	cis	rs7113874	1.000	rs4929926	chr11:8658376	C/T	cg08015107	chr11:8618950	NA	0.35	4.94	0.3	1.46e-6	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.82	11.42	0.59	1.6e-24	Intelligence (multi-trait analysis);
KIRP	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg16989719	chr2:238392110	NA	-0.56	-6.04	-0.36	5.79e-9	Prostate cancer;
KIRP	cis	rs15676	0.783	rs10988119	chr9:131564585	T/C	cg00228799	chr9:131580591	ENDOG	-0.49	-4.99	-0.3	1.14e-6	Blood metabolite levels;
KIRP	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.19	-0.31	4.5e-7	Pulmonary function;
KIRP	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg20312557	chr2:97357134	FER1L5	-0.71	-4.95	-0.3	1.39e-6	Erectile dysfunction and prostate cancer treatment;
KIRP	cis	rs9659323	0.689	rs10923716	chr1:119536119	C/T	cg18261050	chr1:119551319	NA	0.41	5.33	0.32	2.2e-7	Body mass index;
KIRP	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-8.1	-0.46	2.59e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.55	-7.48	-0.43	1.31e-12	Longevity;
KIRP	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg06675538	chr2:114033490	PAX8;LOC440839	-0.38	-5.02	-0.3	9.81e-7	Renal function-related traits (BUN);
KIRP	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	8.72	0.49	4.16e-16	Motion sickness;
KIRP	cis	rs9905704	0.633	rs2526368	chr17:56470310	G/T	cg12560992	chr17:57184187	TRIM37	-0.56	-5.44	-0.33	1.26e-7	Testicular germ cell tumor;
KIRP	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.75	10.36	0.55	4.19e-21	Parkinson's disease;
KIRP	cis	rs734999	0.588	rs876938	chr1:2523212	G/C	cg11382394	chr1:2564504	MMEL1	-0.41	-5.18	-0.31	4.69e-7	Ulcerative colitis;
KIRP	cis	rs7011049	1.000	rs113124539	chr8:53854321	G/A	cg26025543	chr8:53854495	NA	0.75	7.76	0.44	2.25e-13	Systolic blood pressure;
KIRP	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-12.7	-0.63	9.39e-29	Blood metabolite levels;
KIRP	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg19752551	chr11:57585705	CTNND1	-0.69	-11.53	-0.59	7.22e-25	Schizophrenia;
KIRP	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg21360079	chr12:107162445	NA	-0.68	-9.43	-0.52	3.23e-18	Heart rate;
KIRP	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg14683738	chr19:37701593	ZNF585B	0.48	4.94	0.3	1.42e-6	Coronary artery calcification;
KIRP	cis	rs1978968	0.525	rs4819649	chr22:18396329	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	0.48	6.41	0.38	7.38e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.88	-11.17	-0.58	1.09e-23	Vitamin D levels;
KIRP	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.86	0.81	1.44e-59	Prudent dietary pattern;
KIRP	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg13319975	chr6:146136371	FBXO30	0.41	5.71	0.34	3.25e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg17376030	chr22:41985996	PMM1	-0.5	-6.01	-0.36	6.75e-9	Vitiligo;
KIRP	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.66	8.96	0.5	8.07e-17	Coronary artery disease;
KIRP	cis	rs41005	1.000	rs798449	chr2:8106533	G/A	cg03155496	chr2:8117019	LOC339788	0.6	9.9	0.53	1.17e-19	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs2294369	1.000	rs3747179	chr22:40083730	T/G	cg10455938	chr22:40058150	CACNA1I	0.5	5.73	0.34	2.9e-8	Response to methotrexate in juvenile idiopathic arthritis;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg00691168	chr12:100594586	ACTR6	-0.88	-6.07	-0.36	4.74e-9	P wave terminal force;
KIRP	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.61	-6.36	-0.38	9.52e-10	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg08885076	chr2:99613938	TSGA10	0.59	10.27	0.55	8.09e-21	Chronic sinus infection;
KIRP	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.63	7.07	0.41	1.62e-11	Neutrophil percentage of white cells;
KIRP	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg22117172	chr7:91764530	CYP51A1	0.47	6.66	0.39	1.82e-10	Breast cancer;
KIRP	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs10073892	0.626	rs72781838	chr5:101909590	T/C	cg19774478	chr5:101632501	SLCO4C1	0.57	5.6	0.34	5.61e-8	Cognitive decline (age-related);
KIRP	cis	rs11644362	1.000	rs11644362	chr16:12994097	T/C	cg06890432	chr16:12997467	SHISA9	-0.4	-6.12	-0.36	3.65e-9	Positive affect;Subjective well-being;
KIRP	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20887711	chr4:1340912	KIAA1530	-0.47	-5.84	-0.35	1.67e-8	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05043032	chr1:95583073	TMEM56	0.56	7.13	0.41	1.09e-11	Parkinson's disease;
KIRP	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.72	0.49	4.11e-16	Prudent dietary pattern;
KIRP	cis	rs7523050	0.643	rs71655970	chr1:109403895	A/G	cg08274380	chr1:109419600	GPSM2	1.06	8.77	0.49	2.95e-16	Fat distribution (HIV);
KIRP	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg00792783	chr2:198669748	PLCL1	-0.47	-5.26	-0.32	3.2e-7	Intracranial aneurysm;
KIRP	cis	rs13190036	0.748	rs28395268	chr5:176710547	C/G	cg08293303	chr5:176731731	PRELID1;RAB24	-0.51	-5.8	-0.35	2.08e-8	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
KIRP	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-1.02	-10.74	-0.57	2.5e-22	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg09264619	chr17:80180166	NA	0.4	5.7	0.34	3.44e-8	Life satisfaction;
KIRP	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.65	9.4	0.51	4.03e-18	Neutrophil count;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg21345510	chr15:67358094	SMAD3	0.51	6.27	0.37	1.62e-9	Parkinson's disease;
KIRP	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.61	10.11	0.54	2.58e-20	Anterior chamber depth;
KIRP	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg08632701	chr21:37451849	NA	-0.62	-9.15	-0.5	2.27e-17	Mitral valve prolapse;
KIRP	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg06671706	chr8:8559999	CLDN23	0.56	6.28	0.37	1.55e-9	Obesity-related traits;
KIRP	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-1.06	-11.56	-0.59	5.6e-25	Blood protein levels;
KIRP	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg23803603	chr1:2058230	PRKCZ	0.37	5.56	0.33	6.87e-8	Height;
KIRP	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.71	8.48	0.48	2.11e-15	Mammographic density (dense area);
KIRP	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-6.12	-0.36	3.71e-9	Myopia (pathological);
KIRP	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg21640587	chr11:117668038	DSCAML1	0.43	6.39	0.38	8.26e-10	Myopia;
KIRP	cis	rs2278796	0.918	rs11240326	chr1:204955416	G/A	cg04862289	chr1:204966208	NFASC	0.56	7.83	0.45	1.47e-13	Mean platelet volume;
KIRP	cis	rs259842	0.641	rs1486234	chr2:180707742	A/G	cg05687686	chr2:180726697	MIR1258;ZNF385B	-0.39	-5.32	-0.32	2.36e-7	Blood protein levels;
KIRP	cis	rs4762326	1.000	rs7310833	chr12:95610220	G/A	cg07737802	chr12:95537812	FGD6	0.47	6.59	0.39	2.67e-10	Endometriosis;
KIRP	cis	rs4776970	0.632	rs3784706	chr15:68029749	T/C	cg24579218	chr15:68104479	NA	0.38	5.57	0.33	6.74e-8	Waist circumference;Body mass index;
KIRP	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg24009623	chr19:33667908	NA	0.45	5.3	0.32	2.59e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.47	-6.22	-0.37	2.16e-9	Breast cancer;
KIRP	cis	rs2882667	0.861	rs7703288	chr5:138366539	C/G	cg04439458	chr5:138467593	SIL1	-0.43	-7.0	-0.41	2.45e-11	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg04935436	chr20:30431758	NA	0.48	6.16	0.37	2.87e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.52	7.19	0.42	7.86e-12	Hemoglobin concentration;Hematocrit;
KIRP	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	5.98	0.36	7.69e-9	Hemoglobin concentration;
KIRP	cis	rs7174755	0.608	rs10162905	chr15:68396047	A/G	cg22576950	chr15:68522787	CLN6	0.4	5.87	0.35	1.37e-8	Major depressive disorder;
KIRP	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	6.16	0.37	2.99e-9	Ovarian reserve;
KIRP	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.56	-7.58	-0.44	6.88e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.45	-6.07	-0.36	4.87e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg24315340	chr6:146058215	EPM2A	-0.39	-4.92	-0.3	1.6e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg10150615	chr22:24372951	LOC391322	-0.4	-4.95	-0.3	1.37e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6429082	0.875	rs2291688	chr1:235594250	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.52	-6.75	-0.4	1.06e-10	Adiposity;
KIRP	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.7	6.79	0.4	8.26e-11	Lung function (FEV1/FVC);
KIRP	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.88	8.35	0.47	4.9e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.76e-16	Morning vs. evening chronotype;
KIRP	cis	rs17123764	0.710	rs7296281	chr12:49964558	A/G	cg20471783	chr12:50157085	TMBIM6	0.33	5.11	0.31	6.58e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15656261	chr13:101113806	PCCA	0.48	6.31	0.37	1.32e-9	Interleukin-4 levels;
KIRP	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-6.5	-0.38	4.38e-10	Response to antipsychotic treatment;
KIRP	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.48	8.21	0.46	1.25e-14	Erythrocyte sedimentation rate;
KIRP	cis	rs1485395	1.000	rs1485395	chr12:53995077	T/C	cg16917193	chr12:54089295	NA	0.69	6.86	0.4	5.63e-11	Migraine without aura;
KIRP	cis	rs4728302	0.869	rs10156088	chr7:133592544	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.64	0.34	4.56e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.65	8.56	0.48	1.25e-15	Motion sickness;
KIRP	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg02073558	chr3:44770973	ZNF501	0.62	8.79	0.49	2.69e-16	Depressive symptoms;
KIRP	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg18944383	chr4:111397179	ENPEP	0.41	6.44	0.38	6.27e-10	Coronary artery disease;
KIRP	cis	rs4006360	0.579	rs1817965	chr17:39244724	A/T	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.92	-0.53	9.79e-20	Bipolar disorder and schizophrenia;
KIRP	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg24253500	chr15:84953950	NA	0.42	5.33	0.32	2.27e-7	P wave terminal force;
KIRP	cis	rs1712517	0.787	rs1163089	chr10:105043964	G/A	cg05636881	chr10:105038444	INA	0.43	6.2	0.37	2.41e-9	Migraine;
KIRP	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg22117172	chr7:91764530	CYP51A1	0.46	6.44	0.38	6.06e-10	Breast cancer;
KIRP	cis	rs4911253	0.509	rs66499347	chr20:31448696	C/T	cg13636640	chr20:31349939	DNMT3B	-0.65	-8.59	-0.48	1.04e-15	Lymphocyte counts;
KIRP	cis	rs17253792	0.545	rs12879705	chr14:56017684	C/G	cg24579896	chr14:56047964	C14orf33;KTN1	0.78	5.27	0.32	2.94e-7	Putamen volume;
KIRP	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg08975724	chr8:8085496	FLJ10661	-0.55	-5.76	-0.34	2.49e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg04691961	chr3:161091175	C3orf57	-0.59	-9.82	-0.53	2.06e-19	Morning vs. evening chronotype;
KIRP	cis	rs57994353	0.600	rs10870172	chr9:139319469	G/A	cg21253087	chr9:139290292	SNAPC4	0.47	4.95	0.3	1.36e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
KIRP	cis	rs6142102	0.961	rs6059651	chr20:32645052	T/C	cg08999081	chr20:33150536	PIGU	0.51	6.03	0.36	6.12e-9	Skin pigmentation;
KIRP	cis	rs1012068	0.581	rs5753817	chr22:32313727	G/A	cg15333674	chr22:32435499	NA	-0.46	-5.34	-0.32	2.15e-7	Chronic hepatitis C infection;
KIRP	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg24250549	chr1:154909240	PMVK	0.76	9.93	0.53	9.24e-20	Prostate cancer;
KIRP	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg21605333	chr4:119757512	SEC24D	1.59	11.88	0.6	5.19e-26	Cannabis dependence symptom count;
KIRP	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.63	-9.54	-0.52	1.44e-18	Corneal structure;
KIRP	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.89	-15.12	-0.69	5.91e-37	Headache;
KIRP	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg27490568	chr2:178487706	NA	0.57	7.28	0.42	4.52e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7944584	0.502	rs10769256	chr11:47378396	C/T	cg03711944	chr11:47377212	SPI1	-0.29	-5.03	-0.31	9.55e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs8084125	1.000	rs62105185	chr18:74954808	G/A	cg18461021	chr18:74961002	GALR1	0.62	5.99	0.36	7.44e-9	Obesity-related traits;
KIRP	cis	rs10207060	0.500	rs56346503	chr2:240719409	T/C	cg20333904	chr2:240724165	NA	-0.41	-4.91	-0.3	1.65e-6	Obesity-related traits;
KIRP	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	1.01	11.68	0.6	2.36e-25	Blood pressure;
KIRP	cis	rs7116495	0.786	rs4479013	chr11:71673732	C/G	cg26138937	chr11:71823887	C11orf51	-0.72	-5.85	-0.35	1.53e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg14458575	chr2:238380390	NA	0.55	5.81	0.35	1.97e-8	Prostate cancer;
KIRP	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg17796960	chr10:135278976	LOC619207	-0.44	-5.11	-0.31	6.54e-7	Systemic lupus erythematosus;
KIRP	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.63	6.6	0.39	2.48e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg01879757	chr17:41196368	BRCA1	-0.79	-10.85	-0.57	1.15e-22	Menopause (age at onset);
KIRP	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg24879335	chr3:133465180	TF	0.47	7.36	0.42	2.75e-12	Iron status biomarkers;
KIRP	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg14580859	chr9:123691850	NA	0.36	5.1	0.31	6.83e-7	Rheumatoid arthritis;
KIRP	cis	rs7520050	0.966	rs2275426	chr1:46487552	G/A	cg03146154	chr1:46216737	IPP	-0.42	-5.36	-0.32	1.95e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg08992911	chr2:238395768	MLPH	0.68	6.51	0.38	4.09e-10	Prostate cancer;
KIRP	trans	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg24644049	chr4:85504048	CDS1	1.0	6.54	0.38	3.47e-10	Skin colour saturation;
KIRP	cis	rs2916247	1.000	rs746142	chr8:93060566	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.64	-8.84	-0.49	1.86e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg07004394	chr14:106090750	NA	-0.43	-5.0	-0.3	1.07e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs1476670	0.545	rs11210948	chr1:44520113	A/G	cg09470012	chr1:44509516	NA	0.33	5.19	0.31	4.33e-7	Eotaxin levels;
KIRP	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.47	7.16	0.42	9.4e-12	Resting heart rate;
KIRP	cis	rs10982256	0.782	rs1324631	chr9:117254731	G/C	cg13636371	chr9:117264095	DFNB31	-0.43	-5.6	-0.34	5.61e-8	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.78	6.81	0.4	7.57e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg07460842	chr6:66804631	NA	-0.56	-7.25	-0.42	5.33e-12	Blood trace element (Cu levels);
KIRP	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.77	8.34	0.47	5.23e-15	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.55	-8.1	-0.46	2.55e-14	Monocyte percentage of white cells;
KIRP	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-5.46	-0.33	1.18e-7	Personality dimensions;
KIRP	cis	rs580438	0.510	rs9837443	chr3:13426610	T/C	cg10657019	chr3:13328039	NA	-0.51	-6.65	-0.39	1.83e-10	Myringotomy;
KIRP	cis	rs6058796	1.000	rs35220493	chr20:31267831	G/A	cg13636640	chr20:31349939	DNMT3B	0.6	5.31	0.32	2.41e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
KIRP	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	ch.8.33884649F	chr8:33765107	NA	0.58	7.19	0.42	7.56e-12	Body mass index;
KIRP	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg05527609	chr1:210001259	C1orf107	0.53	5.77	0.35	2.39e-8	Red blood cell count;
KIRP	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg24488311	chr11:68621650	NA	0.42	5.1	0.31	6.7e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs8141529	0.515	rs16986861	chr22:29343188	G/C	cg02153584	chr22:29168773	CCDC117	0.57	5.56	0.33	6.99e-8	Lymphocyte counts;
KIRP	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.7	-7.75	-0.44	2.35e-13	Body mass index;
KIRP	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-9.59	-0.52	1.05e-18	Gut microbiome composition (summer);
KIRP	cis	rs10924970	0.935	rs4659674	chr1:235392354	T/A	cg26050004	chr1:235667680	B3GALNT2	0.41	5.05	0.31	8.41e-7	Asthma;
KIRP	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg25547332	chr5:131281432	NA	0.5	5.79	0.35	2.18e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg15358701	chr1:161410459	NA	-0.68	-6.26	-0.37	1.74e-9	Rheumatoid arthritis;
KIRP	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.57	6.57	0.39	2.93e-10	Height;
KIRP	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.7	0.39	1.44e-10	Height;
KIRP	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	5.94	0.35	9.65e-9	Type 2 diabetes;
KIRP	cis	rs1456297	0.513	rs60694229	chr15:51995490	C/T	cg14296394	chr15:51910925	DMXL2	0.71	9.0	0.5	6.26e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg17385448	chr1:15911702	AGMAT	0.26	5.06	0.31	8.11e-7	Systolic blood pressure;
KIRP	cis	rs7123876	0.717	rs58249351	chr11:72463462	G/A	cg04827223	chr11:72435913	ARAP1	-0.55	-6.58	-0.39	2.87e-10	Body mass index;
KIRP	cis	rs3779635	0.742	rs1045512	chr8:27255263	A/G	cg07216194	chr8:27182965	PTK2B	0.46	5.61	0.34	5.3e-8	Neuroticism;
KIRP	cis	rs9462846	0.853	rs7747505	chr6:42839062	A/G	cg20681975	chr6:42897059	CNPY3	-0.39	-4.94	-0.3	1.43e-6	Blood protein levels;
KIRP	trans	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg17145862	chr1:211918768	LPGAT1	-0.54	-6.87	-0.4	5.24e-11	Leprosy;
KIRP	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.44	-5.75	-0.34	2.61e-8	Menarche (age at onset);
KIRP	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.44	5.64	0.34	4.55e-8	Height;
KIRP	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.83	11.09	0.58	1.93e-23	Menarche (age at onset);
KIRP	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg05639522	chr1:247681581	NA	-0.62	-6.81	-0.4	7.52e-11	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15557168	chr22:42548783	NA	-0.43	-5.76	-0.34	2.56e-8	Cognitive function;
KIRP	cis	rs5752326	0.510	rs713998	chr22:26862212	T/C	cg20819150	chr22:26891497	TFIP11	0.53	4.98	0.3	1.18e-6	Ischemic stroke;
KIRP	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	10.99	0.57	4.05e-23	Exhaled nitric oxide levels;
KIRP	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg15556689	chr8:8085844	FLJ10661	0.52	5.99	0.36	7.58e-9	High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg13565492	chr6:43139072	SRF	-0.93	-8.53	-0.48	1.56e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg06565975	chr8:143823917	SLURP1	-0.56	-7.75	-0.44	2.4e-13	Urinary tract infection frequency;
KIRP	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg06521331	chr12:34319734	NA	-0.62	-7.5	-0.43	1.17e-12	Morning vs. evening chronotype;
KIRP	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg26207909	chr14:103986467	CKB	-0.44	-5.36	-0.32	1.88e-7	Coronary artery disease;
KIRP	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.82	9.4	0.51	4.02e-18	Orofacial clefts;
KIRP	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.51	-5.55	-0.33	7.44e-8	Depression;
KIRP	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.62	-8.0	-0.45	5.02e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg04013166	chr16:89971882	TCF25	0.54	5.16	0.31	5.15e-7	Skin colour saturation;
KIRP	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.29	10.43	0.55	2.48e-21	Prostate cancer;
KIRP	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.84	10.08	0.54	3.21e-20	Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17474435	chr12:50135167	TMBIM6	0.56	6.44	0.38	6.21e-10	Smoking initiation;
KIRP	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.6	8.89	0.49	1.31e-16	Systemic lupus erythematosus;
KIRP	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.78	0.35	2.24e-8	Lung cancer;
KIRP	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs6142102	0.886	rs6142098	chr20:32688294	A/C	cg24642439	chr20:33292090	TP53INP2	0.56	6.74	0.39	1.1e-10	Skin pigmentation;
KIRP	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.53	-0.33	8.35e-8	Bipolar disorder;
KIRP	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	14.06	0.67	2.43e-33	Tonsillectomy;
KIRP	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.68	-7.78	-0.44	2.03e-13	Lung cancer;
KIRP	cis	rs10208940	0.920	rs13400463	chr2:68723912	G/A	cg12452813	chr2:68675892	NA	0.47	5.07	0.31	7.97e-7	Urate levels in lean individuals;
KIRP	cis	rs11622475	1.000	rs2273610	chr14:104387642	G/C	cg20488157	chr14:104394430	TDRD9	0.78	10.71	0.56	3.27e-22	Bipolar disorder;
KIRP	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.3e-8	Life satisfaction;
KIRP	cis	rs7737355	0.947	rs6596007	chr5:130588550	A/G	cg25547332	chr5:131281432	NA	-0.45	-5.02	-0.3	9.89e-7	Life satisfaction;
KIRP	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.71	0.39	1.3100000000000001e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.14	9.08	0.5	3.54e-17	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.64	-7.07	-0.41	1.56e-11	Lung cancer;Squamous cell lung carcinoma;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27411370	chr8:25316735	KCTD9;CDCA2	0.43	6.05	0.36	5.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.31	12.44	0.62	7.1e-28	Diabetic retinopathy;
KIRP	cis	rs28595532	0.748	rs17594978	chr4:119336398	T/C	cg21605333	chr4:119757512	SEC24D	1.1	8.23	0.46	1.06e-14	Cannabis dependence symptom count;
KIRP	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.79	-7.75	-0.44	2.42e-13	Bipolar disorder;
KIRP	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.83	-12.55	-0.62	2.98e-28	Strep throat;
KIRP	cis	rs7224685	0.520	rs2603034	chr17:3981837	T/C	cg05562828	chr17:3906858	NA	-0.72	-14.33	-0.67	2.85e-34	Type 2 diabetes;
KIRP	cis	rs72730918	0.564	rs7180329	chr15:51770845	C/T	cg14296394	chr15:51910925	DMXL2	0.78	10.66	0.56	4.67e-22	Intelligence (multi-trait analysis);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg12044889	chr6:3000430	NQO2	0.54	6.21	0.37	2.2e-9	Smoking initiation;
KIRP	cis	rs7009516	0.716	rs371439	chr8:24225477	T/A	cg01759110	chr8:24241694	ADAMDEC1	0.24	4.98	0.3	1.18e-6	Hair greying;
KIRP	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.27	6.39	0.38	8.21e-10	IgG glycosylation;
KIRP	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg21161173	chr5:140098174	VTRNA1-2	0.37	4.91	0.3	1.64e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-6.61	-0.39	2.43e-10	Schizophrenia;
KIRP	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg01763666	chr17:80159506	CCDC57	0.36	4.93	0.3	1.5e-6	Life satisfaction;
KIRP	trans	rs9650657	0.836	rs11250067	chr8:10606954	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.19	-0.37	2.44e-9	Neuroticism;
KIRP	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.64	-9.41	-0.51	3.74e-18	Endometriosis;
KIRP	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.5	6.62	0.39	2.27e-10	Menopause (age at onset);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg17381754	chr15:81293303	MESDC1	-0.48	-6.27	-0.37	1.6e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg21395723	chr22:39101663	GTPBP1	-0.45	-5.67	-0.34	4.02e-8	Menopause (age at onset);
KIRP	trans	rs4650994	0.789	rs2476559	chr1:178592919	A/G	cg05059571	chr16:84539110	KIAA1609	0.53	7.08	0.41	1.46e-11	HDL cholesterol levels;HDL cholesterol;
KIRP	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.54	-15.41	-0.7	5.94e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg22903657	chr4:1355424	KIAA1530	-0.37	-5.09	-0.31	7.24e-7	Obesity-related traits;
KIRP	trans	rs17079247	0.841	rs9566050	chr13:85807671	C/A	cg07750655	chr16:5121855	ALG1	-0.58	-6.06	-0.36	5.01e-9	Bipolar disorder (mania);
KIRP	cis	rs4936891	1.000	rs10790625	chr11:123917393	G/A	cg22125253	chr11:123886957	OR10G4	-0.39	-5.72	-0.34	3.03e-8	Male fertility;
KIRP	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg13047869	chr3:10149882	C3orf24	0.51	5.06	0.31	8.38e-7	Alzheimer's disease;
KIRP	cis	rs10267417	0.651	rs10229420	chr7:19935229	G/C	cg05791153	chr7:19748676	TWISTNB	0.5	5.04	0.31	9.22e-7	Night sleep phenotypes;
KIRP	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg06223162	chr1:101003688	GPR88	0.44	9.08	0.5	3.59e-17	Monocyte count;
KIRP	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg03060546	chr3:49711283	APEH	-0.5	-6.08	-0.36	4.55e-9	Parkinson's disease;
KIRP	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg19610905	chr11:61596333	FADS2	-0.6	-8.51	-0.48	1.76e-15	Trans fatty acid levels;
KIRP	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-8.68	-0.48	5.36e-16	Morning vs. evening chronotype;
KIRP	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.34	5.33	0.32	2.2e-7	QRS complex (12-leadsum);
KIRP	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg10047753	chr17:41438598	NA	1.13	17.72	0.75	7.83e-46	Menopause (age at onset);
KIRP	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg03289416	chr15:75166202	SCAMP2	0.57	8.12	0.46	2.26e-14	Breast cancer;
KIRP	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.01	-11.33	-0.59	3.22e-24	Alzheimer's disease;
KIRP	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-1.05	-9.49	-0.52	2.04e-18	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs3779635	0.742	rs2163174	chr8:27258195	G/A	cg18234130	chr8:27182889	PTK2B	0.52	6.85	0.4	5.98e-11	Neuroticism;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg24511898	chr2:242576823	ATG4B;THAP4	0.5	6.59	0.39	2.61e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	10.72	0.56	3.01e-22	Coronary artery disease;
KIRP	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg13409248	chr3:40428643	ENTPD3	0.38	5.27	0.32	2.98e-7	Renal cell carcinoma;
KIRP	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.7	0.39	1.42e-10	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg05347473	chr6:146136440	FBXO30	-0.59	-8.24	-0.46	1.06e-14	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4936891	0.599	rs10893128	chr11:123890745	C/T	cg22125253	chr11:123886957	OR10G4	-0.37	-4.97	-0.3	1.23e-6	Male fertility;
KIRP	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg00677455	chr12:58241039	CTDSP2	0.77	9.81	0.53	2.26e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.74	9.91	0.53	1.07e-19	Personality dimensions;
KIRP	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg07148914	chr20:33460835	GGT7	-0.52	-6.82	-0.4	7.01e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.68	6.59	0.39	2.63e-10	Menarche (age at onset);
KIRP	cis	rs7845219	0.544	rs9643351	chr8:95917290	C/T	cg13393036	chr8:95962371	TP53INP1	-0.34	-6.58	-0.39	2.84e-10	Type 2 diabetes;
KIRP	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg12559939	chr2:27858050	GPN1	0.42	5.36	0.32	1.95e-7	Oral cavity cancer;
KIRP	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg19468946	chr17:37922297	IKZF3	-0.48	-6.55	-0.39	3.34e-10	Self-reported allergy;
KIRP	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.85	12.22	0.61	3.64e-27	Monocyte count;
KIRP	cis	rs7274811	0.652	rs149236	chr20:32023380	C/T	cg14921437	chr20:32255988	NECAB3;C20orf134	0.43	5.19	0.31	4.5e-7	Height;
KIRP	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg17810781	chr1:201082982	CACNA1S	0.4	6.15	0.36	3.16e-9	Permanent tooth development;
KIRP	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.85	11.92	0.6	3.8e-26	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.8	10.29	0.55	6.79e-21	Ileal carcinoids;
KIRP	trans	rs3733585	0.699	rs6839490	chr4:9965000	C/G	cg02470959	chr12:132196036	SFRS8	0.48	6.12	0.36	3.7e-9	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11987759	chr7:65425863	GUSB	-0.51	-6.6	-0.39	2.49e-10	Aortic root size;
KIRP	cis	rs6142102	0.602	rs2300209	chr20:32643100	T/C	cg24642439	chr20:33292090	TP53INP2	0.47	5.71	0.34	3.24e-8	Skin pigmentation;
KIRP	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.45	5.19	0.31	4.42e-7	Blood metabolite levels;Acylcarnitine levels;
KIRP	trans	rs12517041	1.000	rs10064991	chr5:23318464	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.85	-7.55	-0.43	8.27e-13	Calcium levels;
KIRP	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	6.19	0.37	2.54e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2279817	0.863	rs3766311	chr1:17978186	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.68	-8.05	-0.46	3.61e-14	Neuroticism;
KIRP	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg02264733	chr16:588086	SOLH	-0.42	-5.0	-0.3	1.11e-6	Venous thromboembolism (SNP x SNP interaction);
KIRP	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.62	7.98	0.45	5.69e-14	Vitiligo;
KIRP	cis	rs728616	0.681	rs36023925	chr10:81906846	T/C	cg27417294	chr10:81904244	PLAC9	0.56	5.05	0.31	8.68e-7	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07685180	chr8:600429	NA	0.7	5.16	0.31	5e-7	IgG glycosylation;
KIRP	cis	rs412050	0.547	rs76200689	chr22:22154644	G/A	cg17089214	chr22:22089827	YPEL1	0.64	5.85	0.35	1.55e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	7.42	0.43	1.9e-12	Multiple myeloma (IgH translocation);
KIRP	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18932078	chr1:2524107	MMEL1	-0.43	-6.04	-0.36	5.62e-9	Ulcerative colitis;
KIRP	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg03929089	chr4:120376271	NA	0.69	6.11	0.36	3.84e-9	Axial length;
KIRP	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00889227	chr1:205173544	DSTYK	-0.4	-5.62	-0.34	5.25e-8	Red blood cell count;
KIRP	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.65	-5.83	-0.35	1.69e-8	Facial emotion recognition (sad faces);
KIRP	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg08132940	chr7:1081526	C7orf50	-0.7	-7.05	-0.41	1.83e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg08975724	chr8:8085496	FLJ10661	0.56	7.36	0.42	2.67e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg18135555	chr8:22132992	PIWIL2	0.44	6.49	0.38	4.76e-10	Hypertriglyceridemia;
KIRP	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg00931491	chr16:28608288	SULT1A2	-0.27	-5.45	-0.33	1.25e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-7.16	-0.42	9.52e-12	Menopause (age at onset);
KIRP	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.97	8.13	0.46	2.1e-14	Body mass index;
KIRP	cis	rs41005	1.000	rs798450	chr2:8107093	C/T	cg03155496	chr2:8117019	LOC339788	0.59	9.83	0.53	1.85e-19	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.54	7.52	0.43	1.01e-12	Mean corpuscular volume;
KIRP	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg03734594	chr13:111297400	CARS2	-0.3	-4.85	-0.3	2.19e-6	Coronary artery disease;
KIRP	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.68	-10.37	-0.55	3.99e-21	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.64	6.73	0.39	1.2e-10	Graves' disease;
KIRP	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg14517863	chr17:44321492	NA	0.47	5.44	0.33	1.29e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg08992911	chr2:238395768	MLPH	-0.45	-4.9	-0.3	1.76e-6	Prostate cancer;
KIRP	cis	rs3750965	0.959	rs3168115	chr11:68858090	A/T	cg06818126	chr11:68850279	TPCN2	0.48	5.8	0.35	2.01e-8	Hair color;
KIRP	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.42	5.84	0.35	1.63e-8	Endometrial cancer;
KIRP	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	0.97	10.58	0.56	8.13e-22	Blood protein levels;
KIRP	cis	rs12311304	1.000	rs12311304	chr12:15389637	T/C	cg08258403	chr12:15378311	NA	0.39	5.68	0.34	3.77e-8	Behavioural disinhibition (generation interaction);
KIRP	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg08975724	chr8:8085496	FLJ10661	0.63	8.53	0.48	1.53e-15	Mood instability;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.83	-14.92	-0.69	2.79e-36	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.48	5.81	0.35	1.92e-8	Asthma;
KIRP	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg07701084	chr6:150067640	NUP43	0.69	9.22	0.51	1.42e-17	Lung cancer;
KIRP	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-7.11	-0.41	1.24e-11	Schizophrenia;
KIRP	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.92	9.76	0.53	3.15e-19	Alzheimer's disease;
KIRP	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07167872	chr1:205819463	PM20D1	0.47	5.47	0.33	1.11e-7	Parkinson's disease;
KIRP	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg02640540	chr1:67518911	SLC35D1	-0.41	-4.92	-0.3	1.6e-6	Lymphocyte percentage of white cells;
KIRP	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.35	-5.1	-0.31	6.69e-7	Body mass index;
KIRP	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.67	-7.25	-0.42	5.29e-12	Corneal structure;
KIRP	cis	rs1497828	0.956	rs2646818	chr1:217525655	A/T	cg04411442	chr1:217543379	NA	-0.43	-6.58	-0.39	2.73e-10	Dialysis-related mortality;
KIRP	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.55	-0.52	1.4e-18	Neuroticism;
KIRP	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.57	7.27	0.42	4.88e-12	Bipolar disorder;
KIRP	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg13982505	chr2:233642094	GIGYF2;KCNJ13	0.4	5.75	0.34	2.59e-8	Coronary artery disease;
KIRP	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-5.12	-0.31	6.07e-7	Huntington's disease progression;
KIRP	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg13047869	chr3:10149882	C3orf24	0.61	5.18	0.31	4.61e-7	Alzheimer's disease;
KIRP	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.68	8.16	0.46	1.72e-14	Corneal astigmatism;
KIRP	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.53	6.46	0.38	5.55e-10	Breast cancer;
KIRP	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg16797656	chr11:68205561	LRP5	0.38	4.98	0.3	1.19e-6	Total body bone mineral density;
KIRP	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.55	-8.13	-0.46	2.1e-14	Neuroticism;
KIRP	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg00129232	chr17:37814104	STARD3	0.71	9.54	0.52	1.53e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.93	12.33	0.62	1.66e-27	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.17	0.5	1.91e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	1.0	17.25	0.74	3.03e-44	Breast cancer;
KIRP	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg04362960	chr10:104952993	NT5C2	-0.63	-6.81	-0.4	7.53e-11	Arsenic metabolism;
KIRP	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.44	-4.9	-0.3	1.71e-6	Height;
KIRP	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.59	-6.33	-0.37	1.13e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.98	15.64	0.71	9.32e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.44	4.92	0.3	1.6e-6	Coronary artery disease;
KIRP	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg00204512	chr16:28754710	NA	0.43	5.69	0.34	3.61e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.74	-9.47	-0.52	2.38e-18	Aortic root size;
KIRP	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg00738919	chr7:1100172	C7orf50	0.43	5.0	0.3	1.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg16141378	chr3:129829833	LOC729375	0.57	8.02	0.46	4.34e-14	Neuroticism;
KIRP	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.79	-8.53	-0.48	1.53e-15	Coronary artery disease;
KIRP	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg20818283	chr2:191399100	TMEM194B	0.53	6.67	0.39	1.63e-10	Pulse pressure;
KIRP	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg01557791	chr16:72042693	DHODH	-0.53	-5.84	-0.35	1.61e-8	Blood protein levels;
KIRP	trans	rs2945733	1.000	rs2922445	chr8:134608745	T/G	cg08312152	chr14:92418138	NA	-0.76	-6.71	-0.39	1.32e-10	Intraocular pressure;
KIRP	cis	rs7551222	0.752	rs4328119	chr1:204564986	C/T	cg20240347	chr1:204465584	NA	-0.4	-7.76	-0.44	2.24e-13	Schizophrenia;
KIRP	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	1.13	8.13	0.46	2.08e-14	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.39	-0.43	2.27e-12	Bipolar disorder;
KIRP	cis	rs9469913	0.799	rs28567450	chr6:34747409	T/A	cg17674042	chr6:34482479	PACSIN1	-0.38	-5.17	-0.31	4.73e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.77	11.11	0.58	1.65e-23	Bladder cancer;
KIRP	cis	rs4332428	1.000	rs34373625	chr10:4981201	G/T	cg19648686	chr10:5044992	AKR1C2	-0.92	-8.01	-0.45	4.6e-14	Height;
KIRP	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg10017260	chr10:834428	NA	-0.51	-5.24	-0.32	3.47e-7	Eosinophil percentage of granulocytes;
KIRP	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg21775007	chr8:11205619	TDH	-0.49	-6.29	-0.37	1.45e-9	Joint mobility (Beighton score);
KIRP	cis	rs662064	0.962	rs620405	chr1:10554794	T/C	cg19773385	chr1:10388646	KIF1B	0.36	5.02	0.3	9.79e-7	Asthma;
KIRP	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.69	-9.0	-0.5	6.12e-17	Aortic root size;
KIRP	cis	rs2985684	0.557	rs2985689	chr14:50098031	C/A	cg01941274	chr14:50234650	KLHDC2	0.51	5.76	0.34	2.47e-8	Carotid intima media thickness;
KIRP	cis	rs1823913	0.637	rs11686185	chr2:192154008	C/T	cg12404831	chr2:192114017	MYO1B	-0.48	-6.47	-0.38	5.25e-10	Obesity-related traits;
KIRP	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg16606324	chr3:10149918	C3orf24	0.58	5.44	0.33	1.29e-7	Alzheimer's disease;
KIRP	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.4	6.53	0.38	3.84e-10	Testicular germ cell tumor;
KIRP	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg16558253	chr16:72132732	DHX38	-0.55	-8.2	-0.46	1.33e-14	Fibrinogen levels;
KIRP	cis	rs6580649	0.941	rs72644844	chr12:48465425	A/C	cg26205652	chr12:48591994	NA	-0.5	-5.89	-0.35	1.24e-8	Lung cancer;
KIRP	cis	rs9826463	0.757	rs73238200	chr3:142204634	C/T	cg20824294	chr3:142316082	PLS1	0.39	6.23	0.37	1.96e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	1.04	19.05	0.77	2.5e-50	Heart rate;
KIRP	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-5.68	-0.34	3.74e-8	Response to antipsychotic treatment;
KIRP	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.77	-9.3	-0.51	8.05e-18	Response to antipsychotic treatment;
KIRP	cis	rs2012796	0.957	rs8009083	chr14:81818289	A/G	cg02996355	chr14:81879375	NA	0.39	5.38	0.32	1.76e-7	Night sleep phenotypes;
KIRP	cis	rs2274273	0.870	rs10139000	chr14:55849876	G/T	cg04306507	chr14:55594613	LGALS3	0.45	6.99	0.41	2.59e-11	Protein biomarker;
KIRP	cis	rs12210905	0.925	rs12193820	chr6:27113811	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.75	-6.45	-0.38	5.96e-10	Hip circumference adjusted for BMI;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg00066508	chr12:110355602	TCHP	0.5	6.25	0.37	1.76e-9	Interleukin-4 levels;
KIRP	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	1.0	17.09	0.74	1.06e-43	Menopause (age at onset);
KIRP	cis	rs4356975	0.563	rs6600886	chr4:69969735	G/A	cg27372994	chr4:70080453	UGT2B11	0.41	5.48	0.33	1.05e-7	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.69e-10	Diabetic kidney disease;
KIRP	cis	rs7246657	0.551	rs4806413	chr19:37617716	A/T	cg23950597	chr19:37808831	NA	-0.7	-6.08	-0.36	4.56e-9	Coronary artery calcification;
KIRP	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	0.89	13.05	0.64	6.4e-30	Dupuytren's disease;
KIRP	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-7.66	-0.44	4.32e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08484984	chr2:61298781	KIAA1841	-0.45	-7.1	-0.41	1.35e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg01200585	chr1:228362443	C1orf69	0.47	5.61	0.34	5.51e-8	Diastolic blood pressure;
KIRP	cis	rs1413885	0.516	rs1591364	chr1:65842364	T/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.6	6.68	0.39	1.56e-10	Anticoagulant levels;
KIRP	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.99	15.76	0.71	3.8e-39	Chronic sinus infection;
KIRP	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.81	11.0	0.57	3.62e-23	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9324022	0.722	rs111475476	chr14:101165917	C/T	cg18089426	chr14:101175970	NA	0.67	5.68	0.34	3.79e-8	Plateletcrit;
KIRP	cis	rs490234	0.812	rs12351825	chr9:128265736	T/C	cg14078157	chr9:128172775	NA	-0.6	-6.97	-0.41	2.9e-11	Mean arterial pressure;
KIRP	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05025164	chr4:1340916	KIAA1530	0.4	5.25	0.32	3.34e-7	Obesity-related traits;
KIRP	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-7.52	-0.43	1.04e-12	Bipolar disorder;
KIRP	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-5.77	-0.35	2.41e-8	Coronary artery disease;
KIRP	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	9.53	0.52	1.64e-18	IgG glycosylation;
KIRP	cis	rs3745672	0.590	rs10411299	chr19:12169163	A/C	cg20127191	chr19:12306497	NA	-0.73	-5.96	-0.35	8.91e-9	Multiple sclerosis;
KIRP	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg19913688	chr11:428466	ANO9	-0.73	-5.56	-0.33	7.01e-8	Body mass index;
KIRP	cis	rs6669119	0.668	rs79187116	chr1:19091297	G/A	cg26220594	chr1:19110978	NA	0.65	6.06	0.36	5.15e-9	Percentage gas trapping;
KIRP	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-5.29	-0.32	2.66e-7	Neuroticism;
KIRP	cis	rs12431939	0.762	rs61109194	chr14:51698659	T/C	cg23942311	chr14:51606299	NA	-0.56	-5.9	-0.35	1.21e-8	Cancer;
KIRP	cis	rs490234	0.841	rs1755936	chr9:128388991	C/G	cg14078157	chr9:128172775	NA	-0.39	-4.87	-0.3	1.98e-6	Mean arterial pressure;
KIRP	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.3	5.99	0.36	7.58e-9	Schizophrenia;
KIRP	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg05526886	chr2:227700861	RHBDD1	-0.42	-5.01	-0.3	1.03e-6	Pulmonary function;
KIRP	cis	rs4253772	0.575	rs9615983	chr22:46793314	G/A	cg18190219	chr22:46762943	CELSR1	-0.63	-6.08	-0.36	4.54e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.79	11.3	0.58	4.15e-24	Bladder cancer;
KIRP	trans	rs711355	0.539	rs11632064	chr15:30223562	G/A	cg26418434	chr11:57267120	SLC43A1	-0.3	-6.03	-0.36	5.96e-9	Response to antipsychotic treatment;
KIRP	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg01877450	chr7:97915802	BRI3	-0.56	-7.15	-0.41	9.91e-12	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-7.54	-0.43	9.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs72634258	0.945	rs441597	chr1:8080895	A/G	cg00042356	chr1:8021962	PARK7	0.56	5.5	0.33	9.36e-8	Inflammatory bowel disease;
KIRP	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.54	6.36	0.38	9.95e-10	Glycated hemoglobin levels;
KIRP	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	1.0	13.49	0.65	2.08e-31	Vitamin D levels;
KIRP	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg02023728	chr11:77925099	USP35	-0.31	-5.38	-0.32	1.75e-7	Alzheimer's disease (survival time);
KIRP	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg23682824	chr7:23144976	KLHL7	0.47	5.69	0.34	3.52e-8	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-5.93	-0.35	1.01e-8	Schizophrenia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg19732469	chr14:96968481	PAPOLA	0.48	6.77	0.4	9.42e-11	Survival in pancreatic cancer;
KIRP	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg03647239	chr10:116582469	FAM160B1	0.43	5.18	0.31	4.55e-7	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg03929089	chr4:120376271	NA	0.76	6.96	0.41	3e-11	Axial length;
KIRP	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.54	-0.33	7.76e-8	Life satisfaction;
KIRP	cis	rs1215050	0.755	rs783958	chr4:98893836	A/T	cg17366294	chr4:99064904	C4orf37	-0.38	-5.18	-0.31	4.57e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs1800682	0.528	rs978522	chr10:90748338	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.57	7.25	0.42	5.27e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs883565	0.792	rs784501	chr3:39183895	A/G	cg01426195	chr3:39028469	NA	0.53	7.01	0.41	2.24e-11	Handedness;
KIRP	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.62	-9.13	-0.5	2.61e-17	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13102973	0.640	rs12499343	chr4:135880463	A/G	cg14419869	chr4:135874104	NA	0.41	6.06	0.36	5.22e-9	Subjective well-being;
KIRP	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.47	9.52	0.52	1.65e-18	Monocyte percentage of white cells;
KIRP	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg26338869	chr17:61819248	STRADA	0.46	4.91	0.3	1.67e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7112043	1.000	rs7112043	chr11:34789386	A/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	5.5	0.33	9.71e-8	Lung disease severity in cystic fibrosis;
KIRP	trans	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-7.39	-0.43	2.28e-12	Blood trace element (Cu levels);
KIRP	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-5.21	-0.32	3.91e-7	Neuroticism;
KIRP	cis	rs1109861	0.525	rs606139	chr10:11205719	A/G	cg20379239	chr10:11207015	CUGBP2	0.4	5.08	0.31	7.44e-7	Urinary albumin-to-creatinine ratio;
KIRP	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg13798912	chr7:905769	UNC84A	0.67	6.51	0.38	4.27e-10	Cerebrospinal P-tau181p levels;
KIRP	trans	rs6432860	0.701	rs12992997	chr2:166724833	C/T	cg13971571	chr8:6693247	XKR5	0.52	6.33	0.37	1.12e-9	Febrile seizures (MMR vaccine-unrelated);Febrile seizures;
KIRP	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg14343924	chr8:8086146	FLJ10661	0.53	6.41	0.38	7.42e-10	Neuroticism;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg10011647	chr11:58892585	FAM111B	0.52	6.15	0.37	3.14e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg05220968	chr6:146057943	EPM2A	0.41	5.31	0.32	2.47e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg00405596	chr8:11794950	NA	-0.47	-6.05	-0.36	5.3e-9	Joint mobility (Beighton score);
KIRP	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg08999081	chr20:33150536	PIGU	0.44	5.71	0.34	3.19e-8	Height;
KIRP	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.54	-9.14	-0.5	2.45e-17	Height;
KIRP	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg22437258	chr11:111473054	SIK2	0.48	5.97	0.36	8.08e-9	Primary sclerosing cholangitis;
KIRP	cis	rs7582720	0.887	rs72932755	chr2:203673563	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.15	10.49	0.56	1.63e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg00129232	chr17:37814104	STARD3	0.65	6.97	0.41	2.81e-11	Glomerular filtration rate (creatinine);
KIRP	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg20243544	chr17:37824526	PNMT	0.35	4.88	0.3	1.93e-6	Self-reported allergy;
KIRP	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.69	8.32	0.47	6.08e-15	Aortic root size;
KIRP	cis	rs55728055	0.661	rs41302569	chr22:32046953	C/A	cg01338084	chr22:32026380	PISD	1.02	6.35	0.38	1.01e-9	Age-related hearing impairment;
KIRP	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.8	11.46	0.59	1.2e-24	Mean corpuscular hemoglobin;
KIRP	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg03060546	chr3:49711283	APEH	0.41	5.0	0.3	1.09e-6	Parkinson's disease;
KIRP	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg05082376	chr22:42548792	NA	0.47	6.04	0.36	5.57e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs648163	1.000	rs648163	chr1:199315998	A/G	cg19732653	chr1:245848798	KIF26B	-0.52	-6.34	-0.37	1.09e-9	Educational attainment (years of education);
KIRP	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg02012338	chr4:187126139	CYP4V2	0.61	5.41	0.33	1.46e-7	Blood protein levels;
KIRP	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.4	-5.0	-0.3	1.1e-6	Aortic root size;
KIRP	trans	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg26043149	chr18:55253948	FECH	0.5	6.19	0.37	2.52e-9	Bone mineral density;
KIRP	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-4.95	-0.3	1.37e-6	Response to amphetamines;
KIRP	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	0.74	11.09	0.58	1.94e-23	Lewy body disease;
KIRP	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.76	-11.69	-0.6	2.04e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.68	9.48	0.52	2.33e-18	Body mass index;
KIRP	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	6.32	0.37	1.22e-9	Educational attainment;
KIRP	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.53	6.29	0.37	1.41e-9	Macular telangiectasia type 2;
KIRP	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg10505658	chr17:80084571	CCDC57	-0.27	-4.94	-0.3	1.47e-6	Life satisfaction;
KIRP	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg16329650	chr2:213403929	ERBB4	0.81	13.57	0.65	1.11e-31	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg17366294	chr4:99064904	C4orf37	0.46	5.46	0.33	1.17e-7	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.67	-8.05	-0.46	3.56e-14	Body mass index;
KIRP	cis	rs6901004	0.803	rs354545	chr6:111531412	G/A	cg15721981	chr6:111408429	SLC16A10	-0.58	-7.83	-0.45	1.46e-13	Blood metabolite levels;
KIRP	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg11814155	chr7:99998594	ZCWPW1	0.58	5.41	0.33	1.53e-7	Platelet count;
KIRP	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.17	-0.37	2.83e-9	Colorectal cancer;
KIRP	cis	rs12580194	0.593	rs61956292	chr12:55803346	T/C	cg19537932	chr12:55886519	OR6C68	-0.53	-6.63	-0.39	2.09e-10	Cancer;
KIRP	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs10208940	0.920	rs35878577	chr2:68737456	C/T	cg12452813	chr2:68675892	NA	0.47	5.06	0.31	8.07e-7	Urate levels in lean individuals;
KIRP	cis	rs6960043	0.818	rs2191348	chr7:15064255	G/T	cg19272540	chr7:15055459	NA	-0.24	-6.86	-0.4	5.66e-11	Type 2 diabetes;
KIRP	cis	rs4794202	0.579	rs9896712	chr17:45884543	G/A	cg10638573	chr17:45915098	SCRN2	0.48	5.74	0.34	2.85e-8	Alzheimer's disease (cognitive decline);
KIRP	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg10818794	chr15:86012489	AKAP13	-0.5	-7.15	-0.41	9.9e-12	Coronary artery disease;
KIRP	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg11738485	chr19:12877000	HOOK2	-0.48	-5.56	-0.33	7.05e-8	Mean corpuscular volume;
KIRP	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.46	-7.12	-0.41	1.15e-11	Coronary artery disease;
KIRP	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.63	-7.45	-0.43	1.53e-12	Aortic root size;
KIRP	cis	rs2304069	0.826	rs184960	chr5:149343370	C/T	cg12661370	chr5:149340060	SLC26A2	-0.5	-5.15	-0.31	5.23e-7	HIV-1 control;
KIRP	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg22875332	chr1:76189707	ACADM	-0.34	-4.85	-0.3	2.18e-6	Daytime sleep phenotypes;
KIRP	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.37	-4.99	-0.3	1.15e-6	Blood metabolite levels;
KIRP	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.04	11.61	0.6	3.8e-25	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-0.83	-7.67	-0.44	3.94e-13	Severe influenza A (H1N1) infection;
KIRP	cis	rs742614	0.533	rs6059496	chr20:32446931	T/C	cg06304546	chr20:32448765	NA	-0.9	-14.06	-0.67	2.4e-33	Stearic acid (18:0) levels;
KIRP	cis	rs7005380	0.581	rs2176750	chr8:120937700	T/C	cg21645572	chr8:120931649	DEPDC6	-0.48	-6.44	-0.38	6.31e-10	Interstitial lung disease;
KIRP	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.53	-6.88	-0.4	4.99e-11	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.48	5.83	0.35	1.74e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg08975724	chr8:8085496	FLJ10661	-0.53	-6.78	-0.4	8.91e-11	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2415984	0.622	rs12437018	chr14:46937149	A/G	cg14871534	chr14:47121158	RPL10L	-0.41	-5.05	-0.31	8.64e-7	Number of children ever born;
KIRP	cis	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg00614314	chr15:82944287	LOC80154	0.56	6.5	0.38	4.37e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	trans	rs4308128	0.528	rs1446489	chr2:116514703	C/T	cg04905443	chr8:105519089	LRP12	-0.35	-6.4	-0.38	7.8e-10	Suicide attempts in major depressive disorder;
KIRP	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.96	11.16	0.58	1.1e-23	Corneal astigmatism;
KIRP	cis	rs7737355	0.812	rs152789	chr5:131026590	C/A	cg06307176	chr5:131281290	NA	0.41	4.9	0.3	1.73e-6	Life satisfaction;
KIRP	cis	rs1816752	0.748	rs6490912	chr13:24983079	G/A	cg22771759	chr13:24902376	NA	0.38	4.89	0.3	1.83e-6	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23955903	chr1:112298873	DDX20;C1orf183	0.5	6.26	0.37	1.68e-9	Parkinson's disease;
KIRP	cis	rs7084402	0.967	rs1427223	chr10:60290966	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.97	-0.57	4.76e-23	Refractive error;
KIRP	cis	rs7246657	0.722	rs8110865	chr19:38047387	G/A	cg23950597	chr19:37808831	NA	-0.61	-6.64	-0.39	1.95e-10	Coronary artery calcification;
KIRP	trans	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg24644049	chr4:85504048	CDS1	0.88	6.13	0.36	3.4e-9	Skin colour saturation;
KIRP	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.47	5.82	0.35	1.8e-8	Initial pursuit acceleration;
KIRP	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg21395723	chr22:39101663	GTPBP1	0.47	6.39	0.38	8.31e-10	Menopause (age at onset);
KIRP	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg04369109	chr6:150039330	LATS1	-0.57	-7.26	-0.42	4.93e-12	Lung cancer;
KIRP	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg23161317	chr6:28129485	ZNF389	0.45	5.27	0.32	3.05e-7	Depression;
KIRP	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg11814155	chr7:99998594	ZCWPW1	0.62	5.51	0.33	8.93e-8	Platelet count;
KIRP	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.62	6.35	0.38	1.06e-9	Gut microbiome composition (summer);
KIRP	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg06307176	chr5:131281290	NA	0.55	5.88	0.35	1.33e-8	Life satisfaction;
KIRP	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg17108064	chr15:78857060	CHRNA5	0.37	5.28	0.32	2.81e-7	Sudden cardiac arrest;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg17386128	chr2:173420391	PDK1	0.55	6.69	0.39	1.53e-10	Inflammatory biomarkers;
KIRP	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	8.33	0.47	5.77e-15	Electroencephalogram traits;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg20536432	chr5:82500668	XRCC4	-0.43	-6.73	-0.39	1.17e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6462411	0.938	rs6963058	chr7:3918805	T/A	cg18022346	chr7:3920534	SDK1	-0.43	-4.91	-0.3	1.68e-6	Quantitative traits;
KIRP	cis	rs2797160	0.547	rs4144549	chr6:125945251	C/G	cg05901451	chr6:126070800	HEY2	0.38	5.27	0.32	2.99e-7	Endometrial cancer;
KIRP	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg03714773	chr7:91764589	CYP51A1	0.38	5.46	0.33	1.16e-7	Breast cancer;
KIRP	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.68	6.77	0.4	9.15e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.58	-8.36	-0.47	4.69e-15	Huntington's disease progression;
KIRP	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg24253500	chr15:84953950	NA	0.49	5.7	0.34	3.42e-8	Schizophrenia;
KIRP	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.7	-8.5	-0.48	1.84e-15	Cognitive function;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09646026	chr4:107269030	AIMP1	0.42	6.28	0.37	1.5e-9	Interleukin-4 levels;
KIRP	cis	rs3779635	0.710	rs4733054	chr8:27241082	G/A	cg07216194	chr8:27182965	PTK2B	0.44	5.27	0.32	3.02e-7	Neuroticism;
KIRP	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg23307798	chr14:103986281	CKB	-0.51	-6.83	-0.4	6.61e-11	Coronary artery disease;
KIRP	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.66	-9.94	-0.54	8.45e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9303542	0.625	rs7225995	chr17:46596268	G/C	cg04904318	chr17:46607828	HOXB1	-0.6	-6.59	-0.39	2.69e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg03468072	chr12:39539422	NA	0.41	5.76	0.34	2.46e-8	Morning vs. evening chronotype;
KIRP	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg07827796	chr19:33622959	WDR88	0.44	5.24	0.32	3.47e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg16558253	chr16:72132732	DHX38	-0.41	-4.86	-0.3	2.1e-6	Blood protein levels;
KIRP	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg23748340	chr12:48592721	NA	-0.43	-4.9	-0.3	1.72e-6	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.5	-7.5	-0.43	1.14e-12	Electroencephalogram traits;
KIRP	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	6.98	0.41	2.74e-11	Hip circumference adjusted for BMI;
KIRP	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.75	9.38	0.51	4.67e-18	Aortic root size;
KIRP	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg26876637	chr1:152193138	HRNR	0.71	9.19	0.51	1.71e-17	Atopic dermatitis;
KIRP	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.92	-15.37	-0.7	7.88e-38	Breast cancer;
KIRP	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.64	-7.94	-0.45	6.99e-14	Tonsillectomy;
KIRP	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg25251562	chr2:3704773	ALLC	-0.51	-5.88	-0.35	1.32e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs7017914	0.967	rs7819332	chr8:71668265	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.62	5.41	0.33	1.51e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg21775007	chr8:11205619	TDH	-0.39	-5.14	-0.31	5.56e-7	Morning vs. evening chronotype;
KIRP	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.64	-7.75	-0.44	2.44e-13	Blood protein levels;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.47	-7.06	-0.41	1.66e-11	Lymphocyte counts;
KIRP	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-1.31	-10.36	-0.55	4.24e-21	Hip circumference adjusted for BMI;
KIRP	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.46	-6.22	-0.37	2.12e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19293748	chr19:53237645	ZNF611	0.5	6.78	0.4	8.83e-11	Parkinson's disease;
KIRP	trans	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg24644049	chr4:85504048	CDS1	1.1	7.25	0.42	5.49e-12	Skin colour saturation;
KIRP	cis	rs7224685	0.569	rs35578550	chr17:3996470	A/G	cg11204139	chr17:3907470	NA	0.55	5.13	0.31	5.85e-7	Type 2 diabetes;
KIRP	cis	rs385076	0.502	rs13013695	chr2:32391231	G/A	cg02381751	chr2:32503542	YIPF4	-0.54	-5.4	-0.33	1.6e-7	Interleukin-18 levels;
KIRP	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg06792262	chr3:44622596	ZNF167	0.4	5.3	0.32	2.59e-7	Depressive symptoms;
KIRP	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	6.02	0.36	6.34e-9	Breast cancer;
KIRP	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg15841412	chr13:111365552	ING1	0.48	5.42	0.33	1.4e-7	Coronary artery disease;
KIRP	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg00343986	chr7:65444356	GUSB	0.43	5.07	0.31	7.84e-7	Aortic root size;
KIRP	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs10788264	0.504	rs1034533	chr10:124032434	A/G	cg09507567	chr10:124027408	NA	0.31	5.72	0.34	3.08e-8	Total body bone mineral density;
KIRP	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.76	-12.01	-0.61	1.92e-26	Rheumatoid arthritis;
KIRP	cis	rs300890	0.513	rs6820340	chr4:144120204	A/G	cg01719995	chr4:144104893	USP38	0.4	5.19	0.31	4.35e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.46	-5.4	-0.33	1.57e-7	Fear of minor pain;
KIRP	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.37	-4.97	-0.3	1.27e-6	Metabolite levels;
KIRP	cis	rs8077577	0.747	rs1925	chr17:18177715	G/A	cg18869244	chr17:18121946	NA	0.47	5.31	0.32	2.51e-7	Obesity-related traits;
KIRP	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.61	-6.64	-0.39	2.04e-10	Alcohol dependence;
KIRP	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg26681399	chr22:41777847	TEF	0.5	5.17	0.31	4.89e-7	Vitiligo;
KIRP	cis	rs10875746	0.903	rs11168420	chr12:48515896	C/T	cg26205652	chr12:48591994	NA	0.76	10.37	0.55	3.98e-21	Longevity (90 years and older);
KIRP	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.85	15.92	0.71	1.07e-39	Anterior chamber depth;
KIRP	cis	rs11169552	0.510	rs10876070	chr12:51002088	A/C	cg12884762	chr12:50931848	DIP2B	-0.42	-4.88	-0.3	1.87e-6	Colorectal cancer;
KIRP	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.15	-0.54	1.88e-20	Hemoglobin concentration;
KIRP	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	7.19	0.42	7.66e-12	Retinal vascular caliber;
KIRP	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.7	-9.07	-0.5	4.01e-17	Blood metabolite levels;
KIRP	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.46	7.61	0.44	5.69e-13	Testicular germ cell tumor;
KIRP	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg27494647	chr7:150038898	RARRES2	0.4	5.76	0.34	2.46e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs1881396	0.947	rs10173720	chr2:27855397	A/T	cg27432699	chr2:27873401	GPN1	-0.57	-6.63	-0.39	2.14e-10	Nonalcoholic fatty liver disease;
KIRP	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-8.33	-0.47	5.52e-15	Morning vs. evening chronotype;
KIRP	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg11005552	chr10:105648138	OBFC1	0.41	5.78	0.35	2.27e-8	Coronary artery disease;
KIRP	cis	rs2275620	1.000	rs1934985	chr10:96801753	C/T	cg09036531	chr10:96991505	NA	-0.51	-6.53	-0.38	3.64e-10	Gout;
KIRP	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.54	6.19	0.37	2.5e-9	Vitamin D levels;
KIRP	cis	rs7224685	0.501	rs8066272	chr17:3900528	C/T	cg11204139	chr17:3907470	NA	0.88	17.07	0.74	1.3e-43	Type 2 diabetes;
KIRP	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.63	-6.96	-0.41	3.16e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs3026101	0.671	rs739767	chr17:5290681	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	0.82	10.08	0.54	3.14e-20	Prostate cancer;
KIRP	cis	rs9303542	0.625	rs8072250	chr17:46569216	C/T	cg04904318	chr17:46607828	HOXB1	-0.42	-4.96	-0.3	1.32e-6	Ovarian cancer;Epithelial ovarian cancer;
KIRP	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.47	5.7	0.34	3.36e-8	Blood protein levels;
KIRP	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg14580859	chr9:123691850	NA	0.35	5.0	0.3	1.08e-6	Rheumatoid arthritis;
KIRP	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg25486957	chr4:152246857	NA	-0.52	-5.69	-0.34	3.66e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2273669	0.915	rs2038542	chr6:109295293	T/C	cg05315195	chr6:109294784	ARMC2	-0.51	-5.79	-0.35	2.19e-8	Prostate cancer;
KIRP	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.64	7.25	0.42	5.47e-12	Prudent dietary pattern;
KIRP	cis	rs7927771	0.689	rs10734557	chr11:47380061	A/C	cg20307385	chr11:47447363	PSMC3	0.5	5.25	0.32	3.37e-7	Subjective well-being;
KIRP	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	1.08	8.47	0.48	2.23e-15	Alzheimer's disease;
KIRP	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.71	11.12	0.58	1.5e-23	Resting heart rate;
KIRP	cis	rs9394841	0.692	rs9357371	chr6:41885319	A/C	cg08135965	chr6:41755394	TOMM6	0.51	5.51	0.33	8.96e-8	Mean corpuscular hemoglobin;Red cell distribution width;
KIRP	cis	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg21605333	chr4:119757512	SEC24D	0.79	6.41	0.38	7.31e-10	Cannabis dependence symptom count;
KIRP	cis	rs12973672	0.812	rs12984022	chr19:35754011	A/C	cg12095397	chr19:35769544	USF2	0.67	6.2	0.37	2.33e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs12210905	1.000	rs72838266	chr6:27015052	T/C	cg11502198	chr6:26597334	ABT1	-0.78	-4.98	-0.3	1.18e-6	Hip circumference adjusted for BMI;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27319730	chr6:36237037	PNPLA1	0.54	8.02	0.46	4.21e-14	Survival in pancreatic cancer;
KIRP	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg01689657	chr7:91764605	CYP51A1	0.34	4.86	0.3	2.12e-6	Breast cancer;
KIRP	cis	rs3779635	0.742	rs11775519	chr8:27248019	A/T	cg06815112	chr8:27182871	PTK2B	0.54	6.94	0.4	3.43e-11	Neuroticism;
KIRP	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.58	7.91	0.45	8.8e-14	Prostate cancer;
KIRP	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.54	7.13	0.41	1.09e-11	Sum eosinophil basophil counts;Eosinophil counts;
KIRP	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	8.52	0.48	1.67e-15	Type 2 diabetes;
KIRP	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg08662619	chr6:150070041	PCMT1	0.36	5.79	0.35	2.08e-8	Lung cancer;
KIRP	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.41	5.26	0.32	3.16e-7	Aortic root size;
KIRP	cis	rs1167827	0.805	rs809439	chr7:75161318	T/A	cg15428835	chr7:75027521	TRIM73;TRIM74	0.39	5.0	0.3	1.1e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-8.78	-0.49	2.77e-16	Total cholesterol levels;
KIRP	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.85e-8	Life satisfaction;
KIRP	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-0.97	-12.86	-0.63	2.81e-29	Mean platelet volume;
KIRP	cis	rs6580649	0.883	rs4760621	chr12:48561262	A/G	cg26205652	chr12:48591994	NA	0.5	6.08	0.36	4.6e-9	Lung cancer;
KIRP	cis	rs711830	1.000	rs2113559	chr2:177031099	A/G	cg13092806	chr2:177043255	NA	0.68	7.13	0.41	1.14e-11	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
KIRP	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22117172	chr7:91764530	CYP51A1	0.53	7.76	0.44	2.33e-13	Breast cancer;
KIRP	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.64	9.33	0.51	6.5e-18	Resting heart rate;
KIRP	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg12591125	chr7:1885375	MAD1L1	0.66	6.28	0.37	1.56e-9	Bipolar disorder;
KIRP	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.54	-8.73	-0.49	4.01e-16	Prostate cancer;
KIRP	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.74	9.44	0.52	2.91e-18	Aortic root size;
KIRP	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg08000102	chr2:233561755	GIGYF2	-0.53	-6.47	-0.38	5.25e-10	Coronary artery disease;
KIRP	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	8.6	0.48	9.63e-16	Lung cancer in ever smokers;
KIRP	cis	rs7267005	0.661	rs113183680	chr20:34395360	C/T	cg17201900	chr20:34330562	RBM39	1.05	5.83	0.35	1.73e-8	Response to paliperidone in schizophrenia (Multivariate);
KIRP	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.2	-16.09	-0.72	2.71e-40	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
KIRP	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.48	-6.8	-0.4	7.96e-11	Height;
KIRP	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.46	5.92	0.35	1.09e-8	Life satisfaction;
KIRP	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg21918786	chr6:109611834	NA	0.34	5.12	0.31	6.12e-7	Reticulocyte fraction of red cells;
KIRP	trans	rs12517041	1.000	rs2099091	chr5:23295532	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.91	-8.65	-0.48	6.78e-16	Calcium levels;
KIRP	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.57	-8.02	-0.46	4.21e-14	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs137699	0.652	rs2413589	chr22:39755689	C/T	cg05872129	chr22:39784769	NA	0.44	5.02	0.31	9.78e-7	IgG glycosylation;
KIRP	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg24375607	chr4:120327624	NA	0.57	6.61	0.39	2.39e-10	Corneal astigmatism;
KIRP	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg11859384	chr17:80120422	CCDC57	-0.39	-4.89	-0.3	1.79e-6	Life satisfaction;
KIRP	cis	rs10046574	0.519	rs11505985	chr7:135210197	G/T	cg27474649	chr7:135195673	CNOT4	0.55	5.18	0.31	4.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg00405596	chr8:11794950	NA	-0.48	-6.08	-0.36	4.56e-9	Retinal vascular caliber;
KIRP	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg26695010	chr11:65641043	EFEMP2	0.51	5.1	0.31	6.88e-7	Crohn's disease;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg03700279	chr2:44576358	PREPL	0.42	6.94	0.4	3.5e-11	C-reactive protein;
KIRP	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00938859	chr5:1591904	SDHAP3	0.61	8.21	0.46	1.25e-14	Breast cancer;
KIRP	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg22138327	chr13:27999177	GTF3A	-0.58	-5.67	-0.34	3.93e-8	Body mass index;
KIRP	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg10259518	chr2:233765616	NGEF	0.35	5.13	0.31	5.96e-7	Coronary artery disease;
KIRP	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.56	7.21	0.42	7.07e-12	Lung cancer;
KIRP	cis	rs490234	0.729	rs10819050	chr9:128237178	G/T	cg14078157	chr9:128172775	NA	-0.41	-5.17	-0.31	4.85e-7	Mean arterial pressure;
KIRP	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.34	-0.32	2.13e-7	Skin colour saturation;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg22931738	chr3:128206823	GATA2	-0.43	-6.2	-0.37	2.39e-9	Myopia;
KIRP	cis	rs7903847	0.620	rs3737194	chr10:99130127	A/G	cg20016023	chr10:99160130	RRP12	-0.41	-5.53	-0.33	8.25e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.1	-0.46	2.57e-14	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.89	-12.52	-0.62	3.89e-28	Menopause (age at onset);
KIRP	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs2742417	1.000	rs2742379	chr3:45787835	G/A	cg04037228	chr3:45636386	LIMD1	0.36	5.17	0.31	4.94e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.56	7.24	0.42	5.78e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg10729496	chr3:10149963	C3orf24	0.55	5.01	0.3	1.04e-6	Alzheimer's disease;
KIRP	cis	rs7027203	0.557	rs2487021	chr9:96510300	C/G	cg14598338	chr9:96623480	NA	-0.44	-6.52	-0.38	3.87e-10	DNA methylation (variation);
KIRP	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg20503657	chr10:835505	NA	-0.4	-5.1	-0.31	6.93e-7	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg27411982	chr8:10470053	RP1L1	-0.5	-6.3	-0.37	1.38e-9	Neuroticism;
KIRP	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06481639	chr22:41940642	POLR3H	-0.66	-7.08	-0.41	1.52e-11	Vitiligo;
KIRP	trans	rs1106684	0.925	rs61233128	chr7:131456378	T/C	cg13607082	chr12:122652224	LRRC43	-0.64	-6.71	-0.39	1.32e-10	Body mass index;
KIRP	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg25801113	chr15:45476975	SHF	-0.44	-8.11	-0.46	2.41e-14	Uric acid levels;
KIRP	cis	rs11955398	0.585	rs10063166	chr5:60008844	C/T	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.86	12.14	0.61	7.08e-27	Menopause (age at onset);
KIRP	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg18944383	chr4:111397179	ENPEP	-0.71	-13.29	-0.65	9.53e-31	Coronary artery disease;
KIRP	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg14593290	chr7:50529359	DDC	-0.45	-5.99	-0.36	7.48e-9	Malaria;
KIRP	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.78	9.92	0.53	9.78e-20	Corneal astigmatism;
KIRP	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg13264159	chr8:625131	ERICH1	-0.81	-6.37	-0.38	9.27e-10	IgG glycosylation;
KIRP	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.47	6.65	0.39	1.93e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.53	5.92	0.35	1.06e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg00507259	chr4:95128692	SMARCAD1	0.41	5.23	0.32	3.68e-7	Testicular germ cell tumor;
KIRP	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.99	13.44	0.65	2.97e-31	Menopause (age at onset);
KIRP	cis	rs300890	0.642	rs3805253	chr4:144289502	A/G	cg01719995	chr4:144104893	USP38	-0.44	-5.45	-0.33	1.21e-7	Nasopharyngeal carcinoma;
KIRP	cis	rs4664293	0.867	rs6432557	chr2:160592210	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	17.01	0.74	1.97e-43	Chronic sinus infection;
KIRP	cis	rs7520050	0.931	rs11576305	chr1:46460046	C/T	cg03146154	chr1:46216737	IPP	-0.43	-5.4	-0.33	1.58e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs6540559	0.673	rs17015224	chr1:209968918	G/A	cg22029157	chr1:209979665	IRF6	0.53	5.83	0.35	1.72e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.61	6.78	0.4	8.92e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg20744362	chr22:50050164	C22orf34	0.33	5.31	0.32	2.43e-7	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg10326726	chr10:51549505	MSMB	-0.6	-9.1	-0.5	3.13e-17	Prostate-specific antigen levels;
KIRP	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.57	6.98	0.41	2.76e-11	Aortic root size;
KIRP	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18932078	chr1:2524107	MMEL1	0.43	5.98	0.36	7.76e-9	Ulcerative colitis;
KIRP	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.88	13.16	0.64	2.59e-30	Eosinophil percentage of white cells;
KIRP	cis	rs9603616	0.719	rs9548877	chr13:40247557	T/C	cg26701198	chr13:40229707	COG6	0.44	5.18	0.31	4.57e-7	Rheumatoid arthritis;
KIRP	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-6.95	-0.41	3.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs17407555	0.738	rs3806817	chr4:10118914	C/T	cg11266682	chr4:10021025	SLC2A9	-0.4	-4.87	-0.3	2.04e-6	Schizophrenia (age at onset);
KIRP	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg01879757	chr17:41196368	BRCA1	-0.8	-11.21	-0.58	7.94e-24	Menopause (age at onset);
KIRP	cis	rs4664293	0.738	rs1549580	chr2:160668688	C/G	cg08347373	chr2:160653686	CD302	-0.37	-5.65	-0.34	4.49e-8	Monocyte percentage of white cells;
KIRP	cis	rs2742417	1.000	rs1877932	chr3:45753539	A/G	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	trans	rs10874322	1.000	rs72714355	chr1:83048915	C/T	cg12753787	chr1:3239712	PRDM16	0.66	6.53	0.38	3.83e-10	Response to taxane treatment (docetaxel);
KIRP	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-5.1	-0.31	6.7e-7	Lung cancer;
KIRP	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg07636037	chr3:49044803	WDR6	-0.73	-5.61	-0.34	5.3e-8	Cognitive function;
KIRP	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg10008539	chr14:50087325	RPL36AL;MGAT2	-0.4	-5.05	-0.31	8.8e-7	Carotid intima media thickness;
KIRP	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-7.47	-0.43	1.42e-12	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs7209700	0.547	rs8078614	chr17:45351505	C/T	cg25173405	chr17:45401733	C17orf57	0.53	5.29	0.32	2.66e-7	IgG glycosylation;
KIRP	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg11833968	chr6:79620685	NA	-0.47	-7.18	-0.42	8.31e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg25753631	chr6:25732923	NA	-0.28	-5.26	-0.32	3.08e-7	Iron status biomarkers;
KIRP	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.47	6.49	0.38	4.56e-10	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.81	-11.36	-0.59	2.49e-24	Monocyte count;
KIRP	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.83	-12.82	-0.63	3.59e-29	Blood metabolite levels;
KIRP	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.4	7.65	0.44	4.42e-13	Height;
KIRP	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.46	6.43	0.38	6.71e-10	Sitting height ratio;
KIRP	cis	rs7819412	0.775	rs4840551	chr8:11029039	T/G	cg19847130	chr8:10466454	RP1L1	0.38	5.69	0.34	3.57e-8	Triglycerides;
KIRP	cis	rs7552404	0.731	rs61770552	chr1:76373050	T/C	cg22875332	chr1:76189707	ACADM	0.56	7.34	0.42	3.14e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg07777115	chr5:623756	CEP72	-0.57	-5.74	-0.34	2.83e-8	Lung disease severity in cystic fibrosis;
KIRP	cis	rs981844	0.683	rs4696191	chr4:154740668	G/A	cg14289246	chr4:154710475	SFRP2	-0.54	-7.01	-0.41	2.31e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.36	-5.11	-0.31	6.48e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs5750854	0.503	rs5757752	chr22:40025237	G/C	cg21377881	chr22:40064566	CACNA1I	-0.37	-4.93	-0.3	1.52e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs745080	0.596	rs10136942	chr14:53046368	A/G	cg23333723	chr14:53022898	GPR137C	-0.44	-6.18	-0.37	2.62e-9	Orofacial clefts;
KIRP	cis	rs714027	0.605	rs5763797	chr22:30530125	T/C	cg01021169	chr22:30184971	ASCC2	0.47	5.74	0.34	2.73e-8	Lymphocyte counts;
KIRP	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.74	10.15	0.54	1.85e-20	Multiple sclerosis;
KIRP	cis	rs904251	0.600	rs11756241	chr6:37445101	C/T	cg00360474	chr6:37504404	NA	-0.47	-6.6	-0.39	2.57e-10	Cognitive performance;
KIRP	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.61	8.22	0.46	1.15e-14	Mood instability;
KIRP	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg12369402	chr1:90227771	NA	-0.37	-5.39	-0.33	1.65e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg23815491	chr16:72088622	HP	0.48	7.05	0.41	1.78e-11	Blood protein levels;
KIRP	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg08717414	chr16:71523259	ZNF19	-0.49	-5.26	-0.32	3.17e-7	Post bronchodilator FEV1;
KIRP	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.46	5.65	0.34	4.35e-8	Free thyroxine concentration;
KIRP	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg21775007	chr8:11205619	TDH	0.49	6.64	0.39	1.98e-10	Mood instability;
KIRP	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	6.72	0.39	1.25e-10	Mean corpuscular volume;
KIRP	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.87	13.16	0.64	2.7e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10421328	0.821	rs4808976	chr19:19759299	A/T	cg03709012	chr19:19516395	GATAD2A	0.44	5.16	0.31	5.01e-7	Parental longevity (combined parental age at death);
KIRP	cis	rs42648	0.693	rs194533	chr7:89870777	A/G	cg25739043	chr7:89950458	NA	-0.4	-6.3	-0.37	1.38e-9	Homocysteine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16130454	chr11:3818853	PGAP2;NUP98	0.58	7.25	0.42	5.53e-12	Parkinson's disease;
KIRP	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	cg21523751	chr1:182988639	NA	0.45	7.03	0.41	1.99e-11	Hypertriglyceridemia;
KIRP	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg26207909	chr14:103986467	CKB	-0.44	-5.36	-0.32	1.88e-7	Coronary artery disease;
KIRP	cis	rs5753618	0.529	rs5749298	chr22:31941032	C/T	cg02404636	chr22:31891804	SFI1	0.55	6.46	0.38	5.52e-10	Colorectal cancer;
KIRP	cis	rs71277158	0.688	rs77216745	chr3:169913020	A/T	cg04067573	chr3:169899625	PHC3	0.71	6.83	0.4	6.46e-11	Prostate cancer;
KIRP	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.11	11.45	0.59	1.29e-24	Platelet count;
KIRP	cis	rs7011507	1.000	rs55653841	chr8:49176700	C/T	cg15325961	chr8:49183143	NA	0.59	4.99	0.3	1.14e-6	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg11632617	chr15:75315747	PPCDC	-0.64	-5.22	-0.32	3.87e-7	Lung cancer;
KIRP	cis	rs6977660	0.714	rs9969171	chr7:19827328	T/C	cg07541023	chr7:19748670	TWISTNB	0.58	5.56	0.33	6.88e-8	Thyroid stimulating hormone;
KIRP	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg21698718	chr17:80085957	CCDC57	0.37	5.51	0.33	8.9e-8	Life satisfaction;
KIRP	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16447950	chr5:562315	NA	-0.47	-5.68	-0.34	3.78e-8	Obesity-related traits;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg24816464	chr3:86061715	CADM2	0.43	6.4	0.38	7.72e-10	Cancer;
KIRP	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.86	14.51	0.68	6.89e-35	Plasma homocysteine levels (post-methionine load test);
KIRP	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg06333435	chr8:22102724	POLR3D;MIR320A	0.54	6.96	0.41	3.1e-11	Myopia (pathological);
KIRP	cis	rs904251	0.686	rs2776911	chr6:37439950	T/A	cg08126542	chr6:37504118	NA	-0.53	-5.69	-0.34	3.66e-8	Cognitive performance;
KIRP	trans	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-7.76	-0.44	2.27e-13	Colorectal cancer;
KIRP	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg18882449	chr10:104885122	NT5C2	-0.42	-5.39	-0.33	1.61e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.26	-5.7	-0.34	3.45e-8	Type 2 diabetes;
KIRP	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.69	10.07	0.54	3.45e-20	Lymphocyte counts;
KIRP	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.85	12.19	0.61	4.58e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	1.07	19.06	0.77	2.41e-50	Systemic lupus erythematosus;
KIRP	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg04731861	chr2:219085781	ARPC2	-0.28	-7.04	-0.41	1.89e-11	Colorectal cancer;
KIRP	cis	rs1497828	0.956	rs2132994	chr1:217548036	A/G	cg04411442	chr1:217543379	NA	-0.41	-6.17	-0.37	2.79e-9	Dialysis-related mortality;
KIRP	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg21214613	chr1:16344536	HSPB7	0.35	5.29	0.32	2.68e-7	Dilated cardiomyopathy;
KIRP	cis	rs1550582	0.547	rs6991998	chr8:135580221	C/A	cg17885191	chr8:135476712	NA	0.69	6.76	0.4	1.01e-10	Educational attainment;
KIRP	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	6.92	0.4	3.97e-11	Neuroticism;
KIRP	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.0	-10.74	-0.56	2.67e-22	Alzheimer's disease;
KIRP	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg10761708	chr20:43804764	PI3	0.51	5.27	0.32	2.91e-7	Blood protein levels;
KIRP	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.6	0.81	1e-58	Prudent dietary pattern;
KIRP	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg00507259	chr4:95128692	SMARCAD1	-0.4	-5.02	-0.31	9.74e-7	Testicular germ cell tumor;
KIRP	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	5.98	0.36	7.76e-9	Height;
KIRP	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.48	6.26	0.37	1.66e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg04609801	chr16:28609176	SULT1A2	0.51	5.85	0.35	1.58e-8	Platelet distribution width;
KIRP	cis	rs3849570	0.576	rs4425286	chr3:81992365	G/A	cg07356753	chr3:81810745	GBE1	-0.51	-6.67	-0.39	1.66e-10	Waist circumference;Body mass index;
KIRP	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg05347473	chr6:146136440	FBXO30	0.6	8.51	0.48	1.77e-15	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg08975724	chr8:8085496	FLJ10661	0.57	7.47	0.43	1.41e-12	Myopia (pathological);
KIRP	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.02	-0.36	6.31e-9	Morning vs. evening chronotype;
KIRP	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.56	4.96	0.3	1.29e-6	Bipolar disorder;
KIRP	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.65	-7.99	-0.45	5.34e-14	Height;
KIRP	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg24044564	chr13:99115944	STK24	0.52	5.91	0.35	1.13e-8	Obesity-related traits;
KIRP	cis	rs2033908	0.588	rs1899068	chr11:12872156	A/T	cg25843174	chr11:12811716	TEAD1	0.31	5.78	0.35	2.27e-8	Sitting height ratio;
KIRP	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg08662619	chr6:150070041	PCMT1	0.37	6.08	0.36	4.65e-9	Lung cancer;
KIRP	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	0.64	6.06	0.36	5.14e-9	Skin colour saturation;
KIRP	cis	rs838147	0.844	rs8111288	chr19:49247900	G/A	cg13540341	chr19:49222985	MAMSTR	0.35	5.62	0.34	5.06e-8	Dietary macronutrient intake;
KIRP	cis	rs1800795	0.553	rs1524099	chr7:22781657	G/A	cg05472934	chr7:22766657	IL6	0.47	6.25	0.37	1.83e-9	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
KIRP	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.55	-0.7	1.9e-38	Gut microbiome composition (summer);
KIRP	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg06223162	chr1:101003688	GPR88	0.4	7.81	0.45	1.62e-13	Monocyte count;
KIRP	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.57	7.37	0.43	2.66e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-8.11	-0.46	2.43e-14	Retinal vascular caliber;
KIRP	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg12315302	chr6:26189340	HIST1H4D	1.0	6.87	0.4	5.33e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.63	-7.09	-0.41	1.42e-11	Fear of minor pain;
KIRP	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg02569458	chr12:86230093	RASSF9	-0.51	-7.4	-0.43	2.1e-12	Major depressive disorder;
KIRP	cis	rs6580649	0.941	rs1968071	chr12:48489357	A/G	cg26205652	chr12:48591994	NA	-0.5	-5.96	-0.36	8.75e-9	Lung cancer;
KIRP	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg07541023	chr7:19748670	TWISTNB	0.56	5.45	0.33	1.2e-7	Thyroid stimulating hormone;
KIRP	cis	rs13315871	1.000	rs11706420	chr3:58392411	C/T	cg12435725	chr3:58293450	RPP14	0.48	5.17	0.31	4.87e-7	Cholesterol, total;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15623552	chr7:1040260	C7orf50	-0.45	-6.13	-0.36	3.54e-9	Inflammatory biomarkers;
KIRP	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.8	10.8	0.57	1.6e-22	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg07984980	chr16:89898383	SPIRE2	0.42	5.08	0.31	7.62e-7	Vitiligo;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg27509153	chr3:55908649	ERC2	0.44	6.41	0.38	7.4e-10	Interleukin-4 levels;
KIRP	cis	rs62413470	1.000	rs10807508	chr6:55950812	T/C	cg13327911	chr6:55965977	COL21A1	0.56	5.09	0.31	6.97e-7	Joint mobility (Beighton score);
KIRP	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg12692727	chr7:1102344	C7orf50	0.48	5.13	0.31	5.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	5.73	0.34	2.86e-8	Aortic root size;
KIRP	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg18964960	chr10:1102726	WDR37	-0.63	-7.14	-0.41	1.08e-11	Response to angiotensin II receptor blocker therapy;
KIRP	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.83	-0.35	1.76e-8	Life satisfaction;
KIRP	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg02775129	chr4:119771670	NA	-0.79	-4.89	-0.3	1.79e-6	Cannabis dependence symptom count;
KIRP	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg15507776	chr3:136538369	TMEM22	0.39	5.36	0.32	1.87e-7	Neuroticism;
KIRP	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.66	9.19	0.51	1.66e-17	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18494192	chr6:116448231	COL10A1;NT5DC1	0.42	6.16	0.37	3.02e-9	Migraine with aura;
KIRP	cis	rs12367572	0.620	rs2643140	chr12:45418311	C/T	cg04608330	chr12:45269318	NELL2	-0.36	-4.99	-0.3	1.14e-6	Gut microbiome composition (summer);
KIRP	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg23752985	chr2:85803571	VAMP8	0.49	5.45	0.33	1.25e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.54	-6.69	-0.39	1.52e-10	Resistin levels;
KIRP	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs6832769	0.925	rs60992571	chr4:56440812	C/A	cg05960024	chr4:56376020	CLOCK	-0.62	-8.07	-0.46	3.08e-14	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg16069520	chr11:46867881	CKAP5	0.52	6.67	0.39	1.65e-10	Parkinson's disease;
KIRP	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg20607798	chr8:58055168	NA	-0.79	-6.31	-0.37	1.25e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs1215050	0.791	rs984940	chr4:98811756	T/A	cg17366294	chr4:99064904	C4orf37	0.37	5.02	0.3	9.94e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg15556689	chr8:8085844	FLJ10661	-0.58	-7.67	-0.44	4e-13	Neuroticism;
KIRP	cis	rs6580649	0.657	rs57863747	chr12:48470425	G/T	cg26205652	chr12:48591994	NA	-0.5	-5.92	-0.35	1.05e-8	Lung cancer;
KIRP	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg16989719	chr2:238392110	NA	-0.58	-5.89	-0.35	1.28e-8	Prostate cancer;
KIRP	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.68	8.73	0.49	4.08e-16	Prudent dietary pattern;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg26859901	chr19:35759185	USF2	-0.46	-6.09	-0.36	4.41e-9	Metabolic traits;
KIRP	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg23625390	chr15:77176239	SCAPER	0.52	6.88	0.4	5.02e-11	Blood metabolite levels;
KIRP	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg04058563	chr4:185651563	MLF1IP	-0.51	-7.07	-0.41	1.61e-11	Kawasaki disease;
KIRP	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Urate levels;
KIRP	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	6.24	0.37	1.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs311392	1.000	rs454064	chr8:55088336	C/T	cg11783602	chr8:55087084	NA	-0.59	-7.34	-0.42	3.11e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg20169779	chr10:135381914	SYCE1	-0.42	-4.98	-0.3	1.19e-6	Obesity-related traits;
KIRP	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg25801113	chr15:45476975	SHF	0.41	7.43	0.43	1.82e-12	Uric acid levels;
KIRP	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	7.03	0.41	2.07e-11	Obesity-related traits;
KIRP	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg04691961	chr3:161091175	C3orf57	-0.38	-5.65	-0.34	4.53e-8	Morning vs. evening chronotype;
KIRP	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.94	12.95	0.64	1.34e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.5	6.32	0.37	1.22e-9	Mean platelet volume;
KIRP	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg18806716	chr10:30721971	MAP3K8	-0.32	-4.92	-0.3	1.58e-6	Inflammatory bowel disease;
KIRP	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg12315302	chr6:26189340	HIST1H4D	0.86	6.07	0.36	4.86e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-6.12	-0.36	3.64e-9	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs13361707	0.920	rs59133000	chr5:40798974	C/T	cg01087697	chr5:40835557	RPL37	-0.45	-5.12	-0.31	6.28e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg13165212	chr22:42675999	NA	0.28	5.05	0.31	8.78e-7	Cognitive function;
KIRP	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg06671706	chr8:8559999	CLDN23	0.54	6.22	0.37	2.07e-9	Obesity-related traits;
KIRP	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.54	-8.01	-0.45	4.51e-14	Monocyte percentage of white cells;
KIRP	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg01980928	chr19:1952821	C19orf34;CSNK1G2	-0.47	-5.4	-0.33	1.58e-7	Coronary artery disease;
KIRP	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg14820908	chr5:178986412	RUFY1	0.42	5.95	0.35	9.41e-9	Lung cancer;
KIRP	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.58	-6.06	-0.36	5.02e-9	Ulcerative colitis;
KIRP	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg02782426	chr3:40428986	ENTPD3	-0.33	-4.97	-0.3	1.28e-6	Renal cell carcinoma;
KIRP	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12963246	chr6:28129442	ZNF389	0.38	4.86	0.3	2.14e-6	Cardiac Troponin-T levels;
KIRP	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.44	5.66	0.34	4.18e-8	Height;
KIRP	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-11.84	-0.6	6.9e-26	Longevity;
KIRP	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-0.74	-5.79	-0.35	2.14e-8	IgG glycosylation;
KIRP	trans	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg00405596	chr8:11794950	NA	-0.45	-6.04	-0.36	5.79e-9	Joint mobility (Beighton score);
KIRP	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg24289452	chr6:170231220	NA	-0.74	-4.86	-0.3	2.07e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10761482	0.861	rs4948406	chr10:62110146	G/T	cg01186212	chr10:62110162	ANK3	-0.29	-5.01	-0.3	1.05e-6	Schizophrenia;
KIRP	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.86	-8.61	-0.48	8.92e-16	Coronary artery calcification;
KIRP	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.74	7.49	0.43	1.2e-12	Uric acid levels;
KIRP	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.82	8.45	0.47	2.49e-15	Phospholipid levels (plasma);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg02860732	chr16:12995292	SHISA9	0.45	6.37	0.38	9.07e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	0.93	13.51	0.65	1.74e-31	Dupuytren's disease;
KIRP	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.72	0.44	2.97e-13	Crohn's disease;Inflammatory bowel disease;
KIRP	trans	rs11240594	0.512	rs9438403	chr1:205894469	A/G	cg05440289	chr1:152881119	IVL	-0.63	-6.02	-0.36	6.44e-9	Response to antipsychotic treatment;
KIRP	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg24812749	chr6:127587940	RNF146	0.48	6.21	0.37	2.29e-9	Breast cancer;
KIRP	cis	rs6694270	0.913	rs11261069	chr1:19117300	C/G	cg26220594	chr1:19110978	NA	-0.46	-5.17	-0.31	4.74e-7	Drug-induced liver injury (nitrofurantoin);
KIRP	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.53	-6.83	-0.4	6.57e-11	Type 2 diabetes;
KIRP	cis	rs3803915	1.000	rs3803915	chr19:2160529	C/A	cg09261902	chr19:2140048	AP3D1	-0.56	-4.96	-0.3	1.3e-6	Body mass index;Myocardial infarction;
KIRP	cis	rs661054	0.780	rs12794122	chr11:114440804	G/A	cg19465033	chr11:114479364	NA	0.44	5.29	0.32	2.75e-7	Ulcerative colitis;
KIRP	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg20936604	chr3:58311152	NA	-0.68	-5.23	-0.32	3.64e-7	Cholesterol, total;
KIRP	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.5	5.84	0.35	1.66e-8	Menarche (age at onset);
KIRP	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.76	10.66	0.56	4.74e-22	Dupuytren's disease;
KIRP	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg12369402	chr1:90227771	NA	-0.36	-5.33	-0.32	2.23e-7	Amyotrophic lateral sclerosis (sporadic);
KIRP	cis	rs72781680	0.581	rs116520786	chr2:24272645	C/T	cg08917208	chr2:24149416	ATAD2B	0.67	5.93	0.35	1.05e-8	Lymphocyte counts;
KIRP	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.68	9.19	0.51	1.75e-17	Schizophrenia;
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg16140139	chr2:44126665	LRPPRC	0.37	6.15	0.37	3.08e-9	C-reactive protein;
KIRP	cis	rs35000415	0.688	rs34350562	chr7:128718708	A/G	cg19972273	chr7:128594194	NA	0.61	5.04	0.31	9.2e-7	Systemic lupus erythematosus;
KIRP	cis	rs2151522	0.624	rs12234163	chr6:127202735	G/A	cg21431617	chr6:127135037	NA	0.31	5.31	0.32	2.41e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.48	-8.29	-0.47	7.61e-15	Cystic fibrosis severity;
KIRP	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-9.05	-0.5	4.49e-17	Parkinson's disease;
KIRP	cis	rs526231	0.543	rs257303	chr5:102416727	A/G	cg23492399	chr5:102201601	PAM	-0.49	-5.41	-0.33	1.48e-7	Primary biliary cholangitis;
KIRP	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.73	9.0	0.5	6.33e-17	Menopause (age at onset);
KIRP	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.47	4.89	0.3	1.81e-6	Schizophrenia;
KIRP	cis	rs2562456	0.754	rs112195516	chr19:21593651	A/G	cg18461458	chr19:21324796	ZNF431	-0.52	-4.88	-0.3	1.92e-6	Pain;
KIRP	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.58	7.48	0.43	1.29e-12	Lung cancer;
KIRP	cis	rs7395581	0.877	rs10838691	chr11:47341729	T/C	cg26139080	chr11:47293733	MADD	-0.43	-5.27	-0.32	2.95e-7	HDL cholesterol;
KIRP	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs11718455	0.767	rs6771202	chr3:43990087	A/T	cg08738300	chr3:44038990	NA	0.64	8.69	0.48	5.11e-16	Coronary artery disease;
KIRP	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg10932868	chr11:921992	NA	0.67	9.07	0.5	3.97e-17	Alzheimer's disease (late onset);
KIRP	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg01631408	chr1:248437212	OR2T33	-0.72	-9.56	-0.52	1.25e-18	Common traits (Other);
KIRP	cis	rs7123876	0.717	rs58249351	chr11:72463462	G/A	cg03713592	chr11:72463424	ARAP1	0.54	6.15	0.36	3.15e-9	Body mass index;
KIRP	cis	rs3736485	0.934	rs17609791	chr15:51874824	C/T	cg14296394	chr15:51910925	DMXL2	-0.34	-5.05	-0.31	8.55e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg00977110	chr5:151150581	G3BP1	0.62	6.21	0.37	2.2e-9	Preschool internalizing problems;
KIRP	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-7.38	-0.43	2.5e-12	Aortic root size;
KIRP	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg25036284	chr2:26402008	FAM59B	-0.5	-5.25	-0.32	3.28e-7	Gut microbiome composition (summer);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg18775145	chr11:133992111	JAM3	0.45	6.48	0.38	4.93e-10	Interleukin-4 levels;
KIRP	cis	rs282587	0.569	rs1278658	chr13:113386832	G/C	cg04656015	chr13:113407548	ATP11A	0.66	8.0	0.45	4.8e-14	Glycated hemoglobin levels;
KIRP	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.5	7.21	0.42	6.78e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.41	-5.65	-0.34	4.35e-8	Blood metabolite levels;
KIRP	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	6.55	0.39	3.34e-10	Neuroticism;
KIRP	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.78	9.99	0.54	5.96e-20	Coronary artery disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg00014285	chr2:200716175	NA	0.44	6.04	0.36	5.61e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9840812	0.592	rs1711161	chr3:136080537	G/T	cg15507776	chr3:136538369	TMEM22	0.41	5.09	0.31	6.97e-7	Fibrinogen levels;
KIRP	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.89	0.35	1.24e-8	Monocyte percentage of white cells;
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg18656765	chr4:159644664	PPID	0.6	6.57	0.39	2.97e-10	Lung cancer in ever smokers;
KIRP	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.71	8.27	0.47	8.39e-15	Menarche (age at onset);
KIRP	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg24851858	chr13:114927579	NA	0.41	4.93	0.3	1.48e-6	Schizophrenia;
KIRP	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs6681460	0.834	rs544258	chr1:67219209	T/C	cg02459107	chr1:67143332	SGIP1	-0.43	-5.94	-0.35	9.48e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06481639	chr22:41940642	POLR3H	0.7	7.2	0.42	7.33e-12	Vitiligo;
KIRP	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05165339	chr4:1420672	NA	-0.32	-4.88	-0.3	1.88e-6	Longevity;
KIRP	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.58	7.92	0.45	8.23e-14	Menarche (age at onset);
KIRP	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.53	-8.04	-0.46	3.71e-14	Huntington's disease progression;
KIRP	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.63	7.46	0.43	1.46e-12	Height;
KIRP	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.99	-0.41	2.63e-11	Blood pressure;
KIRP	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-6.43	-0.38	6.61e-10	QT interval;
KIRP	cis	rs9328573	1.000	rs8037666	chr15:100512079	C/T	cg09918751	chr15:100517450	ADAMTS17	0.38	5.29	0.32	2.75e-7	Urate levels in lean individuals;
KIRP	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	1.22	20.24	0.79	2.73e-54	Total cholesterol levels;
KIRP	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.71	-10.07	-0.54	3.33e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.68	-9.55	-0.52	1.37e-18	Mean corpuscular volume;
KIRP	cis	rs981844	0.775	rs62323976	chr4:154739032	A/G	cg14289246	chr4:154710475	SFRP2	0.66	7.73	0.44	2.77e-13	Response to statins (LDL cholesterol change);
KIRP	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg10169327	chr19:45448959	APOC2	0.33	4.97	0.3	1.23e-6	Blood protein levels;
KIRP	cis	rs1800682	0.528	rs4934434	chr10:90747169	C/A	cg03111039	chr10:90751583	FAS;ACTA2	0.57	7.25	0.42	5.27e-12	Chronic lymphocytic leukemia;
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg01763666	chr17:80159506	CCDC57	0.37	4.94	0.3	1.43e-6	Life satisfaction;
KIRP	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.7	5.76	0.34	2.45e-8	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs7656342	0.599	rs10939561	chr4:9851542	T/G	cg11266682	chr4:10021025	SLC2A9	-0.38	-5.88	-0.35	1.33e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg16898833	chr6:26189333	HIST1H4D	-0.82	-5.76	-0.34	2.53e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs9409565	0.826	rs9409550	chr9:97223294	C/G	cg05679027	chr9:99775184	HIATL2	-0.55	-6.67	-0.39	1.67e-10	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs7116495	1.000	rs1939247	chr11:71740521	A/T	cg26138937	chr11:71823887	C11orf51	-0.71	-5.69	-0.34	3.61e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-0.57	-8.29	-0.47	7.48e-15	Coronary artery disease;
KIRP	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	6.22	0.37	2.08e-9	Mean platelet volume;
KIRP	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg06565975	chr8:143823917	SLURP1	0.47	7.35	0.42	2.99e-12	Urinary tract infection frequency;
KIRP	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg16141378	chr3:129829833	LOC729375	0.48	6.31	0.37	1.29e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg05220968	chr6:146057943	EPM2A	0.4	5.06	0.31	8.13e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.39	5.12	0.31	6.04e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg14675211	chr2:100938903	LONRF2	0.49	6.38	0.38	8.59e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs13102973	0.965	rs4535381	chr4:135861313	A/T	cg14419869	chr4:135874104	NA	0.53	8.85	0.49	1.72e-16	Subjective well-being;
KIRP	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg20607798	chr8:58055168	NA	0.62	4.85	0.3	2.2e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs1365505	0.587	rs4238382	chr15:50484746	T/A	cg26188685	chr15:50540269	HDC	-0.39	-6.33	-0.37	1.14e-9	Blood metabolite ratios;
KIRP	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.55	6.95	0.41	3.19e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.69	-7.8	-0.45	1.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg02160872	chr5:212506	CCDC127	-0.46	-5.02	-0.3	1.01e-6	Breast cancer;
KIRP	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	1.13	17.21	0.74	4.33e-44	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.5	7.22	0.42	6.36e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg04935436	chr20:30431758	NA	0.53	6.43	0.38	6.48e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs4478037	1.000	rs57477065	chr3:33162532	A/C	cg19404215	chr3:33155277	CRTAP	0.73	6.78	0.4	8.88e-11	Major depressive disorder;
KIRP	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg08885076	chr2:99613938	TSGA10	0.46	7.83	0.45	1.42e-13	Chronic sinus infection;
KIRP	cis	rs4262150	0.810	rs115323899	chr5:151953203	C/A	cg12297329	chr5:152029980	NA	-0.67	-8.24	-0.46	1.06e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6832769	0.826	rs10462035	chr4:56379178	G/A	cg09317128	chr4:56265301	TMEM165	0.55	7.01	0.41	2.27e-11	Personality dimensions;
KIRP	cis	rs6969780	0.915	rs2107063	chr7:27167346	G/A	cg16651126	chr7:27170552	HOXA4	-0.37	-5.06	-0.31	8.04e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	6.05	0.36	5.29e-9	Bipolar disorder;
KIRP	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.71	-9.98	-0.54	6.38e-20	Blood metabolite levels;
KIRP	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.43	6.07	0.36	4.84e-9	Testicular germ cell tumor;
KIRP	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.84	-10.39	-0.55	3.26e-21	Menarche (age at onset);
KIRP	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.73	9.61	0.52	8.97e-19	Prudent dietary pattern;
KIRP	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.91	14.97	0.69	1.83e-36	IgG glycosylation;
KIRP	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	6.78	0.4	8.77e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-5.21	-0.32	3.93e-7	Parkinson's disease;
KIRP	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.65	8.09	0.46	2.69e-14	Response to bleomycin (chromatid breaks);
KIRP	cis	rs10782582	0.609	rs5745394	chr1:76311731	G/A	cg10523679	chr1:76189770	ACADM	-0.45	-6.3	-0.37	1.39e-9	Daytime sleep phenotypes;
KIRP	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.74	-10.54	-0.56	1.09e-21	Height;
KIRP	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-0.63	-6.99	-0.41	2.61e-11	Initial pursuit acceleration;
KIRP	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	5.96	0.36	8.75e-9	Motion sickness;
KIRP	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.66	-11.03	-0.58	3.05e-23	Menopause (age at onset);
KIRP	cis	rs2235642	0.582	rs2235637	chr16:1567694	G/A	cg07639376	chr16:1584516	IFT140;TMEM204	-0.19	-5.35	-0.32	2.03e-7	Coronary artery disease;
KIRP	cis	rs9660180	0.967	rs66701417	chr1:1698092	A/G	cg20999797	chr1:1681921	NA	0.56	8.55	0.48	1.32e-15	Body mass index;
KIRP	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg22356347	chr1:167427500	CD247	-0.48	-6.54	-0.38	3.55e-10	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg11555438	chr13:111297484	CARS2	0.36	5.84	0.35	1.61e-8	Coronary artery disease;
KIRP	cis	rs1215050	0.791	rs1215049	chr4:98848280	C/T	cg05340658	chr4:99064831	C4orf37	0.54	6.51	0.38	4.17e-10	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg08461772	chr7:95026248	PON3	-0.41	-6.0	-0.36	7.12e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-1.0	-15.03	-0.69	1.2e-36	Coronary artery disease;
KIRP	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg04438997	chr17:70115868	SOX9	0.35	4.86	0.3	2.08e-6	Thyroid hormone levels;
KIRP	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.57	7.48	0.43	1.34e-12	Aortic root size;
KIRP	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.57	-8.11	-0.46	2.44e-14	Extrinsic epigenetic age acceleration;
KIRP	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg00262122	chr8:11665843	FDFT1	0.41	5.14	0.31	5.72e-7	Neuroticism;
KIRP	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.01	16.84	0.73	7.42e-43	Multiple system atrophy;
KIRP	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg01294253	chr9:136912663	BRD3	0.45	5.79	0.35	2.09e-8	Platelet distribution width;
KIRP	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg02160872	chr5:212506	CCDC127	-0.45	-4.88	-0.3	1.88e-6	Breast cancer;
KIRP	cis	rs2979489	0.891	rs17552243	chr8:30362627	T/C	cg26383811	chr8:30366931	RBPMS	-0.44	-5.86	-0.35	1.45e-8	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg26876637	chr1:152193138	HRNR	-0.78	-9.22	-0.51	1.34e-17	Atopic dermatitis;
KIRP	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	1.03	12.68	0.63	1.05e-28	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg05692746	chr2:100937584	LONRF2	-0.39	-5.15	-0.31	5.37e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.59	6.3	0.37	1.4e-9	Alcohol dependence;
KIRP	cis	rs2071403	0.933	rs12328062	chr2:1400567	C/T	cg06500727	chr2:1417164	TPO	-0.47	-7.33	-0.42	3.34e-12	Thyroid peroxidase antibody positivity;
KIRP	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg16988262	chr1:15930761	NA	0.38	4.87	0.3	1.97e-6	Systolic blood pressure;
KIRP	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.8	-11.59	-0.59	4.62e-25	Total body bone mineral density;
KIRP	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg08499158	chr17:42289980	UBTF	0.51	6.56	0.39	3.14e-10	Total body bone mineral density;
KIRP	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	cis	rs4722166	0.598	rs4722178	chr7:22798650	T/C	cg05472934	chr7:22766657	IL6	0.49	6.86	0.4	5.55e-11	Lung cancer;
KIRP	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.65	6.36	0.38	9.59e-10	Axial length;
KIRP	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.46	-5.78	-0.35	2.29e-8	Blood metabolite levels;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg17782706	chr4:184580436	C4orf41;RWDD4A	0.51	6.06	0.36	5.2e-9	Smoking initiation;
KIRP	cis	rs12137294	0.866	rs1172156	chr1:205220087	C/T	cg21643547	chr1:205240462	TMCC2	-0.48	-6.78	-0.4	8.61e-11	Red cell distribution width;
KIRP	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg19913688	chr11:428466	ANO9	-0.67	-5.05	-0.31	8.57e-7	Body mass index;
KIRP	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg13906792	chr15:75199810	C15orf17	-0.37	-5.34	-0.32	2.07e-7	Breast cancer;
KIRP	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.63	-7.29	-0.42	4.28e-12	IgG glycosylation;
KIRP	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg23479056	chr15:41276147	INO80	-0.36	-4.88	-0.3	1.87e-6	Menopause (age at onset);
KIRP	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.78	11.25	0.58	6.03e-24	Blood metabolite ratios;
KIRP	cis	rs12900413	0.687	rs12913409	chr15:90319251	T/A	cg24650279	chr15:90327240	NA	-0.4	-5.05	-0.31	8.5e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.81	-0.49	2.37e-16	Response to antipsychotic treatment;
KIRP	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.21	5.54	0.33	7.71e-8	Primary biliary cholangitis;
KIRP	cis	rs7394190	0.748	rs79936644	chr10:75545117	C/T	cg04833713	chr10:74871078	NUDT13	0.43	4.86	0.3	2.1e-6	Incident atrial fibrillation;
KIRP	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.43	-9.15	-0.5	2.22e-17	Longevity;
KIRP	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.33	6.05	0.36	5.31e-9	Renal cell carcinoma;
KIRP	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg04998671	chr14:104000505	TRMT61A	-0.57	-6.8	-0.4	7.71e-11	Coronary artery disease;
KIRP	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg06521331	chr12:34319734	NA	-0.62	-7.46	-0.43	1.5e-12	Morning vs. evening chronotype;
KIRP	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.59	6.8	0.4	7.68e-11	Corneal astigmatism;
KIRP	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg03959625	chr15:84868606	LOC388152	0.72	8.6	0.48	9.33e-16	Schizophrenia;
KIRP	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.62	-11.53	-0.59	7.35e-25	Intelligence (multi-trait analysis);
KIRP	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	1.02	16.01	0.71	5.18e-40	Alcohol dependence;
KIRP	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-6.68	-0.39	1.56e-10	Obesity-related traits;
KIRP	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.52	-6.71	-0.39	1.3e-10	Body mass index;
KIRP	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg14673194	chr17:80132900	CCDC57	-0.77	-8.66	-0.48	6.54e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.5	7.13	0.41	1.11e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.76	9.48	0.52	2.28e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs478607	0.831	rs11602411	chr11:64449223	A/G	cg09231725	chr11:64357281	SLC22A12	0.62	5.01	0.3	1.06e-6	Urate levels;
KIRP	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg25319279	chr11:5960081	NA	-0.56	-6.18	-0.37	2.6e-9	DNA methylation (variation);
KIRP	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg20243544	chr17:37824526	PNMT	-0.43	-4.88	-0.3	1.89e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg04080417	chr5:1859792	NA	-0.48	-5.45	-0.33	1.22e-7	Cardiovascular disease risk factors;
KIRP	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.36	-0.55	4.07e-21	Hemoglobin concentration;
KIRP	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-8.42	-0.47	3.19e-15	Retinal vascular caliber;
KIRP	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg13334819	chr7:99746414	C7orf59	0.53	6.01	0.36	6.53e-9	Coronary artery disease;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg10207240	chr12:122356781	WDR66	-0.56	-7.6	-0.44	6.19e-13	Mean corpuscular volume;
KIRP	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg13147721	chr7:65941812	NA	1.04	7.24	0.42	5.57e-12	Diabetic kidney disease;
KIRP	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.43	-5.8	-0.35	1.99e-8	Homoarginine levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11283154	chr5:55008216	SLC38A9	0.49	6.41	0.38	7.18e-10	Parkinson's disease;
KIRP	cis	rs7601312	0.903	rs7598908	chr2:229297832	A/T	cg02542817	chr2:229291442	NA	0.56	8.62	0.48	8.17e-16	Schizophrenia;
KIRP	cis	rs10782582	0.609	rs1770889	chr1:76401166	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.48	-0.38	4.98e-10	Daytime sleep phenotypes;
KIRP	cis	rs2651899	0.902	rs1624023	chr1:3079337	C/T	cg01413848	chr1:3081226	PRDM16	0.4	5.35	0.32	2.06e-7	Migraine;
KIRP	cis	rs112591243	0.685	rs117443865	chr21:47959731	C/G	cg26904215	chr21:47823096	PCNT	-0.79	-5.78	-0.35	2.27e-8	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-1.1	-8.97	-0.5	7.95e-17	Body mass index;
KIRP	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.43	5.74	0.34	2.8e-8	Blood metabolite levels;
KIRP	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg17372223	chr3:52568218	NT5DC2	0.32	5.06	0.31	8.05e-7	Electroencephalogram traits;
KIRP	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.68	10.23	0.55	1.06e-20	Dupuytren's disease;
KIRP	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg18944383	chr4:111397179	ENPEP	0.68	12.19	0.61	4.55e-27	Coronary artery disease;
KIRP	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.6	-8.79	-0.49	2.7e-16	Educational attainment;
KIRP	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.46	-5.72	-0.34	3.12e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	trans	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg00405596	chr8:11794950	NA	-0.46	-6.09	-0.36	4.34e-9	Joint mobility (Beighton score);
KIRP	cis	rs71520386	0.632	rs12535331	chr7:22878104	G/T	cg15401507	chr7:22894281	NA	-0.39	-4.93	-0.3	1.55e-6	Fibrinogen levels;
KIRP	cis	rs981844	0.712	rs55656103	chr4:154757478	T/C	cg14289246	chr4:154710475	SFRP2	0.57	7.06	0.41	1.7e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs710913	0.816	rs1727098	chr1:39989327	C/T	cg27567593	chr1:39956653	BMP8A	0.34	5.08	0.31	7.64e-7	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg18093559	chr17:18951025	GRAP	0.55	6.62	0.39	2.27e-10	Schizophrenia;
KIRP	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg16339924	chr4:17578868	LAP3	-0.47	-6.07	-0.36	4.89e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg08076091	chr2:203926405	NBEAL1	0.86	9.08	0.5	3.72e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg24331049	chr13:111365604	ING1	0.93	12.34	0.62	1.54e-27	Coronary artery disease;
KIRP	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg13385521	chr17:29058706	SUZ12P	0.59	5.85	0.35	1.58e-8	Body mass index;
KIRP	cis	rs17020663	0.723	rs12474501	chr2:101642843	A/C	cg12594615	chr2:101643137	TBC1D8	0.34	5.0	0.3	1.11e-6	Pulse pressure;
KIRP	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.79	-7.98	-0.45	5.68e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.31	5.76	0.34	2.55e-8	Monocyte percentage of white cells;
KIRP	cis	rs4728302	0.607	rs6970436	chr7:133614710	A/G	cg10665199	chr7:133106180	EXOC4	0.42	4.96	0.3	1.32e-6	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs8054556	1.000	rs4283241	chr16:29988349	A/G	cg06326092	chr16:30034487	C16orf92	-0.38	-5.56	-0.33	7.11e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	6.69	0.39	1.47e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-1.06	-14.82	-0.69	5.92e-36	Alopecia areata;
KIRP	cis	rs6467136	0.818	rs4551267	chr7:127175236	C/T	cg08586737	chr7:127225949	GCC1	-0.38	-5.2	-0.31	4.18e-7	Type 2 diabetes;
KIRP	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg07701084	chr6:150067640	NUP43	0.75	10.39	0.55	3.41e-21	Lung cancer;
KIRP	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg26751094	chr13:95954534	ABCC4	-0.7	-9.67	-0.52	5.81e-19	Blood metabolite levels;
KIRP	cis	rs2131877	0.529	rs4677813	chr3:194863860	T/C	cg13868855	chr3:194833887	C3orf21	-0.46	-5.14	-0.31	5.52e-7	Non-small cell lung cancer;
KIRP	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg05784532	chr1:230284198	GALNT2	0.42	6.37	0.38	9.41e-10	Coronary artery disease;
KIRP	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.29	-5.65	-0.34	4.4e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg04607699	chr11:48328132	OR4S1	-0.39	-5.54	-0.33	7.88e-8	Migraine - clinic-based;
KIRP	cis	rs2033732	0.601	rs12681393	chr8:85033078	C/G	cg05716166	chr8:85095498	RALYL	0.56	5.13	0.31	5.9e-7	Body mass index;
KIRP	cis	rs2898681	0.614	rs962416	chr4:53695657	G/T	cg00338735	chr4:53728038	RASL11B	-0.42	-5.31	-0.32	2.4e-7	Optic nerve measurement (cup area);
KIRP	cis	rs7712401	0.601	rs442427	chr5:122322265	T/C	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	cis	rs12220238	0.554	rs11001029	chr10:76154777	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.67	6.29	0.37	1.48e-9	Soluble interleukin-2 receptor subunit alpha;
KIRP	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.62	-8.1	-0.46	2.65e-14	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.3	4.97	0.3	1.24e-6	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.6	8.27	0.47	8.26e-15	Morning vs. evening chronotype;
KIRP	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.65	-8.46	-0.47	2.35e-15	Corneal astigmatism;
KIRP	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.65	5.96	0.36	8.85e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.5	6.49	0.38	4.82e-10	Testicular germ cell tumor;
KIRP	cis	rs501120	0.584	rs617019	chr10:44737246	A/G	cg09554077	chr10:44749378	NA	-0.64	-6.74	-0.39	1.1e-10	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.49	7.33	0.42	3.29e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4073416	0.542	rs12433597	chr14:66028847	T/C	cg03016385	chr14:66212404	NA	-0.53	-6.36	-0.38	9.84e-10	N-glycan levels;
KIRP	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg05665937	chr4:1216051	CTBP1	0.44	5.7	0.34	3.46e-8	Obesity-related traits;
KIRP	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.72	10.02	0.54	5.05e-20	Menopause (age at onset);
KIRP	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.95	12.59	0.63	2.25e-28	Homoarginine levels;
KIRP	cis	rs2384207	0.584	rs73192858	chr12:113765822	G/A	cg13296563	chr12:112847257	RPL6	-0.6	-4.92	-0.3	1.61e-6	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	1.0	14.59	0.68	3.71e-35	Cognitive function;
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg10729496	chr3:10149963	C3orf24	0.55	4.95	0.3	1.41e-6	Alzheimer's disease;
KIRP	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.53	5.2	0.31	4.25e-7	Alzheimer's disease;
KIRP	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg03563238	chr19:33554763	RHPN2	-0.34	-5.93	-0.35	1.01e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.47	6.37	0.38	9.41e-10	Testicular germ cell tumor;
KIRP	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.9	-9.01	-0.5	5.98e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg19592336	chr6:28129416	ZNF389	0.48	5.61	0.34	5.45e-8	Depression;
KIRP	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg24879335	chr3:133465180	TF	0.39	5.8	0.35	2.05e-8	Iron status biomarkers;
KIRP	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.78	8.83	0.49	1.98e-16	Corneal astigmatism;
KIRP	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-6.13	-0.36	3.48e-9	Mood instability;
KIRP	cis	rs9304742	0.646	rs10408610	chr19:53463913	G/A	cg09503522	chr19:53445286	ZNF321	-0.4	-5.02	-0.3	9.8e-7	Psoriasis;
KIRP	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.58	-7.62	-0.44	5.39e-13	Mood instability;
KIRP	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.68	9.7	0.53	4.91e-19	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10056811	0.538	rs4632781	chr5:74376658	G/C	cg19683494	chr5:74908142	NA	0.56	5.0	0.3	1.07e-6	Coronary artery disease;
KIRP	cis	rs4919087	0.748	rs1147600	chr10:98981643	T/C	cg25902810	chr10:99078978	FRAT1	-0.46	-4.85	-0.3	2.21e-6	Monocyte count;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02219607	chr4:70504750	UGT2A2;UGT2A1	-0.41	-6.07	-0.36	4.71e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.78	10.23	0.55	1.04e-20	Eye color traits;
KIRP	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.38	7.42	0.43	1.87e-12	Height;
KIRP	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg20673091	chr1:2541236	MMEL1	0.68	10.48	0.56	1.76e-21	Ulcerative colitis;
KIRP	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg24009623	chr19:33667908	NA	0.47	5.71	0.34	3.18e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-10.63	-0.56	5.75e-22	Height;
KIRP	cis	rs883565	1.000	rs883565	chr3:39055317	C/T	cg01426195	chr3:39028469	NA	-0.52	-7.1	-0.41	1.32e-11	Handedness;
KIRP	cis	rs2380205	0.967	rs7903875	chr10:5888785	A/G	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	cis	rs911119	0.913	rs6048928	chr20:23585988	A/G	cg16589663	chr20:23618590	CST3	0.67	6.35	0.38	1.02e-9	Chronic kidney disease;
KIRP	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.65	-9.42	-0.51	3.45e-18	Schizophrenia;
KIRP	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.43	8.42	0.47	3.08e-15	Coronary artery disease;
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.6	8.07	0.46	3.18e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7106204	0.764	rs79427715	chr11:24247046	G/A	ch.11.24196551F	chr11:24239977	NA	0.89	8.12	0.46	2.32e-14	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18932078	chr1:2524107	MMEL1	0.45	6.22	0.37	2.13e-9	Ulcerative colitis;
KIRP	cis	rs8141529	0.600	rs916332	chr22:29308414	C/T	cg02153584	chr22:29168773	CCDC117	0.62	5.98	0.36	7.87e-9	Lymphocyte counts;
KIRP	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg17410650	chr12:54324560	NA	-0.47	-6.46	-0.38	5.53e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
KIRP	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-12.19	-0.61	4.9e-27	Lymphocyte percentage of white cells;
KIRP	cis	rs9912468	0.933	rs12601850	chr17:64302652	C/T	cg19474267	chr17:64306194	PRKCA	0.56	8.07	0.46	3.16e-14	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
KIRP	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg07805332	chr3:99536008	MIR548G;C3orf26	0.38	5.03	0.31	9.45e-7	Axial length;
KIRP	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.84	-9.58	-0.52	1.11e-18	Exhaled nitric oxide output;
KIRP	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg02534363	chr3:47050950	NBEAL2	-0.29	-4.96	-0.3	1.29e-6	Colorectal cancer;
KIRP	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.7	10.49	0.56	1.58e-21	Prostate cancer;
KIRP	cis	rs300890	0.513	rs12500240	chr4:144072660	G/A	cg01719995	chr4:144104893	USP38	-0.43	-5.51	-0.33	9.16e-8	Nasopharyngeal carcinoma;
KIRP	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg05370193	chr1:21551575	ECE1	0.46	6.08	0.36	4.45e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6838801	0.765	rs10213183	chr4:77599601	T/C	cg17476223	chr4:77663285	SHROOM3	0.53	7.27	0.42	4.91e-12	Cleft lip with or without cleft palate;
KIRP	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg01411142	chr8:19674711	INTS10	0.51	5.66	0.34	4.13e-8	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.68	9.82	0.53	2e-19	Lymphocyte counts;
KIRP	cis	rs12496230	0.830	rs4856963	chr3:66858357	A/T	cg04995300	chr3:66848608	NA	0.44	6.86	0.4	5.49e-11	Type 2 diabetes;
KIRP	cis	rs12476592	0.602	rs6546019	chr2:63817440	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-5.04	-0.31	9.19e-7	Childhood ear infection;
KIRP	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.75	-7.55	-0.43	8.72e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg16989719	chr2:238392110	NA	-0.54	-7.58	-0.44	7.12e-13	Prostate cancer;
KIRP	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.77	-8.63	-0.48	7.69e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4494114	0.875	rs7518432	chr1:39363522	G/C	cg25970120	chr1:39325951	RRAGC	-0.4	-5.14	-0.31	5.61e-7	Blood protein levels;
KIRP	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.71	-8.32	-0.47	6.04e-15	Longevity;Endometriosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg14737332	chr10:114709880	TCF7L2	-0.51	-6.12	-0.36	3.66e-9	Interleukin-4 levels;
KIRP	cis	rs3105593	1.000	rs28718130	chr15:50909489	G/A	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.51e-7	QT interval;
KIRP	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg27432699	chr2:27873401	GPN1	-0.51	-6.66	-0.39	1.81e-10	Total body bone mineral density;
KIRP	cis	rs2637030	0.559	rs423014	chr5:52894598	A/G	cg06476337	chr5:52856530	NDUFS4	0.56	6.25	0.37	1.83e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.8	12.48	0.62	5.09e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg05991184	chr2:219186017	PNKD	-0.38	-5.63	-0.34	4.93e-8	Colorectal cancer;
KIRP	cis	rs1448094	0.781	rs7959093	chr12:86335502	C/A	cg00310523	chr12:86230176	RASSF9	0.41	6.38	0.38	8.52e-10	Major depressive disorder;
KIRP	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg17470723	chr8:74884337	TCEB1	0.65	8.38	0.47	3.98e-15	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg21775007	chr8:11205619	TDH	-0.42	-5.5	-0.33	9.65e-8	Neuroticism;
KIRP	cis	rs651907	0.640	rs771573	chr3:101620896	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.42	-4.92	-0.3	1.59e-6	Colorectal cancer;
KIRP	cis	rs2380205	0.967	rs10795590	chr10:5889086	C/T	cg27141509	chr10:5886111	NA	-0.4	-5.72	-0.34	3.09e-8	Breast cancer;
KIRP	cis	rs11249608	0.789	rs1969025	chr5:178425192	A/G	cg21905437	chr5:178450457	ZNF879	0.47	5.41	0.33	1.52e-7	Pubertal anthropometrics;
KIRP	cis	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08380311	chr19:3435252	NFIC	0.63	6.67	0.39	1.64e-10	Height;
KIRP	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07080220	chr10:102295463	HIF1AN	0.75	7.33	0.42	3.29e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg13976753	chr1:24681532	GRHL3	0.61	7.68	0.44	3.83e-13	Interleukin-4 levels;
KIRP	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg06618935	chr21:46677482	NA	0.44	5.01	0.3	1.03e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.98	-12.37	-0.62	1.18e-27	Alzheimer's disease;
KIRP	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.65	-7.5	-0.43	1.18e-12	Type 2 diabetes;
KIRP	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-7.21	-0.42	6.76e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.2	14.15	0.67	1.17e-33	Corneal structure;
KIRP	cis	rs4356975	0.522	rs7693957	chr4:69971796	T/A	cg27372994	chr4:70080453	UGT2B11	0.41	5.42	0.33	1.39e-7	Obesity-related traits;
KIRP	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.88	12.68	0.63	1.07e-28	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg01849789	chr22:41697279	ZC3H7B	-0.43	-5.19	-0.31	4.44e-7	Neuroticism;
KIRP	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg22732515	chr19:44031385	ETHE1	0.62	8.93	0.49	1.02e-16	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	1.07	13.63	0.66	6.62e-32	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs3126085	1.000	rs72696963	chr1:152181189	T/C	cg26876637	chr1:152193138	HRNR	-0.85	-8.46	-0.47	2.4e-15	Atopic dermatitis;
KIRP	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.68	-8.26	-0.47	9.26e-15	Blood protein levels;
KIRP	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg13703089	chr14:106090767	NA	-0.35	-4.87	-0.3	2.04e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
KIRP	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg24315340	chr6:146058215	EPM2A	-0.42	-5.26	-0.32	3.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.55	5.8	0.35	2.01e-8	Vitiligo;
KIRP	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.4	-0.33	1.6e-7	Pulmonary function;
KIRP	cis	rs2299587	0.543	rs12546204	chr8:17796871	A/C	cg01800426	chr8:17659068	MTUS1	-0.53	-6.17	-0.37	2.76e-9	Economic and political preferences;
KIRP	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.64	6.99	0.41	2.51e-11	Gut microbiome composition (summer);
KIRP	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.58	-7.45	-0.43	1.57e-12	Iron status biomarkers;
KIRP	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg00086871	chr4:6988644	TBC1D14	1.07	8.57	0.48	1.13e-15	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.46	5.83	0.35	1.75e-8	Life satisfaction;
KIRP	cis	rs7623687	0.579	rs73082331	chr3:48994943	G/A	cg19401529	chr3:49056140	DALRD3	1.03	6.54	0.38	3.58e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
KIRP	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg21433313	chr16:3507492	NAT15	0.56	7.86	0.45	1.24e-13	Tuberculosis;
KIRP	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg19784848	chr5:219127	SDHA;CCDC127	0.48	5.07	0.31	7.88e-7	Breast cancer;
KIRP	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg22563815	chr15:78856949	CHRNA5	0.51	7.86	0.45	1.23e-13	Sudden cardiac arrest;
KIRP	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg08648136	chr8:956695	NA	0.36	4.98	0.3	1.2e-6	Schizophrenia;
KIRP	cis	rs4073416	0.542	rs6573614	chr14:65958703	G/A	cg03016385	chr14:66212404	NA	-0.53	-6.48	-0.38	5.04e-10	N-glycan levels;
KIRP	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg13753209	chr17:57696993	CLTC	0.53	5.13	0.31	5.74e-7	Hemoglobin concentration;
KIRP	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg05896524	chr21:47604654	C21orf56	0.44	4.99	0.3	1.13e-6	Testicular germ cell tumor;
KIRP	trans	rs28573326	0.543	rs6835701	chr4:166352900	T/C	cg13437084	chr2:26467494	HADHB;HADHA	-0.49	-6.85	-0.4	6.03e-11	Pelvic organ prolapse (moderate/severe);
KIRP	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg16141378	chr3:129829833	LOC729375	-0.52	-7.18	-0.42	8.11e-12	Neuroticism;
KIRP	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.57	7.42	0.43	1.91e-12	Coronary artery disease;
KIRP	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.41	5.29	0.32	2.75e-7	Total body bone mineral density;
KIRP	trans	rs17150703	0.630	rs12545481	chr8:9747377	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	6.35	0.38	1.03e-9	Obesity (early onset extreme);
KIRP	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-17.04	-0.74	1.58e-43	Coronary artery disease;
KIRP	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-6.22	-0.37	2.13e-9	Vitiligo;
KIRP	trans	rs7999699	0.902	rs4942691	chr13:48319580	A/C	cg23237801	chr1:16476620	EPHA2	0.51	6.34	0.37	1.1e-9	Colorectal cancer (diet interaction);
KIRP	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.12	-0.61	7.95e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs853679	0.546	rs200950	chr6:27835772	A/G	cg21204522	chr6:27730016	NA	-0.72	-5.21	-0.32	4.04e-7	Depression;
KIRP	cis	rs4959799	0.655	rs6934279	chr6:3276690	G/A	cg03657281	chr6:3270030	SLC22A23	0.74	5.28	0.32	2.87e-7	Survival in rectal cancer;
KIRP	cis	rs12786942	0.628	rs11224762	chr11:101309210	A/T	cg03942599	chr11:101341554	TRPC6	-0.5	-6.02	-0.36	6.15e-9	Facial depth;
KIRP	cis	rs6142102	0.517	rs6142046	chr20:32514061	C/T	cg24642439	chr20:33292090	TP53INP2	0.48	5.64	0.34	4.64e-8	Skin pigmentation;
KIRP	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.99	16.08	0.72	3.02e-40	Intelligence (multi-trait analysis);
KIRP	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.51	7.27	0.42	4.63e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg02807482	chr3:125708958	NA	-0.55	-5.2	-0.31	4.29e-7	Blood pressure (smoking interaction);
KIRP	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg15556689	chr8:8085844	FLJ10661	0.48	6.3	0.37	1.39e-9	Myopia (pathological);
KIRP	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18255839	chr2:239335447	ASB1	-0.46	-5.5	-0.33	9.72e-8	Multiple system atrophy;
KIRP	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-9.14	-0.5	2.45e-17	Retinal vascular caliber;
KIRP	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11987759	chr7:65425863	GUSB	-0.47	-5.62	-0.34	5.13e-8	Aortic root size;
KIRP	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.79	-11.53	-0.59	7.25e-25	Ulcerative colitis;
KIRP	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.97	17.35	0.74	1.36e-44	Breast cancer;
KIRP	trans	rs4453114	0.623	rs12413616	chr10:4866228	T/C	cg20275697	chr1:809469	FAM41C	1.0	6.29	0.37	1.43e-9	Squamous cell lung carcinoma;
KIRP	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.56	6.54	0.38	3.59e-10	Coronary artery disease;
KIRP	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg16606324	chr3:10149918	C3orf24	0.73	6.04	0.36	5.55e-9	Alzheimer's disease;
KIRP	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg14003231	chr6:33640908	ITPR3	-0.28	-4.97	-0.3	1.27e-6	Plateletcrit;
KIRP	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg08222618	chr4:941054	TMEM175	0.74	11.79	0.6	9.57e-26	Sjögren's syndrome;
KIRP	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.61	-5.46	-0.33	1.18e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.73	10.73	0.56	2.71e-22	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg14993813	chr1:46806288	NSUN4	-0.61	-7.1	-0.41	1.33e-11	Menopause (age at onset);
KIRP	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg12826209	chr6:26865740	GUSBL1	0.79	5.34	0.32	2.08e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg11752832	chr7:134001865	SLC35B4	-0.47	-6.29	-0.37	1.48e-9	Mean platelet volume;
KIRP	cis	rs7113874	0.592	rs34009921	chr11:8618861	A/G	cg08015107	chr11:8618950	NA	-0.75	-8.51	-0.48	1.7e-15	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg14673194	chr17:80132900	CCDC57	-0.77	-8.66	-0.48	6.54e-16	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg26531700	chr6:26746687	NA	0.47	6.8	0.4	7.85e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs16957091	0.738	rs8030587	chr15:42981806	C/T	cg24196017	chr15:43021976	CDAN1	-0.52	-6.87	-0.4	5.19e-11	MGMT methylation in smokers;
KIRP	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12315302	chr6:26189340	HIST1H4D	0.62	5.02	0.3	9.93e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs11138902	0.649	rs11139155	chr9:72145765	T/C	cg14397918	chr9:72078829	APBA1	0.33	5.1	0.31	6.8e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg11344533	chr11:111475393	SIK2	-0.29	-5.0	-0.3	1.07e-6	Primary sclerosing cholangitis;
KIRP	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.65	8.64	0.48	7.4e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg21252483	chr19:49399788	TULP2	-0.48	-6.31	-0.37	1.31e-9	Red cell distribution width;
KIRP	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg21100191	chr22:23484243	RTDR1	0.99	16.28	0.72	6.2e-41	Bone mineral density;
KIRP	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg01620082	chr3:125678407	NA	-1.2	-7.68	-0.44	3.82e-13	Lung cancer in ever smokers;
KIRP	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.45	-6.38	-0.38	8.87e-10	Height;
KIRP	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-6.93	-0.4	3.56e-11	Total body bone mineral density;
KIRP	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg11508081	chr17:41442227	NA	0.37	4.98	0.3	1.2e-6	Menopause (age at onset);
KIRP	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg24579896	chr14:56047964	C14orf33;KTN1	0.82	5.59	0.34	6.17e-8	Putamen volume;
KIRP	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.63	8.65	0.48	6.79e-16	Lymphocyte counts;
KIRP	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-5.31	-0.32	2.4e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	5.19	0.31	4.4e-7	Menopause (age at onset);
KIRP	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.47	6.57	0.39	3.06e-10	Sitting height ratio;
KIRP	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	cg12689670	chr1:183009347	LAMC1	-0.46	-6.59	-0.39	2.59e-10	Colorectal cancer;
KIRP	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg17724175	chr1:150552817	MCL1	0.34	5.88	0.35	1.35e-8	Tonsillectomy;
KIRP	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.51	7.18	0.42	8.19e-12	Systemic lupus erythematosus;
KIRP	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg15655495	chr12:38532458	NA	-0.29	-5.28	-0.32	2.87e-7	Bladder cancer;
KIRP	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-5.91	-0.35	1.16e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.57	5.18	0.31	4.7e-7	Bipolar disorder;
KIRP	cis	rs12541635	0.677	rs34872724	chr8:107033071	C/T	cg10147462	chr8:107024639	NA	-0.34	-5.25	-0.32	3.22e-7	Age of smoking initiation;
KIRP	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg15841412	chr13:111365552	ING1	0.51	5.73	0.34	2.9e-8	Coronary artery disease;
KIRP	cis	rs3947	0.813	rs1293316	chr8:11690915	A/G	cg21775007	chr8:11205619	TDH	-0.48	-5.1	-0.31	6.74e-7	Blood protein levels;
KIRP	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg21698718	chr17:80085957	CCDC57	-0.36	-5.17	-0.31	4.86e-7	Life satisfaction;
KIRP	cis	rs7223966	0.584	rs76957877	chr17:61621330	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	5.75	0.34	2.58e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs7033996	1.000	rs16935868	chr9:35943397	C/T	cg00918944	chr9:35908117	LOC158376	0.38	5.34	0.32	2.12e-7	Urate levels (BMI interaction);
KIRP	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg16691251	chr5:66510806	NA	0.56	7.76	0.44	2.32e-13	Breast cancer;
KIRP	cis	rs72843166	0.562	rs72841392	chr17:61451066	G/A	cg19683800	chr17:61518354	CYB561	-0.42	-5.08	-0.31	7.38e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.68	-9.14	-0.5	2.48e-17	Huntington's disease progression;
KIRP	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg03605463	chr16:89740564	NA	-0.4	-4.86	-0.3	2.06e-6	Vitiligo;
KIRP	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.48	6.94	0.4	3.38e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11608355	0.597	rs9943699	chr12:109840876	G/C	cg19025524	chr12:109796872	NA	-0.5	-6.87	-0.4	5.21e-11	Neuroticism;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.66	6.04	0.36	5.62e-9	Lung function (FEV1);
KIRP	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg05272587	chr13:111038400	COL4A2	-0.35	-5.17	-0.31	4.92e-7	White matter hyperintensity burden;
KIRP	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.4	-4.98	-0.3	1.2e-6	Blood protein levels;
KIRP	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg12549451	chr6:135224345	NA	-0.42	-5.13	-0.31	5.88e-7	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-9.47	-0.52	2.42e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg02336718	chr17:17403227	NA	-0.35	-5.49	-0.33	9.91e-8	Total body bone mineral density;
KIRP	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg24881330	chr22:46731750	TRMU	0.59	6.18	0.37	2.59e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.53	7.23	0.42	6.06e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg24998770	chr7:37888106	TXNDC3	0.43	5.81	0.35	1.89e-8	Alzheimer's disease (late onset);
KIRP	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg20742981	chr22:31644190	LIMK2	0.33	4.85	0.3	2.15e-6	Paclitaxel-induced neuropathy;
KIRP	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.32	-0.37	1.2e-9	Mood instability;
KIRP	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg08132940	chr7:1081526	C7orf50	-0.68	-6.86	-0.4	5.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg15621338	chr7:128577916	IRF5	-0.51	-6.59	-0.39	2.61e-10	Myopia;
KIRP	cis	rs9513627	0.915	rs9585070	chr13:100118843	G/C	cg25919922	chr13:100150906	NA	-0.66	-5.28	-0.32	2.86e-7	Obesity-related traits;
KIRP	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.47	5.84	0.35	1.64e-8	Height;
KIRP	cis	rs4253772	0.938	rs75977757	chr22:46641525	G/T	cg00784671	chr22:46762841	CELSR1	-0.61	-6.15	-0.36	3.14e-9	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs930036	0.602	rs71415231	chr2:171795620	A/G	cg12801329	chr2:171670795	NA	0.43	4.91	0.3	1.67e-6	Menopause (age at onset);
KIRP	cis	rs2117029	0.586	rs10783308	chr12:49531458	T/C	cg24176009	chr12:49580217	TUBA1A	-0.37	-4.95	-0.3	1.4e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs4728302	0.838	rs6974143	chr7:133603550	G/A	cg10665199	chr7:133106180	EXOC4	0.46	5.61	0.34	5.51e-8	Intelligence;Intelligence (multi-trait analysis);
KIRP	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	cg12689670	chr1:183009347	LAMC1	0.47	6.67	0.39	1.72e-10	Hypertriglyceridemia;
KIRP	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.94	10.2	0.55	1.31e-20	Type 2 diabetes nephropathy;
KIRP	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.66	8.51	0.48	1.75e-15	Prudent dietary pattern;
KIRP	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.43	4.86	0.3	2.05e-6	Schizophrenia;
KIRP	cis	rs17655565	0.581	rs1791626	chr12:52759979	T/C	cg07925835	chr12:52762777	KRT85	0.51	5.72	0.34	3.09e-8	Plasma amyloid beta peptide concentrations (ABx-42);
KIRP	cis	rs4233802	0.737	rs734135	chr2:151157597	C/G	cg25300694	chr2:151184358	NA	-0.69	-5.16	-0.31	4.99e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg03060546	chr3:49711283	APEH	0.55	6.86	0.4	5.68e-11	Resting heart rate;
KIRP	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	7.65	0.44	4.58e-13	Bipolar disorder;
KIRP	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-0.41	-5.11	-0.31	6.43e-7	Type 2 diabetes;
KIRP	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg22284058	chr8:142237359	SLC45A4	0.46	5.86	0.35	1.46e-8	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.49	7.89	0.45	1.02e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs8067287	0.688	rs11652843	chr17:16843250	A/C	cg26910001	chr17:16838321	NA	-0.46	-5.12	-0.31	6.18e-7	Diabetic kidney disease;
KIRP	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	1.19	11.32	0.59	3.47e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16524936	chr4:1340807	KIAA1530	-0.42	-5.04	-0.31	8.99e-7	Longevity;
KIRP	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg16434002	chr17:42200994	HDAC5	-0.61	-7.59	-0.44	6.79e-13	Total body bone mineral density;
KIRP	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg18882449	chr10:104885122	NT5C2	-0.48	-6.12	-0.36	3.63e-9	Arsenic metabolism;
KIRP	cis	rs4955124	0.818	rs12639463	chr3:32042746	G/A	cg05935571	chr3:32023257	ZNF860;OSBPL10	0.72	6.29	0.37	1.43e-9	Schizophrenia;
KIRP	cis	rs220519	0.783	rs220498	chr20:37297860	C/T	cg24308336	chr20:37270989	C20orf95	0.24	5.23	0.32	3.62e-7	Schizophrenia;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21831898	chr1:150254439	C1orf51	0.54	6.65	0.39	1.93e-10	Inflammatory biomarkers;
KIRP	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg19554555	chr3:13937349	NA	-0.48	-6.43	-0.38	6.68e-10	Ovarian reserve;
KIRP	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.88	8.45	0.47	2.54e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs55962025	0.711	rs28867436	chr4:3085477	G/A	cg06533319	chr4:3265114	C4orf44	0.4	5.15	0.31	5.35e-7	Parental longevity (mother's age at death);
KIRP	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg22974920	chr21:40686053	BRWD1	-0.44	-5.17	-0.31	4.89e-7	Cognitive function;
KIRP	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17376030	chr22:41985996	PMM1	-0.81	-8.5	-0.48	1.85e-15	Vitiligo;
KIRP	cis	rs12431939	0.947	rs68164178	chr14:51679003	A/C	cg23942311	chr14:51606299	NA	-0.61	-5.49	-0.33	9.78e-8	Cancer;
KIRP	cis	rs6959887	0.926	rs73099202	chr7:35296306	C/T	cg06685737	chr7:35301730	NA	0.45	6.6	0.39	2.49e-10	Birth weight;
KIRP	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-5.47	-0.33	1.12e-7	Morning vs. evening chronotype;
KIRP	cis	rs2669010	0.796	rs2632212	chr12:77043891	A/T	cg14998926	chr12:77026162	NA	0.43	5.82	0.35	1.82e-8	Systemic lupus erythematosus;
KIRP	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg05526886	chr2:227700861	RHBDD1	0.48	5.5	0.33	9.71e-8	Pulmonary function;
KIRP	cis	rs1823913	0.637	rs979967	chr2:192169421	C/T	cg12404831	chr2:192114017	MYO1B	0.44	5.88	0.35	1.35e-8	Obesity-related traits;
KIRP	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.82	0.49	2.13e-16	Motion sickness;
KIRP	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg21827317	chr3:136751795	NA	0.37	5.09	0.31	7.1e-7	Neuroticism;
KIRP	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.35	5.36	0.32	1.88e-7	Ulcerative colitis;
KIRP	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg16497661	chr14:103986332	CKB	-0.5	-6.43	-0.38	6.43e-10	Coronary artery disease;
KIRP	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.59	-6.64	-0.39	1.99e-10	Hair shape;
KIRP	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	0.95	8.62	0.48	8.49e-16	Plateletcrit;
KIRP	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg19500275	chr17:80737654	TBCD	-0.49	-5.86	-0.35	1.46e-8	Glycated hemoglobin levels;
KIRP	cis	rs742614	0.935	rs6057929	chr20:32477633	A/G	cg06304546	chr20:32448765	NA	-0.46	-5.83	-0.35	1.76e-8	Stearic acid (18:0) levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg14431619	chr19:11266544	SPC24	0.44	6.07	0.36	4.92e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.45	-6.79	-0.4	8.49e-11	Schizophrenia;
KIRP	cis	rs3764563	0.935	rs646816	chr19:15695101	T/G	cg20725493	chr19:15740067	CYP4F8	0.86	6.07	0.36	4.73e-9	Inflammatory biomarkers;
KIRP	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.85	-8.69	-0.48	5.1e-16	Platelet count;
KIRP	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.88	-13.75	-0.66	2.77e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2979489	0.891	rs17551512	chr8:30330109	A/G	cg26383811	chr8:30366931	RBPMS	-0.39	-5.34	-0.32	2.1e-7	Mean corpuscular hemoglobin;Plateletcrit;Neutrophil count;Granulocyte count;Sum basophil neutrophil counts;Mean corpuscular volume;Myeloid white cell count;Sum neutrophil eosinophil counts;
KIRP	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg07148914	chr20:33460835	GGT7	-0.43	-5.33	-0.32	2.24e-7	Height;
KIRP	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg00738919	chr7:1100172	C7orf50	0.41	4.97	0.3	1.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.91	-0.35	1.12e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2746347	0.722	rs2746343	chr1:57135814	G/A	cg09935045	chr1:57111199	PRKAA2	0.53	5.5	0.33	9.32e-8	Lymphocyte counts;
KIRP	cis	rs526231	0.543	rs26819	chr5:102529401	G/A	cg23492399	chr5:102201601	PAM	-0.53	-5.72	-0.34	3.09e-8	Primary biliary cholangitis;
KIRP	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-8.99	-0.5	6.55e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.56	-6.97	-0.41	2.85e-11	Uric acid clearance;
KIRP	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg03959625	chr15:84868606	LOC388152	0.71	8.47	0.48	2.22e-15	Schizophrenia;
KIRP	trans	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	6.51	0.38	4.22e-10	Neuroticism;
KIRP	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg12486944	chr17:80159399	CCDC57	-0.4	-5.31	-0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14895029	chr7:2775587	GNA12	-0.41	-4.9	-0.3	1.75e-6	Height;
KIRP	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg26061582	chr7:22766209	IL6	0.4	4.88	0.3	1.89e-6	Lung cancer;
KIRP	cis	rs1448094	0.692	rs7958438	chr12:86326141	A/T	cg02569458	chr12:86230093	RASSF9	0.33	4.91	0.3	1.66e-6	Major depressive disorder;
KIRP	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.73	-11.42	-0.59	1.63e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.82	-11.9	-0.6	4.45e-26	Eye color traits;
KIRP	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17310428	chr7:129777263	NA	0.51	6.08	0.36	4.67e-9	Interleukin-4 levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg16793199	chr2:3453196	TTC15	-0.41	-6.06	-0.36	5.18e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg08807101	chr21:30365312	RNF160	0.61	7.03	0.41	2.07e-11	Cognitive test performance;
KIRP	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.65	8.75	0.49	3.45e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs6832769	0.961	rs11133379	chr4:56306111	G/A	cg09317128	chr4:56265301	TMEM165	0.55	7.35	0.42	2.96e-12	Personality dimensions;
KIRP	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.64	8.61	0.48	8.75e-16	Morning vs. evening chronotype;
KIRP	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg12549451	chr6:135224345	NA	0.44	5.56	0.33	6.9e-8	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	0.4	5.16	0.31	5.06e-7	Acne (severe);
KIRP	cis	rs10518128	1.000	rs28608578	chr4:75713550	C/T	cg20122727	chr4:75719957	BTC	0.59	5.97	0.36	8.15e-9	Electroencephalogram traits;
KIRP	cis	rs7712401	0.601	rs35339188	chr5:122317685	A/T	cg19412675	chr5:122181750	SNX24	-0.5	-5.42	-0.33	1.4e-7	Mean platelet volume;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg06053173	chr3:140696586	SLC25A36	-0.45	-6.44	-0.38	6.15e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.14	0.41	1.06e-11	Bipolar disorder;
KIRP	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27297192	chr10:134578999	INPP5A	-0.56	-7.08	-0.41	1.55e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.92	-12.46	-0.62	5.77e-28	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.07	0.46	3.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg24874828	chr4:187887005	NA	-0.47	-7.05	-0.41	1.79e-11	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10874322	1.000	rs11584879	chr1:83041631	C/A	cg12753787	chr1:3239712	PRDM16	0.66	6.53	0.38	3.83e-10	Response to taxane treatment (docetaxel);
KIRP	cis	rs7818345	0.935	rs6991212	chr8:19276522	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.44	6.29	0.37	1.41e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs4835473	0.932	rs1839448	chr4:144673266	G/C	cg08833778	chr4:144622313	FREM3	0.35	5.13	0.31	5.82e-7	Immature fraction of reticulocytes;
KIRP	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.62	7.35	0.42	2.93e-12	Height;
KIRP	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg00360474	chr6:37504404	NA	-0.48	-6.9	-0.4	4.28e-11	Cognitive performance;
KIRP	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-7.2	-0.42	7.41e-12	Platelet count;
KIRP	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-1.17	-9.8	-0.53	2.34e-19	Hip circumference adjusted for BMI;
KIRP	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg12560992	chr17:57184187	TRIM37	0.61	6.68	0.39	1.58e-10	Testicular germ cell tumor;
KIRP	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg05484376	chr2:27715224	FNDC4	0.38	6.33	0.37	1.15e-9	Total body bone mineral density;
KIRP	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.75	10.03	0.54	4.53e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg25042112	chr7:64838748	ZNF92	0.58	6.08	0.36	4.62e-9	Pain;
KIRP	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.8	11.55	0.59	5.92e-25	Menarche (age at onset);
KIRP	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-5.21	-0.32	3.95e-7	Personality dimensions;
KIRP	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg18209359	chr17:80159595	CCDC57	0.43	5.61	0.34	5.38e-8	Life satisfaction;
KIRP	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg01765077	chr12:122356316	WDR66	0.64	8.78	0.49	2.79e-16	Mean corpuscular volume;
KIRP	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.82	-0.35	1.85e-8	Educational attainment;
KIRP	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs7715811	1.000	rs13436952	chr5:13773993	A/G	cg07548982	chr5:13769939	DNAH5	-0.54	-6.61	-0.39	2.44e-10	Subclinical atherosclerosis traits (other);
KIRP	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2219968	1.000	rs11776951	chr8:78971578	G/C	cg00738934	chr8:78996279	NA	0.4	5.04	0.31	9.15e-7	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.4	4.97	0.3	1.28e-6	Aortic root size;
KIRP	cis	rs6693295	0.755	rs1933530	chr1:246231677	T/G	cg11798871	chr1:246315928	SMYD3	-0.47	-5.75	-0.34	2.63e-8	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.66	9.47	0.52	2.4e-18	Alcohol dependence;
KIRP	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12463550	chr7:65579703	CRCP	0.75	4.87	0.3	2.01e-6	Diabetic kidney disease;
KIRP	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	8.84	0.49	1.92e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg19468946	chr17:37922297	IKZF3	-0.47	-6.57	-0.39	3.04e-10	Self-reported allergy;
KIRP	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.47	6.63	0.39	2.07e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg21546286	chr11:48923668	NA	-0.48	-6.13	-0.36	3.52e-9	HDL cholesterol;
KIRP	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.73	-8.86	-0.49	1.68e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7849270	0.959	rs1410017	chr9:131913430	C/T	cg13538475	chr9:131942899	NA	-0.33	-5.34	-0.32	2.14e-7	Blood metabolite ratios;
KIRP	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg13906792	chr15:75199810	C15orf17	-0.35	-4.98	-0.3	1.22e-6	Breast cancer;
KIRP	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg22563815	chr15:78856949	CHRNA5	0.33	4.87	0.3	2.02e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	cg21523751	chr1:182988639	NA	0.36	5.09	0.31	7.26e-7	Fuchs's corneal dystrophy;
KIRP	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg13385521	chr17:29058706	SUZ12P	0.55	5.35	0.32	2.06e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.6	-7.15	-0.42	9.6e-12	Bipolar disorder and schizophrenia;
KIRP	cis	rs9304742	0.962	rs12461796	chr19:53455088	T/A	cg24044776	chr19:53454761	ZNF816A	-0.48	-7.12	-0.41	1.17e-11	Psoriasis;
KIRP	cis	rs1519814	1.000	rs4871045	chr8:121167814	T/C	cg22335954	chr8:121166405	COL14A1	-0.66	-6.41	-0.38	7.38e-10	Breast cancer;
KIRP	cis	rs1843834	0.721	rs4674939	chr2:225613552	G/A	cg22455342	chr2:225449267	CUL3	0.48	5.6	0.34	5.77e-8	IgE levels in asthmatics (D.p. specific);
KIRP	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.34	-6.66	-0.39	1.75e-10	Monocyte percentage of white cells;
KIRP	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg21231944	chr12:82153410	PPFIA2	-0.42	-5.02	-0.3	9.89e-7	Resting heart rate;
KIRP	cis	rs2904967	0.568	rs2904966	chr11:65090727	C/T	cg12562828	chr11:65076843	NA	0.86	12.0	0.61	2.08e-26	Mean corpuscular volume;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23661309	chr1:33546743	ADC	-0.48	-6.24	-0.37	1.85e-9	Metabolic traits;
KIRP	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-6.82	-0.4	7.01e-11	Total bilirubin levels in HIV-1 infection;
KIRP	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg01304814	chr3:48885189	PRKAR2A	0.59	5.24	0.32	3.48e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.78	11.62	0.6	3.55e-25	Blood metabolite ratios;
KIRP	cis	rs2387326	0.717	rs10829338	chr10:129943625	C/T	cg16087940	chr10:129947807	NA	-0.36	-5.01	-0.3	1.03e-6	Select biomarker traits;
KIRP	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05665937	chr4:1216051	CTBP1	0.57	7.78	0.44	2.01e-13	Obesity-related traits;
KIRP	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg19610905	chr11:61596333	FADS2	-0.46	-7.14	-0.41	1.05e-11	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
KIRP	cis	rs13361707	0.920	rs6872282	chr5:40704090	C/T	cg01087697	chr5:40835557	RPL37	-0.48	-5.38	-0.32	1.77e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs13401104	0.796	rs72617202	chr2:237108405	T/C	cg19324714	chr2:237145437	ASB18	0.47	4.87	0.3	1.99e-6	Educational attainment;
KIRP	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg17376030	chr22:41985996	PMM1	-0.65	-6.77	-0.4	9.19e-11	Vitiligo;
KIRP	cis	rs7520050	0.933	rs6661163	chr1:46255004	A/G	cg15605315	chr1:45957053	TESK2	0.42	5.55	0.33	7.2e-8	Red blood cell count;Reticulocyte count;
KIRP	cis	rs10045504	0.502	rs72746038	chr5:38753999	G/A	cg15396434	chr5:38725168	NA	-0.91	-9.26	-0.51	1.06e-17	Night sleep phenotypes;
KIRP	trans	rs2027099	0.606	rs9564321	chr13:67119841	A/G	cg23817347	chr20:49126808	PTPN1	-0.54	-6.15	-0.37	3.12e-9	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
KIRP	cis	rs9649213	0.519	rs3735258	chr7:97866291	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.61	-7.11	-0.41	1.23e-11	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs963731	0.649	rs297137	chr2:39305721	T/C	cg04010122	chr2:39346883	SOS1	-0.93	-6.39	-0.38	8.09e-10	Corticobasal degeneration;
KIRP	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg18154014	chr19:37997991	ZNF793	0.7	7.6	0.44	6.08e-13	Coronary artery calcification;
KIRP	cis	rs7539409	0.651	rs979757	chr1:84296605	T/C	cg10977910	chr1:84465055	TTLL7	0.58	5.39	0.32	1.67e-7	Alzheimer's disease;
KIRP	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg13512537	chr8:22265999	SLC39A14	-0.38	-4.86	-0.3	2.07e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-1.04	-19.36	-0.78	2.39e-51	Heart rate;
KIRP	cis	rs911119	0.955	rs6048945	chr20:23602228	C/T	cg09631192	chr20:23583594	CST9	-0.49	-5.08	-0.31	7.52e-7	Chronic kidney disease;
KIRP	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.98	10.97	0.57	4.7e-23	Alzheimer's disease;
KIRP	cis	rs6723108	0.654	rs621341	chr2:135295180	T/C	cg12500956	chr2:135428796	TMEM163	0.43	5.29	0.32	2.73e-7	Type 2 diabetes;
KIRP	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg13902645	chr11:5959945	NA	-0.53	-5.3	-0.32	2.53e-7	DNA methylation (variation);
KIRP	cis	rs6589219	0.954	rs7122375	chr11:111171071	T/C	cg25129781	chr11:111156908	C11orf53	-0.5	-6.44	-0.38	6.4e-10	Colorectal cancer;
KIRP	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg05627522	chr15:75251581	NA	0.36	5.46	0.33	1.18e-7	Breast cancer;
KIRP	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-7.59	-0.44	6.62e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg19875535	chr5:140030758	IK	-0.67	-9.47	-0.52	2.38e-18	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs11169552	0.510	rs11169532	chr12:51119935	G/A	cg12884762	chr12:50931848	DIP2B	-0.44	-4.98	-0.3	1.22e-6	Colorectal cancer;
KIRP	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.11	-0.46	2.37e-14	Bipolar disorder;
KIRP	trans	rs12043259	0.730	rs4951135	chr1:204815612	T/C	cg11485465	chr5:54518469	NA	0.39	6.76	0.4	9.86e-11	Addiction;
KIRP	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg00656387	chr3:40428638	ENTPD3	0.38	4.91	0.3	1.65e-6	Renal cell carcinoma;
KIRP	cis	rs7221595	0.825	rs62072388	chr17:3899567	C/A	cg11204139	chr17:3907470	NA	0.57	5.66	0.34	4.13e-8	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia;
KIRP	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.58	8.72	0.49	4.17e-16	Weight;
KIRP	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.48	-5.11	-0.31	6.5e-7	Platelet distribution width;
KIRP	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.57	6.41	0.38	7.51e-10	Aortic root size;
KIRP	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg00074818	chr8:8560427	CLDN23	0.45	6.84	0.4	6.3e-11	Obesity-related traits;
KIRP	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05903289	chr2:130345205	NA	-0.42	-5.55	-0.33	7.54e-8	Response to cytidine analogues (gemcitabine);
KIRP	cis	rs9905704	0.681	rs4277402	chr17:56581651	C/G	cg12560992	chr17:57184187	TRIM37	-0.54	-5.03	-0.31	9.36e-7	Testicular germ cell tumor;
KIRP	cis	rs9473924	0.542	rs36093098	chr6:50833931	G/A	cg14470998	chr6:50812995	TFAP2B	0.99	8.81	0.49	2.32e-16	Body mass index;
KIRP	cis	rs3751972	1.000	rs3751972	chr17:26206414	C/A	cg18091275	chr17:26120155	NOS2	-0.5	-5.93	-0.35	1.03e-8	Fractional exhaled nitric oxide (childhood);
KIRP	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.05	11.79	0.6	9.77e-26	Vitiligo;
KIRP	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg01988459	chr11:68622903	NA	-0.38	-5.33	-0.32	2.24e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg13319975	chr6:146136371	FBXO30	-0.56	-7.75	-0.44	2.47e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg05526886	chr2:227700861	RHBDD1	-0.47	-5.64	-0.34	4.56e-8	Pulmonary function;
KIRP	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.71	-7.85	-0.45	1.25e-13	Body mass index;
KIRP	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg08662619	chr6:150070041	PCMT1	0.34	5.52	0.33	8.49e-8	Lung cancer;
KIRP	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg10570941	chr6:26273029	HIST1H3G;HIST1H2BI	-0.6	-5.16	-0.31	5.02e-7	Gout;Renal underexcretion gout;
KIRP	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg24692254	chr21:30365293	RNF160	-0.5	-5.22	-0.32	3.89e-7	Cognitive test performance;
KIRP	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg23752985	chr2:85803571	VAMP8	0.59	8.72	0.49	4.23e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg26992213	chr6:159290838	NA	-0.54	-6.06	-0.36	5e-9	Menopause (age at onset);
KIRP	cis	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-6.99	-0.41	2.55e-11	Morning vs. evening chronotype;
KIRP	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.52	-6.76	-0.4	9.88e-11	Schizophrenia;
KIRP	cis	rs7224685	0.501	rs7222628	chr17:3890429	A/G	cg11204139	chr17:3907470	NA	0.9	17.46	0.74	5.76e-45	Type 2 diabetes;
KIRP	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg21419209	chr3:44054225	NA	-0.75	-9.36	-0.51	5.28e-18	Coronary artery disease;
KIRP	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg24044564	chr13:99115944	STK24	0.5	5.6	0.34	5.8e-8	Obesity-related traits;
KIRP	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	10.79	0.57	1.84e-22	Exhaled nitric oxide levels;
KIRP	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.96	10.22	0.55	1.15e-20	Alzheimer's disease;
KIRP	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.43	5.97	0.36	8.42e-9	Schizophrenia;
KIRP	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00933542	chr6:150070202	PCMT1	0.28	5.61	0.34	5.51e-8	Lung cancer;
KIRP	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	0.87	9.79	0.53	2.57e-19	Pediatric areal bone mineral density (radius);
KIRP	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.52	5.02	0.3	1.02e-6	Recombination rate (females);
KIRP	cis	rs2224391	0.518	rs17736761	chr6:5288319	A/G	cg13962347	chr6:5174647	LYRM4	-0.7	-6.28	-0.37	1.49e-9	Height;
KIRP	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	0.98	10.06	0.54	3.7799999999999997e-20	Vitiligo;
KIRP	cis	rs13095912	0.889	rs35917986	chr3:185310041	G/A	cg11274856	chr3:185301563	NA	0.51	6.6	0.39	2.55e-10	Systolic blood pressure;
KIRP	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg10189774	chr4:17578691	LAP3	0.43	5.06	0.31	8.33e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs911119	0.913	rs6106685	chr20:23581612	A/C	cg09631192	chr20:23583594	CST9	-0.48	-5.1	-0.31	6.87e-7	Chronic kidney disease;
KIRP	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.67	9.06	0.5	4.26e-17	Obesity-related traits;
KIRP	cis	rs4660306	0.672	rs532639	chr1:46024481	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.47	-5.88	-0.35	1.3e-8	Homocysteine levels;
KIRP	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.58	6.8	0.4	7.65e-11	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg02367723	chr1:46378857	MAST2	0.43	5.03	0.31	9.51e-7	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	trans	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	7.09	0.41	1.42e-11	Neuroticism;
KIRP	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.81	-8.6	-0.48	9.58e-16	Hair shape;
KIRP	cis	rs9400467	0.506	rs17678681	chr6:111582038	T/A	cg22127309	chr6:111907043	TRAF3IP2	0.52	4.86	0.3	2.14e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg00784671	chr22:46762841	CELSR1	-0.81	-7.98	-0.45	5.42e-14	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs2574704	0.851	rs3856795	chr3:11630484	G/A	cg07643000	chr3:11666825	VGLL4	0.35	4.88	0.3	1.87e-6	Body mass index;
KIRP	cis	rs17020663	0.552	rs8179740	chr2:101653528	C/T	cg15506514	chr2:101638852	TBC1D8	-0.5	-5.08	-0.31	7.43e-7	Pulse pressure;
KIRP	cis	rs2446066	0.524	rs7315185	chr12:53924359	T/A	cg16917193	chr12:54089295	NA	0.64	5.69	0.34	3.56e-8	Red blood cell count;
KIRP	cis	rs829661	0.793	rs2609956	chr2:30872191	A/G	cg10949345	chr2:30726833	LCLAT1	1.09	13.36	0.65	5.56e-31	Midgestational circulating levels of PBDEs (fetal genetic effect);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23361084	chr11:73309262	FAM168A	0.51	6.47	0.38	5.33e-10	Parkinson's disease;
KIRP	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg16141378	chr3:129829833	LOC729375	0.5	6.1	0.36	4.01e-9	Neuroticism;
KIRP	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg02733842	chr7:1102375	C7orf50	0.57	5.85	0.35	1.54e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.98	10.44	0.55	2.31e-21	Blood protein levels;
KIRP	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg24633833	chr3:10029261	TMEM111	0.56	5.35	0.32	2.06e-7	Alzheimer's disease;
KIRP	cis	rs2033732	0.955	rs2033731	chr8:85079720	T/G	cg05716166	chr8:85095498	RALYL	0.62	6.68	0.39	1.54e-10	Body mass index;
KIRP	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.46	-5.62	-0.34	5.22e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg22907277	chr7:1156413	C7orf50	0.47	5.8	0.35	1.98e-8	Longevity;Endometriosis;
KIRP	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg19507638	chr5:93509721	C5orf36	0.58	5.34	0.32	2.12e-7	Diabetic retinopathy;
KIRP	cis	rs7851660	0.809	rs12550872	chr9:100653128	G/A	cg13688889	chr9:100608707	NA	-0.68	-8.59	-0.48	1e-15	Strep throat;
KIRP	cis	rs6997458	0.785	rs2548281	chr8:86310776	A/G	cg02393479	chr8:86352350	CA3	-0.33	-5.12	-0.31	6.11e-7	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg19923238	chr8:142232952	SLC45A4	-0.41	-4.86	-0.3	2.05e-6	Immature fraction of reticulocytes;
KIRP	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg07169764	chr2:136633963	MCM6	-0.53	-6.1	-0.36	4.08e-9	Mosquito bite size;
KIRP	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg06640241	chr16:89574553	SPG7	0.66	8.92	0.49	1.06e-16	Multiple myeloma (IgH translocation);
KIRP	cis	rs8067545	1.000	rs34291370	chr17:19942335	G/A	cg04132472	chr17:19861366	AKAP10	0.41	5.57	0.33	6.55e-8	Schizophrenia;
KIRP	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.41	5.08	0.31	7.33e-7	Diabetic retinopathy;
KIRP	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg05163923	chr11:71159392	DHCR7	-0.71	-7.18	-0.42	8.19e-12	Vitamin D levels;
KIRP	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg25356066	chr3:128598488	ACAD9	0.5	5.85	0.35	1.57e-8	IgG glycosylation;
KIRP	cis	rs1215050	0.791	rs1727278	chr4:98853576	A/G	cg17366294	chr4:99064904	C4orf37	-0.37	-5.03	-0.31	9.33e-7	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs7224685	0.569	rs34356467	chr17:3978531	G/T	cg21734707	chr17:3908241	ZZEF1	0.52	4.89	0.3	1.85e-6	Type 2 diabetes;
KIRP	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg20243544	chr17:37824526	PNMT	0.37	4.92	0.3	1.57e-6	Self-reported allergy;
KIRP	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.52	5.4	0.33	1.59e-7	Parkinson's disease;
KIRP	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg27178145	chr22:32340355	YWHAH;C22orf24	0.71	5.05	0.31	8.72e-7	Childhood ear infection;
KIRP	cis	rs71636778	0.722	rs116491347	chr1:27172684	C/T	cg12203394	chr1:27248618	NUDC	0.66	5.96	0.36	8.7e-9	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
KIRP	cis	rs2790457	0.833	rs1265846	chr10:28929097	A/G	cg04045419	chr10:28823091	WAC	-0.43	-4.92	-0.3	1.57e-6	Multiple myeloma;
KIRP	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	0.89	13.14	0.64	3.2e-30	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg01872077	chr2:219646372	CYP27A1	0.41	5.44	0.33	1.32e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg11843606	chr2:227700838	RHBDD1	0.39	5.0	0.3	1.07e-6	Pulmonary function;
KIRP	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.56	6.12	0.36	3.62e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7646881	1.000	rs7646987	chr3:158453442	A/G	cg19483011	chr3:158453295	NA	0.57	6.19	0.37	2.46e-9	Tetralogy of Fallot;
KIRP	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.42	5.35	0.32	1.98e-7	Aortic root size;
KIRP	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg23505145	chr19:12996616	KLF1	0.58	8.64	0.48	7.03e-16	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.76	11.35	0.59	2.82e-24	Height;
KIRP	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.48	-5.98	-0.36	7.71e-9	Monocyte count;
KIRP	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.07	-0.41	1.6e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.85	10.15	0.54	1.88e-20	Exhaled nitric oxide levels;
KIRP	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.05	-0.41	1.84e-11	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg13010199	chr12:38710504	ALG10B	0.45	5.71	0.34	3.25e-8	Morning vs. evening chronotype;
KIRP	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg05555928	chr11:63887634	MACROD1	-0.7	-7.16	-0.42	9.55e-12	Body mass index;
KIRP	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06544989	chr22:39130855	UNC84B	-0.48	-6.94	-0.4	3.46e-11	Menopause (age at onset);
KIRP	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-5.89	-0.35	1.26e-8	Educational attainment;
KIRP	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg10047753	chr17:41438598	NA	0.84	11.37	0.59	2.44e-24	Menopause (age at onset);
KIRP	cis	rs9896052	0.608	rs61264861	chr17:73459278	T/C	cg25649188	chr17:73499917	CASKIN2	0.51	6.63	0.39	2.11e-10	Sight-threatening diabetic retinopathy in type 2 diabetes;
KIRP	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.86	-7.12	-0.41	1.17e-11	Initial pursuit acceleration;
KIRP	cis	rs6700559	0.692	rs12744809	chr1:200593325	C/T	cg07804481	chr1:200639085	DDX59	0.39	5.03	0.31	9.51e-7	Coronary artery disease;
KIRP	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg13010199	chr12:38710504	ALG10B	0.64	8.11	0.46	2.43e-14	Morning vs. evening chronotype;
KIRP	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.0	0.41	2.39e-11	Tonsillectomy;
KIRP	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg10223061	chr2:219282414	VIL1	0.31	5.0	0.3	1.07e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg22604316	chr1:46958801	NA	-0.48	-6.79	-0.4	8.44e-11	Monobrow;
KIRP	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.99	0.3	1.14e-6	Cannabis dependence symptom count;
KIRP	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.49	-5.96	-0.36	8.8e-9	Birth weight;
KIRP	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-7.56	-0.43	7.74e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg20991723	chr1:152506922	NA	-0.46	-5.47	-0.33	1.1e-7	Hair morphology;
KIRP	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.48	5.68	0.34	3.89e-8	Uric acid levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg18923479	chr2:48773405	NA	-0.47	-7.14	-0.41	1.05e-11	Inflammatory biomarkers;
KIRP	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg11569703	chr11:65557185	OVOL1	0.42	7.22	0.42	6.51e-12	Systemic lupus erythematosus;
KIRP	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.57	-7.7	-0.44	3.39e-13	Post bronchodilator FEV1;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg13957837	chr9:140705990	EHMT1	0.48	6.02	0.36	6.38e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18252515	chr7:66147081	NA	0.47	5.66	0.34	4.16e-8	Aortic root size;
KIRP	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.57	8.67	0.48	5.97e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.14	0.46	1.94e-14	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	7.61	0.44	5.89e-13	Rheumatoid arthritis;
KIRP	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg05370193	chr1:21551575	ECE1	0.43	6.05	0.36	5.34e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs838147	0.844	rs11083948	chr19:49248120	A/G	cg13540341	chr19:49222985	MAMSTR	0.35	5.63	0.34	4.86e-8	Dietary macronutrient intake;
KIRP	cis	rs10073892	0.633	rs6884301	chr5:101615705	A/G	cg19774478	chr5:101632501	SLCO4C1	-0.56	-6.09	-0.36	4.27e-9	Cognitive decline (age-related);
KIRP	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs909341	0.909	rs2257885	chr20:62334220	G/A	cg03999872	chr20:62272968	STMN3	-0.56	-6.52	-0.38	3.89e-10	Atopic dermatitis;
KIRP	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.63	7.87	0.45	1.15e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.66	8.8	0.49	2.54e-16	Bladder cancer;
KIRP	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.86	-12.82	-0.63	3.59e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg03808351	chr9:123631620	PHF19	0.39	5.31	0.32	2.43e-7	Rheumatoid arthritis;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06525892	chr5:175792454	ARL10	0.4	6.14	0.36	3.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg10223061	chr2:219282414	VIL1	-0.41	-6.64	-0.39	2.02e-10	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs11099412	1	rs11099412	chr4:137728918	A/G	cg02594498	chr15:22893147	CYFIP1	0.98	6.74	0.39	1.12e-10	P wave terminal force;
KIRP	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg06219351	chr7:158114137	PTPRN2	-0.6	-8.57	-0.48	1.19e-15	Calcium levels;
KIRP	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.46	10.13	0.54	2.28e-20	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs9972944	0.756	rs9894010	chr17:63760156	T/G	cg07283582	chr17:63770753	CCDC46	-0.44	-7.28	-0.42	4.43e-12	Total body bone mineral density;
KIRP	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg16898833	chr6:26189333	HIST1H4D	0.83	5.89	0.35	1.25e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.68	9.37	0.51	5.04e-18	Graves' disease;
KIRP	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.65	-9.84	-0.53	1.75e-19	Educational attainment;
KIRP	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.36	-0.42	2.8e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.66	-7.26	-0.42	5.13e-12	Schizophrenia;
KIRP	cis	rs12200782	1.000	rs10456330	chr6:26436692	C/T	cg11502198	chr6:26597334	ABT1	-0.73	-4.9	-0.3	1.74e-6	Small cell lung carcinoma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07312676	chr16:47338451	ITFG1	-0.42	-6.46	-0.38	5.43e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs988913	0.813	rs4712082	chr6:54771019	G/A	cg03513858	chr6:54763001	FAM83B	-0.38	-5.46	-0.33	1.15e-7	Menarche (age at onset);
KIRP	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.45	9.84	0.53	1.71e-19	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	1.17	11.65	0.6	2.78e-25	Red blood cell traits;
KIRP	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.47	-5.74	-0.34	2.77e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
KIRP	cis	rs9400467	0.506	rs12215189	chr6:111646002	G/C	cg22127309	chr6:111907043	TRAF3IP2	0.54	4.85	0.3	2.21e-6	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg05941025	chr16:89927596	SPIRE2	-0.38	-6.04	-0.36	5.52e-9	Vitiligo;
KIRP	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.49	7.06	0.41	1.69e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg24315340	chr6:146058215	EPM2A	0.39	4.93	0.3	1.53e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs72730918	0.528	rs3751585	chr15:51741056	C/T	cg14296394	chr15:51910925	DMXL2	0.81	10.09	0.54	2.92e-20	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01688590	chr15:32163153	NA	0.45	6.73	0.39	1.16e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg23791538	chr6:167370224	RNASET2	-0.43	-5.34	-0.32	2.14e-7	Primary biliary cholangitis;
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.62	6.04	0.36	5.56e-9	Platelet count;
KIRP	cis	rs273218	1.000	rs156440	chr5:53373656	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.69	7.49	0.43	1.21e-12	Migraine;
KIRP	cis	rs6723108	0.515	rs16831001	chr2:135534794	G/T	cg25422880	chr2:135218333	TMEM163	0.41	5.8	0.35	2.06e-8	Type 2 diabetes;
KIRP	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg08975724	chr8:8085496	FLJ10661	0.68	8.37	0.47	4.44e-15	Mood instability;
KIRP	cis	rs7523273	0.925	rs12132780	chr1:207999605	C/T	cg22525895	chr1:207977042	MIR29B2	-0.66	-8.23	-0.46	1.12e-14	Schizophrenia;
KIRP	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.64	8.49	0.48	2.01e-15	Motion sickness;
KIRP	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.64	9.57	0.52	1.19e-18	Lung cancer;
KIRP	cis	rs3120667	0.790	rs12049036	chr1:152389840	G/A	cg26876637	chr1:152193138	HRNR	-0.53	-5.56	-0.33	7.16e-8	Eating disorders;
KIRP	cis	rs4740619	0.565	rs10738424	chr9:16032142	G/A	cg14451791	chr9:16040625	NA	-0.42	-5.41	-0.33	1.51e-7	Body mass index;
KIRP	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.43	6.08	0.36	4.49e-9	Language performance in older adults (adjusted for episodic memory);
KIRP	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-9.62	-0.52	8.56e-19	Coffee consumption (cups per day);
KIRP	cis	rs939574	0.656	rs113370390	chr2:220132837	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.76	5.26	0.32	3.16e-7	Platelet distribution width;
KIRP	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.55	-6.77	-0.4	9.12e-11	Coffee consumption (cups per day);
KIRP	cis	rs3857747	0.537	rs4421260	chr7:40424908	C/G	cg00420559	chr7:40367873	C7orf10	-0.39	-5.55	-0.33	7.47e-8	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06850241	chr22:41845214	NA	-0.5	-5.62	-0.34	5.12e-8	Vitiligo;
KIRP	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg12463550	chr7:65579703	CRCP	-0.57	-6.94	-0.4	3.46e-11	Aortic root size;
KIRP	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg06640241	chr16:89574553	SPG7	0.78	11.8	0.6	9.24e-26	Multiple myeloma (IgH translocation);
KIRP	cis	rs3789045	0.560	rs1107339	chr1:204411942	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.91	-8.33	-0.47	5.55e-15	Educational attainment (college completion);
KIRP	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.69	-9.18	-0.51	1.81e-17	Huntington's disease progression;
KIRP	trans	rs656319	0.702	rs587328	chr8:9809722	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-6.96	-0.41	3.12e-11	Myopia (pathological);
KIRP	cis	rs9788682	0.624	rs518425	chr15:78883813	A/G	cg24631222	chr15:78858424	CHRNA5	0.72	9.7	0.53	4.86e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs11627756	0.957	rs6575929	chr14:103149447	T/G	cg01864069	chr14:103024347	NA	0.41	4.88	0.3	1.92e-6	Mean platelet volume;
KIRP	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg01872077	chr2:219646372	CYP27A1	0.41	5.31	0.32	2.45e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs4664293	0.867	rs7603274	chr2:160592690	G/C	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs731174	0.959	rs12747993	chr1:38190852	T/C	cg06917450	chr1:38156652	C1orf109	-0.42	-4.96	-0.3	1.31e-6	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4273100	1.000	rs16960499	chr17:19203032	A/G	cg18093559	chr17:18951025	GRAP	-0.61	-5.72	-0.34	3.07e-8	Schizophrenia;
KIRP	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.82	-9.85	-0.53	1.61e-19	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
KIRP	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11987759	chr7:65425863	GUSB	-0.5	-6.47	-0.38	5.2400000000000005e-10	Aortic root size;
KIRP	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-9.3	-0.51	7.93e-18	Body mass index;
KIRP	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.75	9.66	0.52	6.5e-19	Coronary artery disease;
KIRP	cis	rs1656402	1.000	rs6761056	chr2:233437045	T/A	cg03852847	chr2:233439513	NA	-0.72	-12.0	-0.61	2.03e-26	Non-small cell lung cancer (survival);
KIRP	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg09365446	chr1:150670422	GOLPH3L	0.38	5.0	0.3	1.09e-6	Urate levels;
KIRP	cis	rs1881492	0.518	rs940666	chr2:233458679	A/C	cg03852847	chr2:233439513	NA	-0.69	-9.09	-0.5	3.4e-17	Refractive error;
KIRP	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.62	8.32	0.47	6e-15	Morning vs. evening chronotype;
KIRP	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg00684032	chr4:1343700	KIAA1530	0.49	5.44	0.33	1.31e-7	Longevity;
KIRP	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.55	5.0	0.3	1.07e-6	Bipolar disorder;
KIRP	cis	rs7224685	0.501	rs781853	chr17:3953083	T/C	cg21851534	chr17:3907994	ZZEF1	0.65	10.48	0.56	1.68e-21	Type 2 diabetes;
KIRP	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg04226714	chr8:49833948	SNAI2	-0.53	-6.95	-0.41	3.28e-11	Life satisfaction;
KIRP	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08280861	chr8:58055591	NA	0.78	6.28	0.37	1.51e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.86	9.66	0.52	6.39e-19	Exhaled nitric oxide levels;
KIRP	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.62	8.47	0.48	2.29e-15	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	9.63	0.52	8.07e-19	Alzheimer's disease;
KIRP	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.42	-5.13	-0.31	5.98e-7	Facial morphology (factor 20);
KIRP	cis	rs4926611	0.796	rs6588482	chr1:54054618	T/A	cg08927728	chr1:54059983	GLIS1	0.24	5.3	0.32	2.51e-7	Hand grip strength;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg24719912	chr12:75893116	KRR1;GLIPR1	-0.4	-6.27	-0.37	1.65e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg18709589	chr6:96969512	KIAA0776	0.34	5.15	0.31	5.36e-7	Headache;
KIRP	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg24058013	chr18:77568902	NA	-0.74	-10.83	-0.57	1.28e-22	Schizophrenia;
KIRP	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.37	-15.0	-0.69	1.5e-36	Schizophrenia;
KIRP	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg24315340	chr6:146058215	EPM2A	-0.46	-6.14	-0.36	3.3e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs8135828	1.000	rs468852	chr22:29956156	T/C	cg23204276	chr22:29729285	AP1B1;SNORD125	-0.45	-5.0	-0.3	1.1e-6	Lipid traits;
KIRP	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.9	-11.79	-0.6	9.94e-26	Homoarginine levels;
KIRP	cis	rs4073221	0.520	rs66569729	chr3:18189623	A/C	cg07694806	chr3:18168406	NA	-0.89	-7.55	-0.43	8.61e-13	Parkinson's disease;
KIRP	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.55	-0.7	1.96e-38	Gut microbiome composition (summer);
KIRP	cis	rs860295	0.580	rs867548	chr1:155880008	G/C	cg02153340	chr1:155202674	NA	-0.38	-4.88	-0.3	1.92e-6	Body mass index;
KIRP	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.4	-5.72	-0.34	3.13e-8	Bipolar disorder;
KIRP	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.38	5.09	0.31	7.02e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.38	5.1	0.31	6.94e-7	Dupuytren's disease;
KIRP	cis	rs4713675	0.584	rs509539	chr6:33708190	A/C	cg25922239	chr6:33757077	LEMD2	-0.45	-5.21	-0.32	3.97e-7	Plateletcrit;
KIRP	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.67	7.46	0.43	1.52e-12	Hair shape;
KIRP	cis	rs9603616	0.719	rs4334152	chr13:40257420	G/A	cg26701198	chr13:40229707	COG6	0.44	5.18	0.31	4.54e-7	Rheumatoid arthritis;
KIRP	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.5	-6.18	-0.37	2.58e-9	Menarche (age at onset);
KIRP	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg27494647	chr7:150038898	RARRES2	0.38	5.85	0.35	1.57e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.56	7.17	0.42	8.88e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.75	-10.02	-0.54	4.75e-20	Hemoglobin concentration;
KIRP	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg09571762	chr12:39539558	NA	0.36	5.06	0.31	8.25e-7	Morning vs. evening chronotype;
KIRP	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.44	-5.88	-0.35	1.32e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7119167	0.686	rs78053199	chr11:73054908	A/T	cg17517138	chr11:73019481	ARHGEF17	0.48	5.07	0.31	7.79e-7	Blood protein levels;
KIRP	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg16077055	chr2:106428750	NCK2	-0.28	-5.59	-0.34	5.92e-8	Addiction;
KIRP	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.46	-5.69	-0.34	3.69e-8	Personality dimensions;
KIRP	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.61	7.73	0.44	2.77e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.63	-6.39	-0.38	8.45e-10	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.74	6.51	0.38	4.29e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg02527881	chr3:46936655	PTH1R	-0.42	-6.13	-0.36	3.55e-9	Colorectal cancer;
KIRP	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.44	-6.53	-0.38	3.81e-10	Electroencephalogram traits;
KIRP	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg19847130	chr8:10466454	RP1L1	-0.35	-5.06	-0.31	8.32e-7	Retinal vascular caliber;
KIRP	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg05315796	chr3:52349193	DNAH1	0.45	6.99	0.41	2.53e-11	Bipolar disorder;
KIRP	cis	rs687432	0.924	rs11601082	chr11:57727084	C/T	cg19752551	chr11:57585705	CTNND1	-0.69	-9.15	-0.5	2.23e-17	Parkinson's disease;
KIRP	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg22676075	chr6:135203613	NA	-0.65	-8.67	-0.48	5.85e-16	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg14558114	chr2:88469736	THNSL2	0.66	5.37	0.32	1.81e-7	Plasma clusterin levels;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22168489	chr12:122356033	WDR66	-0.61	-9.27	-0.51	1.01e-17	Mean corpuscular volume;
KIRP	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.35	6.1	0.36	4.16e-9	Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg17724175	chr1:150552817	MCL1	-0.34	-5.69	-0.34	3.62e-8	Melanoma;
KIRP	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	0.99	16.36	0.72	3.27e-41	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg27170947	chr2:26402098	FAM59B	-0.64	-7.21	-0.42	6.95e-12	Gut microbiome composition (summer);
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg05577945	chr13:78271874	SLAIN1	0.54	6.21	0.37	2.29e-9	Smoking initiation;
KIRP	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg07972983	chr1:205091412	RBBP5	0.41	4.89	0.3	1.82e-6	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs56161922	1.000	rs17045979	chr1:207842704	T/C	cg09557387	chr1:207818395	CR1L	1.08	6.5	0.38	4.51e-10	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg00142735	chr15:64454827	PPIB	0.54	6.18	0.37	2.69e-9	Lung cancer in ever smokers;
KIRP	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.87	-11.92	-0.61	3.6e-26	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	8.93	0.49	1.03e-16	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.96	14.53	0.68	6.12e-35	Triglycerides;
KIRP	cis	rs55986470	0.630	rs67981771	chr2:239402647	C/T	cg08773314	chr2:239334832	ASB1	-0.32	-5.03	-0.31	9.36e-7	Chronotype;
KIRP	cis	rs8070740	0.838	rs35491297	chr17:5327481	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	7.37	0.43	2.56e-12	Menopause (age at onset);
KIRP	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.11	-0.41	1.24e-11	Blood pressure;
KIRP	cis	rs7289126	0.868	rs2267377	chr22:38629519	T/C	cg25457927	chr22:38595422	NA	-0.32	-7.19	-0.42	7.75e-12	Mammographic density (dense area);Percent mammographic density;
KIRP	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg09904177	chr6:26538194	HMGN4	0.46	6.2	0.37	2.41e-9	Schizophrenia;
KIRP	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06544989	chr22:39130855	UNC84B	0.48	8.05	0.46	3.58e-14	Menopause (age at onset);
KIRP	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg09184832	chr6:79620586	NA	-0.44	-6.06	-0.36	5.06e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg02574844	chr11:5959923	NA	-0.51	-5.02	-0.3	9.81e-7	DNA methylation (variation);
KIRP	cis	rs2712184	0.935	rs2541387	chr2:217666174	A/C	cg05032264	chr2:217675019	NA	-0.52	-7.83	-0.45	1.43e-13	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.52	0.81	1.78e-58	Prudent dietary pattern;
KIRP	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.45	5.21	0.32	4e-7	Glomerular filtration rate (creatinine);
KIRP	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.51	7.4	0.43	2.14e-12	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs77956314	0.901	rs80001826	chr12:117335652	G/C	cg02017074	chr12:117425053	FBXW8	-0.55	-4.92	-0.3	1.59e-6	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg14664628	chr15:75095509	CSK	-0.44	-5.26	-0.32	3.12e-7	Airflow obstruction;
KIRP	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.31	5.93	0.35	1.02e-8	Schizophrenia;
KIRP	trans	rs979961	0.563	rs80040417	chr4:117908687	A/G	cg02574033	chr7:141398961	KIAA1147	0.93	6.14	0.36	3.21e-9	Ulcerative colitis;
KIRP	cis	rs7127900	0.904	rs7123418	chr11:2232378	A/C	cg25635251	chr11:2234043	NA	0.52	7.81	0.45	1.63e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg05519781	chr21:40033154	ERG	0.64	8.71	0.49	4.48e-16	Coronary artery disease;
KIRP	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg14289826	chr9:140003911	NA	0.31	4.91	0.3	1.66e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg17507749	chr15:85114479	UBE2QP1	0.8	8.36	0.47	4.72e-15	Schizophrenia;
KIRP	cis	rs6838801	0.892	rs13108785	chr4:77576070	A/C	cg17476223	chr4:77663285	SHROOM3	0.55	7.96	0.45	6.17e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.75	11.15	0.58	1.23e-23	Oral cavity cancer;
KIRP	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg06565975	chr8:143823917	SLURP1	-0.5	-7.23	-0.42	6.02e-12	Urinary tract infection frequency;
KIRP	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg26441486	chr22:50317300	CRELD2	0.48	7.8	0.45	1.73e-13	Schizophrenia;
KIRP	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.85	-13.03	-0.64	7.18e-30	Prostate cancer;
KIRP	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg12486944	chr17:80159399	CCDC57	-0.4	-5.34	-0.32	2.1e-7	Life satisfaction;
KIRP	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	1.02	19.58	0.78	4.16e-52	Breast cancer;
KIRP	cis	rs16854884	1.000	rs16854886	chr3:143781492	A/G	cg06585982	chr3:143692056	C3orf58	0.53	5.77	0.35	2.36e-8	Economic and political preferences (feminism/equality);
KIRP	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.74	11.71	0.6	1.79e-25	Calcium levels;
KIRP	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.96	-13.49	-0.65	2.02e-31	Dementia and core Alzheimer's disease neuropathologic changes;
KIRP	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.77	9.81	0.53	2.16e-19	Corneal astigmatism;
KIRP	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg04310649	chr10:35416472	CREM	-0.55	-6.1	-0.36	4.13e-9	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg22284058	chr8:142237359	SLC45A4	-0.53	-6.72	-0.39	1.25e-10	Immature fraction of reticulocytes;
KIRP	cis	rs6832769	0.890	rs1980273	chr4:56367401	C/G	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.88	12.81	0.63	4.08e-29	Mean platelet volume;
KIRP	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg13010199	chr12:38710504	ALG10B	0.55	6.87	0.4	5.19e-11	Morning vs. evening chronotype;
KIRP	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.48	6.92	0.4	3.99e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg12598211	chr12:123634384	NA	-0.45	-5.44	-0.33	1.27e-7	Neutrophil percentage of white cells;
KIRP	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg23594656	chr7:65796392	TPST1	0.52	8.26	0.47	8.75e-15	Aortic root size;
KIRP	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg00310523	chr12:86230176	RASSF9	0.55	8.46	0.47	2.38e-15	Major depressive disorder;
KIRP	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.5	6.84	0.4	6.42e-11	Symmetrical dimethylarginine levels;
KIRP	cis	rs2281603	0.521	rs10142879	chr14:64965842	C/T	cg01860774	chr14:64969374	ZBTB25	0.33	5.37	0.32	1.8e-7	Lymphocyte counts;
KIRP	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.68	9.05	0.5	4.52e-17	Response to fenofibrate (adiponectin levels);
KIRP	cis	rs4664293	0.867	rs34392518	chr2:160605878	G/T	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg17294928	chr15:75287854	SCAMP5	0.57	7.72	0.44	2.96e-13	Breast cancer;
KIRP	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.78	-11.22	-0.58	7.02e-24	Blood metabolite levels;
KIRP	cis	rs6684514	1.000	rs12040868	chr1:156284803	G/T	cg16558208	chr1:156270281	VHLL	-0.42	-5.5	-0.33	9.44e-8	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels;
KIRP	cis	rs10992471	0.580	rs10992366	chr9:95317214	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.5	-0.33	9.63e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.6	6.83	0.4	6.53e-11	Obesity-related traits;
KIRP	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.5	-7.72	-0.44	2.9e-13	IgG glycosylation;
KIRP	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg13444842	chr1:152974279	SPRR3	0.38	5.38	0.32	1.74e-7	Inflammatory skin disease;
KIRP	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	1.03	20.06	0.79	1.08e-53	Breast cancer;
KIRP	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.7	9.39	0.51	4.13e-18	Response to fenofibrate (adiponectin levels);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg27271756	chr15:45815164	C15orf21;SLC30A4	-0.47	-6.34	-0.37	1.1e-9	Metabolic traits;
KIRP	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.61	8.07	0.46	3.17e-14	Lung cancer;
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02359409	chr6:42947317	PEX6	-0.51	-7.07	-0.41	1.56e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.57	-6.64	-0.39	1.94e-10	Menopause (age at onset);
KIRP	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg03714773	chr7:91764589	CYP51A1	0.39	5.66	0.34	4.13e-8	Breast cancer;
KIRP	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.46	-7.58	-0.44	6.88e-13	Testicular germ cell tumor;
KIRP	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.04	12.81	0.63	3.89e-29	Vitiligo;
KIRP	cis	rs4481887	0.538	rs10888328	chr1:248378777	G/A	cg01631408	chr1:248437212	OR2T33	-0.4	-4.91	-0.3	1.66e-6	Common traits (Other);
KIRP	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg18306943	chr3:40428807	ENTPD3	-0.4	-5.43	-0.33	1.35e-7	Renal cell carcinoma;
KIRP	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-15.35	-0.7	9.05e-38	Electrocardiographic conduction measures;
KIRP	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg09201719	chr10:104596890	CYP17A1	0.4	5.75	0.34	2.65e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.82	8.95	0.5	8.92e-17	Alzheimer's disease;
KIRP	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.43	5.56	0.33	6.85e-8	Blood metabolite levels;
KIRP	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg09580153	chr6:41068724	NFYA;LOC221442	-0.46	-5.53	-0.33	8.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg05973401	chr12:123451056	ABCB9	0.54	6.2	0.37	2.37e-9	Neutrophil percentage of white cells;
KIRP	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.77	9.49	0.52	2.03e-18	Coronary artery disease;
KIRP	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg13198984	chr17:80129470	CCDC57	0.54	8.43	0.47	3.01e-15	Life satisfaction;
KIRP	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.41	-0.55	2.81e-21	Alzheimer's disease (late onset);
KIRP	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg10223061	chr2:219282414	VIL1	-0.33	-5.41	-0.33	1.51e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg01988459	chr11:68622903	NA	-0.36	-5.19	-0.31	4.5e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs539514	0.563	rs7983875	chr13:76329245	T/C	cg04757411	chr13:76259545	LMO7	-0.47	-6.98	-0.41	2.71e-11	Type 1 diabetes;
KIRP	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.35	5.47	0.33	1.08e-7	Body mass index;
KIRP	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg00129232	chr17:37814104	STARD3	0.72	7.94	0.45	7.28e-14	Glomerular filtration rate (creatinine);
KIRP	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24110177	chr3:50126178	RBM5	-0.65	-8.84	-0.49	1.84e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs876084	0.722	rs2875932	chr8:121043869	C/T	cg22335954	chr8:121166405	COL14A1	-0.42	-5.28	-0.32	2.91e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.43	5.15	0.31	5.42e-7	Lung cancer;Squamous cell lung carcinoma;
KIRP	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg00012203	chr2:219082015	ARPC2	-0.41	-5.07	-0.31	7.7e-7	Ulcerative colitis;
KIRP	cis	rs2594714	0.515	rs10411270	chr19:13940838	A/T	cg18576835	chr19:13944261	NA	-0.37	-5.01	-0.3	1.05e-6	Breast cancer;
KIRP	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	0.84	11.94	0.61	3.06e-26	Homoarginine levels;
KIRP	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.43	0.33	1.37e-7	Developmental language disorder (linguistic errors);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23559352	chr18:74203659	NA	0.53	6.5	0.38	4.42e-10	Parkinson's disease;
KIRP	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg08975724	chr8:8085496	FLJ10661	0.49	6.41	0.38	7.28e-10	Joint mobility (Beighton score);
KIRP	cis	rs1978968	0.763	rs34364976	chr22:18462027	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.79	-11.2	-0.58	8.59e-24	Presence of antiphospholipid antibodies;
KIRP	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg07395648	chr5:131743802	NA	0.5	7.1	0.41	1.31e-11	Breast cancer;
KIRP	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg07775547	chr4:1625484	NA	-0.44	-5.35	-0.32	1.99e-7	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17691542	chr6:26056736	HIST1H1C	0.54	7.27	0.42	4.64e-12	Height;
KIRP	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12893428	chr3:195717962	SDHAP1	0.45	5.95	0.35	9.23e-9	Pancreatic cancer;
KIRP	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-11.08	-0.58	2.09e-23	Response to antipsychotic treatment;
KIRP	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	5.54	0.33	7.76e-8	Personality dimensions;
KIRP	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg12315302	chr6:26189340	HIST1H4D	0.97	6.82	0.4	7.05e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07648498	chr16:89883185	FANCA	0.4	5.03	0.31	9.3e-7	Vitiligo;
KIRP	cis	rs77688320	0.517	rs10497868	chr2:202304040	A/G	cg06431681	chr2:202330990	STRADB	-0.56	-7.15	-0.41	1e-11	Breast cancer;
KIRP	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-5.74	-0.34	2.77e-8	Personality dimensions;
KIRP	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-7.65	-0.44	4.47e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs490234	0.756	rs925473	chr9:128228026	A/G	cg14078157	chr9:128172775	NA	-0.59	-6.86	-0.4	5.54e-11	Mean arterial pressure;
KIRP	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.78	-8.53	-0.48	1.51e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.51	-9.55	-0.52	1.34e-18	Menarche (age at onset);
KIRP	cis	rs77372450	0.636	rs11748443	chr5:157029457	C/T	cg23851860	chr5:157002805	ADAM19	0.45	4.93	0.3	1.54e-6	Bipolar disorder (body mass index interaction);
KIRP	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-5.73	-0.34	2.88e-8	Lung cancer;
KIRP	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.61	6.57	0.39	2.98e-10	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg27122127	chr5:179921426	CNOT6	0.44	6.02	0.36	6.14e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg26876637	chr1:152193138	HRNR	-0.7	-8.75	-0.49	3.4e-16	Atopic dermatitis;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg08140548	chr1:70710389	SFRS11	-0.47	-7.21	-0.42	6.98e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg11608241	chr8:8085544	FLJ10661	-0.42	-5.17	-0.31	4.78e-7	Recombination measurement;
KIRP	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.3e-16	Life satisfaction;
KIRP	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg24169773	chr3:122142474	KPNA1	-0.52	-5.31	-0.32	2.47e-7	LDL cholesterol levels;
KIRP	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg10047753	chr17:41438598	NA	1.14	17.86	0.75	2.67e-46	Menopause (age at onset);
KIRP	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00300879	chr1:26503847	CNKSR1	0.49	7.05	0.41	1.8e-11	Height;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg15111573	chr4:6304483	WFS1	0.5	6.17	0.37	2.84e-9	Interleukin-4 levels;
KIRP	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg25486957	chr4:152246857	NA	-0.46	-5.51	-0.33	9.2e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs4790312	0.875	rs9303241	chr17:1978963	T/A	cg24156229	chr17:1948635	NA	-0.41	-5.15	-0.31	5.45e-7	Left atrial antero-posterior diameter;
KIRP	cis	rs16854884	1.000	rs16854884	chr3:143778708	A/C	cg06585982	chr3:143692056	C3orf58	0.54	6.19	0.37	2.47e-9	Economic and political preferences (feminism/equality);
KIRP	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.74	-8.01	-0.45	4.64e-14	Asthma;
KIRP	cis	rs290268	0.769	rs2562396	chr9:93567425	C/A	cg02608019	chr9:93564028	SYK	0.8	10.71	0.56	3.22e-22	Platelet count;
KIRP	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs735539	0.555	rs8001310	chr13:21339700	G/C	cg04906043	chr13:21280425	IL17D	-0.43	-4.98	-0.3	1.2e-6	Dental caries;
KIRP	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.46	5.16	0.31	5.09e-7	Schizophrenia;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg25154432	chr5:79703725	ZFYVE16	-0.52	-6.67	-0.39	1.69e-10	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-0.78	-10.98	-0.57	4.27e-23	Intelligence (multi-trait analysis);
KIRP	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.48	-5.86	-0.35	1.47e-8	Asthma (sex interaction);
KIRP	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.53	-5.86	-0.35	1.49e-8	Response to simvastatin treatment (PCSK9 protein level change);
KIRP	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.68	9.96	0.54	7.73e-20	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg01849466	chr14:104193079	ZFYVE21	-0.4	-4.85	-0.3	2.24e-6	Schizophrenia;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg01380710	chr6:46459138	NA	-0.6	-6.58	-0.39	2.82e-10	Menopause (age at onset);
KIRP	cis	rs986417	0.818	rs12883272	chr14:61015153	A/G	cg27398547	chr14:60952738	C14orf39	0.58	4.95	0.3	1.38e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-6.6	-0.39	2.52e-10	Height;
KIRP	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.53	-6.57	-0.39	3.04e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.71	0.39	1.3e-10	Colorectal cancer;
KIRP	cis	rs7106204	0.534	rs75335266	chr11:24256395	G/T	ch.11.24196551F	chr11:24239977	NA	0.83	6.9	0.4	4.45e-11	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg01721255	chr8:58191610	C8orf71	0.56	5.16	0.31	5.04e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.18	20.73	0.8	6.56e-56	Cognitive function;
KIRP	cis	rs7011507	1.000	rs78892986	chr8:49189640	T/C	cg15325961	chr8:49183143	NA	0.61	5.2	0.31	4.17e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.15	-15.55	-0.7	1.96e-38	Gut microbiome composition (summer);
KIRP	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg26465581	chr5:140221106	PCDHA6;PCDHA2;PCDHA1;PCDHA7;PCDHA8;PCDHA5;PCDHA3;PCDHA4	-0.41	-5.03	-0.31	9.5e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg13880726	chr7:1868755	MAD1L1	0.52	5.64	0.34	4.55e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs2562456	0.833	rs2650776	chr19:21613397	C/T	cg00806126	chr19:22604979	ZNF98	-0.61	-5.71	-0.34	3.16e-8	Pain;
KIRP	cis	rs4783244	0.794	rs59317411	chr16:82646032	C/T	cg09415485	chr16:82663111	CDH13	-0.29	-5.3	-0.32	2.59e-7	Adiponectin levels;
KIRP	trans	rs656319	0.591	rs17734690	chr8:9713196	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-8.87	-0.49	1.51e-16	Myopia (pathological);
KIRP	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.3	0.32	2.59e-7	Depression;
KIRP	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.24	13.53	0.65	1.44e-31	Uric acid levels;
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg12692727	chr7:1102344	C7orf50	0.48	5.12	0.31	6.03e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	0.62	5.35	0.32	2.05e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs4262150	0.883	rs12657097	chr5:152257408	G/A	cg12297329	chr5:152029980	NA	-0.62	-8.14	-0.46	1.98e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg02733842	chr7:1102375	C7orf50	0.59	6.02	0.36	6.29e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg18357526	chr6:26021779	HIST1H4A	0.39	5.06	0.31	8.32e-7	Height;
KIRP	cis	rs9409565	0.826	rs9409550	chr9:97223294	C/G	cg04523069	chr9:97136363	HIATL1	0.47	6.2	0.37	2.38e-9	Colorectal cancer (alcohol consumption interaction);
KIRP	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg18171855	chr10:2543474	NA	-0.46	-6.59	-0.39	2.72e-10	Age-related hearing impairment;
KIRP	cis	rs7851660	0.874	rs925487	chr9:100636398	C/T	cg13688889	chr9:100608707	NA	-0.67	-8.75	-0.49	3.36e-16	Strep throat;
KIRP	cis	rs7084402	0.967	rs1658457	chr10:60302716	T/C	cg05938607	chr10:60274200	BICC1	-0.45	-10.87	-0.57	9.86e-23	Refractive error;
KIRP	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.49	7.35	0.42	2.84e-12	Resting heart rate;
KIRP	cis	rs7119038	0.509	rs10892258	chr11:118579865	A/G	cg19308663	chr11:118741387	NA	-0.42	-6.69	-0.39	1.52e-10	Sjögren's syndrome;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg10096405	chr4:1208301	CTBP1	-0.41	-6.18	-0.37	2.59e-9	Bladder cancer;
KIRP	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06850241	chr22:41845214	NA	-0.45	-5.64	-0.34	4.58e-8	Vitiligo;
KIRP	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg13628971	chr7:2884303	GNA12	0.39	4.89	0.3	1.85e-6	Height;
KIRP	cis	rs76693355	0.512	rs10892565	chr11:120235560	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.44	-5.77	-0.35	2.42e-8	Intraocular pressure;
KIRP	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	0.98	12.23	0.61	3.5e-27	Blood protein levels;
KIRP	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg05220968	chr6:146057943	EPM2A	-0.38	-4.86	-0.3	2.12e-6	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg06320982	chr16:58718767	SLC38A7	0.57	6.23	0.37	2.06e-9	Lung function (FEV1);
KIRP	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	1.09	20.59	0.8	1.97e-55	Height;
KIRP	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg04935436	chr20:30431758	NA	0.49	6.18	0.37	2.66e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs859767	0.501	rs1568120	chr2:135406890	A/G	cg25422880	chr2:135218333	TMEM163	0.35	5.17	0.31	4.91e-7	Neuroticism;
KIRP	trans	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg14791747	chr16:20752902	THUMPD1	0.63	6.73	0.39	1.16e-10	Cognitive test performance;
KIRP	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	13.95	0.66	5.48e-33	Platelet count;
KIRP	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg09699651	chr6:150184138	LRP11	0.53	7.01	0.41	2.31e-11	Lung cancer;
KIRP	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg05861140	chr6:150128134	PCMT1	-0.51	-7.13	-0.41	1.11e-11	Lung cancer;
KIRP	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.6	7.65	0.44	4.43e-13	Corneal astigmatism;
KIRP	cis	rs16976116	0.901	rs2899580	chr15:55491571	A/G	cg11288833	chr15:55489084	RSL24D1	0.67	7.48	0.43	1.32e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03651054	chr13:50194643	NA	0.74	11.43	0.59	1.46e-24	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.59	5.47	0.33	1.11e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.79	-0.4	8.52e-11	Height;
KIRP	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg15181151	chr6:150070149	PCMT1	0.29	4.97	0.3	1.25e-6	Lung cancer;
KIRP	cis	rs2274273	0.662	rs60445539	chr14:55624245	C/T	cg04306507	chr14:55594613	LGALS3	0.42	5.54	0.33	7.86e-8	Protein biomarker;
KIRP	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.87	8.65	0.48	6.96e-16	Methadone dose in opioid dependence;
KIRP	cis	rs400736	0.602	rs6694154	chr1:8163520	G/A	cg25007680	chr1:8021821	PARK7	-0.45	-5.96	-0.36	8.5e-9	Response to antidepressants and depression;
KIRP	trans	rs9371601	0.859	rs578359	chr6:152717704	C/G	cg05529123	chr2:66910386	NA	-0.45	-6.2	-0.37	2.32e-9	Bipolar disorder;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg15247329	chr7:2764246	NA	-0.34	-4.86	-0.3	2.06e-6	Height;
KIRP	cis	rs897080	0.518	rs1067330	chr2:44627822	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.58	6.42	0.38	6.81e-10	Height;
KIRP	cis	rs593982	0.858	rs480989	chr11:65493992	A/G	cg08755490	chr11:65554678	OVOL1	1.2	15.59	0.71	1.38e-38	Atopic dermatitis;
KIRP	cis	rs113422568	1	rs113422568	chr10:104337938	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-6.15	-0.36	3.19e-9	Sum eosinophil basophil counts;
KIRP	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.6	-8.38	-0.47	3.99e-15	Brugada syndrome;
KIRP	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.11	-0.64	3.91e-30	Alzheimer's disease;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24986058	chr14:100812247	WARS	0.48	6.43	0.38	6.43e-10	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs6832769	0.925	rs6817267	chr4:56338541	G/A	cg09317128	chr4:56265301	TMEM165	0.55	7.44	0.43	1.63e-12	Personality dimensions;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg19377384	chr3:140951430	ACPL2	0.63	6.01	0.36	6.48e-9	Lung function (FEV1);
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25359666	chr3:32544162	CMTM6	-0.46	-6.06	-0.36	5.07e-9	Myopia;
KIRP	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Parkinson's disease;
KIRP	cis	rs3087591	1.000	rs4541129	chr17:29442878	T/C	cg24425628	chr17:29625626	OMG;NF1	0.71	10.04	0.54	4.34e-20	Hip circumference;
KIRP	cis	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg06521331	chr12:34319734	NA	-0.61	-7.18	-0.42	8.24e-12	Morning vs. evening chronotype;
KIRP	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17344932	chr17:38183730	MED24;SNORD124	0.49	7.99	0.45	5.35e-14	White blood cell count (basophil);White blood cell count;
KIRP	cis	rs9318086	0.935	rs2025701	chr13:24440581	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.6	8.09	0.46	2.68e-14	Myopia (pathological);
KIRP	cis	rs3741151	0.892	rs77127734	chr11:73018413	T/A	cg17517138	chr11:73019481	ARHGEF17	0.76	6.37	0.38	9.23e-10	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg10755058	chr3:40428713	ENTPD3	-0.44	-6.42	-0.38	6.83e-10	Renal cell carcinoma;
KIRP	cis	rs10129255	0.556	rs6576224	chr14:107186236	G/A	cg23076370	chr14:107095027	NA	-0.41	-5.16	-0.31	5.07e-7	Kawasaki disease;
KIRP	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.96	8.84	0.49	1.87e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs2458413	0.586	rs2669453	chr8:105368930	C/A	cg08657449	chr8:105351661	TM7SF4	-0.33	-5.5	-0.33	9.65e-8	Paget's disease;
KIRP	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg16077055	chr2:106428750	NCK2	0.29	5.85	0.35	1.57e-8	Addiction;
KIRP	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.41	0.38	7.37e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	trans	rs7939886	0.920	rs11231885	chr11:55804022	T/A	cg03929089	chr4:120376271	NA	0.95	7.05	0.41	1.75e-11	Myopia (pathological);
KIRP	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.83	-12.65	-0.63	1.35e-28	Extrinsic epigenetic age acceleration;
KIRP	cis	rs2273669	0.667	rs12216104	chr6:109317635	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-6.33	-0.37	1.14e-9	Prostate cancer;
KIRP	cis	rs12190007	0.934	rs10455745	chr6:169743497	A/G	cg15038512	chr6:170123185	PHF10	0.39	5.66	0.34	4.1e-8	Obesity-related traits;
KIRP	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	5.02	0.31	9.71e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs988913	0.957	rs4437472	chr6:54838438	C/T	cg03513858	chr6:54763001	FAM83B	-0.38	-5.28	-0.32	2.86e-7	Menarche (age at onset);
KIRP	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-9.23	-0.51	1.33e-17	Parkinson's disease;
KIRP	cis	rs2274273	0.624	rs8014477	chr14:55841477	A/G	cg04306507	chr14:55594613	LGALS3	-0.37	-5.18	-0.31	4.64e-7	Protein biomarker;
KIRP	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.42	5.08	0.31	7.61e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03037437	chr2:232263444	B3GNT7	-0.45	-6.22	-0.37	2.08e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg12833952	chr11:113746456	USP28	-0.46	-6.35	-0.38	1.04e-9	Metabolic traits;
KIRP	cis	rs11203032	0.831	rs9651424	chr10:90932935	A/G	cg16672925	chr10:90967113	CH25H	0.74	7.34	0.42	3.14e-12	Heart failure;
KIRP	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg07636037	chr3:49044803	WDR6	-0.71	-6.74	-0.39	1.14e-10	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg02487422	chr3:49467188	NICN1	0.39	5.31	0.32	2.47e-7	Parkinson's disease;
KIRP	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	11.71	0.6	1.88e-25	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1729407	0.774	rs2849167	chr11:116684744	A/G	cg11861562	chr11:117069780	TAGLN	-0.39	-5.09	-0.31	7.23e-7	Apolipoprotein A-IV levels;
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg13284614	chr3:52569169	NT5DC2;LOC440957	0.34	5.09	0.31	7.01e-7	Electroencephalogram traits;
KIRP	cis	rs1318772	1.000	rs255857	chr5:112743066	G/T	cg12552261	chr5:112820674	MCC	0.78	4.97	0.3	1.26e-6	F-cell distribution;
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg02733842	chr7:1102375	C7orf50	-0.49	-5.08	-0.31	7.55e-7	Bronchopulmonary dysplasia;
KIRP	trans	rs2378383	0.915	rs7044969	chr9:82078913	A/T	cg04305621	chr17:73084263	SLC16A5	0.52	6.49	0.38	4.59e-10	Asthma (childhood onset);
KIRP	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg08975724	chr8:8085496	FLJ10661	-0.52	-6.39	-0.38	8.38e-10	Systolic blood pressure;
KIRP	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.75	11.16	0.58	1.17e-23	Longevity;Endometriosis;
KIRP	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg13647721	chr17:30228624	UTP6	0.54	5.11	0.31	6.35e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.54	-7.46	-0.43	1.49e-12	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.64	8.01	0.45	4.74e-14	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9473924	0.657	rs3857598	chr6:50938101	T/A	cg03432817	chr6:50765336	NA	0.35	5.43	0.33	1.36e-7	Body mass index;
KIRP	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	1.1	8.15	0.46	1.82e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg10790698	chr19:18539756	SSBP4	-0.35	-7.71	-0.44	3.2e-13	Breast cancer;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg26521561	chr2:198283608	SF3B1	-0.42	-6.46	-0.38	5.46e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.45	5.77	0.35	2.38e-8	Motion sickness;
KIRP	cis	rs8084125	0.832	rs62105179	chr18:74950858	A/G	cg18461021	chr18:74961002	GALR1	0.5	5.21	0.32	3.95e-7	Obesity-related traits;
KIRP	cis	rs4727443	0.866	rs6963345	chr7:99618606	G/A	cg22004693	chr7:99632812	ZKSCAN1	0.41	5.23	0.32	3.54e-7	Interstitial lung disease;
KIRP	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.61	-7.91	-0.45	8.56e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs883565	0.610	rs4676600	chr3:39157011	A/G	cg01426195	chr3:39028469	NA	-0.47	-7.15	-0.41	1.01e-11	Handedness;
KIRP	cis	rs6832769	0.961	rs2177127	chr4:56379959	A/C	cg05960024	chr4:56376020	CLOCK	0.73	9.48	0.52	2.34e-18	Personality dimensions;
KIRP	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg01304814	chr3:48885189	PRKAR2A	0.62	5.29	0.32	2.68e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs3789045	0.774	rs12028476	chr1:204476361	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.62	-6.27	-0.37	1.59e-9	Educational attainment (college completion);
KIRP	trans	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg15469184	chr8:337539	NA	0.57	6.06	0.36	4.98e-9	Obesity-related traits;
KIRP	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.78	-10.6	-0.56	7.09e-22	Aortic root size;
KIRP	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg06521331	chr12:34319734	NA	-0.48	-6.12	-0.36	3.59e-9	Morning vs. evening chronotype;
KIRP	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.44	-7.43	-0.43	1.79e-12	Type 2 diabetes;
KIRP	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.86	-13.64	-0.66	6.46e-32	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs5770917	1.000	rs5770911	chr22:51011241	C/T	cg25309564	chr22:51001381	C22orf41	0.94	5.44	0.33	1.3e-7	Narcolepsy;
KIRP	trans	rs694419	0.727	rs595765	chr18:60159889	A/C	cg11881472	chr11:36442485	PRR5L	-0.33	-6.04	-0.36	5.61e-9	Serum albumin level;
KIRP	cis	rs236907	0.859	rs10913683	chr1:171758699	T/C	cg01410279	chr1:171621941	MYOC	-0.49	-5.57	-0.33	6.83e-8	Mean platelet volume;
KIRP	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24110177	chr3:50126178	RBM5	-0.42	-5.46	-0.33	1.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-8.56	-0.48	1.28e-15	Resting heart rate;
KIRP	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.51	-8.89	-0.49	1.3e-16	Lymphocyte counts;
KIRP	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.84	-9.1	-0.5	3.07e-17	Triglycerides;
KIRP	cis	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg04607699	chr11:48328132	OR4S1	-0.35	-4.94	-0.3	1.46e-6	HDL cholesterol;
KIRP	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg05941025	chr16:89927596	SPIRE2	0.34	5.37	0.32	1.79e-7	Vitiligo;
KIRP	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg18154014	chr19:37997991	ZNF793	0.8	8.28	0.47	7.85e-15	Coronary artery calcification;
KIRP	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.62	-6.59	-0.39	2.72e-10	Vitiligo;
KIRP	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.69	10.97	0.57	4.53e-23	Lung cancer;
KIRP	cis	rs2522056	1.000	rs2405528	chr5:131794298	G/A	cg07395648	chr5:131743802	NA	0.57	6.78	0.4	8.93e-11	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg16584676	chr17:46985605	UBE2Z	0.49	6.04	0.36	5.53e-9	Type 2 diabetes;
KIRP	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.74	9.12	0.5	2.7e-17	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.39	4.88	0.3	1.91e-6	Common traits (Other);
KIRP	cis	rs600806	0.778	rs10776698	chr1:110013630	C/T	cg02175308	chr1:109941060	SORT1	-0.28	-5.19	-0.31	4.32e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg17757837	chr7:157058334	UBE3C	0.8	10.73	0.56	2.78e-22	Body mass index;
KIRP	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg11031976	chr2:198649780	BOLL	0.48	4.95	0.3	1.35e-6	Ulcerative colitis;
KIRP	cis	rs7213347	0.581	rs7209460	chr17:2048713	C/T	cg16513277	chr17:2031491	SMG6	-0.43	-4.87	-0.3	1.99e-6	Total body bone mineral density;
KIRP	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg16898833	chr6:26189333	HIST1H4D	-0.83	-5.95	-0.35	9.1e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3779635	0.742	rs2163175	chr8:27258249	A/G	cg18234130	chr8:27182889	PTK2B	0.52	6.85	0.4	5.98e-11	Neuroticism;
KIRP	cis	rs12220238	0.915	rs12217890	chr10:76024496	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	6.49	0.38	4.76e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs1659258	0.568	rs1258438	chr2:88605767	C/T	cg00685853	chr2:88648947	NA	-0.54	-6.21	-0.37	2.25e-9	Visceral fat;
KIRP	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.59	-8.4	-0.47	3.64e-15	Diastolic blood pressure;
KIRP	cis	rs9810890	1.000	rs73207996	chr3:128599110	C/G	cg15033153	chr3:128514015	RAB7A	0.73	5.11	0.31	6.48e-7	Dental caries;
KIRP	trans	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	6.22	0.37	2.09e-9	Mean corpuscular volume;
KIRP	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.89e-7	Life satisfaction;
KIRP	cis	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg00405596	chr8:11794950	NA	0.43	5.25	0.32	3.22e-7	Neuroticism;
KIRP	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg24631222	chr15:78858424	CHRNA5	-0.8	-9.64	-0.52	7.57e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs77688320	0.535	rs6435084	chr2:202325997	T/G	cg06431681	chr2:202330990	STRADB	0.52	6.59	0.39	2.65e-10	Breast cancer;
KIRP	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	-0.43	-6.26	-0.37	1.73e-9	Platelet count;
KIRP	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.83	9.64	0.52	7.45e-19	Systolic blood pressure;
KIRP	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.88	8.5	0.48	1.87e-15	Bronchopulmonary dysplasia;
KIRP	cis	rs17209837	0.607	rs4148820	chr7:87080482	T/C	cg00919237	chr7:87102261	ABCB4	-0.67	-8.58	-0.48	1.07e-15	Gallbladder cancer;
KIRP	cis	rs2295359	1.000	rs11209006	chr1:67619259	T/G	cg11235152	chr1:67600687	NA	0.63	9.51	0.52	1.86e-18	Psoriasis;
KIRP	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.79	-6.93	-0.4	3.62e-11	Mean platelet volume;
KIRP	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg06212747	chr3:49208901	KLHDC8B	0.8	8.09	0.46	2.73e-14	Menarche (age at onset);
KIRP	cis	rs80130819	0.688	rs6580660	chr12:48588112	T/C	cg26205652	chr12:48591994	NA	0.49	5.54	0.33	7.57e-8	Prostate cancer;
KIRP	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg07052231	chr12:7363540	PEX5	0.38	5.08	0.31	7.34e-7	IgG glycosylation;
KIRP	cis	rs11138902	0.673	rs11139279	chr9:72161412	C/T	cg14123607	chr9:72164709	APBA1	-0.41	-5.18	-0.31	4.56e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	1.000	rs5992921	chr22:18445263	C/T	cg02610425	chr22:18483192	MICAL3	0.36	5.05	0.31	8.42e-7	Presence of antiphospholipid antibodies;
KIRP	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg04539111	chr16:67997858	SLC12A4	-0.52	-5.17	-0.31	4.95e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19346786	chr7:2764209	NA	-0.3	-5.17	-0.31	4.92e-7	Height;
KIRP	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg13939156	chr17:80058883	NA	-0.48	-5.58	-0.34	6.19e-8	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg07636037	chr3:49044803	WDR6	-0.77	-7.34	-0.42	3.16e-12	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg24642844	chr7:1081250	C7orf50	-0.37	-5.02	-0.3	1e-6	Longevity;Endometriosis;
KIRP	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg05022688	chr3:170137633	CLDN11	-0.41	-5.03	-0.31	9.58e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs10861342	1.000	rs703683	chr12:105567135	T/C	cg23923672	chr12:105501055	KIAA1033	0.81	6.81	0.4	7.55e-11	IgG glycosylation;
KIRP	cis	rs6540556	0.517	rs1474654	chr1:209884387	A/G	cg23920097	chr1:209922102	NA	-0.48	-5.4	-0.33	1.54e-7	Red blood cell count;
KIRP	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	9.21	0.51	1.45e-17	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.64	6.01	0.36	6.69e-9	Gut microbiome composition (summer);
KIRP	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.48	5.02	0.3	9.98e-7	Obesity (extreme);
KIRP	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.44	5.44	0.33	1.28e-7	Coronary artery disease;
KIRP	cis	rs73206853	0.764	rs7953794	chr12:111081197	A/G	cg12870014	chr12:110450643	ANKRD13A	0.48	4.91	0.3	1.66e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
KIRP	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	cg12689670	chr1:183009347	LAMC1	0.42	5.94	0.35	9.48e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs3779635	0.742	rs4732722	chr8:27258313	G/A	cg14221460	chr8:27183342	PTK2B	0.5	6.54	0.38	3.63e-10	Neuroticism;
KIRP	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg09658497	chr7:2847517	GNA12	-0.35	-5.04	-0.31	8.87e-7	Height;
KIRP	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.84	13.79	0.66	2.01e-32	Intelligence (multi-trait analysis);
KIRP	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg25036284	chr2:26402008	FAM59B	-0.51	-5.29	-0.32	2.72e-7	Gut microbiome composition (summer);
KIRP	cis	rs3752645	0.649	rs10241140	chr7:106744512	T/G	cg02696742	chr7:106810147	HBP1	-0.6	-5.2	-0.31	4.19e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs4720118	0.508	rs3823763	chr7:33407894	A/C	cg22798885	chr7:33102694	NT5C3	-0.44	-5.41	-0.33	1.53e-7	Leprosy;
KIRP	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg07636037	chr3:49044803	WDR6	-0.58	-5.55	-0.33	7.3e-8	Menarche (age at onset);
KIRP	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg26207909	chr14:103986467	CKB	-0.43	-5.33	-0.32	2.17e-7	Coronary artery disease;
KIRP	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg25019033	chr10:957182	NA	-0.65	-7.61	-0.44	5.71e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.22	0.42	6.45e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs4594175	0.926	rs11624975	chr14:51628347	T/C	cg23942311	chr14:51606299	NA	0.5	6.61	0.39	2.36e-10	Cancer;
KIRP	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg17654217	chr7:100282651	GIGYF1	0.53	4.87	0.3	1.99e-6	Other erythrocyte phenotypes;
KIRP	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg17376030	chr22:41985996	PMM1	0.59	6.22	0.37	2.08e-9	Vitiligo;
KIRP	cis	rs7542091	0.704	rs7537294	chr1:210043777	A/G	cg22029157	chr1:209979665	IRF6	0.38	5.88	0.35	1.35e-8	Monobrow;
KIRP	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.59	-7.21	-0.42	6.71e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.46	-6.04	-0.36	5.63e-9	Brain structure;
KIRP	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.67	7.79	0.44	1.85e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg12160578	chr15:63334699	TPM1	0.64	6.78	0.4	8.89e-11	Orofacial clefts;
KIRP	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	7.84	0.45	1.35e-13	Lung cancer in ever smokers;
KIRP	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.42	-6.18	-0.37	2.71e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg10223061	chr2:219282414	VIL1	-0.41	-6.66	-0.39	1.8e-10	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.83	9.12	0.5	2.71e-17	Alzheimer's disease;
KIRP	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13606994	chr1:44402422	ARTN	0.29	5.38	0.32	1.76e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg24879335	chr3:133465180	TF	0.33	4.85	0.3	2.15e-6	Iron status biomarkers;
KIRP	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.12	14.92	0.69	2.74e-36	Lymphocyte percentage of white cells;
KIRP	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg13271783	chr10:134563150	INPP5A	0.35	4.85	0.3	2.2e-6	Migraine;
KIRP	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.73	-10.42	-0.55	2.78e-21	Morning vs. evening chronotype;
KIRP	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg01872077	chr2:219646372	CYP27A1	0.42	5.45	0.33	1.2e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.2	14.8	0.69	6.84e-36	Alzheimer's disease;
KIRP	cis	rs9928842	0.941	rs1808427	chr16:75241394	T/C	cg09066997	chr16:75300724	BCAR1	0.59	4.92	0.3	1.55e-6	Alcoholic chronic pancreatitis;
KIRP	cis	rs9469913	0.688	rs2814985	chr6:34548296	C/T	cg14254433	chr6:34482411	PACSIN1	-0.49	-5.7	-0.34	3.42e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
KIRP	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg02503808	chr4:7069936	GRPEL1	1.05	13.12	0.64	3.62e-30	Monocyte percentage of white cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg25753841	chr19:3500584	DOHH	0.51	6.43	0.38	6.41e-10	Parkinson's disease;
KIRP	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.91	12.16	0.61	5.73e-27	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.76	11.03	0.58	2.99e-23	Hip circumference;
KIRP	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg13293535	chr8:11597251	GATA4	-0.42	-5.45	-0.33	1.25e-7	Retinal vascular caliber;
KIRP	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.53	8.07	0.46	3.17e-14	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
KIRP	cis	rs1978968	0.717	rs13057517	chr22:18402669	G/T	cg03078520	chr22:18463400	MICAL3	-0.52	-6.31	-0.37	1.29e-9	Presence of antiphospholipid antibodies;
KIRP	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.45	-5.84	-0.35	1.61e-8	Crohn's disease;
KIRP	cis	rs6707387	0.598	rs12694303	chr2:214311983	T/C	cg08319019	chr2:214017104	IKZF2	0.42	4.9	0.3	1.77e-6	Fasting insulin (dietary factor interaction);Homeostasis model assessment of insulin resistance (dietary factor interaction);
KIRP	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.05	-0.36	5.28e-9	Parkinson's disease;
KIRP	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.45	-5.82	-0.35	1.87e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg24856050	chr19:3192433	NCLN	0.48	6.16	0.37	3e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs950169	0.656	rs748455	chr15:85149575	T/C	cg17507749	chr15:85114479	UBE2QP1	0.77	8.85	0.49	1.8e-16	Schizophrenia;
KIRP	trans	rs17394429	0.524	rs2134569	chr8:3277007	C/G	cg08428819	chr10:123924042	TACC2	0.45	6.42	0.38	6.95e-10	Obesity-related traits;
KIRP	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-6.26	-0.37	1.74e-9	Height;
KIRP	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.37	-6.37	-0.38	9.16e-10	Lymphocyte counts;
KIRP	cis	rs4523957	0.583	rs8067895	chr17:2030234	G/A	cg16513277	chr17:2031491	SMG6	-0.86	-12.77	-0.63	5.45e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs2013231	0.666	rs1396050	chr4:48108227	A/C	cg13469425	chr4:48175353	TEC	0.36	4.89	0.3	1.78e-6	Platelet distribution width;
KIRP	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.56	-5.9	-0.35	1.18e-8	Chronic sinus infection;
KIRP	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg10189774	chr4:17578691	LAP3	-0.43	-5.04	-0.31	9.18e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-8.2	-0.46	1.36e-14	Personality dimensions;
KIRP	cis	rs1355223	0.902	rs1453387	chr11:34707898	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-5.07	-0.31	7.88e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg20573242	chr4:122745356	CCNA2	0.42	5.11	0.31	6.33e-7	Type 2 diabetes;
KIRP	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg11846333	chr4:119757529	SEC24D	1.15	6.71	0.39	1.33e-10	Cannabis dependence symptom count;
KIRP	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg08508325	chr11:3079039	CARS	0.32	5.65	0.34	4.45e-8	Calcium levels;
KIRP	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg26876637	chr1:152193138	HRNR	0.73	9.82	0.53	2.02e-19	Atopic dermatitis;
KIRP	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg16586182	chr3:47516702	SCAP	-0.68	-9.25	-0.51	1.11e-17	Colorectal cancer;
KIRP	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.48	6.33	0.37	1.16e-9	Hemoglobin concentration;
KIRP	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.63	-7.6	-0.44	6.17e-13	Mean platelet volume;
KIRP	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.62	8.48	0.48	2.11e-15	Myopia (pathological);
KIRP	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg15358701	chr1:161410459	NA	-0.68	-6.26	-0.37	1.74e-9	Rheumatoid arthritis;
KIRP	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.79	-10.56	-0.56	9.65e-22	Longevity;Endometriosis;
KIRP	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.72	10.05	0.54	3.81e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg06963709	chr7:155150793	NA	0.54	6.52	0.38	4.01e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs7395581	0.918	rs1375688	chr11:47327217	G/A	cg25783544	chr11:47291846	MADD	0.44	4.99	0.3	1.14e-6	HDL cholesterol;
KIRP	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg04369109	chr6:150039330	LATS1	-0.56	-7.22	-0.42	6.28e-12	Lung cancer;
KIRP	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg22800045	chr5:56110881	MAP3K1	0.81	8.61	0.48	8.8e-16	Initial pursuit acceleration;
KIRP	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.81	-12.38	-0.62	1.08e-27	Educational attainment;
KIRP	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg18402987	chr7:1209562	NA	0.72	5.05	0.31	8.54e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg08885076	chr2:99613938	TSGA10	-0.64	-11.35	-0.59	2.68e-24	Chronic sinus infection;
KIRP	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.44	5.28	0.32	2.91e-7	Tonsillectomy;
KIRP	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg00348621	chr5:90680542	LOC100129716;ARRDC3	0.48	5.05	0.31	8.42e-7	Smoking behavior;
KIRP	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.2	-0.37	2.41e-9	Neutrophil percentage of white cells;
KIRP	cis	rs13095912	1.000	rs13072061	chr3:185326023	G/T	cg11274856	chr3:185301563	NA	0.53	6.91	0.4	4.17e-11	Systolic blood pressure;
KIRP	cis	rs16975963	0.644	rs75499934	chr19:38113043	C/A	cg18030218	chr19:38865513	PSMD8	0.54	4.85	0.3	2.15e-6	Longevity;
KIRP	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.5	6.84	0.4	6.38e-11	Glioblastoma;Glioma;
KIRP	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.62	7.96	0.45	6.4e-14	Iron status biomarkers;
KIRP	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg24565620	chr2:194026	NA	-0.63	-5.34	-0.32	2.09e-7	Blood protein levels;
KIRP	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.36	-7.25	-0.42	5.38e-12	Type 2 diabetes;
KIRP	cis	rs7224685	0.501	rs1377806	chr17:4019966	A/G	cg09695851	chr17:3907499	NA	0.82	15.04	0.69	1.07e-36	Type 2 diabetes;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg02092708	chr6:97063714	FHL5	0.44	6.04	0.36	5.6e-9	Migraine with aura;
KIRP	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg07435449	chr11:120005650	TRIM29	0.47	6.25	0.37	1.83e-9	Stroke (pediatric);
KIRP	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg23533926	chr12:111358616	MYL2	-0.48	-6.33	-0.37	1.18e-9	Extrinsic epigenetic age acceleration;
KIRP	cis	rs8077577	1.000	rs2015336	chr17:18073610	A/G	cg09161412	chr17:18057145	MYO15A	-0.4	-5.29	-0.32	2.7e-7	Obesity-related traits;
KIRP	cis	rs988913	1.000	rs2221334	chr6:54834541	A/C	cg03513858	chr6:54763001	FAM83B	-0.38	-5.67	-0.34	3.97e-8	Menarche (age at onset);
KIRP	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.89	0.69	3.63e-36	Platelet count;
KIRP	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.52	6.44	0.38	6.13e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg13180566	chr4:1052158	NA	-0.52	-5.28	-0.32	2.81e-7	Recombination rate (females);
KIRP	cis	rs9290877	0.667	rs9866839	chr3:188452557	A/G	cg17392043	chr3:188495102	LPP	-0.48	-6.27	-0.37	1.61e-9	IgE levels;
KIRP	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg21827317	chr3:136751795	NA	0.37	5.09	0.31	7.23e-7	Neuroticism;
KIRP	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-0.56	-7.99	-0.45	5.14e-14	Coronary artery disease;
KIRP	cis	rs4345220	0.546	rs12511338	chr4:41644585	T/G	cg15232654	chr4:41643107	LIMCH1	0.42	5.62	0.34	5.2e-8	Migraine with aura;
KIRP	cis	rs7923609	0.967	rs4486511	chr10:65264266	C/T	cg08743896	chr10:65200160	JMJD1C	-0.4	-5.88	-0.35	1.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-9.5	-0.52	1.93e-18	Chronic sinus infection;
KIRP	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07570687	chr10:102243282	WNT8B	0.49	6.07	0.36	4.7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg08992911	chr2:238395768	MLPH	0.52	5.19	0.31	4.5e-7	Prostate cancer;
KIRP	cis	rs2274273	0.870	rs11625001	chr14:55758160	T/C	cg04306507	chr14:55594613	LGALS3	0.43	6.62	0.39	2.24e-10	Protein biomarker;
KIRP	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.58	-8.97	-0.5	7.67e-17	Neuroticism;
KIRP	trans	rs74233809	0.901	rs4409766	chr10:104616663	A/G	cg04366687	chr8:145107199	OPLAH	-0.41	-6.19	-0.37	2.56e-9	Birth weight;
KIRP	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	12.46	0.62	5.97e-28	Smoking behavior;
KIRP	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg24826892	chr11:71159390	DHCR7	0.47	5.17	0.31	4.75e-7	Vitamin D levels;
KIRP	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.55	-5.85	-0.35	1.54e-8	Depression;
KIRP	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21659725	chr3:3221576	CRBN	-0.58	-7.15	-0.41	9.79e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17507749	chr15:85114479	UBE2QP1	0.72	7.93	0.45	7.76e-14	Schizophrenia;
KIRP	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-5.84	-0.35	1.65e-8	IgG glycosylation;
KIRP	cis	rs6693295	0.729	rs12022431	chr1:246216636	A/T	cg11798871	chr1:246315928	SMYD3	-0.42	-5.26	-0.32	3.17e-7	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.54	-7.15	-0.41	9.96e-12	Total body bone mineral density;
KIRP	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.3	-5.0	-0.3	1.1e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.59	7.22	0.42	6.51e-12	Blood metabolite levels;
KIRP	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg12486944	chr17:80159399	CCDC57	-0.41	-5.54	-0.33	7.74e-8	Life satisfaction;
KIRP	cis	rs273573	0.643	rs11031225	chr11:30873739	T/G	cg14844989	chr11:31128820	NA	0.34	4.87	0.3	1.97e-6	Total body bone mineral density;
KIRP	cis	rs72634258	0.554	rs34305100	chr1:7913029	A/G	cg26816564	chr1:7831052	VAMP3	0.68	6.05	0.36	5.22e-9	Inflammatory bowel disease;
KIRP	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg01294253	chr9:136912663	BRD3	0.4	5.22	0.32	3.81e-7	Platelet distribution width;
KIRP	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.55	5.31	0.32	2.4e-7	Initial pursuit acceleration;
KIRP	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg03684893	chr10:554711	DIP2C	-0.35	-4.92	-0.3	1.59e-6	Psychosis in Alzheimer's disease;
KIRP	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.54	-6.69	-0.39	1.52e-10	Menopause (age at onset);
KIRP	cis	rs7010267	0.935	rs6469789	chr8:119960661	C/G	cg01975934	chr8:119970761	NA	-0.42	-5.33	-0.32	2.17e-7	Total body bone mineral density (age 45-60);
KIRP	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg09754948	chr16:28834200	ATXN2L	0.47	5.4	0.33	1.6e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	1.15	7.99	0.45	5.3e-14	Cannabis dependence symptom count;
KIRP	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg10495392	chr1:46806563	NSUN4	0.48	5.46	0.33	1.18e-7	Menopause (age at onset);
KIRP	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs28489187	0.638	rs233055	chr1:85798486	A/C	cg16011679	chr1:85725395	C1orf52	0.45	5.67	0.34	4.06e-8	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg18461458	chr19:21324796	ZNF431	0.48	4.93	0.3	1.5e-6	Pain;
KIRP	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg19901468	chr14:105411992	AHNAK2	0.73	11.07	0.58	2.16e-23	Rheumatoid arthritis;
KIRP	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg26727032	chr16:67993705	SLC12A4	-0.7	-7.63	-0.44	5.03e-13	HDL cholesterol;Metabolic syndrome;
KIRP	trans	rs10107145	0.509	rs73209953	chr8:10760112	G/C	cg16141378	chr3:129829833	LOC729375	0.54	6.53	0.38	3.73e-10	Systolic blood pressure;
KIRP	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg01879757	chr17:41196368	BRCA1	-0.73	-10.2	-0.55	1.34e-20	Menopause (age at onset);
KIRP	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.73	10.18	0.54	1.5e-20	Crohn's disease;
KIRP	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg02336718	chr17:17403227	NA	-0.33	-5.29	-0.32	2.68e-7	Total body bone mineral density;
KIRP	cis	rs6504622	0.818	rs28451958	chr17:45045894	C/T	cg24703533	chr17:45055318	NA	0.4	5.62	0.34	5.22e-8	Orofacial clefts;
KIRP	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.63	-7.97	-0.45	5.87e-14	Longevity;Endometriosis;
KIRP	cis	rs9914578	1.000	rs9915112	chr17:2007826	A/G	cg16513277	chr17:2031491	SMG6	-0.71	-8.48	-0.48	2.07e-15	Body mass index;
KIRP	cis	rs34779708	0.733	rs3936503	chr10:35549257	A/G	cg03585969	chr10:35415529	CREM	-0.56	-6.56	-0.39	3.09e-10	Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-1.05	-11.22	-0.58	7.52e-24	Post bronchodilator FEV1;
KIRP	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	8.72	0.49	4.33e-16	Motion sickness;
KIRP	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.68	-7.09	-0.41	1.4e-11	Menarche (age at onset);
KIRP	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg03714773	chr7:91764589	CYP51A1	0.37	5.25	0.32	3.37e-7	Breast cancer;
KIRP	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.89	-11.87	-0.6	5.49e-26	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg21221161	chr1:1999183	PRKCZ	-0.43	-6.21	-0.37	2.19e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg15181151	chr6:150070149	PCMT1	0.29	4.87	0.3	1.97e-6	Lung cancer;
KIRP	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg00738919	chr7:1100172	C7orf50	0.42	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg22161376	chr15:67813132	C15orf61	0.41	6.17	0.37	2.72e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg10756647	chr7:56101905	PSPH	0.95	6.96	0.41	3.08e-11	Diabetic kidney disease;
KIRP	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.84	11.74	0.6	1.49e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs13161895	1.000	rs394616	chr5:179418134	T/G	cg02702477	chr5:179499311	RNF130	0.65	5.04	0.31	9.08e-7	LDL cholesterol;
KIRP	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-16.3	-0.72	5.51e-41	Height;
KIRP	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.69	-6.63	-0.39	2.06e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.62	-7.37	-0.43	2.57e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg19507638	chr5:93509721	C5orf36	-0.57	-4.93	-0.3	1.54e-6	Diabetic retinopathy;
KIRP	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	1.02	10.21	0.55	1.22e-20	Psoriasis;
KIRP	cis	rs7395581	0.918	rs7120957	chr11:47340649	A/G	cg25783544	chr11:47291846	MADD	0.44	4.92	0.3	1.58e-6	HDL cholesterol;
KIRP	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg07167872	chr1:205819463	PM20D1	-0.51	-4.95	-0.3	1.38e-6	Menarche (age at onset);
KIRP	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.67	7.79	0.45	1.82e-13	Alcohol dependence;
KIRP	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.95	9.0	0.5	6.18e-17	Type 2 diabetes;
KIRP	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.85	12.34	0.62	1.46e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs3008706	0.850	rs2987037	chr9:15997752	C/A	cg14451791	chr9:16040625	NA	-0.49	-4.98	-0.3	1.18e-6	Bilirubin levels;
KIRP	cis	rs4936894	0.500	rs11219560	chr11:124159965	C/T	cg27160556	chr11:124181099	OR8D1	-0.44	-6.38	-0.38	8.96e-10	Aging (time to death);
KIRP	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg03806693	chr22:41940476	POLR3H	-0.46	-5.53	-0.33	8.23e-8	Neuroticism;
KIRP	cis	rs12220238	0.915	rs11000948	chr10:76031721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.71	-6.64	-0.39	2.05e-10	Soluble interleukin-2 receptor subunit alpha;
KIRP	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.71	9.49	0.52	2.05e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg04539111	chr16:67997858	SLC12A4	-0.57	-5.08	-0.31	7.58e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1144	0.537	rs2470942	chr7:104583772	G/A	cg04380332	chr7:105027541	SRPK2	-0.54	-7.93	-0.45	7.8500000000000006e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
KIRP	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07570687	chr10:102243282	WNT8B	0.5	6.0	0.36	7e-9	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23161317	chr6:28129485	ZNF389	0.42	4.95	0.3	1.39e-6	Depression;
KIRP	cis	rs17453880	0.856	rs11953465	chr5:151960536	A/G	cg12297329	chr5:152029980	NA	-0.67	-10.15	-0.54	1.92e-20	Subjective well-being;
KIRP	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	25.59	0.85	2.66e-71	Chronic sinus infection;
KIRP	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg07395648	chr5:131743802	NA	0.45	5.95	0.35	8.97e-9	Breast cancer;Mosquito bite size;
KIRP	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg15556689	chr8:8085844	FLJ10661	0.49	6.52	0.38	3.91e-10	Neuroticism;
KIRP	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.57	7.46	0.43	1.49e-12	Breast cancer;
KIRP	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.48	6.71	0.39	1.37e-10	Sitting height ratio;
KIRP	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg11895451	chr1:16533891	ARHGEF19	0.5	6.79	0.4	8.22e-11	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg06289844	chr6:126071538	HEY2	0.38	5.52	0.33	8.68e-8	Brugada syndrome;
KIRP	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.49	-5.75	-0.34	2.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.27	5.68	0.34	3.7e-8	Asthma (sex interaction);
KIRP	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg06953865	chr19:18549723	ISYNA1	-0.42	-6.44	-0.38	6.17e-10	Breast cancer;
KIRP	cis	rs9815354	0.953	rs1716655	chr3:41918706	A/G	cg03022575	chr3:42003672	ULK4	-0.48	-5.38	-0.32	1.71e-7	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.56	-15.56	-0.7	1.74e-38	Hip circumference adjusted for BMI;
KIRP	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg09873164	chr1:152488093	CRCT1	0.55	6.37	0.38	9.03e-10	Hair morphology;
KIRP	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.4	7.92	0.45	7.95e-14	Height;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03725130	chr19:16435500	KLF2	0.55	7.14	0.41	1.05e-11	Parkinson's disease;
KIRP	cis	rs524023	0.756	rs475688	chr11:64364291	C/T	cg09231725	chr11:64357281	SLC22A12	-0.63	-7.28	-0.42	4.47e-12	Urate levels in obese individuals;
KIRP	cis	rs11628318	0.515	rs2093259	chr14:103145646	T/A	cg01864069	chr14:103024347	NA	0.41	4.96	0.3	1.31e-6	Platelet count;
KIRP	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.59	7.31	0.42	3.84e-12	Pancreatic cancer;
KIRP	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.67	10.26	0.55	8.33e-21	Intelligence (multi-trait analysis);
KIRP	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	1.15	8.09	0.46	2.69e-14	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg12705353	chr12:122356852	WDR66	0.53	6.98	0.41	2.7e-11	Mean corpuscular volume;
KIRP	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg01620082	chr3:125678407	NA	-0.87	-6.25	-0.37	1.82e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.53	-7.76	-0.44	2.27e-13	Bipolar disorder;
KIRP	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg24112000	chr20:60950667	NA	0.56	8.59	0.48	1.02e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg04995300	chr3:66848608	NA	0.74	8.98	0.5	7.22e-17	Type 2 diabetes;
KIRP	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg10792982	chr14:105748885	BRF1	0.86	12.8	0.63	4.26e-29	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg20999797	chr1:1681921	NA	0.51	7.69	0.44	3.57e-13	Body mass index;
KIRP	cis	rs7551222	0.749	rs6594019	chr1:204568610	T/C	cg20240347	chr1:204465584	NA	-0.41	-7.89	-0.45	9.66e-14	Schizophrenia;
KIRP	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	cis	rs4262150	0.883	rs11949473	chr5:152151759	A/C	cg12297329	chr5:152029980	NA	-0.54	-7.02	-0.41	2.16e-11	Bipolar disorder and schizophrenia;
KIRP	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg18944383	chr4:111397179	ENPEP	-0.39	-6.35	-0.38	1.05e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-11.87	-0.6	5.58e-26	Idiopathic membranous nephropathy;
KIRP	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg00745463	chr17:30367425	LRRC37B	0.72	6.27	0.37	1.61e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.85	9.93	0.53	9.5e-20	Neutrophil percentage of white cells;
KIRP	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.52	7.92	0.45	8.01e-14	Bone mineral density;
KIRP	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg26384229	chr12:38710491	ALG10B	0.49	6.16	0.37	2.92e-9	Morning vs. evening chronotype;
KIRP	cis	rs6910061	0.913	rs35199324	chr6:11112863	C/T	cg27233058	chr6:11094804	LOC221710	0.56	5.76	0.34	2.49e-8	Diabetic kidney disease;
KIRP	cis	rs151450	1	rs151450	chr4:88016514	G/A	cg11209507	chr4:87813803	C4orf36	0.38	4.94	0.3	1.45e-6	Basophil percentage of white cells;
KIRP	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg16524733	chr11:117070046	TAGLN	0.4	4.86	0.3	2.09e-6	Blood protein levels;
KIRP	cis	rs6062509	0.895	rs6011040	chr20:62337406	C/T	cg03999872	chr20:62272968	STMN3	-0.4	-4.92	-0.3	1.56e-6	Prostate cancer;
KIRP	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.28e-7	Bipolar disorder;
KIRP	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg17376030	chr22:41985996	PMM1	-0.83	-8.87	-0.49	1.57e-16	Vitiligo;
KIRP	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-8.23	-0.46	1.1e-14	Monocyte percentage of white cells;
KIRP	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg05991184	chr2:219186017	PNKD	0.34	4.92	0.3	1.58e-6	Colorectal cancer;
KIRP	trans	rs2270927	0.510	rs34596551	chr5:75577143	C/T	cg13563193	chr19:33072644	PDCD5	0.93	6.65	0.39	1.85e-10	Mean corpuscular volume;
KIRP	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg16268157	chr7:99778414	STAG3	-0.51	-5.93	-0.35	9.95e-9	Lung function (FEV1/FVC);
KIRP	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg12315302	chr6:26189340	HIST1H4D	1.09	6.05	0.36	5.45e-9	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg01879488	chr11:35160498	CD44	0.45	6.31	0.37	1.31e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg07274523	chr3:49395745	GPX1	0.58	5.46	0.33	1.15e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs698833	0.828	rs6748528	chr2:44517752	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	4.95	0.3	1.37e-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
KIRP	cis	rs732716	0.889	rs11666856	chr19:4437450	A/G	cg19820705	chr19:4455316	UBXN6	0.68	8.47	0.48	2.25e-15	Mean corpuscular volume;
KIRP	cis	rs1978968	0.956	rs2017932	chr22:18439190	C/A	cg02610425	chr22:18483192	MICAL3	0.36	5.0	0.3	1.1e-6	Presence of antiphospholipid antibodies;
KIRP	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg13939156	chr17:80058883	NA	-0.51	-7.6	-0.44	6.18e-13	Life satisfaction;
KIRP	cis	rs4073416	0.594	rs8022080	chr14:65999088	T/C	cg03016385	chr14:66212404	NA	-0.49	-5.79	-0.35	2.09e-8	N-glycan levels;
KIRP	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-9.0	-0.5	6.44e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.96	10.24	0.55	1.01e-20	Cognitive test performance;
KIRP	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg18944383	chr4:111397179	ENPEP	0.52	9.21	0.51	1.48e-17	Height;
KIRP	cis	rs11910985	0.546	rs9978916	chr21:48080492	A/C	cg23283320	chr21:48055893	PRMT2	1.15	8.66	0.48	6.52e-16	Cerebrospinal fluid t-tau:AB1-42 ratio;
KIRP	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.78	11.72	0.6	1.66e-25	Multiple myeloma (IgH translocation);
KIRP	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg15893493	chr8:124194847	FAM83A	0.89	7.05	0.41	1.84e-11	Urinary uromodulin levels;
KIRP	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.65	-11.06	-0.58	2.48e-23	Paraoxonase activity;
KIRP	cis	rs2904967	0.929	rs2904986	chr11:65031221	A/C	cg12562828	chr11:65076843	NA	0.47	7.14	0.41	1.04e-11	Mean corpuscular volume;
KIRP	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.5	-8.01	-0.45	4.68e-14	Height;
KIRP	cis	rs6142102	0.961	rs4911407	chr20:32683565	C/A	cg08999081	chr20:33150536	PIGU	0.51	6.13	0.36	3.38e-9	Skin pigmentation;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg14957846	chr19:16739131	MED26	-0.47	-6.19	-0.37	2.46e-9	Metabolic traits;
KIRP	cis	rs11239930	0.517	rs492243	chr1:146549478	G/A	cg16700924	chr1:146552102	NA	-0.44	-4.86	-0.3	2.06e-6	AIDS progression;
KIRP	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg08741688	chr4:3415352	RGS12	-0.47	-5.61	-0.34	5.49e-8	Serum sulfate level;
KIRP	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.92	0.4	4e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs11138902	0.649	rs1330331	chr9:72159507	C/T	cg14397918	chr9:72078829	APBA1	0.36	5.48	0.33	1.04e-7	Intelligence;Cognitive ability;Intelligence (multi-trait analysis);
KIRP	cis	rs10463316	1.000	rs10463316	chr5:150746034	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-5.65	-0.34	4.39e-8	Metabolite levels (Pyroglutamine);
KIRP	cis	rs4771122	0.596	rs7334690	chr13:28081535	C/T	cg22138327	chr13:27999177	GTF3A	0.47	5.06	0.31	8.27e-7	Body mass index;
KIRP	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg23156509	chr2:114033830	PAX8;LOC440839	0.38	5.86	0.35	1.51e-8	Lymphocyte counts;
KIRP	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg10402321	chr1:26617780	UBXN11	-0.43	-5.61	-0.34	5.39e-8	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs172166	0.637	rs1225592	chr6:28150242	G/A	cg02631126	chr6:28058918	ZSCAN12L1	0.44	5.21	0.32	3.93e-7	Cardiac Troponin-T levels;
KIRP	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.45	5.77	0.35	2.33e-8	Menopause (age at onset);
KIRP	cis	rs1978968	1.000	rs11704059	chr22:18449543	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-6.75	-0.4	1.08e-10	Presence of antiphospholipid antibodies;
KIRP	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg20818283	chr2:191399100	TMEM194B	0.51	6.51	0.38	4.23e-10	Pulse pressure;
KIRP	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg05669848	chr5:237993	SDHA	-0.49	-5.05	-0.31	8.42e-7	Breast cancer;
KIRP	cis	rs9815354	0.904	rs73079327	chr3:41864697	A/T	cg03022575	chr3:42003672	ULK4	0.51	5.96	0.36	8.8e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg23594656	chr7:65796392	TPST1	-0.43	-5.94	-0.35	9.75e-9	Aortic root size;
KIRP	cis	rs2151522	0.762	rs9388533	chr6:127165845	G/A	cg21431617	chr6:127135037	NA	0.29	5.19	0.31	4.51e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg21546286	chr11:48923668	NA	-0.45	-5.48	-0.33	1.05e-7	HDL cholesterol;
KIRP	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg00717180	chr2:96193071	NA	-0.5	-6.37	-0.38	9.08e-10	Coronary artery disease;
KIRP	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg12131826	chr15:77904385	NA	0.42	5.67	0.34	3.97e-8	Type 2 diabetes;
KIRP	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg23719950	chr11:63933701	MACROD1	-0.67	-6.45	-0.38	5.96e-10	Mean platelet volume;
KIRP	cis	rs13006833	0.668	rs2664252	chr2:191148347	G/A	cg21644426	chr2:191273491	MFSD6	0.47	5.7	0.34	3.37e-8	Urinary metabolites;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg13342158	chr8:30670271	PPP2CB	-0.57	-6.21	-0.37	2.26e-9	Menopause (age at onset);
KIRP	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27297192	chr10:134578999	INPP5A	0.6	7.53	0.43	9.9e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
KIRP	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.56	7.95	0.45	6.75e-14	Blood metabolite levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05368115	chr19:901123	C19orf22	-0.45	-6.65	-0.39	1.83e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.05	-17.41	-0.74	9e-45	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg24579218	chr15:68104479	NA	-0.56	-8.94	-0.5	9.36e-17	Restless legs syndrome;
KIRP	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.7	-7.1	-0.41	1.29e-11	Blood pressure (smoking interaction);
KIRP	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.73	10.72	0.56	2.95e-22	Prostate cancer;
KIRP	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.77	-10.92	-0.57	6.79e-23	Chronic sinus infection;
KIRP	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.77	11.67	0.6	2.47e-25	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg01763666	chr17:80159506	CCDC57	-0.36	-4.95	-0.3	1.41e-6	Life satisfaction;
KIRP	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg04727924	chr7:799746	HEATR2	-0.61	-6.21	-0.37	2.2e-9	Cerebrospinal P-tau181p levels;
KIRP	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg06637938	chr14:75390232	RPS6KL1	0.49	6.9	0.4	4.39e-11	Height;
KIRP	cis	rs703980	1.000	rs12571751	chr10:80942631	C/T	cg18737081	chr10:80999807	ZMIZ1	-0.28	-5.21	-0.32	3.99e-7	Type 2 diabetes;
KIRP	cis	rs7429990	0.896	rs34448818	chr3:47841312	G/A	cg11946769	chr3:48343235	NME6	0.54	5.42	0.33	1.41e-7	Educational attainment (years of education);
KIRP	cis	rs11628318	0.614	rs1190335	chr14:103111358	T/C	cg01864069	chr14:103024347	NA	-0.42	-5.16	-0.31	5.03e-7	Platelet count;
KIRP	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg18944383	chr4:111397179	ENPEP	-0.71	-13.3	-0.65	9.3e-31	Coronary artery disease;
KIRP	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg05692746	chr2:100937584	LONRF2	-0.38	-5.1	-0.31	6.76e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs1978968	0.763	rs9605481	chr22:18465677	C/T	cg03078520	chr22:18463400	MICAL3	-0.78	-9.53	-0.52	1.55e-18	Presence of antiphospholipid antibodies;
KIRP	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.72	9.63	0.52	7.86e-19	Renal function-related traits (BUN);
KIRP	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg15934090	chr1:100435551	SLC35A3	0.51	6.43	0.38	6.58e-10	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs17221829	0.635	rs3018758	chr11:89410463	A/G	cg02982614	chr11:89391479	FOLH1B	0.31	5.25	0.32	3.22e-7	Anxiety in major depressive disorder;
KIRP	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.59	7.53	0.43	9.41e-13	Eosinophil percentage of white cells;
KIRP	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg08313168	chr12:7315531	NA	0.68	6.18	0.37	2.61e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs12049351	0.774	rs12022203	chr1:229658797	C/T	cg11742688	chr1:229674241	ABCB10	-0.4	-5.49	-0.33	1e-7	Circulating myeloperoxidase levels (plasma);
KIRP	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.49	-6.32	-0.37	1.22e-9	Systolic blood pressure;
KIRP	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg21231944	chr12:82153410	PPFIA2	-0.42	-5.06	-0.31	8.2e-7	Resting heart rate;
KIRP	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.56	8.0	0.45	4.83e-14	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg07274523	chr3:49395745	GPX1	0.69	8.58	0.48	1.08e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs742134	0.915	rs909667	chr22:43532156	A/G	cg26453588	chr22:43506021	BIK	0.39	5.47	0.33	1.09e-7	Prostate cancer;
KIRP	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-7.42	-0.43	1.92e-12	Morning vs. evening chronotype;
KIRP	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	4.97	0.3	1.28e-6	Menopause (age at onset);
KIRP	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.52	7.5	0.43	1.18e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.38	5.97	0.36	8.15e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.87	12.83	0.63	3.5e-29	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.61	-4.95	-0.3	1.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs41005	0.967	rs193927	chr2:8108055	G/A	cg03155496	chr2:8117019	LOC339788	0.57	9.59	0.52	1.06e-18	Response to anti-TNF therapy in rheumatoid arthritis;
KIRP	cis	rs7927997	0.708	rs10160518	chr11:76296671	A/G	cg17647271	chr11:76299819	NA	-0.36	-4.89	-0.3	1.84e-6	Gut microbiota (functional units);Crohn's disease;
KIRP	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg08462292	chr1:97188168	PTBP2	0.44	6.18	0.37	2.68e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
KIRP	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-5.52	-0.33	8.71e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.46	8.81	0.49	2.25e-16	Educational attainment (years of education);
KIRP	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.71	9.35	0.51	5.79e-18	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg18882449	chr10:104885122	NT5C2	-0.48	-6.16	-0.37	3e-9	Arsenic metabolism;
KIRP	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg06636001	chr8:8085503	FLJ10661	0.7	9.28	0.51	8.96e-18	Retinal vascular caliber;
KIRP	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg27121462	chr16:89883253	FANCA	-0.51	-6.72	-0.39	1.23e-10	Vitiligo;
KIRP	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.44	5.53	0.33	8.36e-8	Platelet count;
KIRP	cis	rs4237845	0.591	rs2372309	chr12:58329820	G/A	cg02175503	chr12:58329896	NA	0.88	10.79	0.57	1.72e-22	Intelligence (multi-trait analysis);
KIRP	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg15432903	chr11:17409602	KCNJ11	-0.52	-6.02	-0.36	6.17e-9	Systolic blood pressure;
KIRP	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg17376030	chr22:41985996	PMM1	-0.54	-5.79	-0.35	2.1e-8	Vitiligo;
KIRP	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.88	13.34	0.65	6.33e-31	Mean corpuscular hemoglobin;
KIRP	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg09163369	chr1:210001066	C1orf107	-0.66	-6.97	-0.41	2.97e-11	Orofacial clefts;
KIRP	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg12861170	chr19:19639553	YJEFN3	-0.48	-4.9	-0.3	1.73e-6	Bipolar disorder;
KIRP	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg13385521	chr17:29058706	SUZ12P	0.55	5.41	0.33	1.5e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg13409248	chr3:40428643	ENTPD3	-0.37	-5.1	-0.31	6.8e-7	Renal cell carcinoma;
KIRP	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-1.01	-8.69	-0.48	5.26e-16	Blood protein levels;
KIRP	cis	rs4663866	1.000	rs4663300	chr2:239181491	T/C	cg16914508	chr2:239161102	PER2	0.71	5.2	0.31	4.11e-7	Irritable bowel syndrome;
KIRP	cis	rs11209185	0.509	rs9436790	chr1:68447044	G/A	cg22082780	chr1:68452167	NA	0.36	5.28	0.32	2.82e-7	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg00745463	chr17:30367425	LRRC37B	-0.61	-6.31	-0.37	1.29e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-6.78	-0.4	8.77e-11	Heart rate;
KIRP	cis	rs7851660	0.844	rs10119853	chr9:100624981	G/A	cg13688889	chr9:100608707	NA	-0.69	-8.86	-0.49	1.61e-16	Strep throat;
KIRP	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.83	-9.9	-0.53	1.18e-19	Body mass index;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23002097	chr19:58898625	RPS5	-0.44	-6.05	-0.36	5.41e-9	Metabolic traits;
KIRP	cis	rs6959887	0.962	rs1362207	chr7:35282435	T/A	cg06685737	chr7:35301730	NA	0.44	6.47	0.38	5.26e-10	Birth weight;
KIRP	cis	rs2278796	0.918	rs2290138	chr1:204956325	C/G	cg17947172	chr1:204966197	NFASC	-0.58	-7.75	-0.44	2.43e-13	Mean platelet volume;
KIRP	cis	rs2120243	0.647	rs1456099	chr3:157146307	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	-0.34	-5.04	-0.31	9.15e-7	Hepatocellular carcinoma in hepatitis B infection;
KIRP	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.78	-10.58	-0.56	8.35e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg00495681	chr13:53174319	NA	0.36	4.92	0.3	1.6e-6	Lewy body disease;
KIRP	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg08499158	chr17:42289980	UBTF	-0.63	-8.1	-0.46	2.58e-14	Total body bone mineral density;
KIRP	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.85	-0.45	1.28e-13	Total cholesterol levels;
KIRP	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg08610935	chr16:1836813	NUBP2	0.55	6.81	0.4	7.44e-11	Insulin-like growth factors;
KIRP	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg11941060	chr3:133502564	NA	-0.48	-5.95	-0.35	8.95e-9	Iron status biomarkers;
KIRP	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.44	-5.8	-0.35	2.06e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.67	-6.74	-0.39	1.12e-10	Systemic lupus erythematosus;
KIRP	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.79	-9.02	-0.5	5.46e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	trans	rs12545912	0.770	rs12677313	chr8:9543120	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-6.23	-0.37	2.04e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs7209700	0.662	rs8066295	chr17:45348203	A/G	cg08085267	chr17:45401833	C17orf57	-0.42	-4.91	-0.3	1.68e-6	IgG glycosylation;
KIRP	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg25547332	chr5:131281432	NA	0.49	5.52	0.33	8.52e-8	Life satisfaction;
KIRP	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.89	10.71	0.56	3.27e-22	Diastolic blood pressure;Systolic blood pressure;
KIRP	cis	rs7116495	1.000	rs7948821	chr11:71652485	G/A	cg26138937	chr11:71823887	C11orf51	-0.71	-5.72	-0.34	3.08e-8	Severe influenza A (H1N1) infection;
KIRP	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg04374321	chr14:90722782	PSMC1	-0.61	-8.22	-0.46	1.15e-14	Mortality in heart failure;
KIRP	cis	rs6545883	0.783	rs6545888	chr2:61845215	T/G	cg15711740	chr2:61764176	XPO1	-0.53	-6.92	-0.4	3.81e-11	Tuberculosis;
KIRP	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg13147721	chr7:65941812	NA	1.05	7.14	0.41	1.04e-11	Diabetic kidney disease;
KIRP	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg02336718	chr17:17403227	NA	0.35	5.4	0.33	1.55e-7	Total body bone mineral density;
KIRP	cis	rs9547996	1.000	rs9547997	chr13:38222943	G/A	cg13634560	chr13:38173852	POSTN	-0.36	-4.97	-0.3	1.27e-6	Diastolic blood pressure;
KIRP	cis	rs7849270	0.921	rs7019373	chr9:131897221	C/T	cg13538475	chr9:131942899	NA	-0.31	-5.02	-0.3	9.92e-7	Blood metabolite ratios;
KIRP	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg01620082	chr3:125678407	NA	-1.27	-8.07	-0.46	3.11e-14	Depression;
KIRP	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg05791153	chr7:19748676	TWISTNB	0.69	6.05	0.36	5.49e-9	Thyroid stimulating hormone;
KIRP	trans	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg13565492	chr6:43139072	SRF	-0.92	-8.48	-0.48	2.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.55	6.05	0.36	5.36e-9	Coronary artery disease;
KIRP	cis	rs7809615	0.901	rs1581492	chr7:99186826	C/T	cg24024660	chr7:99195788	NA	-0.53	-4.86	-0.3	2.13e-6	Blood metabolite ratios;
KIRP	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg22903471	chr2:27725779	GCKR	0.39	5.43	0.33	1.38e-7	Oral cavity cancer;
KIRP	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	1.26	9.13	0.5	2.52e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.967	rs11169807	chr12:39244161	A/G	cg26384229	chr12:38710491	ALG10B	0.4	4.99	0.3	1.14e-6	Morning vs. evening chronotype;
KIRP	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	7.73	0.44	2.8e-13	Hip circumference adjusted for BMI;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg04633058	chr17:48474099	LRRC59	0.49	6.75	0.4	1.07e-10	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.76	9.87	0.53	1.47e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg11584989	chr19:19387371	SF4	0.61	6.58	0.39	2.75e-10	Bipolar disorder;
KIRP	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-8.98	-0.5	7.06e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg06307176	chr5:131281290	NA	-0.53	-5.87	-0.35	1.41e-8	Life satisfaction;
KIRP	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.73	0.39	1.19e-10	Hypertriglyceridemia;
KIRP	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg25828445	chr12:7781288	NA	0.53	5.4	0.33	1.53e-7	HDL cholesterol levels;
KIRP	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.89	10.58	0.56	8.19e-22	Glomerular filtration rate (creatinine);
KIRP	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	0.75	10.93	0.57	6.26e-23	Prudent dietary pattern;
KIRP	cis	rs12367572	0.501	rs11182829	chr12:45484189	C/T	cg04608330	chr12:45269318	NELL2	0.42	5.38	0.32	1.72e-7	Gut microbiome composition (summer);
KIRP	cis	rs2133450	0.508	rs7653020	chr3:7335201	G/A	cg19930620	chr3:7340148	GRM7	-0.4	-5.79	-0.35	2.12e-8	Early response to risperidone in schizophrenia;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg07846755	chr3:193852699	HES1	0.47	6.17	0.37	2.72e-9	Beard thickness;
KIRP	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg20560298	chr2:73613845	ALMS1	0.45	5.58	0.34	6.29e-8	Metabolite levels;
KIRP	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg12705353	chr12:122356852	WDR66	-0.5	-6.72	-0.39	1.23e-10	Mean corpuscular volume;
KIRP	cis	rs12580194	0.593	rs61956291	chr12:55797964	G/C	cg19537932	chr12:55886519	OR6C68	-0.52	-6.68	-0.39	1.62e-10	Cancer;
KIRP	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg13289132	chr10:30722225	MAP3K8	-0.42	-5.31	-0.32	2.45e-7	Inflammatory bowel disease;
KIRP	cis	rs28721375	0.514	rs708730	chr1:205777780	G/A	cg14159672	chr1:205819179	PM20D1	0.54	5.75	0.34	2.69e-8	Basophil percentage of granulocytes;
KIRP	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.69	-8.34	-0.47	5.38e-15	Aortic root size;
KIRP	cis	rs1873147	1.000	rs4775599	chr15:63311495	A/G	cg12160578	chr15:63334699	TPM1	-0.46	-5.59	-0.34	5.99e-8	Orofacial clefts;
KIRP	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg21253087	chr9:139290292	SNAPC4	0.47	6.6	0.39	2.56e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg03813033	chr19:50380022	AKT1S1;TBC1D17	0.46	6.1	0.36	4.01e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.79	-6.01	-0.36	6.8e-9	Hip circumference adjusted for BMI;
KIRP	cis	rs9398803	0.661	rs1101557	chr6:127067996	T/C	cg19875578	chr6:126661172	C6orf173	-0.42	-5.5	-0.33	9.28e-8	Male-pattern baldness;
KIRP	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.56	6.76	0.4	1.02e-10	Educational attainment;
KIRP	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg26248373	chr2:1572462	NA	-0.63	-5.73	-0.34	2.88e-8	Placebo response in major depressive disorder (% change in symptom score);
KIRP	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.48	-5.47	-0.33	1.11e-7	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.56	-5.12	-0.31	6.24e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.69	9.99	0.54	6.07e-20	Retinal vascular caliber;
KIRP	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg23565292	chr14:50234668	KLHDC2	-0.4	-4.86	-0.3	2.12e-6	Carotid intima media thickness;
KIRP	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.55	-6.61	-0.39	2.33e-10	Mosquito bite size;
KIRP	cis	rs877282	0.797	rs35927768	chr10:753095	T/C	cg17470449	chr10:769945	NA	0.65	6.06	0.36	5.11e-9	Uric acid levels;
KIRP	cis	rs867371	1.000	rs867371	chr15:82438346	A/T	cg00614314	chr15:82944287	LOC80154	-0.52	-6.19	-0.37	2.49e-9	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg17376030	chr22:41985996	PMM1	-0.77	-8.15	-0.46	1.81e-14	Vitiligo;
KIRP	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg12692727	chr7:1102344	C7orf50	0.48	5.07	0.31	7.93e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg06521331	chr12:34319734	NA	-0.64	-7.58	-0.44	7.12e-13	Morning vs. evening chronotype;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11553919	chr4:68604257	GNRHR	-0.44	-6.89	-0.4	4.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-9.39	-0.51	4.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs2072732	0.644	rs75787210	chr1:2942465	A/G	cg06792538	chr1:2954250	NA	0.42	5.01	0.3	1.04e-6	Plateletcrit;
KIRP	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.42	5.21	0.32	3.95e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4764487	0.760	rs740840	chr12:6337254	G/T	cg08284733	chr12:6341482	CD9	0.57	9.58	0.52	1.09e-18	Mean platelet volume;
KIRP	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.47	6.0	0.36	7.12e-9	Motion sickness;
KIRP	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.8	9.76	0.53	3.12e-19	Corneal astigmatism;
KIRP	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.53	-6.16	-0.37	2.88e-9	Aortic root size;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04244215	chr3:66551541	LRIG1	0.54	6.58	0.39	2.78e-10	Parkinson's disease;
KIRP	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	9.18	0.51	1.82e-17	Lymphocyte counts;
KIRP	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-12.0	-0.61	2.05e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg04306507	chr14:55594613	LGALS3	0.53	8.33	0.47	5.86e-15	Protein biomarker;
KIRP	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg21775007	chr8:11205619	TDH	-0.44	-5.72	-0.34	3.06e-8	Neuroticism;
KIRP	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg26875233	chr11:93583750	C11orf90	0.34	6.29	0.37	1.42e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.53	-0.38	3.71e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg05347473	chr6:146136440	FBXO30	0.61	8.69	0.48	5.17e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13185784	0.703	rs17627536	chr5:179678603	G/A	cg23221052	chr5:179740743	GFPT2	0.53	5.15	0.31	5.38e-7	TRAIL levels;
KIRP	cis	rs1514687	0.534	rs73908736	chr2:1465401	C/T	cg03133821	chr2:1513998	TPO	-0.66	-5.27	-0.32	2.94e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);
KIRP	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg23752985	chr2:85803571	VAMP8	0.49	6.04	0.36	5.61e-9	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	1.04	19.79	0.78	8.44e-53	Platelet distribution width;
KIRP	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.25	6.79	0.4	8.5e-11	Crohn's disease;
KIRP	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg13256891	chr4:100009986	ADH5	-0.48	-5.96	-0.36	8.61e-9	Alcohol dependence;
KIRP	cis	rs1018697	1.000	rs11191397	chr10:104558274	C/A	cg04362960	chr10:104952993	NT5C2	0.49	5.9	0.35	1.17e-8	Colorectal adenoma (advanced);
KIRP	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.63	-6.28	-0.37	1.53e-9	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs4073416	0.518	rs7157109	chr14:65900433	C/G	cg03016385	chr14:66212404	NA	-0.54	-6.7	-0.39	1.37e-10	N-glycan levels;
KIRP	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.69	8.52	0.48	1.61e-15	Platelet count;
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Life satisfaction;
KIRP	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg08975724	chr8:8085496	FLJ10661	0.58	8.19	0.46	1.43e-14	Neuroticism;
KIRP	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs1945213	0.694	rs67394518	chr11:55855303	G/A	cg03929089	chr4:120376271	NA	0.66	6.33	0.37	1.17e-9	Acute lymphoblastic leukemia (childhood);
KIRP	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	6.75	0.4	1.06e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs867371	1.000	rs7181655	chr15:82455616	T/C	cg00614314	chr15:82944287	LOC80154	0.55	6.61	0.39	2.4e-10	Cognitive ability;Cognitive ability (multi-trait analysis);
KIRP	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.76	7.68	0.44	3.68e-13	Migraine;Coronary artery disease;
KIRP	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.87	-13.52	-0.65	1.61e-31	Height;
KIRP	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg00677455	chr12:58241039	CTDSP2	-0.55	-6.59	-0.39	2.69e-10	Multiple sclerosis;
KIRP	cis	rs4849845	0.849	rs12711940	chr2:121036386	T/A	cg24070213	chr2:121070622	NA	0.38	5.22	0.32	3.75e-7	Mean platelet volume;
KIRP	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.54	6.16	0.37	2.94e-9	Diisocyanate-induced asthma;
KIRP	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.63	-9.53	-0.52	1.58e-18	Colorectal cancer;
KIRP	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.88	-14.04	-0.67	2.82e-33	Breast cancer;
KIRP	cis	rs4454254	0.966	rs4631439	chr8:141059650	C/T	cg05910124	chr8:141057427	TRAPPC9	-0.28	-5.46	-0.33	1.18e-7	Pulse pressure;
KIRP	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.71	-10.75	-0.57	2.31e-22	Blood metabolite ratios;
KIRP	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg09267113	chr7:98030324	BAIAP2L1	0.46	5.52	0.33	8.49e-8	Prostate cancer (SNP x SNP interaction);
KIRP	cis	rs4713675	0.584	rs9368776	chr6:33696405	A/G	cg15676125	chr6:33679581	C6orf125	0.39	5.18	0.31	4.56e-7	Plateletcrit;
KIRP	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg12598211	chr12:123634384	NA	-0.41	-5.05	-0.31	8.5e-7	Height;Educational attainment;Head circumference (infant);
KIRP	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg04896959	chr15:78267971	NA	0.75	10.3	0.55	6.57e-21	Coronary artery disease or large artery stroke;
KIRP	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-7.51	-0.43	1.08e-12	Colorectal cancer;
KIRP	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg18209359	chr17:80159595	CCDC57	-0.43	-5.55	-0.33	7.28e-8	Blood metabolite levels;
KIRP	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	cg12689670	chr1:183009347	LAMC1	0.47	6.8	0.4	7.95e-11	Colorectal cancer;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg11234017	chr17:42767172	CCDC43	0.54	6.34	0.37	1.11e-9	Smoking initiation;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.54	-6.07	-0.36	4.88e-9	Menopause (age at onset);
KIRP	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.38	-4.89	-0.3	1.78e-6	Testicular germ cell tumor;
KIRP	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg24060327	chr5:131705240	SLC22A5	-0.58	-7.8	-0.45	1.71e-13	Acylcarnitine levels;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg25654301	chr17:73511699	TSEN54;CASKIN2	-0.46	-6.51	-0.38	4.11e-10	Myopia;
KIRP	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg09873164	chr1:152488093	CRCT1	0.57	7.36	0.42	2.68e-12	Hair morphology;
KIRP	cis	rs4919044	0.600	rs78586043	chr10:94612458	T/G	cg05127821	chr10:94822908	CYP26C1	-0.9	-7.05	-0.41	1.8e-11	Coronary artery disease;
KIRP	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.63	-7.2	-0.42	7.44e-12	Response to antineoplastic agents;
KIRP	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg02375832	chr11:62437615	C11orf48	-0.4	-4.92	-0.3	1.6e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
KIRP	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-8.88	-0.49	1.44e-16	Retinal vascular caliber;
KIRP	cis	rs7011049	1.000	rs72640857	chr8:53839067	T/A	cg26025543	chr8:53854495	NA	0.74	7.75	0.44	2.4e-13	Systolic blood pressure;
KIRP	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.83	11.0	0.57	3.68e-23	Coronary artery disease or large artery stroke;
KIRP	cis	rs4356932	1.000	rs6814817	chr4:76951170	C/T	cg00809888	chr4:76862425	NAAA	0.43	6.07	0.36	4.82e-9	Blood protein levels;
KIRP	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.28	7.45	0.43	1.54e-12	Primary biliary cholangitis;
KIRP	cis	rs4262150	0.810	rs72799107	chr5:152053404	C/T	cg12297329	chr5:152029980	NA	-0.67	-8.2	-0.46	1.38e-14	Bipolar disorder and schizophrenia;
KIRP	cis	rs9303542	0.559	rs12946931	chr17:46614080	T/C	cg04904318	chr17:46607828	HOXB1	-0.62	-6.7	-0.39	1.38e-10	Ovarian cancer;Epithelial ovarian cancer;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg04018625	chr2:171608293	NA	0.39	6.12	0.36	3.64e-9	Cancer;
KIRP	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg03171003	chr2:111875934	NA	0.45	6.35	0.38	1.05e-9	Chronic lymphocytic leukemia;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg26243751	chr19:11495794	EPOR	0.38	6.27	0.37	1.61e-9	Survival in pancreatic cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg21147944	chr13:114264438	TFDP1	0.46	6.5	0.38	4.52e-10	Interleukin-4 levels;
KIRP	cis	rs2425143	1.000	rs6060591	chr20:34351476	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.6	-6.1	-0.36	4.01e-9	Blood protein levels;
KIRP	cis	rs62070183	0.938	rs62068432	chr17:31066497	A/G	cg05781649	chr17:31146240	MYO1D	-0.51	-5.06	-0.31	8.38e-7	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs9488822	0.676	rs12154016	chr6:116355188	C/T	cg05304507	chr6:116381966	FRK	0.2	5.53	0.33	8.36e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00338735	chr4:53728038	RASL11B	0.5	5.95	0.35	8.98e-9	Optic nerve measurement (cup area);
KIRP	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg00800038	chr16:89945340	TCF25	-0.77	-5.22	-0.32	3.78e-7	Skin colour saturation;
KIRP	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	13.37	0.65	5.01e-31	Platelet count;
KIRP	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg04287289	chr16:89883240	FANCA	-0.39	-5.14	-0.31	5.62e-7	Vitiligo;
KIRP	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.92	14.83	0.69	5.43e-36	Blood protein levels;
KIRP	cis	rs4356932	1.000	rs4859416	chr4:76986499	A/G	cg19388996	chr4:76862389	NAAA	0.4	5.14	0.31	5.68e-7	Blood protein levels;
KIRP	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.69	8.99	0.5	6.85e-17	Schizophrenia;
KIRP	cis	rs12579753	0.672	rs4509857	chr12:82268017	C/T	cg07988820	chr12:82153109	PPFIA2	-0.48	-6.12	-0.36	3.59e-9	Resting heart rate;
KIRP	cis	rs9900972	0.918	rs8082515	chr17:76876769	C/A	cg00961940	chr17:76876995	TIMP2	0.53	6.85	0.4	5.98e-11	Obesity-related traits;
KIRP	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.53	6.83	0.4	6.58e-11	Longevity;Endometriosis;
KIRP	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.78	-13.16	-0.64	2.62e-30	Calcium levels;
KIRP	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg14675211	chr2:100938903	LONRF2	0.47	6.02	0.36	6.29e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	8.76	0.49	3.16e-16	Bipolar disorder;
KIRP	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg14650228	chr8:144573510	ZC3H3	-0.7	-4.96	-0.3	1.31e-6	Attention deficit hyperactivity disorder;
KIRP	cis	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg12315302	chr6:26189340	HIST1H4D	0.74	5.18	0.31	4.51e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-7.14	-0.41	1.08e-11	Body mass index;
KIRP	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.42	-0.33	1.42e-7	Life satisfaction;
KIRP	trans	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg06521331	chr12:34319734	NA	-0.57	-6.96	-0.41	3.14e-11	Morning vs. evening chronotype;
KIRP	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg16179182	chr5:140090404	VTRNA1-1	-0.42	-5.26	-0.32	3.18e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7766436	0.922	rs2066338	chr6:22611393	C/T	cg13666174	chr6:22585274	NA	-0.46	-6.08	-0.36	4.55e-9	Coronary artery disease;
KIRP	cis	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-4.85	-0.3	2.15e-6	Cervical cancer;
KIRP	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg14255062	chr9:123606675	PSMD5;LOC253039	0.34	5.23	0.32	3.66e-7	Hip circumference adjusted for BMI;
KIRP	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.42	5.39	0.32	1.69e-7	Childhood ear infection;
KIRP	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg08885076	chr2:99613938	TSGA10	-0.55	-9.67	-0.52	6.06e-19	Chronic sinus infection;
KIRP	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg08885076	chr2:99613938	TSGA10	0.48	8.21	0.46	1.27e-14	Chronic sinus infection;
KIRP	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg07068956	chr7:100330872	ZAN	-0.53	-5.63	-0.34	5.03e-8	Other erythrocyte phenotypes;
KIRP	cis	rs7116495	0.609	rs6592457	chr11:71738086	G/C	cg07596299	chr11:71824057	C11orf51	-0.87	-5.44	-0.33	1.27e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.6	8.19	0.46	1.41e-14	Schizophrenia;
KIRP	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.31	-6.39	-0.38	8.11e-10	Schizophrenia;
KIRP	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg21395723	chr22:39101663	GTPBP1	0.44	5.39	0.33	1.63e-7	Menopause (age at onset);
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09163478	chr4:62936530	LPHN3	0.45	6.24	0.37	1.94e-9	Interleukin-4 levels;
KIRP	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.59	-9.6	-0.52	9.61e-19	Itch intensity from mosquito bite;
KIRP	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg15181151	chr6:150070149	PCMT1	0.29	4.94	0.3	1.46e-6	Lung cancer;
KIRP	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.49	4.95	0.3	1.4e-6	Tuberculosis;
KIRP	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.45	6.47	0.38	5.32e-10	Colonoscopy-negative controls vs population controls;
KIRP	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg16141378	chr3:129829833	LOC729375	0.49	6.12	0.36	3.69e-9	Retinal vascular caliber;
KIRP	cis	rs1448094	0.617	rs952851	chr12:86477341	C/T	cg02569458	chr12:86230093	RASSF9	-0.36	-4.92	-0.3	1.57e-6	Major depressive disorder;
KIRP	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.56	7.37	0.43	2.62e-12	Drug-induced liver injury (flucloxacillin);
KIRP	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg16141378	chr3:129829833	LOC729375	0.58	7.37	0.43	2.57e-12	Joint mobility (Beighton score);
KIRP	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.52	-5.76	-0.34	2.52e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03934478	chr11:495069	RNH1	0.88	7.11	0.41	1.23e-11	Body mass index;
KIRP	cis	rs7656342	0.636	rs1914874	chr4:9839490	C/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-4.9	-0.3	1.78e-6	Gut microbiota (bacterial taxa);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg06837842	chr10:27059746	ABI1	0.39	6.13	0.36	3.48e-9	C-reactive protein;
KIRP	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg03959625	chr15:84868606	LOC388152	0.48	5.63	0.34	4.84e-8	Schizophrenia;
KIRP	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	11.01	0.57	3.55e-23	Cognitive test performance;
KIRP	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg17724175	chr1:150552817	MCL1	0.35	5.81	0.35	1.92e-8	Melanoma;
KIRP	cis	rs151997	0.671	rs152926	chr5:50201787	G/A	cg06027927	chr5:50259733	NA	-0.6	-8.4	-0.47	3.51e-15	Callous-unemotional behaviour;
KIRP	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.88	-12.16	-0.61	6.02e-27	Obesity-related traits;
KIRP	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.44	7.53	0.43	9.71e-13	Heart rate;
KIRP	trans	rs2270927	0.510	rs31244	chr5:75594743	G/A	cg13563193	chr19:33072644	PDCD5	0.91	6.66	0.39	1.79e-10	Mean corpuscular volume;
KIRP	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg11766577	chr21:47581405	C21orf56	-0.39	-4.84	-0.3	2.26e-6	Testicular germ cell tumor;
KIRP	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg19126910	chr11:111249659	POU2AF1	0.48	5.66	0.34	4.27e-8	Primary biliary cholangitis;
KIRP	cis	rs6960043	0.905	rs11514706	chr7:15059272	A/C	cg19272540	chr7:15055459	NA	-0.21	-5.54	-0.33	7.74e-8	Type 2 diabetes;
KIRP	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg05315796	chr3:52349193	DNAH1	0.41	6.14	0.36	3.25e-9	Bipolar disorder;
KIRP	cis	rs78487399	0.808	rs28700209	chr2:43667465	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-5.3	-0.32	2.52e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-1.02	-11.96	-0.61	2.79e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.83	-8.78	-0.49	2.84e-16	Exhaled nitric oxide output;
KIRP	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg04944784	chr2:26401820	FAM59B	-0.69	-7.41	-0.43	1.97e-12	Gut microbiome composition (summer);
KIRP	cis	rs193541	0.632	rs1903260	chr5:122135188	T/C	cg19412675	chr5:122181750	SNX24	0.57	5.92	0.35	1.06e-8	Glucose homeostasis traits;
KIRP	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg24315340	chr6:146058215	EPM2A	-0.44	-5.57	-0.33	6.52e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-5.95	-0.35	9.29e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.79	-10.5	-0.56	1.56e-21	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs9962915	0.935	rs1785407	chr18:5594350	A/G	cg12967001	chr18:5544089	EPB41L3	-0.39	-4.97	-0.3	1.27e-6	Glomerular filtration rate (creatinine);
KIRP	cis	rs12580194	0.593	rs61957889	chr12:55724456	C/T	cg11794356	chr12:55725991	OR6C3	-0.56	-6.13	-0.36	3.53e-9	Cancer;
KIRP	trans	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg01620082	chr3:125678407	NA	-1.14	-6.7	-0.39	1.43e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs829883	0.659	rs11109524	chr12:98939172	G/A	cg25150519	chr12:98850993	NA	-0.75	-9.01	-0.5	5.85e-17	Colorectal adenoma (advanced);
KIRP	cis	rs6142102	0.625	rs7263727	chr20:32540939	T/C	cg08999081	chr20:33150536	PIGU	0.4	4.98	0.3	1.21e-6	Skin pigmentation;
KIRP	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg13939156	chr17:80058883	NA	-0.48	-7.23	-0.42	6.21e-12	Life satisfaction;
KIRP	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-6.03	-0.36	6e-9	Multiple sclerosis;
KIRP	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.77	10.16	0.54	1.73e-20	Aortic root size;
KIRP	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.57	5.33	0.32	2.26e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg05072774	chr3:49840536	C3orf54	-0.4	-5.14	-0.31	5.66e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg00319359	chr11:70116639	PPFIA1	0.53	5.6	0.34	5.67e-8	Coronary artery disease;
KIRP	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg06217071	chr17:408420	NA	0.5	7.22	0.42	6.27e-12	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
KIRP	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.56	7.82	0.45	1.51e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg24375607	chr4:120327624	NA	-0.47	-5.16	-0.31	5.13e-7	Corneal astigmatism;
KIRP	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.58	9.67	0.52	6.04e-19	Schizophrenia;
KIRP	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.43	-0.33	1.34e-7	Blood metabolite levels;
KIRP	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg02461776	chr11:598696	PHRF1	0.7	7.69	0.44	3.44e-13	Systemic lupus erythematosus;
KIRP	trans	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17183009	chr3:120277827	NA	0.54	6.14	0.36	3.37e-9	Corneal astigmatism;
KIRP	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.62	5.31	0.32	2.48e-7	Schizophrenia;
KIRP	trans	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg10756647	chr7:56101905	PSPH	1.01	7.5	0.43	1.16e-12	Diabetic kidney disease;
KIRP	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.68	9.6	0.52	9.75e-19	Plateletcrit;Platelet count;
KIRP	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.5	-8.5	-0.48	1.87e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	cg04338863	chr8:33670619	NA	0.48	6.22	0.37	2.11e-9	Body mass index;
KIRP	cis	rs2147904	0.866	rs1886729	chr1:42363966	G/A	cg16685388	chr1:42384056	HIVEP3	0.28	4.87	0.3	1.97e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
KIRP	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-5.96	-0.36	8.47e-9	Aortic root size;
KIRP	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.58	-6.73	-0.39	1.17e-10	Diabetic retinopathy;
KIRP	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	1.2	11.39	0.59	2.07e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.85	7.0	0.41	2.44e-11	Mean platelet volume;
KIRP	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg02160872	chr5:212506	CCDC127	-0.45	-4.93	-0.3	1.53e-6	Breast cancer;
KIRP	cis	rs7116495	0.737	rs7126838	chr11:71826237	A/G	cg11196788	chr11:71737549	NUMA1	-0.56	-5.02	-0.3	1.01e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.9	-8.06	-0.46	3.27e-14	Obesity;Body mass index;
KIRP	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg16898833	chr6:26189333	HIST1H4D	0.8	5.61	0.34	5.5e-8	Autism spectrum disorder or schizophrenia;
KIRP	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg23533926	chr12:111358616	MYL2	-0.52	-6.95	-0.41	3.28e-11	Extrinsic epigenetic age acceleration;
KIRP	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.94	9.14	0.5	2.41e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs258892	0.895	rs36040109	chr5:72050659	A/G	cg21869765	chr5:72125136	TNPO1	-0.51	-5.92	-0.35	1.08e-8	Small cell lung carcinoma;
KIRP	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg06818126	chr11:68850279	TPCN2	-0.47	-5.51	-0.33	9.11e-8	Hair color;
KIRP	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-5.15	-0.31	5.24e-7	Testicular germ cell tumor;
KIRP	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg15691649	chr6:25882328	NA	-0.45	-5.49	-0.33	9.99e-8	Blood metabolite levels;
KIRP	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.32	-0.37	1.2e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	1.32	9.84	0.53	1.73e-19	Intelligence (multi-trait analysis);
KIRP	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg01966878	chr4:90757139	SNCA	-0.44	-4.85	-0.3	2.23e-6	Neuroticism;
KIRP	cis	rs1030877	0.515	rs1866038	chr2:105878522	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.55	6.3	0.37	1.39e-9	Obesity-related traits;
KIRP	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg12405258	chr13:114927641	NA	0.48	6.93	0.4	3.66e-11	Schizophrenia;
KIRP	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg05347473	chr6:146136440	FBXO30	0.54	7.54	0.43	9.29e-13	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1961637	0.670	rs895773	chr2:223892804	C/G	cg02552189	chr2:223891284	NA	-0.48	-6.76	-0.4	9.87e-11	Oropharynx cancer;
KIRP	cis	rs77688320	0.553	rs11681526	chr2:202263760	C/A	cg06431681	chr2:202330990	STRADB	0.52	6.96	0.41	3.06e-11	Breast cancer;
KIRP	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg22563815	chr15:78856949	CHRNA5	0.5	7.58	0.44	6.96e-13	Sudden cardiac arrest;
KIRP	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.03	-17.39	-0.74	1.06e-44	Dilated cardiomyopathy;
KIRP	cis	rs7212590	0.748	rs7211208	chr17:57957109	A/C	cg10252138	chr17:58120427	NA	-0.58	-4.95	-0.3	1.4e-6	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.33	5.22	0.32	3.73e-7	Asthma;
KIRP	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg09455208	chr3:40491958	NA	-0.38	-7.02	-0.41	2.19e-11	Renal cell carcinoma;
KIRP	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.54	7.33	0.42	3.29e-12	Total body bone mineral density;
KIRP	cis	rs7588746	0.571	rs10931896	chr2:201148076	C/T	cg23649088	chr2:200775458	C2orf69	-0.44	-4.85	-0.3	2.2e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg05984388	chr16:30134345	MAPK3	0.49	6.56	0.39	3.19e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10875746	0.903	rs11168427	chr12:48538979	A/G	cg26205652	chr12:48591994	NA	0.78	10.45	0.55	2.22e-21	Longevity (90 years and older);
KIRP	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.47	-9.67	-0.52	6.03e-19	Multiple system atrophy;
KIRP	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg11846333	chr4:119757529	SEC24D	0.92	5.6	0.34	5.75e-8	Cannabis dependence symptom count;
KIRP	cis	rs40363	1.000	rs40535	chr16:3506222	C/G	cg00484396	chr16:3507460	NAT15	0.5	5.27	0.32	2.99e-7	Tuberculosis;
KIRP	cis	rs10181042	0.565	rs62150982	chr2:61280675	T/C	cg18625361	chr2:61244694	PEX13;PUS10	0.4	5.17	0.31	4.91e-7	Crohn's disease;
KIRP	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg25635251	chr11:2234043	NA	0.47	5.75	0.34	2.67e-8	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
KIRP	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg00361562	chr2:198649771	BOLL	-0.49	-4.84	-0.3	2.25e-6	Ulcerative colitis;
KIRP	cis	rs78487399	0.710	rs114510001	chr2:43517088	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-5.02	-0.3	9.89e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg27087555	chr16:88793112	FAM38A	-1.15	-7.01	-0.41	2.29e-11	Plateletcrit;
KIRP	cis	rs2594989	0.943	rs2594970	chr3:11400877	C/T	cg01796438	chr3:11312864	ATG7	-0.71	-8.27	-0.47	8.67e-15	Circulating chemerin levels;
KIRP	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg16479474	chr6:28041457	NA	0.43	4.85	0.3	2.22e-6	Depression;
KIRP	cis	rs9311676	0.609	rs62258077	chr3:58363371	T/C	cg06643156	chr3:58380774	PXK	0.36	5.14	0.31	5.72e-7	Systemic lupus erythematosus;
KIRP	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.39	4.91	0.3	1.68e-6	High light scatter reticulocyte count;
KIRP	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg23216685	chr1:86174607	ZNHIT6	-0.5	-5.31	-0.32	2.48e-7	Urate levels in overweight individuals;
KIRP	cis	rs13401104	0.796	rs10929166	chr2:237111201	C/T	cg19324714	chr2:237145437	ASB18	0.49	5.22	0.32	3.88e-7	Educational attainment;
KIRP	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02725872	chr8:58115012	NA	-0.73	-7.87	-0.45	1.09e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs4006360	0.646	rs7501601	chr17:39293957	G/A	cg25341923	chr17:39239918	KRTAP4-7	-0.63	-8.68	-0.48	5.54e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	1.0	11.53	0.59	7.01e-25	Eosinophil percentage of granulocytes;
KIRP	cis	rs490234	0.783	rs28729336	chr9:128405488	T/G	cg14078157	chr9:128172775	NA	-0.59	-6.8	-0.4	7.76e-11	Mean arterial pressure;
KIRP	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.45	-5.87	-0.35	1.38e-8	Body mass index;
KIRP	cis	rs6838801	0.892	rs28515950	chr4:77575939	A/G	cg17476223	chr4:77663285	SHROOM3	0.55	7.96	0.45	6.17e-14	Cleft lip with or without cleft palate;
KIRP	cis	rs6783573	0.683	rs3806702	chr3:46617502	T/C	cg27371741	chr3:46619158	LRRC2;TDGF1	-0.54	-6.63	-0.39	2.15e-10	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.74	6.02	0.36	6.17e-9	Diabetic retinopathy;
KIRP	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg08975724	chr8:8085496	FLJ10661	0.68	9.28	0.51	8.92e-18	Neuroticism;
KIRP	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg03465714	chr1:152285911	FLG	0.47	5.41	0.33	1.46e-7	Atopic dermatitis;
KIRP	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-6.8	-0.4	7.74e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs6684428	0.706	rs12119904	chr1:56327241	G/T	cg11651538	chr1:56320950	NA	-0.91	-11.98	-0.61	2.43e-26	Airflow obstruction;
KIRP	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg09344028	chr17:70110421	NA	0.49	12.05	0.61	1.33e-26	Thyroid hormone levels;
KIRP	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg00857998	chr1:205179979	DSTYK	0.63	7.56	0.43	8.13e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-6.19	-0.37	2.5e-9	Recombination measurement;
KIRP	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg11905131	chr22:24372483	LOC391322	0.54	6.49	0.38	4.63e-10	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	cis	rs988913	0.581	rs1354288	chr6:54856623	T/G	cg03513858	chr6:54763001	FAM83B	-0.33	-4.87	-0.3	1.96e-6	Menarche (age at onset);
KIRP	cis	rs2737618	0.722	rs2821333	chr1:200093253	A/C	cg21825944	chr1:200113062	NR5A2	-0.57	-7.94	-0.45	7.04e-14	Uric acid levels;
KIRP	cis	rs62413470	1.000	rs12189571	chr6:55933987	A/C	cg13327911	chr6:55965977	COL21A1	0.54	4.89	0.3	1.81e-6	Joint mobility (Beighton score);
KIRP	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.62	8.24	0.47	1.02e-14	Motion sickness;
KIRP	cis	rs13185784	0.662	rs35759987	chr5:179679980	G/T	cg13944838	chr5:179740914	GFPT2	0.54	5.24	0.32	3.49e-7	TRAIL levels;
KIRP	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg09914555	chr8:142094789	NA	-0.47	-6.02	-0.36	6.33e-9	Isovolumetric relaxation time;Response to interferon beta therapy;
KIRP	trans	rs1859156	0.767	rs17429252	chr4:95821655	A/G	cg24204951	chr2:239172084	PER2	0.31	6.62	0.39	2.22e-10	Attention deficit hyperactivity disorder;
KIRP	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.66	-8.8	-0.49	2.51e-16	Glomerular filtration rate;
KIRP	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-9.99	-0.54	6.08e-20	Morning vs. evening chronotype;
KIRP	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-5.23	-0.32	3.68e-7	Total body bone mineral density;
KIRP	trans	rs2324229	0.797	rs1180237	chr6:83943928	A/C	cg24756528	chr16:4466888	CORO7	-0.46	-6.13	-0.36	3.57e-9	Platelet-derived growth factor BB levels;
KIRP	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg12861170	chr19:19639553	YJEFN3	-0.49	-4.97	-0.3	1.28e-6	Bipolar disorder;
KIRP	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg11189052	chr15:85197271	WDR73	0.51	5.21	0.32	3.9e-7	Schizophrenia;
KIRP	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.83	-13.42	-0.65	3.65e-31	Intelligence (multi-trait analysis);
KIRP	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.69	7.88	0.45	1.08e-13	Corneal astigmatism;
KIRP	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg04778012	chr7:99775508	STAG3;GPC2	-0.39	-5.29	-0.32	2.66e-7	Coronary artery disease;
KIRP	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18357526	chr6:26021779	HIST1H4A	0.51	6.51	0.38	4.11e-10	Height;
KIRP	cis	rs11955175	1.000	rs11954632	chr5:40674929	C/G	cg05478818	chr5:40835740	RPL37	0.7	5.44	0.33	1.32e-7	Bipolar disorder and schizophrenia;
KIRP	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.48	6.76	0.4	9.74e-11	Bipolar disorder and schizophrenia;
KIRP	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.65	-6.86	-0.4	5.45e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg01294253	chr9:136912663	BRD3	0.44	5.77	0.35	2.43e-8	Platelet distribution width;
KIRP	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.69	-6.7	-0.39	1.39e-10	Verbal memory performance (residualized delayed recall change);
KIRP	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.86	-9.9	-0.53	1.17e-19	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg21361702	chr7:150065534	REPIN1	0.74	7.49	0.43	1.22e-12	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg03474202	chr17:45855739	NA	-0.52	-8.06	-0.46	3.24e-14	IgG glycosylation;
KIRP	cis	rs2072732	0.861	rs67630839	chr1:2951989	C/T	cg11731671	chr1:2995604	PRDM16	-0.46	-5.85	-0.35	1.6e-8	Plateletcrit;
KIRP	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26617929	chr16:1858877	NA	-0.65	-5.56	-0.33	7.04e-8	Glomerular filtration rate in chronic kidney disease;
KIRP	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	0.57	6.57	0.39	2.91e-10	Coronary artery disease;
KIRP	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg08999081	chr20:33150536	PIGU	0.47	6.28	0.37	1.53e-9	Height;
KIRP	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg17218026	chr1:154582156	ADAR	0.35	5.85	0.35	1.55e-8	Blood protein levels;
KIRP	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.72	6.96	0.41	3.05e-11	Chronic kidney disease;
KIRP	cis	rs9937943	0.615	rs12925346	chr16:74492495	G/C	cg01733217	chr16:74700730	RFWD3	0.6	5.56	0.33	7.09e-8	Neutrophil percentage of white cells;
KIRP	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	0.86	11.85	0.6	6.29e-26	Homoarginine levels;
KIRP	cis	rs9398803	0.713	rs4621656	chr6:126896168	G/C	cg19875578	chr6:126661172	C6orf173	0.4	5.27	0.32	2.98e-7	Male-pattern baldness;
KIRP	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg21161173	chr5:140098174	VTRNA1-2	0.38	4.92	0.3	1.61e-6	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26207909	chr14:103986467	CKB	0.76	11.47	0.59	1.15e-24	Body mass index;
KIRP	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	8.65	0.48	6.65e-16	Mean corpuscular hemoglobin;
KIRP	trans	rs2048656	0.561	rs11776236	chr8:9545167	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.33	-0.37	1.16e-9	Schizophrenia;
KIRP	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg22681709	chr2:178499509	PDE11A	-0.47	-4.94	-0.3	1.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.55	6.55	0.39	3.36e-10	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg03950009	chr9:102669115	STX17	-0.54	-6.43	-0.38	6.41e-10	Brain structure;
KIRP	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg09264619	chr17:80180166	NA	0.4	5.78	0.35	2.23e-8	Life satisfaction;
KIRP	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.67	10.01	0.54	5.13e-20	Dupuytren's disease;
KIRP	cis	rs60871478	1.000	rs62432224	chr7:788284	G/A	cg05535760	chr7:792225	HEATR2	0.86	8.84	0.49	1.87e-16	Cerebrospinal P-tau181p levels;
KIRP	cis	rs17023223	0.537	rs2361270	chr1:119603322	T/C	cg18261050	chr1:119551319	NA	0.5	6.57	0.39	2.94e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg24375607	chr4:120327624	NA	0.59	6.15	0.36	3.19e-9	Corneal astigmatism;
KIRP	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg23172400	chr8:95962367	TP53INP1	-0.34	-6.9	-0.4	4.29e-11	Type 2 diabetes;
KIRP	cis	rs7520050	0.966	rs10789487	chr1:46420221	G/A	cg24296786	chr1:45957014	TESK2	0.38	4.86	0.3	2.09e-6	Red blood cell count;Reticulocyte count;
KIRP	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg08975724	chr8:8085496	FLJ10661	0.49	6.27	0.37	1.6e-9	Retinal vascular caliber;
KIRP	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.3	-6.2	-0.37	2.43e-9	Breast cancer;
KIRP	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg13010199	chr12:38710504	ALG10B	0.5	6.11	0.36	3.94e-9	Heart rate;Heart rate variability traits (RMSSD);
KIRP	cis	rs6693567	0.526	rs698918	chr1:150319762	A/G	cg07843065	chr1:150265600	MRPS21	0.45	6.26	0.37	1.74e-9	Migraine;
KIRP	cis	rs72781680	0.611	rs72797818	chr2:24351107	G/A	cg06627628	chr2:24431161	ITSN2	-0.57	-5.11	-0.31	6.49e-7	Lymphocyte counts;
KIRP	cis	rs26949	0.511	rs2898287	chr5:59884233	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.43	-5.18	-0.31	4.62e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg08126542	chr6:37504118	NA	-0.74	-10.35	-0.55	4.33e-21	Cognitive performance;
KIRP	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg25124228	chr12:125621409	AACS	-0.53	-6.17	-0.37	2.72e-9	Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-4.85	-0.3	2.24e-6	Pulmonary function;
KIRP	cis	rs10864907	0.754	rs3917356	chr2:113592363	C/T	cg03712744	chr2:113669835	IL1F7	-0.37	-5.34	-0.32	2.07e-7	Pulmonary function;
KIRP	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg14541582	chr5:601475	NA	-0.55	-6.17	-0.37	2.85e-9	Lung disease severity in cystic fibrosis;
KIRP	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg15369054	chr17:80825471	TBCD	0.58	5.06	0.31	8.3e-7	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg00277334	chr10:82204260	NA	-0.45	-4.95	-0.3	1.41e-6	Post bronchodilator FEV1;
KIRP	cis	rs7011049	0.778	rs113723883	chr8:53867487	G/A	cg26025543	chr8:53854495	NA	0.58	6.37	0.38	9.43e-10	Systolic blood pressure;
KIRP	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.48	6.45	0.38	5.74e-10	Red cell distribution width;
KIRP	cis	rs742134	1.000	rs760699	chr22:43523188	T/C	cg04042468	chr22:43506033	BIK	0.37	5.01	0.3	1.03e-6	Prostate cancer;
KIRP	cis	rs151997	0.962	rs27844	chr5:50190680	T/G	cg06027927	chr5:50259733	NA	0.59	7.37	0.43	2.57e-12	Callous-unemotional behaviour;
KIRP	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	14.1	0.67	1.8e-33	Tonsillectomy;
KIRP	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-7.67	-0.44	3.9e-13	Mood instability;
KIRP	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg23594656	chr7:65796392	TPST1	0.39	5.79	0.35	2.12e-8	Aortic root size;
KIRP	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.6	6.82	0.4	7.02e-11	Obesity-related traits;
KIRP	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg00631329	chr6:26305371	NA	-0.73	-9.26	-0.51	1.06e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
KIRP	cis	rs7215564	0.908	rs35374347	chr17:78642244	C/T	cg06153925	chr17:78755379	RPTOR	0.49	6.48	0.38	5.1e-10	Myopia (pathological);
KIRP	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	0.59	7.98	0.45	5.59e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	11.62	0.6	3.63e-25	Personality dimensions;
KIRP	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.15	0.41	9.69e-12	Aortic root size;
KIRP	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg00204512	chr16:28754710	NA	0.45	5.99	0.36	7.31e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg23067535	chr8:124195133	FAM83A	-0.71	-6.84	-0.4	6.21e-11	Urinary uromodulin levels;
KIRP	cis	rs12580194	0.593	rs61957938	chr12:55747266	C/G	cg11794356	chr12:55725991	OR6C3	-0.53	-7.09	-0.41	1.41e-11	Cancer;
KIRP	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg20999797	chr1:1681921	NA	0.52	8.06	0.46	3.27e-14	Body mass index;
KIRP	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg02792322	chr13:21280448	IL17D	0.31	5.23	0.32	3.64e-7	Dental caries;
KIRP	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-6.01	-0.36	6.57e-9	Developmental language disorder (linguistic errors);
KIRP	trans	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg01620082	chr3:125678407	NA	-0.97	-6.99	-0.41	2.58e-11	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs4950322	0.570	rs72691093	chr1:146769662	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-5.27	-0.32	2.96e-7	Protein quantitative trait loci;
KIRP	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.83	0.81	1.71e-59	Prudent dietary pattern;
KIRP	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.94	14.07	0.67	2.12e-33	Tonsillectomy;
KIRP	cis	rs71277158	0.688	rs56316750	chr3:169782754	G/A	cg04067573	chr3:169899625	PHC3	0.61	5.6	0.34	5.6e-8	Prostate cancer;
KIRP	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg07884673	chr3:53033167	SFMBT1	0.81	6.35	0.38	1.02e-9	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg08992911	chr2:238395768	MLPH	0.56	5.23	0.32	3.66e-7	Prostate cancer;
KIRP	cis	rs2425143	0.841	rs4911519	chr20:34362326	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.63	6.0	0.36	7.1e-9	Blood protein levels;
KIRP	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg11846333	chr4:119757529	SEC24D	0.94	5.89	0.35	1.25e-8	Cannabis dependence symptom count;
KIRP	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.59	7.39	0.43	2.33e-12	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg02725872	chr8:58115012	NA	-0.54	-6.11	-0.36	3.9e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg01444801	chr10:135216882	MTG1	-0.58	-6.62	-0.39	2.22e-10	Systemic lupus erythematosus;
KIRP	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg06611532	chr13:114900021	NA	0.22	5.04	0.31	9.05e-7	Schizophrenia;
KIRP	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.49	6.15	0.37	3.07e-9	Mean platelet volume;
KIRP	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.86	9.71	0.53	4.44e-19	Blood pressure;
KIRP	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	0.85	7.43	0.43	1.74e-12	Lung disease severity in cystic fibrosis;
KIRP	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg00334542	chr7:100209784	MOSPD3	-0.55	-5.14	-0.31	5.57e-7	Other erythrocyte phenotypes;
KIRP	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.24	-0.51	1.25e-17	Chronic sinus infection;
KIRP	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg19077165	chr18:44547161	KATNAL2	-0.5	-6.11	-0.36	3.83e-9	Educational attainment;
KIRP	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg19610905	chr11:61596333	FADS2	0.46	7.31	0.42	3.8e-12	Trans fatty acid levels;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg09848324	chr4:56458183	PDCL2	-0.48	-6.37	-0.38	9.02e-10	Inflammatory biomarkers;
KIRP	cis	rs6987853	0.814	rs2923411	chr8:42455206	T/C	cg09913449	chr8:42400586	C8orf40	0.4	5.23	0.32	3.69e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.54	-6.81	-0.4	7.63e-11	Longevity;
KIRP	trans	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg15923408	chr8:8750314	MFHAS1	0.52	6.19	0.37	2.46e-9	Electroencephalogram traits;
KIRP	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.49	-5.35	-0.32	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07570687	chr10:102243282	WNT8B	0.49	6.54	0.38	3.62e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.92	-8.56	-0.48	1.21e-15	Rheumatoid arthritis;
KIRP	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg01559446	chr3:44596178	ZNF167	-0.36	-5.06	-0.31	8.24e-7	Depressive symptoms;
KIRP	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.74	9.58	0.52	1.09e-18	Huntington's disease progression;
KIRP	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg00507259	chr4:95128692	SMARCAD1	0.41	5.13	0.31	5.76e-7	QT interval;
KIRP	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.91	-12.46	-0.62	6.09e-28	Cognitive function;
KIRP	cis	rs1413885	0.526	rs9728544	chr1:65847105	A/G	cg13202122	chr1:65886182	LEPROT;LEPR	0.47	5.5	0.33	9.4e-8	Anticoagulant levels;
KIRP	trans	rs1041536	0.898	rs2210456	chr20:9919521	A/G	cg06235973	chr19:14183619	LOC113230	0.46	6.24	0.37	1.91e-9	Cognitive decline rate in late mild cognitive impairment;
KIRP	cis	rs9357620	0.920	rs9395497	chr6:13168535	A/G	cg14462418	chr6:14004536	NA	-0.41	-4.91	-0.3	1.64e-6	Chronotype;Morning vs. evening chronotype;
KIRP	cis	rs35000415	0.688	rs13241591	chr7:128714746	A/G	cg19972273	chr7:128594194	NA	0.61	5.01	0.3	1.05e-6	Systemic lupus erythematosus;
KIRP	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg04025307	chr7:1156635	C7orf50	0.8	8.29	0.47	7.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10781543	0.748	rs68002978	chr9:139325641	C/T	cg14169450	chr9:139327907	INPP5E	0.5	7.22	0.42	6.61e-12	Monocyte percentage of white cells;
KIRP	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg03465714	chr1:152285911	FLG	0.49	5.29	0.32	2.69e-7	Atopic dermatitis;
KIRP	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.89	-12.58	-0.63	2.42e-28	Height;
KIRP	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.39	5.38	0.32	1.72e-7	Coronary artery disease;
KIRP	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.6	-7.58	-0.44	7.05e-13	Perceived unattractiveness to mosquitoes;
KIRP	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.52	-6.23	-0.37	2.05e-9	Squamous cell lung carcinoma;
KIRP	cis	rs2404618	0.624	rs4457358	chr8:1477213	C/A	cg13402656	chr8:1511478	DLGAP2	-0.74	-11.57	-0.59	5.21e-25	Lung cancer;
KIRP	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21545522	chr1:205238299	TMCC2	0.55	7.31	0.42	3.76e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs8060686	0.920	rs55661503	chr16:67836552	T/A	cg04539111	chr16:67997858	SLC12A4	-0.61	-6.3	-0.37	1.34e-9	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	1.1	8.22	0.46	1.14e-14	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg02336718	chr17:17403227	NA	0.34	5.15	0.31	5.32e-7	Total body bone mineral density;
KIRP	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg24009623	chr19:33667908	NA	0.47	5.73	0.34	2.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg21643547	chr1:205240462	TMCC2	-0.7	-10.64	-0.56	5.51e-22	Red blood cell count;
KIRP	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg23422044	chr7:1970798	MAD1L1	-0.47	-5.97	-0.36	8.3e-9	Neuroticism;
KIRP	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	10.2	0.55	1.33e-20	Exhaled nitric oxide output;
KIRP	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg21214613	chr1:16344536	HSPB7	0.34	5.26	0.32	3.17e-7	Dilated cardiomyopathy;
KIRP	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.74	9.69	0.53	5.18e-19	Educational attainment;
KIRP	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg05861140	chr6:150128134	PCMT1	-0.53	-7.61	-0.44	5.89e-13	Lung cancer;
KIRP	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg00666640	chr1:248458726	OR2T12	0.44	5.88	0.35	1.32e-8	Common traits (Other);
KIRP	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-5.51	-0.33	9.24e-8	Metabolite levels;
KIRP	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg04733989	chr22:42467013	NAGA	0.58	7.61	0.44	5.73e-13	Cognitive function;
KIRP	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg10560079	chr2:191398806	TMEM194B	-0.66	-7.91	-0.45	8.61e-14	Diastolic blood pressure;
KIRP	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.64	9.92	0.53	1e-19	Lung cancer;
KIRP	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-7.98	-0.45	5.59e-14	Total body bone mineral density;
KIRP	cis	rs4776059	1.000	rs12914047	chr15:52970993	G/A	cg22715398	chr15:52968154	KIAA1370	-0.67	-7.98	-0.45	5.44e-14	Schizophrenia;
KIRP	trans	rs921874	0.586	rs2513228	chr11:86755539	C/T	cg22937172	chr2:240168862	HDAC4	-0.48	-6.23	-0.37	2.02e-9	Total body bone mineral density;
KIRP	cis	rs41271951	0.512	rs6664387	chr1:151021509	A/G	cg15151059	chr1:150936875	SETDB1	-0.58	-4.93	-0.3	1.51e-6	Blood protein levels;
KIRP	cis	rs7923609	1.000	rs1935	chr10:64927823	C/G	cg08743896	chr10:65200160	JMJD1C	-0.38	-5.61	-0.34	5.36e-8	Educational attainment;Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17123764	0.892	rs9805063	chr12:50141164	T/G	cg20471783	chr12:50157085	TMBIM6	0.42	6.02	0.36	6.3e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg22907277	chr7:1156413	C7orf50	0.87	8.2	0.46	1.33e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	1.08	9.26	0.51	1.03e-17	Blood protein levels;
KIRP	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.45	5.88	0.35	1.3e-8	Neutrophil percentage of white cells;
KIRP	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.29	5.76	0.34	2.49e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-6.31	-0.37	1.26e-9	Height;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14780066	chr19:6373131	ALKBH7	0.45	6.02	0.36	6.3e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg07701084	chr6:150067640	NUP43	0.56	7.17	0.42	8.54e-12	Testicular germ cell tumor;
KIRP	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-20.03	-0.79	1.4e-53	Height;
KIRP	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.05	20.04	0.79	1.24e-53	Testicular germ cell tumor;
KIRP	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	13.49	0.65	2.07e-31	Smoking behavior;
KIRP	cis	rs1524927	1.000	rs12704875	chr7:96341385	G/A	cg03808172	chr7:96339361	SHFM1	0.37	4.9	0.3	1.74e-6	Total body bone mineral density;
KIRP	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.61	-7.7	-0.44	3.42e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg10223061	chr2:219282414	VIL1	0.33	5.53	0.33	8.31e-8	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs1973993	0.561	rs3862909	chr1:96987091	T/G	cg10631902	chr5:14652156	NA	-0.53	-6.54	-0.38	3.46e-10	Weight;
KIRP	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.41	-5.36	-0.32	1.94e-7	Renal cell carcinoma;
KIRP	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg03265037	chr7:99691720	MIR25;MCM7;MIR106B;MIR93	-0.63	-7.13	-0.41	1.1e-11	Coronary artery disease;
KIRP	cis	rs12210905	1.000	rs72843608	chr6:27122750	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.78	-6.68	-0.39	1.6e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg20896738	chr21:46707857	POFUT2;LOC642852	0.46	5.09	0.31	7e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.73	7.61	0.44	5.66e-13	Methadone dose in opioid dependence;
KIRP	cis	rs7224685	0.501	rs781847	chr17:3958194	G/A	cg11204139	chr17:3907470	NA	0.83	15.6	0.71	1.32e-38	Type 2 diabetes;
KIRP	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	8.96	0.5	8.12e-17	Resting heart rate;
KIRP	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	10.02	0.54	4.96e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg00405596	chr8:11794950	NA	-0.39	-5.17	-0.31	4.75e-7	Triglycerides;
KIRP	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.41	-5.0	-0.3	1.07e-6	Neutrophil percentage of white cells;
KIRP	cis	rs6504622	0.818	rs9898527	chr17:45036210	G/A	cg24703533	chr17:45055318	NA	0.38	5.09	0.31	7.14e-7	Orofacial clefts;
KIRP	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23281280	chr6:28129359	ZNF389	-0.48	-5.25	-0.32	3.28e-7	Depression;
KIRP	cis	rs865483	0.895	rs2680718	chr17:35816451	T/C	cg06716730	chr17:35851459	DUSP14	0.25	6.06	0.36	5.03e-9	Monocyte count;
KIRP	cis	rs7819412	0.678	rs2409742	chr8:11069960	C/T	cg19847130	chr8:10466454	RP1L1	0.39	5.76	0.34	2.44e-8	Triglycerides;
KIRP	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13198984	chr17:80129470	CCDC57	0.58	8.69	0.48	5.16e-16	Life satisfaction;
KIRP	cis	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg14629571	chr9:120470582	TLR4	0.4	6.18	0.37	2.61e-9	Survival in pancreatic cancer;
KIRP	cis	rs7395581	0.918	rs10838693	chr11:47350553	G/C	cg26139080	chr11:47293733	MADD	-0.41	-5.16	-0.31	5.07e-7	HDL cholesterol;
KIRP	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg10047753	chr17:41438598	NA	1.12	17.91	0.75	1.74e-46	Menopause (age at onset);
KIRP	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.74	11.39	0.59	2.11e-24	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.16	13.37	0.65	5.21e-31	Platelet count;
KIRP	cis	rs4356932	0.967	rs4407534	chr4:76979326	G/T	cg00809888	chr4:76862425	NAAA	0.44	6.18	0.37	2.59e-9	Blood protein levels;
KIRP	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg23442198	chr4:187126114	CYP4V2	0.78	6.36	0.38	9.81e-10	Blood protein levels;
KIRP	cis	rs7551222	0.752	rs1380576	chr1:204488278	G/C	cg20240347	chr1:204465584	NA	-0.46	-8.7	-0.49	4.69e-16	Schizophrenia;
KIRP	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.9	12.43	0.62	7.39e-28	Schizophrenia;
KIRP	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg00319359	chr11:70116639	PPFIA1	0.57	5.87	0.35	1.4e-8	Coronary artery disease;
KIRP	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.68	6.93	0.4	3.64e-11	Vitiligo;
KIRP	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.68	7.61	0.44	5.73e-13	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.49	6.41	0.38	7.43e-10	Blood metabolite levels;
KIRP	cis	rs11586313	0.546	rs1330703	chr1:152867349	A/T	cg13444842	chr1:152974279	SPRR3	-0.38	-5.06	-0.31	8.32e-7	Vitamin D levels;
KIRP	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg00012203	chr2:219082015	ARPC2	-0.44	-5.49	-0.33	9.76e-8	Ulcerative colitis;
KIRP	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.75	9.62	0.52	8.21e-19	Coronary artery disease;
KIRP	cis	rs282587	0.502	rs416703	chr13:113399219	A/G	cg04656015	chr13:113407548	ATP11A	0.65	7.73	0.44	2.75e-13	Glycated hemoglobin levels;
KIRP	cis	rs17453880	0.929	rs6869129	chr5:152028136	G/A	cg12297329	chr5:152029980	NA	-0.73	-11.24	-0.58	6.5e-24	Subjective well-being;
KIRP	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.61	5.08	0.31	7.51e-7	Bipolar disorder (body mass index interaction);
KIRP	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-5.44	-0.33	1.26e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.5	-6.74	-0.39	1.13e-10	Dilated cardiomyopathy;
KIRP	cis	rs6748734	0.625	rs4563218	chr2:241820035	G/A	cg04034577	chr2:241836375	C2orf54	-0.27	-4.98	-0.3	1.17e-6	Urinary metabolites;
KIRP	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg18016565	chr1:150552671	MCL1	0.4	6.05	0.36	5.29e-9	Melanoma;
KIRP	cis	rs7005380	0.581	rs9297607	chr8:120937071	G/A	cg21645572	chr8:120931649	DEPDC6	-0.5	-6.76	-0.4	9.94e-11	Interstitial lung disease;
KIRP	cis	rs6546324	0.625	rs1430792	chr2:67864744	A/C	cg15745817	chr2:67799979	NA	-0.63	-6.98	-0.41	2.76e-11	Endometriosis;
KIRP	cis	rs1971762	0.965	rs1800633	chr12:54063501	G/A	cg16917193	chr12:54089295	NA	0.68	9.08	0.5	3.77e-17	Height;
KIRP	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9652601	0.779	rs7203793	chr16:11182134	C/G	cg04616529	chr16:11181986	CLEC16A	0.38	5.17	0.31	4.78e-7	Systemic lupus erythematosus;
KIRP	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg19875535	chr5:140030758	IK	0.51	6.35	0.38	1.05e-9	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs7507204	0.723	rs62125964	chr19:3414742	C/A	cg08380311	chr19:3435252	NFIC	0.65	5.86	0.35	1.48e-8	Height;
KIRP	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.61	-8.15	-0.46	1.85e-14	Prostate cancer;
KIRP	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg03788504	chr6:150331562	NA	-0.34	-6.48	-0.38	4.95e-10	Alopecia areata;
KIRP	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg01763666	chr17:80159506	CCDC57	-0.37	-5.07	-0.31	7.82e-7	Life satisfaction;
KIRP	cis	rs17121403	0.661	rs11166394	chr1:100485624	A/C	cg24955406	chr1:100503596	HIAT1	0.78	5.1	0.31	6.92e-7	Pulmonary function decline;
KIRP	cis	rs7937612	1.000	rs7478880	chr11:120261791	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.46	-6.82	-0.4	7.11e-11	Intraocular pressure;
KIRP	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	9.77	0.53	2.95e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.12	0.31	6.03e-7	Triglycerides;
KIRP	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.67	-8.65	-0.48	6.94e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
KIRP	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg15252951	chr6:33757062	LEMD2	0.45	5.18	0.31	4.64e-7	Crohn's disease;
KIRP	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.55	-7.15	-0.41	9.93e-12	Platelet count;
KIRP	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.79	9.02	0.5	5.33e-17	Corneal astigmatism;
KIRP	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.8	-10.09	-0.54	3.04e-20	Blood trace element (Zn levels);
KIRP	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg25039879	chr17:56429692	SUPT4H1	0.54	4.92	0.3	1.61e-6	Cognitive test performance;
KIRP	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.44	8.63	0.48	7.75e-16	Educational attainment (years of education);
KIRP	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.7	8.15	0.46	1.88e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs4953911	1.000	rs2321678	chr2:135067753	T/C	cg18482303	chr2:135041380	MGAT5	-0.29	-5.53	-0.33	8.19e-8	Multiple sclerosis (severity);
KIRP	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg26068271	chr17:76253126	NA	0.56	7.59	0.44	6.5e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.34	-6.56	-0.39	3.13e-10	Urinary metabolites;
KIRP	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.91	14.14	0.67	1.31e-33	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2808634	0.962	rs3122014	chr1:159702161	A/C	cg05357137	chr10:28527770	MPP7	0.39	6.55	0.39	3.34e-10	C-reactive protein;
KIRP	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs7011507	0.786	rs7011956	chr8:49125520	T/A	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	7.45	0.43	1.62e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
KIRP	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.44	-5.62	-0.34	5.17e-8	Aortic root size;
KIRP	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	14.88	0.69	3.77e-36	Platelet count;
KIRP	trans	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg26080798	chr6:20402092	E2F3	-0.42	-6.13	-0.36	3.55e-9	Breast cancer;
KIRP	cis	rs7555523	0.779	rs6662839	chr1:165722646	T/G	cg24409356	chr1:165738333	TMCO1	0.71	5.92	0.35	1.1e-8	Intraocular pressure;Glaucoma (high intraocular pressure);
KIRP	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg24829409	chr8:58192753	C8orf71	-0.59	-5.3	-0.32	2.63e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs4713675	0.584	rs4713667	chr6:33680016	G/C	cg15676125	chr6:33679581	C6orf125	0.41	5.37	0.32	1.87e-7	Plateletcrit;
KIRP	cis	rs8113308	0.810	rs7255377	chr19:52451338	T/C	cg25782003	chr19:52490127	ZNF350	0.54	5.11	0.31	6.44e-7	Survival in endocrine treated breast cancer (estrogen-receptor positive);
KIRP	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21643547	chr1:205240462	TMCC2	-0.72	-10.96	-0.57	5.2e-23	Red blood cell count;
KIRP	cis	rs17221829	0.673	rs12364712	chr11:89373847	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.69	8.12	0.46	2.19e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs7760949	0.963	rs1330117	chr6:13920926	C/T	cg27413430	chr6:13925136	RNF182	0.45	5.7	0.34	3.45e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg01689657	chr7:91764605	CYP51A1	0.44	6.43	0.38	6.7e-10	Breast cancer;
KIRP	cis	rs7173389	0.530	rs11636535	chr15:73681648	T/C	cg01796676	chr15:73680284	NA	0.52	5.93	0.35	1.04e-8	Resting heart rate;
KIRP	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg01872077	chr2:219646372	CYP27A1	-0.39	-5.08	-0.31	7.6e-7	Mean corpuscular hemoglobin concentration;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg27576415	chr15:41709087	RTF1	0.52	6.14	0.36	3.27e-9	Smoking initiation;
KIRP	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg22676075	chr6:135203613	NA	-0.52	-6.67	-0.39	1.72e-10	High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg00684032	chr4:1343700	KIAA1530	0.52	6.9	0.4	4.41e-11	Longevity;
KIRP	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02725872	chr8:58115012	NA	-0.73	-7.8	-0.45	1.76e-13	Developmental language disorder (linguistic errors);
KIRP	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.66	6.56	0.39	3.21e-10	Eotaxin levels;
KIRP	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.02	-12.76	-0.63	5.99e-29	Exhaled nitric oxide output;
KIRP	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	8.43	0.47	2.86e-15	Intelligence (multi-trait analysis);
KIRP	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.6	0.34	5.79e-8	Schizophrenia;
KIRP	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg22139774	chr2:100720529	AFF3	-0.31	-5.28	-0.32	2.85e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-6.29	-0.37	1.42e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg23625390	chr15:77176239	SCAPER	0.52	6.87	0.4	5.18e-11	Blood metabolite levels;
KIRP	trans	rs6456042	1.000	rs3099301	chr6:166524417	C/T	cg00761755	chr17:1531579	SLC43A2	0.48	6.16	0.37	2.92e-9	Asthma;
KIRP	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.5	-8.54	-0.48	1.41e-15	Refractive error;
KIRP	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.97	-14.01	-0.67	3.56e-33	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs151997	0.671	rs3991902	chr5:50203749	A/T	cg06027927	chr5:50259733	NA	0.53	7.33	0.42	3.29e-12	Callous-unemotional behaviour;
KIRP	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg19773385	chr1:10388646	KIF1B	-0.73	-11.46	-0.59	1.23e-24	Hepatocellular carcinoma;
KIRP	cis	rs3741151	0.686	rs7114376	chr11:73227361	T/C	cg17517138	chr11:73019481	ARHGEF17	0.59	5.25	0.32	3.36e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00689492	chr4:1303491	MAEA	0.31	5.3	0.32	2.63e-7	Obesity-related traits;
KIRP	cis	rs1629083	0.790	rs648947	chr11:118067426	A/G	cg18857871	chr11:118064634	AMICA1	0.74	10.69	0.56	3.62e-22	Lung cancer;
KIRP	cis	rs4908768	0.906	rs2144463	chr1:8583293	C/A	cg25722041	chr1:8623473	RERE	0.78	9.76	0.53	3.05e-19	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg27205649	chr11:78285834	NARS2	0.8	11.01	0.57	3.52e-23	Alzheimer's disease (survival time);
KIRP	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg00857998	chr1:205179979	DSTYK	-0.51	-6.32	-0.37	1.22e-9	Red blood cell count;
KIRP	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26002218	chr14:103986227	CKB	0.29	5.92	0.35	1.08e-8	Body mass index;
KIRP	cis	rs4692589	0.581	rs12646523	chr4:170944698	C/T	cg19918862	chr4:170955249	NA	0.56	6.23	0.37	2.06e-9	Anxiety disorder;
KIRP	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg18755752	chr8:142205143	DENND3	-0.47	-6.47	-0.38	5.39e-10	Immature fraction of reticulocytes;
KIRP	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.69	10.51	0.56	1.42e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.29	-6.16	-0.37	3.02e-9	Cutaneous nevi;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg07784442	chr4:153690819	TIGD4	-0.39	-6.24	-0.37	1.89e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs654128	0.764	rs339329	chr6:117208926	C/T	cg12892004	chr6:117198278	RFX6	-0.48	-5.2	-0.31	4.23e-7	Telomere length;
KIRP	cis	rs714027	0.515	rs2412972	chr22:30519825	T/A	cg27665648	chr22:30112403	NA	-0.45	-6.4	-0.38	7.73e-10	Lymphocyte counts;
KIRP	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.5	-6.99	-0.41	2.57e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg24826892	chr11:71159390	DHCR7	-0.45	-5.05	-0.31	8.61e-7	Vitamin D levels;
KIRP	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg21926883	chr2:100939477	LONRF2	-0.52	-6.95	-0.41	3.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg10503236	chr1:231470652	EXOC8	-0.49	-6.67	-0.39	1.64e-10	Hemoglobin concentration;
KIRP	cis	rs8044995	0.517	rs61593058	chr16:68384496	T/C	cg26727032	chr16:67993705	SLC12A4	-0.49	-5.42	-0.33	1.41e-7	Schizophrenia;
KIRP	cis	rs12900413	0.603	rs12906832	chr15:90301314	C/G	cg24650279	chr15:90327240	NA	-0.42	-5.2	-0.31	4.27e-7	Coronary artery aneurysm in Kawasaki disease;
KIRP	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.35	5.87	0.35	1.42e-8	Lymphocyte counts;
KIRP	cis	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg00405596	chr8:11794950	NA	-0.44	-5.92	-0.35	1.06e-8	Monocyte count;
KIRP	cis	rs1832871	0.541	rs11755760	chr6:158886742	A/G	cg07215822	chr6:158701037	NA	-0.51	-5.5	-0.33	9.49e-8	Height;
KIRP	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.67	-8.69	-0.48	5.01e-16	Iron status biomarkers;
KIRP	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg13819577	chr1:248512075	OR14C36	-0.37	-4.85	-0.3	2.17e-6	Common traits (Other);
KIRP	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-6.32	-0.37	1.25e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Alcohol dependence;
KIRP	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	7.66	0.44	4.29e-13	Coffee consumption (cups per day);
KIRP	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg10505658	chr17:80084571	CCDC57	0.27	4.99	0.3	1.12e-6	Life satisfaction;
KIRP	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.73	9.14	0.5	2.35e-17	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg10755058	chr3:40428713	ENTPD3	-0.35	-5.11	-0.31	6.53e-7	Renal cell carcinoma;
KIRP	cis	rs9513593	1.000	rs7323390	chr13:99997968	A/G	cg21788972	chr13:99853209	UBAC2	0.53	5.71	0.34	3.25e-8	Psoriasis;
KIRP	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.46	5.81	0.35	1.91e-8	Motion sickness;
KIRP	cis	rs12200782	1.000	rs12195971	chr6:26460424	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.7	-6.17	-0.37	2.73e-9	Small cell lung carcinoma;
KIRP	cis	rs588177	0.613	rs3782101	chr11:64131280	A/G	cg24431193	chr11:63883947	FLRT1;MACROD1	0.48	6.32	0.37	1.23e-9	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.34	5.38	0.32	1.74e-7	Type 2 diabetes;
KIRP	trans	rs62056376	0.736	rs758293	chr17:32640523	A/T	cg12726354	chr15:28342256	OCA2	0.55	6.23	0.37	2.02e-9	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
KIRP	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg21545522	chr1:205238299	TMCC2	0.41	5.54	0.33	7.73e-8	Red blood cell count;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg14950288	chr6:117002223	KPNA5	-0.48	-6.36	-0.38	9.64e-10	Morning vs. evening chronotype;
KIRP	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg02903104	chr8:1507517	DLGAP2	0.39	5.92	0.35	1.09e-8	Lung cancer;
KIRP	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg00800038	chr16:89945340	TCF25	-0.77	-5.38	-0.32	1.74e-7	Skin colour saturation;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg04232466	chr8:21988724	HR	0.64	6.02	0.36	6.46e-9	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg06766960	chr11:133703094	NA	0.61	7.57	0.43	7.35e-13	Childhood ear infection;
KIRP	cis	rs539514	0.690	rs585233	chr13:76317973	A/G	cg04757411	chr13:76259545	LMO7	0.35	4.99	0.3	1.15e-6	Type 1 diabetes;
KIRP	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.75	9.89	0.53	1.22e-19	Morning vs. evening chronotype;
KIRP	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg12405258	chr13:114927641	NA	0.47	6.63	0.39	2.13e-10	Schizophrenia;
KIRP	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg12989344	chr11:534232	HRAS	0.41	4.94	0.3	1.43e-6	Systemic lupus erythematosus;
KIRP	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg10617943	chr7:1981403	MAD1L1	-0.38	-5.19	-0.31	4.41e-7	Neuroticism;
KIRP	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.39	4.87	0.3	1.96e-6	Parkinson's disease;
KIRP	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs2150410	0.915	rs4818007	chr21:40611307	G/A	cg11890956	chr21:40555474	PSMG1	0.77	5.54	0.33	7.6e-8	Temperament (bipolar disorder);
KIRP	cis	rs17609940	0.906	rs62402708	chr6:35003153	T/A	cg25473981	chr6:34433676	PACSIN1	-0.46	-4.91	-0.3	1.66e-6	Coronary heart disease;
KIRP	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.6	-5.96	-0.36	8.73e-9	Schizophrenia;
KIRP	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg00647317	chr7:50633725	DDC	-0.47	-7.05	-0.41	1.78e-11	Systemic sclerosis;
KIRP	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.51	6.67	0.39	1.71e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg03808351	chr9:123631620	PHF19	0.38	4.99	0.3	1.15e-6	Rheumatoid arthritis;
KIRP	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.48	-6.33	-0.37	1.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg03289416	chr15:75166202	SCAMP2	-0.42	-5.44	-0.33	1.31e-7	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.69	8.13	0.46	2.14e-14	Smoking initiation;
KIRP	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.8	11.03	0.58	3.05e-23	Coronary artery disease;
KIRP	cis	rs1190552	0.637	rs7150548	chr14:102959962	T/C	cg10241871	chr14:102965420	TECPR2	-0.6	-6.34	-0.37	1.07e-9	Blood protein levels;
KIRP	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.8	-11.0	-0.57	3.66e-23	Longevity;
KIRP	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02972257	chr16:68554789	NA	-0.65	-6.74	-0.39	1.12e-10	Ulcerative colitis;
KIRP	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.7	8.03	0.46	4.13e-14	Obesity-related traits;
KIRP	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.38	-4.95	-0.3	1.39e-6	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs5167	0.504	rs7248162	chr19:45454686	T/C	cg13119609	chr19:45449297	APOC2	0.53	7.53	0.43	9.56e-13	Blood protein levels;
KIRP	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.64	-8.28	-0.47	7.78e-15	Prudent dietary pattern;
KIRP	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg16989719	chr2:238392110	NA	-0.6	-8.41	-0.47	3.27e-15	Prostate cancer;
KIRP	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg15556689	chr8:8085844	FLJ10661	-0.6	-7.87	-0.45	1.11e-13	Triglycerides;
KIRP	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21211367	chr2:162094118	NA	0.41	5.56	0.33	6.89e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
KIRP	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg12658694	chr1:38397304	INPP5B	-0.67	-8.14	-0.46	2.02e-14	Coronary artery disease;
KIRP	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg14541582	chr5:601475	NA	-0.58	-6.55	-0.39	3.33e-10	Obesity-related traits;
KIRP	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg20673091	chr1:2541236	MMEL1	0.72	10.88	0.57	9.09e-23	Ulcerative colitis;
KIRP	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.59	7.58	0.44	6.86e-13	Height;
KIRP	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.1	9.95	0.54	7.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	trans	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg13565492	chr6:43139072	SRF	-0.82	-7.55	-0.43	8.32e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg10130564	chr11:117069849	TAGLN	-0.4	-5.05	-0.31	8.46e-7	Blood protein levels;
KIRP	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.54	-5.71	-0.34	3.21e-8	Body mass index;
KIRP	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	0.91	12.26	0.62	2.77e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.55	6.89	0.4	4.6e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg04374321	chr14:90722782	PSMC1	0.84	12.63	0.63	1.67e-28	Mortality in heart failure;
KIRP	cis	rs4722166	1.000	rs4722166	chr7:22738762	G/T	cg26061582	chr7:22766209	IL6	0.45	4.85	0.3	2.21e-6	Lung cancer;
KIRP	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg03289416	chr15:75166202	SCAMP2	-0.42	-5.51	-0.33	9.24e-8	Systemic lupus erythematosus and Systemic sclerosis;
KIRP	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.63	-9.6	-0.52	9.42e-19	Total body bone mineral density;
KIRP	cis	rs745821	0.701	rs11873590	chr18:48100355	A/G	cg18923635	chr18:48083994	NA	0.43	5.12	0.31	6.19e-7	Diastolic blood pressure;
KIRP	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg09742643	chr7:157958748	PTPRN2	0.45	6.28	0.37	1.48e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg03315344	chr16:75512273	CHST6	0.77	12.15	0.61	6.52e-27	Dupuytren's disease;
KIRP	cis	rs2070433	0.756	rs2839295	chr21:47917871	A/T	cg07608496	chr21:47649218	MCM3APAS;LSS	-0.48	-5.37	-0.32	1.82e-7	Lymphocyte counts;
KIRP	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg02733842	chr7:1102375	C7orf50	0.41	4.89	0.3	1.8e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.02e-7	Initial pursuit acceleration;
KIRP	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.58	7.1	0.41	1.33e-11	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs17020663	0.771	rs12622879	chr2:101613847	A/C	cg12594615	chr2:101643137	TBC1D8	-0.46	-5.42	-0.33	1.43e-7	Pulse pressure;
KIRP	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg22117172	chr7:91764530	CYP51A1	0.4	5.52	0.33	8.51e-8	Breast cancer;
KIRP	cis	rs992157	0.764	rs13020391	chr2:219184436	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.5	-5.95	-0.35	9.18e-9	Colorectal cancer;
KIRP	cis	rs4237845	0.613	rs3751327	chr12:58335274	C/A	cg00677455	chr12:58241039	CTDSP2	0.69	7.81	0.45	1.61e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.55	14.2	0.67	7.97e-34	Airflow obstruction;
KIRP	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.6	-6.55	-0.39	3.38e-10	Aortic root size;
KIRP	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.79	9.12	0.5	2.74e-17	Corneal astigmatism;
KIRP	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.73	-6.31	-0.37	1.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg07862535	chr7:139043722	LUC7L2	0.5	5.56	0.33	6.84e-8	Diisocyanate-induced asthma;
KIRP	cis	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg00405596	chr8:11794950	NA	-0.49	-6.58	-0.39	2.89e-10	Monocyte count;
KIRP	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg08975724	chr8:8085496	FLJ10661	0.63	8.56	0.48	1.25e-15	Mood instability;
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.76	12.09	0.61	1.02e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.69	-10.52	-0.56	1.33e-21	Glomerular filtration rate (creatinine);
KIRP	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.72	-10.41	-0.55	2.85e-21	Hip circumference;
KIRP	cis	rs4742903	0.839	rs10761016	chr9:107007721	A/T	cg14250997	chr9:106856677	SMC2	0.38	4.94	0.3	1.44e-6	High-grade serous ovarian cancer;Breast cancer;
KIRP	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	5.38	0.32	1.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.85	0.49	1.79e-16	Motion sickness;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg25494665	chr13:42623369	DGKH	-0.48	-6.07	-0.36	4.85e-9	Migraine with aura;
KIRP	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg20578329	chr17:80767326	TBCD	-0.65	-7.41	-0.43	1.97e-12	Breast cancer;
KIRP	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	cg04338863	chr8:33670619	NA	0.4	5.17	0.31	4.95e-7	Body mass index;
KIRP	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg03289416	chr15:75166202	SCAMP2	0.43	6.08	0.36	4.49e-9	Breast cancer;
KIRP	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg06740227	chr12:86229804	RASSF9	0.47	5.69	0.34	3.68e-8	Major depressive disorder;
KIRP	cis	rs73198271	0.694	rs73201840	chr8:8647067	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-5.93	-0.35	1.05e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.69	10.44	0.55	2.25e-21	Hip circumference;
KIRP	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	20.7	0.8	8.7e-56	Prudent dietary pattern;
KIRP	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg04362960	chr10:104952993	NT5C2	-0.54	-5.78	-0.35	2.26e-8	Arsenic metabolism;
KIRP	trans	rs12043259	0.730	rs869841	chr1:204812118	G/C	cg11485465	chr5:54518469	NA	0.37	6.55	0.39	3.35e-10	Addiction;
KIRP	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg09408571	chr1:101003634	GPR88	-0.23	-5.28	-0.32	2.85e-7	Monocyte count;
KIRP	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-6.79	-0.4	8.27e-11	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.46	-5.89	-0.35	1.24e-8	Blood metabolite levels;
KIRP	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.93	-12.24	-0.62	3.2e-27	Platelet distribution width;
KIRP	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg00800038	chr16:89945340	TCF25	-0.79	-6.04	-0.36	5.52e-9	Skin colour saturation;
KIRP	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.55	5.68	0.34	3.81e-8	Total cholesterol levels;
KIRP	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg04935436	chr20:30431758	NA	0.45	5.74	0.34	2.72e-8	Mean corpuscular hemoglobin;
KIRP	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg23533926	chr12:111358616	MYL2	-0.48	-6.38	-0.38	8.54e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12096438	1.000	rs3924235	chr1:25895526	G/A	cg21452808	chr1:25900135	NA	0.41	6.5	0.38	4.45e-10	Platelet count;Mean platelet volume;
KIRP	cis	rs7646501	0.734	rs954734	chr3:24055654	A/C	cg21910673	chr3:24143257	LOC152024	0.36	5.02	0.3	1.01e-6	Cognitive ability;Intelligence;
KIRP	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg21132104	chr15:45694354	SPATA5L1	0.76	9.33	0.51	6.44e-18	Homoarginine levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06498398	chr8:11627480	NEIL2	-0.45	-6.14	-0.36	3.27e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.83	11.27	0.58	4.86e-24	Morning vs. evening chronotype;
KIRP	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	5.71	0.34	3.19e-8	Bipolar disorder;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg23941581	chr5:110835597	STARD4	-0.41	-6.31	-0.37	1.25e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg09549813	chr16:4587862	C16orf5	0.35	5.01	0.3	1.04e-6	Schizophrenia;
KIRP	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.65	8.76	0.49	3.33e-16	Joint mobility (Beighton score);
KIRP	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.59	-8.5	-0.48	1.91e-15	Diastolic blood pressure;
KIRP	cis	rs4656940	0.506	rs1333064	chr1:160763600	G/A	cg17331569	chr1:160788135	LY9	-0.49	-5.79	-0.35	2.13e-8	Crohn's disease;
KIRP	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.93e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	0.89	12.06	0.61	1.24e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24549020	chr5:56110836	MAP3K1	0.55	5.35	0.32	2.05e-7	Initial pursuit acceleration;
KIRP	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.8	-8.76	-0.49	3.16e-16	Coronary artery disease;
KIRP	cis	rs754423	0.532	rs941625	chr14:52547735	A/G	cg10149976	chr14:52535953	NID2	-0.42	-6.49	-0.38	4.6e-10	Craniofacial microsomia;
KIRP	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.89	-12.23	-0.61	3.55e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
KIRP	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.77	-0.44	2.07e-13	Response to antipsychotic treatment;
KIRP	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	1.11	10.15	0.54	1.85e-20	Lymphocyte counts;
KIRP	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.53	8.74	0.49	3.73e-16	Rheumatoid arthritis;
KIRP	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.86e-15	Prudent dietary pattern;
KIRP	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.34	5.24	0.32	3.45e-7	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.86	12.31	0.62	1.88e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17252645	chr8:143867129	LY6D	-0.54	-9.63	-0.52	7.69e-19	Urinary tract infection frequency;
KIRP	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg13512537	chr8:22265999	SLC39A14	-0.4	-5.2	-0.31	4.21e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs11055008	0.620	rs2111941	chr12:12829404	A/T	cg04607235	chr12:12878440	APOLD1	0.46	5.4	0.33	1.61e-7	Pulse pressure;
KIRP	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg16141378	chr3:129829833	LOC729375	0.5	6.97	0.41	2.83e-11	Neuroticism;
KIRP	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.51	6.2	0.37	2.3e-9	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg07511668	chr11:68622177	NA	0.4	5.29	0.32	2.77e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg23625390	chr15:77176239	SCAPER	0.53	7.03	0.41	2.09e-11	Blood metabolite levels;
KIRP	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg00677455	chr12:58241039	CTDSP2	0.7	8.2	0.46	1.31e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs9826463	1.000	rs9826463	chr3:142328919	C/G	cg20824294	chr3:142316082	PLS1	0.31	5.36	0.32	1.92e-7	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs897080	0.552	rs1085443	chr2:44635015	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.57	5.9	0.35	1.2e-8	Height;
KIRP	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg24009623	chr19:33667908	NA	0.47	5.73	0.34	2.94e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	9.39	0.51	4.38e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-5.77	-0.35	2.33e-8	Calcium levels;
KIRP	trans	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg10756647	chr7:56101905	PSPH	0.93	7.05	0.41	1.82e-11	Diabetic kidney disease;
KIRP	cis	rs11955398	0.585	rs1816861	chr5:60011676	T/A	cg02684056	chr5:59996105	DEPDC1B	-0.44	-5.39	-0.32	1.67e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg08273501	chr6:170599869	DLL1	0.48	6.51	0.38	4.23e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg18944383	chr4:111397179	ENPEP	-0.72	-13.99	-0.67	3.96e-33	Height;
KIRP	cis	rs858239	0.899	rs1881203	chr7:23292808	T/C	cg23682824	chr7:23144976	KLHL7	0.42	4.85	0.3	2.21e-6	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg16479474	chr6:28041457	NA	0.44	4.94	0.3	1.47e-6	Depression;
KIRP	cis	rs9381040	0.672	rs6458197	chr6:41144658	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.47	-5.58	-0.34	6.2e-8	Alzheimer's disease (late onset);
KIRP	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00149659	chr3:10157352	C3orf10	0.94	10.26	0.55	8.73e-21	Alzheimer's disease;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg00303548	chr13:96742413	HS6ST3	0.45	6.23	0.37	1.97e-9	Cancer;
KIRP	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16524936	chr4:1340807	KIAA1530	-0.47	-5.95	-0.35	9.36e-9	Longevity;
KIRP	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.85	11.0	0.57	3.65e-23	Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg13978929	chr19:21580086	ZNF493	0.5	4.89	0.3	1.85e-6	Pain;
KIRP	cis	rs16958440	0.581	rs12386097	chr18:44673268	G/A	cg17192377	chr18:44677553	HDHD2	0.65	6.32	0.37	1.22e-9	Sitting height ratio;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg23693021	chr20:43538936	PABPC1L	0.61	8.05	0.46	3.54e-14	Parkinson's disease;
KIRP	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	1.11	12.59	0.63	2.27e-28	Uric acid levels;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg14712846	chr8:38239917	WHSC1L1	0.43	6.29	0.37	1.41e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-5.49	-0.33	1e-7	Coronary artery disease;
KIRP	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.71	8.98	0.5	7.45e-17	Bladder cancer;
KIRP	cis	rs6738485	0.695	rs28750217	chr2:106770898	G/A	cg16099169	chr2:106886729	NA	-0.41	-5.9	-0.35	1.17e-8	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs4704187	0.687	rs10051422	chr5:74502573	G/A	cg03227963	chr5:74354835	NA	0.4	5.72	0.34	3.04e-8	Response to amphetamines;
KIRP	cis	rs28669119	0.722	rs302485	chr5:88137481	T/A	cg18498987	chr5:88179539	MEF2C	0.51	6.19	0.37	2.52e-9	Schizophrenia;
KIRP	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.65	-7.7	-0.44	3.26e-13	Menarche (age at onset);
KIRP	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.79	-8.12	-0.46	2.22e-14	Bronchopulmonary dysplasia;
KIRP	cis	rs4262150	0.883	rs72804781	chr5:152314450	T/C	cg12297329	chr5:152029980	NA	-0.66	-8.65	-0.48	6.59e-16	Bipolar disorder and schizophrenia;
KIRP	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg26681399	chr22:41777847	TEF	0.45	4.85	0.3	2.19e-6	Vitiligo;
KIRP	cis	rs7119038	0.818	rs11826521	chr11:118610549	G/T	cg19308663	chr11:118741387	NA	0.54	8.45	0.47	2.52e-15	Sjögren's syndrome;
KIRP	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.67	-7.91	-0.45	8.76e-14	Menopause (age at onset);
KIRP	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.85	12.26	0.62	2.67e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs5167	0.504	rs3760625	chr19:45456941	G/A	cg13119609	chr19:45449297	APOC2	0.52	7.36	0.42	2.69e-12	Blood protein levels;
KIRP	cis	rs2710642	0.927	rs2539980	chr2:63208460	T/C	cg17519650	chr2:63277830	OTX1	0.44	5.28	0.32	2.78e-7	LDL cholesterol levels;LDL cholesterol;
KIRP	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-9.3	-0.51	8.03e-18	Migraine;Coronary artery disease;
KIRP	cis	rs6723108	0.678	rs638382	chr2:135288740	T/C	cg25422880	chr2:135218333	TMEM163	-0.41	-5.71	-0.34	3.23e-8	Type 2 diabetes;
KIRP	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.64	-5.48	-0.33	1.04e-7	Menarche (age at onset);
KIRP	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.69	8.92	0.49	1.07e-16	Bladder cancer;
KIRP	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg01721255	chr8:58191610	C8orf71	0.59	4.91	0.3	1.63e-6	Developmental language disorder (linguistic errors);
KIRP	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-6.21	-0.37	2.25e-9	Breast cancer;
KIRP	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg20701182	chr2:24300061	SF3B14	0.5	4.96	0.3	1.33e-6	Lymphocyte counts;
KIRP	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg01721255	chr8:58191610	C8orf71	0.64	5.37	0.32	1.78e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	1.06	14.88	0.69	3.66e-36	Menopause (age at onset);
KIRP	cis	rs1559088	0.901	rs7249983	chr19:33598851	C/A	cg24009623	chr19:33667908	NA	0.46	5.78	0.35	2.28e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26526719	chr5:1949144	NA	0.44	5.25	0.32	3.29e-7	Gut microbiome composition (winter);
KIRP	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-6.66	-0.39	1.75e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg27205649	chr11:78285834	NARS2	-0.55	-5.33	-0.32	2.2e-7	Testicular germ cell tumor;
KIRP	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg21698718	chr17:80085957	CCDC57	-0.35	-5.07	-0.31	7.77e-7	Life satisfaction;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	ch.3.541850R	chr3:25687654	TOP2B	0.46	6.54	0.38	3.52e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg00922110	chr4:57842668	C4orf14	-0.43	-5.53	-0.33	7.98e-8	Response to bleomycin (chromatid breaks);
KIRP	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg11555438	chr13:111297484	CARS2	0.36	5.68	0.34	3.78e-8	Coronary artery disease;
KIRP	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg11645453	chr3:52864694	ITIH4	0.33	4.96	0.3	1.32e-6	Body mass index;
KIRP	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.9	-13.57	-0.65	1.08e-31	Longevity;Endometriosis;
KIRP	cis	rs8018808	0.935	rs11627385	chr14:77936343	T/C	cg20045696	chr14:77926864	AHSA1	0.46	5.58	0.34	6.33e-8	Myeloid white cell count;
KIRP	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	6.78	0.4	9.06e-11	Lung cancer;
KIRP	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.8	9.53	0.52	1.6e-18	Corneal astigmatism;
KIRP	cis	rs10107145	0.509	rs73209954	chr8:10760667	G/C	cg27411982	chr8:10470053	RP1L1	-0.42	-4.86	-0.3	2.1e-6	Systolic blood pressure;
KIRP	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg04608330	chr12:45269318	NELL2	-0.56	-7.68	-0.44	3.7e-13	Gut microbiome composition (summer);
KIRP	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.44	6.07	0.36	4.72e-9	Red blood cell count;
KIRP	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg01872077	chr2:219646372	CYP27A1	0.4	5.23	0.32	3.71e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.43	5.57	0.33	6.55e-8	Total body bone mineral density;
KIRP	cis	rs3026101	0.671	rs2309372	chr17:5298396	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.92	0.35	1.09e-8	Body mass index;
KIRP	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.41	0.43	1.98e-12	Neuroticism;
KIRP	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg21573476	chr21:45109991	RRP1B	-0.56	-7.52	-0.43	1.02e-12	Mean corpuscular volume;
KIRP	cis	rs7180079	0.620	rs477966	chr15:64783725	A/G	cg15337035	chr15:64978493	NA	-0.45	-5.18	-0.31	4.61e-7	Monocyte count;
KIRP	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.06	-0.36	4.97e-9	Morning vs. evening chronotype;
KIRP	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18364779	chr6:26104403	HIST1H4C	0.62	8.16	0.46	1.72e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg17691542	chr6:26056736	HIST1H1C	0.41	5.51	0.33	9.06e-8	Schizophrenia;
KIRP	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg13385521	chr17:29058706	SUZ12P	0.68	5.65	0.34	4.41e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs981844	0.645	rs72731677	chr4:154671475	C/G	cg14289246	chr4:154710475	SFRP2	0.67	7.54	0.43	9.09e-13	Response to statins (LDL cholesterol change);
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03853227	chr12:107487365	CRY1	0.52	6.69	0.39	1.5e-10	Parkinson's disease;
KIRP	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg10504392	chr12:110044639	NA	0.26	5.2	0.31	4.09e-7	Neuroticism;
KIRP	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	1.08	9.79	0.53	2.5e-19	Pulse pressure;
KIRP	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-1.01	-17.11	-0.74	9e-44	Height;
KIRP	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg14289246	chr4:154710475	SFRP2	-0.52	-6.83	-0.4	6.5e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.53	8.56	0.48	1.22e-15	Glomerular filtration rate (creatinine);
KIRP	cis	rs9522267	0.643	rs9522280	chr13:112221334	G/C	cg14952266	chr13:112191215	NA	0.38	5.08	0.31	7.61e-7	Hepatitis;
KIRP	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg27178145	chr22:32340355	YWHAH;C22orf24	0.69	4.84	0.3	2.27e-6	Childhood ear infection;
KIRP	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg00933542	chr6:150070202	PCMT1	0.29	5.58	0.34	6.22e-8	Lung cancer;
KIRP	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.17	-0.42	9e-12	Response to antipsychotic treatment;
KIRP	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg18016565	chr1:150552671	MCL1	0.36	5.65	0.34	4.45e-8	Melanoma;
KIRP	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg04058563	chr4:185651563	MLF1IP	0.52	7.24	0.42	5.85e-12	Kawasaki disease;
KIRP	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-6.92	-0.4	3.94e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg08499158	chr17:42289980	UBTF	0.48	6.18	0.37	2.69e-9	Bone mineral density (hip);Bone mineral density;
KIRP	trans	rs877282	0.735	rs111609055	chr10:826539	A/G	cg22713356	chr15:30763199	NA	0.8	7.79	0.44	1.87e-13	Uric acid levels;
KIRP	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.4	-4.91	-0.3	1.67e-6	Neurofibrillary tangles;
KIRP	cis	rs4704187	0.663	rs7735057	chr5:74403857	T/A	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs11078597	0.671	rs1045806	chr17:1641806	G/A	cg17514665	chr17:1657533	SERPINF2	0.44	5.49	0.33	9.95e-8	Serum albumin level;
KIRP	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg21285383	chr16:89894308	SPIRE2	0.33	6.25	0.37	1.85e-9	Vitiligo;
KIRP	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	1.22	11.23	0.58	6.87e-24	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg13319975	chr6:146136371	FBXO30	-0.41	-5.37	-0.32	1.85e-7	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg06038239	chr11:123612522	ZNF202	0.43	6.04	0.36	5.63e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.38	6.25	0.37	1.85e-9	Electroencephalogram traits;
KIRP	trans	rs365060	0.542	rs5021634	chr2:109582357	A/G	cg13244417	chr13:101327186	TMTC4	0.51	6.21	0.37	2.25e-9	Beard thickness;
KIRP	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.37	-7.18	-0.42	8.32e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
KIRP	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-5.58	-0.34	6.41e-8	Bipolar disorder;
KIRP	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg12486944	chr17:80159399	CCDC57	-0.4	-5.27	-0.32	3.03e-7	Life satisfaction;
KIRP	cis	rs2150410	0.764	rs7280149	chr21:40589535	C/A	cg11890956	chr21:40555474	PSMG1	0.79	5.72	0.34	3.06e-8	Temperament (bipolar disorder);
KIRP	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg27506609	chr1:36549197	TEKT2	0.94	7.54	0.43	8.9e-13	Schizophrenia;
KIRP	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.95	13.2	0.64	1.92e-30	Acute graft versus host disease in bone marrow transplantation (recipient effect);
KIRP	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.54	-6.34	-0.37	1.09e-9	Psoriasis;
KIRP	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.77	9.99	0.54	6.19e-20	Breast cancer;
KIRP	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg18016565	chr1:150552671	MCL1	-0.48	-7.49	-0.43	1.27e-12	Tonsillectomy;
KIRP	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.4	-4.94	-0.3	1.47e-6	Schizophrenia;
KIRP	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.61	8.12	0.46	2.27e-14	Bone mineral density;
KIRP	cis	rs4700695	0.841	rs27569	chr5:65373419	C/T	cg21114390	chr5:65439923	SFRS12	-0.47	-5.48	-0.33	1.05e-7	Facial morphology (factor 19);
KIRP	cis	rs12786942	0.660	rs7951897	chr11:101307853	T/C	cg03942599	chr11:101341554	TRPC6	0.47	5.94	0.35	9.43e-9	Facial depth;
KIRP	cis	rs2487048	0.761	rs1800976	chr9:107690709	C/G	cg14019050	chr9:107690770	ABCA1	-0.31	-5.93	-0.35	1.02e-8	Intraocular pressure;
KIRP	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg06636001	chr8:8085503	FLJ10661	-0.69	-8.99	-0.5	6.84e-17	Myopia (pathological);
KIRP	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	7.31	0.42	3.76e-12	Migraine;Coronary artery disease;
KIRP	cis	rs13161895	0.702	rs74507840	chr5:179487430	G/A	cg06664874	chr5:179499304	RNF130	0.81	5.28	0.32	2.84e-7	LDL cholesterol;
KIRP	cis	rs240764	0.782	rs12216199	chr6:101152723	C/A	cg09795085	chr6:101329169	ASCC3	-0.46	-5.52	-0.33	8.75e-8	Neuroticism;
KIRP	trans	rs2404602	0.692	rs1867197	chr15:76910031	A/G	cg00879163	chr7:66386079	C7orf42	-0.47	-6.06	-0.36	4.98e-9	Blood metabolite levels;
KIRP	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.62	7.04	0.41	1.93e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	1.07	9.05	0.5	4.57e-17	Fat distribution (HIV);
KIRP	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg02175503	chr12:58329896	NA	-0.59	-6.44	-0.38	6.35e-10	Multiple sclerosis;
KIRP	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.43	-5.26	-0.32	3.18e-7	Acne (severe);
KIRP	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg05315796	chr3:52349193	DNAH1	0.49	7.67	0.44	3.95e-13	Electroencephalogram traits;
KIRP	cis	rs7520050	0.933	rs6656022	chr1:46394315	A/G	cg24296786	chr1:45957014	TESK2	0.38	4.87	0.3	2.04e-6	Red blood cell count;Reticulocyte count;
KIRP	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg16141378	chr3:129829833	LOC729375	0.55	7.59	0.44	6.66e-13	Neuroticism;
KIRP	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19346786	chr7:2764209	NA	-0.41	-6.75	-0.4	1.08e-10	Height;
KIRP	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg09029085	chr17:47094198	IGF2BP1	0.25	5.65	0.34	4.49e-8	Intelligence (multi-trait analysis);Body fat percentage;
KIRP	cis	rs7267005	0.661	rs2425085	chr20:34302402	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.85	-0.3	2.16e-6	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs7727544	0.617	rs3843503	chr5:131466629	T/A	cg07395648	chr5:131743802	NA	-0.37	-4.99	-0.3	1.13e-6	Blood metabolite levels;
KIRP	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg05709478	chr1:6581295	PLEKHG5	-0.58	-5.28	-0.32	2.9e-7	Body mass index;
KIRP	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg08017634	chr8:144659831	NAPRT1	0.81	5.14	0.31	5.48e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00933542	chr6:150070202	PCMT1	0.29	5.61	0.34	5.46e-8	Lung cancer;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26769118	chr10:394632	DIP2C	0.5	6.2	0.37	2.42e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg23533926	chr12:111358616	MYL2	-0.49	-6.41	-0.38	7.53e-10	Extrinsic epigenetic age acceleration;
KIRP	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg20965017	chr5:231967	SDHA	-0.58	-6.73	-0.39	1.17e-10	Breast cancer;
KIRP	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg12288994	chr5:1860383	NA	0.49	6.8	0.4	7.92e-11	Cardiovascular disease risk factors;
KIRP	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.46	5.72	0.34	3.09e-8	Menopause (age at onset);
KIRP	cis	rs4073221	0.860	rs36087209	chr3:18217600	G/C	cg07694806	chr3:18168406	NA	-0.71	-6.16	-0.37	2.91e-9	Parkinson's disease;
KIRP	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-5.83	-0.35	1.71e-8	Electroencephalogram traits;
KIRP	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.36	6.02	0.36	6.36e-9	Heart rate;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20951968	chr19:41284348	RAB4B	0.47	6.54	0.38	3.47e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg04935436	chr20:30431758	NA	0.5	6.67	0.39	1.66e-10	Mean corpuscular hemoglobin;
KIRP	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.65	8.02	0.46	4.41e-14	Blood metabolite levels;
KIRP	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg11382394	chr1:2564504	MMEL1	0.38	4.89	0.3	1.81e-6	Ulcerative colitis;
KIRP	cis	rs7769051	0.708	rs62426668	chr6:133225021	C/T	cg22852734	chr6:133119734	C6orf192	0.86	5.29	0.32	2.77e-7	Type 2 diabetes nephropathy;
KIRP	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg23100626	chr2:96804247	ASTL	-0.46	-6.34	-0.37	1.1e-9	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
KIRP	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg02811702	chr13:24901961	NA	0.42	5.55	0.33	7.33e-8	Obesity-related traits;
KIRP	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.7	-6.67	-0.39	1.64e-10	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg07274523	chr3:49395745	GPX1	0.5	4.87	0.3	2e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg26831259	chr4:1366826	KIAA1530	-0.38	-5.14	-0.31	5.57e-7	Obesity-related traits;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg24627793	chr17:79479216	ACTG1	0.53	6.72	0.39	1.23e-10	Parkinson's disease;
KIRP	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17376030	chr22:41985996	PMM1	-0.81	-8.16	-0.46	1.71e-14	Vitiligo;
KIRP	cis	rs4638749	0.501	rs6708539	chr2:108745042	C/A	cg06795125	chr2:108905320	SULT1C2	-0.31	-5.72	-0.34	3.14e-8	Blood pressure;
KIRP	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.76	11.92	0.61	3.59e-26	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7106204	0.590	rs7115417	chr11:24247696	A/G	ch.11.24196551F	chr11:24239977	NA	0.8	9.12	0.5	2.8e-17	Response to Homoharringtonine (cytotoxicity);
KIRP	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	9.89	0.53	1.22e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs6142102	0.602	rs4911399	chr20:32623418	C/A	cg24642439	chr20:33292090	TP53INP2	0.47	5.72	0.34	3.12e-8	Skin pigmentation;
KIRP	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.98	13.26	0.65	1.18e-30	Menopause (age at onset);
KIRP	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.45	-10.15	-0.54	1.93e-20	Alzheimer's disease (late onset);
KIRP	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	0.98	8.37	0.47	4.26e-15	Arsenic metabolism;
KIRP	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.66	11.11	0.58	1.63e-23	Cardiovascular disease risk factors;
KIRP	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg27205649	chr11:78285834	NARS2	0.63	7.44	0.43	1.67e-12	Alzheimer's disease (survival time);
KIRP	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.66	10.11	0.54	2.5e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg25811766	chr13:21894605	NA	-0.62	-6.16	-0.37	3.01e-9	White matter hyperintensity burden;
KIRP	cis	rs447921	0.817	rs11077822	chr17:74455605	G/A	cg16776035	chr17:74542680	NA	0.51	5.32	0.32	2.35e-7	Mitochondrial DNA levels;
KIRP	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.28	5.66	0.34	4.21e-8	Coronary artery disease;
KIRP	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.68	-8.53	-0.48	1.55e-15	Extraversion;
KIRP	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg16434002	chr17:42200994	HDAC5	-0.57	-6.95	-0.41	3.24e-11	Total body bone mineral density;
KIRP	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg17143192	chr8:8559678	CLDN23	0.72	8.37	0.47	4.24e-15	Obesity-related traits;
KIRP	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg07309820	chr7:148901717	ZNF282	0.39	4.98	0.3	1.22e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
KIRP	cis	rs2916247	1.000	rs2011093	chr8:92982608	A/G	cg10183463	chr8:93005414	RUNX1T1	0.56	7.01	0.41	2.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg13206674	chr6:150067644	NUP43	-0.41	-5.06	-0.31	8.35e-7	Lung cancer;
KIRP	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00982548	chr2:198649783	BOLL	-0.57	-5.73	-0.34	2.87e-8	Ulcerative colitis;
KIRP	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-8.91	-0.49	1.17e-16	Resting heart rate;
KIRP	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg08648136	chr8:956695	NA	0.5	7.26	0.42	5.01e-12	Schizophrenia;
KIRP	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg01270228	chr10:1369114	ADARB2	0.45	6.03	0.36	6.1e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg09529537	chr5:78531947	JMY	0.67	8.03	0.46	4.07e-14	Smoking initiation;
KIRP	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg04132472	chr17:19861366	AKAP10	0.39	5.0	0.3	1.07e-6	Schizophrenia;
KIRP	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.74	-10.96	-0.57	5.22e-23	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.44	6.3	0.37	1.37e-9	Testicular germ cell tumor;
KIRP	cis	rs501120	0.925	rs1746052	chr10:44778546	G/T	cg09554077	chr10:44749378	NA	-0.7	-9.69	-0.53	5.14e-19	Coronary artery disease;Coronary heart disease;
KIRP	cis	rs7937612	0.965	rs7131046	chr11:120238534	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.45	-6.63	-0.39	2.11e-10	Intraocular pressure;
KIRP	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.93	13.79	0.66	2.02e-32	Tonsillectomy;
KIRP	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg21970626	chr13:21893289	NA	-0.4	-5.69	-0.34	3.58e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg02100629	chr10:71892760	AIFM2	-0.38	-4.89	-0.3	1.83e-6	Blood protein levels;
KIRP	cis	rs4356932	0.967	rs28505472	chr4:76972727	C/T	cg00809888	chr4:76862425	NAAA	0.44	6.17	0.37	2.77e-9	Blood protein levels;
KIRP	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg09201719	chr10:104596890	CYP17A1	0.4	5.89	0.35	1.25e-8	Immature fraction of reticulocytes;Schizophrenia;
KIRP	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-8.84	-0.49	1.87e-16	Platelet count;
KIRP	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg06654118	chr4:1303317	MAEA	0.28	5.15	0.31	5.43e-7	Obesity-related traits;
KIRP	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg03647239	chr10:116582469	FAM160B1	0.5	5.97	0.36	8.25e-9	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg02002194	chr4:3960332	NA	0.42	6.05	0.36	5.31e-9	Neuroticism;
KIRP	cis	rs3779635	0.742	rs28739491	chr8:27252746	G/C	cg11641102	chr8:27183873	PTK2B	0.46	6.0	0.36	7.15e-9	Neuroticism;
KIRP	cis	rs8177876	0.749	rs2287995	chr16:81095099	C/G	cg08591886	chr16:81111003	C16orf46	-0.65	-5.31	-0.32	2.4e-7	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs7520050	0.778	rs3014238	chr1:46090214	A/G	cg03146154	chr1:46216737	IPP	-0.39	-4.95	-0.3	1.36e-6	Red blood cell count;Reticulocyte count;
KIRP	cis	rs7589728	1.000	rs12473740	chr2:88527647	A/G	cg04511125	chr2:88470314	THNSL2	0.7	5.46	0.33	1.17e-7	Plasma clusterin levels;
KIRP	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg05370193	chr1:21551575	ECE1	-0.36	-4.96	-0.3	1.29e-6	Facial morphology (factor 17, height of vermillion upper lip);
KIRP	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg13611997	chr5:233750	SDHA	-0.43	-5.19	-0.31	4.32e-7	Breast cancer;
KIRP	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-11.04	-0.58	2.76e-23	Height;
KIRP	cis	rs35740288	0.731	rs11638407	chr15:86094655	A/C	cg17133734	chr15:86042851	AKAP13	-0.5	-5.41	-0.33	1.48e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.39	-4.89	-0.3	1.79e-6	Body mass index (alcohol intake interaction);
KIRP	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.47	-7.11	-0.41	1.24e-11	Daytime sleep phenotypes;
KIRP	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.86	-9.61	-0.52	9.22e-19	Platelet count;
KIRP	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	5.7	0.34	3.34e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs778371	0.671	rs13008436	chr2:233719948	C/T	cg11972305	chr2:233791962	NGEF	-0.38	-5.23	-0.32	3.61e-7	Schizophrenia;
KIRP	cis	rs4654899	1.000	rs6426668	chr1:21396596	T/C	cg05370193	chr1:21551575	ECE1	0.44	6.13	0.36	3.5e-9	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg26681399	chr22:41777847	TEF	-0.5	-5.48	-0.33	1.03e-7	Vitiligo;
KIRP	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.8	7.12	0.41	1.19e-11	Obesity-related traits;
KIRP	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.91	7.88	0.45	1.09e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
KIRP	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.96	10.66	0.56	4.6e-22	Corneal astigmatism;
KIRP	cis	rs2151522	0.762	rs35973496	chr6:127163126	C/T	cg21431617	chr6:127135037	NA	0.29	5.16	0.31	4.99e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs8077577	0.895	rs16960983	chr17:18104568	A/T	cg18869244	chr17:18121946	NA	0.45	5.46	0.33	1.18e-7	Obesity-related traits;
KIRP	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.68	10.01	0.54	5.41e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg25486957	chr4:152246857	NA	-0.42	-5.07	-0.31	7.7e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs71277158	0.688	rs2287479	chr3:169787423	G/C	cg04067573	chr3:169899625	PHC3	0.62	5.65	0.34	4.33e-8	Prostate cancer;
KIRP	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	5.58	0.34	6.39e-8	Osteoporosis;
KIRP	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.66	-8.42	-0.47	3.06e-15	Morning vs. evening chronotype;
KIRP	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.59	-7.12	-0.41	1.21e-11	Systemic lupus erythematosus;
KIRP	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg13147721	chr7:65941812	NA	-1.02	-7.05	-0.41	1.84e-11	Diabetic kidney disease;
KIRP	cis	rs1009170	0.794	rs9919953	chr14:92582974	C/A	cg10324096	chr14:92587714	CPSF2;NDUFB1	0.54	5.43	0.33	1.37e-7	Dialysis-related mortality;
KIRP	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.95	-12.9	-0.64	1.94e-29	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg05220968	chr6:146057943	EPM2A	0.39	4.85	0.3	2.22e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg04935436	chr20:30431758	NA	0.47	6.04	0.36	5.62e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs212524	0.544	rs7551107	chr1:21559702	C/A	cg21184320	chr1:21044207	KIF17	0.35	5.22	0.32	3.75e-7	Height;
KIRP	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg00310523	chr12:86230176	RASSF9	0.47	7.39	0.43	2.25e-12	Major depressive disorder;
KIRP	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.71	8.83	0.49	2.01e-16	Coronary artery disease;
KIRP	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.65	-5.33	-0.32	2.19e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.39	-0.32	1.67e-7	Educational attainment;
KIRP	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.76	-9.84	-0.53	1.75e-19	Aortic root size;
KIRP	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	6.78	0.4	8.61e-11	Hypertriglyceridemia;
KIRP	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.56	-6.67	-0.39	1.69e-10	Menopause (age at onset);
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg13356884	chr1:110881579	RBM15	0.48	6.21	0.37	2.22e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg05315796	chr3:52349193	DNAH1	-0.44	-6.79	-0.4	8.5e-11	Bipolar disorder;
KIRP	cis	rs918629	0.761	rs3777166	chr5:95291056	G/C	cg16656078	chr5:95278638	ELL2	-0.52	-7.47	-0.43	1.39e-12	IgG glycosylation;
KIRP	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.75	-12.41	-0.62	8.48e-28	Prostate cancer;
KIRP	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg22916017	chr11:64110731	CCDC88B	0.58	6.47	0.38	5.13e-10	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
KIRP	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.56	-9.36	-0.51	5.37e-18	Prostate cancer;
KIRP	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	28.97	0.88	2.9e-81	Chronic sinus infection;
KIRP	cis	rs6429082	0.871	rs9662392	chr1:235576949	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.5	-6.48	-0.38	4.83e-10	Adiposity;
KIRP	cis	rs2790457	0.793	rs2153302	chr10:28818536	A/C	cg05705492	chr10:28955341	NA	-0.5	-7.52	-0.43	1.03e-12	Multiple myeloma;
KIRP	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-7.32	-0.42	3.62e-12	Glomerular filtration rate;
KIRP	cis	rs35079168	0.809	rs11103483	chr9:137287874	G/A	cg13941235	chr9:137270186	RXRA	-0.25	-5.32	-0.32	2.33e-7	Intelligence;
KIRP	cis	rs240764	0.658	rs9399685	chr6:101204318	C/G	cg09795085	chr6:101329169	ASCC3	-0.43	-5.24	-0.32	3.52e-7	Neuroticism;
KIRP	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.66	8.62	0.48	8.21e-16	Mood instability;
KIRP	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg08885076	chr2:99613938	TSGA10	-0.53	-9.03	-0.5	5.09e-17	Chronic sinus infection;
KIRP	cis	rs7973719	1.000	rs12828421	chr12:7335217	C/T	cg07052231	chr12:7363540	PEX5	-0.4	-5.26	-0.32	3.07e-7	IgG glycosylation;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07226802	chr8:144457703	RHPN1	-0.37	-6.39	-0.38	8.24e-10	Bladder cancer;
KIRP	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.11	13.58	0.65	1.02e-31	IgG glycosylation;
KIRP	trans	rs12643302	0.847	rs12504377	chr4:172356075	A/T	cg01158574	chr2:11809997	NTSR2	-0.44	-6.1	-0.36	4.2e-9	Facial morphology (factor 3, length of philtrum);
KIRP	cis	rs734999	0.549	rs6667564	chr1:2520302	T/C	cg18932078	chr1:2524107	MMEL1	0.39	5.21	0.32	4.03e-7	Ulcerative colitis;
KIRP	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg03474202	chr17:45855739	NA	-0.52	-8.12	-0.46	2.29e-14	IgG glycosylation;
KIRP	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg15655495	chr12:38532458	NA	0.28	5.37	0.32	1.86e-7	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg02462569	chr6:150064036	NUP43	-0.4	-6.13	-0.36	3.52e-9	Lung cancer;
KIRP	cis	rs4141404	0.828	rs2413043	chr22:31648576	G/T	cg22777020	chr22:31556080	RNF185	-0.5	-5.31	-0.32	2.5e-7	Paclitaxel-induced neuropathy;
KIRP	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.96	-14.83	-0.69	5.42e-36	Height;
KIRP	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.99	10.45	0.55	2.09e-21	Exhaled nitric oxide output;
KIRP	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg03959625	chr15:84868606	LOC388152	0.54	6.55	0.39	3.42e-10	Schizophrenia;
KIRP	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg11189052	chr15:85197271	WDR73	0.51	4.86	0.3	2.06e-6	Schizophrenia;
KIRP	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg23594656	chr7:65796392	TPST1	0.44	6.0	0.36	6.87e-9	Aortic root size;
KIRP	cis	rs9400271	0.632	rs9374070	chr6:109586455	G/A	cg01475377	chr6:109611718	NA	-0.39	-5.64	-0.34	4.76e-8	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs2970818	0.831	rs2907495	chr12:4638164	T/C	cg14576962	chr12:4671597	NA	-0.43	-5.13	-0.31	5.75e-7	Phosphorus levels;
KIRP	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.43	6.31	0.37	1.31e-9	Lymphocyte counts;
KIRP	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg21427119	chr20:30132790	HM13	-0.54	-6.18	-0.37	2.61e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.49	5.91	0.35	1.16e-8	Uric acid clearance;
KIRP	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg06818126	chr11:68850279	TPCN2	-0.47	-5.43	-0.33	1.33e-7	Hair color;
KIRP	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg01689657	chr7:91764605	CYP51A1	0.43	6.2	0.37	2.36e-9	Breast cancer;
KIRP	cis	rs9475752	0.793	rs13193465	chr6:56820248	A/G	cg22880620	chr6:56820808	BEND6;DST	0.48	5.02	0.3	1e-6	Menarche (age at onset);
KIRP	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.89	-10.09	-0.54	2.92e-20	White matter hyperintensity burden;
KIRP	cis	rs241257	0.621	rs241271	chr1:4626255	T/C	cg02837536	chr1:4771682	AJAP1	-0.29	-5.15	-0.31	5.27e-7	Anxiety disorder;
KIRP	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	5.0	0.3	1.08e-6	Menopause (age at onset);
KIRP	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	8.5	0.48	1.8e-15	Bipolar disorder;
KIRP	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.72	10.72	0.56	3e-22	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2540949	0.538	rs2540971	chr2:65252385	A/T	cg05010058	chr2:65284262	CEP68	0.4	5.44	0.33	1.26e-7	Atrial fibrillation;
KIRP	cis	rs7851660	0.809	rs10984253	chr9:100664474	A/G	cg13688889	chr9:100608707	NA	-0.68	-8.66	-0.48	6.18e-16	Strep throat;
KIRP	cis	rs11718455	0.767	rs6785433	chr3:43964265	A/G	cg08738300	chr3:44038990	NA	0.67	8.95	0.5	9.1e-17	Coronary artery disease;
KIRP	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg21775007	chr8:11205619	TDH	0.4	5.24	0.32	3.5e-7	Morning vs. evening chronotype;
KIRP	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg21858823	chr1:15850916	CASP9	0.55	5.83	0.35	1.71e-8	Systolic blood pressure;
KIRP	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.85	13.41	0.65	3.83e-31	Ulcerative colitis;
KIRP	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.44	5.05	0.31	8.5e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg18932078	chr1:2524107	MMEL1	0.39	5.29	0.32	2.65e-7	Ulcerative colitis;
KIRP	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg10755058	chr3:40428713	ENTPD3	0.45	6.44	0.38	6.22e-10	Renal cell carcinoma;
KIRP	cis	rs2223471	0.602	rs10948573	chr6:50692351	C/G	cg03432817	chr6:50765336	NA	-0.35	-4.9	-0.3	1.75e-6	Subcutaneous adipose tissue;
KIRP	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg14346243	chr4:90757452	SNCA	-0.38	-4.85	-0.3	2.14e-6	Neuroticism;
KIRP	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg13798575	chr9:95087839	CENPP;NOL8	0.47	5.95	0.35	9.1e-9	Height;
KIRP	cis	rs6959887	0.926	rs6972725	chr7:35285404	C/G	cg06685737	chr7:35301730	NA	0.43	6.23	0.37	2e-9	Birth weight;
KIRP	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.8	9.72	0.53	4.22e-19	Corneal astigmatism;
KIRP	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-8.25	-0.47	9.6e-15	Mean corpuscular volume;
KIRP	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.7	10.14	0.54	2.02e-20	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs4975616	0.933	rs13356727	chr5:1312457	G/A	cg06550200	chr5:1325588	CLPTM1L	0.85	11.77	0.6	1.18e-25	Lung cancer;
KIRP	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg23281280	chr6:28129359	ZNF389	0.47	5.13	0.31	5.97e-7	Depression;
KIRP	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	5.27	0.32	3.01e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs9921338	0.961	rs72773829	chr16:11412623	G/A	cg00044050	chr16:11439710	C16orf75	-0.54	-5.67	-0.34	3.89e-8	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs883565	0.740	rs2293312	chr3:39111140	C/A	cg01426195	chr3:39028469	NA	-0.67	-11.15	-0.58	1.25e-23	Handedness;
KIRP	cis	rs4849845	0.889	rs3933619	chr2:121035007	C/G	cg24070213	chr2:121070622	NA	0.38	5.26	0.32	3.16e-7	Mean platelet volume;
KIRP	cis	rs12210905	0.925	rs12192502	chr6:26995720	A/C	cg23155468	chr6:27110703	HIST1H2BK	0.51	4.94	0.3	1.44e-6	Hip circumference adjusted for BMI;
KIRP	cis	rs1215050	0.904	rs9307215	chr4:98813965	A/G	cg17366294	chr4:99064904	C4orf37	0.38	4.97	0.3	1.28e-6	Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.68	-8.18	-0.46	1.53e-14	Blood protein levels;
KIRP	cis	rs8177876	0.731	rs77145371	chr16:81118660	A/G	cg08591886	chr16:81111003	C16orf46	-0.6	-5.77	-0.35	2.42e-8	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs4073416	0.568	rs7158153	chr14:66034586	C/A	cg03016385	chr14:66212404	NA	-0.51	-6.19	-0.37	2.47e-9	N-glycan levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg02717630	chr16:46865118	C16orf87	0.47	6.04	0.36	5.53e-9	Parkinson's disease;
KIRP	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	5.76	0.34	2.51e-8	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg14210620	chr13:44453864	C13orf31;CCDC122	0.39	5.2	0.31	4.22e-7	Leprosy;
KIRP	cis	rs1712790	0.614	rs17117467	chr11:114638206	G/T	cg19465033	chr11:114479364	NA	-0.39	-5.2	-0.31	4.26e-7	Urinary albumin excretion;
KIRP	cis	rs10256972	0.514	rs2140578	chr7:1214003	T/C	cg18402987	chr7:1209562	NA	0.44	5.13	0.31	6e-7	Longevity;Endometriosis;
KIRP	cis	rs4073221	0.585	rs13093954	chr3:18326007	C/T	cg07694806	chr3:18168406	NA	-0.68	-5.91	-0.35	1.12e-8	Parkinson's disease;
KIRP	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg23307798	chr14:103986281	CKB	0.72	11.24	0.58	6.34e-24	Body mass index;
KIRP	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.52	6.5	0.38	4.47e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3112255	0.512	rs10174721	chr2:101337013	A/C	cg01042948	chr2:101319752	NA	0.36	5.03	0.31	9.6e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.56	7.4	0.43	2.13e-12	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs13132184	0.586	rs67116068	chr4:38100767	C/T	cg19090437	chr4:38080799	TBC1D1	-0.61	-5.21	-0.32	3.96e-7	Verbal declarative memory;
KIRP	cis	rs13132184	0.507	rs12649018	chr4:38060085	A/G	cg19090437	chr4:38080799	TBC1D1	-0.54	-5.2	-0.31	4.22e-7	Verbal declarative memory;
KIRP	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg02527881	chr3:46936655	PTH1R	-0.39	-5.56	-0.33	6.9e-8	Colorectal cancer;
KIRP	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.0	-16.44	-0.72	1.71e-41	Coffee consumption;Coffee consumption (cups per day);
KIRP	cis	rs523522	0.602	rs7970933	chr12:120862474	G/A	cg27279351	chr12:120934652	DYNLL1	0.59	5.37	0.32	1.84e-7	High light scatter reticulocyte count;
KIRP	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg00666640	chr1:248458726	OR2T12	0.47	5.78	0.35	2.26e-8	Common traits (Other);
KIRP	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg06204229	chr3:52865917	ITIH4	0.53	5.93	0.35	1.02e-8	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-8.34	-0.47	5.34e-15	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.41	4.98	0.3	1.22e-6	Diabetic retinopathy;
KIRP	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.56	-7.27	-0.42	4.7e-12	Aortic root size;
KIRP	cis	rs2494938	0.692	rs1033482	chr6:40542073	C/T	cg14084896	chr6:40530702	LRFN2	0.42	5.38	0.32	1.74e-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
KIRP	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg10223061	chr2:219282414	VIL1	-0.33	-5.38	-0.32	1.71e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg24375607	chr4:120327624	NA	0.48	5.24	0.32	3.4e-7	Corneal astigmatism;
KIRP	cis	rs9311676	0.656	rs6773193	chr3:58385960	C/T	cg06643156	chr3:58380774	PXK	0.35	4.9	0.3	1.77e-6	Systemic lupus erythematosus;
KIRP	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-5.33	-0.32	2.22e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs654950	0.807	rs61773660	chr1:41993298	C/T	cg06885757	chr1:42089581	HIVEP3	-0.52	-7.65	-0.44	4.57e-13	Airway imaging phenotypes;
KIRP	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg20140201	chr2:241835670	C2orf54	-0.34	-5.26	-0.32	3.12e-7	Urinary metabolites;
KIRP	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg22325292	chr17:80708367	FN3K	0.36	4.95	0.3	1.38e-6	Glycated hemoglobin levels;
KIRP	cis	rs860295	0.541	rs11264359	chr1:155282829	A/G	cg02153340	chr1:155202674	NA	-0.55	-7.8	-0.45	1.72e-13	Body mass index;
KIRP	cis	rs7656342	0.686	rs3762933	chr4:9825026	C/T	cg11266682	chr4:10021025	SLC2A9	0.32	4.95	0.3	1.38e-6	Gut microbiota (bacterial taxa);
KIRP	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs4132509	1.000	rs4565696	chr1:243918083	C/T	cg25706552	chr1:244017396	NA	0.59	7.16	0.42	9.34e-12	RR interval (heart rate);
KIRP	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg26875233	chr11:93583750	C11orf90	-0.36	-6.66	-0.39	1.75e-10	Response to serotonin reuptake inhibitors in major depressive disorder;
KIRP	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.6	-6.53	-0.38	3.67e-10	Alzheimer's disease (late onset);
KIRP	cis	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg07460842	chr6:66804631	NA	0.48	5.76	0.34	2.5e-8	Metabolite levels;
KIRP	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg17294928	chr15:75287854	SCAMP5	-0.67	-5.62	-0.34	5.04e-8	Lung cancer;
KIRP	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23281280	chr6:28129359	ZNF389	0.46	5.03	0.31	9.4e-7	Depression;
KIRP	cis	rs11749327	0.719	rs36111336	chr5:463616	T/C	cg26850624	chr5:429559	AHRR	-0.48	-6.34	-0.37	1.08e-9	Hemoglobin concentration;Hypospadias;
KIRP	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.43	5.91	0.35	1.12e-8	Sitting height ratio;
KIRP	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.82	-12.8	-0.63	4.27e-29	Blood metabolite levels;
KIRP	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg26913058	chr16:419975	MRPL28	-0.45	-5.05	-0.31	8.7e-7	Morning vs. evening chronotype;
KIRP	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.43	5.26	0.32	3.17e-7	Cognitive test performance;
KIRP	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg14972814	chr11:95582409	MTMR2	0.3	5.16	0.31	5e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs3755132	0.929	rs6431716	chr2:15734621	G/A	cg12888861	chr2:15731646	DDX1	0.41	5.41	0.33	1.48e-7	Wilms tumor;
KIRP	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	0.93	12.12	0.61	8.27e-27	Blood protein levels;
KIRP	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.8	11.77	0.6	1.16e-25	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6991838	0.584	rs66467166	chr8:66486400	C/A	cg13398993	chr8:66546079	ARMC1	-0.47	-5.39	-0.32	1.68e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.53	8.74	0.49	3.78e-16	Rheumatoid arthritis;
KIRP	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg10189774	chr4:17578691	LAP3	0.5	6.12	0.36	3.64e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	8.55	0.48	1.33e-15	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-5.07	-0.31	7.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.31	-5.92	-0.35	1.1e-8	Monocyte percentage of white cells;
KIRP	cis	rs4523957	0.583	rs2760740	chr17:2020989	A/G	cg16513277	chr17:2031491	SMG6	-0.78	-11.54	-0.59	6.73e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
KIRP	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.56	-6.02	-0.36	6.28e-9	Neuroticism (multi-trait analysis);Neuroticism;
KIRP	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg21385522	chr1:16154831	NA	-0.49	-6.23	-0.37	2.06e-9	Dilated cardiomyopathy;
KIRP	cis	rs1816752	0.905	rs7317850	chr13:24994037	C/G	cg02811702	chr13:24901961	NA	0.44	5.68	0.34	3.87e-8	Obesity-related traits;
KIRP	cis	rs6738028	0.535	rs744531	chr2:111951053	A/G	cg23466623	chr2:111982296	NA	-0.53	-7.05	-0.41	1.84e-11	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg04132472	chr17:19861366	AKAP10	0.68	10.55	0.56	1.02e-21	Schizophrenia;
KIRP	trans	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg02030672	chr11:45687055	CHST1	0.5	6.41	0.38	7.39e-10	Obesity-related traits;
KIRP	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg05802129	chr4:122689817	NA	-0.71	-9.35	-0.51	5.47e-18	Type 2 diabetes;
KIRP	cis	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg07460842	chr6:66804631	NA	-0.48	-5.89	-0.35	1.28e-8	Blood trace element (Cu levels);
KIRP	cis	rs526231	0.511	rs10434792	chr5:102389602	G/C	cg23492399	chr5:102201601	PAM	-0.48	-5.33	-0.32	2.18e-7	Primary biliary cholangitis;
KIRP	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg14703610	chr5:56206110	C5orf35	-0.47	-6.65	-0.39	1.87e-10	Coronary artery disease;
KIRP	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg26513180	chr16:89883248	FANCA	0.84	5.61	0.34	5.45e-8	Skin colour saturation;
KIRP	cis	rs4926611	0.863	rs11801290	chr1:54079964	A/G	cg08927728	chr1:54059983	GLIS1	0.27	5.54	0.33	7.67e-8	Hand grip strength;
KIRP	cis	rs13108043	0.605	rs767314	chr4:87960139	C/T	cg11209507	chr4:87813803	C4orf36	0.47	4.97	0.3	1.27e-6	Red blood cell count;
KIRP	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg15038512	chr6:170123185	PHF10	-0.55	-8.44	-0.47	2.79e-15	Obesity-related traits;
KIRP	cis	rs11997175	0.503	rs7013967	chr8:33826107	T/G	cg04338863	chr8:33670619	NA	0.4	5.15	0.31	5.26e-7	Body mass index;
KIRP	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05955559	chr3:44283638	C3orf77	0.41	6.27	0.37	1.59e-9	Pancreatic cancer;
KIRP	cis	rs9653442	0.545	rs11123810	chr2:100759285	T/C	cg07810366	chr2:100720526	AFF3	-0.31	-5.14	-0.31	5.64e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
KIRP	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.75	0.4	1.07e-10	Height;
KIRP	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.52	-5.52	-0.33	8.68e-8	Subjective well-being;
KIRP	cis	rs4654899	0.758	rs10218584	chr1:21474480	C/G	cg05370193	chr1:21551575	ECE1	-0.37	-5.18	-0.31	4.53e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg01422370	chr2:73384389	NA	0.46	6.14	0.36	3.22e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-7.0	-0.41	2.49e-11	Vitiligo;
KIRP	cis	rs4664293	0.867	rs16822558	chr2:160601007	A/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-10.27	-0.55	7.92e-21	Colorectal cancer;
KIRP	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg16309518	chr5:176445507	NA	-0.89	-13.87	-0.66	1.02e-32	Menarche and menopause (age at onset);Menopause (age at onset);
KIRP	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg01721255	chr8:58191610	C8orf71	0.55	5.71	0.34	3.19e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9488822	0.676	rs12202181	chr6:116327102	A/G	cg15226275	chr6:116381976	FRK	0.21	5.93	0.35	1.03e-8	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.7	10.43	0.55	2.44e-21	Dupuytren's disease;
KIRP	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg00784671	chr22:46762841	CELSR1	-0.6	-6.53	-0.38	3.72e-10	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26002218	chr14:103986227	CKB	0.28	5.32	0.32	2.37e-7	Body mass index;
KIRP	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg26531700	chr6:26746687	NA	0.52	7.28	0.42	4.56e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs10875746	0.903	rs58952582	chr12:48458448	T/G	cg26205652	chr12:48591994	NA	0.77	10.3	0.55	6.31e-21	Longevity (90 years and older);
KIRP	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.48	-5.73	-0.34	2.98e-8	Glomerular filtration rate;
KIRP	trans	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	6.98	0.41	2.73e-11	Mean corpuscular volume;
KIRP	cis	rs9399401	0.626	rs7756434	chr6:142775295	A/G	cg03128060	chr6:142623767	GPR126	0.35	5.19	0.31	4.39e-7	Chronic obstructive pulmonary disease;
KIRP	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-6.16	-0.37	2.89e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs6088813	0.885	rs224331	chr20:34022387	A/C	cg14752227	chr20:34000481	UQCC	0.44	5.32	0.32	2.31e-7	Height;
KIRP	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	5.23	0.32	3.59e-7	Schizophrenia;
KIRP	cis	rs7096127	0.903	rs11013975	chr10:24502765	G/T	cg04122385	chr10:24535410	KIAA1217;PRINS	0.4	4.93	0.3	1.55e-6	Lobe attachment (rater scored);
KIRP	cis	rs1107366	0.513	rs35078897	chr3:125973767	T/C	cg01346077	chr3:125931526	NA	0.41	6.44	0.38	6.11e-10	Metabolite levels;
KIRP	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg06565975	chr8:143823917	SLURP1	0.48	7.55	0.43	8.64e-13	Urinary tract infection frequency;
KIRP	cis	rs7258015	0.865	rs1058154	chr19:10446897	C/A	cg25279553	chr19:10444815	RAVER1;ICAM3	0.48	6.21	0.37	2.24e-9	Systemic lupus erythematosus or rheumatoid arthritis;
KIRP	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg06481639	chr22:41940642	POLR3H	-0.45	-4.99	-0.3	1.15e-6	Neuroticism;
KIRP	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg24060327	chr5:131705240	SLC22A5	-0.42	-4.94	-0.3	1.47e-6	Blood metabolite levels;
KIRP	cis	rs4702718	0.616	rs267972	chr5:10727639	G/A	cg14521931	chr5:10832172	NA	-0.45	-6.04	-0.36	5.54e-9	Obesity-related traits;
KIRP	trans	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg19274270	chr17:78178856	CARD14	-0.37	-6.59	-0.39	2.59e-10	Morning vs. evening chronotype;
KIRP	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg10434728	chr15:90938212	IQGAP1	-0.42	-7.73	-0.44	2.72e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs73071352	0.577	rs73075228	chr3:42049629	T/G	cg03022575	chr3:42003672	ULK4	0.73	7.08	0.41	1.49e-11	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
KIRP	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.74	-10.35	-0.55	4.63e-21	Body mass index;
KIRP	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg02569458	chr12:86230093	RASSF9	0.54	7.7	0.44	3.3e-13	Major depressive disorder;
KIRP	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.91	13.06	0.64	5.71e-30	Bladder cancer;
KIRP	cis	rs742614	0.935	rs6057930	chr20:32477972	C/T	cg06304546	chr20:32448765	NA	-0.44	-5.57	-0.33	6.64e-8	Stearic acid (18:0) levels;
KIRP	cis	rs7175404	1.000	rs17708444	chr15:94038540	C/T	cg23502883	chr15:93959149	NA	0.53	5.59	0.34	6.12e-8	Attention deficit hyperactivity disorder;
KIRP	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-7.12	-0.41	1.2e-11	Blood pressure;
KIRP	cis	rs6681460	1.000	rs1329978	chr1:67116231	C/T	cg02459107	chr1:67143332	SGIP1	0.48	6.78	0.4	8.87e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg01566213	chr4:1579287	NA	-0.35	-5.0	-0.3	1.12e-6	Bladder cancer;Urinary bladder cancer;
KIRP	cis	rs7827545	0.545	rs4909477	chr8:135562976	A/G	cg17885191	chr8:135476712	NA	0.7	6.45	0.38	5.84e-10	Hypertension (SNP x SNP interaction);
KIRP	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg21827317	chr3:136751795	NA	0.37	5.18	0.31	4.6e-7	Neuroticism;
KIRP	cis	rs17123764	1.000	rs59261129	chr12:49951377	C/T	cg02054252	chr12:50078554	FMNL3	0.5	5.04	0.31	9.21e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg19468946	chr17:37922297	IKZF3	-0.42	-5.83	-0.35	1.73e-8	Asthma;
KIRP	cis	rs6893300	0.785	rs17617710	chr5:179206107	G/A	cg14593053	chr5:179126677	CANX	-0.58	-7.23	-0.42	6.14e-12	Resting heart rate;
KIRP	trans	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg09844907	chr16:15489619	MPV17L	-0.39	-6.07	-0.36	4.93e-9	Metabolic traits;
KIRP	cis	rs240764	0.580	rs4839789	chr6:101233235	T/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.09	-0.31	7.24e-7	Neuroticism;
KIRP	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.75	9.65	0.52	7.02e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.48	-5.83	-0.35	1.73e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	cis	rs7084402	0.967	rs1658462	chr10:60298284	A/C	cg05938607	chr10:60274200	BICC1	-0.44	-10.72	-0.56	3.06e-22	Refractive error;
KIRP	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.83	11.61	0.59	3.9e-25	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-7.05	-0.41	1.8e-11	Mean corpuscular volume;
KIRP	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	1.0	15.55	0.7	1.88e-38	Alcohol dependence;
KIRP	cis	rs9596863	0.898	rs35863857	chr13:54372546	A/G	ch.13.53330881F	chr13:54432880	NA	0.61	5.97	0.36	8.03e-9	Epilepsy and lamotrigine-induced maculopapular eruptions;
KIRP	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.75	10.14	0.54	2.03e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.43	7.52	0.43	1.01e-12	Renal cell carcinoma;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27525248	chr2:134877576	NA	0.51	6.73	0.39	1.2e-10	Parkinson's disease;
KIRP	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg21479132	chr6:26055353	NA	0.8	5.26	0.32	3.06e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg04374321	chr14:90722782	PSMC1	0.88	14.92	0.69	2.86e-36	Mortality in heart failure;
KIRP	cis	rs7011049	1.000	rs72643580	chr8:53846710	T/G	cg26025543	chr8:53854495	NA	0.75	7.86	0.45	1.16e-13	Systolic blood pressure;
KIRP	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.68	8.65	0.48	6.73e-16	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
KIRP	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg12131826	chr15:77904385	NA	0.5	6.02	0.36	6.4e-9	Type 2 diabetes;
KIRP	trans	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg22037779	chr5:139682734	PFDN1	-0.53	-6.32	-0.37	1.21e-9	Mean platelet volume;
KIRP	trans	rs683250	0.598	rs1943748	chr11:83121922	A/G	cg22584335	chr2:27806067	ZNF512	0.54	6.29	0.37	1.42e-9	Subcortical brain region volumes;
KIRP	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.83	8.46	0.47	2.48e-15	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.51	6.37	0.38	9.42e-10	Subjective well-being;
KIRP	cis	rs13385	0.769	rs269781	chr5:139545447	G/A	cg01860693	chr5:139557145	C5orf32	0.49	5.36	0.32	1.95e-7	Atrial fibrillation;
KIRP	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.54	-6.69	-0.39	1.46e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs6968419	0.747	rs2030977	chr7:115875359	G/C	cg02561103	chr7:115862891	TES	-0.42	-6.03	-0.36	6.12e-9	Intraocular pressure;
KIRP	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.37	-5.42	-0.33	1.42e-7	Monocyte count;
KIRP	cis	rs2522056	1.000	rs2522047	chr5:131795882	G/T	cg07395648	chr5:131743802	NA	0.55	6.56	0.39	3.2e-10	Lymphocyte counts;Fibrinogen;
KIRP	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.3	-6.2	-0.37	2.43e-9	Breast cancer;
KIRP	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg08132940	chr7:1081526	C7orf50	-0.54	-5.51	-0.33	8.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7017914	0.967	rs13254801	chr8:71688984	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.41	-5.07	-0.31	7.67e-7	Bone mineral density;
KIRP	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-7.69	-0.44	3.55e-13	Gut microbiome composition (summer);
KIRP	cis	rs2916247	0.954	rs16914736	chr8:93082043	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.53	-6.93	-0.4	3.64e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs4803455	0.565	rs1800470	chr19:41858921	G/A	cg09537434	chr19:41945824	ATP5SL	-0.68	-8.79	-0.49	2.64e-16	Migraine;Coronary artery disease;
KIRP	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg03060546	chr3:49711283	APEH	-0.58	-4.98	-0.3	1.22e-6	Cognitive function;
KIRP	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.81	10.76	0.57	2.26e-22	Breast cancer;
KIRP	trans	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.4	-0.38	7.73e-10	Neuroticism;
KIRP	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20887711	chr4:1340912	KIAA1530	0.43	5.47	0.33	1.09e-7	Obesity-related traits;
KIRP	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.62	8.71	0.49	4.61e-16	Economic and political preferences (feminism/equality);
KIRP	cis	rs4886920	0.894	rs11637937	chr15:78119830	G/C	cg10461261	chr15:78109450	NA	-0.35	-5.69	-0.34	3.51e-8	Neuroticism;
KIRP	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg08890418	chr1:21044141	KIF17	-0.35	-5.18	-0.31	4.54e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg21253087	chr9:139290292	SNAPC4	0.36	4.88	0.3	1.88e-6	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
KIRP	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg07843065	chr1:150265600	MRPS21	0.44	6.22	0.37	2.14e-9	Migraine;
KIRP	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.63	8.56	0.48	1.22e-15	Morning vs. evening chronotype;
KIRP	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg22356347	chr1:167427500	CD247	-0.45	-6.16	-0.37	3.01e-9	Celiac disease or Rheumatoid arthritis;Celiac disease;
KIRP	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg04691961	chr3:161091175	C3orf57	-0.36	-5.25	-0.32	3.23e-7	Kawasaki disease;
KIRP	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.74	7.67	0.44	4.08e-13	Uric acid levels;
KIRP	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg08499158	chr17:42289980	UBTF	0.51	6.33	0.37	1.16e-9	Total body bone mineral density;
KIRP	cis	rs4692589	0.606	rs12645495	chr4:170933909	T/C	cg19918862	chr4:170955249	NA	0.52	5.78	0.35	2.3e-8	Anxiety disorder;
KIRP	cis	rs1456297	0.806	rs2607117	chr15:51985835	C/T	cg14296394	chr15:51910925	DMXL2	-0.62	-8.64	-0.48	7.3e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs1511802	0.666	rs28698123	chr4:187123189	C/T	cg24794857	chr4:187113578	CYP4V2	0.38	5.3	0.32	2.63e-7	Blood protein levels;
KIRP	cis	rs2625529	0.701	rs62025574	chr15:72236075	C/T	cg16672083	chr15:72433130	SENP8	-0.49	-6.04	-0.36	5.57e-9	Red blood cell count;
KIRP	cis	rs7808935	0.581	rs6968704	chr7:27966984	C/T	cg05786569	chr7:27702416	HIBADH	0.47	5.46	0.33	1.16e-7	Prostate cancer;
KIRP	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.92	-15.71	-0.71	5.3e-39	Headache;
KIRP	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg18350739	chr11:68623251	NA	-0.48	-7.68	-0.44	3.79e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs75064307	0.636	rs3860537	chr3:108103433	T/C	cg14703454	chr3:108065259	HHLA2	-0.54	-5.66	-0.34	4.14e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg23411274	chr6:26421120	BTN2A3	-0.32	-4.92	-0.3	1.6e-6	Intelligence (multi-trait analysis);
KIRP	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.67	6.61	0.39	2.43e-10	Axial length;
KIRP	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.6	6.11	0.36	3.91e-9	Breast cancer;
KIRP	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.87	-11.4	-0.59	1.88e-24	Type 2 diabetes;
KIRP	cis	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg21546286	chr11:48923668	NA	-0.47	-5.96	-0.36	8.5e-9	HDL cholesterol;
KIRP	cis	rs9876781	0.559	rs7611415	chr3:48405149	C/T	cg11946769	chr3:48343235	NME6	0.41	5.02	0.3	9.85e-7	Longevity;
KIRP	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg27147174	chr7:100797783	AP1S1	-0.58	-7.45	-0.43	1.54e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-1.0	-13.74	-0.66	3e-32	Response to antipsychotic treatment;
KIRP	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.7	6.28	0.37	1.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.51	6.04	0.36	5.68e-9	Menopause (age at onset);
KIRP	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.06	-15.31	-0.7	1.29e-37	Alzheimer's disease;
KIRP	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-1.05	-10.64	-0.56	5.57e-22	Red blood cell traits;
KIRP	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg27532560	chr4:187881888	NA	-0.69	-11.11	-0.58	1.65e-23	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs6601327	0.665	rs10113186	chr8:9655426	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-5.15	-0.31	5.22e-7	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs959260	1.000	rs7221050	chr17:73393949	A/T	cg20590849	chr17:73267439	MIF4GD	-0.61	-6.54	-0.38	3.52e-10	Systemic lupus erythematosus;
KIRP	cis	rs6016377	0.798	rs6029182	chr20:39179402	A/C	cg06665391	chr20:39312290	NA	0.4	5.03	0.31	9.44e-7	Birth weight;
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.89	15.4	0.7	6.54e-38	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.69	-9.15	-0.5	2.18e-17	Huntington's disease progression;
KIRP	cis	rs1559088	0.895	rs7246562	chr19:33546088	T/G	cg03563238	chr19:33554763	RHPN2	-0.34	-5.76	-0.34	2.56e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00585698	chr12:123750864	CDK2AP1	0.51	6.41	0.38	7.26e-10	Neutrophil percentage of white cells;
KIRP	cis	rs9488822	0.636	rs10872142	chr6:116369052	C/A	cg18764771	chr6:116381957	FRK	0.18	5.12	0.31	6.2e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.66	9.52	0.52	1.71e-18	Colorectal cancer;
KIRP	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg14993813	chr1:46806288	NSUN4	-0.46	-5.32	-0.32	2.31e-7	Menopause (age at onset);
KIRP	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	0.95	12.66	0.63	1.27e-28	Corneal structure;
KIRP	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.58	-7.53	-0.43	9.36e-13	Aortic root size;
KIRP	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg08603382	chr10:743973	NA	0.48	6.8	0.4	7.87e-11	Psychosis in Alzheimer's disease;
KIRP	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.64	-8.65	-0.48	6.95e-16	Cognitive test performance;
KIRP	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.49	-0.33	9.78e-8	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs2898681	0.614	rs10016904	chr4:53694296	C/A	cg00338735	chr4:53728038	RASL11B	0.42	5.31	0.32	2.48e-7	Optic nerve measurement (cup area);
KIRP	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	1.13	17.87	0.75	2.33e-46	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12826209	chr6:26865740	GUSBL1	0.73	8.69	0.48	5.32e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.37	6.41	0.38	7.28e-10	Lymphocyte counts;
KIRP	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.95	9.51	0.52	1.88e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
KIRP	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-6.36	-0.38	9.94e-10	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg14675211	chr2:100938903	LONRF2	0.55	7.01	0.41	2.29e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.47	6.34	0.37	1.09e-9	Red cell distribution width;
KIRP	cis	rs11997175	0.545	rs4428637	chr8:33666944	T/G	ch.8.33884649F	chr8:33765107	NA	0.5	5.95	0.35	9.24e-9	Body mass index;
KIRP	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg26513180	chr16:89883248	FANCA	0.81	5.49	0.33	1e-7	Skin colour saturation;
KIRP	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg24169773	chr3:122142474	KPNA1	-0.58	-6.47	-0.38	5.27e-10	LDL cholesterol levels;
KIRP	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg24626310	chr20:25276739	ABHD12;PYGB	-0.5	-6.48	-0.38	4.84e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.57	-6.91	-0.4	4.23e-11	Systemic lupus erythematosus;
KIRP	cis	rs1978968	0.717	rs28406897	chr22:18402012	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-5.98	-0.36	7.72e-9	Presence of antiphospholipid antibodies;
KIRP	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-9.61	-0.52	8.88e-19	Coronary artery disease;
KIRP	cis	rs4919044	0.808	rs835280	chr10:94811786	A/G	cg05127821	chr10:94822908	CYP26C1	-1.04	-10.92	-0.57	6.99e-23	Coronary artery disease;
KIRP	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg13611997	chr5:233750	SDHA	-0.44	-5.3	-0.32	2.56e-7	Breast cancer;
KIRP	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-9.05	-0.5	4.33e-17	Asthma;
KIRP	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.49	7.14	0.41	1.03e-11	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs888194	0.649	rs10774697	chr12:109875981	A/G	cg19025524	chr12:109796872	NA	-0.38	-5.09	-0.31	7.25e-7	Neuroticism;
KIRP	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-0.99	-11.56	-0.59	5.82e-25	White matter hyperintensity burden;
KIRP	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.66	9.31	0.51	7.31e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg15841412	chr13:111365552	ING1	0.49	5.61	0.34	5.41e-8	Coronary artery disease;
KIRP	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg19773385	chr1:10388646	KIF1B	-0.72	-10.82	-0.57	1.47e-22	Hepatocellular carcinoma;
KIRP	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	9.44	0.52	2.92e-18	Coffee consumption (cups per day);
KIRP	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.51	-6.33	-0.37	1.13e-9	Neurofibrillary tangles;
KIRP	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg07884673	chr3:53033167	SFMBT1	0.83	6.69	0.39	1.51e-10	Immune reponse to smallpox (secreted IL-2);
KIRP	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg06050784	chr16:88016603	BANP	0.4	5.03	0.31	9.36e-7	Menopause (age at onset);
KIRP	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.98	9.31	0.51	7.46e-18	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs33912345	0.695	rs1254290	chr14:60862848	A/G	cg27398547	chr14:60952738	C14orf39	-0.4	-5.35	-0.32	2.05e-7	Glaucoma (high intraocular pressure);
KIRP	cis	rs1832871	0.672	rs6933928	chr6:158747071	C/T	cg07215822	chr6:158701037	NA	-0.65	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.42	-6.91	-0.4	4.1e-11	Refractive error;
KIRP	trans	rs2290402	0.536	rs2335172	chr4:855282	G/A	cg21249729	chr9:138392748	C9orf116;MRPS2	0.63	6.23	0.37	1.96e-9	Type 2 diabetes;
KIRP	cis	rs12780845	0.522	rs725355	chr10:17202865	T/C	cg01003015	chr10:17271136	VIM	-0.41	-5.05	-0.31	8.79e-7	Homocysteine levels;
KIRP	cis	rs3026101	0.624	rs1806219	chr17:5288073	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.46	5.85	0.35	1.56e-8	Body mass index;
KIRP	cis	rs2625529	0.713	rs16956634	chr15:72552243	C/G	cg16672083	chr15:72433130	SENP8	0.48	5.7	0.34	3.44e-8	Red blood cell count;
KIRP	cis	rs4789580	0.841	rs9898312	chr17:76313609	C/G	cg27206407	chr17:76349089	NA	0.51	5.1	0.31	6.68e-7	IgG glycosylation;
KIRP	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	cg04338863	chr8:33670619	NA	0.42	5.37	0.32	1.81e-7	Body mass index;
KIRP	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg23188430	chr6:125850052	NA	0.35	5.5	0.33	9.36e-8	Brugada syndrome;
KIRP	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	1.13	16.6	0.73	5.18e-42	Breast cancer;
KIRP	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg15655495	chr12:38532458	NA	-0.3	-5.32	-0.32	2.28e-7	Bladder cancer;
KIRP	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg01631408	chr1:248437212	OR2T33	-0.36	-5.0	-0.3	1.1e-6	Common traits (Other);
KIRP	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg24579218	chr15:68104479	NA	-0.53	-7.64	-0.44	4.8e-13	Restless legs syndrome;
KIRP	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11987759	chr7:65425863	GUSB	0.47	6.04	0.36	5.68e-9	Aortic root size;
KIRP	cis	rs11264213	0.901	rs72661631	chr1:36417453	A/G	cg27506609	chr1:36549197	TEKT2	1.17	7.32	0.42	3.61e-12	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg13986501	chr9:115142201	HSDL2	0.57	7.16	0.42	9.43e-12	Parkinson's disease;
KIRP	cis	rs6663390	0.510	rs6693798	chr1:208090018	A/G	cg00387621	chr1:208086895	NA	0.62	4.84	0.3	2.26e-6	Facial morphology (factor 18);
KIRP	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg06212747	chr3:49208901	KLHDC8B	0.49	5.7	0.34	3.45e-8	Resting heart rate;
KIRP	cis	rs7772486	0.790	rs2243665	chr6:146208120	A/C	cg23711669	chr6:146136114	FBXO30	0.69	8.44	0.47	2.73e-15	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg13147721	chr7:65941812	NA	-0.91	-6.59	-0.39	2.73e-10	Diabetic kidney disease;
KIRP	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.81	10.9	0.57	7.97e-23	Morning vs. evening chronotype;
KIRP	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.62	-6.68	-0.39	1.58e-10	Gut microbiome composition (summer);
KIRP	cis	rs6977660	0.714	rs12334001	chr7:19814399	T/C	cg07541023	chr7:19748670	TWISTNB	0.56	5.36	0.32	1.88e-7	Thyroid stimulating hormone;
KIRP	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.5	6.3	0.37	1.38e-9	Iron status biomarkers;
KIRP	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.62	9.88	0.53	1.29e-19	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.92	10.71	0.56	3.18e-22	Neuroticism;
KIRP	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg00800038	chr16:89945340	TCF25	-0.88	-7.16	-0.42	9.03e-12	Skin colour saturation;
KIRP	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.67	-7.79	-0.45	1.82e-13	Alcohol dependence;
KIRP	trans	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg08739755	chr2:172815385	HAT1	0.51	6.26	0.37	1.72e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg09165964	chr15:75287851	SCAMP5	-0.97	-9.54	-0.52	1.49e-18	Lung cancer;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg09761690	chr16:72820681	ZFHX3	0.46	6.21	0.37	2.26e-9	Interleukin-4 levels;
KIRP	cis	rs4936894	0.500	rs12292913	chr11:124171896	T/C	cg27160556	chr11:124181099	OR8D1	-0.45	-6.49	-0.38	4.57e-10	Aging (time to death);
KIRP	cis	rs11997175	1.000	rs6468203	chr8:33749572	T/A	ch.8.33884649F	chr8:33765107	NA	0.53	6.42	0.38	6.91e-10	Body mass index;
KIRP	cis	rs1417569	0.546	rs2934649	chr10:31226419	G/T	cg00428179	chr10:31322131	ZNF438	0.43	6.05	0.36	5.3300000000000004e-09	Tuberculosis;
KIRP	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.77	7.0	0.41	2.47e-11	Hip circumference adjusted for BMI;
KIRP	trans	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg27542767	chr6:40253980	NA	0.41	6.09	0.36	4.35e-9	Breast size;
KIRP	cis	rs7011507	1.000	rs75700091	chr8:49183719	G/T	cg15325961	chr8:49183143	NA	0.61	5.19	0.31	4.47e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg27487796	chr7:28973253	NA	0.22	5.18	0.31	4.69e-7	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
KIRP	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.47	5.86	0.35	1.48e-8	Glomerular filtration rate (creatinine);
KIRP	cis	rs7737355	0.947	rs58991576	chr5:130589540	T/C	cg25547332	chr5:131281432	NA	-0.45	-5.01	-0.3	1.06e-6	Life satisfaction;
KIRP	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-0.74	-8.81	-0.49	2.26e-16	Developmental language disorder (linguistic errors);
KIRP	cis	rs72925845	0.519	rs72907440	chr17:76425989	T/G	cg03830375	chr17:76426088	DNAH17	0.5	5.16	0.31	5.07e-7	Triglycerides;
KIRP	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.56	-6.53	-0.38	3.69e-10	Longevity;Endometriosis;
KIRP	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg06740227	chr12:86229804	RASSF9	0.5	6.43	0.38	6.52e-10	Major depressive disorder;
KIRP	cis	rs2880765	0.527	rs1483578	chr15:86075417	A/G	cg15340431	chr15:86040528	AKAP13	-0.46	-5.85	-0.35	1.56e-8	Coronary artery disease;
KIRP	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	cg12689670	chr1:183009347	LAMC1	0.58	8.07	0.46	3.15e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg26174226	chr8:58114915	NA	-0.62	-7.26	-0.42	5.11e-12	Developmental language disorder (linguistic errors);
KIRP	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg26727032	chr16:67993705	SLC12A4	-0.68	-5.86	-0.35	1.44e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.33	5.09	0.31	6.98e-7	Type 2 diabetes and other traits;Type 2 diabetes;
KIRP	cis	rs1440410	0.835	rs10029373	chr4:144130118	C/T	cg01719995	chr4:144104893	USP38	0.45	6.21	0.37	2.2e-9	Ischemic stroke;
KIRP	cis	rs2637030	0.586	rs1465445	chr5:52848382	A/T	cg06476337	chr5:52856530	NDUFS4	0.56	5.95	0.35	9.14e-9	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
KIRP	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-1.01	-11.93	-0.61	3.34e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7011507	1.000	rs4477059	chr8:49124799	T/C	cg15325961	chr8:49183143	NA	0.61	5.18	0.31	4.63e-7	Inflammatory bowel disease;Ulcerative colitis;
KIRP	cis	rs71636213	0.527	rs12652103	chr5:79660190	A/G	cg12576332	chr5:79646847	LOC441089	-0.39	-5.51	-0.33	9.13e-8	Alzheimer's disease in APOE e4- carriers;
KIRP	cis	rs13385	0.769	rs7727069	chr5:139573265	A/G	cg01860693	chr5:139557145	C5orf32	0.49	5.09	0.31	6.98e-7	Atrial fibrillation;
KIRP	cis	rs448720	0.811	rs2458506	chr15:68182610	G/A	cg24579218	chr15:68104479	NA	-0.35	-5.05	-0.31	8.53e-7	Cognitive performance;
KIRP	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	0.89	10.21	0.55	1.19e-20	Pediatric areal bone mineral density (radius);
KIRP	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg26513180	chr16:89883248	FANCA	0.81	5.49	0.33	1e-7	Skin colour saturation;
KIRP	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg06671706	chr8:8559999	CLDN23	0.52	6.15	0.37	3.07e-9	Obesity-related traits;
KIRP	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg00405596	chr8:11794950	NA	-0.48	-6.05	-0.36	5.27e-9	Retinal vascular caliber;
KIRP	cis	rs13385	0.724	rs4913080	chr5:139696503	G/A	cg01860693	chr5:139557145	C5orf32	0.48	4.95	0.3	1.37e-6	Atrial fibrillation;
KIRP	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.7	-12.8	-0.63	4.44e-29	White blood cell count (basophil);
KIRP	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.5	-6.92	-0.4	3.94e-11	Coronary artery disease;
KIRP	cis	rs6568686	0.577	rs174391	chr6:111917948	C/A	cg22127309	chr6:111907043	TRAF3IP2	0.55	5.16	0.31	5.04e-7	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
KIRP	cis	rs858239	0.600	rs6956595	chr7:23134256	A/G	cg23682824	chr7:23144976	KLHL7	0.45	5.34	0.32	2.15e-7	Cerebrospinal fluid biomarker levels;
KIRP	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-6.41	-0.38	7.33e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
KIRP	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.47	5.83	0.35	1.71e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-0.77	-9.13	-0.5	2.65e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23281280	chr6:28129359	ZNF389	0.46	5.08	0.31	7.54e-7	Depression;
KIRP	cis	rs9826463	0.582	rs116196326	chr3:142059684	A/T	cg20824294	chr3:142316082	PLS1	0.46	6.61	0.39	2.38e-10	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.41	-5.56	-0.33	6.92e-8	Blood metabolite levels;
KIRP	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.99	7.84	0.45	1.38e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.89	13.89	0.66	9.27e-33	Ulcerative colitis;
KIRP	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.63	-6.59	-0.39	2.61e-10	DNA methylation (variation);
KIRP	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26002218	chr14:103986227	CKB	-0.34	-6.98	-0.41	2.76e-11	Body mass index;
KIRP	trans	rs10511652	1.000	rs10511652	chr9:18362865	A/G	cg10821925	chr12:29533733	ERGIC2	-0.44	-6.04	-0.36	5.71e-9	Myopia;
KIRP	cis	rs4919687	0.514	rs3850699	chr10:104414221	A/G	cg04362960	chr10:104952993	NT5C2	0.51	5.75	0.34	2.61e-8	Colorectal cancer;
KIRP	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.13	14.06	0.67	2.32e-33	Platelet count;
KIRP	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg20936604	chr3:58311152	NA	-0.66	-4.89	-0.3	1.82e-6	Cholesterol, total;
KIRP	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15128208	chr22:42549153	NA	-0.45	-5.7	-0.34	3.43e-8	Cognitive function;
KIRP	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg14458575	chr2:238380390	NA	0.5	5.6	0.34	5.72e-8	Prostate cancer;
KIRP	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.44	-5.81	-0.35	1.91e-8	Longevity;Endometriosis;
KIRP	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	-0.4	-4.99	-0.3	1.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg07689907	chr11:61582574	FADS1	0.48	6.07	0.36	4.74e-9	Trans fatty acid levels;
KIRP	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.69	9.69	0.53	5.21e-19	Systolic blood pressure;
KIRP	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg04025307	chr7:1156635	C7orf50	0.8	8.22	0.46	1.18e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs16958440	0.581	rs72907280	chr18:44681130	C/T	cg17192377	chr18:44677553	HDHD2	0.65	6.32	0.37	1.22e-9	Sitting height ratio;
KIRP	cis	rs4852324	0.536	rs71418714	chr2:74219886	G/C	cg19729930	chr2:74357872	NA	0.68	5.36	0.32	1.91e-7	Systemic lupus erythematosus;
KIRP	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.8	-10.47	-0.56	1.86e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
KIRP	trans	rs9863	0.931	rs4765335	chr12:124430812	G/A	cg19453665	chr11:75277538	SERPINH1	0.42	6.18	0.37	2.59e-9	White blood cell count;
KIRP	cis	rs7119038	0.818	rs3889239	chr11:118619960	C/T	cg19308663	chr11:118741387	NA	0.57	8.83	0.49	2.06e-16	Sjögren's syndrome;
KIRP	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.49	-6.91	-0.4	4.06e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs580438	0.569	rs1048620	chr3:13358130	C/T	cg10657019	chr3:13328039	NA	0.5	6.46	0.38	5.66e-10	Myringotomy;
KIRP	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg15660573	chr17:549704	VPS53	-0.84	-12.49	-0.62	4.55e-28	Prostate cancer;
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg13219509	chr22:40440322	TNRC6B	0.52	6.26	0.37	1.67e-9	Educational attainment;
KIRP	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.44	6.12	0.36	3.71e-9	Coronary artery disease;
KIRP	cis	rs10929159	0.665	rs7599602	chr2:236930373	C/T	cg20128773	chr2:236923534	AGAP1	0.28	4.88	0.3	1.94e-6	Parkinson's disease;
KIRP	cis	rs4699052	0.963	rs6533066	chr4:104163607	C/G	cg16532752	chr4:104119610	CENPE	-0.4	-5.0	-0.3	1.1e-6	Testicular germ cell tumor;
KIRP	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg07382826	chr16:28625726	SULT1A1	0.52	6.23	0.37	1.99e-9	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs12476592	0.602	rs10865337	chr2:63720906	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-4.91	-0.3	1.66e-6	Childhood ear infection;
KIRP	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg13180566	chr4:1052158	NA	-0.52	-5.29	-0.32	2.77e-7	Recombination rate (females);
KIRP	cis	rs2976388	0.669	rs1836633	chr8:143774592	G/A	cg02415014	chr8:143852576	LYNX1	-0.34	-5.37	-0.32	1.83e-7	Urinary tract infection frequency;
KIRP	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	0.95	12.19	0.61	4.87e-27	Blood protein levels;
KIRP	cis	rs62413470	1.000	rs62411455	chr6:55968366	A/G	cg13327911	chr6:55965977	COL21A1	0.56	5.08	0.31	7.3e-7	Joint mobility (Beighton score);
KIRP	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.53	6.68	0.39	1.56e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg22038579	chr12:8849964	RIMKLB	0.54	6.24	0.37	1.93e-9	Lung cancer in ever smokers;
KIRP	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.54	5.82	0.35	1.85e-8	Menopause (age at onset);
KIRP	cis	rs9815354	0.812	rs10510733	chr3:42009192	T/C	cg03022575	chr3:42003672	ULK4	0.81	8.22	0.46	1.17e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs675026	0.853	rs609623	chr6:154424959	T/C	cg07813322	chr6:154414604	OPRM1	-0.46	-6.0	-0.36	6.96e-9	Hypertension;
KIRP	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.34	7.03	0.41	2.01e-11	Body mass index;
KIRP	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-19.41	-0.78	1.56e-51	Height;
KIRP	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg13798912	chr7:905769	UNC84A	0.54	5.48	0.33	1.07e-7	Cerebrospinal P-tau181p levels;
KIRP	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.52	7.12	0.41	1.15e-11	Menopause (age at onset);
KIRP	cis	rs6088813	0.845	rs2378349	chr20:33925843	C/A	cg14752227	chr20:34000481	UQCC	0.54	7.09	0.41	1.39e-11	Height;
KIRP	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg18882449	chr10:104885122	NT5C2	-0.49	-6.28	-0.37	1.5e-9	Arsenic metabolism;
KIRP	cis	rs1125355	0.557	rs4362514	chr2:159606976	G/A	cg02251393	chr2:159651559	DAPL1	0.42	4.94	0.3	1.43e-6	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg17554472	chr22:41940697	POLR3H	-0.4	-4.95	-0.3	1.38e-6	Neuroticism;
KIRP	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.49	-6.0	-0.36	7.15e-9	Asthma (sex interaction);
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg11208039	chr11:19138753	ZDHHC13	0.76	6.5	0.38	4.41e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg16235748	chr6:149772707	ZC3H12D	-0.38	-6.37	-0.38	9.1e-10	Dupuytren's disease;
KIRP	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.56	-5.91	-0.35	1.15e-8	Gastric cancer;Non-cardia gastric cancer;
KIRP	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.58	6.92	0.4	3.83e-11	Age-related macular degeneration (geographic atrophy);
KIRP	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg14593290	chr7:50529359	DDC	-0.78	-9.87	-0.53	1.39e-19	Malaria;
KIRP	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.47	7.16	0.42	9.4e-12	Resting heart rate;
KIRP	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg21427119	chr20:30132790	HM13	-0.42	-5.01	-0.3	1.03e-6	Subcortical brain region volumes;Putamen volume;
KIRP	cis	rs6750047	0.625	rs336036	chr2:38261143	C/T	cg07380506	chr2:38303506	CYP1B1	-0.36	-4.86	-0.3	2.14e-6	Cutaneous malignant melanoma;Melanoma;
KIRP	cis	rs16857609	0.628	rs1478586	chr2:218334892	G/A	cg15335768	chr2:218268053	DIRC3	-0.37	-5.52	-0.33	8.72e-8	Breast cancer;Breast cancer (estrogen-receptor negative);
KIRP	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.63	-5.54	-0.33	7.76e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.87	-8.77	-0.49	3.07e-16	Vitamin D levels;
KIRP	cis	rs4851266	0.898	rs12614880	chr2:100849341	A/G	cg05692746	chr2:100937584	LONRF2	-0.43	-5.08	-0.31	7.33e-7	Educational attainment;
KIRP	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.61	8.2	0.46	1.32e-14	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs3767633	0.612	rs2490425	chr1:161949189	C/G	cg09175582	chr1:161736000	ATF6	0.79	5.01	0.3	1.04e-6	IgG glycosylation;
KIRP	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg01280390	chr8:19363452	CSGALNACT1	-0.39	-5.2	-0.31	4.27e-7	Oropharynx cancer;
KIRP	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.95	11.91	0.6	3.93e-26	Cognitive ability;
KIRP	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.6	7.15	0.41	9.84e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs2916247	0.954	rs1484562	chr8:93131247	T/C	cg10183463	chr8:93005414	RUNX1T1	0.41	5.02	0.31	9.74e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg06742321	chr12:123595122	PITPNM2	0.44	5.44	0.33	1.29e-7	Platelet count;
KIRP	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17467752	chr17:38218738	THRA	-0.54	-6.74	-0.39	1.15e-10	White blood cell count;
KIRP	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.79	-12.36	-0.62	1.32e-27	Prostate cancer;
KIRP	cis	rs6662572	0.737	rs55652826	chr1:46442678	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.43	5.04	0.31	8.95e-7	Blood protein levels;
KIRP	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	5.56	0.33	7.06e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs7760535	0.656	rs7766190	chr6:111905066	A/G	cg23652038	chr6:111136640	CDK19	-0.45	-5.89	-0.35	1.29e-8	Metabolic traits;
KIRP	cis	rs1876905	0.680	rs3749867	chr6:111424818	A/G	cg15721981	chr6:111408429	SLC16A10	0.55	4.91	0.3	1.68e-6	Mean corpuscular hemoglobin;
KIRP	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg13482628	chr17:19912719	NA	0.6	8.38	0.47	4.08e-15	Schizophrenia;
KIRP	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg06360820	chr2:242988706	NA	-0.82	-7.28	-0.42	4.44e-12	Obesity-related traits;
KIRP	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg00071950	chr4:10020882	SLC2A9	0.62	9.53	0.52	1.62e-18	Bone mineral density;
KIRP	trans	rs3134353	0.704	rs2386922	chr8:101975479	A/C	cg06664872	chr5:96519548	RIOK2	-0.43	-6.03	-0.36	5.99e-9	Body mass index;
KIRP	cis	rs6684428	0.536	rs7538008	chr1:56396084	A/G	cg11651538	chr1:56320950	NA	-0.54	-7.54	-0.43	9.02e-13	Airflow obstruction;
KIRP	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg12623918	chr2:306882	NA	0.46	5.8	0.35	2.03e-8	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg11846333	chr4:119757529	SEC24D	1.05	6.04	0.36	5.62e-9	Cannabis dependence symptom count;
KIRP	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg02175308	chr1:109941060	SORT1	-0.3	-5.7	-0.34	3.46e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8022179	0.580	rs58153827	chr14:103844630	G/A	cg16497661	chr14:103986332	CKB	-0.53	-6.02	-0.36	6.31e-9	Monocyte count;
KIRP	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.43	5.5	0.33	9.48e-8	Aortic root size;
KIRP	cis	rs6565681	0.760	rs9901680	chr17:78378088	A/G	cg15383979	chr17:78362278	RNF213;LOC100294362	-0.77	-7.19	-0.42	7.55e-12	Moyamoya disease;
KIRP	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.94	6.5	0.38	4.36e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs12282928	0.959	rs1354292	chr11:48264647	G/A	cg26585981	chr11:48327164	OR4S1	-0.51	-6.25	-0.37	1.76e-9	Migraine - clinic-based;
KIRP	cis	rs10861342	1.000	rs11112396	chr12:105568359	T/G	cg23923672	chr12:105501055	KIAA1033	0.87	8.89	0.49	1.29e-16	IgG glycosylation;
KIRP	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.62	-8.48	-0.48	2.13e-15	Menarche (age at onset);
KIRP	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	cg21523751	chr1:182988639	NA	0.44	6.85	0.4	5.8200000000000003e-11	Hypertriglyceridemia;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.46	6.46	0.38	5.72e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.98	11.11	0.58	1.6e-23	Smoking behavior;
KIRP	cis	rs1440410	0.835	rs10857405	chr4:144055514	C/T	cg01719995	chr4:144104893	USP38	0.47	6.51	0.38	4.27e-10	Ischemic stroke;
KIRP	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg10755058	chr3:40428713	ENTPD3	0.49	6.62	0.39	2.28e-10	Renal cell carcinoma;
KIRP	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg09699651	chr6:150184138	LRP11	0.59	8.14	0.46	1.96e-14	Testicular germ cell tumor;
KIRP	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-0.92	-9.19	-0.51	1.72e-17	Developmental language disorder (linguistic errors);
KIRP	cis	rs2274273	0.710	rs67395212	chr14:55591939	T/A	cg04306507	chr14:55594613	LGALS3	0.43	5.66	0.34	4.27e-8	Protein biomarker;
KIRP	cis	rs2458413	0.542	rs2514671	chr8:105364256	G/A	cg08657449	chr8:105351661	TM7SF4	-0.34	-5.58	-0.34	6.21e-8	Paget's disease;
KIRP	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg04025307	chr7:1156635	C7orf50	0.5	5.38	0.32	1.75e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07570687	chr10:102243282	WNT8B	0.52	6.72	0.39	1.29e-10	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg26727032	chr16:67993705	SLC12A4	-0.59	-5.93	-0.35	1.04e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs8028182	0.636	rs28610581	chr15:75812474	A/G	cg20655648	chr15:75932815	IMP3	0.53	6.77	0.4	9.6e-11	Sudden cardiac arrest;
KIRP	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg02297831	chr4:17616191	MED28	0.55	6.96	0.41	3.12e-11	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.27	-22.28	-0.82	6.04e-61	Breast cancer;
KIRP	cis	rs7546094	1.000	rs7544663	chr1:113089006	A/G	cg22162597	chr1:113214053	CAPZA1	-0.45	-6.42	-0.38	6.84e-10	Platelet distribution width;
KIRP	cis	rs9488822	0.636	rs12201275	chr6:116314563	C/G	cg05304507	chr6:116381966	FRK	0.22	5.95	0.35	9.29e-9	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21545522	chr1:205238299	TMCC2	0.49	6.42	0.38	6.81e-10	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.6	7.43	0.43	1.77e-12	Arsenic metabolism;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg21666956	chr8:134012885	TG	-0.45	-6.58	-0.39	2.82e-10	Inflammatory biomarkers;
KIRP	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-1.03	-20.3	-0.79	1.7e-54	Height;
KIRP	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	21.76	0.81	2.97e-59	Prudent dietary pattern;
KIRP	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.42	5.35	0.32	2.06e-7	Renal function-related traits (BUN);
KIRP	cis	rs1887596	0.705	rs2441067	chr13:27268653	A/G	cg01312412	chr13:27282625	NA	0.42	5.07	0.31	7.68e-7	Facial morphology (factor 3, length of philtrum);
KIRP	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg23460707	chr10:133558971	NA	0.35	5.34	0.32	2.14e-7	Survival in rectal cancer;
KIRP	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg27490568	chr2:178487706	NA	-0.61	-8.15	-0.46	1.86e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.53	-7.14	-0.41	1.07e-11	White matter hyperintensity burden;
KIRP	cis	rs601338	1	rs601338	chr19:49206674	G/A	cg07051648	chr19:49177693	NTN5;SEC1	-0.43	-5.61	-0.34	5.49e-8	Number of common colds;Blood metabolite levels;Blood metabolite ratios;
KIRP	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.93	14.08	0.67	2.01e-33	Bladder cancer;
KIRP	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs2046867	0.908	rs9880763	chr3:72789805	G/C	cg25664220	chr3:72788482	NA	-0.41	-5.93	-0.35	1.02e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs1559088	0.948	rs9304844	chr19:33579935	G/T	cg27124370	chr19:33622961	WDR88	0.59	7.27	0.42	4.72e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19671926	chr4:122722719	EXOSC9	0.45	5.5	0.33	9.35e-8	Type 2 diabetes;
KIRP	cis	rs2574704	0.924	rs2574725	chr3:11657017	C/T	cg07643000	chr3:11666825	VGLL4	-0.4	-5.85	-0.35	1.55e-8	Body mass index;
KIRP	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg03647239	chr10:116582469	FAM160B1	0.49	5.84	0.35	1.65e-8	Bipolar disorder or attention deficit hyperactivity disorder;
KIRP	cis	rs73086581	1.000	rs73084594	chr20:3916380	T/G	cg02187196	chr20:3869020	PANK2	0.51	4.95	0.3	1.39e-6	Response to antidepressants in depression;
KIRP	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg26022315	chr17:47021804	SNF8	0.42	5.47	0.33	1.1e-7	Type 2 diabetes;
KIRP	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg21926883	chr2:100939477	LONRF2	-0.64	-8.83	-0.49	1.95e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.74	-6.62	-0.39	2.2e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs1318772	0.932	rs1035409	chr5:112850963	G/A	cg12552261	chr5:112820674	MCC	0.75	5.18	0.31	4.67e-7	F-cell distribution;
KIRP	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.76	6.78	0.4	9.07e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg02820040	chr2:241836501	C2orf54	-0.23	-5.18	-0.31	4.51e-7	Urinary metabolites;
KIRP	cis	rs2380205	0.651	rs7907053	chr10:5926154	A/G	cg27141509	chr10:5886111	NA	-0.36	-5.07	-0.31	7.7300000000000005e-07	Breast cancer;
KIRP	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg19592336	chr6:28129416	ZNF389	0.48	5.51	0.33	8.85e-8	Depression;
KIRP	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg17554472	chr22:41940697	POLR3H	0.67	7.11	0.41	1.22e-11	Vitiligo;
KIRP	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.4	-5.85	-0.35	1.59e-8	Colorectal cancer;
KIRP	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg09788416	chr12:39539408	NA	0.39	5.28	0.32	2.78e-7	Morning vs. evening chronotype;
KIRP	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.69	-8.42	-0.47	3.19e-15	Body mass index;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11911399	chr1:108742837	SLC25A24	0.49	6.43	0.38	6.48e-10	Parkinson's disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19252739	chr3:195163826	ACAP2	0.51	6.23	0.37	1.99e-9	Parkinson's disease;
KIRP	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.66	6.69	0.39	1.47e-10	Urate levels in lean individuals;
KIRP	cis	rs6832769	1.000	rs4865008	chr4:56410855	T/G	cg09317128	chr4:56265301	TMEM165	-0.54	-6.93	-0.4	3.59e-11	Personality dimensions;
KIRP	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg27490568	chr2:178487706	NA	0.65	8.94	0.5	9.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.81	-12.35	-0.62	1.43e-27	Blood metabolite levels;
KIRP	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-1.03	-17.34	-0.74	1.47e-44	Height;
KIRP	cis	rs934734	0.967	rs1866051	chr2:65602149	T/C	cg08085232	chr2:65598271	SPRED2	-0.46	-5.91	-0.35	1.16e-8	Rheumatoid arthritis;
KIRP	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg02524346	chr8:600233	NA	0.72	4.99	0.3	1.12e-6	IgG glycosylation;
KIRP	cis	rs7633770	0.710	rs11710586	chr3:46693457	A/G	cg11219411	chr3:46661640	NA	-0.44	-5.88	-0.35	1.36e-8	Coronary artery disease;
KIRP	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg03060546	chr3:49711283	APEH	-0.72	-5.46	-0.33	1.16e-7	Cognitive function;
KIRP	cis	rs12210905	1.000	rs72843633	chr6:27182949	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.74	-5.85	-0.35	1.58e-8	Hip circumference adjusted for BMI;
KIRP	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg27398547	chr14:60952738	C14orf39	0.53	5.02	0.3	9.86e-7	Gut microbiota (bacterial taxa);
KIRP	cis	rs2904967	0.852	rs667341	chr11:65050182	T/C	cg12562828	chr11:65076843	NA	0.6	8.91	0.49	1.19e-16	Mean corpuscular volume;
KIRP	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg26531700	chr6:26746687	NA	0.41	5.53	0.33	8.34e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg19752551	chr11:57585705	CTNND1	0.77	11.65	0.6	2.78e-25	Schizophrenia;
KIRP	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg15485101	chr11:133734466	NA	0.5	6.86	0.4	5.42e-11	Childhood ear infection;
KIRP	cis	rs9400467	0.506	rs11153281	chr6:111594594	C/T	cg15721981	chr6:111408429	SLC16A10	0.75	6.87	0.4	5.15e-11	Blood metabolite levels;Amino acid levels;
KIRP	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.5	-6.61	-0.39	2.32e-10	Menopause (age at onset);
KIRP	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg25447019	chr17:19030144	GRAPL	0.53	7.4	0.43	2.16e-12	Schizophrenia;
KIRP	cis	rs77372450	0.636	rs55699399	chr5:157028363	C/A	cg05585991	chr5:157099197	C5orf52	0.46	5.52	0.33	8.8e-8	Bipolar disorder (body mass index interaction);
KIRP	cis	rs17681684	0.565	rs12150149	chr17:9764039	A/C	cg26853458	chr17:9805074	RCVRN	-0.57	-5.4	-0.33	1.59e-7	GIP levels in response to oral glucose tolerance test (fasting);
KIRP	trans	rs11191193	0.662	rs10883689	chr10:103586356	A/G	cg04125625	chr1:29564120	PTPRU	0.55	6.73	0.39	1.16e-10	Educational attainment;
KIRP	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg14092571	chr14:90743983	NA	0.43	5.56	0.33	7.02e-8	Mortality in heart failure;
KIRP	cis	rs743757	0.816	rs6792502	chr3:50531201	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.48	5.0	0.3	1.1e-6	Diastolic blood pressure;
KIRP	cis	rs2733201	1.000	rs1426658	chr15:44338919	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.72	-5.75	-0.34	2.58e-8	Lipoprotein phospholipase A2 activity in cardiovascular disease;
KIRP	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg01677386	chr11:118938358	VPS11	0.5	5.76	0.34	2.5e-8	Coronary artery disease;
KIRP	cis	rs12230513	0.732	rs12582120	chr12:55830064	A/G	cg11794356	chr12:55725991	OR6C3	-0.5	-6.15	-0.37	3.04e-9	Contrast sensitivity;
KIRP	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.55	-6.59	-0.39	2.64e-10	Ulcerative colitis;Blood protein levels;Crohn's disease;
KIRP	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg21775007	chr8:11205619	TDH	0.46	6.11	0.36	3.9e-9	Neuroticism;
KIRP	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	7.34	0.42	3.17e-12	Bipolar disorder;
KIRP	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.74	-10.01	-0.54	5.19e-20	Schizophrenia;
KIRP	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg19000871	chr14:103996768	TRMT61A	-0.44	-5.62	-0.34	5.24e-8	Coronary artery disease;
KIRP	cis	rs394563	1.000	rs394563	chr6:149797014	T/G	cg16235748	chr6:149772707	ZC3H12D	-0.33	-5.17	-0.31	4.9e-7	Dupuytren's disease;
KIRP	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg02297831	chr4:17616191	MED28	0.52	6.59	0.39	2.67e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg10047753	chr17:41438598	NA	1.06	17.02	0.74	1.84e-43	Menopause (age at onset);
KIRP	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18252515	chr7:66147081	NA	0.45	5.44	0.33	1.31e-7	Aortic root size;
KIRP	cis	rs55871839	0.643	rs10109566	chr8:59800446	A/G	cg07426533	chr8:59803705	TOX	-0.51	-8.78	-0.49	2.77e-16	Pneumonia;
KIRP	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.72	10.16	0.54	1.82e-20	Mean corpuscular volume;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg09360748	chr14:68086507	ARG2	0.52	6.74	0.39	1.13e-10	Parkinson's disease;
KIRP	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg06598544	chr20:61472147	COL9A3	-0.83	-6.66	-0.39	1.81e-10	Obesity-related traits;
KIRP	cis	rs4956211	0.507	rs62315053	chr4:109712282	G/A	cg07086381	chr4:109682776	AGXT2L1	-0.43	-5.76	-0.34	2.52e-8	Systemic lupus erythematosus;
KIRP	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg01872077	chr2:219646372	CYP27A1	-0.4	-5.19	-0.31	4.44e-7	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06544989	chr22:39130855	UNC84B	0.35	5.71	0.34	3.25e-8	Menopause (age at onset);
KIRP	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23903597	chr17:61704154	MAP3K3	-0.58	-7.21	-0.42	6.66e-12	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.76	-10.52	-0.56	1.28e-21	Plateletcrit;Platelet count;
KIRP	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-6.98	-0.41	2.76e-11	Blood pressure;
KIRP	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	9.88	0.53	1.29e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	trans	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg06521331	chr12:34319734	NA	-0.61	-7.24	-0.42	5.89e-12	Bladder cancer;
KIRP	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.5	6.59	0.39	2.61e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
KIRP	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02359409	chr6:42947317	PEX6	-0.51	-7.04	-0.41	1.88e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg18016565	chr1:150552671	MCL1	0.39	5.89	0.35	1.27e-8	Melanoma;
KIRP	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.27	0.32	2.93e-7	Retinal vascular caliber;
KIRP	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.74	9.9	0.53	1.18e-19	Pancreatic cancer;
KIRP	cis	rs4654899	0.571	rs34530426	chr1:21085204	C/T	cg08890418	chr1:21044141	KIF17	0.33	4.92	0.3	1.6e-6	Superior frontal gyrus grey matter volume;
KIRP	cis	rs10958369	0.588	rs1904072	chr8:54439902	A/T	cg12485204	chr8:54507357	NA	0.44	5.72	0.34	3.06e-8	Response to antineoplastic agents;
KIRP	cis	rs793571	0.521	rs12594872	chr15:58912749	T/C	cg05156742	chr15:59063176	FAM63B	0.55	6.96	0.41	3e-11	Schizophrenia;
KIRP	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.82	12.02	0.61	1.73e-26	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13732083	chr21:47605072	C21orf56	0.41	5.18	0.31	4.58e-7	Testicular germ cell tumor;
KIRP	cis	rs1555895	0.599	rs4881535	chr10:847769	G/A	cg10017260	chr10:834428	NA	-0.41	-5.81	-0.35	1.94e-8	Survival in rectal cancer;
KIRP	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-7.82	-0.45	1.54e-13	Total cholesterol levels;
KIRP	cis	rs6893300	0.785	rs6887507	chr5:179186237	A/G	cg14593053	chr5:179126677	CANX	-0.58	-7.22	-0.42	6.42e-12	Resting heart rate;
KIRP	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg02297831	chr4:17616191	MED28	0.6	7.62	0.44	5.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.74	11.2	0.58	8.44e-24	Type 2 diabetes;
KIRP	cis	rs2859741	0.565	rs11263962	chr1:37509239	C/T	cg09363841	chr1:37513479	NA	-0.4	-5.83	-0.35	1.78e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
KIRP	cis	rs2882667	0.898	rs6862393	chr5:138364698	T/C	cg04439458	chr5:138467593	SIL1	-0.45	-7.46	-0.43	1.48e-12	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg07148914	chr20:33460835	GGT7	0.41	5.15	0.31	5.25e-7	Height;
KIRP	cis	rs8067545	0.532	rs4925074	chr17:19962554	C/T	cg04132472	chr17:19861366	AKAP10	0.42	4.89	0.3	1.85e-6	Schizophrenia;
KIRP	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.82	11.54	0.59	6.67e-25	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
KIRP	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.56	-6.92	-0.4	3.81e-11	Breast cancer;
KIRP	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.45	6.3	0.37	1.37e-9	Sitting height ratio;
KIRP	cis	rs13178130	0.515	rs329309	chr5:133899291	G/T	cg06019726	chr5:133897654	PHF15	0.4	5.95	0.35	9.05e-9	Menarche (age at onset);
KIRP	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs6901250	0.568	rs4946198	chr6:117176599	C/T	cg12892004	chr6:117198278	RFX6	-0.55	-8.01	-0.45	4.51e-14	C-reactive protein levels;
KIRP	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.7	-9.42	-0.52	3.35e-18	Huntington's disease progression;
KIRP	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg12288994	chr5:1860383	NA	0.63	10.45	0.55	2.1e-21	Cardiovascular disease risk factors;
KIRP	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg19077165	chr18:44547161	KATNAL2	-0.44	-5.83	-0.35	1.74e-8	Educational attainment;
KIRP	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.55	-5.79	-0.35	2.09e-8	Total cholesterol levels;
KIRP	trans	rs728616	0.681	rs12769764	chr10:81917113	C/G	cg04578738	chr17:34136331	TAF15	-0.47	-6.04	-0.36	5.51e-9	Chronic obstructive pulmonary disease-related biomarkers;
KIRP	cis	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg04607699	chr11:48328132	OR4S1	-0.39	-5.54	-0.33	7.88e-8	Migraine - clinic-based;
KIRP	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg19025524	chr12:109796872	NA	-0.38	-5.06	-0.31	8.06e-7	Neuroticism;
KIRP	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.49	-5.69	-0.34	3.52e-8	Schizophrenia;
KIRP	cis	rs10489525	0.528	rs360604	chr1:115390019	G/A	cg12756093	chr1:115239321	AMPD1	0.47	5.75	0.34	2.6e-8	Autism;
KIRP	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.92	-14.74	-0.68	1.14e-35	Height;
KIRP	cis	rs10751667	0.558	rs12276666	chr11:1022119	G/A	cg10932868	chr11:921992	NA	0.52	6.0	0.36	6.91e-9	Alzheimer's disease (late onset);
KIRP	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg08885076	chr2:99613938	TSGA10	0.52	8.88	0.49	1.43e-16	Chronic sinus infection;
KIRP	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.5	-5.46	-0.33	1.16e-7	Obesity-related traits;
KIRP	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg06953865	chr19:18549723	ISYNA1	-0.41	-6.26	-0.37	1.66e-9	Breast cancer;
KIRP	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg12501888	chr15:85177176	SCAND2	-0.4	-4.99	-0.3	1.12e-6	P wave terminal force;
KIRP	trans	rs9329221	0.597	rs11776973	chr8:10117411	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-6.58	-0.39	2.88e-10	Neuroticism;
KIRP	cis	rs8077577	0.895	rs11871491	chr17:18105656	T/C	cg18869244	chr17:18121946	NA	0.47	5.34	0.32	2.07e-7	Obesity-related traits;
KIRP	cis	rs9309473	0.519	rs2421583	chr2:73898785	C/G	cg20560298	chr2:73613845	ALMS1	0.44	5.4	0.33	1.59e-7	Metabolite levels;
KIRP	trans	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg23645639	chr19:21203403	ZNF430	-0.55	-6.66	-0.39	1.78e-10	Obesity-related traits;
KIRP	cis	rs6545883	0.894	rs4672431	chr2:61519922	C/A	cg15711740	chr2:61764176	XPO1	0.62	7.96	0.45	6.31e-14	Tuberculosis;
KIRP	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.52	-6.81	-0.4	7.34e-11	Schizophrenia;
KIRP	cis	rs6061231	0.597	rs624313	chr20:60927412	G/A	cg22633769	chr20:60982531	CABLES2	-0.45	-5.69	-0.34	3.54e-8	Colorectal cancer;
KIRP	cis	rs4132509	1.000	rs7534117	chr1:243964902	A/C	cg25706552	chr1:244017396	NA	-0.58	-7.29	-0.42	4.33e-12	RR interval (heart rate);
KIRP	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.46	-6.08	-0.36	4.59e-9	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg21427119	chr20:30132790	HM13	-0.54	-6.17	-0.37	2.8e-9	Mean corpuscular hemoglobin;
KIRP	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	7.49	0.43	1.21e-12	Height;
KIRP	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.92	9.31	0.51	7.62e-18	Methadone dose in opioid dependence;
KIRP	cis	rs12210905	1.000	rs1062834	chr6:27222539	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.84	-6.72	-0.39	1.28e-10	Hip circumference adjusted for BMI;
KIRP	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.54	-7.15	-0.41	1.01e-11	Height;
KIRP	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23161317	chr6:28129485	ZNF389	0.45	5.29	0.32	2.69e-7	Depression;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04968835	chr1:143913847	FAM72D	0.63	7.57	0.43	7.68e-13	Smoking initiation;
KIRP	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.72	8.78	0.49	2.86e-16	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg21546286	chr11:48923668	NA	-0.47	-6.15	-0.36	3.17e-9	HDL cholesterol;
KIRP	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.5	6.58	0.39	2.8e-10	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-7.63	-0.44	5.12e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg19847130	chr8:10466454	RP1L1	0.39	5.85	0.35	1.52e-8	Retinal vascular caliber;
KIRP	cis	rs4908768	0.906	rs56163601	chr1:8751897	G/A	cg25722041	chr1:8623473	RERE	0.8	9.18	0.51	1.8e-17	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
KIRP	cis	rs7224685	0.539	rs2054039	chr17:4014538	C/A	cg17441377	chr17:3906640	NA	0.47	6.66	0.39	1.76e-10	Type 2 diabetes;
KIRP	cis	rs78487399	0.808	rs75135247	chr2:43699399	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.68	-5.14	-0.31	5.69e-7	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
KIRP	cis	rs710913	0.738	rs1180347	chr1:39996716	C/T	cg27567593	chr1:39956653	BMP8A	0.33	4.86	0.3	2.11e-6	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.59	-7.83	-0.45	1.47e-13	Plateletcrit;Platelet count;
KIRP	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.51	-6.64	-0.39	2.02e-10	Blood metabolite levels;
KIRP	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg06212747	chr3:49208901	KLHDC8B	0.52	5.19	0.31	4.44e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
KIRP	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.71	9.65	0.52	7.03e-19	Schizophrenia;
KIRP	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg17133734	chr15:86042851	AKAP13	0.48	6.11	0.36	3.96e-9	Coronary artery disease;
KIRP	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg00933542	chr6:150070202	PCMT1	0.26	4.94	0.3	1.46e-6	Lung cancer;
KIRP	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.53	6.06	0.36	5.05e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg11130432	chr3:121712080	ILDR1	-0.43	-5.08	-0.31	7.62e-7	Multiple sclerosis;
KIRP	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg05861140	chr6:150128134	PCMT1	-0.47	-6.79	-0.4	8.43e-11	Lung cancer;
KIRP	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00933542	chr6:150070202	PCMT1	0.28	5.57	0.33	6.53e-8	Lung cancer;
KIRP	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg24375607	chr4:120327624	NA	0.55	5.6	0.34	5.71e-8	Corneal astigmatism;
KIRP	cis	rs57590327	0.528	rs3821552	chr3:81702139	A/G	cg07356753	chr3:81810745	GBE1	-0.67	-8.04	-0.46	3.68e-14	Extraversion;
KIRP	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg18240062	chr17:79603768	NPLOC4	0.79	10.65	0.56	5.1e-22	Eye color traits;
KIRP	trans	rs7577696	0.741	rs2300703	chr2:31799509	A/G	cg15755476	chr11:47510670	CUGBP1	-0.43	-6.47	-0.38	5.17e-10	Inflammatory biomarkers;
KIRP	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg18032289	chr17:61959525	GH2	-0.39	-5.02	-0.3	1.01e-6	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-8.37	-0.47	4.42e-15	Monocyte percentage of white cells;
KIRP	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11987759	chr7:65425863	GUSB	-0.51	-6.88	-0.4	5.05e-11	Aortic root size;
KIRP	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg23625390	chr15:77176239	SCAPER	0.52	6.76	0.4	9.85e-11	Blood metabolite levels;
KIRP	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.87	13.21	0.64	1.77e-30	Longevity;
KIRP	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.69	-9.47	-0.52	2.4e-18	Triglycerides;
KIRP	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.71	6.95	0.41	3.25e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.67	6.24	0.37	1.88e-9	Alzheimer's disease;
KIRP	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg04990556	chr1:26633338	UBXN11	0.66	6.26	0.37	1.74e-9	Obesity-related traits;
KIRP	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	6.75	0.4	1.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.52	-7.43	-0.43	1.77e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs6840360	0.582	rs57585665	chr4:152327017	G/C	cg25486957	chr4:152246857	NA	-0.42	-4.94	-0.3	1.44e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.92	10.0	0.54	5.5e-20	Type 2 diabetes nephropathy;
KIRP	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.03	-15.9	-0.71	1.22e-39	Homoarginine levels;
KIRP	cis	rs1863824	0.595	rs61859067	chr10:88159997	G/A	cg07322936	chr10:88137208	NA	-0.55	-5.61	-0.34	5.36e-8	Schizophrenia;
KIRP	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg22800045	chr5:56110881	MAP3K1	-0.7	-6.94	-0.4	3.54e-11	Initial pursuit acceleration;
KIRP	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.75	10.79	0.57	1.76e-22	Parkinson's disease;
KIRP	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.03	-13.09	-0.64	4.71e-30	Alzheimer's disease;
KIRP	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg23682824	chr7:23144976	KLHL7	0.54	6.5	0.38	4.48e-10	Blood protein levels;
KIRP	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.94	15.04	0.69	1.11e-36	Coronary artery disease;
KIRP	cis	rs2625529	0.775	rs62023342	chr15:72161305	A/C	cg16672083	chr15:72433130	SENP8	-0.49	-6.03	-0.36	5.98e-9	Red blood cell count;
KIRP	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-7.72	-0.44	2.96e-13	Total cholesterol levels;
KIRP	cis	rs240764	0.658	rs12202621	chr6:101220056	C/A	cg09795085	chr6:101329169	ASCC3	-0.42	-5.08	-0.31	7.42e-7	Neuroticism;
KIRP	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg25019033	chr10:957182	NA	-0.6	-7.17	-0.42	8.77e-12	Eosinophil percentage of granulocytes;
KIRP	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg05347473	chr6:146136440	FBXO30	0.62	8.8	0.49	2.52e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg27411982	chr8:10470053	RP1L1	0.42	5.02	0.31	9.75e-7	Neuroticism;
KIRP	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg23601095	chr6:26197514	HIST1H3D	1.03	8.66	0.48	6.5e-16	Gout;Renal underexcretion gout;
KIRP	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg08533674	chr1:46993347	NA	-0.47	-5.86	-0.35	1.46e-8	Monobrow;
KIRP	cis	rs9434723	0.920	rs9434725	chr1:9293861	C/T	cg04199779	chr1:9294473	H6PD	0.64	7.4	0.43	2.16e-12	Height;
KIRP	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.76	9.24	0.51	1.24e-17	Type 2 diabetes;
KIRP	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.64	8.28	0.47	7.83e-15	Ulcerative colitis;Inflammatory bowel disease;
KIRP	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.92	13.13	0.64	3.37e-30	Bladder cancer;
KIRP	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.93	-9.45	-0.52	2.82e-18	Glomerular filtration rate (creatinine);
KIRP	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.55	-6.3	-0.37	1.34e-9	Gut microbiome composition (summer);
KIRP	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	8.97	0.5	7.97e-17	Motion sickness;
KIRP	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg08076091	chr2:203926405	NBEAL1	0.87	9.12	0.5	2.78e-17	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg00106254	chr7:1943704	MAD1L1	-0.55	-5.91	-0.35	1.12e-8	Bipolar disorder and schizophrenia;
KIRP	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg27124370	chr19:33622961	WDR88	0.6	7.43	0.43	1.84e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs9826463	0.527	rs6780665	chr3:142063689	G/A	cg20824294	chr3:142316082	PLS1	0.43	6.31	0.37	1.32e-9	QRS duration in Tripanosoma cruzi seropositivity;
KIRP	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg06212747	chr3:49208901	KLHDC8B	0.65	8.95	0.5	8.75e-17	Resting heart rate;
KIRP	cis	rs662064	0.962	rs660725	chr1:10557544	A/G	cg19773385	chr1:10388646	KIF1B	0.36	4.95	0.3	1.37e-6	Asthma;
KIRP	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	11.46	0.59	1.2e-24	Mean corpuscular hemoglobin;
KIRP	cis	rs7562790	0.651	rs2049367	chr2:36668219	G/T	cg09467607	chr2:36825704	FEZ2	0.43	5.19	0.31	4.38e-7	QRS duration;QRS complex (Cornell);
KIRP	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.63	-9.69	-0.53	5.03e-19	Prostate cancer;
KIRP	cis	rs6738485	0.930	rs4567955	chr2:106790116	A/G	cg16099169	chr2:106886729	NA	0.39	5.54	0.33	7.84e-8	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
KIRP	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.6	7.74	0.44	2.6e-13	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs9815354	0.812	rs73083333	chr3:41927505	G/A	cg03022575	chr3:42003672	ULK4	0.77	7.99	0.45	5.18e-14	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.41	11.11	0.58	1.7e-23	Prostate cancer;
KIRP	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg01256987	chr12:42539512	GXYLT1	0.45	6.07	0.36	4.88e-9	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.82	7.49	0.43	1.26e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.94	-15.69	-0.71	6.21e-39	Chronic sinus infection;
KIRP	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg24315340	chr6:146058215	EPM2A	-0.4	-4.91	-0.3	1.67e-6	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2820315	0.867	rs2820322	chr1:201880300	T/C	cg11586189	chr1:201857591	SHISA4	-0.43	-6.37	-0.38	9.41e-10	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
KIRP	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11645453	chr3:52864694	ITIH4	0.47	6.47	0.38	5.36e-10	Bipolar disorder;
KIRP	cis	rs13095912	1.000	rs35497918	chr3:185310312	C/T	cg11274856	chr3:185301563	NA	0.51	6.6	0.39	2.55e-10	Systolic blood pressure;
KIRP	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.61	7.54	0.43	8.82e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-10.28	-0.55	7.61e-21	Hemoglobin concentration;
KIRP	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg21775007	chr8:11205619	TDH	-0.51	-6.47	-0.38	5.32e-10	Neuroticism;
KIRP	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	0.81	9.26	0.51	1.05e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	cis	rs2652822	0.935	rs12148069	chr15:63443792	A/T	cg02713581	chr15:63449717	RPS27L	0.67	7.93	0.45	7.91e-14	Metabolic traits;
KIRP	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg12501888	chr15:85177176	SCAND2	-0.44	-5.68	-0.34	3.85e-8	P wave terminal force;
KIRP	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.61	7.51	0.43	1.09e-12	Migraine;
KIRP	cis	rs2425143	1.000	rs8116836	chr20:34453362	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.52	-4.91	-0.3	1.69e-6	Blood protein levels;
KIRP	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.74	6.82	0.4	7.22e-11	Parkinson's disease;
KIRP	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-6.91	-0.4	4.19e-11	Obesity-related traits;
KIRP	trans	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg06521331	chr12:34319734	NA	-0.6	-7.17	-0.42	9.01e-12	Bladder cancer;
KIRP	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.77	-7.71	-0.44	3.13e-13	Developmental language disorder (linguistic errors);
KIRP	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg05315796	chr3:52349193	DNAH1	0.41	6.59	0.39	2.6200000000000003e-10	Electroencephalogram traits;
KIRP	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg07862535	chr7:139043722	LUC7L2	0.46	5.16	0.31	4.99e-7	Diisocyanate-induced asthma;
KIRP	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg20169779	chr10:135381914	SYCE1	-0.69	-7.25	-0.42	5.33e-12	Gout;
KIRP	cis	rs13185784	0.667	rs4309929	chr5:179650988	A/C	cg02891314	chr5:179741120	GFPT2	-0.48	-4.93	-0.3	1.51e-6	TRAIL levels;
KIRP	cis	rs394563	0.622	rs237024	chr6:149721965	T/C	cg03678062	chr6:149772716	ZC3H12D	-0.39	-6.11	-0.36	3.79e-9	Dupuytren's disease;
KIRP	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg26384229	chr12:38710491	ALG10B	0.54	7.07	0.41	1.61e-11	Morning vs. evening chronotype;
KIRP	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	0.74	5.27	0.32	3e-7	Morning vs. evening chronotype;
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg10034481	chr16:87864431	SLC7A5	0.48	6.2	0.37	2.38e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg19847130	chr8:10466454	RP1L1	0.32	4.85	0.3	2.2e-6	Triglycerides;
KIRP	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg15848620	chr12:58087721	OS9	-0.5	-5.86	-0.35	1.52e-8	Celiac disease or Rheumatoid arthritis;
KIRP	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	7.53	0.43	9.41e-13	Mean corpuscular volume;
KIRP	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.99	9.04	0.5	4.82e-17	Blood protein levels;
KIRP	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg06636001	chr8:8085503	FLJ10661	0.6	7.74	0.44	2.54e-13	Retinal vascular caliber;
KIRP	cis	rs960902	0.747	rs9941697	chr2:37728687	T/C	cg25341268	chr2:37734390	NA	0.57	7.61	0.44	6.01e-13	Response to TNF-alpha inhibitors in rheumatoid arthritis;
KIRP	cis	rs7116495	0.609	rs10898812	chr11:71698801	G/A	cg18441811	chr11:71824068	C11orf51	-0.78	-5.29	-0.32	2.67e-7	Severe influenza A (H1N1) infection;
KIRP	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17554472	chr22:41940697	POLR3H	0.68	7.04	0.41	1.96e-11	Vitiligo;
KIRP	cis	rs2671245	0.507	rs11206659	chr1:56143284	A/G	cg11523071	chr1:56160889	NA	0.41	6.07	0.36	4.72e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.76	10.55	0.56	1.04e-21	Parkinson's disease;
KIRP	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg18154014	chr19:37997991	ZNF793	0.91	9.1	0.5	3.2e-17	Coronary artery calcification;
KIRP	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-10.48	-0.56	1.68e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.97	10.28	0.55	7.4e-21	Cognitive test performance;
KIRP	cis	rs8141529	0.529	rs73170633	chr22:29160805	C/T	cg02153584	chr22:29168773	CCDC117	0.56	4.97	0.3	1.23e-6	Lymphocyte counts;
KIRP	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg21747090	chr2:27597821	SNX17	-0.49	-6.82	-0.4	6.85e-11	Total body bone mineral density;
KIRP	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg22535103	chr8:58192502	C8orf71	-0.68	-6.89	-0.4	4.62e-11	Developmental language disorder (linguistic errors);
KIRP	cis	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg04691961	chr3:161091175	C3orf57	-0.48	-7.16	-0.42	9.3e-12	Morning vs. evening chronotype;
KIRP	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg08662619	chr6:150070041	PCMT1	0.35	5.71	0.34	3.17e-8	Lung cancer;
KIRP	cis	rs11731606	0.508	rs28623728	chr4:95290861	C/T	cg00507259	chr4:95128692	SMARCAD1	0.6	5.96	0.36	8.75e-9	Mean platelet volume;
KIRP	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23903597	chr17:61704154	MAP3K3	-0.55	-6.57	-0.39	2.92e-10	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-8.95	-0.5	8.82e-17	Coffee consumption (cups per day);
KIRP	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg02462569	chr6:150064036	NUP43	-0.38	-5.81	-0.35	1.96e-8	Lung cancer;
KIRP	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg08132940	chr7:1081526	C7orf50	-0.62	-6.28	-0.37	1.56e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg06212747	chr3:49208901	KLHDC8B	0.69	8.26	0.47	8.86e-15	Menarche (age at onset);
KIRP	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.64	6.97	0.41	2.86e-11	Alcohol dependence;
KIRP	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg26207909	chr14:103986467	CKB	-0.43	-5.27	-0.32	3.03e-7	Coronary artery disease;
KIRP	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.59	7.24	0.42	5.64e-12	Aortic root size;
KIRP	cis	rs240764	0.817	rs239247	chr6:101088350	T/C	cg09795085	chr6:101329169	ASCC3	0.46	5.36	0.32	1.95e-7	Neuroticism;
KIRP	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg16497661	chr14:103986332	CKB	-0.5	-6.43	-0.38	6.67e-10	Coronary artery disease;
KIRP	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg03060546	chr3:49711283	APEH	0.43	5.7	0.34	3.39e-8	Parkinson's disease;
KIRP	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.86	12.39	0.62	1.01e-27	Glomerular filtration rate (creatinine);
KIRP	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	0.82	6.94	0.4	3.5e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
KIRP	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg00405596	chr8:11794950	NA	-0.4	-4.87	-0.3	2.01e-6	Neuroticism;
KIRP	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.8	-9.46	-0.52	2.61e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg25303436	chr1:84941094	NA	-0.4	-6.02	-0.36	6.37e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs7539542	0.529	rs10920519	chr1:202866331	A/C	cg19681188	chr1:202830198	LOC148709	-0.47	-5.05	-0.31	8.72e-7	Mean platelet volume;
KIRP	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	7.0	0.41	2.39e-11	Tonsillectomy;
KIRP	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.75	13.18	0.64	2.35e-30	Anterior chamber depth;
KIRP	cis	rs812925	0.571	rs3087898	chr2:61765074	G/A	cg15711740	chr2:61764176	XPO1	-0.52	-6.3	-0.37	1.35e-9	Immature fraction of reticulocytes;
KIRP	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.73	9.27	0.51	9.54e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
KIRP	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg18154014	chr19:37997991	ZNF793	0.89	8.59	0.48	1.04e-15	Coronary artery calcification;
KIRP	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.63	9.7	0.53	4.82e-19	Lung cancer;
KIRP	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.51	-5.96	-0.36	8.5e-9	Body mass index;
KIRP	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.62	7.78	0.44	2.05e-13	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg04672837	chr16:48644449	N4BP1	0.5	6.93	0.4	3.61e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg09699651	chr6:150184138	LRP11	0.4	5.19	0.31	4.47e-7	Lung cancer;
KIRP	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg26876637	chr1:152193138	HRNR	-0.78	-9.28	-0.51	8.94e-18	Atopic dermatitis;
KIRP	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg01559446	chr3:44596178	ZNF167	-0.37	-5.39	-0.32	1.68e-7	Depressive symptoms;
KIRP	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	5.75	0.34	2.6e-8	Platelet count;
KIRP	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16346588	chr10:242978	ZMYND11	0.49	6.14	0.36	3.36e-9	Psychosis in Alzheimer's disease;
KIRP	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg11859384	chr17:80120422	CCDC57	-0.41	-5.13	-0.31	5.75e-7	Life satisfaction;
KIRP	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.9	-14.4	-0.68	1.65e-34	Headache;
KIRP	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.64	5.36	0.32	1.87e-7	Diabetic retinopathy;
KIRP	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg00250761	chr1:31883323	NA	-0.31	-5.38	-0.32	1.7e-7	Alcohol dependence;
KIRP	trans	rs10220309	0.513	rs2371149	chr14:80587622	A/T	cg12933314	chr7:4815160	KIAA0415	0.67	6.21	0.37	2.29e-9	Lung function (FEV1);
KIRP	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg05347473	chr6:146136440	FBXO30	-0.61	-8.85	-0.49	1.81e-16	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.69	9.54	0.52	1.48e-18	Bone properties (heel);
KIRP	trans	rs7804356	0.677	rs2082365	chr7:26835945	C/T	cg07115304	chr20:361903	TRIB3	-0.45	-6.03	-0.36	6.1e-9	Type 1 diabetes;
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg16341495	chr8:142228727	SLC45A4	0.4	4.89	0.3	1.8e-6	Immature fraction of reticulocytes;
KIRP	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg19847130	chr8:10466454	RP1L1	0.42	6.12	0.36	3.75e-9	Joint mobility (Beighton score);
KIRP	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.67	-8.19	-0.46	1.39e-14	Aortic root size;
KIRP	cis	rs1707322	0.928	rs925524	chr1:46496709	A/G	cg03146154	chr1:46216737	IPP	-0.57	-6.9	-0.4	4.41e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs965513	0.627	rs7848973	chr9:100588839	A/G	cg13688889	chr9:100608707	NA	-0.6	-7.4	-0.43	2.14e-12	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
KIRP	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg01631408	chr1:248437212	OR2T33	0.6	8.07	0.46	3.11e-14	Common traits (Other);
KIRP	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg24253500	chr15:84953950	NA	0.65	7.36	0.42	2.73e-12	Schizophrenia;
KIRP	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.25	-5.05	-0.31	8.81e-7	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.85	-11.07	-0.58	2.16e-23	Gut microbiota (bacterial taxa);
KIRP	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg04691961	chr3:161091175	C3orf57	-0.52	-8.22	-0.46	1.17e-14	Morning vs. evening chronotype;
KIRP	cis	rs10073892	0.660	rs10040591	chr5:101943045	A/G	cg19774478	chr5:101632501	SLCO4C1	0.55	5.69	0.34	3.62e-8	Cognitive decline (age-related);
KIRP	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24110177	chr3:50126178	RBM5	0.44	5.64	0.34	4.7e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg27539214	chr16:67997921	SLC12A4	-0.55	-5.07	-0.31	7.95e-7	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg10189774	chr4:17578691	LAP3	0.48	5.41	0.33	1.46e-7	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg06289844	chr6:126071538	HEY2	0.34	4.91	0.3	1.68e-6	Brugada syndrome;
KIRP	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg26516362	chr5:178986906	RUFY1	0.44	7.87	0.45	1.16e-13	Lung cancer;
KIRP	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.39	5.06	0.31	8.4e-7	Breast cancer;
KIRP	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.52	5.11	0.31	6.62e-7	Alzheimer's disease;
KIRP	cis	rs11038871	0.815	rs6485686	chr11:46657430	T/G	cg16389345	chr11:46697382	NA	-0.52	-6.93	-0.4	3.65e-11	Immunoglobulin A;
KIRP	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg10117171	chr1:25599238	RHD	-0.39	-5.33	-0.32	2.23e-7	Erythrocyte sedimentation rate;
KIRP	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-1.09	-13.28	-0.65	1.01e-30	Exhaled nitric oxide output;
KIRP	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg19610905	chr11:61596333	FADS2	-0.74	-6.8	-0.4	7.73e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
KIRP	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg25753631	chr6:25732923	NA	-0.27	-5.05	-0.31	8.71e-7	Iron status biomarkers;
KIRP	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25214090	chr10:38739885	LOC399744	0.56	6.9	0.4	4.33e-11	Corneal astigmatism;
KIRP	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.43	8.28	0.47	7.95e-15	Coronary artery disease;
KIRP	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg07701084	chr6:150067640	NUP43	0.6	6.4	0.38	7.78e-10	Lung cancer;
KIRP	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.84	9.83	0.53	1.88e-19	Eosinophil percentage of granulocytes;
KIRP	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.67	8.6	0.48	9.36e-16	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs981844	0.712	rs10014763	chr4:154739140	C/T	cg14289246	chr4:154710475	SFRP2	0.54	7.03	0.41	2.07e-11	Response to statins (LDL cholesterol change);
KIRP	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg13319975	chr6:146136371	FBXO30	-0.49	-7.1	-0.41	1.35e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs3736485	0.966	rs10851500	chr15:51783820	T/C	cg14296394	chr15:51910925	DMXL2	-0.36	-5.42	-0.33	1.4e-7	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
KIRP	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg07701084	chr6:150067640	NUP43	0.7	9.95	0.54	8.3e-20	Lung cancer;
KIRP	cis	rs13082711	1.000	rs13082711	chr3:27537909	T/C	cg02860705	chr3:27208620	NA	0.59	7.59	0.44	6.74e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
KIRP	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.98	13.08	0.64	4.79e-30	Breast cancer;
KIRP	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-5.86	-0.35	1.47e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg03716233	chr17:43128931	DCAKD	0.49	6.04	0.36	5.69e-9	Parkinson's disease;
KIRP	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.69	-11.64	-0.6	3.16e-25	Obesity-related traits;
KIRP	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.59	7.59	0.44	6.72e-13	Endometrial cancer;
KIRP	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg27147174	chr7:100797783	AP1S1	-0.74	-9.54	-0.52	1.53e-18	Life satisfaction;
KIRP	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg06565975	chr8:143823917	SLURP1	0.45	7.1	0.41	1.31e-11	Urinary tract infection frequency;
KIRP	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg01251548	chr11:17372745	DKFZp686O24166	-0.37	-4.96	-0.3	1.34e-6	Type 2 diabetes;
KIRP	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg21698718	chr17:80085957	CCDC57	0.33	4.87	0.3	1.97e-6	Life satisfaction;
KIRP	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	0.93	9.67	0.52	6e-19	Left atrial antero-posterior diameter;
KIRP	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg13147721	chr7:65941812	NA	1.03	7.08	0.41	1.46e-11	Diabetic kidney disease;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg15845603	chr19:38085757	ZNF540;ZNF571	0.54	6.71	0.39	1.3100000000000001e-10	Parkinson's disease;
KIRP	cis	rs5753618	0.504	rs9606847	chr22:31901789	G/C	cg02404636	chr22:31891804	SFI1	0.56	6.55	0.39	3.35e-10	Colorectal cancer;
KIRP	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.66	8.89	0.49	1.33e-16	Height;
KIRP	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg24972876	chr7:65420302	NA	0.47	6.61	0.39	2.39e-10	Calcium levels;
KIRP	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.83	11.2	0.58	8.63e-24	Morning vs. evening chronotype;
KIRP	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.53	14.17	0.67	1.01e-33	Systolic blood pressure;
KIRP	cis	rs7215564	0.908	rs74002838	chr17:78682157	C/T	cg06153925	chr17:78755379	RPTOR	0.32	5.19	0.31	4.39e-7	Myopia (pathological);
KIRP	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.59	11.9	0.6	4.16e-26	Diabetic kidney disease;
KIRP	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg22283653	chr8:49824208	NA	-0.5	-7.38	-0.43	2.46e-12	Sudden cardiac arrest;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg05881034	chr3:42623675	SEC22C	0.51	6.75	0.4	1.08e-10	Parkinson's disease;
KIRP	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	6.6	0.39	2.45e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.31	15.15	0.69	4.61e-37	Psoriasis vulgaris;
KIRP	cis	rs2625529	0.652	rs3759820	chr15:72300031	A/C	cg16672083	chr15:72433130	SENP8	0.46	6.43	0.38	6.55e-10	Red blood cell count;
KIRP	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	0.64	5.75	0.34	2.59e-8	Gut microbiota (bacterial taxa);
KIRP	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg11494091	chr17:61959527	GH2	-0.61	-7.95	-0.45	6.67e-14	Height;
KIRP	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-1.02	-12.5	-0.62	4.38e-28	Breast cancer;
KIRP	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg21775007	chr8:11205619	TDH	0.48	6.28	0.37	1.5e-9	Mood instability;
KIRP	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.48	6.27	0.37	1.58e-9	High light scatter reticulocyte count;
KIRP	cis	rs13343954	0.756	rs2042190	chr19:33532716	T/C	cg27124370	chr19:33622961	WDR88	0.55	6.18	0.37	2.69e-9	Colorectal cancer;
KIRP	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.5	6.66	0.39	1.81e-10	Hemoglobin concentration;
KIRP	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06850241	chr22:41845214	NA	-0.45	-5.15	-0.31	5.25e-7	Vitiligo;
KIRP	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-7.94	-0.45	7.09e-14	Neuroticism;
KIRP	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg00409905	chr10:38381863	ZNF37A	0.54	5.98	0.36	8.02e-9	Obesity (extreme);
KIRP	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg02887458	chr19:19495540	GATAD2A	-0.45	-5.01	-0.3	1.06e-6	Bipolar disorder;
KIRP	cis	rs11997175	0.545	rs7388496	chr8:33667898	A/G	cg04338863	chr8:33670619	NA	0.42	5.24	0.32	3.45e-7	Body mass index;
KIRP	cis	rs7224685	0.515	rs7207986	chr17:3979949	G/A	cg21851534	chr17:3907994	ZZEF1	0.55	5.33	0.32	2.18e-7	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-6.7	-0.39	1.37e-10	Prudent dietary pattern;
KIRP	cis	rs6738028	0.524	rs7565457	chr2:111935478	C/T	cg04202892	chr2:111875749	ACOXL	0.45	6.06	0.36	4.97e-9	Dehydroepiandrosterone sulphate levels;
KIRP	cis	rs4654899	0.772	rs12145203	chr1:21086127	C/T	cg05370193	chr1:21551575	ECE1	0.43	5.66	0.34	4.19e-8	Superior frontal gyrus grey matter volume;
KIRP	cis	rs9367716	0.956	rs7757492	chr6:57120578	T/C	cg03371099	chr6:57305889	PRIM2	0.52	6.48	0.38	4.98e-10	Coronary artery disease;
KIRP	cis	rs9583531	0.714	rs79483970	chr13:111342298	G/A	cg24331049	chr13:111365604	ING1	-0.82	-5.63	-0.34	4.87e-8	Coronary artery disease;
KIRP	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg07741184	chr6:167504864	NA	0.23	6.29	0.37	1.4e-9	Crohn's disease;
KIRP	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.7	7.73	0.44	2.73e-13	Corneal astigmatism;
KIRP	cis	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg08501292	chr6:25962987	TRIM38	0.88	6.16	0.37	2.91e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.4	6.19	0.37	2.49e-9	Lipoprotein (a) levels;
KIRP	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.78	-10.78	-0.57	1.94e-22	Extrinsic epigenetic age acceleration;
KIRP	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24229701	chr12:130821962	PIWIL1	0.41	5.18	0.31	4.7e-7	Menopause (age at onset);
KIRP	cis	rs9815354	1.000	rs73077367	chr3:41851959	G/A	cg03022575	chr3:42003672	ULK4	0.53	5.98	0.36	7.8e-9	Pulse pressure;Diastolic blood pressure;
KIRP	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.63	-7.09	-0.41	1.38e-11	Neuroticism;
KIRP	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.84	8.28	0.47	8.1e-15	Methadone dose in opioid dependence;
KIRP	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg15117754	chr3:10150083	C3orf24	0.53	5.08	0.31	7.48e-7	Alzheimer's disease;
KIRP	cis	rs17023223	0.537	rs17023174	chr1:119593301	T/C	cg05756136	chr1:119680316	WARS2	-0.56	-7.64	-0.44	4.86e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg05861140	chr6:150128134	PCMT1	-0.48	-6.91	-0.4	4.16e-11	Lung cancer;
KIRP	cis	rs6969780	0.915	rs3807597	chr7:27189195	C/T	cg11410718	chr7:27170412	HOXA4	-0.42	-5.35	-0.32	2.01e-7	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);Systolic blood pressure;Hypertension;
KIRP	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	1.22	10.32	0.55	5.67e-21	Corneal curvature;
KIRP	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-7.17	-0.42	9e-12	Response to antipsychotic treatment;
KIRP	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.53	5.74	0.34	2.72e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-8.84	-0.49	1.89e-16	Cleft plate (environmental tobacco smoke interaction);
KIRP	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg11569703	chr11:65557185	OVOL1	0.78	13.91	0.66	7.42e-33	Acne (severe);
KIRP	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	1.09	20.65	0.8	1.22e-55	Bone mineral density;
KIRP	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg02337583	chr1:203763498	ZC3H11A	-0.51	-6.22	-0.37	2.1e-9	Breast cancer;
KIRP	cis	rs10864907	0.614	rs12468164	chr2:113712783	C/T	cg06771106	chr2:113671356	IL1F7	0.43	5.35	0.32	1.99e-7	Pulmonary function;
KIRP	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg12140854	chr5:148520817	ABLIM3	0.54	6.23	0.37	1.98e-9	Breast cancer;
KIRP	cis	rs2901460	0.509	rs12470090	chr2:62094367	T/C	cg02183531	chr2:62113199	CCT4	-0.49	-5.07	-0.31	7.69e-7	Mean corpuscular volume;
KIRP	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-5.83	-0.35	1.78e-8	Response to antipsychotic treatment;
KIRP	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg11833968	chr6:79620685	NA	-0.47	-7.1	-0.41	1.34e-11	Intelligence (multi-trait analysis);
KIRP	cis	rs77633900	0.772	rs284907	chr15:76741569	A/G	cg21673338	chr15:77095150	SCAPER	-0.65	-6.2	-0.37	2.39e-9	Non-glioblastoma glioma;Glioma;
KIRP	cis	rs6593803	1.000	rs6593803	chr1:147205770	C/T	cg27546670	chr1:147246839	GJA5	-0.59	-7.02	-0.41	2.19e-11	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg21211053	chr19:49496578	GYS1;RUVBL2	-0.49	-6.83	-0.4	6.42e-11	Morning vs. evening chronotype;
KIRP	cis	rs812925	0.511	rs11886950	chr2:61399317	A/C	cg15711740	chr2:61764176	XPO1	-0.45	-5.64	-0.34	4.64e-8	Immature fraction of reticulocytes;
KIRP	cis	rs2281603	0.570	rs3742606	chr14:64945089	A/G	cg01860774	chr14:64969374	ZBTB25	0.33	5.51	0.33	9.17e-8	Lymphocyte counts;
KIRP	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	1.14	18.15	0.76	2.63e-47	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg23978390	chr7:1156363	C7orf50	0.54	5.26	0.32	3.17e-7	Bronchopulmonary dysplasia;
KIRP	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg20071744	chr8:141057329	TRAPPC9	-0.36	-4.92	-0.3	1.59e-6	Pulse pressure;
KIRP	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg23127183	chr11:57508653	C11orf31	-0.54	-7.05	-0.41	1.76e-11	Schizophrenia;
KIRP	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.84	11.12	0.58	1.56e-23	Menarche (age at onset);
KIRP	cis	rs7630877	0.962	rs7646149	chr3:179635754	G/A	cg18765712	chr3:179670323	PEX5L	0.52	6.21	0.37	2.21e-9	Type 2 diabetes;
KIRP	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.7	-6.9	-0.4	4.33e-11	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg24633833	chr3:10029261	TMEM111	0.56	5.49	0.33	1.01e-7	Alzheimer's disease;
KIRP	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.28	5.57	0.33	6.67e-8	Red blood cell count;Amyotrophic lateral sclerosis;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg27182915	chr1:150241589	APH1A	0.48	6.02	0.36	6.39e-9	Parkinson's disease;
KIRP	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg03060546	chr3:49711283	APEH	0.44	5.73	0.34	2.91e-8	Parkinson's disease;
KIRP	cis	rs9488822	0.612	rs13209599	chr6:116247394	A/G	cg15226275	chr6:116381976	FRK	0.21	5.01	0.3	1.06e-6	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs7246657	0.722	rs2909098	chr19:38204248	G/A	cg18154014	chr19:37997991	ZNF793	-0.62	-6.74	-0.39	1.13e-10	Coronary artery calcification;
KIRP	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.86	12.25	0.62	3e-27	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg21605333	chr4:119757512	SEC24D	1.66	12.13	0.61	7.19e-27	Cannabis dependence symptom count;
KIRP	cis	rs6445967	1.000	rs14927	chr3:58305033	G/T	cg16569813	chr3:58235849	ABHD6	0.34	5.03	0.31	9.44e-7	Platelet count;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg16050349	chr3:138478129	PIK3CB	0.95	6.13	0.36	3.52e-9	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-7.24	-0.42	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg10223061	chr2:219282414	VIL1	0.3	4.97	0.3	1.27e-6	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.75	11.29	0.58	4.42e-24	Blood metabolite ratios;
KIRP	cis	rs73086581	1.000	rs3746666	chr20:3910861	A/G	cg02187196	chr20:3869020	PANK2	0.5	4.88	0.3	1.9e-6	Response to antidepressants in depression;
KIRP	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.63	8.12	0.46	2.2e-14	Coronary artery disease;
KIRP	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg25039879	chr17:56429692	SUPT4H1	0.59	5.17	0.31	4.82e-7	Cognitive test performance;
KIRP	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.5	5.98	0.36	8.02e-9	Mean platelet volume;
KIRP	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	9.4	0.51	3.87e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.71	-9.94	-0.54	8.92e-20	Morning vs. evening chronotype;
KIRP	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg23594656	chr7:65796392	TPST1	-0.46	-7.25	-0.42	5.41e-12	Aortic root size;
KIRP	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	6.65	0.39	1.86e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg07701084	chr6:150067640	NUP43	0.74	10.15	0.54	1.87e-20	Lung cancer;
KIRP	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	7.63	0.44	5.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg09624528	chr10:1369823	ADARB2	0.45	5.61	0.34	5.36e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	6.93	0.4	3.67e-11	Mean corpuscular hemoglobin;
KIRP	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	11.38	0.59	2.18e-24	Nonalcoholic fatty liver disease;
KIRP	cis	rs7223966	1.000	rs8075273	chr17:61728881	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.46	5.1	0.31	6.64e-7	Hip circumference adjusted for BMI;Body mass index;
KIRP	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg13047869	chr3:10149882	C3orf24	0.59	5.04	0.31	8.82e-7	Alzheimer's disease;
KIRP	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	0.76	11.0	0.57	3.62e-23	Prudent dietary pattern;
KIRP	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.59	-6.35	-0.38	1.01e-9	Corneal astigmatism;
KIRP	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-6.37	-0.38	9.01e-10	IgG glycosylation;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg09096054	chr13:72408750	DACH1	-0.43	-6.59	-0.39	2.66e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.55	-8.2	-0.46	1.38e-14	Coronary artery disease;
KIRP	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg13010199	chr12:38710504	ALG10B	0.57	6.97	0.41	2.86e-11	Morning vs. evening chronotype;
KIRP	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg17279839	chr7:150038598	RARRES2	0.45	5.78	0.35	2.31e-8	Blood protein levels;Circulating chemerin levels;
KIRP	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.75	11.25	0.58	6e-24	Endometriosis;
KIRP	cis	rs8084125	0.832	rs2156646	chr18:74946660	C/T	cg05528293	chr18:74961138	GALR1	0.46	5.25	0.32	3.26e-7	Obesity-related traits;
KIRP	cis	rs113123495	0.510	rs2261565	chr19:5712108	C/T	cg26242866	chr19:5711310	LONP1	0.76	5.3	0.32	2.56e-7	Obsessive-compulsive symptoms;
KIRP	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg21926883	chr2:100939477	LONRF2	-0.57	-7.9	-0.45	9.53e-14	Intelligence (multi-trait analysis);
KIRP	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg05220968	chr6:146057943	EPM2A	-0.4	-5.06	-0.31	8.38e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs2213920	0.620	rs7852799	chr9:118188696	T/C	cg13918206	chr9:118159781	DEC1	1.0	10.45	0.55	2.2e-21	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
KIRP	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg10047753	chr17:41438598	NA	-1.12	-17.93	-0.75	1.53e-46	Menopause (age at onset);
KIRP	cis	rs787274	0.850	rs7873289	chr9:115638386	G/A	cg13803584	chr9:115635662	SNX30	-0.75	-7.96	-0.45	6.36e-14	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg04804543	chr8:142233427	SLC45A4	1.06	19.35	0.78	2.41e-51	Immature fraction of reticulocytes;
KIRP	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg21518248	chr2:162101506	NA	0.43	5.12	0.31	6.26e-7	Intelligence (multi-trait analysis);
KIRP	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.2	16.58	0.73	5.97e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
KIRP	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22117172	chr7:91764530	CYP51A1	0.44	5.97	0.36	8.22e-9	Breast cancer;
KIRP	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.95	15.0	0.69	1.5e-36	Menarche (age at onset);
KIRP	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13939156	chr17:80058883	NA	-0.51	-7.58	-0.44	6.87e-13	Life satisfaction;
KIRP	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	8.42	0.47	3.17e-15	Personality dimensions;
KIRP	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg25512537	chr17:76250053	NA	-0.42	-6.83	-0.4	6.58e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg01416317	chr19:45737208	EXOC3L2	0.53	6.94	0.4	3.52e-11	Monocyte percentage of white cells;
KIRP	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.63	-7.77	-0.44	2.07e-13	Response to antipsychotic treatment;
KIRP	trans	rs2709736	0.815	rs7808965	chr7:20848979	T/C	cg15057250	chr1:40025415	LOC728448	0.51	6.35	0.38	1.03e-9	Bipolar I disorder;
KIRP	cis	rs7224685	0.501	rs2676276	chr17:3919981	C/T	cg21734707	chr17:3908241	ZZEF1	-0.66	-10.19	-0.54	1.44e-20	Type 2 diabetes;
KIRP	cis	rs112998813	0.737	rs7317406	chr13:114989584	G/A	cg19814280	chr13:114963695	NA	-0.6	-4.92	-0.3	1.6e-6	Nodular sclerosis Hodgkin lymphoma;
KIRP	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.9	14.71	0.68	1.44e-35	Menarche (age at onset);
KIRP	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg00343986	chr7:65444356	GUSB	-0.47	-5.84	-0.35	1.62e-8	Corneal structure;
KIRP	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.91	13.11	0.64	3.85e-30	Tonsillectomy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg02818811	chr12:75728458	GLIPR1L1	0.39	6.04	0.36	5.54e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2346160	0.867	rs206975	chr6:167690356	A/G	cg27333441	chr6:167680455	NA	-0.37	-5.15	-0.31	5.22e-7	Parental extreme longevity (95 years and older);
KIRP	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.5	6.13	0.36	3.39e-9	Menopause (age at onset);
KIRP	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.68	6.6	0.39	2.49e-10	Mean platelet volume;
KIRP	cis	rs4713675	0.584	rs3818527	chr6:33661035	A/G	cg15676125	chr6:33679581	C6orf125	-0.46	-6.15	-0.37	3.1e-9	Plateletcrit;
KIRP	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.36	5.18	0.31	4.64e-7	Lymphocyte counts;
KIRP	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.97	-15.04	-0.69	1.12e-36	Height;
KIRP	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.46	7.21	0.42	6.91e-12	Testicular germ cell tumor;
KIRP	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.02	17.17	0.74	5.87e-44	Multiple system atrophy;
KIRP	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.92	14.68	0.68	1.88e-35	Mean corpuscular volume;
KIRP	trans	rs2629046	0.817	rs2256727	chr2:225078351	A/G	cg06102602	chr12:96895446	NA	0.44	6.04	0.36	5.52e-9	Height;
KIRP	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.64	-0.34	4.57e-8	Bipolar disorder;
KIRP	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg12140854	chr5:148520817	ABLIM3	-0.42	-4.84	-0.3	2.25e-6	Breast cancer;
KIRP	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg05315796	chr3:52349193	DNAH1	0.4	5.19	0.31	4.35e-7	Schizophrenia;
KIRP	cis	rs853679	0.546	rs200952	chr6:27836976	C/T	cg21204522	chr6:27730016	NA	-0.72	-5.21	-0.32	4.04e-7	Depression;
KIRP	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.76	12.17	0.61	5.33e-27	Menarche (age at onset);
KIRP	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg01879757	chr17:41196368	BRCA1	-0.79	-11.24	-0.58	6.12e-24	Menopause (age at onset);
KIRP	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg05527609	chr1:210001259	C1orf107	-0.45	-5.48	-0.33	1.07e-7	Red blood cell count;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg00849435	chr19:14607052	GIPC1	0.47	6.11	0.36	3.79e-9	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg08761264	chr16:28874980	SH2B1	-0.46	-4.96	-0.3	1.32e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.56	8.14	0.46	2.04e-14	Huntington's disease progression;
KIRP	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg14650228	chr8:144573510	ZC3H3	-0.75	-5.36	-0.32	1.88e-7	Attention deficit hyperactivity disorder;
KIRP	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.67	-12.13	-0.61	7.38e-27	White blood cell count (basophil);
KIRP	cis	rs17023223	0.537	rs11487668	chr1:119726796	T/C	cg18261050	chr1:119551319	NA	0.5	6.42	0.38	6.84e-10	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg21775007	chr8:11205619	TDH	0.52	6.61	0.39	2.32e-10	Neuroticism;
KIRP	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg05347473	chr6:146136440	FBXO30	-0.46	-6.27	-0.37	1.65e-9	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7017914	0.934	rs7814274	chr8:71570411	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.39	4.91	0.3	1.66e-6	Bone mineral density;
KIRP	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.59	-6.4	-0.38	7.87e-10	Prostate cancer;
KIRP	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg10144569	chr3:42726640	KBTBD5	0.53	5.87	0.35	1.43e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg27452868	chr4:42342980	NA	0.44	6.35	0.38	1.04e-9	Survival in pancreatic cancer;
KIRP	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg04166393	chr7:2884313	GNA12	0.43	5.64	0.34	4.75e-8	Height;
KIRP	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg00677455	chr12:58241039	CTDSP2	-0.51	-5.75	-0.34	2.6e-8	Celiac disease or Rheumatoid arthritis;
KIRP	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-7.71	-0.44	3.18e-13	Body mass index;
KIRP	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.73	9.33	0.51	6.37e-18	Coronary artery disease;
KIRP	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg01346077	chr3:125931526	NA	0.54	8.63	0.48	7.83e-16	Plasma homocysteine levels (post-methionine load test);
KIRP	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18364779	chr6:26104403	HIST1H4C	-0.5	-5.41	-0.33	1.46e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg13789015	chr9:136890014	NCRNA00094	0.62	5.38	0.32	1.71e-7	Mosquito bite size;
KIRP	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg05490132	chr15:43661835	TUBGCP4;ZSCAN29	-0.43	-5.37	-0.32	1.84e-7	Lung cancer;
KIRP	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg15247329	chr7:2764246	NA	-0.39	-5.54	-0.33	7.71e-8	Height;
KIRP	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.42	-5.72	-0.34	3.07e-8	Refractive error;
KIRP	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.85	9.66	0.52	6.23e-19	High light scatter reticulocyte count;
KIRP	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.66	-7.54	-0.43	9.2e-13	Lung cancer;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg11881562	chr19:49633902	PPFIA3	-0.54	-7.21	-0.42	6.93e-12	Parkinson's disease;
KIRP	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg24296786	chr1:45957014	TESK2	0.51	5.69	0.34	3.65e-8	Homocysteine levels;
KIRP	trans	rs6601327	0.613	rs12677507	chr8:9481687	G/C	cg16141378	chr3:129829833	LOC729375	0.49	6.29	0.37	1.47e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.79	10.97	0.57	4.64e-23	Response to antipsychotic treatment;
KIRP	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg19336497	chr11:14380999	RRAS2	-0.33	-4.9	-0.3	1.7e-6	Mitochondrial DNA levels;
KIRP	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.46	4.88	0.3	1.91e-6	Obesity (extreme);
KIRP	cis	rs1656402	1.000	rs1729253	chr2:233428740	G/C	cg03852847	chr2:233439513	NA	0.72	12.18	0.61	5.04e-27	Non-small cell lung cancer (survival);
KIRP	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.75	6.66	0.39	1.8e-10	Diabetic retinopathy;
KIRP	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg04166393	chr7:2884313	GNA12	0.64	7.71	0.44	3.1e-13	Height;
KIRP	cis	rs10940138	0.774	rs16897196	chr5:67228478	G/C	ch.5.1281357F	chr5:67228439	NA	0.78	12.25	0.62	3.04e-27	Menarche (age at onset);
KIRP	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.54	5.94	0.35	9.46e-9	Bone mineral density (spine);
KIRP	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.77	9.36	0.51	5.4e-18	Multiple sclerosis;
KIRP	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.53	-6.83	-0.4	6.7e-11	Testicular germ cell tumor;
KIRP	cis	rs8014252	0.803	rs45523543	chr14:71051088	A/G	cg19730268	chr14:71022823	NA	-0.72	-6.4	-0.38	7.9e-10	Plasma estrone levels in resected estrogen-receptor positive breast cancer;
KIRP	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg19468946	chr17:37922297	IKZF3	-0.49	-7.0	-0.41	2.4e-11	Self-reported allergy;
KIRP	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.78	12.06	0.61	1.26e-26	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00149659	chr3:10157352	C3orf10	0.94	10.23	0.55	1.05e-20	Alzheimer's disease;
KIRP	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.65	9.76	0.53	3.19e-19	Schizophrenia;
KIRP	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg06558623	chr16:89946397	TCF25	1.02	8.74	0.49	3.8e-16	Skin colour saturation;
KIRP	cis	rs3789045	0.913	rs55678522	chr1:204573481	G/A	cg08641003	chr1:204589008	LRRN2	-0.57	-6.09	-0.36	4.24e-9	Educational attainment (college completion);
KIRP	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg11569703	chr11:65557185	OVOL1	0.6	10.49	0.56	1.64e-21	Acne (severe);
KIRP	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.49	-8.0	-0.45	4.97e-14	Height;
KIRP	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.67	-9.52	-0.52	1.74e-18	Colorectal cancer;
KIRP	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg17133734	chr15:86042851	AKAP13	-0.47	-5.86	-0.35	1.47e-8	Coronary artery disease;
KIRP	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.74	10.96	0.57	5.16e-23	Height;
KIRP	trans	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.45	-6.04	-0.36	5.59e-9	Endometrial cancer;
KIRP	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.65	-5.59	-0.34	5.96e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg09655341	chr17:79618100	PDE6G	-0.34	-5.56	-0.33	6.92e-8	Eye color traits;
KIRP	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	9.51	0.52	1.87e-18	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg26384229	chr12:38710491	ALG10B	0.54	7.16	0.42	9.1e-12	Morning vs. evening chronotype;
KIRP	cis	rs71277158	0.688	rs17236830	chr3:169891246	G/A	cg04067573	chr3:169899625	PHC3	0.66	6.27	0.37	1.6e-9	Prostate cancer;
KIRP	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24838063	chr12:130822603	PIWIL1	0.52	6.19	0.37	2.52e-9	Menopause (age at onset);
KIRP	cis	rs9853921	0.609	rs11710953	chr3:117989753	C/G	cg15509235	chr3:117715573	NA	0.33	5.1	0.31	6.87e-7	JT interval (sulfonylurea treatment interaction);
KIRP	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg16558253	chr16:72132732	DHX38	-0.48	-6.72	-0.39	1.23e-10	Fibrinogen levels;
KIRP	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg01420254	chr6:26195488	NA	1.17	8.86	0.49	1.63e-16	Iron status biomarkers (total iron binding capacity);
KIRP	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	5.39	0.33	1.65e-7	Height;
KIRP	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.44	-5.59	-0.34	6.13e-8	Aortic root size;
KIRP	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.55	7.59	0.44	6.43e-13	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs12580194	0.593	rs79104523	chr12:55749220	T/C	cg19537932	chr12:55886519	OR6C68	-0.47	-6.29	-0.37	1.44e-9	Cancer;
KIRP	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.6	5.76	0.34	2.52e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg04780086	chr2:111875790	ACOXL	0.47	6.53	0.38	3.81e-10	Chronic lymphocytic leukemia;
KIRP	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg03289416	chr15:75166202	SCAMP2	0.58	8.25	0.47	9.6e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
KIRP	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg19000871	chr14:103996768	TRMT61A	0.43	5.49	0.33	9.76e-8	Coronary artery disease;
KIRP	cis	rs2191566	0.576	rs420355	chr19:44495325	C/T	cg18700516	chr19:44507157	ZNF230	0.42	4.85	0.3	2.23e-6	Acute lymphoblastic leukemia (childhood);
KIRP	trans	rs1317830	0.603	rs4377609	chr4:34878532	A/G	cg09864156	chr10:70939728	SUPV3L1	0.54	6.66	0.39	1.81e-10	Body mass index in non-asthmatics;
KIRP	trans	rs7939886	0.920	rs17145425	chr11:55950030	A/G	cg03929089	chr4:120376271	NA	0.94	6.47	0.38	5.23e-10	Myopia (pathological);
KIRP	cis	rs58649573	0.530	rs7049026	chr9:126786918	A/C	cg14112217	chr9:126806003	NA	0.36	5.16	0.31	5.09e-7	Post-traumatic stress disorder;
KIRP	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00585698	chr12:123750864	CDK2AP1	-0.49	-6.26	-0.37	1.71e-9	Neutrophil percentage of white cells;
KIRP	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.58	-7.52	-0.43	1.04e-12	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.79	-10.73	-0.56	2.83e-22	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	0.45	6.3	0.37	1.39e-9	Mean corpuscular hemoglobin concentration;
KIRP	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg13010199	chr12:38710504	ALG10B	0.5	6.43	0.38	6.5e-10	Morning vs. evening chronotype;
KIRP	cis	rs4453791	1.000	rs11927309	chr3:38935115	C/T	cg23654821	chr3:39188656	CSRNP1	0.48	4.89	0.3	1.84e-6	Social communication problems;
KIRP	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	7.91	0.45	8.73e-14	IgG glycosylation;
KIRP	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.51	-5.32	-0.32	2.34e-7	Corneal structure;
KIRP	cis	rs1448094	0.690	rs7132879	chr12:86289864	A/G	cg02569458	chr12:86230093	RASSF9	0.37	5.41	0.33	1.46e-7	Major depressive disorder;
KIRP	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.9	-13.02	-0.64	7.8e-30	Diastolic blood pressure;Systolic blood pressure;
KIRP	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.91	-0.53	1.06e-19	Neuroticism;
KIRP	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg16989719	chr2:238392110	NA	-0.57	-6.33	-0.37	1.18e-9	Prostate cancer;
KIRP	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.43	5.6	0.34	5.58e-8	Calcium levels;
KIRP	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg20935368	chr5:178288625	ZNF354B	0.42	5.68	0.34	3.71e-8	Sleep duration;
KIRP	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06481639	chr22:41940642	POLR3H	0.75	7.72	0.44	2.84e-13	Vitiligo;
KIRP	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	cg12689670	chr1:183009347	LAMC1	0.56	7.9	0.45	9.42e-14	Fuchs's corneal dystrophy;
KIRP	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.53	-5.63	-0.34	4.96e-8	Depression;
KIRP	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.58	-7.15	-0.42	9.59e-12	Diastolic blood pressure;
KIRP	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.74	11.18	0.58	9.91e-24	Lewy body disease;
KIRP	cis	rs829883	0.621	rs11109516	chr12:98921035	G/A	cg25150519	chr12:98850993	NA	-0.77	-9.31	-0.51	7.25e-18	Colorectal adenoma (advanced);
KIRP	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.47	-7.14	-0.41	1.05e-11	Vitamin D levels;
KIRP	cis	rs6062509	0.965	rs2315007	chr20:62343845	T/C	cg11503966	chr20:62272292	STMN3	0.33	5.0	0.3	1.08e-6	Prostate cancer;
KIRP	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg05938607	chr10:60274200	BICC1	0.44	10.69	0.56	3.62e-22	Refractive error;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg18905855	chr11:67195993	RPS6KB2	0.5	6.61	0.39	2.31e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs6032067	0.925	rs35751129	chr20:43847658	C/A	cg10761708	chr20:43804764	PI3	0.52	5.3	0.32	2.59e-7	Blood protein levels;
KIRP	cis	rs2071403	0.933	rs11900674	chr2:1406538	G/A	cg06500727	chr2:1417164	TPO	0.49	7.78	0.44	2.04e-13	Thyroid peroxidase antibody positivity;
KIRP	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	0.38	5.01	0.3	1.02e-6	Acne (severe);
KIRP	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.65	7.66	0.44	4.33e-13	Obesity-related traits;
KIRP	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg23307798	chr14:103986281	CKB	0.49	6.66	0.39	1.82e-10	Coronary artery disease;
KIRP	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg08975724	chr8:8085496	FLJ10661	0.53	7.02	0.41	2.18e-11	Retinal vascular caliber;
KIRP	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg00262122	chr8:11665843	FDFT1	-0.4	-4.95	-0.3	1.39e-6	Neuroticism;
KIRP	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg16077055	chr2:106428750	NCK2	0.28	5.74	0.34	2.85e-8	Addiction;
KIRP	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	cg21523751	chr1:182988639	NA	0.41	6.48	0.38	5.08e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15557168	chr22:42548783	NA	-0.42	-5.51	-0.33	9.07e-8	Cognitive function;
KIRP	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg00343986	chr7:65444356	GUSB	0.39	4.87	0.3	2.02e-6	Aortic root size;
KIRP	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg01338084	chr22:32026380	PISD	1.13	7.72	0.44	2.99e-13	Age-related hearing impairment;
KIRP	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg10117171	chr1:25599238	RHD	-0.42	-5.68	-0.34	3.85e-8	Erythrocyte sedimentation rate;
KIRP	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg19847866	chr10:1019161	NA	-0.65	-5.92	-0.35	1.07e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.53	7.32	0.42	3.56e-12	Mean corpuscular volume;
KIRP	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.53	-6.76	-0.4	1.01e-10	Autism;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg22463117	chr5:100221865	ST8SIA4	-0.42	-6.61	-0.39	2.34e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.27	16.94	0.73	3.39e-43	Corneal structure;
KIRP	cis	rs4926298	1.000	rs4926298	chr19:13153035	C/T	cg06417478	chr19:12876846	HOOK2	-0.41	-5.03	-0.31	9.59e-7	Bipolar disorder;
KIRP	trans	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg03929089	chr4:120376271	NA	-0.67	-6.06	-0.36	5.19e-9	Axial length;
KIRP	trans	rs7403037	0.550	rs61993575	chr15:24644185	C/T	cg00996262	chr17:7554930	ATP1B2	0.6	6.14	0.36	3.2e-9	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
KIRP	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22878388	chr2:105853796	NA	-0.43	-6.87	-0.4	5.31e-11	Type 2 diabetes;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg19526908	chr3:49058333	NDUFAF3;DALRD3;MIR425;MIR191	0.54	6.58	0.39	2.83e-10	Parkinson's disease;
KIRP	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.68	9.39	0.51	4.3e-18	Colorectal cancer;
KIRP	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.54	-6.8	-0.4	8.1e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
KIRP	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg08662619	chr6:150070041	PCMT1	0.33	5.34	0.32	2.08e-7	Testicular germ cell tumor;
KIRP	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg11846333	chr4:119757529	SEC24D	1.19	7.12	0.41	1.17e-11	Cannabis dependence symptom count;
KIRP	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.77	5.98	0.36	7.94e-9	Developmental language disorder (linguistic errors);
KIRP	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.52	6.25	0.37	1.76e-9	Mean platelet volume;
KIRP	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg23307798	chr14:103986281	CKB	-0.5	-6.72	-0.39	1.23e-10	Coronary artery disease;
KIRP	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg04226714	chr8:49833948	SNAI2	-0.49	-6.71	-0.39	1.32e-10	Life satisfaction;
KIRP	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg16179182	chr5:140090404	VTRNA1-1	-0.49	-6.47	-0.38	5.19e-10	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg10755058	chr3:40428713	ENTPD3	0.42	5.72	0.34	3.15e-8	Renal cell carcinoma;
KIRP	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg21827317	chr3:136751795	NA	0.37	5.12	0.31	6.29e-7	Neuroticism;
KIRP	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.93	15.16	0.69	4.16e-37	Bone mineral density;
KIRP	trans	rs6764132	1	rs6764132	chr3:39788891	A/G	cg17192681	chr2:10953115	PDIA6	-1.22	-6.95	-0.41	3.2e-11	Thrombomodulin levels in ischemic stroke;
KIRP	cis	rs7630877	0.886	rs41265425	chr3:179605647	C/A	cg18765712	chr3:179670323	PEX5L	0.56	6.7	0.39	1.4e-10	Type 2 diabetes;
KIRP	trans	rs77948430	0.881	rs17190515	chr8:13124350	G/T	cg13546538	chr9:111754815	CTNNAL1	-0.59	-6.4	-0.38	7.68e-10	Itch intensity from mosquito bite adjusted by bite size;
KIRP	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.66	-9.22	-0.51	1.42e-17	Intelligence (multi-trait analysis);
KIRP	cis	rs7267005	1.000	rs112739030	chr20:34453647	T/C	cg17201900	chr20:34330562	RBM39	0.92	5.05	0.31	8.46e-7	Response to paliperidone in schizophrenia (Multivariate);
KIRP	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.64	9.54	0.52	1.51e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
KIRP	cis	rs687432	0.885	rs36071925	chr11:57804427	A/G	cg19752551	chr11:57585705	CTNND1	-0.69	-9.0	-0.5	6.47e-17	Parkinson's disease;
KIRP	cis	rs6832769	1.000	rs3805157	chr4:56364103	A/G	cg05960024	chr4:56376020	CLOCK	0.63	8.07	0.46	3.21e-14	Personality dimensions;
KIRP	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.5	6.48	0.38	4.99e-10	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs3779635	0.742	rs2059969	chr8:27259230	A/C	cg14221460	chr8:27183342	PTK2B	0.5	6.61	0.39	2.36e-10	Neuroticism;
KIRP	cis	rs7212590	0.618	rs59767604	chr17:58041339	C/G	cg10252138	chr17:58120427	NA	-0.67	-5.48	-0.33	1.05e-7	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
KIRP	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.55	7.35	0.42	2.99e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg22532475	chr10:104410764	TRIM8	-0.31	-4.99	-0.3	1.16e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
KIRP	cis	rs4356932	0.935	rs4406046	chr4:76969955	A/G	cg19388996	chr4:76862389	NAAA	0.39	4.98	0.3	1.19e-6	Blood protein levels;
KIRP	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.42	-4.97	-0.3	1.28e-6	Myopia;
KIRP	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.47	6.48	0.38	4.98e-10	Neuroticism;
KIRP	cis	rs7402982	0.625	rs12905392	chr15:99199212	G/A	cg03437748	chr15:99193247	IGF1R	0.78	9.49	0.52	2.13e-18	Birth weight;
KIRP	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg16111737	chr12:117408163	FBXW8	-0.53	-5.17	-0.31	4.88e-7	Subcortical brain region volumes;Hippocampal volume;
KIRP	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	1.0	17.43	0.74	7.3e-45	Breast cancer;
KIRP	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg05484376	chr2:27715224	FNDC4	0.33	5.17	0.31	4.86e-7	Total body bone mineral density;
KIRP	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	8.21	0.46	1.22e-14	IgG glycosylation;
KIRP	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.61	-9.57	-0.52	1.19e-18	Sense of smell;
KIRP	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg01304814	chr3:48885189	PRKAR2A	0.55	5.06	0.31	8.14e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg05756136	chr1:119680316	WARS2	-0.62	-8.41	-0.47	3.43e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.68	-7.04	-0.41	1.88e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.51	7.22	0.42	6.47e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
KIRP	cis	rs17030434	0.813	rs11732480	chr4:154665733	C/A	cg14289246	chr4:154710475	SFRP2	-0.74	-8.74	-0.49	3.59e-16	Electrocardiographic conduction measures;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg14012233	chr17:27276799	PHF12	0.49	6.32	0.37	1.22e-9	Parkinson's disease;
KIRP	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	10.31	0.55	6.2e-21	Parkinson's disease;
KIRP	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.76	11.09	0.58	1.85e-23	Huntington's disease progression;
KIRP	cis	rs4006360	0.537	rs12602811	chr17:39245273	C/T	cg25341923	chr17:39239918	KRTAP4-7	-0.64	-9.83	-0.53	1.88e-19	Bipolar disorder and schizophrenia;
KIRP	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg05526886	chr2:227700861	RHBDD1	-0.43	-5.11	-0.31	6.61e-7	Pulmonary function;
KIRP	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg20243544	chr17:37824526	PNMT	0.52	7.5	0.43	1.13e-12	Asthma;
KIRP	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.38	4.87	0.3	2.02e-6	Reticulocyte fraction of red cells;
KIRP	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg00343127	chr12:129299088	SLC15A4;MGC16384	0.57	7.45	0.43	1.57e-12	Systemic lupus erythematosus;
KIRP	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.99	18.03	0.75	6.89e-47	Birth weight;
KIRP	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg19454999	chr17:41278357	BRCA1;NBR2	0.56	6.18	0.37	2.7e-9	Menopause (age at onset);
KIRP	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.76	10.72	0.56	3.02e-22	Red blood cell count;
KIRP	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg24296786	chr1:45957014	TESK2	0.49	5.59	0.34	5.88e-8	Homocysteine levels;
KIRP	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.56	8.18	0.46	1.53e-14	Immature fraction of reticulocytes;
KIRP	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg00277334	chr10:82204260	NA	-0.46	-5.41	-0.33	1.48e-7	Post bronchodilator FEV1;
KIRP	cis	rs909341	0.909	rs2750480	chr20:62342654	G/A	cg11503966	chr20:62272292	STMN3	-0.42	-5.77	-0.35	2.32e-8	Atopic dermatitis;
KIRP	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg15655495	chr12:38532458	NA	-0.27	-5.17	-0.31	4.92e-7	Bladder cancer;
KIRP	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg01879757	chr17:41196368	BRCA1	-0.73	-10.42	-0.55	2.74e-21	Menopause (age at onset);
KIRP	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.89	14.27	0.67	4.54e-34	Prostate cancer;
KIRP	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.43	-6.14	-0.36	3.29e-9	Mean corpuscular volume;
KIRP	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg16606324	chr3:10149918	C3orf24	0.56	5.25	0.32	3.27e-7	Alzheimer's disease;
KIRP	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	10.05	0.54	3.93e-20	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.45	-10.04	-0.54	4.16e-20	Alzheimer's disease (late onset);
KIRP	cis	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg06521331	chr12:34319734	NA	-0.62	-7.33	-0.42	3.23e-12	Morning vs. evening chronotype;
KIRP	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg06637938	chr14:75390232	RPS6KL1	0.49	6.87	0.4	5.23e-11	Height;
KIRP	cis	rs2274273	0.588	rs11158037	chr14:55832152	C/A	cg04306507	chr14:55594613	LGALS3	0.37	5.14	0.31	5.51e-7	Protein biomarker;
KIRP	cis	rs904251	0.600	rs1874736	chr6:37447994	C/G	cg25019722	chr6:37503610	NA	-0.89	-13.09	-0.64	4.49e-30	Cognitive performance;
KIRP	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg13012494	chr21:47604986	C21orf56	-0.38	-4.88	-0.3	1.89e-6	Testicular germ cell tumor;
KIRP	cis	rs10411936	0.712	rs8100755	chr19:16593415	G/A	cg10248733	chr19:16607483	C19orf44;CALR3	0.5	5.31	0.32	2.42e-7	White blood cell count;Multiple sclerosis;
KIRP	cis	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg21775007	chr8:11205619	TDH	0.45	5.97	0.36	8.38e-9	Retinal vascular caliber;
KIRP	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg25007680	chr1:8021821	PARK7	0.64	8.9	0.49	1.22e-16	Response to antidepressants and depression;
KIRP	cis	rs62070183	0.766	rs62067160	chr17:31246585	T/C	cg05781649	chr17:31146240	MYO1D	-0.5	-4.93	-0.3	1.54e-6	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs4262150	0.693	rs11746770	chr5:152313004	C/T	cg12297329	chr5:152029980	NA	0.47	6.67	0.39	1.64e-10	Bipolar disorder and schizophrenia;
KIRP	cis	rs282587	0.569	rs409896	chr13:113400338	G/T	cg04656015	chr13:113407548	ATP11A	0.65	7.27	0.42	4.8e-12	Glycated hemoglobin levels;
KIRP	cis	rs6832769	0.922	rs28665088	chr4:56251080	A/G	cg05960024	chr4:56376020	CLOCK	0.63	7.75	0.44	2.48e-13	Personality dimensions;
KIRP	cis	rs830383	0.630	rs251793	chr5:165450683	A/G	cg13976338	chr5:165423657	NA	-0.49	-6.15	-0.37	3.07e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs62384625	0.893	rs72799903	chr5:141492061	G/A	cg08523384	chr5:141488047	NDFIP1	-0.36	-5.05	-0.31	8.64e-7	White blood cell count (basophil);
KIRP	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg23166289	chr1:210001082	C1orf107	0.41	5.08	0.31	7.56e-7	Orofacial clefts;
KIRP	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.01	15.26	0.7	1.9e-37	Orofacial clefts;
KIRP	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-8.05	-0.46	3.55e-14	Morning vs. evening chronotype;
KIRP	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg24315340	chr6:146058215	EPM2A	0.44	5.54	0.33	7.72e-8	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg06671706	chr8:8559999	CLDN23	0.56	6.28	0.37	1.5e-9	Obesity-related traits;
KIRP	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.9	-12.46	-0.62	5.9e-28	Platelet distribution width;
KIRP	cis	rs9535307	0.584	rs61961502	chr13:50393700	G/A	cg04663916	chr13:50265991	EBPL	-0.57	-5.56	-0.33	7e-8	Obesity-related traits;
KIRP	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg21475434	chr5:93447410	FAM172A	-0.46	-5.13	-0.31	5.92e-7	Diabetic retinopathy;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg04563119	chr4:177190421	ASB5	-0.4	-6.19	-0.37	2.52e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs10465746	0.967	rs12759527	chr1:84434425	T/C	cg10977910	chr1:84465055	TTLL7	0.48	5.84	0.35	1.61e-8	Obesity-related traits;
KIRP	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg12384639	chr17:618140	VPS53	0.49	6.01	0.36	6.52e-9	Prostate cancer;
KIRP	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13939156	chr17:80058883	NA	-0.5	-7.61	-0.44	5.97e-13	Life satisfaction;
KIRP	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.61	7.35	0.42	2.87e-12	Sum neutrophil eosinophil counts;
KIRP	cis	rs963731	0.649	rs2278912	chr2:39199702	C/T	cg04010122	chr2:39346883	SOS1	-0.88	-5.84	-0.35	1.67e-8	Corticobasal degeneration;
KIRP	cis	rs959260	1.000	rs9909076	chr17:73384809	G/T	cg20590849	chr17:73267439	MIF4GD	-0.59	-6.34	-0.37	1.08e-9	Systemic lupus erythematosus;
KIRP	cis	rs1468333	1.000	rs7729926	chr5:137514641	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.45	5.18	0.31	4.57e-7	Resting heart rate;
KIRP	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.38	5.17	0.31	4.76e-7	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg04332513	chr3:122135059	WDR5B	0.5	6.22	0.37	2.07e-9	Parkinson's disease;
KIRP	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg17182837	chr8:41585554	ANK1	0.54	5.78	0.35	2.29e-8	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
KIRP	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg10360139	chr7:1886902	MAD1L1	-0.45	-4.93	-0.3	1.53e-6	Bipolar disorder and schizophrenia;
KIRP	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg21926883	chr2:100939477	LONRF2	-0.64	-8.75	-0.49	3.48e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs2371030	0.833	rs1024898	chr2:211593520	A/G	cg18417063	chr2:211583084	NA	-0.45	-6.23	-0.37	2.02e-9	Non-small cell lung cancer;
KIRP	cis	rs6032067	1.000	rs6032067	chr20:43864809	G/T	cg10761708	chr20:43804764	PI3	0.53	5.39	0.33	1.61e-7	Blood protein levels;
KIRP	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg18404041	chr3:52824283	ITIH1	-0.45	-5.72	-0.34	3.01e-8	Schizophrenia;
KIRP	cis	rs7011049	1.000	rs11997775	chr8:53833571	C/T	cg26025543	chr8:53854495	NA	-0.68	-7.3	-0.42	3.96e-12	Systolic blood pressure;
KIRP	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg01557791	chr16:72042693	DHODH	-0.72	-9.21	-0.51	1.51e-17	Fibrinogen levels;
KIRP	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-6.2	-0.37	2.42e-9	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-13.28	-0.65	1.01e-30	Heart rate;
KIRP	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg22800045	chr5:56110881	MAP3K1	0.82	8.73	0.49	3.89e-16	Initial pursuit acceleration;
KIRP	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.74	8.46	0.47	2.45e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg15117754	chr3:10150083	C3orf24	0.62	5.09	0.31	7.01e-7	Alzheimer's disease;
KIRP	trans	rs1462872	0.669	rs448423	chr8:31791401	A/T	cg01557648	chr19:51142883	SYT3	0.95	6.02	0.36	6.15e-9	Coronary artery calcification;
KIRP	cis	rs9488822	0.662	rs536160	chr6:116267166	T/C	cg18764771	chr6:116381957	FRK	-0.18	-5.08	-0.31	7.52e-7	Cholesterol, total;LDL cholesterol;
KIRP	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.81	-10.2	-0.55	1.3e-20	Blood protein levels;
KIRP	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.55	-8.82	-0.49	2.19e-16	Trans fatty acid levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10209635	chr21:37692467	MORC3	0.49	6.25	0.37	1.77e-9	Parkinson's disease;
KIRP	trans	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg26518628	chr1:97050305	NA	-0.79	-6.04	-0.36	5.74e-9	Cannabis dependence symptom count;
KIRP	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg19336497	chr11:14380999	RRAS2	0.36	5.12	0.31	6.29e-7	Mitochondrial DNA levels;
KIRP	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.82	12.3	0.62	2.06e-27	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7119038	0.774	rs73005423	chr11:118681079	A/G	cg19308663	chr11:118741387	NA	0.58	9.64	0.52	7.25e-19	Sjögren's syndrome;
KIRP	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.78	-11.06	-0.58	2.36e-23	Height;
KIRP	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.97	8.01	0.45	4.66e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.42	-5.54	-0.33	7.84e-8	Body mass index;
KIRP	trans	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg06521331	chr12:34319734	NA	-0.58	-7.08	-0.41	1.54e-11	Bladder cancer;
KIRP	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.74	9.05	0.5	4.56e-17	Corneal astigmatism;
KIRP	trans	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg24644049	chr4:85504048	CDS1	1.05	7.45	0.43	1.56e-12	Skin colour saturation;
KIRP	cis	rs362272	0.525	rs2471347	chr4:3044435	A/G	cg14003022	chr4:3043019	NA	0.36	4.92	0.3	1.57e-6	Serum sulfate level;
KIRP	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-12.72	-0.63	7.93e-29	Chronic sinus infection;
KIRP	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg00106254	chr7:1943704	MAD1L1	-0.54	-5.95	-0.35	9.34e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg14972814	chr11:95582409	MTMR2	0.29	5.04	0.31	9.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
KIRP	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg23791538	chr6:167370224	RNASET2	-0.49	-5.5	-0.33	9.59e-8	Crohn's disease;
KIRP	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	10.71	0.56	3.15e-22	Total body bone mineral density;
KIRP	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-5.83	-0.35	1.72e-8	Educational attainment;
KIRP	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.77	10.4	0.55	3.12e-21	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.72	-6.18	-0.37	2.66e-9	Schizophrenia;
KIRP	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.87	13.23	0.64	1.58e-30	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.92	10.34	0.55	4.67e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10093031	chr22:50964219	TYMP;SCO2	0.5	6.13	0.36	3.55e-9	Parkinson's disease;
KIRP	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.72	10.21	0.55	1.23e-20	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg26721694	chr19:581428	BSG	0.48	6.23	0.37	1.96e-9	Age-related hearing impairment (SNP x SNP interaction);
KIRP	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg00806126	chr19:22604979	ZNF98	0.67	6.95	0.41	3.26e-11	Pain;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg15312498	chr8:116276590	NA	-0.44	-6.92	-0.4	3.84e-11	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg07395648	chr5:131743802	NA	0.51	6.08	0.36	4.68e-9	Lymphocyte counts;Fibrinogen;
KIRP	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.69	9.17	0.5	1.91e-17	Morning vs. evening chronotype;
KIRP	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg24626310	chr20:25276739	ABHD12;PYGB	0.47	6.01	0.36	6.67e-9	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	7.92	0.45	8e-14	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-7.14	-0.41	1.06e-11	Vitiligo;
KIRP	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.63	7.67	0.44	3.93e-13	Tonsillectomy;
KIRP	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.65	-9.31	-0.51	7.25e-18	Retinal vascular caliber;
KIRP	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.05	0.31	8.53e-7	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs860295	0.702	rs3738590	chr1:155630752	A/G	cg02153340	chr1:155202674	NA	-0.5	-6.7	-0.39	1.43e-10	Body mass index;
KIRP	cis	rs28489187	0.756	rs233047	chr1:85830570	G/A	cg16011679	chr1:85725395	C1orf52	0.52	6.36	0.38	9.97e-10	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
KIRP	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.42	-5.26	-0.32	3.2e-7	Aortic root size;
KIRP	cis	rs35740288	0.895	rs3743332	chr15:86303751	T/C	cg17133734	chr15:86042851	AKAP13	-0.49	-5.35	-0.32	2.03e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
KIRP	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg21497246	chr14:78225524	SNW1;C14orf178	-0.5	-4.99	-0.3	1.14e-6	Fibroblast growth factor basic levels;
KIRP	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.43	8.07	0.46	3.11e-14	Educational attainment (years of education);
KIRP	cis	rs11255291	1.000	rs7917456	chr10:7732323	A/G	cg26051552	chr10:7670683	ITIH5	0.41	5.26	0.32	3.19e-7	Ovarian reserve;
KIRP	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg16989719	chr2:238392110	NA	-0.61	-6.18	-0.37	2.68e-9	Prostate cancer;
KIRP	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg22153745	chr1:153894579	GATAD2B	-0.58	-6.21	-0.37	2.22e-9	Total cholesterol levels;
KIRP	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg03645007	chr3:50255295	SLC38A3	0.37	4.9	0.3	1.76e-6	Schizophrenia;
KIRP	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg00319359	chr11:70116639	PPFIA1	0.58	6.01	0.36	6.65e-9	Coronary artery disease;
KIRP	cis	rs4006360	0.547	rs9901868	chr17:39232963	A/G	cg15015397	chr17:39261100	KRTAP4-9	-0.51	-7.83	-0.45	1.45e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg24550644	chr17:30846204	MYO1D	-0.29	-5.47	-0.33	1.09e-7	Schizophrenia;
KIRP	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-6.51	-0.38	4.13e-10	Bipolar disorder;
KIRP	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.67	7.1	0.41	1.32e-11	Lymphocyte counts;
KIRP	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-7.3	-0.42	3.94e-12	Bipolar disorder;
KIRP	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg23625390	chr15:77176239	SCAPER	0.56	7.45	0.43	1.54e-12	Blood metabolite levels;
KIRP	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.14	-17.74	-0.75	6.66e-46	Ulcerative colitis;
KIRP	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg18105134	chr13:113819100	PROZ	0.69	7.68	0.44	3.76e-13	Blood protein levels;
KIRP	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.54	-6.48	-0.38	4.92e-10	Metabolite levels;
KIRP	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	6.81	0.4	7.48e-11	Menarche (age at onset);
KIRP	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg20255370	chr15:40268687	EIF2AK4	0.5	5.9	0.35	1.17e-8	Corneal curvature;
KIRP	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg23335576	chr14:104009727	NA	0.36	5.0	0.3	1.1e-6	Body mass index;
KIRP	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.06	-17.33	-0.74	1.66e-44	Schizophrenia;
KIRP	cis	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg21204522	chr6:27730016	NA	-0.74	-5.57	-0.33	6.83e-8	Breast cancer;
KIRP	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.82	10.77	0.57	2.06e-22	Myeloid white cell count;
KIRP	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.6	7.81	0.45	1.61e-13	Pulse pressure;
KIRP	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg24488311	chr11:68621650	NA	0.42	5.33	0.32	2.21e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg13409248	chr3:40428643	ENTPD3	0.38	5.12	0.31	6.14e-7	Renal cell carcinoma;
KIRP	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg05785598	chr3:49045655	WDR6	0.32	5.8	0.35	2.06e-8	Parkinson's disease;
KIRP	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.57	-7.01	-0.41	2.23e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
KIRP	cis	rs12311304	0.901	rs12579002	chr12:15409959	A/G	cg08258403	chr12:15378311	NA	0.39	5.75	0.34	2.6e-8	Behavioural disinhibition (generation interaction);
KIRP	trans	rs7448169	1.000	rs1161252	chr5:99127127	A/C	cg03533382	chr5:126853128	PRRC1	0.51	6.27	0.37	1.6e-9	Peripheral arterial disease (traffic-related air pollution interaction);
KIRP	cis	rs17221829	0.528	rs4561217	chr11:89375265	T/C	cg02982614	chr11:89391479	FOLH1B	-0.3	-4.91	-0.3	1.64e-6	Anxiety in major depressive disorder;
KIRP	cis	rs17023223	0.581	rs2765529	chr1:119581900	C/T	cg18261050	chr1:119551319	NA	0.52	6.97	0.41	2.84e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
KIRP	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg01304814	chr3:48885189	PRKAR2A	0.62	5.29	0.32	2.72e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
KIRP	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg02012338	chr4:187126139	CYP4V2	0.89	7.65	0.44	4.65e-13	Blood protein levels;
KIRP	cis	rs7225151	0.710	rs16954548	chr17:5251671	A/G	cg24500398	chr17:5266808	RABEP1	-0.54	-5.46	-0.33	1.17e-7	Alzheimer's disease (late onset);
KIRP	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg11161011	chr14:65562177	MAX	-0.49	-6.15	-0.37	3.09e-9	Obesity-related traits;
KIRP	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-6.31	-0.37	1.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
KIRP	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg08890418	chr1:21044141	KIF17	0.36	5.38	0.32	1.71e-7	Superior frontal gyrus grey matter volume;
KIRP	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg18586891	chr4:952366	TMEM175	0.63	5.66	0.34	4.22e-8	Parkinson's disease;
KIRP	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg04691961	chr3:161091175	C3orf57	-0.36	-5.25	-0.32	3.24e-7	Kawasaki disease;
KIRP	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg21605333	chr4:119757512	SEC24D	1.66	12.15	0.61	6.56e-27	Cannabis dependence symptom count;
KIRP	cis	rs9853921	0.588	rs1566418	chr3:117988169	A/G	cg15509235	chr3:117715573	NA	-0.33	-5.06	-0.31	8.41e-7	JT interval (sulfonylurea treatment interaction);
KIRP	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg08198773	chr8:1697536	NA	0.51	6.25	0.37	1.76e-9	Systolic blood pressure;
KIRP	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.59	-8.15	-0.46	1.81e-14	Breast cancer;
KIRP	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	0.5	9.04	0.5	4.84e-17	QRS complex (12-leadsum);
KIRP	cis	rs2249694	0.520	rs7095379	chr10:135328532	C/T	cg20169779	chr10:135381914	SYCE1	-0.56	-6.24	-0.37	1.85e-9	Obesity-related traits;
KIRP	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.74	10.35	0.55	4.48e-21	Diastolic blood pressure;
KIRP	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.14	21.52	0.81	1.78e-58	Prudent dietary pattern;
KIRP	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg02038168	chr22:39784481	NA	-0.44	-5.12	-0.31	6.24e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.92	13.45	0.65	2.82e-31	Bladder cancer;
KIRP	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.37	6.72	0.39	1.29e-10	Refractive error;
KIRP	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg18306943	chr3:40428807	ENTPD3	-0.44	-6.16	-0.37	2.96e-9	Renal cell carcinoma;
KIRP	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07080220	chr10:102295463	HIF1AN	0.78	7.43	0.43	1.83e-12	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-8.82	-0.49	2.11e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.52	-7.49	-0.43	1.24e-12	Daytime sleep phenotypes;
KIRP	cis	rs1978968	0.701	rs9618179	chr22:18476909	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.53	-6.84	-0.4	6.22e-11	Presence of antiphospholipid antibodies;
KIRP	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg01721255	chr8:58191610	C8orf71	0.54	5.51	0.33	9.08e-8	Developmental language disorder (linguistic errors);
KIRP	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg23594656	chr7:65796392	TPST1	0.37	5.28	0.32	2.86e-7	Aortic root size;
KIRP	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg19847130	chr8:10466454	RP1L1	0.35	5.03	0.31	9.65e-7	Retinal vascular caliber;
KIRP	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg00405596	chr8:11794950	NA	-0.42	-5.37	-0.32	1.8e-7	Morning vs. evening chronotype;
KIRP	cis	rs2117029	0.553	rs2162644	chr12:49548190	G/A	cg24176009	chr12:49580217	TUBA1A	-0.36	-4.89	-0.3	1.82e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7084402	0.967	rs1649074	chr10:60295342	T/G	cg05938607	chr10:60274200	BICC1	-0.43	-10.36	-0.55	4.14e-21	Refractive error;
KIRP	cis	rs41264869	0.600	rs73083129	chr1:205186206	T/C	cg21643547	chr1:205240462	TMCC2	0.41	5.42	0.33	1.44e-7	Blood protein levels;
KIRP	cis	rs172166	0.637	rs1071893	chr6:28167635	G/C	cg23161317	chr6:28129485	ZNF389	0.41	5.07	0.31	7.7300000000000005e-07	Cardiac Troponin-T levels;
KIRP	cis	rs2410601	0.562	rs13275125	chr8:18898352	T/A	cg03215416	chr8:18823341	PSD3	-0.38	-5.01	-0.3	1.03e-6	Urinary albumin excretion rate in type 1 diabetes;
KIRP	trans	rs2150462	0.508	rs6475737	chr9:23353924	A/G	cg00873521	chr9:95056130	IARS;SNORA84	-0.55	-7.17	-0.42	8.55e-12	Neuroticism;
KIRP	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.85	12.02	0.61	1.69e-26	Ileal carcinoids;
KIRP	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12893428	chr3:195717962	SDHAP1	0.41	5.15	0.31	5.23e-7	Pancreatic cancer;
KIRP	cis	rs2014572	0.967	rs8100154	chr19:57765432	A/G	cg24459738	chr19:57751996	ZNF805	-0.58	-7.27	-0.42	4.74e-12	Hyperactive-impulsive symptoms;
KIRP	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03334568	chr3:101395165	ZBTB11;LOC100009676	-0.46	-5.49	-0.33	9.99e-8	Colorectal cancer;
KIRP	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.18	-0.61	5.18e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg09473613	chr1:24152604	HMGCL	0.42	5.18	0.31	4.52e-7	Immature fraction of reticulocytes;
KIRP	cis	rs1829883	0.717	rs1892944	chr5:98886316	A/G	cg08333243	chr5:99726346	NA	-0.43	-5.44	-0.33	1.29e-7	Hemostatic factors and hematological phenotypes;
KIRP	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg00800038	chr16:89945340	TCF25	-0.68	-4.99	-0.3	1.14e-6	Skin colour saturation;
KIRP	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.68	8.21	0.46	1.24e-14	Blood metabolite levels;
KIRP	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.74	-11.0	-0.57	3.73e-23	Colorectal cancer;
KIRP	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg23172400	chr8:95962367	TP53INP1	-0.37	-7.73	-0.44	2.74e-13	Type 2 diabetes;
KIRP	cis	rs9473924	0.542	rs9473928	chr6:50842003	G/A	cg14470998	chr6:50812995	TFAP2B	0.83	7.63	0.44	5.19e-13	Body mass index;
KIRP	cis	rs997295	0.638	rs11854197	chr15:67977384	A/G	cg24579218	chr15:68104479	NA	0.35	4.98	0.3	1.22e-6	Motion sickness;
KIRP	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.63	7.44	0.43	1.69e-12	Mean corpuscular volume;Mean platelet volume;
KIRP	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-1.09	-21.2	-0.8	1.94e-57	Lobe attachment (rater-scored or self-reported);
KIRP	trans	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg25042112	chr7:64838748	ZNF92	-0.6	-6.34	-0.37	1.1e-9	Pain;
KIRP	trans	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg11347411	chr7:150020925	ACTR3C;LRRC61	0.7	9.03	0.5	5.14e-17	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs8077577	0.747	rs11869582	chr17:18136581	G/A	cg18869244	chr17:18121946	NA	0.47	5.1	0.31	6.92e-7	Obesity-related traits;
KIRP	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg23032129	chr1:109941072	SORT1	-0.28	-4.91	-0.3	1.67e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.44	-5.9	-0.35	1.2e-8	Type 2 diabetes;
KIRP	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.63	10.1	0.54	2.72e-20	Bone mineral density;
KIRP	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg02807482	chr3:125708958	NA	-0.52	-4.98	-0.3	1.22e-6	Blood pressure (smoking interaction);
KIRP	cis	rs2635047	0.542	rs1512235	chr18:44781569	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.42	6.47	0.38	5.34e-10	Educational attainment;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg18153499	chr19:47142459	NA	0.41	6.03	0.36	5.93e-9	Parkinson's disease;
KIRP	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.45	-6.07	-0.36	4.89e-9	Intelligence (multi-trait analysis);
KIRP	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.76	-11.27	-0.58	5.13e-24	Height;
KIRP	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12315302	chr6:26189340	HIST1H4D	0.87	6.11	0.36	3.93e-9	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs853679	0.628	rs9368560	chr6:28159960	T/C	cg08968635	chr6:28129556	ZNF389	0.49	5.07	0.31	7.7300000000000005e-07	Depression;
KIRP	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.68	-9.95	-0.54	8.19e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
KIRP	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg25251562	chr2:3704773	ALLC	-0.37	-4.95	-0.3	1.36e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
KIRP	cis	rs13102973	0.965	rs6838419	chr4:135875682	T/C	cg14419869	chr4:135874104	NA	-0.62	-11.11	-0.58	1.64e-23	Subjective well-being;
KIRP	cis	rs7180079	0.620	rs2101225	chr15:64731679	G/A	cg15337035	chr15:64978493	NA	-0.48	-5.25	-0.32	3.24e-7	Monocyte count;
KIRP	cis	rs4886920	0.894	rs1123552	chr15:78109419	C/A	cg10461261	chr15:78109450	NA	-0.33	-5.38	-0.32	1.76e-7	Neuroticism;
KIRP	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg11130432	chr3:121712080	ILDR1	0.47	5.77	0.35	2.37e-8	Multiple sclerosis;
KIRP	cis	rs2916247	1.000	rs7827887	chr8:93026374	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.55	-7.27	-0.42	4.73e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.32	-0.32	2.38e-7	Bipolar disorder;
KIRP	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg05315796	chr3:52349193	DNAH1	0.41	6.47	0.38	5.32e-10	Intelligence (multi-trait analysis);
KIRP	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.54	-5.83	-0.35	1.77e-8	DNA methylation (variation);
KIRP	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg24626310	chr20:25276739	ABHD12;PYGB	0.51	6.77	0.4	9.53e-11	Liver enzyme levels (alkaline phosphatase);
KIRP	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	0.47	5.52	0.33	8.76e-8	Glycated hemoglobin levels;
KIRP	cis	rs4144743	0.528	rs12940207	chr17:45352194	G/T	cg18085866	chr17:45331354	ITGB3	-0.67	-5.19	-0.31	4.31e-7	Body mass index;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg18325794	chr1:32083737	HCRTR1	0.42	6.49	0.38	4.82e-10	Cancer;
KIRP	cis	rs2573652	0.722	rs12903458	chr15:100542673	T/G	cg09918751	chr15:100517450	ADAMTS17	-0.52	-7.48	-0.43	1.28e-12	Height;
KIRP	cis	rs17321999	1.000	rs6548005	chr2:30480196	C/G	cg05247661	chr2:30472410	LBH	0.67	7.52	0.43	1.04e-12	Systemic lupus erythematosus;
KIRP	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg15655495	chr12:38532458	NA	-0.28	-5.09	-0.31	7.26e-7	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.17	0.42	8.8e-12	Bipolar disorder;
KIRP	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg00343986	chr7:65444356	GUSB	-0.44	-5.34	-0.32	2.1e-7	Aortic root size;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg10201608	chr2:85788586	GGCX	0.53	6.08	0.36	4.47e-9	Smoking initiation;
KIRP	cis	rs6901250	0.632	rs1853080	chr6:117196157	T/C	cg12892004	chr6:117198278	RFX6	-0.4	-6.7	-0.39	1.4e-10	C-reactive protein levels;
KIRP	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-9.01	-0.5	5.82e-17	Joint mobility (Beighton score);
KIRP	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.97	-10.34	-0.55	4.77e-21	Palmitoleic acid (16:1n-7) levels;
KIRP	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.46	5.85	0.35	1.58e-8	Recombination rate (males);
KIRP	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.57	-7.41	-0.43	2.03e-12	Endometrial cancer;
KIRP	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg00806126	chr19:22604979	ZNF98	-0.69	-7.28	-0.42	4.61e-12	Pain;
KIRP	cis	rs6882046	0.513	rs616391	chr5:88038845	C/T	cg24804195	chr5:87968844	LOC645323	-0.47	-6.21	-0.37	2.21e-9	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
KIRP	cis	rs7715806	0.500	rs72633985	chr5:75006384	A/G	cg19683494	chr5:74908142	NA	0.5	5.0	0.3	1.07e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
KIRP	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg00800038	chr16:89945340	TCF25	-0.69	-5.05	-0.31	8.53e-7	Skin colour saturation;
KIRP	cis	rs7614311	0.636	rs3774702	chr3:63856870	G/A	cg22134162	chr3:63841271	THOC7	-0.36	-5.17	-0.31	4.85e-7	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.64	-7.6	-0.44	6.02e-13	Bipolar disorder;
KIRP	trans	rs10242455	0.702	rs73397447	chr7:99010949	G/T	cg09045935	chr12:6379348	NA	0.93	6.56	0.39	3.16e-10	Blood metabolite levels;
KIRP	cis	rs7523273	0.546	rs2796261	chr1:207888760	C/T	cg22525895	chr1:207977042	MIR29B2	-0.45	-5.79	-0.35	2.14e-8	Schizophrenia;
KIRP	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg09473613	chr1:24152604	HMGCL	-0.43	-5.22	-0.32	3.72e-7	Immature fraction of reticulocytes;
KIRP	trans	rs1014286	1.000	rs4851617	chr2:103152060	C/T	cg22446445	chr2:219303984	VIL1	0.38	6.18	0.37	2.62e-9	Serum protein levels (sST2);
KIRP	cis	rs77372450	0.515	rs2277948	chr5:157098233	T/C	cg23851860	chr5:157002805	ADAM19	0.46	5.01	0.3	1.06e-6	Bipolar disorder (body mass index interaction);
KIRP	trans	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg06521331	chr12:34319734	NA	-0.49	-6.39	-0.38	8.18e-10	Bladder cancer;
KIRP	cis	rs3857747	0.516	rs3890819	chr7:40461332	G/T	cg00420559	chr7:40367873	C7orf10	-0.39	-5.42	-0.33	1.43e-7	3-hydroxypropylmercapturic acid levels in smokers;
KIRP	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg08283408	chr3:49949060	MON1A	0.42	5.61	0.34	5.44e-8	Body mass index;
KIRP	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.64	5.98	0.36	7.67e-9	Lung function (FEV1/FVC);
KIRP	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg06521331	chr12:34319734	NA	-0.56	-6.8	-0.4	7.81e-11	Morning vs. evening chronotype;
KIRP	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.4	-5.62	-0.34	5.11e-8	Bipolar disorder;
KIRP	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg24631222	chr15:78858424	CHRNA5	1.01	13.56	0.65	1.2e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs6450176	0.909	rs3776721	chr5:53292522	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-11.0	-0.57	3.88e-23	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
KIRP	trans	rs1941687	0.800	rs17753910	chr18:31387643	T/C	cg27147174	chr7:100797783	AP1S1	-0.57	-6.97	-0.41	2.86e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
KIRP	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg01616215	chr22:32340373	YWHAH;C22orf24	0.73	5.2	0.31	4.27e-7	Childhood ear infection;
KIRP	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.68	-10.45	-0.55	2.23e-21	Heart rate;
KIRP	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-5.64	-0.34	4.64e-8	Breast cancer;
KIRP	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg27490568	chr2:178487706	NA	0.46	5.99	0.36	7.55e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-11.45	-0.59	1.27e-24	Chronic sinus infection;
KIRP	cis	rs17065868	1.000	rs9525962	chr13:45065391	A/G	cg10246903	chr13:45222710	NA	-0.58	-6.02	-0.36	6.47e-9	Antineutrophil cytoplasmic antibody-associated vasculitis;
KIRP	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.56	7.75	0.44	2.47e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg09788416	chr12:39539408	NA	0.4	5.37	0.32	1.85e-7	Morning vs. evening chronotype;
KIRP	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.48	4.89	0.3	1.83e-6	Alzheimer's disease;
KIRP	cis	rs311392	0.966	rs454975	chr8:55087514	T/C	cg06042504	chr8:55087323	NA	-0.61	-7.48	-0.43	1.34e-12	Pelvic organ prolapse (moderate/severe);
KIRP	cis	rs16828019	0.777	rs16911	chr1:41498021	C/T	cg18742814	chr1:41828276	NA	0.69	5.85	0.35	1.6e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg19847130	chr8:10466454	RP1L1	0.35	5.1	0.31	6.66e-7	Neuroticism;
KIRP	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg02336718	chr17:17403227	NA	-0.32	-4.89	-0.3	1.83e-6	Total body bone mineral density;
KIRP	cis	rs7737355	0.812	rs11750704	chr5:130911578	C/A	cg06307176	chr5:131281290	NA	0.42	5.02	0.3	9.87e-7	Life satisfaction;
KIRP	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-7.77	-0.44	2.12e-13	Intelligence (multi-trait analysis);
KIRP	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.38	-5.09	-0.31	7.18e-7	Body mass index;
KIRP	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.7	10.7	0.56	3.48e-22	Blood metabolite ratios;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg04025889	chr20:32891089	AHCY	0.56	6.61	0.39	2.38e-10	Smoking initiation;
KIRP	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg27205649	chr11:78285834	NARS2	-0.62	-7.81	-0.45	1.63e-13	Alzheimer's disease (survival time);
KIRP	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg20578329	chr17:80767326	TBCD	-0.65	-7.62	-0.44	5.55e-13	Breast cancer;
KIRP	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	1.17	8.71	0.49	4.56e-16	Intelligence (multi-trait analysis);
KIRP	cis	rs7737355	0.812	rs10463886	chr5:130758893	A/T	cg06307176	chr5:131281290	NA	-0.41	-5.02	-0.3	1.01e-6	Life satisfaction;
KIRP	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-6.59	-0.39	2.6e-10	Educational attainment;
KIRP	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg00262122	chr8:11665843	FDFT1	0.4	5.07	0.31	7.98e-7	Neuroticism;
KIRP	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.65	-8.08	-0.46	2.9e-14	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.72	-8.61	-0.48	8.65e-16	Schizophrenia;
KIRP	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.65	-8.49	-0.48	1.96e-15	Motion sickness;
KIRP	cis	rs9810259	0.522	rs9875338	chr3:12296469	A/G	cg02700894	chr3:12045449	SYN2	0.34	4.84	0.3	2.26e-6	Platelet count;
KIRP	cis	rs73198271	0.628	rs75693229	chr8:8590926	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-5.12	-0.31	6.15e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs228437	0.565	rs4526208	chr6:134957385	C/T	cg24504307	chr6:134963096	NA	0.33	5.57	0.33	6.58e-8	Melanoma;
KIRP	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.62	7.93	0.45	7.46e-14	Alcohol dependence;
KIRP	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-1.09	-22.07	-0.82	2.89e-60	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg05484376	chr2:27715224	FNDC4	0.41	6.81	0.4	7.41e-11	Total body bone mineral density;
KIRP	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	9.01	0.5	5.97e-17	Smoking behavior;
KIRP	cis	rs6977660	0.660	rs7357202	chr7:19817911	T/A	cg05791153	chr7:19748676	TWISTNB	0.6	5.94	0.35	9.5e-9	Thyroid stimulating hormone;
KIRP	trans	rs7301826	0.627	rs7315707	chr12:131272819	A/G	cg07766672	chr8:143808440	C8orf55	0.5	6.04	0.36	5.58e-9	Plasma plasminogen activator levels;
KIRP	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.74	7.9	0.45	9.28e-14	Lymphocyte counts;
KIRP	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	0.97	15.22	0.7	2.52e-37	Schizophrenia;
KIRP	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.5	6.38	0.38	8.88e-10	Schizophrenia;
KIRP	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg22974920	chr21:40686053	BRWD1	0.44	5.16	0.31	5.09e-7	Cognitive function;
KIRP	cis	rs6746082	0.570	rs61671081	chr2:25761103	A/C	cg23192403	chr2:25781496	DTNB	-0.26	-5.36	-0.32	1.96e-7	Multiple myeloma;
KIRP	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.44	-6.45	-0.38	5.77e-10	Daytime sleep phenotypes;
KIRP	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.56	7.18	0.42	8.28e-12	Bipolar disorder;
KIRP	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg13010199	chr12:38710504	ALG10B	-0.48	-6.45	-0.38	5.96e-10	Morning vs. evening chronotype;
KIRP	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg11764359	chr7:65958608	NA	0.75	4.86	0.3	2.11e-6	Gout;
KIRP	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg10664184	chr19:17420304	DDA1	0.79	9.03	0.5	5e-17	Systemic lupus erythematosus;
KIRP	cis	rs28834970	0.571	rs12679874	chr8:27230819	A/G	cg14221460	chr8:27183342	PTK2B	-0.42	-5.1	-0.31	6.72e-7	Alzheimer's disease (late onset);
KIRP	cis	rs6832769	1.000	rs576779	chr4:56274307	G/A	cg05960024	chr4:56376020	CLOCK	0.62	8.17	0.46	1.67e-14	Personality dimensions;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg01010986	chr2:16081096	MYCN;MYCNOS	0.47	6.31	0.37	1.28e-9	Parkinson's disease;
KIRP	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.85	-9.12	-0.5	2.68e-17	Hirschsprung disease;
KIRP	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.66	-7.74	-0.44	2.53e-13	Bone mineral density;
KIRP	cis	rs2505998	0.957	rs2435366	chr10:43571988	T/C	cg15436174	chr10:43711423	RASGEF1A	-0.51	-5.21	-0.32	3.97e-7	Hirschsprung disease;
KIRP	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg06115741	chr20:33292138	TP53INP2	0.41	5.46	0.33	1.19e-7	Coronary artery disease;
KIRP	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.42	5.31	0.32	2.4e-7	Total body bone mineral density;
KIRP	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg16141378	chr3:129829833	LOC729375	0.62	8.85	0.49	1.81e-16	Neuroticism;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06745885	chr16:68345000	PRMT7;SLC7A6OS	0.53	6.57	0.39	2.95e-10	Parkinson's disease;
KIRP	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg11846333	chr4:119757529	SEC24D	1.18	7.11	0.41	1.29e-11	Cannabis dependence symptom count;
KIRP	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.5	11.86	0.6	5.93e-26	Ewing sarcoma;
KIRP	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-8.09	-0.46	2.78e-14	Triglycerides;
KIRP	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.19	13.83	0.66	1.45e-32	Sexual dysfunction (female);
KIRP	cis	rs10554589	1	rs10554589	chr16:89362277	GGATGT/G	cg08822215	chr16:89438651	ANKRD11	-0.58	-4.95	-0.3	1.4e-6	Lymphocyte counts;
KIRP	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.65	7.77	0.44	2.11e-13	Educational attainment;
KIRP	cis	rs282587	0.502	rs391107	chr13:113416198	T/C	cg04656015	chr13:113407548	ATP11A	0.59	6.75	0.4	1.04e-10	Glycated hemoglobin levels;
KIRP	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.66	6.34	0.37	1.07e-9	Schizophrenia;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg06321345	chr1:177150848	FAM5B	0.51	6.59	0.39	2.67e-10	Parkinson's disease;
KIRP	trans	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg06521331	chr12:34319734	NA	-0.6	-7.1	-0.41	1.34e-11	Morning vs. evening chronotype;
KIRP	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg10189774	chr4:17578691	LAP3	0.49	5.97	0.36	8.42e-9	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg18850929	chr19:1828978	REXO1	-0.44	-5.23	-0.32	3.57e-7	Bipolar disorder;
KIRP	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg13409248	chr3:40428643	ENTPD3	-0.39	-5.48	-0.33	1.06e-7	Renal cell carcinoma;
KIRP	cis	rs7246657	0.551	rs10404069	chr19:37638404	C/T	cg18154014	chr19:37997991	ZNF793	0.54	4.89	0.3	1.8e-6	Coronary artery calcification;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg11537619	chr8:82359759	PMP2	-0.41	-6.38	-0.38	8.79e-10	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.72	-11.78	-0.6	1.08e-25	Itch intensity from mosquito bite;
KIRP	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	cg12689670	chr1:183009347	LAMC1	0.43	6.22	0.37	2.11e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg02073558	chr3:44770973	ZNF501	0.61	8.55	0.48	1.33e-15	Depressive symptoms;
KIRP	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg12940923	chr8:10282607	MSRA	-0.38	-4.85	-0.3	2.16e-6	Neuroticism;
KIRP	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.5	-8.48	-0.48	2.11e-15	Refractive error;
KIRP	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg00122941	chr17:4613640	ARRB2	0.82	8.71	0.49	4.49e-16	Lymphocyte counts;
KIRP	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg00543991	chr22:32367038	NA	0.53	4.89	0.3	1.8e-6	Childhood ear infection;
KIRP	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg25706552	chr1:244017396	NA	0.56	6.51	0.38	4.16e-10	RR interval (heart rate);
KIRP	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg17376030	chr22:41985996	PMM1	0.43	5.28	0.32	2.81e-7	Vitiligo;
KIRP	cis	rs2033908	0.502	rs12361858	chr11:12857064	C/T	cg25843174	chr11:12811716	TEAD1	-0.3	-5.63	-0.34	4.97e-8	Sitting height ratio;
KIRP	cis	rs4262150	0.846	rs56313315	chr5:152307156	C/T	cg12297329	chr5:152029980	NA	-0.63	-7.81	-0.45	1.62e-13	Bipolar disorder and schizophrenia;
KIRP	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.51	7.22	0.42	6.45e-12	Response to tocilizumab in rheumatoid arthritis;
KIRP	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg10017260	chr10:834428	NA	-0.56	-5.47	-0.33	1.09e-7	Eosinophil percentage of granulocytes;
KIRP	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg18404041	chr3:52824283	ITIH1	-0.38	-5.49	-0.33	9.89e-8	Red blood cell count;Autism spectrum disorder or schizophrenia;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg21702128	chr5:142784721	NR3C1	0.51	6.95	0.41	3.3e-11	Smoking initiation;
KIRP	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg06521331	chr12:34319734	NA	-0.5	-6.32	-0.37	1.25e-9	Morning vs. evening chronotype;
KIRP	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-7.64	-0.44	4.94e-13	Total cholesterol levels;
KIRP	cis	rs7692976	0.578	rs2298978	chr4:110837667	G/A	cg06981781	chr4:110842888	EGF	-0.26	-5.82	-0.35	1.86e-8	Reticulocyte count;Reticulocyte fraction of red cells;
KIRP	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg16606324	chr3:10149918	C3orf24	0.56	5.23	0.32	3.7e-7	Alzheimer's disease;
KIRP	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.48	-6.75	-0.4	1.07e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
KIRP	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.43	8.43	0.47	2.9e-15	Urinary metabolites;
KIRP	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg18350739	chr11:68623251	NA	-0.51	-7.68	-0.44	3.66e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.66	8.5	0.48	1.79e-15	Prudent dietary pattern;
KIRP	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-20.1	-0.79	8.24e-54	Height;
KIRP	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg12705353	chr12:122356852	WDR66	0.52	7.04	0.41	1.87e-11	Mean corpuscular volume;
KIRP	cis	rs10181042	0.535	rs2441465	chr2:61311187	C/T	cg18625361	chr2:61244694	PEX13;PUS10	-0.4	-5.02	-0.31	9.72e-7	Crohn's disease;
KIRP	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08822215	chr16:89438651	ANKRD11	-0.41	-5.45	-0.33	1.21e-7	Multiple myeloma (IgH translocation);
KIRP	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-5.82	-0.35	1.79e-8	Life satisfaction;
KIRP	cis	rs62355272	0.897	rs4024110	chr5:35919651	G/T	cg13894535	chr5:35919491	CAPSL	-0.51	-6.13	-0.36	3.43e-9	Lymphocyte counts;
KIRP	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-8.12	-0.46	2.24e-14	Personality dimensions;
KIRP	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.73	-9.74	-0.53	3.61e-19	Prudent dietary pattern;
KIRP	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg09184832	chr6:79620586	NA	-0.52	-7.3	-0.42	4e-12	Intelligence (multi-trait analysis);
KIRP	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg19650706	chr5:140594406	PCDHB13	0.45	5.03	0.31	9.68e-7	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	11.38	0.59	2.19e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
KIRP	cis	rs1723838	0.510	rs80217992	chr11:73694260	C/G	cg10064339	chr11:73693792	UCP2	0.88	5.75	0.34	2.65e-8	Obesity-related traits;
KIRP	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.83	9.07	0.5	3.83e-17	Alzheimer's disease;
KIRP	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg00656387	chr3:40428638	ENTPD3	0.38	4.85	0.3	2.14e-6	Renal cell carcinoma;
KIRP	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg13798912	chr7:905769	UNC84A	-0.67	-6.45	-0.38	5.89e-10	Cerebrospinal P-tau181p levels;
KIRP	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.43	6.39	0.38	8.02e-10	Major depressive disorder;
KIRP	cis	rs7224685	0.506	rs12452569	chr17:4023667	T/A	cg11204139	chr17:3907470	NA	0.55	5.17	0.31	4.97e-7	Type 2 diabetes;
KIRP	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.67	9.24	0.51	1.2e-17	Morning vs. evening chronotype;
KIRP	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.68	-7.04	-0.41	1.94e-11	Obesity-related traits;
KIRP	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.61	7.84	0.45	1.39e-13	Longevity;Endometriosis;
KIRP	cis	rs1035491	0.715	rs12153793	chr5:63926423	C/T	cg01791865	chr5:63954708	NA	0.33	5.2	0.31	4.27e-7	Body mass index;
KIRP	cis	rs6142102	0.580	rs9753679	chr20:32540860	G/A	cg24642439	chr20:33292090	TP53INP2	0.5	5.79	0.35	2.16e-8	Skin pigmentation;
KIRP	cis	rs2976388	0.935	rs2978979	chr8:143757286	C/A	cg06565975	chr8:143823917	SLURP1	-0.44	-6.53	-0.38	3.84e-10	Urinary tract infection frequency;
KIRP	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08822215	chr16:89438651	ANKRD11	-0.46	-6.17	-0.37	2.73e-9	Multiple myeloma (IgH translocation);
KIRP	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg07001201	chr5:642380	CEP72	0.68	6.21	0.37	2.29e-9	Lung disease severity in cystic fibrosis;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg24360513	chr1:249120106	SH3BP5L	-0.54	-6.8	-0.4	7.93e-11	Interleukin-4 levels;
KIRP	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg04733989	chr22:42467013	NAGA	-0.58	-7.52	-0.43	1.05e-12	Cognitive function;
KIRP	trans	rs5003154	0.905	rs13273982	chr8:82001360	C/G	cg07192240	chr11:3829780	PGAP2	0.47	6.36	0.38	9.91e-10	Bladder cancer;
KIRP	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21385522	chr1:16154831	NA	0.49	6.27	0.37	1.62e-9	Dilated cardiomyopathy;
KIRP	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.81	-10.86	-0.57	1.09e-22	Systemic lupus erythematosus;
KIRP	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg17517138	chr11:73019481	ARHGEF17	0.81	7.13	0.41	1.14e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
KIRP	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.3	13.51	0.65	1.81e-31	Diabetic retinopathy;
KIRP	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.87	-12.43	-0.62	7.25e-28	Total body bone mineral density;
KIRP	cis	rs11264213	0.901	rs72661613	chr1:36364781	A/G	cg27506609	chr1:36549197	TEKT2	1.15	6.55	0.39	3.32e-10	Schizophrenia;
KIRP	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg08508325	chr11:3079039	CARS	0.33	6.15	0.36	3.15e-9	Calcium levels;
KIRP	cis	rs8060686	0.844	rs3785100	chr16:67997920	T/C	cg09117114	chr16:67998030	SLC12A4	-0.52	-5.53	-0.33	8.03e-8	HDL cholesterol;Metabolic syndrome;
KIRP	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-9.32	-0.51	6.79e-18	Developmental language disorder (linguistic errors);
KIRP	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg00250761	chr1:31883323	NA	-0.31	-5.48	-0.33	1.05e-7	Alcohol dependence;
KIRP	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg14228332	chr4:119757509	SEC24D	0.82	4.97	0.3	1.23e-6	Cannabis dependence symptom count;
KIRP	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.8	10.65	0.56	5.01e-22	Body mass index;
KIRP	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-5.64	-0.34	4.73e-8	Parkinson's disease;
KIRP	cis	rs34286592	0.929	rs9939514	chr16:29855731	G/A	cg08218971	chr16:29826754	C16orf53;PRRT2	0.35	4.86	0.3	2.14e-6	Multiple sclerosis;
KIRP	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg10495392	chr1:46806563	NSUN4	0.48	5.42	0.33	1.39e-7	Menopause (age at onset);
KIRP	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.66	-8.56	-0.48	1.23e-15	Morning vs. evening chronotype;
KIRP	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg23719950	chr11:63933701	MACROD1	-0.63	-5.39	-0.32	1.67e-7	Mean platelet volume;
KIRP	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg16141378	chr3:129829833	LOC729375	0.51	6.22	0.37	2.18e-9	Neuroticism;
KIRP	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.75	10.5	0.56	1.48e-21	Parkinson's disease;
KIRP	cis	rs3105593	1.000	rs11637228	chr15:50899972	G/T	cg05456662	chr15:50716270	USP8	0.41	5.03	0.31	9.51e-7	QT interval;
KIRP	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg02462569	chr6:150064036	NUP43	-0.37	-5.73	-0.34	2.98e-8	Lung cancer;
KIRP	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	8.74	0.49	3.7e-16	Lung cancer in ever smokers;
KIRP	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.6	-7.07	-0.41	1.64e-11	Longevity;Endometriosis;
KIRP	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg15655495	chr12:38532458	NA	-0.28	-5.03	-0.31	9.3e-7	Bladder cancer;
KIRP	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.43	-4.87	-0.3	1.97e-6	Schizophrenia;
KIRP	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg07414643	chr4:187882934	NA	0.38	5.15	0.31	5.22e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs12476592	0.571	rs7584404	chr2:63794342	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-5.01	-0.3	1.03e-6	Childhood ear infection;
KIRP	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg21535247	chr6:8435926	SLC35B3	-0.38	-4.84	-0.3	2.25e-6	Motion sickness;
KIRP	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-5.06	-0.31	8.22e-7	Bipolar disorder and schizophrenia;
KIRP	trans	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg13565492	chr6:43139072	SRF	-0.93	-8.6	-0.48	9.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-7.2	-0.42	7.45e-12	Joint mobility (Beighton score);
KIRP	cis	rs72627123	0.656	rs117129791	chr14:74520871	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	5.26	0.32	3.09e-7	Morning vs. evening chronotype;
KIRP	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.77	6.48	0.38	4.93e-10	Body mass index;
KIRP	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.71	-10.07	-0.54	3.32e-20	Intelligence (multi-trait analysis);
KIRP	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	-0.58	-7.84	-0.45	1.34e-13	Menarche (age at onset);
KIRP	cis	rs3752645	1.000	rs17425839	chr7:106763278	A/C	cg02696742	chr7:106810147	HBP1	0.7	5.21	0.32	4e-7	Bladder cancer (smoking interaction);
KIRP	cis	rs4704187	0.663	rs12523187	chr5:74379625	A/T	cg03227963	chr5:74354835	NA	0.4	5.91	0.35	1.16e-8	Response to amphetamines;
KIRP	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg21858823	chr1:15850916	CASP9	0.53	5.74	0.34	2.84e-8	Systolic blood pressure;
KIRP	cis	rs7715811	1.000	rs1502041	chr5:13758529	A/G	cg07548982	chr5:13769939	DNAH5	-0.52	-6.35	-0.38	1.01e-9	Subclinical atherosclerosis traits (other);
KIRP	cis	rs11605924	0.935	rs6485645	chr11:45862353	A/G	cg23097878	chr11:45879730	CRY2	0.33	6.59	0.39	2.66e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
KIRP	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg11945507	chr8:142233382	SLC45A4	0.9	15.68	0.71	6.73e-39	Immature fraction of reticulocytes;
KIRP	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg19610905	chr11:61596333	FADS2	-0.47	-7.51	-0.43	1.09e-12	Trans fatty acid levels;
KIRP	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.89	12.81	0.63	3.94e-29	Morning vs. evening chronotype;
KIRP	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.7	-6.39	-0.38	8.2e-10	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
KIRP	cis	rs6594499	0.605	rs464275	chr5:110472967	C/G	cg04022379	chr5:110408740	TSLP	-0.42	-5.49	-0.33	1.02e-7	Allergic disease (asthma, hay fever or eczema);
KIRP	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02359409	chr6:42947317	PEX6	0.51	7.1	0.41	1.33e-11	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg18882449	chr10:104885122	NT5C2	-0.49	-6.32	-0.37	1.23e-9	Arsenic metabolism;
KIRP	cis	rs7534824	0.625	rs10493939	chr1:101378026	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.84	7.07	0.41	1.59e-11	Refractive astigmatism;
KIRP	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-7.88	-0.45	1.06e-13	Mean corpuscular volume;
KIRP	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.66	10.06	0.54	3.56e-20	Lung cancer;
KIRP	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	6.74	0.39	1.13e-10	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
KIRP	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.42	-5.14	-0.31	5.63e-7	Diastolic blood pressure;
KIRP	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-1.05	-16.81	-0.73	9.45e-43	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
KIRP	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.64	8.24	0.46	1.05e-14	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs13034020	0.522	rs12464096	chr2:61239332	G/C	cg18625361	chr2:61244694	PEX13;PUS10	0.65	6.25	0.37	1.78e-9	Hodgkin's lymphoma;
KIRP	cis	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg21546286	chr11:48923668	NA	-0.45	-5.64	-0.34	4.59e-8	HDL cholesterol;
KIRP	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg26207909	chr14:103986467	CKB	-0.43	-5.27	-0.32	3.03e-7	Coronary artery disease;
KIRP	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg16810054	chr20:33298113	TP53INP2	0.46	5.8	0.35	2.06e-8	Neuroticism;
KIRP	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.4	5.75	0.34	2.69e-8	Testicular germ cell tumor;
KIRP	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.45	-6.12	-0.36	3.68e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
KIRP	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg02487422	chr3:49467188	NICN1	0.42	5.52	0.33	8.69e-8	Resting heart rate;
KIRP	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg25866889	chr13:114914595	NA	-0.39	-5.43	-0.33	1.35e-7	Schizophrenia;
KIRP	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg00982548	chr2:198649783	BOLL	-0.56	-5.46	-0.33	1.19e-7	Ulcerative colitis;
KIRP	trans	rs2567519	0.710	rs2714012	chr17:70783757	C/T	cg03811519	chr9:134001305	NUP214	0.62	7.5	0.43	1.15e-12	Smoking initiation;
KIRP	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg01689657	chr7:91764605	CYP51A1	0.42	5.9	0.35	1.21e-8	Breast cancer;
KIRP	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.62	8.55	0.48	1.37e-15	Morning vs. evening chronotype;
KIRP	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	cg21523751	chr1:182988639	NA	0.41	6.42	0.38	7.03e-10	Fuchs's corneal dystrophy;
KIRP	cis	rs8077577	0.945	rs11654146	chr17:18076141	A/C	cg09161412	chr17:18057145	MYO15A	-0.4	-5.24	-0.32	3.41e-7	Obesity-related traits;
KIRP	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.81	-8.19	-0.46	1.42e-14	Lung cancer;
KIRP	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.6	7.37	0.43	2.63e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
KIRP	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.8	10.71	0.56	3.32e-22	Aortic root size;
KIRP	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.18	25.6	0.85	2.63e-71	Schizophrenia;
KIRP	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.6	-8.43	-0.47	3.01e-15	Myopia (pathological);
KIRP	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	7.19	0.42	7.6e-12	Aortic root size;
KIRP	cis	rs10875746	0.669	rs10875772	chr12:48609553	C/T	cg26205652	chr12:48591994	NA	0.81	10.15	0.54	1.93e-20	Longevity (90 years and older);
KIRP	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-8.78	-0.49	2.9e-16	Response to antipsychotic treatment;
KIRP	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg16179182	chr5:140090404	VTRNA1-1	-0.51	-6.9	-0.4	4.31e-11	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-7.9	-0.45	9.01e-14	Alzheimer's disease;
KIRP	cis	rs2055729	0.557	rs7000542	chr8:9881135	T/C	cg21625330	chr8:9911636	MSRA	-0.49	-5.91	-0.35	1.11e-8	Multiple myeloma (hyperdiploidy);
KIRP	trans	rs61931739	0.613	rs1817500	chr12:33679809	G/T	cg26592556	chr15:40337420	NA	-0.46	-6.06	-0.36	5.21e-9	Morning vs. evening chronotype;
KIRP	cis	rs6132905	0.590	rs2325893	chr20:2607724	C/T	cg24848351	chr20:2622020	TMC2	-0.61	-5.84	-0.35	1.67e-8	Mumps;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg10307507	chr15:64647710	CSNK1G1	0.49	6.38	0.38	8.61e-10	Parkinson's disease;
KIRP	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg03959625	chr15:84868606	LOC388152	0.59	6.57	0.39	2.93e-10	Schizophrenia;
KIRP	cis	rs1048238	0.605	rs1889785	chr1:16348729	G/A	cg22431228	chr1:16359049	CLCNKA	-0.44	-5.84	-0.35	1.69e-8	Systolic blood pressure;
KIRP	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg24315340	chr6:146058215	EPM2A	-0.42	-5.26	-0.32	3.08e-7	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs9398803	0.865	rs9385400	chr6:126764190	G/T	cg19875578	chr6:126661172	C6orf173	-0.49	-6.22	-0.37	2.12e-9	Male-pattern baldness;
KIRP	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.75	-11.2	-0.58	8.71e-24	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs4073416	0.502	rs4359350	chr14:65863748	T/C	cg03016385	chr14:66212404	NA	-0.42	-5.46	-0.33	1.17e-7	N-glycan levels;
KIRP	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	10.21	0.55	1.28e-20	Educational attainment;
KIRP	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09414673	chr7:1022797	CYP2W1	0.37	4.94	0.3	1.46e-6	Longevity;Endometriosis;
KIRP	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.93	14.18	0.67	9.36e-34	Mean platelet volume;
KIRP	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00933542	chr6:150070202	PCMT1	0.3	5.91	0.35	1.16e-8	Lung cancer;
KIRP	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.83	-9.91	-0.53	1.04e-19	Body mass index;
KIRP	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.8	11.84	0.6	6.9e-26	Heart rate;
KIRP	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.36	6.59	0.39	2.71e-10	Erythrocyte sedimentation rate;
KIRP	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.58	7.41	0.43	1.99e-12	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs258892	0.895	rs2338792	chr5:72066860	G/C	cg21869765	chr5:72125136	TNPO1	-0.54	-5.87	-0.35	1.42e-8	Small cell lung carcinoma;
KIRP	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg03202659	chr2:74981765	NA	-0.44	-6.07	-0.36	4.93e-9	Select biomarker traits;
KIRP	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.84	-9.41	-0.51	3.65e-18	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg24631222	chr15:78858424	CHRNA5	0.76	9.03	0.5	5.24e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
KIRP	cis	rs882732	1.000	rs10142033	chr14:95041623	A/T	cg05186455	chr14:95027692	SERPINA4	-0.39	-5.04	-0.31	9.15e-7	Blood protein levels;
KIRP	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg23555395	chr2:238036564	NA	0.47	5.53	0.33	8.29e-8	Systemic lupus erythematosus;
KIRP	cis	rs754423	0.544	rs34900091	chr14:52511709	T/C	cg05884192	chr14:52515736	NID2	0.52	5.7	0.34	3.46e-8	Craniofacial microsomia;
KIRP	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.47	-10.43	-0.55	2.55e-21	Alzheimer's disease (late onset);
KIRP	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg24130564	chr14:104152367	KLC1	-0.51	-7.01	-0.41	2.29e-11	Body mass index;
KIRP	cis	rs17453880	0.658	rs2964218	chr5:151957849	A/C	cg12297329	chr5:152029980	NA	-0.51	-6.83	-0.4	6.59e-11	Subjective well-being;
KIRP	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg25019033	chr10:957182	NA	-0.67	-7.82	-0.45	1.56e-13	Eosinophil percentage of granulocytes;
KIRP	cis	rs10214930	0.697	rs12667235	chr7:27631631	A/C	cg22168087	chr7:27702803	HIBADH	0.47	4.9	0.3	1.74e-6	Hypospadias;
KIRP	trans	rs1406428	0.748	rs1919427	chr2:51735494	C/T	cg13131840	chr6:112942901	NA	-0.41	-6.29	-0.37	1.42e-9	Response to tocilizumab in rheumatoid arthritis;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg02943769	chr6:35310542	PPARD	0.47	6.49	0.38	4.56e-10	Survival in pancreatic cancer;
KIRP	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.54	-6.57	-0.39	2.96e-10	Uric acid levels;
KIRP	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.95	-8.86	-0.49	1.59e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
KIRP	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-1.06	-14.82	-0.69	5.92e-36	Alopecia areata;
KIRP	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg21466736	chr12:48725269	NA	-0.5	-6.21	-0.37	2.25e-9	Obstructive sleep apnea trait (apnea hypopnea index);
KIRP	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.64	8.87	0.49	1.56e-16	Depressive symptoms (multi-trait analysis);
KIRP	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.51	5.71	0.34	3.26e-8	Vitiligo;
KIRP	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.71	-9.76	-0.53	3.19e-19	Plateletcrit;Platelet count;
KIRP	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.38	-8.08	-0.46	2.86e-14	Body mass index;
KIRP	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.66	8.86	0.49	1.65e-16	Motion sickness;
KIRP	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg24699146	chr1:24152579	HMGCL	0.43	5.56	0.33	6.97e-8	Immature fraction of reticulocytes;
KIRP	cis	rs7224685	0.608	rs17763551	chr17:3882309	C/T	cg21851534	chr17:3907994	ZZEF1	0.47	5.19	0.31	4.3e-7	Type 2 diabetes;
KIRP	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	0.75	10.82	0.57	1.38e-22	Prudent dietary pattern;
KIRP	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg04037228	chr3:45636386	LIMD1	0.35	5.15	0.31	5.42e-7	Response to anti-depressant treatment in major depressive disorder;
KIRP	cis	rs9921338	0.924	rs7204628	chr16:11444572	A/C	cg00044050	chr16:11439710	C16orf75	-0.56	-6.11	-0.36	3.91e-9	Vein graft stenosis in coronary artery bypass grafting;
KIRP	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.41	-5.48	-0.33	1.06e-7	Bone mineral density (spine);Bone mineral density;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg08228914	chr19:53606538	ZNF160	0.49	6.39	0.38	8.44e-10	Parkinson's disease;
KIRP	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg09571762	chr12:39539558	NA	0.34	5.01	0.3	1.02e-6	Morning vs. evening chronotype;
KIRP	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.63	-6.86	-0.4	5.63e-11	Non-glioblastoma glioma;Glioma;
KIRP	trans	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg06636001	chr8:8085503	FLJ10661	0.59	7.64	0.44	4.98e-13	Retinal vascular caliber;
KIRP	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg20749741	chr2:264178	ACP1;SH3YL1	0.46	5.22	0.32	3.83e-7	Spherical equivalent (joint analysis main effects and education interaction);
KIRP	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.53	-6.44	-0.38	6.07e-10	Uric acid levels;
KIRP	cis	rs9815354	0.812	rs73081361	chr3:41912535	G/A	cg03022575	chr3:42003672	ULK4	0.82	8.52	0.48	1.64e-15	Pulse pressure;Diastolic blood pressure;
KIRP	trans	rs17234274	0.500	rs1384489	chr11:23225422	C/G	cg06062571	chr6:7482473	NA	0.44	6.29	0.37	1.44e-9	Cancer;
KIRP	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg22117172	chr7:91764530	CYP51A1	0.41	5.63	0.34	4.96e-8	Breast cancer;
KIRP	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg14851346	chr12:38532713	NA	-0.4	-4.99	-0.3	1.14e-6	Drug-induced liver injury (flucloxacillin);
KIRP	cis	rs6662572	0.737	rs72677545	chr1:46571221	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.47	5.77	0.35	2.41e-8	Blood protein levels;
KIRP	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.63	-6.77	-0.4	9.14e-11	Gut microbiome composition (summer);
KIRP	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg13010199	chr12:38710504	ALG10B	0.48	6.36	0.38	9.66e-10	Morning vs. evening chronotype;
KIRP	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg26681399	chr22:41777847	TEF	0.46	4.95	0.3	1.37e-6	Cannabis dependence symptom count;
KIRP	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg13453750	chr1:205783389	SLC41A1	0.42	6.64	0.39	1.99e-10	Menarche (age at onset);
KIRP	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg04166393	chr7:2884313	GNA12	0.42	5.53	0.33	8.35e-8	Height;
KIRP	cis	rs2964802	0.505	rs7729989	chr5:10822246	A/G	cg14521931	chr5:10832172	NA	-0.74	-11.26	-0.58	5.45e-24	Major depressive disorder;Recurrent major depressive disorder;
KIRP	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg20991723	chr1:152506922	NA	-0.45	-5.32	-0.32	2.36e-7	Hair morphology;
KIRP	cis	rs7937612	1.000	rs10750173	chr11:120288368	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.47	-7.15	-0.41	1e-11	Intraocular pressure;
KIRP	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg16989719	chr2:238392110	NA	-0.57	-6.33	-0.37	1.18e-9	Prostate cancer;
KIRP	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg07117364	chr1:16154769	NA	-0.44	-5.51	-0.33	9.2e-8	Dilated cardiomyopathy;
KIRP	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg23306229	chr2:178417860	TTC30B	0.54	4.89	0.3	1.8e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg19847130	chr8:10466454	RP1L1	-0.33	-5.04	-0.31	8.88e-7	Retinal vascular caliber;
KIRP	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.99	-16.75	-0.73	1.52e-42	Breast cancer;
KIRP	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	0.88	7.07	0.41	1.6e-11	Mitochondrial DNA levels;
KIRP	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.57	5.36	0.32	1.94e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.55	7.28	0.42	4.5e-12	Menarche (age at onset);
KIRP	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg24101359	chr6:42928495	GNMT	0.62	9.23	0.51	1.32e-17	Alzheimer's disease in APOE e4+ carriers;
KIRP	cis	rs3829109	0.564	rs10781511	chr9:139280766	G/A	cg21253087	chr9:139290292	SNAPC4	0.47	5.32	0.32	2.3e-7	Peak insulin response;Acute insulin response;
KIRP	trans	rs4650994	0.623	rs7534394	chr1:178622760	G/A	cg05059571	chr16:84539110	KIAA1609	0.52	6.48	0.38	4.91e-10	HDL cholesterol levels;HDL cholesterol;
KIRP	cis	rs6893300	0.857	rs62406181	chr5:179171803	G/A	cg14593053	chr5:179126677	CANX	-0.58	-6.99	-0.41	2.63e-11	Resting heart rate;
KIRP	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg21775007	chr8:11205619	TDH	-0.5	-6.42	-0.38	6.97e-10	Systolic blood pressure;
KIRP	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	5.01	0.3	1.06e-6	Bipolar disorder;
KIRP	cis	rs10267417	0.657	rs7800274	chr7:19871184	G/T	cg05791153	chr7:19748676	TWISTNB	0.55	5.28	0.32	2.81e-7	Night sleep phenotypes;
KIRP	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg04315214	chr1:2043799	PRKCZ	-0.39	-5.86	-0.35	1.49e-8	Height;
KIRP	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg12315302	chr6:26189340	HIST1H4D	0.94	5.83	0.35	1.75e-8	Autism spectrum disorder or schizophrenia;
KIRP	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-7.79	-0.45	1.83e-13	Total cholesterol levels;
KIRP	cis	rs2071426	0.959	rs1934957	chr10:96815114	T/G	cg09036531	chr10:96991505	NA	-0.56	-6.47	-0.38	5.31e-10	Blood metabolite levels;
KIRP	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18252515	chr7:66147081	NA	0.42	4.88	0.3	1.88e-6	Aortic root size;
KIRP	cis	rs6191	0.935	rs10041520	chr5:142776684	T/C	cg08845721	chr5:142780693	NR3C1	-0.39	-5.29	-0.32	2.67e-7	Night sleep phenotypes;
KIRP	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.44	-6.31	-0.37	1.27e-9	Reticulocyte fraction of red cells;
KIRP	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg06521331	chr12:34319734	NA	-0.58	-7.02	-0.41	2.09e-11	Morning vs. evening chronotype;
KIRP	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.5	-5.35	-0.32	2.04e-7	Body mass index;
KIRP	cis	rs17030434	1.000	rs79094565	chr4:154718997	T/C	cg14289246	chr4:154710475	SFRP2	-0.8	-9.61	-0.52	8.78e-19	Electrocardiographic conduction measures;
KIRP	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.53	6.6	0.39	2.57e-10	Body mass index;
KIRP	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg02023728	chr11:77925099	USP35	0.33	4.89	0.3	1.86e-6	Alzheimer's disease (survival time);
KIRP	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-13.38	-0.65	4.97e-31	Monocyte count;
KIRP	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.97	-15.05	-0.69	1.02e-36	Height;
KIRP	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.66	7.07	0.41	1.59e-11	Vitiligo;
KIRP	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.68	8.47	0.48	2.28e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
KIRP	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg08132940	chr7:1081526	C7orf50	-0.65	-6.9	-0.4	4.27e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
KIRP	cis	rs1318878	0.543	rs11056447	chr12:15512044	A/G	cg08258403	chr12:15378311	NA	-0.37	-4.85	-0.3	2.14e-6	Intelligence (multi-trait analysis);
KIRP	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.44	5.21	0.32	3.98e-7	Longevity;Endometriosis;
KIRP	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.74	9.96	0.54	7.27e-20	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
KIRP	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg23621158	chr4:83206416	NA	0.49	6.14	0.36	3.33e-9	DNA methylation (variation);
KIRP	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg15893493	chr8:124194847	FAM83A	0.93	8.13	0.46	2.14e-14	Urinary uromodulin levels;
KIRP	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.75	9.77	0.53	2.93e-19	Colonoscopy-negative controls vs population controls;
KIRP	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg27411982	chr8:10470053	RP1L1	-0.43	-5.5	-0.33	9.27e-8	Morning vs. evening chronotype;
KIRP	trans	rs67460515	0.529	rs6441364	chr3:160897915	A/C	cg17038902	chr20:60926987	LAMA5	-0.48	-6.07	-0.36	4.78e-9	Parkinson's disease;
KIRP	cis	rs4664293	0.867	rs3771721	chr2:160628155	C/G	cg08347373	chr2:160653686	CD302	-0.41	-6.41	-0.38	7.41e-10	Monocyte percentage of white cells;
KIRP	cis	rs732716	0.889	rs11666856	chr19:4437450	A/G	cg21720385	chr19:4455239	UBXN6	0.71	8.89	0.49	1.33e-16	Mean corpuscular volume;
KIRP	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.66	7.02	0.41	2.19e-11	Eotaxin levels;
KIRP	trans	rs1864729	1.000	rs1431891	chr8:98282716	A/G	cg08679828	chr8:102218111	ZNF706	-0.75	-6.85	-0.4	5.74e-11	Estradiol plasma levels (breast cancer);
KIRP	cis	rs1577917	0.545	rs7755958	chr6:86488511	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.56	6.92	0.4	3.95e-11	Response to antipsychotic treatment;
KIRP	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.37	5.62	0.34	5.22e-8	Fuchs's corneal dystrophy;
KIRP	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.6	6.15	0.37	3.1e-9	Diisocyanate-induced asthma;
KIRP	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg19847130	chr8:10466454	RP1L1	-0.34	-5.02	-0.3	9.95e-7	Retinal vascular caliber;
KIRP	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg03808351	chr9:123631620	PHF19	-0.57	-8.91	-0.49	1.16e-16	Birth weight;
KIRP	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02725872	chr8:58115012	NA	-0.75	-7.94	-0.45	7.26e-14	Developmental language disorder (linguistic errors);
KIRP	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg00800038	chr16:89945340	TCF25	-0.75	-5.25	-0.32	3.21e-7	Skin colour saturation;
KIRP	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.9	-12.15	-0.61	6.22e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
KIRP	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg06345736	chr22:50966936	TYMP	0.62	7.11	0.41	1.26e-11	Granulocyte percentage of myeloid white cells;
KIRP	cis	rs3822411	0.541	rs1080440	chr5:10740422	A/G	cg14521931	chr5:10832172	NA	0.52	6.65	0.39	1.91e-10	Sum eosinophil basophil counts;
KIRP	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.75	-11.22	-0.58	7.53e-24	Liver enzyme levels (gamma-glutamyl transferase);
KIRP	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg13962466	chr20:25176127	ENTPD6	0.47	5.88	0.35	1.36e-8	Colorectal or endometrial cancer;
KIRP	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	1.24	25.5	0.85	5e-71	IgG glycosylation;
KIRP	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06481639	chr22:41940642	POLR3H	0.73	7.11	0.41	1.23e-11	Vitiligo;
KIRP	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.32	-0.42	3.49e-12	Triglycerides;
KIRP	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg04554929	chr8:105342491	NA	-0.41	-5.98	-0.36	7.68e-9	Paget's disease;
KIRP	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.45	-5.83	-0.35	1.7e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
KIRP	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg02961200	chr2:178257176	LOC100130691;AGPS	0.82	11.38	0.59	2.15e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
KIRP	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.47	6.49	0.38	4.75e-10	Red blood cell count;
KIRP	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	0.75	11.03	0.58	3.02e-23	Prudent dietary pattern;
KIRP	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg12046867	chr14:103022105	NA	-0.44	-6.0	-0.36	6.92e-9	Platelet count;
KIRP	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg09264619	chr17:80180166	NA	-0.38	-5.53	-0.33	8.33e-8	Life satisfaction;
KIRP	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.74	6.92	0.4	3.94e-11	Breast cancer;
KIRP	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.89	10.02	0.54	4.86e-20	Eosinophil percentage of granulocytes;
KIRP	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-6.7	-0.39	1.45e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
KIRP	cis	rs769267	0.792	rs4808961	chr19:19577215	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	6.66	0.39	1.79e-10	Tonsillectomy;
KIRP	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.57	-7.75	-0.44	2.48e-13	Depressive symptoms;
KIRP	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg02795151	chr17:7402630	POLR2A	-0.75	-8.17	-0.46	1.63e-14	Androgen levels;
KIRP	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.67	7.97	0.45	6.13e-14	Blood metabolite levels;Acylcarnitine levels;
KIRP	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg16083429	chr3:49237500	CCDC36	-0.39	-5.08	-0.31	7.33e-7	Menarche (age at onset);
KIRP	cis	rs2721195	0.810	rs2721142	chr8:145752467	A/T	cg17328964	chr8:145687451	CYHR1	-0.5	-6.33	-0.37	1.13e-9	Age at first birth;
KIRP	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg26681399	chr22:41777847	TEF	-0.54	-5.39	-0.33	1.65e-7	Vitiligo;
KIRP	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg17757837	chr7:157058334	UBE3C	0.77	10.52	0.56	1.29e-21	Body mass index;
KIRP	cis	rs721917	0.531	rs2758551	chr10:81691940	A/G	cg12667595	chr10:81743362	NA	0.38	4.86	0.3	2.06e-6	Chronic obstructive pulmonary disease;
KIRP	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-0.99	-10.2	-0.55	1.32e-20	Blood pressure (smoking interaction);
KIRP	cis	rs11587400	0.656	rs6689415	chr1:115107469	G/T	cg12756093	chr1:115239321	AMPD1	0.42	5.24	0.32	3.46e-7	Autism;
KIRP	cis	rs6693295	0.877	rs10924523	chr1:246319900	G/T	cg11798871	chr1:246315928	SMYD3	-0.59	-6.59	-0.39	2.67e-10	Migraine - clinic-based;Migraine with aura;
KIRP	cis	rs12476592	0.602	rs262503	chr2:63860437	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-4.97	-0.3	1.25e-6	Childhood ear infection;
KIRP	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg10503236	chr1:231470652	EXOC8	-0.51	-7.05	-0.41	1.84e-11	Hemoglobin concentration;
KIRP	cis	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg21605333	chr4:119757512	SEC24D	0.83	6.73	0.39	1.21e-10	Cannabis dependence symptom count;
KIRP	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg10792982	chr14:105748885	BRF1	0.84	13.2	0.64	2e-30	Mean platelet volume;Platelet distribution width;
KIRP	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg18190219	chr22:46762943	CELSR1	-0.87	-7.23	-0.42	5.93e-12	LDL cholesterol;Cholesterol, total;
KIRP	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.89	12.97	0.64	1.18e-29	Metabolite levels;
KIRP	trans	rs10155879	0.505	rs12704265	chr7:86142678	A/G	cg17422019	chr6:129462493	LAMA2	0.42	6.08	0.36	4.66e-9	Interleukin-4 levels;
KIRP	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.47	-5.58	-0.34	6.31e-8	Lung function (FVC);Lung function (FEV1);
KIRP	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.47	5.68	0.34	3.77e-8	Common traits (Other);
KIRP	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.36	5.04	0.31	9.05e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
KIRP	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg13147721	chr7:65941812	NA	-0.95	-6.67	-0.39	1.72e-10	Diabetic kidney disease;
KIRP	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg17376030	chr22:41985996	PMM1	-0.83	-8.97	-0.5	7.63e-17	Vitiligo;
KIRP	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	5.69	0.34	3.65e-8	Cognitive ability (multi-trait analysis);Cognitive ability;
KIRP	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg18357526	chr6:26021779	HIST1H4A	0.39	4.98	0.3	1.21e-6	Height;
KIRP	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.83	12.87	0.63	2.44e-29	Height;
KIRP	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02725872	chr8:58115012	NA	-0.77	-7.35	-0.42	2.93e-12	Developmental language disorder (linguistic errors);
KIRP	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.34	17.28	0.74	2.4e-44	Uric acid levels;
KIRP	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg25319279	chr11:5960081	NA	-0.52	-5.38	-0.32	1.71e-7	DNA methylation (variation);
KIRP	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.69	11.75	0.6	1.39e-25	Cardiovascular disease risk factors;
KIRP	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg25486957	chr4:152246857	NA	-0.52	-5.62	-0.34	5.23e-8	Intelligence (multi-trait analysis);
KIRP	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg01238044	chr22:24384105	GSTT1	-0.53	-5.43	-0.33	1.38e-7	Urinary 1,3-butadiene metabolite levels in smokers;
KIRP	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg18944383	chr4:111397179	ENPEP	0.52	9.21	0.51	1.51e-17	Height;
KIRP	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.39	-5.28	-0.32	2.83e-7	Bipolar disorder;
KIRP	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.58	-6.32	-0.37	1.22e-9	Initial pursuit acceleration;
KIRP	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18932078	chr1:2524107	MMEL1	-0.39	-5.31	-0.32	2.42e-7	Ulcerative colitis;
KIRP	cis	rs2299587	1.000	rs17514360	chr8:17812577	A/G	cg01800426	chr8:17659068	MTUS1	-0.44	-5.22	-0.32	3.88e-7	Economic and political preferences;
KIRP	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg10017260	chr10:834428	NA	-0.56	-5.52	-0.33	8.54e-8	Eosinophil percentage of granulocytes;
KIRP	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.7	-9.31	-0.51	7.27e-18	Breast cancer;
KIRP	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg25547332	chr5:131281432	NA	0.47	5.31	0.32	2.5e-7	Life satisfaction;
KIRP	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg27144592	chr16:783916	NARFL	0.38	5.21	0.32	3.98e-7	Height;
KIRP	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.14	23.49	0.83	8.99e-65	Schizophrenia;
KIRP	cis	rs7224685	0.648	rs12453576	chr17:3881293	C/T	cg05562828	chr17:3906858	NA	0.56	6.6	0.39	2.47e-10	Type 2 diabetes;
KIRP	cis	rs427941	0.703	rs201440	chr7:101735599	C/T	cg06246474	chr7:101738831	CUX1	0.54	6.7	0.39	1.41e-10	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);
KIRP	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg21775007	chr8:11205619	TDH	-0.43	-5.64	-0.34	4.59e-8	Monocyte count;
KIRP	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg19468946	chr17:37922297	IKZF3	-0.46	-6.74	-0.39	1.11e-10	Asthma;
KIRP	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg25664220	chr3:72788482	NA	-0.42	-6.47	-0.38	5.22e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
KIRP	cis	rs6102059	0.503	rs6102033	chr20:39184691	C/G	cg22477343	chr20:39312069	NA	0.48	6.15	0.37	3.11e-9	LDL cholesterol;
KIRP	cis	rs17453880	0.890	rs12522538	chr5:152002303	A/G	cg12297329	chr5:152029980	NA	-0.7	-10.55	-0.56	1.04e-21	Subjective well-being;
KIRP	cis	rs3779635	0.844	rs56330356	chr8:27278847	A/G	cg06815112	chr8:27182871	PTK2B	0.46	5.87	0.35	1.37e-8	Neuroticism;
KIRP	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15128208	chr22:42549153	NA	-0.44	-5.69	-0.34	3.53e-8	Cognitive function;
KIRP	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg16497661	chr14:103986332	CKB	0.75	11.17	0.58	1.06e-23	Body mass index;
KIRP	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.65	5.76	0.34	2.44e-8	Bipolar disorder;
KIRP	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	cg12689670	chr1:183009347	LAMC1	0.43	6.14	0.36	3.32e-9	Fuchs's corneal dystrophy;
KIRP	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.51	7.05	0.41	1.84e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
KIRP	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg19759923	chr12:105630205	APPL2	0.54	6.1	0.36	3.99e-9	Lung cancer in ever smokers;
KIRP	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07308232	chr7:1071921	C7orf50	-0.76	-10.31	-0.55	5.98e-21	Longevity;Endometriosis;
KIRP	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.5	-6.62	-0.39	2.23e-10	Metabolite levels (Pyroglutamine);
KIRP	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg18478394	chr8:109455254	TTC35	0.52	6.43	0.38	6.47e-10	Dupuytren's disease;
KIRP	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.83	9.07	0.5	3.83e-17	Alzheimer's disease;
KIRP	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.33	-6.38	-0.38	8.56e-10	Monocyte percentage of white cells;
KIRP	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.59	-7.0	-0.41	2.49e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
KIRP	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.87	13.58	0.65	9.73e-32	Height;
KIRP	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	1.09	9.9	0.53	1.15e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
KIRP	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.68	5.47	0.33	1.1e-7	Developmental language disorder (linguistic errors);
KIRP	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg08461772	chr7:95026248	PON3	0.41	6.0	0.36	7.12e-9	Yu-Zhi constitution type in type 2 diabetes;
KIRP	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg02487422	chr3:49467188	NICN1	0.4	5.6	0.34	5.69e-8	Parkinson's disease;
KIRP	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.47	6.01	0.36	6.59e-9	Motion sickness;
KIRP	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg15026998	chr2:160761622	LY75	-0.35	-5.05	-0.31	8.76e-7	Crohn's disease;Inflammatory bowel disease;
KIRP	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.59	-8.3	-0.47	7e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.78	-11.03	-0.58	2.94e-23	Height;
KIRP	cis	rs73200209	0.703	rs17427025	chr12:116677033	C/G	cg01776926	chr12:116560359	MED13L	-0.49	-5.55	-0.33	7.4e-8	Total body bone mineral density;
KIRP	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg05347473	chr6:146136440	FBXO30	0.47	6.83	0.4	6.8e-11	Lobe attachment (rater-scored or self-reported);
KIRP	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-5.3	-0.32	2.57e-7	Bipolar disorder;
KIRP	cis	rs6545883	0.895	rs4430924	chr2:61703856	A/G	cg15711740	chr2:61764176	XPO1	-0.6	-7.7	-0.44	3.31e-13	Tuberculosis;
KIRP	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.68	7.88	0.45	1.07e-13	Corneal astigmatism;
KIRP	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	6.79	0.4	8.33e-11	Electroencephalogram traits;
KIRP	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg15028436	chr7:37888078	TXNDC3	0.76	10.22	0.55	1.17e-20	Alzheimer's disease (late onset);
KIRP	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.8	10.71	0.56	3.12e-22	Platelet count;
KIRP	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.8	11.69	0.6	2.06e-25	Heart rate;
KIRP	cis	rs7520050	0.807	rs5021934	chr1:46109304	A/G	cg24296786	chr1:45957014	TESK2	0.41	5.28	0.32	2.9e-7	Red blood cell count;Reticulocyte count;
KIRP	cis	rs12615966	0.932	rs17030324	chr2:105403251	A/C	cg16465502	chr2:105461796	NA	0.63	5.64	0.34	4.61e-8	Pancreatic cancer;
KIRP	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00933542	chr6:150070202	PCMT1	0.29	5.76	0.34	2.56e-8	Lung cancer;
KIRP	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.7	-10.08	-0.54	3.22e-20	Extrinsic epigenetic age acceleration;
KIRP	cis	rs4141404	0.816	rs5749227	chr22:31581166	A/G	cg22777020	chr22:31556080	RNF185	-0.53	-5.24	-0.32	3.52e-7	Paclitaxel-induced neuropathy;
KIRP	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-6.2	-0.37	2.37e-9	Lung cancer;
KIRP	cis	rs6540559	0.673	rs926346	chr1:209962204	A/T	cg22029157	chr1:209979665	IRF6	0.52	5.82	0.35	1.84e-8	Cleft lip with or without cleft palate;
KIRP	cis	rs1448094	0.842	rs7309725	chr12:86440612	T/C	cg02569458	chr12:86230093	RASSF9	0.35	4.98	0.3	1.21e-6	Major depressive disorder;
KIRP	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.78	-7.46	-0.43	1.52e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
KIRP	trans	rs12545912	0.770	rs7822700	chr8:9540854	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-6.22	-0.37	2.06e-9	Multiple myeloma (hyperdiploidy);
KIRP	cis	rs12693043	0.903	rs4972678	chr2:175379995	G/T	cg11778734	chr2:175439522	WIPF1	-0.45	-6.05	-0.36	5.39e-9	Urate levels (BMI interaction);
KIRP	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg10503236	chr1:231470652	EXOC8	-0.52	-7.13	-0.41	1.09e-11	Hemoglobin concentration;
KIRP	cis	rs7116495	1.000	rs531326	chr11:71570656	A/G	cg26138937	chr11:71823887	C11orf51	0.54	4.85	0.3	2.16e-6	Severe influenza A (H1N1) infection;
KIRP	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg18016565	chr1:150552671	MCL1	0.41	6.09	0.36	4.42e-9	Melanoma;
KIRP	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg02297831	chr4:17616191	MED28	0.54	6.75	0.4	1.04e-10	Parasitemia in Tripanosoma cruzi seropositivity;
KIRP	cis	rs2151522	0.563	rs983669	chr6:127122998	T/C	cg21431617	chr6:127135037	NA	0.33	6.01	0.36	6.73e-9	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
KIRP	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.46	-10.31	-0.55	5.92e-21	Alzheimer's disease (late onset);
KIRP	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg14541582	chr5:601475	NA	-0.58	-6.62	-0.39	2.25e-10	Obesity-related traits;
KIRP	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg03169147	chr2:68290320	C1D	0.46	6.4	0.38	7.84e-10	C-reactive protein levels;Esophageal cancer (squamous cell);
KIRP	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg05457628	chr5:178986728	RUFY1	0.57	9.19	0.51	1.75e-17	Lung cancer;
KIRP	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.28	27.93	0.87	2.91e-78	IgG glycosylation;
KIRP	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg00342743	chr10:76970673	VDAC2	0.46	6.36	0.38	9.66e-10	Survival in pancreatic cancer;
KIRP	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg04025307	chr7:1156635	C7orf50	0.56	5.61	0.34	5.42e-8	Bronchopulmonary dysplasia;
KIRP	trans	rs2074193	0.585	rs11183915	chr12:47770984	C/T	cg18318704	chr5:133968668	SAR1B	-0.5	-6.12	-0.36	3.64e-9	Migraine with aura;
KIRP	cis	rs7630877	0.924	rs11709733	chr3:179628320	A/C	cg18765712	chr3:179670323	PEX5L	0.57	6.69	0.39	1.46e-10	Type 2 diabetes;
KIRP	trans	rs621559	0.892	rs12129124	chr1:43679291	G/C	cg25694032	chr6:164507164	NA	0.35	6.17	0.37	2.78e-9	Telomere length;
KIRP	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.77	7.91	0.45	8.81e-14	Uric acid levels;
KIRP	trans	rs763121	0.962	rs138711	chr22:39139913	C/T	cg00682458	chr6:43139370	SRF	-0.57	-6.11	-0.36	3.81e-9	Menopause (age at onset);
KIRP	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24110177	chr3:50126178	RBM5	-0.42	-5.46	-0.33	1.16e-7	Intelligence (multi-trait analysis);
KIRP	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05585630	chr7:157510462	PTPRN2	-0.55	-8.26	-0.47	9.3e-15	Bipolar disorder and schizophrenia;
KIRP	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-11.72	-0.6	1.74e-25	Dental caries;
KIRP	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg14004847	chr7:1930337	MAD1L1	-0.57	-6.34	-0.37	1.08e-9	Bipolar disorder and schizophrenia;
KIRP	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18252515	chr7:66147081	NA	0.46	5.51	0.33	9.21e-8	Aortic root size;
KIRP	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg08885800	chr1:201084119	NA	0.36	5.14	0.31	5.67e-7	Permanent tooth development;
KIRP	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg23985595	chr17:80112537	CCDC57	-0.36	-5.29	-0.32	2.7e-7	Life satisfaction;
KIRP	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg01631408	chr1:248437212	OR2T33	-0.66	-8.89	-0.49	1.35e-16	Common traits (Other);
KIRP	cis	rs3779635	0.711	rs11775464	chr8:27247647	T/C	cg23736307	chr8:27182930	PTK2B	0.52	6.64	0.39	2.02e-10	Neuroticism;
KIRP	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg11632617	chr15:75315747	PPCDC	0.56	4.98	0.3	1.21e-6	Lung cancer;
KIRP	cis	rs3779635	0.711	rs34947559	chr8:27247339	G/A	cg06815112	chr8:27182871	PTK2B	0.54	6.93	0.4	3.72e-11	Neuroticism;
KIRP	cis	rs11074306	0.561	rs7162123	chr15:28063263	T/C	cg26402630	chr15:28053930	OCA2	0.3	4.92	0.3	1.59e-6	Uveal melanoma;